diff --git "a/test.tsv" "b/test.tsv"
new file mode 100644--- /dev/null
+++ "b/test.tsv"
@@ -0,0 +1,682227 @@
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+packaging	O
+signal	O
+.	O
+
+Under	O
+baseline	O
+conditions	O
+,	O
+a	O
+narrow	O
+unimodal	O
+distribution	B-PROC
+of	I-PROC
+ventilation	I-PROC
+and	O
+perfusion	O
+with	O
+shunt	O
+-	O
+flow	O
+ranging	O
+below	O
+2	O
+%	O
+and	O
+absence	O
+of	O
+perfusion	O
+of	O
+low	O
+V	O
+A	O
+/	O
+Q	O
+(	O
+0	O
+.	O
+01	O
+<	O
+V	O
+A	O
+/	O
+Q	O
+<	O
+0	O
+.	O
+1	O
+)	O
+areas	O
+was	O
+noted	O
+throughout	O
+.	O
+
+Asparaginyl	B-CHED
+-	O
+tRNA	B-FUNC
+,	O
+which	O
+decodes	B-SPEC
+the	O
+A	B-PRGE
+-	I-PRGE
+site	I-PRGE
+codon	I-PRGE
+AAC	I-PRGE
+,	O
+has	O
+the	O
+modified	O
+base	O
+Q	O
+at	O
+the	O
+wobble	O
+position	O
+of	O
+the	O
+anticodon	O
+(	O
+5	O
+'	O
+QUU	O
+3	O
+')	O
+and	O
+it	O
+has	O
+been	O
+speculated	O
+that	O
+Q	O
+may	O
+be	O
+required	O
+for	O
+frameshifting	O
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+of	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+results	O
+in	O
+a	O
+demyelinating	O
+encephalomyelitis	B-DISO
+characterized	O
+by	O
+mononuclear	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+and	O
+white	B-ANAT
+matter	I-ANAT
+destruction	O
+similar	O
+to	O
+the	O
+pathology	B-DISO
+of	O
+the	O
+human	B-SPEC
+demyelinating	B-DISO
+disease	I-DISO
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+Furthermore	O
+,	O
+CD4	B-PRGE
+(-/-)	O
+mice	B-SPEC
+displayed	O
+lower	O
+levels	O
+of	O
+RANTES	O
+(	O
+a	O
+C	O
+-	O
+C	O
+chemokine	O
+)	O
+mRNA	B-CHED
+transcripts	O
+and	O
+protein	B-CHED
+,	O
+suggesting	O
+a	O
+role	O
+for	O
+this	O
+molecule	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+MHV	B-SPEC
+-	O
+induced	O
+neurologic	O
+disease	O
+.	O
+
+Here	O
+we	O
+demonstrate	O
+that	O
+incorporation	O
+is	O
+mediated	O
+by	O
+the	O
+short	O
+carboxy	B-CHED
+-	O
+terminal	O
+segment	O
+comprising	O
+the	O
+transmembrane	B-COMP
+and	O
+endodomain	O
+.	O
+
+They	O
+were	O
+found	O
+to	O
+assemble	O
+only	O
+into	O
+viral	B-COMP
+particles	I-COMP
+of	O
+the	O
+species	B-SPEC
+from	O
+which	O
+their	O
+carboxy	O
+-	O
+terminal	O
+domain	O
+originated	O
+.	O
+
+Thus	O
+,	O
+the	O
+64	O
+-	O
+terminal	O
+-	O
+residue	O
+sequence	O
+suffices	O
+to	O
+draw	O
+the	O
+1308	O
+(	O
+MHV	B-SPEC
+)-	O
+or	O
+1433	O
+(	O
+FIPV	O
+)-	O
+amino	O
+-	O
+acid	O
+-	O
+long	O
+mature	O
+S	B-PRGE
+protein	I-PRGE
+into	O
+VLPs	B-ANAT
+.	O
+
+Because	O
+there	O
+exist	O
+normal	O
+regions	O
+in	O
+the	O
+lung	B-ANAT
+with	O
+ARDS	B-DISO
+and	O
+because	O
+PLV	O
+in	O
+the	O
+normal	O
+lung	B-ANAT
+results	O
+in	O
+worsened	O
+gas	B-ENZY
+exchange	O
+,	O
+we	O
+postulated	O
+that	O
+the	O
+optimal	O
+dose	O
+of	O
+PFC	O
+for	O
+PLV	O
+may	O
+be	O
+less	O
+than	O
+the	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+(	O
+FRC	O
+)	O
+dose	O
+in	O
+the	O
+lung	B-ANAT
+with	O
+limited	O
+disease	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Respiratory	B-PROC
+mechanics	I-PROC
+during	O
+PLV	O
+for	O
+dependent	O
+lung	B-ANAT
+-	O
+dominant	O
+lung	B-ANAT
+injury	O
+were	O
+optimal	O
+at	O
+a	O
+PFC	O
+dose	O
+less	O
+than	O
+the	O
+FRC	B-PROC
+.	O
+
+Of	O
+4302	O
+women	O
+observed	O
+to	O
+or	O
+beyond	O
+20	O
+weeks	O
+'	O
+gestation	B-PROC
+,	O
+1073	O
+(	O
+24	O
+.	O
+9	O
+%)	O
+developed	O
+mild	O
+or	O
+severe	O
+pregnancy	O
+-	O
+associated	O
+hypertension	B-DISO
+or	O
+preeclampsia	B-DISO
+.	O
+
+Hypertension	B-DISO
+,	O
+especially	O
+severe	O
+hypertension	B-DISO
+,	O
+was	O
+associated	O
+with	O
+an	O
+appreciable	O
+increase	O
+in	O
+important	O
+maternal	O
+and	O
+perinatal	B-DISO
+morbidity	I-DISO
+but	O
+not	O
+perinatal	O
+mortality	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Hypertension	B-DISO
+,	O
+especially	O
+severe	O
+hypertension	B-DISO
+,	O
+was	O
+associated	O
+with	O
+an	O
+appreciable	O
+increase	O
+in	O
+important	O
+maternal	O
+and	O
+perinatal	B-DISO
+morbidity	I-DISO
+but	O
+not	O
+perinatal	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+prevalence	O
+and	O
+phylogeny	O
+of	O
+feline	O
+coronaviruses	O
+were	O
+studied	O
+in	O
+urban	O
+cat	B-SPEC
+populations	O
+by	O
+sampling	O
+of	O
+113	O
+clinically	O
+healthy	O
+cats	B-SPEC
+.	O
+
+These	O
+findings	O
+will	O
+hopefully	O
+contribute	O
+to	O
+the	O
+elucidation	O
+of	O
+the	O
+epidemiology	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+It	O
+associates	O
+with	O
+both	O
+viral	O
+genomic	O
+RNA	O
+and	O
+subgenomic	O
+mRNAs	O
+and	O
+has	O
+structural	O
+and	O
+non	O
+-	O
+structural	O
+roles	O
+in	O
+replication	O
+including	O
+viral	O
+RNA	O
+-	O
+dependent	O
+RNA	O
+transcription	B-PROC
+,	O
+genome	O
+replication	O
+,	O
+encapsidation	O
+and	O
+translation	B-PROC
+.	O
+
+To	O
+better	O
+understand	O
+the	O
+RNA	O
+-	O
+binding	B-FUNC
+properties	O
+of	O
+this	O
+multifunctional	O
+protein	B-CHED
+,	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+as	O
+a	O
+chimeric	O
+protein	B-CHED
+fused	O
+to	O
+glutathione	B-PRGE
+-	I-PRGE
+S	I-PRGE
+-	I-PRGE
+transferase	I-PRGE
+(	O
+GST	B-PRGE
+).	O
+
+Together	O
+these	O
+data	O
+demonstrate	O
+a	O
+high	O
+-	O
+affinity	O
+,	O
+specific	O
+interaction	O
+between	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+and	O
+a	O
+conserved	O
+RNA	O
+sequence	O
+present	O
+at	O
+the	O
+5	O
+'-	O
+ends	O
+of	O
+MHV	B-PRGE
+mRNA	B-CHED
+.	O
+
+Site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+and	O
+expression	B-PROC
+studies	O
+showed	O
+that	O
+a	O
+previously	O
+predicted	O
+cleavage	B-PROC
+site	O
+(	O
+Q	O
+(	O
+2583	O
+)-	O
+G	O
+(	O
+2584	O
+))	O
+located	O
+within	O
+the	O
+41	B-PRGE
+-	I-PRGE
+kDa	I-PRGE
+protein	I-PRGE
+-	I-PRGE
+encoding	I-PRGE
+region	I-PRGE
+was	O
+not	O
+utilized	O
+by	O
+3CLP	O
+,	O
+supporting	O
+the	O
+conclusion	O
+that	O
+the	O
+41	B-PRGE
+-	I-PRGE
+kDa	I-PRGE
+protein	I-PRGE
+is	O
+a	O
+mature	O
+viral	O
+product	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+believe	O
+that	O
+the	O
+efficacy	O
+and	O
+safety	O
+of	O
+chelation	B-PROC
+therapy	O
+in	O
+severe	O
+acute	O
+iron	O
+poisoning	O
+may	O
+be	O
+improved	O
+by	O
+targeting	B-PROC
+the	O
+initial	O
+high	O
+levels	O
+of	O
+readily	O
+chelatable	O
+serum	B-COMP
+iron	O
+with	O
+adequate	O
+doses	O
+of	O
+desferrioxamine	O
+without	O
+prolonging	O
+its	O
+use	O
+unnecessarily	O
+.	O
+
+Furthermore	O
+,	O
+MAb	O
+showing	O
+strong	O
+neutralizing	O
+activity	O
+in	O
+Felis	B-SPEC
+catus	I-SPEC
+whole	O
+fetus	B-ANAT
+(	O
+fcwf	O
+-	O
+4	O
+)	O
+cells	B-COMP
+and	O
+Crandell	O
+feline	B-SPEC
+kidney	B-ANAT
+(	O
+CrFK	O
+)	O
+cells	B-COMP
+shows	O
+strong	O
+enhancing	O
+activity	O
+in	O
+feline	B-SPEC
+macrophages	B-ANAT
+,	O
+indicating	O
+that	O
+the	O
+neutralizing	O
+epitope	B-CHED
+and	O
+the	O
+enhancing	O
+epitope	B-CHED
+are	O
+closely	O
+related	O
+.	O
+
+However	O
+,	O
+MAb	O
+FK50	O
+-	O
+4	O
+did	O
+not	O
+exhibit	O
+neutralizing	O
+activity	O
+in	O
+CrFK	O
+cells	B-COMP
+or	O
+fcwf	O
+-	O
+4	O
+cells	O
+,	O
+thus	O
+showing	O
+a	O
+very	O
+unusual	O
+property	O
+.	O
+
+TITLE	O
+:	O
+Contributions	O
+of	O
+Fas	B-DISO
+-	O
+Fas	B-DISO
+ligand	B-PROC
+interactions	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+in	O
+the	O
+central	O
+nervous	O
+system	O
+.	O
+
+Second	O
+,	O
+to	O
+determine	O
+whether	O
+the	O
+volumes	O
+of	O
+blood	B-ANAT
+and	O
+crystalloid	B-COMP
+solutions	O
+administered	O
+in	O
+the	O
+early	O
+posttrauma	O
+period	O
+are	O
+independent	O
+risk	O
+factors	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+severely	O
+traumatized	O
+patients	O
+.	O
+
+Initial	O
+clinical	O
+and	O
+laboratory	O
+data	O
+were	O
+collected	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+,	O
+and	O
+on	O
+a	O
+daily	O
+basis	O
+thereafter	O
+during	O
+the	O
+patient	O
+'	O
+s	O
+intensive	O
+care	O
+unit	O
+stay	O
+.	O
+
+In	O
+this	O
+group	O
+of	O
+severely	O
+injured	O
+trauma	O
+patients	O
+,	O
+the	O
+degree	O
+of	O
+metabolic	B-DISO
+acidosis	I-DISO
+at	O
+the	O
+time	O
+of	O
+admission	O
+identified	O
+those	O
+patients	O
+with	O
+the	O
+highest	O
+probability	O
+of	O
+developing	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Protein	B-CHED
+carbonyl	B-CHED
+measurements	O
+show	O
+evidence	O
+of	O
+early	O
+oxidative	B-DISO
+stress	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Our	O
+results	O
+provide	O
+evidence	O
+of	O
+oxidation	B-PROC
+occurring	O
+early	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+major	O
+trauma	O
+patients	O
+,	O
+with	O
+protein	B-CHED
+carbonyl	B-CHED
+measurements	O
+providing	O
+a	O
+sensitive	O
+index	O
+of	O
+this	O
+process	O
+.	O
+
+High	O
+protein	B-CHED
+carbonyl	B-CHED
+concentrations	O
+in	O
+plasma	B-ANAT
+as	O
+well	O
+as	O
+bronchial	B-ANAT
+aspirates	B-ANAT
+indicate	O
+that	O
+oxidation	B-PROC
+is	O
+not	O
+restricted	O
+to	O
+the	O
+lungs	B-ANAT
+.	O
+
+Comparison	O
+with	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Changes	O
+in	O
+the	O
+alveolar	B-ANAT
+hemostatic	B-PROC
+balance	B-PROC
+in	O
+severe	O
+pneumonia	B-DISO
+were	O
+compared	O
+with	O
+those	O
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+In	O
+all	O
+groups	O
+of	O
+patients	O
+,	O
+BALF	O
+total	O
+procoagulant	O
+activity	O
+was	O
+increased	O
+by	O
+nearly	O
+two	O
+orders	O
+of	O
+magnitude	O
+,	O
+being	O
+largely	O
+attributable	O
+to	O
+the	O
+tissue	B-ANAT
+factor	O
+pathway	B-PROC
+of	O
+coagulation	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+markedly	O
+enhanced	O
+levels	O
+of	O
+plasminogen	B-PRGE
+activator	I-PRGE
+-	I-PRGE
+inhibitor	I-PRGE
+I	I-PRGE
+and	O
+alpha	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+antiplasmin	I-PRGE
+were	O
+noted	O
+in	O
+ARDS	B-DISO
+,	O
+ARDS	O
++	O
+PNEU	O
+,	O
+and	O
+PNEU	O
+-	O
+vent	O
+,	O
+but	O
+not	O
+in	O
+PNEU	O
+-	O
+spon	O
+.	O
+
+In	O
+all	O
+groups	O
+of	O
+patients	O
+,	O
+the	O
+changes	O
+in	O
+the	O
+lavage	O
+enzymatic	O
+activities	O
+were	O
+paralleled	O
+by	O
+manifold	O
+increased	O
+BALF	O
+concentrations	O
+of	O
+fibrinopeptide	B-PRGE
+A	I-PRGE
+and	O
+D	O
+-	O
+dimer	O
+,	O
+reflecting	O
+in	O
+vivo	O
+coagulation	B-PROC
+processes	O
+.	O
+
+Stem	B-ANAT
+-	O
+loop	O
+I	O
+showed	O
+a	O
+high	O
+degree	O
+of	O
+covariance	O
+amongst	O
+the	O
+IBV	B-SPEC
+strains	O
+providing	O
+phylogenetic	O
+evidence	O
+that	O
+this	O
+structure	O
+exists	O
+and	O
+is	O
+potentially	O
+involved	O
+in	O
+replication	O
+,	O
+supporting	O
+previous	O
+observations	O
+that	O
+a	O
+BCoV	O
+stem	B-ANAT
+-	O
+loop	O
+homologue	O
+was	O
+essential	O
+for	O
+replication	O
+of	O
+BCoV	O
+defective	O
+interfering	O
+RNAs	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+life	O
+support	O
+outcome	O
+for	O
+128	O
+pediatric	O
+patients	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Lung	B-PROC
+compliance	I-PROC
+increased	O
+from	O
+0	O
+.	O
+32	O
++/-	O
+0	O
+.	O
+02	O
+mL	O
+/	O
+cm	O
+H2O	B-CHED
+/	O
+kg	O
+to	O
+0	O
+.	O
+59	O
++/-	O
+0	O
+.	O
+03	O
+mL	O
+/	O
+cm	O
+H2O	B-CHED
+/	O
+kg	O
+in	O
+survivors	O
+,	O
+but	O
+only	O
+increased	O
+from	O
+0	O
+.	O
+34	O
++/-	O
+0	O
+.	O
+02	O
+mL	O
+/	O
+cm	O
+H2O	B-CHED
+/	O
+kg	O
+to	O
+0	O
+.	O
+35	O
++/-	O
+0	O
+.	O
+02	O
+mL	O
+/	O
+cm	O
+H2O	B-CHED
+/	O
+kg	O
+in	O
+nonsurvivors	O
+(	O
+P	O
+<.	O
+002	O
+comparing	O
+change	O
+between	O
+survivors	O
+and	O
+nonsurvivors	O
+).	O
+
+TITLE	O
+:	O
+Complications	O
+of	O
+prone	O
+ventilation	O
+in	O
+patients	O
+with	O
+multisystem	O
+trauma	O
+with	O
+fulminant	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+critically	O
+evaluate	O
+our	O
+experience	O
+with	O
+prone	O
+positioning	O
+in	O
+patients	O
+with	O
+severe	O
+postinjury	O
+ARDS	B-DISO
+.	O
+
+The	O
+effect	O
+of	O
+cocaine	B-CHED
+on	O
+IFN	B-PRGE
+production	O
+was	O
+found	O
+to	O
+be	O
+primarily	O
+at	O
+the	O
+transcript	O
+level	O
+in	O
+both	O
+Mphi	O
+and	O
+L929	O
+cells	B-COMP
+.	O
+
+These	O
+findings	O
+further	O
+support	O
+our	O
+previous	O
+research	O
+demonstrating	O
+an	O
+antiviral	B-CHED
+activity	O
+of	O
+cocaine	B-CHED
+in	O
+vitro	O
+.	O
+
+Indirect	O
+fluorescent	O
+-	O
+antibody	B-COMP
+assay	O
+,	O
+immunodot	O
+assay	O
+,	O
+and	O
+immunoprecipitation	O
+were	O
+used	O
+to	O
+select	O
+hybridomas	B-ANAT
+that	O
+produced	O
+anti	O
+-	O
+BRV	B-DISO
+MAbs	O
+.	O
+
+None	O
+of	O
+the	O
+seven	O
+MAbs	O
+were	O
+reactive	O
+with	O
+canine	O
+rotavirus	B-SPEC
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+,	O
+or	O
+uninfected	O
+Madin	O
+-	O
+Darby	O
+bovine	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Immunogenicity	O
+of	O
+porcine	B-PRGE
+transmissible	I-PRGE
+gastroenteritis	I-PRGE
+virus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+expressed	B-PROC
+in	O
+plants	B-SPEC
+.	O
+
+All	O
+three	O
+of	O
+them	O
+were	O
+driven	O
+by	O
+a	O
+strong	O
+plant	B-SPEC
+promoter	O
+.	O
+
+The	O
+third	O
+construct	O
+contained	O
+the	O
+D	O
+epitope	B-CHED
+-	O
+coding	O
+region	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+,	O
+from	O
+nucleotide	B-CHED
+1201	O
+to	O
+1591	O
+,	O
+which	O
+was	O
+fused	O
+to	O
+the	O
+alfalfa	B-PRGE
+beta	B-ENZY
+-	I-ENZY
+amylase	I-ENZY
+gene	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Diagnosis	O
+of	O
+neonatal	O
+pig	B-SPEC
+diarrhea	B-DISO
+.	O
+
+Necropsy	O
+dead	B-PROC
+or	O
+dying	B-PROC
+pigs	B-SPEC
+[	O
+that	O
+]	O
+appear	O
+to	O
+represent	O
+the	O
+problem	O
+.	O
+
+Submit	O
+live	O
+pigs	B-SPEC
+or	O
+appropriate	O
+tissues	B-ANAT
+from	O
+necropsied	O
+pigs	B-SPEC
+to	O
+a	O
+diagnostic	O
+laboratory	O
+.	O
+
+Re	O
+-	O
+evaluate	O
+environmental	O
+conditions	O
+that	O
+may	O
+be	O
+contributing	O
+to	O
+the	O
+problem	O
+(	O
+remember	O
+,	O
+unit	O
+employees	O
+are	O
+a	O
+part	O
+of	O
+the	O
+pigs	B-SPEC
+'	O
+environment	O
+).	O
+
+Prospective	O
+,	O
+randomized	O
+animal	B-SPEC
+study	O
+.	O
+
+The	O
+combination	O
+of	O
+PLA2	B-PRGE
+and	O
+trypsin	B-PRGE
+decreased	O
+Pao2	B-PRGE
+,	O
+lung	B-PROC
+compliance	I-PROC
+,	O
+and	O
+peripheral	O
+counts	O
+of	O
+neutrophils	B-ANAT
+and	O
+platelets	B-ANAT
+and	O
+increased	O
+alveolar	B-ANAT
+/	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+difference	O
+,	O
+lung	B-ANAT
+resistance	B-PROC
+,	O
+wet	O
+weight	O
+/	O
+dry	O
+weight	O
+ratio	O
+,	O
+and	O
+the	O
+number	O
+of	O
+neutrophils	B-ANAT
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+However	O
+,	O
+further	O
+studies	O
+are	O
+required	O
+to	O
+determine	O
+whether	O
+this	O
+drug	O
+has	O
+a	O
+therapeutic	O
+effect	O
+once	O
+the	O
+lung	B-ANAT
+injury	O
+has	O
+developed	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+replicase	O
+gene	O
+(	O
+gene	O
+1	O
+)	O
+of	O
+the	O
+coronavirus	B-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+encodes	O
+two	O
+co	O
+-	O
+amino	O
+-	O
+terminal	O
+polyproteins	O
+presumed	O
+to	O
+incorporate	O
+all	O
+the	O
+virus	B-SPEC
+-	O
+encoded	O
+proteins	B-CHED
+necessary	O
+for	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+When	O
+infected	O
+cells	B-COMP
+were	O
+probed	O
+by	O
+immunofluorescence	O
+laser	B-SPEC
+confocal	O
+microscopy	O
+,	O
+p1a	O
+-	O
+10	O
+,	O
+-	O
+22	O
+,	O
+-	O
+12	O
+,	O
+and	O
+-	O
+15	O
+were	O
+detected	O
+in	O
+discrete	O
+foci	O
+that	O
+were	O
+prominent	O
+in	O
+the	O
+perinuclear	O
+region	O
+but	O
+were	O
+widely	O
+distributed	O
+throughout	O
+the	O
+cytoplasm	O
+as	O
+well	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+objectively	O
+measure	O
+sleep	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+requiring	O
+mechanical	O
+ventilation	O
+and	O
+to	O
+define	O
+selection	O
+criteria	O
+for	O
+future	O
+studies	O
+of	O
+sleep	B-PROC
+continuity	O
+in	O
+this	O
+population	O
+.	O
+
+Patients	O
+were	O
+divided	O
+into	O
+three	O
+groups	O
+based	O
+on	O
+24	O
+-	O
+h	O
+polysomnography	O
+(	O
+PSG	B-COMP
+)	O
+findings	O
+.	O
+
+Severe	O
+sleep	B-DISO
+fragmentation	I-DISO
+was	O
+reflected	O
+by	O
+a	O
+high	O
+frequency	O
+of	O
+arousals	O
+(	O
+20	O
++/-	O
+
+The	O
+combined	O
+atypical	O
+sleep	B-PROC
+and	O
+coma	B-DISO
+groups	O
+had	O
+a	O
+higher	O
+APS	B-DISO
+(	O
+13	O
++/-	O
+4	O
+vs	O
+6	O
++/-	O
+
+CONCLUSIONS	O
+:	O
+Sleep	B-PROC
+,	O
+as	O
+it	O
+is	O
+conventionally	O
+measured	O
+,	O
+was	O
+identified	O
+only	O
+in	O
+a	O
+subgroup	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+requiring	O
+mechanical	O
+ventilation	O
+and	O
+was	O
+severely	O
+disrupted	O
+.	O
+
+CTL	B-ANAT
+determinants	O
+in	O
+the	O
+viral	O
+particle	O
+can	O
+be	O
+mapped	O
+to	O
+the	O
+spike	O
+and	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+but	O
+not	O
+to	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+.	O
+
+The	O
+results	O
+indicate	O
+that	O
+an	O
+internal	O
+entry	O
+mechanism	O
+,	O
+possibly	O
+in	O
+conjunction	O
+with	O
+leaky	O
+scanning	O
+,	O
+is	O
+used	O
+for	O
+the	O
+expression	B-PROC
+of	O
+ORF	B-PRGE
+3b	I-PRGE
+from	O
+TGEV	B-SPEC
+mRNA	B-CHED
+3	O
+.	O
+
+One	O
+possible	O
+consequence	O
+of	O
+this	O
+feature	O
+is	O
+that	O
+ORF	B-PRGE
+3b	I-PRGE
+might	O
+also	O
+be	O
+expressed	B-PROC
+from	O
+mRNAs	O
+1	O
+and	O
+2	O
+.	O
+
+Protection	O
+following	O
+administration	O
+of	O
+T	B-ANAT
+lymphocytes	I-ANAT
+could	O
+be	O
+observed	O
+in	O
+chicks	O
+with	O
+three	O
+distinct	O
+MHC	B-PRGE
+haplotypes	I-PRGE
+:	O
+B	O
+(	O
+8	O
+)/	O
+B	O
+(	O
+8	O
+),	O
+B	O
+(	O
+12	O
+)/	O
+B	O
+(	O
+12	O
+),	O
+and	O
+B	O
+(	O
+19	O
+)/	O
+B	O
+(	O
+19	O
+).	O
+
+Chimeric	O
+spike	O
+protein	B-CHED
+mutants	O
+containing	O
+substitutions	O
+of	O
+the	O
+entire	O
+transmembrane	B-COMP
+anchor	O
+and	O
+cys	B-CHED
+domain	O
+with	O
+the	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+glycoprotein	B-CHED
+D	O
+(	O
+gD	O
+-	O
+1	O
+)	O
+anchor	O
+demonstrated	O
+that	O
+fusion	O
+activity	O
+requires	O
+the	O
+presence	O
+of	O
+the	O
+A59	O
+membrane	B-COMP
+-	O
+spanning	O
+domain	O
+and	O
+the	O
+portion	O
+of	O
+the	O
+cys	O
+domain	O
+that	O
+lies	O
+upstream	O
+of	O
+the	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+.	O
+
+However	O
+,	O
+addition	O
+of	O
+the	O
+cys	B-CHED
+domain	O
+to	O
+fusion	O
+-	O
+defective	O
+chimeric	O
+proteins	B-CHED
+was	O
+unable	O
+to	O
+restore	O
+fusion	O
+activity	O
+.	O
+
+TITLE	O
+:	O
+Unique	O
+N	O
+-	O
+linked	O
+glycosylation	B-PROC
+of	O
+murine	B-PRGE
+coronavirus	I-PRGE
+MHV	B-SPEC
+-	I-PRGE
+2	I-PRGE
+membrane	B-COMP
+protein	B-CHED
+at	O
+the	O
+conserved	O
+O	O
+-	O
+linked	O
+glycosylation	O
+site	O
+.	O
+
+TITLE	O
+:	O
+Capture	O
+ELISA	O
+systems	O
+for	O
+the	O
+detection	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+-	I-PRGE
+specific	I-PRGE
+IgA	I-PRGE
+and	I-PRGE
+IgM	I-PRGE
+antibodies	B-COMP
+in	O
+milk	O
+and	O
+serum	B-COMP
+.	O
+
+The	O
+capture	O
+ELISAs	O
+showed	O
+higher	O
+sensitivity	O
+than	O
+indirect	O
+ELISAs	O
+for	O
+detection	O
+of	O
+BCV	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgA	I-PRGE
+and	O
+IgM	B-PRGE
+.	O
+In	O
+the	O
+capture	O
+ELISAs	O
+the	O
+agreement	O
+between	O
+detection	O
+in	O
+milk	O
+and	O
+serum	B-COMP
+samples	O
+was	O
+94	O
+%	O
+for	O
+IgA	B-PRGE
+and	O
+86	O
+%	O
+for	O
+IgM	B-PRGE
+.	O
+The	O
+correlation	O
+between	O
+log	O
+(	O
+10	O
+)	O
+titres	O
+in	O
+milk	O
+and	O
+serum	B-COMP
+was	O
+r	O
+=	O
+0	O
+.	O
+82	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+for	O
+IgA	B-PRGE
+and	O
+0	O
+.	O
+84	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+for	O
+IgM	B-PRGE
+.	O
+Milk	O
+seemed	O
+a	O
+better	O
+target	O
+than	O
+serum	B-COMP
+for	O
+diagnosing	O
+specific	O
+IgA	B-PRGE
+at	O
+low	O
+levels	O
+.	O
+
+The	O
+IgA	B-PRGE
+and	O
+IgM	B-PRGE
+capture	O
+ELISAs	O
+differentiated	B-PROC
+between	O
+primarily	O
+BCV	B-SPEC
+infected	O
+and	O
+reinfected	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Previously	O
+,	O
+we	O
+have	O
+reported	O
+protective	O
+vaccination	O
+of	O
+mice	B-SPEC
+against	O
+a	O
+coronavirus	B-DISO
+infection	I-DISO
+using	O
+rabbit	B-SPEC
+polyclonal	O
+noninternal	O
+image	O
+Ab2gamma	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+idiotypic	I-PRGE
+(	O
+anti	O
+-	O
+Id	O
+)	O
+antibody	B-COMP
+specific	O
+for	O
+a	O
+virus	B-SPEC
+-	O
+neutralizing	O
+and	O
+protective	O
+monoclonal	O
+antibody	B-COMP
+(	O
+mAb	O
+)	O
+7	O
+-	O
+10A	O
+against	O
+the	O
+viral	B-PRGE
+surface	I-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+.	O
+
+The	O
+antisera	O
+against	O
+turkey	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+bluecomb	O
+agent	O
+),	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+),	O
+bovine	B-SPEC
+Breda	B-SPEC
+-	O
+1	O
+virus	B-SPEC
+,	O
+bovine	B-SPEC
+Breda	B-SPEC
+-	O
+2	O
+virus	B-SPEC
+,	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+and	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+of	O
+swine	B-SPEC
+were	O
+evaluated	O
+by	O
+dot	O
+-	O
+immunobinding	O
+avidin	O
+-	O
+biotin	B-CHED
+-	O
+enhanced	O
+ELISA	O
+and	O
+did	O
+not	O
+react	O
+with	O
+SSA	O
+.	O
+
+A	O
+RT	O
+-	O
+PCR	O
+was	O
+performed	O
+with	O
+known	O
+primers	O
+specific	O
+for	O
+NDV	B-SPEC
+,	O
+IBV	B-SPEC
+,	O
+BCV	B-SPEC
+,	O
+and	O
+TGEV	B-SPEC
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+cycle	O
+sequencing	O
+techniques	O
+were	O
+used	O
+to	O
+elucidate	O
+the	O
+genetic	O
+and	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+relationships	O
+among	O
+the	O
+isolates	O
+.	O
+
+The	O
+Mississippi	O
+isolates	O
+had	O
+less	O
+than	O
+2	O
+.	O
+3	O
+%	O
+nucleotide	B-CHED
+and	O
+5	O
+.	O
+2	O
+%	O
+amino	B-CHED
+acid	I-CHED
+variation	O
+when	O
+compared	O
+with	O
+the	O
+vaccine	O
+strain	O
+Ark	O
+DPI	O
+and	O
+less	O
+than	O
+3	O
+.	O
+0	O
+%	O
+nucleotide	B-CHED
+and	O
+5	O
+.	O
+2	O
+%	O
+amino	B-CHED
+acid	I-CHED
+variation	O
+when	O
+compared	O
+with	O
+the	O
+Ark	B-PRGE
+-	I-PRGE
+type	I-PRGE
+Georgia	I-PRGE
+variant	I-PRGE
+.	O
+
+This	O
+study	O
+suggests	O
+that	O
+the	O
+26	O
+IBV	B-SPEC
+isolates	O
+that	O
+are	O
+genetically	O
+closely	O
+related	O
+to	O
+the	O
+vaccine	O
+strain	O
+may	O
+be	O
+derived	O
+from	O
+the	O
+vaccine	O
+strain	O
+by	O
+point	O
+mutation	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+rapid	O
+-	O
+plate	O
+hemagglutination	O
+(	O
+HA	O
+)	O
+test	O
+to	O
+detect	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+in	O
+allantoic	B-ANAT
+fluid	I-ANAT
+of	O
+embryonated	O
+eggs	O
+was	O
+introduced	O
+into	O
+routine	O
+procedures	O
+for	O
+IBV	B-SPEC
+identification	O
+.	O
+
+An	O
+apparent	O
+synergistic	O
+effect	O
+in	O
+dually	O
+inoculated	O
+turkeys	B-SPEC
+was	O
+indicated	O
+by	O
+increased	O
+mortality	O
+,	O
+enhanced	O
+growth	B-PROC
+depression	B-DISO
+,	O
+and	O
+enhanced	O
+AE	O
+lesion	O
+development	B-PROC
+.	O
+
+They	O
+received	O
+the	O
+same	O
+induction	O
+chemotherapy	O
+(	O
+IDR	O
+12	O
+mg	O
+/	O
+m2	O
+for	O
+four	O
+days	O
+and	O
+cytarabine	B-CHED
+100	O
+mg	O
+/	O
+m2	O
+for	O
+ten	O
+days	O
+).	O
+
+The	O
+fetal	B-ANAT
+gastrointestinal	I-ANAT
+tract	I-ANAT
+complications	O
+may	O
+have	O
+been	O
+due	O
+to	O
+severe	O
+myelosuppression	O
+and	O
+mucosal	B-ANAT
+damage	O
+in	O
+these	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+group	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+,	O
+a	O
+genetic	O
+grouping	O
+method	O
+based	O
+on	O
+hypervariable	O
+region	O
+1	O
+(	O
+HVR	O
+1	O
+,	O
+nucleotides	B-CHED
+168	O
+to	O
+197	O
+)	O
+was	O
+compared	O
+with	O
+that	O
+based	O
+on	O
+the	O
+whole	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+change	O
+in	O
+cardiac	B-ANAT
+index	O
+from	O
+0	O
+to	O
+30	O
+cm	O
+H2O	B-CHED
+Paw	B-ANAT
+correlated	O
+with	O
+baseline	O
+values	O
+for	O
+RAP	O
+,	O
+PAOP	O
+,	O
+and	O
+right	O
+ventricular	B-ANAT
+EDVI	O
+(	O
+r2	O
+=	O
+.	O
+68	O
+,	O
+.	O
+43	O
+,	O
+and	O
+.	O
+34	O
+,	O
+respectively	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+8	O
+.	O
+0	O
+x	O
+10	O
+(	O
+9	O
+)	O
+cells	B-COMP
+/	O
+L	O
+in	O
+the	O
+control	O
+group	O
+during	O
+the	O
+same	O
+time	O
+period	O
+.	O
+
+Pulmonary	B-DISO
+interstitial	B-ANAT
+emphysema	I-DISO
+,	O
+serious	O
+intraventricular	B-DISO
+hemorrhage	I-DISO
+,	O
+and	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+occurred	O
+more	O
+frequently	O
+in	O
+patients	O
+with	O
+early	O
+neutropenia	O
+.	O
+
+A	O
+low	O
+concentration	O
+of	O
+mature	O
+neutrophils	B-ANAT
+in	O
+the	O
+systemic	O
+circulation	B-PROC
+of	O
+premature	O
+infants	O
+within	O
+2	O
+hours	O
+of	O
+birth	B-PROC
+is	O
+associated	O
+with	O
+more	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+during	O
+the	O
+first	O
+postnatal	O
+week	O
+and	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+serious	O
+complications	O
+of	O
+prematurity	O
+.	O
+
+As	O
+revealed	O
+by	O
+class	B-SPEC
+I	O
+tetramer	O
+technology	O
+the	O
+paralytic	O
+variant	O
+was	O
+superior	O
+in	O
+inducing	O
+specific	O
+CD8	O
++	O
+T	B-ANAT
+cells	I-ANAT
+during	O
+the	O
+acute	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+present	O
+data	O
+thus	O
+indicate	O
+that	O
+in	O
+immunocompetent	O
+mice	B-SPEC
+,	O
+effector	B-CHED
+CD8	O
++	O
+T	B-ANAT
+cells	I-ANAT
+control	O
+infection	B-DISO
+without	O
+mediating	O
+either	O
+clinical	O
+disease	O
+or	O
+demyelination	B-DISO
+.	O
+
+In	O
+this	O
+report	O
+we	O
+demonstrate	O
+that	O
+the	O
+synthesis	B-PROC
+and	O
+molar	B-ANAT
+ratios	O
+of	O
+subgenomic	O
+negative	O
+strands	O
+are	O
+similar	O
+in	O
+alternative	O
+host	B-COMP
+cells	B-COMP
+,	O
+suggesting	O
+that	O
+these	O
+RNAs	O
+function	O
+as	O
+important	O
+mediators	O
+of	O
+positive	O
+-	O
+strand	O
+synthesis	B-PROC
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+the	O
+subgenomic	O
+-	O
+length	O
+negative	O
+strands	O
+are	O
+the	O
+principal	O
+templates	O
+of	O
+positive	O
+-	O
+strand	O
+synthesis	B-PROC
+during	O
+MHV	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+bronchitis	B-PRGE
+virus	B-SPEC
+E	I-PRGE
+protein	B-CHED
+is	O
+targeted	B-PROC
+to	O
+the	O
+Golgi	B-COMP
+complex	I-COMP
+and	O
+directs	O
+release	B-PATH
+of	O
+virus	O
+-	O
+like	O
+particles	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-PRGE
+E	I-PRGE
+protein	B-CHED
+is	O
+a	O
+poorly	O
+characterized	O
+small	B-PRGE
+envelope	I-PRGE
+protein	B-CHED
+present	O
+in	O
+low	O
+levels	O
+in	O
+virions	B-COMP
+.	O
+
+Among	O
+mouse	B-SPEC
+viruses	B-SPEC
+,	O
+high	O
+positivity	O
+rates	O
+were	O
+observed	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+Theiler	O
+'	O
+s	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+(	O
+THEMV	O
+),	O
+minute	B-SPEC
+virus	I-SPEC
+of	I-SPEC
+mice	I-SPEC
+(	O
+MVM	O
+),	O
+Sendai	B-SPEC
+virus	I-SPEC
+and	O
+pneumonia	B-SPEC
+virus	I-SPEC
+of	I-SPEC
+mice	I-SPEC
+(	O
+PVM	B-SPEC
+);	O
+the	O
+prevalence	O
+rates	O
+were	O
+high	O
+in	O
+rats	B-SPEC
+with	O
+Khilam	O
+'	O
+s	O
+rat	B-SPEC
+virus	B-SPEC
+(	O
+KRV	O
+),	O
+THEMV	O
+,	O
+Toolan	O
+'	O
+s	O
+H	B-SPEC
+-	I-SPEC
+1	I-SPEC
+virus	I-SPEC
+,	O
+Sendai	B-SPEC
+virus	I-SPEC
+,	O
+Parker	O
+'	O
+s	O
+rat	B-SPEC
+coronavirus	B-SPEC
+(	O
+RCV	O
+/	O
+SDA	B-DISO
+)	O
+and	O
+PVM	B-SPEC
+.	O
+
+During	O
+the	O
+last	O
+decade	O
+,	O
+the	O
+prevalence	O
+of	O
+some	O
+agents	O
+such	O
+as	O
+MHV	B-SPEC
+,	O
+Sendai	B-SPEC
+virus	I-SPEC
+,	O
+THEMV	O
+,	O
+PVM	B-SPEC
+and	O
+MVM	O
+has	O
+apparently	O
+decreased	O
+although	O
+they	O
+were	O
+still	O
+present	O
+in	O
+1997	O
+(	O
+except	O
+for	O
+PVM	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Structure	O
+,	O
+stability	O
+and	O
+function	O
+of	O
+RNA	O
+pseudoknots	O
+involved	O
+in	O
+stimulating	O
+ribosomal	B-COMP
+frameshifting	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Programmed	O
+-	O
+1	O
+ribosomal	O
+frameshifting	O
+has	O
+become	O
+the	O
+subject	O
+of	O
+increasing	O
+interest	O
+over	O
+the	O
+last	O
+several	O
+years	O
+,	O
+due	O
+in	O
+part	O
+to	O
+the	O
+ubiquitous	O
+nature	O
+of	O
+this	O
+translational	B-PROC
+recoding	O
+mechanism	O
+in	O
+pathogenic	O
+animal	B-SPEC
+and	O
+plant	B-SPEC
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+virus	O
+disease	O
+that	O
+displays	O
+dermal	O
+ulceration	B-DISO
+and	O
+high	O
+mortality	O
+has	O
+been	O
+occurring	O
+since	O
+1996	O
+in	O
+color	O
+carp	B-DISO
+Cyprinus	B-SPEC
+carpio	I-SPEC
+reared	O
+in	O
+warm	O
+water	B-CHED
+in	O
+Japan	O
+.	O
+
+In	O
+histological	O
+examinations	O
+,	O
+initial	O
+erosive	O
+lesions	O
+displayed	O
+necrosis	B-PROC
+,	O
+hemorrhage	B-DISO
+and	O
+fibrin	B-DISO
+deposition	I-DISO
+in	O
+the	O
+dermal	O
+loose	B-ANAT
+connective	I-ANAT
+tissue	I-ANAT
+and	O
+were	O
+accompanied	O
+by	O
+the	O
+partial	O
+destruction	O
+of	O
+the	O
+epidermis	B-ANAT
+.	O
+
+The	O
+putative	O
+virus	O
+was	O
+isolated	O
+and	O
+cultured	O
+in	O
+epithelioma	B-DISO
+papillosum	O
+cyprini	O
+(	O
+EPC	O
+)	O
+cells	B-COMP
+.	O
+
+The	O
+binding	B-FUNC
+site	O
+in	O
+the	O
+amino	O
+region	O
+of	O
+N	O
+was	O
+either	O
+not	O
+present	O
+or	O
+only	O
+partially	O
+present	O
+in	O
+the	O
+first	O
+91	O
+residues	O
+because	O
+no	O
+interaction	O
+with	O
+RNA	O
+was	O
+observed	O
+with	O
+the	O
+polypeptide	B-CHED
+incorporating	O
+these	O
+residues	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+newborns	O
+with	O
+glomerulocystic	O
+kidney	O
+disease	O
+manifesting	O
+as	O
+late	O
+onset	O
+oligohydramnion	O
+and	O
+neonatal	B-DISO
+anuria	I-DISO
+,	O
+yet	O
+without	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+are	O
+presented	O
+.	O
+
+These	O
+results	O
+hold	O
+promise	O
+for	O
+the	O
+development	B-PROC
+of	O
+a	O
+gene	O
+therapy	O
+treatment	O
+for	O
+chronic	B-DISO
+viral	I-DISO
+hepatitis	I-DISO
+based	O
+on	O
+liver	B-ANAT
+-	O
+restricted	O
+expression	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha2	I-PRGE
+.	O
+
+Moreover	O
+,	O
+the	O
+mechanism	O
+by	O
+which	O
+lesions	O
+are	O
+produced	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+is	O
+still	O
+not	O
+clear	O
+.	O
+
+Cerebral	B-ANAT
+magnetic	O
+resonance	O
+showed	O
+ischemic	O
+lesions	O
+in	O
+the	O
+tail	O
+of	O
+the	O
+right	B-ANAT
+caudate	I-ANAT
+nucleus	I-ANAT
+and	O
+right	O
+corona	B-ANAT
+radiata	I-ANAT
+and	O
+the	O
+posteromedial	O
+part	O
+of	O
+the	O
+right	B-ANAT
+putamen	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Proinflammatory	O
+cytokines	O
+and	O
+viral	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+pigs	B-SPEC
+.	O
+
+The	O
+first	O
+part	O
+of	O
+this	O
+review	O
+concentrates	O
+on	O
+known	O
+clinical	O
+and	O
+pathogenetic	O
+features	O
+of	O
+these	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Effect	O
+of	O
+bronchial	B-ANAT
+drainage	B-ANAT
+on	O
+the	O
+improvement	O
+in	O
+gas	B-ENZY
+exchange	O
+observed	O
+in	O
+ventral	O
+decubitus	O
+in	O
+ARDS	O
+].	O
+
+Concerning	O
+secretions	B-ANAT
+,	O
+we	O
+collected	O
+3	O
+.	O
+0	O
++/-	O
+
+TITLE	O
+:	O
+Experiences	O
+with	O
+severe	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+malaria	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+All	O
+patients	O
+who	O
+died	B-PROC
+required	O
+haemofiltration	O
+because	O
+of	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+As	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+is	O
+a	O
+potentially	O
+life	O
+-	O
+threatening	O
+disease	O
+,	O
+reliable	O
+criteria	O
+for	O
+ICU	O
+admission	O
+should	O
+be	O
+defined	O
+and	O
+risk	O
+factors	O
+identified	O
+.	O
+
+Early	O
+ICU	O
+monitoring	O
+should	O
+be	O
+attempted	O
+,	O
+especially	O
+under	O
+the	O
+following	O
+conditions	O
+:	O
+(	O
+1	O
+)	O
+lack	O
+of	O
+clinical	O
+response	O
+to	O
+anti	O
+-	O
+malarial	O
+treatment	O
+within	O
+48	O
+h	O
+and	O
+/	O
+or	O
+(	O
+2	O
+)	O
+any	O
+signs	O
+of	O
+neurological	O
+disturbance	O
+(	O
+hypoglycaemia	B-DISO
+excluded	O
+).	O
+
+The	O
+conventional	O
+treatment	O
+includes	O
+intravenous	O
+N	B-CHED
+-	I-CHED
+acetylcysteine	I-CHED
+,	O
+L	O
+-	O
+3	O
+,	O
+4	O
+-	O
+dehydroproline	O
+,	O
+methylene	B-CHED
+blue	I-CHED
+,	O
+and	O
+respiratory	O
+support	O
+according	O
+to	O
+the	O
+lung	B-ANAT
+protective	O
+strategy	O
+.	O
+
+892	O
+gm	O
+birth	B-PROC
+weight	O
+,	O
+p	O
+=	O
+0	O
+.	O
+021	O
+),	O
+with	O
+higher	O
+peak	O
+postpartum	O
+blood	B-ANAT
+pressures	O
+(<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+with	O
+more	O
+abnormal	O
+laboratory	O
+values	O
+indicative	O
+of	O
+multisystem	O
+disease	O
+,	O
+compared	O
+with	O
+patients	O
+without	O
+this	O
+complication	B-DISO
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+support	O
+in	O
+an	O
+adult	O
+with	O
+severe	O
+carbon	B-CHED
+monoxide	I-CHED
+poisoning	O
+and	O
+shock	O
+following	O
+smoke	O
+inhalation	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+Airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+and	O
+intermittent	O
+prone	O
+positioning	O
+therapy	O
+were	O
+instituted	O
+.	O
+
+Smoke	O
+inhalation	B-PROC
+and	O
+carbon	B-CHED
+monoxide	I-CHED
+poisoning	O
+may	O
+lead	O
+to	O
+life	O
+-	O
+threatening	O
+hypoxemia	O
+associated	O
+with	O
+resultant	O
+cardiovascular	B-ANAT
+instability	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+significant	O
+increase	O
+in	O
+hepatic	B-ANAT
+enzymes	O
+and	O
+MPO	B-FUNC
+activity	O
+was	O
+induced	O
+by	O
+AP	O
+and	O
+mirrored	O
+by	O
+intraperitoneal	O
+elastase	O
+.	O
+
+From	O
+1	O
+/	O
+RD	O
+the	O
+number	O
+needed	O
+to	O
+treat	O
+(	O
+NNT	O
+)	O
+for	O
+benefits	O
+,	O
+and	O
+number	O
+needed	O
+to	O
+harm	O
+(	O
+NNH	B-DISO
+)	O
+for	O
+adverse	B-DISO
+effects	I-DISO
+,	O
+were	O
+calculated	O
+.	O
+
+In	O
+the	O
+subgroup	O
+of	O
+four	O
+trials	O
+where	O
+a	O
+high	O
+volume	O
+strategy	O
+(	O
+HVS	B-FUNC
+)	O
+was	O
+used	O
+,	O
+HFOV	O
+results	O
+in	O
+more	O
+favourable	O
+pulmonary	B-ANAT
+outcomes	O
+.	O
+
+In	O
+the	O
+subgroup	O
+of	O
+two	O
+trials	O
+(	O
+HIFI	O
+1989	O
+,	O
+Rettwitz	O
+-	O
+Volk	O
+1998	O
+)	O
+not	O
+using	O
+a	O
+HVS	B-FUNC
+there	O
+is	O
+no	O
+effect	O
+of	O
+HFOV	O
+on	O
+the	O
+rate	O
+of	O
+CLD	B-DISO
+;	O
+however	O
+,	O
+there	O
+is	O
+an	O
+increase	O
+in	O
+the	O
+rate	O
+of	O
+PVL	O
+[	O
+summary	O
+RR	O
+1	O
+.	O
+64	O
+(	O
+1	O
+.	O
+02	O
+,	O
+2	O
+.	O
+64	O
+).	O
+
+TITLE	O
+:	O
+Elective	O
+high	O
+frequency	O
+jet	O
+ventilation	O
+versus	O
+conventional	O
+ventilation	O
+for	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+preterm	O
+infants	O
+.	O
+
+Trials	O
+which	O
+used	O
+HFJV	O
+to	O
+'	O
+rescue	O
+'	O
+preterm	O
+infants	O
+due	O
+to	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+usually	O
+beyond	O
+24	O
+hours	O
+,	O
+and	O
+trials	O
+that	O
+used	O
+HFJV	O
+for	O
+a	O
+mandatory	O
+time	O
+period	O
+and	O
+then	O
+switched	O
+back	B-ANAT
+to	O
+CV	O
+,	O
+were	O
+not	O
+included	O
+in	O
+this	O
+review	O
+.	O
+
+Searches	O
+were	O
+made	O
+of	O
+the	O
+Oxford	O
+Database	O
+of	O
+Perinatal	O
+Trials	O
+,	O
+Medline	O
+(	O
+MeSH	O
+terms	O
+:	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+;	O
+text	O
+word	O
+:	O
+early	O
+;	O
+limits	O
+:	O
+age	O
+,	O
+newborn	O
+:	O
+publication	O
+type	O
+,	O
+clinical	O
+trial	O
+),	O
+PubMed	O
+,	O
+abstracts	O
+,	O
+conference	O
+and	O
+symposia	O
+proceedings	O
+,	O
+expert	O
+informants	O
+,	O
+and	O
+journal	O
+hand	O
+searching	O
+in	O
+the	O
+English	O
+language	O
+.	O
+
+Further	O
+analysis	O
+of	O
+data	O
+with	O
+regard	O
+to	O
+surfactant	B-CHED
+type	O
+was	O
+performed	O
+.	O
+
+The	O
+meta	B-SPEC
+-	O
+analyses	O
+demonstrated	O
+significant	O
+reductions	O
+in	O
+risk	O
+of	O
+pneumothorax	B-DISO
+(	O
+Typical	O
+RR	O
+0	O
+.	O
+70	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+59	O
+,	O
+0	O
+.	O
+82	O
+;	O
+Typical	O
+RD	O
+-	O
+0	O
+.	O
+05	O
+,	O
+95	O
+%	O
+CI	O
+-	O
+0	O
+.	O
+08	O
+,	O
+-	O
+0	O
+.	O
+03	O
+),	O
+and	O
+pulmonary	B-DISO
+interstitial	B-ANAT
+emphysema	I-DISO
+(	O
+Typical	O
+RR	O
+0	O
+.	O
+63	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+43	O
+,	O
+0	O
+.	O
+93	O
+;	O
+Typical	O
+RD	O
+-	O
+0	O
+.	O
+06	O
+,	O
+95	O
+%	O
+CI	O
+-	O
+0	O
+.	O
+10	O
+,	O
+-	O
+0	O
+.	O
+01	O
+)	O
+in	O
+infants	O
+randomized	O
+to	O
+early	O
+selective	O
+surfactant	B-CHED
+administration	O
+.	O
+
+Early	O
+selective	O
+surfactant	B-CHED
+administration	O
+given	O
+to	O
+infants	O
+with	O
+RDS	O
+requiring	O
+assisted	O
+ventilation	O
+leads	O
+to	O
+a	O
+decreased	O
+risk	O
+of	O
+acute	O
+pulmonary	B-ANAT
+injury	O
+(	O
+decreased	O
+risk	O
+of	O
+pneumothorax	B-DISO
+and	O
+pulmonary	B-DISO
+interstitial	B-ANAT
+emphysema	I-DISO
+)	O
+and	O
+a	O
+decreased	O
+risk	O
+of	O
+neonatal	O
+mortality	O
+and	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+compared	O
+to	O
+delaying	O
+treatment	O
+of	O
+such	O
+infants	O
+until	O
+they	O
+develop	O
+established	O
+RDS	O
+.	O
+
+TITLE	O
+:	O
+Histoplasmosis	B-DISO
+presenting	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+exposure	O
+to	O
+bat	B-ENZY
+feces	B-ANAT
+in	O
+a	O
+home	O
+basement	O
+.	O
+
+The	O
+adult	O
+died	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+more	O
+severe	O
+presentation	O
+of	O
+the	O
+disease	O
+in	O
+this	O
+patient	O
+may	O
+be	O
+partly	O
+explained	O
+by	O
+a	O
+heavier	O
+exposure	O
+to	O
+the	O
+feces	B-ANAT
+of	O
+bats	B-SPEC
+.	O
+
+Mutant	B-DISO
+M	O
+proteins	B-CHED
+which	O
+were	O
+not	O
+able	O
+to	O
+assemble	O
+into	O
+viruslike	O
+particles	O
+(	O
+VLPs	B-ANAT
+)	O
+by	O
+themselves	O
+(	O
+C	O
+.	O
+A	O
+.	O
+M	O
+.	O
+de	O
+Haan	O
+,	O
+L	O
+.	O
+Kuo	O
+,	O
+P	O
+.	O
+S	O
+.	O
+Masters	O
+,	O
+H	O
+.	O
+Vennema	O
+,	O
+and	O
+P	O
+.	O
+J	O
+.	O
+M	O
+.	O
+Rottier	O
+,	O
+J	O
+.	O
+Virol	O
+.	O
+
+Finally	O
+,	O
+we	O
+tested	O
+the	O
+stringency	O
+with	O
+which	O
+membrane	B-COMP
+proteins	B-CHED
+are	O
+selected	O
+for	O
+incorporation	O
+into	O
+the	O
+coronavirus	B-SPEC
+envelope	B-COMP
+by	O
+probing	O
+the	O
+coassembly	O
+of	O
+some	O
+foreign	O
+proteins	B-CHED
+.	O
+
+Defective	O
+genomes	O
+with	O
+shortened	O
+poly	O
+(	O
+A	O
+)	O
+tails	B-ANAT
+consisting	O
+of	O
+5	O
+or	O
+10	O
+A	O
+residues	O
+were	O
+replicated	O
+after	O
+transfection	B-PROC
+into	O
+helper	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+RNAs	O
+with	O
+shortened	O
+poly	O
+(	O
+A	O
+)	O
+tails	B-ANAT
+exhibited	O
+less	O
+in	O
+vitro	O
+PABP	O
+binding	B-FUNC
+,	O
+suggesting	O
+that	O
+decreased	O
+interactions	O
+with	O
+the	O
+protein	B-CHED
+may	O
+affect	O
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Decontamination	O
+of	O
+human	B-SPEC
+xenotransplantable	O
+tumor	B-DISO
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+by	O
+implantation	B-PROC
+in	O
+nude	O
+rat	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+The	O
+difference	O
+between	O
+the	O
+two	O
+trials	O
+was	O
+the	O
+duration	O
+of	O
+implantation	B-PROC
+of	O
+the	O
+tumor	B-DISO
+in	O
+the	O
+nude	O
+rat	B-SPEC
+,	O
+i	O
+.	O
+e	O
+.,	O
+12	O
+days	O
+in	O
+the	O
+first	O
+and	O
+24	O
+days	O
+in	O
+the	O
+second	O
+trial	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+MHV	B-SPEC
+-	O
+TY	O
+strain	O
+was	O
+performed	O
+on	O
+major	O
+structural	O
+,	O
+spike	O
+(	O
+S	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+),	O
+proteins	B-CHED
+directly	O
+from	O
+PCR	O
+products	O
+.	O
+
+Clinically	O
+,	O
+as	O
+the	O
+severity	O
+of	O
+VOL	O
+increased	O
+,	O
+the	O
+amount	O
+of	O
+ascites	O
+observed	O
+during	O
+autopsy	O
+increased	O
+significantly	O
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+the	O
+time	O
+from	O
+hospitalization	O
+to	O
+death	B-PROC
+was	O
+significantly	O
+longer	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Fatty	B-DISO
+degeneration	I-DISO
+tended	O
+to	O
+be	O
+milder	O
+as	O
+VOL	O
+increased	O
+in	O
+severity	O
+although	O
+the	O
+difference	O
+was	O
+not	O
+significant	O
+,	O
+whereas	O
+bile	B-ANAT
+retention	B-PROC
+tended	O
+to	O
+be	O
+more	O
+marked	O
+.	O
+
+The	O
+pathologic	O
+change	O
+induced	O
+by	O
+the	O
+direct	O
+viral	O
+invasion	B-DISO
+cannot	O
+be	O
+responsible	O
+for	O
+all	O
+of	O
+the	O
+symptoms	O
+,	O
+especially	O
+for	O
+the	O
+rapid	O
+and	O
+severe	O
+clinical	O
+course	O
+of	O
+the	O
+disease	O
+within	O
+24	O
+-	O
+48	O
+h	O
+after	O
+the	O
+initial	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Cells	B-COMP
+infected	O
+with	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+were	O
+solubilized	O
+with	O
+Triton	B-CHED
+X	I-CHED
+-	I-CHED
+100	I-CHED
+to	O
+yield	O
+a	O
+cell	B-COMP
+lysate	O
+(	O
+CL	O
+)	O
+antigen	B-CHED
+having	O
+high	O
+hemagglutinating	O
+(	O
+HA	O
+)	O
+titers	O
+.	O
+
+The	O
+animals	B-SPEC
+were	O
+challenged	O
+with	O
+virus	B-SPEC
+1	O
+wk	O
+after	O
+the	O
+second	O
+inoculation	O
+.	O
+
+During	O
+infection	B-DISO
+,	O
+the	O
+bacteria	B-SPEC
+produce	O
+leukotoxin	O
+(	O
+LKT	O
+)	O
+and	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+),	O
+both	O
+potent	O
+inducers	O
+of	O
+inflammation	B-DISO
+.	O
+
+Despite	O
+research	O
+in	O
+this	O
+field	O
+,	O
+the	O
+pathogenesis	B-DISO
+of	O
+PP	O
+is	O
+still	O
+incomplete	O
+.	O
+
+Accumulating	O
+data	O
+suggest	O
+that	O
+the	O
+maximization	O
+and	O
+maintenance	O
+of	O
+lung	B-ANAT
+recruitment	B-DISO
+may	O
+reduce	O
+lung	B-ANAT
+parenchymal	O
+injury	O
+from	O
+positive	O
+pressure	O
+ventilation	O
+in	O
+ARDS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Accumulating	O
+data	O
+suggest	O
+that	O
+the	O
+maximization	O
+and	O
+maintenance	O
+of	O
+lung	B-ANAT
+recruitment	B-DISO
+may	O
+reduce	O
+lung	B-ANAT
+parenchymal	O
+injury	O
+from	O
+positive	O
+pressure	O
+ventilation	O
+in	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Dying	B-PROC
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+or	O
+multiple	B-DISO
+organ	I-DISO
+system	I-DISO
+failure	I-DISO
+with	O
+sepsis	B-DISO
+.	O
+
+The	O
+average	O
+time	O
+from	O
+the	O
+DNR	O
+order	B-SPEC
+to	O
+death	B-PROC
+was	O
+2	O
+days	O
+.	O
+
+Families	O
+of	O
+42	O
+%	O
+of	O
+the	O
+patients	O
+who	O
+died	B-PROC
+reported	O
+one	O
+or	O
+more	O
+substantial	O
+burden	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+20089	O
+nucleotide	B-CHED
+(	O
+nt	O
+)	O
+sequence	O
+was	O
+determined	O
+for	O
+the	O
+5	O
+'	O
+end	O
+of	O
+the	O
+(+)-	O
+ssRNA	O
+genome	O
+of	O
+gill	B-SPEC
+-	I-SPEC
+associated	I-SPEC
+virus	I-SPEC
+(	O
+GAV	O
+),	O
+a	O
+yellow	O
+head	B-ANAT
+-	O
+like	O
+virus	B-SPEC
+infecting	O
+Penaeus	B-SPEC
+monodon	I-SPEC
+prawns	O
+.	O
+
+The	O
+ORFs	O
+are	O
+structurally	O
+related	O
+to	O
+the	O
+ORF1a	B-PRGE
+and	I-PRGE
+ORF1ab	I-PRGE
+polyproteins	I-PRGE
+of	O
+coronaviruses	O
+and	O
+arteriviruses	B-SPEC
+.	O
+
+The	O
+99	O
+nt	O
+overlap	O
+between	O
+ORF1a	O
+and	O
+ORF1b	O
+contains	O
+a	O
+putative	O
+AAAUUUU	O
+'	O
+slippery	O
+'	O
+sequence	O
+associated	O
+with	O
+-	O
+1	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+.	O
+
+Thus	O
+,	O
+the	O
+direct	O
+use	O
+of	O
+phage	O
+-	O
+displayed	O
+peptides	B-CHED
+to	O
+evaluate	O
+protective	O
+antiviral	B-CHED
+immune	B-PROC
+responses	I-PROC
+complements	O
+their	O
+use	O
+to	O
+characterize	O
+antibody	B-COMP
+-	O
+binding	B-FUNC
+epitopes	O
+.	O
+
+A	O
+need	O
+exists	O
+for	O
+collaborative	O
+education	O
+of	O
+physicians	O
+and	O
+nurses	O
+in	O
+performing	O
+,	O
+obtaining	O
+,	O
+and	O
+interpreting	O
+information	O
+from	O
+the	O
+use	O
+of	O
+pulmonary	B-ANAT
+artery	I-ANAT
+catheters	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+carries	O
+a	O
+high	O
+mortality	O
+of	O
+about	O
+60	O
+%.	O
+
+We	O
+report	O
+the	O
+use	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+to	O
+rescue	O
+a	O
+child	O
+with	O
+ARDS	B-DISO
+.	O
+
+With	O
+ECMO	O
+support	O
+,	O
+gas	B-ENZY
+exchange	O
+was	O
+well	O
+maintained	O
+with	O
+a	O
+lower	O
+ventilator	O
+setting	O
+,	O
+and	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injuries	O
+were	O
+avoided	O
+.	O
+
+Viral	O
+antigen	B-CHED
+was	O
+detected	O
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+tracheal	B-ANAT
+epithelium	I-ANAT
+from	O
+16	O
+hr	O
+to	O
+6	O
+days	O
+post	O
+-	O
+inoculation	O
+(	O
+p	O
+.	O
+i	O
+.)	O
+with	O
+a	O
+peak	O
+on	O
+4	O
+days	O
+p	O
+.	O
+i	O
+.	O
+
+A	O
+few	B-PRGE
+IgG	I-PRGE
++,	I-PRGE
+IgM	B-PRGE
++	I-PRGE
+and	O
+IgA	B-PRGE
++	I-PRGE
+cells	B-COMP
+were	O
+detected	O
+in	O
+the	O
+submucosa	B-ANAT
+from	O
+8	O
+hr	O
+p	O
+.	O
+i	O
+.	O
+
+Following	O
+differential	O
+centrifugation	O
+of	O
+lysates	O
+of	O
+MHV	B-SPEC
+-	O
+infected	O
+DBT	B-CHED
+cells	B-COMP
+,	O
+gene	B-PRGE
+1	I-PRGE
+proteins	I-PRGE
+as	O
+well	O
+as	O
+the	O
+structural	O
+N	O
+and	O
+M	O
+proteins	B-CHED
+were	O
+detected	O
+almost	O
+exclusively	O
+in	O
+a	O
+high	O
+-	O
+speed	O
+small	O
+membrane	O
+pellet	O
+.	O
+
+Following	O
+fractionation	O
+of	O
+the	O
+small	O
+membrane	B-COMP
+pellet	O
+on	O
+an	O
+iodixanol	B-CHED
+density	O
+gradient	O
+,	O
+the	O
+gene	B-PRGE
+1	I-PRGE
+proteins	B-CHED
+p28	B-COMP
+and	O
+helicase	B-PRGE
+cofractionated	O
+with	O
+dense	O
+membranes	B-ANAT
+(	O
+1	O
+.	O
+12	O
+to	O
+1	O
+.	O
+13	O
+g	O
+/	O
+ml	O
+)	O
+that	O
+also	O
+contained	O
+peak	O
+concentrations	O
+of	O
+N	O
+.	O
+In	O
+contrast	O
+,	O
+p65	B-PRGE
+and	O
+p1a	B-PRGE
+-	I-PRGE
+22	I-PRGE
+were	O
+detected	O
+in	O
+a	O
+distinct	O
+population	O
+of	O
+less	O
+dense	O
+membranes	B-ANAT
+(	O
+1	O
+.	O
+05	O
+to	O
+1	O
+.	O
+09	O
+g	O
+/	O
+ml	O
+).	O
+
+Because	O
+HFOV	O
+is	O
+considered	O
+to	O
+be	O
+a	O
+""""	O
+rescue	O
+""""	O
+therapy	O
+,	O
+intervention	O
+with	O
+HFOV	O
+is	O
+usually	O
+in	O
+the	O
+later	O
+stages	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+consideration	O
+of	O
+the	O
+time	O
+to	O
+intervention	O
+has	O
+not	O
+been	O
+previously	O
+examined	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+of	O
+respiratory	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+,	O
+other	O
+cytocidal	O
+viruses	B-SPEC
+,	O
+and	O
+Pasteurella	B-SPEC
+spp	B-ENZY
+from	O
+cattle	O
+involved	O
+in	O
+two	O
+natural	O
+outbreaks	O
+of	O
+shipping	B-DISO
+fever	I-DISO
+.	O
+
+105	O
+and	O
+120	O
+castrated	O
+male	O
+4	O
+-	O
+to	O
+8	O
+-	O
+month	O
+-	O
+old	O
+feedlot	O
+cattle	B-SPEC
+involved	O
+in	O
+1997	O
+and	O
+1998	O
+outbreaks	O
+,	O
+respectively	O
+.	O
+
+93	O
+of	O
+105	O
+cattle	B-SPEC
+and	O
+106	O
+of	O
+120	O
+cattle	B-SPEC
+developed	O
+signs	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+during	O
+1997	O
+and	O
+1998	O
+,	O
+respectively	O
+,	O
+and	O
+RBCV	O
+was	O
+isolated	O
+from	O
+81	O
+and	O
+89	O
+sick	O
+cattle	O
+,	O
+respectively	O
+,	O
+while	O
+at	O
+the	O
+order	B-SPEC
+-	O
+buyer	O
+'	O
+s	O
+barn	O
+or	O
+the	O
+day	O
+after	O
+arrival	O
+at	O
+the	O
+feedlot	O
+.	O
+
+Results	O
+suggest	O
+that	O
+RBCV	O
+may	O
+play	O
+a	O
+causative	O
+role	O
+in	O
+outbreaks	O
+of	O
+shipping	B-DISO
+fever	I-DISO
+in	O
+cattle	B-SPEC
+.	O
+
+More	O
+than	O
+80	O
+%	O
+of	O
+the	O
+sick	O
+cattle	B-SPEC
+shed	O
+RBCV	O
+at	O
+the	O
+beginning	O
+of	O
+2	O
+outbreaks	O
+when	O
+the	O
+Pasteurella	B-SPEC
+spp	B-ENZY
+infection	B-DISO
+rate	O
+was	O
+low	O
+.	O
+
+RESULTS	O
+:	O
+93	O
+of	O
+105	O
+cattle	B-SPEC
+and	O
+106	O
+of	O
+120	O
+cattle	B-SPEC
+developed	O
+signs	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+during	O
+1997	O
+and	O
+1998	O
+,	O
+respectively	O
+,	O
+and	O
+RBCV	O
+was	O
+isolated	O
+from	O
+81	O
+and	O
+89	O
+sick	O
+cattle	B-SPEC
+,	O
+respectively	O
+,	O
+while	O
+at	O
+the	O
+order	B-SPEC
+-	O
+buyer	O
+'	O
+s	O
+barn	O
+or	O
+the	O
+day	O
+after	O
+arrival	O
+at	O
+the	O
+feedlot	O
+.	O
+
+ABSTRACT	O
+:	O
+Systemic	O
+hemodynamics	B-PROC
+,	O
+oxygenating	O
+function	O
+of	O
+the	O
+lungs	B-ANAT
+,	O
+and	O
+oxygen	B-CHED
+budgeting	O
+were	O
+studied	O
+in	O
+32	O
+patients	O
+with	O
+acute	O
+bowel	B-DISO
+obstruction	I-DISO
+(	O
+ABO	O
+)	O
+with	O
+severe	O
+endotoxicosis	B-DISO
+.	O
+
+The	O
+severity	O
+of	O
+pancreatic	B-ANAT
+and	O
+pulmonary	B-ANAT
+injuries	O
+was	O
+evaluated	O
+1	O
+,	O
+3	O
+,	O
+and	O
+8	O
+days	O
+after	O
+the	O
+induction	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+by	O
+morphometric	O
+and	O
+pulmonary	B-ANAT
+mechanical	O
+studies	O
+.	O
+
+Biliopancreatic	O
+duct	B-ANAT
+pressure	O
+was	O
+measured	O
+during	O
+infusion	O
+of	O
+solutions	O
+in	O
+SAL	B-CHED
+and	O
+TAU	B-CHED
+groups	O
+.	O
+
+There	O
+was	O
+an	O
+increase	O
+in	O
+polymorphonuclear	B-ANAT
+cells	I-ANAT
+in	O
+alveolar	B-ANAT
+septa	O
+on	O
+day	O
+1	O
+only	O
+in	O
+the	O
+TAU	B-CHED
+group	O
+(	O
+p	O
+<	O
+.	O
+001	O
+).	O
+
+In	O
+contrast	O
+,	O
+both	O
+experimental	O
+groups	O
+presented	O
+greater	O
+values	O
+of	O
+PMN	B-PROC
+cells	B-COMP
+on	O
+day	O
+8	O
+compared	O
+with	O
+the	O
+SHAM	O
+group	O
+(	O
+p	O
+<	O
+.	O
+001	O
+).	O
+
+In	O
+contrast	O
+,	O
+the	O
+SAL	B-CHED
+group	O
+had	O
+lower	O
+mortality	O
+than	O
+the	O
+TAU	B-CHED
+group	O
+in	O
+the	O
+first	O
+two	O
+days	O
+(	O
+17	O
+%	O
+and	O
+52	O
+%,	O
+respectively	O
+,	O
+p	O
+=	O
+.	O
+03	O
+).	O
+
+These	O
+changes	O
+are	O
+worse	O
+in	O
+the	O
+presence	O
+of	O
+sodium	B-CHED
+taurocholate	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+introduction	O
+of	O
+Perfluorochemicals	O
+into	O
+medicine	O
+and	O
+especially	O
+into	O
+the	O
+treatment	O
+of	O
+severe	O
+lung	B-ANAT
+injury	O
+is	O
+a	O
+fascinating	O
+scientific	O
+task	O
+.	O
+
+The	O
+clinical	O
+appearance	O
+,	O
+which	O
+was	O
+initially	O
+normal	O
+,	O
+deteriorated	O
+with	O
+a	O
+respiratory	B-DISO
+distress	I-DISO
+in	O
+30	O
+to	O
+60	O
+minutes	O
+.	O
+
+Concurrent	O
+infections	B-DISO
+with	O
+other	O
+enteropathogen	O
+(	O
+s	O
+)	O
+were	O
+detected	O
+in	O
+31	O
+.	O
+3	O
+%,	O
+33	O
+.	O
+3	O
+%,	O
+20	O
+.	O
+6	O
+%	O
+and	O
+3	O
+.	O
+4	O
+%	O
+of	O
+the	O
+rotavirus	B-SPEC
+infected	O
+calves	O
+in	O
+the	O
+age	O
+-	O
+groups	O
+1	O
+-	O
+7	O
+,	O
+8	O
+-	O
+14	O
+,	O
+15	O
+-	O
+21	O
+and	O
+22	O
+-	O
+30	O
+d	O
+,	O
+respectively	O
+.	O
+
+National	O
+Acute	B-DISO
+Chest	B-ANAT
+Syndrome	I-DISO
+Study	O
+Group	O
+.	O
+
+Neurologic	O
+events	O
+occurred	O
+in	O
+11	O
+percent	O
+of	O
+patients	O
+,	O
+among	O
+whom	O
+46	O
+percent	O
+had	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Treatment	O
+with	O
+phenotypically	O
+matched	O
+transfusions	O
+improved	O
+oxygenation	B-PROC
+,	O
+with	O
+a	O
+1	O
+percent	O
+rate	O
+of	O
+alloimmunization	B-DISO
+.	O
+
+Treatment	O
+with	O
+transfusions	O
+and	O
+bronchodilators	O
+improves	O
+oxygenation	B-PROC
+,	O
+and	O
+with	O
+aggressive	B-DISO
+treatment	O
+,	O
+most	O
+patients	O
+who	O
+have	O
+respiratory	B-DISO
+failure	I-DISO
+recover	B-PROC
+.	O
+
+TITLE	O
+:	O
+Localization	B-PROC
+of	O
+linear	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+on	O
+infectious	B-DISO
+bronchitis	B-PRGE
+virus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+Sera	B-COMP
+against	O
+Australia	O
+T	O
+,	O
+China	O
+Ch5	O
+,	O
+Singapore	O
+P4	O
+,	O
+USA	O
+M41	O
+and	O
+China	O
+T3	O
+isolates	O
+were	O
+used	O
+to	O
+study	O
+the	O
+conservation	O
+and	O
+localization	B-PROC
+of	O
+the	O
+antigenic	O
+region	O
+on	O
+the	O
+IBV	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+Thirty	O
+-	O
+one	O
+(	O
+31	O
+)	O
+formalin	B-CHED
+-	O
+fixed	B-ANAT
+hearts	B-ANAT
+from	O
+domestic	B-SPEC
+cats	I-SPEC
+who	O
+died	B-PROC
+of	O
+idiopathic	B-DISO
+cardiomyopathy	I-DISO
+were	O
+randomly	O
+selected	O
+from	O
+pathology	B-DISO
+archives	O
+.	O
+
+Six	O
+patients	O
+with	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+PEEP	B-CHED
+by	O
+itself	O
+does	O
+not	O
+have	O
+a	O
+consistent	O
+effect	O
+on	O
+splanchnic	O
+blood	B-PROC
+flow	I-PROC
+and	O
+metabolism	B-PROC
+when	O
+cardiac	B-ANAT
+index	O
+is	O
+stable	O
+and	O
+patients	O
+are	O
+ventilated	O
+within	O
+the	O
+linear	O
+part	O
+of	O
+the	O
+pv	O
+curve	O
+.	O
+
+TITLE	O
+:	O
+Abdominal	B-ANAT
+compartment	I-ANAT
+syndrome	I-DISO
+in	O
+children	O
+:	O
+experience	O
+with	O
+three	O
+cases	O
+.	O
+
+The	O
+first	O
+child	O
+sustained	O
+a	O
+thoracoabdominal	O
+crush	O
+injury	O
+,	O
+underwent	O
+immediate	O
+celiotomy	O
+for	O
+splenic	B-ANAT
+avulsion	O
+and	O
+a	O
+liver	B-ANAT
+laceration	O
+,	O
+and	O
+required	O
+decompression	O
+5	O
+hours	O
+postoperatively	O
+.	O
+
+The	O
+second	O
+underwent	O
+ligation	O
+of	O
+her	O
+bluntly	O
+transected	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+;	O
+because	O
+of	O
+massive	B-DISO
+edema	I-DISO
+,	O
+her	O
+abdominal	B-ANAT
+wall	I-ANAT
+could	O
+not	O
+be	O
+closed	O
+,	O
+and	O
+prophylactic	O
+decompression	O
+had	O
+to	O
+be	O
+performed	O
+.	O
+
+Subsequently	O
+,	O
+each	O
+child	O
+underwent	O
+abdominal	B-ANAT
+wall	I-ANAT
+reconstruction	O
+and	O
+recovered	O
+uneventfully	O
+.	O
+
+In	O
+our	O
+previous	O
+studies	O
+,	O
+the	O
+proteinase	B-PROC
+was	O
+identified	O
+as	O
+a	O
+33	O
+-	O
+kDa	O
+protein	B-CHED
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+,	O
+and	O
+its	O
+catalytic	O
+center	O
+was	O
+shown	O
+to	O
+consist	O
+of	O
+H	O
+(	O
+2820	O
+)	O
+and	O
+C	O
+(	O
+2922	O
+)	O
+residues	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+further	O
+characterization	O
+of	O
+the	O
+two	O
+cleavage	B-PROC
+sites	O
+demonstrates	O
+that	O
+the	O
+N	O
+-	O
+terminal	O
+Q	O
+(	O
+2779	O
+)-	O
+S	O
+(	O
+2780	O
+)	O
+site	O
+is	O
+tolerant	O
+to	O
+mutations	O
+at	O
+the	O
+P1	O
+position	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+shedding	O
+,	O
+tissue	B-ANAT
+distribution	O
+and	O
+quasispecies	O
+composition	O
+of	O
+feline	B-SPEC
+coronaviruses	O
+were	O
+studied	O
+in	O
+naturally	O
+and	O
+experimentally	O
+infected	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+a	O
+novel	O
+""""	O
+small	O
+round	O
+virus	O
+""""	O
+(	O
+SRV	O
+)	O
+isolated	O
+from	O
+poult	O
+enteritis	B-DISO
+and	O
+mortality	O
+syndrome	B-DISO
+(	O
+PEMS	B-DISO
+)	O
+cases	O
+in	O
+inducing	O
+PEMS	B-DISO
+and	O
+associated	O
+immune	O
+alterations	O
+was	O
+examined	O
+in	O
+this	O
+study	O
+.	O
+
+Peripheral	B-ANAT
+blood	I-ANAT
+lymphocytes	B-ANAT
+(	O
+PBLs	O
+),	O
+thymocytes	B-ANAT
+,	O
+and	O
+splenic	B-ANAT
+lymphocytes	B-ANAT
+from	O
+inoculated	O
+poults	O
+or	O
+lymphocytes	B-ANAT
+isolated	O
+from	O
+healthy	O
+poults	O
+after	O
+incubation	O
+with	O
+SRV	O
+in	O
+vitro	O
+were	O
+examined	O
+for	O
+lymphoproliferative	O
+potential	O
+against	O
+concanavalin	O
+A	O
+(	O
+Con	O
+A	O
+).	O
+
+The	O
+SRV	B-PRGE
+antigen	I-PRGE
+was	O
+detected	O
+in	O
+intestinal	B-ANAT
+tissues	B-ANAT
+soon	O
+after	O
+infection	B-DISO
+(	O
+i	O
+.	O
+e	O
+.,	O
+at	O
+2	O
+and	O
+4	O
+DPI	O
+),	O
+whereas	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+such	O
+as	O
+thymus	B-SPEC
+,	O
+bursa	B-SPEC
+,	O
+and	O
+spleen	B-ANAT
+were	O
+positive	O
+for	O
+SRV	B-PRGE
+antigen	I-PRGE
+starting	O
+at	O
+4	O
+DPI	O
+until	O
+8	O
+DPI	O
+,	O
+suggesting	O
+virus	B-SPEC
+translocation	B-DISO
+to	O
+lymphoid	B-ANAT
+organs	I-ANAT
+.	O
+
+No	O
+differences	O
+were	O
+observed	O
+in	O
+CD4	B-PRGE
++	I-PRGE
+CD8	B-PRGE
+-	O
+lymphocyte	B-ANAT
+numbers	O
+in	O
+controls	O
+vs	O
+.	O
+SRV	O
+-	O
+infected	O
+poults	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+agents	O
+associated	O
+with	O
+poult	O
+enteritis	B-DISO
+and	O
+mortality	O
+syndrome	B-DISO
+:	O
+the	O
+role	O
+of	O
+a	O
+small	O
+round	O
+virus	O
+and	O
+a	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCV	B-SPEC
+),	O
+avian	B-SPEC
+rotaviruses	B-SPEC
+,	O
+reovirus	B-SPEC
+,	O
+and	O
+a	O
+yet	O
+undefined	O
+small	O
+round	O
+virus	B-SPEC
+(	O
+SRV	O
+)	O
+were	O
+detected	O
+.	O
+
+The	O
+DACS	B-FUNC
+procedure	O
+was	O
+further	O
+evaluated	O
+with	O
+a	O
+panel	O
+of	O
+""""	O
+unknowns	O
+""""	O
+comprised	O
+of	O
+IBV	B-SPEC
+reference	O
+strains	O
+,	O
+field	O
+isolates	O
+,	O
+and	O
+variant	O
+serotypes	O
+collected	O
+by	O
+our	O
+laboratory	O
+.	O
+
+The	O
+DACS	B-FUNC
+procedure	O
+provided	O
+high	O
+-	O
+quality	O
+and	O
+reproducible	O
+S	O
+-	O
+1	O
+sequence	O
+for	O
+all	O
+IBV	B-SPEC
+serotypes	O
+tested	O
+,	O
+including	O
+variant	O
+serotypes	O
+that	O
+had	O
+not	O
+been	O
+sequenced	O
+previously	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+an	O
+unusual	O
+case	O
+of	O
+fulminant	O
+tracheobronchial	O
+and	O
+pulmonary	B-DISO
+aspergillosis	I-DISO
+presenting	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+patient	O
+,	O
+who	O
+was	O
+apparently	O
+immunocompetent	O
+,	O
+was	O
+admitted	O
+with	O
+severe	O
+Plasmodium	B-DISO
+falciparum	I-DISO
+malaria	B-PATH
+but	O
+died	B-PROC
+from	O
+aspergillosis	B-DISO
+.	O
+
+The	O
+dynamic	O
+equilibrium	B-PROC
+of	O
+the	O
+extracellular	B-COMP
+matrix	I-COMP
+(	O
+ECM	B-COMP
+)	O
+under	O
+physiological	O
+conditions	O
+is	O
+a	O
+consequence	O
+of	O
+the	O
+balance	B-PROC
+between	O
+the	O
+regulation	B-PROC
+of	I-PROC
+synthesis	I-PROC
+and	O
+degradation	O
+of	O
+ECM	B-PRGE
+components	I-PRGE
+.	O
+
+This	O
+review	O
+details	O
+our	O
+knowledge	O
+of	O
+the	O
+involvement	O
+of	O
+MMPs	O
+,	O
+namely	O
+MMP	O
+-	O
+2	O
+and	O
+MMP	B-CHED
+-	O
+9	O
+,	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+These	O
+data	O
+show	O
+that	O
+exposure	O
+to	O
+high	O
+endotoxin	O
+concentrations	O
+in	O
+swine	B-SPEC
+buildings	O
+can	O
+precipitate	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+PRCV	O
+-	O
+infected	O
+pigs	B-SPEC
+,	O
+and	O
+that	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+is	O
+probably	O
+an	O
+important	O
+mediator	O
+of	O
+these	O
+effects	O
+.	O
+
+High	O
+-	O
+dose	O
+glucocorticoid	B-CHED
+,	O
+anticoagulation	B-PROC
+with	O
+heparin	B-CHED
+,	O
+plasmapheresis	O
+and	O
+cyclophosphamide	B-CHED
+improved	O
+her	O
+clinical	O
+condition	B-DISO
+.	O
+
+Two	O
+cases	O
+were	O
+CD4	B-PRGE
+(+),	O
+2	O
+cases	O
+were	O
+CD8	B-PRGE
+(+),	O
+and	O
+2	O
+cases	O
+had	O
+admixed	O
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+cells	B-COMP
+without	O
+clear	O
+subset	O
+predominance	O
+.	O
+
+(	O
+Blood	B-ANAT
+.	O
+
+We	O
+also	O
+examined	O
+the	O
+effects	O
+of	O
+stem	B-ANAT
+segment	O
+mutations	O
+on	O
+the	O
+replication	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+defective	O
+interfering	O
+RNAs	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+results	O
+confirmed	O
+most	O
+of	O
+the	O
+previously	O
+proposed	O
+structure	O
+,	O
+but	O
+they	O
+revealed	O
+that	O
+the	O
+terminal	B-COMP
+loop	I-COMP
+and	O
+an	O
+internal	O
+loop	O
+are	O
+larger	O
+than	O
+originally	O
+thought	O
+.	O
+
+The	O
+binding	B-FUNC
+of	O
+srr7	O
+and	O
+srr11	O
+to	O
+both	O
+MHVR1	B-PRGE
+and	O
+MHVR2	O
+was	O
+revealed	O
+lower	O
+by	O
+two	O
+-	O
+to	O
+fourfold	O
+relative	O
+to	O
+the	O
+wt	O
+binding	B-FUNC
+.	O
+
+On	O
+admission	O
+,	O
+a	O
+thick	O
+blood	B-ANAT
+smear	O
+revealed	O
+severe	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+parasitemia	B-DISO
+.	O
+
+She	O
+was	O
+given	O
+doxycycline	B-CHED
+and	O
+quinine	B-CHED
+,	O
+but	O
+as	O
+her	O
+parasitemia	B-DISO
+resolved	O
+,	O
+dyspnea	B-DISO
+and	O
+hypoxemia	O
+developed	O
+and	O
+she	O
+consequently	O
+required	O
+placement	O
+of	O
+an	O
+endotracheal	O
+tube	O
+.	O
+
+This	O
+report	O
+shows	O
+that	O
+patients	O
+with	O
+P	O
+falciparum	B-DISO
+malaria	I-DISO
+should	O
+be	O
+monitored	O
+closely	O
+and	O
+transferred	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+for	O
+additional	O
+management	O
+if	O
+respiratory	B-DISO
+distress	I-DISO
+develops	O
+.	O
+
+This	O
+virus	B-SPEC
+also	O
+modulated	O
+the	O
+activity	O
+of	O
+matrix	O
+metalloproteinases	O
+-	O
+2	O
+and	O
+-	O
+9	O
+and	O
+augmented	O
+nitric	B-CHED
+oxide	I-CHED
+production	O
+in	O
+both	O
+U	O
+-	O
+373MG	O
+cells	B-COMP
+and	O
+the	O
+human	B-SPEC
+microglial	B-ANAT
+cell	I-ANAT
+line	O
+CHME	O
+-	O
+5	O
+.	O
+
+Although	O
+PEEP	B-CHED
+did	O
+not	O
+exceed	O
+7	O
+cm	O
+H2O	B-CHED
+,	O
+PPV	B-CHED
+was	O
+complicated	O
+by	O
+interstitial	B-DISO
+emphysema	I-DISO
+,	O
+pneumomediastinum	B-DISO
+,	O
+and	O
+bilateral	O
+pneumothorax	B-DISO
+as	O
+a	O
+result	O
+of	O
+barotrauma	O
+.	O
+
+High	O
+PCWP	O
+values	O
+were	O
+inconsistent	O
+with	O
+the	O
+diagnosis	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+authors	O
+suggest	O
+that	O
+high	O
+PCWP	O
+was	O
+caused	O
+by	O
+high	O
+intraalveolar	O
+pressure	O
+,	O
+pneumomediastinum	B-DISO
+,	O
+and	O
+venule	B-ANAT
+constriction	B-COMP
+in	O
+the	O
+hypoxic	B-DISO
+sites	O
+of	O
+the	O
+lung	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Spectrum	O
+of	O
+clinical	O
+illness	O
+in	O
+hospitalized	O
+patients	O
+with	O
+""""	O
+common	B-DISO
+cold	I-DISO
+""""	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+This	O
+is	O
+primarily	O
+an	O
+autoimmune	B-DISO
+,	O
+post	O
+-	O
+infectious	B-DISO
+,	O
+demyelinating	O
+,	O
+peripheral	B-ANAT
+nervous	I-ANAT
+system	B-PROC
+process	I-PROC
+.	O
+
+Although	O
+most	O
+children	O
+with	O
+GBS	B-DISO
+have	O
+a	O
+relatively	O
+benign	O
+clinical	O
+course	O
+,	O
+some	O
+become	O
+very	O
+ill	B-DISO
+and	O
+require	O
+intubation	O
+with	O
+intensive	O
+care	O
+monitoring	O
+.	O
+
+A	O
+histidine	B-CHED
+-	O
+tagged	O
+form	O
+of	O
+this	O
+protein	B-CHED
+,	O
+HEL	B-PRGE
+,	O
+was	O
+expressed	B-PROC
+using	O
+baculovirus	B-SPEC
+vectors	O
+in	O
+insect	B-SPEC
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+47	O
+-	O
+year	O
+-	O
+old	O
+male	O
+patient	O
+with	O
+fulminant	O
+ornithosis	O
+who	O
+developed	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+leading	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+complicated	O
+by	O
+gastrointestinal	O
+,	O
+neurological	O
+and	O
+renal	B-ANAT
+symptoms	O
+.	O
+
+ARDS	B-DISO
+was	O
+successfully	O
+treated	O
+by	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+.	O
+
+Lung	B-ANAT
+recruitment	B-DISO
+strategies	O
+,	O
+such	O
+as	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+and	O
+partial	O
+liquid	O
+ventilation	O
+(	O
+PLV	O
+),	O
+improve	O
+gas	B-ENZY
+exchange	O
+and	O
+attenuate	O
+lung	B-DISO
+inflammation	I-DISO
+when	O
+instituted	O
+immediately	O
+after	O
+birth	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+conclude	O
+that	O
+each	O
+lung	B-ANAT
+recruitment	B-DISO
+strategy	O
+improved	O
+oxygenation	B-PROC
+in	O
+premature	O
+lambs	B-SPEC
+with	O
+established	O
+lung	B-ANAT
+injury	O
+.	O
+
+Pathogen	O
+-	O
+free	O
+Sprague	B-SPEC
+-	I-SPEC
+Dawley	I-SPEC
+rats	I-SPEC
+weighing	O
+225	O
+-	O
+250	O
+g	O
+.	O
+Sterile	B-DISO
+,	O
+endotoxin	O
+-	O
+and	O
+cytokine	O
+-	O
+free	O
+pancreatic	B-DISO
+ascites	I-DISO
+tested	O
+for	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+1beta	O
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+was	O
+obtained	O
+from	O
+rats	B-SPEC
+18	O
+hrs	B-DISO
+after	O
+the	O
+induction	O
+of	O
+severe	O
+,	O
+acute	O
+pancreatitis	O
+.	O
+
+After	O
+the	O
+intravenous	O
+administration	O
+of	O
+pancreatic	B-DISO
+ascites	I-DISO
+,	O
+the	O
+number	O
+of	O
+leukocytes	B-ANAT
+and	O
+the	O
+protein	B-CHED
+concentration	O
+within	O
+the	O
+bronchoalveolar	O
+fluid	O
+were	O
+increased	O
+and	O
+pulmonary	B-ANAT
+histology	O
+was	O
+worsened	O
+consistent	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+all	O
+p	O
+<	O
+.	O
+001	O
+vs	O
+.	O
+sham	O
+).	O
+
+Inhibition	B-PROC
+of	O
+p38	B-FUNC
+mitogen	B-CHED
+activated	O
+kinase	O
+decreases	O
+the	O
+pulmonary	B-ANAT
+injury	O
+through	O
+attenuated	O
+production	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+NO	O
+suggesting	O
+a	O
+primary	O
+role	O
+for	O
+these	O
+mediators	O
+in	O
+pancreatitis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+Pulmonary	B-ANAT
+NF	B-PROC
+-	I-PROC
+kappaB	I-PROC
+activation	I-PROC
+,	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	B-FUNC
+)	O
+gene	B-PROC
+expression	I-PROC
+,	O
+and	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+(	O
+myeloperoxidase	B-PRGE
+)	O
+were	O
+determined	O
+and	O
+myeloperoxidase	B-PRGE
+experiments	O
+repeated	O
+in	O
+p55	B-PRGE
+TNF	B-PRGE
+receptor	I-PRGE
+-	O
+deficient	O
+(	O
+TNF	B-PRGE
+KO	I-PRGE
+)	O
+animals	B-SPEC
+.	O
+
+Additional	O
+animals	O
+received	O
+pyrrolidine	B-CHED
+dithiocarbamate	O
+(	O
+PDTC	O
+),	O
+an	O
+inhibitor	B-CHED
+of	O
+NF	B-PROC
+-	I-PROC
+kappaB	I-PROC
+activation	I-PROC
+,	O
+and	O
+TNF	B-PRGE
+protein	I-PRGE
+and	O
+pulmonary	B-ANAT
+microvascular	B-PROC
+permeability	I-PROC
+were	O
+measured	O
+after	O
+elastase	O
+administration	O
+.	O
+
+To	O
+determine	O
+whether	O
+a	O
+patient	O
+has	O
+a	O
+transudative	O
+or	O
+exudative	B-DISO
+pleural	I-DISO
+effusion	I-DISO
+,	O
+Light	O
+'	O
+s	O
+criteria	O
+should	O
+be	O
+applied	O
+to	O
+measure	O
+the	O
+concentrations	O
+of	O
+protein	B-CHED
+and	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+in	O
+the	O
+pleural	B-ANAT
+fluid	I-ANAT
+and	O
+serum	B-COMP
+.	O
+
+If	O
+the	O
+effusion	B-DISO
+is	O
+exudative	O
+,	O
+attempts	O
+should	O
+be	O
+made	O
+to	O
+define	O
+the	O
+etiology	O
+.	O
+
+Talc	O
+is	O
+not	O
+recommended	O
+because	O
+it	O
+induces	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+about	O
+5	O
+%	O
+of	O
+patients	O
+,	O
+with	O
+an	O
+overall	O
+mortality	O
+of	O
+1	O
+%.	O
+
+However	O
+,	O
+on	O
+day	O
+4	O
+she	O
+developed	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+bronchospasm	B-DISO
+and	O
+visible	O
+cyanosis	B-DISO
+with	O
+oxygen	B-CHED
+saturation	O
+of	O
+88	O
+%	O
+while	O
+on	O
+2	O
+L	O
+oxygen	B-CHED
+.	O
+
+Itraconazole	B-CHED
+therapy	O
+was	O
+instituted	O
+without	O
+any	O
+adverse	O
+sequelae	O
+.	O
+
+In	O
+these	O
+diseases	O
+,	O
+the	O
+pulmonary	B-ANAT
+bloodflow	O
+is	O
+impaired	B-DISO
+by	O
+a	O
+pathologic	B-DISO
+constriction	I-DISO
+of	O
+blood	B-ANAT
+vessels	I-ANAT
+that	O
+may	O
+lead	O
+to	O
+right	O
+ventricular	B-ANAT
+overloading	O
+as	O
+well	O
+as	O
+serious	O
+worsening	O
+of	O
+gas	B-ENZY
+exchange	O
+mainly	O
+caused	O
+by	O
+ventilation	O
+/	O
+perfusion	O
+mismatch	O
+.	O
+
+Pre	O
+-	O
+existing	O
+antibody	B-COMP
+titres	O
+(	O
+as	O
+a	O
+result	O
+of	O
+natural	O
+infection	B-DISO
+)	O
+in	O
+the	O
+serum	B-COMP
+of	O
+these	O
+animals	B-SPEC
+were	O
+found	O
+to	O
+be	O
+significantly	O
+increased	O
+as	O
+a	O
+result	O
+of	O
+a	O
+single	O
+shot	O
+vaccination	O
+carried	O
+out	O
+between	O
+2	O
+and	O
+12	O
+weeks	O
+before	O
+calving	O
+.	O
+
+By	O
+contrast	O
+,	O
+a	O
+significant	O
+number	O
+of	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+which	O
+contained	O
+detectable	O
+viral	O
+RNA	O
+were	O
+recovered	O
+from	O
+spinal	B-ANAT
+cords	I-ANAT
+of	O
+V	O
+-	O
+1	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+The	O
+replicase	B-PRGE
+polyprotein	O
+is	O
+extensively	O
+processed	O
+by	O
+viral	O
+and	O
+perhaps	O
+cellular	B-COMP
+proteinases	O
+to	O
+give	O
+rise	O
+to	O
+a	O
+functional	O
+replicase	B-PRGE
+complex	I-PRGE
+.	O
+
+Pulse	B-PROC
+-	O
+chase	O
+experiments	O
+showed	O
+that	O
+p150	B-PRGE
+is	O
+rapidly	O
+generated	O
+in	O
+MHV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+and	O
+that	O
+p44	B-PRGE
+is	O
+processed	O
+from	O
+the	O
+p150	B-PRGE
+precursor	I-PRGE
+.	O
+
+Protease	B-CHED
+inhibitor	I-CHED
+studies	O
+revealed	O
+that	O
+unlike	O
+3CLpro	O
+activity	O
+,	O
+PLP2	B-PRGE
+activity	O
+is	O
+not	O
+sensitive	O
+to	O
+cysteine	B-CHED
+protease	I-CHED
+inhibitor	I-CHED
+E64d	O
+.	O
+
+These	O
+data	O
+indicated	O
+that	O
+M	B-PRGE
+protein	I-PRGE
+interacted	O
+with	O
+the	O
+nucleocapsid	B-COMP
+,	O
+consisting	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+and	O
+mRNA	B-PRGE
+1	I-PRGE
+,	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+The	O
+majority	O
+of	O
+IBV	B-SPEC
+strains	O
+cause	O
+tracheal	O
+lesions	O
+and	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+low	O
+mortality	O
+due	O
+to	O
+secondary	O
+bacterial	B-DISO
+infections	I-DISO
+,	O
+primarily	O
+in	O
+broilers	O
+.	O
+
+Nephropathogenic	O
+strains	O
+,	O
+in	O
+addition	O
+to	O
+tracheal	O
+lesions	O
+,	O
+also	O
+induce	O
+prominent	O
+kidney	B-ANAT
+lesions	O
+with	O
+mortality	O
+of	O
+up	O
+to	O
+25	O
+%	O
+in	O
+broilers	O
+.	O
+
+Virus	B-SPEC
+neutralisation	O
+test	O
+in	O
+tracheal	O
+organ	B-ANAT
+culture	O
+is	O
+the	O
+best	O
+method	O
+for	O
+antigenic	O
+typing	O
+.	O
+
+Mycoplasma	B-DISO
+spp	B-ENZY
+.	O
+are	O
+regularly	O
+found	O
+in	O
+an	O
+upper	O
+respiratory	B-DISO
+disease	I-DISO
+syndrome	B-DISO
+complicated	O
+by	O
+opportunistic	O
+bacterial	O
+pathogens	O
+.	O
+
+These	O
+diseases	O
+are	O
+present	O
+in	O
+North	O
+,	O
+Central	O
+and	O
+South	O
+America	O
+where	O
+the	O
+associated	O
+ornithophilic	O
+mosquito	B-SPEC
+vectors	O
+occur	O
+.	O
+
+Equine	B-SPEC
+and	O
+human	B-SPEC
+vaccines	O
+are	O
+apparently	O
+safe	O
+and	O
+efficacious	O
+in	O
+ratites	O
+.	O
+
+Physical	O
+examination	O
+revealed	O
+marked	O
+pain	O
+on	O
+pressure	O
+over	O
+the	O
+throacic	O
+spine	B-COMP
+.	O
+
+Although	O
+in	O
+most	O
+cases	O
+the	O
+adverse	B-DISO
+effects	I-DISO
+are	O
+unpredictable	O
+,	O
+they	O
+can	O
+be	O
+reduced	O
+to	O
+a	O
+minimum	O
+or	O
+prevented	O
+if	O
+some	O
+drugs	O
+are	O
+avoided	O
+or	O
+stopped	O
+in	O
+time	O
+.	O
+
+Recently	O
+,	O
+outbreaks	O
+of	O
+TGE	B-DISO
+of	O
+reduced	O
+virulence	B-PROC
+were	O
+reported	O
+in	O
+the	O
+field	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+deletion	O
+region	O
+of	O
+the	O
+three	O
+PRCV	O
+isolates	O
+revealed	O
+identical	O
+deletions	O
+between	O
+nt	O
+105	O
+-	O
+752	O
+,	O
+which	O
+differ	O
+from	O
+deletions	O
+previously	O
+reported	O
+among	O
+PRCV	O
+strains	O
+.	O
+
+Thus	O
+,	O
+sequence	O
+analysis	O
+and	O
+pathogenicity	O
+studies	O
+indicate	O
+that	O
+this	O
+TGEV	B-SPEC
+isolate	O
+resembles	O
+other	O
+enteropathogenic	O
+TGEV	B-SPEC
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+total	O
+of	O
+446	O
+serum	O
+samples	O
+from	O
+88	O
+herds	O
+in	O
+Korea	O
+were	O
+examined	O
+for	O
+antibody	B-COMP
+to	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+)	O
+using	O
+blocking	B-DISO
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+ABSTRACT	O
+:	O
+Formaldehyde	B-CHED
+is	O
+a	O
+physiological	O
+intermediary	O
+metabolite	O
+taking	O
+part	O
+in	O
+many	O
+biological	B-PROC
+process	I-PROC
+in	O
+the	O
+body	B-ANAT
+.	O
+
+The	O
+expression	B-PROC
+of	O
+interferon	B-PRGE
+response	I-PRGE
+gene	I-PRGE
+47	I-PRGE
+and	O
+interferon	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+1	I-PRGE
+genes	I-PRGE
+takes	O
+place	O
+after	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+activation	O
+in	O
+both	O
+macrophages	B-ANAT
+,	O
+indicating	O
+their	O
+activation	O
+.	O
+
+TITLE	O
+:	O
+Traumatic	O
+hemorrhage	B-DISO
+of	O
+occult	O
+pheochromocytoma	B-DISO
+:	O
+a	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+.	O
+
+Animal	B-SPEC
+studies	O
+have	O
+shown	O
+that	O
+early	O
+treatment	O
+with	O
+alpha	O
+blockers	O
+can	O
+prevent	O
+some	O
+,	O
+if	O
+not	O
+all	O
+of	O
+these	O
+complications	O
+.	O
+
+Proper	O
+management	O
+of	O
+hemorrhagic	O
+pheochromocytoma	B-DISO
+should	O
+include	O
+a	O
+high	O
+index	O
+of	O
+suspicion	O
+with	O
+early	O
+diagnosis	O
+and	O
+treatment	O
+with	O
+alpha	O
+blockers	O
+and	O
+surgical	O
+resection	O
+of	O
+the	O
+tumor	O
+when	O
+the	O
+patient	O
+is	O
+stable	O
+enough	O
+to	O
+tolerate	O
+the	O
+procedure	O
+.	O
+
+Mouse	B-SPEC
+eyes	B-ANAT
+harvested	O
+at	O
+varying	O
+times	O
+after	O
+inoculation	O
+were	O
+evaluated	O
+for	O
+apoptotic	O
+and	O
+immunologic	O
+events	O
+by	O
+hematoxylin	B-CHED
+and	O
+eosin	O
+staining	O
+,	O
+immunohistochemical	O
+staining	O
+,	O
+in	O
+situ	O
+terminal	B-PRGE
+deoxynucleotidyltransferase	I-PRGE
+dUTP	B-CHED
+nick	O
+-	O
+end	O
+labeling	O
+(	O
+TUNEL	O
+)	O
+assay	O
+,	O
+and	O
+electron	O
+microscopy	O
+.	O
+
+Isolated	O
+retinas	B-ANAT
+were	O
+analyzed	O
+for	O
+infectious	B-DISO
+virus	B-SPEC
+and	O
+for	O
+expression	B-PROC
+of	O
+apoptosis	B-PATH
+-	O
+associated	O
+genes	O
+.	O
+
+Overexpression	B-PROC
+of	O
+hnRNP	B-PRGE
+A1	I-PRGE
+accelerated	O
+the	O
+kinetics	O
+of	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+whereas	O
+the	O
+expression	B-PROC
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+a	O
+dominant	B-PRGE
+-	I-PRGE
+negative	I-PRGE
+hnRNP	I-PRGE
+A1	I-PRGE
+mutant	B-DISO
+that	O
+lacks	O
+the	O
+nuclear	B-PROC
+transport	I-PROC
+domain	O
+significantly	O
+delayed	O
+it	O
+.	O
+
+The	O
+main	O
+and	O
+unusual	O
+cause	O
+of	O
+ARD	B-ENZY
+was	O
+hypophosphataemia	B-DISO
+.	O
+
+Seroconversion	O
+to	O
+BCV	B-SPEC
+during	O
+the	O
+initial	O
+28	O
+days	O
+after	O
+arrival	O
+was	O
+detected	O
+in	O
+473	O
+of	O
+814	O
+(	O
+58	O
+%)	O
+cattle	B-SPEC
+tested	O
+(	O
+range	O
+,	O
+20	O
+.	O
+3	O
+to	O
+84	O
+.	O
+1	O
+%	O
+within	O
+specific	O
+groups	O
+).	O
+
+TITLE	O
+:	O
+Association	O
+between	O
+infection	B-DISO
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+attributable	O
+to	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+health	O
+and	O
+growth	O
+performance	O
+of	O
+cattle	B-SPEC
+in	O
+feedlots	O
+.	O
+
+TITLE	O
+:	O
+Serologic	O
+survey	O
+of	O
+selected	O
+viral	O
+agents	O
+in	O
+recently	O
+captured	O
+wild	O
+North	O
+American	O
+river	B-SPEC
+otters	I-SPEC
+(	O
+Lontra	B-SPEC
+canadensis	I-SPEC
+).	O
+
+MHV	B-SPEC
+-	O
+induced	O
+28S	B-PRGE
+rRNA	I-PRGE
+cleavage	B-PROC
+was	O
+detected	O
+in	O
+all	O
+MHV	B-SPEC
+-	O
+susceptible	O
+cell	B-ANAT
+lines	I-ANAT
+and	O
+all	O
+MHV	B-SPEC
+strains	O
+tested	O
+.	O
+
+In	O
+certain	O
+combination	O
+of	O
+cells	B-COMP
+and	O
+viruses	B-SPEC
+,	O
+pretreatment	O
+of	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+with	O
+interferon	B-PRGE
+activates	O
+a	O
+cellular	B-COMP
+endoribonuclease	O
+,	O
+RNase	B-PRGE
+L	I-PRGE
+,	O
+that	O
+causes	O
+rRNA	B-PROC
+degradation	I-PROC
+.	O
+
+Furthermore	O
+,	O
+28S	B-PRGE
+rRNA	I-PRGE
+cleavage	B-PROC
+occurred	O
+in	O
+an	O
+MHV	B-SPEC
+-	O
+infected	O
+mouse	B-ANAT
+embryonic	I-ANAT
+fibroblast	I-ANAT
+cell	B-ANAT
+line	I-ANAT
+derived	O
+from	O
+RNase	B-PRGE
+L	I-PRGE
+knockout	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Helicase	B-PRGE
+and	O
+capping	B-PROC
+enzyme	O
+active	O
+site	O
+mutations	O
+in	O
+brome	B-SPEC
+mosaic	I-SPEC
+virus	I-SPEC
+protein	B-CHED
+1a	O
+cause	O
+defects	O
+in	O
+template	O
+recruitment	O
+,	O
+negative	O
+-	O
+strand	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+and	O
+viral	O
+RNA	B-PROC
+capping	I-PROC
+.	O
+
+These	O
+results	O
+are	O
+discussed	O
+in	O
+relation	O
+to	O
+the	O
+interconnected	O
+functions	O
+required	O
+for	O
+different	O
+steps	O
+of	O
+positive	O
+-	O
+strand	O
+RNA	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Sequencing	O
+of	O
+nucleocapsid	B-ANAT
+protein	B-CHED
+(	O
+N	O
+)	O
+gene	O
+amplicons	O
+revealed	O
+point	B-PROC
+mutations	I-PROC
+in	O
+OC43	O
+,	O
+some	O
+consistently	O
+found	O
+in	O
+three	O
+MS	O
+patient	O
+brains	B-ANAT
+and	O
+one	O
+normal	O
+control	O
+but	O
+never	O
+observed	O
+in	O
+laboratory	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+(	O
+EAV	B-SPEC
+),	O
+the	O
+prototype	O
+arterivirus	B-SPEC
+,	O
+is	O
+an	O
+enveloped	O
+plus	O
+-	O
+strand	O
+RNA	O
+virus	B-SPEC
+with	O
+a	O
+genome	O
+of	O
+approximately	O
+13	O
+kb	O
+.	O
+
+Using	O
+recombination	B-PROC
+assays	O
+based	O
+on	O
+EDI	O
+RNA	O
+and	O
+full	O
+-	O
+length	O
+EAV	B-SPEC
+genomes	O
+containing	O
+specific	O
+mutations	O
+,	O
+the	O
+rates	O
+of	O
+homologous	O
+RNA	O
+recombination	B-PROC
+in	O
+the	O
+3	O
+'-	O
+and	O
+5	O
+'-	O
+proximal	O
+regions	O
+of	O
+the	O
+EAV	B-SPEC
+genome	O
+were	O
+studied	O
+.	O
+
+Several	O
+experimental	O
+animal	B-SPEC
+models	O
+have	O
+been	O
+developed	O
+to	O
+study	O
+the	O
+mechanism	O
+of	O
+virus	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+,	O
+including	O
+coronavirus	B-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+The	O
+envelope	B-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	B-CHED
+of	O
+MHV	B-SPEC
+contains	O
+determinants	O
+of	O
+properties	O
+essential	O
+for	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+.	O
+
+Whether	O
+any	O
+of	O
+these	O
+also	O
+function	O
+in	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+is	O
+unknown	O
+.	O
+
+We	O
+also	O
+constructed	O
+a	O
+mutant	B-DISO
+in	O
+which	O
+translation	B-PROC
+of	O
+the	O
+intraleader	O
+ORF	O
+was	O
+disrupted	O
+.	O
+
+This	O
+mutant	B-DISO
+had	O
+a	O
+wild	O
+-	O
+type	O
+phenotype	O
+,	O
+indicating	O
+that	O
+,	O
+at	O
+least	O
+in	O
+cell	O
+culture	O
+,	O
+the	O
+product	O
+of	O
+this	O
+ORF	O
+does	O
+not	O
+play	O
+a	O
+role	O
+in	O
+the	O
+EAV	B-SPEC
+replication	O
+cycle	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Changes	O
+in	O
+emergency	B-DISO
+visits	O
+of	O
+patients	O
+infected	O
+by	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+since	O
+the	O
+widespread	O
+use	O
+of	O
+protease	O
+inhibitors	O
+].	O
+
+Comparison	O
+on	O
+the	O
+visits	O
+made	O
+during	O
+a	O
+period	O
+prior	O
+to	O
+and	O
+after	O
+use	O
+of	O
+protease	B-CHED
+inhibitor	I-CHED
+.	O
+
+After	O
+the	O
+generalisation	O
+of	O
+the	O
+protease	B-PROC
+inhibitors	I-PROC
+the	O
+visits	O
+rate	O
+decreased	O
+,	O
+the	O
+motives	O
+for	O
+consulting	O
+with	O
+the	O
+physician	O
+and	O
+complementary	O
+examinations	O
+changed	O
+,	O
+invasive	O
+therapeutic	O
+procedures	O
+,	O
+admissions	O
+from	O
+urgencies	O
+and	O
+death	B-PROC
+rates	O
+decreased	O
+.	O
+
+Of	O
+the	O
+evaluations	O
+performed	O
+at	O
+slaughter	O
+,	O
+only	O
+detection	O
+of	O
+lung	B-ANAT
+lesions	O
+was	O
+consistently	O
+associated	O
+with	O
+a	O
+decrease	O
+in	O
+ADG	O
+.	O
+
+Results	O
+suggest	O
+that	O
+subclinical	B-DISO
+infection	I-DISO
+with	O
+any	O
+of	O
+a	O
+variety	O
+of	O
+pathogens	O
+commonly	O
+found	O
+in	O
+swine	B-SPEC
+herds	O
+was	O
+associated	O
+with	O
+a	O
+decrease	O
+in	O
+ADG	O
+.	O
+
+Genome	O
+-	O
+length	O
+replicative	O
+intermediate	O
+(	O
+RI	O
+)	O
+RNA	O
+was	O
+purified	O
+by	O
+two	O
+-	O
+dimensional	O
+gel	O
+electrophoresis	O
+of	O
+intracellular	B-COMP
+RNAs	O
+from	O
+cells	B-COMP
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+RNase	B-PRGE
+A	I-PRGE
+treatment	O
+of	O
+the	O
+purified	O
+genome	O
+-	O
+length	O
+RI	O
+resulted	O
+in	O
+the	O
+production	O
+of	O
+the	O
+genome	O
+-	O
+length	O
+replicative	O
+form	O
+RNA	O
+,	O
+indicating	O
+that	O
+the	O
+genome	O
+-	O
+length	O
+RI	O
+included	O
+genome	O
+-	O
+length	O
+template	B-CHED
+RNA	I-CHED
+.	O
+
+RNase	B-PRGE
+protection	O
+assays	O
+using	O
+the	O
+purified	O
+genome	O
+-	O
+length	O
+RI	O
+and	O
+two	O
+probes	O
+,	O
+which	O
+corresponded	O
+to	O
+the	O
+5	O
+'	O
+300	O
+-	O
+nt	O
+region	O
+of	O
+mRNA	O
+6	O
+and	O
+to	O
+the	O
+same	O
+region	O
+of	O
+mRNA	B-CHED
+7	O
+,	O
+showed	O
+the	O
+presence	O
+of	O
+nascent	O
+leader	O
+sequence	O
+-	O
+containing	O
+subgenomic	O
+mRNAs	O
+in	O
+the	O
+genome	O
+-	O
+length	O
+RI	O
+.	O
+
+The	O
+protein	B-CHED
+also	O
+had	O
+both	O
+RNA	O
+and	O
+DNA	O
+duplex	O
+-	O
+unwinding	O
+activities	O
+that	O
+required	O
+the	O
+presence	O
+of	O
+5	O
+'	O
+single	O
+-	O
+stranded	O
+regions	O
+on	O
+the	O
+partial	O
+-	O
+duplex	O
+substrates	O
+,	O
+indicating	O
+a	O
+5	O
+'-	O
+to	O
+-	O
+3	O
+'	O
+polarity	O
+in	O
+the	O
+unwinding	O
+reaction	O
+.	O
+
+Results	O
+of	O
+this	O
+study	O
+suggest	O
+a	O
+close	O
+functional	O
+relationship	O
+between	O
+the	O
+arterivirus	B-SPEC
+nsp10	O
+and	O
+the	O
+coronavirus	B-SPEC
+helicase	O
+,	O
+for	O
+which	O
+NTPase	O
+and	O
+duplex	O
+-	O
+unwinding	O
+activities	O
+were	O
+recently	O
+demonstrated	O
+.	O
+
+Furthermore	O
+,	O
+when	O
+potato	B-SPEC
+tubers	B-SPEC
+expressing	O
+N	O
+-	O
+gS	O
+were	O
+fed	O
+directly	O
+to	O
+mice	B-SPEC
+,	O
+they	O
+developed	O
+serum	B-COMP
+antibodies	B-COMP
+specific	O
+for	O
+gS	B-PRGE
+protein	I-PRGE
+,	O
+demonstrating	O
+the	O
+oral	B-ANAT
+immunogenicity	O
+of	O
+the	O
+plant	B-SPEC
+derived	O
+spike	O
+protein	B-CHED
+from	O
+TGEV	B-SPEC
+.	O
+
+Only	O
+one	O
+patient	O
+had	O
+multiple	O
+deletions	O
+in	O
+the	O
+mtDNA	B-COMP
+.	O
+
+Anti	O
+-	O
+TCV	B-SPEC
+hyperimmune	O
+turkey	B-SPEC
+serum	B-COMP
+and	O
+normal	O
+turkey	B-SPEC
+serum	B-COMP
+were	O
+used	O
+as	O
+positive	O
+or	O
+negative	O
+control	O
+serum	B-COMP
+for	O
+optimization	O
+of	O
+the	O
+ELISA	O
+system	O
+.	O
+
+The	O
+ELISA	O
+values	O
+of	O
+all	O
+45	O
+normal	O
+turkey	B-SPEC
+sera	B-COMP
+were	O
+completely	O
+separated	O
+from	O
+that	O
+of	O
+IFA	O
+-	O
+positive	O
+sera	B-COMP
+.	O
+
+All	O
+birds	B-SPEC
+were	O
+tested	O
+to	O
+be	O
+free	O
+from	O
+Mycoplasma	B-SPEC
+gallisepticum	I-SPEC
+and	O
+Mycoplasma	B-SPEC
+synoviae	I-SPEC
+.	O
+
+Analysis	O
+of	O
+data	O
+from	O
+both	O
+studies	O
+showed	O
+that	O
+protection	O
+to	O
+IB	O
+in	O
+groups	O
+that	O
+received	O
+only	O
+IB	O
+vaccines	O
+at	O
+hatch	B-PROC
+ranged	O
+from	O
+55	O
+.	O
+0	O
+%	O
+to	O
+77	O
+.	O
+3	O
+%,	O
+whereas	O
+protection	O
+to	O
+IB	O
+in	O
+groups	O
+receiving	O
+both	O
+MD	O
+and	O
+IB	O
+vaccines	O
+ranged	O
+from	O
+50	O
+.	O
+0	O
+%	O
+to	O
+95	O
+.	O
+5	O
+%.	O
+
+The	O
+fifth	O
+isolate	O
+,	O
+Ark	B-PRGE
+/	O
+1535	O
+/	O
+95	O
+,	O
+may	O
+constitute	O
+another	O
+subtype	O
+of	O
+the	O
+Ark	B-PRGE
+serotype	I-PRGE
+.	O
+
+Vaccination	O
+of	O
+SPF	B-PRGE
+chickens	I-PRGE
+with	O
+a	O
+high	O
+-	O
+titering	O
+commercially	O
+available	O
+live	O
+vaccine	O
+containing	O
+the	O
+Ark	O
+DPI	O
+strain	O
+provided	O
+solid	O
+protection	O
+(>	O
+90	O
+%)	O
+against	O
+challenge	O
+with	O
+the	O
+RT	O
+-	O
+PCR	O
+Ark	O
+-	O
+positive	O
+field	O
+isolates	O
+.	O
+
+Primers	O
+for	O
+RT	O
+-	O
+PCR	O
+were	O
+designed	O
+to	O
+distinguish	O
+between	O
+the	O
+Ark	B-PRGE
+subtypes	O
+and	O
+the	O
+Ark	B-PRGE
+reference	O
+strains	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+characteristic	O
+six	O
+-	O
+nucleotide	B-CHED
+deletion	O
+identified	O
+in	O
+the	O
+S	B-PRGE
+-	I-PRGE
+1	I-PRGE
+gene	I-PRGE
+of	O
+the	O
+Ark	B-PRGE
+subtypes	O
+.	O
+
+With	O
+RT	O
+-	O
+PCR	O
+,	O
+restriction	O
+fragment	O
+length	O
+polymorphism	B-PROC
+analysis	O
+,	O
+and	O
+DNA	O
+sequencing	O
+techniques	O
+,	O
+the	O
+presence	O
+of	O
+Ark	B-PRGE
+subtype	O
+viruses	B-SPEC
+was	O
+demonstrated	O
+in	O
+two	O
+commercial	O
+Ark	O
+DPI	O
+strain	O
+vaccines	O
+and	O
+in	O
+our	O
+Ark	B-PRGE
+DPI	O
+laboratory	O
+stocks	O
+that	O
+were	O
+the	O
+original	O
+source	O
+of	O
+the	O
+virus	B-SPEC
+used	O
+for	O
+vaccine	O
+development	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Fifteen	O
+isolations	O
+of	O
+infectious	O
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+virus	B-SPEC
+were	O
+made	O
+from	O
+a	O
+total	O
+of	O
+126	O
+Brazilian	O
+poultry	O
+flocks	O
+of	O
+all	O
+ages	O
+that	O
+were	O
+examined	O
+.	O
+
+The	O
+RT	O
+-	O
+PCR	O
+,	O
+MAb	O
+-	O
+based	O
+fluorescent	O
+antibody	B-COMP
+(	O
+FA	O
+),	O
+and	O
+MAb	O
+-	O
+based	O
+immunoperoxidase	O
+(	O
+IP	O
+)	O
+procedures	O
+were	O
+compared	O
+with	O
+virus	B-SPEC
+isolation	O
+(	O
+VI	O
+)	O
+for	O
+detection	O
+of	O
+TCV	B-SPEC
+in	O
+experimentally	O
+infected	O
+turkeys	B-SPEC
+.	O
+
+Hepatic	B-DISO
+failure	I-DISO
+was	O
+a	O
+criterion	O
+indicating	O
+the	O
+failure	O
+of	O
+CPAP	O
+:	O
+1	O
+/	O
+16	O
+vs	O
+.	O
+26	O
+/	O
+48	O
+(	O
+p	O
+=	O
+.	O
+001	O
+).	O
+
+In	O
+multivariate	O
+analysis	O
+,	O
+two	O
+variables	O
+were	O
+predictive	O
+of	O
+failure	O
+of	O
+CPAP	O
+:	O
+Simplified	O
+Acute	O
+Physiology	O
+Score	O
+II	O
+(	O
+58	O
++/-	O
+14	O
+vs	O
+.	O
+41	O
++/-	O
+11	O
+)	O
+and	O
+a	O
+hepatic	B-DISO
+failure	I-DISO
+at	O
+the	O
+entry	O
+into	O
+the	O
+study	O
+.	O
+
+Case	O
+#	O
+2	O
+:	O
+A	O
+previously	O
+healthy	O
+4	O
+yr	O
+-	O
+old	O
+girl	O
+was	O
+admitted	O
+to	O
+the	O
+PICU	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+She	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+cardiomyopathy	B-DISO
+with	O
+complete	B-DISO
+atrioventricular	I-DISO
+block	I-DISO
+,	O
+shock	O
+,	O
+capillary	B-ANAT
+leak	O
+,	O
+liver	B-DISO
+dysfunction	I-DISO
+,	O
+and	O
+RHS	B-DISO
+(	O
+pancytopenia	B-DISO
+and	O
+hemophagocytosis	B-DISO
+on	O
+bone	B-ANAT
+marrow	I-ANAT
+aspirate	I-ANAT
+).	O
+
+In	O
+acute	O
+influenza	B-DISO
+and	O
+ARVI	O
+the	O
+majority	O
+of	O
+the	O
+postcapillary	O
+veins	B-ANAT
+and	O
+capillaries	B-ANAT
+were	O
+affected	O
+with	O
+sludge	B-ANAT
+syndrome	B-DISO
+,	O
+there	O
+were	O
+marked	O
+perivascular	O
+and	O
+vascular	B-ANAT
+changes	O
+.	O
+
+Convalescence	O
+was	O
+accompanied	O
+with	O
+reduced	O
+permeability	O
+and	O
+intravascular	O
+aggregation	O
+of	O
+erythrocytes	B-ANAT
+,	O
+microvessels	O
+improved	O
+tonicity	O
+.	O
+
+The	O
+application	O
+of	O
+this	O
+new	O
+knowledge	O
+regarding	O
+salt	B-CHED
+and	O
+water	B-PROC
+transport	B-PROC
+in	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+in	O
+relation	O
+to	O
+pathologic	O
+conditions	O
+has	O
+been	O
+successful	O
+in	O
+clinically	O
+relevant	O
+experimental	O
+studies	O
+,	O
+as	O
+well	O
+as	O
+in	O
+a	O
+few	O
+clinical	O
+studies	O
+.	O
+
+Exogenous	O
+catecholamines	B-CHED
+can	O
+increase	O
+the	O
+rate	O
+of	O
+alveolar	B-ANAT
+fluid	O
+clearance	O
+in	O
+several	O
+species	B-SPEC
+,	O
+including	O
+the	O
+human	B-SPEC
+lung	B-ANAT
+,	O
+and	O
+it	O
+is	O
+also	O
+apparent	O
+that	O
+release	B-PATH
+of	O
+endogenous	O
+catecholamines	B-CHED
+can	O
+upregulate	O
+alveolar	B-ANAT
+fluid	O
+clearance	O
+in	O
+animals	B-SPEC
+with	O
+septic	O
+or	O
+hypovolemic	B-DISO
+shock	I-DISO
+.	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Because	O
+of	O
+its	O
+property	O
+as	O
+a	O
+""""	O
+selective	O
+""""	O
+pulmonary	B-ANAT
+vasodilator	B-CHED
+and	O
+because	O
+of	O
+its	O
+apparent	O
+clinical	O
+safety	O
+,	O
+inhaled	B-PROC
+NO	O
+has	O
+been	O
+proposed	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+to	O
+improve	O
+severe	O
+hypoxemia	O
+.	O
+
+In	O
+addition	O
+to	O
+high	O
+-	O
+dose	O
+methylprednisolone	B-CHED
+the	O
+patient	O
+was	O
+given	O
+intravenous	O
+pulse	B-PROC
+cyclophosphamide	B-CHED
+fortnightly	O
+for	O
+six	O
+weeks	O
+and	O
+afterwards	O
+every	O
+4	O
+weeks	O
+.	O
+
+TITLE	O
+:	O
+Disturbances	O
+in	O
+leptin	B-PRGE
+metabolism	B-PROC
+are	O
+related	O
+to	O
+energy	O
+imbalance	B-DISO
+during	O
+acute	O
+exacerbations	O
+of	O
+chronic	O
+obstructive	O
+pulmonary	O
+disease	O
+.	O
+
+Experimental	O
+and	O
+clinical	O
+research	O
+supports	O
+the	O
+hypothesis	O
+of	O
+involvement	O
+of	O
+the	O
+hormone	B-CHED
+leptin	B-PRGE
+in	O
+body	B-ANAT
+weight	O
+and	O
+energy	B-PROC
+balance	I-PROC
+homeostasis	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+dietary	B-PROC
+intake	I-PROC
+/	O
+REE	O
+ratio	O
+was	O
+not	O
+only	O
+inversely	O
+related	O
+with	O
+LN	B-PRGE
+leptin	I-PRGE
+(-	O
+0	O
+.	O
+74	O
+,	O
+p	O
+=	O
+0	O
+.	O
+037	O
+),	O
+but	O
+also	O
+with	O
+sTNF	O
+-	O
+R55	O
+(	O
+r	O
+=	O
+-	O
+0	O
+.	O
+93	O
+,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+on	O
+day	O
+seven	O
+.	O
+
+(	O
+b	O
+)	O
+To	O
+propose	O
+a	O
+new	O
+ARDS	B-DISO
+Severity	O
+Score	O
+to	O
+identify	O
+patients	O
+with	O
+a	O
+high	O
+mortality	O
+risk	O
+.	O
+
+A	O
+new	O
+ARDS	B-DISO
+Severity	O
+Score	O
+based	O
+on	O
+CT	O
+lung	B-ANAT
+morphology	O
+and	O
+cardiorespiratory	O
+parameters	O
+accurately	O
+identified	O
+patients	O
+with	O
+the	O
+most	O
+severe	O
+forms	O
+of	O
+ARDS	B-DISO
+and	O
+a	O
+mortality	O
+rate	O
+above	O
+60	O
+%.	O
+
+Recent	O
+evidence	O
+suggests	O
+that	O
+the	O
+FIPV	O
+has	O
+evolved	O
+as	O
+a	O
+deletion	B-PROC
+mutation	I-PROC
+of	O
+FECV	B-SPEC
+.	O
+
+Applying	O
+indicator	B-CHED
+-	O
+dilution	O
+techniques	O
+,	O
+we	O
+measured	O
+single	O
+-	O
+pass	O
+transpulmonary	O
+hydrolysis	O
+of	O
+the	O
+synthetic	B-PRGE
+ACE	I-PRGE
+substrate	I-PRGE
+(	I-PRGE
+3	I-PRGE
+)	I-PRGE
+H	I-PRGE
+-	I-PRGE
+benzoyl	B-CHED
+-	I-PRGE
+Phe	B-CHED
+-	I-PRGE
+Ala	B-CHED
+-	I-PRGE
+Pro	B-CHED
+(	O
+BPAP	O
+)	O
+in	O
+33	O
+mechanically	O
+ventilated	O
+,	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+a	O
+lung	B-ANAT
+injury	O
+score	O
+(	O
+LIS	B-FUNC
+)	O
+ranging	O
+from	O
+0	O
+(	O
+no	O
+lung	B-ANAT
+injury	O
+)	O
+to	O
+3	O
+.	O
+7	O
+(	O
+severe	O
+lung	B-ANAT
+injury	O
+)	O
+and	O
+calculated	O
+the	O
+kinetic	O
+parameter	O
+A	O
+(	O
+max	O
+)/	O
+K	O
+(	O
+m	O
+).	O
+
+The	O
+spore	B-COMP
+wall	I-COMP
+showed	O
+an	O
+enlarged	O
+endospore	O
+and	O
+delaminated	O
+exospore	B-COMP
+.	O
+
+Mature	O
+spores	O
+had	O
+a	O
+complete	O
+cytoplasmic	B-COMP
+disorganization	O
+and	O
+a	O
+swollen	O
+and	O
+delaminated	O
+cell	B-COMP
+wall	I-COMP
+.	O
+
+This	O
+study	O
+compared	O
+consecutive	O
+Far	O
+-	O
+East	O
+Asian	O
+men	O
+with	O
+OSAS	B-DISO
+(	O
+n	O
+=	O
+50	O
+)	O
+with	O
+two	O
+selected	O
+groups	O
+of	O
+White	O
+men	O
+with	O
+OSAS	B-DISO
+(	O
+n	O
+=	O
+50	O
+in	O
+each	O
+group	O
+).	O
+
+The	O
+majority	O
+of	O
+the	O
+Far	O
+-	O
+East	O
+Asian	O
+men	O
+in	O
+this	O
+study	O
+were	O
+found	O
+to	O
+be	O
+nonobese	O
+,	O
+despite	O
+the	O
+presence	O
+of	O
+severe	O
+OSAS	B-DISO
+.	O
+
+When	O
+compared	O
+with	O
+white	O
+men	O
+,	O
+Far	O
+-	O
+East	O
+Asian	O
+men	O
+were	O
+less	O
+obese	B-DISO
+but	O
+had	O
+greater	O
+severity	O
+of	O
+OSAS	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+immunoprophylactic	O
+effects	O
+of	O
+chicken	B-PRGE
+egg	B-ANAT
+yolk	B-COMP
+immunoglobulin	B-PROC
+(	O
+Ig	O
+Y	O
+)	O
+against	O
+PEDV	B-SPEC
+were	O
+investigated	O
+in	O
+neonatal	O
+pigs	B-SPEC
+.	O
+
+Deletion	O
+of	O
+this	O
+sequence	O
+abrogated	O
+transcriptional	B-PROC
+activity	O
+and	O
+disrupted	O
+the	O
+predicted	O
+stem	B-ANAT
+-	O
+loops	O
+and	O
+overall	O
+RNA	O
+secondary	O
+structure	O
+at	O
+the	O
+5	O
+'	O
+untranslated	O
+region	O
+,	O
+suggesting	O
+that	O
+the	O
+secondary	O
+structure	O
+formed	O
+by	O
+this	O
+35	O
+-	O
+nt	O
+sequence	O
+may	O
+facilitate	O
+the	O
+downstream	O
+consensus	O
+sequence	O
+accessible	O
+for	O
+the	O
+discontinuous	O
+RNA	O
+transcription	B-PROC
+.	O
+
+The	O
+5	O
+'-	O
+most	O
+24	O
+nt	O
+are	O
+not	O
+essential	O
+for	O
+transcription	B-PROC
+,	O
+while	O
+the	O
+9	O
+nt	O
+immediately	O
+downstream	O
+of	O
+the	O
+leader	O
+enhances	O
+RNA	O
+transcription	B-PROC
+.	O
+
+This	O
+study	O
+thus	O
+defines	O
+the	O
+cis	B-DISO
+-	O
+acting	O
+transcription	B-PROC
+signal	O
+at	O
+the	O
+5	O
+'	O
+end	O
+of	O
+the	O
+DI	O
+genome	O
+.	O
+
+Transcripts	O
+derived	O
+from	O
+the	O
+full	O
+-	O
+length	O
+TGEV	B-SPEC
+construct	O
+were	O
+infectious	O
+,	O
+and	O
+progeny	O
+virions	B-COMP
+were	O
+serially	O
+passaged	O
+in	O
+permissive	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+The	O
+recombinant	O
+viruses	B-SPEC
+were	O
+sequenced	O
+across	O
+the	O
+unique	O
+interconnecting	O
+junctions	O
+,	O
+conclusively	O
+demonstrating	O
+the	O
+marker	O
+mutations	O
+and	O
+restriction	O
+sites	O
+that	O
+were	O
+engineered	O
+into	O
+the	O
+component	O
+clones	O
+.	O
+
+Fifty	O
+-	O
+seven	O
+patients	O
+operated	O
+for	O
+esophageal	B-DISO
+cancer	I-DISO
+in	O
+1997	O
+and	O
+1998	O
+were	O
+treated	O
+with	O
+perioperative	O
+steroid	B-CHED
+therapy	O
+.	O
+
+Days	O
+until	O
+extubation	O
+and	O
+hospital	O
+stay	O
+were	O
+significantly	O
+shorter	O
+for	O
+the	O
+steroid	B-CHED
+group	O
+.	O
+
+Inflammatory	O
+mediators	O
+,	O
+body	B-ANAT
+temperature	O
+,	O
+heart	B-ANAT
+rate	O
+,	O
+and	O
+respiratory	O
+index	O
+after	O
+the	O
+surgical	O
+procedure	O
+were	O
+significantly	O
+lower	O
+in	O
+the	O
+steroid	B-CHED
+group	O
+.	O
+
+Adverse	B-DISO
+effects	I-DISO
+possibly	O
+caused	O
+by	O
+steroid	B-CHED
+therapy	O
+were	O
+not	O
+observed	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+effect	O
+of	O
+vitamin	O
+A	O
+supplementation	O
+on	O
+the	O
+risk	O
+of	O
+diarrhea	B-DISO
+and	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+.	O
+
+Vitamin	B-CHED
+A	I-CHED
+supplements	O
+provide	O
+a	O
+low	O
+-	O
+cost	O
+intervention	O
+against	O
+morbidity	O
+in	O
+HIV	B-DISO
+-	O
+infected	O
+and	O
+undernourished	B-DISO
+children	O
+.	O
+
+Whether	O
+these	O
+apparent	O
+detrimental	O
+effects	O
+of	O
+vitamin	B-CHED
+A	I-CHED
+are	O
+transient	O
+or	O
+long	O
+-	O
+term	O
+needs	O
+to	O
+be	O
+examined	O
+.	O
+
+RESULTS	O
+:	O
+Relative	O
+to	O
+those	O
+receiving	O
+placebo	O
+,	O
+children	O
+receiving	O
+vitamin	B-CHED
+A	I-CHED
+had	O
+a	O
+significantly	O
+smaller	O
+risk	O
+of	O
+severe	O
+watery	B-DISO
+diarrhea	I-DISO
+(	O
+multivariate	O
+odds	O
+ratio	O
+=	O
+0	O
+.	O
+56	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+32	O
+-	O
+0	O
+.	O
+99	O
+,	O
+P	O
+=.	O
+04	O
+)	O
+but	O
+a	O
+higher	O
+risk	O
+of	O
+cough	B-DISO
+and	O
+rapid	O
+respiratory	O
+rate	O
+(	O
+multivariate	O
+odds	O
+ratio	O
+=	O
+1	O
+.	O
+67	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+17	O
+-	O
+2	O
+.	O
+36	O
+,	O
+P	O
+=.	O
+004	O
+).	O
+
+Sequence	O
+analysis	O
+of	O
+virus	B-SPEC
+genome	O
+N	O
+-,	O
+G1	O
+-,	O
+and	O
+G2	O
+-	O
+encoding	O
+fragments	O
+showed	O
+this	O
+to	O
+be	O
+a	O
+novel	O
+hantavirus	B-SPEC
+,	O
+Choclo	B-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Dengue	B-DISO
+:	O
+a	O
+new	O
+approach	O
+].	O
+
+TITLE	O
+:	O
+Serious	O
+complications	O
+of	O
+bacteremia	B-DISO
+caused	O
+by	O
+Viridans	O
+streptococci	O
+in	O
+neutropenic	O
+patients	O
+with	O
+cancer	O
+.	O
+
+TITLE	O
+:	O
+Optimization	O
+of	O
+bovine	B-PRGE
+coronavirus	B-SPEC
+hemagglutinin	I-PRGE
+-	I-PRGE
+estrase	I-PRGE
+glycoprotein	B-CHED
+expression	B-PROC
+in	O
+E3	O
+deleted	O
+bovine	O
+adenovirus	B-DISO
+-	O
+3	O
+.	O
+
+ABSTRACT	O
+:	O
+Adenoviral	B-SPEC
+vectors	O
+expressing	O
+foreign	O
+genes	O
+have	O
+many	O
+desirable	O
+properties	O
+in	O
+applications	O
+such	O
+as	O
+vaccination	O
+.	O
+
+ABSTRACT	O
+:	O
+Ten	O
+calves	O
+which	O
+had	O
+contracted	O
+acute	B-DISO
+diarrhoea	I-DISO
+caused	O
+by	O
+rotavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+and	O
+Cryptosporidium	B-SPEC
+were	O
+used	O
+to	O
+test	O
+the	O
+hypothesis	O
+that	O
+feeding	O
+lactose	B-CHED
+-	O
+hydrolysed	O
+cow	B-SPEC
+'	O
+s	O
+milk	O
+instead	O
+of	O
+unprocessed	O
+cow	B-SPEC
+'	O
+s	O
+milk	O
+improves	O
+sugar	O
+absorption	O
+in	O
+diarrhoeic	O
+calves	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+constitutes	O
+an	O
+important	O
+advance	O
+in	O
+the	O
+management	O
+of	O
+children	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Conventional	O
+and	O
+HFOV	O
+ventilatory	O
+,	O
+gasometric	O
+and	O
+hemodynamic	B-PROC
+parameters	O
+of	O
+patients	O
+included	O
+in	O
+the	O
+protocol	O
+during	O
+a	O
+5	O
+-	O
+month	O
+period	O
+were	O
+registered	O
+,	O
+and	O
+the	O
+first	O
+24	O
+hours	O
+were	O
+analyzed	O
+.	O
+
+TITLE	O
+:	O
+Functional	O
+analysis	O
+of	O
+an	O
+epitope	B-CHED
+in	O
+the	O
+S2	O
+subunit	O
+of	O
+the	O
+murine	B-PRGE
+coronavirus	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+:	O
+involvement	O
+in	O
+fusion	O
+activity	O
+.	O
+
+Presumably	O
+this	O
+occurs	O
+because	O
+the	O
+consensus	O
+IG	O
+sequence	O
+serves	O
+as	O
+the	O
+template	O
+switching	O
+site	O
+for	O
+the	O
+viral	B-PRGE
+encoded	I-PRGE
+polymerase	I-PRGE
+.	O
+
+Instead	O
+of	O
+measuring	O
+the	O
+protection	O
+of	O
+vaccinated	O
+animals	B-SPEC
+against	O
+virulent	O
+pathogens	O
+,	O
+the	O
+serological	O
+response	O
+after	O
+vaccination	O
+can	O
+be	O
+quantified	O
+for	O
+some	O
+vaccines	O
+.	O
+
+The	O
+question	O
+,	O
+however	O
+,	O
+of	O
+whether	O
+the	O
+improved	O
+ECMO	O
+can	O
+really	O
+challenge	O
+the	O
+advanced	O
+conventional	O
+treatment	O
+of	O
+adult	O
+ARDS	B-DISO
+is	O
+unanswered	O
+and	O
+will	O
+need	O
+evaluation	O
+by	O
+a	O
+future	O
+RCT	O
+.	O
+
+ABSTRACT	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+(	O
+GBS	B-DISO
+)	O
+is	O
+an	O
+acute	O
+immune	O
+-	O
+mediated	O
+polyneuropathy	O
+.	O
+
+Two	O
+thirds	O
+of	O
+GBS	B-DISO
+patients	O
+are	O
+unable	O
+to	O
+walk	O
+at	O
+their	O
+most	O
+severe	O
+state	O
+of	O
+disease	O
+.	O
+
+These	O
+""""	O
+treatment	O
+related	O
+clinical	O
+fluctuations	B-DISO
+""""	O
+are	O
+more	O
+frequently	O
+seen	O
+in	O
+relatively	O
+young	O
+patients	O
+with	O
+severe	O
+motor	O
+and	O
+sensory	O
+involvement	O
+associated	O
+with	O
+a	O
+preceding	O
+and	O
+possibly	O
+ongoing	O
+cytomegalovirus	O
+infection	O
+.	O
+
+His	O
+past	O
+history	O
+revealed	O
+a	O
+severe	O
+trauma	O
+4	O
+years	O
+ago	O
+,	O
+including	O
+multiple	O
+bone	B-ANAT
+fractures	O
+,	O
+rupture	O
+of	O
+the	O
+spleen	B-ANAT
+,	O
+as	O
+well	O
+as	O
+renal	B-DISO
+failure	I-DISO
+,	O
+and	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+from	O
+which	O
+he	O
+showed	O
+good	O
+recovery	O
+.	O
+
+However	O
+,	O
+eighteen	O
+months	O
+ago	O
+,	O
+he	O
+complained	O
+about	O
+a	O
+transient	O
+weakness	B-DISO
+of	O
+his	O
+left	O
+arm	B-ANAT
+and	I-ANAT
+leg	I-ANAT
+.	O
+
+This	O
+could	O
+be	O
+confirmed	O
+by	O
+CT	O
+-	O
+and	O
+MR	O
+-	O
+based	O
+angiography	O
+,	O
+which	O
+also	O
+revealed	O
+a	O
+reopened	O
+embolic	B-DISO
+occlusion	I-DISO
+of	O
+the	O
+M1	O
+-	O
+segment	O
+of	O
+the	O
+right	B-ANAT
+middle	I-ANAT
+cerebral	I-ANAT
+artery	I-ANAT
+.	O
+
+The	O
+patient	O
+presented	O
+with	O
+symptoms	O
+compatible	O
+with	O
+a	O
+severe	O
+systemic	O
+reaction	O
+to	O
+BCG	B-PRGE
+therapy	O
+,	O
+a	O
+rare	O
+but	O
+possible	O
+adverse	B-DISO
+effect	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+coronavirus	B-SPEC
+was	O
+isolated	O
+from	O
+feces	O
+of	O
+a	O
+diarrheic	O
+foal	O
+and	O
+serially	O
+propagated	O
+in	O
+human	B-SPEC
+rectal	B-DISO
+adenocarcinoma	I-DISO
+(	O
+HRT	O
+-	O
+18	O
+)	O
+cells	B-COMP
+.	O
+
+COMPOSITE	O
+OUTCOMES	O
+:	O
+No	O
+significant	O
+differences	O
+in	O
+outcome	O
+were	O
+found	O
+between	O
+the	O
+two	O
+protocol	O
+groups	O
+in	O
+terms	O
+of	O
+patients	O
+who	O
+either	O
+died	B-PROC
+or	O
+had	O
+serious	O
+complications	O
+,	O
+nor	O
+for	O
+patients	O
+who	O
+either	O
+died	B-PROC
+or	O
+had	O
+known	O
+poor	O
+health	O
+.	O
+
+Institution	O
+of	O
+invasive	O
+therapeutic	O
+methods	O
+:	O
+continuous	O
+mandatory	O
+ventilation	O
+(	O
+CMV	B-SPEC
+)	O
+with	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+and	O
+plasmapheresis	O
+,	O
+together	O
+with	O
+antibioticotherapy	O
+resulted	O
+in	O
+complete	O
+recovery	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+coronaviruses	O
+produced	O
+little	O
+CPE	O
+in	O
+A3	O
+-	O
+1M	O
+and	O
+CMT	O
+-	O
+93	O
+cells	B-COMP
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+B16	O
+and	O
+IC	O
+-	O
+21	O
+cells	B-COMP
+are	O
+suitable	O
+for	O
+large	O
+-	O
+scale	O
+preparation	O
+and	O
+isolation	O
+of	O
+murine	B-SPEC
+coronaviruses	O
+,	O
+respectively	O
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+between	O
+the	O
+2	O
+groups	O
+with	O
+respect	O
+to	O
+eclampsia	B-DISO
+(	O
+16	O
+%	O
+vs	O
+13	O
+%),	O
+abruptio	B-DISO
+placentae	I-DISO
+(	O
+6	O
+%	O
+vs	O
+9	O
+%),	O
+disseminated	O
+intravascular	O
+coagulopathy	B-DISO
+(	O
+13	O
+%	O
+vs	O
+0	O
+%),	O
+pulmonary	B-DISO
+edema	I-DISO
+(	O
+13	O
+%	O
+vs	O
+6	O
+%),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+3	O
+%	O
+vs	O
+0	O
+%),	O
+pleural	B-DISO
+effusion	I-DISO
+(	O
+3	O
+%	O
+vs	O
+3	O
+%),	O
+or	O
+ascites	O
+(	O
+6	O
+%	O
+vs	O
+16	O
+%).	O
+
+No	O
+significant	O
+differences	O
+were	O
+found	O
+between	O
+the	O
+2	O
+groups	O
+with	O
+respect	O
+to	O
+neonatal	B-DISO
+death	I-DISO
+(	O
+11	O
+%	O
+vs	O
+17	O
+%),	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+78	O
+%	O
+vs	O
+86	O
+%),	O
+or	O
+composite	O
+neonatal	O
+morbidity	O
+.	O
+
+Moreover	O
+,	O
+TGEV	B-SPEC
+-	O
+specific	O
+secretory	B-PROC
+IgA	B-PRGE
+was	O
+detected	O
+in	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+and	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+the	O
+immunized	O
+animals	B-SPEC
+.	O
+
+Time	O
+-	O
+dependent	O
+determination	O
+of	O
+the	O
+AE	O
+activity	O
+of	O
+purified	O
+RBCV	O
+OK	O
+and	O
+LSU	O
+particles	O
+showed	O
+lower	O
+AE	O
+activity	O
+at	O
+39	O
+degrees	O
+C	O
+than	O
+at	O
+37	O
+degrees	O
+C	O
+,	O
+whereas	O
+the	O
+purified	O
+EBCV	O
+LY	O
+particles	O
+retained	O
+full	O
+AE	O
+activity	O
+at	O
+both	O
+37	O
+degrees	O
+C	O
+and	O
+39	O
+degrees	O
+C	O
+.	O
+Transiently	O
+expressed	B-PROC
+RBCV	O
+HE	O
+exhibited	O
+a	O
+marked	O
+reduction	O
+of	O
+AE	O
+activity	O
+after	O
+40	O
+min	O
+of	O
+assay	O
+time	O
+at	O
+37	O
+degrees	O
+C	O
+.	O
+In	O
+contrast	O
+,	O
+the	O
+AE	O
+activity	O
+of	O
+the	O
+transiently	O
+expressed	B-PROC
+EBCV	O
+HE	O
+remained	O
+stable	O
+beyond	O
+40	O
+min	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+impaired	B-DISO
+generation	O
+of	O
+cGMP	O
+may	O
+account	O
+for	O
+the	O
+pulmonary	B-DISO
+hypertension	I-DISO
+seen	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+drawn	O
+for	O
+plasma	B-ANAT
+cGMP	B-CHED
+determinations	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+VAI	O
+increased	O
+the	O
+pulmonary	B-ANAT
+artery	I-ANAT
+pressure	O
+(	O
+by	O
+181	O
+%,	O
+P	O
+<.	O
+05	O
+)	O
+after	O
+15	O
+minutes	O
+of	O
+air	B-CHED
+infusion	O
+without	O
+changing	O
+the	O
+cardiac	B-ANAT
+index	O
+.	O
+
+The	O
+type	O
+of	O
+transplantation	O
+,	O
+determined	O
+after	O
+an	O
+exhaustive	O
+work	O
+-	O
+up	O
+ruling	O
+out	O
+all	O
+contraindications	O
+,	O
+is	O
+generally	O
+a	O
+single	O
+lung	B-ANAT
+transplantation	O
+if	O
+there	O
+is	O
+no	O
+bronchial	B-DISO
+infection	I-DISO
+or	O
+two	O
+-	O
+lung	B-ANAT
+transplantation	O
+or	O
+heart	B-ANAT
+-	O
+lung	B-ANAT
+transplantation	O
+in	O
+case	O
+of	O
+bronchiectasis	B-DISO
+or	O
+pulmonary	B-DISO
+artery	I-DISO
+hypertension	I-DISO
+.	O
+
+Transplantation	O
+improves	O
+exercise	O
+capacity	O
+,	O
+quality	O
+of	O
+life	O
+and	O
+lung	B-PROC
+function	I-PROC
+.	O
+
+TITLE	O
+:	O
+A	O
+serological	O
+survey	O
+for	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+and	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+antibodies	B-COMP
+in	O
+backyard	O
+(	O
+free	O
+-	O
+range	O
+)	O
+village	O
+chickens	B-SPEC
+in	O
+Mexico	O
+.	O
+
+A	O
+seroprevalence	O
+survey	O
+in	O
+30	O
+villages	O
+using	O
+haemagglutination	B-PROC
+inhibition	B-PROC
+(	O
+HI	O
+)	O
+tests	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+NDV	B-SPEC
+antibodies	B-COMP
+was	O
+carried	O
+out	O
+from	O
+December	O
+1997	O
+to	O
+June	O
+1998	O
+.	O
+
+The	O
+implications	O
+of	O
+these	O
+findings	O
+are	O
+discussed	O
+,	O
+including	O
+the	O
+highly	O
+susceptible	O
+status	O
+of	O
+the	O
+backyard	O
+chickens	O
+in	O
+Yucatan	O
+to	O
+NDV	B-SPEC
+and	O
+the	O
+possibility	O
+of	O
+this	O
+virus	B-SPEC
+being	O
+one	O
+cause	O
+of	O
+the	O
+syndrome	B-DISO
+known	O
+as	O
+mortandad	O
+by	O
+the	O
+local	O
+people	O
+.	O
+
+For	O
+scoring	O
+the	O
+severity	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+the	O
+lung	B-ANAT
+injury	O
+score	O
+(	O
+LIS	B-FUNC
+)	O
+according	O
+to	O
+Murray	O
+and	O
+the	O
+SOFA	O
+score	O
+lung	B-ANAT
+(	O
+sepsis	B-DISO
+-	O
+related	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+)	O
+according	O
+to	O
+Vincent	O
+were	O
+evaluated	O
+.	O
+
+1	O
+.	O
+0	O
+),	O
+the	O
+SOFA	O
+score	O
+lung	B-ANAT
+3	O
+.	O
+0	O
+(+/-	O
+0	O
+.	O
+9	O
+).	O
+
+Consistent	O
+kinetic	O
+therapy	O
+integrated	O
+in	O
+a	O
+standardised	O
+treatment	O
+regimen	O
+contributes	O
+towards	O
+improving	O
+the	O
+negative	O
+outcome	O
+to	O
+date	O
+of	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+after	O
+major	O
+trauma	O
+.	O
+
+Cores	O
+were	O
+composed	O
+of	O
+the	O
+nucleoprotein	O
+,	O
+RNA	O
+,	O
+and	O
+the	O
+C	O
+domain	O
+of	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+.	O
+
+At	O
+high	O
+salt	B-CHED
+concentrations	O
+(	O
+200	O
+to	O
+300	O
+mM	O
+),	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+was	O
+no	O
+longer	O
+associated	O
+with	O
+the	O
+nucleocapsid	B-COMP
+,	O
+which	O
+resulted	O
+in	O
+destruction	O
+of	O
+the	O
+core	O
+structure	O
+.	O
+
+Our	O
+study	O
+suggests	O
+that	O
+increased	O
+concentrations	O
+of	O
+vWf	O
+:	O
+Ag	O
+in	O
+plasma	B-ANAT
+are	O
+predictive	O
+of	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+and	O
+signal	O
+poor	O
+prognosis	O
+in	O
+patients	O
+following	O
+severe	O
+trauma	O
+.	O
+
+Near	O
+-	O
+term	O
+infants	O
+with	O
+severe	O
+RDS	O
+often	O
+respond	O
+to	O
+exogenous	O
+surfactant	B-CHED
+,	O
+suggesting	O
+a	O
+functional	O
+deficiency	O
+of	O
+endogenous	O
+surfactant	B-CHED
+at	O
+a	O
+""""	O
+late	O
+""""	O
+stage	O
+in	O
+their	O
+disease	O
+process	O
+.	O
+
+To	O
+determine	O
+functional	O
+significance	O
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+infected	O
+mice	B-SPEC
+were	O
+treated	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+Mig	I-PRGE
+antisera	I-PRGE
+,	O
+and	O
+the	O
+severity	O
+of	O
+disease	O
+was	O
+evaluated	O
+.	O
+
+S	O
+(	O
+A59	O
+)	O
+R13	O
+,	O
+expressing	O
+the	O
+A59	B-PRGE
+spike	I-PRGE
+gene	I-PRGE
+,	O
+replicated	O
+to	O
+a	O
+somewhat	O
+lower	O
+titer	O
+and	O
+induced	O
+moderate	O
+to	O
+severe	O
+hepatitis	B-DISO
+with	O
+zonal	B-DISO
+necrosis	I-DISO
+,	O
+similar	O
+to	O
+MHV	B-SPEC
+-	O
+A59	O
+.	O
+
+Multicenter	O
+,	O
+double	O
+-	O
+blind	B-DISO
+,	O
+randomized	O
+,	O
+placebo	O
+-	O
+controlled	O
+study	O
+.	O
+
+There	O
+were	O
+no	O
+differences	O
+in	O
+types	O
+and	O
+occurrences	O
+of	O
+adverse	O
+events	O
+,	O
+including	O
+ARDS	B-DISO
+,	O
+or	O
+in	O
+outcome	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+Three	O
+of	O
+four	O
+placebo	O
+-	O
+treated	O
+patients	O
+had	O
+persistent	O
+bacterial	O
+growth	B-PROC
+on	O
+bronchoscopy	O
+repeated	O
+after	O
+48	O
+h	O
+compared	O
+with	O
+2	O
+of	O
+10	O
+filgrastim	O
+-	O
+treated	O
+patients	O
+.	O
+
+Larger	O
+studies	O
+to	O
+determine	O
+the	O
+benefit	O
+of	O
+filgrastim	O
+in	O
+patients	O
+with	O
+pneumonia	B-DISO
+and	O
+sepsis	B-DISO
+or	O
+organ	B-ANAT
+dysfunction	O
+are	O
+warranted	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Filgrastim	O
+appeared	O
+to	O
+be	O
+well	O
+tolerated	O
+in	O
+this	O
+population	O
+of	O
+patients	O
+with	O
+pneumonia	B-DISO
+and	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+examine	O
+the	O
+hypothesis	O
+that	O
+the	O
+response	O
+to	O
+inhaled	B-PROC
+prostacyclin	B-CHED
+(	O
+PGI2	B-CHED
+on	O
+oxygenation	B-PROC
+and	O
+pulmonary	B-ANAT
+hemodynamics	B-PROC
+may	O
+be	O
+related	O
+to	O
+different	O
+morphologic	O
+features	O
+that	O
+are	O
+supposed	O
+to	O
+be	O
+present	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+originating	O
+from	O
+pulmonary	B-ANAT
+(	O
+primary	O
+ARDS	B-DISO
+[	O
+ARDS	B-DISO
+(	O
+PR	O
+)])	O
+and	O
+from	O
+extrapulmonary	O
+disease	O
+(	O
+secondary	O
+ARDS	B-DISO
+[	O
+ARDS	B-DISO
+(	O
+SEC	B-CHED
+)]).	O
+
+Eight	O
+patients	O
+responded	O
+to	O
+PGI2	B-CHED
+nebulization	O
+on	O
+oxygenation	B-PROC
+(	O
+all	O
+were	O
+in	O
+the	O
+ARDS	B-DISO
+(	O
+SEC	B-CHED
+)	O
+subgroup	O
+),	O
+whereas	O
+seven	O
+did	O
+not	O
+(	O
+all	O
+but	O
+one	O
+were	O
+in	O
+the	O
+ARDS	B-DISO
+(	O
+PR	O
+)	O
+subgroup	O
+).	O
+
+Based	O
+on	O
+the	O
+data	O
+from	O
+this	O
+study	O
+,	O
+the	O
+clinical	O
+recognition	O
+of	O
+the	O
+two	O
+types	O
+of	O
+the	O
+syndrome	B-DISO
+together	O
+with	O
+the	O
+CT	O
+number	O
+frequency	O
+distribution	O
+analysis	O
+may	O
+be	O
+associated	O
+with	O
+a	O
+prediction	O
+of	O
+the	O
+PGI2	B-CHED
+nebulization	O
+response	O
+on	O
+oxygenation	B-PROC
+.	O
+
+Further	O
+epidemiological	O
+studies	O
+to	O
+determine	O
+the	O
+frequency	O
+of	O
+these	O
+viruses	B-SPEC
+in	O
+the	O
+community	O
+and	O
+to	O
+identify	O
+their	O
+mechanisms	O
+of	O
+transmission	O
+are	O
+needed	O
+,	O
+as	O
+are	O
+further	O
+studies	O
+to	O
+elucidate	O
+the	O
+pathophysiology	O
+of	O
+diseases	O
+due	O
+to	O
+these	O
+agents	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+induced	O
+by	O
+fulminant	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H3	O
+N2	O
+)	O
+pneumonia	B-DISO
+].	O
+
+This	O
+patient	O
+was	O
+treated	O
+with	O
+high	O
+doses	O
+of	O
+methylprednisolone	B-CHED
+,	O
+antibiotics	B-CHED
+,	O
+globulins	O
+,	O
+urinastatin	O
+,	O
+neutrophilic	B-PRGE
+elastase	B-CHED
+inhibitor	I-CHED
+,	O
+nitric	B-CHED
+oxide	I-CHED
+inhalation	B-PROC
+,	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+but	O
+died	B-PROC
+on	O
+the	O
+thirteenth	O
+hospital	O
+day	O
+.	O
+
+High	O
+inspiratory	B-PROC
+pressures	O
+were	O
+avoided	O
+and	O
+arterial	B-ANAT
+saturation	O
+as	O
+low	O
+as	O
+70	O
+%	O
+was	O
+accepted	O
+on	O
+venovenous	O
+bypass	O
+.	O
+
+The	O
+cause	O
+of	O
+death	O
+in	O
+the	O
+three	O
+nonsurvivors	O
+was	O
+intracranial	B-ANAT
+complications	O
+leading	O
+to	O
+total	O
+cerebral	B-DISO
+infarction	I-DISO
+.	O
+
+Furthermore	O
+,	O
+this	O
+state	O
+appears	O
+to	O
+be	O
+related	O
+to	O
+the	O
+onset	O
+of	O
+more	O
+severe	O
+systemic	O
+inflammation	B-DISO
+and	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+our	O
+experience	O
+with	O
+inhaled	B-PROC
+NO	O
+in	O
+10	O
+adult	O
+patients	O
+with	O
+burn	O
+injuries	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+-	O
+related	O
+oxygenation	B-PROC
+failure	O
+.	O
+
+Although	O
+the	O
+immediate	O
+effects	O
+may	O
+seem	O
+impressive	O
+,	O
+long	O
+-	O
+term	O
+outcome	O
+regarding	O
+residual	O
+pulmonary	B-DISO
+hypertension	I-DISO
+and	O
+other	O
+sequelae	O
+has	O
+been	O
+studied	O
+in	O
+only	O
+a	O
+very	O
+few	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strain	O
+CT	O
+/	O
+7852	O
+/	O
+97	O
+was	O
+isolated	O
+from	O
+a	O
+commercial	O
+layer	B-ANAT
+flock	O
+experiencing	O
+decreased	O
+egg	B-ANAT
+production	O
+and	O
+poor	O
+egg	B-ANAT
+quality	O
+.	O
+
+The	O
+highest	O
+nucleotide	B-CHED
+homology	O
+with	O
+H120	O
+(	O
+97	O
+%)	O
+and	O
+the	O
+least	O
+homology	O
+(	O
+62	O
+%)	O
+with	O
+Delaware	O
+(	O
+De	O
+/	O
+072	O
+/	O
+92	O
+)	O
+were	O
+observed	O
+.	O
+
+Six	O
+of	O
+the	O
+isolates	O
+were	O
+neutralized	O
+by	O
+Mass	O
+monoclonal	O
+antibodies	B-COMP
+,	O
+whereas	O
+the	O
+other	O
+four	O
+were	O
+not	O
+.	O
+
+The	O
+electrophoretic	O
+patterns	O
+for	O
+the	O
+four	O
+isolates	O
+were	O
+identical	O
+but	O
+were	O
+different	O
+from	O
+other	O
+known	O
+IBV	B-SPEC
+isolates	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Maternal	O
+and	O
+perinatal	B-DISO
+morbidity	I-DISO
+and	O
+mortality	O
+associated	O
+with	O
+hellp	B-DISO
+syndrome	I-DISO
+]	O
+.	O
+
+Six	O
+perinatal	O
+deaths	B-PROC
+were	O
+related	O
+to	O
+abruptio	B-DISO
+placenta	I-DISO
+,	O
+intrauterine	B-DISO
+asphyxia	I-DISO
+and	O
+extreme	O
+prematurity	O
+.	O
+
+TITLE	O
+:	O
+Chylous	O
+abdominal	B-ANAT
+effusion	B-DISO
+in	O
+a	O
+cat	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Epidemiology	O
+of	O
+viral	O
+nosocomial	B-DISO
+infections	I-DISO
+in	O
+pediatrics	O
+].	O
+
+It	O
+often	O
+begins	O
+before	O
+the	O
+clinical	O
+signs	O
+appear	O
+and	O
+ends	O
+after	O
+the	O
+healing	B-PROC
+.	O
+
+Minimal	O
+infective	O
+doses	O
+depend	O
+on	O
+the	O
+route	O
+of	O
+inoculation	O
+and	O
+the	O
+kind	O
+of	O
+virus	B-SPEC
+.	O
+
+Low	O
+doses	O
+are	O
+for	O
+example	O
+sufficient	O
+for	O
+rotavirus	B-SPEC
+,	O
+adenovirus	B-DISO
+and	O
+calicivirus	O
+.	O
+
+The	O
+infection	B-DISO
+with	O
+RBCV	O
+was	O
+detected	O
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+of	O
+86	O
+cattle	B-SPEC
+,	O
+and	O
+81	O
+of	O
+them	O
+developed	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+,	O
+including	O
+fatal	O
+pneumonia	B-DISO
+.	O
+
+The	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+glycoprotein	B-CHED
+was	O
+the	O
+least	O
+immunogenic	O
+of	O
+the	O
+major	O
+viral	O
+structural	O
+proteins	B-CHED
+.	O
+
+The	O
+results	O
+were	O
+compared	O
+to	O
+previously	O
+reported	O
+data	O
+derived	O
+from	O
+the	O
+corresponding	O
+NS3	B-PRGE
+protease	I-PRGE
+domain	I-PRGE
+assay	O
+.	O
+
+Airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+(	O
+APRV	O
+)	O
+with	O
+the	O
+patient	O
+'	O
+s	O
+superimposed	O
+spontaneous	O
+breathing	B-PROC
+was	O
+implemented	O
+and	O
+maintained	O
+,	O
+also	O
+during	O
+prone	O
+episodes	O
+.	O
+
+APRV	O
+and	O
+maintenance	O
+of	O
+patients	O
+'	O
+spontaneous	O
+ventilation	O
+is	O
+feasible	O
+during	O
+prone	O
+positioning	O
+,	O
+and	O
+this	O
+approach	O
+may	O
+have	O
+beneficial	O
+synergistic	O
+effects	O
+on	O
+gas	O
+exhange	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+CONCLUSIONS	O
+:	O
+APRV	O
+and	O
+maintenance	O
+of	O
+patients	O
+'	O
+spontaneous	O
+ventilation	O
+is	O
+feasible	O
+during	O
+prone	O
+positioning	O
+,	O
+and	O
+this	O
+approach	O
+may	O
+have	O
+beneficial	O
+synergistic	O
+effects	O
+on	O
+gas	B-ENZY
+exhange	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Alteration	O
+of	O
+fatty	B-CHED
+acid	I-CHED
+profiles	O
+in	O
+different	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+phospholipids	B-CHED
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+We	O
+conclude	O
+that	O
+marked	O
+changes	O
+in	O
+the	O
+FA	O
+composition	O
+of	O
+the	O
+predominant	O
+surfactant	B-CHED
+PL	O
+classes	O
+occur	O
+,	O
+both	O
+in	O
+ARDS	B-DISO
+triggered	O
+by	O
+nonpulmonary	O
+events	O
+and	O
+PNEU	O
+.	O
+
+At	O
+a	O
+dose	O
+of	O
+10	O
+(	O
+8	O
+)	O
+cfu	O
+/	O
+clot	B-DISO
+the	O
+animals	B-SPEC
+had	O
+resolving	O
+infection	B-DISO
+,	O
+and	O
+a	O
+dose	O
+of	O
+10	O
+(	O
+9	O
+)	O
+cfu	O
+/	O
+clot	B-DISO
+resulted	O
+in	O
+persistent	B-DISO
+infection	I-DISO
+at	O
+24	O
+h	O
+,	O
+with	O
+minimal	O
+systemic	O
+manifestations	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+case	O
+of	O
+severe	O
+,	O
+pyogranulomatous	O
+and	O
+necrotizing	O
+orchitis	O
+in	O
+a	O
+cat	B-SPEC
+,	O
+which	O
+later	O
+succumbed	O
+to	O
+systemic	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+is	O
+described	O
+.	O
+
+TITLE	O
+:	O
+Variations	O
+in	O
+disparate	O
+regions	O
+of	O
+the	O
+murine	B-PRGE
+coronavirus	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+impact	O
+the	O
+initiation	O
+of	O
+membrane	O
+fusion	O
+.	O
+
+This	O
+virus	B-SPEC
+encodes	O
+spike	O
+(	O
+S	O
+)	O
+glycoproteins	B-CHED
+that	O
+are	O
+extraordinarily	O
+effective	O
+mediators	O
+of	O
+intercellular	O
+membrane	B-PROC
+fusion	I-PROC
+,	O
+unique	O
+in	O
+their	O
+ability	O
+to	O
+initiate	O
+fusion	O
+even	O
+without	O
+prior	O
+interaction	O
+with	O
+the	O
+primary	O
+MHV	B-PRGE
+receptor	I-PRGE
+,	O
+a	O
+murine	B-SPEC
+carcinoembryonic	O
+antigen	B-CHED
+-	O
+related	O
+cell	B-PROC
+adhesion	B-DISO
+molecule	O
+(	O
+CEACAM	O
+).	O
+
+In	O
+considering	O
+the	O
+possible	O
+role	O
+of	O
+this	O
+hyperactive	O
+membrane	B-PROC
+fusion	I-PROC
+activity	I-PROC
+in	O
+neurovirulence	O
+,	O
+we	O
+discovered	O
+that	O
+the	O
+growth	B-PROC
+of	O
+JHM	O
+in	O
+tissue	B-ANAT
+culture	O
+selected	O
+for	O
+variants	O
+that	O
+had	O
+lost	B-CHED
+murine	B-SPEC
+CEACAM	O
+-	O
+independent	O
+fusion	O
+activity	O
+.	O
+
+Among	O
+the	O
+collection	O
+of	O
+variants	O
+,	O
+mutations	O
+were	O
+identified	O
+in	O
+regions	O
+encoding	O
+both	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+(	O
+S1	O
+)	O
+and	O
+fusion	O
+-	O
+inducing	O
+(	O
+S2	O
+)	O
+subunits	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+-	I-PRGE
+neutralizing	I-PRGE
+monoclonal	I-PRGE
+antibody	B-COMP
+expressed	B-PROC
+in	O
+milk	O
+of	O
+transgenic	B-SPEC
+mice	I-SPEC
+provides	O
+full	O
+protection	O
+against	O
+virus	O
+-	O
+induced	O
+encephalitis	B-DISO
+.	O
+
+Transgene	O
+expression	B-PROC
+was	O
+targeted	B-PROC
+to	O
+the	O
+lactating	O
+mammary	B-ANAT
+gland	I-ANAT
+by	O
+using	O
+the	O
+ovine	O
+beta	B-PRGE
+-	I-PRGE
+lactoglobulin	I-PRGE
+promoter	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+causes	O
+acute	O
+encephalitis	B-DISO
+and	O
+chronic	O
+demyelinating	O
+encephalomyelitis	B-DISO
+in	O
+rodents	B-SPEC
+.	O
+
+Previous	O
+results	O
+indicated	O
+that	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+infiltrating	B-DISO
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+were	O
+largely	O
+antigen	B-CHED
+specific	O
+in	O
+both	O
+diseases	O
+.	O
+
+Herein	O
+we	O
+show	O
+that	O
+by	O
+7	O
+days	O
+postinoculation	O
+,	O
+nearly	O
+30	O
+%	O
+of	O
+the	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+in	O
+the	O
+acutely	O
+infected	O
+CNS	B-CHED
+were	O
+MHV	B-SPEC
+specific	O
+by	O
+using	O
+intracellular	B-COMP
+gamma	B-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+staining	O
+assays	O
+.	O
+
+In	O
+mice	B-SPEC
+with	O
+chronic	O
+demyelination	B-DISO
+,	O
+10	O
+to	O
+15	O
+%	O
+of	O
+the	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+secreted	B-PROC
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+in	O
+response	O
+to	O
+MHV	B-SPEC
+-	O
+specific	O
+peptides	B-CHED
+.	O
+
+Thus	O
+,	O
+these	O
+results	O
+show	O
+that	O
+infection	B-DISO
+of	O
+the	O
+CNS	B-CHED
+is	O
+characterized	O
+by	O
+a	O
+large	O
+influx	O
+of	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+specific	O
+for	O
+MHV	B-SPEC
+and	O
+that	O
+these	O
+cells	B-COMP
+remain	O
+functional	O
+,	O
+as	O
+measured	O
+by	O
+cytokine	B-PROC
+secretion	I-PROC
+,	O
+in	O
+mice	B-SPEC
+with	O
+chronic	O
+demyelination	B-DISO
+.	O
+
+Pulmonary	B-ANAT
+consequences	O
+of	O
+inhaled	B-PROC
+amyl	O
+and	O
+butyl	B-CHED
+nitrites	B-CHED
+,	O
+crystalline	O
+methamphetamine	B-CHED
+(	O
+ice	O
+),	O
+and	O
+phencyclidine	B-DISO
+have	O
+been	O
+less	O
+well	O
+documented	O
+.	O
+
+The	O
+immunohistological	O
+examination	O
+detected	O
+IgA	B-PRGE
+,	O
+IgM	B-PRGE
+and	O
+C3	O
+deposits	O
+.	O
+
+Only	O
+after	O
+treatment	O
+of	O
+hepatitis	B-DISO
+B	I-DISO
+infection	I-DISO
+with	O
+recombinant	B-PRGE
+interferon	I-PRGE
+alpha	I-PRGE
+together	O
+with	O
+administration	O
+of	O
+zidovudine	B-CHED
+(	O
+treatment	O
+of	O
+choice	O
+at	O
+that	O
+time	O
+)	O
+the	O
+lesions	O
+quickly	O
+disappeared	O
+without	O
+further	O
+relapses	O
+.	O
+
+hnRNP	B-ANAT
+A1	O
+thus	O
+has	O
+been	O
+proposed	O
+as	O
+a	O
+host	B-COMP
+factor	O
+in	O
+MHV	B-SPEC
+transcription	B-PROC
+.	O
+
+VI	O
+,	O
+FAT	B-PRGE
+,	O
+and	O
+TEM	B-COMP
+were	O
+tested	O
+over	O
+a	O
+course	O
+of	O
+time	O
+before	O
+the	O
+in	O
+situ	O
+hybridization	B-PROC
+was	O
+performed	O
+.	O
+
+Positive	O
+hybridization	B-PROC
+signals	O
+were	O
+detected	O
+in	O
+duodenal	B-ANAT
+,	O
+jejunal	B-ANAT
+,	O
+and	O
+ileal	B-ANAT
+enterocytes	B-ANAT
+from	O
+21	O
+pigs	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+ECMO	O
+is	O
+a	O
+therapeutic	O
+option	O
+for	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+likely	O
+to	O
+increase	O
+survival	O
+.	O
+
+This	O
+is	O
+illustrated	O
+by	O
+the	O
+identification	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+of	O
+an	O
+Australian	O
+isolate	O
+of	O
+CCV	B-DISO
+(	O
+UWSMN	O
+-	O
+1	O
+).	O
+
+Although	O
+uncommon	O
+,	O
+echovirus	B-SPEC
+type	O
+6	O
+infection	B-DISO
+may	O
+produce	O
+a	O
+spectrum	O
+of	O
+pathologic	O
+findings	O
+similar	O
+to	O
+those	O
+seen	O
+with	O
+the	O
+more	O
+commonly	O
+virulent	O
+echovirus	B-SPEC
+type	O
+11	O
+.	O
+
+To	O
+further	O
+map	O
+antigenic	O
+sites	O
+,	O
+neutralization	O
+escape	O
+mutants	O
+of	O
+BCV	B-SPEC
+were	O
+selected	O
+with	O
+a	O
+group	O
+A	O
+MAb	O
+which	O
+has	O
+both	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+virus	B-SPEC
+-	O
+neutralizing	O
+ability	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+bovine	B-SPEC
+coronaviruses	O
+(	O
+RBCV	O
+)	O
+emerged	O
+as	O
+an	O
+infectious	B-DISO
+agent	O
+most	O
+frequently	O
+isolated	O
+from	O
+respiratory	B-ANAT
+tract	I-ANAT
+samples	O
+of	O
+cattle	B-SPEC
+with	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+diseases	I-DISO
+.	O
+
+Infectivity	O
+-	O
+neutralizing	O
+(	O
+IN	O
+)	O
+and	O
+hemagglutinin	O
+-	O
+inhibiting	O
+(	O
+HAI	B-PRGE
+)	O
+antibodies	B-COMP
+induced	O
+by	O
+RBCV	O
+infections	B-DISO
+were	O
+monitored	O
+in	O
+sequential	O
+serum	B-COMP
+samples	O
+collected	O
+from	O
+cattle	B-SPEC
+during	O
+a	O
+naturally	O
+evolving	O
+and	O
+experimentally	O
+monitored	O
+epizootic	O
+of	O
+shipping	B-DISO
+fever	I-DISO
+pneumonia	B-DISO
+(	O
+SFP	O
+).	O
+
+The	O
+RBCV	O
+isolation	O
+-	O
+positive	O
+cattle	B-SPEC
+that	O
+developed	O
+fatal	O
+SFP	O
+had	O
+minimal	O
+serum	B-COMP
+IN	O
+and	O
+HAI	O
+antibodies	B-COMP
+during	O
+the	O
+course	O
+of	O
+disease	O
+development	B-PROC
+.	O
+
+Cattle	B-SPEC
+that	O
+remained	O
+negative	O
+in	O
+RBCV	O
+isolation	O
+tests	O
+entered	O
+this	O
+epizootic	O
+with	O
+high	O
+levels	O
+of	O
+serum	B-PRGE
+IN	I-PRGE
+and	O
+HAI	B-PRGE
+antibodies	I-PRGE
+,	O
+which	O
+dramatically	O
+increased	O
+during	O
+the	O
+next	O
+two	O
+weeks	O
+.	O
+
+MHV	B-SPEC
+replication	O
+and	O
+transcription	B-PROC
+take	O
+place	O
+via	O
+the	O
+synthesis	B-PROC
+of	O
+negative	O
+-	O
+strand	O
+RNA	O
+intermediates	O
+from	O
+a	O
+positive	O
+-	O
+strand	O
+genomic	O
+template	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+two	O
+-	O
+hit	O
+theory	O
+has	O
+emerged	O
+as	O
+a	O
+mechanism	O
+to	O
+explain	O
+the	O
+development	B-PROC
+of	O
+organ	B-DISO
+failure	I-DISO
+after	O
+traumatic	O
+injury	O
+.	O
+
+Mice	B-SPEC
+undergoing	O
+H	O
+/	O
+R	O
+alone	O
+were	O
+labeled	O
+as	O
+the	O
+H	O
+/	O
+R	O
+group	O
+.	O
+
+Respiratory	B-PROC
+function	I-PROC
+was	O
+determined	O
+by	O
+using	O
+whole	O
+-	O
+body	B-ANAT
+plethysmography	O
+and	O
+lung	B-ANAT
+gas	B-ENZY
+diffusion	O
+.	O
+
+Comparison	O
+of	O
+the	O
+three	O
+groups	O
+at	O
+4	O
+hours	O
+did	O
+not	O
+demonstrate	O
+any	O
+differences	O
+in	O
+serum	B-COMP
+concentrations	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+.	O
+
+Exploratory	O
+laparotomy	O
+resulted	O
+in	O
+a	O
+significant	O
+change	O
+in	O
+pulmonary	B-PROC
+function	I-PROC
+.	O
+
+Colloids	O
+and	O
+crystalloids	O
+do	O
+not	O
+appear	O
+to	O
+differ	O
+notably	O
+in	O
+their	O
+effects	O
+on	O
+preload	O
+recruitable	O
+stroke	B-DISO
+volume	O
+or	O
+oxygen	B-CHED
+delivery	O
+.	O
+
+However	O
+,	O
+the	O
+applicability	O
+of	O
+this	O
+mechanism	O
+may	O
+be	O
+limited	O
+,	O
+due	O
+to	O
+the	O
+operation	O
+of	O
+compensatory	O
+mechanisms	O
+such	O
+as	O
+increased	O
+lymphatic	B-ANAT
+drainage	B-ANAT
+.	O
+
+Colloids	O
+can	O
+be	O
+considered	O
+in	O
+patients	O
+with	O
+severe	O
+or	O
+acute	O
+shock	O
+or	O
+hypovolaemia	O
+resulting	O
+from	O
+sudden	O
+plasma	B-ANAT
+loss	O
+.	O
+
+The	O
+development	B-PROC
+and	O
+characterisation	O
+of	O
+an	O
+indirect	O
+ELISA	O
+for	O
+the	O
+detection	O
+of	O
+antibodies	B-COMP
+(	O
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+)	O
+to	O
+CCV	B-DISO
+was	O
+undertaken	O
+.	O
+
+Of	O
+those	O
+dogs	B-SPEC
+that	O
+were	O
+presented	O
+with	O
+clinical	O
+signs	O
+of	O
+gastroenteritis	B-DISO
+such	O
+as	O
+diarrhoea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+(	O
+n	O
+=	O
+29	O
+),	O
+85	O
+%	O
+were	O
+positive	O
+in	O
+the	O
+IgM	B-PRGE
+ELISA	O
+and	O
+85	O
+.	O
+7	O
+%	O
+in	O
+the	O
+IgG	B-PRGE
+ELISA	O
+for	O
+antibodies	B-COMP
+to	O
+CCV	B-DISO
+.	O
+
+The	O
+prevalence	O
+of	O
+antibodies	B-COMP
+varies	O
+greatly	O
+among	O
+different	O
+populations	O
+,	O
+with	O
+an	O
+average	O
+of	O
+40	O
+.	O
+8	O
+%	O
+positive	O
+in	O
+kennelled	O
+populations	O
+and	O
+15	O
+.	O
+8	O
+%	O
+in	O
+the	O
+open	O
+population	O
+.	O
+
+TITLE	O
+:	O
+Plant	B-SPEC
+-	O
+based	O
+vaccines	O
+:	O
+unique	O
+advantages	O
+.	O
+
+TITLE	O
+:	O
+Lymphocytic	B-DISO
+hypophysitis	I-DISO
+in	O
+a	O
+man	B-CHED
+presenting	O
+with	O
+hypercalcemia	B-DISO
+.	O
+
+He	O
+was	O
+found	O
+to	O
+have	O
+a	O
+subnormal	O
+cortisol	B-CHED
+level	O
+of	O
+2	O
+.	O
+3	O
+microg	O
+/	O
+dL	O
+at	O
+baseline	O
+,	O
+which	O
+increased	O
+to	O
+only	O
+5	O
+.	O
+6	O
+microg	O
+/	O
+dL	O
+60	O
+minutes	O
+after	O
+a	O
+250	O
+-	O
+microg	O
+corticotropin	B-PRGE
+intravenous	O
+stimulation	O
+test	O
+.	O
+
+TITLE	O
+:	O
+MHV	B-SPEC
+infection	B-DISO
+of	O
+the	O
+CNS	B-CHED
+:	O
+mechanisms	O
+of	O
+immune	O
+-	O
+mediated	O
+control	O
+.	O
+
+The	O
+E	B-PRGE
+protein	I-PRGE
+is	O
+an	O
+integral	O
+membrane	B-COMP
+protein	B-CHED
+.	O
+
+Retention	B-PROC
+of	O
+the	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+envelope	B-COMP
+protein	B-CHED
+in	O
+the	O
+pre	O
+-	O
+Golgi	B-COMP
+compartments	B-ANAT
+and	O
+physical	B-FUNC
+interaction	I-FUNC
+between	O
+the	O
+envelope	B-COMP
+and	O
+membrane	B-COMP
+proteins	B-CHED
+.	O
+
+Immunofluorescent	O
+staining	O
+of	O
+cells	B-COMP
+coexpressing	O
+M	O
+and	O
+E	O
+supports	O
+that	O
+E	O
+interacts	O
+with	O
+M	O
+and	O
+relocates	O
+M	O
+to	O
+the	O
+same	O
+subcellular	O
+compartments	B-ANAT
+that	O
+E	O
+resides	O
+in	O
+.	O
+
+The	O
+third	O
+domain	O
+of	O
+E	O
+that	O
+plays	O
+a	O
+crucial	O
+role	O
+in	O
+virus	B-SPEC
+budding	B-PATH
+is	O
+a	O
+putative	O
+transmembrane	B-COMP
+domain	O
+present	O
+at	O
+the	O
+N	O
+-	O
+terminal	O
+region	O
+,	O
+because	O
+deletion	O
+of	O
+the	O
+domain	O
+resulted	O
+in	O
+a	O
+free	O
+distribution	O
+of	O
+the	O
+mutant	B-DISO
+protein	B-CHED
+and	O
+in	O
+dysfunctional	O
+viral	B-PROC
+assembly	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+the	O
+immunogenicity	O
+of	O
+chimeric	O
+987P	O
+fimbriae	B-COMP
+on	O
+a	O
+Salmonella	B-DISO
+vaccine	O
+strain	O
+was	O
+improved	O
+by	O
+optimizing	O
+fimbrial	O
+expression	B-PROC
+.	O
+
+Exogeous	O
+NO	O
+may	O
+lead	O
+to	O
+down	B-PROC
+regulation	I-PROC
+of	O
+endogenous	O
+NO	O
+production	O
+,	O
+and	O
+further	O
+lead	O
+to	O
+rapid	O
+hydrolization	O
+of	O
+cyclic	O
+guanosine	B-CHED
+3	O
+',	O
+5	O
+'	O
+monophosphate	O
+(	O
+cGMP	B-CHED
+),	O
+the	O
+smooth	B-ANAT
+muscle	I-ANAT
+relaxant	O
+,	O
+by	O
+the	O
+enzyme	O
+phosphodiesterase	B-PROC
+.	O
+
+In	O
+vivo	O
+genotoxicity	B-DISO
+studies	O
+--	O
+micronucleus	B-COMP
+,	O
+chromosome	B-DISO
+aberration	I-DISO
+,	O
+dominant	O
+lethal	O
+and	O
+Drosophila	B-SPEC
+tests	O
+--	O
+generally	O
+have	O
+shown	O
+no	O
+activity	O
+but	O
+one	O
+mouse	B-SPEC
+intraperitoneal	O
+study	O
+showed	O
+bone	B-ANAT
+marrow	I-ANAT
+cell	I-ANAT
+chromosome	B-DISO
+aberrations	I-DISO
+.	O
+
+Although	O
+suggestions	O
+for	O
+appropriate	O
+management	O
+can	O
+be	O
+made	O
+based	O
+on	O
+available	O
+evidence	O
+,	O
+the	O
+supporting	O
+literature	O
+is	O
+spotty	B-DISO
+.	O
+
+She	O
+had	O
+had	O
+RA	O
+for	O
+12	O
+years	O
+,	O
+which	O
+had	O
+been	O
+controlled	O
+well	O
+with	O
+prednisolone	B-CHED
+(	O
+3	O
+mg	O
+/	O
+day	O
+)	O
+at	O
+the	O
+orthopedic	O
+clinic	O
+.	O
+
+TITLE	O
+:	O
+Health	O
+and	O
+exposures	O
+of	O
+United	O
+Kingdom	B-SPEC
+Gulf	O
+war	O
+veterans	O
+.	O
+
+Seven	O
+years	O
+after	O
+the	O
+war	O
+subjects	O
+completed	O
+a	O
+questionnaire	O
+about	O
+their	O
+health	O
+in	O
+the	O
+past	O
+month	O
+,	O
+including	O
+95	O
+symptom	B-DISO
+questions	O
+and	O
+two	O
+manikins	O
+on	O
+which	O
+to	O
+shade	O
+areas	O
+of	O
+pain	O
+or	O
+numbness	B-DISO
+and	O
+tingling	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+introduction	O
+of	O
+highly	O
+active	O
+antiretroviral	O
+therapy	O
+with	O
+protease	B-PROC
+inhibitors	I-PROC
+in	O
+1996	O
+has	O
+changed	O
+the	O
+morbidity	O
+and	O
+mortality	O
+of	O
+acquired	B-DISO
+immune	I-DISO
+deficiency	I-DISO
+syndrome	I-DISO
+patients	O
+.	O
+
+Therefore	O
+,	O
+the	O
+aetiologies	O
+and	O
+prognostic	O
+factors	O
+of	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)-	O
+infected	O
+patients	O
+with	O
+life	O
+-	O
+threatening	O
+respiratory	B-DISO
+failure	I-DISO
+requiring	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admission	O
+need	O
+to	O
+be	O
+reassessed	O
+.	O
+
+TITLE	O
+:	O
+Treatment	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+final	O
+report	O
+on	O
+a	O
+phase	O
+I	O
+study	O
+.	O
+
+Twenty	O
+patients	O
+suffering	B-DISO
+from	O
+ARDS	B-DISO
+secondary	O
+to	O
+trauma	O
+and	O
+/	O
+or	O
+sepsis	B-DISO
+failed	O
+to	O
+respond	O
+to	O
+treatment	O
+with	O
+mechanical	O
+ventilation	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+.	O
+
+No	O
+bleeding	B-DISO
+occurred	O
+and	O
+clotting	B-PROC
+parameters	O
+remained	O
+normal	O
+.	O
+
+Here	O
+we	O
+demonstrate	O
+with	O
+haemagglutination	B-PROC
+and	O
+haemagglutination	B-PROC
+-	O
+inhibition	B-PROC
+assays	O
+that	O
+TGEV	B-SPEC
+and	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+K99	O
+differ	O
+in	O
+their	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+activities	O
+with	O
+respect	O
+to	O
+the	O
+type	O
+and	O
+amount	O
+of	O
+sialic	B-CHED
+acid	I-CHED
+residues	O
+required	O
+on	O
+the	O
+erythrocytes	B-ANAT
+surface	O
+as	O
+well	O
+as	O
+with	O
+respect	O
+to	O
+the	O
+type	O
+of	O
+sialoglycoconjugate	O
+preferentially	O
+recognized	O
+.	O
+
+All	O
+ARDS	B-DISO
+survivors	O
+with	O
+cognitive	B-DISO
+deficits	I-DISO
+were	O
+disabled	O
+,	O
+whereas	O
+only	O
+22	O
+.	O
+9	O
+%	O
+(	O
+n	O
+=	O
+8	O
+)	O
+of	O
+the	O
+cognitively	O
+not	O
+impaired	B-DISO
+patients	O
+gave	O
+evidence	O
+of	O
+disability	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+proportions	O
+of	O
+cats	O
+in	O
+which	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+was	O
+diagnosed	O
+on	O
+an	O
+annual	O
+,	O
+monthly	O
+,	O
+and	O
+regional	O
+basis	O
+and	O
+identify	O
+unique	O
+characteristics	O
+of	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+The	O
+proportion	O
+of	O
+new	O
+accessions	O
+for	O
+which	O
+a	O
+diagnosis	O
+of	O
+FIP	B-DISO
+was	O
+recorded	O
+did	O
+not	O
+vary	O
+significantly	O
+among	O
+years	O
+,	O
+months	O
+,	O
+or	O
+regions	O
+of	O
+the	O
+country	O
+.	O
+
+Results	O
+indicated	O
+that	O
+FIP	B-DISO
+continues	O
+to	O
+be	O
+a	O
+clinically	O
+important	O
+disease	O
+in	O
+North	O
+America	O
+and	O
+that	O
+sexually	O
+intact	O
+male	O
+cats	B-SPEC
+may	O
+be	O
+at	O
+increased	O
+risk	O
+,	O
+and	O
+spayed	O
+females	O
+at	O
+reduced	O
+risk	O
+,	O
+for	O
+FIP	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Approximately	O
+1	O
+of	O
+every	O
+200	O
+new	O
+feline	B-SPEC
+and	O
+1	O
+of	O
+every	O
+300	O
+total	O
+feline	B-SPEC
+accessions	O
+at	O
+VMTH	O
+in	O
+North	O
+America	O
+and	O
+approximately	O
+1	O
+of	O
+every	O
+100	O
+accessions	O
+at	O
+the	O
+diagnostic	O
+laboratories	O
+represented	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+film	O
+showed	O
+bilateral	O
+alveolar	B-ANAT
+infiltrates	B-DISO
+.	O
+
+He	O
+fully	O
+recovered	O
+by	O
+intensive	O
+treatment	O
+with	O
+antibiotics	B-CHED
+,	O
+mechanical	O
+ventilation	O
+and	O
+endotoxin	O
+eliminating	O
+therapy	O
+.	O
+
+Anasarcous	O
+skin	B-ANAT
+lesions	O
+exhibited	O
+a	O
+separated	O
+epidermis	B-ANAT
+,	O
+expanded	O
+scale	O
+-	O
+sacs	B-DISO
+,	O
+and	O
+an	O
+edematous	B-DISO
+dermis	B-ANAT
+accompanied	O
+by	O
+hemorrhage	B-DISO
+and	O
+necrosis	B-PROC
+.	O
+
+These	O
+changes	O
+appeared	O
+to	O
+be	O
+induced	O
+by	O
+bacterial	O
+toxins	B-CHED
+because	O
+bacterial	O
+cells	B-COMP
+did	O
+not	O
+directly	O
+invade	O
+these	O
+affected	O
+tissues	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleocapsid	B-ANAT
+(	O
+N	O
+)	O
+gene	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCV	B-SPEC
+)	O
+was	O
+amplified	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+,	O
+cloned	O
+,	O
+and	O
+expressed	B-PROC
+in	O
+the	O
+baculovirus	B-SPEC
+expression	B-PROC
+system	O
+.	O
+
+A	O
+recombinant	O
+baculovirus	B-SPEC
+containing	O
+the	O
+TCV	B-PRGE
+N	I-PRGE
+gene	I-PRGE
+(	O
+rBTCV	O
+/	O
+N	O
+)	O
+was	O
+identified	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+expression	B-PROC
+of	O
+TCV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+as	O
+determined	O
+by	O
+western	O
+immunoblot	O
+analysis	O
+.	O
+
+Two	O
+TCV	B-SPEC
+-	O
+specific	O
+proteins	B-CHED
+,	O
+52	O
+and	O
+43	O
+kDa	O
+,	O
+were	O
+expressed	B-PROC
+by	O
+rBTCV	O
+/	O
+N	O
+;	O
+one	O
+of	O
+these	O
+proteins	B-CHED
+,	O
+p52	B-PRGE
+,	O
+was	O
+comparable	O
+in	O
+size	O
+to	O
+native	B-PRGE
+TCV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+However	O
+,	O
+experimental	O
+inoculation	O
+of	O
+1	O
+-	O
+day	O
+-	O
+old	O
+SPF	O
+chicks	O
+in	O
+two	O
+trials	O
+with	O
+the	O
+same	O
+virus	B-SPEC
+resulted	O
+in	O
+no	O
+clinical	O
+signs	O
+or	O
+macroscopic	O
+or	O
+microscopic	O
+lesions	O
+.	O
+
+No	O
+coronaviruses	O
+were	O
+detected	O
+from	O
+intestinal	O
+contents	O
+,	O
+and	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+body	B-ANAT
+weights	O
+of	O
+inoculated	O
+and	O
+noninoculated	O
+control	O
+chicks	O
+.	O
+
+A	O
+421	O
+-	O
+bp	O
+sequence	O
+in	O
+the	O
+hypervariable	O
+region	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+was	O
+examined	O
+,	O
+and	O
+phylogenetic	O
+analysis	O
+on	O
+that	O
+region	O
+indicated	O
+that	O
+these	O
+viruses	B-SPEC
+are	O
+closely	O
+related	O
+but	O
+fall	O
+into	O
+unique	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+epidemiology	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolates	O
+from	O
+China	O
+and	O
+Southeast	O
+Asia	O
+.	O
+
+Some	O
+isolates	O
+formed	O
+a	O
+distinct	O
+Asian	O
+phylogenetic	O
+group	O
+,	O
+suggesting	O
+that	O
+IBV	B-SPEC
+has	O
+existed	O
+for	O
+some	O
+time	O
+in	O
+Asia	O
+.	O
+
+TITLE	O
+:	O
+The	O
+exacerbating	O
+effect	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-DISO
+infection	I-DISO
+on	O
+the	O
+infectious	B-DISO
+bursal	I-DISO
+disease	I-DISO
+virus	I-SPEC
+-	O
+induced	O
+suppression	B-DISO
+of	O
+opsonization	B-PROC
+by	O
+Escherichia	B-PRGE
+coil	I-PRGE
+antibody	B-COMP
+in	I-PRGE
+chickens	B-SPEC
+.	O
+
+Those	O
+macrophages	B-ANAT
+also	O
+had	O
+adequate	O
+bactericidal	B-PROC
+activity	I-PROC
+,	O
+indicating	O
+that	O
+IBV	B-SPEC
+and	O
+IBDV	B-SPEC
+infections	B-DISO
+had	O
+not	O
+affected	O
+their	O
+phagocytic	O
+activity	O
+or	O
+bactericidal	O
+function	O
+.	O
+
+Factors	O
+involved	O
+in	O
+the	O
+propagation	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+after	O
+perinatal	O
+aspiration	B-DISO
+of	I-DISO
+meconium	I-DISO
+include	O
+obstruction	B-DISO
+of	O
+the	O
+airways	O
+,	O
+ventilation	O
+/	O
+perfusion	O
+mismatch	O
+,	O
+increase	O
+of	O
+the	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+and	O
+a	O
+rapidly	O
+developing	O
+parenchymal	O
+and	O
+alveolar	B-ANAT
+inflammatory	B-DISO
+reaction	I-DISO
+with	O
+associated	O
+surfactant	B-CHED
+dysfunction	O
+.	O
+
+Although	O
+the	O
+early	O
+pulmonary	B-ANAT
+inflammatory	B-DISO
+response	I-DISO
+is	O
+believed	O
+to	O
+play	O
+a	O
+central	O
+pathogenetic	O
+role	O
+in	O
+the	O
+meconium	B-ANAT
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+damage	O
+,	O
+its	O
+initiating	O
+mechanisms	O
+are	O
+still	O
+poorly	O
+defined	O
+.	O
+
+However	O
+,	O
+increasing	O
+evidence	O
+indicates	O
+a	O
+direct	O
+toxic	O
+effect	O
+of	O
+meconium	B-ANAT
+.	O
+
+Several	O
+host	B-COMP
+cell	I-COMP
+proteins	B-CHED
+have	O
+previously	O
+been	O
+shown	O
+to	O
+interact	O
+with	O
+this	O
+regulatory	O
+region	O
+.	O
+
+Anorexia	B-DISO
+occurs	O
+during	O
+such	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Anorexia	B-DISO
+in	O
+response	O
+to	O
+bacterial	O
+lipopolysaccharide	B-CHED
+administration	O
+,	O
+which	O
+is	O
+also	O
+linked	O
+to	O
+plasma	B-PRGE
+TNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+is	O
+however	O
+,	O
+caused	O
+only	O
+via	O
+a	O
+decrease	O
+in	O
+meal	O
+number	O
+.	O
+
+The	O
+differences	O
+in	O
+the	O
+decrease	O
+in	O
+the	O
+feeding	O
+pattern	O
+between	O
+the	O
+SDA	B-DISO
+viral	O
+and	O
+a	O
+bacterial	B-DISO
+infection	I-DISO
+suggest	O
+that	O
+factors	O
+other	O
+than	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+alone	O
+play	O
+a	O
+significant	O
+role	O
+in	O
+the	O
+mechanism	O
+of	O
+anorexia	B-DISO
+during	O
+a	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Falciparum	B-DISO
+malaria	I-DISO
+remains	O
+a	O
+major	O
+killer	O
+in	O
+developing	O
+countries	O
+,	O
+particularly	O
+for	O
+African	O
+children	O
+.	O
+
+In	O
+nonimmune	O
+adults	O
+,	O
+besides	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+pictures	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+with	O
+shock	O
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+are	O
+common	O
+.	O
+
+This	O
+study	O
+shows	O
+that	O
+,	O
+in	O
+contrast	O
+to	O
+NO	O
+inhalation	B-PROC
+,	O
+infusion	O
+of	O
+ANP	B-PRGE
+neither	O
+improves	O
+oxygenation	B-PROC
+nor	O
+attenuates	O
+pulmonary	B-DISO
+hypertension	I-DISO
+or	O
+pulmonary	B-DISO
+edema	I-DISO
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+The	O
+shaken	O
+-	O
+baby	O
+syndrome	B-DISO
+causes	O
+severe	O
+encephalopathy	B-DISO
+and	O
+vision	B-PROC
+problems	O
+,	O
+blindness	B-DISO
+in	O
+many	O
+cases	O
+,	O
+after	O
+showing	O
+voluminous	O
+subdural	B-ANAT
+and	O
+/	O
+or	O
+epidural	B-ANAT
+hematomas	B-DISO
+which	O
+lead	O
+to	O
+a	O
+severe	O
+neuronal	O
+lost	B-CHED
+and	O
+gliosis	B-DISO
+.	O
+
+Shaken	O
+-	O
+baby	O
+syndrome	B-DISO
+is	O
+not	O
+always	O
+associated	O
+with	O
+skull	B-ANAT
+fracture	O
+nor	O
+is	O
+necessarily	O
+related	O
+with	O
+battered	O
+-	O
+child	B-DISO
+syndrome	I-DISO
+.	O
+
+Immunodeficiency	B-DISO
+was	O
+present	O
+in	O
+60	O
+patients	O
+,	O
+including	O
+38	O
+with	O
+AIDS	O
+.	O
+
+Histologically	O
+,	O
+the	O
+lesions	O
+consisted	O
+of	O
+angioblastic	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+and	O
+immature	O
+capillary	B-ANAT
+vascular	B-ANAT
+structures	O
+coursing	O
+through	O
+the	O
+edematous	B-DISO
+myxomatous	O
+dermis	B-ANAT
+and	O
+subcutis	B-ANAT
+.	O
+
+Proliferating	O
+capillaries	B-ANAT
+often	O
+were	O
+surrounded	O
+by	O
+large	O
+and	O
+foamy	O
+macrophages	B-ANAT
+that	O
+stained	O
+positively	O
+for	O
+PRRSV	B-SPEC
+by	O
+immunohistochemistry	O
+.	O
+
+A	O
+high	O
+percentage	O
+of	O
+both	O
+maternal	O
+antibody	B-COMP
+-	O
+positive	O
+(	O
+Mab	O
++)	O
+and	O
+maternal	O
+antibody	B-COMP
+-	O
+negative	O
+(	O
+Mab	O
+-)	O
+chicks	O
+failed	O
+to	O
+produce	O
+IBV	B-SPEC
+antibody	B-COMP
+when	O
+vaccinated	O
+at	O
+1	O
+day	O
+of	O
+age	O
+by	O
+the	O
+intraocular	B-ANAT
+route	O
+.	O
+
+In	O
+addition	O
+,	O
+Mab	O
++	O
+chickens	B-SPEC
+had	O
+a	O
+weaker	O
+virus	B-SPEC
+-	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+to	O
+a	O
+second	O
+IBV	B-SPEC
+vaccination	O
+compared	O
+to	O
+Mab	O
+-	O
+birds	B-SPEC
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Arterial	B-ANAT
+blood	I-ANAT
+gas	O
+tensions	B-DISO
+,	O
+hemodynamic	B-PROC
+variables	O
+,	O
+and	O
+the	O
+oxygenation	B-PROC
+index	O
+were	O
+recorded	O
+after	O
+each	O
+dose	O
+of	O
+5	O
+mL	O
+/	O
+kg	O
+.	O
+
+Rotational	O
+positioning	O
+produced	O
+significantly	O
+more	O
+uniform	O
+perflubron	B-CHED
+distribution	O
+during	O
+both	O
+CMV	B-SPEC
+and	O
+HFOV	O
+.	O
+
+There	O
+was	O
+no	O
+relationship	O
+between	O
+oxygenation	B-PROC
+improvements	O
+and	O
+nondependent	O
+perflubron	B-CHED
+distribution	O
+.	O
+
+A	O
+review	O
+of	O
+the	O
+literature	O
+shows	O
+that	O
+pulmonary	B-DISO
+complications	I-DISO
+of	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+are	O
+rare	O
+but	O
+occur	O
+more	O
+frequently	O
+than	O
+generally	O
+acknowledged	O
+.	O
+
+Moreover	O
+,	O
+prone	O
+position	O
+causes	O
+,	O
+both	O
+in	O
+healthy	O
+subject	O
+and	O
+in	O
+obese	B-DISO
+patients	O
+,	O
+an	O
+improvement	O
+in	O
+oxygenation	B-PROC
+and	O
+in	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+without	O
+affecting	O
+respiratory	B-ANAT
+system	I-ANAT
+,	I-ANAT
+lung	I-ANAT
+and	O
+chest	B-ANAT
+wall	I-ANAT
+compliance	O
+.	O
+
+We	O
+have	O
+recently	O
+finished	O
+a	O
+randomized	O
+-	O
+controlled	O
+trial	O
+in	O
+order	B-SPEC
+to	O
+investigate	O
+the	O
+clinical	O
+impact	O
+of	O
+this	O
+procedure	O
+.	O
+
+A	O
+specific	O
+non	O
+-	O
+sense	B-PROC
+mutation	O
+was	O
+identified	O
+for	O
+the	O
+nucleotide	B-CHED
+at	O
+position	O
+88	O
+of	O
+the	O
+putative	O
+4	O
+.	O
+9	O
+kDa	O
+protein	B-CHED
+gene	O
+of	O
+RBCoV	O
+isolates	O
+resulting	O
+in	O
+29	O
+rather	O
+that	O
+43	O
+aa	O
+residues	O
+.	O
+
+ABSTRACT	O
+:	O
+Iron	O
+is	O
+an	O
+essential	O
+requirement	O
+for	O
+the	O
+growth	O
+,	O
+development	B-PROC
+,	O
+and	O
+long	O
+term	O
+survival	O
+of	O
+most	O
+aerobic	O
+organisms	O
+.	O
+
+Therefore	O
+,	O
+the	O
+carbon	B-CHED
+dioxide	I-CHED
+dependence	B-DISO
+of	O
+respiratory	B-PROC
+mechanics	I-PROC
+in	O
+healthy	O
+anesthetized	O
+,	O
+paralyzed	O
+subjects	O
+was	O
+investigated	O
+.	O
+
+Interrupter	O
+resistance	B-PROC
+(	O
+Rint	O
+),	O
+additional	O
+tissue	B-ANAT
+viscoelastic	O
+resistance	B-PROC
+(	O
+deltaR	O
+),	O
+and	O
+quasi	O
+-	O
+static	O
+elastance	O
+(	O
+Est	O
+)	O
+of	O
+lung	B-ANAT
+(	O
+L	O
+)	O
+and	O
+chest	B-ANAT
+wall	I-ANAT
+were	O
+assessed	O
+by	O
+means	O
+of	O
+the	O
+rapid	O
+end	O
+-	O
+inspiratory	B-PROC
+occlusion	B-DISO
+method	O
+in	O
+two	O
+groups	O
+of	O
+seven	O
+healthy	O
+paralyzed	O
+subjects	O
+anesthetized	O
+with	O
+diazepam	B-CHED
+or	O
+isoflurane	B-CHED
+.	O
+
+The	O
+carbon	B-CHED
+dioxide	I-CHED
+bronchodilating	O
+effects	O
+are	O
+probably	O
+direct	O
+for	O
+peripheral	O
+structures	O
+and	O
+are	O
+paralleled	O
+by	O
+a	O
+tendency	O
+of	O
+lung	B-ANAT
+tissue	I-ANAT
+resistance	B-PROC
+to	O
+decrease	O
+.	O
+
+Serial	O
+passage	O
+of	O
+the	O
+recombinant	O
+virus	B-SPEC
+vector	O
+led	O
+to	O
+its	O
+gradual	O
+replacement	O
+by	O
+viral	O
+mutants	O
+carrying	O
+deletions	O
+in	O
+the	O
+GFP	B-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+reduction	O
+in	O
+viral	O
+fitness	O
+associated	O
+with	O
+the	O
+insertion	O
+of	O
+the	O
+expression	B-PROC
+cassette	O
+into	O
+the	O
+EAV	B-SPEC
+genome	O
+apparently	O
+caused	O
+genetic	O
+instability	O
+of	O
+the	O
+recombinant	O
+virus	B-SPEC
+.	O
+
+Mortality	O
+remains	O
+high	O
+among	O
+children	O
+with	O
+ARDS	B-DISO
+,	O
+particularly	O
+when	O
+serious	O
+underlying	O
+conditions	O
+co	O
+-	O
+exist	O
+,	O
+sepsis	B-DISO
+occurs	O
+,	O
+and	O
+when	O
+there	O
+is	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Both	O
+demyelination	B-DISO
+and	O
+axonal	O
+damage	O
+were	O
+apparent	O
+by	O
+7	O
+days	O
+posttransfer	O
+.	O
+
+Remarkably	O
+,	O
+there	O
+appeared	O
+to	O
+be	O
+a	O
+minimal	O
+,	O
+if	O
+any	O
+,	O
+interval	O
+of	O
+time	O
+between	O
+the	O
+appearance	O
+of	O
+demyelination	B-DISO
+and	O
+that	O
+of	O
+axonal	O
+injury	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+full	O
+-	O
+term	O
+neonates	O
+].	O
+
+Four	O
+patients	O
+died	B-PROC
+(	O
+1x	O
+syndrome	B-DISO
+of	O
+cerebral	B-DISO
+death	B-PROC
+associated	O
+with	O
+severe	O
+hypoxic	B-DISO
+-	I-DISO
+ischaemic	I-DISO
+encephalopathy	I-DISO
+,	O
+2x	O
+severe	O
+irreversible	O
+haemorrhage	B-DISO
+,	O
+into	O
+the	O
+abdominal	B-ANAT
+and	O
+thoracic	B-ANAT
+cavity	B-DISO
+,	O
+1x	O
+periventricular	O
+intraventricular	B-DISO
+haemorrhage	I-DISO
+grade	O
+III	O
+.).	O
+
+RESULTS	O
+:	O
+Venoarterial	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+was	O
+successful	O
+in	O
+75	O
+%	O
+patients	O
+who	O
+survived	O
+.	O
+
+On	O
+comparison	O
+of	O
+the	O
+surviving	O
+group	O
+(	O
+S	O
+)	O
+and	O
+the	O
+non	O
+-	O
+surviving	O
+group	O
+(	O
+NS	O
+)	O
+there	O
+was	O
+a	O
+significant	O
+difference	O
+in	O
+the	O
+necessity	O
+of	O
+continuous	O
+inotropic	O
+adrenaline	B-CHED
+support	O
+during	O
+EMCO	O
+.	O
+
+To	O
+determine	O
+its	O
+extent	O
+,	O
+the	O
+gene	O
+encoding	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+TCV	B-SPEC
+was	O
+amplified	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+from	O
+RNA	O
+purified	O
+from	O
+intestines	B-ANAT
+of	O
+embryos	B-ANAT
+of	O
+turkeys	B-SPEC
+infected	O
+with	O
+various	O
+TCV	B-SPEC
+isolates	O
+and	O
+from	O
+allantoic	B-ANAT
+fluid	I-ANAT
+of	O
+chicken	B-SPEC
+embryos	B-ANAT
+infected	O
+with	O
+IBV	B-SPEC
+M41	O
+strain	O
+,	O
+the	O
+obtained	O
+N	O
+genes	O
+were	O
+cloned	O
+,	O
+sequenced	O
+and	O
+compared	O
+with	O
+known	O
+sequences	O
+of	O
+N	O
+genes	O
+of	O
+five	O
+IBV	B-SPEC
+strains	O
+.	O
+
+Seventy	O
+-	O
+three	O
+per	O
+cent	O
+of	O
+the	O
+virus	B-DISO
+shedding	I-DISO
+episodes	O
+lasted	O
+up	O
+to	O
+three	O
+months	O
+and	O
+95	O
+per	O
+cent	O
+up	O
+to	O
+nine	O
+months	O
+.	O
+
+The	O
+clinical	O
+course	O
+was	O
+rapidly	O
+fatal	O
+despite	O
+corticosteroid	B-CHED
+therapy	O
+.	O
+
+TITLE	O
+:	O
+Dicaffeoyl	O
+-	O
+or	O
+digalloyl	O
+pyrrolidine	B-CHED
+and	O
+furan	B-CHED
+derivatives	O
+as	O
+HIV	B-PROC
+integrase	I-PROC
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+caspase	B-PROC
+-	I-PROC
+dependent	I-PROC
+apoptosis	B-PATH
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+by	O
+the	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+Replication	O
+of	O
+IBV	B-SPEC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+causes	O
+extensive	O
+cytopathic	B-DISO
+effects	I-DISO
+(	O
+CPE	O
+),	O
+leading	O
+to	O
+destruction	O
+of	O
+the	O
+entire	O
+monolayer	O
+and	O
+the	O
+death	B-PROC
+of	O
+infected	O
+cells	B-COMP
+.	O
+
+The	O
+results	O
+show	O
+that	O
+both	O
+necrosis	B-PROC
+and	O
+apoptosis	B-PATH
+may	O
+contribute	O
+to	O
+the	O
+death	B-PROC
+of	O
+infected	O
+cells	B-COMP
+in	O
+lytic	B-DISO
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+A	O
+region	O
+of	O
+the	O
+mRNA	B-CHED
+encoding	O
+GFP	O
+was	O
+amplified	O
+by	O
+PCR	O
+and	O
+shown	O
+to	O
+have	O
+the	O
+unique	O
+mRNA	B-CHED
+leader	O
+-	O
+body	B-ANAT
+junction	O
+indicative	O
+of	O
+coronavirus	B-SPEC
+-	O
+mediated	O
+transcription	B-PROC
+.	O
+
+TITLE	O
+:	O
+Mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+replicase	I-PRGE
+protein	B-CHED
+complexes	I-PRGE
+are	O
+translocated	O
+to	O
+sites	O
+of	O
+M	B-PRGE
+protein	I-PRGE
+accumulation	O
+in	O
+the	O
+ERGIC	O
+at	O
+late	O
+times	O
+of	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Outbreaks	O
+of	O
+an	O
+avian	B-DISO
+disease	I-DISO
+in	O
+infectious	B-DISO
+bronchitis	B-DISO
+-	O
+vaccinated	O
+chickens	B-SPEC
+in	O
+China	O
+have	O
+led	O
+to	O
+the	O
+characterization	O
+of	O
+coronaviral	O
+isolates	O
+Q1	O
+,	O
+J2	O
+,	O
+and	O
+T3	O
+,	O
+which	O
+were	O
+isolated	O
+from	O
+proventricular	O
+tissues	B-ANAT
+of	O
+the	O
+affected	O
+young	O
+layer	B-ANAT
+flocks	O
+.	O
+
+Seven	O
+novel	O
+RFLP	O
+patterns	O
+were	O
+detected	O
+among	O
+the	O
+other	O
+nine	O
+foreign	O
+IBV	B-SPEC
+isolates	O
+.	O
+
+With	O
+the	O
+RFLP	O
+patterns	O
+and	O
+the	O
+deduced	O
+S1	O
+amino	O
+acid	O
+sequence	O
+data	O
+as	O
+a	O
+reference	O
+,	O
+none	O
+of	O
+the	O
+IBV	B-SPEC
+isolates	O
+foreign	O
+to	O
+the	O
+United	O
+States	O
+have	O
+been	O
+detected	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+In	O
+three	O
+relatively	O
+older	O
+NICU	O
+-	O
+patients	O
+RML	O
+was	O
+due	O
+to	O
+lipid	B-CHED
+lowering	O
+drugs	O
+assumption	O
+.	O
+
+ALI	O
+/	O
+ARDS	B-DISO
+accounted	O
+for	O
+41	O
+%	O
+of	O
+our	O
+hospital	O
+mortality	O
+.	O
+
+ALI	O
+/	O
+ARDS	B-DISO
+accounted	O
+for	O
+41	O
+%	O
+of	O
+our	O
+hospital	O
+mortality	O
+.	O
+
+Axillary	B-ANAT
+artery	I-ANAT
+and	O
+vein	B-ANAT
+thromboses	B-DISO
+were	O
+soon	O
+confirmed	O
+by	O
+ultrasonography	O
+and	O
+arteriography	O
+.	O
+
+The	O
+doppler	O
+ultrasonographies	O
+which	O
+were	O
+performed	O
+subsequently	O
+confirmed	O
+a	O
+complete	O
+revascularization	O
+of	O
+axillary	B-ANAT
+artery	I-ANAT
+and	O
+vein	B-ANAT
+.	O
+
+This	O
+panda	O
+most	O
+likely	O
+contracted	O
+Tyzzer	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+subsequent	O
+to	O
+having	O
+a	O
+compromised	O
+immune	B-ANAT
+system	I-ANAT
+after	O
+corticosteroid	B-CHED
+administration	O
+and	O
+concurrent	O
+disease	O
+.	O
+
+The	O
+nursing	B-PROC
+workload	O
+remains	O
+stable	O
+during	O
+NIPSV	O
+and	O
+does	O
+not	O
+result	O
+predominantly	O
+from	O
+respiratory	O
+therapy	O
+interventions	O
+.	O
+
+In	O
+contrast	O
+,	O
+PL2pro	O
+,	O
+whose	O
+proteolytic	B-PROC
+activity	O
+and	O
+specificity	O
+were	O
+established	O
+in	O
+this	O
+study	O
+,	O
+cleaved	B-ANAT
+the	O
+same	O
+site	O
+efficiently	O
+in	O
+the	O
+presence	O
+of	O
+the	O
+upstream	O
+domains	O
+.	O
+
+Collectively	O
+,	O
+our	O
+results	O
+imply	O
+that	O
+the	O
+p195	B-PRGE
+/	O
+p210	B-PRGE
+autoprocessing	O
+mechanisms	O
+may	O
+be	O
+conserved	O
+among	O
+coronaviruses	O
+to	O
+an	O
+extent	O
+not	O
+appreciated	O
+previously	O
+,	O
+with	O
+PL2pro	O
+playing	O
+a	O
+major	O
+role	O
+.	O
+
+Adult	O
+rats	B-SPEC
+(	O
+body	B-ANAT
+weight	O
+285	O
+to	O
+315	O
+g	O
+,	O
+n	O
+=	O
+45	O
+)	O
+were	O
+allocated	O
+randomly	O
+to	O
+either	O
+a	O
+negative	O
+control	O
+group	O
+(	O
+N	O
+-	O
+Control	O
+,	O
+n	O
+=	O
+9	O
+)	O
+with	O
+only	O
+sham	O
+laparotomy	O
+,	O
+or	O
+groups	O
+(	O
+n	O
+=	O
+9	O
+each	O
+)	O
+for	O
+induction	O
+of	O
+I	O
+/	O
+R	O
+by	O
+occlusion	B-DISO
+of	I-DISO
+superior	B-ANAT
+mesenteric	I-ANAT
+artery	I-ANAT
+,	O
+followed	O
+by	O
+treatment	O
+with	O
+(	O
+1	O
+)	O
+surfactant	B-CHED
+at	O
+100	O
+mg	O
+/	O
+kg	O
+(	O
+Surf	O
+),	O
+(	O
+2	O
+)	O
+iNO	O
+at	O
+20	O
+ppm	O
+(	O
+NO	O
+),	O
+(	O
+3	O
+)	O
+both	O
+surfactant	B-CHED
+and	O
+iNO	O
+(	O
+SNO	B-FUNC
+),	O
+or	O
+(	O
+4	O
+)	O
+no	O
+surfactant	B-CHED
+no	O
+iNO	B-PRGE
+(	O
+a	O
+positive	O
+control	O
+,	O
+P	O
+-	O
+Control	O
+).	O
+
+Mechanical	O
+ventilation	O
+was	O
+provided	O
+for	O
+120	O
+minutes	O
+with	O
+variable	O
+peak	O
+insufflation	O
+pressure	O
+and	O
+FIO2	O
+to	O
+achieve	O
+adequate	O
+arterial	B-ANAT
+pH	O
+,	O
+PaO2	O
+,	O
+and	O
+PaCO2	O
+.	O
+
+The	O
+lungs	B-ANAT
+of	O
+the	O
+SNO	B-FUNC
+group	O
+had	O
+significantly	O
+alleviated	O
+edema	B-DISO
+and	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+compared	O
+with	O
+the	O
+P	O
+-	O
+Control	O
+.	O
+
+The	O
+lungs	B-ANAT
+of	O
+the	O
+SNO	B-FUNC
+group	O
+had	O
+significantly	O
+alleviated	O
+edema	B-DISO
+and	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+compared	O
+with	O
+the	O
+P	O
+-	O
+Control	O
+.	O
+
+To	O
+compare	O
+the	O
+IP	O
+test	O
+with	O
+the	O
+neutralizing	O
+test	O
+(	O
+NT	O
+),	O
+sera	B-COMP
+from	O
+240	O
+healthy	O
+dogs	B-SPEC
+and	O
+from	O
+3	O
+experimentally	O
+CCV	B-DISO
+-	O
+infected	O
+dogs	B-SPEC
+were	O
+examined	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+the	O
+IP	O
+test	O
+specifically	O
+detected	O
+anti	O
+-	O
+CCV	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+derived	O
+expression	B-PROC
+systems	O
+.	O
+
+ABSTRACT	O
+:	O
+Both	O
+helper	O
+dependent	O
+expression	B-PROC
+systems	O
+,	O
+based	O
+on	O
+two	O
+components	O
+,	O
+and	O
+single	O
+genomes	O
+constructed	O
+by	O
+targeted	O
+recombination	B-PROC
+,	O
+or	O
+by	O
+using	O
+infectious	B-DISO
+cDNA	O
+clones	O
+,	O
+have	O
+been	O
+developed	O
+.	O
+
+The	O
+possibility	O
+of	O
+engineering	O
+the	O
+tissue	B-ANAT
+and	O
+species	B-SPEC
+tropism	B-PROC
+to	O
+target	O
+expression	B-PROC
+to	O
+different	O
+organs	B-ANAT
+and	O
+animal	B-SPEC
+species	B-SPEC
+,	O
+including	O
+humans	B-SPEC
+,	O
+increases	O
+the	O
+potential	O
+of	O
+coronaviruses	O
+as	O
+vectors	O
+.	O
+
+ABSTRACT	O
+:	O
+Antiviral	B-CHED
+roles	O
+of	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cell	B-COMP
+subsets	O
+were	O
+examined	O
+in	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+infected	O
+with	O
+murine	B-SPEC
+cytomegalovirus	I-SPEC
+(	O
+MCMV	B-SPEC
+)	O
+and	O
+other	O
+viruses	B-SPEC
+,	O
+including	O
+lymphocytic	B-SPEC
+choriomeningitis	I-SPEC
+virus	I-SPEC
+(	O
+LCMV	B-SPEC
+),	O
+vaccinia	B-SPEC
+virus	I-SPEC
+(	O
+VV	O
+),	O
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+Striking	O
+results	O
+were	O
+seen	O
+with	O
+a	O
+mAb	O
+(	O
+1F8	O
+)	O
+reactive	O
+with	O
+the	O
+positively	O
+signaling	B-CHED
+molecule	I-CHED
+Ly49H	B-PRGE
+,	O
+present	O
+in	O
+MCMV	B-SPEC
+-	O
+resistant	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+.	O
+
+Titers	O
+of	O
+LCMV	B-SPEC
+or	O
+VV	O
+were	O
+not	O
+enhanced	O
+.	O
+
+Rats	B-SPEC
+aged	O
+1	O
+and	O
+2	O
+weeks	O
+were	O
+generally	O
+similar	O
+in	O
+terms	O
+of	O
+mortality	O
+and	O
+mean	O
+time	O
+to	O
+death	B-PROC
+,	O
+regardless	O
+of	O
+inoculation	O
+route	O
+,	O
+except	O
+for	O
+the	O
+oral	B-ANAT
+route	O
+,	O
+which	O
+had	O
+little	O
+effect	O
+.	O
+
+routes	O
+died	B-PROC
+,	O
+but	O
+all	O
+those	O
+inoculated	O
+by	O
+other	O
+routes	O
+survived	O
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+enteric	O
+viruses	B-SPEC
+are	O
+difficult	O
+or	O
+impossible	O
+to	O
+propagate	O
+in	O
+tissue	O
+culture	O
+.	O
+
+Coronaviruses	O
+and	O
+toroviruses	B-SPEC
+are	O
+large	O
+,	O
+enveloped	O
+,	O
+plus	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+in	O
+the	O
+order	B-SPEC
+Nidovirales	I-SPEC
+that	O
+cause	O
+enteric	O
+disease	O
+in	O
+young	O
+pigs	B-SPEC
+,	O
+cows	B-SPEC
+,	O
+dogs	B-SPEC
+,	O
+mice	B-SPEC
+,	O
+cats	B-SPEC
+and	O
+horses	B-SPEC
+.	O
+
+One	O
+specific	O
+site	O
+on	O
+the	O
+S	O
+glycoprotein	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+must	O
+be	O
+cleaved	B-ANAT
+by	O
+an	O
+intracellular	B-COMP
+protease	O
+or	O
+trypsin	B-PRGE
+to	O
+activate	O
+viral	O
+infectivity	O
+and	O
+cell	B-PROC
+fusion	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+safety	O
+and	O
+efficacy	O
+of	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+in	O
+adult	O
+patients	O
+with	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+oxygenation	B-PROC
+failure	O
+.	O
+
+However	O
+,	O
+cells	B-COMP
+infected	O
+with	O
+an	O
+MHV	B-SPEC
+strain	O
+unable	O
+to	O
+induce	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+are	O
+resistant	O
+to	O
+lysis	B-DISO
+and	O
+lysis	B-DISO
+of	O
+JHMV	O
+-	O
+infected	O
+cells	B-COMP
+is	O
+inhibited	O
+by	O
+an	O
+anti	B-PRGE
+-	I-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	I-PRGE
+nonneutralizing	I-PRGE
+mAb	I-PRGE
+which	O
+prevents	O
+S	O
+-	O
+protein	B-CHED
+-	O
+mediated	O
+cell	B-PROC
+fusion	I-PROC
+.	O
+
+To	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+documentation	O
+of	O
+any	O
+microbial	O
+efficacy	O
+testing	O
+conducted	O
+on	O
+filtered	O
+shipping	O
+containers	O
+for	O
+laboratory	O
+animals	B-SPEC
+.	O
+
+Persistent	O
+pneumonia	B-DISO
+confirmed	O
+by	O
+biopsy	B-ANAT
+specimen	I-ANAT
+was	O
+usually	O
+accompanied	O
+by	O
+histologic	O
+manifestations	O
+of	O
+acute	B-PROC
+cellular	I-PROC
+rejection	I-PROC
+and	O
+was	O
+associated	O
+with	O
+poor	O
+patient	O
+outcome	O
+(	O
+ie	O
+,	O
+death	B-PROC
+or	O
+subsequent	O
+development	B-PROC
+of	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+syndrome	B-DISO
+).	O
+
+Because	O
+these	O
+processes	O
+often	O
+demonstrate	O
+overlapping	O
+clinical	O
+and	O
+morphologic	O
+features	O
+requiring	O
+multiple	O
+diagnostic	O
+techniques	O
+for	O
+resolution	O
+,	O
+a	O
+systematic	O
+multimodality	O
+approach	O
+to	O
+diagnosis	O
+is	O
+advantageous	O
+for	O
+determining	O
+the	O
+causes	O
+of	O
+decline	O
+in	O
+individual	O
+patients	O
+and	O
+for	O
+estimating	O
+the	O
+incidences	O
+of	O
+the	O
+different	O
+causes	O
+of	O
+early	O
+graft	B-ANAT
+and	O
+patient	O
+loss	O
+in	O
+the	O
+lung	B-ANAT
+transplant	B-ANAT
+population	O
+.	O
+
+RESULTS	O
+:	O
+Infections	B-DISO
+accounted	O
+for	O
+the	O
+greatest	O
+number	O
+of	O
+deaths	B-PROC
+(	O
+bacterial	B-DISO
+pneumonia	I-DISO
+,	O
+four	O
+patients	O
+;	O
+catheter	O
+-	O
+related	O
+bacteremia	B-DISO
+,	O
+one	O
+patient	O
+).	O
+
+TITLE	O
+:	O
+Is	O
+amiodarone	B-CHED
+an	O
+underrecognized	O
+cause	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+the	O
+ICU	O
+?	O
+
+We	O
+also	O
+provide	O
+a	O
+hypothesis	O
+to	O
+explain	O
+the	O
+mechanism	O
+by	O
+which	O
+amiodarone	B-CHED
+causes	O
+lung	B-ANAT
+damage	O
+.	O
+
+Half	O
+of	O
+the	O
+piglets	O
+fed	O
+HCC	B-DISO
+showed	O
+diarrhea	B-DISO
+and	O
+recovered	O
+,	O
+and	O
+all	O
+piglets	O
+survived	O
+.	O
+
+The	O
+Ab	O
+cross	O
+-	O
+reacted	O
+with	O
+a	O
+40	O
+-	O
+kDa	O
+protein	B-CHED
+from	O
+human	B-SPEC
+,	O
+rat	B-SPEC
+and	O
+sheep	B-SPEC
+liver	B-ANAT
+,	O
+but	O
+not	O
+with	O
+liver	B-ANAT
+extracts	O
+from	O
+the	O
+silver	B-CHED
+side	O
+fish	B-SPEC
+(	O
+Odontesthes	B-SPEC
+bonariensis	I-SPEC
+).	O
+
+No	O
+correlation	O
+was	O
+found	O
+between	O
+the	O
+development	B-PROC
+of	O
+the	O
+hypergammaglobulinemia	B-DISO
+that	O
+followed	O
+the	O
+viral	B-DISO
+infection	I-DISO
+and	O
+the	O
+occurrence	O
+of	O
+the	O
+autoAb	O
+.	O
+
+ABSTRACT	O
+:	O
+CD8	O
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+are	O
+required	O
+to	O
+control	O
+acute	O
+viral	B-PROC
+replication	I-PROC
+in	O
+the	O
+CNS	B-CHED
+following	O
+infection	B-DISO
+with	O
+neurotropic	O
+coronavirus	B-SPEC
+.	O
+
+In	O
+cats	B-SPEC
+with	O
+EUE	O
+,	O
+myeloid	O
+/	O
+histiocyte	B-ANAT
+antigen	B-CHED
+-	O
+positive	O
+macrophages	B-ANAT
+were	O
+relatively	O
+numerous	O
+,	O
+suggesting	O
+recruitment	B-DISO
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+monocytes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Type	O
+-	O
+specific	O
+identification	O
+of	O
+human	B-SPEC
+adenovirus	B-DISO
+3	O
+,	O
+7	O
+,	O
+and	O
+21	O
+by	O
+a	O
+multiplex	O
+PCR	O
+assay	O
+.	O
+
+Type	O
+-	O
+specific	O
+primers	O
+designed	O
+to	O
+the	O
+hypervariable	O
+regions	O
+correctly	O
+identified	O
+Ad3	O
+,	O
+Ad7	B-DISO
+,	O
+and	O
+Ad21	O
+prototype	O
+strains	O
+and	O
+53	O
+previously	O
+typed	O
+Ad	O
+field	O
+isolates	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+robustness	O
+of	O
+soluble	O
+L	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+,	O
+correcting	O
+for	O
+a	O
+broad	O
+spectrum	O
+of	O
+physiological	O
+variables	O
+.	O
+
+The	O
+prevalence	O
+of	O
+alcoholic	O
+cirrhosis	O
+and	O
+the	O
+number	O
+of	O
+potential	O
+candidates	O
+for	O
+liver	B-ANAT
+transplantation	O
+is	O
+unknown	O
+but	O
+certainly	O
+underestimated	O
+.	O
+
+Despite	O
+physicians	O
+'	O
+ethical	O
+reserves	O
+concerning	O
+this	O
+self	O
+-	O
+inflicted	O
+disease	O
+and	O
+the	O
+public	O
+'	O
+s	O
+misgivings	O
+,	O
+liver	B-ANAT
+transplantation	O
+for	O
+alcoholic	B-DISO
+cirrhosis	I-DISO
+can	O
+provide	O
+survival	O
+rates	O
+comparable	O
+with	O
+those	O
+observed	O
+for	O
+other	O
+chronic	O
+liver	B-DISO
+diseases	I-DISO
+.	O
+
+He	O
+presented	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+following	O
+a	O
+very	O
+long	O
+hyperbaric	O
+oxygen	B-CHED
+therapy	O
+(	O
+using	O
+a	O
+US	O
+.	O
+
+The	O
+principal	O
+histological	O
+findings	O
+were	O
+atrophy	B-DISO
+of	O
+small	O
+intestinal	B-ANAT
+villi	I-ANAT
+,	O
+lymphoid	O
+depletion	O
+,	O
+hepatitis	B-DISO
+and	O
+bronchopneumonia	B-DISO
+.	O
+
+We	O
+describe	O
+an	O
+ARDS	B-DISO
+patient	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+caused	O
+by	O
+a	O
+severe	O
+Chlamydiaceae	B-SPEC
+species	B-SPEC
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+(	O
+CAP	B-DISO
+).	O
+
+The	O
+evidence	O
+from	O
+the	O
+literature	O
+for	O
+survival	O
+advantage	O
+of	O
+lung	B-ANAT
+protective	O
+and	O
+other	O
+strategies	O
+is	O
+critically	O
+reviewed	O
+.	O
+
+ABSTRACT	O
+:	O
+Passive	O
+protection	O
+experiments	O
+were	O
+conducted	O
+to	O
+determine	O
+the	O
+frequency	O
+and	O
+amounts	O
+of	O
+hyperimmune	O
+antiserum	O
+needed	O
+to	O
+block	O
+a	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+challenge	O
+infection	B-DISO
+and	O
+to	O
+identify	O
+monoclonal	O
+antibodies	B-COMP
+that	O
+are	O
+partially	O
+protective	O
+against	O
+TGEV	B-SPEC
+.	O
+
+Three	O
+-	O
+day	O
+-	O
+old	O
+piglets	O
+were	O
+challenged	O
+with	O
+virulent	O
+virus	B-SPEC
+that	O
+had	O
+been	O
+preincubated	O
+with	O
+antiserum	O
+or	O
+monoclonal	O
+antibodies	B-COMP
+.	O
+
+An	O
+increased	O
+understanding	O
+of	O
+both	O
+the	O
+benefits	O
+and	O
+hazards	O
+has	O
+led	O
+to	O
+a	O
+general	O
+consensus	O
+regarding	O
+the	O
+optimal	O
+techniques	O
+to	O
+ensure	O
+adequate	O
+gas	B-ENZY
+exchange	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+results	O
+in	O
+reduced	O
+lung	B-PROC
+compliance	I-PROC
+and	O
+a	O
+marked	O
+decrease	O
+in	O
+the	O
+volume	O
+of	O
+functional	O
+lung	B-ANAT
+.	O
+
+Some	O
+cases	O
+of	O
+severe	O
+angioedema	B-DISO
+have	O
+been	O
+recently	O
+reported	O
+after	O
+treatment	O
+with	O
+fibrinolytic	O
+agents	O
+.	O
+
+Estrogen	B-CHED
+and	O
+ACE	B-PRGE
+inhibitors	B-CHED
+should	O
+be	O
+avoided	O
+in	O
+a	O
+patient	O
+with	O
+congenital	O
+or	O
+acquired	O
+C1	O
+-	O
+INH	O
+deficiency	O
+.	O
+
+Serum	B-COMP
+was	O
+collected	O
+from	O
+the	O
+852	O
+animals	B-SPEC
+enrolled	O
+to	O
+determine	O
+titers	O
+to	O
+H	B-SPEC
+.	I-SPEC
+somnus	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+bovine	B-DISO
+viral	I-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+.	O
+
+Vaccination	O
+with	O
+H	O
+.	O
+somnus	O
+in	O
+combination	O
+with	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+and	O
+with	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+alone	O
+reduced	O
+the	O
+risk	O
+of	O
+UBRD	O
+.	O
+
+However	O
+,	O
+the	O
+association	O
+changed	O
+with	O
+time	O
+of	O
+BRD	O
+treatment	O
+;	O
+animals	B-SPEC
+diagnosed	O
+and	O
+treated	O
+for	O
+UBRD	O
+on	O
+or	O
+after	O
+day	O
+10	O
+showed	O
+little	O
+evidence	O
+of	O
+exposure	O
+to	O
+H	B-SPEC
+.	I-SPEC
+somnus	I-SPEC
+,	O
+despite	O
+evidence	O
+of	O
+natural	O
+H	B-SPEC
+.	I-SPEC
+somnus	I-SPEC
+exposure	O
+in	O
+the	O
+unvaccinated	O
+group	O
+.	O
+
+The	O
+method	O
+could	O
+provide	O
+a	O
+useful	O
+tool	O
+for	O
+demonstrating	O
+the	O
+role	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+in	O
+infections	B-DISO
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+Following	O
+intranasal	O
+inoculation	O
+with	O
+MHV	B-SPEC
+A59	O
+,	O
+p	O
+/	O
+p	O
+mice	B-SPEC
+developed	O
+markedly	O
+fewer	O
+and	O
+smaller	O
+lesions	O
+in	O
+the	O
+liver	B-ANAT
+than	O
++/+	O
+or	O
+heterozygous	O
+(+/	O
+p	O
+)	O
+mice	B-SPEC
+.	O
+
+p	O
+/	O
+p	O
+mice	B-SPEC
+survived	O
+a	O
+dose	O
+100	O
+-	O
+fold	O
+higher	O
+than	O
+the	O
+lethal	O
+dose	O
+of	O
+virus	B-SPEC
+for	O
++/+	O
+mice	B-SPEC
+.	O
+
+Patients	O
+with	O
+PC	O
+from	O
+isolated	O
+chest	B-ANAT
+trauma	O
+who	O
+had	O
+admission	O
+chest	B-ANAT
+computed	O
+tomographic	O
+scan	O
+were	O
+identified	O
+from	O
+the	O
+registry	O
+of	O
+a	O
+Level	O
+I	O
+trauma	O
+center	O
+over	O
+a	O
+1	O
+.	O
+5	O
+-	O
+year	O
+period	O
+.	O
+
+There	O
+was	O
+a	O
+trend	O
+toward	O
+higher	O
+pneumonia	B-DISO
+rate	O
+in	O
+the	O
+severe	O
+group	O
+,	O
+with	O
+50	O
+%	O
+of	O
+patients	O
+in	O
+the	O
+severe	O
+group	O
+developing	O
+pneumonia	B-DISO
+as	O
+compared	O
+with	O
+28	O
+%	O
+in	O
+the	O
+moderate	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+20	O
+).	O
+
+We	O
+conclude	O
+that	O
+the	O
+Fas	B-DISO
+/	O
+FasL	B-PRGE
+system	O
+contributes	O
+to	O
+the	O
+development	B-PROC
+of	O
+permeability	O
+changes	O
+and	O
+tissue	B-ANAT
+injury	O
+during	O
+-	O
+gram	O
+negative	O
+bacterial	B-DISO
+pneumonia	I-DISO
+.	O
+
+The	O
+Fas	B-DISO
+/	O
+FasL	B-PRGE
+system	O
+did	O
+not	O
+have	O
+a	O
+major	O
+role	O
+in	O
+the	O
+clearance	O
+of	O
+aerosolized	O
+bacteria	B-SPEC
+from	O
+the	O
+lungs	B-ANAT
+at	O
+the	O
+bacterial	O
+doses	O
+tested	O
+.	O
+
+TITLE	O
+:	O
+Mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+type	O
+-	O
+2	O
+infection	B-DISO
+in	O
+mice	B-SPEC
+:	O
+an	O
+experimental	O
+model	O
+system	O
+of	O
+acute	O
+meningitis	B-DISO
+and	O
+hepatitis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+submitted	O
+to	O
+protective	O
+ventilation	O
+:	O
+incidence	O
+,	O
+clinical	O
+implications	O
+,	O
+and	O
+prognosis	O
+.	O
+
+ACP	B-DISO
+was	O
+associated	O
+with	O
+pulmonary	B-DISO
+artery	I-DISO
+hypertension	I-DISO
+,	O
+increased	O
+heart	B-ANAT
+rate	O
+,	O
+and	O
+decreased	O
+stroke	B-DISO
+index	O
+.	O
+
+However	O
+,	O
+ACP	B-DISO
+patients	O
+who	O
+recovered	O
+required	O
+a	O
+longer	O
+period	O
+of	O
+respiratory	O
+support	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+intravenous	O
+fat	O
+emulsions	O
+on	O
+lung	B-PROC
+function	I-PROC
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+or	O
+sepsis	B-DISO
+.	O
+
+Concomitantly	O
+,	O
+pulmonary	B-ANAT
+shunt	O
+fraction	O
+,	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+difference	O
+[	O
+P	O
+(	O
+a	O
+-	O
+a	O
+)	O
+o2	O
+]/	O
+Pao2	B-PRGE
+,	O
+and	O
+cardiac	B-ANAT
+index	O
+increased	O
+as	O
+well	O
+,	O
+whereas	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+and	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+declined	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Critical	O
+state	O
+medicine	B-CHED
+.	O
+
+Viral	O
+wheezers	O
+with	O
+colds	B-DISO
+reported	O
+significantly	O
+more	O
+URT	O
+symptoms	O
+than	O
+controls	O
+(	O
+median	O
+scores	O
+(	O
+interquartile	O
+range	O
+):	O
+24	O
+(	O
+10	O
+-	O
+37	O
+)	O
+and	O
+6	O
+(	O
+4	O
+-	O
+15	O
+),	O
+respectively	O
+p	O
+=	O
+0	O
+.	O
+014	O
+).	O
+
+The	O
+fall	O
+in	O
+PC20	O
+affected	O
+both	O
+atopic	B-DISO
+and	O
+nonatopic	O
+subjects	O
+equally	O
+.	O
+
+The	O
+inhibition	B-PROC
+of	O
+acetylcholinesterase	B-PRGE
+causes	O
+accumulation	O
+of	O
+acetylcholine	B-CHED
+at	O
+synapses	B-COMP
+,	O
+and	O
+overstimulation	O
+of	O
+neurotransmission	B-PROC
+occurs	O
+as	O
+a	O
+result	O
+of	O
+this	O
+accumulation	O
+.	O
+
+Positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+was	O
+titrated	O
+to	O
+keep	O
+SaO2	B-PROC
+above	O
+94	O
+%	O
+with	O
+40	O
+%	O
+FIO2	O
+.	O
+
+Intermediate	B-DISO
+syndrome	I-DISO
+was	O
+observed	O
+in	O
+9	O
+(	O
+19	O
+.	O
+1	O
+%)	O
+patients	O
+.	O
+
+These	O
+complications	O
+were	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+14	O
+patients	O
+),	O
+aspiration	B-DISO
+pneumonia	I-DISO
+(	O
+10	O
+patients	O
+),	O
+urinary	B-ANAT
+system	I-ANAT
+infection	B-DISO
+(	O
+6	O
+patients	O
+),	O
+convulsion	B-DISO
+(	O
+4	O
+patients	O
+)	O
+and	O
+septic	B-DISO
+shock	I-DISO
+(	O
+1	O
+patient	O
+).	O
+
+Three	O
+of	O
+the	O
+patients	O
+who	O
+did	O
+not	O
+receive	O
+pralidoxime	B-CHED
+because	O
+of	O
+unavailability	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+increases	O
+cardiac	B-ANAT
+performance	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Temperature	O
+and	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+/	O
+fractional	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+FiO2	O
+)	O
+were	O
+similar	O
+among	O
+the	O
+patients	O
+.	O
+
+3	O
+for	O
+PCV	B-CHED
+to	O
+12	O
++/-	O
+
+TITLE	O
+:	O
+Variation	O
+of	O
+the	O
+sequence	O
+in	O
+the	O
+gene	O
+encoding	O
+for	O
+transmembrane	B-COMP
+protein	B-CHED
+M	O
+of	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCV	B-DISO
+).	O
+
+Moreover	O
+,	O
+the	O
+nucleotide	B-CHED
+substitutions	O
+occurring	O
+over	O
+the	O
+whole	O
+fragment	O
+of	O
+the	O
+five	O
+samples	O
+analysed	O
+were	O
+similar	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+demonstrates	O
+the	O
+use	O
+of	O
+stochastic	O
+genetic	O
+epidemiological	O
+models	O
+for	O
+quantifying	O
+the	O
+consequences	O
+of	O
+selecting	O
+animals	B-SPEC
+for	O
+resistance	B-PROC
+to	O
+a	O
+microparasitic	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+the	O
+base	O
+population	O
+,	O
+the	O
+basic	O
+reproductive	B-PROC
+ratio	O
+,	O
+R0	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+the	O
+expected	O
+number	O
+of	O
+secondary	O
+cases	O
+after	O
+the	O
+introduction	O
+of	O
+a	O
+single	O
+infected	O
+animal	B-SPEC
+)	O
+was	O
+2	O
+.	O
+24	O
+,	O
+in	O
+agreement	O
+with	O
+previous	O
+studies	O
+.	O
+
+Normal	O
+rats	B-SPEC
+had	O
+a	O
+well	O
+-	O
+defined	O
+upper	O
+inflection	O
+point	O
+(	O
+UIP	B-DISO
+)	O
+at	O
+low	O
+airway	B-ANAT
+pressure	O
+.	O
+
+These	O
+observations	O
+may	O
+have	O
+clinical	O
+relevance	O
+in	O
+the	O
+context	O
+of	O
+the	O
+""""	O
+open	O
+lung	B-ANAT
+""""	O
+strategy	O
+.	O
+
+TITLE	O
+:	O
+Cooperation	O
+of	O
+an	O
+RNA	O
+packaging	O
+signal	O
+and	O
+a	O
+viral	B-PRGE
+envelope	I-PRGE
+protein	B-CHED
+in	O
+coronavirus	B-SPEC
+RNA	O
+packaging	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+subcellular	O
+localization	B-PROC
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+(	O
+group	O
+I	O
+and	O
+group	O
+II	O
+coronaviruses	O
+,	O
+respectively	O
+)	O
+nucleoproteins	O
+(	O
+N	O
+proteins	B-CHED
+)	O
+were	O
+examined	O
+by	O
+confocal	O
+microscopy	O
+.	O
+
+Patients	O
+who	O
+initially	O
+were	O
+randomized	O
+to	O
+treatment	O
+with	O
+CV	O
+showed	O
+pulmonary	B-PROC
+function	I-PROC
+evidence	O
+of	O
+decreased	O
+peak	O
+expiratory	B-PROC
+flow	O
+,	O
+increased	O
+residual	O
+lung	B-PROC
+volume	I-PROC
+,	O
+and	O
+maldistribution	O
+of	O
+ventilation	O
+.	O
+
+Surfactant	B-CHED
+replacement	O
+combined	O
+with	O
+early	O
+HFOV	O
+using	O
+a	O
+lung	B-ANAT
+recruitment	B-DISO
+strategy	O
+ameliorates	O
+the	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+that	O
+predisposes	O
+some	O
+preterm	O
+infants	O
+to	O
+develop	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Relationship	O
+between	O
+pancreatitis	B-DISO
+and	O
+lung	B-DISO
+diseases	I-DISO
+.	O
+
+Most	O
+patients	O
+who	O
+die	O
+during	O
+the	O
+early	O
+stages	O
+of	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+die	O
+either	O
+with	O
+or	O
+as	O
+a	O
+result	O
+of	O
+this	O
+lung	B-ANAT
+injury	O
+.	O
+
+These	O
+studies	O
+have	O
+indicated	O
+that	O
+adhesion	B-DISO
+molecules	O
+such	O
+as	O
+intracellular	B-PRGE
+adhesion	B-DISO
+molecule	I-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+),	O
+neutrophils	B-ANAT
+,	O
+platelet	B-PRGE
+activating	I-PRGE
+factor	I-PRGE
+(	O
+PAF	B-DISO
+),	O
+substance	O
+P	O
+,	O
+and	O
+chemokines	O
+acting	O
+via	O
+the	O
+CCR	B-PRGE
+-	I-PRGE
+1	I-PRGE
+chemokine	I-PRGE
+receptor	I-PRGE
+play	O
+a	O
+pro	B-CHED
+-	O
+inflammatory	O
+role	O
+while	O
+complement	B-PRGE
+factor	I-PRGE
+C5a	I-PRGE
+plays	O
+an	O
+anti	O
+-	O
+inflammatory	O
+role	O
+in	O
+pancreatitis	B-DISO
+and	O
+lung	B-ANAT
+injury	O
+.	O
+
+However	O
+,	O
+by	O
+day	O
+12	O
+pi	O
+,	O
+T	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+into	O
+the	O
+CNS	B-CHED
+of	O
+infected	O
+CCR5	B-PRGE
+(-/-)	I-PRGE
+and	O
+CCR5	B-PRGE
+(+/+)	O
+mice	B-SPEC
+was	O
+similar	O
+and	O
+both	O
+strains	O
+exhibited	O
+comparable	O
+viral	O
+titers	O
+,	O
+indicating	O
+that	O
+CCR5	B-PRGE
+expression	B-PROC
+is	O
+not	O
+essential	O
+for	O
+host	B-PROC
+defense	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+examine	O
+whether	O
+measurement	O
+of	O
+procalcitonin	O
+(	O
+PCT	B-DISO
+)	O
+in	O
+comparison	O
+with	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+is	O
+a	O
+reliable	O
+marker	O
+to	O
+score	O
+the	O
+extent	O
+of	O
+lung	B-ANAT
+contusion	O
+in	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluids	B-ANAT
+in	O
+polytrauma	O
+patients	O
+.	O
+
+They	O
+can	O
+be	O
+used	O
+as	O
+pedicled	O
+or	O
+free	B-ANAT
+flaps	I-ANAT
+and	O
+are	O
+a	O
+beneficial	O
+reconstruction	O
+strategy	O
+for	O
+major	O
+defects	O
+,	O
+provided	O
+there	O
+is	O
+tissue	B-ANAT
+available	O
+adjacent	O
+to	O
+these	O
+defects	O
+.	O
+
+In	O
+four	O
+cases	O
+,	O
+a	O
+partial	O
+or	O
+total	O
+necrosis	B-PROC
+of	O
+a	O
+fillet	O
+flap	B-ANAT
+occurred	O
+(	O
+one	O
+patient	O
+with	O
+diabetic	B-DISO
+vascular	I-DISO
+disease	I-DISO
+,	O
+one	O
+with	O
+Dupuytren	B-DISO
+'	I-DISO
+s	I-DISO
+contracture	I-DISO
+,	O
+and	O
+two	O
+with	O
+high	O
+-	O
+voltage	B-CHED
+electrical	O
+injuries	O
+).	O
+Thirty	O
+-	O
+six	O
+pedicled	O
+limb	B-ANAT
+fillet	O
+flaps	B-ANAT
+were	O
+used	O
+in	O
+35	O
+cases	O
+.	O
+
+In	O
+seven	O
+other	O
+cases	O
+,	O
+sacral	B-ANAT
+,	O
+pelvic	B-ANAT
+,	O
+groin	B-ANAT
+,	O
+hip	B-ANAT
+,	O
+abdominal	B-ANAT
+wall	I-ANAT
+,	O
+or	O
+lumbar	B-ANAT
+defects	O
+were	O
+reconstructed	O
+with	O
+fillet	O
+-	O
+of	O
+-	O
+thigh	B-ANAT
+or	O
+entire	O
+-	O
+limb	B-ANAT
+fillet	O
+flaps	B-ANAT
+.	O
+
+This	O
+complication	B-DISO
+rate	O
+seems	O
+acceptable	O
+.	O
+
+ABSTRACT	O
+:	O
+Toxic	O
+epidermal	O
+necrolysis	O
+(	O
+TEN	O
+)	O
+is	O
+a	O
+rare	O
+severe	O
+acute	O
+exfoliative	O
+drug	O
+-	O
+induced	O
+skin	B-DISO
+disorder	I-DISO
+which	O
+has	O
+recently	O
+been	O
+ascribed	O
+to	O
+alterations	O
+in	O
+the	O
+control	O
+of	O
+keratinocyte	B-PROC
+apoptosis	B-PATH
+,	O
+mediated	O
+by	O
+an	O
+interaction	O
+between	O
+the	O
+cell	B-COMP
+surface	I-COMP
+death	B-PRGE
+receptor	I-PRGE
+Fas	B-DISO
+and	O
+its	O
+respective	O
+ligand	B-PROC
+.	O
+
+Eight	O
+patients	O
+were	O
+healed	O
+and	O
+1	O
+died	B-PROC
+of	O
+septic	B-DISO
+shock	I-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Many	O
+of	O
+these	O
+viruses	B-SPEC
+induce	O
+diseases	O
+resulting	O
+in	O
+important	O
+economic	O
+losses	O
+of	O
+lower	O
+vertebrates	B-SPEC
+,	O
+especially	O
+in	O
+fish	B-SPEC
+aquaculture	O
+.	O
+
+In	O
+addition	O
+,	O
+some	O
+of	O
+the	O
+DNA	O
+viruses	B-SPEC
+seem	O
+to	O
+be	O
+emerging	O
+pathogens	O
+involved	O
+in	O
+the	O
+worldwide	O
+decline	O
+in	O
+wildlife	O
+.	O
+
+The	O
+computing	O
+distances	O
+among	O
+their	O
+S	O
+gene	O
+sequences	O
+resulted	O
+in	O
+the	O
+grouping	O
+of	O
+these	O
+coronaviruses	O
+into	O
+four	O
+clusters	B-CHED
+,	O
+one	O
+of	O
+them	O
+exclusively	O
+formed	O
+by	O
+the	O
+Purdue	O
+viruses	B-SPEC
+.	O
+
+Comparison	O
+of	O
+the	O
+TGEV	B-PRGE
+polymerase	I-PRGE
+sequence	I-PRGE
+with	O
+that	O
+of	O
+other	O
+RNA	O
+viruses	B-SPEC
+revealed	O
+high	O
+sequence	O
+homology	O
+with	O
+the	O
+A	O
+-	O
+E	O
+domains	O
+of	O
+the	O
+palm	B-ANAT
+subdomain	O
+of	O
+nucleic	B-CHED
+acid	I-CHED
+polymerases	I-PRGE
+.	O
+
+These	O
+virus	B-SPEC
+-	O
+receptor	B-PROC
+interactions	I-PROC
+can	O
+be	O
+highly	O
+species	B-SPEC
+specific	O
+;	O
+for	O
+example	O
+,	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+can	O
+use	O
+human	B-PRGE
+APN	I-PRGE
+(	O
+hAPN	O
+)	O
+but	O
+not	O
+porcine	B-PRGE
+APN	I-PRGE
+(	O
+pAPN	O
+)	O
+as	O
+its	O
+cellular	B-COMP
+receptor	O
+,	O
+and	O
+porcine	B-SPEC
+coronaviruses	O
+can	O
+use	O
+pAPN	O
+but	O
+not	O
+hAPN	O
+.	O
+
+Paired	O
+serum	B-COMP
+samples	O
+obtained	O
+were	O
+tested	O
+for	O
+antibodies	B-COMP
+to	O
+BCV	B-SPEC
+,	O
+using	O
+antibody	B-COMP
+-	O
+detection	O
+ELISA	O
+.	O
+
+Some	O
+cattle	B-SPEC
+(	O
+25	O
+/	O
+46	O
+,	O
+45	O
+%)	O
+shed	O
+BECV	B-SPEC
+and	O
+BRCV	O
+.	O
+
+There	O
+were	O
+25	O
+/	O
+29	O
+(	O
+86	O
+%)	O
+cattle	B-SPEC
+positive	O
+for	O
+BECV	B-SPEC
+that	O
+shed	O
+BRCV	O
+,	O
+but	O
+only	O
+1	O
+/	O
+27	O
+(	O
+4	O
+%)	O
+cattle	B-SPEC
+negative	O
+to	O
+BECV	B-SPEC
+shed	O
+BRCV	O
+.	O
+
+Twenty	O
+-	O
+seven	O
+of	O
+48	O
+(	O
+56	O
+%)	O
+paired	O
+nasal	B-ANAT
+swab	O
+specimens	O
+and	O
+fecal	B-ANAT
+samples	O
+positive	O
+for	O
+BECV	B-SPEC
+were	O
+positive	O
+for	O
+BRCV	O
+.	O
+
+The	O
+antibody	B-COMP
+patterns	O
+in	O
+the	O
+broiler	O
+breeders	O
+indicated	O
+frequent	O
+field	O
+infections	B-DISO
+breaking	O
+through	O
+vaccinal	O
+immunity	B-PROC
+.	O
+
+8	O
+and	O
+mean	O
+oxygenation	B-PROC
+index	O
+[	O
+OI	O
+]	O
+of	O
+42	O
++/-	O
+
+The	O
+volume	O
+-	O
+preset	O
+,	O
+assist	O
+-	O
+control	O
+mode	O
+is	O
+recommended	O
+for	O
+better	O
+control	O
+of	O
+V	O
+(	O
+T	O
+),	O
+and	O
+the	O
+respiratory	O
+rate	O
+should	O
+be	O
+increased	O
+as	O
+V	O
+(	O
+T	O
+)	O
+is	O
+reduced	O
+,	O
+so	O
+as	O
+to	O
+maintain	O
+minute	O
+ventilation	O
+and	O
+prevent	O
+acute	O
+hypercapnia	B-DISO
+.	O
+
+The	O
+complete	O
+ORF5	O
+gene	O
+of	O
+eight	O
+acute	O
+PRRSV	B-SPEC
+isolates	O
+from	O
+herds	O
+experiencing	O
+acute	O
+PRRS	B-DISO
+outbreaks	O
+in	O
+Iowa	O
+and	O
+North	O
+Carolina	O
+was	O
+amplified	O
+and	O
+sequenced	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+the	O
+acute	O
+PRRSV	B-SPEC
+isolates	O
+analyzed	O
+in	O
+this	O
+study	O
+differed	O
+from	O
+each	O
+other	O
+in	O
+ORF5	O
+genes	O
+,	O
+although	O
+they	O
+all	O
+clustered	O
+within	O
+the	O
+North	O
+American	O
+genotype	O
+.	O
+
+Nasal	B-ANAT
+brush	B-ANAT
+cells	I-ANAT
+were	O
+stained	O
+immunohistochemically	O
+for	O
+Langerhans	B-ANAT
+cells	I-ANAT
+,	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+monocytes	B-ANAT
+,	O
+neutrophils	B-ANAT
+,	O
+B	B-ANAT
+cells	I-ANAT
+,	O
+macrophages	B-ANAT
+,	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cells	B-ANAT
+,	I-ANAT
+mast	I-ANAT
+cells	B-COMP
+,	O
+eosinophils	B-ANAT
+,	O
+eotaxin	O
+,	O
+and	O
+RANTES	B-PRGE
+.	O
+
+Four	O
+rhinovirus	B-SPEC
+,	O
+four	O
+coronavirus	B-SPEC
+,	O
+three	O
+RSV	B-SPEC
+,	O
+one	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+and	O
+one	O
+influenza	B-PATH
+A	I-PATH
+/	O
+enterovirus	B-SPEC
+double	O
+infection	B-DISO
+were	O
+confirmed	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+of	O
+Pneumocystis	B-DISO
+carinii	I-DISO
+pneumonia	I-DISO
+(	O
+PCP	B-DISO
+)	O
+in	O
+which	O
+acute	O
+lung	B-ANAT
+tissue	I-ANAT
+destruction	O
+progressed	O
+within	O
+a	O
+few	O
+days	O
+to	O
+form	O
+multiple	O
+bullae	B-DISO
+in	O
+a	O
+patient	O
+with	O
+no	O
+HIV	B-DISO
+-	I-DISO
+1	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+present	O
+case	O
+demonstrated	O
+that	O
+HIV	B-PATH
+infection	I-PATH
+was	O
+not	O
+an	O
+essential	O
+factor	O
+in	O
+the	O
+development	B-PROC
+of	O
+bullous	O
+changes	O
+.	O
+
+ABSTRACT	O
+:	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+and	O
+Streptococcus	B-SPEC
+pyogenes	I-SPEC
+produce	O
+a	O
+lot	O
+of	O
+toxins	B-CHED
+,	O
+some	O
+of	O
+them	O
+responsible	O
+for	O
+specific	O
+diseases	O
+.	O
+
+Seven	O
+toxins	B-CHED
+have	O
+been	O
+isolated	O
+so	O
+far	O
+.	O
+
+Bullous	B-DISO
+impetigo	I-DISO
+is	O
+also	O
+due	O
+to	O
+exfoliatin	O
+.	O
+
+Scarlet	B-DISO
+fever	I-DISO
+is	O
+related	O
+to	O
+the	O
+streptococcal	O
+erythrogenic	O
+toxins	O
+.	O
+
+Toxic	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+is	O
+defined	O
+as	O
+a	O
+multi	B-DISO
+organ	I-DISO
+failure	I-DISO
+syndrome	B-DISO
+with	O
+a	O
+rapid	O
+onset	O
+,	O
+fever	B-PROC
+,	O
+rash	B-DISO
+followed	O
+by	O
+desquamation	O
+,	O
+vomiting	B-DISO
+and	O
+diarrhea	B-DISO
+,	O
+hypotension	O
+,	O
+conjunctivitis	B-DISO
+and	O
+strawberry	B-DISO
+tongue	B-ANAT
+.	O
+
+Necrotizing	B-DISO
+fasciitis	I-DISO
+complicating	O
+varicella	B-DISO
+is	O
+a	O
+classic	O
+cause	O
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+In	O
+vivo	O
+expression	B-PROC
+of	O
+major	B-PRGE
+histocompatibility	I-PRGE
+complex	I-PRGE
+molecules	I-PRGE
+on	O
+oligodendrocytes	B-ANAT
+and	O
+neurons	B-ANAT
+during	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+set	O
+out	O
+to	O
+precisely	O
+define	O
+which	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+cells	B-COMP
+express	O
+MHC	B-PRGE
+molecules	I-PRGE
+in	O
+vivo	O
+during	O
+infection	B-DISO
+with	O
+a	O
+strain	O
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+that	O
+causes	O
+a	O
+chronic	O
+,	O
+inflammatory	O
+demyelinating	B-DISO
+disease	I-DISO
+.	O
+
+Vascular	B-PROC
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PROC
+(	O
+VEGF	B-PRGE
+)	O
+is	O
+upregulated	O
+only	O
+in	O
+susceptible	O
+mice	B-SPEC
+during	O
+the	O
+secondary	O
+(	O
+retinal	B-DISO
+degeneration	I-DISO
+)	O
+phase	O
+.	O
+
+Results	O
+were	O
+expressed	B-PROC
+as	O
+mean	O
+,	O
+range	O
+and	O
+standard	O
+deviation	O
+.	O
+
+Twenty	O
+-	O
+two	O
+patients	O
+needed	O
+dialysis	B-SPEC
+.	O
+
+ARF	B-DISO
+necessitating	O
+dialysis	B-SPEC
+was	O
+seen	O
+in	O
+92	O
+%	O
+of	O
+patients	O
+with	O
+ARF	B-DISO
+in	O
+malaria	B-PATH
+.	O
+
+Infection	B-DISO
+of	O
+mice	B-SPEC
+lacking	O
+CCR2	B-PRGE
+(	O
+CCR2	B-PRGE
+(-/-))	O
+with	O
+MHV	B-SPEC
+resulted	O
+in	O
+increased	O
+mortality	O
+and	O
+enhanced	O
+viral	O
+recovery	O
+from	O
+the	O
+brain	B-ANAT
+that	O
+correlated	O
+with	O
+reduced	O
+(	O
+p	O
+<	O
+or	O
+=	O
+0	O
+.	O
+04	O
+)	O
+T	B-ANAT
+cell	I-ANAT
+and	O
+macrophage	B-ANAT
+/	O
+microglial	B-ANAT
+(	O
+determined	O
+by	O
+F4	O
+/	O
+80	O
+Ag	O
+expression	B-PROC
+,	O
+p	O
+<	O
+or	O
+=	O
+0	O
+.	O
+004	O
+)	O
+infiltration	B-DISO
+into	O
+the	O
+CNS	B-CHED
+.	O
+
+Moreover	O
+,	O
+MHV	B-SPEC
+-	O
+infected	O
+CCR2	O
+(-/-)	O
+mice	B-SPEC
+displayed	O
+a	O
+significant	O
+decrease	O
+in	O
+Th1	O
+-	O
+associated	O
+factors	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+(	O
+p	O
+<	O
+or	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+RANTES	B-PRGE
+/	O
+CCL5	B-PRGE
+(	O
+p	O
+<	O
+or	O
+=	O
+0	O
+.	O
+002	O
+)	O
+within	O
+the	O
+CNS	B-CHED
+as	O
+compared	O
+with	O
+CCR2	O
+(+/+)	O
+mice	O
+.	O
+
+Collectively	O
+,	O
+these	O
+results	O
+indicate	O
+an	O
+important	O
+role	O
+for	O
+CCR2	B-PRGE
+in	O
+host	B-PROC
+defense	I-PROC
+and	O
+disease	O
+by	O
+regulating	O
+leukocyte	B-PROC
+activation	I-PROC
+and	O
+trafficking	B-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Bronchopulmonary	B-DISO
+disease	I-DISO
+in	O
+drug	O
+abusers	O
+].	O
+
+Finally	O
+repeated	O
+intravenous	O
+injections	O
+of	O
+various	O
+drugs	O
+designed	O
+for	O
+oral	B-ANAT
+intake	O
+can	O
+lead	O
+to	O
+severe	O
+complications	O
+such	O
+as	O
+pulmonary	B-DISO
+hypertension	I-DISO
+or	O
+toxic	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+effective	O
+host	B-PROC
+response	I-PROC
+against	O
+viral	B-DISO
+infection	I-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+is	O
+the	O
+principal	O
+factor	O
+dictating	O
+the	O
+outcome	O
+of	O
+infection	B-DISO
+.	O
+
+Throat	B-ANAT
+,	O
+rectal	B-ANAT
+swab	I-ANAT
+and	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+samples	O
+were	O
+subjected	O
+to	O
+viral	O
+isolation	O
+and	O
+viral	O
+isolates	O
+were	O
+identified	O
+by	O
+immunofluorescence	O
+,	O
+micro	O
+-	O
+neutralisation	O
+using	O
+human	B-SPEC
+rhabdomyosarcoma	B-DISO
+(	O
+RD	O
+)	O
+cells	B-COMP
+,	O
+and	O
+reverse	O
+transcritpase	B-PRGE
+polymerase	I-PRGE
+chain	I-PRGE
+reaction	O
+.	O
+
+Echovirus	B-SPEC
+7	O
+infection	B-DISO
+associated	O
+with	O
+encephalomyelitis	B-DISO
+could	O
+be	O
+fatal	O
+due	O
+to	O
+indirect	O
+involvement	O
+of	O
+the	O
+heart	B-ANAT
+resulting	O
+in	O
+severe	O
+left	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+.	O
+
+Using	O
+standard	O
+operant	O
+techniques	O
+and	O
+a	O
+'	O
+go	O
+,	O
+no	O
+-	O
+go	O
+'	O
+successive	O
+discrimination	O
+paradigm	O
+,	O
+six	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+trained	O
+to	O
+discriminate	O
+between	O
+the	O
+presentation	O
+of	O
+an	O
+air	B-CHED
+or	O
+odor	O
+stimulus	O
+(	O
+three	O
+mice	B-SPEC
+for	O
+each	O
+of	O
+the	O
+odorants	O
+propanol	B-CHED
+and	O
+propyl	B-CHED
+acetate	B-CHED
+).	O
+
+Following	O
+criterion	O
+performance	O
+,	O
+each	O
+mouse	B-SPEC
+received	O
+an	O
+additional	O
+2000	O
+trials	O
+of	O
+overtraining	O
+.	O
+
+These	O
+viruses	B-SPEC
+were	O
+isolated	O
+between	O
+the	O
+years	O
+1997	O
+and	O
+2000	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immune	B-PROC
+response	I-PROC
+to	O
+a	O
+naked	O
+plasmid	O
+DNA	O
+encoding	O
+the	O
+nucleoprotein	O
+(	O
+N	O
+protein	B-CHED
+)	O
+of	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+was	O
+investigated	O
+in	O
+this	O
+study	O
+.	O
+
+To	O
+evaluate	O
+the	O
+immunogenicity	O
+of	O
+the	O
+construct	O
+,	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+intramuscularly	O
+immunized	O
+with	O
+different	O
+doses	O
+(	O
+50	O
+,	O
+100	O
+and	O
+200	O
+microg	O
+/	O
+mouse	B-SPEC
+)	O
+of	O
+pcDNA	O
+/	O
+N	O
+twice	O
+at	O
+a	O
+5	O
+-	O
+week	O
+interval	O
+.	O
+
+Moreover	O
+,	O
+spleen	B-ANAT
+cells	B-COMP
+from	O
+these	O
+mice	B-SPEC
+showed	O
+stronger	O
+immune	B-PROC
+responses	I-PROC
+than	O
+those	O
+from	O
+live	O
+vaccine	O
+or	O
+parental	O
+vector	O
+immunized	O
+mice	B-SPEC
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+construct	O
+can	O
+elicit	O
+both	O
+humoral	O
+and	O
+cell	B-COMP
+-	O
+mediated	O
+immune	O
+(	O
+CMI	O
+)	O
+responses	O
+against	O
+TGEV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+in	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+turkey	B-SPEC
+poults	O
+infected	O
+with	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Turkey	B-SPEC
+poults	O
+were	O
+orally	B-ANAT
+inoculated	O
+with	O
+TCV	B-SPEC
+at	O
+10	O
+d	O
+of	O
+age	O
+,	O
+and	O
+the	O
+immune	B-PROC
+responses	I-PROC
+were	O
+analyzed	O
+at	O
+1	O
+,	O
+3	O
+,	O
+7	O
+,	O
+14	O
+,	O
+21	O
+,	O
+28	O
+,	O
+42	O
+,	O
+and	O
+63	O
+d	O
+postinfection	O
+(	O
+PI	O
+)	O
+in	O
+three	O
+different	O
+experiments	O
+.	O
+
+In	O
+addition	O
+,	O
+Ig	O
+gradually	O
+increased	O
+from	O
+7	O
+to	O
+21	O
+d	O
+PI	O
+and	O
+remained	O
+at	O
+80	O
+immunofluroescent	O
+antibody	B-COMP
+assay	O
+(	O
+IFA	O
+)	O
+titers	O
+or	O
+more	O
+thereafter	O
+.	O
+
+Lymphocyte	B-PROC
+proliferation	B-DISO
+responses	O
+of	O
+spleen	B-ANAT
+cells	B-COMP
+to	O
+concanavalin	O
+A	O
+were	O
+higher	O
+in	O
+TCV	B-SPEC
+-	O
+infected	O
+turkeys	B-SPEC
+than	O
+in	O
+noninfected	O
+control	O
+turkeys	B-SPEC
+with	O
+significant	O
+differences	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+being	O
+noted	O
+at	O
+14	O
+and	O
+63	O
+d	O
+PI	O
+in	O
+Experiment	O
+2	O
+and	O
+at	O
+3	O
+and	O
+28	O
+d	O
+PI	O
+in	O
+Experiment	O
+3	O
+.	O
+
+In	O
+Experiment	O
+3	O
+,	O
+the	O
+IgG	B-PRGE
+isotype	I-PRGE
+antibody	I-PRGE
+response	O
+to	O
+TCV	B-SPEC
+was	O
+markedly	O
+increased	O
+after	O
+21	O
+d	O
+PI	O
+and	O
+remained	O
+high	O
+until	O
+63	O
+d	O
+PI	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+is	O
+one	O
+of	O
+the	O
+viral	O
+proteinases	O
+responsible	O
+for	O
+processing	O
+of	O
+the	O
+1a	O
+and	O
+1a	O
+/	O
+1b	O
+polyproteins	O
+to	O
+multiple	O
+mature	O
+products	O
+.	O
+
+In	O
+cells	B-COMP
+infected	O
+with	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+three	O
+proteins	B-CHED
+of	O
+100	O
+,	O
+39	O
+,	O
+and	O
+35	O
+kDa	O
+,	O
+respectively	O
+,	O
+were	O
+previously	O
+identified	O
+as	O
+mature	O
+cleavage	B-PROC
+products	O
+released	O
+from	O
+the	O
+1b	O
+region	O
+of	O
+the	O
+1a	O
+/	O
+1b	O
+polyprotein	O
+by	O
+the	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	I-PRGE
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+show	O
+the	O
+identification	O
+of	O
+two	O
+more	O
+cleavage	B-PROC
+products	O
+of	O
+68	O
+and	O
+58	O
+kDa	O
+released	O
+from	O
+the	O
+same	O
+region	O
+of	O
+the	O
+polyprotein	O
+.	O
+
+However	O
+,	O
+while	O
+virus	B-SPEC
+was	O
+cleared	O
+from	O
+the	O
+CNS	B-CHED
+of	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+,	O
+virus	B-SPEC
+persisted	O
+in	O
+the	O
+CNS	B-CHED
+of	O
+muMT	O
+mice	B-SPEC
+.	O
+
+To	O
+determine	O
+how	O
+B	B-ANAT
+cells	I-ANAT
+mediate	O
+viral	O
+clearance	O
+,	O
+we	O
+first	O
+assessed	O
+CD4	B-PRGE
+(+)	O
+T	B-PROC
+cell	I-PROC
+activation	I-PROC
+in	O
+the	O
+absence	O
+of	O
+B	B-ANAT
+cells	I-ANAT
+as	O
+APC	B-COMP
+.	O
+
+The	O
+muMT	O
+mice	B-SPEC
+that	O
+received	O
+A59	O
+-	O
+specific	O
+Ab	O
+had	O
+decreased	O
+virus	B-SPEC
+,	O
+while	O
+mice	B-SPEC
+with	O
+B	B-ANAT
+cells	I-ANAT
+deficient	O
+in	O
+Ab	O
+secretion	B-PROC
+did	O
+not	O
+clear	O
+virus	B-SPEC
+from	O
+the	O
+CNS	B-CHED
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+clearance	O
+of	O
+infectious	B-DISO
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+from	O
+the	O
+CNS	B-CHED
+requires	O
+Ab	O
+production	O
+and	O
+perhaps	O
+B	B-ANAT
+cell	I-ANAT
+support	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+;	O
+however	O
+,	O
+virus	B-SPEC
+is	O
+cleared	O
+from	O
+the	O
+liver	B-ANAT
+without	O
+the	O
+involvement	O
+of	O
+Abs	O
+or	O
+B	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+determined	O
+pulmonary	B-ANAT
+oxygen	B-CHED
+consumption	O
+(	O
+VO2lung	O
+)	O
+in	O
+low	O
+-	O
+birthweight	O
+infants	O
+with	O
+acute	O
+lung	B-DISO
+disease	I-DISO
+to	O
+help	O
+explain	O
+the	O
+greater	O
+whole	O
+-	O
+body	B-ANAT
+oxygen	B-CHED
+consumption	O
+(	O
+VO2wb	O
+)	O
+in	O
+these	O
+infants	O
+with	O
+than	O
+in	O
+those	O
+without	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+Randomized	O
+,	O
+controlled	O
+experimental	O
+study	O
+in	O
+an	O
+animal	B-SPEC
+research	O
+laboratory	O
+.	O
+
+Hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+,	O
+intra	O
+-	O
+alveolar	B-ANAT
+neutrophil	B-ANAT
+(	O
+PMN	B-PROC
+)	O
+accumulation	O
+and	O
+intra	O
+-	O
+alveolar	B-ANAT
+/	O
+perivascular	O
+haemorrhage	B-DISO
+were	O
+graded	O
+semiquantitatively	O
+(	O
+0	O
+-	O
+4	O
+).	O
+
+Benefits	O
+of	O
+HFOV	O
+in	O
+terms	O
+of	O
+CLD	B-DISO
+appear	O
+to	O
+be	O
+outweighed	O
+by	O
+concerns	O
+about	O
+increased	O
+rates	O
+of	O
+pulmonary	B-ANAT
+air	B-CHED
+leak	O
+and	O
+severe	O
+IVH	O
+.	O
+
+ARDS	B-DISO
+usually	O
+appears	O
+within	O
+12	O
+to	O
+72	O
+hours	O
+of	O
+an	O
+identifiable	O
+clinical	O
+event	O
+and	O
+progresses	O
+through	O
+three	O
+phases	O
+:	O
+1	O
+.	O
+
+exudative	O
+phase	O
+;	O
+2	O
+.	O
+alveolar	B-ANAT
+membrane	B-COMP
+damage	O
+and	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+systems	O
+;	O
+and	O
+3	O
+.	O
+
+Nearly	O
+all	O
+of	O
+the	O
+deaths	B-PROC
+occur	O
+within	O
+30	O
+days	O
+of	O
+the	O
+onset	O
+of	O
+the	O
+syndrome	B-DISO
+.	O
+
+TITLE	O
+:	O
+Auricular	B-ANAT
+chondritis	B-DISO
+in	O
+a	O
+cat	B-SPEC
+.	O
+
+The	O
+ear	B-DISO
+disease	I-DISO
+responded	O
+rapidly	O
+to	O
+treatment	O
+with	O
+prednisolone	B-CHED
+and	O
+,	O
+apart	O
+from	O
+slight	O
+thickening	O
+and	O
+curling	O
+of	O
+the	O
+pinnae	O
+,	O
+the	O
+cat	B-SPEC
+remained	O
+normal	O
+and	O
+pain	O
+-	O
+free	O
+.	O
+
+After	O
+two	O
+years	O
+,	O
+the	O
+prednisolone	B-CHED
+was	O
+withdrawn	B-DISO
+,	O
+and	O
+there	O
+was	O
+no	O
+recurrence	B-DISO
+of	O
+the	O
+condition	B-DISO
+in	O
+a	O
+follow	O
+-	O
+up	O
+period	O
+of	O
+14	O
+months	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+protein	B-CHED
+encoded	O
+by	O
+ORF	O
+4	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+is	O
+not	O
+required	O
+for	O
+growth	B-PROC
+of	O
+some	O
+strains	O
+in	O
+tissue	B-ANAT
+culture	O
+cells	B-COMP
+,	O
+but	O
+its	O
+role	O
+in	O
+pathogenesis	B-DISO
+in	O
+the	O
+murine	B-SPEC
+host	B-COMP
+has	O
+not	O
+been	O
+defined	O
+previously	O
+in	O
+a	O
+controlled	O
+manner	O
+.	O
+
+Srr7	O
+showed	O
+apparently	O
+reduced	O
+neurovirulence	O
+relative	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+(	O
+wt	O
+)	O
+JHMV	O
+in	O
+terms	O
+of	O
+the	O
+LD50	O
+and	O
+survival	O
+time	O
+,	O
+while	O
+the	O
+others	O
+showed	O
+slightly	O
+reduced	O
+virulence	B-PROC
+.	O
+
+The	O
+major	O
+difference	O
+was	O
+that	O
+apoptotic	O
+cells	O
+were	O
+frequently	O
+encountered	O
+in	O
+the	O
+srr7	O
+-	O
+infected	O
+mouse	B-ANAT
+brain	I-ANAT
+,	O
+but	O
+not	O
+in	O
+wt	O
+-	O
+infected	O
+mice	B-SPEC
+on	O
+day	O
+2	O
+p	O
+.	O
+i	O
+.	O
+
+Military	O
+research	O
+altitude	O
+chamber	B-ANAT
+.	O
+
+Positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+increases	O
+from	O
+5	O
+to	O
+12	O
+.	O
+5	O
+cm	O
+H2O	B-CHED
+were	O
+required	O
+to	O
+bring	O
+the	O
+PaO2	O
+in	O
+the	O
+injured	O
+pigs	B-SPEC
+to	O
+75	O
+torr	O
+(	O
+10	O
+.	O
+0	O
+kPa	O
+).	O
+
+One	O
+animal	B-SPEC
+crossed	O
+over	O
+from	O
+Fio2	O
+to	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+and	O
+achieved	O
+a	O
+PaO2	O
+of	O
+75	O
+torr	O
+(	O
+10	O
+.	O
+0	O
+kPa	O
+)	O
+with	O
+5	O
+cm	O
+H2O	B-CHED
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+.	O
+
+TITLE	O
+:	O
+Secondary	O
+structural	O
+elements	O
+within	O
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+JHM	O
+genomic	O
+RNA	O
+.	O
+
+ABSTRACT	O
+:	O
+Previously	O
+,	O
+we	O
+characterized	O
+two	O
+host	O
+protein	B-FUNC
+binding	I-FUNC
+elements	O
+located	O
+within	O
+the	O
+3	O
+'-	O
+terminal	O
+166	O
+nucleotides	B-CHED
+of	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+genome	O
+and	O
+assessed	O
+their	O
+functions	O
+in	O
+defective	O
+-	O
+interfering	O
+(	O
+DI	O
+)	O
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+To	O
+determine	O
+the	O
+role	O
+of	O
+RNA	O
+secondary	O
+structures	O
+within	O
+these	O
+two	O
+host	B-COMP
+protein	B-FUNC
+binding	I-FUNC
+elements	O
+in	O
+viral	B-PROC
+replication	I-PROC
+,	O
+we	O
+explored	O
+the	O
+secondary	O
+structure	O
+of	O
+the	O
+3	O
+'-	O
+terminal	O
+166	O
+nucleotides	B-CHED
+of	O
+the	O
+MHV	B-SPEC
+strain	O
+JHM	O
+genome	O
+using	O
+limited	O
+RNase	B-PRGE
+digestion	B-PROC
+assays	O
+.	O
+
+Mutant	B-DISO
+and	O
+wild	O
+-	O
+type	O
+DIssEs	O
+were	O
+employed	O
+to	O
+test	O
+the	O
+function	O
+of	O
+secondary	O
+structure	O
+elements	O
+in	O
+DI	O
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+Mutations	O
+interfering	O
+with	O
+the	O
+pairing	O
+of	O
+nucleotides	B-CHED
+67	O
+to	O
+63	O
+with	O
+nucleotides	B-CHED
+52	O
+to	O
+56	O
+had	O
+only	O
+minor	O
+effects	O
+on	O
+DIssE	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+difference	O
+in	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+compositions	O
+between	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+virion	B-COMP
+and	O
+the	O
+core	O
+has	O
+been	O
+studied	O
+.	O
+
+ABSTRACT	O
+:	O
+Major	O
+advances	O
+in	O
+the	O
+study	O
+of	O
+the	O
+molecular	O
+biology	O
+of	O
+RNA	O
+viruses	O
+have	O
+resulted	O
+from	O
+the	O
+ability	O
+to	O
+generate	O
+and	O
+manipulate	O
+full	O
+-	O
+length	O
+genomic	O
+cDNAs	O
+of	O
+the	O
+viral	O
+genomes	O
+with	O
+the	O
+subsequent	O
+synthesis	B-PROC
+of	O
+infectious	B-DISO
+RNA	O
+for	O
+the	O
+generation	O
+of	O
+recombinant	O
+viruses	B-SPEC
+.	O
+
+Patients	O
+with	O
+major	O
+trauma	O
+underwent	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+levels	O
+were	O
+measured	O
+in	O
+BAL	B-ENZY
+fluid	O
+by	O
+ELISA	O
+.	O
+
+Human	B-SPEC
+macrophages	B-ANAT
+were	O
+derived	O
+from	O
+peripheral	B-ANAT
+blood	I-ANAT
+monocytes	B-ANAT
+from	O
+healthy	O
+volunteers	O
+.	O
+
+Rabbit	B-SPEC
+alveolar	B-ANAT
+macrophages	I-ANAT
+were	O
+obtained	O
+from	O
+ex	O
+-	O
+vivo	O
+lavage	O
+of	O
+healthy	O
+rabbit	B-SPEC
+lungs	B-ANAT
+.	O
+
+Macrophages	B-ANAT
+were	O
+culture	O
+under	O
+normoxic	O
+or	O
+hypoxic	O
+(	O
+PO2	B-PROC
+26	O
+mmHg	O
+)	O
+conditions	O
+.	O
+
+In	O
+human	B-SPEC
+monocyte	B-ANAT
+derived	I-ANAT
+macrophages	I-ANAT
+hypoxia	B-DISO
+rapidly	O
+upregulated	O
+IL	B-PRGE
+-	I-PRGE
+8	I-PRGE
+protein	B-CHED
+(	O
+within	O
+2	O
+hours	O
+)	O
+and	O
+mRNA	B-PROC
+expression	B-PROC
+(	O
+within	O
+30	O
+mins	O
+).	O
+
+Hypoxia	B-DISO
+increased	O
+DNA	B-FUNC
+binding	I-FUNC
+activity	O
+of	O
+AP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+C	B-PRGE
+/	I-PRGE
+EBP	I-PRGE
+but	O
+not	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+.	O
+Hypoxia	B-DISO
+induced	O
+HIF	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expression	B-PROC
+,	O
+but	O
+cobaltous	O
+ions	B-CHED
+and	O
+desferrioxamine	B-CHED
+did	O
+not	O
+mimic	O
+hypoxic	B-DISO
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+induction	O
+.	O
+
+Hypoxia	B-DISO
+downregulated	O
+a	O
+range	O
+of	O
+other	O
+proinflammatory	O
+mediators	O
+,	O
+including	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+ultrastructural	O
+characterization	O
+of	O
+a	O
+novel	O
+virus	B-SPEC
+from	O
+fish	B-SPEC
+.	O
+
+The	O
+virion	B-COMP
+has	O
+a	O
+bacilliform	O
+shape	O
+(	O
+170	O
+-	O
+200x75	O
+-	O
+88	O
+nm	O
+)	O
+reminiscent	O
+of	O
+rhabdoviruses	B-SPEC
+with	O
+an	O
+envelope	B-COMP
+containing	O
+coronavirus	B-SPEC
+-	O
+like	O
+spikes	O
+(	O
+20	O
+-	O
+25	O
+nm	O
+).	O
+
+The	O
+buoyant	O
+density	O
+of	O
+the	O
+virus	B-SPEC
+determined	O
+in	O
+sucrose	B-CHED
+was	O
+1	O
+.	O
+17	O
+-	O
+1	O
+.	O
+19	O
+g	O
+/	O
+ml	O
+.	O
+
+Preliminary	O
+biochemical	O
+characterization	O
+revealed	O
+the	O
+presence	O
+of	O
+six	B-PRGE
+antigenic	I-PRGE
+glycoproteins	I-PRGE
+,	O
+three	O
+of	O
+which	O
+contain	O
+sugars	O
+with	O
+concanavalin	O
+-	O
+A	O
+specificity	O
+.	O
+
+In	O
+summary	O
+,	O
+the	O
+first	O
+characterization	O
+of	O
+a	O
+new	O
+virus	B-SPEC
+that	O
+might	O
+represent	O
+a	O
+member	O
+of	O
+a	O
+novel	O
+virus	B-SPEC
+family	B-SPEC
+that	O
+has	O
+morphological	O
+features	O
+resembling	O
+those	O
+found	O
+in	O
+rhabdo	O
+-,	O
+corona	B-CHED
+-	O
+and	O
+baculoviruses	O
+is	O
+presented	O
+.	O
+
+15	O
+male	O
+Suffolk	O
+sheep	B-SPEC
+.	O
+
+Mean	O
+systemic	O
+arterial	B-PROC
+pressure	I-PROC
+,	O
+mean	O
+pulmonary	B-ANAT
+arterial	B-PROC
+pressure	I-PROC
+,	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+(	O
+PO2	B-PROC
+),	O
+pulmonary	B-PRGE
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+,	O
+and	O
+neutrophil	B-ANAT
+respiratory	B-PROC
+burst	I-PROC
+activity	O
+.	O
+
+It	O
+reduced	O
+pulmonary	B-PRGE
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+and	O
+peripheral	O
+neutropenia	O
+and	O
+increased	O
+neutrophil	B-ANAT
+respiratory	B-PROC
+burst	I-PROC
+activity	O
+.	O
+
+This	O
+data	O
+suggest	O
+that	O
+taurine	B-CHED
+may	O
+have	O
+a	O
+therapeutic	O
+role	O
+in	O
+preventing	O
+the	O
+lung	B-ANAT
+injury	O
+seen	O
+in	O
+endotoxaemia	O
+.	O
+
+We	O
+report	O
+a	O
+severe	O
+form	O
+of	O
+GBL	O
+withdrawal	B-DISO
+,	O
+characterized	O
+by	O
+delirium	B-DISO
+,	O
+psychosis	B-DISO
+,	O
+autonomic	B-DISO
+instability	I-DISO
+,	O
+and	O
+resistance	B-PROC
+to	O
+benzodiazepine	B-CHED
+therapy	O
+.	O
+
+Test	O
+results	O
+for	O
+ethanol	B-CHED
+and	O
+routine	O
+drugs	O
+of	O
+abuse	B-DISO
+were	O
+negative	O
+.	O
+
+Pentobarbital	B-CHED
+was	O
+then	O
+administered	O
+,	O
+resulting	O
+in	O
+excellent	O
+control	O
+of	O
+behavioral	B-PROC
+,	O
+autonomic	B-ANAT
+,	O
+and	O
+psychiatric	B-DISO
+symptoms	I-DISO
+and	O
+in	O
+rapid	O
+reduction	O
+or	O
+avoidance	O
+of	O
+benzodiazepines	B-CHED
+.	O
+
+GBL	O
+discontinuation	O
+can	O
+result	O
+in	O
+severe	O
+withdrawal	B-DISO
+,	O
+necessitating	O
+ICU	O
+admission	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	O
+(	O
+TGE	B-DISO
+)	O
+and	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+are	O
+highly	O
+contagious	O
+enteric	O
+diseases	O
+of	O
+piglets	O
+.	O
+
+This	O
+completes	O
+the	O
+sequence	O
+of	O
+the	O
+entire	O
+genome	O
+of	O
+strain	O
+CV777	O
+,	O
+which	O
+was	O
+found	O
+to	O
+be	O
+28	O
+,	O
+033	O
+nucleotides	B-CHED
+(	O
+nt	O
+)	O
+in	O
+length	O
+(	O
+excluding	O
+the	O
+poly	O
+A	O
+-	O
+tail	O
+).	O
+
+Primary	O
+sequences	O
+derived	O
+from	O
+these	O
+products	O
+were	O
+used	O
+to	O
+design	O
+additional	O
+primers	O
+resulting	O
+in	O
+the	O
+amplification	B-DISO
+and	O
+sequencing	O
+of	O
+the	O
+entire	O
+ORF1	O
+of	O
+PEDV	B-SPEC
+.	O
+
+By	O
+analogy	O
+to	O
+other	O
+coronavirus	B-PRGE
+replicase	I-PRGE
+gene	I-PRGE
+products	I-PRGE
+,	O
+three	O
+protease	O
+and	O
+one	O
+growth	B-PROC
+factor	O
+-	O
+like	O
+motif	O
+were	O
+seen	O
+in	O
+ORF1a	O
+,	O
+and	O
+one	O
+polymerase	O
+domain	O
+,	O
+one	O
+metal	B-CHED
+ion	O
+-	O
+binding	B-FUNC
+domain	O
+,	O
+and	O
+one	O
+helicase	B-PRGE
+motif	I-PRGE
+could	O
+be	O
+assigned	O
+within	O
+ORF1b	O
+.	O
+
+Percentages	O
+of	O
+intrahepatic	O
+CD4	B-PRGE
+(+)	O
+cells	B-COMP
+decreased	O
+in	O
+attenuated	O
+YAC	O
+-	O
+MHV3	O
+-	O
+infected	O
+mice	B-SPEC
+,	O
+while	O
+they	O
+increased	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+pathogenic	O
+L2	O
+-	O
+MHV3	O
+,	O
+compared	O
+with	O
+uninfected	O
+animals	B-SPEC
+.	O
+
+Ex	O
+vivo	O
+studies	O
+showed	O
+that	O
+only	O
+the	O
+intrahepatic	O
+CD8	B-PRGE
+(+)	O
+cells	B-COMP
+that	O
+were	O
+increased	O
+in	O
+YAC	O
+-	O
+MHV3	O
+-	O
+infected	O
+mice	B-SPEC
+could	O
+be	O
+stimulated	O
+by	O
+lectins	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+attenuated	O
+phenotype	O
+of	O
+the	O
+YAC	O
+-	O
+MHV3	O
+virus	B-SPEC
+is	O
+related	O
+to	O
+two	O
+different	O
+mechanisms	O
+:	O
+the	O
+first	O
+involves	O
+no	O
+increase	O
+of	O
+intrahepatic	O
+CD4	B-PRGE
+(+)	I-PRGE
+alphabeta	I-PRGE
+-	I-PRGE
+TCR	I-PRGE
+(	O
+inter	O
+)	O
+or	O
+NK	O
+-	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+while	O
+the	O
+second	O
+favors	O
+the	O
+recruitment	B-DISO
+and	O
+activation	O
+of	O
+CD8	B-PRGE
+(+)	O
+cells	B-COMP
+in	O
+liver	B-ANAT
+.	O
+
+Major	O
+protein	O
+bands	O
+of	O
+purified	O
+viruses	B-SPEC
+analyzed	O
+by	O
+SDS	B-DISO
+-	O
+PAGE	O
+were	O
+located	O
+at	O
+200	O
+,	O
+100	O
+-	O
+110	O
+,	O
+50	O
+-	O
+60	O
+,	O
+and	O
+30	O
+-	O
+35	O
+kDa	O
+.	O
+
+A	O
+568	O
+bp	O
+nucleotide	B-CHED
+fragment	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+gene	O
+was	O
+amplified	O
+from	O
+RNA	O
+of	O
+inoculated	O
+turkey	B-SPEC
+embryo	B-ANAT
+intestine	B-ANAT
+or	O
+purified	O
+virus	B-SPEC
+.	O
+
+They	O
+also	O
+indicate	O
+that	O
+genetic	O
+RNA	O
+recombination	B-PROC
+(	O
+especially	O
+the	O
+nonhomologous	O
+one	O
+)	O
+is	O
+a	O
+major	O
+factor	O
+responsible	O
+for	O
+the	O
+emergence	O
+of	O
+new	O
+viral	O
+strains	O
+or	O
+species	B-SPEC
+.	O
+
+Among	O
+them	O
+,	O
+brome	B-SPEC
+mosaic	I-SPEC
+virus	I-SPEC
+(	O
+BMV	B-SPEC
+),	O
+a	O
+model	O
+(+)	O
+RNA	O
+virus	B-SPEC
+offers	O
+the	O
+best	O
+opportunities	O
+to	O
+investigate	O
+various	O
+aspects	O
+of	O
+genetic	O
+RNA	O
+recombination	B-PROC
+in	O
+vivo	O
+.	O
+
+That	O
+is	O
+why	O
+in	O
+this	O
+review	O
+we	O
+present	O
+and	O
+thoroughly	O
+discuss	O
+all	O
+results	O
+concerning	O
+nonhomologous	O
+recombination	B-PROC
+in	O
+BMV	B-SPEC
+that	O
+have	O
+been	O
+obtained	O
+until	O
+now	O
+.	O
+
+There	O
+were	O
+four	O
+dietary	O
+treatments	O
+in	O
+Experiment	O
+1	O
+representing	O
+a	O
+2	O
+x	O
+2	O
+factorial	O
+design	O
+of	O
+additional	O
+Arg	B-CHED
+(	O
+120	O
+%	O
+of	O
+NRC	O
+)	O
+or	O
+additional	O
+Lys	B-CHED
+(	O
+120	O
+%	O
+of	O
+NRC	O
+)	O
+added	O
+to	O
+a	O
+control	O
+diet	O
+containing	O
+100	O
+%	O
+of	O
+NRC	O
+Arg	B-CHED
+and	O
+Lys	B-CHED
+(	O
+six	O
+replications	O
+per	O
+treatment	O
+).	O
+
+In	O
+Experiment	O
+2	O
+,	O
+treatment	O
+differences	O
+in	O
+growth	B-PROC
+responses	O
+,	O
+lymphoid	B-ANAT
+organ	I-ANAT
+development	O
+,	O
+and	O
+primary	O
+antibody	B-COMP
+titers	O
+to	O
+SRBC	O
+did	O
+not	O
+occur	O
+.	O
+
+A	O
+dietary	O
+Arg	B-CHED
+level	O
+near	O
+the	O
+NRC	O
+(	O
+1994	O
+)	O
+recommendation	O
+should	O
+support	O
+proper	O
+immune	B-ANAT
+system	I-ANAT
+functions	O
+in	O
+healthy	O
+chicks	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+relationship	O
+between	O
+the	O
+dietary	O
+level	O
+of	O
+vitamin	B-CHED
+E	I-CHED
+(	O
+VE	O
+)	O
+and	O
+the	O
+immune	B-PROC
+response	I-PROC
+of	O
+broilers	O
+was	O
+studied	O
+in	O
+three	O
+experiments	O
+.	O
+
+Immunity	B-PROC
+was	O
+assessed	O
+as	O
+antibody	B-PROC
+production	I-PROC
+to	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+SRBC	O
+,	O
+and	O
+Brucella	B-DISO
+abortus	I-DISO
+(	O
+BA	O
+)	O
+antigens	B-CHED
+,	O
+mitogenic	O
+response	O
+to	O
+phytohemagglutinin	O
+A	O
+(	O
+PHA	B-DISO
+)	O
+and	O
+concanavalin	O
+A	O
+(	O
+Con	B-PRGE
+A	I-PRGE
+),	O
+cutaneous	O
+basophil	B-ANAT
+hypersensitivity	B-DISO
+(	O
+CBH	O
+)	O
+to	O
+PHA	B-DISO
+,	O
+and	O
+lipopolysaccharide	B-CHED
+induction	O
+of	O
+acute	O
+-	O
+phase	O
+proteins	B-CHED
+(	O
+APP	B-CHED
+)	O
+and	O
+heterophilia	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+vascular	B-PROC
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PROC
+and	O
+Flt	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+fetuses	B-ANAT
+,	O
+in	O
+acute	O
+and	O
+chronic	B-DISO
+lung	B-ANAT
+disease	I-DISO
+,	O
+and	O
+in	O
+persistent	O
+pulmonary	O
+hypertension	O
+of	O
+the	O
+newborn	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+RDS	O
+)	O
+and	O
+development	B-PROC
+of	O
+bronchopulmonary	B-DISO
+dysplasia	I-DISO
+(	O
+BPD	B-DISO
+)	O
+are	O
+characterized	O
+by	O
+endothelial	B-ANAT
+cell	I-ANAT
+damage	O
+.	O
+
+VEGF	B-PRGE
+was	O
+measured	O
+in	O
+tracheal	O
+aspirates	B-ANAT
+from	O
+31	O
+preterm	O
+infants	O
+,	O
+5	O
+intubated	O
+term	O
+infants	O
+without	O
+primary	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+12	O
+infants	O
+with	O
+PPHN	O
+during	O
+the	O
+first	O
+10	O
+postnatal	O
+days	O
+,	O
+and	O
+from	O
+8	O
+infants	O
+with	O
+BPD	B-DISO
+.	O
+
+Preterm	O
+infants	O
+with	O
+more	O
+severe	O
+RDS	O
+had	O
+lower	O
+VEGF	B-PRGE
+than	O
+those	O
+who	O
+recovered	O
+.	O
+
+The	O
+persistent	O
+expression	B-PROC
+of	O
+VEGF	B-PRGE
+and	O
+Flt	B-PRGE
+-	I-PRGE
+1	I-PRGE
+during	O
+the	O
+fetal	B-ANAT
+and	O
+neonatal	O
+period	O
+supports	O
+a	O
+physiological	B-CHED
+role	I-CHED
+for	O
+VEGF	B-PRGE
+in	O
+human	B-SPEC
+lung	B-PROC
+development	B-PROC
+.	O
+
+In	O
+PPHN	O
+,	O
+that	O
+more	O
+cell	B-COMP
+types	O
+express	O
+VEGF	B-PRGE
+and	O
+Flt	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+and	O
+the	O
+tendency	O
+toward	O
+a	O
+higher	O
+concentration	O
+of	O
+pulmonary	B-ANAT
+VEGF	B-PRGE
+may	O
+represent	O
+enhanced	O
+production	O
+of	O
+VEGF	B-PRGE
+in	O
+response	O
+to	O
+impaired	B-DISO
+endothelial	B-ANAT
+function	O
+.	O
+
+Comparisons	O
+were	O
+made	O
+between	O
+low	O
+and	O
+high	O
+tidal	O
+volume	O
+ventilation	O
+as	O
+well	O
+as	O
+across	O
+five	O
+PEEP	B-CHED
+levels	O
+.	O
+
+Static	O
+compliance	O
+was	O
+highest	O
+at	O
+PEEP	B-CHED
+of	O
+10	O
+and	O
+15	O
+cmH2O	O
+,	O
+regardless	O
+of	O
+tidal	O
+volume	O
+.	O
+
+With	O
+PEEP	B-CHED
+set	O
+at	O
+5	O
+cmH2O	O
+,	O
+static	O
+compliance	O
+was	O
+significantly	O
+lower	O
+with	O
+6	O
+mL	O
+/	O
+kg	O
+than	O
+with	O
+10	O
+mL	O
+/	O
+kg	O
+tidal	O
+volumes	O
+.	O
+
+The	O
+possible	O
+role	O
+of	O
+an	O
+immunopathologic	O
+response	O
+to	O
+T	O
+gondii	O
+in	O
+the	O
+lungs	B-ANAT
+in	O
+triggering	O
+ARDS	B-DISO
+is	O
+discussed	O
+.	O
+
+Fluorescence	O
+confocal	O
+microscopy	O
+of	O
+isolated	O
+bioconjugate	O
+-	O
+bound	O
+CHO	B-ANAT
+cells	B-COMP
+indicated	O
+that	O
+the	O
+bioconjugated	O
+nanoparticles	B-CHED
+were	O
+primarily	O
+located	O
+near	O
+the	O
+cell	B-COMP
+periphery	I-COMP
+;	O
+however	O
+,	O
+transduction	B-PROC
+of	O
+the	O
+nanoparticle	B-CHED
+into	O
+the	O
+cells	B-COMP
+also	O
+occurred	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+the	O
+receptor	B-PRGE
+tyrosine	I-PRGE
+kinase	I-PRGE
+Ron	B-PRGE
+in	O
+nickel	B-CHED
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+),	O
+a	O
+severe	O
+respiratory	O
+syndrome	B-DISO
+,	O
+develops	O
+in	O
+response	O
+to	O
+numerous	O
+insults	O
+and	O
+responds	O
+poorly	O
+to	O
+therapeutic	O
+intervention	O
+.	O
+
+ABSTRACT	O
+:	O
+VirOligo	O
+is	O
+a	O
+database	O
+of	O
+virus	O
+-	O
+specific	O
+oligonucleotides	B-CHED
+.	O
+
+Each	O
+oligonucleotide	B-CHED
+entry	O
+contains	O
+links	O
+to	O
+PubMed	O
+,	O
+GenBank	O
+,	O
+NCBI	O
+Taxonomy	O
+databases	O
+and	O
+BLAST	B-ANAT
+.	O
+
+The	O
+viruses	B-SPEC
+are	O
+bovine	B-SPEC
+herpes	B-SPEC
+virus	I-SPEC
+types	O
+1	O
+,	O
+3	O
+,	O
+4	O
+and	O
+5	O
+,	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+bovine	B-SPEC
+parainfluenza	I-SPEC
+3	I-SPEC
+virus	I-SPEC
+,	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+bovine	B-SPEC
+adenovirus	B-DISO
+,	O
+bovine	B-SPEC
+rhinovirus	B-SPEC
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+,	O
+bovine	B-SPEC
+reovirus	B-SPEC
+,	O
+bovine	B-SPEC
+enterovirus	I-SPEC
+and	O
+alcelaphine	B-SPEC
+herpesvirus	I-SPEC
+-	O
+1	O
+.	O
+
+for	O
+30	O
+min	O
+before	O
+the	O
+oleic	B-CHED
+acid	I-CHED
+and	O
+then	O
+0	O
+.	O
+5	O
+mg	O
+/	O
+kg	O
+/	O
+h	O
+,	O
+i	O
+.	O
+v	O
+.	O
+
+We	O
+conclude	O
+that	O
+methylprednisolone	B-CHED
+did	O
+not	O
+attenuate	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+this	O
+can	O
+be	O
+explained	O
+partly	O
+by	O
+its	O
+failure	O
+to	O
+reduce	O
+the	O
+increase	O
+of	O
+phospholipase	B-PRGE
+A	I-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+activity	O
+and	O
+the	O
+surfactant	B-CHED
+degradation	O
+in	O
+the	O
+lung	B-ANAT
+,	O
+which	O
+might	O
+also	O
+account	O
+for	O
+its	O
+clinical	O
+ineffectiveness	O
+against	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+report	O
+this	O
+case	O
+because	O
+it	O
+is	O
+relatively	O
+rare	O
+for	O
+PBC	B-DISO
+to	O
+be	O
+complicated	O
+by	O
+severe	O
+interstitial	B-DISO
+pneumonia	I-DISO
+,	O
+and	O
+it	O
+may	O
+offer	O
+insight	O
+into	O
+the	O
+etiology	O
+of	O
+these	O
+diseases	O
+.	O
+
+Despite	O
+development	B-PROC
+of	O
+new	O
+analgesic	B-CHED
+drugs	O
+and	O
+different	O
+therapeutic	O
+modalities	O
+in	O
+pain	O
+treatment	O
+,	O
+acute	O
+postoperative	B-DISO
+pain	I-DISO
+represents	O
+a	O
+negative	O
+experience	O
+for	O
+many	O
+surgical	O
+patients	O
+.	O
+
+Anesthesiologists	O
+have	O
+a	O
+central	O
+role	O
+in	O
+perioperative	O
+treatment	O
+of	O
+surgical	O
+patients	O
+(	O
+from	O
+the	O
+preoperative	O
+preparation	O
+through	O
+anesthesia	B-DISO
+and	O
+intraoperative	O
+monitoring	O
+to	O
+postoperative	O
+treatment	O
+and	O
+monitoring	O
+at	O
+the	O
+department	O
+of	O
+the	O
+intensive	O
+care	O
+and	O
+at	O
+the	O
+department	O
+of	O
+postanesthetic	O
+care	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+reasons	O
+of	O
+inefficacy	O
+of	O
+many	O
+analgesic	B-CHED
+therapeutic	O
+methods	O
+are	O
+multiple	O
+.	O
+
+Histopathology	O
+reveals	O
+surfactant	B-CHED
+disruption	O
+,	O
+epithelial	O
+perturbation	O
+and	O
+sepsis	B-DISO
+,	O
+either	O
+as	O
+initiating	O
+factors	O
+or	O
+as	O
+secondary	O
+complications	O
+,	O
+which	O
+in	O
+turn	O
+increase	O
+the	O
+expression	B-PROC
+of	O
+cytokines	O
+that	O
+sequester	O
+and	O
+activate	O
+inflammatory	B-ANAT
+cells	I-ANAT
+,	O
+most	O
+notably	O
+,	O
+neutrophils	B-ANAT
+.	O
+
+Together	O
+these	O
+events	O
+orchestrate	O
+the	O
+principal	O
+clinical	O
+manifestations	O
+of	O
+the	O
+syndrome	B-DISO
+,	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+atelectasis	B-DISO
+.	O
+
+TITLE	O
+:	O
+First	O
+isolation	O
+of	O
+rotavirus	B-SPEC
+associated	O
+with	O
+neonatal	B-DISO
+diarrhoea	I-DISO
+in	O
+guanacos	B-SPEC
+(	O
+Lama	B-SPEC
+guanicoe	I-SPEC
+)	O
+in	O
+the	O
+Argentinean	O
+Patagonia	O
+region	O
+.	O
+
+We	O
+determined	O
+the	O
+influence	O
+of	O
+trauma	O
+severity	O
+for	O
+endothelium	B-ANAT
+activation	O
+/	O
+injury	O
+by	O
+measurement	O
+of	O
+specific	O
+endothelial	B-ANAT
+cell	I-ANAT
+markers	O
+--	O
+soluble	O
+E	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+(	O
+sES	B-PRGE
+)	O
+and	O
+von	B-PRGE
+Willebrand	I-PRGE
+factor	I-PRGE
+antigen	I-PRGE
+(	O
+vWF	B-PRGE
+:	O
+Ag	O
+).	O
+
+Thirty	O
+six	O
+severely	O
+traumatized	O
+patients	O
+were	O
+stratified	O
+according	O
+to	O
+an	O
+Injury	O
+Severity	O
+Score	O
+(	O
+ISS	B-DISO
+).	O
+
+Significant	O
+correlation	O
+between	O
+plasma	B-ANAT
+vWF	B-PRGE
+:	O
+Ag	O
+and	O
+serum	B-COMP
+sES	B-PRGE
+concentration	O
+was	O
+also	O
+observed	O
+(	O
+Rs	O
+=	O
+0	O
+.	O
+501	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+This	O
+suggests	O
+that	O
+IBV	B-SPEC
+E	O
+is	O
+associated	O
+with	O
+the	O
+Golgi	B-COMP
+matrix	O
+through	O
+interactions	O
+of	O
+its	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+and	O
+may	O
+have	O
+interesting	O
+implications	O
+for	O
+coronavirus	B-SPEC
+assembly	O
+in	O
+early	O
+Golgi	B-COMP
+compartments	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Transcription	B-PROC
+regulatory	O
+sequences	O
+and	O
+mRNA	B-PROC
+expression	B-PROC
+levels	O
+in	O
+the	O
+coronavirus	B-SPEC
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+.	O
+
+The	O
+relevant	O
+sequences	O
+contributing	O
+to	O
+TRS	B-DISO
+activity	O
+have	O
+been	O
+studied	O
+by	O
+extending	O
+the	O
+CS	O
+5	O
+'	O
+upstream	O
+and	O
+3	O
+'	O
+downstream	O
+.	O
+
+As	O
+the	O
+E	O
+and	O
+M	O
+proteins	B-CHED
+are	O
+essential	O
+for	O
+TGEV	B-SPEC
+virion	B-COMP
+budding	B-PATH
+,	O
+these	O
+replicon	O
+RNAs	O
+should	O
+replicate	O
+but	O
+not	O
+result	O
+in	O
+the	O
+production	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+.	O
+
+Leader	O
+-	O
+containing	O
+GFP	O
+transcripts	O
+containing	O
+the	O
+ORF	O
+3B	O
+and	O
+E	O
+gene	B-PROC
+deletions	I-PROC
+were	O
+detected	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+When	O
+proper	O
+dialysis	B-SPEC
+and	O
+intensive	O
+care	O
+facilities	O
+together	O
+with	O
+around	O
+the	O
+clock	O
+dedicated	O
+human	B-SPEC
+effort	B-PROC
+are	O
+available	O
+,	O
+crush	O
+injury	O
+-	O
+related	O
+ARF	B-DISO
+patients	O
+have	O
+a	O
+lower	O
+mortality	O
+.	O
+
+Mortality	O
+,	O
+when	O
+it	O
+occurs	O
+,	O
+is	O
+mainly	O
+associated	O
+with	O
+thoracic	B-DISO
+and	O
+abdominal	B-ANAT
+trauma	O
+and	O
+medical	O
+problems	O
+such	O
+as	O
+DIC	B-DISO
+and	O
+/	O
+or	O
+ARDS	B-DISO
+/	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+often	O
+in	O
+conjunction	O
+with	O
+sepsis	B-DISO
+.	O
+
+This	O
+in	O
+turn	O
+will	O
+allow	O
+new	O
+approaches	O
+to	O
+the	O
+study	O
+of	O
+viral	O
+and	O
+cellular	B-COMP
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+,	O
+as	O
+methods	O
+to	O
+study	O
+the	O
+biology	O
+and	O
+pathogenesis	B-DISO
+of	O
+MHV	B-SPEC
+infection	B-DISO
+at	O
+a	O
+cellular	B-COMP
+level	O
+.	O
+
+To	O
+examine	O
+age	O
+as	O
+an	O
+independent	O
+risk	O
+factor	O
+in	O
+recovery	O
+and	O
+intensive	O
+care	O
+unit	O
+discharge	B-ANAT
+after	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+In	O
+a	O
+multivariable	O
+Cox	O
+proportional	O
+hazards	O
+analysis	O
+,	O
+age	O
+of	O
+70	O
+years	O
+or	O
+older	O
+was	O
+a	O
+strong	O
+predictor	O
+of	O
+in	O
+-	O
+hospital	O
+death	B-PROC
+(	O
+hazard	O
+ratio	O
+,	O
+2	O
+.	O
+5	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+2	O
+.	O
+0	O
+to	O
+3	O
+.	O
+2	O
+];	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Although	O
+the	O
+survival	O
+rate	O
+among	O
+patients	O
+70	O
+years	O
+of	O
+age	O
+or	O
+older	O
+was	O
+high	O
+,	O
+these	O
+patients	O
+were	O
+twice	O
+as	O
+likely	O
+to	O
+die	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+compared	O
+with	O
+their	O
+younger	O
+counterparts	O
+,	O
+even	O
+after	O
+adjustment	O
+for	O
+covariates	O
+.	O
+
+ABSTRACT	O
+:	O
+Three	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+,	O
+CU82792	O
+,	O
+CU82805	O
+,	O
+and	O
+CU82808	O
+,	O
+were	O
+recovered	O
+from	O
+sentinel	O
+chickens	B-SPEC
+placed	O
+with	O
+three	O
+different	O
+layer	B-ANAT
+flocks	O
+of	O
+a	O
+large	O
+commercial	O
+poultry	O
+farm	O
+in	O
+New	O
+York	O
+State	O
+.	O
+
+Flocks	O
+had	O
+an	O
+ongoing	O
+history	O
+of	O
+bacterial	O
+-	O
+complicated	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+mortality	O
+rates	O
+as	O
+high	O
+as	O
+28	O
+%	O
+in	O
+spite	O
+of	O
+receiving	O
+live	O
+vaccinations	O
+for	O
+Massachusetts	O
+and	O
+Connecticut	O
+strains	O
+of	O
+IBV	B-SPEC
+.	O
+
+Three	O
+isolates	O
+(	O
+18	O
+%)	O
+were	O
+similar	O
+to	O
+the	O
+BL	O
+-	O
+56	O
+genotype	O
+,	O
+a	O
+unique	O
+Mexican	O
+IBV	B-SPEC
+strain	O
+observed	O
+initially	O
+in	O
+1996	O
+.	O
+
+The	O
+acute	O
+and	O
+severe	O
+proliferation	B-DISO
+of	O
+lung	B-ANAT
+macrophages	B-ANAT
+may	O
+cause	O
+acute	O
+respiratory	B-DISO
+dysfunction	I-DISO
+and	O
+be	O
+one	O
+of	O
+the	O
+factors	O
+inducing	O
+mortality	O
+in	O
+infected	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+earlier	O
+studies	O
+in	O
+our	O
+laboratory	O
+,	O
+we	O
+found	O
+that	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+was	O
+pathogenic	O
+for	O
+1	O
+-	O
+day	O
+-	O
+old	O
+turkey	B-SPEC
+poults	O
+.	O
+
+Both	O
+the	O
+one	O
+-	O
+step	O
+RT	O
+-	O
+PCR	O
+and	O
+the	O
+nested	O
+PCR	O
+amplified	O
+cell	B-COMP
+culture	O
+-	O
+passaged	O
+isolates	O
+of	O
+calf	B-ANAT
+diarrhea	B-DISO
+strains	O
+of	O
+BCV	B-SPEC
+but	O
+none	O
+of	O
+the	O
+15	O
+tested	O
+TOCVs	O
+or	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+of	O
+swine	B-SPEC
+.	O
+
+TOCVs	O
+also	O
+did	O
+not	O
+cross	O
+-	O
+react	O
+in	O
+a	O
+BCV	O
+antigen	B-CHED
+-	O
+capture	O
+(	O
+AC	O
+)	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+system	O
+with	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+against	O
+N	O
+,	O
+spike	O
+glycoprotein	B-CHED
+,	O
+and	O
+hemagglutinin	B-PRGE
+esterase	I-PRGE
+glycoprotein	I-PRGE
+proteins	B-CHED
+of	O
+BCV	B-SPEC
+as	O
+coating	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+Mortality	O
+patterns	O
+associated	O
+with	O
+poult	O
+enteritis	B-DISO
+mortality	O
+syndrome	B-DISO
+(	O
+PEMS	B-DISO
+)	O
+and	O
+coronaviral	O
+enteritis	O
+in	O
+turkey	B-SPEC
+flocks	O
+raised	O
+in	O
+PEMS	B-DISO
+-	O
+affected	O
+regions	O
+.	O
+
+This	O
+study	O
+was	O
+designed	O
+to	O
+establish	O
+mortality	O
+patterns	O
+for	O
+flocks	O
+experiencing	O
+excess	O
+mortality	O
+and	O
+TCV	B-SPEC
+infection	B-DISO
+in	O
+PEMS	O
+-	O
+affected	O
+regions	O
+and	O
+to	O
+delineate	O
+the	O
+possible	O
+role	O
+of	O
+TCV	B-SPEC
+in	O
+PEMS	O
+-	O
+affected	O
+flocks	O
+.	O
+
+Four	O
+health	O
+status	O
+groups	O
+were	O
+evident	O
+:	O
+healthy	O
+,	O
+PEMS	O
+positive	O
+,	O
+TCV	B-SPEC
+positive	O
+,	O
+and	O
+PEMS	O
++	O
+TCV	B-SPEC
+positive	O
+.	O
+
+His	O
+absorbed	O
+-	O
+dose	O
+distribution	O
+throughout	O
+the	O
+body	B-ANAT
+was	O
+very	O
+inhomogeneous	O
+because	O
+of	O
+the	O
+closeness	O
+of	O
+the	O
+standing	B-PROC
+point	O
+to	O
+the	O
+mixing	O
+tank	O
+.	O
+
+Restoration	O
+of	O
+the	O
+bone	B-ANAT
+marrow	I-ANAT
+function	O
+,	O
+prevention	O
+of	O
+skin	B-ANAT
+fibrosis	B-DISO
+,	O
+radiation	O
+lung	B-ANAT
+damage	O
+,	O
+and	O
+repair	B-PROC
+of	O
+gastrointestinal	B-ANAT
+mucosa	I-ANAT
+,	O
+and	O
+final	O
+recovery	O
+of	O
+the	O
+patient	O
+were	O
+elusive	O
+.	O
+
+The	O
+parents	O
+filled	O
+a	O
+questionnaire	O
+about	O
+the	O
+occurrence	O
+of	O
+respiratory	B-DISO
+symptoms	I-DISO
+four	O
+weeks	O
+before	O
+and	O
+two	O
+weeks	O
+after	O
+the	O
+surgery	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+spleen	B-ANAT
+cell	B-COMP
+-	O
+derived	O
+supernatants	O
+(	O
+natural	O
+IFN	B-PRGE
+)	O
+inhibited	O
+tracheal	B-DISO
+ring	I-DISO
+ciliostasis	O
+mediated	O
+by	O
+the	O
+Gray	O
+strain	O
+of	O
+IBV	O
+.	O
+
+After	O
+2	O
+or	O
+6	O
+hours	O
+of	O
+LPS	B-DISO
+intravenous	O
+administration	O
+,	O
+severe	O
+lung	B-ANAT
+injury	O
+and	O
+positive	O
+signals	O
+of	O
+NT	O
+occurred	O
+with	O
+the	O
+latter	O
+located	O
+in	O
+the	O
+pulmonary	B-ANAT
+macrophages	I-ANAT
+,	O
+endothelia	O
+,	O
+subendothelial	O
+and	O
+muscular	B-ANAT
+layers	B-ANAT
+of	O
+the	O
+pulmonary	B-ANAT
+artery	I-ANAT
+.	O
+
+Administration	O
+of	O
+exogenous	O
+ONOO	O
+(-)	O
+caused	O
+dose	O
+-	O
+dependent	O
+increase	O
+in	O
+LC	O
+,	O
+W	O
+/	O
+D	O
+,	O
+ater	O
+and	O
+EB	O
+contents	O
+and	O
+in	O
+the	O
+number	O
+of	O
+MB	O
+-	O
+labelled	O
+blood	B-ANAT
+vessels	I-ANAT
+in	O
+rat	B-SPEC
+lungs	B-ANAT
+,	O
+together	O
+with	O
+significant	O
+pathological	O
+alterations	O
+such	O
+as	O
+diffuse	O
+alveolar	B-ANAT
+collapse	B-DISO
+,	O
+capillary	B-ANAT
+congestion	B-DISO
+in	O
+the	O
+septa	O
+and	O
+focal	O
+hemorrhage	B-DISO
+.	O
+
+There	O
+is	O
+consensus	O
+that	O
+severe	O
+maternal	B-DISO
+hypertension	I-DISO
+(	O
+blood	B-PROC
+pressure	I-PROC
+>	O
+or	O
+=	O
+170	O
+/	O
+110	O
+mmHg	O
+)	O
+should	O
+be	O
+treated	O
+to	O
+minimize	O
+the	O
+risk	O
+of	O
+acute	O
+cerebrovascular	O
+complications	O
+.	O
+
+Virus	B-SPEC
+clearance	O
+followed	O
+similar	O
+kinetics	O
+in	O
+all	O
+mice	B-SPEC
+,	O
+confirming	O
+initial	O
+control	O
+of	O
+virus	B-PROC
+replication	I-PROC
+by	O
+cellular	B-PROC
+immunity	I-PROC
+.	O
+
+This	O
+case	O
+is	O
+characteristic	O
+for	O
+acute	O
+intoxications	O
+with	O
+irreversible	O
+acetylcholinesterase	B-PRGE
+inhibitors	I-CHED
+,	O
+such	O
+as	O
+organophosphate	O
+compounds	O
+.	O
+
+Ten	O
+patients	O
+were	O
+admitted	O
+to	O
+Lampoon	O
+Provincial	O
+Hospital	O
+with	O
+a	O
+history	O
+of	O
+high	O
+fever	B-PROC
+,	O
+watery	B-DISO
+diarrhea	I-DISO
+,	O
+severe	O
+myalgia	B-DISO
+and	O
+ecchymosis	O
+rashes	B-DISO
+.	O
+
+Blood	B-ANAT
+culture	O
+and	O
+genetic	O
+investigation	O
+(	O
+16	O
+s	O
+rRNA	B-CHED
+polymerase	O
+chain	O
+reaction	O
+with	O
+restriction	O
+enzyme	O
+PstII	O
+)	O
+confirmed	O
+diagnoses	O
+of	O
+the	O
+same	O
+species	B-SPEC
+of	O
+Streptococcus	B-SPEC
+suis	I-SPEC
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Comparative	O
+clinical	O
+and	O
+immunological	O
+parameters	O
+in	O
+convalescence	O
+of	O
+patients	O
+with	O
+icterohemorrhagic	B-DISO
+leptospirosis	I-DISO
+].	O
+
+Acute	O
+leptospirosis	B-DISO
+period	O
+was	O
+characterized	O
+with	O
+polymorphic	O
+clinical	O
+picture	O
+impeding	O
+precise	O
+diagnosis	O
+and	O
+threatening	O
+with	O
+such	O
+complications	O
+as	O
+bacterial	O
+shock	O
+,	O
+acute	O
+renal	B-DISO
+failure	I-DISO
+,	I-DISO
+acute	I-DISO
+renal	B-ANAT
+-	O
+hepatic	B-DISO
+failure	I-DISO
+,	O
+DIC	B-DISO
+-	O
+syndrome	B-DISO
+,	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+sialate	B-CHED
+-	O
+4	O
+-	O
+O	O
+-	O
+acetylesterases	O
+of	O
+coronaviruses	O
+related	O
+to	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+:	O
+a	O
+proposal	O
+to	O
+reorganize	O
+group	O
+2	O
+Coronaviridae	O
+.	O
+
+De	O
+-	O
+O	O
+-	O
+acetylation	B-PROC
+of	O
+the	O
+glycoproteins	B-CHED
+by	O
+alkaline	O
+treatment	O
+or	O
+incubation	O
+with	O
+the	O
+viral	O
+esterases	B-FUNC
+resulted	O
+in	O
+a	O
+complete	O
+loss	O
+of	O
+recognition	O
+,	O
+indicating	O
+a	O
+specific	O
+interaction	O
+of	O
+MHV	B-SPEC
+-	O
+like	O
+coronaviruses	O
+with	O
+Neu4	B-PRGE
+,	O
+5Ac2	O
+.	O
+
+Combined	O
+with	O
+evidence	O
+for	O
+distinct	O
+phylogenetic	O
+lineages	O
+of	O
+group	O
+2	O
+coronaviruses	O
+,	O
+subdivision	O
+into	O
+subgroups	O
+2a	O
+(	O
+MHV	B-SPEC
+-	O
+like	O
+viruses	B-SPEC
+)	O
+and	O
+2b	O
+(	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+-	O
+like	O
+viruses	B-SPEC
+)	O
+is	O
+suggested	O
+.	O
+
+No	O
+respiratory	O
+clinical	O
+signs	O
+were	O
+observed	O
+during	O
+the	O
+entire	O
+experimental	O
+period	O
+,	O
+but	O
+elevated	O
+rectal	O
+temperatures	O
+were	O
+detected	O
+during	O
+diarrhea	B-DISO
+in	O
+the	O
+BCV	B-SPEC
+-	O
+inoculated	O
+calves	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+present	O
+1	O
+-	O
+step	O
+RT	O
+-	O
+PCR	O
+and	O
+nested	O
+PCR	O
+assays	O
+were	O
+highly	O
+sensitive	O
+to	O
+detect	O
+BCV	B-SPEC
+in	O
+nasal	B-ANAT
+swab	O
+and	O
+fecal	B-ANAT
+specimens	O
+.	O
+
+Therefore	O
+,	O
+these	O
+assays	O
+should	O
+be	O
+useful	O
+to	O
+diagnose	O
+BCV	B-SPEC
+infections	B-DISO
+in	O
+calves	O
+and	O
+adult	O
+cows	B-SPEC
+.	O
+
+At	O
+6	O
+h	O
+post	O
+-	O
+inoculation	O
+(	O
+hpi	B-DISO
+),	O
+the	O
+mean	O
+score	O
+of	O
+the	O
+villous	O
+height	O
+/	O
+crypt	B-ANAT
+depth	O
+(	O
+VH	O
+/	O
+CD	O
+)	O
+ratio	O
+of	O
+pigs	B-SPEC
+inoculated	O
+with	O
+the	O
+Purdue	O
+or	O
+Miller	O
+strain	O
+was	O
+significantly	O
+less	O
+than	O
+that	O
+of	O
+pigs	B-SPEC
+inoculated	O
+with	O
+the	O
+Korean	O
+strain	O
+or	O
+uninfected	O
+control	O
+pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Interstitial	B-ANAT
+lung	B-ANAT
+disease	I-DISO
+is	O
+one	O
+of	O
+the	O
+most	O
+common	O
+respiratory	O
+manifestations	O
+in	O
+polymyositis	B-DISO
+and	O
+dermatomyositis	B-DISO
+.	O
+
+Moreover	O
+,	O
+clinical	O
+presentation	O
+of	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+can	O
+be	O
+dichotomized	O
+,	O
+according	O
+to	O
+patients	O
+'	O
+pulmonary	B-ANAT
+manifestations	O
+,	O
+into	O
+:	O
+1	O
+)	O
+both	O
+acute	O
+and	O
+aggressive	B-DISO
+lung	B-DISO
+disease	I-DISO
+similar	O
+to	O
+Hamman	B-DISO
+-	I-DISO
+Rich	I-DISO
+syndrome	I-DISO
+;	O
+2	O
+)	O
+slowly	O
+progressive	O
+lung	B-DISO
+disease	I-DISO
+;	O
+and	O
+3	O
+)	O
+an	O
+asymptomatic	O
+pattern	O
+.	O
+
+The	O
+ideal	O
+vector	O
+should	O
+efficiently	O
+transduce	O
+non	O
+-	O
+dividing	O
+cells	B-COMP
+with	O
+minimal	O
+toxicity	O
+,	O
+thus	O
+endowing	O
+the	O
+system	O
+with	O
+persistent	O
+transgene	O
+expression	B-PROC
+.	O
+
+Mice	B-SPEC
+injected	O
+with	O
+HD	O
+-	O
+TET	B-PRGE
+-	O
+IFN	B-PRGE
+showed	O
+high	O
+levels	O
+of	O
+serum	B-COMP
+mIFN	B-PRGE
+(	I-PRGE
+alpha	I-PRGE
+)	I-PRGE
+only	O
+upon	O
+transcriptional	B-PROC
+activation	I-PROC
+.	O
+
+The	O
+transgene	O
+expression	B-PROC
+was	O
+reinducible	O
+to	O
+the	O
+same	O
+high	O
+level	O
+up	O
+to	O
+3	O
+months	O
+p	O
+.	O
+i	O
+.,	O
+and	O
+the	O
+amount	O
+of	O
+expressed	B-PROC
+cytokine	O
+could	O
+be	O
+regulated	O
+by	O
+dosing	O
+doxycycline	B-CHED
+.	O
+
+Rather	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+was	O
+critical	O
+for	O
+optimal	O
+activation	O
+or	O
+migration	O
+of	O
+macrophages	B-ANAT
+or	O
+microglia	B-ANAT
+into	O
+the	O
+white	B-ANAT
+matter	I-ANAT
+in	O
+the	O
+context	O
+of	O
+CD8	B-PRGE
+T	I-PRGE
+cell	O
+-	O
+mediated	O
+demyelination	B-DISO
+.	O
+
+TITLE	O
+:	O
+Isotype	O
+-	O
+specific	O
+antibody	B-ANAT
+-	I-ANAT
+secreting	B-PROC
+cells	B-COMP
+in	O
+systemic	O
+and	O
+mucosal	B-ANAT
+associated	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+and	O
+antibody	B-PROC
+responses	I-PROC
+in	O
+serum	B-COMP
+of	O
+conventional	O
+pigs	B-SPEC
+inoculated	O
+with	O
+PEDV	B-SPEC
+.	O
+
+A	O
+total	O
+number	O
+of	O
+28	O
+eleven	O
+-	O
+day	O
+-	O
+old	O
+conventional	O
+pigs	B-SPEC
+were	O
+orally	B-ANAT
+inoculated	O
+with	O
+the	O
+field	O
+isolate	O
+of	O
+the	O
+PEDV	B-SPEC
+strain	O
+CV	O
+-	O
+777	O
+.	O
+
+In	O
+the	O
+systemic	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+the	O
+number	O
+of	O
+IgG	B-PRGE
+and	O
+IgA	B-PRGE
+ASC	O
+detected	O
+were	O
+lower	O
+than	O
+in	O
+the	O
+mucosal	B-ANAT
+tissues	I-ANAT
+,	O
+however	O
+,	O
+in	O
+the	O
+blood	B-ANAT
+,	O
+presence	O
+of	O
+IgA	B-PRGE
+ASC	I-PRGE
+was	O
+constantly	O
+detected	O
+from	O
+PID	B-DISO
+14	O
+until	O
+the	O
+end	O
+of	O
+the	O
+experiment	O
+.	O
+
+The	O
+authors	O
+examined	O
+the	O
+effects	O
+of	O
+infection	B-DISO
+with	O
+HCoV	O
+on	O
+ciliary	O
+structure	O
+and	O
+function	O
+in	O
+healthy	O
+volunteers	O
+infected	O
+by	O
+intranasal	O
+inoculation	O
+with	O
+HCoV	O
+229E	O
+.	O
+
+Expression	B-PROC
+of	O
+the	O
+reporter	B-PRGE
+gene	I-PRGE
+beta	I-PRGE
+-	I-PRGE
+glucuronidase	I-PRGE
+(	O
+GUS	B-PRGE
+)	O
+(	O
+2	O
+-	O
+8	O
+microg	O
+per	O
+10	O
+(	O
+6	O
+)	O
+cells	B-COMP
+)	O
+and	O
+the	O
+porcine	B-SPEC
+respiratory	I-SPEC
+and	I-SPEC
+reproductive	I-SPEC
+syndrome	B-DISO
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+)	O
+ORF5	O
+(	O
+1	O
+-	O
+2	O
+microg	O
+per	O
+10	O
+(	O
+6	O
+)	O
+cells	B-COMP
+)	O
+has	O
+been	O
+shown	O
+using	O
+a	O
+TGEV	B-SPEC
+-	O
+derived	O
+minigenome	O
+.	O
+
+GUS	B-PRGE
+expression	B-PROC
+levels	O
+increased	O
+about	O
+eightfold	O
+with	O
+the	O
+m	O
+.	O
+o	O
+.	O
+i	O
+.	O
+and	O
+were	O
+maintained	O
+for	O
+more	O
+than	O
+eight	O
+passages	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+ABSTRACT	O
+:	O
+Formation	B-PROC
+of	O
+the	O
+coronavirus	B-SPEC
+replication	O
+-	O
+transcription	B-PROC
+complex	O
+involves	O
+the	O
+synthesis	B-PROC
+of	O
+large	O
+polyprotein	O
+precursors	O
+that	O
+are	O
+extensively	O
+processed	O
+by	O
+virus	B-SPEC
+-	O
+encoded	O
+cysteine	B-PRGE
+proteases	I-PRGE
+.	O
+
+The	O
+data	O
+strongly	O
+suggest	O
+that	O
+,	O
+first	O
+,	O
+the	O
+FIPV	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+catalytic	O
+system	O
+employs	O
+His	O
+(	O
+41	O
+)	O
+and	O
+Cys	B-CHED
+(	O
+144	O
+)	O
+as	O
+the	O
+principal	O
+catalytic	O
+residues	O
+.	O
+
+Surprisingly	O
+,	O
+some	O
+of	O
+the	O
+Asn	B-CHED
+(	O
+64	O
+)	O
+mutants	O
+even	O
+exhibited	O
+strongly	O
+increased	O
+activities	O
+.	O
+
+Similar	O
+results	O
+were	O
+obtained	O
+for	O
+human	B-PRGE
+coronavirus	I-PRGE
+(	O
+HCoV	B-SPEC
+)	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+mutants	O
+in	O
+which	O
+the	O
+equivalent	O
+Asn	B-CHED
+residue	O
+(	O
+HCoV	B-SPEC
+3CL	O
+(	O
+pro	B-CHED
+)	O
+Asn	B-CHED
+(	O
+64	O
+))	O
+was	O
+substituted	O
+.	O
+
+These	O
+data	O
+lead	O
+us	O
+to	O
+conclude	O
+that	O
+both	O
+the	O
+catalytic	O
+systems	O
+and	O
+substrate	O
+-	O
+binding	B-FUNC
+pockets	O
+of	O
+coronavirus	B-SPEC
+main	O
+proteases	O
+differ	O
+from	O
+those	O
+of	O
+other	O
+RNA	B-PRGE
+virus	I-PRGE
+3C	I-PRGE
+and	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+.	O
+
+TITLE	O
+:	O
+An	O
+elderly	O
+patient	O
+with	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+due	O
+to	O
+severe	O
+mycoplasma	B-DISO
+pneumonia	I-DISO
+with	O
+marked	O
+hypercytokinemia	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+nitric	B-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+type	O
+-	O
+2	O
+(	O
+NOS2	B-PRGE
+)-	O
+derived	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)-	O
+induced	O
+central	B-DISO
+nervous	I-DISO
+system	I-DISO
+disease	I-DISO
+was	O
+examined	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+transfer	O
+of	O
+protective	O
+genes	O
+to	O
+the	O
+alveolar	O
+epithelium	O
+can	O
+attenuate	O
+lung	B-ANAT
+injury	O
+if	O
+accomplished	O
+before	O
+its	O
+onset	O
+.	O
+
+X	O
+-	O
+gal	B-CHED
+staining	O
+72	O
+h	O
+postinfection	O
+revealed	O
+transgene	O
+expression	B-PROC
+in	O
+all	O
+segments	O
+of	O
+room	O
+air	B-CHED
+control	O
+and	O
+hyperoxic	O
+lungs	B-ANAT
+infected	O
+with	O
+either	O
+dose	O
+of	O
+adbeta	B-PRGE
+-	I-PRGE
+gal	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+effective	O
+system	O
+for	O
+specific	O
+prevention	O
+of	O
+transmissive	O
+swine	O
+gastroenteritis	B-DISO
+(	O
+TSG	O
+)	O
+is	O
+based	O
+on	O
+the	O
+use	O
+of	O
+combined	O
+vaccine	O
+and	O
+combined	O
+vaccination	O
+.	O
+
+ABSTRACT	O
+:	O
+Supplemental	O
+oxygen	B-CHED
+therapy	O
+is	O
+frequently	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+pulmonary	B-DISO
+insufficiency	I-DISO
+,	O
+as	O
+is	O
+encountered	O
+in	O
+premature	O
+infants	O
+,	O
+and	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+However	O
+,	O
+hyperoxia	B-DISO
+causes	O
+lung	B-ANAT
+damage	O
+in	O
+experimental	O
+animals	B-SPEC
+and	O
+may	O
+do	O
+so	O
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+results	O
+show	O
+that	O
+the	O
+S	B-PRGE
+-	I-PRGE
+fg	I-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+is	O
+highly	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+among	O
+different	O
+IBV	B-SPEC
+serotypes	O
+,	O
+and	O
+the	O
+S	O
+-	O
+fg	O
+ELISA	O
+is	O
+found	O
+to	O
+be	O
+a	O
+convenient	O
+,	O
+economical	O
+,	O
+and	O
+efficient	O
+method	O
+for	O
+antibody	B-COMP
+detection	O
+against	O
+IBV	B-SPEC
+.	O
+
+All	O
+hepatocytes	B-ANAT
+in	O
+BALB	O
+-	O
+GKO	O
+mice	B-SPEC
+were	O
+necrotic	B-PROC
+at	O
+5	O
+days	O
+post	O
+-	O
+infection	B-DISO
+,	O
+which	O
+was	O
+clearly	O
+distinct	O
+from	O
+large	O
+but	O
+limited	O
+lesion	O
+in	O
+the	O
+liver	B-ANAT
+from	O
+infected	O
+B6	O
+-	O
+GKO	O
+mice	B-SPEC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+BALB	O
+-	O
+GKO	O
+and	O
+B6	O
+-	O
+GKO	O
+mice	B-SPEC
+clearly	O
+show	O
+different	O
+diseases	O
+following	O
+MHV	B-SPEC
+infection	B-DISO
+,	O
+although	O
+wild	O
+type	O
+counterparts	O
+of	O
+both	O
+mice	B-SPEC
+apparently	O
+showed	O
+the	O
+same	O
+clinical	O
+course	O
+after	O
+MHV	B-SPEC
+infection	B-DISO
+.	O
+
+The	O
+relative	O
+risk	O
+for	O
+combined	O
+morbidity	O
+(	O
+death	B-PROC
+,	O
+intracranial	B-DISO
+hemorrhage	I-DISO
+,	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+)	O
+was	O
+increased	O
+(	O
+3	O
+.	O
+0	O
+,	O
+P	O
+=.	O
+019	O
+)	O
+when	O
+compared	O
+with	O
+matched	O
+control	O
+infants	O
+.	O
+
+RESULTS	O
+:	O
+PROM20	O
+infants	O
+had	O
+an	O
+increased	O
+acute	O
+respiratory	B-DISO
+morbidity	I-DISO
+(	O
+higher	O
+ventilator	O
+settings	O
+and	O
+increased	O
+incidence	O
+of	O
+hypoxemia	O
+,	O
+hypercapnia	B-DISO
+,	O
+and	O
+pulmonary	B-DISO
+hypertension	I-DISO
+)	O
+and	O
+a	O
+trend	O
+to	O
+more	O
+air	B-CHED
+leaks	O
+.	O
+
+No	O
+cross	O
+-	O
+infection	O
+were	O
+observed	O
+from	O
+community	O
+-	O
+acquired	O
+respiratory	O
+-	O
+syncitial	O
+virus	B-SPEC
+or	O
+influenza	B-DISO
+-	O
+infected	O
+children	O
+to	O
+neonates	O
+.	O
+
+TITLE	O
+:	O
+Mucosal	B-ANAT
+and	O
+systemic	O
+isotype	O
+-	O
+specific	O
+antibody	B-PROC
+responses	I-PROC
+and	O
+protection	O
+in	O
+conventional	O
+pigs	B-SPEC
+exposed	O
+to	O
+virulent	O
+or	O
+attenuated	O
+porcine	O
+epidemic	O
+diarrhoea	O
+virus	O
+.	O
+
+Only	O
+a	O
+small	O
+response	O
+was	O
+detected	O
+in	O
+the	O
+groups	O
+inoculated	O
+with	O
+attenuated	O
+PEDV	O
+,	O
+whereas	O
+in	O
+the	O
+group	O
+previously	O
+exposed	O
+to	O
+the	O
+virulent	O
+virus	B-SPEC
+on	O
+PID	B-DISO
+21	O
+a	O
+large	O
+number	O
+of	O
+IgG	B-PRGE
+and	O
+IgA	B-PRGE
+ASC	O
+was	O
+detected	O
+.	O
+
+A	O
+controlled	O
+-	O
+challenge	O
+protocol	O
+was	O
+developed	O
+to	O
+mimic	O
+natural	O
+infection	B-DISO
+and	O
+to	O
+yield	O
+a	O
+higher	O
+rate	O
+of	O
+mortality	O
+following	O
+Escherichia	B-SPEC
+coli	I-SPEC
+(	O
+EC	O
+)	O
+challenge	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+rapid	O
+growth	B-PROC
+rate	O
+substantially	O
+reduces	O
+broiler	O
+viability	O
+,	O
+whereas	O
+Ab	O
+levels	O
+produced	O
+in	O
+response	O
+to	O
+acute	O
+pathogenic	O
+challenge	O
+without	O
+prior	O
+vaccination	O
+do	O
+not	O
+contribute	O
+to	O
+disease	B-PROC
+resistance	I-PROC
+.	O
+
+TITLE	O
+:	O
+Indications	O
+for	O
+mechanical	O
+ventilation	O
+in	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Indications	O
+for	O
+IPPV	O
+based	O
+on	O
+specific	O
+threshold	O
+values	O
+for	O
+P	O
+(	O
+CO2	B-CHED
+)	O
+and	O
+pH	O
+or	O
+on	O
+various	O
+indices	O
+of	O
+arterial	B-ANAT
+oxygenation	B-PROC
+have	O
+generally	O
+not	O
+been	O
+validated	O
+by	O
+clinical	O
+evidence	O
+,	O
+and	O
+it	O
+is	O
+unlikely	O
+that	O
+any	O
+cutoff	O
+value	O
+would	O
+be	O
+applicable	O
+to	O
+all	O
+patients	O
+or	O
+all	O
+categories	O
+of	O
+acute	O
+respiratory	O
+failure	O
+.	O
+
+The	O
+use	O
+of	O
+IPPV	O
+may	O
+improve	O
+outcomes	O
+in	O
+patients	O
+with	O
+severe	O
+cardiogenic	B-DISO
+shock	I-DISO
+.	O
+
+The	O
+current	O
+study	O
+utilized	O
+chickens	B-SPEC
+to	O
+examine	O
+the	O
+effect	O
+of	O
+embryonic	B-ANAT
+lead	O
+exposure	O
+on	O
+immune	O
+and	O
+cellular	B-COMP
+responses	O
+during	O
+viral	O
+challenge	O
+.	O
+
+TITLE	O
+:	O
+Recruitment	B-DISO
+kinetics	O
+and	O
+composition	O
+of	O
+antibody	B-ANAT
+-	I-ANAT
+secreting	B-PROC
+cells	B-COMP
+within	O
+the	O
+central	B-ANAT
+nervous	B-DISO
+system	I-ANAT
+following	O
+viral	O
+encephalomyelitis	O
+.	O
+
+This	O
+supports	O
+a	O
+critical	O
+role	O
+of	O
+humoral	B-PROC
+immunity	I-PROC
+in	O
+regulating	O
+viral	O
+CNS	B-CHED
+persistence	O
+.	O
+
+TITLE	O
+:	O
+Beneficial	O
+effects	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+inhalation	B-PROC
+on	O
+pulmonary	B-ANAT
+bacterial	O
+clearance	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+beneficial	O
+effects	O
+of	O
+nitric	O
+oxide	O
+inhalation	B-PROC
+on	O
+oxygenation	B-PROC
+during	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+are	O
+well	O
+described	O
+.	O
+
+Male	O
+Sprague	B-SPEC
+-	I-SPEC
+Dawley	I-SPEC
+rats	I-SPEC
+.	O
+
+Thus	O
+,	O
+an	O
+education	O
+for	O
+timely	O
+recognition	O
+and	O
+urgent	O
+care	O
+of	O
+TRALI	B-DISO
+should	O
+be	O
+initiated	O
+.	O
+
+Vascular	B-ANAT
+immunotargeting	O
+of	O
+the	O
+H	O
+(	O
+2	O
+)	O
+O	O
+(	O
+2	O
+)-	O
+generating	O
+enzyme	O
+glucose	B-PRGE
+oxidase	I-PRGE
+(	O
+GOX	B-PRGE
+)	O
+to	O
+the	O
+pulmonary	B-ANAT
+endothelium	B-ANAT
+causes	O
+an	O
+acute	O
+oxidative	O
+lung	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+.(	O
+1	O
+)	O
+In	O
+the	O
+present	O
+study	O
+we	O
+compared	O
+the	O
+pulmonary	B-DISO
+thrombosis	I-DISO
+and	O
+leukocyte	B-ANAT
+transmigration	O
+caused	O
+by	O
+GOX	B-ENZY
+targeting	B-PROC
+to	O
+the	O
+endothelial	B-PRGE
+antigens	B-CHED
+platelet	B-ANAT
+-	I-PRGE
+endothelial	B-ANAT
+cell	I-ANAT
+adhesion	I-PRGE
+molecule	I-PRGE
+(	O
+PECAM	B-PRGE
+)	O
+and	O
+thrombomodulin	B-PRGE
+(	O
+TM	O
+).	O
+
+ABSTRACT	O
+:	O
+It	O
+is	O
+unclear	O
+whether	O
+respiratory	O
+and	O
+enteric	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BoCV	O
+)	O
+strains	O
+are	O
+distinctive	O
+in	O
+biological	O
+,	O
+antigenic	O
+and	O
+genetic	O
+characteristics	O
+.	O
+
+The	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+were	O
+distributed	O
+throughout	O
+the	O
+S1	O
+subunit	O
+with	O
+clustering	O
+around	O
+residues	O
+40	O
+-	O
+118	O
+,	O
+146	O
+-	O
+179	O
+,	O
+and	O
+458	O
+-	O
+531	O
+.	O
+
+Molecular	O
+masses	O
+of	O
+the	O
+IgE	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+proteins	B-CHED
+and	O
+cross	O
+-	O
+reactivity	O
+among	O
+the	O
+P	B-SPEC
+.	I-SPEC
+acerifolia	I-SPEC
+pollen	O
+and	O
+different	O
+food	O
+extracts	O
+were	O
+also	O
+determined	O
+.	O
+
+Enzyme	O
+allergosorbent	O
+(	O
+EAST	O
+)-	O
+inhibition	B-PROC
+showed	O
+high	O
+inhibition	B-PROC
+values	O
+when	O
+P	B-SPEC
+.	I-SPEC
+acerifolia	I-SPEC
+pollen	O
+extract	O
+was	O
+used	O
+as	O
+free	O
+phase	O
+.	O
+
+OAS	B-DISO
+in	O
+these	O
+patients	O
+may	O
+have	O
+been	O
+caused	O
+by	O
+primary	O
+respiratory	O
+sensitization	B-PROC
+.	O
+
+Furthermore	O
+,	O
+IP	O
+-	O
+10	O
+(-/-)	O
+mice	B-SPEC
+infected	O
+with	O
+a	O
+neurotropic	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+had	O
+an	O
+impaired	B-DISO
+ability	O
+to	O
+control	O
+viral	B-PROC
+replication	I-PROC
+in	O
+the	O
+brain	B-ANAT
+.	O
+
+This	O
+was	O
+associated	O
+with	O
+decreased	O
+recruitment	B-DISO
+of	O
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+lymphocytes	B-ANAT
+into	O
+the	O
+brain	B-ANAT
+,	O
+reduced	O
+levels	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+and	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	O
+induced	O
+chemokines	O
+monokine	B-PRGE
+induced	I-PRGE
+by	I-PRGE
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+(	O
+Mig	B-PRGE
+,	O
+CXCL9	B-PRGE
+)	O
+and	O
+IFN	B-PRGE
+-	O
+inducible	O
+T	B-PRGE
+cell	I-PRGE
+alpha	I-PRGE
+chemoattractant	I-PRGE
+(	O
+I	B-PRGE
+-	I-PRGE
+TAC	I-PRGE
+,	O
+CXCL11	B-PRGE
+)	O
+in	O
+the	O
+brain	B-ANAT
+,	O
+decreased	O
+numbers	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+secreting	I-PRGE
+CD8	I-PRGE
+(+)	O
+cells	B-COMP
+in	O
+the	O
+spleen	B-ANAT
+,	O
+and	O
+reduced	O
+levels	O
+of	O
+demyelination	B-DISO
+in	O
+the	O
+CNS	B-CHED
+.	O
+
+To	O
+investigate	O
+membrane	B-COMP
+alterations	O
+and	O
+to	O
+characterize	O
+the	O
+RC	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+we	O
+performed	O
+biochemical	O
+and	O
+ultrastructural	O
+studies	O
+using	O
+MHV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Biochemical	O
+fractionation	O
+showed	O
+that	O
+all	O
+10	O
+of	O
+the	O
+MHV	B-SPEC
+gene	O
+1	O
+polyprotein	O
+products	O
+examined	O
+pelleted	O
+with	O
+the	O
+membrane	B-ANAT
+fraction	I-ANAT
+,	O
+consistent	O
+with	O
+membrane	B-COMP
+association	O
+of	O
+the	O
+RC	O
+.	O
+
+The	O
+ultrastructural	O
+analysis	O
+revealed	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+(	O
+DMVs	O
+)	O
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+MHV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+These	O
+integral	O
+membrane	B-COMP
+proteins	B-CHED
+assemble	O
+within	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+of	O
+infected	O
+cells	B-COMP
+and	O
+are	O
+subsequently	O
+endoproteolyzed	O
+in	O
+the	O
+Golgi	B-COMP
+,	O
+generating	O
+noncovalently	O
+associated	O
+S1	O
+and	O
+S2	O
+fragments	O
+.	O
+
+CEACAM	O
+binding	O
+did	O
+indeed	O
+alter	O
+S1	O
+conformations	O
+,	O
+generating	O
+alternative	O
+disulfide	B-CHED
+linkages	O
+that	O
+were	O
+revealed	O
+on	O
+SDS	B-DISO
+gels	O
+.	O
+
+Optimal	O
+iNO	B-PRGE
+dose	O
+was	O
+around	O
+0	O
+.	O
+8	O
+micromol	O
+/	O
+L	O
+as	O
+higher	O
+methemoglobin	B-PRGE
+(	O
+MetHb	O
+,	O
+>	O
+3	O
+%)	O
+was	O
+found	O
+at	O
+higher	O
+NO	O
+.	O
+
+iNO	O
+had	O
+no	O
+adverse	B-DISO
+effects	I-DISO
+on	O
+surfactant	B-CHED
+phospholipids	B-CHED
+and	O
+lung	B-ANAT
+fluid	B-PROC
+balance	I-PROC
+,	O
+but	O
+attenuated	O
+expression	B-PROC
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+,	O
+beta2	B-PRGE
+integrin	I-PRGE
+CD11b	I-PRGE
+,	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+mRNA	I-PRGE
+in	O
+the	O
+lungs	B-ANAT
+by	O
+22	O
+%,	O
+44	O
+%,	O
+and	O
+25	O
+%,	O
+respectively	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+outcome	O
+of	O
+early	O
+PC	O
+-	O
+IRV	B-PROC
+in	O
+severe	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+infectious	B-DISO
+agents	O
+in	O
+laboratory	O
+rodents	B-SPEC
+:	O
+traditional	O
+and	O
+molecular	O
+techniques	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleotide	B-CHED
+sequences	O
+of	O
+the	O
+coding	O
+region	O
+of	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+gene	O
+of	O
+12	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+strains	O
+recently	O
+found	O
+in	O
+animal	B-SPEC
+facilities	O
+in	O
+Japan	O
+were	O
+analyzed	O
+.	O
+
+It	O
+therefore	O
+seems	O
+that	O
+the	O
+inhibitory	O
+effect	O
+of	O
+the	O
+ExPLIs	O
+was	O
+not	O
+due	O
+to	O
+their	O
+PLA	B-CHED
+(	O
+2	O
+)	O
+inhibiting	O
+capacity	O
+.	O
+
+It	O
+is	O
+proposed	O
+that	O
+the	O
+ExPLIs	O
+may	O
+be	O
+considered	O
+a	O
+prototype	O
+of	O
+potent	O
+suppressors	O
+of	O
+specific	O
+endotoxin	O
+-	O
+induced	O
+inflammatory	B-DISO
+responses	I-DISO
+,	O
+with	O
+potential	O
+implications	O
+for	O
+the	O
+therapy	O
+of	O
+subsequent	O
+severe	O
+inflammation	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Late	O
+onset	O
+central	O
+hypoventilation	B-DISO
+syndrome	I-DISO
+may	O
+be	O
+associated	O
+with	O
+cerebral	B-DISO
+venous	B-ANAT
+thrombosis	I-DISO
+.	O
+
+Thirty	O
+of	O
+these	O
+commercial	O
+herds	O
+had	O
+a	O
+clinical	O
+history	O
+of	O
+TGEV	O
+infection	B-DISO
+and	O
+a	O
+positive	O
+TGEV	B-SPEC
+fluorescent	O
+antibody	B-COMP
+test	O
+recorded	O
+at	O
+necropsy	O
+within	O
+the	O
+last	O
+35	O
+months	O
+,	O
+while	O
+70	O
+herds	O
+had	O
+no	O
+history	O
+of	O
+clinical	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+In	O
+repeatability	O
+experiments	O
+,	O
+the	O
+ELISA	O
+gave	O
+consistent	O
+results	O
+when	O
+the	O
+same	O
+sera	B-COMP
+were	O
+evaluated	O
+on	O
+different	O
+days	O
+(	O
+kappa	O
+0	O
+.	O
+889	O
+)	O
+and	O
+when	O
+sera	B-COMP
+were	O
+evaluated	O
+before	O
+and	O
+after	O
+heating	O
+(	O
+kappa	O
+0	O
+.	O
+888	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+optimal	O
+pressure	O
+of	O
+sustained	O
+inflation	O
+(	O
+SI	O
+)	O
+in	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+pathogenicity	O
+of	O
+25	O
+strains	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolated	O
+in	O
+Australia	O
+between	O
+1961	O
+and	O
+1994	O
+was	O
+compared	O
+in	O
+white	O
+leghorn	O
+specific	O
+pathogen	O
+-	O
+free	O
+chicks	O
+.	O
+
+The	O
+IBV	B-SPEC
+strains	O
+identified	O
+as	O
+nephropathogenic	O
+induced	O
+clinical	O
+nephritis	B-DISO
+,	O
+gross	O
+and	O
+histological	O
+kidney	B-ANAT
+lesions	O
+,	O
+and	O
+mortality	O
+of	O
+5	O
+-	O
+90	O
+%.	O
+
+As	O
+his	O
+clinical	O
+situation	O
+deteriorated	O
+rapidly	O
+,	O
+BMT	B-ENZY
+was	O
+performed	O
+with	O
+unmanipulated	O
+marrow	O
+stem	B-ANAT
+cells	I-ANAT
+from	O
+his	O
+EBV	O
+-	O
+positive	O
+HLA	B-PRGE
+-	O
+identical	O
+sister	O
+after	O
+conditioning	O
+with	O
+dexamethasone	B-CHED
+(	O
+1	O
+.	O
+75	O
+mg	O
+/	O
+kg	O
+/	O
+day	O
+),	O
+cyclophosphamide	B-CHED
+(	O
+114	O
+mg	O
+/	O
+kg	O
+)	O
+and	O
+etoposide	B-CHED
+(	O
+10	O
+mg	O
+/	O
+kg	O
+),	O
+with	O
+no	O
+immunosuppression	B-PROC
+given	O
+post	O
+transplant	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+:	O
+report	O
+of	O
+a	O
+clinical	O
+look	O
+-	O
+back	B-ANAT
+investigation	O
+.	O
+
+We	O
+have	O
+constructed	O
+a	O
+mutant	B-DISO
+,	O
+M	O
+(	O
+Delta	O
+)	O
+2	O
+,	O
+containing	O
+a	O
+two	O
+-	O
+amino	O
+-	O
+acid	O
+truncation	B-DISO
+of	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+that	O
+was	O
+previously	O
+thought	O
+to	O
+be	O
+lethal	O
+.	O
+
+Comparison	O
+of	O
+cells	B-COMP
+expressing	O
+IBV	B-SPEC
+N	O
+protein	B-CHED
+with	O
+controls	O
+indicated	O
+that	O
+cells	B-COMP
+expressing	O
+N	B-PRGE
+protein	I-PRGE
+had	O
+delayed	O
+cellular	B-PROC
+growth	B-PROC
+.	O
+
+TITLE	O
+:	O
+What	O
+is	O
+the	O
+optimal	O
+duration	O
+of	O
+ventilation	O
+in	O
+the	O
+prone	O
+position	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+?	O
+
+Helminth	O
+parasites	O
+include	O
+liver	B-SPEC
+flukes	I-SPEC
+(	O
+Fascioloides	B-SPEC
+and	O
+Fasciola	B-SPEC
+),	O
+gastrointestinal	O
+nematodes	B-SPEC
+of	O
+the	O
+family	B-SPEC
+Trichostrongylidae	I-SPEC
+,	O
+pulmonary	B-ANAT
+lungworms	B-SPEC
+of	O
+the	O
+genus	B-SPEC
+Dictyocaulus	B-SPEC
+and	O
+extra	O
+-	O
+pulmonary	B-ANAT
+lungworms	B-SPEC
+of	O
+the	O
+family	B-SPEC
+Protostrongylidae	B-SPEC
+.	O
+
+Three	O
+patients	O
+were	O
+transferred	O
+in	O
+intensive	O
+care	O
+unit	O
+for	O
+respiratory	B-DISO
+distress	I-DISO
+or	O
+shock	B-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+discuss	O
+the	O
+structural	O
+basis	O
+of	O
+virus	B-SPEC
+receptor	O
+activities	O
+of	O
+murine	B-PRGE
+CEACAM1	I-PRGE
+proteins	B-CHED
+,	O
+binding	B-FUNC
+of	O
+Neisseria	B-SPEC
+to	O
+human	B-SPEC
+CEACAM1	O
+,	O
+and	O
+other	O
+homophilic	O
+and	O
+heterophilic	O
+interactions	O
+of	O
+CEA	B-PRGE
+family	B-SPEC
+members	I-PRGE
+.	O
+
+Occurrence	O
+of	O
+negative	O
+middle	B-ANAT
+ear	I-ANAT
+pressure	O
+in	O
+winter	O
+-	O
+spring	O
+colds	B-DISO
+was	O
+significantly	O
+greater	O
+than	O
+in	O
+fall	O
+colds	B-DISO
+for	O
+unexplained	O
+reasons	O
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+isolated	O
+from	O
+15	O
+/	O
+15	O
+of	O
+the	O
+jejunal	B-ANAT
+samples	O
+from	O
+the	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+pigs	B-SPEC
+.	O
+
+Indications	O
+for	O
+operation	O
+were	O
+a	O
+true	O
+or	O
+false	B-DISO
+aneurysm	I-DISO
+(	O
+65	O
+.	O
+6	O
+%),	O
+severe	O
+calcified	B-DISO
+aortic	I-DISO
+valve	I-DISO
+stenosis	B-DISO
+(	O
+4	O
+.	O
+2	O
+%)	O
+or	O
+severe	O
+aortic	B-DISO
+insufficiency	I-DISO
+(	O
+2	O
+.	O
+1	O
+%)	O
+with	O
+dilated	O
+ascending	B-ANAT
+aorta	I-ANAT
+,	O
+acute	O
+dissection	O
+(	O
+2	O
+.	O
+1	O
+%),	O
+or	O
+combination	O
+of	O
+indications	O
+(	O
+26	O
+%).	O
+
+No	O
+patient	O
+died	B-PROC
+of	O
+flange	O
+-	O
+related	O
+complications	O
+.	O
+
+The	O
+new	O
+created	O
+sinuses	B-ANAT
+and	O
+the	O
+flange	O
+are	O
+especially	O
+helpful	O
+to	O
+continue	O
+physiologic	O
+function	O
+of	O
+the	O
+aortic	B-ANAT
+root	I-ANAT
+.	O
+
+The	O
+role	O
+of	O
+these	O
+viruses	B-SPEC
+in	O
+more	O
+serious	O
+respiratory	O
+illnesses	O
+resulting	O
+in	O
+hospitalization	O
+is	O
+less	O
+well	O
+defined	O
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+-	O
+provoked	O
+rhinitis	B-DISO
+in	O
+patients	O
+who	O
+have	O
+allergies	B-DISO
+.	O
+
+""""	O
+Viruses	B-SPEC
+commonly	O
+associated	O
+with	O
+these	O
+upper	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+URI	O
+)	O
+include	O
+rhinoviruses	B-SPEC
+(	O
+RVs	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+corona	B-CHED
+virus	B-SPEC
+,	O
+and	O
+adenoviruses	B-SPEC
+.	O
+
+Clinical	O
+observations	O
+have	O
+suggested	O
+that	O
+patients	O
+with	O
+allergic	B-DISO
+rhinitis	I-DISO
+and	O
+asthma	B-PATH
+experience	O
+more	O
+pronounced	O
+symptoms	O
+during	O
+a	O
+viral	O
+URI	O
+than	O
+patients	O
+who	O
+do	O
+not	O
+have	O
+allergies	B-DISO
+and	O
+who	O
+are	O
+infected	O
+with	O
+the	O
+same	O
+virus	B-SPEC
+under	O
+similar	O
+circumstances	O
+.	O
+
+Many	O
+patients	O
+who	O
+survive	O
+ARDS	B-DISO
+have	O
+permanent	O
+,	O
+mild	O
+to	O
+moderate	O
+impairment	B-DISO
+of	O
+lung	B-PROC
+function	I-PROC
+.	O
+
+Quality	O
+of	O
+life	O
+after	O
+hospitalization	O
+with	O
+ARDS	B-DISO
+may	O
+be	O
+poorer	O
+than	O
+that	O
+in	O
+similar	O
+patients	O
+without	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+replication	O
+-	O
+induced	O
+p38	B-FUNC
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+activation	O
+promotes	O
+interleukin	O
+-	O
+6	O
+production	O
+and	O
+virus	B-PROC
+replication	I-PROC
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Analyses	O
+of	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinases	I-PRGE
+(	O
+MAPKs	O
+)	O
+in	O
+a	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)-	O
+infected	O
+macrophage	B-ANAT
+-	O
+derived	O
+J774	O
+.	O
+1	O
+cell	B-ANAT
+line	I-ANAT
+showed	O
+activation	O
+of	O
+two	O
+MAPKs	O
+,	O
+p38	B-FUNC
+MAPK	B-FUNC
+and	O
+c	B-PRGE
+-	I-PRGE
+Jun	I-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+kinase	I-PRGE
+(	O
+JNK	B-FUNC
+),	O
+but	O
+not	O
+of	O
+extracellular	B-ENZY
+signal	I-ENZY
+-	I-ENZY
+regulated	I-ENZY
+kinase	I-ENZY
+(	O
+ERK	B-FUNC
+).	O
+
+The	O
+reduced	O
+MHV	B-SPEC
+production	O
+in	O
+SB	O
+203580	O
+-	O
+treated	O
+cells	B-COMP
+was	O
+,	O
+at	O
+least	O
+in	O
+part	O
+,	O
+due	O
+to	O
+a	O
+decrease	O
+in	O
+virus	B-SPEC
+-	O
+specific	O
+protein	B-PROC
+synthesis	I-PROC
+and	O
+virus	B-SPEC
+-	O
+specific	O
+mRNA	B-CHED
+accumulation	O
+.	O
+
+Interestingly	O
+,	O
+there	O
+was	O
+a	O
+transient	O
+increase	O
+in	O
+the	O
+amount	O
+of	O
+phosphorylation	B-PROC
+of	O
+the	O
+translation	B-PRGE
+initiation	I-PRGE
+factor	I-PRGE
+4E	I-PRGE
+(	O
+eIF4E	B-PRGE
+)	O
+in	O
+infected	O
+cells	B-COMP
+,	O
+and	O
+this	O
+eIF4E	B-PRGE
+phosphorylation	B-PROC
+was	O
+p38	B-PRGE
+MAPK	B-FUNC
+dependent	O
+;	O
+it	O
+is	O
+known	O
+that	O
+phosphorylated	O
+eIF4E	B-PRGE
+enhances	O
+translation	B-PROC
+rates	O
+of	O
+cap	B-DISO
+-	O
+containing	O
+mRNAs	O
+.	O
+
+TITLE	O
+:	O
+Binding	B-FUNC
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+to	O
+cell	B-COMP
+surface	I-COMP
+sialoglycoproteins	O
+.	O
+
+(	O
+i	O
+)	O
+Binding	B-FUNC
+to	O
+porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+pAPN	O
+)	O
+is	O
+essential	O
+for	O
+the	O
+initiation	O
+of	O
+infection	B-DISO
+.	O
+
+(	O
+ii	O
+)	O
+Binding	B-FUNC
+to	O
+sialic	B-PRGE
+acid	I-PRGE
+residues	I-PRGE
+on	I-PRGE
+glycoproteins	B-CHED
+is	O
+dispensable	O
+for	O
+the	O
+infection	B-DISO
+of	O
+cultured	B-ANAT
+cells	I-ANAT
+but	O
+is	O
+required	O
+for	O
+enteropathogenicity	O
+.	O
+
+In	O
+the	O
+presence	O
+of	O
+a	O
+functional	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	B-PROC
+activity	I-PROC
+,	O
+the	O
+amount	O
+of	O
+virus	B-SPEC
+bound	O
+to	O
+two	O
+different	O
+porcine	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+was	O
+increased	O
+sixfold	O
+compared	O
+to	O
+the	O
+binding	B-FUNC
+of	O
+the	O
+mutant	B-DISO
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Membrane	B-ANAT
+association	O
+and	O
+dimerization	O
+of	O
+a	O
+cysteine	B-CHED
+-	O
+rich	O
+,	O
+16	B-PRGE
+-	I-PRGE
+kilodalton	I-PRGE
+polypeptide	I-PRGE
+released	O
+from	O
+the	O
+C	O
+-	O
+terminal	O
+region	O
+of	O
+the	O
+coronavirus	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+1a	O
+polyprotein	O
+.	O
+
+ABSTRACT	O
+:	O
+More	O
+than	O
+10	O
+mature	O
+proteins	B-CHED
+processed	O
+from	O
+coronavirus	B-SPEC
+gene	O
+1	O
+-	O
+encoded	O
+polyproteins	O
+have	O
+been	O
+identified	O
+in	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+identification	O
+of	O
+the	O
+most	O
+C	O
+-	O
+terminal	O
+cleavage	B-PROC
+product	O
+of	O
+the	O
+1a	O
+polyprotein	O
+as	O
+a	O
+16	O
+-	O
+kDa	O
+protein	B-CHED
+in	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+-	O
+infected	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+Furthermore	O
+,	O
+increased	O
+accumulation	O
+of	O
+the	O
+16	B-PRGE
+-	I-PRGE
+kDa	I-PRGE
+protein	I-PRGE
+upon	O
+stimulation	O
+with	O
+epidermal	B-FUNC
+growth	B-PROC
+factor	I-FUNC
+was	O
+observed	O
+,	O
+providing	O
+preliminary	O
+evidence	O
+that	O
+the	O
+protein	B-CHED
+might	O
+be	O
+involved	O
+in	O
+the	O
+growth	B-PROC
+factor	O
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+fluorogenic	O
+nuclease	O
+RT	O
+-	O
+PCR	O
+assay	O
+should	O
+provide	O
+a	O
+potentially	O
+high	O
+-	O
+throughput	O
+,	O
+PCR	O
+-	O
+based	O
+method	O
+to	O
+detect	O
+rodent	B-SPEC
+coronaviruses	O
+in	O
+infected	O
+rodents	B-SPEC
+and	O
+contaminated	O
+biological	O
+materials	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+bolus	O
+instillation	O
+of	O
+surfactant	B-CHED
+can	O
+lead	O
+to	O
+acute	O
+pulmonary	B-ANAT
+,	O
+hemodynamic	B-PROC
+and	O
+cerebral	B-ANAT
+side	O
+effects	O
+,	O
+we	O
+tested	O
+whether	O
+pulmonary	B-ANAT
+mechanics	O
+and	O
+gas	B-ENZY
+exchange	O
+differ	O
+between	O
+slow	O
+surfactant	B-CHED
+infusion	O
+and	O
+bolus	O
+administration	O
+.	O
+
+Of	O
+20	O
+consecutive	O
+preterm	O
+infants	O
+(	O
+27	O
+-	O
+35	O
+weeks	O
+'	O
+gestation	B-PROC
+)	O
+with	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+)	O
+who	O
+were	O
+enrolled	O
+14	O
+with	O
+bovine	B-SPEC
+surfactant	B-CHED
+finally	O
+were	O
+analyzed	O
+.	O
+
+The	O
+purpose	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+impact	O
+of	O
+bronchoscopic	O
+surfactant	B-CHED
+administration	O
+,	O
+on	O
+the	O
+biochemical	O
+and	O
+biophysical	O
+surfactant	B-CHED
+properties	O
+,	O
+in	O
+patients	O
+with	O
+severe	O
+and	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+These	O
+included	O
+a	O
+massive	O
+alveolar	B-ANAT
+protein	B-CHED
+load	O
+,	O
+a	O
+reduced	O
+percentage	O
+of	O
+large	O
+surfactant	B-CHED
+aggregates	O
+(	O
+LA	O
+),	O
+a	O
+loss	O
+of	O
+palmitoylated	O
+phosphatidylcholine	O
+species	B-SPEC
+and	O
+a	O
+significant	O
+reduction	O
+of	O
+surfactant	B-CHED
+apoprotein	B-CHED
+(	O
+SP	B-CHED
+)-	O
+A	O
+,	O
+SP	B-PRGE
+-	I-PRGE
+B	I-PRGE
+and	O
+SP	B-PRGE
+-	I-PRGE
+C	I-PRGE
+in	O
+the	O
+LA	O
+fraction	O
+.	O
+
+Bronchoscopic	O
+administration	O
+of	O
+large	O
+quantities	O
+of	O
+natural	O
+bovine	B-SPEC
+surfactant	B-CHED
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+causes	O
+far	O
+-	O
+reaching	B-PROC
+restoration	O
+of	O
+biochemical	O
+surfactant	B-CHED
+properties	O
+and	O
+significant	O
+improvement	O
+,	O
+however	O
+not	O
+full	O
+normalization	O
+,	O
+of	O
+biophysical	O
+surfactant	B-CHED
+function	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+feasibility	O
+and	O
+efficacy	O
+of	O
+bronchoscopic	O
+surfactant	B-CHED
+administration	O
+in	O
+a	O
+noncontrolled	O
+multicentre	O
+study	O
+in	O
+five	O
+university	O
+centres	O
+.	O
+
+A	O
+total	O
+number	O
+of	O
+27	O
+patients	O
+,	O
+suffering	B-DISO
+from	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+mean	O
++/-	O
+SEM	B-DISO
+lung	B-ANAT
+injury	O
+score	O
+:	O
+3	O
+.	O
+15	O
++/-	O
+0	O
+.	O
+06	O
+)	O
+and	O
+septic	B-DISO
+shock	I-DISO
+(	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+(	O
+APACHE	O
+)	O
+II	O
+score	O
+at	O
+study	O
+entry	O
+33	O
+.	O
+2	O
++/-	O
+1	O
+.	O
+3	O
+,	O
+lactate	B-CHED
+4	O
+.	O
+3	O
++/-	O
+0	O
+.	O
+6	O
+mmol	O
+x	O
+L	O
+(-	O
+1	O
+))	O
+were	O
+studied	O
+.	O
+
+Percutaneous	O
+decompression	O
+is	O
+a	O
+safe	O
+and	O
+effective	O
+method	O
+of	O
+decreasing	O
+IAH	B-FUNC
+and	O
+preventing	O
+ACS	B-FUNC
+in	O
+patients	O
+with	O
+less	O
+than	O
+80	O
+%	O
+TBSA	O
+thermal	O
+injury	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+laryngeal	B-ANAT
+injury	O
+due	O
+to	O
+a	O
+nasogastric	B-ANAT
+tube	O
+].	O
+
+Following	O
+the	O
+repeated	O
+passage	O
+of	O
+these	O
+mutants	O
+through	O
+BHK	O
+-	O
+R2	O
+cells	B-COMP
+,	O
+viruses	B-SPEC
+were	O
+no	O
+longer	O
+isolated	O
+from	O
+srr11	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+while	O
+two	O
+distinct	O
+mutants	O
+,	O
+srr7A	O
+and	O
+srr7B	O
+,	O
+were	O
+obtained	O
+from	O
+srr7	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Srr7A	O
+and	O
+srr7B	O
+grew	O
+2	O
+log10	O
+higher	O
+than	O
+srr7	O
+and	O
+induced	O
+fusion	O
+in	O
+BHK	O
+-	O
+R2	O
+cells	O
+,	O
+being	O
+similar	O
+to	O
+wt	O
+virus	B-SPEC
+.	O
+
+As	O
+all	O
+recombinant	O
+deletion	O
+mutant	O
+viruses	B-SPEC
+appeared	O
+to	O
+be	O
+viable	O
+,	O
+we	O
+conclude	O
+that	O
+the	O
+MHV	B-SPEC
+group	O
+-	O
+specific	O
+genes	O
+are	O
+nonessential	O
+,	O
+accessory	O
+genes	O
+.	O
+
+The	O
+prevalence	O
+of	O
+FIV	B-SPEC
+antibodies	B-COMP
+was	O
+significantly	O
+higher	O
+in	O
+entire	O
+males	O
+and	O
+neutered	O
+males	O
+than	O
+in	O
+females	O
+,	O
+in	O
+cats	B-SPEC
+over	O
+two	O
+years	O
+old	O
+compared	O
+with	O
+younger	O
+cats	B-SPEC
+,	O
+and	O
+in	O
+cats	B-SPEC
+suffering	B-DISO
+disease	O
+of	O
+non	O
+-	O
+traumatic	O
+origin	O
+rather	O
+than	O
+in	O
+healthy	O
+cats	B-SPEC
+or	O
+cats	B-SPEC
+suffering	B-DISO
+only	O
+from	O
+trauma	O
+.	O
+
+Respiration	B-PROC
+rates	O
+were	O
+recorded	O
+hourly	O
+.	O
+
+The	O
+breed	O
+x	O
+time	O
+interaction	O
+tended	O
+to	O
+affect	O
+(	O
+p	O
+=	O
+0	O
+.	O
+14	O
+)	O
+growth	B-FUNC
+hormone	I-FUNC
+and	O
+influenced	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+respiration	B-PROC
+rates	O
+.	O
+
+First	O
+,	O
+we	O
+compared	O
+intra	O
+-	O
+and	O
+intermolecular	O
+integrative	O
+as	O
+well	O
+as	O
+excisive	O
+recombination	B-PROC
+pathways	B-PROC
+on	O
+episomal	O
+substrates	O
+after	O
+co	O
+-	O
+transfection	B-PROC
+with	O
+recombinase	B-PRGE
+expression	B-PROC
+vectors	O
+.	O
+
+This	O
+basic	O
+activity	O
+was	O
+stimulated	O
+several	O
+-	O
+fold	O
+when	O
+arm	B-ANAT
+-	O
+type	O
+DNA	O
+sequences	O
+were	O
+present	O
+in	O
+addition	O
+to	O
+core	O
+sites	O
+.	O
+
+It	O
+also	O
+provides	O
+a	O
+potential	O
+means	O
+to	O
+control	O
+site	O
+-	O
+specific	O
+recombination	B-PROC
+in	O
+eukaryotic	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+clinical	O
+course	O
+in	O
+the	O
+perioperative	O
+period	O
+was	O
+satisfactory	O
+and	O
+the	O
+bladder	B-ANAT
+balloon	O
+catheter	O
+was	O
+removed	O
+on	O
+the	O
+seventh	O
+hospital	O
+day	O
+.	O
+
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+showed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Blood	B-PROC
+coagulation	I-PROC
+data	O
+showed	O
+pre	O
+-	O
+disseminated	O
+intravascular	O
+coagulation	O
+.	O
+
+Emergent	O
+left	O
+orchiectomy	O
+was	O
+performed	O
+under	O
+local	B-PROC
+anesthesia	I-PROC
+on	O
+the	O
+twelfth	O
+hospital	O
+day	O
+.	O
+
+Highest	O
+mean	O
+(	O
+SD	O
+)	O
+SNAP	B-FUNC
+scores	O
+occurred	O
+in	O
+infants	O
+ventilated	O
+for	O
+meconium	B-DISO
+aspiration	I-DISO
+(	O
+18	O
+(	O
+9	O
+)),	O
+and	O
+perinatal	O
+asphyxia	O
+(	O
+17	O
+(	O
+9	O
+)),	O
+compared	O
+with	O
+pulmonary	B-DISO
+hypertension	I-DISO
+(	O
+14	O
+(	O
+6	O
+))	O
+and	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+13	O
+(	O
+5	O
+)).	O
+
+Formalin	B-CHED
+-	O
+fixed	B-ANAT
+intestinal	B-ANAT
+tissues	B-ANAT
+were	O
+examined	O
+by	O
+light	O
+and	O
+electron	O
+microscopy	O
+for	O
+attaching	O
+and	O
+effacing	O
+(	O
+AE	O
+)	O
+lesions	O
+characteristic	O
+of	O
+EPEC	O
+,	O
+and	O
+frozen	O
+(-	O
+75	O
+C	O
+)	O
+intestinal	B-ANAT
+contents	I-ANAT
+were	O
+examined	O
+for	O
+presence	O
+of	O
+EPEC	O
+.	O
+
+AE	O
+lesions	O
+were	O
+identified	O
+by	O
+light	O
+microscopy	O
+in	O
+Giemsa	O
+-	O
+stained	O
+intestines	B-ANAT
+from	O
+7	O
+of	O
+12	O
+PEMS	O
+-	O
+affected	O
+turkey	B-SPEC
+flocks	O
+.	O
+
+These	O
+findings	O
+provide	O
+additional	O
+evidence	O
+suggesting	O
+a	O
+possible	O
+role	O
+for	O
+EPEC	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+PEMS	O
+.	O
+
+Antibodies	B-COMP
+to	O
+BCV	B-SPEC
+or	O
+TGEV	B-SPEC
+were	O
+not	O
+reactive	O
+with	O
+any	O
+of	O
+the	O
+TCV	B-SPEC
+isolates	O
+.	O
+
+The	O
+first	O
+case	O
+occurred	O
+in	O
+an	O
+81	O
+-	O
+year	O
+-	O
+old	O
+ASA	B-CHED
+II	O
+woman	O
+scheduled	O
+for	O
+emergency	B-DISO
+abdominal	B-ANAT
+surgery	O
+.	O
+
+Severe	O
+haemodynamic	B-DISO
+instability	I-DISO
+and	O
+bronchospasm	B-DISO
+occurred	O
+after	O
+rocuronium	B-CHED
+.	O
+
+We	O
+present	O
+data	O
+from	O
+three	O
+adolescents	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+who	O
+received	O
+HFO	O
+with	O
+the	O
+Sensormedics	O
+3100B	O
+oscillator	O
+after	O
+failure	O
+of	O
+conventional	O
+mechanical	O
+ventilation	O
+.	O
+
+First	O
+evidence	O
+for	O
+the	O
+role	O
+of	O
+early	B-PRGE
+cytokines	I-PRGE
+in	O
+pneumonia	B-DISO
+in	O
+swine	B-SPEC
+came	O
+from	O
+experimental	O
+infections	B-DISO
+with	O
+Mycoplasma	B-SPEC
+hyopneumoniae	I-SPEC
+and	O
+Actinobacillus	B-SPEC
+pleuropneumoniae	I-SPEC
+.	O
+
+In	O
+comparison	O
+with	O
+the	O
+respective	O
+single	O
+inoculations	O
+,	O
+which	O
+were	O
+subclinical	O
+,	O
+there	O
+was	O
+a	O
+true	O
+potentiation	O
+of	O
+disease	O
+and	O
+production	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+.	O
+
+TITLE	O
+:	O
+A	O
+case	O
+of	O
+lung	B-ANAT
+transplantation	O
+following	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+infection	B-DISO
+.	O
+
+Due	O
+to	O
+persistent	O
+respiratory	O
+insufficiency	O
+and	O
+long	O
+-	O
+term	O
+failure	O
+to	O
+wean	B-PROC
+the	O
+patient	O
+from	O
+a	O
+respirator	O
+,	O
+a	O
+lung	B-ANAT
+transplantation	O
+was	O
+performed	O
+.	O
+
+Clostridium	B-SPEC
+perfringens	I-SPEC
+epsilon	B-PRGE
+-	I-PRGE
+toxin	I-PRGE
+could	O
+possibly	O
+be	O
+aerosolized	O
+to	O
+produce	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+.	O
+
+The	O
+growth	B-PROC
+rate	O
+of	O
+birds	B-SPEC
+that	O
+received	O
+0	O
+.	O
+5	O
+%	O
+arginine	B-CHED
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+of	O
+birds	B-SPEC
+receiving	O
+1	O
+.	O
+0	O
+or	O
+3	O
+.	O
+0	O
+%	O
+arginine	O
+,	O
+whereas	O
+the	O
+growth	B-PROC
+of	O
+the	O
+latter	O
+groups	O
+did	O
+not	O
+differ	O
+.	O
+
+It	O
+is	O
+defined	O
+as	O
+chronic	O
+alveolar	B-DISO
+hypoventilation	I-DISO
+(	O
+PaO	B-PROC
+(	O
+2	O
+)<	O
+70	O
+mmHg	O
+,	O
+PaCO	O
+(	O
+2	O
+)	O
+>	O
+45	O
+mmHg	O
+)	O
+in	O
+obese	B-DISO
+patient	O
+with	O
+a	O
+body	B-ANAT
+mass	O
+index	O
+>	O
+30	O
+kg	O
+/	O
+m	O
+(	O
+2	O
+)	O
+who	O
+have	O
+no	O
+other	O
+respiratory	B-DISO
+disease	I-DISO
+explaining	O
+the	O
+gas	B-ENZY
+anomalies	O
+.	O
+
+Obesity	B-DISO
+-	I-DISO
+hypoventilation	I-DISO
+syndrome	I-DISO
+must	O
+be	O
+distinguished	O
+from	O
+obstructive	B-DISO
+sleep	I-DISO
+apnea	I-DISO
+,	O
+although	O
+the	O
+two	O
+conditions	O
+are	O
+often	O
+associated	O
+.	O
+
+Mean	O
+daily	O
+rectal	O
+temperature	O
+and	O
+heart	B-ANAT
+rate	O
+were	O
+not	O
+affected	O
+by	O
+dietary	O
+treatment	O
+.	O
+
+Average	O
+packed	O
+cell	B-COMP
+volume	O
+was	O
+higher	O
+in	O
+treated	O
+calves	O
+than	O
+in	O
+control	O
+(	O
+35	O
+.	O
+0	O
+and	O
+27	O
+.	O
+0	O
+%).	O
+
+Control	O
+calves	O
+tended	O
+to	O
+have	O
+a	O
+greater	O
+average	O
+respiration	B-PROC
+rate	O
+compared	O
+with	O
+treated	O
+(	O
+28	O
+.	O
+7	O
+vs	O
+.	O
+26	O
+.	O
+8	O
+breaths	O
+/	O
+min	O
+).	O
+
+TITLE	O
+:	O
+Specific	O
+mucosal	B-ANAT
+IgA	B-PRGE
+immunity	B-PROC
+in	O
+turkey	B-SPEC
+poults	O
+infected	O
+with	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Turkey	B-SPEC
+poults	O
+were	O
+orally	B-ANAT
+inoculated	O
+with	O
+TCV	B-SPEC
+at	O
+10	O
+days	O
+of	O
+age	O
+.	O
+
+The	O
+kinetics	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+IgA	B-COMP
+antibody	I-COMP
+responses	O
+in	O
+duodenum	B-ANAT
+,	O
+jejunum	B-ANAT
+,	O
+and	O
+ileum	B-ANAT
+were	O
+similar	O
+:	O
+gradually	O
+increased	O
+from	O
+1	O
+week	O
+PI	O
+,	O
+reached	O
+the	O
+peak	O
+at	O
+3	O
+or	O
+4	O
+weeks	O
+PI	O
+,	O
+and	O
+declined	O
+afterward	O
+.	O
+
+Ten	O
+calves	O
+were	O
+inoculated	O
+intranasally	O
+with	O
+BVDV	B-SPEC
+Type	O
+1	O
+.	O
+
+All	O
+calves	O
+,	O
+including	O
+the	O
+controls	O
+,	O
+showed	O
+at	O
+least	O
+one	O
+of	O
+the	O
+following	O
+clinical	O
+signs	O
+during	O
+days	O
+3	O
+-	O
+15	O
+after	O
+the	O
+trial	O
+started	O
+:	O
+fever	B-PROC
+(>	O
+or	O
+=	O
+40	O
+degrees	O
+C	O
+),	O
+depressed	O
+general	O
+condition	B-DISO
+,	O
+diarrhoea	B-DISO
+,	O
+and	O
+cough	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Today	O
+ARDS	B-DISO
+is	O
+more	O
+frequently	O
+recognized	O
+and	O
+managed	O
+in	O
+tropical	O
+countries	O
+,	O
+although	O
+published	O
+data	O
+from	O
+most	O
+locations	O
+is	O
+meager	O
+.	O
+
+Additionally	O
+,	O
+tropical	O
+infections	B-DISO
+and	O
+other	O
+disorders	O
+are	O
+seen	O
+far	O
+more	O
+commonly	O
+.	O
+
+Both	O
+of	O
+these	O
+illnesses	O
+give	O
+lead	O
+to	O
+severe	O
+forms	O
+of	O
+disease	O
+,	O
+such	O
+as	O
+falciparum	B-DISO
+malaria	I-DISO
+,	O
+acute	O
+miliary	B-DISO
+TB	I-DISO
+or	O
+TB	O
+bronchopneumonia	B-DISO
+,	O
+and	O
+may	O
+cause	O
+ARDS	B-DISO
+.	O
+
+With	O
+proper	O
+management	O
+,	O
+most	O
+patients	O
+recover	B-PROC
+fully	O
+within	O
+six	O
+hours	O
+.	O
+
+Here	O
+,	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+33	O
+.	O
+1	O
+kDa	O
+transmissible	O
+gastroenteritis	B-DISO
+(	O
+corona	B-CHED
+)	O
+virus	B-SPEC
+M	O
+(	O
+pro	B-CHED
+)	O
+is	O
+reported	O
+.	O
+
+Severe	O
+dyspnea	B-DISO
+developed	O
+after	O
+the	O
+bronchofiberscopy	O
+,	O
+when	O
+the	O
+chest	B-ANAT
+radiograph	O
+revealed	O
+bilateral	O
+ground	O
+-	O
+glass	O
+shadows	O
+and	O
+the	O
+oxygen	B-CHED
+saturation	O
+in	O
+the	O
+room	O
+air	B-CHED
+fell	O
+to	O
+60	O
+%.	O
+
+It	O
+was	O
+suspected	O
+that	O
+the	O
+patient	O
+had	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+so	O
+that	O
+methylprednisolone	B-CHED
+was	O
+given	O
+intravenously	O
+at	O
+a	O
+dose	O
+of	O
+250	O
+mg	O
+daily	O
+for	O
+3	O
+days	O
+,	O
+which	O
+resulted	O
+in	O
+a	O
+reduction	O
+in	O
+ground	O
+glass	O
+shadows	O
+and	O
+an	O
+improvement	O
+in	O
+oxygen	B-CHED
+saturation	O
+.	O
+
+We	O
+diagnosed	O
+miliary	B-DISO
+tuberculosis	I-DISO
+because	O
+the	O
+transbronchial	O
+lung	B-ANAT
+biopsy	B-ANAT
+specimen	I-ANAT
+showed	O
+caseous	O
+granuloma	B-DISO
+and	O
+the	O
+PCR	O
+test	O
+for	O
+Mycobacterium	B-SPEC
+tuberculosis	I-SPEC
+in	O
+the	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+was	O
+positive	O
+.	O
+
+Increased	O
+induction	O
+of	O
+MMP	B-PRGE
+,	O
+TIMP	B-PRGE
+,	O
+and	O
+chemokine	O
+expression	B-PROC
+correlated	O
+with	O
+increased	O
+virus	B-PROC
+replication	I-PROC
+but	O
+not	O
+with	O
+inflammatory	B-DISO
+cell	I-DISO
+infiltration	I-DISO
+.	O
+
+These	O
+data	O
+indicate	O
+an	O
+association	O
+between	O
+the	O
+magnitude	O
+of	O
+inflammatory	O
+gene	O
+expression	O
+within	O
+the	O
+CNS	B-CHED
+and	O
+viral	O
+virulence	B-PROC
+.	O
+
+TITLE	O
+:	O
+Assessment	O
+of	O
+static	O
+isolator	O
+cages	O
+with	O
+automatic	O
+watering	O
+when	O
+used	O
+with	O
+conventional	O
+husbandry	O
+techniques	O
+as	O
+a	O
+factor	O
+in	O
+the	O
+transmission	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+More	O
+than	O
+50	O
+%	O
+of	O
+the	O
+mice	B-SPEC
+were	O
+breeding	B-PROC
+mice	B-SPEC
+,	O
+and	O
+30	O
+%	O
+were	O
+genetically	O
+altered	O
+.	O
+
+One	O
+cage	O
+of	O
+mice	B-SPEC
+on	O
+each	O
+shelf	O
+on	O
+both	O
+sides	O
+of	O
+the	O
+rack	O
+was	O
+infected	O
+with	O
+MHV	B-SPEC
+-	O
+A59	O
+.	O
+
+TITLE	O
+:	O
+A	O
+randomized	O
+phase	O
+II	O
+trial	O
+of	O
+granulocyte	B-PRGE
+-	I-PRGE
+macrophage	B-ANAT
+colony	I-PRGE
+-	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+therapy	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+with	O
+respiratory	B-DISO
+dysfunction	I-DISO
+.	O
+
+We	O
+investigated	O
+whether	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+therapy	O
+improved	O
+clinically	O
+diagnosed	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+respiratory	B-DISO
+dysfunction	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+-	O
+treated	O
+patients	O
+showed	O
+improvement	O
+in	O
+Pa	O
+(	O
+O	O
+(	O
+2	O
+))/	O
+FI	O
+(	O
+O	O
+(	O
+2	O
+))	O
+over	O
+5	O
+days	O
+(	O
+p	O
+=	O
+0	O
+.	O
+02	O
+)	O
+and	O
+increased	O
+peripheral	O
+blood	B-ANAT
+neutrophils	I-ANAT
+(	O
+p	O
+=	O
+0	O
+.	O
+08	O
+),	O
+whereas	O
+alveolar	B-ANAT
+neutrophils	B-ANAT
+decreased	O
+(	O
+p	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+TITLE	O
+:	O
+Management	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Significant	O
+advances	O
+have	O
+occurred	O
+in	O
+the	O
+knowledge	O
+of	O
+the	O
+pathogenesis	O
+of	O
+ARDS	B-DISO
+.	O
+
+Alternative	O
+modes	O
+of	O
+supporting	O
+gas	B-ENZY
+exchange	O
+,	O
+such	O
+as	O
+with	O
+partial	O
+liquid	O
+ventilation	O
+and	O
+extracorporeal	O
+gas	B-ENZY
+-	O
+exchange	O
+,	O
+may	O
+serve	O
+as	O
+rescue	O
+therapies	O
+.	O
+
+Advances	O
+in	O
+cell	B-COMP
+and	O
+molecular	O
+biology	O
+have	O
+contributed	O
+to	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+role	O
+of	O
+inflammatory	B-ANAT
+cells	I-ANAT
+and	O
+mediators	O
+that	O
+contribute	O
+to	O
+the	O
+acute	O
+lung	O
+injury	O
+and	O
+the	O
+pathophysiology	O
+of	O
+the	O
+syndrome	B-DISO
+that	O
+manifests	O
+as	O
+ARDS	B-DISO
+.	O
+
+A	O
+15	O
+-	O
+year	O
+-	O
+old	O
+girl	O
+presented	O
+with	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+fever	B-PROC
+,	O
+seizures	B-DISO
+and	O
+abdominal	B-DISO
+pain	I-DISO
+.	O
+
+The	O
+percentage	O
+of	O
+PBMC	O
+MIF	O
+expression	B-PROC
+was	O
+higher	O
+in	O
+ARDS	B-DISO
+patients	O
+than	O
+in	O
+normal	O
+controls	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+CONCLUSIONS	O
+:	O
+There	O
+is	O
+a	O
+potential	O
+role	O
+for	O
+a	O
+combined	O
+therapy	O
+with	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+and	O
+surfactant	B-CHED
+replacement	O
+in	O
+reperfusion	O
+injury	O
+after	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+This	O
+possibility	O
+was	O
+examined	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+a	O
+well	O
+-	O
+described	O
+model	O
+of	O
+virus	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+These	O
+findings	O
+demonstrate	O
+a	O
+novel	O
+mechanism	O
+for	O
+immune	O
+-	O
+mediated	O
+neuropathology	O
+and	O
+show	O
+that	O
+activated	O
+CD8	B-PRGE
+T	B-ANAT
+cells	I-ANAT
+may	O
+serve	O
+as	O
+important	O
+mediators	O
+of	O
+bystander	O
+demyelination	B-DISO
+during	O
+times	O
+of	O
+infection	B-DISO
+,	O
+including	O
+in	O
+patients	O
+with	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+He	O
+was	O
+treated	O
+with	O
+positive	O
+pressure	O
+ventilation	O
+,	O
+beta	B-CHED
+-	I-CHED
+adrenergic	I-CHED
+agonists	I-CHED
+,	O
+and	O
+corticosteroids	B-CHED
+.	O
+
+Recent	O
+evidence	O
+suggests	O
+that	O
+progressive	O
+ARDS	B-DISO
+is	O
+closely	O
+linked	O
+to	O
+activation	O
+of	O
+inflammation	B-DISO
+and	O
+coagulation	B-PROC
+.	O
+
+All	O
+samples	O
+ELISA	O
+positive	O
+for	O
+BCV	B-SPEC
+were	O
+matched	O
+with	O
+an	O
+equal	O
+number	O
+of	O
+BCV	B-SPEC
+ELISA	O
+-	O
+negative	O
+samples	O
+and	O
+analyzed	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+of	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+.	O
+
+Paired	O
+sera	B-COMP
+were	O
+collected	O
+at	O
+arrival	O
+and	O
+21	O
+DPA	B-CHED
+and	O
+tested	O
+for	O
+antibodies	B-COMP
+to	O
+BCV	B-SPEC
+using	O
+an	O
+indirect	O
+ELISA	O
+.	O
+
+The	O
+peak	O
+of	O
+BCV	B-SPEC
+nasal	B-ANAT
+and	O
+fecal	B-ANAT
+shedding	O
+occurred	O
+at	O
+4	O
+DPA	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+prevalence	O
+and	O
+spatial	O
+distribution	O
+of	O
+air	B-CHED
+cysts	B-DISO
+and	O
+bronchiectasis	B-DISO
+associated	O
+with	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Severity	O
+of	O
+changes	O
+revealed	O
+by	O
+computed	O
+tomographic	O
+imaging	O
+seems	O
+to	O
+be	O
+associated	O
+mainly	O
+with	O
+the	O
+high	O
+inspiratory	B-PROC
+pressures	O
+required	O
+and	O
+the	O
+length	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+Vasopressin	B-PRGE
+(	O
+0	O
+.	O
+04	O
+units	O
+/	O
+min	O
+)	O
+was	O
+administered	O
+through	O
+a	O
+peripheral	O
+venous	B-ANAT
+catheter	O
+for	O
+hypotension	O
+unresponsive	O
+to	O
+exogenous	O
+catecholamines	B-CHED
+.	O
+
+It	O
+can	O
+cause	O
+life	O
+-	O
+threatening	O
+morbidities	O
+,	O
+including	O
+cardiac	B-DISO
+arrhythmia	I-DISO
+and	O
+ischemia	B-DISO
+,	O
+hypertension	B-DISO
+,	O
+and	O
+respiratory	B-DISO
+arrest	I-DISO
+,	O
+and	O
+even	O
+death	B-PROC
+.	O
+
+The	O
+role	O
+of	O
+granulocyte	B-PRGE
+-	I-PRGE
+macrophage	B-ANAT
+colony	I-PRGE
+-	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+in	O
+mediating	O
+the	O
+ALI	O
+associated	O
+with	O
+secretagogue	O
+-	O
+induced	O
+experimental	O
+pancreatitis	B-DISO
+was	O
+evaluated	O
+with	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+knockout	O
+mice	B-SPEC
+(	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+-/-).	O
+
+The	O
+immune	B-PROC
+response	I-PROC
+to	O
+S	B-PRGE
+protein	I-PRGE
+was	O
+barely	O
+detectable	O
+in	O
+naturally	O
+infected	O
+dogs	B-SPEC
+,	O
+whereas	O
+anti	O
+-	O
+M	O
+and	O
+anti	O
+-	O
+N	O
+antibodies	B-COMP
+were	O
+detected	O
+with	O
+a	O
+very	O
+strong	O
+reaction	O
+and	O
+for	O
+a	O
+long	O
+time	O
+post	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+effects	O
+of	O
+inhalation	B-PROC
+of	O
+a	O
+novel	O
+nitric	B-CHED
+oxide	I-CHED
+donor	I-CHED
+,	O
+DETA	O
+/	O
+NO	O
+,	O
+in	O
+a	O
+patient	O
+with	O
+severe	O
+hypoxaemia	O
+due	O
+to	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+External	O
+PEEP	B-CHED
+was	O
+adjusted	O
+to	O
+keep	O
+the	O
+total	O
+PEEP	B-CHED
+and	O
+the	O
+plateau	O
+pressure	O
+constant	O
+.	O
+
+RESULTS	O
+:	O
+Increase	O
+in	O
+respiratory	O
+rate	O
+resulted	O
+in	O
+significantly	O
+higher	O
+PEEPi	O
+(	O
+1	O
+.	O
+3	O
++/-	O
+0	O
+.	O
+4	O
+versus	O
+3	O
+.	O
+9	O
++/-	O
+1	O
+.	O
+1	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+and	O
+trapped	O
+volume	O
+(	O
+70	O
++/-	O
+43	O
+versus	O
+244	O
++/-	O
+127	O
+ml	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Long	O
+-	O
+distance	O
+interhospital	O
+ground	O
+transfer	O
+of	O
+even	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+severe	O
+unstable	O
+respiratory	O
+and	O
+circulatory	B-DISO
+failure	I-DISO
+is	O
+safe	O
+if	O
+a	O
+dedicated	O
+transport	B-PROC
+team	O
+and	O
+a	O
+specially	O
+equipped	O
+transport	B-PROC
+vehicle	O
+are	O
+used	O
+.	O
+
+ABSTRACT	O
+:	O
+Because	O
+of	O
+its	O
+high	O
+diffusing	O
+capacity	O
+through	O
+the	O
+alveolar	O
+-	O
+blood	B-ANAT
+barrier	O
+and	O
+its	O
+high	O
+selectivity	O
+for	O
+the	O
+pulmonary	B-ANAT
+vasculature	I-ANAT
+,	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+has	O
+been	O
+recently	O
+shown	O
+to	O
+be	O
+a	O
+viable	O
+and	O
+efficient	O
+approach	O
+to	O
+restore	O
+pulmonary	B-ANAT
+NO	O
+deficiency	O
+.	O
+
+TITLE	O
+:	O
+Hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+partial	O
+upper	B-DISO
+airway	I-DISO
+obstruction	I-DISO
+during	O
+high	O
+frequency	O
+oscillatory	O
+ventilation	O
+in	O
+an	O
+adult	O
+burn	O
+patient	O
+.	O
+
+A	O
+6	O
+.	O
+0	O
+-	O
+mm	O
+nasotracheal	O
+tube	O
+was	O
+inserted	O
+into	O
+the	O
+supraglottic	O
+hypopharynx	B-ANAT
+to	O
+palliate	O
+presumed	O
+expiratory	B-PROC
+upper	B-DISO
+airway	I-DISO
+obstruction	I-DISO
+.	O
+
+TITLE	O
+:	O
+Adult	B-DISO
+onset	I-DISO
+Still	I-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+as	O
+a	O
+cause	O
+of	O
+ARDS	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+patient	O
+had	O
+a	O
+markedly	O
+elevated	O
+serum	B-PRGE
+ferritin	I-PRGE
+concentration	O
+of	O
+7880	O
+micrograms	O
+/	O
+L	O
+,	O
+a	O
+specific	O
+finding	O
+for	O
+the	O
+adult	B-DISO
+onset	I-DISO
+Still	I-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+(	O
+AOSD	O
+).	O
+
+Sequencing	O
+of	O
+various	O
+regions	O
+of	O
+the	O
+spike	O
+and	O
+polymerase	O
+genes	O
+confirms	O
+that	O
+UWSMN	O
+-	O
+1	O
+is	O
+widely	O
+divergent	O
+from	O
+other	O
+CCV	B-DISO
+and	O
+feline	B-SPEC
+coronavirus	B-SPEC
+strains	O
+.	O
+
+The	O
+IN	O
+and	O
+HAI	O
+antibody	B-PROC
+responses	I-PROC
+against	O
+the	O
+two	O
+EBCV	O
+strains	O
+did	O
+not	O
+differ	O
+significantly	O
+,	O
+but	O
+the	O
+lowest	O
+titers	O
+were	O
+detected	O
+with	O
+EBCV	O
+strain	O
+L9	O
+-	O
+81	O
+.	O
+
+Major	O
+amino	O
+acid	O
+changes	O
+involved	O
+insertion	O
+of	O
+two	O
+stretches	B-DISO
+(	O
+aa118	O
+-	O
+119	O
+:	O
+Arg	B-CHED
+-	O
+Ser	B-COMP
+and	O
+aa141	B-PRGE
+-	I-PRGE
+145	I-PRGE
+:	O
+Sys	B-PRGE
+-	I-PRGE
+Ser	I-PRGE
+-	I-PRGE
+Asn	B-CHED
+-	I-PRGE
+Ala	B-CHED
+-	I-PRGE
+Ser	B-COMP
+-	I-PRGE
+Cys	B-CHED
+)	O
+located	O
+at	O
+N	O
+-	O
+terrminal	O
+and	O
+C	O
+-	O
+terminal	O
+regions	O
+of	O
+HVR	O
+-	O
+2	O
+.	O
+
+ABSTRACT	O
+:	O
+Transfusion	O
+-	O
+related	O
+acute	O
+lung	O
+injury	O
+(	O
+TRALI	B-DISO
+)	O
+has	O
+been	O
+implicated	O
+with	O
+use	O
+of	O
+almost	O
+all	O
+types	O
+of	O
+blood	B-ANAT
+products	O
+that	O
+contain	O
+variable	O
+amounts	O
+of	O
+plasma	B-ANAT
+.	O
+
+Diagnosing	O
+TRALI	B-DISO
+has	O
+implications	O
+not	O
+only	O
+for	O
+the	O
+plasma	B-ANAT
+exchange	O
+recipient	O
+,	O
+but	O
+also	O
+for	O
+the	O
+management	O
+of	O
+donors	O
+found	O
+to	O
+have	O
+leukocyte	B-ANAT
+antibodies	B-COMP
+.	O
+
+In	O
+conclusion	O
+,	O
+sialodacryoadenitis	O
+virus	B-DISO
+infection	I-DISO
+in	O
+rats	B-SPEC
+was	O
+associated	O
+with	O
+increased	O
+frequency	O
+of	O
+hepatic	B-ANAT
+mtDNA	B-COMP
+deletions	O
+.	O
+
+The	O
+major	O
+delayed	O
+diagnoses	O
+included	O
+pneumothorax	B-DISO
+hematopneumothorax	O
+,	O
+intraperitoneal	O
+organ	B-ANAT
+injury	O
+,	O
+and	O
+fracture	O
+.	O
+
+RESULTS	O
+:	O
+Seventy	O
+-	O
+six	O
+cases	O
+survived	O
+and	O
+twelve	O
+cases	O
+died	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+optimal	O
+treatment	O
+for	O
+the	O
+hematological	O
+toxicity	O
+of	O
+acute	O
+radiation	O
+syndrome	O
+(	O
+ARS	O
+)	O
+is	O
+not	O
+fully	O
+established	O
+,	O
+especially	O
+in	O
+cases	O
+of	O
+high	O
+-	O
+dose	O
+nonuniform	O
+irradiation	O
+by	O
+mixed	O
+neutrons	O
+and	O
+gamma	O
+-	O
+rays	B-SPEC
+,	O
+because	O
+estimation	O
+of	O
+the	O
+irradiation	O
+dose	O
+(	O
+dosimetry	O
+)	O
+and	O
+prediction	O
+of	O
+autologous	O
+hematological	O
+recovery	O
+are	O
+complicated	O
+.	O
+
+Donor	B-CHED
+/	O
+recipient	O
+mixed	O
+chimerism	O
+was	O
+attained	O
+;	O
+thereafter	O
+rapid	O
+autologous	O
+hematopoietic	O
+recovery	O
+was	O
+achieved	O
+in	O
+concordance	O
+with	O
+the	O
+termination	O
+of	O
+immunosuppressants	O
+.	O
+
+Endogenous	O
+immunoglobulin	B-PROC
+production	I-PROC
+was	O
+also	O
+suppressed	O
+until	O
+120	O
+days	O
+after	O
+the	O
+accident	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+fast	B-FUNC
+neutrons	O
+in	O
+doses	O
+higher	O
+than	O
+8	O
+to	O
+10	O
+Gy	O
+cause	O
+complete	O
+abrogation	O
+of	O
+the	O
+human	B-SPEC
+immune	B-ANAT
+system	I-ANAT
+,	O
+which	O
+may	O
+lead	O
+to	O
+fatal	O
+outcome	O
+even	O
+if	O
+autologous	O
+hematopoiesis	B-PROC
+recovers	O
+.	O
+
+The	O
+patient	O
+died	B-PROC
+nine	O
+months	O
+later	O
+due	O
+to	O
+respiratory	B-DISO
+complications	I-DISO
+.	O
+
+We	O
+hypothesized	O
+that	O
+alveolar	B-ANAT
+macrophage	I-ANAT
+(	O
+AMPhi	O
+)	O
+chemokine	O
+and	O
+cytokine	O
+release	B-PATH
+after	O
+hemorrhage	B-DISO
+and	O
+sepsis	B-DISO
+is	O
+regulated	O
+by	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+and	O
+MAPK	B-FUNC
+.	O
+
+Activation	B-PROC
+of	I-PROC
+NF	I-PROC
+-	I-PROC
+kappaB	I-PROC
+increased	O
+in	O
+lungs	B-ANAT
+from	O
+the	O
+hemorrhage	B-DISO
+and	O
+CLP	O
+group	O
+compared	O
+with	O
+shams	O
+.	O
+
+The	O
+remaining	O
+cases	O
+were	O
+not	O
+associated	O
+with	O
+any	O
+other	O
+condition	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleoprotein	O
+(	O
+NP	O
+)	O
+of	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+)	O
+functions	O
+primarily	O
+to	O
+encapsidate	O
+the	O
+virus	B-SPEC
+genome	O
+for	O
+the	O
+purpose	O
+of	O
+RNA	O
+transcription	B-PROC
+,	O
+replication	O
+,	O
+and	O
+packaging	O
+.	O
+
+In	O
+addition	O
+,	O
+a	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitope	B-CHED
+of	O
+the	O
+S2	B-PRGE
+glycoprotein	I-PRGE
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+was	O
+inserted	O
+in	O
+-	O
+frame	O
+to	O
+replace	O
+the	O
+NP	O
+-	O
+IDE	B-CHED
+.	O
+
+Recombinant	O
+viruses	B-SPEC
+properly	O
+expressing	O
+the	O
+introduced	O
+MHV	O
+epitope	B-CHED
+were	O
+successfully	O
+generated	O
+,	O
+demonstrating	O
+that	O
+the	O
+NP	B-PRGE
+-	I-PRGE
+IDE	I-PRGE
+not	O
+only	O
+is	O
+dispensable	O
+for	O
+virus	B-PROC
+replication	I-PROC
+but	O
+also	O
+can	O
+be	O
+replaced	O
+by	O
+foreign	O
+sequences	O
+.	O
+
+The	O
+combination	O
+of	O
+ARDS	B-DISO
+and	O
+severe	O
+brain	B-ANAT
+injury	O
+needs	O
+special	O
+treatment	O
+,	O
+which	O
+includes	O
+extensive	O
+monitoring	O
+techniques	O
+to	O
+find	O
+a	O
+solution	O
+for	O
+therapeutic	O
+conflicts	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+situ	O
+hybridization	B-PROC
+and	O
+immunohistochemistry	O
+were	O
+utilized	O
+to	O
+identify	O
+tissues	B-ANAT
+infected	O
+in	O
+ovo	B-SPEC
+with	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+At	O
+24	O
+,	O
+48	O
+,	O
+72	O
+,	O
+and	O
+120	O
+hr	O
+postinfection	O
+(	O
+HPI	B-DISO
+),	O
+bursa	B-SPEC
+,	O
+lung	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+and	O
+thymus	B-SPEC
+were	O
+collected	O
+,	O
+fixed	B-ANAT
+in	O
+10	O
+%	O
+neutral	O
+buffered	O
+formalin	B-CHED
+,	O
+and	O
+paraffin	O
+embedded	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+in	O
+situ	O
+hybridization	B-PROC
+can	O
+be	O
+useful	O
+in	O
+detection	O
+of	O
+IBV	B-SPEC
+-	O
+infected	O
+chickens	B-SPEC
+and	O
+in	O
+understanding	O
+the	O
+pathogenesis	B-DISO
+and	O
+virulence	B-PROC
+of	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Tissue	B-ANAT
+distribution	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+following	O
+in	O
+ovo	B-SPEC
+inoculation	O
+of	O
+chicken	B-SPEC
+embryos	B-ANAT
+examined	O
+by	O
+in	O
+situ	O
+hybridization	B-PROC
+with	O
+antisense	O
+digoxigenin	B-CHED
+-	O
+labeled	O
+universal	O
+riboprobe	O
+.	O
+
+The	O
+results	O
+demonstrated	O
+strict	O
+epitheliotropic	O
+nature	O
+and	O
+wide	O
+tissue	B-PROC
+tropism	B-PROC
+of	O
+strains	O
+of	O
+IBV	B-SPEC
+in	O
+the	O
+chicken	B-SPEC
+embryo	B-ANAT
+and	O
+the	O
+universality	O
+of	O
+our	O
+riboprobe	O
+.	O
+
+Neutrophil	B-ANAT
+activity	O
+was	O
+assessed	O
+by	O
+18FDG	O
+uptake	O
+.	O
+
+Neutrophils	B-ANAT
+were	O
+counted	O
+in	O
+histologic	O
+sections	O
+of	O
+saline	O
+-	O
+perfused	O
+lungs	B-ANAT
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+develop	O
+a	O
+standardized	O
+and	O
+reproducible	O
+model	O
+of	O
+hyperdynamic	O
+sepsis	B-DISO
+after	O
+smoke	O
+inhalation	B-PROC
+in	O
+sheep	B-SPEC
+.	O
+
+During	O
+halothane	B-CHED
+anesthesia	B-DISO
+,	O
+live	O
+bacteria	B-SPEC
+suspended	O
+in	O
+a	O
+30	O
+-	O
+mL	O
+saline	O
+solution	O
+containing	O
+2	O
+-	O
+5	O
+x	O
+10	O
+(	O
+11	O
+)	O
+colony	O
+-	O
+forming	O
+units	O
+were	O
+instilled	O
+through	O
+a	O
+bronchoscope	O
+into	O
+the	O
+right	O
+lower	O
+and	O
+middle	O
+lung	B-ANAT
+lobes	B-ANAT
+(	O
+10	O
+mL	O
+each	O
+)	O
+and	O
+left	O
+lower	B-ANAT
+lung	I-ANAT
+lobe	I-ANAT
+(	O
+10	O
+mL	O
+;	O
+n	O
+=	O
+10	O
+).	O
+
+The	O
+animals	B-SPEC
+were	O
+monitored	O
+for	O
+48	O
+hrs	B-DISO
+.	O
+
+Mean	O
+arterial	B-PROC
+pressures	I-PROC
+at	O
+48	O
+hrs	B-DISO
+in	O
+the	O
+smoke	O
+-	O
+alone	O
+and	O
+the	O
+smoke	O
++	O
+sepsis	B-DISO
+group	O
+were	O
+85	O
+.	O
+5	O
++/-	O
+
+Although	O
+the	O
+incidence	O
+of	O
+postoperative	O
+visual	B-DISO
+loss	I-DISO
+is	O
+low	O
+(-	O
+0	O
+.	O
+002	O
+%),	O
+awareness	O
+of	O
+this	O
+entity	O
+must	O
+be	O
+raised	O
+within	O
+the	O
+trauma	O
+surgical	O
+community	O
+.	O
+
+He	O
+had	O
+been	O
+diagnosed	O
+6	O
+years	O
+earlier	O
+with	O
+IgA	B-DISO
+nephropathy	I-DISO
+(	O
+IgA	B-PRGE
+-	I-PRGE
+N	I-PRGE
+).	O
+
+Ending	O
+HFOV	O
+after	O
+6	O
+.	O
+6	O
+(	O
+SD	O
+3	O
+.	O
+2	O
+)	O
+days	O
+,	O
+survivors	O
+(	O
+n	O
+=	O
+11	O
+)	O
+significantly	O
+reduced	O
+their	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+Score	O
+(	O
+SOFA	O
+)	O
+compared	O
+to	O
+baseline	O
+.	O
+
+CONCLUSIONS	O
+:	O
+HFOV	O
+effectively	O
+improves	O
+oxygenation	B-PROC
+without	O
+haemodynamic	O
+compromise	O
+.	O
+
+This	O
+pathological	B-DISO
+process	I-DISO
+is	O
+primarily	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+and	O
+MHV	B-SPEC
+infection	B-DISO
+of	O
+mice	B-SPEC
+lacking	O
+B	O
+and	O
+T	B-ANAT
+cells	I-ANAT
+does	O
+not	O
+result	O
+in	O
+demyelination	B-DISO
+.	O
+
+These	O
+results	O
+show	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+that	O
+gamma	O
+delta	O
+T	B-ANAT
+cells	I-ANAT
+can	O
+substitute	O
+for	O
+alpha	O
+beta	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+a	O
+virus	B-SPEC
+model	O
+of	O
+demyelination	B-DISO
+and	O
+further	O
+support	O
+a	O
+pathological	O
+role	O
+for	O
+gamma	O
+delta	O
+T	O
+cells	O
+in	O
+patients	O
+with	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+method	O
+was	O
+developed	O
+to	O
+assemble	O
+a	O
+full	O
+-	O
+length	O
+infectious	O
+cDNA	O
+of	O
+the	O
+group	O
+II	O
+coronavirus	B-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+).	O
+
+RNA	O
+transcripts	O
+derived	O
+from	O
+the	O
+full	O
+-	O
+length	O
+MHV	B-SPEC
+-	O
+A59	O
+construct	O
+were	O
+infectious	B-DISO
+,	O
+although	O
+transfection	B-PROC
+frequencies	O
+were	O
+enhanced	O
+10	O
+-	O
+to	O
+15	O
+-	O
+fold	O
+in	O
+the	O
+presence	O
+of	O
+transcripts	O
+encoding	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+N	O
+.	O
+Plaque	B-DISO
+-	O
+purified	O
+virus	B-SPEC
+derived	O
+from	O
+the	O
+infectious	B-DISO
+construct	O
+replicated	O
+efficiently	O
+and	O
+displayed	O
+similar	O
+growth	B-PROC
+kinetics	O
+,	O
+plaque	B-DISO
+morphology	O
+,	O
+and	O
+cytopathology	O
+in	O
+murine	B-SPEC
+cells	B-COMP
+as	O
+did	O
+wild	O
+-	O
+type	O
+MHV	B-SPEC
+-	O
+A59	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+whether	O
+early	O
+surfactant	B-CHED
+administration	O
+is	O
+superior	O
+to	O
+selective	O
+delayed	O
+treatment	O
+in	O
+terms	O
+of	O
+improving	O
+survival	O
+and	O
+/	O
+or	O
+reducing	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+in	O
+extremely	O
+premature	O
+neonates	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+RDS	O
+)	O
+treated	O
+by	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+).	O
+
+All	O
+were	O
+ventilated	O
+by	O
+HFOV	O
+as	O
+the	O
+primary	O
+mode	O
+of	O
+ventilation	O
+using	O
+the	O
+high	O
+volume	O
+strategy	O
+aimed	O
+at	O
+optimizing	O
+lung	B-PROC
+volume	I-PROC
+.	O
+
+When	O
+compared	O
+to	O
+delayed	O
+dosing	O
+,	O
+early	O
+administration	O
+of	O
+surfactant	B-CHED
+followed	O
+by	O
+HFOV	O
+facilitates	O
+and	O
+accelerates	O
+respiratory	O
+stabilization	O
+during	O
+the	O
+acute	O
+phase	O
+of	O
+severe	O
+RDS	O
+,	O
+may	O
+reduce	O
+the	O
+incidence	O
+of	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+or	O
+death	B-PROC
+and	O
+may	O
+positively	O
+influence	O
+the	O
+incidence	O
+of	O
+severe	O
+intracranial	B-ANAT
+pathology	B-DISO
+in	O
+extremely	O
+premature	O
+infants	O
+with	O
+primary	O
+surfactant	B-CHED
+insufficiency	O
+.	O
+
+If	O
+this	O
+hypothesis	O
+is	O
+confirmed	O
+,	O
+it	O
+will	O
+require	O
+a	O
+new	O
+approach	O
+in	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+patients	O
+who	O
+exhibit	O
+this	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Two	O
+methods	O
+were	O
+developed	O
+to	O
+displace	O
+the	O
+antibodies	B-COMP
+from	O
+BEV	B-SPEC
+and	O
+BPV	B-SPEC
+and	O
+thereby	O
+render	O
+them	O
+accessible	O
+for	O
+titration	O
+.	O
+
+To	O
+risk	O
+-	O
+adjust	O
+patients	O
+with	O
+longer	O
+,	O
+more	O
+severe	O
+illnesses	O
+like	O
+sepsis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+several	O
+models	O
+of	O
+organ	B-ANAT
+dysfunction	O
+or	O
+failure	O
+have	O
+become	O
+available	O
+,	O
+including	O
+the	O
+Multiple	O
+Organ	B-ANAT
+Dysfunction	O
+Score	O
+(	O
+MODS	B-DISO
+),	O
+the	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+(	O
+SOFA	O
+),	O
+and	O
+the	O
+Logistic	O
+Organ	B-ANAT
+Dysfunction	O
+Score	O
+(	O
+LODS	O
+).	O
+
+The	O
+PCR	O
+products	O
+were	O
+cloned	O
+and	O
+sequenced	O
+and	O
+their	O
+nucleic	B-CHED
+acid	I-CHED
+structure	O
+and	O
+similarity	O
+to	O
+the	O
+published	O
+sequences	O
+of	O
+IBV	B-SPEC
+were	O
+analyzed	O
+.	O
+
+Gene	O
+5	O
+containing	O
+two	O
+overlapping	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+),	O
+5a	O
+and	O
+5b	O
+,	O
+was	O
+localized	O
+between	O
+M	O
+and	O
+N	O
+genes	O
+of	O
+TCV	B-SPEC
+.	O
+
+The	O
+Sindbis	O
+replicon	O
+vector	O
+and	O
+the	O
+ectopic	O
+TGEV	B-PRGE
+E	I-PRGE
+protein	B-CHED
+did	O
+not	O
+interfere	O
+with	O
+the	O
+rescue	O
+of	O
+infectious	B-DISO
+TGEV	B-SPEC
+from	O
+full	O
+-	O
+length	O
+cDNA	O
+.	O
+
+All	O
+patients	O
+developed	O
+neurologic	O
+complications	O
+resulting	O
+from	O
+ACS	B-FUNC
+episodes	O
+,	O
+including	O
+seizures	B-DISO
+(	O
+n	O
+=	O
+2	O
+),	O
+silent	O
+cerebral	B-DISO
+infarcts	I-DISO
+(	O
+n	O
+=	O
+3	O
+),	O
+cerebral	B-DISO
+hemorrhage	I-DISO
+(	O
+n	O
+=	O
+2	O
+),	O
+and	O
+reversible	B-DISO
+posterior	I-DISO
+leukoencephalopathy	I-DISO
+syndrome	I-DISO
+(	O
+n	O
+=	O
+3	O
+).	O
+
+However	O
+,	O
+comparative	O
+sequence	O
+analysis	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+revealed	O
+that	O
+the	O
+identity	O
+was	O
+not	O
+100	O
+%	O
+to	O
+any	O
+of	O
+the	O
+strains	O
+of	O
+this	O
+serotype	O
+that	O
+we	O
+analysed	O
+.	O
+
+A	O
+virus	B-SPEC
+related	O
+to	O
+the	O
+Dutch	O
+-	O
+type	O
+strain	O
+,	O
+D274	O
+,	O
+was	O
+also	O
+identified	O
+on	O
+one	O
+farm	O
+.	O
+
+Surprisingly	O
+,	O
+from	O
+1997	O
+,	O
+the	O
+year	O
+that	O
+vaccination	O
+commenced	O
+with	O
+a	O
+live	O
+Massachusetts	O
+serotype	O
+vaccine	O
+,	O
+the	O
+majority	O
+of	O
+viruses	B-SPEC
+detected	O
+had	O
+S1	O
+sequences	O
+identical	O
+to	O
+the	O
+live	O
+Massachusetts	O
+vaccine	O
+strain	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+relationship	O
+between	O
+the	O
+level	O
+of	O
+particulate	O
+air	B-CHED
+pollution	O
+(	O
+PM	O
+(	O
+10	O
+))	O
+and	O
+the	O
+mortality	O
+and	O
+morbidity	O
+rates	O
+from	O
+respiratory	O
+and	O
+cardiovascular	B-DISO
+diseases	I-DISO
+is	O
+well	O
+established	O
+,	O
+but	O
+the	O
+biological	O
+mechanisms	O
+responsible	O
+for	O
+these	O
+associations	O
+are	O
+still	O
+unclear	O
+.	O
+
+In	O
+vitro	O
+and	O
+in	O
+vivo	O
+studies	O
+suggest	O
+that	O
+alveolar	B-ANAT
+macrophage	I-ANAT
+produce	O
+the	O
+mediators	O
+implicated	O
+in	O
+the	O
+bone	B-ANAT
+marrow	I-ANAT
+response	O
+to	O
+ambient	O
+particles	O
+.	O
+
+We	O
+conclude	O
+that	O
+exposure	O
+to	O
+ambient	O
+particulate	O
+matter	O
+air	B-CHED
+pollution	O
+induces	O
+a	O
+systemic	O
+inflammatory	B-DISO
+response	I-DISO
+that	O
+includes	O
+the	O
+release	B-PATH
+of	O
+inflammatory	O
+mediators	O
+into	O
+the	O
+circulation	B-PROC
+that	O
+stimulate	O
+the	O
+bone	B-ANAT
+marrow	I-ANAT
+to	O
+release	B-PATH
+leukocytes	B-ANAT
+and	O
+platelets	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+therapy	O
+in	O
+premature	O
+infants	O
+with	O
+mild	O
+to	O
+moderate	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+incidence	O
+of	O
+other	O
+acute	O
+complications	O
+as	O
+well	O
+as	O
+early	O
+neonatal	B-DISO
+death	I-DISO
+,	O
+were	O
+comparable	O
+between	O
+the	O
+groups	O
+.	O
+
+The	O
+failure	B-DISO
+to	I-DISO
+thrive	I-DISO
+,	O
+psychomotor	O
+retardation	O
+,	O
+hypotonic	B-DISO
+or	O
+spastic	B-DISO
+quadruparesis	O
+,	O
+hypertrophic	B-DISO
+cardiomyopathy	I-DISO
+,	O
+hepatopathy	B-DISO
+and	O
+hyperlactacidaemia	O
+developed	O
+after	O
+birth	B-PROC
+.	O
+
+Five	O
+children	O
+died	B-PROC
+in	O
+the	O
+first	O
+year	O
+of	O
+life	O
+during	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+,	O
+one	O
+girl	O
+died	B-PROC
+at	O
+the	O
+age	O
+of	O
+3	O
+months	O
+with	O
+sudden	B-DISO
+death	I-DISO
+syndrome	B-DISO
+,	O
+only	O
+one	O
+boy	O
+with	O
+spastic	B-DISO
+quadruparesis	O
+and	O
+severe	O
+psychomotor	O
+retardation	O
+survived	O
+to	O
+the	O
+age	O
+of	O
+8	O
+years	O
+.	O
+
+Instillation	O
+of	O
+100mg	O
+/	O
+kg	O
+surfactant	B-CHED
+into	O
+the	O
+lungs	B-ANAT
+was	O
+well	O
+tolerated	O
+and	O
+improved	O
+tidal	O
+volume	O
+,	O
+pulmonary	B-ANAT
+compliance	O
+and	O
+alveolar	B-ANAT
+expansion	O
+.	O
+
+The	O
+surfactant	B-CHED
+preparation	O
+used	O
+reduced	O
+baseline	O
+TNF	B-PROC
+production	I-PROC
+by	O
+murine	B-SPEC
+alveolar	B-ANAT
+macrophages	I-ANAT
+,	O
+indicating	O
+that	O
+the	O
+exaggeration	O
+of	O
+ventilation	O
+-	O
+induced	O
+TNF	B-PRGE
+release	B-PATH
+cannot	O
+be	O
+explained	O
+by	O
+a	O
+direct	O
+effect	O
+of	O
+surfactant	B-CHED
+on	O
+these	O
+cells	B-COMP
+.	O
+
+We	O
+hypothesize	O
+that	O
+ventilation	O
+-	O
+induced	O
+mediator	O
+release	B-PATH
+is	O
+explained	O
+by	O
+stretching	O
+of	O
+lung	B-ANAT
+cells	B-COMP
+,	O
+which	O
+is	O
+reinforced	O
+by	O
+surfactant	B-CHED
+.	O
+
+All	O
+studied	O
+variables	O
+were	O
+significantly	O
+associated	O
+with	O
+ARDS	B-DISO
+in	O
+univariate	O
+analyses	O
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+-	O
+induced	O
+conformational	O
+changes	O
+of	O
+murine	B-PRGE
+coronavirus	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+murine	O
+coronavirus	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+enters	O
+cells	B-COMP
+by	O
+virus	B-SPEC
+-	O
+cell	B-COMP
+membrane	I-COMP
+fusion	O
+triggered	O
+by	O
+its	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+it	O
+is	O
+not	O
+well	O
+known	O
+how	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+participates	O
+in	O
+fusion	O
+events	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+demonstrate	O
+that	O
+soMHVR	O
+induces	O
+the	O
+conformational	O
+changes	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+as	O
+shown	O
+by	O
+the	O
+proteinase	B-PROC
+digestion	B-PROC
+test	O
+.	O
+
+Its	O
+origins	O
+are	O
+during	O
+fetal	B-PROC
+development	B-PROC
+.	O
+
+There	O
+is	O
+no	O
+published	O
+method	O
+known	O
+to	O
+us	O
+of	O
+determining	O
+the	O
+time	O
+of	O
+origin	O
+of	O
+these	O
+markers	O
+except	O
+that	O
+the	O
+injury	O
+causing	O
+astrogliosis	B-DISO
+must	O
+have	O
+occurred	O
+at	O
+least	O
+4	O
+days	O
+before	O
+death	B-PROC
+(	O
+Del	O
+Bigio	O
+and	O
+Becker	O
+,	O
+1994	O
+).	O
+
+It	O
+seems	O
+likely	O
+that	O
+the	O
+""""	O
+acute	O
+control	O
+""""	O
+group	O
+of	O
+Kinney	O
+et	O
+al	O
+(	O
+1995	O
+)	O
+died	B-PROC
+too	O
+quickly	O
+to	O
+develop	O
+gliosis	B-DISO
+or	O
+severe	O
+depletion	O
+of	O
+the	O
+neurotransmitter	B-CHED
+systems	O
+.	O
+
+We	O
+can	O
+conclude	O
+that	O
+the	O
+acute	O
+controls	O
+had	O
+no	O
+previous	O
+episodes	O
+of	O
+severe	O
+hypoxia	B-DISO
+,	O
+unlike	O
+SIDS	B-DISO
+or	O
+their	O
+""""	O
+chronic	O
+controls	O
+.	O
+
+Hypoplasia	B-DISO
+of	O
+the	O
+arcuate	B-ANAT
+nucleus	I-ANAT
+was	O
+stated	O
+to	O
+occur	O
+in	O
+5	O
+%	O
+of	O
+their	O
+SIDS	B-DISO
+cases	O
+by	O
+Kinney	O
+et	O
+al	O
+(	O
+2001	O
+),	O
+but	O
+this	O
+is	O
+a	O
+""""	O
+primary	O
+developmental	B-DISO
+defect	I-DISO
+""""	O
+according	O
+to	O
+Matturri	O
+et	O
+al	O
+(	O
+2002	O
+)	O
+with	O
+a	O
+larger	O
+series	O
+,	O
+many	O
+of	O
+whom	O
+were	O
+stillbirths	B-DISO
+.	O
+
+Feline	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+that	O
+express	O
+fAPN	O
+and	O
+hamster	B-SPEC
+kidney	B-ANAT
+fibroblasts	B-ANAT
+that	O
+do	O
+not	O
+express	O
+fAPN	O
+were	O
+inoculated	O
+with	O
+IBV	B-SPEC
+and	O
+monitored	O
+for	O
+replication	O
+by	O
+indirect	O
+fluorescent	O
+assay	O
+and	O
+confocal	O
+microscopy	O
+and	O
+in	O
+chicken	B-SPEC
+embryonated	O
+eggs	O
+.	O
+
+Investigation	O
+into	O
+the	O
+prevalence	O
+of	O
+FCoV	O
+in	O
+exotic	O
+Felidae	B-SPEC
+has	O
+relied	O
+primarily	O
+on	O
+serology	O
+.	O
+
+Serum	B-COMP
+samples	O
+collected	O
+from	O
+all	O
+but	O
+12	O
+of	O
+these	O
+animals	B-SPEC
+were	O
+tested	O
+for	O
+antibodies	B-COMP
+to	O
+type	O
+I	O
+and	O
+type	O
+II	O
+FCoV	O
+by	O
+indirect	O
+immunofluorescence	O
+.	O
+
+Sentinel	O
+pigs	B-SPEC
+were	O
+commingled	O
+with	O
+the	O
+PRCV	O
+-	O
+infected	O
+pigs	B-SPEC
+at	O
+8	O
+weeks	O
+after	O
+exposure	O
+,	O
+and	O
+no	O
+virus	B-SPEC
+transmission	O
+occurred	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+acute	O
+non	O
+-	O
+immune	O
+injury	O
+in	O
+the	O
+lung	B-ANAT
+allograft	O
+may	O
+impact	O
+,	O
+not	O
+only	O
+on	O
+early	O
+survival	O
+,	O
+but	O
+also	O
+on	O
+longer	O
+term	O
+survival	O
+by	O
+increasing	O
+the	O
+incidence	O
+of	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+syndrome	B-DISO
+(	O
+BOS	B-DISO
+).	O
+
+RESULTS	O
+:	O
+Early	O
+graft	B-ANAT
+biopsy	O
+was	O
+available	O
+in	O
+291	O
+of	O
+the	O
+recipients	O
+following	O
+transplantation	O
+.	O
+
+The	O
+most	O
+severe	O
+respiratory	B-DISO
+infection	I-DISO
+is	O
+pneumonia	B-DISO
+which	O
+can	O
+be	O
+associated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+death	B-PROC
+.	O
+
+We	O
+still	O
+don	O
+'	O
+t	O
+have	O
+a	O
+special	O
+treatment	O
+for	O
+these	O
+kinds	O
+of	O
+infections	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+time	O
+course	O
+and	O
+level	O
+of	O
+activation	O
+of	O
+sPLA	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+I	I-PRGE
+and	O
+trypsinogen	B-PRGE
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+relative	O
+to	O
+severity	O
+.	O
+
+Activation	O
+of	O
+sPLA	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+I	I-PRGE
+is	O
+associated	O
+with	O
+the	O
+early	O
+pathogenesis	B-DISO
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+but	O
+not	O
+in	O
+the	O
+development	B-PROC
+of	O
+distant	O
+organ	B-ANAT
+damage	O
+.	O
+
+Outcomes	O
+included	O
+mortality	O
+,	O
+pneumonia	B-DISO
+(>	O
+or	O
+=	O
+10	O
+colony	O
+-	O
+forming	O
+units	O
+/	O
+mL	O
+in	O
+bronchoalveolar	O
+lavage	O
+effluent	O
+),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+bacteremia	B-DISO
+,	O
+ventilator	O
+days	O
+,	O
+and	O
+intensive	O
+care	O
+unit	O
+and	O
+hospital	O
+length	O
+of	O
+stay	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+their	O
+high	O
+frequency	O
+of	O
+RNA	O
+recombination	B-PROC
+,	O
+the	O
+plus	O
+-	O
+strand	O
+coronaviruses	O
+have	O
+a	O
+characteristic	O
+,	O
+strictly	O
+conserved	O
+genome	O
+organization	O
+with	O
+the	O
+essential	O
+genes	O
+occurring	O
+in	O
+the	O
+order	B-PRGE
+5	I-PRGE
+'-	I-PRGE
+polymerase	I-PRGE
+(	O
+pol	B-PRGE
+)-	O
+S	O
+-	O
+E	O
+-	O
+M	O
+-	O
+N	O
+-	O
+3	O
+'.	O
+
+The	O
+recombinant	O
+virus	B-SPEC
+with	O
+the	O
+gene	O
+order	B-SPEC
+5	O
+'-	O
+pol	O
+-	O
+E	O
+-	O
+M	O
+-	O
+S	O
+-	O
+N	O
+-	O
+3	O
+'	O
+was	O
+also	O
+tested	O
+for	O
+the	O
+ability	O
+to	O
+replicate	O
+in	O
+the	O
+natural	O
+host	B-COMP
+,	O
+the	O
+mouse	B-SPEC
+.	O
+
+Inhibition	B-PROC
+of	O
+MHV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+by	O
+the	O
+pancaspase	O
+inhibitor	B-CHED
+Z	B-PRGE
+-	I-PRGE
+VAD	I-PRGE
+-	I-PRGE
+FMK	I-PRGE
+promoted	O
+virus	B-SPEC
+production	O
+late	O
+in	O
+infection	B-DISO
+,	O
+indicating	O
+that	O
+apoptosis	B-PATH
+could	O
+be	O
+a	O
+host	B-PROC
+response	I-PROC
+to	O
+limit	O
+the	O
+production	O
+of	O
+viral	O
+progeny	O
+.	O
+
+Activation	O
+of	O
+the	O
+mitochondria	B-COMP
+-	O
+mediated	O
+apoptotic	O
+pathway	B-PROC
+was	O
+indicated	O
+by	O
+the	O
+activation	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+9	I-PRGE
+and	O
+delay	O
+of	O
+apoptosis	B-PATH
+by	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+overexpression	B-PROC
+.	O
+
+All	O
+our	O
+data	O
+indicate	O
+that	O
+a	O
+mitochondria	B-COMP
+-	O
+mediated	O
+pathway	B-PROC
+played	O
+a	O
+major	O
+regulatory	O
+role	O
+in	O
+apoptosis	B-PATH
+in	O
+MHV	B-SPEC
+-	O
+infected	O
+17Cl	B-CHED
+-	O
+1	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Targeted	B-PROC
+RNA	O
+recombination	B-PROC
+of	O
+the	O
+membrane	B-COMP
+and	O
+nucleocapsid	B-COMP
+protein	B-CHED
+genes	O
+between	O
+mouse	B-SPEC
+hepatitis	I-DISO
+virus	O
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Further	O
+analysis	O
+of	O
+the	O
+recombinant	O
+viruses	B-SPEC
+indicated	O
+that	O
+there	O
+combination	O
+had	O
+taken	O
+place	O
+within	O
+the	O
+region	O
+of	O
+222	O
+nucleotides	B-CHED
+between	O
+positions	O
+916	O
+and	O
+1	O
+,	O
+137	O
+of	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+.	O
+
+We	O
+speculate	O
+that	O
+the	O
+enhanced	O
+lung	B-ANAT
+recruitment	B-DISO
+by	O
+HFOV	O
+enhances	O
+the	O
+effects	O
+of	O
+low	O
+dose	O
+iNO	O
+on	O
+gas	B-ENZY
+exchange	O
+.	O
+
+TITLE	O
+:	O
+Incidence	O
+,	O
+clinical	O
+course	O
+,	O
+and	O
+outcome	O
+in	O
+217	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+It	O
+was	O
+discovered	O
+that	O
+polyclonal	O
+antisera	O
+significantly	O
+inhibited	O
+plaque	B-DISO
+formation	B-PROC
+by	O
+PEDV	B-SPEC
+,	O
+suggesting	O
+that	O
+this	O
+region	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+contains	O
+the	O
+epitope	B-CHED
+(	O
+s	O
+)	O
+that	O
+is	O
+capable	O
+of	O
+inducing	O
+PEDV	B-SPEC
+-	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+region	O
+that	O
+corresponds	O
+to	O
+the	O
+neutralizing	O
+epitope	B-CHED
+of	O
+TGEV	B-SPEC
+may	O
+also	O
+be	O
+involved	O
+in	O
+neutralizing	O
+PEDV	B-SPEC
+,	O
+although	O
+the	O
+two	O
+viruses	B-SPEC
+are	O
+serologically	O
+quite	O
+distinct	O
+.	O
+
+Twenty	O
+-	O
+three	O
+patients	O
+who	O
+had	O
+ARDS	B-DISO
+(	O
+0	O
+.	O
+5	O
+-	O
+months	O
+to	O
+12	O
+.	O
+6	O
+-	O
+years	O
+-	O
+old	O
+),	O
+were	O
+placed	O
+in	O
+the	O
+prone	O
+position	O
+within	O
+56	O
++/-	O
+109	O
+h	O
+after	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Gastric	B-ANAT
+gross	O
+and	O
+microscopic	O
+lesions	O
+caused	O
+by	O
+the	O
+UNAM	O
+-	O
+97	O
+variant	O
+strain	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+after	O
+the	O
+eighth	O
+passage	O
+in	O
+specific	O
+pathogen	O
+-	O
+free	O
+chicken	B-SPEC
+embryos	B-ANAT
+.	O
+
+To	O
+study	O
+whether	O
+toroviruses	B-SPEC
+use	O
+a	O
+similar	O
+transcription	B-PROC
+mechanism	O
+,	O
+we	O
+characterized	O
+the	O
+5	O
+'	O
+termini	O
+of	O
+the	O
+genome	O
+and	O
+the	O
+four	O
+sg	O
+mRNAs	O
+of	O
+Berne	O
+virus	B-SPEC
+(	O
+BEV	B-SPEC
+).	O
+
+Apparently	O
+,	O
+BEV	O
+combines	O
+discontinuous	O
+and	O
+non	O
+-	O
+discontinuous	O
+RNA	B-PROC
+synthesis	I-PROC
+to	O
+produce	O
+its	O
+sg	O
+mRNAs	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+surfactant	B-CHED
+treatment	O
+on	O
+oxygenation	B-PROC
+in	O
+8	O
+infants	O
+(	O
+age	O
+range	O
+:	O
+1	O
+mo	O
+to	O
+13	O
+y	O
+)	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+owing	O
+to	O
+viral	O
+,	O
+bacterial	O
+or	O
+Pneumocystis	B-DISO
+Carinii	I-DISO
+pneumonia	I-DISO
+.	O
+
+Instillation	O
+of	O
+a	O
+modified	O
+porcine	B-SPEC
+surfactant	B-CHED
+(	O
+Curosurf	O
+)	O
+improved	O
+gas	B-ENZY
+exchange	O
+immediately	O
+.	O
+
+However	O
+,	O
+6	O
+patients	O
+(	O
+75	O
+%)	O
+were	O
+immunodeficient	B-DISO
+,	O
+so	O
+that	O
+the	O
+observed	O
+mortality	O
+rate	O
+was	O
+mainly	O
+due	O
+to	O
+the	O
+underlying	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+interstitial	B-DISO
+pneumonitis	I-DISO
+related	O
+to	O
+Gemcitabine	B-CHED
+].	O
+
+ABSTRACT	O
+:	O
+Gemcitabine	B-CHED
+is	O
+used	O
+to	O
+treat	O
+solid	O
+tumours	O
+such	O
+as	O
+non	O
+small	O
+-	O
+cell	B-COMP
+lung	B-DISO
+cancer	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Delivery	O
+of	O
+subunit	O
+vaccines	O
+in	O
+maize	B-SPEC
+seed	O
+.	O
+
+We	O
+have	O
+previously	O
+demonstrated	O
+high	O
+level	O
+expression	B-PROC
+of	O
+the	O
+B	O
+-	O
+subunit	O
+of	O
+Escherichia	B-SPEC
+coli	I-SPEC
+heat	O
+-	O
+labile	O
+enterotoxin	O
+and	O
+the	O
+spike	O
+protein	O
+of	O
+swine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+in	O
+corn	B-DISO
+,	O
+and	O
+have	O
+demonstrated	O
+that	O
+these	O
+antigens	B-CHED
+delivered	O
+in	O
+the	O
+seed	O
+elicit	O
+protective	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+Because	O
+the	O
+fundamental	O
+aim	O
+of	O
+supportive	O
+treatment	O
+is	O
+to	O
+improve	O
+arterial	B-ANAT
+oxygenation	B-PROC
+,	O
+several	O
+alternatives	O
+to	O
+mechanical	O
+ventilation	O
+with	O
+PEEP	B-CHED
+have	O
+been	O
+used	O
+.	O
+
+ABSTRACT	O
+:	O
+Polypyrimidine	B-PRGE
+-	I-PRGE
+tract	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+protein	B-CHED
+(	O
+PTB	B-PRGE
+)	O
+has	O
+been	O
+shown	O
+to	O
+bind	B-FUNC
+specifically	O
+to	O
+the	O
+5	O
+'	O
+ends	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+RNA	O
+and	O
+its	O
+complementary	O
+strand	O
+.	O
+
+We	O
+observed	O
+that	O
+both	O
+the	O
+full	O
+-	O
+length	O
+and	O
+the	O
+truncated	O
+PTB	O
+,	O
+when	O
+overexpressed	O
+,	O
+functioned	O
+in	O
+a	O
+dominant	O
+-	O
+negative	O
+manner	O
+in	O
+MHV	B-SPEC
+replication	O
+.	O
+
+However	O
+,	O
+the	O
+truncated	O
+form	O
+exhibited	O
+more	O
+severe	O
+effects	O
+on	O
+syncytia	B-ANAT
+formation	B-PROC
+,	O
+virus	B-SPEC
+production	O
+,	O
+and	O
+synthesis	B-PROC
+of	O
+viral	O
+RNA	O
+and	O
+viral	O
+proteins	O
+.	O
+
+Transcription	B-PROC
+of	O
+the	O
+DI	O
+RNA	O
+during	O
+MHV	B-SPEC
+infection	B-DISO
+was	O
+greatly	O
+inhibited	O
+in	O
+these	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+indicating	O
+that	O
+PTB	B-PRGE
+modulates	O
+MHV	B-SPEC
+transcription	B-PROC
+.	O
+
+Initially	O
+,	O
+mechanical	O
+ventilation	O
+and	O
+nitric	B-CHED
+oxide	I-CHED
+inhalation	B-PROC
+were	O
+used	O
+,	O
+but	O
+these	O
+did	O
+not	O
+improve	O
+the	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-CHED
+gradient	O
+.	O
+
+Reactivation	O
+in	O
+antibody	B-COMP
+-	O
+deficient	O
+mice	B-SPEC
+is	O
+not	O
+associated	O
+with	O
+increased	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+,	O
+but	O
+is	O
+prevented	O
+via	O
+transfer	O
+of	O
+neutralizing	O
+antibody	O
+.	O
+
+A	O
+vital	O
+role	O
+for	O
+humoral	B-PROC
+immunity	I-PROC
+during	O
+persistence	O
+is	O
+supported	O
+by	O
+the	O
+accumulation	O
+and	O
+retention	B-PROC
+of	O
+virus	B-SPEC
+-	O
+specific	O
+antibody	B-ANAT
+secreting	B-PROC
+cells	B-COMP
+following	O
+clearance	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Construction	O
+and	O
+immunogenicity	O
+studies	O
+of	O
+recombinant	O
+fowl	O
+poxvirus	B-SPEC
+containing	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+Massachusetts	O
+41	O
+strain	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+Visceral	B-DISO
+gout	I-DISO
+and	O
+urolithiasis	B-DISO
+were	O
+less	O
+frequently	O
+observed	O
+.	O
+
+Minimal	O
+respiratory	B-DISO
+disease	I-DISO
+signs	O
+were	O
+noted	O
+in	O
+broilers	O
+.	O
+
+Sequencing	O
+of	O
+the	O
+S1	O
+subunit	O
+gene	O
+of	O
+21	O
+IBV	B-SPEC
+isolates	O
+showed	O
+the	O
+NIB	O
+outbreak	O
+to	O
+be	O
+associated	O
+with	O
+two	O
+unique	O
+genotypes	O
+,	O
+PA	O
+/	O
+Wolgemuth	O
+/	O
+98	O
+and	O
+PA	O
+/	O
+171	O
+/	O
+99	O
+.	O
+
+The	O
+NIB	O
+viruses	B-SPEC
+were	O
+unrelated	O
+to	O
+previously	O
+recognized	O
+endemic	O
+strains	O
+in	O
+Pennsylvania	O
+and	O
+were	O
+also	O
+dissimilar	O
+to	O
+each	O
+other	O
+.	O
+
+Serum	B-COMP
+IBV	B-SPEC
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+antibody	B-COMP
+geometric	O
+mean	O
+titers	O
+(	O
+GMTs	O
+)	O
+after	O
+vaccination	O
+with	O
+the	O
+combinations	O
+of	O
+live	O
+attenuated	O
+strains	O
+were	O
+low	O
+,	O
+ranging	O
+from	O
+184	O
+to	O
+1	O
+,	O
+354	O
+,	O
+prior	O
+to	O
+NIBV	O
+challenge	O
+at	O
+10	O
+wk	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+Poult	O
+enteritis	O
+mortality	O
+syndrome	B-DISO
+(	O
+PEMS	O
+)	O
+has	O
+been	O
+an	O
+economically	O
+devastating	O
+disease	O
+in	O
+North	O
+Carolina	O
+since	O
+the	O
+early	O
+1990s	O
+.	O
+
+A	O
+chicken	B-SPEC
+usually	O
+lays	O
+about	O
+280	O
+eggs	O
+in	O
+a	O
+year	O
+,	O
+and	O
+egg	B-ANAT
+yolk	B-COMP
+contains	O
+100	O
+-	O
+150	O
+mg	O
+of	O
+IgY	O
+per	O
+yolk	B-COMP
+,	O
+suggesting	O
+that	O
+more	O
+than	O
+40	O
+g	O
+of	O
+IgY	O
+per	O
+year	O
+can	O
+be	O
+obtained	O
+from	O
+each	O
+chicken	B-SPEC
+through	O
+eggs	O
+.	O
+
+Mice	B-SPEC
+deficient	O
+in	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+,	O
+IL	O
+-	O
+2Ralpha	O
+,	O
+and	O
+IL	B-PRGE
+-	I-PRGE
+2Rbeta	I-PRGE
+are	O
+each	O
+characterized	O
+by	O
+a	O
+rapid	O
+lethal	O
+autoimmune	B-DISO
+lymphoproliferative	B-DISO
+disorder	I-DISO
+that	O
+complicates	O
+their	O
+use	O
+in	O
+studies	O
+aimed	O
+at	O
+investigating	O
+the	O
+role	O
+of	O
+these	O
+cytokines	O
+and	O
+receptors	O
+for	O
+immune	B-PROC
+responses	I-PROC
+in	O
+vivo	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+these	O
+mice	B-SPEC
+were	O
+used	O
+to	O
+investigate	O
+the	O
+extent	O
+by	O
+which	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+are	O
+essential	O
+for	O
+T	B-ANAT
+cell	I-ANAT
+immunity	B-PROC
+in	O
+vivo	O
+.	O
+
+It	O
+has	O
+been	O
+extensively	O
+used	O
+in	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+with	O
+acute	O
+or	O
+acute	B-DISO
+-	I-DISO
+on	I-DISO
+-	I-DISO
+chronic	I-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+A	O
+novel	O
+120	O
+-	O
+kDa	O
+subunit	O
+was	O
+formed	O
+following	O
+incubation	O
+of	O
+the	O
+receptor	O
+-	O
+triggered	O
+S	O
+(	O
+A59	O
+)	O
+H716D	O
+virions	B-COMP
+with	O
+trypsin	B-PRGE
+at	O
+4	O
+degrees	O
+C	O
+.	O
+The	O
+data	O
+show	O
+that	O
+unlike	O
+class	B-PRGE
+1	I-PRGE
+fusion	I-PRGE
+glycoproteins	B-CHED
+of	O
+other	O
+enveloped	O
+viruses	B-SPEC
+,	O
+the	O
+murine	B-PRGE
+coronavirus	I-PRGE
+S	I-PRGE
+protein	B-CHED
+can	O
+be	O
+triggered	O
+to	O
+a	O
+membrane	B-COMP
+-	O
+binding	B-FUNC
+conformation	O
+at	O
+37	O
+degrees	O
+C	O
+either	O
+by	O
+soluble	O
+receptor	O
+at	O
+neutral	O
+pH	O
+or	O
+by	O
+alkaline	O
+pH	O
+alone	O
+,	O
+without	O
+requiring	O
+previous	O
+activation	O
+by	O
+cleavage	B-PROC
+between	O
+S1	O
+and	O
+S2	O
+.	O
+
+In	O
+contrast	O
+,	O
+soluble	O
+mCEACAM1	O
+(	O
+b	O
+)	O
+allowed	O
+viruses	B-SPEC
+with	O
+the	O
+MHV	B-SPEC
+-	O
+A59	O
+RBD	O
+to	O
+associate	O
+with	O
+liposomes	O
+more	O
+efficiently	O
+than	O
+did	O
+viruses	B-SPEC
+with	O
+the	O
+MHV	B-SPEC
+-	O
+4	O
+RBD	O
+.	O
+
+In	O
+the	O
+second	O
+assay	O
+,	O
+which	O
+requires	O
+virus	B-SPEC
+entry	O
+and	O
+replication	O
+,	O
+all	O
+recombinant	O
+viruses	B-SPEC
+replicated	O
+efficiently	O
+in	O
+BHK	O
+cells	B-COMP
+expressing	O
+mCEACAM1	O
+(	O
+a	O
+).	O
+
+We	O
+have	O
+developed	O
+a	O
+protocol	O
+which	O
+prevents	O
+hyperglycaemia	B-DISO
+and	O
+can	O
+be	O
+used	O
+easily	O
+by	O
+ward	O
+staff	O
+.	O
+
+The	O
+initial	O
+scale	O
+is	O
+selected	O
+according	O
+to	O
+the	O
+patient	O
+'	O
+s	O
+current	O
+subcutaneous	O
+insulin	B-PRGE
+dose	O
+and	O
+advanced	O
+if	O
+the	O
+blood	B-ANAT
+glucose	B-CHED
+is	O
+>	O
+or	O
+=	O
+10	O
+.	O
+1	O
+mmol	O
+/	O
+l	O
+for	O
+2	O
+consecutive	O
+hours	O
+.	O
+
+The	O
+median	O
+amount	O
+of	O
+supplementary	O
+intravenous	O
+insulin	B-PRGE
+required	O
+was	O
+74	O
+U	O
+(	O
+range	O
+32	O
+-	O
+88	O
+U	O
+);	O
+the	O
+median	O
+glucose	B-CHED
+values	O
+achieved	O
+were	O
+5	O
+.	O
+8	O
+-	O
+8	O
+.	O
+9	O
+mmol	O
+/	O
+l	O
+.	O
+
+In	O
+the	O
+present	O
+prospective	O
+randomized	O
+study	O
+,	O
+we	O
+compared	O
+the	O
+effectiveness	O
+of	O
+oxygen	B-CHED
+treatment	O
+administered	O
+by	O
+a	O
+face	B-DISO
+mask	O
+vs	O
+.	O
+nasal	B-ANAT
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+NCPAP	O
+).	O
+
+Thirty	O
+-	O
+seven	O
+patients	O
+with	O
+DSS	B-DISO
+complicated	O
+by	O
+respiratory	B-DISO
+failure	I-DISO
+were	O
+enrolled	O
+.	O
+
+We	O
+included	O
+children	O
+aged	O
+2	O
+-	O
+16	O
+years	O
+with	O
+active	O
+asthma	B-PATH
+,	O
+defined	O
+as	O
+three	O
+or	O
+more	O
+recurrent	O
+episodes	O
+of	O
+reversible	O
+wheezing	B-DISO
+.	O
+
+Ten	O
+of	O
+these	O
+individuals	O
+(	O
+14	O
+%	O
+of	O
+total	O
+)	O
+were	O
+positive	O
+for	O
+M	B-SPEC
+.	I-SPEC
+synoviae	I-SPEC
+by	O
+hemagglutination	B-PROC
+inhibition	B-PROC
+testing	O
+.	O
+
+Reticuloendotheliosis	B-SPEC
+virus	I-SPEC
+was	O
+isolated	O
+from	O
+one	O
+of	O
+these	O
+individuals	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+tested	O
+the	O
+hypothesis	O
+that	O
+activated	O
+neutrophil	O
+-	O
+endothelial	B-ANAT
+cell	I-ANAT
+interaction	O
+in	O
+DIC	B-DISO
+can	O
+cause	O
+endothelial	B-ANAT
+injury	O
+contributing	O
+to	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+)	O
+and	O
+a	O
+poor	O
+outcome	O
+after	O
+trauma	O
+.	O
+
+TITLE	O
+:	O
+Rhinovirus	B-SPEC
+-	O
+induced	O
+wheezing	B-DISO
+in	O
+infancy	O
+--	O
+the	O
+first	O
+sign	O
+of	O
+childhood	B-DISO
+asthma	I-DISO
+?	O
+
+Studies	O
+using	O
+animal	B-SPEC
+models	O
+of	O
+successful	O
+remyelination	B-PROC
+delineate	O
+a	O
+progression	O
+of	O
+events	O
+facilitating	O
+remyelination	B-PROC
+.	O
+
+Ten	O
+patients	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+on	O
+mechanical	O
+ventilation	O
+.	O
+
+Inspiration	B-PROC
+increased	O
+alveolar	B-ANAT
+recruitment	B-DISO
+at	O
+all	O
+PEEP	B-CHED
+levels	O
+.	O
+
+A	O
+pronounced	O
+predictive	O
+antigenicity	O
+in	O
+the	O
+HVR2	O
+region	O
+was	O
+also	O
+associated	O
+with	O
+layer	B-ANAT
+-	O
+type	O
+chickens	B-SPEC
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+Undiluted	O
+pulmonary	B-DISO
+edema	I-DISO
+fluid	O
+and	O
+plasma	B-ANAT
+samples	O
+were	O
+collected	O
+within	O
+24	O
+hrs	B-DISO
+of	O
+endotracheal	O
+intubation	O
+in	O
+all	O
+patients	O
+.	O
+
+Nine	O
+sheep	B-SPEC
+(	O
+29	O
+.	O
+2	O
++/-	O
+
+After	O
+stabilization	O
+,	O
+high	O
+-	O
+frequency	O
+oscillation	O
+was	O
+initiated	O
+at	O
+a	O
+mean	O
+airway	B-ANAT
+pressure	O
+equal	O
+to	O
+the	O
+point	O
+of	O
+maximum	O
+curvature	O
+on	O
+the	O
+deflation	O
+limb	B-ANAT
+of	O
+the	O
+pressure	O
+-	O
+volume	O
+curve	O
+(	O
+26	O
++/-	O
+
+Positioning	O
+the	O
+patient	O
+with	O
+the	O
+""""	O
+good	O
+lung	B-ANAT
+down	O
+""""	O
+and	O
+using	O
+differential	O
+ventilation	O
+with	O
+selective	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+are	O
+the	O
+two	O
+currently	O
+accepted	O
+ventilatory	O
+strategies	O
+to	O
+be	O
+applied	O
+in	O
+patients	O
+with	O
+severe	O
+unilateral	O
+lung	B-ANAT
+injury	O
+.	O
+
+To	O
+determine	O
+the	O
+lag	O
+between	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+priming	O
+and	O
+optimal	O
+activity	O
+within	O
+the	O
+CNS	B-CHED
+,	O
+the	O
+accumulation	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+CNS	B-CHED
+relative	O
+to	O
+that	O
+in	O
+peripheral	O
+lymphoid	B-ANAT
+organs	I-ANAT
+was	O
+assessed	O
+by	O
+using	O
+gamma	O
+interferon	B-PRGE
+-	O
+specific	O
+ELISPOT	O
+assays	O
+and	O
+class	B-SPEC
+I	O
+tetramer	O
+staining	O
+.	O
+
+Virus	B-SPEC
+-	O
+specific	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+were	O
+first	O
+detected	O
+in	O
+the	O
+cervical	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+.	O
+
+TITLE	O
+:	O
+The	O
+use	O
+of	O
+corticosteroids	B-CHED
+in	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+outline	O
+the	O
+effects	O
+of	O
+mechanical	O
+ventilation	O
+on	O
+injured	O
+lungs	B-ANAT
+and	O
+explore	O
+the	O
+underlying	O
+mechanisms	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+manifestation	O
+of	O
+acute	O
+injury	O
+to	O
+the	O
+lung	O
+,	O
+commonly	O
+resulting	O
+from	O
+sepsis	B-DISO
+,	O
+trauma	O
+,	O
+and	O
+severe	O
+pulmonary	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+management	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+frequently	O
+requires	O
+endotracheal	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+Timely	O
+correction	O
+of	O
+the	O
+inciting	O
+clinical	O
+condition	B-DISO
+is	O
+essential	O
+for	O
+preventing	O
+further	O
+injury	O
+.	O
+
+Bacterial	O
+invasion	O
+and	O
+toxicity	O
+of	O
+outer	B-COMP
+membrane	I-COMP
+with	O
+generation	O
+of	O
+cytokines	O
+,	O
+chemokines	O
+,	O
+and	O
+cellular	B-PROC
+infiltration	B-DISO
+are	O
+important	O
+in	O
+cellular	B-COMP
+injury	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+new	O
+method	O
+were	O
+compared	O
+with	O
+in	O
+situ	O
+hybridization	B-PROC
+.	O
+
+Blood	B-PROC
+gas	B-ENZY
+measurements	O
+were	O
+obtained	O
+10	O
+-	O
+15	O
+mins	O
+after	O
+initiation	O
+or	O
+any	O
+increase	O
+in	O
+INO	O
+dosage	O
+to	O
+assess	O
+the	O
+effect	O
+on	O
+Pao2	O
+/	O
+Fio2	O
+.	O
+
+Arterial	B-ANAT
+blood	I-ANAT
+gases	O
+and	O
+ventilator	O
+settings	O
+were	O
+recorded	O
+at	O
+four	O
+time	O
+points	O
+:	O
+during	O
+conventional	O
+ventilation	O
+just	O
+before	O
+initiating	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+,	O
+during	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+just	O
+before	O
+initiating	O
+INO	O
+,	O
+after	O
+30	O
+mins	O
+on	O
+the	O
+optimal	O
+dose	O
+of	O
+INO	O
+,	O
+and	O
+8	O
+-	O
+12	O
+hrs	B-DISO
+after	O
+starting	O
+INO	O
+.	O
+
+In	O
+addition	O
+,	O
+specific	O
+markers	O
+may	O
+be	O
+useful	O
+for	O
+predicting	O
+development	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+or	O
+for	O
+assessing	O
+prognosis	O
+.	O
+
+TITLE	O
+:	O
+Safety	O
+of	O
+percutaneous	O
+dilational	O
+tracheostomy	O
+in	O
+patients	O
+ventilated	O
+with	O
+high	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+).	O
+
+In	O
+the	O
+high	O
+PEEP	B-CHED
+group	O
+the	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FIO	O
+(	O
+2	O
+)	O
+ratio	O
+was	O
+lower	O
+(	O
+243	O
++/-	O
+90	O
+vs	O
+285	O
++/-	O
+78	O
+mmHg	O
+)	O
+and	O
+PaCO	O
+(	O
+2	O
+)	O
+higher	O
+(	O
+45	O
++/-	O
+9	O
+.	O
+4	O
+vs	O
+39	O
++/-	O
+7	O
+.	O
+1	O
+mmHg	O
+)	O
+when	O
+compared	O
+to	O
+the	O
+low	O
+PEEP	B-CHED
+group	O
+.	O
+
+Bronchoscopically	O
+guided	O
+PDT	B-CHED
+in	O
+our	O
+patients	O
+on	O
+high	O
+PEEP	B-CHED
+did	O
+not	O
+jeopardise	O
+oxygenation	B-PROC
+1	O
+h	O
+and	O
+24	O
+h	O
+following	O
+PDT	B-CHED
+.	O
+
+The	O
+estimated	O
+yearly	O
+incidence	O
+rate	O
+of	O
+KS	O
+among	O
+HHV	B-SPEC
+-	O
+positive	O
+persons	O
+was	O
+twice	O
+as	O
+high	O
+in	O
+men	O
+(	O
+1	O
+:	O
+2200	O
+)	O
+as	O
+in	O
+women	O
+(	O
+1	O
+:	O
+4110	O
+).	O
+
+The	O
+immunoglobulins	O
+are	O
+chicken	B-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+S2	I-PRGE
+peplomeric	I-PRGE
+protein	B-CHED
+-	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+isolated	O
+by	O
+immunoaffinity	O
+chromatography	O
+on	O
+synthetic	O
+peptide	B-CHED
+coupled	O
+to	O
+CNBr	O
+-	O
+activated	O
+Sepharose	B-CHED
+4B	O
+or	O
+rabbit	B-PRGE
+polyclonal	I-PRGE
+IgG	I-PRGE
+purified	O
+from	O
+the	O
+serum	B-COMP
+using	O
+Protein	B-PRGE
+A	I-PRGE
+Sepharose	B-CHED
+4B	I-PRGE
+.	O
+
+The	O
+relative	O
+sensitivity	O
+of	O
+the	O
+test	O
+ranged	O
+between	O
+10	O
+(	O
+5	O
+)	O
+and	O
+10	O
+(	O
+6	O
+)	O
+median	O
+egg	B-ANAT
+infectious	B-DISO
+doses	O
+(	O
+EID	O
+(	O
+50	O
+))	O
+for	O
+chicken	B-SPEC
+IgG	B-PRGE
+and	O
+between	O
+10	O
+(	O
+3	O
+)	O
+and	O
+10	O
+(	O
+4	O
+)	O
+EID	O
+(	O
+50	O
+)	O
+for	O
+rabbit	B-PRGE
+IgG	I-PRGE
+,	O
+depending	O
+on	O
+the	O
+test	O
+strain	O
+.	O
+
+We	O
+then	O
+examined	O
+the	O
+-	O
+372	O
+to	O
+-	O
+306	O
+sequence	O
+within	O
+the	O
+1	O
+.	O
+3	O
+-	O
+kb	O
+fgl2	B-PRGE
+promoter	O
+region	O
+upstream	O
+from	O
+the	O
+transcription	B-PROC
+start	O
+site	O
+that	O
+was	O
+previously	O
+identified	O
+as	O
+necessary	O
+for	O
+N	O
+protein	B-CHED
+-	O
+induced	O
+gene	B-PROC
+transcription	I-PROC
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+presentation	O
+of	O
+severe	B-DISO
+anemia	I-DISO
+in	O
+pediatric	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+anemia	B-SPEC
+seen	O
+in	O
+Enugu	O
+,	O
+Nigeria	O
+.	O
+
+Caregivers	O
+need	O
+to	O
+be	O
+educated	O
+on	O
+how	O
+to	O
+recognize	O
+anemia	B-DISO
+among	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+anemia	B-SPEC
+when	O
+they	O
+develop	O
+febrile	B-PROC
+episodes	O
+.	O
+
+Her	O
+chest	B-ANAT
+radiograph	O
+revealed	O
+consolidation	O
+in	O
+the	O
+right	B-ANAT
+lung	I-ANAT
+.	O
+
+She	O
+was	O
+diagnosed	O
+as	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+pneumonia	B-DISO
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+treated	O
+with	O
+clarithromycin	B-CHED
+and	O
+methylprednisolone	B-CHED
+.	O
+
+However	O
+,	O
+the	O
+clinical	O
+courses	O
+of	O
+twin	O
+sisters	O
+,	O
+who	O
+should	O
+be	O
+very	O
+similar	O
+in	O
+their	O
+immune	B-PROC
+response	I-PROC
+to	O
+the	O
+same	O
+antigen	B-CHED
+,	O
+were	O
+very	O
+different	O
+from	O
+each	O
+other	O
+.	O
+
+These	O
+results	O
+emphasized	O
+the	O
+importance	O
+of	O
+early	O
+diagnosis	O
+of	O
+the	O
+patients	O
+with	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+pneumonia	B-DISO
+and	O
+the	O
+adequate	O
+chemotherapy	O
+to	O
+prevent	O
+developing	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Oleic	O
+acid	O
+-	O
+induced	O
+hypoxemia	O
+is	O
+an	O
+animal	B-SPEC
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+measure	O
+local	O
+(	O
+peritoneal	O
+fluid	O
+)	O
+and	O
+systemic	O
+(	O
+plasma	B-ANAT
+)	O
+cytokine	O
+profiles	O
+in	O
+patients	O
+with	O
+infection	B-DISO
+-	O
+inflammation	B-DISO
+of	O
+the	O
+vermiform	B-ANAT
+appendix	I-ANAT
+,	O
+a	O
+relatively	O
+mild	O
+,	O
+localized	O
+inflammatory	O
+process	O
+.	O
+
+Peritoneal	B-ANAT
+fluid	I-ANAT
+(	O
+PF	O
+)	O
+was	O
+obtained	O
+by	O
+intraoperative	O
+lavage	O
+.	O
+
+Patient	O
+plasma	B-ANAT
+inhibited	O
+LPS	B-DISO
+-	O
+induced	O
+stimulation	O
+of	O
+a	O
+monocyte	B-ANAT
+cell	B-ANAT
+line	I-ANAT
+,	O
+and	O
+this	O
+inhibition	B-PROC
+was	O
+accentuated	O
+by	O
+complicated	O
+disease	O
+.	O
+
+Patient	O
+plasma	B-ANAT
+inhibited	O
+LPS	B-DISO
+-	O
+induced	O
+stimulation	O
+of	O
+a	O
+monocyte	B-ANAT
+cell	B-ANAT
+line	I-ANAT
+,	O
+and	O
+this	O
+inhibition	B-PROC
+was	O
+accentuated	O
+by	O
+complicated	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Perforin	B-PRGE
+-	O
+mediated	O
+effector	B-CHED
+function	O
+within	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+requires	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	O
+mediated	O
+MHC	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+.	O
+
+Untreated	O
+PKO	O
+/	O
+GKO	O
+mice	B-SPEC
+were	O
+unable	O
+to	O
+control	O
+the	O
+infection	B-DISO
+and	O
+died	B-PROC
+of	O
+lethal	O
+encephalomyelitis	B-DISO
+within	O
+16	O
+days	O
+,	O
+despite	O
+substantially	O
+higher	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+accumulation	O
+in	O
+the	O
+CNS	B-CHED
+compared	O
+with	O
+controls	O
+.	O
+
+The	O
+data	O
+further	O
+imply	O
+that	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+plays	O
+a	O
+crucial	O
+role	O
+in	O
+pathogenesis	B-DISO
+by	O
+regulating	O
+the	O
+balance	B-PROC
+between	O
+virus	B-PROC
+replication	I-PROC
+in	O
+oligodendrocytes	B-ANAT
+,	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+effector	B-CHED
+function	O
+,	O
+and	O
+demyelination	B-DISO
+.	O
+
+TITLE	O
+:	O
+Neutrophils	B-ANAT
+promote	O
+mononuclear	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+during	O
+viral	O
+-	O
+induced	O
+encephalitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Alcohol	O
+is	O
+one	O
+of	O
+the	O
+most	O
+commonly	O
+used	O
+drugs	O
+in	O
+the	O
+world	O
+and	O
+causes	O
+dysfunction	O
+in	O
+many	O
+vital	O
+organs	B-ANAT
+.	O
+
+The	O
+incidence	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+in	O
+patients	O
+with	O
+a	O
+positive	O
+history	O
+of	O
+chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+was	O
+70	O
+%	O
+(	O
+46	O
+of	O
+66	O
+),	O
+compared	O
+with	O
+31	O
+%	O
+(	O
+47	O
+of	O
+154	O
+)	O
+in	O
+individuals	O
+without	O
+a	O
+history	O
+of	O
+chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+(	O
+p	O
+<	O
+.	O
+001	O
+).	O
+
+Mixed	O
+breed	B-PROC
+sheep	B-SPEC
+.	O
+
+Sheep	B-SPEC
+in	O
+both	O
+groups	O
+progressively	O
+deteriorated	O
+and	O
+died	B-PROC
+with	O
+cardiocirculatory	O
+failure	O
+and	O
+multiple	B-DISO
+system	I-DISO
+organ	I-DISO
+failure	I-DISO
+within	O
+12	O
+-	O
+24	O
+hrs	B-DISO
+from	O
+start	O
+of	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Population	O
+dynamics	O
+of	O
+sealworm	B-SPEC
+,	O
+Pseudoterranova	B-SPEC
+decipienssensu	O
+lato	O
+,	O
+in	O
+sculpins	B-SPEC
+,	O
+Myoxocephalus	B-SPEC
+scorpius	I-SPEC
+,	O
+from	O
+two	O
+areas	O
+in	O
+Norway	O
+between	O
+1990	O
+and	O
+1996	O
+.	O
+
+When	O
+correcting	O
+for	O
+size	O
+differences	O
+,	O
+young	O
+sculpins	B-SPEC
+(	O
+2	O
+-	O
+4	O
+years	O
+)	O
+from	O
+Torbjørnskjaer	O
+had	O
+higher	O
+abundances	O
+than	O
+those	O
+from	O
+Vega	O
+,	O
+while	O
+in	O
+old	O
+sculpins	B-SPEC
+(	O
+5	O
+-	O
+7	O
+years	O
+)	O
+the	O
+abundances	O
+seemed	O
+similar	O
+and	O
+stabilised	O
+.	O
+
+We	O
+report	O
+here	O
+a	O
+29	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+chronic	O
+pulmonary	B-DISO
+thromboembolism	I-DISO
+(	O
+CPTE	O
+).	O
+
+Preoperative	O
+examination	O
+showed	O
+high	O
+pulmonary	B-ANAT
+artery	I-ANAT
+pressure	O
+(	O
+85	O
+/	O
+41	O
+,	O
+mean	O
+50	O
+mmHg	O
+),	O
+and	O
+high	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+predicted	O
+poor	O
+postoperative	O
+course	O
+.	O
+
+We	O
+conclude	O
+that	O
+recruitment	B-DISO
+maneuver	O
+and	O
+high	O
+PEEP	B-CHED
+may	O
+be	O
+useful	O
+for	O
+RPE	B-ANAT
+developed	O
+after	O
+PTE	B-PRGE
+.	O
+
+Moreover	O
+,	O
+these	O
+molecules	O
+also	O
+regulate	O
+T	B-PROC
+-	I-PROC
+cell	I-PROC
+activation	I-PROC
+and	O
+differentiation	B-PROC
+following	O
+antigenic	O
+stimulation	O
+.	O
+
+CCL3	B-CHED
+(-/-)	O
+mice	B-SPEC
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+exhibited	O
+a	O
+significant	O
+reduction	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+within	O
+the	O
+CNS	B-CHED
+,	O
+correlating	O
+with	O
+delayed	O
+viral	O
+clearance	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+CCL3	B-PRGE
+not	O
+only	O
+mediates	O
+macrophage	B-PROC
+chemotaxis	I-PROC
+but	O
+also	O
+significantly	O
+enhances	O
+differentiation	B-PROC
+of	O
+primed	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+into	O
+effector	B-CHED
+cells	B-COMP
+and	O
+their	O
+release	B-PATH
+into	O
+circulation	B-PROC
+,	O
+thus	O
+potentiating	O
+effective	O
+migration	B-PROC
+to	O
+the	O
+site	O
+of	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genome	O
+of	O
+the	O
+coronavirus	B-SPEC
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+has	O
+been	O
+engineered	O
+as	O
+an	O
+expression	B-PROC
+vector	O
+with	O
+an	O
+infectious	B-DISO
+cDNA	O
+.	O
+
+These	O
+results	O
+demonstrated	O
+that	O
+IBV	B-SPEC
+specific	O
+CD8	B-PRGE
+(+)	O
+memory	B-PROC
+T	B-ANAT
+cells	I-ANAT
+generated	O
+at	O
+3	O
+to	O
+6	O
+weeks	O
+p	O
+.	O
+i	O
+.	O
+
+Chronic	O
+lung	B-DISO
+transplant	B-PROC
+rejection	I-PROC
+Bronchiolitis	B-DISO
+obliterans	I-DISO
+(	O
+BO	O
+)	O
+is	O
+an	O
+inflammatory	O
+process	O
+that	O
+leads	O
+to	O
+fibrous	O
+scarring	B-DISO
+of	O
+the	O
+terminal	O
+and	O
+respiratory	B-ANAT
+bronchioles	I-ANAT
+and	O
+subsequent	O
+total	O
+occlusion	B-DISO
+of	O
+the	O
+airways	O
+.	O
+
+BO	O
+is	O
+an	O
+alloimmune	O
+phenomenon	O
+,	O
+aggravated	O
+by	O
+airway	B-ANAT
+ischemia	B-DISO
+,	O
+and	O
+infection	B-DISO
+but	O
+predicted	O
+by	O
+frequent	O
+and	O
+severe	O
+acute	O
+vascular	B-ANAT
+rejection	O
+.	O
+
+Airway	B-ANAT
+neutrophilia	O
+,	O
+and	O
+activation	O
+of	O
+neutrophilis	O
+with	O
+release	B-PATH
+of	O
+their	O
+granules	O
+into	O
+the	O
+airway	B-ANAT
+is	O
+a	O
+precursor	O
+of	O
+progressive	O
+BO	O
+.	O
+
+Loss	O
+of	O
+normal	O
+protective	O
+mechanisms	O
+--	O
+leukocyte	B-ANAT
+antiproteases	O
+--	O
+against	O
+this	O
+oxidative	O
+insult	O
+may	O
+be	O
+an	O
+integral	O
+part	O
+of	O
+disease	B-DISO
+progression	I-DISO
+.	O
+
+To	O
+date	O
+treatment	O
+of	O
+BOS	B-DISO
+is	O
+infrequently	O
+successful	O
+.	O
+
+To	O
+investigate	O
+the	O
+role	O
+of	O
+VEGF	B-PRGE
+in	O
+progressively	O
+impaired	B-DISO
+lung	B-PROC
+function	I-PROC
+as	O
+the	O
+major	O
+complication	B-DISO
+and	O
+cause	O
+of	O
+death	B-PROC
+in	O
+septic	O
+patients	O
+.	O
+
+The	O
+changes	O
+in	O
+blood	B-PROC
+gas	B-ENZY
+dynamics	O
+,	O
+blood	B-PROC
+gas	B-ENZY
+acid	O
+-	O
+base	O
+status	O
+and	O
+electrolytes	O
+,	O
+along	O
+with	O
+the	O
+histological	O
+changes	O
+in	O
+the	O
+lung	B-ANAT
+tissues	I-ANAT
+were	O
+comparatively	O
+analyzed	O
+between	O
+the	O
+3	O
+groups	O
+.	O
+
+In	O
+all	O
+the	O
+groups	O
+,	O
+obvious	O
+lung	B-ANAT
+tissue	I-ANAT
+injuries	O
+were	O
+observed	O
+under	O
+optical	O
+microscope	O
+after	O
+seawater	O
+perfusion	O
+.	O
+
+Observation	O
+with	O
+electron	O
+microscope	O
+revealed	O
+injuries	O
+to	O
+type	O
+II	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+broadened	O
+respiratory	O
+mucosa	B-ANAT
+,	O
+and	O
+platelet	B-ANAT
+adherence	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+values	O
+of	O
+PaO	B-PROC
+(	O
+2	O
+),	O
+PaCO	O
+(	O
+2	O
+),	O
+pH	O
+,	O
+actual	O
+bicarbonate	B-CHED
+(	O
+AB	O
+),	O
+base	O
+excess	O
+(	O
+BE	O
+),	O
+tidal	O
+volume	O
+,	O
+and	O
+respiration	B-PROC
+rate	O
+in	O
+groups	O
+A	O
+and	O
+R	O
+were	O
+significantly	O
+different	O
+from	O
+those	O
+in	O
+group	O
+D	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+and	O
+in	O
+groups	O
+A	O
+and	O
+R	O
+,	O
+the	O
+above	O
+measurements	O
+at	O
+every	O
+stage	O
+after	O
+seawater	O
+perfusion	O
+were	O
+significantly	O
+different	O
+from	O
+those	O
+before	O
+perfusion	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+During	O
+48	O
+hours	O
+,	O
+control	O
+sheep	B-SPEC
+developed	O
+multiple	O
+signs	O
+of	O
+ARDS	B-DISO
+.	O
+
+These	O
+pathologies	O
+were	O
+associated	O
+with	O
+a	O
+large	O
+increase	O
+in	O
+tracheal	O
+blood	O
+flow	O
+and	O
+elevated	O
+plasma	B-ANAT
+NO2	B-CHED
+-/	O
+NO3	B-CHED
+-	O
+(	O
+NOx	O
+)	O
+levels	O
+.	O
+
+These	O
+variables	O
+were	O
+all	O
+stable	O
+in	O
+sham	O
+animals	B-SPEC
+.	O
+
+Improved	O
+understanding	O
+of	O
+disease	O
+heterogeneity	O
+through	O
+use	O
+of	O
+evolving	O
+biologic	O
+,	O
+genomic	O
+,	O
+and	O
+genetic	O
+approaches	O
+should	O
+provide	O
+major	O
+new	O
+insights	O
+into	O
+pathogenesis	B-DISO
+of	O
+ALI	O
+.	O
+
+TITLE	O
+:	O
+Switching	O
+species	B-SPEC
+tropism	B-PROC
+:	O
+an	O
+effective	O
+way	O
+to	O
+manipulate	O
+the	O
+feline	B-SPEC
+coronavirus	B-SPEC
+genome	O
+.	O
+
+Viral	O
+recrudescence	O
+is	O
+prevented	O
+by	O
+the	O
+transfer	O
+of	O
+antiviral	B-CHED
+antibody	B-COMP
+(	O
+Ab	O
+).	O
+
+Nonneutralizing	O
+monoclonal	O
+Abs	O
+specific	O
+for	O
+the	O
+spike	O
+,	O
+matrix	O
+,	O
+and	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+did	O
+not	O
+prevent	O
+recrudescence	O
+,	O
+demonstrating	O
+that	O
+neutralization	O
+is	O
+critical	O
+for	O
+maintaining	O
+JHM	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+persistence	O
+within	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+.	O
+
+Furthermore	O
+,	O
+neutralizing	O
+Ab	O
+delayed	O
+but	O
+did	O
+not	O
+prevent	O
+virus	B-SPEC
+recrudescence	O
+.	O
+
+ABSTRACT	O
+:	O
+Recombinant	O
+murine	O
+coronaviruses	O
+,	O
+differing	O
+only	O
+in	O
+the	O
+spike	O
+gene	O
+and	O
+containing	O
+the	O
+strain	O
+A59	O
+(	O
+moderately	O
+hepatotropic	O
+)	O
+and	O
+JHM	O
+(	O
+neurotropic	O
+)	O
+spike	O
+genes	O
+in	O
+the	O
+background	O
+of	O
+the	O
+JHM	O
+genome	O
+,	O
+were	O
+compared	O
+for	O
+the	O
+ability	O
+to	O
+replicate	O
+in	O
+the	O
+liver	B-ANAT
+and	O
+induce	O
+hepatitis	B-DISO
+in	O
+weanling	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+.	O
+
+Lung	B-ANAT
+protective	O
+ventilation	O
+is	O
+accepted	O
+as	O
+a	O
+proven	O
+therapy	O
+and	O
+the	O
+use	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+as	O
+well	O
+as	O
+spontaneous	O
+breathing	B-PROC
+during	O
+controlled	O
+ventilation	O
+are	O
+common	O
+therapies	O
+.	O
+
+Recent	O
+work	O
+has	O
+also	O
+demonstrated	O
+that	O
+activated	O
+bystander	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+mediate	O
+significant	O
+demyelination	B-DISO
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+CD4	B-PRGE
+T	B-ANAT
+cells	I-ANAT
+must	O
+recognize	O
+antigen	B-CHED
+in	O
+the	O
+CNS	B-CHED
+in	O
+order	B-SPEC
+to	O
+cause	O
+demyelination	B-DISO
+.	O
+
+DNA	O
+fragments	O
+of	O
+228	O
+and	O
+400	O
+base	B-FUNC
+pairs	I-FUNC
+in	O
+length	O
+were	O
+amplified	O
+among	O
+IBV	B-SPEC
+isolates	O
+in	O
+multiplex	O
+PCR	O
+,	O
+suggesting	O
+that	O
+there	O
+were	O
+no	O
+apparent	O
+deletions	O
+or	O
+insertions	O
+in	O
+these	O
+regions	O
+.	O
+
+The	O
+most	O
+common	O
+presenting	O
+symptoms	O
+were	O
+fever	B-PROC
+(	O
+in	O
+100	O
+percent	O
+of	O
+cases	O
+)	O
+and	O
+malaise	B-DISO
+(	O
+in	O
+70	O
+percent	O
+),	O
+followed	O
+by	O
+nonproductive	B-DISO
+cough	I-DISO
+(	O
+in	O
+100	O
+percent	O
+)	O
+and	O
+dyspnea	B-DISO
+(	O
+in	O
+80	O
+percent	O
+)	O
+associated	O
+with	O
+infiltrates	B-DISO
+on	O
+chest	B-ANAT
+radiography	O
+(	O
+in	O
+100	O
+percent	O
+).	O
+
+The	O
+role	O
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+or	O
+both	O
+requires	O
+further	O
+investigation	O
+.	O
+
+Fever	B-PROC
+followed	O
+by	O
+rapidly	O
+progressive	O
+respiratory	O
+compromise	O
+is	O
+the	O
+key	O
+complex	O
+of	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+from	O
+which	O
+the	O
+syndrome	B-DISO
+derives	O
+its	O
+name	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Ogilvie	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+--	O
+acute	O
+colonic	B-DISO
+pseudo	I-DISO
+-	I-DISO
+obstruction	I-DISO
+.	O
+
+The	O
+diagnosis	O
+was	O
+determined	O
+by	O
+confirming	O
+an	O
+increase	O
+of	O
+specific	O
+antibody	B-COMP
+.	O
+
+All	O
+patients	O
+were	O
+treated	O
+with	O
+minocycline	B-CHED
+,	O
+and	O
+all	O
+recovered	O
+,	O
+excluding	O
+one	O
+patient	O
+with	O
+a	O
+fulminant	O
+course	O
+.	O
+
+The	O
+creatine	B-PRGE
+kinase	I-PRGE
+(	O
+CK	O
+)	O
+value	O
+was	O
+high	O
+in	O
+14	O
+of	O
+22	O
+patients	O
+,	O
+suggesting	O
+the	O
+presence	O
+of	O
+myositis	B-DISO
+.	O
+
+She	O
+was	O
+found	O
+to	O
+have	O
+extravasated	O
+a	O
+9	O
+-	O
+cm	O
+x	O
+9	O
+-	O
+cm	O
+pocket	O
+of	O
+hyperalimentation	B-DISO
+into	O
+the	O
+liver	B-ANAT
+parenchyma	I-ANAT
+,	O
+most	O
+likely	O
+caused	O
+by	O
+arterial	B-ANAT
+placement	O
+of	O
+the	O
+PICC	O
+.	O
+
+No	O
+clinical	O
+signs	O
+or	O
+microscopic	O
+lesions	O
+were	O
+observed	O
+in	O
+control	O
+pigs	B-SPEC
+that	O
+had	O
+not	O
+been	O
+inoculated	O
+.	O
+
+TITLE	O
+:	O
+A	O
+major	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Hong	O
+Kong	O
+.	O
+
+Peripheral	O
+air	B-CHED
+-	O
+space	O
+consolidation	O
+was	O
+commonly	O
+observed	O
+on	O
+thoracic	B-DISO
+computed	O
+tomographic	O
+scanning	O
+.	O
+
+SARS	B-DISO
+is	O
+a	O
+serious	O
+respiratory	O
+illness	O
+that	O
+led	O
+to	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+in	O
+our	O
+cohort	O
+.	O
+
+A	O
+summary	O
+of	O
+published	O
+medical	O
+literature	O
+from	O
+MEDLINE	O
+search	O
+files	O
+and	O
+other	O
+reviews	O
+published	O
+concerning	O
+chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+and	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+More	O
+importantly	O
+,	O
+similar	O
+changes	O
+have	O
+been	O
+reported	O
+in	O
+humans	B-SPEC
+with	O
+a	O
+history	O
+of	O
+chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+.	O
+
+The	O
+National	O
+Heart	B-ANAT
+,	O
+Lung	B-ANAT
+,	O
+and	O
+Blood	B-ANAT
+Institute	O
+'	O
+s	O
+ARDS	B-DISO
+Network	O
+currently	O
+is	O
+testing	O
+the	O
+use	O
+of	O
+methylprednisolone	B-CHED
+in	O
+late	O
+ARDS	B-DISO
+.	O
+
+It	O
+is	O
+also	O
+unclear	O
+whether	O
+such	O
+a	O
+response	O
+,	O
+if	O
+present	O
+,	O
+predisposes	O
+patients	O
+to	O
+ongoing	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+the	O
+development	B-PROC
+of	O
+late	O
+fibroproliferative	O
+ARDS	B-DISO
+,	O
+or	O
+if	O
+it	O
+is	O
+predictive	O
+of	O
+a	O
+beneficial	O
+response	O
+to	O
+steroids	B-CHED
+.	O
+
+TITLE	O
+:	O
+Anticoagulant	B-CHED
+therapy	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+In	O
+the	O
+lung	B-ANAT
+,	O
+alveolar	B-ANAT
+and	O
+interstitial	B-ANAT
+fibrin	B-DISO
+deposition	I-DISO
+are	O
+the	O
+hallmarks	O
+of	O
+early	O
+phase	O
+ALI	O
+.	O
+
+Finally	O
+,	O
+plasminogen	B-PROC
+activators	I-PROC
+may	O
+improve	O
+gas	B-ENZY
+exchange	O
+in	O
+ALI	O
+,	O
+but	O
+studies	O
+in	O
+humans	B-SPEC
+are	O
+limited	O
+.	O
+
+In	O
+the	O
+CMV	B-SPEC
+group	O
+,	O
+these	O
+deleterious	O
+conditions	O
+remained	O
+during	O
+the	O
+4	O
+-	O
+hr	O
+observation	O
+period	O
+,	O
+and	O
+severe	O
+lung	B-ANAT
+injury	O
+was	O
+noted	O
+histologically	O
+.	O
+
+All	O
+treatment	O
+groups	O
+demonstrated	O
+a	O
+significant	O
+increase	O
+in	O
+Pao	B-PROC
+(	O
+2	O
+)	O
+compared	O
+with	O
+the	O
+CMV	B-SPEC
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+1914	O
+,	O
+Schottmueller	O
+wrote	O
+""""	O
+Septicemia	O
+is	O
+a	O
+state	O
+of	O
+microbial	O
+invasion	B-DISO
+from	O
+a	O
+portal	B-ANAT
+of	O
+entry	O
+into	O
+the	O
+blood	B-ANAT
+stream	O
+which	O
+causes	O
+signs	O
+of	O
+illness	O
+.	O
+
+This	O
+review	O
+will	O
+highlight	O
+and	O
+discuss	O
+recent	O
+advances	O
+in	O
+the	O
+pathophysiology	O
+and	O
+management	O
+of	O
+sepsis	B-DISO
+.	O
+
+The	O
+current	O
+study	O
+was	O
+carried	O
+out	O
+to	O
+investigate	O
+the	O
+combined	O
+antiviral	B-CHED
+effect	O
+in	O
+a	O
+model	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+Type	O
+2	O
+(	O
+MHV	B-SPEC
+-	O
+2	O
+)	O
+infection	B-DISO
+,	O
+in	O
+which	O
+fulminant	B-DISO
+hepatitis	I-DISO
+is	O
+developed	O
+.	O
+
+This	O
+is	O
+consistent	O
+with	O
+the	O
+lower	O
+levels	O
+of	O
+hepatocellular	B-PRGE
+necrosis	I-PRGE
+and	I-PRGE
+serum	B-COMP
+ALT	B-FUNC
+and	O
+the	O
+decreased	O
+titers	O
+of	O
+MHV	B-SPEC
+-	O
+2	O
+virus	B-SPEC
+in	O
+the	O
+liver	B-ANAT
+tissues	I-ANAT
+(	O
+48	O
+hr	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+;	O
+72	O
+hr	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+SARS	B-DISO
+is	O
+thought	O
+to	O
+be	O
+caused	O
+by	O
+an	O
+unknown	O
+infectious	B-DISO
+agent	O
+.	O
+
+Infected	O
+patients	O
+showed	O
+seroconversion	O
+on	O
+the	O
+Vero	B-ANAT
+cells	I-ANAT
+in	O
+which	O
+the	O
+virus	B-SPEC
+was	O
+isolated	O
+.	O
+
+Recent	O
+evidence	O
+suggests	O
+that	O
+cross	O
+-	O
+reactivity	O
+represents	O
+the	O
+inherent	O
+nature	O
+of	O
+the	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+repertoire	O
+.	O
+
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+reacting	O
+to	O
+the	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+-	I-PRGE
+presented	I-PRGE
+peptide	B-CHED
+from	I-PRGE
+HPV16	I-PRGE
+E7	I-PRGE
+(	O
+11	O
+-	O
+19	O
+(	O
+20	O
+))	O
+recognized	O
+also	O
+the	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+binding	B-FUNC
+peptide	B-CHED
+TMLDIQPED	O
+(	O
+amino	B-CHED
+acids	I-CHED
+52	O
+to	O
+60	O
+)	O
+from	O
+the	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+NS2	B-DISO
+gene	I-PRGE
+product	I-PRGE
+.	O
+
+Establishment	O
+of	O
+coronavirus	O
+NS2	B-DISO
+-	O
+specific	O
+,	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+-	O
+restricted	O
+CD8	B-PRGE
+(+)-	O
+T	O
+-	O
+cell	B-ANAT
+clones	I-ANAT
+and	O
+ex	O
+vivo	O
+analysis	O
+of	O
+HPV16	O
+E7	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+obtained	O
+by	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+tetramer	I-PRGE
+-	O
+guided	O
+sorting	B-PROC
+from	O
+PBL	O
+or	O
+tumor	B-ANAT
+-	I-ANAT
+infiltrating	B-DISO
+lymphocytes	I-ANAT
+obtained	O
+from	O
+patients	O
+with	O
+cervical	B-DISO
+cancer	B-SPEC
+showed	O
+that	O
+cross	O
+-	O
+reactivity	O
+with	O
+HPV16	O
+E7	O
+(	O
+11	O
+-	O
+19	O
+(	O
+20	O
+))	O
+and	O
+coronavirus	B-SPEC
+NS2	B-DISO
+(	O
+52	O
+-	O
+60	O
+)	O
+represents	O
+a	O
+common	O
+feature	O
+of	O
+this	O
+antiviral	B-CHED
+immune	B-PROC
+response	I-PROC
+defined	O
+by	O
+cytokine	B-PROC
+production	I-PROC
+.	O
+
+These	O
+data	O
+imply	O
+that	O
+the	O
+measurement	O
+of	O
+the	O
+HPV16	O
+E7	O
+(	O
+11	O
+-	O
+19	O
+(	O
+20	O
+))	O
+CD8	B-PRGE
+(+)-	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+may	O
+reflect	O
+cross	O
+-	O
+reactivity	O
+with	O
+a	O
+common	O
+pathogen	O
+and	O
+that	O
+variant	O
+peptides	B-CHED
+may	O
+be	O
+employed	O
+to	O
+drive	O
+an	O
+effective	O
+cellular	B-PROC
+immune	I-PROC
+response	I-PROC
+against	O
+HPV	O
+.	O
+
+TITLE	O
+:	O
+Control	O
+of	O
+communicable	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+existing	O
+regulations	O
+are	O
+outdated	O
+and	O
+do	O
+not	O
+address	O
+communicable	B-DISO
+diseases	I-DISO
+that	O
+currently	O
+pose	O
+a	O
+substantial	O
+public	O
+health	O
+threat	O
+.	O
+
+At	O
+the	O
+hospitals	O
+where	O
+the	O
+first	O
+cases	O
+were	O
+treated	O
+the	O
+disease	O
+spread	O
+quickly	O
+among	O
+healthcare	O
+workers	O
+,	O
+and	O
+then	O
+out	O
+into	O
+the	O
+community	O
+as	O
+family	B-SPEC
+members	O
+became	O
+infected	O
+.	O
+
+TITLE	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+gene	O
+7	O
+is	O
+not	O
+essential	O
+but	O
+influences	O
+in	O
+vivo	O
+virus	B-SPEC
+replication	I-PROC
+and	O
+virulence	B-PROC
+.	O
+
+Examination	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+demonstrated	O
+WBC	B-ANAT
+6	O
+.	O
+2	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+l	O
+with	O
+45	O
+.	O
+5	O
+%	O
+blasts	B-ANAT
+at	O
+admission	O
+.	O
+
+In	O
+DS	O
+patients	O
+,	O
+superfluous	O
+toxicities	O
+due	O
+to	O
+MTX	B-PRGE
+and	O
+AraC	O
+treatment	O
+have	O
+been	O
+reported	O
+,	O
+and	O
+these	O
+toxicities	O
+have	O
+been	O
+considered	O
+due	O
+to	O
+altered	O
+pharmacokinetics	B-PROC
+in	O
+patients	O
+with	O
+DS	O
+.	O
+
+Public	O
+health	O
+measures	O
+are	O
+being	O
+implemented	O
+at	O
+the	O
+local	O
+,	O
+provincial	O
+,	O
+and	O
+national	O
+levels	O
+to	O
+identify	O
+new	O
+cases	O
+and	O
+prevent	O
+secondary	B-DISO
+transmission	I-DISO
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+reported	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Patients	O
+who	O
+were	O
+household	O
+contacts	O
+of	O
+other	O
+infected	O
+people	O
+and	O
+had	O
+older	O
+age	O
+,	O
+lymphopenia	O
+,	O
+and	O
+liver	B-DISO
+dysfunction	I-DISO
+were	O
+associated	O
+with	O
+severe	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Mechanical	O
+transmission	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+by	O
+domestic	O
+houseflies	O
+(	O
+Musca	B-SPEC
+domestica	I-SPEC
+Linnaeaus	O
+).	O
+
+TCV	B-SPEC
+was	O
+detected	O
+in	O
+dissected	O
+crops	B-ANAT
+from	O
+exposed	O
+flies	B-SPEC
+for	O
+up	O
+to	O
+9	O
+hr	O
+postexposure	O
+;	O
+no	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+crops	B-ANAT
+of	O
+sham	O
+-	O
+exposed	O
+flies	B-SPEC
+.	O
+
+Animals	B-SPEC
+were	O
+ventilated	O
+and	O
+monitored	O
+for	O
+48	O
+hours	O
+.	O
+
+We	O
+tested	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+samples	O
+obtained	O
+from	O
+HSCT	O
+recipients	O
+with	O
+acute	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+for	O
+HRV	O
+(	O
+n	O
+=	O
+122	O
+)	O
+and	O
+coronavirus	B-SPEC
+(	O
+n	O
+=	O
+46	O
+)	O
+by	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+D	O
+-	O
+RNA	O
+CD	O
+-	O
+61	O
+derived	O
+from	O
+the	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+was	O
+used	O
+as	O
+an	O
+RNA	O
+vector	O
+for	O
+the	O
+expression	B-PROC
+of	O
+chicken	B-PRGE
+gamma	I-PRGE
+interferon	I-PRGE
+(	O
+chIFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+).	O
+
+The	O
+reported	O
+SARS	B-DISO
+cases	O
+include	O
+78	O
+deaths	B-PROC
+(	O
+case	O
+-	O
+fatality	O
+proportion	O
+:	O
+3	O
+.	O
+5	O
+%).	O
+
+This	O
+report	O
+summarizes	O
+SARS	B-DISO
+cases	O
+among	O
+U	O
+.	O
+S	O
+.	O
+residents	O
+and	O
+surveillance	O
+and	O
+prevention	O
+activities	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+The	O
+sequence	O
+of	O
+the	O
+complete	O
+genome	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+determined	O
+,	O
+and	O
+the	O
+initial	O
+characterization	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+is	O
+presented	O
+in	O
+this	O
+report	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Genome	O
+sequence	O
+of	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	O
+intra	O
+-	O
+abdominal	O
+hypertension	O
+causes	O
+profound	O
+physiologic	O
+abnormalities	O
+,	O
+both	O
+within	O
+and	O
+outside	O
+the	O
+abdomen	B-ANAT
+.	O
+
+Infection	B-DISO
+with	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+has	O
+been	O
+implicated	O
+as	O
+a	O
+possible	O
+cause	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+that	O
+first	O
+manifested	O
+in	O
+humans	B-SPEC
+in	O
+China	O
+in	O
+November	O
+2002	O
+and	O
+has	O
+subsequently	O
+spread	O
+worldwide	O
+.	O
+
+To	O
+describe	O
+the	O
+clinical	O
+characteristics	O
+and	O
+short	O
+-	O
+term	O
+outcomes	O
+of	O
+SARS	B-DISO
+in	O
+the	O
+first	O
+large	O
+group	O
+of	O
+patients	O
+in	O
+North	O
+America	O
+;	O
+to	O
+describe	O
+how	O
+these	O
+patients	O
+were	O
+treated	O
+and	O
+the	O
+variables	O
+associated	O
+with	O
+poor	O
+outcome	O
+.	O
+
+Common	O
+laboratory	O
+features	O
+included	O
+elevated	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+87	O
+%),	O
+hypocalcemia	B-DISO
+(	O
+60	O
+%),	O
+and	O
+lymphopenia	B-DISO
+(	O
+54	O
+%).	O
+
+Testing	O
+for	O
+other	O
+enteric	O
+pathogens	O
+was	O
+performed	O
+by	O
+ADDL	B-PRGE
+,	O
+and	O
+the	O
+results	O
+were	O
+analyzed	O
+with	O
+the	O
+BoTV	O
+data	O
+.	O
+
+All	O
+these	O
+patients	O
+were	O
+Caucasians	O
+and	O
+presented	O
+with	O
+dyspnea	B-DISO
+,	O
+productive	B-DISO
+cough	I-DISO
+,	O
+an	O
+obstructive	O
+or	O
+mixed	O
+impairment	O
+on	O
+pulmonary	B-PROC
+function	I-PROC
+tests	O
+and	O
+chest	B-ANAT
+HRCT	O
+features	O
+strongly	O
+suggesting	O
+a	O
+grade	O
+II	O
+to	O
+IV	O
+DPB	B-DISO
+.	O
+
+We	O
+suggest	O
+that	O
+diseases	O
+classified	O
+as	O
+IB	O
+in	O
+this	O
+study	O
+might	O
+be	O
+homogeneous	O
+entities	O
+which	O
+are	O
+clinically	O
+and	O
+radiologically	O
+similar	O
+to	O
+DPB	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+did	O
+a	O
+case	O
+-	O
+control	O
+study	O
+in	O
+five	O
+Hong	O
+Kong	O
+hospitals	O
+,	O
+with	O
+241	O
+non	O
+-	O
+infected	O
+and	O
+13	O
+infected	O
+staff	O
+with	O
+documented	O
+exposures	O
+to	O
+11	O
+index	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+during	O
+patient	O
+care	O
+.	O
+
+Coagulopathy	B-DISO
+is	O
+usually	O
+uncomplicated	O
+and	O
+early	O
+CT	O
+of	O
+the	O
+chest	B-ANAT
+may	O
+elucidate	O
+hidden	O
+lung	B-ANAT
+changes	O
+and	O
+facilitate	O
+a	O
+rapid	O
+diagnosis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Common	O
+thin	O
+-	O
+section	O
+CT	O
+features	O
+of	O
+SARS	B-DISO
+are	O
+ground	O
+-	O
+glass	O
+opacification	O
+and	O
+lower	O
+lobe	B-ANAT
+and	O
+peripheral	O
+distribution	O
+.	O
+
+The	O
+disease	O
+can	O
+produce	O
+a	O
+severe	O
+bilateral	B-DISO
+pneumonia	I-DISO
+,	O
+with	O
+progressive	O
+hypoxemia	O
+.	O
+
+Two	O
+principal	O
+authors	O
+met	B-CHED
+with	O
+core	O
+team	O
+members	O
+and	O
+mental	O
+health	O
+care	O
+providers	O
+at	O
+Mount	O
+Sinai	O
+Hospital	O
+,	O
+Toronto	O
+,	O
+to	O
+compile	O
+retrospectively	O
+descriptions	O
+of	O
+the	O
+experiences	O
+of	O
+staff	O
+and	O
+patients	O
+based	O
+on	O
+informal	O
+observation	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+coronavirus	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+It	O
+is	O
+a	O
+rare	O
+,	O
+but	O
+rather	O
+benign	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+It	O
+is	O
+referred	O
+to	O
+under	O
+the	O
+term	O
+SARS	B-DISO
+.	O
+
+Import	O
+infections	B-DISO
+appeared	O
+in	O
+many	O
+other	O
+parts	O
+of	O
+the	O
+world	O
+.	O
+
+We	O
+analysed	O
+the	O
+data	O
+of	O
+two	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+one	O
+suspected	O
+patient	O
+.	O
+
+This	O
+report	O
+updates	O
+information	O
+on	O
+reported	O
+SARS	B-DISO
+cases	O
+worldwide	O
+and	O
+among	O
+U	O
+.	O
+S	O
+.	O
+residents	O
+and	O
+summarizes	O
+information	O
+on	O
+one	O
+additional	O
+case	O
+with	O
+laboratory	O
+evidence	O
+of	O
+infection	B-DISO
+with	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Mature	O
+RCV	O
+particles	O
+were	O
+distributed	O
+around	O
+the	O
+ER	O
+pools	O
+,	O
+cytoplasm	B-COMP
+,	O
+and	O
+intercellular	B-COMP
+space	I-COMP
+,	O
+and	O
+the	O
+RCVs	O
+in	O
+the	O
+endosome	B-COMP
+/	O
+lysosome	B-COMP
+were	O
+devoid	O
+of	O
+the	O
+envelop	O
+and	O
+nuclear	O
+capsid	B-ANAT
+.	O
+
+The	O
+Result	O
+of	O
+Blast	B-ANAT
+shows	O
+only	O
+the	O
+difference	O
+in	O
+one	O
+nucleic	B-CHED
+acid	I-CHED
+from	O
+the	O
+TOR2	B-PRGE
+strain	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Specific	O
+fragments	O
+were	O
+amplified	O
+from	O
+the	O
+sputum	O
+samples	O
+of	O
+SARS	B-DISO
+patients	O
+,	O
+which	O
+were	O
+confirmed	O
+by	O
+DNA	O
+cloning	O
+and	O
+sequencing	O
+to	O
+belong	O
+to	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+detection	O
+of	O
+polymerase	B-PRGE
+gene	I-PRGE
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+].	O
+
+Specific	O
+amplicons	O
+can	O
+be	O
+amplified	O
+from	O
+the	O
+sputum	B-ANAT
+samples	O
+,	O
+throat	B-ANAT
+swab	I-ANAT
+and	O
+plasma	B-ANAT
+of	O
+most	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+8	O
+were	O
+random	O
+selected	O
+and	O
+sequenced	O
+.	O
+
+The	O
+BNI109	O
+fragment	O
+showed	O
+75	O
+%	O
+homology	O
+with	O
+BCV	B-SPEC
+and	O
+MHV	B-SPEC
+at	O
+amino	B-CHED
+acid	I-CHED
+level	O
+.	O
+
+Among	O
+the	O
+patients	O
+with	O
+a	O
+nonruptured	O
+aneurysm	B-DISO
+,	O
+two	O
+deaths	B-PROC
+(	O
+9	O
+.	O
+1	O
+%)	O
+occurred	O
+because	O
+of	O
+aorto	O
+-	O
+broncho	O
+-	O
+esophageal	O
+fistulae	O
+or	O
+cardiac	O
+arrest	O
+due	O
+to	O
+severe	O
+asthma	B-DISO
+attack	I-DISO
+within	O
+30	O
+days	O
+,	O
+and	O
+the	O
+other	O
+three	O
+hospital	O
+deaths	B-PROC
+were	O
+due	O
+to	O
+aspiration	B-DISO
+pneumonia	I-DISO
+,	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+with	O
+preoperative	O
+renal	B-ANAT
+dysfunction	O
+,	O
+or	O
+low	B-DISO
+cardiac	I-DISO
+output	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+perioperative	O
+myocardial	B-DISO
+infarction	I-DISO
+.	O
+
+SARS	B-DISO
+may	O
+well	O
+be	O
+a	O
+zoonosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+diversity	O
+of	O
+a	O
+canine	O
+coronavirus	B-SPEC
+detected	O
+in	O
+pups	O
+with	O
+diarrhoea	B-DISO
+in	O
+Italy	O
+.	O
+
+The	O
+evident	O
+genetic	B-PROC
+divergence	I-PROC
+between	O
+the	O
+reference	O
+CCoV	O
+strains	O
+and	O
+the	O
+newly	O
+identified	O
+Elmo	B-PRGE
+/	I-PRGE
+02	I-PRGE
+-	I-PRGE
+like	I-PRGE
+CCoVs	I-PRGE
+strongly	O
+suggests	O
+that	O
+a	O
+novel	O
+genotype	O
+of	O
+CCoV	O
+is	O
+widespread	O
+in	O
+the	O
+dog	B-SPEC
+population	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+retrospectively	O
+evaluate	O
+the	O
+radiographic	O
+appearances	O
+and	O
+pattern	O
+of	O
+progression	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+Initial	O
+focal	O
+air	B-CHED
+-	O
+space	O
+opacity	B-DISO
+in	O
+44	O
+of	O
+59	O
+patients	O
+(	O
+74	O
+.	O
+6	O
+%)	O
+progressed	O
+to	O
+unilateral	O
+multifocal	O
+or	O
+bilateral	O
+involvement	O
+during	O
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+an	O
+analysis	O
+of	O
+the	O
+first	O
+10	O
+weeks	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Excluding	O
+SSEs	O
+,	O
+we	O
+estimate	O
+that	O
+2	O
+.	O
+7	O
+secondary	B-DISO
+infections	I-DISO
+were	O
+generated	O
+per	O
+case	O
+on	O
+average	O
+at	O
+the	O
+start	O
+of	O
+the	O
+epidemic	O
+,	O
+with	O
+a	O
+substantial	O
+contribution	O
+from	O
+hospital	O
+transmission	O
+.	O
+
+Transmission	O
+rates	O
+fell	O
+during	O
+the	O
+epidemic	O
+,	O
+primarily	O
+as	O
+a	O
+result	O
+of	O
+reductions	O
+in	O
+population	O
+contact	O
+rates	O
+and	O
+improved	O
+hospital	B-DISO
+infection	I-DISO
+control	O
+,	O
+but	O
+also	O
+because	O
+of	O
+more	O
+rapid	O
+hospital	O
+attendance	O
+by	O
+symptomatic	O
+individuals	O
+.	O
+
+ABSTRACT	O
+:	O
+Hong	O
+Kong	O
+has	O
+been	O
+severely	O
+affected	O
+by	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+severity	O
+of	O
+the	O
+disease	O
+,	O
+combined	O
+with	O
+its	O
+rapid	O
+spread	O
+along	O
+international	O
+air	B-CHED
+-	O
+travel	O
+routes	O
+,	O
+prompted	O
+WHO	O
+to	O
+set	O
+up	O
+a	O
+network	O
+of	O
+scientists	O
+from	O
+11	O
+laboratories	O
+around	O
+the	O
+world	O
+to	O
+try	O
+to	O
+identify	O
+the	O
+causal	O
+agent	O
+and	O
+develop	O
+a	O
+diagnostic	O
+test	O
+.	O
+
+The	O
+network	O
+unites	O
+laboratories	O
+with	O
+different	O
+methods	O
+and	O
+capacities	O
+to	O
+rapidly	O
+fulfil	O
+all	O
+postulates	O
+for	O
+establishing	O
+a	O
+virus	B-SPEC
+as	O
+the	O
+cause	O
+of	O
+a	O
+disease	O
+.	O
+
+Stem	B-ANAT
+-	O
+loop	O
+III	O
+is	O
+presumed	O
+to	O
+function	O
+in	O
+the	O
+positive	O
+strand	O
+,	O
+but	O
+its	O
+strand	O
+of	O
+action	O
+has	O
+not	O
+been	O
+established	O
+.	O
+
+No	O
+cases	O
+of	O
+secondary	B-DISO
+transmission	I-DISO
+were	O
+identified	O
+in	O
+the	O
+21	O
+days	O
+following	O
+the	O
+implementation	O
+of	O
+these	O
+precautions	O
+at	O
+our	O
+institution	O
+.	O
+
+In	O
+the	O
+hemorrhagic	B-DISO
+shock	I-DISO
+model	O
+,	O
+plasma	B-ANAT
+concentrations	O
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+,	O
+and	O
+macrophage	B-ANAT
+inflammatory	O
+protein	B-CHED
+-	O
+2	O
+were	O
+significantly	O
+lower	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+10	I-PRGE
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+albumin	B-PRGE
+-	O
+treated	O
+groups	O
+compared	O
+with	O
+the	O
+Ringer	O
+'	O
+s	O
+lactate	B-CHED
+-	O
+treated	O
+group	O
+.	O
+
+The	O
+decreased	B-PROC
+cytokine	I-PROC
+production	I-PROC
+was	O
+associated	O
+with	O
+a	O
+reduction	O
+of	O
+hydrogen	B-PROC
+peroxide	I-PROC
+formation	I-PROC
+with	O
+albumin	B-PRGE
+resuscitation	O
+.	O
+
+We	O
+conclude	O
+that	O
+resuscitation	O
+with	O
+albumin	B-PRGE
+may	O
+have	O
+utility	O
+in	O
+reducing	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+after	O
+hemorrhagic	B-DISO
+shock	I-DISO
+,	O
+but	O
+not	O
+after	O
+endotoxic	B-DISO
+shock	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+coronavirus	O
+has	O
+been	O
+implicated	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+with	O
+convalescent	O
+plasma	B-ANAT
+.	O
+
+This	O
+report	O
+is	O
+of	O
+a	O
+hospital	O
+medical	O
+officer	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+most	O
+severe	O
+cases	O
+of	O
+the	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+,	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+can	O
+be	O
+used	O
+to	O
+facilitate	O
+gas	B-ENZY
+exchange	O
+.	O
+
+The	O
+DeltaStream	O
+blood	B-ANAT
+pump	O
+is	O
+a	O
+small	O
+-	O
+sized	O
+rotary	O
+blood	B-ANAT
+pump	O
+that	O
+may	O
+reduce	O
+extracorporeal	B-ANAT
+blood	I-ANAT
+volume	O
+,	O
+foreign	O
+surfaces	O
+,	O
+contact	O
+activation	O
+of	O
+the	O
+coagulation	B-PROC
+system	O
+,	O
+and	O
+blood	B-ANAT
+trauma	O
+.	O
+
+In	O
+animals	B-SPEC
+with	O
+ALI	O
+,	O
+hemodynamics	B-PROC
+remained	O
+stable	O
+and	O
+gas	B-ENZY
+transfer	O
+across	O
+the	O
+extracorporeal	O
+oxygenators	O
+was	O
+optimal	O
+,	O
+but	O
+only	O
+in	O
+2	O
+animals	B-SPEC
+was	O
+a	O
+marked	O
+increase	O
+in	O
+PaO2	O
+observed	O
+.	O
+
+We	O
+describe	O
+the	O
+clinical	O
+,	O
+laboratory	O
+,	O
+and	O
+radiologic	O
+features	O
+of	O
+the	O
+index	O
+patient	O
+and	O
+the	O
+patient	O
+'	O
+s	O
+initial	O
+contacts	O
+affected	O
+with	O
+probable	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Health	O
+authorities	O
+worldwide	O
+,	O
+especially	O
+in	O
+the	O
+Asia	O
+Pacific	O
+region	O
+,	O
+are	O
+seeking	O
+effective	O
+public	O
+-	O
+health	O
+interventions	O
+in	O
+the	O
+continuing	O
+epidemic	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+time	O
+between	O
+onset	O
+of	O
+symptoms	O
+and	O
+admission	O
+to	O
+hospital	O
+did	O
+not	O
+alter	O
+outcome	O
+,	O
+but	O
+shorter	O
+intervals	O
+will	O
+be	O
+important	O
+to	O
+the	O
+wider	O
+population	O
+by	O
+restricting	O
+the	O
+infectious	B-DISO
+period	O
+before	O
+patients	O
+are	O
+placed	O
+in	O
+quarantine	O
+.	O
+
+The	O
+alveolar	B-ANAT
+pneumocytes	B-ANAT
+also	O
+showed	O
+cytomegaly	B-ANAT
+with	O
+granular	B-ANAT
+amphophilic	O
+cytoplasm	B-COMP
+.	O
+
+The	O
+patient	O
+for	O
+whom	O
+full	O
+autopsy	O
+was	O
+done	O
+had	O
+atrophy	B-DISO
+of	O
+the	O
+white	B-ANAT
+pulp	I-ANAT
+of	O
+the	O
+spleen	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+cause	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+new	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Survival	O
+of	O
+severe	O
+ARDS	B-DISO
+with	O
+five	O
+-	O
+organ	B-ANAT
+system	I-ANAT
+failure	O
+following	O
+burns	O
+and	O
+inhalation	B-PROC
+injury	O
+in	O
+a	O
+15	O
+-	O
+year	O
+-	O
+old	O
+patient	O
+.	O
+
+Case	O
+report	O
+of	O
+a	O
+patient	O
+with	O
+severe	O
+inhalation	B-PROC
+injury	O
+and	O
+burns	O
+in	O
+an	O
+intensive	O
+care	O
+unit	O
+setting	O
+,	O
+undergoing	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+(	O
+CPR	B-ENZY
+),	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)-	O
+inhalation	B-PROC
+,	O
+surfactant	B-CHED
+-,	O
+kinetic	O
+-,	O
+and	O
+urodilatin	O
+-	O
+therapy	O
+.	O
+
+A	O
+15	O
+-	O
+year	O
+-	O
+old	O
+male	O
+presented	O
+with	O
+deep	O
+dermal	O
+and	O
+full	O
+thickness	O
+thermal	O
+injuries	O
+involving	O
+25	O
+%	O
+of	O
+his	O
+total	B-ANAT
+body	I-ANAT
+surface	I-ANAT
+area	O
+.	O
+
+ABSTRACT	O
+:	O
+Nutrition	O
+support	O
+in	O
+the	O
+severely	O
+injured	O
+trauma	O
+patient	O
+is	O
+crucial	O
+to	O
+minimize	O
+the	O
+hypermetabolic	O
+stress	B-PATH
+response	I-PATH
+.	O
+
+Even	O
+though	O
+enteral	O
+nutrition	B-PROC
+is	O
+the	O
+preferred	O
+method	O
+of	O
+feeding	O
+,	O
+it	O
+is	O
+not	O
+always	O
+feasible	O
+after	O
+multiple	O
+trauma	O
+.	O
+
+On	O
+post	O
+-	O
+trauma	O
+day	O
+27	O
+,	O
+bowel	B-ANAT
+edema	B-DISO
+was	O
+significantly	O
+less	O
+,	O
+and	O
+a	O
+nasoenteric	O
+feeding	O
+tube	O
+was	O
+placed	O
+and	O
+enteral	O
+feeding	O
+initiated	O
+.	O
+
+The	O
+patient	O
+did	O
+well	O
+and	O
+was	O
+eventually	O
+extubated	O
+and	O
+eating	B-PROC
+a	O
+regular	O
+diet	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+occurring	O
+after	O
+chemotherapy	O
+for	O
+non	B-DISO
+-	I-DISO
+seminomatous	I-DISO
+germ	I-DISO
+-	I-DISO
+cell	I-DISO
+tumors	I-DISO
+(	O
+NSGCT	O
+)	O
+with	O
+diffuse	O
+lung	B-DISO
+metastases	I-DISO
+,	O
+we	O
+conducted	O
+a	O
+retrospective	O
+study	O
+in	O
+a	O
+15	O
+-	O
+bed	B-DISO
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+in	O
+a	O
+comprehensive	O
+cancer	B-DISO
+center	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+sendai	B-SPEC
+virus	I-SPEC
+and	O
+pneumonia	B-SPEC
+virus	I-SPEC
+of	I-SPEC
+mice	I-SPEC
+by	O
+use	O
+of	O
+fluorogenic	B-PRGE
+nuclease	I-PRGE
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Sendai	B-SPEC
+virus	I-SPEC
+may	O
+induce	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+in	O
+laboratory	O
+mice	B-SPEC
+and	O
+is	O
+a	O
+common	O
+contaminant	O
+of	O
+biological	O
+materials	O
+.	O
+
+Fluorogenic	O
+nuclease	O
+RT	O
+-	O
+PCR	O
+assays	O
+(	O
+fnRT	O
+-	O
+PCR	O
+)	O
+combine	O
+RT	O
+-	O
+PCR	O
+with	O
+an	O
+internal	O
+fluorogenic	O
+hybridization	B-PROC
+probe	O
+,	O
+thereby	O
+potentially	O
+enhancing	O
+specificity	O
+and	O
+eliminating	O
+post	O
+-	O
+PCR	O
+processing	O
+.	O
+
+The	O
+Sendai	B-SPEC
+virus	I-SPEC
+and	O
+PVM	B-SPEC
+fnRT	O
+-	O
+PCR	O
+assays	O
+detected	O
+only	O
+Sendai	O
+virusand	O
+PVM	B-SPEC
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+coronavirus	B-SPEC
+genetic	O
+elements	O
+were	O
+detected	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+from	O
+blood	B-ANAT
+,	O
+fecal	B-ANAT
+samples	O
+,	O
+and	O
+effusive	O
+fluid	O
+collected	O
+from	O
+33	O
+cheetahs	B-SPEC
+in	O
+the	O
+U	O
+.	O
+S	O
+.	O
+A	O
+.	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+-	O
+specific	O
+serum	B-COMP
+antibodies	B-COMP
+were	O
+also	O
+measured	O
+by	O
+indirect	O
+immunofluorescence	O
+.	O
+
+These	O
+relatively	O
+healthy	O
+carrier	O
+animals	B-SPEC
+were	O
+a	O
+source	O
+of	O
+virus	B-SPEC
+for	O
+contact	O
+animals	B-SPEC
+.	O
+
+Screening	O
+programs	O
+in	O
+cheetah	B-SPEC
+populations	O
+for	O
+feline	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+may	O
+be	O
+most	O
+reliable	O
+if	O
+a	O
+combination	O
+of	O
+serologic	O
+analysis	O
+and	O
+viral	O
+detection	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+is	O
+used	O
+.	O
+
+TITLE	O
+:	O
+Possible	O
+mechanisms	O
+underlying	O
+development	B-PROC
+of	O
+transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+:	O
+roles	O
+of	O
+anti	O
+-	O
+major	O
+histocompatibility	O
+complex	O
+class	B-SPEC
+II	O
+DR	O
+antibody	B-COMP
+.	O
+
+However	O
+,	O
+the	O
+precise	O
+mechanisms	O
+of	O
+TRALI	B-DISO
+development	B-PROC
+remain	O
+unclear	O
+.	O
+
+We	O
+observed	O
+that	O
+the	O
+granulocyte	B-PRGE
+-	I-PRGE
+macrophage	B-ANAT
+colony	I-PRGE
+-	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+markedly	O
+enhances	O
+the	O
+expression	B-PROC
+of	O
+MHC	B-PRGE
+class	B-SPEC
+II	I-PRGE
+DR	I-PRGE
+in	O
+PMNs	O
+.	O
+
+The	O
+binding	B-FUNC
+for	O
+one	O
+protein	B-PROC
+-	I-PROC
+protein	B-CHED
+interaction	I-PROC
+pair	O
+(	O
+D757	O
+-	O
+R761	O
+motif	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+to	O
+P585	O
+-	O
+A653	O
+domain	O
+of	O
+CD13	O
+)	O
+has	O
+been	O
+simulated	O
+by	O
+molecular	O
+modeling	O
+and	O
+docking	B-PROC
+simulation	O
+methods	O
+.	O
+
+The	O
+probable	O
+genomic	O
+packaging	O
+signal	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+analogous	O
+to	O
+that	O
+of	O
+MHV	B-SPEC
+and	O
+BCoV	O
+,	O
+with	O
+the	O
+corresponding	O
+secondary	O
+RNA	O
+structure	O
+locating	O
+at	O
+the	O
+similar	O
+region	O
+of	O
+ORF1b	O
+.	O
+
+The	O
+positions	O
+where	O
+genomic	O
+packaging	O
+signals	O
+exist	O
+have	O
+suffered	B-DISO
+rounds	O
+of	O
+mutations	O
+,	O
+which	O
+may	O
+influence	O
+the	O
+primary	O
+structures	O
+of	O
+the	O
+N	O
+and	O
+M	O
+proteins	B-CHED
+consequently	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+putative	O
+genomic	O
+packaging	O
+signal	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+locates	O
+at	O
+the	O
+3	O
+'	O
+end	O
+of	O
+ORF1b	O
+near	O
+that	O
+of	O
+MHV	B-SPEC
+and	O
+BCoV	O
+,	O
+where	O
+is	O
+the	O
+most	O
+variable	O
+region	O
+of	O
+this	O
+gene	O
+.	O
+
+It	O
+seems	O
+that	O
+the	O
+mutation	O
+rate	O
+of	O
+packaging	O
+signal	O
+sequences	O
+is	O
+much	O
+higher	O
+than	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+while	O
+only	O
+subtle	O
+variations	O
+for	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+3D	O
+model	O
+adopts	O
+a	O
+similar	O
+fold	O
+of	O
+the	O
+TGEV	B-SPEC
+Mpro	O
+,	O
+its	O
+structure	O
+and	O
+binding	B-FUNC
+pocket	O
+feature	O
+are	O
+almost	O
+as	O
+same	O
+as	O
+that	O
+of	O
+TGEV	B-SPEC
+Mpro	O
+.	O
+
+The	O
+tested	O
+virtual	O
+screening	O
+indicated	O
+that	O
+73	B-PRGE
+available	I-PRGE
+proteinase	I-PRGE
+inhibitors	B-CHED
+in	O
+the	O
+MDDR	O
+database	O
+might	O
+dock	B-SPEC
+into	O
+both	O
+the	O
+binding	B-FUNC
+pockets	O
+of	O
+the	O
+TGEV	B-SPEC
+Mpro	O
+and	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+proteinase	B-PROC
+.	O
+
+TITLE	O
+:	O
+Small	B-PRGE
+envelope	I-PRGE
+protein	B-CHED
+E	I-PRGE
+of	O
+SARS	B-DISO
+:	O
+cloning	O
+,	O
+expression	B-PROC
+,	O
+purification	O
+,	O
+CD	O
+determination	O
+,	O
+and	O
+bioinformatics	O
+analysis	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+pure	B-FUNC
+sample	O
+of	O
+SARS	B-DISO
+E	O
+protein	B-CHED
+was	O
+obtained	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+Takayasu	O
+arteritis	O
+with	O
+a	O
+presentation	O
+of	O
+a	O
+pulmonary	B-DISO
+-	I-DISO
+renal	B-ANAT
+syndrome	I-DISO
+in	O
+a	O
+22	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+.	O
+
+Thoracic	B-DISO
+and	O
+abdominal	B-ANAT
+angiogram	O
+confirmed	O
+MRA	O
+findings	O
+of	O
+type	O
+IV	O
+Takayasu	B-DISO
+arteritis	I-DISO
+.	O
+
+Lung	B-ANAT
+diffusing	O
+capacity	O
+decreased	O
+in	O
+hypergravity	O
+compared	O
+with	O
+1	O
+G	O
+(	O
+ANOVA	O
+,	O
+P	O
+=	O
+0	O
+.	O
+002	O
+);	O
+it	O
+decreased	O
+by	O
+46	O
+%	O
+in	O
+the	O
+supine	O
+posture	O
+compared	O
+with	O
+25	O
+%	O
+in	O
+the	O
+prone	O
+(	O
+P	O
+=	O
+0	O
+.	O
+01	O
+for	O
+supine	O
+vs	O
+.	O
+prone	O
+).	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+functional	O
+residual	O
+capacity	O
+decreased	O
+by	O
+33	O
+and	O
+23	O
+%,	O
+respectively	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+for	O
+supine	O
+vs	O
+.	O
+prone	O
+),	O
+and	O
+cardiac	B-ANAT
+output	O
+by	O
+40	O
+and	O
+31	O
+%	O
+(	O
+P	O
+=	O
+0	O
+.	O
+007	O
+for	O
+supine	O
+vs	O
+.	O
+prone	O
+),	O
+despite	O
+an	O
+increase	O
+in	O
+heart	B-ANAT
+rate	O
+of	O
+16	O
+and	O
+28	O
+%	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+for	O
+supine	O
+vs	O
+.	O
+prone	O
+),	O
+respectively	O
+.	O
+
+A	O
+reduced	O
+pulmonary	B-ANAT
+-	O
+capillary	B-ANAT
+blood	I-ANAT
+flow	O
+and	O
+a	O
+reduced	O
+estimated	O
+alveolar	B-ANAT
+volume	O
+can	O
+explain	O
+most	O
+of	O
+the	O
+reduction	O
+in	O
+diffusing	O
+capacity	O
+when	O
+supine	O
+.	O
+
+The	O
+contrast	O
+enhanced	O
+chest	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+revealed	O
+an	O
+acute	B-DISO
+aortic	I-DISO
+dissection	I-DISO
+(	O
+Stanford	O
+type	O
+A	O
+).	O
+
+We	O
+attempted	O
+to	O
+perform	O
+cardiac	B-ANAT
+massage	O
+,	O
+but	O
+we	O
+could	O
+not	O
+bring	O
+her	O
+back	B-ANAT
+to	O
+life	O
+.	O
+
+The	O
+results	O
+show	O
+that	O
+the	O
+diameter	O
+of	O
+newly	O
+isolated	O
+virus	B-SPEC
+is	O
+about	O
+50	O
+nm	O
+without	O
+envelope	B-COMP
+or	O
+100	O
+nm	O
+with	O
+envelope	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	B-PRGE
+peplomer	I-PRGE
+S1	I-PRGE
+subunit	I-PRGE
+sequence	I-PRGE
+from	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+Vic	O
+S	O
+strain	O
+was	O
+expressed	B-PROC
+in	O
+a	O
+plasmid	O
+under	O
+the	O
+control	O
+of	O
+the	O
+fowl	O
+adenovirus	B-DISO
+(	O
+FAV	O
+)	O
+major	B-PRGE
+late	I-PRGE
+promoter	I-PRGE
+(	O
+MLP	B-PRGE
+).	O
+
+Although	O
+precise	O
+pathogenic	O
+mechanisms	O
+have	O
+been	O
+under	O
+debate	O
+,	O
+the	O
+NE	O
+-	O
+mediated	O
+severe	O
+pulmonary	B-ANAT
+tissue	B-ANAT
+damage	O
+,	O
+based	O
+upon	O
+the	O
+protease	O
+-	O
+antiprotease	O
+imbalance	B-DISO
+hypothesis	O
+,	O
+may	O
+be	O
+a	O
+major	O
+pathogenic	O
+determinant	O
+of	O
+these	O
+diseases	O
+,	O
+in	O
+particular	O
+COPD	B-DISO
+.	O
+
+Identification	O
+of	O
+the	O
+SARS	B-DISO
+causative	O
+agent	O
+and	O
+development	B-PROC
+of	O
+a	O
+diagnostic	O
+test	O
+are	O
+important	O
+.	O
+
+The	O
+genome	O
+sequence	O
+reveals	O
+that	O
+this	O
+coronavirus	B-SPEC
+is	O
+only	O
+moderately	O
+related	O
+to	O
+other	O
+known	O
+coronaviruses	O
+.	O
+
+Other	O
+therapies	O
+such	O
+as	O
+convalescent	O
+plasma	B-ANAT
+are	O
+being	O
+explored	O
+.	O
+
+ABSTRACT	O
+:	O
+Neuromyalgic	O
+syndrome	B-DISO
+(	O
+NMS	B-DISO
+)	O
+is	O
+clinically	O
+and	O
+electroneuromyographically	O
+(	O
+ENMG	O
+)	O
+first	O
+-	O
+ever	O
+described	O
+in	O
+50	O
+children	O
+aged	O
+2	O
+-	O
+13	O
+.	O
+
+ABSTRACT	O
+:	O
+Community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+due	I-DISO
+to	I-DISO
+Chlamydia	I-DISO
+pneumoniae	O
+is	O
+associated	O
+with	O
+a	O
+benign	O
+clinical	O
+course	O
+.	O
+
+Severe	O
+,	O
+life	O
+-	O
+threatening	O
+pneumonia	B-DISO
+is	O
+rare	O
+and	O
+occurs	O
+only	O
+in	O
+immunocompromised	O
+hosts	B-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+Why	O
+viral	O
+(	O
+SARS	B-DISO
+,	O
+Ebola	O
+and	O
+AIDS	O
+)	O
+epidemics	O
+now	O
+?].	O
+
+There	O
+are	O
+many	O
+hypotheses	O
+to	O
+explain	O
+this	O
+paradox	O
+;	O
+1	O
+)	O
+Is	O
+it	O
+the	O
+hygiene	O
+theory	O
+,	O
+namely	O
+extensive	O
+use	O
+of	O
+wide	O
+spread	O
+and	O
+too	O
+potent	O
+antibiotics	B-CHED
+which	O
+eliminate	O
+protective	O
+infecting	O
+agent	O
+?	O
+
+Be	O
+it	O
+as	O
+it	O
+may	O
+,	O
+the	O
+globalization	O
+and	O
+the	O
+employment	O
+of	O
+long	O
+distance	O
+flights	O
+make	O
+the	O
+spread	O
+easy	O
+to	O
+extreme	O
+points	O
+in	O
+the	O
+globe	B-ANAT
+(	O
+Shanghai	O
+-	O
+Toronto	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+first	O
+recognized	O
+in	O
+Toronto	O
+in	O
+a	O
+woman	O
+who	O
+returned	O
+from	O
+Hong	O
+Kong	O
+on	O
+February	O
+23	O
+,	O
+2003	O
+(	O
+1	O
+).	O
+
+After	O
+implementation	O
+of	O
+provincewide	O
+public	O
+health	O
+measures	O
+that	O
+included	O
+strict	O
+infection	B-DISO
+-	O
+control	O
+practices	O
+,	O
+the	O
+number	O
+of	O
+recognized	O
+cases	O
+of	O
+SARS	B-DISO
+declined	O
+substantially	O
+,	O
+and	O
+no	O
+cases	O
+were	O
+detected	O
+after	O
+April	O
+20	O
+.	O
+
+This	O
+report	O
+describes	O
+a	O
+second	O
+wave	O
+of	O
+SARS	B-DISO
+cases	O
+among	O
+patients	O
+,	O
+visitors	O
+,	O
+and	O
+health	O
+-	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+that	O
+occurred	O
+at	O
+a	O
+Toronto	O
+hospital	O
+approximately	O
+4	O
+weeks	O
+after	O
+SARS	B-DISO
+transmission	O
+was	O
+thought	O
+to	O
+have	O
+been	O
+interrupted	O
+.	O
+
+The	O
+investigation	O
+underscores	O
+the	O
+need	O
+for	O
+monitoring	O
+fever	B-PROC
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+hospitalized	O
+patients	O
+and	O
+visitors	O
+,	O
+particularly	O
+after	O
+a	O
+decline	O
+in	O
+the	O
+number	O
+of	O
+reported	O
+SARS	B-DISO
+cases	O
+.	O
+
+This	O
+report	O
+updates	O
+SARS	B-DISO
+cases	O
+reported	O
+worldwide	O
+and	O
+in	O
+the	O
+United	O
+States	O
+,	O
+and	O
+describes	O
+the	O
+eighth	O
+probable	O
+U	O
+.	O
+S	O
+.	O
+SARS	B-DISO
+case	O
+with	O
+laboratory	O
+evidence	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Cloning	O
+and	O
+sequence	O
+analysis	O
+of	O
+the	O
+nucleocapsid	B-COMP
+gene	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+Chinju99	O
+.	O
+
+It	O
+consisted	O
+of	O
+405	O
+adenine	B-CHED
+(	O
+30	O
+.	O
+5	O
+%),	O
+293	O
+cytosine	B-CHED
+(	O
+22	O
+.	O
+1	O
+%),	O
+334	O
+guanines	O
+(	O
+25	O
+.	O
+2	O
+%)	O
+and	O
+294	O
+thymines	O
+(	O
+22	O
+.	O
+2	O
+%)	O
+residues	O
+.	O
+
+To	O
+determine	O
+the	O
+approximate	O
+position	O
+of	O
+the	O
+cleavage	B-PROC
+site	O
+,	O
+we	O
+expressed	B-PROC
+constructs	O
+that	O
+extended	O
+various	O
+distances	O
+upstream	O
+from	O
+the	O
+previously	O
+defined	O
+C	O
+-	O
+terminal	O
+end	O
+of	O
+MP1	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Thin	O
+-	O
+section	O
+CT	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+following	O
+hospital	O
+discharge	B-ANAT
+:	O
+preliminary	O
+experience	O
+.	O
+
+Patients	O
+were	O
+assigned	O
+to	O
+group	O
+1	O
+(	O
+with	O
+CT	O
+evidence	O
+of	O
+fibrosis	B-DISO
+)	O
+and	O
+group	O
+2	O
+(	O
+without	O
+CT	O
+evidence	O
+of	O
+fibrosis	B-DISO
+)	O
+for	O
+analysis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Pulmonary	B-DISO
+fibrosis	I-DISO
+may	O
+develop	O
+early	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+who	O
+have	O
+been	O
+discharged	O
+after	O
+treatment	O
+.	O
+
+This	O
+report	O
+provides	O
+an	O
+update	O
+on	O
+reported	O
+SARS	B-DISO
+cases	O
+worldwide	O
+and	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+WHO	O
+and	O
+CDC	O
+received	O
+first	O
+information	O
+about	O
+a	O
+new	O
+syndrome	B-DISO
+by	O
+the	O
+end	O
+of	O
+February	O
+2003	O
+,	O
+after	O
+the	O
+first	O
+cases	O
+outside	O
+the	O
+Republic	O
+of	O
+China	O
+had	O
+been	O
+observed	O
+.	O
+
+Dr	O
+.	O
+Urbani	O
+died	B-PROC
+from	O
+SARS	B-DISO
+,	O
+as	O
+did	O
+many	O
+other	O
+health	O
+care	O
+workers	O
+.	O
+
+In	O
+addition	O
+,	O
+intensifying	O
+classical	O
+quarantine	O
+and	O
+hospital	O
+hygiene	O
+measures	O
+,	O
+it	O
+was	O
+possible	O
+to	O
+limit	O
+SARS	B-DISO
+in	O
+many	O
+countries	O
+to	O
+sporadic	O
+cases	O
+,	O
+and	O
+to	O
+reduce	O
+the	O
+disease	O
+in	O
+countries	O
+such	O
+as	O
+Canada	O
+and	O
+Vietnam	O
+.	O
+
+One	O
+infant	O
+received	O
+INO	O
+(	O
+20	O
+-	O
+40	O
+ppm	O
+)	O
+followed	O
+by	O
+exogenous	O
+surfactant	B-CHED
+(	O
+100mg	O
+/	O
+kg	O
+);	O
+the	O
+other	O
+two	O
+received	O
+surfactant	B-CHED
+followed	O
+by	O
+INO	O
+.	O
+
+The	O
+chest	B-ANAT
+roentgenogram	O
+may	O
+be	O
+normal	O
+initially	O
+but	O
+at	O
+a	O
+later	O
+stage	O
+progressive	O
+consolidations	O
+in	O
+the	O
+majority	O
+of	O
+peripheral	O
+parts	O
+of	O
+the	O
+lung	B-ANAT
+are	O
+observed	O
+,	O
+which	O
+cannot	O
+be	O
+differentiated	B-PROC
+from	O
+pneumonias	B-DISO
+of	O
+other	O
+origin	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+glycyrrhizin	B-CHED
+should	O
+be	O
+assessed	O
+for	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Prophylactic	O
+protection	O
+by	O
+N	B-CHED
+-	I-CHED
+acetylcysteine	I-CHED
+against	O
+the	O
+pulmonary	B-ANAT
+injury	O
+induced	O
+by	O
+2	B-CHED
+-	I-CHED
+chloroethyl	I-CHED
+ethyl	B-CHED
+sulfide	I-CHED
+,	O
+a	O
+mustard	O
+analogue	O
+.	O
+
+Guinea	B-SPEC
+pigs	I-SPEC
+were	O
+given	O
+single	O
+exposure	O
+(	O
+0	O
+.	O
+5	O
+-	O
+6	O
+mg	O
+/	O
+kg	O
+body	B-ANAT
+weight	O
+)	O
+of	O
+2	B-CHED
+-	I-CHED
+chloroethyl	I-CHED
+ethyl	B-CHED
+sulfide	I-CHED
+(	O
+CEES	O
+)	O
+as	O
+a	O
+mustard	O
+analogue	O
+intratracheally	O
+and	O
+maintained	O
+for	O
+various	O
+lengths	O
+of	O
+time	O
+(	O
+1	O
+h	O
+to	O
+21	O
+days	O
+).	O
+
+Within	O
+1	O
+h	O
+of	O
+CEES	O
+infusion	O
+at	O
+4	O
+mg	O
+/	O
+kg	O
+,	O
+high	O
+levels	O
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+),	O
+ceramides	B-CHED
+,	O
+and	O
+nuclear	B-PRGE
+factor	I-PRGE
+kappaB	I-PRGE
+accumulated	O
+in	O
+lung	B-ANAT
+and	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+.	O
+
+Number	O
+of	O
+confirmed	O
+cases	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+most	O
+common	O
+findings	O
+included	O
+lymphopenia	B-DISO
+in	O
+153	O
+(	O
+98	O
+%)	O
+of	O
+the	O
+157	O
+patients	O
+,	O
+neutrophilia	O
+in	O
+129	O
+(	O
+82	O
+%),	O
+thrombocytopenia	O
+in	O
+87	O
+patients	O
+(	O
+55	O
+%),	O
+followed	O
+by	O
+thrombocytosis	B-DISO
+in	O
+77	O
+(	O
+49	O
+%),	O
+and	O
+isolated	O
+prolonged	O
+activated	O
+partial	O
+thromboplastin	B-PRGE
+time	O
+in	O
+96	O
+patients	O
+(	O
+63	O
+%).	O
+
+Multivariate	O
+analysis	O
+showed	O
+that	O
+advanced	O
+age	O
+and	O
+a	O
+high	O
+concentration	O
+of	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+at	O
+presentation	O
+were	O
+independent	O
+predictors	O
+of	O
+an	O
+adverse	O
+outcome	O
+.	O
+
+Low	O
+counts	O
+of	O
+CD4	B-PRGE
+and	O
+CD8	B-ANAT
+cells	B-COMP
+at	O
+presentation	O
+were	O
+associated	O
+with	O
+adverse	O
+outcomes	O
+.	O
+
+In	O
+hospitalized	O
+SARS	B-DISO
+patients	O
+,	O
+the	O
+abnormalities	O
+tend	O
+to	O
+progress	O
+to	O
+bilateral	O
+air	B-CHED
+-	O
+space	O
+consolidation	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Epidemiological	O
+study	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Guangdong	O
+province	O
+].	O
+
+Family	O
+and	O
+hospital	O
+aggregation	O
+of	O
+patients	O
+comprised	O
+the	O
+another	O
+two	O
+important	O
+characteristics	O
+of	O
+SARS	B-DISO
+(	O
+account	O
+for	O
+37	O
+.	O
+1	O
+%	O
+of	O
+the	O
+total	O
+patients	O
+).	O
+
+Family	B-SPEC
+and	O
+hospital	O
+aggregation	O
+of	O
+patients	O
+comprised	O
+the	O
+another	O
+two	O
+important	O
+characteristics	O
+of	O
+SARS	B-DISO
+(	O
+account	O
+for	O
+37	O
+.	O
+1	O
+%	O
+of	O
+the	O
+total	O
+patients	O
+).	O
+
+Improving	O
+ventilation	O
+and	O
+regular	O
+disinfection	O
+over	O
+air	B-CHED
+and	O
+stuff	O
+in	O
+hospital	O
+wards	O
+were	O
+also	O
+recommended	O
+.	O
+
+There	O
+were	O
+36	O
+deaths	B-PROC
+,	O
+aged	O
+from	O
+5	O
+to	O
+89	O
+,	O
+with	O
+half	O
+of	O
+them	O
+older	O
+than	O
+60	O
+.	O
+
+Three	O
+patients	O
+experienced	O
+numbness	B-DISO
+and	O
+tingling	B-DISO
+in	O
+their	O
+hands	B-ANAT
+and	O
+feet	B-ANAT
+,	O
+and	O
+2	O
+developed	O
+frank	O
+tetany	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+acute	O
+White	O
+-	O
+Spirit	O
+poisoning	O
+with	O
+pulmonary	B-DISO
+hypertension	I-DISO
+].	O
+
+After	O
+a	O
+36	O
+h	O
+stay	O
+in	O
+Pediatric	O
+Intensive	O
+Care	O
+Unit	O
+(	O
+PICU	B-SPEC
+),	O
+acute	O
+lung	B-ANAT
+injury	O
+required	O
+mechanical	O
+ventilation	O
+and	O
+vasoactive	O
+support	O
+.	O
+
+Pulmonary	B-DISO
+hypertension	I-DISO
+should	O
+be	O
+checked	O
+for	O
+in	O
+case	O
+of	O
+White	O
+-	O
+Spirit	O
+ingestion	O
+complicated	O
+with	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+packaging	O
+signal	O
+is	O
+located	O
+at	O
+the	O
+5	O
+'	O
+end	O
+of	O
+the	O
+virus	B-SPEC
+genome	O
+.	O
+
+Interestingly	O
+,	O
+virus	B-SPEC
+mRNAs	O
+were	O
+detected	O
+in	O
+partially	O
+purified	O
+virus	B-SPEC
+but	O
+not	O
+in	O
+virus	B-SPEC
+immunopurified	O
+using	O
+stringent	O
+conditions	O
+.	O
+
+The	O
+presence	O
+of	O
+this	O
+packaging	O
+signal	O
+was	O
+further	O
+confirmed	O
+by	O
+showing	O
+the	O
+expression	B-PROC
+and	O
+rescue	O
+of	O
+the	O
+mRNA	B-CHED
+including	O
+the	O
+first	O
+649	O
+nt	O
+of	O
+the	O
+TGEV	B-SPEC
+genome	O
+under	O
+control	O
+of	O
+the	O
+cytomegalovirus	B-SPEC
+promoter	O
+in	O
+TGEV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+This	O
+mRNA	B-CHED
+was	O
+successfully	O
+amplified	O
+and	O
+encapsidated	O
+,	O
+indicating	O
+that	O
+the	O
+first	O
+649	O
+nt	O
+of	O
+TGEV	B-SPEC
+genome	O
+also	O
+contained	O
+the	O
+5	O
+'	O
+cis	B-DISO
+-	O
+acting	O
+replication	O
+signals	O
+.	O
+
+The	O
+encapsidation	O
+efficiency	O
+of	O
+this	O
+mRNA	B-CHED
+was	O
+about	O
+30	O
+-	O
+fold	O
+higher	O
+than	O
+the	O
+genome	O
+encapsidation	O
+efficiency	O
+,	O
+as	O
+estimated	O
+by	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+.	O
+
+In	O
+contrast	O
+,	O
+viral	O
+mRNAs	O
+presented	O
+significantly	O
+lower	O
+encapsidation	O
+efficiencies	O
+(	O
+about	O
+100	O
+-	O
+fold	O
+)	O
+than	O
+those	O
+of	O
+the	O
+virus	B-SPEC
+genome	O
+,	O
+strongly	O
+suggesting	O
+that	O
+TGEV	B-SPEC
+mRNAs	O
+in	O
+fact	O
+lacked	O
+an	O
+alternative	O
+TGEV	B-PRGE
+Psi	I-PRGE
+.	O
+
+Children	O
+with	O
+SARS	B-DISO
+presented	O
+with	O
+fever	B-PROC
+,	O
+nonproductive	B-DISO
+cough	I-DISO
+,	O
+malaise	B-DISO
+,	O
+chills	B-DISO
+,	O
+headache	B-DISO
+,	O
+myalgia	B-DISO
+,	O
+and	O
+loss	B-DISO
+of	I-DISO
+appetite	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+affects	O
+children	O
+,	O
+but	O
+the	O
+course	O
+is	O
+less	O
+severe	O
+.	O
+
+Venoarterial	O
+patients	O
+had	O
+significantly	O
+greater	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-CHED
+gradients	O
+and	O
+lower	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FIO	O
+(	O
+2	O
+)	O
+ratios	O
+than	O
+venovenous	O
+patients	O
+(	O
+p	O
+<.	O
+03	O
+).	O
+
+Thirty	O
+-	O
+five	O
+percent	O
+of	O
+venovenous	O
+patients	O
+and	O
+36	O
+%	O
+of	O
+venoarterial	O
+patients	O
+required	O
+at	O
+least	O
+one	O
+vasopressor	O
+infusion	O
+at	O
+time	O
+of	O
+cannulation	O
+(	O
+p	O
+=	O
+nonsignificant	O
+);	O
+vasopressor	O
+dependence	B-DISO
+decreased	O
+over	O
+the	O
+course	O
+of	O
+ECMO	O
+in	O
+both	O
+groups	O
+.	O
+
+Median	O
+duration	O
+on	O
+venovenous	O
+ECMO	O
+for	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+was	O
+218	O
+hrs	B-DISO
+(	O
+range	O
+,	O
+24	O
+-	O
+921	O
+).	O
+
+TITLE	O
+:	O
+Emergence	O
+of	O
+a	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+mutant	B-DISO
+with	O
+a	O
+truncated	B-PRGE
+3b	I-PRGE
+gene	I-PRGE
+:	O
+functional	O
+characterization	O
+of	O
+the	O
+3b	O
+protein	O
+in	O
+pathogenesis	B-DISO
+and	O
+replication	O
+.	O
+
+The	O
+normal	O
+product	O
+of	O
+the	O
+3b	O
+gene	O
+is	O
+64	O
+amino	B-CHED
+acids	I-CHED
+long	O
+,	O
+whereas	O
+the	O
+frameshifting	O
+product	O
+is	O
+34	O
+amino	B-CHED
+acids	I-CHED
+long	O
+with	O
+only	O
+17	O
+homogeneous	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+at	O
+the	O
+N	O
+-	O
+terminal	O
+half	O
+.	O
+
+Comparison	O
+of	O
+the	O
+complete	O
+genome	O
+sequences	O
+(	O
+27	O
+.	O
+6	O
+kb	O
+)	O
+of	O
+isolates	O
+p20c22	O
+and	O
+p36c12	O
+(	O
+from	O
+passages	O
+20	O
+and	O
+36	O
+,	O
+respectively	O
+)	O
+revealed	O
+that	O
+p36c12	O
+contains	O
+three	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+,	O
+two	O
+in	O
+the	O
+195	O
+-	O
+kDa	O
+protein	B-CHED
+(	O
+encoded	O
+by	O
+gene	B-PRGE
+1	I-PRGE
+)	O
+and	O
+one	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+in	O
+addition	O
+to	O
+the	O
+frameshifting	O
+3b	O
+product	O
+.	O
+
+Further	O
+characterization	O
+of	O
+the	O
+two	O
+isolates	O
+demonstrated	O
+that	O
+p36c12	O
+showed	O
+growth	B-PROC
+advantage	O
+over	O
+p20c22	O
+in	O
+both	O
+Vero	B-ANAT
+cells	I-ANAT
+and	O
+chicken	B-SPEC
+embryos	B-ANAT
+and	O
+was	O
+more	O
+virulent	O
+in	O
+chicken	B-SPEC
+embryos	B-ANAT
+than	O
+p20c22	O
+.	O
+
+TITLE	O
+:	O
+The	O
+antiviral	B-CHED
+activity	O
+of	O
+naturally	O
+occurring	O
+proteins	B-CHED
+and	O
+their	O
+peptide	B-CHED
+fragments	O
+after	O
+chemical	O
+modification	O
+.	O
+
+McMaster	O
+and	O
+Visser	O
+sieve	O
+techniques	O
+were	O
+used	O
+to	O
+determine	O
+helminth	O
+and	O
+coccidia	B-SPEC
+from	O
+pooled	O
+fresh	B-ANAT
+faecal	B-ANAT
+samples	O
+.	O
+
+Eimeria	B-SPEC
+species	B-SPEC
+were	O
+also	O
+isolated	O
+in	O
+32	O
+%	O
+of	O
+the	O
+villages	O
+investigated	O
+.	O
+
+(	O
+3	O
+)	O
+Timely	O
+administration	O
+of	O
+Ribavirin	B-CHED
+,	O
+Methylprednisolone	B-CHED
+,	O
+immunoenhancer	O
+(	O
+such	O
+as	O
+interferon	O
+alpha	O
+-	O
+2b	O
+,	O
+thymosin	B-PRGE
+-	I-PRGE
+alpha1	I-PRGE
+)	O
+to	O
+SARS	B-DISO
+patients	O
+was	O
+efficacious	O
+to	O
+certain	O
+extent	O
+in	O
+controlling	O
+the	O
+development	B-PROC
+of	O
+the	O
+disease	O
+.	O
+
+It	O
+is	O
+very	O
+important	O
+for	O
+clinicians	O
+to	O
+pay	O
+great	O
+attention	O
+to	O
+protect	O
+themselves	O
+from	O
+infection	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+The	O
+contagiousness	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+in	O
+SARS	B-DISO
+patients	O
+was	O
+extremely	O
+strong	O
+,	O
+especially	O
+in	O
+their	O
+acute	O
+stage	O
+.	O
+
+The	O
+following	O
+factors	O
+were	O
+associated	O
+with	O
+a	O
+significantly	O
+higher	O
+mortality	O
+rate	O
+in	O
+the	O
+SARS	B-DISO
+with	O
+ARDS	B-DISO
+patients	O
+,	O
+including	O
+age	O
+increase	O
+(	O
+OR	O
+=	O
+1	O
+.	O
+203	O
+,	O
+CI	O
+=	O
+1	O
+.	O
+036	O
+to	O
+1	O
+.	O
+396	O
+,	O
+P	O
+=	O
+0	O
+.	O
+016	O
+),	O
+long	O
+-	O
+time	O
+hypoxia	B-DISO
+(	O
+OR	O
+=	O
+1	O
+.	O
+067	O
+,	O
+CI	O
+=	O
+1	O
+.	O
+014	O
+to	O
+1	O
+.	O
+122	O
+,	O
+P	O
+=	O
+0	O
+.	O
+013	O
+),	O
+thrombocytopenia	O
+(	O
+OR	O
+=	O
+111	O
+.	O
+932	O
+,	O
+CI	O
+=	O
+6	O
+.	O
+096	O
+to	O
+2	O
+055	O
+.	O
+252	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+),	O
+hypernatremia	B-DISO
+(	O
+OR	O
+=	O
+26	O
+.	O
+667	O
+,	O
+CI	O
+=	O
+2	O
+.	O
+242	O
+to	O
+317	O
+.	O
+147	O
+,	O
+P	O
+=	O
+0	O
+.	O
+009	O
+),	O
+and	O
+elevation	O
+of	O
+serum	O
+creatinine	B-CHED
+levels	O
+(	O
+OR	O
+=	O
+111	O
+.	O
+932	O
+,	O
+CI	O
+=	O
+6	O
+.	O
+096	O
+to	O
+2	O
+055	O
+.	O
+252	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+following	O
+factors	O
+were	O
+associated	O
+with	O
+a	O
+significantly	O
+higher	O
+mortality	O
+rate	O
+in	O
+the	O
+SARS	B-DISO
+with	O
+ARDS	B-DISO
+patients	O
+,	O
+including	O
+age	O
+increase	O
+(	O
+OR	O
+=	O
+1	O
+.	O
+203	O
+,	O
+CI	O
+=	O
+1	O
+.	O
+036	O
+to	O
+1	O
+.	O
+396	O
+,	O
+P	O
+=	O
+0	O
+.	O
+016	O
+),	O
+long	O
+-	O
+time	O
+hypoxia	B-DISO
+(	O
+OR	O
+=	O
+1	O
+.	O
+067	O
+,	O
+CI	O
+=	O
+1	O
+.	O
+014	O
+to	O
+1	O
+.	O
+122	O
+,	O
+P	O
+=	O
+0	O
+.	O
+013	O
+),	O
+thrombocytopenia	O
+(	O
+OR	O
+=	O
+111	O
+.	O
+932	O
+,	O
+CI	O
+=	O
+6	O
+.	O
+096	O
+to	O
+2	O
+055	O
+.	O
+252	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+),	O
+hypernatremia	B-DISO
+(	O
+OR	O
+=	O
+26	O
+.	O
+667	O
+,	O
+CI	O
+=	O
+2	O
+.	O
+242	O
+to	O
+317	O
+.	O
+147	O
+,	O
+P	O
+=	O
+0	O
+.	O
+009	O
+),	O
+and	O
+elevation	O
+of	O
+serum	B-COMP
+creatinine	B-CHED
+levels	O
+(	O
+OR	O
+=	O
+111	O
+.	O
+932	O
+,	O
+CI	O
+=	O
+6	O
+.	O
+096	O
+to	O
+2	O
+055	O
+.	O
+252	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+appearing	O
+time	O
+,	O
+site	O
+,	O
+range	O
+and	O
+imaging	O
+features	O
+of	O
+pulmonary	B-ANAT
+lesions	O
+in	O
+chest	B-ANAT
+radiograms	O
+were	O
+observed	O
+in	O
+118	O
+patients	O
+with	O
+clinically	O
+confirmed	O
+SARS	B-DISO
+treated	O
+in	O
+our	O
+hospital	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+therapy	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+38	O
+cases	O
+retrospective	O
+analysis	O
+].	O
+
+Thirty	O
+cases	O
+were	O
+cured	O
+(	O
+78	O
+.	O
+9	O
+%),	O
+of	O
+them	O
+11	O
+cases	O
+had	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+(	O
+36	O
+.	O
+7	O
+%),	O
+8	O
+patients	O
+died	B-PROC
+(	O
+21	O
+.	O
+1	O
+%)	O
+in	O
+all	O
+cases	O
+.	O
+
+RESULTS	O
+:	O
+Chest	B-ANAT
+X	O
+-	O
+rays	B-SPEC
+radiogram	O
+showed	O
+significant	O
+changes	O
+until	O
+peak	O
+stage	O
+(	O
+4	O
+-	O
+12	O
+days	O
+)	O
+with	O
+the	O
+same	O
+doses	O
+of	O
+methylprednisolone	B-CHED
+,	O
+but	O
+it	O
+was	O
+dissolved	O
+consistently	O
+afterwards	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Evaluation	O
+of	O
+glucocorticoid	B-CHED
+in	O
+treatment	O
+for	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+Their	O
+age	O
+,	O
+sex	O
+,	O
+APACHE	O
+II	O
+score	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+,	O
+Qs	O
+/	O
+Qt	O
+,	O
+use	O
+of	O
+artificial	O
+ventilation	O
+and	O
+its	O
+duration	O
+,	O
+level	O
+of	O
+PEEP	B-CHED
+,	O
+and	O
+the	O
+extent	O
+of	O
+relief	O
+from	O
+hypoxemia	O
+showed	O
+no	O
+significant	O
+differences	O
+between	O
+two	O
+groups	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+mortality	O
+of	O
+patients	O
+who	O
+were	O
+given	O
+GC	O
+before	O
+or	O
+during	O
+24	O
+hours	O
+of	O
+the	O
+establishment	O
+of	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+(	O
+66	O
+.	O
+7	O
+%	O
+and	O
+68	O
+.	O
+2	O
+%)	O
+was	O
+lower	O
+than	O
+those	O
+who	O
+were	O
+given	O
+GC	O
+24	O
+hours	O
+after	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+(	O
+90	O
+.	O
+0	O
+%).	O
+
+The	O
+disease	O
+has	O
+been	O
+etiologically	O
+linked	O
+to	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+has	O
+been	O
+named	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+The	O
+beneficial	O
+effects	O
+of	O
+the	O
+early	O
+use	O
+of	O
+steroids	B-CHED
+in	O
+ALI	O
+remained	O
+unaltered	O
+at	O
+Day	O
+30	O
+.	O
+
+This	O
+report	O
+updates	O
+reported	O
+SARS	B-DISO
+cases	O
+worldwide	O
+and	O
+in	O
+the	O
+United	O
+States	O
+,	O
+and	O
+summarizes	O
+changes	O
+in	O
+travel	O
+recommendations	O
+for	O
+Beijing	O
+and	O
+Taiwan	O
+,	O
+where	O
+travel	O
+advisories	O
+have	O
+been	O
+downgraded	O
+to	O
+travel	O
+alerts	O
+.	O
+
+This	O
+report	O
+summarizes	O
+the	O
+hematological	O
+findings	O
+in	O
+SARS	B-DISO
+patients	O
+and	O
+proposes	O
+a	O
+hypothesis	O
+for	O
+the	O
+pathophysiology	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+related	O
+abnormal	B-DISO
+hematopoiesis	I-DISO
+.	O
+
+From	O
+31st	O
+March	O
+,	O
+there	O
+was	O
+an	O
+outbreak	O
+of	O
+SARS	B-DISO
+among	O
+his	O
+contacts	O
+in	O
+the	O
+family	B-SPEC
+and	O
+in	O
+the	O
+hospital	O
+he	O
+was	O
+admitted	O
+to	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Study	O
+on	O
+the	O
+epidemiological	O
+characteristics	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Shanxi	O
+province	O
+].	O
+
+Case	O
+identification	O
+at	O
+early	O
+stage	O
+as	O
+well	O
+as	O
+taking	O
+measures	O
+to	O
+decrease	O
+the	O
+chance	O
+of	O
+transmission	O
+were	O
+strategically	O
+crucial	O
+for	O
+controlling	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+in	O
+the	O
+community	O
+.	O
+
+The	O
+second	O
+phase	O
+was	O
+from	O
+April	O
+16	O
+to	O
+April	O
+28	O
+,	O
+with	O
+the	O
+appearance	O
+of	O
+secondary	B-DISO
+infection	I-DISO
+,	O
+having	O
+sharp	O
+rise	O
+of	O
+the	O
+cases	O
+and	O
+spreading	O
+to	O
+24	O
+counties	O
+in	O
+10	O
+prefectures	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+application	O
+of	O
+indirect	O
+immuno	O
+-	O
+fluorescence	O
+assay	O
+in	O
+the	O
+diagnosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+Clinically	O
+confirmed	O
+SARS	B-DISO
+patients	O
+,	O
+suspected	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+controls	O
+were	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+CONCLUSIONS	O
+:	O
+IFA	O
+can	O
+be	O
+used	O
+to	O
+assist	O
+diagnosis	O
+of	O
+SARS	B-DISO
+after	O
+10	O
+days	O
+of	O
+the	O
+onset	O
+of	O
+disease	O
+.	O
+
+SARS	B-DISO
+pneumonia	B-DISO
+can	O
+manifest	O
+as	O
+focal	O
+peripheral	O
+consolidation	O
+that	O
+clears	O
+relatively	O
+quickly	O
+and	O
+does	O
+not	O
+cause	O
+secondary	O
+complications	O
+or	O
+that	O
+progresses	O
+to	O
+bilateral	O
+consolidation	O
+and	O
+a	O
+more	O
+protracted	O
+clinical	O
+course	O
+.	O
+
+No	O
+correlation	O
+was	O
+found	O
+between	O
+the	O
+severity	O
+of	O
+head	B-ANAT
+injury	O
+(	O
+GCS	O
+score	O
+,	O
+Marshall	O
+score	O
+,	O
+or	O
+intracranial	B-ANAT
+abnormality	O
+)	O
+and	O
+development	B-PROC
+of	O
+ALI	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+of	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+III	O
+in	O
+the	O
+54	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+III	O
+(	O
+APACHE	O
+III	O
+)	O
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+and	O
+its	O
+significance	O
+in	O
+prognosis	O
+.	O
+
+Physical	O
+examination	O
+of	O
+the	O
+chest	B-ANAT
+revealed	O
+bubbling	O
+rales	B-DISO
+and	O
+dullness	O
+on	O
+percussion	O
+.	O
+
+Some	O
+of	O
+the	O
+technologies	O
+brought	O
+forward	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+may	O
+have	O
+been	O
+primarily	O
+motivated	O
+by	O
+marketing	O
+efforts	O
+,	O
+or	O
+were	O
+more	O
+directed	O
+towards	O
+reassuring	O
+people	O
+that	O
+""""	O
+something	O
+is	O
+being	O
+done	O
+","""	O
+ie	O
+,	O
+fighting	O
+an	O
+""""	O
+epidemic	O
+of	O
+fear	O
+.	O
+
+Nasal	B-ANAT
+lavage	O
+and	O
+induced	B-ANAT
+sputum	I-ANAT
+were	O
+collected	O
+prior	O
+to	O
+inoculation	O
+(	O
+day	O
+0	O
+)	O
+and	O
+2	O
+,	O
+4	O
+and	O
+17	O
+days	O
+later	O
+.	O
+
+The	O
+change	O
+in	O
+nasal	B-ANAT
+neutrophil	B-ANAT
+counts	O
+in	O
+all	O
+subjects	O
+correlated	O
+with	O
+nasal	B-DISO
+symptom	I-DISO
+scores	O
+.	O
+
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+is	O
+likely	O
+to	O
+be	O
+an	O
+important	O
+chemokine	O
+in	O
+this	O
+process	O
+.	O
+
+Symptoms	O
+and	O
+airway	B-ANAT
+responsiveness	O
+were	O
+correlated	O
+with	O
+change	O
+in	O
+neutrophils	B-ANAT
+.	O
+
+None	O
+of	O
+the	O
+results	O
+was	O
+influenced	O
+by	O
+the	O
+atopic	B-DISO
+status	O
+of	O
+the	O
+subjects	O
+in	O
+either	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+a	O
+liver	B-ANAT
+transplant	B-ANAT
+recipient	O
+and	O
+guidelines	O
+for	O
+donor	B-CHED
+SARS	B-DISO
+screening	O
+.	O
+
+Due	O
+to	O
+the	O
+potential	O
+severity	O
+of	O
+SARS	B-DISO
+in	O
+transplant	B-ANAT
+recipients	O
+and	O
+the	O
+large	O
+number	O
+of	O
+cases	O
+of	O
+SARS	B-DISO
+in	O
+the	O
+community	O
+,	O
+in	O
+order	B-SPEC
+to	O
+avoid	O
+transmission	O
+of	O
+SARS	B-DISO
+from	O
+a	O
+donor	B-CHED
+,	O
+we	O
+developed	O
+guidelines	O
+for	O
+SARS	B-DISO
+screening	O
+of	O
+organ	B-ANAT
+donors	O
+.	O
+
+As	O
+SARS	B-DISO
+spreads	O
+throughout	O
+the	O
+world	O
+,	O
+it	O
+may	O
+become	O
+an	O
+increasingly	O
+significant	O
+problem	O
+for	O
+transplant	B-ANAT
+patients	O
+and	O
+programs	O
+.	O
+
+ABSTRACT	O
+:	O
+Thirty	O
+colostrum	O
+-	O
+deprived	O
+piglets	O
+aged	O
+1	O
+day	O
+were	O
+inoculated	O
+with	O
+a	O
+Korean	O
+strain	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+At	O
+24	O
+-	O
+60	O
+h	O
+post	O
+-	O
+inoculation	O
+(	O
+hpi	B-DISO
+),	O
+the	O
+villous	O
+height	O
+/	O
+crypt	B-ANAT
+depth	O
+(	O
+VH	O
+/	O
+CD	O
+)	O
+ratio	O
+of	O
+infected	O
+pigs	B-SPEC
+was	O
+significantly	O
+less	O
+than	O
+that	O
+of	O
+control	O
+pigs	B-SPEC
+.	O
+
+PEDV	B-SPEC
+nucleic	B-CHED
+acid	I-CHED
+and	O
+antigen	B-CHED
+were	O
+detected	O
+in	O
+the	O
+duodenum	B-ANAT
+,	O
+jejunum	B-ANAT
+and	O
+ileum	B-ANAT
+of	O
+experimentally	O
+infected	O
+pigs	B-SPEC
+.	O
+
+The	O
+software	O
+ZCURVE_CoV	O
+can	O
+also	O
+be	O
+downloaded	O
+freely	O
+from	O
+the	O
+web	B-DISO
+address	O
+mentioned	O
+above	O
+and	O
+run	O
+in	O
+computers	O
+under	O
+the	O
+platforms	O
+of	O
+Windows	O
+or	O
+Linux	O
+.	O
+
+When	O
+patients	O
+are	O
+overtreated	O
+,	O
+neurologic	O
+damage	O
+can	O
+be	O
+prevented	O
+by	O
+relowering	O
+the	O
+serum	B-COMP
+sodium	O
+(	O
+SNa	O
+)	O
+so	O
+that	O
+the	O
+daily	O
+increase	O
+in	O
+SNa	O
+remains	O
+below	O
+10	O
+mmol	O
+/	O
+L	O
+/	O
+24	O
+hours	O
+.	O
+
+The	O
+IgG	B-PRGE
+peaked	O
+one	O
+month	O
+after	O
+the	O
+onset	O
+and	O
+remained	O
+at	O
+high	O
+levels	O
+in	O
+the	O
+following	O
+2	O
+months	O
+.	O
+
+The	O
+antibody	B-PROC
+responses	I-PROC
+suggest	O
+that	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-DISO
+is	O
+immunodominant	O
+and	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+viral	B-DISO
+pathogenesis	I-DISO
+.	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+injected	O
+with	O
+the	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+of	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+Cov	I-PRGE
+into	O
+the	O
+foot	B-ANAT
+-	O
+pads	O
+for	O
+the	O
+immunization	O
+,	O
+and	O
+the	O
+popliteal	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+were	O
+isolated	O
+15	O
+d	O
+later	O
+for	O
+mAb	O
+-	O
+producing	O
+hybridomas	B-ANAT
+,	O
+from	O
+which	O
+the	O
+mAbs	O
+against	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-DISO
+-	O
+Cov	O
+were	O
+screened	O
+.	O
+
+The	O
+identification	O
+of	O
+the	O
+mAb	O
+against	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-DISO
+-	O
+Cov	O
+was	O
+performed	O
+using	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+),	O
+indirect	O
+fluorescent	O
+-	O
+antibody	B-COMP
+assay	O
+(	O
+IFA	O
+),	O
+and	O
+Western	O
+immunoblotting	O
+.	O
+
+Of	O
+the	O
+4	O
+strains	O
+,	O
+2	O
+were	O
+identified	O
+as	O
+the	O
+immunoglobulin	B-COMP
+G1	I-COMP
+(	O
+IgG1	B-COMP
+)	O
+isotype	O
+,	O
+1	O
+IgG2a	O
+,	O
+and	O
+the	O
+other	O
+IgG2b	B-COMP
+,	O
+with	O
+affinity	O
+constants	O
+(	O
+Ka	O
+)	O
+of	O
+2	O
+of	O
+the	O
+strains	O
+being	O
+4	O
+.	O
+14	O
+x	O
+10	O
+(-	O
+9	O
+)	O
+M	O
+and	O
+3	O
+.	O
+19	O
+x	O
+10	O
+(-	O
+9	O
+)	O
+M	O
+respectively	O
+.	O
+
+Of	O
+the	O
+4	O
+strains	O
+,	O
+2	O
+were	O
+identified	O
+as	O
+the	O
+immunoglobulin	B-COMP
+G1	I-COMP
+(	O
+IgG1	B-COMP
+)	O
+isotype	O
+,	O
+1	O
+IgG2a	B-COMP
+,	O
+and	O
+the	O
+other	O
+IgG2b	B-COMP
+,	O
+with	O
+affinity	O
+constants	O
+(	O
+Ka	O
+)	O
+of	O
+2	O
+of	O
+the	O
+strains	O
+being	O
+4	O
+.	O
+14	O
+x	O
+10	O
+(-	O
+9	O
+)	O
+M	O
+and	O
+3	O
+.	O
+19	O
+x	O
+10	O
+(-	O
+9	O
+)	O
+M	O
+respectively	O
+.	O
+
+Two	O
+of	O
+these	O
+patients	O
+had	O
+died	B-PROC
+by	O
+8	O
+weeks	O
+'	O
+follow	O
+-	O
+up	O
+.	O
+
+Retrospective	O
+case	O
+series	O
+of	O
+adult	O
+patients	O
+with	O
+probable	O
+SARS	B-DISO
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+of	O
+a	O
+hospital	O
+in	O
+Singapore	O
+between	O
+March	O
+6	O
+and	O
+June	O
+6	O
+,	O
+2003	O
+.	O
+
+The	O
+primary	O
+outcome	O
+measure	O
+was	O
+28	O
+-	O
+day	O
+mortality	O
+after	O
+symptom	B-DISO
+onset	O
+.	O
+
+It	O
+is	O
+caused	O
+by	O
+the	O
+infection	B-DISO
+with	O
+a	O
+coronavirus	B-SPEC
+,	O
+a	O
+single	O
+strand	O
+RNA	O
+capsulated	O
+virus	B-SPEC
+,	O
+recently	O
+found	O
+in	O
+a	O
+small	O
+mammalian	B-SPEC
+,	O
+the	O
+masked	B-SPEC
+palm	I-SPEC
+civet	I-SPEC
+.	O
+
+The	O
+first	O
+cases	O
+of	O
+SARS	B-DISO
+have	O
+been	O
+reported	O
+in	O
+the	O
+Chinese	O
+province	O
+of	O
+Guangdong	O
+and	O
+,	O
+since	O
+then	O
+,	O
+probable	O
+cases	O
+have	O
+been	O
+reported	O
+world	O
+wide	O
+.	O
+
+We	O
+found	O
+7	O
+cases	O
+(	O
+14	O
+%)	O
+of	O
+type	O
+2	O
+hiatal	B-DISO
+hernia	I-DISO
+complicated	O
+by	O
+pulmonary	B-ANAT
+manifestations	O
+as	O
+the	O
+only	O
+symptoms	O
+of	O
+GERD	B-DISO
+.	O
+
+The	O
+series	O
+is	O
+illustrated	O
+by	O
+the	O
+report	O
+of	O
+1	O
+patient	O
+who	O
+experienced	O
+acute	B-DISO
+bronchospasm	I-DISO
+and	O
+cardiopulmonary	B-DISO
+arrest	I-DISO
+as	O
+a	O
+complication	B-DISO
+of	O
+GERD	B-DISO
+.	O
+
+Nested	O
+RT	O
+-	O
+PCR	O
+was	O
+used	O
+to	O
+amplify	O
+the	O
+RNA	B-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+of	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+and	O
+the	O
+PCR	O
+products	O
+were	O
+sequenced	O
+directly	O
+or	O
+after	O
+cloned	O
+to	O
+pMD18	O
+-	O
+T	O
+vector	O
+.	O
+
+A	O
+novel	B-SPEC
+Coronavirus	I-SPEC
+has	O
+been	O
+identified	O
+by	O
+electron	O
+microscopy	O
+and	O
+molecular	O
+assays	O
+in	O
+multiple	O
+laboratories	O
+from	O
+respiratory	O
+specimens	O
+throughout	O
+the	O
+world	O
+.	O
+
+The	O
+syndrome	O
+has	O
+been	O
+defined	O
+as	O
+SARS	B-DISO
+(	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+)	O
+by	O
+WHO	O
+,	O
+and	O
+is	O
+characterized	O
+by	O
+an	O
+incubation	O
+period	O
+between	O
+1	O
+and	O
+10	O
+days	O
+(	O
+average	O
+5	O
+days	O
+)	O
+and	O
+by	O
+a	O
+febrile	B-PROC
+phase	O
+that	O
+usually	O
+lasts	O
+approximately	O
+3	O
+days	O
+.	O
+
+Alimentotherapy	O
+,	O
+respiratory	O
+auxiliaring	O
+ventilation	O
+,	O
+anti	O
+-	O
+infective	O
+and	O
+glucocorticoid	B-CHED
+methods	O
+were	O
+used	O
+in	O
+western	O
+medicine	B-CHED
+;	O
+Chinese	O
+herbal	O
+medicine	B-CHED
+was	O
+used	O
+according	O
+to	O
+syndrome	B-DISO
+differentiation	B-PROC
+in	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+terms	O
+of	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+theory	O
+,	O
+SARS	B-DISO
+is	O
+referred	O
+to	O
+""""	O
+infectious	B-DISO
+febrile	B-PROC
+disease	O
+""","	O
+the	O
+therapeutic	O
+strategies	O
+of	O
+integrative	O
+traditional	O
+Chinese	O
+and	O
+western	O
+on	O
+SARS	B-DISO
+have	O
+been	O
+shown	O
+effective	O
+,	O
+and	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+played	O
+a	O
+positive	O
+role	O
+in	O
+it	O
+.	O
+
+IgG	B-PRGE
+anticardiolipin	I-PRGE
+,	O
+IgG	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+beta2	I-PRGE
+-	I-PRGE
+glycoprotein	I-PRGE
+I	I-PRGE
+,	I-PRGE
+IgG	I-PRGE
+antiphosphatidic	I-PRGE
+acid	I-PRGE
+and	I-PRGE
+IgG	I-PRGE
+antiphosphatidylserine	I-PRGE
+antibodies	B-COMP
+were	O
+detected	O
+by	O
+ELISA	O
+in	O
+low	O
+titers	O
+within	O
+the	O
+normal	O
+range	O
+in	O
+the	O
+BALF	O
+and	O
+serum	B-COMP
+of	O
+nine	O
+patients	O
+with	O
+ALI	O
+and	O
+17	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+In	O
+contrast	O
+,	O
+its	O
+isogenic	O
+pgtE	O
+mutant	B-DISO
+produced	O
+fimbriae	B-COMP
+consisting	O
+exclusively	O
+of	O
+intact	O
+chimeric	O
+subunits	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+of	O
+the	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+Chinju99	O
+which	O
+was	O
+previously	O
+isolated	O
+in	O
+Chinju	O
+,	O
+Korea	O
+was	O
+cloned	O
+and	O
+sequenced	O
+to	O
+aid	O
+in	O
+the	O
+development	B-PROC
+of	O
+genetically	O
+engineered	O
+vaccines	O
+and	O
+diagnostic	O
+reagents	B-CHED
+against	O
+PEDV	B-SPEC
+.	O
+
+The	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+contained	O
+27	O
+potential	O
+sites	O
+for	O
+asparagine	B-CHED
+(	O
+N	O
+)-	O
+linked	O
+glycosylation	B-PROC
+and	O
+there	O
+was	O
+a	O
+stretch	O
+of	O
+highly	O
+hydrophobic	O
+residues	O
+at	O
+position	O
+1	O
+,	O
+325	O
+-	O
+1	O
+,	O
+350	O
+.	O
+
+Recognition	O
+of	O
+ALI	O
+as	O
+the	O
+important	O
+index	O
+for	O
+critical	O
+SARS	B-DISO
+and	O
+comprehensive	O
+supportive	O
+management	O
+are	O
+of	O
+paramount	O
+in	O
+decreasing	O
+the	O
+mortality	O
+of	O
+the	O
+disease	O
+.	O
+
+(	O
+2	O
+)	O
+The	O
+initial	O
+temperature	O
+was	O
+(	O
+38	O
+.	O
+3	O
++/-	O
+0	O
+.	O
+6	O
+)	O
+degrees	O
+C	O
+,	O
+while	O
+the	O
+highest	O
+was	O
+(	O
+39	O
+.	O
+2	O
++/-	O
+0	O
+.	O
+6	O
+)	O
+degrees	O
+C	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+with	O
+fever	B-PROC
+duration	O
+of	O
+(	O
+9	O
+.	O
+0	O
++/-	O
+4	O
+.	O
+2	O
+)	O
+days	O
+.	O
+
+The	O
+number	O
+of	O
+affected	O
+lung	B-ANAT
+fields	O
+was	O
+1	O
+.	O
+2	O
++/-	O
+
+The	O
+interval	O
+from	O
+the	O
+beginning	O
+of	O
+fever	B-PROC
+to	O
+the	O
+onset	O
+of	O
+abnormal	O
+chest	B-ANAT
+radiographs	O
+was	O
+(	O
+3	O
+.	O
+5	O
++/-	O
+2	O
+.	O
+3	O
+)	O
+days	O
+,	O
+which	O
+increased	O
+in	O
+size	O
+,	O
+extent	O
+,	O
+and	O
+severity	O
+to	O
+the	O
+maximum	O
+(	O
+6	O
+.	O
+7	O
++/-	O
+3	O
+.	O
+5	O
+)	O
+days	O
+later	O
+.	O
+
+0	O
+.	O
+72	O
+)	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+.	O
+(	O
+6	O
+)	O
+The	O
+lowest	O
+arterial	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+was	O
+(	O
+94	O
+.	O
+8	O
++/-	O
+
+Also	O
+included	O
+is	O
+a	O
+summation	B-PROC
+of	O
+the	O
+clinical	O
+features	O
+of	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+SARS	B-DISO
+appears	O
+to	O
+have	O
+high	O
+infectivity	O
+;	O
+(	O
+2	O
+)	O
+the	O
+most	O
+common	O
+symptom	B-DISO
+is	O
+fever	B-PROC
+;	O
+(	O
+3	O
+)	O
+the	O
+count	O
+of	O
+leukocyte	B-ANAT
+is	O
+normal	O
+or	O
+decreased	O
+;	O
+(	O
+4	O
+)	O
+most	O
+patients	O
+(	O
+35	O
+/	O
+45	O
+,	O
+77	O
+.	O
+8	O
+%)	O
+had	O
+experienced	O
+a	O
+24	O
+-	O
+hour	O
+fever	B-PROC
+prior	O
+to	O
+the	O
+abnormal	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+changes	O
+which	O
+showed	O
+progression	O
+of	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+within	O
+48	O
+hours	O
+in	O
+71	O
+.	O
+1	O
+%	O
+(	O
+32	O
+/	O
+45	O
+)	O
+of	O
+the	O
+patients	O
+and	O
+,	O
+(	O
+5	O
+)	O
+the	O
+percentage	O
+of	O
+patients	O
+who	O
+developed	O
+severe	O
+pneumonia	B-DISO
+(	O
+24	O
+.	O
+4	O
+%)	O
+is	O
+higher	O
+than	O
+those	O
+who	O
+developed	O
+typical	O
+pneumonia	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Abnormal	O
+CT	O
+findings	O
+were	O
+noted	O
+in	O
+all	O
+the	O
+patients	O
+,	O
+but	O
+abnormal	O
+chest	B-ANAT
+radiographic	O
+findings	O
+in	O
+17	O
+cases	O
+(	O
+60	O
+.	O
+7	O
+%,	O
+17	O
+/	O
+28	O
+).	O
+
+All	O
+the	O
+five	O
+patients	O
+who	O
+died	B-PROC
+had	O
+CD	O
+(	O
+4	O
+)(+)	O
+counts	O
+less	O
+than	O
+200	O
+/	O
+microliter	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+numbers	O
+of	O
+CD	O
+(	O
+3	O
+)(+),	O
+CD	O
+(	O
+4	O
+)(+),	O
+and	O
+CD	O
+(	O
+8	O
+)(+)	O
+lymphocytes	B-ANAT
+all	O
+significantly	O
+decreased	O
+in	O
+acute	O
+phase	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+[(	O
+722	O
++/-	O
+533	O
+)/	O
+microliter	O
+,	O
+(	O
+438	O
++/-	O
+353	O
+)/	O
+microliter	O
+,	O
+(	O
+307	O
++/-	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+providing	O
+care	O
+while	O
+minimizing	O
+personal	O
+risks	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+poses	O
+a	O
+threat	O
+to	O
+most	O
+countries	O
+because	O
+of	O
+easy	O
+and	O
+convenient	O
+travel	O
+across	O
+the	O
+globe	B-ANAT
+in	O
+a	O
+matter	O
+of	O
+hours	O
+.	O
+
+By	O
+the	O
+end	O
+of	O
+the	O
+epidemic	O
+,	O
+131	O
+,	O
+132	O
+persons	O
+had	O
+been	O
+placed	O
+in	O
+quarantine	O
+,	O
+including	O
+50	O
+,	O
+319	O
+close	O
+contacts	O
+of	O
+SARS	B-DISO
+patients	O
+and	O
+80	O
+,	O
+813	O
+travelers	O
+from	O
+WHO	O
+-	O
+designated	O
+SARS	B-DISO
+-	O
+affected	O
+areas	O
+.	O
+
+SARS	B-DISO
+is	O
+pathologically	O
+characterized	O
+by	O
+interstitial	B-ANAT
+exudative	B-DISO
+inflammation	I-DISO
+of	O
+lung	B-ANAT
+with	O
+the	O
+formation	B-PROC
+of	O
+hyaline	B-DISO
+membrane	B-COMP
+in	O
+acute	O
+phase	O
+.	O
+
+Haemorrhagic	B-DISO
+inflammation	I-DISO
+exists	O
+in	O
+extrapulmonary	O
+organs	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Gefitinib	B-CHED
+is	O
+a	O
+potent	O
+drug	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+nonsmall	O
+-	O
+cell	B-COMP
+lung	B-DISO
+cancer	B-SPEC
+(	O
+NSCLC	B-DISO
+).	O
+
+Adverse	O
+drug	O
+reactions	O
+,	O
+although	O
+frequent	O
+,	O
+are	O
+mild	O
+,	O
+and	O
+include	O
+acne	B-DISO
+-	O
+like	O
+skin	B-DISO
+rash	I-DISO
+and	O
+diarrhoea	B-DISO
+.	O
+
+The	O
+present	O
+study	O
+describes	O
+the	O
+case	O
+of	O
+a	O
+56	O
+-	O
+yr	O
+-	O
+old	O
+male	O
+with	O
+NSCLC	B-DISO
+who	O
+,	O
+4	O
+weeks	O
+after	O
+treatment	O
+with	O
+gefitinib	B-CHED
+,	O
+suffered	B-DISO
+from	O
+a	O
+severe	O
+alveolar	B-ANAT
+haemorrhage	B-DISO
+diagnosed	O
+by	O
+bronchoalveolar	O
+lavage	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+case	O
+report	O
+of	O
+an	O
+acute	O
+life	O
+-	O
+threatening	O
+lung	B-ANAT
+injury	O
+in	O
+a	O
+patient	O
+with	O
+nonsmall	O
+-	O
+cell	B-COMP
+lung	B-DISO
+cancer	B-SPEC
+who	O
+had	O
+been	O
+given	O
+gefitinib	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Long	O
+-	O
+term	O
+results	O
+of	O
+prosthetic	O
+mitral	B-ANAT
+valve	I-ANAT
+replacement	O
+with	O
+home	O
+-	O
+made	O
+tilting	O
+disc	B-COMP
+valve	B-ANAT
+:	O
+a	O
+report	O
+of	O
+125	O
+cases	O
+].	O
+
+One	O
+hundred	O
+and	O
+five	O
+patients	O
+,	O
+including	O
+31	O
+patients	O
+with	O
+rheumatic	B-DISO
+mitral	I-DISO
+stenosis	I-DISO
+,	O
+92	O
+patients	O
+with	O
+mixed	O
+mitral	B-DISO
+stenosis	I-DISO
+and	O
+regurgitation	B-DISO
+,	O
+and	O
+2	O
+patients	O
+with	O
+bacterial	B-DISO
+endocarditis	I-DISO
+,	O
+underwent	O
+prosthetic	O
+mitral	B-ANAT
+valve	I-ANAT
+replacement	O
+with	O
+home	O
+-	O
+made	O
+tilting	O
+disc	B-COMP
+valve	B-ANAT
+from	O
+September	O
+1978	O
+to	O
+June	O
+1982	O
+.	O
+
+The	O
+earliest	O
+symptom	B-DISO
+of	O
+all	O
+3	O
+cases	O
+was	O
+hyperpyrexia	B-DISO
+and	O
+followed	O
+by	O
+progressive	O
+dyspnea	B-DISO
+and	O
+appearance	O
+of	O
+lung	B-ANAT
+field	I-ANAT
+shadows	O
+in	O
+X	O
+rays	B-SPEC
+findings	O
+.	O
+
+The	O
+exudated	O
+organization	O
+tended	O
+to	O
+become	O
+glomeruloid	O
+organizing	O
+pneumonitis	B-DISO
+in	O
+a	O
+few	O
+avaoli	O
+.	O
+
+Electronic	O
+microscopy	O
+demonstrated	O
+clusters	B-CHED
+of	O
+virus	B-COMP
+particles	I-COMP
+seen	O
+in	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+Lungs	B-ANAT
+,	O
+immune	B-ANAT
+system	I-ANAT
+and	O
+systemic	O
+small	B-ANAT
+vessels	I-ANAT
+are	O
+the	O
+main	O
+target	O
+organs	B-ANAT
+attacked	O
+by	O
+the	O
+virus	B-SPEC
+.	O
+
+Other	O
+atypical	O
+pathological	O
+changes	O
+,	O
+such	O
+as	O
+hydropic	B-DISO
+degeneration	I-DISO
+,	O
+fatty	B-DISO
+degeneration	I-DISO
+,	O
+interstitial	B-ANAT
+cell	I-ANAT
+proliferation	O
+and	O
+some	O
+lesions	O
+observed	O
+in	O
+liver	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+pancreas	B-ANAT
+may	O
+have	O
+existed	O
+before	O
+the	O
+hospitalization	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Pathological	O
+and	O
+ultramicrostructural	O
+changes	O
+of	O
+tissues	B-ANAT
+in	O
+a	O
+patient	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+One	O
+autopsy	O
+case	O
+of	O
+diagnosed	O
+SARS	B-DISO
+was	O
+investigated	O
+.	O
+
+Lung	B-ANAT
+puncture	O
+was	O
+performed	O
+immediately	O
+after	O
+the	O
+patient	O
+died	B-PROC
+,	O
+and	O
+the	O
+autopsy	O
+was	O
+done	O
+after	O
+12	O
+h	O
+.	O
+The	O
+specimens	O
+from	O
+lymph	B-ANAT
+nodes	I-ANAT
+,	O
+spleen	B-ANAT
+,	O
+small	B-ANAT
+intestine	I-ANAT
+,	O
+colon	B-ANAT
+and	O
+bone	B-ANAT
+marrow	I-ANAT
+were	O
+studied	O
+by	O
+immunohistochemical	O
+technique	O
+.	O
+
+Virus	B-SPEC
+-	O
+like	O
+inclusions	O
+occasionally	O
+contained	O
+cytoplasm	B-COMP
+of	O
+the	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+,	O
+which	O
+were	O
+positive	O
+by	O
+histochemical	O
+staining	O
+.	O
+
+The	O
+structures	O
+of	O
+lymph	B-ANAT
+nodes	I-ANAT
+and	O
+spleen	B-ANAT
+were	O
+damaged	O
+with	O
+lymph	B-ANAT
+follicles	B-ANAT
+depletion	O
+and	O
+splenic	B-ANAT
+nodules	B-DISO
+atrophy	B-DISO
+.	O
+
+The	O
+specific	O
+lesions	O
+of	O
+SARS	B-DISO
+consist	O
+of	O
+lobular	O
+intrastitial	O
+pneumonia	B-DISO
+with	O
+the	O
+formation	B-PROC
+of	O
+hyaline	B-DISO
+membranes	B-ANAT
+of	O
+lung	B-ANAT
+,	O
+haemorrhage	B-DISO
+,	O
+necrosis	B-PROC
+,	O
+inflammation	B-DISO
+of	O
+blood	B-ANAT
+vessels	I-ANAT
+and	O
+the	O
+damages	O
+of	O
+extralung	O
+lymphohemopioetic	O
+system	O
+.	O
+
+According	O
+to	O
+the	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+found	O
+in	O
+lung	B-ANAT
+of	O
+the	O
+SARS	B-DISO
+case	O
+,	O
+it	O
+is	O
+considered	O
+that	O
+these	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+may	O
+be	O
+a	O
+new	O
+kind	O
+of	O
+coronavirus	B-SPEC
+which	O
+caused	O
+the	O
+""""	O
+atypical	B-DISO
+pneumonia	I-DISO
+"""."	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+,	O
+the	O
+extent	O
+of	O
+SARS	O
+related	O
+coronavirus	B-SPEC
+amplification	B-DISO
+was	O
+measured	O
+in	O
+terms	O
+of	O
+the	O
+increase	O
+in	O
+fluorescence	O
+during	O
+the	O
+amplification	B-DISO
+process	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+entry	O
+is	O
+mediated	O
+by	O
+the	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+.	O
+
+Heptad	O
+repeat	O
+(	O
+HR	O
+)	O
+regions	O
+are	O
+found	O
+in	O
+fusion	O
+proteins	B-CHED
+of	O
+many	O
+different	O
+viruses	B-SPEC
+and	O
+form	O
+an	O
+important	O
+characteristic	O
+of	O
+class	B-SPEC
+I	O
+viral	O
+fusion	O
+proteins	B-CHED
+.	O
+
+Using	O
+biological	O
+assays	O
+,	O
+the	O
+HR2	O
+peptide	B-CHED
+was	O
+shown	O
+to	O
+be	O
+a	O
+potent	O
+inhibitor	B-CHED
+of	O
+virus	B-SPEC
+entry	O
+into	O
+the	O
+cell	B-COMP
+,	O
+as	O
+well	O
+as	O
+of	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+.	O
+
+TITLE	O
+:	O
+Recombinant	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+expressing	O
+a	O
+heterologous	O
+spike	O
+gene	O
+demonstrates	O
+that	O
+the	O
+spike	O
+protein	O
+is	O
+a	O
+determinant	O
+of	O
+cell	B-COMP
+tropism	B-PROC
+.	O
+
+Genomic	O
+DNA	O
+and	O
+mRNA	B-CHED
+analyses	O
+of	O
+the	O
+transformed	O
+plantlets	O
+confirmed	O
+the	O
+integration	B-PROC
+of	O
+the	O
+foreign	O
+cDNA	O
+into	O
+the	O
+potato	B-SPEC
+genome	O
+,	O
+as	O
+well	O
+as	O
+its	O
+transcription	B-PROC
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+DNA	O
+vaccination	O
+with	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+either	O
+in	O
+ovo	B-SPEC
+or	O
+intramuscularly	O
+can	O
+provide	O
+birds	B-SPEC
+with	O
+some	O
+protection	O
+against	O
+clinical	O
+disease	O
+after	O
+homologous	O
+IBV	B-SPEC
+challenge	O
+.	O
+
+In	O
+that	O
+study	O
+,	O
+inapparent	O
+or	O
+mild	O
+disease	O
+was	O
+observed	O
+in	O
+turkeys	B-SPEC
+inoculated	O
+with	O
+only	O
+TCV	B-SPEC
+or	O
+EPEC	O
+,	O
+whereas	O
+severe	O
+growth	B-PROC
+depression	B-DISO
+and	O
+high	O
+mortality	O
+were	O
+observed	O
+in	O
+dually	O
+inoculated	O
+turkeys	B-SPEC
+.	O
+
+The	O
+purpose	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+further	O
+evaluate	O
+the	O
+pathogenesis	B-DISO
+of	O
+combined	O
+TCV	B-SPEC
+/	O
+EPEC	O
+infection	B-DISO
+in	O
+young	O
+turkeys	B-SPEC
+and	O
+determine	O
+the	O
+role	O
+of	O
+these	O
+agents	O
+in	O
+the	O
+observed	O
+synergistic	O
+interaction	O
+.	O
+
+No	O
+clinical	O
+sign	O
+of	O
+disease	O
+and	O
+no	O
+attaching	O
+and	O
+effacing	O
+(	O
+AE	O
+)	O
+lesions	O
+characteristic	O
+of	O
+EPEC	O
+were	O
+observed	O
+in	O
+turkeys	O
+inoculated	O
+with	O
+only	O
+EPEC	O
+isolate	O
+R98	O
+/	O
+5	O
+,	O
+even	O
+when	O
+turkeys	B-SPEC
+were	O
+inoculated	O
+with	O
+10	O
+(	O
+10	O
+)	O
+colony	O
+forming	O
+units	O
+(	O
+CFU	O
+)	O
+EPEC	O
+(	O
+high	O
+dose	O
+exposure	O
+).	O
+
+Coinfection	B-DISO
+of	O
+turkeys	B-SPEC
+with	O
+TCV	B-SPEC
+and	O
+EPEC	O
+resulted	O
+in	O
+significantly	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+shedding	O
+of	O
+EPEC	O
+,	O
+but	O
+not	O
+TCV	B-SPEC
+,	O
+in	O
+intestinal	B-ANAT
+contents	I-ANAT
+of	O
+turkeys	B-SPEC
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+TCV	B-SPEC
+infection	B-DISO
+predisposes	O
+young	O
+turkeys	B-SPEC
+to	O
+secondary	O
+EPEC	O
+infection	B-DISO
+and	O
+potentiates	O
+the	O
+expression	B-PROC
+of	O
+EPEC	O
+pathogenicity	O
+in	O
+young	O
+turkeys	B-SPEC
+.	O
+
+The	O
+agents	O
+in	O
+the	O
+organs	B-ANAT
+and	O
+cell	B-COMP
+cultures	O
+were	O
+revealed	O
+by	O
+immunoassay	O
+.	O
+
+RESULTS	O
+:	O
+Both	O
+Chlamydia	B-SPEC
+-	O
+like	O
+and	O
+coronavirus	B-SPEC
+-	O
+like	O
+particles	O
+were	O
+found	O
+in	O
+EM	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+the	O
+transcription	B-PROC
+factor	O
+(	O
+s	O
+)	O
+that	O
+is	O
+essential	O
+for	O
+activation	O
+of	O
+mfgl2	O
+prothrombinase	B-PRGE
+/	O
+fibroleukin	B-PRGE
+gene	I-PRGE
+in	O
+response	O
+to	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+of	I-PRGE
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+type	I-PRGE
+3	I-PRGE
+(	O
+MHV	B-SPEC
+-	O
+3	O
+).	O
+
+Western	O
+blotting	O
+was	O
+performed	O
+to	O
+investigate	O
+whether	O
+HNF4	B-PRGE
+is	O
+expressed	B-PROC
+in	O
+macrophages	B-ANAT
+of	O
+Ba1b	O
+/	O
+c	O
+mice	B-SPEC
+where	O
+mfgl2	O
+is	O
+expressed	B-PROC
+.	O
+
+Therefore	O
+SARS	B-DISO
+microbiologic	O
+origins	O
+remain	O
+unclear	O
+.	O
+
+TITLE	O
+:	O
+Protecting	O
+against	O
+SARS	B-DISO
+during	O
+equipment	O
+maintenance	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+raises	O
+questions	O
+about	O
+the	O
+appropriate	O
+infection	B-DISO
+control	O
+measures	O
+to	O
+use	O
+when	O
+conducting	B-PROC
+maintenance	O
+procedures	O
+on	O
+medical	O
+devices	O
+that	O
+may	O
+have	O
+been	O
+exposed	O
+to	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+--	O
+that	O
+is	O
+,	O
+devices	O
+that	O
+have	O
+been	O
+used	O
+on	O
+,	O
+or	O
+located	O
+in	O
+the	O
+same	O
+room	O
+as	O
+,	O
+a	O
+patient	O
+with	O
+(	O
+or	O
+suspected	O
+to	O
+have	O
+)	O
+SARS	B-DISO
+.	O
+
+This	O
+article	O
+provides	O
+guidance	O
+for	O
+clinical	O
+engineering	O
+,	O
+respiratory	O
+therapy	O
+,	O
+and	O
+other	O
+personnel	O
+involved	O
+in	O
+maintaining	O
+potentially	O
+SARS	B-DISO
+-	O
+exposed	O
+equipment	O
+.	O
+
+This	O
+raises	O
+safety	O
+concerns	O
+about	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+being	O
+carried	O
+by	O
+droplets	O
+that	O
+exit	O
+from	O
+the	O
+exhalation	B-PROC
+limb	B-ANAT
+of	O
+the	O
+ventilator	O
+.	O
+
+Patients	O
+with	O
+the	O
+diagnosis	O
+of	O
+probable	O
+or	O
+suspected	O
+SARS	B-DISO
+admitted	O
+to	O
+the	O
+Taipei	O
+Veterans	O
+General	O
+Hospital	O
+during	O
+the	O
+period	O
+from	O
+March	O
+26	O
+,	O
+2003	O
+to	O
+May	O
+25	O
+,	O
+2003	O
+were	O
+included	O
+.	O
+
+Four	O
+probable	O
+SARS	B-DISO
+cases	O
+were	O
+enrolled	O
+.	O
+
+Initially	O
+chest	B-ANAT
+patterns	O
+included	O
+focal	O
+consolidation	O
+,	O
+interstitial	B-ANAT
+infiltration	B-DISO
+or	O
+normal	O
+.	O
+
+RESULTS	O
+:	O
+Aerosolized	O
+PGI	B-CHED
+(	O
+2	O
+)	O
+therapy	O
+(	O
+mean	O
+dose	O
+28	O
++/-	O
+
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+image	O
+features	O
+in	O
+36	O
+patients	O
+with	O
+severe	O
+SARS	B-DISO
+were	O
+retrospectively	O
+analyzed	O
+.	O
+
+Out	O
+of	O
+the	O
+11	O
+severe	O
+SARS	B-DISO
+patients	O
+who	O
+died	B-PROC
+,	O
+nine	O
+had	O
+large	O
+area	O
+of	O
+ground	O
+-	O
+glass	O
+shadow	O
+with	O
+air	B-CHED
+bronchogram	O
+in	O
+both	O
+lungs	B-ANAT
+before	O
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+Pathological	O
+study	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+relationship	O
+between	O
+serum	B-PRGE
+interleukins	I-PRGE
+and	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+observe	O
+the	O
+changes	O
+of	O
+serum	B-COMP
+interleukins	O
+(	O
+IL	O
+),	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+,	O
+and	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+(	O
+WBC	B-ANAT
+)	O
+count	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+to	O
+investigate	O
+the	O
+relationship	O
+between	O
+injured	O
+immune	B-PROC
+function	I-PROC
+,	O
+immune	B-PROC
+response	I-PROC
+and	O
+disturbed	O
+immune	O
+adjustment	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+relationship	O
+between	O
+the	O
+measured	O
+results	O
+and	O
+WBC	B-ANAT
+count	O
+was	O
+further	O
+analyzed	O
+.	O
+
+The	O
+peripheral	B-ANAT
+blood	I-ANAT
+WBC	B-ANAT
+counts	O
+were	O
+lower	O
+than	O
+4	O
+.	O
+0	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+in	O
+10	O
+patients	O
+,	O
+and	O
+their	O
+CD	O
+(	O
+3	O
+)(+),	O
+CD	O
+(	O
+4	O
+)(+)	O
+and	O
+CD	O
+(	O
+8	O
+)(+)	O
+counts	O
+were	O
+583	O
+.	O
+90	O
+(	O
+315	O
+.	O
+58	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+,	O
+272	O
+.	O
+00	O
+(	O
+94	O
+.	O
+13	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+and	O
+209	O
+.	O
+00	O
+(	O
+72	O
+.	O
+21	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+,	O
+respectively	O
+.	O
+
+The	O
+decreased	O
+CD	O
+(	O
+3	O
+)(+),	O
+CD	O
+(	O
+4	O
+)(+)	O
+and	O
+CD	O
+(	O
+8	O
+)(+)	O
+counts	O
+were	O
+consistent	O
+with	O
+the	O
+decreased	O
+WBC	B-ANAT
+counts	O
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+of	O
+a	O
+fluorescent	O
+polymerase	O
+chain	O
+reaction	O
+method	O
+for	O
+the	O
+detection	O
+of	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+and	O
+its	O
+clinical	O
+application	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+and	O
+imaging	O
+findings	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Clinical	O
+symptoms	O
+were	O
+mild	O
+,	O
+but	O
+X	O
+-	O
+ray	B-SPEC
+and	O
+CT	O
+findings	O
+were	O
+distinct	O
+.	O
+
+After	O
+treatment	O
+,	O
+most	O
+lesions	O
+were	O
+absorbed	O
+completely	O
+,	O
+but	O
+slowly	O
+in	O
+patients	O
+with	O
+multi	O
+-	O
+lobe	B-ANAT
+consolidation	O
+and	O
+/	O
+or	O
+extensive	O
+interstitial	B-ANAT
+infiltration	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	B-SPEC
+to	O
+stimulate	O
+the	O
+development	B-PROC
+of	O
+drugs	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+based	O
+on	O
+the	O
+atomic	O
+coordinates	O
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+main	I-PRGE
+proteinase	B-PROC
+determined	O
+recently	O
+[	O
+Science	O
+13	O
+(	O
+May	O
+)	O
+(	O
+2003	O
+)	O
+(	O
+online	O
+)],	O
+studies	O
+of	O
+docking	B-PROC
+KZ7088	O
+(	O
+a	O
+derivative	O
+of	O
+AG7088	O
+)	O
+and	O
+the	O
+AVLQSGFR	O
+octapeptide	O
+to	O
+the	O
+enzyme	O
+were	O
+conducted	O
+.	O
+
+We	O
+show	O
+that	O
+IBV	B-SPEC
+E	O
+and	O
+M	O
+can	O
+be	O
+crosslinked	O
+to	O
+each	O
+other	O
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+and	O
+transfected	O
+cells	B-COMP
+,	O
+indicating	O
+that	O
+they	O
+interact	O
+.	O
+
+We	O
+also	O
+examined	O
+the	O
+ability	O
+of	O
+the	O
+mutant	B-DISO
+and	O
+chimeric	O
+E	O
+and	O
+M	O
+proteins	B-CHED
+to	O
+form	O
+VLPs	B-ANAT
+.	O
+
+The	O
+authors	O
+reviewed	O
+their	O
+experience	O
+with	O
+the	O
+use	O
+of	O
+ECMO	O
+in	O
+pediatric	O
+and	O
+adult	O
+trauma	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+at	O
+a	O
+children	O
+'	O
+s	O
+medical	O
+center	O
+.	O
+
+Patients	O
+were	O
+treated	O
+with	O
+blood	B-ANAT
+product	O
+replacement	O
+,	O
+epsilon	B-CHED
+-	I-CHED
+aminocaproic	I-CHED
+acid	I-CHED
+(	O
+EACA	B-CHED
+),	O
+and	O
+aprotinin	B-PRGE
+infusions	O
+.	O
+
+Surgical	O
+intervention	O
+was	O
+not	O
+required	O
+for	O
+bleeding	B-DISO
+.	O
+
+Children	O
+and	O
+adults	O
+with	O
+severe	O
+posttraumatic	O
+ARDS	B-DISO
+can	O
+be	O
+treated	O
+successfully	O
+on	O
+VV	O
+extracorporeal	O
+support	O
+.	O
+
+Replication	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+macaques	B-SPEC
+of	O
+pneumonia	B-DISO
+similar	O
+to	O
+that	O
+in	O
+human	B-SPEC
+beings	O
+with	O
+SARS	B-DISO
+,	O
+combined	O
+with	O
+the	O
+high	O
+prevalence	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+SARS	B-DISO
+patients	O
+,	O
+fulfill	O
+the	O
+criteria	O
+required	O
+to	O
+prove	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+the	O
+primary	O
+cause	O
+of	O
+SARS	B-DISO
+.	O
+
+It	O
+follows	O
+an	O
+asthmatic	B-DISO
+attack	I-DISO
+and	O
+the	O
+prognosis	O
+is	O
+poor	O
+.	O
+
+Our	O
+objective	O
+is	O
+to	O
+describe	O
+a	O
+case	O
+of	O
+Hopkins	B-DISO
+Syndrome	I-DISO
+in	O
+Brazil	O
+affecting	O
+a	O
+patient	O
+younger	O
+than	O
+1	O
+year	O
+.	O
+
+At	O
+that	O
+time	O
+,	O
+he	O
+presented	O
+with	O
+flaccid	B-DISO
+paralysis	I-DISO
+,	O
+arreflexia	O
+and	O
+atrophy	O
+of	O
+the	O
+LL	O
+.	O
+
+MUSCLE	B-ANAT
+BIOPSY	O
+:	O
+type	O
+grouping	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Hopkins	B-DISO
+syndrome	I-DISO
+should	O
+be	O
+included	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+any	O
+flaccid	B-DISO
+paralysis	I-DISO
+when	O
+it	O
+is	O
+associated	O
+with	O
+an	O
+asthma	B-DISO
+attack	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+SARS	B-DISO
+,	O
+possible	O
+zoonosis	B-DISO
+in	O
+the	O
+area	O
+of	O
+conflict	O
+of	O
+pathogenic	O
+coronaviruses	O
+of	O
+animals	B-SPEC
+].	O
+
+A	O
+broad	O
+body	B-ANAT
+of	O
+knowledge	O
+originating	O
+from	O
+research	O
+in	O
+veterinary	O
+medicine	B-CHED
+indicates	O
+that	O
+development	B-PROC
+of	O
+vaccines	O
+against	O
+the	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+may	O
+be	O
+problematic	O
+.	O
+
+Eight	O
+patients	O
+came	O
+from	O
+a	O
+family	B-SPEC
+,	O
+and	O
+15	O
+patients	O
+were	O
+medical	O
+staff	O
+.	O
+
+The	O
+mean	O
+leucocyte	B-ANAT
+count	O
+was	O
+(	O
+4	O
+.	O
+6	O
++/-	O
+1	O
+.	O
+4	O
+)	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+,	O
+and	O
+the	O
+mean	O
+lymphocyte	B-ANAT
+ratio	O
+was	O
+0	O
+.	O
+27	O
++/-	O
+0	O
+.	O
+11	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+features	O
+and	O
+therapy	O
+of	O
+106	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+A	O
+total	O
+of	O
+106	O
+cases	O
+of	O
+SARS	B-DISO
+were	O
+analyzed	O
+prospectively	O
+.	O
+
+Almost	O
+all	O
+patients	O
+suffered	B-DISO
+from	O
+hypoxemia	O
+(	O
+PaO	B-PROC
+(	O
+2	O
+)	O
+less	O
+than	O
+90	O
+mm	O
+Hg	O
+in	O
+90	O
+.	O
+2	O
+%,	O
+less	O
+than	O
+70	O
+mm	O
+Hg	O
+in	O
+28	O
+.	O
+6	O
+%).	O
+
+Meanwhile	O
+,	O
+emphasis	O
+was	O
+placed	O
+on	O
+oxygen	B-CHED
+support	O
+and	O
+coping	O
+with	O
+their	O
+underlying	O
+diseases	O
+.	O
+
+Effective	O
+treatment	O
+includes	O
+various	O
+regimens	O
+,	O
+oxygen	B-CHED
+support	O
+and	O
+small	O
+doses	O
+of	O
+steroids	B-CHED
+.	O
+
+Three	O
+severe	O
+patients	O
+had	O
+secondary	B-DISO
+infection	I-DISO
+after	O
+administration	O
+of	O
+a	O
+large	O
+dose	O
+of	O
+glucocorticoid	B-CHED
+.	O
+
+A	O
+large	O
+dose	O
+of	O
+glucocorticoid	B-CHED
+may	O
+aggravate	O
+the	O
+suppression	B-DISO
+and	O
+make	O
+the	O
+body	B-ANAT
+in	O
+an	O
+active	O
+metabolic	B-PROC
+state	O
+(	O
+the	O
+increase	O
+of	O
+blood	B-ANAT
+glucose	B-CHED
+and	O
+the	O
+decrease	O
+of	O
+sera	B-PRGE
+albumin	I-PRGE
+).	O
+
+RESULTS	O
+:	O
+Before	O
+treatment	O
+by	O
+methylprednisolone	B-CHED
+,	O
+the	O
+counts	O
+of	O
+CD	O
+(	O
+4	O
+)(+),	O
+CD	O
+(	O
+8	O
+)(+)	O
+and	O
+CD	O
+(	O
+3	O
+)(+)	O
+of	O
+27	O
+SARS	B-DISO
+patients	O
+were	O
+(	O
+401	O
++/-	O
+203	O
+),	O
+(	O
+340	O
++/-	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+was	O
+discovered	O
+in	O
+association	O
+with	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+recently	O
+.	O
+
+The	O
+first	O
+step	O
+in	O
+coronavirus	B-DISO
+infection	I-DISO
+is	O
+binding	B-FUNC
+of	O
+the	O
+viral	O
+spike	O
+protein	B-CHED
+to	O
+certain	O
+receptor	O
+on	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Thus	O
+,	O
+to	O
+develop	O
+and	O
+expression	B-PROC
+protein	B-CHED
+fragment	O
+from	O
+spike	O
+protein	B-CHED
+gene	O
+are	O
+the	O
+purposes	O
+of	O
+this	O
+experiment	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+analysis	O
+of	O
+190	O
+cases	O
+of	O
+outbreak	O
+with	O
+atypical	B-DISO
+pneumonia	I-DISO
+in	O
+Guangzhou	O
+in	O
+spring	O
+,	O
+2003	O
+].	O
+
+Most	O
+of	O
+patients	O
+,	O
+manifestation	O
+of	O
+lungs	B-ANAT
+was	O
+negative	O
+.	O
+
+Of	O
+these	O
+cases	O
+,	O
+36	O
+cases	O
+develop	O
+to	O
+ARDS	B-DISO
+and	O
+11	O
+cases	O
+died	B-PROC
+with	O
+severity	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Management	O
+of	O
+critical	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+risk	O
+factors	O
+for	O
+death	B-PROC
+].	O
+
+Among	O
+them	O
+,	O
+18	O
+patients	O
+who	O
+presented	O
+with	O
+SpO	O
+(	O
+2	O
+)	O
+of	O
+90	O
+%	O
+-	O
+93	O
+%	O
+at	O
+rest	B-FUNC
+under	O
+O	O
+(	O
+2	O
+)	O
+inhalation	B-PROC
+5	O
+L	O
+/	O
+min	O
+were	O
+further	O
+recorded	O
+for	O
+their	O
+SpO	O
+(	O
+2	O
+)	O
+during	O
+slight	O
+physical	O
+movement	B-PROC
+and	O
+CPAP	O
+.	O
+
+Noninvasive	O
+as	O
+an	O
+add	B-DISO
+-	O
+on	O
+management	O
+may	O
+probably	O
+cut	O
+down	O
+on	O
+the	O
+dosage	O
+and	O
+duration	O
+of	O
+corticosteriod	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+78	O
+patients	O
+:	O
+a	O
+retrospective	O
+study	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+clinical	O
+features	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+the	O
+disease	O
+.	O
+
+Seventy	O
+-	O
+eight	O
+patients	O
+with	O
+SARS	B-DISO
+referred	O
+to	O
+the	O
+Guangzhou	O
+Institute	O
+of	O
+Respiratory	B-DISO
+Diseases	I-DISO
+(	O
+GIRD	O
+),	O
+China	O
+from	O
+December	O
+22	O
+,	O
+2002	O
+to	O
+March	O
+2003	O
+were	O
+studied	O
+retrospectively	O
+.	O
+
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+and	O
+CT	O
+scanning	O
+revealed	O
+changes	O
+related	O
+to	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Serum	B-ANAT
+antibodies	B-COMP
+detection	O
+for	O
+serological	O
+diagnosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+The	O
+Kappa	O
+of	O
+IFA	O
+and	O
+ELISA	O
+for	O
+IgM	B-PRGE
+and	O
+IgG	B-PRGE
+were	O
+0	O
+.	O
+640	O
+and	O
+0	O
+.	O
+779	O
+respectively	O
+.	O
+
+Lungs	B-ANAT
+fibrosis	B-DISO
+was	O
+found	O
+in	O
+some	O
+patients	O
+in	O
+the	O
+recovery	O
+phase	O
+.	O
+
+Blood	B-ANAT
+specimens	O
+from	O
+51	O
+patients	O
+with	O
+AIDS	O
+and	O
+57	O
+normal	O
+persons	O
+were	O
+collected	O
+as	O
+controls	O
+and	O
+subjected	O
+to	O
+the	O
+same	O
+measurements	O
+.	O
+
+The	O
+levels	O
+of	O
+CD3	B-PRGE
+(+),	I-PRGE
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+in	O
+SARS	B-DISO
+group	O
+[(	O
+589	O
++/-	O
+435	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+,	O
+(	O
+316	O
++/-	O
+267	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+and	O
+(	O
+215	O
++/-	O
+165	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+,	O
+respectively	O
+]	O
+were	O
+significantly	O
+lower	O
+than	O
+those	O
+of	O
+the	O
+normal	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+count	O
+of	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+of	O
+SARS	B-DISO
+group	O
+decreased	O
+to	O
+the	O
+lowest	O
+level	O
+during	O
+the	O
+10	O
+(	O
+th	O
+)	O
+and	O
+12	O
+(	O
+th	O
+)	O
+day	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+ABSTRACT	O
+:	O
+Investigate	O
+the	O
+features	O
+of	O
+outbreak	O
+epidemic	O
+,	O
+clinical	O
+disease	B-DISO
+progression	I-DISO
+of	O
+the	O
+first	O
+SARS	B-DISO
+cases	O
+in	O
+Beijing	O
+and	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+therapeutic	O
+regimen	O
+.	O
+
+Twenty	O
+patients	O
+showed	O
+the	O
+severe	O
+syndrome	B-DISO
+with	O
+various	O
+time	O
+ranged	O
+from	O
+1	O
+day	O
+to	O
+14	O
+days	O
+.	O
+
+Two	O
+patients	O
+died	B-PROC
+of	O
+progressive	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+clinical	O
+manifestations	O
+,	O
+treatment	O
+,	O
+and	O
+outcome	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+clinical	O
+data	O
+of	O
+108	O
+SARS	B-DISO
+in	O
+-	O
+patients	O
+were	O
+analyzed	O
+.	O
+
+Ninety	O
+-	O
+four	O
+cases	O
+were	O
+discharged	O
+,	O
+14	O
+cases	O
+died	B-PROC
+.	O
+
+Treatment	O
+by	O
+combination	O
+of	O
+TCM	O
+and	O
+Western	O
+medicine	B-CHED
+was	O
+effective	O
+.	O
+
+METHODS	O
+:	O
+The	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+was	O
+reviewed	O
+.	O
+
+A	O
+case	O
+of	O
+SARS	B-DISO
+outbreak	O
+beginning	O
+from	O
+a	O
+male	O
+,	O
+74	O
+-	O
+year	O
+-	O
+old	O
+patient	O
+in	O
+Beijing	O
+.	O
+
+The	O
+first	O
+onset	O
+symptom	B-DISO
+of	O
+the	O
+27	O
+cases	O
+is	O
+high	O
+fever	B-PROC
+accompany	O
+with	O
+toxic	B-DISO
+symptom	I-DISO
+such	O
+as	O
+muscular	B-ANAT
+soreness	B-DISO
+,	O
+headache	B-DISO
+,	O
+etc	O
+.	O
+
+The	O
+amount	O
+of	O
+end	O
+-	O
+brush	O
+blood	B-ANAT
+WBC	B-ANAT
+decrease	O
+,	O
+especially	O
+the	O
+lymphocyte	B-ANAT
+decrease	O
+more	O
+obviously	O
+.	O
+
+The	O
+course	O
+of	O
+a	O
+infectious	B-DISO
+atypical	B-DISO
+pneumonia	I-DISO
+is	O
+almost	O
+3	O
+weeks	O
+,	O
+the	O
+1st	O
+week	O
+can	O
+be	O
+decided	O
+as	O
+early	O
+stage	O
+,	O
+the	O
+2nd	O
+week	O
+is	O
+decided	O
+as	O
+fastigium	B-ANAT
+,	O
+the	O
+3rd	O
+week	O
+is	O
+decided	O
+as	O
+stage	O
+of	O
+recovery	O
+.	O
+
+The	O
+CD	O
+(	O
+4	O
+)(+),	O
+CD	O
+(	O
+8	O
+)(+)	O
+and	O
+CD	O
+(	O
+3	O
+)(+)	O
+of	O
+SARS	B-DISO
+patient	O
+decrease	O
+obviously	O
+,	O
+it	O
+seems	O
+the	O
+immuno	O
+-	O
+function	O
+inhibited	O
+seriously	O
+.	O
+
+Whether	O
+the	O
+state	O
+of	O
+the	O
+illness	O
+is	O
+serious	O
+or	O
+not	O
+seems	O
+no	O
+obvious	O
+relationship	O
+to	O
+when	O
+they	O
+are	O
+treated	O
+by	O
+steroid	B-CHED
+.	O
+
+The	O
+possibility	O
+that	O
+10	O
+or	O
+more	O
+percent	O
+of	O
+the	O
+world	O
+population	O
+at	O
+risk	O
+could	O
+eventually	O
+be	O
+infected	O
+with	O
+the	O
+virus	B-SPEC
+in	O
+conjunction	O
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+3	O
+-	O
+7	O
+%	O
+or	O
+more	O
+,	O
+and	O
+indications	O
+of	O
+significant	O
+improvement	O
+in	O
+Toronto	O
+support	O
+the	O
+stringent	O
+measures	O
+that	O
+have	O
+been	O
+taken	O
+to	O
+isolate	O
+diagnosed	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Protection	O
+against	O
+CTL	B-ANAT
+escape	O
+and	O
+clinical	O
+disease	O
+in	O
+a	O
+murine	B-SPEC
+model	O
+of	O
+virus	B-SPEC
+persistence	O
+.	O
+
+ABSTRACT	O
+:	O
+CTL	O
+escape	O
+mutations	O
+have	O
+been	O
+identified	O
+in	O
+several	O
+chronic	B-DISO
+infections	I-DISO
+,	O
+including	O
+mice	B-SPEC
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+JHM	O
+.	O
+
+One	O
+outstanding	O
+question	O
+in	O
+understanding	O
+CTL	B-ANAT
+escape	O
+is	O
+whether	O
+a	O
+CD8	B-PRGE
+T	I-PRGE
+cell	O
+response	O
+to	O
+two	O
+or	O
+more	O
+immunodominant	O
+CTL	B-ANAT
+epitopes	O
+would	O
+prevent	O
+CTL	B-ANAT
+escape	O
+.	O
+
+To	O
+resolve	O
+this	O
+apparent	O
+contradiction	O
+,	O
+we	O
+engineered	O
+a	O
+recombinant	O
+variant	O
+of	O
+JHM	O
+that	O
+expressed	B-PROC
+the	O
+well	O
+-	O
+characterized	O
+gp33	B-PRGE
+epitope	I-PRGE
+of	O
+lymphocytic	B-SPEC
+choriomeningitis	I-SPEC
+virus	I-SPEC
+,	O
+an	O
+epitope	B-CHED
+with	O
+high	O
+functional	O
+avidity	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+virus	B-SPEC
+replicase	I-PRGE
+polyprotein	I-PRGE
+ORF1b	I-PRGE
+is	O
+undergoing	O
+negative	O
+selection	O
+;	O
+negative	O
+selection	O
+force	O
+is	O
+also	O
+probably	O
+operating	O
+on	O
+spike	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+May	O
+8th	O
+,	O
+Beijing	O
+'	O
+s	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+is	O
+on	O
+a	O
+continuous	O
+decline	O
+.	O
+
+The	O
+desquamation	O
+and	O
+hyperplasia	B-DISO
+of	O
+alveolar	B-ANAT
+lining	O
+cells	B-COMP
+was	O
+also	O
+apparent	O
+.	O
+
+Upon	O
+admission	O
+into	O
+ICU	O
+,	O
+all	O
+patients	O
+had	O
+poor	O
+nutrients	B-CHED
+intake	O
+for	O
+an	O
+average	O
+of	O
+11	O
+days	O
+and	O
+16	O
+patients	O
+(	O
+76	O
+.	O
+2	O
+%)	O
+were	O
+diagnosed	O
+as	O
+malnutrition	B-DISO
+.	O
+
+The	O
+blood	B-ANAT
+glucose	B-CHED
+maintained	O
+at	O
+lower	O
+level	O
+in	O
+the	O
+surviving	O
+patients	O
+when	O
+compared	O
+with	O
+those	O
+who	O
+died	B-PROC
+[(	O
+9	O
+.	O
+5	O
++/-	O
+2	O
+.	O
+3	O
+)	O
+mmol	O
+/	O
+L	O
+vs	O
+(	O
+6	O
+.	O
+3	O
++/-	O
+
+80	O
+.	O
+0	O
+%	O
+of	O
+the	O
+patients	O
+who	O
+died	B-PROC
+need	O
+insulin	B-PRGE
+versus	O
+only	O
+18	O
+.	O
+8	O
+%	O
+of	O
+the	O
+surviving	O
+patients	O
+.	O
+
+Among	O
+these	O
+46	O
+SARS	B-DISO
+patients	O
+,	O
+17	O
+cases	O
+(	O
+37	O
+.	O
+0	O
+%)	O
+were	O
+stool	B-ANAT
+SARS	B-DISO
+-	O
+CoV	O
+RT	O
+-	O
+PCR	O
+negative	O
+,	O
+and	O
+29	O
+cases	O
+(	O
+63	O
+.	O
+0	O
+%)	O
+were	O
+SARS	B-DISO
+-	O
+CoV	O
+RT	O
+-	O
+PCR	O
+positive	O
+.	O
+
+The	O
+clinical	O
+symptoms	O
+are	O
+non	O
+-	O
+specific	O
+and	O
+during	O
+the	O
+first	O
+few	O
+days	O
+in	O
+particular	O
+,	O
+are	O
+not	O
+clinically	O
+distinguishable	O
+from	O
+those	O
+of	O
+many	O
+other	O
+viral	O
+or	O
+bacterial	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+implementation	O
+of	O
+hygienic	O
+measures	O
+requires	O
+attention	O
+,	O
+because	O
+the	O
+infection	B-DISO
+of	O
+personnel	O
+in	O
+Toronto	O
+hospitals	O
+still	O
+occurred	O
+after	O
+the	O
+virus	O
+and	O
+transmission	O
+routes	O
+were	O
+known	O
+.	O
+
+SARS	B-DISO
+is	O
+a	O
+group	O
+A	O
+notifiable	O
+disease	O
+(	O
+report	O
+if	O
+suspected	O
+).	O
+
+The	O
+mean	O
+age	O
+of	O
+the	O
+cases	O
+followed	O
+up	O
+with	O
+diagnosis	O
+of	O
+HELLP	B-DISO
+syndrome	I-DISO
+were	O
+30	O
+.	O
+2	O
++/-	O
+
+HELLP	B-DISO
+syndrome	I-DISO
+was	O
+diagnosed	O
+on	O
+average	O
+in	O
+the	O
+32	O
+.	O
+6	O
++/-	O
+
+Birth	B-PROC
+weights	O
+of	O
+eleven	O
+babies	O
+(	O
+30	O
+%)	O
+were	O
+below	O
+1500	O
+g	O
+.	O
+
+Six	O
+of	O
+the	O
+thirteen	O
+patients	O
+who	O
+had	O
+ARF	B-DISO
+were	O
+given	O
+hemodialysis	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+):	O
+a	O
+review	O
+of	O
+the	O
+history	O
+,	O
+epidemiology	O
+,	O
+prevention	O
+,	O
+and	O
+concerns	O
+for	O
+the	O
+future	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+clinical	O
+characteristics	O
+and	O
+therapeutic	O
+effect	O
+in	O
+the	O
+early	O
+stage	O
+of	O
+patients	O
+with	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+43	O
+(	O
+95	O
+.	O
+6	O
+%)	O
+of	O
+all	O
+45	O
+patients	O
+had	O
+exposure	O
+to	O
+SARS	B-DISO
+patients	O
+and	O
+the	O
+average	O
+incubation	O
+time	O
+was	O
+(	O
+7	O
+.	O
+3	O
++/-	O
+
+The	O
+clinical	O
+features	O
+including	O
+fatigue	B-DISO
+(	O
+60	O
+%),	O
+dry	B-DISO
+cough	I-DISO
+(	O
+68	O
+.	O
+9	O
+%),	O
+dyspnea	B-DISO
+(	O
+53	O
+.	O
+3	O
+%),	O
+joint	B-DISO
+pain	I-DISO
+(	O
+26	O
+.	O
+7	O
+%)	O
+and	O
+diarrhea	B-DISO
+(	O
+26	O
+.	O
+7	O
+%).	O
+
+2	O
+.	O
+9	O
+)	O
+days	O
+from	O
+the	O
+onset	O
+,	O
+and	O
+CT	O
+scanning	O
+was	O
+better	O
+than	O
+X	O
+-	O
+ray	B-SPEC
+in	O
+the	O
+early	O
+diagnosis	O
+.	O
+
+There	O
+was	O
+a	O
+significant	O
+difference	O
+in	O
+the	O
+dosage	O
+of	O
+steroid	B-CHED
+between	O
+severe	O
+and	O
+mild	O
+patients	O
+[(	O
+610	O
+.	O
+6	O
++/-	O
+
+The	O
+IgG	B-COMP
+antibody	I-COMP
+was	O
+detected	O
+in	O
+22	O
+out	O
+of	O
+34	O
+(	O
+64	O
+.	O
+7	O
+%)	O
+patients	O
+and	O
+the	O
+average	O
+time	O
+for	O
+the	O
+occurrence	O
+of	O
+antibody	B-COMP
+was	O
+(	O
+18	O
+.	O
+2	O
++/-	O
+
+The	O
+plasma	B-ANAT
+levels	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+IgG	B-COMP
+antibody	I-COMP
+of	O
+57	O
+normal	O
+subjects	O
+,	O
+127	O
+physicians	O
+and	O
+nurses	O
+worked	O
+in	O
+SARS	B-DISO
+wards	O
+for	O
+one	O
+month	O
+and	O
+73	O
+SARS	B-DISO
+patients	O
+with	O
+different	O
+course	O
+of	O
+SARS	B-DISO
+were	O
+measured	O
+by	O
+enzyme	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+retrospectively	O
+analyze	O
+the	O
+X	O
+-	O
+ray	O
+and	O
+CT	O
+features	O
+of	O
+patients	O
+with	O
+suggestive	O
+of	O
+SARS	B-DISO
+at	O
+the	O
+early	O
+stages	O
+.	O
+
+91	O
+.	O
+3	O
+%	O
+cases	O
+had	O
+bilateral	O
+involvement	O
+and	O
+91	O
+.	O
+2	O
+%	O
+had	O
+multifield	O
+involvement	O
+(	O
+two	O
+lung	B-ANAT
+fields	O
+involvement	O
+is	O
+47	O
+.	O
+8	O
+%,	O
+three	O
+and	O
+four	O
+lung	B-ANAT
+fields	O
+involvement	O
+are	O
+both	O
+21	O
+.	O
+7	O
+%).	O
+
+The	O
+improvement	O
+of	O
+acute	O
+stage	O
+lesion	O
+in	O
+17	O
+cases	O
+is	O
+related	O
+to	O
+the	O
+usage	O
+and	O
+increased	O
+dosage	O
+of	O
+corticosteroid	B-CHED
+,	O
+some	O
+cases	O
+showed	O
+non	O
+-	O
+parallel	O
+with	O
+symptom	B-DISO
+and	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+chest	B-ANAT
+X	O
+ray	B-SPEC
+of	O
+SARS	B-DISO
+has	O
+some	O
+features	O
+and	O
+its	O
+changes	O
+can	O
+reflect	O
+the	O
+clinical	O
+situation	O
+.	O
+
+There	O
+was	O
+no	O
+SARS	B-DISO
+affected	O
+among	O
+the	O
+medical	O
+faculty	O
+during	O
+the	O
+course	O
+of	O
+NIPPV	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+analysis	O
+of	O
+45	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+clinical	O
+and	O
+radiology	O
+features	O
+of	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+80	O
+percent	O
+of	O
+SARS	B-DISO
+patients	O
+became	O
+fever	B-PROC
+for	O
+24	O
+hours	O
+and	O
+then	O
+have	O
+abnormal	O
+chest	B-ANAT
+radiographs	O
+,	O
+serial	O
+chest	B-ANAT
+radiographs	O
+showed	O
+progression	O
+of	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+within	O
+48	O
+hours	O
+in	O
+71	O
+.	O
+1	O
+percent	O
+of	O
+patients	O
+.	O
+
+Seven	O
+hundreds	O
+and	O
+twenty	O
+medical	O
+workers	O
+including	O
+doctors	O
+,	O
+nurses	O
+and	O
+nurse	O
+-	O
+assistants	O
+were	O
+involved	O
+in	O
+the	O
+medical	O
+care	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+From	O
+March	O
+15th	O
+,	O
+2003	O
+to	O
+May	O
+18th	O
+,	O
+2003	O
+,	O
+224	O
+patients	O
+with	O
+clinical	O
+confirmed	O
+SARS	B-DISO
+and	O
+72	O
+patients	O
+with	O
+clinical	O
+suspected	O
+SARS	B-DISO
+were	O
+presented	O
+in	O
+our	O
+hospital	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Predict	O
+SARS	B-DISO
+infection	B-DISO
+with	O
+the	O
+small	O
+world	O
+network	O
+model	O
+].	O
+
+The	O
+results	O
+show	O
+that	O
+the	O
+SIR	O
+model	O
+s	O
+applicable	O
+approximately	O
+for	O
+describing	O
+the	O
+SARS	B-DISO
+epidemic	O
+situation	O
+.	O
+
+The	O
+forecasting	O
+for	O
+SARS	B-DISO
+epidemic	O
+situation	O
+is	O
+also	O
+given	O
+.	O
+
+(	O
+4	O
+)	O
+Collection	O
+,	O
+transportation	O
+,	O
+pre	O
+-	O
+disposal	O
+and	O
+storage	B-PROC
+of	O
+specimen	O
+from	O
+patients	O
+with	O
+SARS	B-DISO
+for	O
+testing	O
+should	O
+be	O
+done	O
+in	O
+leak	O
+-	O
+resistant	O
+environment	O
+.	O
+
+RESULTS	O
+:	O
+92	O
+%	O
+of	O
+the	O
+residents	O
+focused	O
+on	O
+SARS	O
+epidemic	O
+in	O
+Beijing	O
+and	O
+72	O
+.	O
+5	O
+%	O
+didn	O
+'	O
+t	O
+worry	O
+that	O
+they	O
+would	O
+be	O
+attacked	O
+by	O
+SARS	B-DISO
+.	O
+
+Meanwhile	O
+,	O
+60	O
+%	O
+could	O
+follow	O
+the	O
+government	O
+recommendation	O
+to	O
+prevent	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+learn	B-PROC
+the	O
+knowledge	O
+,	O
+attitude	O
+and	O
+practice	O
+(	O
+KAP	O
+)	O
+of	O
+rural	O
+people	O
+towards	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+),	O
+and	O
+to	O
+quickly	O
+provide	O
+the	O
+informations	O
+to	O
+decision	O
+-	O
+making	O
+department	O
+.	O
+
+SARS	B-DISO
+is	O
+extremely	O
+contagious	O
+.	O
+
+ABSTRACT	O
+:	O
+Limitin	B-PRGE
+has	O
+sequence	O
+homology	O
+with	O
+alpha	B-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+and	O
+utilizes	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+receptor	I-PRGE
+.	O
+
+While	O
+limitin	O
+has	O
+antiviral	B-CHED
+activity	O
+as	O
+strong	O
+as	O
+that	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+in	O
+vitro	O
+(	O
+the	O
+concentration	O
+that	O
+provided	O
+50	O
+%	O
+inhibition	B-PROC
+of	O
+cytopathic	B-DISO
+effect	I-DISO
+is	O
+approximately	O
+30	O
+pg	O
+/	O
+ml	O
+),	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+1	I-PRGE
+(	O
+IRF	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+dependencies	O
+for	O
+induction	O
+of	O
+an	O
+antiviral	B-CHED
+state	O
+were	O
+different	O
+for	O
+limitin	B-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+putative	O
+NTPase	B-PRGE
+/	O
+helicase	B-PRGE
+protein	B-CHED
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+postulated	O
+to	O
+play	O
+a	O
+number	O
+of	O
+crucial	O
+roles	O
+in	O
+the	O
+viral	B-PROC
+life	I-PROC
+cycle	I-PROC
+,	O
+making	O
+it	O
+an	O
+attractive	O
+target	O
+for	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+therapy	O
+.	O
+
+All	O
+eight	O
+common	O
+NTPs	O
+and	O
+dNTPs	O
+were	O
+hydrolyzed	O
+by	O
+the	O
+SARS	O
+helicase	O
+in	O
+a	O
+magnesium	B-CHED
+-	O
+dependent	O
+reaction	O
+,	O
+stimulated	O
+by	O
+the	O
+presence	O
+of	O
+either	O
+single	B-CHED
+-	I-CHED
+stranded	I-CHED
+DNA	I-CHED
+or	O
+RNA	O
+.	O
+
+The	O
+availability	O
+of	O
+recombinant	O
+forms	O
+of	O
+key	O
+replicative	O
+enzymes	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+should	O
+pave	O
+the	O
+way	O
+for	O
+high	O
+-	O
+throughput	O
+screening	O
+approaches	O
+to	O
+identify	O
+candidate	O
+inhibitors	O
+in	O
+compound	O
+libraries	O
+.	O
+
+TITLE	O
+:	O
+Current	O
+status	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+China	O
+.	O
+
+On	O
+April	O
+16	O
+,	O
+2003	O
+,	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+formally	O
+declared	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+an	O
+etiological	O
+agent	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+clinical	O
+presentation	O
+,	O
+chest	B-ANAT
+radiographs	O
+,	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+and	O
+outcome	O
+of	O
+45	O
+SARS	B-DISO
+patients	O
+from	O
+April	O
+5	O
+to	O
+20	O
+2003	O
+were	O
+compared	O
+,	O
+with	O
+those	O
+of	O
+80	O
+CAP	B-DISO
+patients	O
+from	O
+October	O
+1	O
+2002	O
+to	O
+April	O
+1	O
+2003	O
+in	O
+our	O
+hospital	O
+,	O
+and	O
+the	O
+clinical	O
+features	O
+of	O
+SARS	B-DISO
+were	O
+summarized	O
+.	O
+
+(	O
+1	O
+)	O
+Fever	B-PROC
+above	O
+38	O
+.	O
+5	O
+centigrade	O
+,	O
+dry	B-DISO
+cough	I-DISO
+,	O
+short	B-DISO
+of	I-DISO
+breath	I-DISO
+,	O
+headache	B-DISO
+,	O
+myalgia	B-DISO
+,	O
+diarrhea	B-DISO
+in	O
+SARS	B-DISO
+were	O
+more	O
+common	O
+in	O
+SARS	B-DISO
+patients	O
+than	O
+those	O
+in	O
+CAP	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+(	O
+2	O
+)	O
+Leucopenia	B-DISO
+was	O
+more	O
+common	O
+and	O
+leukocytosis	B-DISO
+was	O
+less	O
+common	O
+in	O
+SARS	B-DISO
+than	O
+those	O
+in	O
+CAP	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+(	O
+5	O
+)	O
+The	O
+ratio	O
+of	O
+severe	O
+pneumonia	B-DISO
+and	O
+mortality	O
+in	O
+SARS	B-DISO
+was	O
+much	O
+higher	O
+than	O
+in	O
+CAP	B-DISO
+(	O
+both	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+most	O
+common	O
+symptoms	O
+included	O
+fever	B-PROC
+(	O
+in	O
+100	O
+.	O
+0	O
+percent	O
+of	O
+the	O
+patients	O
+),	O
+cough	B-DISO
+(	O
+74	O
+.	O
+3	O
+percent	O
+),	O
+headache	B-DISO
+(	O
+45	O
+.	O
+7	O
+percent	O
+),	O
+myalgia	B-DISO
+(	O
+45	O
+.	O
+7	O
+percent	O
+)	O
+and	O
+lymphopenia	B-DISO
+(	O
+20	O
+/	O
+33	O
+).	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+is	O
+a	O
+serious	O
+respiratory	O
+illness	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+M	O
+protein	B-CHED
+,	O
+the	O
+most	O
+abundant	O
+coronaviral	O
+envelope	B-COMP
+component	O
+,	O
+is	O
+invariably	O
+glycosylated	O
+,	O
+which	O
+provides	O
+the	O
+virion	B-COMP
+with	O
+a	O
+diffuse	O
+,	O
+hydrophilic	O
+cover	O
+on	O
+its	O
+outer	O
+surface	O
+.	O
+
+However	O
+,	O
+it	O
+affected	O
+their	O
+interferogenic	O
+capacity	O
+as	O
+measured	O
+using	O
+fixed	B-ANAT
+,	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Viruses	B-SPEC
+containing	O
+M	O
+proteins	B-CHED
+with	O
+N	O
+-	O
+linked	O
+sugars	O
+induced	O
+type	O
+I	O
+interferons	O
+to	O
+higher	O
+levels	O
+than	O
+viruses	B-SPEC
+carrying	O
+M	O
+proteins	B-CHED
+with	O
+O	O
+-	O
+linked	O
+sugars	O
+.	O
+
+Strikingly	O
+,	O
+their	O
+abilities	O
+to	O
+replicate	O
+in	O
+the	O
+liver	B-ANAT
+correlated	O
+with	O
+their	O
+in	O
+vitro	O
+interferogenic	O
+capacity	O
+.	O
+
+This	O
+apparent	O
+correlation	O
+might	O
+be	O
+explained	O
+by	O
+the	O
+functioning	O
+of	O
+lectins	O
+,	O
+such	O
+as	O
+the	O
+mannose	B-PRGE
+receptor	I-PRGE
+,	O
+which	O
+are	O
+abundantly	O
+expressed	B-PROC
+in	O
+the	O
+liver	B-ANAT
+but	O
+also	O
+play	O
+a	O
+role	O
+in	O
+the	O
+induction	O
+of	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+by	O
+dendritic	B-ANAT
+cells	B-COMP
+.	O
+
+A	O
+large	O
+quantity	O
+of	O
+proliferated	O
+macrophages	B-ANAT
+could	O
+be	O
+observed	O
+in	O
+the	O
+lungs	B-ANAT
+,	O
+spleens	B-ANAT
+and	O
+lymph	B-ANAT
+nodes	I-ANAT
+of	O
+the	O
+SARS	B-DISO
+patients	O
+,	O
+some	O
+of	O
+which	O
+were	O
+positive	O
+for	O
+CD25	B-PRGE
+marker	O
+(	O
+active	O
+macrophages	B-ANAT
+).	O
+
+Significantly	O
+enhanced	O
+activity	O
+of	O
+the	O
+macrophages	B-ANAT
+occurs	O
+in	O
+SARS	B-DISO
+as	O
+the	O
+major	O
+reactive	O
+cells	B-COMP
+,	O
+but	O
+T	B-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+are	O
+obviously	O
+decreased	O
+,	O
+indicating	O
+the	O
+important	O
+roles	O
+of	O
+the	O
+macrophages	B-ANAT
+and	O
+T	B-ANAT
+lymphocytes	I-ANAT
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+A	O
+large	O
+quantity	O
+of	O
+proliferated	O
+macrophages	B-ANAT
+could	O
+be	O
+observed	O
+in	O
+the	O
+lungs	B-ANAT
+,	O
+spleens	B-ANAT
+and	O
+lymph	B-ANAT
+nodes	I-ANAT
+of	O
+the	O
+SARS	B-DISO
+patients	O
+,	O
+some	O
+of	O
+which	O
+were	O
+positive	O
+for	O
+CD25	B-PRGE
+marker	O
+(	O
+active	O
+macrophages	B-ANAT
+).	O
+
+CONCLUSIONS	O
+:	O
+Significantly	O
+enhanced	O
+activity	O
+of	O
+the	O
+macrophages	B-ANAT
+occurs	O
+in	O
+SARS	B-DISO
+as	O
+the	O
+major	O
+reactive	O
+cells	B-COMP
+,	O
+but	O
+T	B-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+are	O
+obviously	O
+decreased	O
+,	O
+indicating	O
+the	O
+important	O
+roles	O
+of	O
+the	O
+macrophages	B-ANAT
+and	O
+T	B-ANAT
+lymphocytes	I-ANAT
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+This	O
+study	O
+was	O
+designed	O
+to	O
+clarify	O
+the	O
+role	O
+of	O
+iNOS	B-PRGE
+in	O
+mediating	O
+extrapulmonary	O
+comorbidity	O
+in	O
+sheep	B-SPEC
+after	O
+combined	O
+burn	O
+and	O
+smoke	O
+inhalation	B-PROC
+injuries	O
+using	O
+a	O
+potent	O
+and	O
+highly	O
+selective	O
+iNOS	B-PRGE
+dimerization	I-PRGE
+inhibitor	I-PRGE
+,	O
+BBS	B-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+The	O
+outbreak	O
+started	O
+with	O
+a	O
+SARS	B-DISO
+patient	O
+from	O
+the	O
+community	O
+on	O
+30	O
+January	O
+2003	O
+,	O
+followed	O
+by	O
+a	O
+total	O
+of	O
+96	O
+people	O
+[	O
+76	O
+women	O
+and	O
+20	O
+men	O
+;	O
+mean	O
+age	O
+(	O
+29	O
+.	O
+5	O
++/-	O
+
+68	O
+.	O
+8	O
+%	O
+of	O
+the	O
+patients	O
+were	O
+treated	O
+with	O
+methylprednisolone	B-CHED
+for	O
+a	O
+mean	O
+period	O
+l	O
+of	O
+(	O
+4	O
+.	O
+9	O
++/-	O
+
+RESULTS	O
+:	O
+The	O
+outbreak	O
+started	O
+with	O
+a	O
+SARS	B-DISO
+patient	O
+from	O
+the	O
+community	O
+on	O
+30	O
+January	O
+2003	O
+,	O
+followed	O
+by	O
+a	O
+total	O
+of	O
+96	O
+people	O
+[	O
+76	O
+women	O
+and	O
+20	O
+men	O
+;	O
+mean	O
+age	O
+(	O
+29	O
+.	O
+5	O
++/-	O
+
+37	O
+SARS	B-DISO
+patients	O
+fulfilled	O
+the	O
+Guangdong	O
+provincial	O
+diagnostic	O
+criteria	O
+for	O
+infectious	B-DISO
+atypical	B-DISO
+pneumonia	I-DISO
+and	O
+35	O
+health	O
+controls	O
+were	O
+investigated	O
+.	O
+
+Evidence	O
+to	O
+date	O
+suggests	O
+that	O
+SARS	B-DISO
+is	O
+a	O
+severe	O
+respiratory	O
+illness	O
+spread	O
+mainly	O
+by	O
+respiratory	O
+droplets	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genome	O
+organization	O
+and	O
+expression	B-PROC
+strategy	O
+of	O
+the	O
+newly	O
+identified	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+were	O
+predicted	O
+using	O
+recently	O
+published	O
+genome	O
+sequences	O
+.	O
+
+Fourteen	O
+putative	O
+open	O
+reading	O
+frames	O
+were	O
+identified	O
+,	O
+12	O
+of	O
+which	O
+were	O
+predicted	O
+to	O
+be	O
+expressed	B-PROC
+from	O
+a	O
+nested	O
+set	O
+of	O
+eight	O
+subgenomic	O
+mRNAs	O
+.	O
+
+The	O
+synthesis	B-PROC
+of	O
+these	O
+mRNAs	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+was	O
+confirmed	O
+experimentally	O
+.	O
+
+The	O
+4382	O
+-	O
+and	O
+7073	O
+amino	B-CHED
+acid	I-CHED
+residue	I-CHED
+SARS	B-DISO
+-	O
+CoV	O
+replicase	B-PRGE
+polyproteins	O
+are	O
+predicted	O
+to	O
+be	O
+cleaved	B-ANAT
+into	O
+16	O
+subunits	O
+by	O
+two	O
+viral	O
+proteinases	O
+(	O
+bringing	O
+the	O
+total	O
+number	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+proteins	B-CHED
+to	O
+28	O
+).	O
+
+To	O
+describe	O
+the	O
+radiographic	O
+features	O
+of	O
+SARS	B-DISO
+in	O
+a	O
+cluster	O
+of	O
+affected	O
+children	O
+.	O
+
+Severe	O
+malaria	B-PATH
+is	O
+almost	O
+exclusively	O
+caused	O
+by	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+.	O
+
+Renal	B-ANAT
+replacement	O
+therapy	O
+should	O
+be	O
+initiated	O
+early	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+first	O
+SARS	B-DISO
+case	O
+was	O
+identified	O
+in	O
+Foshan	O
+municipality	O
+on	O
+November	O
+16	O
+,	O
+2002	O
+,	O
+followed	O
+by	O
+1	O
+511	O
+clinically	O
+confirmed	O
+cases	O
+(	O
+including	O
+58	O
+deaths	B-PROC
+)	O
+up	O
+to	O
+May	O
+15	O
+,	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+effect	O
+of	O
+glucocorticoid	O
+in	O
+the	O
+treatment	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+(	O
+2	O
+)	O
+Average	O
+length	O
+of	O
+hospital	O
+stay	O
+was	O
+16	O
+.	O
+9	O
+days	O
+for	O
+the	O
+all	O
+70	O
+cases	O
+,	O
+and	O
+16	O
+.	O
+8	O
+days	O
+for	O
+the	O
+11	O
+cases	O
+without	O
+glucocorticoid	B-CHED
+treatment	O
+,	O
+without	O
+statistical	O
+significance	O
+(	O
+F	O
+=	O
+1	O
+.	O
+018	O
+,	O
+P	O
+=	O
+0	O
+.	O
+39	O
+).	O
+
+(	O
+3	O
+)	O
+The	O
+other	O
+59	O
+cases	O
+were	O
+administered	O
+with	O
+40	O
+mg	O
+to	O
+640	O
+mg	O
+of	O
+methylprednisolone	B-CHED
+daily	O
+.	O
+
+(	O
+4	O
+)	O
+Average	O
+hospital	O
+stay	O
+was	O
+15	O
+days	O
+for	O
+the	O
+23	O
+cases	O
+with	O
+lower	O
+dose	O
+of	O
+40	O
+mg	O
+to	O
+80	O
+mg	O
+methylprednisolone	B-CHED
+daily	O
+,	O
+18	O
+.	O
+5	O
+days	O
+for	O
+the	O
+27	O
+cases	O
+with	O
+medium	O
+dose	O
+of	O
+120	O
+mg	O
+to	O
+240	O
+mg	O
+daily	O
+,	O
+and	O
+17	O
+.	O
+9	O
+days	O
+for	O
+the	O
+nine	O
+cases	O
+with	O
+higher	O
+dose	O
+of	O
+320	O
+mg	O
+to	O
+640	O
+mg	O
+daily	O
+(	O
+F	O
+=	O
+1	O
+.	O
+018	O
+,	O
+P	O
+=	O
+0	O
+.	O
+39	O
+).	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+Sixty	O
+-	O
+three	O
+of	O
+70	O
+cases	O
+of	O
+SARS	B-DISO
+recovered	O
+and	O
+seven	O
+cases	O
+died	B-PROC
+,	O
+with	O
+a	O
+case	O
+-	O
+fatality	O
+ratio	O
+of	O
+10	O
+%.	O
+
+(	O
+4	O
+)	O
+Average	O
+hospital	O
+stay	O
+was	O
+15	O
+days	O
+for	O
+the	O
+23	O
+cases	O
+with	O
+lower	O
+dose	O
+of	O
+40	O
+mg	O
+to	O
+80	O
+mg	O
+methylprednisolone	B-CHED
+daily	O
+,	O
+18	O
+.	O
+5	O
+days	O
+for	O
+the	O
+27	O
+cases	O
+with	O
+medium	O
+dose	O
+of	O
+120	O
+mg	O
+to	O
+240	O
+mg	O
+daily	O
+,	O
+and	O
+17	O
+.	O
+9	O
+days	O
+for	O
+the	O
+nine	O
+cases	O
+with	O
+higher	O
+dose	O
+of	O
+320	O
+mg	O
+to	O
+640	O
+mg	O
+daily	O
+(	O
+F	O
+=	O
+1	O
+.	O
+018	O
+,	O
+P	O
+=	O
+0	O
+.	O
+39	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+influence	O
+of	O
+the	O
+surveillance	O
+system	O
+and	O
+preventive	O
+measurements	O
+on	O
+the	O
+control	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+a	O
+university	O
+in	O
+Guangdong	O
+Province	O
+.	O
+
+SARS	B-DISO
+could	O
+be	O
+effectively	O
+controlled	O
+in	O
+university	O
+only	O
+if	O
+strict	O
+surveillance	O
+system	O
+is	O
+built	O
+up	O
+,	O
+and	O
+all	O
+-	O
+round	O
+preventions	O
+,	O
+including	O
+early	O
+isolation	O
+of	O
+both	O
+confirmed	O
+or	O
+suspected	O
+cases	O
+and	O
+close	O
+contacted	O
+persons	O
+,	O
+are	O
+carried	O
+out	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+could	O
+be	O
+effectively	O
+controlled	O
+in	O
+university	O
+only	O
+if	O
+strict	O
+surveillance	O
+system	O
+is	O
+built	O
+up	O
+,	O
+and	O
+all	O
+-	O
+round	O
+preventions	O
+,	O
+including	O
+early	O
+isolation	O
+of	O
+both	O
+confirmed	O
+or	O
+suspected	O
+cases	O
+and	O
+close	O
+contacted	O
+persons	O
+,	O
+are	O
+carried	O
+out	O
+.	O
+
+IHF	O
+'	O
+s	O
+ability	O
+for	O
+concerted	O
+binding	B-FUNC
+and	O
+bending	B-DISO
+of	O
+DNA	O
+is	O
+key	O
+to	O
+its	O
+biological	B-PROC
+function	I-PROC
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+design	O
+,	O
+characterization	O
+and	O
+application	O
+of	O
+a	O
+single	O
+polypeptide	B-CHED
+chain	I-CHED
+IHF	O
+,	O
+termed	O
+scIHF2	O
+.	O
+
+DNA	B-FUNC
+binding	I-FUNC
+and	O
+DNA	O
+bending	B-DISO
+assays	O
+revealed	O
+that	O
+purified	O
+wild	O
+-	O
+type	O
+IHF	O
+and	O
+scIHF2	O
+behave	O
+very	O
+similarly	O
+.	O
+
+The	O
+dictum	O
+of	O
+public	O
+health	O
+practice	O
+especially	O
+for	O
+infectious	B-DISO
+disease	I-DISO
+is	O
+""""	O
+prevention	O
+better	O
+than	O
+cure	O
+"""."	O
+
+With	O
+the	O
+emergence	O
+of	O
+SARS	B-DISO
+,	O
+this	O
+might	O
+be	O
+the	O
+time	O
+to	O
+globalise	O
+public	O
+health	O
+medicine	B-CHED
+as	O
+an	O
+important	O
+component	O
+of	O
+medical	O
+practice	O
+.	O
+
+there	O
+are	O
+not	O
+a	O
+strong	O
+relationship	O
+of	O
+diarrhoea	B-DISO
+by	O
+shortage	O
+environmental	O
+health	O
+in	O
+this	O
+study	O
+;	O
+6	O
+.	O
+
+TITLE	O
+:	O
+Exogenous	O
+porcine	B-SPEC
+viruses	B-SPEC
+.	O
+
+The	O
+ability	O
+of	O
+several	O
+porcine	B-SPEC
+viruses	B-SPEC
+to	O
+cause	O
+transplacental	O
+fetal	B-DISO
+infection	I-DISO
+(	O
+parvoviruses	B-SPEC
+,	O
+circoviruses	O
+,	O
+and	O
+arteriviruses	B-SPEC
+),	O
+emergence	O
+or	O
+recognition	O
+of	O
+several	O
+new	O
+porcine	B-SPEC
+viruses	B-SPEC
+during	O
+the	O
+last	O
+two	O
+decades	O
+(	O
+porcine	B-SPEC
+circovirus	I-SPEC
+,	O
+arterivirus	B-SPEC
+,	O
+paramyxoviruses	O
+,	O
+herpesviruses	B-SPEC
+,	O
+and	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+)	O
+and	O
+the	O
+immunosuppressed	O
+state	O
+of	O
+the	O
+transplant	B-ANAT
+recipients	O
+increases	O
+the	O
+xenozoonoses	O
+risk	O
+of	O
+humans	B-SPEC
+to	O
+porcine	B-SPEC
+viruses	B-SPEC
+through	O
+transplantation	O
+.	O
+
+We	O
+have	O
+also	O
+presented	O
+information	O
+on	O
+porcine	B-SPEC
+parvovirus	I-SPEC
+,	O
+Japanese	B-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+,	O
+encephalomyocarditis	B-SPEC
+virus	I-SPEC
+,	O
+herpesviruses	B-SPEC
+(	O
+pseudorabies	B-SPEC
+virus	I-SPEC
+,	O
+porcine	B-SPEC
+lymphotropic	O
+herpesvirus	B-SPEC
+,	O
+porcine	B-SPEC
+cytomegalovirus	I-SPEC
+),	O
+coronaviruses	O
+(	O
+TGEV	B-SPEC
+,	O
+PRCV	O
+,	O
+HEV	B-SPEC
+,	O
+PEDV	B-SPEC
+)	O
+and	O
+adenovirus	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+siRNA	O
+may	O
+be	O
+effective	O
+in	O
+inhibiting	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+replication	O
+.	O
+
+Among	O
+the	O
+96	O
+cases	O
+,	O
+26	O
+cases	O
+(	O
+27	O
+%)	O
+had	O
+diarrhea	B-DISO
+,	O
+17	O
+(	O
+18	O
+%)	O
+had	O
+nausea	B-DISO
+,	O
+6	O
+(	O
+6	O
+%)	O
+had	O
+vomiting	B-DISO
+,	O
+16	O
+(	O
+17	O
+%)	O
+had	O
+bellyache	B-DISO
+,	O
+and	O
+8	O
+(	O
+8	O
+%)	O
+had	O
+ALT	B-FUNC
+elevation	O
+.	O
+
+Patients	O
+with	O
+SARS	B-DISO
+may	O
+have	O
+digestive	B-ANAT
+system	I-ANAT
+manifestations	O
+;	O
+diarrhea	B-DISO
+is	O
+the	O
+most	O
+common	O
+symptom	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+sudden	O
+unexpected	O
+death	B-PROC
+is	O
+reported	O
+in	O
+a	O
+15	O
+-	O
+month	O
+old	O
+boy	O
+,	O
+born	O
+with	O
+an	O
+extremely	O
+low	O
+birth	B-PROC
+weight	O
+and	O
+then	O
+had	O
+suffered	B-DISO
+prolonged	O
+respiratory	B-DISO
+complications	I-DISO
+arising	O
+from	O
+infantile	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+clarify	O
+the	O
+immunohistochemical	O
+distribution	O
+of	O
+surfactant	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+protein	B-CHED
+A	I-PRGE
+(	O
+SP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+)	O
+for	O
+early	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+with	O
+special	O
+regard	O
+to	O
+hyaline	B-DISO
+membrane	B-COMP
+(	O
+HM	O
+)	O
+formation	B-PROC
+.	O
+
+ARDS	B-DISO
+were	O
+observed	O
+in	O
+23	O
+cases	O
+,	O
+showing	O
+speckled	O
+SP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+immunostaining	O
+.	O
+
+During	O
+the	O
+early	O
+,	O
+exudative	O
+phase	O
+of	O
+ARDS	B-DISO
+,	O
+characteristic	O
+SP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+distribution	O
+showed	O
+intense	O
+staining	O
+in	O
+the	O
+intra	O
+-	O
+alveolar	B-ANAT
+massive	O
+aggregates	O
+and	O
+thick	O
+'	B-DISO
+peeling	I-DISO
+'-	O
+like	O
+substances	O
+accompanied	O
+with	O
+a	O
+lot	O
+of	O
+granular	B-ANAT
+staining	O
+.	O
+
+Characteristic	O
+SP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+distribution	O
+in	O
+the	O
+exudative	O
+phase	O
+appeared	O
+to	O
+be	O
+especially	O
+useful	O
+for	O
+early	O
+histopathological	O
+diagnosis	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+even	O
+prior	O
+to	O
+the	O
+appearance	O
+of	O
+typical	O
+HMs	B-DISO
+.	O
+
+These	O
+results	O
+might	O
+reflect	O
+chronic	O
+hypoxic	O
+condition	B-DISO
+before	O
+death	B-PROC
+,	O
+because	O
+ORP	B-PRGE
+-	I-PRGE
+150	I-PRGE
+is	O
+only	O
+induced	O
+when	O
+a	O
+hypoxic	B-DISO
+condition	B-DISO
+exist	O
+,	O
+but	O
+not	O
+acute	O
+hypoxia	B-DISO
+.	O
+
+And	O
+chronic	O
+hypoxic	B-DISO
+state	O
+is	O
+likely	O
+to	O
+be	O
+antecedent	O
+to	O
+SIDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+principles	O
+and	O
+current	O
+therapy	O
+.	O
+
+RESULTS	O
+:	O
+MARS	O
+therapy	O
+was	O
+associated	O
+with	O
+marked	O
+reduction	O
+of	O
+albumin	B-PRGE
+bound	O
+toxins	B-CHED
+and	O
+water	B-CHED
+soluble	O
+toxins	B-CHED
+,	O
+together	O
+with	O
+a	O
+significant	O
+removal	O
+of	O
+NO	O
+and	O
+certain	O
+cytokines	O
+,	O
+such	O
+as	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+INF	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+summarize	O
+the	O
+clinical	O
+features	O
+of	O
+liver	B-ANAT
+injury	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+providing	O
+information	O
+for	O
+further	O
+mechanism	O
+and	O
+clinical	O
+study	O
+.	O
+
+In	O
+the	O
+first	O
+week	O
+,	O
+only	O
+15	O
+.	O
+2	O
+%	O
+patients	O
+had	O
+elevated	O
+serum	B-PRGE
+endotoxin	I-PRGE
+level	O
+.	O
+
+ABSTRACT	O
+:	O
+Multiple	O
+sequence	O
+alignment	O
+among	O
+12	O
+complete	O
+SARS	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+sequences	O
+reveals	O
+that	O
+the	O
+major	O
+parts	O
+of	O
+29708	O
+b	O
+of	O
+the	O
+genomes	O
+have	O
+99	O
+.	O
+82	O
+%	O
+identical	O
+bases	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Genomic	O
+characterization	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+:	O
+a	O
+novel	O
+member	O
+of	O
+coronavirus	B-SPEC
+].	O
+
+SARS	B-DISO
+-	O
+CoV	O
+evolutionally	O
+closes	O
+to	O
+other	O
+coronavirus	B-SPEC
+in	O
+their	O
+corresponding	O
+proteins	B-CHED
+,	O
+such	O
+as	O
+spike	O
+protein	B-CHED
+,	O
+small	B-PRGE
+membrane	I-PRGE
+protein	B-CHED
+and	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+previously	O
+healthy	O
+patient	O
+was	O
+transferred	O
+to	O
+our	O
+infectious	B-DISO
+department	O
+with	O
+a	O
+9	O
+-	O
+day	O
+-	O
+history	O
+of	O
+continued	O
+fever	B-PROC
+.	O
+
+We	O
+initiated	O
+MARS	O
+therapy	O
+(	O
+extracorporeal	O
+liver	B-ANAT
+support	O
+utilizing	O
+albumin	B-PRGE
+dialysis	B-SPEC
+)	O
+with	O
+intention	O
+to	O
+positively	O
+influence	O
+the	O
+organ	B-ANAT
+functions	O
+in	O
+his	O
+MODS	B-DISO
+on	O
+the	O
+basis	O
+of	O
+recently	O
+published	O
+studies	O
+which	O
+suggested	O
+a	O
+positive	O
+impact	O
+of	O
+MARS	O
+in	O
+multiorgan	O
+failure	O
+secondary	O
+to	O
+respiratory	O
+illnesses	O
+and	O
+the	O
+possible	O
+influence	O
+on	O
+inflammatory	O
+mediators	O
+and	O
+cytokines	O
+.	O
+
+Immunohistochemical	O
+examination	O
+demonstrated	O
+a	O
+marked	O
+increase	O
+in	O
+immunoreactivity	B-PROC
+for	O
+intracellular	B-PRGE
+adhesion	B-DISO
+molecule	I-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+),	O
+P	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+and	O
+E	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+in	O
+the	O
+pancreas	B-ANAT
+and	O
+lung	B-ANAT
+of	O
+cerulein	B-CHED
+-	O
+treated	O
+mice	B-SPEC
+.	O
+
+We	O
+have	O
+constructed	O
+a	O
+prototype	O
+RNA	O
+vector	O
+containing	O
+the	O
+5	O
+'	O
+and	O
+3	O
+'	O
+ends	O
+of	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+genome	O
+,	O
+the	O
+entire	O
+human	B-PRGE
+coronavirus	I-PRGE
+replicase	I-PRGE
+gene	I-PRGE
+,	O
+and	O
+three	O
+reporter	O
+genes	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+the	O
+chloramphenicol	B-PRGE
+acetyltransferase	I-PRGE
+[	I-PRGE
+CAT	B-SPEC
+]	I-PRGE
+gene	I-PRGE
+,	O
+the	O
+firefly	O
+luciferase	O
+[	O
+LUC	O
+]	O
+gene	O
+,	O
+and	O
+the	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+[	O
+GFP	O
+]	O
+gene	O
+).	O
+
+In	O
+summary	O
+,	O
+we	O
+describe	O
+a	O
+new	O
+class	B-SPEC
+of	O
+eukaryotic	O
+,	O
+multigene	O
+expression	B-PROC
+vectors	O
+that	O
+are	O
+based	O
+on	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+and	O
+have	O
+the	O
+ability	O
+to	O
+transduce	O
+human	B-SPEC
+dendritic	B-ANAT
+cells	B-COMP
+.	O
+
+The	O
+current	O
+authors	O
+tested	O
+a	O
+therapeutic	O
+intervention	O
+on	O
+a	O
+previously	O
+defined	O
+pathophysiological	O
+model	O
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+dose	O
+pulse	B-PROC
+versus	O
+nonpulse	O
+corticosteroid	B-CHED
+regimens	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+treatment	O
+of	O
+atypical	O
+pneumonia	O
+,	O
+subsequently	O
+termed	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+is	O
+controversial	O
+,	O
+and	O
+the	O
+efficacy	O
+of	O
+corticosteroid	B-CHED
+therapy	O
+is	O
+unknown	O
+.	O
+
+Chest	B-ANAT
+radiographs	O
+were	O
+scored	O
+according	O
+to	O
+the	O
+percentage	O
+of	O
+lung	B-ANAT
+field	I-ANAT
+involved	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+children	O
+.	O
+
+The	O
+causative	O
+agent	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+and	O
+children	O
+appear	O
+to	O
+acquire	O
+the	O
+infection	B-DISO
+by	O
+close	O
+-	O
+contact	O
+household	O
+exposure	O
+to	O
+an	O
+infected	O
+adult	O
+.	O
+
+Diagnosis	O
+was	O
+characteristically	O
+delayed	O
+until	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+complicated	O
+a	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+at	O
+13	O
+months	O
+,	O
+prompting	O
+high	O
+-	O
+resolution	O
+computerized	O
+tomography	O
+(	O
+HRCT	O
+)	O
+of	O
+the	O
+chest	B-ANAT
+.	O
+
+He	O
+gradually	O
+deteriorated	O
+,	O
+eventually	O
+requiring	O
+ventilatory	O
+support	O
+;	O
+death	B-PROC
+occurred	O
+at	O
+age	O
+15	O
+months	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+a	O
+new	O
+coronavirus	B-SPEC
+from	O
+the	O
+Chinese	O
+dragon	O
+'	O
+s	O
+lair	O
+.	O
+
+TITLE	O
+:	O
+Application	O
+of	O
+Molecular	O
+Adsorbents	O
+Recirculating	O
+System	O
+to	O
+remove	O
+NO	O
+and	O
+cytokines	O
+in	O
+severe	O
+liver	B-DISO
+failure	I-DISO
+patients	O
+with	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+can	O
+confirm	O
+the	O
+positive	O
+therapeutic	O
+impact	O
+and	O
+safety	O
+to	O
+use	O
+MARS	O
+on	O
+liver	B-DISO
+failure	I-DISO
+patients	O
+with	O
+MODS	B-DISO
+associated	O
+with	O
+elevated	O
+levels	O
+of	O
+NO	O
+and	O
+cytokines	O
+.	O
+
+This	O
+was	O
+later	O
+termed	O
+by	O
+the	O
+World	O
+Health	O
+Organisation	B-PROC
+as	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+When	O
+compared	O
+to	O
+uvMHV3	O
+,	O
+a	O
+single	O
+immunization	O
+with	O
+a	O
+related	O
+infectious	O
+MHV	B-SPEC
+strain	O
+induced	O
+a	O
+higher	O
+antibody	B-COMP
+synthesis	B-PROC
+and	O
+led	O
+the	O
+HIII	O
+mice	B-SPEC
+to	O
+resist	O
+the	O
+MHV3	O
+challenge	O
+.	O
+
+Our	O
+findings	O
+also	O
+suggest	O
+that	O
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+induction	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+conferring	O
+protection	O
+on	O
+hepatocytes	B-ANAT
+from	O
+oxidative	B-PATH
+damage	I-PATH
+caused	O
+by	O
+free	O
+heme	B-CHED
+.	O
+
+Virus	B-COMP
+particles	I-COMP
+were	O
+at	O
+various	O
+stages	O
+of	O
+fusion	O
+at	O
+the	O
+cell	B-COMP
+surface	I-COMP
+,	O
+since	O
+entry	O
+was	O
+not	O
+a	O
+synchronised	O
+process	O
+.	O
+
+After	O
+entry	O
+(	O
+10	O
+and	O
+15	O
+min	O
+),	O
+spherical	O
+core	O
+particles	O
+moved	O
+into	O
+the	O
+cytoplasm	B-COMP
+within	O
+large	O
+vacuoles	B-COMP
+.	O
+
+Quite	O
+surprising	O
+at	O
+such	O
+early	O
+stages	O
+of	O
+infection	B-DISO
+(	O
+20	O
+min	O
+),	O
+a	O
+virus	B-SPEC
+-	O
+induced	O
+change	O
+in	O
+the	O
+infected	O
+cells	B-COMP
+was	O
+evident	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+analyzed	O
+temporal	O
+stability	O
+and	O
+geographic	O
+trends	O
+in	O
+cumulative	O
+case	O
+-	O
+fatality	O
+rates	O
+and	O
+average	O
+doubling	O
+times	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+He	O
+later	O
+developed	O
+a	O
+myocardial	B-DISO
+infarct	I-DISO
+and	O
+coagulopathy	B-DISO
+,	O
+and	O
+succumbed	O
+to	O
+his	O
+illness	O
+.	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+HLA	B-PRGE
+class	B-SPEC
+I	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+HLA	B-PRGE
+-	O
+class	B-SPEC
+I	O
+and	O
+II	O
+allele	O
+typing	O
+by	O
+PCR	O
+-	O
+SSOP	O
+was	O
+performed	O
+on	O
+37	O
+cases	O
+of	O
+probable	O
+SARS	B-DISO
+,	O
+28	O
+fever	B-PROC
+patients	O
+excluded	O
+later	O
+as	O
+probable	O
+SARS	B-DISO
+,	O
+and	O
+101	O
+non	O
+-	O
+infected	O
+health	O
+care	O
+workers	O
+who	O
+were	O
+exposed	O
+or	O
+possibly	O
+exposed	O
+to	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+After	O
+selecting	O
+only	O
+a	O
+""""	O
+severe	O
+cases	O
+""""	O
+patient	O
+group	O
+from	O
+the	O
+infected	O
+""""	O
+probable	O
+SARS	B-DISO
+""""	O
+patient	O
+group	O
+and	O
+comparing	O
+them	O
+with	O
+the	O
+high	O
+risk	O
+health	O
+care	O
+workers	O
+group	O
+,	O
+the	O
+severity	O
+of	O
+SARS	B-DISO
+was	O
+shown	O
+to	O
+be	O
+significantly	O
+associated	O
+with	O
+HLA	B-PRGE
+-	O
+B	O
+*	O
+4601	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0008	O
+or	O
+Pc	O
+=	O
+0	O
+.	O
+0279	O
+).	O
+
+Densely	O
+populated	O
+regions	O
+with	O
+genetically	O
+related	O
+southern	O
+Asian	O
+populations	O
+appear	O
+to	O
+be	O
+more	O
+affected	O
+by	O
+the	O
+spreading	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Enhanced	O
+virulence	B-PROC
+mediated	O
+by	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+JHM	O
+,	O
+is	O
+associated	O
+with	O
+a	O
+glycine	O
+at	O
+residue	O
+310	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+.	O
+
+One	O
+strain	O
+,	O
+JHM	O
+.	O
+SD	O
+,	O
+caused	O
+acute	O
+encephalitis	B-DISO
+,	O
+while	O
+infection	B-DISO
+with	O
+JHM	O
+.	O
+IA	O
+resulted	O
+in	O
+no	O
+acute	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+vitro	O
+studies	O
+revealed	O
+that	O
+S310G	O
+was	O
+associated	O
+with	O
+decreased	O
+S1	O
+-	O
+S2	O
+stability	O
+and	O
+with	O
+enhanced	O
+ability	O
+to	O
+mediate	O
+infection	B-DISO
+of	O
+cells	B-COMP
+lacking	O
+the	O
+primary	O
+receptor	O
+for	O
+JHM	O
+"("""	O
+receptor	O
+-	O
+independent	O
+spread	O
+""")."	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+expression	B-PROC
+,	O
+intracellular	B-PROC
+localization	I-PROC
+,	O
+and	O
+replication	O
+complex	O
+association	O
+of	O
+the	O
+putative	O
+mouse	O
+hepatitis	B-PRGE
+virus	I-PRGE
+RNA	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	B-PATH
+polymerase	I-PATH
+.	O
+
+TITLE	O
+:	O
+Multiple	O
+type	O
+A	O
+/	O
+B	O
+heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoproteins	I-PRGE
+(	O
+hnRNPs	O
+)	O
+can	O
+replace	O
+hnRNP	B-PRGE
+A1	I-PRGE
+in	O
+mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoprotein	I-PRGE
+(	O
+hnRNP	B-ANAT
+)	O
+A1	O
+has	O
+previously	O
+been	O
+shown	O
+to	O
+bind	B-FUNC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+RNA	O
+at	O
+the	O
+3	O
+'	O
+end	O
+of	O
+both	O
+plus	O
+and	O
+minus	O
+strands	O
+and	O
+modulate	O
+MHV	B-SPEC
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+set	O
+out	O
+to	O
+identify	O
+these	O
+proteins	B-CHED
+.	O
+
+UV	O
+cross	O
+-	O
+linking	O
+experiments	O
+revealed	O
+that	O
+several	O
+CB3	O
+cellular	B-COMP
+proteins	B-CHED
+similar	O
+in	O
+size	O
+to	O
+hnRNP	B-PRGE
+A1	I-PRGE
+interacted	O
+with	O
+the	O
+MHV	B-SPEC
+RNA	O
+.	O
+
+The	O
+major	O
+potential	O
+benefit	O
+from	O
+implementing	O
+these	O
+guidelines	O
+is	O
+improved	O
+clinical	O
+outcomes	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+(	O
+reduced	O
+mortality	O
+and	O
+ICU	O
+stay	O
+).	O
+
+The	O
+sensitive	O
+rate	O
+of	O
+imipenem	B-CHED
+,	O
+piperacillin	B-CHED
+/	O
+tazobactan	O
+was	O
+100	O
+.	O
+0	O
+percent	O
+,	O
+44	O
+.	O
+5	O
+percent	O
+,	O
+respectively	O
+.	O
+
+The	O
+states	O
+of	O
+dead	B-PROC
+patients	O
+were	O
+severe	O
+and	O
+the	O
+deterioration	O
+of	O
+patients	O
+'	O
+condition	B-DISO
+was	O
+rapid	O
+.	O
+
+The	O
+data	O
+of	O
+patients	O
+with	O
+acute	O
+renal	B-ANAT
+dysfunction	O
+hospitalized	O
+in	O
+ICU	O
+of	O
+Peking	O
+union	O
+medical	O
+college	O
+hospital	O
+during	O
+August	O
+1999	O
+to	O
+May	O
+2001	O
+were	O
+retrospectively	O
+investigated	O
+and	O
+the	O
+high	O
+risk	O
+factors	O
+related	O
+to	O
+hospital	O
+mortality	O
+were	O
+analyzed	O
+.	O
+
+Among	O
+1	O
+218	O
+critical	O
+patients	O
+hospitalized	O
+during	O
+August	O
+1999	O
+to	O
+May	O
+2001	O
+,	O
+there	O
+were	O
+149	O
+patients	O
+with	O
+acute	O
+renal	B-ANAT
+dysfunction	O
+.	O
+
+By	O
+multivariate	O
+analysis	O
+,	O
+only	O
+APACHEII	O
+score	O
+and	O
+management	O
+of	O
+noradrenaline	B-CHED
+and	O
+CVVH	O
+were	O
+determined	O
+as	O
+risk	O
+factors	O
+of	O
+hospital	O
+mortality	O
+independently	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+prognosis	O
+of	O
+critical	O
+patients	O
+with	O
+the	O
+acute	O
+renal	B-ANAT
+dysfunction	O
+correlate	O
+with	O
+degree	O
+of	O
+basic	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+recently	O
+recognized	O
+infectious	B-DISO
+disease	I-DISO
+associated	O
+with	O
+severe	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Preliminary	O
+result	O
+on	O
+the	O
+nosocomial	B-DISO
+infection	I-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+one	O
+hospital	O
+of	O
+Beijing	O
+].	O
+
+There	O
+was	O
+also	O
+a	O
+clue	O
+to	O
+the	O
+probability	O
+of	O
+aerosol	O
+or	O
+droplet	O
+nuclei	B-CHED
+infection	B-DISO
+through	O
+air	B-CHED
+-	O
+conditioning	O
+and	O
+ventilation	O
+system	O
+.	O
+
+There	O
+was	O
+also	O
+a	O
+clue	O
+to	O
+the	O
+probability	O
+of	O
+aerosol	O
+or	O
+droplet	O
+nuclei	B-CHED
+infection	B-DISO
+through	O
+air	B-CHED
+-	O
+conditioning	O
+and	O
+ventilation	O
+system	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+first	O
+imported	O
+SARS	B-DISO
+case	O
+introduced	O
+to	O
+Beijing	O
+had	O
+infected	O
+9	O
+people	O
+within	O
+the	O
+family	B-SPEC
+and	O
+at	O
+the	O
+hospital	O
+,	O
+with	O
+two	O
+of	O
+whom	O
+died	B-PROC
+of	O
+the	O
+same	O
+disease	O
+.	O
+
+The	O
+disease	O
+appeared	O
+to	O
+be	O
+sporadic	O
+but	O
+the	O
+case	O
+of	O
+outbreaks	O
+in	O
+family	B-SPEC
+or	O
+university	O
+only	O
+seen	O
+in	O
+three	O
+streets	O
+.	O
+
+The	O
+course	O
+of	O
+SARS	B-DISO
+epidemic	O
+in	O
+this	O
+district	O
+could	O
+be	O
+divided	O
+into	O
+three	O
+phases	O
+:	O
+initial	O
+-	O
+which	O
+last	O
+for	O
+days	O
+,	O
+peak	O
+-	O
+21	O
+days	O
+and	O
+then	O
+rapid	O
+decline	O
+-	O
+for	O
+26	O
+days	O
+.	O
+
+RESULTS	O
+:	O
+From	O
+April	O
+13	O
+through	O
+May	O
+8	O
+,	O
+2003	O
+,	O
+there	O
+were	O
+175	O
+SARS	B-DISO
+cases	O
+including	O
+imported	O
+ones	O
+,	O
+were	O
+identified	O
+with	O
+an	O
+incidence	O
+rate	O
+of	O
+1	O
+.	O
+9	O
+cases	O
+per	O
+100	O
+,	O
+000	O
+.	O
+
+Here	O
+we	O
+report	O
+2	O
+well	O
+-	O
+documented	O
+cases	O
+of	O
+pneumonia	B-DISO
+related	O
+to	O
+coronavirus	B-SPEC
+229E	O
+,	O
+each	O
+with	O
+a	O
+different	O
+clinical	O
+presentation	O
+.	O
+
+Bad	B-PRGE
+prognosis	I-PRGE
+factors	I-PRGE
+were	O
+identified	O
+:	O
+severe	O
+state	O
+on	O
+admission	O
+,	O
+shock	O
+on	O
+admission	O
+or	O
+subsequently	O
+,	O
+non	O
+adapted	O
+initial	O
+antibiotherapy	O
+,	O
+Child	O
+'	O
+s	O
+score	O
+B	O
+and	O
+C	O
+,	O
+Streptococus	O
+pneumoniae	O
+,	O
+complications	O
+:	O
+ARDS	B-DISO
+,	O
+superinfections	B-DISO
+,	O
+coagulopathy	B-DISO
+,	O
+multi	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+4	O
+-	O
+substituted	O
+anilino	B-CHED
+and	O
+4	O
+-	O
+substituted	O
+phenoxymethyl	O
+pyrrolo	O
+[	O
+1	O
+,	O
+2	O
+-	O
+a	O
+]	O
+quinoxalines	O
+and	O
+N	O
+-[	O
+4	O
+-(	O
+pyrrolo	O
+[	O
+1	O
+,	O
+2	O
+-	O
+a	O
+]	O
+quinoxalin	O
+-	O
+4	O
+-	O
+yl	O
+)	O
+amino	O
+and	O
+hydroxymethyl	B-CHED
+]	O
+benzoyl	B-CHED
+glutamates	O
+.	O
+
+However	O
+,	O
+one	O
+strain	O
+was	O
+unusual	O
+in	O
+that	O
+it	O
+infected	O
+the	O
+majority	O
+of	O
+cats	B-SPEC
+in	O
+the	O
+household	O
+simultaneously	O
+and	O
+was	O
+still	O
+being	O
+shed	O
+18	O
+months	O
+later	O
+.	O
+
+TITLE	O
+:	O
+Cloaked	O
+similarity	O
+between	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+suggests	O
+an	O
+anti	O
+-	O
+SARS	B-DISO
+strategy	O
+.	O
+
+RESULTS	O
+:	O
+Sequence	O
+analysis	O
+reveals	O
+that	O
+the	O
+two	O
+viral	O
+proteins	B-CHED
+share	O
+the	O
+sequence	O
+motifs	O
+that	O
+construct	O
+their	O
+active	O
+conformation	O
+.	O
+
+The	O
+exact	O
+origin	O
+of	O
+the	O
+cause	O
+of	O
+the	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+still	O
+an	O
+open	O
+question	O
+.	O
+
+The	O
+congruence	O
+of	O
+the	O
+relationship	O
+outcomes	O
+with	O
+the	O
+known	O
+classification	O
+indicates	O
+that	O
+there	O
+exist	O
+phylogenetic	O
+signals	O
+in	O
+the	O
+tetra	B-CHED
+-	O
+nucleotide	B-CHED
+usage	O
+patterns	O
+,	O
+that	O
+is	O
+most	O
+prominent	O
+in	O
+the	O
+replicase	B-PRGE
+open	O
+reading	O
+frames	O
+.	O
+
+ABSTRACT	O
+:	O
+Adeno	B-SPEC
+-	I-SPEC
+associated	I-SPEC
+virus	I-SPEC
+(	O
+AAV	O
+)	O
+vectors	O
+are	O
+capable	O
+of	O
+delivering	O
+a	O
+therapeutic	O
+gene	O
+to	O
+the	O
+mouse	B-ANAT
+brain	I-ANAT
+that	O
+can	O
+result	O
+in	O
+long	O
+-	O
+term	O
+and	O
+widespread	O
+protein	B-CHED
+production	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+observation	O
+on	O
+treatment	O
+of	O
+40	O
+SARS	B-DISO
+uncertain	O
+patients	O
+with	O
+integrative	O
+traditional	O
+Chinese	O
+and	O
+Western	O
+medicine	O
+].	O
+
+Myocardial	O
+performance	O
+may	O
+be	O
+impaired	B-DISO
+in	O
+cytokine	O
+-	O
+mediated	O
+immune	O
+reactions	O
+.	O
+
+No	O
+significant	O
+valvular	O
+disease	O
+or	O
+pulmonary	B-DISO
+hypertension	I-DISO
+was	O
+found	O
+.	O
+
+These	O
+would	O
+include	O
+SARS	B-DISO
+peptides	B-CHED
+,	O
+adjuvants	B-CHED
+,	O
+DNA	O
+vaccine	O
+vectors	O
+and	O
+clinical	O
+grade	O
+viral	O
+vectors	O
+.	O
+
+TITLE	O
+:	O
+Lung	B-ANAT
+pathology	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+):	O
+a	O
+study	O
+of	O
+8	O
+autopsy	O
+cases	O
+from	O
+Singapore	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+infectious	B-DISO
+condition	B-DISO
+caused	O
+by	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+a	O
+new	O
+member	O
+in	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+.	O
+
+To	O
+evaluate	O
+the	O
+lung	B-ANAT
+pathology	B-DISO
+in	O
+this	O
+life	O
+-	O
+threatening	O
+respiratory	O
+illness	O
+,	O
+we	O
+studied	O
+postmortem	O
+lung	B-ANAT
+sections	O
+from	O
+8	O
+patients	O
+who	O
+died	B-PROC
+from	O
+SARS	B-DISO
+during	O
+the	O
+spring	O
+2003	O
+Singapore	O
+outbreak	O
+.	O
+
+Multinucleated	O
+cells	B-COMP
+were	O
+shown	O
+to	O
+be	O
+both	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+and	O
+macrophages	B-ANAT
+by	O
+pancytokeratin	O
+,	O
+thyroid	B-PRGE
+transcription	B-PROC
+factor	I-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+and	O
+CD68	B-PRGE
+staining	O
+.	O
+
+Understanding	O
+the	O
+pathology	B-DISO
+of	O
+DAD	O
+in	O
+SARS	B-DISO
+patients	O
+may	O
+provide	O
+the	O
+basis	O
+for	O
+therapeutic	O
+strategies	O
+.	O
+
+Anatomicopathological	O
+,	O
+microbiological	O
+and	O
+serological	O
+examinations	O
+were	O
+carried	O
+out	O
+on	O
+birds	B-SPEC
+derived	O
+from	O
+26	O
+pheasantries	O
+,	O
+including	O
+birds	B-SPEC
+randomly	O
+selected	O
+from	O
+18	O
+flocks	O
+and	O
+sick	O
+or	O
+dead	B-PROC
+birds	B-SPEC
+sent	O
+from	O
+8	O
+pheasantries	O
+.	O
+
+Marble	B-DISO
+spleen	I-DISO
+disease	I-DISO
+and	O
+salmonellosis	B-DISO
+proved	O
+to	O
+be	O
+the	O
+most	O
+frequent	O
+cause	O
+of	O
+death	B-PROC
+during	O
+the	O
+growing	O
+period	O
+.	O
+
+Rather	O
+,	O
+twelve	O
+nucleobases	O
+forming	O
+six	O
+base	B-FUNC
+pairs	I-FUNC
+joined	O
+by	O
+mutually	O
+exclusive	O
+hydrogen	B-CHED
+bonding	O
+patterns	O
+are	O
+possible	O
+within	O
+the	O
+geometry	O
+of	O
+the	O
+Watson	O
+-	O
+Crick	O
+pair	O
+(	O
+Fig	O
+.	O
+1	O
+).	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+the	O
+artificial	O
+genetic	O
+information	O
+systems	O
+(	O
+AEGIS	O
+)	O
+that	O
+we	O
+have	O
+developed	O
+have	O
+been	O
+used	O
+in	O
+FDA	O
+-	O
+approved	O
+commercial	O
+tests	O
+for	O
+managing	O
+HIV	B-DISO
+and	O
+hepatitis	B-PATH
+C	I-PATH
+infections	B-DISO
+in	O
+individual	O
+patients	O
+,	O
+and	O
+in	O
+a	O
+tool	O
+that	O
+seeks	O
+the	O
+virus	B-SPEC
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+An	O
+indirect	O
+search	O
+for	O
+a	O
+protein	B-CHED
+structure	O
+to	O
+be	O
+used	O
+as	O
+a	O
+template	O
+for	O
+3D	O
+modelling	O
+has	O
+been	O
+performed	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+genomic	O
+organisation	B-PROC
+similarity	O
+generally	O
+exhibited	O
+by	O
+coronaviruses	O
+.	O
+
+The	O
+overall	O
+shape	O
+and	O
+the	O
+surface	O
+hydrophobicity	O
+of	O
+the	O
+two	O
+subunits	O
+in	O
+the	O
+obtained	O
+models	O
+suggest	O
+the	O
+localisation	B-PROC
+of	O
+the	O
+most	O
+relevant	O
+regions	O
+for	O
+their	O
+activity	O
+.	O
+
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+is	O
+spread	O
+by	O
+multiple	O
+mechanisms	O
+,	O
+including	O
+direct	O
+contact	O
+and	O
+large	O
+-	O
+droplet	O
+aerosolization	O
+,	O
+and	O
+may	O
+be	O
+spread	O
+by	O
+droplet	O
+nuclei	B-CHED
+as	O
+well	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Dynamic	O
+changes	O
+of	O
+plasma	B-ANAT
+cytokine	O
+levels	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+TNF	B-PRGE
+alpha	I-PRGE
+probably	O
+play	O
+important	O
+roles	O
+in	O
+mediating	O
+strong	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+which	O
+are	O
+thought	O
+to	O
+be	O
+responsible	O
+for	O
+lung	B-ANAT
+injury	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Enteric	O
+involvement	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Intestinal	B-ANAT
+specimens	O
+were	O
+obtained	O
+by	O
+colonoscopy	O
+or	O
+postmortem	O
+examination	O
+to	O
+detect	O
+the	O
+presence	O
+of	O
+coronavirus	B-SPEC
+by	O
+electron	O
+microscopy	O
+,	O
+virus	B-SPEC
+culture	O
+,	O
+and	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+The	O
+mean	O
+number	O
+of	O
+days	O
+with	O
+diarrhea	B-DISO
+was	O
+3	O
+.	O
+7	O
++/-	O
+
+Diarrhea	B-DISO
+is	O
+a	O
+common	O
+presenting	O
+symptom	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+need	O
+for	O
+an	O
+outbreak	O
+response	O
+unit	O
+is	O
+crucial	O
+to	O
+combat	B-CHED
+any	O
+future	O
+outbreak	O
+.	O
+
+Using	O
+this	O
+combination	O
+approach	O
+,	O
+we	O
+found	O
+that	O
+human	B-SPEC
+laryngeal	B-DISO
+carcinoma	I-DISO
+(	O
+HEp	B-DISO
+-	O
+2	O
+)	O
+cells	B-COMP
+were	O
+superior	O
+to	O
+rhesus	B-SPEC
+monkey	I-SPEC
+kidney	B-ANAT
+(	O
+LLC	B-COMP
+-	O
+MK2	O
+)	O
+cells	B-COMP
+commonly	O
+used	O
+in	O
+previous	O
+studies	O
+for	O
+isolation	O
+of	O
+HMPV	B-SPEC
+.	O
+
+All	O
+patients	O
+,	O
+except	O
+two	O
+,	O
+received	O
+ribavirin	B-CHED
+and	O
+steroid	B-CHED
+combination	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+analysis	O
+of	O
+pregnancy	O
+in	O
+second	O
+and	O
+third	O
+trimesters	O
+complicated	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+and	O
+analyze	O
+the	O
+clinical	O
+manifestation	O
+,	O
+diagnosis	O
+,	O
+management	O
+and	O
+maternal	O
+-	O
+perinatal	O
+prognosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+complicated	B-DISO
+pregnancy	I-DISO
+in	O
+second	O
+and	O
+third	O
+trimesters	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+diagnosis	O
+of	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+by	O
+real	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Evaluate	O
+whether	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+infect	O
+and	O
+replicate	O
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+)	O
+of	O
+infected	O
+persons	O
+and	O
+reveal	O
+any	O
+dynamic	O
+changes	O
+to	O
+the	O
+virus	B-SPEC
+during	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+.	O
+
+Peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+collected	O
+from	O
+SARS	B-DISO
+cases	O
+infected	O
+by	O
+the	O
+same	O
+infectious	B-DISO
+source	O
+were	O
+tested	O
+for	O
+both	O
+negative	O
+-	O
+stranded	O
+RNA	O
+(	O
+minus	O
+-	O
+RNA	O
+,	O
+""""	O
+replicative	O
+intermediates	O
+""")"	O
+and	O
+positive	O
+-	O
+stranded	O
+RNA	O
+(	O
+genomic	O
+RNA	O
+)	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+during	O
+the	O
+course	O
+of	O
+hospitalization	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+Comparison	O
+of	O
+phylogenetic	O
+trees	O
+for	O
+11	O
+known	O
+host	B-COMP
+-	O
+species	B-SPEC
+and	O
+36	O
+coronaviruses	O
+,	O
+representing	O
+coronavirus	B-SPEC
+groups	O
+1	O
+-	O
+3	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+based	O
+on	O
+N	O
+showed	O
+statistical	O
+incongruence	O
+indicating	O
+multiple	O
+host	B-COMP
+-	O
+species	B-SPEC
+shifts	O
+for	O
+coronaviruses	O
+.	O
+
+Five	O
+days	O
+later	O
+,	O
+Escherichia	B-SPEC
+coli	I-SPEC
+506	O
+strain	O
+was	O
+given	O
+intratracheally	O
+(	O
+5	O
+.	O
+6	O
+to	O
+8	O
+.	O
+8	O
+log	O
+(	O
+10	O
+)	O
+colony	O
+forming	O
+units	O
+/	O
+broiler	O
+).	O
+
+A	O
+systematic	O
+search	O
+for	O
+perinatal	O
+transmission	O
+of	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+,	O
+including	O
+serial	B-PRGE
+reverse	I-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+assays	O
+,	O
+viral	O
+cultures	O
+,	O
+and	O
+paired	O
+serologic	O
+titers	O
+,	O
+failed	O
+to	O
+detect	O
+the	O
+virus	B-SPEC
+in	O
+any	O
+of	O
+the	O
+infants	O
+.	O
+
+One	O
+preterm	O
+infant	O
+developed	O
+jejunal	B-ANAT
+perforation	O
+and	O
+another	O
+developed	O
+necrotizing	B-DISO
+enterocolitis	I-DISO
+with	O
+ileal	B-ANAT
+perforation	O
+shortly	O
+after	O
+birth	B-PROC
+.	O
+
+The	O
+exposure	O
+consisted	O
+of	O
+direct	O
+contact	O
+with	O
+at	O
+least	O
+1	O
+adult	O
+probable	O
+SARS	B-DISO
+case	O
+in	O
+11	O
+children	O
+,	O
+travel	O
+from	O
+a	O
+World	O
+Health	O
+Organization	O
+-	O
+designated	O
+affected	O
+area	O
+in	O
+Asia	O
+in	O
+9	O
+children	O
+,	O
+and	O
+presence	O
+in	O
+a	O
+Toronto	O
+area	O
+hospital	O
+in	O
+which	O
+secondary	O
+SARS	B-DISO
+spread	O
+had	O
+occurred	O
+in	O
+5	O
+children	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swab	I-ANAT
+specimens	O
+were	O
+negative	O
+for	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+by	O
+an	O
+in	O
+-	O
+house	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+in	O
+all	O
+25	O
+children	O
+.	O
+
+To	O
+the	O
+authors	O
+'	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+experimental	O
+evidence	O
+that	O
+MHV	B-SPEC
+transmission	O
+can	O
+occur	O
+for	O
+several	O
+months	O
+,	O
+from	O
+persistently	O
+infected	O
+mice	B-SPEC
+to	O
+sentinel	O
+mice	B-SPEC
+,	O
+over	O
+a	O
+short	O
+-	O
+term	O
+exposure	O
+period	O
+.	O
+
+Heart	B-ANAT
+rate	O
+,	O
+oxygen	B-CHED
+saturation	O
+,	O
+temperature	O
+,	O
+and	O
+alanine	B-PRGE
+aminotransferase	I-PRGE
+(	O
+ALT	B-FUNC
+)	O
+and	O
+aspartate	B-PRGE
+aminotransferase	I-PRGE
+(	O
+AST	B-PRGE
+)	O
+levels	O
+were	O
+recorded	O
+daily	O
+.	O
+
+Serum	B-COMP
+levels	O
+of	O
+ILs	B-DISO
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+TGF	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+1	I-PRGE
+were	O
+measured	O
+in	O
+all	O
+subjects	O
+.	O
+
+Concurrently	O
+,	O
+the	O
+mean	O
+concentration	O
+of	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+13	I-FUNC
+decreased	O
+gradually	O
+,	O
+and	O
+the	O
+mean	O
+concentration	O
+of	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+level	O
+in	O
+SARS	B-DISO
+patients	O
+was	O
+lower	O
+than	O
+that	O
+of	O
+the	O
+control	O
+group	O
+during	O
+all	O
+the	O
+courses	O
+of	O
+SARS	B-DISO
+,	O
+suggesting	O
+that	O
+the	O
+immune	O
+state	O
+of	O
+the	O
+patients	O
+with	O
+SARS	B-DISO
+was	O
+obviously	O
+abnormal	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+genotype	O
+and	O
+its	O
+characteristics	O
+.	O
+
+It	O
+was	O
+interesting	O
+to	O
+find	O
+that	O
+two	O
+(	O
+A	O
+/	O
+G	O
+and	O
+C	O
+/	O
+T	O
+)	O
+of	O
+the	O
+five	O
+mutation	O
+loci	O
+occurred	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+,	O
+which	O
+caused	O
+changes	O
+of	O
+Asp	B-CHED
+to	O
+Gly	B-CHED
+and	O
+Thr	B-CHED
+to	O
+Ile	B-CHED
+in	O
+the	O
+protein	B-CHED
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Ventilation	O
+of	O
+wards	O
+and	O
+nosocomial	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+among	O
+healthcare	O
+workers	O
+.	O
+
+RESULTS	O
+:	O
+Four	O
+types	O
+of	O
+isolation	O
+wards	O
+were	O
+analyzed	O
+,	O
+including	O
+the	O
+ward	O
+where	O
+the	O
+thirty	O
+-	O
+first	O
+bed	B-DISO
+was	O
+located	O
+on	O
+the	O
+twelfth	O
+floor	O
+,	O
+the	O
+laminar	O
+flow	O
+ward	O
+in	O
+the	O
+Intensive	O
+Care	O
+Unit	O
+where	O
+the	O
+tenth	O
+bed	B-DISO
+was	O
+located	O
+on	O
+the	O
+fifteenth	O
+floor	O
+,	O
+the	O
+ward	O
+where	O
+the	O
+twenty	O
+-	O
+seventh	O
+bed	B-DISO
+was	O
+located	O
+on	O
+the	O
+thirteenth	O
+floor	O
+of	O
+the	O
+Lingnan	O
+Building	O
+,	O
+and	O
+thirty	O
+wards	O
+on	O
+the	O
+fourteenth	O
+to	O
+eighteenth	O
+floors	O
+of	O
+the	O
+Zhongshan	O
+Building	O
+.	O
+
+The	O
+infection	B-DISO
+rates	O
+of	O
+the	O
+healthcare	O
+workers	O
+in	O
+the	O
+areas	O
+mentioned	O
+above	O
+were	O
+73	O
+.	O
+2	O
+%,	O
+32	O
+.	O
+1	O
+%,	O
+27	O
+.	O
+5	O
+%	O
+and	O
+1	O
+.	O
+7	O
+%,	O
+respectively	O
+.	O
+
+The	O
+difference	O
+in	O
+the	O
+infection	B-DISO
+rates	O
+was	O
+of	O
+statistical	O
+significance	O
+.	O
+
+Air	B-CHED
+oxidation	B-PROC
+subsequently	O
+forms	O
+BN	O
+in	O
+the	O
+heat	O
+which	O
+immediately	O
+yields	O
+orange	O
+-	O
+yellow	O
+(	O
+4	O
+'	O
+RS	O
+)-	O
+4	O
+'-	O
+chloro	B-CHED
+-	O
+1	O
+',	O
+4	O
+'-	O
+dihydrobananin	O
+by	O
+1	O
+,	O
+4	O
+-	O
+addition	O
+of	O
+hydrogen	B-CHED
+chloride	I-CHED
+.	O
+
+This	O
+article	O
+attempts	O
+to	O
+summarize	O
+some	O
+of	O
+the	O
+recent	O
+developments	O
+in	O
+this	O
+newly	O
+recognized	O
+condition	B-DISO
+from	O
+the	O
+Asia	O
+Pacific	O
+perspective	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+outbreaks	O
+,	O
+hospital	O
+workers	O
+are	O
+at	O
+high	O
+risk	O
+for	O
+nosocomial	O
+infection	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+lessons	O
+of	O
+SARS	B-DISO
+.	O
+
+Third	O
+,	O
+despite	O
+trends	O
+toward	O
+commercialization	O
+,	O
+easier	O
+lives	O
+,	O
+and	O
+self	O
+-	O
+centered	O
+individualism	O
+,	O
+the	O
+response	O
+of	O
+health	O
+care	O
+professionals	O
+to	O
+SARS	B-DISO
+reaffirmed	O
+dedication	O
+to	O
+caring	O
+for	O
+the	O
+sick	O
+even	O
+at	O
+great	O
+personal	O
+risks	O
+as	O
+the	O
+core	O
+ethical	O
+principle	O
+of	O
+medicine	O
+.	O
+
+CONCLUSIONS	O
+:	O
+NIP3L	B-PRGE
+may	O
+be	O
+involved	O
+in	O
+lung	B-ANAT
+injury	O
+,	O
+which	O
+is	O
+one	O
+of	O
+the	O
+major	O
+causes	O
+of	O
+death	B-PROC
+in	O
+cases	O
+of	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Molecular	O
+modeling	O
+and	O
+simulation	O
+have	O
+confirmed	O
+8	O
+caveolin	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+sites	I-PRGE
+.	O
+
+Caveolin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+may	O
+serve	O
+as	O
+a	O
+possible	O
+receptor	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+,	O
+which	O
+may	O
+be	O
+associated	O
+with	O
+the	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+replication	O
+,	O
+assembly	O
+,	O
+and	O
+budding	O
+.	O
+
+RESULTS	O
+:	O
+Thirty	O
+six	O
+caveolin	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+motifs	I-PRGE
+in	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+have	O
+been	O
+mapped	O
+out	O
+using	O
+bioinformatics	O
+analysis	O
+tools	O
+.	O
+
+Her	O
+electrocardiographic	O
+changes	O
+were	O
+consistent	O
+with	O
+a	O
+diagnosis	O
+of	O
+anteroseptal	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+.	O
+
+However	O
+,	O
+angiography	O
+showed	O
+normal	O
+coronary	B-ANAT
+arteries	I-ANAT
+.	O
+
+Peripheral	O
+eosinophilia	B-DISO
+was	O
+detected	O
+.	O
+
+Eight	O
+months	O
+after	O
+her	O
+original	O
+presentation	O
+,	O
+she	O
+developed	O
+urticarial	B-DISO
+lesions	O
+on	O
+her	O
+abdomen	B-ANAT
+and	O
+legs	B-ANAT
+,	O
+with	O
+muscle	B-DISO
+soreness	I-DISO
+but	O
+no	O
+other	O
+associated	B-DISO
+symptoms	I-DISO
+.	O
+
+After	O
+the	O
+diagnosis	O
+of	O
+Churg	B-DISO
+-	I-DISO
+Strauss	I-DISO
+syndrome	I-DISO
+,	O
+the	O
+patient	O
+remained	O
+symptom	B-DISO
+free	O
+with	O
+a	O
+normal	O
+ejection	O
+fraction	O
+for	O
+15	O
+months	O
+while	O
+taking	O
+prednisone	B-CHED
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+in	O
+the	O
+69	O
+followed	O
+-	O
+up	O
+patients	O
+,	O
+impairment	B-DISO
+of	O
+the	O
+hepatic	B-PROC
+function	I-PROC
+was	O
+found	O
+in	O
+5	O
+cases	O
+,	O
+hypoimmune	O
+state	O
+in	O
+18	O
+,	O
+impediment	O
+of	O
+ventilation	O
+in	O
+the	O
+distal	O
+air	B-CHED
+passages	O
+with	O
+normal	O
+major	O
+air	B-CHED
+passages	O
+in	O
+15	O
+,	O
+increased	O
+residual	O
+volume	O
+in	O
+40	O
+,	O
+mild	O
+disturbance	O
+of	O
+pulmonary	B-PROC
+diffusion	I-PROC
+function	O
+in	O
+14	O
+,	O
+incomplete	O
+absorption	O
+of	O
+inflammatory	O
+exudates	B-ANAT
+,	O
+focal	O
+or	O
+multiple	O
+interstitial	B-ANAT
+lesions	O
+,	O
+pulmonary	B-ANAT
+interstitial	B-ANAT
+fibrosis	I-DISO
+and	O
+pleural	B-DISO
+adhesion	I-DISO
+in	O
+24	O
+;	O
+increased	O
+resistance	B-PROC
+or	O
+mild	O
+systolic	B-DISO
+hypertension	I-DISO
+in	O
+the	O
+pulmonary	B-PROC
+circulation	B-PROC
+,	O
+and	O
+segmental	O
+ischemia	B-DISO
+of	O
+the	O
+left	O
+myocardium	B-ANAT
+in	O
+34	O
+;	O
+and	O
+decreased	O
+visual	O
+acuity	O
+in	O
+2	O
+.	O
+
+Noninvasive	O
+ventilation	O
+should	O
+be	O
+used	O
+as	O
+a	O
+substitutive	O
+tool	O
+for	O
+endotracheal	O
+intubation	O
+an	O
+alternative	O
+treatment	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+related	O
+to	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Although	O
+NIPPV	O
+administered	O
+via	O
+full	O
+-	O
+face	B-DISO
+masks	O
+might	O
+be	O
+an	O
+effective	O
+treatment	O
+for	O
+rapidly	O
+improving	O
+vital	O
+signs	O
+and	O
+gas	B-ENZY
+exchange	O
+and	O
+sense	B-PROC
+of	O
+dyspnea	B-DISO
+in	O
+both	O
+groups	O
+during	O
+the	O
+initial	O
+24	O
+hours	O
+of	O
+ventilatory	O
+support	O
+,	O
+the	O
+patients	O
+in	O
+non	O
+-	O
+survivor	O
+group	O
+had	O
+higher	O
+APACHEII	O
+score	O
+,	O
+respiratory	O
+rates	O
+and	O
+lower	O
+SpO	O
+(	O
+2	O
+),	O
+MRI	O
+than	O
+the	O
+patients	O
+in	O
+survivor	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+at	O
+the	O
+same	O
+intervals	O
+after	O
+initiation	O
+of	O
+support	O
+.	O
+
+Expression	B-PROC
+levels	O
+increased	O
+when	O
+the	O
+luciferase	B-PRGE
+gene	I-PRGE
+was	O
+inserted	O
+closer	O
+to	O
+the	O
+3	O
+'	O
+end	O
+of	O
+the	O
+genome	O
+.	O
+
+Virus	B-SPEC
+binding	B-FUNC
+assays	O
+with	O
+cryosections	O
+of	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+from	O
+a	O
+suckling	O
+piglet	O
+revealed	O
+the	O
+binding	B-FUNC
+of	O
+TGEV	B-SPEC
+to	O
+mucin	B-PRGE
+-	O
+producing	O
+goblet	B-ANAT
+cells	I-ANAT
+.	O
+
+Indirect	O
+immunofluorescent	O
+assay	O
+and	O
+double	O
+-	O
+antigen	B-CHED
+sandwich	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+were	O
+used	O
+to	O
+detect	O
+the	O
+virus	B-SPEC
+-	O
+specific	O
+antibodies	B-COMP
+in	O
+sera	B-COMP
+of	O
+1	O
+,	O
+060	O
+non	O
+-	O
+SARS	B-DISO
+children	O
+in	O
+Guangzhou	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+the	O
+serum	B-COMP
+samples	O
+from	O
+the	O
+1	O
+,	O
+060	O
+non	O
+-	O
+SARS	B-DISO
+children	O
+were	O
+negative	O
+for	O
+both	O
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+as	O
+determined	O
+by	O
+indirect	O
+immunofluorescent	O
+assay	O
+,	O
+with	O
+only	O
+two	O
+serum	O
+samples	O
+showing	O
+weak	O
+positivity	O
+for	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+-	I-PRGE
+specific	I-PRGE
+antibodies	B-COMP
+identified	O
+by	O
+double	O
+-	O
+antigen	B-CHED
+sandwich	O
+ELISA	O
+.	O
+
+The	O
+two	O
+peptides	B-CHED
+corresponding	O
+to	O
+the	O
+two	O
+self	O
+-	O
+cleavage	B-PROC
+sites	O
+are	O
+the	O
+two	O
+with	O
+highest	O
+cleavage	B-PROC
+efficiency	O
+,	O
+whereas	O
+peptides	B-CHED
+with	O
+non	O
+-	O
+canonical	O
+residues	O
+at	O
+P2	O
+or	O
+P1	O
+'	O
+positions	O
+react	O
+slower	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+was	O
+identified	O
+in	O
+2003	O
+as	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+a	O
+member	O
+of	O
+the	O
+coronavirus	B-SPEC
+family	B-SPEC
+not	O
+observed	O
+previously	O
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Media	B-ANAT
+portrayal	O
+of	O
+nurses	O
+'	O
+perspectives	O
+and	O
+concerns	O
+in	O
+the	O
+SARS	B-DISO
+crisis	O
+in	O
+Toronto	O
+.	O
+
+One	O
+-	O
+day	O
+-	O
+old	O
+turkey	B-SPEC
+poults	O
+developed	O
+diarrhea	B-DISO
+at	O
+48	O
+hr	O
+postinoculation	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+,	O
+unlike	O
+the	O
+mammalian	B-SPEC
+coronaviruses	O
+,	O
+propensity	O
+for	O
+frequent	O
+genetic	B-DISO
+change	I-DISO
+may	O
+not	O
+be	O
+inherent	O
+in	O
+the	O
+IBV	B-SPEC
+genome	O
+.	O
+
+Because	O
+of	O
+the	O
+widespread	O
+nature	O
+of	O
+the	O
+GA98	O
+virus	B-SPEC
+in	O
+the	O
+southeastern	O
+United	O
+States	O
+and	O
+the	O
+lack	O
+of	O
+adequate	O
+protection	O
+with	O
+the	O
+DE072	O
+vaccine	O
+,	O
+we	O
+developed	O
+a	O
+specific	O
+vaccine	O
+for	O
+the	O
+GA98	O
+serotype	O
+.	O
+
+Routine	O
+typing	O
+of	O
+vaccine	O
+strains	O
+of	O
+IBV	B-SPEC
+was	O
+possible	O
+with	O
+this	O
+technology	O
+,	O
+but	O
+high	O
+standard	O
+deviations	O
+associated	O
+with	O
+the	O
+melting	O
+curve	O
+analysis	O
+of	O
+the	O
+FRET	O
+probes	O
+described	O
+herein	O
+made	O
+it	O
+difficult	O
+to	O
+use	O
+this	O
+test	O
+reliably	O
+for	O
+routine	O
+typing	O
+of	O
+IBV	B-SPEC
+field	O
+isolates	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+global	O
+initiatives	O
+for	O
+disease	O
+diagnosis	O
+.	O
+
+With	O
+high	O
+morbidity	O
+and	O
+mortality	O
+,	O
+SARS	B-DISO
+is	O
+an	O
+important	O
+respiratory	B-DISO
+disease	I-DISO
+which	O
+may	O
+be	O
+encountered	O
+world	O
+-	O
+wide	O
+.	O
+
+For	O
+the	O
+respiratory	O
+physician	O
+,	O
+detecting	O
+SARS	B-DISO
+in	O
+its	O
+earliest	O
+stages	O
+,	O
+identifying	O
+pathways	B-PROC
+of	O
+transmission	O
+,	O
+and	O
+implementing	O
+preventive	O
+and	O
+therapeutic	O
+strategies	O
+are	O
+all	O
+important	O
+.	O
+
+Past	O
+or	O
+current	O
+infection	B-DISO
+was	O
+evaluated	O
+.	O
+
+Serology	O
+indicated	O
+the	O
+infecting	O
+virus	B-SPEC
+was	O
+most	O
+closely	O
+related	O
+to	O
+type	B-PRGE
+I	I-PRGE
+FCoV	I-PRGE
+.	O
+Antibody	B-COMP
+levels	O
+in	O
+the	O
+majority	O
+of	O
+animals	B-SPEC
+were	O
+low	O
+,	O
+even	O
+in	O
+those	O
+actively	O
+infected	O
+.	O
+
+TITLE	O
+:	O
+A	O
+serologic	O
+survey	O
+of	O
+wild	O
+felids	B-SPEC
+from	O
+central	O
+west	O
+Saudi	O
+Arabia	O
+.	O
+
+Within	O
+a	O
+few	O
+weeks	O
+,	O
+the	O
+coronavirus	B-SPEC
+associated	O
+with	O
+SARS	B-DISO
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+was	O
+identified	O
+and	O
+sequenced	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Nursing	B-PROC
+patients	O
+with	O
+SARS	B-DISO
+was	O
+challenging	O
+as	O
+the	O
+disease	O
+was	O
+highly	O
+contagious	O
+and	O
+potentially	O
+lethal	O
+,	O
+and	O
+not	O
+much	O
+was	O
+known	O
+about	O
+this	O
+disease	O
+.	O
+
+In	O
+patients	O
+without	O
+a	O
+history	O
+of	O
+close	O
+contact	O
+with	O
+SARS	B-DISO
+cases	O
+,	O
+antibiotic	B-CHED
+effect	O
+was	O
+a	O
+major	O
+factor	O
+influencing	O
+doctors	O
+'	O
+diagnosis	O
+.	O
+
+In	O
+patients	O
+without	O
+a	O
+history	O
+of	O
+close	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+,	O
+all	O
+the	O
+five	O
+criteria	O
+were	O
+met	B-CHED
+after	O
+combination	O
+antibiotic	B-CHED
+therapy	O
+had	O
+failed	O
+.	O
+
+TITLE	O
+:	O
+Experiencing	O
+SARS	B-DISO
+:	O
+perspectives	O
+of	O
+the	O
+elderly	O
+residents	O
+and	O
+health	O
+care	O
+professionals	O
+in	O
+a	O
+Hong	O
+Kong	O
+nursing	O
+home	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+has	O
+affected	O
+many	O
+areas	O
+of	O
+the	O
+world	O
+recently	O
+and	O
+is	O
+becoming	O
+a	O
+global	O
+problem	O
+.	O
+
+(	O
+1	O
+)	O
+The	O
+time	O
+for	O
+improving	O
+symptom	B-DISO
+in	O
+the	O
+ICWM	O
+group	O
+was	O
+5	O
+.	O
+10	O
+days	O
+and	O
+that	O
+in	O
+the	O
+control	O
+group	O
+was	O
+7	O
+.	O
+62	O
+days	O
+,	O
+the	O
+difference	O
+between	O
+them	O
+was	O
+significant	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+);	O
+(	O
+2	O
+)	O
+The	O
+days	O
+and	O
+amount	O
+for	O
+use	O
+hormone	B-CHED
+before	O
+subtract	O
+in	O
+the	O
+two	O
+group	O
+were	O
+similar	O
+,	O
+with	O
+insignificant	O
+difference	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+);	O
+(	O
+3	O
+)	O
+The	O
+days	O
+and	O
+amount	O
+for	O
+use	O
+hormone	O
+after	O
+subtract	O
+in	O
+the	O
+two	O
+groups	O
+were	O
+significantly	O
+different	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+);	O
+(	O
+4	O
+)	O
+The	O
+time	O
+for	O
+improving	O
+peripheral	O
+WBC	B-ANAT
+count	O
+and	O
+absolute	O
+value	O
+of	O
+lymphocyte	B-ANAT
+,	O
+as	O
+well	O
+as	O
+for	O
+absorption	O
+time	O
+of	O
+shadow	O
+in	O
+chest	B-ANAT
+film	O
+were	O
+not	O
+different	O
+significantly	O
+between	O
+the	O
+two	O
+groups	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+The	O
+time	O
+for	O
+improving	O
+symptom	B-DISO
+in	O
+the	O
+ICWM	O
+group	O
+was	O
+5	O
+.	O
+10	O
+days	O
+and	O
+that	O
+in	O
+the	O
+control	O
+group	O
+was	O
+7	O
+.	O
+62	O
+days	O
+,	O
+the	O
+difference	O
+between	O
+them	O
+was	O
+significant	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+);	O
+(	O
+2	O
+)	O
+The	O
+days	O
+and	O
+amount	O
+for	O
+use	O
+hormone	B-CHED
+before	O
+subtract	O
+in	O
+the	O
+two	O
+group	O
+were	O
+similar	O
+,	O
+with	O
+insignificant	O
+difference	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+);	O
+(	O
+3	O
+)	O
+The	O
+days	O
+and	O
+amount	O
+for	O
+use	O
+hormone	B-CHED
+after	O
+subtract	O
+in	O
+the	O
+two	O
+groups	O
+were	O
+significantly	O
+different	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+);	O
+(	O
+4	O
+)	O
+The	O
+time	O
+for	O
+improving	O
+peripheral	O
+WBC	B-ANAT
+count	O
+and	O
+absolute	O
+value	O
+of	O
+lymphocyte	B-ANAT
+,	O
+as	O
+well	O
+as	O
+for	O
+absorption	O
+time	O
+of	O
+shadow	O
+in	O
+chest	B-ANAT
+film	O
+were	O
+not	O
+different	O
+significantly	O
+between	O
+the	O
+two	O
+groups	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+effect	O
+of	O
+integrative	O
+medical	O
+treatment	O
+(	O
+IMT	O
+)	O
+with	O
+serial	O
+Chinese	O
+recipes	O
+on	O
+quality	O
+of	O
+life	O
+(	O
+QOF	O
+)	O
+of	O
+rehabilitation	O
+stage	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+we	O
+have	O
+developed	O
+a	O
+coronavirus	B-SPEC
+-	O
+specific	O
+gene	O
+-	O
+finding	O
+system	O
+,	O
+ZCURVE_CoV	O
+1	O
+.	O
+0	O
+.	O
+
+The	O
+cleavage	B-PROC
+sites	O
+of	O
+the	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	I-PRGE
+and	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+are	O
+highly	O
+conserved	O
+.	O
+
+METHODS	O
+:	O
+To	O
+use	O
+a	O
+back	B-ANAT
+projection	O
+technique	O
+to	O
+construct	O
+the	O
+infection	B-DISO
+curve	O
+of	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+result	O
+showed	O
+2	O
+/	O
+66	O
+cases	O
+(	O
+3	O
+.	O
+0	O
+%)	O
+were	O
+positive	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+IgG	B-COMP
+antibody	I-COMP
+and	O
+66	O
+cases	O
+were	O
+negative	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+IgM	B-COMP
+antibody	I-COMP
+in	O
+the	O
+66	O
+cases	O
+healthy	O
+controls	O
+;	O
+in	O
+31	O
+cases	O
+with	O
+SLE	B-DISO
+,	O
+positive	O
+rates	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+IgG	I-PRGE
+and	I-PRGE
+IgM	B-COMP
+antibody	I-COMP
+were	O
+58	O
+.	O
+1	O
+%	O
+(	O
+18	O
+/	O
+31	O
+)	O
+and	O
+29	O
+%	O
+(	O
+9	O
+/	O
+31	O
+),	O
+respectively	O
+,	O
+in	O
+which	O
+7	O
+cases	O
+(	O
+22	O
+.	O
+6	O
+%)	O
+were	O
+positive	O
+of	O
+both	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+IgG	I-PRGE
+and	O
+IgM	B-COMP
+antibody	B-PROC
+.	O
+
+The	O
+ELISA	O
+kit	B-FUNC
+coated	O
+by	O
+non	O
+-	O
+purification	O
+antigen	B-CHED
+may	O
+induce	O
+the	O
+false	O
+-	O
+positive	O
+of	O
+SARS	O
+-	O
+CoV	O
+antibody	B-COMP
+in	O
+patients	O
+with	O
+SLE	B-DISO
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+explore	O
+the	O
+development	O
+of	O
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+against	O
+SARS	B-PRGE
+CoV	I-PRGE
+and	O
+characteristics	O
+of	O
+changes	O
+of	O
+antibody	B-COMP
+titers	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+to	O
+search	O
+the	O
+opportunity	O
+for	O
+collecting	O
+specific	O
+anti	O
+-	O
+serum	B-COMP
+from	O
+convalescent	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+consequence	O
+of	O
+systemic	O
+vasoconstriction	B-DISO
+is	O
+volume	O
+and	O
+pressure	O
+loading	O
+in	O
+the	O
+pulmonary	B-PROC
+circulation	B-PROC
+.	O
+
+In	O
+animal	B-SPEC
+and	O
+isolated	O
+lung	B-ANAT
+studies	O
+,	O
+endotoxin	O
+produces	O
+acute	O
+lung	B-ANAT
+injury	O
+that	O
+is	O
+associated	O
+with	O
+increases	O
+in	O
+cytokines	O
+and	O
+inducible	O
+NOS	O
+mRNA	B-PROC
+expression	B-PROC
+,	O
+suggesting	O
+that	O
+NO	O
+is	O
+toxic	O
+to	O
+the	O
+lung	B-ANAT
+in	O
+endotoxin	O
+shock	O
+.	O
+
+Our	O
+early	O
+and	O
+recent	O
+studies	O
+on	O
+ARDS	B-DISO
+and	O
+PE	O
+may	O
+provide	O
+information	O
+for	O
+clinical	O
+practice	O
+and	O
+the	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+Based	O
+on	O
+genetic	O
+and	O
+serological	O
+relationships	O
+,	O
+groups	O
+1	O
+,	O
+2	O
+and	O
+3	O
+were	O
+previously	O
+recognized	O
+in	O
+the	O
+Coronavirus	B-SPEC
+genus	B-SPEC
+.	O
+
+However	O
+,	O
+severe	O
+exposure	O
+by	O
+any	O
+route	O
+may	O
+result	O
+in	O
+an	O
+acute	O
+and	O
+occasionally	O
+fatal	O
+illness	O
+that	O
+bears	B-SPEC
+all	O
+the	O
+hallmarks	O
+of	O
+being	O
+mediated	O
+by	O
+uncoupling	O
+of	O
+oxidative	B-PATH
+phosphorylation	I-PATH
+.	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+-	O
+mediated	O
+protection	O
+against	O
+cytotoxic	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+escape	O
+in	O
+coronavirus	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+C57BL	O
+/	O
+6	O
+(	O
+B6	O
+)	O
+mice	B-SPEC
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+strain	O
+JHM	O
+develop	O
+a	O
+clinically	O
+evident	O
+,	O
+demyelinating	O
+encephalomyelitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+causes	O
+demyelination	B-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+in	O
+rats	B-SPEC
+and	O
+mice	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+established	O
+a	O
+rat	B-SPEC
+oligodendrocyte	B-ANAT
+culture	O
+that	O
+is	O
+morphologically	O
+and	O
+phenotypically	O
+indistinguishable	O
+from	O
+the	O
+primary	O
+rat	B-SPEC
+oligodendrocytes	B-ANAT
+.	O
+
+Treatment	O
+with	O
+the	O
+pan	B-PRGE
+-	I-PRGE
+caspase	I-PRGE
+inhibitor	B-CHED
+Z	B-PRGE
+-	I-PRGE
+VAD	I-PRGE
+-	I-PRGE
+fmk	I-PRGE
+blocked	O
+MHV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+,	O
+suggesting	O
+an	O
+involvement	O
+of	O
+the	O
+caspase	B-PRGE
+-	O
+dependent	O
+pathway	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+highly	O
+infective	O
+disease	O
+caused	O
+by	O
+a	O
+newly	O
+identified	O
+coronavirus	B-SPEC
+.	O
+
+In	O
+this	O
+patient	O
+,	O
+the	O
+course	O
+of	O
+disease	O
+and	O
+duration	O
+of	O
+viral	B-DISO
+shedding	I-DISO
+was	O
+apparently	O
+prolonged	O
+,	O
+thus	O
+highlighting	O
+the	O
+need	O
+for	O
+increased	O
+infection	B-DISO
+control	O
+.	O
+
+Of	O
+these	O
+4	O
+dialysis	B-SPEC
+patients	O
+,	O
+1	O
+patient	O
+was	O
+receiving	O
+hemodialysis	O
+while	O
+the	O
+other	O
+3	O
+patients	O
+were	O
+on	O
+continuous	O
+ambulatory	O
+peritoneal	B-ANAT
+dialysis	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+a	O
+prospective	O
+evaluation	O
+of	O
+malaria	O
+prophylaxis	O
+in	O
+pregnancy	O
+in	O
+a	O
+refugee	O
+population	O
+on	O
+the	O
+north	O
+-	O
+western	O
+border	B-ANAT
+of	O
+Thailand	O
+from	O
+1987	O
+to	O
+1990	O
+,	O
+an	O
+extremely	O
+high	O
+infant	O
+mortality	O
+rate	O
+(	O
+18	O
+%)	O
+was	O
+documented	O
+despite	O
+good	O
+access	O
+to	O
+health	O
+care	O
+.	O
+
+Infantile	O
+beri	B-DISO
+-	I-DISO
+beri	B-SPEC
+was	O
+recognized	O
+as	O
+the	O
+main	O
+cause	O
+of	O
+death	B-PROC
+accounting	O
+for	O
+40	O
+%	O
+of	O
+all	O
+infant	O
+mortality	O
+.	O
+
+The	O
+overall	O
+infant	O
+mortality	O
+rates	O
+declined	O
+from	O
+183	O
+to	O
+78	O
+per	O
+1000	O
+live	O
+births	B-PROC
+.	O
+
+Post	O
+-	O
+neonatal	O
+deaths	B-PROC
+fell	O
+by	O
+79	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+65	O
+-	O
+87	O
+%)	O
+while	O
+neonatal	O
+mortality	O
+remained	O
+unchanged	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+neutrophil	B-PROC
+apoptosis	B-PATH
+in	O
+the	O
+resolution	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+newborn	O
+infants	O
+.	O
+
+134	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+samples	O
+were	O
+obtained	O
+from	O
+32	O
+infants	O
+requiring	O
+mechanical	O
+ventilation	O
+for	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+RDS	B-DISO
+):	O
+13	O
+infants	O
+(	O
+median	O
+gestation	B-PROC
+26	O
+weeks	O
+,	O
+range	O
+23	O
+to	O
+28	O
+)	O
+subsequently	O
+developed	O
+CLD	B-DISO
+(	O
+CLD	B-DISO
+group	O
+),	O
+and	O
+19	O
+infants	O
+(	O
+gestation	B-PROC
+31	O
+weeks	O
+,	O
+range	O
+25	O
+to	O
+39	O
+)	O
+recovered	O
+fully	O
+(	O
+RDS	B-DISO
+group	O
+).	O
+
+RESULTS	O
+:	O
+Neutrophil	B-PROC
+apoptosis	B-PATH
+was	O
+increased	O
+in	O
+the	O
+RDS	O
+group	O
+(	O
+mean	O
+(	O
+SEM	B-DISO
+)	O
+neutrophil	B-PROC
+apoptosis	B-PATH
+on	O
+day	O
+7	O
+BAL	B-ENZY
+:	O
+RDS	O
+17	O
+.	O
+0	O
+(	O
+8	O
+.	O
+6	O
+)%	O
+v	O
+CLD	B-DISO
+0	O
+.	O
+7	O
+(	O
+0	O
+.	O
+2	O
+)%	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)).	O
+
+TITLE	O
+:	O
+Efficiency	O
+of	O
+quarantine	O
+during	O
+an	O
+epidemic	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+Beijing	O
+,	O
+China	O
+,	O
+2003	O
+.	O
+
+Chloroquine	B-CHED
+exerts	B-PROC
+direct	O
+antiviral	B-CHED
+effects	O
+,	O
+inhibiting	O
+pH	O
+-	O
+dependent	O
+steps	O
+of	O
+the	O
+replication	O
+of	O
+several	O
+viruses	B-SPEC
+including	O
+members	O
+of	O
+the	O
+flaviviruses	B-SPEC
+,	O
+retroviruses	B-SPEC
+,	O
+and	O
+coronaviruses	O
+.	O
+
+Lymphocyte	O
+subsets	O
+were	O
+analysed	O
+by	O
+flow	O
+cytometry	O
+,	O
+using	O
+a	O
+whole	B-ANAT
+blood	I-ANAT
+indirect	O
+immunofluorescence	O
+technique	O
+and	O
+mAbs	O
+specific	O
+for	O
+feline	B-PRGE
+CD5	I-PRGE
+,	O
+CD4	B-PRGE
+,	O
+CD8	B-PRGE
+,	O
+CD21	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Involvement	O
+of	O
+viruses	O
+in	O
+human	B-SPEC
+neurodegenerative	B-DISO
+diseases	I-DISO
+and	O
+the	O
+underlying	O
+pathologic	O
+mechanisms	O
+remain	O
+generally	O
+unclear	O
+.	O
+
+Although	O
+this	O
+acute	O
+encephalitis	O
+appears	O
+generally	O
+similar	O
+to	O
+that	O
+induced	O
+by	O
+murine	B-SPEC
+coronaviruses	O
+,	O
+an	O
+important	O
+difference	O
+rests	O
+in	O
+the	O
+prominent	O
+spongiform	O
+-	O
+like	O
+degeneration	B-DISO
+that	O
+could	O
+trigger	O
+neuropathology	B-DISO
+in	O
+surviving	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+5	O
+'	O
+and	O
+3	O
+'	O
+UTR	O
+sequences	O
+on	O
+the	O
+coronavirus	B-SPEC
+genome	O
+are	O
+known	O
+to	O
+carry	O
+cis	B-DISO
+-	O
+acting	O
+elements	O
+for	O
+DI	B-PRGE
+RNA	I-PRGE
+replication	O
+and	O
+presumably	O
+also	O
+virus	B-SPEC
+genome	O
+replication	O
+.	O
+
+Extensive	O
+regions	O
+of	O
+highly	O
+similar	O
+UTR	O
+sequences	O
+were	O
+found	O
+but	O
+small	O
+regions	O
+of	O
+divergence	O
+were	O
+also	O
+found	O
+indicating	O
+group	O
+2	O
+coronaviruses	O
+could	O
+be	O
+subdivided	O
+into	O
+those	O
+that	O
+are	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	B-SPEC
+)-	O
+like	O
+(	O
+BCoV	B-SPEC
+,	O
+human	B-PRGE
+respiratory	I-PRGE
+coronavirus	B-SPEC
+-	I-PRGE
+OC43	I-PRGE
+,	O
+human	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+,	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+,	O
+and	O
+equine	B-SPEC
+coronavirus	B-SPEC
+)	O
+and	O
+those	O
+that	O
+are	O
+murine	B-SPEC
+hepatitis	I-DISO
+virus	O
+(	O
+MHV	B-SPEC
+)-	O
+like	O
+(	O
+A59	O
+,	O
+2	O
+,	O
+and	O
+JHM	O
+strains	O
+of	O
+MHV	B-SPEC
+,	O
+puffinosis	O
+virus	B-SPEC
+,	O
+and	O
+rat	B-SPEC
+sialodacryoadenitis	O
+virus	B-SPEC
+).	O
+
+The	O
+3	O
+'	O
+UTRs	O
+of	O
+BCoV	O
+and	O
+MHV	B-SPEC
+have	O
+been	O
+previously	O
+shown	O
+to	O
+be	O
+interchangeable	O
+.	O
+
+Here	O
+,	O
+a	O
+reporter	O
+-	O
+containing	O
+BCoV	B-PRGE
+DI	I-PRGE
+RNA	I-PRGE
+was	O
+shown	O
+to	O
+be	O
+replicated	O
+by	O
+all	O
+five	O
+BCoV	O
+-	O
+like	O
+helper	O
+viruses	B-SPEC
+and	O
+by	O
+MHV	B-SPEC
+-	O
+H2	O
+(	O
+a	O
+human	B-SPEC
+cell	B-COMP
+-	O
+adapted	O
+MHV	B-SPEC
+strain	O
+),	O
+a	O
+representative	O
+of	O
+the	O
+MHV	B-SPEC
+-	O
+like	O
+subgroup	O
+,	O
+demonstrating	O
+group	O
+2	O
+common	O
+5	O
+'	O
+and	O
+3	O
+'	O
+replication	O
+signaling	B-PROC
+elements	O
+.	O
+
+According	O
+to	O
+our	O
+case	O
+definition	O
+,	O
+there	O
+were	O
+227	O
+cases	O
+of	O
+confirmed	O
+SARS	B-DISO
+and	O
+40	O
+cases	O
+of	O
+probable	O
+SARS	B-DISO
+.	O
+
+Sixty	O
+-	O
+nine	O
+patients	O
+(	O
+26	O
+%)	O
+required	O
+intensive	O
+care	O
+because	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Respiratory	O
+management	O
+in	O
+a	O
+patient	O
+with	O
+severe	O
+tracheal	B-DISO
+stenosis	I-DISO
+caused	O
+by	O
+compression	O
+from	O
+the	O
+ascending	O
+aortic	O
+arch	O
+aneurysm	O
+].	O
+
+ABSTRACT	O
+:	O
+In	O
+cases	O
+of	O
+tracheal	O
+compression	O
+by	O
+a	O
+mediastinal	B-ANAT
+mass	O
+or	O
+aortic	B-DISO
+aneurysm	I-DISO
+,	O
+muscle	B-DISO
+relaxant	I-DISO
+might	O
+induce	O
+fetal	B-ANAT
+ventilatory	B-DISO
+failure	I-DISO
+.	O
+
+After	O
+the	O
+induction	O
+of	O
+general	B-PROC
+anesthesia	I-PROC
+for	O
+video	O
+-	O
+assisted	O
+thoracic	B-DISO
+surgery	O
+(	O
+VATS	O
+)	O
+for	O
+high	O
+-	O
+pneumothorax	B-DISO
+,	O
+she	O
+was	O
+placed	O
+in	O
+lateral	O
+position	O
+.	O
+
+Astrocytes	B-ANAT
+are	O
+the	O
+major	O
+target	O
+for	O
+MHV	B-SPEC
+persistence	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+has	O
+been	O
+called	O
+the	O
+first	O
+global	O
+epidemic	O
+of	O
+the	O
+21st	O
+century	O
+and	O
+has	O
+been	O
+the	O
+cause	O
+of	O
+a	O
+massive	O
+and	O
+varied	O
+public	O
+health	O
+response	O
+in	O
+many	O
+countries	O
+of	O
+the	O
+world	O
+.	O
+
+TITLE	O
+:	O
+Monitoring	O
+community	O
+responses	O
+to	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+:	O
+from	O
+day	O
+10	O
+to	O
+day	O
+62	O
+.	O
+
+Most	O
+of	O
+the	O
+respondents	O
+believed	O
+that	O
+SARS	B-DISO
+could	O
+be	O
+transmitted	B-DISO
+via	O
+direct	O
+body	B-ANAT
+contact	O
+and	O
+droplets	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+related	O
+perceptions	O
+and	O
+behaviours	O
+evolved	O
+rapidly	O
+during	O
+the	O
+epidemic	O
+and	O
+Hong	O
+Kong	O
+residents	O
+quickly	O
+adopted	O
+appropriate	O
+SARS	B-DISO
+prevention	O
+measures	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+features	O
+and	O
+management	O
+of	O
+recurrence	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+These	O
+patients	O
+were	O
+treated	O
+with	O
+glucocorticoids	B-CHED
+.	O
+
+RESULTS	O
+:	O
+One	O
+hundred	O
+and	O
+twenty	O
+three	O
+patients	O
+with	O
+SARS	B-DISO
+were	O
+referred	O
+to	O
+the	O
+First	O
+Hospital	O
+of	O
+Peking	O
+University	O
+from	O
+8	O
+,	O
+April	O
+to	O
+14	O
+,	O
+May	O
+this	O
+year	O
+and	O
+of	O
+whom	O
+51	O
+were	O
+the	O
+critical	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Cardiac	B-ANAT
+presentations	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+].	O
+
+During	O
+an	O
+outbreak	O
+,	O
+even	O
+patients	O
+with	O
+low	O
+suspicion	O
+of	O
+SARS	B-DISO
+should	O
+be	O
+promptly	O
+isolated	O
+,	O
+and	O
+all	O
+contacts	O
+quarantined	O
+.	O
+
+To	O
+counter	B-CHED
+a	O
+possible	O
+resurgence	O
+of	O
+SARS	O
+,	O
+a	O
+system	O
+of	O
+prepared	O
+isolation	O
+and	O
+quarantine	O
+facilities	O
+is	O
+important	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Rational	O
+therapeutic	O
+regime	O
+of	O
+glucocorticoid	B-CHED
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+its	O
+receptor	O
+mechanism	O
+].	O
+
+Because	O
+the	O
+ELISA	O
+titer	O
+correlated	O
+well	O
+with	O
+the	O
+protection	O
+results	O
+,	O
+the	O
+specificity	O
+and	O
+sensitivity	O
+of	O
+the	O
+ELISA	O
+were	O
+further	O
+evaluated	O
+with	O
+sera	B-COMP
+collected	O
+from	O
+pigs	B-SPEC
+reared	O
+on	O
+1	O
+farm	O
+on	O
+which	O
+animals	B-SPEC
+had	O
+acute	O
+septicemia	B-DISO
+,	O
+2	O
+farms	O
+on	O
+which	O
+the	O
+animals	B-SPEC
+were	O
+infected	O
+or	O
+free	O
+from	O
+infection	B-DISO
+,	O
+and	O
+10	O
+farms	O
+on	O
+which	O
+the	O
+animals	B-SPEC
+were	O
+vaccinated	O
+with	O
+live	O
+vaccine	O
+,	O
+among	O
+others	O
+.	O
+
+The	O
+high	O
+frequency	O
+of	O
+ARDS	O
+in	O
+patients	O
+with	O
+MTP	O
+defects	O
+suggests	O
+that	O
+this	O
+inborn	O
+error	O
+may	O
+be	O
+a	O
+risk	O
+factor	O
+for	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Onset	O
+time	O
+of	O
+complications	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+receiving	O
+nonoperative	O
+therapy	O
+.	O
+
+The	O
+95	O
+%	O
+confidence	O
+interval	O
+of	O
+total	O
+average	O
+for	O
+the	O
+complications	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+shock	O
+and	O
+kidney	B-DISO
+failure	I-DISO
+was	O
+between	O
+2	O
+to	O
+4	O
+days	O
+,	O
+and	O
+for	O
+encephalopathy	B-DISO
+,	O
+hemorrhage	B-DISO
+of	O
+the	O
+digestive	B-ANAT
+tract	I-ANAT
+,	O
+bacterial	B-DISO
+infection	I-DISO
+,	O
+fungous	O
+infection	B-DISO
+and	O
+abscess	B-DISO
+between	O
+3	O
+to	O
+6	O
+days	O
+,	O
+3	O
+to	O
+5	O
+days	O
+,	O
+13	O
+to	O
+16	O
+days	O
+,	O
+13	O
+to	O
+16	O
+days	O
+,	O
+and	O
+14	O
+to	O
+23	O
+days	O
+respectively	O
+.	O
+
+The	O
+95	O
+%	O
+confidence	O
+interval	O
+of	O
+total	O
+average	O
+in	O
+18	O
+deaths	B-PROC
+(	O
+21	O
+%)	O
+was	O
+between	O
+5	O
+to	O
+6	O
+days	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+95	O
+%	O
+confidence	O
+interval	O
+of	O
+total	O
+average	O
+for	O
+the	O
+complications	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+shock	O
+and	O
+kidney	B-DISO
+failure	I-DISO
+was	O
+between	O
+2	O
+to	O
+4	O
+days	O
+,	O
+and	O
+for	O
+encephalopathy	B-DISO
+,	O
+hemorrhage	B-DISO
+of	O
+the	O
+digestive	B-ANAT
+tract	I-ANAT
+,	O
+bacterial	B-DISO
+infection	I-DISO
+,	O
+fungous	O
+infection	B-DISO
+and	O
+abscess	B-DISO
+between	O
+3	O
+to	O
+6	O
+days	O
+,	O
+3	O
+to	O
+5	O
+days	O
+,	O
+13	O
+to	O
+16	O
+days	O
+,	O
+13	O
+to	O
+16	O
+days	O
+,	O
+and	O
+14	O
+to	O
+23	O
+days	O
+respectively	O
+.	O
+
+In	O
+the	O
+past	O
+the	O
+clinical	O
+significance	O
+of	O
+some	O
+viruses	B-SPEC
+was	O
+underestimated	O
+.	O
+
+Acute	O
+respiratory	O
+viruses	B-SPEC
+commonly	O
+induce	O
+inflammatory	O
+chemokines	O
+such	O
+as	O
+CCL3	B-PRGE
+(	O
+also	O
+known	O
+as	O
+macrophage	B-PRGE
+inflammatory	I-PRGE
+protein	B-CHED
+-	I-PRGE
+1alpha	I-PRGE
+)	O
+and	O
+CCL5	B-PRGE
+(	O
+RANTES	B-PRGE
+),	O
+which	O
+can	O
+amplify	O
+inflammatory	B-DISO
+responses	I-DISO
+leading	O
+to	O
+immunopathology	B-DISO
+.	O
+
+Inflammatory	O
+chemokines	O
+play	O
+both	O
+beneficial	O
+and	O
+harmful	O
+roles	O
+in	O
+infectious	O
+diseases	B-DISO
+caused	I-DISO
+by	I-DISO
+viruses	I-DISO
+.	O
+
+Immunity	B-PROC
+assay	O
+with	O
+BALB	O
+/	O
+C	O
+mice	B-SPEC
+showed	O
+that	O
+expression	B-PROC
+products	O
+of	O
+transgenic	O
+potato	B-SPEC
+with	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+IBV	B-SPEC
+were	O
+immunogenic	O
+,	O
+and	O
+ELISA	O
+antibody	B-COMP
+titer	O
+reached	O
+1	O
+:	O
+20	O
+to	O
+1	O
+:	O
+40	O
+and	O
+1	O
+:	O
+80	O
+to	O
+1	O
+:	O
+160	O
+with	O
+doses	O
+of	O
+0	O
+.	O
+5	O
+g	O
+and	O
+1	O
+g	O
+,	O
+respectively	O
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+isolated	O
+in	O
+58	O
+(	O
+16	O
+%)	O
+of	O
+361	O
+patients	O
+whose	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+was	O
+sampled	O
+.	O
+
+HSV	B-SPEC
+in	O
+the	O
+throat	B-ANAT
+was	O
+associated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+with	O
+increased	O
+length	O
+of	O
+stay	O
+in	O
+intensive	O
+care	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+or	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+of	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+?	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+infection	B-DISO
+control	O
+in	O
+Taiwan	O
+:	O
+investigation	O
+of	O
+nurses	O
+'	O
+professional	O
+obligation	O
+.	O
+
+Nurses	O
+'	O
+levels	O
+of	O
+agreement	O
+with	O
+general	O
+SARS	B-DISO
+infection	B-DISO
+control	O
+measures	O
+,	O
+self	O
+-	O
+treatment	O
+of	O
+relief	O
+of	O
+fever	B-PROC
+and	O
+cough	B-DISO
+,	O
+necessity	O
+to	O
+close	O
+Hoping	O
+and	O
+Jenchi	O
+hospitals	O
+,	O
+nurses	O
+'	O
+physical	O
+health	O
+status	O
+,	O
+and	O
+holding	O
+a	O
+bachelor	O
+'	O
+s	O
+degree	O
+were	O
+statistically	O
+significant	O
+predictors	O
+of	O
+nurses	O
+'	O
+willingness	O
+to	O
+care	O
+for	O
+SARS	O
+patients	O
+.	O
+
+We	O
+compared	O
+clinical	O
+symptoms	O
+between	O
+SARS	B-DISO
+and	O
+influenza	B-DISO
+and	O
+discussed	O
+infection	B-DISO
+-	O
+control	O
+measures	O
+.	O
+
+Since	O
+both	O
+SARS	B-DISO
+and	O
+influenza	B-DISO
+mainly	O
+spread	O
+by	O
+droplet	O
+infection	B-DISO
+,	O
+preventive	O
+measures	O
+against	O
+this	O
+route	O
+are	O
+important	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+probably	O
+here	O
+to	O
+stay	O
+,	O
+and	O
+every	O
+health	O
+care	O
+institution	O
+should	O
+take	O
+precautions	O
+against	O
+an	O
+outbreak	O
+.	O
+
+Serum	B-COMP
+protein	B-CHED
+electrophoresis	O
+and	O
+the	O
+concentration	O
+of	O
+haptoglobin	B-PRGE
+(	O
+Hp	O
+),	O
+serum	B-PRGE
+amyloid	B-DISO
+A	I-PRGE
+(	O
+SAA	O
+),	O
+alpha	O
+(	O
+1	O
+)-	O
+acid	O
+glycoprotein	B-CHED
+(	O
+AGP	B-PRGE
+),	O
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+were	O
+evaluated	O
+in	O
+cats	B-SPEC
+exposed	O
+to	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+and	O
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+The	O
+disease	O
+presents	O
+variably	O
+with	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+seizures	B-DISO
+,	I-DISO
+generalized	I-DISO
+effusion	B-DISO
+,	O
+or	O
+shock	O
+.	O
+
+Neurological	O
+FIP	B-DISO
+is	O
+clinically	O
+and	O
+pathologically	O
+more	O
+homogeneous	O
+than	O
+systemic	O
+'	O
+wet	O
+'	O
+or	O
+'	O
+dry	O
+'	O
+FIP	B-DISO
+;	O
+thus	O
+,	O
+comparison	O
+of	O
+cytokine	O
+profiles	O
+from	O
+cats	B-SPEC
+with	O
+neurological	O
+FIP	B-DISO
+,	O
+wet	B-DISO
+FIP	I-DISO
+,	O
+and	O
+non	O
+-	O
+FIP	B-DISO
+neurological	B-DISO
+disease	I-DISO
+may	O
+provide	O
+insight	O
+into	O
+some	O
+baseline	O
+characteristics	O
+relating	O
+to	O
+the	O
+immunopathogenesis	O
+of	O
+neurological	O
+FIP	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+new	O
+,	O
+sometimes	O
+lethal	O
+disease	O
+of	O
+humans	B-SPEC
+that	O
+is	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+bioinformatic	O
+analysis	O
+has	O
+predicted	O
+a	O
+number	O
+of	O
+enzymatic	O
+activities	O
+associated	O
+with	O
+proteins	B-CHED
+of	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+-	I-PRGE
+transcriptase	I-PRGE
+complex	O
+.	O
+
+We	O
+describe	O
+herein	O
+a	O
+DNA	O
+microarray	O
+-	O
+based	O
+platform	O
+for	O
+novel	O
+virus	B-SPEC
+identification	O
+and	O
+characterization	O
+.	O
+
+During	O
+an	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+March	O
+2003	O
+,	O
+hybridization	B-PROC
+to	O
+this	O
+microarray	O
+revealed	O
+the	O
+presence	O
+of	O
+a	O
+previously	O
+uncharacterized	O
+coronavirus	B-SPEC
+in	O
+a	O
+viral	O
+isolate	O
+cultivated	O
+from	O
+a	O
+SARS	B-DISO
+patient	O
+.	O
+
+We	O
+abstracted	O
+data	O
+(	O
+n	O
+=	O
+62	O
+)	O
+on	O
+the	O
+radiologic	O
+appearance	O
+and	O
+course	O
+of	O
+SARS	B-DISO
+in	O
+pediatric	O
+patients	O
+with	O
+suspect	O
+(	O
+n	O
+=	O
+25	O
+)	O
+or	O
+probable	O
+(	O
+n	O
+=	O
+37	O
+)	O
+SARS	B-DISO
+,	O
+diagnosed	O
+in	O
+five	O
+hospital	O
+sites	O
+located	O
+in	O
+three	O
+cities	O
+:	O
+Toronto	O
+,	O
+Singapore	O
+,	O
+and	O
+Hong	O
+Kong	O
+.	O
+
+Swollen	B-DISO
+tongue	I-DISO
+body	O
+was	O
+found	O
+in	O
+23	O
+patients	O
+(	O
+14	O
+.	O
+8	O
+%)	O
+and	O
+teeth	B-ANAT
+print	O
+on	O
+margin	B-ANAT
+was	O
+found	O
+in	O
+19	O
+patients	O
+(	O
+12	O
+.	O
+3	O
+%).	O
+
+Patients	O
+with	O
+affected	O
+lung	B-ANAT
+>	O
+or	O
+=	O
+3	O
+lobules	B-ANAT
+mostly	O
+had	O
+pale	B-DISO
+dark	O
+proper	O
+and	O
+yellow	O
+coating	O
+on	O
+root	B-ANAT
+,	O
+but	O
+those	O
+with	O
+involved	O
+lung	B-ANAT
+<	O
+3	O
+lobules	B-ANAT
+mostly	O
+had	O
+light	O
+red	O
+proper	O
+and	O
+thin	O
+white	O
+coating	O
+.	O
+
+Tongue	B-ANAT
+picture	O
+is	O
+one	O
+of	O
+the	O
+objective	O
+evidence	O
+for	O
+judging	O
+state	O
+of	O
+illness	O
+and	O
+Syndrome	B-DISO
+Differentiation	B-PROC
+based	O
+on	O
+treatment	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+This	O
+infection	B-DISO
+spreads	O
+by	O
+droplet	O
+transmission	O
+and	O
+children	O
+appear	O
+to	O
+acquire	O
+SARS	B-DISO
+through	O
+close	O
+household	O
+contact	O
+exposure	O
+to	O
+infected	O
+adults	O
+.	O
+
+The	O
+virus	B-SPEC
+is	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+which	O
+may	O
+have	O
+an	O
+origin	O
+in	O
+wild	O
+animals	B-SPEC
+such	O
+as	O
+civet	B-SPEC
+cats	I-SPEC
+in	O
+southern	O
+China	O
+.	O
+
+Its	O
+genome	O
+structure	O
+,	O
+gene	B-PROC
+expression	I-PROC
+pattern	O
+and	O
+protein	B-CHED
+profiles	O
+are	O
+similar	O
+to	O
+those	O
+of	O
+other	O
+coronaviruses	O
+.	O
+
+The	O
+mechanism	O
+of	O
+SARS	B-DISO
+pathogenesis	B-DISO
+may	O
+involve	O
+both	O
+direct	O
+viral	O
+cytocidal	O
+effects	O
+on	O
+the	O
+target	B-ANAT
+cells	I-ANAT
+and	O
+immune	O
+-	O
+mediated	O
+mechanisms	O
+.	O
+
+TITLE	O
+:	O
+Maintaining	O
+dental	O
+education	O
+and	O
+specialist	O
+dental	O
+care	O
+during	O
+an	O
+outbreak	O
+of	O
+a	O
+new	O
+coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+causal	O
+agent	O
+for	O
+SARS	O
+is	O
+considered	O
+as	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+has	O
+never	O
+been	O
+described	O
+both	O
+in	O
+human	B-SPEC
+and	O
+animals	B-SPEC
+previously	O
+.	O
+
+Serum	B-COMP
+levels	O
+of	O
+ILs	B-DISO
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+were	O
+measured	O
+in	O
+all	O
+cases	O
+.	O
+
+Although	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+in	O
+sera	B-COMP
+decreased	O
+in	O
+over	O
+14	O
+day	O
+group	O
+,	O
+the	O
+average	O
+was	O
+still	O
+higher	O
+than	O
+that	O
+of	O
+the	O
+control	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+In	O
+the	O
+early	O
+stage	O
+of	O
+SARS	B-DISO
+(	O
+within	O
+10	O
+days	O
+),	O
+the	O
+expression	B-PROC
+of	O
+CD40	B-PRGE
+decreased	O
+significantly	O
+as	O
+compared	O
+with	O
+healthy	O
+adults	O
+(	O
+F	O
+=	O
+5	O
+.	O
+13	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+number	O
+of	O
+B	B-ANAT
+cells	I-ANAT
+in	O
+severe	O
+SARS	B-DISO
+and	O
+mild	O
+cases	O
+were	O
+(	O
+347	O
++/-	O
+156	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+and	O
+(	O
+268	O
++/-	O
+211	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+respectively	O
+.	O
+
+The	O
+difference	O
+of	O
+the	O
+infection	B-DISO
+rates	O
+was	O
+of	O
+statistical	O
+significance	O
+.	O
+
+RESULTS	O
+:	O
+Four	O
+kinds	O
+of	O
+isolation	O
+wards	O
+were	O
+evaluated	O
+,	O
+including	O
+the	O
+ward	O
+where	O
+the	O
+thirty	O
+-	O
+first	O
+bed	B-DISO
+lied	O
+in	O
+on	O
+the	O
+twelfth	O
+floor	O
+,	O
+the	O
+laminar	O
+flow	O
+ward	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+where	O
+the	O
+tenth	O
+bed	B-DISO
+lied	O
+in	O
+on	O
+the	O
+fifteenth	O
+floor	O
+,	O
+the	O
+ward	O
+where	O
+the	O
+twenty	O
+-	O
+seventh	O
+bed	B-DISO
+lied	O
+in	O
+on	O
+the	O
+thirteenth	O
+floor	O
+of	O
+Building	O
+A	O
+,	O
+and	O
+thirty	O
+wards	O
+on	O
+the	O
+fourteenth	O
+to	O
+eighteenth	O
+floors	O
+of	O
+Building	O
+B	O
+.	O
+The	O
+ratios	O
+(	O
+m2	O
+/	O
+m3	O
+)	O
+of	O
+the	O
+area	O
+of	O
+the	O
+ventilation	O
+windows	O
+to	O
+the	O
+volume	O
+of	O
+the	O
+room	O
+were	O
+0	O
+,	O
+0	O
+,	O
+1	O
+:	O
+95	O
+and	O
+1	O
+:	O
+40	O
+,	O
+respectively	O
+.	O
+
+We	O
+investigated	O
+whether	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+can	O
+be	O
+detected	O
+in	O
+serum	B-COMP
+and	O
+plasma	B-ANAT
+samples	O
+during	O
+the	O
+early	O
+stages	O
+of	O
+SARS	B-DISO
+and	O
+studied	O
+the	O
+potential	O
+prognostic	O
+implications	O
+of	O
+such	O
+an	O
+approach	O
+.	O
+
+We	O
+developed	O
+two	O
+real	O
+-	O
+time	O
+quantitative	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assays	O
+,	O
+one	O
+for	O
+the	O
+polymerase	O
+and	O
+the	O
+other	O
+for	O
+the	O
+nucleocapsid	B-COMP
+region	O
+of	O
+the	O
+virus	B-SPEC
+genome	O
+,	O
+for	O
+measuring	O
+the	O
+concentration	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+in	O
+serum	B-COMP
+/	O
+plasma	B-ANAT
+samples	O
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+identification	O
+of	O
+these	O
+antigenic	O
+peptides	B-CHED
+contributes	O
+to	O
+the	O
+understanding	O
+of	O
+the	O
+immunogenicity	O
+and	O
+persistence	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Histologic	O
+changes	O
+in	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+include	O
+lymphoid	B-DISO
+hyperplasia	I-DISO
+,	O
+lymphoid	O
+depletion	O
+,	O
+histiocytosis	B-DISO
+,	O
+and	O
+granuloma	B-PROC
+formation	I-PROC
+.	O
+
+A	O
+possible	O
+role	O
+for	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+in	O
+the	O
+previously	O
+described	O
+FIPV	O
+-	O
+induced	O
+lymphocyte	B-PROC
+apoptosis	B-PATH
+is	O
+also	O
+suggested	O
+.	O
+
+TITLE	O
+:	O
+Vaccine	O
+efficacy	O
+of	O
+a	O
+cell	B-COMP
+lysate	O
+with	O
+recombinant	O
+baculovirus	B-SPEC
+-	O
+expressed	B-PROC
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	O
+)	O
+virus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+against	O
+progression	O
+of	O
+FIP	B-DISO
+.	O
+
+Cats	B-SPEC
+immunized	O
+with	O
+this	O
+vaccine	O
+produced	O
+antibodies	O
+against	O
+FIPV	O
+virion	B-COMP
+-	O
+derived	O
+N	B-PRGE
+protein	I-PRGE
+but	O
+did	O
+not	O
+produce	O
+virus	B-SPEC
+-	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+This	O
+study	O
+showed	O
+that	O
+immunization	O
+with	O
+the	O
+cell	B-COMP
+lysate	O
+with	O
+baculovirus	B-SPEC
+-	O
+expressed	B-PROC
+N	B-PRGE
+protein	I-PRGE
+was	O
+effective	O
+in	O
+preventing	O
+the	O
+progression	O
+of	O
+FIP	B-DISO
+without	O
+inducing	O
+ADE	B-CHED
+of	O
+FIPV	O
+infection	B-DISO
+in	O
+cats	B-SPEC
+.	O
+
+Physical	O
+examination	O
+was	O
+performed	O
+and	O
+nasal	B-ANAT
+brush	O
+samples	O
+were	O
+taken	O
+during	O
+routine	O
+visits	O
+every	O
+6	O
+months	O
+and	O
+during	O
+an	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+URTI	B-DISO
+)	O
+(	O
+sick	O
+visits	O
+).	O
+
+During	O
+routine	O
+visits	O
+at	O
+12	O
+months	O
+,	O
+a	O
+higher	O
+prevalence	O
+of	O
+rhinovirus	B-SPEC
+infections	B-DISO
+was	O
+found	O
+in	O
+infants	O
+who	O
+attended	O
+day	O
+-	O
+care	O
+compared	O
+with	O
+those	O
+who	O
+did	O
+not	O
+.	O
+
+We	O
+did	O
+not	O
+observe	O
+a	O
+relation	O
+between	O
+breast	B-ANAT
+-	O
+feeding	O
+or	O
+smoking	O
+by	O
+one	O
+or	O
+both	O
+parents	O
+and	O
+the	O
+prevalence	O
+of	O
+rhinovirus	B-SPEC
+infections	B-DISO
+.	O
+
+The	O
+parental	O
+history	O
+of	O
+atopy	B-DISO
+was	O
+not	O
+related	O
+to	O
+the	O
+prevalence	O
+of	O
+rhinovirus	B-DISO
+infection	I-DISO
+,	O
+indicating	O
+that	O
+the	O
+genetic	O
+risk	O
+of	O
+allergic	O
+disease	O
+does	O
+not	O
+seem	O
+to	O
+increase	O
+the	O
+chance	O
+of	O
+rhinovirus	B-SPEC
+infections	B-DISO
+.	O
+
+Good	O
+hospital	O
+organization	O
+and	O
+appropriate	O
+infection	B-DISO
+control	O
+strategies	O
+are	O
+essential	O
+to	O
+prevent	O
+/	O
+interrupt	O
+disease	B-DISO
+transmission	I-DISO
+from	O
+patients	O
+to	O
+HCWs	O
+(	O
+and	O
+vice	O
+versa	O
+)	O
+and	O
+among	O
+inpatients	O
+and	O
+HCWs	O
+themselves	O
+.	O
+
+Moreover	O
+,	O
+work	O
+on	O
+viral	B-PRGE
+neuraminidase	I-PRGE
+has	O
+led	O
+to	O
+the	O
+licensing	O
+of	O
+potent	O
+selective	O
+antiviral	B-CHED
+drugs	I-CHED
+,	O
+and	O
+economic	O
+decision	O
+modelling	O
+provides	O
+further	O
+justification	O
+for	O
+annual	O
+vaccination	O
+and	O
+a	O
+framework	O
+for	O
+the	O
+use	O
+of	O
+neuraminidase	B-PROC
+inhibitors	I-PROC
+.	O
+
+TITLE	O
+:	O
+Neutralization	O
+of	O
+enteric	O
+coronaviruses	O
+with	O
+Escherichia	B-SPEC
+coli	I-SPEC
+cells	B-COMP
+expressing	O
+single	O
+-	O
+chain	O
+Fv	B-PRGE
+-	I-PRGE
+autotransporter	I-PRGE
+fusions	O
+.	O
+
+This	O
+result	O
+raises	O
+prospects	O
+for	O
+antiviral	B-CHED
+strategies	O
+aimed	O
+at	O
+hindering	O
+the	O
+entry	O
+into	O
+target	B-ANAT
+cells	I-ANAT
+by	O
+bacteria	B-SPEC
+that	O
+naturally	O
+colonize	O
+the	O
+same	O
+intestinal	B-ANAT
+niches	O
+.	O
+
+Finally	O
+,	O
+anti	B-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+but	O
+not	O
+anti	B-PRGE
+-	I-PRGE
+ACE1	I-PRGE
+antibody	I-PRGE
+blocked	O
+viral	B-PROC
+replication	I-PROC
+on	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+In	O
+other	O
+severe	O
+diseases	O
+requiring	O
+ventilatory	O
+support	O
+,	O
+the	O
+use	O
+of	O
+surfactants	B-CHED
+is	O
+still	O
+controversial	O
+,	O
+and	O
+data	O
+in	O
+the	O
+literature	O
+are	O
+limited	O
+and	O
+conflicting	O
+.	O
+
+Further	O
+studies	O
+should	O
+be	O
+conducted	O
+to	O
+improve	O
+surfactants	B-CHED
+-	O
+mainly	O
+their	O
+resistance	B-PROC
+to	O
+inhibition	B-PROC
+-	O
+and	O
+the	O
+treatment	O
+of	O
+diseases	O
+other	O
+than	O
+RDS	O
+.	O
+
+RESULTS	O
+:	O
+Eighteen	O
+children	O
+(	O
+10	O
+males	O
+),	O
+whose	O
+mean	O
+age	O
+was	O
+11	O
+.	O
+5	O
+-/+	O
+11	O
+.	O
+5	O
+months	O
+,	O
+with	O
+initial	O
+PaO	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)/	I-PRGE
+FiO	I-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+of	O
+96	O
+.	O
+06	O
+-/+	O
+41	O
+.	O
+78	O
+,	O
+participated	O
+in	O
+the	O
+study	O
+.	O
+
+After	O
+one	O
+hour	O
+in	O
+the	O
+prone	O
+position	O
+,	O
+27	O
+.	O
+7	O
+%	O
+of	O
+the	O
+patients	O
+(	O
+5	O
+/	O
+18	O
+)	O
+improved	O
+their	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+ratio	O
+(	O
+P	O
+=	O
+0	O
+.	O
+045	O
+).	O
+
+In	O
+phylogenetic	O
+analysis	O
+of	O
+18	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+,	O
+two	O
+classes	O
+were	O
+observed	O
+and	O
+there	O
+is	O
+different	O
+differential	O
+time	O
+between	O
+these	O
+two	O
+classes	O
+and	O
+the	O
+different	O
+isolates	O
+in	O
+each	O
+class	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Immunohistochemical	O
+investigation	O
+of	O
+lungs	B-ANAT
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+The	O
+numbers	O
+of	O
+blood	B-ANAT
+vessels	I-ANAT
+decreased	O
+in	O
+the	O
+fibrotic	O
+and	O
+consolidated	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+and	O
+the	O
+vessel	B-ANAT
+cavities	B-DISO
+enlarged	O
+,	O
+losing	O
+the	O
+normal	O
+contour	O
+of	O
+alveolar	B-ANAT
+septa	O
+.	O
+
+Diffusing	O
+capacity	O
+for	O
+carbon	B-CHED
+monoxide	I-CHED
+(	O
+DLco	O
+%)	O
+of	O
+level	O
+2	O
+and	O
+3	O
+were	O
+statistically	O
+lower	O
+than	O
+that	O
+of	O
+level	O
+0	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Assessment	O
+of	O
+health	O
+-	O
+related	O
+quality	O
+of	O
+life	O
+in	O
+cured	O
+SARS	B-DISO
+patients	O
+].	O
+
+One	O
+hundred	O
+and	O
+nineteen	O
+SARS	B-DISO
+outpatients	O
+,	O
+including	O
+64	O
+men	O
+and	O
+55	O
+women	O
+,	O
+with	O
+mean	O
+age	O
+(	O
+34	O
+.	O
+1	O
++/-	O
+
+11	O
+.	O
+4	O
+)	O
+years	O
+and	O
+average	O
+days	O
+of	O
+discharge	B-ANAT
+from	O
+hospital	O
+(	O
+28	O
+.	O
+0	O
++/-	O
+
+SGRQ	O
+is	O
+a	O
+sensitive	O
+tool	O
+for	O
+assessing	O
+quality	O
+of	O
+life	O
+in	O
+cured	O
+SARS	B-DISO
+patients	O
+.	O
+
+Coronavirus	B-SPEC
+was	O
+observed	O
+in	O
+the	O
+culture	O
+supernatant	O
+by	O
+negative	O
+-	O
+stain	O
+electron	O
+microscopy	O
+.	O
+
+T	B-ANAT
+lymphocytes	I-ANAT
+of	O
+SARS	B-DISO
+patients	O
+decreased	O
+dramatically	O
+but	O
+could	O
+be	O
+obviously	O
+resumed	O
+in	O
+a	O
+short	O
+time	O
+.	O
+
+People	O
+were	O
+all	O
+susceptible	O
+to	O
+SARS	B-DISO
+,	O
+which	O
+mainly	O
+threatened	O
+the	O
+young	O
+adults	O
+and	O
+the	O
+middle	O
+-	O
+aged	O
+,	O
+as	O
+well	O
+as	O
+health	O
+care	O
+workers	O
+and	O
+the	O
+retired	O
+workers	O
+.	O
+
+RESULTS	O
+:	O
+Totally	O
+,	O
+572	O
+cases	O
+notified	O
+were	O
+collected	O
+during	O
+this	O
+period	O
+in	O
+Dongcheng	O
+District	O
+,	O
+Beijing	O
+,	O
+and	O
+99	O
+of	O
+them	O
+were	O
+excluded	O
+from	O
+SARS	B-DISO
+,	O
+because	O
+of	O
+diagnosis	O
+of	O
+common	B-DISO
+cold	I-DISO
+,	O
+pneumonia	B-DISO
+,	O
+measles	B-PATH
+,	O
+or	O
+rubella	B-DISO
+,	O
+etc	O
+.	O
+
+Persons	O
+were	O
+all	O
+susceptible	O
+to	O
+SARS	B-DISO
+,	O
+with	O
+the	O
+highest	O
+proportion	O
+at	O
+ages	O
+of	O
+20	O
+-	O
+50	O
+years	O
+,	O
+which	O
+accounted	O
+for	O
+68	O
+.	O
+7	O
+%	O
+of	O
+the	O
+total	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Reliability	O
+of	O
+detecting	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibody	B-COMP
+for	O
+diagnosis	O
+of	O
+SARS	B-DISO
+].	O
+
+In	O
+addition	O
+,	O
+the	O
+AC	O
+and	O
+PC	O
+of	O
+CD95	B-PRGE
++	I-PRGE
+CD4	I-PRGE
++/	I-PRGE
+CD4	B-PRGE
+and	O
+CD95	B-PRGE
++	I-PRGE
+CD8	I-PRGE
+/	O
+CD8	B-PRGE
+subset	O
+in	O
+group	O
+III	O
+were	O
+highest	O
+while	O
+group	O
+I	O
+was	O
+lowest	O
+.	O
+
+All	O
+patients	O
+were	O
+given	O
+ribavirin	B-CHED
+and	O
+antibiotics	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+tracheal	O
+intubation	O
+and	O
+respiratory	O
+treatment	O
+in	O
+the	O
+critical	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+patients	O
+.	O
+
+Review	O
+and	O
+analyze	O
+tracheal	O
+intubation	O
+and	O
+respiratory	O
+treatment	O
+in	O
+critical	O
+SARS	B-DISO
+patients	O
+in	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+).	O
+
+Conventional	O
+PCR	O
+and	O
+real	O
+-	O
+time	O
+PCR	O
+alone	O
+identified	O
+fewer	O
+SARS	B-DISO
+-	O
+CoV	O
+positive	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+rapidly	O
+progressive	O
+,	O
+and	O
+sometime	O
+fatal	O
+disease	O
+with	O
+more	O
+than	O
+1800	O
+patients	O
+in	O
+over	O
+a	O
+dozen	O
+countries	O
+in	O
+Asia	O
+,	O
+Europe	O
+,	O
+and	O
+North	O
+America	O
+(	O
+including	O
+the	O
+United	O
+States	O
+and	O
+Canada	O
+)	O
+within	O
+two	O
+months	O
+.	O
+
+This	O
+essay	O
+presents	O
+a	O
+qualitative	O
+flowchart	O
+that	O
+follows	O
+SARS	B-DISO
+from	O
+its	O
+origin	O
+in	O
+China	O
+to	O
+the	O
+accumulation	O
+of	O
+global	O
+damage	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+diagnostics	O
+of	O
+atypical	B-DISO
+pneumonia	I-DISO
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+model	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+polymerase	I-PRGE
+:	O
+implications	O
+for	O
+biochemical	O
+functions	O
+and	O
+drug	O
+design	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+designing	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+therapies	O
+can	O
+benefit	O
+from	O
+successful	O
+experiences	O
+in	O
+design	O
+of	O
+other	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+Toronto	O
+,	O
+its	O
+impact	O
+on	O
+anesthesia	B-DISO
+practice	O
+and	O
+the	O
+infection	B-DISO
+control	O
+guidelines	O
+adopted	O
+to	O
+manage	O
+patients	O
+in	O
+the	O
+operating	O
+room	O
+(	O
+OR	O
+)	O
+and	O
+to	O
+provide	O
+emergency	B-DISO
+intubation	O
+outside	O
+the	O
+OR	O
+.	O
+
+ABSTRACT	O
+:	O
+Wisconsin	O
+is	O
+blessed	O
+with	O
+an	O
+abundance	O
+of	O
+high	O
+quality	O
+water	B-CHED
+that	O
+has	O
+played	O
+a	O
+significant	O
+role	O
+in	O
+the	O
+economic	O
+and	O
+social	O
+development	B-PROC
+of	O
+the	O
+state	O
+.	O
+
+While	O
+easy	O
+access	O
+to	O
+modern	O
+medical	O
+care	O
+combined	O
+with	O
+improved	O
+water	B-CHED
+treatment	O
+technologies	O
+have	O
+greatly	O
+decreased	O
+waterborne	O
+disease	O
+,	O
+the	O
+microbiology	O
+of	O
+Wisconsin	O
+'	O
+s	O
+waters	O
+still	O
+deserves	O
+continued	O
+vigilance	O
+and	O
+attention	O
+.	O
+
+The	O
+World	O
+Health	O
+Organization	O
+currently	O
+estimates	O
+that	O
+,	O
+on	O
+a	O
+global	O
+basis	O
+,	O
+4	O
+billion	O
+annual	O
+cases	O
+of	O
+waterborne	O
+diarrhea	O
+result	O
+in	O
+more	O
+than	O
+2	O
+million	O
+deaths	B-PROC
+per	O
+year	O
+--	O
+the	O
+equivalent	O
+of	O
+20	O
+jumbo	O
+jet	O
+crashes	O
+per	O
+day	O
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+data	O
+from	O
+488	O
+cats	O
+(	O
+1979	O
+-	O
+2000	O
+)	O
+with	O
+histopathologically	O
+confirmed	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+and	O
+620	O
+comparable	O
+controls	O
+were	O
+evaluated	O
+retrospectively	O
+to	O
+assess	O
+the	O
+value	O
+of	O
+several	O
+diagnostic	O
+tests	O
+frequently	O
+used	O
+in	O
+the	O
+evaluation	O
+of	O
+cats	B-SPEC
+with	O
+suspected	O
+FIP	B-DISO
+.	O
+
+presence	O
+of	O
+immune	O
+complexes	O
+measured	O
+by	O
+a	O
+competitive	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+were	O
+0	O
+.	O
+67	O
+and	O
+0	O
+.	O
+84	O
+,	O
+and	O
+detection	O
+of	O
+viral	O
+RNA	O
+by	O
+serum	B-COMP
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+were	O
+0	O
+.	O
+90	O
+and	O
+0	O
+.	O
+47	O
+.	O
+
+In	O
+contrast	O
+,	O
+N	B-PRGE
+protein	I-PRGE
+association	O
+in	O
+the	O
+majority	O
+of	O
+the	O
+intracellular	B-COMP
+RNP	B-COMP
+complexes	O
+was	O
+susceptible	O
+to	O
+RNase	B-PRGE
+A	I-PRGE
+-	O
+treatment	O
+.	O
+
+Histopathological	O
+examination	O
+revealed	O
+serous	O
+,	O
+fibrinous	O
+and	O
+haemorrhagic	B-DISO
+inflammation	I-DISO
+in	O
+most	O
+pulmonary	B-ANAT
+alveoli	I-ANAT
+,	O
+with	O
+capillary	B-ANAT
+engorgement	B-DISO
+and	O
+some	O
+capillary	B-ANAT
+microthrombosis	O
+.	O
+
+The	O
+subgroup	O
+who	O
+had	O
+received	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+as	O
+rescue	O
+therapy	O
+,	O
+showed	O
+no	O
+difference	O
+in	O
+overall	O
+death	B-PROC
+rate	O
+and	O
+rates	O
+of	O
+oxygen	B-CHED
+desaturation	O
+and	O
+intubation	O
+compared	O
+with	O
+the	O
+matched	O
+cohort	O
+,	O
+and	O
+received	O
+a	O
+higher	O
+mean	O
+dose	O
+of	O
+methylprednisolone	B-CHED
+.	O
+
+A	O
+randomised	O
+double	O
+-	O
+blind	B-DISO
+placebo	O
+-	O
+controlled	O
+trial	O
+is	O
+recommended	O
+during	O
+future	O
+epidemics	O
+to	O
+further	O
+evaluate	O
+this	O
+treatment	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+addition	O
+of	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+to	O
+a	O
+standard	O
+treatment	O
+protocol	O
+as	O
+an	O
+initial	O
+treatment	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+appeared	O
+to	O
+be	O
+associated	O
+with	O
+improved	O
+clinical	O
+outcome	O
+.	O
+
+Research	O
+efforts	O
+to	O
+mitigate	O
+their	O
+effects	O
+have	O
+concentrated	O
+on	O
+improved	O
+surveillance	O
+and	O
+diagnostic	O
+capabilities	O
+,	O
+as	O
+well	O
+as	O
+on	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+and	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+reports	O
+on	O
+the	O
+development	B-PROC
+of	O
+a	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+for	O
+the	O
+specific	O
+detection	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+).	O
+
+To	O
+overcome	O
+the	O
+problem	O
+of	O
+IBV	B-SPEC
+amplification	B-DISO
+,	O
+a	O
+set	O
+of	O
+separate	O
+primers	O
+was	O
+designed	O
+from	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+of	O
+IBV	B-SPEC
+.	O
+
+The	O
+RT	O
+-	O
+PCR	O
+under	O
+the	O
+same	O
+conditions	O
+as	O
+above	O
+could	O
+effectively	O
+differentiate	O
+between	O
+TCoV	O
+and	O
+IBV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+on	O
+an	O
+unusual	O
+case	O
+of	O
+a	O
+young	O
+African	O
+male	O
+with	O
+systemic	O
+lupus	O
+erythematosus	O
+who	O
+developed	O
+an	O
+acute	O
+,	O
+severe	O
+Guillain	O
+-	O
+Barré	O
+-	O
+like	O
+peripheral	B-DISO
+neuropathy	I-DISO
+associated	O
+with	O
+ascites	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+a	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+vaccine	O
+in	O
+monkeys	B-SPEC
+.	O
+
+All	O
+vaccinated	O
+animals	B-SPEC
+showed	O
+strong	O
+neutralising	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+vitro	O
+.	O
+
+Between	O
+March	O
+28	O
+and	O
+June	O
+30	O
+'	O
+2003	O
+,	O
+29	O
+patients	O
+with	O
+probable	O
+SARS	B-DISO
+seen	O
+at	O
+Shin	B-ANAT
+Kong	O
+Wu	O
+Ho	O
+-	O
+Su	O
+Memorial	O
+Hospital	O
+,	O
+Taipei	O
+,	O
+were	O
+analysed	O
+.	O
+
+RESULTS	O
+:	O
+Presenting	O
+symptoms	O
+included	O
+fever	B-PROC
+(	O
+100	O
+%),	O
+cough	B-DISO
+(	O
+69	O
+.	O
+0	O
+%),	O
+chills	B-DISO
+or	O
+rigor	B-DISO
+(	O
+62	O
+.	O
+1	O
+%),	O
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+(	O
+41	O
+.	O
+4	O
+%).	O
+
+The	O
+risk	O
+factors	O
+associated	O
+with	O
+severe	O
+disease	O
+were	O
+presence	O
+of	O
+diarrhoea	B-DISO
+,	O
+high	O
+peak	O
+LDH	B-PRGE
+and	O
+CRP	B-PRGE
+,	O
+high	O
+AST	B-PRGE
+and	O
+creatine	B-PRGE
+kinase	I-PRGE
+on	O
+admission	O
+and	O
+high	O
+peak	O
+values	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+2003	O
+epidemic	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+CDC	O
+and	O
+the	O
+Council	O
+of	O
+State	O
+and	O
+Territorial	O
+Epidemiologists	O
+(	O
+CSTE	O
+)	O
+developed	O
+surveillance	O
+criteria	O
+to	O
+identify	O
+persons	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+position	O
+statement	O
+included	O
+criteria	O
+for	O
+defining	O
+a	O
+SARS	B-DISO
+case	O
+for	O
+national	O
+reporting	O
+.	O
+
+This	O
+report	O
+summarizes	O
+the	O
+new	O
+U	O
+.	O
+S	O
+.	O
+surveillance	O
+case	O
+definition	O
+for	O
+SARS	B-DISO
+and	O
+updates	O
+reported	O
+cases	O
+of	O
+SARS	B-DISO
+worldwide	O
+and	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+evolution	B-PROC
+in	O
+the	O
+emergence	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+By	O
+using	O
+traditional	O
+yeast	B-SPEC
+genetics	O
+,	O
+host	B-COMP
+genes	O
+have	O
+been	O
+identified	O
+that	O
+function	O
+in	O
+controlling	O
+BMV	B-SPEC
+translation	B-PROC
+,	O
+selecting	O
+BMV	B-SPEC
+RNAs	O
+as	O
+replication	O
+templates	O
+,	O
+activating	O
+the	O
+replication	O
+complex	O
+,	O
+maintaining	O
+a	O
+lipid	B-CHED
+composition	O
+required	O
+for	O
+membrane	B-COMP
+-	O
+associated	O
+RNA	B-PROC
+replication	I-PROC
+,	O
+and	O
+other	O
+steps	O
+.	O
+
+Approximately	O
+4500	O
+yeast	B-SPEC
+deletion	O
+strains	O
+(	O
+approximately	O
+80	O
+%	O
+of	O
+yeast	B-SPEC
+genes	O
+)	O
+were	O
+screened	O
+in	O
+duplicate	O
+and	O
+selected	O
+strains	O
+analyzed	O
+further	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+was	O
+discovered	O
+as	O
+the	O
+pathogen	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+recombinant	O
+protein	B-CHED
+was	O
+identified	O
+by	O
+Western	O
+blot	O
+and	O
+mass	O
+spectrometry	O
+.	O
+
+The	O
+majority	O
+of	O
+patients	O
+(	O
+80	O
+%)	O
+and	O
+next	O
+of	O
+kin	B-PRGE
+(	O
+76	O
+%)	O
+were	O
+at	O
+least	O
+moderately	O
+satisfied	O
+with	O
+current	O
+restricted	O
+limiting	O
+hours	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+is	O
+a	O
+devastating	O
+disease	O
+that	O
+caused	O
+widespread	O
+morbidity	O
+and	O
+mortality	O
+,	O
+as	O
+well	O
+as	O
+tremendous	O
+fear	O
+and	O
+uncertainty	O
+across	O
+the	O
+global	O
+village	O
+.	O
+
+But	O
+it	O
+all	O
+paled	O
+in	O
+comparison	O
+with	O
+what	O
+followed	O
+,	O
+as	O
+we	O
+coped	O
+with	O
+the	O
+outbreak	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+membrane	B-COMP
+-	O
+associated	O
+carboxypeptidase	O
+angiotensin	O
+-	O
+converting	O
+enzyme	O
+2	O
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+an	O
+essential	O
+regulator	O
+of	O
+heart	B-PROC
+function	I-PROC
+.	O
+
+After	O
+Koch	O
+'	O
+s	O
+postulates	O
+had	O
+been	O
+fulfilled	O
+,	O
+WHO	O
+officially	O
+declared	O
+on	O
+16	O
+April	O
+2003	O
+that	O
+this	O
+virus	B-SPEC
+never	O
+before	O
+seen	O
+in	O
+humans	O
+is	O
+the	O
+cause	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+vaccine	O
+development	B-PROC
+:	O
+experiences	O
+of	O
+vaccination	O
+against	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Genetic	O
+lines	O
+of	O
+chickens	B-SPEC
+differ	O
+in	O
+the	O
+extent	O
+to	O
+which	O
+IBV	B-SPEC
+causes	O
+mortality	O
+in	O
+chicks	O
+,	O
+and	O
+in	O
+respect	O
+of	O
+clearance	O
+of	O
+the	O
+virus	B-SPEC
+after	O
+the	O
+acute	O
+phase	O
+.	O
+
+This	O
+increases	O
+protection	O
+of	O
+the	O
+laying	O
+birds	B-SPEC
+against	O
+egg	B-ANAT
+production	O
+losses	O
+and	O
+induces	O
+a	O
+sustained	O
+level	O
+of	O
+serum	B-PRGE
+antibody	B-COMP
+,	O
+which	O
+is	O
+passed	O
+to	O
+progeny	O
+.	O
+
+The	O
+large	O
+spike	O
+glycoprotein	B-CHED
+(	O
+S	O
+)	O
+comprises	O
+a	O
+carboxy	B-CHED
+-	O
+terminal	O
+S2	O
+subunit	O
+(	O
+approximately	O
+625	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+),	O
+which	O
+anchors	O
+S	O
+in	O
+the	O
+virus	B-SPEC
+envelope	B-COMP
+,	O
+and	O
+an	O
+amino	O
+-	O
+terminal	O
+S1	O
+subunit	O
+(	O
+approximately	O
+520	O
+residues	O
+),	O
+believed	O
+to	O
+largely	O
+form	O
+the	O
+distal	O
+bulbous	O
+part	O
+of	O
+S	O
+.	O
+The	O
+S1	B-PRGE
+subunit	I-PRGE
+(	O
+purified	O
+from	O
+IBV	B-SPEC
+virus	B-SPEC
+,	O
+expressed	B-PROC
+using	O
+baculovirus	B-SPEC
+or	O
+expressed	B-PROC
+in	O
+birds	B-SPEC
+from	O
+a	O
+fowlpoxvirus	B-SPEC
+vector	O
+)	O
+induced	O
+virus	B-SPEC
+neutralizing	O
+antibody	B-COMP
+.	O
+
+It	O
+is	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+probably	O
+of	O
+animal	B-SPEC
+origin	O
+.	O
+
+A	O
+high	O
+index	O
+of	O
+suspicion	O
+for	O
+the	O
+disease	O
+,	O
+isolation	O
+of	O
+patients	O
+,	O
+strict	O
+observation	O
+of	O
+infection	B-DISO
+control	O
+practices	O
+and	O
+compliance	O
+with	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+are	O
+necessary	O
+to	O
+prevent	O
+nosocomial	B-DISO
+infection	I-DISO
+.	O
+
+Prevention	O
+of	O
+future	O
+outbreaks	O
+requires	O
+strengthening	O
+of	O
+infection	B-DISO
+control	O
+practices	O
+in	O
+hospitals	O
+,	O
+development	B-PROC
+of	O
+a	O
+rapid	O
+diagnostic	O
+test	O
+and	O
+a	O
+vaccine	O
+,	O
+and	O
+removal	O
+of	O
+any	O
+animal	B-SPEC
+reservoir	O
+and	O
+environmental	O
+conditions	O
+that	O
+led	O
+to	O
+the	O
+spread	O
+of	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+viruses	B-SPEC
+set	O
+to	O
+soar	O
+.	O
+
+ABSTRACT	O
+:	O
+Community	O
+-	O
+based	O
+elderly	O
+studies	O
+concerning	O
+microbiology	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+are	O
+scarce	O
+.	O
+
+Participants	O
+,	O
+persons	O
+>/=	O
+60	O
+years	O
+,	O
+reported	O
+daily	O
+the	O
+presence	O
+of	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+a	O
+diary	O
+.	O
+
+This	O
+study	O
+supports	O
+the	O
+importance	O
+of	O
+rhinovirus	B-SPEC
+infections	B-DISO
+in	O
+community	O
+-	O
+dwelling	O
+elderly	O
+persons	O
+,	O
+whereas	O
+asymptomatic	O
+elderly	O
+persons	O
+can	O
+also	O
+harbor	O
+pathogens	O
+as	O
+detected	O
+by	O
+PCR	O
+,	O
+and	O
+thus	O
+might	O
+be	O
+a	O
+source	O
+of	O
+infection	B-DISO
+for	O
+their	O
+environment	O
+.	O
+
+In	O
+4	O
+%	O
+of	O
+the	O
+symptom	B-DISO
+-	O
+free	O
+control	O
+periods	B-PROC
+a	O
+virus	B-SPEC
+was	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+addition	O
+to	O
+maintaining	O
+the	O
+GenBank	O
+(	O
+R	O
+)	O
+nucleic	B-CHED
+acid	I-CHED
+sequence	O
+database	O
+,	O
+the	O
+National	O
+Center	O
+for	O
+Biotechnology	O
+Information	O
+(	O
+NCBI	O
+)	O
+provides	O
+data	O
+analysis	O
+and	O
+retrieval	O
+resources	O
+for	O
+the	O
+data	O
+in	O
+GenBank	O
+and	O
+other	O
+biological	O
+data	O
+made	O
+available	O
+through	O
+NCBI	O
+'	O
+s	O
+website	O
+.	O
+
+NCBI	O
+resources	O
+include	O
+Entrez	O
+,	O
+PubMed	O
+,	O
+PubMed	O
+Central	O
+,	O
+LocusLink	O
+,	O
+the	O
+NCBI	O
+Taxonomy	O
+Browser	O
+,	O
+BLAST	B-ANAT
+,	O
+BLAST	B-ANAT
+Link	O
+(	O
+BLink	B-PROC
+),	O
+Electronic	O
+PCR	O
+,	O
+OrfFinder	O
+,	O
+Spidey	O
+,	O
+RefSeq	O
+,	O
+UniGene	O
+,	O
+HomoloGene	O
+,	O
+ProtEST	O
+,	O
+dbMHC	O
+,	O
+dbSNP	O
+,	O
+Cancer	B-DISO
+Chromosome	B-DISO
+Aberration	I-DISO
+Project	O
+(	O
+CCAP	O
+),	O
+Entrez	O
+Genomes	O
+and	O
+related	O
+tools	O
+,	O
+the	O
+Map	O
+Viewer	O
+,	O
+Model	O
+Maker	O
+,	O
+Evidence	O
+Viewer	O
+,	O
+Clusters	B-CHED
+of	O
+Orthologous	O
+Groups	O
+(	O
+COGs	O
+)	O
+database	O
+,	O
+Retroviral	B-SPEC
+Genotyping	O
+Tools	O
+,	O
+SARS	B-DISO
+Coronavirus	B-SPEC
+Resource	O
+,	O
+SAGEmap	O
+,	O
+Gene	B-PROC
+Expression	I-PROC
+Omnibus	O
+(	O
+GEO	O
+),	O
+Online	B-PRGE
+Mendelian	I-PRGE
+Inheritance	I-PRGE
+in	I-PRGE
+Man	B-CHED
+(	O
+OMIM	O
+),	O
+the	O
+Molecular	O
+Modeling	O
+Database	O
+(	O
+MMDB	O
+),	O
+the	O
+Conserved	O
+Domain	O
+Database	O
+(	O
+CDD	B-DISO
+)	O
+and	O
+the	O
+Conserved	O
+Domain	O
+Architecture	O
+Retrieval	O
+Tool	O
+(	O
+CDART	O
+).	O
+
+Although	O
+many	O
+infected	O
+persons	O
+traveled	O
+on	O
+commercial	O
+aircraft	O
+,	O
+the	O
+risk	O
+,	O
+if	O
+any	O
+,	O
+of	O
+in	O
+-	O
+flight	B-PROC
+transmission	O
+is	O
+unknown	O
+.	O
+
+In	O
+contrast	O
+,	O
+another	O
+flight	B-PROC
+carrying	O
+four	O
+symptomatic	O
+persons	O
+resulted	O
+in	O
+transmission	O
+to	O
+at	O
+most	O
+one	O
+other	O
+person	O
+,	O
+and	O
+no	O
+illness	O
+was	O
+documented	O
+in	O
+passengers	O
+on	O
+the	O
+flight	B-PROC
+that	O
+carried	O
+a	O
+person	O
+who	O
+had	O
+presymptomatic	O
+SARS	B-DISO
+.	O
+
+Using	O
+twelve	O
+gene	O
+prediction	O
+methods	O
+to	O
+predict	O
+coronavirus	B-SPEC
+known	O
+genes	O
+,	O
+we	O
+select	O
+four	O
+better	O
+methods	O
+including	O
+Heuristic	O
+models	O
+,	O
+Gene	O
+Identification	O
+,	O
+ZCURVE_CoV	O
+and	O
+ORF	O
+FINDER	O
+to	O
+predict	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+BJ01	O
+),	O
+and	O
+use	O
+ATGpr	O
+for	O
+analyzing	O
+probability	O
+of	O
+initiation	O
+codon	O
+and	O
+Kozak	O
+rule	O
+,	O
+search	O
+transcription	B-PROC
+regulating	O
+sequence	O
+(	O
+TRS	B-DISO
+)	O
+in	O
+order	B-SPEC
+to	O
+improve	O
+the	O
+accuracy	O
+of	O
+predicted	O
+genes	O
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+we	O
+separate	O
+the	O
+21	O
+ORFs	O
+into	O
+four	O
+classes	O
+using	O
+codition	O
+of	O
+four	O
+gene	O
+prediction	O
+methods	O
+,	O
+match	O
+score	O
+,	O
+match	O
+expection	O
+and	O
+match	O
+length	O
+between	O
+predicted	O
+gene	O
+and	O
+Coronavirus	B-SPEC
+known	O
+gene	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+high	O
+-	O
+resolution	O
+CT	O
+(	O
+HRCT	O
+)	O
+findings	O
+at	O
+presentation	O
+and	O
+after	O
+hospital	O
+admission	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+predominant	O
+HRCT	O
+findings	O
+at	O
+presentation	O
+consisted	O
+of	O
+unilateral	O
+(	O
+n	O
+=	O
+6	O
+)	O
+or	O
+bilateral	O
+(	O
+n	O
+=	O
+2	O
+)	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+or	O
+focal	O
+unilateral	O
+(	O
+n	O
+=	O
+2	O
+)	O
+or	O
+bilateral	O
+(	O
+n	O
+=	O
+2	O
+)	O
+areas	O
+of	O
+consolidation	O
+.	O
+
+This	O
+arrangement	O
+freed	O
+the	O
+other	O
+CT	O
+scanners	O
+in	O
+the	O
+main	O
+department	O
+for	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+.	O
+
+In	O
+5	O
+weeks	O
+,	O
+90	O
+studies	O
+were	O
+performed	O
+;	O
+no	O
+cases	O
+of	O
+cross	B-DISO
+infection	I-DISO
+of	O
+health	O
+care	O
+workers	O
+were	O
+reported	O
+.	O
+
+Mobile	O
+CT	O
+may	O
+be	O
+used	O
+to	O
+provide	O
+dedicated	O
+radiology	O
+services	O
+to	O
+seriously	O
+ill	B-DISO
+patients	O
+requiring	O
+strict	O
+isolation	O
+during	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+outbreak	O
+.	O
+
+However	O
+,	O
+the	O
+receptor	O
+of	O
+the	O
+PEDV	B-SPEC
+has	O
+not	O
+been	O
+identified	O
+yet	O
+.	O
+
+The	O
+binding	B-FUNC
+ability	O
+of	O
+PEDV	B-SPEC
+to	O
+porcine	B-PRGE
+APN	I-PRGE
+(	O
+pAPN	O
+)	O
+and	O
+the	O
+effects	O
+of	O
+pAPN	O
+on	O
+infectivity	O
+of	O
+PEDV	B-SPEC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+were	O
+also	O
+investigated	O
+.	O
+
+With	O
+occurrence	O
+of	O
+the	O
+first	O
+SARS	B-DISO
+case	O
+in	O
+Germany	O
+a	O
+nationwide	O
+surveillance	O
+system	O
+for	O
+SARS	B-DISO
+was	O
+established	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Evaluation	O
+on	O
+the	O
+functions	O
+and	O
+cost	O
+of	O
+'	B-PROC
+fever	I-PROC
+clinics	O
+'	O
+during	O
+the	O
+period	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemics	O
+in	O
+Beijing	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+the	O
+experiences	O
+and	O
+lessons	O
+learned	B-PROC
+on	O
+'	B-PROC
+fever	I-PROC
+clinics	O
+'	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+in	O
+Beijing	O
+and	O
+to	O
+propose	O
+a	O
+better	O
+model	O
+in	O
+monitoring	O
+SARS	B-DISO
+to	O
+fit	B-DISO
+the	O
+'	B-PROC
+fever	I-PROC
+clinics	O
+'	O
+into	O
+current	O
+situation	O
+.	O
+
+The	O
+setting	O
+,	O
+functions	O
+and	O
+administration	O
+of	O
+current	O
+63	O
+'	B-PROC
+fever	I-PROC
+clinics	O
+'	O
+in	O
+Beijing	O
+;	O
+2	O
+.	O
+
+Survey	O
+on	O
+patients	O
+with	O
+fever	B-PROC
+who	O
+had	O
+visited	O
+'	B-PROC
+fever	I-PROC
+clinics	O
+'	O
+and	O
+randomly	O
+selected	O
+from	O
+the	O
+63	O
+fever	B-PROC
+clinics	O
+;	O
+3	O
+.	O
+
+Short	O
+-	O
+term	O
+and	O
+long	O
+-	O
+term	O
+suggestions	O
+were	O
+proposed	O
+regarding	O
+SARS	B-DISO
+monitoring	O
+through	O
+the	O
+functions	O
+of	O
+'	B-PROC
+fever	I-PROC
+clinics	O
+'	O
+in	O
+Beijing	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+viruses	B-SPEC
+cause	O
+serious	O
+medical	O
+problems	O
+and	O
+social	O
+disruption	O
+every	O
+year	O
+in	O
+particular	O
+countries	O
+of	O
+the	O
+world	O
+.	O
+
+The	O
+SARS	B-DISO
+outbreak	O
+has	O
+illuminated	O
+weaknesses	B-DISO
+in	O
+planning	O
+for	O
+sudden	O
+outbreaks	O
+of	O
+disease	O
+in	O
+a	O
+modern	O
+society	O
+and	O
+in	O
+particular	O
+how	O
+panic	O
+can	O
+grip	B-PROC
+and	O
+cause	O
+intense	O
+economic	O
+disruption	O
+.	O
+
+Many	O
+communities	O
+in	O
+the	O
+world	O
+are	O
+neither	O
+prepared	O
+for	O
+a	O
+global	O
+pandemic	O
+nor	O
+a	O
+very	O
+acute	O
+epidemic	O
+of	O
+influenza	B-DISO
+.	O
+
+A	O
+series	O
+of	O
+co	O
+-	O
+immunoprecipitation	O
+assays	O
+have	O
+established	O
+that	O
+these	O
+four	O
+MHV	B-PRGE
+RNA	B-FUNC
+binding	I-FUNC
+proteins	B-CHED
+are	O
+associated	O
+,	O
+even	O
+in	O
+the	O
+absence	O
+of	O
+MHV	B-SPEC
+RNA	O
+.	O
+
+However	O
+,	O
+it	O
+may	O
+lead	O
+to	O
+severe	O
+withdrawal	B-DISO
+symptoms	I-DISO
+:	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+jitteriness	B-DISO
+,	O
+convulsions	B-DISO
+,	O
+hypoglycaemia	B-DISO
+,	O
+an	O
+impaired	B-DISO
+muscle	B-PROC
+tone	I-PROC
+and	O
+necrotising	B-DISO
+enterocolitis	I-DISO
+.	O
+
+Within	O
+the	O
+first	O
+days	O
+the	O
+patient	O
+also	O
+developed	O
+cerebral	B-ANAT
+seizures	B-DISO
+.	O
+
+Fecal	B-ANAT
+samples	O
+were	O
+evaluated	O
+for	O
+Eimeria	B-PRGE
+spp	B-ENZY
+,	I-PRGE
+Giardia	B-DISO
+spp	B-ENZY
+,	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+,	O
+enteric	O
+viruses	B-SPEC
+,	O
+and	O
+Salmonella	B-PRGE
+spp	B-ENZY
+.	O
+
+The	O
+virus	B-SPEC
+killed	O
+4	O
+-	O
+week	O
+-	O
+old	O
+mice	B-SPEC
+readily	O
+by	O
+all	O
+routes	O
+of	O
+inoculation	O
+except	O
+the	O
+oral	B-ANAT
+,	O
+and	O
+8	O
+-	O
+week	O
+-	O
+old	O
+mice	B-SPEC
+by	O
+i	O
+.	O
+c	O
+.,	O
+i	O
+.	O
+n	O
+.	O
+or	O
+s	O
+.	O
+c	O
+.	O
+
+To	O
+follow	O
+the	O
+spread	O
+of	O
+HEV	B-SPEC
+from	O
+peripheral	B-ANAT
+nerves	I-ANAT
+to	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+),	O
+the	O
+virus	B-SPEC
+was	O
+inoculated	O
+subcutaneously	O
+into	O
+the	O
+right	O
+hind	O
+leg	B-ANAT
+of	O
+4	O
+-	O
+week	O
+-	O
+old	O
+mice	O
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+first	O
+detected	O
+in	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+on	O
+day	O
+2	O
+,	O
+and	O
+in	O
+the	O
+brain	B-ANAT
+on	O
+day	O
+3	O
+.	O
+
+TITLE	O
+:	O
+Interferon	B-PRGE
+alfacon	I-PRGE
+-	I-PRGE
+1	I-PRGE
+plus	O
+corticosteroids	B-CHED
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+preliminary	O
+study	O
+.	O
+
+Of	O
+the	O
+13	O
+patients	O
+treated	O
+with	O
+corticosteroids	B-CHED
+alone	O
+,	O
+5	O
+(	O
+38	O
+.	O
+5	O
+%)	O
+were	O
+transferred	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+,	O
+3	O
+(	O
+23	O
+.	O
+1	O
+%)	O
+required	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+1	O
+(	O
+7	O
+.	O
+7	O
+%)	O
+died	B-PROC
+.	O
+
+Of	O
+the	O
+9	O
+patients	O
+in	O
+the	O
+interferon	B-PRGE
+alfacon	I-PRGE
+-	I-PRGE
+1	I-PRGE
+treatment	O
+group	O
+,	O
+3	O
+(	O
+33	O
+.	O
+3	O
+%)	O
+were	O
+transferred	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+,	O
+1	O
+(	O
+11	O
+.	O
+1	O
+%)	O
+required	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+none	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Ethical	O
+and	O
+legal	O
+challenges	O
+posed	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+implications	O
+for	O
+the	O
+control	O
+of	O
+severe	O
+infectious	O
+disease	O
+threats	O
+.	O
+
+The	O
+article	O
+articulates	O
+a	O
+set	O
+of	O
+legal	O
+and	O
+ethical	O
+recommendations	O
+for	O
+responding	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+threats	O
+,	O
+seeking	O
+to	O
+reconcile	O
+the	O
+tension	B-DISO
+between	O
+the	O
+public	O
+'	O
+s	O
+health	O
+and	O
+individual	O
+rights	O
+to	O
+privacy	O
+,	O
+liberty	O
+,	O
+and	O
+freedom	O
+of	O
+movement	B-PROC
+.	O
+
+TITLE	O
+:	O
+CXC	O
+chemokine	O
+ligand	B-PROC
+10	O
+controls	O
+viral	B-DISO
+infection	I-DISO
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+:	O
+evidence	O
+for	O
+a	O
+role	O
+in	O
+innate	O
+immune	O
+response	O
+through	O
+recruitment	B-DISO
+and	O
+activation	O
+of	O
+natural	B-ANAT
+killer	I-ANAT
+cells	I-ANAT
+.	O
+
+This	O
+pseudoknot	O
+was	O
+also	O
+shown	O
+to	O
+be	O
+essential	O
+for	O
+replication	O
+,	O
+and	O
+it	O
+has	O
+a	O
+conserved	O
+counterpart	O
+in	O
+every	O
+group	O
+1	O
+and	O
+group	O
+2	O
+coronavirus	B-SPEC
+.	O
+
+Additionally	O
+,	O
+we	O
+have	O
+identified	O
+a	O
+pseudoknot	O
+loop	O
+insertion	B-PROC
+mutation	I-PROC
+that	O
+appears	O
+to	O
+point	O
+to	O
+a	O
+genetic	O
+interaction	O
+between	O
+the	O
+pseudoknot	O
+and	O
+a	O
+distant	O
+region	O
+of	O
+the	O
+genome	O
+.	O
+
+TITLE	O
+:	O
+Sequence	O
+motifs	O
+involved	O
+in	O
+the	O
+regulation	B-PROC
+of	O
+discontinuous	O
+coronavirus	B-SPEC
+subgenomic	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+transcription	B-PROC
+leads	O
+to	O
+the	O
+synthesis	B-PROC
+of	O
+a	O
+nested	O
+set	O
+of	O
+mRNAs	O
+with	O
+a	O
+leader	O
+sequence	O
+derived	O
+from	O
+the	O
+5	O
+'	O
+end	O
+of	O
+the	O
+genome	O
+.	O
+
+The	O
+mRNAs	O
+are	O
+produced	O
+by	O
+a	O
+discontinuous	O
+transcription	B-PROC
+in	O
+which	O
+the	O
+leader	O
+is	O
+linked	O
+to	O
+the	O
+mRNA	B-CHED
+coding	O
+sequences	O
+.	O
+
+Treatment	O
+with	O
+oral	B-ANAT
+prednisolone	B-CHED
+and	O
+ribavirin	B-CHED
+normalized	O
+her	O
+lymphopenia	B-DISO
+,	O
+altered	O
+transaminases	O
+,	O
+chest	B-ANAT
+radiograph	O
+and	O
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+appearances	O
+rapidly	O
+.	O
+
+TITLE	O
+:	O
+Novel	O
+N	O
+-	O
+thiolated	O
+beta	B-CHED
+-	I-CHED
+lactam	I-CHED
+antibiotics	I-CHED
+selectively	O
+induce	O
+apoptosis	B-PATH
+in	O
+human	B-SPEC
+tumor	B-DISO
+and	O
+transformed	O
+,	O
+but	O
+not	O
+normal	O
+or	O
+nontransformed	O
+,	O
+cells	O
+.	O
+
+T	B-ANAT
+lymphocytes	I-ANAT
+play	O
+an	O
+important	O
+role	O
+in	O
+MHV	B-SPEC
+infection	B-DISO
+,	O
+and	O
+costimulatory	O
+signals	O
+are	O
+an	O
+important	O
+component	O
+of	O
+T	B-ANAT
+cell	I-ANAT
+function	O
+.	O
+
+Thus	O
+,	O
+CD28	B-PRGE
+,	O
+the	O
+costimulatory	O
+T	B-ANAT
+cell	I-ANAT
+molecule	O
+,	O
+is	O
+not	O
+required	O
+for	O
+MHV	B-SPEC
+infection	B-DISO
+and	O
+MHV	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+TITLE	O
+:	O
+Sensitive	O
+and	O
+quantitative	O
+detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+by	O
+real	O
+-	O
+time	O
+nested	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+All	O
+children	O
+except	O
+1	O
+(	O
+patient	O
+3	O
+)	O
+received	O
+corticosteroids	B-CHED
+.	O
+
+The	O
+current	O
+evidence	O
+does	O
+not	O
+support	O
+the	O
+use	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+monoclonal	I-PRGE
+antibody	I-PRGE
+in	O
+this	O
+group	O
+of	O
+children	O
+.	O
+
+Similarly	O
+,	O
+plasma	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+concentrations	O
+were	O
+significantly	O
+decreased	O
+7	O
+to	O
+10	O
+days	O
+after	O
+the	O
+drug	O
+treatment	O
+.	O
+
+Additionally	O
+,	O
+there	O
+is	O
+in	O
+vitro	O
+evidence	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+'	O
+s	O
+ability	O
+to	O
+infect	O
+neural	O
+cells	B-COMP
+.	O
+
+Possible	O
+agents	O
+include	O
+smallpox	B-DISO
+,	O
+haemorrhagic	B-DISO
+fever	I-DISO
+viruses	B-SPEC
+,	O
+anthrax	B-DISO
+,	O
+tularaemia	B-DISO
+and	O
+plague	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+analysis	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Beijing	O
+area	O
+].	O
+
+The	O
+most	O
+common	O
+symptom	B-DISO
+were	O
+fever	B-PROC
+(	O
+100	O
+.	O
+
+TITLE	O
+:	O
+Antigenicity	O
+and	O
+receptor	O
+-	O
+binding	B-FUNC
+ability	O
+of	O
+recombinant	B-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+.	O
+
+In	O
+order	B-SPEC
+to	O
+analyze	O
+the	O
+antigenicity	O
+and	O
+receptor	O
+-	O
+binding	B-FUNC
+ability	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+,	O
+we	O
+expressed	B-PROC
+the	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+using	O
+a	O
+pET	B-PRGE
+expression	B-PROC
+vector	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+began	O
+in	O
+Canada	O
+in	O
+February	O
+2003	O
+.	O
+
+However	O
+,	O
+without	O
+a	O
+""""	O
+gold	B-CHED
+standard	O
+","""	O
+it	O
+was	O
+impossible	O
+to	O
+determine	O
+the	O
+usefulness	O
+of	O
+these	O
+tests	O
+.	O
+
+We	O
+describe	O
+how	O
+these	O
+tests	O
+were	O
+used	O
+during	O
+the	O
+first	O
+phase	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+Toronto	O
+and	O
+offer	O
+some	O
+recommendations	O
+that	O
+may	O
+be	O
+useful	O
+if	O
+SARS	B-DISO
+returns	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+the	O
+rapid	O
+diagnostic	O
+tests	O
+in	O
+use	O
+at	O
+the	O
+time	O
+of	O
+the	O
+initial	O
+outbreak	O
+lack	O
+sufficient	O
+sensitivity	O
+to	O
+be	O
+used	O
+clinically	O
+to	O
+rule	O
+out	O
+SARS	B-DISO
+.	O
+
+In	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+specimens	O
+taken	O
+from	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+stool	B-ANAT
+samples	O
+test	O
+positive	O
+by	O
+means	O
+of	O
+RT	O
+-	O
+PCR	O
+more	O
+often	O
+than	O
+do	O
+samples	O
+taken	O
+from	O
+other	O
+areas	O
+.	O
+
+Severe	O
+necrotizing	B-DISO
+pancreatitis	I-DISO
+(	O
+SNP	O
+)	O
+was	O
+induced	O
+by	O
+retrograde	O
+injection	O
+of	O
+3	O
+%	O
+taurocholate	B-CHED
+into	O
+the	O
+common	O
+biliopancreatic	O
+duct	B-ANAT
+.	O
+
+It	O
+also	O
+suppressed	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+and	O
+MPO	B-FUNC
+activity	O
+of	O
+the	O
+pancreatic	B-ANAT
+tissue	B-ANAT
+.	O
+
+Items	O
+with	O
+significant	O
+differences	O
+among	O
+symptoms	O
+,	O
+signs	O
+,	O
+and	O
+laboratory	O
+tests	O
+on	O
+presentation	O
+between	O
+SARS	B-DISO
+and	O
+non	O
+-	O
+SARS	B-DISO
+groups	O
+were	O
+determined	O
+and	O
+used	O
+to	O
+develop	O
+the	O
+scoring	O
+system	O
+.	O
+
+In	O
+nonendemic	O
+areas	O
+,	O
+the	O
+febrile	B-PROC
+patients	O
+with	O
+recent	O
+contact	O
+with	O
+SARS	B-DISO
+or	O
+travel	O
+history	O
+to	O
+endemic	O
+areas	O
+could	O
+be	O
+screened	O
+for	O
+the	O
+probability	O
+of	O
+SARS	B-DISO
+by	O
+the	O
+use	O
+of	O
+clinical	O
+and	O
+symptom	B-DISO
+scores	O
+.	O
+
+TITLE	O
+:	O
+An	O
+emergency	B-DISO
+department	O
+response	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+prototype	O
+response	O
+to	O
+bioterrorism	O
+.	O
+
+Among	O
+10	O
+,	O
+075	O
+persons	O
+discharged	O
+from	O
+the	O
+ED	O
+,	O
+there	O
+were	O
+28	O
+reattending	O
+patients	O
+who	O
+were	O
+admitted	O
+and	O
+diagnosed	O
+with	O
+SARS	B-DISO
+,	O
+giving	O
+an	O
+undertriage	O
+rate	O
+of	O
+0	O
+.	O
+3	O
+%	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+0	O
+.	O
+1	O
+%	O
+to	O
+0	O
+.	O
+4	O
+%).	O
+
+The	O
+scoring	O
+system	O
+for	O
+SARS	B-DISO
+can	O
+provide	O
+a	O
+rapid	O
+and	O
+reliable	O
+clinical	O
+decision	O
+to	O
+help	O
+emergency	B-DISO
+physicians	O
+detect	O
+cases	O
+of	O
+SARS	B-DISO
+more	O
+accurately	O
+in	O
+the	O
+endemic	O
+area	O
+.	O
+
+Seventy	O
+-	O
+nine	O
+SARS	B-DISO
+and	O
+220	O
+non	O
+-	O
+SARS	B-DISO
+cases	O
+were	O
+analyzed	O
+.	O
+
+During	O
+an	O
+outbreak	O
+period	O
+,	O
+recognition	O
+of	O
+possible	O
+SARS	B-DISO
+cases	O
+depends	O
+on	O
+the	O
+heightened	O
+awareness	O
+of	O
+its	O
+clinical	O
+presentation	O
+.	O
+
+The	O
+development	B-PROC
+of	O
+the	O
+response	O
+to	O
+SARS	B-DISO
+raised	O
+a	O
+number	O
+of	O
+more	O
+general	O
+issues	O
+relevant	O
+to	O
+future	O
+infectious	B-DISO
+epidemic	O
+threats	O
+.	O
+
+All	O
+countries	O
+will	O
+need	O
+to	O
+be	O
+vigilant	O
+and	O
+plan	B-DISO
+their	O
+response	O
+to	O
+the	O
+possibility	O
+of	O
+a	O
+renewed	O
+SARS	O
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+maternal	O
+respiratory	B-DISO
+distress	I-DISO
+due	O
+to	O
+the	O
+amniotic	B-DISO
+fluid	I-DISO
+embolism	I-DISO
+syndrome	B-DISO
+in	O
+a	O
+twin	O
+pregnancy	O
+.	O
+
+No	O
+evidence	O
+for	O
+venous	B-ANAT
+thromboembolism	B-DISO
+,	I-DISO
+pulmonary	I-DISO
+infection	B-DISO
+or	O
+myocardial	B-DISO
+infarction	I-DISO
+was	O
+found	O
+.	O
+
+Subsequently	O
+a	O
+mild	O
+coagulopathy	B-DISO
+and	O
+foetal	B-DISO
+distress	I-DISO
+developed	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+by	O
+conventional	O
+and	O
+real	O
+-	O
+time	O
+quantitative	O
+reverse	O
+transcription	O
+-	O
+PCR	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+The	O
+impact	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+on	O
+otorhinolaryngological	O
+services	O
+at	O
+the	O
+Prince	O
+of	O
+Wales	O
+Hospital	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+changes	O
+in	O
+these	O
+parameters	O
+were	O
+determined	O
+against	O
+the	O
+background	O
+of	O
+new	O
+SARS	B-DISO
+cases	O
+.	O
+
+The	O
+temporary	O
+closure	O
+of	O
+the	O
+accident	O
+and	O
+emergency	B-DISO
+department	O
+contributed	O
+to	O
+the	O
+decrease	O
+in	O
+ward	O
+admissions	O
+and	O
+emergency	B-DISO
+surgical	O
+procedures	O
+.	O
+
+RESULTS	O
+:	O
+Since	O
+the	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+March	O
+2003	O
+,	O
+the	O
+weekly	O
+outpatient	O
+clinic	O
+attendance	O
+has	O
+declined	O
+by	O
+59	O
+%,	O
+the	O
+number	O
+of	O
+operations	O
+performed	O
+by	O
+79	O
+%,	O
+the	O
+average	O
+ward	O
+bed	B-DISO
+occupancy	O
+rate	O
+by	O
+79	O
+%	O
+and	O
+the	O
+daily	O
+admission	O
+rate	O
+by	O
+84	O
+%.	O
+
+Nonessential	O
+elective	O
+surgery	O
+was	O
+suspended	O
+soon	O
+after	O
+the	O
+outbreak	O
+,	O
+accounting	O
+for	O
+the	O
+decrease	O
+in	O
+the	O
+number	O
+of	O
+surgical	O
+procedures	O
+performed	O
+and	O
+partially	O
+for	O
+the	O
+decrease	O
+in	O
+ward	O
+bed	B-DISO
+occupancy	O
+and	O
+ward	O
+admissions	O
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+studies	O
+have	O
+been	O
+published	O
+in	O
+western	O
+literature	O
+on	O
+incidence	O
+,	O
+prevalence	O
+,	O
+clinical	O
+course	O
+,	O
+outcome	O
+and	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+).	O
+
+Although	O
+she	O
+has	O
+been	O
+free	O
+of	O
+chest	B-ANAT
+symptoms	O
+for	O
+seven	O
+months	O
+,	O
+further	O
+follow	O
+-	O
+up	O
+may	O
+be	O
+necessary	O
+to	O
+assess	O
+the	O
+potential	O
+danger	O
+of	O
+relapse	B-DISO
+.	O
+
+A	O
+63	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+was	O
+admitted	O
+to	O
+our	O
+hospital	O
+for	O
+intensive	O
+care	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+diffuse	O
+infiltration	B-DISO
+in	O
+both	O
+lungs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Managing	O
+obstetrical	O
+patients	O
+during	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+described	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+ACE2	B-PRGE
+sequence	I-PRGE
+is	O
+similar	O
+(	O
+sequence	O
+identities	O
+43	O
+%	O
+and	B-PRGE
+35	O
+%,	O
+and	O
+similarities	O
+61	O
+%	O
+and	O
+55	O
+%,	O
+respectively	O
+)	O
+to	O
+those	O
+of	O
+the	O
+testis	B-ANAT
+-	O
+specific	O
+form	O
+of	O
+ACE	B-PRGE
+(	O
+tACE	B-PRGE
+)	O
+and	O
+the	O
+Drosophila	B-PRGE
+homolog	I-PRGE
+of	I-PRGE
+ACE	B-ENZY
+(	O
+AnCE	B-PRGE
+).	O
+
+The	O
+high	O
+level	O
+of	O
+sequence	O
+similarity	O
+allowed	O
+us	O
+to	O
+build	O
+a	O
+robust	O
+homology	O
+model	O
+of	O
+the	O
+ACE2	B-PRGE
+structure	O
+with	O
+a	O
+root	B-ANAT
+-	O
+mean	O
+-	O
+square	O
+deviation	O
+from	O
+the	O
+aligned	O
+crystal	B-ANAT
+structures	O
+of	O
+tACE	B-PRGE
+and	O
+AnCE	B-PRGE
+less	O
+than	O
+0	O
+.	O
+5A	O
+.	O
+
+The	O
+study	O
+was	O
+carried	O
+out	O
+with	O
+32	O
+fecal	B-ANAT
+samples	O
+collected	O
+just	O
+before	O
+inoculation	O
+and	O
+at	O
+28	O
+days	O
+postinoculation	O
+.	O
+
+Both	O
+the	O
+naturally	O
+and	O
+the	O
+experimentally	O
+infected	O
+dogs	B-SPEC
+developed	O
+high	O
+levels	O
+of	O
+fecal	B-ANAT
+IgAs	O
+.	O
+
+Antibody	B-COMP
+titers	O
+increased	O
+up	O
+to	O
+70	O
+days	O
+,	O
+and	O
+high	O
+antibody	B-COMP
+titers	O
+were	O
+maintained	O
+at	O
+least	O
+for	O
+another	O
+3	O
+months	O
+.	O
+
+Eighteen	O
+subjects	O
+were	O
+investigated	O
+,	O
+and	O
+results	O
+indicated	O
+that	O
+blood	B-ANAT
+samples	I-ANAT
+contain	O
+sufficient	O
+virus	B-SPEC
+for	O
+detection	O
+by	O
+using	O
+quantitative	O
+real	O
+-	O
+time	O
+PCR	O
+.	O
+
+None	O
+of	O
+the	O
+patients	O
+with	O
+unifocal	O
+lesions	O
+or	O
+single	O
+-	O
+lung	B-ANAT
+involvement	O
+were	O
+admitted	O
+to	O
+the	O
+ICU	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+(	O
+in	O
+both	O
+comparisons	O
+).	O
+
+Especially	O
+the	O
+high	O
+rate	O
+of	O
+complications	O
+and	O
+nosocomial	B-DISO
+infections	I-DISO
+has	O
+caused	O
+severe	O
+public	O
+health	O
+problems	O
+in	O
+China	O
+and	O
+Canada	O
+.	O
+
+The	O
+numbers	O
+of	O
+patients	O
+newly	O
+identified	O
+with	O
+new	B-DISO
+variant	I-DISO
+Creutzfeldt	I-DISO
+-	I-DISO
+Jakob	I-DISO
+disease	I-DISO
+are	O
+not	O
+rising	O
+,	O
+but	O
+rather	O
+constant	O
+or	O
+even	O
+declining	O
+,	O
+making	O
+a	O
+large	O
+epidemic	O
+of	O
+vCJD	B-DISO
+unlikely	O
+.	O
+
+Morbidity	O
+indicators	O
+were	O
+surgery	O
+other	O
+than	O
+curettage	B-ANAT
+,	O
+prolonged	O
+hospitalization	O
+and	O
+permanent	O
+damage	O
+.	O
+
+By	O
+multivariate	O
+analysis	O
+,	O
+positive	O
+RT	O
+-	O
+PCR	O
+on	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+samples	O
+was	O
+an	O
+independent	O
+predictor	O
+of	O
+death	B-PROC
+within	O
+30	O
+days	O
+.	O
+
+None	O
+of	O
+these	O
+healthcare	O
+workers	O
+had	O
+antibody	B-COMP
+to	O
+SARS	B-PRGE
+CoV	I-PRGE
+,	O
+indicating	O
+that	O
+subclinical	O
+or	O
+mild	O
+infection	B-DISO
+attributable	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+adults	O
+is	O
+rare	O
+.	O
+
+Results	O
+of	O
+studies	O
+in	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+models	O
+of	O
+inflammation	B-DISO
+and	O
+malignancy	B-DISO
+have	O
+also	O
+suggested	O
+central	O
+roles	O
+for	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+in	O
+programmed	B-PROC
+cell	I-PROC
+death	I-PROC
+,	O
+or	O
+apoptosis	B-PATH
+.	O
+
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+plays	O
+a	O
+central	O
+role	O
+in	O
+a	O
+variety	O
+of	O
+acute	O
+and	O
+chronic	O
+inflammatory	O
+diseases	O
+.	O
+
+The	O
+number	O
+of	O
+granulocytes	B-ANAT
+was	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+that	O
+of	O
+lymphocytes	B-ANAT
+was	O
+decreased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+respectively	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+data	O
+suggested	O
+that	O
+lymphocytes	B-ANAT
+,	O
+particularly	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+were	O
+probably	O
+the	O
+target	B-ANAT
+cells	I-ANAT
+of	O
+SARS	B-DISO
+CoV	O
+.	O
+The	O
+viruses	B-SPEC
+may	O
+actively	O
+infected	O
+the	O
+immune	O
+cells	B-COMP
+during	O
+SARS	B-DISO
+CoV	O
+acute	B-DISO
+infection	I-DISO
+phase	O
+and	O
+the	O
+destruction	O
+of	O
+target	B-ANAT
+cells	I-ANAT
+may	O
+be	O
+one	O
+of	O
+the	O
+important	O
+reasons	O
+for	O
+the	O
+death	B-PROC
+of	O
+the	O
+circulating	O
+leukocytes	B-ANAT
+in	O
+SARS	B-DISO
+.	O
+
+Meticulous	O
+attention	O
+to	O
+infection	B-DISO
+control	O
+and	O
+teamwork	O
+are	O
+essential	O
+to	O
+minimize	O
+cross	O
+-	O
+contamination	O
+and	O
+prevent	O
+staff	O
+from	O
+contracting	O
+the	O
+illness	O
+.	O
+
+By	O
+5	O
+days	O
+postinfection	O
+,	O
+these	O
+mice	B-SPEC
+showed	O
+significantly	O
+(	O
+approximately	O
+20	O
+-	O
+fold	O
+)	O
+lower	O
+titers	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+in	O
+the	O
+brain	B-ANAT
+compared	O
+to	O
+control	O
+mice	B-SPEC
+.	O
+
+Despite	O
+its	O
+spectral	O
+Doppler	O
+capability	O
+,	O
+HCU	O
+missed	O
+diagnoses	O
+that	O
+were	O
+adequately	O
+identified	O
+by	O
+TTE	O
+:	O
+elevated	O
+left	O
+ventricular	B-ANAT
+pressure	O
+(	O
+n	O
+=	O
+2	O
+),	O
+relevant	O
+valvulopathy	O
+(	O
+n	O
+=	O
+2	O
+)	O
+and	O
+moderate	O
+(	O
+n	O
+=	O
+4	O
+)	O
+or	O
+severe	O
+(	O
+n	O
+=	O
+2	O
+)	O
+pulmonary	B-DISO
+hypertension	I-DISO
+.	O
+
+RESULTS	O
+:	O
+During	O
+a	O
+2	O
+-	O
+month	O
+period	O
+,	O
+55	O
+consecutive	O
+patients	O
+(	O
+age	O
+:	O
+61	O
++/-	O
+16	O
+years	O
+,	O
+simplified	O
+acute	O
+physiology	O
+score	O
+46	O
++/-	O
+15	O
+,	O
+body	B-ANAT
+mass	O
+index	O
+26	O
++/-	O
+7	O
+)	O
+were	O
+studied	O
+,	O
+40	O
+of	O
+them	O
+being	O
+mechanically	O
+ventilated	O
+(	O
+73	O
+%).	O
+
+The	O
+outbreak	O
+prompted	O
+the	O
+health	O
+authorities	O
+to	O
+implement	O
+a	O
+series	O
+of	O
+public	O
+health	O
+measures	O
+and	O
+hospital	O
+policies	O
+,	O
+including	O
+a	O
+guideline	O
+for	O
+the	O
+diagnosis	O
+and	O
+management	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Three	O
+hybridomas	B-ANAT
+producing	O
+mAbs	O
+specific	O
+to	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+was	O
+obtained	O
+,	O
+with	O
+a	O
+relative	O
+molecular	O
+mass	O
+of	O
+48	O
+,	O
+500	O
+.	O
+
+Using	O
+primer	O
+Premier	O
+5	O
+.	O
+0	O
+software	O
+,	O
+two	O
+pairs	O
+of	O
+nested	O
+PCR	O
+primers	O
+were	O
+designed	O
+to	O
+amplify	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+.	O
+
+Most	O
+of	O
+the	O
+Hong	O
+Kong	O
+viruses	B-SPEC
+(	O
+139	O
+/	O
+142	O
+),	O
+including	O
+those	O
+from	O
+a	O
+large	O
+outbreak	O
+in	O
+an	O
+apartment	O
+block	O
+,	O
+clustered	O
+closely	O
+together	O
+with	O
+the	O
+isolate	O
+from	O
+a	O
+single	O
+index	O
+case	O
+(	O
+HKU	O
+-	O
+33	O
+)	O
+who	O
+came	O
+from	O
+Guangdong	O
+to	O
+Hong	O
+Kong	O
+in	O
+late	O
+February	O
+.	O
+
+The	O
+World	O
+Health	O
+Organization	O
+has	O
+a	O
+Global	O
+Outbreak	O
+Alert	O
+and	O
+Response	O
+Network	O
+,	O
+which	O
+was	O
+involved	O
+at	O
+an	O
+early	O
+stage	O
+in	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+feature	O
+of	O
+four	O
+cases	O
+with	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+].	O
+
+On	O
+pulmonary	B-ANAT
+CT	O
+/	O
+high	O
+-	O
+resolution	O
+CT	O
+(	O
+HRCT	O
+),	O
+patchy	O
+opacity	B-DISO
+and	O
+bronchial	B-DISO
+wall	I-DISO
+thickening	I-DISO
+were	O
+seen	O
+in	O
+each	O
+patient	O
+.	O
+
+However	O
+,	O
+the	O
+condition	B-DISO
+of	O
+one	O
+patient	O
+was	O
+not	O
+improved	O
+,	O
+although	O
+the	O
+wheezing	B-DISO
+disappeared	O
+.	O
+
+Crackles	B-DISO
+and	O
+wheezing	B-DISO
+were	O
+the	O
+most	O
+common	O
+signs	O
+in	O
+the	O
+BO	O
+.	O
+
+Cdyn	O
+and	O
+Raw	B-PRGE
+were	O
+only	O
+improved	O
+for	O
+short	O
+time	O
+in	O
+the	O
+Surf	O
+,	O
+NO	O
+and	O
+SNO	B-FUNC
+groups	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Subacute	O
+motor	B-DISO
+neuropathy	I-DISO
+induced	O
+by	O
+T3	O
+hyperthyroidism	B-DISO
+].	O
+
+Electromyography	O
+confirmed	O
+the	O
+presence	O
+of	O
+axonal	B-DISO
+neuropathy	I-DISO
+,	O
+with	O
+predominant	O
+motor	O
+involvement	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+a	O
+main	O
+surface	O
+antigen	B-CHED
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+antigen	B-CHED
+candidates	O
+for	O
+vaccine	O
+design	O
+.	O
+
+MHV	B-SPEC
+,	O
+a	O
+member	O
+of	O
+coronavirus	B-SPEC
+group	I-SPEC
+2	I-SPEC
+,	O
+is	O
+a	O
+natural	O
+pathogen	O
+of	O
+the	O
+mouse	B-SPEC
+;	O
+MHV	B-SPEC
+infection	B-DISO
+of	O
+the	O
+mouse	B-SPEC
+is	O
+considered	O
+one	O
+of	O
+the	O
+best	O
+models	O
+for	O
+the	O
+study	O
+of	O
+demyelinating	B-DISO
+disease	I-DISO
+,	O
+such	O
+as	O
+multiple	B-DISO
+sclerosis	I-DISO
+,	O
+in	O
+humans	B-SPEC
+.	O
+
+Future	O
+research	O
+on	O
+SARS	B-DISO
+needs	O
+to	O
+be	O
+based	O
+on	O
+all	O
+the	O
+knowledge	O
+that	O
+coronavirologists	O
+have	O
+generated	O
+over	O
+more	O
+than	O
+30	O
+years	O
+of	O
+research	O
+.	O
+
+No	O
+statistical	O
+differences	O
+were	O
+found	O
+in	O
+modes	O
+of	O
+oxygen	B-CHED
+therapy	O
+and	O
+sorts	B-PROC
+of	O
+antibiotics	B-CHED
+prescribed	O
+among	O
+the	O
+various	O
+transmission	O
+generations	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+);	O
+however	O
+,	O
+as	O
+with	O
+the	O
+advanced	O
+transmission	O
+generations	O
+,	O
+the	O
+number	O
+of	O
+cases	O
+prescribed	O
+with	O
+methylprednisolone	B-CHED
+,	O
+human	B-SPEC
+gamma	B-PRGE
+-	I-PRGE
+globulin	I-PRGE
+,	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+antiviral	B-CHED
+drugs	I-CHED
+(	O
+oral	B-ANAT
+ribavirin	B-CHED
+or	O
+oseltamivir	B-CHED
+)	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+time	O
+from	O
+admission	O
+to	O
+starting	O
+these	O
+medication	O
+shortened	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Full	O
+or	O
+partial	O
+genomes	O
+of	O
+44	O
+SARS	B-DISO
+-	O
+CoV	O
+strains	O
+were	O
+collected	O
+from	O
+GenBank	O
+.	O
+
+There	O
+were	O
+188	O
+point	B-PROC
+mutations	I-PROC
+in	O
+the	O
+33	O
+virus	B-SPEC
+full	O
+genomes	O
+with	O
+the	O
+counts	O
+of	O
+mutation	O
+mounting	O
+to	O
+297	O
+.	O
+
+There	O
+were	O
+4	O
+mutation	O
+loci	O
+in	O
+S1	B-PRGE
+domain	I-PRGE
+of	I-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+.	O
+
+By	O
+bioinformatics	O
+processing	O
+and	O
+analysis	O
+,	O
+the	O
+nucleotides	B-CHED
+at	O
+7	O
+loci	O
+of	O
+genome	O
+(	O
+T	O
+:	O
+T	O
+:	O
+A	O
+:	O
+G	O
+:	O
+T	O
+:	O
+C	O
+:	O
+T	O
+/	O
+C	O
+:	O
+G	O
+:	O
+G	O
+:	O
+A	O
+:	O
+C	O
+:	O
+T	O
+:	O
+C	O
+)	O
+can	O
+classify	O
+SARS	B-DISO
+-	O
+CoV	O
+into	O
+two	O
+types	O
+.	O
+
+RESULTS	O
+:	O
+There	O
+were	O
+188	O
+point	B-PROC
+mutations	I-PROC
+in	O
+the	O
+33	O
+virus	B-SPEC
+full	O
+genomes	O
+with	O
+the	O
+counts	O
+of	O
+mutation	O
+mounting	O
+to	O
+297	O
+.	O
+
+Compared	O
+to	O
+various	O
+strains	O
+among	O
+SARS	B-DISO
+-	O
+CoV	O
+Yexin	O
+genotype	O
+and	O
+Xiaohong	O
+genotype	O
+,	O
+GD01	O
+strain	O
+of	O
+Yexin	O
+genotype	O
+is	O
+more	O
+closely	O
+related	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+like	O
+-	O
+virus	B-SPEC
+from	O
+animals	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+results	O
+mentioned	O
+above	O
+suggest	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+responding	O
+to	O
+host	B-COMP
+immunological	O
+pressures	O
+and	O
+experiencing	O
+variation	O
+which	O
+provide	O
+clues	O
+,	O
+information	O
+and	O
+evidence	O
+of	O
+molecular	O
+biology	O
+for	O
+the	O
+clinical	O
+pathology	B-DISO
+,	O
+vaccine	O
+developing	O
+and	O
+epidemic	O
+investigation	O
+.	O
+
+Nested	O
+RT	O
+-	O
+PCR	O
+was	O
+also	O
+developed	O
+to	O
+detect	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+gene	I-PRGE
+fragment	I-PRGE
+from	O
+the	O
+specimens	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+and	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+characteristics	O
+of	O
+5	O
+cases	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+children	O
+in	O
+Shenzhen	O
+area	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+clinical	O
+and	O
+chest	O
+X	O
+-	O
+ray	B-SPEC
+features	O
+of	O
+SARS	B-DISO
+in	O
+children	O
+to	O
+facilitate	O
+correct	O
+diagnosis	O
+.	O
+
+All	O
+the	O
+5	O
+cases	O
+developed	O
+nonproductive	B-DISO
+cough	I-DISO
+;	O
+on	O
+auscultation	O
+,	O
+both	O
+moist	O
+and	O
+dry	O
+rales	B-DISO
+could	O
+be	O
+heard	O
+in	O
+3	O
+out	O
+of	O
+the	O
+5	O
+cases	O
+.	O
+
+Mean	O
+total	O
+white	O
+count	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+was	O
+(	O
+2	O
+.	O
+96	O
+-	O
+6	O
+.	O
+9	O
+)	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+,	O
+and	O
+was	O
+<	O
+5	O
+.	O
+0	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+in	O
+4	O
+cases	O
+.	O
+
+Our	O
+series	O
+documents	O
+the	O
+difficulties	O
+encountered	O
+at	O
+autopsy	O
+during	O
+the	O
+initial	O
+phases	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+when	O
+the	O
+pattern	O
+of	O
+infection	B-DISO
+and	O
+definitive	O
+diagnostic	O
+laboratory	O
+criteria	O
+were	O
+yet	O
+to	O
+be	O
+established	O
+.	O
+
+Autopsy	O
+tissue	B-ANAT
+was	O
+submitted	O
+to	O
+the	O
+Virology	O
+Department	O
+,	O
+Singapore	O
+General	O
+Hospital	O
+,	O
+for	O
+analysis	O
+,	O
+and	O
+in	O
+situ	O
+hybridization	B-PROC
+for	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+was	O
+carried	O
+out	O
+at	O
+the	O
+National	O
+Institute	O
+of	O
+Infectious	B-DISO
+Diseases	I-DISO
+,	O
+Tokyo	O
+,	O
+Japan	O
+.	O
+
+Four	O
+radiographic	O
+patterns	O
+were	O
+seen	O
+:	O
+normal	O
+(	O
+group	O
+1	O
+)	O
+in	O
+19	O
+.	O
+6	O
+%	O
+(	O
+10	O
+/	O
+51	O
+),	O
+focal	O
+opacity	B-DISO
+(	O
+group	O
+2	O
+)	O
+in	O
+39	O
+.	O
+2	O
+%	O
+(	O
+20	O
+/	O
+51	O
+),	O
+multifocal	O
+opacities	B-DISO
+(	O
+group	O
+3	O
+)	O
+in	O
+27	O
+.	O
+5	O
+%	O
+(	O
+14	O
+/	O
+51	O
+),	O
+and	O
+diffuse	O
+air	B-CHED
+-	O
+space	O
+opacification	O
+(	O
+group	O
+4	O
+)	O
+in	O
+13	O
+.	O
+7	O
+%	O
+(	O
+7	O
+/	O
+51	O
+).	O
+
+Patients	O
+with	O
+SARS	B-DISO
+present	O
+with	O
+recognizable	O
+patterns	O
+of	O
+disease	O
+that	O
+have	O
+prognostic	O
+significance	O
+.	O
+
+Death	B-PROC
+occurred	O
+at	O
+a	O
+mean	O
+interval	O
+of	O
+18	O
+.	O
+2	O
+days	O
+(	O
+range	O
+,	O
+9	O
+-	O
+36	O
+days	O
+)	O
+from	O
+the	O
+initial	O
+exposure	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Patients	O
+presenting	O
+with	O
+normal	O
+findings	O
+or	O
+focal	O
+air	B-CHED
+-	O
+space	O
+opacity	B-DISO
+on	O
+chest	B-ANAT
+radiographs	O
+had	O
+a	O
+good	O
+clinical	O
+outcome	O
+.	O
+
+Wet	O
+markets	O
+sell	O
+live	O
+poultry	O
+,	O
+fish	B-SPEC
+,	O
+reptiles	B-SPEC
+,	O
+and	O
+mammals	B-SPEC
+of	O
+every	O
+kind	O
+.	O
+
+Live	O
+-	O
+poultry	O
+markets	O
+(	O
+mostly	O
+chicken	B-SPEC
+,	O
+pigeon	B-SPEC
+,	O
+quail	O
+,	O
+ducks	B-SPEC
+,	O
+geese	B-SPEC
+,	O
+and	O
+a	O
+wide	O
+range	O
+of	O
+exotic	O
+wild	O
+-	O
+caught	O
+and	O
+farm	O
+-	O
+raised	O
+fowl	O
+)	O
+are	O
+usually	O
+separated	O
+from	O
+markets	O
+selling	O
+fish	B-SPEC
+or	O
+red	O
+-	O
+meat	O
+animals	B-SPEC
+,	O
+but	O
+the	O
+stalls	O
+can	O
+be	O
+near	O
+each	O
+other	O
+with	O
+no	O
+physical	O
+separation	B-DISO
+.	O
+
+By	O
+chromatography	O
+on	O
+nickel	B-CHED
+-	O
+agarose	B-CHED
+column	B-ANAT
+,	O
+the	O
+expressed	B-PROC
+N	B-PRGE
+protein	I-PRGE
+was	O
+purified	O
+to	O
+near	O
+homogeneity	O
+as	O
+judged	O
+by	O
+sodium	B-CHED
+dodecyl	I-CHED
+sulfate	I-CHED
+-	O
+polyacrylamide	B-CHED
+gel	O
+electrophoresis	O
+analysis	O
+.	O
+
+These	O
+results	O
+indicated	O
+that	O
+the	O
+expressed	B-PROC
+N	B-PRGE
+protein	I-PRGE
+is	O
+a	O
+superior	O
+source	O
+of	O
+TCoV	B-PRGE
+antigen	I-PRGE
+for	O
+development	B-PROC
+of	O
+antibody	B-COMP
+-	O
+capture	O
+ELISA	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+TCoV	O
+.	O
+
+All	O
+were	O
+treated	O
+with	O
+corticosteroids	B-CHED
+,	O
+ribavirin	B-CHED
+,	O
+broad	O
+spectrum	O
+antimicrobials	B-CHED
+and	O
+supportive	O
+therapy	O
+.	O
+
+All	O
+patients	O
+were	O
+admitted	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+also	O
+examined	O
+respondents	O
+'	O
+perceived	O
+effects	O
+of	O
+SARS	B-DISO
+on	O
+work	O
+and	O
+organisations	O
+and	O
+their	O
+attitudes	O
+toward	O
+issues	O
+of	O
+privacy	O
+and	O
+disclosure	O
+of	O
+medical	O
+information	O
+.	O
+
+Findings	O
+also	O
+suggest	O
+that	O
+having	O
+a	O
+SARS	B-DISO
+or	O
+probable	O
+SARS	B-DISO
+case	O
+in	O
+the	O
+company	O
+would	O
+disrupt	O
+the	O
+flow	O
+of	O
+work	O
+and	O
+affect	O
+employees	O
+'	O
+morale	O
+.	O
+
+Based	O
+on	O
+seroconversion	O
+to	O
+BRSV	B-SPEC
+and	O
+clinical	O
+picture	O
+,	O
+67	O
+pairs	O
+of	O
+sera	B-COMP
+were	O
+selected	O
+from	O
+calves	O
+with	O
+a	O
+BRSV	B-SPEC
+-	O
+associated	O
+PRDS	B-DISO
+for	O
+circulating	O
+MC	B-PRGE
+tryptase	I-PRGE
+determination	O
+.	O
+
+The	O
+absence	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+abrogated	O
+demyelination	B-DISO
+but	O
+did	O
+not	O
+change	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+or	O
+expression	B-PROC
+levels	O
+of	O
+inflammatory	O
+cytokines	O
+or	O
+chemokines	O
+in	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+.	O
+
+In	O
+Hong	O
+Kong	O
+,	O
+People	O
+'	O
+s	O
+Republic	O
+of	O
+China	O
+,	O
+1	O
+,	O
+755	O
+SARS	B-DISO
+cases	O
+and	O
+299	O
+deaths	B-PROC
+had	O
+occurred	O
+as	O
+of	O
+September	O
+22	O
+,	O
+2003	O
+.	O
+
+The	O
+data	O
+series	O
+includes	O
+details	O
+regarding	O
+sex	O
+,	O
+age	O
+,	O
+and	O
+chronic	B-DISO
+disease	I-DISO
+history	O
+.	O
+
+Symptoms	B-DISO
+and	I-DISO
+signs	I-DISO
+of	O
+the	O
+children	O
+were	O
+much	O
+less	O
+severe	O
+and	O
+aggressive	B-DISO
+than	O
+adults	O
+cases	O
+.	O
+
+Part	O
+of	O
+the	O
+patients	O
+had	O
+temporary	O
+abnormality	O
+of	O
+myocardial	O
+enzyme	O
+and	O
+liver	B-PROC
+function	I-PROC
+.	O
+
+The	O
+patients	O
+were	O
+treated	O
+with	O
+antiviral	B-CHED
+agents	I-CHED
+and	O
+corticosteroid	B-CHED
+.	O
+
+No	O
+child	O
+needed	O
+assisted	O
+ventilation	O
+and	O
+no	O
+death	B-PROC
+,	O
+nor	O
+lung	B-DISO
+fibrosis	I-DISO
+occurred	O
+.	O
+
+The	O
+same	O
+virus	B-SPEC
+was	O
+detected	O
+subsequently	O
+in	O
+86	O
+humans	B-SPEC
+who	O
+handled	O
+affected	O
+poultry	O
+and	O
+in	O
+three	O
+of	O
+their	O
+family	B-SPEC
+members	O
+.	O
+
+The	O
+commencement	O
+of	O
+hemodiafiltration	O
+itself	O
+has	O
+not	O
+been	O
+shown	O
+to	O
+significantly	O
+influence	O
+the	O
+requirement	O
+for	O
+propofol	B-CHED
+.	O
+
+RESULTS	O
+:	O
+The	O
+administration	O
+of	O
+morphine	B-CHED
+was	O
+fundamental	O
+to	O
+achieving	O
+an	O
+optimal	O
+level	O
+of	O
+sedation	B-DISO
+.	O
+
+Untreated	O
+SCID	B-DISO
+mice	B-SPEC
+exhibited	O
+uncontrolled	O
+virus	B-PROC
+replication	I-PROC
+in	O
+all	O
+CNS	B-CHED
+cell	B-COMP
+types	O
+but	O
+had	O
+little	O
+or	O
+no	O
+demyelination	B-DISO
+.	O
+
+The	O
+main	O
+clinical	O
+manifestations	O
+were	O
+high	O
+fever	B-PROC
+and	O
+cough	B-DISO
+while	O
+no	O
+severe	O
+toxic	O
+symptoms	O
+,	O
+nor	O
+respiratory	B-DISO
+failure	I-DISO
+was	O
+seen	O
+;	O
+few	O
+symptoms	O
+or	O
+signs	O
+suggesting	O
+involvement	O
+of	O
+systems	O
+other	O
+than	O
+respiratory	B-ANAT
+system	I-ANAT
+were	O
+seen	O
+.	O
+
+Ground	O
+-	O
+glass	O
+opacification	O
+and	O
+interstitial	B-ANAT
+thickening	O
+were	O
+present	O
+at	O
+CT	O
+in	O
+all	O
+eight	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+CT	O
+features	O
+of	O
+late	O
+-	O
+stage	O
+ARDS	B-DISO
+caused	O
+by	O
+SARS	B-DISO
+are	O
+similar	O
+to	O
+those	O
+seen	O
+in	O
+late	O
+-	O
+stage	O
+ARDS	B-DISO
+of	O
+other	O
+causes	O
+,	O
+with	O
+no	O
+apparent	O
+differences	O
+between	O
+patients	O
+who	O
+do	O
+and	O
+patients	O
+who	O
+do	O
+not	O
+receive	O
+prolonged	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+pathophysiology	O
+of	O
+ARDS	B-DISO
+includes	O
+abnormalities	O
+of	O
+surfactant	B-CHED
+function	O
+as	O
+well	O
+as	O
+pulmonary	B-DISO
+inflammation	I-DISO
+.	O
+
+We	O
+attempted	O
+to	O
+combine	O
+surfactant	B-CHED
+lavage	O
+'	O
+s	O
+ability	O
+to	O
+reverse	O
+the	O
+surfactant	B-CHED
+dysfunction	O
+,	O
+while	O
+acting	O
+as	O
+a	O
+vehicle	O
+to	O
+deliver	O
+Lidocaine	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+angiotensin	O
+-	O
+converting	O
+enzyme	O
+(	O
+ACE	B-ENZY
+)-	O
+related	O
+carboxypeptidase	O
+,	O
+ACE2	B-PRGE
+,	O
+is	O
+a	O
+type	B-PRGE
+I	I-PRGE
+integral	I-PRGE
+membrane	I-PRGE
+protein	B-CHED
+of	O
+805	O
+amino	B-CHED
+acids	I-CHED
+that	O
+contains	O
+one	O
+HEXXH	B-PRGE
++	I-PRGE
+E	I-PRGE
+zinc	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+consensus	I-PRGE
+sequence	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+-	O
+associated	O
+communicable	O
+respiratory	B-DISO
+disease	I-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+spread	O
+worldwide	O
+after	O
+an	O
+outbreak	O
+in	O
+Guangdong	O
+Province	O
+of	O
+the	O
+People	O
+'	O
+s	O
+Republic	O
+of	O
+China	O
+in	O
+November	O
+2002	O
+.	O
+
+There	O
+are	O
+two	O
+main	O
+moments	O
+marking	O
+the	O
+reemergence	O
+and	O
+evolution	B-PROC
+of	O
+SARS	B-DISO
+:	O
+firstly	O
+,	O
+the	O
+onset	O
+of	O
+the	O
+epidemic	O
+in	O
+China	O
+in	O
+November	O
+2002	O
+followed	O
+by	O
+the	O
+worldwide	O
+spread	O
+of	O
+the	O
+epidemiological	O
+process	O
+,	O
+and	O
+secondly	O
+the	O
+discovery	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+as	O
+a	O
+mutant	B-DISO
+of	O
+coronaviruses	O
+in	O
+March	O
+-	O
+April	O
+2003	O
+in	O
+USA	O
+,	O
+Canada	O
+,	O
+and	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+with	O
+high	O
+morbidity	O
+and	O
+mortality	O
+and	O
+potential	O
+for	O
+global	O
+spread	O
+.	O
+
+As	O
+immunization	O
+against	O
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+becomes	O
+more	O
+widely	O
+used	O
+,	O
+the	O
+complications	O
+of	O
+bacterial	O
+lower	O
+respiratory	B-DISO
+infections	I-DISO
+will	O
+diminish	O
+markedly	O
+.	O
+
+ABSTRACT	O
+:	O
+Smallpox	B-DISO
+was	O
+declared	O
+to	O
+be	O
+eradicated	O
+on	O
+8	O
+May	O
+1980	O
+,	O
+during	O
+the	O
+Thirty	O
+-	O
+third	O
+World	O
+Health	O
+Assembly	O
+.	O
+
+Risk	O
+categorization	O
+ensured	O
+that	O
+no	O
+cross	O
+-	O
+infection	B-DISO
+occurred	O
+among	O
+patients	O
+and	O
+that	O
+no	O
+one	O
+contracted	O
+SARS	B-DISO
+in	O
+the	O
+ED	O
+.	O
+
+At	O
+first	O
+,	O
+Western	O
+blotting	O
+with	O
+the	O
+convalescent	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+demonstrated	O
+that	O
+there	O
+were	O
+various	O
+structural	O
+proteins	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+the	O
+cultured	O
+supernatant	O
+of	O
+virus	B-SPEC
+infected	O
+-	O
+Vero	O
+E6	O
+cells	B-COMP
+and	O
+that	O
+nucleocaspid	O
+(	O
+N	O
+)	O
+protein	B-CHED
+had	O
+a	O
+prominent	O
+immunogenicity	O
+to	O
+the	O
+convalescent	O
+sera	B-COMP
+from	O
+the	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+while	O
+the	O
+immune	B-PROC
+response	I-PROC
+of	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+probably	O
+binding	O
+with	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+glycoprotein	B-CHED
+was	O
+much	O
+weaker	O
+.	O
+
+Three	O
+structural	O
+proteins	B-CHED
+named	O
+S	O
+,	O
+N	O
+and	O
+M	O
+proteins	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+uncovered	O
+with	O
+the	O
+sequence	O
+coverage	O
+of	O
+38	O
+.	O
+9	O
+,	O
+93	O
+.	O
+1	O
+and	O
+28	O
+.	O
+1	O
+%	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Theiler	O
+'	O
+s	O
+murine	B-DISO
+encephalomyelitis	I-DISO
+virus	B-SPEC
+(	O
+TMEV	O
+)	O
+causes	O
+demyelination	B-DISO
+with	O
+inflammation	B-DISO
+of	I-DISO
+the	I-DISO
+central	I-DISO
+nervous	I-DISO
+system	I-DISO
+(	O
+CNS	B-CHED
+)	O
+in	O
+mice	B-SPEC
+and	O
+is	O
+used	O
+as	O
+an	O
+animal	B-SPEC
+model	O
+for	O
+multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+).	O
+
+This	O
+likely	O
+reflects	O
+a	O
+difference	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+TMEV	O
+infection	B-DISO
+from	O
+that	O
+of	O
+two	O
+other	O
+animal	B-SPEC
+models	O
+for	O
+MS	O
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-DISO
+infection	I-DISO
+and	O
+experimental	O
+allergic	O
+encephalomyelitis	B-DISO
+(	O
+EAE	O
+),	O
+where	O
+blocking	B-DISO
+of	O
+IP	O
+-	O
+10	O
+resulted	O
+in	O
+clinical	O
+and	O
+histological	O
+improvement	O
+with	O
+suppression	B-DISO
+of	O
+antigen	B-CHED
+specific	O
+lymphoproliferation	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+compare	O
+and	O
+contrast	O
+the	O
+roles	O
+of	O
+IP	O
+-	O
+10	O
+between	O
+the	O
+three	O
+animal	B-SPEC
+models	O
+for	O
+MS	O
+,	O
+and	O
+discuss	O
+the	O
+relevance	O
+to	O
+MS	O
+patients	O
+with	O
+different	O
+clinical	O
+courses	O
+.	O
+
+ABSTRACT	O
+:	O
+Seven	O
+cases	O
+of	O
+autopsy	O
+from	O
+SARS	O
+patients	O
+are	O
+studied	O
+to	O
+investigate	O
+the	O
+pathogenesis	B-DISO
+and	O
+the	O
+pathologic	O
+changes	O
+of	O
+the	O
+major	O
+organs	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+liver	B-ANAT
+shows	O
+massive	B-DISO
+necrosis	I-DISO
+(	O
+1	O
+case	O
+)	O
+and	O
+nodular	O
+cirrhosis	B-DISO
+(	O
+1	O
+case	O
+).	O
+
+Secondary	B-DISO
+infection	I-DISO
+is	O
+a	O
+common	O
+complication	B-DISO
+,	O
+which	O
+should	O
+be	O
+paid	O
+close	O
+attention	O
+in	O
+the	O
+management	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Fungal	B-DISO
+infection	I-DISO
+is	O
+noted	O
+in	O
+2	O
+cases	O
+.	O
+
+All	O
+SARS	B-DISO
+cases	O
+had	O
+been	O
+reported	O
+to	O
+the	O
+relative	O
+authorities	O
+.	O
+
+The	O
+remaining	O
+39	O
+%	O
+quarantinees	O
+who	O
+did	O
+not	O
+have	O
+a	O
+direct	O
+contact	O
+history	O
+with	O
+SARS	B-DISO
+patients	O
+had	O
+not	O
+developed	O
+SARS	B-DISO
+during	O
+the	O
+period	O
+under	O
+quarantine	O
+.	O
+
+Data	O
+from	O
+daily	O
+hematological	O
+,	O
+biochemical	O
+,	O
+radiological	O
+,	O
+and	O
+microbiological	O
+investigations	O
+were	O
+prospectively	O
+collected	O
+,	O
+and	O
+the	O
+correlation	O
+of	O
+these	O
+findings	O
+with	O
+diarrhea	B-DISO
+was	O
+retrospectively	O
+analyzed	O
+.	O
+
+Sixty	O
+-	O
+nine	O
+patients	O
+(	O
+48	O
+.	O
+6	O
+%)	O
+developed	O
+diarrhea	B-DISO
+at	O
+a	O
+mean	O
+(+/-	O
+
+The	O
+diarrhea	B-DISO
+was	O
+most	O
+severe	O
+at	O
+a	O
+mean	O
+(+/-	O
+SD	O
+)	O
+of	O
+8	O
+.	O
+8	O
++/-	O
+2	O
+.	O
+4	O
+days	O
+after	O
+onset	O
+,	O
+with	O
+a	O
+maximum	O
+frequency	O
+of	O
+24	O
+episodes	O
+per	O
+day	O
+(	O
+median	O
+,	O
+5	O
+episodes	O
+;	O
+range	O
+,	O
+3	O
+-	O
+24	O
+episodes	O
+).	O
+
+The	O
+patient	O
+reported	O
+no	O
+respiratory	O
+complaints	O
+,	O
+and	O
+the	O
+findings	O
+of	O
+serial	O
+chest	B-ANAT
+radiographs	O
+were	O
+normal	O
+.	O
+
+It	O
+is	O
+also	O
+of	O
+the	O
+utmost	O
+importance	O
+that	O
+the	O
+global	O
+scientific	O
+community	O
+enhance	O
+mechanisms	O
+for	O
+international	O
+cooperation	O
+and	O
+planning	O
+for	O
+SARS	O
+research	O
+,	O
+as	O
+well	O
+as	O
+for	O
+other	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+threats	O
+that	O
+are	O
+certain	O
+to	O
+arise	O
+in	O
+the	O
+future	O
+.	O
+
+Although	O
+the	O
+clinical	O
+features	O
+of	O
+acute	B-DISO
+infection	I-DISO
+have	O
+been	O
+well	O
+described	O
+,	O
+mildly	O
+symptomatic	O
+or	O
+asymptomatic	B-DISO
+infections	I-DISO
+have	O
+not	O
+been	O
+well	O
+characterized	O
+.	O
+
+There	O
+was	O
+a	O
+trend	O
+towards	O
+protection	O
+for	O
+HCWs	O
+who	O
+,	O
+while	O
+fully	O
+protected	O
+,	O
+had	O
+had	O
+contact	O
+with	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+Although	O
+the	O
+majority	O
+of	O
+cases	O
+of	O
+SARS	B-DISO
+are	O
+associated	O
+with	O
+pneumonia	B-DISO
+,	O
+a	O
+small	O
+number	O
+of	O
+mildly	O
+symptomatic	O
+individuals	O
+do	O
+seroconvert	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+21	O
+patients	O
+with	O
+SARS	B-DISO
+were	O
+treated	O
+at	O
+our	O
+hospital	O
+.	O
+
+Real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+provides	O
+a	O
+tool	O
+for	O
+large	O
+-	O
+scale	O
+epidemiological	O
+studies	O
+to	O
+further	O
+clarify	O
+the	O
+role	O
+that	O
+coronavirus	B-DISO
+infection	I-DISO
+plays	O
+in	O
+RTI	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Percutaneous	O
+liver	B-ANAT
+biopsies	O
+were	O
+performed	O
+.	O
+
+Other	O
+common	O
+pathologic	O
+features	O
+included	O
+ballooning	O
+of	O
+hepatocytes	B-ANAT
+and	O
+mild	O
+to	O
+moderate	O
+lobular	O
+lymphocytic	O
+infiltration	O
+.	O
+
+The	O
+prominence	O
+of	O
+mitotic	O
+activity	O
+of	O
+hepatocytes	B-ANAT
+is	O
+unique	O
+and	O
+may	O
+be	O
+due	O
+to	O
+a	O
+hyperproliferative	O
+state	O
+with	O
+or	O
+without	O
+disruption	O
+of	O
+cell	B-PATH
+cycle	I-PATH
+by	O
+the	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+a	O
+three	O
+-	O
+color	O
+flow	O
+cytometry	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+virus	O
+-	O
+specific	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+cat	B-SPEC
+.	O
+
+Moreover	O
+,	O
+feline	B-SPEC
+calicivirus	I-SPEC
+(	O
+FCV	B-CHED
+)-	O
+specific	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+were	O
+detected	O
+in	O
+the	O
+spleens	B-ANAT
+of	O
+FCV	B-CHED
+-	O
+vaccinated	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+usefulness	O
+of	O
+ascites	O
+as	O
+a	O
+material	O
+for	O
+viral	O
+tests	O
+in	O
+cats	B-SPEC
+with	O
+effusive	B-DISO
+feline	I-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+we	O
+attempted	O
+to	O
+detect	O
+anti	O
+-	O
+feline	B-SPEC
+coronavirus	B-SPEC
+antibody	B-COMP
+,	O
+anti	O
+-	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+antibody	B-COMP
+,	O
+and	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+antigen	B-CHED
+in	O
+ascites	O
+from	O
+88	O
+cats	B-SPEC
+clinically	O
+suspected	O
+with	O
+effusive	O
+FIP	B-DISO
+.	O
+
+The	O
+fold	O
+superficially	O
+resembles	O
+an	O
+OB	O
+-	O
+fold	O
+with	O
+a	O
+C	O
+-	O
+terminal	O
+extension	O
+and	O
+is	O
+related	O
+to	O
+both	O
+of	O
+the	O
+two	O
+subdomains	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+which	O
+belongs	O
+to	O
+the	O
+serine	B-PRGE
+protease	I-PRGE
+superfamily	B-SPEC
+).	O
+
+We	O
+show	O
+that	O
+nsp9	O
+binds	B-FUNC
+RNA	O
+and	O
+interacts	O
+with	O
+nsp8	O
+,	O
+activities	O
+that	O
+may	O
+be	O
+essential	O
+for	O
+its	O
+function	O
+(	O
+s	O
+).	O
+
+TITLE	O
+:	O
+How	O
+did	O
+general	O
+practitioners	O
+protect	O
+themselves	O
+,	O
+their	O
+family	B-SPEC
+,	O
+and	O
+staff	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+?	O
+
+All	O
+agreed	O
+SARS	B-DISO
+had	O
+changed	O
+their	O
+clinical	O
+practices	O
+.	O
+
+The	O
+study	O
+estimates	O
+the	O
+initial	O
+attack	O
+size	O
+that	O
+would	O
+result	O
+in	O
+failed	O
+invasion	B-DISO
+.	O
+
+It	O
+is	O
+shown	O
+that	O
+there	O
+exist	O
+threshold	O
+levels	O
+of	O
+interventions	O
+at	O
+which	O
+the	O
+SARS	B-DISO
+epidemic	O
+settles	B-DISO
+down	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Initial	O
+attack	O
+size	O
+is	O
+one	O
+of	O
+the	O
+determinants	O
+of	O
+whether	O
+SARS	B-DISO
+can	O
+successfully	O
+invade	O
+the	O
+community	O
+or	O
+not	O
+.	O
+
+The	O
+joining	O
+of	O
+this	O
+leader	O
+sequence	O
+to	O
+different	O
+segments	O
+(	O
+mRNA	B-CHED
+bodies	O
+)	O
+from	O
+the	O
+genomic	O
+3	O
+'-	O
+proximal	O
+region	O
+presumably	O
+involves	O
+a	O
+unique	O
+mechanism	O
+of	O
+discontinuous	O
+minus	O
+-	O
+strand	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+Besides	O
+evidence	O
+for	O
+a	O
+direct	O
+role	O
+of	O
+the	O
+LTH	O
+in	O
+subgenomic	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+indications	O
+for	O
+a	O
+role	O
+of	O
+the	O
+LTH	O
+region	O
+in	O
+genome	O
+replication	O
+and	O
+/	O
+or	O
+translation	B-PROC
+were	O
+obtained	O
+.	O
+
+The	O
+sera	B-COMP
+from	O
+health	O
+donors	O
+,	O
+which	O
+were	O
+collected	O
+before	O
+the	O
+out	O
+-	O
+break	O
+of	O
+SARS	B-DISO
+,	O
+were	O
+used	O
+as	O
+negative	O
+control	O
+in	O
+the	O
+study	O
+.	O
+
+The	O
+molecular	O
+weight	O
+of	O
+recombinant	B-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+is	O
+about	O
+64	O
+000	O
+.	O
+
+RESULTS	O
+:	O
+Sequencing	O
+analysis	O
+confirmed	O
+that	O
+the	O
+desired	O
+DNA	O
+sequence	O
+in	O
+recombinant	O
+plasmid	O
+was	O
+correct	O
+and	O
+had	O
+the	O
+same	O
+sequence	O
+of	O
+natural	O
+N	O
+-	O
+terminal	O
+of	O
+SARS	B-PRGE
+virus	B-SPEC
+S1	I-PRGE
+subunit	I-PRGE
+.	O
+
+The	O
+recombinant	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+could	O
+react	O
+with	O
+three	O
+antibody	B-COMP
+positive	O
+samples	O
+from	O
+recovered	O
+SARS	B-DISO
+patients	O
+,	O
+which	O
+showed	O
+specific	O
+bands	O
+at	O
+64	O
+000	O
+,	O
+but	O
+not	O
+with	O
+the	O
+control	O
+samples	O
+according	O
+to	O
+results	O
+of	O
+western	O
+blot	O
+.	O
+
+TITLE	O
+:	O
+Mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+neurovirulence	O
+:	O
+evidence	O
+of	O
+a	O
+linkage	B-PROC
+between	O
+S	B-PRGE
+glycoprotein	I-PRGE
+expression	B-PROC
+and	O
+immunopathology	B-DISO
+.	O
+
+Previously	O
+,	O
+we	O
+found	O
+that	O
+MHV	B-SPEC
+-	O
+JHM	O
+neurovirulence	O
+was	O
+marked	O
+by	O
+diminished	O
+expression	B-PROC
+of	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+(	O
+IFN	O
+-	O
+gamma	O
+)	O
+mRNA	B-CHED
+and	O
+a	O
+reduced	O
+presence	O
+of	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+in	O
+the	O
+CNS	B-CHED
+concomitant	O
+with	O
+heightened	O
+macrophage	B-ANAT
+inflammatory	O
+protein	B-CHED
+(	O
+MIP	B-DISO
+)-	O
+1	O
+transcript	O
+levels	O
+and	O
+greater	O
+macrophage	B-ANAT
+infiltration	B-DISO
+relative	O
+to	O
+MHV	B-SPEC
+-	O
+A59	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Differential	O
+regulation	B-PROC
+of	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+viral	B-DISO
+encephalitis	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+sought	O
+to	O
+understand	O
+the	O
+immunological	O
+basis	O
+for	O
+the	O
+fatal	O
+encephalitis	B-DISO
+following	O
+infection	B-DISO
+with	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)-	O
+JHM	O
+,	O
+in	O
+contrast	O
+with	O
+the	O
+more	O
+attenuated	O
+MHV	B-SPEC
+-	O
+A59	O
+.	O
+
+Furthermore	O
+,	O
+high	O
+levels	O
+of	O
+macrophage	B-PRGE
+-	I-PRGE
+inflammatory	I-PRGE
+protein	B-CHED
+(	I-PRGE
+MIP	B-DISO
+)-	I-PRGE
+1alpha	I-PRGE
+,	O
+MIP	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+,	O
+and	O
+MIP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+mRNA	B-CHED
+were	O
+observed	O
+at	O
+the	O
+onset	O
+of	O
+MHV	B-SPEC
+-	O
+JHM	O
+infection	B-DISO
+and	O
+correlated	O
+with	O
+a	O
+marked	O
+elevation	O
+in	O
+the	O
+number	O
+of	O
+macrophages	B-ANAT
+in	O
+the	O
+brain	B-ANAT
+on	O
+day	O
+7	O
+compared	O
+to	O
+MHV	B-SPEC
+-	O
+A59	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Infection	B-DISO
+control	O
+for	O
+the	O
+otolaryngologist	O
+in	O
+the	O
+era	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+affected	O
+more	O
+than	O
+8400	O
+persons	O
+in	O
+28	O
+countries	O
+,	O
+with	O
+more	O
+than	O
+800	O
+deaths	B-PROC
+.	O
+
+The	O
+mode	O
+of	O
+action	O
+of	O
+chloroquine	B-CHED
+in	O
+prevention	O
+of	O
+malaria	B-PATH
+is	O
+not	O
+known	O
+,	O
+but	O
+it	O
+may	O
+be	O
+to	O
+minimize	O
+replication	O
+of	O
+the	O
+parasite	O
+in	O
+the	O
+liver	B-ANAT
+cells	I-ANAT
+,	O
+which	O
+occurs	O
+before	O
+invasion	B-DISO
+of	O
+the	O
+erythrocytes	B-ANAT
+,	O
+by	O
+facilitating	O
+premature	O
+apoptosis	B-PATH
+of	O
+the	O
+infected	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+In	O
+the	O
+case	O
+of	O
+SARS	B-DISO
+,	O
+the	O
+coronavirus	B-SPEC
+appears	O
+to	O
+have	O
+accessed	O
+a	O
+new	O
+niche	O
+where	O
+it	O
+proves	O
+to	O
+be	O
+lethal	O
+to	O
+its	O
+host	B-COMP
+.	O
+
+In	O
+the	O
+case	O
+of	O
+AIDS	O
+,	O
+the	O
+HIV	B-DISO
+(	O
+which	O
+has	O
+had	O
+a	O
+long	O
+-	O
+term	O
+symbiotic	O
+relationship	O
+with	O
+primates	B-SPEC
+)	O
+has	O
+run	O
+amuck	B-DISO
+because	O
+the	O
+infected	O
+cells	B-COMP
+are	O
+now	O
+substantially	O
+more	O
+tolerant	O
+to	O
+the	O
+toxins	B-CHED
+(	O
+i	O
+.	O
+e	O
+.,	O
+resistant	O
+to	O
+apoptosis	B-PATH
+)	O
+that	O
+they	O
+secrete	B-PROC
+than	O
+the	O
+uninfected	O
+bystander	O
+cells	B-COMP
+,	O
+which	O
+are	O
+not	O
+unusually	O
+resistant	O
+to	O
+apoptosis	B-PATH
+.	O
+
+All	O
+cases	O
+of	O
+malaria	B-PATH
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+of	O
+the	O
+Sarawak	O
+General	O
+Hospital	O
+from	O
+January	O
+1996	O
+to	O
+December	O
+2001	O
+were	O
+identified	O
+from	O
+the	O
+intensive	O
+care	O
+records	O
+and	O
+retrospectively	O
+reviewed	O
+.	O
+
+The	O
+fatal	O
+cases	O
+,	O
+at	O
+presentation	O
+,	O
+had	O
+higher	O
+parasite	O
+counts	O
+,	O
+higher	O
+bilirubin	B-CHED
+,	O
+aminotransferase	O
+,	O
+potassium	B-CHED
+and	O
+urea	B-CHED
+levels	O
+,	O
+but	O
+lower	O
+haemoglobin	B-CHED
+and	O
+platelet	B-ANAT
+counts	O
+,	O
+and	O
+more	O
+deranged	O
+coagulation	B-PROC
+profiles	O
+compared	O
+to	O
+surviving	O
+patients	O
+.	O
+
+Several	O
+infections	B-DISO
+of	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+are	O
+still	O
+associated	O
+with	O
+significant	O
+mortality	O
+.	O
+
+The	O
+isolated	O
+case	O
+of	O
+death	B-PROC
+from	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+infection	B-DISO
+argues	O
+against	O
+complacency	O
+in	O
+the	O
+management	O
+of	O
+even	O
+the	O
+""""	O
+benign	O
+""""	O
+form	O
+of	O
+the	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+summarize	O
+the	O
+clinical	O
+characteristics	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+observe	O
+the	O
+therapeutic	O
+effect	O
+with	O
+integrative	O
+Chinese	O
+and	O
+western	O
+medicine	B-CHED
+(	O
+ICWM	O
+)	O
+approach	O
+in	O
+treating	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+measured	O
+CD8	B-PRGE
+T	I-PRGE
+cell	O
+clonotypic	O
+diversity	O
+to	O
+three	O
+epitopes	O
+recognized	O
+in	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+strain	O
+JHM	O
+,	O
+or	O
+lymphocytic	B-SPEC
+choriomeningitis	I-SPEC
+virus	I-SPEC
+.	O
+
+We	O
+identified	O
+three	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+epitopes	O
+in	O
+SNV	O
+presented	O
+by	O
+HLA	B-PRGE
+-	O
+B	O
+*	O
+3501	O
+and	O
+quantitated	O
+circulating	O
+SNV	O
+-	O
+specific	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+11	O
+acute	O
+HPS	B-DISO
+patients	O
+using	O
+HLA	B-PRGE
+/	I-PRGE
+peptide	B-CHED
+tetramers	I-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+Role	O
+of	O
+the	O
+occupational	O
+physician	O
+in	O
+the	O
+management	O
+of	O
+the	O
+emergency	B-DISO
+of	O
+SARS	B-DISO
+].	O
+
+Current	O
+information	O
+indicates	O
+that	O
+most	O
+transmission	O
+is	O
+via	O
+respiratory	O
+droplets	O
+coming	O
+from	O
+a	O
+person	O
+who	O
+is	O
+symptomatic	O
+with	O
+SARS	B-DISO
+"("""	O
+close	O
+contact	O
+""")."	O
+
+The	O
+aim	O
+of	O
+our	O
+study	O
+is	O
+to	O
+evidence	O
+the	O
+critical	O
+role	O
+of	O
+the	O
+family	B-SPEC
+physician	O
+,	O
+the	O
+first	O
+health	O
+-	O
+care	O
+worker	O
+who	O
+cares	O
+with	O
+suspected	O
+/	O
+probable	O
+SARS	B-DISO
+patients	O
+,	O
+underlying	O
+the	O
+importance	O
+of	O
+the	O
+correct	O
+use	O
+and	O
+management	O
+of	O
+the	O
+personal	O
+protective	O
+equipment	O
+.	O
+
+The	O
+use	O
+of	O
+aggressive	B-DISO
+immune	B-PROC
+surveillance	I-PROC
+,	O
+nutritional	O
+support	O
+,	O
+and	O
+fluid	O
+management	O
+is	O
+critical	O
+to	O
+support	O
+ventilator	O
+management	O
+for	O
+oxygenation	B-PROC
+and	O
+ventilation	O
+.	O
+
+Physicians	O
+must	O
+establish	O
+reasonable	O
+therapeutic	O
+goals	O
+based	O
+on	O
+oxygen	B-CHED
+delivery	O
+rather	O
+than	O
+arbitrary	O
+normal	O
+values	O
+of	O
+blood	B-ANAT
+gas	B-ENZY
+measurement	O
+.	O
+
+Overall	O
+,	O
+ARDS	B-DISO
+represents	O
+a	O
+clear	O
+indication	O
+that	O
+the	O
+patient	O
+is	O
+failing	O
+to	O
+meet	O
+the	O
+demands	O
+of	O
+their	O
+stress	O
+and	O
+without	O
+prompt	O
+attention	O
+likely	O
+will	O
+die	O
+.	O
+
+The	O
+RM	O
+was	O
+performed	O
+in	O
+pressure	O
+-	O
+controlled	O
+ventilation	O
+at	O
+FIO2	O
+of	O
+1	O
+.	O
+0	O
+until	O
+PaO2	O
+reached	O
+250	O
+mmHg	O
+or	O
+a	O
+maximal	O
+plateau	O
+pressure	O
+/	O
+PEEP	B-CHED
+of	O
+60	O
+/	O
+45	O
+cmH2O	O
+was	O
+achieved	O
+.	O
+
+The	O
+PEEP	B-CHED
+of	O
+recruitment	B-DISO
+was	O
+36	O
++/-	O
+
+In	O
+disease	O
+processes	O
+with	O
+high	O
+airways	O
+resistance	B-PROC
+and	O
+obstructive	O
+mucus	B-DISO
+plugging	I-DISO
+,	O
+HFOV	O
+may	O
+predispose	O
+to	O
+air	B-CHED
+-	O
+trapping	O
+and	O
+increased	O
+morbidity	O
+secondary	O
+to	O
+air	B-CHED
+leak	O
+syndromes	B-DISO
+.	O
+
+For	O
+example	O
+,	O
+the	O
+presence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+or	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+portends	O
+NPPV	O
+failure	O
+,	O
+as	O
+does	O
+lack	O
+of	O
+oxygenation	B-PROC
+improvement	O
+after	O
+an	O
+hour	O
+on	O
+NPPV	O
+.	O
+
+TITLE	O
+:	O
+A	O
+combination	O
+of	O
+mutations	O
+in	O
+the	O
+S1	O
+part	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+gene	O
+of	O
+coronavirus	B-SPEC
+MHV	B-SPEC
+-	O
+A59	O
+abolishes	O
+demyelination	O
+.	O
+
+Analyses	O
+of	O
+these	O
+full	O
+-	O
+length	O
+sequences	O
+showed	O
+a	O
+positive	O
+selection	O
+occurring	O
+during	O
+SARS	O
+-	O
+CoV	O
+virus	B-SPEC
+evolution	B-PROC
+.	O
+
+The	O
+estimated	O
+genome	B-PROC
+mutation	I-PROC
+rate	O
+was	O
+approximately	O
+0	O
+.	O
+1	O
+per	O
+genome	O
+,	O
+demonstrating	O
+possibly	O
+one	O
+of	O
+the	O
+lowest	O
+rates	O
+among	O
+known	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+effectiveness	O
+of	O
+the	O
+Australian	O
+border	O
+entry	O
+screening	O
+program	O
+to	O
+detect	O
+arriving	O
+travellers	O
+with	O
+symptoms	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+To	O
+determine	O
+the	O
+number	O
+of	O
+international	O
+travellers	O
+who	O
+were	O
+symptomatic	O
+on	O
+arrival	O
+in	O
+Australia	O
+but	O
+missed	O
+by	O
+screening	O
+,	O
+data	O
+were	O
+obtained	O
+on	O
+the	O
+number	O
+of	O
+arrivals	O
+screened	O
+and	O
+the	O
+number	O
+with	O
+symptoms	O
+(	O
+from	O
+the	O
+Australian	O
+Quarantine	O
+and	O
+Inspection	O
+Service	O
+[	O
+AQIS	O
+]),	O
+as	O
+well	O
+as	O
+the	O
+number	O
+of	O
+people	O
+investigated	O
+for	O
+SARS	B-DISO
+(	O
+from	O
+the	O
+Australian	O
+SARS	B-DISO
+Case	O
+Register	O
+).	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+humoral	O
+responses	O
+in	O
+mice	B-SPEC
+immunized	O
+with	O
+plasmid	O
+DNAs	O
+encoding	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+gene	O
+fragments	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immunological	O
+characteristics	O
+of	O
+SARS	O
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+were	O
+investigated	O
+by	O
+administering	O
+mice	B-SPEC
+with	O
+plasmids	O
+encoding	O
+various	O
+S	O
+gene	O
+fragments	O
+.	O
+
+Recently	O
+,	O
+this	O
+technique	O
+was	O
+employed	O
+in	O
+anti	O
+-	O
+virus	B-SPEC
+infections	B-DISO
+in	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+and	O
+hepatitis	B-PATH
+C	I-PATH
+/	O
+B	B-SPEC
+virus	I-SPEC
+.	O
+
+Our	O
+study	O
+provided	O
+evidence	O
+that	O
+RNAi	B-PROC
+could	O
+be	O
+a	O
+tool	O
+for	O
+inhibition	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+dynamic	O
+changes	O
+of	O
+dendritic	B-ANAT
+cell	B-COMP
+subsets	O
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+of	O
+patients	O
+infected	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+evaluate	O
+their	O
+roles	O
+in	O
+the	O
+immunopathogenesis	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Nosocomial	O
+transmission	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+from	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+to	O
+healthcare	O
+workers	O
+has	O
+been	O
+a	O
+prominent	O
+and	O
+worrisome	O
+feature	O
+of	O
+existing	O
+outbreaks	O
+.	O
+
+In	O
+the	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+loose	O
+aggregates	O
+of	O
+macrophages	B-ANAT
+were	O
+seen	O
+more	O
+frequently	O
+in	O
+the	O
+sputum	B-ANAT
+.	O
+
+These	O
+macrophages	B-ANAT
+frequently	O
+showed	O
+morphological	O
+changes	O
+,	O
+such	O
+as	O
+cytoplasmic	B-COMP
+foaminess	O
+,	O
+vacuole	B-ANAT
+formation	B-PROC
+,	O
+and	O
+nuclear	O
+changes	O
+(	O
+including	O
+multinucleation	O
+and	O
+a	O
+ground	O
+glass	O
+appearance	O
+)	O
+when	O
+compared	O
+with	O
+the	O
+control	O
+samples	O
+.	O
+
+These	O
+macrophages	B-ANAT
+frequently	O
+showed	O
+morphological	O
+changes	O
+,	O
+such	O
+as	O
+cytoplasmic	B-COMP
+foaminess	O
+,	O
+vacuole	B-COMP
+formation	B-PROC
+,	O
+and	O
+nuclear	O
+changes	O
+(	O
+including	O
+multinucleation	O
+and	O
+a	O
+ground	O
+glass	O
+appearance	O
+)	O
+when	O
+compared	O
+with	O
+the	O
+control	O
+samples	O
+.	O
+
+Fibrogranulation	O
+tissue	B-ANAT
+proliferation	B-DISO
+in	O
+small	O
+airways	O
+and	O
+airspaces	O
+(	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+organising	I-DISO
+pneumonia	I-DISO
+-	O
+like	O
+lesions	O
+)	O
+in	O
+subpleural	O
+locations	O
+was	O
+also	O
+seen	O
+in	O
+some	O
+patients	O
+.	O
+
+Postmortem	O
+examination	O
+allows	O
+tissue	B-ANAT
+to	O
+be	O
+sampled	O
+for	O
+virological	O
+investigations	O
+and	O
+ultrastructural	O
+examination	O
+,	O
+and	O
+when	O
+coupled	O
+with	O
+the	O
+appropriate	O
+lung	B-ANAT
+morphological	O
+changes	O
+,	O
+is	O
+valuable	O
+to	O
+confirm	O
+the	O
+diagnosis	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+particularly	O
+in	O
+clinically	O
+unapparent	O
+or	O
+suspicious	O
+but	O
+unconfirmed	O
+cases	O
+.	O
+
+To	O
+move	B-PROC
+toward	O
+a	O
+mechanistic	O
+understanding	O
+of	O
+these	O
+phenomena	O
+,	O
+we	O
+used	O
+growth	B-PROC
+media	B-ANAT
+enriched	O
+with	O
+methyl	B-CHED
+-	O
+beta	B-CHED
+-	I-CHED
+cyclodextrin	I-CHED
+or	O
+cholesterol	B-CHED
+to	O
+reduce	O
+or	O
+elevate	O
+cellular	B-COMP
+membrane	I-COMP
+sterols	B-CHED
+,	O
+respectively	O
+.	O
+
+We	O
+considered	O
+whether	O
+cholesterol	B-CHED
+was	O
+indirectly	O
+involved	O
+in	O
+membrane	O
+fusion	O
+by	O
+condensing	O
+CEACAMs	O
+into	O
+""""	O
+lipid	B-COMP
+raft	I-COMP
+""""	O
+membrane	B-COMP
+microdomains	O
+,	O
+thereby	O
+creating	O
+opportunities	O
+for	O
+simultaneous	O
+binding	B-FUNC
+of	O
+multiple	O
+S	O
+proteins	B-CHED
+that	O
+subsequently	O
+cooperate	O
+in	O
+the	O
+receptor	O
+-	O
+triggered	O
+membrane	B-PROC
+fusion	I-PROC
+process	O
+.	O
+
+However	O
+,	O
+coronavirus	B-SPEC
+D	O
+-	O
+RNA	B-PROC
+expression	I-PROC
+vectors	O
+display	O
+an	O
+inherent	O
+instability	O
+following	O
+serial	O
+passage	O
+with	O
+helper	O
+virus	B-SPEC
+,	O
+resulting	O
+in	O
+the	O
+eventual	O
+loss	O
+of	O
+the	O
+heterologous	O
+genes	O
+.	O
+
+ISAV	B-SPEC
+presumably	O
+represents	O
+a	O
+new	O
+genus	B-SPEC
+within	O
+the	O
+Orthomyxoviridae	B-SPEC
+.	O
+
+ISAV	B-SPEC
+has	O
+been	O
+shown	O
+earlier	O
+to	O
+exhibit	O
+a	O
+receptor	O
+-	O
+destroying	O
+activity	O
+,	O
+which	O
+was	O
+defined	O
+as	O
+an	O
+acetylesterase	B-ENZY
+with	O
+unknown	O
+specificity	O
+.	O
+
+When	O
+we	O
+used	O
+a	O
+glycosidically	O
+bound	O
+substrate	O
+,	O
+ISAV	B-SPEC
+was	O
+unable	O
+to	O
+hydrolyze	O
+9	O
+-	O
+O	B-CHED
+-	I-CHED
+acetylated	I-CHED
+sialic	I-CHED
+acid	I-CHED
+,	O
+which	O
+represents	O
+the	O
+major	O
+substrate	O
+for	O
+the	O
+influenza	B-PRGE
+C	I-PRGE
+virus	I-PRGE
+esterase	I-PRGE
+.	O
+
+Thus	O
+,	O
+the	O
+enzymatic	B-PROC
+activity	I-PROC
+of	O
+the	O
+hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+of	O
+ISAV	B-SPEC
+is	O
+comparable	O
+to	O
+that	O
+of	O
+the	O
+sialate	B-CHED
+-	O
+4	O
+-	O
+O	O
+-	O
+esterases	B-FUNC
+of	O
+murine	B-SPEC
+coronaviruses	O
+and	O
+related	O
+group	O
+2	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+temporal	O
+lung	B-ANAT
+changes	O
+at	O
+thin	O
+-	O
+section	O
+CT	O
+in	O
+30	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+lung	O
+abnormalities	O
+on	O
+serial	O
+thin	O
+-	O
+section	O
+computed	O
+tomographic	O
+(	O
+CT	O
+)	O
+scans	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+during	O
+acute	O
+and	O
+convalescent	O
+periods	B-PROC
+.	O
+
+When	O
+specific	O
+opacities	B-DISO
+were	O
+analyzed	O
+in	O
+17	O
+patients	O
+,	O
+consolidation	O
+generally	O
+resolved	O
+completely	O
+(	O
+n	O
+=	O
+4	O
+)	O
+or	O
+to	O
+minimal	O
+residual	O
+opacities	B-DISO
+;	O
+six	O
+(	O
+55	O
+%)	O
+of	O
+11	O
+patients	O
+with	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+had	O
+substantial	O
+residual	B-DISO
+disease	I-DISO
+(	O
+CT	O
+scores	O
+>	O
+5	O
+)	O
+on	O
+final	O
+scans	O
+.	O
+
+CONCLUSIONS	O
+:	O
+There	O
+is	O
+a	O
+temporal	O
+pattern	O
+of	O
+lung	B-ANAT
+abnormalities	O
+at	O
+thin	O
+-	O
+section	O
+CT	O
+in	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Noninvasive	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+in	O
+elderly	O
+cardiogenic	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+compare	O
+the	O
+physiological	O
+effects	O
+and	O
+the	O
+clinical	O
+efficacy	O
+of	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+CPAP	O
+)	O
+vs	O
+standard	O
+medical	O
+treatment	O
+in	O
+elderly	O
+patients	O
+(>	O
+or	O
+=	O
+75	O
+years	O
+)	O
+with	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+related	O
+to	O
+cardiogenic	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+.	O
+
+Noninvasive	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+promotes	O
+early	O
+clinical	O
+improvement	O
+in	O
+elderly	O
+patients	O
+attending	O
+emergency	B-DISO
+departments	O
+for	O
+a	O
+severe	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+but	O
+only	O
+reduces	O
+early	O
+48	O
+-	O
+h	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+After	O
+various	O
+observational	O
+studies	O
+demonstrated	O
+a	O
+benefit	O
+of	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	B-PROC
+)	O
+in	O
+the	O
+therapy	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+ECMO	B-PROC
+now	O
+represents	O
+an	O
+important	O
+contribution	O
+for	O
+ARDS	B-DISO
+therapy	O
+using	O
+clinical	O
+algorithms	O
+despite	O
+a	O
+lack	O
+of	O
+positive	O
+controlled	O
+studies	O
+.	O
+
+After	O
+these	O
+new	O
+developments	O
+indications	O
+for	O
+ECMO	O
+could	O
+be	O
+extended	O
+from	O
+use	O
+not	O
+only	O
+as	O
+ultimate	O
+ratio	O
+but	O
+to	O
+less	O
+severe	O
+ARDS	O
+to	O
+enable	O
+lung	B-ANAT
+protective	O
+,	O
+less	O
+invasive	O
+mechanical	O
+ventilation	O
+.	O
+
+Fifteen	O
+Korean	O
+IBV	B-SPEC
+isolates	O
+were	O
+classified	O
+into	O
+4	O
+groups	O
+by	O
+their	O
+RFLP	O
+patterns	O
+using	O
+restriction	O
+enzymes	O
+,	O
+HaeIII	O
+,	O
+BstYI	O
+,	O
+and	O
+XcmI	O
+.	O
+The	O
+RFLP	O
+patterns	O
+for	O
+3	O
+,	O
+1	O
+,	O
+and	O
+1	O
+of	O
+15	O
+isolates	O
+corresponded	O
+to	O
+the	O
+patterns	O
+of	O
+IBV	B-SPEC
+Arkansas	O
+,	O
+Connecticut	O
+,	O
+and	O
+Massachusetts	O
+strains	O
+,	O
+respectively	O
+.	O
+
+Moreover	O
+,	O
+significant	O
+toxicity	O
+,	O
+such	O
+as	O
+hemolytic	B-DISO
+anemia	I-DISO
+,	O
+has	O
+been	O
+attributed	O
+to	O
+ribavirin	O
+.	O
+
+Other	O
+agents	O
+,	O
+including	O
+the	O
+HIV	B-PRGE
+protease	I-PRGE
+inhibitor	I-PRGE
+glycyrrhizin	B-CHED
+and	O
+convalescent	O
+plasma	B-ANAT
+,	O
+remain	O
+to	O
+be	O
+evaluated	O
+.	O
+
+Two	O
+periods	B-PROC
+were	O
+studied	O
+.	O
+
+Questionnaires	O
+were	O
+distributed	O
+to	O
+all	O
+willing	O
+employees	O
+of	O
+Sunnybrook	O
+and	O
+Women	O
+'	O
+s	O
+College	O
+Health	O
+Sciences	O
+Centre	O
+between	O
+Apr	B-CHED
+.	O
+10	O
+and	O
+22	O
+,	O
+2003	O
+.	O
+
+Two	O
+-	O
+thirds	O
+of	O
+the	O
+respondents	O
+reported	O
+SARS	B-DISO
+-	O
+related	O
+concern	O
+for	O
+their	O
+own	O
+or	O
+their	O
+family	B-SPEC
+'	O
+s	O
+health	O
+.	O
+
+Masks	O
+were	O
+reported	O
+to	O
+be	O
+the	O
+most	O
+bothersome	O
+infection	B-DISO
+control	O
+precaution	O
+.	O
+
+The	O
+sequence	O
+obtained	O
+from	O
+the	O
+array	O
+is	O
+highly	O
+reproducible	O
+,	O
+accurate	O
+(>	O
+99	O
+.	O
+99	O
+%	O
+accuracy	O
+)	O
+and	O
+capable	O
+of	O
+identifying	O
+known	O
+and	O
+novel	O
+variants	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Notably	O
+,	O
+we	O
+applied	O
+this	O
+technology	O
+to	O
+a	O
+field	O
+specimen	O
+of	O
+probable	O
+SARS	B-DISO
+and	O
+rapidly	O
+deduced	O
+its	O
+infectious	B-DISO
+source	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+applied	O
+RT	O
+-	O
+nested	O
+PCR	O
+for	O
+the	O
+detection	O
+of	O
+MHV	O
+genomic	O
+RNA	O
+in	O
+a	O
+modified	O
+manner	O
+to	O
+obtain	O
+RNA	O
+from	O
+the	O
+intestines	B-ANAT
+of	O
+mice	B-SPEC
+and	O
+from	O
+filter	O
+dust	O
+in	O
+the	O
+ventilation	O
+ducts	B-ANAT
+of	O
+the	O
+room	O
+in	O
+which	O
+a	O
+contaminated	O
+mouse	B-SPEC
+colony	O
+was	O
+kept	O
+.	O
+
+Furthermore	O
+,	O
+sequences	O
+of	O
+FD2	O
+and	O
+of	O
+filter	O
+dust	O
+from	O
+another	O
+contaminated	O
+mouse	B-SPEC
+room	O
+,	O
+No	O
+.	O
+7	O
+(	O
+FD7	O
+)	O
+showed	O
+38	O
+nucleotide	B-CHED
+exchanges	O
+among	O
+368	O
+-	O
+bp	O
+(	O
+10	O
+.	O
+3	O
+%),	O
+suggesting	O
+that	O
+two	O
+different	O
+MHV	B-SPEC
+strains	O
+were	O
+contaminating	O
+our	O
+facilities	O
+.	O
+
+Knowledge	O
+of	O
+this	O
+pathology	B-DISO
+is	O
+crucial	O
+,	O
+for	O
+although	O
+it	O
+is	O
+essential	O
+to	O
+rule	O
+out	O
+aetiologies	O
+requiring	O
+specific	O
+management	O
+such	O
+as	O
+microbial	O
+infection	B-DISO
+or	O
+drug	O
+-	O
+related	O
+syndromes	B-DISO
+,	O
+diagnosis	O
+should	O
+not	O
+be	O
+delayed	O
+as	O
+its	O
+severe	O
+clinical	O
+course	O
+is	O
+improved	O
+by	O
+corticosteroids	B-CHED
+.	O
+
+Dramatic	O
+clinical	O
+resolution	O
+was	O
+obtained	O
+by	O
+using	O
+corticosteroids	B-CHED
+.	O
+
+It	O
+is	O
+a	O
+type	O
+1	O
+viral	O
+fusion	O
+protein	B-CHED
+that	O
+characteristically	O
+contains	O
+two	O
+heptad	O
+repeat	O
+regions	O
+,	O
+denoted	O
+HR	O
+-	O
+N	O
+and	O
+HR	O
+-	O
+C	O
+,	O
+that	O
+form	O
+coiled	O
+-	O
+coil	O
+structures	O
+within	O
+the	O
+ectodomain	O
+of	O
+the	O
+protein	B-CHED
+.	O
+
+Evidence	O
+-	O
+based	O
+recommendations	O
+can	O
+be	O
+made	O
+regarding	O
+many	O
+aspects	O
+of	O
+the	O
+acute	O
+management	O
+of	O
+sepsis	B-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+that	O
+will	O
+hopefully	O
+translate	O
+into	O
+improved	O
+outcomes	O
+for	O
+the	O
+critically	B-DISO
+ill	I-DISO
+patient	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+some	O
+nation	O
+states	O
+,	O
+sustained	O
+integrated	O
+global	O
+epidemiological	O
+surveillance	O
+has	O
+been	O
+weakened	O
+as	O
+a	O
+result	O
+of	O
+political	O
+unrest	B-DISO
+,	O
+disinterest	O
+,	O
+and	O
+a	O
+poorly	O
+developed	O
+infrastructure	O
+due	O
+to	O
+rapidly	O
+increasing	O
+global	O
+inequality	O
+.	O
+
+The	O
+system	O
+has	O
+uncovered	O
+unreported	O
+infectious	B-DISO
+diseases	I-DISO
+of	O
+international	O
+importance	O
+including	O
+cholera	B-DISO
+,	O
+plague	B-DISO
+,	O
+and	O
+influenza	B-DISO
+;	O
+current	O
+trends	O
+of	O
+acute	O
+flaccid	B-DISO
+paralysis	I-DISO
+surveillance	O
+in	O
+polio	B-DISO
+eradication	O
+;	O
+and	O
+prevalence	O
+of	O
+HIV	B-DISO
+,	O
+syphilis	B-DISO
+,	O
+hepatitis	B-DISO
+B	I-DISO
+,	O
+and	O
+hepatitis	B-PATH
+C	I-PATH
+in	O
+individual	O
+areas	O
+covered	O
+by	O
+the	O
+sentinels	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+treatment	O
+center	O
+.	O
+
+ABSTRACT	O
+:	O
+Mortality	O
+rates	O
+remain	O
+high	O
+for	O
+the	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+despite	O
+standardised	O
+treatment	O
+algorithms	O
+.	O
+
+ABSTRACT	O
+:	O
+Basic	O
+facts	O
+about	O
+SARS	B-DISO
+are	O
+presented	O
+,	O
+including	O
+epidemiology	O
+,	O
+clinical	O
+symptoms	O
+and	O
+the	O
+course	O
+of	O
+disease	O
+,	O
+multinational	O
+search	O
+of	O
+etiological	O
+factor	O
+,	O
+diagnostic	O
+approaches	O
+and	O
+others	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+retrospective	O
+study	O
+is	O
+to	O
+evaluate	O
+the	O
+effectiveness	O
+of	O
+a	O
+triage	O
+policy	O
+and	O
+risk	O
+-	O
+stratified	O
+infection	B-DISO
+control	O
+measures	O
+in	O
+preventing	O
+nosocomial	O
+SARS	B-DISO
+infection	B-DISO
+among	O
+paediatric	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+at	O
+the	O
+Prince	O
+of	O
+Wales	O
+Hospital	O
+,	O
+a	O
+general	O
+hospital	O
+to	O
+which	O
+children	O
+with	O
+SARS	B-DISO
+are	O
+referred	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+implementation	O
+of	O
+different	O
+levels	O
+of	O
+infection	B-DISO
+control	O
+precautions	O
+was	O
+guided	O
+by	O
+this	O
+risk	O
+stratification	O
+strategy	O
+.	O
+
+Twenty	O
+-	O
+six	O
+HCWs	O
+worked	O
+in	O
+the	O
+ultra	O
+high	O
+-	O
+risk	O
+area	O
+caring	O
+for	O
+SARS	B-DISO
+patients	O
+and	O
+88	O
+HCWs	O
+managed	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+in	O
+other	O
+ward	O
+areas	O
+.	O
+
+TITLE	O
+:	O
+Hypoxia	B-DISO
+from	O
+vasculitic	O
+pulmonary	B-DISO
+haemorrhage	I-DISO
+improved	O
+by	O
+prone	O
+position	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recently	O
+identified	O
+etiological	O
+agent	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+belongs	O
+to	O
+Coronaviridae	B-SPEC
+(	O
+CoV	O
+),	O
+a	O
+family	B-SPEC
+of	O
+viruses	B-SPEC
+replicating	O
+by	O
+a	O
+poorly	O
+understood	O
+mechanism	O
+.	O
+
+To	O
+investigate	O
+the	O
+role	O
+of	O
+viral	B-DISO
+infections	I-DISO
+,	O
+allergen	B-CHED
+sensitization	B-PROC
+,	O
+and	O
+exposure	O
+to	O
+indoor	O
+allergens	O
+as	O
+risk	O
+factors	O
+for	O
+acute	O
+wheezing	B-DISO
+in	O
+children	O
+0	O
+to	O
+12	O
+years	O
+old	O
+.	O
+
+Detection	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+antigen	B-CHED
+,	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+RNA	O
+,	O
+adenovirus	B-DISO
+,	O
+influenza	B-DISO
+,	O
+and	O
+parainfluenza	B-DISO
+antigens	B-CHED
+was	O
+performed	O
+in	O
+nasal	B-ANAT
+washes	O
+.	O
+
+Among	O
+children	O
+2	O
+to	O
+12	O
+years	O
+old	O
+,	O
+sensitization	B-PROC
+to	O
+inhalant	O
+allergens	O
+was	O
+the	O
+major	O
+risk	O
+factor	O
+for	O
+wheezing	B-DISO
+(	O
+odds	O
+ratio	O
+,	O
+2	O
+.	O
+7	O
+;	O
+P	O
+=	O
+.	O
+03	O
+).	O
+
+Six	O
+patients	O
+had	O
+direct	O
+exposure	O
+to	O
+persons	O
+with	O
+chickenpox	B-DISO
+infection	B-DISO
+.	O
+
+There	O
+were	O
+3	O
+deaths	B-PROC
+(	O
+25	O
+%);	O
+2	O
+were	O
+above	O
+65	O
+years	O
+old	O
+and	O
+1	O
+was	O
+37	O
+years	O
+old	O
+with	O
+acute	B-DISO
+myeloid	I-DISO
+leukaemia	I-DISO
+on	O
+chemotherapy	O
+.	O
+
+There	O
+were	O
+3	O
+deaths	B-PROC
+(	O
+25	O
+%);	O
+2	O
+were	O
+above	O
+65	O
+years	O
+old	O
+and	O
+1	O
+was	O
+37	O
+years	O
+old	O
+with	O
+acute	B-DISO
+myeloid	I-DISO
+leukaemia	I-DISO
+on	O
+chemotherapy	O
+.	O
+
+Hospital	O
+databases	O
+and	O
+electronic	O
+patient	O
+records	O
+covering	O
+the	O
+4	O
+months	O
+duration	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+and	O
+an	O
+equivalent	O
+period	O
+preceding	O
+SARS	B-DISO
+were	O
+compared	O
+.	O
+
+TITLE	O
+:	O
+Prolonged	O
+disturbances	O
+of	O
+in	O
+vitro	O
+cytokine	B-PROC
+production	I-PROC
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+treated	O
+with	O
+ribavirin	B-CHED
+and	O
+steroids	B-CHED
+.	O
+
+We	O
+conclude	O
+that	O
+prolonged	O
+dysregulated	O
+cytokine	B-PROC
+production	I-PROC
+occurs	O
+in	O
+SARS	B-DISO
+and	O
+that	O
+future	O
+studies	O
+should	O
+be	O
+directed	O
+at	O
+improving	O
+anti	O
+-	O
+inflammatory	O
+and	O
+antiviral	B-CHED
+therapies	O
+in	O
+order	B-SPEC
+to	O
+limit	O
+cytokine	O
+impairment	B-DISO
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+glycoprotein	O
+-	O
+mediated	O
+viral	O
+entry	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+were	O
+able	O
+to	O
+develop	O
+a	O
+cell	O
+-	O
+cell	B-COMP
+fusion	O
+assay	O
+that	O
+could	O
+be	O
+used	O
+to	O
+monitor	O
+S	O
+glycoprotein	B-CHED
+-	O
+dependent	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+Hypoxia	B-DISO
+progressed	O
+gradually	O
+and	O
+she	O
+was	O
+transferred	O
+to	O
+ICU	O
+with	O
+tracheal	O
+intubation	O
+.	O
+
+Stored	O
+serum	B-COMP
+specimens	O
+of	O
+the	O
+patients	O
+were	O
+detected	O
+for	O
+IgG	B-COMP
+antibody	I-COMP
+against	O
+SARS	B-DISO
+Co	O
+-	O
+V	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+Persons	O
+were	O
+all	O
+susceptible	O
+to	O
+infection	B-DISO
+of	O
+SARS	B-DISO
+Co	O
+-	O
+V	O
+,	O
+with	O
+the	O
+highest	O
+proportion	O
+at	O
+ages	O
+of	O
+20	O
+-	O
+50	O
+years	O
+,	O
+which	O
+accounted	O
+for	O
+68	O
+.	O
+7	O
+%	O
+of	O
+the	O
+total	O
+cases	O
+.	O
+
+And	O
+7	O
+.	O
+4	O
+%	O
+(	O
+attack	O
+rate	O
+)	O
+of	O
+those	O
+exposed	O
+to	O
+SARS	B-DISO
+cases	O
+suffered	B-DISO
+from	O
+the	O
+illness	O
+during	O
+the	O
+periods	B-PROC
+of	O
+quarantine	O
+.	O
+
+This	O
+finding	O
+thus	O
+led	O
+to	O
+a	O
+kit	B-FUNC
+sensitivity	O
+,	O
+specificity	O
+,	O
+and	O
+accuracy	O
+of	O
+100	O
+,	O
+99	O
+.	O
+5	O
+,	O
+and	O
+99	O
+.	O
+6	O
+%,	O
+respectively	O
+.	O
+
+The	O
+resulting	O
+rapid	O
+test	O
+has	O
+an	O
+excellent	O
+agreement	O
+of	O
+99	O
+.	O
+6	O
+%,	O
+with	O
+a	O
+kappa	B-PRGE
+value	I-PRGE
+of	I-PRGE
+1	I-PRGE
+.	I-PRGE
+00	I-PRGE
+,	O
+with	O
+the	O
+ELISA	O
+.	O
+
+The	O
+PPV	B-CHED
+and	O
+NPV	O
+for	O
+the	O
+rapid	O
+test	O
+thus	O
+reached	O
+95	O
+.	O
+3	O
+and	O
+100	O
+%,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Normal	O
+piglets	O
+weaned	B-PROC
+onto	O
+soy	O
+-	O
+or	O
+egg	B-ANAT
+-	O
+based	O
+diets	O
+generated	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+fed	O
+protein	B-CHED
+.	O
+
+Paradoxically	O
+,	O
+TGEV	B-SPEC
+-	O
+infected	O
+animals	B-SPEC
+showed	O
+an	O
+enhanced	O
+primary	O
+IgG1	B-COMP
+antibody	I-COMP
+response	O
+to	O
+injected	O
+soy	O
+at	O
+4	O
+weeks	O
+of	O
+age	O
+,	O
+but	O
+they	O
+subsequently	O
+showed	O
+a	O
+reduced	O
+secondary	O
+response	O
+after	O
+an	O
+intraperitoneal	O
+challenge	O
+at	O
+9	O
+weeks	O
+of	O
+age	O
+in	O
+comparison	O
+to	O
+uninfected	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Profiles	O
+of	O
+antibody	B-PROC
+responses	I-PROC
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+recombinant	O
+proteins	O
+and	O
+their	O
+potential	O
+use	O
+as	O
+diagnostic	O
+markers	O
+.	O
+
+METHODS	O
+:	O
+According	O
+to	O
+the	O
+experience	O
+and	O
+information	O
+,	O
+to	O
+select	O
+several	O
+perspective	O
+candidates	O
+from	O
+anti	O
+-	O
+SARS	B-DISO
+effective	O
+TCM	O
+prescriptions	O
+and	O
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+an	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0201	I-PRGE
+-	O
+restricted	O
+CD8	B-PRGE
++	I-PRGE
+T	I-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitope	B-CHED
+SSp	I-PRGE
+-	I-PRGE
+1	I-PRGE
+of	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Following	O
+intranasal	O
+administration	O
+,	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+replicated	O
+to	O
+high	O
+titers	O
+in	O
+the	O
+respiratory	B-ANAT
+tracts	I-ANAT
+of	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+Recent	O
+findings	O
+indicate	O
+that	O
+the	O
+calcium	B-CHED
+antagonist	B-PROC
+nifedipine	B-CHED
+might	O
+be	O
+a	O
+better	O
+alternative	O
+.	O
+
+Large	O
+randomized	O
+controlled	O
+trials	O
+are	O
+urgently	O
+needed	O
+to	O
+determine	O
+whether	O
+antihypertensive	B-CHED
+therapy	O
+in	O
+pregnancy	O
+results	O
+in	O
+greater	O
+benefit	O
+than	O
+risks	O
+for	O
+mother	B-ANAT
+and	I-ANAT
+fetus	I-ANAT
+.	O
+
+In	O
+1994	O
+and	O
+1997	O
+,	O
+CDC	O
+reported	O
+clusters	B-CHED
+of	O
+acute	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+(	O
+APH	O
+)	O
+among	O
+infants	O
+in	O
+Cleveland	O
+,	O
+Ohio	O
+.	O
+
+In	O
+developing	O
+this	O
+response	O
+,	O
+CDC	O
+recommends	O
+a	O
+definition	O
+for	O
+a	O
+clinically	O
+confirmed	O
+case	O
+of	O
+AIPH	O
+among	O
+infants	O
+on	O
+the	O
+basis	O
+of	O
+evidence	O
+of	O
+blood	B-ANAT
+in	O
+the	O
+airway	B-ANAT
+,	O
+age	O
+</=	O
+1	O
+year	O
+,	O
+absence	O
+of	O
+medical	O
+conditions	O
+related	O
+to	O
+pulmonary	B-ANAT
+hemorrhage	I-DISO
+,	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+or	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+CDC	O
+staff	O
+will	O
+work	O
+with	O
+state	O
+and	O
+local	O
+health	O
+departments	O
+to	O
+investigate	O
+reported	O
+clusters	B-CHED
+of	O
+cases	O
+of	O
+AIPH	O
+among	O
+infants	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+:	O
+clinical	O
+virology	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+originated	O
+in	O
+Southern	O
+China	O
+in	O
+November	O
+2002	O
+,	O
+and	O
+was	O
+brought	O
+to	O
+Hong	O
+Kong	O
+in	O
+February	O
+2003	O
+.	O
+
+The	O
+disease	O
+is	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+and	O
+is	O
+transmitted	B-DISO
+by	O
+droplets	O
+or	O
+direct	O
+inoculation	O
+from	O
+contact	O
+with	O
+infected	O
+surfaces	O
+.	O
+
+Temporal	O
+lung	B-ANAT
+changes	O
+documented	O
+on	O
+HRCT	O
+suggest	O
+that	O
+some	O
+residual	O
+opacities	B-DISO
+found	O
+may	O
+not	O
+be	O
+reversible	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+:	O
+clinical	O
+features	O
+and	O
+diagnosis	O
+.	O
+
+The	O
+constellation	O
+of	O
+compatible	O
+clinical	O
+and	O
+laboratory	O
+findings	O
+,	O
+together	O
+with	O
+the	O
+rather	O
+characteristic	O
+radiological	O
+features	O
+especially	O
+on	O
+HRCT	O
+and	O
+the	O
+lack	O
+of	O
+clinical	O
+response	O
+to	O
+broad	O
+-	O
+spectrum	O
+antibiotics	O
+,	O
+should	O
+quickly	O
+arouse	O
+suspicion	O
+of	O
+SARS	B-DISO
+.	O
+
+Recently	O
+,	O
+quantitative	O
+measurement	O
+of	O
+blood	B-ANAT
+SARS	B-DISO
+CoV	O
+RNA	O
+with	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+technique	O
+has	O
+been	O
+developed	O
+with	O
+a	O
+detection	O
+rate	O
+of	O
+80	O
+%	O
+as	O
+early	O
+as	O
+day	O
+1	O
+of	O
+hospital	O
+admission	O
+but	O
+the	O
+detection	O
+rates	O
+drop	O
+to	O
+75	O
+%	O
+and	O
+42	O
+%	O
+on	O
+day	O
+7	O
+and	O
+day	O
+14	O
+,	O
+respectively	O
+.	O
+
+Anecdotal	O
+experience	O
+strongly	O
+supports	O
+the	O
+use	O
+of	O
+steroid	B-CHED
+,	O
+at	O
+least	O
+in	O
+a	O
+subset	O
+of	O
+SARS	B-DISO
+patients	O
+,	O
+particularly	O
+with	O
+'	O
+critical	O
+SARS	B-DISO
+'	O
+who	O
+display	O
+continued	O
+clinical	O
+instability	O
+or	O
+deterioration	O
+and	O
+progressive	O
+radiographic	O
+or	O
+HRCT	O
+deterioration	O
+.	O
+
+A	O
+retrospective	O
+study	O
+carried	O
+out	O
+of	O
+72	O
+probable	O
+SARS	O
+patients	O
+has	O
+shown	O
+that	O
+cases	O
+who	O
+received	O
+pulse	B-PROC
+methylprendisolone	O
+did	O
+not	O
+differ	O
+in	O
+cumulative	O
+steroid	B-CHED
+dosage	O
+or	O
+adverse	O
+reactions	O
+,	O
+although	O
+the	O
+former	O
+patients	O
+had	O
+less	O
+oxygen	B-CHED
+requirement	O
+,	O
+better	O
+radiographic	O
+outcome	O
+,	O
+and	O
+less	O
+likelihood	O
+of	O
+requiring	O
+rescue	O
+pulse	B-PROC
+steroid	B-CHED
+therapy	O
+than	O
+their	O
+counterparts	O
+.	O
+
+Secondary	B-DISO
+infections	I-DISO
+could	O
+be	O
+troublesome	O
+,	O
+particular	O
+for	O
+patients	O
+with	O
+prolonged	O
+hospitalization	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+Spontaneous	O
+pneumomediastinum	B-DISO
+and	O
+pneumothorax	B-DISO
+in	O
+SARS	B-DISO
+is	O
+common	O
+.	O
+
+In	O
+the	O
+majority	O
+of	O
+nosocomial	B-DISO
+infections	I-DISO
+,	O
+there	O
+was	O
+a	O
+history	O
+of	O
+close	O
+contact	O
+with	O
+a	O
+SARS	B-DISO
+patient	O
+,	O
+and	O
+transmission	O
+occurred	O
+via	O
+large	O
+droplets	O
+,	O
+direct	O
+contact	O
+with	O
+infectious	B-DISO
+material	O
+or	O
+by	O
+contact	O
+with	O
+fomites	O
+contaminated	O
+by	O
+infectious	B-DISO
+material	O
+.	O
+
+In	O
+Hong	O
+Kong	O
+,	O
+where	O
+there	O
+are	O
+few	O
+private	O
+rooms	O
+for	O
+patient	O
+isolation	O
+,	O
+some	O
+hospitals	O
+have	O
+obtained	O
+good	O
+outcome	O
+by	O
+having	O
+designated	O
+SARS	O
+teams	O
+and	O
+separate	O
+wards	O
+for	O
+patient	O
+triage	O
+,	O
+confirmed	O
+SARS	B-DISO
+cases	O
+and	O
+step	O
+-	O
+down	O
+of	O
+patients	O
+in	O
+whom	O
+SARS	B-DISO
+had	O
+been	O
+ruled	O
+out	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+:	O
+public	O
+health	O
+measures	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+prevalence	O
+of	O
+FCoV	O
+types	O
+in	O
+Austrian	O
+cat	B-SPEC
+populations	O
+without	O
+FIP	B-DISO
+has	O
+been	O
+surveyed	O
+recently	O
+indicating	O
+that	O
+type	O
+I	O
+infections	B-DISO
+predominate	O
+.	O
+
+PCR	O
+assays	O
+have	O
+been	O
+developed	O
+amplifying	O
+parts	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+.	O
+
+By	O
+simplifying	O
+the	O
+model	O
+to	O
+a	O
+two	O
+-	O
+compartment	B-ANAT
+suspect	O
+-	O
+probable	O
+model	O
+and	O
+a	O
+single	O
+-	O
+compartment	B-ANAT
+probable	O
+model	O
+and	O
+using	O
+limited	O
+data	O
+,	O
+we	O
+are	O
+able	O
+to	O
+simulate	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+Beijing	O
+.	O
+
+We	O
+estimate	O
+that	O
+the	O
+reproduction	B-PROC
+number	O
+varies	O
+from	O
+1	O
+.	O
+0698	O
+to	O
+3	O
+.	O
+2524	O
+and	O
+obtain	O
+certain	O
+important	O
+epidemiological	O
+parameters	O
+.	O
+
+Our	O
+results	O
+are	O
+consistent	O
+with	O
+a	O
+hypothesis	O
+of	O
+viral	O
+host	B-COMP
+jumping	O
+events	O
+,	O
+concomitant	O
+with	O
+the	O
+reassortment	O
+of	O
+bird	B-SPEC
+and	O
+mammalian	B-SPEC
+coronaviruses	O
+,	O
+a	O
+scenario	O
+analogous	O
+to	O
+earlier	O
+outbreaks	O
+of	O
+influenzae	O
+.	O
+
+N	O
+proteins	B-CHED
+of	O
+other	O
+coronavirus	B-SPEC
+have	O
+been	O
+reported	O
+to	O
+be	O
+involved	O
+in	O
+forming	O
+the	O
+viral	B-ANAT
+core	I-ANAT
+and	O
+also	O
+in	O
+the	O
+packaging	O
+and	O
+transcription	B-PROC
+of	O
+the	O
+viral	O
+RNA	O
+.	O
+
+Finally	O
+,	O
+the	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+expressed	B-PROC
+and	O
+purified	O
+from	O
+baculovirus	B-SPEC
+system	O
+was	O
+found	O
+to	O
+form	O
+different	O
+levels	O
+of	O
+higher	O
+order	B-SPEC
+structures	O
+as	O
+detected	O
+by	O
+Western	O
+blot	O
+analysis	O
+of	O
+the	O
+fractionated	O
+proteins	B-CHED
+.	O
+
+Collectively	O
+,	O
+these	O
+results	O
+may	O
+aid	O
+us	O
+in	O
+elucidating	O
+the	O
+mechanism	O
+pertaining	O
+to	O
+formation	B-PROC
+of	O
+viral	B-COMP
+nucleocapsid	I-COMP
+core	O
+,	O
+and	O
+designing	O
+molecular	O
+approaches	O
+to	O
+intervene	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+.	O
+
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+remains	O
+the	O
+most	O
+important	O
+cause	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+in	O
+the	O
+very	O
+elderly	O
+(	O
+80	O
+years	O
+and	O
+over	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+infectious	O
+disease	O
+first	O
+recognized	O
+in	O
+November	O
+2002	O
+in	O
+Guangdong	O
+Province	O
+,	O
+China	O
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+quickly	O
+found	O
+to	O
+be	O
+the	O
+etiological	O
+agent	O
+of	O
+SARS	B-DISO
+in	O
+April	O
+2003	O
+.	O
+
+The	O
+common	O
+laboratory	O
+findings	O
+include	O
+lymphopenia	B-DISO
+,	O
+thrombocytopenia	O
+,	O
+elevated	O
+serum	B-ANAT
+alanine	B-CHED
+and	I-PRGE
+aspartate	B-ENZY
+aminotransferase	I-ENZY
+,	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+,	O
+creatine	B-CHED
+phosphokinase	O
+,	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+.	O
+
+Rhinovirus	B-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+adenovirus	B-DISO
+,	O
+parainfluenza	B-DISO
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+and	O
+coronavirus	B-SPEC
+are	O
+etiologies	O
+most	O
+often	O
+associated	O
+with	O
+infections	B-DISO
+of	O
+the	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+This	O
+article	O
+summarizes	O
+major	O
+principles	O
+of	O
+antiviral	B-CHED
+efficacy	O
+and	O
+reviews	O
+recent	O
+clinical	O
+trials	O
+.	O
+
+TITLE	O
+:	O
+Pro	B-CHED
+/	O
+con	O
+clinical	O
+debate	O
+:	O
+steroids	B-CHED
+are	O
+a	O
+key	O
+component	O
+in	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+A	O
+large	O
+percentage	O
+of	O
+patients	O
+(	O
+many	O
+being	O
+health	O
+care	O
+workers	O
+themselves	O
+)	O
+became	O
+critically	B-DISO
+ill	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+transmissible	O
+febrile	B-PROC
+respiratory	O
+illness	O
+caused	O
+by	O
+a	O
+recently	O
+discovered	O
+coronavirus	B-SPEC
+.	O
+
+To	O
+aid	O
+in	O
+the	O
+differential	O
+diagnosis	O
+and	O
+management	O
+of	O
+SARS	B-DISO
+,	O
+radiologists	O
+must	O
+be	O
+familiar	O
+with	O
+the	O
+typical	O
+clinical	O
+and	O
+histopathologic	O
+findings	O
+,	O
+as	O
+well	O
+as	O
+the	O
+radiologic	O
+features	O
+of	O
+the	O
+disease	O
+.	O
+
+Experiments	O
+were	O
+performed	O
+to	O
+elucidate	O
+the	O
+duration	O
+of	O
+enterotropic	O
+MHV	B-SPEC
+-	O
+Y	O
+shedding	O
+by	O
+immunocompetent	O
+BALB	O
+/	O
+c	O
+and	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+and	O
+immunocompromised	O
+B	O
+and	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+deficient	O
+mice	B-SPEC
+.	O
+
+Based	O
+on	O
+6	O
+strains	O
+with	O
+accurate	O
+dates	O
+of	O
+host	O
+death	B-PROC
+,	O
+we	O
+estimated	O
+the	O
+time	O
+of	O
+the	O
+last	O
+common	O
+ancestor	O
+to	O
+be	O
+about	O
+August	O
+or	O
+September	O
+2002	O
+,	O
+and	O
+the	O
+evolution	B-PROC
+rate	O
+to	O
+be	O
+about	O
+0	O
+.	O
+16	O
+base	O
+/	O
+day	O
+,	O
+that	O
+is	O
+,	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+would	O
+on	O
+average	O
+change	O
+a	O
+base	O
+every	O
+seven	O
+days	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+related	O
+virus	B-SPEC
+predating	O
+SARS	B-DISO
+outbreak	O
+,	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+Using	O
+immunofluorescence	O
+and	O
+neutralization	O
+assays	O
+,	O
+we	O
+detected	O
+antibodies	O
+to	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+/	O
+or	O
+animal	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+like	O
+virus	B-SPEC
+in	O
+17	O
+(	O
+1	O
+.	O
+8	O
+%)	O
+of	O
+938	O
+adults	O
+recruited	O
+in	O
+2001	O
+.	O
+
+To	O
+address	O
+speculations	O
+that	O
+the	O
+virus	B-SPEC
+originated	O
+in	O
+domesticated	O
+animals	B-SPEC
+,	O
+or	O
+that	O
+domestic	O
+species	B-SPEC
+were	O
+susceptible	O
+to	O
+the	O
+virus	B-SPEC
+,	O
+we	O
+inoculated	O
+6	O
+-	O
+week	O
+-	O
+old	O
+pigs	B-SPEC
+and	O
+chickens	B-SPEC
+intravenously	O
+,	O
+intranasally	O
+,	O
+ocularly	O
+,	O
+and	O
+orally	B-ANAT
+with	O
+106	O
+PFU	B-CHED
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+surveillance	O
+during	O
+emergency	B-DISO
+public	O
+health	O
+response	O
+,	O
+United	O
+States	O
+,	O
+March	O
+-	O
+July	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+response	O
+to	O
+the	O
+emergence	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+the	O
+United	O
+States	O
+established	O
+national	O
+surveillance	O
+using	O
+a	O
+sensitive	O
+case	O
+definition	O
+incorporating	O
+clinical	O
+,	O
+epidemiologic	O
+,	O
+and	O
+laboratory	O
+criteria	O
+.	O
+
+Five	O
+probable	O
+cases	O
+occurred	O
+from	O
+March	O
+through	O
+April	O
+2003	O
+;	O
+four	O
+were	O
+confirmed	O
+as	O
+SARS	B-DISO
+coronavirus	B-SPEC
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+,	O
+serologic	O
+testing	O
+,	O
+or	O
+both	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+studied	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Taiwan	O
+,	O
+using	O
+the	O
+daily	O
+case	O
+-	O
+reporting	O
+data	O
+from	O
+May	O
+5	O
+to	O
+June	O
+4	O
+to	O
+learn	B-PROC
+how	O
+it	O
+had	O
+spread	O
+so	O
+rapidly	O
+.	O
+
+Our	O
+results	O
+indicate	O
+that	O
+most	O
+SARS	B-DISO
+-	O
+infected	O
+persons	O
+had	O
+symptoms	O
+and	O
+were	O
+admitted	O
+before	O
+their	O
+infections	B-DISO
+were	O
+reclassified	O
+as	O
+probable	O
+cases	O
+.	O
+
+The	O
+high	O
+percentage	O
+of	O
+nosocomial	B-DISO
+infections	I-DISO
+in	O
+Taiwan	O
+suggests	O
+that	O
+infection	B-DISO
+from	O
+hospitalized	O
+patients	O
+with	O
+suspected	O
+,	O
+but	O
+not	O
+yet	O
+classified	O
+,	O
+cases	O
+is	O
+a	O
+major	O
+factor	O
+in	O
+the	O
+spread	O
+of	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+early	O
+April	O
+2003	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+diagnosed	O
+in	O
+a	O
+Pennsylvania	O
+resident	O
+after	O
+his	O
+exposure	O
+to	O
+persons	O
+with	O
+SARS	B-DISO
+in	O
+Toronto	O
+,	O
+Canada	O
+.	O
+
+Laboratory	O
+evaluation	O
+of	O
+clinical	O
+specimens	O
+showed	O
+no	O
+evidence	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+to	O
+any	O
+close	O
+contact	O
+of	O
+this	O
+patient	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+better	O
+assess	O
+the	O
+risk	O
+for	O
+transmission	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+we	O
+obtained	O
+serial	O
+specimens	O
+and	O
+clinical	O
+and	O
+exposure	O
+data	O
+from	O
+seven	O
+confirmed	O
+U	O
+.	O
+S	O
+.	O
+SARS	B-DISO
+patients	O
+and	O
+their	O
+10	O
+household	O
+contacts	O
+.	O
+
+A	O
+case	O
+-	O
+control	O
+analysis	O
+identified	O
+risk	O
+factors	O
+for	O
+secondary	B-DISO
+infection	I-DISO
+.	O
+
+SARS	B-DISO
+transmission	O
+at	O
+the	O
+household	O
+level	O
+was	O
+not	O
+negligible	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Lack	O
+of	O
+transmission	O
+in	O
+the	O
+United	O
+States	O
+may	O
+be	O
+related	O
+to	O
+the	O
+relative	O
+absence	O
+of	O
+high	O
+-	O
+risk	O
+procedures	O
+or	O
+patients	O
+,	O
+factors	O
+that	O
+may	O
+place	O
+healthcare	O
+workers	O
+at	O
+higher	O
+risk	O
+for	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Serum	B-COMP
+samples	O
+were	O
+obtained	O
+from	O
+healthcare	O
+workers	O
+5	O
+weeks	O
+after	O
+exposure	O
+to	O
+an	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+We	O
+conclude	O
+that	O
+activities	O
+related	O
+to	O
+intubation	O
+increase	O
+SARS	B-DISO
+risk	O
+and	O
+use	O
+of	O
+a	O
+mask	O
+(	O
+particularly	O
+a	O
+N95	O
+mask	O
+)	O
+is	O
+protective	O
+.	O
+
+TITLE	O
+:	O
+Superspreading	O
+SARS	B-DISO
+events	O
+,	O
+Beijing	O
+,	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+Atypical	O
+SARS	B-DISO
+in	O
+geriatric	O
+patient	O
+.	O
+
+TITLE	O
+:	O
+Cluster	O
+of	O
+SARS	B-DISO
+among	O
+medical	O
+students	O
+exposed	O
+to	O
+single	O
+patient	O
+,	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+risk	O
+of	O
+contracting	O
+SARS	B-DISO
+was	O
+sevenfold	O
+greater	O
+among	O
+students	O
+who	O
+definitely	O
+visited	O
+the	O
+index	O
+case	O
+'	O
+s	O
+cubicle	O
+than	O
+in	O
+those	O
+who	O
+did	O
+not	O
+(	O
+10	O
+/	O
+27	O
+[	O
+41	O
+%]	O
+versus	O
+1	O
+/	O
+20	O
+[	O
+5	O
+%],	O
+relative	O
+risk	O
+7	O
+.	O
+4	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+0	O
+to	O
+53	O
+.	O
+3	O
+).	O
+
+Inconsistent	O
+use	O
+of	O
+goggles	O
+,	O
+gowns	O
+,	O
+gloves	O
+,	O
+and	O
+caps	O
+was	O
+associated	O
+with	O
+a	O
+higher	O
+risk	O
+for	O
+SARS	B-DISO
+infection	B-DISO
+(	O
+unadjusted	O
+odds	O
+ratio	O
+2	O
+.	O
+42	O
+to	O
+20	O
+.	O
+54	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+After	O
+its	O
+causative	O
+agent	O
+,	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+was	O
+confirmed	O
+,	O
+laboratory	O
+methods	O
+,	O
+including	O
+virus	B-SPEC
+isolation	O
+,	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+and	O
+serologic	O
+methods	O
+,	O
+have	O
+been	O
+quickly	O
+developed	O
+.	O
+
+TITLE	O
+:	O
+Real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+for	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+was	O
+more	O
+sensitive	O
+than	O
+a	O
+conventional	O
+RT	O
+-	O
+PCR	O
+assay	O
+or	O
+culture	O
+isolation	O
+and	O
+proved	O
+suitable	O
+to	O
+detect	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+clinical	O
+specimens	O
+.	O
+
+Virions	B-COMP
+were	O
+spherical	O
+,	O
+78	O
+nm	O
+in	O
+mean	O
+diameter	O
+,	O
+and	O
+composed	O
+of	O
+a	O
+helical	O
+nucleocapsid	B-COMP
+within	O
+an	O
+envelope	B-COMP
+with	O
+surface	O
+projections	O
+.	O
+
+Electron	O
+microscopic	O
+studies	O
+were	O
+critical	O
+in	O
+identifying	O
+the	O
+etiologic	O
+agent	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+and	O
+in	O
+guiding	O
+subsequent	O
+laboratory	O
+and	O
+epidemiologic	O
+investigations	O
+.	O
+
+Cough	B-DISO
+,	O
+chest	B-DISO
+pain	I-DISO
+,	O
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+were	O
+present	O
+in	O
+approximately	O
+one	O
+quarter	O
+of	O
+the	O
+patients	O
+;	O
+79	O
+.	O
+0	O
+%	O
+had	O
+lymphopenia	B-DISO
+;	O
+40	O
+.	O
+3	O
+%	O
+had	O
+thrombocytopenia	O
+;	O
+19	O
+.	O
+4	O
+%	O
+had	O
+leukopenia	B-DISO
+;	O
+and	O
+75	O
+.	O
+8	O
+%	O
+showed	O
+changes	O
+on	O
+chest	B-ANAT
+radiograph	O
+.	O
+
+Fever	B-PROC
+developed	O
+on	O
+the	O
+first	O
+day	O
+of	O
+illness	O
+onset	O
+,	O
+and	O
+both	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+radiographic	O
+changes	O
+occurred	O
+on	O
+day	O
+4	O
+.	O
+
+The	O
+complications	O
+of	O
+SARS	B-DISO
+included	O
+invasive	O
+intubation	O
+and	O
+ventilation	O
+(	O
+11	O
+.	O
+3	O
+%)	O
+and	O
+death	B-PROC
+(	O
+9	O
+.	O
+7	O
+%).	O
+
+TITLE	O
+:	O
+Possible	O
+central	B-DISO
+nervous	I-DISO
+system	I-DISO
+infection	I-DISO
+by	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+There	O
+was	O
+no	O
+evidence	O
+of	O
+viral	B-DISO
+shedding	I-DISO
+at	O
+delivery	O
+.	O
+
+SARS	B-DISO
+was	O
+diagnosed	O
+when	O
+a	O
+chest	B-ANAT
+infiltrate	B-DISO
+developed	O
+and	O
+when	O
+the	O
+patient	O
+'	O
+s	O
+brother	O
+was	O
+hospitalized	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+We	O
+highlight	O
+problems	O
+in	O
+atypical	O
+cases	O
+and	O
+offer	O
+infection	B-DISO
+control	O
+suggestions	O
+.	O
+
+ABSTRACT	O
+:	O
+Before	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+,	O
+the	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+'	O
+s	O
+(	O
+CDC	O
+)	O
+legal	O
+authority	O
+to	O
+apprehend	O
+,	O
+detain	O
+,	O
+or	O
+conditionally	O
+release	B-PATH
+persons	O
+was	O
+limited	O
+to	O
+seven	O
+listed	O
+diseases	O
+,	O
+not	O
+including	O
+SARS	B-DISO
+,	O
+and	O
+could	O
+only	O
+be	O
+changed	O
+using	O
+a	O
+two	O
+-	O
+step	O
+process	O
+:	O
+1	O
+)	O
+executive	O
+order	B-SPEC
+of	O
+the	O
+President	O
+of	O
+the	O
+United	O
+States	O
+on	O
+recommendation	O
+by	O
+the	O
+Secretary	O
+,	O
+U	O
+.	O
+S	O
+.	O
+Department	O
+of	O
+Health	O
+and	O
+Human	B-SPEC
+Services	O
+(	O
+HHS	B-DISO
+),	O
+and	O
+2	O
+)	O
+amendment	O
+to	O
+CDC	O
+quarantine	O
+regulations	O
+(	O
+42	O
+CFR	O
+Parts	O
+70	O
+and	O
+71	O
+).	O
+
+Mitigating	O
+fear	O
+and	O
+discrimination	O
+directed	O
+toward	O
+persons	O
+infected	O
+with	O
+,	O
+and	O
+affected	O
+by	O
+,	O
+infectious	B-DISO
+disease	I-DISO
+can	O
+be	O
+important	O
+in	O
+controlling	O
+transmission	O
+.	O
+
+Four	O
+public	O
+health	O
+issues	O
+were	O
+considered	O
+:	O
+prevention	O
+measures	O
+,	O
+self	O
+-	O
+health	O
+evaluation	O
+,	O
+SARS	B-DISO
+knowledge	O
+,	O
+and	O
+appraisal	O
+of	O
+crisis	O
+management	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+Taiwan	O
+,	O
+a	O
+temperature	O
+-	O
+monitoring	O
+campaign	O
+and	O
+hotline	O
+for	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+fever	B-PROC
+were	O
+implemented	O
+in	O
+June	O
+2003	O
+.	O
+
+In	O
+a	O
+cross	O
+-	O
+sectional	O
+telephone	O
+survey	O
+,	O
+95	O
+%	O
+(	O
+n	O
+=	O
+1	O
+,	O
+060	O
+)	O
+of	O
+households	O
+knew	O
+about	O
+the	O
+campaign	O
+and	O
+7	O
+households	O
+reported	O
+fever	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+,	O
+electronic	O
+media	B-ANAT
+made	O
+it	O
+possible	O
+to	O
+disseminate	O
+prevention	O
+messages	O
+rapidly	O
+.	O
+
+We	O
+cloned	O
+and	O
+purified	O
+the	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+and	O
+spike	O
+polypeptide	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+examined	O
+their	O
+immunogenicity	O
+with	O
+serum	B-COMP
+from	O
+patients	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+pneumonia	B-DISO
+.	O
+
+Our	O
+findings	O
+support	O
+the	O
+existence	O
+of	O
+subclinical	O
+or	O
+non	O
+-	O
+pneumonic	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+novel	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+IgG	B-COMP
+antibody	I-COMP
+to	O
+SARS	B-PRGE
+CoV	I-PRGE
+was	O
+first	O
+detected	O
+between	O
+day	O
+5	O
+and	O
+day	O
+47	O
+after	O
+onset	O
+of	O
+illness	O
+(	O
+mean	O
++/-	O
+
+We	O
+evaluated	O
+the	O
+susceptibility	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+related	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+CoV	O
+)	O
+to	O
+ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)-	O
+alpha	O
+in	O
+vitro	O
+by	O
+use	O
+of	O
+cytopathic	B-DISO
+effect	I-DISO
+,	O
+plaque	B-DISO
+assay	O
+,	O
+and	O
+immunoblot	O
+analysis	O
+.	O
+
+Clinical	O
+trials	O
+with	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+might	O
+be	O
+justified	O
+to	O
+determine	O
+a	O
+beneficial	O
+effect	O
+on	O
+the	O
+outcome	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+results	O
+of	O
+the	O
+last	O
+Critical	O
+Assessment	O
+of	O
+Techniques	O
+for	O
+Protein	B-CHED
+Structure	O
+Prediction	O
+(	O
+CASP5	O
+)	O
+demonstrated	O
+that	O
+the	O
+quality	O
+of	O
+homology	O
+modeling	O
+prediction	O
+has	O
+improved	O
+;	O
+reaching	B-PROC
+a	O
+level	O
+of	O
+reliability	O
+that	O
+biologists	O
+can	O
+now	O
+confidently	O
+use	O
+homology	O
+modeling	O
+.	O
+
+With	O
+improvements	O
+in	O
+modeling	O
+software	O
+and	O
+the	O
+growing	O
+number	O
+of	O
+known	O
+protein	B-CHED
+structures	O
+,	O
+homology	O
+modeling	O
+is	O
+becoming	O
+a	O
+more	O
+and	O
+more	O
+powerful	O
+and	O
+reliable	O
+tool	O
+.	O
+
+The	O
+ensuing	O
+neuropathology	B-DISO
+during	O
+the	O
+chronic	O
+stage	O
+of	O
+disease	O
+is	O
+primarily	O
+immune	O
+mediated	O
+and	O
+similar	O
+to	O
+that	O
+of	O
+the	O
+human	B-SPEC
+demyelinating	B-DISO
+disease	I-DISO
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+The	O
+CC	O
+chemokine	O
+ligand	B-PROC
+(	O
+CCL	B-DISO
+)	O
+5	O
+is	O
+localized	O
+in	O
+white	B-ANAT
+matter	I-ANAT
+tracts	B-ANAT
+undergoing	O
+demyelination	B-DISO
+,	O
+suggesting	O
+that	O
+this	O
+chemokine	O
+participates	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+disease	O
+by	O
+attracting	O
+inflammatory	B-ANAT
+cells	I-ANAT
+into	O
+the	O
+CNS	B-CHED
+.	O
+
+In	O
+addition	O
+,	O
+administration	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+CCL5	I-PRGE
+improved	O
+neurological	B-PROC
+function	I-PROC
+and	O
+significantly	O
+(	O
+p	O
+<	O
+or	O
+=	O
+0	O
+.	O
+005	O
+)	O
+reduced	O
+the	O
+severity	O
+of	O
+demyelination	B-DISO
+and	O
+macrophage	B-ANAT
+accumulation	O
+within	O
+the	O
+CNS	B-CHED
+.	O
+
+TITLE	O
+:	O
+The	O
+public	O
+'	O
+s	O
+response	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Toronto	O
+and	O
+the	O
+United	O
+States	O
+.	O
+
+Some	O
+of	O
+the	O
+community	O
+-	O
+wide	O
+problems	O
+with	O
+SARS	B-DISO
+might	O
+have	O
+been	O
+avoided	O
+with	O
+better	O
+communication	O
+by	O
+public	O
+health	O
+officials	O
+and	O
+clinicians	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+114	O
+-	O
+day	O
+epidemic	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+swept	O
+29	O
+countries	O
+,	O
+affected	O
+a	O
+reported	O
+8	O
+,	O
+098	O
+people	O
+,	O
+left	O
+774	O
+patients	O
+dead	B-PROC
+and	O
+almost	O
+paralyzed	O
+the	O
+Asian	O
+economy	O
+.	O
+
+TITLE	O
+:	O
+Changing	O
+health	O
+in	O
+China	O
+:	O
+re	O
+-	O
+evaluating	O
+the	O
+epidemiological	O
+transition	B-DISO
+model	O
+.	O
+
+Lung	B-ANAT
+injury	O
+was	O
+quantified	O
+in	O
+terms	O
+of	O
+lung	B-ANAT
+microvascular	B-PROC
+permeability	I-PROC
+(	O
+Evans	O
+blue	O
+dye	B-CHED
+extravasation	B-DISO
+),	O
+tissue	B-ANAT
+lipid	B-PROC
+peroxidation	I-PROC
+(	O
+thiobarbituric	B-CHED
+acid	I-CHED
+reactive	O
+substances	O
+),	O
+and	O
+tissue	B-ANAT
+polymorphonuclear	B-ANAT
+leukocyte	I-ANAT
+accumulation	O
+(	O
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+).	O
+
+The	O
+tissue	B-ANAT
+concentrations	O
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+and	O
+cytokine	O
+-	O
+induced	O
+neutrophil	B-ANAT
+chemoattractant	O
+-	O
+1	O
+(	O
+CINC	B-CHED
+-	O
+1	O
+)	O
+were	O
+also	O
+measured	O
+.	O
+
+The	O
+protective	O
+effects	O
+of	O
+pioglitazone	B-CHED
+treatment	O
+were	O
+correlated	O
+with	O
+the	O
+reduction	O
+by	O
+79	O
+%	O
+of	O
+the	O
+increase	O
+of	O
+thiobarbituric	B-CHED
+acid	I-CHED
+reactive	O
+substances	O
+(	O
+P	O
+=	O
+0	O
+.	O
+045	O
+)	O
+and	O
+the	O
+reduction	O
+by	O
+58	O
+%	O
+of	O
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+increase	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Pioglitazone	B-CHED
+treatment	O
+before	O
+ischemia	B-DISO
+attenuated	O
+lung	B-DISO
+ischemia	I-DISO
+-	O
+reperfusion	O
+injury	O
+in	O
+rats	B-SPEC
+.	O
+
+Pioglitazone	B-CHED
+did	O
+not	O
+affect	O
+the	O
+lung	B-ANAT
+in	O
+the	O
+sham	O
+animals	B-SPEC
+.	O
+
+Previously	O
+the	O
+functional	O
+role	O
+of	O
+this	O
+extra	O
+domain	O
+has	O
+been	O
+completely	O
+unknown	O
+,	O
+and	O
+it	O
+was	O
+believed	O
+that	O
+the	O
+coronavirus	B-SPEC
+3CL	O
+proteases	O
+share	O
+the	O
+same	O
+enzymatic	O
+mechanism	O
+with	O
+picornavirus	B-SPEC
+3C	O
+proteases	O
+,	O
+which	O
+contain	O
+the	O
+chymotrypsin	B-PRGE
+fold	O
+but	O
+have	O
+no	O
+extra	O
+domain	O
+.	O
+
+This	O
+discovery	O
+not	O
+only	O
+separates	O
+the	O
+coronavirus	B-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+from	I-PRGE
+the	I-PRGE
+picornavirus	B-SPEC
+3C	I-PRGE
+protease	I-PRGE
+in	O
+terms	O
+of	O
+the	O
+enzymatic	O
+mechanism	O
+but	O
+also	O
+defines	O
+the	O
+dimerization	O
+interface	O
+on	O
+the	O
+extra	O
+helical	O
+domain	O
+as	O
+a	O
+new	O
+target	O
+for	O
+design	O
+of	O
+the	O
+specific	O
+protease	B-PROC
+inhibitors	I-PROC
+.	O
+
+Co	O
+-	O
+delivery	O
+of	O
+inactivated	O
+pseudorabies	B-DISO
+herpesvirus	B-SPEC
+(	O
+iPRV	O
+)	O
+with	O
+protein	B-CHED
+redirected	O
+IgG1	B-COMP
+-	O
+dominated	O
+tetanus	B-DISO
+toxoid	O
+-	O
+specific	O
+responses	O
+towards	O
+an	O
+IgG1	B-COMP
+/	O
+IgG2a	B-COMP
+balanced	O
+response	O
+.	O
+
+These	O
+findings	O
+have	O
+a	O
+bearing	O
+on	O
+the	O
+understanding	O
+of	O
+immune	O
+responsiveness	O
+to	O
+virus	B-ANAT
+structures	I-ANAT
+and	O
+the	O
+design	O
+of	O
+vaccines	O
+containing	O
+virus	B-ANAT
+components	I-ANAT
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+assess	O
+the	O
+frequency	O
+,	O
+epidemiological	O
+factors	O
+,	O
+complications	O
+,	O
+and	O
+outcome	O
+of	O
+severe	O
+preeclampsia	O
+and	O
+eclampsia	O
+and	O
+compare	O
+them	O
+according	O
+to	O
+severity	O
+of	O
+the	O
+condition	B-DISO
+in	O
+Kerman	O
+,	O
+southeastern	O
+Iran	O
+.	O
+
+72	O
+.	O
+7	O
+%	O
+of	O
+eclamptic	O
+patients	O
+suffered	B-DISO
+their	O
+first	O
+convulsion	B-DISO
+at	O
+home	O
+and	O
+not	O
+in	O
+the	O
+presence	O
+of	O
+medical	O
+help	O
+.	O
+
+All	O
+six	O
+maternal	B-PROC
+deaths	I-PROC
+during	O
+the	O
+period	O
+of	O
+the	O
+study	O
+occurred	O
+in	O
+eclamptic	O
+cases	O
+(	O
+mortality	O
+rate	O
+18	O
+%),	O
+four	O
+relating	O
+to	O
+patients	O
+who	O
+had	O
+not	O
+received	O
+prenatal	O
+care	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+chest	B-ANAT
+syndrome	I-DISO
+(	O
+ACS	O
+)	O
+is	O
+the	O
+leading	O
+cause	O
+of	O
+death	B-PROC
+in	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+Severe	O
+ACS	B-FUNC
+often	O
+develops	O
+in	O
+the	O
+course	O
+of	O
+a	O
+vasoocclusive	O
+crisis	O
+(	O
+VOC	O
+),	O
+and	O
+frequently	O
+involves	O
+pulmonary	B-DISO
+fat	I-DISO
+embolism	I-DISO
+.	O
+
+However	O
+,	O
+translational	B-PROC
+selection	O
+and	O
+gene	O
+length	O
+have	O
+no	O
+effect	O
+on	O
+the	O
+variations	O
+of	O
+synonymous	O
+codon	O
+usage	O
+in	O
+these	O
+virus	B-SPEC
+genes	O
+.	O
+
+All	O
+57	O
+persons	O
+with	O
+close	O
+contact	O
+with	O
+the	O
+12	O
+medical	O
+staff	O
+suffering	B-DISO
+SARS	B-DISO
+in	O
+the	O
+latent	O
+period	O
+or	O
+with	O
+one	O
+having	O
+early	O
+-	O
+stage	O
+SARS	O
+did	O
+not	O
+show	O
+any	O
+signs	O
+of	O
+SARS	B-DISO
+during	O
+one	O
+month	O
+for	O
+observation	O
+in	O
+isolation	O
+.	O
+
+SARS	B-DISO
+patients	O
+may	O
+have	O
+no	O
+or	O
+very	O
+limited	O
+infectivity	O
+during	O
+the	O
+latent	O
+period	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+singular	B-CHED
+epidemic	O
+of	O
+viral	B-DISO
+pneumonia	I-DISO
+].	O
+
+Transmission	O
+is	O
+inter	O
+-	O
+human	B-SPEC
+,	O
+via	O
+respiratory	O
+particles	O
+mainly	O
+.	O
+
+The	O
+clinical	O
+presentation	O
+is	O
+highly	O
+variable	O
+,	O
+from	O
+a	O
+mild	O
+fever	B-PROC
+to	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Ribavirin	B-CHED
+associated	O
+with	O
+steroids	B-CHED
+have	O
+been	O
+used	O
+with	O
+success	O
+in	O
+numerous	O
+cases	O
+.	O
+
+More	O
+than	O
+8	O
+,	O
+000	O
+people	O
+were	O
+infected	O
+and	O
+774	O
+died	B-PROC
+.	O
+
+Although	O
+diagnostic	O
+criteria	O
+for	O
+SARS	B-DISO
+have	O
+been	O
+issued	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+),	O
+simple	O
+adoption	O
+of	O
+the	O
+established	O
+criteria	O
+may	O
+lead	O
+to	O
+overdiagnosis	O
+in	O
+patients	O
+with	O
+cancer	B-DISO
+or	O
+to	O
+an	O
+increase	O
+in	O
+the	O
+risk	O
+of	O
+spreading	O
+SARS	B-DISO
+within	O
+cancer	B-DISO
+hospitals	O
+.	O
+
+8	O
+samples	O
+per	O
+pool	O
+)	O
+were	O
+spiked	O
+with	O
+plasma	B-ANAT
+of	O
+an	O
+imported	O
+case	O
+of	O
+SARS	B-DISO
+or	O
+of	O
+a	O
+subsequently	O
+infected	O
+contact	O
+person	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Interaction	O
+between	O
+heptad	O
+repeat	O
+1	O
+and	O
+2	O
+regions	O
+in	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	B-SPEC
+:	O
+implications	O
+for	O
+virus	B-SPEC
+fusogenic	O
+mechanism	O
+and	O
+identification	O
+of	O
+fusion	O
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Synthetic	O
+peptide	B-CHED
+studies	O
+on	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+spike	O
+glycoprotein	B-CHED
+:	O
+perspective	O
+for	O
+SARS	B-DISO
+vaccine	O
+development	B-PROC
+.	O
+
+This	O
+suggested	O
+that	O
+our	O
+S5	O
+and	O
+S6	O
+peptides	B-CHED
+may	O
+represent	O
+two	O
+minimum	O
+biologically	O
+active	O
+sequences	O
+of	O
+the	O
+immunogenic	O
+regions	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+Synthetic	O
+peptides	B-CHED
+can	O
+elicit	O
+specific	O
+antibodies	B-COMP
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+The	O
+study	O
+provides	O
+insights	O
+for	O
+the	O
+future	O
+development	B-PROC
+of	O
+SARS	B-DISO
+vaccine	O
+via	O
+the	O
+synthetic	O
+-	O
+peptide	B-CHED
+-	O
+based	O
+approach	O
+.	O
+
+This	O
+suggested	O
+that	O
+our	O
+S5	O
+and	O
+S6	O
+peptides	B-CHED
+may	O
+represent	O
+two	O
+minimum	O
+biologically	O
+active	O
+sequences	O
+of	O
+the	O
+immunogenic	O
+regions	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+They	O
+still	O
+induced	O
+an	O
+immune	B-PROC
+response	I-PROC
+,	O
+however	O
+,	O
+as	O
+judged	O
+from	O
+the	O
+high	O
+levels	O
+of	O
+virus	O
+-	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+The	O
+new	O
+guidelines	O
+are	O
+designed	O
+to	O
+reduce	O
+the	O
+incidence	O
+of	O
+pneumonia	B-DISO
+and	O
+other	O
+severe	O
+,	O
+acute	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+acute	O
+-	O
+care	O
+hospitals	O
+and	O
+in	O
+other	O
+health	O
+-	O
+care	O
+settings	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+ambulatory	O
+and	O
+long	O
+-	O
+term	O
+care	O
+institutions	O
+)	O
+and	O
+other	O
+facilities	O
+where	O
+health	O
+care	O
+is	O
+provided	O
+.	O
+
+Among	O
+the	O
+changes	O
+in	O
+the	O
+recommendations	O
+to	O
+prevent	O
+bacterial	B-DISO
+pneumonia	I-DISO
+,	O
+especially	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+,	O
+are	O
+the	O
+preferential	O
+use	O
+of	O
+oro	B-CHED
+-	O
+tracheal	O
+rather	O
+than	O
+naso	B-SPEC
+-	O
+tracheal	O
+tubes	O
+in	O
+patients	O
+who	O
+receive	O
+mechanically	O
+assisted	O
+ventilation	O
+,	O
+the	O
+use	O
+of	O
+noninvasive	O
+ventilation	O
+to	O
+reduce	O
+the	O
+need	O
+for	O
+and	O
+duration	O
+of	O
+endotracheal	O
+intubation	O
+,	O
+changing	O
+the	O
+breathing	B-PROC
+circuits	O
+of	O
+ventilators	O
+when	O
+they	O
+malfunction	O
+or	O
+are	O
+visibly	O
+contaminated	O
+,	O
+and	O
+(	O
+when	O
+feasible	O
+)	O
+the	O
+use	O
+of	O
+an	O
+endotracheal	O
+tube	O
+with	O
+a	O
+dorsal	O
+lumen	O
+to	O
+allow	O
+drainage	B-ANAT
+of	O
+respiratory	O
+secretions	B-ANAT
+;	O
+no	O
+recommendations	O
+were	O
+made	O
+about	O
+the	O
+use	O
+of	O
+sucralfate	O
+,	O
+histamine	B-PRGE
+-	I-PRGE
+2	I-PRGE
+receptor	I-PRGE
+antagonists	B-CHED
+,	O
+or	O
+antacids	B-CHED
+for	O
+stress	O
+-	O
+bleeding	B-DISO
+prophylaxis	O
+.	O
+
+For	O
+prevention	O
+of	O
+health	O
+-	O
+care	O
+--	O
+associated	O
+Legionnaires	B-DISO
+disease	I-DISO
+,	O
+the	O
+changes	O
+include	O
+maintaining	O
+potable	O
+hot	O
+water	B-CHED
+at	O
+temperatures	O
+not	O
+suitable	O
+for	O
+amplification	B-DISO
+of	O
+Legionella	B-SPEC
+spp	B-ENZY
+.,	O
+considering	O
+routine	O
+culturing	O
+of	O
+water	B-CHED
+samples	O
+from	O
+the	O
+potable	O
+water	B-CHED
+system	O
+of	O
+a	O
+facility	O
+'	O
+s	O
+organ	B-ANAT
+-	O
+transplant	B-ANAT
+unit	O
+when	O
+it	O
+is	O
+done	O
+as	O
+part	O
+of	O
+the	O
+facility	O
+'	O
+s	O
+comprehensive	O
+program	O
+to	O
+prevent	O
+and	O
+control	O
+health	O
+-	O
+care	O
+--	O
+associated	O
+Legionnaires	B-DISO
+disease	I-DISO
+,	O
+and	O
+initiating	O
+an	O
+investigation	O
+for	O
+the	O
+source	O
+of	O
+Legionella	B-SPEC
+spp	B-ENZY
+.	O
+
+when	O
+one	O
+definite	O
+or	O
+one	O
+possible	O
+case	O
+of	O
+laboratory	O
+-	O
+confirmed	O
+health	O
+-	O
+care	O
+--	O
+associated	O
+Legionnaires	B-DISO
+disease	I-DISO
+is	O
+identified	O
+in	O
+an	O
+inpatient	O
+hemopoietic	O
+stem	B-ANAT
+-	O
+cell	B-ANAT
+transplant	I-ANAT
+(	O
+HSCT	B-ANAT
+)	O
+recipient	O
+or	O
+in	O
+two	O
+or	O
+more	O
+HSCT	B-ANAT
+recipients	O
+who	O
+had	O
+visited	O
+an	O
+outpatient	O
+HSCT	B-ANAT
+unit	O
+during	O
+all	O
+or	O
+part	O
+of	O
+the	O
+2	O
+-	O
+10	O
+day	O
+period	O
+before	O
+illness	O
+onset	O
+.	O
+
+Most	O
+commonly	O
+TRALI	B-DISO
+may	O
+appear	O
+during	O
+whole	B-ANAT
+blood	I-ANAT
+,	O
+packed	O
+cells	B-COMP
+and	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+transfusions	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+general	O
+strategy	O
+based	O
+on	O
+the	O
+use	O
+of	O
+a	O
+plastic	O
+film	O
+that	O
+allows	O
+reverse	B-PROC
+transcription	I-PROC
+and	O
+nested	O
+-	O
+PCR	O
+in	O
+a	O
+single	O
+closed	O
+-	O
+tube	O
+has	O
+been	O
+developed	O
+.	O
+
+Blood	B-ANAT
+leucocytes	B-ANAT
+and	O
+lymphocyte	B-ANAT
+subsets	O
+were	O
+reported	O
+to	O
+decrease	O
+,	O
+respectively	O
+,	O
+in	O
+47	O
+%	O
+and	O
+up	O
+to	O
+100	O
+%	O
+of	O
+38	O
+patients	O
+in	O
+Beijing	O
+.	O
+
+To	O
+investigate	O
+serum	B-COMP
+total	O
+LD	O
+,	O
+LD	O
+isoenzymes	O
+,	O
+and	O
+other	O
+parameters	O
+including	O
+blood	B-ANAT
+lymphocyte	B-ANAT
+subsets	O
+as	O
+prognostic	O
+indicators	O
+in	O
+SARS	B-DISO
+patients	O
+for	O
+adverse	O
+clinical	O
+outcomes	O
+in	O
+terms	O
+of	O
+admission	O
+to	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+and	O
+death	B-PROC
+.	O
+
+A	O
+total	O
+of	O
+109	O
+patients	O
+with	O
+a	O
+clinical	O
+diagnosis	O
+of	O
+SARS	B-DISO
+according	O
+to	O
+the	O
+modified	O
+World	O
+Health	O
+Organization	O
+case	O
+definition	O
+of	O
+SARS	B-DISO
+were	O
+recruited	O
+from	O
+two	O
+major	O
+acute	O
+hospitals	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Receiver	O
+operating	O
+characteristic	O
+curve	O
+analysis	O
+was	O
+used	O
+to	O
+determine	O
+and	O
+compare	O
+different	O
+cut	B-PRGE
+-	O
+offs	O
+for	O
+various	O
+biochemical	O
+and	O
+immunological	O
+parameters	O
+at	O
+peak	O
+serum	B-COMP
+total	O
+LD	O
+concentration	O
+in	O
+predicting	O
+adverse	O
+clinical	O
+outcomes	O
+.	O
+
+CD3	B-PRGE
++,	I-PRGE
+CD4	B-PRGE
++,	I-PRGE
+CD8	B-PRGE
++	I-PRGE
+and	O
+natural	B-ANAT
+killer	I-ANAT
+cell	I-ANAT
+counts	O
+were	O
+promising	O
+immunological	O
+prognostic	O
+indicators	O
+for	O
+predicting	O
+admission	O
+to	O
+ICU	O
+with	O
+AUC	O
+of	O
+0	O
+.	O
+94	O
+(	O
+CI	O
+=	O
+0	O
+.	O
+86	O
+-	O
+0	O
+.	O
+98	O
+),	O
+0	O
+.	O
+91	O
+(	O
+CI	O
+=	O
+0	O
+.	O
+81	O
+-	O
+0	O
+.	O
+96	O
+),	O
+0	O
+.	O
+93	O
+(	O
+CI	O
+=	O
+0	O
+.	O
+85	O
+-	O
+0	O
+.	O
+98	O
+),	O
+and	O
+0	O
+.	O
+87	O
+(	O
+CI	O
+=	O
+0	O
+.	O
+76	O
+-	O
+0	O
+.	O
+94	O
+),	O
+respectively	O
+.	O
+
+This	O
+technique	O
+is	O
+reliable	O
+and	O
+its	O
+application	O
+for	O
+screening	O
+large	O
+number	O
+of	O
+clinical	O
+samples	O
+would	O
+improve	O
+the	O
+diagnosis	O
+of	O
+HCoVs	O
+respiratory	B-DISO
+infection	I-DISO
+and	O
+our	O
+knowledge	O
+of	O
+these	O
+viruses	B-SPEC
+epidemiology	O
+.	O
+
+Adverse	O
+health	O
+outcomes	O
+resulting	O
+from	O
+accessibility	O
+barriers	O
+posed	O
+by	O
+the	O
+fear	O
+of	O
+SARS	B-DISO
+should	O
+not	O
+be	O
+overlooked	O
+.	O
+
+EP2	B-PRGE
+and	O
+EP4	B-PRGE
+possessed	B-DISO
+linear	O
+epitopes	O
+,	O
+whereas	O
+EP1	B-PRGE
+and	O
+EP2	B-PRGE
+were	O
+able	O
+to	O
+form	O
+conformational	O
+epitopes	O
+that	O
+could	O
+react	O
+with	O
+most	O
+(>	O
+80	O
+%)	O
+of	O
+the	O
+tested	O
+sera	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Last	O
+year	O
+,	O
+more	O
+than	O
+8	O
+,	O
+000	O
+people	O
+worldwide	O
+contracted	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+leading	O
+to	O
+774	O
+deaths	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+February	O
+2003	O
+,	O
+Hong	O
+Kong	O
+was	O
+hit	O
+by	O
+a	O
+community	O
+-	O
+wide	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Effective	O
+personal	O
+protective	O
+clothing	O
+for	O
+health	O
+care	O
+workers	O
+attending	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Included	O
+in	O
+the	O
+talks	O
+were	O
+state	O
+-	O
+of	O
+-	O
+the	O
+-	O
+art	O
+presentations	O
+about	O
+infectious	B-DISO
+clone	O
+technology	O
+and	O
+recombinant	O
+viruses	B-SPEC
+,	O
+pathogen	O
+and	O
+receptor	B-PROC
+interactions	I-PROC
+at	O
+the	O
+cellular	B-COMP
+and	O
+molecular	O
+level	O
+,	O
+genomic	O
+responses	O
+to	O
+infection	B-DISO
+,	O
+and	O
+new	O
+information	O
+on	O
+antiviral	B-CHED
+mechanisms	O
+of	O
+action	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Serum	B-ANAT
+levels	O
+of	O
+luteinizing	O
+hormone	B-CHED
+,	O
+testosterone	B-CHED
+and	O
+prolactin	B-PROC
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+].	O
+
+TITLE	O
+:	O
+[	O
+Central	O
+issues	O
+of	O
+prevention	O
+of	O
+nosocomial	B-DISO
+infections	I-DISO
+--	O
+status	O
+in	O
+2004	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Glucocorticoid	B-CHED
+-	O
+induced	O
+diabetes	B-DISO
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+the	O
+impact	O
+of	O
+high	O
+dosage	O
+and	O
+duration	O
+of	O
+methylprednisolone	O
+therapy	O
+].	O
+
+If	O
+the	O
+patients	O
+were	O
+treated	O
+with	O
+an	O
+average	O
+dose	O
+less	O
+than	O
+90	O
+mg	O
+/	O
+d	O
+and	O
+treatment	O
+duration	O
+shorter	O
+than	O
+15	O
+days	O
+,	O
+the	O
+diabetes	B-DISO
+incidence	O
+was	O
+10	O
+.	O
+5	O
+%.	O
+
+Decreasing	O
+the	O
+daily	O
+maximal	O
+dosage	O
+may	O
+be	O
+beneficial	O
+to	O
+the	O
+reduction	O
+of	O
+corticosteroid	B-CHED
+-	O
+induced	O
+of	O
+diabetes	B-DISO
+.	O
+
+Ninety	O
+eyes	B-ANAT
+from	O
+45	O
+patients	O
+with	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+during	O
+an	O
+epidemic	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+were	O
+analyzed	O
+.	O
+
+The	O
+center	O
+continues	O
+to	O
+operate	O
+as	O
+a	O
+part	O
+of	O
+Ontario	O
+'	O
+s	O
+commitment	O
+as	O
+a	O
+result	O
+of	O
+diligence	O
+in	O
+transport	B-PROC
+medicine	B-CHED
+and	O
+infection	B-DISO
+control	O
+,	O
+even	O
+though	O
+no	O
+new	O
+cases	O
+of	O
+SARS	B-DISO
+were	O
+reported	O
+since	O
+June	O
+12	O
+,	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+status	O
+of	O
+infection	B-DISO
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronovirus	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+traders	O
+of	O
+wild	O
+animals	B-SPEC
+wholesale	O
+markets	O
+in	O
+Guangzhou	O
+.	O
+
+Attack	O
+rate	O
+in	O
+health	O
+-	O
+care	O
+workers	O
+was	O
+higher	O
+at	O
+general	O
+hospitals	O
+,	O
+hospital	O
+accepting	O
+more	O
+cases	O
+in	O
+critical	O
+conditions	O
+and	O
+hospitals	O
+with	O
+poor	O
+precautious	O
+measures	O
+,	O
+and	O
+lower	O
+in	O
+hospitals	O
+with	O
+isolated	O
+wards	O
+or	O
+areas	O
+,	O
+or	O
+department	O
+of	O
+infection	O
+,	O
+specially	O
+caring	O
+for	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+those	O
+with	O
+effective	O
+intervention	O
+measures	O
+to	O
+prevent	O
+secondary	B-DISO
+infection	I-DISO
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+serum	B-COMP
+level	O
+of	O
+C3	O
+between	O
+the	O
+three	O
+groups	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Determination	O
+of	O
+serum	B-COMP
+level	O
+of	O
+C4	O
+,	O
+CRP	B-PRGE
+and	O
+PA	O
+in	O
+suspected	O
+patients	O
+is	O
+beneficial	O
+to	O
+early	O
+differential	O
+diagnosis	O
+for	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Effectiveness	O
+of	O
+personal	O
+protective	O
+measures	O
+in	O
+prevention	O
+of	O
+nosocomial	O
+transmission	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+effectiveness	O
+of	O
+personal	O
+protective	O
+measures	O
+of	O
+health	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+In	O
+its	O
+severe	O
+form	O
+,	O
+it	O
+is	O
+clinically	O
+indistinguishable	O
+from	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TRALI	B-DISO
+is	O
+associated	O
+with	O
+antibodies	B-COMP
+to	O
+white	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+and	O
+biologically	O
+active	O
+lipids	B-CHED
+in	O
+trans	O
+-	O
+fused	O
+blood	B-ANAT
+components	I-ANAT
+.	O
+
+The	O
+degree	O
+of	O
+malnutrition	B-DISO
+,	O
+control	O
+of	O
+ascites	O
+,	O
+level	O
+of	O
+encephalopathy	B-DISO
+,	O
+prothrombin	B-PRGE
+time	O
+,	O
+concentration	O
+of	O
+serum	B-PRGE
+albumin	I-PRGE
+,	O
+and	O
+concentration	O
+of	O
+serum	B-COMP
+bilirubin	B-CHED
+predict	O
+the	O
+risk	O
+of	O
+complications	O
+and	O
+death	B-PROC
+following	O
+surgery	O
+.	O
+
+ABSTRACT	O
+:	O
+Inhaled	O
+nitric	B-CHED
+oxide	I-CHED
+has	O
+been	O
+shown	O
+to	O
+improve	O
+oxygenation	B-PROC
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Days	O
+patients	O
+were	O
+alive	O
+following	O
+a	O
+successful	O
+2	O
+-	O
+hour	O
+unassisted	O
+ventilation	O
+trial	O
+were	O
+a	O
+mean	O
+(	O
+SD	O
+)	O
+of	O
+11	O
+.	O
+9	O
+(	O
+9	O
+.	O
+9	O
+)	O
+for	O
+placebo	O
+and	O
+11	O
+.	O
+4	O
+(	O
+9	O
+.	O
+8	O
+)	O
+for	O
+nitric	B-CHED
+oxide	I-CHED
+patients	O
+(	O
+P	O
+=.	O
+54	O
+).	O
+
+Days	O
+alive	O
+and	O
+meeting	O
+criteria	O
+for	O
+extubation	O
+were	O
+also	O
+similar	O
+:	O
+17	O
+.	O
+0	O
+placebo	O
+vs	O
+16	O
+.	O
+7	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+P	O
+=.	O
+89	O
+).	O
+
+TITLE	O
+:	O
+Performance	O
+and	O
+Cost	O
+evaluation	O
+of	O
+one	O
+commercial	O
+and	O
+six	O
+in	O
+-	O
+house	O
+conventional	O
+and	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+pcr	O
+assays	O
+for	O
+detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+evaluated	O
+seven	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assays	O
+,	O
+including	O
+six	O
+in	O
+-	O
+house	O
+assays	O
+and	O
+one	O
+commercial	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+RNA	O
+in	O
+clinical	O
+specimens	O
+.	O
+
+The	O
+results	O
+demonstrated	O
+good	O
+performance	O
+for	O
+all	O
+assays	O
+,	O
+providing	O
+laboratories	O
+that	O
+need	O
+to	O
+do	O
+SARS	B-DISO
+RNA	O
+testing	O
+with	O
+a	O
+choice	O
+of	O
+assay	O
+formats	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+two	O
+sets	O
+of	O
+truncated	O
+fragments	O
+of	O
+spike	O
+protein	B-CHED
+were	O
+generated	O
+,	O
+the	O
+first	O
+were	O
+approximately	O
+210	O
+-	O
+bp	O
+nonoverlapping	O
+fragments	O
+and	O
+the	O
+second	O
+were	O
+overlapping	O
+segments	O
+of	O
+750	O
+to	O
+900	O
+bp	O
+.	O
+
+The	O
+isolates	O
+in	O
+10	O
+samples	O
+were	O
+recognized	O
+as	O
+CCoV	B-PRGE
+type	I-PRGE
+I	I-PRGE
+,	O
+and	O
+the	O
+isolates	O
+in	O
+6	O
+samples	O
+were	O
+recognized	O
+as	O
+CCoV	B-PRGE
+type	I-PRGE
+II	I-PRGE
+,	O
+while	O
+isolates	O
+of	O
+both	O
+genotypes	O
+were	O
+simultaneously	O
+detected	O
+in	O
+53	O
+samples	O
+.	O
+
+We	O
+show	O
+that	O
+the	O
+success	O
+of	O
+these	O
+control	O
+measures	O
+is	O
+determined	O
+as	O
+much	O
+by	O
+the	O
+proportion	O
+of	O
+transmission	O
+occurring	O
+prior	O
+to	O
+the	O
+onset	O
+of	O
+overt	O
+clinical	O
+symptoms	O
+(	O
+or	O
+via	O
+asymptomatic	B-DISO
+infection	I-DISO
+)	O
+as	O
+the	O
+inherent	O
+transmissibility	O
+of	O
+the	O
+etiological	O
+agent	O
+(	O
+measured	O
+by	O
+the	O
+reproductive	B-PROC
+number	O
+R	O
+(	O
+0	O
+)).	O
+
+The	O
+purpose	O
+of	O
+this	O
+review	O
+is	O
+primarily	O
+to	O
+review	O
+the	O
+clinical	O
+features	O
+,	O
+diagnosis	O
+,	O
+and	O
+management	O
+of	O
+SARS	B-DISO
+,	O
+but	O
+also	O
+to	O
+comment	O
+briefly	O
+on	O
+the	O
+epidemiology	O
+and	O
+pathogen	O
+.	O
+
+Apart	O
+from	O
+influenza	B-DISO
+,	O
+there	O
+are	O
+no	O
+vaccines	O
+and	O
+very	O
+few	O
+antiviral	B-CHED
+chemotherapeutic	O
+agents	O
+available	O
+for	O
+the	O
+prevention	O
+and	O
+treatment	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+-	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+human	B-SPEC
+illness	O
+.	O
+
+The	O
+late	O
+1990s	O
+were	O
+a	O
+period	O
+of	O
+unprecedented	O
+activity	O
+in	O
+the	O
+development	B-PROC
+of	O
+new	O
+and	O
+much	O
+superior	O
+antivirals	B-CHED
+for	O
+the	O
+treatment	O
+of	O
+influenza	B-DISO
+infections	B-DISO
+.	O
+
+If	O
+not	O
+,	O
+previous	O
+ventilator	O
+settings	O
+were	O
+resumed	O
+for	O
+another	O
+24	O
+hrs	B-DISO
+after	O
+recruiting	O
+the	O
+lungs	B-ANAT
+once	O
+again	O
+.	O
+
+After	O
+recruitment	B-DISO
+,	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+ratio	O
+was	O
+higher	O
+in	O
+all	O
+patients	O
+.	O
+
+This	O
+excess	O
+mortality	O
+rate	O
+could	O
+be	O
+explained	O
+by	O
+the	O
+higher	O
+risk	O
+of	O
+intensive	O
+care	O
+unit	O
+acquired	O
+complications	O
+among	O
+obese	B-DISO
+patients	O
+than	O
+among	O
+the	O
+unexposed	O
+ones	O
+(	O
+odds	O
+ratio	O
+,	O
+4	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+4	O
+-	O
+11	O
+.	O
+8	O
+).	O
+
+All	O
+four	O
+patients	O
+suffered	B-DISO
+from	O
+fever	B-PROC
+,	O
+runny	B-DISO
+nose	I-DISO
+,	O
+and	O
+dry	B-DISO
+cough	I-DISO
+,	O
+and	O
+all	O
+four	O
+had	O
+underlying	O
+or	O
+additional	O
+morbidity	O
+.	O
+
+Our	O
+data	O
+will	O
+enable	O
+the	O
+development	B-PROC
+of	O
+diagnostic	O
+tests	O
+to	O
+study	O
+the	O
+prevalence	O
+and	O
+clinical	O
+impact	O
+of	O
+this	O
+virus	B-SPEC
+in	O
+humans	B-SPEC
+in	O
+more	O
+detail	O
+.	O
+
+Moreover	O
+,	O
+it	O
+will	O
+be	O
+important	O
+to	O
+discriminate	O
+this	O
+previously	O
+undescribed	O
+coronavirus	B-SPEC
+from	O
+HCoV	O
+229E	O
+and	O
+OC43	O
+and	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+In	O
+the	O
+first	O
+wave	O
+(	O
+1985	O
+-	O
+1986	O
+),	O
+eight	O
+bombings	O
+occurred	O
+in	O
+Paris	B-SPEC
+,	O
+killing	O
+13	O
+and	O
+injuring	O
+281	O
+.	O
+
+TITLE	O
+:	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+and	O
+Giardia	B-SPEC
+intestinalis	I-SPEC
+in	O
+calf	B-ANAT
+diarrhoea	B-DISO
+in	O
+Sweden	O
+.	O
+
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+,	O
+either	O
+alone	O
+or	O
+together	O
+with	O
+G	B-SPEC
+.	I-SPEC
+intestinalis	I-SPEC
+and	O
+/	O
+or	O
+rotavirus	B-SPEC
+,	O
+was	O
+detected	O
+in	O
+16	O
+(	O
+11	O
+%)	O
+and	O
+6	O
+(	O
+5	O
+%)	O
+of	O
+the	O
+samples	O
+from	O
+diarrhoeic	O
+and	O
+healthy	O
+calves	O
+,	O
+respectively	O
+.	O
+
+These	O
+compounds	O
+or	O
+analogues	O
+warrant	O
+further	O
+evaluation	O
+as	O
+potential	O
+therapies	O
+for	O
+treating	O
+SARS	B-DISO
+or	O
+could	O
+be	O
+used	O
+as	O
+lead	B-CHED
+compounds	I-CHED
+for	O
+discovery	O
+of	O
+more	O
+potent	O
+SARSCoV	O
+inhibitors	B-CHED
+.	O
+
+Whereas	O
+in	O
+the	O
+past	O
+,	O
+reactive	O
+oxygen	B-CHED
+and	O
+reactive	B-CHED
+nitrogen	I-CHED
+species	I-CHED
+were	O
+mainly	O
+known	O
+as	O
+harmful	O
+agents	O
+,	O
+recent	O
+investigations	O
+have	O
+given	O
+a	O
+new	O
+insight	O
+into	O
+the	O
+(	O
+patho	O
+)	O
+physiological	O
+importance	O
+of	O
+these	O
+substances	O
+as	O
+powerful	O
+messenger	O
+molecules	O
+involved	O
+in	O
+gene	B-PROC
+regulation	I-PROC
+,	O
+thereby	O
+enabling	O
+the	O
+synthesis	B-PROC
+of	O
+cytokines	O
+or	O
+adhesion	B-DISO
+molecules	O
+necessary	O
+for	O
+defending	O
+inflammatory	O
+processes	O
+.	O
+
+As	O
+shown	O
+in	O
+this	O
+review	O
+,	O
+there	O
+are	O
+numerous	O
+possibilities	O
+for	O
+the	O
+quantification	O
+of	O
+oxidative	B-DISO
+stress	I-DISO
+.	O
+
+Several	O
+investigations	O
+showed	O
+a	O
+close	O
+association	O
+of	O
+single	O
+or	O
+multiple	O
+parameters	O
+,	O
+such	O
+as	O
+total	O
+antioxidative	O
+capacity	O
+,	O
+lipid	B-PROC
+peroxidation	I-PROC
+,	O
+vitamins	B-CHED
+C	O
+and	O
+E	O
+,	O
+the	O
+activation	O
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+,	O
+and	O
+respiratory	B-PROC
+burst	I-PROC
+,	O
+with	O
+the	O
+patient	O
+'	O
+s	O
+outcome	O
+.	O
+
+The	O
+measurement	O
+of	O
+a	O
+cluster	O
+of	O
+assays	O
+representative	O
+of	O
+the	O
+quantification	O
+of	O
+reactive	O
+species	B-SPEC
+or	O
+of	O
+antioxidants	B-CHED
+may	O
+improve	O
+the	O
+usefulness	O
+of	O
+therapeutic	O
+intervention	O
+and	O
+increase	O
+knowledge	O
+of	O
+pathophysiological	O
+alterations	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+22	O
+-	O
+yr	O
+-	O
+old	O
+,	O
+86	O
+-	O
+kg	O
+,	O
+morbidly	O
+obese	B-DISO
+female	O
+orangutan	B-SPEC
+(	O
+Pongo	B-SPEC
+pygmaeus	I-SPEC
+abelii	I-SPEC
+)	O
+was	O
+immobilized	O
+and	O
+transported	O
+to	O
+the	O
+Denver	O
+Zoological	O
+Gardens	O
+hospital	O
+for	O
+a	O
+routine	O
+physical	O
+examination	O
+.	O
+
+Immediately	O
+after	O
+arriving	O
+at	O
+the	O
+hospital	O
+,	O
+cyanosis	B-DISO
+and	O
+apparent	O
+inadequate	O
+ventilatory	O
+efforts	O
+were	O
+noted	O
+.	O
+
+The	O
+orangutan	B-SPEC
+was	O
+maintained	O
+on	O
+a	O
+mechanical	O
+ventilator	O
+using	O
+the	O
+neuromuscular	O
+blocking	B-DISO
+agent	O
+cisatracurium	B-CHED
+besylate	I-CHED
+and	O
+sedation	B-DISO
+with	O
+periodic	O
+doses	O
+of	O
+isoflurane	B-CHED
+and	O
+midazolam	O
+for	O
+48	O
+hr	O
+.	O
+
+TITLE	O
+:	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	I-PRGE
+from	O
+SARS	B-DISO
+coronavirus	B-SPEC
+catalyzes	O
+substrate	O
+hydrolysis	O
+by	O
+a	O
+general	O
+base	O
+mechanism	O
+.	O
+
+Lack	O
+of	O
+a	O
+suitable	O
+assay	O
+has	O
+been	O
+a	O
+major	O
+hindrance	O
+for	O
+enzyme	O
+kinetic	O
+studies	O
+and	O
+a	O
+large	O
+-	O
+scale	O
+inhibitor	B-CHED
+screen	O
+for	O
+SARS	B-PRGE
+3CL	I-PRGE
+proteinase	B-PROC
+.	O
+
+It	O
+is	O
+known	O
+for	O
+other	O
+coronaviruses	O
+that	O
+the	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+is	O
+required	O
+for	O
+both	O
+viral	O
+attachment	O
+to	O
+permissive	O
+cells	B-COMP
+and	O
+for	O
+fusion	O
+of	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+with	O
+the	O
+host	B-COMP
+cell	I-COMP
+membrane	I-COMP
+.	O
+
+The	O
+codon	O
+-	O
+optimized	O
+and	O
+native	O
+S	O
+glycoproteins	B-CHED
+exhibit	O
+similar	O
+molecular	O
+weight	O
+as	O
+determined	O
+by	O
+Western	O
+blot	O
+analysis	O
+,	O
+indicating	O
+that	O
+synthetic	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+is	O
+modified	O
+correctly	O
+in	O
+a	O
+mammalian	B-SPEC
+expression	B-PROC
+system	O
+.	O
+
+This	O
+interaction	O
+is	O
+blocked	O
+with	O
+serum	B-COMP
+obtained	O
+from	O
+recovering	O
+SARS	B-DISO
+patients	O
+,	O
+indicating	O
+that	O
+the	O
+binding	B-FUNC
+is	O
+specific	O
+.	O
+
+The	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+etiological	O
+agent	O
+for	O
+SARS	B-DISO
+.	O
+
+The	O
+number	O
+of	O
+NK	B-ANAT
+cells	I-ANAT
+and	O
+the	O
+expression	B-PROC
+of	O
+CD158b	B-PRGE
+on	O
+the	O
+surface	O
+of	O
+NK	B-ANAT
+cells	I-ANAT
+changed	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+correlated	O
+with	O
+disease	O
+severity	O
+and	O
+the	O
+presence	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+-	I-PRGE
+specific	I-PRGE
+antibodies	B-COMP
+;	O
+SARS	B-DISO
+differed	O
+from	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+infection	B-DISO
+in	O
+pathogenesis	B-DISO
+involving	O
+NK	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+SARS	B-DISO
+-	O
+nucleoprotein	O
+-	O
+specific	B-PROC
+immune	I-PROC
+response	I-PROC
+by	O
+use	O
+of	O
+DNA	O
+vaccine	O
+.	O
+
+We	O
+found	O
+that	O
+the	O
+DNA	O
+vaccination	O
+induced	O
+both	O
+N	O
+protein	B-CHED
+-	O
+specific	O
+antibody	B-COMP
+and	O
+specific	O
+CTL	B-ANAT
+activity	O
+to	O
+the	O
+target	O
+.	O
+
+In	O
+the	O
+case	O
+of	O
+two	O
+vaccine	O
+injections	O
+,	O
+CTL	B-ANAT
+activity	O
+was	O
+also	O
+high	O
+(	O
+56	O
+.	O
+6	O
++/-	O
+12	O
+.	O
+7	O
+%	O
+(	O
+E	O
+:	O
+T	O
+=	O
+25	O
+:	O
+1	O
+),	O
+57	O
+.	O
+4	O
++/-	O
+11	O
+.	O
+7	O
+%	O
+(	O
+E	O
+:	O
+T	O
+=	O
+50	O
+:	O
+1	O
+)	O
+and	O
+63	O
+.	O
+0	O
++/-	O
+6	O
+.	O
+3	O
+%	O
+(	O
+E	O
+:	O
+T	O
+=	O
+100	O
+:	O
+1	O
+))	O
+However	O
+,	O
+antibody	B-COMP
+titres	O
+were	O
+much	O
+lower	O
+(	O
+1	O
+:	O
+200	O
+-	O
+1	O
+:	O
+3200	O
+,	O
+average	O
+titre	O
+is	O
+1	O
+:	O
+980	O
+).	O
+
+Exposure	O
+to	O
+agrochemical	B-CHED
+products	O
+was	O
+evaluated	O
+.	O
+
+However	O
+,	O
+81	O
+%	O
+of	O
+my	O
+48	O
+recently	O
+-	O
+summarized	O
+type	O
+-	O
+2	O
+diabetes	B-DISO
+patients	O
+with	O
+polyneuropathy	B-DISO
+,	O
+adequately	O
+-	O
+treated	O
+with	O
+intravenous	O
+immunoglobulin	B-PRGE
+-	I-PRGE
+G	I-PRGE
+,	O
+off	O
+-	O
+label	B-CHED
+,	O
+were	O
+relieved	O
+,	O
+sometimes	O
+completely	O
+,	O
+of	O
+various	O
+motor	O
+and	O
+sensory	O
+symptoms	O
+,	O
+including	O
+pain	O
+,	O
+thereby	O
+resembling	O
+Chronic	O
+Immune	O
+Dysschwannian	O
+/	O
+Dysneuronal	O
+Polyneuropathy	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+still	O
+threatening	O
+the	O
+world	O
+because	O
+of	O
+a	O
+possible	O
+resurgence	O
+.	O
+
+Pediatric	O
+considerations	O
+included	O
+a	O
+more	O
+likely	O
+need	O
+for	O
+intubation	O
+due	O
+to	O
+low	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+;	O
+more	O
+difficult	O
+intravenous	O
+access	O
+;	O
+fluid	O
+resuscitation	O
+based	O
+on	O
+weight	O
+with	O
+40	O
+-	O
+60	O
+mL	O
+/	O
+kg	O
+or	O
+higher	O
+needed	O
+;	O
+decreased	O
+cardiac	B-ANAT
+output	O
+and	O
+increased	O
+systemic	B-PROC
+vascular	I-PROC
+resistance	I-PROC
+as	O
+the	O
+most	O
+common	O
+hemodynamic	B-PROC
+profile	O
+;	O
+greater	O
+use	O
+of	O
+physical	O
+examination	O
+therapeutic	O
+end	O
+points	O
+;	O
+unsettled	O
+issue	O
+of	O
+high	O
+-	O
+dose	O
+steroids	B-CHED
+for	O
+therapy	O
+of	O
+septic	B-DISO
+shock	I-DISO
+;	O
+and	O
+greater	O
+risk	O
+of	O
+hypoglycemia	B-DISO
+with	O
+aggressive	B-DISO
+glucose	B-CHED
+control	O
+.	O
+
+Pediatric	O
+considerations	O
+included	O
+a	O
+more	O
+likely	O
+need	O
+for	O
+intubation	O
+due	O
+to	O
+low	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+;	O
+more	O
+difficult	O
+intravenous	O
+access	O
+;	O
+fluid	O
+resuscitation	O
+based	O
+on	O
+weight	O
+with	O
+40	O
+-	O
+60	O
+mL	O
+/	O
+kg	O
+or	O
+higher	O
+needed	O
+;	O
+decreased	O
+cardiac	B-ANAT
+output	O
+and	O
+increased	O
+systemic	B-PROC
+vascular	I-PROC
+resistance	I-PROC
+as	O
+the	O
+most	O
+common	O
+hemodynamic	B-PROC
+profile	O
+;	O
+greater	O
+use	O
+of	O
+physical	O
+examination	O
+therapeutic	O
+end	O
+points	O
+;	O
+unsettled	O
+issue	O
+of	O
+high	O
+-	O
+dose	O
+steroids	B-CHED
+for	O
+therapy	O
+of	O
+septic	B-DISO
+shock	I-DISO
+;	O
+and	O
+greater	O
+risk	O
+of	O
+hypoglycemia	B-DISO
+with	O
+aggressive	B-DISO
+glucose	B-CHED
+control	O
+.	O
+
+In	O
+this	O
+report	O
+we	O
+have	O
+cloned	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+studied	O
+its	O
+property	O
+of	O
+self	O
+-	O
+association	O
+to	O
+form	O
+dimers	O
+.	O
+
+To	O
+describe	O
+the	O
+spectrum	O
+of	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+a	O
+large	O
+outbreak	O
+and	O
+to	O
+compare	O
+diagnoses	O
+based	O
+on	O
+clinical	O
+judgment	O
+with	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+test	O
+.	O
+
+RESULTS	O
+:	O
+145	O
+of	O
+553	O
+(	O
+26	O
+%)	O
+patients	O
+had	O
+serologic	O
+evidence	O
+of	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+IgM	B-PRGE
+antibodies	B-COMP
+decreased	O
+and	O
+became	O
+undetectable	O
+11	O
+weeks	O
+into	O
+the	O
+recovery	O
+phase	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+viraemia	B-DISO
+mainly	O
+appeared	O
+1	O
+week	O
+after	O
+the	O
+onset	O
+of	O
+illness	O
+and	O
+then	O
+decreased	O
+over	O
+a	O
+period	O
+of	O
+1	O
+month	O
+,	O
+becoming	O
+undetectable	O
+in	O
+the	O
+blood	B-ANAT
+samples	I-ANAT
+of	O
+the	O
+convalescent	O
+patients	O
+.	O
+
+The	O
+attenuated	O
+nature	O
+of	O
+MVA	B-CHED
+and	O
+the	O
+ability	O
+of	O
+MVA	B-CHED
+/	O
+S	O
+to	O
+induce	O
+neutralizing	O
+antibody	B-COMP
+that	O
+protects	O
+mice	B-SPEC
+support	O
+further	O
+development	B-PROC
+of	O
+this	O
+candidate	O
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+),	O
+a	O
+spike	O
+(	O
+S	O
+)	O
+gene	B-DISO
+deletion	I-DISO
+mutant	B-DISO
+of	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+causes	O
+mild	O
+or	O
+subclinical	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+pigs	B-SPEC
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+nested	O
+-	O
+RT	O
+-	O
+PCR	O
+was	O
+as	O
+sensitive	O
+as	O
+CCIF	O
+for	O
+PRCV	O
+detection	O
+in	O
+nasal	B-ANAT
+swabs	O
+,	O
+but	O
+was	O
+more	O
+sensitive	O
+than	O
+CCIF	O
+for	O
+PRCV	O
+detection	O
+in	O
+fecal	B-ANAT
+samples	O
+;	O
+alternatively	O
+PRCV	O
+shed	O
+in	O
+feces	B-ANAT
+was	O
+more	O
+labile	O
+with	O
+loss	O
+of	O
+infectivity	O
+.	O
+
+These	O
+new	O
+PRCV	O
+isolates	O
+should	O
+be	O
+useful	O
+to	O
+understand	O
+the	O
+molecular	O
+basis	O
+of	O
+coronavirus	B-SPEC
+tropism	B-PROC
+and	O
+evolution	B-PROC
+in	O
+infected	O
+swine	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Radiographic	O
+appearance	O
+and	O
+clinical	O
+outcome	O
+correlates	O
+in	O
+26	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Four	O
+patients	O
+(	O
+15	O
+%)	O
+had	O
+pleural	B-DISO
+effusion	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+initial	O
+predominant	O
+radiographic	O
+feature	O
+of	O
+SARS	B-DISO
+was	O
+air	B-CHED
+-	O
+space	O
+consolidation	O
+in	O
+the	O
+lateral	O
+and	O
+lower	O
+lung	B-ANAT
+zones	O
+.	O
+
+The	O
+risks	O
+for	O
+the	O
+different	O
+units	O
+matched	O
+the	O
+virus	B-SPEC
+concentrations	O
+predicted	O
+with	O
+the	O
+use	O
+of	O
+multizone	O
+modeling	O
+.	O
+
+Airborne	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+appears	O
+to	O
+explain	O
+this	O
+large	O
+community	O
+outbreak	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+future	O
+efforts	O
+at	O
+prevention	O
+and	O
+control	O
+must	O
+take	O
+into	O
+consideration	O
+the	O
+potential	O
+for	O
+airborne	O
+spread	O
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+Prevention	O
+of	O
+Mycobacterium	B-SPEC
+tuberculosis	I-SPEC
+transmission	O
+also	O
+requires	O
+effective	O
+infection	B-DISO
+control	O
+in	O
+health	O
+-	O
+care	O
+facilities	O
+.	O
+
+In	O
+Taipei	O
+,	O
+Taiwan	O
+,	O
+an	O
+area	O
+with	O
+moderate	O
+to	O
+high	O
+incidence	O
+of	O
+tuberculosis	B-PATH
+(	O
+TB	O
+)	O
+(	O
+50	O
+-	O
+74	O
+cases	O
+per	O
+100	O
+,	O
+000	O
+population	O
+),	O
+health	O
+-	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+are	O
+at	O
+increased	O
+risk	O
+for	O
+M	B-SPEC
+.	I-SPEC
+tuberculosis	I-SPEC
+(	O
+Taiwan	O
+Center	O
+for	O
+Disease	O
+Control	O
+,	O
+unpublished	O
+data	O
+,	O
+2002	O
+).	O
+
+TITLE	O
+:	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+induces	O
+an	O
+exaggerated	O
+pro	B-CHED
+-	O
+and	O
+anti	B-PROC
+-	I-PROC
+inflammatory	I-PROC
+response	I-PROC
+in	O
+peritoneal	B-ANAT
+macrophages	I-ANAT
+of	O
+children	O
+compared	O
+with	O
+adults	O
+.	O
+
+ABSTRACT	O
+:	O
+Children	O
+have	O
+a	O
+lower	O
+incidence	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+compared	O
+with	O
+adults	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+induced	O
+an	O
+11	O
+-	O
+fold	O
+increase	O
+in	O
+IL	B-PRGE
+-	I-PRGE
+10	I-PRGE
+production	I-PROC
+in	O
+pediatric	O
+PMs	B-DISO
+(	O
+659	O
++/-	O
+103	O
+vs	O
+.	O
+60	O
++/-	O
+25	O
+control	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+exaggerated	O
+anti	B-PRGE
+-	I-PRGE
+inflammatory	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+10	I-PRGE
+response	O
+in	O
+children	O
+may	O
+be	O
+an	O
+important	O
+factor	O
+in	O
+the	O
+observed	O
+differences	O
+in	O
+ALI	O
+between	O
+children	O
+and	O
+adults	O
+.	O
+
+The	O
+latter	O
+was	O
+recently	O
+established	O
+when	O
+a	O
+causative	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+isolated	O
+and	O
+full	O
+-	O
+length	O
+sequenced	O
+(	O
+Marra	O
+et	O
+al	O
+.,	O
+Science	O
+2003	O
+:	O
+300	O
+:	O
+1399	O
+-	O
+404	O
+).	O
+
+The	O
+scan	O
+includes	O
+all	O
+nine	O
+human	B-SPEC
+HLA	B-ANAT
+supertypes	O
+in	O
+total	O
+covering	O
+>	O
+99	O
+%	O
+of	O
+all	O
+individuals	O
+of	O
+all	O
+major	O
+human	O
+populations	O
+(	O
+Sette	O
+&	O
+Sidney	O
+,	O
+Immunogenetics	O
+1999	O
+:	O
+50	O
+:	O
+201	O
+-	O
+12	O
+).	O
+
+We	O
+describe	O
+an	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+a	O
+chest	B-ANAT
+ward	O
+of	O
+a	O
+medical	O
+center	O
+in	O
+southern	O
+Taiwan	O
+and	O
+seek	O
+to	O
+identify	O
+the	O
+risk	O
+factors	O
+of	O
+those	O
+SARS	B-DISO
+patients	O
+who	O
+required	O
+mechanical	O
+ventilation	O
+.	O
+
+A	O
+2500	O
+-	O
+bed	B-DISO
+medical	O
+center	O
+in	O
+southern	O
+Taiwan	O
+.	O
+
+Risk	O
+factors	O
+for	O
+SARS	B-DISO
+patients	O
+who	O
+had	O
+been	O
+healthy	O
+prior	O
+to	O
+their	O
+illness	O
+included	O
+old	O
+age	O
+,	O
+high	O
+peak	O
+fever	B-PROC
+grade	O
+,	O
+increased	O
+neutrophil	B-ANAT
+count	O
+,	O
+increased	O
+neutrophil	B-ANAT
+percentage	O
+,	O
+and	O
+close	O
+or	O
+prolonged	O
+contact	O
+with	O
+a	O
+SARS	B-DISO
+patient	O
+.	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+for	O
+ARDS	B-DISO
+due	O
+to	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+ACS	B-FUNC
+evolving	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+rare	O
+but	O
+severe	O
+complication	B-DISO
+.	O
+
+TITLE	O
+:	O
+Partial	O
+liquid	O
+ventilation	O
+for	O
+the	O
+prevention	O
+of	O
+mortality	O
+and	O
+morbidity	O
+in	O
+paediatric	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+are	O
+syndromes	B-DISO
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Children	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	O
+respiratory	O
+syndrome	B-DISO
+have	O
+high	O
+mortality	O
+and	O
+significant	O
+morbidity	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+an	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+on	O
+a	O
+hospital	O
+in	O
+Taiwan	O
+,	O
+ROC	O
+.	O
+
+Thirty	O
+eight	O
+patients	O
+were	O
+hospitalised	O
+with	O
+suspected	O
+SARS	B-DISO
+,	O
+of	O
+which	O
+three	O
+received	O
+the	O
+final	O
+diagnosis	O
+of	O
+probable	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+A	O
+mean	O
+of	O
+5100	O
+persons	O
+per	O
+day	O
+(	O
+95	O
+%	O
+CI	O
+4580	O
+to	O
+5610	O
+)	O
+underwent	O
+fever	B-PROC
+screening	O
+at	O
+the	O
+outpatient	O
+and	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+entrances	O
+to	O
+the	O
+hospital	O
+,	O
+of	O
+which	O
+35	O
+per	O
+day	O
+(	O
+95	O
+%	O
+CI	O
+30	O
+to	O
+40	O
+)	O
+were	O
+referred	O
+for	O
+further	O
+evaluation	O
+for	O
+suspected	O
+or	O
+probable	O
+SARS	B-DISO
+.	O
+
+Analysis	O
+of	O
+the	O
+active	O
+site	O
+cavity	O
+reveals	O
+the	O
+presence	O
+of	O
+subsites	O
+that	O
+can	O
+be	O
+targeted	B-PROC
+with	O
+specific	O
+chemical	O
+functionalities	O
+.	O
+
+It	O
+was	O
+found	O
+that	O
+bifunctional	O
+aryl	O
+boronic	B-CHED
+acid	I-CHED
+compounds	O
+were	O
+particularly	O
+effective	O
+at	O
+inhibiting	O
+the	O
+protease	O
+,	O
+with	O
+inhibition	B-PROC
+constants	O
+as	O
+strong	O
+as	O
+40	O
+nM	O
+.	O
+Isothermal	O
+titration	O
+microcalorimetric	O
+experiments	O
+indicate	O
+that	O
+these	O
+inhibitors	B-CHED
+bind	B-FUNC
+reversibly	O
+to	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+in	O
+an	O
+enthalpically	O
+favorable	O
+fashion	O
+,	O
+implying	O
+that	O
+they	O
+establish	O
+strong	O
+interactions	O
+with	O
+the	O
+protease	O
+molecule	O
+,	O
+thus	O
+defining	O
+attractive	O
+molecular	O
+scaffolds	O
+for	O
+further	O
+optimization	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+recent	O
+global	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+thousands	O
+of	O
+patients	O
+received	O
+treatments	O
+of	O
+uncertain	O
+efficacy	O
+and	O
+known	O
+toxicity	O
+such	O
+as	O
+ribavirin	B-CHED
+and	O
+corticosteroids	B-CHED
+.	O
+
+Overall	O
+,	O
+the	O
+molecular	O
+and	O
+biologic	O
+characteristics	O
+of	O
+the	O
+strain	O
+HSR1	O
+provide	O
+evidence	O
+that	O
+SARS	O
+-	O
+CoV	O
+forms	O
+a	O
+fourth	O
+genetic	O
+coronavirus	B-SPEC
+group	I-SPEC
+with	O
+distinct	O
+genomic	O
+and	O
+biologic	O
+features	O
+.	O
+
+Antibiotic	B-CHED
+treatment	O
+was	O
+ineffective	O
+,	O
+and	O
+he	O
+died	B-PROC
+8	O
+days	O
+after	O
+illness	O
+onset	O
+.	O
+
+TITLE	O
+:	O
+Microbicides	B-CHED
+and	O
+the	O
+environmental	O
+control	O
+of	O
+nosocomial	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+It	O
+is	O
+anticipated	O
+that	O
+these	O
+approaches	O
+will	O
+result	O
+in	O
+reducing	O
+the	O
+health	O
+and	O
+economic	O
+impact	O
+of	O
+nosocomial	B-DISO
+infections	I-DISO
+due	O
+to	O
+viruses	B-SPEC
+.	O
+
+Binding	B-FUNC
+analysis	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+main	I-PRGE
+proteinase	B-FUNC
+with	O
+HIV	B-DISO
+,	O
+psychotic	B-DISO
+and	O
+parasite	O
+drugs	O
+.	O
+
+A	O
+paper	O
+-	O
+based	O
+survey	O
+to	O
+assess	O
+how	O
+individuals	O
+obtained	O
+health	O
+information	O
+relating	O
+to	O
+bioterrorism	O
+and	O
+anthrax	B-DISO
+during	O
+late	O
+2001	O
+.	O
+
+While	O
+traditional	O
+media	B-ANAT
+provided	O
+the	O
+primary	O
+source	O
+of	O
+information	O
+on	O
+anthrax	B-DISO
+and	O
+bioterrorism	O
+,	O
+21	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+15	O
+%-	O
+27	O
+%)	O
+of	O
+respondents	O
+reported	O
+searching	O
+the	O
+Internet	O
+for	O
+this	O
+information	O
+during	O
+late	O
+2001	O
+.	O
+
+Respondents	O
+reported	O
+trusting	O
+information	O
+from	O
+physicians	O
+the	O
+most	O
+,	O
+and	O
+information	O
+from	O
+health	O
+websites	O
+slightly	O
+more	O
+than	O
+information	O
+from	O
+any	O
+traditional	O
+media	B-ANAT
+source	O
+.	O
+
+Many	O
+people	O
+already	O
+look	O
+to	O
+the	O
+Internet	O
+for	O
+information	O
+during	O
+a	O
+public	O
+health	O
+crisis	O
+,	O
+and	O
+information	O
+found	O
+online	O
+can	O
+positively	O
+influence	O
+behavioral	B-PROC
+responses	O
+to	O
+such	O
+crises	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+report	O
+of	O
+treatment	O
+and	O
+outcome	O
+after	O
+a	O
+major	O
+outbreak	O
+.	O
+
+Laboratory	O
+confirmation	O
+of	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+was	O
+established	O
+in	O
+132	O
+(	O
+95	O
+.	O
+7	O
+%).	O
+
+Methylprednisolone	B-CHED
+was	O
+used	O
+in	O
+107	O
+patients	O
+,	O
+of	O
+whom	O
+95	O
+(	O
+88	O
+.	O
+8	O
+%)	O
+responded	O
+favourably	O
+.	O
+
+There	O
+were	O
+15	O
+deaths	B-PROC
+(	O
+mortality	O
+rate	O
+10	O
+.	O
+9	O
+%),	O
+most	O
+with	O
+significant	O
+co	O
+-	O
+morbidities	O
+,	O
+whereas	O
+122	O
+(	O
+88	O
+.	O
+4	O
+%)	O
+had	O
+been	O
+discharged	O
+home	O
+4	O
+months	O
+after	O
+the	O
+outbreak	O
+onset	O
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+and	O
+prevention	O
+of	O
+occupational	O
+infections	B-DISO
+in	O
+orthopaedic	O
+surgeons	O
+.	O
+
+Aerosol	O
+-	O
+generating	O
+procedures	O
+in	O
+patients	O
+with	O
+tuberculosis	B-PATH
+or	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+may	O
+facilitate	O
+airborne	O
+transmission	O
+.	O
+
+TITLE	O
+:	O
+Stability	O
+and	O
+inactivation	B-DISO
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Faecal	B-ANAT
+shedding	O
+is	O
+common	O
+and	O
+prolonged	O
+and	O
+has	O
+caused	O
+an	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+We	O
+studied	O
+the	O
+stability	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+under	O
+different	O
+conditions	O
+,	O
+both	O
+in	O
+suspension	O
+and	O
+dried	B-ANAT
+on	O
+surfaces	O
+,	O
+in	O
+comparison	O
+with	O
+other	O
+human	B-SPEC
+-	O
+pathogenic	O
+viruses	B-SPEC
+,	O
+including	O
+human	B-SPEC
+coronavirus	I-SPEC
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+If	O
+protein	B-CHED
+-	O
+containing	O
+solutions	O
+are	O
+to	O
+be	O
+inactivated	O
+,	O
+heat	O
+treatment	O
+at	O
+60	O
+degrees	O
+C	O
+for	O
+at	O
+least	O
+30	O
+min	O
+must	O
+be	O
+used	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+encephalitogenic	O
+viruses	B-SPEC
+:	O
+lyssaviruses	B-SPEC
+and	O
+henipaviruses	B-SPEC
+transmitted	B-DISO
+by	O
+frugivorous	O
+bats	O
+.	O
+
+Because	O
+of	O
+the	O
+link	O
+with	O
+contact	O
+with	O
+a	O
+prairie	B-SPEC
+dog	I-SPEC
+,	O
+initial	O
+evaluation	O
+of	O
+the	O
+disease	O
+was	O
+focused	O
+toward	O
+diseases	O
+commonly	O
+associated	O
+with	O
+this	O
+animal	B-SPEC
+(	O
+e	O
+.	O
+g	O
+.,	O
+tularemia	B-DISO
+,	O
+plague	B-DISO
+).	O
+
+The	O
+second	O
+most	O
+frequent	O
+virus	B-SPEC
+was	O
+coronavirus	B-SPEC
+,	O
+followed	O
+by	O
+calicivirus	O
+.	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+for	O
+feline	B-SPEC
+coronavirus	B-SPEC
+seropositivity	O
+in	O
+cats	B-SPEC
+relinquished	O
+to	O
+a	O
+UK	O
+rescue	O
+charity	O
+.	O
+
+If	O
+host	B-COMP
+genetics	O
+could	O
+be	O
+shown	O
+to	O
+play	O
+a	O
+role	O
+in	O
+disease	O
+,	O
+it	O
+may	O
+allow	O
+the	O
+detection	O
+of	O
+cats	B-SPEC
+with	O
+a	O
+susceptibility	O
+to	O
+FIP	B-DISO
+and	O
+the	O
+development	B-PROC
+of	O
+increased	O
+population	O
+resistance	B-PROC
+through	O
+selective	O
+breeding	B-PROC
+.	O
+
+In	O
+this	O
+preliminary	O
+study	O
+,	O
+we	O
+used	O
+clonal	B-ANAT
+sequence	O
+analysis	O
+or	O
+reference	O
+strand	O
+conformational	O
+analysis	O
+(	O
+RSCA	O
+)	O
+to	O
+analyse	O
+the	O
+class	B-SPEC
+II	O
+FLA	O
+-	O
+DRB	O
+of	O
+25	O
+cats	B-SPEC
+for	O
+which	O
+the	O
+outcome	O
+of	O
+FCoV	O
+exposure	O
+was	O
+known	O
+.	O
+
+No	O
+particular	O
+allele	O
+appeared	O
+to	O
+be	O
+associated	O
+with	O
+either	O
+the	O
+development	B-PROC
+of	O
+FIP	B-DISO
+,	O
+resistance	B-PROC
+to	O
+FCoV	O
+,	O
+or	O
+the	O
+carrier	O
+status	O
+.	O
+
+Experimentally	O
+infected	O
+animals	B-SPEC
+started	O
+shedding	B-DISO
+virus	I-DISO
+as	O
+soon	O
+as	O
+2	O
+days	O
+after	O
+infection	B-DISO
+.	O
+
+The	O
+infection	B-DISO
+rate	O
+only	O
+increased	O
+from	O
+11	O
+to	O
+15	O
+%	O
+in	O
+1	O
+week	O
+.	O
+
+The	O
+most	O
+noteworthy	O
+changes	O
+were	O
+in	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+and	O
+interferon	B-PRGE
+gamma	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+levels	O
+.	O
+
+A	O
+complete	O
+remission	B-DISO
+(	O
+over	O
+2	O
+years	O
+)	O
+and	O
+a	O
+partial	O
+remission	B-DISO
+(	O
+2	O
+to	O
+5	O
+months	O
+)	O
+were	O
+observed	O
+in	O
+four	O
+(	O
+33	O
+.	O
+3	O
+%)	O
+and	O
+four	O
+(	O
+33	O
+.	O
+3	O
+%)	O
+cases	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Modified	O
+vaccinia	B-SPEC
+virus	I-SPEC
+Ankara	O
+as	O
+a	O
+vaccine	O
+against	O
+feline	B-SPEC
+coronavirus	B-SPEC
+:	O
+immunogenicity	O
+and	O
+efficacy	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+is	O
+a	O
+coronavirus	B-SPEC
+that	O
+induces	O
+a	O
+fatal	O
+systemic	B-DISO
+disease	I-DISO
+mediated	O
+by	O
+an	O
+inappropriate	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+TITLE	O
+:	O
+FIP	B-DISO
+:	O
+a	O
+novel	O
+approach	O
+to	O
+vaccination	O
+.	O
+
+Proceedings	O
+from	O
+the	O
+2nd	O
+International	O
+FCoV	O
+/	O
+FIP	B-DISO
+Symposium	O
+,	O
+Glasgow	O
+,	O
+4	O
+-	O
+7	O
+August	O
+2002	O
+.	O
+
+Stable	O
+helper	B-ANAT
+cell	I-ANAT
+line	O
+clones	O
+have	O
+been	O
+established	O
+by	O
+transfection	B-PROC
+of	O
+CRFK	O
+cells	B-COMP
+with	O
+FFV	O
+tas	B-DISO
+and	O
+assessed	O
+using	O
+beta	B-PRGE
+-	I-PRGE
+galactosidase	I-PRGE
+assays	O
+,	O
+PCR	O
+,	O
+immunofluorescence	O
+and	O
+western	O
+blotting	O
+.	O
+
+TITLE	O
+:	O
+Recommendations	O
+from	O
+workshops	O
+of	O
+the	O
+second	O
+international	O
+feline	B-SPEC
+coronavirus	B-SPEC
+/	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+symposium	O
+.	O
+
+Crystal	B-ANAT
+structure	O
+of	O
+mouse	B-SPEC
+hepatitis	I-DISO
+virus	O
+spike	O
+protein	B-CHED
+fusion	O
+core	O
+.	O
+
+Renal	B-ANAT
+biopsy	O
+showed	O
+diffuse	B-DISO
+endocapillary	I-DISO
+proliferative	I-DISO
+glomerulonephritis	I-DISO
+,	O
+with	O
+mesangial	O
+and	O
+capillary	B-ANAT
+walls	O
+,	O
+granular	B-ANAT
+deposits	O
+of	O
+IgG	B-PRGE
+and	O
+C3	O
+by	O
+immunofluorescence	O
+.	O
+
+She	O
+was	O
+given	O
+corticosteroids	B-CHED
+with	O
+progressive	O
+normalization	O
+of	O
+her	O
+renal	B-PROC
+function	I-PROC
+.	O
+
+In	O
+addition	O
+to	O
+its	O
+public	O
+health	O
+responsibilities	O
+,	O
+BCCDC	O
+was	O
+pivotal	O
+in	O
+the	O
+science	O
+defining	O
+SARS	B-DISO
+.	O
+
+The	O
+amino	B-CHED
+acid	I-CHED
+pairs	O
+whose	O
+actual	O
+frequencies	O
+are	O
+larger	O
+than	O
+their	O
+predicted	O
+frequencies	O
+are	O
+more	O
+likely	O
+to	O
+be	O
+targeted	B-PROC
+by	O
+mutations	O
+,	O
+whereas	O
+the	O
+amino	B-CHED
+acid	I-CHED
+pairs	O
+whose	O
+actual	O
+frequencies	O
+are	O
+smaller	O
+than	O
+their	O
+predicted	O
+frequencies	O
+are	O
+more	O
+likely	O
+to	O
+be	O
+formed	O
+after	O
+mutations	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+aetiological	O
+diagnosis	O
+by	O
+infective	O
+agent	O
+is	O
+as	O
+follows	O
+:	O
+150	O
+patients	O
+(	O
+25	O
+.	O
+2	O
+%)	O
+had	O
+virus	B-SPEC
+infections	B-DISO
+,	O
+of	O
+which	O
+90	O
+.	O
+7	O
+%	O
+(	O
+136	O
+/	O
+150	O
+)	O
+were	O
+by	O
+rhinovirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+clinical	O
+characteristics	O
+and	O
+long	O
+-	O
+term	O
+effects	O
+of	O
+SARS	B-DISO
+.	O
+
+0	O
+.	O
+4	O
+degrees	O
+C	O
+),	O
+median	O
+of	O
+fever	B-PROC
+length	O
+were	O
+7	O
+.	O
+0	O
+d	O
+(	O
+0	O
+.	O
+4	O
+approximately	O
+50	O
+d	O
+)	O
+and	O
+2	O
+.	O
+3	O
+d	O
+(	O
+0	O
+.	O
+3	O
+approximately	O
+37	O
+d	O
+)	O
+respectively	O
+.	O
+
+Some	O
+patients	O
+with	O
+other	O
+respiratory	B-DISO
+diseases	I-DISO
+were	O
+misdiagnosed	O
+as	O
+SARS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Some	O
+patients	O
+with	O
+other	O
+respiratory	B-DISO
+diseases	I-DISO
+were	O
+misdiagnosed	O
+as	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Prognostic	O
+analysis	O
+of	O
+lung	B-PROC
+function	I-PROC
+and	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+changes	O
+of	O
+258	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+rehabilitation	O
+after	O
+discharge	B-ANAT
+].	O
+
+Compared	O
+to	O
+155	O
+SARS	B-DISO
+-	O
+Co	O
+virus	B-SPEC
+IgG	B-PRGE
+positive	O
+patients	O
+without	O
+lung	B-ANAT
+diffusion	O
+abnormity	O
+and	O
+50	O
+SARS	B-DISO
+-	O
+Co	O
+virus	B-SPEC
+IgG	B-PRGE
+negative	O
+patients	O
+,	O
+the	O
+53	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+Co	I-PRGE
+virus	B-SPEC
+IgG	I-PRGE
+positive	O
+patients	O
+with	O
+lung	B-ANAT
+diffusion	O
+abnormity	O
+had	O
+longer	O
+fever	B-PROC
+course	O
+,	O
+higher	O
+dosages	O
+of	O
+glucocorticoid	B-CHED
+therapy	O
+,	O
+higher	O
+percentage	O
+of	O
+oxygen	B-CHED
+therapy	O
+and	O
+non	O
+-	O
+invasive	O
+ventilation	O
+.	O
+
+This	O
+finding	O
+suggests	O
+that	O
+lung	B-DISO
+fibrosis	I-DISO
+caused	O
+by	O
+SARS	B-DISO
+mostly	O
+occurs	O
+in	O
+severe	O
+patients	O
+,	O
+and	O
+it	O
+can	O
+resolve	O
+spontaneously	O
+.	O
+
+(	O
+1	O
+)	O
+The	O
+device	O
+designed	O
+is	O
+capable	O
+of	O
+ensuring	O
+control	O
+of	O
+inhalation	B-PROC
+of	O
+PFIB	O
+;	O
+(	O
+2	O
+)	O
+Exposure	O
+to	O
+PFIB	O
+for	O
+30	O
+mins	O
+,	O
+canines	O
+all	O
+met	B-CHED
+the	O
+criteria	O
+for	O
+diagnosing	O
+ARDS	B-DISO
+22	O
+hours	O
+after	O
+inhalation	B-PROC
+,	O
+therefore	O
+the	O
+modeling	O
+is	O
+successful	O
+;	O
+(	O
+3	O
+)	O
+PFIB	O
+specifically	O
+damages	O
+the	O
+lung	B-ANAT
+by	O
+causing	O
+excessive	O
+inflammation	B-DISO
+.	O
+
+Thus	O
+,	O
+the	O
+RT	O
+-	O
+LAMP	O
+assay	O
+reported	O
+here	O
+has	O
+the	O
+advantages	O
+of	O
+rapid	O
+amplification	B-DISO
+,	O
+simple	O
+operation	O
+,	O
+and	O
+easy	O
+detection	O
+and	O
+will	O
+be	O
+useful	O
+for	O
+rapid	O
+and	O
+reliable	O
+clinical	O
+diagnosis	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+developing	O
+countries	O
+.	O
+
+PCR	O
+inhibitors	B-CHED
+were	O
+removed	O
+by	O
+ethanol	B-CHED
+precipitation	B-PROC
+,	O
+and	O
+a	O
+PCR	O
+for	O
+the	O
+pig	B-PRGE
+beta	I-PRGE
+-	I-PRGE
+actin	I-PRGE
+gene	I-PRGE
+was	O
+used	O
+as	O
+a	O
+positive	O
+control	O
+for	O
+all	O
+clinical	O
+samples	O
+.	O
+
+ABSTRACT	O
+:	O
+First	O
+-	O
+generation	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assays	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+gave	O
+false	O
+-	O
+negative	O
+results	O
+in	O
+a	O
+considerable	O
+fraction	O
+of	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+two	O
+real	O
+-	O
+time	O
+quantitative	O
+assays	O
+for	O
+detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+A	O
+total	O
+of	O
+812	O
+people	O
+died	B-PROC
+due	O
+to	O
+respiratory	B-DISO
+insufficiency	I-DISO
+.	O
+
+However	O
+,	O
+potential	O
+transmission	O
+by	O
+blood	B-ANAT
+transfusion	O
+could	O
+not	O
+be	O
+definitely	O
+excluded	O
+.	O
+
+Two	O
+real	O
+-	O
+time	O
+SARS	B-DISO
+-	O
+specific	O
+PCR	O
+assays	O
+were	O
+assessed	O
+for	O
+their	O
+sensitivities	O
+,	O
+agreement	O
+of	O
+test	O
+results	O
+,	O
+and	O
+intra	O
+-	O
+assay	O
+variabilities	O
+.	O
+
+Dilutions	O
+of	O
+gamma	O
+-	O
+irradiated	O
+cell	B-COMP
+culture	O
+supernatants	O
+of	O
+SARS	B-DISO
+CoV	O
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+were	O
+prepared	O
+to	O
+determine	O
+the	O
+precisions	O
+,	O
+linear	O
+ranges	O
+,	O
+and	O
+accuracies	O
+of	O
+the	O
+assays	O
+.	O
+
+The	O
+present	O
+ELISA	O
+appears	O
+to	O
+be	O
+a	O
+sensitive	O
+test	O
+for	O
+serodiagnosis	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+pneumonia	B-DISO
+,	O
+is	O
+much	O
+more	O
+economical	O
+and	O
+less	O
+labor	B-PROC
+-	O
+intensive	O
+than	O
+the	O
+indirect	O
+immunofluorescence	O
+assay	O
+,	O
+and	O
+does	O
+not	O
+require	O
+cultivation	O
+of	O
+SARS	O
+-	O
+CoV	O
+.	O
+
+Non	O
+-	O
+specific	O
+inflammation	B-DISO
+in	O
+the	O
+liver	B-ANAT
+was	O
+observed	O
+in	O
+pathological	O
+examination	O
+in	O
+4	O
+cases	O
+.	O
+
+Histopathology	O
+of	O
+liver	B-ANAT
+was	O
+non	O
+-	O
+specific	O
+hepatitis	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+of	O
+relation	O
+between	O
+the	O
+usage	O
+of	O
+corticosteroid	B-CHED
+in	O
+treatment	O
+and	O
+arthralgia	B-DISO
+as	O
+a	O
+sequela	O
+of	O
+SARS	O
+patients	O
+].	O
+
+There	O
+were	O
+26	O
+of	O
+30	O
+patients	O
+(	O
+86	O
+.	O
+67	O
+percent	O
+)	O
+experienced	O
+arthralgia	B-DISO
+symptom	B-DISO
+during	O
+convalescence	O
+.	O
+
+In	O
+3	O
+.	O
+6	O
+percent	O
+of	O
+patients	O
+arthralgia	B-DISO
+occurred	O
+within	O
+one	O
+month	O
+after	O
+SARS	B-DISO
+,	O
+53	O
+.	O
+85	O
+percent	O
+of	O
+the	O
+patients	O
+experienced	O
+low	O
+-	O
+grade	O
+arthralgia	B-DISO
+.	O
+
+By	O
+unifactor	O
+analysis	O
+,	O
+the	O
+total	O
+dosage	O
+and	O
+its	O
+duration	O
+of	O
+use	O
+,	O
+the	O
+highest	O
+dosage	O
+and	O
+its	O
+duration	O
+,	O
+speed	O
+of	O
+reduction	O
+of	O
+dosage	O
+of	O
+corticosteroids	B-CHED
+were	O
+correlated	O
+with	O
+the	O
+degree	O
+of	O
+arthralgia	B-DISO
+,	O
+respectively	O
+.	O
+
+Age	O
+was	O
+not	O
+correlated	O
+with	O
+either	O
+the	O
+degree	O
+or	O
+the	O
+persisting	O
+time	O
+of	O
+arthralgia	B-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+average	O
+total	O
+dosage	O
+of	O
+methylprednisolone	B-CHED
+was	O
+(	O
+4	O
+244	O
+.	O
+16	O
++/-	O
+2	O
+292	O
+.	O
+30	O
+)	O
+mg	O
+,	O
+and	O
+the	O
+duration	O
+of	O
+use	O
+of	O
+the	O
+treatment	O
+was	O
+(	O
+25	O
+.	O
+36	O
++/-	O
+5	O
+.	O
+88	O
+)	O
+days	O
+(	O
+ranging	O
+from	O
+12	O
+to	O
+35	O
+days	O
+).	O
+
+This	O
+might	O
+be	O
+related	O
+to	O
+SARS	B-DISO
+related	O
+pulmonary	B-ANAT
+injuries	O
+,	O
+intensive	O
+cough	B-DISO
+and	O
+high	O
+mechanical	O
+ventilation	O
+pressure	O
+.	O
+
+RESULTS	O
+:	O
+Pneumothorax	B-DISO
+and	O
+mediastinal	B-DISO
+emphysema	I-DISO
+occurred	O
+in	O
+7	O
+of	O
+27	O
+serious	O
+cases	O
+of	O
+SARS	B-DISO
+with	O
+NIPPV	O
+,	O
+and	O
+mediastinal	B-DISO
+emphysema	I-DISO
+occurred	O
+in	O
+1	O
+of	O
+189	O
+cases	O
+of	O
+SARS	B-DISO
+without	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+).	O
+
+Chi	B-CHED
+-	O
+square	O
+for	O
+trend	O
+test	O
+revealed	O
+that	O
+the	O
+positive	O
+rates	O
+of	O
+stools	B-ANAT
+and	O
+sputa	O
+of	O
+SARS	B-DISO
+patients	O
+decreased	O
+with	O
+the	O
+development	B-PROC
+of	O
+the	O
+disease	O
+(	O
+chi	B-CHED
+(	O
+2	O
+)	O
+for	O
+trend	O
+=	O
+12	O
+.	O
+55	O
+and	O
+16	O
+.	O
+408	O
+,	O
+P	O
+=	O
+0	O
+.	O
+0004	O
+and	O
+P	O
+=	O
+0	O
+.	O
+000	O
+05	O
+respectively	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+on	O
+the	O
+dynamics	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+lymphocytes	B-ANAT
+and	O
+their	O
+subpopulations	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+absolute	O
+numbers	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+lymphocytes	B-ANAT
+and	O
+their	O
+subpopulations	O
+(	O
+CD45	B-PRGE
+,	O
+CD3	B-PRGE
+,	O
+CD4	B-PRGE
+,	O
+CD8	B-PRGE
+)	O
+were	O
+1298	O
++/-	O
+
+Of	O
+SARS	B-DISO
+patients	O
+,	O
+severe	O
+group	O
+(	O
+1095	O
++/-	O
+740	O
+,	O
+740	O
++/-	O
+
+TITLE	O
+:	O
+Psychological	B-DISO
+impact	O
+of	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+on	O
+health	O
+care	O
+workers	O
+in	O
+a	O
+medium	O
+size	O
+regional	O
+general	O
+hospital	O
+in	O
+Singapore	O
+.	O
+
+Support	O
+from	O
+supervisors	O
+/	O
+colleagues	O
+was	O
+a	O
+significant	O
+negative	O
+predictor	O
+for	O
+psychiatric	B-DISO
+symptoms	I-DISO
+and	O
+PTSD	B-DISO
+.	O
+
+Many	O
+health	O
+care	O
+workers	O
+were	O
+emotionally	O
+affected	O
+and	O
+traumatized	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+homology	O
+modeling	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+main	O
+protease	O
+for	O
+structure	O
+based	O
+drug	O
+design	O
+.	O
+
+The	O
+PCR	O
+designated	O
+primer	O
+sets	O
+of	O
+spike	O
+protein	B-CHED
+detected	O
+only	O
+HEV	B-PRGE
+viral	I-PRGE
+RNA	I-PRGE
+among	O
+other	O
+related	O
+nidoviruses	B-SPEC
+.	O
+
+These	O
+results	O
+contribute	O
+to	O
+characterization	O
+of	O
+the	O
+SARS	B-DISO
+agent	O
+and	O
+development	B-PROC
+of	O
+new	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+Anti	O
+-	O
+P2	O
+antibodies	B-COMP
+and	O
+the	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+could	O
+specifically	O
+detect	O
+the	O
+recombinant	B-PRGE
+SARS	I-PRGE
+protein	B-CHED
+3a	I-PRGE
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Protein	B-PRGE
+3a	I-PRGE
+was	O
+also	O
+detected	O
+in	O
+the	O
+alveolar	B-ANAT
+lining	O
+pneumocytes	B-ANAT
+and	O
+some	O
+intra	O
+-	O
+alveolar	B-ANAT
+cells	B-COMP
+of	O
+a	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+patient	O
+'	O
+s	O
+lung	B-ANAT
+specimen	O
+.	O
+
+TITLE	O
+:	O
+The	O
+antiviral	B-CHED
+effect	O
+of	O
+interferon	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+against	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+is	O
+not	O
+mediated	O
+by	O
+MxA	B-PRGE
+protein	B-CHED
+.	O
+
+Interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+,	O
+by	O
+contrast	O
+,	O
+were	O
+less	O
+effective	O
+.	O
+
+This	O
+course	O
+of	O
+interventions	O
+is	O
+designed	O
+for	O
+the	O
+consideration	O
+of	O
+nurses	O
+caring	O
+for	O
+SARS	B-DISO
+patients	O
+and	O
+to	O
+bolster	O
+their	O
+ability	O
+to	O
+fight	O
+the	O
+disease	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+whether	O
+spotted	B-SPEC
+hyenas	I-SPEC
+also	O
+had	O
+been	O
+infected	O
+with	O
+these	O
+viruses	B-SPEC
+and	O
+to	O
+assess	O
+risk	O
+factors	O
+for	O
+infection	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+radio	B-CHED
+-	O
+tracking	O
+of	O
+gray	O
+foxes	O
+in	O
+the	O
+rural	O
+zone	O
+indicated	O
+that	O
+all	O
+three	O
+of	O
+the	O
+rural	O
+CPV	O
+-	O
+seropositive	O
+foxes	O
+had	O
+traveled	O
+into	O
+adjoining	O
+small	O
+towns	O
+,	O
+whereas	O
+only	O
+one	O
+of	O
+the	O
+11	O
+seronegative	O
+animals	B-SPEC
+had	O
+done	O
+so	O
+.	O
+
+Individual	O
+bobcats	B-SPEC
+with	O
+positive	O
+FCV	B-CHED
+antibody	B-COMP
+titers	O
+had	O
+patterns	O
+of	O
+movement	B-PROC
+that	O
+intercepted	O
+park	B-DISO
+inholdings	O
+where	O
+domestic	B-SPEC
+cats	I-SPEC
+lived	O
+.	O
+
+High	O
+seroprevalence	O
+was	O
+detected	O
+for	O
+B	B-SPEC
+.	I-SPEC
+henselae	I-SPEC
+and	O
+T	B-SPEC
+.	I-SPEC
+gondii	I-SPEC
+in	O
+both	O
+zones	O
+.	O
+
+Combining	O
+behavioral	B-PROC
+information	O
+from	O
+radio	B-CHED
+-	O
+tracking	O
+with	O
+data	O
+on	O
+pathogen	O
+exposure	O
+or	O
+disease	O
+incidence	O
+can	O
+provide	O
+valuable	O
+insights	O
+into	O
+the	O
+ecology	O
+of	O
+wildlife	O
+disease	O
+that	O
+might	O
+be	O
+missed	O
+with	O
+broad	O
+-	O
+scale	O
+,	O
+population	O
+-	O
+level	O
+comparisons	O
+alone	O
+.	O
+
+There	O
+is	O
+no	O
+proven	O
+antiviral	B-CHED
+agent	I-CHED
+against	O
+SARS	B-DISO
+CoV	O
+.	O
+The	O
+most	O
+remarkable	O
+feature	O
+about	O
+the	O
+SARS	B-DISO
+epidemic	O
+was	O
+the	O
+speed	O
+with	O
+which	O
+the	O
+global	O
+community	O
+acted	O
+in	O
+a	O
+coordinated	O
+way	O
+to	O
+control	O
+it	O
+.	O
+
+TITLE	O
+:	O
+T	B-ANAT
+-	I-ANAT
+cell	B-COMP
+epitopes	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+elicit	O
+a	O
+specific	O
+T	O
+-	O
+cell	O
+immune	B-PROC
+response	I-PROC
+in	O
+patients	O
+who	O
+recover	B-PROC
+from	O
+SARS	B-DISO
+.	O
+
+We	O
+employed	O
+online	O
+database	O
+analysis	O
+to	O
+compare	O
+the	O
+differences	O
+in	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+the	O
+homologous	O
+T	O
+epitopes	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229e	I-SPEC
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+identified	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitope	B-CHED
+peptides	B-CHED
+were	O
+synthesized	O
+,	O
+and	O
+their	O
+binding	B-FUNC
+affinities	O
+for	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+were	O
+validated	O
+and	O
+compared	O
+in	O
+the	O
+T2	O
+cell	B-COMP
+system	O
+.	O
+
+Online	O
+database	O
+analysis	O
+and	O
+the	O
+T2	O
+cell	B-COMP
+binding	B-FUNC
+test	O
+disclosed	O
+that	O
+the	O
+number	O
+of	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+-	O
+restricted	O
+immunogenic	O
+epitopes	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+decreased	O
+or	O
+even	O
+lost	B-CHED
+in	O
+comparison	O
+with	O
+the	O
+homologous	O
+sequences	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229e	I-SPEC
+.	O
+
+Among	O
+the	O
+peptides	B-CHED
+used	O
+in	O
+the	O
+study	O
+,	O
+the	O
+affinity	O
+of	O
+peptides	B-CHED
+from	O
+HCoV	B-SPEC
+-	I-SPEC
+229e	I-SPEC
+(	O
+H77	O
+and	O
+H881	O
+)	O
+and	O
+peptides	B-CHED
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+S978	O
+and	O
+S1203	O
+)	O
+for	O
+binding	B-FUNC
+to	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+was	O
+higher	O
+than	O
+that	O
+of	O
+other	O
+sequences	O
+.	O
+
+Here	O
+,	O
+we	O
+characterized	O
+the	O
+enzymatic	O
+activities	O
+of	O
+a	O
+recombinant	O
+form	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+helicase	I-PRGE
+(	O
+nonstructural	O
+protein	B-CHED
+[	O
+nsp	O
+]	O
+13	O
+),	O
+a	O
+superfamily	B-PRGE
+1	I-PRGE
+helicase	I-PRGE
+with	O
+an	O
+N	O
+-	O
+terminal	O
+zinc	B-CHED
+-	O
+binding	B-FUNC
+domain	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+established	O
+an	O
+RNA	B-PRGE
+5	I-PRGE
+'-	I-PRGE
+triphosphatase	I-PRGE
+activity	O
+for	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp13	I-PRGE
+helicase	I-PRGE
+which	O
+may	O
+be	O
+involved	O
+in	O
+the	O
+formation	B-PROC
+of	O
+the	O
+5	O
+'	O
+cap	B-DISO
+structure	O
+of	O
+viral	O
+RNAs	O
+.	O
+
+TITLE	O
+:	O
+pH	O
+-	O
+dependent	O
+entry	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+is	O
+mediated	O
+by	O
+the	O
+spike	O
+glycoprotein	O
+and	O
+enhanced	O
+by	O
+dendritic	B-ANAT
+cell	B-COMP
+transfer	O
+through	O
+DC	O
+-	O
+SIGN	O
+.	O
+
+Peptide	B-CHED
+-	O
+conjugated	O
+morpholino	O
+-	O
+oligomers	O
+exhibited	O
+low	O
+toxicity	O
+in	O
+DBT	B-CHED
+astrocytoma	B-DISO
+cells	B-COMP
+used	O
+for	O
+culturing	O
+MHV	B-SPEC
+.	O
+
+We	O
+also	O
+identified	O
+a	O
+novel	O
+dibasic	O
+motif	O
+(-	O
+KXHXX	O
+-	O
+COOH	O
+)	O
+in	O
+the	O
+cytoplasmic	B-ANAT
+tails	B-ANAT
+of	O
+S	O
+proteins	B-CHED
+from	O
+group	O
+1	O
+coronaviruses	O
+and	O
+from	O
+the	O
+newly	O
+identified	O
+coronavirus	B-SPEC
+implicated	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+To	O
+define	O
+the	O
+determinants	O
+of	O
+CS1	B-PRGE
+cleavage	B-PROC
+and	O
+the	O
+role	O
+of	O
+processing	O
+at	O
+this	O
+site	O
+during	O
+MHV	B-SPEC
+replication	O
+,	O
+mutations	O
+and	O
+deletions	O
+were	O
+engineered	O
+in	O
+the	O
+replicase	B-PRGE
+polyprotein	I-PRGE
+at	O
+CS1	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Organ	B-ANAT
+distribution	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+SARS	O
+patients	O
+:	O
+implications	O
+for	O
+pathogenesis	B-DISO
+and	O
+virus	B-SPEC
+transmission	O
+pathways	B-PROC
+.	O
+
+The	O
+pathological	O
+changes	O
+in	O
+these	O
+organs	B-ANAT
+may	O
+be	O
+caused	O
+directly	O
+by	O
+the	O
+cytopathic	B-DISO
+effect	I-DISO
+mediated	O
+by	O
+local	O
+replication	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+;	O
+or	O
+indirectly	O
+as	O
+a	O
+result	O
+of	O
+systemic	O
+responses	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+or	O
+the	O
+harmful	O
+immune	B-PROC
+response	I-PROC
+induced	O
+by	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+outbreak	O
+was	O
+declared	O
+contained	O
+on	O
+July	O
+5	O
+,	O
+2003	O
+,	O
+after	O
+the	O
+last	O
+human	B-SPEC
+chain	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+had	O
+been	O
+broken	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+occurs	O
+in	O
+almost	O
+all	O
+admitted	O
+patients	O
+and	O
+most	O
+require	O
+mechanical	O
+ventilation	O
+.	O
+
+One	O
+of	O
+the	O
+precluding	O
+factors	O
+in	O
+this	O
+regard	O
+is	O
+a	O
+greater	O
+understanding	O
+of	O
+the	O
+environmental	O
+conditions	O
+that	O
+will	O
+support	O
+transplant	B-ANAT
+-	O
+mediated	O
+remyelination	B-PROC
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+nelfinavir	O
+should	O
+be	O
+examined	O
+clinically	O
+for	O
+the	O
+treatment	O
+of	O
+SARS	O
+and	O
+has	O
+potential	O
+as	O
+a	O
+good	O
+lead	O
+compound	O
+for	O
+designing	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+virus	B-SPEC
+belongs	O
+to	O
+the	O
+Coronaviridea	O
+family	B-SPEC
+of	O
+viruses	B-SPEC
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+three	O
+-	O
+dimensional	O
+structure	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Assembly	O
+of	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+-	O
+like	O
+particles	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	B-ANAT
+particles	I-ANAT
+of	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+CoV	O
+)	O
+consist	O
+of	O
+three	O
+virion	B-COMP
+structural	O
+proteins	B-CHED
+,	O
+including	O
+spike	O
+protein	B-CHED
+,	O
+membrane	B-COMP
+protein	B-CHED
+,	O
+and	O
+envelope	B-COMP
+protein	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+prepared	O
+a	O
+peptide	B-CHED
+with	O
+fluorescence	O
+quenching	O
+pair	O
+(	O
+Dabcyl	O
+and	O
+Edans	O
+)	O
+at	O
+both	O
+ends	O
+of	O
+a	O
+peptide	B-CHED
+substrate	O
+and	O
+used	O
+this	O
+fluorogenic	O
+peptide	B-CHED
+substrate	O
+to	O
+characterize	O
+SARS	B-PRGE
+main	I-PRGE
+protease	I-PRGE
+and	O
+screen	O
+inhibitors	B-CHED
+.	O
+
+Most	O
+respondents	O
+took	O
+action	O
+to	O
+avoid	O
+being	O
+infected	O
+by	O
+SARS	B-DISO
+,	O
+including	O
+,	O
+most	O
+commonly	O
+,	O
+efforts	O
+to	O
+improve	O
+indoor	O
+ventilation	O
+,	O
+to	O
+disinfect	O
+the	O
+indoor	O
+environment	O
+and	O
+to	O
+increase	O
+hand	O
+-	O
+washing	O
+frequency	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+inhibition	B-PROC
+using	O
+spike	O
+protein	B-CHED
+heptad	O
+repeat	O
+-	O
+derived	O
+peptides	B-CHED
+.	O
+
+With	O
+the	O
+aim	O
+of	O
+developing	O
+therapeutic	O
+agents	O
+,	O
+we	O
+have	O
+tested	O
+peptides	B-CHED
+derived	O
+from	O
+the	O
+membrane	B-COMP
+-	O
+proximal	O
+(	O
+HR2	O
+)	O
+and	O
+membrane	B-COMP
+-	O
+distal	O
+(	O
+HR1	O
+)	O
+heptad	O
+repeat	O
+region	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+as	O
+inhibitors	B-CHED
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+of	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+Proper	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+(	O
+PPE	B-CHED
+)	O
+and	O
+scrupulous	O
+attention	O
+to	O
+hand	O
+hygiene	O
+are	O
+critical	O
+to	O
+reducing	O
+transmission	O
+of	O
+SARS	B-DISO
+,	O
+especially	O
+in	O
+health	O
+care	O
+facilities	O
+.	O
+
+ABSTRACT	O
+:	O
+Antibiotic	B-CHED
+-	O
+resistant	O
+bacteria	B-SPEC
+are	O
+an	O
+increasingly	O
+common	O
+problem	O
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+),	O
+and	O
+they	O
+are	O
+capable	O
+of	O
+impacting	O
+on	O
+patient	O
+outcome	O
+,	O
+the	O
+ICU	O
+'	O
+s	O
+budget	O
+and	O
+bed	B-DISO
+availability	O
+.	O
+
+This	O
+issue	O
+,	O
+coupled	O
+with	O
+recent	O
+outbreaks	O
+of	O
+illnesses	O
+that	O
+pose	O
+a	O
+direct	O
+risk	O
+to	O
+ICU	O
+staff	O
+(	O
+such	O
+as	O
+SARS	B-DISO
+[	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+]),	O
+has	O
+led	O
+to	O
+renewed	O
+emphasis	O
+on	O
+infection	B-DISO
+control	O
+measures	O
+and	O
+practitioners	O
+in	O
+the	O
+ICU	O
+.	O
+
+The	O
+diagnosis	O
+is	O
+suggested	O
+by	O
+the	O
+paucity	O
+of	O
+clinical	O
+signs	O
+with	O
+an	O
+abnormal	O
+chest	B-ANAT
+radiograph	O
+,	O
+and	O
+laboratory	O
+evidence	O
+of	O
+leucopenia	B-DISO
+,	O
+lymphopenia	B-DISO
+,	O
+and	O
+thrombocytopenia	O
+.	O
+
+From	O
+this	O
+perspective	O
+,	O
+we	O
+analyzed	O
+eGFP	O
+mRNA	O
+expression	B-PROC
+and	O
+eGFP	O
+fluorescence	O
+in	O
+experimental	O
+models	O
+of	O
+nervous	B-ANAT
+system	I-ANAT
+lesions	O
+,	O
+such	O
+as	O
+motoneuron	B-ANAT
+axotomy	O
+and	O
+cerebral	B-DISO
+stroke	I-DISO
+induced	O
+by	O
+middle	B-DISO
+cerebral	I-DISO
+artery	I-DISO
+occlusion	B-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Determination	O
+and	O
+comparison	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+antibody	B-COMP
+in	O
+children	O
+and	O
+adults	O
+].	O
+
+The	O
+results	O
+showed	O
+that	O
+both	O
+the	O
+positive	O
+rates	O
+of	O
+IgG	B-COMP
+antibody	I-COMP
+in	O
+paediatric	O
+patients	O
+and	O
+healthy	O
+children	O
+were	O
+about	O
+2	O
+%	O
+(	O
+4	O
+/	O
+197	O
+and	O
+3	O
+/	O
+156	O
+),	O
+while	O
+the	O
+positive	O
+rates	O
+in	O
+adult	O
+patients	O
+and	O
+healthy	O
+adults	O
+were	O
+about	O
+0	O
+.	O
+2	O
+%	O
+(	O
+1	O
+/	O
+453	O
+and	O
+1	O
+/	O
+502	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+a	O
+newly	O
+identified	O
+member	O
+of	O
+Family	B-SPEC
+Coronaviridae	I-SPEC
+.	O
+
+Here	O
+we	O
+report	O
+that	O
+by	O
+using	O
+in	O
+vitro	O
+bio	O
+-	O
+engineering	O
+techniques	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+HR1	O
+and	O
+HR2	O
+bind	B-FUNC
+to	O
+each	O
+other	O
+and	O
+form	O
+a	O
+typical	O
+6	O
+-	O
+helix	O
+bundle	O
+.	O
+
+TITLE	O
+:	O
+Quantitation	O
+of	O
+canine	O
+coronavirus	B-SPEC
+RNA	O
+in	O
+the	O
+faeces	B-ANAT
+of	O
+dogs	B-SPEC
+by	O
+TaqMan	O
+RT	O
+-	O
+PCR	O
+.	O
+
+In	O
+addition	O
+,	O
+by	O
+the	O
+fluorogenic	O
+assay	O
+CCoV	O
+shedding	O
+in	O
+the	O
+faecal	O
+samples	O
+of	O
+an	O
+experimentally	O
+infected	O
+dog	B-SPEC
+was	O
+monitored	O
+for	O
+28	O
+days	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+thought	O
+to	O
+be	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+355	O
+(	O
+45	O
+%)	O
+specimens	O
+of	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+and	O
+150	O
+(	O
+28	O
+%)	O
+of	O
+faeces	B-ANAT
+were	O
+positive	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+RNA	O
+.	O
+
+This	O
+virus	B-SPEC
+also	O
+was	O
+found	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Glycan	B-CHED
+arrays	O
+lead	O
+to	O
+the	O
+discovery	O
+of	O
+autoimmunogenic	O
+activity	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+Using	O
+carbohydrate	O
+microarrays	O
+,	O
+we	O
+characterized	O
+the	O
+carbohydrate	B-FUNC
+binding	B-PROC
+activity	I-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+elicited	O
+by	O
+an	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+.	O
+
+In	O
+these	O
+antibodies	B-COMP
+,	O
+we	O
+detected	O
+undesired	O
+autoantibody	O
+reactivity	O
+specific	O
+for	O
+the	O
+carbohydrate	B-CHED
+moieties	O
+of	O
+an	O
+abundant	O
+human	B-SPEC
+serum	B-COMP
+glycoprotein	B-CHED
+asialo	O
+-	O
+orosomucoid	O
+(	O
+ASOR	O
+).	O
+
+Our	O
+results	O
+may	O
+help	O
+in	O
+the	O
+design	O
+of	O
+anti	O
+-	O
+SARS	B-DISO
+therapeutics	O
+.	O
+
+TITLE	O
+:	O
+Serum	B-ANAT
+hepatic	B-ANAT
+enzyme	O
+manifestations	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+retrospective	O
+analysis	O
+.	O
+
+Entry	O
+of	O
+coronaviruses	O
+into	O
+target	B-ANAT
+cells	I-ANAT
+is	O
+mediated	O
+by	O
+the	O
+viral	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+patients	O
+were	O
+divided	O
+into	O
+three	O
+groups	O
+(	O
+G	O
+(	O
+1	O
+),	O
+G	O
+(	O
+2	O
+),	O
+and	O
+G	O
+(	O
+3	O
+))	O
+according	O
+to	O
+the	O
+depth	O
+of	O
+mucosal	B-ANAT
+damage	O
+.	O
+
+There	O
+were	O
+no	O
+deaths	B-PROC
+related	O
+to	O
+the	O
+procedure	O
+.	O
+
+Thus	O
+such	O
+a	O
+molecular	O
+complex	O
+is	O
+expected	O
+to	O
+serve	O
+as	O
+a	O
+parameter	O
+for	O
+the	O
+diagnosis	O
+of	O
+thrombus	O
+formation	B-PROC
+and	O
+DIC	B-DISO
+,	O
+in	O
+particular	O
+its	O
+early	O
+stage	O
+.	O
+
+Especially	O
+,	O
+ALI	O
+followed	O
+by	O
+pneumoniae	O
+associated	O
+with	O
+SIRS	B-DISO
+could	O
+depend	O
+on	O
+patient	O
+'	O
+s	O
+prognosis	O
+and	O
+life	O
+.	O
+
+Thus	O
+such	O
+a	O
+molecular	O
+complex	O
+is	O
+expected	O
+to	O
+serve	O
+as	O
+a	O
+parameter	O
+for	O
+the	O
+diagnosis	O
+of	O
+coagulopathy	B-DISO
+,	O
+in	O
+particular	O
+its	O
+early	O
+stage	O
+.	O
+
+Four	O
+additional	O
+pups	O
+,	O
+which	O
+had	O
+shown	O
+no	O
+sign	O
+of	O
+illness	O
+,	O
+were	O
+separated	O
+and	O
+vaccinated	O
+,	O
+but	O
+two	O
+of	O
+these	O
+developed	O
+a	O
+severe	O
+,	O
+fatal	O
+nervous	B-DISO
+form	O
+15	O
+days	O
+later	O
+.	O
+
+Most	O
+importantly	O
+,	O
+the	O
+replicon	O
+RNA	O
+mediates	O
+reporter	O
+gene	B-PROC
+expression	I-PROC
+as	O
+a	O
+marker	O
+for	O
+coronavirus	B-SPEC
+replication	O
+.	O
+
+We	O
+have	O
+used	O
+a	O
+replicon	O
+RNA	O
+-	O
+containing	O
+cell	B-ANAT
+line	I-ANAT
+to	O
+test	O
+the	O
+inhibitory	O
+effect	O
+of	O
+several	O
+compounds	O
+that	O
+are	O
+currently	O
+being	O
+assessed	O
+for	O
+SARS	B-DISO
+treatment	O
+.	O
+
+Staff	O
+personal	O
+protection	O
+,	O
+patient	O
+risk	O
+categorization	O
+,	O
+and	O
+reorganization	O
+of	O
+operating	O
+room	O
+workflow	O
+processes	O
+formed	O
+the	O
+key	O
+elements	O
+for	O
+the	O
+containment	O
+of	O
+SARS	B-DISO
+transmission	O
+.	O
+
+One	O
+hundred	O
+twenty	O
+-	O
+four	O
+healthcare	O
+workers	O
+had	O
+direct	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+during	O
+these	O
+procedures	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+epidemiology	O
+of	O
+ALI	O
+and	O
+ARDS	B-DISO
+has	O
+some	O
+issues	O
+to	O
+improve	O
+,	O
+such	O
+as	O
+the	O
+accuracy	O
+of	O
+the	O
+clinical	O
+criteria	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+This	O
+paper	O
+reviews	O
+the	O
+current	O
+status	O
+of	O
+this	O
+knowledge	O
+base	O
+,	O
+with	O
+particular	O
+reference	O
+to	O
+the	O
+critically	B-DISO
+ill	I-DISO
+patient	O
+.	O
+
+It	O
+would	O
+use	O
+clusters	B-CHED
+of	O
+symptoms	O
+tied	O
+to	O
+temporal	O
+,	O
+demographic	O
+and	O
+spatial	O
+data	O
+to	O
+increase	O
+sensitivity	O
+and	O
+specificity	O
+.	O
+
+Emergency	B-DISO
+departments	O
+and	O
+Telehealth	O
+in	O
+Ontario	O
+lend	O
+themselves	O
+as	O
+first	O
+contacts	O
+to	O
+the	O
+healthcare	O
+system	O
+as	O
+excellent	O
+opportunities	O
+to	O
+perform	O
+syndrome	B-DISO
+surveillance	O
+.	O
+
+Interviews	O
+were	O
+conducted	O
+with	O
+key	O
+informants	O
+from	O
+Telehealth	O
+staff	O
+,	O
+the	O
+public	O
+health	O
+services	O
+of	O
+Ontario	O
+and	O
+the	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+,	O
+Atlanta	B-SPEC
+,	O
+GA	O
+,	O
+USA	O
+.	O
+
+ABSTRACT	O
+:	O
+Nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+(	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+)	O
+is	O
+a	O
+transcription	B-PROC
+factor	O
+which	O
+plays	O
+a	O
+pivotal	O
+role	O
+in	O
+the	O
+induction	O
+of	O
+genes	O
+involved	O
+in	O
+the	O
+response	O
+to	O
+injury	O
+and	O
+inflammation	B-DISO
+.	O
+
+Intraperitoneal	O
+injection	O
+of	O
+cerulein	B-CHED
+in	O
+mice	O
+resulted	O
+in	O
+severe	O
+,	O
+acute	B-DISO
+pancreatitis	I-DISO
+characterised	O
+by	O
+oedema	B-DISO
+,	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+,	O
+tissue	B-ANAT
+haemorrhage	B-DISO
+and	O
+necrosis	B-PROC
+and	O
+elevated	O
+serum	B-COMP
+levels	O
+of	O
+amylase	B-PRGE
+and	O
+lipase	B-PRGE
+.	O
+
+It	O
+is	O
+known	O
+for	O
+some	O
+viruses	B-SPEC
+(	O
+including	O
+members	O
+of	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+)	O
+that	O
+CPE	B-PRGE
+can	O
+be	O
+caused	O
+either	O
+by	O
+virus	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+(	O
+active	O
+death	B-PROC
+)	O
+or	O
+cell	B-COMP
+necrosis	B-PROC
+(	O
+passive	O
+death	B-PROC
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+examined	O
+the	O
+apoptosis	B-PATH
+in	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Indeed	O
+,	O
+the	O
+results	O
+do	O
+show	O
+that	O
+the	O
+CPE	O
+was	O
+induced	O
+by	O
+apoptosis	B-PATH
+rather	O
+than	O
+necrosis	B-PROC
+,	O
+shown	O
+by	O
+typical	O
+DNA	B-PROC
+fragmentation	I-PROC
+,	O
+through	O
+the	O
+existence	O
+of	O
+apoptotic	O
+bodies	O
+and	O
+swollen	O
+mitochondria	O
+.	O
+
+TITLE	O
+:	O
+The	O
+life	O
+cycle	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Serial	O
+serum	B-COMP
+specimens	O
+from	O
+12	O
+RT	O
+-	O
+PCR	O
+-	O
+confirmed	O
+SARS	B-DISO
+patients	O
+were	O
+assayed	O
+by	O
+ELISA	O
+using	O
+the	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+as	O
+coated	O
+antigen	B-CHED
+.	O
+
+Children	O
+are	O
+susceptible	O
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Development	B-PROC
+and	O
+evaluation	O
+of	O
+the	O
+kit	B-FUNC
+for	O
+detection	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+Coronavirus	I-DISO
+RNA	O
+].	O
+
+Testing	O
+of	O
+clinical	O
+samples	O
+from	O
+patients	O
+with	O
+suspected	O
+SARS	B-DISO
+showed	O
+that	O
+diagnostic	O
+sensitivity	O
+of	O
+the	O
+kit	B-FUNC
+was	O
+95	O
+%.	O
+
+The	O
+emergence	O
+of	O
+new	O
+respiratory	O
+viruses	B-SPEC
+and	O
+a	O
+high	O
+probability	O
+that	O
+influenza	B-DISO
+will	O
+cause	O
+further	O
+pandemics	O
+highlights	O
+the	O
+necessity	O
+for	O
+developing	O
+better	O
+preventative	O
+strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+Non	O
+-	O
+compliance	O
+with	O
+treatment	O
+of	O
+pulmonary	O
+tuberculosis	B-PATH
+(	O
+TB	B-PATH
+)	O
+by	O
+an	O
+individual	O
+can	O
+put	O
+the	O
+community	O
+at	O
+risk	O
+of	O
+transmission	O
+of	O
+TB	B-PATH
+.	O
+
+Two	O
+recent	O
+cases	O
+in	O
+New	O
+South	O
+Wales	O
+illustrate	O
+the	O
+process	O
+of	O
+issuing	O
+a	O
+public	O
+health	O
+order	B-SPEC
+in	O
+NSW	O
+,	O
+and	O
+some	O
+of	O
+the	O
+issues	O
+that	O
+may	O
+arise	O
+.	O
+
+The	O
+NSW	O
+law	O
+can	O
+also	O
+be	O
+applied	O
+to	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+or	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+.	O
+
+TITLE	O
+:	O
+Common	O
+respiratory	O
+manifestations	O
+of	O
+food	B-DISO
+allergy	I-DISO
+:	O
+a	O
+critical	O
+focus	O
+on	O
+otitis	B-DISO
+media	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+investigations	O
+have	O
+established	O
+the	O
+pathogenic	O
+role	O
+of	O
+food	O
+allergy	O
+in	O
+respiratory	B-ANAT
+tract	I-ANAT
+symptoms	O
+,	O
+which	O
+rarely	O
+occur	O
+in	O
+isolation	O
+.	O
+
+During	O
+an	O
+outbreak	O
+,	O
+active	O
+in	O
+-	O
+hospital	O
+surveillance	O
+for	O
+SARS	B-DISO
+-	O
+like	O
+illnesses	O
+and	O
+heightened	O
+infection	B-DISO
+-	O
+control	O
+measures	O
+are	O
+essential	O
+.	O
+
+In	O
+response	O
+to	O
+the	O
+control	O
+measures	O
+of	O
+Toronto	O
+Public	O
+Health	O
+,	O
+the	O
+number	O
+of	O
+persons	O
+who	O
+were	O
+exposed	O
+to	O
+SARS	B-DISO
+in	O
+nonhospital	O
+and	O
+nonhousehold	O
+settings	O
+dropped	O
+from	O
+20	O
+(	O
+13	O
+percent	O
+)	O
+before	O
+the	O
+control	O
+measures	O
+were	O
+instituted	O
+(	O
+phase	O
+1	O
+)	O
+to	O
+0	O
+afterward	O
+(	O
+phase	O
+2	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+polyneuropathy	I-DISO
+and	O
+encephalopathy	B-DISO
+caused	O
+by	O
+arsenic	B-CHED
+poisoning	O
+].	O
+
+Instead	O
+of	O
+chelating	B-PROC
+therapy	O
+patient	O
+died	B-PROC
+due	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+investigated	O
+the	O
+relationship	O
+between	O
+hospital	O
+nurses	O
+'	O
+professional	O
+care	O
+obligation	O
+,	O
+their	O
+attitudes	O
+towards	O
+SARS	O
+infection	B-DISO
+control	O
+measures	O
+,	O
+whether	O
+they	O
+had	O
+ever	O
+cared	O
+for	O
+SARS	B-DISO
+patients	O
+,	O
+their	O
+current	O
+health	O
+status	O
+,	O
+selected	O
+demographic	O
+characteristics	O
+,	O
+and	O
+the	O
+time	O
+frame	O
+of	O
+the	O
+data	O
+collection	O
+(	O
+from	O
+May	O
+6	O
+to	O
+May	O
+12	O
+2003	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+and	O
+from	O
+June	O
+17	O
+to	O
+June	O
+24	O
+2003	O
+after	O
+the	O
+SARS	B-DISO
+epidemic	O
+).	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+a	O
+virulent	O
+canine	O
+coronavirus	B-SPEC
+BGF	O
+strain	O
+.	O
+
+The	O
+binding	B-FUNC
+strength	O
+of	O
+each	O
+of	O
+the	O
+X	O
+(	O
+j	O
+)	O
+reagents	B-CHED
+to	O
+each	O
+other	O
+is	O
+measured	O
+,	O
+for	O
+example	O
+by	O
+an	O
+ELISA	O
+assay	O
+,	O
+giving	O
+an	O
+N	O
+x	O
+N	O
+matrix	O
+K	O
+.	O
+The	O
+matrix	O
+K	O
+is	O
+used	O
+to	O
+define	O
+another	O
+set	O
+of	O
+N	O
+reagents	B-CHED
+called	O
+Y	O
+(	O
+j	O
+),	O
+with	O
+j	O
+=	O
+1	O
+to	O
+N	O
+,	O
+each	O
+of	O
+which	O
+is	O
+a	O
+linear	O
+combination	O
+of	O
+the	O
+X	O
+(	O
+j	O
+)	O
+reagents	B-CHED
+and	O
+each	O
+of	O
+which	O
+is	O
+tailored	O
+to	O
+be	O
+complementary	O
+to	O
+one	O
+of	O
+the	O
+X	O
+(	O
+j	O
+)	O
+reagents	B-CHED
+.	O
+
+The	O
+definition	O
+of	O
+these	O
+axes	O
+facilitates	O
+proteomic	O
+analysis	O
+of	O
+diverse	O
+biological	O
+samples	O
+,	O
+for	O
+example	O
+,	O
+mixtures	O
+of	O
+proteins	B-CHED
+such	O
+as	O
+serum	B-COMP
+samples	O
+or	O
+T	O
+cell	B-ANAT
+extracts	I-ANAT
+.	O
+
+This	O
+leads	O
+to	O
+methods	O
+for	O
+using	O
+the	O
+N	O
+reagent	B-CHED
+pairs	O
+in	O
+the	O
+diagnosis	O
+of	O
+diseases	O
+and	O
+in	O
+the	O
+formulation	O
+of	O
+preventive	O
+and	O
+therapeutic	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+passing	O
+of	O
+more	O
+than	O
+a	O
+year	O
+since	O
+the	O
+first	O
+outbreak	O
+of	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+),	O
+efficient	O
+counter	B-CHED
+-	O
+measures	O
+are	O
+still	O
+few	O
+and	O
+many	O
+believe	O
+that	O
+reappearance	O
+of	O
+SARS	B-DISO
+,	O
+or	O
+a	O
+similar	O
+disease	O
+caused	O
+by	O
+a	O
+coronavirus	B-SPEC
+,	O
+is	O
+not	O
+unlikely	O
+.	O
+
+For	O
+other	O
+virus	B-SPEC
+families	O
+like	O
+the	O
+picornaviruses	B-SPEC
+it	O
+is	O
+known	O
+that	O
+pathology	B-DISO
+is	O
+related	O
+to	O
+proteolytic	B-PROC
+cleavage	B-PROC
+of	O
+host	B-COMP
+proteins	B-CHED
+by	O
+viral	O
+proteinases	O
+.	O
+
+Furthermore	O
+,	O
+several	O
+studies	O
+indicate	O
+that	O
+virus	B-SPEC
+proliferation	B-DISO
+can	O
+be	O
+arrested	B-DISO
+using	O
+specific	O
+proteinase	B-PROC
+inhibitors	B-CHED
+supporting	O
+the	O
+belief	O
+that	O
+proteinases	O
+are	O
+indeed	O
+important	O
+during	O
+infection	B-DISO
+.	O
+
+Cleavage	B-PROC
+sites	O
+were	O
+predicted	O
+in	O
+proteins	B-CHED
+such	O
+as	O
+the	O
+cystic	B-PROC
+fibrosis	I-PROC
+transmembrane	B-COMP
+conductance	I-PROC
+regulator	I-PROC
+(	O
+CFTR	B-PRGE
+),	O
+transcription	B-PROC
+factors	O
+CREB	B-PRGE
+-	I-PRGE
+RP	I-PRGE
+and	O
+OCT	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+and	O
+components	O
+of	O
+the	O
+ubiquitin	B-PROC
+pathway	B-PROC
+.	O
+
+Cleavage	B-PROC
+sites	O
+were	O
+predicted	O
+in	O
+proteins	B-CHED
+such	O
+as	O
+the	O
+cystic	B-PROC
+fibrosis	I-PROC
+transmembrane	B-COMP
+conductance	I-PROC
+regulator	I-PROC
+(	O
+CFTR	B-PRGE
+),	O
+transcription	B-PROC
+factors	O
+CREB	B-PRGE
+-	I-PRGE
+RP	I-PRGE
+and	O
+OCT	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+and	O
+components	O
+of	O
+the	O
+ubiquitin	B-PROC
+pathway	B-PROC
+.	O
+
+None	O
+of	O
+the	O
+discharged	O
+survivors	O
+required	O
+continuation	O
+of	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+Her	O
+CXR	O
+showed	O
+features	O
+suggestive	O
+of	O
+pneumomediastinum	B-DISO
+,	O
+which	O
+was	O
+confirmed	O
+by	O
+high	O
+-	O
+resolution	O
+CT	O
+scan	O
+of	O
+the	O
+thorax	B-ANAT
+.	O
+
+(	O
+1	O
+)	O
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+image	O
+:	O
+among	O
+45	O
+cases	O
+,	O
+23	O
+were	O
+common	O
+type	O
+:	O
+the	O
+time	O
+to	O
+appearance	O
+of	O
+unilateral	O
+patched	O
+shadow	O
+of	O
+the	O
+lung	B-ANAT
+were	O
+2	O
+to	O
+5	O
+(	O
+2	O
+.	O
+9	O
++/-	O
+
+Noticeably	O
+,	O
+the	O
+time	O
+to	O
+pan	B-COMP
+-	O
+consolidation	O
+of	O
+the	O
+lung	B-ANAT
+were	O
+less	O
+than	O
+7	O
+days	O
+in	O
+7	O
+fatal	O
+cases	O
+.	O
+
+Moreover	O
+,	O
+this	O
+construct	O
+significantly	O
+reduced	O
+the	O
+plaque	B-DISO
+formation	B-PROC
+of	O
+SARS	B-DISO
+coronaviruses	O
+in	O
+Vero	O
+-	O
+E6	O
+cells	B-COMP
+.	O
+
+Phylogeny	O
+-	O
+based	O
+clustering	O
+based	O
+on	O
+replicase	B-PRGE
+genes	I-PRGE
+was	O
+identical	O
+to	O
+the	O
+antigen	B-CHED
+-	O
+based	O
+classification	O
+of	O
+coronaviruses	O
+into	O
+three	O
+groups	O
+.	O
+
+A	O
+number	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+were	O
+developed	O
+against	O
+the	O
+fusion	O
+protein	B-CHED
+.	O
+
+Using	O
+a	O
+panel	O
+of	O
+sera	B-COMP
+collected	O
+at	O
+different	O
+points	O
+in	O
+time	O
+,	O
+the	O
+amount	O
+of	O
+circulating	O
+N	B-PRGE
+antigen	I-PRGE
+was	O
+found	O
+to	O
+peak	O
+6	O
+to	O
+10	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+efficiency	O
+detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+genetic	O
+material	O
+.	O
+
+The	O
+review	O
+and	O
+study	O
+of	O
+these	O
+papers	O
+'	O
+headlines	O
+highlight	O
+the	O
+intense	O
+media	B-ANAT
+coverage	O
+given	O
+in	O
+the	O
+French	O
+press	O
+primarily	O
+from	O
+April	O
+to	O
+May	O
+2003	O
+,	O
+accompanied	O
+by	O
+an	O
+evolution	B-PROC
+of	O
+the	O
+themes	O
+being	O
+tackled	O
+above	O
+all	O
+which	O
+concerned	O
+the	O
+world	O
+-	O
+wide	O
+alert	O
+from	O
+WHO	O
+which	O
+originally	O
+comprised	O
+the	O
+countries	O
+of	O
+the	O
+East	O
+(	O
+mainly	O
+China	O
+)	O
+as	O
+well	O
+as	O
+Canada	O
+,	O
+European	O
+countries	O
+(	O
+including	O
+France	O
+)	O
+and	O
+finally	O
+whose	O
+scale	O
+reached	O
+that	O
+of	O
+global	O
+proportions	O
+.	O
+
+Plasma	B-ANAT
+was	O
+harvested	O
+for	O
+detection	B-PROC
+of	I-PROC
+virus	I-PROC
+load	O
+,	O
+cytokines	O
+,	O
+and	O
+nitrite	B-CHED
+/	O
+nitrate	B-CHED
+levels	O
+,	O
+and	O
+blood	B-ANAT
+leukocytes	I-ANAT
+were	O
+subjected	O
+to	O
+flow	O
+cytometric	O
+analysis	O
+of	O
+intracellular	B-COMP
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinases	I-PRGE
+(	O
+MAPKs	O
+)	O
+in	O
+different	O
+leukocytes	B-ANAT
+.	O
+
+Patients	O
+with	O
+SARS	B-DISO
+had	O
+significantly	O
+higher	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+levels	O
+(	O
+p	O
+=	O
+0	O
+.	O
+016	O
+)	O
+in	O
+early	O
+stage	O
+,	O
+and	O
+higher	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+levels	O
+(	O
+p	O
+=	O
+0	O
+.	O
+039	O
+)	O
+in	O
+late	O
+stage	O
+than	O
+normal	O
+controls	O
+.	O
+
+In	O
+contrast	O
+,	O
+TGF	O
+-	O
+beta	O
+and	O
+PGE	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+levels	O
+were	O
+significantly	O
+elevated	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+complete	O
+nucleotide	O
+sequences	O
+of	O
+the	O
+S1	O
+and	O
+N	O
+genes	O
+of	O
+three	O
+Japanese	O
+and	O
+one	O
+Taiwanese	O
+field	O
+strains	O
+of	O
+IBV	B-SPEC
+are	O
+reported	O
+.	O
+
+Moreover	O
+,	O
+the	O
+S1	O
+proteins	B-CHED
+of	O
+all	O
+these	O
+Japanese	O
+and	O
+Taiwanese	O
+strains	O
+exhibit	O
+only	O
+a	O
+limited	O
+sequence	O
+homology	O
+to	O
+strains	O
+of	O
+Massachusetts	O
+and	O
+Connecticut	O
+serotypes	O
+that	O
+have	O
+been	O
+commonly	O
+used	O
+as	O
+vaccine	O
+strains	O
+.	O
+
+Furthermore	O
+,	O
+small	O
+pneumothoraces	O
+in	O
+these	O
+patients	O
+can	O
+cause	O
+severe	O
+hemodynamic	B-PROC
+or	O
+pulmonary	B-ANAT
+compromise	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Preparatory	O
+guidelines	O
+for	O
+local	O
+health	O
+services	O
+on	O
+how	O
+to	O
+respond	O
+to	O
+new	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)].	O
+
+The	O
+Trx	B-PRGE
+-	O
+S2	O
+fusion	O
+protein	B-CHED
+was	O
+expressed	B-PROC
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+The	O
+fusion	O
+protein	B-CHED
+could	O
+react	O
+with	O
+all	O
+the	O
+sera	B-COMP
+from	O
+convalescent	O
+SARS	B-DISO
+patients	O
+but	O
+not	O
+with	O
+the	O
+sera	B-COMP
+from	O
+healthy	O
+donors	O
+.	O
+
+RESULTS	O
+:	O
+According	O
+to	O
+the	O
+SDS	B-DISO
+-	O
+PAGE	O
+analysis	O
+,	O
+the	O
+relative	O
+molecular	O
+mass	O
+(	O
+M	O
+(	O
+r	O
+))	O
+of	O
+the	O
+Trx	O
+-	O
+S2	O
+fusion	O
+protein	O
+is	O
+about	O
+76	O
+x	O
+10	O
+(	O
+3	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+changes	O
+of	O
+peripheral	O
+blood	O
+T	B-ANAT
+cell	I-ANAT
+subsets	I-ANAT
+and	O
+their	O
+activated	O
+molecules	O
+in	O
+convalescent	O
+SARS	B-DISO
+patients	O
+.	O
+
+As	O
+for	O
+the	O
+percentages	O
+of	O
+CD3	B-PRGE
+(+),	O
+CD8	B-PRGE
+(+),	O
+CD4	B-PRGE
+(+)/	O
+CD8	B-PRGE
+(+),	O
+CD3	B-PRGE
+(+)	I-PRGE
+CD25	I-PRGE
+(+),	I-PRGE
+CD3	B-PRGE
+(+)	I-PRGE
+CD69	I-PRGE
+(+)	I-PRGE
+and	O
+CD3	B-PRGE
+(+)	I-PRGE
+HLA	I-PRGE
+-	I-PRGE
+DR	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+there	O
+was	O
+marked	O
+difference	O
+between	O
+1st	O
+and	O
+2nd	O
+follow	O
+-	O
+up	O
+results	O
+,	O
+but	O
+for	O
+other	O
+molecules	O
+there	O
+was	O
+no	O
+notable	O
+difference	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+this	O
+vaccine	O
+,	O
+when	O
+administered	O
+to	O
+previously	O
+sensitized	O
+gilts	O
+,	O
+can	O
+boost	O
+neutralizing	O
+antibody	B-COMP
+levels	O
+in	O
+the	O
+animals	B-SPEC
+'	O
+serum	B-COMP
+,	O
+colostrum	B-ANAT
+and	O
+milk	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+receptor	O
+for	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+However	O
+,	O
+viral	B-PROC
+protein	I-PROC
+synthesis	I-PROC
+was	O
+not	O
+affected	O
+by	O
+treatment	O
+of	O
+SB203580	O
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+protein	B-CHED
+,	O
+U274	O
+,	O
+is	O
+transported	O
+to	O
+the	O
+cell	B-ANAT
+surface	I-ANAT
+and	O
+undergoes	O
+endocytosis	B-PATH
+.	O
+
+In	O
+addition	O
+,	O
+this	O
+genome	O
+also	O
+contains	O
+nine	O
+other	O
+potential	O
+ORFs	O
+varying	O
+in	O
+length	O
+from	O
+39	O
+to	O
+274	O
+amino	B-CHED
+acids	I-CHED
+.	O
+
+Deletion	O
+of	O
+a	O
+cytoplasmic	B-ANAT
+domain	I-ANAT
+of	O
+U274	O
+,	O
+which	O
+contains	O
+Yxxphi	O
+and	O
+diacidic	O
+motifs	O
+,	O
+abolished	O
+its	O
+transport	B-PROC
+to	O
+the	O
+cell	B-COMP
+surface	I-COMP
+.	O
+
+A	O
+protein	B-CHED
+fragment	O
+(	O
+S	O
+-	O
+II	O
+)	O
+containing	O
+predicted	O
+epitopes	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+was	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+These	O
+monoclonal	O
+antibodies	B-COMP
+were	O
+capable	O
+of	O
+blocking	B-DISO
+S	O
+-	O
+II	O
+attachment	O
+to	O
+Vero	B-ANAT
+cells	I-ANAT
+and	O
+exhibited	O
+in	O
+vitro	O
+antiviral	B-CHED
+activity	O
+.	O
+
+To	O
+investigate	O
+SCoV	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+,	O
+full	O
+-	O
+length	O
+and	O
+individual	O
+domains	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+were	O
+expressed	B-PROC
+on	O
+the	O
+surface	O
+of	O
+insect	B-SPEC
+cells	B-COMP
+and	O
+were	O
+characterized	O
+for	O
+cleavability	O
+and	O
+reactivity	O
+with	O
+serum	B-COMP
+samples	O
+obtained	O
+from	O
+patients	O
+during	O
+the	O
+convalescent	O
+phase	O
+of	O
+SARS	B-DISO
+.	O
+
+Recombinant	O
+SCoV	O
+S	O
+protein	O
+appears	O
+to	O
+be	O
+a	O
+suitable	O
+antigen	B-CHED
+for	O
+the	O
+development	B-PROC
+of	O
+an	O
+efficient	O
+and	O
+sensitive	O
+diagnostic	O
+test	O
+for	O
+SARS	B-DISO
+,	O
+but	O
+our	O
+data	O
+suggest	O
+that	O
+assay	O
+format	O
+and	O
+choice	O
+of	O
+S	B-PRGE
+antigen	I-PRGE
+are	O
+important	O
+considerations	O
+.	O
+
+The	O
+percentage	O
+of	O
+intrahepatic	O
+NK1	B-PRGE
+.	I-PRGE
+1	I-PRGE
+(+)	I-PRGE
+T	I-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+(	O
+TCR	B-COMP
+)-	O
+cells	B-COMP
+did	O
+not	O
+increase	O
+while	O
+NK1	B-PRGE
+.	I-PRGE
+1	I-PRGE
+(+)	I-PRGE
+TCR	O
+(	O
+inter	O
+)	O
+cells	B-COMP
+decreased	O
+in	O
+both	O
+L2	O
+-	O
+MHV3	O
+-	O
+and	O
+YAC	O
+-	O
+MHV3	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+on	O
+the	O
+status	O
+of	O
+lung	B-DISO
+cancer	B-SPEC
+chemotherapy	O
+patients	O
+and	O
+a	O
+correlation	O
+of	O
+the	O
+signs	O
+and	O
+symptoms	O
+.	O
+
+The	O
+patients	O
+filled	O
+out	O
+questionnaires	O
+regarding	O
+lung	B-DISO
+cancer	B-SPEC
+treatment	O
+and	O
+the	O
+risk	O
+of	O
+getting	O
+SARS	B-DISO
+from	O
+the	O
+hospital	O
+.	O
+
+Twenty	O
+-	O
+one	O
+patients	O
+(	O
+36	O
+.	O
+2	O
+%)	O
+felt	O
+that	O
+a	O
+SARS	B-DISO
+infection	B-DISO
+was	O
+more	O
+severe	O
+and	O
+fatal	O
+than	O
+their	O
+lung	B-DISO
+cancer	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Misleading	O
+chest	B-ANAT
+radiography	O
+in	O
+a	O
+patient	O
+with	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+PiCCO	O
+monitoring	O
+of	O
+4	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+].	O
+
+The	O
+risks	O
+and	O
+complications	O
+of	O
+the	O
+usual	O
+method	O
+of	O
+monitoring	O
+by	O
+Swan	B-SPEC
+-	O
+Ganz	O
+catheter	O
+are	O
+well	O
+-	O
+known	O
+.	O
+
+Six	O
+others	O
+,	O
+with	O
+different	O
+working	O
+patterns	O
+,	O
+indicated	O
+that	O
+they	O
+did	O
+not	O
+have	O
+contact	O
+with	O
+a	O
+SARS	B-DISO
+patient	O
+.	O
+
+Tracheal	B-ANAT
+aspirate	I-ANAT
+and	O
+stool	B-ANAT
+samples	O
+had	O
+a	O
+higher	O
+diagnostic	O
+yield	O
+(	O
+RT	O
+-	O
+PCR	O
+average	O
+positive	O
+rate	O
+for	O
+first	O
+2	O
+weeks	O
+:	O
+66	O
+.	O
+7	O
+%	O
+and	O
+56	O
+.	O
+5	O
+%,	O
+respectively	O
+).	O
+
+The	O
+collection	O
+procedures	O
+for	O
+stool	B-ANAT
+and	O
+pooled	O
+nasal	B-ANAT
+and	O
+throat	B-ANAT
+swab	I-ANAT
+specimens	O
+were	O
+the	O
+least	O
+likely	O
+to	O
+transmit	O
+infection	O
+,	O
+and	O
+the	O
+combination	O
+gave	O
+the	O
+highest	O
+yield	O
+for	O
+coronavirus	B-SPEC
+detection	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+found	O
+infrequent	O
+transmission	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+to	O
+healthcare	O
+workers	O
+involved	O
+in	O
+the	O
+care	O
+of	O
+the	O
+first	O
+five	O
+case	O
+-	O
+patients	O
+in	O
+Taiwan	O
+,	O
+despite	O
+a	O
+substantial	O
+number	O
+of	O
+unprotected	O
+exposures	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+vitro	O
+with	O
+clinically	O
+approved	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+A	O
+drug	O
+-	O
+screening	O
+assay	O
+that	O
+scores	O
+for	O
+virus	B-SPEC
+-	O
+induced	O
+cytopathic	B-DISO
+effects	I-DISO
+on	O
+cultured	B-ANAT
+cells	I-ANAT
+was	O
+used	O
+.	O
+
+In	O
+Hong	O
+Kong	O
+,	O
+therefore	O
+,	O
+community	O
+-	O
+acquired	O
+infection	O
+did	O
+not	O
+make	O
+up	O
+most	O
+transmissions	O
+,	O
+and	O
+public	O
+health	O
+measures	O
+have	O
+contributed	O
+substantially	O
+to	O
+the	O
+control	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+Potential	O
+targets	O
+for	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+in	O
+the	O
+structural	O
+proteins	B-CHED
+from	O
+SARS	B-DISO
+related	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+replication	O
+and	O
+pathogenesis	B-DISO
+:	O
+Implications	O
+for	O
+the	O
+recent	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+the	O
+challenge	O
+for	O
+vaccine	O
+development	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+has	O
+been	O
+recently	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+that	O
+has	O
+accounted	O
+for	O
+more	O
+than	O
+8000	O
+infected	O
+people	O
+worldwide	O
+.	O
+
+A	O
+total	O
+of	O
+1	O
+,	O
+454	O
+clinically	O
+confirmed	O
+cases	O
+(	O
+and	O
+55	O
+deaths	B-PROC
+)	O
+occurred	O
+;	O
+the	O
+epidemic	O
+peak	O
+was	O
+in	O
+the	O
+first	O
+week	O
+of	O
+February	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+construct	O
+an	O
+expression	O
+vector	O
+pGEX	O
+-	O
+2T	O
+/	O
+N	O
+,	O
+and	O
+to	O
+express	O
+the	O
+fusion	O
+protein	B-CHED
+consisting	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+GST	B-PRGE
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+(	O
+1	O
+)	O
+As	O
+compared	O
+with	O
+the	O
+sequences	O
+in	O
+GenBank	O
+,	O
+20	O
+bp	O
+were	O
+deleted	O
+in	O
+DNA	O
+sequence	O
+of	O
+the	O
+cloned	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+the	O
+incidence	O
+of	O
+avascular	O
+osteonecrosis	O
+(	O
+AVN	O
+)	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+.	O
+
+Sixty	O
+-	O
+seven	O
+SARS	B-DISO
+patients	O
+who	O
+had	O
+large	O
+joint	B-DISO
+pain	I-DISO
+between	O
+March	O
+2003	O
+and	O
+May	O
+2003	O
+underwent	O
+both	O
+plain	O
+radiographs	O
+and	O
+magnetic	O
+resonance	O
+imaging	O
+(	O
+MRI	O
+)	O
+examination	O
+on	O
+the	O
+same	O
+day	O
+.	O
+
+CONCLUSIONS	O
+:	O
+AVN	O
+can	O
+occur	O
+in	O
+the	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+patient	O
+had	O
+previously	O
+presented	O
+to	O
+the	O
+emergency	B-DISO
+department	O
+with	O
+multiple	O
+fractures	O
+and	O
+hemodynamic	B-DISO
+instability	I-DISO
+sustained	O
+in	O
+a	O
+motor	O
+vehicle	O
+accident	O
+.	O
+
+The	O
+patient	O
+was	O
+returned	O
+to	O
+the	O
+supine	O
+position	O
+,	O
+but	O
+despite	O
+maneuvers	O
+to	O
+improve	O
+oxygen	B-CHED
+saturation	O
+,	O
+the	O
+patient	O
+'	O
+s	O
+saturation	O
+remained	O
+below	O
+87	O
+%	O
+and	O
+pulmonary	O
+thromboembolism	O
+was	O
+suspected	O
+.	O
+
+TITLE	O
+:	O
+Childhood	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+coronavirus	B-DISO
+infections	I-DISO
+and	O
+asthma	B-PATH
+.	O
+
+TITLE	O
+:	O
+Contributions	O
+of	O
+the	O
+structural	O
+proteins	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+to	O
+protective	O
+immunity	O
+.	O
+
+This	O
+vector	O
+provided	O
+direct	O
+immunization	O
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+the	O
+major	O
+site	O
+of	O
+SARS	B-DISO
+transmission	O
+,	O
+replication	O
+,	O
+and	O
+disease	O
+.	O
+
+Immunization	O
+with	O
+BHPIV3	O
+expressing	O
+S	O
+provided	O
+complete	O
+protection	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+challenge	O
+in	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+partial	O
+protection	O
+in	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+TITLE	O
+:	O
+[	O
+Cardiogenic	B-DISO
+shock	I-DISO
+associated	O
+with	O
+inappropriate	O
+nutritional	O
+regimen	O
+:	O
+refeeding	B-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+Reviewed	O
+are	O
+the	O
+clinical	O
+features	O
+and	O
+outcome	O
+of	O
+12	O
+chronic	O
+dialysis	O
+patients	O
+(	O
+six	O
+men	O
+)	O
+who	O
+contracted	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+compared	O
+with	O
+23	O
+sex	O
+-	O
+and	O
+age	O
+-	O
+matched	O
+nonuremic	O
+SARS	B-DISO
+patients	O
+as	O
+controls	O
+.	O
+
+Three	O
+dialysis	B-SPEC
+patients	O
+had	O
+persistent	O
+positive	O
+stool	B-ANAT
+PCR	O
+after	O
+5	O
+wk	O
+,	O
+whereas	O
+all	O
+nondialysis	O
+patients	O
+had	O
+negative	O
+stool	B-ANAT
+PCR	O
+after	O
+1	O
+wk	O
+.	O
+
+TITLE	O
+:	O
+Retrospective	O
+comparison	O
+of	O
+convalescent	O
+plasma	B-ANAT
+with	O
+continuing	O
+high	O
+-	O
+dose	O
+methylprednisolone	B-CHED
+treatment	O
+in	O
+SARS	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+replication	O
+by	O
+niclosamide	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+in	O
+newborns	O
+and	O
+children	O
+.	O
+
+Infants	O
+born	O
+to	O
+pregnant	O
+women	O
+with	O
+SARS	B-DISO
+did	O
+not	O
+appear	O
+to	O
+acquire	O
+the	O
+infection	B-DISO
+through	O
+vertical	B-DISO
+transmission	I-DISO
+.	O
+
+TITLE	O
+:	O
+Spontaneous	O
+pneumomediastinum	B-DISO
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+examine	O
+the	O
+incidence	O
+,	O
+risk	O
+factors	O
+and	O
+the	O
+outcomes	O
+of	O
+SP	O
+in	O
+a	O
+cohort	O
+of	O
+SARS	B-DISO
+victims	O
+from	O
+a	O
+community	O
+outbreak	O
+.	O
+
+Drainage	B-ANAT
+was	O
+required	O
+in	O
+five	O
+cases	O
+.	O
+
+Chickens	B-SPEC
+immunized	O
+orally	B-ANAT
+and	O
+intramuscularly	O
+with	O
+transgenic	O
+potato	B-SPEC
+tubers	B-SPEC
+expressing	O
+S	O
+protein	B-CHED
+generated	O
+the	O
+detectable	O
+levels	O
+of	O
+serum	B-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+and	O
+were	O
+protected	O
+against	O
+the	O
+challenge	O
+with	O
+the	O
+virulent	O
+IBV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Mucosal	B-ANAT
+immunisation	O
+of	O
+African	B-SPEC
+green	I-SPEC
+monkeys	I-SPEC
+(	O
+Cercopithecus	B-SPEC
+aethiops	I-SPEC
+)	O
+with	O
+an	O
+attenuated	O
+parainfluenza	B-DISO
+virus	B-SPEC
+expressing	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+for	O
+the	O
+prevention	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+2002	O
+was	O
+caused	O
+by	O
+a	O
+previously	O
+unknown	O
+coronavirus	B-SPEC
+-	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+a	O
+unique	O
+group	O
+-	O
+specific	O
+protein	B-CHED
+(	O
+U122	O
+)	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+U122	O
+was	O
+expressed	B-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+,	O
+as	O
+it	O
+could	O
+be	O
+detected	O
+by	O
+Western	O
+blot	O
+and	O
+immunofluorescence	O
+analyses	O
+.	O
+
+Mutational	O
+analyses	O
+showed	O
+that	O
+both	O
+the	O
+signal	O
+peptide	B-CHED
+sequence	O
+and	O
+ER	O
+retrieval	O
+motif	O
+were	O
+functional	O
+.	O
+
+A	O
+viable	O
+MHV	B-SPEC
+-	O
+SGFP	O
+was	O
+obtained	O
+,	O
+infection	B-DISO
+by	O
+which	O
+could	O
+be	O
+visualized	O
+by	O
+the	O
+fluorescence	O
+induced	O
+.	O
+
+Probably	O
+due	O
+to	O
+this	O
+disadvantage	O
+,	O
+deletion	O
+mutants	O
+,	O
+having	O
+lost	B-CHED
+the	O
+foreign	O
+sequences	O
+,	O
+rapidly	O
+evolved	O
+and	O
+outcompeted	O
+the	O
+chimeric	O
+viruses	B-SPEC
+during	O
+virus	B-SPEC
+propagation	O
+.	O
+
+To	O
+exploit	O
+the	O
+possibility	O
+of	O
+using	O
+RNA	B-PROC
+interference	I-PROC
+as	O
+a	O
+therapeutic	O
+approach	O
+to	O
+fight	O
+the	O
+disease	O
+,	O
+plasmid	O
+-	O
+mediated	O
+small	O
+interfering	O
+RNAs	O
+(	O
+siRNAs	O
+)	O
+were	O
+generated	O
+to	O
+target	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Pumpless	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+using	O
+arterio	B-ANAT
+-	I-ANAT
+venous	I-ANAT
+shunt	O
+in	O
+severe	O
+ARDS	B-DISO
+.	O
+
+For	O
+this	O
+system	O
+,	O
+only	O
+""""	O
+low	O
+dose	O
+""""	O
+continuous	O
+heparin	B-CHED
+infusion	O
+is	O
+required	O
+.	O
+
+The	O
+mean	O
+duration	O
+of	O
+pECLA	O
+therapy	O
+was	O
+6	O
+.	O
+5	O
+days	O
+,	O
+15	O
+patients	O
+(	O
+50	O
+%)	O
+died	B-PROC
+due	O
+to	O
+ARDS	B-DISO
+or	O
+non	O
+-	O
+ARDS	B-DISO
+related	O
+reasons	O
+.	O
+
+The	O
+mean	O
+duration	O
+of	O
+pECLA	O
+therapy	O
+was	O
+6	O
+.	O
+5	O
+days	O
+,	O
+15	O
+patients	O
+(	O
+50	O
+%)	O
+died	B-PROC
+due	O
+to	O
+ARDS	B-DISO
+or	O
+non	O
+-	O
+ARDS	B-DISO
+related	O
+reasons	O
+.	O
+
+CONCLUSIONS	O
+:	O
+pECLA	O
+represents	O
+a	O
+feasable	O
+and	O
+effective	O
+treatment	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+All	O
+other	O
+tissues	B-ANAT
+and	O
+cell	B-COMP
+types	O
+expressing	O
+ACE2	B-PRGE
+may	O
+be	O
+potential	O
+targets	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Moreover	O
+,	O
+the	O
+interaction	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+the	O
+immunological	O
+or	O
+lymphoid	B-ANAT
+system	I-ANAT
+remains	O
+to	O
+be	O
+defined	O
+.	O
+
+Pharmacists	O
+were	O
+actively	O
+involved	O
+in	O
+battling	O
+the	O
+SARS	B-DISO
+crises	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+caused	O
+a	O
+severe	O
+global	O
+epidemic	O
+in	O
+2003	O
+which	O
+led	O
+to	O
+hundreds	O
+of	O
+deaths	B-PROC
+and	O
+many	O
+thousands	O
+of	O
+hospitalizations	O
+.	O
+
+After	O
+a	O
+quiet	O
+summer	O
+and	O
+fall	O
+in	O
+2003	O
+,	O
+the	O
+newly	O
+emerged	O
+SARS	B-DISO
+cases	O
+in	O
+Asia	O
+,	O
+particularly	O
+the	O
+latest	O
+cases	O
+in	O
+China	O
+,	O
+are	O
+reinforcing	O
+a	O
+wide	O
+-	O
+spread	O
+belief	O
+that	O
+the	O
+SARS	B-DISO
+epidemic	O
+would	O
+strike	O
+back	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+examine	O
+the	O
+significance	O
+of	O
+interactions	O
+between	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+various	O
+respiratory	O
+pathogens	O
+during	O
+outbreaks	O
+of	O
+colibacillosis	B-DISO
+-	O
+associated	O
+mortality	O
+in	O
+layer	B-ANAT
+hen	O
+flocks	O
+under	O
+field	O
+conditions	O
+.	O
+
+The	O
+study	O
+failed	O
+to	O
+detect	O
+any	O
+consistent	O
+interactions	O
+between	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+the	O
+aforementioned	O
+pathogens	O
+.	O
+
+EE	O
+indices	O
+were	O
+also	O
+calculated	O
+by	O
+dividing	O
+the	O
+EE	O
+ratios	O
+of	O
+inoculated	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+by	O
+the	O
+mean	O
+EE	O
+ratio	O
+of	O
+uninoculated	O
+controls	O
+,	O
+or	O
+in	O
+the	O
+case	O
+of	O
+virus	B-PROC
+neutralization	I-PROC
+tests	O
+by	O
+the	O
+mean	O
+EE	O
+ratio	O
+of	O
+eggs	O
+inoculated	O
+with	O
+virus	B-SPEC
+alone	O
+.	O
+
+Although	O
+this	O
+mean	O
+EE	O
+index	O
+did	O
+not	O
+reflect	O
+the	O
+dwarfing	O
+(	O
+or	O
+lack	O
+of	O
+it	O
+)	O
+in	O
+individual	O
+eggs	O
+,	O
+it	O
+served	O
+as	O
+a	O
+group	O
+indicator	B-CHED
+.	O
+
+The	O
+cDNA	O
+derived	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+was	O
+cloned	O
+and	O
+sequenced	O
+.	O
+
+The	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+S1	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+had	O
+a	O
+similar	O
+degree	O
+of	O
+identity	O
+(>	O
+or	O
+=	O
+92	O
+%)	O
+among	O
+the	O
+five	O
+Chinese	O
+IBV	O
+isolates	O
+.	O
+
+This	O
+clearly	O
+showed	O
+that	O
+the	O
+five	O
+Chinese	O
+IBV	B-SPEC
+isolates	O
+comprised	O
+a	O
+separate	O
+genotype	O
+.	O
+
+4	O
+.	O
+4	O
+days	O
+of	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+).	O
+
+Currently	O
+,	O
+no	O
+effective	O
+antiviral	B-CHED
+agents	I-CHED
+exist	O
+against	O
+this	O
+type	O
+of	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+Singapore	O
+,	O
+of	O
+236	O
+patients	O
+with	O
+probable	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+2	O
+were	O
+coinfected	O
+with	O
+tuberculosis	B-PATH
+,	O
+a	O
+phenomenon	O
+not	O
+previously	O
+reported	O
+.	O
+
+Horse	B-SPEC
+polyclonal	O
+antibody	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+bound	O
+onto	O
+the	O
+PZ	O
+crystal	B-ANAT
+surface	O
+in	O
+an	O
+ordered	O
+orientation	O
+through	O
+protein	B-CHED
+A	O
+.	O
+The	O
+antigen	B-CHED
+sample	O
+was	O
+atomized	O
+into	O
+aerosol	O
+by	O
+an	O
+ultrasonator	O
+,	O
+by	O
+which	O
+the	O
+antibody	B-COMP
+on	O
+the	O
+crystal	B-ANAT
+could	O
+specifically	O
+adsorb	O
+SARS	B-PRGE
+antigen	B-CHED
+and	O
+the	O
+changed	O
+mass	O
+of	O
+crystal	B-ANAT
+would	O
+lead	O
+a	O
+frequency	O
+shift	O
+.	O
+
+Compared	O
+with	O
+IBV	B-SPEC
+strains	O
+from	O
+GenBank	O
+,	O
+the	O
+nucleotide	B-CHED
+and	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+isolate	O
+SC021202	O
+shared	O
+60	O
+.	O
+0	O
+-	O
+91	O
+.	O
+4	O
+%	O
+and	O
+49	O
+.	O
+1	O
+-	O
+88	O
+.	O
+9	O
+%	O
+identities	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+What	O
+do	O
+we	O
+do	O
+with	O
+the	O
+SARS	B-DISO
+reports	O
+?	O
+
+One	O
+week	O
+after	O
+the	O
+second	O
+immunization	O
+,	O
+mice	B-SPEC
+sera	B-COMP
+were	O
+collected	O
+to	O
+detect	O
+serum	B-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+possible	O
+risk	O
+factors	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndromes	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+workers	O
+from	O
+animal	B-SPEC
+markets	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Comparison	O
+among	O
+four	O
+kits	O
+in	O
+detection	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+in	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+compare	O
+the	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+four	O
+kits	O
+for	O
+detection	O
+of	O
+anti	O
+-	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+IgG	B-PRGE
+in	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+was	O
+first	O
+determined	O
+in	O
+sera	B-COMP
+on	O
+the	O
+9th	O
+day	O
+by	O
+Euroimmun	O
+IFA	O
+,	O
+12th	O
+day	O
+by	O
+EIA	B-DISO
+No	O
+.	O
+B	O
+,	O
+13th	O
+day	O
+by	O
+Australian	O
+IFA	O
+,	O
+and	O
+16th	O
+day	O
+by	O
+EIA	B-PRGE
+No	I-PRGE
+.	I-PRGE
+A	I-PRGE
+.	O
+The	O
+positive	O
+rates	O
+of	O
+antibody	B-COMP
+on	O
+the	O
+3rd	O
+week	O
+after	O
+onset	O
+were	O
+84	O
+.	O
+2	O
+%	O
+(	O
+16	O
+/	O
+19	O
+),	O
+94	O
+.	O
+7	O
+%	O
+(	O
+18	O
+/	O
+19	O
+),	O
+78	O
+.	O
+9	O
+%	O
+(	O
+15	O
+/	O
+19	O
+)	O
+and	O
+52	O
+.	O
+6	O
+%	O
+(	O
+10	O
+/	O
+19	O
+)	O
+respectively	O
+.	O
+
+Among	O
+3405	O
+subjects	O
+interviewed	O
+,	O
+more	O
+than	O
+95	O
+%	O
+gave	O
+right	O
+answers	O
+on	O
+the	O
+SARS	B-DISO
+related	O
+questions	O
+.	O
+
+All	O
+hospitals	O
+having	O
+received	O
+SARS	B-DISO
+inpatients	O
+were	O
+involved	O
+in	O
+the	O
+project	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+database	O
+involved	O
+2148	O
+probable	O
+SARS	B-DISO
+cases	O
+in	O
+accordant	O
+with	O
+the	O
+clinical	O
+diagnosis	O
+criteria	O
+,	O
+including	O
+1291	O
+with	O
+complete	O
+records	O
+.	O
+
+METHODS	O
+:	O
+1291	O
+hospital	O
+records	O
+of	O
+clinically	O
+diagnosed	O
+SARS	B-DISO
+patients	O
+with	O
+complete	O
+data	O
+gathered	O
+from	O
+""""	O
+2003	O
+Beijing	O
+SARS	B-DISO
+Clinical	O
+Database	O
+""""	O
+were	O
+analyzed	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Delayed	O
+hospitalization	O
+would	O
+cause	O
+the	O
+situation	O
+of	O
+SARS	B-DISO
+patient	O
+to	O
+deteriorate	O
+,	O
+losing	O
+the	O
+best	O
+chance	O
+for	O
+treatment	O
+and	O
+increase	O
+case	O
+fatality	O
+.	O
+
+The	O
+average	O
+medical	O
+cost	O
+per	O
+person	O
+/	O
+day	O
+was	O
+calculated	O
+on	O
+1272	O
+SARS	B-DISO
+cases	O
+with	O
+complete	O
+hospitalization	O
+data	O
+from	O
+the	O
+Beijing	O
+SARS	B-DISO
+clinical	O
+database	O
+.	O
+
+The	O
+medical	O
+expenditure	O
+on	O
+SARS	B-DISO
+patients	O
+at	O
+the	O
+hospital	O
+was	O
+higher	O
+than	O
+that	O
+on	O
+patients	O
+with	O
+common	O
+diseases	O
+which	O
+was	O
+associated	O
+to	O
+the	O
+following	O
+factors	O
+as	O
+:	O
+days	O
+of	O
+hospitalization	O
+,	O
+severity	O
+of	O
+disease	O
+,	O
+stage	O
+of	O
+the	O
+disease	O
+break	O
+-	O
+out	O
+,	O
+patient	O
+'	O
+s	O
+occupation	O
+,	O
+baseline	O
+disease	O
+status	O
+,	O
+medical	O
+insurance	O
+status	O
+etc	O
+.	O
+
+The	O
+most	O
+prevalent	O
+APN	O
+variations	O
+in	O
+this	O
+population	O
+(	O
+C956T	O
+leading	O
+to	O
+an	O
+alanine	B-CHED
+to	O
+valine	B-CHED
+substitution	O
+,	O
+G978T	O
+,	O
+G987A	O
+and	O
+intron3	O
+-	O
+C389T	O
+)	O
+always	O
+occurred	O
+together	O
+at	O
+an	O
+allele	O
+frequency	O
+of	O
+8	O
+.	O
+5	O
+%.	O
+
+Three	O
+polymorphisms	B-PROC
+in	O
+intron	O
+3	O
+,	O
+intron3	O
+-	O
+G395C	O
+,	O
+intron3	O
+-	O
+C86T	O
+,	O
+and	O
+intron3	O
+-	O
+C429T	O
+,	O
+were	O
+identified	O
+with	O
+an	O
+allele	O
+frequency	O
+of	O
+3	O
+.	O
+5	O
+%,	O
+1	O
+%	O
+and	O
+0	O
+.	O
+5	O
+%	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+evaluation	O
+of	O
+an	O
+efficient	O
+3	O
+'-	O
+noncoding	O
+region	O
+based	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+)	O
+RT	O
+-	O
+PCR	O
+assay	O
+for	O
+detection	O
+of	O
+SARS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+The	O
+ideal	O
+amplification	B-DISO
+efficiency	O
+of	O
+a	O
+sensitive	O
+SARS	B-DISO
+-	O
+CoV	O
+RT	O
+-	O
+PCR	O
+assay	O
+should	O
+yield	O
+an	O
+E	O
+value	O
+(	O
+PCR	O
+product	O
+concentration	O
+increase	O
+per	O
+amplification	B-DISO
+cycle	O
+)	O
+equal	O
+to	O
+2	O
+.	O
+0	O
+.	O
+
+The	O
+assay	O
+'	O
+s	O
+detection	O
+sensitivity	O
+could	O
+reach	B-PROC
+0	O
+.	O
+005	O
+pfu	B-CHED
+or	O
+6	O
+-	O
+8	O
+GE	O
+per	O
+assay	O
+.	O
+
+The	O
+utility	O
+of	O
+these	O
+mAbs	O
+for	O
+diagnostic	O
+development	B-PROC
+is	O
+demonstrated	O
+.	O
+
+TITLE	O
+:	O
+Sequence	O
+comparison	O
+of	O
+the	O
+ORF	O
+7	O
+region	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+viruses	B-SPEC
+isolated	O
+in	O
+Japan	O
+.	O
+
+Nine	O
+Japanese	O
+TGEV	B-SPEC
+strains	O
+have	O
+been	O
+isolated	O
+over	O
+the	O
+past	O
+40	O
+years	O
+(	O
+1956	O
+-	O
+1997	O
+).	O
+
+ABSTRACT	O
+:	O
+An	O
+international	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+a	O
+recently	O
+recognized	O
+syndrome	B-DISO
+caused	O
+by	O
+the	O
+newly	O
+identified	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+,	O
+began	O
+in	O
+November	O
+2002	O
+and	O
+ended	O
+in	O
+July	O
+2003	O
+.	O
+
+Insights	O
+into	O
+the	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+have	O
+been	O
+made	O
+:	O
+one	O
+study	O
+suggests	O
+that	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+HLA	B-ANAT
+-	O
+B	O
+*	O
+4601	O
+is	O
+a	O
+possible	O
+risk	O
+factor	O
+for	O
+more	O
+severe	O
+disease	O
+,	O
+while	O
+another	O
+identifies	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+as	O
+a	O
+cellular	B-COMP
+receptor	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Recovery	O
+from	O
+lung	B-ANAT
+injury	O
+in	O
+survivors	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+difference	O
+between	O
+pulmonary	O
+and	O
+extrapulmonary	O
+subtypes	O
+.	O
+
+In	O
+an	O
+evaluation	O
+of	O
+clinical	O
+specimens	O
+from	O
+SARS	B-DISO
+patients	O
+,	O
+34	O
+(	O
+52	O
+%)	O
+of	O
+66	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+samples	O
+from	O
+50	O
+patients	O
+,	O
+5	O
+(	O
+5	O
+%)	O
+of	O
+94	O
+urine	B-ANAT
+samples	O
+from	O
+94	O
+patients	O
+,	O
+and	O
+36	O
+(	O
+55	O
+%)	O
+of	O
+65	O
+fecal	B-ANAT
+samples	O
+from	O
+65	O
+patients	O
+tested	O
+positive	O
+for	O
+SARS	B-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+VeroE6	O
+cells	B-COMP
+,	O
+fetal	B-ANAT
+rhesus	B-SPEC
+monkey	I-SPEC
+kidney	B-ANAT
+cells	B-COMP
+,	O
+and	O
+human	B-SPEC
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+were	O
+the	O
+only	O
+cells	B-COMP
+known	O
+to	O
+be	O
+susceptible	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+We	O
+developed	O
+a	O
+multiplex	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+assay	O
+to	O
+analyze	O
+the	O
+susceptibility	O
+of	O
+cells	B-COMP
+derived	O
+from	O
+a	O
+variety	O
+of	O
+tissues	B-ANAT
+and	O
+species	B-SPEC
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Additionally	O
+,	O
+productive	O
+infection	B-DISO
+was	O
+determined	O
+by	O
+titration	O
+of	O
+cellular	B-COMP
+supernatants	O
+.	O
+
+Mv1Lu	O
+cells	B-COMP
+produce	O
+little	O
+SARS	B-DISO
+-	O
+CoV	O
+compared	O
+to	O
+that	O
+produced	O
+by	O
+VeroE6	O
+cells	B-COMP
+,	O
+which	O
+indicates	O
+that	O
+they	O
+are	O
+a	O
+safer	O
+alternative	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+diagnostics	O
+.	O
+
+Evaluation	O
+of	O
+cells	B-COMP
+permissive	O
+to	O
+other	O
+coronaviruses	O
+indicated	O
+that	O
+these	O
+cell	B-COMP
+types	O
+are	O
+not	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+providing	O
+additional	O
+evidence	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+binds	B-FUNC
+an	O
+alternative	O
+receptor	O
+.	O
+
+Analysis	O
+of	O
+human	B-SPEC
+cells	B-COMP
+derived	O
+from	O
+lung	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+and	O
+intestine	B-ANAT
+led	O
+to	O
+the	O
+discovery	O
+that	O
+human	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+were	O
+productively	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+This	O
+study	O
+identifies	O
+new	O
+cell	B-ANAT
+lines	I-ANAT
+that	O
+may	O
+be	O
+used	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+diagnostics	O
+and	O
+/	O
+or	O
+basic	O
+research	O
+.	O
+
+Our	O
+data	O
+and	O
+other	O
+in	O
+vivo	O
+studies	O
+indicate	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+a	O
+wide	O
+host	B-COMP
+range	O
+,	O
+suggesting	O
+that	O
+the	O
+cellular	B-COMP
+receptor	O
+(	O
+s	O
+)	O
+utilized	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+highly	O
+conserved	O
+and	O
+is	O
+expressed	B-PROC
+by	O
+a	O
+variety	O
+of	O
+tissues	B-ANAT
+.	O
+
+Comparing	O
+these	O
+nucleotide	B-CHED
+sequences	O
+to	O
+DNA	O
+databank	O
+entries	O
+(	O
+National	O
+Institutes	O
+of	O
+Health	O
+)	O
+conclusively	O
+identified	O
+them	O
+as	O
+SARS	B-DISO
+-	O
+CoV	O
+sequences	O
+.	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+human	B-PRGE
+-	I-PRGE
+leukocyte	B-ANAT
+-	I-PRGE
+antigen	B-CHED
+class	B-SPEC
+I	O
+(	O
+B	O
+*	O
+0703	O
+)	O
+and	O
+class	B-SPEC
+II	O
+(	O
+DRB1	O
+*	O
+0301	O
+)	O
+genotypes	O
+with	O
+susceptibility	O
+and	O
+resistance	O
+to	O
+the	O
+development	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Also	O
+discussed	O
+are	O
+related	O
+guidelines	O
+from	O
+building	O
+and	O
+equipment	O
+professional	O
+organizations	O
+and	O
+novel	O
+infection	B-DISO
+control	O
+techniques	O
+used	O
+successfully	O
+by	O
+various	O
+hospitals	O
+in	O
+Asia	O
+,	O
+Canada	O
+,	O
+and	O
+the	O
+United	O
+States	O
+during	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemic	O
+.	O
+
+These	O
+results	O
+show	O
+that	O
+it	O
+is	O
+possible	O
+to	O
+interrogate	O
+the	O
+memory	B-PROC
+repertoire	O
+of	O
+immune	O
+donors	O
+to	O
+rapidly	O
+and	O
+efficiently	O
+isolate	O
+neutralizing	O
+antibodies	B-COMP
+that	O
+have	O
+been	O
+selected	O
+in	O
+the	O
+course	O
+of	O
+natural	O
+infection	O
+.	O
+
+TITLE	O
+:	O
+Uncertain	O
+benefit	O
+:	O
+the	O
+public	O
+policy	O
+of	O
+approving	O
+smallpox	B-DISO
+vaccine	O
+research	O
+.	O
+
+This	O
+model	O
+for	O
+review	O
+of	O
+pediatric	O
+research	O
+that	O
+may	O
+be	O
+without	O
+benefit	O
+will	O
+be	O
+especially	O
+important	O
+as	O
+challenging	O
+studies	O
+of	O
+various	O
+vaccines	O
+against	O
+a	O
+range	O
+of	O
+infectious	B-DISO
+properties	O
+,	O
+such	O
+as	O
+anthrax	B-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+emerge	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+structural	O
+changes	O
+of	O
+the	O
+lung	B-ANAT
+might	O
+correlate	O
+with	O
+symptoms	O
+and	O
+pulmonary	B-PROC
+function	I-PROC
+.	O
+
+Compared	O
+with	O
+the	O
+GGO	O
+group	O
+,	O
+the	O
+GGO	O
++	O
+F	O
+group	O
+showed	O
+significantly	O
+lower	O
+FEV	B-SPEC
+(	O
+1	O
+),	O
+FVC	B-PROC
+,	O
+total	O
+lung	B-PROC
+capacity	I-PROC
+,	O
+residual	O
+volume	O
+,	O
+and	O
+DLCO	O
+.	O
+
+Compared	O
+with	O
+the	O
+GGO	O
+group	O
+,	O
+the	O
+GGO	O
++	O
+F	O
+group	O
+showed	O
+significantly	O
+lower	O
+FEV	B-SPEC
+(	O
+1	O
+),	O
+FVC	B-PROC
+,	O
+total	O
+lung	B-PROC
+capacity	I-PROC
+,	O
+residual	O
+volume	O
+,	O
+and	O
+DLCO	O
+.	O
+
+Comparative	O
+study	O
+was	O
+conducted	O
+in	O
+133	O
+SARS	B-DISO
+inpatients	O
+in	O
+Beijing	O
+Ditan	B-CHED
+Hospital	O
+,	O
+who	O
+were	O
+divided	O
+into	O
+3	O
+groups	O
+according	O
+to	O
+the	O
+treatment	O
+applied	O
+,	O
+the	O
+basic	O
+treated	O
+group	O
+,	O
+the	O
+low	O
+dose	O
+steroid	B-CHED
+group	O
+and	O
+the	O
+high	O
+dose	O
+steroid	B-CHED
+group	O
+,	O
+and	O
+all	O
+the	O
+3	O
+groups	O
+were	O
+subdivided	O
+into	O
+two	O
+groups	O
+,	O
+Chinese	O
+herbs	O
+and	O
+non	O
+-	O
+Chinese	O
+herbs	O
+added	O
+,	O
+respectively	O
+.	O
+
+Retrospective	O
+analysis	O
+for	O
+significance	O
+test	O
+on	O
+changes	O
+of	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+before	O
+and	O
+after	O
+treatment	O
+were	O
+carried	O
+out	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+case	O
+of	O
+a	O
+72	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+probable	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+is	O
+reported	O
+.	O
+
+The	O
+causative	O
+agent	O
+of	O
+SARS	B-DISO
+is	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+receptor	O
+for	O
+group	O
+I	O
+and	O
+III	O
+CoV	O
+is	O
+aminopeptidase	O
+N	O
+(	O
+CD13	B-PRGE
+).	O
+
+CD13	B-PRGE
+has	O
+been	O
+identified	O
+in	O
+human	B-PRGE
+bone	B-ANAT
+marrow	I-ANAT
+CD34	I-PRGE
++	I-PRGE
+cells	B-COMP
+,	O
+platelets	B-ANAT
+,	O
+megakaryocytes	B-ANAT
+,	O
+myeloid	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+erythroid	B-ANAT
+cells	I-ANAT
+,	O
+but	O
+not	O
+in	O
+lymphocytes	B-ANAT
+.	O
+
+CD66a	B-PRGE
+is	O
+an	O
+adhesion	B-DISO
+molecule	O
+expressed	B-PROC
+on	O
+bone	B-ANAT
+marrow	I-ANAT
+CD34	O
++	O
+cells	B-COMP
+,	O
+platelets	B-ANAT
+,	O
+granulocytes	B-ANAT
+and	O
+activated	O
+lymphocytes	B-ANAT
+.	O
+
+The	O
+optical	O
+density	O
+value	O
+of	O
+the	O
+immunological	O
+reaction	O
+of	O
+synthesized	O
+8	O
+peptides	B-CHED
+with	O
+SARS	B-DISO
+patient	O
+serum	B-COMP
+was	O
+1	O
+.	O
+5	O
+-	O
+2	O
+.	O
+6	O
+times	O
+higher	O
+than	O
+that	O
+with	O
+normal	O
+serum	B-COMP
+.	O
+
+The	O
+8	O
+peptides	B-CHED
+from	O
+S1	O
+domain	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+appear	O
+to	O
+have	O
+low	O
+immunogenicity	O
+to	O
+the	O
+serum	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+,	O
+indicating	O
+that	O
+these	O
+peptides	B-CHED
+may	O
+not	O
+be	O
+the	O
+epitope	B-CHED
+of	O
+the	O
+SARS	B-DISO
+-	O
+Cov	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+optical	O
+density	O
+value	O
+of	O
+the	O
+immunological	O
+reaction	O
+of	O
+synthesized	O
+8	O
+peptides	B-CHED
+with	O
+SARS	B-DISO
+patient	O
+serum	B-COMP
+was	O
+1	O
+.	O
+5	O
+-	O
+2	O
+.	O
+6	O
+times	O
+higher	O
+than	O
+that	O
+with	O
+normal	O
+serum	O
+.	O
+
+Being	O
+a	O
+cell	B-ANAT
+line	I-ANAT
+of	O
+human	B-SPEC
+origin	O
+,	O
+LoVo	O
+cells	B-COMP
+could	O
+be	O
+a	O
+useful	O
+in	O
+vitro	O
+model	O
+for	O
+studying	O
+the	O
+biology	O
+and	O
+persistent	B-DISO
+infection	I-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Our	O
+results	O
+on	O
+the	O
+expression	B-PROC
+of	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+a	O
+recently	O
+identified	O
+cellular	B-COMP
+receptor	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+in	O
+these	O
+cell	B-ANAT
+lines	I-ANAT
+indicated	O
+that	O
+it	O
+might	O
+not	O
+be	O
+the	O
+sole	B-ANAT
+determinant	O
+for	O
+cells	B-COMP
+to	O
+be	O
+susceptible	O
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+test	O
+was	O
+specific	O
+(	O
+77	O
+-	O
+98	O
+%)	O
+for	O
+all	O
+specimen	O
+types	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+and	O
+B	O
+,	O
+depending	O
+upon	O
+incubation	O
+conditions	O
+.	O
+
+A	O
+positive	O
+test	O
+is	O
+useful	O
+,	O
+for	O
+both	O
+directing	O
+initiation	O
+of	O
+therapy	O
+in	O
+the	O
+clinician	O
+'	O
+s	O
+office	O
+,	O
+and	O
+making	O
+a	O
+positive	O
+diagnosis	O
+of	O
+influenza	O
+in	O
+patients	O
+with	O
+influenza	B-DISO
+-	O
+like	O
+clinical	O
+syndromes	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Epidemiology	O
+and	O
+diagnosis	O
+of	O
+respiratory	O
+syncitial	O
+virus	B-SPEC
+in	O
+adults	O
+].	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+is	O
+rarely	O
+searched	O
+for	O
+in	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+adults	O
+.	O
+
+Finally	O
+,	O
+in	O
+the	O
+51	O
+acute	O
+pneumonias	B-DISO
+hospitalised	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+a	O
+virus	B-SPEC
+was	O
+identified	O
+in	O
+17	O
+(	O
+33	O
+.	O
+3	O
+%)	O
+cases	O
+,	O
+including	O
+3	O
+(	O
+5	O
+.	O
+5	O
+%)	O
+RSV	B-SPEC
+,	O
+6	O
+influenza	B-PATH
+A	I-PATH
+,	O
+3	O
+rhinovirus	B-SPEC
+,	O
+2	O
+adenovirus	B-DISO
+,	O
+2	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+and	O
+1	O
+cytomegalovirus	B-SPEC
+.	O
+
+It	O
+can	O
+sometimes	O
+cause	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illness	O
+,	O
+which	O
+can	O
+be	O
+severe	O
+,	O
+and	O
+should	O
+be	O
+considered	O
+in	O
+the	O
+differential	O
+diagnosis	O
+in	O
+such	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+safe	O
+neutralization	O
+assay	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+characterization	O
+of	O
+S	B-PRGE
+-	I-PRGE
+glycoprotein	B-CHED
+.	O
+
+The	O
+protein	B-CHED
+is	O
+glycosylated	O
+with	O
+high	O
+mannose	B-CHED
+and	O
+/	O
+or	O
+hybrid	O
+oligosaccharides	B-CHED
+,	O
+which	O
+account	O
+for	O
+approximately	O
+30	O
+kDa	O
+of	O
+the	O
+apparent	O
+protein	B-CHED
+mass	O
+.	O
+
+To	O
+facilitate	O
+quantifying	O
+pseudovirus	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+which	O
+are	O
+stained	O
+blue	O
+with	O
+X	O
+-	O
+Gal	B-CHED
+,	O
+we	O
+devised	O
+an	O
+automated	O
+procedure	O
+using	O
+an	O
+ELISPOT	O
+analyzer	O
+.	O
+
+The	O
+analysis	O
+of	O
+proteins	B-CHED
+E6	O
+and	O
+E7	O
+showed	O
+that	O
+ANN	O
+models	O
+appear	O
+to	O
+be	O
+more	O
+accurate	O
+for	O
+prediction	O
+of	O
+HLA	B-PRGE
+-	I-PRGE
+A3	I-PRGE
+hot	B-DISO
+spots	I-DISO
+and	O
+HMM	B-CHED
+models	O
+for	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+predictions	O
+.	O
+
+RESULTS	O
+:	O
+Our	O
+predictions	O
+against	O
+experimental	O
+data	O
+from	O
+four	O
+melanoma	B-PATH
+-	O
+related	O
+proteins	B-CHED
+showed	O
+that	O
+MULTIPRED	O
+ANN	O
+and	O
+HMM	B-CHED
+models	O
+could	O
+predict	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitopes	I-PRGE
+with	O
+high	O
+accuracy	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+effects	O
+of	O
+the	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+on	O
+the	O
+Singapore	O
+General	O
+Hospital	O
+'	O
+s	O
+Department	O
+of	O
+Anaesthesia	B-DISO
+are	O
+described	O
+.	O
+
+Anaesthetists	O
+were	O
+at	O
+risk	O
+and	O
+anaesthetic	B-CHED
+practice	O
+had	O
+to	O
+change	O
+in	O
+view	O
+of	O
+strict	O
+infection	B-DISO
+control	O
+provisions	O
+.	O
+
+Protease	B-PROC
+inhibitors	I-PROC
+(	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+)	O
+in	O
+combination	O
+with	O
+ribavirin	B-CHED
+may	O
+play	O
+a	O
+role	O
+as	O
+antiviral	B-CHED
+therapy	O
+in	O
+the	O
+early	O
+phase	O
+,	O
+whereas	O
+the	O
+role	O
+of	O
+IFN	B-PRGE
+and	O
+systemic	O
+steroid	B-CHED
+in	O
+preventing	O
+immune	O
+-	O
+mediated	O
+lung	B-ANAT
+injury	O
+deserves	O
+further	O
+investigation	O
+.	O
+
+In	O
+addition	O
+,	O
+other	O
+antiviral	B-CHED
+treatment	O
+,	O
+RNA	B-PROC
+interference	I-PROC
+,	O
+monoclonal	O
+antibody	B-COMP
+,	O
+synthetic	O
+peptides	B-CHED
+,	O
+and	O
+vaccines	O
+are	O
+being	O
+developed	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+detect	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+RNA	O
+in	O
+excreta	O
+and	O
+oropharyngeal	B-ANAT
+washing	O
+fluid	O
+(	O
+OWF	O
+)	O
+from	O
+the	O
+convalescence	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+to	O
+determine	O
+whether	O
+convalescence	O
+patients	O
+carry	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+and	O
+whether	O
+having	O
+infectivity	O
+.	O
+
+About	O
+10	O
+%	O
+convalescence	O
+SARS	B-DISO
+patients	O
+might	O
+still	O
+carry	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+hospitalization	O
+.	O
+
+However	O
+,	O
+temperature	O
+monitoring	O
+procedures	O
+have	O
+a	O
+powerful	O
+psychological	B-DISO
+effect	O
+of	O
+reassuring	O
+parents	O
+and	O
+the	O
+public	O
+that	O
+schools	O
+are	O
+safe	O
+during	O
+a	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+clinical	O
+presentation	O
+,	O
+findings	O
+,	O
+and	O
+outcomes	O
+of	O
+older	O
+adults	O
+(>	O
+60	O
+)	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+compare	O
+these	O
+with	O
+a	O
+control	O
+group	O
+of	O
+younger	O
+patients	O
+(<	O
+or	O
+or	O
+=	O
+60	O
+).	O
+
+Fever	B-PROC
+,	O
+chills	B-DISO
+,	O
+and	O
+diarrhea	B-DISO
+were	O
+more	O
+common	O
+in	O
+younger	O
+patients	O
+,	O
+whereas	O
+decrease	B-DISO
+in	I-DISO
+appetite	I-DISO
+and	O
+general	O
+condition	B-DISO
+occurred	O
+only	O
+in	O
+older	O
+patients	O
+.	O
+
+The	O
+cumulative	O
+30	O
+-	O
+and	O
+150	O
+-	O
+day	O
+mortality	O
+rates	O
+were	O
+3	O
+.	O
+8	O
+%	O
+and	O
+7	O
+.	O
+6	O
+%,	O
+respectively	O
+,	O
+in	O
+young	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+56	O
+%	O
+and	O
+60	O
+%,	O
+respectively	O
+,	O
+in	O
+older	O
+patients	O
+(	O
+P	O
+<.	O
+001	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Older	O
+patients	O
+with	O
+SARS	B-DISO
+more	O
+often	O
+presented	O
+with	O
+nonspecific	O
+symptoms	O
+,	O
+and	O
+the	O
+prognosis	O
+was	O
+poor	O
+.	O
+
+Until	O
+reliable	O
+diagnostic	O
+tests	O
+,	O
+vaccine	O
+and	O
+medications	O
+are	O
+available	O
+,	O
+control	O
+of	O
+SARS	B-DISO
+outbreaks	O
+depends	O
+on	O
+close	O
+surveillance	O
+,	O
+early	O
+identification	O
+of	O
+index	O
+cases	O
+,	O
+quick	O
+isolation	O
+of	O
+carriers	O
+and	O
+effective	O
+infection	B-DISO
+control	O
+and	O
+public	O
+health	O
+measures	O
+.	O
+
+In	O
+conclusion	O
+,	O
+B	B-ANAT
+cell	I-ANAT
+epitopes	O
+of	O
+SARS	B-DISO
+corresponded	O
+to	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+The	O
+method	O
+is	O
+based	O
+on	O
+counting	O
+the	O
+appearance	O
+frequency	O
+of	O
+oligopeptides	B-CHED
+of	O
+a	O
+fixed	B-ANAT
+length	O
+(	O
+up	O
+to	O
+K	O
+=	O
+6	O
+)	O
+in	O
+the	O
+collection	O
+of	O
+protein	B-CHED
+sequences	O
+of	O
+a	O
+species	B-SPEC
+.	O
+
+16	O
+.	O
+6	O
+;	O
+P	O
+=.	O
+002	O
+)	O
+and	O
+had	O
+higher	O
+frequency	O
+of	O
+comorbid	O
+lung	B-ANAT
+illnesses	O
+(	O
+nine	O
+of	O
+20	O
+vs	O
+two	O
+of	O
+32	O
+,	O
+P	O
+=.	O
+001	O
+),	O
+maximal	O
+lesion	O
+extent	O
+score	O
+of	O
+7	O
+or	O
+higher	O
+(	O
+20	O
+of	O
+20	O
+vs	O
+five	O
+of	O
+32	O
+,	O
+P	O
+<.	O
+001	O
+),	O
+involvement	O
+of	O
+four	O
+or	O
+more	O
+lung	B-ANAT
+zones	O
+(	O
+17	O
+of	O
+20	O
+vs	O
+four	O
+of	O
+32	O
+,	O
+P	O
+<.	O
+001	O
+),	O
+bilateral	O
+lung	B-ANAT
+involvement	O
+(	O
+19	O
+of	O
+20	O
+vs	O
+14	O
+of	O
+32	O
+,	O
+P	O
+<.	O
+001	O
+),	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+(	O
+18	O
+of	O
+20	O
+vs	O
+two	O
+of	O
+32	O
+,	O
+P	O
+<.	O
+001	O
+),	O
+and	O
+higher	O
+percentage	O
+of	O
+affected	O
+areas	O
+(	O
+41	O
+.	O
+5	O
+%	O
++/-	O
+
+On	O
+chest	B-ANAT
+radiographs	O
+,	O
+maximal	O
+SARS	B-DISO
+-	O
+related	O
+lesion	O
+extent	O
+score	O
+of	O
+7	O
+or	O
+higher	O
+is	O
+a	O
+strong	O
+predictor	O
+of	O
+mortality	O
+,	O
+especially	O
+in	O
+patients	O
+with	O
+comorbid	O
+lung	B-ANAT
+illnesses	O
+and	O
+involvement	O
+of	O
+four	O
+or	O
+more	O
+lung	B-ANAT
+zones	O
+.	O
+
+Although	O
+56	O
+%	O
+of	O
+respondents	O
+replied	O
+that	O
+they	O
+could	O
+continue	O
+to	O
+visit	O
+the	O
+department	O
+if	O
+a	O
+SARS	B-DISO
+patient	O
+was	O
+admitted	O
+to	O
+the	O
+unit	O
+in	O
+the	O
+hospital	O
+before	O
+they	O
+read	O
+the	O
+information	O
+,	O
+the	O
+proportion	O
+of	O
+those	O
+who	O
+intended	O
+to	O
+continue	O
+outpatient	O
+care	O
+significantly	O
+increased	O
+by	O
+15	O
+%	O
+after	O
+they	O
+read	O
+it	O
+.	O
+
+Severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+Pa	O
+(	O
+o	O
+(	O
+2	O
+))/	O
+Fi	O
+(	O
+o	O
+(	O
+2	O
+))	O
+ratio	O
+10	O
+.	O
+7	O
+kPa	O
+)	O
+developed	O
+within	O
+24	O
+h	O
+.	O
+Conventional	O
+pressure	O
+-	O
+controlled	O
+ventilation	O
+(	O
+PCV	B-CHED
+)	O
+with	O
+high	O
+airway	B-ANAT
+pressures	O
+and	O
+low	O
+tidal	O
+volumes	O
+failed	O
+to	O
+improve	O
+oxygenation	B-PROC
+.	O
+
+Stepwise	O
+reduction	O
+of	O
+the	O
+mean	O
+airway	B-ANAT
+pressure	O
+(	O
+26	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+),	O
+and	O
+oscillating	O
+frequencies	O
+(	O
+3	O
+.	O
+5	O
+Hz	O
+),	O
+as	O
+well	O
+as	O
+increasing	O
+the	O
+oscillating	O
+amplitudes	O
+(	O
+95	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+)	O
+resulted	O
+in	O
+an	O
+unchanged	O
+Pa	O
+(	O
+co	O
+(	O
+2	O
+)),	O
+but	O
+oxygenation	B-PROC
+worsened	O
+.	O
+
+A	O
+case	O
+or	O
+suspected	O
+case	O
+of	O
+SARS	B-DISO
+may	O
+thus	O
+unwillingly	O
+be	O
+treated	O
+at	O
+the	O
+dental	O
+office	O
+.	O
+
+It	O
+is	O
+therefore	O
+necessary	O
+to	O
+adopt	O
+protective	O
+measures	O
+for	O
+the	O
+dental	O
+personnel	O
+and	O
+to	O
+implement	O
+and	O
+enforce	O
+infection	O
+control	O
+measures	O
+in	O
+order	B-SPEC
+to	O
+eliminate	O
+the	O
+risk	O
+of	O
+viral	O
+contamination	O
+.	O
+
+Blood	B-ANAT
+-	O
+borne	O
+contamination	O
+may	O
+be	O
+achieved	O
+only	O
+by	O
+adopting	O
+a	O
+high	O
+level	O
+,	O
+between	O
+-	O
+patients	O
+disinfection	O
+protocol	O
+of	O
+the	O
+DUWLs	O
+based	O
+on	O
+the	O
+use	O
+of	O
+chemical	O
+agents	O
+with	O
+biocidal	O
+activity	O
+against	O
+spores	O
+,	O
+viruses	B-SPEC
+,	O
+bacteria	B-SPEC
+and	O
+fungi	B-SPEC
+(	O
+Autosteril	O
+method	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+immediate	O
+,	O
+specific	O
+response	O
+of	O
+the	O
+University	O
+of	O
+Toronto	O
+CME	O
+program	O
+to	O
+SARS	B-DISO
+is	O
+described	O
+for	O
+the	O
+period	O
+from	O
+March	O
+2003	O
+to	O
+September	O
+2003	O
+.	O
+
+Other	O
+variable	O
+features	O
+include	O
+multinucleated	B-ANAT
+giant	I-ANAT
+cells	B-COMP
+,	O
+pneumocytes	B-ANAT
+with	O
+cytomegaly	B-ANAT
+and	O
+variable	O
+amounts	O
+of	O
+inflammatory	B-ANAT
+cells	I-ANAT
+and	O
+foamy	O
+macrophages	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+CD13	O
+,	O
+a	O
+receptor	O
+for	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+),	O
+was	O
+identified	O
+as	O
+a	O
+major	O
+component	O
+of	O
+the	O
+Triton	B-CHED
+X	I-CHED
+-	I-CHED
+100	I-CHED
+-	O
+resistant	O
+membrane	B-ANAT
+microdomain	I-ANAT
+in	O
+human	B-SPEC
+fibroblasts	B-ANAT
+.	O
+
+A	O
+caveolin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+knockdown	O
+by	O
+RNA	B-PROC
+interference	I-PROC
+also	O
+reduced	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+considerably	O
+.	O
+
+The	O
+results	O
+indicate	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+first	O
+binds	B-FUNC
+to	O
+CD13	B-PRGE
+in	O
+the	O
+Triton	B-CHED
+X	I-CHED
+-	I-CHED
+100	I-CHED
+-	O
+resistant	O
+microdomain	O
+,	O
+then	O
+clusters	B-CHED
+CD13	B-PRGE
+by	O
+cross	O
+-	O
+linking	O
+,	O
+and	O
+thereby	O
+reaches	O
+the	O
+caveolar	O
+region	O
+before	O
+entering	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+respiratory	I-PRGE
+coronavirus	B-SPEC
+OC43	I-PRGE
+:	O
+genetic	O
+stability	O
+and	O
+neuroinvasion	O
+.	O
+
+Of	O
+patients	O
+,	O
+25	O
+%	O
+(	O
+n	O
+=	O
+20	O
+)	O
+requested	O
+psychological	B-DISO
+follow	O
+-	O
+up	O
+.	O
+
+During	O
+the	O
+'	B-PROC
+repair	I-PROC
+'	O
+phase	O
+,	O
+when	O
+the	O
+infection	B-DISO
+was	O
+being	O
+brought	O
+under	O
+control	O
+,	O
+depression	B-DISO
+and	O
+avoidance	O
+were	O
+evident	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	O
+-	O
+Cov	O
+is	O
+the	O
+etiologic	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+spectrum	O
+of	O
+SARS	B-DISO
+-	O
+specific	O
+antibody	B-COMP
+profiles	O
+in	O
+SARS	B-DISO
+patients	O
+was	O
+investigated	O
+from	O
+7	O
+to	O
+210	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+the	O
+symptoms	O
+.	O
+
+IgM	B-COMP
+antibody	B-PROC
+declined	O
+and	O
+became	O
+undetectable	O
+between	O
+60	O
+to	O
+180	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+the	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+infection	I-DISO
+of	O
+spotted	B-SPEC
+hyenas	I-SPEC
+in	O
+the	O
+Serengeti	O
+ecosystem	O
+.	O
+
+ABSTRACT	O
+:	O
+Sera	B-COMP
+from	O
+38	O
+free	O
+-	O
+ranging	O
+spotted	O
+hyenas	O
+(	O
+Crocuta	B-SPEC
+crocuta	I-SPEC
+)	O
+in	O
+the	O
+Serengeti	O
+ecosystem	O
+,	O
+Tanzania	O
+,	O
+were	O
+screened	O
+for	O
+exposure	O
+to	O
+coronavirus	B-SPEC
+of	O
+antigenic	B-PRGE
+group	I-PRGE
+1	I-PRGE
+.	O
+
+Application	O
+of	O
+RT	O
+-	O
+PCR	O
+to	O
+27	O
+fecal	B-ANAT
+samples	O
+revealed	O
+viral	O
+RNA	O
+in	O
+three	O
+samples	O
+(	O
+11	O
+%).	O
+
+Estimation	O
+of	O
+the	O
+phylogenetic	O
+relationship	O
+among	O
+coronavirus	B-SPEC
+isolates	O
+indicated	O
+considerable	O
+divergence	O
+of	O
+the	O
+hyena	B-SPEC
+variant	O
+from	O
+those	O
+in	O
+European	O
+,	O
+American	O
+and	O
+Japanese	O
+domestic	B-SPEC
+cats	I-SPEC
+and	O
+dogs	B-SPEC
+.	O
+
+Based	O
+on	O
+the	O
+present	O
+study	O
+,	O
+it	O
+was	O
+shown	O
+that	O
+the	O
+method	O
+for	O
+diagnosis	O
+of	O
+viruses	B-SPEC
+in	O
+biological	O
+materials	O
+should	O
+be	O
+employed	O
+only	O
+after	O
+the	O
+sensitivity	O
+has	O
+been	O
+determined	O
+for	O
+the	O
+viruses	B-SPEC
+of	O
+interest	O
+implying	O
+that	O
+the	O
+most	O
+sensitive	O
+method	O
+needs	O
+to	O
+be	O
+determined	O
+independently	O
+for	O
+each	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+define	O
+the	O
+origin	O
+and	O
+evolution	O
+of	O
+recent	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+in	O
+Japan	O
+,	O
+a	O
+genetic	O
+analysis	O
+was	O
+performed	O
+.	O
+
+However	O
+,	O
+apoptosis	B-PATH
+was	O
+independent	O
+of	O
+the	O
+p53	B-PRGE
+and	O
+Fas	B-DISO
+signalling	B-PROC
+pathways	B-PROC
+.	O
+
+Evidence	O
+of	O
+perinatal	O
+transmission	B-PROC
+of	I-PROC
+virus	I-PROC
+was	O
+assessed	O
+with	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+on	O
+cord	B-ANAT
+blood	I-ANAT
+,	O
+placenta	B-ANAT
+tissue	B-ANAT
+,	O
+and	O
+subsequent	O
+follow	O
+-	O
+up	O
+of	O
+the	O
+neonate	O
+on	O
+serology	O
+.	O
+
+Two	O
+mothers	O
+recovered	O
+without	O
+delivery	O
+,	O
+but	O
+their	O
+ongoing	O
+pregnancies	B-PROC
+were	O
+complicated	O
+by	O
+intrauterine	B-DISO
+growth	B-PROC
+restriction	I-DISO
+.	O
+
+No	O
+newborn	O
+infant	O
+had	O
+clinical	O
+SARS	B-DISO
+and	O
+all	O
+investigations	O
+were	O
+negative	O
+for	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+New	O
+paradigm	O
+for	O
+protection	O
+:	O
+the	O
+emergency	B-DISO
+ambulance	O
+services	O
+in	O
+the	O
+time	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Intracellular	B-COMP
+viral	O
+RNA	O
+copies	O
+were	O
+reduced	O
+50	O
+%	O
+by	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+at	O
+a	O
+concentration	O
+of	O
+25	O
+U	O
+/	O
+ml	O
+and	O
+by	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+at	O
+a	O
+concentration	O
+of	O
+14	O
+U	O
+/	O
+ml	O
+.	O
+
+The	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+receptor	I-PRGE
+signaling	O
+pathway	O
+in	O
+host	B-COMP
+cells	B-COMP
+is	O
+mainly	O
+involved	O
+in	O
+the	O
+inhibition	B-PROC
+of	O
+SCoV	O
+infection	B-DISO
+and	O
+replication	O
+.	O
+
+TITLE	O
+:	O
+Knowledge	O
+,	O
+attitude	O
+and	O
+practice	O
+towards	O
+SARS	B-DISO
+.	O
+
+Three	O
+-	O
+fifths	O
+(	O
+60	O
+.	O
+1	O
+%)	O
+were	O
+afraid	O
+to	O
+travel	O
+for	O
+fear	O
+of	O
+being	O
+affected	O
+by	O
+SARS	B-DISO
+.	O
+
+If	O
+the	O
+two	O
+ts	O
+mutants	O
+were	O
+allowed	O
+to	O
+enter	O
+cells	B-COMP
+at	O
+32	O
+degrees	O
+C	O
+,	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+was	O
+synthesized	O
+,	O
+core	O
+-	O
+glycosylated	O
+and	O
+at	O
+least	O
+partially	O
+modified	O
+at	O
+40	O
+degrees	O
+C	O
+.	O
+However	O
+,	O
+compared	O
+with	O
+wt	O
+virus	B-SPEC
+and	O
+the	O
+revertant	O
+,	O
+no	O
+infectious	B-DISO
+particles	O
+of	O
+these	O
+ts	O
+mutants	O
+were	O
+assembled	O
+and	O
+released	O
+from	O
+the	O
+ts	O
+mutant	B-DISO
+-	O
+infected	O
+cells	B-COMP
+at	O
+40	O
+degrees	O
+C	O
+.	O
+Evidence	O
+presented	O
+demonstrated	O
+that	O
+the	O
+Q294	O
+-	O
+to	O
+-	O
+L294	O
+mutation	O
+,	O
+located	O
+at	O
+a	O
+highly	O
+conserved	O
+domain	O
+of	O
+the	O
+S1	B-PRGE
+subunit	I-PRGE
+,	O
+might	O
+hamper	O
+processing	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+to	O
+a	O
+matured	O
+180	O
+-	O
+kDa	O
+,	O
+endo	B-PRGE
+-	I-PRGE
+glycosidase	I-PRGE
+H	I-PRGE
+-	O
+resistant	O
+glycoprotein	B-CHED
+and	O
+the	O
+translocation	B-DISO
+of	O
+the	O
+protein	B-CHED
+to	O
+the	O
+cell	B-COMP
+surface	I-COMP
+.	O
+
+1	O
+.	O
+9	O
+days	O
+after	O
+fever	B-PROC
+onset	O
+,	O
+and	O
+35	O
+patients	O
+(	O
+66	O
+%)	O
+had	O
+diarrhea	B-DISO
+beginning	O
+at	O
+a	O
+mean	O
+time	O
+of	O
+6	O
+.	O
+0	O
++/-	O
+
+None	O
+of	O
+the	O
+presenting	O
+symptoms	O
+or	O
+laboratory	O
+findings	O
+are	O
+pathognomonic	O
+for	O
+SARS	B-DISO
+.	O
+
+In	O
+the	O
+recent	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+,	O
+ribavirin	B-CHED
+was	O
+used	O
+in	O
+various	O
+countries	O
+against	O
+this	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+We	O
+conducted	O
+a	O
+retrospective	O
+analysis	O
+to	O
+assess	O
+the	O
+efficacy	O
+of	O
+ribavirin	B-CHED
+in	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+in	O
+Singapore	O
+.	O
+
+Ninety	O
+-	O
+seven	O
+(	O
+42	O
+.	O
+4	O
+%)	O
+patients	O
+received	O
+ribavirin	B-CHED
+at	O
+a	O
+mean	O
+of	O
+6	O
+.	O
+4	O
+days	O
+of	O
+illness	O
+.	O
+
+Clinical	O
+and	O
+laboratory	O
+parameters	O
+taken	O
+at	O
+the	O
+start	O
+of	O
+ribavirin	B-CHED
+treatment	O
+were	O
+compared	O
+with	O
+day	O
+5	O
+,	O
+6	O
+or	O
+7	O
+parameters	O
+of	O
+those	O
+patients	O
+not	O
+on	O
+treatment	O
+.	O
+
+The	O
+treatment	O
+group	O
+had	O
+younger	O
+women	O
+with	O
+more	O
+symptoms	O
+of	O
+myalgia	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+sorting	B-PROC
+signal	O
+for	O
+intracellular	B-PROC
+localization	I-PROC
+is	O
+present	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+a	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+but	O
+absent	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+Replication	O
+of	O
+the	O
+approximately	O
+30	O
+-	O
+kb	O
+positive	O
+-	O
+strand	O
+RNA	O
+genome	O
+of	O
+coronaviruses	O
+and	O
+discontinuous	O
+synthesis	B-PROC
+of	O
+an	O
+extensive	O
+set	O
+of	O
+subgenome	O
+-	O
+length	O
+RNAs	O
+(	O
+transcription	B-PROC
+)	O
+are	O
+mediated	O
+by	O
+the	O
+replicase	B-PRGE
+-	I-PRGE
+transcriptase	I-PRGE
+,	O
+a	O
+barely	O
+characterized	O
+protein	B-COMP
+complex	I-COMP
+that	O
+comprises	O
+several	O
+cellular	B-COMP
+proteins	B-CHED
+and	O
+up	O
+to	O
+16	O
+viral	O
+subunits	O
+.	O
+
+Here	O
+,	O
+we	O
+established	O
+and	O
+characterized	O
+the	O
+activity	O
+of	O
+one	O
+of	O
+these	O
+enzymes	O
+,	O
+replicative	O
+nidoviral	O
+uridylate	B-CHED
+-	O
+specific	O
+endoribonuclease	O
+(	O
+NendoU	O
+).	O
+
+Bacterially	O
+expressed	B-PROC
+forms	O
+of	O
+NendoU	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+were	O
+revealed	O
+to	O
+cleave	O
+single	O
+-	O
+stranded	O
+and	O
+double	O
+-	O
+stranded	O
+RNA	O
+in	O
+a	O
+Mn	O
+(	O
+2	O
++)-	O
+dependent	O
+manner	O
+.	O
+
+2	O
+'-	O
+O	O
+-	O
+ribose	B-CHED
+-	O
+methylated	O
+RNA	O
+substrates	O
+proved	O
+to	O
+be	O
+resistant	O
+to	O
+cleavage	B-PROC
+by	O
+NendoU	O
+,	O
+indicating	O
+a	O
+functional	O
+link	O
+with	O
+the	O
+2	O
+'-	O
+O	O
+-	O
+ribose	B-CHED
+methyltransferase	O
+located	O
+adjacent	O
+to	O
+NendoU	O
+in	O
+the	O
+coronavirus	B-SPEC
+replicative	O
+polyprotein	O
+.	O
+
+Substitution	O
+of	O
+D6408	O
+by	O
+Ala	B-CHED
+was	O
+shown	O
+to	O
+abolish	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+demonstrating	O
+that	O
+NendoU	O
+has	O
+critical	O
+functions	O
+in	O
+viral	B-PROC
+replication	I-PROC
+and	O
+transcription	B-PROC
+.	O
+
+We	O
+present	O
+analyses	O
+of	O
+data	O
+on	O
+key	O
+parameters	O
+and	O
+distributions	O
+and	O
+discuss	O
+the	O
+processes	O
+of	O
+data	O
+capture	O
+,	O
+analysis	O
+and	O
+public	O
+health	O
+policy	O
+formulation	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+are	O
+discussed	O
+.	O
+
+The	O
+low	O
+transmissibility	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+combined	O
+with	O
+the	O
+onset	O
+of	O
+peak	O
+infectiousness	O
+following	O
+the	O
+onset	O
+of	O
+clinical	O
+symptoms	O
+of	O
+disease	O
+,	O
+transpired	O
+to	O
+make	O
+simple	O
+public	O
+health	O
+measures	O
+,	O
+such	O
+as	O
+isolating	O
+patients	O
+and	O
+quarantining	O
+their	O
+contacts	O
+,	O
+very	O
+effective	O
+in	O
+the	O
+control	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+search	O
+for	O
+animal	B-SPEC
+host	B-COMP
+origins	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+has	O
+so	O
+far	O
+remained	O
+focused	O
+on	O
+wildlife	O
+markets	O
+,	O
+restaurants	O
+and	O
+farms	O
+within	O
+China	O
+.	O
+
+The	O
+three	O
+species	B-SPEC
+that	O
+have	O
+so	O
+far	O
+been	O
+implicated	O
+,	O
+a	O
+viverrid	O
+,	O
+a	O
+mustelid	B-SPEC
+and	O
+a	O
+canid	B-SPEC
+,	O
+are	O
+part	O
+of	O
+a	O
+large	O
+suite	O
+of	O
+small	O
+carnivores	B-SPEC
+distributed	O
+across	O
+this	O
+region	O
+currently	O
+overexploited	O
+by	O
+this	O
+international	O
+wildlife	O
+trade	O
+.	O
+
+To	O
+address	O
+these	O
+dual	O
+threats	O
+to	O
+the	O
+long	O
+-	O
+term	O
+future	O
+of	O
+biodiversity	O
+,	O
+including	O
+man	B-CHED
+,	O
+requires	O
+a	O
+less	O
+anthropocentric	O
+and	O
+more	O
+interdisciplinary	O
+approach	O
+to	O
+problems	O
+that	O
+require	O
+the	O
+combined	O
+research	O
+expertise	O
+of	O
+ecologists	O
+,	O
+conservation	O
+biologists	O
+,	O
+veterinarians	O
+,	O
+epidemiologists	O
+,	O
+virologists	O
+,	O
+as	O
+well	O
+as	O
+human	B-SPEC
+health	O
+professionals	O
+.	O
+
+There	O
+was	O
+a	O
+close	O
+linkage	B-PROC
+between	O
+civet	B-SPEC
+cats	I-SPEC
+and	O
+humans	B-SPEC
+in	O
+terms	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+sudden	O
+arrival	O
+of	O
+an	O
+internationally	O
+spreading	O
+outbreak	O
+of	O
+a	O
+newly	O
+identified	O
+infectious	O
+disease	O
+in	O
+early	O
+2003	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+provided	O
+an	O
+opportunity	O
+for	O
+a	O
+coordinated	O
+international	O
+response	O
+based	O
+on	O
+information	O
+and	O
+evidence	O
+obtained	O
+in	O
+real	O
+time	O
+through	O
+standard	O
+and	O
+electronic	O
+communications	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+described	O
+as	O
+the	O
+first	O
+major	O
+emerging	O
+infectious	O
+disease	O
+of	O
+the	O
+twenty	O
+-	O
+first	O
+century	O
+.	O
+
+Fifty	O
+-	O
+three	O
+percent	O
+of	O
+the	O
+patients	O
+had	O
+abnormal	B-DISO
+liver	I-DISO
+function	I-DISO
+during	O
+hospitalization	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Psychosocial	O
+status	O
+of	O
+students	O
+was	O
+influenced	O
+by	O
+their	O
+knowledge	O
+and	O
+attitude	O
+on	O
+SARS	B-DISO
+.	O
+
+Multivariate	O
+analysis	O
+showed	O
+that	O
+lung	O
+involvement	O
+of	O
+more	O
+than	O
+two	O
+zones	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+=	O
+7	O
+.	O
+0	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]:	O
+2	O
+.	O
+7	O
+to	O
+17	O
+.	O
+9	O
+),	O
+older	O
+age	O
+(	O
+OR	O
+for	O
+each	O
+decade	O
+of	O
+life	O
+=	O
+1	O
+.	O
+5	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+1	O
+to	O
+2	O
+.	O
+0	O
+),	O
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+on	O
+admission	O
+(	O
+OR	O
+=	O
+2	O
+.	O
+8	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+1	O
+to	O
+7	O
+.	O
+4	O
+)	O
+were	O
+independent	O
+predictors	O
+of	O
+an	O
+adverse	O
+outcome	O
+.	O
+
+Frontal	O
+chest	B-ANAT
+radiographs	O
+on	O
+presentation	O
+may	O
+have	O
+prognostic	O
+value	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+Multivariate	O
+analysis	O
+showed	O
+that	O
+lung	B-ANAT
+involvement	O
+of	O
+more	O
+than	O
+two	O
+zones	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+=	O
+7	O
+.	O
+0	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]:	O
+2	O
+.	O
+7	O
+to	O
+17	O
+.	O
+9	O
+),	O
+older	O
+age	O
+(	O
+OR	O
+for	O
+each	O
+decade	O
+of	O
+life	O
+=	O
+1	O
+.	O
+5	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+1	O
+to	O
+2	O
+.	O
+0	O
+),	O
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+on	O
+admission	O
+(	O
+OR	O
+=	O
+2	O
+.	O
+8	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+1	O
+to	O
+7	O
+.	O
+4	O
+)	O
+were	O
+independent	O
+predictors	O
+of	O
+an	O
+adverse	O
+outcome	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Frontal	O
+chest	B-ANAT
+radiographs	O
+on	O
+presentation	O
+may	O
+have	O
+prognostic	O
+value	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+S	O
+-	O
+pseudotyped	O
+MLV	O
+particles	O
+were	O
+used	O
+to	O
+analyze	O
+viral	O
+tropism	B-PROC
+.	O
+
+A	O
+cat	B-SPEC
+cell	B-ANAT
+line	I-ANAT
+and	O
+a	O
+dog	B-SPEC
+cell	B-ANAT
+line	I-ANAT
+were	O
+not	O
+susceptible	O
+.	O
+
+Recombinant	O
+viruses	B-SPEC
+between	O
+MHV	B-SPEC
+-	O
+A59	O
+and	O
+MHV	B-SPEC
+/	O
+BHK	O
+were	O
+selected	O
+in	O
+hamster	B-SPEC
+cells	B-COMP
+.	O
+
+All	O
+of	O
+the	O
+recombinants	O
+retained	O
+21	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+and	O
+a	O
+7	O
+-	O
+amino	O
+-	O
+acid	O
+insert	O
+found	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+region	O
+of	O
+S	O
+of	O
+MHV	O
+/	O
+BHK	O
+,	O
+suggesting	O
+that	O
+these	O
+residues	O
+were	O
+responsible	O
+for	O
+the	O
+extended	O
+host	B-COMP
+range	O
+of	O
+MHV	B-SPEC
+/	O
+BHK	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aims	O
+to	O
+investigate	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+)-	O
+related	O
+behaviours	O
+of	O
+travellers	O
+returning	O
+to	O
+Hong	O
+Kong	O
+by	O
+air	B-CHED
+.	O
+
+Approximately	O
+16	O
+%	O
+of	O
+the	O
+respondents	O
+stated	O
+that	O
+they	O
+would	O
+delay	O
+their	O
+medical	O
+consultation	O
+for	O
+flu	B-DISO
+-	I-DISO
+like	I-DISO
+symptoms	I-DISO
+until	O
+returning	O
+to	O
+Hong	O
+Kong	O
+.	O
+
+Leptospirosis	B-DISO
+may	O
+manifest	O
+with	O
+severe	O
+lung	B-ANAT
+injury	O
+characterized	O
+by	O
+diffuse	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+be	O
+accompanied	O
+by	O
+high	O
+mortality	O
+rates	O
+.	O
+
+Although	O
+the	O
+principle	O
+of	O
+universal	O
+precautions	O
+is	O
+widely	O
+advocated	O
+and	O
+followed	O
+throughout	O
+the	O
+dental	O
+community	O
+,	O
+additional	O
+precautionary	O
+measures	O
+-	O
+termed	O
+standard	O
+precaution	O
+may	O
+be	O
+necessary	O
+to	O
+help	O
+control	O
+the	O
+spread	O
+of	O
+this	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+fact	O
+,	O
+an	O
+autopsy	O
+also	O
+subject	O
+prosectors	O
+and	O
+others	O
+to	O
+a	O
+wide	O
+variety	O
+of	O
+hazards	O
+,	O
+including	O
+bloodborne	O
+,	O
+aerosolized	O
+pathogens	O
+and	O
+others	O
+(	O
+for	O
+example	O
+SARS	B-DISO
+).	O
+
+The	O
+aim	O
+of	O
+this	O
+paper	O
+is	O
+to	O
+introduce	O
+the	O
+integrative	O
+model	O
+of	O
+environmental	O
+health	O
+and	O
+explore	O
+its	O
+potential	O
+to	O
+illuminate	O
+the	O
+Toronto	O
+SARS	B-DISO
+experience	O
+.	O
+
+This	O
+knowledge	O
+comes	O
+through	O
+research	O
+on	O
+topics	O
+such	O
+as	O
+;	O
+chemicals	O
+,	O
+pesticides	B-CHED
+,	O
+soil	O
+erosion	B-DISO
+,	O
+killing	O
+of	O
+forests	O
+,	O
+contamination	O
+of	O
+water	B-CHED
+,	O
+destabilization	O
+of	O
+climate	O
+,	O
+and	O
+social	O
+disruption	O
+from	O
+wars	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+risk	O
+factors	O
+related	O
+to	O
+severe	O
+cases	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+order	B-SPEC
+to	O
+find	O
+the	O
+early	O
+warning	O
+signs	O
+of	O
+deterioration	O
+of	O
+this	O
+disease	O
+.	O
+
+Retrospective	O
+analysis	O
+was	O
+conducted	O
+in	O
+the	O
+clinical	O
+symptoms	O
+,	O
+physical	O
+signs	O
+and	O
+the	O
+results	O
+of	O
+laboratory	O
+examinations	O
+from	O
+1170	O
+cases	O
+with	O
+SARS	B-DISO
+in	O
+Beijing	O
+,	O
+and	O
+the	O
+clinical	O
+characteristics	O
+in	O
+different	O
+stages	O
+of	O
+the	O
+disease	O
+were	O
+compared	O
+.	O
+
+Hypoxemia	O
+was	O
+a	O
+common	O
+characteristic	O
+in	O
+SARS	B-DISO
+.	O
+
+The	O
+decrease	O
+in	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+artery	B-ANAT
+and	O
+oxygen	B-CHED
+saturation	O
+in	O
+pulse	B-PROC
+oximeter	O
+with	O
+normal	O
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+was	O
+found	O
+in	O
+most	O
+patients	O
+at	O
+the	O
+second	O
+week	O
+.	O
+
+Some	O
+patients	O
+suffered	B-DISO
+from	O
+temporary	O
+multiple	O
+organ	B-ANAT
+dysfunctions	O
+(	O
+mainly	O
+impairments	O
+of	O
+liver	B-ANAT
+and	O
+myocardium	B-ANAT
+).	O
+
+Some	O
+patients	O
+suffered	B-DISO
+from	O
+temporary	O
+multiple	O
+organ	B-ANAT
+dysfunctions	O
+(	O
+mainly	O
+impairments	O
+of	O
+liver	B-ANAT
+and	O
+myocardium	B-ANAT
+).	O
+
+With	O
+descending	O
+in	O
+infectious	B-DISO
+generation	O
+,	O
+cases	O
+treated	O
+with	O
+methylprednisolone	B-CHED
+,	O
+human	B-SPEC
+gamma	B-PRGE
+-	I-PRGE
+immunoglobulin	I-PRGE
+,	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+and	O
+antiviral	B-CHED
+drugs	I-CHED
+(	O
+oral	B-ANAT
+ribavirin	B-CHED
+or	O
+oseltamivir	B-CHED
+)	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+the	O
+duration	O
+of	O
+their	O
+use	O
+also	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+No	O
+statistical	O
+differences	O
+in	O
+age	O
+,	O
+sex	O
+ratio	O
+,	O
+incubation	O
+period	O
+and	O
+hospitalization	O
+duration	O
+among	O
+various	O
+infectious	B-DISO
+generations	O
+were	O
+found	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+situation	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+infection	B-DISO
+in	O
+the	O
+hemodialysis	O
+units	O
+in	O
+Beijing	O
+.	O
+
+Eighty	O
+-	O
+one	O
+hemodialysis	O
+units	O
+were	O
+investigated	O
+on	O
+the	O
+incidence	O
+and	O
+preventive	O
+measures	O
+for	O
+SARS	B-DISO
+from	O
+March	O
+to	O
+July	O
+2003	O
+by	O
+a	O
+standardized	O
+investigation	O
+form	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+of	O
+average	O
+age	O
+(	O
+t	O
+=	O
+-	O
+1	O
+.	O
+08	O
+,	O
+P	O
+=	O
+0	O
+.	O
+2808	O
+)	O
+and	O
+the	O
+time	O
+from	O
+SARS	B-DISO
+onset	O
+to	O
+hospitalization	O
+(	O
+P	O
+=	O
+0	O
+.	O
+2797	O
+)	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+There	O
+was	O
+no	O
+live	O
+SARS	B-DISO
+-	O
+CoV	O
+detected	O
+in	O
+the	O
+sewage	O
+in	O
+this	O
+study	O
+.	O
+
+After	O
+disinfection	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+could	O
+only	O
+be	O
+detected	O
+from	O
+the	O
+samples	O
+from	O
+the	O
+309th	O
+Hospital	O
+,	O
+and	O
+the	O
+others	O
+were	O
+negative	O
+.	O
+
+Pulmonary	B-PROC
+function	I-PROC
+was	O
+assessed	O
+at	O
+2	O
+months	O
+,	O
+1	O
+year	O
+and	O
+2	O
+years	O
+post	O
+-	O
+transplant	B-ANAT
+.	O
+
+From	O
+the	O
+regression	O
+analysis	O
+,	O
+the	O
+best	O
+reading	O
+is	O
+taken	O
+from	O
+the	O
+maximum	O
+temperature	O
+in	O
+the	O
+eye	B-ANAT
+region	I-ANAT
+,	O
+followed	O
+by	O
+the	O
+maximum	O
+temperature	O
+in	O
+the	O
+forehead	B-ANAT
+region	O
+.	O
+
+The	O
+radiographic	O
+features	O
+of	O
+unusual	O
+diffuse	O
+lung	B-DISO
+diseases	I-DISO
+published	O
+in	O
+the	O
+past	O
+two	O
+years	O
+are	O
+described	O
+.	O
+
+Nodules	B-DISO
+less	O
+than	O
+10	O
+mm	O
+in	O
+size	O
+in	O
+immunocompromised	O
+patients	O
+are	O
+highly	O
+suggestive	O
+of	O
+viral	O
+infections	O
+.	O
+
+The	O
+triad	B-COMP
+of	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+,	O
+ill	B-DISO
+-	O
+defined	O
+centrilobular	O
+nodules	B-DISO
+and	O
+cysts	B-DISO
+and	O
+focal	O
+areas	O
+of	O
+air	B-DISO
+trapping	I-DISO
+is	O
+highly	O
+suggestive	O
+of	O
+subacute	O
+hypersensitivity	B-DISO
+pneumonitis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Infection	B-DISO
+of	O
+cultured	O
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+We	O
+analyzed	O
+serum	B-COMP
+samples	O
+obtained	O
+from	O
+623	O
+patients	O
+with	O
+SARS	B-DISO
+in	O
+Beijing	O
+,	O
+to	O
+determine	O
+whether	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+elicit	O
+neutralizing	O
+antibodies	B-COMP
+(	O
+NAbs	O
+).	O
+
+NAbs	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+are	O
+broadly	O
+elicited	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+,	O
+according	O
+to	O
+their	O
+kinetics	O
+,	O
+may	O
+correlate	O
+with	O
+viral	O
+load	O
+during	O
+the	O
+early	O
+stages	O
+of	O
+the	O
+disease	O
+.	O
+
+The	O
+serum	B-COMP
+samples	O
+could	O
+neutralize	O
+the	O
+pseudotype	O
+particles	O
+bearing	O
+the	O
+spike	O
+glycoproteins	B-CHED
+from	O
+different	O
+SARS	B-DISO
+-	O
+CoV	O
+strains	O
+,	O
+suggesting	O
+that	O
+the	O
+NAbs	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+broadly	O
+reactive	O
+.	O
+
+To	O
+study	O
+sequence	O
+variation	O
+in	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+,	O
+we	O
+determined	O
+the	O
+nucleic	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+the	O
+S	O
+and	O
+N	O
+genes	O
+directly	O
+from	O
+clinical	O
+specimens	O
+from	O
+10	O
+patients	O
+--	O
+1	O
+specimen	O
+with	O
+no	O
+matched	O
+SARS	B-DISO
+-	O
+CoV	O
+isolate	O
+,	O
+from	O
+2	O
+patients	O
+;	O
+multiple	O
+specimens	O
+from	O
+3	O
+patients	O
+;	O
+and	O
+matched	O
+clinical	O
+-	O
+specimen	O
+/	O
+cell	B-COMP
+-	O
+culture	O
+-	O
+isolate	O
+pairs	O
+from	O
+6	O
+patients	O
+.	O
+
+These	O
+findings	O
+are	O
+a	O
+part	O
+of	O
+the	O
+expanding	O
+investigation	O
+of	O
+the	O
+evolution	B-PROC
+of	O
+how	O
+this	O
+virus	B-SPEC
+adapts	O
+to	O
+a	O
+new	O
+host	B-COMP
+.	O
+
+APC	B-COMP
+inhibits	O
+ET	O
+-	O
+induced	O
+TNF	B-PROC
+-	I-PROC
+alpha	I-PROC
+production	I-PROC
+in	O
+vitro	O
+in	O
+human	B-SPEC
+monocytes	B-ANAT
+by	O
+inhibiting	O
+activation	O
+of	O
+NFkappaB	O
+and	O
+AP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+by	O
+inhibiting	O
+degradation	O
+of	O
+IkappaB	O
+and	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+pathways	B-PROC
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+(	O
+N	B-PRGE
+protein	B-CHED
+)	O
+is	O
+one	O
+of	O
+the	O
+major	O
+virion	B-COMP
+structural	O
+proteins	B-CHED
+of	O
+a	O
+newly	O
+identified	O
+coronavirus	B-SPEC
+,	O
+which	O
+has	O
+been	O
+confirmed	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Symptoms	O
+of	O
+posttraumatic	B-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+)	O
+and	O
+depression	B-DISO
+were	O
+observed	O
+in	O
+28	O
+.	O
+9	O
+%	O
+and	O
+31	O
+.	O
+2	O
+%	O
+of	O
+respondents	O
+,	O
+respectively	O
+.	O
+
+This	O
+finding	O
+,	O
+with	O
+the	O
+high	O
+detection	O
+rate	O
+a	O
+median	O
+of	O
+4	O
+days	O
+after	O
+disease	O
+onset	O
+and	O
+before	O
+the	O
+development	B-PROC
+of	O
+lung	B-ANAT
+lesions	O
+in	O
+four	O
+patients	O
+,	O
+suggests	O
+that	O
+throat	B-ANAT
+wash	O
+and	O
+saliva	O
+should	O
+be	O
+included	O
+in	O
+sample	O
+collection	O
+guidelines	O
+for	O
+SARS	B-DISO
+diagnosis	O
+.	O
+
+ABSTRACT	O
+:	O
+With	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+occurring	O
+across	O
+geographic	O
+regions	O
+,	O
+data	O
+collection	O
+on	O
+the	O
+effectiveness	O
+of	O
+intervention	O
+strategies	O
+should	O
+be	O
+standardized	O
+to	O
+facilitate	O
+analysis	O
+.	O
+
+We	O
+propose	O
+a	O
+minimum	O
+dataset	O
+to	O
+capture	O
+data	O
+needed	O
+to	O
+examine	O
+the	O
+basic	O
+reproduction	B-PROC
+rate	O
+,	O
+case	O
+status	O
+and	O
+criteria	O
+,	O
+symptoms	O
+,	O
+and	O
+outcomes	O
+of	O
+SARS	B-DISO
+.	O
+
+Thus	O
+,	O
+binding	B-FUNC
+of	O
+autoAb	O
+to	O
+insolubilized	O
+FAH	O
+could	O
+be	O
+inhibited	O
+by	O
+MHV	B-SPEC
+depending	O
+on	O
+the	O
+mouse	B-SPEC
+serum	B-COMP
+or	O
+the	O
+experimental	O
+protocol	O
+used	O
+.	O
+
+TITLE	O
+:	O
+A	O
+clinical	O
+prediction	O
+rule	O
+for	O
+diagnosing	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+emergency	B-DISO
+department	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+a	O
+simple	O
+model	O
+that	O
+uses	O
+clinical	O
+data	O
+at	O
+the	O
+time	O
+of	O
+presentation	O
+to	O
+an	O
+emergency	B-DISO
+department	O
+during	O
+an	O
+acute	O
+outbreak	O
+predicted	O
+the	O
+incidence	O
+of	O
+SARS	B-DISO
+and	O
+provided	O
+good	O
+diagnostic	O
+utility	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+a	O
+case	O
+of	O
+acute	O
+methemoglobinemia	B-DISO
+in	O
+a	O
+patient	O
+treated	O
+with	O
+celecoxib	O
+for	O
+osteoarthritis	B-DISO
+.	O
+
+The	O
+focus	O
+of	O
+the	O
+17th	O
+International	O
+Conference	O
+on	O
+Antiviral	O
+Research	O
+was	O
+the	O
+discovery	O
+and	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+agents	I-CHED
+(	O
+chemistry	O
+,	O
+biology	O
+,	O
+animal	B-SPEC
+models	O
+and	O
+clinical	O
+trial	O
+results	O
+)	O
+against	O
+a	O
+variety	O
+of	O
+human	B-SPEC
+infectious	B-DISO
+agents	O
+including	O
+HIV	B-DISO
+,	O
+herpes	B-DISO
+viruses	B-SPEC
+,	O
+hepatitis	B-DISO
+viruses	B-SPEC
+,	O
+respiratory	O
+viruses	B-SPEC
+and	O
+emerging	O
+/	O
+re	O
+-	O
+emerging	O
+pathogens	O
+.	O
+
+Within	O
+each	O
+infectious	B-DISO
+agent	O
+session	O
+the	O
+presentations	O
+included	O
+those	O
+describing	O
+the	O
+development	B-PROC
+of	O
+new	O
+and	O
+novel	O
+anti	O
+-	O
+infectives	O
+,	O
+including	O
+research	O
+based	O
+on	O
+the	O
+preclinical	O
+development	B-PROC
+of	O
+new	O
+molecules	O
+,	O
+and	O
+the	O
+results	O
+of	O
+animal	B-SPEC
+modelling	O
+and	O
+clinical	O
+studies	O
+on	O
+advanced	O
+-	O
+stage	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+A	O
+summary	O
+of	O
+the	O
+meeting	O
+highlights	O
+,	O
+segregated	O
+by	O
+infectious	B-DISO
+agent	O
+,	O
+will	O
+be	O
+presented	O
+in	O
+this	O
+review	O
+.	O
+
+We	O
+have	O
+genetically	O
+dissected	O
+these	O
+domains	O
+in	O
+the	O
+MHV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+to	O
+localize	O
+the	O
+determinants	O
+of	O
+S	O
+incorporation	O
+into	O
+virions	B-COMP
+.	O
+
+Immunoblot	O
+analysis	O
+of	O
+infected	O
+-	O
+cell	B-COMP
+lysates	O
+identified	O
+proteins	B-CHED
+of	O
+the	O
+predicted	O
+sizes	O
+.	O
+
+Trends	O
+were	O
+analyzed	O
+and	O
+displayed	O
+on	O
+the	O
+secure	O
+Web	B-DISO
+site	O
+.	O
+
+CONCLUSIONS	O
+:	O
+A	O
+regional	O
+emergency	B-DISO
+medicine	B-CHED
+Internet	O
+approach	O
+permitted	O
+rapid	O
+implementation	O
+of	O
+multisite	O
+syndromic	O
+surveillance	O
+without	O
+additional	O
+staff	O
+.	O
+
+However	O
+,	O
+the	O
+nutritional	O
+status	O
+of	O
+the	O
+host	B-COMP
+,	O
+until	O
+recently	O
+,	O
+has	O
+not	O
+been	O
+considered	O
+a	O
+contributing	O
+factor	O
+to	O
+the	O
+emergence	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+label	B-CHED
+was	O
+also	O
+politically	O
+convenient	O
+.	O
+
+A	O
+middle	O
+ground	O
+for	O
+reasonable	O
+expectations	O
+from	O
+HCW	O
+when	O
+treating	O
+diseases	O
+that	O
+have	O
+serious	O
+risk	O
+of	O
+infection	B-DISO
+should	O
+be	O
+expected	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+is	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+new	O
+type	O
+of	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+treatment	O
+for	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+that	O
+happened	O
+epidemically	O
+this	O
+spring	O
+confirmed	O
+again	O
+that	O
+the	O
+integrated	O
+traditional	O
+Chinese	O
+and	O
+western	O
+medicine	B-CHED
+had	O
+its	O
+clinical	O
+advantage	O
+and	O
+vitality	O
+,	O
+and	O
+indicated	O
+that	O
+this	O
+integration	B-PROC
+could	O
+benefit	O
+the	O
+pathologic	O
+understanding	O
+and	O
+therapeutic	O
+strategies	O
+for	O
+the	O
+diseases	O
+.	O
+
+Based	O
+on	O
+the	O
+experimental	O
+research	O
+,	O
+western	O
+medicine	B-CHED
+focuses	O
+on	O
+the	O
+histological	O
+and	O
+structural	O
+changes	O
+of	O
+the	O
+diseases	O
+.	O
+
+Their	O
+combination	O
+and	O
+unity	O
+is	O
+the	O
+key	O
+point	O
+for	O
+the	O
+integration	O
+of	O
+TCM	O
+with	O
+western	O
+medicine	B-CHED
+in	O
+order	B-SPEC
+to	O
+improve	O
+the	O
+clinical	O
+effectiveness	O
+and	O
+TCM	O
+development	B-PROC
+.	O
+
+The	O
+positive	O
+rate	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+in	O
+cases	O
+who	O
+were	O
+not	O
+in	O
+chain	O
+of	O
+transmission	O
+was	O
+12	O
+.	O
+59	O
+%(	O
+18	O
+/	O
+143	O
+)	O
+which	O
+was	O
+statistically	O
+significantly	O
+different	O
+from	O
+that	O
+of	O
+cases	O
+in	O
+chain	O
+of	O
+transmission	O
+,	O
+Chi	B-CHED
+square	O
+=	O
+199	O
+.	O
+64	O
+,	O
+P	O
+less	O
+than	O
+0	O
+.	O
+001	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+appeared	O
+as	O
+early	O
+as	O
+7	O
+days	O
+after	O
+onset	O
+and	O
+reached	O
+the	O
+peak	O
+at	O
+about	O
+weeks	O
+4	O
+.	O
+
+Thirty	O
+-	O
+five	O
+cases	O
+had	O
+common	O
+atypical	B-DISO
+pneumonia	I-DISO
+(	O
+non	O
+-	O
+SARS	B-DISO
+),	O
+21	O
+were	O
+males	O
+while	O
+14	O
+were	O
+females	O
+,	O
+20	O
+cases	O
+received	O
+methylprednisolone	B-CHED
+treatment	O
+.	O
+
+Out	O
+of	O
+121	O
+patients	O
+studied	O
+,	O
+71	O
+.	O
+1	O
+%	O
+were	O
+SARS	B-DISO
+specific	O
+IgG	B-PRGE
+positive	O
+.	O
+
+Patients	O
+younger	O
+than	O
+15	O
+years	O
+,	O
+between	O
+15	O
+to	O
+59	O
+years	O
+,	O
+older	O
+than	O
+59	O
+years	O
+had	O
+positive	O
+rates	O
+of	O
+60	O
+.	O
+0	O
+%,	O
+70	O
+.	O
+2	O
+%,	O
+and	O
+85	O
+.	O
+7	O
+%,	O
+respectively	O
+with	O
+no	O
+statistically	O
+significance	O
+(	O
+P	O
+=	O
+0	O
+.	O
+766	O
+);	O
+patients	O
+with	O
+or	O
+without	O
+steroid	B-CHED
+treatment	O
+showed	O
+positive	O
+rates	O
+of	O
+70	O
+.	O
+6	O
+%	O
+and	O
+72	O
+.	O
+4	O
+%,	O
+respectively	O
+(	O
+P	O
+=	O
+0	O
+.	O
+84	O
+);	O
+patients	O
+exhibiting	O
+either	O
+severe	O
+or	O
+light	O
+syndromes	B-DISO
+showed	O
+positive	O
+rates	O
+of	O
+78	O
+.	O
+1	O
+%	O
+and	O
+67	O
+.	O
+4	O
+%,	O
+respectively	O
+(	O
+P	O
+=	O
+0	O
+.	O
+493	O
+);	O
+both	O
+male	O
+and	O
+female	O
+patients	O
+showed	O
+the	O
+same	O
+positive	O
+rate	O
+of	O
+71	O
+.	O
+1	O
+%.	O
+
+Their	O
+corpuscles	O
+in	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+were	O
+tested	O
+every	O
+two	O
+days	O
+,	O
+and	O
+the	O
+results	O
+were	O
+analyzed	O
+.	O
+
+RESULTS	O
+:	O
+SARS	B-DISO
+virus	B-SPEC
+cDNA	O
+chip	O
+was	O
+successfully	O
+prepared	O
+by	O
+using	O
+PCR	O
+method	O
+.	O
+
+An	O
+unknown	O
+gene	O
+at	O
+the	O
+position	O
+28130	O
+-	O
+28426	O
+bp	O
+,	O
+named	O
+as	O
+U	O
+gene	O
+,	O
+may	O
+play	O
+an	O
+important	O
+role	O
+during	O
+the	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Pathogens	O
+were	O
+isolated	O
+from	O
+variety	O
+of	O
+samples	O
+collected	O
+from	O
+atypical	B-DISO
+pneumonia	I-DISO
+patient	O
+by	O
+using	O
+MDCK	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+identified	O
+with	O
+serological	O
+and	O
+molecular	O
+methods	O
+.	O
+
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+was	O
+isolated	O
+from	O
+patients	O
+with	O
+atypical	B-DISO
+pneumonia	I-DISO
+,	O
+from	O
+which	O
+an	O
+RNA	O
+fragment	O
+of	O
+279	O
+nt	O
+was	O
+amplified	O
+by	O
+nested	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Indirect	O
+immunofluorescence	O
+test	O
+showed	O
+a	O
+specific	O
+antigen	B-CHED
+-	O
+antibody	B-COMP
+reactivity	O
+between	O
+the	O
+coronavirus	B-SPEC
+and	O
+convalescent	O
+-	O
+phase	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+pathological	O
+features	O
+and	O
+pathogenesis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+to	O
+provide	O
+evidence	O
+for	O
+the	O
+clinical	O
+treatment	O
+and	O
+prevention	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+major	O
+pathological	O
+changes	O
+of	O
+2	O
+autopsy	O
+cases	O
+of	O
+SARS	B-DISO
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+were	O
+acute	O
+pulmonary	B-ANAT
+interstitial	B-ANAT
+and	O
+alveolar	B-ANAT
+exudative	B-DISO
+inflammation	I-DISO
+,	O
+and	O
+2	O
+autopsy	O
+and	O
+one	O
+biopsy	O
+lung	B-ANAT
+tissues	I-ANAT
+showed	O
+alveolar	B-ANAT
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+.	O
+
+Among	O
+6	O
+cases	O
+,	O
+2	O
+biopsy	O
+cases	O
+presented	O
+early	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+and	O
+alveolar	B-ANAT
+organization	O
+.	O
+
+Histologically	O
+,	O
+the	O
+pulmonary	B-ANAT
+changes	O
+could	O
+be	O
+divided	O
+into	O
+acute	O
+inflammatory	O
+exudative	O
+,	O
+terminal	O
+bronchiolar	B-ANAT
+and	O
+alveolar	B-ANAT
+desquamative	O
+and	O
+proliferative	B-DISO
+repair	B-PROC
+stages	O
+or	O
+types	O
+during	O
+the	O
+pathological	B-DISO
+process	I-DISO
+of	O
+SARS	B-DISO
+.	O
+
+In	O
+Cox	O
+'	O
+s	O
+proportional	O
+hazard	O
+models	O
+,	O
+severe	O
+lymphopenia	B-DISO
+was	O
+significant	O
+predictor	O
+associated	O
+with	O
+prolongation	O
+of	O
+stay	O
+in	O
+hospital	O
+.	O
+
+RESULTS	O
+:	O
+Fifty	O
+per	O
+cent	O
+of	O
+the	O
+participants	O
+were	O
+not	O
+concerned	O
+about	O
+travelling	O
+to	O
+Toronto	O
+,	O
+while	O
+the	O
+other	O
+50	O
+%	O
+expressed	B-PROC
+some	O
+concern	O
+ranging	O
+from	O
+mild	O
+to	O
+serious	O
+.	O
+
+Reasons	O
+for	O
+attending	O
+the	O
+conference	O
+despite	O
+concern	O
+included	O
+a	O
+desire	O
+for	O
+continuing	O
+education	O
+,	O
+decrease	O
+in	O
+the	O
+number	O
+of	O
+reported	O
+SARS	B-DISO
+cases	O
+,	O
+and	O
+perceived	O
+minimal	O
+risk	O
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+patients	O
+with	O
+end	B-DISO
+-	I-DISO
+stage	I-DISO
+renal	I-DISO
+disease	I-DISO
+(	O
+ERSD	O
+)	O
+visiting	O
+our	O
+hospital	O
+for	O
+hemodialysis	O
+treatment	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+wore	O
+an	O
+N95	O
+mask	O
+.	O
+
+The	O
+relatively	O
+deep	O
+grooves	B-ANAT
+on	O
+the	O
+surface	O
+of	O
+the	O
+central	O
+coiled	O
+coil	O
+will	O
+be	O
+a	O
+good	O
+target	O
+site	O
+for	O
+the	O
+design	O
+of	O
+viral	O
+fusion	O
+inhibitors	B-CHED
+.	O
+
+Using	O
+the	O
+immediate	O
+Hotel	O
+M	O
+contact	O
+isolates	O
+as	O
+roots	O
+,	O
+we	O
+observed	O
+that	O
+the	O
+SARS	B-DISO
+epidemic	O
+has	O
+generated	O
+four	O
+major	O
+genetic	O
+groups	O
+that	O
+are	O
+geographically	O
+associated	O
+:	O
+two	O
+Singapore	O
+isolates	O
+,	O
+one	O
+Taiwan	O
+isolate	O
+,	O
+and	O
+one	O
+North	O
+China	O
+isolate	O
+which	O
+appears	O
+most	O
+closely	O
+related	O
+to	O
+the	O
+putative	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+isolated	O
+from	O
+a	O
+palm	B-ANAT
+civet	B-SPEC
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+well	O
+adapted	O
+to	O
+growth	B-PROC
+in	O
+culture	O
+and	O
+did	O
+not	O
+appear	O
+to	O
+undergo	O
+specific	O
+selection	O
+in	O
+human	B-SPEC
+populations	O
+.	O
+
+Requests	O
+from	O
+hospitals	O
+,	O
+quarantined	O
+individuals	O
+,	O
+and	O
+febrile	B-PROC
+citizens	O
+accounted	O
+for	O
+23	O
+%,	O
+18	O
+%,	O
+and	O
+59	O
+%	O
+of	O
+SARS	B-DISO
+-	O
+related	O
+transports	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+serology	O
+was	O
+available	O
+in	O
+74	O
+.	O
+1	O
+%	O
+of	O
+EMTs	O
+who	O
+were	O
+alive	O
+.	O
+
+RESULTS	O
+:	O
+During	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+there	O
+were	O
+five	O
+cases	O
+of	O
+probable	O
+SARS	B-DISO
+and	O
+three	O
+cases	O
+of	O
+suspect	O
+SARS	B-DISO
+.	O
+
+During	O
+the	O
+five	O
+peak	O
+days	O
+of	O
+SARS	B-DISO
+-	O
+2	O
+,	O
+the	O
+combined	O
+number	O
+of	O
+quarantine	O
+days	O
+was	O
+910	O
+.	O
+
+It	O
+was	O
+found	O
+that	O
+the	O
+bases	B-CHED
+of	O
+six	O
+nucleotide	B-CHED
+positions	O
+(	O
+nt9404	O
+,	O
+nt9479	O
+,	O
+nt19838	O
+,	O
+nt21721	O
+,	O
+nt22222	O
+and	O
+nt27827	O
+)	O
+with	O
+high	O
+-	O
+mutation	O
+rate	O
+have	O
+an	O
+important	O
+relationship	O
+with	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+The	O
+discriminating	O
+oligonucleotides	B-CHED
+contain	O
+on	O
+the	O
+5	O
+'	O
+end	O
+""""	O
+cZip	O
+Codes	O
+""""	O
+that	O
+are	O
+used	O
+to	O
+direct	O
+LDR	O
+product	O
+to	O
+specific	O
+Zip	O
+Codes	O
+attached	O
+covalently	O
+to	O
+a	O
+slide	O
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+inactivated	O
+by	O
+ultraviolet	O
+light	O
+(	O
+UV	O
+)	O
+at	O
+254	O
+nm	O
+,	O
+heat	O
+treatment	O
+of	O
+65	O
+degrees	O
+C	O
+or	O
+greater	O
+,	O
+alkaline	O
+(	O
+pH	O
+>	O
+12	O
+)	O
+or	O
+acidic	O
+(	O
+pH	O
+<	O
+3	O
+)	O
+conditions	O
+,	O
+formalin	B-CHED
+and	O
+glutaraldehyde	B-CHED
+treatments	O
+.	O
+
+TITLE	O
+:	O
+A	O
+large	O
+outbreak	O
+of	O
+acute	O
+encephalitis	B-DISO
+with	O
+high	O
+fatality	O
+rate	O
+in	O
+children	O
+in	O
+Andhra	O
+Pradesh	O
+,	O
+India	O
+,	O
+in	O
+2003	O
+,	O
+associated	O
+with	O
+Chandipura	O
+virus	O
+.	O
+
+Chandipura	O
+viral	O
+antigen	O
+and	O
+RNA	O
+were	O
+detected	O
+in	O
+brain	B-ANAT
+tissue	I-ANAT
+of	O
+a	O
+deceased	B-PROC
+child	O
+by	O
+immunofluorescent	O
+antibody	B-COMP
+test	O
+and	O
+PCR	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+this	O
+outbreak	O
+of	O
+acute	O
+encephalitis	B-DISO
+in	O
+Andhra	O
+Pradesh	O
+was	O
+associated	O
+with	O
+Chandipura	B-SPEC
+virus	I-SPEC
+,	O
+adding	O
+to	O
+the	O
+evidence	O
+suggesting	O
+that	O
+this	O
+virus	B-SPEC
+should	O
+be	O
+considered	O
+as	O
+an	O
+important	O
+emerging	O
+pathogen	O
+.	O
+
+Administration	O
+of	O
+dexamethasone	B-CHED
+improved	O
+LPS	B-DISO
+-	O
+induced	O
+ALI	O
+and	O
+retained	O
+expression	B-PROC
+of	O
+AQP1	B-PRGE
+.	O
+
+However	O
+,	O
+depletion	O
+of	O
+AQP1	B-PRGE
+did	O
+not	O
+affect	O
+lung	B-DISO
+edema	I-DISO
+formation	B-PROC
+,	O
+lung	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+,	O
+or	O
+lung	B-ANAT
+histology	O
+.	O
+
+Importantly	O
+,	O
+the	O
+same	O
+region	O
+has	O
+been	O
+found	O
+to	O
+be	O
+required	O
+for	O
+multimerization	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+(	O
+He	O
+et	O
+al	O
+.,	O
+2004	O
+)	O
+suggesting	O
+this	O
+region	O
+may	O
+be	O
+crucial	O
+in	O
+maintaining	O
+correct	O
+conformation	O
+of	O
+the	O
+N	O
+protein	B-CHED
+for	O
+self	O
+-	O
+interaction	O
+and	O
+interaction	O
+with	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+In	O
+vitro	O
+inhibition	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+by	O
+chloroquine	B-CHED
+.	O
+
+In	O
+controlling	O
+SARS	B-DISO
+outbreaks	O
+,	O
+timely	O
+alerts	O
+have	O
+been	O
+essential	O
+:	O
+Delaying	O
+the	O
+institution	O
+of	O
+control	O
+measures	O
+by	O
+1	O
+week	O
+would	O
+have	O
+nearly	O
+tripled	O
+the	O
+epidemic	O
+size	O
+and	O
+would	O
+have	O
+increased	O
+the	O
+expected	O
+epidemic	O
+duration	O
+by	O
+4	O
+weeks	O
+.	O
+
+The	O
+viruses	B-SPEC
+responsible	O
+will	O
+be	O
+discussed	O
+individually	O
+.	O
+
+7	O
+.	O
+6	O
+degrees	O
+C	O
+,	O
+suggesting	O
+that	O
+coronary	B-ANAT
+virus	B-DISO
+infection	I-DISO
+,	O
+which	O
+has	O
+been	O
+considered	O
+to	O
+cause	O
+SARS	B-DISO
+by	O
+now	O
+,	O
+may	O
+be	O
+most	O
+active	O
+at	O
+9	O
+degrees	O
+C	O
+-	O
+24	O
+degrees	O
+C	O
+.	O
+(	O
+2	O
+)	O
+Occupational	O
+hygiene	O
+in	O
+hospital	O
+proved	O
+to	O
+be	O
+an	O
+important	O
+socio	O
+-	O
+behavior	O
+factor	O
+for	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Infection	B-DISO
+spread	O
+to	O
+the	O
+brain	B-ANAT
+as	O
+it	O
+was	O
+cleared	O
+from	O
+the	O
+lung	B-ANAT
+,	O
+again	O
+without	O
+leukocyte	B-ANAT
+accumulation	O
+.	O
+
+Infected	O
+mice	B-SPEC
+had	O
+a	O
+relative	O
+failure	B-DISO
+to	I-DISO
+thrive	I-DISO
+,	O
+gaining	B-DISO
+weight	I-DISO
+significantly	O
+more	O
+slowly	O
+than	O
+uninfected	O
+mice	B-SPEC
+.	O
+
+This	O
+study	O
+also	O
+provides	O
+information	O
+useful	O
+for	O
+designing	O
+SARS	B-DISO
+vaccines	O
+and	O
+understanding	O
+the	O
+SARS	B-DISO
+pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Health	O
+care	O
+workers	O
+continued	O
+to	O
+contract	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+even	O
+after	O
+barrier	O
+precautions	O
+were	O
+widely	O
+implemented	O
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+surveillance	O
+in	O
+Indonesia	O
+:	O
+1999	O
+-	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+influenza	B-DISO
+is	O
+recognized	O
+for	O
+its	O
+worldwide	O
+importance	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+disease	O
+from	O
+tropical	O
+countries	O
+like	O
+Indonesia	O
+.	O
+
+Adults	O
+(	O
+age	O
+,	O
+>	O
+14	O
+years	O
+)	O
+and	O
+children	O
+(	O
+age	O
+,	O
+4	O
+-	O
+14	O
+years	O
+)	O
+presenting	O
+with	O
+respiratory	O
+symptoms	O
+suggestive	O
+of	O
+influenza	B-DISO
+were	O
+asked	O
+to	O
+enroll	O
+in	O
+the	O
+study	O
+.	O
+
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+and	O
+H3N2	B-CHED
+)	O
+and	O
+B	O
+viruses	B-SPEC
+were	O
+detected	O
+at	O
+all	O
+sites	O
+.	O
+
+This	O
+period	O
+was	O
+characterized	O
+by	O
+the	O
+upgrading	O
+of	O
+infection	B-DISO
+control	O
+precautions	O
+,	O
+which	O
+included	O
+the	O
+wearing	O
+of	O
+gloves	O
+and	O
+gowns	O
+all	O
+the	O
+time	O
+,	O
+an	O
+extensive	O
+use	O
+of	O
+steroids	B-CHED
+,	O
+and	O
+a	O
+change	O
+in	O
+antibiotic	B-CHED
+prescribing	O
+practices	O
+.	O
+
+Data	O
+on	O
+MRSA	B-DISO
+acquisition	O
+and	O
+VAP	O
+rates	O
+were	O
+collected	O
+prospectively	O
+.	O
+
+The	O
+VAP	O
+rate	O
+was	O
+high	O
+,	O
+at	O
+36	O
+.	O
+5	O
+episodes	O
+per	O
+1000	O
+ventilator	O
+-	O
+days	O
+,	O
+and	O
+47	O
+%	O
+of	O
+episodes	O
+were	O
+caused	O
+by	O
+MRSA	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Ampligen	O
+[	O
+polyI	O
+:	O
+polyC12U	O
+]	O
+is	O
+a	O
+mismatched	O
+double	O
+-	O
+stranded	O
+RNA	O
+that	O
+acts	O
+by	O
+inducing	O
+interferon	B-PROC
+production	I-PROC
+(	O
+immunomodulator	B-CHED
+)	O
+and	O
+by	O
+activating	O
+an	O
+intracellular	B-COMP
+enzyme	O
+(	O
+RNase	B-PRGE
+-	I-PRGE
+L	I-PRGE
+)	O
+against	O
+viral	O
+RNA	O
+transcripts	O
+(	O
+antiviral	B-CHED
+).	O
+
+In	O
+May	O
+2003	O
+,	O
+Hemispherx	O
+Biopharma	O
+and	O
+the	O
+Center	O
+for	O
+Cell	B-COMP
+and	O
+Gene	O
+Therapy	O
+entered	O
+into	O
+a	O
+research	O
+project	O
+agreement	O
+that	O
+will	O
+see	O
+Ampligen	O
+implemented	O
+in	O
+a	O
+protocol	O
+used	O
+in	O
+patients	O
+with	O
+relapsed	O
+EBV	O
+-	O
+positive	O
+Hodgkin	B-DISO
+'	I-DISO
+s	I-DISO
+Lymphoma	I-DISO
+.	O
+
+In	O
+the	O
+US	O
+,	O
+Ampligen	O
+has	O
+been	O
+granted	O
+orphan	B-CHED
+drug	I-CHED
+status	O
+for	O
+the	O
+treatment	O
+of	O
+AIDS	O
+,	O
+renal	B-PATH
+cell	I-PATH
+carcinoma	I-PATH
+(	O
+phase	O
+II	O
+,	O
+completed	O
+),	O
+chronic	B-DISO
+fatigue	I-DISO
+syndrome	I-DISO
+(	O
+phase	O
+III	O
+)	O
+and	O
+invasive	O
+/	O
+metastatic	B-DISO
+malignant	I-DISO
+melanoma	I-DISO
+(	O
+phase	O
+II	O
+).	O
+
+In	O
+2000	O
+,	O
+Hemispherx	O
+Europe	O
+(	O
+Hemispherx	O
+)	O
+obtained	O
+orphan	B-CHED
+drug	I-CHED
+status	O
+for	O
+Ampligen	O
+for	O
+the	O
+treatment	O
+of	O
+chronic	B-DISO
+fatigue	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+EU	O
+,	O
+providing	O
+Hemispherx	O
+with	O
+10	O
+years	O
+of	O
+marketing	O
+exclusivity	O
+following	O
+the	O
+launch	O
+of	O
+the	O
+drug	O
+,	O
+as	O
+well	O
+as	O
+potential	O
+financial	O
+research	O
+benefits	O
+for	O
+the	O
+agent	O
+.	O
+
+Mutagenesis	B-PROC
+experiments	O
+were	O
+carried	O
+out	O
+for	O
+validating	O
+the	O
+binding	B-FUNC
+model	O
+,	O
+whose	O
+correctness	O
+was	O
+assessed	O
+by	O
+the	O
+observed	O
+effects	O
+on	O
+the	O
+binding	O
+affinities	O
+between	O
+the	O
+proteins	B-CHED
+.	O
+
+Such	O
+presently	O
+observed	O
+SARS_NP	O
+-	O
+hCypA	O
+interaction	O
+model	O
+might	O
+provide	O
+a	O
+new	O
+hint	O
+for	O
+facilitating	O
+the	O
+understanding	O
+of	O
+another	O
+possible	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+pathway	B-PROC
+against	O
+human	B-SPEC
+cell	B-COMP
+.	O
+
+Furthermore	O
+,	O
+we	O
+show	O
+that	O
+pharmacophores	O
+derived	O
+from	O
+clusters	B-CHED
+of	O
+compounds	O
+resulting	O
+out	O
+of	O
+virtual	O
+screening	O
+could	O
+be	O
+useful	O
+probes	O
+for	O
+future	O
+structure	O
+-	O
+activity	O
+relationship	O
+studies	O
+(	O
+SARs	O
+)	O
+and	O
+fine	O
+-	O
+tune	O
+the	O
+lead	O
+molecules	O
+identified	O
+.	O
+
+A	O
+compound	O
+library	O
+consisting	O
+of	O
+960	O
+commercially	O
+available	O
+drugs	O
+and	O
+biologically	O
+active	O
+substances	O
+was	O
+screened	O
+for	O
+inhibition	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+.	O
+
+Detailed	O
+mechanism	O
+studies	O
+using	O
+a	O
+fluorescence	O
+-	O
+based	O
+protease	O
+assay	O
+demonstrated	O
+that	O
+the	O
+three	O
+compounds	O
+acted	O
+as	O
+competitive	O
+inhibitors	B-CHED
+(	O
+Ki	O
+=	O
+0	O
+.	O
+7	O
+,	O
+2	O
+.	O
+4	O
+,	O
+and	O
+13	O
+.	O
+7	O
+microM	O
+for	O
+phenylmercuric	B-CHED
+acetate	I-CHED
+,	O
+thimerosal	B-CHED
+,	O
+and	O
+hexachlorophene	O
+,	O
+respectively	O
+).	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CLpro	O
+)	O
+mediates	O
+the	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+replicase	B-PRGE
+polypeptides	I-PRGE
+1a	I-PRGE
+and	O
+1ab	O
+into	O
+functional	O
+proteins	B-CHED
+,	O
+playing	O
+an	O
+important	O
+role	O
+in	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+function	I-PROC
+and	O
+exercise	O
+capacity	O
+in	O
+survivors	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+We	O
+did	O
+the	O
+right	O
+thing	O
+:	O
+an	O
+intervention	O
+analysis	O
+approach	O
+to	O
+modeling	O
+intervened	O
+SARS	B-DISO
+propagation	O
+in	O
+Singapore	O
+.	O
+
+ABSTRACT	O
+:	O
+Chemokine	B-PRGE
+-	I-PRGE
+like	I-PRGE
+factor	I-PRGE
+1	I-PRGE
+(	O
+CKLF1	B-PRGE
+)	O
+was	O
+recently	O
+identified	O
+as	O
+a	O
+novel	O
+cytokine	O
+.	O
+
+CKLF1	B-PRGE
+-	O
+expressing	O
+plasmid	O
+,	O
+pCDI	B-PRGE
+-	I-PRGE
+CKLF1	I-PRGE
+,	O
+was	O
+constructed	O
+and	O
+injected	O
+into	O
+the	O
+skeletal	B-ANAT
+muscles	I-ANAT
+followed	O
+by	O
+electroporation	O
+.	O
+
+The	O
+pathological	O
+changes	O
+in	O
+the	O
+lungs	B-ANAT
+were	O
+observed	O
+by	O
+light	O
+microscope	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+outbreak	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+the	O
+spring	O
+of	O
+2003	O
+,	O
+strict	O
+infection	B-DISO
+control	O
+measures	O
+were	O
+implemented	O
+in	O
+Toronto	O
+and	O
+surrounding	O
+hospitals	O
+.	O
+
+These	O
+measures	O
+included	O
+extreme	O
+restrictions	O
+on	O
+those	O
+who	O
+would	O
+normally	O
+accompany	O
+patients	O
+to	O
+the	O
+hospital	O
+,	O
+screening	O
+for	O
+SARS	B-DISO
+,	O
+and	O
+protective	O
+attire	O
+for	O
+hospital	O
+staff	O
+,	O
+including	O
+masks	O
+,	O
+face	B-DISO
+shields	O
+,	O
+goggles	O
+,	O
+gloves	O
+and	O
+gowns	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+progression	O
+in	O
+morphologic	O
+changes	O
+of	O
+lungs	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+There	O
+was	O
+an	O
+increase	O
+in	O
+reticulin	B-CHED
+fiber	B-ANAT
+formation	B-PROC
+.	O
+
+The	O
+reactive	O
+fibroblasts	B-ANAT
+were	O
+highlighted	O
+by	O
+desmin	B-COMP
+and	O
+vimentin	B-COMP
+.	O
+
+TITLE	O
+:	O
+Effectiveness	O
+of	O
+noninvasive	O
+positive	O
+pressure	O
+ventilation	O
+in	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+All	O
+patients	O
+with	O
+the	O
+diagnosis	O
+of	O
+probable	O
+SARS	B-DISO
+admitted	O
+to	O
+a	O
+regional	O
+hospital	O
+in	O
+Hong	O
+Kong	O
+from	O
+March	O
+9	O
+to	O
+April	O
+28	O
+,	O
+2003	O
+,	O
+and	O
+who	O
+had	O
+SARS	B-DISO
+-	O
+related	O
+respiratory	B-DISO
+distress	I-DISO
+complications	O
+were	O
+recruited	O
+for	O
+NIPPV	O
+usage	O
+.	O
+
+NIPPV	O
+was	O
+effective	O
+in	O
+the	O
+treatment	O
+of	O
+ARF	B-DISO
+in	O
+the	O
+patients	O
+with	O
+SARS	B-DISO
+studied	O
+,	O
+and	O
+its	O
+use	O
+was	O
+safe	O
+for	O
+health	O
+-	O
+care	O
+workers	O
+.	O
+
+Coronavirus	B-SPEC
+serology	O
+was	O
+positive	O
+in	O
+95	O
+%	O
+(	O
+19	O
+of	O
+20	O
+patients	O
+).	O
+
+There	O
+were	O
+no	O
+infections	B-DISO
+among	O
+the	O
+105	O
+health	O
+-	O
+care	O
+workers	O
+caring	O
+for	O
+the	O
+patients	O
+receiving	O
+NIPPV	O
+.	O
+
+TITLE	O
+:	O
+Protein	B-CHED
+chip	O
+array	O
+profiling	O
+analysis	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+identified	O
+serum	O
+amyloid	B-DISO
+a	O
+protein	B-CHED
+as	O
+a	O
+biomarker	B-CHED
+potentially	O
+useful	O
+in	O
+monitoring	O
+the	O
+extent	O
+of	O
+pneumonia	B-DISO
+.	O
+
+Phage	O
+antibody	B-COMP
+library	O
+for	O
+human	B-SPEC
+Fab	B-PRGE
+fragment	I-PRGE
+has	O
+been	O
+constructed	O
+successfully	O
+,	O
+which	O
+lays	O
+the	O
+foundation	O
+for	O
+further	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+expressed	B-PROC
+and	O
+characterized	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+protein	B-CHED
+in	O
+cDNA	O
+-	O
+transfected	O
+mammalian	B-SPEC
+cells	B-COMP
+.	O
+
+Expressed	B-PROC
+cytoplasmic	B-COMP
+p28	B-COMP
+induces	O
+the	O
+stabilization	O
+of	O
+p53	B-PRGE
+,	O
+and	O
+accumulated	O
+p53	B-PRGE
+causes	O
+transcriptional	B-PROC
+upregulation	B-PROC
+of	O
+p21	B-PRGE
+(	O
+Cip1	B-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+origin	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+remains	O
+unclear	O
+.	O
+
+Evidence	O
+based	O
+on	O
+Bayesian	O
+scanning	O
+plots	O
+and	O
+phylogenetic	O
+analysis	O
+using	O
+maximum	O
+likelihood	O
+(	O
+ML	O
+)	O
+and	O
+Bayesian	O
+methods	O
+indicates	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+for	O
+the	O
+largest	O
+part	O
+of	O
+the	O
+genome	O
+(	O
+approximately	O
+80	O
+%),	O
+is	O
+more	O
+closely	O
+related	O
+to	O
+Group	O
+II	O
+coronaviruses	O
+sequences	O
+,	O
+whereas	O
+in	O
+three	O
+regions	O
+in	O
+the	O
+ORF1ab	B-PRGE
+gene	I-PRGE
+it	O
+shows	O
+no	O
+apparent	O
+similarity	O
+to	O
+any	O
+of	O
+the	O
+previously	O
+characterized	O
+groups	O
+of	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+analyzed	O
+the	O
+effect	O
+of	O
+phasic	O
+tracheal	O
+gas	B-ENZY
+insufflation	O
+at	O
+mid	O
+-	O
+to	O
+end	B-PROC
+-	I-PROC
+expiration	I-PROC
+in	O
+patients	O
+with	O
+severe	O
+head	B-ANAT
+trauma	O
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+We	O
+measured	O
+(	O
+hemodynamics	B-PROC
+,	O
+oxygenation	B-PROC
+,	O
+lung	B-ANAT
+mechanics	O
+,	O
+and	O
+cerebral	B-ANAT
+parameters	O
+)	O
+in	O
+basal	O
+situation	O
+and	O
+during	O
+and	O
+after	O
+tracheal	O
+insufflation	O
+.	O
+
+Tracheal	O
+gas	B-ENZY
+insufflation	O
+allowed	O
+a	O
+significant	O
+decrease	O
+in	O
+tidal	O
+volume	O
+from	O
+9	O
+.	O
+1	O
+to	O
+7	O
+.	O
+2	O
+ml	O
+/	O
+kg	O
+,	O
+with	O
+associated	O
+reduction	O
+in	O
+driving	O
+pressure	O
+(	O
+plateau	O
+pressure	O
+minus	O
+positive	O
+end	O
+-	O
+expiratory	O
+pressure	O
+,	O
+PEEP	B-CHED
+)	O
+from	O
+18	O
+.	O
+1	O
+to	O
+13	O
+.	O
+2	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+.	O
+Total	O
+PEEP	B-CHED
+increased	O
+from	O
+9	O
+.	O
+3	O
+to	O
+12	O
+.	O
+7	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+due	O
+to	O
+the	O
+generation	O
+of	O
+lung	B-DISO
+hyperinflation	I-DISO
+.	O
+
+Oxygenation	B-PROC
+improved	O
+slightly	O
+during	O
+tracheal	O
+gas	B-ENZY
+insufflation	O
+,	O
+and	O
+this	O
+improvement	O
+remained	O
+after	O
+stopping	O
+tracheal	O
+insufflation	O
+.	O
+
+In	O
+patients	O
+with	O
+severe	O
+head	B-ANAT
+trauma	O
+and	O
+ALI	O
+receiving	O
+mechanical	O
+ventilation	O
+,	O
+expiratory	B-PROC
+tracheal	O
+gas	B-ENZY
+insufflation	O
+allowed	O
+the	O
+targeted	B-PROC
+arterial	B-ANAT
+PCO	B-DISO
+(	O
+2	O
+)	O
+level	O
+to	O
+be	O
+maintained	O
+together	O
+with	O
+a	O
+substantial	O
+reduction	O
+in	O
+tidal	O
+volume	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+adhesion	O
+of	O
+microbial	O
+pathogens	O
+to	O
+host	B-COMP
+cells	B-COMP
+is	O
+mediated	O
+by	O
+adhesins	O
+.	O
+
+In	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+associated	O
+human	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+,	O
+the	O
+spike	O
+glycoprotein	B-CHED
+and	O
+nsps	O
+(	O
+nsp2	B-PRGE
+,	O
+nsp5	B-PRGE
+,	O
+nsp6	O
+and	O
+nsp7	O
+)	O
+were	O
+identified	O
+as	O
+having	O
+adhesin	O
+-	O
+like	O
+characteristics	O
+.	O
+
+Three	O
+radiologists	O
+in	O
+consensus	O
+retrospectively	O
+assessed	O
+the	O
+frontal	O
+chest	B-ANAT
+radiographs	O
+obtained	O
+at	O
+presentation	O
+and	O
+during	O
+treatment	O
+(	O
+n	O
+=	O
+2045	O
+)	O
+for	O
+the	O
+distribution	O
+(	O
+each	O
+lung	B-ANAT
+was	O
+divided	O
+into	O
+upper	O
+,	O
+middle	O
+,	O
+and	O
+lower	O
+zones	O
+)	O
+and	O
+extent	O
+of	O
+lung	B-ANAT
+parenchymal	O
+abnormality	O
+.	O
+
+Thirty	O
+-	O
+six	O
+(	O
+26	O
+.	O
+1	O
+%)	O
+patients	O
+required	O
+ICU	O
+care	O
+,	O
+and	O
+eight	O
+(	O
+5	O
+.	O
+8	O
+%)	O
+died	B-PROC
+.	O
+
+RESULTS	O
+:	O
+Thirty	O
+-	O
+six	O
+(	O
+26	O
+.	O
+1	O
+%)	O
+patients	O
+required	O
+ICU	O
+care	O
+,	O
+and	O
+eight	O
+(	O
+5	O
+.	O
+8	O
+%)	O
+died	B-PROC
+.	O
+
+Plateau	O
+pressures	O
+well	O
+below	O
+the	O
+""""	O
+upper	O
+corner	O
+point	O
+""""	O
+(	O
+airway	B-ANAT
+pressure	O
+where	O
+compliance	O
+decreases	O
+)	O
+resulted	O
+in	O
+significant	O
+alveolar	B-ANAT
+overstretching	O
+.	O
+
+None	O
+of	O
+the	O
+objective	O
+characteristics	O
+of	O
+the	O
+pressure	O
+-	O
+volume	O
+curve	O
+was	O
+predictive	O
+for	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+atelectasis	B-DISO
+,	O
+overstretching	O
+,	O
+or	O
+optimal	O
+airway	B-ANAT
+pressure	O
+.	O
+
+RESULTS	O
+:	O
+Simultaneous	O
+alveolar	B-ANAT
+recruitment	B-DISO
+and	O
+overstretching	O
+during	O
+inflation	O
+were	O
+more	O
+pronounced	O
+than	O
+alveolar	B-ANAT
+derecruitment	O
+and	O
+overstretching	O
+during	O
+deflation	O
+.	O
+
+The	O
+ancestral	O
+,	O
+unduplicated	O
+form	O
+of	O
+ACE	B-PRGE
+is	O
+still	O
+expressed	B-PROC
+during	O
+the	O
+terminal	B-PROC
+differentiation	I-PROC
+of	O
+human	B-SPEC
+spermatocytes	O
+,	O
+suggesting	O
+a	O
+critical	O
+role	O
+in	O
+reproduction	B-PROC
+.	O
+
+sACE	O
+may	O
+auto	O
+-	O
+dimerize	O
+via	O
+a	O
+novel	O
+protein	B-CHED
+motif	O
+,	O
+the	O
+""""	O
+disulfide	B-CHED
+zipper	O
+.	O
+
+Of	O
+these	O
+104	O
+compounds	O
+,	O
+2	O
+target	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+main	O
+protease	O
+(	O
+M	O
+(	O
+pro	B-CHED
+)),	O
+7	O
+target	O
+helicase	B-PRGE
+(	O
+Hel	B-PRGE
+),	O
+and	O
+18	O
+target	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+-	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)-	O
+mediated	O
+viral	O
+entry	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+clinical	O
+criteria	O
+for	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+autopsy	O
+findings	O
+.	O
+
+Only	O
+patients	O
+who	O
+died	B-PROC
+and	O
+underwent	O
+autopsy	O
+could	O
+be	O
+included	O
+in	O
+this	O
+study	O
+,	O
+so	O
+these	O
+results	O
+may	O
+not	O
+apply	O
+to	O
+less	O
+severe	O
+cases	O
+of	O
+ARDS	B-DISO
+.	O
+
+Of	O
+these	O
+405	O
+patients	O
+,	O
+255	O
+were	O
+placed	O
+on	O
+ECLS	O
+for	O
+severe	O
+ARDS	B-DISO
+refractory	O
+to	O
+all	O
+other	O
+treatment	O
+.	O
+
+Sixty	O
+-	O
+seven	O
+percent	O
+were	O
+weaned	B-PROC
+off	O
+ECLS	O
+,	O
+and	O
+52	O
+%	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+Extracorporeal	O
+life	O
+support	O
+for	O
+severe	O
+ARDS	B-DISO
+in	O
+adults	O
+is	O
+a	O
+successful	O
+therapeutic	O
+option	O
+in	O
+those	O
+patients	O
+who	O
+do	O
+not	O
+respond	O
+to	O
+conventional	O
+mechanical	O
+ventilator	O
+strategies	O
+.	O
+
+Also	O
+,	O
+alveolar	B-ANAT
+deadspace	O
+volume	O
+increased	O
+by	O
+more	O
+than	O
+200	O
+%	O
+with	O
+isoflurane	B-CHED
+.	O
+
+Although	O
+significant	O
+increases	O
+in	O
+Vd	O
+(	O
+phys	O
+)	O
+resulted	O
+with	O
+PPV	B-CHED
+combined	O
+with	O
+TIVA	O
+,	O
+these	O
+adverse	O
+changes	O
+were	O
+much	O
+less	O
+compared	O
+with	O
+isoflurane	B-CHED
+inhalation	B-PROC
+and	O
+PPV	B-CHED
+.	O
+
+The	O
+extenuation	O
+time	O
+of	O
+corticosteroid	B-CHED
+'	O
+dosage	O
+was	O
+(	O
+33	O
++/-	O
+26	O
+)	O
+mg	O
+/	O
+d	O
+.	O
+
+Two	O
+patients	O
+were	O
+suffering	B-DISO
+from	O
+osteoporosis	B-DISO
+and	O
+30	O
+patients	O
+were	O
+with	O
+bone	B-ANAT
+density	O
+decrement	O
+.	O
+
+Of	O
+the	O
+40	O
+patients	O
+,	O
+36	O
+were	O
+IgG	B-PRGE
+positive	O
+with	O
+an	O
+average	O
+A	O
+value	O
+of	O
+(	O
+0	O
+.	O
+91	O
++/-	O
+
+RESULTS	O
+:	O
+The	O
+incidence	O
+rates	O
+of	O
+critical	O
+conditions	O
+and	O
+MODS	B-DISO
+in	O
+SARS	B-DISO
+cases	O
+were	O
+34	O
+.	O
+86	O
+%	O
+and	O
+13	O
+.	O
+71	O
+%	O
+respectively	O
+.	O
+
+To	O
+create	O
+a	O
+novel	O
+trial	O
+vaccine	O
+and	O
+evaluate	O
+its	O
+potency	O
+,	O
+we	O
+attempted	O
+to	O
+generate	O
+a	O
+SARS	B-DISO
+inactivated	O
+vaccine	O
+using	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+strain	O
+F69	O
+treated	O
+with	O
+formaldehyde	B-CHED
+and	O
+mixed	O
+with	O
+Al	B-CHED
+(	I-CHED
+OH	I-CHED
+)	I-CHED
+3	I-CHED
+.	O
+
+The	O
+in	O
+vitro	O
+neutralization	O
+assay	O
+has	O
+important	O
+implications	O
+for	O
+the	O
+design	O
+of	O
+an	O
+effective	O
+,	O
+protein	B-CHED
+-	O
+based	O
+vaccine	O
+preventing	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+It	O
+is	O
+essential	O
+for	O
+the	O
+interaction	O
+of	O
+the	O
+virons	O
+with	O
+host	B-COMP
+cell	I-COMP
+receptors	O
+and	O
+subsequent	O
+fusion	O
+of	O
+the	O
+viral	O
+envelop	O
+with	O
+host	B-COMP
+cell	I-COMP
+membrane	I-COMP
+to	O
+allow	O
+infection	B-DISO
+.	O
+
+In	O
+order	B-SPEC
+to	O
+investigate	O
+the	O
+maturation	B-PROC
+and	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-DISO
+CoV	O
+,	O
+we	O
+generated	O
+S1	O
+and	O
+S2	O
+subunit	O
+specific	O
+antibodies	B-COMP
+(	O
+Abs	O
+)	O
+as	O
+well	O
+as	O
+N	O
+,	O
+E	O
+and	O
+3CL	O
+protein	B-CHED
+-	O
+specific	O
+Abs	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+anti	O
+-	O
+S1	O
+and	O
+S2	B-PRGE
+Abs	I-PRGE
+were	O
+proved	O
+to	O
+be	O
+capable	O
+of	O
+binding	B-FUNC
+to	O
+SARS	B-PRGE
+CoV	I-PRGE
+under	O
+electron	O
+microscope	O
+observation	O
+.	O
+
+Small	O
+-	O
+scale	O
+screening	O
+identified	O
+a	O
+class	B-SPEC
+of	O
+imidazole	B-CHED
+nucleoside	B-CHED
+/	O
+nucleotide	B-CHED
+analogues	O
+with	O
+antiviral	B-CHED
+activity	O
+against	O
+Lassa	B-SPEC
+virus	I-SPEC
+.	O
+
+The	O
+compounds	O
+also	O
+inhibited	O
+replication	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+in	O
+analogous	O
+assays	O
+,	O
+although	O
+to	O
+a	O
+lesser	O
+extent	O
+than	O
+Lassa	O
+virus	O
+.	O
+
+We	O
+achieved	O
+this	O
+by	O
+using	O
+a	O
+two	O
+-	O
+step	O
+screening	O
+method	O
+consisting	O
+of	O
+frontal	O
+affinity	O
+chromatography	O
+-	O
+mass	O
+spectrometry	O
+coupled	O
+with	O
+a	O
+viral	B-DISO
+infection	I-DISO
+assay	O
+based	O
+on	O
+a	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)-	O
+luc	O
+/	O
+SARS	B-DISO
+pseudotyped	O
+virus	B-SPEC
+.	O
+
+Two	O
+small	O
+molecules	O
+,	O
+tetra	B-CHED
+-	O
+O	O
+-	O
+galloyl	O
+-	O
+beta	B-CHED
+-	I-CHED
+D	I-CHED
+-	I-CHED
+glucose	I-CHED
+(	O
+TGG	O
+)	O
+and	O
+luteolin	B-CHED
+,	O
+were	O
+identified	O
+,	O
+whose	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+activities	O
+were	O
+confirmed	O
+by	O
+using	O
+a	O
+wild	O
+-	O
+type	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+Replication	O
+of	O
+viruses	B-SPEC
+in	O
+species	B-SPEC
+other	O
+than	O
+their	O
+natural	O
+hosts	B-COMP
+is	O
+frequently	O
+limited	O
+by	O
+entry	O
+and	O
+postentry	O
+barriers	O
+.	O
+
+Murine	B-SPEC
+3T3	O
+cells	B-COMP
+expressing	O
+human	B-SPEC
+ACE2	O
+supported	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+,	O
+whereas	O
+replication	O
+was	O
+less	O
+than	O
+10	O
+%	O
+as	O
+efficient	O
+in	O
+the	O
+same	O
+cells	B-COMP
+expressing	O
+murine	B-PRGE
+ACE2	I-PRGE
+.	O
+
+TITLE	O
+:	O
+What	O
+are	O
+the	O
+most	O
+appropriate	O
+methods	O
+of	O
+surveillance	O
+for	O
+monitoring	O
+an	O
+emerging	O
+respiratory	B-DISO
+infection	I-DISO
+such	O
+as	O
+SARS	B-DISO
+?	O
+
+Lung	B-PROC
+function	I-PROC
+abnormalities	O
+were	O
+detected	O
+in	O
+43	O
+patients	O
+(	O
+75	O
+.	O
+4	O
+%),	O
+with	O
+restrictive	O
+defects	O
+(	O
+n	O
+=	O
+16	O
+)	O
+being	O
+most	O
+common	O
+(	O
+28	O
+.	O
+1	O
+%).	O
+
+Only	O
+the	O
+use	O
+of	O
+pulse	B-PROC
+corticosteroids	B-CHED
+was	O
+associated	O
+with	O
+the	O
+presence	O
+of	O
+CT	O
+abnormalities	O
+(	O
+p	O
+=	O
+0	O
+.	O
+043	O
+,	O
+OR	O
+6	O
+.	O
+65	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+06	O
+to	O
+41	O
+.	O
+73	O
+).	O
+
+Only	O
+the	O
+use	O
+of	O
+pulse	B-PROC
+corticosteroids	B-CHED
+was	O
+associated	O
+with	O
+the	O
+presence	O
+of	O
+CT	O
+abnormalities	O
+(	O
+p	O
+=	O
+0	O
+.	O
+043	O
+,	O
+OR	O
+6	O
+.	O
+65	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+06	O
+to	O
+41	O
+.	O
+73	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+international	O
+consensus	O
+definitions	O
+for	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+have	O
+formed	O
+the	O
+basis	O
+for	O
+recruitment	B-DISO
+into	O
+randomized	O
+,	O
+controlled	O
+trials	O
+and	O
+,	O
+more	O
+recently	O
+,	O
+standardized	O
+the	O
+protocols	O
+for	O
+ventilatory	O
+treatment	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Although	O
+possibly	O
+appropriate	O
+for	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+,	O
+these	O
+criteria	O
+may	O
+not	O
+be	O
+appropriate	O
+for	O
+posttraumatic	O
+ARDS	B-DISO
+if	O
+the	O
+disease	O
+patterns	O
+are	O
+widely	O
+divergent	O
+.	O
+
+Patients	O
+from	O
+whom	O
+support	O
+was	O
+withdrawn	B-DISO
+within	O
+48	O
+hours	O
+were	O
+excluded	O
+.	O
+
+A	O
+significant	O
+difference	O
+between	O
+the	O
+two	O
+groups	O
+was	O
+also	O
+seen	O
+in	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+score	O
+,	O
+incidence	O
+of	O
+sepsis	B-DISO
+,	O
+and	O
+incidence	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Intranasal	O
+BCV	B-PRGE
+antigen	B-CHED
+concentration	O
+and	O
+antibody	B-COMP
+titer	O
+against	O
+BCV	B-SPEC
+were	O
+measured	O
+on	O
+entry	O
+to	O
+a	O
+feedlot	O
+.	O
+
+A	O
+task	O
+force	O
+designed	O
+to	O
+ensure	O
+representation	O
+of	O
+all	O
+interested	O
+parties	O
+developed	O
+a	O
+multi	O
+-	O
+phase	O
+approach	O
+which	O
+included	O
+(	O
+a	O
+)	O
+culling	O
+of	O
+nonessential	O
+animals	B-SPEC
+,	O
+(	O
+b	O
+)	O
+cessation	O
+of	O
+breeding	B-PROC
+,	O
+(	O
+c	O
+)	O
+testing	O
+and	O
+culling	O
+of	O
+individual	O
+animals	B-SPEC
+,	O
+and	O
+(	O
+d	O
+)	O
+cross	O
+-	O
+fostering	O
+to	O
+clean	O
+dams	O
+.	O
+
+This	O
+multi	O
+-	O
+phase	O
+approach	O
+may	O
+be	O
+useful	O
+for	O
+other	O
+institutions	O
+attempting	O
+to	O
+eradicate	O
+mouse	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+new	O
+lignan	B-CHED
+glycoside	B-CHED
+and	O
+phenylethanoid	O
+glycosides	B-CHED
+from	O
+Strobilanthes	B-SPEC
+cusia	I-SPEC
+BREMEK	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+a	O
+new	O
+lignan	B-CHED
+glycoside	B-CHED
+(	O
+6	O
+)	O
+and	O
+two	O
+new	O
+phenylethanoid	O
+glycosides	B-CHED
+(	O
+7	O
+,	O
+8	O
+)	O
+together	O
+with	O
+five	O
+known	O
+compounds	O
+as	O
+chemical	O
+constituents	O
+of	O
+Strobilanthes	B-SPEC
+cusia	I-SPEC
+root	B-ANAT
+.	O
+
+Among	O
+the	O
+tested	O
+samples	O
+,	O
+lupeol	B-CHED
+showed	O
+anti	O
+-	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+activity	O
+(	O
+EC	O
+(	O
+50	O
+):	O
+11	O
+.	O
+7	O
+microM	O
+)	O
+and	O
+showed	O
+100	O
+%	O
+inhibition	B-PROC
+of	O
+virus	B-SPEC
+plaque	B-DISO
+formation	B-PROC
+at	O
+58	O
+.	O
+7	O
+microM	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+only	O
+a	O
+very	O
+small	O
+part	O
+of	O
+viral	B-DISO
+gastroenteritis	I-DISO
+can	O
+be	O
+diagnosed	O
+and	O
+notified	O
+.	O
+
+The	O
+ethics	O
+of	O
+visitation	O
+restrictions	O
+-	O
+lessons	O
+learned	B-PROC
+from	O
+SARS	B-DISO
+.	O
+
+Infections	O
+with	O
+CRCoV	O
+occurred	O
+mostly	O
+during	O
+the	O
+first	O
+week	O
+of	O
+a	O
+dog	B-SPEC
+'	O
+s	O
+stay	O
+at	O
+the	O
+kennel	O
+,	O
+whereas	O
+CPIV	O
+and	O
+CHV	O
+were	O
+detected	O
+at	O
+later	O
+time	O
+points	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+evaluation	O
+of	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+CPIV	O
+and	O
+an	O
+immunofluorescence	O
+assay	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+CHV	O
+is	O
+described	O
+.	O
+
+TITLE	O
+:	O
+Factors	O
+associated	O
+with	O
+transmission	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+among	O
+health	O
+-	O
+care	O
+workers	O
+in	O
+Singapore	O
+.	O
+
+A	O
+case	O
+-	O
+control	O
+study	O
+with	O
+36	O
+cases	O
+and	O
+50	O
+controls	O
+was	O
+conducted	O
+of	O
+factors	O
+associated	O
+with	O
+the	O
+transmission	O
+of	O
+SARS	B-DISO
+within	O
+the	O
+hospital	O
+.	O
+
+Multivariate	O
+analysis	O
+confirmed	O
+the	O
+strong	O
+role	O
+of	O
+contact	O
+with	O
+respiratory	O
+secretions	B-ANAT
+(	O
+adjusted	O
+OR	O
+21	O
+.	O
+8	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+7	O
+274	O
+.	O
+8	O
+,	O
+P	O
+=	O
+0	O
+.	O
+017	O
+).	O
+
+After	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+a	O
+total	O
+of	O
+750	O
+staff	O
+nurses	O
+(	O
+response	O
+rate	O
+90	O
+%)	O
+at	O
+one	O
+hospital	O
+completed	O
+a	O
+questionnaire	O
+assessing	O
+their	O
+intention	O
+to	O
+provide	O
+care	O
+to	O
+SARS	B-DISO
+patients	O
+.	O
+
+Four	O
+factors	O
+explaining	O
+35	O
+%	O
+of	O
+the	O
+variance	O
+in	O
+nurses	O
+'	O
+intention	O
+to	O
+care	O
+for	O
+SARS	B-DISO
+patients	O
+were	O
+self	O
+-	O
+efficacy	O
+(	O
+beta	O
+=	O
+0	O
+.	O
+39	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+attitude	O
+(	O
+beta	O
+=	O
+0	O
+.	O
+25	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+years	O
+of	O
+working	O
+in	O
+the	O
+study	O
+hospital	O
+(	O
+beta	O
+=	O
+-	O
+0	O
+.	O
+15	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+receiving	O
+resources	O
+from	O
+the	O
+hospital	O
+(	O
+beta	O
+=	O
+0	O
+.	O
+13	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+results	O
+are	O
+helpful	O
+for	O
+human	B-SPEC
+resources	O
+managers	O
+facing	O
+a	O
+new	O
+contagious	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Virus	B-PRGE
+-	I-PRGE
+like	I-PRGE
+particles	I-PRGE
+(	O
+VLPs	B-ANAT
+)	O
+produced	O
+by	O
+recombinant	O
+expression	B-PROC
+of	O
+the	O
+major	O
+viral	O
+structural	O
+proteins	B-CHED
+could	O
+be	O
+an	O
+attractive	O
+method	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+control	O
+.	O
+
+Co	B-DISO
+-	I-DISO
+infections	I-DISO
+of	O
+insect	B-SPEC
+cells	B-COMP
+with	O
+two	O
+recombinant	O
+viruses	B-SPEC
+demonstrated	O
+that	O
+M	O
+and	O
+E	O
+could	O
+assemble	O
+readily	O
+to	O
+form	O
+smooth	O
+surfaced	O
+VLPs	B-ANAT
+.	O
+
+It	O
+investigates	O
+the	O
+way	O
+that	O
+SARS	B-DISO
+was	O
+presented	O
+as	O
+a	O
+dangerous	O
+threat	O
+to	O
+the	O
+UK	O
+public	O
+,	O
+whilst	O
+almost	O
+immediately	O
+the	O
+threat	O
+was	O
+said	O
+to	O
+be	O
+'	O
+contained	O
+'	O
+using	O
+the	O
+mechanism	O
+of	O
+'	O
+othering	O
+':	O
+SARS	B-DISO
+was	O
+said	O
+to	O
+be	O
+unlikely	O
+to	O
+personally	O
+affect	O
+the	O
+UK	O
+reader	O
+because	O
+the	O
+Chinese	O
+were	O
+so	O
+different	O
+to	O
+'	O
+us	O
+';	O
+so	O
+'	O
+other	O
+'.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+auto	O
+-	O
+cleavage	B-PROC
+assay	O
+for	O
+studying	O
+mutational	O
+effects	O
+on	O
+the	O
+active	O
+site	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3C	O
+-	O
+like	O
+protease	O
+.	O
+
+The	O
+antibodies	B-COMP
+recognized	O
+RBD	O
+on	O
+S1	B-PRGE
+domain	I-PRGE
+and	O
+completely	O
+inhibited	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+at	O
+a	O
+serum	B-COMP
+dilution	O
+of	O
+1	O
+:	O
+10	O
+,	O
+240	O
+.	O
+
+TITLE	O
+:	O
+Medical	O
+treatment	O
+of	O
+viral	B-DISO
+pneumonia	I-DISO
+including	O
+SARS	B-DISO
+in	O
+immunocompetent	O
+adult	O
+.	O
+
+These	O
+studies	O
+suggest	O
+that	O
+combination	B-PRGE
+IFN	I-PRGE
+treatment	O
+warrants	O
+further	O
+investigation	O
+as	O
+a	O
+treatment	O
+for	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Membrane	B-PROC
+fusion	I-PROC
+between	O
+virus	B-SPEC
+and	O
+host	B-COMP
+cells	B-COMP
+is	O
+the	O
+key	O
+step	O
+for	O
+enveloped	O
+virus	B-SPEC
+entry	O
+and	O
+is	O
+mediated	O
+by	O
+the	O
+viral	B-PRGE
+envelope	I-PRGE
+fusion	I-PRGE
+protein	B-CHED
+.	O
+
+To	O
+facilitate	O
+the	O
+solution	O
+of	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+this	O
+fusion	O
+core	O
+,	O
+we	O
+deployed	O
+an	O
+Escherichia	B-SPEC
+coli	I-SPEC
+in	O
+vitro	O
+expression	B-PROC
+system	O
+to	O
+express	O
+the	O
+HR1	O
+and	O
+HR2	O
+regions	O
+linked	O
+together	O
+by	O
+a	O
+flexible	O
+linker	O
+as	O
+a	O
+single	O
+chain	O
+(	O
+named	O
+2	O
+-	O
+helix	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+rapid	O
+worldwide	O
+spread	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+demonstrated	O
+the	O
+potential	O
+threat	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+poses	O
+in	O
+a	O
+closely	O
+interconnected	O
+and	O
+interdependent	O
+world	O
+.	O
+
+Our	O
+model	O
+can	O
+be	O
+used	O
+to	O
+predict	O
+the	O
+worldwide	O
+spread	O
+of	O
+future	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+to	O
+identify	O
+endangered	O
+regions	O
+in	O
+advance	O
+.	O
+
+SIGNR1	O
+,	O
+a	O
+murine	B-SPEC
+DC	O
+-	O
+SIGN	O
+homologue	O
+,	O
+also	O
+enhanced	O
+infection	B-DISO
+driven	O
+by	O
+MARV	O
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+GP	O
+and	O
+could	O
+be	O
+targeted	B-PROC
+to	O
+assess	O
+the	O
+role	O
+of	O
+attachment	O
+factors	O
+in	O
+filovirus	B-SPEC
+infection	B-DISO
+in	O
+vivo	O
+.	O
+
+Anxiety	O
+scores	O
+ranged	O
+from	O
+20	O
+to	O
+80	O
+,	O
+and	O
+mean	O
+(	O
+standard	O
+deviation	O
+)	O
+scores	O
+were	O
+higher	O
+among	O
+staff	O
+who	O
+had	O
+had	O
+contact	O
+with	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+than	O
+among	O
+those	O
+who	O
+had	O
+not	O
+(	O
+52	O
+.	O
+6	O
+[	O
+10	O
+.	O
+5	O
+]	O
+versus	O
+49	O
+.	O
+8	O
+[	O
+10	O
+.	O
+1	O
+],	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Anxiety	O
+scores	O
+were	O
+correlated	O
+with	O
+burnout	O
+scores	O
+(	O
+Pearson	O
+'	O
+s	O
+correlation	O
+coefficient	O
+,	O
+0	O
+.	O
+52	O
+-	O
+0	O
+.	O
+59	O
+)	O
+and	O
+with	O
+discomfort	B-DISO
+from	O
+wearing	O
+protective	O
+gear	O
+(	O
+0	O
+.	O
+21	O
+-	O
+0	O
+.	O
+32	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+implemented	O
+a	O
+3	O
+-	O
+step	O
+strategy	O
+to	O
+test	O
+the	O
+intriguing	O
+hypothesis	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+might	O
+have	O
+been	O
+derived	O
+from	O
+a	O
+recombinant	O
+virus	B-SPEC
+.	O
+
+The	O
+analysis	O
+of	O
+extensive	O
+morbidity	O
+rates	O
+among	O
+different	O
+age	O
+groups	O
+of	O
+the	O
+population	O
+showed	O
+that	O
+children	O
+were	O
+affected	O
+by	O
+coronavirus	B-DISO
+infection	I-DISO
+5	O
+-	O
+7	O
+times	O
+more	O
+often	O
+than	O
+adults	O
+.	O
+
+Mucosal	B-ANAT
+antibodies	B-COMP
+to	O
+coronaviruses	O
+in	O
+the	O
+secretions	B-ANAT
+of	O
+the	O
+nasal	B-ANAT
+cavity	I-ANAT
+proved	O
+to	O
+be	O
+more	O
+important	O
+than	O
+serum	B-COMP
+antibodies	B-COMP
+not	O
+only	O
+in	O
+protection	O
+from	O
+infection	B-DISO
+,	O
+but	O
+also	O
+in	O
+the	O
+pattern	O
+of	O
+clinical	O
+manifestations	O
+of	O
+the	O
+disease	O
+.	O
+
+Despite	O
+the	O
+fact	O
+that	O
+patients	O
+with	O
+thrombocytosis	B-DISO
+had	O
+a	O
+greater	O
+severity	O
+of	O
+illness	O
+,	O
+the	O
+ICU	O
+mortality	O
+was	O
+comparable	O
+among	O
+patients	O
+with	O
+and	O
+without	O
+thrombocytosis	B-DISO
+(	O
+8	O
+vs	O
+14	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+34	O
+).	O
+
+Unless	O
+additional	O
+risk	O
+factors	O
+are	O
+present	O
+,	O
+reactive	B-DISO
+thrombocytosis	I-DISO
+is	O
+not	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+thromboembolic	B-DISO
+events	I-DISO
+.	O
+
+TITLE	O
+:	O
+Factors	O
+associated	O
+with	O
+psychosis	B-DISO
+among	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+case	O
+-	O
+control	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+observed	O
+that	O
+a	O
+number	O
+of	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+developed	O
+affective	B-DISO
+psychosis	I-DISO
+during	O
+the	O
+acute	O
+phase	O
+of	O
+their	O
+illness	O
+.	O
+
+We	O
+reviewed	O
+all	O
+SARS	B-DISO
+-	O
+related	O
+psychiatric	O
+consultations	O
+in	O
+Hong	O
+Kong	O
+and	O
+investigated	O
+the	O
+risk	O
+factors	O
+for	O
+psychosis	B-DISO
+among	O
+patients	O
+with	O
+SARS	B-DISO
+in	O
+a	O
+matched	O
+case	O
+-	O
+control	O
+study	O
+.	O
+
+The	O
+findings	O
+of	O
+the	O
+present	O
+study	O
+suggest	O
+that	O
+steroid	B-CHED
+toxicity	O
+,	O
+personal	O
+vulnerability	O
+,	O
+and	O
+,	O
+probably	O
+,	O
+psychosocial	B-DISO
+stressors	I-DISO
+jointly	O
+contributed	O
+to	O
+the	O
+development	B-PROC
+of	O
+psychosis	B-DISO
+in	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+To	O
+evaluate	O
+the	O
+sensitivity	O
+of	O
+the	O
+assay	O
+,	O
+a	O
+gel	O
+-	O
+based	O
+RT	O
+-	O
+PCR	O
+method	O
+targeted	B-PROC
+at	O
+the	O
+same	O
+101	O
+bp	O
+sequence	O
+was	O
+also	O
+developed	O
+.	O
+
+The	O
+study	O
+indicates	O
+that	O
+the	O
+LUX	O
+assay	O
+reported	O
+below	O
+is	O
+rapid	O
+,	O
+reliable	O
+and	O
+sensitive	O
+and	O
+it	O
+has	O
+the	O
+potential	O
+for	O
+use	O
+as	O
+an	O
+alternative	O
+molecular	O
+method	O
+for	O
+TGEV	B-SPEC
+diagnosis	O
+.	O
+
+To	O
+express	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+at	O
+high	O
+-	O
+level	O
+in	O
+vitro	O
+,	O
+the	O
+M	O
+gene	O
+fragment	O
+was	O
+amplified	O
+and	O
+cloned	O
+it	O
+into	O
+the	O
+Pichia	B-SPEC
+Pastoris	I-SPEC
+expression	B-PROC
+vector	O
+pPICZalphaA	O
+.	O
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+Western	O
+blotting	O
+analysis	O
+of	O
+the	O
+induced	O
+products	O
+of	O
+recombinant	O
+yeast	B-SPEC
+transformant	O
+indicated	O
+that	O
+successful	O
+high	O
+-	O
+level	O
+expression	B-PROC
+of	O
+M	B-PRGE
+protein	I-PRGE
+was	O
+achieved	O
+,	O
+and	O
+that	O
+the	O
+expression	B-PROC
+product	O
+was	O
+similar	O
+antigenically	O
+to	O
+the	O
+natural	O
+protein	B-CHED
+.	O
+
+Purified	O
+recombinant	B-PRGE
+M	I-PRGE
+protein	I-PRGE
+was	O
+used	O
+subsequently	O
+as	O
+an	O
+ELISA	O
+antigen	B-CHED
+for	O
+detection	O
+of	O
+eight	O
+serum	B-COMP
+samples	O
+screened	O
+previously	O
+by	O
+whole	O
+virus	B-SPEC
+ELISA	O
+and	O
+immunofluorescence	O
+assay	O
+,	O
+and	O
+consistent	O
+results	O
+were	O
+obtained	O
+.	O
+
+Similarly	O
+,	O
+by	O
+taking	O
+moderate	O
+daily	O
+doses	O
+of	O
+corticosteroids	B-CHED
+as	O
+a	O
+prophylactic	O
+,	O
+it	O
+may	O
+be	O
+possible	O
+to	O
+avoid	O
+clinical	B-DISO
+infection	I-DISO
+with	O
+SARS	B-DISO
+.	O
+
+In	O
+this	O
+article	O
+,	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+from	O
+the	O
+SARS	B-DISO
+and	O
+influenza	B-SPEC
+viruses	I-SPEC
+representing	O
+likely	O
+homology	O
+to	O
+human	B-PRGE
+ACTH	B-CHED
+are	O
+identified	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+a	O
+panel	O
+of	O
+murine	B-SPEC
+monoclonal	O
+antibodies	B-COMP
+specific	O
+for	O
+the	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+.	O
+
+Initial	O
+blood	B-ANAT
+glucose	B-CHED
+,	O
+systolic	O
+pressure	O
+(	O
+SBP	O
+),	O
+and	O
+diastolic	O
+pressure	O
+(	O
+DBP	B-CHED
+)	O
+were	O
+no	O
+significant	O
+difference	O
+between	O
+GCS	O
+group	O
+and	O
+non	O
+-	O
+GCS	O
+group	O
+.	O
+
+Histologically	O
+,	O
+the	O
+lungs	B-ANAT
+showed	O
+severe	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+and	O
+bronchopneumonia	B-DISO
+,	O
+but	O
+no	O
+viral	O
+inclusion	O
+.	O
+
+No	O
+specific	O
+pathological	O
+change	O
+was	O
+seen	O
+in	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+and	O
+kidneys	B-ANAT
+.	O
+
+The	O
+research	O
+presented	O
+here	O
+used	O
+computational	O
+models	O
+of	O
+the	O
+lung	B-ANAT
+to	O
+analyze	O
+the	O
+effect	O
+of	O
+altitude	O
+on	O
+the	O
+PaO2	O
+/	O
+FIO2	O
+ratio	O
+and	O
+pulmonary	B-ANAT
+shunt	O
+.	O
+
+In	O
+contrast	O
+to	O
+the	O
+high	O
+positive	O
+rate	O
+of	O
+feces	B-ANAT
+RT	O
+-	O
+PCR	O
+(	O
+97	O
+%)	O
+in	O
+Amoy	O
+Gardens	O
+,	O
+our	O
+positive	O
+rate	O
+in	O
+rectal	B-ANAT
+swab	I-ANAT
+RT	O
+-	O
+PCT	B-DISO
+(	O
+0	O
+%)	O
+was	O
+significantly	O
+lower	O
+(	O
+P	O
+=	O
+0	O
+.	O
+00000002	O
+).	O
+
+The	O
+authors	O
+trace	O
+the	O
+emergence	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+from	O
+southern	O
+China	O
+and	O
+its	O
+spread	O
+worldwide	O
+,	O
+discuss	O
+the	O
+viral	O
+etiology	O
+of	O
+the	O
+infection	B-DISO
+and	O
+its	O
+clinical	O
+features	O
+,	O
+and	O
+review	O
+the	O
+infection	B-DISO
+control	O
+guidelines	O
+issued	O
+during	O
+the	O
+outbreak	O
+by	O
+the	O
+health	O
+authorities	O
+in	O
+Hong	O
+Kong	O
+,	O
+the	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+and	O
+the	O
+American	O
+Dental	O
+Association	O
+.	O
+
+On	O
+days	O
+8	O
+,	O
+12	O
+,	O
+16	O
+,	O
+and	O
+20	O
+,	O
+the	O
+cumulative	O
+proportion	O
+of	O
+patients	O
+with	O
+undetectable	O
+virus	B-SPEC
+in	O
+plasma	B-ANAT
+was	O
+31	O
+%,	O
+69	O
+%,	O
+92	O
+%,	O
+and	O
+100	O
+%,	O
+respectively	O
+.	O
+
+Plasma	B-ANAT
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+concentrations	O
+in	O
+the	O
+second	O
+and	O
+third	O
+week	O
+of	O
+illness	O
+were	O
+significantly	O
+higher	O
+in	O
+patients	O
+who	O
+received	O
+initial	O
+hydrocortisone	B-CHED
+treatment	O
+(	O
+n	O
+=	O
+9	O
+),	O
+as	O
+compared	O
+to	O
+those	O
+who	O
+received	O
+placebo	O
+(	O
+n	O
+=	O
+7	O
+)(	O
+AUC	O
+;	O
+Mann	O
+-	O
+Whitney	O
+,	O
+P	O
+=	O
+0	O
+.	O
+023	O
+).	O
+
+Problems	O
+with	O
+the	O
+inadequacy	O
+of	O
+the	O
+primary	O
+report	O
+of	O
+the	O
+one	O
+included	O
+study	O
+do	O
+not	O
+allow	O
+us	O
+to	O
+report	O
+any	O
+quantitative	O
+results	O
+for	O
+patients	O
+with	O
+ALI	O
+or	O
+ARDS	B-DISO
+.	O
+
+Although	O
+respondents	O
+were	O
+highly	O
+aware	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+the	O
+outbreak	O
+did	O
+not	O
+result	O
+in	O
+unnecessary	O
+precautionary	O
+actions	O
+or	O
+fears	O
+.	O
+
+TITLE	O
+:	O
+Leukocyte	B-ANAT
+antibodies	B-COMP
+and	O
+biologically	O
+active	O
+mediators	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+.	O
+
+In	O
+severe	O
+cases	O
+,	O
+the	O
+most	O
+prominent	O
+feature	O
+is	O
+acute	O
+onset	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+a	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+:	O
+an	O
+experience	O
+in	O
+Taiwan	O
+.	O
+
+There	O
+were	O
+significant	O
+differences	O
+on	O
+condition	B-DISO
+classifications	O
+(	O
+p	O
+=	O
+0	O
+.	O
+000	O
+),	O
+increased	O
+rate	O
+of	O
+patients	O
+that	O
+underwent	O
+endotracheal	O
+intubation	O
+(	O
+p	O
+=	O
+0	O
+.	O
+003	O
+),	O
+needed	O
+mechanical	O
+ventilation	O
+(	O
+p	O
+=	O
+0	O
+.	O
+020	O
+),	O
+and	O
+admission	O
+(	O
+p	O
+=	O
+0	O
+.	O
+000	O
+).	O
+
+The	O
+number	O
+of	O
+visits	O
+that	O
+underwent	O
+chest	B-ANAT
+radiological	O
+examination	O
+increased	O
+(	O
+p	O
+=	O
+0	O
+.	O
+000	O
+)	O
+and	O
+upper	B-ANAT
+abdomen	I-ANAT
+sonography	O
+(	O
+p	O
+=	O
+0	O
+.	O
+007	O
+)	O
+decreased	O
+significantly	O
+in	O
+May	O
+.	O
+
+Viral	O
+load	O
+in	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+n	O
+=	O
+142	O
+)	O
+from	O
+day	O
+10	O
+to	O
+day	O
+15	O
+after	O
+onset	O
+of	O
+symptoms	O
+was	O
+associated	O
+with	O
+oxygen	B-CHED
+desaturation	O
+,	O
+mechanical	O
+ventilation	O
+,	O
+diarrhea	B-DISO
+,	O
+hepatic	B-DISO
+dysfunction	I-DISO
+,	O
+and	O
+death	B-PROC
+.	O
+
+The	O
+assay	O
+was	O
+developed	O
+by	O
+epitope	B-CHED
+mapping	O
+,	O
+using	O
+synthetic	O
+peptides	B-CHED
+from	O
+the	O
+spike	O
+,	O
+membrane	B-COMP
+,	O
+and	O
+nucleocapsid	B-COMP
+protein	B-CHED
+sequences	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+total	O
+of	O
+1	O
+,	O
+068	O
+asymptomatic	O
+close	O
+contacts	O
+of	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+(	O
+SARS	O
+)	O
+from	O
+the	O
+2003	O
+epidemic	O
+in	O
+Hong	O
+Kong	O
+were	O
+serologically	O
+tested	O
+,	O
+and	O
+2	O
+(	O
+0	O
+.	O
+19	O
+%)	O
+were	O
+positive	O
+for	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+immunoglobulin	B-PROC
+G	I-PRGE
+antibody	B-COMP
+.	O
+
+One	O
+hour	O
+of	O
+NPPV	O
+therapy	O
+led	O
+to	O
+significant	O
+increases	O
+in	O
+PaO	B-PROC
+(	O
+2	O
+),	O
+SpO	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+and	I-PRGE
+PaO	I-PRGE
+(	I-PRGE
+2	I-PRGE
+)/	I-PRGE
+FiO	I-PRGE
+(	I-PRGE
+2	I-PRGE
+),	I-PRGE
+and	O
+decrease	O
+in	O
+respiratory	O
+rate	O
+(	O
+all	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+As	O
+there	O
+was	O
+a	O
+high	O
+incidence	O
+of	O
+remarkable	O
+barotrauma	O
+,	O
+a	O
+careful	O
+lung	B-ANAT
+protective	O
+strategy	O
+is	O
+necessary	O
+during	O
+the	O
+administration	O
+of	O
+NPPV	O
+as	O
+well	O
+as	O
+invasive	O
+mechanical	O
+ventilation	O
+.	O
+
+RESULTS	O
+:	O
+At	O
+6	O
+weeks	O
+of	O
+SARS	B-DISO
+onset	O
+,	O
+25	O
+%	O
+(	O
+30	O
+/	O
+120	O
+)	O
+patients	O
+had	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Applications	O
+of	O
+compartmental	O
+models	O
+to	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+)	O
+resulted	O
+in	O
+estimates	O
+of	O
+the	O
+fundamental	O
+quantity	O
+called	O
+the	O
+basic	O
+reproductive	B-PROC
+number	O
+R0	O
+--	O
+the	O
+number	O
+of	O
+new	O
+cases	O
+of	O
+SARS	B-DISO
+resulting	O
+from	O
+a	O
+single	O
+initial	O
+case	O
+--	O
+above	O
+one	O
+,	O
+implying	O
+that	O
+,	O
+without	O
+public	O
+health	O
+intervention	O
+,	O
+most	O
+outbreaks	O
+should	O
+spark	O
+large	O
+-	O
+scale	O
+epidemics	O
+.	O
+
+The	O
+crude	O
+incidence	O
+of	O
+SARS	B-DISO
+in	O
+our	O
+cohort	O
+was	O
+10	O
+%.	O
+
+The	O
+SARS	B-DISO
+case	O
+fatality	O
+was	O
+14	O
+%.	O
+
+ABSTRACT	O
+:	O
+Crystals	B-ANAT
+of	O
+a	O
+2	O
+-	O
+Helix	O
+fusion	O
+-	O
+core	O
+construct	O
+of	O
+MHV	B-PRGE
+spike	I-PRGE
+protein	B-CHED
+(	O
+commonly	O
+referred	O
+to	O
+as	O
+E2	O
+)	O
+have	O
+been	O
+grown	O
+at	O
+291	O
+K	O
+using	O
+PEG	B-CHED
+4000	O
+as	O
+precipitant	O
+.	O
+
+Five	O
+patients	O
+had	O
+positive	O
+stool	B-ANAT
+samples	O
+,	O
+collected	O
+in	O
+weeks	O
+5	O
+-	O
+9	O
+.	O
+
+ABSTRACT	O
+:	O
+Four	O
+cases	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+that	O
+occurred	O
+from	O
+December	O
+16	O
+,	O
+2003	O
+,	O
+to	O
+January	O
+8	O
+,	O
+2004	O
+,	O
+in	O
+the	O
+city	O
+of	O
+Guangzhou	O
+,	O
+Guangdong	O
+Province	O
+,	O
+China	O
+,	O
+were	O
+investigated	O
+.	O
+
+The	O
+green	O
+fluorescence	O
+,	O
+mean	O
+fluorescence	O
+intensity	O
+,	O
+and	O
+SARS	O
+-	O
+CoV	O
+S	O
+RNA	O
+transcripts	O
+were	O
+found	O
+significantly	O
+reduced	O
+,	O
+and	O
+the	O
+expression	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+was	O
+strongly	O
+inhibited	O
+in	O
+those	O
+cells	B-COMP
+co	O
+-	O
+transfected	O
+with	O
+either	O
+EGFP	O
+-	O
+or	O
+S	O
+-	O
+specific	O
+siRNAs	O
+.	O
+
+ABSTRACT	O
+:	O
+Programmed	O
+-	O
+1	O
+ribosomal	B-ANAT
+frameshifting	I-PROC
+is	O
+an	O
+alternate	O
+mechanism	O
+of	O
+translation	B-PROC
+used	O
+by	O
+coronavirus	B-SPEC
+to	O
+synthesize	O
+replication	O
+proteins	B-CHED
+encoded	O
+by	O
+two	O
+overlapping	O
+open	O
+reading	O
+frames	O
+.	O
+
+Toroviruses	B-SPEC
+and	O
+group	O
+2	O
+coronaviruses	O
+bind	B-FUNC
+to	O
+O	O
+-	O
+acetylated	O
+Sias	O
+,	O
+presumably	O
+via	O
+their	O
+spike	O
+proteins	B-CHED
+(	O
+S	O
+),	O
+whereas	O
+other	O
+glycoproteins	B-CHED
+,	O
+the	O
+hemagglutinin	O
+-	O
+esterases	B-FUNC
+(	O
+HE	O
+),	O
+destroy	O
+Sia	B-PRGE
+receptors	I-PRGE
+by	O
+de	O
+-	O
+O	O
+-	O
+acetylation	B-PROC
+.	O
+
+Whereas	O
+most	O
+rodent	B-SPEC
+coronaviruses	O
+express	O
+sialate	B-CHED
+-	O
+4	O
+-	O
+O	O
+-	O
+acetylesterases	O
+,	O
+the	O
+HE	O
+of	O
+murine	O
+coronavirus	O
+DVIM	O
+cleaves	O
+9	O
+-	O
+O	O
+-	O
+acetylated	O
+Sias	O
+.	O
+
+There	O
+are	O
+striking	O
+parallels	O
+between	O
+orthomyxo	O
+-	O
+and	O
+nidovirus	B-SPEC
+biology	O
+.	O
+
+As	O
+for	O
+orthomyxovirus	B-SPEC
+reassortants	O
+,	O
+the	O
+fitness	O
+of	O
+nidovirus	B-SPEC
+recombinant	O
+offspring	O
+probably	O
+depends	O
+both	O
+on	O
+antigenic	O
+properties	O
+and	O
+on	O
+compatibility	O
+of	O
+receptor	O
+-	O
+binding	B-FUNC
+and	O
+receptor	O
+-	O
+destroying	O
+activities	O
+.	O
+
+Biochemical	O
+and	O
+thermodynamic	O
+investigation	O
+in	O
+conjunction	O
+with	O
+molecular	B-PROC
+dynamics	I-PROC
+simulations	O
+.	O
+
+Blocking	B-DISO
+either	O
+the	O
+5	O
+'	O
+or	O
+3	O
+'	O
+terminus	O
+did	O
+not	O
+affect	O
+cleavage	B-PROC
+.	O
+
+Concentrations	O
+of	O
+Mn	O
+(	O
+2	O
++)	O
+needed	O
+for	O
+endoribonuclease	B-FUNC
+activity	I-FUNC
+induced	O
+significant	O
+conformation	O
+change	O
+(	O
+s	O
+)	O
+in	O
+the	O
+protein	B-CHED
+,	O
+as	O
+measured	O
+by	O
+changes	O
+in	O
+tryptophan	B-CHED
+fluorescence	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+two	O
+viral	O
+genes	O
+,	O
+encoding	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+proteins	B-CHED
+,	O
+are	O
+necessary	O
+and	O
+sufficient	O
+for	O
+formation	B-PROC
+of	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+.	O
+
+The	O
+S	O
+,	O
+M	O
+,	O
+and	O
+N	O
+proteins	B-CHED
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+are	O
+,	O
+therefore	O
+,	O
+necessary	O
+and	O
+sufficient	O
+for	O
+pseudovirus	O
+assembly	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+construction	O
+of	O
+a	O
+set	O
+of	O
+transmissible	O
+gastroenteritis	O
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)-	O
+derived	O
+replicons	O
+as	O
+bacterial	O
+artificial	O
+chromosomes	B-COMP
+is	O
+reported	O
+.	O
+
+TGEV	B-SPEC
+replicons	O
+were	O
+functional	O
+in	O
+several	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+including	O
+the	O
+human	B-ANAT
+cell	B-COMP
+line	I-ANAT
+293T	O
+,	O
+in	O
+which	O
+no	O
+or	O
+very	O
+low	O
+cytopathic	B-DISO
+effect	I-DISO
+was	O
+observed	O
+,	O
+and	O
+expressed	B-PROC
+high	O
+amounts	O
+of	O
+heterologous	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+,	O
+purification	O
+and	O
+sublocalization	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+in	O
+insect	B-SPEC
+cells	B-ANAT
+.	O
+
+The	O
+need	O
+for	O
+oxygen	B-CHED
+supplementation	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+)	O
+and	O
+lymphopenia	B-DISO
+during	O
+the	O
+course	B-DISO
+of	I-DISO
+illness	I-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+012	O
+)	O
+were	O
+significant	O
+risk	O
+factors	O
+in	O
+predicting	O
+abnormal	O
+HRCT	O
+.	O
+
+The	O
+coronavirus	B-SPEC
+spike	O
+proteins	B-CHED
+belong	O
+to	O
+class	B-PRGE
+I	I-PRGE
+fusion	I-PRGE
+proteins	B-CHED
+,	O
+and	O
+are	O
+characterized	O
+by	O
+the	O
+existence	O
+of	O
+two	O
+heptad	O
+repeat	O
+(	O
+HR	O
+)	O
+regions	O
+,	O
+HR1	O
+and	O
+HR2	O
+.	O
+
+All	O
+15	O
+patients	O
+had	O
+fever	B-PROC
+,	O
+3	O
+(	O
+20	O
+%)	O
+had	O
+chills	B-DISO
+,	O
+and	O
+11	O
+(	O
+73	O
+%)	O
+had	O
+cough	B-DISO
+.	O
+
+Children	O
+with	O
+SARS	B-DISO
+had	O
+significantly	O
+lower	O
+incidences	O
+of	O
+rhinorrhea	B-DISO
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+0	O
+.	O
+01	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+0	O
+.	O
+00	O
+-	O
+0	O
+.	O
+09	O
+),	O
+sputum	B-PROC
+production	I-PROC
+(	O
+OR	O
+,	O
+0	O
+.	O
+10	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+02	O
+-	O
+0	O
+.	O
+63	O
+),	O
+and	O
+sore	B-DISO
+throat	I-DISO
+(	O
+OR	O
+,	O
+0	O
+.	O
+17	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+03	O
+-	O
+0	O
+.	O
+85	O
+)	O
+than	O
+children	O
+with	O
+influenza	B-DISO
+.	O
+
+Both	O
+groups	O
+had	O
+similar	O
+incidences	O
+of	O
+leukopenia	B-DISO
+or	O
+lymphopenia	B-DISO
+,	O
+but	O
+SARS	B-DISO
+patients	O
+had	O
+a	O
+significantly	O
+higher	O
+incidence	O
+of	O
+monocytopenia	O
+(	O
+33	O
+%	O
+vs	O
+0	O
+%,	O
+P	O
+=	O
+.	O
+04	O
+).	O
+
+ABSTRACT	O
+:	O
+As	O
+yet	O
+,	O
+no	O
+one	O
+has	O
+written	O
+a	O
+comprehensive	O
+epidemiologic	O
+account	O
+of	O
+a	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+from	O
+an	O
+affected	O
+country	O
+.	O
+
+To	O
+provide	O
+a	O
+comprehensive	O
+epidemiologic	O
+account	O
+of	O
+a	O
+SARS	B-DISO
+outbreak	O
+from	O
+an	O
+affected	O
+territory	O
+.	O
+
+The	O
+2003	O
+Hong	O
+Kong	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Sociodemographic	O
+characteristics	O
+;	O
+infection	B-DISO
+clusters	B-CHED
+by	O
+time	O
+,	O
+occupation	O
+,	O
+setting	O
+,	O
+and	O
+workplace	O
+;	O
+and	O
+geospatial	O
+relationships	O
+were	O
+determined	O
+.	O
+
+The	O
+mean	O
+and	O
+variance	O
+in	O
+time	O
+from	O
+onset	O
+to	O
+admission	O
+,	O
+from	O
+admission	O
+to	O
+discharge	B-ANAT
+,	O
+or	O
+from	O
+admission	O
+to	O
+death	B-PROC
+were	O
+calculated	O
+.	O
+
+Mean	O
+time	O
+from	O
+onset	O
+to	O
+death	B-PROC
+was	O
+23	O
+.	O
+7	O
+days	O
+(	O
+CI	O
+,	O
+22	O
+.	O
+0	O
+to	O
+25	O
+.	O
+3	O
+days	O
+),	O
+and	O
+mean	O
+time	O
+from	O
+onset	O
+to	O
+discharge	B-ANAT
+was	O
+26	O
+.	O
+5	O
+days	O
+(	O
+CI	O
+,	O
+25	O
+.	O
+8	O
+to	O
+27	O
+.	O
+2	O
+days	O
+).	O
+
+Increasing	O
+age	O
+,	O
+male	O
+sex	O
+,	O
+atypical	O
+presenting	O
+symptoms	O
+,	O
+presence	O
+of	O
+comorbid	O
+conditions	O
+,	O
+and	O
+high	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+level	O
+on	O
+admission	O
+were	O
+associated	O
+with	O
+a	O
+greater	O
+risk	O
+for	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+22	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+was	O
+admitted	O
+to	O
+the	O
+acute	O
+intoxication	O
+unit	O
+after	O
+suicidal	O
+intoxication	O
+with	O
+100	O
+tablets	O
+of	O
+verapamil	B-CHED
+,	O
+diltiazem	B-CHED
+and	O
+isosorbide	B-CHED
+mononitrate	I-CHED
+.	O
+
+E	B-PRGE
+protein	I-PRGE
+expressed	B-PROC
+in	O
+bacterial	O
+and	O
+mammalian	B-SPEC
+cells	B-COMP
+under	O
+reducing	O
+conditions	O
+existed	O
+as	O
+monomers	O
+,	O
+but	O
+formed	O
+homodimer	O
+and	O
+homotrimer	O
+under	O
+non	O
+-	O
+reducing	O
+conditions	O
+.	O
+
+Pair	O
+-	O
+wise	O
+comparison	O
+of	O
+gene	B-PRGE
+3	I-PRGE
+,	O
+M	B-PRGE
+gene	I-PRGE
+,	O
+gene	O
+5	O
+,	O
+or	O
+N	B-PRGE
+gene	I-PRGE
+sequences	O
+with	O
+their	O
+counterparts	O
+of	O
+IBV	B-SPEC
+revealed	O
+high	O
+levels	O
+(	O
+82	O
+.	O
+1	O
+-	O
+92	O
+.	O
+0	O
+%)	O
+of	O
+similarity	O
+.	O
+
+However	O
+,	O
+the	O
+low	O
+viral	O
+load	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+makes	O
+early	O
+diagnosis	O
+of	O
+SARS	B-DISO
+a	O
+diagnostic	O
+challenge	O
+,	O
+although	O
+improvements	O
+in	O
+the	O
+sensitivity	O
+of	O
+molecular	O
+diagnostic	O
+methods	O
+continue	O
+to	O
+be	O
+made	O
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+and	O
+genetic	O
+analysis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Key	O
+factors	O
+that	O
+determine	O
+the	O
+speed	O
+and	O
+scale	O
+of	O
+transmission	O
+of	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+were	O
+estimated	O
+using	O
+statistical	O
+and	O
+mathematical	O
+modelling	O
+approaches	O
+,	O
+and	O
+phylogenetic	O
+analyses	O
+provided	O
+insights	O
+into	O
+the	O
+origin	O
+and	O
+evolution	B-PROC
+of	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+The	O
+SARS	B-DISO
+literature	O
+continues	O
+to	O
+grow	O
+,	O
+and	O
+it	O
+is	O
+hoped	O
+that	O
+international	O
+collaboration	O
+in	O
+the	O
+analysis	O
+of	O
+epidemiological	O
+and	O
+contact	O
+-	O
+network	O
+databases	O
+will	O
+provide	O
+further	O
+insights	O
+into	O
+the	O
+spread	O
+of	O
+this	O
+newly	O
+emergent	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Human	B-SPEC
+metapneumovirus	I-SPEC
+pneumonia	I-DISO
+in	O
+an	O
+adult	O
+patient	O
+hospitalized	O
+for	O
+suspected	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)].	O
+
+TITLE	O
+:	O
+Canine	O
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+Turkish	O
+dog	B-SPEC
+population	O
+.	O
+
+Mobile	O
+teams	O
+investigated	O
+22	O
+reports	O
+of	O
+SARS	B-DISO
+in	O
+20	O
+hospitals	O
+(	O
+1	O
+,	O
+5	O
+,	O
+and	O
+14	O
+hospitals	O
+in	O
+Lao	O
+PDR	B-DISO
+,	O
+Taiwan	O
+,	O
+and	O
+Thailand	O
+,	O
+respectively	O
+).	O
+
+At	O
+the	O
+time	O
+of	O
+mobile	O
+team	O
+visits	O
+,	O
+5	O
+(	O
+25	O
+%)	O
+hospitals	O
+implemented	O
+infection	B-DISO
+control	O
+practices	O
+consistent	O
+with	O
+World	O
+Health	O
+Organization	O
+recommendations	O
+on	O
+visitor	O
+policies	O
+,	O
+private	O
+negative	O
+-	O
+pressure	O
+rooms	O
+,	O
+and	O
+personal	O
+protective	O
+equipment	O
+.	O
+
+TITLE	O
+:	O
+Universal	O
+SARS	B-DISO
+preventive	O
+measures	O
+in	O
+an	O
+obstetrics	O
+unit	O
+:	O
+experience	O
+of	O
+health	O
+care	O
+staff	O
+.	O
+
+It	O
+is	O
+also	O
+a	O
+major	O
+immunogen	B-CHED
+and	O
+a	O
+target	O
+for	O
+entry	O
+inhibitors	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+possible	O
+effect	O
+of	O
+integrated	O
+traditional	O
+Chinese	O
+and	O
+Western	O
+medicine	O
+on	O
+severe	O
+acute	O
+respiratory	O
+syndromes	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+treatment	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+at	O
+best	O
+controversial	O
+,	O
+although	O
+there	O
+is	O
+considerable	O
+anecdotal	O
+experience	O
+to	O
+show	O
+the	O
+benefits	O
+of	O
+corticosteroid	B-CHED
+therapy	O
+for	O
+selected	O
+patients	O
+.	O
+
+To	O
+attempt	O
+to	O
+determine	O
+the	O
+clinical	O
+efficacy	O
+of	O
+pentaglobin	O
+,	O
+an	O
+IgM	B-PRGE
+-	O
+enriched	O
+immunoglobulin	B-PROC
+preparation	O
+,	O
+on	O
+12	O
+severe	O
+SARS	B-DISO
+patients	O
+who	O
+continued	O
+to	O
+deteriorate	O
+despite	O
+corticosteroid	B-CHED
+and	O
+ribavirin	B-CHED
+therapy	O
+.	O
+
+Similarly	O
+,	O
+there	O
+was	O
+significant	O
+improvement	O
+in	O
+oxygen	B-CHED
+requirement	O
+,	O
+when	O
+compared	O
+with	O
+day	O
+1	O
+,	O
+on	O
+days	O
+6	O
+and	O
+7	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+after	O
+commencement	O
+of	O
+pentaglobin	O
+treatment	O
+.	O
+
+Surprisingly	O
+,	O
+several	O
+of	O
+the	O
+UC	O
+-	O
+ORFs	O
+exhibit	O
+considerable	O
+similarity	O
+with	O
+other	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORFs	I-PRGE
+.	O
+
+In	O
+addition	O
+,	O
+weak	O
+activation	O
+of	O
+Akt	B-PRGE
+cannot	O
+prevent	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+-	O
+induced	O
+apoptosis	B-PATH
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+As	O
+STAT3	B-PRGE
+acts	O
+as	O
+an	O
+activator	O
+of	O
+transcription	B-PROC
+in	O
+the	O
+nucleus	B-COMP
+,	O
+these	O
+results	O
+suggest	O
+that	O
+STAT3	B-PRGE
+lacks	O
+its	O
+activity	O
+on	O
+transcription	B-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+These	O
+species	B-SPEC
+will	O
+be	O
+useful	O
+for	O
+the	O
+evaluation	O
+of	O
+the	O
+immunogenicity	O
+of	O
+candidate	O
+vaccines	O
+,	O
+but	O
+the	O
+lack	O
+of	O
+apparent	O
+clinical	O
+illness	O
+in	O
+all	O
+three	O
+species	B-SPEC
+,	O
+variability	O
+from	O
+animal	B-SPEC
+to	O
+animal	B-SPEC
+in	O
+level	O
+of	O
+viral	B-PROC
+replication	I-PROC
+,	O
+and	O
+rapid	O
+clearance	O
+of	O
+virus	O
+and	O
+pneumonitis	B-DISO
+in	O
+AGMs	O
+must	O
+be	O
+taken	O
+into	O
+account	O
+by	O
+investigators	O
+considering	O
+the	O
+use	O
+of	O
+these	O
+species	B-SPEC
+in	O
+efficacy	O
+and	O
+challenge	O
+studies	O
+.	O
+
+ABSTRACT	O
+:	O
+Antigenic	O
+sites	O
+on	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+were	O
+mapped	O
+by	O
+Pepscan	O
+analysis	O
+with	O
+overlapping	O
+peptides	B-CHED
+that	O
+span	O
+the	O
+N	O
+protein	B-CHED
+sequence	O
+.	O
+
+Several	O
+minor	O
+immunodominant	O
+epitopes	O
+were	O
+reactive	O
+with	O
+about	O
+50	O
+%	O
+of	O
+the	O
+SARS	B-DISO
+sera	B-COMP
+.	O
+
+Several	O
+monoclonal	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+bound	O
+to	O
+the	O
+N	O
+-	O
+or	O
+C	O
+-	O
+terminal	O
+antigenic	O
+sites	O
+.	O
+
+The	O
+test	O
+was	O
+optimized	O
+for	O
+use	O
+with	O
+intestines	B-ANAT
+/	O
+feces	B-ANAT
+from	O
+naturally	O
+infected	O
+turkeys	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+chronology	O
+of	O
+the	O
+2002	O
+-	O
+2003	O
+SARS	B-DISO
+mini	O
+pandemic	O
+.	O
+
+Within	O
+11	O
+weeks	O
+from	O
+the	O
+first	O
+SARS	B-DISO
+case	O
+in	O
+Hong	O
+Kong	O
+it	O
+had	O
+spread	O
+to	O
+an	O
+additional	O
+27	O
+countries	O
+or	O
+special	O
+administrative	O
+regions	O
+.	O
+
+Early	O
+in	O
+the	O
+outbreak	O
+the	O
+infection	B-DISO
+had	O
+been	O
+transmitted	B-DISO
+primarily	O
+via	O
+household	O
+contacts	O
+and	O
+healthcare	O
+settings	O
+.	O
+
+Radiographic	O
+findings	O
+are	O
+non	O
+-	O
+specific	O
+but	O
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+of	O
+the	O
+thorax	B-ANAT
+in	O
+clinically	O
+suspected	O
+cases	O
+may	O
+be	O
+an	O
+early	O
+diagnostic	B-CHED
+aid	I-CHED
+when	O
+initial	O
+chest	B-ANAT
+radiographs	O
+appear	O
+normal	O
+.	O
+
+Absence	O
+of	O
+seroconversion	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+beyond	O
+28	O
+days	O
+from	O
+disease	O
+onset	O
+generally	O
+excludes	O
+the	O
+diagnosis	O
+.	O
+
+Respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+are	O
+the	O
+most	O
+common	O
+childhood	O
+illnesses	O
+and	O
+paediatric	O
+SARS	B-DISO
+poses	O
+special	O
+problems	O
+in	O
+diagnosis	O
+because	O
+of	O
+its	O
+non	O
+-	O
+specific	O
+presentation	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+:	O
+future	O
+research	O
+and	O
+vaccine	O
+.	O
+
+Television	O
+(	O
+91	O
+.	O
+6	O
+%),	O
+newspaper	O
+(	O
+65	O
+.	O
+2	O
+%)	O
+and	O
+radio	B-CHED
+(	O
+30	O
+.	O
+4	O
+%)	O
+formed	O
+the	O
+top	O
+3	O
+sources	O
+of	O
+information	O
+on	O
+SARS	B-DISO
+.	O
+
+However	O
+,	O
+60	O
+respondents	O
+would	O
+nonetheless	O
+take	O
+public	O
+transport	B-PROC
+to	O
+TTSH	O
+[	O
+by	O
+taxi	O
+8	O
+.	O
+5	O
+%,	O
+mass	O
+rapid	O
+transit	O
+(	O
+MRT	B-ANAT
+)	O
+or	O
+bus	O
+1	O
+.	O
+9	O
+%].	O
+
+RESULTS	O
+:	O
+The	O
+majority	O
+(	O
+92	O
+.	O
+7	O
+%)	O
+of	O
+the	O
+respondents	O
+were	O
+aware	O
+of	O
+SARS	B-DISO
+symptoms	O
+.	O
+
+The	O
+expression	B-PROC
+level	O
+and	O
+activation	O
+were	O
+detected	O
+by	O
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+Western	O
+-	O
+blot	O
+respectively	O
+.	O
+
+Beetles	B-SPEC
+were	O
+fed	O
+virus	B-SPEC
+-	O
+infected	O
+feces	B-ANAT
+mixed	O
+with	O
+chicken	B-SPEC
+feed	O
+.	O
+
+Direct	O
+immunofluorescence	O
+was	O
+used	O
+to	O
+determine	O
+the	O
+presence	O
+of	O
+TCV	B-SPEC
+.	O
+
+The	O
+main	O
+dysfunctioning	O
+organs	B-ANAT
+were	O
+the	O
+lung	B-ANAT
+(	O
+76	O
+.	O
+9x	O
+),	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+(	O
+92	O
+.	O
+3x	O
+),	O
+the	O
+cardiovascular	B-ANAT
+system	I-ANAT
+(	O
+30	O
+.	O
+8x	O
+),	O
+the	O
+blood	B-ANAT
+system	O
+(	O
+61	O
+.	O
+5x	O
+),	O
+the	O
+liver	B-ANAT
+(	O
+38	O
+.	O
+5x	O
+),	O
+and	O
+the	O
+kidney	B-ANAT
+(	O
+53	O
+.	O
+8x	O
+).	O
+
+Dysfunction	O
+of	O
+organs	B-ANAT
+are	O
+closely	O
+correlated	O
+with	O
+prognosis	O
+of	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Above	O
+90	O
+.	O
+00	O
+%	O
+patients	O
+had	O
+normal	O
+or	O
+low	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+(	O
+WBC	B-ANAT
+)	O
+count	O
+on	O
+the	O
+first	O
+day	O
+.	O
+
+Clinically	O
+confirmed	O
+SARS	B-DISO
+patients	O
+,	O
+patients	O
+with	O
+other	O
+viral	B-DISO
+pneumonias	I-DISO
+,	O
+and	O
+healthy	O
+controls	O
+were	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+In	O
+convalescent	O
+stage	O
+,	O
+all	O
+the	O
+tests	O
+were	O
+returned	O
+to	O
+normal	O
+ranges	O
+except	O
+ALT	B-FUNC
+,	O
+AST	B-PRGE
+were	O
+still	O
+elevated	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Modelling	O
+strategies	O
+for	O
+controlling	O
+SARS	B-DISO
+outbreaks	O
+.	O
+
+We	O
+examine	O
+mathematically	O
+the	O
+impact	O
+of	O
+isolation	O
+and	O
+quarantine	O
+on	O
+the	O
+control	O
+of	O
+SARS	B-DISO
+during	O
+the	O
+outbreaks	O
+in	O
+Toronto	O
+,	O
+Hong	O
+Kong	O
+,	O
+Singapore	O
+and	O
+Beijing	O
+using	O
+a	O
+deterministic	O
+model	O
+that	O
+closely	O
+mimics	O
+the	O
+data	O
+for	O
+cumulative	O
+infected	O
+cases	O
+and	O
+SARS	B-DISO
+-	O
+related	O
+deaths	B-PROC
+in	O
+the	O
+first	O
+three	O
+regions	O
+but	O
+not	O
+in	O
+Beijing	O
+until	O
+mid	O
+-	O
+April	O
+,	O
+when	O
+China	O
+started	O
+to	O
+report	O
+data	O
+more	O
+accurately	O
+.	O
+
+The	O
+Western	O
+immunoblot	O
+assay	O
+was	O
+able	O
+to	O
+detect	O
+antibodies	B-COMP
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+all	O
+40	O
+serum	B-COMP
+specimens	O
+from	O
+SARS	B-DISO
+patients	O
+and	O
+differentiate	O
+the	O
+SARS	O
+-	O
+positive	O
+samples	O
+from	O
+those	O
+of	O
+the	O
+healthy	O
+donor	B-CHED
+or	O
+non	O
+-	O
+SARS	B-DISO
+patient	O
+controls	O
+(	O
+150	O
+samples	O
+)	O
+when	O
+set	O
+criteria	O
+were	O
+followed	O
+.	O
+
+In	O
+addition	O
+,	O
+when	O
+the	O
+immunoblot	O
+was	O
+used	O
+to	O
+test	O
+samples	O
+considered	O
+falsely	O
+positive	O
+by	O
+an	O
+in	O
+-	O
+house	O
+-	O
+developed	O
+SARS	B-DISO
+-	O
+specific	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+,	O
+band	B-ANAT
+patterns	O
+different	O
+from	O
+those	O
+with	O
+samples	O
+from	O
+SARS	B-DISO
+patients	O
+were	O
+obtained	O
+.	O
+
+TITLE	O
+:	O
+SYNCRIP	B-PRGE
+,	O
+a	O
+member	O
+of	O
+the	O
+heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoprotein	I-PRGE
+family	B-SPEC
+,	O
+is	O
+involved	O
+in	O
+mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+cellular	B-COMP
+proteins	B-CHED
+,	O
+including	O
+several	O
+heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoproteins	I-PRGE
+(	O
+hnRNPs	O
+),	O
+have	O
+been	O
+shown	O
+to	O
+function	O
+as	O
+regulatory	O
+factors	O
+for	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+RNA	B-PROC
+synthesis	I-PROC
+as	O
+a	O
+result	O
+of	O
+their	O
+binding	B-FUNC
+to	O
+the	O
+5	O
+'	O
+and	O
+3	O
+'	O
+untranslated	O
+regions	O
+(	O
+UTRs	O
+)	O
+of	O
+the	O
+viral	O
+RNA	O
+.	O
+
+SYNCRIP	B-PRGE
+is	O
+a	O
+member	O
+of	O
+the	O
+hnRNP	B-PRGE
+family	B-SPEC
+and	O
+localizes	O
+largely	O
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+The	O
+bacterially	O
+expressed	O
+SYNCRIP	B-PRGE
+was	O
+also	O
+able	O
+to	O
+bind	B-FUNC
+to	O
+the	O
+5	O
+'-	O
+UTR	O
+of	O
+both	O
+strands	O
+.	O
+
+The	O
+SYNCRIP	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+site	I-PRGE
+was	O
+mapped	O
+to	O
+the	O
+leader	O
+sequence	O
+of	O
+the	O
+5	O
+'-	O
+UTR	O
+,	O
+requiring	O
+the	O
+UCUAA	O
+repeat	O
+sequence	O
+.	O
+
+Recombinant	O
+human	O
+activated	O
+protein	B-CHED
+C	O
+is	O
+recommended	O
+in	O
+patients	O
+at	O
+high	O
+risk	O
+of	O
+death	B-PROC
+(	O
+septic	B-DISO
+shock	I-DISO
+,	O
+sepsis	B-DISO
+-	O
+induced	O
+acute	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	I-DISO
+Acute	I-DISO
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+score	O
+of	O
+>/=	O
+25	O
+,	O
+and	O
+sepsis	B-DISO
+-	O
+induced	O
+multiorgan	B-DISO
+failure	I-DISO
+)	O
+and	O
+no	O
+absolute	O
+contraindication	O
+related	O
+to	O
+bleeding	B-DISO
+risk	O
+or	O
+relative	O
+contraindication	O
+that	O
+outweighs	O
+the	O
+potential	O
+benefit	O
+.	O
+
+The	O
+transfected	O
+cell	B-COMP
+cultures	O
+were	O
+treated	O
+with	O
+antisense	O
+phosphorothioated	O
+oligonucleotides	B-CHED
+(	O
+antisense	O
+PS	O
+-	O
+ODN	O
+,	O
+20mer	O
+)	O
+or	O
+a	O
+control	O
+oligonucleotide	B-CHED
+by	O
+addition	O
+to	O
+the	O
+culture	O
+medium	O
+.	O
+
+This	O
+8	O
+-	O
+month	O
+prospective	O
+study	O
+of	O
+14	O
+patients	O
+with	O
+hospital	O
+-	O
+acquired	O
+SARS	B-DISO
+in	O
+Taipei	O
+,	O
+Taiwan	O
+,	O
+was	O
+conducted	O
+from	O
+April	O
+through	O
+December	O
+2003	O
+.	O
+
+The	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+was	O
+associated	O
+with	O
+bilateral	O
+lung	B-ANAT
+involvement	O
+on	O
+the	O
+initial	O
+chest	B-ANAT
+radiograph	O
+and	O
+higher	O
+peak	O
+levels	O
+of	O
+LDH	B-PRGE
+and	O
+CRP	B-PRGE
+.	O
+
+At	O
+8	O
+months	O
+after	O
+disease	O
+onset	O
+,	O
+patients	O
+with	O
+mild	O
+or	O
+moderate	O
+SARS	B-DISO
+had	O
+normal	O
+findings	O
+or	O
+only	O
+focal	B-DISO
+fibrosis	I-DISO
+on	O
+chest	B-ANAT
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+.	O
+
+One	O
+patient	O
+with	O
+severe	O
+SARS	B-DISO
+died	B-PROC
+;	O
+she	O
+was	O
+elderly	O
+and	O
+had	O
+other	O
+comorbidities	O
+.	O
+
+The	O
+clinical	O
+picture	O
+of	O
+our	O
+patients	O
+presenting	O
+with	O
+hospital	O
+-	O
+acquired	O
+SARS	B-DISO
+revealed	O
+atypical	B-DISO
+pneumonia	I-DISO
+associated	O
+with	O
+lymphopenia	B-DISO
+,	O
+elevated	O
+serum	B-COMP
+levels	O
+of	O
+LDH	B-PRGE
+,	O
+rapid	O
+clinical	O
+deterioration	O
+,	O
+and	O
+lack	O
+of	O
+response	O
+to	O
+empirical	O
+antibiotic	B-CHED
+therapy	O
+.	O
+
+Over	O
+a	O
+20	O
+-	O
+day	O
+inclusive	O
+period	O
+,	O
+176	O
+subjects	O
+(	O
+49	O
+hospital	O
+inpatients	O
+without	O
+SARS	B-DISO
+or	O
+suspected	O
+SARS	B-DISO
+,	O
+99	O
+health	O
+clinic	O
+attendees	O
+and	O
+28	O
+healthy	O
+volunteers	O
+)	O
+were	O
+recruited	O
+.	O
+
+In	O
+addition	O
+,	O
+chest	B-ANAT
+radiography	O
+showed	O
+decreased	O
+spread	O
+or	O
+density	O
+of	O
+lung	B-ANAT
+infiltrates	B-DISO
+,	O
+and	O
+the	O
+physiological	B-PROC
+effects	I-PROC
+remained	O
+after	O
+termination	O
+of	O
+inhaled	B-PROC
+NO	O
+therapy	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+describe	O
+the	O
+genome	O
+structure	O
+and	O
+the	O
+transcription	B-PROC
+strategy	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+by	O
+experimental	O
+analysis	O
+of	O
+the	O
+viral	O
+subgenomic	O
+mRNAs	O
+.	O
+
+Northern	O
+blot	O
+analysis	O
+indicated	O
+that	O
+the	O
+expression	B-PROC
+level	O
+among	O
+the	O
+sg	O
+mRNAs	O
+differs	O
+significantly	O
+,	O
+with	O
+the	O
+sg	O
+mRNA	B-CHED
+encoding	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+being	O
+the	O
+most	O
+abundant	O
+.	O
+
+Because	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+has	O
+a	O
+low	O
+pathogenicity	O
+and	O
+is	O
+able	O
+to	O
+grow	O
+easily	O
+in	O
+cell	B-COMP
+culture	O
+,	O
+this	O
+virus	B-SPEC
+can	O
+be	O
+a	O
+powerful	O
+tool	O
+to	O
+study	O
+SARS	B-DISO
+coronavirus	B-SPEC
+pathogenesis	B-DISO
+.	O
+
+The	O
+role	O
+of	O
+ACE2	B-PRGE
+in	O
+these	O
+peptide	B-CHED
+systems	O
+has	O
+yet	O
+to	O
+be	O
+revealed	O
+.	O
+
+The	O
+value	O
+of	O
+border	B-ANAT
+screening	O
+in	O
+deterring	O
+travel	O
+by	O
+ill	B-DISO
+persons	O
+and	O
+in	O
+building	O
+public	O
+confidence	O
+remains	O
+unquantified	O
+.	O
+
+N	B-PRGE
+protein	I-PRGE
+can	O
+be	O
+used	O
+as	O
+an	O
+early	O
+diagnostic	O
+maker	O
+for	O
+SARS	B-DISO
+.	O
+
+We	O
+developed	O
+a	O
+mass	O
+spectrometric	O
+decision	O
+tree	O
+classification	O
+algorithm	O
+using	O
+surface	O
+-	O
+enhanced	O
+laser	B-SPEC
+desorption	O
+/	O
+ionization	O
+time	O
+-	O
+of	O
+-	O
+flight	B-PROC
+mass	O
+spectrometry	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Coronavirus	B-SPEC
+infection	I-DISO
+in	O
+immunodeficient	B-DISO
+patients	O
+with	O
+hemoblastosis	O
+and	O
+deficient	O
+hemopoesis	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Preventive	O
+measures	O
+suggested	O
+to	O
+protect	O
+health	O
+workers	O
+from	O
+the	O
+risk	O
+due	O
+to	O
+a	O
+potential	O
+exposure	O
+to	O
+SARS	B-DISO
+agents	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+Authors	O
+describe	O
+the	O
+personal	O
+and	O
+environmental	O
+preventive	O
+measures	O
+suggested	O
+to	O
+protect	O
+health	O
+workers	O
+from	O
+the	O
+risks	O
+due	O
+to	O
+a	O
+potential	O
+exposure	O
+to	O
+SARS	B-DISO
+agents	O
+.	O
+
+Considering	O
+that	O
+large	O
+and	O
+medium	O
+droplets	O
+may	O
+infect	O
+floors	O
+and	O
+surfaces	O
+,	O
+in	O
+addition	O
+to	O
+gloves	O
+,	O
+gowns	O
+,	O
+masks	O
+and	O
+eyes	B-ANAT
+protection	O
+,	O
+the	O
+available	O
+list	O
+of	O
+viral	O
+and	O
+bacterial	O
+factors	O
+implicated	O
+in	O
+SARS	B-DISO
+ethiology	O
+suggests	O
+a	O
+better	O
+hand	O
+antisepsis	O
+using	O
+frequently	O
+the	O
+alcohol	O
+based	O
+gels	O
+(	O
+containing	O
+an	O
+high	O
+percentage	O
+of	O
+emollients	O
+substances	O
+),	O
+if	O
+available	O
+.	O
+
+It	O
+is	O
+recommended	O
+that	O
+adequate	O
+masks	O
+,	O
+eye	B-ANAT
+-	O
+protection	O
+and	O
+protective	O
+gowns	O
+should	O
+be	O
+adopted	O
+for	O
+heath	O
+care	O
+workers	O
+during	O
+the	O
+process	O
+of	O
+clinical	O
+diagnoses	O
+and	O
+treatment	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Study	O
+on	O
+the	O
+risk	O
+factors	O
+related	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+among	O
+close	O
+contactors	O
+in	O
+Beijing	O
+].	O
+
+No	O
+one	O
+was	O
+infected	O
+among	O
+459	O
+close	O
+contacts	O
+to	O
+SARS	B-DISO
+in	O
+the	O
+working	O
+unit	O
+.	O
+
+The	O
+number	O
+of	O
+NK	B-ANAT
+cells	I-ANAT
+was	O
+in	O
+the	O
+low	O
+level	O
+at	O
+onset	O
+,	O
+and	O
+keep	O
+decreasing	O
+at	O
+the	O
+2nd	O
+week	O
+.	O
+
+However	O
+,	O
+it	O
+was	O
+increasing	O
+with	O
+the	O
+recovery	O
+of	O
+the	O
+disease	O
+,	O
+but	O
+did	O
+not	O
+reach	B-PROC
+to	O
+normal	O
+level	O
+at	O
+the	O
+5th	O
+week	O
+after	O
+onset	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+absolute	O
+numbers	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+B	B-ANAT
+lymphocytes	I-ANAT
+and	O
+NK	B-ANAT
+cells	I-ANAT
+were	O
+associated	O
+with	O
+the	O
+severity	O
+of	O
+the	O
+disease	O
+,	O
+and	O
+detection	O
+of	O
+these	O
+two	O
+kinds	O
+of	O
+cells	B-COMP
+was	O
+useful	O
+for	O
+predicting	O
+the	O
+prognosis	O
+of	O
+SARS	B-DISO
+.	O
+
+Here	O
+a	O
+molecular	B-PROC
+assembly	I-PROC
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+peplomer	O
+which	O
+accounts	O
+for	O
+the	O
+available	O
+functional	O
+data	O
+is	O
+suggested	O
+.	O
+
+Using	O
+an	O
+interrupted	O
+time	O
+series	O
+analysis	O
+,	O
+we	O
+compared	O
+the	O
+2003	O
+data	O
+for	O
+the	O
+periods	O
+before	O
+,	O
+during	O
+and	O
+after	O
+the	O
+SARS	B-DISO
+periods	B-PROC
+with	O
+the	O
+modeled	O
+data	O
+for	O
+significant	O
+differences	O
+in	O
+the	O
+3	O
+aforementioned	O
+outcomes	O
+of	O
+interest	O
+.	O
+
+Moreover	O
+,	O
+we	O
+identified	O
+a	O
+role	O
+for	O
+LIX	B-PRGE
+in	O
+the	O
+induction	O
+of	O
+ALI	O
+,	O
+and	O
+therefore	O
+LIX	O
+may	O
+serve	O
+as	O
+a	O
+novel	O
+therapeutic	O
+target	O
+for	O
+the	O
+minimization	O
+of	O
+ALI	O
+.	O
+
+The	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+activation	O
+of	O
+macrophages	B-ANAT
+derived	O
+from	O
+A	O
+/	O
+J	O
+or	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+yielded	O
+two	O
+different	O
+patterns	O
+of	O
+antiviral	B-CHED
+state	O
+in	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+3	O
+infection	B-DISO
+,	O
+which	O
+were	O
+related	O
+to	O
+a	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+the	O
+main	O
+virus	B-SPEC
+receptor	O
+.	O
+
+Using	O
+cDNA	O
+hybridization	B-PROC
+to	O
+evaluate	O
+mRNA	B-CHED
+accumulation	O
+in	O
+the	O
+cells	B-COMP
+,	O
+we	O
+were	O
+able	O
+to	O
+identify	O
+several	O
+genes	O
+that	O
+are	O
+differently	O
+up	O
+-	O
+or	O
+down	O
+-	O
+regulated	O
+by	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+in	O
+A	O
+/	O
+J	O
+(	O
+267	O
+and	O
+266	O
+genes	O
+,	O
+respectively	O
+,	O
+up	O
+-	O
+and	O
+down	O
+-	O
+regulated	O
+)	O
+or	O
+BALB	O
+/	O
+c	O
+(	O
+297	O
+and	O
+58	O
+genes	O
+,	O
+respectively	O
+,	O
+up	O
+-	O
+and	O
+down	O
+-	O
+regulated	O
+)	O
+mouse	B-SPEC
+macrophages	B-ANAT
+.	O
+
+The	O
+possible	O
+implication	O
+of	O
+the	O
+role	O
+of	O
+some	O
+of	O
+the	O
+gene	O
+products	O
+relevant	O
+to	O
+macrophage	B-ANAT
+biology	O
+can	O
+now	O
+be	O
+further	O
+scrutinized	O
+.	O
+
+We	O
+started	O
+intravenous	O
+erythromycin	B-CHED
+(	O
+EM	O
+)	O
+(	O
+1	O
+,	O
+500mg	O
+/	O
+day	O
+)	O
+and	O
+methylprednisolone	B-CHED
+pulse	B-PROC
+therapy	O
+(	O
+1	O
+,	O
+000mg	O
+x	O
+3days	O
+)	O
+and	O
+full	O
+controlled	O
+mechanical	O
+ventilation	O
+supported	O
+with	O
+PEEP	B-CHED
+.	O
+
+Legionella	B-SPEC
+pneumophila	I-SPEC
+(	O
+serogroup	O
+6	O
+)	O
+was	O
+isolated	O
+in	O
+her	O
+private	O
+whirlpool	O
+bath	O
+too	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+containment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+);	O
+experience	O
+from	O
+Bamrasnaradura	O
+Institute	O
+,	O
+Thailand	O
+.	O
+
+Hospitalization	O
+of	O
+one	O
+of	O
+the	O
+earliest	O
+SARS	B-DISO
+patients	O
+with	O
+documented	O
+coronavirus	B-SPEC
+shedding	O
+provided	O
+multiple	O
+opportunities	O
+for	O
+spread	O
+to	O
+the	O
+hospital	O
+staff	O
+,	O
+but	O
+strict	O
+enforcement	O
+of	O
+conservative	O
+infection	B-DISO
+control	O
+recommendations	O
+throughout	O
+the	O
+hospitalization	O
+was	O
+associated	O
+with	O
+no	O
+transmission	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+WHO	O
+physician	O
+died	B-PROC
+from	O
+respiratory	B-DISO
+failure	I-DISO
+on	O
+day	O
+19	O
+.	O
+
+Serum	B-COMP
+samples	O
+from	O
+35	O
+close	O
+contacts	O
+obtained	O
+after	O
+day	O
+28	O
+had	O
+a	O
+negative	O
+result	O
+for	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+antibody	B-COMP
+.	O
+
+The	O
+intensive	O
+care	O
+unit	O
+had	O
+to	O
+be	O
+dedicated	O
+to	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Epidemiological	O
+perspectives	O
+on	O
+SARS	B-DISO
+and	O
+avian	B-DISO
+influenza	I-DISO
+].	O
+
+In	O
+1997	O
+it	O
+was	O
+observed	O
+that	O
+type	O
+AH5N1	O
+jumped	O
+interspecies	O
+barrier	O
+and	O
+affected	O
+18	O
+humans	B-SPEC
+,	O
+and	O
+6	O
+of	O
+them	O
+died	B-PROC
+.	O
+
+In	O
+contrast	O
+,	O
+processing	O
+at	O
+the	O
+nsp2	B-PRGE
+/	I-PRGE
+3	I-PRGE
+site	I-PRGE
+is	O
+less	O
+efficient	O
+,	O
+since	O
+a	O
+approximately	O
+300	O
+-	O
+kDa	O
+intermediate	O
+(	O
+NSP2	O
+-	O
+3	O
+)	O
+is	O
+detected	O
+,	O
+but	O
+ultimately	O
+nsp2	B-PRGE
+(	O
+p71	B-PRGE
+)	O
+and	O
+nsp3	B-PRGE
+(	O
+p213	O
+)	O
+are	O
+generated	O
+.	O
+
+Bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+from	O
+ALI	O
+/	O
+ARDS	B-DISO
+patients	O
+activates	O
+procollagen	B-PRGE
+I	I-PRGE
+promoter	I-PRGE
+,	O
+which	O
+is	O
+due	O
+partly	O
+to	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+.	O
+
+During	O
+an	O
+outbreak	O
+of	O
+such	O
+a	O
+disease	O
+,	O
+the	O
+environment	O
+that	O
+the	O
+infectious	B-DISO
+agent	O
+experiences	O
+is	O
+therefore	O
+changing	O
+due	O
+to	O
+the	O
+subsequent	O
+control	O
+measures	O
+taken	O
+.	O
+
+A	O
+description	O
+of	O
+the	O
+diagnostic	O
+findings	O
+is	O
+provided	O
+in	O
+chronological	O
+order	B-SPEC
+.	O
+
+Lambs	B-SPEC
+were	O
+consecutively	O
+assigned	O
+to	O
+CMV	B-SPEC
+treatment	O
+(	O
+n	O
+=	O
+8	O
+)	O
+or	O
+CMV	B-SPEC
+plus	O
+AV	O
+-	O
+ECMO	O
+therapy	O
+using	O
+up	O
+to	O
+15	O
+%	O
+of	O
+the	O
+cardiac	B-ANAT
+output	O
+for	O
+the	O
+AV	B-ANAT
+shunt	I-ANAT
+flow	O
+during	O
+a	O
+6	O
+-	O
+hour	O
+study	O
+period	O
+(	O
+n	O
+=	O
+9	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	O
+)	O
+has	O
+been	O
+described	O
+in	O
+association	O
+with	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+examined	O
+whether	O
+SARS	B-DISO
+-	O
+CoV	O
+could	O
+productively	O
+infect	O
+purified	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+(	O
+PM	O
+)	O
+derived	O
+from	O
+human	B-SPEC
+donor	B-CHED
+cells	B-COMP
+.	O
+
+This	O
+finding	O
+was	O
+similar	O
+to	O
+results	O
+reported	O
+for	O
+OC43	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+with	O
+titers	O
+ranging	O
+from	O
+10	O
+(	O
+1	O
+.	O
+2	O
+)	O
+to	O
+10	O
+(	O
+2	O
+.	O
+7	O
+)	O
+TCID50	O
+/	O
+ml	O
+.	O
+
+Of	O
+interest	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+were	O
+detected	O
+only	O
+in	O
+PM	O
+that	O
+did	O
+not	O
+produce	O
+significant	O
+amounts	O
+of	O
+interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+alpha	O
+,	O
+and	O
+in	O
+one	O
+such	O
+case	O
+,	O
+preliminary	O
+electron	O
+microscope	O
+studies	O
+demonstrated	O
+that	O
+SARS	O
+-	O
+CoV	O
+-	O
+like	O
+particles	O
+could	O
+enter	O
+the	O
+cells	B-COMP
+,	O
+possibly	O
+via	O
+phagocytosis	B-PROC
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+like	O
+human	B-PRGE
+CoV	I-PRGE
+OC43	I-PRGE
+,	O
+poorly	O
+infects	O
+human	B-SPEC
+PM	O
+,	O
+and	O
+production	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+by	O
+these	O
+cells	B-COMP
+further	O
+limits	O
+the	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+modify	O
+conventional	O
+poly	O
+-	O
+L	O
+-	O
+lysine	O
+coating	O
+for	O
+oligonucleotide	B-CHED
+microarray	O
+preparation	O
+so	O
+as	O
+to	O
+enhance	O
+the	O
+sensitivity	O
+of	O
+the	O
+microarray	O
+.	O
+
+METHODS	O
+:	O
+The	O
+proposed	O
+chemical	O
+approaches	O
+included	O
+silanizing	O
+the	O
+slides	O
+with	O
+3	O
+-	O
+glycid	O
+-	O
+oxypropyltrimethoxysilane	O
+(	O
+GOPS	O
+)	O
+after	O
+cleaning	O
+,	O
+followed	O
+by	O
+slide	O
+coating	O
+with	O
+polymers	B-CHED
+(	O
+poly	O
+-	O
+L	B-CHED
+-	I-CHED
+lysine	I-CHED
+)	O
+that	O
+was	O
+covalently	O
+bound	O
+to	O
+the	O
+modified	O
+glass	O
+.	O
+
+The	O
+mean	O
+IgG	B-PRGE
+level	O
+peaked	O
+in	O
+July	O
+(	O
+1	O
+.	O
+203	O
+),	O
+about	O
+35	O
+days	O
+after	O
+discharge	B-ANAT
+,	O
+and	O
+then	O
+gradually	O
+declined	O
+to	O
+0	O
+.	O
+857	O
+in	O
+December	O
+,	O
+a	O
+decline	O
+by	O
+27	O
+.	O
+3	O
+%.	O
+
+CONCLUSIONS	O
+:	O
+All	O
+SARS	B-DISO
+patients	O
+generate	O
+specific	O
+antibody	B-COMP
+against	O
+the	O
+coronavirus	B-SPEC
+.	O
+
+Twelve	O
+sets	O
+of	O
+rabbit	B-SPEC
+serum	B-COMP
+were	O
+sampled	O
+from	O
+the	O
+third	O
+day	O
+to	O
+the	O
+seventy	O
+-	O
+fourth	O
+day	O
+after	O
+the	O
+first	O
+vaccination	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+SARS	B-DISO
+is	O
+discussed	O
+as	O
+a	O
+disease	O
+,	O
+as	O
+well	O
+as	O
+its	O
+diagnosis	O
+,	O
+management	O
+and	O
+pharmacotherapy	O
+.	O
+
+TITLE	O
+:	O
+The	O
+state	O
+of	O
+the	O
+science	O
+of	O
+health	O
+care	O
+epidemiology	O
+,	O
+infection	B-DISO
+control	O
+,	O
+and	O
+patient	O
+safety	O
+,	O
+2004	O
+.	O
+
+Transmission	O
+is	O
+possible	O
+when	O
+aerosolised	O
+viral	B-COMP
+particles	I-COMP
+come	O
+into	O
+contact	O
+with	O
+the	O
+susceptible	O
+host	O
+'	O
+s	O
+mucous	B-ANAT
+membrane	I-ANAT
+,	O
+most	O
+commonly	O
+the	O
+nose	B-ANAT
+,	O
+but	O
+also	O
+the	O
+mouth	B-ANAT
+and	O
+eyes	B-ANAT
+.	O
+
+These	O
+include	O
+determinations	O
+of	O
+virus	B-SPEC
+yield	O
+and	O
+measurements	O
+of	O
+virus	B-PROC
+replication	I-PROC
+to	O
+flow	O
+cytometry	O
+and	O
+confocal	O
+analysis	O
+of	O
+the	O
+host	B-COMP
+cell	I-COMP
+.	O
+
+About	O
+30	O
+new	O
+diseases	O
+have	O
+been	O
+identified	O
+,	O
+including	O
+Legionnaires	B-DISO
+'	I-DISO
+disease	I-DISO
+,	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)/	O
+acquired	B-DISO
+immune	I-DISO
+deficiency	I-DISO
+syndrome	I-DISO
+(	O
+AIDS	O
+),	O
+hepatitis	B-PATH
+C	I-PATH
+,	O
+bovine	B-DISO
+spongiform	I-DISO
+encephalopathy	I-DISO
+(	O
+BSE	B-DISO
+)/	O
+variant	B-DISO
+Creutzfeldt	I-DISO
+-	I-DISO
+Jakob	I-DISO
+disease	I-DISO
+(	O
+vCJD	B-DISO
+),	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+several	O
+viral	B-DISO
+hemorrhagic	I-DISO
+fevers	I-DISO
+and	O
+,	O
+most	O
+recently	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+Dengue	B-DISO
+fever	I-DISO
+is	O
+endemic	O
+in	O
+many	O
+of	O
+the	O
+countries	O
+in	O
+which	O
+the	O
+large	O
+SARS	B-DISO
+outbreaks	O
+occurred	O
+in	O
+early	O
+2003	O
+.	O
+
+We	O
+compared	O
+the	O
+laboratory	O
+features	O
+of	O
+55	O
+adult	O
+patients	O
+with	O
+SARS	B-DISO
+at	O
+presentation	O
+(	O
+who	O
+were	O
+all	O
+admitted	O
+before	O
+radiological	O
+changes	O
+had	O
+occurred	O
+)	O
+and	O
+147	O
+patients	O
+with	O
+dengue	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Multivariate	O
+analysis	O
+identified	O
+3	O
+laboratory	O
+features	O
+that	O
+together	O
+are	O
+highly	O
+predictive	O
+of	O
+a	O
+diagnosis	O
+of	O
+dengue	B-DISO
+and	O
+able	O
+to	O
+rule	O
+out	O
+the	O
+possibility	O
+of	O
+SARS	B-DISO
+:	O
+platelet	B-ANAT
+count	O
+of	O
+<	O
+140	O
+x	O
+10	O
+(	O
+9	O
+)	O
+platelets	B-ANAT
+/	O
+L	O
+,	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+of	O
+<	O
+5x10	O
+(	O
+9	O
+)	O
+cells	B-COMP
+/	O
+L	O
+,	O
+and	O
+aspartate	B-PRGE
+aminotransferase	I-PRGE
+level	O
+of	O
+>	O
+34	O
+IU	O
+/	O
+L	O
+.	O
+A	O
+combination	O
+of	O
+these	O
+parameters	O
+has	O
+a	O
+sensitivity	O
+of	O
+75	O
+%	O
+and	O
+a	O
+specificity	O
+of	O
+100	O
+%.	O
+
+TITLE	O
+:	O
+The	O
+-	O
+omics	O
+era	B-CHED
+and	O
+its	O
+impact	O
+.	O
+
+Manuscripts	O
+address	O
+the	O
+use	O
+of	O
+molecular	O
+techniques	O
+in	O
+the	O
+detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+bacterial	B-PRGE
+ribosome	I-PRGE
+mutations	I-PRGE
+,	O
+which	O
+may	O
+lead	O
+to	O
+ribosome	B-COMP
+-	O
+targeted	B-PROC
+drug	B-PROC
+resistance	I-PROC
+;	O
+pharmacogenomics	O
+as	O
+a	O
+clinical	O
+laboratory	O
+service	O
+and	O
+example	O
+of	O
+warfarin	B-CHED
+dosing	O
+using	O
+CYP2C9	B-PRGE
+mutation	I-PRGE
+analysis	O
+;	O
+definition	O
+of	O
+the	O
+potential	O
+of	O
+cytosine	B-CHED
+arabinoside	I-CHED
+incorporation	O
+into	O
+DNA	O
+to	O
+disrupt	O
+transcription	B-PROC
+using	O
+an	O
+in	O
+vitro	O
+model	O
+of	O
+oligonucleotides	B-CHED
+;	O
+use	O
+of	O
+laser	B-SPEC
+capture	O
+microdissection	O
+to	O
+isolate	O
+solid	B-DISO
+tumor	I-DISO
+cells	O
+free	O
+of	O
+nontumor	O
+cells	B-COMP
+;	O
+and	O
+molecular	O
+methods	O
+used	O
+to	O
+classify	O
+lymphomas	B-DISO
+.	O
+
+Laser	B-SPEC
+capture	O
+microdissection	O
+of	O
+tumor	B-ANAT
+cells	B-COMP
+can	O
+provide	O
+an	O
+adequate	O
+number	O
+of	O
+cells	B-COMP
+for	O
+whole	O
+genome	O
+amplification	B-DISO
+.	O
+
+MEDLINE	O
+search	O
+of	O
+all	O
+studies	O
+related	O
+to	O
+SARS	B-DISO
+,	O
+including	O
+review	O
+of	O
+the	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+,	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+),	O
+and	O
+Health	O
+Canada	O
+Web	B-DISO
+sites	O
+.	O
+
+Elderly	O
+people	O
+and	O
+those	O
+with	O
+comorbid	O
+illnesses	O
+were	O
+at	O
+greatest	O
+risk	O
+of	O
+complications	O
+or	O
+death	B-PROC
+.	O
+
+The	O
+use	O
+of	O
+gloves	O
+,	O
+gowns	O
+,	O
+N95	O
+masks	O
+,	O
+and	O
+eye	B-ANAT
+protection	O
+was	O
+effective	O
+in	O
+preventing	O
+transmission	O
+.	O
+
+These	O
+results	O
+were	O
+validated	O
+by	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+immunohistochemistry	O
+studies	O
+,	O
+with	O
+PBEF	B-PRGE
+protein	I-PRGE
+levels	O
+significantly	O
+increased	O
+in	O
+both	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+and	O
+serum	B-COMP
+of	O
+ALI	O
+models	O
+and	O
+in	O
+cytokine	O
+-	O
+or	O
+cyclic	O
+stretch	O
+-	O
+activated	O
+lung	B-ANAT
+microvascular	O
+endothelium	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Exogenous	O
+nitric	B-CHED
+oxide	I-CHED
+donor	I-CHED
+and	O
+related	O
+compounds	O
+protect	O
+against	O
+lung	B-ANAT
+inflammatory	B-PROC
+response	I-PROC
+after	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+resuscitation	O
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+capability	O
+of	O
+an	O
+exogenous	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+donor	B-CHED
+,	O
+sodium	B-CHED
+nitroprusside	I-CHED
+(	O
+NP	O
+);	O
+a	O
+NO	O
+substrate	O
+,	O
+L	B-CHED
+-	I-CHED
+arginine	I-CHED
+;	O
+and	O
+an	O
+inducible	O
+NO	B-PRGE
+synthase	I-PRGE
+inhibitor	B-CHED
+,	O
+L	O
+-	O
+N6	O
+-(	O
+1	O
+-	O
+iminoethyl	O
+)	O
+lysine	B-CHED
+(	O
+L	O
+-	O
+NIL	O
+)	O
+to	O
+reduce	O
+lung	B-ANAT
+injury	O
+in	O
+an	O
+animal	B-SPEC
+model	O
+of	O
+mixed	O
+controlled	O
+and	O
+uncontrolled	O
+hemorrhagic	B-DISO
+shock	I-DISO
+.	O
+
+After	O
+the	O
+period	O
+of	O
+hemorrhagic	B-DISO
+shock	I-DISO
+,	O
+resuscitation	O
+of	O
+the	O
+groups	O
+was	O
+accomplished	O
+using	O
+normal	O
+saline	O
+(	O
+groups	O
+1	O
+and	O
+3	O
+),	O
+NP	O
+(	O
+0	O
+.	O
+5	O
+mg	O
+/	O
+kg	O
+)	O
+(	O
+groups	O
+2	O
+and	O
+4	O
+),	O
+L	B-CHED
+-	I-CHED
+arginine	I-CHED
+(	O
+300	O
+mg	O
+/	O
+kg	O
+)	O
+(	O
+group	O
+5	O
+),	O
+or	O
+L	O
+-	O
+NIL	O
+(	O
+50	O
+mg	O
+/	O
+kg	O
+)	O
+(	O
+group	O
+6	O
+).	O
+
+Furthermore	O
+,	O
+the	O
+expression	B-PROC
+of	O
+cytokines	O
+was	O
+reduced	O
+by	O
+NP	O
+treatment	O
+.	O
+
+Hold	O
+disaster	O
+drills	B-SPEC
+in	O
+which	O
+you	O
+must	O
+handle	O
+infectious	B-DISO
+patients	O
+.	O
+
+ED	O
+staff	O
+,	O
+particularly	O
+the	O
+triage	O
+nurses	O
+,	O
+need	O
+training	O
+in	O
+early	O
+recognition	O
+of	O
+presenting	O
+symptoms	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Serum	B-COMP
+anti	O
+-	O
+N	O
+immunoglobulins	O
+and	O
+splenocytes	O
+proliferative	B-DISO
+responses	O
+against	O
+N	B-PRGE
+protein	I-PRGE
+were	O
+observed	O
+in	O
+immunized	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+study	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+this	O
+highly	O
+contagious	O
+virus	B-SPEC
+,	O
+we	O
+established	O
+a	O
+clonal	B-ANAT
+cell	B-COMP
+-	O
+line	O
+,	O
+CHO	B-FUNC
+-	O
+SG	O
+,	O
+from	O
+the	O
+Chinese	B-SPEC
+hamster	I-SPEC
+ovary	B-ANAT
+cells	B-COMP
+that	O
+stably	O
+expresses	O
+C	O
+-	O
+terminally	O
+EGFP	O
+-	O
+tagged	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+(	O
+S	O
+-	O
+EGFP	O
+).	O
+
+This	O
+interaction	O
+could	O
+be	O
+blocked	O
+by	O
+either	O
+the	O
+serum	B-COMP
+from	O
+a	O
+SARS	B-DISO
+convalescent	O
+patient	O
+or	O
+a	O
+goat	B-SPEC
+anti	B-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+antibody	I-PRGE
+,	O
+indicating	O
+that	O
+the	O
+interaction	O
+is	O
+specific	O
+.	O
+
+The	O
+region	O
+is	O
+useful	O
+for	O
+studying	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+future	O
+vaccine	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Inhaling	B-PROC
+to	O
+mitigate	O
+exhaled	B-PROC
+bioaerosols	O
+.	O
+
+These	O
+""""	O
+exhaled	B-PROC
+bioaerosols	O
+""""	O
+may	O
+carry	O
+airborne	O
+pathogens	O
+and	O
+thereby	O
+magnify	O
+the	O
+spread	O
+of	O
+certain	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+influenza	B-DISO
+,	O
+tuberculosis	B-PATH
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+hypothesize	O
+that	O
+,	O
+by	O
+altering	O
+lung	B-ANAT
+airway	B-ANAT
+surface	O
+properties	O
+through	O
+an	O
+inhaled	B-PROC
+nontoxic	O
+aerosol	O
+,	O
+we	O
+might	O
+substantially	O
+diminish	O
+the	O
+number	O
+of	O
+exhaled	B-PROC
+bioaerosol	O
+droplets	O
+and	O
+thereby	O
+provide	O
+a	O
+simple	O
+means	O
+to	O
+potentially	O
+mitigate	O
+the	O
+spread	O
+of	O
+airborne	O
+infectious	B-DISO
+disease	I-DISO
+independently	O
+of	O
+the	O
+identity	O
+of	O
+the	O
+airborne	O
+pathogen	O
+or	O
+the	O
+nature	O
+of	O
+any	O
+specific	O
+therapy	O
+.	O
+
+For	O
+DNA	O
+viruses	B-SPEC
+such	O
+as	O
+variola	B-DISO
+(	O
+smallpox	B-DISO
+),	O
+three	O
+target	O
+genomes	O
+provide	O
+sufficient	O
+guidance	O
+for	O
+selecting	O
+species	O
+-	O
+wide	O
+signatures	O
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+Ebola	O
+Zaire	O
+are	O
+exceptional	O
+,	O
+as	O
+additional	O
+target	O
+genomes	O
+currently	O
+do	O
+not	O
+improve	O
+predictions	O
+,	O
+but	O
+near	O
+-	O
+neighbor	O
+sequences	O
+are	O
+urgently	O
+needed	O
+.	O
+
+The	O
+crystals	B-ANAT
+have	O
+unit	O
+-	O
+cell	B-COMP
+parameters	O
+a	O
+=	O
+121	O
+.	O
+2	O
+,	O
+b	O
+=	O
+66	O
+.	O
+3	O
+,	O
+c	O
+=	O
+70	O
+.	O
+0	O
+A	O
+,	O
+alpha	O
+=	O
+gamma	O
+=	O
+90	O
+,	O
+beta	O
+=	O
+107	O
+.	O
+4	O
+degrees	O
+and	O
+belong	O
+to	O
+space	O
+group	O
+C2	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+examine	O
+the	O
+short	O
+-	O
+term	O
+adjustment	O
+outcomes	O
+including	O
+distress	O
+,	O
+self	O
+-	O
+esteem	O
+,	O
+and	O
+quality	O
+of	O
+life	O
+among	O
+Chinese	O
+patients	O
+after	O
+1	O
+-	O
+month	O
+recovery	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Hong	O
+Kong	O
+and	O
+to	O
+investigate	O
+the	O
+predictive	O
+abilities	O
+of	O
+a	O
+set	O
+of	O
+selected	O
+variables	O
+on	O
+the	O
+outcomes	O
+.	O
+
+Future	O
+research	O
+on	O
+the	O
+long	O
+-	O
+term	O
+impact	O
+of	O
+SARS	B-DISO
+is	O
+recommended	O
+.	O
+
+Here	O
+,	O
+we	O
+examined	O
+the	O
+heat	O
+inactivation	B-DISO
+ability	O
+of	O
+an	O
+agent	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+).	O
+
+RESULTS	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+easily	O
+inactivated	O
+by	O
+this	O
+treatment	O
+for	O
+60	O
+min	O
+in	O
+all	O
+in	O
+-	O
+process	O
+samples	O
+.	O
+
+The	O
+incidence	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+heart	B-ANAT
+injury	O
+,	O
+brain	B-ANAT
+injury	O
+,	O
+and	O
+atropine	B-CHED
+poisoning	O
+were	O
+also	O
+lower	O
+in	O
+pre	O
+-	O
+hospital	O
+group	O
+compared	O
+with	O
+in	O
+-	O
+patient	O
+group	O
+(	O
+all	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Recombinant	O
+baculovirus	B-SPEC
+expressing	O
+different	O
+deletion	O
+and	O
+insertion	O
+fragments	O
+identified	O
+the	O
+functional	O
+region	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+from	O
+aa	O
+324	O
+-	O
+688	O
+(	O
+particularly	O
+the	O
+N	O
+-	O
+terminal	O
+aa	O
+324	O
+-	O
+488	O
+and	O
+the	O
+C	O
+-	O
+terminal	O
+aa	O
+609	O
+-	O
+688	O
+),	O
+which	O
+is	O
+responsible	O
+for	O
+IL	O
+-	O
+8	O
+production	O
+.	O
+
+The	O
+loss	O
+of	O
+control	O
+in	O
+trafficking	B-PROC
+these	O
+cells	B-COMP
+contributes	O
+to	O
+inflammatory	O
+diseases	O
+.	O
+
+The	O
+group	O
+recommended	O
+preparation	O
+for	O
+studies	O
+,	O
+including	O
+protocols	O
+,	O
+ethical	O
+considerations	O
+,	O
+Web	B-DISO
+-	O
+based	O
+registries	O
+,	O
+and	O
+data	O
+entry	O
+systems	O
+.	O
+
+All	O
+,	O
+but	O
+one	O
+received	O
+quinine	B-CHED
+therapy	O
+and	O
+a	O
+loading	O
+dose	O
+was	O
+performed	O
+in	O
+34	O
+%.	O
+
+Seven	O
+patients	O
+(	O
+22	O
+%)	O
+had	O
+community	O
+-	O
+acquired	O
+coinfections	B-DISO
+and	O
+six	O
+(	O
+19	O
+%)	O
+had	O
+nosocomial	B-DISO
+infections	I-DISO
+.	O
+
+Causes	O
+of	O
+death	B-PROC
+were	O
+refractory	B-DISO
+shock	I-DISO
+,	O
+cerebral	B-DISO
+edema	I-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+of	O
+cellular	B-COMP
+oncogene	O
+Bcl	B-PRGE
+-	I-PRGE
+xL	I-PRGE
+prevents	O
+coronavirus	B-SPEC
+-	O
+induced	O
+cell	B-PROC
+death	I-PROC
+and	O
+converts	O
+acute	B-DISO
+infection	I-DISO
+to	O
+persistent	B-DISO
+infection	I-DISO
+in	O
+progenitor	O
+rat	B-SPEC
+oligodendrocytes	B-ANAT
+.	O
+
+This	O
+finding	O
+indicates	O
+that	O
+intracellular	B-COMP
+factors	O
+rather	O
+than	O
+viral	B-ANAT
+components	I-ANAT
+play	O
+a	O
+critical	O
+role	O
+in	O
+establishing	O
+viral	O
+persistence	O
+in	O
+CNS	B-CHED
+cells	B-COMP
+.	O
+
+Although	O
+viral	O
+genomic	O
+RNAs	O
+continuously	O
+persisted	O
+in	O
+Bcl	B-PRGE
+-	I-PRGE
+xL	I-PRGE
+-	O
+expressing	O
+CG	O
+-	O
+4	O
+cells	B-COMP
+over	O
+10	O
+passages	O
+,	O
+infectious	B-DISO
+virus	B-SPEC
+could	O
+no	O
+longer	O
+be	O
+isolated	O
+beyond	O
+2	O
+passages	O
+of	O
+the	O
+cell	B-COMP
+.	O
+
+Thus	O
+,	O
+the	O
+establishment	O
+of	O
+a	O
+persistent	O
+,	O
+nonproductive	O
+infection	B-DISO
+in	O
+CG	O
+-	O
+4	O
+cells	B-COMP
+may	O
+provide	O
+a	O
+useful	O
+in	O
+vitro	O
+model	O
+for	O
+studying	O
+viral	O
+persistence	O
+in	O
+animal	B-SPEC
+CNS	B-CHED
+.	O
+
+When	O
+administered	O
+intranasally	O
+,	O
+SARS	B-DISO
+CoV	O
+replicates	O
+to	O
+high	O
+titers	O
+in	O
+the	O
+lungs	B-ANAT
+and	O
+nasal	B-ANAT
+turbinates	I-ANAT
+.	O
+
+TITLE	O
+:	O
+[	O
+Respiratory	O
+and	O
+cadiovascular	O
+management	O
+of	O
+septic	O
+ALI	O
+-	O
+ARDS	B-DISO
+and	O
+shock	O
+].	O
+
+Aggressive	B-DISO
+infusion	O
+of	O
+crystalloid	B-COMP
+and	O
+colloid	B-ANAT
+is	O
+recommended	O
+for	O
+septic	B-DISO
+shock	I-DISO
+,	O
+but	O
+blood	B-ANAT
+transfusion	O
+and	O
+bicarbonate	B-CHED
+administration	O
+are	O
+not	O
+recommended	O
+.	O
+
+Vasopressors	O
+are	O
+recommended	O
+for	O
+septic	B-DISO
+shock	I-DISO
+:	O
+preference	O
+for	O
+norepinephrine	B-CHED
+and	O
+cautious	O
+use	O
+of	O
+vasopressin	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+an	O
+unexpected	O
+cause	O
+of	O
+carboxyhemoglobinemia	B-DISO
+associated	O
+with	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+therapy	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+winter	O
+season	O
+2001	O
+-	O
+2002	O
+,	O
+239	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+and	O
+15	O
+bronchoalveolar	O
+lavage	O
+samples	O
+from	O
+208	O
+patients	O
+(	O
+135	O
+pediatric	O
+and	O
+73	O
+adults	O
+,	O
+including	O
+19	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+)	O
+admitted	O
+to	O
+hospital	O
+because	O
+of	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+were	O
+examined	O
+for	O
+rapid	O
+diagnosis	O
+of	O
+respiratory	O
+viruses	B-SPEC
+by	O
+two	O
+diagnostic	O
+approaches	O
+:	O
+immunological	O
+,	O
+using	O
+specific	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAb	O
+);	O
+and	O
+molecular	O
+,	O
+using	O
+specific	O
+reverse	B-PROC
+transcription	I-PROC
+(	O
+RT	O
+)-	O
+PCR	O
+assays	O
+.	O
+
+Both	O
+methods	O
+detected	O
+influenza	B-SPEC
+viruses	I-SPEC
+A	O
+(	O
+H1N1	O
+and	O
+H3N2	B-CHED
+)	O
+and	O
+B	O
+,	O
+human	B-SPEC
+parainfluenza	B-DISO
+virus	B-SPEC
+types	O
+1	O
+to	O
+3	O
+,	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+hRSV	B-SPEC
+)	O
+types	O
+A	O
+and	O
+B	O
+,	O
+and	O
+human	B-SPEC
+adenoviruses	B-SPEC
+.	O
+
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+,	O
+TGF	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+,	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+MIG	O
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+but	O
+not	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+13	I-FUNC
+,	O
+or	O
+TNFRI	B-PRGE
+,	O
+were	O
+highly	O
+elevated	O
+in	O
+the	O
+acute	O
+phase	O
+sera	B-COMP
+of	O
+Taiwan	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+model	O
+structures	O
+the	O
+incidence	O
+of	O
+infection	B-DISO
+according	O
+to	O
+the	O
+location	O
+of	O
+an	O
+infected	O
+individual	O
+at	O
+exposure	O
+,	O
+and	O
+requires	O
+knowledge	O
+of	O
+the	O
+infectivity	O
+kernel	O
+and	O
+the	O
+initial	O
+rate	O
+of	O
+exponential	O
+increase	O
+of	O
+cases	O
+.	O
+
+Inactivated	O
+GZ50	O
+was	O
+used	O
+to	O
+immunize	O
+mice	B-SPEC
+intranasally	O
+either	O
+alone	O
+,	O
+or	O
+after	O
+precipitation	B-PROC
+with	O
+polyethylene	B-CHED
+glycol	I-CHED
+(	O
+PEG	B-CHED
+),	O
+or	O
+with	O
+CpG	O
+,	O
+or	O
+CTB	O
+as	O
+an	O
+adjuvant	B-CHED
+.	O
+
+CoVs	O
+enter	O
+target	B-ANAT
+cells	I-ANAT
+through	O
+fusion	O
+of	O
+viral	O
+and	O
+cellular	B-COMP
+membranes	B-ANAT
+mediated	O
+by	O
+the	O
+viral	B-PRGE
+envelope	I-PRGE
+glycoprotein	B-CHED
+S	I-PRGE
+.	O
+We	O
+have	O
+determined	O
+by	O
+x	O
+-	O
+ray	B-SPEC
+crystallography	O
+the	O
+structure	O
+of	O
+a	O
+proteolytically	O
+stable	O
+core	O
+fragment	O
+from	O
+the	O
+heptad	O
+repeat	O
+(	O
+HR	O
+)	O
+regions	O
+HR1	O
+and	O
+HR2	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+structures	O
+presented	O
+here	O
+can	O
+thus	O
+open	O
+the	O
+path	O
+to	O
+the	O
+design	O
+of	O
+small	O
+-	O
+molecule	O
+inhibitors	B-CHED
+of	O
+viral	O
+entry	O
+and	O
+candidate	O
+vaccine	O
+antigens	B-CHED
+against	O
+this	O
+virus	B-SPEC
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+highlight	O
+three	O
+examples	O
+of	O
+emerging	O
+pathogens	O
+:	O
+Nipah	O
+and	O
+Hendra	B-SPEC
+virus	I-SPEC
+,	O
+which	O
+emerged	O
+in	O
+Malaysia	O
+and	O
+Australia	O
+in	O
+the	O
+1990s	O
+respectively	O
+,	O
+with	O
+recent	O
+outbreaks	O
+caused	O
+by	O
+similar	O
+viruses	B-SPEC
+in	O
+India	O
+in	O
+2000	O
+and	O
+Bangladesh	O
+in	O
+2004	O
+;	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+which	O
+emerged	O
+in	O
+the	O
+New	O
+World	O
+in	O
+1999	O
+;	O
+and	O
+amphibian	B-SPEC
+chytridiomycosis	O
+,	O
+which	O
+has	O
+emerged	O
+globally	O
+as	O
+a	O
+threat	O
+to	O
+amphibian	B-SPEC
+populations	O
+and	O
+a	O
+major	O
+cause	O
+of	O
+amphibian	B-SPEC
+population	O
+declines	O
+.	O
+
+Since	O
+E	B-PRGE
+-	I-PRGE
+CR1	I-PRGE
+expression	B-PROC
+is	O
+influenced	O
+by	O
+the	O
+genetic	B-PROC
+polymorphisms	I-PROC
+in	O
+the	O
+CR1	B-PRGE
+gene	I-PRGE
+,	O
+a	O
+major	O
+genetic	B-PROC
+polymorphism	I-PROC
+located	O
+within	O
+intron	O
+27	O
+of	O
+the	O
+CR1	B-PRGE
+gene	I-PRGE
+was	O
+simultaneously	O
+analysed	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+and	O
+restriction	O
+fragment	O
+length	O
+polymorphism	B-PROC
+(	O
+RFLP	O
+).	O
+
+ABSTRACT	O
+:	O
+Abstract	O
+Serum	B-COMP
+levels	O
+of	O
+IgG	B-PRGE
+,	O
+IgM	B-PRGE
+and	O
+IgA	B-PRGE
+against	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+were	O
+detected	O
+serially	O
+with	O
+the	O
+use	O
+of	O
+immunofluorescent	O
+antibody	B-COMP
+assays	O
+in	O
+30	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+A	O
+high	O
+IgG	B-PRGE
+level	O
+(	O
+1	O
+:	O
+800	O
+)	O
+could	O
+persist	O
+for	O
+>	O
+3	O
+months	O
+.	O
+
+Significantly	O
+more	O
+GPs	B-DISO
+had	O
+worked	O
+in	O
+SARS	B-DISO
+affected	O
+facilities	O
+and	O
+had	O
+been	O
+directly	O
+involved	O
+in	O
+the	O
+care	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+than	O
+the	O
+TCM	O
+practitioners	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Fatal	O
+SARS	B-DISO
+was	O
+associated	O
+with	O
+multiorgan	O
+viral	O
+dissemination	O
+in	O
+a	O
+distribution	O
+that	O
+has	O
+implications	O
+for	O
+disease	O
+manifestation	O
+,	O
+viral	B-DISO
+shedding	I-DISO
+,	O
+and	O
+transmission	O
+.	O
+
+Their	O
+lengths	O
+range	O
+from	O
+27	O
+,	O
+317	O
+nt	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+to	O
+31	O
+,	O
+357	O
+nt	O
+for	O
+the	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+A59	O
+,	O
+establishing	O
+the	O
+coronavirus	B-SPEC
+genome	O
+as	O
+the	O
+largest	O
+known	O
+among	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+Genes	O
+for	O
+the	O
+major	O
+structural	O
+proteins	B-CHED
+in	O
+all	O
+coronaviruses	O
+occur	O
+in	O
+the	O
+5	O
+'	O
+to	O
+3	O
+'	O
+order	B-SPEC
+as	O
+S	O
+,	O
+E	O
+,	O
+M	O
+,	O
+and	O
+N	O
+.	O
+The	O
+precise	O
+strategy	O
+used	O
+by	O
+coronaviruses	O
+for	O
+genome	O
+replication	O
+is	O
+not	O
+yet	O
+known	O
+,	O
+but	O
+many	O
+features	O
+have	O
+been	O
+established	O
+.	O
+
+Like	O
+many	O
+other	O
+RNA	O
+viruses	O
+,	O
+coronavirus	B-SPEC
+may	O
+subvert	O
+these	O
+cellular	B-COMP
+proteins	B-CHED
+from	O
+cellular	B-COMP
+RNA	B-PROC
+processing	I-PROC
+or	O
+translation	B-PROC
+machineries	O
+to	O
+play	O
+a	O
+role	O
+in	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Additionally	O
+,	O
+the	O
+relative	O
+strengths	O
+and	O
+limitations	O
+of	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+and	O
+infectious	B-DISO
+cDNA	O
+systems	O
+are	O
+contrasted	O
+.	O
+
+ABSTRACT	O
+:	O
+Knowledge	O
+of	O
+coronavirus	O
+replication	O
+,	O
+transcription	B-PROC
+,	O
+and	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+has	O
+been	O
+recently	O
+improved	O
+by	O
+engineering	O
+of	O
+coronavirus	B-SPEC
+infectious	B-DISO
+cDNAs	O
+.	O
+
+In	O
+addition	O
+,	O
+mixed	O
+-	O
+metal	B-CHED
+couples	O
+such	O
+as	O
+valency	O
+unmatched	O
+forms	O
+in	O
+CuI	O
+/	O
+FeII	O
+and	O
+FeIII	O
+/	O
+MnIV	O
+can	O
+recycle	O
+electrons	O
+.	O
+
+Furthermore	O
+,	O
+denaturation	B-PROC
+-	O
+renaturation	O
+experiments	O
+revealed	O
+that	O
+,	O
+during	O
+protein	B-PROC
+refolding	I-PROC
+,	O
+Zn2	O
++	O
+is	O
+essential	O
+for	O
+the	O
+rescue	O
+of	O
+the	O
+enzymatic	O
+activities	O
+of	O
+nidovirus	O
+helicases	O
+.	O
+
+nsp10	O
+ATPase	B-PRGE
+/	O
+helicase	B-PRGE
+deficiency	O
+resulting	O
+from	O
+single	O
+-	O
+residue	O
+substitutions	O
+in	O
+the	O
+ZBD	O
+or	O
+deletion	O
+of	O
+the	O
+entire	O
+domain	O
+could	O
+not	O
+be	O
+complemented	O
+in	O
+trans	O
+by	O
+wild	O
+-	O
+type	O
+ZBD	O
+,	O
+suggesting	O
+a	O
+critical	O
+function	O
+of	O
+the	O
+ZBD	O
+in	O
+cis	B-DISO
+.	O
+
+Collectively	O
+,	O
+our	O
+data	O
+suggest	O
+that	O
+the	O
+ZBD	O
+is	O
+critically	O
+involved	O
+in	O
+nidovirus	B-SPEC
+replication	O
+and	O
+transcription	B-PROC
+by	O
+modulating	O
+the	O
+enzymatic	O
+activities	O
+of	O
+the	O
+helicase	B-PRGE
+domain	I-PRGE
+and	O
+other	O
+,	O
+yet	O
+unknown	O
+,	O
+mechanisms	O
+.	O
+
+ABSTRACT	O
+:	O
+Phosphorylation	B-PROC
+of	O
+the	O
+coronavirus	B-SPEC
+nucleoprotein	O
+(	O
+N	O
+protein	B-CHED
+)	O
+has	O
+been	O
+predicted	O
+to	O
+play	O
+a	O
+role	O
+in	O
+RNA	B-FUNC
+binding	I-FUNC
+.	O
+
+Mass	O
+spectroscopic	O
+analysis	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+identified	O
+phosphorylation	B-PROC
+sites	O
+that	O
+were	O
+proximal	O
+to	O
+RNA	B-FUNC
+binding	I-FUNC
+domains	O
+.	O
+
+Group	O
+A	O
+was	O
+injected	O
+intramuscularly	O
+(	O
+IM	O
+)	O
+with	O
+soluble	O
+pAPN	O
+at	O
+one	O
+hour	O
+before	O
+intramuscular	O
+infection	B-DISO
+of	O
+PEDV	B-SPEC
+on	O
+the	O
+same	O
+site	O
+,	O
+group	B-DISO
+B	I-DISO
+for	O
+IM	O
+simultaneous	O
+injection	O
+of	O
+pAPN	O
+and	O
+PEDV	B-SPEC
+,	O
+and	O
+group	O
+C	O
+for	O
+IM	O
+injection	O
+of	O
+PEDV	B-SPEC
+only	O
+.	O
+
+The	O
+study	O
+included	O
+patients	O
+transferred	O
+to	O
+the	O
+Intensive	O
+Care	O
+with	O
+a	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+diagnosis	O
+and	O
+with	O
+a	O
+respiratory	O
+,	O
+circulatory	B-PROC
+and	O
+renal	B-DISO
+insufficiency	I-DISO
+or	O
+coagulopathy	B-DISO
+,	O
+or	O
+with	O
+the	O
+combination	O
+of	O
+the	O
+above	O
+.	O
+
+The	O
+unfavourable	O
+course	O
+of	O
+the	O
+condition	B-DISO
+was	O
+also	O
+characterized	O
+by	O
+a	O
+need	O
+for	O
+more	O
+intensive	O
+therapies	O
+:	O
+those	O
+,	O
+who	O
+exited	O
+,	O
+had	O
+been	O
+cathetrized	O
+more	O
+often	O
+and	O
+they	O
+had	O
+required	O
+more	O
+surgical	O
+interventions	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+quantitative	O
+assessment	O
+from	O
+chest	B-ANAT
+radiographs	O
+with	O
+clinical	O
+and	O
+prognostic	O
+correlation	O
+.	O
+
+Most	O
+studies	O
+focused	O
+on	O
+intravenous	O
+fish	B-SPEC
+oil	O
+and	O
+suggest	O
+beneficial	O
+effects	O
+both	O
+on	O
+inflammatory	O
+/	O
+immune	O
+parameters	O
+and	O
+patient	O
+outcome	O
+.	O
+
+Studies	O
+suggest	O
+that	O
+lipid	B-CHED
+use	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+may	O
+be	O
+improved	O
+by	O
+increased	O
+knowledge	O
+of	O
+genetic	O
+determinants	O
+of	O
+severity	O
+of	O
+injury	O
+and	O
+response	O
+to	O
+therapeutic	O
+agents	O
+as	O
+well	O
+as	O
+by	O
+the	O
+development	B-PROC
+of	O
+tools	O
+that	O
+allow	O
+better	O
+timing	O
+of	O
+immunonutritional	O
+intervention	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	B-SPEC
+to	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+convalescent	O
+plasma	O
+therapy	O
+in	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+80	O
+SARS	B-DISO
+patients	O
+were	O
+given	O
+convalescent	O
+plasma	B-ANAT
+at	O
+Prince	O
+of	O
+Wales	O
+Hospital	O
+,	O
+Hong	O
+Kong	O
+,	O
+between	O
+20	O
+March	O
+and	O
+26	O
+May	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+manifestations	O
+of	O
+two	O
+cases	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+I	O
+-	O
+Lan	B-DISO
+County	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+new	O
+respiratory	B-ANAT
+tract	I-ANAT
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+They	O
+both	O
+developed	O
+infiltrations	O
+over	O
+uni	O
+-	O
+or	O
+bilateral	O
+lungs	B-ANAT
+but	O
+recovered	O
+without	O
+intubations	O
+.	O
+
+Fecal	B-ANAT
+samples	O
+found	O
+positive	O
+by	O
+RT	O
+-	O
+PCR	O
+-	O
+based	O
+agarose	B-CHED
+gel	O
+electrophoresis	O
+were	O
+always	O
+found	O
+positive	O
+by	O
+RT	O
+-	O
+PCR	O
+-	O
+based	O
+dot	O
+blot	O
+hybridization	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+reverse	O
+genetics	O
+system	O
+for	O
+the	O
+avian	O
+coronavirus	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+has	O
+been	O
+described	O
+in	O
+which	O
+a	O
+full	O
+-	O
+length	O
+cDNA	O
+,	O
+corresponding	O
+to	O
+the	O
+IBV	B-SPEC
+(	O
+Beaudette	O
+-	O
+CK	O
+)	O
+genome	O
+,	O
+was	O
+inserted	O
+into	O
+the	O
+vaccinia	B-SPEC
+virus	I-SPEC
+genome	O
+following	O
+in	O
+vitro	O
+assembly	O
+of	O
+three	O
+contiguous	O
+cDNAs	O
+[	O
+Casais	O
+,	O
+R	O
+.,	O
+Thiel	O
+,	O
+V	O
+.,	O
+Siddell	O
+,	O
+S	O
+.	O
+G	O
+.,	O
+Cavanagh	O
+,	O
+D	O
+.,	O
+Britton	O
+,	O
+P	O
+.,	O
+2001	O
+.	O
+
+This	O
+study	O
+is	O
+a	O
+retrospective	O
+review	O
+of	O
+a	O
+mask	O
+-	O
+fitting	B-DISO
+programme	O
+carried	O
+out	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+of	O
+the	O
+Prince	O
+of	O
+Wales	O
+Hospital	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Disease	O
+spread	O
+can	O
+occur	O
+through	O
+direct	O
+contact	O
+or	O
+via	O
+indirect	O
+methods	O
+(	O
+airborne	O
+droplets	O
+,	O
+vectors	O
+,	O
+fomites	O
+,	O
+water	B-CHED
+or	O
+food	O
+).	O
+
+Patients	O
+admitted	O
+due	O
+to	O
+suspicion	O
+of	O
+SARS	B-DISO
+with	O
+a	O
+subsequent	O
+diagnosis	O
+of	O
+SARS	B-DISO
+or	O
+Mycoplasma	B-DISO
+pneumoniae	I-DISO
+pneumonia	I-DISO
+were	O
+included	O
+.	O
+
+In	O
+those	O
+with	O
+unsatisfactory	O
+resolution	O
+of	O
+the	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+,	O
+corticosteroid	B-CHED
+therapy	O
+was	O
+associated	O
+with	O
+rapid	O
+radiographic	O
+improvement	O
+.	O
+
+A	O
+56	O
+-	O
+year	O
+-	O
+old	O
+female	O
+patient	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+with	O
+tracheoesophageal	B-DISO
+fistula	I-DISO
+is	O
+reported	O
+.	O
+
+She	O
+was	O
+intubated	O
+for	O
+ventilatory	O
+support	O
+3	O
+days	O
+after	O
+admission	O
+because	O
+of	O
+progressive	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+Methylprednisolone	B-CHED
+pulse	B-PROC
+therapy	O
+followed	O
+by	O
+a	O
+maintenance	O
+dosage	O
+was	O
+given	O
+due	O
+to	O
+persistence	O
+of	O
+bilateral	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+Tracheal	O
+resection	O
+and	O
+primary	O
+repair	B-PROC
+for	O
+the	O
+esophageal	O
+defect	O
+was	O
+performed	O
+via	O
+a	O
+cervical	O
+incision	B-ANAT
+combined	O
+with	O
+partial	O
+sternotomy	O
+.	O
+
+In	O
+SARS	B-DISO
+patients	O
+with	O
+persistent	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+and	O
+under	O
+prolonged	O
+corticosteroid	B-CHED
+treatment	O
+,	O
+special	O
+care	O
+should	O
+be	O
+given	O
+to	O
+avoid	O
+intubation	O
+-	O
+related	O
+tracheal	O
+injury	O
+during	O
+the	O
+period	O
+of	O
+ventilatory	O
+support	O
+.	O
+
+This	O
+requires	O
+the	O
+development	B-PROC
+of	O
+methods	O
+of	O
+reading	O
+genomes	O
+with	O
+high	O
+accuracy	O
+.	O
+
+Rapid	O
+development	B-PROC
+of	O
+sequencing	O
+methods	O
+,	O
+like	O
+shotgun	O
+sequencing	O
+or	O
+sequencing	O
+by	O
+hybridization	B-PROC
+(	O
+SBH	B-DISO
+),	O
+gives	O
+scientists	O
+a	O
+good	O
+tool	O
+for	O
+reading	O
+genomes	O
+.	O
+
+We	O
+detected	O
+fifteen	O
+substitutions	O
+of	O
+nucleotides	B-CHED
+by	O
+comparisons	O
+with	O
+the	O
+seventeen	O
+published	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+sequences	O
+,	O
+eight	O
+(	O
+53	O
+.	O
+3	O
+%)	O
+of	O
+which	O
+are	O
+non	O
+-	O
+synonymous	O
+mutations	O
+leading	O
+to	O
+amino	B-CHED
+acid	I-CHED
+alternations	O
+with	O
+predicted	O
+physiochemical	O
+changes	O
+.	O
+
+The	O
+possible	O
+antigenic	O
+determinants	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+are	O
+predicted	O
+,	O
+and	O
+the	O
+result	O
+is	O
+confirmed	O
+by	O
+ELISA	O
+(	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+)	O
+with	O
+synthesized	O
+peptides	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+studied	O
+structural	O
+and	O
+immunological	O
+properties	O
+of	O
+the	O
+SARS	O
+-	O
+CoV	O
+M	O
+(	O
+membrane	B-COMP
+)	O
+protein	B-CHED
+,	O
+based	O
+on	O
+comparative	O
+analyses	O
+of	O
+sequence	O
+features	O
+,	O
+phylogenetic	O
+investigation	O
+,	O
+and	O
+experimental	O
+results	O
+.	O
+
+The	O
+four	O
+substitutions	O
+detected	O
+in	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+,	O
+which	O
+cause	O
+non	O
+-	O
+synonymous	O
+changes	O
+,	O
+can	O
+be	O
+classified	O
+into	O
+three	O
+types	O
+.	O
+
+Phylogenetic	O
+tree	O
+building	O
+based	O
+on	O
+the	O
+variations	O
+of	O
+the	O
+M	O
+protein	O
+appears	O
+to	O
+support	O
+the	O
+non	O
+-	O
+human	B-SPEC
+origin	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+To	O
+investigate	O
+its	O
+immunogenicity	O
+,	O
+we	O
+synthesized	O
+eight	O
+oligopeptides	B-CHED
+covering	O
+69	O
+.	O
+2	O
+%	O
+of	O
+the	O
+entire	O
+ORF	O
+and	O
+screened	O
+them	O
+by	O
+using	O
+ELISA	O
+(	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+)	O
+with	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+The	O
+E	B-PRGE
+protein	I-PRGE
+is	O
+a	O
+multifunctional	O
+membrane	B-COMP
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+The	O
+E	B-PRGE
+(	I-PRGE
+envelope	B-COMP
+)	I-PRGE
+protein	I-PRGE
+is	O
+the	O
+smallest	O
+structural	O
+protein	B-CHED
+in	O
+all	O
+coronaviruses	O
+and	O
+is	O
+the	O
+only	O
+viral	O
+structural	O
+protein	B-CHED
+in	O
+which	O
+no	O
+variation	O
+has	O
+been	O
+detected	O
+.	O
+
+Our	O
+phylogenetic	O
+analyses	O
+of	O
+the	O
+E	O
+protein	B-CHED
+sequences	O
+in	O
+all	O
+published	O
+coronaviruses	O
+place	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+an	O
+independent	O
+group	O
+in	O
+Coronaviridae	B-SPEC
+and	O
+suggest	O
+a	O
+non	O
+-	O
+human	B-SPEC
+animal	B-SPEC
+origin	O
+.	O
+
+The	O
+abundant	O
+antigenic	O
+sites	O
+predicted	O
+in	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+as	O
+well	O
+as	O
+experimental	O
+evidence	O
+with	O
+synthesized	O
+polypeptides	O
+,	O
+indicate	O
+that	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+is	O
+one	O
+of	O
+the	O
+major	O
+antigens	B-CHED
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Compared	O
+with	O
+other	O
+viral	O
+structural	O
+proteins	B-CHED
+,	O
+the	O
+low	O
+variation	O
+rate	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+with	O
+regards	O
+to	O
+its	O
+size	O
+suggests	O
+its	O
+importance	O
+to	O
+the	O
+survival	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+can	O
+be	O
+mild	O
+in	O
+children	O
+.	O
+
+The	O
+use	O
+of	O
+the	O
+World	O
+Health	O
+Organization	O
+/	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+case	O
+definitions	O
+may	O
+not	O
+be	O
+adequate	O
+for	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Successful	O
+treatment	O
+of	O
+ARDS	B-DISO
+and	O
+severe	O
+pulmonary	B-DISO
+hypertension	I-DISO
+in	O
+a	O
+child	O
+with	O
+Bordetella	B-SPEC
+pertussis	B-DISO
+infection	B-DISO
+.	O
+
+Pulmonary	B-DISO
+hypertension	I-DISO
+is	O
+an	O
+early	O
+sign	O
+of	O
+potentially	O
+fatal	O
+disease	O
+and	O
+can	O
+cause	O
+failure	O
+of	O
+conventional	O
+respiratory	O
+therapy	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+After	O
+conventional	O
+ventilation	O
+,	O
+surfactant	B-CHED
+and	O
+high	O
+frequency	O
+oscillation	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+failed	O
+,	O
+treatment	O
+with	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+improved	O
+oxygenation	B-PROC
+,	O
+allowing	O
+recovery	O
+without	O
+the	O
+need	O
+for	O
+ECMO	O
+.	O
+
+We	O
+now	O
+report	O
+complete	O
+genome	O
+sequences	O
+of	O
+the	O
+BJ	O
+Group	O
+,	O
+including	O
+four	O
+isolates	O
+(	O
+Isolates	O
+BJ01	O
+,	O
+BJ02	O
+,	O
+BJ03	O
+,	O
+and	O
+BJ04	O
+)	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+It	O
+is	O
+remarkable	O
+that	O
+all	O
+members	O
+of	O
+the	O
+BJ	O
+Group	O
+share	O
+a	O
+common	O
+haplotype	O
+,	O
+consisting	O
+of	O
+seven	O
+loci	O
+that	O
+differentiate	O
+the	O
+group	O
+from	O
+other	O
+isolates	O
+published	O
+to	O
+date	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	O
+to	O
+develop	O
+clinical	O
+diagnostic	O
+tools	O
+for	O
+rapid	O
+detection	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+)	O
+and	O
+to	O
+identify	O
+candidate	O
+proteins	B-CHED
+for	O
+vaccine	O
+development	B-PROC
+,	O
+the	O
+C	O
+-	O
+terminal	O
+portion	O
+of	O
+the	O
+nucleocapsid	B-COMP
+(	O
+NC	O
+)	O
+gene	O
+was	O
+amplified	O
+using	O
+RT	O
+-	O
+PCR	O
+from	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+,	O
+cloned	O
+into	O
+a	O
+yeast	B-SPEC
+expression	B-PROC
+vector	O
+(	O
+pEGH	O
+),	O
+and	O
+expressed	B-PROC
+as	O
+a	O
+glutathione	B-PRGE
+S	O
+-	O
+transferase	O
+(	O
+GST	B-PRGE
+)	O
+and	O
+Hisx6	O
+double	O
+-	O
+tagged	O
+fusion	O
+protein	B-CHED
+under	O
+the	O
+control	O
+of	O
+an	O
+inducible	O
+promoter	O
+.	O
+
+The	O
+NC	B-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+demonstrated	O
+high	O
+antigenicity	O
+with	O
+high	O
+specificity	O
+,	O
+and	O
+therefore	O
+,	O
+it	O
+should	O
+have	O
+great	O
+potential	O
+in	O
+designing	O
+clinical	O
+diagnostic	O
+tools	O
+and	O
+provide	O
+useful	O
+information	O
+for	O
+vaccine	O
+development	O
+.	O
+
+Whether	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+antigenic	O
+remains	O
+to	O
+be	O
+elucidated	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+epitope	B-CHED
+sites	O
+in	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+were	O
+determined	O
+by	O
+competition	O
+experiments	O
+,	O
+in	O
+which	O
+the	O
+recombinant	O
+proteins	B-CHED
+or	O
+the	O
+synthesized	O
+peptides	B-CHED
+competed	O
+against	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+to	O
+bind	B-FUNC
+to	O
+the	O
+antibodies	B-COMP
+raised	O
+in	O
+SARS	B-DISO
+sera	B-COMP
+.	O
+
+Using	O
+Enzyme	O
+-	O
+Linked	O
+Immunosorbent	O
+Assay	O
+(	O
+ELISA	O
+),	O
+these	O
+peptides	B-CHED
+were	O
+screened	O
+in	O
+the	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+According	O
+to	O
+these	O
+results	O
+,	O
+two	O
+fragments	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+were	O
+amplified	O
+by	O
+PCR	O
+and	O
+cloned	O
+into	O
+pET	B-PRGE
+-	I-PRGE
+32a	I-PRGE
+.	O
+
+Eight	O
+ORFs	O
+partially	O
+overlapped	O
+with	O
+or	O
+embedded	O
+into	O
+those	O
+of	O
+known	O
+genes	O
+,	O
+revealing	O
+that	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+is	O
+a	O
+small	O
+and	O
+compact	O
+one	O
+with	O
+overlapped	O
+coding	O
+regions	O
+.	O
+
+We	O
+have	O
+also	O
+annotated	O
+non	O
+-	O
+coding	O
+regions	O
+and	O
+identified	O
+the	O
+transcription	B-PROC
+regulating	O
+sequences	O
+(	O
+TRS	B-DISO
+)	O
+in	O
+the	O
+intergenic	O
+regions	O
+.	O
+
+TITLE	O
+:	O
+Preliminary	O
+study	O
+on	O
+the	O
+detection	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+specific	O
+target	O
+cDNA	O
+fragments	O
+by	O
+multiplex	O
+PCR	O
+.	O
+
+The	O
+target	O
+cDNA	O
+fragments	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+synthesized	O
+artificially	O
+according	O
+to	O
+the	O
+genome	O
+sequence	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+GenBank	O
+submitted	O
+by	O
+The	O
+Chinese	O
+University	O
+of	O
+Hong	O
+Kong	O
+,	O
+and	O
+were	O
+used	O
+as	O
+simulated	O
+positive	O
+samples	O
+.	O
+
+However	O
+,	O
+although	O
+the	O
+rapid	O
+identification	O
+of	O
+the	O
+agent	O
+represented	O
+an	O
+important	O
+breakthrough	O
+,	O
+our	O
+understanding	O
+of	O
+the	O
+deadly	O
+virus	B-SPEC
+remains	O
+limited	O
+.	O
+
+ELISA	O
+detection	O
+verified	O
+10	O
+positive	O
+phage	O
+antibodies	B-COMP
+that	O
+were	O
+highly	O
+specific	O
+for	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+Human	B-SPEC
+phage	O
+antibody	B-COMP
+library	O
+against	O
+SARS	B-DISO
+virus	B-SPEC
+has	O
+been	O
+constructed	O
+successfully	O
+,	O
+from	O
+which	O
+10	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+SARS	I-PRGE
+virus	B-SPEC
+antibodies	B-COMP
+were	O
+obtained	O
+.	O
+
+DNA	O
+sequencing	O
+confirmed	O
+that	O
+the	O
+amplified	O
+fragment	O
+was	O
+N	O
+protein	B-CHED
+gene	O
+.	O
+
+RESULTS	O
+:	O
+DNA	O
+sequencing	O
+confirmed	O
+that	O
+the	O
+amplified	O
+fragment	O
+was	O
+N	O
+protein	B-CHED
+gene	O
+.	O
+
+The	O
+percentages	O
+of	O
+CD3	B-PRGE
+(+)	I-PRGE
+and	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+lower	O
+than	O
+normal	O
+reference	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+and	O
+P	O
+<	O
+0	O
+.	O
+01	O
+,	O
+respectively	O
+).	O
+
+And	O
+the	O
+expressions	O
+of	O
+TCR	B-PRGE
+Vbeta4	I-PRGE
+,	O
+Vbeta22	O
+and	O
+Vbeta23	O
+in	O
+SARS	B-DISO
+patients	O
+treated	O
+with	O
+glucocorticoid	B-CHED
+(>	O
+1	O
+000	O
+U	O
+)	O
+were	O
+higher	O
+than	O
+those	O
+in	O
+SARS	B-DISO
+patients	O
+without	O
+treatment	O
+.	O
+
+The	O
+increased	O
+Ta	O
+and	O
+Ba	O
+expressions	O
+may	O
+be	O
+associated	O
+with	O
+activation	O
+of	O
+T	O
+and	O
+B	B-ANAT
+cells	I-ANAT
+.	O
+
+And	O
+the	O
+expressions	O
+of	O
+TCR	B-PRGE
+Vbeta4	I-PRGE
+,	O
+Vbeta22	O
+and	O
+Vbeta23	O
+in	O
+SARS	B-DISO
+patients	O
+treated	O
+with	O
+glucocorticoid	B-CHED
+(>	O
+1	O
+000	O
+U	O
+)	O
+were	O
+higher	O
+than	O
+those	O
+in	O
+SARS	B-DISO
+patients	O
+without	O
+treatment	O
+.	O
+
+Serum	B-COMP
+specimens	O
+tested	O
+included	O
+those	O
+from	O
+21	O
+clinically	O
+confirmed	O
+pediatric	O
+SARS	B-DISO
+cases	O
+(	O
+aged	O
+from	O
+8	O
+months	O
+to	O
+14	O
+years	O
+,	O
+11	O
+male	O
+and	O
+10	O
+female	O
+)	O
+and	O
+their	O
+23	O
+parents	O
+who	O
+had	O
+close	O
+contact	O
+with	O
+the	O
+children	O
+,	O
+36	O
+adult	O
+patients	O
+in	O
+convalescence	O
+stage	O
+of	O
+SARS	B-DISO
+,	O
+24	O
+children	O
+(	O
+aged	O
+1	O
+.	O
+5	O
+to	O
+14	O
+years	O
+)	O
+and	O
+other	O
+34	O
+adults	O
+who	O
+had	O
+close	O
+contact	O
+with	O
+infected	O
+adults	O
+.	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+The	O
+positive	O
+rates	O
+of	O
+specific	O
+IgG	B-PRGE
+and	O
+mixed	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+38	O
+%	O
+(	O
+8	O
+/	O
+21	O
+)	O
+and	O
+33	O
+%	O
+(	O
+7	O
+/	O
+21	O
+)	O
+in	O
+pediatric	O
+cases	O
+;	O
+whereas	O
+the	O
+rates	O
+were	O
+75	O
+%	O
+(	O
+27	O
+/	O
+36	O
+)	O
+and	O
+69	O
+%	O
+(	O
+25	O
+/	O
+36	O
+)	O
+in	O
+adult	O
+patients	O
+.	O
+
+The	O
+positive	O
+rates	O
+of	O
+IgM	B-PRGE
+,	O
+IgG	B-PRGE
+and	O
+total	O
+antibodies	B-COMP
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+146	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+collected	O
+in	O
+different	O
+phases	O
+of	O
+the	O
+disease	O
+were	O
+61	O
+.	O
+64	O
+%,	O
+53	O
+.	O
+43	O
+%	O
+and	O
+69	O
+.	O
+86	O
+%,	O
+respectively	O
+.	O
+
+Serum	B-COMP
+from	O
+one	O
+medical	O
+worker	O
+who	O
+had	O
+been	O
+close	O
+contact	O
+to	O
+SARS	B-DISO
+patients	O
+was	O
+positive	O
+for	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+and	O
+total	O
+antibodies	B-COMP
+.	O
+
+RESULTS	O
+:	O
+The	O
+positive	O
+rates	O
+of	O
+IgM	B-PRGE
+,	O
+IgG	B-PRGE
+and	O
+total	O
+antibodies	B-COMP
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+146	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+collected	O
+in	O
+different	O
+phases	O
+of	O
+the	O
+disease	O
+were	O
+61	O
+.	O
+64	O
+%,	O
+53	O
+.	O
+43	O
+%	O
+and	O
+69	O
+.	O
+86	O
+%,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Serological	O
+investigation	O
+on	O
+close	O
+contacts	O
+to	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+an	O
+SARS	B-DISO
+outbreak	O
+].	O
+
+According	O
+to	O
+our	O
+survey	O
+,	O
+there	O
+was	O
+no	O
+latent	B-DISO
+infection	I-DISO
+among	O
+close	O
+contacts	O
+.	O
+
+Nested	O
+-	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+was	O
+used	O
+to	O
+amplify	O
+the	O
+N	O
+protein	B-CHED
+gene	O
+of	O
+the	O
+SARS	B-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+from	O
+these	O
+washing	O
+solutions	O
+.	O
+
+The	O
+isolate	O
+could	O
+cause	O
+typical	O
+cytopathic	B-DISO
+effects	I-DISO
+,	O
+similar	O
+to	O
+those	O
+SARS	B-DISO
+-	O
+CoV	O
+on	O
+Vero	O
+-	O
+E6	O
+cells	B-COMP
+and	O
+the	O
+effects	O
+could	O
+be	O
+stably	O
+passed	O
+.	O
+
+SARS	B-DISO
+patients	O
+could	O
+still	O
+shed	O
+SARS	B-DISO
+-	O
+CoV	O
+even	O
+during	O
+the	O
+recovery	O
+phase	O
+.	O
+
+RESULTS	O
+:	O
+Positive	O
+rates	O
+of	O
+RT	O
+-	O
+PCR	O
+test	O
+on	O
+air	B-CHED
+samples	O
+were	O
+29	O
+.	O
+03	O
+%	O
+in	O
+the	O
+wards	O
+and	O
+20	O
+.	O
+0	O
+%	O
+in	O
+balcony	O
+respectively	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+existed	O
+in	O
+the	O
+air	B-CHED
+hospital	O
+,	O
+where	O
+SARS	B-DISO
+patients	O
+were	O
+admitted	O
+to	O
+,	O
+but	O
+the	O
+activity	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+air	B-CHED
+samples	O
+was	O
+rather	O
+low	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+prepare	O
+monoclonal	O
+antibodies	O
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+on	O
+the	O
+purpose	O
+to	O
+explore	O
+the	O
+diagnosis	O
+methods	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+hybridoma	B-ANAT
+cell	B-COMP
+strains	O
+were	O
+screened	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+),	O
+indirect	O
+fluorescent	O
+-	O
+antibody	B-COMP
+assay	O
+(	O
+IFA	O
+)	O
+and	O
+Western	O
+blotting	O
+.	O
+
+The	O
+hybridomas	B-ANAT
+were	O
+tested	O
+to	O
+have	O
+specific	O
+reactions	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+no	O
+cross	O
+-	O
+reactivates	O
+with	O
+other	O
+common	O
+respiratory	B-DISO
+disease	I-DISO
+causing	O
+pathogens	O
+.	O
+
+Of	O
+the	O
+6	O
+strains	O
+,	O
+1	O
+was	O
+identified	O
+as	O
+the	O
+immunoglobulin	B-PRGE
+G3	I-PRGE
+(	O
+IgG3	B-COMP
+)	O
+isotype	O
+,	O
+5	O
+were	O
+IgG1	B-COMP
+.	O
+
+Western	O
+blotting	O
+showed	O
+that	O
+one	O
+strain	O
+(	O
+M2	O
+)	O
+reacted	O
+with	O
+68000	O
+-	O
+Dalton	O
+(	O
+68KD	O
+)	O
+protein	B-CHED
+and	O
+four	O
+strains	O
+with	O
+27000	O
+-	O
+dalton	O
+(	O
+27KD	O
+)	O
+protein	B-CHED
+.	O
+
+Band	B-ANAT
+of	O
+M4	O
+stain	O
+was	O
+not	O
+got	O
+by	O
+western	O
+blotting	O
+.	O
+
+Osteonecrosis	B-DISO
+was	O
+found	O
+in	O
+3	O
+cases	O
+.	O
+
+One	O
+was	O
+involved	O
+in	O
+bilateral	O
+femoral	B-ANAT
+head	I-ANAT
+,	O
+and	O
+another	O
+was	O
+unilateral	O
+femoral	B-ANAT
+head	I-ANAT
+,	O
+and	O
+the	O
+remaining	O
+one	O
+was	O
+bilateral	O
+femoral	B-ANAT
+heads	I-ANAT
+and	O
+unilateral	O
+femoral	B-ANAT
+condyle	I-ANAT
+and	O
+tibial	B-ANAT
+condyle	B-ANAT
+.	O
+
+Femoral	B-ANAT
+infarction	B-DISO
+with	O
+significant	O
+calcification	B-PROC
+occurred	O
+in	O
+one	O
+health	O
+care	O
+worker	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+86	O
+health	O
+care	O
+workers	O
+,	O
+5	O
+cases	O
+were	O
+found	O
+positive	O
+in	O
+the	O
+lower	B-ANAT
+extremity	I-ANAT
+.	O
+
+The	O
+former	O
+group	O
+also	O
+reported	O
+more	O
+frequent	B-DISO
+headaches	I-DISO
+,	O
+difficulty	B-DISO
+breathing	I-DISO
+,	O
+dizziness	B-DISO
+,	O
+rhinorrhea	B-DISO
+,	O
+and	O
+sore	B-DISO
+throat	I-DISO
+.	O
+
+Respondents	O
+with	O
+higher	O
+levels	O
+of	O
+anxiety	O
+,	O
+better	O
+knowledge	O
+about	O
+SARS	B-DISO
+,	O
+and	O
+greater	O
+risk	O
+perceptions	O
+were	O
+more	O
+likely	O
+to	O
+take	O
+comprehensive	O
+precautionary	O
+measures	O
+against	O
+the	O
+infection	B-DISO
+,	O
+as	O
+were	O
+older	O
+,	O
+female	O
+,	O
+and	O
+more	O
+educated	O
+individuals	O
+.	O
+
+With	O
+a	O
+spontaneously	O
+breathing	B-PROC
+patient	O
+,	O
+to	O
+reduce	O
+the	O
+work	B-PROC
+of	I-PROC
+breathing	I-PROC
+and	O
+improve	O
+patient	O
+-	O
+ventilator	O
+interaction	O
+,	O
+it	O
+is	O
+crucial	O
+to	O
+set	O
+an	O
+adequate	O
+inspiratory	B-PROC
+flow	O
+,	O
+inspiratory	B-PROC
+time	O
+,	O
+trigger	O
+sensitivity	O
+,	O
+and	O
+ventilator	O
+-	O
+applied	O
+PEEP	B-CHED
+.	O
+
+The	O
+highest	O
+rate	O
+of	O
+stress	B-PROC
+reaction	I-PROC
+syndrome	B-DISO
+was	O
+observed	O
+in	O
+the	O
+group	O
+that	O
+originally	O
+worked	O
+in	O
+a	O
+high	O
+-	O
+risk	O
+unit	O
+,	O
+and	O
+the	O
+conscripted	O
+group	O
+experienced	O
+the	O
+most	O
+severe	O
+distress	O
+on	O
+average	O
+.	O
+
+To	O
+investigate	O
+the	O
+autocrine	B-PROC
+activation	O
+of	O
+BALB	O
+/	O
+c	O
+and	O
+A	O
+/	O
+J	O
+Mphi	O
+,	O
+we	O
+activated	O
+them	O
+with	O
+interleukin	B-PRGE
+-	I-PRGE
+12	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+)	O
+and	O
+/	O
+or	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+,	O
+and	O
+quantified	O
+IFNgamma	O
+production	O
+,	O
+the	O
+anti	O
+-	O
+MHV3	O
+state	O
+and	O
+arginine	B-PROC
+metabolism	I-PROC
+.	O
+
+As	O
+a	O
+consequence	O
+of	O
+nitric	B-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+synthesis	B-PROC
+and	O
+arginine	B-CHED
+consumption	O
+in	O
+IFNgamma	O
+activated	O
+BMMphi	O
+,	O
+we	O
+observed	O
+a	O
+higher	O
+synthesis	B-PROC
+of	O
+citrulline	B-CHED
+.	O
+
+Upon	O
+infection	B-DISO
+with	O
+MHV3	O
+,	O
+we	O
+observed	O
+a	O
+higher	O
+synthesis	B-PROC
+of	O
+spermine	B-CHED
+.	O
+
+Difluoromethylornithine	O
+treatment	O
+,	O
+which	O
+leads	O
+to	O
+inhibition	B-PROC
+of	O
+polyamine	B-PROC
+synthesis	I-PROC
+,	O
+induced	O
+a	O
+decreased	O
+MHV3	O
+multiplication	O
+in	O
+both	O
+BALB	O
+/	O
+c	O
+and	O
+A	O
+/	O
+J	O
+BMMphi	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+diseases	O
+of	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+of	O
+cats	B-SPEC
+.	O
+
+For	O
+pneumonia	B-DISO
+,	O
+NAATs	O
+offer	O
+advantages	O
+over	O
+conventional	O
+tests	O
+for	O
+the	O
+detection	O
+of	O
+Mycoplasma	B-PRGE
+pneumoniae	I-PRGE
+,	I-PRGE
+Legionella	B-SPEC
+spp	B-ENZY
+.	O
+
+and	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+.	O
+
+PCR	O
+can	O
+now	O
+be	O
+considered	O
+the	O
+rapid	O
+diagnostic	O
+test	O
+of	O
+choice	O
+for	O
+pertussis	O
+and	O
+some	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+explored	O
+the	O
+incidence	O
+of	O
+femoral	B-ANAT
+head	I-ANAT
+necrosis	B-PROC
+in	O
+some	O
+of	O
+the	O
+individuals	O
+recovering	O
+from	O
+SARS	B-DISO
+.	O
+
+Those	O
+individuals	O
+who	O
+were	O
+found	O
+to	O
+have	O
+lung	O
+diffusion	O
+abnormities	O
+(	O
+transfer	O
+coefficient	O
+for	O
+carbon	B-CHED
+monoxide	I-CHED
+[	O
+DLCO	O
+]	O
+<	O
+80	O
+%	O
+of	O
+predicted	O
+value	O
+[	O
+pred	O
+])	O
+received	O
+regular	O
+lung	B-PROC
+function	I-PROC
+tests	O
+and	O
+HRCT	O
+examinations	O
+in	O
+the	O
+follow	O
+-	O
+up	O
+phase	O
+in	O
+order	B-SPEC
+to	O
+document	O
+the	O
+changes	O
+in	O
+their	O
+lung	B-ANAT
+condition	B-DISO
+.	O
+
+The	O
+lack	O
+of	O
+sero	O
+-	O
+positive	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+some	O
+individuals	O
+suggests	O
+that	O
+there	O
+may	O
+have	O
+been	O
+some	O
+misdiagnosed	O
+cases	O
+among	O
+the	O
+subjects	O
+included	O
+in	O
+this	O
+study	O
+.	O
+
+Finally	O
+,	O
+some	O
+of	O
+the	O
+subjects	O
+developed	O
+femoral	B-ANAT
+head	I-ANAT
+necrosis	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genome	O
+comparison	O
+of	O
+inter	O
+-	O
+species	O
+and	O
+intra	O
+-	O
+species	B-SPEC
+can	O
+give	O
+us	O
+much	O
+information	O
+about	O
+the	O
+origin	O
+and	O
+evolution	B-PROC
+of	O
+viruses	B-SPEC
+.	O
+
+The	O
+substitution	O
+bias	B-SPEC
+of	O
+nucleotide	B-CHED
+acids	O
+and	O
+amino	B-CHED
+acids	I-CHED
+indicates	O
+the	O
+non	O
+-	O
+random	O
+drift	O
+products	O
+.	O
+
+Serial	O
+RT	O
+-	O
+PCRs	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+performed	O
+in	O
+the	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+,	O
+stool	B-ANAT
+and	O
+urine	B-ANAT
+of	O
+45	O
+SARS	B-DISO
+patients	O
+who	O
+survived	O
+until	O
+discharge	B-ANAT
+.	O
+
+For	O
+patients	O
+with	O
+positive	O
+RT	O
+-	O
+PCR	O
+on	O
+discharge	B-ANAT
+,	O
+the	O
+median	O
+(	O
+range	O
+)	O
+time	O
+to	O
+RT	O
+-	O
+PCR	O
+conversion	O
+after	O
+discharge	B-ANAT
+was	O
+13	O
+days	O
+(	O
+2	O
+-	O
+60	O
+).	O
+
+ABSTRACT	O
+:	O
+Endothelial	B-ANAT
+injury	O
+is	O
+an	O
+important	O
+prognostic	O
+factor	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+In	O
+conclusion	O
+,	O
+decreased	O
+vascular	B-PROC
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PROC
+levels	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+may	O
+participate	O
+in	O
+the	O
+decrease	O
+in	O
+lung	B-ANAT
+perfusion	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+2003	O
+global	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+provided	O
+numerous	O
+challenges	O
+to	O
+the	O
+delivery	O
+of	O
+critical	O
+care	O
+.	O
+
+The	O
+influx	O
+of	O
+critically	O
+ill	O
+patients	O
+and	O
+the	O
+transmission	O
+of	O
+SARS	B-DISO
+to	O
+front	O
+line	O
+workers	O
+created	O
+a	O
+tremendous	O
+strain	O
+on	O
+Toronto	O
+'	O
+s	O
+healthcare	O
+system	O
+.	O
+
+From	O
+a	O
+critical	O
+care	O
+perspective	O
+,	O
+the	O
+most	O
+important	O
+limitation	O
+in	O
+the	O
+response	O
+to	O
+SARS	B-DISO
+was	O
+the	O
+absence	O
+of	O
+a	O
+coordinated	O
+leadership	O
+and	O
+communication	O
+infrastructure	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+experience	O
+from	O
+treatment	O
+of	O
+seven	O
+SARS	B-DISO
+patients	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Development	B-PROC
+and	O
+preliminary	O
+application	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+against	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-DISO
+virus	B-SPEC
+].	O
+
+CONCLUSIONS	O
+:	O
+The	O
+monoclonal	O
+antibody	B-COMP
+has	O
+good	O
+specificity	O
+and	O
+may	O
+be	O
+used	O
+to	O
+detect	O
+SARS	B-PRGE
+virus	B-SPEC
+antigen	B-CHED
+.	O
+
+S1	O
+domain	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+,	O
+which	O
+has	O
+been	O
+demonstrated	O
+harboring	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+,	O
+successfully	O
+elicited	O
+SARS	B-DISO
+-	O
+CoV	O
+specific	O
+IgG	B-COMP
+antibody	I-COMP
+in	O
+mouse	B-SPEC
+after	O
+combined	O
+immunization	O
+with	O
+DNA	O
+and	O
+purified	O
+S1	B-PRGE
+protein	I-PRGE
+;	O
+the	O
+antibody	B-COMP
+elicited	O
+solely	O
+by	O
+S1	O
+could	O
+potently	O
+neutralize	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+HKU	O
+-	O
+39849	O
+)	O
+in	O
+vitro	O
+,	O
+50	O
+%	O
+of	O
+1	O
+000	O
+TCID50	O
+SARS	B-DISO
+-	O
+CoV	O
+challenged	O
+cells	B-COMP
+were	O
+protected	O
+from	O
+viral	B-DISO
+infection	I-DISO
+by	O
+a	O
+1	O
+:	O
+1499	O
+.	O
+68	O
+dilution	O
+of	O
+mice	B-SPEC
+sera	B-COMP
+immunized	O
+with	O
+S1	B-PRGE
+protein	I-PRGE
+,	O
+but	O
+negative	O
+control	O
+sera	B-COMP
+showed	O
+no	O
+protection	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+all	O
+the	O
+patients	O
+with	O
+abnormal	O
+X	O
+-	O
+ray	B-SPEC
+result	O
+,	O
+19	O
+were	O
+male	O
+(	O
+54	O
+.	O
+29	O
+%),	O
+16	O
+(	O
+45	O
+.	O
+71	O
+%)	O
+were	O
+female	O
+,	O
+P	O
+>	O
+0	O
+.	O
+01	O
+;	O
+7	O
+(	O
+58	O
+.	O
+33	O
+%)	O
+were	O
+above	O
+the	O
+age	O
+of	O
+45	O
+;	O
+28	O
+(	O
+34	O
+.	O
+57	O
+%)	O
+were	O
+below	O
+the	O
+age	O
+of	O
+45	O
+,	O
+P	O
+>	O
+0	O
+.	O
+01	O
+;	O
+hyperpyrexia	B-DISO
+(>/=	O
+39	O
+),	O
+26	O
+(	O
+50	O
+.	O
+00	O
+%),	O
+below	O
+39	O
+,	O
+9	O
+(	O
+21	O
+.	O
+95	O
+%);	O
+multiple	O
+-	O
+lesion	O
+,	O
+22	O
+(	O
+52	O
+.	O
+38	O
+%),	O
+mono	B-DISO
+-	O
+lesion	O
+,	O
+13	O
+(	O
+25	O
+.	O
+49	O
+%),	O
+P	O
+<	O
+0	O
+.	O
+01	O
+;	O
+glucocorticoid	B-CHED
+administration	O
+time	O
+within	O
+5	O
+days	O
+,	O
+22	O
+(	O
+38	O
+.	O
+60	O
+%)	O
+after	O
+5	O
+days	O
+,	O
+12	O
+(	O
+33	O
+.	O
+33	O
+%),	O
+P	O
+>	O
+0	O
+.	O
+01	O
+;	O
+within	O
+7	O
+days	O
+,	O
+21	O
+(	O
+30	O
+.	O
+00	O
+%),	O
+after	O
+7	O
+days	O
+,	O
+14	O
+(	O
+60	O
+.	O
+87	O
+%),	O
+P	O
+<	O
+0	O
+.	O
+01	O
+.	O
+
+When	O
+tested	O
+with	O
+hemagglutinin	O
+inhibition	B-PROC
+assay	O
+,	O
+64	O
+cases	O
+(	O
+61	O
+.	O
+54	O
+%)	O
+showed	O
+a	O
+4	O
+-	O
+fold	O
+increase	O
+against	O
+H3N2	B-PRGE
+antigen	B-CHED
+.	O
+
+Results	O
+of	O
+Western	O
+-	O
+blot	O
+showed	O
+that	O
+this	O
+expressed	B-PROC
+protein	B-CHED
+could	O
+react	O
+with	O
+antibodies	B-COMP
+in	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+during	O
+convalescence	O
+.	O
+
+This	O
+provided	O
+the	O
+basis	O
+for	O
+the	O
+further	O
+study	O
+on	O
+SARS	B-DISO
+virus	B-SPEC
+vaccine	O
+and	O
+diagnostic	O
+agents	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+independent	O
+risk	O
+factors	O
+to	O
+predict	O
+mortality	O
+of	O
+critical	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+were	O
+investigated	O
+.	O
+
+One	O
+hundred	O
+and	O
+two	O
+patients	O
+diagnosed	O
+with	O
+critical	O
+SARS	B-DISO
+were	O
+admitted	O
+to	O
+hospitals	O
+of	O
+Shanxi	O
+Province	O
+,	O
+from	O
+March	O
+7	O
+,	O
+2003	O
+to	O
+June	O
+4	O
+,	O
+2003	O
+.	O
+
+The	O
+patients	O
+were	O
+prospectively	O
+studied	O
+after	O
+admission	O
+to	O
+access	O
+their	O
+short	O
+term	O
+outcomes	O
+and	O
+the	O
+risk	O
+factors	O
+associated	O
+with	O
+adverse	O
+outcomes	O
+,	O
+defined	O
+as	O
+death	B-PROC
+.	O
+
+Fragment	O
+450	O
+-	O
+650	O
+(	O
+S450	O
+-	O
+650	O
+)	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+contains	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+and	O
+neutralizing	O
+epitopes	O
+.	O
+
+On	O
+-	O
+column	B-ANAT
+refolding	O
+and	O
+purification	O
+was	O
+performed	O
+.	O
+
+S	O
+(	O
+GD03T0013	O
+)	O
+depended	O
+less	O
+on	O
+the	O
+hACE	B-PRGE
+-	I-PRGE
+2	I-PRGE
+receptor	I-PRGE
+and	O
+was	O
+markedly	O
+resistant	O
+to	O
+Ab	O
+inhibition	O
+.	O
+
+Furthermore	O
+,	O
+of	O
+16	O
+sera	B-COMP
+collected	O
+from	O
+four	O
+patients	O
+during	O
+the	O
+SARS	B-DISO
+recurrence	B-DISO
+in	O
+Guangzhou	O
+,	O
+5	O
+sera	B-COMP
+collected	O
+from	O
+7	O
+to	O
+9	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+were	O
+positive	O
+for	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+In	O
+conclusion	O
+,	O
+an	O
+antigen	B-CHED
+capture	O
+ELISA	O
+reveals	O
+a	O
+high	O
+N	O
+protein	B-CHED
+detection	O
+rate	O
+in	O
+acute	O
+-	O
+phase	O
+sera	B-COMP
+of	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+which	O
+makes	O
+it	O
+useful	O
+for	O
+early	O
+diagnosis	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+priorities	O
+for	O
+further	O
+research	O
+in	O
+protecting	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+from	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+other	O
+respiratory	O
+pathogens	O
+by	O
+summarizing	O
+the	O
+basic	O
+science	O
+of	O
+infectious	B-DISO
+bioaerosols	O
+and	O
+the	O
+efficacy	O
+of	O
+facial	B-ANAT
+protective	O
+equipment	O
+;	O
+the	O
+organizational	O
+,	O
+environmental	O
+,	O
+and	O
+individual	O
+factors	O
+that	O
+influence	O
+the	O
+success	O
+of	O
+infection	B-DISO
+control	O
+and	O
+occupational	O
+health	O
+programs	O
+;	O
+and	O
+factors	O
+identified	O
+by	O
+HCWs	O
+as	O
+important	O
+.	O
+
+In	O
+all	O
+susceptible	O
+cell	B-ANAT
+lines	I-ANAT
+mRNA	B-CHED
+of	O
+the	O
+Angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+the	O
+functional	O
+receptor	O
+for	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+could	O
+be	O
+detected	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Early	O
+administration	O
+of	O
+antiviral	B-CHED
+agents	I-CHED
+and	O
+extensive	O
+management	O
+were	O
+thought	O
+to	O
+be	O
+necessary	O
+for	O
+such	O
+patients	O
+with	O
+severe	O
+complications	O
+.	O
+
+The	O
+study	O
+population	O
+was	O
+composed	O
+of	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+warranting	O
+presentation	O
+to	O
+Queensland	O
+hospitals	O
+.	O
+
+All	O
+patients	O
+positive	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+required	O
+admission	O
+to	O
+hospital	O
+.	O
+
+Two	O
+group	O
+2	O
+coronaviruses	O
+,	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+),	O
+show	O
+remarkable	O
+antigenic	O
+and	O
+genetic	O
+similarities	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+report	O
+the	O
+first	O
+complete	O
+genome	O
+sequence	O
+(	O
+30	O
+,	O
+738	O
+nucleotides	B-CHED
+)	O
+of	O
+the	O
+prototype	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+strain	O
+(	O
+ATCC	O
+VR759	O
+).	O
+
+TITLE	O
+:	O
+Molecular	O
+and	O
+biological	O
+characterization	O
+of	O
+human	B-PRGE
+monoclonal	I-PRGE
+antibodies	B-COMP
+binding	B-FUNC
+to	O
+the	O
+spike	O
+and	O
+nucleocapsid	O
+proteins	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Two	O
+MAbs	O
+reacted	O
+with	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+One	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+MAbs	I-PRGE
+recognized	O
+a	O
+linear	O
+epitope	B-CHED
+conserved	O
+between	O
+all	O
+published	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+,	O
+and	O
+the	O
+other	O
+bound	O
+to	O
+a	O
+nonlinear	O
+N	O
+epitope	B-CHED
+.	O
+
+These	O
+two	O
+N	O
+MAbs	O
+did	O
+not	O
+compete	O
+for	O
+binding	B-FUNC
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Four	O
+MAbs	O
+reacted	O
+with	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+,	O
+and	O
+three	O
+of	O
+these	O
+MAbs	O
+neutralized	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+vitro	O
+.	O
+
+We	O
+found	O
+that	O
+an	O
+organic	O
+NO	O
+donor	B-CHED
+,	O
+S	O
+-	O
+nitroso	B-CHED
+-	O
+N	B-CHED
+-	I-CHED
+acetylpenicillamine	I-CHED
+,	O
+significantly	O
+inhibited	O
+the	O
+replication	O
+cycle	O
+of	O
+SARS	B-PRGE
+CoV	I-PRGE
+in	O
+a	O
+concentration	O
+-	O
+dependent	O
+manner	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+Legionella	B-DISO
+pneumonia	I-DISO
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+treated	O
+with	O
+methylprednisolone	O
+and	O
+sivelestat	O
+sodium	O
+in	O
+combination	O
+with	O
+intravenous	O
+erythromycin	B-CHED
+and	O
+ciprofloxacin	B-CHED
+].	O
+
+His	O
+chest	B-ANAT
+radiography	O
+showed	O
+patchy	O
+consolidations	O
+in	O
+the	O
+lower	B-ANAT
+lobe	I-ANAT
+of	I-ANAT
+the	I-ANAT
+right	I-ANAT
+lung	I-ANAT
+and	O
+in	O
+the	O
+middle	O
+field	O
+of	O
+the	O
+left	B-ANAT
+lung	I-ANAT
+,	O
+and	O
+severe	O
+hypoxia	B-DISO
+was	O
+present	O
+.	O
+
+Many	O
+dental	O
+procedures	O
+produce	O
+extensive	O
+aerosols	O
+and	O
+splatter	O
+that	O
+are	O
+routinely	O
+contaminated	O
+with	O
+bacteria	B-SPEC
+,	O
+viruses	B-SPEC
+,	O
+and	O
+blood	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+by	O
+siRNA	O
+.	O
+
+RNA	B-PROC
+interference	I-PROC
+in	O
+animals	B-SPEC
+and	O
+post	B-PROC
+-	I-PROC
+transcriptional	I-PROC
+gene	I-PROC
+silencing	I-PROC
+plants	B-SPEC
+is	O
+mediated	O
+by	O
+small	O
+double	O
+-	O
+stranded	O
+RNA	O
+molecules	O
+named	O
+small	O
+interfering	O
+RNA	O
+(	O
+siRNA	O
+).	O
+
+PGF	B-CHED
+was	O
+tested	O
+for	O
+acceptance	O
+with	O
+30	O
+-	O
+day	O
+and	O
+all	O
+-	O
+cause	O
+hospital	O
+mortality	O
+rates	O
+,	O
+overall	O
+survival	O
+,	O
+hospital	O
+length	O
+of	O
+stay	O
+(	O
+HLOS	O
+),	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+best	O
+6	O
+-	O
+min	O
+walk	O
+test	O
+(	O
+6MWT	O
+)	O
+distance	O
+achieved	O
+within	O
+12	O
+months	O
+.	O
+
+The	O
+overall	O
+incidence	O
+of	O
+PGF	B-CHED
+was	O
+11	O
+.	O
+8	O
+%	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+7	O
+.	O
+9	O
+to	O
+15	O
+.	O
+9	O
+%).	O
+
+At	O
+all	O
+study	O
+sites	O
+,	O
+the	O
+majority	O
+of	O
+RSV	B-SPEC
+cases	O
+occurred	O
+in	O
+infants	O
+.	O
+
+During	O
+viral	O
+and	O
+target	O
+cell	B-COMP
+membrane	I-COMP
+fusion	O
+,	O
+the	O
+heptad	O
+repeat	O
+(	O
+HR	O
+)	O
+regions	O
+of	O
+the	O
+S2	O
+subunit	O
+assume	O
+a	O
+trimer	O
+-	O
+of	O
+-	O
+hairpins	O
+structure	O
+,	O
+positioning	O
+the	O
+fusion	O
+peptide	B-CHED
+in	O
+close	O
+proximity	O
+to	O
+the	O
+C	O
+-	O
+terminal	O
+region	O
+of	O
+the	O
+ectodomain	O
+.	O
+
+The	O
+formation	B-PROC
+of	O
+this	O
+structure	O
+appears	O
+to	O
+drive	O
+apposition	O
+and	O
+subsequent	O
+fusion	O
+of	O
+viral	O
+and	O
+target	O
+cell	B-COMP
+membranes	I-COMP
+;	O
+however	O
+,	O
+the	O
+exact	O
+mechanism	O
+is	O
+unclear	O
+.	O
+
+Here	O
+,	O
+we	O
+characterize	O
+an	O
+aromatic	B-CHED
+amino	I-CHED
+acid	I-CHED
+rich	O
+region	O
+within	O
+the	O
+ectodomain	O
+of	O
+the	O
+S2	O
+subunit	O
+that	O
+both	O
+partitions	O
+into	O
+lipid	B-CHED
+membranes	B-ANAT
+and	O
+has	O
+the	O
+capacity	O
+to	O
+perturb	O
+lipid	B-CHED
+vesicle	B-COMP
+integrity	O
+.	O
+
+A	O
+few	O
+mucosal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+lymphocytes	B-ANAT
+in	O
+the	O
+intestine	B-ANAT
+were	O
+positively	O
+stained	O
+for	O
+coronavirus	B-SPEC
+with	O
+ISH	B-DISO
+.	O
+
+The	O
+findings	O
+provide	O
+possible	O
+explanations	O
+for	O
+the	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+and	O
+the	O
+presence	O
+of	O
+virus	B-SPEC
+in	O
+the	O
+stool	B-ANAT
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+profile	O
+of	O
+immune	B-PROC
+response	I-PROC
+genes	O
+in	O
+patients	O
+with	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+.	O
+
+Our	O
+study	O
+shows	O
+for	O
+the	O
+first	O
+time	O
+how	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+responds	O
+to	O
+the	O
+SARS	B-DISO
+infection	B-DISO
+,	O
+and	O
+opens	O
+new	O
+possibilities	O
+for	O
+designing	O
+new	O
+diagnostics	O
+and	O
+treatments	O
+for	O
+this	O
+new	O
+life	O
+-	O
+threatening	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Emergency	B-DISO
+departments	O
+(	O
+ED	O
+)	O
+were	O
+on	O
+the	O
+front	O
+lines	O
+for	O
+possible	O
+cases	O
+of	O
+transmission	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+.	O
+
+The	O
+SARS	B-DISO
+catastrophe	O
+affected	O
+the	O
+ED	O
+visit	O
+volume	O
+,	O
+finances	O
+,	O
+various	O
+patient	O
+characteristics	O
+,	O
+and	O
+stress	O
+levels	O
+in	O
+the	O
+ED	O
+physicians	O
+and	O
+nurses	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+HCoV	O
+-	O
+NH	O
+infection	B-DISO
+is	O
+associated	O
+with	O
+Kawasaki	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+total	O
+of	O
+525	O
+respiratory	O
+specimens	O
+,	O
+collected	O
+in	O
+Canada	O
+primarily	O
+during	O
+the	O
+winter	O
+months	O
+of	O
+2001	O
+-	O
+2002	O
+,	O
+were	O
+tested	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+;	O
+19	O
+tested	O
+positive	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+demonstrating	O
+virus	B-SPEC
+activity	O
+during	O
+January	O
+-	O
+March	O
+2002	O
+.	O
+
+Both	O
+MAbs	O
+bound	O
+to	O
+S	B-PRGE
+glycoprotein	I-PRGE
+expressed	B-PROC
+on	O
+transfected	O
+cells	B-COMP
+but	O
+differed	O
+in	O
+their	O
+ability	O
+to	O
+block	O
+binding	B-FUNC
+of	O
+S	B-PRGE
+glycoprotein	I-PRGE
+to	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Reflective	O
+practice	O
+is	O
+useful	O
+to	O
+guide	O
+and	O
+examine	O
+nurses	O
+'	O
+professional	O
+action	O
+during	O
+the	O
+crisis	O
+,	O
+and	O
+to	O
+put	O
+the	O
+experience	O
+into	O
+a	O
+learning	B-PROC
+perspective	O
+.	O
+
+Superinfection	B-DISO
+after	O
+the	O
+immune	O
+injury	O
+is	O
+the	O
+main	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+characterize	O
+enzymatic	B-PROC
+activity	I-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+(	O
+pro	B-CHED
+))	O
+and	O
+its	O
+four	O
+site	O
+-	O
+directed	O
+mutants	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+showed	O
+substantial	O
+pH	O
+and	O
+temperature	O
+-	O
+triggered	O
+activity	O
+switches	O
+,	O
+and	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+analysis	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+revealed	O
+that	O
+substitutions	O
+of	O
+His41	O
+,	O
+Cys145	O
+,	O
+and	O
+His163	O
+resulted	O
+in	O
+complete	O
+loss	O
+of	O
+enzymatic	B-PROC
+activity	I-PROC
+,	O
+while	O
+replacement	O
+of	O
+Met162	O
+with	O
+Ala	B-CHED
+caused	O
+strongly	O
+increased	O
+activity	O
+.	O
+
+Although	O
+partial	O
+ventilatory	O
+support	O
+modalities	O
+were	O
+initially	O
+developed	O
+for	O
+weaning	B-PROC
+from	O
+mechanical	O
+ventilation	O
+,	O
+they	O
+are	O
+increasingly	O
+used	O
+as	O
+primary	O
+modes	O
+of	O
+ventilation	O
+,	O
+even	O
+in	O
+patients	O
+in	O
+the	O
+acute	O
+phase	O
+of	O
+pulmonary	B-ANAT
+dysfunction	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+paper	O
+is	O
+to	O
+review	O
+the	O
+role	O
+of	O
+spontaneous	O
+breathing	B-PROC
+ventilatory	O
+modalities	O
+with	O
+respect	O
+to	O
+their	O
+physiologic	O
+or	O
+clinical	O
+evidence	O
+.	O
+
+In	O
+the	O
+former	O
+,	O
+however	O
+,	O
+it	O
+remains	O
+unclear	O
+whether	O
+noninvasive	O
+ventilation	O
+offers	O
+any	O
+significant	O
+advantages	O
+over	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+.	O
+
+This	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+(	O
+hGST	O
+-	O
+N	O
+)	O
+was	O
+purified	O
+and	O
+used	O
+to	O
+measure	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+N	O
+-	O
+specific	O
+antibody	B-COMP
+in	O
+the	O
+sera	B-COMP
+of	O
+eight	O
+SARS	B-DISO
+patients	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Specific	O
+antibody	B-PROC
+response	I-PROC
+to	O
+this	O
+purified	O
+recombinant	O
+N	O
+protein	B-CHED
+was	O
+100	O
+%	O
+positive	O
+in	O
+the	O
+SARS	B-DISO
+patients	O
+'	O
+sera	B-COMP
+,	O
+while	O
+none	O
+of	O
+the	O
+control	O
+sera	B-COMP
+from	O
+30	O
+healthy	O
+people	O
+gave	O
+a	O
+positive	O
+reaction	O
+in	O
+the	O
+same	O
+assay	O
+.	O
+
+Results	O
+from	O
+hierarchical	O
+linear	O
+modeling	O
+showed	O
+that	O
+trait	O
+anxiety	O
+as	O
+well	O
+as	O
+the	O
+situation	O
+-	O
+appropriate	O
+coping	O
+strategies	O
+of	O
+avoidance	O
+and	O
+personal	O
+hygiene	O
+practice	O
+accounted	O
+for	O
+changes	O
+in	O
+state	B-DISO
+anxiety	I-DISO
+.	O
+
+With	O
+regard	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+,	O
+several	O
+mechanisms	O
+involving	O
+both	O
+direct	O
+effects	O
+on	O
+target	B-ANAT
+cells	I-ANAT
+and	O
+indirect	O
+effects	O
+via	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+may	O
+exist	O
+.	O
+
+Even	O
+in	O
+a	O
+situation	O
+of	O
+no	O
+new	O
+infections	B-DISO
+,	O
+SARS	B-DISO
+remains	O
+a	O
+major	O
+health	O
+hazard	O
+,	O
+as	O
+new	O
+epidemics	O
+may	O
+arise	O
+.	O
+
+TITLE	O
+:	O
+In	O
+vitro	O
+assembled	O
+,	O
+recombinant	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+demonstrate	O
+that	O
+the	O
+5a	O
+open	O
+reading	O
+frame	O
+is	O
+not	O
+essential	O
+for	O
+replication	O
+.	O
+
+The	O
+cells	B-COMP
+were	O
+overlaid	O
+onto	O
+the	O
+susceptible	O
+Vero	B-ANAT
+cells	I-ANAT
+and	O
+viable	O
+virus	B-SPEC
+was	O
+recovered	O
+from	O
+the	O
+molecular	O
+clone	O
+.	O
+
+The	O
+molecularly	O
+cloned	O
+IBV	B-SPEC
+(	O
+MIBV	O
+)	O
+demonstrated	O
+growth	B-PROC
+kinetics	O
+,	O
+and	O
+plaque	B-DISO
+size	O
+and	O
+morphology	O
+that	O
+resembled	O
+the	O
+parental	O
+Beaudette	O
+strain	O
+IBV	B-SPEC
+.	O
+
+The	O
+rescued	O
+recombinant	O
+virus	B-SPEC
+,	O
+expressing	O
+EGFP	O
+(	O
+GIBV	O
+),	O
+replicated	O
+to	O
+lower	O
+viral	O
+titers	O
+and	O
+formed	O
+smaller	O
+plaques	O
+compared	O
+to	O
+the	O
+parental	O
+virus	B-SPEC
+and	O
+the	O
+MIBV	O
+.	O
+
+ABSTRACT	O
+:	O
+Lactobacillus	B-SPEC
+casei	I-SPEC
+strain	O
+Shirota	O
+was	O
+selected	O
+as	O
+a	O
+bacterial	O
+carrier	O
+for	O
+the	O
+development	B-PROC
+of	O
+live	O
+mucosal	B-ANAT
+vaccines	O
+against	O
+coronavirus	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+6	O
+-	O
+10	O
+blood	B-ANAT
+samples	I-ANAT
+from	O
+animals	B-SPEC
+of	O
+different	O
+ages	O
+were	O
+collected	O
+from	O
+each	O
+herd	O
+,	O
+resulting	O
+in	O
+169	O
+samples	O
+.	O
+
+ABSTRACT	O
+:	O
+Inactivated	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+samples	O
+were	O
+used	O
+for	O
+an	O
+external	O
+quality	O
+assurance	O
+study	O
+within	O
+the	O
+World	O
+Health	O
+Organization	O
+SARS	B-DISO
+Reference	O
+and	O
+Verification	O
+Network	O
+and	O
+other	O
+reference	O
+institutions	O
+.	O
+
+Of	O
+58	O
+participants	O
+,	O
+51	O
+correctly	O
+detected	O
+virus	B-SPEC
+in	O
+all	O
+samples	O
+>	O
+or	O
+=	O
+9	O
+,	O
+400	O
+RNA	O
+copies	O
+per	O
+milliliter	O
+and	O
+none	O
+in	O
+negative	O
+samples	O
+.	O
+
+Of	O
+a	O
+group	O
+of	O
+81	O
+animals	B-SPEC
+in	O
+which	O
+FIP	B-DISO
+had	O
+been	O
+confirmed	O
+by	O
+post	O
+-	O
+mortem	O
+examination	O
+,	O
+75	O
+(	O
+93	O
+%)	O
+tested	O
+positive	O
+,	O
+whereas	O
+17	O
+cats	B-SPEC
+with	O
+different	O
+pathologies	O
+(	O
+non	O
+-	O
+FIP	O
+cases	O
+)	O
+all	O
+tested	O
+negative	O
+.	O
+
+The	O
+basis	O
+of	O
+the	O
+assay	O
+is	O
+the	O
+cleavage	B-PROC
+of	O
+target	O
+RNA	O
+by	O
+RNase	B-PRGE
+H	I-PRGE
+mediated	O
+by	O
+sequence	O
+-	O
+specific	O
+chimeric	O
+oligonucleotides	B-CHED
+followed	O
+by	O
+sample	O
+to	O
+residual	O
+ratio	O
+quantitation	O
+(	O
+SRRQ	O
+)	O
+using	O
+RRT	O
+-	O
+PCR	O
+.	O
+
+Once	O
+it	O
+was	O
+evident	O
+that	O
+no	O
+lung	B-ANAT
+injury	O
+had	O
+occurred	O
+,	O
+we	O
+designed	O
+a	O
+more	O
+severe	O
+model	O
+.	O
+
+These	O
+pigs	B-SPEC
+were	O
+monitored	O
+more	O
+invasively	O
+and	O
+continuously	O
+in	O
+an	O
+intensive	O
+care	O
+setting	O
+for	O
+48	O
+h	O
+and	O
+followed	O
+,	O
+treated	O
+,	O
+and	O
+assessed	O
+in	O
+a	O
+similar	O
+fashion	O
+to	O
+group	O
+1	O
+.	O
+
+The	O
+addition	O
+of	O
+a	O
+second	O
+""""	O
+hit	O
+""""	O
+(	O
+SMA	B-DISO
+occlusion	B-DISO
+,	O
+I	O
+/	O
+R	O
+)	O
+to	O
+a	O
+FC	O
+sepsis	B-DISO
+model	O
+resulted	O
+in	O
+severe	O
+lung	B-ANAT
+injury	O
+that	O
+developed	O
+within	O
+a	O
+3	O
+-	O
+day	O
+period	O
+.	O
+
+The	O
+vaccine	O
+was	O
+administered	O
+orally	B-ANAT
+at	O
+2	O
+,	O
+4	O
+,	O
+10	O
+,	O
+and	O
+14	O
+wk	O
+of	O
+age	O
+.	O
+
+At	O
+26	O
+wk	O
+of	O
+age	O
+,	O
+blood	B-ANAT
+was	O
+obtained	O
+to	O
+determine	O
+testosterone	B-CHED
+concentrations	O
+,	O
+and	O
+reproductive	B-PROC
+tracts	B-ANAT
+were	O
+removed	O
+to	O
+analyze	O
+daily	O
+sperm	B-ANAT
+production	O
+and	O
+to	O
+detect	O
+epididymal	O
+stones	O
+.	O
+
+0	O
+.	O
+76	O
+g	O
+),	O
+as	O
+compared	O
+with	O
+nonvaccinated	O
+roosters	O
+without	O
+epididymal	B-ANAT
+stones	O
+(	O
+15	O
+.	O
+2	O
++/-	O
+
+Owing	O
+to	O
+the	O
+lack	O
+of	O
+available	O
+drugs	O
+for	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+,	O
+the	O
+discovery	O
+of	O
+inhibitors	B-CHED
+for	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+that	O
+can	O
+potentially	O
+be	O
+optimized	O
+as	O
+drugs	O
+appears	O
+to	O
+be	O
+highly	O
+desirable	O
+.	O
+
+Issues	O
+regarding	O
+cabin	O
+air	B-CHED
+quality	O
+and	O
+the	O
+potential	O
+risks	O
+of	O
+transmission	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+during	O
+flight	B-PROC
+have	O
+been	O
+investigated	O
+and	O
+debated	O
+previously	O
+,	O
+but	O
+,	O
+with	O
+the	O
+advent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+influenza	B-DISO
+outbreaks	O
+,	O
+these	O
+issues	O
+have	O
+recently	O
+taken	O
+on	O
+heightened	O
+importance	O
+.	O
+
+We	O
+hypothesised	O
+that	O
+the	O
+occurrence	O
+of	O
+alveolar	B-ANAT
+hyperinflation	B-DISO
+during	O
+the	O
+application	O
+of	O
+PEEP	B-CHED
+would	O
+lead	O
+to	O
+an	O
+increase	O
+in	O
+PaCO	O
+(	O
+2	O
+)	O
+responsible	O
+for	O
+a	O
+rise	O
+in	O
+intracranial	B-PROC
+pressure	I-PROC
+.	O
+
+The	O
+mortality	O
+rate	O
+was	O
+significantly	O
+higher	O
+among	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+impairment	I-DISO
+compared	O
+with	O
+those	O
+with	O
+SARS	B-DISO
+and	O
+no	O
+renal	B-DISO
+impairment	I-DISO
+(	O
+91	O
+.	O
+7	O
+%	O
+vs	O
+.	O
+8	O
+.	O
+8	O
+%)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Renal	B-ANAT
+tissues	B-ANAT
+revealed	O
+predominantly	O
+acute	B-DISO
+tubular	I-DISO
+necrosis	I-DISO
+with	O
+no	O
+evidence	O
+of	O
+glomerular	B-ANAT
+pathology	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Among	O
+these	O
+536	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+36	O
+(	O
+6	O
+.	O
+7	O
+%)	O
+developed	O
+acute	B-DISO
+renal	I-DISO
+impairment	I-DISO
+occurring	O
+at	O
+a	O
+median	O
+duration	O
+of	O
+20	O
+days	O
+(	O
+range	O
+5	O
+-	O
+48	O
+days	O
+)	O
+after	O
+the	O
+onset	O
+of	O
+viral	B-DISO
+infection	I-DISO
+despite	O
+a	O
+normal	B-ANAT
+plasma	I-ANAT
+creatinine	B-CHED
+level	O
+at	O
+first	O
+clinical	O
+presentation	O
+.	O
+
+The	O
+objectives	O
+of	O
+the	O
+present	O
+study	O
+were	O
+to	O
+examine	O
+the	O
+degree	O
+and	O
+the	O
+sources	O
+of	O
+mental	O
+distress	O
+and	O
+the	O
+coping	O
+strategies	O
+adopted	O
+by	O
+healthcare	O
+workers	O
+(	O
+HCW	O
+)	O
+of	O
+emergency	B-DISO
+departments	O
+(	O
+ED	O
+)	O
+in	O
+Hong	O
+Kong	O
+during	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+At	O
+the	O
+time	O
+of	O
+admission	O
+,	O
+on	O
+physical	O
+examination	O
+she	O
+had	O
+revealed	O
+a	O
+butterfly	B-SPEC
+rash	B-DISO
+over	O
+the	O
+cheeks	B-ANAT
+,	O
+purpura	B-DISO
+,	O
+acute	B-DISO
+synovitis	I-DISO
+and	O
+oedema	B-DISO
+of	O
+the	O
+legs	B-ANAT
+.	O
+
+Dialysis	B-SPEC
+was	O
+instituted	O
+on	O
+two	O
+consecutive	O
+days	O
+from	O
+the	O
+eighth	O
+day	O
+.	O
+
+Infected	O
+B	B-ANAT
+cell	I-ANAT
+-	O
+deficient	O
+mice	B-SPEC
+developed	O
+chronic	O
+subclinical	B-DISO
+infection	I-DISO
+also	O
+restricted	O
+to	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+.	O
+
+However	O
+,	O
+by	O
+2	O
+weeks	O
+,	O
+mice	B-SPEC
+developed	O
+peritonitis	B-DISO
+,	O
+and	O
+viral	O
+RNA	O
+was	O
+detected	O
+in	O
+mesentery	B-ANAT
+and	O
+visceral	B-ANAT
+peritoneum	I-ANAT
+.	O
+
+Comparative	O
+analysis	O
+of	O
+the	O
+frameshift	B-DISO
+region	O
+reveals	O
+a	O
+universal	O
+shift	O
+site	O
+U_UUA_AAC	O
+,	O
+followed	O
+by	O
+a	O
+predicted	O
+downstream	O
+RNA	O
+structure	O
+in	O
+the	O
+form	O
+of	O
+either	O
+a	O
+pseudoknot	O
+or	O
+kissing	O
+stem	B-ANAT
+loops	O
+.	O
+
+Mutagenic	O
+analysis	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+shift	O
+site	O
+and	O
+mass	O
+spectrometry	O
+of	O
+an	O
+affinity	O
+tagged	O
+frameshift	B-DISO
+product	O
+confirmed	O
+tandem	O
+tRNA	B-FUNC
+slippage	O
+on	O
+the	O
+sequence	O
+U_UUA_AAC	O
+.	O
+
+Analysis	O
+of	O
+the	O
+downstream	O
+pseudoknot	O
+stimulator	O
+of	O
+frameshifting	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+shows	O
+that	O
+a	O
+proposed	O
+RNA	O
+secondary	O
+structure	O
+in	O
+loop	O
+II	O
+and	O
+two	O
+unpaired	O
+nucleotides	B-CHED
+at	O
+the	O
+stem	B-ANAT
+I	O
+-	O
+stem	B-ANAT
+II	O
+junction	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+are	O
+important	O
+for	O
+frameshift	B-DISO
+stimulation	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+Beta	B-PRGE
+interferon	I-PRGE
+induction	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+suggests	O
+a	O
+two	O
+-	O
+step	O
+model	O
+for	O
+activation	O
+of	O
+interferon	O
+regulatory	O
+factor	O
+3	O
+.	O
+
+By	O
+contrast	O
+,	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+remained	O
+in	O
+the	O
+nucleus	B-COMP
+of	O
+cells	B-COMP
+infected	O
+with	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+inducing	I-PRGE
+control	I-PRGE
+virus	I-PRGE
+Bunyamwera	I-PRGE
+delNSs	I-PRGE
+.	O
+
+To	O
+test	O
+the	O
+susceptibility	O
+of	O
+civets	B-SPEC
+to	O
+experimental	O
+infection	B-DISO
+by	O
+different	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+,	O
+10	O
+civets	B-SPEC
+were	O
+inoculated	O
+with	O
+two	O
+human	B-SPEC
+isolates	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+BJ01	O
+(	O
+with	O
+a	O
+29	O
+-	O
+nucleotide	B-CHED
+deletion	O
+)	O
+and	O
+GZ01	O
+(	O
+without	O
+the	O
+29	O
+-	O
+nucleotide	B-CHED
+deletion	O
+).	O
+
+We	O
+report	O
+that	O
+controlling	O
+a	O
+SARS	B-DISO
+outbreak	O
+in	O
+a	O
+teaching	O
+hospital	O
+over	O
+an	O
+8	O
+-	O
+week	O
+period	O
+cost	O
+dollar12	O
+million	O
+Canadian	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+report	O
+that	O
+controlling	O
+a	O
+SARS	B-DISO
+outbreak	O
+in	O
+a	O
+teaching	O
+hospital	O
+over	O
+an	O
+8	O
+-	O
+week	O
+period	O
+cost	O
+dollar12	O
+million	O
+Canadian	O
+.	O
+
+Lost	B-CHED
+revenue	O
+and	O
+labour	B-PROC
+accounted	O
+for	O
+two	O
+thirds	O
+of	O
+the	O
+costs	O
+incurred	O
+while	O
+excess	O
+spending	O
+on	O
+services	O
+,	O
+materials	O
+,	O
+supplies	O
+and	O
+renovation	O
+of	O
+existing	O
+space	O
+accounted	O
+for	O
+the	O
+remaining	O
+one	O
+third	O
+.	O
+
+For	O
+the	O
+thermally	O
+induced	O
+unfolding	O
+at	O
+pH	O
+7	O
+.	O
+4	O
+,	O
+the	O
+apparent	O
+activation	O
+energy	O
+(	O
+E	O
+(	O
+app	B-CHED
+))	O
+and	O
+transition	B-DISO
+midpoint	O
+temperature	O
+(	O
+Tm	O
+)	O
+were	O
+determined	O
+to	O
+be	O
+16	O
+.	O
+3	O
++/-	O
+
+Secondary	O
+and	O
+three	O
+-	O
+dimensional	O
+structural	O
+predictions	O
+by	O
+homology	O
+modeling	O
+indicated	O
+that	O
+SARS_S1b	O
+folded	O
+as	O
+a	O
+globular	O
+-	O
+like	O
+structure	O
+by	O
+beta	O
+-	O
+sheets	O
+and	O
+loops	O
+;	O
+two	O
+of	O
+the	O
+four	O
+tryptophans	O
+are	O
+located	O
+on	O
+the	O
+protein	B-CHED
+surface	O
+,	O
+which	O
+is	O
+in	O
+agreement	O
+with	O
+the	O
+tryptophan	B-CHED
+fluorescence	O
+result	O
+.	O
+
+The	O
+two	O
+truncated	O
+fragments	O
+of	O
+S	B-PRGE
+gene	I-PRGE
+were	O
+separately	O
+cloned	O
+into	O
+the	O
+prokaryotic	O
+expression	B-PROC
+vector	O
+pET	B-PRGE
+-	I-PRGE
+15b	I-PRGE
+and	O
+expressed	B-PROC
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+The	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+was	O
+cloned	O
+into	O
+the	O
+eukaryotic	O
+expression	B-PROC
+plasmid	O
+pSecTagB	O
+to	O
+prepare	O
+recombinant	O
+plasmid	O
+pSecS	O
+as	O
+the	O
+DNA	O
+vaccine	O
+to	O
+immunize	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+for	O
+inducing	O
+the	O
+secretion	B-PROC
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	B-CHED
+.	O
+
+Both	O
+the	O
+truncated	B-PRGE
+recombinant	I-PRGE
+proteins	I-PRGE
+were	O
+expressed	B-PROC
+in	O
+soluble	O
+forms	O
+and	O
+reacted	O
+specifically	O
+with	O
+the	O
+sera	O
+from	O
+immunized	O
+pSecS	O
+mice	B-SPEC
+and	O
+clinically	O
+diagnosed	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+vaccine	O
+could	O
+induce	O
+the	O
+production	O
+of	O
+specific	O
+antibody	B-COMP
+,	O
+which	O
+offers	O
+clues	O
+for	O
+the	O
+research	O
+of	O
+SARS	B-DISO
+DNA	O
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+presentation	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+non	O
+-	O
+specific	O
+and	O
+isolation	O
+of	O
+all	O
+suspected	O
+patients	O
+is	O
+difficult	O
+because	O
+of	O
+the	O
+limited	O
+availability	O
+of	O
+isolation	O
+facilities	O
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+pancoronavirus	O
+RT	O
+-	O
+PCR	O
+assay	O
+:	O
+frequent	O
+detection	O
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+in	O
+children	O
+hospitalized	O
+with	O
+respiratory	O
+tract	O
+infections	O
+in	O
+Belgium	O
+.	O
+
+Further	O
+research	O
+showed	O
+that	O
+HAb18G	O
+/	O
+CD147	B-PRGE
+,	O
+a	O
+transmembrane	B-COMP
+molecule	O
+,	O
+was	O
+highly	O
+expressed	B-PROC
+on	O
+293	O
+cells	B-COMP
+and	O
+that	O
+CyPA	B-SPEC
+was	O
+integrated	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+HAb18G	O
+/	O
+CD147	B-PRGE
+-	O
+antagonistic	O
+peptide	B-CHED
+(	O
+AP	B-CHED
+)-	O
+9	O
+,	O
+an	O
+AP	B-CHED
+of	O
+HAb18G	O
+/	O
+CD147	B-PRGE
+,	O
+had	O
+a	O
+high	O
+rate	O
+of	O
+binding	B-FUNC
+to	O
+293	O
+cells	B-COMP
+and	O
+an	O
+inhibitory	O
+effect	O
+on	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+These	O
+results	O
+show	O
+that	O
+HAb18G	O
+/	O
+CD147	B-PRGE
+,	O
+mediated	O
+by	O
+CyPA	B-PRGE
+bound	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+,	O
+plays	O
+a	O
+functional	O
+role	O
+in	O
+facilitating	O
+invasion	O
+of	O
+host	B-COMP
+cells	B-COMP
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Our	O
+findings	O
+provide	O
+some	O
+evidence	O
+for	O
+the	O
+cytologic	O
+mechanism	O
+of	O
+invasion	B-DISO
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+provide	O
+a	O
+molecular	O
+basis	O
+for	O
+screening	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+Twelve	O
+TCM	O
+prescriptions	O
+of	O
+herbal	O
+drugs	O
+(	O
+orally	B-ANAT
+or	O
+i	O
+.	O
+v	O
+.)	O
+were	O
+used	O
+to	O
+treat	O
+16	O
+cases	O
+of	O
+SARS	B-DISO
+without	O
+using	O
+glucocorticoids	B-CHED
+,	O
+anti	B-CHED
+-	I-CHED
+viral	I-CHED
+agents	I-CHED
+,	O
+immune	O
+-	O
+regulators	O
+or	O
+antibiotics	B-CHED
+(	O
+in	O
+case	O
+there	O
+was	O
+no	O
+definite	O
+bacterial	B-DISO
+infections	I-DISO
+).	O
+
+The	O
+symptoms	O
+,	O
+signs	O
+,	O
+chest	B-ANAT
+roentgenograms	O
+and	O
+lab	O
+examinations	O
+were	O
+carefully	O
+monitored	O
+and	O
+recorded	O
+for	O
+evaluation	O
+of	O
+the	O
+effectiveness	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+average	O
+fever	B-PROC
+abatement	O
+time	O
+was	O
+4	O
+.	O
+44	O
++/-	O
+
+RNA	O
+detection	O
+by	O
+all	O
+the	O
+formats	O
+was	O
+unaffected	O
+by	O
+the	O
+presence	O
+of	O
+human	B-SPEC
+sputum	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Three	O
+-	O
+dimensional	O
+model	O
+of	O
+a	O
+substrate	O
+-	O
+bound	O
+SARS	B-PRGE
+chymotrypsin	B-ENZY
+-	O
+like	O
+cysteine	B-PRGE
+proteinase	B-PROC
+predicted	O
+by	O
+multiple	O
+molecular	O
+dynamics	O
+simulations	O
+:	O
+catalytic	O
+efficiency	O
+regulated	O
+by	O
+substrate	O
+binding	B-FUNC
+.	O
+
+The	O
+protein	B-CHED
+sequence	O
+of	O
+the	O
+chymotrypsin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+cysteine	B-CHED
+proteinase	B-PROC
+(	O
+CCP	B-DISO
+)	O
+responsible	O
+for	O
+SARS	B-DISO
+viral	B-PROC
+replication	I-PROC
+has	O
+been	O
+identified	O
+as	O
+a	O
+target	O
+for	O
+developing	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+Here	O
+,	O
+I	O
+report	O
+the	O
+ATVRLQ	O
+(	O
+p1	O
+)	O
+A	O
+(	O
+p1	O
+')-	O
+bound	O
+CCP	B-DISO
+3D	O
+model	O
+predicted	O
+by	O
+420	O
+different	O
+molecular	B-PROC
+dynamics	I-PROC
+simulations	O
+(	O
+2	O
+.	O
+0	O
+ns	O
+for	O
+each	O
+simulation	O
+with	O
+a	O
+1	O
+.	O
+0	O
+-	O
+fs	O
+time	O
+step	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+producer	O
+administered	O
+2	O
+US	O
+Department	O
+of	O
+Agriculture	O
+-	O
+licensed	O
+adjuvanted	O
+veterinary	O
+vaccines	O
+(	O
+inactivated	O
+bovine	B-SPEC
+rotavirus	B-SPEC
+-	O
+coronavirus	B-SPEC
+vaccine	O
+;	O
+Clostridium	B-SPEC
+perfringens	I-SPEC
+type	O
+C	O
+-	O
+Escherichia	B-SPEC
+coli	I-SPEC
+bacterin	O
+-	O
+toxoid	O
+)	O
+into	O
+muscles	B-ANAT
+of	O
+the	O
+left	O
+and	O
+right	O
+hips	B-ANAT
+of	O
+469	O
+pregnant	O
+beef	O
+cows	B-SPEC
+.	O
+
+Histological	O
+samples	O
+revealed	O
+granulomatous	B-DISO
+myositis	I-DISO
+with	O
+intralesional	O
+oil	O
+.	O
+
+The	O
+key	O
+issues	O
+identified	O
+by	O
+the	O
+COPD	B-DISO
+Roundtable	O
+Group	O
+for	O
+comment	O
+are	O
+:	O
+(	O
+i	O
+)	O
+where	O
+there	O
+is	O
+no	O
+access	O
+to	O
+spirometry	O
+,	O
+diagnosis	O
+of	O
+COPD	O
+could	O
+be	O
+suspected	O
+on	O
+the	O
+basis	O
+of	O
+history	O
+,	O
+symptoms	O
+and	O
+physical	O
+signs	O
+;	O
+(	O
+ii	O
+)	O
+inhaled	B-PROC
+bronchodilators	O
+are	O
+the	O
+preferred	O
+regular	O
+treatment	O
+for	O
+COPD	B-DISO
+in	O
+the	O
+region	O
+,	O
+but	O
+oral	B-ANAT
+bronchodilators	O
+may	O
+be	O
+considered	O
+if	O
+the	O
+cost	O
+of	O
+inhaled	B-PROC
+bronchodilators	O
+is	O
+a	O
+barrier	O
+to	O
+treatment	O
+;	O
+(	O
+iii	O
+)	O
+the	O
+use	O
+of	O
+a	O
+Metered	O
+Dose	O
+Inhaler	O
+with	O
+spacer	O
+in	O
+place	O
+of	O
+a	O
+nebulizer	O
+is	O
+recommended	O
+in	O
+the	O
+treatment	O
+of	O
+acute	O
+airflow	B-PROC
+obstruction	B-DISO
+in	O
+patients	O
+with	O
+COPD	B-DISO
+;	O
+(	O
+iv	O
+)	O
+influenza	B-DISO
+vaccination	O
+is	O
+recommended	O
+for	O
+all	O
+patients	O
+with	O
+COPD	B-DISO
+in	O
+communities	O
+where	O
+there	O
+is	O
+a	O
+high	O
+likelihood	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+;	O
+and	O
+(	O
+v	O
+)	O
+simplified	O
+pulmonary	B-ANAT
+rehabilitation	O
+programmes	O
+should	O
+be	O
+established	O
+in	O
+areas	O
+where	O
+comprehensive	O
+programmes	O
+are	O
+unavailable	O
+.	O
+
+It	O
+has	O
+been	O
+observed	O
+that	O
+the	O
+catalytic	O
+dyad	O
+(	O
+His	O
+-	O
+41	O
+/	O
+Cys	B-CHED
+-	O
+145	O
+)	O
+site	O
+between	O
+domains	O
+I	O
+and	O
+II	O
+attracts	O
+the	O
+pi	O
+electron	O
+density	O
+from	O
+the	O
+peptide	B-CHED
+bond	O
+Gln	B-CHED
+-	O
+Ser	B-COMP
+,	O
+increasing	O
+the	O
+positive	O
+charge	O
+on	O
+C	O
+(	O
+CO	O
+)	O
+of	O
+Gln	B-CHED
+and	O
+the	O
+negative	O
+charge	O
+on	O
+N	O
+(	O
+NH	O
+)	O
+of	O
+Ser	B-COMP
+,	O
+so	O
+as	O
+to	O
+weaken	O
+the	O
+Gln	B-CHED
+-	O
+Ser	B-COMP
+peptide	B-CHED
+bond	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+and	O
+avian	B-DISO
+influenza	I-DISO
+have	O
+many	O
+common	O
+features	O
+.	O
+
+Prospective	O
+cohort	O
+analysis	O
+was	O
+done	O
+from	O
+117	O
+very	O
+low	O
+-	O
+birthweight	O
+infants	O
+who	O
+were	O
+born	O
+in	O
+Seoul	O
+National	O
+University	O
+Hospital	O
+and	O
+survived	O
+more	O
+than	O
+36	O
+weeks	O
+postmenstrual	O
+age	O
+(	O
+PMA	B-CHED
+).	O
+
+Chronic	O
+oxygen	B-CHED
+requirement	O
+pattern	O
+showed	O
+that	O
+infants	O
+with	O
+RDS	O
+(+)	O
+CA	O
+(+)	O
+CLD	B-DISO
+required	O
+the	O
+highest	O
+concentrations	O
+of	O
+oxygen	B-CHED
+not	O
+only	O
+initially	O
+but	O
+also	O
+thereafter	O
+until	O
+the	O
+28th	O
+day	O
+of	O
+life	O
+and	O
+36	O
+weeks	O
+PMA	B-CHED
+.	O
+
+Phylogenetic	O
+analysis	O
+suggested	O
+an	O
+independent	O
+viral	O
+invasion	B-DISO
+from	O
+animal	B-SPEC
+to	O
+human	B-SPEC
+in	O
+this	O
+new	O
+episode	O
+.	O
+
+CONCLUSIONS	O
+:	O
+One	O
+fourth	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+developed	O
+hypouricemia	B-DISO
+,	O
+which	O
+might	O
+result	O
+from	O
+a	O
+defect	O
+in	O
+renal	B-ANAT
+UA	O
+handling	O
+and	O
+was	O
+associated	O
+with	O
+a	O
+high	O
+serum	B-COMP
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+level	O
+.	O
+
+Negative	O
+appraisals	O
+at	O
+the	O
+acute	O
+phase	O
+and	O
+1	O
+-	O
+month	O
+recovery	O
+significantly	O
+accounted	O
+for	O
+substantial	O
+portions	O
+of	O
+variances	O
+for	O
+anxiety	O
+and	O
+depressive	B-DISO
+symptoms	I-DISO
+,	O
+after	O
+the	O
+effects	O
+of	O
+other	O
+psychosocial	O
+variables	O
+were	O
+controlled	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+posed	O
+an	O
+unprecedented	O
+threat	O
+and	O
+a	O
+great	O
+challenge	O
+to	O
+health	O
+professionals	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Socio	O
+-	O
+demographic	O
+and	O
+stress	O
+variables	O
+were	O
+entered	O
+into	O
+a	O
+logistic	O
+regression	O
+analysis	O
+to	O
+find	O
+out	O
+the	O
+variables	O
+associated	O
+with	O
+psychological	B-DISO
+morbidity	O
+.	O
+
+The	O
+healthcare	O
+workers	O
+'	O
+psychological	B-DISO
+morbidity	O
+was	O
+best	O
+understood	O
+by	O
+the	O
+perceptions	O
+of	O
+personal	O
+vulnerability	O
+,	O
+stress	O
+and	O
+support	O
+in	O
+the	O
+workplace	O
+.	O
+
+Forty	O
+-	O
+two	O
+percent	O
+of	O
+parents	O
+feared	O
+catching	B-DISO
+an	O
+infection	B-DISO
+from	O
+their	O
+children	O
+,	O
+and	O
+36	O
+.	O
+1	O
+%	O
+of	O
+parents	O
+feared	O
+transmitting	O
+HIV	B-DISO
+to	O
+their	O
+children	O
+.	O
+
+Twenty	O
+-	O
+eight	O
+percent	O
+of	O
+parents	O
+avoided	O
+at	O
+least	O
+1	O
+type	O
+of	O
+interaction	O
+with	O
+their	O
+children	O
+""""	O
+a	O
+lot	O
+""""	O
+because	O
+they	O
+feared	O
+transmitting	O
+HIV	B-DISO
+or	O
+catching	B-DISO
+an	O
+opportunistic	B-DISO
+infection	I-DISO
+.	O
+
+Among	O
+the	O
+serological	O
+tests	O
+currently	O
+available	O
+for	O
+the	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+a	O
+whole	O
+-	O
+virus	B-SPEC
+-	O
+based	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+)	O
+was	O
+considered	O
+one	O
+of	O
+the	O
+most	O
+sensitive	O
+assays	O
+and	O
+served	O
+as	O
+a	O
+""""	O
+gold	B-CHED
+standard	O
+""""	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Singapore	O
+in	O
+2003	O
+.	O
+
+Thus	O
+,	O
+the	O
+novel	O
+N	O
+-	O
+S	O
+fusion	O
+antigen	B-CHED
+-	O
+based	O
+IFA	O
+could	O
+be	O
+an	O
+attractive	O
+alternative	O
+to	O
+present	O
+whole	O
+-	O
+virus	B-SPEC
+-	O
+based	O
+IFAs	O
+for	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+is	O
+a	O
+phenomenological	O
+study	O
+that	O
+examined	O
+nursing	B-PROC
+students	O
+'	O
+perception	O
+of	O
+nursing	B-PROC
+professional	O
+identity	O
+during	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+in	O
+2003	O
+.	O
+
+Establishing	O
+the	O
+diagnosis	O
+for	O
+this	O
+patient	O
+increased	O
+public	O
+awareness	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+was	O
+soon	O
+followed	O
+by	O
+a	O
+halting	O
+of	O
+poultry	O
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+Livestock	O
+pathogens	O
+are	O
+subjected	O
+to	O
+pressures	O
+resulting	O
+from	O
+the	O
+production	O
+,	O
+processing	O
+and	O
+retail	O
+environment	O
+which	O
+together	O
+alter	O
+host	B-COMP
+contact	O
+rate	O
+,	O
+population	O
+size	O
+and	O
+/	O
+or	O
+microbial	O
+traffic	O
+flows	O
+in	O
+the	O
+food	O
+chain	O
+.	O
+
+In	O
+both	O
+scenarios	O
+,	O
+environmental	O
+factors	O
+relating	O
+to	O
+demography	O
+,	O
+land	B-COMP
+pressure	O
+and	O
+imbalances	O
+in	O
+production	O
+intensification	O
+have	O
+led	O
+to	O
+an	O
+unstable	O
+epidemiological	O
+situation	O
+,	O
+as	O
+evidenced	O
+by	O
+the	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	I-DISO
+upsurge	O
+early	O
+in	O
+2004	O
+,	O
+when	O
+the	O
+main	O
+outbreaks	O
+were	O
+located	O
+in	O
+areas	O
+which	O
+had	O
+both	O
+large	O
+scale	O
+,	O
+peri	O
+-	O
+urban	O
+commercial	O
+holdings	O
+and	O
+a	O
+high	O
+density	O
+of	O
+smallholder	O
+poultry	O
+units	O
+.	O
+
+In	O
+the	O
+second	O
+pattern	O
+,	O
+direct	O
+or	O
+vector	O
+-	O
+mediated	O
+animal	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+is	O
+the	O
+usual	O
+source	O
+of	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Animal	B-SPEC
+coronaviruses	O
+:	O
+what	O
+can	O
+they	O
+teach	O
+us	O
+about	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+?	O
+
+This	O
+review	O
+focuses	O
+on	O
+the	O
+comparative	O
+pathogenesis	B-DISO
+of	O
+CoV	O
+infections	B-DISO
+,	O
+including	O
+the	O
+factors	O
+that	O
+accentuate	O
+CoV	O
+respiratory	B-DISO
+disease	I-DISO
+,	O
+with	O
+emphasis	O
+on	O
+livestock	O
+and	O
+poultry	O
+.	O
+
+Risk	O
+factors	O
+for	O
+infection	B-DISO
+in	O
+HCWs	O
+included	O
+lack	O
+of	O
+awareness	O
+and	O
+preparedness	O
+when	O
+the	O
+disease	O
+first	O
+struck	B-DISO
+,	O
+poor	O
+institutional	B-DISO
+infection	I-DISO
+control	O
+measures	O
+,	O
+lack	O
+of	O
+training	O
+in	O
+infection	B-DISO
+control	O
+procedures	O
+,	O
+poor	O
+compliance	O
+with	O
+the	O
+use	O
+of	O
+personal	O
+protection	O
+equipment	O
+(	O
+PPE	B-CHED
+),	O
+exposure	O
+to	O
+high	O
+-	O
+risk	O
+procedures	O
+such	O
+as	O
+intubation	O
+and	O
+nebulization	O
+,	O
+and	O
+exposure	O
+to	O
+unsuspected	O
+SARS	B-DISO
+patients	O
+.	O
+
+This	O
+motif	O
+is	O
+missing	O
+from	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+resulting	O
+in	O
+high	O
+level	O
+of	O
+surface	O
+expression	B-PROC
+of	O
+the	O
+spike	O
+protein	B-CHED
+when	O
+it	O
+is	O
+expressed	B-PROC
+on	O
+its	O
+own	O
+in	O
+vitro	O
+.	O
+
+In	O
+addition	O
+,	O
+3a	O
+can	O
+bind	O
+to	O
+the	O
+spike	O
+protein	B-CHED
+and	O
+through	O
+this	O
+interaction	O
+,	O
+it	O
+may	O
+be	O
+able	O
+to	O
+cause	O
+the	O
+spike	O
+protein	B-CHED
+to	O
+become	O
+internalized	O
+,	O
+resulting	O
+in	O
+a	O
+decrease	O
+in	O
+its	O
+surface	O
+expression	B-PROC
+.	O
+
+A	O
+total	O
+of	O
+254	O
+patients	O
+with	O
+confirmed	O
+SARS	B-DISO
+treated	O
+with	O
+steroids	B-CHED
+underwent	O
+evaluation	O
+with	O
+magnetic	O
+resonance	O
+(	O
+MR	O
+)	O
+imaging	O
+for	O
+osteonecrosis	B-DISO
+.	O
+
+MR	O
+images	O
+in	O
+12	O
+(	O
+5	O
+%)	O
+of	O
+254	O
+patients	O
+showed	O
+evidence	O
+of	O
+subchondral	O
+osteonecrosis	B-DISO
+in	O
+the	O
+proximal	B-ANAT
+femur	I-ANAT
+(	O
+n	O
+=	O
+9	O
+),	O
+distal	B-ANAT
+femur	I-ANAT
+(	O
+n	O
+=	O
+2	O
+),	O
+and	O
+proximal	O
+and	O
+distal	O
+femora	O
+and	O
+proximal	O
+tibiae	O
+(	O
+n	O
+=	O
+1	O
+).	O
+
+TITLE	O
+:	O
+Anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+immunoglobulin	B-PROC
+G	O
+in	O
+healthcare	O
+workers	O
+,	O
+Guangzhou	O
+,	O
+China	O
+.	O
+
+Peripheral	B-ANAT
+blood	I-ANAT
+microscopy	O
+,	O
+parasite	O
+antigen	B-CHED
+-	O
+based	O
+assays	O
+,	O
+and	O
+parasite	O
+18s	O
+rRNA	B-CHED
+gene	O
+-	O
+based	O
+polymerase	O
+chain	O
+reaction	O
+showed	O
+the	O
+presence	O
+of	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+and	O
+absence	O
+of	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Vaccination	O
+against	O
+the	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+is	O
+an	O
+attractive	O
+means	O
+to	O
+control	O
+the	O
+spread	O
+of	O
+viruses	B-SPEC
+in	O
+public	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+the	O
+N	O
+,	O
+M	O
+,	O
+and	O
+E	O
+genes	O
+could	O
+be	O
+used	O
+as	O
+the	O
+targets	O
+to	O
+prevent	O
+SARS	O
+-	O
+CoV	O
+infection	O
+in	O
+the	O
+DNA	O
+vaccine	O
+development	B-PROC
+.	O
+
+Surveillance	O
+for	O
+SARS	B-DISO
+was	O
+initiated	O
+on	O
+14	O
+March	O
+2003	O
+.	O
+
+Between	O
+14	O
+March	O
+and	O
+30	O
+July	O
+2003	O
+a	O
+total	O
+of	O
+668	O
+probable	O
+cases	O
+of	O
+SARS	B-DISO
+were	O
+reported	O
+.	O
+
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+was	O
+identified	O
+as	O
+the	O
+aetiological	O
+agent	O
+of	O
+SARS	B-DISO
+and	O
+the	O
+30kb	O
+viral	B-COMP
+genome	I-COMP
+was	O
+deciphered	O
+with	O
+unprecedented	O
+speed	O
+in	O
+a	O
+coordinated	O
+manner	O
+by	O
+the	O
+global	O
+community	O
+.	O
+
+Physiopathology	O
+of	O
+TRALI	B-DISO
+is	O
+poorly	O
+understood	O
+,	O
+and	O
+still	O
+controversial	O
+.	O
+
+In	O
+addition	O
+,	O
+ADS	O
+-	O
+MVA	B-CHED
+induced	O
+potent	O
+immune	B-PROC
+responses	I-PROC
+which	O
+very	O
+likely	O
+protected	O
+Chinese	O
+rhesus	B-SPEC
+monkeys	I-SPEC
+from	O
+pathogenic	O
+SARS	B-DISO
+-	O
+CoV	O
+challenge	O
+.	O
+
+We	O
+also	O
+describe	O
+improvements	O
+in	O
+the	O
+use	O
+of	O
+the	O
+coronavirus	O
+reverse	O
+genetic	O
+system	O
+based	O
+on	O
+vaccinia	B-SPEC
+virus	I-SPEC
+cloning	O
+vectors	O
+.	O
+
+These	O
+modifications	O
+facilitate	O
+(	O
+i	O
+)	O
+the	O
+mutagenesis	B-PROC
+of	O
+cloned	O
+cDNA	O
+by	O
+using	O
+vaccinia	B-SPEC
+virus	I-SPEC
+-	O
+mediated	O
+homologous	B-PATH
+recombination	I-PATH
+and	O
+(	O
+ii	O
+)	O
+the	O
+rescue	O
+of	O
+recombinant	O
+coronaviruses	O
+by	O
+using	O
+a	O
+stable	O
+nucleocapsid	B-COMP
+protein	B-CHED
+-	O
+expressing	O
+cell	B-ANAT
+line	I-ANAT
+for	O
+the	O
+electroporation	O
+of	O
+infectious	B-DISO
+full	O
+-	O
+length	O
+genomes	O
+.	O
+
+We	O
+reviewed	O
+14	O
+brain	B-ANAT
+and	O
+three	O
+spinal	O
+MR	O
+images	O
+:	O
+nonenhanced	O
+and	O
+contrast	O
+-	O
+enhanced	O
+T1	O
+-	O
+weighted	O
+images	O
+(	O
+T1WIs	O
+)	O
+and	O
+T2	O
+-	O
+weighted	O
+images	O
+(	O
+T2WIs	O
+),	O
+nonenhanced	O
+fluid	O
+-	O
+attenuated	O
+inversion	B-DISO
+recovery	O
+(	O
+FLAIR	O
+)	O
+images	O
+(	O
+11	O
+patients	O
+)	O
+and	O
+enhanced	O
+FLAIR	O
+images	O
+(	O
+three	O
+patients	O
+),	O
+with	O
+diffusion	O
+-	O
+weighted	O
+(	O
+DW	O
+)	O
+images	O
+and	O
+apparent	O
+diffusion	O
+coefficient	O
+maps	O
+.	O
+
+WNV	B-DISO
+infection	B-DISO
+was	O
+diagnosed	O
+by	O
+means	O
+of	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+with	O
+a	O
+plaque	B-DISO
+reduction	O
+neutralization	O
+test	O
+.	O
+
+RESULTS	O
+:	O
+MR	O
+imaging	O
+findings	O
+included	O
+:	O
+1	O
+)	O
+normal	O
+(	O
+five	O
+patients	O
+);	O
+2	O
+)	O
+DW	O
+imaging	O
+-	O
+only	O
+abnormalities	O
+in	O
+the	O
+white	B-ANAT
+matter	I-ANAT
+,	O
+corona	B-ANAT
+radiata	I-ANAT
+,	O
+and	O
+internal	B-ANAT
+capsule	I-ANAT
+(	O
+four	O
+patients	O
+);	O
+3	O
+)	O
+hyperintensity	O
+on	O
+FLAIR	O
+images	O
+and	O
+T2WIs	O
+in	O
+the	O
+lobar	O
+gray	O
+and	O
+white	B-ANAT
+matter	I-ANAT
+,	O
+cerebellum	B-ANAT
+,	O
+basal	B-ANAT
+ganglia	I-ANAT
+,	O
+thalamus	B-ANAT
+and	O
+internal	B-ANAT
+capsule	I-ANAT
+,	O
+pons	B-ANAT
+and	O
+midbrain	B-ANAT
+(	O
+three	O
+patients	O
+);	O
+4	O
+)	O
+meningeal	O
+involvement	O
+(	O
+two	O
+patients	O
+);	O
+and	O
+5	O
+)	O
+spinal	B-ANAT
+cord	I-ANAT
+,	O
+cauda	B-ANAT
+equina	I-ANAT
+,	O
+and	O
+nerve	B-ANAT
+root	I-ANAT
+involvement	O
+(	O
+three	O
+patients	O
+).	O
+
+Effects	O
+of	O
+methylprednisolone	B-CHED
+and	O
+lidocaine	B-CHED
+on	O
+histopathology	O
+and	O
+neutrophils	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+is	O
+to	O
+demonstrate	O
+if	O
+these	O
+2	O
+agents	O
+,	O
+given	O
+at	O
+an	O
+early	O
+stage	O
+,	O
+can	O
+reduce	O
+lung	B-ANAT
+damage	O
+and	O
+improve	O
+oxygenation	B-PROC
+.	O
+
+The	O
+study	O
+was	O
+carried	O
+out	O
+at	O
+the	O
+animal	B-SPEC
+laboratories	O
+of	O
+Ataturk	O
+University	O
+,	O
+Medical	O
+Faculty	O
+,	O
+Erzurum	O
+,	O
+Turkey	B-SPEC
+during	O
+the	O
+year	O
+2002	O
+,	O
+and	O
+performed	O
+on	O
+a	O
+rabbit	B-SPEC
+acid	O
+aspiration	B-DISO
+model	O
+.	O
+
+For	O
+this	O
+purpose	O
+,	O
+we	O
+have	O
+analyzed	O
+the	O
+results	O
+of	O
+molecular	B-PROC
+dynamics	I-PROC
+simulations	O
+where	O
+all	O
+possible	O
+conformational	O
+and	O
+aggregational	O
+space	O
+was	O
+systematically	O
+explored	O
+.	O
+
+The	O
+second	O
+is	O
+that	O
+protein	B-CHED
+E	O
+forms	O
+the	O
+same	O
+type	O
+of	O
+transmembrane	B-COMP
+oligomer	O
+and	O
+with	O
+identical	O
+backbone	B-ANAT
+structure	O
+in	O
+different	O
+coronaviruses	O
+.	O
+
+Thirty	O
+-	O
+two	O
+acute	O
+-	O
+care	O
+hospitals	O
+were	O
+required	O
+to	O
+report	O
+their	O
+previous	O
+day	O
+'	O
+s	O
+unscheduled	O
+admissions	O
+for	O
+11	O
+syndromes	B-DISO
+(	O
+pneumonia	B-DISO
+,	O
+hemoptysis	B-DISO
+,	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+acute	O
+neurologic	O
+illness	O
+,	O
+nontraumatic	O
+paralysis	O
+,	O
+sepsis	B-DISO
+and	O
+nontraumatic	O
+shock	O
+,	O
+fever	B-DISO
+with	I-DISO
+rash	I-DISO
+,	O
+fever	B-PROC
+of	O
+unknown	O
+cause	O
+,	O
+acute	O
+gastrointestinal	O
+illness	O
+,	O
+and	O
+possible	O
+cutaneous	B-DISO
+anthrax	I-DISO
+,	O
+and	O
+suspected	O
+illness	O
+clusters	B-CHED
+).	O
+
+HASS	O
+was	O
+sensitive	O
+enough	O
+to	O
+reflect	O
+annual	O
+increases	O
+in	O
+hospital	O
+-	O
+admission	O
+rates	O
+for	O
+pneumonia	B-DISO
+during	O
+the	O
+influenza	B-DISO
+season	O
+and	O
+to	O
+confirm	O
+an	O
+outbreak	O
+of	O
+gastrointestinal	O
+illness	O
+.	O
+
+This	O
+system	O
+was	O
+created	O
+for	O
+early	O
+detection	O
+of	O
+infectious	B-DISO
+-	O
+disease	O
+outbreaks	O
+,	O
+either	O
+natural	O
+or	O
+intentional	O
+.	O
+
+During	O
+March	O
+2003	O
+,	O
+the	O
+system	O
+generated	O
+a	O
+4	O
+-	O
+day	O
+citywide	O
+respiratory	O
+signal	O
+and	O
+a	O
+simultaneous	O
+1	O
+-	O
+day	O
+hospital	O
+-	O
+level	O
+fever	B-PROC
+signal	O
+in	O
+a	O
+predominantly	O
+Asian	O
+community	O
+.	O
+
+In	O
+those	O
+instances	O
+,	O
+epidemiologic	O
+investigation	O
+provided	O
+reassurance	O
+that	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+was	O
+not	O
+present	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+Surveillance	O
+Project	O
+--	O
+Internet	O
+-	O
+enabled	O
+multiregion	O
+surveillance	O
+for	O
+rapidly	O
+emerging	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Is	O
+thermal	O
+scanner	O
+losing	O
+its	O
+bite	B-PROC
+in	O
+mass	O
+screening	O
+of	O
+fever	B-PROC
+due	O
+to	O
+SARS	B-DISO
+?	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+highly	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+coronavirus	B-SPEC
+.	O
+
+It	O
+is	O
+believed	O
+that	O
+IR	O
+cameras	O
+can	O
+potentially	O
+be	O
+used	O
+to	O
+detect	O
+subjects	O
+with	O
+fever	B-PROC
+,	O
+the	O
+cardinal	B-SPEC
+symptom	B-DISO
+of	O
+SARS	B-DISO
+,	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+It	O
+is	O
+also	O
+limited	O
+by	O
+the	O
+fact	O
+that	O
+the	O
+thermal	O
+imager	O
+measures	O
+the	O
+skin	B-ANAT
+temperature	O
+and	O
+not	O
+the	O
+core	O
+body	O
+temperature	O
+.	O
+
+Fever	B-PROC
+happens	O
+if	O
+the	O
+hypothalamus	B-ANAT
+detects	O
+pyrogens	O
+and	O
+then	O
+raises	O
+the	O
+set	O
+point	O
+.	O
+
+False	O
+negative	O
+results	O
+should	O
+be	O
+avoided	O
+at	O
+all	O
+costs	O
+,	O
+as	O
+letting	O
+a	O
+SARS	B-DISO
+infected	O
+person	O
+through	O
+the	O
+screening	O
+process	O
+may	O
+result	O
+in	O
+potentially	O
+catastrophic	O
+results	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+coronavirus	B-SPEC
+from	O
+domestic	O
+peafowl	B-SPEC
+(	O
+Pavo	B-SPEC
+cristatus	I-SPEC
+)	O
+and	O
+teal	O
+(	O
+Anas	O
+).	O
+
+Taken	O
+together	O
+,	O
+this	O
+information	O
+suggests	O
+that	O
+pf	O
+/	O
+CH	O
+/	O
+LKQ3	O
+/	O
+03	O
+might	O
+be	O
+a	O
+revertant	O
+,	O
+attenuated	O
+vaccine	O
+IBV	B-SPEC
+strain	O
+,	O
+whereas	O
+tl	O
+/	O
+CH	O
+/	O
+LDT3	O
+/	O
+03	O
+is	O
+a	O
+nephropathogenic	O
+field	O
+IBV	B-SPEC
+strain	O
+,	O
+generated	O
+through	O
+recombination	B-PROC
+.	O
+
+Many	O
+valuable	O
+lessons	O
+have	O
+been	O
+learned	B-PROC
+through	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+Lung	B-ANAT
+computerized	O
+tomography	O
+(	O
+CT	O
+)	O
+was	O
+obtained	O
+in	O
+both	O
+the	O
+supine	O
+position	O
+and	O
+10	O
+min	O
+after	O
+prone	O
+position	O
+.	O
+
+The	O
+changes	O
+of	O
+the	O
+PaO	B-PROC
+(	O
+2	O
+)	O
+were	O
+similar	O
+to	O
+the	O
+PaO	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)/	I-PRGE
+FiO	I-PRGE
+(	I-PRGE
+2	I-PRGE
+).	I-PRGE
+
+PPV	B-CHED
+could	O
+be	O
+used	O
+to	O
+improve	O
+severe	O
+hypoxemia	O
+of	O
+ARDS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+It	O
+is	O
+very	O
+important	O
+for	O
+physicians	O
+to	O
+be	O
+alert	O
+to	O
+the	O
+epidemiological	O
+data	O
+for	O
+an	O
+early	O
+diagnosis	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+therefore	O
+early	O
+isolation	O
+and	O
+initiation	O
+of	O
+appropriate	O
+treatment	O
+.	O
+
+Liver	B-DISO
+damage	I-DISO
+of	O
+patients	O
+with	O
+SARS	B-DISO
+usually	O
+occurs	O
+in	O
+the	O
+early	O
+stage	O
+of	O
+the	O
+disease	O
+with	O
+a	O
+high	O
+occurrence	O
+rate	O
+and	O
+a	O
+prolonged	O
+profile	O
+,	O
+which	O
+can	O
+be	O
+characterized	O
+by	O
+early	O
+,	O
+obvious	O
+decrease	O
+of	O
+albumin	B-PRGE
+levels	O
+and	O
+slightly	O
+abnormal	O
+levels	O
+of	O
+ALT	B-FUNC
+.	O
+
+The	O
+liver	B-DISO
+damage	I-DISO
+induced	O
+by	O
+SARS	B-DISO
+seems	O
+to	O
+be	O
+caused	O
+by	O
+SARS	B-DISO
+virus	B-SPEC
+directly	O
+rather	O
+than	O
+by	O
+low	O
+SaO2	B-PROC
+or	O
+high	O
+fever	B-PROC
+.	O
+
+Hepatic	B-ANAT
+histological	O
+examination	O
+of	O
+4	O
+patients	O
+demonstrated	O
+that	O
+non	O
+-	O
+specific	O
+inflammation	B-DISO
+existed	O
+in	O
+the	O
+liver	B-ANAT
+.	O
+
+LPS	B-FUNC
+binding	I-FUNC
+to	O
+its	O
+receptors	O
+is	O
+the	O
+crucial	O
+step	O
+in	O
+the	O
+causation	O
+of	O
+these	O
+multistep	O
+events	O
+.	O
+
+Software	O
+implementing	O
+the	O
+algorithm	O
+and	O
+the	O
+benchmark	O
+is	O
+available	O
+under	O
+GPL	O
+from	O
+http	O
+://	O
+www	O
+.	O
+biowiki	O
+.	O
+org	O
+/	O
+RESULTS	O
+:	O
+We	O
+present	O
+an	O
+algorithm	O
+for	O
+maximum	O
+-	O
+likelihood	O
+estimation	O
+of	O
+insertion	O
+and	O
+deletion	O
+rates	O
+from	O
+multiple	O
+sequence	O
+alignments	O
+,	O
+using	O
+EM	O
+,	O
+under	O
+the	O
+single	O
+-	O
+residue	O
+indel	B-PROC
+model	O
+owing	O
+to	O
+Thorne	O
+,	O
+Kishino	O
+and	O
+Felsenstein	O
+(	O
+the	O
+'	O
+TKF91	O
+'	O
+model	O
+).	O
+
+TITLE	O
+:	O
+Increased	O
+epitope	B-CHED
+-	O
+specific	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+prevent	O
+murine	B-SPEC
+coronavirus	I-SPEC
+spread	O
+to	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+and	O
+subsequent	O
+demyelination	O
+.	O
+
+P14	O
+splenocytes	O
+(	O
+transgenic	O
+for	O
+a	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+specific	O
+for	O
+the	O
+gp33	B-PRGE
+epitope	I-PRGE
+)	O
+were	O
+transferred	O
+at	O
+different	O
+times	O
+pre	O
+-	O
+and	O
+postinfection	O
+(	O
+p	O
+.	O
+i	O
+.).	O
+
+Following	O
+intracranial	B-ANAT
+inoculation	O
+of	O
+mice	B-SPEC
+,	O
+the	O
+viruses	B-SPEC
+encoding	O
+Tyr6398His	O
+/	O
+Leu94Pro	O
+substitutions	O
+and	O
+the	O
+Tyr6398His	O
+substitution	O
+alone	O
+demonstrated	O
+log10	O
+50	O
+%	O
+lethal	O
+dose	O
+(	O
+LD50	O
+)	O
+values	O
+too	O
+great	O
+to	O
+be	O
+measured	O
+.	O
+
+The	O
+experiments	O
+have	O
+defined	O
+residues	O
+in	O
+ORF	B-PRGE
+1b	I-PRGE
+and	I-PRGE
+ORF	I-PRGE
+2a	I-PRGE
+that	O
+attenuate	O
+virus	B-PROC
+replication	I-PROC
+and	O
+virulence	B-PROC
+in	O
+mice	B-SPEC
+but	O
+do	O
+not	O
+affect	O
+in	O
+vitro	O
+replication	O
+.	O
+
+TITLE	O
+:	O
+B	B-ANAT
+-	I-ANAT
+cell	B-COMP
+responses	O
+in	O
+patients	O
+who	O
+have	O
+recovered	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+target	O
+a	O
+dominant	O
+site	O
+in	O
+the	O
+S2	O
+domain	O
+of	O
+the	O
+surface	O
+spike	O
+glycoprotein	O
+.	O
+
+One	O
+child	O
+developed	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+pericardial	B-DISO
+effusion	I-DISO
+followed	O
+by	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+quantitative	O
+assay	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+correlation	O
+of	O
+GAPDH	B-PRGE
+mRNA	B-CHED
+with	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+clinical	O
+specimens	O
+.	O
+
+This	O
+Q	O
+-	O
+RT	O
+-	O
+PCR	O
+assay	O
+can	O
+be	O
+used	O
+to	O
+detect	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Moreover	O
+,	O
+GAPDH	B-PRGE
+mRNA	B-CHED
+may	O
+be	O
+useful	O
+to	O
+rule	O
+out	O
+false	O
+negative	O
+results	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+detection	O
+,	O
+and	O
+the	O
+current	O
+extraction	O
+method	O
+for	O
+urine	B-ANAT
+may	O
+not	O
+be	O
+sensitive	O
+enough	O
+to	O
+detect	O
+low	O
+titres	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+RESULTS	O
+:	O
+Varying	O
+amounts	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+found	O
+in	O
+the	O
+26	O
+SARS	B-DISO
+-	O
+CoV	O
+positive	O
+specimens	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+not	O
+detected	O
+in	O
+the	O
+40	O
+follow	O
+up	O
+specimens	O
+and	O
+controls	O
+.	O
+
+Human	B-SPEC
+metapneumovirus	I-SPEC
+has	O
+now	O
+been	O
+detected	O
+worldwide	O
+,	O
+causing	O
+severe	O
+respiratory	B-ANAT
+tract	I-ANAT
+illnesses	O
+primarily	O
+in	O
+very	O
+young	O
+,	O
+elderly	O
+and	O
+immunocompromised	O
+individuals	O
+.	O
+
+Considerable	O
+genetic	O
+and	O
+antigenic	B-PROC
+diversity	I-PROC
+was	O
+observed	O
+for	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+but	O
+the	O
+implication	O
+of	O
+this	O
+diversity	O
+for	O
+vaccine	O
+development	B-PROC
+and	O
+virus	B-SPEC
+epidemiology	O
+requires	O
+further	O
+study	O
+.	O
+
+This	O
+paper	O
+presents	O
+a	O
+detailed	O
+study	O
+of	O
+environmental	O
+evidence	O
+of	O
+possible	O
+airborne	O
+transmission	O
+in	O
+a	O
+hospital	O
+ward	O
+during	O
+the	O
+largest	O
+nosocomial	O
+SARS	B-DISO
+outbreak	O
+in	O
+Hong	O
+Kong	O
+in	O
+March	O
+2003	O
+.	O
+
+Our	O
+study	O
+revealed	O
+the	O
+need	O
+for	O
+the	O
+development	B-PROC
+of	O
+improved	O
+ventilation	O
+and	O
+air	B-CHED
+-	O
+conditioning	O
+systems	O
+in	O
+an	O
+isolation	O
+ward	O
+or	O
+a	O
+general	O
+hospital	O
+ward	O
+for	O
+infectious	B-DISO
+respiratory	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+outbreak	O
+in	O
+Ward	O
+8A	O
+,	O
+which	O
+was	O
+in	O
+a	O
+general	O
+hospital	O
+and	O
+could	O
+house	O
+nearly	O
+40	O
+patients	O
+,	O
+demonstrated	O
+the	O
+cross	O
+-	O
+infection	B-DISO
+risks	O
+of	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+hospitals	O
+if	O
+a	O
+potential	O
+highly	O
+infectious	B-DISO
+patient	O
+was	O
+not	O
+identified	O
+and	O
+isolated	O
+.	O
+
+TITLE	O
+:	O
+Multi	O
+-	O
+zone	O
+modeling	O
+of	O
+probable	O
+SARS	B-DISO
+virus	B-SPEC
+transmission	O
+by	O
+airflow	B-PROC
+between	O
+flats	O
+in	O
+Block	O
+E	O
+,	O
+Amoy	O
+Gardens	O
+.	O
+
+TITLE	O
+:	O
+Persistence	O
+of	O
+Mycoplasma	B-SPEC
+gallisepticum	I-SPEC
+in	O
+chickens	B-SPEC
+after	O
+treatment	O
+with	O
+enrofloxacin	B-CHED
+without	O
+development	O
+of	O
+resistance	B-PROC
+.	O
+
+Groups	O
+of	O
+specific	O
+pathogen	O
+free	O
+chickens	B-SPEC
+were	O
+experimentally	O
+infected	O
+with	O
+M	B-SPEC
+.	I-SPEC
+gallisepticum	I-SPEC
+and	O
+treated	O
+with	O
+enrofloxacin	B-CHED
+at	O
+increasing	O
+concentrations	O
+up	O
+to	O
+the	O
+therapeutic	O
+dose	O
+.	O
+
+The	O
+soluble	O
+30kDa	B-PRGE
+SA59B	I-PRGE
+scFv	I-PRGE
+-	I-PRGE
+antibody	I-PRGE
+was	O
+verified	O
+in	O
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+Western	O
+-	O
+blot	O
+.	O
+
+TITLE	O
+:	O
+Quality	O
+management	O
+case	O
+studies	O
+in	O
+health	O
+service	O
+emergencies	B-DISO
+:	O
+SARS	B-DISO
+and	O
+wildland	O
+-	O
+urban	O
+interface	O
+fires	O
+.	O
+
+TITLE	O
+:	O
+New	O
+antiviral	B-CHED
+drugs	I-CHED
+,	O
+vaccines	O
+and	O
+classic	O
+public	O
+health	O
+interventions	O
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+In	O
+this	O
+review	O
+,	O
+several	O
+antiviral	B-CHED
+substances	O
+shown	O
+to	O
+be	O
+active	O
+in	O
+vitro	O
+will	O
+be	O
+introduced	O
+and	O
+summarized	O
+in	O
+the	O
+order	B-SPEC
+of	O
+the	O
+virus	B-SPEC
+'	O
+replication	O
+steps	O
+;	O
+that	O
+is	O
+,	O
+binding	B-FUNC
+to	O
+cellular	B-PRGE
+receptor	I-PRGE
+,	O
+fusion	O
+and	O
+entry	O
+to	O
+the	O
+cells	B-COMP
+,	O
+viral	O
+RNA	B-PROC
+replication	I-PROC
+and	O
+transcription	B-PROC
+,	O
+protein	B-PROC
+processing	I-PROC
+and	O
+so	O
+on	O
+.	O
+
+Lymphopenia	B-DISO
+and	O
+raised	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+was	O
+seen	O
+in	O
+seven	O
+patients	O
+.	O
+
+The	O
+primary	O
+abnormality	O
+on	O
+chest	B-ANAT
+radiograph	O
+was	O
+air	B-CHED
+-	O
+space	O
+opacification	O
+.	O
+
+Early	O
+isolation	O
+of	O
+febrile	B-PROC
+patients	O
+with	O
+a	O
+positive	O
+contact	O
+history	O
+must	O
+be	O
+undertaken	O
+,	O
+even	O
+in	O
+the	O
+face	B-DISO
+of	O
+another	O
+identifiable	O
+cause	O
+.	O
+
+TITLE	O
+:	O
+The	O
+protein	B-CHED
+X4	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+is	O
+expressed	B-PROC
+on	O
+both	O
+virus	O
+-	O
+infected	O
+cells	B-COMP
+and	O
+lung	B-ANAT
+tissue	I-ANAT
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+patients	O
+and	O
+inhibits	O
+growth	B-PROC
+of	O
+Balb	O
+/	O
+c	O
+3T3	O
+cell	B-ANAT
+line	I-ANAT
+.	O
+
+The	O
+deduced	O
+sequence	O
+contains	O
+a	O
+probable	O
+cleaved	B-ANAT
+signal	O
+peptide	B-CHED
+sequence	O
+and	O
+a	O
+C	O
+-	O
+terminal	O
+transmembrane	B-COMP
+helix	O
+,	O
+indicating	O
+that	O
+protein	B-CHED
+X4	O
+is	O
+likely	O
+to	O
+be	O
+a	O
+type	O
+I	O
+membrane	B-COMP
+protein	B-CHED
+.	O
+
+We	O
+expressed	B-PROC
+and	O
+purified	O
+soluble	O
+recombinant	B-PRGE
+protein	I-PRGE
+X4	I-PRGE
+from	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+,	O
+and	O
+generated	O
+specific	O
+antibodies	B-COMP
+against	O
+protein	B-CHED
+X4	O
+.	O
+
+It	O
+was	O
+also	O
+detected	O
+in	O
+the	O
+lung	B-ANAT
+tissues	I-ANAT
+from	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+results	O
+provide	O
+the	O
+evidence	O
+of	O
+protein	B-CHED
+X4	O
+expression	B-PROC
+following	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+and	O
+may	O
+facilitate	O
+further	O
+investigation	O
+of	O
+the	O
+immunopathological	O
+mechanism	O
+of	O
+SARS	B-DISO
+.	O
+
+Unfortunately	O
+,	O
+despite	O
+long	O
+-	O
+term	O
+efforts	O
+,	O
+effective	O
+vaccines	O
+to	O
+prevent	O
+enteric	O
+CoV	O
+infections	B-DISO
+remain	O
+elusive	O
+,	O
+and	O
+generally	O
+live	O
+,	O
+but	O
+not	O
+killed	O
+vaccines	O
+,	O
+have	O
+induced	O
+the	O
+most	O
+consistent	O
+protection	O
+against	O
+animal	B-SPEC
+CoVs	O
+.	O
+
+During	O
+hospitalization	O
+,	O
+lymphopenia	B-DISO
+was	O
+found	O
+in	O
+57	O
+patients	O
+(	O
+85	O
+.	O
+1	O
+%);	O
+and	O
+elevated	O
+levels	O
+of	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+;	O
+n	O
+=	O
+55	O
+;	O
+83	O
+.	O
+3	O
+%),	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+n	O
+=	O
+55	O
+;	O
+83	O
+.	O
+3	O
+%),	O
+aminotransferases	O
+(	O
+n	O
+=	O
+44	O
+;	O
+65	O
+.	O
+7	O
+%),	O
+and	O
+creatine	B-ENZY
+kinase	I-ENZY
+(	O
+n	O
+=	O
+14	O
+;	O
+20	O
+.	O
+9	O
+%)	O
+were	O
+also	O
+noted	O
+.	O
+
+The	O
+overall	O
+mortality	O
+rate	O
+was	O
+31	O
+.	O
+3	O
+%	O
+(	O
+21	O
+/	O
+67	O
+),	O
+whereas	O
+the	O
+rate	O
+for	O
+patients	O
+who	O
+developed	O
+ARDS	B-DISO
+was	O
+63	O
+.	O
+6	O
+%	O
+(	O
+21	O
+/	O
+33	O
+).	O
+
+TITLE	O
+:	O
+Catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+:	O
+a	O
+rare	O
+cause	O
+of	O
+disseminated	O
+microvascular	O
+thrombotic	O
+injury	O
+-	O
+a	O
+case	O
+report	O
+with	O
+pathological	O
+and	O
+molecular	O
+correlative	O
+studies	O
+.	O
+
+We	O
+report	O
+a	O
+fatal	O
+case	O
+of	O
+catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+in	O
+a	O
+young	O
+woman	O
+with	O
+a	O
+history	O
+of	O
+polymyositis	B-DISO
+and	O
+Hodgkin	B-DISO
+lymphoma	I-DISO
+.	O
+
+TITLE	O
+:	O
+Cloning	O
+and	O
+sequence	O
+analysis	O
+of	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+LJB	O
+/	O
+03	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+of	O
+virus	B-SPEC
+from	O
+a	O
+SARS	B-DISO
+patient	O
+and	O
+genome	O
+-	O
+wide	O
+analysis	O
+of	O
+genetic	B-PROC
+mutations	I-PROC
+related	O
+to	O
+pathogenesis	O
+and	O
+epidemiology	O
+from	O
+47	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+.	O
+
+The	O
+presence	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+determined	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+confirmed	O
+by	O
+electron	O
+microscopy	O
+.	O
+
+Genetic	B-PROC
+mutations	I-PROC
+with	O
+potential	O
+implications	O
+to	O
+pathogenesis	B-DISO
+and	O
+the	O
+epidemic	O
+were	O
+characterized	O
+.	O
+
+This	O
+viral	B-ANAT
+genome	I-ANAT
+consists	O
+of	O
+29	O
+,	O
+728	O
+nucleotides	B-CHED
+with	O
+overall	O
+organization	O
+in	O
+agreement	O
+with	O
+that	O
+of	O
+published	O
+isolates	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+control	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+like	O
+SARS	B-DISO
+,	O
+it	O
+is	O
+necessary	O
+to	O
+resort	O
+to	O
+basic	O
+control	O
+measures	O
+that	O
+limit	O
+exposures	O
+to	O
+infectious	B-DISO
+individuals	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+not	O
+only	O
+responsible	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+but	O
+also	O
+a	O
+major	O
+antigenic	B-CHED
+determinant	I-CHED
+capable	O
+of	O
+inducing	O
+protective	O
+immunity	B-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+demonstrated	O
+that	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+is	O
+an	O
+important	O
+immunogenic	O
+site	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+rabbits	B-SPEC
+immunized	O
+with	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Serum	B-COMP
+samples	O
+from	O
+convalescent	O
+SARS	B-DISO
+patients	O
+and	O
+immunized	O
+rabbits	B-SPEC
+had	O
+potent	O
+neutralizing	O
+activities	O
+against	O
+infection	B-DISO
+by	O
+pseudovirus	O
+expressing	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+Two	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+1A5	O
+and	O
+2C5	O
+)	O
+targeting	B-PROC
+at	O
+the	O
+RBD	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+were	O
+isolated	O
+from	O
+mice	B-SPEC
+immunized	O
+with	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Both	O
+1A5	O
+and	O
+2C5	O
+possessed	B-DISO
+potent	O
+neutralizing	O
+activities	O
+,	O
+although	O
+they	O
+directed	O
+against	O
+distinct	O
+conformation	O
+-	O
+dependant	O
+epitopes	O
+as	O
+shown	O
+by	O
+ELISA	O
+and	O
+binding	B-FUNC
+competition	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+host	B-COMP
+range	O
+of	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+(	O
+MHV	B-SPEC
+)	O
+is	O
+limited	O
+to	O
+susceptible	O
+mice	B-SPEC
+and	O
+murine	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+by	O
+interactions	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+(	O
+S	O
+)	O
+with	O
+its	O
+receptor	O
+,	O
+mCEACAM1a	O
+.	O
+
+High	O
+neutralizing	O
+titers	O
+against	O
+SARS	O
+-	O
+CoV	O
+were	O
+detected	O
+with	O
+two	O
+mAbs	O
+(	O
+1A5	O
+and	O
+2C5	O
+)	O
+targeting	B-PROC
+at	O
+a	O
+subdomain	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+(	O
+aa	O
+310	O
+-	O
+535	O
+),	O
+consistent	O
+with	O
+the	O
+previous	O
+report	O
+that	O
+this	O
+segment	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+contains	O
+the	O
+major	O
+neutralizing	O
+domain	O
+.	O
+
+Most	O
+prominently	O
+,	O
+based	O
+solely	O
+on	O
+viral	B-COMP
+genome	I-COMP
+information	O
+,	O
+silencers	O
+of	O
+viral	O
+genes	O
+,	O
+viral	O
+-	O
+enzyme	O
+blockers	O
+and	O
+viral	O
+-	O
+entry	O
+inhibitors	B-CHED
+were	O
+suggested	O
+as	O
+potential	O
+therapeutic	O
+agents	O
+for	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Guidelines	O
+issued	O
+by	O
+the	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+and	O
+the	O
+World	O
+Health	O
+Organisation	O
+state	O
+that	O
+healthcare	O
+workers	O
+should	O
+wear	O
+N95	O
+masks	O
+or	O
+higher	O
+-	O
+level	O
+protection	O
+during	O
+all	O
+contact	O
+with	O
+suspected	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BoCV	O
+)	O
+was	O
+consistently	O
+detected	O
+in	O
+all	O
+herds	O
+with	O
+WD	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+efficacy	O
+of	O
+an	O
+herbal	O
+formula	O
+in	O
+the	O
+prevention	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+transmission	O
+among	O
+health	O
+care	O
+workers	O
+.	O
+
+Improvements	O
+in	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+symptoms	I-DISO
+and	O
+quality	O
+of	O
+life	O
+measurements	O
+were	O
+also	O
+observed	O
+among	O
+herbal	O
+supplement	O
+users	O
+.	O
+
+TITLE	O
+:	O
+General	B-PROC
+anesthesia	I-PROC
+with	O
+remifentanil	B-CHED
+for	O
+Cesarean	O
+section	O
+in	O
+a	O
+patient	O
+with	O
+HELLP	B-DISO
+syndrome	I-DISO
+.	O
+
+It	O
+is	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+adverse	O
+outcome	O
+for	O
+both	O
+the	O
+mother	O
+and	O
+the	O
+fetus	B-ANAT
+.	O
+
+Before	O
+delivery	O
+,	O
+aggressive	B-DISO
+obstetric	O
+management	O
+is	O
+directed	O
+toward	O
+stabilization	O
+of	O
+the	O
+affected	O
+organ	B-ANAT
+systems	I-ANAT
+,	O
+if	O
+possible	O
+,	O
+and	O
+interruption	O
+of	O
+the	O
+pregnancy	O
+in	O
+the	O
+early	O
+phase	O
+of	O
+the	O
+accelerated	O
+disease	B-DISO
+progression	I-DISO
+.	O
+
+SARS	B-DISO
+is	O
+difficult	O
+to	O
+recognize	O
+in	O
+hospitalized	O
+patients	O
+with	O
+a	O
+variety	O
+of	O
+underlying	O
+conditions	O
+in	O
+the	O
+absence	O
+of	O
+epidemiologic	O
+links	O
+.	O
+
+We	O
+have	O
+designed	O
+and	O
+synthesized	O
+34	O
+peptide	B-CHED
+substrates	O
+and	O
+determined	O
+their	O
+hydrolysis	O
+activities	O
+.	O
+
+TITLE	O
+:	O
+Growth	B-PROC
+kinetics	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Pulmonary	B-DISO
+toxicity	I-DISO
+is	O
+very	O
+rare	O
+.	O
+
+Few	O
+cases	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+following	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+administration	O
+have	O
+been	O
+reported	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+the	O
+COOH	O
+portion	O
+of	O
+the	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+in	O
+an	O
+antigen	B-CHED
+-	O
+capturing	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+for	O
+specific	O
+and	O
+sensitive	O
+detection	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Antibody	B-COMP
+detection	O
+with	O
+a	O
+recombinant	O
+COOH	O
+portion	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+,	O
+N13	O
+(	O
+amino	B-CHED
+acids	I-CHED
+221	O
+to	O
+422	O
+),	O
+was	O
+demonstrated	O
+to	O
+be	O
+more	O
+specific	O
+and	O
+sensitive	O
+than	O
+that	O
+with	O
+the	O
+full	O
+-	O
+length	O
+N	O
+protein	B-CHED
+,	O
+and	O
+an	O
+N13	O
+-	O
+based	O
+antigen	B-CHED
+-	O
+capturing	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+providing	O
+a	O
+convenient	O
+and	O
+specific	O
+test	O
+for	O
+serodiagnosis	O
+and	O
+epidemiological	O
+study	O
+of	O
+SARS	B-DISO
+was	O
+developed	O
+.	O
+
+The	O
+application	O
+of	O
+HFOV	O
+was	O
+mainly	O
+reported	O
+as	O
+a	O
+rescue	O
+ventilatory	O
+mode	O
+in	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+who	O
+were	O
+thought	O
+to	O
+have	O
+failed	O
+conventional	O
+ventilation	O
+.	O
+
+HFOV	O
+has	O
+been	O
+an	O
+indispensable	O
+ventilation	O
+modality	O
+in	O
+our	O
+burn	O
+center	O
+,	O
+and	O
+has	O
+played	O
+an	O
+important	O
+role	O
+in	O
+reversing	O
+oxygenation	B-PROC
+failure	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+in	O
+facilitating	O
+early	O
+excision	O
+and	O
+closure	O
+of	O
+the	O
+burn	O
+wound	O
+in	O
+these	O
+patients	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+have	O
+now	O
+used	O
+HFOV	O
+in	O
+36	O
+severely	O
+burned	O
+patients	O
+,	O
+33	O
+%	O
+of	O
+whom	O
+had	O
+an	O
+associated	O
+smoke	O
+inhalation	B-PROC
+injury	O
+.	O
+
+Published	O
+studies	O
+evaluating	O
+the	O
+use	O
+of	O
+iNO	B-PRGE
+,	O
+PP	O
+,	O
+and	O
+HFOV	O
+in	O
+adult	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+It	O
+is	O
+important	O
+to	O
+recognize	O
+that	O
+patients	O
+evolve	O
+from	O
+severe	O
+ARDS	B-DISO
+through	O
+phases	O
+of	O
+recovery	O
+to	O
+the	O
+resolution	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+that	O
+ventilatory	O
+management	O
+,	O
+as	O
+well	O
+as	O
+sedative	B-CHED
+and	O
+related	O
+medication	O
+requirements	O
+,	O
+will	O
+vary	O
+markedly	O
+over	O
+the	O
+course	O
+of	O
+this	O
+process	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+review	O
+the	O
+technique	O
+and	O
+clinical	O
+application	O
+of	O
+high	O
+-	O
+frequency	O
+percussive	O
+ventilation	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Patients	O
+were	O
+transitioned	O
+from	O
+standardized	O
+conventional	O
+ventilation	O
+to	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+beginning	O
+with	O
+an	O
+initial	O
+cycle	O
+of	O
+up	O
+to	O
+three	O
+sustained	O
+inflation	O
+recruitment	B-DISO
+maneuvers	O
+(	O
+40	O
+cm	O
+H2O	B-CHED
+x	O
+40	O
+secs	O
+),	O
+followed	O
+by	O
+a	O
+decremental	O
+titration	O
+of	O
+Fio2	O
+and	O
+then	O
+mean	O
+airway	B-ANAT
+pressure	O
+.	O
+
+A	O
+median	O
+of	O
+seven	O
+(	O
+four	O
+to	O
+11	O
+)	O
+recruitment	B-DISO
+maneuvers	O
+was	O
+performed	O
+per	O
+patient	O
+over	O
+the	O
+study	O
+period	O
+,	O
+with	O
+only	O
+eight	O
+of	O
+244	O
+(	O
+3	O
+.	O
+3	O
+%)	O
+being	O
+aborted	O
+.	O
+
+Additionally	O
+PMNL	O
+diapedesis	B-PROC
+and	O
+interstitial	B-ANAT
+lung	B-DISO
+oedema	I-DISO
+were	O
+determined	O
+by	O
+histological	O
+analysis	O
+.	O
+
+In	O
+the	O
+face	B-DISO
+of	O
+an	O
+induced	O
+lung	B-ANAT
+contusion	O
+,	O
+reamed	O
+femoral	B-ANAT
+nailing	O
+resulted	O
+in	O
+significant	O
+increases	O
+in	O
+PMNL	O
+activation	O
+,	O
+pulmonary	B-ANAT
+permeability	O
+and	O
+interstitial	B-ANAT
+lung	B-DISO
+oedema	I-DISO
+,	O
+compared	O
+with	O
+external	O
+fixation	O
+.	O
+
+No	O
+clinical	O
+signs	O
+were	O
+observed	O
+in	O
+all	O
+the	O
+ferrets	B-SPEC
+challenged	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+On	O
+the	O
+other	O
+hand	O
+,	O
+vaccination	O
+did	O
+not	O
+prevent	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+ferrets	B-SPEC
+.	O
+
+In	O
+contrast	O
+,	O
+immunized	O
+ferrets	B-SPEC
+(	O
+particularly	O
+those	O
+immunized	O
+with	O
+rMVA	O
+-	O
+spike	O
+)	O
+exhibited	O
+significantly	O
+stronger	O
+inflammatory	B-DISO
+responses	I-DISO
+and	O
+focal	B-DISO
+necrosis	I-DISO
+in	O
+liver	B-ANAT
+tissue	I-ANAT
+after	O
+SARS	B-DISO
+-	O
+CoV	O
+challenge	O
+than	O
+control	O
+animals	B-SPEC
+.	O
+
+India	O
+and	O
+Pakistan	O
+,	O
+the	O
+major	O
+users	O
+of	O
+dangerous	O
+nerve	B-ANAT
+tissue	I-ANAT
+derived	O
+Semple	O
+type	O
+vaccine	O
+,	O
+are	O
+now	O
+considering	O
+following	O
+suite	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+four	O
+hospitals	O
+assessed	O
+in	O
+this	O
+study	O
+use	O
+active	O
+surveillance	O
+cultures	O
+for	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+MRSA	B-DISO
+)	O
+and	O
+contact	O
+precautions	O
+for	O
+MRSA	B-DISO
+-	O
+positive	O
+patients	O
+as	O
+part	O
+of	O
+routine	O
+infection	B-DISO
+control	O
+practices	O
+.	O
+
+Increased	O
+attention	O
+was	O
+paid	O
+to	O
+infection	B-DISO
+control	O
+education	O
+following	O
+the	O
+outbreak	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+nosocomial	O
+rate	O
+of	O
+MRSA	B-DISO
+in	O
+all	O
+four	O
+hospitals	O
+combined	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+(	O
+3	O
+.	O
+7	O
+per	O
+10	O
+,	O
+000	O
+patient	O
+-	O
+days	O
+)	O
+was	O
+not	O
+significantly	O
+different	O
+from	O
+that	O
+before	O
+(	O
+4	O
+.	O
+7	O
+per	O
+10	O
+,	O
+000	O
+patient	O
+-	O
+days	O
+)	O
+or	O
+after	O
+(	O
+3	O
+.	O
+4	O
+per	O
+10	O
+,	O
+000	O
+patient	O
+-	O
+days	O
+)	O
+the	O
+outbreak	O
+(	O
+P	O
+=	O
+.	O
+30	O
+and	O
+P	O
+=	O
+.	O
+76	O
+,	O
+respectively	O
+).	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+risk	O
+perceptions	O
+in	O
+healthcare	O
+workers	O
+,	O
+Japan	O
+.	O
+
+The	O
+pseudotype	O
+assay	O
+does	O
+not	O
+require	O
+handling	O
+live	O
+SARS	B-DISO
+virus	O
+;	O
+it	O
+is	O
+a	O
+useful	O
+tool	O
+to	O
+determine	O
+neutralizing	O
+titers	O
+during	O
+natural	O
+infection	B-DISO
+and	O
+the	O
+preclinical	O
+evaluation	O
+of	O
+candidate	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+isolated	O
+from	O
+a	O
+pig	B-SPEC
+during	O
+a	O
+survey	O
+for	O
+possible	O
+routes	O
+of	O
+viral	B-PROC
+transmission	I-PROC
+after	O
+a	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+Biochemical	O
+and	O
+immunological	O
+studies	O
+of	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+229E	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+RESULTS	O
+:	O
+Literature	O
+searches	O
+were	O
+conducted	O
+in	O
+several	O
+databases	O
+for	O
+articles	O
+published	O
+in	O
+the	O
+last	O
+15	O
+years	O
+that	O
+related	O
+to	O
+infection	B-DISO
+control	O
+practices	O
+,	O
+occupational	O
+health	O
+and	O
+safety	O
+issues	O
+,	O
+environmental	O
+factors	O
+,	O
+and	O
+other	O
+issues	O
+of	O
+importance	O
+in	O
+protecting	O
+workers	O
+against	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+health	O
+care	O
+settings	O
+.	O
+
+Recent	O
+studies	O
+revealed	O
+that	O
+3a	O
+could	O
+interact	O
+specifically	O
+with	O
+many	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+structural	I-PRGE
+proteins	B-CHED
+,	O
+such	O
+as	O
+M	O
+,	O
+E	O
+and	O
+S	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+H	O
+strain	O
+of	O
+infectious	O
+bronchitis	B-DISO
+(	O
+IB	B-DISO
+)	O
+was	O
+one	O
+of	O
+the	O
+earliest	O
+live	O
+attenuated	O
+IB	B-DISO
+vaccines	O
+to	O
+be	O
+developed	O
+and	O
+has	O
+continued	O
+to	O
+be	O
+use	O
+in	O
+most	O
+parts	O
+of	O
+the	O
+world	O
+for	O
+almost	O
+50	O
+years	O
+.	O
+
+Ninety	O
+-	O
+five	O
+per	O
+cent	O
+of	O
+positive	O
+control	O
+birds	B-SPEC
+developed	O
+arthritis	B-DISO
+.	O
+
+After	O
+the	O
+single	O
+intravenous	O
+,	O
+low	O
+-	O
+dose	O
+M	B-SPEC
+.	I-SPEC
+synoviae	I-SPEC
+inoculation	O
+11	O
+%	O
+of	O
+birds	B-SPEC
+developed	O
+joint	B-ANAT
+lesions	O
+,	O
+whereas	O
+70	O
+%	O
+of	O
+those	O
+receiving	O
+the	O
+second	O
+inoculation	O
+developed	O
+lesions	O
+.	O
+
+Two	O
+hatches	O
+of	O
+1	O
+-	O
+day	O
+-	O
+old	O
+chicks	O
+from	O
+four	O
+lines	O
+were	O
+mistakenly	O
+vaccinated	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+using	O
+a	O
+moderately	O
+attenuated	O
+vaccine	O
+designed	O
+for	O
+chicks	O
+of	O
+an	O
+older	O
+age	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+a	O
+793	O
+/	O
+B	O
+field	O
+isolate	O
+after	O
+passage	O
+in	O
+embryonated	O
+eggs	O
+,	O
+then	O
+in	O
+chickens	B-SPEC
+and	O
+then	O
+again	O
+in	O
+eggs	O
+revealed	O
+selection	O
+for	O
+a	O
+serine	B-CHED
+and	O
+alanine	B-CHED
+at	O
+S1	O
+amino	B-CHED
+acid	I-CHED
+position	O
+95	O
+in	O
+chicken	B-SPEC
+-	O
+passaged	O
+and	O
+egg	B-ANAT
+-	O
+passaged	O
+virus	B-SPEC
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Four	O
+different	O
+types	O
+of	O
+human	O
+interferon	O
+,	O
+interferon	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+),	O
+recombinant	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+alpha2a	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+alpha2b	I-PRGE
+and	O
+natural	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+were	O
+tested	O
+for	O
+antiviral	B-CHED
+activity	O
+against	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+.	O
+
+Four	O
+""""	O
+probable	O
+""""	O
+cases	O
+of	O
+SARS	B-DISO
+were	O
+studied	O
+.	O
+
+The	O
+pulmonary	B-ANAT
+specimens	O
+were	O
+taken	O
+on	O
+day	O
+7	O
+after	O
+symptom	B-DISO
+onset	O
+in	O
+patient	O
+1	O
+,	O
+day	O
+11	O
+in	O
+patient	O
+2	O
+,	O
+day	O
+17	O
+in	O
+patient	O
+3	O
+,	O
+and	O
+day	O
+21	O
+in	O
+patient	O
+4	O
+.	O
+
+Few	O
+CD68	B-PRGE
+-	O
+positive	O
+syncytial	O
+multinucleated	B-ANAT
+giant	I-ANAT
+cells	B-COMP
+were	O
+also	O
+seen	O
+in	O
+the	O
+specimens	O
+but	O
+no	O
+viral	B-ANAT
+inclusion	I-ANAT
+body	I-ANAT
+could	O
+be	O
+identified	O
+in	O
+these	O
+cells	B-COMP
+.	O
+
+The	O
+number	O
+of	O
+CD3	B-PRGE
+-	O
+positive	O
+lymphocytes	B-ANAT
+and	O
+of	O
+CD68	B-PRGE
+-	O
+positive	O
+macrophages	B-ANAT
+in	O
+this	O
+specimen	O
+from	O
+a	O
+patient	O
+in	O
+the	O
+fibrotic	O
+phase	O
+of	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+DAD	B-DISO
+)	O
+whose	O
+condition	B-DISO
+deteriorated	O
+was	O
+less	O
+than	O
+in	O
+the	O
+specimen	O
+from	O
+case	O
+3	O
+who	O
+was	O
+in	O
+the	O
+early	O
+proliferative	B-DISO
+phase	O
+of	O
+DAD	B-DISO
+and	O
+eventually	O
+recovered	O
+.	O
+
+The	O
+number	O
+of	O
+CD3	B-PRGE
+-	O
+positive	O
+lymphocytes	B-ANAT
+and	O
+of	O
+CD68	B-PRGE
+-	O
+positive	O
+macrophages	B-ANAT
+in	O
+this	O
+specimen	O
+from	O
+a	O
+patient	O
+in	O
+the	O
+fibrotic	O
+phase	O
+of	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+DAD	B-DISO
+)	O
+whose	O
+condition	B-DISO
+deteriorated	O
+was	O
+less	O
+than	O
+in	O
+the	O
+specimen	O
+from	O
+case	O
+3	O
+who	O
+was	O
+in	O
+the	O
+early	O
+proliferative	B-DISO
+phase	O
+of	O
+DAD	B-DISO
+and	O
+eventually	O
+recovered	O
+.	O
+
+In	O
+addition	O
+,	O
+global	O
+research	O
+efforts	O
+have	O
+focused	O
+on	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+against	O
+SARS	B-DISO
+.	O
+
+Of	O
+the	O
+126	O
+transcripts	O
+found	O
+to	O
+be	O
+differentially	O
+expressed	B-PROC
+between	O
+viral	O
+and	O
+sham	O
+infections	B-DISO
+,	O
+the	O
+majority	O
+were	O
+related	O
+to	O
+immunological	O
+responses	O
+.	O
+
+ABSTRACT	O
+:	O
+Critical	O
+deep	O
+venous	O
+thrombosis	O
+and	O
+occlusion	B-DISO
+constitutes	O
+a	O
+small	O
+percentage	O
+of	O
+patients	O
+with	O
+venous	B-DISO
+disease	I-DISO
+,	O
+who	O
+exhibit	O
+severe	O
+symptomatology	O
+.	O
+
+Therapeutic	O
+modalities	O
+including	O
+thrombolysis	O
+,	O
+mechanical	O
+thrombectomy	O
+,	O
+percutaneous	O
+venoplasty	O
+and	O
+stent	O
+placement	O
+,	O
+temporary	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+filtration	O
+,	O
+and	O
+ultrasound	O
+guidance	O
+were	O
+used	O
+in	O
+all	O
+cases	O
+in	O
+conjunction	O
+with	O
+long	O
+-	O
+term	O
+systemic	O
+anticoagulation	O
+.	O
+
+Sex	O
+,	O
+degree	O
+of	O
+CSF	B-ANAT
+inflammation	B-DISO
+,	O
+neuroanatomical	O
+location	O
+and	O
+systemic	O
+signs	O
+provided	O
+little	O
+contributory	O
+information	O
+to	O
+the	O
+final	O
+diagnosis	O
+.	O
+
+Overall	O
+,	O
+despite	O
+extensive	O
+diagnostic	O
+evaluation	O
+,	O
+a	O
+specific	O
+diagnosis	O
+could	O
+not	O
+be	O
+made	O
+in	O
+37	O
+%	O
+of	O
+cats	B-SPEC
+.	O
+
+Shelters	O
+differed	O
+in	O
+the	O
+prevalence	O
+of	O
+pathogens	O
+and	O
+many	O
+cats	B-SPEC
+appeared	O
+positive	O
+for	O
+infection	B-DISO
+after	O
+about	O
+1	O
+week	O
+of	O
+sheltering	O
+.	O
+
+TITLE	O
+:	O
+Extravascular	O
+lung	B-ANAT
+water	B-CHED
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+:	O
+a	O
+prospective	O
+cohort	O
+study	O
+.	O
+
+EVLW	O
+correlated	O
+moderately	O
+with	O
+the	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+but	O
+did	O
+not	O
+account	O
+for	O
+all	O
+respiratory	O
+derangements	O
+.	O
+
+EVLW	O
+may	O
+improve	O
+both	O
+risk	O
+stratification	O
+and	O
+management	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Twenty	O
+-	O
+five	O
+of	O
+the	O
+29	O
+patients	O
+(	O
+86	O
+%)	O
+were	O
+mechanically	O
+ventilated	O
+,	O
+15	O
+of	O
+the	O
+29	O
+patients	O
+(	O
+52	O
+%)	O
+developed	O
+ARDS	B-DISO
+,	O
+and	O
+overall	O
+28	O
+-	O
+day	O
+mortality	O
+was	O
+41	O
+%.	O
+
+The	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+/	O
+fractional	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+,	O
+lung	B-ANAT
+injury	O
+score	O
+,	O
+and	O
+chest	B-ANAT
+radiograph	O
+scores	O
+correlated	O
+with	O
+EVLW	O
+(	O
+r2	O
+=	O
+0	O
+.	O
+27	O
+,	O
+r2	O
+=	O
+0	O
+.	O
+18	O
+,	O
+and	O
+r2	O
+=	O
+0	O
+.	O
+28	O
+,	O
+respectively	O
+;	O
+all	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+An	O
+indirect	O
+antibody	B-COMP
+ELISA	O
+method	O
+was	O
+developed	O
+and	O
+clinical	O
+positive	O
+and	O
+negative	O
+sera	B-COMP
+for	O
+their	O
+antibodies	B-COMP
+against	O
+GST	B-PRGE
+-	O
+N2	O
+fusion	O
+protein	B-CHED
+were	O
+assayed	O
+.	O
+
+The	O
+remote	O
+effects	O
+of	O
+I	O
+/	O
+R	O
+are	O
+most	O
+frequently	O
+observed	O
+in	O
+the	O
+lungs	B-ANAT
+and	O
+pulmonary	B-ANAT
+damage	O
+may	O
+vary	O
+from	O
+acute	O
+lung	B-ANAT
+injury	O
+with	O
+mild	O
+dysfunction	O
+to	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+or	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Using	O
+indirect	O
+immunofluorescence	O
+(	O
+IF	O
+)	O
+labeling	O
+,	O
+all	O
+mixed	B-DISO
+infections	I-DISO
+revealed	O
+dually	O
+infected	O
+cells	B-COMP
+,	O
+however	O
+,	O
+only	O
+incidentally	O
+and	O
+in	O
+low	O
+numbers	O
+.	O
+
+Synthetic	O
+21	O
+-	O
+23	O
+nucleotide	B-CHED
+(	O
+nt	O
+)	O
+small	O
+interfering	O
+RNA	O
+(	O
+siRNA	O
+)	O
+with	O
+2	O
+nt	O
+3	O
+'	O
+overhangs	O
+was	O
+recently	O
+found	O
+to	O
+mediate	O
+efficient	O
+sequence	O
+-	O
+specific	O
+mRNA	B-PROC
+degradation	I-PROC
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+.	O
+
+The	O
+essential	O
+sequence	O
+was	O
+mapped	O
+to	O
+the	O
+membrane	B-COMP
+-	O
+proximal	O
+region	O
+of	O
+the	O
+cytoplasmic	B-ANAT
+domain	I-ANAT
+,	O
+which	O
+is	O
+also	O
+known	O
+to	O
+be	O
+of	O
+critical	O
+importance	O
+for	O
+the	O
+fusion	O
+function	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+deliberate	O
+release	B-PATH
+of	O
+a	O
+biological	O
+agent	O
+is	O
+one	O
+of	O
+the	O
+possible	O
+scenarios	O
+of	O
+emergence	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+3a	O
+protein	B-CHED
+is	O
+one	O
+of	O
+the	O
+opening	O
+reading	O
+frames	O
+in	O
+the	O
+viral	B-COMP
+genome	I-COMP
+with	O
+no	O
+homologue	O
+in	O
+other	O
+known	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+chemokine	O
+response	O
+of	O
+eight	O
+children	O
+with	O
+serologically	O
+confirmed	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+was	O
+longitudinally	O
+monitored	O
+.	O
+
+The	O
+comparison	O
+of	O
+the	O
+genomic	O
+sequence	O
+of	O
+different	O
+strains	O
+has	O
+generated	O
+discrepancies	O
+as	O
+for	O
+if	O
+the	O
+SARS	B-DISO
+epidemic	O
+arose	O
+as	O
+an	O
+unique	O
+outbreak	O
+or	O
+it	O
+was	O
+produced	O
+for	O
+more	O
+than	O
+one	O
+genotype	O
+.	O
+
+As	O
+shown	O
+in	O
+2003	O
+by	O
+the	O
+elucidation	O
+of	O
+the	O
+SARS	B-DISO
+pandemia	O
+and	O
+the	O
+human	B-DISO
+monkeypox	I-DISO
+outbreak	O
+in	O
+US	O
+,	O
+EM	O
+is	O
+well	O
+suited	O
+as	O
+a	O
+safe	O
+,	O
+front	O
+-	O
+line	O
+diagnostic	O
+method	O
+in	O
+infectious	B-DISO
+diseases	I-DISO
+emergencies	B-DISO
+and	O
+/	O
+or	O
+in	O
+possible	O
+bioterrorist	O
+attacks	O
+.	O
+
+Relationships	O
+between	O
+BCoV	O
+shedding	O
+and	O
+age	O
+group	O
+,	O
+seroconversion	O
+and	O
+clinical	O
+signs	O
+in	O
+cattle	B-SPEC
+were	O
+also	O
+analysed	O
+.	O
+
+Further	O
+studies	O
+are	O
+needed	O
+to	O
+isolate	O
+BCoV	O
+strains	O
+in	O
+Turkey	B-SPEC
+and	O
+to	O
+investigate	O
+their	O
+antigenic	O
+and	O
+genetic	O
+properties	O
+.	O
+
+Regulated	O
+on	O
+activation	O
+normally	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+expressed	B-PROC
+and	O
+secreted	B-PROC
+(	O
+RANTES	O
+)	O
+levels	O
+were	O
+decreased	O
+,	O
+while	O
+monocyte	B-PRGE
+chemoattractant	I-PRGE
+protein	B-CHED
+-	I-PRGE
+1	I-PRGE
+(	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+was	O
+elevated	O
+in	O
+acute	O
+patients	O
+.	O
+
+Both	O
+serum	B-COMP
+-	O
+positive	O
+rates	O
+and	O
+titers	O
+of	O
+specific	O
+IgM	O
+and	O
+IgG	B-PRGE
+antibodies	I-PRGE
+responding	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+peaked	O
+at	O
+days	O
+41	O
+-	O
+60	O
+from	O
+the	O
+onset	O
+of	O
+SARS	B-DISO
+.	O
+
+By	O
+combining	O
+these	O
+two	O
+complementary	O
+strategies	O
+,	O
+355	O
+unique	O
+proteins	B-CHED
+were	O
+identified	O
+and	O
+quantitated	O
+with	O
+186	O
+of	O
+them	O
+differentially	O
+expressed	B-PROC
+(	O
+at	O
+least	O
+1	O
+.	O
+5	O
+-	O
+fold	O
+quantitative	O
+alteration	O
+)	O
+between	O
+infected	O
+and	O
+uninfected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+The	O
+implication	O
+for	O
+cellular	B-COMP
+responses	O
+to	O
+virus	B-SPEC
+infection	I-PROC
+was	O
+analyzed	O
+in	O
+depth	O
+according	O
+to	O
+the	O
+proteomic	O
+results	O
+.	O
+
+The	O
+data	O
+collected	O
+included	O
+demographic	O
+and	O
+occupational	O
+information	O
+,	O
+in	O
+addition	O
+to	O
+perceptions	O
+of	O
+SARS	B-DISO
+'	O
+impact	O
+on	O
+patient	O
+care	O
+,	O
+factors	O
+contributing	O
+to	O
+adverse	O
+impacts	O
+on	O
+patient	O
+care	O
+,	O
+working	O
+conditions	O
+,	O
+decision	O
+-	O
+making	O
+,	O
+communication	O
+and	O
+relations	O
+,	O
+sources	O
+of	O
+support	O
+,	O
+and	O
+the	O
+impact	O
+on	O
+workers	O
+'	O
+lives	O
+outside	O
+work	O
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+coronaviruses	O
+establish	O
+persistent	O
+infections	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+,	O
+however	O
+it	O
+is	O
+unknown	O
+whether	O
+persistence	O
+is	O
+a	O
+feature	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+life	O
+cycle	O
+.	O
+
+Changes	O
+in	O
+viral	O
+genomic	O
+sequences	O
+during	O
+persistent	B-DISO
+infection	I-DISO
+were	O
+examined	O
+by	O
+DNA	O
+sequencing	O
+.	O
+
+Cytopathic	B-DISO
+effect	I-DISO
+was	O
+extensive	O
+after	O
+initial	O
+inoculation	O
+but	O
+diminished	O
+with	O
+serial	O
+passages	O
+.	O
+
+Persistence	O
+is	O
+associated	O
+with	O
+selected	O
+mutations	O
+in	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+.	O
+
+The	O
+tagged	O
+C145A	B-PRGE
+mutant	I-PRGE
+protein	B-CHED
+served	O
+as	O
+a	O
+substrate	O
+for	O
+the	O
+wild	B-PRGE
+-	I-PRGE
+type	I-PRGE
+protease	I-PRGE
+,	O
+and	O
+the	O
+N	O
+terminus	O
+was	O
+first	O
+digested	O
+(	O
+55	O
+-	O
+fold	O
+faster	O
+)	O
+at	O
+the	O
+Gln	B-CHED
+(-	O
+1	O
+)-	O
+Ser1	O
+site	O
+followed	O
+by	O
+the	O
+C	O
+-	O
+terminal	O
+cleavage	B-PROC
+at	O
+the	O
+Gln306	O
+-	O
+Gly307	O
+site	O
+.	O
+
+All	O
+three	O
+S	O
+proteins	B-CHED
+bound	O
+to	O
+and	O
+utilized	O
+palm	B-ANAT
+-	O
+civet	B-SPEC
+ACE2	O
+efficiently	O
+,	O
+but	O
+the	O
+latter	O
+two	O
+S	O
+proteins	B-CHED
+utilized	O
+human	B-PRGE
+ACE2	I-PRGE
+markedly	O
+less	O
+efficiently	O
+than	O
+did	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+obtained	O
+during	O
+the	O
+earlier	O
+human	B-SPEC
+outbreak	O
+.	O
+
+The	O
+lower	O
+affinity	O
+of	O
+these	O
+S	O
+proteins	B-CHED
+could	O
+be	O
+complemented	O
+by	O
+altering	O
+specific	O
+residues	O
+within	O
+the	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+site	I-PRGE
+of	O
+human	B-PRGE
+ACE2	I-PRGE
+to	O
+those	O
+of	O
+civet	B-SPEC
+ACE2	O
+,	O
+or	O
+by	O
+altering	O
+S	O
+-	O
+protein	B-CHED
+residues	O
+479	O
+and	O
+487	O
+to	O
+residues	O
+conserved	O
+during	O
+the	O
+2002	O
+-	O
+2003	O
+outbreak	O
+.	O
+
+Collectively	O
+,	O
+these	O
+data	O
+describe	O
+molecular	O
+interactions	O
+important	O
+to	O
+the	O
+adaptation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+to	O
+human	B-SPEC
+cells	B-COMP
+,	O
+and	O
+provide	O
+insight	O
+into	O
+the	O
+severity	O
+of	O
+the	O
+2002	O
+-	O
+2003	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+Routine	O
+laboratory	O
+tests	O
+,	O
+including	O
+determination	O
+of	O
+absolute	O
+lymphocyte	B-ANAT
+count	O
+,	O
+should	O
+not	O
+be	O
+used	O
+in	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+or	O
+incorporated	O
+into	O
+current	O
+case	O
+definitions	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recombinant	B-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+(	O
+rNP	B-COMP
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+expressed	B-PROC
+in	O
+a	O
+baculovirus	B-SPEC
+system	O
+.	O
+
+Two	O
+-	O
+hundred	O
+and	O
+seventy	O
+-	O
+six	O
+serum	B-COMP
+samples	O
+were	O
+collected	O
+from	O
+health	O
+care	O
+workers	O
+in	O
+a	O
+hospital	O
+in	O
+which	O
+a	O
+nosocomial	O
+SARS	B-DISO
+outbreak	O
+took	O
+place	O
+and	O
+used	O
+for	O
+evaluation	O
+.	O
+
+By	O
+contrast	O
+,	O
+bystander	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+numbers	O
+declined	O
+to	O
+background	O
+numbers	O
+following	O
+control	O
+of	O
+CNS	B-CHED
+virus	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+results	O
+show	O
+that	O
+participants	O
+in	O
+both	O
+samples	O
+had	O
+equal	O
+,	O
+if	O
+not	O
+more	O
+,	O
+concern	O
+about	O
+infecting	O
+others	O
+(	O
+especially	O
+family	B-SPEC
+members	O
+)	O
+than	O
+being	O
+self	O
+-	O
+infected	O
+.	O
+
+TITLE	O
+:	O
+Genosensor	O
+on	O
+gold	B-CHED
+films	O
+with	O
+enzymatic	O
+electrochemical	O
+detection	O
+of	O
+a	O
+SARS	B-DISO
+virus	B-SPEC
+sequence	O
+.	O
+
+A	O
+complementary	O
+strand	O
+(	O
+probe	O
+),	O
+labelled	O
+with	O
+a	O
+thiol	B-CHED
+group	I-CHED
+at	O
+the	O
+3	O
+'-	O
+end	O
+,	O
+was	O
+immobilised	O
+on	O
+the	O
+film	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+evaluation	O
+of	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+against	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+S450	O
+-	O
+650	O
+-	O
+based	O
+ELISA	O
+detected	O
+IgG	B-PRGE
+Abs	I-PRGE
+in	O
+41	O
+out	O
+of	O
+51	O
+serum	B-COMP
+samples	O
+from	O
+22	O
+hospitalized	O
+patients	O
+with	O
+probable	O
+SARS	B-DISO
+,	O
+a	O
+result	O
+closely	O
+correlated	O
+with	O
+that	O
+obtained	O
+with	O
+a	O
+virus	B-SPEC
+-	O
+based	O
+ELISA	O
+(	O
+r	O
+=	O
+0	O
+.	O
+75	O
+,	O
+k	O
+=	O
+0	O
+.	O
+8	O
+).	O
+
+The	O
+S450	O
+-	O
+650	O
+-	O
+based	O
+ELISA	O
+can	O
+detect	O
+anti	B-PRGE
+-	I-PRGE
+S	I-PRGE
+IgG	I-PRGE
+Abs	I-PRGE
+with	O
+high	O
+sensitivity	O
+and	O
+specificity	O
+.	O
+
+Paired	O
+serum	B-ANAT
+samples	O
+were	O
+assayed	O
+for	O
+increasing	O
+titer	O
+against	O
+SARS	B-DISO
+CoV	O
+.	O
+In	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+Artus	O
+and	O
+Roche	O
+PCR	O
+assays	O
+exhibited	O
+sensitivities	O
+of	O
+87	O
+%	O
+and	O
+85	O
+%	O
+for	O
+respiratory	O
+specimens	O
+(	O
+n	O
+=	O
+64	O
+),	O
+91	O
+%	O
+and	O
+88	O
+%	O
+for	O
+stool	B-ANAT
+(	O
+n	O
+=	O
+44	O
+),	O
+and	O
+82	O
+%	O
+for	O
+urine	B-ANAT
+(	O
+n	O
+=	O
+29	O
+).	O
+
+For	O
+post	O
+-	O
+epidemic	O
+period	O
+,	O
+no	O
+SARS	B-PRGE
+CoV	I-PRGE
+was	O
+identified	O
+among	O
+56	O
+respiratory	O
+specimens	O
+by	O
+all	O
+PCR	O
+assays	O
+.	O
+
+Inhibitors	B-CHED
+to	O
+PCR	O
+assays	O
+were	O
+detected	O
+at	O
+an	O
+average	O
+rate	O
+of	O
+7	O
+-	O
+8	O
+%	O
+among	O
+202	O
+clinical	O
+specimens	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+highlights	O
+the	O
+high	O
+throughput	O
+and	O
+performance	O
+of	O
+automatic	O
+RNA	O
+extraction	O
+in	O
+coordination	B-PROC
+with	O
+standardized	O
+real	O
+-	O
+time	O
+PCR	O
+assays	O
+suitable	O
+for	O
+large	O
+-	O
+scale	O
+routine	O
+diagnosis	O
+in	O
+case	O
+of	O
+future	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+Suppose	O
+a	O
+sub	O
+-	O
+sequence	O
+is	O
+denoted	O
+as	O
+P2	O
+-	O
+P1	O
+-	O
+P1	O
+'-	O
+P2	O
+',	O
+the	O
+conventional	O
+inductive	O
+programming	O
+method	O
+may	O
+result	O
+in	O
+a	O
+rule	O
+like	O
+'	O
+if	O
+P1	O
+=	O
+Q	O
+,	O
+then	O
+the	O
+sub	O
+-	O
+sequence	O
+is	O
+cleaved	B-ANAT
+,	O
+otherwise	O
+non	O
+-	O
+cleaved	B-ANAT
+'.	O
+
+Fever	B-PROC
+was	O
+the	O
+most	O
+common	O
+presenting	O
+symptom	B-DISO
+(	O
+91	O
+.	O
+6	O
+percent	O
+),	O
+and	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+were	O
+the	O
+least	O
+(	O
+6	O
+.	O
+9	O
+percent	O
+).	O
+
+Surveillance	O
+data	O
+on	O
+medical	O
+sick	O
+leave	O
+of	O
+staff	O
+,	O
+all	O
+inpatient	O
+fevers	B-PROC
+,	O
+all	O
+febrile	B-PROC
+(	O
+temperature	O
+greater	O
+than	O
+or	O
+equal	O
+to	O
+38	O
+degrees	O
+Celsius	O
+)	O
+inpatient	O
+pneumonia	B-DISO
+,	O
+including	O
+atypical	B-DISO
+pneumonia	I-DISO
+,	O
+and	O
+deaths	B-PROC
+from	O
+pneumonia	B-DISO
+were	O
+collected	O
+from	O
+sick	O
+leave	O
+reports	O
+,	O
+ward	O
+reports	O
+,	O
+isolation	O
+room	O
+rounds	O
+and	O
+mortuary	O
+reports	O
+from	O
+1	O
+to	O
+28	O
+September	O
+2003	O
+.	O
+
+Of	O
+27	O
+cases	O
+with	O
+fever	B-PROC
+,	O
+pneumonia	B-DISO
+and	O
+a	O
+total	O
+white	O
+count	O
+of	O
+less	O
+than	O
+10	O
+,	O
+000	O
+cells	B-COMP
+per	O
+cubic	O
+mm	O
+as	O
+per	O
+Ministry	O
+of	O
+Health	O
+,	O
+Singapore	O
+criteria	O
+for	O
+the	O
+diagnosis	O
+of	O
+atypical	B-DISO
+pneumonia	I-DISO
+,	O
+only	O
+five	O
+were	O
+identified	O
+by	O
+clinicians	O
+.	O
+
+To	O
+determine	O
+the	O
+in	O
+vivo	O
+role	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+during	O
+CNS	B-DISO
+infection	I-DISO
+,	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+signaling	B-PROC
+was	O
+inhibited	O
+via	O
+administration	O
+of	O
+a	O
+neutralizing	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+-	O
+specific	O
+monoclonal	B-PRGE
+antibody	I-PRGE
+(	O
+mAb	O
+).	O
+
+In	O
+contrast	O
+to	O
+depletion	O
+of	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+inhibition	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+signaling	B-PROC
+did	O
+not	O
+influence	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+,	O
+effector	B-ANAT
+cell	B-COMP
+function	O
+or	O
+survival	O
+within	O
+the	O
+CNS	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+an	O
+established	O
+therapy	O
+for	O
+the	O
+treatment	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Control	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+is	O
+being	O
+challenged	O
+by	O
+many	O
+factors	O
+,	O
+like	O
+standards	O
+of	O
+living	O
+,	O
+human	B-SPEC
+behaviour	B-PROC
+,	O
+mass	O
+population	O
+movements	B-PROC
+,	O
+emergence	O
+of	O
+infectious	B-DISO
+like	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+and	O
+SARS	B-DISO
+,	O
+the	O
+re	O
+-	O
+emergence	O
+of	O
+infections	B-DISO
+such	O
+as	O
+tuberculosis	B-PATH
+,	O
+development	B-PROC
+of	O
+resistance	B-PROC
+in	O
+bacteria	B-SPEC
+,	O
+viruses	B-SPEC
+and	O
+parasites	O
+,	O
+modern	O
+rate	O
+of	O
+global	O
+travel	O
+,	O
+etc	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+in	O
+depth	O
+the	O
+experiences	O
+of	O
+nurses	O
+'	O
+caring	O
+for	O
+SARS	B-DISO
+patients	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+findings	O
+of	O
+this	O
+study	O
+indicate	O
+that	O
+extensive	O
+and	O
+ongoing	O
+support	O
+is	O
+needed	O
+to	O
+prepare	O
+and	O
+enable	O
+nurses	O
+to	O
+care	O
+for	O
+SARS	B-DISO
+patients	O
+during	O
+a	O
+crisis	O
+and	O
+make	O
+it	O
+easier	O
+for	O
+nurses	O
+to	O
+deal	O
+with	O
+the	O
+various	O
+uncertainties	O
+.	O
+
+Two	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)-	O
+positive	O
+air	B-CHED
+samples	O
+were	O
+obtained	O
+from	O
+a	O
+room	O
+occupied	O
+by	O
+a	O
+patient	O
+with	O
+SARS	B-DISO
+,	O
+indicating	O
+the	O
+presence	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+air	B-CHED
+of	O
+the	O
+room	O
+.	O
+
+In	O
+addition	O
+,	O
+several	O
+PCR	O
+-	O
+positive	O
+swab	O
+samples	O
+were	O
+recovered	O
+from	O
+frequently	O
+touched	O
+surfaces	O
+in	O
+rooms	O
+occupied	O
+by	O
+patients	O
+with	O
+SARS	B-DISO
+(	O
+a	O
+bed	B-DISO
+table	O
+and	O
+a	O
+television	O
+remote	O
+control	O
+)	O
+and	O
+in	O
+a	O
+nurses	O
+'	O
+station	O
+used	O
+by	O
+staff	O
+(	O
+a	O
+medication	O
+refrigerator	O
+door	O
+).	O
+
+Here	O
+we	O
+describe	O
+a	O
+new	O
+phylogenetic	O
+analytical	O
+method	O
+to	O
+study	O
+the	O
+sources	O
+and	O
+dissemination	O
+paths	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infections	B-DISO
+in	O
+Taiwan	O
+.	O
+
+Subsequently	O
+,	O
+this	O
+new	O
+tool	O
+was	O
+applied	O
+to	O
+provide	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+entire	O
+complement	O
+of	O
+Taiwanese	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+,	O
+including	O
+20	O
+previously	O
+published	O
+and	O
+19	O
+identified	O
+in	O
+this	O
+study	O
+.	O
+
+The	O
+outbreaks	O
+of	O
+SARS	B-DISO
+in	O
+Taiwan	O
+originated	O
+from	O
+multiple	O
+sources	O
+.	O
+
+Those	O
+with	O
+elevated	O
+ALT	B-FUNC
+were	O
+compared	O
+with	O
+those	O
+with	O
+normal	O
+liver	B-PROC
+functions	I-PROC
+for	O
+clinical	O
+outcome	O
+.	O
+
+Adverse	O
+outcomes	O
+were	O
+defined	O
+as	O
+oxygen	B-CHED
+desaturation	O
+,	O
+need	O
+of	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+and	O
+mechanical	O
+ventilation	O
+and	O
+death	B-PROC
+.	O
+
+Our	O
+data	O
+suggest	O
+that	O
+we	O
+have	O
+identified	O
+peptides	B-CHED
+derived	O
+from	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+which	O
+are	O
+useful	O
+for	O
+SARS	B-DISO
+treatment	O
+and	O
+diagnosis	O
+.	O
+
+We	O
+sequenced	O
+the	O
+genomes	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+from	O
+3	O
+clinical	O
+specimens	O
+obtained	O
+in	O
+Taiwan	O
+.	O
+
+Of	O
+these	O
+17	O
+sequenced	O
+variants	O
+,	O
+two	O
+loci	O
+(	O
+positions	O
+26203	O
+and	O
+27812	O
+)	O
+were	O
+segregated	O
+together	O
+as	O
+a	O
+specific	O
+genotype	O
+-	O
+T	O
+:	O
+T	O
+or	O
+C	O
+:	O
+C	O
+.	O
+Phylogenetic	O
+analysis	O
+showed	O
+two	O
+major	O
+clusters	O
+of	O
+SARS	B-DISO
+patients	O
+in	O
+Taiwan	O
+.	O
+
+This	O
+article	O
+describes	O
+one	O
+community	O
+hospital	O
+'	O
+s	O
+response	O
+to	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+crisis	O
+and	O
+the	O
+important	O
+,	O
+although	O
+initially	O
+overlooked	O
+,	O
+role	O
+of	O
+staff	O
+development	B-PROC
+in	O
+keeping	O
+SARS	B-DISO
+out	O
+of	O
+this	O
+Ontario	O
+hospital	O
+.	O
+
+Although	O
+the	O
+perceived	O
+threats	O
+of	O
+new	O
+infections	B-DISO
+such	O
+as	O
+SARS	B-DISO
+,	O
+new	B-DISO
+variant	I-DISO
+Creutzfeldt	I-DISO
+-	I-DISO
+Jakob	I-DISO
+disease	I-DISO
+and	O
+anthrax	B-DISO
+are	O
+real	O
+,	O
+these	O
+outbreaks	O
+have	O
+caused	O
+less	O
+than	O
+1	O
+,	O
+000	O
+deaths	B-PROC
+globally	O
+,	O
+a	O
+death	B-PROC
+toll	O
+AIDS	O
+and	O
+tuberculosis	B-PATH
+exact	O
+every	O
+2	O
+h	O
+.	O
+In	O
+2003	O
+,	O
+40	O
+million	O
+people	O
+were	O
+infected	O
+with	O
+HIV	B-DISO
+,	O
+2	O
+billion	O
+with	O
+M	B-SPEC
+.	I-SPEC
+tuberculosis	I-SPEC
+,	O
+and	O
+15	O
+million	O
+with	O
+both	O
+.	O
+
+We	O
+report	O
+our	O
+experience	O
+in	O
+treating	O
+SARS	B-DISO
+patients	O
+.	O
+
+There	O
+was	O
+no	O
+recurrence	B-DISO
+of	O
+WS	O
+.	O
+
+In	O
+children	O
+with	O
+normal	O
+development	B-PROC
+and	O
+regular	O
+school	O
+performance	O
+an	O
+idiopathic	O
+etiology	O
+can	O
+be	O
+presumed	O
+.	O
+
+The	O
+outcome	O
+of	O
+these	O
+children	O
+is	O
+determined	O
+by	O
+the	O
+brain	B-ANAT
+damage	O
+other	O
+than	O
+by	O
+epilepsy	B-DISO
+itself	O
+.	O
+
+Regarding	O
+the	O
+treatment	O
+with	O
+synthetic	O
+ACTH	B-PRGE
+or	O
+vigabatrin	B-CHED
+,	O
+the	O
+control	O
+of	O
+WS	O
+was	O
+the	O
+same	O
+for	O
+cryptogenic	O
+and	O
+symptomatic	O
+forms	O
+,	O
+one	O
+drug	O
+may	O
+be	O
+effective	O
+if	O
+the	O
+other	O
+drug	O
+fails	O
+.	O
+
+Vigabatrin	B-CHED
+can	O
+be	O
+suggested	O
+as	O
+the	O
+first	O
+drug	O
+for	O
+WS	O
+;	O
+if	O
+spasms	B-DISO
+persist	O
+after	O
+15	O
+days	O
+with	O
+a	O
+dose	O
+of	O
+150	O
+mg	O
+/	O
+kg	O
+,	O
+synthetic	O
+ACTH	B-PRGE
+should	O
+be	O
+considered	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+emerged	O
+infection	B-DISO
+that	O
+is	O
+caused	O
+by	O
+a	O
+previously	O
+unrecognized	O
+virus	B-SPEC
+-	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+designated	O
+as	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Transmission	O
+of	O
+SARS	B-DISO
+is	O
+facilitated	O
+by	O
+close	O
+contact	O
+with	O
+patients	O
+with	O
+symptomatic	O
+infection	B-DISO
+.	O
+
+The	O
+majority	O
+of	O
+cases	O
+have	O
+been	O
+reported	O
+among	O
+healthcare	O
+providers	O
+and	O
+family	B-SPEC
+members	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+We	O
+found	O
+that	O
+,	O
+surprisingly	O
+,	O
+militaristic	O
+language	O
+was	O
+largely	O
+absent	O
+,	O
+as	O
+was	O
+the	O
+judgemental	O
+discourse	O
+of	O
+plague	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+or	O
+perimyocarditis	O
+?--	O
+case	O
+report	O
+].	O
+
+The	O
+need	O
+for	O
+isolation	O
+units	O
+became	O
+acute	O
+when	O
+many	O
+countries	O
+prepared	O
+themselves	O
+for	O
+a	O
+possible	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+in	O
+Europe	O
+.	O
+
+On	O
+clinical	O
+and	O
+epidemiological	O
+grounds	O
+the	O
+outbreaks	O
+were	O
+first	O
+thought	O
+to	O
+be	O
+caused	O
+by	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+Common	O
+clinical	O
+manifestations	O
+were	O
+cough	B-DISO
+(	O
+74	O
+%),	O
+rhinorrhoea	B-DISO
+(	O
+59	O
+%)	O
+and	O
+sore	B-DISO
+throat	I-DISO
+(	O
+53	O
+%).	O
+
+TITLE	O
+:	O
+Critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+and	O
+myopathy	B-DISO
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Hyperplastic	B-DISO
+,	O
+well	O
+-	O
+differentiated	B-PROC
+bile	B-ANAT
+ductules	O
+were	O
+seen	O
+on	O
+liver	B-ANAT
+biopsy	O
+in	O
+the	O
+absence	O
+of	O
+any	O
+identifiable	O
+biliary	B-DISO
+disease	I-DISO
+.	O
+
+Polymerase	O
+chain	O
+reaction	O
+is	O
+a	O
+rapid	O
+and	O
+sensitive	O
+method	O
+for	O
+the	O
+detection	O
+of	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+which	O
+have	O
+gained	O
+greater	O
+importance	O
+in	O
+recent	O
+years	O
+.	O
+
+In	O
+addition	O
+to	O
+the	O
+lung	B-ANAT
+,	O
+positive	O
+viral	O
+staining	O
+was	O
+also	O
+found	O
+in	O
+the	O
+mucosal	B-ANAT
+epithelium	B-ANAT
+of	O
+the	O
+large	B-ANAT
+intestine	I-ANAT
+in	O
+another	O
+patient	O
+who	O
+had	O
+the	O
+clinical	O
+symptom	B-DISO
+of	O
+diarrhea	B-DISO
+.	O
+
+No	O
+evidence	O
+of	O
+viral	O
+staining	O
+was	O
+found	O
+in	O
+other	O
+organs	B-ANAT
+including	O
+kidney	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+lymph	B-ANAT
+node	I-ANAT
+and	O
+spleen	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+Positive	O
+viral	O
+staining	O
+was	O
+only	O
+found	O
+in	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+taken	O
+from	O
+the	O
+patients	O
+who	O
+died	B-PROC
+in	O
+the	O
+early	O
+stage	O
+of	O
+the	O
+disease	O
+,	O
+usually	O
+less	O
+than	O
+10	O
+days	O
+after	O
+symptom	B-DISO
+onset	O
+.	O
+
+CONCLUSIONS	O
+:	O
+PCT	B-DISO
+inactivates	O
+a	O
+broad	O
+spectrum	O
+of	O
+pathogenic	O
+,	O
+blood	B-ANAT
+-	O
+borne	O
+viruses	B-SPEC
+.	O
+
+There	O
+is	O
+no	O
+significant	O
+difference	O
+in	O
+the	O
+genotypic	O
+distributions	O
+and	O
+the	O
+allelic	O
+frequencies	O
+of	O
+the	O
+ACE	B-PRGE
+I	I-PRGE
+/	I-PRGE
+D	I-PRGE
+polymorphism	B-PROC
+between	O
+the	O
+SARS	B-DISO
+patients	O
+and	O
+the	O
+healthy	O
+control	O
+subjects	O
+.	O
+
+In	O
+multivariate	O
+logistic	O
+analysis	O
+,	O
+age	O
+is	O
+the	O
+only	O
+factor	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+while	O
+age	O
+and	O
+male	O
+sex	O
+are	O
+independent	O
+factors	O
+associated	O
+with	O
+the	O
+requirement	O
+of	O
+intensive	O
+care	O
+.	O
+
+METHODS	O
+:	O
+One	O
+hundred	O
+and	O
+forty	O
+genetically	O
+unrelated	O
+Chinese	O
+SARS	B-DISO
+patients	O
+and	O
+326	O
+healthy	O
+volunteers	O
+were	O
+recruited	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+murine	B-SPEC
+CD8	B-PRGE
+T	I-PRGE
+cell	I-PRGE
+epitopes	I-PRGE
+in	O
+codon	O
+-	O
+optimized	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+spike	O
+protein	O
+.	O
+
+The	O
+spike	O
+protein	B-CHED
+,	O
+a	O
+main	O
+surface	O
+antigen	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+antigen	B-CHED
+candidates	O
+for	O
+vaccine	O
+design	O
+.	O
+
+TITLE	O
+:	O
+Temporal	O
+-	O
+spatial	O
+analysis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+among	O
+hospital	O
+inpatients	O
+.	O
+
+Essential	O
+risk	O
+factors	O
+for	O
+development	B-PROC
+of	O
+candidosis	B-DISO
+are	O
+the	O
+expanded	O
+use	O
+of	O
+antibiotics	B-CHED
+and	O
+immunocompromised	O
+patients	O
+,	O
+caused	O
+either	O
+as	O
+a	O
+result	O
+of	O
+a	O
+severe	O
+underlying	O
+disease	O
+or	O
+iatrogenically	O
+induced	O
+after	O
+organ	B-ANAT
+transplantation	O
+.	O
+
+Blood	B-ANAT
+cultures	O
+are	O
+only	O
+positive	O
+in	O
+massive	O
+fungemia	B-DISO
+.	O
+
+A	O
+recurrent	O
+Candida	B-SPEC
+septicemia	B-DISO
+with	O
+prolonged	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+severe	O
+liver	B-DISO
+dysfunction	I-DISO
+in	O
+form	O
+of	O
+cholestatic	O
+hepatosis	B-DISO
+,	O
+that	O
+improved	O
+several	O
+times	O
+with	O
+antimycotic	O
+therapy	O
+in	O
+combination	O
+with	O
+evidence	O
+based	O
+intensive	O
+care	O
+measures	O
+and	O
+artificial	O
+organ	B-ANAT
+support	O
+is	O
+a	O
+comparatively	O
+rare	O
+event	O
+.	O
+
+We	O
+report	O
+about	O
+two	O
+cases	O
+of	O
+pulmonary	B-ANAT
+zygomycosis	B-DISO
+,	O
+caused	O
+by	O
+Rhizopus	B-SPEC
+spp	B-ENZY
+.:	O
+patient	O
+1	O
+,	O
+female	O
+73	O
+years	O
+old	O
+:	O
+Delayed	O
+clinical	O
+course	O
+according	O
+to	O
+hip	B-ANAT
+arthroplasty	O
+infection	B-DISO
+and	O
+infection	B-DISO
+of	O
+a	O
+femoropopliteal	O
+bypass	O
+of	O
+the	O
+right	O
+leg	O
+,	O
+eventually	O
+exarticulation	O
+of	O
+the	O
+right	B-ANAT
+hip	I-ANAT
+joint	I-ANAT
+,	O
+Pseudomonas	B-SPEC
+pneumonia	B-DISO
+,	O
+severe	B-DISO
+sepsis	I-DISO
+caused	O
+by	O
+staphylococci	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDs	B-DISO
+),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+multiple	O
+use	O
+of	O
+antibiotics	B-CHED
+.	O
+
+Patient	O
+2	O
+,	O
+male	O
+68	O
+years	O
+old	O
+:	O
+transplantation	O
+of	O
+kidney	B-ANAT
+in	O
+past	O
+medical	O
+history	O
+,	O
+presenting	O
+with	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+with	O
+quite	O
+a	O
+few	O
+infections	B-DISO
+before	O
+.	O
+
+In	O
+the	O
+sequel	O
+development	B-PROC
+of	O
+abscessing	O
+pneumonia	B-DISO
+on	O
+the	O
+right	O
+side	O
+with	O
+a	O
+pleural	B-DISO
+empyema	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Anaesthesia	B-DISO
+and	O
+prostate	B-ANAT
+surgery	O
+].	O
+
+Whether	O
+open	O
+transvesical	B-ANAT
+or	O
+transurethral	O
+prostatectomy	O
+for	O
+treatment	O
+of	O
+benign	O
+hypertrophy	B-DISO
+depends	O
+on	O
+the	O
+size	O
+of	O
+the	O
+gland	B-ANAT
+:	O
+transurethral	O
+resection	O
+is	O
+safe	O
+up	O
+to	O
+80	O
+g	O
+.	O
+Intrathecal	B-ANAT
+anaesthesia	B-DISO
+with	O
+a	O
+T9	O
+cephalad	O
+spread	O
+of	O
+sensory	O
+block	O
+,	O
+produces	O
+adequate	O
+conditions	O
+for	O
+transurethral	O
+prostatectomy	O
+and	O
+allows	O
+a	O
+rapid	O
+diagnosis	O
+of	O
+irrigating	O
+fluid	O
+absorption	O
+syndrome	B-DISO
+.	O
+
+In	O
+spite	O
+of	O
+recommended	O
+preoperative	O
+antibiotic	B-CHED
+prophylaxis	O
+,	O
+bacteriemias	O
+are	O
+frequent	O
+during	O
+transurethral	O
+prostate	B-ANAT
+resection	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+leader	O
+-	O
+body	B-ANAT
+fusion	O
+sites	O
+of	O
+each	O
+sgRNA	O
+showed	O
+that	O
+the	O
+junction	O
+sequences	O
+and	O
+the	O
+corresponding	O
+transcription	B-PROC
+-	O
+regulatory	O
+sequence	O
+(	O
+TRS	B-DISO
+)	O
+are	O
+unique	O
+for	O
+each	O
+species	B-SPEC
+of	O
+sgRNA	O
+and	O
+are	O
+consistent	O
+after	O
+virus	B-SPEC
+passages	O
+.	O
+
+Coexistence	O
+of	O
+both	O
+plus	O
+and	O
+minus	O
+strands	O
+of	O
+SARS	B-PRGE
+CoV	I-PRGE
+sgRNAs	I-PRGE
+and	O
+evidence	O
+for	O
+derivation	O
+of	O
+the	O
+sgRNA	O
+core	O
+sequence	O
+from	O
+the	O
+body	B-ANAT
+core	O
+sequence	O
+favor	O
+the	O
+model	O
+of	O
+discontinuous	O
+transcription	B-PROC
+during	O
+minus	O
+-	O
+strand	O
+synthesis	B-PROC
+.	O
+
+TITLE	O
+:	O
+Aged	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+as	O
+a	O
+model	O
+for	O
+increased	O
+severity	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+elderly	O
+humans	O
+.	O
+
+Over	O
+the	O
+past	O
+decade	O
+,	O
+the	O
+global	O
+effort	B-PROC
+to	O
+identify	O
+and	O
+characterize	O
+infectious	B-DISO
+agents	O
+,	O
+decipher	O
+the	O
+underlying	O
+pathways	B-PROC
+by	O
+which	O
+they	O
+cause	O
+disease	O
+,	O
+and	O
+develop	O
+preventive	O
+measures	O
+and	O
+treatments	O
+for	O
+many	O
+of	O
+the	O
+world	O
+'	O
+s	O
+most	O
+dangerous	O
+pathogens	O
+has	O
+resulted	O
+in	O
+considerable	O
+progress	O
+.	O
+
+A	O
+recombinant	O
+named	O
+pPROEX	O
+HTc	O
+-	O
+hp	O
+was	O
+constructed	O
+via	O
+inserting	O
+ORF7	O
+gene	O
+into	O
+prokaryotic	O
+expression	B-PROC
+vector	O
+pPROEX	O
+HTc	O
+.	O
+
+The	O
+recombinant	O
+was	O
+sequenced	O
+and	O
+compared	O
+the	O
+DNA	O
+and	O
+its	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+(	O
+aa	O
+)	O
+sequences	O
+with	O
+that	O
+of	O
+some	O
+reference	O
+strains	O
+after	O
+restriction	O
+endonuclease	O
+and	O
+PCR	O
+analysis	O
+.	O
+
+The	O
+sequences	O
+of	O
+hp	O
+gene	O
+and	O
+Hp	B-PRGE
+protein	I-PRGE
+share	O
+89	O
+%-	O
+97	O
+%	O
+and	O
+87	O
+%-	O
+96	O
+%	O
+homologous	O
+identities	O
+compared	O
+with	O
+11	O
+TGEV	B-SPEC
+reference	O
+strains	O
+derived	O
+from	O
+other	O
+regions	O
+or	O
+countries	O
+respectively	O
+,	O
+which	O
+revealed	O
+that	O
+there	O
+are	O
+significant	O
+variation	O
+within	O
+-	O
+strains	O
+,	O
+even	O
+though	O
+the	O
+ORF7	O
+region	O
+is	O
+relatively	O
+conservative	O
+.	O
+
+Anesthesia	B-DISO
+was	O
+applied	O
+with	O
+ketamine	B-CHED
+(	O
+50	O
+mg	O
+kg	O
+(-	O
+1	O
+)	O
+h	O
+(-	O
+1	O
+),	O
+i	O
+.	O
+m	O
+.)	O
+and	O
+tracheostomy	O
+was	O
+performed	O
+.	O
+
+dexamethasone	B-CHED
+.	O
+
+MDA	B-CHED
+levels	O
+of	O
+the	O
+plasma	B-ANAT
+,	O
+neutrophil	B-ANAT
+and	O
+platelet	B-ANAT
+counts	O
+,	O
+and	O
+arterial	B-ANAT
+blood	I-ANAT
+gases	O
+were	O
+recorded	O
+at	O
+the	O
+beginning	O
+of	O
+the	O
+study	O
+and	O
+then	O
+at	O
+two	O
+and	O
+five	O
+hours	O
+.	O
+
+TITLE	O
+:	O
+Critical	O
+assessment	O
+of	O
+important	O
+regions	O
+in	O
+the	O
+subunit	O
+association	O
+and	O
+catalytic	O
+action	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+main	O
+protease	O
+.	O
+
+However	O
+,	O
+the	O
+amino	B-PRGE
+acids	I-PRGE
+1	I-PRGE
+-	I-PRGE
+4	I-PRGE
+-	I-PRGE
+truncated	I-PRGE
+protease	I-PRGE
+showed	O
+the	O
+major	O
+form	O
+to	O
+be	O
+a	O
+monomer	O
+and	O
+had	O
+little	O
+enzyme	B-FUNC
+activity	I-FUNC
+.	O
+
+As	O
+early	O
+as	O
+30	O
+min	O
+post	O
+-	O
+entry	O
+into	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+,	O
+high	O
+-	O
+mannosylated	O
+S	O
+assembles	O
+into	O
+trimers	O
+prior	O
+to	O
+acquisition	O
+of	O
+complex	O
+N	B-CHED
+-	I-CHED
+glycans	I-CHED
+in	O
+the	O
+Golgi	B-COMP
+.	O
+
+A	O
+single	O
+inoculation	O
+with	O
+the	O
+RV	O
+-	O
+based	O
+vaccine	O
+expressing	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+induced	O
+a	O
+strong	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+neutralizing	I-PRGE
+antibody	B-FUNC
+response	I-PROC
+.	O
+
+Now	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+story	O
+has	O
+entered	O
+a	O
+new	O
+phase	O
+,	O
+a	O
+search	O
+for	O
+preventive	O
+strategies	O
+and	O
+a	O
+cure	O
+for	O
+the	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+)	O
+is	O
+an	O
+autoimmune	B-DISO
+disease	I-DISO
+associated	O
+with	O
+environmental	O
+factors	O
+,	O
+possibly	O
+including	O
+several	O
+viruses	B-SPEC
+such	O
+as	O
+the	O
+coronaviruses	O
+.	O
+
+Intracerebral	O
+infection	B-DISO
+of	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+with	O
+MHV	B-SPEC
+-	O
+A59	O
+revealed	O
+that	O
+viral	B-PROC
+replication	I-PROC
+was	O
+efficient	O
+and	O
+that	O
+clearance	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+occurred	O
+as	O
+soon	O
+as	O
+7	O
+days	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+Concordingly	O
+,	O
+an	O
+important	O
+activation	O
+of	O
+auto	O
+-	O
+reactive	O
+T	B-ANAT
+cells	I-ANAT
+specific	O
+to	O
+myelin	B-PRGE
+basic	I-PRGE
+protein	B-CHED
+was	O
+demonstrated	O
+.	O
+
+The	O
+primary	O
+determinant	O
+of	O
+the	O
+pantropism	O
+is	O
+the	O
+enhanced	O
+proteolytic	B-PROC
+cleavability	O
+of	O
+the	O
+fusion	O
+(	O
+F	O
+)	O
+protein	B-CHED
+of	O
+F1	O
+-	O
+R	O
+,	O
+which	O
+allows	O
+the	O
+virus	B-SPEC
+to	O
+undergo	O
+multiple	O
+rounds	O
+of	O
+replication	O
+in	O
+many	O
+different	O
+organs	B-ANAT
+,	O
+whereas	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+can	O
+only	O
+undergo	O
+multiple	O
+rounds	O
+of	O
+replication	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+),	O
+three	O
+N	O
+fragments	O
+(	O
+N1	O
+,	O
+N2	O
+,	O
+and	O
+N3	O
+)	O
+and	O
+the	O
+intraviral	O
+domain	O
+of	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+(	O
+M2	O
+)	O
+were	O
+cloned	O
+and	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+as	O
+histidine	B-CHED
+-	O
+tagged	O
+proteins	B-CHED
+.	O
+
+Both	O
+female	O
+sex	O
+and	O
+being	O
+a	O
+resident	O
+of	O
+Amoy	O
+Gardens	O
+Estate	O
+were	O
+associated	O
+with	O
+diarrhea	B-DISO
+.	O
+
+The	O
+CXR	O
+scores	O
+during	O
+the	O
+peak	O
+of	O
+diarrhea	B-DISO
+were	O
+not	O
+correlated	O
+with	O
+the	O
+maximum	O
+frequency	O
+of	O
+diarrhea	B-DISO
+(	O
+r	O
+=	O
+-	O
+0	O
+.	O
+09	O
+,	O
+P	O
+=	O
+0	O
+.	O
+5	O
+).	O
+
+Fever	B-PROC
+(>	O
+38	O
+degrees	O
+C	O
+)	O
+was	O
+the	O
+earliest	O
+symptom	B-DISO
+(	O
+50	O
+/	O
+53	O
+SARS	B-DISO
+vs	O
+.	O
+5	O
+/	O
+31	O
+non	O
+-	O
+SARS	B-DISO
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+preceding	O
+cough	B-DISO
+by	O
+a	O
+mean	O
+of	O
+4	O
+.	O
+5	O
+days	O
+.	O
+
+Initial	O
+lymphopenia	O
+,	O
+thrombocytopenia	O
+,	O
+and	O
+elevated	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+were	O
+all	O
+more	O
+common	O
+in	O
+SARS	B-DISO
+than	O
+non	O
+-	O
+SARS	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Western	O
+blot	O
+assay	O
+further	O
+demonstrated	O
+the	O
+specificity	O
+of	O
+the	O
+induced	O
+serum	B-COMP
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+studied	O
+the	O
+adjuvanticity	B-PROC
+of	O
+recombinant	B-PRGE
+Onchocerca	I-PRGE
+volvulus	I-PRGE
+activation	I-PRGE
+associated	I-PRGE
+protein	B-CHED
+-	I-PRGE
+1	I-PRGE
+(	O
+rOv	B-PRGE
+-	I-PRGE
+ASP	I-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+for	O
+ovalbumin	B-PRGE
+(	O
+OVA	B-PRGE
+)	O
+in	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Mannose	B-CHED
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+),	O
+a	O
+key	O
+molecule	O
+in	O
+innate	B-PROC
+immunity	I-PROC
+,	O
+functions	O
+as	O
+an	O
+ante	O
+-	O
+antibody	B-COMP
+before	O
+the	O
+specific	O
+antibody	B-PROC
+response	I-PROC
+.	O
+
+Inhibition	B-PROC
+of	O
+the	O
+infectivity	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+by	O
+MBL	O
+in	O
+fetal	B-ANAT
+rhesus	O
+kidney	B-ANAT
+cells	B-COMP
+(	O
+FRhK	O
+-	O
+4	O
+)	O
+was	O
+also	O
+observed	O
+.	O
+
+IBV	B-SPEC
+was	O
+inactivated	O
+upon	O
+contact	O
+with	O
+the	O
+FTA	O
+,	O
+as	O
+shown	O
+by	O
+the	O
+inability	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+be	O
+propagated	O
+in	O
+embryonating	O
+chicken	B-SPEC
+eggs	O
+.	O
+
+RT	O
+-	O
+PCR	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+showed	O
+that	O
+viral	O
+RNA	O
+in	O
+allantoic	B-ANAT
+fluid	I-ANAT
+remained	O
+stable	O
+after	O
+storage	B-PROC
+on	O
+FTA	O
+filter	O
+cards	O
+and	O
+that	O
+the	O
+stability	O
+was	O
+time	O
+and	O
+temperature	O
+sensitive	O
+for	O
+the	O
+large	O
+(	O
+1700	O
+base	B-FUNC
+pair	I-FUNC
+[	O
+bp	O
+])	O
+but	O
+not	O
+the	O
+small	O
+(	O
+383	O
+bp	O
+)	O
+PCR	O
+products	O
+.	O
+
+Cloacal	B-ANAT
+swabs	O
+and	O
+intestinal	B-ANAT
+samples	O
+were	O
+obtained	O
+at	O
+1	O
+,	O
+2	O
+,	O
+3	O
+,	O
+4	O
+,	O
+6	O
+,	O
+9	O
+,	O
+14	O
+,	O
+17	O
+,	O
+and	O
+21	O
+days	O
+after	O
+inoculation	O
+,	O
+processed	O
+,	O
+and	O
+tested	O
+for	O
+virus	B-SPEC
+detection	O
+by	O
+RRT	O
+-	O
+PCR	O
+Cloacal	B-ANAT
+swabs	O
+from	O
+TAstV	O
+-	O
+2	O
+-	O
+and	O
+TCV	B-SPEC
+-	O
+infected	O
+poults	O
+were	O
+shown	O
+to	O
+have	O
+sensitivity	O
+for	O
+virus	B-SPEC
+detection	O
+similar	O
+to	O
+that	O
+of	O
+intestinal	B-ANAT
+samples	O
+when	O
+compared	O
+directly	O
+.	O
+
+Cleavage	B-PROC
+products	O
+were	O
+visualized	O
+by	O
+agarose	B-CHED
+gel	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+,	O
+purification	O
+,	O
+and	O
+characterization	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+RNA	B-PATH
+polymerase	I-PATH
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+RNA	O
+-	O
+dependent	O
+RNA	O
+polymerase	O
+(	O
+RdRp	B-FUNC
+)	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+essential	O
+for	O
+viral	B-PROC
+replication	I-PROC
+and	O
+a	O
+potential	O
+target	O
+for	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Cells	B-ANAT
+of	O
+human	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+CD13	B-PRGE
+)	O
+transgenic	B-SPEC
+mice	I-SPEC
+are	O
+infected	O
+by	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+229E	O
+in	O
+vitro	O
+,	O
+but	O
+not	O
+in	O
+vivo	O
+.	O
+
+hAPN	O
+-	O
+transgenic	B-SPEC
+mice	I-SPEC
+expressed	B-PROC
+hAPN	B-PRGE
+mRNA	I-PRGE
+in	O
+the	O
+kidney	B-ANAT
+,	O
+small	B-ANAT
+intestine	I-ANAT
+,	O
+liver	B-ANAT
+,	O
+and	O
+lung	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Central	O
+ions	B-CHED
+and	O
+lateral	O
+asparagine	B-CHED
+/	O
+glutamine	B-CHED
+zippers	O
+stabilize	O
+the	O
+post	O
+-	O
+fusion	O
+hairpin	O
+conformation	O
+of	O
+the	O
+SARS	O
+coronavirus	B-SPEC
+spike	O
+glycoprotein	B-CHED
+.	O
+
+The	O
+swabs	O
+were	O
+examined	O
+by	O
+virus	B-SPEC
+culture	O
+and	O
+PCR	O
+for	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+,	O
+canine	B-SPEC
+adenovirus	I-SPEC
+,	O
+canine	B-SPEC
+herpesvirus	I-SPEC
+(	O
+CHV	O
+)	O
+and	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+).	O
+
+By	O
+PCR	O
+three	O
+dogs	B-SPEC
+were	O
+found	O
+positive	O
+for	O
+CRCoV	O
+in	O
+one	O
+kennel	O
+whereas	O
+all	O
+PCR	O
+tests	O
+for	O
+other	O
+viruses	B-SPEC
+were	O
+negative	O
+for	O
+both	O
+kennels	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+detect	O
+the	O
+RNA	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+by	O
+using	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+targeted	B-PROC
+for	O
+a	O
+two	O
+loci	O
+and	O
+a	O
+modified	O
+nested	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+as	O
+to	O
+improving	O
+the	O
+reliability	O
+and	O
+sensitivity	O
+of	O
+tests	O
+.	O
+
+It	O
+might	O
+improve	O
+the	O
+reliability	O
+of	O
+test	O
+by	O
+employing	O
+RT	O
+-	O
+PCR	O
+targeted	B-PROC
+for	O
+two	O
+or	O
+more	O
+fragments	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+.	O
+
+RESULTS	O
+:	O
+Two	O
+positives	O
+were	O
+found	O
+in	O
+the	O
+3	O
+SARS	B-DISO
+probable	O
+patients	O
+,	O
+and	O
+none	O
+positive	O
+in	O
+4	O
+SARS	B-DISO
+suspect	O
+patients	O
+and	O
+other	O
+27	O
+patients	O
+with	O
+fever	B-PROC
+,	O
+using	O
+the	O
+nested	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Of	O
+42	O
+patients	O
+with	O
+cystic	O
+or	O
+/	O
+and	O
+urethral	B-ANAT
+injury	O
+,	O
+35	O
+underwent	O
+cystostomy	O
+and	O
+delayed	O
+reconstruction	O
+,	O
+and	O
+7	O
+received	O
+a	O
+primary	O
+realignment	O
+.	O
+
+Furthermore	O
+,	O
+in	O
+the	O
+presence	O
+of	O
+the	O
+targeting	B-PROC
+antibody	B-COMP
+,	O
+infected	O
+cancer	B-ANAT
+cells	B-COMP
+formed	O
+syncytia	B-ANAT
+typical	O
+of	O
+productive	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemic	O
+in	O
+Taiwan	O
+,	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+Taiwan	O
+,	O
+since	O
+the	O
+first	O
+case	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+was	O
+identified	O
+on	O
+February	O
+25	O
+,	O
+2003	O
+,	O
+a	O
+total	O
+of	O
+3032	O
+cases	O
+of	O
+suspected	O
+or	O
+probable	O
+SARS	B-DISO
+were	O
+reported	O
+prior	O
+to	O
+July	O
+5	O
+,	O
+2003	O
+.	O
+
+These	O
+antibodies	B-COMP
+potently	O
+neutralize	O
+infectious	B-DISO
+virus	B-SPEC
+in	O
+tissue	B-ANAT
+cultures	O
+and	O
+animal	B-SPEC
+models	O
+,	O
+and	O
+,	O
+alone	O
+or	O
+in	O
+combination	O
+with	O
+vaccines	O
+and	O
+other	O
+drugs	O
+,	O
+may	O
+have	O
+potential	O
+for	O
+the	O
+prevention	O
+and	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+Of	O
+the	O
+1191	O
+unique	O
+genes	O
+represented	O
+on	O
+the	O
+array	O
+,	O
+the	O
+expression	B-PROC
+of	O
+a	O
+total	O
+of	O
+327	O
+genes	O
+(	O
+27	O
+%	O
+of	O
+total	O
+)	O
+were	O
+altered	O
+by	O
+two	O
+-	O
+fold	O
+or	O
+more	O
+from	O
+6	O
+through	O
+72	O
+h	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+They	O
+received	O
+standard	O
+antimicrobial	B-CHED
+therapy	O
+and	O
+extensive	O
+supportive	O
+therapy	O
+as	O
+required	O
+.	O
+
+The	O
+determinants	O
+of	O
+health	O
+-	O
+be	O
+they	O
+a	O
+SARS	B-DISO
+virus	B-SPEC
+or	O
+a	O
+predilection	O
+for	O
+fatty	O
+foods	O
+-	O
+have	O
+joined	O
+us	O
+in	O
+our	O
+global	O
+mobility	O
+.	O
+
+The	O
+RT	O
+-	O
+PCR	O
+multiplex	O
+1	O
+and	O
+the	O
+hemi	O
+-	O
+nested	O
+multiplex	O
+1	O
+detected	O
+1	O
+and	O
+0	O
+.	O
+1	O
+TCID50	O
+of	O
+RSV	B-PRGE
+A	I-PRGE
+,	O
+respectively	O
+,	O
+and	O
+0	O
+.	O
+01	O
+and	O
+0	O
+.	O
+001	O
+TCID50	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+/	O
+H3N2	B-CHED
+,	O
+respectively	O
+.	O
+
+Carcasses	O
+were	O
+stored	O
+in	O
+a	O
+cold	B-DISO
+room	O
+at	O
+4	O
+degrees	O
+C	O
+.	O
+After	O
+1	O
+,	O
+3	O
+,	O
+6	O
+,	O
+9	O
+,	O
+12	O
+or	O
+24	O
+h	O
+of	O
+storage	B-PROC
+,	O
+necropsies	O
+were	O
+carried	O
+out	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+inactivation	B-DISO
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+wastewater	O
+with	O
+sodium	O
+hypochlorite	B-CHED
+and	O
+chlorine	B-CHED
+dioxide	I-CHED
+was	O
+also	O
+studied	O
+.	O
+
+Free	O
+chlorine	B-CHED
+was	O
+found	O
+to	O
+inactivate	O
+SARS	B-DISO
+-	O
+CoV	O
+better	O
+than	O
+chlorine	B-CHED
+dioxide	I-CHED
+.	O
+
+TITLE	O
+:	O
+Sumoylation	B-PROC
+of	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Similar	O
+to	O
+other	O
+coronavirus	B-SPEC
+N	O
+proteins	B-CHED
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+is	O
+predicted	O
+to	O
+be	O
+phosphorylated	O
+and	O
+may	O
+contain	O
+nuclear	O
+localization	B-PROC
+signals	O
+,	O
+serine	B-CHED
+/	O
+arginine	B-CHED
+-	O
+rich	O
+motif	O
+,	O
+RNA	B-FUNC
+binding	I-FUNC
+domain	O
+and	O
+regions	O
+responsible	O
+for	O
+self	O
+-	O
+association	O
+and	O
+homo	B-SPEC
+-	O
+oligomerization	O
+.	O
+
+The	O
+expression	B-PROC
+vector	O
+of	O
+this	O
+siRNA	O
+was	O
+constructed	O
+and	O
+confirmed	O
+to	O
+reduce	O
+N	O
+and	O
+EGFP	O
+expression	B-PROC
+efficiently	O
+in	O
+both	O
+cultured	B-ANAT
+cells	I-ANAT
+and	O
+adult	O
+mouse	B-SPEC
+muscles	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Spectrum	O
+of	O
+antiviral	B-CHED
+activity	O
+of	O
+o	O
+-(	O
+acetoxyphenyl	O
+)	O
+hept	B-CHED
+-	O
+2	O
+-	O
+ynyl	O
+sulphide	B-CHED
+(	O
+APHS	O
+).	O
+
+ABSTRACT	O
+:	O
+After	O
+decades	O
+of	O
+neglect	O
+,	O
+the	O
+resurgence	O
+of	O
+tuberculosis	O
+in	O
+the	O
+United	O
+States	O
+between	O
+1985	O
+and	O
+1992	O
+renewed	O
+interest	O
+in	O
+the	O
+use	O
+of	O
+upper	O
+room	O
+ultraviolet	O
+germicidal	O
+irradiation	O
+to	O
+interrupt	O
+the	O
+transmission	O
+of	O
+airborne	O
+infections	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+recombinant	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+was	O
+shown	O
+to	O
+be	O
+dimeric	O
+by	O
+analytical	O
+ultracentrifugation	O
+,	O
+size	O
+exclusion	O
+chromatography	O
+coupled	O
+with	O
+light	O
+scattering	O
+,	O
+and	O
+chemical	O
+cross	O
+-	O
+linking	O
+.	O
+
+Treatment	O
+with	O
+steroids	B-CHED
+,	O
+chemotherapy	O
+,	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+),	O
+or	O
+imatinib	B-CHED
+-	O
+mesylate	O
+may	O
+improve	O
+the	O
+prognosis	O
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+young	O
+male	O
+patient	O
+with	O
+a	O
+six	O
+-	O
+year	O
+history	O
+of	O
+HES	B-DISO
+and	O
+severe	O
+heart	B-ANAT
+involvement	O
+who	O
+,	O
+after	O
+unsuccessful	O
+treatment	O
+attempts	O
+with	O
+steroids	B-CHED
+,	O
+hydroxyurea	B-CHED
+and	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+had	O
+a	O
+prompt	O
+,	O
+clinical	O
+and	O
+hematological	O
+complete	O
+remission	B-DISO
+following	O
+administration	O
+of	O
+imatinib	B-CHED
+.	O
+
+As	O
+his	O
+cardiac	B-PROC
+function	I-PROC
+also	O
+markedly	O
+improved	O
+,	O
+he	O
+was	O
+considered	O
+for	O
+heart	B-ANAT
+transplant	B-ANAT
+.	O
+
+However	O
+,	O
+seven	O
+years	O
+after	O
+the	O
+onset	O
+of	O
+the	O
+disease	O
+and	O
+four	O
+months	O
+after	O
+the	O
+termination	O
+of	O
+imatinib	B-CHED
+treatment	O
+the	O
+patient	O
+died	B-PROC
+of	O
+a	O
+cerebral	B-DISO
+hemorrhage	I-DISO
+that	O
+occurred	O
+during	O
+an	O
+episode	O
+of	O
+acute	O
+respiratory	O
+sepsis	O
+.	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+RANTES	B-PRGE
+with	O
+the	O
+replication	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+in	O
+THP	O
+-	O
+1	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+novel	O
+infectious	B-DISO
+disease	I-DISO
+which	O
+is	O
+characterized	O
+by	O
+an	O
+overaggressive	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+Chemokines	O
+are	O
+important	O
+inflammatory	O
+mediators	O
+and	O
+regulate	O
+disease	O
+due	O
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Macrophages	B-ANAT
+,	O
+induced	O
+by	O
+THP	B-CHED
+-	O
+1	O
+cells	B-COMP
+,	O
+were	O
+used	O
+as	O
+cell	B-COMP
+model	O
+.	O
+
+RANTES	B-PRGE
+itself	O
+could	O
+inhibit	O
+the	O
+replication	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+THP	B-CHED
+-	O
+1	O
+cells	B-COMP
+when	O
+it	O
+was	O
+added	O
+into	O
+the	O
+culture	O
+before	O
+or	O
+at	O
+the	O
+same	O
+time	O
+with	O
+the	O
+virus	B-SPEC
+;	O
+No	O
+inhibition	B-PROC
+effect	O
+was	O
+shown	O
+when	O
+RANTES	O
+were	O
+added	O
+into	O
+the	O
+culture	O
+after	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+the	O
+cells	B-COMP
+.	O
+
+Especially	O
+,	O
+it	O
+is	O
+useful	O
+for	O
+the	O
+planning	O
+of	O
+the	O
+outbreaks	O
+of	O
+emerging	O
+diseases	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+or	O
+for	O
+bioterrorism	O
+attacks	O
+involving	O
+such	O
+diseases	O
+as	O
+smallpox	B-DISO
+.	O
+
+In	O
+further	O
+research	O
+,	O
+we	O
+will	O
+have	O
+to	O
+take	O
+into	O
+account	O
+the	O
+population	O
+people	O
+vaccinated	O
+of	O
+for	O
+smallpox	B-DISO
+,	O
+who	O
+account	O
+for	O
+about	O
+70	O
+%	O
+of	O
+the	O
+total	O
+population	O
+in	O
+Japan	O
+.	O
+
+RESULTS	O
+:	O
+Most	O
+episodes	O
+occurred	O
+during	O
+vaso	O
+-	O
+occlusive	O
+crisis	O
+,	O
+which	O
+was	O
+associated	O
+with	O
+a	O
+severe	B-DISO
+pain	I-DISO
+event	O
+.	O
+
+When	O
+80R	B-PRGE
+IgG1	I-PRGE
+was	O
+given	O
+prophylactically	O
+to	O
+mice	B-SPEC
+at	O
+doses	O
+therapeutically	O
+achievable	O
+in	O
+humans	B-SPEC
+,	O
+viral	B-PROC
+replication	I-PROC
+was	O
+reduced	O
+by	O
+more	O
+than	O
+4	O
+orders	O
+of	O
+magnitude	O
+to	O
+below	O
+assay	O
+limits	O
+.	O
+
+Amino	B-CHED
+acids	I-CHED
+critical	O
+for	O
+80R	O
+binding	B-FUNC
+were	O
+identified	O
+.	O
+
+We	O
+propose	O
+that	O
+by	O
+establishing	O
+the	O
+susceptibility	O
+and	O
+resistance	B-PROC
+profiles	O
+of	O
+newly	O
+emerging	O
+SARS	B-DISO
+-	O
+CoVs	O
+through	O
+early	O
+S1	O
+genotyping	O
+of	O
+the	O
+core	O
+180	O
+-	O
+amino	O
+-	O
+acid	O
+neutralizing	O
+epitope	B-CHED
+of	O
+80R	O
+,	O
+an	O
+effective	O
+immunoprophylaxis	O
+strategy	O
+with	O
+80R	O
+should	O
+be	O
+possible	O
+in	O
+an	O
+outbreak	O
+setting	O
+.	O
+
+Our	O
+study	O
+also	O
+cautions	O
+that	O
+for	O
+any	O
+prophylaxis	O
+strategy	O
+based	O
+on	O
+neutralizing	O
+antibody	B-PROC
+responses	I-PROC
+,	O
+whether	O
+by	O
+passive	O
+or	O
+active	O
+immunization	O
+,	O
+a	O
+genotyping	O
+monitor	O
+will	O
+be	O
+necessary	O
+for	O
+effective	O
+use	O
+.	O
+
+These	O
+results	O
+show	O
+that	O
+microglia	B-ANAT
+express	O
+functional	O
+MHVR	O
+that	O
+mediates	O
+JHMV	O
+infection	B-DISO
+.	O
+
+IBV	B-PRGE
+3a	I-PRGE
+protein	B-CHED
+is	O
+expressed	B-PROC
+in	O
+infected	O
+cells	B-COMP
+but	O
+is	O
+not	O
+detected	O
+in	O
+virions	B-COMP
+.	O
+
+These	O
+puncta	O
+did	O
+not	O
+overlap	O
+cellular	B-COMP
+organelles	B-COMP
+or	O
+other	O
+punctate	O
+structures	O
+.	O
+
+TITLE	O
+:	O
+Immunological	O
+detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+by	O
+monoclonal	O
+antibodies	B-COMP
+.	O
+
+The	O
+substance	O
+also	O
+inhibits	O
+aldehyde	B-PRGE
+dehydrogenase	I-PRGE
+and	O
+can	O
+produce	O
+acetaldehyde	B-CHED
+syndrome	B-DISO
+(	O
+e	O
+.	O
+g	O
+.,	O
+vomiting	B-DISO
+,	O
+parasympathetic	O
+hyperactivity	O
+,	O
+dyspnea	B-DISO
+,	O
+hypotension	O
+,	O
+and	O
+confusion	B-DISO
+)	O
+when	O
+exposure	O
+coincides	O
+with	O
+alcohol	O
+use	O
+.	O
+
+After	O
+Dormex	O
+(	O
+Degussa	O
+AG	O
+,	O
+Trostberg	O
+,	O
+Germany	O
+),	O
+a	O
+pesticide	B-CHED
+product	O
+containing	O
+hydrogen	B-CHED
+cyanamide	B-CHED
+(	O
+49	O
+%	O
+by	O
+weight	O
+),	O
+was	O
+introduced	O
+in	O
+Italy	O
+in	O
+2000	O
+,	O
+a	O
+total	O
+of	O
+23	O
+cases	O
+of	O
+acute	O
+illness	O
+associated	O
+with	O
+exposure	O
+to	O
+this	O
+chemical	O
+were	O
+identified	O
+in	O
+early	O
+2001	O
+.	O
+
+This	O
+led	O
+to	O
+a	O
+temporary	O
+suspension	O
+of	O
+sales	B-CHED
+and	O
+usage	O
+of	O
+Dormex	O
+on	O
+February	O
+23	O
+,	O
+2002	O
+,	O
+and	O
+strengthening	O
+of	O
+protective	O
+measures	O
+,	O
+as	O
+specified	O
+on	O
+the	O
+pesticide	O
+label	B-CHED
+when	O
+sales	B-CHED
+were	O
+resumed	O
+on	O
+June	O
+20	O
+,	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+relationship	O
+between	O
+ambient	O
+air	O
+pollution	O
+and	O
+daily	O
+mortality	O
+of	O
+SARS	B-DISO
+in	O
+Beijing	O
+.	O
+
+An	O
+increase	O
+of	O
+each	O
+10	O
+microg	O
+/	O
+m3	O
+over	O
+a	O
+5	O
+-	O
+day	O
+moving	B-PROC
+average	O
+of	O
+PM10	O
+,	O
+SO2	B-CHED
+and	O
+NO2	B-CHED
+corresponded	O
+to	O
+1	O
+.	O
+06	O
+(	O
+1	O
+.	O
+00	O
+-	O
+1	O
+.	O
+12	O
+),	O
+0	O
+.	O
+74	O
+(	O
+0	O
+.	O
+48	O
+-	O
+1	O
+.	O
+13	O
+)	O
+and	O
+1	O
+.	O
+22	O
+(	O
+1	O
+.	O
+01	O
+-	O
+1	O
+.	O
+48	O
+)	O
+relative	O
+risks	O
+(	O
+RRs	B-DISO
+)	O
+of	O
+daily	O
+SARS	B-DISO
+mortality	O
+,	O
+respectively	O
+.	O
+
+Heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoprotein	I-PRGE
+A1	I-PRGE
+(	O
+hnRNP	B-PRGE
+A1	I-PRGE
+)	O
+is	O
+related	O
+to	O
+the	O
+pre	B-PROC
+-	I-PROC
+mRNA	I-PROC
+splicing	I-PROC
+in	O
+the	O
+nucleus	B-COMP
+and	O
+translation	B-PROC
+regulation	B-PROC
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+Moreover	O
+,	O
+kinetic	O
+analyses	O
+by	O
+surface	O
+plasmon	O
+resonance	O
+(	O
+SPR	O
+)	O
+technology	O
+revealed	O
+that	O
+SARS_N	O
+protein	O
+has	O
+a	O
+specific	O
+binding	B-FUNC
+affinity	O
+against	O
+human	B-PRGE
+hnRNP	B-ANAT
+A1	I-PRGE
+with	O
+K	O
+(	O
+D	O
+)	O
+at	O
+0	O
+.	O
+35	O
++/-	O
+
+It	O
+is	O
+suggested	O
+that	O
+both	O
+SARS_N	O
+and	O
+hnRNP	B-PRGE
+A1	I-PRGE
+proteins	B-CHED
+are	O
+possibly	O
+within	O
+the	O
+SARS_CoV	O
+replication	O
+/	O
+transcription	B-PROC
+complex	O
+and	O
+SARS_N	O
+/	O
+human	B-PRGE
+hnRNP	B-ANAT
+A1	I-PRGE
+interaction	O
+might	O
+function	O
+in	O
+the	O
+regulation	B-PROC
+of	O
+SARS_CoV	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+in	O
+Singapore	O
+:	O
+surveillance	O
+strategies	O
+in	O
+a	O
+globalising	O
+city	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+the	O
+IgG	B-PRGE
+ELISA	I-PRGE
+using	I-PRGE
+whole	I-PRGE
+virus	I-PRGE
+antigen	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+a	O
+high	O
+sensitivity	O
+and	O
+specificity	O
+in	O
+detecting	O
+SARS	B-DISO
+IgG	B-PRGE
+antibodies	I-PRGE
+.	O
+
+Expression	B-PROC
+levels	O
+for	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+and	O
+CXCL10	B-PRGE
+consistently	O
+peaked	O
+within	O
+4	O
+days	O
+of	O
+peak	O
+viral	O
+load	O
+.	O
+
+The	O
+recombinant	O
+plasmid	O
+pET30a	O
+(+)-	O
+nsp13	O
+was	O
+confirmed	O
+by	O
+restriction	O
+enzymes	O
+and	O
+sequencing	O
+analysis	O
+,	O
+and	O
+transformed	O
+into	O
+Escherichia	B-SPEC
+coli	I-SPEC
+BL21	B-ANAT
+(	O
+DE3	O
+).	O
+
+The	O
+His	O
+-	O
+tag	B-DISO
+-	O
+fused	O
+protein	B-CHED
+was	O
+expressed	B-PROC
+by	O
+induction	O
+of	O
+0	O
+.	O
+5mM	O
+IPTG	B-CHED
+and	O
+purified	O
+by	O
+a	O
+single	O
+Ni	O
+(	O
+2	O
++)	O
+affinity	O
+chromatography	O
+.	O
+
+TITLE	O
+:	O
+Preparedness	O
+of	O
+the	O
+cardiac	B-ANAT
+catheterization	O
+laboratory	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	O
+)	O
+and	O
+other	O
+epidemics	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+that	O
+has	O
+led	O
+to	O
+large	O
+hospital	O
+and	O
+community	O
+outbreaks	O
+,	O
+necessitating	O
+stringent	O
+infection	B-DISO
+control	O
+in	O
+its	O
+management	O
+.	O
+
+Among	O
+90	O
+SARS	B-DISO
+patients	O
+in	O
+our	O
+institution	O
+in	O
+the	O
+2003	O
+outbreak	O
+,	O
+2	O
+underwent	O
+cardiac	B-ANAT
+catheterization	O
+.	O
+
+Using	O
+this	O
+assay	O
+,	O
+we	O
+also	O
+detected	O
+an	O
+apparently	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+related	O
+coronavirus	B-SPEC
+in	O
+the	O
+throat	B-ANAT
+swab	I-ANAT
+specimens	O
+from	O
+masked	B-SPEC
+palm	I-SPEC
+civets	I-SPEC
+in	O
+the	O
+west	O
+part	O
+of	O
+Hubei	O
+Province	O
+,	O
+People	O
+'	O
+s	O
+Republic	O
+of	O
+China	O
+.	O
+
+It	O
+could	O
+be	O
+an	O
+alternative	O
+for	O
+early	O
+and	O
+rapid	O
+diagnosis	O
+,	O
+should	O
+SARS	B-DISO
+return	O
+in	O
+the	O
+future	O
+.	O
+
+Granulomatous	O
+phlebitis	B-DISO
+at	O
+different	O
+stages	O
+of	O
+development	B-PROC
+was	O
+observed	O
+.	O
+
+In	O
+June	O
+2003	O
+she	O
+was	O
+referred	O
+to	O
+our	O
+department	O
+,	O
+presenting	O
+symptoms	B-DISO
+and	I-DISO
+signs	I-DISO
+of	O
+ileus	B-DISO
+.	O
+
+Hemodynamic	B-PROC
+stabilization	O
+and	O
+resuscitation	O
+required	O
+low	O
+doses	O
+of	O
+epinephrine	B-CHED
+,	O
+diuretics	B-CHED
+,	O
+and	O
+a	O
+high	O
+concentration	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+in	O
+combination	O
+with	O
+bronchodilators	O
+.	O
+
+TRALI	B-DISO
+syndrome	B-DISO
+is	O
+an	O
+immune	O
+-	O
+mediated	O
+transfusion	B-DISO
+reaction	I-DISO
+which	O
+can	O
+cause	O
+severe	O
+complications	O
+or	O
+even	O
+death	B-PROC
+.	O
+
+However	O
+,	O
+only	O
+in	O
+three	O
+samples	O
+were	O
+significant	O
+TGEV	B-SPEC
+concentrations	O
+demonstrated	O
+.	O
+
+The	O
+results	O
+suggest	O
+(	O
+1	O
+)	O
+that	O
+anti	O
+-	O
+S	O
+and	O
+anti	O
+-	O
+N	O
+antibodies	B-COMP
+are	O
+diagnostic	O
+markers	O
+and	O
+in	O
+particular	O
+that	O
+S3	O
+is	O
+immunogenic	O
+and	O
+therefore	O
+is	O
+a	O
+good	O
+candidate	O
+as	O
+a	O
+subunit	O
+vaccine	O
+antigen	B-CHED
+;	O
+and	O
+(	O
+2	O
+)	O
+that	O
+,	O
+from	O
+a	O
+virus	B-ANAT
+structure	I-ANAT
+viewpoint	O
+,	O
+the	O
+presence	O
+in	O
+some	O
+human	B-SPEC
+sera	B-COMP
+of	O
+antibodies	B-COMP
+reacting	O
+with	O
+two	O
+recombinant	O
+polypeptides	B-CHED
+,	O
+3a	O
+and	O
+9b	O
+,	O
+supports	O
+the	O
+hypothesis	O
+that	O
+they	O
+are	O
+synthesized	O
+during	O
+the	O
+virus	B-SPEC
+cycle	O
+.	O
+
+He	O
+evolved	O
+with	O
+findings	O
+suggestive	O
+of	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+,	O
+with	O
+electrocardiographic	O
+and	O
+enzymatic	O
+alterations	O
+compatible	O
+with	O
+that	O
+diagnosis	O
+.	O
+
+TITLE	O
+:	O
+High	O
+prevalence	O
+of	O
+gastroesophageal	B-DISO
+reflux	I-DISO
+in	O
+children	O
+after	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+Gastroesophageal	B-DISO
+reflux	I-DISO
+disease	I-DISO
+(	O
+GERD	B-DISO
+)	O
+may	O
+be	O
+a	O
+contributing	O
+factor	O
+for	O
+the	O
+development	B-PROC
+of	O
+BOS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+immunosenescence	B-DISO
+:	O
+is	O
+it	O
+infectious	B-DISO
+?	O
+
+ABSTRACT	O
+:	O
+Morbidity	O
+and	O
+mortality	O
+due	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+is	O
+greater	O
+in	O
+the	O
+elderly	O
+than	O
+in	O
+the	O
+young	O
+,	O
+at	O
+least	O
+partly	O
+because	O
+of	O
+age	O
+-	O
+associated	O
+decreased	O
+immune	O
+competence	O
+,	O
+which	O
+renders	O
+individuals	O
+more	O
+susceptible	O
+to	O
+pathogens	O
+.	O
+
+These	O
+findings	O
+support	O
+our	O
+hypothesis	O
+that	O
+the	O
+manner	O
+in	O
+which	O
+CMV	B-SPEC
+and	O
+the	O
+host	B-COMP
+immune	B-ANAT
+system	I-ANAT
+interact	O
+is	O
+critical	O
+in	O
+determining	O
+the	O
+IRP	B-PRGE
+and	O
+hence	O
+is	O
+predictive	O
+of	O
+mortality	O
+.	O
+
+In	O
+this	O
+sense	B-PROC
+,	O
+then	O
+,	O
+we	O
+suggest	O
+that	O
+immunosenescence	B-DISO
+is	O
+contagious	O
+.	O
+
+TITLE	O
+:	O
+Mutational	O
+and	O
+inhibitive	O
+analysis	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+by	O
+fluorescence	O
+resonance	O
+energy	O
+transfer	O
+-	O
+based	O
+assays	O
+.	O
+
+Computational	O
+analyses	O
+of	O
+the	O
+frameshift	B-DISO
+signal	O
+predicted	O
+the	O
+presence	O
+of	O
+an	O
+mRNA	B-CHED
+pseudoknot	O
+containing	O
+three	O
+double	O
+-	O
+stranded	O
+RNA	O
+stem	B-ANAT
+structures	O
+rather	O
+than	O
+two	O
+.	O
+
+Though	O
+the	O
+presence	O
+of	O
+the	O
+three	O
+-	O
+stemmed	O
+structure	O
+is	O
+supported	O
+by	O
+nuclease	O
+mapping	O
+and	O
+two	O
+-	O
+dimensional	O
+nuclear	O
+magnetic	O
+resonance	O
+studies	O
+,	O
+our	O
+findings	O
+suggest	O
+that	O
+interactions	O
+between	O
+the	O
+stem	B-ANAT
+structures	O
+may	O
+result	O
+in	O
+local	O
+distortions	B-DISO
+in	O
+the	O
+A	O
+-	O
+form	O
+RNA	O
+.	O
+
+TITLE	O
+:	O
+Monoclonal	O
+antibodies	B-COMP
+to	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+):	O
+identification	O
+of	O
+neutralizing	O
+and	O
+antibodies	O
+reactive	O
+to	O
+S	O
+,	O
+N	O
+,	O
+M	O
+and	O
+E	O
+viral	O
+proteins	B-CHED
+.	O
+
+Five	O
+mAbs	O
+reacted	O
+against	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+two	O
+against	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+,	O
+and	O
+one	O
+each	O
+against	O
+the	O
+N	O
+and	O
+E	O
+proteins	B-CHED
+.	O
+
+While	O
+two	O
+of	O
+the	O
+three	O
+non	O
+-	O
+neutralizing	O
+antibodies	B-COMP
+recognized	O
+at	O
+second	O
+epitope	B-CHED
+within	O
+amino	B-CHED
+acids	I-CHED
+270	O
+-	O
+350	O
+.	O
+
+Four	O
+of	O
+these	O
+extracts	O
+showed	O
+moderate	O
+to	O
+potent	O
+antiviral	B-CHED
+activities	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+with	O
+50	O
+%	O
+effective	O
+concentration	O
+(	O
+EC50	O
+)	O
+ranging	O
+from	O
+2	O
+.	O
+4	O
++/-	O
+
+The	O
+results	O
+suggested	O
+that	O
+four	O
+herbal	O
+extracts	O
+and	O
+the	O
+compound	O
+lycorine	B-CHED
+are	O
+candidates	O
+for	O
+the	O
+development	B-PROC
+of	O
+new	O
+anti	O
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+drugs	O
+in	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+confirmed	O
+as	O
+the	O
+pathogen	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+HRCT	O
+scores	O
+were	O
+increased	O
+and	O
+correlated	O
+with	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+numbers	O
+and	O
+their	O
+subpopulations	O
+,	O
+and	O
+inversely	O
+with	O
+CD4	B-PRGE
+/	O
+CD8	B-PRGE
+ratio	O
+.	O
+
+Viral	B-COMP
+particles	I-COMP
+in	O
+AM	O
+were	O
+detected	O
+by	O
+electron	O
+microscopy	O
+in	O
+7	O
+of	O
+12	O
+SARS	B-DISO
+patients	O
+with	O
+high	O
+HRCT	O
+score	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Resolution	O
+of	O
+pneumonitis	B-DISO
+is	O
+delayed	O
+in	O
+some	O
+patients	O
+during	O
+SARS	B-DISO
+recovery	O
+and	O
+may	O
+be	O
+associated	O
+with	O
+delayed	O
+clearance	O
+of	O
+coronavirus	B-SPEC
+,	O
+Complete	O
+resolution	O
+may	O
+occur	O
+by	O
+90	O
+days	O
+or	O
+later	O
+.	O
+
+Our	O
+findings	O
+demonstrated	O
+that	O
+SARS	B-DISO
+crisis	O
+had	O
+some	O
+positive	O
+impact	O
+on	O
+the	O
+infection	B-DISO
+control	O
+practices	O
+and	O
+awareness	O
+of	O
+medical	O
+staff	O
+especially	O
+on	O
+those	O
+with	O
+direct	O
+SARS	B-DISO
+involvement	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+few	O
+months	O
+after	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+,	O
+a	O
+sample	O
+of	O
+Canadian	O
+undergraduate	O
+university	O
+students	O
+completed	O
+a	O
+questionnaire	O
+that	O
+showed	O
+that	O
+,	O
+despite	O
+believing	O
+media	B-ANAT
+coverage	O
+of	O
+the	O
+outbreak	O
+was	O
+excessive	O
+,	O
+they	O
+had	O
+little	O
+anxiety	O
+about	O
+acquiring	O
+SARS	B-DISO
+.	O
+
+Although	O
+some	O
+information	O
+is	O
+lost	B-CHED
+due	O
+to	O
+the	O
+approximate	O
+description	O
+of	O
+the	O
+Z	O
+-	O
+curve	O
+,	O
+the	O
+phylogenetic	O
+tree	O
+constructed	O
+based	O
+on	O
+these	O
+parameters	O
+is	O
+consistent	O
+with	O
+those	O
+of	O
+previous	O
+analyses	O
+.	O
+
+We	O
+found	O
+that	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+vector	O
+RNAs	O
+that	O
+lack	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+were	O
+greatly	O
+impaired	B-DISO
+in	O
+their	O
+ability	O
+to	O
+replicate	O
+,	O
+whereas	O
+the	O
+transcription	B-PROC
+of	O
+subgenomic	O
+mRNA	B-CHED
+from	O
+these	O
+vectors	O
+was	O
+easily	O
+detectable	O
+.	O
+
+Furthermore	O
+,	O
+modification	O
+of	O
+the	O
+transcription	B-PROC
+signal	O
+required	O
+for	O
+the	O
+synthesis	B-PROC
+of	O
+N	B-PRGE
+protein	I-PRGE
+mRNAs	O
+in	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+genome	O
+resulted	O
+in	O
+the	O
+selective	O
+replication	O
+of	O
+genomes	O
+that	O
+are	O
+able	O
+to	O
+express	O
+the	O
+N	O
+protein	O
+.	O
+
+As	O
+a	O
+target	O
+for	O
+screening	O
+,	O
+both	O
+a	O
+homology	O
+model	O
+and	O
+the	O
+crystallographic	O
+structure	O
+of	O
+the	O
+binding	B-FUNC
+pocket	O
+of	O
+the	O
+enzyme	O
+were	O
+used	O
+.	O
+
+Binding	B-FUNC
+of	O
+both	O
+cinanserin	O
+and	O
+its	O
+hydrochloride	B-CHED
+to	O
+bacterially	O
+expressed	O
+3CLpro	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+the	O
+related	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+was	O
+demonstrated	O
+by	O
+surface	O
+plasmon	O
+resonance	O
+technology	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+expression	B-PROC
+of	O
+CCL2	B-PRGE
+is	O
+sufficient	O
+to	O
+induce	O
+demyelination	B-DISO
+in	O
+RAG1	B-PRGE
+-/-	O
+mice	B-SPEC
+infected	O
+with	O
+a	O
+neurotropic	O
+coronavirus	O
+.	O
+
+A	O
+common	O
+feature	O
+of	O
+demyelination	B-DISO
+in	O
+these	O
+models	O
+is	O
+extensive	O
+infiltration	B-DISO
+of	O
+macrophages	B-ANAT
+/	O
+microglia	B-ANAT
+into	O
+the	O
+white	B-ANAT
+matter	I-ANAT
+.	O
+
+CCL2	B-PRGE
+has	O
+been	O
+implicated	O
+in	O
+macrophage	B-ANAT
+infiltration	B-DISO
+into	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+and	O
+is	O
+involved	O
+in	O
+demyelination	B-DISO
+in	O
+many	O
+experimental	O
+models	O
+of	O
+demyelination	B-DISO
+.	O
+
+Both	O
+peptides	B-CHED
+are	O
+hydrophobic	O
+and	O
+rich	O
+in	O
+alanine	O
+,	O
+glycine	B-CHED
+,	O
+and	O
+/	O
+or	O
+phenylalanine	B-CHED
+residues	O
+and	O
+contain	O
+a	O
+canonical	O
+fusion	O
+tripeptide	B-CHED
+along	O
+with	O
+a	O
+central	O
+proline	B-CHED
+residue	I-CHED
+.	O
+
+The	O
+activity	O
+of	O
+this	O
+synthetic	O
+peptide	B-CHED
+appeared	O
+to	O
+be	O
+dependent	O
+on	O
+its	O
+amino	B-CHED
+acid	I-CHED
+(	O
+aa	O
+)	O
+sequence	O
+,	O
+as	O
+scrambling	O
+the	O
+peptide	B-CHED
+rendered	O
+it	O
+unable	O
+to	O
+partition	O
+into	O
+LUV	O
+,	O
+assume	O
+a	O
+defined	O
+secondary	O
+structure	O
+,	O
+or	O
+induce	O
+both	O
+fusion	O
+and	O
+leakage	B-DISO
+of	O
+LUV	O
+.	O
+
+CDV	B-CHED
+,	O
+may	O
+be	O
+useful	O
+against	O
+orthopoxvirus	B-SPEC
+infections	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+work	O
+we	O
+propose	O
+a	O
+simple	O
+mathematical	O
+model	O
+for	O
+the	O
+analysis	O
+of	O
+the	O
+impact	O
+of	O
+control	O
+measures	O
+against	O
+an	O
+emerging	O
+infection	O
+,	O
+namely	O
+,	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+S	O
+-	O
+A5D5	O
+reacted	O
+specifically	O
+react	O
+with	O
+both	O
+recombinant	O
+and	O
+native	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+SARS	B-DISO
+CoV	O
+.	O
+The	O
+reactivity	O
+of	O
+S	O
+-	O
+A5D5	O
+with	O
+purified	O
+N195	O
+protein	B-CHED
+and	O
+utilization	O
+of	O
+the	O
+MAb	O
+as	O
+a	O
+detector	O
+antibody	B-COMP
+to	O
+develop	O
+an	O
+antigen	B-CHED
+capture	O
+ELISA	O
+was	O
+assessed	O
+.	O
+
+TITLE	O
+:	O
+Production	O
+of	O
+a	O
+monoclonal	O
+antibody	B-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+with	O
+single	O
+intrasplenic	O
+immunization	O
+of	O
+plasmid	O
+DNA	O
+.	O
+
+In	O
+this	O
+assay	O
+,	O
+the	O
+protective	O
+effect	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+was	O
+determined	O
+by	O
+the	O
+cell	B-PROC
+viability	I-PROC
+which	O
+is	O
+measured	O
+by	O
+the	O
+uptake	O
+of	O
+neutral	O
+red	O
+dye	B-CHED
+at	O
+A540	O
+.	O
+
+To	O
+directly	O
+compare	O
+and	O
+contrast	O
+endotoxin	O
+and	O
+oleic	B-CHED
+acid	I-CHED
+models	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+in	O
+terms	O
+of	O
+their	O
+physiologic	O
+,	O
+biochemical	O
+,	O
+histopathologic	O
+,	O
+and	O
+imaging	O
+manifestations	O
+.	O
+
+Under	O
+the	O
+conditions	O
+of	O
+these	O
+studies	O
+,	O
+only	O
+mice	B-SPEC
+exposed	O
+to	O
+oleic	B-CHED
+acid	I-CHED
+showed	O
+both	O
+structural	O
+and	O
+functional	O
+characteristics	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+RESULTS	O
+:	O
+Endotoxin	O
+alone	O
+caused	O
+only	O
+mild	O
+pulmonary	B-ANAT
+neutrophilic	B-PROC
+inflammation	B-DISO
+with	O
+little	O
+functional	O
+or	O
+structural	O
+damage	O
+to	O
+the	O
+alveolar	B-ANAT
+architecture	O
+.	O
+
+ABSTRACT	O
+:	O
+N	O
+-	O
+Substituted	O
+isatin	B-CHED
+derivatives	O
+were	O
+prepared	O
+from	O
+the	O
+reaction	O
+of	O
+isatin	B-CHED
+and	O
+various	O
+bromides	B-CHED
+via	O
+two	O
+steps	O
+.	O
+
+TITLE	O
+:	O
+Primary	O
+care	O
+physicians	O
+in	O
+Hong	O
+Kong	O
+and	O
+Canada	O
+--	O
+how	O
+did	O
+their	O
+practices	O
+differ	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+?	O
+
+In	O
+Toronto	O
+,	O
+150	O
+questionnaires	O
+were	O
+sent	O
+to	O
+academic	O
+family	B-SPEC
+physicians	O
+affiliated	O
+with	O
+the	O
+University	O
+of	O
+Toronto	O
+with	O
+51	O
+replies	O
+(	O
+34	O
+%).	O
+
+All	O
+agreed	O
+SARS	B-DISO
+had	O
+changed	O
+their	O
+clinical	O
+behaviour	B-PROC
+.	O
+
+RESULTS	O
+:	O
+All	O
+agreed	O
+SARS	B-DISO
+had	O
+changed	O
+their	O
+clinical	O
+behaviour	B-PROC
+.	O
+
+However	O
+,	O
+discovery	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+CoV	O
+revealed	O
+that	O
+highly	O
+pathogenic	O
+human	B-SPEC
+CoVs	O
+(	O
+HCoVs	O
+)	O
+can	O
+evolve	O
+.	O
+
+TITLE	O
+:	O
+Plasma	B-ANAT
+cytokine	O
+measurements	O
+augment	O
+prognostic	O
+scores	O
+as	O
+indicators	O
+of	O
+outcome	O
+in	O
+patients	O
+with	O
+severe	O
+sepsis	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+recent	O
+advances	O
+in	O
+the	O
+prospective	O
+identification	O
+of	O
+the	O
+patient	O
+with	O
+sepsis	B-DISO
+who	O
+may	O
+benefit	O
+from	O
+anti	O
+-	O
+inflammatory	O
+or	O
+antithrombotic	O
+therapies	O
+,	O
+successful	O
+treatment	O
+regimens	O
+have	O
+been	O
+fairly	O
+modest	O
+.	O
+
+In	O
+5	O
+of	O
+11	O
+and	O
+10	O
+of	O
+11	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+paired	O
+serum	B-COMP
+samples	O
+showed	O
+a	O
+>	O
+or	O
+=	O
+4	O
+-	O
+fold	O
+increase	O
+in	O
+antibody	B-COMP
+titers	O
+against	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+respectively	O
+,	O
+by	O
+IFA	O
+.	O
+
+Without	O
+sufficient	O
+knowledge	O
+about	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+it	O
+is	O
+impossible	O
+to	O
+define	O
+the	O
+candidate	O
+for	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+targets	I-PRGE
+.	O
+
+Then	O
+the	O
+recombinant	O
+eukaryotic	O
+expression	B-PROC
+vector	O
+pCI	O
+-	O
+neo	O
+/	O
+nsp2	B-PRGE
+was	O
+transfected	O
+into	O
+COS	B-ANAT
+-	I-ANAT
+7	I-ANAT
+cells	B-COMP
+using	O
+lipofectin	O
+reagent	B-CHED
+to	O
+express	O
+the	O
+nsp2	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+three	O
+-	O
+dimensional	O
+structure	O
+of	O
+the	O
+nsp2	B-PRGE
+protein	I-PRGE
+was	O
+successfully	O
+constructed	O
+.	O
+
+The	O
+eukaryotic	O
+expression	B-PROC
+plasmid	O
+pEGFP	O
+-	O
+C1	O
+-	O
+N	O
+,	O
+containing	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+gene	I-PRGE
+,	O
+was	O
+co	O
+-	O
+transfected	O
+into	O
+293	O
+cells	B-COMP
+with	O
+either	O
+the	O
+RNAi	B-PROC
+plasmid	O
+pshRNA	O
+-	O
+N	O
+or	O
+unrelated	O
+control	O
+plasmid	O
+pshRNA	O
+-	O
+HBV	B-DISO
+-	O
+C4	O
+.	O
+
+For	O
+unknown	O
+reason	O
+,	O
+a	O
+subset	O
+of	O
+ARDS	B-DISO
+patients	O
+does	O
+not	O
+respond	O
+favorably	O
+to	O
+iNO	B-PRGE
+therapy	O
+.	O
+
+The	O
+morphology	O
+of	O
+coherently	O
+pathologic	O
+lung	B-ANAT
+tissue	I-ANAT
+was	O
+characterized	O
+by	O
+the	O
+length	O
+of	O
+the	O
+borderline	O
+between	O
+consolidated	O
+,	O
+infiltrated	B-DISO
+and	O
+atelectatic	O
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+radiologically	O
+normal	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+This	O
+quantity	O
+was	O
+expressed	B-PROC
+as	O
+relative	O
+fraction	O
+of	O
+the	O
+visceral	O
+pleural	O
+circumference	O
+and	O
+averaged	O
+over	O
+all	O
+CT	O
+slices	O
+.	O
+
+Total	O
+fraction	O
+of	O
+consolidated	O
+lung	B-ANAT
+tissue	I-ANAT
+volume	O
+was	O
+not	O
+different	O
+between	O
+iNO	O
+non	O
+-	O
+responders	O
+and	O
+responders	O
+(	O
+60	O
++/-	O
+
+RESULTS	O
+:	O
+In	O
+n	O
+=	O
+6	O
+non	O
+-	O
+responders	O
+to	O
+iNO	B-PRGE
+(	O
+DeltaPaO2	O
+<	O
+10	O
+%),	O
+we	O
+determined	O
+a	O
+short	O
+relative	O
+borderline	O
+between	O
+normal	O
+and	O
+consolidated	O
+lung	B-ANAT
+tissue	I-ANAT
+due	O
+to	O
+the	O
+presence	O
+of	O
+large	O
+and	O
+coherently	O
+consolidated	O
+lung	B-ANAT
+regions	O
+.	O
+
+Retrospective	O
+cases	O
+involving	O
+801	O
+patients	O
+admitted	O
+to	O
+hospitals	O
+in	O
+Beijing	O
+between	O
+March	O
+and	O
+June	O
+2003	O
+,	O
+with	O
+a	O
+diagnosis	O
+of	O
+probable	O
+SARS	B-DISO
+,	O
+moderate	O
+type	O
+.	O
+
+From	O
+8	O
+to	O
+16	O
+d	O
+,	O
+the	O
+patients	O
+presented	O
+progressive	O
+cough	B-DISO
+(	O
+29	O
+.	O
+96	O
+%),	O
+sputum	B-PROC
+production	I-PROC
+(	O
+13	O
+.	O
+09	O
+%),	O
+chest	B-ANAT
+distress	O
+(	O
+29	O
+.	O
+96	O
+%)	O
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+(	O
+35	O
+.	O
+34	O
+%).	O
+
+SPR	B-PRGE
+Opt	I-PRGE
+calculates	O
+all	O
+SNP	O
+or	O
+PCR	O
+-	O
+RFLP	O
+variations	O
+present	O
+in	O
+the	O
+sequences	O
+,	O
+groups	O
+them	O
+into	O
+haplotypes	O
+according	O
+to	O
+their	O
+co	O
+-	O
+segregation	O
+across	O
+those	O
+sequences	O
+,	O
+and	O
+performs	O
+combinatoric	O
+analyses	O
+to	O
+determine	O
+which	O
+sets	O
+of	O
+haplotypes	O
+provide	O
+maximal	O
+discrimination	O
+among	O
+all	O
+the	O
+input	O
+sequences	O
+.	O
+
+Analyses	O
+of	O
+mumps	B-DISO
+and	O
+SARS	B-DISO
+viruses	B-SPEC
+are	O
+summarized	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+male	O
+infant	O
+(	O
+gestational	O
+age	O
+,	O
+26	O
+weeks	O
+and	O
+1	O
+day	O
+;	O
+birthweight	O
+,	O
+752	O
+g	O
+)	O
+was	O
+treated	O
+for	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+thereafter	O
+required	O
+mechanical	O
+ventilation	O
+due	O
+to	O
+chronic	O
+pulmonary	B-DISO
+insufficiency	I-DISO
+.	O
+
+Only	O
+treatment	O
+with	O
+glucocorticoids	B-CHED
+was	O
+effective	O
+.	O
+
+There	O
+has	O
+been	O
+no	O
+previous	O
+report	O
+of	O
+a	O
+case	O
+accompanied	O
+by	O
+cerebral	B-DISO
+infarction	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+deficient	O
+public	O
+health	O
+system	O
+as	O
+a	O
+contributing	O
+cause	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+in	O
+mainland	O
+China	O
+.	O
+
+Our	O
+results	O
+indicate	O
+that	O
+quarantine	O
+is	O
+effective	O
+in	O
+containing	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+and	O
+also	O
+cost	O
+saving	O
+when	O
+compared	O
+to	O
+not	O
+implementing	O
+a	O
+widespread	O
+containment	O
+mechanism	O
+.	O
+
+TITLE	O
+:	O
+Longitudinal	O
+assessment	O
+of	O
+community	O
+psychobehavioral	O
+responses	O
+during	O
+and	O
+after	O
+the	O
+2003	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Hong	O
+Kong	O
+.	O
+
+In	O
+addition	O
+to	O
+causing	O
+upper	O
+respiratory	B-DISO
+disease	I-DISO
+,	O
+we	O
+found	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+can	O
+present	O
+as	O
+croup	B-DISO
+,	O
+asthma	B-PATH
+exacerbation	O
+,	O
+febrile	B-DISO
+seizures	I-DISO
+,	O
+and	O
+high	O
+fever	B-PROC
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+viruses	B-SPEC
+appeared	O
+to	O
+cluster	O
+into	O
+2	O
+evolutionary	O
+lineages	O
+,	O
+and	O
+viruses	B-SPEC
+from	O
+both	O
+lineages	O
+cocirculated	O
+in	O
+the	O
+same	O
+season	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+cirrhotic	O
+patients	O
+with	O
+ARDS	B-DISO
+after	O
+MCT	B-ENZY
+were	O
+compared	O
+with	O
+others	O
+without	O
+ARDS	B-DISO
+.	O
+
+The	O
+postoperative	O
+cumulative	O
+water	B-PROC
+balance	B-CHED
+until	O
+the	O
+third	O
+day	O
+was	O
+1	O
+,	O
+692	O
++/-	O
+
+TITLE	O
+:	O
+Interferon	B-PRGE
+alfacon1	I-PRGE
+is	O
+an	O
+inhibitor	B-CHED
+of	O
+SARS	B-DISO
+-	O
+corona	B-CHED
+virus	B-SPEC
+in	O
+cell	B-COMP
+-	O
+based	O
+models	O
+.	O
+
+ABSTRACT	O
+:	O
+Preliminary	O
+data	O
+examining	O
+interferon	O
+alfacon1	O
+treatment	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+corona	B-CHED
+virus	B-SPEC
+)-	O
+infected	O
+patients	O
+suggests	O
+this	O
+therapy	O
+is	O
+well	O
+tolerated	O
+and	O
+of	O
+therapeutic	O
+benefit	O
+.	O
+
+The	O
+extract	O
+potently	O
+suppressed	O
+acute	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+(	O
+IIIB	O
+)	O
+infection	B-DISO
+in	O
+MT	O
+-	O
+4	O
+cells	B-COMP
+with	O
+EC50	O
+values	O
+of	O
+0	O
+.	O
+5	O
+microg	O
+/	O
+ml	O
+but	O
+exhibited	O
+low	O
+cytotoxicity	B-DISO
+to	O
+MT	O
+-	O
+4	O
+cells	B-COMP
+even	O
+at	O
+a	O
+high	O
+concentration	O
+(	O
+CC50	O
+>	O
+1000	O
+microg	O
+/	O
+ml	O
+).	O
+
+Sukumo	O
+extract	O
+was	O
+found	O
+to	O
+interact	O
+with	O
+both	O
+the	O
+viral	B-PRGE
+envelope	I-PRGE
+glycoprotein	B-CHED
+and	I-PRGE
+cellular	B-COMP
+receptors	I-PRGE
+,	O
+thus	O
+blocking	B-DISO
+virus	B-SPEC
+-	O
+cell	B-COMP
+binding	B-FUNC
+and	O
+virus	B-SPEC
+-	O
+induced	O
+syncytium	B-PROC
+formation	I-PROC
+.	O
+
+There	O
+was	O
+a	O
+good	O
+correlation	O
+between	O
+the	O
+extract	O
+'	O
+s	O
+anti	O
+-	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+activity	O
+and	O
+its	O
+inhibitory	O
+effects	O
+on	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+binding	B-FUNC
+.	O
+
+The	O
+inhibitory	O
+activity	O
+of	O
+the	O
+extract	O
+was	O
+also	O
+not	O
+reduced	O
+after	O
+pronase	O
+digestion	B-PROC
+.	O
+
+TITLE	O
+:	O
+Inhibitory	O
+effect	O
+of	O
+mizoribine	O
+and	O
+ribavirin	B-CHED
+on	O
+the	O
+replication	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+We	O
+purified	O
+RNA	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+obtained	O
+from	O
+routinely	O
+collected	O
+peripheral	B-ANAT
+blood	I-ANAT
+and	O
+sputum	B-ANAT
+samples	O
+of	O
+34	O
+patients	O
+who	O
+had	O
+been	O
+identified	O
+as	O
+probable	O
+SARS	B-DISO
+patients	O
+by	O
+following	O
+the	O
+interim	O
+U	O
+.	O
+S	O
+.	O
+case	O
+definition	O
+.	O
+
+Two	O
+of	O
+the	O
+34	O
+patients	O
+were	O
+only	O
+3	O
+days	O
+post	O
+-	O
+onset	O
+of	O
+symptoms	O
+and	O
+were	O
+subsequently	O
+confirmed	O
+to	O
+be	O
+SARS	B-DISO
+positive	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+blind	B-DISO
+-	O
+test	O
+of	O
+both	O
+peripheral	B-ANAT
+blood	I-ANAT
+and	O
+sputum	B-ANAT
+specimens	O
+lead	O
+to	O
+the	O
+positive	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+31	O
+out	O
+of	O
+34	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+frequently	O
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+In	O
+some	O
+of	O
+these	O
+patients	O
+,	O
+the	O
+clinical	O
+course	O
+can	O
+progress	O
+relentlessly	O
+to	O
+septic	B-DISO
+shock	I-DISO
+and	O
+/	O
+or	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+).	O
+
+The	O
+stomach	B-ANAT
+represents	O
+a	O
+potential	O
+site	O
+of	O
+secondary	O
+colonization	O
+and	O
+reservoir	O
+of	O
+nosocomial	O
+Gram	O
+-	O
+negative	O
+bacilli	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+experience	O
+of	O
+SARS	B-DISO
+-	O
+related	O
+stigma	O
+at	O
+Amoy	O
+Gardens	O
+.	O
+
+Residents	O
+attributed	O
+stigma	O
+to	O
+government	O
+mismanagement	O
+,	O
+contagiousness	O
+of	O
+the	O
+mysterious	O
+SARS	B-DISO
+virus	B-SPEC
+,	O
+and	O
+alarmist	O
+media	B-ANAT
+reporting	O
+.	O
+
+Here	O
+,	O
+the	O
+results	O
+of	O
+a	O
+screening	O
+for	O
+coronavirus	B-SPEC
+are	O
+presented	O
+,	O
+using	O
+a	O
+universal	O
+coronavirus	B-SPEC
+RT	O
+-	O
+PCR	O
+,	O
+of	O
+the	O
+bird	B-SPEC
+species	B-SPEC
+graylag	B-SPEC
+goose	I-SPEC
+(	O
+Anser	B-SPEC
+anser	I-SPEC
+),	O
+feral	O
+pigeon	B-SPEC
+(	O
+Columbia	O
+livia	O
+)	O
+and	O
+mallard	B-SPEC
+(	O
+Anas	B-SPEC
+platyrhynchos	I-SPEC
+).	O
+
+In	O
+the	O
+graylag	B-SPEC
+goose	I-SPEC
+,	O
+40	O
+of	O
+163	O
+sampled	O
+birds	B-SPEC
+were	O
+coronavirus	B-SPEC
+positive	O
+,	O
+whereas	O
+two	O
+of	O
+100	O
+sampled	O
+pigeons	B-SPEC
+and	O
+one	O
+of	O
+five	O
+sampled	O
+mallards	B-SPEC
+tested	O
+positive	O
+.	O
+
+In	O
+this	O
+paper	O
+we	O
+analyse	O
+the	O
+reasons	O
+why	O
+tuberculosis	B-PATH
+is	O
+considered	O
+to	O
+be	O
+an	O
+occupational	B-DISO
+disease	I-DISO
+in	O
+health	O
+personnel	O
+;	O
+which	O
+activities	O
+entail	O
+most	O
+risk	O
+and	O
+the	O
+measures	O
+that	O
+should	O
+be	O
+adopted	O
+to	O
+reduce	O
+nosocomial	O
+transmission	O
+.	O
+
+ABSTRACT	O
+:	O
+Close	O
+proximity	O
+of	O
+persons	O
+together	O
+with	O
+handling	O
+of	O
+human	B-SPEC
+secretions	B-ANAT
+(	O
+eg	O
+respiratory	O
+secretions	B-ANAT
+)	O
+make	O
+health	O
+care	O
+workers	O
+(	O
+HCW	O
+)	O
+particularly	O
+vulnerable	O
+to	O
+transmission	O
+of	O
+droplet	O
+-	O
+transmitted	B-DISO
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+article	O
+is	O
+to	O
+review	O
+common	O
+airborne	O
+and	O
+droplet	O
+-	O
+transmitted	B-DISO
+bacterial	O
+and	O
+viral	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+with	O
+regard	O
+to	O
+their	O
+impact	O
+on	O
+health	O
+care	O
+workers	O
+.	O
+
+Enforced	O
+implementation	O
+of	O
+stringent	O
+droplet	O
+precautions	O
+during	O
+the	O
+SARS	O
+crisis	O
+should	O
+be	O
+maintained	O
+;	O
+and	O
+this	O
+will	O
+most	O
+likely	O
+have	O
+a	O
+major	O
+additional	O
+impact	O
+on	O
+other	O
+nosocomial	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Persistence	O
+was	O
+established	O
+after	O
+most	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+died	B-PROC
+.	O
+
+RNA	O
+of	O
+the	O
+defective	O
+interfering	O
+virus	B-SPEC
+was	O
+not	O
+observed	O
+in	O
+the	O
+persistently	O
+infected	O
+cells	B-COMP
+by	O
+Northern	O
+blot	O
+analysis	O
+.	O
+
+Immature	O
+but	O
+mature	O
+Hsp60	B-PRGE
+causes	O
+in	O
+vitro	O
+the	O
+release	B-PATH
+of	O
+NO	O
+by	O
+macrophages	B-ANAT
+,	O
+suggesting	O
+that	O
+the	O
+extracellular	B-COMP
+release	B-PATH
+of	O
+the	O
+immature	O
+Hsp60	B-PRGE
+associated	O
+with	O
+traumatic	O
+cell	B-COMP
+necrosis	B-PROC
+could	O
+be	O
+involved	O
+in	O
+the	O
+release	B-PATH
+of	O
+NO	O
+by	O
+immune	O
+competent	O
+cells	B-COMP
+,	O
+leading	O
+to	O
+an	O
+activation	O
+of	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+within	O
+the	O
+lung	B-ANAT
+or	O
+other	O
+organs	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+that	O
+occurred	O
+in	O
+Hong	O
+Kong	O
+in	O
+2003	O
+caused	O
+serious	O
+public	O
+health	O
+consequences	O
+.	O
+
+A	O
+new	O
+coronavirus	B-SPEC
+was	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+and	O
+named	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+virus	B-SPEC
+.	O
+
+All	O
+patients	O
+who	O
+died	B-PROC
+at	O
+Sahlgrenska	O
+University	O
+Hospital	O
+in	O
+Goteborg	O
+,	O
+Sweden	O
+,	O
+in	O
+whom	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+(	O
+CPR	B-ENZY
+)	O
+was	O
+not	O
+attempted	O
+during	O
+a	O
+period	O
+of	O
+one	O
+year	O
+.	O
+
+Among	O
+674	O
+patients	O
+,	O
+71	O
+%	O
+suffered	B-DISO
+respiratory	B-DISO
+insufficiency	I-DISO
+,	O
+43	O
+%	O
+were	O
+unconscious	O
+and	O
+32	O
+%	O
+had	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+during	O
+the	O
+24h	O
+before	O
+death	B-PROC
+.	O
+
+In	O
+the	O
+vast	O
+majority	O
+of	O
+patients	O
+,	O
+the	O
+diagnosis	O
+on	O
+admission	O
+to	O
+hospital	O
+was	O
+the	O
+same	O
+as	O
+the	O
+primary	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+The	O
+cause	O
+of	O
+death	B-PROC
+was	O
+life	O
+-	O
+threatening	O
+organ	B-DISO
+failure	I-DISO
+,	O
+including	O
+malignancy	B-DISO
+(	O
+44	O
+%),	O
+cerebral	B-DISO
+lesion	I-DISO
+(	O
+10	O
+%)	O
+and	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+(	O
+10	O
+%).	O
+
+TITLE	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+:	O
+analysis	O
+of	O
+a	O
+series	O
+of	O
+47	O
+patients	O
+.	O
+
+Cases	O
+with	O
+ARDS	B-DISO
+were	O
+selected	O
+from	O
+the	O
+web	B-DISO
+site	O
+based	O
+international	O
+registry	O
+of	O
+patients	O
+with	O
+catastrophic	O
+APS	B-DISO
+(	O
+CAPS	O
+registry	O
+)	O
+(	O
+http	O
+://	O
+www	O
+.	O
+med	O
+.	O
+ub	O
+.	O
+es	O
+/	O
+MIMMUN	O
+/	O
+FORUM	O
+/	O
+CAPS	B-PRGE
+.	O
+HTM	O
+)	O
+and	O
+their	O
+characteristics	O
+examined	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+transgenic	O
+mouse	B-SPEC
+model	O
+susceptible	O
+to	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+remains	O
+unclear	O
+.	O
+
+TITLE	O
+:	O
+Coronaviral	O
+hypothetical	O
+and	O
+structural	O
+proteins	B-CHED
+were	O
+found	O
+in	O
+the	O
+intestinal	B-ANAT
+surface	I-ANAT
+enterocytes	B-ANAT
+and	O
+pneumocytes	B-ANAT
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+presence	O
+of	O
+these	O
+proteins	B-CHED
+were	O
+first	O
+verified	O
+in	O
+coronavirus	B-SPEC
+-	O
+infected	O
+Vero	O
+E6	O
+tissue	B-ANAT
+culture	O
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+compare	O
+the	O
+4	O
+test	O
+kits	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+gene	O
+,	O
+antigen	B-CHED
+and	O
+antibody	B-COMP
+for	O
+early	O
+diagnose	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+By	O
+measuring	O
+airflow	B-PROC
+and	O
+ventilation	O
+distribution	O
+of	O
+ward	O
+building	O
+,	O
+to	O
+explore	O
+and	O
+verify	O
+the	O
+hypothesis	O
+of	O
+airborne	O
+transmission	O
+and	O
+risk	O
+factor	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+nosocomial	B-DISO
+infection	I-DISO
+.	O
+
+Architecture	O
+and	O
+ventilation	O
+system	O
+of	O
+the	O
+inpatient	O
+building	O
+in	O
+the	O
+hospital	O
+contributed	O
+to	O
+the	O
+aerodynamic	O
+condition	B-DISO
+of	O
+SARS	B-DISO
+nosocomial	B-DISO
+infection	I-DISO
+through	O
+airborne	O
+transmission	O
+.	O
+
+It	O
+was	O
+possible	O
+that	O
+SARS	B-DISO
+could	O
+have	O
+been	O
+transmitted	B-DISO
+to	O
+for	O
+distance	O
+by	O
+aerosol	O
+or	O
+other	O
+carriers	O
+.	O
+
+RESULTS	O
+:	O
+Tracer	B-CHED
+gas	B-ENZY
+was	O
+detected	O
+from	O
+the	O
+wards	O
+of	O
+8th	O
+to	O
+13th	O
+floor	O
+.	O
+
+TITLE	O
+:	O
+Efficacy	O
+of	O
+various	O
+disinfectants	B-CHED
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Combined	O
+treatment	O
+with	O
+ICS	B-DISO
+and	O
+long	B-PRGE
+acting	I-PRGE
+beta2	I-PRGE
+agonists	I-PRGE
+(	O
+LABA	O
+)	O
+may	O
+provide	O
+benefit	O
+to	O
+the	O
+stability	O
+of	O
+COPD	B-DISO
+,	O
+but	O
+it	O
+is	O
+unknown	O
+if	O
+withdrawal	B-DISO
+of	O
+ICS	B-DISO
+will	O
+result	O
+in	O
+disease	O
+deterioration	O
+.	O
+
+Hong	O
+Kong	O
+was	O
+ill	B-DISO
+-	O
+prepared	O
+at	O
+the	O
+early	O
+stage	O
+of	O
+the	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+Neopterin	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+)	O
+concentrations	O
+were	O
+determined	O
+in	O
+serum	B-COMP
+samples	O
+from	O
+129	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+and	O
+156	O
+healthy	O
+blood	B-ANAT
+donors	O
+.	O
+
+All	O
+SARS	B-DISO
+patients	O
+had	O
+elevated	O
+neopterin	B-CHED
+concentrations	O
+(>	O
+10	O
+nmol	O
+/	O
+L	O
+)	O
+within	O
+9	O
+days	O
+after	O
+the	O
+onset	O
+.	O
+
+The	O
+mean	O
+neopterin	B-CHED
+concentrations	O
+were	O
+34	O
+.	O
+2	O
+nmol	O
+/	O
+L	O
+in	O
+acute	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+,	O
+5	O
+.	O
+1	O
+nmol	O
+/	O
+L	O
+in	O
+convalescent	O
+sera	B-COMP
+,	O
+and	O
+6	O
+.	O
+7	O
+nmol	O
+/	O
+L	O
+in	O
+healthy	O
+controls	O
+.	O
+
+Using	O
+general	O
+estimating	O
+equations	O
+(	O
+GEE	O
+)	O
+statistical	O
+analysis	O
+to	O
+control	O
+possible	O
+for	O
+affecting	O
+factors	O
+,	O
+we	O
+found	O
+that	O
+the	O
+nursing	B-PROC
+staff	O
+'	O
+s	O
+anxiety	O
+and	O
+depression	B-DISO
+along	O
+with	O
+sleep	B-PROC
+quality	O
+started	O
+to	O
+improve	O
+2	O
+weeks	O
+after	O
+the	O
+initiation	O
+of	O
+SARS	B-DISO
+prevention	O
+controls	O
+.	O
+
+Monitoring	O
+of	O
+right	O
+-	O
+sided	O
+heart	B-PROC
+function	I-PROC
+is	O
+essential	O
+in	O
+a	O
+clinical	O
+setting	O
+associated	O
+with	O
+hemodynamic	B-DISO
+instability	I-DISO
+,	O
+such	O
+as	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+acute	O
+coronary	B-ANAT
+artery	I-ANAT
+obstruction	O
+,	O
+and	O
+also	O
+in	O
+that	O
+it	O
+is	O
+associated	O
+with	O
+increased	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+,	O
+as	O
+in	O
+massive	O
+pulmonary	B-DISO
+embolism	I-DISO
+or	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+METHODS	O
+:	O
+Hematoxylin	B-CHED
+and	O
+eosin	O
+staining	O
+and	O
+light	O
+microscopy	O
+were	O
+used	O
+to	O
+examine	O
+the	O
+histology	O
+of	O
+the	O
+thyroid	B-ANAT
+tissues	B-ANAT
+from	O
+4	O
+dead	B-PROC
+SARS	B-DISO
+patients	O
+and	O
+5	O
+healthy	O
+thyroid	B-ANAT
+samples	O
+used	O
+as	O
+negative	O
+controls	O
+.	O
+
+RESULTS	O
+:	O
+Deformation	O
+,	O
+enlargement	B-DISO
+,	O
+and	O
+dystrophy	B-DISO
+of	O
+follicular	B-ANAT
+cells	B-COMP
+in	O
+thyroid	B-ANAT
+glands	I-ANAT
+were	O
+found	O
+in	O
+the	O
+SARS	B-DISO
+patients	O
+.	O
+
+PTH	B-PRGE
+positive	O
+cells	B-COMP
+were	O
+seen	O
+in	O
+the	O
+normal	O
+thyroid	B-ANAT
+glands	I-ANAT
+and	O
+those	O
+of	O
+the	O
+SARS	B-DISO
+patients	O
+with	O
+a	O
+slightly	O
+weaker	O
+intensity	O
+of	O
+reaction	O
+,	O
+however	O
+,	O
+with	O
+significant	O
+difference	O
+in	O
+IOD	B-CHED
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+and	O
+without	O
+significant	O
+difference	O
+in	O
+mean	O
+slight	O
+absorption	O
+MOD	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+Health	O
+care	O
+practitioners	O
+need	O
+to	O
+be	O
+aware	O
+of	O
+infection	B-DISO
+control	O
+measures	O
+to	O
+prevent	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+interaction	O
+between	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3C	O
+-	O
+like	O
+proteinase	B-PROC
+and	O
+a	O
+dimeric	O
+inhibitor	O
+by	O
+capillary	B-ANAT
+electrophoresis	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+SARS	B-PRGE
+3CL	I-PRGE
+proteinase	B-PROC
+was	O
+able	O
+to	O
+complex	O
+with	O
+the	O
+octapeptide	O
+competitively	O
+,	O
+with	O
+binding	B-FUNC
+constants	O
+of	O
+2	O
+.	O
+44	O
+x	O
+10	O
+(	O
+4	O
+)	O
+M	O
+(-	O
+1	O
+)	O
+at	O
+20	O
+degrees	O
+C	O
+and	O
+2	O
+.	O
+11	O
+x	O
+10	O
+(	O
+4	O
+)	O
+M	O
+(-	O
+1	O
+)	O
+at	O
+37	O
+degrees	O
+C	O
+.	O
+In	O
+addition	O
+,	O
+the	O
+thermodynamic	O
+parameters	O
+deduced	O
+reveal	O
+that	O
+hydrophobic	B-PROC
+interaction	I-PROC
+might	O
+play	O
+major	O
+roles	O
+,	O
+along	O
+with	O
+electrostatic	O
+force	O
+,	O
+in	O
+the	O
+binding	B-FUNC
+process	O
+.	O
+
+Self	O
+-	O
+administered	O
+mail	O
+questionnaires	O
+survey	O
+to	O
+308	O
+SARS	B-DISO
+patients	O
+after	O
+discharging	O
+from	O
+hospital	O
+.	O
+
+In	O
+multiple	O
+linear	O
+regression	O
+analysis	O
+,	O
+use	O
+of	O
+pulse	B-PROC
+steroid	B-CHED
+and	O
+total	O
+dosages	O
+of	O
+pulse	B-PROC
+steroid	B-CHED
+during	O
+hospitalisation	O
+were	O
+predictive	O
+for	O
+anxiety	O
+-	O
+depression	B-DISO
+,	O
+psychosis	B-DISO
+and	O
+behavioural	O
+symptoms	O
+in	O
+acute	O
+phase	O
+,	O
+the	O
+effects	O
+persisted	O
+in	O
+convalescent	O
+phase	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	O
+-	O
+CoV	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Our	O
+results	O
+indicated	O
+that	O
+extracts	O
+from	O
+Puer	O
+and	O
+black	B-SPEC
+tea	I-SPEC
+were	O
+more	O
+potent	O
+than	O
+that	O
+from	O
+green	O
+or	O
+oolong	O
+teas	O
+in	O
+their	O
+inhibitory	O
+activities	O
+against	O
+3CL	O
+(	O
+Pro	B-CHED
+).	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+an	O
+alternative	O
+5	O
+'-	O
+untranslated	O
+exon	O
+and	O
+new	O
+polymorphisms	B-PROC
+of	O
+angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+gene	I-PRGE
+:	O
+lack	O
+of	O
+association	O
+with	O
+SARS	O
+in	O
+the	O
+Vietnamese	O
+population	O
+.	O
+
+It	O
+was	O
+55	O
+%	O
+in	O
+sepsis	B-DISO
+,	O
+33	O
+%	O
+in	O
+destructive	O
+pancreatis	O
+,	O
+8	O
+.	O
+3	O
+%	O
+in	O
+urosepsis	B-DISO
+,	O
+8	O
+%	O
+in	O
+acute	B-DISO
+interstitial	I-DISO
+nephritis	I-DISO
+,	O
+64	O
+.	O
+7	O
+%	O
+in	O
+rapidly	B-DISO
+progressive	I-DISO
+glomerulonephritis	I-DISO
+.	O
+
+As	O
+for	O
+the	O
+patients	O
+with	O
+the	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+the	O
+score	O
+values	O
+ranged	O
+from	O
+0	O
+.	O
+3	O
+to	O
+1	O
+.	O
+3	O
+and	O
+only	O
+one	O
+patient	O
+from	O
+this	O
+group	O
+died	B-PROC
+(	O
+4	O
+.	O
+34	O
+%).	O
+
+Review	O
+of	O
+the	O
+literature	O
+was	O
+used	O
+to	O
+analyse	O
+TRALI	B-DISO
+.	O
+
+Patients	O
+who	O
+underwent	O
+urgent	O
+surgical	O
+treatment	O
+and	O
+/	O
+or	O
+died	B-PROC
+in	O
+the	O
+hospital	O
+had	O
+higher	O
+peak	O
+CRP	B-PRGE
+levels	O
+(	O
+25	O
+.	O
+1	O
++/-	O
+12	O
+.	O
+3	O
+vs	O
+.	O
+16	O
+.	O
+1	O
++/-	O
+7	O
+.	O
+4	O
+mg	O
+/	O
+dl	O
+,	O
+P	O
+=	O
+0	O
+.	O
+010	O
+)	O
+than	O
+those	O
+who	O
+did	O
+not	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+a	O
+newly	O
+emerged	O
+,	O
+highly	O
+pathogenic	O
+agent	O
+that	O
+caused	O
+over	O
+8000	O
+human	B-SPEC
+infections	B-DISO
+with	O
+nearly	O
+800	O
+deaths	B-PROC
+between	O
+November	O
+2002	O
+and	O
+September	O
+2003	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+viraemia	B-DISO
+does	O
+not	O
+seem	O
+to	O
+reach	B-PROC
+high	O
+titres	O
+,	O
+however	O
+,	O
+it	O
+has	O
+to	O
+be	O
+excluded	O
+that	O
+virus	B-SPEC
+transmission	O
+may	O
+occur	O
+via	O
+blood	B-ANAT
+transfusion	O
+or	O
+application	O
+of	O
+therapeutic	O
+plasma	B-ANAT
+products	I-ANAT
+,	O
+e	O
+.	O
+g	O
+.	O
+fresh	B-ANAT
+-	O
+frozen	O
+plasma	B-ANAT
+or	O
+single	O
+components	O
+derived	O
+thereof	O
+.	O
+
+The	O
+work	O
+reported	O
+here	O
+demonstrates	O
+:	O
+(	O
+1	O
+)	O
+fusion	O
+of	O
+SUMO	O
+(	O
+small	O
+ubiquitin	B-PROC
+-	O
+related	O
+modifier	O
+),	O
+a	O
+100	O
+amino	B-CHED
+acid	I-CHED
+polypeptide	B-CHED
+,	O
+to	O
+the	O
+N	O
+-	O
+termini	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+dramatically	O
+enhances	O
+expression	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+cells	B-COMP
+and	O
+(	O
+2	O
+)	O
+6x	O
+His	O
+-	O
+tagged	O
+SUMO	B-PRGE
+-	I-PRGE
+fusions	I-PRGE
+facilitate	O
+rapid	O
+purification	O
+of	O
+the	O
+viral	O
+proteins	B-CHED
+on	O
+a	O
+large	O
+scale	O
+.	O
+
+This	O
+study	O
+not	O
+only	O
+first	O
+made	O
+a	O
+human	B-SPEC
+neutralizing	O
+antibody	B-COMP
+,	O
+which	O
+recognized	O
+an	O
+epitope	B-CHED
+on	O
+S2	O
+protein	B-CHED
+like	O
+natural	O
+antibody	B-COMP
+in	O
+sera	B-COMP
+,	O
+but	O
+also	O
+may	O
+help	O
+us	O
+to	O
+better	O
+understand	O
+the	O
+immunological	O
+characteristics	O
+of	O
+SARS	B-DISO
+protein	B-CHED
+and	O
+SARS	B-DISO
+vaccine	O
+design	O
+.	O
+
+(	O
+2	O
+)	O
+Physician	O
+'	O
+s	O
+alertness	O
+/	O
+sense	B-PROC
+and	O
+practice	O
+of	O
+self	O
+-	O
+protection	O
+on	O
+SARS	B-DISO
+,	O
+measures	O
+on	O
+quarantine	O
+and	O
+isolation	O
+to	O
+the	O
+patients	O
+,	O
+ventilation	O
+and	O
+disinfection	O
+process	O
+in	O
+the	O
+wards	O
+appeared	O
+to	O
+be	O
+the	O
+key	O
+variables	O
+for	O
+the	O
+control	O
+of	O
+epidemics	O
+.	O
+
+(	O
+3	O
+)	O
+""""	O
+Screening	O
+for	O
+fever	B-PROC
+""""	O
+practice	O
+on	O
+each	O
+patient	O
+at	O
+the	O
+entrance	O
+of	O
+the	O
+hospital	O
+did	O
+not	O
+seem	O
+to	O
+act	O
+as	O
+an	O
+important	O
+factor	O
+to	O
+the	O
+control	O
+of	O
+the	O
+epidemics	O
+.	O
+
+Regarding	O
+factor	O
+analysis	O
+,	O
+geographic	O
+relationship	O
+,	O
+population	O
+density	O
+,	O
+the	O
+amount	O
+of	O
+doctors	O
+and	O
+hospitals	O
+appeared	O
+to	O
+be	O
+the	O
+key	O
+elements	O
+influencing	O
+the	O
+transmission	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+predictable	O
+number	O
+of	O
+SARS	B-DISO
+cases	O
+evolving	O
+with	O
+time	O
+were	O
+also	O
+calculated	O
+.	O
+
+RNA	O
+was	O
+extracted	O
+and	O
+nested	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+was	O
+carried	O
+out	O
+using	O
+SARS	B-DISO
+-	O
+CoV	O
+specific	O
+primers	O
+.	O
+
+Among	O
+the	O
+276	O
+samples	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+was	O
+detected	O
+in	O
+6	O
+cases	O
+(	O
+38	O
+.	O
+8	O
+%)	O
+by	O
+nested	O
+RT	O
+-	O
+PCR	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+276	O
+samples	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+was	O
+detected	O
+in	O
+6	O
+cases	O
+(	O
+38	O
+.	O
+8	O
+%)	O
+by	O
+nested	O
+RT	O
+-	O
+PCR	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+prepare	O
+and	O
+characterize	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAb	O
+)	O
+and	O
+polyclonal	O
+antibodies	B-COMP
+against	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+to	O
+establish	O
+antibodies	B-COMP
+-	O
+based	O
+sandwich	O
+ELISA	O
+for	O
+detecting	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+which	O
+might	O
+apply	O
+to	O
+early	O
+diagnosis	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Capturing	O
+and	O
+detecting	O
+antibodies	B-COMP
+were	O
+selected	O
+by	O
+pairing	O
+the	O
+mAbs	O
+and	O
+polyclonal	O
+antibodies	B-COMP
+one	O
+by	O
+one	O
+and	O
+an	O
+antibodies	B-COMP
+-	O
+based	O
+sandwich	O
+antigen	O
+capture	O
+ELISA	O
+was	O
+used	O
+for	O
+detecting	O
+N	B-PRGE
+antigen	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Nine	O
+mAbs	O
+and	O
+hyperimmune	O
+rabbit	B-SPEC
+polyclonal	O
+antibodies	B-COMP
+,	O
+specifically	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+were	O
+obtained	O
+.	O
+
+RESULTS	O
+:	O
+Nine	O
+mAbs	O
+and	O
+hyperimmune	O
+rabbit	B-SPEC
+polyclonal	O
+antibodies	B-COMP
+,	O
+specifically	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+were	O
+obtained	O
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	O
+contusion	O
+is	O
+frequently	O
+followed	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+pneumonia	B-DISO
+,	O
+and	O
+sepsis	B-DISO
+.	O
+
+The	O
+cytokine	O
+release	B-PATH
+of	O
+cultured	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+,	O
+peritoneal	B-ANAT
+macrophages	I-ANAT
+,	O
+splenocytes	O
+,	O
+and	O
+splenic	B-ANAT
+macrophages	B-ANAT
+and	O
+plasma	B-ANAT
+levels	O
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+from	O
+those	O
+animals	B-SPEC
+were	O
+quantified	O
+.	O
+
+At	O
+24	O
+hrs	B-DISO
+and	O
+,	O
+in	O
+part	O
+,	O
+already	O
+at	O
+2	O
+hrs	B-DISO
+,	O
+cytokine	O
+release	B-PATH
+from	O
+peritoneal	B-ANAT
+macrophages	I-ANAT
+,	O
+splenic	B-ANAT
+macrophages	B-ANAT
+,	O
+and	O
+splenocytes	O
+was	O
+significantly	O
+suppressed	O
+.	O
+
+Moreover	O
+,	O
+this	O
+immunosuppression	B-PROC
+is	O
+associated	O
+with	O
+an	O
+increased	O
+susceptibility	O
+to	O
+infectious	B-DISO
+complications	O
+,	O
+which	O
+results	O
+in	O
+a	O
+decreased	O
+survival	O
+rate	O
+if	O
+blunt	O
+chest	B-ANAT
+trauma	O
+is	O
+followed	O
+by	O
+a	O
+septic	O
+insult	O
+.	O
+
+1	O
+.	O
+5	O
+mL	O
+/	O
+kg	O
+;	O
+p	O
+<	O
+.	O
+05	O
+),	O
+and	O
+lung	B-ANAT
+mechanics	O
+were	O
+improved	O
+.	O
+
+Bronchoalveolar	O
+lavage	O
+showed	O
+a	O
+lesser	O
+percentage	O
+of	O
+polymorphonuclear	B-ANAT
+leukocytes	I-ANAT
+(	O
+S	O
++	O
+IN	O
+vs	O
+.	O
+S	O
+,	O
+70	O
+%	O
++/-	O
+
+A	O
+topically	O
+applied	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+inhibitor	B-CHED
+improves	O
+lung	B-DISO
+edema	I-DISO
+and	O
+lung	B-PROC
+volumes	I-PROC
+and	O
+reduces	O
+inflammation	B-DISO
+in	O
+this	O
+newborn	O
+piglet	O
+model	O
+of	O
+airway	B-ANAT
+lavage	O
+.	O
+
+Measurement	O
+of	O
+antibody	B-COMP
+avidity	O
+can	O
+be	O
+used	O
+to	O
+differentiate	O
+primary	B-DISO
+infection	I-DISO
+from	O
+reexposure	O
+and	O
+to	O
+assess	O
+humoral	O
+responses	O
+to	O
+candidate	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+caused	O
+by	O
+a	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	B-SPEC
+),	O
+designated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	B-SPEC
+,	O
+is	O
+a	O
+highly	O
+contagious	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+the	O
+lungs	B-ANAT
+as	O
+a	O
+major	O
+target	O
+.	O
+
+Concern	O
+for	O
+the	O
+transfer	O
+of	O
+donor	B-CHED
+antileukocyte	O
+antibodies	B-COMP
+has	O
+prompted	O
+major	O
+changes	O
+in	O
+the	O
+management	O
+of	O
+the	O
+blood	B-PROC
+supply	I-PROC
+in	O
+some	O
+countries	O
+;	O
+however	O
+,	O
+recent	O
+studies	O
+have	O
+suggested	O
+alternative	O
+pathophyslological	O
+mechanisms	O
+for	O
+TRALI	B-DISO
+related	O
+to	O
+the	O
+shelf	O
+life	O
+of	O
+cellular	B-COMP
+blood	B-ANAT
+products	O
+.	O
+
+Surviving	O
+SARS	B-DISO
+patients	O
+were	O
+seen	O
+at	O
+least	O
+twice	O
+within	O
+3	O
+months	O
+after	O
+discharge	B-ANAT
+and	O
+underwent	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+IgG	B-COMP
+antibody	I-COMP
+testing	O
+,	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+,	O
+and	O
+chest	B-ANAT
+radiography	O
+and	O
+/	O
+or	O
+high	O
+-	O
+resolution	O
+CT	O
+(	O
+HRCT	O
+)	O
+examinations	O
+at	O
+Chinese	O
+PLA	B-CHED
+General	O
+Hospital	O
+.	O
+
+For	O
+these	O
+patients	O
+,	O
+51	O
+of	O
+53	O
+patients	O
+with	O
+positive	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+results	O
+and	O
+a	O
+lung	B-ANAT
+diffusion	O
+abnormality	O
+underwent	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+after	O
+approximately	O
+1	O
+month	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+lung	B-ANAT
+fibrotic	O
+changes	O
+caused	O
+by	O
+SARS	B-DISO
+disease	O
+occurred	O
+mostly	O
+in	O
+severely	O
+sick	O
+patients	O
+and	O
+may	O
+be	O
+self	O
+-	O
+rehabilitated	O
+.	O
+
+D	O
+(	O
+LCO	B-CHED
+)	O
+scores	O
+might	O
+be	O
+more	O
+sensitive	O
+than	O
+HRCT	O
+when	O
+evaluating	O
+lung	B-ANAT
+fibrotic	O
+changes	O
+.	O
+
+The	O
+specific	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+(	O
+IgG	B-PRGE
+)	O
+against	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+IgG	B-PRGE
+against	O
+S1	B-PRGE
+domain	I-PRGE
+of	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+and	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+in	O
+these	O
+sera	B-COMP
+were	O
+detected	O
+by	O
+ELISA	O
+.	O
+
+The	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+positive	O
+rate	O
+in	O
+the	O
+healthy	O
+persons	O
+was	O
+1	O
+.	O
+88	O
+%	O
+(	O
+14	O
+.	O
+745	O
+).	O
+
+TITLE	O
+:	O
+[	O
+An	O
+immunofluorescence	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+SARS	B-DISO
+associated	O
+coronavirus	B-SPEC
+antibody	B-COMP
+based	O
+on	O
+recombinant	O
+nucleocapsid	O
+antigen	B-CHED
+and	O
+its	O
+application	O
+].	O
+
+Immunofluorescence	O
+assay	O
+(	O
+IFA	O
+)	O
+technique	O
+and	O
+plaque	B-DISO
+reduction	O
+neutralization	O
+test	O
+(	O
+PRNT	O
+)	O
+were	O
+used	O
+to	O
+detect	O
+7	O
+samples	O
+of	O
+sera	B-COMP
+of	O
+4	O
+newly	O
+diagnosed	O
+SARS	B-DISO
+patients	O
+collected	O
+in	O
+different	O
+days	O
+,	O
+48	O
+samples	O
+of	O
+convalescent	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+,	O
+24	O
+serum	B-COMP
+samples	O
+of	O
+healthy	O
+person	O
+undergoing	O
+physical	O
+examination	O
+,	O
+and	O
+40	O
+serum	B-COMP
+samples	O
+from	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+with	O
+fever	B-PROC
+by	O
+double	O
+blind	B-DISO
+test	O
+.	O
+
+SARS	B-DISO
+antibody	B-COMP
+could	O
+be	O
+detected	O
+since	O
+the	O
+sixth	O
+day	O
+after	O
+onset	O
+,	O
+and	O
+the	O
+titer	O
+increased	O
+from	O
+1	O
+:	O
+40	O
+to	O
+1	O
+:	O
+600	O
+on	O
+the	O
+ninth	O
+day	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+recombinant	O
+SARS	B-DISO
+-	O
+specific	O
+antigen	B-CHED
+reacted	O
+only	O
+with	O
+SARS	B-DISO
+positive	O
+sera	B-COMP
+but	O
+not	O
+with	O
+normal	O
+sera	B-COMP
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+established	O
+a	O
+high	O
+-	O
+throughput	O
+FRET	O
+technique	O
+for	O
+screening	O
+for	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	O
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Pathogenesis	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+the	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+lectin	I-PRGE
+CD209L	I-PRGE
+(	O
+also	O
+known	O
+L	O
+-	O
+SIGN	O
+),	O
+and	O
+DC	O
+-	O
+SIGN	O
+bind	B-FUNC
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+but	O
+ACE2	B-PRGE
+appears	O
+to	O
+be	O
+the	O
+key	O
+functional	O
+receptor	O
+for	O
+the	O
+virus	B-SPEC
+.	O
+
+By	O
+contrast	O
+there	O
+may	O
+be	O
+a	O
+lack	O
+of	O
+type	B-PRGE
+1	I-PRGE
+interferon	I-PRGE
+response	O
+.	O
+
+Seventy	O
+-	O
+eight	O
+(	O
+45	O
+.	O
+61	O
+%)	O
+patients	O
+continued	O
+to	O
+require	O
+prednisolone	B-CHED
+(<	O
+0	O
+.	O
+5mg	O
+.	O
+kg	O
+-	O
+1	O
+.	O
+d	O
+-	O
+1	O
+)	O
+for	O
+residual	O
+lung	B-ANAT
+opacities	B-DISO
+when	O
+data	O
+were	O
+collected	O
+.	O
+
+The	O
+detailed	O
+pathology	B-DISO
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+the	O
+viral	B-DISO
+infection	I-DISO
+are	O
+still	O
+not	O
+known	O
+.	O
+
+The	O
+3a	B-PRGE
+gene	I-PRGE
+encodes	O
+a	O
+non	O
+-	O
+structural	O
+viral	O
+protein	B-CHED
+,	O
+which	O
+is	O
+predicted	O
+to	O
+be	O
+a	O
+transmembrane	B-COMP
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+The	O
+impact	O
+of	O
+work	O
+-	O
+related	O
+risk	O
+on	O
+nurses	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+highly	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+with	O
+high	O
+potential	O
+for	O
+transmission	O
+to	O
+close	O
+contacts	O
+,	O
+particularly	O
+among	O
+healthcare	O
+workers	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+homogeneous	O
+screening	O
+assay	O
+for	O
+automated	O
+detection	O
+of	O
+antiviral	B-CHED
+agents	I-CHED
+active	O
+against	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+Thus	O
+,	O
+a	O
+screening	O
+system	O
+for	O
+anti	O
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+agents	O
+was	O
+developed	O
+,	O
+which	O
+evaluated	O
+compound	O
+potency	O
+,	O
+specificity	O
+and	O
+cytotoxicity	B-DISO
+at	O
+the	O
+initial	O
+screening	O
+phase	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+ability	O
+of	O
+residents	O
+to	O
+cope	O
+with	O
+the	O
+stress	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+was	O
+enhanced	O
+by	O
+the	O
+communication	O
+of	O
+relevant	O
+information	O
+and	O
+by	O
+the	O
+leadership	O
+of	O
+their	O
+supervisors	O
+and	O
+infection	B-DISO
+control	O
+officers	O
+.	O
+
+In	O
+addition	O
+,	O
+numbers	O
+of	O
+circulating	O
+CD4	B-PRGE
+and	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+exhibited	O
+milder	O
+reductions	O
+(	O
+2	O
+.	O
+1	O
+-	O
+and	O
+1	O
+.	O
+8	O
+-	O
+fold	O
+at	O
+week	O
+1	O
+)	O
+and	O
+earlier	O
+return	O
+to	O
+normal	O
+at	O
+a	O
+mean	O
+of	O
+weeks	O
+3	O
+and	O
+4	O
+,	O
+respectively	O
+.	O
+
+Our	O
+novel	O
+findings	O
+thus	O
+suggest	O
+that	O
+the	O
+acute	O
+SARS	B-DISO
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+probably	O
+contributes	O
+to	O
+the	O
+initial	O
+reduction	O
+of	O
+DC	O
+and	O
+T	O
+-	O
+cell	O
+subsets	O
+in	O
+blood	B-ANAT
+,	O
+and	O
+that	O
+high	O
+-	O
+dose	O
+steroid	B-CHED
+administration	O
+may	O
+subsequently	O
+exacerbate	O
+and	O
+prolong	O
+low	O
+expression	B-PROC
+of	O
+the	O
+cell	B-COMP
+subsets	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+dynamics	O
+of	O
+bovine	O
+respiratory	O
+syncytial	O
+virus	O
+(	O
+BRSV	B-SPEC
+),	O
+bovine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+3	I-SPEC
+(	O
+PIV	O
+-	O
+3	O
+),	O
+bovine	B-PRGE
+corona	B-CHED
+virus	B-SPEC
+(	I-PRGE
+BCoV	I-PRGE
+)	I-PRGE
+and	O
+bovine	B-DISO
+viral	I-DISO
+diarrhoea	I-DISO
+virus	B-SPEC
+(	O
+BVDV	B-SPEC
+)	O
+infections	B-DISO
+were	O
+studied	O
+in	O
+118	O
+dairy	O
+herds	O
+in	O
+south	O
+western	O
+Sweden	O
+.	O
+
+Despite	O
+the	O
+low	O
+knowledge	O
+score	O
+,	O
+the	O
+overall	O
+mean	O
+satisfaction	O
+score	O
+of	O
+the	O
+government	O
+'	O
+s	O
+response	O
+to	O
+SARS	B-DISO
+was	O
+4	O
+.	O
+47	O
+(	O
+out	O
+of	O
+possible	O
+highest	O
+score	O
+of	O
+5	O
+.	O
+00	O
+),	O
+with	O
+>	O
+93	O
+%	O
+of	O
+adult	O
+Singaporeans	O
+indicating	O
+that	O
+they	O
+were	O
+satisfied	O
+or	O
+very	O
+satisfied	O
+with	O
+the	O
+government	O
+'	O
+s	O
+response	O
+to	O
+SARS	B-DISO
+.	O
+
+It	O
+was	O
+subsequently	O
+given	O
+the	O
+name	B-SPEC
+""""	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+""""	O
+(	O
+SARS	B-DISO
+)	O
+following	O
+the	O
+occurrence	O
+of	O
+further	O
+outbreaks	O
+in	O
+Hanoi	O
+and	O
+Hong	O
+Kong	O
+in	O
+February	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+[	O
+RNase	B-ENZY
+III	I-ENZY
+-	O
+prepared	O
+short	O
+interfering	O
+RNAs	O
+induce	O
+degradation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+mRNAs	I-PRGE
+in	O
+human	B-SPEC
+cells	B-COMP
+].	O
+
+This	O
+work	O
+evaluated	O
+if	O
+RNase	B-PRGE
+III	I-PRGE
+-	O
+prepared	O
+short	O
+interfering	O
+RNAs	O
+can	O
+induce	O
+specific	O
+degradation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+mRNAs	I-PRGE
+in	O
+human	B-SPEC
+cells	B-COMP
+.	O
+
+Above	O
+plasmids	O
+and	O
+esiRNAs	O
+were	O
+co	O
+-	O
+transfected	O
+to	O
+HEK293F	O
+cells	B-COMP
+with	O
+reference	O
+plasmid	B-PRGE
+pRL	I-PRGE
+-	I-PRGE
+TK	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+changes	O
+and	O
+pattern	O
+of	O
+pulmonary	O
+function	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+during	O
+convalescent	O
+period	O
+.	O
+
+Restrictive	O
+pulmonary	B-PROC
+ventilation	I-PROC
+function	O
+and	O
+diffusing	O
+dysfunction	O
+of	O
+the	O
+lung	B-ANAT
+were	O
+found	O
+in	O
+one	O
+third	O
+of	O
+the	O
+patients	O
+during	O
+third	O
+to	O
+sixth	O
+month	O
+from	O
+onset	O
+.	O
+
+Pulmonary	B-ANAT
+dysfunction	O
+is	O
+found	O
+among	O
+some	O
+SARS	B-DISO
+patients	O
+after	O
+convalescence	O
+presenting	O
+mainly	O
+as	O
+restrictive	O
+ventilatory	O
+function	O
+and	O
+diffusing	O
+capacity	O
+abnormality	O
+.	O
+
+The	O
+laboratory	O
+findings	O
+of	O
+the	O
+4	O
+cases	O
+with	O
+SARS	B-DISO
+occurring	O
+in	O
+Guangzhou	O
+,	O
+People	O
+'	O
+s	O
+Republic	O
+of	O
+China	O
+,	O
+in	O
+2004	O
+were	O
+analyzed	O
+and	O
+compared	O
+with	O
+that	O
+during	O
+epidemic	O
+.	O
+
+The	O
+change	O
+in	O
+laboratory	O
+findings	O
+is	O
+less	O
+than	O
+that	O
+,	O
+which	O
+might	O
+be	O
+attributable	O
+to	O
+milder	O
+virulence	B-PROC
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+antibody	B-COMP
+appears	O
+earlier	O
+in	O
+these	O
+patients	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+eliminated	O
+rapidly	O
+.	O
+
+T	O
+cell	O
+subsets	O
+,	O
+and	O
+the	O
+number	O
+of	O
+leukocyte	B-ANAT
+are	O
+abnormal	O
+in	O
+some	O
+patients	O
+convalescent	O
+from	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinical	O
+,	O
+laboratory	O
+,	O
+and	O
+radiological	O
+features	O
+at	O
+presentation	O
+of	O
+16	O
+children	O
+(<	O
+12	O
+years	O
+)	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+pneumonia	B-DISO
+were	O
+compared	O
+with	O
+32	O
+age	O
+matched	O
+patients	O
+with	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+for	O
+determination	O
+of	O
+predictive	O
+factors	O
+that	O
+could	O
+allow	O
+early	O
+differentiation	B-PROC
+of	O
+the	O
+two	O
+conditions	O
+.	O
+
+A	O
+definitive	O
+contact	O
+history	O
+was	O
+the	O
+most	O
+important	O
+predictor	O
+for	O
+SARS	B-DISO
+.	O
+
+We	O
+measured	O
+risk	O
+perception	O
+and	O
+impact	O
+on	O
+personal	O
+and	O
+work	O
+life	O
+of	O
+15	O
+,	O
+025	O
+HCWs	O
+from	O
+9	O
+major	O
+healthcare	O
+institutions	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Singapore	O
+using	O
+a	O
+self	O
+-	O
+administered	O
+questionnaire	O
+and	O
+Impact	O
+of	O
+Events	O
+Scale	O
+and	O
+analyzed	O
+the	O
+results	O
+with	O
+bivariate	O
+and	O
+multivariate	O
+statistics	O
+.	O
+
+RESULTS	O
+:	O
+From	O
+10	O
+,	O
+511	O
+valid	O
+questionnaires	O
+(	O
+70	O
+%	O
+response	O
+),	O
+we	O
+found	O
+that	O
+although	O
+the	O
+majority	O
+(	O
+76	O
+%)	O
+perceived	O
+a	O
+great	O
+personal	O
+risk	O
+of	O
+falling	O
+ill	B-DISO
+with	O
+SARS	B-DISO
+,	O
+they	O
+(	O
+69	O
+.	O
+5	O
+%)	O
+also	O
+accepted	O
+the	O
+risk	O
+as	O
+part	O
+of	O
+their	O
+job	O
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+of	O
+potent	O
+anilide	B-CHED
+inhibitors	B-CHED
+against	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+3CL	O
+protease	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+epidemic	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+posed	O
+a	O
+worldwide	O
+threat	O
+to	O
+public	O
+health	O
+and	O
+economic	O
+stability	O
+.	O
+
+We	O
+expanded	O
+the	O
+specificity	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+epitope	B-CHED
+and	O
+identified	O
+4	O
+novel	O
+conformational	O
+epitopes	O
+(	O
+amino	B-CHED
+acids	I-CHED
+1	O
+-	O
+69	O
+,	O
+68	O
+-	O
+213	O
+,	O
+212	O
+-	O
+341	O
+,	O
+and	O
+337	O
+-	O
+422	O
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+a	O
+group	O
+of	O
+N	O
+individuals	O
+,	O
+carrying	O
+an	O
+infection	O
+with	O
+prevalence	O
+pi	O
+,	O
+the	O
+exact	O
+probability	O
+P	O
+of	O
+failing	O
+in	O
+detecting	O
+the	O
+infection	B-DISO
+is	O
+evaluated	O
+when	O
+a	O
+diagnostic	O
+test	O
+of	O
+sensitivity	O
+s	O
+and	O
+specificity	O
+s	O
+'	O
+is	O
+carried	O
+out	O
+on	O
+a	O
+sample	O
+of	O
+n	O
+individuals	O
+extracted	O
+without	O
+replacement	O
+from	O
+the	O
+group	O
+.	O
+
+These	O
+results	O
+are	O
+applied	O
+to	O
+recent	O
+data	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+A	O
+molecular	O
+docking	B-PROC
+model	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S1	I-PRGE
+protein	B-CHED
+in	O
+complex	O
+with	O
+its	O
+receptor	O
+,	O
+human	B-PRGE
+ACE2	I-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+virion	B-COMP
+N	O
+protein	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+is	O
+more	O
+phosphorylated	O
+than	O
+the	O
+N	B-PRGE
+protein	B-CHED
+from	O
+infected	O
+cell	B-COMP
+lysates	O
+.	O
+
+Although	O
+single	O
+substitution	O
+of	O
+these	O
+two	O
+residues	O
+had	O
+no	O
+effects	O
+on	O
+the	O
+infectivity	O
+of	O
+huSARS	O
+-	O
+CoV	O
+,	O
+these	O
+recombinant	O
+S	O
+proteins	B-CHED
+bound	O
+to	O
+human	B-PRGE
+ACE2	I-PRGE
+with	O
+different	O
+levels	O
+of	O
+reduced	O
+affinity	O
+,	O
+and	O
+the	O
+two	O
+-	O
+amino	B-CHED
+acid	I-CHED
+-	O
+substituted	O
+S	O
+protein	B-CHED
+showed	O
+extremely	O
+low	O
+affinity	O
+.	O
+
+This	O
+EVW	O
+delivers	O
+a	O
+broadband	O
+waveform	O
+that	O
+contains	O
+discrete	O
+frequencies	O
+blended	O
+to	O
+provide	O
+a	O
+tidal	O
+breath	O
+,	O
+followed	O
+by	O
+passive	O
+exhalation	B-PROC
+.	O
+
+Correlations	O
+were	O
+found	O
+between	O
+the	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+(	O
+PaO2	O
+)	O
+and	O
+the	O
+levels	O
+and	O
+frequency	O
+-	O
+dependent	O
+features	O
+of	O
+R	O
+and	O
+E	O
+that	O
+are	O
+indicative	O
+of	O
+mechanical	O
+heterogeneity	O
+and	O
+tissue	B-ANAT
+disease	O
+.	O
+
+Patients	O
+with	O
+dengue	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+are	O
+at	O
+high	O
+risk	O
+of	O
+mortality	O
+due	O
+to	O
+refractory	B-DISO
+shock	I-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Information	O
+about	O
+virion	B-COMP
+morphology	O
+and	O
+architecture	O
+,	O
+antigenic	O
+and	O
+biological	O
+properties	O
+,	O
+viral	B-COMP
+genome	I-COMP
+,	O
+protein	B-CHED
+composition	O
+,	O
+thermal	O
+and	O
+chemical	O
+stability	O
+,	O
+and	O
+pH	O
+and	O
+proteolytic	B-PROC
+enzymes	O
+resistance	B-PROC
+is	O
+also	O
+summarized	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+benefits	O
+of	O
+using	O
+plant	O
+-	O
+based	O
+oral	B-ANAT
+vaccines	O
+are	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreaks	O
+on	O
+the	O
+use	O
+of	O
+emergency	B-DISO
+department	O
+medical	O
+resources	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+impact	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+2003	O
+on	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+medical	O
+needs	O
+of	O
+adult	O
+patients	O
+has	O
+not	O
+been	O
+elucidated	O
+.	O
+
+The	O
+numbers	O
+of	O
+patients	O
+with	O
+ambulance	O
+transport	B-PROC
+,	O
+inter	O
+-	O
+hospital	O
+referral	O
+,	O
+and	O
+critical	B-DISO
+illnesses	I-DISO
+,	O
+including	O
+DOA	B-SPEC
+,	O
+categorized	O
+as	O
+triage	O
+1	O
+,	O
+or	O
+admitted	O
+to	O
+a	O
+ward	O
+or	O
+intensive	O
+care	O
+unit	O
+after	O
+the	O
+ED	O
+visit	O
+,	O
+were	O
+not	O
+influenced	O
+by	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+Nine	O
+broad	O
+categories	O
+were	O
+identified	O
+:	O
+uncertainty	O
+,	O
+information	O
+control	O
+,	O
+feelings	O
+of	O
+anger	O
+and	O
+guilt	O
+,	O
+lack	O
+of	O
+preparation	O
+and	O
+fear	O
+of	O
+death	B-PROC
+,	O
+feelings	O
+of	O
+isolation	O
+and	O
+loneliness	O
+,	O
+physical	O
+effects	O
+,	O
+support	O
+,	O
+change	O
+of	O
+perspective	O
+of	O
+life	O
+,	O
+and	O
+change	O
+of	O
+perspective	O
+of	O
+nursing	B-PROC
+.	O
+
+Mutations	O
+in	O
+ABCA3	B-PRGE
+cause	O
+fatal	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+newborns	O
+and	O
+severe	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+in	O
+infancy	O
+.	O
+
+A	O
+porcine	B-SPEC
+surfactant	B-CHED
+(	O
+poractant	O
+alfa	O
+)	O
+acts	O
+more	O
+rapidly	O
+than	O
+a	O
+bovine	B-SPEC
+preparation	O
+(	O
+beractant	O
+)	O
+in	O
+infants	O
+with	O
+moderate	O
+to	O
+severe	O
+RDS	O
+.	O
+
+CONCLUSIONS	O
+:	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+neutrophil	B-ANAT
+activator	O
+production	O
+by	O
+the	O
+isolated	O
+perfused	O
+liver	B-ANAT
+,	O
+in	O
+response	O
+to	O
+a	O
+'	O
+second	O
+hit	O
+'	O
+of	O
+portal	B-ANAT
+LPS	B-DISO
+,	O
+does	O
+not	O
+appear	O
+to	O
+be	O
+enhanced	O
+during	O
+AP	O
+.	O
+
+Two	O
+outbreaks	O
+,	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+have	O
+recently	O
+provided	O
+important	O
+lessons	O
+on	O
+how	O
+transplant	B-ANAT
+patients	O
+are	O
+affected	O
+,	O
+and	O
+how	O
+transplant	B-ANAT
+programmes	O
+must	O
+adapt	O
+and	O
+evolve	O
+in	O
+the	O
+face	B-DISO
+of	O
+emerging	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+the	O
+last	O
+years	O
+,	O
+several	O
+observational	O
+studies	O
+have	O
+suggested	O
+that	O
+extracorporeal	O
+lung	O
+assist	O
+(	O
+ECLA	O
+)	O
+may	O
+be	O
+an	O
+important	O
+contribution	O
+to	O
+clinical	O
+algorithms	O
+for	O
+the	O
+treatment	O
+of	O
+most	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Today	O
+ECLA	O
+is	O
+used	O
+only	O
+as	O
+a	O
+rescue	O
+therapy	O
+in	O
+life	O
+threatening	O
+gas	B-ENZY
+exchange	O
+disorders	O
+if	O
+maximal	O
+conventional	O
+therapy	O
+fails	O
+to	O
+prevent	O
+from	O
+hypoxemia	O
+.	O
+
+TITLE	O
+:	O
+Phylogenetic	O
+and	O
+recombination	B-PROC
+analysis	O
+of	O
+coronavirus	B-SPEC
+HKU1	O
+,	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+from	O
+patients	O
+with	O
+pneumonia	O
+.	O
+
+ABSTRACT	O
+:	O
+All	O
+living	O
+organisms	O
+are	O
+continuously	O
+exposed	O
+to	O
+a	O
+plethora	O
+of	O
+viruses	B-SPEC
+.	O
+
+Recent	O
+examples	O
+of	O
+viruses	B-SPEC
+that	O
+have	O
+crossed	O
+the	O
+species	B-SPEC
+barrier	O
+from	O
+animal	B-SPEC
+reservoirs	O
+to	O
+humans	B-SPEC
+are	O
+hantavirus	B-SPEC
+,	O
+haemorrhagic	B-DISO
+fever	I-DISO
+viruses	B-SPEC
+,	O
+arboviruses	O
+,	O
+Nipah	O
+and	O
+Hendra	O
+viruses	B-SPEC
+,	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AI	O
+),	O
+monkeypox	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Against	O
+this	O
+background	O
+the	O
+intensified	O
+use	O
+of	O
+viruses	B-SPEC
+and	O
+their	O
+genetically	O
+modified	O
+variants	O
+as	O
+viral	O
+gene	O
+transfer	O
+vectors	O
+for	O
+biomedical	O
+research	O
+,	O
+experimental	O
+gene	O
+therapy	O
+and	O
+for	O
+live	O
+-	O
+vector	O
+vaccines	O
+is	O
+a	O
+cause	O
+for	O
+concern	O
+.	O
+
+The	O
+issues	O
+are	O
+raised	O
+with	O
+the	O
+intention	O
+to	O
+assist	O
+in	O
+risk	O
+assessments	O
+for	O
+activities	O
+with	O
+vector	O
+viruses	B-SPEC
+.	O
+
+Out	O
+of	O
+the	O
+total	O
+24	O
+fecal	B-ANAT
+samples	O
+from	O
+raccoon	B-SPEC
+dogs	I-SPEC
+,	O
+22	O
+were	O
+CCV	B-DISO
+positive	O
+for	O
+type	O
+II	O
+and	O
+16	O
+for	O
+type	O
+I	O
+.	O
+M	O
+gene	O
+fragments	O
+of	O
+8	O
+samples	O
+were	O
+sequenced	O
+,	O
+4	O
+of	O
+which	O
+were	O
+confirmed	O
+as	O
+CCV	B-PRGE
+type	I-PRGE
+I	I-PRGE
+and	O
+the	O
+other	O
+4	O
+as	O
+CCV	B-DISO
+type	O
+II	O
+.	O
+
+Interestingly	O
+,	O
+the	O
+sequence	O
+at	O
+several	O
+nucleic	O
+acid	O
+sites	O
+of	O
+CCV	B-PRGE
+type	I-PRGE
+II	I-PRGE
+differed	O
+between	O
+foxes	O
+and	O
+raccoon	B-SPEC
+dogs	I-SPEC
+.	O
+
+The	O
+first	O
+radiographic	O
+study	O
+showed	O
+a	O
+mass	O
+filling	O
+the	O
+whole	O
+left	B-ANAT
+thorax	I-ANAT
+cage	O
+causing	O
+erosion	B-DISO
+of	O
+the	O
+inferior	O
+edge	O
+of	O
+the	O
+third	B-ANAT
+rib	I-ANAT
+.	O
+
+Microscopically	O
+,	O
+it	O
+was	O
+an	O
+inflammatory	B-DISO
+myofibroblastic	I-DISO
+tumor	I-DISO
+.	O
+
+It	O
+was	O
+composed	O
+mainly	O
+of	O
+spindle	B-COMP
+-	O
+shaped	O
+cells	B-COMP
+without	O
+malignant	O
+features	O
+.	O
+
+To	O
+compare	O
+the	O
+BMD	B-DISO
+of	O
+SARS	B-DISO
+patients	O
+with	O
+normal	O
+range	O
+data	O
+,	O
+a	O
+cross	O
+-	O
+sectional	O
+survey	O
+was	O
+conducted	O
+.	O
+
+S	O
+-	O
+peptide	B-CHED
+,	O
+mice	B-SPEC
+primed	O
+with	O
+i	O
+.	O
+m	O
+.	O
+
+tPA	B-PRGE
+-	I-PRGE
+S	I-PRGE
+-	I-PRGE
+DNA	I-PRGE
+boosted	O
+with	O
+i	O
+.	O
+p	O
+.	O
+
+A	O
+series	O
+of	O
+tripeptide	B-CHED
+alpha	O
+,	O
+beta	O
+-	O
+unsaturated	O
+esters	B-CHED
+and	O
+ketomethylene	O
+isosteres	O
+,	O
+including	O
+AG7088	O
+,	O
+are	O
+synthesized	O
+and	O
+assayed	O
+to	O
+target	O
+the	O
+3CL	B-PRGE
+protease	I-PRGE
+.	O
+
+All	O
+cats	B-SPEC
+diagnosed	O
+with	O
+FIP	B-DISO
+at	O
+a	O
+veterinary	O
+teaching	O
+hospital	O
+over	O
+a	O
+16	O
+-	O
+year	O
+period	O
+were	O
+identified	O
+.	O
+
+TITLE	O
+:	O
+VEGF	B-PRGE
+levels	O
+in	O
+the	O
+alveolar	B-ANAT
+compartment	B-ANAT
+do	O
+not	O
+distinguish	O
+between	O
+ARDS	B-DISO
+and	O
+hydrostatic	O
+pulmonary	B-ANAT
+oedema	I-DISO
+.	O
+
+Vascular	B-PROC
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PROC
+levels	O
+in	O
+pulmonary	B-DISO
+oedema	I-DISO
+fluid	O
+were	O
+depressed	O
+both	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+hydrostatic	O
+pulmonary	B-DISO
+oedema	I-DISO
+.	O
+
+Six	O
+patients	O
+developed	O
+a	O
+non	B-DISO
+-	I-DISO
+Hodgkin	I-DISO
+'	I-DISO
+s	I-DISO
+lymphoma	I-DISO
+,	O
+and	O
+five	O
+died	B-PROC
+.	O
+
+The	O
+remaining	O
+patients	O
+survived	O
+showing	O
+a	O
+good	O
+neurologic	B-PROC
+function	I-PROC
+.	O
+
+Rates	O
+of	O
+rejection	O
+,	O
+decline	O
+in	O
+forced	B-PROC
+expiratory	I-PROC
+volume	I-PROC
+(	O
+L	O
+)	O
+in	O
+1	O
+s	O
+(	O
+FEV	B-SPEC
+-	O
+1	O
+)	O
+and	O
+bacterial	O
+and	O
+fungal	O
+superinfection	B-DISO
+were	O
+compared	O
+at	O
+the	O
+3	O
+-	O
+month	O
+primary	O
+endpoint	O
+.	O
+
+Few	O
+studies	O
+have	O
+been	O
+conducted	O
+into	O
+the	O
+function	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+nsp5	B-PRGE
+.	O
+
+The	O
+protein	B-CHED
+encoded	O
+by	O
+the	O
+nsp5	B-PRGE
+gene	I-PRGE
+was	O
+expressed	B-PROC
+in	O
+COS	O
+-	O
+7	O
+cells	B-COMP
+and	O
+analyzed	O
+by	O
+sodium	B-CHED
+dodecylsulfate	I-CHED
+-	O
+polyacrylamide	B-CHED
+gel	O
+electrophoresis	O
+(	O
+SDS	B-DISO
+-	O
+PAGE	O
+).	O
+
+PaO2	O
+/	O
+FIO2	O
+was	O
+significantly	O
+better	O
+in	O
+PP	O
+:	O
+190	O
++/-	O
+26	O
+vs	O
+.	O
+113	O
++/-	O
+9	O
+mmHg	O
+for	O
+PP1	B-PRGE
+/	O
+SP1	B-PRGE
+,	O
+175	O
++/-	O
+22	O
+vs	O
+.	O
+135	O
++/-	O
+16	O
+mmHg	O
+for	O
+PP2	B-PRGE
+/	O
+SP2	B-PRGE
+,	O
+and	O
+199	O
++/-	O
+24	O
+vs	O
+.	O
+151	O
++/-	O
+13	O
+mmHg	O
+for	O
+PP3	B-PRGE
+/	O
+SP3	B-PRGE
+.	O
+
+However	O
+,	O
+no	O
+recombinant	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+(	O
+S	O
+)-	O
+based	O
+ELISA	O
+is	O
+currently	O
+available	O
+.	O
+
+The	O
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+-	O
+based	O
+immunoglobulin	B-PRGE
+M	I-PRGE
+(	O
+IgM	B-PRGE
+)	O
+and	O
+IgG	B-PRGE
+ELISAs	I-PRGE
+were	O
+evaluated	O
+and	O
+compared	O
+with	O
+the	O
+corresponding	O
+N	O
+-	O
+based	O
+ELISA	O
+for	O
+serodiagnosis	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+pneumonia	B-DISO
+,	O
+using	O
+sera	B-COMP
+from	O
+148	O
+healthy	O
+blood	B-ANAT
+donors	O
+who	O
+donated	O
+blood	B-ANAT
+3	O
+years	O
+ago	O
+as	O
+controls	O
+and	O
+95	O
+SARS	B-DISO
+-	O
+CoV	O
+pneumonia	B-DISO
+patients	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+the	O
+most	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+is	O
+a	O
+devastating	O
+clinical	O
+syndrome	B-DISO
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+(	O
+30	O
+-	O
+60	O
+%)	O
+(	O
+refs	O
+1	O
+-	O
+3	O
+).	O
+
+ABSTRACT	O
+:	O
+Gas	B-PRGE
+exchange	O
+alterations	O
+have	O
+been	O
+described	O
+in	O
+cirrhotic	O
+patients	O
+;	O
+but	O
+by	O
+the	O
+moment	O
+,	O
+a	O
+few	O
+prospective	O
+studies	O
+have	O
+focused	O
+in	O
+them	O
+.	O
+
+The	O
+most	O
+prevalent	O
+gas	B-ENZY
+exchange	O
+abnormality	O
+in	O
+cirrhosis	B-DISO
+was	O
+the	O
+alteration	O
+of	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+gradient	O
+,	O
+directly	O
+correlated	O
+with	O
+hepatocellur	O
+disfunction	O
+.	O
+
+Inapparent	B-DISO
+infection	I-DISO
+with	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+is	O
+not	O
+well	O
+characterized	O
+.	O
+
+On	O
+multivariate	O
+analysis	O
+,	O
+hemoglobin	B-PRGE
+level	O
+was	O
+an	O
+independent	O
+prognostic	O
+correlate	O
+of	O
+hypoxemia	O
+or	O
+mortality	O
+(	O
+odds	O
+ratio	O
+,	O
+2	O
+.	O
+0	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+1	O
+to	O
+3	O
+.	O
+8	O
+;	O
+p	O
+=	O
+0	O
+.	O
+03	O
+).	O
+
+Only	O
+one	O
+of	O
+seven	O
+SARS	B-DISO
+patients	O
+(	O
+14	O
+%)	O
+who	O
+was	O
+not	O
+receiving	O
+ribavirin	B-CHED
+became	O
+anemic	O
+,	O
+but	O
+this	O
+individual	O
+was	O
+not	O
+hypoxemic	O
+.	O
+
+Hypoxia	B-DISO
+combined	O
+with	O
+anemia	B-DISO
+increased	O
+the	O
+risk	O
+for	O
+death	B-PROC
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+For	O
+random	O
+networks	O
+with	O
+a	O
+high	O
+average	O
+number	O
+of	O
+connections	O
+per	O
+node	B-ANAT
+,	O
+little	O
+clustering	O
+of	O
+connections	O
+and	O
+short	O
+latency	O
+periods	B-PROC
+,	O
+contact	O
+tracing	O
+is	O
+typically	O
+ineffective	O
+.	O
+
+In	O
+this	O
+case	O
+,	O
+isolation	O
+of	O
+infected	O
+nodes	B-ANAT
+is	O
+the	O
+dominant	O
+factor	O
+in	O
+determining	O
+disease	B-DISO
+epidemic	I-DISO
+size	O
+and	O
+duration	O
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+and	O
+laboratory	O
+data	O
+indicate	O
+that	O
+the	O
+liver	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+incidence	O
+,	O
+pathogenesis	B-DISO
+,	O
+and	O
+outcome	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+When	O
+only	O
+the	O
+lung	B-ANAT
+was	O
+perfused	O
+,	O
+endotoxin	O
+caused	O
+pulmonary	B-DISO
+hypertension	I-DISO
+and	O
+neutropenia	O
+;	O
+but	O
+oxygenation	B-PROC
+was	O
+maintained	O
+;	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+and	O
+8	B-CHED
+-	I-CHED
+isoprostane	I-CHED
+levels	O
+were	O
+minimally	O
+elevated	O
+;	O
+and	O
+there	O
+was	O
+no	O
+lung	B-DISO
+edema	I-DISO
+.	O
+
+We	O
+conclude	O
+that	O
+the	O
+direct	O
+effects	O
+of	O
+endotoxemia	O
+on	O
+the	O
+lungs	B-ANAT
+include	O
+vasoconstriction	B-DISO
+and	O
+leukocyte	B-ANAT
+sequestration	O
+,	O
+but	O
+not	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+several	O
+months	O
+of	O
+2003	O
+,	O
+a	O
+newly	O
+identified	O
+illness	O
+termed	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+spread	O
+rapidly	O
+through	O
+the	O
+world	O
+.	O
+
+In	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+potential	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+.	O
+
+Seven	O
+of	O
+nine	O
+(	O
+77	O
+.	O
+8	O
+%)	O
+patients	O
+survived	O
+;	O
+two	O
+died	B-PROC
+because	O
+of	O
+severe	O
+ARDS	B-DISO
+,	O
+MODS	B-DISO
+,	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+It	O
+is	O
+easy	O
+to	O
+provide	O
+good	O
+sanitation	O
+practices	O
+for	O
+human	B-SPEC
+,	O
+pigs	B-SPEC
+and	O
+chickens	B-SPEC
+,	O
+introducing	O
+collection	O
+and	O
+treatment	O
+of	O
+excreta	O
+.	O
+
+Spatial	O
+analysis	O
+of	O
+case	O
+specimens	O
+by	O
+use	O
+of	O
+GIS	O
+indicated	O
+that	O
+diarrhea	B-DISO
+was	O
+widespread	O
+throughout	O
+the	O
+entire	O
+shelter	O
+,	O
+and	O
+spatial	O
+statistical	O
+analysis	O
+revealed	O
+no	O
+evidence	O
+of	O
+spatial	O
+clustering	O
+of	O
+case	O
+specimens	O
+.	O
+
+Thus	O
+ACE2	O
+has	O
+only	O
+one	O
+chloride	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+site	I-PRGE
+(	O
+CL1	B-PRGE
+)	O
+whereas	O
+ACE	B-PRGE
+has	O
+two	O
+sites	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+study	O
+to	O
+address	O
+the	O
+differences	O
+that	O
+exist	O
+between	O
+ACE2	B-PRGE
+and	O
+ACE	B-PRGE
+at	O
+the	O
+molecular	O
+level	O
+.	O
+
+In	O
+situ	O
+hybridization	B-PROC
+for	O
+coronavirus	B-SPEC
+was	O
+negative	O
+in	O
+all	O
+subjects	O
+.	O
+
+The	O
+viral	O
+culture	O
+yielded	O
+no	O
+organisms	O
+and	O
+there	O
+were	O
+no	O
+viral	B-COMP
+particles	I-COMP
+seen	O
+on	O
+electron	O
+microscopic	O
+examination	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+recruited	O
+688	O
+hospital	O
+healthcare	O
+workers	O
+who	O
+cared	O
+for	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+did	O
+not	O
+develop	O
+the	O
+disease	O
+in	O
+the	O
+Hong	O
+Kong	O
+outbreak	O
+in	O
+2003	O
+.	O
+
+The	O
+mean	O
+absolute	O
+neutrophil	B-ANAT
+count	O
+of	O
+patients	O
+was	O
+398	O
+.	O
+2	O
++/-	O
+
+During	O
+follow	O
+-	O
+up	O
+,	O
+respiratory	B-DISO
+infections	I-DISO
+developed	O
+in	O
+24	O
+cases	O
+,	O
+oral	B-DISO
+manifestations	I-DISO
+in	O
+20	O
+patients	O
+.	O
+
+Three	O
+patients	O
+died	B-PROC
+of	O
+recurrent	O
+infections	B-DISO
+.	O
+
+Stem	B-ANAT
+cell	I-ANAT
+banks	O
+should	O
+assure	O
+the	O
+quality	O
+,	O
+traceability	O
+and	O
+safety	O
+of	O
+cultures	O
+for	O
+transplantation	O
+and	O
+must	O
+implement	O
+an	O
+effective	O
+programme	O
+to	O
+prevent	O
+contamination	O
+of	O
+the	O
+final	O
+product	O
+.	O
+
+The	O
+proportion	O
+of	O
+doctors	O
+and	O
+nurses	O
+who	O
+undertook	O
+each	O
+measure	O
+significantly	O
+improved	O
+(	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+9	O
+.	O
+8551	O
+,	O
+P	O
+=	O
+0	O
+.	O
+043	O
+)	O
+after	O
+the	O
+onset	O
+of	O
+secondary	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Important	O
+roles	O
+for	O
+gamma	B-PRGE
+interferon	I-PRGE
+and	O
+NKG2D	B-PRGE
+in	O
+gammadelta	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+-	O
+induced	O
+demyelination	B-DISO
+in	O
+T	O
+-	O
+cell	O
+receptor	O
+beta	O
+-	O
+deficient	O
+mice	B-SPEC
+infected	O
+with	O
+a	O
+coronavirus	B-SPEC
+.	O
+
+Most	O
+strikingly	O
+,	O
+our	O
+results	O
+also	O
+show	O
+a	O
+major	O
+role	O
+for	O
+NKG2D	B-PRGE
+,	O
+expressed	B-PROC
+on	O
+gammadelta	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+in	O
+the	O
+demyelinating	O
+process	O
+with	O
+in	O
+vivo	O
+blockade	O
+of	O
+NKG2D	B-PRGE
+interactions	O
+resulting	O
+in	O
+a	O
+60	O
+%	O
+reduction	O
+in	O
+demyelination	B-DISO
+.	O
+
+Importantly	O
+,	O
+both	O
+ACE	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+viral	B-PRGE
+antigen	I-PRGE
+appeared	O
+to	O
+preferentially	O
+colocalize	O
+at	O
+the	O
+apical	O
+domain	O
+of	O
+infected	O
+cells	B-COMP
+.	O
+
+Active	O
+P	O
+-	O
+PMO	O
+were	O
+effective	O
+when	O
+administered	O
+at	O
+any	O
+time	O
+prior	O
+to	O
+peak	O
+viral	O
+synthesis	B-PROC
+and	O
+exerted	B-PROC
+sustained	O
+antiviral	O
+effects	O
+while	O
+present	O
+in	O
+culture	O
+medium	O
+.	O
+
+After	O
+several	O
+viral	O
+passages	O
+in	O
+the	O
+presence	O
+of	O
+a	O
+TRS	B-DISO
+-	O
+targeted	B-PROC
+P	O
+-	O
+PMO	O
+,	O
+partially	O
+drug	O
+-	O
+resistant	O
+SARS	B-DISO
+-	O
+CoV	O
+mutants	O
+arose	O
+which	O
+contained	O
+three	O
+contiguous	O
+base	O
+point	B-PROC
+mutations	I-PROC
+at	O
+the	O
+binding	B-FUNC
+site	O
+of	O
+a	O
+TRS	B-DISO
+-	O
+targeted	B-PROC
+P	O
+-	O
+PMO	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+defined	O
+the	O
+mechanism	O
+and	O
+extent	O
+of	O
+lipid	B-COMP
+raft	I-COMP
+involvement	O
+in	O
+MHV	B-SPEC
+replication	O
+.	O
+
+Furthermore	O
+,	O
+MHV	B-PRGE
+spike	I-PRGE
+protein	B-CHED
+bound	O
+to	O
+nonraftraft	O
+membrane	B-COMP
+at	O
+4	O
+degrees	O
+C	O
+but	O
+shifted	O
+to	O
+lipid	B-COMP
+rafts	I-COMP
+at	O
+37	O
+degrees	O
+C	O
+,	O
+indicating	O
+a	O
+redistribution	O
+of	O
+membrane	B-COMP
+following	O
+virus	B-SPEC
+binding	B-FUNC
+.	O
+
+We	O
+also	O
+found	O
+that	O
+the	O
+viral	O
+spike	O
+protein	B-CHED
+in	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+of	O
+the	O
+infected	O
+cells	B-COMP
+was	O
+associated	O
+with	O
+lipid	B-COMP
+rafts	I-COMP
+,	O
+whereas	O
+that	O
+in	O
+the	O
+Golgi	B-COMP
+membrane	I-COMP
+,	O
+where	O
+MHV	B-SPEC
+matures	O
+,	O
+was	O
+not	O
+.	O
+
+However	O
+,	O
+MHV	B-SPEC
+spike	O
+protein	B-CHED
+has	O
+an	O
+inherent	O
+ability	O
+to	O
+associate	O
+with	O
+lipid	B-COMP
+rafts	I-COMP
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+MHV	B-SPEC
+entry	O
+requires	O
+specific	O
+interactions	O
+between	O
+the	O
+spike	O
+protein	B-CHED
+and	O
+lipid	B-COMP
+rafts	I-COMP
+,	O
+probably	O
+during	O
+the	O
+virus	B-SPEC
+internalization	O
+step	O
+.	O
+
+The	O
+authors	O
+conducted	O
+15	O
+focus	O
+groups	O
+of	O
+health	O
+care	O
+workers	O
+representing	O
+seven	O
+different	O
+job	O
+classifications	O
+in	O
+two	O
+Canadian	O
+provinces	O
+where	O
+SARS	B-DISO
+outbreaks	O
+occurred	O
+in	O
+2003	O
+using	O
+a	O
+theoretical	O
+framework	O
+which	O
+divided	O
+factors	O
+associated	O
+with	O
+self	O
+-	O
+protective	O
+behaviour	B-PROC
+at	O
+work	O
+into	O
+organizational	O
+,	O
+environmental	O
+,	O
+and	O
+individual	O
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+recognized	O
+as	O
+a	O
+new	O
+human	B-SPEC
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Elderly	O
+participants	O
+who	O
+perceived	O
+greater	O
+personal	O
+vulnerability	O
+to	O
+the	O
+disease	O
+,	O
+who	O
+possessed	B-DISO
+greater	O
+self	O
+-	O
+efficacy	O
+,	O
+who	O
+had	O
+greater	O
+confidence	O
+in	O
+local	O
+health	O
+authorities	O
+,	O
+and	O
+who	O
+had	O
+lower	O
+educational	O
+attainment	O
+were	O
+more	O
+likely	O
+to	O
+adopt	O
+the	O
+suggested	O
+SARS	B-DISO
+preventive	O
+behaviors	B-PROC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+on	O
+successful	O
+craniotomy	O
+under	O
+ECMO	O
+treatment	O
+in	O
+a	O
+multiply	O
+traumatized	O
+patient	O
+with	O
+severe	O
+thoracic	B-DISO
+and	O
+brain	B-ANAT
+injuries	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Effectiveness	O
+of	O
+hemofiltration	O
+in	O
+patients	O
+with	O
+peritonitis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+TITLE	O
+:	O
+Occupational	O
+deaths	B-PROC
+among	O
+healthcare	O
+workers	O
+.	O
+
+Most	O
+emergency	B-DISO
+departments	O
+provided	O
+PPE	B-CHED
+(	O
+80	O
+%)	O
+and	O
+implemented	O
+ICMs	O
+(	O
+66	O
+%)	O
+at	O
+late	O
+stages	O
+of	O
+the	O
+outbreak	O
+.	O
+
+Of	O
+all	O
+exposed	O
+HCWs	O
+,	O
+7	O
+.	O
+5	O
+%	O
+had	O
+asymptomatic	O
+SARS	B-DISO
+-	O
+positive	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Adenoviral	B-SPEC
+expression	B-PROC
+of	O
+a	O
+truncated	O
+S1	O
+subunit	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+results	O
+in	O
+specific	O
+humoral	O
+immune	O
+responses	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+rats	B-SPEC
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+all	O
+of	O
+the	O
+immunized	O
+animals	B-SPEC
+generated	O
+humoral	B-PROC
+immunity	I-PROC
+against	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+,	O
+and	O
+the	O
+sera	B-COMP
+of	O
+immunized	O
+rats	B-SPEC
+showed	O
+strong	O
+capable	O
+of	O
+protecting	O
+from	O
+SARS	O
+-	O
+CoV	O
+infection	O
+in	O
+vitro	O
+.	O
+
+Clinically	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+was	O
+found	O
+to	O
+be	O
+second	O
+to	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+alone	O
+,	O
+as	O
+a	O
+cause	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+while	O
+duration	O
+of	O
+virus	B-SPEC
+excretion	B-PROC
+appeared	O
+to	O
+correlate	O
+with	O
+severity	O
+of	O
+infection	B-DISO
+,	O
+and	O
+virus	B-SPEC
+load	O
+in	O
+NPA	B-CHED
+with	O
+the	O
+stage	O
+of	O
+respiratory	B-DISO
+infection	I-DISO
+.	O
+
+RESULTS	O
+:	O
+RT	O
+-	O
+PCR	O
+detected	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+in	O
+40	O
+/	O
+306	O
+(	O
+13	O
+.	O
+1	O
+%)	O
+children	O
+positive	O
+for	O
+respiratory	O
+viruses	B-SPEC
+,	O
+with	O
+an	O
+incidence	O
+intermediate	O
+between	O
+that	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+58	O
+patients	O
+,	O
+18	O
+.	O
+9	O
+%)	O
+and	O
+that	O
+of	O
+influenzavirus	B-SPEC
+infections	B-DISO
+(	O
+29	O
+patients	O
+,	O
+9	O
+.	O
+5	O
+%).	O
+
+Hydrophobic	O
+regions	O
+with	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+from	O
+61	O
+to	O
+90	O
+,	O
+from	O
+91	O
+to	O
+100	O
+,	O
+from	O
+136	O
+to	O
+170	O
+,	O
+are	O
+essential	O
+for	O
+this	O
+protein	B-CHED
+aggregation	O
+.	O
+
+Korean	O
+IBV	B-SPEC
+isolates	O
+K069	O
+-	O
+01	O
+,	O
+K281	O
+-	O
+01	O
+,	O
+K434	O
+-	O
+01	O
+,	O
+K504	O
+-	O
+01	O
+,	O
+K774	O
+-	O
+01	O
+,	O
+K748	O
+-	O
+01	O
+,	O
+K044	O
+-	O
+02	O
+,	O
+K058	O
+-	O
+02	O
+,	O
+K161	O
+-	O
+02	O
+,	O
+K203	O
+-	O
+02	O
+,	O
+and	O
+K234	O
+-	O
+02	O
+formed	O
+an	O
+independent	O
+cluster	O
+comprised	O
+only	O
+of	O
+Korean	O
+IBV	B-SPEC
+isolates	O
+.	O
+
+With	O
+regard	O
+to	O
+analytical	O
+sensitivity	O
+,	O
+RICT	O
+detected	O
+N	O
+-	O
+Ag	O
+at	O
+31	O
+pg	O
+/	O
+mL	O
+for	O
+recombinant	O
+N	O
+-	O
+Ag	O
+,	O
+and	O
+at	O
+1	O
+.	O
+99	O
+x	O
+10	O
+(	O
+2	O
+)	O
+TCID	O
+(	O
+50	O
+)/	O
+mL	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+specificity	O
+of	O
+RICT	O
+was	O
+100	O
+%	O
+when	O
+150	O
+human	B-SPEC
+sera	B-COMP
+and	O
+50	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+NSPs	O
+)	O
+were	O
+used	O
+.	O
+
+The	O
+results	O
+have	O
+relevance	O
+to	O
+any	O
+radiotherapy	O
+department	O
+preparing	O
+contingency	O
+plans	O
+in	O
+the	O
+event	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+The	O
+N	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+has	O
+been	O
+cloned	O
+into	O
+a	O
+yeast	B-SPEC
+expression	B-PROC
+vector	O
+pPIC9	O
+,	O
+transformed	O
+into	O
+Pichia	B-SPEC
+pastoris	I-SPEC
+strain	O
+GS115	O
+and	O
+induced	O
+for	O
+expression	B-PROC
+by	O
+methanol	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+No	O
+antibodies	B-COMP
+against	O
+organs	B-ANAT
+but	O
+lung	B-ANAT
+were	O
+found	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+method	O
+for	O
+cultivation	O
+and	O
+inactivation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+In	O
+order	B-SPEC
+to	O
+choose	O
+the	O
+sensitive	O
+cell	B-ANAT
+strain	I-ANAT
+and	O
+the	O
+best	O
+infection	B-DISO
+dose	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+Vero	O
+,	O
+Vero	O
+-	O
+E6	O
+and	O
+2BS	O
+cell	B-ANAT
+lines	I-ANAT
+were	O
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+cultivation	O
+temperature	O
+was	O
+selected	O
+among	O
+25	O
+degrees	O
+C	O
+,	O
+33	O
+degrees	O
+C	O
+and	O
+37	O
+degrees	O
+C	O
+.	O
+The	O
+best	O
+inactivating	O
+time	O
+and	O
+effect	O
+were	O
+observed	O
+with	O
+beta	B-CHED
+-	I-CHED
+propiolactone	I-CHED
+whose	O
+concentration	O
+ranged	O
+from	O
+1	O
+:	O
+2000	O
+to	O
+1	O
+:	O
+20	O
+,	O
+000	O
+at	O
+room	O
+temperature	O
+.	O
+
+The	O
+36	O
+serum	B-COMP
+samples	O
+and	O
+40	O
+mouthwash	O
+of	O
+SARS	B-DISO
+patients	O
+and	O
+80	O
+samples	O
+of	O
+healthy	O
+people	O
+were	O
+tested	O
+.	O
+
+The	O
+simple	O
+nested	O
+RT	O
+-	O
+PCR	O
+method	O
+was	O
+a	O
+rapid	O
+,	O
+efficient	O
+and	O
+sensitive	O
+one	O
+for	O
+SARS	B-DISO
+early	O
+diagnosis	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+positive	O
+rate	O
+of	O
+patient	O
+serum	B-COMP
+and	O
+mouthwash	O
+was	O
+33	O
+.	O
+6	O
+%,	O
+(	O
+12	O
+/	O
+36	O
+)	O
+and	O
+67	O
+.	O
+5	O
+%,	O
+(	O
+27	O
+/	O
+40	O
+),	O
+respectively	O
+,	O
+while	O
+the	O
+positive	O
+rate	O
+of	O
+healthy	O
+people	O
+was	O
+zero	O
+(	O
+0	O
+/	O
+160	O
+).	O
+
+TITLE	O
+:	O
+A	O
+case	O
+-	O
+control	O
+study	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+general	O
+practice	O
+patients	O
+in	O
+The	O
+Netherlands	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+asymptomatic	O
+persons	O
+could	O
+have	O
+a	O
+subclinical	B-DISO
+infection	I-DISO
+and	O
+thus	O
+act	O
+as	O
+a	O
+source	O
+of	O
+transmission	O
+.	O
+
+Viruses	B-SPEC
+were	O
+detected	O
+in	O
+58	O
+%	O
+of	O
+the	O
+case	O
+patients	O
+,	O
+beta	O
+-	O
+hemolytic	O
+streptococci	O
+group	O
+A	O
+were	O
+detected	O
+in	O
+11	O
+%,	O
+and	O
+mixed	B-DISO
+infections	I-DISO
+were	O
+detected	O
+in	O
+3	O
+%.	O
+
+This	O
+study	O
+confirms	O
+that	O
+most	O
+ARTIs	O
+are	O
+viral	O
+and	O
+supports	O
+the	O
+reserved	O
+policy	O
+of	O
+prescribing	O
+antibiotics	B-CHED
+.	O
+
+The	O
+variant	O
+feline	B-SPEC
+coronaviruses	O
+that	O
+cause	O
+invariably	O
+-	O
+fatal	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+arise	O
+by	O
+sporadic	O
+mutation	O
+of	O
+an	O
+ubiquitous	O
+and	O
+only	O
+mildly	O
+pathogenic	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+);	O
+a	O
+finding	O
+that	O
+has	O
+substantial	O
+management	O
+implications	O
+for	O
+cat	B-SPEC
+breeders	O
+and	O
+veterinarians	O
+.	O
+
+Conversely	O
+,	O
+canine	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+CECV	O
+)	O
+shows	O
+considerable	O
+genetic	O
+and	O
+antigenic	B-PROC
+diversity	I-PROC
+but	O
+causes	O
+only	O
+mild	O
+,	O
+self	O
+-	O
+limiting	O
+diarrhoea	B-DISO
+in	O
+puppies	O
+.	O
+
+Feline	B-SPEC
+and	O
+canine	O
+rotaviruses	B-SPEC
+have	O
+combined	O
+with	O
+human	B-SPEC
+rotaviruses	B-SPEC
+to	O
+produce	O
+new	O
+,	O
+reassortant	O
+,	O
+zoonotic	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Chest	B-ANAT
+radiograph	O
+screening	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+ED	O
+.	O
+
+The	O
+prevalence	O
+of	O
+SARS	B-DISO
+was	O
+13	O
+.	O
+3	O
+%	O
+among	O
+1328	O
+patients	O
+included	O
+.	O
+
+Serial	O
+chest	B-ANAT
+radiography	O
+had	O
+sensitivity	O
+94	O
+.	O
+4	O
+%,	O
+specificity	O
+93	O
+.	O
+9	O
+%,	O
+positive	O
+likelihood	O
+ratio	O
+15	O
+.	O
+48	O
+,	O
+negative	O
+likelihood	O
+ratio	O
+0	O
+.	O
+06	O
+,	O
+positive	O
+predictive	O
+value	O
+71	O
+.	O
+4	O
+%,	O
+and	O
+negative	O
+predictive	O
+value	O
+99	O
+.	O
+0	O
+%.	O
+
+TITLE	O
+:	O
+Autoantibodies	O
+against	O
+human	B-SPEC
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+endothelial	B-ANAT
+cells	I-ANAT
+after	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+results	O
+revealed	O
+that	O
+serum	B-COMP
+levels	O
+of	O
+IgG	B-PRGE
+anti	O
+-	O
+A549	O
+cells	B-COMP
+antibodies	B-COMP
+,	O
+IgG	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+HUVEC	I-PRGE
+antibodies	I-PRGE
+,	O
+and	O
+IgM	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+HPEC	I-PRGE
+antibodies	B-COMP
+were	O
+significantly	O
+higher	O
+in	O
+SARS	B-DISO
+patients	O
+at	O
+phase	O
+II	O
+/	O
+phase	O
+III	O
+than	O
+those	O
+in	O
+healthy	O
+controls	O
+.	O
+
+Sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+at	O
+phase	O
+II	O
+/	O
+phase	O
+III	O
+could	O
+mediate	O
+complement	O
+dependent	O
+cytotoxicity	B-DISO
+against	O
+some	O
+A549	O
+cells	B-COMP
+and	O
+HPEC	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleocapsid	B-PRGE
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+is	O
+the	O
+only	O
+phosphorylated	O
+structural	O
+protein	B-CHED
+of	O
+the	O
+coronavirus	B-SPEC
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+Lesions	O
+typical	O
+of	O
+a	O
+mixed	O
+form	O
+(	O
+effusive	O
+and	O
+non	O
+-	O
+effusive	O
+)	O
+of	O
+FIP	B-DISO
+were	O
+observed	O
+and	O
+by	O
+RT	O
+-	O
+PCR	O
+a	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+type	O
+I	O
+strain	O
+was	O
+detected	O
+in	O
+several	O
+tissues	B-ANAT
+.	O
+
+As	O
+a	O
+part	O
+of	O
+preparedness	O
+,	O
+development	B-PROC
+of	O
+a	O
+safe	O
+and	O
+effective	O
+vaccine	O
+is	O
+one	O
+of	O
+the	O
+highest	O
+priorities	O
+in	O
+fighting	O
+SARS	B-DISO
+.	O
+
+It	O
+was	O
+demonstrated	O
+that	O
+there	O
+was	O
+no	O
+live	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+all	O
+samples	O
+collected	O
+,	O
+but	O
+the	O
+RNA	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+could	O
+be	O
+detected	O
+in	O
+seven	O
+stool	B-ANAT
+samples	O
+from	O
+SARS	B-DISO
+patients	O
+with	O
+any	O
+one	O
+of	O
+the	O
+symptoms	O
+of	O
+fever	B-PROC
+,	O
+malaise	B-DISO
+,	O
+cough	B-DISO
+,	O
+or	O
+dyspnea	B-DISO
+,	O
+in	O
+10	O
+sewage	O
+samples	O
+before	O
+disinfection	O
+and	O
+3	O
+samples	O
+after	O
+disinfection	O
+from	O
+the	O
+two	O
+hospitals	O
+.	O
+
+Location	O
+,	O
+abnormal	O
+distribution	O
+,	O
+appearance	O
+of	O
+lung	B-ANAT
+abnormalities	O
+,	O
+effusion	B-DISO
+of	O
+pericadiaum	O
+and	O
+pleura	B-ANAT
+,	O
+and	O
+lymphadenopathy	O
+were	O
+observed	O
+.	O
+
+Initial	O
+chest	B-ANAT
+radiographs	O
+were	O
+normal	O
+in	O
+36	O
+of	O
+79	O
+patients	O
+(	O
+45	O
+.	O
+5	O
+%).	O
+
+The	O
+main	O
+abnormal	O
+radiographic	O
+appearance	O
+of	O
+lung	B-ANAT
+in	O
+patients	O
+with	O
+SARS	B-DISO
+is	O
+exudative	O
+changes	O
+.	O
+
+To	O
+exploit	O
+a	O
+new	O
+strategy	O
+to	O
+fight	O
+this	O
+disease	O
+,	O
+we	O
+investigated	O
+the	O
+effect	O
+of	O
+interference	O
+RNA	O
+(	O
+RNAi	B-PROC
+)	O
+on	O
+the	O
+virus	B-DISO
+infection	I-DISO
+and	O
+replication	O
+with	O
+3	O
+-(	O
+4	O
+,	O
+5	O
+-	O
+dimethyl	B-CHED
+-	O
+2	O
+-	O
+thiazolyl	O
+)-	O
+2	O
+,	O
+5	O
+-	O
+diphenyltetrazolium	O
+bromide	B-CHED
+(	O
+MTT	B-CHED
+),	O
+plaque	B-DISO
+-	O
+forming	O
+,	O
+Western	O
+-	O
+blot	O
+and	O
+real	O
+-	O
+time	O
+PCR	O
+assays	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+effect	O
+of	O
+corticosteroids	O
+in	O
+the	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Established	O
+adverse	O
+prognostic	O
+factors	O
+including	O
+old	O
+age	O
+,	O
+comorbidities	O
+and	O
+high	O
+LDH	B-PRGE
+levels	O
+were	O
+used	O
+as	O
+covariates	O
+in	O
+multiple	O
+logistic	O
+regressions	B-DISO
+to	O
+adjust	O
+for	O
+their	O
+confounding	O
+effect	O
+on	O
+adverse	O
+outcomes	O
+.	O
+
+While	O
+concentrations	O
+of	O
+sTNFR2	O
+proteins	B-CHED
+were	O
+elevated	O
+in	O
+both	O
+BALB	O
+/	O
+c	O
+(	O
+p	O
+<	O
+0	O
+.	O
+00005	O
+)	O
+and	O
+CD	O
+-	O
+1	O
+(	O
+p	O
+<	O
+0	O
+.	O
+005	O
+)	O
+mice	B-SPEC
+compared	O
+to	O
+controls	O
+,	O
+concentrations	O
+were	O
+higher	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+(	O
+p	O
+<	O
+0	O
+.	O
+0005	O
+).	O
+
+Gene	O
+expression	O
+of	O
+iNOS	O
+while	O
+initially	O
+high	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+decreased	O
+during	O
+the	O
+acute	O
+phase	O
+of	O
+infection	B-DISO
+,	O
+while	O
+it	O
+increased	O
+in	O
+CD	O
+-	O
+1	O
+mice	B-SPEC
+.	O
+
+It	O
+is	O
+conserved	O
+in	O
+all	O
+known	O
+isolates	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+has	O
+been	O
+verified	O
+by	O
+in	O
+vitro	O
+peptide	B-CHED
+-	O
+binding	B-FUNC
+studies	O
+to	O
+be	O
+a	O
+good	O
+to	O
+intermediate	O
+binder	O
+to	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0301	I-PRGE
+and	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+1101	I-PRGE
+,	O
+with	O
+IC50	O
+values	O
+of	O
+70	O
+and	O
+186	O
+nM	O
+,	O
+respectively	O
+[	O
+Sylvester	O
+-	O
+Hvid	O
+et	O
+al	O
+.	O
+(	O
+2004	O
+),	O
+Tissue	B-ANAT
+Antigens	B-CHED
+,	O
+63	O
+,	O
+395	O
+-	O
+400	O
+].	O
+
+In	O
+terms	O
+of	O
+the	O
+residues	O
+lining	O
+the	O
+peptide	B-CHED
+-	O
+binding	B-FUNC
+groove	B-ANAT
+,	O
+the	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+1101	I-PRGE
+-	I-PRGE
+SNP362	I-PRGE
+-	I-PRGE
+370	I-PRGE
+complex	I-PRGE
+is	O
+very	O
+similar	O
+to	O
+other	O
+known	O
+structures	O
+of	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+1101	I-PRGE
+and	O
+HLA	B-PRGE
+-	O
+A	O
+*	O
+6801	O
+.	O
+
+For	O
+vaccine	O
+development	B-PROC
+,	O
+there	O
+seems	O
+to	O
+be	O
+a	O
+potential	O
+for	O
+optimization	O
+targeted	B-PROC
+at	O
+this	O
+position	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+provided	O
+evidence	O
+for	O
+evolutionary	O
+reclassification	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+The	O
+results	O
+provide	O
+important	O
+insights	O
+into	O
+the	O
+biochemical	O
+properties	O
+of	O
+the	O
+coronaviral	O
+PLP	B-PRGE
+family	I-PRGE
+and	O
+a	O
+promising	O
+therapeutic	O
+way	O
+to	O
+fight	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+Due	O
+to	O
+the	O
+threat	O
+of	O
+re	O
+-	O
+emergence	O
+,	O
+the	O
+overall	O
+fatality	O
+rate	O
+of	O
+approximately	O
+10	O
+%,	O
+and	O
+the	O
+rapid	O
+dispersion	O
+of	O
+the	O
+virus	B-SPEC
+via	O
+international	O
+travel	O
+,	O
+viable	O
+vaccine	O
+candidates	O
+providing	O
+protection	O
+from	O
+SARS	B-DISO
+are	O
+clearly	O
+needed	O
+.	O
+
+The	O
+sensor	O
+head	B-ANAT
+is	O
+an	O
+optic	B-ANAT
+-	O
+mechanical	O
+device	O
+which	O
+consists	O
+of	O
+imagining	O
+optics	O
+for	O
+focusing	O
+the	O
+infrared	O
+source	O
+information	O
+on	O
+the	O
+infrared	O
+detector	O
+.	O
+
+Taken	O
+together	O
+,	O
+we	O
+have	O
+demonstrated	O
+that	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+S2	I-PRGE
+Abs	I-PRGE
+in	O
+SARS	B-DISO
+patient	O
+sera	B-COMP
+cause	O
+cytotoxic	O
+injury	O
+as	O
+well	O
+as	O
+enhance	O
+immune	O
+cell	B-PROC
+adhesion	B-DISO
+to	O
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+medical	O
+records	O
+of	O
+children	O
+diagnosed	O
+with	O
+bacterial	B-DISO
+tracheitis	I-DISO
+and	O
+admitted	O
+to	O
+our	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+(	O
+PICU	B-SPEC
+)	O
+from	O
+June	O
+1992	O
+to	O
+May	O
+2004	O
+(	O
+12	O
+years	O
+)	O
+were	O
+analyzed	O
+.	O
+
+The	O
+following	O
+variables	O
+were	O
+recorded	O
+:	O
+age	O
+,	O
+sex	O
+,	O
+personal	O
+history	O
+,	O
+need	O
+for	O
+endotracheal	O
+intubation	O
+,	O
+duration	O
+of	O
+intubation	O
+,	O
+isolated	O
+bacteria	B-SPEC
+,	O
+antibiotic	B-CHED
+treatment	O
+,	O
+steroid	B-CHED
+administration	O
+,	O
+and	O
+length	O
+of	O
+stay	O
+in	O
+the	O
+PICU	B-SPEC
+.	O
+
+These	O
+results	O
+provide	O
+a	O
+new	O
+insight	O
+for	O
+further	O
+functional	O
+studies	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3b	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Descending	O
+necrotizing	B-DISO
+mediastinitis	I-DISO
+(	O
+DNM	O
+)	O
+is	O
+a	O
+severe	O
+infection	B-DISO
+spreading	O
+from	O
+the	O
+cervical	B-ANAT
+region	I-ANAT
+to	O
+the	O
+mediastinal	B-ANAT
+connective	B-ANAT
+tissue	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Using	O
+herbal	O
+medicine	B-CHED
+as	O
+a	O
+means	O
+of	O
+prevention	O
+experience	O
+during	O
+the	O
+SARS	B-DISO
+crisis	O
+.	O
+
+ABSTRACT	O
+:	O
+One	O
+of	O
+the	O
+hallmark	O
+findings	O
+in	O
+patients	O
+suffering	B-DISO
+from	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+is	O
+lymphopenia	B-DISO
+,	O
+which	O
+is	O
+the	O
+result	O
+of	O
+massive	O
+lymphocyte	B-ANAT
+death	B-PROC
+.	O
+
+These	O
+findings	O
+identify	O
+the	O
+common	B-SPEC
+marmoset	I-SPEC
+as	O
+a	O
+promising	O
+nonhuman	O
+primate	B-SPEC
+to	O
+study	O
+SARS	B-DISO
+-	O
+CoV	O
+pathogenesis	B-DISO
+.	O
+
+These	O
+cases	O
+confirm	O
+the	O
+effectiveness	O
+of	O
+drotrecogin	O
+alfa	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+as	O
+part	O
+of	O
+multidirectional	O
+therapy	O
+.	O
+
+The	O
+Ministry	O
+of	O
+Health	O
+,	O
+Singapore	O
+centralised	O
+SARS	B-DISO
+cases	O
+in	O
+the	O
+study	O
+hospital	O
+and	O
+its	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+became	O
+the	O
+national	O
+screening	O
+centre	O
+.	O
+
+Indeed	O
+,	O
+the	O
+appearance	O
+of	O
+SARS	B-DISO
+during	O
+the	O
+past	O
+year	O
+is	O
+the	O
+latest	O
+example	O
+of	O
+the	O
+continuing	O
+challenges	O
+posed	O
+by	O
+agents	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+Emerging	O
+agents	O
+are	O
+threats	O
+not	O
+only	O
+to	O
+the	O
+general	O
+population	O
+,	O
+but	O
+also	O
+to	O
+recipients	O
+of	O
+blood	B-ANAT
+transfusions	O
+.	O
+
+To	O
+determine	O
+whether	O
+nsp1	B-PRGE
+is	O
+required	O
+for	O
+MHV	B-SPEC
+replication	O
+and	O
+to	O
+identify	O
+residues	O
+critical	O
+for	O
+protein	B-PROC
+function	I-PROC
+,	O
+mutant	B-DISO
+viruses	B-SPEC
+that	O
+contained	O
+deletions	O
+or	O
+point	B-PROC
+mutations	I-PROC
+within	O
+the	O
+nsp1	B-PRGE
+-	I-PRGE
+coding	I-PRGE
+region	I-PRGE
+were	O
+generated	O
+and	O
+assayed	O
+for	O
+defects	O
+in	O
+viral	B-PROC
+replication	I-PROC
+,	O
+viral	O
+protein	B-PROC
+expression	B-PROC
+,	O
+protein	B-PROC
+localization	I-PROC
+,	O
+and	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+In	O
+summary	O
+,	O
+we	O
+identified	O
+LSECtin	O
+as	O
+an	O
+attachment	O
+factor	O
+that	O
+in	O
+conjunction	O
+with	O
+DC	O
+-	O
+SIGNR	O
+might	O
+concentrate	O
+viral	O
+pathogens	O
+in	O
+liver	B-ANAT
+and	O
+lymph	B-ANAT
+nodes	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+virus	O
+(	O
+FIPV	O
+)	O
+(	O
+Coronaviridae	B-SPEC
+)	O
+causes	O
+the	O
+most	O
+lethal	O
+viral	B-DISO
+infection	I-DISO
+in	O
+cats	B-SPEC
+:	O
+FIP	B-DISO
+.	O
+
+Why	O
+these	O
+feline	B-SPEC
+coronaviruses	O
+manifest	O
+so	O
+differently	O
+in	O
+vivo	O
+is	O
+not	O
+known	O
+.	O
+
+Considering	O
+all	O
+22	O
+investigated	O
+cats	B-SPEC
+,	O
+3	O
+/	O
+22	O
+were	O
+not	O
+susceptible	O
+for	O
+FIPV	O
+and	O
+FECV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-DISO
+hypertension	I-DISO
+complicates	O
+the	O
+course	O
+of	O
+many	O
+newborns	O
+with	O
+congenital	B-DISO
+diaphragmatic	I-DISO
+hernia	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Myocardial	B-DISO
+stunning	I-DISO
+frequently	O
+has	O
+been	O
+described	O
+in	O
+patients	O
+with	O
+an	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+.	O
+
+Transthoracic	O
+and	O
+transoesophageal	O
+echocardiography	O
+was	O
+used	O
+to	O
+assess	O
+left	B-PROC
+ventricular	I-PROC
+ejection	I-PROC
+fraction	O
+(	O
+LVEF	O
+)	O
+and	O
+disturbances	O
+of	O
+segmental	O
+contractility	O
+.	O
+
+TITLE	O
+:	O
+Report	O
+of	O
+a	O
+patient	O
+with	O
+severe	O
+transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+after	O
+multiple	O
+transfusions	O
+,	O
+resuscitated	O
+with	O
+albumin	O
+.	O
+
+To	O
+this	O
+end	O
+,	O
+ACE2	B-PRGE
+may	O
+counterbalance	O
+the	O
+effects	O
+of	O
+ACE	B-PRGE
+within	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+(	O
+RAS	B-PRGE
+).	O
+
+The	O
+pathogenesis	B-DISO
+of	O
+FIP	B-DISO
+involves	O
+a	O
+viral	O
+associated	O
+,	O
+disseminated	O
+phlebitis	B-DISO
+and	O
+periphlebitis	B-DISO
+which	O
+can	O
+arise	O
+at	O
+many	O
+sites	O
+.	O
+
+A	O
+comparison	O
+of	O
+scores	O
+for	O
+the	O
+serial	O
+thin	O
+-	O
+section	O
+CT	O
+examinations	O
+indicated	O
+a	O
+significant	O
+reduction	O
+in	O
+the	O
+extent	O
+of	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+(	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+interstitial	B-ANAT
+opacity	B-DISO
+(	O
+P	O
+<	O
+.	O
+001	O
+)	O
+but	O
+not	O
+in	O
+that	O
+of	O
+air	B-DISO
+trapping	I-DISO
+(	O
+P	O
+=	O
+.	O
+38	O
+)	O
+at	O
+follow	O
+-	O
+up	O
+examination	O
+.	O
+
+At	O
+initial	O
+thin	O
+-	O
+section	O
+CT	O
+,	O
+scores	O
+for	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+,	O
+interstitial	B-ANAT
+opacity	B-DISO
+,	O
+and	O
+air	B-DISO
+trapping	I-DISO
+correlated	O
+with	O
+age	O
+;	O
+those	O
+for	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+and	O
+air	B-DISO
+trapping	I-DISO
+,	O
+with	O
+peak	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+level	O
+.	O
+
+RESULTS	O
+:	O
+Air	B-DISO
+trapping	I-DISO
+,	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+,	O
+and	O
+reticulation	O
+were	O
+found	O
+in	O
+37	O
+(	O
+92	O
+%),	O
+36	O
+(	O
+90	O
+%),	O
+and	O
+28	O
+(	O
+70	O
+%)	O
+of	O
+40	O
+patients	O
+,	O
+respectively	O
+,	O
+at	O
+initial	O
+thin	O
+-	O
+section	O
+CT	O
+examination	O
+and	O
+in	O
+16	O
+(	O
+80	O
+%),	O
+14	O
+(	O
+70	O
+%),	O
+and	O
+10	O
+(	O
+50	O
+%)	O
+of	O
+20	O
+patients	O
+,	O
+respectively	O
+,	O
+at	O
+follow	O
+-	O
+up	O
+examination	O
+.	O
+
+Mutational	O
+analysis	O
+of	O
+the	O
+extra	O
+stem	B-ANAT
+suggests	O
+frameshift	B-DISO
+efficiency	O
+can	O
+be	O
+modulated	O
+via	O
+manipulation	O
+of	O
+the	O
+secondary	O
+structure	O
+within	O
+the	O
+loop	O
+2	O
+of	O
+an	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+-	O
+type	O
+pseudoknot	O
+.	O
+
+Furthermore	O
+,	O
+frameshift	B-DISO
+efficiency	O
+can	O
+be	O
+reduced	O
+to	O
+half	O
+in	O
+the	O
+presence	O
+of	O
+the	O
+attenuation	O
+signal	O
+in	O
+vivo	O
+.	O
+
+Two	O
+(	O
+3	O
+.	O
+3	O
+%)	O
+of	O
+the	O
+hypocortisolic	O
+cohort	O
+had	O
+transient	O
+subclinical	O
+thyrotoxicosis	B-DISO
+.	O
+
+These	O
+preliminary	O
+findings	O
+highlight	O
+a	O
+possible	O
+aetiologic	O
+role	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+in	O
+causing	O
+a	O
+reversible	O
+hypophysitis	B-DISO
+or	O
+direct	O
+hypothalamic	B-ANAT
+effect	O
+,	O
+with	O
+the	O
+HPA	B-CHED
+axis	B-SPEC
+affected	O
+more	O
+frequently	O
+than	O
+the	O
+HPT	O
+axis	B-SPEC
+.	O
+
+Eight	O
+had	O
+subnormal	O
+DHEAS	B-CHED
+levels	O
+.	O
+
+The	O
+ratio	O
+of	O
+PaO2	O
+/	O
+FiO2	O
+/	O
+VO2	B-CHED
+is	O
+proposed	O
+to	O
+consider	O
+to	O
+be	O
+a	O
+criterion	O
+for	O
+the	O
+effectiveness	O
+of	O
+respiratory	O
+support	O
+in	O
+ALLS	O
+/	O
+ARDS	B-DISO
+and	O
+a	O
+marker	O
+of	O
+energy	O
+deficiency	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+etiology	O
+of	O
+Kawasaki	B-DISO
+disease	I-DISO
+(	O
+KD	O
+)	O
+remains	O
+unknown	O
+despite	O
+several	O
+years	O
+of	O
+dedicated	O
+research	O
+in	O
+this	O
+direction	O
+.	O
+
+There	O
+has	O
+been	O
+some	O
+concern	O
+about	O
+increased	O
+risk	O
+for	O
+premature	O
+atherosclerosis	B-DISO
+in	O
+patients	O
+with	O
+childhood	O
+KD	O
+who	O
+had	O
+coronary	B-ANAT
+artery	I-ANAT
+abnormalities	O
+.	O
+
+TITLE	O
+:	O
+Procalcitonin	O
+and	O
+infection	B-DISO
+in	O
+elderly	O
+patients	O
+.	O
+
+This	O
+finding	O
+may	O
+also	O
+be	O
+related	O
+to	O
+aging	B-PROC
+per	O
+se	O
+.	O
+
+PCT	B-DISO
+may	O
+be	O
+useful	O
+to	O
+identify	O
+severely	O
+ill	B-DISO
+elderly	O
+patients	O
+admitted	O
+to	O
+an	O
+acute	O
+geriatric	O
+ward	O
+but	O
+not	O
+to	O
+discriminate	O
+patients	O
+with	O
+infection	B-DISO
+from	O
+those	O
+without	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+mediates	O
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+entry	O
+by	O
+its	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+,	O
+and	O
+infection	B-DISO
+is	O
+sensitive	O
+to	O
+lysosomotropic	O
+agents	O
+that	O
+perturb	O
+endosomal	O
+pH	O
+.	O
+We	O
+demonstrate	O
+here	O
+that	O
+the	O
+lysosomotropic	O
+-	O
+agent	O
+-	O
+mediated	O
+block	O
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+is	O
+overcome	O
+by	O
+protease	O
+treatment	O
+of	O
+target	O
+-	O
+cell	B-COMP
+-	O
+associated	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+framework	O
+for	O
+capturing	O
+the	O
+interactions	O
+between	O
+laypersons	O
+'	O
+understanding	O
+of	O
+disease	O
+,	O
+information	O
+gathering	O
+behaviors	B-PROC
+,	O
+and	O
+actions	O
+taken	O
+during	O
+an	O
+epidemic	O
+.	O
+
+This	O
+review	O
+therefore	O
+summarizes	O
+the	O
+current	O
+pathophysiological	O
+concepts	O
+underlying	O
+the	O
+evolution	B-PROC
+of	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+focuses	O
+on	O
+:	O
+(	O
+1	O
+)	O
+possible	O
+reasons	O
+for	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+;	O
+(	O
+2	O
+)	O
+cellular	B-COMP
+and	O
+humoral	O
+mediator	O
+responses	O
+leading	O
+to	O
+a	O
+sustained	O
+and	O
+self	O
+-	O
+perpetuating	O
+inflammation	B-DISO
+of	O
+the	O
+lung	B-ANAT
+;	O
+(	O
+3	O
+)	O
+consequences	O
+with	O
+regard	O
+to	O
+fluid	B-PROC
+balance	I-PROC
+,	O
+pulmonary	B-ANAT
+perfusion	O
+,	O
+ventilation	O
+,	O
+and	O
+efficiency	O
+of	O
+gas	B-ENZY
+exchange	O
+;	O
+and	O
+(	O
+4	O
+)	O
+mechanisms	O
+underlying	O
+the	O
+aggravating	O
+complications	O
+commonly	O
+seen	O
+in	O
+ARDS	B-DISO
+,	O
+especially	O
+ventilator	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+,	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+,	O
+and	O
+lung	B-DISO
+fibrosis	I-DISO
+.	O
+
+The	O
+current	O
+state	O
+of	O
+knowledge	O
+about	O
+this	O
+severe	O
+illness	O
+and	O
+its	O
+associated	O
+mediators	O
+has	O
+come	O
+from	O
+the	O
+study	O
+of	O
+relevant	O
+animal	B-SPEC
+models	O
+.	O
+
+This	O
+is	O
+an	O
+exciting	O
+time	O
+for	O
+research	O
+in	O
+long	O
+-	O
+term	O
+outcomes	O
+of	O
+ARDS	B-DISO
+,	O
+with	O
+potential	O
+for	O
+future	O
+studies	O
+that	O
+validate	O
+these	O
+single	O
+-	O
+center	O
+hypotheses	O
+,	O
+explore	O
+their	O
+ramifications	O
+,	O
+and	O
+investigate	O
+the	O
+impacts	O
+of	O
+changing	O
+practices	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+in	O
+the	O
+acute	O
+phase	O
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+MR	O
+diffusion	O
+tensor	O
+imaging	O
+,	O
+fiber	B-ANAT
+tracking	O
+,	O
+and	O
+single	O
+-	O
+voxel	O
+spectroscopy	O
+findings	O
+in	O
+an	O
+unusual	O
+MELAS	O
+case	O
+.	O
+
+Initially	O
+focusing	O
+on	O
+the	O
+diagnostic	O
+value	O
+of	O
+PCT	B-DISO
+,	O
+20	O
+%	O
+of	O
+the	O
+patients	O
+had	O
+a	O
+serum	B-COMP
+PCT	B-DISO
+level	O
+<	O
+0	O
+.	O
+5	O
+ng	O
+/	O
+ml	O
+,	O
+30	O
+%	O
+between	O
+0	O
+.	O
+5	O
+ng	O
+/	O
+ml	O
+and	O
+2	O
+ng	O
+/	O
+ml	O
+,	O
+and	O
+50	O
+%>/=	O
+2	O
+ng	O
+/	O
+ml	O
+.	O
+
+A	O
+combination	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	I-PRGE
+-	I-PRGE
+gamma	I-PRGE
+strongly	O
+inhibited	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+while	O
+the	O
+single	O
+cytokines	O
+were	O
+much	O
+less	O
+effective	O
+.	O
+
+This	O
+study	O
+provides	O
+evidence	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+able	O
+to	O
+induce	O
+in	O
+normal	O
+PBMC	O
+a	O
+coordinate	O
+induction	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	I-PRGE
+-	I-PRGE
+gamma	I-PRGE
+gene	I-PRGE
+expression	O
+.	O
+
+Concomitant	O
+activation	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	I-PRGE
+-	I-PRGE
+gamma	I-PRGE
+gene	I-PRGE
+expression	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+vivo	O
+may	O
+be	O
+relevant	O
+for	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+disease	O
+,	O
+both	O
+for	O
+the	O
+possible	O
+involvement	O
+in	O
+immunomediated	O
+damage	O
+of	O
+the	O
+tissues	B-ANAT
+and	O
+for	O
+the	O
+strong	O
+inhibition	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+as	O
+a	O
+result	O
+of	O
+combined	O
+cytokine	O
+action	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+caused	O
+large	O
+outbreaks	O
+of	O
+atypical	B-DISO
+pneumonia	I-DISO
+in	O
+2003	O
+,	O
+with	O
+the	O
+largest	O
+localized	O
+outbreak	O
+occurring	O
+in	O
+Beijing	O
+,	O
+China	O
+.	O
+
+The	O
+lymphopenia	B-DISO
+was	O
+prolonged	O
+,	O
+reaching	B-PROC
+a	O
+nadir	O
+during	O
+days	O
+7	O
+-	O
+9	O
+in	O
+the	O
+second	O
+week	O
+of	O
+illness	O
+before	O
+returning	O
+towards	O
+normal	O
+after	O
+five	O
+weeks	O
+,	O
+with	O
+the	O
+lowest	O
+mean	O
+CD4	B-ANAT
++	I-ANAT
+cell	B-COMP
+count	O
+of	O
+317	O
+cellsx10	O
+(	O
+6	O
+)/	O
+L	O
+at	O
+day	O
+7	O
+,	O
+and	O
+CD8	B-PRGE
++	I-PRGE
+cell	B-COMP
+count	O
+of	O
+239	O
+cellsx10	O
+(	O
+6	O
+)/	O
+L	O
+at	O
+day	O
+8	O
+.	O
+
+RESULTS	O
+:	O
+There	O
+was	O
+a	O
+significant	O
+decrease	O
+in	O
+the	O
+CD45	B-PRGE
++,	I-PRGE
+CD3	B-PRGE
++,	I-PRGE
+CD4	B-PRGE
++,	I-PRGE
+CD8	B-PRGE
++,	I-PRGE
+CD19	B-PRGE
++	I-PRGE
+and	O
+CD16	B-PRGE
++/	I-PRGE
+56	O
++	O
+cell	B-COMP
+counts	O
+over	O
+the	O
+five	O
+weeks	O
+of	O
+the	O
+SARS	B-DISO
+illness	O
+although	O
+CD4	B-PRGE
++/	I-PRGE
+CD8	B-PRGE
++	I-PRGE
+ratios	O
+did	O
+not	O
+change	O
+significantly	O
+.	O
+
+Blood	B-ANAT
+-	O
+free	O
+wet	O
+-	O
+to	O
+-	O
+dry	O
+ratio	O
+and	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+activity	O
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+serum	B-COMP
+,	O
+and	O
+supernatant	O
+of	O
+lung	B-ANAT
+homogenate	O
+were	O
+measured	O
+in	O
+another	O
+set	O
+of	O
+experiments	O
+(	O
+n	O
+=	O
+4	O
+for	O
+each	O
+group	O
+).	O
+
+RESULTS	O
+:	O
+Nine	O
+thousand	O
+one	O
+hundred	O
+twenty	O
+-	O
+six	O
+with	O
+blunt	O
+injury	O
+were	O
+ICU	O
+admissions	O
+,	O
+and	O
+5	O
+,	O
+260	O
+(	O
+58	O
+%)	O
+met	B-CHED
+study	O
+criteria	O
+(	O
+72	O
+%	O
+male	O
+).	O
+
+TITLE	O
+:	O
+Genetic	O
+analysis	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+spike	O
+glycoprotein	B-CHED
+functional	O
+domains	O
+involved	O
+in	O
+cell	B-ANAT
+-	O
+surface	O
+expression	B-PROC
+and	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-PROC
+fusion	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+the	O
+etiological	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+body	B-ANAT
+temperature	O
+of	O
+the	O
+infected	O
+monkeys	B-SPEC
+was	O
+monitored	O
+three	O
+times	O
+a	O
+day	O
+,	O
+and	O
+blood	B-ANAT
+and	O
+fecal	B-ANAT
+samples	O
+were	O
+periodically	O
+collected	O
+for	O
+specific	O
+immunology	O
+determinations	O
+.	O
+
+The	O
+highest	O
+temperature	O
+in	O
+the	O
+animals	B-SPEC
+recorded	O
+was	O
+40	O
+.	O
+4	O
+degrees	O
+C	O
+.	O
+After	O
+a	O
+recovery	O
+phase	O
+,	O
+the	O
+macaques	O
+developed	O
+a	O
+second	O
+febrile	B-PROC
+condition	B-DISO
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+a	O
+major	O
+virion	B-COMP
+structural	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+a	O
+main	O
+surface	O
+antigen	B-CHED
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+is	O
+considered	O
+to	O
+be	O
+one	O
+of	O
+the	O
+most	O
+important	O
+protective	O
+antigen	B-CHED
+candidates	O
+for	O
+targets	O
+for	O
+vaccine	O
+design	O
+against	O
+the	O
+virus	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+secreted	B-PROC
+recombinant	O
+expression	B-PROC
+plasmid	O
+,	O
+pVAX	O
+-	O
+S1	O
+,	O
+encoding	O
+the	O
+partial	O
+S	B-PRGE
+protein	I-PRGE
+with	O
+a	O
+signal	O
+peptide	B-CHED
+,	O
+was	O
+constructed	O
+and	O
+used	O
+to	O
+immunize	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+through	O
+electroporation	O
+.	O
+
+The	O
+expressed	B-PROC
+protein	B-CHED
+could	O
+be	O
+detected	O
+specifically	O
+by	O
+Western	O
+blot	O
+analysis	O
+.	O
+
+Furthermore	O
+,	O
+in	O
+the	O
+experimental	O
+group	O
+,	O
+a	O
+decrease	O
+in	O
+the	O
+ratio	O
+of	O
+CD4	B-PRGE
+(+)	O
+to	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+and	O
+an	O
+increase	O
+level	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+in	O
+serum	B-COMP
+were	O
+observed	O
+.	O
+
+In	O
+summary	O
+,	O
+at	O
+least	O
+one	O
+selected	O
+compound	O
+of	O
+the	O
+synthesized	O
+test	O
+materials	O
+represents	O
+an	O
+interesting	O
+drug	O
+candidate	O
+for	O
+treatment	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+induced	O
+human	B-SPEC
+disease	O
+(	O
+SARS	B-DISO
+).	O
+
+No	O
+infectious	B-DISO
+virus	B-SPEC
+was	O
+detected	O
+after	O
+treatment	O
+when	O
+up	O
+to	O
+one	O
+-	O
+third	O
+of	O
+the	O
+APC	B-PRGE
+unit	I-PRGE
+was	O
+assayed	O
+,	O
+demonstrating	O
+a	O
+mean	O
+log10	O
+-	O
+reduction	O
+of	O
+>	O
+6	O
+.	O
+2	O
+.	O
+
+The	O
+main	O
+symptoms	O
+were	O
+fever	B-PROC
+(	O
+61	O
+%),	O
+rhinitis	B-DISO
+(	O
+39	O
+%),	O
+bronchiolitis	B-DISO
+(	O
+39	O
+%),	O
+digestive	B-DISO
+problems	I-DISO
+(	O
+33	O
+%),	O
+otitis	B-DISO
+(	O
+28	O
+%),	O
+pharyngitis	B-DISO
+(	O
+22	O
+%),	O
+and	O
+conjunctivitis	B-DISO
+(	O
+17	O
+%).	O
+
+In	O
+contrast	O
+,	O
+I	O
+/	O
+R	O
+resulted	O
+in	O
+a	O
+15	O
+-	O
+and	O
+10	O
+-	O
+fold	O
+increase	O
+in	O
+KC	O
+mRNA	B-CHED
+after	O
+4	O
+and	O
+24	O
+hours	O
+of	O
+reperfusion	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Numerous	O
+emerging	O
+respiratory	B-ANAT
+tract	I-ANAT
+viruses	B-SPEC
+have	O
+been	O
+identified	O
+as	O
+significant	O
+causes	O
+of	O
+acute	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illness	O
+in	O
+children	O
+.	O
+
+Human	B-SPEC
+metapneumovirus	I-SPEC
+is	O
+a	O
+paramyxovirus	O
+discovered	O
+in	O
+2001	O
+in	O
+the	O
+Netherlands	O
+,	O
+with	O
+a	O
+seasonal	O
+occurrence	O
+and	O
+spectrum	O
+of	O
+clinical	O
+illness	O
+most	O
+similar	O
+to	O
+the	O
+closely	O
+related	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+To	O
+develop	O
+an	O
+alternative	O
+system	O
+for	O
+the	O
+study	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+we	O
+introduced	O
+individual	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+genes	I-PRGE
+(	O
+open	O
+reading	O
+frames	O
+[	O
+ORFs	O
+])	O
+into	O
+the	O
+genome	O
+of	O
+an	O
+attenuated	O
+murine	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+One	O
+protein	B-CHED
+,	O
+the	O
+product	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORF6	I-PRGE
+,	O
+converted	O
+a	O
+sublethal	O
+infection	B-DISO
+to	O
+a	O
+uniformly	O
+lethal	O
+encephalitis	B-DISO
+and	O
+enhanced	O
+virus	B-SPEC
+growth	B-PROC
+in	O
+tissue	B-ANAT
+culture	O
+cells	B-COMP
+,	O
+indicating	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+function	O
+in	O
+the	O
+context	O
+of	O
+a	O
+heterologous	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+is	O
+phosphorylated	O
+and	O
+localizes	O
+in	O
+the	O
+cytoplasm	O
+by	O
+14	O
+-	O
+3	O
+-	O
+3	O
+-	O
+mediated	O
+translocation	B-DISO
+.	O
+
+Coincidentally	O
+,	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+also	O
+found	O
+to	O
+downregulate	O
+the	O
+expression	B-PROC
+of	O
+the	O
+theta	O
+isoform	O
+of	O
+14	O
+-	O
+3	O
+-	O
+3	O
+(	O
+14	O
+-	O
+3	O
+-	O
+3theta	O
+),	O
+leading	O
+to	O
+the	O
+accumulation	O
+of	O
+phosphorylated	O
+N	B-PRGE
+protein	I-PRGE
+in	O
+the	O
+nucleus	B-COMP
+,	O
+in	O
+the	O
+absence	O
+of	O
+growth	B-PROC
+factors	O
+.	O
+
+Using	O
+short	O
+interfering	O
+RNA	O
+specific	O
+to	O
+14	O
+-	O
+3	O
+-	O
+3theta	O
+we	O
+have	O
+inhibited	O
+its	O
+expression	B-PROC
+to	O
+show	O
+accumulation	O
+of	O
+phosphorylated	O
+N	B-PRGE
+protein	I-PRGE
+in	O
+the	O
+nucleus	B-COMP
+.	O
+
+Thus	O
+,	O
+the	O
+data	O
+presented	O
+here	O
+provide	O
+a	O
+possible	O
+mechanism	O
+for	O
+phosphorylation	B-PROC
+-	O
+dependent	O
+nucleocytoplasmic	B-PROC
+shuttling	I-PROC
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+Due	O
+to	O
+the	O
+low	O
+positive	O
+rate	O
+of	O
+the	O
+PCR	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+the	O
+low	O
+positive	O
+predictive	O
+value	O
+of	O
+reported	O
+cases	O
+,	O
+the	O
+factuality	O
+of	O
+cases	O
+with	O
+unknown	O
+sources	O
+of	O
+infection	B-DISO
+should	O
+be	O
+further	O
+verified	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinical	O
+relevance	O
+of	O
+infections	B-DISO
+with	O
+the	O
+novel	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+)	O
+has	O
+not	O
+been	O
+investigated	O
+systematically	O
+.	O
+
+A	O
+strong	O
+association	O
+with	O
+croup	B-DISO
+was	O
+apparent	O
+:	O
+43	O
+%	O
+of	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+-	O
+positive	O
+patients	O
+with	O
+high	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+load	O
+and	O
+absence	O
+of	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+suffered	B-DISO
+from	O
+croup	B-DISO
+,	O
+compared	O
+to	O
+6	O
+%	O
+in	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+-	O
+negative	O
+group	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+.	O
+
+Till	O
+now	O
+,	O
+there	O
+is	O
+no	O
+report	O
+about	O
+the	O
+function	O
+of	O
+3b	B-PRGE
+protein	I-PRGE
+.	O
+
+When	O
+a	O
+given	O
+concentration	O
+of	O
+particulate	O
+sarin	O
+simulant	O
+was	O
+introduced	O
+into	O
+the	O
+contaminated	O
+area	O
+,	O
+it	O
+could	O
+not	O
+be	O
+detected	O
+in	O
+either	O
+the	O
+semicontaminated	O
+area	O
+or	O
+clean	O
+area	O
+,	O
+and	O
+particles	O
+>	O
+0	O
+.	O
+3	O
+microm	O
+in	O
+size	O
+were	O
+not	O
+detected	O
+in	O
+the	O
+exhaust	O
+air	B-CHED
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+this	O
+,	O
+further	O
+cynomolgus	O
+and	O
+rhesus	B-SPEC
+macaques	I-SPEC
+were	O
+selected	O
+and	O
+experimentally	O
+inoculated	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+the	O
+quality	O
+they	O
+serve	O
+as	O
+animal	B-SPEC
+model	O
+for	O
+SARS	B-DISO
+was	O
+evaluated	O
+.	O
+
+After	O
+inoculated	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+all	O
+inoculated	O
+cynomolgus	O
+and	O
+rhesus	B-SPEC
+macaques	I-SPEC
+had	O
+developed	O
+interstitial	B-DISO
+pneumonia	I-DISO
+of	O
+differing	O
+severity	O
+.	O
+
+Except	O
+interstitial	B-DISO
+pneumonia	I-DISO
+,	O
+no	O
+other	O
+characterized	O
+pathological	O
+changes	O
+were	O
+observed	O
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	B-COMP
+antibody	I-COMP
+was	O
+detected	O
+using	O
+indirect	O
+immunofluorescence	O
+technique	O
+and	O
+quantified	O
+by	O
+two	O
+-	O
+fold	O
+serial	O
+dilutions	O
+.	O
+
+Correlations	O
+between	O
+IgG	B-PRGE
+levels	O
+and	O
+important	O
+laboratory	O
+parameters	O
+were	O
+assessed	O
+.	O
+
+A	O
+total	O
+of	O
+325	O
+laboratory	O
+-	O
+confirmed	O
+SARS	O
+cases	O
+were	O
+analyzed	O
+;	O
+of	O
+which	O
+301	O
+(	O
+92	O
+.	O
+6	O
+%)	O
+had	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+detected	O
+in	O
+their	O
+sera	B-COMP
+at	O
+the	O
+time	O
+of	O
+sampling	O
+.	O
+
+Diagnosing	O
+the	O
+disease	O
+effectively	O
+and	O
+accurately	O
+at	O
+early	O
+stage	O
+is	O
+essential	O
+for	O
+preventing	O
+the	O
+disease	B-DISO
+transmission	I-DISO
+and	O
+performing	O
+antiviral	B-CHED
+treatment	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+all	O
+of	O
+the	O
+six	O
+raised	O
+mAbs	O
+were	O
+divided	O
+into	O
+two	O
+groups	O
+recognizing	O
+the	O
+region	O
+of	O
+amino	B-CHED
+acids	I-CHED
+249	O
+-	O
+317	O
+(	O
+A	O
+group	O
+)	O
+or	O
+317	O
+-	O
+395	O
+(	O
+B	O
+group	O
+).	O
+
+This	O
+region	O
+spanning	O
+amino	B-CHED
+acids	I-CHED
+249	O
+-	O
+395	O
+contains	O
+predominant	O
+B	B-ANAT
+cell	I-ANAT
+epitopes	O
+located	O
+at	O
+the	O
+C	O
+-	O
+terminus	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+Knowledge	O
+and	O
+attitude	O
+of	O
+respondents	O
+concerning	O
+SARS	B-DISO
+were	O
+good	O
+.	O
+
+TITLE	O
+:	O
+Chloroquine	B-CHED
+is	O
+a	O
+potent	O
+inhibitor	B-CHED
+of	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+and	O
+spread	O
+.	O
+
+We	O
+report	O
+,	O
+however	O
+,	O
+that	O
+chloroquine	B-CHED
+has	O
+strong	O
+antiviral	B-CHED
+effects	O
+on	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+of	O
+primate	B-SPEC
+cells	B-COMP
+.	O
+
+In	O
+addition	O
+to	O
+the	O
+well	O
+-	O
+known	O
+functions	O
+of	O
+chloroquine	B-CHED
+such	O
+as	O
+elevations	O
+of	O
+endosomal	O
+pH	O
+,	O
+the	O
+drug	O
+appears	O
+to	O
+interfere	O
+with	O
+terminal	B-PROC
+glycosylation	I-PROC
+of	O
+the	O
+cellular	B-COMP
+receptor	O
+,	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+.	O
+
+This	O
+may	O
+negatively	O
+influence	O
+the	O
+virus	B-PRGE
+-	I-PRGE
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+abrogate	O
+the	O
+infection	B-DISO
+,	O
+with	O
+further	O
+ramifications	O
+by	O
+the	O
+elevation	O
+of	O
+vesicular	O
+pH	O
+,	O
+resulting	O
+in	O
+the	O
+inhibition	B-PROC
+of	O
+infection	B-DISO
+and	O
+spread	O
+of	O
+SARS	B-DISO
+CoV	O
+at	O
+clinically	O
+admissible	O
+concentrations	O
+.	O
+
+TITLE	O
+:	O
+Anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+effects	O
+of	O
+Isatis	B-SPEC
+indigotica	I-SPEC
+root	B-ANAT
+and	O
+plant	B-SPEC
+-	O
+derived	O
+phenolic	O
+compounds	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+possible	O
+mechanism	O
+for	O
+the	O
+extensive	O
+damage	O
+seen	O
+in	O
+the	O
+major	O
+target	O
+organs	B-ANAT
+for	O
+this	O
+disease	O
+.	O
+
+A	O
+recent	O
+study	O
+of	O
+the	O
+cell	B-COMP
+entry	O
+mechanism	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+reveals	O
+that	O
+it	O
+takes	O
+an	O
+endosomal	O
+pathway	B-PROC
+.	O
+
+We	O
+found	O
+that	O
+proteases	O
+such	O
+as	O
+trypsin	B-PRGE
+and	O
+thermolysin	B-ENZY
+enabled	O
+SARS	B-DISO
+-	O
+CoV	O
+adsorbed	O
+onto	O
+the	O
+cell	B-COMP
+surface	I-COMP
+to	O
+enter	O
+cells	B-COMP
+directly	O
+from	O
+that	O
+site	O
+.	O
+
+Likewise	O
+,	O
+elastase	B-PRGE
+,	O
+a	O
+major	O
+protease	O
+produced	O
+in	O
+the	O
+lungs	B-ANAT
+during	O
+inflammation	B-DISO
+,	O
+also	O
+enhanced	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+developed	O
+a	O
+surveillance	O
+system	O
+that	O
+can	O
+detect	O
+a	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+a	O
+hospital	O
+as	O
+quickly	O
+as	O
+possible	O
+using	O
+the	O
+""""	O
+SARS	B-DISO
+alert	O
+""""	O
+strategy	O
+proposed	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+).	O
+
+We	O
+defined	O
+patients	O
+with	O
+a	O
+fever	B-PROC
+of	O
+over	O
+38	O
+degrees	O
+C	O
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+as	O
+""""	O
+cases	O
+with	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+The	O
+siRNAs	O
+used	O
+provided	O
+relief	O
+from	O
+SCV	B-SPEC
+infection	B-DISO
+-	O
+induced	O
+fever	B-PROC
+,	O
+diminished	O
+SCV	B-SPEC
+viral	O
+levels	O
+and	O
+reduced	O
+acute	O
+diffuse	O
+alveoli	B-ANAT
+damage	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+article	O
+is	O
+to	O
+review	O
+the	O
+Hong	O
+Kong	O
+'	O
+s	O
+response	O
+to	O
+SARS	B-DISO
+from	O
+the	O
+perspective	O
+of	O
+two	O
+inquiries	O
+.	O
+
+A	O
+future	O
+follow	O
+-	O
+up	O
+study	O
+of	O
+the	O
+Hong	O
+Kong	O
+government	O
+and	O
+health	O
+system	O
+'	O
+s	O
+capacity	O
+to	O
+respond	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+would	O
+be	O
+useful	O
+.	O
+
+No	O
+other	O
+article	O
+reviews	O
+the	O
+Hong	O
+Kong	O
+health	O
+system	O
+'	O
+s	O
+SARS	B-DISO
+response	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+preliminary	O
+study	O
+of	O
+the	O
+structure	O
+prediction	O
+and	O
+expression	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+].	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+the	O
+encoding	O
+sequences	O
+of	O
+SARS	O
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+were	O
+analyzed	O
+by	O
+bioinformatics	O
+methods	O
+,	O
+the	O
+structural	O
+characteristics	O
+and	O
+functions	O
+were	O
+forecasted	O
+based	O
+on	O
+available	O
+data	O
+.	O
+
+The	O
+Kolmogorov	O
+-	O
+Smirnov	O
+test	O
+showed	O
+that	O
+the	O
+neutralizing	O
+antibody	B-COMP
+titers	O
+conform	O
+to	O
+normal	O
+distribution	O
+,	O
+which	O
+suggests	O
+that	O
+the	O
+average	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+antibody	B-COMP
+level	O
+in	O
+this	O
+study	O
+was	O
+representative	O
+of	O
+the	O
+convalescent	O
+antibody	O
+level	O
+of	O
+the	O
+SARS	B-DISO
+population	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+was	O
+caused	O
+by	O
+a	O
+newly	O
+identified	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+2003	O
+.	O
+
+The	O
+SARS	B-DISO
+-	O
+S	O
+,	O
+-	O
+M	O
+,	O
+and	O
+-	O
+N	O
+primer	O
+/	O
+probe	O
+sets	O
+described	O
+in	O
+this	O
+paper	O
+could	O
+detect	O
+one	O
+to	O
+ten	O
+copies	O
+of	O
+in	O
+vitro	O
+transcribed	O
+S	O
+,	O
+M	O
+,	O
+and	O
+N	O
+RNA	O
+per	O
+test	O
+using	O
+both	O
+the	O
+ABI	O
+and	O
+Roche	O
+assay	O
+systems	O
+.	O
+
+The	O
+relative	O
+sensitivities	O
+for	O
+detecting	O
+cell	B-COMP
+culture	O
+-	O
+derived	O
+SARS	O
+-	O
+CoV	O
+were	O
+0	O
+.	O
+01	O
+,	O
+0	O
+.	O
+01	O
+,	O
+and	O
+0	O
+.	O
+001	O
+PFU	B-CHED
+/	O
+test	O
+,	O
+respectively	O
+.	O
+
+In	O
+addition	O
+,	O
+SARS	B-DISO
+-	O
+S	O
+and	O
+SARS	B-DISO
+-	O
+M	O
+also	O
+demonstrated	O
+equivalent	O
+sensitivity	O
+to	O
+the	O
+commercially	O
+available	O
+RealArt	O
+HPA	B-CHED
+-	O
+Coronavirus	B-SPEC
+reagents	B-CHED
+(	O
+Artus	O
+).	O
+
+Therefore	O
+,	O
+not	O
+only	O
+is	O
+it	O
+compatible	O
+with	O
+the	O
+ABI	O
+and	O
+Roche	O
+systems	O
+,	O
+this	O
+multiple	O
+-	O
+gene	O
+detection	O
+assay	O
+also	O
+has	O
+the	O
+merit	O
+of	O
+being	O
+a	O
+rapid	O
+,	O
+safe	O
+,	O
+sensitive	O
+,	O
+and	O
+specific	O
+tool	O
+for	O
+accurate	O
+diagnosis	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+To	O
+further	O
+characterize	O
+the	O
+role	O
+of	O
+glycosylation	B-PROC
+and	O
+identify	O
+residues	O
+important	O
+for	O
+its	O
+function	O
+as	O
+an	O
+interacting	O
+partner	O
+of	O
+ACE2	B-PRGE
+,	O
+we	O
+have	O
+cloned	O
+,	O
+expressed	B-PROC
+and	O
+characterized	O
+various	O
+soluble	O
+fragments	O
+of	O
+S	O
+containing	O
+RBD	O
+,	O
+and	O
+mutated	O
+all	O
+potential	O
+glycosylation	B-PROC
+sites	O
+and	O
+32	O
+other	O
+residues	O
+.	O
+
+Mutation	O
+of	O
+each	O
+of	O
+these	O
+sites	O
+to	O
+either	O
+alanine	O
+or	O
+glutamine	B-CHED
+,	O
+as	O
+well	O
+as	O
+mutation	O
+of	O
+residue	O
+318	O
+to	O
+alanine	B-CHED
+in	O
+longer	O
+fragments	O
+resulted	O
+in	O
+the	O
+same	O
+decrease	O
+of	O
+molecular	O
+weight	O
+(	O
+by	O
+approximately	O
+3	O
+kDa	O
+)	O
+suggesting	O
+that	O
+all	O
+glycosylation	B-PROC
+sites	O
+are	O
+functional	O
+.	O
+
+Simultaneous	O
+mutation	O
+of	O
+all	O
+glycosylation	B-PROC
+sites	O
+resulted	O
+in	O
+lack	O
+of	O
+expression	B-PROC
+suggesting	O
+that	O
+at	O
+least	O
+one	O
+glycosylation	B-PROC
+site	O
+(	O
+any	O
+of	O
+the	O
+three	O
+)	O
+is	O
+required	O
+for	O
+expression	B-PROC
+.	O
+
+Predisposing	O
+events	O
+included	O
+sepsis	B-DISO
+(	O
+3	O
+patients	O
+),	O
+pneumomia	O
+(	O
+7	O
+patients	O
+),	O
+pancreatitis	B-DISO
+(	O
+1	O
+patient	O
+)	O
+and	O
+two	O
+children	O
+with	O
+other	O
+infections	B-DISO
+.	O
+
+Only	O
+one	O
+patient	O
+developed	O
+an	O
+air	B-CHED
+leak	O
+complication	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pregnancy	O
+outcome	O
+after	O
+exposure	O
+to	O
+injectable	O
+ribavirin	B-CHED
+during	O
+embryogenesis	B-PROC
+.	O
+
+RESULTS	O
+:	O
+Many	O
+inflammatory	O
+and	O
+anti	O
+-	O
+viral	O
+genes	O
+were	O
+differentially	O
+expressed	B-PROC
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genus	B-SPEC
+Coronavirus	B-SPEC
+contains	O
+about	O
+25	O
+species	B-SPEC
+of	O
+coronaviruses	O
+(	O
+CoVs	O
+),	O
+which	O
+are	O
+important	O
+pathogens	O
+causing	O
+highly	O
+prevalent	O
+diseases	O
+and	O
+often	O
+severe	O
+or	O
+fatal	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+No	O
+licensed	O
+specific	O
+drugs	O
+are	O
+available	O
+to	O
+prevent	O
+their	O
+infection	B-DISO
+.	O
+
+A	O
+structure	O
+-	O
+assisted	O
+optimization	O
+program	O
+has	O
+yielded	O
+compounds	O
+with	O
+fast	B-FUNC
+in	O
+vitro	O
+inactivation	B-DISO
+of	O
+multiple	O
+CoV	B-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+s	I-PRGE
+,	O
+potent	O
+antiviral	B-CHED
+activity	O
+,	O
+and	O
+extremely	O
+low	O
+cellular	B-COMP
+toxicity	O
+in	O
+cell	B-COMP
+-	O
+based	O
+assays	O
+.	O
+
+Based	O
+on	O
+the	O
+clinical	O
+data	O
+collected	O
+previously	O
+,	O
+the	O
+available	O
+literature	O
+and	O
+our	O
+in	O
+vitro	O
+experimentation	O
+,	O
+we	O
+propose	O
+that	O
+IFN	O
+-	O
+gamma	O
+may	O
+be	O
+responsible	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+the	O
+late	O
+phase	O
+of	O
+the	O
+SARS	B-DISO
+pathology	B-DISO
+.	O
+
+Data	O
+of	O
+SARS	B-DISO
+cases	O
+reported	O
+from	O
+the	O
+Beijing	O
+Municipal	O
+Centers	O
+for	O
+Disease	O
+Prevention	O
+and	O
+Control	O
+(	O
+BCDC	O
+)	O
+were	O
+collected	O
+and	O
+analyzed	O
+by	O
+descriptive	O
+epidemiology	O
+.	O
+
+After	O
+eluted	O
+from	O
+the	O
+surfaces	O
+of	O
+wafers	O
+,	O
+the	O
+infectivity	O
+of	O
+viruses	B-SPEC
+and	O
+propagation	O
+of	O
+bacteria	B-SPEC
+were	O
+measured	O
+.	O
+
+Exposures	O
+to	O
+the	O
+surfaces	O
+of	O
+Ag	O
+/	O
+Al2O3	B-CHED
+and	O
+Cu	O
+/	O
+Al2O3	B-CHED
+destroy	O
+the	O
+replication	O
+and	O
+propagation	O
+abilities	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+baculovirus	B-SPEC
+and	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+recombinant	O
+protein	B-CHED
+(	O
+rS268	O
+,	O
+corresponding	O
+to	O
+residues	O
+268	O
+-	O
+1255	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+)	O
+was	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+was	O
+purified	O
+to	O
+near	O
+homogeneity	O
+.	O
+
+These	O
+models	O
+can	O
+be	O
+viewed	O
+as	O
+age	O
+of	O
+infection	B-DISO
+epidemic	O
+models	O
+and	O
+analyzed	O
+using	O
+the	O
+approach	O
+of	O
+the	O
+full	O
+Kermack	O
+-	O
+McKendrick	O
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+prospective	O
+study	O
+was	O
+undertaken	O
+to	O
+identify	O
+clinical	O
+,	O
+radiographical	O
+,	O
+haematological	O
+and	O
+biochemical	O
+profiles	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+patients	O
+.	O
+
+We	O
+sought	O
+to	O
+determine	O
+whether	O
+pneumothoraces	O
+are	O
+induced	O
+by	O
+high	O
+ventilatory	O
+pressure	O
+or	O
+volume	O
+and	O
+if	O
+they	O
+are	O
+associated	O
+with	O
+mortality	O
+in	O
+mechanically	O
+ventilated	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+mechanically	O
+ventilated	O
+SARS	B-DISO
+patients	O
+were	O
+divided	O
+into	O
+two	O
+groups	O
+either	O
+with	O
+or	O
+without	O
+pneumothorax	B-DISO
+.	O
+
+TITLE	O
+:	O
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+The	O
+incidence	O
+of	O
+organ	B-ANAT
+dysfunction	O
+was	O
+high	O
+in	O
+patients	O
+with	O
+IAH	B-FUNC
+:	O
+respiratory	B-DISO
+failure	I-DISO
+95	O
+%,	O
+cardiovascular	B-ANAT
+failure	O
+91	O
+%,	O
+and	O
+renal	B-DISO
+failure	I-DISO
+86	O
+%.	O
+
+ABSTRACT	O
+:	O
+The	O
+escalating	O
+number	O
+of	O
+emergency	O
+department	O
+(	O
+ED	O
+)	O
+visits	O
+,	O
+length	O
+of	O
+stay	O
+,	O
+and	O
+hospital	O
+overcrowding	O
+have	O
+been	O
+associated	O
+with	O
+an	O
+increasing	O
+number	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+cared	O
+for	O
+in	O
+the	O
+ED	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+interesting	O
+question	O
+posed	O
+by	O
+the	O
+current	O
+evidence	O
+that	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+may	O
+be	O
+originated	O
+from	O
+an	O
+animal	B-SPEC
+coronavirus	B-SPEC
+is	O
+how	O
+such	O
+an	O
+animal	B-SPEC
+coronavirus	B-SPEC
+breaks	O
+the	O
+host	B-COMP
+species	B-SPEC
+barrier	O
+and	O
+becomes	O
+zoonotic	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+develop	O
+a	O
+multiplex	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+method	O
+for	O
+differential	O
+detection	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+),	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+).	O
+
+This	O
+is	O
+the	O
+first	O
+complete	O
+torovirus	B-SPEC
+genome	O
+sequence	O
+to	O
+be	O
+reported	O
+.	O
+
+Sequence	O
+alignments	O
+and	O
+protein	O
+secondary	O
+structure	O
+prediction	O
+data	O
+suggest	O
+the	O
+presence	O
+of	O
+a	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+serine	I-PRGE
+protease	I-PRGE
+domain	I-PRGE
+with	O
+similarity	O
+to	O
+the	O
+arterivirus	B-SPEC
+3C	B-ENZY
+-	I-ENZY
+like	I-ENZY
+serine	I-ENZY
+protease	I-ENZY
+and	O
+a	O
+single	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+cysteine	B-CHED
+protease	I-PRGE
+domain	I-PRGE
+with	O
+similarity	O
+to	O
+the	O
+picornavirus	B-SPEC
+leader	O
+protease	O
+.	O
+
+Within	O
+the	O
+pp1b	B-PRGE
+sequence	I-PRGE
+the	I-PRGE
+polymerase	I-PRGE
+and	O
+helicase	B-PRGE
+domains	O
+were	O
+identified	O
+,	O
+as	O
+well	O
+as	O
+sequences	O
+predicted	O
+to	O
+be	O
+involved	O
+in	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+,	O
+including	O
+the	O
+conserved	O
+slippery	O
+sequence	O
+UUUAAAC	O
+and	O
+two	O
+potential	O
+pseudoknot	O
+structures	O
+.	O
+
+Twenty	O
+-	O
+seven	O
+novel	O
+signature	O
+variation	O
+residues	O
+(	O
+SNVs	O
+)	O
+were	O
+identified	O
+on	O
+the	O
+spike	O
+gene	O
+and	O
+were	O
+analyzed	O
+for	O
+their	O
+phylogenetic	O
+relationships	O
+,	O
+based	O
+on	O
+17	O
+sequences	O
+obtained	O
+from	O
+animals	B-SPEC
+in	O
+our	O
+study	O
+and	O
+from	O
+other	O
+published	O
+studies	O
+.	O
+
+Initially	O
+,	O
+seven	O
+SNV	O
+sites	O
+caused	O
+six	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+,	O
+at	O
+positions	O
+147	O
+,	O
+228	O
+,	O
+240	O
+,	O
+479	O
+,	O
+821	O
+,	O
+and	O
+1080	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+,	O
+to	O
+generate	O
+low	O
+-	O
+pathogenicity	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Survival	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+activation	I-PROC
+in	O
+Vero	O
+E6	O
+cells	O
+expressing	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+is	O
+dose	O
+-	O
+dependent	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+dataset	O
+of	O
+103	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+(	O
+101	O
+human	O
+patients	O
+and	O
+2	O
+palm	B-ANAT
+civets	B-SPEC
+)	O
+was	O
+investigated	O
+on	O
+different	O
+aspects	O
+of	O
+genome	O
+polymorphism	B-PROC
+and	O
+isolate	O
+classification	O
+.	O
+
+Distribution	O
+of	O
+substitution	O
+categories	O
+per	O
+codon	O
+positions	O
+,	O
+as	O
+well	O
+as	O
+synonymous	O
+and	O
+non	O
+-	O
+synonymous	O
+substitutions	O
+in	O
+coding	O
+regions	O
+of	O
+annotated	O
+isolates	O
+,	O
+was	O
+determined	O
+,	O
+along	O
+with	O
+amino	B-CHED
+acid	I-CHED
+(	O
+a	O
+.	O
+a	O
+.)	O
+property	O
+changes	O
+.	O
+
+Similar	O
+analysis	O
+was	O
+performed	O
+for	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+in	O
+all	O
+the	O
+isolates	O
+(	O
+55	O
+of	O
+them	O
+being	O
+predicted	O
+for	O
+the	O
+first	O
+time	O
+).	O
+
+Peak	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+activity	O
+occurred	O
+in	O
+March	O
+.	O
+
+Several	O
+physicians	O
+(	O
+10	O
+.	O
+9	O
+%)	O
+reported	O
+entering	O
+the	O
+hospital	O
+despite	O
+experiencing	O
+identified	O
+SARS	B-DISO
+symptoms	O
+.	O
+
+Although	O
+the	O
+exact	O
+mechanism	O
+linking	O
+sleep	B-DISO
+apnea	I-DISO
+with	O
+cardiovascular	B-DISO
+disease	I-DISO
+is	O
+unknown	O
+,	O
+there	O
+is	O
+evidence	O
+that	O
+obstructive	O
+apnea	B-DISO
+is	O
+associated	O
+with	O
+a	O
+group	O
+of	O
+proinflammatory	O
+and	O
+prothrombic	O
+factors	O
+that	O
+are	O
+also	O
+important	O
+in	O
+the	O
+development	B-PROC
+of	O
+atherosclerosis	B-DISO
+.	O
+
+Apnea	B-DISO
+,	O
+hypoxia	B-DISO
+,	O
+CO2	B-DISO
+retention	B-PROC
+and	O
+arousals	O
+provoke	O
+elevated	O
+sympathetic	O
+activity	O
+,	O
+increased	O
+afterload	O
+and	O
+elevated	O
+left	O
+ventricular	B-ANAT
+transmural	O
+pressure	O
+,	O
+and	O
+promote	O
+the	O
+progression	O
+of	O
+heart	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+for	O
+Shwachman	B-DISO
+-	I-DISO
+Diamond	I-DISO
+syndrome	I-DISO
+:	O
+experience	O
+of	O
+the	O
+French	O
+neutropenia	O
+registry	O
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+study	O
+the	O
+outcome	O
+of	O
+allogeneic	O
+hematopoietic	O
+stem	O
+cell	O
+transplantation	O
+(	O
+HSCT	O
+)	O
+for	O
+Shwachman	B-DISO
+-	I-DISO
+Diamond	I-DISO
+Syndrome	I-DISO
+(	O
+SDS	B-DISO
+).	O
+
+The	O
+conditioning	O
+regimen	O
+consisted	O
+of	O
+a	O
+busulfan	B-CHED
+-	O
+cyclophosphamide	B-CHED
+combination	O
+(	O
+n	O
+=	O
+6	O
+)	O
+or	O
+total	O
+body	B-ANAT
+irradiation	O
+plus	O
+chemotherapy	O
+(	O
+n	O
+=	O
+4	O
+).	O
+
+These	O
+latter	O
+two	O
+patients	O
+died	B-PROC
+of	O
+infections	B-DISO
+32	O
+and	O
+36	O
+days	O
+after	O
+HSCT	O
+,	O
+with	O
+grade	O
+IV	O
+graft	O
+-	O
+versus	O
+-	O
+host	B-COMP
+disease	O
+and	O
+multiorgan	O
+dysfunction	O
+.	O
+
+We	O
+conclude	O
+that	O
+HSCT	O
+is	O
+feasible	O
+for	O
+patients	O
+with	O
+SDS	B-DISO
+who	O
+develop	O
+bone	B-DISO
+marrow	I-DISO
+failure	I-DISO
+or	O
+malignant	B-DISO
+transformation	I-DISO
+.	O
+
+The	O
+results	O
+showed	O
+the	O
+neutralization	O
+titres	O
+of	O
+F	O
+(	O
+ab	O
+')	O
+2	O
+from	O
+three	O
+horses	B-SPEC
+all	O
+reached	O
+at	O
+least	O
+1	O
+:	O
+1600	O
+,	O
+and	O
+50	O
+microg	O
+of	O
+the	O
+F	O
+(	O
+ab	O
+')	O
+2	O
+fragments	O
+could	O
+completely	O
+neutralize	O
+1x10	O
+(	O
+4	O
+)	O
+TCID50	O
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+vivo	O
+.	O
+
+Five	O
+of	O
+these	O
+peptides	B-CHED
+showed	O
+high	O
+cross	O
+-	O
+immunoreactivities	O
+(	O
+approximately	O
+66	O
+.	O
+7	O
+to	O
+90	O
+.	O
+5	O
+%)	O
+to	O
+SARS	B-DISO
+convalescent	O
+patients	O
+'	O
+sera	B-COMP
+from	O
+the	O
+severest	O
+epidemic	O
+regions	O
+of	O
+the	O
+China	O
+mainland	O
+.	O
+
+Most	O
+interestingly	O
+,	O
+S	O
+(	O
+471	O
+-	O
+503	O
+),	O
+a	O
+peptide	B-CHED
+located	O
+at	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+could	O
+specifically	O
+block	O
+the	O
+binding	B-FUNC
+between	O
+the	O
+RBD	O
+and	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+,	O
+resulting	O
+in	O
+the	O
+inhibition	B-PROC
+of	O
+SARS	O
+-	O
+CoV	O
+entrance	O
+into	O
+host	B-COMP
+cells	B-COMP
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Using	O
+an	O
+integrated	O
+infection	B-DISO
+control	O
+strategy	O
+during	O
+outbreak	O
+control	O
+to	O
+minimize	O
+nosocomial	B-DISO
+infection	I-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+among	O
+healthcare	O
+workers	O
+.	O
+
+TITLE	O
+:	O
+Response	O
+of	O
+acoustic	O
+transmission	O
+to	O
+positive	O
+airway	B-ANAT
+pressure	O
+therapy	O
+in	O
+experimental	O
+lung	B-ANAT
+injury	O
+.	O
+
+Prospective	O
+experimental	O
+study	O
+in	O
+the	O
+animal	B-SPEC
+laboratory	O
+in	O
+an	O
+academic	O
+medical	O
+center	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+causes	O
+regional	O
+acoustic	O
+transmission	O
+abnormalities	O
+that	O
+are	O
+reversed	O
+during	O
+alveolar	B-ANAT
+recruitment	B-DISO
+with	O
+PEEP	B-CHED
+.	O
+
+TITLE	O
+:	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+inhibits	O
+the	O
+caspase	B-PROC
+-	I-PROC
+dependent	I-PROC
+apoptosis	B-PATH
+induced	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+without	O
+affecting	O
+virus	B-SPEC
+replication	I-PROC
+kinetics	O
+.	O
+
+Finally	O
+,	O
+matched	O
+duplexes	O
+were	O
+detected	O
+by	O
+using	O
+a	O
+laser	B-SPEC
+-	O
+induced	O
+fluorescence	O
+scanner	O
+.	O
+
+The	O
+usefulness	O
+of	O
+this	O
+method	O
+was	O
+illustrated	O
+by	O
+analyzing	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+RNA	O
+.	O
+
+In	O
+conclusion	O
+,	O
+we	O
+demonstrate	O
+that	O
+a	O
+3	O
+-	O
+D	O
+structure	O
+can	O
+be	O
+defined	O
+from	O
+a	O
+2	O
+-	O
+D	O
+membrane	B-COMP
+patterned	O
+image	O
+and	O
+that	O
+a	O
+SARS	B-DISO
+viral	O
+associated	O
+membrane	B-COMP
+change	O
+has	O
+been	O
+identified	O
+as	O
+cubic	O
+membrane	B-COMP
+morphology	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+is	O
+frequently	O
+complicated	O
+by	O
+respiratory	B-DISO
+failure	I-DISO
+requiring	O
+ventilatory	O
+support	O
+.	O
+
+We	O
+aimed	O
+to	O
+compare	O
+the	O
+efficacy	O
+of	O
+non	O
+-	O
+invasive	O
+ventilation	O
+against	O
+invasive	O
+mechanical	O
+ventilation	O
+treating	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+this	O
+disease	O
+.	O
+
+Compared	O
+to	O
+IMV	O
+Hospitals	O
+(	O
+451	O
+patients	O
+),	O
+NIV	O
+Hospital	O
+had	O
+lower	O
+adjusted	O
+odds	O
+ratios	O
+for	O
+intubation	O
+(	O
+0	O
+.	O
+36	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+164	O
+-	O
+0	O
+.	O
+791	O
+,	O
+P	O
+=	O
+0	O
+.	O
+011	O
+)	O
+and	O
+death	B-PROC
+(	O
+0	O
+.	O
+235	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+077	O
+-	O
+0	O
+.	O
+716	O
+,	O
+P	O
+=	O
+0	O
+.	O
+011	O
+),	O
+and	O
+improved	O
+earlier	O
+after	O
+pulsed	O
+steroid	B-CHED
+rescue	O
+.	O
+
+There	O
+were	O
+no	O
+instances	O
+of	O
+transmission	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+among	O
+health	O
+care	O
+workers	O
+due	O
+to	O
+the	O
+use	O
+of	O
+non	O
+-	O
+invasive	O
+ventilation	O
+.	O
+
+Compared	O
+to	O
+invasive	O
+mechanical	O
+ventilation	O
+,	O
+non	O
+-	O
+invasive	O
+ventilation	O
+as	O
+initial	O
+ventilatory	O
+support	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+the	O
+presence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+appeared	O
+to	O
+be	O
+associated	O
+with	O
+reduced	O
+intubation	O
+need	O
+and	O
+mortality	O
+.	O
+
+A	O
+novel	O
+virus	B-SPEC
+belonging	O
+to	O
+the	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+was	O
+found	O
+to	O
+be	O
+a	O
+cause	O
+of	O
+this	O
+infection	B-DISO
+.	O
+
+Since	O
+this	O
+case	O
+occurred	O
+,	O
+our	O
+intensive	O
+care	O
+unit	O
+has	O
+instituted	O
+recommendations	O
+for	O
+the	O
+prevention	O
+of	O
+lorazepam	B-CHED
+-	O
+associated	O
+propylene	B-CHED
+glycol	I-CHED
+toxicity	O
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+evidence	O
+that	O
+stem	B-ANAT
+-	O
+loop	O
+IV	O
+,	O
+a	O
+bulged	O
+stem	B-ANAT
+-	O
+loop	O
+mapping	O
+at	O
+nt	O
+186	O
+through	O
+215	O
+,	O
+(	O
+i	O
+)	O
+is	O
+phylogenetically	O
+conserved	O
+among	O
+group	O
+2	O
+coronaviruses	O
+and	O
+may	O
+have	O
+a	O
+homolog	O
+in	O
+groups	O
+1	O
+and	O
+3	O
+,	O
+(	O
+ii	O
+)	O
+exists	O
+as	O
+a	O
+higher	O
+-	O
+order	B-SPEC
+structure	O
+on	O
+the	O
+basis	O
+of	O
+enzyme	O
+probing	O
+,	O
+(	O
+iii	O
+)	O
+is	O
+required	O
+as	O
+a	O
+higher	O
+-	O
+order	B-SPEC
+element	O
+for	O
+replication	O
+of	O
+a	O
+BCoV	O
+defective	O
+interfering	B-PRGE
+(	I-PRGE
+DI	I-PRGE
+)	I-PRGE
+RNA	I-PRGE
+in	O
+the	O
+positive	O
+but	O
+not	O
+the	O
+negative	O
+strand	O
+,	O
+and	O
+(	O
+iv	O
+)	O
+as	O
+a	O
+higher	O
+-	O
+order	B-SPEC
+structure	O
+in	O
+wild	O
+-	O
+type	O
+(	O
+wt	O
+)	O
+and	O
+mutant	B-DISO
+molecules	O
+that	O
+replicate	O
+,	O
+specifically	O
+binds	B-FUNC
+six	O
+cellular	B-COMP
+proteins	B-CHED
+in	O
+the	O
+molecular	O
+mass	O
+range	O
+of	O
+25	O
+to	O
+58	O
+kDa	O
+as	O
+determined	O
+by	O
+electrophoretic	O
+mobility	O
+shift	O
+and	O
+UV	O
+cross	O
+-	O
+linking	O
+assays	O
+;	O
+binding	O
+to	O
+viral	O
+proteins	B-CHED
+was	O
+not	O
+detected	O
+.	O
+
+We	O
+observed	O
+many	O
+petechias	O
+and	O
+ecchymoses	O
+which	O
+suggested	O
+vascular	B-ANAT
+haemorrhagic	B-DISO
+diathesis	I-DISO
+.	O
+
+It	O
+was	O
+found	O
+that	O
+the	O
+patient	O
+had	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+and	O
+rhabdomyolysis	B-DISO
+with	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+which	O
+was	O
+treated	O
+by	O
+dialysis	B-SPEC
+.	O
+
+The	O
+presence	O
+of	O
+high	O
+concentration	O
+of	O
+amphetamine	B-CHED
+,	O
+MDMA	B-CHED
+and	O
+THC	B-DISO
+in	O
+blood	B-ANAT
+,	O
+extreme	O
+dehydration	B-DISO
+and	O
+electrolytes	O
+disturbances	O
+caused	O
+rhabdomyolysis	B-DISO
+,	O
+DIC	B-DISO
+syndrome	I-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+which	O
+make	O
+the	O
+prognosis	O
+worse	O
+and	O
+complicate	O
+the	O
+treatment	O
+.	O
+
+The	O
+patient	O
+is	O
+alive	O
+(	O
+what	O
+is	O
+a	O
+big	O
+success	O
+),	O
+probably	O
+thanks	O
+to	O
+quick	O
+arrival	O
+to	O
+specialized	O
+medical	O
+centre	O
+and	O
+dialysis	B-SPEC
+treatment	O
+which	O
+was	O
+started	O
+early	O
+.	O
+
+Ninety	O
+-	O
+four	O
+patients	O
+who	O
+recovered	O
+from	O
+SARS	B-DISO
+were	O
+assessed	O
+at	O
+a	O
+uniform	O
+time	O
+point	O
+of	O
+1	O
+year	O
+after	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+There	O
+was	O
+one	O
+patient	O
+(	O
+1	O
+%)	O
+who	O
+had	O
+moderate	O
+impairment	B-DISO
+of	O
+FVC	B-PROC
+,	O
+one	O
+patient	O
+(	O
+1	O
+%)	O
+who	O
+had	O
+moderate	O
+impairment	B-DISO
+of	O
+the	O
+FEV1	O
+/	O
+FVC	B-PROC
+ratio	O
+,	O
+and	O
+three	O
+patients	O
+(	O
+3	O
+%)	O
+who	O
+had	O
+moderate	O
+impairment	B-DISO
+of	O
+the	O
+D	O
+(	O
+LCO	B-CHED
+).	O
+
+Findings	O
+on	O
+presentation	O
+included	O
+tachycardia	O
+and	O
+tachypnoea	B-DISO
+in	O
+all	O
+foals	O
+,	O
+with	O
+fever	B-PROC
+recorded	O
+in	O
+8	O
+cases	O
+.	O
+
+All	O
+foals	O
+were	O
+treated	O
+with	O
+intranasal	O
+oxygen	B-CHED
+and	O
+antimicrobial	B-CHED
+drugs	I-CHED
+;	O
+13	O
+received	O
+corticosteroids	B-CHED
+.	O
+
+Follow	O
+-	O
+up	O
+was	O
+available	O
+for	O
+7	O
+foals	O
+;	O
+all	O
+performed	O
+as	O
+well	O
+as	O
+age	O
+mates	B-SPEC
+or	O
+siblings	O
+,	O
+and	O
+one	O
+was	O
+racing	O
+successfully	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+complexed	O
+with	O
+receptor	O
+.	O
+
+TITLE	O
+:	O
+Facing	O
+SARS	B-DISO
+:	O
+psychological	B-DISO
+impacts	O
+on	O
+SARS	B-DISO
+team	O
+nurses	O
+and	O
+psychiatric	O
+services	O
+in	O
+a	O
+Taiwan	O
+general	O
+hospital	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+reinforces	O
+the	O
+importance	O
+and	O
+benefits	O
+of	O
+psychiatric	O
+services	O
+for	O
+SARS	B-DISO
+team	O
+members	O
+in	O
+reducing	O
+their	O
+secondary	O
+traumatization	O
+.	O
+
+Neutralizing	O
+antibody	B-COMP
+to	O
+human	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+also	O
+was	O
+detected	O
+in	O
+bats	B-SPEC
+with	O
+lower	O
+viral	O
+loads	O
+.	O
+
+The	O
+widespread	O
+use	O
+of	O
+qRT	O
+-	O
+PCR	O
+assays	O
+for	O
+diagnosis	O
+and	O
+the	O
+detection	O
+of	O
+disease	O
+-	O
+specific	O
+prognostic	O
+markers	O
+in	O
+leukaemia	B-DISO
+patients	O
+provide	O
+further	O
+examples	O
+of	O
+their	O
+usefulness	O
+.	O
+
+Successful	O
+control	O
+of	O
+the	O
+global	O
+SARS	B-DISO
+epidemic	O
+will	O
+require	O
+rapid	O
+and	O
+sensitive	O
+diagnostic	O
+tests	O
+to	O
+monitor	O
+its	O
+spread	O
+,	O
+as	O
+well	O
+as	O
+,	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+and	O
+new	O
+antiviral	B-CHED
+compounds	O
+including	O
+neutralizing	O
+antibodies	B-COMP
+that	O
+effectively	O
+prevent	O
+or	O
+treat	O
+this	O
+disease	O
+.	O
+
+For	O
+the	O
+discovery	O
+of	O
+a	O
+novel	O
+efficient	O
+way	O
+to	O
+modify	O
+oligonucleotides	B-CHED
+,	O
+a	O
+series	O
+of	O
+single	O
+isonucleotide	O
+-	O
+incorporated	O
+antisense	O
+oligodeoxynucleotides	O
+have	O
+been	O
+synthesized	O
+,	O
+in	O
+which	O
+an	O
+isonucleotide	O
+was	O
+introduced	O
+at	O
+different	O
+positions	O
+of	O
+the	O
+sequences	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pentameric	O
+B	O
+subunit	O
+of	O
+Escherichia	B-SPEC
+coli	I-SPEC
+heat	O
+-	O
+labile	O
+enterotoxin	O
+(	O
+LTB	O
+)	O
+can	O
+be	O
+used	O
+as	O
+an	O
+efficient	O
+mucosal	B-ANAT
+carrier	O
+of	O
+either	O
+immunogenic	O
+or	O
+tolerogenic	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+.	O
+
+Co	O
+-	O
+delivery	O
+of	O
+therapeutic	O
+proteins	B-CHED
+with	O
+carrier	O
+proteins	B-CHED
+could	O
+increase	O
+the	O
+effectiveness	O
+of	O
+the	O
+antigen	B-CHED
+.	O
+
+This	O
+suggested	O
+that	O
+the	O
+fusion	O
+protein	B-CHED
+retained	O
+both	O
+its	O
+native	O
+antigenicity	O
+and	O
+the	O
+ability	O
+to	O
+form	O
+pentamers	O
+.	O
+
+According	O
+to	O
+different	O
+treatment	O
+regimens	O
+,	O
+the	O
+patients	O
+were	O
+divided	O
+into	O
+hormone	B-CHED
+group	O
+(	O
+n	O
+=	O
+35	O
+)	O
+and	O
+non	O
+-	O
+hormone	B-CHED
+group	O
+(	O
+n	O
+=	O
+59	O
+).	O
+
+The	O
+control	O
+groups	O
+consisted	O
+of	O
+65	O
+patients	O
+with	O
+interstitial	B-DISO
+pneumonia	I-DISO
+,	O
+78	O
+with	O
+bacterial	B-DISO
+pneumonia	I-DISO
+and	O
+57	O
+with	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+At	O
+each	O
+time	O
+point	O
+of	O
+measurement	O
+,	O
+the	O
+body	B-ANAT
+temperature	O
+of	O
+SARS	B-DISO
+patients	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+of	O
+patients	O
+with	O
+other	O
+diseases	O
+(	O
+P	O
+<	O
+0	O
+.	O
+03	O
+),	O
+with	O
+a	O
+fluctuation	B-DISO
+of	O
+0	O
+.	O
+2	O
+to	O
+0	O
+.	O
+5	O
+degrees	O
+C	O
+;	O
+and	O
+following	O
+a	O
+pattern	O
+of	O
+variation	O
+similar	O
+to	O
+those	O
+of	O
+the	O
+other	O
+diseases	O
+.	O
+
+Hormone	B-CHED
+therapy	O
+may	O
+not	O
+produce	O
+significant	O
+effect	O
+in	O
+controlling	O
+the	O
+temperature	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Expression	B-PROC
+of	O
+the	O
+recombinant	B-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+in	O
+Pichia	B-SPEC
+pastoris	I-SPEC
+and	O
+identification	O
+of	O
+its	O
+bioactivity	O
+].	O
+
+The	O
+plasmid	O
+was	O
+linearized	O
+and	O
+then	O
+transformed	O
+into	O
+P	B-SPEC
+.	I-SPEC
+pastoris	I-SPEC
+(	O
+His	O
+-	O
+Mut	O
++)	O
+by	O
+electroporation	O
+method	O
+.	O
+
+The	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+expressed	B-PROC
+was	O
+about	O
+6	O
+%	O
+of	O
+the	O
+total	O
+cell	B-COMP
+proteins	B-CHED
+,	O
+410	O
+mg	O
+/	O
+L	O
+of	O
+recombinant	O
+N	O
+protein	B-CHED
+and	O
+45	O
+OD600	O
+were	O
+achieved	O
+in	O
+shake	B-DISO
+flask	O
+.	O
+
+Through	O
+electroporation	O
+transformantion	O
+to	O
+TCP1	B-PRGE
+,	O
+the	O
+recombinant	O
+S	B-SPEC
+.	I-SPEC
+pombe	I-SPEC
+strains	O
+capable	O
+of	O
+expressing	O
+the	O
+5	O
+fragments	O
+were	O
+constructed	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+Monte	O
+Carlo	O
+test	O
+results	O
+demonstrate	O
+that	O
+the	O
+multiple	O
+univariate	O
+combination	O
+methods	O
+of	O
+Fisher	B-SPEC
+and	O
+Edgington	O
+provide	O
+the	O
+most	O
+robust	O
+detection	O
+performance	O
+across	O
+the	O
+scenarios	O
+tested	O
+.	O
+
+TITLE	O
+:	O
+Rhabdomyolysis	B-DISO
+associated	O
+with	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+SARS	B-DISO
+complicated	O
+with	O
+rhabdomyolysis	B-DISO
+has	O
+rarely	O
+been	O
+reported	O
+.	O
+
+Soluble	O
+vascular	B-PRGE
+cell	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+sVCAM	O
+-	O
+1	O
+)	O
+and	O
+soluble	B-PRGE
+Fas	I-PRGE
+ligand	B-PROC
+(	O
+sFasL	O
+)	O
+in	O
+plasma	B-ANAT
+were	O
+measured	O
+by	O
+ELISA	O
+,	O
+and	O
+intracellular	B-COMP
+activated	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+fragment	I-PRGE
+in	O
+different	O
+leukocytes	B-ANAT
+was	O
+determined	O
+by	O
+flow	O
+cytometry	O
+.	O
+
+TITLE	O
+:	O
+Sirolimus	B-CHED
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+renal	B-ANAT
+transplant	B-ANAT
+recipient	O
+.	O
+
+ABSTRACT	O
+:	O
+Sirolimus	O
+is	O
+a	O
+new	O
+potent	O
+immunosuppressive	O
+drug	O
+used	O
+in	O
+organ	B-ANAT
+transplantation	O
+;	O
+its	O
+major	O
+advantage	O
+is	O
+the	O
+absence	O
+of	O
+deterioration	O
+in	O
+renal	B-PROC
+function	I-PROC
+.	O
+
+The	O
+pathogenesis	B-DISO
+of	O
+the	O
+disease	O
+is	O
+complex	O
+with	O
+many	O
+unresolved	O
+issues	O
+relating	O
+to	O
+the	O
+role	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+However	O
+,	O
+one	O
+cell	B-ANAT
+type	I-ANAT
+stands	O
+out	O
+as	O
+being	O
+the	O
+key	O
+element	O
+in	O
+both	O
+the	O
+""""	O
+wet	O
+""""	O
+and	O
+""""	O
+dry	O
+""""	O
+forms	O
+of	O
+FIP	B-DISO
+:	O
+the	O
+macrophage	B-ANAT
+.	O
+
+Serum	B-PRGE
+antibody	B-COMP
+(	O
+IgG	B-PRGE
+)	O
+titre	O
+was	O
+>	O
+640	O
+.	O
+
+As	O
+part	O
+of	O
+the	O
+routine	O
+check	O
+with	O
+donated	O
+plasma	B-ANAT
+,	O
+the	O
+convalescent	O
+plasma	B-ANAT
+was	O
+confirmed	O
+free	O
+of	O
+residual	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Regulatory	O
+authorities	O
+in	O
+Europe	O
+(	O
+EMEA	O
+)	O
+and	O
+in	O
+the	O
+United	O
+States	O
+(	O
+FDA	O
+)	O
+have	O
+encouraged	O
+biological	O
+manufactures	O
+to	O
+reduce	O
+or	O
+eliminate	O
+the	O
+use	O
+of	O
+live	O
+animals	B-SPEC
+and	O
+/	O
+or	O
+products	O
+of	O
+animal	B-SPEC
+origin	O
+in	O
+biological	O
+manufacturing	O
+processes	O
+.	O
+
+Among	O
+them	O
+,	O
+28	O
+suffered	B-DISO
+seizure	B-DISO
+attacks	O
+during	O
+AED	B-CHED
+withdrawal	B-DISO
+.	O
+
+AED	B-CHED
+withdrawal	B-DISO
+produced	O
+a	O
+significant	O
+increase	O
+in	O
+seizure	B-DISO
+frequency	O
+.	O
+
+TITLE	O
+:	O
+ADP	B-CHED
+-	I-PRGE
+ribose	B-CHED
+-	I-PRGE
+1	I-PRGE
+"""-"	I-PRGE
+monophosphatase	I-PRGE
+:	O
+a	O
+conserved	O
+coronavirus	B-SPEC
+enzyme	O
+that	O
+is	O
+dispensable	O
+for	O
+viral	B-PROC
+replication	I-PROC
+in	O
+tissue	B-ANAT
+culture	O
+.	O
+
+ABSTRACT	O
+:	O
+Replication	O
+of	O
+the	O
+approximately	O
+30	O
+-	O
+kb	O
+plus	O
+-	O
+strand	O
+RNA	O
+genome	O
+of	O
+coronaviruses	O
+and	O
+synthesis	B-PROC
+of	O
+an	O
+extensive	O
+set	O
+of	O
+subgenome	O
+-	O
+length	O
+RNAs	O
+are	O
+mediated	O
+by	O
+the	O
+replicase	B-PRGE
+-	I-PRGE
+transcriptase	I-PRGE
+,	O
+a	O
+membrane	B-COMP
+-	O
+bound	O
+protein	B-COMP
+complex	I-COMP
+containing	O
+several	O
+cellular	B-COMP
+proteins	B-CHED
+and	O
+up	O
+to	O
+16	O
+viral	O
+nonstructural	O
+proteins	B-CHED
+(	O
+nsps	O
+)	O
+with	O
+multiple	O
+enzymatic	O
+activities	O
+,	O
+including	O
+protease	O
+,	O
+polymerase	B-PRGE
+,	I-PRGE
+helicase	I-PRGE
+,	I-PRGE
+methyltransferase	I-PRGE
+,	O
+and	O
+RNase	B-PRGE
+activities	O
+.	O
+
+The	O
+enzyme	O
+had	O
+no	O
+detectable	O
+activity	O
+on	O
+several	O
+other	O
+nucleoside	B-CHED
+phosphates	I-CHED
+.	O
+
+Guided	O
+by	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+AF1521	O
+,	O
+an	O
+X	B-PRGE
+domain	I-PRGE
+homolog	I-PRGE
+from	I-PRGE
+Archaeoglobus	I-PRGE
+fulgidus	O
+,	O
+potential	O
+active	O
+-	O
+site	O
+residues	O
+of	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+X	I-PRGE
+domain	I-PRGE
+were	O
+targeted	B-PROC
+by	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+.	O
+
+Characterization	O
+of	O
+an	O
+Appr	O
+-	O
+1	O
+"""-"	O
+pase	O
+-	O
+deficient	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+mutant	B-DISO
+revealed	O
+no	O
+significant	O
+effects	O
+on	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+virus	B-SPEC
+titer	O
+,	O
+and	O
+no	O
+reversion	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+sequence	O
+was	O
+observed	O
+when	O
+the	O
+mutant	B-DISO
+virus	B-SPEC
+was	O
+passaged	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+The	O
+extent	O
+of	O
+this	O
+process	O
+appeared	O
+to	O
+depend	O
+strongly	O
+on	O
+the	O
+coronaviral	O
+genomic	O
+background	O
+,	O
+the	O
+luciferase	B-PRGE
+gene	I-PRGE
+being	O
+much	O
+more	O
+stable	O
+in	O
+the	O
+feline	B-SPEC
+than	O
+in	O
+the	O
+mouse	B-SPEC
+coronavirus	B-SPEC
+genome	O
+.	O
+
+The	O
+collaborative	O
+efforts	O
+of	O
+the	O
+global	O
+scientific	O
+community	O
+have	O
+provided	O
+,	O
+within	O
+a	O
+short	O
+period	O
+of	O
+time	O
+,	O
+substantial	O
+insights	O
+into	O
+the	O
+molecular	O
+biology	O
+and	O
+immunology	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Although	O
+the	O
+outbreak	O
+has	O
+been	O
+contained	O
+,	O
+there	O
+is	O
+continuous	O
+concern	O
+that	O
+the	O
+virus	B-SPEC
+may	O
+resurface	O
+into	O
+the	O
+human	B-SPEC
+population	O
+through	O
+seasonal	O
+changes	O
+,	O
+animal	B-SPEC
+reservoirs	O
+or	O
+laboratory	O
+accidents	O
+.	O
+
+Novel	O
+variant	O
+strains	O
+,	O
+unrelated	O
+by	O
+S1	O
+sequencing	O
+and	O
+restriction	O
+fragment	O
+length	O
+polymorphism	B-PROC
+analyses	O
+to	O
+reference	O
+and	O
+vaccine	O
+strains	O
+,	O
+were	O
+also	O
+identified	O
+.	O
+
+Based	O
+on	O
+S1	O
+sequence	O
+identity	O
+to	O
+available	O
+vaccines	O
+,	O
+the	O
+potential	O
+to	O
+use	O
+vaccination	O
+to	O
+control	O
+IBV	O
+infections	B-DISO
+was	O
+evaluated	O
+.	O
+
+When	O
+tears	B-ANAT
+were	O
+collected	O
+using	O
+filter	O
+papers	O
+,	O
+IgG	B-PRGE
+was	O
+detected	O
+in	O
+eluted	O
+samples	O
+but	O
+at	O
+significantly	O
+lower	O
+levels	O
+than	O
+in	O
+those	O
+collected	O
+by	O
+pipette	O
+.	O
+
+Of	O
+the	O
+158	O
+hips	B-ANAT
+examined	O
+,	O
+28	O
+had	O
+AVN	O
+(	O
+11	O
+with	O
+bilateral	O
+hip	B-PRGE
+AVN	I-PRGE
+,	O
+three	O
+with	O
+right	B-ANAT
+hip	I-ANAT
+AVN	O
+,	O
+and	O
+three	O
+with	O
+left	B-ANAT
+hip	I-ANAT
+AVN	O
+).	O
+
+The	O
+mean	O
+ADC	B-CHED
+was	O
+markedly	O
+greater	O
+in	O
+the	O
+AVN	O
+femoral	B-ANAT
+head	I-ANAT
+(	O
+1	O
+.	O
+66	O
+x	O
+10	O
+(-	O
+3	O
+)	O
+mm	O
+(	O
+2	O
+)/	O
+second	O
++/-	O
+0	O
+.	O
+20	O
+)	O
+than	O
+in	O
+the	O
+normal	O
+femoral	B-ANAT
+head	I-ANAT
+(	O
+0	O
+.	O
+47	O
+x	O
+10	O
+(-	O
+3	O
+)	O
+mm	O
+(	O
+2	O
+)/	O
+second	O
++/-	O
+0	O
+.	O
+082	O
+;	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Common	O
+classification	O
+system	O
+were	O
+used	O
+for	O
+staging	O
+of	O
+hip	B-ANAT
+(	O
+ARCO	B-SPEC
+),	O
+knee	B-ANAT
+(	O
+Lotka	O
+)	O
+and	O
+shoulder	B-ANAT
+(	O
+Cruess	O
+).	O
+
+No	O
+osteonecrosis	B-DISO
+was	O
+detected	O
+in	O
+12	O
+patients	O
+without	O
+corticosteroid	B-CHED
+.	O
+
+The	O
+dosage	O
+of	O
+corticosteroid	B-CHED
+was	O
+(	O
+5842	O
++/-	O
+
+CONCLUSIONS	O
+:	O
+About	O
+one	O
+-	O
+third	O
+patients	O
+with	O
+SARS	B-DISO
+who	O
+were	O
+treated	O
+with	O
+a	O
+high	O
+dose	O
+of	O
+corticosteroid	B-CHED
+occurred	O
+osteonecrosis	B-DISO
+.	O
+
+However	O
+,	O
+only	O
+a	O
+minor	O
+form	O
+of	O
+the	O
+Endo	B-PRGE
+H	I-PRGE
+-	I-PRGE
+resistant	I-PRGE
+glycoproteins	B-CHED
+(	O
+approximately	O
+130	O
+kDa	O
+)	O
+was	O
+detected	O
+in	O
+CHO	B-FUNC
+/	O
+dhFr	B-PROC
+-	O
+cells	B-COMP
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+and	O
+real	O
+-	O
+time	O
+quantitative	O
+PCR	O
+and	O
+immunohistochemical	O
+staining	O
+were	O
+performed	O
+to	O
+analyze	O
+the	O
+production	O
+of	O
+IP	O
+-	O
+10	O
+in	O
+lung	O
+tissue	O
+at	O
+autopsy	O
+.	O
+
+RESULTS	O
+:	O
+Increases	O
+in	O
+IP	O
+-	O
+10	O
+,	O
+MIG	O
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+during	O
+the	O
+first	O
+week	O
+after	O
+onset	O
+of	O
+fever	B-PROC
+were	O
+associated	O
+with	O
+adverse	O
+outcome	O
+(	O
+intensive	O
+care	O
+unit	O
+admission	O
+or	O
+death	B-PROC
+)	O
+in	O
+the	O
+univariate	O
+analysis	O
+.	O
+
+In	O
+the	O
+ethanol	B-CHED
+group	O
+,	O
+serum	B-COMP
+and	O
+tissue	B-ANAT
+MDA	B-CHED
+levels	O
+and	O
+MPO	B-FUNC
+activities	O
+were	O
+increased	O
+(	O
+p	O
+=	O
+0	O
+.	O
+007	O
+,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+and	O
+p	O
+=	O
+0	O
+.	O
+000	O
+),	O
+and	O
+lung	B-ANAT
+tissue	I-ANAT
+Na	O
+(+)-	O
+K	O
+(+)	O
+ATPase	B-PRGE
+activities	O
+and	O
+erythrocyte	B-ANAT
+GSH	B-DISO
+were	O
+decreased	O
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+and	O
+p	O
+=	O
+0	O
+.	O
+000	O
+)	O
+compared	O
+to	O
+the	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+clone	O
+and	O
+express	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+,	O
+and	O
+to	O
+evaluate	O
+its	O
+antigenicity	O
+and	O
+application	O
+value	O
+in	O
+the	O
+development	B-PROC
+of	O
+serological	O
+diagnostic	O
+test	O
+for	O
+SARS	B-DISO
+.	O
+
+The	O
+recombinant	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+associated	I-PRGE
+coronavirus	I-PRGE
+N	I-PRGE
+protein	B-CHED
+possessed	B-DISO
+better	O
+antigenicity	O
+and	O
+specificity	O
+and	O
+could	O
+be	O
+employed	O
+to	O
+establish	O
+a	O
+new	O
+,	O
+sensitive	O
+,	O
+and	O
+specific	O
+ELISA	O
+for	O
+SARS	B-DISO
+diagnosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+public	O
+health	O
+emergencies	O
+involving	O
+anthrax	B-DISO
+,	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+shortages	O
+of	O
+influenza	B-DISO
+vaccine	O
+have	O
+dramatized	O
+the	O
+need	O
+for	O
+restrictive	O
+public	O
+health	O
+measures	O
+such	O
+as	O
+quarantine	O
+,	O
+isolation	O
+,	O
+and	O
+rationing	O
+.	O
+
+Front	O
+-	O
+line	O
+physicians	O
+will	O
+face	B-DISO
+ethical	O
+dilemmas	O
+during	O
+public	O
+health	O
+emergencies	B-DISO
+when	O
+patients	O
+disagree	O
+with	O
+these	O
+measures	O
+.	O
+
+Results	O
+from	O
+the	O
+ESCAPE	O
+trial	O
+of	O
+patients	O
+with	O
+severe	O
+heart	B-DISO
+failure	I-DISO
+were	O
+also	O
+included	O
+.	O
+
+Hemodynamic	B-PROC
+goals	O
+and	O
+treatment	O
+strategies	O
+varied	O
+among	O
+trials	O
+.	O
+
+The	O
+present	O
+study	O
+attempted	O
+to	O
+fill	O
+this	O
+void	B-PROC
+by	O
+presenting	O
+a	O
+detailed	O
+account	O
+of	O
+a	O
+comprehensive	O
+and	O
+integrated	O
+approach	O
+to	O
+developing	O
+,	O
+implementing	O
+,	O
+and	O
+evaluating	O
+a	O
+tabletop	O
+exercise	O
+designed	O
+to	O
+enhance	O
+emergency	B-DISO
+preparedness	O
+and	O
+response	O
+of	O
+public	O
+health	O
+workers	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+prevalence	O
+of	O
+antibodies	O
+to	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	B-SPEC
+)	O
+serotypes	O
+1	O
+and	O
+2	O
+in	O
+Switzerland	O
+and	O
+their	O
+association	O
+with	O
+different	O
+disease	O
+manifestations	O
+,	O
+a	O
+serological	O
+study	O
+based	O
+on	O
+immunofluorescence	O
+tests	O
+was	O
+conducted	O
+with	O
+Swiss	O
+field	O
+cats	B-SPEC
+using	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+FCoV	B-PRGE
+type	I-PRGE
+1	I-PRGE
+and	O
+FCoV	B-PRGE
+type	I-PRGE
+2	I-PRGE
+as	O
+antigens	B-CHED
+.	O
+
+We	O
+conclude	O
+that	O
+a	O
+vaccine	O
+against	O
+FCoV	O
+should	O
+be	O
+based	O
+on	O
+FCoV	B-PRGE
+type	I-PRGE
+1	I-PRGE
+-	I-PRGE
+related	I-PRGE
+antigens	I-PRGE
+and	O
+that	O
+for	O
+serodiagnosis	O
+of	O
+FCoV	O
+infection	B-DISO
+TGEV	B-SPEC
+should	O
+be	O
+used	O
+to	O
+attain	O
+the	O
+highest	O
+diagnostic	O
+efficiency	O
+.	O
+
+When	O
+serology	O
+is	O
+used	O
+in	O
+addition	O
+to	O
+clinical	O
+signs	O
+,	O
+hematology	O
+,	O
+and	O
+clinical	O
+chemistry	O
+results	O
+as	O
+an	O
+aid	O
+to	O
+diagnose	O
+clinical	O
+FIP	B-DISO
+,	O
+TGEV	B-SPEC
+shows	O
+a	O
+diagnostic	O
+efficiency	O
+equal	O
+to	O
+that	O
+of	O
+a	O
+FCoV	B-PRGE
+antigen	I-PRGE
+.	O
+
+The	O
+finding	O
+was	O
+the	O
+structural	O
+definition	O
+,	O
+persevering	O
+through	O
+a	O
+difficult	O
+time	O
+is	O
+dispiriting	O
+trepidation	O
+arising	O
+with	O
+witnessing	O
+suffering	B-DISO
+.	O
+
+It	O
+is	O
+a	O
+smothering	O
+connectedness	O
+with	O
+sequestering	B-PROC
+protection	O
+as	O
+unsettling	O
+contentment	O
+emerges	O
+amid	O
+unburdening	O
+hope	O
+.	O
+
+These	O
+chaperoning	O
+properties	O
+facilitate	O
+proper	O
+protein	B-PROC
+folding	I-PROC
+,	O
+which	O
+enhances	O
+the	O
+solubility	O
+and	O
+biological	O
+activity	O
+of	O
+the	O
+purified	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Prediction	O
+of	O
+functional	O
+class	B-SPEC
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+proteins	B-CHED
+by	O
+a	O
+statistical	O
+learning	B-PROC
+method	O
+.	O
+
+Support	O
+vector	O
+machines	O
+(	O
+SVM	O
+),	O
+useful	O
+for	O
+predicting	O
+the	O
+functional	O
+class	B-SPEC
+of	O
+distantly	O
+related	O
+proteins	B-CHED
+,	O
+is	O
+employed	O
+to	O
+ascribe	O
+a	O
+possible	O
+functional	O
+class	B-SPEC
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+.	O
+
+A	O
+combination	O
+of	O
+the	O
+sequence	O
+comparison	O
+method	O
+BLAST	B-ANAT
+and	O
+SVMProt	O
+can	O
+further	O
+improve	O
+the	O
+prediction	O
+accuracy	O
+of	O
+SMVProt	O
+such	O
+that	O
+the	O
+functional	O
+class	O
+of	O
+two	O
+additional	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+is	O
+correctly	O
+predicted	O
+.	O
+
+The	O
+antigen	B-CHED
+detection	O
+limit	O
+for	O
+the	O
+Con	B-PRGE
+A	I-PRGE
+-	O
+S	O
+-	O
+ELISA	O
+was	O
+10	O
+(	O
+5	O
+,	O
+1	O
+)	O
+EID	O
+(	O
+50	O
+)/	O
+mL	O
+.	O
+Three	O
+homologous	O
+and	O
+four	O
+heterologous	O
+IBV	B-SPEC
+strains	O
+were	O
+similarly	O
+detected	O
+.	O
+
+Strong	O
+humoral	O
+responses	O
+have	O
+been	O
+found	O
+in	O
+most	O
+patients	O
+following	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+with	O
+high	O
+titers	O
+of	O
+neutralizing	O
+Abs	B-PRGE
+present	O
+in	O
+their	O
+convalescent	O
+sera	B-COMP
+.	O
+
+It	O
+is	O
+likely	O
+that	O
+the	O
+immune	B-PROC
+responses	I-PROC
+induced	O
+by	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+could	O
+also	O
+cause	O
+pathological	O
+damage	O
+to	O
+the	O
+host	B-COMP
+,	O
+especially	O
+in	O
+the	O
+case	O
+of	O
+proinflammatory	O
+cytokines	O
+.	O
+
+Our	O
+experience	O
+indicates	O
+that	O
+RT	O
+-	O
+PCR	O
+for	O
+dengue	B-DISO
+can	O
+be	O
+set	O
+up	O
+rapidly	O
+in	O
+a	O
+clinical	O
+laboratory	O
+,	O
+with	O
+very	O
+sensitive	O
+and	O
+specific	O
+results	O
+for	O
+the	O
+diagnosis	O
+of	O
+dengue	B-DISO
+,	O
+particularly	O
+in	O
+the	O
+first	O
+5	O
+days	O
+from	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+The	O
+peak	O
+inflammatory	B-DISO
+response	I-DISO
+was	O
+obtained	O
+at	O
+24	O
+h	O
+when	O
+the	O
+fluid	O
+volume	O
+,	O
+protein	B-CHED
+concentration	O
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+and	O
+cell	B-COMP
+infiltration	B-DISO
+were	O
+maximums	O
+.	O
+
+In	O
+cats	B-SPEC
+that	O
+died	B-PROC
+from	O
+FIP	B-DISO
+,	O
+viral	O
+loads	O
+were	O
+significantly	O
+higher	O
+,	O
+indicating	O
+a	O
+higher	O
+rate	O
+of	O
+viral	B-PROC
+replication	I-PROC
+or	O
+a	O
+reduced	O
+capacity	O
+for	O
+viral	O
+clearance	O
+in	O
+cats	B-SPEC
+developing	O
+and	O
+/	O
+or	O
+suffering	B-DISO
+from	O
+FIP	B-DISO
+.	O
+
+The	O
+dimer	O
+interface	O
+consists	O
+of	O
+a	O
+continuous	O
+four	O
+-	O
+stranded	O
+beta	O
+-	O
+sheet	O
+superposed	O
+by	O
+two	O
+long	O
+alpha	O
+helices	B-SPEC
+,	O
+reminiscent	O
+of	O
+that	O
+found	O
+in	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+porcine	B-SPEC
+respiratory	I-SPEC
+and	I-SPEC
+reproductive	I-SPEC
+syndrome	B-DISO
+virus	I-SPEC
+.	O
+
+The	O
+geographical	O
+relationships	O
+were	O
+important	O
+during	O
+the	O
+early	O
+phase	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Beijing	O
+.	O
+
+A	O
+two	O
+step	O
+inactivation	B-DISO
+procedure	O
+involving	O
+sequential	O
+formaldehyde	B-CHED
+and	O
+U	O
+.	O
+V	O
+.	O
+inactivation	B-DISO
+was	O
+utilised	O
+in	O
+order	B-SPEC
+to	O
+ensure	O
+an	O
+extremely	O
+high	O
+safety	O
+margin	B-ANAT
+with	O
+respect	O
+to	O
+residual	O
+infectivity	O
+.	O
+
+The	O
+immunogenicity	O
+of	O
+this	O
+double	O
+-	O
+inactivated	O
+vaccine	O
+was	O
+characterised	O
+in	O
+the	O
+mouse	B-SPEC
+model	O
+.	O
+
+This	O
+article	O
+reviews	O
+the	O
+alterations	O
+in	O
+the	O
+immune	O
+response	O
+that	O
+underlie	O
+ARDS	B-DISO
+,	O
+discusses	O
+the	O
+physiology	O
+of	O
+dietary	O
+oils	O
+as	O
+immunonutrients	O
+,	O
+summarizes	O
+animal	B-SPEC
+and	O
+human	B-SPEC
+studies	O
+that	O
+explore	O
+the	O
+therapeutic	O
+effects	O
+of	O
+dietary	O
+oils	O
+,	O
+and	O
+provides	O
+clinical	O
+recommendations	O
+for	O
+their	O
+use	O
+.	O
+
+ABSTRACT	O
+:	O
+Historically	O
+,	O
+pneumonia	B-DISO
+during	O
+pregnancy	O
+has	O
+been	O
+associated	O
+with	O
+increased	O
+morbidity	O
+and	O
+mortality	O
+compared	O
+with	O
+nonpregnant	O
+women	O
+.	O
+
+Beta	B-CHED
+-	I-CHED
+lactam	I-CHED
+and	O
+macrolide	B-CHED
+antibiotics	I-CHED
+are	O
+considered	O
+safe	O
+in	O
+pregnancy	O
+and	O
+are	O
+effective	O
+for	O
+most	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+in	O
+pregnancy	O
+.	O
+
+Pneumocystis	B-DISO
+pneumonia	I-DISO
+continues	O
+to	O
+carry	O
+significant	O
+maternal	O
+risk	O
+to	O
+an	O
+immunocompromised	O
+population	O
+.	O
+
+RESULTS	O
+:	O
+Coexisting	O
+maternal	O
+disease	O
+,	O
+including	O
+asthma	B-PATH
+and	O
+anemia	B-DISO
+,	O
+increase	O
+the	O
+risk	O
+of	O
+contracting	O
+pneumonia	B-DISO
+in	O
+pregnancy	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+prone	O
+positioning	O
+and	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Keeping	O
+the	O
+lung	B-ANAT
+open	O
+could	O
+also	O
+potentially	O
+be	O
+lung	B-ANAT
+protective	O
+.	O
+
+The	O
+oxygenation	B-PROC
+index	O
+({	O
+mean	O
+airway	B-ANAT
+pressure	O
+x	O
+Fio2	O
+x	O
+100	O
+}/	O
+Pao2	O
+)	O
+decreased	O
+in	O
+the	O
+prone	O
+-	O
+CV	O
+and	O
+prone	O
+-	O
+HFOV	O
+groups	O
+and	O
+was	O
+lower	O
+than	O
+in	O
+the	O
+supine	O
+-	O
+HFOV	O
+group	O
+.	O
+
+Neutrophil	B-ANAT
+counts	O
+were	O
+higher	O
+in	O
+the	O
+supine	O
+-	O
+HFOV	O
+group	O
+than	O
+in	O
+the	O
+prone	O
+-	O
+CV	O
+group	O
+.	O
+
+Prone	O
+-	O
+HFOV	O
+produced	O
+similar	O
+improvement	O
+in	O
+oxygenation	B-PROC
+like	O
+prone	O
+-	O
+CV	O
+but	O
+was	O
+associated	O
+with	O
+higher	O
+BALF	O
+indexes	O
+of	O
+inflammation	B-DISO
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+causes	O
+disparate	O
+effects	O
+on	O
+crypt	B-ANAT
+proliferation	B-DISO
+and	O
+apoptosis	B-PATH
+,	O
+which	O
+occur	O
+,	O
+at	O
+least	O
+in	O
+part	O
+,	O
+through	O
+differing	O
+mechanisms	O
+involving	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+4	I-PRGE
+and	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+virus	B-SPEC
+non	O
+-	O
+structural	O
+protein	B-CHED
+15	O
+is	O
+a	O
+Mn2	O
++-	O
+dependent	O
+endoribonuclease	O
+with	O
+specificity	O
+for	O
+cleavage	B-PROC
+at	O
+uridylate	B-CHED
+residues	O
+.	O
+
+Nineteen	O
+of	O
+the	O
+mutants	O
+were	O
+soluble	O
+and	O
+were	O
+analyzed	O
+for	O
+enzymatic	B-PROC
+activity	I-PROC
+.	O
+
+TITLE	O
+:	O
+Screening	O
+of	O
+electrophilic	O
+compounds	O
+yields	O
+an	O
+aziridinyl	O
+peptide	B-CHED
+as	O
+new	O
+active	O
+-	O
+site	O
+directed	O
+SARS	O
+-	O
+CoV	O
+main	O
+protease	B-CHED
+inhibitor	I-CHED
+.	O
+
+The	O
+second	O
+part	O
+of	O
+this	O
+review	O
+focuses	O
+on	O
+new	O
+challenges	O
+for	O
+infection	B-DISO
+control	O
+,	O
+such	O
+as	O
+1	O
+)	O
+the	O
+ever	O
+-	O
+growing	O
+number	O
+of	O
+immunocompromised	O
+patients	O
+and	O
+basic	O
+control	O
+measures	O
+to	O
+avoid	O
+opportunistic	B-DISO
+infections	I-DISO
+;	O
+2	O
+)	O
+the	O
+concerns	O
+about	O
+the	O
+capacity	O
+of	O
+the	O
+public	O
+health	O
+systems	O
+to	O
+deal	O
+with	O
+terrorist	O
+acts	O
+;	O
+3	O
+)	O
+the	O
+practice	O
+of	O
+high	O
+-	O
+risk	O
+procedures	O
+in	O
+facilities	O
+lacking	O
+trained	O
+personnel	O
+,	O
+efficient	O
+laboratories	O
+,	O
+and	O
+protective	O
+items	O
+;	O
+and	O
+4	O
+)	O
+gene	O
+therapy	O
+and	O
+its	O
+potential	O
+infectious	B-DISO
+complications	O
+.	O
+
+TITLE	O
+:	O
+Crystal	B-ANAT
+structures	O
+of	O
+the	O
+main	O
+peptidase	O
+from	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+inhibited	O
+by	O
+a	O
+substrate	O
+-	O
+like	O
+aza	O
+-	O
+peptide	O
+epoxide	B-CHED
+.	O
+
+We	O
+report	O
+the	O
+irreversible	O
+inhibition	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+by	O
+an	O
+aza	O
+-	O
+peptide	B-CHED
+epoxide	B-CHED
+(	O
+APE	B-SPEC
+;	O
+k	O
+(	O
+inact	O
+)/	O
+K	O
+(	O
+i	O
+)	O
+=	O
+1900	O
+(+/-	O
+400	O
+)	O
+M	O
+(-	O
+1	O
+)	O
+s	O
+(-	O
+1	O
+)).	O
+
+ABSTRACT	O
+:	O
+In	O
+2003	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+affected	O
+1	O
+,	O
+755	O
+people	O
+in	O
+Hong	O
+Kong	O
+,	O
+including	O
+386	O
+health	O
+care	O
+professionals	O
+,	O
+some	O
+of	O
+whom	O
+were	O
+infected	O
+during	O
+resuscitation	O
+attempts	O
+of	O
+affected	O
+patients	O
+.	O
+
+Hong	O
+Kong	O
+medical	O
+students	O
+feel	O
+able	O
+to	O
+perform	O
+BLS	B-DISO
+if	O
+required	O
+.	O
+
+In	O
+all	O
+situations	O
+they	O
+were	O
+significantly	O
+more	O
+likely	O
+to	O
+perform	O
+mouth	B-ANAT
+-	O
+to	O
+-	O
+mouth	B-ANAT
+ventilation	O
+for	O
+a	O
+family	B-SPEC
+member	O
+compared	O
+with	O
+a	O
+stranger	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+to	O
+withhold	O
+mouth	B-ANAT
+-	O
+to	O
+-	O
+mouth	B-ANAT
+ventilation	O
+if	O
+either	O
+vomit	B-DISO
+or	O
+blood	B-ANAT
+were	O
+present	O
+in	O
+the	O
+victim	O
+'	O
+s	O
+mouth	B-ANAT
+.	O
+
+The	O
+majority	O
+of	O
+practices	O
+reported	O
+that	O
+they	O
+had	O
+policies	O
+or	O
+procedures	O
+in	O
+place	O
+to	O
+isolate	O
+potentially	O
+infectious	B-DISO
+patients	O
+from	O
+others	O
+in	O
+the	O
+waiting	O
+room	O
+.	O
+
+Duty	O
+to	O
+care	O
+is	O
+not	O
+based	O
+upon	O
+particular	O
+virtues	O
+of	O
+the	O
+health	O
+professions	O
+,	O
+but	O
+arises	O
+from	O
+social	O
+reflection	O
+on	O
+what	O
+response	O
+to	O
+an	O
+epidemic	O
+would	O
+be	O
+consistent	O
+with	O
+our	O
+values	O
+and	O
+our	O
+needs	O
+,	O
+recognizing	O
+our	O
+shared	O
+vulnerability	O
+to	O
+disease	O
+and	O
+death	B-PROC
+.	O
+
+Immunohistochemically	O
+,	O
+antibodies	B-COMP
+of	O
+cytokeratin	B-PRGE
+(	O
+CK	O
+),	O
+CD34	B-PRGE
+,	O
+CD68	B-PRGE
+,	O
+Vimentin	B-COMP
+and	O
+CD3	B-PRGE
+were	O
+applied	O
+to	O
+demonstrate	O
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+,	O
+endothelial	B-ANAT
+cells	I-ANAT
+,	O
+macrophages	B-ANAT
+,	O
+fibroblasts	B-ANAT
+and	O
+T	B-ANAT
+cells	I-ANAT
+respectively	O
+.	O
+
+Three	O
+hybridoma	B-ANAT
+cell	B-ANAT
+lines	I-ANAT
+(	O
+8A5	O
+,	O
+8H6	O
+and	O
+4A2	O
+)	O
+stable	O
+in	O
+secreting	B-PROC
+specific	O
+monoclonal	O
+antibodies	B-COMP
+were	O
+successfully	O
+obtained	O
+.	O
+
+Monoclonal	O
+antibodies	B-COMP
+of	O
+high	O
+specificity	O
+against	O
+protein	O
+X4	O
+have	O
+been	O
+successfully	O
+prepared	O
+,	O
+which	O
+laid	O
+the	O
+foundation	O
+for	O
+the	O
+further	O
+study	O
+of	O
+protein	B-CHED
+X4	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Monoclonal	O
+antibodies	B-COMP
+of	O
+high	O
+specificity	O
+against	O
+protein	B-CHED
+X4	O
+have	O
+been	O
+successfully	O
+prepared	O
+,	O
+which	O
+laid	O
+the	O
+foundation	O
+for	O
+the	O
+further	O
+study	O
+of	O
+protein	B-CHED
+X4	O
+.	O
+
+These	O
+studies	O
+showed	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Vero	I-PRGE
+E6	I-PRGE
+cell	B-COMP
+lysates	O
+for	O
+the	O
+ELISA	O
+to	O
+detect	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibodies	B-COMP
+could	O
+lead	O
+to	O
+the	O
+false	O
+-	O
+positive	O
+reactions	O
+or	O
+cross	O
+-	O
+reactions	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibodies	B-COMP
+in	O
+non	O
+-	O
+SARS	B-DISO
+diseases	O
+and	O
+healthy	O
+controls	O
+,	O
+and	O
+the	O
+false	O
+-	O
+positive	O
+reactions	O
+or	O
+cross	O
+-	O
+reactions	O
+were	O
+related	O
+to	O
+Vero	O
+E6	O
+cell	B-COMP
+lysates	O
+and	O
+autoantibodies	O
+in	O
+non	O
+-	O
+SARS	B-DISO
+population	O
+.	O
+
+Here	O
+,	O
+an	O
+infectious	B-DISO
+cDNA	O
+clone	O
+of	O
+IBV	B-SPEC
+was	O
+used	O
+to	O
+address	O
+the	O
+importance	O
+of	O
+the	O
+S	O
+protein	B-PROC
+trafficking	B-PROC
+signals	O
+to	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+M	O
+endodomain	O
+interacts	O
+with	O
+the	O
+viral	B-COMP
+nucleocapsid	I-COMP
+,	O
+which	O
+consists	O
+of	O
+the	O
+positive	O
+-	O
+strand	O
+RNA	O
+genome	O
+helically	O
+encapsidated	O
+by	O
+N	O
+protein	B-CHED
+monomers	O
+.	O
+
+Further	O
+,	O
+we	O
+found	O
+that	O
+fusion	O
+of	O
+domain	O
+3	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+to	O
+the	O
+carboxy	B-CHED
+terminus	O
+of	O
+a	O
+heterologous	O
+protein	B-CHED
+caused	O
+it	O
+to	O
+be	O
+incorporated	O
+into	O
+MHV	B-SPEC
+virions	B-COMP
+.	O
+
+The	O
+Deltansp2	O
+mutant	B-DISO
+viruses	B-SPEC
+lacked	O
+expression	B-PROC
+of	O
+both	O
+nsp2	B-PRGE
+and	O
+an	O
+nsp2	B-PRGE
+-	I-PRGE
+nsp3	I-PRGE
+precursor	I-PRGE
+,	O
+but	O
+cleaved	B-ANAT
+the	O
+engineered	B-PRGE
+chimeric	I-PRGE
+nsp1	I-PRGE
+-	I-PRGE
+nsp3	I-PRGE
+cleavage	B-PROC
+site	O
+as	O
+efficiently	O
+as	O
+the	O
+native	O
+nsp1	B-PRGE
+-	I-PRGE
+nsp2	I-PRGE
+cleavage	B-PROC
+site	O
+.	O
+
+No	O
+induction	O
+of	O
+cytokine	O
+genes	O
+(	O
+alpha	B-PRGE
+interferon	I-PRGE
+[	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+],	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+28A	I-PRGE
+/	I-PRGE
+B	I-PRGE
+[	O
+IL	O
+-	O
+28A	O
+/	O
+B	O
+],	O
+IL	O
+-	O
+29	O
+,	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+,	O
+CCL5	B-PRGE
+,	O
+or	O
+CXCL10	B-PRGE
+)	O
+or	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+-	O
+induced	O
+MxA	B-PRGE
+gene	I-PRGE
+was	O
+seen	O
+in	O
+SCV	B-SPEC
+-	O
+infected	O
+A549	O
+cells	B-COMP
+,	O
+macrophages	B-ANAT
+,	O
+or	O
+DCs	B-DISO
+.	O
+
+The	O
+detecting	O
+results	O
+of	O
+animal	B-SPEC
+samples	O
+from	O
+Dongmen	O
+Market	O
+(	O
+Shenzhen	O
+)	O
+and	O
+other	O
+markets	O
+and	O
+farms	O
+in	O
+peripheral	O
+areas	O
+show	O
+that	O
+:	O
+the	O
+total	O
+positive	O
+rate	O
+of	O
+4	O
+kinds	O
+of	O
+wild	O
+animal	B-SPEC
+(	O
+civet	B-SPEC
+cat	I-SPEC
+,	O
+raccoon	B-SPEC
+dog	I-SPEC
+,	O
+hog	O
+-	O
+badge	O
+and	O
+Chinese	O
+ferret	B-SPEC
+-	O
+badge	O
+)	O
+is	O
+39	O
+.	O
+02	O
+%	O
+,	O
+which	O
+has	O
+an	O
+significant	O
+difference	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+compared	O
+with	O
+the	O
+positive	O
+rate	O
+of	O
+other	O
+animals	B-SPEC
+as	O
+0	O
+.	O
+
+The	O
+results	O
+could	O
+support	O
+the	O
+hypothesis	O
+that	O
+animals	B-SPEC
+(	O
+especially	O
+civet	B-SPEC
+cat	I-SPEC
+)	O
+could	O
+carry	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+10	O
+positive	O
+were	O
+detected	O
+from	O
+41	O
+SARS	B-DISO
+clinical	O
+confirmed	O
+cases	O
+(	O
+24	O
+.	O
+39	O
+%).	O
+
+Of	O
+50	O
+animal	B-SPEC
+specimens	O
+,	O
+23	O
+were	O
+positive	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+sensitivity	O
+of	O
+real	O
+-	O
+time	O
+PCR	O
+was	O
+10	O
+-	O
+100	O
+copies	O
+/	O
+ml	O
+,	O
+there	O
+was	O
+no	O
+cross	B-PROC
+reaction	I-PROC
+to	O
+other	O
+respiratory	O
+viruses	B-SPEC
+such	O
+as	O
+influenza	B-SPEC
+virus	I-SPEC
+etc	O
+.	O
+
+Furthermore	O
+,	O
+SARS	B-DISO
+virus	B-SPEC
+RNA	O
+was	O
+detected	O
+in	O
+feces	B-ANAT
+and	O
+in	O
+serum	B-COMP
+during	O
+the	O
+acute	O
+phase	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+explore	O
+the	O
+experience	O
+of	O
+home	O
+quarantine	O
+during	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Toronto	O
+in	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+A	O
+simple	O
+and	O
+rapid	O
+approach	O
+for	O
+screening	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+genotypes	O
+:	O
+an	O
+evaluation	O
+study	O
+.	O
+
+This	O
+information	O
+can	O
+be	O
+used	O
+as	O
+a	O
+footprint	O
+for	O
+tracing	O
+the	O
+epidemiology	O
+of	O
+infections	B-DISO
+and	O
+monitor	O
+viral	O
+evolution	B-PROC
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+epidemiology	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+,	O
+Beijing	O
+.	O
+
+The	O
+pathogens	O
+detected	O
+most	O
+frequently	O
+were	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+14	O
+patients	O
+),	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+(	O
+8	O
+),	O
+coronavirus	B-SPEC
+(	O
+6	O
+),	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+5	O
+),	O
+and	O
+rhinoviruses	B-SPEC
+(	O
+5	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+elaborate	O
+on	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+blast	B-ANAT
+injury	O
+of	O
+the	O
+lungs	B-ANAT
+in	O
+extensively	O
+burned	O
+patients	O
+.	O
+
+Five	O
+patients	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+all	O
+the	O
+patients	O
+experienced	O
+pulmonary	B-DISO
+infection	I-DISO
+.	O
+
+Fourteen	O
+cases	O
+were	O
+finally	O
+cured	O
+,	O
+and	O
+2	O
+died	B-PROC
+of	O
+severe	O
+blast	B-ANAT
+injury	O
+of	O
+the	O
+lungs	B-ANAT
+and	O
+severe	O
+systemic	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Last	O
+month	O
+'	O
+s	O
+article	O
+considered	O
+the	O
+role	O
+of	O
+the	O
+law	O
+in	O
+preventing	O
+the	O
+spread	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+in	O
+cases	O
+such	O
+as	O
+tuberculosis	B-PATH
+and	O
+SARS	B-DISO
+where	O
+isolation	O
+,	O
+quarantine	O
+and	O
+treatment	O
+are	O
+effective	O
+in	O
+controlling	O
+the	O
+outbreak	O
+.	O
+
+Only	O
+1	O
+(	O
+2	O
+%)	O
+of	O
+48	O
+patients	O
+with	O
+acute	O
+KD	O
+was	O
+positive	O
+by	O
+RT	O
+-	O
+PCR	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+/	O
+NH	O
+in	O
+a	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Biochemical	O
+and	O
+biophysical	O
+characterization	O
+of	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+fusion	O
+core	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+TGEV	B-SPEC
+fusion	O
+core	O
+(	O
+HR1	O
+-	O
+SGGRGG	O
+-	O
+HR2	O
+),	O
+in	O
+vitro	O
+expressed	B-PROC
+in	O
+GST	B-PRGE
+prokaryotic	O
+expression	B-PROC
+system	O
+,	O
+shares	O
+the	O
+typical	O
+properties	O
+of	O
+the	O
+trimer	O
+of	O
+coiled	O
+-	O
+coil	O
+heterodimer	O
+(	O
+six	O
+alpha	O
+-	O
+helix	O
+bundle	O
+),	O
+which	O
+has	O
+been	O
+confirmed	O
+by	O
+a	O
+combined	O
+series	O
+of	O
+biochemical	O
+and	O
+biophysical	O
+evidences	O
+including	O
+size	O
+exclusion	O
+chromatography	O
+(	O
+gel	O
+-	O
+filtration	O
+),	O
+chemical	O
+crossing	O
+,	O
+and	O
+circular	O
+diagram	O
+.	O
+
+Taken	O
+together	O
+,	O
+TGEV	O
+spiker	O
+protein	B-CHED
+belongs	O
+to	O
+the	O
+class	B-SPEC
+I	O
+fusion	O
+protein	B-CHED
+,	O
+characterized	O
+by	O
+the	O
+existence	O
+of	O
+two	O
+heptad	O
+-	O
+repeat	O
+(	O
+HR	O
+)	O
+regions	O
+,	O
+HR1	O
+and	O
+HR2	O
+,	O
+and	O
+the	O
+present	O
+knowledge	O
+about	O
+the	O
+truncated	O
+TGEV	B-SPEC
+fusion	O
+protein	B-CHED
+core	O
+may	O
+facilitate	O
+in	O
+the	O
+design	O
+of	O
+the	O
+small	O
+molecule	O
+or	O
+polypeptide	B-CHED
+drugs	O
+targeting	B-PROC
+the	O
+membrane	B-PROC
+fusion	I-PROC
+between	O
+TGEV	B-SPEC
+and	O
+its	O
+host	B-COMP
+.	O
+
+Lessons	O
+from	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+Toronto	O
+.	O
+
+Of	O
+the	O
+Internet	O
+users	O
+,	O
+68	O
+%	O
+(	O
+485	O
+/	O
+711	O
+)	O
+had	O
+already	O
+searched	O
+the	O
+World	O
+Wide	O
+Web	B-DISO
+for	O
+health	O
+information	O
+,	O
+and	O
+75	O
+%	O
+(	O
+533	O
+/	O
+711	O
+)	O
+were	O
+interested	O
+in	O
+communicating	O
+with	O
+health	O
+professionals	O
+using	O
+the	O
+Internet	O
+as	O
+part	O
+of	O
+their	O
+ongoing	O
+care	O
+.	O
+
+Patients	O
+who	O
+required	O
+ICU	O
+admission	O
+(	O
+n	O
+=	O
+31	O
+)	O
+showed	O
+higher	O
+CXR	O
+scores	O
+(	O
+1	O
+.	O
+6	O
+[	O
+SD	O
+,	O
+3	O
+.	O
+1	O
+];	O
+vs	O
+0	O
+.	O
+4	O
+[	O
+SD	O
+,	O
+1	O
+.	O
+1	O
+];	O
+p	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+lower	O
+percentage	O
+of	O
+predicted	O
+FVC	B-PROC
+,	O
+TLC	O
+,	O
+and	O
+Dlco	O
+than	O
+those	O
+who	O
+did	O
+not	O
+,	O
+but	O
+there	O
+were	O
+no	O
+differences	O
+in	O
+6MWD	O
+and	O
+health	O
+status	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+analyzed	O
+the	O
+pathological	O
+changes	O
+of	O
+testes	B-ANAT
+from	O
+six	O
+patients	O
+who	O
+died	B-PROC
+of	O
+SARS	B-DISO
+.	O
+
+SARS	B-DISO
+viral	O
+genomic	O
+sequences	O
+were	O
+not	O
+detected	O
+in	O
+the	O
+testes	B-ANAT
+by	O
+in	O
+situ	O
+hybridization	B-PROC
+.	O
+
+Our	O
+findings	O
+indicated	O
+that	O
+orchitis	O
+is	O
+a	O
+complication	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+STAR	B-DISO
+demonstrated	O
+similar	O
+or	O
+better	O
+sensitivity	O
+and	O
+precision	O
+compared	O
+to	O
+two	O
+commonly	O
+used	O
+methods	O
+,	O
+SYBR	O
+Green	O
+-	O
+based	O
+and	O
+TaqMan	O
+probe	O
+-	O
+based	O
+real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Blinded	O
+studies	O
+using	O
+RNA	O
+extracted	O
+from	O
+various	O
+tissues	B-ANAT
+of	O
+a	O
+SARS	B-DISO
+-	O
+infected	O
+individual	O
+showed	O
+that	O
+STAR	B-DISO
+correctly	O
+identified	O
+all	O
+samples	O
+containing	O
+SARS	B-DISO
+virus	B-SPEC
+and	O
+yielded	O
+negative	O
+results	O
+for	O
+non	O
+-	O
+SARS	B-DISO
+control	O
+samples	O
+.	O
+
+TITLE	O
+:	O
+In	O
+silico	O
+analysis	O
+of	O
+ORF1ab	O
+in	O
+coronavirus	B-SPEC
+HKU1	O
+genome	O
+reveals	O
+a	O
+unique	O
+putative	O
+cleavage	B-PROC
+site	O
+of	O
+coronavirus	O
+HKU1	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+.	O
+
+This	O
+probably	O
+represents	O
+a	O
+novel	O
+cleavage	B-PROC
+site	O
+because	O
+the	O
+same	O
+mutation	O
+was	O
+consistently	O
+observed	O
+in	O
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+sequences	O
+from	O
+multiple	O
+specimens	O
+of	O
+different	O
+patients	O
+;	O
+the	O
+P2	O
+and	O
+P1	O
+'-	O
+P12	O
+'	O
+positions	O
+of	O
+this	O
+cleavage	B-PROC
+site	O
+are	O
+consistent	O
+between	O
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+and	O
+other	O
+coronaviruses	O
+;	O
+and	O
+as	O
+the	O
+helicase	B-PRGE
+is	O
+one	O
+of	O
+the	O
+most	O
+conserved	O
+proteins	B-CHED
+in	O
+coronaviruses	O
+,	O
+cleavage	B-PROC
+between	O
+nsp10	O
+and	O
+nsp11	O
+should	O
+be	O
+an	O
+essential	O
+step	O
+for	O
+the	O
+generation	O
+of	O
+the	O
+mature	B-PRGE
+functional	I-PRGE
+helicase	I-PRGE
+.	O
+
+Recent	O
+data	O
+have	O
+shown	O
+stable	O
+patterns	O
+of	O
+activation	O
+among	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+and	O
+neutrophils	B-ANAT
+in	O
+healthy	O
+human	B-SPEC
+subjects	O
+.	O
+
+There	O
+will	O
+usually	O
+remain	O
+a	O
+probability	O
+of	O
+releasing	O
+from	O
+quarantine	O
+some	O
+infected	O
+individuals	O
+and	O
+the	O
+impact	O
+of	O
+early	O
+release	B-PATH
+will	O
+depend	O
+on	O
+the	O
+size	O
+of	O
+the	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+Due	O
+to	O
+variations	O
+in	O
+serotypes	O
+among	O
+different	O
+strains	O
+of	O
+avian	O
+infectious	O
+bronchitis	O
+viruses	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+vaccination	O
+of	O
+chicks	O
+with	O
+imported	O
+vaccines	O
+fails	O
+to	O
+protect	O
+them	O
+from	O
+IBV	B-SPEC
+infections	B-DISO
+in	O
+Taiwan	O
+.	O
+
+The	O
+attenuated	O
+vaccine	O
+was	O
+not	O
+pathogenic	O
+in	O
+1	O
+-	O
+week	O
+-	O
+old	O
+chicks	O
+,	O
+had	O
+a	O
+neutralization	O
+index	O
+(	O
+NI	O
+)	O
+of	O
+greater	O
+than	O
+4	O
+.	O
+4	O
+and	O
+efficacy	O
+of	O
+90	O
+%	O
+when	O
+inoculated	O
+birds	B-SPEC
+were	O
+challenged	O
+with	O
+a	O
+field	O
+IBV	B-SPEC
+strain	O
+.	O
+
+In	O
+conclusion	O
+,	O
+these	O
+attenuated	O
+vaccines	O
+have	O
+potential	O
+for	O
+controlling	O
+local	O
+Taiwanese	O
+IBV	O
+infections	B-DISO
+in	O
+chickens	B-SPEC
+.	O
+
+TITLE	O
+:	O
+pH	O
+-	O
+dependent	O
+conformational	O
+flexibility	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+main	O
+proteinase	B-PROC
+(	O
+M	O
+(	O
+pro	B-CHED
+))	O
+dimer	O
+:	O
+molecular	B-PROC
+dynamics	I-PROC
+simulations	O
+and	O
+multiple	O
+X	O
+-	O
+ray	B-SPEC
+structure	O
+analyses	O
+.	O
+
+The	O
+results	O
+demonstrate	O
+that	O
+,	O
+compared	O
+with	O
+other	O
+compounds	O
+reported	O
+so	O
+far	O
+,	O
+AVLQSGFR	O
+is	O
+the	O
+most	O
+active	O
+in	O
+inhibiting	O
+replication	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+that	O
+no	O
+detectable	O
+toxicity	O
+is	O
+observed	O
+on	O
+Vero	B-ANAT
+cells	I-ANAT
+under	O
+the	O
+condition	B-DISO
+of	O
+experimental	O
+concentration	O
+.	O
+
+Of	O
+these	O
+23	O
+,	O
+five	O
+non	O
+-	O
+immune	O
+persons	O
+subsequently	O
+developed	O
+coma	O
+,	O
+shock	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+or	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+;	O
+this	O
+led	O
+to	O
+death	B-PROC
+in	O
+2	O
+of	O
+these	O
+cases	O
+.	O
+
+Twenty	O
+of	O
+28	O
+patients	O
+who	O
+received	O
+ECMO	O
+with	O
+severe	O
+trauma	O
+related	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+mean	O
+PaO2	O
+/	O
+FiO2	O
+of	O
+62	O
+mmHg	O
+)	O
+survived	O
+.	O
+
+CONCLUSIONS	O
+:	O
+A	O
+high	O
+proportion	O
+of	O
+trauma	O
+patients	O
+treated	O
+with	O
+ECMO	O
+for	O
+severe	O
+lung	B-ANAT
+injury	O
+survived	O
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+recent	O
+gene	O
+patent	O
+controversies	O
+have	O
+energized	O
+and	O
+refocused	O
+the	O
+human	B-SPEC
+gene	O
+patent	O
+debate	O
+in	O
+Canada	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+usefulness	O
+of	O
+continuous	O
+noninvasive	O
+mechanical	O
+ventilation	O
+and	O
+mechanical	O
+coughing	O
+aids	O
+to	O
+avoid	O
+endotracheal	O
+intubation	O
+and	O
+tracheostomy	O
+during	O
+episodes	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+neuromuscular	B-DISO
+disease	I-DISO
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+respiratory	B-PROC
+function	I-PROC
+between	O
+the	O
+successfully	O
+treated	O
+and	O
+unsuccessfully	O
+treated	O
+groups	O
+before	O
+the	O
+current	O
+episode	O
+.	O
+
+TITLE	O
+:	O
+Hypercoagulant	O
+states	O
+in	O
+malignant	B-DISO
+lymphoma	I-DISO
+.	O
+
+At	O
+day	O
+7	O
+of	O
+chemotherapy	O
+,	O
+leukocyte	B-ANAT
+TF	O
+mRNA	B-CHED
+levels	O
+were	O
+significantly	O
+increased	O
+.	O
+
+The	O
+recombinant	B-PRGE
+virus	I-PRGE
+CAV	B-SPEC
+-	I-PRGE
+2	I-PRGE
+-	I-PRGE
+S1	I-PRGE
+was	O
+gained	O
+through	O
+4	O
+passages	O
+in	O
+MDCK	O
+,	O
+which	O
+showed	O
+classical	O
+CPE	O
+of	O
+CAV	B-SPEC
+-	O
+2	O
+.	O
+
+The	O
+expressed	B-PROC
+S1	B-PRGE
+protein	I-PRGE
+of	O
+CCV	B-DISO
+,	O
+which	O
+was	O
+identified	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+Western	O
+blot	O
+,	O
+can	O
+be	O
+specifically	O
+recognized	O
+by	O
+polyclonal	O
+antibody	O
+against	O
+CCV	B-DISO
+.	O
+
+Conjugation	B-PROC
+to	O
+mannose	B-CHED
+dendrimers	O
+is	O
+a	O
+rarely	O
+explored	O
+but	O
+potentially	O
+powerful	O
+strategy	O
+for	O
+enhancing	O
+immunogenicity	O
+of	O
+synthetic	O
+peptides	B-CHED
+relying	O
+on	O
+direct	O
+delivery	O
+to	O
+dendritic	B-ANAT
+cells	B-COMP
+.	O
+
+The	O
+ribavirin	B-CHED
+photoprobes	O
+were	O
+obtained	O
+by	O
+directly	O
+coupling	O
+the	O
+azidotriazole	O
+to	O
+the	O
+protected	O
+ribose	B-CHED
+sugar	O
+,	O
+while	O
+the	O
+EICAR	O
+probe	O
+was	O
+prepared	O
+by	O
+diazotizing	O
+AICAR	B-CHED
+and	O
+subsequently	O
+substituting	O
+with	O
+NaN3	O
+.	O
+
+At	O
+zero	O
+PEEP	B-CHED
+PV	O
+curves	O
+of	O
+respiratory	B-ANAT
+system	I-ANAT
+,	I-ANAT
+lung	I-ANAT
+,	O
+and	O
+chest	B-ANAT
+wall	I-ANAT
+were	O
+constructed	O
+.	O
+
+Postural	O
+reduction	O
+in	O
+lower	O
+inflection	O
+point	O
+pressure	O
+of	O
+lung	B-ANAT
+PV	O
+curve	O
+was	O
+the	O
+sole	B-ANAT
+independent	O
+predictor	O
+of	O
+pronation	B-PROC
+-	O
+induced	O
+increases	O
+in	O
+PaO2	O
+/	O
+FIO2	O
+(	O
+R2	O
+=	O
+0	O
+.	O
+76	O
+).	O
+
+ABSTRACT	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+,	O
+and	O
+biological	O
+evaluation	O
+of	O
+peptidomimetic	B-CHED
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+chymotrypsin	O
+-	O
+like	O
+protease	O
+(	O
+SARS	B-PRGE
+-	I-PRGE
+3CLpro	I-PRGE
+)	O
+inhibitors	B-CHED
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+are	O
+described	O
+.	O
+
+Among	O
+them	O
+were	O
+the	O
+trials	O
+that	O
+tested	O
+the	O
+infusion	O
+of	O
+activated	O
+protein	B-CHED
+C	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+tight	O
+glycemic	O
+control	O
+in	O
+surgical	O
+intensive	O
+care	O
+patients	O
+,	O
+and	O
+use	O
+of	O
+lung	B-ANAT
+protective	O
+mechanical	O
+ventilation	O
+by	O
+using	O
+small	O
+tidal	O
+volumes	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Although	O
+results	O
+of	O
+these	O
+trials	O
+were	O
+sufficiently	O
+strong	O
+to	O
+,	O
+at	O
+least	O
+,	O
+consider	O
+implementation	O
+of	O
+these	O
+strategies	O
+in	O
+critical	O
+care	O
+medicine	B-CHED
+,	O
+published	O
+and	O
+yet	O
+unpublished	O
+reports	O
+show	O
+that	O
+there	O
+is	O
+significant	O
+struggle	O
+with	O
+implementation	O
+of	O
+these	O
+therapies	O
+.	O
+
+The	O
+virus	B-COMP
+particle	I-COMP
+consists	O
+of	O
+four	O
+structural	O
+proteins	B-CHED
+:	O
+spike	O
+(	O
+S	O
+),	O
+small	O
+envelope	B-COMP
+(	O
+E	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+),	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+).	O
+
+Western	O
+blot	O
+analysis	O
+of	O
+the	O
+culture	O
+medium	O
+from	O
+transfection	O
+experiments	O
+revealed	O
+that	O
+both	O
+E	O
+and	O
+M	O
+expressed	B-PROC
+alone	O
+could	O
+be	O
+released	O
+in	O
+sedimentable	O
+particles	O
+and	O
+that	O
+E	O
+and	O
+M	O
+proteins	B-CHED
+are	O
+likely	O
+to	O
+form	O
+VLPs	B-ANAT
+when	O
+they	O
+are	O
+coexpressed	O
+.	O
+
+Because	O
+both	O
+cellular	B-COMP
+and	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+are	O
+generated	O
+by	O
+gene	O
+-	O
+based	O
+vaccination	O
+and	O
+inactivated	O
+viral	O
+boosting	O
+,	O
+this	O
+strategy	O
+may	O
+prove	O
+useful	O
+in	O
+the	O
+generation	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Only	O
+a	O
+relatively	O
+few	O
+mutations	O
+in	O
+its	O
+spike	O
+protein	O
+allow	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+to	O
+switch	O
+from	O
+a	O
+murine	B-SPEC
+-	O
+restricted	O
+tropism	B-PROC
+to	O
+an	O
+extended	O
+host	B-COMP
+range	O
+by	O
+being	O
+passaged	O
+in	O
+vitro	O
+.	O
+
+The	O
+adaptation	B-PROC
+of	O
+the	O
+virus	B-SPEC
+through	O
+the	O
+use	O
+of	O
+heparan	B-CHED
+sulfate	I-CHED
+as	O
+an	O
+attachment	O
+/	O
+entry	O
+receptor	O
+was	O
+demonstrated	O
+by	O
+increased	O
+heparin	B-FUNC
+binding	I-FUNC
+as	O
+well	O
+as	O
+by	O
+inhibition	B-PROC
+of	O
+infection	B-DISO
+through	O
+treatment	O
+of	O
+cells	B-COMP
+and	O
+the	O
+virus	B-SPEC
+with	O
+heparinase	B-ENZY
+and	O
+heparin	B-CHED
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+exhibits	O
+a	O
+high	O
+mortality	O
+rate	O
+and	O
+the	O
+potential	O
+for	O
+rapid	O
+epidemic	O
+spread	O
+.	O
+
+However	O
+,	O
+RNA	O
+amplification	B-DISO
+methods	O
+have	O
+been	O
+demonstrated	O
+to	O
+be	O
+more	O
+sensitive	O
+for	O
+the	O
+detection	O
+of	O
+some	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+The	O
+N	O
+targets	O
+were	O
+found	O
+to	O
+be	O
+consistently	O
+more	O
+sensitive	O
+than	O
+the	O
+Pol	B-PRGE
+targets	I-PRGE
+,	O
+and	O
+the	O
+real	O
+-	O
+time	O
+NASBA	O
+assay	O
+demonstrates	O
+equivalent	O
+sensitivity	O
+when	O
+compared	O
+to	O
+testing	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Similarly	O
+,	O
+the	O
+sera	B-COMP
+of	O
+immunized	O
+mice	B-SPEC
+could	O
+also	O
+react	O
+specifically	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+particles	O
+.	O
+
+RESULTS	O
+:	O
+Recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+reacted	O
+strongly	O
+and	O
+specifically	O
+with	O
+the	O
+sera	B-COMP
+from	O
+immunized	O
+mice	B-SPEC
+and	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Undiagnosed	O
+cases	O
+of	O
+respiratory	O
+tract	O
+disease	O
+suspected	O
+of	O
+an	O
+infectious	B-DISO
+aetiology	O
+peak	O
+during	O
+the	O
+winter	O
+months	O
+.	O
+
+Although	O
+virus	B-SPEC
+isolation	O
+and	O
+serology	O
+were	O
+useful	O
+early	O
+in	O
+the	O
+SARS	B-DISO
+outbreak	O
+for	O
+diagnosing	O
+new	O
+cases	O
+,	O
+these	O
+tests	O
+are	O
+not	O
+generally	O
+useful	O
+because	O
+virus	B-SPEC
+culture	O
+requires	O
+a	O
+BSL	O
+-	O
+3	O
+laboratory	O
+and	O
+seroconversion	O
+is	O
+often	O
+delayed	O
+until	O
+2	O
+to	O
+3	O
+weeks	O
+after	O
+infection	B-DISO
+.	O
+
+Ten	O
+rhesus	B-SPEC
+monkeys	I-SPEC
+were	O
+divided	O
+into	O
+two	O
+groups	O
+,	O
+5	O
+in	O
+interferon	O
+group	O
+,	O
+and	O
+5	O
+in	O
+control	O
+group	O
+.	O
+
+Among	O
+which	O
+,	O
+one	O
+monkey	B-SPEC
+showed	O
+part	O
+of	O
+thickened	O
+septum	B-COMP
+fused	O
+with	O
+each	O
+other	O
+.	O
+
+These	O
+lesions	O
+in	O
+the	O
+interferon	B-PRGE
+treated	O
+animals	B-SPEC
+were	O
+similar	O
+to	O
+those	O
+seen	O
+in	O
+the	O
+animals	B-SPEC
+in	O
+control	O
+group	O
+,	O
+but	O
+with	O
+smaller	O
+scope	O
+of	O
+pathological	O
+changes	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Recombinant	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+alpha2b	I-PRGE
+could	O
+effectively	O
+interdict	O
+or	O
+weaken	O
+SARS	B-DISO
+-	O
+CoV	O
+injury	O
+in	O
+monkeys	B-SPEC
+.	O
+
+The	O
+incidence	O
+of	O
+exanthem	B-DISO
+in	O
+the	O
+control	O
+group	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+in	O
+the	O
+experimental	O
+group	O
+.	O
+
+The	O
+side	B-DISO
+effect	I-DISO
+of	O
+bloody	O
+nasal	B-ANAT
+mucus	I-ANAT
+was	O
+not	O
+observed	O
+in	O
+experimental	O
+group	O
+,	O
+which	O
+had	O
+been	O
+reported	O
+by	O
+other	O
+authors	O
+in	O
+several	O
+volunteer	O
+studies	O
+.	O
+
+Using	O
+recombinant	B-PRGE
+human	I-PRGE
+interferon	I-PRGE
+alpha	I-PRGE
+-	I-PRGE
+2b	I-PRGE
+for	O
+nasal	B-ANAT
+spray	O
+could	O
+lead	O
+to	O
+some	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+symptoms	I-DISO
+,	O
+however	O
+,	O
+all	O
+those	O
+symptoms	O
+were	O
+mild	O
+,	O
+reversible	O
+,	O
+and	O
+relieved	O
+after	O
+completion	O
+of	O
+the	O
+use	O
+of	O
+the	O
+trial	O
+drug	O
+.	O
+
+RESULTS	O
+:	O
+During	O
+the	O
+period	O
+of	O
+using	O
+interferon	O
+,	O
+body	B-ANAT
+temperature	O
+of	O
+the	O
+experimental	O
+group	O
+was	O
+normal	O
+compared	O
+to	O
+the	O
+control	O
+group	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+field	O
+trial	O
+of	O
+recombinant	B-PRGE
+human	I-PRGE
+interferon	I-PRGE
+alpha	I-PRGE
+-	I-PRGE
+2b	I-PRGE
+for	O
+nasal	B-ANAT
+spray	O
+to	O
+prevent	O
+SARS	B-DISO
+and	O
+other	O
+respiratory	O
+viral	O
+infections	O
+].	O
+
+The	O
+recombinant	B-PRGE
+human	I-PRGE
+interferon	I-PRGE
+alpha	I-PRGE
+-	I-PRGE
+2b	I-PRGE
+for	O
+nasal	B-ANAT
+spray	O
+could	O
+decrease	O
+the	O
+rates	O
+of	O
+common	O
+respiratory	O
+viruses	B-SPEC
+infection	B-DISO
+in	O
+the	O
+selected	O
+population	O
+.	O
+
+RESULTS	O
+:	O
+Three	O
+recombinant	O
+plasmids	O
+(	O
+pQE	O
+-	O
+30	O
+/	O
+S1a	B-PRGE
+,	O
+pQE	O
+-	O
+30	O
+/	O
+S1b	B-PRGE
+,	O
+pQE	O
+-	O
+30	O
+/	O
+S1c	O
+)	O
+were	O
+constructed	O
+.	O
+
+TITLE	O
+:	O
+Cross	O
+-	O
+reactivity	O
+of	O
+antibody	B-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+with	O
+IL	B-FUNC
+-	I-FUNC
+11	I-FUNC
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+spike	O
+protein	B-CHED
+fusion	O
+core	O
+and	O
+the	O
+main	O
+protease	O
+have	O
+been	O
+the	O
+most	O
+extensively	O
+studied	O
+,	O
+with	O
+the	O
+aim	O
+of	O
+designing	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+therapeutics	O
+.	O
+
+Attention	O
+is	O
+now	O
+being	O
+focused	O
+on	O
+replicase	B-PRGE
+proteins	I-PRGE
+,	O
+which	O
+should	O
+enhance	O
+our	O
+understanding	O
+of	O
+the	O
+replication	O
+and	O
+transcription	B-PROC
+machinery	O
+.	O
+
+The	O
+extent	O
+and	O
+severity	O
+of	O
+the	O
+lung	B-DISO
+disease	I-DISO
+associated	O
+with	O
+ALI	O
+varies	O
+with	O
+those	O
+patients	O
+having	O
+the	O
+most	O
+severe	O
+manifestations	O
+of	O
+lung	B-DISO
+disease	I-DISO
+being	O
+grouped	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Successful	O
+treatment	O
+of	O
+a	O
+patient	O
+with	O
+severe	O
+Churg	B-DISO
+-	I-DISO
+Strauss	I-DISO
+syndrome	I-DISO
+by	O
+a	O
+combination	O
+of	O
+pulse	B-PROC
+corticosteroids	B-CHED
+,	O
+pulse	B-PROC
+cyclophosphamide	B-CHED
+,	O
+and	O
+high	O
+-	O
+dose	O
+intravenous	O
+immunoglobulin	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+24	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+a	O
+4	O
+-	O
+year	O
+history	O
+of	O
+bronchial	B-DISO
+asthma	B-PATH
+suffered	B-DISO
+from	O
+bloody	B-DISO
+sputum	I-DISO
+,	O
+numbness	B-DISO
+of	O
+the	O
+extremities	B-ANAT
+,	O
+elevated	O
+eosinophil	B-ANAT
+count	O
+,	O
+and	O
+hypoxemia	O
+.	O
+
+Levels	O
+of	O
+antimyeloperoxidase	B-PRGE
+-	I-PRGE
+antineutrophil	I-PRGE
+cytoplasmic	I-PRGE
+antibodies	B-COMP
+,	O
+soluble	O
+thrombomodulin	B-PRGE
+,	O
+soluble	O
+interleukin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+receptor	I-PRGE
+,	O
+eosinophil	B-ANAT
+cationic	O
+protein	B-CHED
+were	O
+elevated	O
+and	O
+returned	O
+to	O
+the	O
+normal	O
+range	O
+in	O
+remission	O
+.	O
+
+Cough	B-DISO
+was	O
+frequent	O
+in	O
+both	O
+patients	O
+with	O
+uncomplicated	O
+malaria	B-PATH
+(	O
+50	O
+%)	O
+and	O
+those	O
+with	O
+severe	O
+malaria	B-PATH
+(	O
+30	O
+%)	O
+and	O
+resolved	O
+by	O
+day	O
+14	O
+.	O
+
+Pulmonary	B-DISO
+complications	I-DISO
+of	O
+leptospirosis	B-DISO
+were	O
+defined	O
+as	O
+the	O
+occurrence	O
+of	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+an	O
+abnormal	O
+CXR	O
+.	O
+
+Among	O
+the	O
+157	O
+patients	O
+with	O
+leptospirosis	B-DISO
+,	O
+eight	O
+patients	O
+had	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+Three	O
+patients	O
+had	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+and	O
+pulmonary	B-DISO
+oedema	I-DISO
+.	O
+
+Factors	O
+associated	O
+with	O
+pulmonary	B-DISO
+complications	I-DISO
+were	O
+delayed	O
+antibiotic	B-CHED
+treatment	O
+and	O
+thrombocytopenia	O
+(	O
+platelet	B-ANAT
+count	O
+<	O
+100	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+).	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+157	O
+patients	O
+with	O
+leptospirosis	B-DISO
+,	O
+eight	O
+patients	O
+had	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+We	O
+measured	O
+systemic	O
+and	O
+mesenteric	B-ANAT
+(	O
+portal	B-ANAT
+venous	B-ANAT
+blood	I-ANAT
+flow	O
+,	O
+jejunal	B-ANAT
+mucosal	B-ANAT
+perfusion	O
+)	O
+haemodynamic	O
+parameters	O
+,	O
+mesenteric	B-ANAT
+oxygenation	B-PROC
+(	O
+jejunal	B-ANAT
+tissue	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+)	O
+and	O
+systemic	O
+cytokines	O
+(	O
+tumour	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+).	O
+
+We	O
+calculated	O
+mesenteric	B-ANAT
+lactate	B-CHED
+flux	O
+and	O
+mesenteric	B-ANAT
+oxygen	B-CHED
+delivery	O
+,	O
+uptake	O
+and	O
+extraction	O
+ratio	O
+.	O
+
+In	O
+the	O
+animals	B-SPEC
+given	O
+3H	O
+-	O
+OA	O
+,	O
+we	O
+measured	O
+3H	O
+-	O
+OA	O
+in	O
+different	O
+tissues	B-ANAT
+(	O
+lungs	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+stomach	B-ANAT
+,	O
+jejunum	B-ANAT
+,	O
+colon	B-ANAT
+and	O
+arterial	B-ANAT
+blood	I-ANAT
+).	O
+
+ABSTRACT	O
+:	O
+Little	O
+information	O
+is	O
+available	O
+on	O
+persistent	B-DISO
+infection	I-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+established	O
+persistent	B-DISO
+infection	I-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+the	O
+Vero	O
+E6	O
+cell	B-ANAT
+line	I-ANAT
+.	O
+
+The	O
+objectives	O
+of	O
+this	O
+study	O
+were	O
+to	O
+develop	O
+a	O
+rapid	O
+immunoturbidimetric	O
+assay	O
+for	O
+measurement	O
+of	O
+AGP	O
+in	O
+feline	B-SPEC
+serum	B-COMP
+and	O
+peritoneal	B-ANAT
+fluid	I-ANAT
+and	O
+to	O
+compare	O
+the	O
+results	O
+with	O
+those	O
+obtained	O
+by	O
+RID	O
+.	O
+
+Clinical	O
+samples	O
+of	O
+feline	B-SPEC
+peritoneal	B-ANAT
+fluid	I-ANAT
+(	O
+n	O
+=	O
+55	O
+)	O
+and	O
+serum	B-COMP
+(	O
+n	O
+=	O
+59	O
+)	O
+were	O
+assayed	O
+for	O
+AGP	O
+and	O
+results	O
+from	O
+the	O
+immunoturbidimetric	O
+and	O
+RID	O
+methods	O
+were	O
+compared	O
+.	O
+
+TITLE	O
+:	O
+Sensitivity	O
+of	O
+Tru	O
+-	O
+cut	B-PRGE
+and	O
+fine	O
+needle	O
+aspiration	B-DISO
+biopsies	O
+of	O
+liver	B-ANAT
+and	O
+kidney	B-ANAT
+for	O
+diagnosis	O
+of	O
+feline	O
+infectious	O
+peritonitis	O
+.	O
+
+Diagnostic	O
+sensitivity	O
+was	O
+calculated	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+number	O
+of	O
+false	O
+-	O
+negative	O
+and	O
+true	O
+-	O
+positive	O
+specimens	O
+,	O
+compared	O
+with	O
+the	O
+number	O
+of	O
+organs	B-ANAT
+bearing	O
+histologic	O
+lesions	O
+of	O
+FIP	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+crystal	B-ANAT
+structure	O
+of	O
+a	O
+conserved	O
+domain	O
+of	O
+nonstructural	O
+protein	B-CHED
+3	O
+(	O
+nsP3	O
+)	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+solved	O
+by	O
+single	O
+-	O
+wavelength	O
+anomalous	O
+dispersion	O
+to	O
+1	O
+.	O
+4	O
+A	O
+resolution	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+one	O
+-	O
+step	O
+,	O
+real	O
+-	O
+time	O
+,	O
+quantitative	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+PCR	O
+assays	O
+for	O
+absolute	O
+quantitation	O
+of	O
+human	O
+coronaviruses	O
+OC43	O
+and	O
+229E	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinical	O
+significance	O
+of	O
+human	B-SPEC
+coronaviruses	O
+in	O
+more	O
+severe	O
+respiratory	O
+illnesses	O
+has	O
+recently	O
+been	O
+shown	O
+to	O
+be	O
+higher	O
+than	O
+was	O
+previously	O
+assumed	O
+.	O
+
+Rapid	O
+and	O
+reliable	O
+diagnosis	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+therefore	O
+becomes	O
+indispensable	O
+in	O
+a	O
+routine	O
+clinical	O
+setting	O
+.	O
+
+The	O
+HCoV	O
+OC43	O
+assay	O
+allows	O
+quantitation	O
+over	O
+a	O
+range	O
+from	O
+20	O
+to	O
+2	O
+x	O
+10	O
+(	O
+8	O
+)	O
+RNA	O
+copies	O
+per	O
+reaction	O
+mixture	B-CHED
+(	O
+5	O
+microl	O
+RNA	O
+extract	O
+).	O
+
+The	O
+real	O
+-	O
+time	O
+qRT	O
+-	O
+PCR	O
+assays	O
+described	O
+here	O
+allow	O
+the	O
+rapid	O
+,	O
+specific	O
+,	O
+and	O
+sensitive	O
+laboratory	O
+detection	O
+and	O
+quantitation	O
+of	O
+human	B-SPEC
+coronaviruses	O
+OC43	O
+and	O
+229E	O
+.	O
+
+TITLE	O
+:	O
+Transfer	O
+of	O
+the	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplant	B-ANAT
+patient	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+:	O
+does	O
+it	O
+really	O
+matter	O
+?	O
+
+ABSTRACT	O
+:	O
+We	O
+critically	O
+reviewed	O
+published	O
+English	O
+language	O
+literature	O
+and	O
+concluded	O
+that	O
+from	O
+1998	O
+onward	O
+the	O
+survival	O
+of	O
+hematopoietic	O
+stem	O
+cell	O
+transplant	B-ANAT
+(	O
+SCT	B-DISO
+)	O
+patients	O
+who	O
+experienced	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+transfer	O
+has	O
+improved	O
+.	O
+
+New	O
+strategies	O
+to	O
+improve	O
+upon	O
+SCT	O
+patient	O
+outcome	O
+include	O
+use	O
+of	O
+a	O
+scoring	O
+system	O
+to	O
+predict	O
+mortality	O
+,	O
+better	O
+therapies	O
+for	O
+MOSF	O
+and	O
+integration	B-PROC
+of	O
+ICU	O
+components	O
+and	O
+multispecialist	O
+involvement	O
+earlier	O
+in	O
+the	O
+clinical	O
+course	O
+to	O
+prevent	O
+severe	O
+complications	O
+such	O
+as	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+Cov	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+:	O
+soluble	O
+expression	B-PROC
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+,	O
+purification	O
+and	O
+functional	O
+characterization	O
+.	O
+
+The	O
+geometrical	O
+mean	O
+of	O
+GST	B-PRGE
+and	O
+GST	B-PRGE
+/	O
+RBD	O
+binding	B-FUNC
+to	O
+Vero	O
+E6	O
+cells	B-COMP
+were	O
+77	O
+.	O
+08	O
+and	O
+352	O
+.	O
+73	O
+respectively	O
+.	O
+
+The	O
+viscosity	O
+of	O
+total	O
+blood	B-ANAT
+and	O
+plasma	B-ANAT
+,	O
+the	O
+hematocrit	O
+,	O
+and	O
+the	O
+erythrocyte	B-ANAT
+osmotic	O
+fragility	B-DISO
+were	O
+all	O
+increased	O
+.	O
+
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+genetic	O
+expression	O
+moved	O
+up	O
+after	O
+1	O
+h	O
+and	O
+reached	O
+its	O
+peak	O
+value	O
+after	O
+9	O
+h	O
+.	O
+MD	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+ASP	B-CHED
+following	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+The	O
+case	O
+fatality	O
+rate	O
+of	O
+SARS	B-DISO
+in	O
+Beijing	O
+was	O
+7	O
+.	O
+66	O
+%,	O
+and	O
+had	O
+an	O
+ascending	O
+trend	O
+while	O
+the	O
+age	O
+of	O
+cases	O
+was	O
+getting	O
+older	O
+,	O
+and	O
+a	O
+descending	O
+trend	O
+while	O
+the	O
+epidemic	O
+development	B-PROC
+.	O
+
+The	O
+risk	O
+of	O
+death	B-PROC
+increases	O
+with	O
+the	O
+increment	O
+of	O
+age	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Classic	O
+plasma	B-ANAT
+markers	O
+of	O
+endothelial	B-ANAT
+injury	O
+,	O
+tPA	B-FUNC
+and	O
+sTM	O
+significantly	O
+elevated	O
+in	O
+SARS	B-DISO
+patients	O
+in	O
+comparison	O
+to	O
+controls	O
+[	O
+t	O
+-	O
+PA	O
+:	O
+1	O
+.	O
+48	O
++/-	O
+
+It	O
+may	O
+not	O
+only	O
+provide	O
+a	O
+useful	O
+treatment	O
+and	O
+prognostic	O
+index	O
+but	O
+also	O
+allow	O
+a	O
+further	O
+understanding	O
+of	O
+the	O
+pathological	O
+condition	B-DISO
+of	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Serological	O
+responses	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+and	O
+cross	O
+-	O
+reactivity	O
+with	O
+human	O
+coronaviruses	O
+229E	O
+,	O
+OC43	O
+,	O
+and	O
+NL63	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+serological	O
+response	O
+profile	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infection	B-DISO
+was	O
+defined	O
+by	O
+neutralization	O
+tests	O
+and	O
+subclass	B-SPEC
+-	O
+specific	O
+immunofluorescent	O
+(	O
+IF	O
+)	O
+tests	O
+using	O
+serial	O
+sera	B-COMP
+from	O
+20	O
+patients	O
+.	O
+
+SARS	B-DISO
+CoV	O
+total	O
+immunoglobulin	B-PROC
+(	O
+Ig	O
+)	O
+(	O
+IgG	B-PRGE
+,	O
+IgA	B-PRGE
+,	O
+and	O
+IgM	B-PRGE
+[	O
+IgGAM	O
+])	O
+was	O
+the	O
+first	O
+antibody	B-COMP
+to	O
+be	O
+detectable	O
+.	O
+
+There	O
+was	O
+no	O
+difference	O
+in	O
+time	O
+to	O
+seroconversion	O
+between	O
+the	O
+patients	O
+who	O
+survived	O
+(	O
+n	O
+=	O
+14	O
+)	O
+and	O
+those	O
+who	O
+died	B-PROC
+(	O
+n	O
+=	O
+6	O
+).	O
+
+There	O
+was	O
+no	O
+change	O
+in	O
+IF	O
+IgG	B-PRGE
+titer	O
+for	O
+virus	B-PRGE
+capsid	B-ANAT
+antigen	B-CHED
+from	O
+the	O
+herpesvirus	B-SPEC
+that	O
+was	O
+used	O
+as	O
+an	O
+unrelated	O
+control	O
+,	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+.	O
+
+15c	O
+showed	O
+synergistic	O
+antiviral	B-CHED
+activity	O
+with	O
+AZT	B-CHED
+.	O
+
+Increasing	O
+trends	O
+of	O
+incidences	O
+of	O
+several	O
+of	O
+these	O
+bacteria	B-SPEC
+causing	O
+all	O
+nosocomial	B-DISO
+infections	I-DISO
+or	O
+nosocomial	O
+bloodstream	B-PROC
+infections	B-DISO
+were	O
+noted	O
+from	O
+1991	O
+to	O
+2003	O
+.	O
+
+Of	O
+the	O
+participants	O
+10	O
+%	O
+to	O
+18	O
+%	O
+reported	O
+symptoms	O
+related	O
+to	O
+posttraumatic	B-DISO
+stress	I-DISO
+disorder	I-DISO
+,	O
+anxiety	O
+,	O
+and	O
+depression	B-DISO
+.	O
+
+Participants	O
+who	O
+personally	O
+knew	O
+someone	O
+who	O
+had	O
+SARS	B-DISO
+were	O
+more	O
+likely	O
+to	O
+be	O
+affected	O
+by	O
+depressive	B-DISO
+symptoms	I-DISO
+.	O
+
+Studies	O
+of	O
+MHV	B-SPEC
+and	O
+other	O
+coronaviruses	O
+have	O
+indicated	O
+a	O
+role	O
+for	O
+RNA	O
+secondary	O
+and	O
+tertiary	O
+elements	O
+in	O
+replication	O
+.	O
+
+When	O
+the	O
+identical	O
+mutations	O
+were	O
+directly	O
+inserted	O
+into	O
+the	O
+MHV	B-SPEC
+genome	O
+,	O
+most	O
+mutant	B-DISO
+genomes	O
+were	O
+viable	O
+but	O
+formed	O
+smaller	O
+plaques	B-DISO
+than	O
+the	O
+wild	O
+-	O
+type	O
+parent	O
+virus	B-SPEC
+.	O
+
+One	O
+mutant	B-DISO
+was	O
+not	O
+viable	O
+.	O
+
+Angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+the	O
+receptor	O
+for	O
+both	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+the	O
+related	O
+human	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+NL63	O
+,	O
+was	O
+expressed	B-PROC
+in	O
+human	B-SPEC
+airway	B-ANAT
+epithelia	O
+as	O
+well	O
+as	O
+lung	B-ANAT
+parenchyma	I-ANAT
+.	O
+
+These	O
+findings	O
+have	O
+implications	O
+for	O
+understanding	O
+disease	O
+pathogenesis	B-DISO
+associated	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+NL63	O
+infections	B-DISO
+.	O
+
+To	O
+determine	O
+the	O
+significance	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+group	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+ORFs	I-PRGE
+in	O
+virus	B-PROC
+replication	I-PROC
+in	O
+vitro	O
+and	O
+in	O
+mice	B-SPEC
+,	O
+we	O
+systematically	O
+deleted	O
+five	O
+of	O
+the	O
+eight	O
+group	O
+-	O
+specific	O
+ORFs	O
+,	O
+ORF3a	O
+,	O
+OF3b	O
+,	O
+ORF6	B-PRGE
+,	O
+ORF7a	O
+,	O
+and	O
+ORF7b	O
+,	O
+and	O
+characterized	O
+recombinant	O
+virus	B-PROC
+replication	I-PROC
+and	O
+gene	B-PROC
+expression	I-PROC
+in	O
+vitro	O
+.	O
+
+Deletion	O
+of	O
+the	O
+group	O
+-	O
+specific	O
+ORFs	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+either	O
+alone	O
+or	O
+in	O
+various	O
+combinations	O
+,	O
+did	O
+not	O
+dramatically	O
+influence	O
+replication	O
+efficiency	O
+in	O
+cell	B-COMP
+culture	O
+or	O
+in	O
+the	O
+levels	O
+of	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+The	O
+greatest	O
+reduction	O
+in	O
+virus	B-SPEC
+growth	B-PROC
+was	O
+noted	O
+following	O
+ORF3a	O
+deletion	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+6	O
+-	O
+year	O
+-	O
+old	O
+girl	O
+developed	O
+shock	O
+and	O
+multiple	O
+organ	O
+dysfunction	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+association	O
+with	O
+parvovirus	B-DISO
+B19	I-DISO
+infection	I-DISO
+.	O
+
+It	O
+seems	O
+likely	O
+,	O
+but	O
+it	O
+was	O
+not	O
+proved	O
+,	O
+that	O
+the	O
+parvovirus	B-DISO
+infection	I-DISO
+caused	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Our	O
+data	O
+suggests	O
+that	O
+coronavirus	B-SPEC
+NL63	O
+causes	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+symptoms	O
+and	O
+is	O
+acquired	O
+in	O
+early	O
+life	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+produce	O
+a	O
+large	O
+amount	O
+of	O
+ScFv	B-PRGE
+H12	I-PRGE
+,	O
+pET28a	B-PRGE
+-	I-PRGE
+H12	I-PRGE
+expression	B-PROC
+vector	O
+was	O
+constructed	O
+and	O
+ScFv	B-PRGE
+H12	I-PRGE
+was	O
+expressed	B-PROC
+at	O
+yield	O
+about	O
+30	O
+%	O
+of	O
+total	O
+proteins	B-CHED
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+Here	O
+two	O
+different	O
+refolding	O
+procedures	O
+were	O
+used	O
+to	O
+refold	O
+ScFv	O
+H12	O
+from	O
+inclusion	B-COMP
+body	I-COMP
+:	O
+gel	O
+filtration	O
+chromatography	O
+and	O
+dilution	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+ScFv	B-PRGE
+H12	I-PRGE
+could	O
+be	O
+efficiently	O
+refolded	O
+by	O
+both	O
+procedures	O
+.	O
+
+The	O
+outbreak	O
+of	O
+this	O
+novel	O
+disease	O
+,	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+the	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+),	O
+hit	O
+hardest	O
+in	O
+the	O
+Asian	O
+Pacific	O
+region	O
+,	O
+though	O
+eventually	O
+it	O
+spread	O
+to	O
+five	O
+continents	O
+.	O
+
+An	O
+international	O
+collaborative	O
+effort	B-PROC
+through	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+has	O
+helped	O
+to	O
+identify	O
+the	O
+aetiological	O
+agent	O
+about	O
+1	O
+month	O
+after	O
+the	O
+onset	O
+of	O
+the	O
+epidemic	O
+.	O
+
+The	O
+power	O
+of	O
+molecular	O
+biology	O
+and	O
+bioinformatics	O
+has	O
+enabled	O
+the	O
+complete	O
+decoding	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+within	O
+weeks	O
+.	O
+
+Over	O
+1000	O
+publications	O
+on	O
+the	O
+phylogeny	O
+,	O
+epidemiology	O
+,	O
+genomics	O
+,	O
+laboratory	O
+diagnostics	O
+,	O
+antiviral	B-CHED
+,	O
+immunization	O
+,	O
+pathogenesis	B-DISO
+,	O
+clinical	O
+disease	O
+,	O
+and	O
+management	O
+accumulated	O
+within	O
+just	O
+1	O
+year	O
+.	O
+
+This	O
+article	O
+reviews	O
+what	O
+is	O
+currently	O
+known	O
+about	O
+the	O
+virus	B-SPEC
+and	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Validity	O
+and	O
+reliability	O
+of	O
+an	O
+instrument	O
+for	O
+predictive	O
+nursing	B-PROC
+intention	O
+for	O
+SARS	B-DISO
+patient	O
+care	O
+].	O
+
+The	O
+Three	O
+-	O
+phase	O
+design	O
+involved	O
+a	O
+)	O
+salient	O
+beliefs	O
+generated	O
+from	O
+clinical	O
+nurses	O
+(	O
+n	O
+=	O
+43	O
+)	O
+b	O
+)	O
+content	O
+validation	O
+by	O
+expert	O
+panel	O
+evaluations	O
+(	O
+n	O
+=	O
+5	O
+)	O
+c	O
+)	O
+face	B-DISO
+validation	O
+by	O
+plot	O
+testing	O
+(	O
+n	O
+=	O
+10	O
+)	O
+d	O
+)	O
+and	O
+instrument	O
+validation	O
+in	O
+a	O
+cross	O
+sectional	O
+survey	O
+(	O
+n	O
+=	O
+299	O
+).	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+fingerprint	O
+map	O
+for	O
+detecting	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+Spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+is	O
+the	O
+most	O
+important	O
+membrane	O
+protein	B-CHED
+on	O
+the	O
+surface	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Recent	O
+studies	O
+point	O
+out	O
+to	O
+a	O
+cell	B-COMP
+entry	O
+mechanism	O
+of	O
+this	O
+virus	B-SPEC
+similar	O
+to	O
+other	O
+enveloped	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+.	O
+
+A	O
+prominent	O
+example	O
+,	O
+central	O
+to	O
+our	O
+current	O
+understanding	O
+of	O
+epidemic	O
+spread	O
+,	O
+is	O
+the	O
+basic	O
+reproductive	B-PROC
+number	O
+,	O
+R	O
+(	O
+0	O
+),	O
+which	O
+is	O
+defined	O
+as	O
+the	O
+mean	O
+number	O
+of	O
+infections	B-DISO
+caused	O
+by	O
+an	O
+infected	O
+individual	O
+in	O
+a	O
+susceptible	O
+population	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+article	O
+is	O
+to	O
+quantify	O
+the	O
+public	O
+health	O
+risk	O
+associated	O
+with	O
+inhalation	O
+of	O
+indoor	O
+airborne	O
+infection	B-DISO
+based	O
+on	O
+a	O
+probabilistic	O
+transmission	O
+dynamic	O
+modeling	O
+approach	O
+.	O
+
+The	O
+specific	O
+IgG	B-PRGE
+and	O
+neutralizing	O
+antibody	B-COMP
+titers	O
+peaked	O
+at	O
+approximately	O
+week	O
+7	O
+after	O
+the	O
+first	O
+immunization	O
+,	O
+with	O
+a	O
+maximum	O
+value	O
+of	O
+1	O
+:	O
+14210	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+specific	O
+IgG	B-PRGE
+and	O
+neutralizing	O
+antibody	B-COMP
+titers	O
+peaked	O
+at	O
+approximately	O
+week	O
+7	O
+after	O
+the	O
+first	O
+immunization	O
+,	O
+with	O
+a	O
+maximum	O
+value	O
+of	O
+1	O
+:	O
+14210	O
+.	O
+
+TITLE	O
+:	O
+The	O
+2003	O
+SARS	B-DISO
+outbreak	O
+and	O
+its	O
+impact	O
+on	O
+infection	B-DISO
+control	O
+practices	O
+.	O
+
+The	O
+efficiency	O
+of	O
+transmission	O
+within	O
+healthcare	O
+facilities	O
+was	O
+recognised	O
+following	O
+significant	O
+hospital	O
+outbreaks	O
+of	O
+SARS	B-DISO
+in	O
+Canada	O
+,	O
+China	O
+,	O
+Hong	O
+Kong	O
+,	O
+Singapore	O
+,	O
+Taiwan	O
+and	O
+Vietnam	O
+.	O
+
+Effective	O
+and	O
+safe	O
+discharge	B-ANAT
+criteria	O
+were	O
+established	O
+from	O
+the	O
+lessons	O
+learnt	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+United	O
+Kingdom	O
+was	O
+assessed	O
+as	O
+a	O
+low	O
+risk	O
+country	O
+throughout	O
+the	O
+2003	O
+global	O
+SARS	B-DISO
+outbreaks	O
+.	O
+
+Lessons	O
+learned	B-PROC
+from	O
+mounting	O
+a	O
+UK	O
+response	O
+to	O
+SARS	B-DISO
+included	O
+:	O
+the	O
+importance	O
+of	O
+international	O
+collaboration	O
+;	O
+formation	B-PROC
+of	O
+a	O
+UK	O
+-	O
+wide	O
+,	O
+multidisciplinary	O
+Task	O
+Force	O
+;	O
+flexible	O
+case	O
+reporting	O
+mechanisms	O
+;	O
+integration	B-PROC
+of	O
+surveillance	O
+and	O
+laboratory	O
+data	O
+;	O
+generation	O
+of	O
+prompt	O
+and	O
+web	B-DISO
+-	O
+accessible	O
+guidance	O
+and	O
+advice	O
+;	O
+availability	O
+of	O
+surge	O
+capacity	O
+;	O
+and	O
+contingency	O
+planning	O
+.	O
+
+These	O
+studies	O
+demonstrate	O
+that	O
+progenitor	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+remyelination	B-PROC
+is	O
+not	O
+the	O
+result	O
+of	O
+modulating	O
+the	O
+composition	O
+of	O
+the	O
+cellular	B-DISO
+infiltrate	I-DISO
+nor	O
+cytokine	O
+expression	B-PROC
+by	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+suggest	O
+that	O
+remyelination	B-PROC
+may	O
+not	O
+depend	O
+on	O
+amelioration	O
+of	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+or	O
+alteration	O
+of	O
+cytokine	B-PROC
+secretion	I-PROC
+by	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+develop	O
+CpG	O
+oligodeoxynucleotides	O
+(	O
+CpG	O
+ODNs	O
+)	O
+based	O
+therapy	O
+for	O
+prevention	O
+and	O
+treatment	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+we	O
+selected	O
+a	O
+novel	O
+CpG	O
+ODN	O
+(	O
+BW001	O
+),	O
+which	O
+displays	O
+B	O
+-	O
+type	O
+CpG	O
+ODN	O
+structure	O
+feature	O
+at	O
+the	O
+5	O
+'	O
+and	O
+A	O
+-	O
+type	O
+CpG	O
+ODN	O
+structure	O
+feature	O
+at	O
+the	O
+3	O
+',	O
+and	O
+tested	O
+for	O
+its	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+activity	O
+.	O
+
+BW001	O
+could	O
+stimulate	O
+human	B-SPEC
+PBMCs	O
+and	O
+pDCs	O
+to	O
+secrete	B-PROC
+high	O
+level	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+promote	O
+human	B-SPEC
+PBMCs	O
+and	O
+B	B-ANAT
+cells	I-ANAT
+to	O
+proliferate	O
+.	O
+
+Participants	O
+were	O
+physicians	O
+who	O
+staffed	O
+a	O
+SARS	B-DISO
+hotline	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Taipei	O
+,	O
+Taiwan	O
+from	O
+June	O
+1	O
+to	O
+10	O
+,	O
+2003	O
+.	O
+
+The	O
+results	O
+obtained	O
+suggest	O
+that	O
+knowledge	O
+of	O
+SARS	B-DISO
+was	O
+generally	O
+good	O
+although	O
+obtained	O
+from	O
+both	O
+medical	O
+and	O
+non	O
+-	O
+medical	O
+sources	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+is	O
+a	O
+viral	O
+RNA	O
+-	O
+binding	B-FUNC
+protein	B-CHED
+with	O
+multiple	O
+functions	O
+in	O
+terms	O
+of	O
+virus	B-PROC
+replication	I-PROC
+and	O
+modulating	O
+cell	B-COMP
+signalling	B-PROC
+pathways	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+a	O
+member	O
+of	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+,	O
+has	O
+caused	O
+a	O
+devastating	O
+enteric	O
+disease	O
+in	O
+the	O
+Korean	O
+swine	B-SPEC
+industry	O
+.	O
+
+This	O
+suggests	O
+that	O
+measurement	O
+of	O
+PEDV	B-SPEC
+shedding	O
+viral	O
+load	O
+in	O
+pigs	B-SPEC
+,	O
+by	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+,	O
+may	O
+be	O
+a	O
+useful	O
+tool	O
+for	O
+estimating	O
+the	O
+transmission	O
+potential	O
+of	O
+PEDV	B-SPEC
+in	O
+the	O
+swine	B-SPEC
+population	O
+.	O
+
+Of	O
+19	O
+surviving	O
+grafts	B-ANAT
+,	O
+18	O
+(	O
+95	O
+%)	O
+remain	O
+steroid	B-CHED
+and	O
+15	O
+(	O
+79	O
+%)	O
+CNI	O
+-	O
+free	O
+.	O
+
+TITLE	O
+:	O
+Age	O
+-	O
+and	O
+gender	O
+-	O
+related	O
+difference	O
+of	O
+ACE2	B-PRGE
+expression	B-PROC
+in	O
+rat	B-ANAT
+lung	I-ANAT
+.	O
+
+ACE2	B-PRGE
+was	O
+predominantly	O
+expressed	B-PROC
+in	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+,	O
+bronchiolar	B-ANAT
+epithelium	B-ANAT
+,	O
+endothelium	B-ANAT
+and	O
+smooth	B-COMP
+muscle	I-COMP
+cells	I-COMP
+of	O
+pulmonary	B-ANAT
+vessels	B-ANAT
+with	O
+similar	O
+content	O
+,	O
+whereas	O
+no	O
+obvious	O
+signal	O
+was	O
+detected	O
+in	O
+the	O
+bronchiolar	B-ANAT
+smooth	B-COMP
+muscle	I-COMP
+cells	I-COMP
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+more	O
+elevated	O
+ACE2	O
+in	O
+young	O
+adults	O
+as	O
+compared	O
+to	O
+aged	O
+groups	O
+may	O
+contribute	O
+to	O
+the	O
+predominance	O
+in	O
+SARS	B-DISO
+attacks	O
+in	O
+this	O
+age	O
+group	O
+.	O
+
+Accumulation	O
+of	O
+hypo	O
+-	O
+or	O
+non	O
+-	O
+phosphorylated	O
+pRb	B-PRGE
+thus	O
+prevents	O
+cell	B-PROC
+cycle	I-PROC
+progression	I-PROC
+at	O
+G0	O
+/	O
+G1	B-PROC
+phase	I-PROC
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+:	O
+understanding	O
+the	O
+virus	B-SPEC
+and	O
+development	B-PROC
+of	O
+rational	O
+therapy	O
+.	O
+
+A	O
+hitherto	O
+unknown	O
+animal	B-SPEC
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+that	O
+had	O
+crossed	O
+the	O
+species	B-SPEC
+barrier	O
+through	O
+close	O
+contact	O
+of	O
+humans	B-SPEC
+with	O
+infected	O
+animals	B-SPEC
+was	O
+identified	O
+as	O
+the	O
+etiological	O
+agent	O
+.	O
+
+Increasingly	O
+,	O
+however	O
+,	O
+the	O
+government	O
+has	O
+become	O
+involved	O
+in	O
+more	O
+targeted	B-PROC
+countermeasure	O
+development	B-PROC
+efforts	O
+.	O
+
+TITLE	O
+:	O
+A	O
+point	B-PROC
+mutation	I-PROC
+within	O
+the	O
+replicase	B-PRGE
+gene	I-PRGE
+differentially	O
+affects	O
+coronavirus	B-SPEC
+genome	O
+versus	O
+minigenome	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+construction	O
+of	O
+the	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+full	O
+-	O
+length	O
+cDNA	O
+clone	O
+,	O
+a	O
+point	B-PROC
+mutation	I-PROC
+at	O
+position	O
+637	O
+that	O
+was	O
+present	O
+in	O
+the	O
+defective	O
+minigenome	O
+DI	O
+-	O
+C	O
+was	O
+maintained	O
+as	O
+a	O
+genetic	B-PROC
+marker	I-PROC
+.	O
+
+In	O
+contrast	O
+,	O
+T	O
+or	O
+A	O
+at	O
+position	O
+637	O
+was	O
+required	O
+for	O
+minigenome	O
+rescue	O
+in	O
+trans	O
+by	O
+the	O
+helper	O
+virus	B-SPEC
+.	O
+
+This	O
+position	O
+is	O
+predicted	O
+to	O
+map	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+polyprotein	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+(	O
+PLP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+cleavage	B-PROC
+site	O
+at	O
+the	O
+p9	O
+/	O
+p87	B-PRGE
+junction	O
+.	O
+
+Competition	O
+experiments	O
+with	O
+mixed	B-DISO
+infections	I-DISO
+revealed	O
+that	O
+this	O
+was	O
+not	O
+due	O
+to	O
+the	O
+enzymatic	B-PROC
+activity	I-PROC
+:	O
+MHVs	O
+expressing	O
+HE	O
++	O
+or	O
+HE0	O
+propagated	O
+with	O
+equal	O
+efficiencies	O
+.	O
+
+However	O
+,	O
+viral	O
+proteins	B-CHED
+other	O
+than	O
+S	O
+also	O
+contribute	O
+to	O
+pathogenicity	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+HE	O
+in	O
+combination	O
+with	O
+A59	O
+S	O
+did	O
+not	O
+affect	O
+the	O
+tropism	B-PROC
+,	O
+pathogenicity	O
+,	O
+or	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+vivo	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+identification	O
+and	O
+characterization	O
+of	O
+a	O
+316	O
+-	O
+amino	O
+-	O
+acid	O
+catalytic	O
+core	O
+domain	O
+of	O
+PLpro	O
+that	O
+can	O
+efficiently	O
+cleave	O
+replicase	B-PRGE
+substrates	O
+in	O
+trans	O
+-	O
+cleavage	B-PROC
+assays	O
+and	O
+peptide	B-CHED
+substrates	O
+in	O
+fluorescent	O
+resonance	O
+energy	B-PROC
+transfer	I-PROC
+-	O
+based	O
+protease	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+The	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+from	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+is	O
+a	O
+deubiquitinating	B-PROC
+enzyme	I-FUNC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+confirm	O
+this	O
+prediction	O
+,	O
+we	O
+overexpressed	O
+and	O
+purified	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+(	O
+amino	B-CHED
+acids	I-CHED
+[	O
+aa	O
+]	O
+1507	O
+to	O
+1858	O
+)	O
+from	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+To	O
+this	O
+end	O
+,	O
+the	O
+soR	B-PRGE
+domain	I-PRGE
+was	O
+coupled	O
+to	O
+single	O
+-	O
+chain	O
+monoclonal	O
+antibody	B-COMP
+425	O
+,	O
+which	O
+is	O
+directed	O
+against	O
+the	O
+human	B-SPEC
+epidermal	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+receptor	I-PRGE
+(	O
+EGFR	B-FUNC
+),	O
+resulting	O
+in	O
+a	O
+bispecific	O
+adapter	O
+protein	B-CHED
+(	O
+soR	B-PRGE
+-	I-PRGE
+425	I-PRGE
+).	O
+
+Using	O
+reciprocal	O
+bone	B-ANAT
+marrow	I-ANAT
+transplantation	O
+(	O
+BMT	B-ENZY
+)	O
+to	O
+generate	O
+HO	O
+-	O
+1	O
+-	O
+chimeric	O
+mice	B-SPEC
+,	O
+we	O
+found	O
+that	O
+absence	O
+of	O
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+the	O
+lung	B-ANAT
+parenchyma	I-ANAT
+,	O
+not	O
+in	O
+bone	B-ANAT
+marrow	I-ANAT
+-	O
+derived	O
+inflammatory	B-ANAT
+cells	I-ANAT
+,	O
+was	O
+responsible	O
+for	O
+enhanced	O
+SP	B-PRGE
+-	I-PRGE
+B	I-PRGE
+downregulation	B-PROC
+and	O
+severe	O
+physiologic	O
+lung	B-ANAT
+dysfunction	O
+.	O
+
+These	O
+findings	O
+suggest	O
+a	O
+possible	O
+role	O
+of	O
+S	O
+and	O
+S2	B-PRGE
+protein	I-PRGE
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+induced	O
+apoptosis	B-PATH
+and	O
+the	O
+molecular	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+Over	O
+8439	O
+SARS	B-DISO
+cases	O
+and	O
+812	O
+SARS	B-DISO
+-	O
+related	O
+deaths	B-PROC
+were	O
+reported	O
+to	O
+the	O
+World	O
+Health	O
+Organization	O
+from	O
+32	O
+countries	O
+around	O
+the	O
+world	O
+up	O
+to	O
+5	O
+July	O
+2003	O
+.	O
+
+The	O
+mechanism	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+has	O
+been	O
+limited	O
+only	O
+to	O
+close	O
+contacts	O
+with	O
+patients	O
+.	O
+
+The	O
+nucleic	B-CHED
+acid	I-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+found	O
+in	O
+the	O
+sewage	O
+before	O
+disinfection	O
+from	O
+both	O
+hospitals	O
+by	O
+PCR	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+the	O
+virus	B-SPEC
+can	O
+survive	O
+for	O
+14	O
+days	O
+in	O
+sewage	O
+at	O
+4	O
+degrees	O
+C	O
+,	O
+2	O
+days	O
+at	O
+20	O
+degrees	O
+C	O
+,	O
+and	O
+its	O
+RNA	O
+can	O
+be	O
+detected	O
+for	O
+8	O
+days	O
+though	O
+the	O
+virus	B-SPEC
+had	O
+been	O
+inactivated	O
+.	O
+
+ABSTRACT	O
+:	O
+Humanized	O
+mice	O
+are	O
+crucial	O
+tools	O
+for	O
+studying	O
+human	B-SPEC
+pathogens	O
+in	O
+systemic	O
+situations	O
+.	O
+
+TITLE	O
+:	O
+Progressive	O
+cavitating	O
+leukoencephalopathy	B-DISO
+:	O
+a	O
+novel	O
+childhood	O
+disease	O
+.	O
+
+After	O
+repeated	O
+episodes	O
+,	O
+areas	O
+of	O
+tissue	B-ANAT
+loss	O
+coalesce	O
+with	O
+older	O
+lesions	O
+to	O
+become	O
+larger	O
+cystic	O
+regions	O
+in	O
+brain	B-ANAT
+or	O
+spinal	B-ANAT
+cord	I-ANAT
+.	O
+
+Diffuse	O
+spasticity	B-DISO
+,	O
+dementia	B-DISO
+,	O
+vegetative	B-DISO
+state	I-DISO
+,	O
+or	O
+death	B-PROC
+ensues	O
+.	O
+
+Pathological	O
+studies	O
+show	O
+severe	O
+loss	O
+of	O
+myelin	B-COMP
+sparing	O
+U	O
+-	O
+fibers	O
+,	O
+axonal	O
+disruption	O
+,	O
+and	O
+cavitary	O
+lesions	O
+without	O
+inflammation	B-DISO
+.	O
+
+Familial	O
+occurrence	O
+and	O
+consanguinity	O
+suggest	O
+autosomal	B-COMP
+recessive	B-PROC
+inheritance	I-PROC
+of	O
+this	O
+distinct	O
+entity	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+review	O
+the	O
+clinicopathological	O
+findings	O
+in	O
+naturally	O
+-	O
+occurring	O
+,	O
+histopathologically	O
+confirmed	O
+cases	O
+of	O
+feline	O
+infectious	O
+peritonitis	O
+in	O
+client	O
+-	O
+owned	O
+cats	B-SPEC
+in	O
+Sydney	O
+,	O
+Australia	O
+,	O
+with	O
+the	O
+purpose	O
+of	O
+identifying	O
+factors	O
+assisting	O
+in	O
+the	O
+diagnosis	O
+of	O
+this	O
+complex	O
+disease	O
+syndrome	B-DISO
+and	O
+to	O
+characterise	O
+the	O
+disease	O
+as	O
+it	O
+occurs	O
+in	O
+this	O
+region	O
+.	O
+
+Significant	O
+features	O
+of	O
+this	O
+study	O
+that	O
+unique	O
+to	O
+the	O
+contemporary	O
+literature	O
+are	O
+i	O
+)	O
+the	O
+over	O
+-	O
+representation	O
+of	O
+certain	O
+breeds	O
+(	O
+Burmese	O
+,	O
+Australian	O
+Mist	O
+,	O
+British	O
+Shorthaired	O
+,	O
+and	O
+Cornish	O
+Rex	B-FUNC
+)	O
+and	O
+the	O
+under	O
+-	O
+representation	O
+of	O
+other	O
+breeds	B-PROC
+(	O
+Domestic	O
+Shorthaired	O
+,	O
+Persian	O
+);	O
+ii	O
+)	O
+the	O
+overrepresentation	O
+of	O
+males	O
+;	O
+iii	O
+)	O
+the	O
+tendency	O
+for	O
+effusive	O
+disease	O
+in	O
+Australian	O
+Mist	O
+cats	B-SPEC
+and	O
+non	O
+-	O
+effusive	O
+disease	O
+in	O
+Burmese	O
+;	O
+iv	O
+)	O
+the	O
+even	O
+age	O
+distribution	O
+of	O
+disease	O
+seen	O
+in	O
+cats	B-SPEC
+older	O
+than	O
+2	O
+years	O
+-	O
+of	O
+-	O
+age	O
+;	O
+and	O
+v	O
+)	O
+the	O
+presence	O
+of	O
+fulminant	O
+immune	O
+-	O
+mediated	O
+haemolytic	B-DISO
+anaemia	I-DISO
+in	O
+two	O
+cats	B-SPEC
+in	O
+this	O
+study	O
+.	O
+
+TITLE	O
+:	O
+When	O
+family	B-SPEC
+-	O
+centered	O
+care	O
+is	O
+challenged	O
+by	O
+infectious	B-DISO
+disease	I-DISO
+:	O
+pediatric	O
+health	O
+care	O
+delivery	O
+during	O
+the	O
+SARS	O
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+ethnographic	O
+study	O
+,	O
+the	O
+authors	O
+examined	O
+the	O
+experiences	O
+and	O
+perspectives	O
+of	O
+children	O
+hospitalized	O
+because	O
+of	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+),	O
+their	O
+parents	O
+,	O
+and	O
+pediatric	O
+health	O
+care	O
+providers	O
+.	O
+
+Issues	O
+related	O
+to	O
+social	O
+isolation	O
+due	O
+to	O
+infection	B-DISO
+control	O
+precautions	O
+were	O
+predominant	O
+.	O
+
+A	O
+phylogenetic	O
+tree	O
+constructed	O
+from	O
+these	O
+amplimers	O
+,	O
+that	O
+spanned	O
+the	O
+HVR	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+,	O
+revealed	O
+the	O
+IBV	B-SPEC
+isolates	O
+clustered	O
+into	O
+two	O
+demarcated	O
+groups	O
+which	O
+had	O
+<	O
+60	O
+%	O
+homology	O
+.	O
+
+Our	O
+findings	O
+have	O
+implications	O
+for	O
+understanding	O
+the	O
+pathogenesis	O
+of	O
+SARS	B-DISO
+and	O
+for	O
+SARS	B-DISO
+vaccine	O
+research	O
+and	O
+development	B-PROC
+.	O
+
+One	O
+hundred	O
+and	O
+thirty	O
+-	O
+three	O
+patients	O
+referred	O
+from	O
+a	O
+SARS	B-DISO
+Review	O
+Clinic	O
+solely	O
+for	O
+physiotherapy	O
+were	O
+included	O
+.	O
+
+TITLE	O
+:	O
+Immunopathogenesis	O
+of	O
+coronavirus	B-DISO
+infections	I-DISO
+:	O
+implications	O
+for	O
+SARS	B-DISO
+.	O
+
+We	O
+discuss	O
+the	O
+differential	O
+diagnosis	O
+of	O
+upper	O
+airway	B-DISO
+obstructions	I-DISO
+and	O
+of	O
+the	O
+entities	O
+related	O
+to	O
+bronchial	B-ANAT
+cast	B-ANAT
+formation	B-PROC
+,	O
+in	O
+particular	O
+the	O
+clinical	O
+and	O
+pathophysiological	O
+features	O
+of	O
+plastic	B-DISO
+bronchitis	I-DISO
+and	O
+the	O
+treatment	O
+options	O
+available	O
+.	O
+
+Yolk	B-PRGE
+immunoglobulin	B-PROC
+(	O
+IgY	O
+)	O
+was	O
+extracted	O
+using	O
+the	O
+water	B-CHED
+dilution	O
+method	O
+,	O
+followed	O
+by	O
+further	O
+purification	O
+on	O
+a	O
+Sephadex	O
+G	O
+-	O
+75	O
+column	B-ANAT
+.	O
+
+Lyophilization	O
+and	O
+stability	O
+tests	O
+showed	O
+that	O
+lyophilized	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+IgY	I-PRGE
+had	O
+promising	O
+physical	O
+properties	O
+,	O
+with	O
+no	O
+significant	O
+reduction	O
+in	O
+reactive	O
+activity	O
+and	O
+good	O
+thermal	O
+stability	O
+.	O
+
+This	O
+article	O
+demonstrates	O
+a	O
+genome	O
+-	O
+to	O
+-	O
+drug	O
+-	O
+lead	O
+approach	O
+that	O
+uses	O
+terascale	O
+computing	O
+to	O
+model	O
+flexible	O
+regions	O
+of	O
+proteins	B-CHED
+,	O
+thus	O
+permitting	O
+the	O
+utilization	O
+of	O
+genetic	O
+information	O
+to	O
+identify	O
+drug	O
+leads	O
+expeditiously	O
+.	O
+
+These	O
+results	O
+show	O
+that	O
+respiratory	B-DISO
+virus	I-DISO
+infection	I-DISO
+-	O
+particularly	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+during	O
+epidemic	O
+periods	B-PROC
+-	O
+is	O
+common	O
+among	O
+patients	O
+hospitalized	O
+for	O
+acute	O
+cardiorespiratory	B-DISO
+failure	I-DISO
+.	O
+
+A	O
+strong	O
+link	O
+was	O
+found	O
+between	O
+the	O
+rate	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+positivity	O
+and	O
+the	O
+incidence	O
+of	O
+flu	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+in	O
+the	O
+community	O
+(	O
+p	O
+=	O
+0	O
+.	O
+017	O
+).	O
+
+Because	O
+X4	O
+does	O
+not	O
+reveal	O
+significant	O
+sequence	O
+homologies	O
+to	O
+proteins	B-CHED
+in	O
+the	O
+data	O
+bases	B-CHED
+,	O
+we	O
+carried	O
+out	O
+a	O
+structure	O
+based	O
+similarity	O
+search	O
+for	O
+proteins	B-CHED
+with	O
+known	O
+function	O
+.	O
+
+TITLE	O
+:	O
+The	O
+N	O
+-	O
+terminal	O
+octapeptide	O
+acts	O
+as	O
+a	O
+dimerization	O
+inhibitor	B-CHED
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-FUNC
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+influenza	B-PATH
+A	I-PATH
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+in	O
+an	O
+elderly	O
+subject	O
+hospitalised	O
+in	O
+intensive	O
+care	O
+unit	O
+].	O
+
+Influenza	B-DISO
+pneumonia	I-DISO
+is	O
+a	O
+significant	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+,	O
+especially	O
+during	O
+influenza	B-DISO
+epidemics	O
+.	O
+
+In	O
+addition	O
+,	O
+based	O
+on	O
+both	O
+peptide	B-CHED
+-	O
+based	O
+assay	O
+and	O
+autocleavage	O
+assay	O
+,	O
+Ile	B-CHED
+at	O
+the	O
+P1	O
+'	O
+position	O
+could	O
+not	O
+be	O
+hydrolyzed	O
+,	O
+but	O
+the	O
+mutant	B-DISO
+L27A	O
+could	O
+hydrolyze	O
+the	O
+Ile	B-CHED
+peptide	B-CHED
+fragment	O
+.	O
+
+The	O
+specificity	O
+information	O
+of	O
+the	O
+enzyme	O
+is	O
+helpful	O
+for	O
+potent	O
+anti	O
+-	O
+virus	B-SPEC
+inhibitor	B-CHED
+design	O
+and	O
+useful	O
+for	O
+other	O
+coronavirus	B-SPEC
+studies	O
+.	O
+
+TITLE	O
+:	O
+Design	O
+and	O
+biological	O
+activities	O
+of	O
+novel	O
+inhibitory	O
+peptides	B-CHED
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+and	O
+angiotensin	O
+-	O
+converting	O
+enzyme	O
+2	O
+interaction	O
+.	O
+
+Interactions	O
+between	O
+N	O
+proteins	B-CHED
+and	O
+RNA	O
+are	O
+thus	O
+crucial	O
+for	O
+the	O
+assembly	O
+of	O
+infectious	B-DISO
+virus	B-COMP
+particles	I-COMP
+.	O
+
+We	O
+obtained	O
+a	O
+stable	O
+fragment	O
+of	O
+14	O
+.	O
+7	O
+kDa	O
+spanning	O
+its	O
+N	O
+-	O
+terminal	O
+residues	O
+29	O
+-	O
+160	O
+(	O
+IBV	B-SPEC
+-	O
+N29	O
+-	O
+160	O
+).	O
+
+In	O
+addition	O
+to	O
+hostcell	O
+receptors	O
+,	O
+lysosomal	B-PRGE
+cysteine	B-CHED
+proteases	I-PRGE
+are	O
+required	O
+for	O
+productive	O
+infection	B-DISO
+by	O
+some	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+pathogenesis	B-DISO
+and	O
+the	O
+emerging	O
+pathogen	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+While	O
+there	O
+was	O
+no	O
+change	O
+in	O
+the	O
+extent	O
+of	O
+phosphorylated	O
+eNOS	O
+at	O
+ser	B-COMP
+,	O
+chronic	O
+EtOH	B-CHED
+stimulation	O
+caused	O
+dose	O
+-	O
+dependent	O
+increases	O
+in	O
+NO	O
+production	O
+and	O
+increased	O
+eNOS	O
+expression	B-PROC
+,	O
+effects	O
+that	O
+were	O
+attenuated	O
+by	O
+the	O
+transcriptional	B-PROC
+inhibitor	B-CHED
+,	O
+alpha	B-PRGE
+-	I-PRGE
+amanitin	I-PRGE
+(	O
+AA	O
+),	O
+and	O
+wortmannin	B-CHED
+,	O
+a	O
+specific	O
+phosphatidylinositol	B-PRGE
+3	I-PRGE
+kinase	I-PRGE
+(	O
+PI3	B-PRGE
+K	I-PRGE
+)	O
+inhibitor	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	O
+replicase	O
+-	O
+transcriptase	B-PROC
+complex	O
+is	O
+an	O
+assembly	O
+of	O
+viral	O
+and	O
+cellular	B-COMP
+proteins	B-CHED
+that	O
+mediate	O
+the	O
+synthesis	B-PROC
+of	O
+genome	O
+and	O
+subgenome	O
+-	O
+sized	O
+mRNAs	O
+in	O
+the	O
+virus	B-SPEC
+-	O
+infected	O
+cell	B-COMP
+.	O
+
+Further	O
+biochemical	O
+analysis	O
+of	O
+these	O
+mutants	O
+should	O
+allow	O
+us	O
+to	O
+identify	O
+intermediates	O
+in	O
+this	O
+pathway	B-PROC
+and	O
+elucidate	O
+the	O
+precise	O
+function	O
+(	O
+s	O
+)	O
+of	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+proteins	I-PRGE
+involved	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Addition	O
+of	O
+an	O
+arterio	B-ANAT
+-	I-ANAT
+venous	I-ANAT
+shunt	O
+during	O
+veno	O
+-	O
+arterial	B-ANAT
+extracorporeal	O
+life	O
+support	O
+in	O
+a	O
+patient	O
+with	O
+Hantavirus	O
+pulmonary	B-ANAT
+syndrome	O
+].	O
+
+In	O
+addition	O
+,	O
+it	O
+is	O
+noted	O
+that	O
+two	O
+highly	O
+conserved	O
+amino	B-CHED
+acids	I-CHED
+(	O
+L218	O
+and	O
+L219	O
+)	O
+in	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+are	O
+not	O
+involved	O
+in	O
+this	O
+interaction	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+electrostatic	O
+interactions	O
+between	O
+the	O
+carboxyl	O
+termini	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+membrane	B-COMP
+protein	B-CHED
+and	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+largely	O
+mediate	O
+the	O
+interaction	O
+of	O
+these	O
+two	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Vasculitis	B-DISO
+and	O
+systemic	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+outbreak	O
+of	O
+an	O
+epidemic	B-DISO
+disease	I-DISO
+,	O
+for	O
+example	O
+,	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+the	O
+number	O
+of	O
+daily	O
+infected	O
+cases	O
+often	O
+exhibit	O
+multiple	O
+trends	O
+:	O
+monotone	O
+increasing	O
+during	O
+the	O
+growing	O
+stage	O
+,	O
+stationary	O
+during	O
+the	O
+stabilized	O
+stage	O
+and	O
+then	O
+decreasing	O
+during	O
+the	O
+declining	O
+stage	O
+.	O
+
+A	O
+series	O
+of	O
+microfluidic	O
+workstations	O
+with	O
+integrated	O
+chip	O
+manipulation	O
+as	O
+well	O
+as	O
+laser	B-SPEC
+induced	O
+fluorescence	O
+(	O
+LIF	O
+),	O
+ultraviolet	O
+(	O
+UV	O
+),	O
+electrochemical	O
+and	O
+chemiluminescence	O
+detection	O
+modules	O
+have	O
+been	O
+developed	O
+to	O
+attain	O
+the	O
+abilities	O
+of	O
+complex	O
+microfluidic	O
+control	O
+and	O
+data	O
+acquisition	O
+schemes	O
+.	O
+
+An	O
+ultra	O
+-	O
+rapid	O
+microchip	O
+electrophoresis	O
+method	O
+was	O
+established	O
+for	O
+simultaneous	O
+determination	O
+intracellular	B-COMP
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+and	O
+reduced	B-CHED
+glutathione	I-CHED
+(	O
+GSH	B-DISO
+)	O
+related	O
+to	O
+apoptosis	B-PATH
+and	O
+oxidative	B-DISO
+stress	I-DISO
+.	O
+
+In	O
+an	O
+effort	B-PROC
+to	O
+develop	O
+a	O
+novel	O
+microfluidic	O
+based	O
+drug	O
+screening	O
+platform	O
+,	O
+systematic	O
+studies	O
+on	O
+the	O
+interaction	O
+between	O
+granulocyte	B-FUNC
+colony	I-FUNC
+-	I-FUNC
+stimulating	I-FUNC
+factor	I-FUNC
+(	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+and	O
+sulfated	O
+oligosaccharides	B-CHED
+were	O
+carried	O
+out	O
+at	O
+both	O
+molecular	O
+and	O
+cellular	B-COMP
+levels	O
+.	O
+
+To	O
+assess	O
+the	O
+necessity	O
+of	O
+this	O
+mechanism	O
+,	O
+we	O
+deleted	O
+most	O
+of	O
+the	O
+sequence	O
+representing	O
+3a	O
+and	O
+3b	O
+to	O
+produce	O
+a	O
+gene	O
+in	O
+which	O
+ORF	O
+3c	O
+(	O
+E	O
+)	O
+was	O
+adjacent	O
+to	O
+the	O
+gene	O
+3	O
+transcription	B-PROC
+-	O
+associated	O
+sequence	O
+.	O
+
+Nevertheless	O
+,	O
+titers	O
+produced	O
+in	O
+CK	O
+cells	B-COMP
+,	O
+embryos	B-ANAT
+,	O
+and	O
+TOCs	O
+were	O
+similar	O
+to	O
+those	O
+of	O
+the	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+,	O
+although	O
+they	O
+declined	O
+earlier	O
+in	O
+TOCs	O
+,	O
+probably	O
+due	O
+to	O
+the	O
+absence	O
+of	O
+the	O
+3a	O
+protein	B-CHED
+.	O
+
+Thus	O
+,	O
+neither	O
+the	O
+tricistronic	O
+arrangement	O
+of	O
+gene	B-PRGE
+3	I-PRGE
+,	O
+the	O
+internal	O
+initiation	O
+of	O
+translation	B-PROC
+of	O
+E	B-PRGE
+protein	I-PRGE
+,	O
+nor	O
+the	O
+3a	O
+and	O
+3b	O
+proteins	B-CHED
+are	O
+essential	O
+for	O
+replication	O
+per	O
+se	O
+,	O
+suggesting	O
+that	O
+these	O
+proteins	B-CHED
+are	O
+accessory	O
+proteins	B-CHED
+that	O
+may	O
+have	O
+roles	O
+in	O
+vivo	O
+.	O
+
+We	O
+found	O
+a	O
+drastic	O
+increase	O
+in	O
+caspase	B-PROC
+-	I-PROC
+8	I-PROC
+activity	I-PROC
+and	O
+cleavage	B-PROC
+of	O
+Bid	O
+at	O
+24	O
+h	O
+p	O
+.	O
+i	O
+.	O
+
+Starter	O
+intake	O
+from	O
+d	O
+1	O
+to	O
+56	O
+was	O
+reduced	O
+from	O
+919	O
+to	O
+717	O
+g	O
+/	O
+d	O
+in	O
+calves	O
+fed	O
+fixed	B-ANAT
+and	O
+variable	O
+amounts	O
+of	O
+milk	O
+replacer	O
+,	O
+respectively	O
+.	O
+
+Plasma	B-PRGE
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+-	I-PRGE
+alpha	I-PRGE
+was	O
+highest	O
+in	O
+calves	O
+with	O
+the	O
+highest	O
+plasma	B-ANAT
+IgG	B-PRGE
+concentrations	O
+on	O
+the	O
+day	O
+of	O
+arrival	O
+and	O
+might	O
+be	O
+related	O
+to	O
+the	O
+calf	B-ANAT
+'	O
+s	O
+ability	O
+to	O
+identify	O
+pathogens	O
+in	O
+the	O
+environment	O
+.	O
+
+Our	O
+patient	O
+was	O
+newly	O
+diagnosed	O
+to	O
+have	O
+autoimmune	B-DISO
+hepatitis	I-DISO
+that	O
+may	O
+have	O
+predisposed	O
+her	O
+to	O
+toxicity	O
+from	O
+corticosteroids	B-CHED
+and	O
+neuromuscular	O
+-	O
+blocking	B-DISO
+agents	O
+,	O
+but	O
+she	O
+recovered	O
+her	O
+strength	O
+completely	O
+.	O
+
+Given	O
+the	O
+apparent	O
+prevalence	O
+and	O
+underreporting	O
+of	O
+CCM	B-DISO
+in	O
+the	O
+ICU	O
+,	O
+it	O
+is	O
+important	O
+for	O
+rheumatology	O
+consultants	O
+to	O
+include	O
+this	O
+entity	O
+in	O
+their	O
+differential	O
+diagnosis	O
+of	O
+weakness	B-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+children	O
+and	O
+adults	O
+,	O
+and	O
+to	O
+recommend	O
+appropriate	O
+evaluation	O
+.	O
+
+Using	O
+consensus	O
+fold	O
+recognition	O
+with	O
+the	O
+3D	O
+-	O
+JURY	O
+meta	B-SPEC
+-	O
+predictor	O
+followed	O
+by	O
+model	O
+building	O
+and	O
+refinement	O
+,	O
+we	O
+developed	O
+a	O
+structural	O
+model	O
+for	O
+the	O
+single	O
+PLpro	O
+present	O
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SCoV	O
+)	O
+genome	O
+,	O
+based	O
+on	O
+significant	O
+structural	O
+relationships	O
+to	O
+the	O
+catalytic	O
+core	O
+domain	O
+of	O
+HAUSP	O
+,	O
+a	O
+ubiquitin	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+protease	I-PRGE
+(	O
+USP	B-FUNC
+).	O
+
+TITLE	O
+:	O
+Shrinking	B-DISO
+lung	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+14	O
+-	O
+year	O
+-	O
+old	O
+boy	O
+with	O
+systemic	B-PATH
+lupus	I-PATH
+erythematosus	I-PATH
+.	O
+
+Electron	O
+microscopy	O
+has	O
+led	O
+to	O
+the	O
+discovery	O
+of	O
+many	O
+new	O
+viruses	B-SPEC
+,	O
+most	O
+notably	O
+the	O
+various	O
+viruses	B-SPEC
+associated	O
+with	O
+gastroenteritis	B-DISO
+,	O
+for	O
+which	O
+it	O
+remained	O
+the	O
+principal	O
+diagnostic	O
+method	O
+until	O
+fairly	O
+recent	O
+times	O
+.	O
+
+The	O
+label	B-CHED
+imposes	O
+spatial	O
+constraints	O
+on	O
+the	O
+protein	B-CHED
+topology	O
+.	O
+
+A	O
+significant	O
+association	O
+was	O
+identified	O
+between	O
+an	O
+acute	O
+exposure	O
+to	O
+transfused	O
+blood	B-ANAT
+and	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+.	O
+
+A	O
+review	O
+of	O
+variant	B-DISO
+Creutzfeldt	I-DISO
+-	I-DISO
+Jakob	I-DISO
+disease	I-DISO
+is	O
+followed	O
+by	O
+a	O
+discussion	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Two	O
+articles	O
+on	O
+human	B-SPEC
+papillomavirus	I-SPEC
+(	O
+HPV	O
+)	O
+infection	B-DISO
+address	O
+the	O
+association	O
+between	O
+viral	B-DISO
+infection	I-DISO
+and	O
+neoplasia	B-DISO
+,	O
+as	O
+do	O
+reviews	O
+on	O
+viruses	B-SPEC
+and	O
+lymphoma	B-DISO
+/	O
+leukaemia	B-DISO
+,	O
+and	O
+Kaposi	B-SPEC
+'	I-SPEC
+s	I-SPEC
+sarcoma	I-SPEC
+-	I-SPEC
+associated	I-SPEC
+herpesvirus	I-SPEC
+(	O
+human	B-SPEC
+herpesvirus	I-SPEC
+8	I-SPEC
+,	O
+HHV8	B-DISO
+).	O
+
+Reviews	O
+on	O
+Helicobacter	B-SPEC
+and	O
+gastric	B-ANAT
+neoplasia	B-DISO
+,	O
+innate	O
+defences	O
+against	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	I-DISO
+MRSA	I-DISO
+)	I-DISO
+infection	I-DISO
+,	O
+and	O
+the	O
+function	O
+of	O
+granulomas	B-DISO
+in	O
+tuberculosis	B-PATH
+also	O
+address	O
+aspects	O
+of	O
+tissue	B-ANAT
+responses	O
+to	O
+bacterial	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+reviews	O
+assembled	O
+here	O
+bridge	O
+several	O
+gaps	O
+:	O
+between	O
+microbiology	O
+and	O
+cellular	B-DISO
+pathology	I-DISO
+;	O
+between	O
+host	B-COMP
+and	O
+infecting	O
+organism	O
+;	O
+and	O
+between	O
+disease	O
+and	O
+therapy	O
+.	O
+
+Specific	O
+histological	O
+changes	O
+are	O
+not	O
+detected	O
+in	O
+other	O
+organs	B-ANAT
+.	O
+
+The	O
+surveillance	O
+of	O
+Japanese	B-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+activity	O
+has	O
+been	O
+effectively	O
+conducted	O
+by	O
+using	O
+seroprevalence	O
+of	O
+pigs	B-SPEC
+for	O
+more	O
+than	O
+20	O
+years	O
+in	O
+Japan	O
+.	O
+
+Polio	B-DISO
+acute	I-DISO
+flaccid	B-DISO
+paralysis	I-DISO
+(	O
+AFP	O
+)	O
+surveillance	O
+has	O
+been	O
+also	O
+effectively	O
+conducted	O
+,	O
+although	O
+polio	B-DISO
+cases	O
+are	O
+decreasing	O
+in	O
+the	O
+world	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	O
+)	O
+was	O
+caused	O
+by	O
+a	O
+previously	O
+unrecognized	O
+new	O
+type	O
+coronavirus	B-SPEC
+.	O
+
+L	O
+-	O
+SIGN	O
+is	O
+expressed	B-PROC
+in	O
+both	O
+non	O
+-	O
+SARS	B-DISO
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+lung	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Intestinal	B-ANAT
+invasion	B-DISO
+and	O
+disseminated	O
+disease	O
+associated	O
+with	O
+Penicillium	B-SPEC
+chrysogenum	I-SPEC
+.	O
+
+Diagnosis	O
+can	O
+be	O
+difficult	O
+,	O
+but	O
+Penicillium	B-SPEC
+sp	O
+.	O
+grows	O
+rapidly	O
+on	O
+routine	O
+fungal	O
+cultures	O
+.	O
+
+Prognosis	O
+remains	O
+very	O
+poor	O
+,	O
+but	O
+aggressive	B-DISO
+treatment	O
+is	O
+essential	O
+,	O
+including	O
+surgical	O
+debridement	O
+and	O
+the	O
+removal	O
+of	O
+foci	O
+of	O
+infection	B-DISO
+along	O
+with	O
+the	O
+use	O
+of	O
+amphotericin	B-CHED
+B	I-CHED
+.	O
+The	O
+clinical	O
+utility	O
+of	O
+newer	O
+antifungal	B-CHED
+agents	I-CHED
+remains	O
+to	O
+be	O
+determined	O
+.	O
+
+Transmission	O
+chain	O
+and	O
+outbreak	O
+clusters	B-CHED
+were	O
+investigated	O
+.	O
+
+TITLE	O
+:	O
+Management	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+using	O
+pumpless	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+assays	O
+were	O
+used	O
+to	O
+retrospectively	O
+detect	O
+HCoV	O
+-	O
+NL	O
+and	O
+to	O
+correlate	O
+its	O
+presence	O
+with	O
+clinical	O
+symptoms	O
+.	O
+
+One	O
+-	O
+hundred	O
+and	O
+seventy	O
+patients	O
+met	B-CHED
+criteria	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+incidence	O
+,	O
+27	O
+%;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+24	O
+-	O
+31	O
+%).	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+was	O
+also	O
+independently	O
+associated	O
+with	O
+an	O
+increased	O
+intensive	O
+care	O
+unit	O
+length	O
+of	O
+stay	O
+(	O
+15	O
+%,	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+5	O
+-	O
+27	O
+%).	O
+
+Patients	O
+receiving	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+had	O
+worse	O
+oxygenation	B-PROC
+and	O
+higher	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+requirements	O
+compared	O
+with	O
+those	O
+who	O
+did	O
+not	O
+,	O
+but	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+arterial	B-ANAT
+pH	O
+or	O
+Pco2	O
+.	O
+
+If	O
+antiviral	B-CHED
+therapy	O
+is	O
+considered	O
+for	O
+future	O
+treatment	O
+,	O
+it	O
+should	O
+be	O
+focused	O
+on	O
+this	O
+two	O
+-	O
+week	O
+period	O
+of	O
+acute	O
+clinical	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+more	O
+and	O
+more	O
+protein	B-CHED
+sequences	O
+are	O
+available	O
+,	O
+homolog	O
+identification	O
+becomes	O
+increasingly	O
+important	O
+for	O
+functional	O
+,	O
+structural	O
+,	O
+and	O
+evolutional	O
+studies	O
+of	O
+proteins	O
+.	O
+
+However	O
+,	O
+the	O
+mechanisms	O
+evoking	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+a	O
+fulminant	O
+systemic	O
+response	O
+remain	O
+unclear	O
+.	O
+
+Fourteen	O
+hospitalized	O
+patients	O
+with	O
+a	O
+diagnosis	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+infection	B-DISO
+at	O
+National	O
+Taiwan	O
+University	O
+Hospital	O
+from	O
+March	O
+to	O
+May	O
+2003	O
+were	O
+included	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+elevation	O
+of	O
+serum	B-PRGE
+IL	I-PRGE
+-	I-PRGE
+1beta	I-PRGE
+levels	O
+in	O
+any	O
+of	O
+the	O
+14	O
+patients	O
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+peak	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+between	O
+patients	O
+with	O
+and	O
+without	O
+ARDS	B-DISO
+.	O
+
+The	O
+peak	O
+level	O
+of	O
+serum	B-PRGE
+TNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+tends	O
+to	O
+be	O
+higher	O
+in	O
+patients	O
+who	O
+die	O
+of	O
+SARS	B-DISO
+than	O
+in	O
+those	O
+who	O
+survive	O
+.	O
+
+The	O
+results	O
+also	O
+indicate	O
+that	O
+the	O
+glycyrrhizin	B-CHED
+concentrations	O
+of	O
+3	O
+-	O
+6	O
+months	O
+old	O
+pot	B-DISO
+plants	B-SPEC
+were	O
+similar	O
+or	O
+even	O
+higher	O
+than	O
+the	O
+previously	O
+reported	O
+values	O
+for	O
+3	O
+-	O
+4	O
+years	O
+old	O
+field	O
+-	O
+grown	O
+plants	B-SPEC
+and	O
+confirm	O
+that	O
+high	O
+concentration	O
+of	O
+glycyrrhizin	B-CHED
+production	O
+is	O
+possible	O
+within	O
+a	O
+very	O
+short	O
+production	O
+period	O
+under	O
+controlled	O
+environments	O
+.	O
+
+In	O
+contrast	O
+,	O
+N	O
+-	O
+GST	B-PRGE
+elicited	O
+strong	O
+T	O
+cell	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+but	O
+minimal	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+responses	O
+and	O
+a	O
+much	O
+greater	O
+antibody	B-PROC
+response	I-PROC
+.	O
+
+Despite	O
+these	O
+differences	O
+,	O
+however	O
+,	O
+the	O
+immunodominant	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+ELISpot	O
+responses	O
+to	O
+each	O
+of	O
+the	O
+three	O
+immunogens	O
+were	O
+elicited	O
+by	O
+the	O
+same	O
+N	O
+peptides	B-CHED
+,	O
+with	O
+the	O
+greatest	O
+responses	O
+being	O
+generated	O
+by	O
+a	O
+cluster	O
+of	O
+five	O
+overlapping	O
+peptides	B-CHED
+,	O
+N76	O
+-	O
+114	O
+,	O
+each	O
+of	O
+which	O
+contained	O
+nonameric	O
+H2d	O
+binding	B-FUNC
+domains	O
+with	O
+high	O
+binding	B-FUNC
+scores	O
+for	O
+both	O
+class	B-SPEC
+I	O
+and	O
+,	O
+except	O
+for	O
+N76	O
+-	O
+93	O
+,	O
+class	B-SPEC
+II	O
+alleles	O
+.	O
+
+The	O
+prohibitive	O
+cost	O
+of	O
+antiretroviral	O
+(	O
+ARV	O
+)	O
+drugs	O
+for	O
+most	O
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+in	O
+sub	O
+-	O
+Saharan	O
+Africa	O
+and	O
+the	O
+serious	O
+side	O
+effects	O
+in	O
+those	O
+who	O
+have	O
+access	O
+to	O
+ARV	O
+drugs	O
+make	O
+a	O
+compelling	O
+case	O
+for	O
+the	O
+study	O
+of	O
+complementary	O
+and	O
+alternative	O
+therapies	O
+.	O
+
+The	O
+potency	O
+and	O
+virus	B-SPEC
+specificity	O
+of	O
+the	O
+pyridine	B-CHED
+N	I-CHED
+-	I-CHED
+oxide	I-CHED
+derivatives	O
+varied	O
+depending	O
+the	O
+nature	O
+and	O
+specific	O
+location	O
+of	O
+substituents	O
+(	O
+i	O
+.	O
+e	O
+.	O
+alkyl	O
+,	O
+halogeno	O
+,	O
+nitro	B-CHED
+,	O
+etc	O
+.)	O
+on	O
+the	O
+different	O
+parts	O
+of	O
+the	O
+molecule	O
+.	O
+
+TITLE	O
+:	O
+Immunogenicity	O
+and	O
+protective	O
+efficacy	O
+in	O
+monkeys	B-SPEC
+of	O
+purified	O
+inactivated	O
+Vero	O
+-	O
+cell	B-COMP
+SARS	B-DISO
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2003	O
+,	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+resulted	O
+in	O
+hundreds	O
+of	O
+infections	B-DISO
+and	O
+deaths	B-PROC
+globally	O
+.	O
+
+The	O
+purity	O
+of	O
+SARS	B-DISO
+vaccine	O
+was	O
+97	O
+.	O
+6	O
+%	O
+by	O
+HPLC	O
+identification	O
+and	O
+reacted	O
+with	O
+convalescent	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+purified	O
+inactivated	O
+SARS	B-DISO
+vaccine	O
+could	O
+induce	O
+high	O
+levels	O
+of	O
+neutralizing	O
+antibody	B-COMP
+,	O
+and	O
+protect	O
+the	O
+monkeys	B-SPEC
+from	O
+the	O
+challenge	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+SARS	B-DISO
+vaccine	O
+prepared	O
+in	O
+the	O
+study	O
+appeared	O
+to	O
+be	O
+safe	O
+in	O
+monkeys	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Late	B-DISO
+infantile	I-DISO
+neuronal	I-DISO
+ceroid	I-DISO
+lipofuscinosis	I-DISO
+(	O
+LINCL	B-DISO
+),	O
+a	O
+pediatric	O
+autosomal	B-COMP
+recessive	O
+neurodegenerative	O
+lysosomal	B-DISO
+storage	B-PROC
+disorder	I-DISO
+,	O
+results	O
+from	O
+mutations	O
+in	O
+the	O
+CLN2	B-PRGE
+gene	I-PRGE
+and	O
+consequent	O
+deficiency	O
+in	O
+tripeptidyl	B-PRGE
+-	I-PRGE
+peptidase	I-PRGE
+I	I-PRGE
+(	O
+TPP	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+and	O
+progressive	O
+destruction	O
+of	O
+neurons	B-ANAT
+.	O
+
+Histopathological	O
+examination	O
+of	O
+the	O
+CNS	B-CHED
+demonstrated	O
+that	O
+1	O
+week	O
+after	O
+administration	O
+,	O
+AAV2	B-SPEC
+(	O
+CU	O
+)	O
+hCLN2	O
+produced	O
+transient	O
+minor	O
+white	B-ANAT
+matter	I-ANAT
+edema	B-DISO
+with	O
+reactive	O
+glial	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+corona	B-ANAT
+radiata	I-ANAT
+of	O
+the	O
+cerebrum	B-ANAT
+along	O
+the	O
+injection	O
+track	O
+and	O
+in	O
+the	O
+surrounding	O
+white	B-ANAT
+matter	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+affymetrix	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+resequencing	O
+GeneChips	O
+in	O
+characterization	O
+of	O
+the	O
+genomes	O
+of	O
+two	O
+strains	O
+of	O
+coronavirus	O
+infecting	O
+humans	B-SPEC
+.	O
+
+A	O
+number	O
+of	O
+immunologic	O
+and	O
+molecular	O
+studies	O
+of	O
+the	O
+clinical	O
+samples	O
+led	O
+to	O
+the	O
+conclusion	O
+that	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+associated	O
+with	O
+the	O
+outbreak	O
+.	O
+
+Cytokines	O
+and	O
+chemokines	O
+that	O
+best	O
+predicted	O
+the	O
+combination	O
+of	O
+acid	O
+and	O
+small	O
+gastric	B-ANAT
+particles	O
+were	O
+cytokine	O
+-	O
+induced	O
+neutrophil	B-ANAT
+chemoattractant	O
+1	O
+(	O
+6	O
+h	O
+)	O
+and	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+24	O
+h	O
+)	O
+in	O
+rats	B-SPEC
+,	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+/	O
+macrophage	B-ANAT
+inflammatory	O
+protein	B-CHED
+2	O
+(	O
+5	O
+h	O
+)	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+/	I-PRGE
+MCP	B-FUNC
+-	I-PRGE
+1	I-PRGE
+(	O
+24	O
+h	O
+)	O
+in	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+,	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+/	O
+macrophage	B-ANAT
+inflammatory	O
+protein	B-CHED
+2	O
+(	O
+5	O
+h	O
+)	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+/	O
+keratinocyte	B-ANAT
+-	O
+derived	O
+cytokine	O
+(	O
+24	O
+h	O
+)	O
+in	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(-/-)	O
+mice	B-SPEC
+.	O
+
+Most	O
+respiratory	O
+pathogens	O
+can	O
+be	O
+transmitted	B-DISO
+by	O
+more	O
+than	O
+one	O
+route	O
+.	O
+
+Recent	O
+human	B-SPEC
+investigations	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+have	O
+shown	O
+that	O
+the	O
+prone	O
+position	O
+was	O
+able	O
+to	O
+abolish	O
+tidal	O
+expiratory	B-PROC
+flow	O
+limitation	O
+,	O
+to	O
+improve	O
+oxygenation	B-PROC
+in	O
+the	O
+case	O
+of	O
+localized	O
+infiltrates	B-DISO
+,	O
+to	O
+allow	O
+for	O
+reducing	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+level	O
+,	O
+and	O
+to	O
+reduce	O
+lung	B-ANAT
+stress	O
+and	O
+strain	O
+.	O
+
+Because	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+has	O
+been	O
+reported	O
+to	O
+play	B-DISO
+roles	I-DISO
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+the	O
+present	O
+study	O
+explores	O
+the	O
+effects	O
+on	O
+VILI	O
+of	O
+NO	O
+derived	O
+from	O
+chronically	O
+overexpressed	O
+endothelial	B-PRGE
+nitric	B-CHED
+oxide	I-CHED
+synthase	I-PRGE
+(	O
+eNOS	B-PRGE
+).	O
+
+In	O
+conclusion	O
+,	O
+chronic	O
+eNOS	O
+overexpression	B-PROC
+may	O
+protect	O
+the	O
+lung	B-ANAT
+from	O
+VILI	O
+by	O
+inhibiting	O
+the	O
+production	O
+of	O
+inflammatory	O
+chemokines	O
+and	O
+cytokines	O
+that	O
+are	O
+associated	O
+with	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+into	O
+the	O
+air	B-CHED
+space	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+the	O
+growing	O
+potential	O
+of	O
+an	O
+influenza	B-DISO
+pandemic	O
+force	O
+us	O
+to	O
+consider	O
+the	O
+fact	O
+that	O
+despite	O
+great	O
+advances	O
+in	O
+critical	O
+care	O
+medicine	B-CHED
+,	O
+we	O
+lack	O
+the	O
+capacity	O
+to	O
+provide	O
+intensive	O
+care	O
+to	O
+the	O
+large	O
+number	O
+of	O
+patients	O
+that	O
+may	O
+be	O
+generated	O
+in	O
+an	O
+epidemic	O
+or	O
+multisite	O
+bioterrorism	O
+event	O
+.	O
+
+A	O
+digital	B-ANAT
+ring	O
+fence	O
+is	O
+constructed	O
+around	O
+each	O
+location	O
+(	O
+hot	O
+-	O
+spot	B-SPEC
+)	O
+using	O
+Non	O
+-	O
+Homogeneous	O
+Poisson	O
+Process	O
+(	O
+NHPP	O
+)	O
+modeling	O
+based	O
+on	O
+data	O
+of	O
+individuals	O
+coming	O
+into	O
+contact	O
+with	O
+each	O
+probable	O
+case	O
+.	O
+
+RESULTS	O
+:	O
+Simulation	O
+studies	O
+have	O
+demonstrated	O
+that	O
+the	O
+DRiF	O
+strategy	O
+could	O
+provide	O
+a	O
+novel	O
+approach	O
+to	O
+containment	O
+of	O
+acute	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+short	O
+review	O
+article	O
+on	O
+some	O
+pertinent	O
+observations	O
+in	O
+the	O
+unfolding	O
+story	O
+of	O
+interferon	B-PRGE
+is	O
+dedicated	O
+to	O
+Professor	O
+Ilona	O
+Béládi	O
+on	O
+the	O
+occasion	O
+of	O
+her	O
+80th	O
+birthday	O
+.	O
+
+Additionally	O
+,	O
+for	O
+the	O
+genome	O
+of	O
+Amsacta	B-SPEC
+moorei	I-SPEC
+entomopoxvirus	I-SPEC
+,	O
+probably	O
+with	O
+the	O
+lowest	O
+genomic	O
+GC	O
+content	O
+among	O
+the	O
+sequenced	O
+organisms	O
+,	O
+the	O
+accuracy	O
+of	O
+ZCURVE_V	O
+is	O
+much	O
+better	O
+than	O
+that	O
+of	O
+GeneMark	O
+,	O
+because	O
+the	O
+later	O
+predicts	O
+hundreds	O
+of	O
+false	O
+-	O
+positive	O
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+Vascular	B-ANAT
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PRGE
+(	O
+VEGF	O
+)	O
+is	O
+a	O
+pluripotent	O
+growth	B-PROC
+and	O
+permeability	O
+factor	O
+that	O
+has	O
+a	O
+broad	O
+impact	O
+on	O
+endothelial	B-ANAT
+cell	I-ANAT
+function	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+IBV	B-SPEC
+-	O
+H120	O
+vaccination	O
+in	O
+broilers	O
+on	O
+colibacillosis	B-DISO
+susceptibility	O
+after	O
+infection	B-DISO
+with	O
+a	O
+virulent	O
+Massachusetts	O
+-	O
+type	O
+IBV	O
+strain	O
+.	O
+
+IBV	B-SPEC
+vaccination	O
+reduced	O
+both	O
+the	O
+number	O
+of	O
+broilers	O
+with	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+airsacculitis	B-DISO
+as	O
+well	O
+as	O
+the	O
+severity	O
+of	O
+airsacculitis	O
+significantly	O
+after	O
+challenge	O
+with	O
+IBV	B-SPEC
+-	O
+M41	O
+and	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+506	O
+.	O
+
+The	O
+data	O
+were	O
+obtained	O
+from	O
+clinical	O
+samples	O
+submitted	O
+to	O
+our	O
+laboratory	O
+from	O
+birds	B-SPEC
+with	O
+clinical	O
+signs	O
+characteristic	O
+of	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+Ark	B-PRGE
+-	O
+like	O
+isolates	O
+,	O
+defined	O
+as	O
+having	O
+a	O
+similar	O
+but	O
+unique	O
+RFLP	O
+pattern	O
+from	O
+the	O
+Ark	B-PRGE
+-	I-PRGE
+DPI	I-PRGE
+vaccine	O
+strain	O
+were	O
+identified	O
+every	O
+year	O
+of	O
+the	O
+study	O
+except	O
+in	O
+1996	O
+.	O
+
+Our	O
+observations	O
+highlight	O
+the	O
+importance	O
+of	O
+constantly	O
+monitoring	O
+IBV	B-SPEC
+as	O
+well	O
+as	O
+other	O
+coronaviruses	O
+like	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+that	O
+have	O
+the	O
+ability	O
+to	O
+change	O
+and	O
+emerge	O
+to	O
+cause	O
+disease	O
+in	O
+a	O
+susceptible	O
+host	B-COMP
+.	O
+
+For	O
+example	O
+,	O
+infliximab	O
+,	O
+a	O
+monoclonal	O
+TNF	B-PRGE
+antibody	I-PRGE
+,	O
+was	O
+experimentally	O
+tested	O
+in	O
+rats	B-SPEC
+and	O
+it	O
+was	O
+able	O
+to	O
+significantly	O
+reduce	O
+the	O
+pathologic	O
+score	O
+and	O
+serum	B-COMP
+amylase	B-FUNC
+activity	I-FUNC
+,	O
+and	O
+also	O
+alleviate	O
+alveolar	B-DISO
+edema	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+no	O
+studies	O
+are	O
+available	O
+in	O
+clinical	O
+human	B-SPEC
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Some	O
+of	O
+the	O
+vacuoles	B-COMP
+contained	O
+folded	O
+membranous	B-ANAT
+structures	O
+along	O
+with	O
+virions	B-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+study	O
+of	O
+pulmonary	B-ANAT
+inflammatory	B-DISO
+reaction	I-DISO
+induced	O
+by	O
+N	O
+-	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+rat	B-SPEC
+models	O
+and	O
+effects	O
+of	O
+glucocorticoids	O
+on	O
+it	O
+].	O
+
+The	O
+blood	B-ANAT
+samples	I-ANAT
+,	O
+bronchial	B-ANAT
+alveolar	I-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+)	O
+and	O
+lung	B-ANAT
+tissue	I-ANAT
+were	O
+collected	O
+after	O
+challenge	O
+.	O
+
+The	O
+cytological	O
+and	O
+histopathologic	O
+changes	O
+of	O
+lung	B-ANAT
+tissues	I-ANAT
+were	O
+observed	O
+and	O
+the	O
+wet	O
+/	O
+dry	O
+ratios	O
+(	O
+W	O
+/	O
+D	O
+)	O
+of	O
+lung	B-ANAT
+tissue	I-ANAT
+were	O
+determined	O
+.	O
+
+(	O
+2	O
+)	O
+Compared	O
+with	O
+the	O
+total	O
+WBC	B-ANAT
+of	O
+BALF	O
+in	O
+Nc	O
+group	O
+[(	O
+95	O
++/-	O
+29	O
+)	O
+x	O
+10	O
+(	O
+7	O
+)],	O
+that	O
+in	O
+P2	O
+group	O
+[(	O
+160	O
++/-	O
+60	O
+)	O
+x	O
+10	O
+(	O
+7	O
+)]	O
+was	O
+significantly	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+);	O
+but	O
+compared	O
+with	O
+P2	O
+group	O
+,	O
+that	O
+in	O
+P	O
++	O
+D	O
+group	O
+[(	O
+62	O
++/-	O
+23	O
+)	O
+x	O
+10	O
+(	O
+7	O
+)]	O
+was	O
+significantly	O
+decreased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+(	O
+4	O
+)	O
+Compared	O
+with	O
+Nc	O
+group	O
+,	O
+the	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+in	O
+both	O
+serum	B-COMP
+and	O
+BALF	O
+of	O
+P1	O
+group	O
+were	O
+significantly	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+and	O
+the	O
+levels	O
+of	O
+these	O
+cytokines	O
+in	O
+P2	O
+group	O
+were	O
+significantly	O
+higher	O
+than	O
+those	O
+in	O
+P1	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+but	O
+significantly	O
+lower	O
+in	O
+P	O
++	O
+D	O
+group	O
+compared	O
+with	O
+P2	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+(	O
+4	O
+)	O
+Compared	O
+with	O
+Nc	O
+group	O
+,	O
+the	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+in	O
+both	O
+serum	B-COMP
+and	O
+BALF	O
+of	O
+P1	O
+group	O
+were	O
+significantly	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+and	O
+the	O
+levels	O
+of	O
+these	O
+cytokines	O
+in	O
+P2	O
+group	O
+were	O
+significantly	O
+higher	O
+than	O
+those	O
+in	O
+P1	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+but	O
+significantly	O
+lower	O
+in	O
+P	O
++	O
+D	O
+group	O
+compared	O
+with	O
+P2	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+:	O
+clinical	O
+presentation	O
+,	O
+transmission	O
+,	O
+pathogenesis	B-DISO
+and	O
+treatment	O
+options	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+appeared	O
+as	O
+the	O
+first	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+of	O
+this	O
+century	O
+.	O
+
+How	O
+the	O
+virus	B-SPEC
+has	O
+successfully	O
+jumped	O
+the	O
+species	B-SPEC
+barrier	O
+is	O
+still	O
+a	O
+mystery	O
+.	O
+
+The	O
+superspreading	O
+events	O
+that	O
+occurred	O
+within	O
+hospital	O
+,	O
+hotel	O
+and	O
+high	O
+-	O
+density	O
+housing	O
+estate	O
+opens	O
+a	O
+new	O
+chapter	O
+in	O
+the	O
+mechanisms	O
+and	O
+routes	O
+of	O
+virus	B-SPEC
+transmission	O
+.	O
+
+Proc	O
+Natl	O
+Acad	B-DISO
+Sci	O
+U	O
+.	O
+S	O
+.	O
+A	O
+.	O
+58	O
+,	O
+2268	O
+-	O
+73	O
+].	O
+
+The	O
+surface	O
+glycoprotein	B-CHED
+is	O
+a	O
+major	O
+virulence	B-PROC
+factor	O
+in	O
+most	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+HPS	B-DISO
+has	O
+a	O
+mortality	O
+rate	O
+of	O
+40	O
+%	O
+and	O
+,	O
+unlike	O
+many	O
+other	O
+severe	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+often	O
+occurs	O
+in	O
+young	O
+,	O
+healthy	O
+adults	O
+.	O
+
+There	O
+is	O
+no	O
+obvious	O
+cytopathology	O
+associated	O
+with	O
+infection	B-DISO
+,	O
+and	O
+beta	B-PRGE
+(	I-PRGE
+3	I-PRGE
+)	I-PRGE
+integrins	I-PRGE
+do	O
+not	O
+appear	O
+to	O
+be	O
+critical	O
+for	O
+respiratory	O
+epithelial	B-ANAT
+cell	I-ANAT
+monolayer	O
+integrity	O
+.	O
+
+Preincubation	O
+of	O
+MHV	B-SPEC
+with	O
+the	O
+adapter	O
+proteins	B-CHED
+and	O
+subsequent	O
+inoculation	O
+of	O
+human	B-SPEC
+cells	B-COMP
+expressing	O
+an	O
+artificial	O
+His	O
+receptor	O
+resulted	O
+in	O
+infection	B-DISO
+of	O
+these	O
+otherwise	O
+nonsusceptible	O
+cells	B-COMP
+and	O
+led	O
+to	O
+subsequent	O
+production	O
+of	O
+progeny	O
+virus	B-SPEC
+.	O
+
+When	O
+inoculated	O
+onto	O
+murine	B-SPEC
+LR7	B-ANAT
+cells	B-COMP
+,	O
+the	O
+resulting	O
+recombinant	O
+virus	B-SPEC
+indeed	O
+expressed	B-PROC
+the	O
+adapter	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Palmitoylations	O
+on	O
+murine	B-SPEC
+coronavirus	I-SPEC
+spike	O
+proteins	B-CHED
+are	O
+essential	O
+for	O
+virion	B-PROC
+assembly	I-PROC
+and	O
+infectivity	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+are	O
+palmitoylated	O
+at	O
+several	O
+cysteine	B-CHED
+residues	O
+clustered	O
+near	O
+their	O
+transmembrane	B-COMP
+-	O
+spanning	O
+domains	O
+.	O
+
+2	O
+-	O
+BP	O
+effected	O
+only	O
+two	O
+-	O
+to	O
+fivefold	O
+reductions	O
+in	O
+S	O
+palmitoylation	B-PROC
+,	O
+yet	O
+this	O
+correlated	O
+with	O
+reduced	O
+S	O
+complexing	O
+with	O
+virion	B-COMP
+membrane	I-COMP
+(	O
+M	O
+)	O
+proteins	B-CHED
+and	O
+consequent	O
+exclusion	O
+of	O
+S	O
+from	O
+virions	B-COMP
+.	O
+
+At	O
+defined	O
+2	O
+-	O
+BP	O
+doses	O
+,	O
+underpalmitoylated	O
+S	O
+proteins	O
+instead	O
+trafficked	B-PROC
+to	O
+infected	O
+cell	B-COMP
+surfaces	O
+and	O
+elicited	O
+cell	B-COMP
+-	O
+cell	B-COMP
+membrane	I-COMP
+fusions	O
+,	O
+suggesting	O
+that	O
+the	O
+acyl	O
+chain	O
+adducts	O
+are	O
+more	O
+critical	O
+to	O
+virion	B-PROC
+assembly	I-PROC
+than	O
+to	O
+S	O
+-	O
+induced	O
+syncytial	O
+developments	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+responsible	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+activity	O
+of	O
+S	O
+was	O
+monitored	O
+by	O
+a	O
+Renilla	B-SPEC
+luciferase	B-ENZY
+-	O
+based	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+assay	O
+.	O
+
+S	O
+(	O
+VSV	O
+-	O
+Cyt	B-CHED
+),	O
+an	O
+S	O
+chimera	B-DISO
+with	O
+a	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+derived	O
+from	O
+vesicular	B-PRGE
+stomatitis	I-PRGE
+virus	I-PRGE
+G	I-PRGE
+protein	B-CHED
+(	O
+VSV	O
+-	O
+G	O
+),	O
+and	O
+S	O
+(	O
+MHV	B-SPEC
+-	O
+TMDCyt	O
+),	O
+an	O
+S	O
+chimera	B-DISO
+with	O
+the	O
+cytoplasmic	B-COMP
+and	O
+transmembrane	B-COMP
+domains	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+displayed	O
+wild	B-PRGE
+-	I-PRGE
+type	I-PRGE
+-	I-PRGE
+like	I-PRGE
+activity	O
+in	O
+both	O
+assays	O
+.	O
+
+Coronavirus	B-DISO
+infection	I-DISO
+of	O
+the	O
+murine	B-SPEC
+CNS	B-CHED
+illustrates	O
+the	O
+contributions	O
+of	O
+both	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+and	O
+specific	O
+host	B-COMP
+effector	B-CHED
+mechanisms	O
+that	O
+control	O
+virus	B-PROC
+replication	I-PROC
+in	O
+distinct	O
+CNS	B-CHED
+cell	B-COMP
+types	O
+.	O
+
+The	O
+NIH	B-ANAT
+3T3	I-ANAT
+cell	I-ANAT
+,	O
+a	O
+non	O
+-	O
+permissive	O
+cell	B-ANAT
+line	I-ANAT
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+was	O
+used	O
+as	O
+controls	O
+.	O
+
+The	O
+appropriate	O
+expression	B-PROC
+of	O
+the	O
+proteins	B-CHED
+was	O
+confirmed	O
+by	O
+Western	O
+blotting	O
+using	O
+both	O
+SARS	B-DISO
+patients	O
+'	O
+sera	B-COMP
+and	O
+anti	O
+-	O
+6	O
+x	O
+histidine	B-CHED
+antibody	B-COMP
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+S260	O
+-	O
+600	O
+protein	B-CHED
+did	O
+not	O
+bind	B-FUNC
+NIH3T3	O
+cells	B-COMP
+.	O
+
+The	O
+S260	O
+-	O
+600	O
+fragment	O
+probably	O
+contains	O
+the	O
+important	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+and	O
+could	O
+be	O
+a	O
+potential	O
+candidate	O
+for	O
+the	O
+development	B-PROC
+of	O
+SARS	B-DISO
+vaccine	O
+and	O
+anti	O
+-	O
+SARS	B-DISO
+therapeutics	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+recombinant	O
+proteins	B-CHED
+S260	O
+-	O
+600	O
+and	O
+S397	O
+-	O
+796	O
+were	O
+efficiently	O
+expressed	B-PROC
+in	O
+an	O
+insoluble	O
+form	O
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+Lithium	B-CHED
+may	O
+help	O
+correct	O
+a	O
+chemical	O
+imbalance	B-DISO
+in	O
+the	O
+brain	B-ANAT
+;	O
+however	O
+,	O
+it	O
+has	O
+a	O
+comparatively	O
+narrow	O
+therapeutic	O
+index	O
+.	O
+
+Here	O
+we	O
+present	O
+a	O
+forty	O
+-	O
+two	O
+-	O
+year	O
+-	O
+old	O
+Caucasian	O
+female	O
+with	O
+altered	B-DISO
+mental	I-DISO
+status	I-DISO
+,	O
+inability	O
+to	O
+eat	B-PROC
+,	O
+speak	O
+or	O
+walk	O
+properly	O
+,	O
+with	O
+shaking	B-DISO
+and	O
+vomiting	B-DISO
+for	O
+three	O
+days	O
+.	O
+
+In	O
+the	O
+meantime	O
+the	O
+patient	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+,	O
+was	O
+intubated	O
+on	O
+clinical	O
+grounds	O
+and	O
+was	O
+transferred	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+capacity	O
+of	O
+the	O
+surface	O
+glycoproteins	B-CHED
+of	O
+enveloped	O
+viruses	B-SPEC
+to	O
+mediate	O
+virus	B-SPEC
+/	O
+cell	B-COMP
+binding	B-FUNC
+and	O
+membrane	B-PROC
+fusion	I-PROC
+requires	O
+a	O
+proper	O
+thiol	B-CHED
+/	O
+disulfide	B-CHED
+balance	B-PROC
+.	O
+
+Chemical	O
+manipulation	O
+of	O
+their	O
+redox	B-PROC
+state	I-PROC
+using	O
+reducing	B-CHED
+agents	I-CHED
+or	O
+free	O
+sulfhydryl	O
+reagents	B-CHED
+affects	O
+virus	B-SPEC
+/	O
+cell	B-PROC
+interaction	I-PROC
+.	O
+
+Thus	O
+,	O
+in	O
+contrast	O
+to	O
+various	O
+viruses	B-SPEC
+including	O
+HIV	B-DISO
+(	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+)	O
+examined	O
+in	O
+parallel	O
+,	O
+the	O
+functions	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Spike	I-PRGE
+glycoprotein	B-CHED
+exhibit	O
+a	O
+significant	O
+and	O
+surprising	O
+independence	O
+of	O
+redox	B-PROC
+state	I-PROC
+,	O
+which	O
+may	O
+contribute	O
+to	O
+the	O
+wide	O
+host	B-COMP
+range	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+The	O
+children	O
+selected	O
+the	O
+physician	O
+in	O
+SARS	B-DISO
+standard	O
+precautions	O
+attire	O
+as	O
+most	O
+liked	O
+17	O
+.	O
+5	O
+%	O
+of	O
+the	O
+time	O
+and	O
+least	O
+liked	O
+53	O
+.	O
+3	O
+%	O
+of	O
+the	O
+time	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+may	O
+be	O
+severe	O
+.	O
+
+In	O
+addition	O
+,	O
+HCMV	O
+was	O
+detected	O
+in	O
+association	O
+with	O
+a	O
+respiratory	O
+virus	B-SPEC
+in	O
+4	O
+/	O
+18	O
+HCMV	O
+-	O
+positive	O
+patients	O
+,	O
+and	O
+was	O
+found	O
+at	O
+a	O
+high	O
+concentration	O
+(>	O
+10	O
+(	O
+5	O
+)	O
+DNA	O
+copies	O
+/	O
+ml	O
+)	O
+in	O
+3	O
+/	O
+16	O
+(	O
+18	O
+.	O
+7	O
+%)	O
+patients	O
+with	O
+HCMV	O
+-	O
+positive	O
+bronchoalveolar	O
+lavage	O
+samples	O
+and	O
+pneumonia	B-DISO
+.	O
+
+Respiratory	B-DISO
+syncytial	I-DISO
+virus	I-DISO
+pneumonia	I-DISO
+should	O
+also	O
+be	O
+suspected	O
+during	O
+the	O
+winter	O
+in	O
+patients	O
+with	O
+coryza	B-DISO
+,	O
+wheezing	B-DISO
+,	O
+low	O
+-	O
+grade	O
+fever	B-PROC
+,	O
+and	O
+patchy	O
+infiltrates	B-DISO
+,	O
+especially	O
+if	O
+negative	O
+for	O
+influenza	B-DISO
+on	O
+rapid	O
+testing	O
+.	O
+
+Because	O
+clinical	O
+features	O
+and	O
+periods	O
+of	O
+activity	O
+for	O
+many	O
+viruses	B-SPEC
+overlap	O
+,	O
+laboratory	O
+confirmation	O
+of	O
+influenza	B-DISO
+is	O
+recommended	O
+for	O
+cases	O
+involving	O
+seriously	O
+ill	B-DISO
+or	O
+institutionalized	O
+patients	O
+.	O
+
+Selected	O
+breeding	B-PROC
+pairs	O
+of	O
+the	O
+affected	O
+lines	O
+were	O
+divided	O
+into	O
+four	O
+treatment	O
+groups	O
+:	O
+1	O
+)	O
+transfer	O
+of	O
+embryos	B-ANAT
+to	O
+pseudopregnant	O
+B6D2F1	O
+female	O
+mice	B-SPEC
+,	O
+2	O
+)	O
+fostering	O
+offspring	O
+to	O
+B6D2F1	O
+dams	O
+,	O
+3	O
+)	O
+fostering	O
+offspring	O
+to	O
+a	O
+different	O
+dam	O
+of	O
+the	O
+same	O
+line	O
+,	O
+and	O
+4	O
+)	O
+offspring	O
+raised	O
+by	O
+the	O
+birth	B-PROC
+dam	O
+.	O
+
+Fostering	O
+significantly	O
+reduced	O
+the	O
+stimulant	O
+response	B-PROC
+to	I-PROC
+ethanol	I-PROC
+of	O
+only	O
+one	O
+mouse	B-SPEC
+line	O
+selectively	O
+bred	O
+for	O
+high	O
+sensitivity	O
+to	O
+ethanol	B-CHED
+-	O
+induced	O
+stimulation	O
+,	O
+although	O
+the	O
+stimulant	O
+response	O
+of	O
+the	O
+fostered	O
+groups	O
+was	O
+still	O
+quite	O
+robust	O
+.	O
+
+Several	O
+studies	O
+have	O
+shown	O
+that	O
+there	O
+exists	O
+an	O
+interaction	O
+between	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+and	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+.	O
+
+ROC	O
+curve	O
+areas	O
+were	O
+largest	O
+for	O
+an	O
+N	O
+-	O
+terminal	O
+fragment	O
+of	O
+complement	O
+C3c	O
+alpha	O
+chain	O
+(	O
+m	O
+/	O
+z	O
+28	O
+119	O
+)	O
+and	O
+an	O
+internal	O
+fragment	O
+of	O
+fibrinogen	B-PRGE
+alpha	I-PRGE
+-	O
+E	O
+chain	O
+(	O
+m	O
+/	O
+z	O
+5908	O
+).	O
+
+Specific	O
+proteomic	O
+fingerprints	O
+in	O
+the	O
+sera	B-COMP
+of	O
+adult	O
+SARS	B-DISO
+patients	O
+could	O
+be	O
+used	O
+to	O
+identify	O
+SARS	B-DISO
+cases	O
+early	O
+during	O
+onset	O
+with	O
+high	O
+specificity	O
+and	O
+sensitivity	O
+.	O
+
+TITLE	O
+:	O
+Exploratory	O
+study	O
+on	O
+psychosocial	O
+impact	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+on	O
+Chinese	O
+students	O
+living	O
+in	O
+Japan	O
+.	O
+
+The	O
+results	O
+showed	O
+approximately	O
+60	O
+%	O
+(	O
+96	O
+/	O
+161	O
+)	O
+of	O
+the	O
+respondents	O
+felt	O
+an	O
+impact	O
+of	O
+SARS	B-DISO
+on	O
+college	O
+life	O
+;	O
+they	O
+had	O
+experienced	O
+SARS	B-DISO
+-	O
+related	O
+fear	O
+,	O
+worry	O
+,	O
+depression	B-DISO
+as	O
+well	O
+as	O
+social	O
+discrimination	O
+and	O
+had	O
+taken	O
+SARS	B-DISO
+prevention	O
+measures	O
+for	O
+daily	O
+protection	O
+in	O
+Japan	O
+during	O
+the	O
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+Learning	B-PROC
+to	O
+respect	O
+a	O
+patient	O
+'	O
+s	O
+spiritual	O
+needs	O
+concerning	O
+an	O
+unknown	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+article	O
+also	O
+gives	O
+an	O
+overview	O
+of	O
+the	O
+2003	O
+SARS	B-DISO
+epidemic	O
+in	O
+Taiwan	O
+,	O
+and	O
+discusses	O
+people	O
+'	O
+s	O
+general	O
+perceptions	O
+towards	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+their	O
+coping	O
+strategies	O
+concerning	O
+disease	O
+,	O
+and	O
+their	O
+spiritual	O
+beliefs	O
+,	O
+the	O
+psychological	B-DISO
+impact	O
+of	O
+the	O
+2003	O
+SARS	B-DISO
+outbreak	O
+in	O
+Chinese	O
+communities	O
+,	O
+Chinese	O
+myths	O
+about	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+and	O
+the	O
+religious	O
+activities	O
+of	O
+a	O
+SARS	B-DISO
+-	O
+infected	O
+intern	O
+in	O
+Taiwan	O
+.	O
+
+There	O
+is	O
+a	O
+wide	O
+range	O
+of	O
+options	O
+for	O
+processing	O
+plant	B-SPEC
+tissues	B-ANAT
+to	O
+allow	O
+for	O
+oral	B-ANAT
+delivery	O
+of	O
+a	O
+palatable	O
+product	O
+.	O
+
+Coexpression	O
+of	O
+E2F1	B-PRGE
+under	O
+such	O
+conditions	O
+could	O
+restore	O
+the	O
+expression	B-PROC
+of	O
+S	B-PROC
+phase	I-PROC
+genes	O
+.	O
+
+Whereas	O
+N	B-PRGE
+protein	I-PRGE
+could	O
+directly	O
+bind	B-FUNC
+to	O
+cyclin	B-PRGE
+D	I-PRGE
+and	O
+inhibit	O
+the	O
+activity	O
+of	O
+CDK4	B-PRGE
+-	O
+cyclin	B-PRGE
+D	I-PRGE
+complex	I-PRGE
+;	O
+inhibition	B-PROC
+of	O
+CDK2	B-PRGE
+activity	O
+appeared	O
+to	O
+be	O
+achieved	O
+in	O
+two	O
+different	O
+ways	O
+:	O
+indirectly	O
+by	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+protein	B-CHED
+levels	O
+of	O
+CDK2	B-PRGE
+,	O
+cyclin	B-PRGE
+E	I-PRGE
+,	O
+and	O
+cyclin	B-PRGE
+A	I-PRGE
+and	O
+by	O
+direct	O
+binding	B-FUNC
+of	O
+N	B-PRGE
+protein	I-PRGE
+to	O
+CDK2	B-PRGE
+-	O
+cyclin	B-FUNC
+complex	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+3a	O
+protein	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+is	O
+expressed	B-PROC
+and	O
+transported	O
+to	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+in	O
+tissue	B-ANAT
+cells	B-COMP
+of	O
+infected	O
+patients	O
+.	O
+
+RNA	B-PROC
+interference	I-PROC
+induced	O
+by	O
+small	O
+interfering	O
+RNA	O
+can	O
+inhibit	O
+the	O
+expression	B-PROC
+of	O
+viral	O
+antigens	B-CHED
+and	O
+so	O
+provides	O
+a	O
+new	O
+approach	O
+to	O
+the	O
+therapy	O
+of	O
+pathogenic	O
+viruses	B-SPEC
+.	O
+
+Although	O
+most	O
+of	O
+the	O
+PPE	B-CHED
+do	O
+not	O
+confer	O
+absolute	O
+protection	O
+against	O
+SARS	B-DISO
+,	O
+it	O
+seems	O
+that	O
+they	O
+may	O
+lower	O
+exposure	O
+to	O
+the	O
+virus	O
+,	O
+leading	O
+to	O
+a	O
+lower	O
+risk	O
+of	O
+secondary	B-DISO
+transmission	I-DISO
+,	O
+and	O
+be	O
+associated	O
+with	O
+relatively	O
+mild	O
+disease	O
+and	O
+a	O
+better	O
+early	O
+outcome	O
+.	O
+
+Three	O
+catheter	O
+positions	O
+have	O
+been	O
+described	O
+as	O
+safe	O
+when	O
+radiologically	O
+confirmed	O
+:	O
+the	O
+superior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+,	O
+the	O
+point	O
+where	O
+the	O
+superior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+meets	O
+the	O
+atrium	B-ANAT
+,	O
+and	O
+the	O
+midpoint	O
+of	O
+the	O
+innominate	B-ANAT
+vein	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+,	O
+which	O
+first	O
+appeared	O
+in	O
+Foshan	O
+City	O
+,	O
+China	O
+on	O
+22	O
+December	O
+2002	O
+.	O
+
+TITLE	O
+:	O
+CNS	B-ANAT
+viral	B-DISO
+infection	I-DISO
+diverts	O
+homing	O
+of	O
+antibody	B-ANAT
+-	I-ANAT
+secreting	B-PROC
+cells	B-COMP
+from	O
+lymphoid	B-ANAT
+organs	I-ANAT
+to	O
+the	O
+CNS	B-ANAT
+.	O
+
+Virus	B-SPEC
+-	O
+specific	O
+ASC	O
+within	O
+the	O
+CNS	B-CHED
+peaked	O
+rapidly	O
+1	O
+wk	O
+after	O
+control	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+and	O
+were	O
+retained	O
+throughout	O
+chronic	B-DISO
+infection	I-DISO
+,	O
+consistent	O
+with	O
+intrathecal	B-ANAT
+Ab	O
+synthesis	B-PROC
+.	O
+
+The	O
+data	O
+suggest	O
+that	O
+CNS	O
+infection	O
+provides	O
+strong	O
+stimuli	O
+to	O
+recruit	O
+ASC	B-PRGE
+into	O
+the	O
+inflamed	O
+tissue	B-ANAT
+through	O
+sustained	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+the	O
+CXCR3	B-PRGE
+ligands	O
+CXCL9	B-PRGE
+and	O
+CXCL10	B-PRGE
+.	O
+
+Liver	B-ANAT
+tissues	I-ANAT
+were	O
+obtained	O
+from	O
+23	O
+patients	O
+with	O
+severe	O
+acute	O
+chronic	O
+(	O
+AOC	O
+)	O
+hepatitis	B-DISO
+B	I-DISO
+and	O
+13	O
+patients	O
+with	O
+mild	O
+chronic	B-DISO
+hepatitis	I-DISO
+B	I-DISO
+.	O
+Fourteen	O
+patients	O
+with	O
+mild	O
+chronic	B-DISO
+hepatitis	I-DISO
+B	I-DISO
+with	O
+cirrhosis	B-DISO
+and	O
+4	O
+liver	B-ANAT
+donors	O
+served	O
+as	O
+normal	O
+controls	O
+.	O
+
+In	O
+addition	O
+,	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMC	O
+)	O
+were	O
+isolated	O
+from	O
+30	O
+patients	O
+(	O
+unpaired	O
+)	O
+with	O
+severe	O
+AOC	O
+hepatitis	B-DISO
+B	I-DISO
+and	O
+10	O
+healthy	O
+volunteers	O
+as	O
+controls	O
+.	O
+
+Liver	B-ANAT
+tissues	I-ANAT
+from	O
+the	O
+patients	O
+with	O
+severe	O
+AOC	O
+hepatitis	B-DISO
+B	I-DISO
+had	O
+classical	O
+pathological	O
+features	O
+of	O
+acute	O
+necroinflammation	O
+.	O
+
+There	O
+was	O
+a	O
+positive	O
+correlation	O
+between	O
+hfgl2	O
+expression	B-PROC
+and	O
+the	O
+severity	O
+of	O
+the	O
+liver	B-DISO
+disease	I-DISO
+as	O
+indicated	O
+by	O
+the	O
+levels	O
+of	O
+TBil	O
+.	O
+
+PCA	B-DISO
+significantly	O
+increased	O
+in	O
+PBMC	O
+in	O
+patients	O
+with	O
+severe	O
+AOC	O
+hepatitis	B-DISO
+B	I-DISO
+.	O
+CONCLUSIONS	O
+:	O
+The	O
+molecular	O
+and	O
+cellular	B-COMP
+results	O
+reported	O
+here	O
+in	O
+both	O
+mice	B-SPEC
+and	O
+patients	O
+with	O
+severe	O
+viral	B-DISO
+hepatitis	I-DISO
+suggest	O
+that	O
+virus	B-SPEC
+-	O
+induced	O
+hfgl2	O
+prothrombinase	B-PRGE
+/	O
+fibroleukin	B-PRGE
+expression	B-PROC
+and	O
+the	O
+coagulation	B-PROC
+activity	O
+associated	O
+with	O
+the	O
+encoded	O
+fgl2	B-PRGE
+protein	I-PRGE
+play	O
+a	O
+pivotal	O
+role	O
+in	O
+initiating	O
+severe	O
+hepatitis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Immunomodulatory	O
+effects	O
+of	O
+a	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+with	O
+potential	O
+antiviral	B-CHED
+activity	O
+:	O
+a	O
+self	O
+-	O
+control	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Traditional	O
+Chinese	O
+medicine	O
+(	O
+TCM	O
+)	O
+has	O
+been	O
+used	O
+for	O
+prevention	O
+and	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Hong	O
+Kong	O
+during	O
+the	O
+outbreak	O
+in	O
+spring	O
+2003	O
+.	O
+
+Thirty	O
+-	O
+seven	O
+healthy	O
+volunteers	O
+were	O
+given	O
+the	O
+oral	B-ANAT
+TCM	O
+regimen	O
+daily	O
+for	O
+14	O
+days	O
+.	O
+
+Peripheral	O
+venous	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+taken	O
+on	O
+days	O
+0	O
+,	O
+15	O
+and	O
+29	O
+for	O
+hematology	O
+,	O
+biochemistry	O
+and	O
+immunology	O
+tests	O
+,	O
+including	O
+the	O
+measurement	O
+of	O
+blood	B-ANAT
+lymphocyte	B-ANAT
+subsets	O
+and	O
+plasma	B-ANAT
+T	B-ANAT
+-	I-ANAT
+helper	I-ANAT
+lymphocyte	I-ANAT
+types	O
+1	O
+and	O
+2	O
+cytokines	O
+and	O
+receptor	O
+.	O
+
+ABSTRACT	O
+:	O
+By	O
+using	O
+lambda	O
+-	O
+lysogen	O
+as	O
+a	O
+model	O
+,	O
+the	O
+inhibitory	O
+effects	O
+of	O
+anti	O
+-	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+traditional	O
+Chinese	O
+medicines	O
+(	O
+TCMs	O
+)	O
+prescription	O
+I	O
+on	O
+the	O
+UV	O
+irradiation	O
+were	O
+investigated	O
+in	O
+this	O
+present	O
+study	O
+.	O
+
+It	O
+was	O
+found	O
+that	O
+the	O
+prescription	O
+I	O
+possessed	B-DISO
+obvious	O
+inhibitory	O
+effects	O
+on	O
+the	O
+UV	O
+induction	O
+of	O
+lambda	O
+-	O
+lysogen	O
+,	O
+the	O
+inhibitory	O
+rate	O
+reaching	B-PROC
+83	O
+.	O
+87	O
+%.	O
+
+SARS	B-DISO
+was	O
+diagnosed	O
+according	O
+to	O
+the	O
+modified	O
+World	O
+Health	O
+Organization	O
+case	O
+definition	O
+(	O
+May	O
+1	O
+,	O
+2003	O
+).	O
+
+Five	O
+patients	O
+with	O
+probable	O
+SARS	B-DISO
+(	O
+11	O
+.	O
+6	O
+%)	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+human	B-SPEC
+monoclonal	O
+antibodies	B-COMP
+against	O
+diseases	O
+caused	O
+by	O
+emerging	O
+and	O
+biodefense	O
+-	O
+related	O
+viruses	O
+.	O
+
+The	O
+humanized	O
+mAb	O
+Synagis	O
+(	O
+palivizumab	O
+),	O
+which	O
+is	O
+still	O
+the	O
+only	O
+mAb	O
+against	O
+a	O
+viral	B-DISO
+disease	I-DISO
+approved	O
+by	O
+the	O
+US	O
+FDA	O
+,	O
+has	O
+been	O
+widely	O
+used	O
+as	O
+a	O
+prophylactic	O
+measure	O
+against	O
+respiratory	B-DISO
+syncytial	I-DISO
+virus	I-DISO
+infections	I-DISO
+in	O
+neonates	O
+and	O
+immunocompromised	O
+individuals	O
+.	O
+
+The	O
+first	O
+fully	O
+human	B-SPEC
+mAbs	O
+against	O
+two	O
+other	O
+paramyxoviruses	O
+,	O
+Hendra	O
+and	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+which	O
+can	O
+cause	O
+high	O
+(	O
+up	O
+to	O
+75	O
+%)	O
+mortality	O
+,	O
+were	O
+recently	O
+developed	O
+;	O
+one	O
+of	O
+them	O
+,	O
+m101	O
+,	O
+showed	O
+exceptional	O
+potency	O
+against	O
+infectious	B-DISO
+virus	B-SPEC
+.	O
+
+A	O
+related	O
+problem	O
+is	O
+the	O
+low	O
+binding	B-FUNC
+affinity	O
+of	O
+crossreactive	O
+antibodies	B-COMP
+able	O
+to	O
+neutralize	O
+a	O
+variety	O
+of	O
+primary	O
+isolates	O
+.	O
+
+Six	O
+(	O
+7	O
+.	O
+6	O
+%)	O
+had	O
+taken	O
+sick	O
+leave	O
+from	O
+March	O
+2003	O
+to	O
+June	O
+2004	O
+(	O
+mean	O
+2	O
+days	O
+;	O
+range	O
+1	O
+-	O
+4	O
+days	O
+)	O
+and	O
+47	O
+(	O
+59	O
+.	O
+5	O
+%)	O
+required	O
+use	O
+of	O
+abortive	O
+analgesics	O
+because	O
+of	O
+headache	B-DISO
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+showed	O
+that	O
+pre	O
+-	O
+existing	O
+headaches	O
+[	O
+P	O
+=	O
+0	O
+.	O
+041	O
+,	O
+OR	O
+=	O
+1	O
+.	O
+97	O
+(	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+03	O
+-	O
+3	O
+.	O
+77	O
+)]	O
+and	O
+continuous	O
+use	O
+of	O
+the	O
+N95	O
+face	B-DISO
+-	O
+mask	O
+exceeding	O
+4	O
+h	O
+[	O
+P	O
+=	O
+0	O
+.	O
+053	O
+,	O
+OR	O
+=	O
+1	O
+.	O
+85	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+99	O
+-	O
+3	O
+.	O
+43	O
+)]	O
+were	O
+associated	O
+with	O
+development	B-PROC
+of	O
+headaches	B-DISO
+.	O
+
+We	O
+evaluated	O
+the	O
+efficacy	O
+of	O
+an	O
+aggressive	B-DISO
+systemic	O
+protocol	O
+including	O
+strategies	O
+improving	O
+body	B-ANAT
+'	O
+s	O
+immune	B-PROC
+function	I-PROC
+.	O
+
+Patients	O
+were	O
+subjected	O
+to	O
+a	O
+protocol	O
+including	O
+(	O
+i	O
+)	O
+withdrawal	B-DISO
+of	O
+most	O
+immunosuppressants	O
+,	O
+(	O
+ii	O
+)	O
+early	O
+use	O
+of	O
+immunoenhancers	O
+and	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+CRRT	O
+),	O
+(	O
+iii	O
+)	O
+reasonable	O
+administration	O
+of	O
+antibiotic	B-CHED
+regimen	O
+,	O
+(	O
+iv	O
+)	O
+prompt	O
+mechanical	O
+ventilating	O
+strategy	O
+,	O
+and	O
+(	O
+v	O
+)	O
+adequate	O
+nutrition	B-PROC
+.	O
+
+Pathogens	O
+directly	O
+or	O
+indirectly	O
+transmitted	B-DISO
+by	O
+aerosolized	O
+droplets	O
+,	O
+such	O
+as	O
+avian	O
+influenza	O
+and	O
+SARS	B-DISO
+,	O
+pose	O
+considerable	O
+containment	O
+challenges	O
+.	O
+
+ABSTRACT	O
+:	O
+Typing	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strains	O
+is	O
+useful	O
+for	O
+implementation	O
+of	O
+control	O
+measures	O
+and	O
+for	O
+understanding	O
+the	O
+epidemiology	O
+and	O
+evolution	B-PROC
+of	O
+IBV	B-SPEC
+.	O
+
+Three	O
+different	O
+restriction	O
+endonucleases	O
+,	O
+AluI	O
+,	O
+Sau3AI	O
+and	O
+MnlI	O
+,	O
+were	O
+used	O
+to	O
+digest	O
+the	O
+7	O
+.	O
+5	O
+kb	O
+PCR	O
+product	O
+from	O
+different	O
+IBV	B-SPEC
+strains	O
+and	O
+the	O
+resultant	O
+RFLP	O
+patterns	O
+were	O
+compared	O
+.	O
+
+Personal	O
+resources	O
+and	O
+mental	O
+health	O
+factors	O
+are	O
+likely	O
+to	O
+influence	O
+the	O
+public	O
+'	O
+s	O
+ability	O
+to	O
+learn	B-PROC
+about	O
+,	O
+rationally	O
+appraise	O
+the	O
+threat	O
+of	O
+,	O
+and	O
+minimize	O
+stigmatization	O
+of	O
+emerging	O
+infectious	O
+diseases	O
+such	O
+as	O
+AIDS	O
+and	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Preparing	O
+the	O
+biochemistry	O
+laboratory	O
+for	O
+the	O
+next	O
+outbreak	O
+:	O
+lessons	O
+from	O
+SARS	B-DISO
+in	O
+Singapore	O
+.	O
+
+Singapore	O
+was	O
+affected	O
+by	O
+the	O
+global	O
+pandemic	O
+in	O
+early	O
+2003	O
+,	O
+with	O
+238	O
+cases	O
+and	O
+33	O
+deaths	B-PROC
+.	O
+
+The	O
+animals	B-SPEC
+were	O
+raised	O
+in	O
+homes	O
+,	O
+dog	B-SPEC
+schools	O
+or	O
+farms	O
+.	O
+
+No	O
+CCVs	O
+was	O
+detected	O
+from	O
+healthy	O
+mink	B-SPEC
+feces	B-ANAT
+.	O
+
+Sequence	O
+analysis	O
+found	O
+that	O
+ten	O
+type	O
+II	O
+CCVs	O
+fragments	O
+of	O
+M	B-PRGE
+gene	I-PRGE
+shared	O
+a	O
+high	O
+similarity	O
+with	O
+reference	O
+strain	O
+CCV	B-DISO
+1	O
+-	O
+71	O
+(	O
+96	O
+.	O
+5	O
+-	O
+99	O
+.	O
+5	O
+%),	O
+and	O
+four	O
+type	O
+I	O
+CCVs	O
+shared	O
+a	O
+high	O
+similarity	O
+(	O
+96	O
+.	O
+7	O
+%-	O
+98	O
+.	O
+1	O
+%)	O
+with	O
+a	O
+reported	O
+FCV	B-CHED
+-	O
+like	O
+CCV	B-DISO
+strain	O
+.	O
+
+The	O
+key	O
+intermediate	O
+(+)-	O
+12a	O
+was	O
+utilized	O
+for	O
+the	O
+synthesis	B-PROC
+of	O
+unnatural	O
+five	O
+-	O
+membered	O
+ring	O
+heterocyclic	O
+carbocyclic	O
+nucleosides	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+time	O
+course	O
+of	O
+impairment	B-DISO
+of	O
+respiratory	B-PROC
+mechanics	I-PROC
+and	O
+gas	B-ENZY
+exchange	O
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+poorly	O
+defined	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+due	O
+to	O
+the	O
+changes	O
+in	O
+respiratory	B-PROC
+mechanics	I-PROC
+over	O
+time	O
+,	O
+ventilatory	O
+strategies	O
+based	O
+on	O
+rigid	B-DISO
+volume	O
+or	O
+pressure	O
+limits	O
+might	O
+fail	O
+to	O
+prevent	O
+overdistension	O
+throughout	O
+the	O
+disease	O
+process	O
+.	O
+
+(	O
+1	O
+)	O
+UIP	B-DISO
+decreased	O
+from	O
+early	O
+to	O
+established	O
+(	O
+intermediate	O
+and	O
+late	O
+)	O
+ARDS	B-DISO
+[	O
+30	O
+(	O
+28	O
+-	O
+30	O
+)	O
+cmH2O	O
+,	O
+27	O
+(	O
+25	O
+-	O
+30	O
+)	O
+cmH2O	O
+and	O
+25	O
+(	O
+23	O
+-	O
+28	O
+)	O
+cmH2O	O
+(	O
+P	O
+=	O
+0	O
+.	O
+014	O
+)];	O
+(	O
+2	O
+)	O
+oxygenation	B-PROC
+improved	O
+in	O
+survivors	O
+and	O
+in	O
+patients	O
+with	O
+non	O
+-	O
+pulmonary	B-ANAT
+etiology	O
+in	O
+late	O
+ARDS	B-DISO
+,	O
+whereas	O
+all	O
+patients	O
+developed	O
+hypercapnia	B-DISO
+from	O
+early	O
+to	O
+established	O
+ARDS	B-DISO
+;	O
+and	O
+(	O
+3	O
+)	O
+dead	B-PROC
+-	O
+space	O
+ventilation	O
+and	O
+pulmonary	B-ANAT
+shunt	O
+were	O
+larger	O
+in	O
+patients	O
+with	O
+pulmonary	B-ANAT
+etiology	O
+during	O
+late	O
+ARDS	B-DISO
+.	O
+
+If	O
+applied	O
+to	O
+our	O
+data	O
+,	O
+the	O
+inspiratory	B-PROC
+pressure	O
+limit	O
+advocated	O
+by	O
+the	O
+ARDSnet	O
+(	O
+30	O
+cmH2O	O
+)	O
+would	O
+produce	O
+ventilation	O
+over	O
+the	O
+UIP	B-DISO
+,	O
+with	O
+a	O
+consequent	O
+increased	O
+risk	O
+of	O
+overdistension	O
+in	O
+12	O
+%,	O
+43	O
+%	O
+and	O
+65	O
+%	O
+of	O
+our	O
+patients	O
+during	O
+the	O
+acute	O
+,	O
+intermediate	O
+and	O
+late	O
+phases	O
+of	O
+ARDS	B-DISO
+,	O
+respectively	O
+.	O
+
+After	O
+surfactant	B-CHED
+instillation	O
+,	O
+similar	O
+improvements	O
+in	O
+gas	B-ENZY
+exchange	O
+and	O
+lung	B-ANAT
+mechanics	O
+were	O
+observed	O
+for	O
+the	O
+lucinactant	O
+and	O
+poractant	O
+-	O
+alpha	O
+groups	O
+at	O
+1	O
+hour	O
+(	O
+pH	O
+:	O
+7	O
+.	O
+3	O
++/-	O
+0	O
+.	O
+1	O
+vs	O
+7	O
+.	O
+4	O
++/-	O
+
+0	O
+.	O
+1	O
+mL	O
+/	O
+cm	O
+H2O	B-CHED
+per	O
+kg	O
+).	O
+
+Among	O
+preterm	O
+lambs	B-SPEC
+with	O
+severe	O
+RDS	O
+,	O
+lucinactant	O
+produced	O
+improvements	O
+in	O
+gas	B-ENZY
+exchange	O
+and	O
+lung	B-ANAT
+mechanics	O
+similar	O
+to	O
+those	O
+observed	O
+with	O
+a	O
+porcine	B-SPEC
+-	O
+derived	O
+surfactant	B-CHED
+.	O
+
+Cardiovascular	B-ANAT
+profiles	O
+remained	O
+stable	O
+in	O
+both	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+Immunotherapy	O
+with	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+offers	O
+safe	O
+interventions	O
+for	O
+the	O
+prevention	O
+of	O
+infection	B-DISO
+in	O
+patients	O
+after	O
+organ	B-ANAT
+transplantation	O
+and	O
+for	O
+the	O
+treatment	O
+of	O
+cancers	B-DISO
+and	O
+autoimmune	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+efficacy	O
+of	O
+MAb	O
+201	O
+in	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+was	O
+evaluated	O
+in	O
+golden	O
+Syrian	B-SPEC
+hamsters	I-SPEC
+,	O
+an	O
+animal	B-SPEC
+model	O
+that	O
+supports	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+to	O
+high	O
+levels	O
+and	O
+displays	O
+severe	O
+pathological	O
+changes	O
+associated	O
+with	O
+infection	B-DISO
+,	O
+including	O
+pneumonitis	B-DISO
+and	O
+pulmonary	B-DISO
+consolidation	I-DISO
+.	O
+
+After	O
+a	O
+hamster	B-SPEC
+is	O
+treated	O
+with	O
+MAb	O
+201	O
+,	O
+its	O
+viral	O
+burden	O
+is	O
+reduced	O
+by	O
+102	O
+.	O
+4	O
+-	O
+103	O
+.	O
+9	O
+50	O
+%	O
+tissue	B-ANAT
+-	O
+culture	O
+infectious	B-DISO
+doses	O
+per	O
+gram	O
+of	O
+tissue	B-ANAT
+,	O
+and	O
+the	O
+severity	O
+of	O
+associated	O
+pathological	O
+findings	O
+,	O
+including	O
+interstitial	B-DISO
+pneumonitis	I-DISO
+and	O
+consolidation	O
+,	O
+is	O
+also	O
+remarkably	O
+reduced	O
+.	O
+
+The	O
+demonstration	O
+of	O
+successful	O
+postexposure	O
+MAb	O
+201	O
+therapy	O
+in	O
+an	O
+animal	B-SPEC
+model	O
+that	O
+demonstrates	O
+viral	B-PROC
+replication	I-PROC
+and	O
+associated	O
+pulmonary	B-ANAT
+pathological	O
+findings	O
+suggests	O
+that	O
+MAb	O
+201	O
+may	O
+be	O
+useful	O
+in	O
+the	O
+arsenal	O
+of	O
+tools	O
+to	O
+combat	B-CHED
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Postexposure	O
+treatment	O
+with	O
+MAb	O
+201	O
+can	O
+alleviate	O
+the	O
+viral	O
+burden	O
+and	O
+associated	O
+pathological	O
+findings	O
+in	O
+a	O
+golden	O
+Syrian	B-SPEC
+hamster	I-SPEC
+model	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+After	O
+a	O
+hamster	B-SPEC
+is	O
+treated	O
+with	O
+MAb	O
+201	O
+,	O
+its	O
+viral	O
+burden	O
+is	O
+reduced	O
+by	O
+102	O
+.	O
+4	O
+-	O
+103	O
+.	O
+9	O
+50	O
+%	O
+tissue	B-ANAT
+-	O
+culture	O
+infectious	B-DISO
+doses	O
+per	O
+gram	O
+of	O
+tissue	B-ANAT
+,	O
+and	O
+the	O
+severity	O
+of	O
+associated	O
+pathological	O
+findings	O
+,	O
+including	O
+interstitial	B-DISO
+pneumonitis	I-DISO
+and	O
+consolidation	O
+,	O
+is	O
+also	O
+remarkably	O
+reduced	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+single	O
+intratracheal	O
+exposure	O
+to	O
+chlorhexidine	B-CHED
+gluconate	I-CHED
+on	O
+the	O
+rat	B-ANAT
+lung	I-ANAT
+.	O
+
+At	O
+the	O
+higher	O
+concentrations	O
+of	O
+CHX	O
+(	O
+0	O
+.	O
+1	O
+%	O
+and	O
+1	O
+%),	O
+severe	O
+congestion	B-DISO
+to	O
+the	O
+alveoli	B-ANAT
+and	O
+capillaries	B-ANAT
+and	O
+perivascular	O
+and	O
+intra	O
+-	O
+alveolar	B-ANAT
+hemorrhages	B-DISO
+were	O
+observed	O
+1	O
+day	O
+after	O
+exposure	O
+.	O
+
+ABSTRACT	O
+:	O
+Taiwan	O
+experienced	O
+a	O
+series	O
+of	O
+outbreaks	O
+of	O
+nosocomial	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+infections	B-DISO
+in	O
+2003	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+were	O
+detected	O
+by	O
+using	O
+enzyme	O
+immunoassays	O
+and	O
+confirmed	O
+by	O
+a	O
+combination	O
+of	O
+Western	O
+blot	O
+assays	O
+,	O
+neutralizing	O
+antibody	B-COMP
+tests	O
+,	O
+and	O
+commercial	O
+SARS	B-DISO
+tests	O
+.	O
+
+TITLE	O
+:	O
+Functional	O
+peptide	B-CHED
+microarrays	O
+for	O
+specific	O
+and	O
+sensitive	O
+antibody	B-COMP
+diagnostics	O
+.	O
+
+Our	O
+method	O
+relies	O
+on	O
+the	O
+efficiency	O
+of	O
+site	O
+-	O
+specific	O
+solution	O
+-	O
+phase	O
+coupling	O
+of	O
+biotinylated	O
+synthetic	O
+peptides	B-CHED
+to	O
+NeutrAvidin	O
+(	O
+NA	O
+)	O
+and	O
+localized	O
+microdispensing	O
+of	O
+peptide	B-CHED
+-	O
+NA	O
+-	O
+complexes	O
+onto	O
+activated	O
+glass	O
+surfaces	O
+.	O
+
+Vero	O
+E6	O
+mainly	O
+expressed	B-PROC
+p90RSK1	B-PRGE
+and	O
+showed	O
+weak	O
+expression	B-PROC
+of	O
+p90RSK2	B-PRGE
+.	O
+
+This	O
+is	O
+the	O
+first	O
+detailed	O
+report	O
+regarding	O
+regulation	B-PROC
+of	O
+p90RSK	B-PRGE
+phosphorylation	B-PROC
+by	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+in	O
+85	O
+sera	B-COMP
+(	O
+47	O
+%)	O
+and	O
+HPS	B-DISO
+in	O
+33	O
+sera	B-COMP
+(	O
+18	O
+%).	O
+
+Nurse	O
+participants	O
+were	O
+from	O
+two	O
+SARS	B-DISO
+units	O
+(	O
+regular	O
+SARS	B-DISO
+[	O
+N	O
+=	O
+44	O
+]	O
+and	O
+SARS	B-DISO
+ICU	O
+[	O
+N	O
+=	O
+26	O
+])	O
+and	O
+two	O
+non	O
+-	O
+SARS	B-DISO
+units	O
+(	O
+Neurology	O
+[	O
+N	O
+=	O
+15	O
+]	O
+and	O
+CCU	O
+[	O
+N	O
+=	O
+17	O
+]).	O
+
+Participants	O
+periodically	O
+self	O
+-	O
+evaluated	O
+their	O
+depression	B-DISO
+,	O
+anxiety	O
+,	O
+post	O
+-	O
+traumatic	O
+stress	B-DISO
+symptoms	I-DISO
+,	O
+sleep	B-DISO
+disturbance	I-DISO
+,	O
+attitude	O
+towards	O
+SARS	B-DISO
+and	O
+family	B-SPEC
+support	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+virulent	O
+viral	B-DISO
+infection	I-DISO
+that	O
+affects	O
+a	O
+number	O
+of	O
+organs	B-ANAT
+and	O
+systems	O
+.	O
+
+Antibodies	B-COMP
+were	O
+also	O
+detected	O
+for	O
+some	O
+putative	O
+proteins	B-CHED
+,	O
+noticeably	O
+the	O
+C	O
+-	O
+termini	O
+of	O
+SARS3a	O
+and	O
+SARS6	O
+.	O
+
+CCoV	O
+and	O
+feline	B-SPEC
+coronavirus	B-SPEC
+are	O
+classified	O
+as	O
+group	O
+1	O
+coronaviruses	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+examined	O
+the	O
+prevalence	O
+of	O
+antibodies	B-COMP
+to	O
+group	O
+2	O
+coronaviruses	O
+in	O
+domestic	O
+dogs	B-SPEC
+and	O
+cats	B-SPEC
+in	O
+Japan	O
+by	O
+a	O
+neutralization	O
+test	O
+using	O
+BCoV	O
+.	O
+All	O
+104	O
+feline	B-SPEC
+serum	B-COMP
+samples	O
+were	O
+negative	O
+(<	O
+1	O
+:	O
+5	O
+)	O
+for	O
+anti	O
+-	O
+BCoV	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+Antiretroviral	O
+drugs	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+Preliminary	O
+results	O
+for	O
+SARS	B-DISO
+treatment	O
+with	O
+protease	O
+and	O
+entry	O
+inhibitors	O
+,	O
+although	O
+at	O
+early	O
+stages	O
+of	O
+development	B-PROC
+,	O
+are	O
+promising	O
+.	O
+
+Group	O
+G	O
+streptococci	O
+cause	O
+a	O
+variety	O
+of	O
+common	O
+and	O
+severe	O
+infections	B-DISO
+.	O
+
+However	O
+,	O
+he	O
+developed	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+was	O
+transferred	O
+to	O
+the	O
+intensive	O
+-	O
+care	O
+unit	O
+for	O
+mechanical	O
+ventilation	O
+.	O
+
+After	O
+the	O
+patient	O
+was	O
+treated	O
+with	O
+doxycycline	B-CHED
+200	O
+mg	O
+i	O
+.	O
+v	O
+.	O
+
+TITLE	O
+:	O
+The	O
+validity	O
+and	O
+reliability	O
+of	O
+the	O
+functional	O
+impairment	B-DISO
+checklist	O
+(	O
+FIC	O
+)	O
+in	O
+the	O
+evaluation	O
+of	O
+functional	O
+consequences	O
+of	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+Moreover	O
+,	O
+the	O
+FIC	O
+scales	B-ANAT
+correlated	O
+with	O
+St	O
+.	O
+George	O
+'	O
+s	O
+respiratory	O
+questionnaire	O
+(	O
+SGRQ	O
+)	O
+(	O
+0	O
+.	O
+19	O
+to	O
+0	O
+.	O
+52	O
+)	O
+and	O
+short	O
+form	O
+36	O
+Hong	O
+Kong	O
+(	O
+SF	O
+-	O
+36	O
+)	O
+domains	O
+(-	O
+0	O
+.	O
+19	O
+to	O
+-	O
+0	O
+.	O
+59	O
+).	O
+
+FIC	O
+reduced	O
+significantly	O
+at	O
+6	O
+months	O
+while	O
+the	O
+SF	B-PRGE
+-	I-PRGE
+36	I-PRGE
+PCS	I-PRGE
+and	O
+MCS	B-COMP
+did	O
+not	O
+show	O
+any	O
+change	O
+.	O
+
+TITLE	O
+:	O
+Promoter	O
+activity	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+5	I-PRGE
+'	I-PRGE
+UTR	I-PRGE
+sequence	I-PRGE
+in	O
+eukaryotic	B-ANAT
+cells	I-ANAT
+.	O
+
+casei	O
+in	O
+0	O
+.	O
+1	O
+ml	O
+PBS	B-DISO
+with	O
+the	O
+aid	O
+of	O
+an	O
+intubation	O
+needle	O
+at	O
+1	O
+,	O
+2	O
+and	O
+3	O
+d	O
+of	O
+age	O
+.	O
+
+The	O
+SARS	B-DISO
+-	O
+CoV	O
+first	O
+appeared	O
+in	O
+2002	O
+and	O
+spread	O
+rapidly	O
+around	O
+the	O
+globe	B-ANAT
+.	O
+
+The	O
+several	O
+studies	O
+carried	O
+out	O
+by	O
+different	O
+researchers	O
+have	O
+focused	O
+upon	O
+the	O
+epidemiological	O
+relevance	O
+of	O
+these	O
+viruses	B-SPEC
+and	O
+,	O
+considering	O
+the	O
+wide	O
+diffusion	O
+of	O
+CCoV	O
+infections	B-DISO
+among	O
+dog	B-SPEC
+populations	O
+,	O
+the	O
+author	O
+underlines	O
+the	O
+need	O
+for	O
+further	O
+investigation	O
+on	O
+the	O
+biology	O
+of	O
+CCoV	O
+and	O
+on	O
+the	O
+pathogenetic	O
+role	O
+of	O
+their	O
+infections	B-DISO
+.	O
+
+By	O
+changing	O
+the	O
+donor	B-CHED
+sequence	O
+,	O
+acceptor	B-CHED
+sites	O
+between	O
+genomic	O
+nt	O
+33	O
+and	O
+97	O
+(	O
+identical	O
+between	O
+the	O
+DI	O
+RNA	O
+and	O
+the	O
+viral	B-COMP
+genome	I-COMP
+)	O
+could	O
+be	O
+used	O
+to	O
+generate	O
+sgmRNAs	O
+detectable	O
+by	O
+Northern	O
+analysis	O
+(	O
+approximately	O
+2	O
+to	O
+32	O
+molecules	O
+per	O
+cell	B-COMP
+)	O
+by	O
+24	O
+h	O
+postinfection	O
+.	O
+
+Herein	O
+,	O
+we	O
+show	O
+that	O
+the	O
+JHM	O
+strain	O
+also	O
+productively	O
+infected	O
+DCs	B-DISO
+.	O
+
+Results	O
+from	O
+a	O
+pilot	O
+study	O
+to	O
+evaluate	O
+the	O
+clinical	O
+efficacy	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+treatment	O
+of	O
+SARS	B-DISO
+patients	O
+provided	O
+evidence	O
+for	O
+IFN	B-PRGE
+-	O
+inducible	O
+resolution	O
+of	O
+disease	O
+.	O
+
+Notably	O
+,	O
+our	O
+data	O
+suggest	O
+that	O
+MHV	B-SPEC
+-	O
+1	O
+infection	B-DISO
+,	O
+as	O
+for	O
+the	O
+Urbani	O
+SARS	B-DISO
+coronoavirus	O
+,	O
+inhibits	O
+an	O
+IFN	B-PRGE
+response	O
+,	O
+inferred	O
+from	O
+the	O
+lack	O
+of	O
+activation	O
+of	O
+pkr	O
+and	O
+2	O
+'	O
+5	O
+'-	O
+oas	B-DISO
+,	O
+genes	O
+associated	O
+with	O
+mediating	O
+the	O
+antiviral	B-CHED
+activities	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alphas	I-PRGE
+.	O
+
+To	O
+identify	O
+potential	O
+target	O
+genes	O
+that	O
+are	O
+activated	O
+downstream	O
+of	O
+the	O
+IFN	B-PRGE
+-	O
+inducible	O
+signaling	B-PROC
+effectors	O
+we	O
+identified	O
+,	O
+and	O
+that	O
+mediate	O
+protection	O
+from	O
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+we	O
+examined	O
+the	O
+gene	B-PROC
+expression	I-PROC
+profiles	O
+in	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+of	O
+SARS	B-DISO
+patients	O
+who	O
+received	O
+IFN	B-PRGE
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+-	O
+associated	O
+puppy	O
+mortality	O
+without	O
+evidence	O
+of	O
+concurrent	O
+canine	B-DISO
+parvovirus	B-SPEC
+infection	I-DISO
+.	O
+
+The	O
+puppy	O
+died	B-PROC
+within	O
+12	O
+hours	O
+of	O
+admission	O
+and	O
+was	O
+submitted	O
+for	O
+diagnostic	O
+workup	O
+.	O
+
+Immunohistochemistry	O
+(	O
+IHC	O
+)	O
+on	O
+gut	B-ANAT
+sections	O
+was	O
+positive	O
+for	O
+CCV	B-DISO
+and	O
+negative	O
+for	O
+CPV	B-SPEC
+-	O
+2	O
+.	O
+
+Electron	O
+microscopy	O
+of	O
+the	O
+intestinal	B-ANAT
+contents	I-ANAT
+was	O
+positive	O
+for	O
+coronavirus	B-SPEC
+and	O
+negative	O
+for	O
+parvovirus	B-DISO
+.	O
+
+These	O
+cases	O
+emphasize	O
+the	O
+importance	O
+of	O
+pursuing	O
+a	O
+diagnosis	O
+of	O
+CCV	B-DISO
+in	O
+young	O
+puppies	O
+when	O
+CPV	B-SPEC
+-	O
+2	O
+disease	O
+has	O
+been	O
+ruled	O
+out	O
+by	O
+IHC	O
+.	O
+
+For	O
+Cp	O
+felis	B-SPEC
+,	O
+the	O
+majority	O
+of	O
+seropositive	O
+animals	B-SPEC
+had	O
+relatively	O
+low	O
+antibody	B-COMP
+titres	O
+,	O
+and	O
+the	O
+risk	O
+of	O
+these	O
+animals	B-SPEC
+infecting	O
+others	O
+is	O
+not	O
+known	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+different	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+vaccine	O
+strategies	O
+were	O
+evaluated	O
+for	O
+their	O
+ability	O
+to	O
+protect	O
+against	O
+live	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+challenge	O
+in	O
+a	O
+murine	B-SPEC
+model	O
+of	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+the	O
+relationships	O
+between	O
+changes	O
+in	O
+the	O
+elastic	O
+behavior	O
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+and	O
+biological	O
+markers	O
+of	O
+extra	O
+-	O
+cellular	B-COMP
+matrix	I-COMP
+or	O
+surfactant	B-CHED
+turn	O
+-	O
+over	O
+could	O
+give	O
+some	O
+insights	O
+into	O
+its	O
+pathophysiological	O
+determinants	O
+.	O
+
+ABSTRACT	O
+:	O
+Lymphocyte	B-ANAT
+infiltration	B-DISO
+into	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+following	O
+viral	B-DISO
+infection	I-DISO
+represents	O
+an	O
+important	O
+component	O
+of	O
+host	B-PROC
+defense	I-PROC
+and	O
+is	O
+required	O
+for	O
+control	O
+of	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Predicting	O
+case	O
+numbers	O
+during	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+when	O
+some	O
+cases	O
+are	O
+undiagnosed	O
+.	O
+
+A	O
+Bayesian	O
+Markov	O
+chain	O
+Monte	O
+Carlo	O
+approach	O
+is	O
+used	O
+to	O
+fit	B-DISO
+a	O
+model	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+transmission	I-DISO
+that	O
+takes	O
+account	O
+of	O
+undiagnosed	O
+cases	O
+.	O
+
+The	O
+in	O
+-	O
+hospital	O
+mortality	O
+was	O
+15	O
+of	O
+58	O
+(	O
+25	O
+.	O
+9	O
+%);	O
+13	O
+(	O
+22	O
+.	O
+4	O
+%)	O
+patients	O
+died	B-PROC
+in	O
+the	O
+ICU	O
+.	O
+
+The	O
+mean	O
+survival	O
+of	O
+patients	O
+who	O
+died	O
+was	O
+53	O
+.	O
+6	O
+days	O
+(	O
+range	O
+1	O
+-	O
+229	O
+),	O
+with	O
+50	O
+%	O
+of	O
+the	O
+patients	O
+dying	B-PROC
+within	O
+the	O
+first	O
+32	O
+days	O
+.	O
+
+The	O
+factors	O
+independently	O
+associated	O
+with	O
+mortality	O
+were	O
+:	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+,	O
+chronic	B-DISO
+pancreatitis	I-DISO
+,	O
+sepsis	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+nosocomial	B-DISO
+pneumonia	I-DISO
+.	O
+
+Induction	O
+level	O
+of	O
+suppressor	B-PRGE
+of	I-PRGE
+cytokine	I-PRGE
+signaling	O
+-	O
+3	O
+(	O
+SOCS3	B-PRGE
+)	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+by	O
+RSV	B-SPEC
+in	O
+spite	O
+of	O
+the	O
+significant	O
+production	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+.	O
+
+They	O
+were	O
+interviewed	O
+and	O
+asked	O
+to	O
+provide	O
+a	O
+blood	B-ANAT
+sample	I-ANAT
+for	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+immunoglobulin	B-PROC
+G	I-PRGE
+antibody	B-COMP
+testing	O
+.	O
+
+Key	O
+nursing	B-PROC
+personnel	O
+were	O
+also	O
+interviewed	O
+.	O
+
+Infection	B-DISO
+control	O
+overshadowed	O
+the	O
+family	B-SPEC
+-	O
+centred	O
+nursing	B-PROC
+practices	O
+in	O
+the	O
+management	O
+of	O
+SARS	B-DISO
+paediatric	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Seroprevalence	O
+of	O
+IgG	B-PRGE
+antibodies	I-PRGE
+to	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+in	O
+asymptomatic	O
+or	O
+subclinical	O
+population	O
+groups	O
+.	O
+
+Health	O
+-	O
+care	O
+workers	O
+and	O
+others	O
+who	O
+had	O
+close	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+had	O
+a	O
+slightly	O
+higher	O
+degree	O
+of	O
+seroconversion	O
+(	O
+0	O
+.	O
+23	O
+%,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+02	O
+-	O
+0	O
+.	O
+45	O
+)	O
+compared	O
+to	O
+healthy	O
+blood	B-ANAT
+donors	O
+,	O
+others	O
+from	O
+the	O
+general	O
+community	O
+or	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+recruited	O
+from	O
+the	O
+health	O
+-	O
+care	O
+setting	O
+(	O
+0	O
+.	O
+16	O
+%,	O
+95	O
+%	O
+CI	O
+0	O
+-	O
+0	O
+.	O
+37	O
+).	O
+
+Potential	O
+epidemiological	O
+and	O
+laboratory	O
+pitfalls	O
+are	O
+also	O
+discussed	O
+as	O
+they	O
+may	O
+give	O
+rise	O
+to	O
+false	O
+or	O
+inconsistent	O
+results	O
+in	O
+measuring	O
+the	O
+seroprevalence	O
+of	O
+IgG	O
+antibodies	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+study	O
+sought	O
+to	O
+identify	O
+factors	O
+involved	O
+in	O
+the	O
+emergence	O
+,	O
+prevention	O
+and	O
+elimination	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Hong	O
+Kong	O
+during	O
+11	O
+March	O
+to	O
+22	O
+May	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+3	O
+'-	O
+end	O
+structural	O
+protein	B-CHED
+-	O
+encoding	O
+region	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+)	O
+isolates	O
+associated	O
+with	O
+outbreaks	O
+of	O
+acute	O
+enteritis	B-DISO
+in	O
+Indiana	O
+,	O
+North	O
+Carolina	O
+,	O
+or	O
+Minnesota	O
+.	O
+
+The	O
+phylogenetic	O
+tree	O
+based	O
+on	O
+other	O
+genes	O
+had	O
+a	O
+very	O
+different	O
+topology	O
+with	O
+TCoV	O
+isolates	O
+randomly	O
+forming	O
+groups	O
+with	O
+different	O
+IBV	B-SPEC
+strains	O
+.	O
+
+Recrudescence	O
+of	O
+neurotropic	O
+coronavirus	B-SPEC
+due	O
+to	O
+loss	O
+of	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+immune	O
+control	O
+provided	O
+an	O
+experimental	O
+model	O
+to	O
+test	O
+T	B-ANAT
+cell	I-ANAT
+vaccination	O
+efficacy	O
+in	O
+the	O
+absence	O
+of	O
+Ab	O
+.	O
+
+Severely	O
+reduced	O
+MHC	B-PROC
+expression	B-PROC
+on	O
+glial	B-ANAT
+cells	I-ANAT
+at	O
+the	O
+time	O
+of	O
+recrudescence	O
+suggested	O
+that	O
+memory	B-PROC
+T	B-ANAT
+cells	I-ANAT
+,	O
+although	O
+fully	O
+armed	O
+to	O
+exert	B-PROC
+antiviral	B-CHED
+activity	O
+upon	O
+Ag	O
+recognition	O
+in	O
+vitro	O
+,	O
+are	O
+not	O
+responsive	O
+in	O
+an	O
+environment	O
+presenting	O
+few	O
+if	O
+any	O
+target	B-PRGE
+MHC	I-PRGE
+molecules	I-PRGE
+.	O
+
+These	O
+studies	O
+demonstrate	O
+that	O
+vaccine	O
+-	O
+induced	O
+T	O
+cell	B-ANAT
+memory	B-PROC
+alone	O
+is	O
+unable	O
+to	O
+control	O
+persisting	O
+virus	B-SPEC
+in	O
+a	O
+tissue	B-ANAT
+with	O
+strict	O
+IFN	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+MHC	I-PRGE
+regulation	B-PROC
+,	O
+as	O
+evident	O
+in	O
+immune	O
+privileged	O
+sites	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+provides	O
+an	O
+overview	O
+of	O
+the	O
+Hong	O
+Kong	O
+government	O
+'	O
+s	O
+influenza	B-DISO
+preparedness	O
+plan	B-DISO
+and	O
+the	O
+key	O
+roles	O
+of	O
+public	O
+health	O
+nurses	O
+in	O
+that	O
+plan	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+threat	O
+of	O
+a	O
+human	B-DISO
+influenza	I-DISO
+pandemic	O
+has	O
+greatly	O
+increased	O
+over	O
+the	O
+past	O
+several	O
+years	O
+with	O
+the	O
+emergence	O
+of	O
+highly	O
+virulent	O
+avian	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+notably	O
+H5N1	B-DISO
+viruses	B-SPEC
+,	O
+which	O
+have	O
+infected	O
+humans	B-SPEC
+in	O
+several	O
+Asian	O
+and	O
+European	O
+countries	O
+.	O
+
+Screening	O
+and	O
+quarantining	O
+entering	O
+travelers	O
+at	O
+international	O
+borders	O
+did	O
+not	O
+substantially	O
+delay	O
+virus	B-SPEC
+introduction	O
+in	O
+past	O
+pandemics	O
+,	O
+except	O
+in	O
+some	O
+island	O
+countries	O
+,	O
+and	O
+will	O
+likely	O
+be	O
+even	O
+less	O
+effective	O
+in	O
+the	O
+modern	O
+era	B-CHED
+.	O
+
+Using	O
+simulation	O
+studies	O
+of	O
+SARS	B-DISO
+-	O
+like	O
+outbreaks	O
+,	O
+we	O
+have	O
+shown	O
+that	O
+the	O
+method	O
+may	O
+be	O
+used	O
+for	O
+early	O
+monitoring	O
+of	O
+the	O
+effect	O
+of	O
+control	O
+measures	O
+.	O
+
+After	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+cells	B-COMP
+were	O
+observed	O
+for	O
+cytopathic	B-DISO
+effects	I-DISO
+,	O
+and	O
+quantitative	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+was	O
+used	O
+to	O
+measure	O
+ongoing	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+These	O
+results	O
+indicated	O
+that	O
+the	O
+region	O
+around	O
+residues	O
+156	O
+-	O
+175	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+is	O
+immunogenic	O
+in	O
+the	O
+mouse	B-SPEC
+,	O
+monkey	B-SPEC
+,	O
+and	O
+human	B-SPEC
+.	O
+
+We	O
+found	O
+that	O
+peptides	B-CHED
+corresponding	O
+to	O
+residues	O
+1	O
+-	O
+30	O
+,	O
+86	O
+-	O
+100	O
+,	O
+306	O
+-	O
+320	O
+,	O
+and	O
+351	O
+-	O
+365	O
+contained	O
+murine	B-SPEC
+immunodominant	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+.	O
+
+Livers	B-ANAT
+recovered	O
+from	O
+untreated	O
+infected	O
+mice	O
+showed	O
+greater	O
+than	O
+90	O
+%	O
+necrosis	B-PROC
+.	O
+
+Clinically	O
+,	O
+HRC	O
+203	O
+-	O
+treated	O
+mice	B-SPEC
+behaved	O
+normally	O
+,	O
+in	O
+contrast	O
+to	O
+ribavirin	B-CHED
+-	O
+treated	O
+mice	B-SPEC
+,	O
+which	O
+developed	O
+lethargy	B-DISO
+and	O
+abnormal	O
+fur	O
+texture	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+the	O
+ecto	O
+-	O
+domain	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+vaccine	O
+,	O
+with	O
+or	O
+without	O
+adjuvant	B-CHED
+,	O
+is	O
+immunogenic	O
+and	O
+induces	O
+high	O
+titers	O
+of	O
+virus	B-SPEC
+neutralizing	O
+antibodies	B-COMP
+to	O
+levels	O
+similar	O
+to	O
+those	O
+achieved	O
+with	O
+the	O
+full	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+vaccine	O
+.	O
+
+Syndromic	O
+and	O
+traditional	O
+surveillance	O
+play	O
+a	O
+role	O
+in	O
+early	O
+identification	O
+of	O
+SARS	B-DISO
+in	O
+an	O
+endemic	O
+area	O
+.	O
+
+Results	O
+from	O
+637	O
+Coronase	O
+and	O
+191	O
+7B	O
+FIP	B-DISO
+antibody	B-COMP
+tests	O
+were	O
+recorded	O
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+differentiation	B-PROC
+of	O
+current	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccine	O
+strains	O
+and	O
+field	O
+isolates	O
+in	O
+Australia	O
+.	O
+
+A	O
+fragment	O
+of	O
+6	O
+.	O
+5	O
+kilobases	O
+that	O
+contains	O
+the	O
+S	O
+,	O
+M	O
+and	O
+N	O
+genes	O
+was	O
+amplified	O
+by	O
+RT	O
+-	O
+PCR	O
+from	O
+ten	O
+different	O
+IBV	B-SPEC
+strains	O
+,	O
+including	O
+vaccine	O
+strains	O
+and	O
+field	O
+isolates	O
+,	O
+and	O
+then	O
+sequenced	O
+.	O
+
+Comparison	O
+of	O
+the	O
+sequences	O
+of	O
+these	O
+strains	O
+revealed	O
+a	O
+deletion	O
+of	O
+58	O
+bases	B-CHED
+in	O
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+(	O
+UTR	O
+)	O
+of	O
+IBV	B-SPEC
+vaccine	O
+strains	O
+but	O
+not	O
+in	O
+the	O
+field	O
+isolates	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+procedure	O
+is	O
+a	O
+rapid	O
+,	O
+sensitive	O
+and	O
+inexpensive	O
+method	O
+for	O
+discrimination	O
+between	O
+most	O
+current	O
+Australian	O
+vaccine	O
+strains	O
+and	O
+field	O
+isolates	O
+of	O
+IBV	B-SPEC
+.	O
+
+In	O
+the	O
+ITCWM	O
+group	O
+,	O
+average	O
+time	O
+in	O
+hospital	O
+was	O
+shortened	O
+(	O
+P	O
+=	O
+0	O
+.	O
+058	O
+),	O
+pneumonia	B-DISO
+duration	O
+was	O
+shortened	O
+(	O
+P	O
+=	O
+0	O
+.	O
+057	O
+),	O
+mortality	O
+fell	O
+(	O
+P	O
+=	O
+-	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+observation	O
+indexes	O
+were	O
+time	O
+in	O
+hospital	O
+,	O
+pneumonia	B-DISO
+duration	O
+,	O
+mortality	O
+,	O
+glucocorticoid	B-CHED
+'	O
+s	O
+gross	O
+dosage	O
+,	O
+glucocorticoid	B-CHED
+'	O
+s	O
+average	O
+dosage	O
+of	O
+days	O
+and	O
+glucocorticoid	B-CHED
+use	O
+time	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Compared	O
+with	O
+the	O
+group	O
+of	O
+simplicity	O
+western	O
+mendicine	O
+,	O
+in	O
+the	O
+group	O
+of	O
+integratived	O
+Chinese	O
+and	O
+western	O
+mendicine	O
+,	O
+time	O
+in	O
+hospital	O
+shorten	O
+,	O
+pneumonia	B-DISO
+duration	O
+shorten	O
+,	O
+mortality	O
+fall	O
+,	O
+simultaneity	O
+,	O
+glucocorticoid	B-CHED
+'	O
+s	O
+average	O
+dosage	O
+is	O
+decreased	O
+.	O
+
+TITLE	O
+:	O
+Disseminated	O
+adenovirus	B-DISO
+infection	I-DISO
+with	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+pediatric	O
+liver	B-ANAT
+transplant	B-ANAT
+recipients	O
+:	O
+impact	O
+of	O
+intravenous	O
+cidofovir	O
+and	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+.	O
+
+This	O
+process	O
+is	O
+generally	O
+programmed	O
+by	O
+signals	O
+at	O
+defined	O
+locations	O
+in	O
+a	O
+specific	O
+mRNA	B-CHED
+.	O
+
+Taken	O
+together	O
+,	O
+this	O
+study	O
+identifies	O
+the	O
+hepta	O
+-	O
+and	O
+octo	O
+-	O
+uridine	B-CHED
+stretches	B-DISO
+that	O
+function	O
+as	O
+sole	B-ANAT
+elements	O
+for	O
+efficient	O
++	O
+1	O
+and	O
+-	O
+1	O
+ribosomal	B-PROC
+frameshift	B-DISO
+events	O
+.	O
+
+To	O
+study	O
+the	O
+cellular	B-COMP
+response	O
+in	O
+the	O
+acute	O
+phase	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)-	O
+host	B-COMP
+cell	I-COMP
+interaction	O
+,	O
+we	O
+investigated	O
+the	O
+induction	O
+of	O
+chemokines	O
+,	O
+adhesion	B-DISO
+molecules	O
+,	O
+and	O
+DC	O
+-	O
+SIGN	O
+(	O
+dendritic	B-ANAT
+cell	B-COMP
+-	O
+specific	O
+ICAM	B-PRGE
+-	I-PRGE
+3	I-PRGE
+-	I-PRGE
+grabbing	I-PRGE
+nonintegrin	I-PRGE
+)	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Immunohistochemistry	O
+revealed	O
+neutrophil	B-ANAT
+,	O
+macrophage	B-ANAT
+,	O
+and	O
+CD8	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+in	O
+the	O
+lung	B-ANAT
+autopsy	O
+of	O
+a	O
+SARS	B-DISO
+patient	O
+who	O
+died	B-PROC
+during	O
+the	O
+acute	O
+phase	O
+of	O
+illness	O
+.	O
+
+Additionally	O
+,	O
+pneumocytes	B-ANAT
+and	O
+macrophages	B-ANAT
+in	O
+the	O
+patient	O
+'	O
+s	O
+lung	B-ANAT
+expressed	B-PROC
+P	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+and	O
+DC	O
+-	O
+SIGN	O
+.	O
+
+Moreover	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+induced	O
+THP	B-CHED
+-	O
+1	O
+cells	B-COMP
+to	O
+express	O
+CCL2	B-PRGE
+/	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+CXCL8	B-PRGE
+/	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+CCL3	B-PRGE
+/	O
+MIP	B-PRGE
+-	I-PRGE
+1alpha	I-PRGE
+,	O
+CXCL10	B-PRGE
+/	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+,	O
+CCL4	B-PRGE
+/	O
+MIP	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+,	O
+and	O
+CCL5	B-PRGE
+/	O
+RANTES	B-PRGE
+,	O
+which	O
+attracted	O
+neutrophils	B-ANAT
+,	O
+monocytes	B-ANAT
+,	O
+and	O
+activated	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+a	O
+chemotaxis	B-PROC
+assay	O
+.	O
+
+IBV	B-SPEC
+strains	O
+of	O
+subgroup	O
+1	O
+have	O
+S1	O
+and	O
+N	O
+proteins	B-CHED
+that	O
+share	O
+a	O
+high	O
+degree	O
+of	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+,	O
+81	O
+to	O
+98	O
+%	O
+in	O
+S1	O
+and	O
+91	O
+to	O
+99	O
+%	O
+in	O
+N	O
+.	O
+Subgroup	O
+2	O
+strains	O
+possess	B-DISO
+S1	O
+and	O
+N	O
+proteins	B-CHED
+that	O
+share	O
+a	O
+low	O
+level	O
+of	O
+identity	O
+with	O
+subgroup	O
+1	O
+strains	O
+:	O
+54	O
+to	O
+62	O
+%	O
+in	O
+S1	O
+and	O
+60	O
+to	O
+62	O
+%	O
+in	O
+N	O
+.	O
+This	O
+paper	O
+describes	O
+the	O
+isolation	O
+and	O
+characterisation	O
+of	O
+a	O
+third	O
+,	O
+previously	O
+undetected	O
+genetic	O
+group	O
+of	O
+IBV	B-SPEC
+in	O
+Australia	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Some	O
+medical	O
+staff	O
+positive	O
+for	O
+serum	B-PRGE
+SARS	B-DISO
+coronavirus	B-SPEC
+antibody	B-COMP
+IgG	I-PRGE
+have	O
+only	O
+mild	O
+symptoms	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+patients	O
+with	O
+SARS	O
+coronavirus	B-DISO
+infection	I-DISO
+who	O
+have	O
+only	O
+mild	O
+symptoms	O
+.	O
+
+RESULTS	O
+:	O
+Serum	B-COMP
+IgG	B-COMP
+antibody	I-COMP
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+was	O
+detected	O
+in	O
+all	O
+the	O
+19	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+among	O
+the	O
+200	O
+staff	O
+members	O
+,	O
+20	O
+(	O
+10	O
+%)	O
+were	O
+found	O
+positive	O
+for	O
+the	O
+antibody	B-COMP
+but	O
+with	O
+no	O
+obvious	O
+or	O
+only	O
+mild	O
+symptoms	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Serum	B-COMP
+IgG	B-COMP
+antibody	I-COMP
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+is	O
+positive	O
+in	O
+a	O
+small	O
+proportion	O
+(	O
+around	O
+10	O
+%)	O
+of	O
+the	O
+medical	O
+staff	O
+members	O
+exposed	O
+to	O
+the	O
+virus	B-SPEC
+in	O
+our	O
+hospital	O
+,	O
+but	O
+may	O
+not	O
+cause	O
+obvious	O
+symptoms	O
+,	O
+suggesting	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+might	O
+in	O
+some	O
+cases	O
+have	O
+mild	O
+or	O
+even	O
+no	O
+clinical	O
+manifestations	O
+.	O
+
+The	O
+extent	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+was	O
+evaluated	O
+by	O
+lung	B-ANAT
+weight	O
+/	O
+body	B-ANAT
+weight	O
+ratio	O
+,	O
+lung	B-ANAT
+weight	O
+gain	O
+,	O
+protein	B-CHED
+concentration	O
+in	O
+bronchoalveolar	O
+lavage	O
+,	O
+and	O
+exhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+.	O
+
+We	O
+also	O
+measured	O
+plasma	B-ANAT
+nitrate	B-CHED
+/	O
+nitrite	B-CHED
+and	O
+methyl	B-CHED
+guanidine	B-CHED
+.	O
+
+In	O
+addition	O
+,	O
+histopathologic	O
+changes	O
+of	O
+the	O
+lung	B-ANAT
+were	O
+examined	O
+.	O
+
+Lipopolysaccharide	B-CHED
+caused	O
+systemic	O
+hypotension	O
+and	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+with	O
+increases	O
+in	O
+plasma	B-ANAT
+nitrate	B-CHED
+/	O
+nitrite	B-CHED
+and	O
+methyl	B-CHED
+guanidine	B-CHED
+.	O
+
+Insulin	B-PRGE
+also	O
+attenuated	O
+the	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+increases	O
+in	O
+nitrate	B-CHED
+/	O
+nitrite	B-CHED
+and	O
+methyl	B-CHED
+guanidine	B-CHED
+.	O
+
+It	O
+is	O
+mainly	O
+localized	O
+to	O
+the	O
+ER	O
+and	O
+the	O
+Golgi	B-COMP
+apparatus	I-COMP
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+signaling	B-PROC
+in	O
+oligodendroglia	B-ANAT
+delays	O
+coronavirus	B-SPEC
+clearance	O
+without	O
+altering	O
+demyelination	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Virus	B-SPEC
+entry	O
+into	O
+cells	B-COMP
+is	O
+mediated	O
+through	O
+interactions	O
+between	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+and	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+).	O
+
+22	O
+-	O
+44	O
+and	O
+22	O
+-	O
+57	O
+)	O
+exhibited	O
+a	O
+modest	O
+antiviral	B-CHED
+activity	O
+with	O
+IC50	O
+of	O
+about	O
+50	O
+microM	O
+and	O
+6	O
+microM	O
+,	O
+respectively	O
+.	O
+
+Clinical	O
+disease	O
+,	O
+CNS	B-CHED
+inflammation	B-DISO
+and	O
+demyelination	B-DISO
+in	O
+infected	O
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+-/-	O
+mice	B-SPEC
+were	O
+similar	O
+to	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+.	O
+
+Similar	O
+kinetics	O
+of	O
+class	B-SPEC
+I	O
+and	O
+class	B-SPEC
+II	O
+upregulation	B-PROC
+on	O
+microglia	B-ANAT
+further	O
+suggested	O
+no	O
+role	O
+of	O
+NK	B-ANAT
+cells	I-ANAT
+in	O
+regulating	O
+major	B-PROC
+histocompatibility	I-PROC
+complex	I-PROC
+(	O
+MHC	O
+)	O
+molecule	O
+expression	B-PROC
+on	O
+resident	O
+CNS	B-CHED
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Valinomycin	B-CHED
+was	O
+recently	O
+reported	O
+to	O
+be	O
+the	O
+most	O
+potent	O
+agent	O
+against	O
+severe	O
+acute	O
+respiratory	O
+-	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Targeted	B-PROC
+disruption	O
+of	O
+a	O
+nonribosomal	B-PROC
+peptide	I-PROC
+synthetase	I-PROC
+(	O
+NRPS	O
+)	O
+gene	O
+abolishes	O
+valinomycin	B-CHED
+production	O
+,	O
+which	O
+confirms	O
+its	O
+predicted	O
+nonribosomal	O
+-	O
+peptide	B-CHED
+origin	O
+.	O
+
+Like	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+was	O
+a	O
+zoonotic	B-DISO
+infection	I-DISO
+,	O
+perhaps	O
+derived	O
+from	O
+related	O
+coronaviruses	O
+in	O
+bats	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Biological	O
+properties	O
+of	O
+the	O
+chick	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolated	O
+in	O
+Russia	O
+].	O
+
+ABSTRACT	O
+:	O
+A	O
+field	O
+chick	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+was	O
+isolated	O
+from	O
+the	O
+pathological	O
+material	O
+on	O
+chick	B-ANAT
+embryos	I-ANAT
+.	O
+
+A	O
+cross	O
+-	O
+neutralization	O
+test	O
+using	O
+sera	B-COMP
+to	O
+various	O
+IBV	B-SPEC
+seroptypes	O
+was	O
+performed	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+epidemiology	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+on	O
+the	O
+basis	O
+of	O
+comparative	O
+analyses	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+attractive	O
+features	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+,	O
+such	O
+as	O
+high	O
+specificity	O
+and	O
+effective	O
+recruitment	B-DISO
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+would	O
+seem	O
+to	O
+make	O
+them	O
+excellent	O
+candidates	O
+as	O
+anti	B-CHED
+-	I-CHED
+infective	I-CHED
+agents	I-CHED
+.	O
+
+Although	O
+the	O
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+)	O
+S	O
+glycoproteins	B-CHED
+share	O
+membership	O
+in	O
+this	O
+class	B-SPEC
+of	O
+envelope	B-PRGE
+glycoproteins	B-CHED
+,	O
+cleavage	B-PROC
+to	O
+generate	O
+the	O
+respective	O
+S1	O
+and	O
+S2	O
+subunits	O
+appears	O
+absent	O
+in	O
+a	O
+subset	O
+of	O
+CoV	B-SPEC
+species	B-SPEC
+,	O
+including	O
+that	O
+responsible	O
+for	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+This	O
+effect	O
+on	O
+the	O
+cell	O
+-	O
+cell	B-COMP
+fusion	O
+activity	O
+by	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+is	O
+not	O
+,	O
+however	O
+,	O
+reflected	O
+in	O
+the	O
+infectivity	O
+of	O
+pseudotyped	O
+lentiviruses	O
+bearing	O
+the	O
+cleaved	B-ANAT
+glycoprotein	B-CHED
+.	O
+
+Because	O
+of	O
+its	O
+critical	O
+role	O
+in	O
+viral	O
+entry	O
+,	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+is	O
+an	O
+important	O
+target	O
+for	O
+the	O
+development	B-PROC
+of	O
+anti	O
+-	O
+SARS	B-DISO
+CoV	O
+therapeutics	O
+and	O
+prophylactics	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+association	O
+between	O
+body	B-ANAT
+mass	O
+index	O
+(	O
+BMI	O
+)	O
+and	O
+hospital	O
+mortality	O
+for	O
+critically	B-DISO
+ill	I-DISO
+adults	O
+.	O
+
+Published	O
+articles	O
+on	O
+experimental	O
+and	O
+clinical	O
+studies	O
+of	O
+coagulation	B-PROC
+and	O
+fibrinolysis	B-PROC
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+the	O
+incidence	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+(	O
+GBS	B-DISO
+)	O
+in	O
+Iran	O
+.	O
+
+The	O
+temporary	O
+interruption	O
+of	O
+the	O
+PD	O
+was	O
+an	O
+effective	O
+measure	O
+to	O
+avoid	O
+the	O
+recurrence	B-DISO
+of	O
+the	O
+MAH	O
+.	O
+
+The	O
+goal	O
+of	O
+the	O
+research	O
+is	O
+to	O
+determine	O
+by	O
+retrospective	O
+study	O
+number	O
+of	O
+cases	O
+of	O
+acute	B-DISO
+polyradiculoneuritis	I-DISO
+during	O
+the	O
+war	O
+in	O
+the	O
+Sarajevo	O
+under	O
+the	O
+siege	O
+and	O
+their	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Developments	O
+in	O
+antiviral	B-CHED
+drug	I-CHED
+design	O
+,	O
+discovery	O
+and	O
+development	B-PROC
+in	O
+2004	O
+.	O
+
+In	O
+case	O
+of	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+inflammation	B-DISO
+spill	O
+over	O
+from	O
+the	O
+lungs	B-ANAT
+,	O
+particularly	O
+there	O
+is	O
+a	O
+persistent	O
+increase	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+CRP	B-PRGE
+in	O
+serum	B-COMP
+,	O
+and	O
+this	O
+is	O
+associated	O
+with	O
+a	O
+worst	O
+prognosis	O
+and	O
+possible	O
+development	B-PROC
+of	O
+sepsis	B-DISO
+-	O
+related	O
+complications	O
+.	O
+
+Recent	O
+randomized	O
+controlled	O
+clinical	O
+trials	O
+on	O
+patients	O
+with	O
+severe	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+support	O
+the	O
+use	O
+of	O
+prolonged	O
+infusion	O
+of	O
+low	O
+doses	O
+of	O
+hydrocortisone	B-CHED
+to	O
+accelerate	O
+the	O
+resolution	O
+of	O
+the	O
+pneumonia	B-DISO
+and	O
+prevent	O
+the	O
+development	B-PROC
+of	O
+complications	O
+due	O
+to	O
+sepsis	B-DISO
+.	O
+
+(	O
+7	O
+)	O
+Lung	B-DISO
+fibrosis	I-DISO
+was	O
+seen	O
+in	O
+five	O
+patients	O
+(	O
+5	O
+/	O
+6	O
+),	O
+with	O
+alveolar	B-ANAT
+septa	O
+and	O
+interstitium	B-ANAT
+thickening	O
+(	O
+5	O
+/	O
+6	O
+),	O
+intraalveolar	O
+organizing	O
+exudates	B-ANAT
+(	O
+6	O
+/	O
+6	O
+)	O
+and	O
+pleura	B-DISO
+thickening	I-DISO
+(	O
+4	O
+/	O
+6	O
+).	O
+
+Proliferation	B-DISO
+of	O
+collagen	B-COMP
+was	O
+confirmed	O
+by	O
+Masson	O
+trichromal	O
+staining	O
+,	O
+most	O
+of	O
+which	O
+was	O
+type	B-PRGE
+III	I-PRGE
+collagen	I-PRGE
+by	O
+immunostaining	O
+.	O
+
+The	O
+formation	B-PROC
+of	O
+distinctive	O
+fibroblast	B-ANAT
+/	O
+myofibroblast	B-ANAT
+foci	O
+was	O
+seen	O
+in	O
+five	O
+patients	O
+(	O
+5	O
+/	O
+6	O
+)	O
+by	O
+light	O
+microscopy	O
+and	O
+immunochemistry	O
+.	O
+
+(	O
+10	O
+)	O
+Accompanying	O
+infection	B-DISO
+was	O
+present	O
+in	O
+two	O
+patients	O
+,	O
+one	O
+was	O
+bacteria	B-SPEC
+,	O
+the	O
+other	O
+was	O
+fungus	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Four	O
+of	O
+six	O
+patients	O
+had	O
+serological	O
+and	O
+RT	O
+-	O
+PCR	O
+evidence	O
+of	O
+recent	O
+infection	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Morphologic	O
+changes	O
+are	O
+summarized	O
+as	O
+follows	O
+:	O
+(	O
+1	O
+)	O
+Diffuse	O
+and	O
+bilateral	O
+lung	B-DISO
+consolidation	I-DISO
+was	O
+seen	O
+in	O
+all	O
+patients	O
+(	O
+6	O
+/	O
+6	O
+)	O
+with	O
+increasing	O
+lung	B-ANAT
+weight	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Direct	O
+injury	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+on	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+,	O
+prominent	O
+macrophage	B-ANAT
+infiltration	B-DISO
+and	O
+distinctive	O
+fibroblast	B-ANAT
+/	O
+myofibroblast	B-ANAT
+proliferation	B-DISO
+may	O
+play	O
+major	O
+roles	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+Of	O
+the	O
+1	O
+,	O
+488	O
+patients	O
+,	O
+49	O
+suffered	B-DISO
+postoperative	O
+ARDS	B-DISO
+.	O
+
+The	O
+occurrence	O
+of	O
+ARDS	B-DISO
+was	O
+negatively	O
+related	O
+to	O
+the	O
+interaction	O
+of	O
+FEV1	O
+%,	O
+(	O
+FEV1	O
+/	O
+FVC	B-PROC
+)%,	O
+MVV	O
+%	O
+and	O
+age	O
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+,	O
+P	O
+=	O
+0	O
+.	O
+005	O
+,	O
+P	O
+=	O
+0	O
+.	O
+048	O
+).	O
+
+Of	O
+the	O
+49	O
+patients	O
+suffered	B-DISO
+severe	O
+preoperative	O
+lung	B-PROC
+function	I-PROC
+damage	O
+,	O
+32	O
+received	O
+intensive	O
+care	O
+right	O
+after	O
+operation	O
+,	O
+of	O
+whom	O
+2	O
+(	O
+6	O
+.	O
+2	O
+%)	O
+had	O
+ARDS	B-DISO
+;	O
+5	O
+(	O
+29	O
+.	O
+4	O
+%)	O
+of	O
+the	O
+remaining	O
+17	O
+had	O
+ARDS	B-DISO
+.	O
+
+Traditional	O
+pulmonary	B-PROC
+function	I-PROC
+test	O
+have	O
+some	O
+correlations	O
+to	O
+postoperative	O
+ARDS	B-DISO
+.	O
+
+While	O
+the	O
+coronaviruses	O
+in	O
+these	O
+species	O
+have	O
+all	O
+been	O
+in	O
+coronavirus	B-SPEC
+Group	I-SPEC
+3	I-SPEC
+,	O
+as	O
+for	O
+the	O
+better	O
+known	O
+coronaviruses	O
+of	O
+the	O
+domestic	O
+fowl	O
+(	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+[	O
+IBV	B-SPEC
+],	O
+in	O
+Gallus	B-SPEC
+gallus	I-SPEC
+),	O
+turkey	B-SPEC
+(	O
+Meleagris	B-SPEC
+gallopavo	I-SPEC
+)	O
+and	O
+pheasant	O
+(	O
+Phasianus	B-SPEC
+colchicus	I-SPEC
+),	O
+there	O
+is	O
+experimental	O
+evidence	O
+to	O
+suggest	O
+that	O
+birds	B-SPEC
+are	O
+not	O
+limited	O
+to	O
+infection	B-DISO
+with	O
+Group	O
+3	O
+coronaviruses	O
+.	O
+
+In	O
+China	O
+coronaviruses	O
+have	O
+been	O
+isolated	O
+from	O
+peafowl	B-SPEC
+(	O
+Pavo	B-SPEC
+),	O
+guinea	B-SPEC
+fowl	I-SPEC
+(	O
+Numida	B-SPEC
+meleagris	I-SPEC
+;	O
+also	O
+isolated	O
+in	O
+Brazil	O
+),	O
+partridge	O
+(	O
+Alectoris	B-SPEC
+)	O
+and	O
+also	O
+from	O
+a	O
+non	O
+-	O
+gallinaceous	O
+bird	B-SPEC
+,	O
+the	O
+teal	O
+(	O
+Anas	B-SPEC
+),	O
+all	O
+of	O
+which	O
+were	O
+being	O
+reared	O
+in	O
+the	O
+vicinity	O
+of	O
+domestic	O
+fowl	O
+.	O
+
+This	O
+study	O
+assessed	O
+quantitative	O
+brain	B-ANAT
+and	O
+ventricular	B-ANAT
+volumes	O
+in	O
+survivors	O
+of	O
+ARDS	B-DISO
+with	O
+brain	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+scans	O
+compared	O
+to	O
+normal	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+monitor	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+infection	B-DISO
+,	O
+a	O
+coronavirus	B-SPEC
+protein	B-CHED
+microarray	O
+that	O
+harbors	O
+proteins	B-CHED
+from	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+five	O
+additional	O
+coronaviruses	O
+was	O
+constructed	O
+.	O
+
+Virus	B-SPEC
+entry	O
+into	O
+cells	B-COMP
+was	O
+inhibited	O
+by	O
+acidotropic	O
+bases	B-CHED
+and	O
+by	O
+other	O
+inhibitors	B-CHED
+of	O
+pH	O
+-	O
+dependent	O
+endocytosis	B-PATH
+.	O
+
+The	O
+wild	O
+-	O
+type	O
+S	O
+(	O
+L	O
+)	O
+form	O
+was	O
+processed	O
+to	O
+the	O
+S	O
+(	O
+H	O
+)	O
+form	O
+,	O
+whereas	O
+the	O
+S	O
+(	O
+L	O
+)	O
+form	O
+of	O
+the	O
+913P	O
+mutant	B-DISO
+was	O
+inefficiently	O
+converted	O
+to	O
+the	O
+S	O
+(	O
+H	O
+)	O
+form	O
+after	O
+biosynthesis	B-PROC
+.	O
+
+None	O
+of	O
+these	O
+mutations	O
+affected	O
+cell	B-COMP
+surface	I-COMP
+expression	B-PROC
+or	O
+binding	B-FUNC
+to	O
+its	O
+cognate	O
+ACE2	B-PRGE
+receptor	I-PRGE
+.	O
+
+The	O
+mutation	O
+at	O
+Ile	B-CHED
+-	O
+1151	O
+did	O
+not	O
+affect	O
+membrane	B-PROC
+fusion	I-PROC
+or	O
+viral	O
+entry	O
+.	O
+
+To	O
+produce	O
+recombinant	O
+viral	B-COMP
+particles	I-COMP
+,	O
+pBAC	O
+-	O
+OC43	O
+(	O
+FL	O
+)	O
+was	O
+transfected	O
+into	O
+BHK	O
+-	O
+21	O
+cells	B-COMP
+.	O
+
+Sweet	B-DISO
+syndrome	I-DISO
+was	O
+confirmed	O
+by	O
+skin	B-ANAT
+biopsy	O
+.	O
+
+Only	O
+three	O
+cases	O
+of	O
+Sweet	B-DISO
+syndrome	I-DISO
+presenting	O
+with	O
+pulmonary	B-DISO
+involvement	I-DISO
+before	O
+the	O
+appearance	O
+of	O
+skin	B-ANAT
+lesions	O
+are	O
+reported	O
+in	O
+the	O
+literature	O
+.	O
+
+Interventional	O
+lung	B-ANAT
+assist	O
+led	O
+to	O
+an	O
+acute	O
+and	O
+moderate	O
+increase	O
+in	O
+arterial	B-ANAT
+oxygenation	B-PROC
+(	O
+Pao2	B-PRGE
+/	O
+Fio2	B-PRGE
+ratio	I-PRGE
+2	I-PRGE
+hrs	I-PRGE
+after	O
+initiation	O
+of	O
+iLA	B-PRGE
+[	O
+median	O
+and	O
+interquartile	O
+range	O
+],	O
+82	O
+mm	O
+Hg	O
+[	O
+64	O
+-	O
+103	O
+])	O
+compared	O
+with	O
+pre	O
+-	O
+iLA	O
+(	O
+58	O
+mm	O
+Hg	O
+[	O
+47	O
+-	O
+78	O
+],	O
+p	O
+<	O
+.	O
+05	O
+).	O
+
+Oxygenation	B-PROC
+continued	O
+to	O
+improve	O
+for	O
+24	O
+hrs	B-DISO
+after	O
+implementation	O
+(	O
+101	O
+mm	O
+Hg	O
+[	O
+74	O
+-	O
+142	O
+],	O
+p	O
+<	O
+.	O
+05	O
+).	O
+
+Interventional	O
+lung	B-ANAT
+assist	O
+might	O
+provide	O
+a	O
+sufficient	O
+rescue	O
+measure	O
+with	O
+easy	O
+handling	O
+properties	O
+and	O
+low	O
+cost	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+persistent	O
+hypoxia	B-DISO
+/	O
+hypercapnia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+For	O
+developing	O
+efficient	O
+vaccines	O
+,	O
+it	O
+is	O
+essential	O
+to	O
+identify	O
+which	O
+amino	O
+acid	O
+changes	O
+are	O
+most	O
+important	O
+to	O
+the	O
+survival	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Patients	O
+>	O
+or	O
+=	O
+18	O
+years	O
+old	O
+who	O
+either	O
+had	O
+not	O
+received	O
+corticosteroid	B-CHED
+or	O
+had	O
+taken	O
+corticosteroids	B-CHED
+within	O
+14	O
+days	O
+from	O
+symptom	B-DISO
+onset	O
+were	O
+included	O
+.	O
+
+Patients	O
+receiving	O
+corticosteroids	B-CHED
+beyond	O
+15	O
+days	O
+or	O
+other	O
+investigational	O
+treatment	O
+within	O
+21	O
+days	O
+from	O
+symptom	B-DISO
+onset	O
+were	O
+excluded	O
+.	O
+
+Of	O
+1313	O
+eligible	O
+patients	O
+,	O
+1287	O
+with	O
+major	O
+corticosteroid	B-CHED
+dosage	O
+-	O
+type	O
+combinations	O
+were	O
+analysed	O
+.	O
+
+Among	O
+four	O
+corticosteroid	B-CHED
+groups	O
+studied	O
+,	O
+mortality	O
+was	O
+lowest	O
+in	O
+the	O
+low	O
+-	O
+dose	O
+oral	B-ANAT
+prednisolone	B-CHED
+(	O
+Group	O
+P	O
+)	O
+and	O
+high	O
+-	O
+dose	O
+methylprednisolone	B-CHED
+(	O
+Group	O
+MP	O
+)	O
+groups	O
+.	O
+
+RESULTS	O
+:	O
+Crude	O
+death	B-PROC
+rate	O
+was	O
+lower	O
+among	O
+1188	O
+steroid	B-CHED
+-	O
+treated	O
+patients	O
+compared	O
+to	O
+99	O
+patients	O
+in	O
+Group	O
+No	O
+Steroid	B-CHED
+(	O
+17	O
+.	O
+0	O
+%	O
+vs	O
+.	O
+28	O
+.	O
+3	O
+%).	O
+
+All	O
+patients	O
+were	O
+monitored	O
+by	O
+the	O
+transpulmonary	O
+double	O
+-	O
+indicator	O
+(	O
+thermo	O
+-	O
+dye	B-CHED
+dilution	O
+)	O
+technique	O
+using	O
+a	O
+thermistor	O
+and	O
+calibrated	O
+fiber	B-ANAT
+-	O
+optic	B-ANAT
+system	O
+(	O
+Pulsiocath	O
+4F	O
+,	O
+PV	O
+2024L	O
+,	O
+Pulsion	O
+Medical	O
+Systems	O
+,	O
+Munich	O
+,	O
+Germany	O
+).	O
+
+For	O
+each	O
+measurement	O
+,	O
+a	O
+dosage	O
+of	O
+0	O
+.	O
+3	O
+mg	O
+/	O
+kg	O
+ICG	B-COMP
+was	O
+injected	O
+central	O
+-	O
+venously	O
+.	O
+
+Transpulmonary	O
+ICG	B-COMP
+concentration	O
+curves	O
+were	O
+analyzed	O
+automatically	O
+using	O
+a	O
+computer	O
+system	O
+(	O
+COLD	B-DISO
+-	O
+Z021	O
+,	O
+Pulsion	O
+Medical	O
+Systems	O
+,	O
+Munich	O
+,	O
+Germany	O
+).	O
+
+Linear	O
+regression	O
+analysis	O
+revealed	O
+a	O
+correlation	O
+of	O
+r2	O
+=	O
+0	O
+.	O
+77	O
+between	O
+ICG	B-COMP
+-	O
+PDR	B-DISO
+and	O
+ICG	B-COMP
+blood	B-ANAT
+clearance	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+develop	O
+a	O
+specific	O
+SARS	B-DISO
+virus	B-SPEC
+-	O
+targeted	B-PROC
+antibody	B-COMP
+preparation	O
+for	O
+emergent	O
+prophylaxis	O
+and	O
+treatment	O
+of	O
+SARS	B-DISO
+virus	B-DISO
+infection	I-DISO
+.	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+immunized	O
+with	O
+the	O
+recombinant	O
+N	O
+proteins	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+229E	O
+and	O
+OC43	O
+to	O
+obtain	O
+the	O
+mAbs	O
+by	O
+means	O
+of	O
+hybridoma	B-ANAT
+.	O
+
+Cross	O
+-	O
+reactivity	O
+between	O
+the	O
+N	O
+proteins	B-CHED
+of	O
+the	O
+3	O
+coronaviruses	O
+was	O
+analyzed	O
+with	O
+the	O
+prepared	O
+mAbs	O
+.	O
+
+The	O
+mAbs	O
+against	O
+the	O
+recombinant	O
+N	O
+proteins	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+229E	O
+and	O
+OC43	O
+were	O
+obtained	O
+,	O
+which	O
+reacted	O
+specifically	O
+with	O
+the	O
+corresponding	O
+viral	O
+N	O
+protein	B-CHED
+as	O
+shown	O
+by	O
+indirect	O
+ELISA	O
+,	O
+Western	O
+blotting	O
+and	O
+indirect	O
+immunofluorescence	O
+assay	O
+.	O
+
+Between	O
+epidemics	O
+,	O
+VEE	O
+disappears	O
+for	O
+periods	B-PROC
+up	O
+to	O
+decades	O
+,	O
+and	O
+the	O
+viral	O
+source	O
+of	O
+outbreaks	O
+has	O
+remained	O
+enigmatic	O
+.	O
+
+These	O
+results	O
+underscore	O
+the	O
+ability	O
+of	O
+RNA	O
+viruses	B-SPEC
+to	O
+alter	O
+their	O
+host	B-COMP
+range	O
+,	O
+virulence	B-PROC
+,	O
+and	O
+epidemic	O
+potential	O
+via	O
+minor	O
+genetic	O
+changes	O
+.	O
+
+ABSTRACT	O
+:	O
+Replication	O
+of	O
+the	O
+giant	B-DISO
+RNA	O
+genome	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+and	O
+synthesis	B-PROC
+of	O
+as	O
+many	O
+as	O
+eight	O
+subgenomic	O
+(	O
+sg	O
+)	O
+mRNAs	O
+are	O
+mediated	O
+by	O
+a	O
+viral	B-PRGE
+replicase	I-PRGE
+-	I-PRGE
+transcriptase	I-PRGE
+of	O
+outstanding	O
+complexity	O
+that	O
+includes	O
+an	O
+essential	O
+endoribonuclease	B-FUNC
+activity	I-FUNC
+.	O
+
+When	O
+part	O
+of	O
+dsRNA	B-CHED
+or	O
+in	O
+the	O
+presence	O
+of	O
+nonlabeled	O
+dsRNA	B-CHED
+,	O
+the	O
+5	O
+'-	O
+labeled	O
+RNA	O
+substrates	O
+were	O
+processed	O
+to	O
+significantly	O
+smaller	O
+products	O
+,	O
+indicating	O
+that	O
+binding	B-FUNC
+to	O
+dsRNA	B-CHED
+in	O
+cis	B-DISO
+or	O
+trans	O
+modulates	O
+the	O
+exonucleolytic	O
+activity	O
+of	O
+nsp14	O
+.	O
+
+CRCoV	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+(	O
+CIRD	O
+)	O
+either	O
+by	O
+predisposing	O
+to	O
+further	O
+and	O
+potentially	O
+more	O
+serious	O
+viral	O
+and	O
+bacterial	B-DISO
+infections	I-DISO
+or	O
+possibly	O
+as	O
+a	O
+primary	O
+pathogen	O
+.	O
+
+Novel	O
+treatments	O
+will	O
+target	O
+both	O
+the	O
+proinflammatory	O
+and	O
+procoagulation	O
+cascades	O
+of	O
+sepsis	B-DISO
+.	O
+
+Purified	O
+soluble	O
+S	O
+-	O
+protein	O
+was	O
+readily	O
+detected	O
+by	O
+Western	O
+blot	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+Myc	I-PRGE
+antibody	I-PRGE
+and	O
+showed	O
+the	O
+ability	O
+to	O
+bind	B-FUNC
+to	O
+surface	O
+of	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+demonstrating	O
+that	O
+the	O
+soluble	B-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	I-PRGE
+could	O
+remain	O
+the	O
+biologic	O
+activity	O
+in	O
+the	O
+native	O
+molecule	O
+.	O
+
+Purified	B-PRGE
+soluble	I-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	I-PRGE
+was	O
+readily	O
+detected	O
+by	O
+Western	O
+blot	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+Myc	I-PRGE
+antibody	I-PRGE
+and	O
+showed	O
+the	O
+ability	O
+to	O
+bind	B-FUNC
+to	O
+surface	O
+of	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+demonstrating	O
+that	O
+the	O
+soluble	B-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	I-PRGE
+could	O
+remain	O
+the	O
+biologic	O
+activity	O
+in	O
+the	O
+native	O
+molecule	O
+.	O
+
+The	O
+high	O
+risk	O
+of	O
+infection	B-DISO
+and	O
+death	B-PROC
+associated	O
+with	O
+caring	O
+for	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+had	O
+a	O
+great	O
+impact	O
+on	O
+nurse	O
+retention	B-PROC
+in	O
+hospitals	O
+.	O
+
+Three	O
+hundred	O
+and	O
+thirty	O
+nurses	O
+working	O
+at	O
+a	O
+Taiwan	O
+hospital	O
+during	O
+the	O
+time	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+completed	O
+the	O
+Meyer	O
+,	O
+Allen	O
+&	O
+Smith	O
+Organizational	O
+and	O
+Occupational	O
+Commitment	O
+Scales	B-ANAT
+,	O
+Intention	O
+to	O
+Leave	O
+and	O
+Perceived	O
+Stress	O
+of	O
+Infection	B-DISO
+Scales	B-ANAT
+between	O
+July	O
+and	O
+August	O
+2003	O
+.	O
+
+The	O
+possible	O
+role	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CLpro	O
+)	O
+in	O
+virus	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+is	O
+characterized	O
+in	O
+this	O
+study	O
+.	O
+
+This	O
+finding	O
+is	O
+likely	O
+to	O
+be	O
+responsible	O
+for	O
+virus	O
+-	O
+induced	O
+apoptotic	O
+signalling	B-PROC
+.	O
+
+Four	O
+of	O
+52	O
+patients	O
+who	O
+had	O
+multiple	O
+BAL	B-ENZY
+samples	O
+submitted	O
+on	O
+the	O
+same	O
+day	O
+had	O
+negative	O
+and	O
+positive	O
+results	O
+by	O
+NAT	B-ENZY
+on	O
+different	O
+samples	O
+.	O
+
+NAT	B-ENZY
+improves	O
+detection	O
+of	O
+potential	O
+pathogens	O
+from	O
+ETT	O
+and	O
+BAL	B-ENZY
+samples	O
+.	O
+
+The	O
+number	O
+of	O
+cats	B-SPEC
+per	O
+household	O
+at	O
+the	O
+time	O
+of	O
+blood	B-ANAT
+collection	O
+had	O
+a	O
+strong	O
+positive	O
+association	O
+with	O
+Immunocomb	O
+score	O
+.	O
+
+ABSTRACT	O
+:	O
+Ventilation	O
+in	O
+the	O
+prone	O
+position	O
+for	O
+about	O
+7	O
+h	O
+/	O
+d	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+does	O
+not	O
+decrease	O
+mortality	O
+.	O
+
+Guidelines	O
+were	O
+established	O
+for	O
+ventilator	O
+settings	O
+and	O
+weaning	B-PROC
+.	O
+
+2	O
+.	O
+9	O
+;	O
+p	O
+=	O
+0	O
+.	O
+01	O
+)	O
+and	O
+a	O
+lower	O
+ratio	O
+of	O
+GRalpha	O
+:	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+in	O
+nuclear	O
+staining	O
+(	O
+0	O
+.	O
+5	O
++/-	O
+0	O
+.	O
+2	O
+vs	O
+.	O
+1	O
+.	O
+5	O
++/-	O
+
+If	O
+24	O
+hrs	B-DISO
+after	O
+meeting	O
+ARDS	B-DISO
+criteria	O
+,	O
+the	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+remained	O
+<	O
+or	O
+=	O
+200	O
+mm	O
+Hg	O
+on	O
+standard	O
+ventilator	O
+settings	O
+,	O
+patients	O
+were	O
+randomized	O
+into	O
+two	O
+groups	O
+:	O
+control	O
+and	O
+Pflex	O
+/	O
+LTV	O
+.	O
+
+A	O
+review	O
+of	O
+articles	O
+reporting	O
+on	O
+the	O
+diagnosis	O
+and	O
+management	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+The	O
+destruction	O
+of	O
+pancreatic	B-ANAT
+parenchyma	I-ANAT
+induces	O
+a	O
+systemic	O
+activation	B-PROC
+of	I-PROC
+coagulation	I-PROC
+,	O
+kinin	B-PRGE
+,	O
+complement	O
+and	O
+fibrinolytic	O
+cascades	O
+with	O
+liberation	O
+of	O
+cytokines	O
+and	O
+reactive	O
+oxygen	B-CHED
+metabolites	B-CHED
+which	O
+,	O
+if	O
+severe	O
+and	O
+overwhelming	O
+,	O
+can	O
+lead	O
+to	O
+shock	O
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+85	O
+-	O
+90	O
+%	O
+of	O
+patients	O
+,	O
+acute	B-DISO
+pancreatitis	I-DISO
+is	O
+self	O
+-	O
+limiting	O
+and	O
+subsides	O
+spontaneously	O
+within	O
+4	O
+-	O
+7	O
+days	O
+.	O
+
+Respiratory	B-DISO
+complications	I-DISO
+of	O
+chronic	B-DISO
+renal	I-DISO
+failure	I-DISO
+include	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+fibrinous	B-DISO
+pleuritis	I-DISO
+,	O
+pulmonary	B-DISO
+calcification	B-PROC
+,	O
+and	O
+a	O
+predisposition	O
+to	O
+tuberculosis	B-PATH
+.	O
+
+Sleep	B-DISO
+disturbances	I-DISO
+are	O
+extremely	O
+common	O
+in	O
+patients	O
+with	O
+end	B-DISO
+-	I-DISO
+stage	I-DISO
+renal	I-DISO
+disease	I-DISO
+,	O
+with	O
+sleep	B-DISO
+apnea	I-DISO
+occurring	O
+in	O
+60	O
+%	O
+or	O
+more	O
+of	O
+such	O
+patients	O
+.	O
+
+The	O
+mass	O
+migration	B-PROC
+during	O
+the	O
+Hajj	O
+is	O
+unparalleled	O
+in	O
+scale	O
+,	O
+and	O
+pilgrims	O
+face	B-DISO
+numerous	O
+health	O
+hazards	O
+.	O
+
+TITLE	O
+:	O
+The	O
+comparative	O
+pathology	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+subtype	O
+H5N1	O
+--	O
+a	O
+review	O
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+associated	O
+coronavirus	B-SPEC
+disseminates	O
+to	O
+blood	B-ANAT
+,	O
+urine	B-ANAT
+,	O
+feces	B-ANAT
+,	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+,	O
+and	O
+liver	B-ANAT
+.	O
+
+M	B-SPEC
+.	I-SPEC
+bovis	I-SPEC
+pneumonia	B-DISO
+and	O
+polyarthritis	B-DISO
+has	O
+emerged	O
+as	O
+an	O
+important	O
+cause	O
+of	O
+mortality	O
+in	O
+Ontario	O
+beef	O
+feedlots	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+influenza	I-DISO
+(	O
+H5N1	B-DISO
+):	O
+implications	O
+for	O
+intensive	O
+care	O
+.	O
+
+Review	O
+of	O
+the	O
+cases	O
+of	O
+influenza	B-DISO
+A	I-DISO
+/	I-DISO
+H5N1	I-DISO
+reported	O
+to	O
+date	O
+demonstrates	O
+that	O
+it	O
+causes	O
+a	O
+severe	O
+illness	O
+,	O
+with	O
+a	O
+high	O
+proportion	O
+of	O
+patients	O
+(	O
+63	O
+%)	O
+requiring	O
+advanced	O
+organ	B-ANAT
+support	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+features	O
+and	O
+correlates	O
+of	O
+gemcitabine	B-CHED
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+:	O
+findings	O
+from	O
+the	O
+RADAR	B-PRGE
+project	O
+.	O
+
+ABSTRACT	O
+:	O
+Gemcitabine	B-CHED
+is	O
+a	O
+commonly	O
+used	O
+chemotherapeutic	O
+agent	O
+structurally	O
+and	O
+pharmacologically	O
+similar	O
+to	O
+cytarabine	B-CHED
+.	O
+
+Clinical	O
+data	O
+were	O
+obtained	O
+by	O
+reviewing	O
+adverse	O
+event	O
+case	O
+reports	O
+for	O
+gemcitabine	B-CHED
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+as	O
+reported	O
+in	O
+the	O
+medical	O
+literature	O
+and	O
+in	O
+the	O
+FDA	O
+AERS	O
+database	O
+.	O
+
+The	O
+taxanes	O
+,	O
+docetaxel	B-CHED
+and	O
+paclitaxel	B-CHED
+,	O
+were	O
+frequently	O
+reported	O
+as	O
+coadministered	O
+therapies	O
+.	O
+
+The	O
+neurologic	B-DISO
+signs	I-DISO
+of	O
+limb	B-DISO
+numbness	I-DISO
+and	O
+water	B-CHED
+phobia	B-DISO
+occurred	O
+from	O
+61	O
+days	O
+after	O
+the	O
+dog	B-SPEC
+bite	B-PROC
+;	O
+the	O
+clinical	O
+course	O
+was	O
+progressive	O
+,	O
+with	O
+the	O
+most	O
+severe	O
+clinical	O
+manifestations	O
+being	O
+fever	B-PROC
+,	O
+encephalitis	B-DISO
+,	O
+and	O
+ARDS	B-DISO
+.	O
+
+Immunohistochemistry	O
+stain	O
+and	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+for	O
+rabies	B-SPEC
+virus	I-SPEC
+failed	O
+to	O
+demonstrate	O
+the	O
+organism	O
+in	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+To	O
+support	O
+the	O
+clinical	O
+development	B-PROC
+of	O
+each	O
+of	O
+these	O
+vaccine	O
+candidates	O
+,	O
+preclinical	O
+studies	O
+were	O
+performed	O
+to	O
+screen	O
+for	O
+potential	O
+toxicities	O
+(	O
+intrinsic	O
+and	O
+immunotoxicities	O
+).	O
+
+These	O
+data	O
+build	O
+on	O
+the	O
+biodistribution	O
+studies	O
+performed	O
+(	O
+see	O
+companion	O
+article	O
+,	O
+Sheets	O
+et	O
+al	O
+.,	O
+2006	O
+)	O
+to	O
+demonstrate	O
+the	O
+safety	O
+and	O
+suitability	O
+for	O
+investigational	O
+human	B-SPEC
+use	O
+of	O
+DNA	O
+plasmid	O
+vaccine	O
+candidates	O
+for	O
+a	O
+variety	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+prevention	O
+indications	O
+.	O
+
+In	O
+the	O
+course	O
+of	O
+these	O
+studies	O
+,	O
+it	O
+has	O
+been	O
+observed	O
+that	O
+regardless	O
+of	O
+the	O
+gene	O
+insert	O
+(	O
+expressing	O
+the	O
+vaccine	O
+immunogen	B-CHED
+or	O
+cytokine	O
+adjuvant	B-CHED
+)	O
+and	O
+regardless	O
+of	O
+the	O
+promoter	O
+used	O
+to	O
+drive	O
+expression	B-PROC
+of	O
+the	O
+gene	O
+insert	O
+in	O
+the	O
+plasmid	O
+backbone	B-ANAT
+,	O
+the	O
+plasmid	O
+vaccines	O
+do	O
+not	O
+biodistribute	O
+widely	O
+and	O
+remain	O
+essentially	O
+in	O
+the	O
+site	O
+of	O
+injection	O
+,	O
+in	O
+the	O
+muscle	O
+and	O
+overlying	O
+subcutis	B-ANAT
+.	O
+
+This	O
+pattern	O
+of	O
+biodistribution	O
+(	O
+confined	O
+to	O
+the	O
+injection	O
+site	O
+)	O
+and	O
+clearance	O
+(	O
+within	O
+2	O
+months	O
+)	O
+is	O
+consistent	O
+regardless	O
+of	O
+differences	O
+in	O
+the	O
+promoter	O
+in	O
+the	O
+plasmid	O
+backbone	B-ANAT
+or	O
+differences	O
+in	O
+the	O
+gene	O
+insert	O
+being	O
+expressed	B-PROC
+by	O
+the	O
+plasmid	O
+vaccine	O
+.	O
+
+Besides	O
+WN	O
+virus	B-SPEC
+,	O
+the	O
+compound	O
+also	O
+inhibited	O
+other	O
+flaviviruses	B-SPEC
+(	O
+dengue	B-DISO
+,	O
+yellow	B-DISO
+fever	I-DISO
+,	O
+and	O
+St	B-DISO
+.	I-DISO
+Louis	I-DISO
+encephalitis	I-DISO
+viruses	B-SPEC
+),	O
+an	O
+alphavirus	B-SPEC
+(	O
+Western	B-SPEC
+equine	I-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+),	O
+a	O
+coronavirus	B-SPEC
+(	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+),	O
+and	O
+a	O
+rhabdovirus	B-SPEC
+(	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+).	O
+
+TITLE	O
+:	O
+Expanding	O
+ICU	O
+facilities	O
+in	O
+an	O
+epidemic	O
+:	O
+recommendations	O
+based	O
+on	O
+experience	O
+from	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+and	O
+Singapore	O
+.	O
+
+One	O
+of	O
+the	O
+principal	O
+factors	O
+that	O
+control	O
+the	O
+outcome	O
+of	O
+infection	B-DISO
+is	O
+the	O
+localized	O
+tissue	B-ANAT
+response	O
+and	O
+subsequent	O
+immune	B-PROC
+response	I-PROC
+directed	O
+against	O
+the	O
+invading	O
+toxic	O
+agent	O
+.	O
+
+Indeed	O
+,	O
+studies	O
+with	O
+a	O
+neurotropic	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+have	O
+provided	O
+important	O
+insight	O
+into	O
+the	O
+functional	O
+roles	O
+of	O
+chemokines	O
+and	O
+chemokine	O
+receptors	O
+in	O
+participating	O
+in	O
+various	O
+aspects	O
+of	O
+host	O
+defense	O
+as	O
+well	O
+as	O
+disease	O
+development	B-PROC
+within	O
+the	O
+CNS	B-CHED
+.	O
+
+These	O
+are	O
+processed	O
+primarily	O
+by	O
+the	O
+chymotrypsin	B-ENZY
+-	O
+like	O
+main	O
+proteinases	O
+(	O
+M	O
+(	O
+pro	B-CHED
+)	O
+s	O
+).	O
+
+Heterologous	O
+expression	B-PROC
+of	O
+this	O
+domain	O
+resulted	O
+in	O
+autoprocessing	O
+at	O
+flanking	O
+cleavage	B-PROC
+sites	O
+.	O
+
+N	O
+-	O
+terminal	O
+sequence	O
+analysis	O
+of	O
+cleavage	B-PROC
+products	O
+tentatively	O
+identified	O
+FxxQ	O
+downward	O
+arrow	O
+(	O
+S	O
+,	O
+A	O
+)	O
+as	O
+the	O
+substrate	O
+consensus	O
+sequence	O
+.	O
+
+A	O
+review	O
+of	O
+articles	O
+reported	O
+from	O
+1980	O
+to	O
+2002	O
+and	O
+identified	O
+through	O
+a	O
+MEDLINE	O
+search	O
+on	O
+metabolic	B-DISO
+encephalopathy	I-DISO
+,	O
+polyneuropathy	B-DISO
+and	O
+myopathy	B-DISO
+in	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+Apart	O
+from	O
+treatment	O
+of	O
+the	O
+underlying	O
+cause	O
+(	O
+e	O
+.	O
+g	O
+sepsis	B-DISO
+),	O
+there	O
+is	O
+no	O
+specific	O
+treatment	O
+,	O
+although	O
+a	O
+44	O
+%	O
+reduction	O
+in	O
+the	O
+incidence	O
+of	O
+critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+has	O
+been	O
+described	O
+in	O
+mechanically	O
+ventilated	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+who	O
+received	O
+intensive	O
+insulin	B-PRGE
+therapy	O
+to	O
+maintain	O
+the	O
+blood	B-ANAT
+glucose	B-CHED
+level	O
+between	O
+4	O
+.	O
+4	O
+-	O
+6	O
+.	O
+1	O
+mmol	O
+/	O
+L	O
+.	O
+Recovery	O
+usually	O
+occurs	O
+over	O
+weeks	O
+to	O
+months	O
+depending	O
+on	O
+the	O
+severity	O
+of	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Sialic	B-CHED
+acids	I-CHED
+as	O
+receptor	O
+determinants	O
+for	O
+coronaviruses	O
+.	O
+
+In	O
+fact	O
+,	O
+many	O
+different	O
+viruses	B-SPEC
+use	O
+members	O
+of	O
+the	O
+sialic	B-CHED
+acid	I-CHED
+family	B-SPEC
+either	O
+as	O
+their	O
+main	O
+receptor	O
+or	O
+as	O
+an	O
+initial	O
+attachment	O
+factor	O
+.	O
+
+The	O
+latter	O
+,	O
+originally	O
+discovered	O
+in	O
+influenza	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+,	O
+are	O
+also	O
+found	O
+in	O
+certain	O
+nidoviruses	B-SPEC
+,	O
+namely	O
+in	O
+group	O
+2	O
+coronaviruses	O
+and	O
+in	O
+toroviruses	B-SPEC
+,	O
+as	O
+well	O
+as	O
+in	O
+infectious	B-SPEC
+salmon	I-SPEC
+anemia	B-DISO
+virus	I-SPEC
+,	O
+an	O
+orthomyxovirus	B-SPEC
+of	O
+teleosts	O
+.	O
+
+Until	O
+now	O
+,	O
+the	O
+distribution	O
+of	O
+these	O
+sialic	B-CHED
+acids	I-CHED
+in	O
+mouse	B-ANAT
+brain	I-ANAT
+was	O
+not	O
+thoroughly	O
+investigated	O
+.	O
+
+TITLE	O
+:	O
+The	O
+war	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+
+This	O
+article	O
+outlines	O
+the	O
+USFK	O
+campaign	O
+plan	B-DISO
+for	O
+the	O
+SARS	B-DISO
+epidemic	O
+and	O
+documents	O
+lessons	O
+learned	B-PROC
+for	O
+future	O
+outbreaks	O
+of	O
+highly	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+RAS	B-CHED
+has	O
+been	O
+implicated	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+pulmonary	B-DISO
+hypertension	I-DISO
+and	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+,	O
+both	O
+commonly	O
+seen	O
+in	O
+chronic	O
+lung	B-DISO
+diseases	I-DISO
+such	O
+as	O
+chronic	B-DISO
+obstructive	I-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+Thus	O
+,	O
+the	O
+RAS	B-CHED
+appears	O
+to	O
+play	O
+a	O
+critical	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+,	O
+purification	O
+and	O
+crystallization	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+macro	O
+domain	O
+.	O
+
+Both	O
+native	O
+and	O
+selenomethionine	O
+-	O
+labelled	O
+crystals	B-ANAT
+diffract	O
+to	O
+1	O
+.	O
+8	O
+angstroms	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+analysis	O
+of	O
+Brazilian	O
+strains	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+reveals	O
+a	O
+deletion	O
+within	O
+the	O
+hypervariable	O
+region	O
+of	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+spike	O
+glycoprotein	O
+also	O
+found	O
+in	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+.	O
+
+No	O
+such	O
+expansion	O
+of	O
+their	O
+alpha	O
+beta	O
+T	B-ANAT
+cell	I-ANAT
+pools	O
+was	O
+detected	O
+.	O
+
+These	O
+findings	O
+are	O
+compatible	O
+with	O
+the	O
+possibility	O
+that	O
+V	B-PRGE
+gamma	I-PRGE
+9V	I-PRGE
+delta	I-PRGE
+2	I-PRGE
+T	I-PRGE
+cells	O
+play	O
+a	O
+protective	O
+role	O
+during	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Antigenic	O
+and	O
+molecular	O
+characterization	O
+of	O
+isolates	O
+of	O
+the	O
+Italy	O
+02	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+genotype	O
+.	O
+
+Given	O
+that	O
+little	O
+was	O
+known	O
+about	O
+this	O
+new	O
+emergent	O
+IBV	B-SPEC
+strain	O
+we	O
+have	O
+characterized	O
+the	O
+four	O
+isolates	O
+by	O
+sequencing	O
+the	O
+entire	O
+S1	O
+part	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+and	O
+have	O
+compared	O
+them	O
+with	O
+many	O
+reference	O
+IBV	B-SPEC
+serotypes	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+of	O
+a	O
+coronavirus	B-SPEC
+from	O
+a	O
+green	O
+-	O
+cheeked	O
+Amazon	B-SPEC
+parrot	I-SPEC
+(	O
+Amazon	B-SPEC
+viridigenalis	O
+Cassin	O
+).	O
+
+The	O
+partial	O
+sequences	O
+analysed	O
+spanned	O
+the	O
+hypervariable	O
+amino	O
+terminus	O
+region	O
+of	O
+S1	O
+from	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+48	O
+to	O
+219	O
+,	O
+based	O
+on	O
+the	O
+Beaudette	O
+strain	O
+.	O
+
+The	O
+antibody	B-COMP
+-	O
+bound	O
+RBD	O
+structure	O
+is	O
+completely	O
+defined	O
+,	O
+revealing	O
+two	O
+previously	O
+unresolved	O
+segments	O
+(	O
+residues	O
+376	O
+-	O
+381	O
+and	O
+503	O
+-	O
+512	O
+)	O
+and	O
+a	O
+new	O
+disulfide	B-CHED
+bond	O
+(	O
+between	O
+residues	O
+378	O
+and	O
+511	O
+).	O
+
+Interestingly	O
+,	O
+the	O
+overall	O
+structure	O
+of	O
+the	O
+m396	O
+-	O
+bound	O
+RBD	O
+is	O
+not	O
+significantly	O
+different	O
+from	O
+that	O
+of	O
+the	O
+ACE2	B-PRGE
+-	O
+bound	O
+RBD	O
+.	O
+
+The	O
+available	O
+structural	O
+information	O
+indicates	O
+that	O
+the	O
+SCV	B-SPEC
+entry	O
+may	O
+not	O
+be	O
+mediated	O
+by	O
+ACE2	B-PRGE
+-	O
+induced	O
+conformational	O
+changes	O
+in	O
+the	O
+RBD	O
+but	O
+may	O
+involve	O
+other	O
+conformational	O
+changes	O
+or	O
+/	O
+and	O
+yet	O
+to	O
+be	O
+identified	O
+coreceptors	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+pulmonary	O
+embolism	O
+increases	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+and	O
+may	O
+lead	O
+to	O
+acute	B-DISO
+right	I-DISO
+ventricular	I-DISO
+failure	I-DISO
+and	O
+cardiocirculatory	O
+collapse	B-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+possibly	O
+resulting	O
+in	O
+substantial	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+This	O
+case	O
+series	O
+describes	O
+our	O
+experience	O
+with	O
+inhaled	B-PROC
+NO	O
+administered	O
+to	O
+four	O
+patients	O
+suffering	B-DISO
+from	O
+acute	B-DISO
+massive	I-DISO
+pulmonary	I-DISO
+embolism	I-DISO
+following	O
+abdominal	B-ANAT
+surgery	O
+.	O
+
+The	O
+four	O
+described	O
+patients	O
+recovering	O
+from	O
+small	B-ANAT
+bowel	I-ANAT
+resection	O
+,	O
+pancreatoduodenectomy	O
+,	O
+hemipelvectomy	O
+,	O
+or	O
+recent	O
+gastrointestinal	B-DISO
+bleeding	I-DISO
+had	O
+severe	O
+respiratory	O
+and	O
+hemodynamic	B-PROC
+deterioration	O
+due	O
+to	O
+pulmonary	B-DISO
+embolism	I-DISO
+.	O
+
+Her	O
+anosmia	B-DISO
+persisted	O
+for	O
+more	O
+than	O
+2	O
+years	O
+during	O
+following	O
+up	O
+.	O
+
+Olfactory	B-PROC
+neuropathy	B-DISO
+,	O
+which	O
+rarely	O
+occurred	O
+in	O
+typical	O
+peripheral	B-DISO
+neuropathy	I-DISO
+,	O
+could	O
+be	O
+a	O
+special	O
+type	O
+of	O
+neuropathy	B-DISO
+induced	O
+by	O
+corona	B-DISO
+virus	B-PROC
+infection	I-PROC
+in	O
+SARS	B-DISO
+.	O
+
+The	O
+pathophysiology	O
+and	O
+therapeutic	O
+strategy	O
+of	O
+this	O
+special	O
+type	O
+of	O
+permanent	O
+olfactory	B-PROC
+dysfunction	O
+deserve	O
+further	O
+investigation	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Microenvironment	O
+of	O
+positive	O
+pressure	O
+powered	O
+air	B-CHED
+purifying	O
+medical	O
+protective	O
+equipment	O
+].	O
+
+The	O
+medical	O
+protective	O
+equipment	O
+can	O
+protect	O
+the	O
+doctor	O
+and	O
+nurse	O
+in	O
+SARS	B-DISO
+contaminated	O
+areas	O
+effectively	O
+and	O
+improve	O
+their	O
+work	O
+conditions	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+medical	O
+protective	O
+equipment	O
+can	O
+protect	O
+the	O
+doctor	O
+and	O
+nurse	O
+in	O
+SARS	B-DISO
+contaminated	O
+areas	O
+effectively	O
+and	O
+improve	O
+their	O
+work	O
+conditions	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+3C	O
+-	O
+like	O
+protease	O
+(	O
+3CL	O
+(	O
+pro	B-CHED
+))	O
+mediates	O
+extensive	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+replicase	B-PRGE
+polyproteins	I-PRGE
+,	O
+and	O
+is	O
+considered	O
+a	O
+promising	O
+target	O
+for	O
+anti	O
+-	O
+SARS	B-DISO
+drug	O
+development	B-PROC
+.	O
+
+Susceptibility	O
+of	O
+each	O
+peptide	B-CHED
+substrate	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+cleavage	B-PROC
+was	O
+monitored	O
+simultaneously	O
+by	O
+matrix	O
+-	O
+assisted	O
+laser	O
+desorption	O
+/	O
+ionization	O
+time	O
+-	O
+of	O
+-	O
+flight	B-PROC
+mass	O
+spectrometry	O
+(	O
+MALDI	O
+-	O
+TOF	B-DISO
+MS	O
+).	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+spike	O
+and	O
+nucleoprotein	O
+genes	O
+demonstrates	O
+genetic	B-PROC
+drift	I-PROC
+between	O
+chronologically	O
+distinct	O
+strains	O
+.	O
+
+In	O
+comparison	O
+with	O
+Influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+and	O
+Sendai	B-SPEC
+virus	I-SPEC
+,	O
+IBV	B-SPEC
+was	O
+most	O
+sensitive	O
+to	O
+pre	O
+-	O
+treatment	O
+of	O
+cells	B-COMP
+with	O
+neuraminidase	B-PRGE
+.	O
+
+Overall	O
+,	O
+inoculation	O
+by	O
+a	O
+mucosal	B-ANAT
+route	O
+produced	O
+more	O
+prominent	O
+disease	O
+than	O
+did	O
+intravenous	O
+inoculation	O
+.	O
+
+The	O
+experiments	O
+were	O
+performed	O
+on	O
+seven	O
+pigs	B-SPEC
+(	O
+48	O
+-	O
+60	O
+kg	O
+body	B-ANAT
+weight	O
+).	O
+
+The	O
+pigs	B-SPEC
+were	O
+anesthetized	O
+and	O
+mechanically	O
+ventilated	O
+.	O
+
+O2	O
+delivery	O
+through	O
+ILA	O
+increased	O
+with	O
+extracorporeal	O
+shunt	O
+flow	O
+(	O
+36	O
+(+/-	O
+14	O
+)	O
+ml	O
+O2	O
+/	O
+min	O
+versus	O
+47	O
+(+/-	O
+17	O
+)	O
+ml	O
+O2	O
+/	O
+min	O
+)	O
+and	O
+reduced	O
+arterialization	B-PROC
+of	O
+the	O
+inlet	O
+blood	B-ANAT
+.	O
+
+Sheep	B-SPEC
+were	O
+allocated	O
+to	O
+a	O
+)	O
+sham	O
+group	O
+,	O
+b	O
+)	O
+saline	O
+continuous	O
+nebulization	O
+group	O
+,	O
+c	O
+)	O
+20	O
+mg	O
+of	O
+albuterol	B-CHED
+continuous	O
+nebulization	O
+group	O
+,	O
+or	O
+d	O
+)	O
+40	O
+mg	O
+of	O
+albuterol	B-CHED
+continuous	O
+nebulization	O
+group	O
+(	O
+n	O
+=	O
+5	O
+animals	B-SPEC
+per	O
+group	O
+).	O
+
+Pulmonary	B-ANAT
+and	O
+cardiac	B-PROC
+function	I-PROC
+,	O
+lung	B-ANAT
+lymph	B-PROC
+flow	I-PROC
+,	O
+bronchial	B-ANAT
+obstruction	B-DISO
+score	O
+,	O
+and	O
+wet	O
+/	O
+dry	O
+lung	B-ANAT
+weights	O
+were	O
+recorded	O
+.	O
+
+The	O
+wet	O
+-	O
+to	O
+-	O
+dry	O
+lung	B-ANAT
+weight	O
+ratio	O
+and	O
+bronchial	B-ANAT
+obstruction	B-DISO
+scores	O
+were	O
+lower	O
+for	O
+sheep	B-SPEC
+receiving	O
+albuterol	B-CHED
+.	O
+
+Comorbidities	O
+of	O
+diabetes	B-DISO
+and	O
+heart	B-DISO
+failure	I-DISO
+were	O
+more	O
+common	O
+in	O
+patients	O
+who	O
+developed	O
+ARF	B-DISO
+(	O
+38	O
+%	O
+vs	O
+6	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+and	O
+38	O
+%	O
+vs	O
+2	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+respectively	O
+)	O
+and	O
+the	O
+incidence	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+85	O
+%	O
+vs	O
+26	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+mortality	O
+(	O
+77	O
+%	O
+vs	O
+8	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+also	O
+higher	O
+.	O
+
+Development	B-PROC
+of	O
+ARF	B-DISO
+during	O
+the	O
+disease	O
+course	O
+in	O
+SARS	B-DISO
+patients	O
+is	O
+associated	O
+with	O
+catastrophic	O
+outcome	O
+.	O
+
+The	O
+cause	O
+of	O
+ARF	B-DISO
+in	O
+SARS	B-DISO
+patients	O
+is	O
+often	O
+associated	O
+with	O
+pre	O
+-	O
+renal	B-ANAT
+factors	O
+,	O
+hypotension	O
+,	O
+rhabdomyolysis	B-DISO
+,	O
+and	O
+previous	O
+comorbidities	O
+including	O
+diabetes	B-DISO
+and	O
+old	O
+age	O
+.	O
+
+Universal	O
+precautions	O
+to	O
+prevent	O
+viral	B-PROC
+transmission	I-PROC
+are	O
+mandatory	O
+for	O
+medical	O
+staff	O
+performing	O
+renal	B-ANAT
+replacement	O
+therapy	O
+.	O
+
+ABSTRACT	O
+:	O
+Proteases	O
+fulfill	O
+multiple	O
+roles	O
+in	O
+health	O
+and	O
+disease	O
+,	O
+and	O
+considerable	O
+interest	O
+has	O
+been	O
+expressed	O
+in	O
+the	O
+design	O
+and	O
+development	B-PROC
+of	O
+synthetic	O
+inhibitors	B-CHED
+of	O
+disease	O
+-	O
+related	O
+proteases	O
+.	O
+
+ABSTRACT	O
+:	O
+Helicases	B-PRGE
+are	O
+promising	O
+antiviral	B-CHED
+drug	I-CHED
+targets	O
+because	O
+their	O
+enzymatic	O
+activities	O
+are	O
+essential	O
+for	O
+viral	B-PROC
+genome	I-PROC
+replication	I-PROC
+,	O
+transcription	B-PROC
+,	O
+and	O
+translation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+and	O
+inhibition	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+main	I-PRGE
+protease	I-PRGE
+.	O
+
+Thus	O
+,	O
+alpha	O
+,	O
+beta	O
+-	O
+unsaturated	O
+peptidomimetics	B-CHED
+,	O
+anilides	O
+,	O
+metal	B-CHED
+-	O
+conjugated	O
+compounds	O
+,	O
+boronic	B-CHED
+acids	I-CHED
+,	O
+quinolinecarboxylate	O
+derivatives	O
+,	O
+thiophenecarboxylates	O
+,	O
+phthalhydrazide	O
+-	O
+substituted	O
+ketoglutamine	O
+analogues	O
+,	O
+isatin	B-CHED
+and	O
+natural	B-CHED
+products	I-CHED
+have	O
+been	O
+identified	O
+as	O
+potent	O
+inhibitors	B-CHED
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+main	I-PRGE
+protease	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+functionally	O
+important	O
+negatively	O
+charged	O
+residues	O
+in	O
+the	O
+carboxy	B-CHED
+end	O
+of	O
+mouse	B-SPEC
+hepatitis	I-DISO
+coronavirus	B-SPEC
+A59	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+is	O
+a	O
+multifunctional	O
+viral	O
+gene	O
+product	O
+that	O
+encapsidates	O
+the	O
+RNA	O
+genome	O
+and	O
+also	O
+plays	O
+some	O
+as	O
+yet	O
+not	O
+fully	O
+defined	O
+role	O
+in	O
+viral	O
+RNA	B-PROC
+replication	I-PROC
+and	O
+/	O
+or	O
+transcription	B-PROC
+.	O
+
+A	O
+number	O
+of	O
+conserved	O
+negatively	O
+charged	O
+amino	B-CHED
+acids	I-CHED
+are	O
+located	O
+within	O
+domain	O
+III	O
+in	O
+the	O
+carboxy	B-CHED
+end	O
+of	O
+all	O
+coronavirus	B-SPEC
+N	O
+proteins	B-CHED
+.	O
+
+Previous	O
+studies	O
+suggested	O
+that	O
+the	O
+negatively	O
+charged	O
+residues	O
+are	O
+involved	O
+in	O
+virus	B-PROC
+assembly	I-PROC
+by	O
+mediating	O
+interaction	O
+between	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+carboxy	B-CHED
+tail	O
+and	O
+nucleocapsids	O
+.	O
+
+When	O
+either	O
+amino	B-CHED
+acid	I-CHED
+was	O
+replaced	O
+by	O
+a	O
+positively	O
+charged	O
+residue	O
+or	O
+both	O
+were	O
+changed	O
+to	O
+alanine	B-CHED
+,	O
+viruses	B-SPEC
+were	O
+recovered	O
+that	O
+contained	O
+second	O
+-	O
+site	O
+changes	O
+within	O
+N	O
+,	O
+but	O
+not	O
+in	O
+the	O
+M	B-PRGE
+or	I-PRGE
+envelope	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+arterial	B-ANAT
+hypoxemia	O
+,	O
+and	O
+prone	O
+position	O
+(	O
+PP	O
+)	O
+is	O
+one	O
+possible	O
+management	O
+strategy	O
+.	O
+
+The	O
+objective	O
+here	O
+was	O
+to	O
+evaluate	O
+the	O
+effects	O
+of	O
+PP	O
+on	O
+oxygenation	B-PROC
+.	O
+
+The	O
+paired	B-PRGE
+-	I-PRGE
+t	I-PRGE
+and	O
+Dunnett	O
+tests	O
+were	O
+used	O
+.	O
+
+A	O
+notable	O
+clinical	O
+improvement	O
+in	O
+oxygenation	B-PROC
+(>	O
+15	O
+%)	O
+was	O
+detected	O
+in	O
+78	O
+.	O
+0	O
+%	O
+of	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Drug	O
+-,	O
+toxin	O
+-,	O
+and	O
+radiation	O
+therapy	O
+-	O
+induced	O
+eosinophilic	B-DISO
+pneumonia	I-DISO
+.	O
+
+Antibiotics	B-CHED
+and	O
+NSAID	B-CHED
+,	O
+are	O
+the	O
+most	O
+commonly	O
+reported	O
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+pulmonary	B-DISO
+hypertension	I-DISO
+associated	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+predictive	O
+value	O
+of	O
+computed	O
+tomography	O
+.	O
+
+95	O
+patients	O
+(	O
+92	O
+.	O
+2	O
+%)	O
+with	O
+ARDS	B-DISO
+had	O
+pulmonary	B-DISO
+artery	I-DISO
+hypertension	I-DISO
+,	O
+16	O
+of	O
+them	O
+(	O
+16	O
+.	O
+8	O
+%)	O
+mild	O
+,	O
+72	O
+(	O
+75	O
+.	O
+8	O
+%)	O
+moderate	O
+,	O
+and	O
+7	O
+(	O
+7	O
+.	O
+4	O
+%)	O
+severe	O
+,	O
+as	O
+assessed	O
+by	O
+right	B-ANAT
+heart	I-ANAT
+catheterization	O
+.	O
+
+The	O
+diagnosis	O
+of	O
+pulmonary	O
+hypertension	O
+by	O
+PAT	B-DISO
+diameter	O
+measurements	O
+was	O
+incorrect	O
+in	O
+43	O
+.	O
+7	O
+%	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Peptides	B-CHED
+analogous	O
+to	O
+regions	O
+of	O
+the	O
+N	O
+-	O
+terminus	O
+or	O
+the	O
+pre	O
+-	O
+transmembrane	O
+domain	O
+of	O
+the	O
+S2	O
+subunit	O
+inhibited	O
+SARS	B-DISO
+-	O
+CoV	O
+plaque	B-DISO
+formation	B-PROC
+by	O
+40	O
+-	O
+70	O
+%	O
+at	O
+concentrations	O
+of	O
+15	O
+-	O
+30	O
+microM	O
+.	O
+Interestingly	O
+,	O
+peptides	B-CHED
+analogous	O
+to	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+or	O
+MHV	B-SPEC
+loop	O
+region	O
+inhibited	O
+viral	O
+plaque	B-DISO
+formation	B-PROC
+by	O
+>	O
+80	O
+%	O
+at	O
+similar	O
+concentrations	O
+.	O
+
+The	O
+antiviral	B-CHED
+activity	O
+of	O
+the	O
+CoV	O
+peptides	B-CHED
+tested	O
+provides	O
+an	O
+attractive	O
+basis	O
+for	O
+the	O
+development	B-PROC
+of	O
+new	O
+fusion	O
+peptide	B-CHED
+inhibitors	B-CHED
+corresponding	O
+to	O
+regions	O
+outside	O
+the	O
+fusion	O
+protein	B-CHED
+heptad	O
+repeat	O
+regions	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+enhanced	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+ERT	O
+-	O
+PCR	O
+)	O
+assay	O
+to	O
+detect	O
+the	O
+coronavirus	O
+associated	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+-	O
+Cov	O
+)	O
+has	O
+been	O
+designed	O
+for	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+Cov	I-PRGE
+with	O
+high	O
+sensitivity	O
+and	O
+easy	O
+-	O
+to	O
+-	O
+interpret	O
+results	O
+,	O
+in	O
+which	O
+a	O
+target	O
+gene	O
+pre	O
+-	O
+amplification	B-DISO
+step	O
+preceded	O
+TaqMan	O
+real	O
+-	O
+time	O
+fluorescent	O
+PCR	O
+.	O
+
+A	O
+minority	O
+of	O
+cats	B-SPEC
+,	O
+however	O
+,	O
+develop	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+a	O
+fatal	O
+systemic	B-DISO
+granulomatous	I-DISO
+disease	I-DISO
+.	O
+
+The	O
+obvious	O
+functional	O
+differences	O
+of	O
+lymphatic	B-ANAT
+tissues	I-ANAT
+in	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+with	O
+and	O
+without	O
+FIP	B-DISO
+suggest	O
+that	O
+they	O
+contribute	O
+to	O
+the	O
+outcome	O
+of	O
+FCoV	O
+infection	B-DISO
+.	O
+
+Findings	O
+indicate	O
+that	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+which	O
+do	O
+not	O
+develop	O
+FIP	B-DISO
+are	O
+able	O
+to	O
+mount	O
+an	O
+effective	O
+FCoV	O
+-	O
+specific	B-PROC
+immune	I-PROC
+response	I-PROC
+and	O
+can	O
+avoid	O
+excessive	O
+macrophage	B-PROC
+activation	I-PROC
+and	O
+FIP	B-DISO
+,	O
+possibly	O
+by	O
+upregulation	B-PROC
+of	O
+IL	B-PROC
+-	I-PROC
+10	I-PROC
+production	I-PROC
+.	O
+
+TITLE	O
+:	O
+Enhancement	O
+of	O
+the	O
+infectivity	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+by	O
+IMP	B-PRGE
+dehydrogenase	I-PRGE
+inhibitors	B-CHED
+,	O
+including	O
+ribavirin	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+significance	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)-	O
+X4	O
+protein	B-PROC
+expression	B-PROC
+in	O
+lungs	B-ANAT
+of	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Microscopically	O
+,	O
+all	O
+lungs	B-ANAT
+from	O
+4	O
+cases	O
+showed	O
+edema	B-DISO
+,	O
+erythrocyte	B-ANAT
+and	O
+fibrin	O
+exudates	B-ANAT
+in	O
+the	O
+alveoli	B-ANAT
+,	O
+hyperplasia	B-DISO
+of	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+,	O
+necrosis	B-PROC
+,	O
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+and	O
+fibroblast	B-ANAT
+foci	O
+.	O
+
+S2	O
+gene	O
+of	O
+GD322	O
+SARS	O
+-	O
+CoV	O
+is	O
+relatively	O
+stable	O
+during	O
+the	O
+epidemic	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+and	O
+mutation	O
+at	O
+the	O
+57th	O
+amino	B-CHED
+acids	I-CHED
+of	O
+S2	B-PRGE
+protein	I-PRGE
+may	O
+affect	O
+the	O
+T	B-PRGE
+cell	I-PRGE
+antigen	B-CHED
+epitope	B-CHED
+.	O
+
+T	B-PRGE
+cell	I-PRGE
+antigen	B-CHED
+epitopes	I-PRGE
+of	O
+S2	O
+protein	B-CHED
+were	O
+predicted	O
+on	O
+the	O
+basis	O
+of	O
+Internet	O
+database	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+partial	O
+ventilatory	O
+support	O
+modalities	O
+on	O
+respiratory	B-PROC
+function	I-PROC
+in	O
+severe	O
+hypoxemic	O
+lung	O
+injury	O
+.	O
+
+This	O
+study	O
+compares	O
+the	O
+effects	O
+of	O
+assisted	O
+ventilatory	O
+techniques	O
+on	O
+breathing	B-PROC
+pattern	O
+,	O
+gas	B-ENZY
+exchange	O
+,	O
+hemodynamic	B-PROC
+function	O
+,	O
+and	O
+respiratory	O
+effort	B-PROC
+with	O
+those	O
+of	O
+controlled	O
+mechanical	O
+ventilation	O
+in	O
+similarly	O
+sedated	O
+subjects	O
+.	O
+
+We	O
+argue	O
+that	O
+there	O
+is	O
+a	O
+pressing	O
+need	O
+to	O
+clarify	O
+the	O
+rights	O
+and	O
+responsibilities	O
+of	O
+HCPs	O
+in	O
+the	O
+current	O
+context	O
+of	O
+pandemic	O
+flu	B-DISO
+preparedness	O
+,	O
+and	O
+that	O
+these	O
+rights	O
+and	O
+responsibilities	O
+ought	O
+to	O
+be	O
+codified	O
+in	O
+professional	O
+codes	O
+of	O
+ethics	O
+.	O
+
+Eye	B-PRGE
+protection	O
+was	O
+perceived	O
+as	O
+only	O
+moderately	O
+effective	O
+in	O
+protecting	O
+against	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+reported	O
+compliance	O
+was	O
+relatively	O
+poor	O
+among	O
+ED	O
+staff	O
+.	O
+
+This	O
+article	O
+defines	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+summarizes	O
+historical	O
+background	O
+,	O
+and	O
+discusses	O
+factors	O
+that	O
+contribute	O
+to	O
+emergence	O
+.	O
+
+The	O
+author	O
+reports	O
+field	O
+observations	O
+and	O
+describes	O
+five	O
+selected	O
+examples	O
+of	O
+highly	O
+innovative	O
+,	O
+SARS	B-DISO
+-	O
+related	O
+infection	B-DISO
+control	O
+practices	O
+observed	O
+in	O
+three	O
+affected	O
+countries	O
+during	O
+the	O
+height	O
+of	O
+the	O
+2003	O
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Faeces	O
+of	O
+230	O
+calves	O
+with	O
+and	O
+without	O
+diarrhoea	B-DISO
+collected	O
+during	O
+the	O
+winter	O
+period	O
+2004	O
+/	O
+2005	O
+in	O
+100	O
+Austrian	O
+farms	O
+(	O
+Styria	O
+and	O
+Lower	O
+Austria	O
+)	O
+were	O
+examined	O
+for	O
+viral	O
+,	O
+bacterial	O
+and	O
+parasitic	O
+enteropathogens	O
+.	O
+
+Consequently	O
+,	O
+the	O
+regulation	B-PROC
+of	O
+DC	O
+maturation	B-PROC
+should	O
+reflect	O
+these	O
+multifaceted	O
+immunological	O
+processes	O
+.	O
+
+In	O
+contrast	O
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+alone	O
+or	O
+in	O
+combination	O
+with	O
+the	O
+TLR	O
+ligands	O
+was	O
+a	O
+poor	O
+inducer	O
+of	O
+DC	O
+maturation	O
+,	O
+but	O
+co	O
+-	O
+operated	O
+with	O
+T	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+in	O
+the	O
+presence	O
+of	O
+antigen	B-CHED
+to	O
+induce	O
+DC	O
+maturation	B-PROC
+.	O
+
+These	O
+matured	O
+MoDCs	O
+displayed	O
+an	O
+enhanced	O
+ability	O
+to	O
+present	O
+antigen	B-CHED
+to	O
+and	O
+thus	O
+stimulate	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Moreover	O
+,	O
+our	O
+identified	O
+N317	O
+-	O
+325	O
+and	O
+S1042	O
+-	O
+1050	O
+CTL	B-ANAT
+epitopes	O
+could	O
+induce	O
+recall	O
+responses	O
+when	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+stimulation	O
+of	O
+blood	B-ANAT
+CD8	O
++	O
+T	B-ANAT
+-	I-ANAT
+cells	I-ANAT
+revealed	O
+significant	O
+difference	O
+between	O
+normal	O
+healthy	O
+donors	O
+and	O
+SARS	B-DISO
+-	O
+recovered	O
+patients	O
+after	O
+those	O
+PBMCs	O
+were	O
+in	O
+vitro	O
+vaccinated	O
+with	O
+their	O
+cognate	O
+antigen	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+comparative	O
+analysis	O
+of	O
+the	O
+2002	O
+-	O
+2003	O
+infectious	O
+disease	O
+outbreak	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+the	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+epidemic	O
+that	O
+has	O
+affected	O
+the	O
+world	O
+over	O
+the	O
+past	O
+two	O
+decades	O
+reveals	O
+the	O
+significant	O
+role	O
+of	O
+socio	O
+-	O
+cultural	O
+beliefs	O
+and	O
+attitudes	O
+in	O
+the	O
+shaping	O
+of	O
+people	O
+'	O
+s	O
+lifestyles	O
+and	O
+approaches	O
+to	O
+the	O
+control	O
+and	O
+prevention	O
+of	O
+epidemics	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+main	I-PRGE
+proteinase	B-PROC
+is	O
+a	O
+prime	O
+target	O
+for	O
+antiviral	O
+therapy	O
+.	O
+
+Virus	B-SPEC
+generates	O
+drug	B-PROC
+resistance	I-PROC
+through	O
+fast	B-FUNC
+mutagenesis	B-PROC
+and	O
+escapes	O
+antiviral	B-CHED
+treatment	O
+.	O
+
+These	O
+studies	O
+have	O
+been	O
+driven	O
+by	O
+three	O
+factors	O
+,	O
+namely	O
+international	O
+collaboration	O
+;	O
+specific	O
+situations	O
+like	O
+disasters	O
+,	O
+terrorism	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+;	O
+and	O
+international	O
+attention	O
+to	O
+specific	O
+topics	O
+like	O
+maternal	O
+depression	B-DISO
+.	O
+
+He	O
+had	O
+previously	O
+undergone	O
+tricuspid	B-ANAT
+valve	I-ANAT
+replacement	O
+with	O
+bioprosthetic	O
+valves	B-ANAT
+on	O
+two	O
+occasions	O
+:	O
+the	O
+initial	O
+surgery	O
+for	O
+severe	O
+native	O
+tricuspid	B-DISO
+valve	I-DISO
+stenosis	B-SPEC
+and	O
+the	O
+redo	O
+surgery	O
+for	O
+severe	O
+prosthetic	O
+valve	B-ANAT
+stenosis	B-DISO
+and	O
+regurgitation	B-DISO
+.	O
+
+Conventional	O
+imaging	O
+assessment	O
+using	O
+transoesophageal	O
+echocardiography	O
+was	O
+suboptimal	O
+and	O
+comprehensive	O
+assessment	O
+of	O
+prosthetic	O
+valve	B-ANAT
+function	O
+was	O
+aided	O
+by	O
+the	O
+use	O
+of	O
+intracardiac	B-ANAT
+echocardiography	O
+(	O
+ICE	O
+).	O
+
+It	O
+was	O
+further	O
+revealed	O
+that	O
+wt	O
+JHMV	O
+S1	O
+,	O
+but	O
+not	O
+srr7	O
+,	O
+was	O
+released	O
+from	O
+the	O
+cell	B-COMP
+surface	I-COMP
+when	O
+S	B-PRGE
+protein	I-PRGE
+was	O
+expressed	B-PROC
+on	O
+cells	B-COMP
+.	O
+
+Immediate	O
+discontinuance	O
+of	O
+amiodarone	B-CHED
+and	O
+high	O
+-	O
+dose	O
+pulse	B-PROC
+glucocorticoid	B-CHED
+therapy	O
+with	O
+intubation	O
+slightly	O
+improved	O
+the	O
+infiltrations	O
+on	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Investigation	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+(	O
+H5N1	B-DISO
+)	O
+outbreak	O
+in	O
+humans	B-SPEC
+--	O
+Thailand	O
+,	O
+2004	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+16	O
+patients	O
+with	O
+confirmed	O
+H5N1	B-DISO
+were	O
+identified	O
+for	O
+the	O
+case	O
+-	O
+control	O
+study	O
+.	O
+
+TITLE	O
+:	O
+Enzymatic	B-PROC
+activity	I-PROC
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+main	I-PRGE
+proteinase	B-PROC
+dimer	O
+.	O
+
+The	O
+gene	O
+for	O
+the	O
+enzyme	O
+was	O
+cloned	O
+in	O
+the	O
+absence	O
+of	O
+purification	O
+tags	O
+,	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+the	O
+enzyme	O
+purified	O
+.	O
+
+Enzyme	B-FUNC
+activity	I-FUNC
+from	O
+the	O
+SARS	B-PRGE
+CoV	I-PRGE
+main	I-PRGE
+proteinase	B-PROC
+dimer	I-PRGE
+could	O
+readily	O
+be	O
+detected	O
+at	O
+low	O
+pM	O
+concentrations	O
+.	O
+
+Among	O
+309	O
+bats	B-SPEC
+of	O
+13	O
+species	B-SPEC
+captured	O
+from	O
+20	O
+different	O
+locations	O
+in	O
+rural	O
+areas	O
+of	O
+Hong	O
+Kong	O
+over	O
+a	O
+16	O
+-	O
+month	O
+period	O
+,	O
+coronaviruses	O
+were	O
+amplified	O
+from	O
+anal	B-ANAT
+swabs	O
+of	O
+37	O
+(	O
+12	O
+%)	O
+bats	B-SPEC
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Although	O
+neither	O
+prophylactic	O
+antibiotics	B-CHED
+,	O
+nor	O
+BRD	O
+vaccines	O
+were	O
+used	O
+,	O
+less	O
+than	O
+0	O
+.	O
+7	O
+-	O
+13	O
+.	O
+2	O
+%	O
+(	O
+mean	O
+5	O
+%)	O
+of	O
+the	O
+calves	O
+(	O
+n	O
+=	O
+970	O
+)	O
+required	O
+treatment	O
+for	O
+BRD	O
+during	O
+the	O
+first	O
+five	O
+weeks	O
+following	O
+entry	O
+.	O
+
+ABSTRACT	O
+:	O
+Hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	O
+)	O
+is	O
+believed	O
+to	O
+assemble	O
+by	O
+budding	B-PATH
+into	O
+membranes	B-ANAT
+of	O
+the	O
+early	O
+secretory	B-PROC
+pathway	I-PROC
+,	O
+consistent	O
+with	O
+the	O
+membrane	B-COMP
+location	O
+where	O
+the	O
+viral	B-PRGE
+envelope	I-PRGE
+glycoproteins	B-CHED
+E1	I-PRGE
+and	I-PRGE
+E2	I-PRGE
+accumulate	O
+when	O
+expressed	B-PROC
+.	O
+
+TITLE	O
+:	O
+Inflammation	B-DISO
+inhibitors	B-CHED
+were	O
+remarkably	O
+up	O
+-	O
+regulated	O
+in	O
+plasma	B-ANAT
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+patients	O
+at	O
+progressive	O
+phase	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+infectious	B-DISO
+disease	I-DISO
+that	O
+has	O
+affected	O
+many	O
+countries	O
+and	O
+regions	O
+since	O
+2002	O
+.	O
+
+However	O
+,	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+is	O
+still	O
+elusive	O
+.	O
+
+By	O
+comparing	O
+the	O
+plasma	B-ANAT
+proteins	B-CHED
+of	O
+SARS	B-DISO
+patients	O
+with	O
+those	O
+of	O
+a	O
+normal	O
+control	O
+group	O
+,	O
+several	O
+proteins	B-CHED
+with	O
+a	O
+significant	O
+alteration	O
+were	O
+found	O
+.	O
+
+We	O
+carried	O
+out	O
+an	O
+assessment	O
+on	O
+SARS	B-DISO
+patients	O
+after	O
+their	O
+recovery	O
+from	O
+their	O
+acute	O
+illness	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+the	O
+major	O
+neutralizing	O
+epitopes	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+have	O
+been	O
+apparently	O
+maintained	O
+during	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+,	O
+and	O
+that	O
+RBD	O
+-	O
+based	O
+vaccines	O
+may	O
+induce	O
+broad	O
+protection	O
+against	O
+both	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+variants	O
+.	O
+
+TITLE	O
+:	O
+Epidemiologic	O
+study	O
+and	O
+containment	O
+of	O
+a	O
+nosocomial	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+medical	O
+center	O
+in	O
+Kaohsiung	O
+,	O
+Taiwan	O
+.	O
+
+The	O
+presence	O
+of	O
+underlying	O
+lung	B-DISO
+disease	I-DISO
+and	O
+immunocompromise	O
+in	O
+some	O
+patients	O
+made	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+difficult	O
+.	O
+
+Multiple	O
+factors	O
+were	O
+likely	O
+responsible	O
+for	O
+SARS	B-DISO
+in	O
+these	O
+HCWs	O
+,	O
+including	O
+the	O
+performance	O
+of	O
+high	O
+-	O
+risk	O
+patient	O
+care	O
+procedures	O
+,	O
+inconsistent	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+,	O
+fatigue	B-DISO
+,	O
+and	O
+lack	O
+of	O
+adequate	O
+infection	B-DISO
+control	O
+training	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Multiple	O
+factors	O
+were	O
+likely	O
+responsible	O
+for	O
+SARS	B-DISO
+in	O
+these	O
+HCWs	O
+,	O
+including	O
+the	O
+performance	O
+of	O
+high	O
+-	O
+risk	O
+patient	O
+care	O
+procedures	O
+,	O
+inconsistent	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+,	O
+fatigue	B-DISO
+,	O
+and	O
+lack	O
+of	O
+adequate	O
+infection	B-DISO
+control	O
+training	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+used	O
+a	O
+sensitive	O
+polymerase	O
+chain	O
+reaction	O
+method	O
+coupled	O
+with	O
+filter	O
+sampling	O
+to	O
+detect	O
+the	O
+presence	O
+of	O
+airborne	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+in	O
+an	O
+isolation	O
+patient	O
+room	O
+with	O
+a	O
+patient	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+receiving	O
+mechanical	O
+ventilatory	O
+support	O
+.	O
+
+We	O
+tested	O
+the	O
+polymorphisms	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+for	O
+their	O
+associations	O
+with	O
+SARS	B-DISO
+.	O
+
+Individuals	O
+with	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
++	I-PRGE
+874	I-PRGE
+AA	I-PRGE
+and	O
+AT	O
+genotype	O
+had	O
+a	O
+5	O
+.	O
+19	O
+-	O
+fold	O
+(	O
+95	O
+%	O
+Confidence	O
+Interval	O
+[	O
+CI	O
+],	O
+2	O
+.	O
+78	O
+-	O
+9	O
+.	O
+68	O
+)	O
+and	O
+2	O
+.	O
+57	O
+-	O
+fold	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+35	O
+-	O
+4	O
+.	O
+88	O
+)	O
+increased	O
+risk	O
+of	O
+developing	O
+SARS	B-DISO
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+antibodies	B-COMP
+to	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+by	O
+a	O
+recombinant	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+-	O
+based	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Frequency	O
+and	O
+natural	O
+history	O
+of	O
+rhinovirus	B-SPEC
+infections	B-DISO
+in	O
+adults	O
+during	O
+autumn	O
+.	O
+
+Treatment	O
+of	O
+picornavirus	B-DISO
+infections	I-DISO
+.	O
+
+Increasing	O
+evidences	O
+also	O
+describe	O
+the	O
+link	O
+between	O
+HRV	O
+infection	B-DISO
+and	O
+more	O
+serious	O
+medical	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+feline	B-SPEC
+(	O
+FIPV	O
+)	O
+and	O
+human	B-SPEC
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+by	O
+semisynthetic	O
+derivatives	O
+of	O
+glycopeptide	B-CHED
+antibiotics	B-CHED
+.	O
+
+Several	O
+glycopeptide	B-CHED
+derivatives	O
+modified	O
+with	O
+hydrophobic	O
+substituents	O
+showed	O
+selective	O
+antiviral	B-CHED
+activity	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+and	O
+oil	O
+type	O
+-	O
+based	O
+efficacy	O
+of	O
+emulsion	O
+adjuvants	B-CHED
+.	O
+
+The	O
+use	O
+of	O
+a	O
+polymeric	O
+emulsifier	B-CHED
+allowed	O
+for	O
+direct	O
+comparison	O
+of	O
+three	O
+types	O
+of	O
+emulsions	O
+,	O
+water	B-CHED
+-	O
+in	O
+-	O
+oil	O
+(	O
+W	O
+/	O
+O	O
+),	O
+oil	O
+-	O
+in	O
+-	O
+water	B-CHED
+(	O
+O	O
+/	O
+W	O
+)	O
+and	O
+W	O
+/	O
+O	O
+-	O
+in	O
+-	O
+water	B-CHED
+(	O
+W	O
+/	O
+O	O
+/	O
+W	O
+),	O
+while	O
+maintaining	O
+an	O
+identical	O
+content	O
+of	O
+components	O
+for	O
+each	O
+vehicle	O
+.	O
+
+In	O
+general	O
+,	O
+mineral	B-CHED
+oil	O
+vaccines	O
+showed	O
+superior	O
+efficacy	O
+compared	O
+to	O
+Miglyol	O
+840	O
+-	O
+based	O
+vaccines	O
+.	O
+
+SARS	B-DISO
+mimotopes	O
+were	O
+obtained	O
+by	O
+phage	O
+peptide	B-CHED
+library	O
+screening	O
+.	O
+
+ABSTRACT	O
+:	O
+Apertura	O
+pyriformis	O
+stenosis	B-DISO
+in	O
+the	O
+newborn	O
+.	O
+
+The	O
+distribution	O
+of	O
+proximal	O
+femoral	B-ANAT
+marrow	O
+on	O
+MR	O
+imaging	O
+of	O
+148	O
+health	O
+care	O
+workers	O
+with	O
+recovered	O
+SARS	B-DISO
+including	O
+106	O
+cases	O
+treated	O
+with	O
+varied	O
+dosage	O
+of	O
+steroids	B-CHED
+and	O
+42	O
+cases	O
+without	O
+steroid	B-CHED
+,	O
+and	O
+97	O
+age	O
+and	O
+sex	O
+matched	O
+health	O
+adults	O
+as	O
+controls	O
+were	O
+observed	O
+.	O
+
+In	O
+106	O
+cases	O
+treated	O
+with	O
+steroid	B-CHED
+of	O
+the	O
+148	O
+health	O
+care	O
+workers	O
+,	O
+femoral	O
+head	O
+osteonecrosis	B-DISO
+was	O
+found	O
+in	O
+4	O
+cases	O
+,	O
+bilateral	O
+femoral	B-ANAT
+marrow	O
+edema	B-DISO
+in	O
+2	O
+cases	O
+,	O
+femoral	B-ANAT
+marrow	O
+infarction	B-DISO
+in	O
+1	O
+case	O
+.	O
+
+The	O
+index	O
+of	O
+marrow	O
+conversion	O
+in	O
+the	O
+normal	O
+controls	O
+,	O
+in	O
+SARS	B-DISO
+patients	O
+treated	O
+without	O
+and	O
+with	O
+steroids	B-CHED
+was	O
+(	O
+79	O
+.	O
+4	O
++/-	O
+6	O
+.	O
+8	O
+)%,	O
+(	O
+86	O
+.	O
+9	O
++/-	O
+7	O
+.	O
+4	O
+)%,	O
+(	O
+88	O
+.	O
+6	O
++/-	O
+5	O
+.	O
+9	O
+)%,	O
+respectively	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+106	O
+cases	O
+treated	O
+with	O
+steroid	B-CHED
+of	O
+the	O
+148	O
+health	O
+care	O
+workers	O
+,	O
+femoral	B-ANAT
+head	I-ANAT
+osteonecrosis	B-DISO
+was	O
+found	O
+in	O
+4	O
+cases	O
+,	O
+bilateral	O
+femoral	B-ANAT
+marrow	O
+edema	B-DISO
+in	O
+2	O
+cases	O
+,	O
+femoral	B-ANAT
+marrow	O
+infarction	B-DISO
+in	O
+1	O
+case	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+clinical	O
+manifestations	O
+and	O
+the	O
+chest	O
+imaging	O
+characteristics	O
+of	O
+an	O
+epidemic	O
+outbreak	O
+of	O
+respiratory	B-DISO
+infection	I-DISO
+caused	O
+by	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+(	O
+CP	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+hematological	O
+changes	O
+and	O
+related	O
+gene	B-PROC
+mutation	I-PROC
+of	O
+post	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+with	O
+osteonecrosis	B-DISO
+so	O
+as	O
+to	O
+find	O
+the	O
+sensitive	O
+molecular	O
+symbols	O
+for	O
+early	O
+screening	O
+of	O
+the	O
+high	O
+risk	O
+populations	O
+.	O
+
+The	O
+levels	O
+of	O
+PC	O
+,	O
+AT	B-PRGE
+-	I-PRGE
+III	I-PRGE
+,	O
+and	O
+PLG	B-CHED
+of	O
+the	O
+osteonecrosis	B-DISO
+group	O
+were	O
+85	O
+%	O
++/-	O
+
+APTT	O
+,	O
+PC	O
+,	O
+AT	B-PRGE
+-	I-PRGE
+III	I-PRGE
+,	O
+and	O
+PLG	B-PRGE
+can	O
+be	O
+used	O
+as	O
+sensitive	O
+indicator	B-CHED
+for	O
+screening	O
+high	O
+risk	O
+populations	O
+of	O
+osteonecrosis	B-DISO
+.	O
+
+This	O
+paper	O
+assesses	O
+factors	O
+related	O
+to	O
+public	O
+health	O
+nurses	O
+'	O
+confidence	O
+in	O
+managing	O
+community	O
+SARS	B-DISO
+control	O
+programs	O
+.	O
+
+RESULTS	O
+:	O
+Most	O
+public	O
+health	O
+nurses	O
+(	O
+71	O
+.	O
+9	O
+%)	O
+expressed	B-PROC
+a	O
+general	O
+lack	O
+of	O
+confidence	O
+in	O
+handling	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+The	O
+epidemic	O
+spread	O
+rapidly	O
+within	O
+China	O
+and	O
+internationally	O
+,	O
+with	O
+8454	O
+recorded	O
+infections	B-DISO
+and	O
+792	O
+deaths	B-PROC
+by	O
+June	O
+15	O
+,	O
+2003	O
+.	O
+
+If	O
+an	O
+influenza	O
+pandemic	O
+struck	B-DISO
+today	O
+,	O
+borders	O
+might	O
+close	O
+,	O
+the	O
+global	O
+economy	O
+would	O
+be	O
+severely	O
+impacted	B-DISO
+,	O
+international	O
+vaccine	O
+supplies	O
+and	O
+health	O
+are	O
+systems	O
+would	O
+be	O
+overwhelmed	O
+,	O
+and	O
+some	O
+people	O
+might	O
+panic	O
+.	O
+
+$	O
+100	O
+million	O
+is	O
+being	O
+provided	O
+initially	O
+with	O
+another	O
+$	O
+250	O
+million	O
+due	O
+later	O
+this	O
+year	O
+to	O
+assist	O
+states	O
+in	O
+pandemic	O
+flu	B-DISO
+preparedness	O
+.	O
+
+Two	O
+(	O
+0	O
+.	O
+57	O
+%)	O
+of	O
+353	O
+asymptomatic	O
+children	O
+from	O
+the	O
+high	O
+-	O
+risk	O
+area	O
+were	O
+tested	O
+positive	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+antibody	B-COMP
+compared	O
+with	O
+0	O
+of	O
+361	O
+in	O
+the	O
+low	O
+-	O
+risk	O
+region	O
+.	O
+
+The	O
+very	O
+low	O
+seroprevalence	O
+implies	O
+little	O
+or	O
+no	O
+population	O
+herd	B-PROC
+immunity	I-PROC
+to	O
+protect	O
+against	O
+future	O
+resurgence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+a	O
+distant	O
+member	O
+of	O
+the	O
+Group	O
+2	O
+coronaviruses	O
+,	O
+has	O
+recently	O
+been	O
+identified	O
+as	O
+the	O
+etiological	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+These	O
+results	O
+provide	O
+new	O
+directions	O
+for	O
+studies	O
+of	O
+the	O
+role	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3b	I-PRGE
+protein	B-CHED
+in	O
+SARS	B-DISO
+pathogenesis	B-DISO
+.	O
+
+Alcohol	O
+causes	O
+acute	O
+and	O
+chronic	O
+dysfunction	O
+in	O
+multiple	O
+organ	B-ANAT
+systems	I-ANAT
+,	O
+and	O
+the	O
+underlying	O
+mechanisms	O
+responsible	O
+for	O
+organ	B-ANAT
+injury	O
+are	O
+complex	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+provide	O
+an	O
+overview	O
+of	O
+the	O
+mechanisms	O
+thought	O
+to	O
+contribute	O
+to	O
+ARDS	B-DISO
+and	O
+multiple	O
+organ	O
+dysfunction	O
+.	O
+
+TITLE	O
+:	O
+An	O
+evaluation	O
+of	O
+nursing	B-PROC
+practice	O
+models	O
+in	O
+the	O
+context	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+:	O
+a	O
+preliminary	O
+study	O
+.	O
+
+RESULTS	O
+:	O
+Conventional	O
+practice	O
+from	O
+the	O
+findings	O
+consisted	O
+of	O
+cubicle	O
+and	O
+named	O
+nurse	O
+nursing	B-PROC
+.	O
+
+Preliminary	O
+findings	O
+concerning	O
+infection	B-DISO
+control	O
+and	O
+nurse	O
+satisfaction	O
+revealed	O
+that	O
+the	O
+alternative	O
+model	O
+had	O
+an	O
+advantage	O
+over	O
+the	O
+conventional	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+an	O
+integrated	O
+clinical	O
+trial	O
+database	O
+to	O
+evaluate	O
+the	O
+effect	O
+of	O
+timing	O
+of	O
+drotrecogin	O
+alfa	O
+(	O
+activated	O
+)	O
+treatment	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Using	O
+a	O
+recently	O
+constructed	O
+integrated	O
+severe	B-DISO
+sepsis	I-DISO
+database	O
+,	O
+our	O
+objectives	O
+in	O
+this	O
+study	O
+were	O
+to	O
+describe	O
+the	O
+influence	O
+of	O
+baseline	O
+clinical	O
+characteristics	O
+on	O
+timing	O
+of	O
+DrotAA	O
+treatment	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+to	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+DrotAA	O
+with	O
+respect	O
+to	O
+timing	O
+of	O
+administration	O
+,	O
+and	O
+to	O
+examine	O
+the	O
+association	O
+between	O
+early	O
+intervention	O
+with	O
+DrotAA	O
+and	O
+patient	O
+outcomes	O
+,	O
+using	O
+adjustments	O
+for	O
+imbalances	O
+.	O
+
+TITLE	O
+:	O
+Biochemical	O
+evidence	O
+for	O
+the	O
+presence	O
+of	O
+mixed	O
+membrane	B-COMP
+topologies	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+envelope	B-COMP
+protein	B-CHED
+expressed	B-PROC
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+.	O
+
+Intriguingly	O
+,	O
+a	O
+minor	O
+proportion	O
+of	O
+the	O
+SARS	O
+-	O
+CoV	O
+E	O
+protein	B-CHED
+was	O
+found	O
+to	O
+be	O
+modified	O
+by	O
+N	O
+-	O
+linked	O
+glycosylation	B-PROC
+on	O
+Asn	B-CHED
+66	O
+and	O
+inserted	O
+into	O
+the	O
+membranes	B-ANAT
+once	O
+with	O
+the	O
+C	O
+-	O
+terminus	O
+exposed	O
+to	O
+the	O
+luminal	B-CHED
+side	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+effect	O
+of	O
+high	O
+-	O
+volume	O
+continuous	O
+hemofiltration	O
+on	O
+experimental	O
+pancreatitis	B-DISO
+associated	O
+lung	B-ANAT
+injury	O
+(	O
+PALI	O
+)	O
+in	O
+pigs	B-SPEC
+.	O
+
+Plasma	B-ANAT
+cytokines	O
+in	O
+the	O
+high	O
+-	O
+volume	O
+group	O
+were	O
+significantly	O
+lower	O
+than	O
+in	O
+the	O
+LV	O
+and	O
+control	O
+groups	O
+.	O
+
+In	O
+the	O
+HV	O
+group	O
+,	O
+the	O
+expression	B-PROC
+of	O
+NF	O
+-	O
+ê	O
+B	O
+activation	O
+at	O
+6	O
+h	O
+,	O
+12	O
+h	O
+and	O
+24	O
+h	O
+was	O
+lower	O
+than	O
+in	O
+the	O
+control	O
+and	O
+LV	O
+groups	O
+respectively	O
+.	O
+
+CONCLUSIONS	O
+:	O
+CVVH	O
+can	O
+reduce	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+the	O
+severity	O
+of	O
+PALI	O
+in	O
+pigs	B-SPEC
+with	O
+high	O
+-	O
+volume	O
+CVVH	O
+being	O
+significantly	O
+better	O
+than	O
+low	O
+-	O
+volume	O
+CVVH	O
+.	O
+
+In	O
+Phase	O
+2	O
+,	O
+MIGET	O
+showed	O
+diversion	O
+of	O
+blood	B-PROC
+flow	I-PROC
+from	O
+normal	O
+to	O
+true	O
+-	O
+shunt	O
+lung	B-ANAT
+compartments	B-ANAT
+and	O
+,	O
+transiently	O
+,	O
+to	O
+poorly	O
+ventilated	O
+compartments	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+identify	O
+movements	B-PROC
+of	O
+the	O
+likely	B-PRGE
+eukaryotic	I-PRGE
+ribosomal	I-PRGE
+helicase	I-PRGE
+and	O
+confirm	O
+a	O
+direct	O
+interaction	O
+between	O
+the	O
+translocase	B-PRGE
+eEF2	I-PRGE
+and	O
+the	O
+P	O
+-	O
+site	O
+tRNA	B-FUNC
+.	O
+
+TITLE	O
+:	O
+Southwest	O
+Oncology	O
+Group	O
+phase	O
+II	O
+study	O
+of	O
+arsenic	B-CHED
+trioxide	I-CHED
+in	O
+patients	O
+with	O
+refractory	O
+germ	B-ANAT
+cell	I-ANAT
+malignancies	B-DISO
+.	O
+
+Their	O
+synthesis	B-PROC
+involves	O
+a	O
+process	O
+of	O
+discontinuous	O
+RNA	B-PROC
+synthesis	I-PROC
+that	O
+resembles	O
+similarity	O
+-	O
+assisted	O
+RNA	O
+recombination	B-PROC
+.	O
+
+The	O
+internalization	O
+did	O
+not	O
+occur	O
+spontaneously	O
+,	O
+as	O
+it	O
+was	O
+not	O
+observed	O
+in	O
+cells	B-COMP
+incubated	O
+with	O
+medium	O
+or	O
+non	O
+-	O
+specific	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+ACE2	B-PRGE
+in	O
+polarized	O
+epithelial	B-ANAT
+cells	I-ANAT
+:	O
+surface	O
+expression	B-PROC
+and	O
+function	O
+as	O
+receptor	O
+for	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+Here	O
+,	O
+these	O
+results	O
+were	O
+confirmed	O
+and	O
+extended	O
+by	O
+including	O
+a	O
+colon	B-DISO
+carcinoma	B-ANAT
+cell	I-ANAT
+line	O
+(	O
+Caco	O
+-	O
+2	O
+),	O
+a	O
+lung	B-DISO
+carcinoma	B-ANAT
+cell	I-ANAT
+line	O
+(	O
+Calu	O
+-	O
+3	O
+)	O
+and	O
+Vero	O
+E6	O
+cells	B-COMP
+in	O
+our	O
+analysis	O
+.	O
+
+All	O
+three	O
+cell	B-COMP
+types	O
+expressed	B-PROC
+human	B-PRGE
+ACE2	I-PRGE
+on	O
+the	O
+apical	B-ANAT
+membrane	I-ANAT
+domain	O
+and	O
+were	O
+infected	O
+via	O
+this	O
+route	O
+,	O
+as	O
+determined	O
+with	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+pseudotypes	O
+containing	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+In	O
+a	O
+histological	O
+analysis	O
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+ACE2	B-PRGE
+was	O
+detected	O
+in	O
+the	O
+trachea	O
+,	O
+main	B-ANAT
+bronchus	I-ANAT
+and	O
+alveoli	B-ANAT
+,	O
+and	O
+occasionally	O
+also	O
+in	O
+the	O
+small	O
+bronchi	B-ANAT
+.	O
+
+We	O
+give	O
+examples	O
+of	O
+the	O
+Cavbase	O
+similarity	O
+analysis	O
+detecting	O
+pronounced	O
+similarities	O
+in	O
+the	O
+binding	B-FUNC
+sites	O
+of	O
+proteins	B-CHED
+unrelated	O
+in	O
+sequence	O
+.	O
+
+A	O
+similarity	O
+search	O
+using	O
+SARS	B-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+protease	I-PRGE
+subpockets	I-PRGE
+as	O
+queries	O
+retrieved	O
+ligands	O
+and	O
+ligand	B-PROC
+fragments	O
+accommodated	O
+in	O
+a	O
+physicochemical	O
+environment	O
+similar	O
+to	O
+that	O
+of	O
+the	O
+query	O
+.	O
+
+A	O
+cluster	O
+analysis	O
+procedure	O
+for	O
+the	O
+functional	O
+classification	O
+of	O
+binding	B-FUNC
+pockets	O
+was	O
+implemented	O
+and	O
+calibrated	O
+using	O
+a	O
+diverse	O
+set	O
+of	O
+enzyme	B-FUNC
+binding	I-FUNC
+sites	O
+.	O
+
+We	O
+propose	O
+a	O
+relevant	O
+classification	O
+of	O
+both	O
+protein	B-CHED
+families	O
+,	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+binding	B-FUNC
+motifs	O
+in	O
+their	O
+active	O
+sites	O
+.	O
+
+The	O
+prevalence	O
+of	O
+subclinical	O
+udder	B-ANAT
+infection	B-DISO
+in	O
+camels	B-SPEC
+can	O
+reach	B-PROC
+very	O
+high	O
+proportions	O
+in	O
+dairy	O
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Template	O
+-	O
+based	O
+coiled	O
+-	O
+coil	O
+antigens	B-CHED
+elicit	O
+neutralizing	O
+antibodies	B-COMP
+to	O
+the	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+.	O
+
+It	O
+contains	O
+two	O
+hydrophobic	O
+heptad	O
+repeat	O
+(	O
+HR	O
+)	O
+regions	O
+,	O
+denoted	O
+HRN	B-CHED
+and	O
+HRC	O
+,	O
+which	O
+oligomerize	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+into	O
+a	O
+trimer	O
+in	O
+the	O
+native	O
+state	O
+and	O
+when	O
+activated	O
+collapse	B-DISO
+into	O
+a	O
+six	O
+-	O
+helix	O
+bundle	O
+structure	O
+driving	O
+fusion	O
+of	O
+the	O
+host	B-COMP
+and	O
+viral	O
+membranes	B-ANAT
+.	O
+
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+peptides	B-CHED
+of	O
+the	O
+HR	O
+regions	O
+can	O
+inhibit	O
+viral	O
+infectivity	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+all	O
+of	O
+the	O
+elicited	O
+anti	O
+-	O
+sera	B-COMP
+can	O
+specifically	O
+recognize	O
+HRN	B-CHED
+or	O
+HRC	B-PRGE
+peptides	I-PRGE
+and	O
+the	O
+native	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+in	O
+an	O
+ELISA	O
+format	O
+.	O
+
+Flow	O
+cytometry	O
+(	O
+FACS	O
+)	O
+analysis	O
+,	O
+however	O
+,	O
+showed	O
+only	O
+HRC1	B-PRGE
+and	O
+HRC2	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+sera	I-PRGE
+could	O
+bind	B-FUNC
+to	O
+native	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+expressed	B-PROC
+on	O
+the	O
+cell	B-COMP
+surface	I-COMP
+of	O
+Chinese	B-SPEC
+hamster	I-SPEC
+ovary	B-ANAT
+cells	B-COMP
+,	O
+i	O
+.	O
+e	O
+.,	O
+the	O
+cell	B-ANAT
+surface	I-ANAT
+structure	I-ANAT
+of	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+precluded	O
+the	O
+ability	O
+of	O
+the	O
+HRN1	O
+or	O
+HRN2	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+sera	I-PRGE
+to	O
+see	O
+their	O
+respective	O
+epitope	B-CHED
+sites	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+)	O
+potentiates	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+proinflammatory	O
+cytokine	B-PROC
+production	I-PROC
+in	O
+the	O
+lungs	B-ANAT
+upon	O
+intratracheal	O
+inoculation	O
+with	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)	O
+at	O
+1	O
+day	O
+of	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Emergent	O
+viruses	B-SPEC
+:	O
+SARS	B-DISO
+-	O
+associate	O
+coronavirus	B-SPEC
+and	O
+H5N1	B-DISO
+influenza	I-DISO
+virus	O
+].	O
+
+In	O
+french	O
+laboratories	O
+of	O
+medical	O
+virology	O
+,	O
+procedures	O
+are	O
+ready	O
+to	O
+diagnose	O
+the	O
+first	O
+case	O
+of	O
+A	O
+/	O
+H5N1	B-DISO
+virus	B-DISO
+infection	I-DISO
+and	O
+cases	O
+of	O
+reemerging	O
+SARS	B-DISO
+virus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+responsible	O
+for	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+contains	O
+a	O
+small	B-PRGE
+envelope	I-PRGE
+protein	B-CHED
+,	O
+E	O
+,	O
+with	O
+putative	O
+involvement	O
+in	O
+host	B-COMP
+apoptosis	B-PATH
+and	O
+virus	B-SPEC
+morphogenesis	B-PROC
+.	O
+
+We	O
+have	O
+independently	O
+confirmed	O
+that	O
+the	O
+full	O
+polypeptide	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+can	O
+also	O
+aggregate	O
+as	O
+pentamers	O
+after	O
+expression	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+ARDS	B-DISO
+develops	O
+in	O
+response	O
+to	O
+inflammatory	O
+stresses	O
+including	O
+sepsis	B-DISO
+,	O
+trauma	O
+,	O
+and	O
+severe	O
+pneumonia	B-DISO
+,	O
+and	O
+despite	O
+aggressive	B-DISO
+critical	O
+care	O
+management	O
+,	O
+it	O
+still	O
+has	O
+a	O
+mortality	O
+of	O
+30	O
+-	O
+50	O
+%.	O
+
+At	O
+the	O
+time	O
+of	O
+its	O
+original	O
+description	O
+in	O
+1967	O
+,	O
+relatively	O
+little	O
+was	O
+known	O
+about	O
+the	O
+specific	O
+mechanisms	O
+by	O
+which	O
+the	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+regulated	O
+lung	B-ANAT
+fluid	B-PROC
+balance	I-PROC
+.	O
+
+The	O
+results	O
+may	O
+contribute	O
+to	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+therapeutics	O
+for	O
+IBV	B-SPEC
+and	O
+studying	O
+the	O
+determinants	O
+for	O
+viral	O
+and	O
+cell	B-PROC
+interaction	I-PROC
+.	O
+
+Two	O
+patients	O
+had	O
+disease	O
+beyond	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+There	O
+have	O
+been	O
+occasional	O
+reports	O
+of	O
+OP	O
+occurring	O
+in	O
+patients	O
+with	O
+hematologic	B-DISO
+malignancies	I-DISO
+.	O
+
+Five	O
+patients	O
+were	O
+treated	O
+with	O
+prednisone	B-CHED
+and	O
+all	O
+experienced	O
+symptomatic	O
+improvement	O
+with	O
+documented	O
+radiologic	O
+resolution	O
+in	O
+4	O
+.	O
+
+RESULTS	O
+:	O
+Underlying	O
+hematologic	B-DISO
+disorders	I-DISO
+included	O
+lymphoma	B-DISO
+(	O
+2	O
+),	O
+acute	B-DISO
+leukemia	I-DISO
+(	O
+2	O
+),	O
+cutaneous	B-DISO
+T	I-DISO
+-	I-DISO
+cell	I-DISO
+lymphoma	I-DISO
+(	O
+1	O
+),	O
+and	O
+myelodysplastic	B-DISO
+syndrome	I-DISO
+(	O
+1	O
+).	O
+
+The	O
+induction	O
+of	O
+human	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+mouse	B-SPEC
+/	I-PRGE
+anti	I-PRGE
+-	I-PRGE
+rat	B-SPEC
+antibodies	B-COMP
+was	O
+detected	O
+in	O
+5	O
+out	O
+of	O
+16	O
+(	O
+31	O
+%)	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+High	O
+molecular	O
+weight	O
+kininogen	O
+in	O
+inflammation	B-DISO
+and	O
+angiogenesis	B-PROC
+:	O
+a	O
+review	O
+of	O
+its	O
+properties	O
+and	O
+therapeutic	O
+applications	O
+].	O
+
+It	O
+has	O
+been	O
+shown	O
+that	O
+KKS	O
+activation	O
+in	O
+the	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+results	O
+in	O
+decrease	O
+of	O
+its	O
+component	O
+plasma	B-ANAT
+proteins	B-CHED
+.	O
+
+It	O
+has	O
+been	O
+found	O
+that	O
+in	O
+HK	O
+deficient	O
+Lewis	O
+rats	B-SPEC
+,	O
+experimental	O
+IBD	B-DISO
+was	O
+much	O
+less	O
+severe	O
+.	O
+
+Furthermore	O
+,	O
+it	O
+has	O
+been	O
+shown	O
+that	O
+a	O
+bradykinin	B-PRGE
+2	I-PRGE
+receptor	I-PRGE
+(	O
+B2R	B-PRGE
+)	O
+antagonist	B-PROC
+attenuates	O
+the	O
+inflammatory	O
+changes	O
+in	O
+the	O
+same	O
+animal	B-SPEC
+model	O
+.	O
+
+Such	O
+systems	O
+focus	O
+on	O
+detecting	O
+clusters	O
+of	O
+syndromes	B-DISO
+in	O
+excess	O
+of	O
+baseline	O
+levels	O
+,	O
+which	O
+may	O
+indicate	O
+an	O
+outbreak	O
+.	O
+
+Thresholds	O
+were	O
+set	O
+to	O
+3	O
+or	O
+more	O
+cases	O
+presenting	O
+with	O
+particular	O
+syndromes	B-DISO
+and	O
+a	O
+temperature	O
+reading	O
+of	O
+>	O
+or	O
+=	O
+38oC	O
+(	O
+T	O
+>	O
+or	O
+=	O
+38	O
+).	O
+
+Monte	O
+Carlo	O
+simulation	O
+was	O
+used	O
+to	O
+insert	O
+simulated	O
+SARS	B-DISO
+outbreaks	O
+of	O
+various	O
+sizes	O
+onto	O
+the	O
+background	O
+incidence	O
+of	O
+febrile	B-PROC
+cases	O
+,	O
+accounting	O
+for	O
+distribution	O
+of	O
+SARS	O
+incubation	O
+period	O
+,	O
+delay	O
+from	O
+onset	O
+to	O
+first	O
+consult	O
+,	O
+and	O
+likelihood	O
+of	O
+presenting	O
+with	O
+T	O
+>	O
+or	O
+=	O
+38	O
+to	O
+the	O
+SAF	O
+medical	O
+centre	O
+.	O
+
+Surveillance	O
+based	O
+on	O
+clusters	B-CHED
+of	O
+cases	O
+with	O
+T	O
+>	O
+or	O
+=	O
+38	O
+helps	O
+reduce	O
+background	O
+noise	O
+in	O
+primary	O
+care	O
+data	O
+,	O
+but	O
+the	O
+major	O
+limitation	O
+of	O
+such	O
+systems	O
+is	O
+that	O
+they	O
+are	O
+still	O
+only	O
+able	O
+to	O
+confidently	O
+detect	O
+large	O
+outbreaks	O
+.	O
+
+Both	O
+viral	O
+and	O
+cellular	B-COMP
+proteins	B-CHED
+are	O
+required	O
+for	O
+replication	O
+and	O
+transcription	B-PROC
+,	O
+and	O
+the	O
+role	O
+of	O
+selected	O
+proteins	B-CHED
+is	O
+addressed	O
+.	O
+
+TITLE	O
+:	O
+Do	O
+children	O
+know	O
+their	O
+parent	O
+'	O
+s	O
+HIV	B-DISO
+status	O
+?	O
+
+Reasons	O
+children	O
+did	O
+not	O
+know	O
+their	O
+parent	O
+'	O
+s	O
+HIV	B-DISO
+status	O
+included	O
+that	O
+the	O
+parent	O
+was	O
+worried	O
+about	O
+the	O
+emotional	O
+consequences	O
+of	O
+disclosure	O
+(	O
+67	O
+%),	O
+was	O
+worried	O
+the	O
+child	O
+would	O
+tell	O
+other	O
+people	O
+(	O
+36	O
+%),	O
+and	O
+did	O
+not	O
+know	O
+how	O
+to	O
+tell	O
+their	O
+child	O
+(	O
+28	O
+%).	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+fusion	O
+core	O
+:	O
+implications	O
+for	O
+structure	O
+basis	O
+of	O
+coronavirus	B-SPEC
+membrane	B-ANAT
+fusion	I-PROC
+.	O
+
+Patients	O
+'	O
+clinical	O
+information	O
+,	O
+the	O
+extent	O
+of	O
+radiographic	O
+opacification	O
+during	O
+the	O
+acute	O
+phase	O
+of	O
+illness	O
+,	O
+and	O
+conventional	O
+pulmonary	B-PROC
+function	I-PROC
+test	O
+results	O
+on	O
+follow	O
+-	O
+up	O
+were	O
+obtained	O
+for	O
+correlation	O
+.	O
+
+Parenchymal	O
+scars	B-DISO
+remained	O
+unchanged	O
+from	O
+the	O
+6	O
+-	O
+to	O
+12	O
+-	O
+month	O
+follow	O
+-	O
+up	O
+in	O
+all	O
+six	O
+patients	O
+with	O
+that	O
+finding	O
+.	O
+
+We	O
+found	O
+that	O
+32	O
+%	O
+of	O
+the	O
+children	O
+(	O
+15	O
+/	O
+47	O
+)	O
+affected	O
+with	O
+SARS	B-DISO
+showed	O
+thin	O
+-	O
+section	O
+CT	O
+abnormalities	O
+up	O
+to	O
+12	O
+months	O
+after	O
+diagnosis	O
+despite	O
+clinical	O
+remission	B-DISO
+and	O
+unremarkable	O
+pulmonary	B-PROC
+function	I-PROC
+assessment	O
+.	O
+
+Lymphopenia	B-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+03	O
+),	O
+extent	O
+of	O
+radiographic	O
+opacification	O
+at	O
+acute	O
+illness	O
+(	O
+p	O
+=	O
+0	O
+.	O
+047	O
+),	O
+and	O
+duration	O
+of	O
+use	O
+of	O
+ribavirin	B-CHED
+(	O
+p	O
+=	O
+0	O
+.	O
+03	O
+)	O
+were	O
+significant	O
+risk	O
+factors	O
+in	O
+predicting	O
+whether	O
+abnormal	O
+CT	O
+features	O
+persisted	O
+12	O
+months	O
+after	O
+diagnosis	O
+.	O
+
+This	O
+review	O
+focuses	O
+on	O
+ARF	B-DISO
+in	O
+cancer	B-DISO
+patients	O
+.	O
+
+This	O
+review	O
+discusses	O
+risks	O
+and	O
+benefits	O
+from	O
+invasive	O
+and	O
+non	O
+invasive	O
+diagnostic	O
+and	O
+therapeutic	O
+strategies	O
+in	O
+critically	B-DISO
+ill	I-DISO
+cancer	B-DISO
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+main	O
+feature	O
+shared	O
+by	O
+these	O
+three	O
+potential	O
+inhibitors	B-CHED
+as	O
+well	O
+as	O
+the	O
+information	O
+of	O
+the	O
+involved	O
+side	O
+chains	O
+of	O
+SARS	B-DISO
+Cov	O
+Mpro	O
+may	O
+provide	O
+useful	O
+insights	O
+for	O
+the	O
+development	O
+of	O
+potent	O
+inhibitors	B-CHED
+against	O
+SARS	B-PRGE
+enzyme	I-PRGE
+.	O
+
+The	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	B-PROC
+activity	I-PROC
+may	O
+allow	O
+TGEV	B-SPEC
+to	O
+overcome	O
+the	O
+mucus	B-ANAT
+barrier	O
+in	O
+the	O
+gut	B-ANAT
+and	O
+to	O
+get	O
+access	O
+to	O
+the	O
+intestinal	B-ANAT
+epithelium	I-ANAT
+for	O
+initiation	O
+of	O
+infection	B-DISO
+.	O
+
+This	O
+study	O
+evaluated	O
+the	O
+impact	O
+of	O
+preexisting	O
+immunity	B-PROC
+to	O
+human	B-SPEC
+adenovirus	B-DISO
+on	O
+the	O
+efficacy	O
+of	O
+adenovirus	B-DISO
+-	O
+based	O
+vaccines	O
+against	O
+the	O
+coronavirus	B-SPEC
+that	O
+causes	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+biosensor	O
+technique	O
+based	O
+on	O
+imaging	O
+ellipsometry	O
+was	O
+employed	O
+directly	O
+to	O
+detect	O
+two	O
+neutralizing	O
+monoclonal	O
+antibodies	B-COMP
+and	O
+serial	O
+serum	B-COMP
+samples	O
+from	O
+10	O
+SARS	B-DISO
+patients	O
+and	O
+12	O
+volunteers	O
+who	O
+had	O
+not	O
+SARS	B-DISO
+.	O
+
+As	O
+a	O
+label	B-CHED
+free	O
+method	O
+,	O
+the	O
+biosensor	O
+based	O
+on	O
+imaging	O
+ellipsometry	O
+proved	O
+to	O
+be	O
+a	O
+more	O
+competent	O
+mechanism	O
+for	O
+measuring	O
+serum	B-ANAT
+samples	O
+from	O
+SARS	B-DISO
+patients	O
+and	O
+the	O
+affinity	O
+between	O
+these	O
+antibodies	B-COMP
+and	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Viral	B-DISO
+infections	I-DISO
+were	O
+diagnosed	O
+by	O
+either	O
+immunological	O
+(	O
+monoclonal	O
+antibodies	B-COMP
+)	O
+or	O
+molecular	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+methods	O
+.	O
+
+Here	O
+,	O
+we	O
+further	O
+characterized	O
+the	O
+antigenic	O
+structure	O
+in	O
+the	O
+RBD	O
+by	O
+a	O
+panel	O
+of	O
+novel	O
+mAbs	O
+isolated	O
+from	O
+the	O
+mice	B-SPEC
+immunized	O
+with	O
+an	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+.	O
+
+Cell	B-COMP
+attenuated	O
+DR13	O
+was	O
+orally	B-ANAT
+or	O
+intramuscularly	O
+(	O
+IM	O
+)	O
+administered	O
+to	O
+late	O
+-	O
+term	O
+pregnant	O
+sows	O
+,	O
+and	O
+mortality	O
+resulting	O
+from	O
+the	O
+highly	O
+virulent	O
+PEDV	B-SPEC
+challenge	O
+was	O
+investigated	O
+in	O
+passively	O
+immunized	O
+suckling	O
+piglets	O
+of	O
+the	O
+two	O
+different	O
+groups	O
+.	O
+
+The	O
+mortality	O
+rate	O
+of	O
+the	O
+oral	B-ANAT
+group	O
+(	O
+13	O
+%)	O
+was	O
+lower	O
+than	O
+that	O
+of	O
+the	O
+IM	O
+group	O
+(	O
+60	O
+%).	O
+
+In	O
+particular	O
+,	O
+the	O
+concentration	O
+of	O
+IgA	B-PRGE
+against	O
+PEDV	B-SPEC
+was	O
+higher	O
+in	O
+piglets	O
+of	O
+sows	O
+in	O
+the	O
+oral	B-ANAT
+group	O
+,	O
+compared	O
+to	O
+the	O
+IM	O
+group	O
+.	O
+
+The	O
+attenuated	O
+DR13	O
+virus	B-SPEC
+remained	O
+safe	O
+,	O
+even	O
+after	O
+three	O
+backpassages	O
+in	O
+piglets	O
+.	O
+
+TITLE	O
+:	O
+Emodin	B-CHED
+blocks	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+and	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+interaction	O
+.	O
+
+To	O
+achieve	O
+a	O
+PRV	B-DISO
+genome	O
+-	O
+based	O
+virus	B-SPEC
+live	O
+vector	O
+,	O
+aiming	O
+at	O
+further	O
+TGEV	B-SPEC
+/	O
+PRV	B-DISO
+bivalent	O
+vaccine	O
+development	B-PROC
+,	O
+a	O
+recombinant	O
+plasmid	O
+pUG	O
+was	O
+constructed	O
+via	O
+inserting	O
+partial	O
+PK	O
+and	O
+full	O
+-	O
+length	O
+gG	O
+genes	O
+of	O
+PRV	B-DISO
+strain	O
+Bartha	O
+K	O
+-	O
+61	O
+amplified	O
+into	O
+pUC119	O
+vector	O
+.	O
+
+In	O
+parallel	O
+,	O
+another	O
+recombinant	O
+pHS	B-DISO
+was	O
+generated	O
+by	O
+introducing	O
+a	O
+fragment	O
+designated	O
+S1	O
+encoding	O
+the	O
+major	O
+antigen	B-CHED
+sites	O
+of	O
+S	B-PRGE
+gene	I-PRGE
+from	O
+TGEV	B-SPEC
+strain	O
+TH	O
+-	O
+98	O
+into	O
+a	O
+prokaryotic	O
+expression	B-PROC
+vector	O
+pP	O
+(	O
+RO	O
+)	O
+EX	O
+HTc	O
+.	O
+
+The	O
+SV40	O
+polyA	O
+sequence	O
+was	O
+then	O
+inserted	O
+into	O
+the	O
+downstream	O
+of	O
+S1	O
+fragment	O
+of	O
+pHS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+outbreaks	O
+:	O
+old	O
+lessons	O
+and	O
+new	O
+challenges	O
+for	O
+obstetrician	O
+-	O
+gynecologists	O
+.	O
+
+The	O
+MHV	B-PRGE
+type	I-PRGE
+2	I-PRGE
+(	O
+MHV	B-SPEC
+-	O
+2	O
+)	O
+strain	O
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+differs	O
+from	O
+other	O
+strains	O
+in	O
+that	O
+it	O
+expresses	O
+an	O
+uncleaved	O
+spike	O
+and	O
+cannot	O
+induce	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+at	O
+neutral	O
+pH	O
+values	O
+.	O
+
+By	O
+use	O
+of	O
+an	O
+A59	O
+/	O
+MHV	B-SPEC
+-	O
+2	O
+chimeric	O
+virus	B-SPEC
+,	O
+the	O
+susceptibility	O
+to	O
+lysosomotropic	O
+agents	O
+is	O
+mapped	O
+to	O
+the	O
+MHV	B-SPEC
+-	O
+2	O
+spike	O
+,	O
+suggesting	O
+a	O
+requirement	O
+of	O
+acidification	B-PROC
+of	O
+endosomes	O
+for	O
+MHV	B-SPEC
+-	O
+2	O
+spike	O
+-	O
+mediated	O
+entry	O
+.	O
+
+Samples	O
+from	O
+56	O
+healthy	O
+blood	B-ANAT
+donors	O
+were	O
+also	O
+detected	O
+as	O
+healthy	O
+controls	O
+.	O
+
+A	O
+rapid	O
+restoration	O
+in	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+was	O
+observed	O
+during	O
+a	O
+short	O
+period	O
+after	O
+infection	B-DISO
+.	O
+
+Total	O
+lymphocytes	B-ANAT
+,	O
+T	B-PRGE
+lymphocyte	I-PRGE
+,	I-PRGE
+CD4	I-PRGE
++	I-PRGE
+T	I-PRGE
+and	O
+naive	O
+CD4	B-PRGE
++	O
+T	B-ANAT
+cell	I-ANAT
+were	O
+still	O
+significantly	O
+lower	O
+than	O
+the	O
+normal	O
+levels	O
+even	O
+one	O
+year	O
+after	O
+disease	O
+onset	O
+.	O
+
+Comparison	O
+of	O
+the	O
+coronavirus	B-SPEC
+NoRSs	O
+with	O
+known	O
+cellular	B-COMP
+and	O
+other	O
+viral	O
+NoRSs	O
+revealed	O
+that	O
+these	O
+motifs	O
+have	O
+conserved	O
+arginine	B-CHED
+residues	O
+.	O
+
+There	O
+are	O
+many	O
+causative	O
+agents	O
+of	O
+acute	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+;	O
+and	O
+it	O
+is	O
+rather	O
+difficult	O
+to	O
+identify	O
+the	O
+relevant	O
+agent	O
+in	O
+a	O
+given	O
+case	O
+by	O
+rapid	O
+clinical	O
+means	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+alpha1	B-PRGE
+-	I-PRGE
+antitrypsin	I-PRGE
+deficiency	O
+and	O
+UC	O
+,	O
+the	O
+present	O
+patient	O
+likely	O
+developed	O
+severe	O
+systemic	O
+vasculitis	B-DISO
+with	O
+multi	O
+-	O
+organ	B-ANAT
+involvement	O
+.	O
+
+TITLE	O
+:	O
+Study	O
+of	O
+automatic	O
+enhancement	O
+for	O
+chest	B-ANAT
+radiograph	O
+.	O
+
+A	O
+young	O
+patient	O
+was	O
+admitted	O
+in	O
+our	O
+clinic	O
+with	O
+critical	O
+condition	B-DISO
+without	O
+any	O
+significant	O
+previous	O
+medical	O
+history	O
+.	O
+
+Physical	O
+examination	O
+showed	O
+a	O
+normally	O
+-	O
+developed	O
+,	O
+well	O
+-	O
+nourished	O
+female	O
+in	O
+severe	O
+distress	O
+with	O
+an	O
+extremely	O
+distended	O
+abdomen	B-ANAT
+.	O
+
+Functional	O
+study	O
+revealed	O
+that	O
+overexpression	B-PROC
+of	O
+SARS	B-PRGE
+8b	I-PRGE
+induced	O
+DNA	B-PROC
+synthesis	I-PROC
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+seven	O
+placentas	B-ANAT
+were	O
+studied	O
+.	O
+
+Various	O
+risk	O
+factors	O
+for	O
+the	O
+development	B-PROC
+of	O
+osteonecrosis	B-DISO
+were	O
+assessed	O
+using	O
+receiver	O
+operating	O
+characteristics	O
+curve	O
+comparison	O
+with	O
+appropriate	O
+test	O
+statistics	O
+and	O
+Spearman	O
+'	O
+s	O
+coefficients	O
+of	O
+rank	O
+correlation	O
+with	O
+biochemical	O
+bone	B-ANAT
+markers	O
+.	O
+
+A	O
+total	O
+corticosteroid	B-CHED
+dosage	O
+of	O
+>	O
+1900	O
+mg	O
+hydrocortisone	B-CHED
+,	O
+>	O
+2000	O
+mg	O
+methylprednisolone	B-CHED
+,	O
+>	O
+13	O
+340	O
+mg	O
+hydrocortisone	B-CHED
+-	O
+equivalent	O
+corticosteroid	B-CHED
+therapy	O
+,	O
+and	O
+>	O
+18	O
+days	O
+on	O
+corticosteroid	B-CHED
+therapy	O
+were	O
+found	O
+to	O
+be	O
+significant	O
+risk	O
+factors	O
+for	O
+the	O
+subsequent	O
+development	B-PROC
+of	O
+osteonecrosis	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Biochemical	O
+markers	O
+of	O
+bone	B-PROC
+metabolism	B-PROC
+showed	O
+significant	O
+bone	B-PROC
+resorption	B-PROC
+as	O
+evidenced	O
+by	O
+a	O
+marked	O
+increase	O
+in	O
+serum	B-COMP
+C	O
+-	O
+terminal	O
+telopeptide	O
+concentration	O
+(	O
+CTx	B-DISO
+)	O
+from	O
+Day	O
+28	O
+-	O
+44	O
+after	O
+the	O
+onset	O
+of	O
+fever	B-PROC
+.	O
+
+These	O
+two	O
+genes	O
+encode	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RDRP	B-FUNC
+)	O
+and	O
+envelope	B-PRGE
+E	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+RDRP	B-FUNC
+and	O
+envelope	B-PRGE
+E	I-PRGE
+genes	I-PRGE
+,	O
+based	O
+on	O
+published	O
+sequences	O
+,	O
+have	O
+been	O
+synthesized	O
+and	O
+cloned	O
+into	O
+mammalian	B-SPEC
+expression	B-PROC
+vectors	O
+.	O
+
+In	O
+addition	O
+,	O
+four	O
+siRNA	O
+sites	O
+for	O
+the	O
+RDRP	B-PRGE
+gene	I-PRGE
+and	O
+two	O
+siRNA	O
+sites	O
+for	O
+envelope	B-PRGE
+E	I-PRGE
+gene	I-PRGE
+were	O
+designed	O
+and	O
+tested	O
+.	O
+
+Furthermore	O
+,	O
+these	O
+molecules	O
+could	O
+potentially	O
+be	O
+developed	O
+into	O
+therapeutic	O
+agents	O
+for	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+patient	O
+with	O
+asymptomatic	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+antigenemia	O
+from	O
+the	O
+2003	O
+-	O
+2004	O
+community	O
+outbreak	O
+of	O
+SARS	O
+in	O
+Guangzhou	O
+,	O
+China	O
+.	O
+
+Epidemiological	O
+information	O
+and	O
+laboratory	O
+findings	O
+suggested	O
+that	O
+the	O
+findings	O
+for	O
+the	O
+patient	O
+with	O
+asymptomatic	B-DISO
+infection	I-DISO
+,	O
+together	O
+with	O
+the	O
+findings	O
+from	O
+previously	O
+reported	O
+serological	O
+analyses	O
+of	O
+handlers	O
+of	O
+wild	O
+animals	B-SPEC
+and	O
+the	O
+4	O
+index	O
+case	O
+patients	O
+from	O
+the	O
+2004	O
+community	O
+outbreak	O
+,	O
+reflected	O
+a	O
+likely	O
+intermediate	O
+phase	O
+of	O
+animal	B-SPEC
+-	O
+to	O
+-	O
+human	O
+transmission	O
+of	O
+infection	B-DISO
+,	O
+rather	O
+than	O
+a	O
+case	O
+of	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+were	O
+processed	O
+for	O
+study	O
+of	O
+respiratory	O
+viruses	B-SPEC
+through	O
+antigen	B-CHED
+detection	O
+by	O
+indirect	O
+immunofluorescence	O
+assay	O
+,	O
+isolation	O
+of	O
+viruses	B-SPEC
+in	O
+cell	B-COMP
+culture	O
+and	O
+detection	O
+of	O
+nucleic	B-CHED
+acids	I-CHED
+by	O
+two	O
+independent	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+assays	O
+.	O
+
+Serology	O
+detected	O
+6	O
+viruses	B-SPEC
+,	O
+immunofluorescence	O
+8	O
+,	O
+viral	O
+culture	O
+12	O
+,	O
+and	O
+PCR	O
+45	O
+.	O
+
+For	O
+the	O
+viruses	B-SPEC
+that	O
+could	O
+be	O
+diagnosed	O
+with	O
+conventional	O
+methods	O
+,	O
+the	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+RT	O
+-	O
+PCR	O
+was	O
+85	O
+%	O
+and	O
+92	O
+%,	O
+respectively	O
+.	O
+
+They	O
+were	O
+generally	O
+inactive	O
+in	O
+these	O
+antiviral	B-CHED
+assay	O
+systems	O
+(	O
+at	O
+concentrations	O
+up	O
+to	O
+100	O
+microg	O
+/	O
+mL	O
+).	O
+
+TITLE	O
+:	O
+Plasma	B-ANAT
+glucose	B-CHED
+levels	O
+and	O
+diabetes	B-DISO
+are	O
+independent	O
+predictors	O
+for	O
+mortality	O
+and	O
+morbidity	O
+in	O
+patients	O
+with	O
+SARS	O
+.	O
+
+Before	O
+steroid	B-CHED
+treatment	O
+,	O
+the	O
+mean	O
+FPG	O
+level	O
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+SARS	B-DISO
+group	O
+(	O
+deceased	B-PROC
+vs	O
+.	O
+survivors	O
+vs	O
+.	O
+non	O
+-	O
+SARS	B-DISO
+pneumonia	B-DISO
+group	O
+:	O
+9	O
+.	O
+7	O
++/-	O
+5	O
+.	O
+2	O
+vs	O
+.	O
+6	O
+.	O
+5	O
++/-	O
+3	O
+.	O
+0	O
+vs	O
+.	O
+5	O
+.	O
+1	O
++/-	O
+
+For	O
+example	O
+,	O
+infliximab	O
+,	O
+a	O
+monoclonal	O
+TNF	B-PRGE
+antibody	I-PRGE
+,	O
+was	O
+experimentally	O
+tested	O
+in	O
+rats	B-SPEC
+and	O
+it	O
+was	O
+found	O
+to	O
+significantly	O
+reduce	O
+the	O
+pathologic	O
+score	O
+and	O
+serum	B-COMP
+amylase	B-FUNC
+activity	I-FUNC
+and	O
+also	O
+to	O
+alleviate	O
+alveolar	B-DISO
+edema	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+however	O
+,	O
+no	O
+studies	O
+are	O
+available	O
+in	O
+clinical	O
+human	B-SPEC
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Thus	O
+,	O
+the	O
+main	O
+problem	O
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+especially	O
+in	O
+the	O
+severe	O
+form	O
+of	O
+the	O
+disease	O
+,	O
+is	O
+the	O
+difficulty	O
+of	O
+planning	O
+clinical	O
+studies	O
+capable	O
+of	O
+giving	O
+reliable	O
+statistically	O
+significant	O
+answers	O
+regarding	O
+the	O
+benefits	O
+of	O
+the	O
+various	O
+proposed	O
+therapeutic	O
+agents	O
+previously	O
+tested	O
+in	O
+experimental	O
+settings	O
+.	O
+
+Microarray	O
+analysis	O
+was	O
+applied	O
+to	O
+assess	O
+changes	O
+in	O
+cellular	B-COMP
+expression	B-PROC
+profiles	O
+during	O
+different	O
+stages	O
+of	O
+two	O
+independent	O
+,	O
+highly	O
+controlled	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infections	B-DISO
+in	O
+vitro	O
+.	O
+
+Total	O
+RNA	O
+was	O
+harvested	O
+from	O
+MHV	B-SPEC
+-	O
+or	O
+mock	O
+-	O
+infected	O
+L	O
+cells	B-COMP
+at	O
+3	O
+,	O
+5	O
+and	O
+6	O
+h	O
+post	O
+-	O
+infection	B-DISO
+and	O
+hybridized	O
+to	O
+Affymetrix	O
+microarrays	O
+representing	O
+approximately	O
+12	O
+,	O
+500	O
+murine	B-SPEC
+genes	O
+and	O
+expressed	B-PROC
+sequences	O
+.	O
+
+Possibly	O
+,	O
+the	O
+interferon	B-PRGE
+response	O
+is	O
+actively	O
+counteracted	O
+by	O
+a	O
+virus	B-SPEC
+-	O
+encoded	O
+antagonist	B-PROC
+as	O
+has	O
+been	O
+described	O
+previously	O
+for	O
+other	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+ascertain	O
+the	O
+prevalence	O
+of	O
+subclinical	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+and	O
+study	O
+the	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+a	O
+local	O
+outbreak	O
+at	O
+a	O
+residential	O
+care	O
+home	O
+for	O
+the	O
+elderly	O
+.	O
+
+Among	O
+the	O
+90	O
+eligible	O
+residents	O
+,	O
+three	O
+died	B-PROC
+,	O
+one	O
+moved	O
+out	O
+,	O
+and	O
+19	O
+refused	O
+to	O
+participate	O
+.	O
+
+None	O
+of	O
+the	O
+remaining	O
+93	O
+participants	O
+tested	O
+positive	O
+for	O
+antibody	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Based	O
+on	O
+the	O
+chronological	O
+order	B-SPEC
+,	O
+resident	O
+A	O
+might	O
+have	O
+transmitted	B-DISO
+infection	B-DISO
+to	O
+resident	O
+B	O
+and	O
+staff	O
+C	O
+.	O
+Sitting	O
+close	O
+to	O
+the	O
+bathroom	O
+doorway	O
+while	O
+resident	O
+A	O
+took	O
+a	O
+shower	O
+was	O
+the	O
+only	O
+contact	O
+of	O
+resident	O
+B	O
+with	O
+resident	O
+A	O
+.	O
+The	O
+only	O
+opportunity	O
+for	O
+staff	O
+C	O
+to	O
+have	O
+contact	O
+with	O
+body	B-ANAT
+fluids	I-ANAT
+/	O
+excreta	O
+of	O
+resident	O
+A	O
+was	O
+in	O
+the	O
+handling	O
+of	O
+rubbish	O
+from	O
+the	O
+resident	O
+'	O
+s	O
+room	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+90	O
+eligible	O
+residents	O
+,	O
+three	O
+died	B-PROC
+,	O
+one	O
+moved	O
+out	O
+,	O
+and	O
+19	O
+refused	O
+to	O
+participate	O
+.	O
+
+None	O
+of	O
+the	O
+remaining	O
+93	O
+participants	O
+tested	O
+positive	O
+for	O
+antibody	B-COMP
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Based	O
+on	O
+the	O
+chronological	O
+order	B-SPEC
+,	O
+resident	O
+A	O
+might	O
+have	O
+transmitted	B-DISO
+infection	B-DISO
+to	O
+resident	O
+B	O
+and	O
+staff	O
+C	O
+.	O
+Sitting	O
+close	O
+to	O
+the	O
+bathroom	O
+doorway	O
+while	O
+resident	O
+A	O
+took	O
+a	O
+shower	O
+was	O
+the	O
+only	O
+contact	O
+of	O
+resident	O
+B	O
+with	O
+resident	O
+A	O
+.	O
+The	O
+only	O
+opportunity	O
+for	O
+staff	O
+C	O
+to	O
+have	O
+contact	O
+with	O
+body	B-ANAT
+fluids	I-ANAT
+/	O
+excreta	O
+of	O
+resident	O
+A	O
+was	O
+in	O
+the	O
+handling	O
+of	O
+rubbish	O
+from	O
+the	O
+resident	O
+'	O
+s	O
+room	O
+.	O
+
+Laboratory	O
+testing	O
+identified	O
+influenza	B-PATH
+A	I-PATH
+for	O
+44	O
+%;	O
+sequence	O
+analysis	O
+demonstrated	O
+that	O
+these	O
+were	O
+Fujian	O
+-	O
+like	O
+influenza	B-DISO
+strains	O
+,	O
+which	O
+represented	O
+the	O
+predominant	O
+strain	O
+found	O
+globally	O
+in	O
+2003	O
+/	O
+2004	O
+.	O
+
+The	O
+data	O
+was	O
+divided	O
+into	O
+three	O
+periods	B-PROC
+:	O
+(	O
+1	O
+)	O
+before	O
+PPE	B-CHED
+was	O
+instituted	O
+from	O
+1	O
+November	O
+2002	O
+to	O
+31	O
+March	O
+2003	O
+;	O
+(	O
+2	O
+)	O
+during	O
+SARS	B-DISO
+(	O
+when	O
+PPE	B-CHED
+use	O
+was	O
+mandatory	O
+)	O
+from	O
+1	O
+April	O
+to	O
+31	O
+July	O
+2003	O
+;	O
+(	O
+3	O
+)	O
+post	O
+-	O
+SARs	B-DISO
+(	O
+when	O
+PPE	B-CHED
+use	O
+was	O
+non	O
+-	O
+mandatory	O
+but	O
+encouraged	O
+)	O
+from	O
+1	O
+August	O
+to	O
+31	O
+March	O
+2004	O
+.	O
+
+There	O
+was	O
+no	O
+change	O
+in	O
+patient	O
+demographics	O
+during	O
+the	O
+three	O
+periods	B-PROC
+.	O
+
+There	O
+were	O
+significant	O
+increases	O
+in	O
+the	O
+proportion	O
+of	O
+resuscitation	O
+cases	O
+and	O
+airway	O
+interventions	O
+during	O
+the	O
+SARS	B-DISO
+period	O
+compared	O
+to	O
+the	O
+pre	O
+-	O
+SARS	B-DISO
+period	O
+.	O
+
+The	O
+DNA	O
+hybridization	B-PROC
+sensor	O
+is	O
+designed	O
+immobilizing	O
+the	O
+complementary	O
+probe	O
+on	O
+the	O
+pre	O
+-	O
+treated	O
+electrode	O
+surface	O
+and	O
+,	O
+then	O
+,	O
+the	O
+hybridization	B-PROC
+reaction	O
+takes	O
+place	O
+with	O
+the	O
+gold	B-CHED
+labeled	O
+strand	O
+.	O
+
+For	O
+the	O
+discrimination	O
+of	O
+a	O
+single	O
+-	O
+base	O
+mismatch	O
+,	O
+is	O
+needed	O
+to	O
+use	O
+stringent	O
+conditions	O
+(	O
+50	O
+%	O
+of	O
+formamide	B-CHED
+in	O
+the	O
+hybridization	B-PROC
+buffer	B-CHED
+).	O
+
+It	O
+contains	O
+two	O
+heptad	O
+repeat	O
+regions	O
+,	O
+denoted	O
+HRN	B-CHED
+and	O
+HRC	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+the	O
+binding	B-FUNC
+of	O
+the	O
+HRC	O
+analogs	O
+to	O
+HRN	B-CHED
+does	O
+not	O
+correlate	O
+with	O
+the	O
+coiled	O
+-	O
+coil	O
+stability	O
+of	O
+the	O
+HRC	O
+analogs	O
+,	O
+but	O
+their	O
+interactions	O
+with	O
+HRC	O
+does	O
+correlate	O
+with	O
+their	O
+stability	O
+,	O
+except	O
+for	O
+HRC7	O
+.	O
+
+For	O
+example	O
+,	O
+our	O
+study	O
+shows	O
+the	O
+important	O
+role	O
+of	O
+alpha	O
+-	O
+helical	O
+structure	O
+in	O
+the	O
+formation	B-PROC
+of	O
+the	O
+six	O
+-	O
+helix	O
+bundle	O
+where	O
+the	O
+lactam	B-CHED
+bridge	O
+constrained	O
+analog	O
+(	O
+HRC5	O
+)	O
+provided	O
+the	O
+best	O
+interaction	O
+with	O
+HRN	B-CHED
+.	O
+
+Detection	O
+of	O
+cognitive	O
+abnormalities	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+survivors	O
+using	O
+a	O
+telephone	O
+-	O
+administered	O
+test	O
+battery	O
+derived	O
+from	O
+standard	O
+cognitive	O
+tests	O
+is	O
+feasible	O
+and	O
+has	O
+evidence	O
+of	O
+construct	O
+validity	O
+.	O
+
+Subjects	O
+with	O
+cognitive	B-DISO
+impairment	I-DISO
+had	O
+no	O
+detectable	O
+difference	O
+in	O
+the	O
+physical	O
+function	O
+domains	O
+of	O
+the	O
+Short	O
+Form	O
+36	O
+.	O
+
+When	O
+administered	O
+to	O
+the	O
+validation	O
+population	O
+,	O
+telephone	O
+tests	O
+of	O
+memory	B-PROC
+,	O
+attention	O
+,	O
+reasoning	O
+,	O
+and	O
+executive	O
+functions	O
+had	O
+good	O
+intraclass	O
+correlation	O
+with	O
+the	O
+in	O
+-	O
+face	B-DISO
+interviews	O
+(	O
+P	O
+<	O
+.	O
+01	O
+).	O
+
+In	O
+addition	O
+,	O
+we	O
+have	O
+demonstrated	O
+the	O
+presence	O
+of	O
+Oct	O
+-	O
+4	O
++	O
+long	O
+-	O
+term	O
+BrdU	B-CHED
+label	B-CHED
+-	O
+retaining	O
+cells	B-COMP
+at	O
+the	O
+bronchoalveolar	O
+junction	O
+of	O
+neonatal	O
+lung	B-ANAT
+,	O
+providing	O
+a	O
+link	O
+between	O
+the	O
+Oct	B-PRGE
+-	I-PRGE
+4	I-PRGE
++	I-PRGE
+cells	B-COMP
+in	O
+vivo	O
+and	O
+in	O
+vitro	O
+and	O
+strengthening	O
+their	O
+identity	O
+as	O
+putative	O
+neonatal	O
+lung	B-ANAT
+stem	B-ANAT
+/	O
+progenitor	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+X	O
+-	O
+ray	B-SPEC
+structures	O
+of	O
+the	O
+N	O
+-	O
+and	O
+C	O
+-	O
+terminal	O
+domains	O
+of	O
+a	O
+coronavirus	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+:	O
+implications	O
+for	O
+nucleocapsid	O
+formation	B-PROC
+.	O
+
+We	O
+describe	O
+the	O
+structure	O
+of	O
+the	O
+two	O
+proteolytically	O
+resistant	O
+domains	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+from	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+a	O
+prototype	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Novel	O
+mfgl2	O
+antisense	O
+plasmid	O
+inhibits	O
+murine	B-SPEC
+fgl2	B-PRGE
+expression	B-PROC
+and	O
+ameliorates	O
+murine	B-SPEC
+hepatitis	I-DISO
+virus	O
+type	O
+3	O
+-	O
+induced	O
+fulminant	B-DISO
+hepatitis	I-DISO
+in	O
+BALB	O
+/	O
+cJ	O
+mice	B-SPEC
+.	O
+
+The	O
+appearance	O
+of	O
+a	O
+case	O
+of	O
+FIP	B-DISO
+in	O
+the	O
+cattery	O
+was	O
+associated	O
+with	O
+an	O
+increased	O
+expression	B-PROC
+of	O
+cytokines	O
+,	O
+in	O
+particular	O
+there	O
+was	O
+an	O
+increased	O
+production	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+suggesting	O
+that	O
+these	O
+cytokines	O
+might	O
+protect	O
+infected	O
+cats	O
+from	O
+the	O
+disease	O
+.	O
+
+Among	O
+the	O
+401	O
+SARS	B-DISO
+patients	O
+studied	O
+,	O
+147	O
+of	O
+249	O
+noncritical	O
+patients	O
+(	O
+59	O
+.	O
+0	O
+%)	O
+received	O
+corticosteroids	B-CHED
+(	O
+mean	O
+daily	O
+dose	O
+,	O
+105	O
+.	O
+3	O
++/-	O
+
+However	O
+,	O
+when	O
+focused	O
+on	O
+152	O
+critical	O
+SARS	B-DISO
+cases	O
+,	O
+factors	O
+correlated	O
+with	O
+these	O
+end	O
+points	O
+indicated	O
+by	O
+univariate	O
+analysis	O
+included	O
+use	O
+of	O
+corticosteroid	B-CHED
+,	O
+age	O
+,	O
+rigor	B-DISO
+at	O
+onset	O
+,	O
+secondary	O
+respiratory	B-DISO
+infections	I-DISO
+,	O
+pulmonary	B-ANAT
+rales	B-DISO
+,	O
+grading	O
+of	O
+OI	O
+,	O
+and	O
+use	O
+of	O
+invasive	O
+ventilation	O
+.	O
+
+This	O
+Guangzhou	O
+retrospective	O
+study	O
+revealed	O
+that	O
+proper	O
+use	O
+of	O
+corticosteroid	B-CHED
+in	O
+confirmed	O
+critical	O
+SARS	B-DISO
+resulted	O
+in	O
+lowered	O
+mortality	O
+and	O
+shorter	O
+hospitalization	O
+stay	O
+,	O
+and	O
+was	O
+not	O
+associated	O
+with	O
+significant	O
+secondary	O
+lower	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+and	O
+other	O
+complications	O
+.	O
+
+Incidence	O
+of	O
+complications	O
+was	O
+significantly	O
+associated	O
+with	O
+the	O
+need	O
+for	O
+invasive	O
+ventilation	O
+but	O
+not	O
+with	O
+use	O
+of	O
+corticosteroids	B-CHED
+.	O
+
+Strict	O
+defense	O
+and	O
+antisepsis	O
+measures	O
+were	O
+pivotal	O
+in	O
+preventing	O
+SARS	B-DISO
+infection	B-DISO
+among	O
+high	O
+-	O
+risk	O
+medical	O
+personnel	O
+.	O
+
+The	O
+drug	O
+-	O
+induced	O
+lymphocyte	B-ANAT
+stimulating	O
+test	O
+results	O
+indicated	O
+170	O
+%	O
+of	O
+oseltamivir	B-CHED
+and	O
+150	O
+%	O
+of	O
+cefcapene	O
+.	O
+
+None	O
+of	O
+the	O
+serum	B-COMP
+specimens	O
+collected	O
+from	O
+healthy	O
+children	O
+before	O
+and	O
+during	O
+epidemic	O
+in	O
+Beijing	O
+and	O
+children	O
+from	O
+non	O
+-	O
+epidemic	O
+region	O
+was	O
+positive	O
+when	O
+IFA	O
+methods	O
+and	O
+ELISA	O
+with	O
+Beier	O
+kits	O
+were	O
+used	O
+for	O
+detection	O
+,	O
+but	O
+some	O
+were	O
+positive	O
+when	O
+ELISA	O
+with	O
+the	O
+diagnostic	O
+kit	B-FUNC
+from	O
+other	O
+source	O
+was	O
+applied	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+synthetic	O
+peptide	B-CHED
+corresponding	O
+to	O
+amino	B-CHED
+acids	I-CHED
+(	O
+aa	O
+)	O
+15	O
+-	O
+28	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+3a	O
+protein	B-CHED
+was	O
+used	O
+to	O
+raise	O
+polyclonal	O
+antibodies	B-COMP
+in	O
+rabbits	B-SPEC
+.	O
+
+Interestingly	O
+,	O
+only	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+3a	I-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+antibody	I-PRGE
+can	O
+inhibit	O
+SARS	B-DISO
+-	O
+CoV	O
+propagation	O
+in	O
+Vero	O
+E6	O
+culture	O
+although	O
+the	O
+binding	B-FUNC
+affinity	O
+of	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+3a	I-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+antibody	I-PRGE
+was	O
+lower	O
+than	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+3a	I-PRGE
+C	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+antibody	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Systemic	O
+activation	O
+of	O
+complement	O
+is	O
+a	O
+pathophysiological	O
+response	O
+common	O
+to	O
+severe	O
+disturbances	O
+such	O
+as	O
+hemorrhagic	B-DISO
+shock	I-DISO
+,	O
+major	O
+burn	O
+injury	O
+and	O
+sepsis	B-DISO
+.	O
+
+B	O
+group	O
+:	O
+large	O
+V	O
+(	O
+T	O
+)	O
+(	O
+20	O
+ml	O
+/	O
+kg	O
+)	O
+with	O
+respiratory	O
+rate	O
+30	O
+/	O
+minutes	O
+,	O
+high	O
+inspiratory	B-PROC
+flow	O
+20	O
+ml	O
+.	O
+kg	O
+(-	O
+1	O
+).	O
+s	O
+(-	O
+1	O
+).	O
+
+D	O
+group	O
+:	O
+large	O
+V	O
+(	O
+T	O
+)	O
+(	O
+20	O
+ml	O
+/	O
+kg	O
+)	O
+with	O
+respiratory	O
+rate	O
+15	O
+/	O
+minutes	O
+,	O
+low	O
+inspiratory	B-PROC
+flow	O
+10	O
+ml	O
+.	O
+kg	O
+(-	O
+1	O
+).	O
+s	O
+(-	O
+1	O
+).	O
+
+Lung	B-ANAT
+wet	O
+/	O
+dry	O
+weight	O
+ratio	O
+(	O
+W	O
+/	O
+D	O
+)	O
+was	O
+measured	O
+.	O
+
+NF	B-PRGE
+-	I-PRGE
+KappaB	I-PRGE
+p65	B-PRGE
+activity	O
+in	O
+B	O
+group	O
+[(	O
+33	O
+.	O
+56	O
++/-	O
+2	O
+.	O
+85	O
+)%]	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+of	O
+A	O
+[(	O
+10	O
+.	O
+35	O
++/-	O
+0	O
+.	O
+60	O
+)%]	O
+and	O
+D	O
+[(	O
+10	O
+.	O
+79	O
++/-	O
+1	O
+.	O
+02	O
+)%]	O
+groups	O
+,	O
+but	O
+there	O
+was	O
+no	O
+difference	O
+between	O
+B	O
+and	O
+C	O
+[(	O
+30	O
+.	O
+87	O
++/-	O
+1	O
+.	O
+16	O
+)%]	O
+groups	O
+.	O
+
+The	O
+remaining	O
+44	O
+SARS	B-DISO
+patients	O
+constituted	O
+the	O
+non	O
+-	O
+serious	O
+SARS	B-DISO
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+mortality	O
+rate	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+is	O
+still	O
+high	O
+(	O
+20	O
+to	O
+65	O
+%)	O
+despite	O
+the	O
+advances	O
+in	O
+critical	O
+care	O
+.	O
+
+A	O
+total	O
+of	O
+396	O
+cleavage	B-PROC
+points	O
+are	O
+found	O
+in	O
+the	O
+36	O
+SARS	B-DISO
+-	O
+Coronavirus	B-SPEC
+and	O
+11	O
+cleavable	O
+octapeptides	O
+abstracted	O
+from	O
+the	O
+396	O
+cleavage	B-PROC
+sites	O
+.	O
+
+Idiopathic	B-DISO
+hypereosinophilic	I-DISO
+syndrome	I-DISO
+had	O
+been	O
+diagnosed	O
+in	O
+1994	O
+.	O
+
+Despite	O
+treatment	O
+with	O
+steroid	B-CHED
+pulse	B-PROC
+therapy	O
+and	O
+cytarabine	B-CHED
+,	O
+the	O
+blood	B-ANAT
+eosinophil	I-ANAT
+count	O
+did	O
+not	O
+decrease	O
+,	O
+and	O
+the	O
+patient	O
+'	O
+s	O
+respiratory	O
+condition	B-DISO
+worsened	O
+.	O
+
+Although	O
+very	O
+safe	O
+in	O
+daily	O
+use	O
+,	O
+complications	O
+of	O
+this	O
+bowel	B-ANAT
+-	O
+cleansing	O
+procedure	O
+have	O
+been	O
+reported	O
+and	O
+aspiration	B-DISO
+of	O
+the	O
+PEG	B-CHED
+solution	O
+is	O
+a	O
+possible	O
+and	O
+serious	O
+hazard	O
+.	O
+
+A	O
+case	O
+report	O
+is	O
+presented	O
+of	O
+a	O
+patient	O
+who	O
+aspirated	B-DISO
+the	O
+PEG	B-CHED
+solution	O
+and	O
+ultimately	O
+died	B-PROC
+because	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+157	O
+specimens	O
+(	O
+78	O
+fecal	B-ANAT
+and	O
+79	O
+intestinal	B-ANAT
+samples	O
+)	O
+from	O
+piglets	O
+with	O
+acute	B-DISO
+gastroenteritis	I-DISO
+were	O
+collected	O
+in	O
+Korea	O
+between	O
+January	O
+2004	O
+and	O
+May	O
+2005	O
+.	O
+
+Coinfections	B-DISO
+with	O
+PEDV	B-SPEC
+and	O
+porcine	B-SPEC
+GAR	B-FUNC
+were	O
+identified	O
+in	O
+16	O
+farms	O
+(	O
+43	O
+.	O
+2	O
+%).	O
+
+Saikosaponins	O
+represent	O
+a	O
+group	O
+of	O
+oleanane	O
+derivatives	O
+,	O
+usually	O
+as	O
+glucosides	B-CHED
+,	O
+that	O
+are	O
+found	O
+in	O
+a	O
+number	O
+of	O
+plant	B-SPEC
+families	O
+.	O
+
+Comparisons	O
+were	O
+made	O
+for	O
+perinatal	O
+survival	O
+and	O
+neonatal	O
+morbidities	O
+including	O
+abnormalities	O
+on	O
+brain	B-ANAT
+imaging	O
+.	O
+
+Neonatal	O
+morbidities	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+,	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+,	O
+requirement	O
+for	O
+ventilatory	O
+assistance	O
+,	O
+patent	B-DISO
+ductus	I-DISO
+arteriosus	I-DISO
+,	O
+hypotension	O
+,	O
+and	O
+oliguric	O
+renal	B-DISO
+failure	I-DISO
+had	O
+a	O
+lower	O
+incidence	O
+in	O
+the	O
+laser	B-SPEC
+group	O
+.	O
+
+Cardiac	B-ANAT
+output	O
+was	O
+continuously	O
+deteriorating	O
+during	O
+the	O
+recruitment	B-DISO
+manoeuvre	O
+in	O
+both	O
+study	O
+groups	O
+(	O
+HFOV	O
+:	O
+T	O
+(	O
+Ali	O
+):	O
+6	O
+.	O
+1	O
++/-	O
+
+A	O
+sustained	O
+inflation	O
+followed	O
+by	O
+an	O
+incremental	O
+mean	O
+airway	B-ANAT
+pressure	O
+trial	O
+in	O
+HFOV	O
+improved	O
+oxygenation	B-PROC
+at	O
+a	O
+lower	O
+mPaw	O
+than	O
+during	O
+conventional	O
+lung	B-ANAT
+protective	O
+ventilation	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+novel	O
+vaccine	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+developed	O
+based	O
+on	O
+the	O
+rAAV	O
+delivery	O
+system	O
+.	O
+
+TITLE	O
+:	O
+Generality	O
+of	O
+the	O
+final	O
+size	O
+formula	O
+for	O
+an	O
+epidemic	O
+of	O
+a	O
+newly	O
+invading	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+For	O
+an	O
+effective	O
+immune	O
+prophylaxis	O
+in	O
+humans	B-SPEC
+,	O
+broad	O
+coverage	O
+of	O
+different	O
+strains	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+control	O
+of	O
+potential	O
+neutralization	O
+escape	O
+variants	O
+will	O
+be	O
+required	O
+.	O
+
+In	O
+vitro	O
+experiments	O
+confirmed	O
+that	O
+binding	B-FUNC
+of	O
+CR3014	O
+to	O
+a	O
+recombinant	B-PRGE
+S	I-PRGE
+fragment	I-PRGE
+(	I-PRGE
+amino	I-PRGE
+acid	I-PRGE
+residues	I-PRGE
+318	I-PRGE
+-	I-PRGE
+510	I-PRGE
+)	I-PRGE
+harboring	O
+this	O
+mutation	O
+was	O
+abolished	O
+.	O
+
+Conversely	O
+,	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+expressed	B-PROC
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+did	O
+not	O
+induce	O
+apoptosis	B-PATH
+.	O
+
+We	O
+examined	O
+the	O
+epidemiologic	O
+and	O
+clinical	O
+factors	O
+associated	O
+with	O
+death	B-PROC
+for	O
+all	O
+laboratory	O
+-	O
+confirmed	O
+SARS	B-DISO
+patients	O
+in	O
+Taiwan	O
+.	O
+
+Both	O
+fatalities	O
+(	O
+n	O
+=	O
+73	O
+;	O
+21	O
+.	O
+1	O
+%)	O
+and	O
+survivors	O
+had	O
+elevated	O
+plasma	B-ANAT
+concentration	O
+of	O
+initial	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+),	O
+but	O
+the	O
+mean	O
+CRP	B-PRGE
+concentration	O
+was	O
+higher	O
+in	O
+fatalities	O
+(	O
+47	O
+.	O
+7	O
++/-	O
+
+CONCLUSIONS	O
+:	O
+Initial	O
+neutrophil	B-ANAT
+count	O
+,	O
+CRP	B-PRGE
+and	O
+LDH	B-PRGE
+levels	O
+are	O
+important	O
+predictors	O
+of	O
+mortality	O
+from	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Bayesian	O
+modelling	O
+of	O
+an	O
+epidemic	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+infectivity	O
+of	O
+symptomatic	O
+SARS	B-DISO
+cases	O
+in	O
+hospital	O
+and	O
+in	O
+the	O
+community	O
+was	O
+estimated	O
+.	O
+
+TITLE	O
+:	O
+Hosting	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+:	O
+specific	O
+cell	B-COMP
+factors	O
+required	O
+for	O
+infection	O
+.	O
+
+As	O
+part	O
+of	O
+the	O
+Sino	O
+-	O
+European	O
+Project	O
+on	O
+SARS	B-DISO
+Diagnostics	O
+and	O
+Antivirals	B-CHED
+(	O
+SEPSDA	O
+),	O
+an	O
+immune	O
+phage	O
+-	O
+display	O
+library	O
+is	O
+being	O
+created	O
+from	O
+convalescent	O
+patients	O
+in	O
+a	O
+phagemid	O
+system	O
+for	O
+the	O
+selection	O
+of	O
+single	O
+-	O
+chain	O
+fragment	O
+variables	O
+(	O
+scFv	O
+)	O
+antibodies	B-COMP
+recognizing	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+This	O
+review	O
+describes	O
+the	O
+basic	O
+biology	O
+of	O
+VEGF	B-PRGE
+and	O
+its	O
+receptors	O
+as	O
+an	O
+essential	O
+prerequisite	O
+to	O
+discussing	O
+the	O
+available	O
+and	O
+sometimes	O
+paradoxical	O
+published	O
+data	O
+,	O
+before	O
+considering	O
+a	O
+paradigm	O
+for	O
+the	O
+role	O
+of	O
+VEGF	B-PRGE
+in	O
+the	O
+human	B-SPEC
+lung	B-ANAT
+.	O
+
+The	O
+authors	O
+compared	O
+the	O
+expected	O
+influenza	B-DISO
+-	O
+related	O
+hospitalizations	O
+in	O
+the	O
+first	O
+eight	O
+weeks	O
+of	O
+a	O
+mild	O
+,	O
+moderate	O
+,	O
+or	O
+severe	O
+pandemic	O
+with	O
+the	O
+actual	O
+reduction	O
+in	O
+the	O
+number	O
+of	O
+hospital	O
+admissions	O
+in	O
+Toronto	O
+,	O
+Ontario	O
+,	O
+during	O
+the	O
+first	O
+eight	O
+weeks	O
+of	O
+the	O
+SARS	O
+-	O
+related	O
+restrictions	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+naval	O
+diver	O
+.	O
+
+However	O
+,	O
+the	O
+mechanisms	O
+of	O
+establishment	O
+of	O
+persistent	B-DISO
+infection	I-DISO
+are	O
+still	O
+unclear	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+enters	O
+cells	B-COMP
+through	O
+the	O
+activities	O
+of	O
+a	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+which	O
+has	O
+receptor	O
+-	O
+binding	B-FUNC
+(	O
+S1	O
+)	O
+and	O
+membrane	B-PROC
+fusion	I-PROC
+(	O
+S2	O
+)	O
+regions	O
+.	O
+
+Lowered	O
+pH	O
+induces	O
+an	O
+irreversible	O
+transition	B-DISO
+from	O
+flexible	O
+,	O
+L	O
+-	O
+shaped	O
+S	O
+-	O
+e	O
+monomers	O
+to	O
+clove	B-SPEC
+-	O
+shaped	O
+trimers	O
+.	O
+
+The	O
+pathogenic	O
+phenotype	O
+for	O
+each	O
+strain	O
+is	O
+determined	O
+by	O
+the	O
+genetic	O
+composition	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+,	O
+as	O
+well	O
+as	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+.	O
+
+Using	O
+another	O
+set	O
+of	O
+isogenic	O
+recombinant	O
+viruses	B-SPEC
+with	O
+JHM	O
+background	O
+genes	O
+expressing	O
+either	O
+the	O
+JHM	O
+or	O
+A59	O
+spike	O
+,	O
+we	O
+have	O
+further	O
+investigated	O
+the	O
+roles	O
+of	O
+viral	O
+genes	O
+in	O
+pathogenesis	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrate	O
+that	O
+the	O
+high	O
+neurovirulence	O
+of	O
+JHM	O
+is	O
+associated	O
+with	O
+accelerated	O
+spread	O
+through	O
+the	O
+brain	B-ANAT
+and	O
+a	O
+heightened	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+that	O
+is	O
+characterized	O
+by	O
+high	O
+numbers	O
+of	O
+infiltrating	B-DISO
+neutrophils	B-ANAT
+and	O
+macrophages	B-ANAT
+,	O
+suggesting	O
+an	O
+immunopathogenic	O
+component	O
+to	O
+neurovirulence	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+analysis	O
+of	O
+22	O
+coronavirus	B-SPEC
+HKU1	O
+genomes	O
+reveals	O
+a	O
+novel	O
+genotype	O
+and	O
+evidence	O
+of	O
+natural	O
+recombination	O
+in	O
+coronavirus	B-SPEC
+HKU1	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+24	O
+putative	O
+proteins	B-CHED
+and	O
+polypeptides	B-CHED
+showed	O
+that	O
+the	O
+22	O
+CoV	O
+HKU1	O
+strains	O
+fell	O
+into	O
+three	O
+clusters	B-CHED
+(	O
+genotype	O
+A	O
+,	O
+13	O
+strains	O
+;	O
+genotype	O
+B	O
+,	O
+3	O
+strains	O
+and	O
+genotype	O
+C	O
+,	O
+6	O
+strains	O
+).	O
+
+After	O
+the	O
+mice	B-SPEC
+had	O
+been	O
+immunized	O
+intramuscularly	O
+and	O
+/	O
+or	O
+intraperitoneally	O
+with	O
+pcDNA3	O
+.	O
+1	O
+-	O
+N	O
+and	O
+rAd	O
+-	O
+N	O
+in	O
+prime	O
+-	O
+triple	O
+boost	O
+immunization	O
+,	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+were	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+All	O
+coronaviruses	O
+encode	O
+a	O
+small	O
+hydrophobic	O
+envelope	O
+(	O
+E	O
+)	O
+protein	B-CHED
+,	O
+which	O
+mediates	O
+viral	B-PROC
+assembly	I-PROC
+and	O
+morphogenesis	B-PROC
+by	O
+an	O
+unknown	O
+mechanism	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+a	O
+single	O
+JHMV	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+immunodominant	I-PRGE
+CD4	I-PRGE
+T	I-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitope	B-CHED
+is	O
+critical	O
+for	O
+severe	O
+disease	O
+.	O
+
+All	O
+the	O
+specimens	O
+were	O
+detected	O
+,	O
+the	O
+total	O
+positive	O
+rate	O
+was	O
+100	O
+%;	O
+the	O
+sensitivity	O
+of	O
+the	O
+method	O
+was	O
+10e2	O
+(	O
+pfu	B-CHED
+/	O
+ml	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Follow	O
+up	O
+study	O
+on	O
+viruses	B-SPEC
+associated	O
+with	O
+SARS	B-DISO
+among	O
+the	O
+SARS	B-DISO
+patients	O
+].	O
+
+No	O
+positive	O
+results	O
+for	O
+antibody	B-COMP
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+detected	O
+in	O
+the	O
+25	O
+healthy	O
+persons	O
+.	O
+
+The	O
+positive	O
+rate	O
+of	O
+the	O
+poliovirus	B-SPEC
+antibody	B-COMP
+in	O
+the	O
+serum	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+2	O
+years	O
+after	O
+recovery	O
+was	O
+significantly	O
+different	O
+from	O
+that	O
+of	O
+the	O
+normal	O
+controls	O
+,	O
+and	O
+the	O
+positive	O
+rate	O
+of	O
+poliovirus	B-SPEC
+in	O
+the	O
+fecal	B-ANAT
+specimens	O
+was	O
+still	O
+very	O
+high	O
+,	O
+and	O
+more	O
+importantly	O
+back	B-ANAT
+mutations	O
+have	O
+occurred	O
+in	O
+the	O
+attenuating	O
+mutation	O
+sites	O
+at	O
+nucleotide	B-CHED
+position	O
+which	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+poliomyelitis	B-DISO
+.	O
+
+RESULTS	O
+:	O
+All	O
+the	O
+specimens	O
+were	O
+negative	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+reovirus	B-SPEC
+by	O
+RT	O
+-	O
+PCR	O
+,	O
+but	O
+the	O
+fecal	B-ANAT
+specimens	O
+from	O
+4	O
+persons	O
+were	O
+positive	O
+for	O
+poliovirus	B-SPEC
+.	O
+
+Previously	O
+we	O
+have	O
+shown	O
+that	O
+the	O
+coronavirus	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+will	O
+localize	O
+to	O
+the	O
+nucleolus	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+using	O
+the	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+coronavirus	B-SPEC
+,	O
+we	O
+have	O
+shown	O
+that	O
+virus	B-DISO
+infection	I-DISO
+results	O
+in	O
+a	O
+number	O
+of	O
+changes	O
+to	O
+the	O
+nucleolus	B-COMP
+both	O
+in	O
+terms	O
+of	O
+gross	O
+morphology	O
+and	O
+protein	B-CHED
+content	O
+.	O
+
+However	O
+,	O
+research	O
+on	O
+different	O
+aspects	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+not	O
+waning	O
+,	O
+as	O
+it	O
+is	O
+not	O
+known	O
+if	O
+this	O
+virus	B-SPEC
+will	O
+re	O
+-	O
+emerge	O
+,	O
+especially	O
+since	O
+its	O
+origins	O
+and	O
+potential	O
+reservoir	O
+(	O
+s	O
+)	O
+are	O
+unresolved	O
+.	O
+
+Any	O
+organism	O
+can	O
+cause	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+SARS	B-PRGE
+susceptibility	I-PRGE
+with	O
+single	O
+nucleic	B-CHED
+acid	I-CHED
+polymorphisms	B-PROC
+of	O
+OAS1	B-PRGE
+and	O
+MxA	B-PRGE
+genes	I-PRGE
+:	O
+a	O
+case	O
+-	O
+control	O
+study	O
+.	O
+
+A	O
+collective	O
+of	O
+66	O
+SARS	B-DISO
+cases	O
+and	O
+64	O
+close	O
+contact	O
+uninfected	O
+controls	O
+were	O
+enrolled	O
+in	O
+this	O
+study	O
+.	O
+
+Information	O
+on	O
+other	O
+factors	O
+associated	O
+with	O
+SARS	B-DISO
+infection	B-DISO
+was	O
+collected	O
+using	O
+a	O
+pre	O
+-	O
+tested	O
+questionnaire	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+influence	O
+of	O
+ambroxol	O
+on	O
+paraquat	B-CHED
+poisoning	O
+induced	O
+acute	O
+lung	B-ANAT
+tissue	I-ANAT
+injury	O
+and	O
+the	O
+change	O
+of	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+associated	O
+protein	B-CHED
+A	O
+in	O
+the	O
+experimental	O
+rats	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Survey	O
+of	O
+dogs	B-SPEC
+in	O
+Japan	O
+for	O
+group	O
+2	O
+canine	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Intentions	O
+and	O
+attitudes	O
+toward	O
+SARS	B-DISO
+patient	O
+care	O
+among	O
+Korean	O
+clinical	O
+nurses	O
+were	O
+moderate	O
+,	O
+but	O
+their	O
+subjective	O
+norm	O
+and	O
+perceive	O
+behavioral	O
+control	O
+of	O
+SARS	B-DISO
+patients	O
+care	O
+were	O
+negative	O
+.	O
+
+Nurses	O
+were	O
+in	O
+conflicts	O
+between	O
+professional	O
+responsibilities	O
+to	O
+care	O
+for	O
+SARS	B-DISO
+patients	O
+and	O
+personal	O
+safety	O
+.	O
+
+Under	O
+the	O
+circumstance	O
+where	O
+several	O
+fatal	O
+communicable	B-DISO
+diseases	I-DISO
+are	O
+predictable	O
+,	O
+conflicts	O
+between	O
+professional	O
+responsibility	O
+and	O
+their	O
+personal	O
+risks	O
+should	O
+be	O
+taken	O
+into	O
+considerations	O
+by	O
+nurses	O
+themselves	O
+and	O
+by	O
+nursing	B-PROC
+administrators	O
+in	O
+order	B-SPEC
+to	O
+improve	O
+quality	O
+of	O
+care	O
+.	O
+
+ABSTRACT	O
+:	O
+Emergency	B-DISO
+infection	B-DISO
+control	O
+measures	O
+are	O
+essential	O
+in	O
+hospitals	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+level	O
+of	O
+preparedness	O
+of	O
+emergency	B-DISO
+infection	B-DISO
+control	O
+measures	O
+in	O
+Japan	O
+and	O
+to	O
+quantify	O
+the	O
+differences	O
+in	O
+preparedness	O
+across	O
+institutions	O
+and	O
+disciplines	O
+.	O
+
+From	O
+July	O
+to	O
+September	O
+2003	O
+,	O
+a	O
+questionnaire	O
+survey	O
+concerning	O
+the	O
+perceptions	O
+of	O
+risks	O
+and	O
+countermeasures	O
+and	O
+knowledge	O
+about	O
+SARS	B-DISO
+was	O
+distributed	O
+at	O
+seven	O
+tertiary	O
+hospitals	O
+.	O
+
+The	O
+article	O
+ends	O
+with	O
+a	O
+discussion	O
+of	O
+how	O
+practice	O
+and	O
+regulations	O
+have	O
+changed	O
+in	O
+Canada	O
+since	O
+SARS	B-DISO
+and	O
+some	O
+suggestions	O
+on	O
+how	O
+practice	O
+or	O
+regulations	O
+could	O
+further	O
+improve	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emerging	O
+disease	O
+SARS	O
+is	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+encodes	O
+several	O
+unusual	O
+RNA	O
+-	O
+processing	O
+enzymes	O
+,	O
+including	O
+non	B-PRGE
+-	I-PRGE
+structural	I-PRGE
+protein	I-PRGE
+15	I-PRGE
+(	O
+Nsp15	O
+),	O
+a	O
+hexameric	O
+endoribonuclease	O
+that	O
+preferentially	O
+cleaves	O
+at	O
+uridine	B-CHED
+residues	O
+.	O
+
+A	O
+two	O
+-	O
+dimensional	O
+crystal	B-ANAT
+of	O
+Nsp15	O
+in	O
+complex	O
+with	O
+RNA	O
+showed	O
+that	O
+at	O
+least	O
+two	O
+RNA	O
+molecules	O
+could	O
+be	O
+bound	O
+per	O
+hexamer	O
+.	O
+
+Eighty	O
+-	O
+nine	O
+per	O
+cent	O
+had	O
+exposures	O
+to	O
+7	O
+wards	O
+which	O
+had	O
+cases	O
+of	O
+SARS	B-DISO
+that	O
+were	O
+not	O
+isolated	O
+on	O
+admission	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+in	O
+Singapore	O
+--	O
+predictors	O
+of	O
+disease	O
+severity	O
+.	O
+
+Advanced	O
+age	O
+,	O
+neutrophilia	O
+and	O
+high	O
+LDH	B-PRGE
+predict	O
+poor	O
+outcomes	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+On	O
+admission	O
+,	O
+21	O
+%	O
+had	O
+leukopenia	B-DISO
+,	O
+18	O
+%	O
+had	O
+thrombocytopaenia	O
+,	O
+29	O
+%	O
+had	O
+hyponatraemia	O
+,	O
+31	O
+%	O
+had	O
+hypokalaemia	O
+,	O
+21	O
+%	O
+had	O
+transaminitis	O
+.	O
+
+Overall	O
+,	O
+12	O
+%	O
+of	O
+the	O
+patients	O
+were	O
+probable	O
+SARS	B-DISO
+with	O
+atypical	O
+presentations	O
+.	O
+
+Patients	O
+infected	O
+with	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+had	O
+a	O
+wide	O
+clinical	O
+presentation	O
+with	O
+non	O
+-	O
+specific	O
+symptoms	O
+.	O
+
+Chest	B-ANAT
+radiographic	O
+appearances	O
+have	O
+been	O
+reported	O
+as	O
+non	O
+-	O
+specific	O
+,	O
+ranging	O
+from	O
+normal	O
+to	O
+peribronchial	O
+thickening	O
+and	O
+ill	B-DISO
+-	O
+defined	O
+airspace	O
+shadowing	O
+.	O
+
+This	O
+study	O
+is	O
+a	O
+retrospective	O
+review	O
+of	O
+chest	B-ANAT
+radiographic	O
+findings	O
+in	O
+children	O
+with	O
+suspected	O
+and	O
+probable	O
+SARS	B-DISO
+during	O
+the	O
+2003	O
+outbreak	O
+in	O
+Singapore	O
+.	O
+
+Subsequently	O
+,	O
+we	O
+identified	O
+the	O
+radiographs	O
+of	O
+patients	O
+who	O
+were	O
+categorised	O
+as	O
+suspected	O
+or	O
+probable	O
+SARS	B-DISO
+.	O
+
+The	O
+abnormalities	O
+had	O
+a	O
+predominantly	O
+lower	O
+zone	O
+distribution	O
+on	O
+chest	B-ANAT
+radiographs	O
+,	O
+followed	O
+by	O
+mid	O
+-	O
+zone	O
+involvement	O
+.	O
+
+In	O
+children	O
+,	O
+SARS	B-DISO
+appears	O
+to	O
+have	O
+a	O
+relatively	O
+mild	O
+and	O
+nonspecific	O
+pattern	O
+of	O
+respiratory	O
+illness	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+rapid	O
+containment	O
+of	O
+the	O
+Singapore	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+2003	O
+involved	O
+the	O
+introduction	O
+of	O
+several	O
+stringent	O
+control	O
+measures	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+emerged	O
+in	O
+a	O
+world	O
+where	O
+information	O
+about	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+travels	O
+at	O
+speeds	O
+and	O
+in	O
+ways	O
+not	O
+imagined	O
+just	O
+30	O
+years	O
+ago	O
+,	O
+and	O
+where	O
+scientists	O
+are	O
+increasingly	O
+working	O
+together	O
+on	O
+detecting	O
+and	O
+responding	O
+to	O
+public	O
+health	O
+events	O
+that	O
+threaten	O
+international	O
+public	O
+health	O
+and	O
+economic	O
+security	O
+.	O
+
+ABSTRACT	O
+:	O
+Following	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+2003	O
+,	O
+a	O
+large	O
+number	O
+of	O
+clinical	O
+and	O
+environmental	B-SPEC
+samples	I-SPEC
+containing	O
+/	O
+potentially	O
+containing	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARSCoV	O
+)	O
+as	O
+well	O
+as	O
+SARS	B-DISO
+-	O
+CoV	O
+stocks	O
+were	O
+retained	O
+in	O
+clinical	O
+and	O
+research	O
+laboratories	O
+.	O
+
+It	O
+is	O
+imperative	O
+that	O
+safe	O
+practice	O
+and	O
+techniques	O
+,	O
+safety	O
+equipment	O
+and	O
+appropriate	O
+facility	O
+design	O
+should	O
+be	O
+in	O
+place	O
+to	O
+reduce	O
+or	O
+eliminate	O
+exposure	O
+of	O
+laboratory	O
+workers	O
+,	O
+other	O
+persons	O
+and	O
+the	O
+outside	O
+environment	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+containing	O
+materials	O
+.	O
+
+It	O
+was	O
+agreed	O
+that	O
+an	O
+inventory	O
+of	O
+all	O
+specimens	O
+with	O
+the	O
+potential	O
+presence	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+collected	O
+for	O
+any	O
+diagnostic	O
+or	O
+research	O
+purposes	O
+from	O
+November	O
+2002	O
+to	O
+July	O
+2003	O
+should	O
+be	O
+established	O
+in	O
+each	O
+laboratory	O
+.	O
+
+A	O
+contingency	O
+plan	B-DISO
+should	O
+be	O
+in	O
+place	O
+in	O
+the	O
+laboratory	O
+and	O
+a	O
+drill	B-SPEC
+conducted	O
+regularly	O
+to	O
+test	O
+its	O
+efficacy	O
+.	O
+
+No	O
+other	O
+disease	O
+had	O
+had	O
+such	O
+a	O
+phenomenal	O
+impact	O
+on	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+),	O
+who	O
+formed	O
+about	O
+21	O
+%	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+At	O
+the	O
+beginning	O
+of	O
+the	O
+outbreak	O
+,	O
+there	O
+was	O
+practically	O
+no	O
+information	O
+on	O
+this	O
+disease	O
+,	O
+which	O
+did	O
+not	O
+even	O
+have	O
+a	O
+name	B-SPEC
+until	O
+16	O
+March	O
+2003	O
+,	O
+except	O
+that	O
+it	O
+was	O
+infectious	B-DISO
+and	O
+could	O
+result	O
+in	O
+potentially	O
+fatal	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Photochemical	O
+treatment	O
+of	O
+plasma	B-ANAT
+with	O
+amotosalen	O
+and	O
+long	O
+-	O
+wavelength	O
+ultraviolet	O
+light	O
+inactivates	O
+pathogens	O
+while	O
+retaining	O
+coagulation	O
+function	O
+.	O
+
+Jumbo	O
+(	O
+600	O
+mL	O
+)	O
+plasma	B-ANAT
+units	O
+were	O
+inoculated	O
+with	O
+high	O
+titers	O
+of	O
+test	O
+pathogens	O
+and	O
+treated	O
+with	O
+150	O
+micromol	O
+per	O
+L	O
+amotosalen	O
+and	O
+3	O
+J	O
+per	O
+cm	O
+(	O
+2	O
+)	O
+long	O
+-	O
+wavelength	O
+ultraviolet	O
+light	O
+.	O
+
+The	O
+more	O
+recent	O
+design	O
+of	O
+wide	O
+-	O
+spectrum	O
+inhibitors	B-CHED
+targeting	B-PROC
+the	O
+coronavirus	B-SPEC
+main	O
+proteases	O
+may	O
+lead	O
+to	O
+the	O
+discovery	O
+of	O
+new	O
+antivirals	B-CHED
+against	O
+multiple	O
+coronavirus	B-SPEC
+induced	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SCoV	O
+)	O
+7a	O
+protein	B-CHED
+is	O
+one	O
+of	O
+the	O
+viral	O
+accessory	O
+proteins	B-CHED
+.	O
+
+In	O
+expressing	O
+cells	B-COMP
+,	O
+7a	O
+protein	B-CHED
+exhibits	O
+a	O
+variety	O
+of	O
+biological	O
+activities	O
+,	O
+including	O
+induction	B-PROC
+of	I-PROC
+apoptosis	I-PROC
+,	O
+activation	O
+of	O
+the	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+signaling	B-PROC
+pathway	I-PROC
+,	O
+inhibition	B-PROC
+of	O
+host	B-COMP
+protein	B-PROC
+translation	B-PROC
+,	O
+and	O
+suppression	B-DISO
+of	O
+cell	B-PROC
+growth	B-PROC
+progression	O
+.	O
+
+Coexpression	O
+of	O
+7a	O
+protein	B-CHED
+with	O
+SCoV	O
+S	O
+,	O
+M	O
+,	O
+N	O
+,	O
+and	O
+E	O
+proteins	B-CHED
+resulted	O
+in	O
+production	O
+of	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+carrying	O
+7a	B-PRGE
+protein	I-PRGE
+,	O
+while	O
+7a	B-PRGE
+protein	I-PRGE
+was	O
+not	O
+released	O
+from	O
+cells	B-COMP
+expressing	O
+7a	O
+protein	B-CHED
+alone	O
+.	O
+
+Phylogenetic	O
+analyses	O
+of	O
+the	O
+spike	O
+,	O
+envelope	B-COMP
+,	O
+membrane	B-COMP
+,	O
+and	O
+nucleoprotein	O
+structural	O
+proteins	B-CHED
+and	O
+the	O
+two	O
+conserved	O
+replicase	B-PRGE
+domains	O
+,	O
+putative	O
+RNA	O
+-	O
+dependent	O
+RNA	O
+polymerase	O
+and	O
+RNA	B-PRGE
+helicase	I-PRGE
+,	O
+revealed	O
+that	O
+bat	B-ENZY
+coronaviruses	O
+cluster	O
+in	O
+three	O
+different	O
+groups	O
+:	O
+group	O
+1	O
+,	O
+another	O
+group	O
+that	O
+includes	O
+all	O
+SARS	B-DISO
+and	O
+SARS	B-DISO
+-	O
+like	O
+coronaviruses	O
+(	O
+putative	O
+group	O
+4	O
+),	O
+and	O
+an	O
+independent	O
+bat	B-ENZY
+coronavirus	B-SPEC
+group	I-SPEC
+(	O
+putative	O
+group	O
+5	O
+).	O
+
+This	O
+review	O
+aims	O
+to	O
+provide	O
+a	O
+comprehensive	O
+account	O
+of	O
+drug	O
+discovery	O
+on	O
+SARS	B-DISO
+.	O
+
+The	O
+experiences	O
+with	O
+the	O
+SARS	B-DISO
+outbreak	O
+and	O
+drug	O
+discovery	O
+would	O
+certainly	O
+be	O
+an	O
+important	O
+lesson	O
+for	O
+the	O
+drug	O
+development	B-PROC
+for	O
+any	O
+new	O
+viral	O
+outbreaks	O
+that	O
+may	O
+emerge	O
+in	O
+the	O
+future	O
+.	O
+
+ABSTRACT	O
+:	O
+Peptides	B-CHED
+derived	O
+from	O
+the	O
+membrane	B-COMP
+proximal	O
+region	O
+of	O
+fusion	O
+proteins	B-CHED
+of	O
+human	B-SPEC
+immunodeficiency	B-DISO
+viruses	B-SPEC
+1	O
+and	O
+2	O
+,	O
+Coronavirus	B-SPEC
+229	O
+E	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+were	O
+all	O
+potent	O
+antagonists	B-CHED
+of	O
+the	O
+formyl	B-CHED
+peptide	B-CHED
+receptor	O
+expressed	B-PROC
+in	O
+Chinese	B-SPEC
+hamster	I-SPEC
+ovary	B-ANAT
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+E	B-PRGE
+protein	I-PRGE
+is	O
+a	O
+membrane	B-COMP
+component	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Moreover	O
+,	O
+the	O
+majority	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
++	I-PRGE
+CD4	I-PRGE
++	I-PRGE
+T	I-PRGE
+cells	O
+were	O
+central	O
+memory	B-ANAT
+cells	B-COMP
+expressing	O
+CD45RO	B-PRGE
++	I-PRGE
+CCR7	I-PRGE
++	I-PRGE
+CD62L	I-PRGE
+-;	O
+whereas	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
++	I-PRGE
+CD8	I-PRGE
++	I-PRGE
+memory	B-PROC
+T	B-ANAT
+cells	I-ANAT
+were	O
+mostly	O
+effector	B-CHED
+memory	B-PROC
+cells	B-COMP
+expressing	O
+CD45RO	O
+-	O
+CCR7	B-PRGE
+-	O
+CD62L	B-PRGE
+-.	O
+
+Interestingly	O
+,	O
+blood	B-ANAT
+collected	O
+at	O
+the	O
+2	O
+-	O
+h	O
+time	O
+point	O
+in	O
+pancreatic	B-ANAT
+rats	B-SPEC
+induced	O
+pulmonary	B-ANAT
+injury	O
+in	O
+normal	O
+lungs	B-ANAT
+while	O
+blood	B-ANAT
+collected	O
+at	O
+the	O
+6	O
+-	O
+h	O
+time	O
+-	O
+point	O
+was	O
+not	O
+toxic	O
+.	O
+
+TITLE	O
+:	O
+M	O
+and	O
+N	O
+proteins	B-CHED
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+induce	O
+apoptosis	B-PATH
+in	O
+HPF	O
+cells	B-COMP
+.	O
+
+The	O
+cases	O
+were	O
+classified	O
+as	O
+dry	O
+-	O
+bite	B-PROC
+(	O
+n	O
+=	O
+1	O
+,	O
+caused	O
+by	O
+M	B-SPEC
+.	I-SPEC
+lemniscatus	I-SPEC
+;	O
+did	O
+not	O
+receive	O
+antivenom	O
+),	O
+mild	O
+(	O
+n	O
+=	O
+2	O
+,	O
+local	O
+manifestations	O
+with	O
+no	O
+acute	O
+myasthenic	B-DISO
+syndrome	I-DISO
+;	O
+M	B-SPEC
+.	I-SPEC
+frontalis	I-SPEC
+and	O
+Micrurus	B-SPEC
+spp	B-ENZY
+.),	O
+moderate	O
+(	O
+n	O
+=	O
+5	O
+,	O
+mild	O
+myasthenia	B-DISO
+)	O
+or	O
+severe	O
+(	O
+n	O
+=	O
+3	O
+,	O
+important	O
+myasthenia	B-DISO
+;	O
+one	O
+of	O
+them	O
+caused	O
+by	O
+M	B-SPEC
+.	I-SPEC
+frontalis	I-SPEC
+).	O
+
+Overall	O
+,	O
+human	B-SPEC
+rhinoviruses	B-SPEC
+(	O
+HRVs	O
+)	O
+were	O
+the	O
+most	O
+frequently	O
+identified	O
+target	O
+(	O
+n	O
+=	O
+140	O
+)	O
+followed	O
+by	O
+human	B-SPEC
+adenoviruses	B-SPEC
+(	O
+HAdVs	O
+;	O
+n	O
+=	O
+25	O
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+;	O
+n	O
+=	O
+18	O
+),	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBoV	O
+;	O
+n	O
+=	O
+15	O
+),	O
+human	O
+respiratory	O
+syncytial	O
+virus	O
+(	O
+HRSV	B-SPEC
+;	O
+n	O
+=	O
+12	O
+),	O
+human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+;	O
+n	O
+=	O
+11	O
+),	O
+and	O
+human	B-SPEC
+herpesvirus	I-SPEC
+-	O
+6	O
+(	O
+n	O
+=	O
+11	O
+).	O
+
+TITLE	O
+:	O
+Perspectives	O
+on	O
+the	O
+basic	O
+reproductive	B-PROC
+ratio	O
+.	O
+
+The	O
+minimum	O
+surface	O
+tension	B-DISO
+of	O
+LA	O
+was	O
+impaired	B-DISO
+(	O
+p	O
+<	O
+.	O
+001	O
+)	O
+in	O
+V	O
+-	O
+PCP	B-DISO
+more	O
+than	O
+in	O
+SB	O
+-	O
+PCP	B-DISO
+and	O
+was	O
+strongly	O
+correlated	O
+with	O
+the	O
+reduction	O
+in	O
+palmitic	B-CHED
+acid	I-CHED
+levels	O
+in	O
+PC	O
+LA	O
+(	O
+r	O
+=	O
+-.	O
+81	O
+).	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+enteral	O
+feeding	O
+with	O
+eicosapentaenoic	B-CHED
+acid	I-CHED
+,	O
+gamma	B-CHED
+-	I-CHED
+linolenic	I-CHED
+acid	I-CHED
+,	O
+and	O
+antioxidants	B-CHED
+in	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+Several	O
+studies	O
+using	O
+animal	B-SPEC
+models	O
+of	O
+sepsis	B-DISO
+demonstrate	O
+that	O
+enteral	O
+nutrition	B-PROC
+enriched	O
+with	O
+omega	B-CHED
+-	I-CHED
+3	I-CHED
+fatty	I-CHED
+acids	I-CHED
+reduces	O
+mortality	O
+rate	O
+.	O
+
+This	O
+study	O
+investigated	O
+whether	O
+an	O
+enteral	O
+diet	O
+enriched	O
+with	O
+EPA	B-PRGE
+,	O
+GLA	B-PRGE
+,	O
+and	O
+antioxidant	B-CHED
+vitamins	B-CHED
+can	O
+improve	O
+outcomes	O
+and	O
+reduce	O
+28	O
+-	O
+day	O
+all	O
+-	O
+cause	O
+mortality	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+1	O
+.	O
+0	O
+,	O
+p	O
+<	O
+.	O
+001	O
+),	O
+more	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)-	O
+free	O
+days	O
+(	O
+10	O
+.	O
+8	O
++/-	O
+1	O
+.	O
+1	O
+vs	O
+.	O
+4	O
+.	O
+6	O
++/-	O
+0	O
+.	O
+9	O
+,	O
+p	O
+<	O
+.	O
+001	O
+),	O
+and	O
+a	O
+lesser	O
+development	B-PROC
+of	O
+new	O
+organ	B-ANAT
+dysfunctions	O
+(	O
+p	O
+<	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Improving	O
+older	O
+adults	O
+'	O
+knowledge	O
+and	O
+practice	O
+of	O
+preventive	O
+measures	O
+through	O
+a	O
+telephone	O
+health	O
+education	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+:	O
+a	O
+pilot	O
+study	O
+.	O
+
+BeauR	B-PRGE
+-	I-PRGE
+M41	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+EP10	I-PRGE
+was	O
+more	O
+efficacious	O
+than	O
+BeauR	O
+-	O
+M41	O
+(	O
+S	O
+)	O
+protecting	O
+more	O
+birds	B-SPEC
+against	O
+virulent	O
+challenge	O
+and	O
+providing	O
+a	O
+better	O
+serological	O
+antibody	B-PROC
+response	I-PROC
+.	O
+
+We	O
+hypothesized	O
+that	O
+oxygenation	B-PROC
+would	O
+improve	O
+in	O
+injured	O
+patients	O
+with	O
+severe	O
+hypoxemia	O
+who	O
+were	O
+converted	O
+to	O
+HFPV	O
+after	O
+initial	O
+management	O
+with	O
+conventional	O
+ventilation	O
+.	O
+
+Chart	O
+review	O
+identified	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+managed	O
+with	O
+HFPV	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+demonstrate	O
+that	O
+treatment	O
+of	O
+Vero	O
+E6	O
+cells	B-COMP
+with	O
+interleukin	B-PRGE
+-	I-PRGE
+4	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+)	O
+decreased	O
+the	O
+susceptibility	O
+of	O
+these	O
+cells	B-COMP
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Eight	O
+poultry	O
+farms	O
+in	O
+Nigeria	O
+,	O
+including	O
+chickens	B-SPEC
+from	O
+nine	O
+breeder	O
+,	O
+14	O
+broiler	O
+,	O
+28	O
+pullet	O
+,	O
+11	O
+layer	B-ANAT
+,	O
+and	O
+three	O
+cockerel	O
+flocks	O
+,	O
+were	O
+tested	O
+for	O
+antibody	B-COMP
+seroprevalence	O
+to	O
+the	O
+following	O
+poultry	O
+viruses	B-SPEC
+of	O
+potential	O
+economic	O
+importance	O
+:	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+avian	B-SPEC
+reovirus	I-SPEC
+,	O
+avian	B-SPEC
+pneumovirus	I-SPEC
+(	O
+APV	O
+),	O
+infectious	B-SPEC
+laryngotracheitis	B-DISO
+virus	I-SPEC
+(	O
+ILTV	B-SPEC
+),	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AIV	O
+),	O
+and	O
+avian	B-SPEC
+leukosis	I-SPEC
+virus	I-SPEC
+(	O
+ALV	B-SPEC
+).	O
+
+Serum	B-COMP
+samples	O
+were	O
+collected	O
+between	O
+1999	O
+and	O
+2004	O
+and	O
+were	O
+tested	O
+for	O
+antibodies	B-COMP
+using	O
+commercial	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+kits	O
+.	O
+
+However	O
+,	O
+more	O
+specific	O
+assays	O
+did	O
+not	O
+confirm	O
+AIV	O
+antibodies	O
+,	O
+indicating	O
+that	O
+all	O
+flocks	O
+tested	O
+were	O
+free	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+Massachusetts	O
+and	O
+Arkansas	O
+serotypes	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+broilers	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+prognostic	O
+rules	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+low	O
+-	O
+and	O
+high	O
+-	O
+resource	O
+settings	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+model	O
+performs	O
+well	O
+and	O
+could	O
+be	O
+useful	O
+in	O
+assessing	O
+prognosis	O
+for	O
+patients	O
+who	O
+are	O
+infected	O
+with	O
+re	O
+-	O
+emergent	O
+SARS	B-DISO
+.	O
+
+At	O
+least	O
+one	O
+premenstrual	B-DISO
+symptom	I-DISO
+was	O
+experienced	O
+by	O
+448	O
+women	O
+(	O
+96	O
+.	O
+6	O
+%),	O
+and	O
+176	O
+(	O
+37	O
+.	O
+5	O
+%)	O
+had	O
+a	O
+high	O
+symptom	B-DISO
+severity	O
+score	O
+.	O
+
+Moreover	O
+,	O
+women	O
+with	O
+PMS	B-DISO
+might	O
+eliminate	O
+sweet	B-PROC
+-	O
+tasting	B-PROC
+food	O
+and	O
+caffeine	B-DISO
+-	O
+containing	O
+beverages	O
+,	O
+particularly	O
+coffee	B-SPEC
+,	O
+from	O
+their	O
+diet	O
+.	O
+
+Serum	B-COMP
+samples	O
+also	O
+were	O
+tested	O
+,	O
+by	O
+Western	O
+blot	O
+and	O
+ELISA	O
+,	O
+for	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+(	O
+FeLV	O
+)	O
+specific	O
+antibodies	B-COMP
+and	O
+antigen	B-CHED
+,	O
+respectively	O
+,	O
+by	O
+Western	O
+blot	O
+for	O
+antibodies	B-COMP
+to	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+),	O
+and	O
+by	O
+indirect	O
+ELISA	O
+for	O
+antibodies	B-COMP
+to	O
+puma	B-SPEC
+lentivirus	I-SPEC
+(	O
+PLV	O
+).	O
+
+TITLE	O
+:	O
+Diverse	O
+implications	O
+of	O
+a	O
+national	O
+health	O
+crisis	O
+:	O
+A	O
+qualitative	O
+exploration	O
+of	O
+community	O
+nurses	O
+'	O
+SARS	B-DISO
+experiences	O
+.	O
+
+The	O
+zinc	B-CHED
+finger	B-ANAT
+sequence	O
+motifs	O
+are	O
+conserved	O
+among	O
+all	O
+three	O
+coronavirus	B-SPEC
+antigenic	O
+groups	O
+,	O
+implicating	O
+an	O
+essential	O
+function	O
+for	O
+nsp10	O
+in	O
+all	O
+coronaviruses	O
+.	O
+
+Based	O
+on	O
+the	O
+structure	O
+,	O
+we	O
+propose	O
+that	O
+nsp10	O
+is	O
+a	O
+transcription	O
+factor	O
+for	O
+coronavirus	B-SPEC
+replication	O
+/	O
+transcription	B-PROC
+.	O
+
+TITLE	O
+:	O
+New	O
+antiviral	B-CHED
+target	O
+revealed	O
+by	O
+the	O
+hexameric	O
+structure	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+nonstructural	O
+protein	O
+nsp15	O
+.	O
+
+The	O
+crystal	B-ANAT
+structure	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+nsp15	O
+is	O
+reported	O
+at	O
+2	O
+.	O
+15	O
+-	O
+A	O
+resolution	O
+.	O
+
+Two	O
+nsp15	O
+trimers	O
+form	O
+a	O
+back	B-ANAT
+-	O
+to	O
+-	O
+back	B-ANAT
+hexamer	O
+that	O
+is	O
+believed	O
+to	O
+be	O
+the	O
+functional	O
+unit	O
+.	O
+
+Gel	O
+filtration	O
+and	O
+enzyme	B-FUNC
+activity	I-FUNC
+assays	O
+confirmed	O
+that	O
+the	O
+hexamer	O
+is	O
+the	O
+active	O
+form	O
+for	O
+nsp15	O
+and	O
+demonstrate	O
+the	O
+specificity	O
+of	O
+nsp15	O
+for	O
+uridylate	B-CHED
+.	O
+
+A	O
+novel	O
+methodology	O
+of	O
+single	O
+-	O
+particle	O
+image	O
+analysis	O
+was	O
+applied	O
+to	O
+selected	O
+virus	B-SPEC
+features	O
+to	O
+obtain	O
+a	O
+detailed	O
+model	O
+of	O
+the	O
+oligomeric	O
+state	O
+and	O
+spatial	O
+relationships	O
+among	O
+viral	O
+structural	O
+proteins	B-CHED
+.	O
+
+Trimeric	O
+glycoprotein	B-CHED
+spikes	O
+were	O
+in	O
+register	O
+with	O
+four	O
+underlying	O
+ribonucleoprotein	B-COMP
+densities	O
+.	O
+
+TITLE	O
+:	O
+The	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+8b	O
+protein	B-CHED
+is	O
+distinct	O
+from	O
+its	O
+counterpart	O
+in	O
+animal	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+down	O
+-	O
+regulates	O
+the	O
+expression	B-PROC
+of	O
+the	O
+envelope	B-COMP
+protein	B-CHED
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+isolated	O
+from	O
+humans	B-SPEC
+infected	O
+during	O
+the	O
+peak	O
+of	O
+epidemic	O
+,	O
+encodes	O
+two	O
+accessory	O
+proteins	B-CHED
+termed	O
+as	O
+8a	O
+and	O
+8b	O
+.	O
+
+These	O
+results	O
+may	O
+suggest	O
+that	O
+the	O
+conformations	O
+of	O
+8a	O
+and	O
+8b	O
+are	O
+different	O
+from	O
+8ab	O
+although	O
+nearly	O
+all	O
+the	O
+amino	B-CHED
+acids	I-CHED
+in	O
+8a	O
+and	O
+8b	O
+are	O
+found	O
+in	O
+8ab	O
+.	O
+
+Progress	O
+in	O
+the	O
+investigation	O
+of	O
+these	O
+processes	O
+has	O
+been	O
+enhanced	O
+by	O
+the	O
+development	B-PROC
+of	O
+reverse	O
+genetic	O
+systems	O
+,	O
+an	O
+advance	O
+that	O
+was	O
+heretofore	O
+obstructed	O
+by	O
+the	O
+enormous	O
+size	O
+of	O
+the	O
+coronavirus	B-SPEC
+genome	O
+.	O
+
+Right	O
+atrial	B-ANAT
+pressure	O
+,	O
+mean	O
+pulmonary	B-ANAT
+arterial	B-PROC
+pressure	I-PROC
+,	O
+pulmonary	B-ANAT
+arterial	B-PROC
+wedge	I-PROC
+pressure	I-PROC
+,	O
+and	O
+left	O
+ventricular	B-ANAT
+stroke	B-DISO
+work	O
+index	O
+were	O
+determined	O
+using	O
+a	O
+thermodilution	O
+catheter	O
+.	O
+
+The	O
+optimal	O
+cutoff	O
+point	O
+for	O
+predicting	O
+mortality	O
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+was	O
+a	O
+BNP	O
+level	O
+of	O
+650	O
+pg	O
+mL	O
+on	O
+day	O
+2	O
+,	O
+in	O
+which	O
+sensitivity	O
+and	O
+specificity	O
+were	O
+92	O
+%	O
+and	O
+80	O
+%,	O
+respectively	O
+.	O
+
+Our	O
+purpose	O
+was	O
+to	O
+determine	O
+maternal	O
+outcome	O
+in	O
+pregnancies	B-PROC
+complicated	O
+by	O
+HELLP	B-DISO
+syndrome	I-DISO
+(	O
+hemolysis	B-DISO
+,	O
+elevated	O
+liver	B-ANAT
+enzymes	O
+and	O
+low	O
+platelet	B-ANAT
+count	O
+)	O
+that	O
+required	O
+intensive	O
+care	O
+management	O
+.	O
+
+37	O
+patients	O
+with	O
+HELLP	B-DISO
+syndrome	I-DISO
+admitted	O
+to	O
+the	O
+obstetric	O
+intensive	O
+care	O
+unit	O
+were	O
+analyzed	O
+retrospectively	O
+from	O
+1992	O
+to	O
+2004	O
+.	O
+
+Bypasses	O
+were	O
+exclusively	O
+arterial	B-ANAT
+(	O
+left	O
+or	O
+right	O
+internal	B-ANAT
+mammary	I-ANAT
+arteries	I-ANAT
+).	O
+
+Perceptions	O
+of	O
+the	O
+infectivity	O
+and	O
+health	O
+conditions	O
+of	O
+recovered	O
+SARS	B-DISO
+patients	O
+and	O
+avoidance	O
+and	O
+discrimination	O
+towards	O
+them	O
+were	O
+measured	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+approximately	O
+30	O
+-	O
+kb	O
+coronavirus	B-SPEC
+(+)	O
+RNA	O
+genome	O
+is	O
+replicated	O
+and	O
+transcribed	O
+by	O
+a	O
+membrane	B-COMP
+-	O
+bound	O
+replicase	B-PRGE
+complex	I-PRGE
+made	O
+up	O
+of	O
+16	O
+viral	O
+nonstructural	O
+proteins	B-CHED
+(	O
+nsp	O
+)	O
+with	O
+multiple	O
+enzymatic	O
+activities	O
+.	O
+
+The	O
+complex	O
+includes	O
+an	O
+RNA	B-PRGE
+endonuclease	I-PRGE
+,	O
+NendoU	O
+,	O
+that	O
+is	O
+conserved	O
+among	O
+nidoviruses	B-SPEC
+but	O
+no	O
+other	O
+RNA	O
+virus	B-SPEC
+,	O
+making	O
+it	O
+a	O
+genetic	B-PROC
+marker	I-PROC
+of	O
+this	O
+virus	B-SPEC
+order	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+human	B-SPEC
+nasal	B-ANAT
+cannulas	O
+during	O
+bronchoscopy	O
+procedures	O
+as	O
+a	O
+simple	O
+method	O
+for	O
+maintaining	O
+adequate	O
+oxygen	O
+saturation	O
+in	O
+pigtailed	O
+macaques	B-SPEC
+(	O
+Macaca	B-SPEC
+nemestrina	I-SPEC
+).	O
+
+The	O
+crystal	B-ANAT
+structure	O
+of	O
+TG	O
+-	O
+0205221	O
+(	O
+resolution	O
+=	O
+1	O
+.	O
+93	O
+A	O
+)	O
+has	O
+revealed	O
+a	O
+unique	O
+binding	B-FUNC
+mode	O
+comprising	O
+a	O
+covalent	B-PROC
+bond	O
+,	O
+hydrogen	B-CHED
+bonds	O
+,	O
+and	O
+numerous	O
+hydrophobic	B-PROC
+interactions	I-PROC
+.	O
+
+The	O
+'	O
+impacted	O
+group	O
+'	O
+had	O
+higher	O
+depressive	O
+levels	O
+,	O
+poorer	O
+neighborhood	O
+relationships	O
+,	O
+poorer	O
+self	O
+-	O
+perceived	O
+health	O
+,	O
+and	O
+a	O
+higher	O
+economic	O
+impact	O
+than	O
+the	O
+'	O
+non	O
+-	O
+impacted	B-DISO
+group	O
+'.	O
+
+Fever	B-PROC
+and	O
+other	O
+respiratory	B-DISO
+symptoms	I-DISO
+were	O
+examined	O
+to	O
+determine	O
+their	O
+value	O
+in	O
+predicting	O
+influenza	B-SPEC
+virus	I-SPEC
+-	O
+positive	O
+status	O
+in	O
+children	O
+.	O
+
+Cough	B-DISO
+(	O
+positive	O
+predictive	O
+value	O
+,	O
+70	O
+%;	O
+95	O
+%	O
+CI	O
+,	O
+64	O
+%-	O
+75	O
+%),	O
+but	O
+not	O
+fever	B-PROC
+,	O
+was	O
+the	O
+best	O
+predictor	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+-	O
+positive	O
+status	O
+in	O
+children	O
+aged	O
+5	O
+-	O
+12	O
+years	O
+in	O
+the	O
+oseltamivir	B-CHED
+trials	O
+,	O
+but	O
+neither	O
+cough	B-DISO
+nor	O
+fever	B-PROC
+were	O
+successful	O
+predictors	O
+in	O
+young	O
+children	O
+1	O
+-	O
+4	O
+years	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+describes	O
+a	O
+loophole	O
+in	O
+the	O
+international	O
+quarantine	O
+system	O
+during	O
+the	O
+recent	O
+Asian	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Observations	O
+and	O
+immunohistochemical	O
+detection	O
+of	O
+Coronavirus	B-SPEC
+,	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+and	O
+Giardia	B-DISO
+intestinalis	I-SPEC
+in	O
+neonatal	B-DISO
+diarrhoea	I-DISO
+in	O
+lambs	B-SPEC
+and	O
+kids	O
+.	O
+
+These	O
+two	O
+protozoa	O
+were	O
+detected	O
+together	O
+in	O
+4	O
+animals	B-SPEC
+upon	O
+faeces	B-ANAT
+examination	O
+.	O
+
+Following	O
+immunohistochemical	O
+examination	O
+,	O
+all	O
+cryptosporidiosis	B-DISO
+cases	O
+were	O
+confirmed	O
+by	O
+positive	O
+immunostaining	O
+of	O
+intestinal	O
+sections	O
+.	O
+
+All	O
+donor	B-CHED
+kidneys	B-ANAT
+were	O
+recovered	O
+laparoscopically	O
+.	O
+
+There	O
+was	O
+no	O
+cytomegalovirus	B-SPEC
+disease	O
+or	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Hospice	O
+utilization	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+Taiwan	O
+.	O
+
+ABSTRACT	O
+:	O
+Live	O
+virus	B-SPEC
+vaccines	O
+provide	O
+significant	O
+protection	O
+against	O
+many	O
+detrimental	O
+human	B-SPEC
+and	O
+animal	B-DISO
+diseases	I-DISO
+,	O
+but	O
+reversion	O
+to	O
+virulence	B-PROC
+by	O
+mutation	O
+and	O
+recombination	B-PROC
+has	O
+reduced	O
+appeal	O
+.	O
+
+The	O
+M	O
+gene	O
+sequences	O
+of	O
+these	O
+new	O
+feline	B-SPEC
+strains	O
+had	O
+at	O
+most	O
+88	O
+per	O
+cent	O
+identity	O
+with	O
+the	O
+fcov	O
+-	O
+like	O
+ccov	O
+strain	O
+259	O
+/	O
+01	O
+and	O
+only	O
+up	O
+to	O
+85	O
+per	O
+cent	O
+with	O
+any	O
+fcov	O
+sequence	O
+available	O
+in	O
+GenBank	O
+.	O
+
+Our	O
+study	O
+objectives	O
+were	O
+to	O
+determine	O
+the	O
+optimal	O
+extraction	O
+method	O
+for	O
+SARS	B-DISO
+CoV	O
+RNA	O
+detection	O
+and	O
+to	O
+examine	O
+the	O
+effect	O
+of	O
+increased	O
+specimen	O
+volume	O
+for	O
+the	O
+detection	O
+of	O
+SARS	B-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+in	O
+stool	B-ANAT
+specimens	O
+.	O
+
+Examination	O
+of	O
+the	O
+copy	O
+numbers	O
+detected	O
+and	O
+the	O
+generation	O
+of	O
+10	O
+-	O
+fold	O
+dilutions	O
+of	O
+the	O
+extracted	O
+material	O
+indicated	O
+that	O
+a	O
+number	O
+of	O
+extraction	O
+methods	O
+retained	O
+inhibitory	O
+substances	O
+that	O
+prevented	O
+optimal	O
+amplification	B-DISO
+.	O
+
+TITLE	O
+:	O
+Knowledge	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+among	O
+community	O
+physicians	O
+,	O
+nurses	O
+,	O
+and	O
+emergency	B-DISO
+medical	O
+responders	O
+.	O
+
+The	O
+evolution	B-PROC
+of	O
+the	O
+Simian	O
+virus	B-SPEC
+(	O
+SIV	B-DISO
+)	O
+into	O
+a	O
+human	B-SPEC
+virus	B-SPEC
+(	O
+HIV	B-DISO
+)	O
+is	O
+regarded	O
+as	O
+an	O
+artifact	O
+.	O
+
+SARS	B-DISO
+and	O
+Ebola	O
+also	O
+fit	B-DISO
+this	O
+pattern	O
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+the	O
+past	O
+20	O
+years	O
+,	O
+headlines	O
+have	O
+documented	O
+an	O
+increasing	O
+number	O
+of	O
+emerging	O
+diseases	O
+;	O
+most	O
+have	O
+an	O
+animal	O
+source	O
+(	O
+zoonoses	B-DISO
+).	O
+
+Real	O
+-	O
+time	O
+fluorescence	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+also	O
+proved	O
+the	O
+neutralizing	O
+capacity	O
+of	O
+M1A	O
+.	O
+
+These	O
+data	O
+showed	O
+that	O
+the	O
+number	O
+of	O
+virus	B-SPEC
+copies	O
+was	O
+significantly	O
+reduced	O
+in	O
+the	O
+M1A	B-CHED
+-	O
+treated	O
+group	O
+,	O
+suggesting	O
+an	O
+important	O
+role	O
+for	O
+M1A	B-CHED
+in	O
+passive	O
+immunoprophylaxis	O
+against	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Fourteen	O
+ORFs	O
+have	O
+been	O
+identified	O
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+genome	O
+.	O
+
+TITLE	O
+:	O
+Coronaviruses	O
+in	O
+bent	O
+-	O
+winged	B-ANAT
+bats	B-SPEC
+(	O
+Miniopterus	B-SPEC
+spp	B-ENZY
+.).	O
+
+These	O
+findings	O
+show	O
+that	O
+group	O
+1	O
+coronaviruses	O
+are	O
+endemic	O
+in	O
+these	O
+bat	B-ENZY
+populations	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+In	O
+contrast	O
+to	O
+BS	O
+-	O
+IQFSs	O
+,	O
+the	O
+RS	O
+-	O
+IQFS	O
+was	O
+not	O
+susceptible	O
+to	O
+fluorescence	O
+interference	O
+from	O
+coloured	O
+samples	O
+and	O
+allowed	O
+for	O
+successful	O
+screening	O
+of	O
+marine	O
+natural	B-CHED
+products	I-CHED
+and	O
+identification	O
+of	O
+a	O
+coumarin	B-CHED
+derivative	O
+,	O
+esculetin	B-CHED
+-	O
+4	O
+-	O
+carboxylic	B-CHED
+acid	I-CHED
+ethyl	B-CHED
+ester	B-CHED
+,	O
+a	O
+novel	O
+3CLpro	O
+inhibitor	B-CHED
+(	O
+IC50	O
+=	O
+46	O
+microM	O
+)	O
+and	O
+anti	O
+-	O
+SARS	B-DISO
+agent	O
+(	O
+EC50	O
+=	O
+112	O
+microM	O
+;	O
+median	O
+toxic	O
+concentration	O
+>	O
+800	O
+microM	O
+)	O
+from	O
+the	O
+tropical	O
+marine	O
+sponge	B-SPEC
+Axinella	B-SPEC
+corrugata	I-SPEC
+.	O
+
+Only	O
+two	O
+HCW	O
+involved	O
+in	O
+different	O
+clusters	B-CHED
+,	O
+reported	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Adrenal	B-DISO
+insufficiency	I-DISO
+in	O
+severe	O
+West	B-DISO
+Nile	I-DISO
+Virus	I-DISO
+infection	I-DISO
+.	O
+
+Relative	O
+adrenal	B-DISO
+insufficiency	I-DISO
+,	O
+defined	O
+by	O
+a	O
+corticotropin	B-PRGE
+response	O
+below	O
+9	O
+microg	O
+/	O
+dl	O
+,	O
+was	O
+observed	O
+in	O
+seven	O
+while	O
+the	O
+remaining	O
+three	O
+had	O
+normal	O
+cortisol	B-CHED
+response	O
+;	O
+six	O
+out	O
+of	O
+these	O
+seven	O
+died	B-PROC
+in	O
+the	O
+ICU	O
+.	O
+
+ABSTRACT	O
+:	O
+Aggressive	O
+behaviours	O
+represent	O
+major	O
+obstacles	O
+to	O
+the	O
+integration	B-PROC
+into	O
+society	O
+of	O
+individuals	O
+with	O
+intellectual	B-DISO
+disability	I-DISO
+(	O
+ID	O
+)	O
+and	O
+pose	O
+significant	O
+management	O
+issues	O
+for	O
+carers	O
+.	O
+
+The	O
+present	O
+study	O
+assessed	O
+the	O
+prevalence	O
+and	O
+severity	O
+of	O
+five	O
+types	O
+of	O
+aggressive	B-DISO
+behaviours	I-DISO
+in	O
+3165	O
+adult	O
+men	O
+and	O
+women	O
+with	O
+ID	O
+receiving	O
+services	O
+from	O
+three	O
+rehabilitation	O
+agencies	O
+in	O
+Québec	O
+by	O
+surveying	O
+their	O
+carers	O
+using	O
+the	O
+Modified	O
+Overt	O
+Aggressive	B-DISO
+Scale	O
+.	O
+
+The	O
+12	O
+-	O
+month	O
+prevalence	O
+of	O
+aggressive	B-DISO
+behaviour	I-DISO
+was	O
+51	O
+.	O
+8	O
+%:	O
+24	O
+%	O
+property	O
+damage	O
+,	O
+37	O
+.	O
+6	O
+%	O
+verbal	O
+,	O
+24	O
+.	O
+4	O
+%	O
+self	O
+-	O
+oriented	O
+and	O
+24	O
+.	O
+4	O
+%	O
+physical	O
+aggression	B-DISO
+,	O
+and	O
+9	O
+.	O
+8	O
+%	O
+sexually	O
+aggressive	B-DISO
+behaviour	I-DISO
+,	O
+most	O
+of	O
+which	O
+being	O
+mild	O
+in	O
+severity	O
+.	O
+
+TITLE	O
+:	O
+Maternal	O
+antibody	B-COMP
+transfer	O
+from	O
+dams	O
+to	O
+their	O
+egg	B-ANAT
+yolks	O
+,	O
+egg	B-ANAT
+whites	B-SPEC
+,	O
+and	O
+chicks	O
+in	O
+meat	O
+lines	O
+of	O
+chickens	O
+.	O
+
+To	O
+gain	O
+insight	O
+into	O
+maternal	O
+antibody	B-COMP
+transfer	O
+and	O
+endogenous	O
+production	O
+of	O
+antibodies	B-COMP
+in	O
+broiler	O
+chicks	O
+,	O
+total	O
+IgY	O
+,	O
+IgA	B-PRGE
+,	O
+IgM	B-PRGE
+,	O
+as	O
+well	O
+as	O
+anti	O
+-	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+)	O
+and	O
+anti	O
+-	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IBV	B-SPEC
+)	O
+antibody	B-COMP
+levels	O
+were	O
+examined	O
+in	O
+the	O
+dams	O
+'	O
+plasma	B-ANAT
+,	O
+egg	B-ANAT
+yolks	O
+,	O
+egg	B-ANAT
+whites	B-SPEC
+,	O
+and	O
+chicks	O
+'	O
+plasma	B-ANAT
+on	O
+d	O
+3	O
+,	O
+7	O
+,	O
+14	O
+,	O
+and	O
+21	O
+.	O
+
+Given	O
+an	O
+epidemic	O
+curve	O
+for	O
+a	O
+historical	O
+outbreak	O
+,	O
+this	O
+modeling	O
+approach	O
+calls	O
+for	O
+Monte	O
+Carlo	O
+calculations	O
+(	O
+that	O
+define	O
+the	O
+average	O
+new	O
+infection	B-DISO
+rate	O
+)	O
+and	O
+solutions	O
+to	O
+integro	O
+-	O
+differential	O
+equations	O
+(	O
+that	O
+describe	O
+outbreak	O
+dynamics	O
+in	O
+an	O
+aggregate	O
+population	O
+or	O
+across	O
+all	O
+network	O
+connectivity	O
+classes	O
+).	O
+
+The	O
+full	O
+length	O
+NP	O
+could	O
+be	O
+expressed	B-PROC
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+at	O
+very	O
+high	O
+level	O
+within	O
+inclusion	B-COMP
+bodies	I-COMP
+.	O
+
+The	O
+polyclonal	O
+antiserum	O
+from	O
+animals	B-SPEC
+immunized	O
+with	O
+this	O
+recombinant	B-PRGE
+NP	I-PRGE
+protein	I-PRGE
+was	O
+found	O
+to	O
+specifically	O
+recognize	O
+the	O
+NP	O
+and	O
+its	O
+subfragments	O
+,	O
+thus	O
+demonstrating	O
+the	O
+immunogenic	O
+nature	O
+of	O
+the	O
+recombinant	O
+protein	O
+.	O
+
+Excluding	O
+job	O
+categories	O
+with	O
+<	O
+3	O
+workers	O
+,	O
+the	O
+highest	O
+SARS	B-DISO
+attack	O
+rates	O
+occurred	O
+among	O
+nurses	O
+who	O
+worked	O
+in	O
+the	O
+outpatient	O
+and	O
+inpatient	O
+general	O
+wards	O
+(	O
+57	O
+.	O
+1	O
+,	O
+47	O
+.	O
+4	O
+%,	O
+respectively	O
+).	O
+
+Here	O
+we	O
+characterized	O
+the	O
+activation	O
+of	O
+an	O
+immediate	B-PRGE
+-	I-PRGE
+early	I-PRGE
+transcription	I-PRGE
+factor	I-PRGE
+Egr	I-PRGE
+-	I-PRGE
+1	I-PRGE
+by	O
+MHV	B-SPEC
+infection	B-DISO
+in	O
+an	O
+astrocytoma	B-DISO
+cell	B-ANAT
+line	I-ANAT
+.	O
+
+We	O
+further	O
+found	O
+that	O
+over	O
+-	O
+expression	B-PROC
+of	O
+Egr	B-PRGE
+-	I-PRGE
+1	I-PRGE
+suppressed	O
+the	O
+expression	B-PROC
+of	O
+BNip3	B-PRGE
+,	O
+a	O
+pro	B-CHED
+-	O
+apoptotic	O
+member	O
+of	O
+the	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+family	I-PRGE
+.	O
+
+Furthermore	O
+,	O
+knockdown	O
+of	O
+Egr	B-PRGE
+-	I-PRGE
+1	I-PRGE
+by	O
+an	O
+siRNA	O
+inhibited	O
+MHV	B-SPEC
+propagation	O
+,	O
+suggesting	O
+the	O
+biological	O
+relevance	O
+of	O
+Egr	B-PRGE
+-	I-PRGE
+1	I-PRGE
+induction	O
+to	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+These	O
+results	O
+indicate	O
+a	O
+correlation	O
+between	O
+the	O
+ability	O
+of	O
+MHVs	O
+to	O
+induce	O
+Egr	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expression	B-PROC
+and	O
+their	O
+ability	O
+to	O
+cause	O
+demyelination	B-DISO
+in	O
+the	O
+CNS	B-CHED
+,	O
+which	O
+may	O
+suggest	O
+a	O
+potential	O
+role	O
+for	O
+the	O
+induction	O
+of	O
+Egr	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+viral	B-DISO
+pathogenesis	I-DISO
+.	O
+
+All	O
+six	O
+patients	O
+were	O
+transferred	O
+to	O
+the	O
+care	O
+of	O
+the	O
+authors	O
+at	O
+an	O
+intensive	O
+care	O
+unit	O
+at	O
+a	O
+public	O
+hospital	O
+,	O
+where	O
+they	O
+received	O
+intensive	O
+cardiopulmonary	O
+support	O
+(	O
+including	O
+dialysis	B-SPEC
+),	O
+high	O
+-	O
+dose	O
+methylprednisolone	B-CHED
+,	O
+and	O
+an	O
+anti	B-PRGE
+-	I-PRGE
+interleukin	I-PRGE
+-	I-PRGE
+2	I-PRGE
+receptor	I-PRGE
+antagonist	B-PROC
+antibody	B-COMP
+.	O
+
+Prolonged	O
+cardiovascular	B-ANAT
+shock	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+developed	O
+in	O
+two	O
+patients	O
+,	O
+who	O
+required	O
+intensive	O
+organ	B-ANAT
+support	O
+for	O
+8	O
+and	O
+16	O
+days	O
+.	O
+
+ABSTRACT	O
+:	O
+Transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+(	O
+TRALI	B-DISO
+)	O
+is	O
+an	O
+immune	O
+-	O
+mediated	O
+transfusion	B-DISO
+reaction	I-DISO
+that	O
+can	O
+cause	O
+severe	O
+complications	O
+or	O
+even	O
+death	B-PROC
+.	O
+
+In	O
+1992	O
+,	O
+diagnostic	O
+criteria	O
+for	O
+ARDS	B-DISO
+were	O
+published	O
+in	O
+an	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+and	O
+the	O
+term	O
+ACUTE	B-PRGE
+LUNG	I-PRGE
+INJURY	I-PRGE
+(	O
+ALI	O
+)	O
+was	O
+adopted	O
+to	O
+encompass	O
+patients	O
+with	O
+a	O
+spectrum	O
+of	O
+less	O
+severe	O
+forms	O
+of	O
+the	O
+same	O
+pathological	O
+entity	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+importance	O
+of	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+in	O
+maintaining	O
+normal	O
+lung	B-PROC
+function	I-PROC
+,	O
+and	O
+the	O
+observations	O
+that	O
+alterations	O
+in	O
+endogenous	O
+surfactant	B-CHED
+contribute	O
+to	O
+the	O
+lung	B-ANAT
+dysfunction	O
+associated	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+provide	O
+a	O
+rationale	O
+for	O
+administering	O
+exogenous	O
+surfactant	B-CHED
+in	O
+this	O
+setting	O
+.	O
+
+The	O
+results	O
+of	O
+clinical	O
+trials	O
+have	O
+been	O
+variable	O
+,	O
+however	O
+,	O
+in	O
+part	O
+due	O
+to	O
+the	O
+various	O
+surfactant	B-CHED
+preparations	O
+used	O
+,	O
+the	O
+different	O
+delivery	O
+and	O
+dosing	O
+methods	O
+employed	O
+,	O
+and	O
+the	O
+types	O
+of	O
+patients	O
+targeted	B-PROC
+for	O
+this	O
+therapy	O
+.	O
+
+Based	O
+on	O
+extensive	O
+in	O
+vitro	O
+data	O
+as	O
+well	O
+as	O
+in	O
+vivo	O
+animal	O
+studies	O
+demonstrating	O
+the	O
+anti	O
+-	O
+inflammatory	O
+and	O
+antibacterial	O
+functions	O
+of	O
+various	O
+surfactant	B-CHED
+components	O
+,	O
+administration	O
+of	O
+surfactant	B-CHED
+earlier	O
+in	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+,	O
+when	O
+lung	B-DISO
+inflammation	I-DISO
+is	O
+present	O
+but	O
+before	O
+severe	O
+lung	B-ANAT
+dysfunction	O
+occurs	O
+,	O
+may	O
+prove	O
+to	O
+be	O
+optimal	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+extracorporeal	O
+life	O
+support	O
+and	O
+liquid	O
+ventilation	O
+for	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+in	O
+adults	O
+.	O
+
+Additionally	O
+,	O
+ventilator	O
+settings	O
+are	O
+reduced	O
+to	O
+""""	O
+rest	B-FUNC
+""""	O
+settings	O
+,	O
+avoiding	O
+the	O
+consequences	O
+of	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+that	O
+can	O
+contribute	O
+to	O
+a	O
+worse	O
+outcome	O
+.	O
+
+Systemic	O
+heparinization	O
+is	O
+a	O
+mainstay	O
+of	O
+ECLS	O
+therapy	O
+because	O
+of	O
+platelet	B-PROC
+activation	I-PROC
+in	O
+the	O
+circuit	O
+.	O
+
+Although	O
+not	O
+currently	O
+in	O
+clinical	O
+practice	O
+,	O
+liquid	O
+ventilation	O
+using	O
+perfluorocarbons	O
+to	O
+provide	O
+gas	B-ENZY
+exchange	O
+in	O
+the	O
+lungs	B-ANAT
+is	O
+a	O
+potentially	O
+useful	O
+adjunct	O
+in	O
+the	O
+management	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+,	O
+a	O
+new	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+From	O
+the	O
+mid	O
+-	O
+1960s	O
+onwards	O
+,	O
+it	O
+was	O
+believed	O
+that	O
+only	O
+two	O
+human	O
+coronavirus	O
+species	B-SPEC
+infect	O
+humans	B-SPEC
+:	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+.	O
+
+Then	O
+,	O
+in	O
+2003	O
+,	O
+a	O
+novel	O
+member	O
+of	O
+the	O
+coronavirus	B-SPEC
+family	B-SPEC
+was	O
+introduced	O
+into	O
+the	O
+human	B-SPEC
+population	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+causing	O
+an	O
+aggressive	B-DISO
+lung	B-DISO
+disease	I-DISO
+.	O
+
+Collectively	O
+,	O
+these	O
+results	O
+suggest	O
+to	O
+further	O
+evaluate	O
+the	O
+role	O
+of	O
+viral	O
+macro	O
+domains	O
+in	O
+host	B-PROC
+response	I-PROC
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+expression	B-PROC
+of	O
+DC	O
+-	O
+SIGN	O
+augments	O
+NL63	O
+spike	O
+(	O
+S	O
+)-	O
+protein	B-CHED
+-	O
+driven	O
+infection	B-DISO
+of	O
+susceptible	O
+cells	B-COMP
+,	O
+while	O
+only	O
+expression	B-PROC
+of	O
+ACE2	B-PRGE
+but	O
+not	O
+DC	O
+-	O
+SIGN	O
+is	O
+sufficient	O
+for	O
+entry	O
+into	O
+nonpermissive	O
+cells	B-COMP
+,	O
+indicating	O
+that	O
+ACE2	B-PRGE
+fulfills	O
+the	O
+criteria	O
+of	O
+a	O
+bona	O
+fide	O
+hCoV	B-PRGE
+-	I-PRGE
+NL63	I-PRGE
+receptor	I-PRGE
+.	O
+
+The	O
+prevalence	O
+of	O
+pneumonia	B-DISO
+during	O
+the	O
+course	O
+of	O
+ARDS	B-DISO
+seems	O
+to	O
+be	O
+particularly	O
+high	O
+,	O
+but	O
+whether	O
+persons	O
+with	O
+ARDS	B-DISO
+are	O
+more	O
+susceptible	O
+to	O
+pneumonia	B-DISO
+or	O
+simply	O
+have	O
+more	O
+risk	O
+factors	O
+remains	O
+unknown	O
+because	O
+of	O
+methodological	O
+limitations	O
+.	O
+
+The	O
+core	O
+structures	O
+of	O
+these	O
+two	O
+hits	O
+,	O
+defined	O
+by	O
+the	O
+docking	B-PROC
+study	O
+,	O
+are	O
+used	O
+for	O
+further	O
+analogue	O
+search	O
+.	O
+
+Interestingly	O
+,	O
+the	O
+most	O
+potent	O
+inhibitor	B-CHED
+induces	O
+protein	B-CHED
+conformational	O
+changes	O
+,	O
+and	O
+the	O
+inhibition	B-PROC
+mechanisms	O
+,	O
+particularly	O
+the	O
+disruption	O
+of	O
+catalytic	O
+dyad	O
+(	O
+His41	O
+and	O
+Cys145	O
+),	O
+are	O
+elaborated	O
+.	O
+
+ABSTRACT	O
+:	O
+Protein	B-CHED
+ubiquitination	B-PROC
+has	O
+been	O
+identified	O
+as	O
+a	O
+regulatory	O
+mechanism	O
+in	O
+key	O
+cellular	B-COMP
+activities	O
+,	O
+and	O
+deubiquitination	B-PROC
+is	O
+recognized	O
+as	O
+an	O
+important	O
+step	O
+in	O
+processes	O
+governed	O
+by	O
+ubiquitin	B-PROC
+and	O
+ubiquitin	B-PROC
+-	O
+like	O
+modifiers	O
+.	O
+
+Most	O
+gram	B-SPEC
+-	I-SPEC
+positive	I-SPEC
+bacteria	I-SPEC
+,	O
+such	O
+as	O
+Enterococcus	B-SPEC
+spp	B-ENZY
+.	O
+
+Although	O
+antibody	B-COMP
+-	O
+based	O
+diagnosis	O
+of	O
+SARS	B-DISO
+has	O
+been	O
+demonstrated	O
+to	O
+be	O
+a	O
+reliable	O
+proof	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+,	O
+it	O
+is	O
+not	O
+sensitive	O
+enough	O
+for	O
+detection	O
+during	O
+the	O
+early	O
+phase	O
+of	O
+the	O
+disease	O
+.	O
+
+Sequence	O
+variations	O
+were	O
+observed	O
+in	O
+the	O
+SAR	B-CHED
+-	O
+CoV	O
+obtained	O
+from	O
+different	O
+patients	O
+in	O
+this	O
+epidemic	O
+.	O
+
+The	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-PROC
+fusion	I-PROC
+efficiency	O
+was	O
+simply	O
+determined	O
+for	O
+quantitative	O
+analysis	O
+based	O
+on	O
+the	O
+number	O
+of	O
+syncytium	B-ANAT
+detected	O
+by	O
+flow	O
+cytometry	O
+.	O
+
+Such	O
+new	O
+cell	O
+-	O
+to	O
+-	O
+cell	B-PROC
+fusion	I-PROC
+model	O
+was	O
+further	O
+assessed	O
+by	O
+the	O
+potent	O
+HR2	O
+peptide	B-CHED
+inhibitor	B-CHED
+,	O
+which	O
+led	O
+to	O
+the	O
+obvious	O
+decrease	O
+of	O
+the	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-PROC
+fusion	I-PROC
+efficiency	O
+.	O
+
+CONCLUSIONS	O
+:	O
+These	O
+results	O
+suggested	O
+that	O
+we	O
+successfully	O
+established	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+ARDS	B-DISO
+with	O
+H5N1	B-DISO
+viral	B-DISO
+infection	I-DISO
+,	O
+which	O
+may	O
+benefit	O
+further	O
+investigation	O
+into	O
+the	O
+pathogenesis	B-DISO
+of	O
+human	B-DISO
+ARDS	I-DISO
+induced	O
+by	O
+H5N1	B-DISO
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Severe	O
+respiratory	B-DISO
+failure	I-DISO
+:	O
+advanced	O
+treatment	O
+options	O
+.	O
+
+Our	O
+understanding	O
+of	O
+lung	B-ANAT
+pathophysiology	O
+and	O
+the	O
+role	O
+of	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+through	O
+basic	O
+science	O
+investigation	O
+has	O
+led	O
+to	O
+advances	O
+in	O
+lung	B-ANAT
+protective	O
+strategies	O
+for	O
+the	O
+mechanical	O
+ventilation	O
+support	O
+of	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+studied	O
+the	O
+immunogenicity	O
+of	O
+an	O
+anti	O
+-	O
+SARS	O
+subunit	O
+vaccine	O
+comprised	O
+of	O
+the	O
+fragment	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+protein	B-CHED
+amino	B-CHED
+acids	I-CHED
+318	O
+-	O
+510	O
+(	O
+S318	O
+-	O
+510	O
+)	O
+containing	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+.	O
+
+The	O
+monoclonal	O
+antibodies	B-COMP
+bound	O
+to	O
+the	O
+central	O
+and	O
+carboxyterminal	O
+half	O
+of	O
+the	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+indicating	O
+prominent	O
+exposure	O
+and	O
+immunogenicity	O
+of	O
+this	O
+part	O
+of	O
+the	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Putative	O
+cis	B-DISO
+-	O
+acting	O
+stem	B-ANAT
+-	O
+loops	O
+in	O
+the	O
+5	O
+'	O
+untranslated	O
+region	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+can	O
+substitute	O
+for	O
+their	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+counterparts	O
+.	O
+
+Chimeric	O
+genomes	O
+were	O
+transcribed	O
+in	O
+vitro	O
+,	O
+and	O
+viruses	B-SPEC
+were	O
+recovered	O
+after	O
+electroporation	O
+into	O
+permissive	O
+cells	B-COMP
+.	O
+
+In	O
+pulmonary	B-PROC
+function	I-PROC
+tests	O
+,	O
+the	O
+diffusing	O
+capacity	O
+of	O
+the	O
+lungs	B-ANAT
+showed	O
+a	O
+moderate	O
+decrease	O
+.	O
+
+We	O
+speculate	O
+that	O
+these	O
+two	O
+fragments	O
+came	O
+from	O
+a	O
+Conn	O
+and	O
+a	O
+Mass	O
+virus	O
+,	O
+respectively	O
+,	O
+and	O
+were	O
+incorporated	O
+into	O
+a	O
+virus	B-SPEC
+largely	O
+derived	O
+from	O
+ArkDPI	O
+.	O
+
+Since	O
+Ark	B-PRGE
+,	O
+Conn	O
+and	O
+Mass	O
+strains	O
+have	O
+been	O
+simultaneously	O
+used	O
+as	O
+live	O
+vaccines	O
+in	O
+California	B-SPEC
+,	O
+both	O
+point	B-PROC
+mutations	I-PROC
+and	O
+recombination	B-PROC
+among	O
+vaccine	O
+strains	O
+may	O
+have	O
+contributed	O
+to	O
+the	O
+emergence	O
+of	O
+the	O
+Cal99	O
+variant	O
+virus	B-SPEC
+.	O
+
+Analysis	O
+of	O
+the	O
+structural	O
+protein	B-CHED
+genes	O
+of	O
+six	O
+Cal99	O
+isolates	O
+demonstrated	O
+that	O
+viruses	B-SPEC
+of	O
+this	O
+serotype	O
+may	O
+differ	O
+substantially	O
+in	O
+the	O
+non	O
+-	O
+S1	O
+structural	O
+genes	O
+.	O
+
+Finally	O
+,	O
+we	O
+performed	O
+a	O
+challenge	O
+study	O
+with	O
+Cal99	O
+and	O
+demonstrated	O
+that	O
+the	O
+virus	B-SPEC
+causes	O
+late	O
+-	O
+onset	O
+respiratory	B-DISO
+disease	I-DISO
+,	O
+with	O
+a	O
+severity	O
+comparable	O
+to	O
+that	O
+of	O
+the	O
+M41	B-PRGE
+IBV	I-PRGE
+challenge	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+Animal	B-SPEC
+models	O
+and	O
+antibody	B-COMP
+assays	O
+for	O
+evaluating	O
+candidate	O
+SARS	B-DISO
+vaccines	O
+:	O
+summary	O
+of	O
+a	O
+technical	O
+meeting	O
+25	O
+-	O
+26	O
+August	O
+2005	O
+,	O
+London	O
+,	O
+UK	O
+.	O
+
+Several	O
+mechanisms	O
+are	O
+involved	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+virus	B-SPEC
+-	O
+related	O
+nephropathy	B-DISO
+,	O
+including	O
+tropism	B-PROC
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+kidney	B-ANAT
+,	O
+induction	O
+of	O
+abnormal	O
+immune	O
+complexes	O
+,	O
+direct	O
+cytopathogenic	O
+effects	O
+,	O
+and	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+Hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+is	O
+associated	O
+with	O
+membranous	B-DISO
+nephropathy	I-DISO
+and	O
+mesangiocapillary	B-DISO
+glomerulonephritis	I-DISO
+in	O
+endemic	O
+areas	O
+.	O
+
+Leptospirosis	B-DISO
+-	O
+induced	O
+lesions	O
+,	O
+predominantly	O
+in	O
+the	O
+proximal	B-ANAT
+tubule	I-ANAT
+,	O
+were	O
+responsible	O
+for	O
+the	O
+polyuria	B-DISO
+and	O
+natriuresis	B-PROC
+observed	O
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+diseases	I-DISO
+emerging	O
+from	O
+Chinese	O
+wet	O
+-	O
+markets	O
+:	O
+zoonotic	O
+origins	O
+of	O
+severe	O
+respiratory	O
+viral	O
+infections	O
+.	O
+
+An	O
+astonishing	O
+diversity	O
+of	O
+coronaviruses	O
+was	O
+also	O
+discovered	O
+in	O
+different	O
+species	B-SPEC
+of	O
+bats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+etiologic	O
+agents	O
+of	O
+respiratory	O
+and	O
+enteric	O
+diseases	O
+in	O
+humans	O
+and	O
+in	O
+animals	B-SPEC
+.	O
+
+A	O
+thickened	O
+gallbladder	B-ANAT
+wall	I-ANAT
+was	O
+found	O
+in	O
+19	O
+cases	O
+,	O
+all	O
+were	O
+women	O
+,	O
+and	O
+periportal	O
+tracking	O
+and	O
+a	O
+dilated	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+in	O
+17	O
+CTs	B-DISO
+.	O
+
+Alternatively	O
+,	O
+APN	B-PRGE
+should	O
+be	O
+included	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+systemic	O
+diseases	O
+that	O
+cause	O
+gallbladder	B-ANAT
+wall	I-ANAT
+thickening	O
+to	O
+avoid	O
+misdiagnosing	O
+it	O
+as	O
+acute	B-DISO
+cholecystitis	I-DISO
+.	O
+
+Laboratory	O
+diagnosis	O
+of	O
+these	O
+viral	B-DISO
+infections	I-DISO
+based	O
+on	O
+viral	O
+isolation	O
+or	O
+detection	O
+by	O
+immune	O
+electron	O
+microscopy	O
+,	O
+immunoassay	O
+and	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+has	O
+dramatically	O
+improved	O
+in	O
+the	O
+recent	O
+years	O
+,	O
+and	O
+SARS	B-DISO
+represents	O
+a	O
+good	O
+example	O
+of	O
+a	O
+diagnostic	O
+approach	O
+to	O
+emerging	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Formation	B-PROC
+of	O
+THMs	O
+and	O
+HAAs	O
+does	O
+not	O
+exceed	O
+the	O
+drinking	B-PROC
+water	B-CHED
+standard	O
+.	O
+
+TITLE	O
+:	O
+Accumulation	O
+of	O
+recombinant	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+in	O
+plant	B-SPEC
+cytosol	B-COMP
+and	O
+chloroplasts	B-COMP
+indicate	O
+potential	O
+for	O
+development	O
+of	O
+plant	B-SPEC
+-	O
+derived	O
+oral	B-ANAT
+vaccines	O
+.	O
+
+In	O
+the	O
+construction	O
+of	O
+both	O
+nuclear	O
+and	O
+plastid	B-COMP
+transformation	B-DISO
+vectors	O
+,	O
+a	O
+2	O
+-	O
+kilobase	O
+nucleotide	B-CHED
+sequence	O
+encoding	O
+amino	B-CHED
+acids	I-CHED
+1	O
+-	O
+658	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+(	O
+S1	O
+)	O
+was	O
+modified	O
+with	O
+nucleotide	B-CHED
+changes	O
+,	O
+but	O
+not	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+,	O
+to	O
+optimize	O
+codon	O
+usage	O
+for	O
+expression	B-PROC
+in	O
+plants	B-SPEC
+.	O
+
+It	O
+has	O
+been	O
+observed	O
+that	O
+all	O
+pharmacophores	O
+of	O
+the	O
+three	O
+peptides	B-CHED
+overlap	O
+very	O
+well	O
+,	O
+and	O
+that	O
+ATLQANEV	O
+binds	B-FUNC
+best	O
+with	O
+the	O
+receptor	O
+,	O
+followed	O
+by	O
+AVLQSGFR	O
+,	O
+and	O
+then	O
+ATLQAIAS	O
+.	O
+
+During	O
+the	O
+process	O
+of	O
+docking	B-PROC
+the	O
+octapeptides	O
+to	O
+the	O
+SARS	B-DISO
+enzyme	O
+,	O
+the	O
+residues	O
+of	O
+the	O
+catalytic	O
+dyad	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+His	O
+-	O
+41	O
+and	O
+Cys	B-CHED
+-	O
+145	O
+are	O
+actively	O
+involved	O
+in	O
+forming	O
+the	O
+hydrogen	B-CHED
+bonds	O
+,	O
+so	O
+is	O
+the	O
+center	O
+residue	O
+(	O
+Gln	B-CHED
+)	O
+of	O
+all	O
+the	O
+three	O
+octapeptides	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+and	O
+partially	O
+characterize	O
+a	O
+coronaviruslike	O
+virus	O
+isolated	O
+from	O
+naturally	O
+infected	O
+pigeons	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+when	O
+the	O
+virus	B-SPEC
+was	O
+inoculated	O
+into	O
+SPF	B-PRGE
+chickens	I-PRGE
+,	O
+pancreatitis	B-DISO
+developed	O
+.	O
+
+There	O
+is	O
+,	O
+however	O
+,	O
+only	O
+minimal	O
+understanding	O
+of	O
+the	O
+dynamics	O
+of	O
+virus	B-SPEC
+-	O
+laden	O
+aerosols	O
+,	O
+and	O
+so	O
+the	O
+ability	O
+to	O
+control	O
+and	O
+prevent	O
+virus	B-SPEC
+spread	O
+is	O
+severely	O
+reduced	O
+,	O
+as	O
+was	O
+clearly	O
+demonstrated	O
+during	O
+the	O
+recent	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+Seven	O
+-	O
+mer	O
+phage	O
+random	O
+peptide	B-CHED
+libraries	O
+were	O
+panned	O
+against	O
+2C10	O
+,	O
+a	O
+monoclonal	O
+antibody	B-COMP
+that	O
+showed	O
+neutralizing	O
+activities	O
+against	O
+PEDV	B-SPEC
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+S1	O
+receptor	B-PRGE
+binding	I-PRGE
+domain	I-PRGE
+(	O
+RBD	O
+)	O
+in	O
+complex	O
+with	O
+a	O
+neutralizing	O
+antibody	B-COMP
+,	O
+80R	O
+,	O
+at	O
+2	O
+.	O
+3	O
+A	O
+resolution	O
+,	O
+as	O
+well	O
+as	O
+the	O
+structure	O
+of	O
+the	O
+uncomplexed	O
+S1	O
+RBD	O
+at	O
+2	O
+.	O
+2	O
+A	O
+resolution	O
+.	O
+
+Although	O
+we	O
+previously	O
+detected	O
+,	O
+isolated	O
+,	O
+and	O
+characterized	O
+BCoV	O
+strains	O
+from	O
+adult	O
+cattle	B-SPEC
+with	O
+WD	O
+(	O
+WD	O
+-	O
+BCoV	O
+strains	O
+)	O
+during	O
+the	O
+winter	O
+in	O
+South	O
+Korea	O
+,	O
+the	O
+precise	O
+epidemiology	O
+,	O
+as	O
+well	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+diarrhea	B-DISO
+in	O
+adult	O
+cattle	B-SPEC
+in	O
+the	O
+warmer	O
+seasons	O
+,	O
+has	O
+not	O
+been	O
+examined	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+and	O
+hemagglutinin	O
+/	O
+esterase	B-PRGE
+(	O
+HE	O
+)	O
+proteins	B-CHED
+revealed	O
+that	O
+all	O
+the	O
+Korean	O
+BCoVs	O
+clustered	O
+together	O
+regardless	O
+of	O
+season	O
+and	O
+were	O
+distinct	O
+from	O
+the	O
+other	O
+known	O
+BCoVs	O
+,	O
+suggesting	O
+a	O
+distinct	O
+evolutionary	O
+pathway	B-PROC
+for	O
+the	O
+Korean	O
+BCoVs	O
+.	O
+
+These	O
+and	O
+previous	O
+results	O
+revealed	O
+a	O
+high	O
+prevalence	O
+and	O
+widespread	O
+geographical	O
+distribution	O
+of	O
+BCoV	O
+,	O
+suggesting	O
+that	O
+this	O
+virus	B-SPEC
+is	O
+endemic	O
+in	O
+adult	O
+cattle	B-SPEC
+with	O
+diarrhea	B-DISO
+in	O
+all	O
+seasons	O
+in	O
+South	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+of	O
+patients	O
+with	O
+scleroderma	B-DISO
+admitted	O
+to	O
+intensive	O
+care	O
+unit	O
+.	O
+
+We	O
+present	O
+the	O
+features	O
+,	O
+clinical	O
+course	O
+and	O
+outcome	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+scleroderma	B-DISO
+that	O
+were	O
+admitted	O
+to	O
+the	O
+ICU	O
+.	O
+
+Although	O
+infections	B-DISO
+are	O
+treatable	O
+,	O
+the	O
+high	O
+mortality	O
+rate	O
+for	O
+this	O
+group	O
+of	O
+patients	O
+was	O
+dependent	O
+on	O
+the	O
+severity	O
+of	O
+the	O
+underlying	O
+visceral	O
+organ	B-ANAT
+involvement	O
+,	O
+particularly	O
+severe	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+Limitations	O
+of	O
+conventional	O
+crisis	O
+management	O
+and	O
+current	O
+findings	O
+in	O
+post	O
+-	O
+traumatic	O
+growth	B-PROC
+research	O
+are	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Cooperative	O
+involvement	O
+of	O
+the	O
+S1	O
+and	O
+S2	O
+subunits	O
+of	O
+the	O
+murine	B-PRGE
+coronavirus	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+in	O
+receptor	O
+binding	O
+and	O
+extended	O
+host	B-COMP
+range	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+process	O
+of	O
+spike	O
+(	O
+S	O
+)-	O
+receptor	O
+interaction	O
+during	O
+coronavirus	B-SPEC
+entry	O
+,	O
+we	O
+evaluated	O
+the	O
+contributions	O
+of	O
+mutations	O
+in	O
+different	O
+regions	O
+of	O
+the	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+S	O
+protein	B-CHED
+to	O
+natural	O
+receptor	O
+murine	B-SPEC
+carcinoembryonic	O
+antigen	B-CHED
+-	O
+related	O
+cell	B-PROC
+adhesion	B-DISO
+molecule	O
+1a	O
+(	O
+CEACAM1a	O
+)	O
+dependence	B-DISO
+and	O
+to	O
+the	O
+acquisition	O
+of	O
+extended	O
+host	B-COMP
+range	O
+.	O
+
+These	O
+variant	O
+viruses	B-SPEC
+contain	O
+several	O
+mutations	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+that	O
+confer	O
+to	O
+the	O
+viruses	B-SPEC
+the	O
+ability	O
+to	O
+enter	O
+cells	B-COMP
+in	O
+a	O
+heparan	B-CHED
+sulfate	I-CHED
+-	O
+dependent	O
+manner	O
+(	O
+C	O
+.	O
+A	O
+.	O
+de	O
+Haan	O
+,	O
+Z	O
+.	O
+Li	B-SPEC
+,	O
+E	O
+.	O
+te	O
+Lintelo	O
+,	O
+B	O
+.	O
+J	O
+.	O
+Bosch	O
+,	O
+B	O
+.	O
+J	O
+.	O
+Haijema	O
+,	O
+and	O
+P	O
+.	O
+J	O
+.	O
+M	O
+.	O
+Rottier	O
+,	O
+J	O
+.	O
+Virol	O
+.	O
+
+Severe	O
+clinical	O
+septic	O
+and	O
+traumatic	B-DISO
+shock	I-DISO
+cases	O
+were	O
+studied	O
+.	O
+
+Besides	O
+,	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+results	O
+of	O
+CPET	O
+between	O
+subjects	O
+recovered	O
+from	O
+SARS	B-DISO
+and	O
+those	O
+never	O
+infected	O
+.	O
+
+Besides	O
+,	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+results	O
+of	O
+CPET	O
+between	O
+subjects	O
+recovered	O
+from	O
+SARS	B-DISO
+and	O
+those	O
+never	O
+infected	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+survey	O
+aimed	O
+to	O
+illustrate	O
+factors	O
+that	O
+contribute	O
+to	O
+nurses	O
+'	O
+fear	O
+when	O
+faced	O
+with	O
+a	O
+possible	O
+human	O
+-	O
+to	O
+-	O
+human	B-SPEC
+avian	B-DISO
+flu	I-DISO
+pandemic	O
+and	O
+their	O
+willingness	O
+to	O
+care	O
+for	O
+patients	O
+with	O
+avian	B-DISO
+flu	I-DISO
+in	O
+Taiwan	O
+.	O
+
+Two	O
+monkey	B-SPEC
+epithelial	B-ANAT
+cell	I-ANAT
+lines	O
+,	O
+LLC	B-PRGE
+-	I-PRGE
+MK2	I-PRGE
+and	O
+Vero	O
+-	O
+B4	O
+,	O
+showed	O
+a	O
+cytopathic	B-DISO
+effect	I-DISO
+(	O
+CPE	B-DISO
+)	O
+and	O
+clear	O
+viral	B-PROC
+replication	I-PROC
+,	O
+whereas	O
+no	O
+CPE	B-DISO
+or	O
+replication	O
+was	O
+observed	O
+in	O
+human	B-SPEC
+lung	B-ANAT
+fibroblasts	B-ANAT
+MRC	O
+-	O
+5s	O
+.	O
+
+TITLE	O
+:	O
+Noninvasive	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+:	O
+An	O
+experimental	O
+model	O
+to	O
+assess	O
+air	B-CHED
+and	O
+particle	O
+dispersion	O
+.	O
+
+When	O
+IPAP	O
+was	O
+increased	O
+to	O
+18	O
+cm	O
+H2O	B-CHED
+,	O
+the	O
+vertical	O
+plume	O
+extended	O
+to	O
+0	O
+.	O
+45	O
+m	O
+above	O
+the	O
+patient	O
+with	O
+some	O
+horizontal	O
+spreading	O
+along	O
+the	O
+ward	O
+ceiling	O
+.	O
+
+Substantial	O
+exposure	O
+to	O
+exhaled	B-ANAT
+air	B-CHED
+occurs	O
+within	O
+a	O
+0	O
+.	O
+5	O
+-	O
+m	O
+radius	B-ANAT
+of	O
+patients	O
+receiving	O
+NPPV	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Substantial	O
+exposure	O
+to	O
+exhaled	B-ANAT
+air	B-CHED
+occurs	O
+within	O
+a	O
+0	O
+.	O
+5	O
+-	O
+m	O
+radius	B-ANAT
+of	O
+patients	O
+receiving	O
+NPPV	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+domestic	O
+or	O
+European	O
+ferret	O
+(	O
+Mustela	B-SPEC
+putorius	I-SPEC
+furo	I-SPEC
+)	O
+has	O
+been	O
+domesticated	O
+for	O
+thousands	O
+of	O
+years	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+Vero	O
+E6	O
+cells	B-COMP
+transfected	O
+with	O
+a	O
+construct	O
+for	O
+expressing	O
+3b	O
+underwent	O
+necrosis	B-PROC
+as	O
+early	O
+as	O
+6h	O
+after	O
+transfection	B-PROC
+and	O
+underwent	O
+simultaneous	O
+necrosis	B-PROC
+and	O
+apoptosis	B-PATH
+at	O
+later	O
+time	O
+-	O
+points	O
+.	O
+
+The	O
+3bDelta124	O
+-	O
+154	O
+mutant	B-DISO
+behaves	O
+in	O
+a	O
+similar	O
+manner	O
+indicating	O
+that	O
+the	O
+localization	B-PROC
+of	O
+the	O
+3b	B-PRGE
+protein	I-PRGE
+does	O
+not	O
+seems	O
+to	O
+be	O
+important	O
+for	O
+the	O
+cell	B-COMP
+-	O
+death	B-PROC
+pathways	B-PROC
+since	O
+full	O
+-	O
+length	O
+3b	O
+is	O
+localized	O
+predominantly	O
+to	O
+the	O
+nucleolus	B-COMP
+,	O
+while	O
+the	O
+mutant	B-DISO
+is	O
+found	O
+to	O
+be	O
+concentrated	O
+in	O
+the	O
+peri	O
+-	O
+nuclear	O
+regions	O
+.	O
+
+In	O
+total	O
+69	O
+bacterial	O
+species	B-SPEC
+were	O
+isolated	O
+from	O
+65	O
+(	O
+54	O
+.	O
+8	O
+%)	O
+of	O
+120	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+:	O
+systematic	O
+review	O
+of	O
+treatment	O
+effects	O
+.	O
+
+To	O
+determine	O
+the	O
+role	O
+in	O
+replication	O
+of	O
+processing	O
+between	O
+nsp2	B-PRGE
+and	O
+nsp3	B-PRGE
+at	O
+cleavage	B-PROC
+site	O
+2	O
+(	O
+CS2	B-CHED
+)	O
+and	O
+PLP1	B-PRGE
+proteinase	I-PRGE
+activity	O
+,	O
+mutations	O
+were	O
+engineered	O
+into	O
+the	O
+MHV	B-SPEC
+genome	O
+at	O
+CS2	B-CHED
+,	O
+at	O
+CS1	B-PRGE
+and	O
+CS2	B-PRGE
+,	O
+and	O
+at	O
+the	O
+PLP1	B-PRGE
+catalytic	I-PRGE
+site	I-PRGE
+,	O
+alone	O
+and	O
+in	O
+combination	O
+.	O
+
+Mutant	B-DISO
+viruses	B-SPEC
+with	O
+abolished	O
+cleavage	B-PROC
+at	O
+CS2	B-CHED
+were	O
+delayed	O
+in	O
+growth	B-PROC
+and	O
+RNA	B-PROC
+synthesis	I-PROC
+but	O
+grew	O
+to	O
+wild	O
+-	O
+type	O
+titers	O
+of	O
+>	O
+10	O
+(	O
+7	O
+)	O
+PFU	B-CHED
+/	O
+ml	O
+.	O
+
+To	O
+determine	O
+whether	O
+HECV	O
+-	O
+4408	O
+infects	O
+gnotobiotic	O
+calves	O
+and	O
+induces	O
+cross	O
+-	O
+protective	O
+immunity	B-PROC
+against	O
+the	O
+virulent	O
+enteric	O
+BCoV	O
+DB2	O
+strain	O
+,	O
+gnotobiotic	O
+calves	O
+(	O
+n	O
+=	O
+4	O
+)	O
+were	O
+orally	B-ANAT
+inoculated	O
+with	O
+HECV	O
+-	O
+4408	O
+and	O
+then	O
+challenged	O
+with	O
+BCoV	O
+DB2	O
+at	O
+postinoculation	O
+day	O
+(	O
+PID	B-DISO
+)	O
+21	O
+.	O
+
+At	O
+postchallenge	O
+day	O
+7	O
+,	O
+serum	B-COMP
+IgG	B-PRGE
+and	O
+fecal	B-ANAT
+IgA	B-COMP
+antibody	I-COMP
+titers	O
+remained	O
+the	O
+same	O
+or	O
+increased	O
+only	O
+twofold	O
+compared	O
+to	O
+prechallenge	O
+titers	O
+.	O
+
+This	O
+domain	O
+was	O
+shown	O
+to	O
+interact	O
+with	O
+the	O
+genomic	O
+RNA	O
+for	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+This	O
+study	O
+thus	O
+identifies	O
+residues	O
+critical	O
+for	O
+RNA	B-FUNC
+binding	I-FUNC
+on	O
+the	O
+nucleocapsid	B-COMP
+surface	O
+,	O
+and	O
+presents	O
+biochemical	O
+and	O
+genetic	O
+evidence	O
+that	O
+directly	O
+links	O
+the	O
+RNA	B-FUNC
+binding	I-FUNC
+capacity	O
+of	O
+the	O
+coronavirus	B-SPEC
+N	O
+protein	B-CHED
+to	O
+the	O
+viral	O
+infectivity	O
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+.	O
+
+This	O
+information	O
+would	O
+be	O
+useful	O
+in	O
+development	B-PROC
+of	O
+preventive	O
+and	O
+treatment	O
+approaches	O
+against	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Pigs	B-SPEC
+were	O
+ventilated	O
+at	O
+random	O
+conventionally	O
+with	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+2	O
+-	O
+3	O
+cm	O
+H2O	B-CHED
+and	O
+tidal	O
+volume	O
+10	O
+-	O
+12	O
+mL	O
+/	O
+kg	O
+(	O
+control	O
+),	O
+with	O
+CLPV	O
+(	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+10	O
+cm	O
+H2O	B-CHED
+,	O
+tidal	O
+volume	O
+6	O
+mL	O
+/	O
+kg	O
+),	O
+or	O
+with	O
+HFOV	O
+.	O
+
+Compared	O
+with	O
+control	O
+,	O
+oxygenation	B-PROC
+was	O
+worse	O
+with	O
+CLPV	O
+and	O
+HFOV	O
+.	O
+
+With	O
+HFOV	O
+and	O
+CLPV	O
+,	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+,	O
+cardiac	B-ANAT
+output	O
+,	O
+and	O
+stroke	B-DISO
+volume	O
+decreased	O
+significantly	O
+;	O
+pulmonary	B-ANAT
+arterial	B-ANAT
+elastance	O
+increased	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+a	O
+fluid	O
+resuscitation	O
+strategy	O
+,	O
+CLPV	O
+and	O
+HFOV	O
+caused	O
+decreased	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+,	O
+cardiac	B-ANAT
+output	O
+,	O
+and	O
+stroke	B-DISO
+volume	O
+and	O
+worsened	O
+oxygenation	B-PROC
+in	O
+this	O
+normal	O
+lung	B-ANAT
+animal	B-SPEC
+model	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+antigenic	O
+epitope	B-CHED
+at	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+protein	B-CHED
+and	O
+characterization	O
+of	O
+monoclonal	O
+antibody	O
+against	O
+the	O
+protein	B-CHED
+.	O
+
+Coronavirus	B-SPEC
+nucleoproteins	O
+(	O
+N	O
+)	O
+are	O
+nonspecific	O
+RNA	O
+-	O
+binding	B-FUNC
+proteins	B-CHED
+with	O
+long	O
+disordered	O
+regions	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+have	O
+shown	O
+that	O
+purified	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+also	O
+has	O
+RNA	O
+chaperone	B-PROC
+activity	I-PROC
+.	O
+
+In	O
+silico	O
+predictions	O
+of	O
+disordered	O
+domains	O
+showed	O
+a	O
+similar	O
+pattern	O
+for	O
+all	O
+coronavirus	O
+N	O
+proteins	B-CHED
+evaluated	O
+.	O
+
+Altogether	O
+,	O
+these	O
+data	O
+led	O
+us	O
+to	O
+suggest	O
+that	O
+all	O
+coronavirus	B-SPEC
+N	O
+proteins	B-CHED
+might	O
+be	O
+RNA	O
+chaperones	O
+.	O
+
+TITLE	O
+:	O
+An	O
+arginine	B-CHED
+-	O
+to	O
+-	O
+proline	O
+mutation	O
+in	O
+a	O
+domain	O
+with	O
+undefined	O
+functions	O
+within	O
+the	O
+helicase	B-PRGE
+protein	B-CHED
+(	O
+Nsp13	O
+)	O
+is	O
+lethal	O
+to	O
+the	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+.	O
+
+However	O
+,	O
+mutation	O
+of	O
+the	O
+Arg132	O
+residue	O
+to	O
+Leu	B-CHED
+,	O
+a	O
+conserved	O
+residue	O
+in	O
+other	O
+coronaviruses	O
+at	O
+the	O
+same	O
+position	O
+,	O
+reduced	O
+the	O
+recovery	O
+rate	O
+of	O
+the	O
+in	O
+vitro	O
+-	O
+synthesized	O
+transcripts	O
+.	O
+
+The	O
+recovered	O
+mutant	B-DISO
+virus	B-SPEC
+showed	O
+much	O
+smaller	O
+-	O
+sized	O
+plaques	B-DISO
+.	O
+
+TITLE	O
+:	O
+ANN	O
+-	O
+based	O
+mapping	O
+of	O
+febrile	B-PROC
+subjects	O
+in	O
+mass	O
+thermogram	O
+screening	O
+:	O
+facts	O
+and	O
+myths	O
+.	O
+
+In	O
+particular	O
+,	O
+in	O
+a	O
+competing	O
+risks	O
+context	O
+,	O
+the	O
+case	O
+fatality	O
+ratio	O
+is	O
+defined	O
+by	O
+the	O
+limiting	O
+value	O
+of	O
+the	O
+sub	O
+-	O
+distribution	O
+function	O
+,	O
+F	O
+(	O
+1	O
+)(	O
+t	O
+)	O
+=	O
+Pr	O
+(	O
+T	O
+<	O
+or	O
+=	O
+t	O
+and	O
+J	O
+=	O
+1	O
+),	O
+associated	O
+with	O
+death	B-PROC
+,	O
+as	O
+t	O
+-->	O
+infinity	O
+,	O
+where	O
+T	O
+denotes	O
+the	O
+time	O
+from	O
+onset	O
+to	O
+death	B-PROC
+(	O
+J	O
+=	O
+1	O
+)	O
+or	O
+recovery	O
+(	O
+J	O
+=	O
+2	O
+).	O
+
+Finally	O
+,	O
+according	O
+to	O
+recent	O
+studies	O
+,	O
+the	O
+stabilization	O
+of	O
+the	O
+trimeric	O
+bundle	O
+is	O
+linked	O
+to	O
+a	O
+higher	O
+fusion	O
+activity	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+,	O
+and	O
+the	O
+possible	O
+influence	O
+of	O
+the	O
+GxxxG	O
+motif	O
+on	O
+this	O
+feature	O
+is	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Communicable	O
+respiratory	O
+threats	O
+in	O
+the	O
+ED	O
+:	O
+tuberculosis	B-PATH
+,	O
+influenza	B-DISO
+,	O
+SARS	B-DISO
+,	O
+and	O
+other	O
+aerosolized	O
+infections	O
+.	O
+
+These	O
+diseases	O
+include	O
+influenza	B-DISO
+,	O
+tuberculosis	B-PATH
+,	O
+and	O
+measles	B-PATH
+,	O
+together	O
+accounting	O
+for	O
+25	O
+%	O
+of	O
+infectious	B-DISO
+causes	O
+of	O
+death	B-PROC
+worldwide	O
+.	O
+
+These	O
+are	O
+emerging	O
+and	O
+biothreat	O
+agents	O
+that	O
+follow	O
+the	O
+same	O
+route	O
+of	O
+transmission	O
+,	O
+such	O
+as	O
+pneumonic	B-DISO
+plague	I-DISO
+.	O
+
+We	O
+discuss	O
+epidemiology	O
+,	O
+pathogenesis	B-DISO
+,	O
+diagnosis	O
+,	O
+and	O
+treatment	O
+of	O
+each	O
+agent	O
+.	O
+
+TITLE	O
+:	O
+A	O
+prospective	O
+hospital	O
+-	O
+based	O
+study	O
+of	O
+the	O
+clinical	O
+impact	O
+of	O
+non	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+Non	O
+-	O
+SARS	B-DISO
+)-	O
+related	O
+human	B-SPEC
+coronavirus	I-SPEC
+infection	O
+.	O
+
+Six	O
+hundred	O
+and	O
+eighty	O
+-	O
+six	O
+women	O
+admitted	O
+with	O
+a	O
+diagnosis	O
+of	O
+pre	B-DISO
+-	I-DISO
+eclampsia	I-DISO
+were	O
+included	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+results	O
+suggest	O
+that	O
+rapid	O
+production	O
+of	O
+type	B-PRGE
+I	I-PRGE
+IFNs	I-PRGE
+by	O
+pDCs	O
+is	O
+essential	O
+for	O
+the	O
+control	O
+of	O
+potentially	O
+lethal	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+spleen	B-ANAT
+T	B-ANAT
+lymphocytes	I-ANAT
+were	O
+analyzed	O
+by	O
+flow	O
+cytometry	O
+(	O
+FCM	B-CHED
+)	O
+to	O
+evaluate	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+immune	B-PROC
+responses	I-PROC
+,	O
+the	O
+antigen	B-CHED
+-	O
+specific	O
+responses	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+evaluated	O
+by	O
+cytotoxic	B-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+(	O
+CTL	B-ANAT
+)	O
+assay	O
+,	O
+and	O
+the	O
+level	O
+of	O
+IgG	B-PRGE
+in	O
+antisera	O
+from	O
+immunized	O
+mice	B-SPEC
+was	O
+determined	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+These	O
+results	O
+are	O
+promising	O
+for	O
+the	O
+protective	O
+immunization	O
+of	O
+humans	B-SPEC
+.	O
+
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strain	O
+closely	O
+related	O
+to	O
+Massachusetts	O
+(	O
+Mass	O
+)	O
+serotype	O
+was	O
+isolated	O
+from	O
+broiler	O
+chickens	B-SPEC
+suffering	B-DISO
+from	O
+severe	O
+renal	B-ANAT
+and	O
+respiratory	O
+distresses	O
+.	O
+
+Periodical	O
+evaluation	O
+of	O
+cross	O
+-	O
+protective	O
+capabilities	O
+of	O
+IBV	B-SPEC
+vaccine	O
+(	O
+s	O
+)	O
+versus	O
+recently	O
+recovered	O
+field	O
+isolates	O
+should	O
+be	O
+performed	O
+to	O
+ensure	O
+optimum	O
+control	O
+of	O
+IBV	B-SPEC
+.	O
+
+Protection	O
+based	O
+criteria	O
+were	O
+:	O
+virus	B-SPEC
+re	O
+-	O
+isolation	O
+attempts	O
+from	O
+trachea	B-DISO
+,	O
+tracheal	O
+and	O
+renal	B-ANAT
+histopathology	O
+as	O
+well	O
+as	O
+IBV	B-SPEC
+antigens	B-CHED
+detection	O
+by	O
+immunofluorescent	O
+antibody	B-COMP
+technique	O
+in	O
+kidney	B-ANAT
+sections	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+White	B-SPEC
+bream	I-SPEC
+virus	I-SPEC
+reveals	O
+a	O
+novel	O
+genetic	O
+cluster	O
+of	O
+nidoviruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+order	O
+Nidovirales	O
+comprises	O
+viruses	B-SPEC
+from	O
+the	O
+families	O
+Coronaviridae	B-SPEC
+(	O
+genera	O
+Coronavirus	B-SPEC
+and	O
+Torovirus	B-SPEC
+),	O
+Roniviridae	B-SPEC
+(	O
+genus	B-SPEC
+Okavirus	I-SPEC
+),	O
+and	O
+Arteriviridae	B-SPEC
+(	O
+genus	B-SPEC
+Arterivirus	I-SPEC
+).	O
+
+Intriguingly	O
+,	O
+ACE2	B-PRGE
+acts	O
+as	O
+a	O
+protective	O
+factor	O
+in	O
+various	O
+experimental	O
+models	O
+of	O
+acute	O
+lung	B-ANAT
+failure	O
+and	O
+,	O
+therefore	O
+,	O
+acts	O
+not	O
+only	O
+as	O
+a	O
+key	O
+determinant	O
+for	O
+SARS	B-DISO
+virus	B-SPEC
+entry	O
+into	O
+cells	B-COMP
+but	O
+also	O
+contributes	O
+to	O
+SARS	B-DISO
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Quantitative	O
+comparison	O
+of	O
+the	O
+efficiency	O
+of	O
+antibodies	B-COMP
+against	O
+S1	O
+and	O
+S2	O
+subunit	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+in	O
+virus	B-PROC
+neutralization	I-PROC
+and	O
+blocking	B-DISO
+of	O
+receptor	B-FUNC
+binding	I-FUNC
+:	O
+implications	O
+for	O
+the	O
+functional	O
+roles	O
+of	O
+S2	B-PRGE
+subunit	I-PRGE
+.	O
+
+The	O
+efficiency	O
+of	O
+these	O
+purified	O
+IgGs	O
+in	O
+virus	B-PROC
+neutralization	I-PROC
+and	O
+blocking	B-DISO
+of	O
+receptor	B-FUNC
+binding	I-FUNC
+were	O
+compared	O
+quantitatively	O
+using	O
+virus	B-PROC
+neutralization	I-PROC
+assay	O
+and	O
+a	O
+previously	O
+developed	O
+cell	B-COMP
+-	O
+based	O
+receptor	B-FUNC
+binding	I-FUNC
+assay	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+epizootiology	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+in	O
+Russia	O
+.	O
+
+The	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+similarities	O
+between	O
+the	O
+eight	O
+IB	O
+vaccine	O
+strains	O
+and	O
+the	O
+field	O
+strain	O
+,	O
+tl	O
+/	O
+CH	O
+/	O
+LDT3	O
+/	O
+03	O
+,	O
+which	O
+was	O
+isolated	O
+from	O
+a	O
+teal	O
+(	O
+Anas	B-SPEC
+sp	O
+.),	O
+were	O
+not	O
+more	O
+than	O
+81	O
+.	O
+1	O
+%	O
+and	O
+79	O
+.	O
+2	O
+%,	O
+respectively	O
+.	O
+
+To	O
+evaluate	O
+the	O
+molecular	O
+mechanisms	O
+involved	O
+in	O
+the	O
+viral	B-DISO
+infection	I-DISO
+,	O
+in	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+role	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	B-CHED
+in	O
+the	O
+regulation	B-PROC
+of	O
+cyclooxygenase	B-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+).	O
+
+Expression	B-PROC
+of	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+stimulated	O
+by	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+was	O
+verified	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+western	O
+blot	O
+assay	O
+.	O
+
+The	O
+native	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+was	O
+modified	O
+at	O
+A	O
++	O
+T	O
+abundant	O
+regions	O
+;	O
+n	O
+.	O
+t	O
+.	O
+777	O
+-	O
+1683	O
+,	O
+n	O
+.	O
+t	O
+.	O
+1041	O
+-	O
+1050	O
+,	O
+n	O
+.	O
+t	O
+.	O
+1236	O
+-	O
+1248	O
+,	O
+n	O
+.	O
+t	O
+.	O
+1317	O
+-	O
+1335	O
+,	O
+n	O
+.	O
+t	O
+.	O
+1590	O
+-	O
+1605	O
+;	O
+based	O
+on	O
+the	O
+same	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+.	O
+
+The	O
+resultant	O
+plasmid	O
+pPIC9K	O
+-	O
+S1	O
+was	O
+transformed	O
+into	O
+Pichia	B-SPEC
+pastoris	I-SPEC
+GS	O
+115	O
+and	O
+the	O
+protein	B-PROC
+expression	B-PROC
+was	O
+induced	O
+with	O
+methanol	B-CHED
+.	O
+
+SDS	B-DISO
+-	O
+PAGE	O
+confirmed	O
+that	O
+the	O
+recombinant	O
+SI	O
+was	O
+secreted	B-PROC
+in	O
+the	O
+supernatant	O
+of	O
+induced	O
+GS	O
+115	O
+.	O
+
+The	O
+protein	B-CHED
+yield	O
+reached	O
+69	O
+mg	O
+/	O
+l	O
+.	O
+
+ELISA	O
+and	O
+Western	O
+blot	O
+demonstrated	O
+that	O
+the	O
+S1	O
+could	O
+react	O
+with	O
+the	O
+convalescent	O
+sera	B-COMP
+of	O
+people	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Furthermore	O
+,	O
+ligand	B-PROC
+blot	O
+assay	O
+showed	O
+that	O
+the	O
+recombinant	O
+S1	O
+could	O
+react	O
+with	O
+ACE2	B-PRGE
+,	O
+the	O
+receptor	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+The	O
+molecular	O
+mass	O
+of	O
+expressed	B-PROC
+S1	O
+was	O
+about	O
+70	O
+kDa	O
+,	O
+which	O
+was	O
+higher	O
+than	O
+that	O
+of	O
+the	O
+30	O
+kDa	O
+expected	O
+.	O
+
+TITLE	O
+:	O
+Pathology	B-DISO
+of	O
+the	O
+thyroid	B-ANAT
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Follicular	B-ANAT
+architecture	O
+was	O
+altered	O
+and	O
+showed	O
+distortion	B-DISO
+,	O
+dilatation	B-DISO
+,	O
+and	O
+collapse	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+is	O
+a	O
+newly	O
+identified	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+that	O
+causes	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+performances	O
+of	O
+four	O
+multiplex	O
+PCR	O
+(	O
+m	O
+-	O
+PCR	O
+)	O
+were	O
+compared	O
+to	O
+direct	O
+immunofluorescence	O
+assay	O
+(	O
+DFA	B-CHED
+)	O
+and	O
+HuH7	O
+cell	B-COMP
+culture	O
+for	O
+the	O
+detection	O
+of	O
+viruses	B-SPEC
+in	O
+263	O
+children	O
+admitted	O
+to	O
+hospital	O
+with	O
+an	O
+acute	O
+respiratory	O
+illness	O
+.	O
+
+The	O
+m	O
+-	O
+PCR	O
+detected	O
+124	O
+viruses	B-SPEC
+which	O
+were	O
+not	O
+found	O
+by	O
+conventional	O
+methods	O
+:	O
+68	O
+rhinovirus	B-SPEC
+,	O
+17	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+15	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+8	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+),	O
+5	O
+coronavirus	B-SPEC
+229E	O
+,	O
+3	O
+OC43	O
+and	O
+3	O
+NL63	O
+,	O
+4	O
+enterovirus	B-SPEC
+,	O
+2	O
+influenza	B-SPEC
+virus	I-SPEC
+B	O
+and	O
+C	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+negative	O
+-	O
+pressure	O
+operating	O
+theater	O
+is	O
+required	O
+to	O
+limit	O
+the	O
+spread	O
+of	O
+respiratory	B-DISO
+diseases	I-DISO
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+tuberculosis	B-DISO
+,	I-DISO
+avian	B-SPEC
+influenza	B-DISO
+,	O
+or	O
+similar	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+introduce	O
+its	O
+ventilation	O
+design	O
+and	O
+evaluate	O
+the	O
+airflow	B-PROC
+performance	O
+in	O
+relation	O
+to	O
+different	O
+combinations	O
+of	O
+medical	O
+lamp	O
+configurations	O
+and	O
+modes	O
+of	O
+launching	O
+infectious	B-DISO
+particles	O
+into	O
+the	O
+room	O
+air	B-CHED
+.	O
+
+The	O
+airflow	B-PROC
+pattern	O
+effectively	O
+controlled	O
+the	O
+dispersion	O
+of	O
+infectious	B-DISO
+particles	O
+.	O
+
+Computational	O
+fluid	O
+dynamics	O
+can	O
+be	O
+used	O
+to	O
+assess	O
+airflow	B-PROC
+in	O
+a	O
+negative	O
+-	O
+pressure	O
+operating	O
+room	O
+and	O
+model	O
+the	O
+dispersion	O
+of	O
+infectious	B-DISO
+particles	O
+from	O
+the	O
+patient	O
+.	O
+
+RESULTS	O
+:	O
+Our	O
+analyses	O
+showed	O
+that	O
+the	O
+airflow	B-PROC
+performance	O
+in	O
+the	O
+negative	O
+-	O
+pressure	O
+operating	O
+theater	O
+was	O
+satisfactory	O
+and	O
+comparable	O
+to	O
+the	O
+original	O
+positive	O
+-	O
+pressure	O
+design	O
+.	O
+
+Applying	O
+this	O
+method	O
+to	O
+SARS	B-DISO
+DNA	O
+sequence	O
+analysis	O
+,	O
+a	O
+characteristic	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+differing	O
+from	O
+non	O
+-	O
+SARS	B-DISO
+is	O
+discovered	O
+.	O
+
+The	O
+use	O
+of	O
+models	O
+leads	O
+to	O
+a	O
+'	O
+made	O
+-	O
+to	O
+-	O
+measure	O
+'	O
+analysis	O
+ofthe	O
+effects	O
+and	O
+costs	O
+of	O
+preventative	O
+and	O
+intervention	O
+measures	O
+which	O
+takes	O
+account	O
+of	O
+the	O
+specific	O
+characteristics	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+envelops	O
+the	O
+genomic	O
+RNA	O
+to	O
+form	O
+long	O
+helical	O
+nucleocapsid	B-COMP
+during	O
+virion	B-PROC
+assembly	I-PROC
+.	O
+
+The	O
+frequency	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+increased	O
+from	O
+1	O
+%	O
+in	O
+2003	O
+-	O
+2004	O
+to	O
+10	O
+%	O
+in	O
+2004	O
+-	O
+2005	O
+.	O
+
+Effective	O
+methods	O
+for	O
+inactivating	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+protein	B-CHED
+solutions	O
+are	O
+described	O
+in	O
+this	O
+report	O
+.	O
+
+The	O
+presence	O
+of	O
+bovine	B-PRGE
+serum	B-COMP
+albumin	I-PRGE
+limited	O
+the	O
+ability	O
+of	O
+UVC	O
+and	O
+UVA	O
+to	O
+inactivate	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+octanoic	B-CHED
+acid	I-CHED
+treatment	O
+does	O
+not	O
+reduce	O
+the	O
+infectivity	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+spiked	O
+protein	B-CHED
+solutions	O
+.	O
+
+RESULTS	O
+:	O
+Viral	O
+inactivation	B-DISO
+by	O
+heat	O
+treatment	O
+at	O
+60	O
+degrees	O
+C	O
+required	O
+15	O
+to	O
+30	O
+minutes	O
+to	O
+inactivate	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+UVC	O
+efficiently	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+40	O
+minutes	O
+,	O
+whereas	O
+UVA	O
+required	O
+the	O
+addition	O
+of	O
+psoralen	B-CHED
+to	O
+enhance	O
+inactivation	B-DISO
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+biosensors	O
+in	O
+the	O
+detection	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+There	O
+is	O
+no	O
+doubt	O
+that	O
+the	O
+glucose	B-CHED
+biosensor	O
+,	O
+the	O
+gene	O
+chip	O
+,	O
+the	O
+protein	B-CHED
+chip	O
+,	O
+etc	O
+.	O
+have	O
+all	O
+played	O
+and	O
+are	O
+still	O
+playing	O
+a	O
+significant	O
+role	O
+in	O
+monitoring	O
+various	O
+biomolecules	O
+.	O
+
+Western	O
+blot	O
+analysis	O
+revealed	O
+the	O
+efficient	O
+expression	B-PROC
+of	O
+both	O
+the	O
+SIP	B-PRGE
+and	O
+IgA	B-PRGE
+molecules	O
+.	O
+
+We	O
+generated	O
+a	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+protein	B-CHED
+-	O
+expressing	O
+recombinant	O
+vaccinia	B-SPEC
+virus	I-SPEC
+(	O
+RVV	O
+-	O
+S	O
+)	O
+using	O
+highly	O
+attenuated	O
+strain	O
+LC16m8	O
+.	O
+
+Intradermal	O
+administration	O
+of	O
+RVV	O
+-	O
+S	O
+into	O
+rabbits	B-SPEC
+induced	O
+neutralizing	O
+(	O
+NT	O
+)	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+1	O
+week	O
+after	O
+administration	O
+and	O
+the	O
+NT	O
+titer	O
+reached	O
+1	O
+:	O
+1000	O
+after	O
+boost	O
+immunization	O
+with	O
+RVV	O
+-	O
+S	O
+.	O
+Significantly	O
+,	O
+NT	O
+antibodies	B-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+induced	O
+by	O
+administration	O
+of	O
+RVV	O
+-	O
+S	O
+to	O
+rabbits	B-SPEC
+that	O
+had	O
+been	O
+pre	O
+-	O
+immunized	O
+with	O
+LC16m8	O
+.	O
+
+These	O
+include	O
+the	O
+integration	B-PROC
+of	O
+the	O
+emergency	B-DISO
+medical	O
+services	O
+and	O
+health	O
+-	O
+facility	O
+medical	O
+systems	O
+with	O
+other	O
+response	O
+systems	O
+;	O
+the	O
+use	O
+of	O
+the	O
+hospital	O
+emergency	O
+incident	O
+command	O
+system	O
+;	O
+crisis	O
+risk	O
+-	O
+communications	O
+approaches	O
+;	O
+and	O
+the	O
+use	O
+of	O
+practical	O
+,	O
+hands	B-ANAT
+-	O
+on	O
+training	O
+programs	O
+.	O
+
+This	O
+comprises	O
+health	O
+requirements	O
+for	O
+inbound	O
+and	O
+outbound	O
+travellers	O
+at	O
+the	O
+border	B-ANAT
+checkpoints	O
+and	O
+global	O
+information	O
+exchange	O
+to	O
+mitigate	O
+the	O
+risks	O
+of	O
+travel	O
+abroad	O
+.	O
+
+Early	O
+initiation	O
+of	O
+ECMO	O
+therapy	O
+along	O
+with	O
+protective	O
+mechanical	O
+ventilation	O
+strategy	O
+resulted	O
+in	O
+an	O
+excellent	O
+maternal	O
+and	O
+fetal	B-ANAT
+outcome	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+can	O
+be	O
+life	O
+saving	O
+when	O
+initiated	O
+early	O
+in	O
+pregnant	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+insufficiency	I-DISO
+unresponsive	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+.	O
+
+Pneumonia	B-DISO
+was	O
+diagnosed	O
+based	O
+on	O
+predefined	O
+criteria	O
+and	O
+retrospectively	O
+confirmed	O
+by	O
+two	O
+observers	O
+.	O
+
+Delaying	O
+intubation	O
+may	O
+increase	O
+the	O
+risk	O
+of	O
+early	O
+-	O
+onset	O
+pneumonia	B-DISO
+.	O
+
+Positive	O
+selection	O
+was	O
+detected	O
+in	O
+the	O
+first	O
+two	O
+groups	O
+,	O
+which	O
+represent	O
+the	O
+course	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+interspecies	O
+transmission	O
+and	O
+of	O
+viral	O
+adaptation	B-PROC
+to	O
+human	B-SPEC
+host	B-COMP
+,	O
+respectively	O
+.	O
+
+These	O
+indicate	O
+that	O
+S	B-PRGE
+protein	I-PRGE
+experiences	O
+variable	O
+positive	O
+selective	O
+pressures	O
+before	O
+reaching	B-PROC
+stabilization	O
+.	O
+
+Coincubation	O
+with	O
+a	O
+minimum	O
+of	O
+10	O
+(	O
+5	O
+)/	O
+ml	O
+of	O
+fluorescent	O
+microspheres	O
+showed	O
+that	O
+particles	O
+with	O
+a	O
+diameter	O
+of	O
+20	O
+nm	O
+but	O
+not	O
+100	O
+nm	O
+crossed	O
+the	O
+ZP	O
+of	O
+murine	B-SPEC
+blastocysts	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+New	O
+and	O
+emerging	O
+diseases	O
+,	O
+combined	O
+with	O
+the	O
+rapid	O
+spread	O
+of	O
+pathogens	O
+resistant	O
+to	O
+antibiotics	O
+and	O
+of	O
+disease	O
+-	O
+carrying	O
+insects	B-SPEC
+resistant	O
+to	O
+insecticides	B-CHED
+,	O
+are	O
+daunting	O
+challenges	O
+to	O
+human	B-SPEC
+health	O
+.	O
+
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+are	O
+almost	O
+instantaneously	O
+a	O
+global	O
+concern	O
+because	O
+of	O
+the	O
+speed	O
+with	O
+which	O
+people	O
+,	O
+animals	B-SPEC
+and	O
+products	O
+move	B-PROC
+around	O
+the	O
+world	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genomic	O
+sequences	O
+,	O
+a	O
+key	O
+residue	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+and	O
+deletions	O
+in	O
+nonstructural	O
+protein	O
+3b	O
+of	O
+US	O
+strains	O
+of	O
+the	O
+virulent	O
+and	O
+attenuated	O
+coronaviruses	O
+,	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+isolates	O
+that	O
+have	O
+been	O
+adapted	O
+to	O
+passage	O
+in	O
+cell	B-COMP
+culture	O
+maintain	O
+their	O
+infectivity	O
+in	O
+vitro	O
+but	O
+may	O
+lose	O
+their	O
+pathogenicity	O
+in	O
+vivo	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+(+)	O
+RNA	O
+coronaviruses	O
+,	O
+replication	O
+and	O
+transcription	O
+of	O
+the	O
+giant	B-DISO
+approximately	O
+30	O
+kb	O
+genome	O
+to	O
+produce	O
+genome	O
+-	O
+and	O
+subgenome	O
+-	O
+size	O
+RNAs	O
+of	O
+both	O
+polarities	O
+are	O
+mediated	O
+by	O
+a	O
+cognate	O
+membrane	B-COMP
+-	O
+bound	O
+enzymatic	O
+complex	O
+.	O
+
+Its	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-PATH
+)	O
+activity	O
+appears	O
+to	O
+be	O
+supplied	O
+by	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+12	O
+(	O
+nsp12	O
+)	O
+that	O
+includes	O
+an	O
+RdRp	B-PATH
+domain	O
+conserved	O
+in	O
+all	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+This	O
+protein	B-CHED
+strongly	O
+prefers	O
+the	O
+internal	O
+5	O
+'-(	O
+G	O
+/	O
+U	O
+)	O
+CC	O
+-	O
+3	O
+'	O
+trinucleotides	O
+on	O
+RNA	O
+templates	O
+to	O
+initiate	O
+the	O
+synthesis	B-PROC
+of	O
+complementary	O
+oligonucleotides	B-CHED
+of	O
+<	O
+6	O
+residues	O
+in	O
+a	O
+reaction	O
+whose	O
+fidelity	O
+is	O
+relatively	O
+low	O
+.	O
+
+Distant	O
+structural	O
+homology	O
+between	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+of	O
+nsp8	O
+and	O
+the	O
+catalytic	O
+palm	B-ANAT
+subdomain	O
+of	O
+RdRps	O
+of	O
+RNA	O
+viruses	B-SPEC
+suggests	O
+a	O
+common	O
+origin	O
+of	O
+the	O
+two	O
+coronavirus	B-SPEC
+RdRps	O
+,	O
+which	O
+however	O
+may	O
+have	O
+evolved	O
+different	O
+sets	O
+of	O
+catalytic	O
+residues	O
+.	O
+
+The	O
+identification	O
+of	O
+a	O
+viral	O
+gene	O
+,	O
+M	O
+,	O
+in	O
+SSH	O
+cDNA	O
+library	O
+shows	O
+the	O
+long	O
+-	O
+term	O
+existence	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+vivo	O
+.	O
+
+In	O
+addition	O
+,	O
+some	O
+oxidative	B-DISO
+stress	I-DISO
+sensitive	O
+genes	O
+,	O
+heat	B-PROC
+shock	I-PROC
+proteins	B-CHED
+,	O
+transcription	B-PROC
+factors	O
+,	O
+and	O
+cytokines	O
+showed	O
+remarkable	O
+elevation	O
+.	O
+
+Similarly	O
+,	O
+the	O
+important	O
+cause	O
+of	O
+mortality	O
+in	O
+2001	O
+was	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+71	O
+.	O
+10	O
+%)	O
+with	O
+predominant	O
+presentation	O
+of	O
+jaundice	B-DISO
+and	O
+renal	B-DISO
+failure	I-DISO
+,	O
+whereas	O
+in	O
+1994	O
+,	O
+it	O
+was	O
+cerebral	B-DISO
+malaria	B-PATH
+(	O
+77	O
+.	O
+96	O
+%).	O
+
+The	O
+observation	O
+of	O
+changing	O
+spectrum	O
+of	O
+severe	O
+malaria	B-PATH
+in	O
+this	O
+study	O
+and	O
+a	O
+significant	O
+increase	O
+in	O
+presentation	O
+with	O
+jaundice	B-DISO
+as	O
+an	O
+important	O
+manifestation	O
+is	O
+highly	O
+essential	O
+for	O
+primary	O
+,	O
+secondary	O
+and	O
+tertiary	O
+level	O
+health	O
+care	O
+providers	O
+for	O
+proper	O
+diagnosis	O
+and	O
+management	O
+.	O
+
+Influenza	B-SPEC
+virus	I-SPEC
+also	O
+causes	O
+a	O
+significant	O
+burden	O
+of	O
+disease	O
+in	O
+young	O
+children	O
+,	O
+although	O
+its	O
+significance	O
+in	O
+children	O
+was	O
+not	O
+fully	O
+recognized	O
+until	O
+recently	O
+.	O
+
+The	O
+escalating	O
+rate	O
+of	O
+emergence	O
+of	O
+new	O
+infectious	B-DISO
+agents	O
+,	O
+fortunately	O
+meeting	O
+with	O
+equally	O
+rapid	O
+advancements	O
+in	O
+molecular	O
+methods	O
+of	O
+surveillance	O
+and	O
+pathogen	O
+discovery	O
+,	O
+means	O
+that	O
+new	O
+organisms	O
+will	O
+soon	O
+be	O
+added	O
+to	O
+the	O
+list	O
+.	O
+
+A	O
+close	O
+relationship	O
+between	O
+bovine	B-SPEC
+coronaviruses	O
+(	O
+BCoVs	O
+)	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+has	O
+recently	O
+been	O
+demonstrated	O
+.	O
+
+Cryptosporidium	B-SPEC
+oocysts	O
+were	O
+detected	O
+in	O
+291	O
+of	O
+779	O
+(	O
+37	O
+.	O
+4	O
+%)	O
+animals	B-SPEC
+.	O
+
+The	O
+prevalence	O
+rates	O
+of	O
+rotavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+and	O
+Escherichia	B-SPEC
+coli	I-SPEC
+K99	O
++	O
+were	O
+lower	O
+as	O
+seen	O
+in	O
+242	O
+of	O
+806	O
+(	O
+30	O
+.	O
+0	O
+%),	O
+46	O
+/	O
+806	O
+(	O
+5	O
+.	O
+7	O
+%),	O
+and	O
+16	O
+/	O
+421	O
+(	O
+3	O
+.	O
+8	O
+%)	O
+of	O
+animals	B-SPEC
+,	O
+respectively	O
+.	O
+
+in	O
+calves	O
+and	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Numerous	O
+studies	O
+have	O
+suggested	O
+that	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+used	O
+as	O
+rescue	O
+therapy	O
+may	O
+improve	O
+oxygenation	B-PROC
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+.	O
+
+In	O
+1918	O
+,	O
+Toronto	O
+'	O
+s	O
+MOH	O
+Charles	O
+Hastings	O
+was	O
+the	O
+acknowledged	O
+leader	O
+of	O
+efforts	O
+to	O
+contain	O
+the	O
+disease	O
+,	O
+care	O
+for	O
+the	O
+sick	O
+,	O
+and	O
+develop	O
+an	O
+effective	O
+vaccine	O
+,	O
+because	O
+neither	O
+a	O
+federal	O
+health	O
+department	O
+nor	O
+an	O
+international	O
+body	B-ANAT
+like	O
+WHO	O
+existed	O
+.	O
+
+With	O
+growing	O
+concern	O
+about	O
+a	O
+flu	O
+pandemic	O
+,	O
+the	O
+lessons	O
+of	O
+the	O
+past	O
+provide	O
+a	O
+foundation	O
+for	O
+future	O
+communicable	B-DISO
+disease	I-DISO
+control	O
+activities	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+Recent	O
+studies	O
+have	O
+suggested	O
+a	O
+remote	O
+effect	O
+of	O
+ARF	B-DISO
+on	O
+pulmonary	B-ANAT
+homeostasis	B-PROC
+.	O
+
+For	O
+elucidation	O
+of	O
+the	O
+impact	O
+of	O
+ARF	B-DISO
+on	O
+aseptic	O
+ALI	O
+,	O
+a	O
+murine	B-SPEC
+two	O
+-	O
+hit	O
+model	O
+that	O
+consists	O
+of	O
+acute	O
+uremia	B-DISO
+(	O
+AU	O
+)	O
+and	O
+subsequent	O
+ALI	O
+was	O
+developed	O
+.	O
+
+Between	O
+normal	O
+and	O
+uremic	O
+neutrophils	B-ANAT
+,	O
+there	O
+were	O
+no	O
+differences	O
+in	O
+apoptosis	B-PATH
+or	O
+superoxide	B-CHED
+production	O
+.	O
+
+In	O
+conclusion	O
+,	O
+it	O
+is	O
+shown	O
+that	O
+AU	O
+but	O
+not	O
+renal	B-ANAT
+inflammation	B-DISO
+attenuates	O
+aseptic	O
+,	O
+neutrophil	B-ANAT
+-	O
+dependent	O
+ALI	O
+and	O
+exerts	B-PROC
+an	O
+anti	O
+-	O
+inflammatory	O
+effect	O
+by	O
+attenuating	O
+pulmonary	B-ANAT
+neutrophil	B-PROC
+recruitment	B-DISO
+.	O
+
+The	O
+antibody	B-COMP
+was	O
+used	O
+as	O
+target	O
+and	O
+three	O
+rounds	O
+of	O
+bio	O
+-	O
+panning	O
+were	O
+conducted	O
+with	O
+phage	O
+-	O
+display	O
+peptide	B-CHED
+library	O
+.	O
+
+After	O
+the	O
+third	O
+panning	O
+,	O
+20	O
+phage	O
+-	O
+plague	B-DISO
+clones	O
+were	O
+randomly	O
+picked	O
+and	O
+analyzed	O
+for	O
+the	O
+binding	B-FUNC
+ability	O
+with	O
+the	O
+MAb	O
+2C5	O
+by	O
+ELISA	O
+.	O
+
+Interestingly	O
+,	O
+mutagenesis	B-PROC
+of	O
+Tyr414	O
+showed	O
+that	O
+while	O
+this	O
+residue	O
+can	O
+tolerate	O
+a	O
+number	O
+of	O
+substitutions	O
+,	O
+it	O
+was	O
+intolerant	O
+of	O
+Lysine	O
+or	O
+deletion	O
+.	O
+
+TITLE	O
+:	O
+The	O
+nsp2	B-PRGE
+proteins	I-PRGE
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+and	O
+SARS	B-DISO
+coronavirus	B-SPEC
+are	O
+dispensable	O
+for	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+SCID	B-DISO
+-	O
+PBL	O
+/	O
+hu	O
+mice	B-SPEC
+were	O
+immunized	O
+with	O
+SARS	B-DISO
+(	O
+N	O
+)	O
+DNA	O
+or	O
+(	O
+M	O
+)	O
+DNA	O
+and	O
+analyzed	O
+for	O
+a	O
+human	B-SPEC
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+immune	B-PROC
+response	I-PROC
+.	O
+
+Furthermore	O
+,	O
+the	O
+SARS	B-DISO
+N	O
+DNA	O
+vaccine	O
+induced	O
+CTL	B-ANAT
+activity	O
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+production	O
+by	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+or	O
+N	B-PRGE
+protein	I-PRGE
+-	O
+pulsed	O
+autologous	O
+B	O
+blast	B-ANAT
+cells	I-ANAT
+)	O
+and	O
+proliferation	B-DISO
+of	O
+spleen	B-ANAT
+cells	B-COMP
+in	O
+SCID	B-DISO
+-	O
+PBL	O
+/	O
+hu	O
+mice	B-SPEC
+.	O
+
+By	O
+immobilizing	O
+the	O
+DNA	O
+probe	O
+through	O
+the	O
+use	O
+of	O
+GBP	O
+-	O
+fused	O
+cSA	B-DISO
+,	O
+specific	O
+hybridization	B-PROC
+of	O
+the	O
+target	O
+DNA	O
+prepared	O
+from	O
+Salmonella	B-DISO
+could	O
+also	O
+be	O
+achieved	O
+.	O
+
+TITLE	O
+:	O
+The	O
+relationship	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+with	O
+avian	B-SPEC
+and	O
+other	O
+coronaviruses	O
+.	O
+
+An	O
+enormous	O
+,	O
+previously	O
+unrecognized	O
+reservoir	O
+of	O
+coronaviruses	O
+exists	O
+among	O
+animals	B-SPEC
+.	O
+
+Vaccine	O
+development	B-PROC
+is	O
+a	O
+key	O
+component	O
+in	O
+the	O
+prevention	O
+of	O
+widespread	O
+viral	B-DISO
+infection	I-DISO
+and	O
+in	O
+the	O
+reduction	O
+of	O
+morbidity	O
+and	O
+mortality	O
+associated	O
+with	O
+many	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+These	O
+animals	B-SPEC
+developed	O
+a	O
+less	O
+robust	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+response	O
+to	O
+MHV	B-SPEC
+-	O
+1	O
+infection	B-DISO
+than	O
+resistant	O
+C57BL	O
+/	O
+6J	O
+mice	B-SPEC
+,	O
+and	O
+treatment	O
+with	O
+recombinant	B-PRGE
+beta	I-PRGE
+interferon	I-PRGE
+improved	O
+survival	O
+.	O
+
+Certain	O
+families	O
+of	O
+bats	B-SPEC
+including	O
+the	O
+Pteropodidae	B-SPEC
+,	O
+Molossidae	B-SPEC
+,	O
+Phyllostomidae	B-SPEC
+,	O
+and	O
+Vespertilionidae	B-SPEC
+are	O
+most	O
+frequently	O
+associated	O
+with	O
+known	O
+human	B-SPEC
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+recovery	O
+from	O
+post	O
+-	O
+traumatic	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+17	O
+-	O
+year	O
+-	O
+old	O
+patient	O
+who	O
+had	O
+sustained	O
+blunt	O
+thoracic	B-DISO
+trauma	O
+presented	O
+with	O
+severe	O
+hypoxaemia	O
+on	O
+admission	O
+and	O
+whole	B-ANAT
+body	I-ANAT
+computed	O
+tomography	O
+showed	O
+pulmonary	B-ANAT
+contusion	O
+and	O
+substantial	O
+bilateral	O
+atelectasis	B-DISO
+.	O
+
+Therefore	O
+we	O
+applied	O
+an	O
+alveolar	B-ANAT
+recruitment	B-DISO
+manoeuvre	O
+7	O
+h	O
+after	O
+admission	O
+.	O
+
+Oxygenation	B-PROC
+and	O
+lung	B-PROC
+compliance	I-PROC
+improved	O
+rapidly	O
+and	O
+aeration	O
+of	O
+the	O
+entire	B-ANAT
+lung	I-ANAT
+was	O
+confirmed	O
+by	O
+computed	O
+tomography	O
+27	O
+h	O
+after	O
+the	O
+recruitment	B-DISO
+manoeuvre	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Although	O
+robust	O
+evidence	O
+is	O
+still	O
+lacking	O
+,	O
+several	O
+lines	O
+of	O
+evidence	O
+suggest	O
+potential	O
+benefits	O
+of	O
+timely	O
+alveolar	B-ANAT
+recruitment	B-DISO
+.	O
+
+TITLE	O
+:	O
+Social	O
+support	O
+during	O
+intensive	O
+care	O
+unit	O
+stay	O
+might	O
+improve	O
+mental	B-DISO
+impairment	I-DISO
+and	O
+consequently	O
+health	O
+-	O
+related	O
+quality	O
+of	O
+life	O
+in	O
+survivors	O
+of	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+We	O
+wished	O
+to	O
+evaluate	O
+the	O
+influence	O
+of	O
+PTSD	B-DISO
+on	O
+HRQoL	O
+and	O
+to	O
+investigate	O
+the	O
+influence	O
+of	O
+perceived	O
+social	O
+support	O
+during	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+treatment	O
+on	O
+both	O
+PTSD	B-DISO
+symptoms	O
+and	O
+HRQoL	O
+.	O
+In	O
+ARDS	B-DISO
+patients	O
+we	O
+prospectively	O
+measured	O
+HRQoL	O
+(	O
+Medical	O
+Outcomes	O
+Study	O
+36	O
+-	O
+Item	O
+Short	O
+Form	O
+;	O
+SF	O
+-	O
+36	O
+),	O
+symptoms	O
+of	O
+PTSD	B-DISO
+(	O
+Post	B-DISO
+-	I-DISO
+Traumatic	I-DISO
+Stress	I-DISO
+Syndrome	I-DISO
+10	O
+-	O
+Questions	O
+Inventory	O
+;	O
+PTSS	O
+-	O
+10	O
+),	O
+perceived	O
+social	O
+support	O
+(	O
+Questionnaire	O
+for	O
+Social	O
+Support	O
+;	O
+F	O
+-	O
+Sozu	O
+)	O
+and	O
+symptoms	O
+of	O
+psychopathology	O
+(	O
+Symptom	B-DISO
+Checklist	O
+-	O
+90	O
+-	O
+R	O
+);	O
+and	O
+collected	O
+sociodemographic	O
+data	O
+including	O
+current	O
+employment	O
+status	O
+.	O
+
+In	O
+this	O
+group	O
+of	O
+patients	O
+there	O
+was	O
+a	O
+trend	O
+towards	O
+permanent	O
+or	O
+temporary	O
+disability	O
+,	O
+independent	O
+of	O
+the	O
+period	O
+between	O
+discharge	B-ANAT
+from	O
+ICU	O
+and	O
+study	O
+entry	O
+.	O
+
+The	O
+latter	O
+displayed	O
+a	O
+less	O
+severe	O
+infection	B-DISO
+and	O
+presented	O
+detectable	O
+levels	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+as	O
+nitrosyl	B-CHED
+complexes	O
+in	O
+blood	B-ANAT
+and	O
+liver	B-ANAT
+at	O
+72	O
+hpi	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+released	O
+from	O
+macrophages	B-ANAT
+and	O
+TNF	B-PRGE
+-	I-PRGE
+receptor	I-PRGE
+(	I-PRGE
+TNFR	I-PRGE
+)	I-PRGE
+1	I-PRGE
+and	O
+TNFR2	B-PRGE
+mRNA	I-PRGE
+expression	B-PROC
+in	O
+lymphocytes	B-ANAT
+were	O
+closely	O
+involved	O
+in	O
+this	O
+apoptosis	B-PROC
+induction	I-PROC
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+suggest	O
+that	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+produced	O
+by	O
+virus	B-SPEC
+-	O
+infected	O
+macrophages	B-ANAT
+,	O
+is	O
+responsible	O
+for	O
+induction	B-PROC
+of	I-PROC
+apoptosis	I-PROC
+in	O
+uninfected	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+primarily	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Both	O
+molecular	O
+modeling	O
+and	O
+Q189A	O
+mutation	O
+revealed	O
+that	O
+Gln189	O
+plays	O
+a	O
+key	O
+role	O
+in	O
+the	O
+binding	B-FUNC
+.	O
+
+Bioassay	O
+results	O
+reveal	O
+salient	O
+features	O
+of	O
+the	O
+structure	O
+-	O
+activity	O
+relationship	O
+of	O
+the	O
+new	O
+compounds	O
+:	O
+(	O
+1	O
+)	O
+removal	O
+of	O
+the	O
+7	O
+-	O
+hydroxy	O
+group	O
+of	O
+the	O
+quercetin	B-CHED
+moiety	O
+decreases	O
+the	O
+bioactivity	O
+of	O
+the	O
+derivatives	O
+;	O
+(	O
+2	O
+)	O
+acetoxylation	O
+of	O
+the	O
+sugar	O
+moiety	O
+abolishes	O
+inhibitor	B-CHED
+action	O
+;	O
+(	O
+3	O
+)	O
+introduction	O
+of	O
+a	O
+large	O
+sugar	O
+substituent	O
+on	O
+7	O
+-	O
+hydroxy	B-CHED
+of	O
+quercetin	B-CHED
+can	O
+be	O
+tolerated	O
+;	O
+(	O
+4	O
+)	O
+replacement	O
+of	O
+the	O
+galactose	B-CHED
+moiety	O
+with	O
+other	O
+sugars	O
+does	O
+not	O
+affect	O
+inhibitor	B-CHED
+potency	O
+.	O
+
+Covariates	O
+positively	O
+associated	O
+with	O
+transmission	O
+in	O
+univariate	O
+analysis	O
+at	O
+p	O
+<	O
+0	O
+.	O
+05	O
+included	O
+delay	O
+to	O
+isolation	O
+(	O
+Day	O
+7	O
+of	O
+illness	O
+or	O
+later	O
+),	O
+admission	O
+to	O
+a	O
+non	O
+-	O
+isolation	O
+facility	O
+,	O
+pre	O
+-	O
+existing	O
+chronic	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+and	O
+immunosuppressive	O
+disease	O
+,	O
+need	O
+for	O
+oxygen	B-CHED
+,	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+and	O
+higher	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+levels	O
+and	O
+higher	O
+neutrophil	B-ANAT
+counts	O
+.	O
+
+The	O
+potential	O
+anti	O
+-	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+activity	O
+of	O
+the	O
+POMs	O
+[	O
+alpha	O
+-	O
+PTi	B-CHED
+(	O
+2	O
+)	O
+W	O
+(	O
+10	O
+)	O
+O	O
+(	O
+40	O
+)](	O
+7	O
+-)	O
+isomers	O
+was	O
+investigated	O
+in	O
+this	O
+paper	O
+by	O
+molecular	O
+modeling	O
+method	O
+.	O
+
+Affinity	O
+/	O
+Insight	O
+II	O
+was	O
+used	O
+to	O
+explore	O
+possible	O
+binding	B-FUNC
+locations	O
+for	O
+POMs	O
+/	O
+3CL	O
+(	O
+pro	B-PRGE
+)	O
+interaction	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+hygiene	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+.	O
+
+The	O
+possible	O
+predisposing	O
+and	O
+perpetuating	O
+factors	O
+in	O
+developing	O
+mental	B-DISO
+symptoms	I-DISO
+were	O
+investigated	O
+.	O
+
+Participantsconsisted	O
+of	O
+135	O
+health	O
+care	O
+workers	O
+who	O
+had	O
+had	O
+contact	O
+with	O
+or	O
+took	O
+care	O
+of	O
+patients	O
+who	O
+were	O
+probable	O
+or	O
+suspected	O
+SARS	B-DISO
+cases	O
+,	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+at	O
+a	O
+teaching	O
+hospital	O
+in	O
+southern	O
+Taiwan	O
+.	O
+
+3	O
+.	O
+8	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+/	O
+l	O
+and	O
+5	O
+.	O
+6	O
++/-	O
+
+TITLE	O
+:	O
+Mosaic	O
+structure	O
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+,	O
+one	O
+thousand	O
+years	O
+of	O
+evolution	B-PROC
+.	O
+
+The	O
+genomes	O
+are	O
+27	O
+,	O
+538	O
+and	O
+27	O
+,	O
+550	O
+nucleotides	B-CHED
+long	O
+,	O
+respectively	O
+,	O
+and	O
+share	O
+the	O
+same	O
+genome	O
+organization	O
+.	O
+
+Using	O
+this	O
+evolutionary	O
+rate	O
+we	O
+determined	O
+that	O
+HCoV	O
+-	O
+NL63	O
+diverged	O
+in	O
+the	O
+11th	O
+century	O
+from	O
+its	O
+closest	O
+relative	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+Flow	O
+cytometry	O
+and	O
+ELISPOT	O
+analysis	O
+of	O
+lymphocytes	O
+as	O
+well	O
+as	O
+a	O
+serologic	O
+analysis	O
+of	O
+antibody	B-COMP
+showed	O
+that	O
+these	O
+peptides	B-CHED
+could	O
+trigger	O
+a	O
+rapid	O
+,	O
+highly	O
+effective	O
+,	O
+and	O
+relatively	O
+safe	O
+immune	B-PROC
+response	I-PROC
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+Fusion	O
+protein	B-CHED
+between	O
+green	B-PRGE
+fluorescence	I-PRGE
+protein	I-PRGE
+(	O
+GFP	B-CHED
+)	O
+and	O
+S450	O
+-	O
+650	O
+(	O
+S450	O
+-	O
+650	O
+-	O
+GFP	B-CHED
+)	O
+was	O
+able	O
+to	O
+stain	O
+Vero	O
+E6	O
+cells	B-COMP
+and	O
+deletion	O
+of	O
+the	O
+beta6	B-PRGE
+fragment	I-PRGE
+rendered	O
+the	O
+fusion	O
+product	O
+(	O
+S511	O
+-	O
+650	O
+-	O
+GFP	B-CHED
+)	O
+unable	O
+to	O
+do	O
+so	O
+.	O
+
+The	O
+effects	O
+of	O
+some	O
+crucial	O
+parameters	O
+,	O
+such	O
+as	O
+buffer	B-CHED
+type	O
+,	O
+pH	O
+,	O
+wavelength	O
+and	O
+running	O
+voltage	B-CHED
+on	O
+the	O
+separation	B-DISO
+were	O
+studied	O
+systematically	O
+.	O
+
+One	O
+hundred	O
+millimolars	O
+sodium	B-CHED
+tetraborate	I-CHED
+buffer	B-CHED
+containing	O
+20	O
+mM	O
+sodium	B-CHED
+dihydrogen	I-CHED
+phosphate	I-CHED
+with	O
+a	O
+final	O
+pH	O
+9	O
+.	O
+8	O
+was	O
+used	O
+as	O
+a	O
+running	O
+buffer	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+March	O
+2003	O
+,	O
+the	O
+Institute	O
+of	O
+Medicine	B-CHED
+published	O
+an	O
+update	O
+to	O
+its	O
+1992	O
+landmark	O
+report	O
+on	O
+emerging	O
+infections	B-DISO
+.	O
+
+An	O
+unprecedented	O
+worldwide	O
+collaborative	O
+effort	B-PROC
+was	O
+undertaken	O
+to	O
+determine	O
+the	O
+cause	O
+of	O
+the	O
+illness	O
+and	O
+implement	O
+prevention	O
+measures	O
+.	O
+
+The	O
+emergence	O
+of	O
+SARS	B-DISO
+is	O
+a	O
+timely	O
+reminder	O
+of	O
+the	O
+need	O
+to	O
+expect	O
+the	O
+unexpected	O
+and	O
+to	O
+ensure	O
+strong	O
+national	O
+and	O
+global	O
+public	O
+health	O
+partnerships	O
+when	O
+preparing	O
+for	O
+and	O
+responding	O
+to	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+Where	O
+do	O
+pets	O
+fit	B-DISO
+into	O
+human	B-SPEC
+quarantines	O
+?	O
+
+The	O
+possible	O
+role	O
+of	O
+household	O
+pets	O
+in	O
+disease	B-DISO
+transmission	I-DISO
+in	O
+community	O
+-	O
+based	O
+quarantines	O
+has	O
+previously	O
+been	O
+overlooked	O
+.	O
+
+RM	O
+was	O
+effective	O
+in	O
+17	O
+patients	O
+except	O
+one	O
+case	O
+of	O
+severe	O
+pulmonary	B-DISO
+infection	I-DISO
+,	O
+whose	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+was	O
+only	O
+improved	O
+by	O
+40	O
+%.	O
+
+Sepsis	B-DISO
+syndrome	I-DISO
+often	O
+induces	O
+severe	O
+pulmonary	B-ANAT
+lesions	O
+with	O
+a	O
+picture	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Previous	O
+work	O
+has	O
+pointed	O
+to	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+telomeres	B-COMP
+and	O
+DNA	B-PROC
+repair	I-PROC
+pathways	B-PROC
+as	O
+important	O
+and	O
+distinct	O
+determinants	O
+of	O
+a	O
+normal	O
+healthy	O
+lifespan	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+explored	O
+the	O
+genetic	O
+interactions	O
+of	O
+telomeres	B-COMP
+and	O
+DNA	B-PRGE
+-	I-PRGE
+PKcs	I-PRGE
+,	O
+a	O
+protein	B-CHED
+involved	O
+in	O
+non	B-PATH
+-	I-PATH
+homologous	I-PATH
+end	I-PATH
+-	I-PATH
+joining	I-PATH
+(	O
+NHEJ	B-PROC
+)	O
+and	O
+immune	B-PROC
+responses	I-PROC
+,	O
+in	O
+the	O
+context	O
+of	O
+a	O
+key	O
+aspect	O
+of	O
+aging	B-PROC
+and	O
+lifespan	O
+--	O
+the	O
+capacity	O
+to	O
+mount	O
+an	O
+acute	O
+and	O
+appropriate	O
+immune	O
+-	O
+mediated	O
+stress	B-PATH
+response	I-PATH
+.	O
+
+These	O
+results	O
+raise	O
+speculation	O
+that	O
+these	O
+genetic	O
+factors	O
+may	O
+contribute	O
+to	O
+misdirected	O
+immune	B-PROC
+responses	I-PROC
+of	O
+the	O
+aged	O
+under	O
+conditions	O
+of	O
+acute	O
+and	O
+chronic	O
+stress	O
+.	O
+
+Notably	O
+,	O
+attenuated	O
+PEDV	B-SPEC
+DR13	O
+has	O
+previously	O
+been	O
+found	O
+to	O
+exhibit	O
+reduced	O
+pathogenicity	O
+in	O
+pigs	B-SPEC
+.	O
+
+After	O
+the	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+scares	O
+[	O
+1	O
+],	O
+attention	O
+has	O
+turned	O
+towards	O
+the	O
+possibility	O
+of	O
+an	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+hybridizing	O
+with	O
+a	O
+human	B-DISO
+influenza	B-SPEC
+virus	I-SPEC
+to	O
+create	O
+a	O
+highly	O
+virulent	O
+,	O
+as	O
+yet	O
+unknown	O
+,	O
+killer	O
+,	O
+on	O
+a	O
+scale	O
+unseen	O
+since	O
+the	O
+Spanish	O
+flu	B-DISO
+outbreak	O
+of	O
+1918	O
+,	O
+which	O
+produced	O
+more	O
+fatalities	O
+than	O
+the	O
+Great	O
+War	O
+.	O
+
+In	O
+deciding	O
+how	O
+countries	O
+should	O
+react	O
+to	O
+this	O
+potential	O
+pandemic	O
+,	O
+individually	O
+and	O
+collectively	O
+,	O
+a	O
+reasonable	O
+and	O
+practical	O
+balance	B-PROC
+must	O
+be	O
+struck	B-DISO
+between	O
+the	O
+rights	O
+and	O
+obligations	O
+of	O
+individual	O
+citizens	O
+and	O
+protection	O
+of	O
+the	O
+wider	O
+community	O
+and	O
+,	O
+indeed	O
+,	O
+society	O
+as	O
+a	O
+whole	O
+.	O
+
+In	O
+this	O
+communication	O
+,	O
+ethical	O
+issues	O
+are	O
+discussed	O
+in	O
+the	O
+context	O
+of	O
+some	O
+of	O
+the	O
+scientific	O
+questions	O
+relating	O
+to	O
+a	O
+potential	O
+influenza	B-DISO
+pandemic	O
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+has	O
+been	O
+proposed	O
+that	O
+immune	O
+injury	O
+is	O
+the	O
+central	O
+mechanism	O
+of	O
+pathogenesis	O
+of	O
+the	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+We	O
+performed	O
+autopsies	O
+on	O
+six	O
+confirmed	O
+SARS	B-DISO
+cases	O
+,	O
+with	O
+six	O
+normal	O
+subjects	O
+as	O
+controls	O
+;	O
+spleen	B-ANAT
+samples	O
+from	O
+these	O
+autopsies	O
+were	O
+examined	O
+with	O
+hematoxylin	B-CHED
+and	O
+eosin	O
+(	O
+H	O
+&	O
+E	O
+)	O
+sections	O
+,	O
+in	O
+situ	O
+hybridization	B-PROC
+for	O
+SARS	B-DISO
+virus	B-SPEC
+genomic	O
+sequences	O
+,	O
+and	O
+immunohistochemistry	O
+with	O
+seven	O
+monoclonal	O
+antibodies	B-COMP
+to	O
+five	O
+cell	B-COMP
+types	O
+.	O
+
+The	O
+SARS	B-DISO
+spleens	B-ANAT
+all	O
+had	O
+severe	O
+damage	O
+to	O
+the	O
+white	B-ANAT
+pulp	I-ANAT
+and	O
+showed	O
+an	O
+alteration	O
+of	O
+the	O
+normal	O
+distribution	O
+of	O
+various	O
+cell	B-COMP
+types	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+identify	O
+routine	O
+laboratory	O
+variables	O
+that	O
+might	O
+indicate	O
+the	O
+need	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+testing	O
+.	O
+
+TITLE	O
+:	O
+Mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+does	O
+not	O
+induce	O
+Beta	B-PRGE
+interferon	I-PRGE
+synthesis	B-PROC
+and	O
+does	O
+not	O
+inhibit	O
+its	O
+induction	O
+by	O
+double	O
+-	O
+stranded	O
+RNA	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+show	O
+that	O
+the	O
+essential	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+transcription	I-PRGE
+factors	I-PRGE
+NF	I-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+and	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+are	O
+not	O
+activated	O
+for	O
+nuclear	B-PROC
+translocation	I-PROC
+and	O
+gene	B-PROC
+induction	I-PROC
+during	O
+infection	B-DISO
+.	O
+
+However	O
+,	O
+MHV	B-SPEC
+was	O
+unable	O
+to	O
+inhibit	O
+the	O
+activation	O
+of	O
+these	O
+factors	O
+and	O
+subsequent	O
+IFN	B-PROC
+-	I-PROC
+beta	I-PROC
+production	I-PROC
+induced	O
+by	O
+poly	O
+(	O
+I	O
+:	O
+C	O
+).	O
+
+Further	O
+,	O
+MHV	B-SPEC
+infection	B-DISO
+did	O
+not	O
+inhibit	O
+IFN	B-PROC
+-	I-PROC
+beta	I-PROC
+production	I-PROC
+mediated	O
+by	O
+known	O
+host	B-COMP
+pattern	O
+recognition	O
+receptors	O
+(	O
+PRRs	B-DISO
+)	O
+(	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+,	O
+Mda	B-PRGE
+-	I-PRGE
+5	I-PRGE
+,	O
+and	O
+TLR3	B-PRGE
+).	O
+
+This	O
+model	O
+of	O
+lethal	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+should	O
+be	O
+useful	O
+for	O
+studies	O
+of	O
+pathogenesis	B-DISO
+and	O
+for	O
+the	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+therapies	O
+.	O
+
+Of	O
+the	O
+eight	O
+putative	O
+accessory	O
+proteins	B-CHED
+encoded	O
+by	O
+the	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+only	O
+two	O
+-	O
+open	O
+reading	O
+frame	O
+3a	O
+(	O
+ORF3a	O
+)	O
+and	O
+ORF7a	O
+-	O
+have	O
+been	O
+identified	O
+in	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+to	O
+date	O
+.	O
+
+The	O
+ORF7b	B-PRGE
+protein	I-PRGE
+is	O
+a	O
+putative	O
+viral	O
+accessory	O
+protein	B-CHED
+encoded	O
+on	O
+subgenomic	O
+(	O
+sg	O
+)	O
+RNA	O
+7	O
+.	O
+
+ORF7b	O
+localizes	O
+to	O
+the	O
+Golgi	B-COMP
+compartment	B-ANAT
+and	O
+is	O
+incorporated	O
+into	O
+SARS	B-DISO
+-	O
+CoV	O
+particles	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+on	O
+weaning	B-PROC
+from	O
+mechanical	O
+ventilation	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+The	O
+inclusion	O
+criterion	O
+was	O
+invasive	O
+mechanical	O
+ventilation	O
+for	O
+>	O
+or	O
+=	O
+48	O
+hrs	B-DISO
+.	O
+
+These	O
+autoAb	O
+bound	O
+mainly	O
+to	O
+N	O
+-	O
+and	O
+C	B-PRGE
+-	I-PRGE
+terminal	I-PRGE
+FAH	I-PRGE
+peptides	I-PRGE
+,	O
+the	O
+most	O
+reactive	O
+sequences	O
+being	O
+1	O
+-	O
+50	O
+and	O
+390	O
+-	O
+420	O
+,	O
+respectively	O
+.	O
+
+Herein	O
+,	O
+we	O
+show	O
+that	O
+this	O
+response	O
+is	O
+similarly	O
+public	O
+when	O
+the	O
+NP366	O
++	O
+Vbeta4	O
++	O
+CD8	B-PRGE
+T	I-PRGE
+cell	O
+response	O
+is	O
+analyzed	O
+.	O
+
+Therefore	O
+,	O
+even	O
+in	O
+CD8	B-PRGE
+T	I-PRGE
+cell	O
+responses	O
+that	O
+appear	O
+to	O
+be	O
+oligoclonotypic	O
+,	O
+the	O
+total	O
+response	O
+is	O
+highly	O
+diverse	O
+.	O
+
+TITLE	O
+:	O
+Insight	O
+into	O
+the	O
+activity	O
+of	O
+SARS	B-PRGE
+main	I-PRGE
+protease	I-PRGE
+:	O
+Molecular	B-PROC
+dynamics	I-PROC
+study	O
+of	O
+dimeric	O
+and	O
+monomeric	O
+form	O
+of	O
+enzyme	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+phenomenon	O
+that	O
+SARS	O
+coronavirus	B-SPEC
+main	O
+protease	O
+(	O
+SARS	B-DISO
+M	O
+(	O
+pro	B-CHED
+))	O
+dimer	O
+is	O
+the	O
+main	O
+functional	O
+form	O
+has	O
+been	O
+confirmed	O
+by	O
+experiment	O
+.	O
+
+At	O
+present	O
+,	O
+only	O
+the	O
+first	O
+two	O
+conditions	O
+have	O
+been	O
+met	B-CHED
+.	O
+
+Expected	O
+worldwide	O
+human	B-SPEC
+mortality	O
+from	O
+a	O
+moderate	O
+pandemic	O
+scenario	O
+is	O
+45	O
+million	O
+people	O
+or	O
+more	O
+than	O
+75	O
+%	O
+of	O
+the	O
+current	O
+annual	O
+global	O
+death	B-PROC
+burden	O
+.	O
+
+Donor	O
+support	O
+in	O
+financial	O
+,	O
+material	O
+and	O
+technical	O
+assistance	O
+remains	O
+critical	O
+to	O
+disease	O
+control	O
+efforts	O
+-	O
+particularly	O
+in	O
+developing	O
+countries	O
+where	O
+avian	B-DISO
+influenza	I-DISO
+predominately	O
+occurs	O
+at	O
+present	O
+.	O
+
+Nine	O
+children	O
+weighted	O
+3	O
+.	O
+1	O
+kg	O
+-	O
+14	O
+.	O
+0	O
+kg	O
+with	O
+septic	B-DISO
+shock	I-DISO
+were	O
+treated	O
+with	O
+continuous	O
+veno	O
+-	O
+venous	B-ANAT
+hemofiltration	O
+(	O
+CVVH	O
+)	O
+which	O
+is	O
+also	O
+referred	O
+to	O
+as	O
+CBP	B-PRGE
+with	O
+blood	B-ANAT
+access	O
+of	O
+double	O
+-	O
+lumen	B-ANAT
+hemodialysis	O
+catheter	O
+of	O
+6	O
+.	O
+5	O
+to	O
+8Fr	O
+inserted	O
+via	O
+central	B-ANAT
+vein	I-ANAT
+,	O
+hemofilters	O
+of	O
+Minifilter	O
+plus	O
+(	O
+for	O
+children	O
+with	O
+body	B-ANAT
+weight	O
+<	O
+5	O
+kg	O
+)	O
+or	O
+AV400s	O
+(	O
+for	O
+children	O
+with	O
+body	B-ANAT
+weight	O
+>	O
+or	O
+=	O
+5	O
+kg	O
+),	O
+child	O
+'	O
+s	O
+type	O
+extracorporeal	O
+circuit	O
+vessel	B-ANAT
+and	O
+heparin	B-CHED
+anticoagulation	B-PROC
+.	O
+
+33	O
+,	O
+CRT	B-CHED
+>	O
+5	O
+s	O
+,	O
+urine	B-ANAT
+output	O
+was	O
+0	O
+.	O
+85	O
++/-	O
+
+63	O
+,	O
+CRT	B-CHED
+<	O
+2	O
+s	O
+,	O
+and	O
+the	O
+adrenalin	B-CHED
+dosage	O
+0	O
+.	O
+08	O
++/-	O
+
+Both	O
+cohorts	O
+completed	O
+standardized	O
+rating	O
+scales	B-ANAT
+on	O
+depression	B-DISO
+,	O
+anxiety	O
+,	O
+and	O
+social	O
+support	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+the	O
+occurrence	O
+of	O
+bacterial	O
+,	O
+mycoplasmal	O
+and	O
+viral	O
+pathogens	O
+in	O
+the	O
+lower	O
+respiratory	O
+tract	O
+of	O
+calves	O
+in	O
+all	O
+-	O
+in	O
+all	O
+-	O
+out	O
+calf	B-ANAT
+-	O
+rearing	O
+units	O
+.	O
+
+TBL	B-CHED
+samples	O
+from	O
+healthy	O
+or	O
+suspect	O
+calves	O
+were	O
+more	O
+often	O
+negative	O
+in	O
+bacterial	O
+culture	O
+than	O
+samples	O
+from	O
+diseased	O
+calves	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Forty	O
+years	O
+of	O
+clinical	O
+and	O
+basic	O
+science	O
+research	O
+have	O
+elaborated	O
+many	O
+of	O
+the	O
+pathophysiologic	O
+mechanisms	O
+that	O
+link	O
+initiating	O
+insults	O
+to	O
+the	O
+development	B-PROC
+of	O
+alveolar	B-ANAT
+membrane	B-COMP
+failure	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+affects	O
+some	O
+10	O
+%	O
+to	O
+15	O
+%	O
+of	O
+ICU	O
+patients	O
+and	O
+is	O
+associated	O
+with	O
+mortality	O
+rates	O
+of	O
+40	O
+%	O
+to	O
+50	O
+%.	O
+
+Improved	O
+understanding	O
+of	O
+the	O
+systemic	O
+factors	O
+involved	O
+in	O
+the	O
+development	B-PROC
+and	O
+evolution	B-PROC
+of	O
+ARDS	B-DISO
+and	O
+MODS	B-DISO
+should	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+new	O
+therapeutic	O
+agents	O
+that	O
+will	O
+improve	O
+outcomes	O
+in	O
+these	O
+patients	O
+.	O
+
+A	O
+total	O
+of	O
+192	O
+rats	B-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+three	O
+groups	O
+:	O
+control	O
+(	O
+C	O
+group	O
+);	O
+ANP	B-PRGE
+without	O
+treatment	O
+(	O
+P	O
+group	O
+);	O
+and	O
+ANP	B-PRGE
+treated	O
+with	O
+ligustrazine	O
+(	O
+T	O
+group	O
+).	O
+
+Compared	O
+with	O
+C	O
+group	O
+,	O
+the	O
+lung	B-ANAT
+wet	O
+/	O
+dry	O
+ratios	O
+in	O
+both	O
+the	O
+P	O
+and	O
+T	O
+groups	O
+were	O
+significantly	O
+increased	O
+,	O
+but	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+between	O
+them	O
+.	O
+
+In	O
+the	O
+T	O
+group	O
+,	O
+although	O
+the	O
+MPO	B-FUNC
+activity	O
+was	O
+also	O
+higher	O
+than	O
+in	O
+the	O
+C	O
+group	O
+,	O
+it	O
+much	O
+less	O
+increased	O
+than	O
+in	O
+the	O
+P	O
+group	O
+.	O
+
+ALI	O
+was	O
+induced	O
+in	O
+female	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+by	O
+the	O
+intranasal	O
+administration	O
+of	O
+0	O
+.	O
+1	O
+mg	O
+/	O
+kg	O
+LPS	B-DISO
+.	O
+
+No	O
+special	O
+findings	O
+were	O
+observed	O
+in	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+obtained	O
+by	O
+transbronchial	O
+lung	B-ANAT
+biopsy	O
+.	O
+
+The	O
+commonest	O
+indication	O
+for	O
+PICU	B-SPEC
+admission	O
+was	O
+persistent	O
+shock	O
+(	O
+39	O
+patients	O
+)	O
+followed	O
+by	O
+requirement	O
+for	O
+positive	O
+pressure	O
+ventilation	O
+in	O
+29	O
+patients	O
+(	O
+10	O
+of	O
+whom	O
+had	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+[	O
+ARDS	B-DISO
+])	O
+and	O
+neurological	B-DISO
+symptoms	I-DISO
+in	O
+24	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+It	O
+was	O
+found	O
+that	O
+complications	O
+such	O
+as	O
+DIC	B-DISO
+,	O
+diastolic	B-DISO
+dysfunction	I-DISO
+,	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+,	O
+ARDS	B-DISO
+and	O
+hepatic	B-DISO
+dysfunction	I-DISO
+were	O
+more	O
+frequent	O
+in	O
+severe	O
+established	O
+shock	O
+.	O
+
+The	O
+histopathological	O
+features	O
+of	O
+ReoV	O
+infected	O
+animals	B-SPEC
+consisted	O
+of	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+,	O
+with	O
+scattered	O
+hemorrhage	B-DISO
+,	O
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+and	O
+interstitial	B-DISO
+pneumonia	I-DISO
+.	O
+
+This	O
+study	O
+demonstrated	O
+that	O
+the	O
+newly	O
+isolated	O
+ReoV	O
+might	O
+be	O
+a	O
+virulent	O
+pathogen	O
+for	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Effect	O
+of	O
+high	O
+volume	O
+hemofiltration	O
+on	O
+respiration	B-PROC
+,	O
+hemodynamics	B-PROC
+and	O
+oxygen	B-PROC
+metabolism	I-PROC
+in	O
+sepsis	B-SPEC
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+Acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHEII	O
+)	O
+scores	O
+,	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+)	O
+evaluation	O
+scores	O
+and	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+were	O
+observed	O
+before	O
+and	O
+after	O
+HVHF	O
+.	O
+
+The	O
+nucleotide	B-CHED
+sequence	O
+of	O
+the	O
+3	O
+'-	O
+terminal	O
+portion	O
+of	O
+the	O
+CRCoV	O
+genome	O
+was	O
+determined	O
+including	O
+all	O
+open	O
+reading	O
+frames	O
+from	O
+the	O
+NS2	B-PRGE
+gene	I-PRGE
+to	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+region	O
+between	O
+the	O
+spike	O
+and	O
+the	O
+E	B-PRGE
+gene	I-PRGE
+was	O
+found	O
+to	O
+be	O
+the	O
+most	O
+variable	O
+and	O
+was	O
+used	O
+for	O
+phylogenetic	O
+analysis	O
+of	O
+several	O
+CRCoV	O
+strains	O
+.	O
+
+The	O
+culture	O
+of	O
+CRCoV	O
+will	O
+enable	O
+analysis	O
+of	O
+the	O
+expression	B-PROC
+and	O
+function	O
+of	O
+this	O
+and	O
+other	O
+CRCoV	O
+proteins	B-CHED
+as	O
+well	O
+as	O
+allowing	O
+the	O
+study	O
+of	O
+the	O
+role	O
+of	O
+CRCoV	O
+in	O
+the	O
+aetiology	O
+of	O
+canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Mutational	O
+analysis	O
+of	O
+aminopeptidase	B-PRGE
+N	I-PRGE
+,	O
+a	O
+receptor	O
+for	O
+several	O
+group	O
+1	O
+coronaviruses	O
+,	O
+identifies	O
+key	O
+determinants	O
+of	O
+viral	O
+host	O
+range	O
+.	O
+
+Between	O
+these	O
+two	O
+ends	O
+is	O
+a	O
+hypervariable	O
+region	O
+(	O
+HVR	O
+)	O
+that	O
+is	O
+only	O
+poorly	O
+conserved	O
+between	O
+MHV	B-SPEC
+and	O
+other	O
+group	O
+2	O
+coronaviruses	O
+.	O
+
+Paradoxically	O
+,	O
+buried	O
+within	O
+the	O
+HVR	O
+is	O
+an	O
+octanucleotide	O
+motif	O
+(	O
+oct	O
+),	O
+5	O
+'-	O
+GGAAGAGC	O
+-	O
+3	O
+',	O
+which	O
+is	O
+almost	O
+universally	O
+conserved	O
+in	O
+coronaviruses	O
+and	O
+is	O
+therefore	O
+assumed	O
+to	O
+have	O
+a	O
+critical	O
+biological	B-PROC
+function	I-PROC
+.	O
+
+By	O
+contrast	O
+,	O
+the	O
+HVR	O
+deletion	O
+mutant	B-DISO
+was	O
+highly	O
+attenuated	O
+in	O
+mice	B-SPEC
+,	O
+causing	O
+no	O
+signs	O
+of	O
+clinical	O
+disease	O
+and	O
+minimal	O
+weight	O
+loss	O
+compared	O
+to	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Alveolar	B-ANAT
+recruitment	B-DISO
+versus	O
+hyperinflation	B-DISO
+:	O
+A	O
+balancing	B-PROC
+act	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+address	O
+lung	B-ANAT
+recruitment	B-DISO
+according	O
+to	O
+pressure	O
+/	O
+volume	O
+curves	O
+,	O
+along	O
+with	O
+regional	O
+recruitment	B-DISO
+versus	O
+hyperinflation	B-DISO
+evidence	O
+from	O
+computed	O
+tomography	O
+and	O
+electrical	B-PROC
+impedance	I-PROC
+tomography	O
+.	O
+
+Balancing	B-PROC
+recruitment	B-DISO
+versus	O
+overdistension	O
+may	O
+require	O
+thoracic	B-DISO
+tomography	O
+,	O
+to	O
+assure	O
+sufficient	O
+improvement	O
+in	O
+oxygenation	B-PROC
+while	O
+limiting	O
+hypercarbia	B-DISO
+.	O
+
+We	O
+describe	O
+the	O
+effect	O
+of	O
+methylation	B-PROC
+on	O
+the	O
+physico	O
+-	O
+chemical	O
+properties	O
+of	O
+these	O
+proteins	B-CHED
+,	O
+and	O
+show	O
+that	O
+it	O
+led	O
+to	O
+diffraction	O
+-	O
+quality	O
+crystals	B-ANAT
+from	O
+four	O
+proteins	B-CHED
+and	O
+structures	O
+for	O
+three	O
+that	O
+had	O
+hitherto	O
+proved	O
+refractory	O
+to	O
+crystallization	O
+.	O
+
+Development	B-PROC
+and	O
+high	O
+-	O
+throughput	O
+screening	O
+of	O
+efficacious	O
+drugs	O
+is	O
+therefore	O
+critical	O
+.	O
+
+Partial	O
+SARS	B-DISO
+-	O
+CoV	O
+cDNAs	O
+and	O
+antibiotic	B-CHED
+resistance	B-PROC
+/	O
+reporter	O
+gene	O
+DNA	O
+were	O
+generated	O
+and	O
+assembled	O
+in	O
+vitro	O
+to	O
+produce	O
+the	O
+replicon	O
+transcription	B-PROC
+template	O
+,	O
+which	O
+was	O
+then	O
+transcribed	O
+in	O
+vitro	O
+to	O
+generate	O
+the	O
+replicon	O
+RNA	O
+.	O
+
+The	O
+suitability	O
+of	O
+this	O
+replicon	O
+cell	B-ANAT
+line	I-ANAT
+in	O
+drug	O
+screening	O
+was	O
+demonstrated	O
+by	O
+testing	O
+the	O
+inhibitory	O
+effect	O
+of	O
+several	O
+existing	O
+drugs	O
+and	O
+the	O
+results	O
+demonstrate	O
+that	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+replicon	O
+cell	B-ANAT
+lines	I-ANAT
+provide	O
+a	O
+safe	O
+tool	O
+for	O
+the	O
+identification	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+replicase	I-PRGE
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Mental	B-DISO
+disorders	I-DISO
+in	O
+general	O
+hospital	O
+patients	O
+].	O
+
+Short	O
+-	O
+term	O
+consequences	O
+of	O
+cardiac	B-ANAT
+surgery	O
+included	O
+adjustment	B-DISO
+disorders	I-DISO
+with	O
+depressed	O
+features	O
+(	O
+32	O
+.	O
+4	O
+%),	O
+acute	O
+full	O
+in	O
+-	O
+hospital	O
+PTSD	B-DISO
+(	O
+17	O
+.	O
+6	O
+%),	O
+and	O
+in	O
+-	O
+hospital	O
+major	B-DISO
+depression	I-DISO
+(	O
+17	O
+.	O
+6	O
+%).	O
+
+To	O
+adequately	O
+diagnose	O
+and	O
+treat	O
+patients	O
+at	O
+risk	O
+of	O
+developing	O
+PTSD	B-DISO
+,	O
+close	O
+collaboration	O
+between	O
+physicians	O
+of	O
+all	O
+subspecialties	O
+and	O
+C	O
+-	O
+L	O
+psychiatrists	O
+will	O
+be	O
+necessary	O
+.	O
+
+If	O
+a	O
+newly	O
+emergent	O
+airborne	O
+infection	B-DISO
+should	O
+appear	O
+,	O
+the	O
+model	O
+could	O
+be	O
+quickly	O
+calibrated	O
+to	O
+data	O
+and	O
+intervention	O
+options	O
+at	O
+the	O
+early	O
+stage	O
+of	O
+the	O
+outbreak	O
+.	O
+
+In	O
+addition	O
+,	O
+she	O
+also	O
+developed	O
+myocarditis	B-DISO
+and	O
+renal	B-DISO
+failure	I-DISO
+.	O
+
+This	O
+high	O
+pathogenicity	O
+suggests	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+developed	O
+mechanisms	O
+to	O
+overcome	O
+the	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+protein	B-CHED
+6	O
+accelerates	O
+murine	B-SPEC
+coronavirus	I-SPEC
+infections	O
+.	O
+
+ABSTRACT	O
+:	O
+One	O
+or	O
+more	O
+of	O
+the	O
+unique	O
+3	O
+'-	O
+proximal	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+may	O
+encode	O
+determinants	O
+of	O
+virus	B-SPEC
+virulence	B-PROC
+.	O
+
+The	O
+SARS	B-DISO
+coronavirus	B-SPEC
+encodes	O
+a	O
+novel	O
+membrane	B-COMP
+protein	B-CHED
+6	O
+that	O
+can	O
+accelerate	O
+replication	O
+of	O
+a	O
+related	O
+mouse	B-SPEC
+virus	B-SPEC
+,	O
+a	O
+property	O
+that	O
+may	O
+explain	O
+its	O
+ability	O
+to	O
+increase	O
+in	O
+vivo	O
+virus	B-SPEC
+virulence	B-PROC
+.	O
+
+SARS	B-DISO
+is	O
+related	O
+to	O
+a	O
+high	O
+morbidity	O
+and	O
+mortality	O
+and	O
+first	O
+appeared	O
+during	O
+an	O
+epidemic	O
+in	O
+2002	O
+-	O
+2003	O
+.	O
+
+Due	O
+to	O
+the	O
+rapid	O
+spread	O
+of	O
+SARS	B-DISO
+during	O
+the	O
+epidemics	O
+in	O
+2002	O
+-	O
+2003	O
+,	O
+randomised	O
+and	O
+controlled	O
+multicentre	O
+studies	O
+were	O
+not	O
+performed	O
+.	O
+
+As	O
+compared	O
+to	O
+wild	O
+-	O
+type	O
+,	O
+STAT6	B-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+had	O
+increased	O
+lung	B-ANAT
+injury	O
+from	O
+1	O
+to	O
+6	O
+h	O
+,	O
+with	O
+full	O
+recovery	O
+by	O
+12	O
+h	O
+.	O
+An	O
+opposite	O
+pattern	O
+was	O
+observed	O
+in	O
+STAT4	B-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+with	O
+mild	O
+injury	O
+seen	O
+at	O
+1	O
+and	O
+6	O
+h	O
+,	O
+and	O
+maximal	O
+injury	O
+at	O
+12	O
+h	O
+.	O
+MPO	B-FUNC
+activity	O
+was	O
+significantly	O
+increased	O
+at	O
+6	O
+h	O
+in	O
+caerulein	B-CHED
+-	O
+treated	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+compared	O
+to	O
+saline	O
+-	O
+treated	O
+controls	O
+.	O
+
+The	O
+prolonged	O
+procedure	O
+during	O
+which	O
+the	O
+susceptible	O
+lung	B-ANAT
+was	O
+exposed	O
+to	O
+longer	O
+duration	O
+of	O
+high	O
+airway	O
+pressure	O
+was	O
+thought	O
+to	O
+be	O
+the	O
+mechanism	O
+of	O
+rapid	O
+deterioration	O
+of	O
+the	O
+preexisting	O
+barotrauma	O
+.	O
+
+During	O
+the	O
+initial	O
+phases	O
+of	O
+infection	B-DISO
+the	O
+virus	B-SPEC
+causes	O
+pauci	O
+-	O
+inflammatory	O
+alveolar	B-ANAT
+and	O
+interstitial	B-DISO
+edema	I-DISO
+that	O
+result	O
+in	O
+imaging	O
+abnormalities	O
+dominated	O
+by	O
+ground	O
+glass	O
+opacities	B-DISO
+(	O
+GGO	O
+).	O
+
+Indirect	O
+immunofluorescence	O
+assays	O
+showed	O
+that	O
+in	O
+the	O
+infected	O
+cells	B-COMP
+expressing	O
+each	O
+of	O
+the	O
+siRNAs	O
+,	O
+there	O
+was	O
+aspecific	O
+silencing	O
+of	O
+S	O
+,	O
+3a	O
+and	O
+7a	O
+,	O
+respectively	O
+,	O
+but	O
+the	O
+expression	B-PROC
+of	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+was	O
+not	O
+affected	O
+.	O
+
+Two	O
+cases	O
+with	O
+hepatorenal	O
+syndrome	O
+died	B-PROC
+,	O
+and	O
+three	O
+patients	O
+with	O
+coinfection	B-DISO
+by	O
+bacteria	B-SPEC
+and	O
+fungi	B-SPEC
+died	B-PROC
+.	O
+
+Between	O
+17	O
+March	O
+and	O
+7	O
+July	O
+2003	O
+,	O
+as	O
+a	O
+result	O
+of	O
+dilemmas	O
+in	O
+balancing	B-PROC
+sensitivity	O
+and	O
+specificity	O
+,	O
+five	O
+different	O
+case	O
+definitions	O
+were	O
+used	O
+.	O
+
+Initially	O
+,	O
+we	O
+investigated	O
+IBV	B-SPEC
+isolations	O
+from	O
+cases	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+association	O
+with	O
+the	O
+presence	O
+of	O
+thymic	O
+and	O
+/	O
+or	O
+bursal	O
+atrophy	B-DISO
+in	O
+322	O
+submissions	O
+during	O
+1997	O
+to	O
+2002	O
+.	O
+
+ABSTRACT	O
+:	O
+Twelve	O
+complete	O
+genomes	O
+of	O
+three	O
+novel	O
+coronaviruses	O
+-	O
+bat	B-SPEC
+coronavirus	I-SPEC
+HKU4	I-SPEC
+(	O
+bat	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+HKU4	I-PRGE
+),	O
+bat	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+HKU5	I-PRGE
+(	O
+putative	O
+group	O
+2c	O
+),	O
+and	O
+bat	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+HKU9	I-PRGE
+(	O
+putative	O
+group	O
+2d	O
+)-	O
+were	O
+sequenced	O
+.	O
+
+Unique	O
+genomic	O
+features	O
+distinguishing	O
+between	O
+these	O
+four	O
+subgroups	O
+,	O
+including	O
+the	O
+number	O
+of	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+,	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+hemagglutinin	B-PRGE
+esterase	I-PRGE
+,	O
+small	O
+ORFs	O
+between	O
+the	O
+membrane	B-COMP
+and	O
+nucleocapsid	B-COMP
+genes	O
+and	O
+ORFs	O
+(	O
+NS7a	O
+and	O
+NS7b	O
+),	O
+bulged	O
+stem	B-ANAT
+-	O
+loop	O
+and	O
+pseudoknot	O
+structures	O
+downstream	O
+of	O
+the	O
+nucleocapsid	B-COMP
+gene	O
+,	O
+transcription	B-PROC
+regulatory	O
+sequence	O
+,	O
+and	O
+ribosomal	B-COMP
+recognition	O
+signal	O
+for	O
+the	O
+envelope	B-PRGE
+gene	I-PRGE
+,	O
+were	O
+also	O
+observed	O
+.	O
+
+The	O
+high	O
+Ka	O
+/	O
+Ks	O
+ratio	O
+of	O
+NS7a	O
+and	O
+NS7b	O
+in	O
+bat	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+HKU9	I-PRGE
+implies	O
+that	O
+these	O
+two	O
+group	O
+2d	O
+-	O
+specific	O
+genes	O
+are	O
+under	O
+high	O
+selective	O
+pressure	O
+and	O
+hence	O
+are	O
+rapidly	O
+evolving	O
+.	O
+
+Further	O
+molecular	O
+epidemiological	O
+studies	O
+on	O
+coronaviruses	O
+in	O
+the	O
+bats	B-SPEC
+of	O
+other	O
+countries	O
+,	O
+as	O
+well	O
+as	O
+in	O
+other	O
+animals	B-SPEC
+,	O
+and	O
+complete	O
+genome	O
+sequencing	O
+will	O
+shed	O
+more	O
+light	O
+on	O
+coronavirus	B-SPEC
+diversity	O
+and	O
+their	O
+evolutionary	O
+histories	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+ProTide	B-CHED
+approach	O
+is	O
+highly	O
+successful	O
+when	O
+applied	O
+to	O
+L	O
+-	O
+Cd4A	O
+with	O
+potency	O
+improvements	O
+in	O
+vitro	O
+as	O
+high	O
+as	O
+9000	O
+-	O
+fold	O
+against	O
+HIV	O
+.	O
+
+As	O
+we	O
+learn	B-PROC
+more	O
+about	O
+the	O
+molecular	O
+consequences	O
+of	O
+allelic	O
+variation	O
+,	O
+new	O
+therapies	O
+based	O
+on	O
+a	O
+new	O
+generation	O
+of	O
+surfactant	B-CHED
+diagnostics	O
+and	O
+individualized	O
+therapies	O
+may	O
+follow	O
+.	O
+
+Lectins	O
+of	O
+algal	O
+origin	O
+whose	O
+antiviral	B-CHED
+properties	O
+make	O
+them	O
+candidate	O
+agents	O
+for	O
+prevention	O
+of	O
+viral	B-PROC
+transmission	I-PROC
+through	O
+topical	O
+applications	O
+include	O
+cyanovirin	O
+-	O
+N	O
+,	O
+Microcystis	B-SPEC
+viridis	I-SPEC
+lectin	O
+,	O
+scytovirin	O
+,	O
+and	O
+griffithsin	O
+.	O
+
+This	O
+review	O
+summarizes	O
+the	O
+current	O
+state	O
+of	O
+knowledge	O
+of	O
+the	O
+structures	O
+of	O
+algal	O
+lectins	O
+,	O
+their	O
+mode	O
+of	O
+binding	B-FUNC
+of	O
+carbohydrates	B-CHED
+,	O
+and	O
+their	O
+potential	O
+medical	O
+applications	O
+.	O
+
+Moreover	O
+,	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+was	O
+highly	O
+expressed	B-PROC
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+The	O
+active	O
+group	O
+received	O
+SIT	O
+with	O
+a	O
+standardized	O
+depot	O
+Dermatophagoides	B-SPEC
+pteronyssinus	I-SPEC
+(	O
+Der	O
+p	O
+)	O
+extract	O
+absorbed	O
+to	O
+aluminium	B-CHED
+hydroxide	I-CHED
+(	O
+Alutard	O
+SQ	O
+,	O
+ALK	O
+-	O
+Abelló	O
+,	O
+Denmark	O
+),	O
+while	O
+the	O
+control	O
+group	O
+received	O
+a	O
+placebo	O
+containing	O
+histamine	B-CHED
+dihydrochloride	O
+by	O
+subcutaneous	O
+injections	O
+for	O
+1	O
+year	O
+.	O
+
+The	O
+mean	O
+daily	O
+symptom	B-DISO
+scores	O
+in	O
+4	O
+-	O
+weekly	O
+began	O
+to	O
+diverge	O
+at	O
+the	O
+29th	O
+-	O
+32nd	O
+week	O
+with	O
+the	O
+active	O
+group	O
+showing	O
+a	O
+significant	O
+lower	O
+scores	O
+(	O
+0	O
+.	O
+17	O
++/-	O
+0	O
+.	O
+33	O
+)	O
+than	O
+the	O
+control	O
+group	O
+(	O
+0	O
+.	O
+39	O
++/-	O
+
+There	O
+were	O
+significant	O
+differences	O
+in	O
+subjective	O
+judgement	O
+of	O
+the	O
+improvement	O
+about	O
+overall	O
+asthmatic	B-DISO
+symptoms	O
+,	O
+exacerbation	O
+severity	O
+and	O
+exacerbation	O
+frequency	O
+between	O
+the	O
+active	O
+group	O
+(	O
+96	O
+.	O
+9	O
+%,	O
+95	O
+.	O
+3	O
+%,	O
+95	O
+.	O
+4	O
+%)	O
+and	O
+the	O
+control	O
+group	O
+(	O
+80	O
+.	O
+0	O
+%,	O
+75	O
+.	O
+4	O
+%,	O
+83	O
+.	O
+1	O
+%)	O
+with	O
+the	O
+self	O
+-	O
+evaluation	O
+questionnaire	O
+(	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+13	O
+.	O
+246	O
+,	O
+11	O
+.	O
+576	O
+,	O
+16	O
+.	O
+204	O
+,	O
+all	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Although	O
+significant	O
+difference	O
+was	O
+found	O
+in	O
+adverse	O
+reactions	O
+between	O
+groups	O
+(	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+4	O
+.	O
+705	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+all	O
+were	O
+mild	O
+or	O
+moderate	O
+.	O
+
+Children	O
+whose	O
+only	O
+detectable	O
+respiratory	O
+virus	B-SPEC
+was	O
+a	O
+coronavirus	B-SPEC
+were	O
+more	O
+likely	O
+to	O
+have	O
+underlying	O
+chronic	B-DISO
+disease	I-DISO
+than	O
+were	O
+children	O
+coinfected	O
+with	O
+another	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+The	O
+hope	O
+is	O
+that	O
+future	O
+management	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+with	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+lung	B-ANAT
+injury	O
+will	O
+be	O
+directed	O
+against	O
+the	O
+production	O
+of	O
+noxious	O
+cytokines	O
+.	O
+
+Pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+,	O
+including	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+),	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+),	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+),	O
+were	O
+found	O
+in	O
+lung	B-ANAT
+secretions	B-ANAT
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+infected	O
+pigs	B-SPEC
+,	O
+and	O
+correlated	O
+with	O
+the	O
+intensity	O
+of	O
+clinical	O
+signs	O
+,	O
+whereas	O
+prior	O
+vaccination	O
+against	O
+influenza	O
+strongly	O
+reduced	O
+the	O
+production	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+and	O
+cytokines	O
+in	O
+the	O
+lungs	B-ANAT
+upon	O
+challenge	O
+,	O
+which	O
+was	O
+associated	O
+with	O
+clinical	O
+protection	O
+.	O
+
+An	O
+early	O
+type	B-PROC
+I	I-PROC
+IFN	I-PROC
+production	I-PROC
+was	O
+also	O
+found	O
+in	O
+coronavirus	B-SPEC
+infected	O
+pigs	B-SPEC
+,	O
+including	O
+at	O
+mucosal	B-ANAT
+sites	O
+.	O
+
+Given	O
+the	O
+IFN	B-PRGE
+mediated	O
+antiviral	B-CHED
+and	O
+immunomodulatory	O
+effects	O
+,	O
+the	O
+use	O
+of	O
+IFN	B-PRGE
+or	O
+IFN	B-PRGE
+inducers	O
+may	O
+prove	O
+an	O
+efficient	O
+strategy	O
+for	O
+a	O
+better	O
+control	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+pigs	B-SPEC
+.	O
+
+The	O
+mean	O
+body	B-ANAT
+weights	O
+of	O
+cocks	O
+and	O
+hens	O
+were	O
+2	O
+.	O
+28	O
++/-	O
+
+However	O
+,	O
+there	O
+are	O
+very	O
+few	O
+convincing	O
+reports	O
+of	O
+persistent	O
+pulmonary	B-ANAT
+sequelae	O
+,	O
+as	O
+demonstrated	O
+by	O
+spirometry	O
+,	O
+radiology	O
+and	O
+pathology	B-DISO
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+gene	B-PROC
+expression	I-PROC
+by	O
+adenovirus	B-DISO
+-	O
+delivered	O
+small	O
+hairpin	O
+RNA	O
+.	O
+
+The	O
+effects	O
+of	O
+adenovirus	B-DISO
+-	O
+delivered	O
+small	O
+hairpin	O
+RNA	O
+on	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+gene	B-PROC
+expression	I-PROC
+were	O
+determined	O
+by	O
+RT	O
+-	O
+PCR	O
+,	O
+Western	O
+blot	O
+,	O
+and	O
+luciferase	B-PROC
+activity	I-PROC
+assays	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+performed	O
+this	O
+study	O
+in	O
+order	B-SPEC
+to	O
+delineate	O
+the	O
+prevalence	O
+,	O
+the	O
+potential	O
+clinical	O
+impacts	O
+and	O
+evaluation	O
+of	O
+the	O
+genetic	O
+characterization	O
+of	O
+this	O
+pathogen	O
+in	O
+young	O
+children	O
+who	O
+presented	O
+with	O
+acute	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ALRI	O
+).	O
+
+We	O
+report	O
+our	O
+experience	O
+of	O
+managing	O
+five	O
+patients	O
+with	O
+paraquat	B-CHED
+poisoning	O
+using	O
+immunosuppressive	O
+therapy	O
+.	O
+
+Five	O
+(	O
+5	O
+.	O
+9	O
+percent	O
+)	O
+out	O
+of	O
+the	O
+84	O
+patients	O
+were	O
+admitted	O
+with	O
+a	O
+diagnosis	O
+of	O
+paraquat	B-CHED
+poisoning	O
+.	O
+
+All	O
+patients	O
+had	O
+hepatic	B-DISO
+failure	I-DISO
+with	O
+median	O
+peak	O
+bilirubin	B-CHED
+being	O
+22	O
+.	O
+1	O
++/-	O
+
+TITLE	O
+:	O
+[	O
+Emerging	O
+viral	B-DISO
+diseases	I-DISO
+].	O
+
+The	O
+management	O
+and	O
+treatment	O
+of	O
+these	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+calls	O
+for	O
+new	O
+approaches	O
+,	O
+organizations	O
+and	O
+infrastructures	O
+.	O
+
+We	O
+sought	O
+to	O
+determine	O
+the	O
+contribution	O
+of	O
+respiratory	O
+viruses	B-SPEC
+to	O
+asthma	B-PATH
+exacerbations	O
+in	O
+children	O
+with	O
+a	O
+panel	O
+of	O
+PCR	O
+assays	O
+for	O
+common	O
+and	O
+newly	O
+discovered	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Respiratory	O
+specimens	O
+from	O
+children	O
+aged	O
+2	O
+to	O
+17	O
+years	O
+with	O
+asthma	B-PATH
+exacerbations	O
+(	O
+case	O
+patients	O
+,	O
+n	O
+=	O
+65	O
+)	O
+and	O
+with	O
+well	O
+-	O
+controlled	O
+asthma	B-PATH
+(	O
+control	O
+subjects	O
+,	O
+n	O
+=	O
+77	O
+),	O
+frequency	O
+matched	O
+by	O
+age	O
+and	O
+season	O
+of	O
+enrollment	O
+,	O
+were	O
+tested	O
+for	O
+rhinoviruses	B-SPEC
+,	O
+enteroviruses	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+coronaviruses	O
+229E	O
+and	O
+OC43	O
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+1	O
+to	O
+3	O
+,	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+adenoviruses	B-SPEC
+,	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+.	O
+
+However	O
+,	O
+in	O
+children	O
+without	O
+clinically	O
+manifested	O
+viral	O
+respiratory	B-ANAT
+tract	I-ANAT
+illness	O
+,	O
+the	O
+prevalence	O
+of	O
+rhinovirus	B-DISO
+infection	I-DISO
+was	O
+similar	O
+in	O
+case	O
+patients	O
+(	O
+29	O
+.	O
+2	O
+%)	O
+versus	O
+control	O
+subjects	O
+(	O
+23	O
+.	O
+4	O
+%,	O
+P	O
+>	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Genetic	O
+distance	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+from	O
+the	O
+recent	O
+natural	O
+case	O
+.	O
+
+ABSTRACT	O
+:	O
+Phylogenetic	O
+analysis	O
+of	O
+SARS	O
+coronavirus	B-SPEC
+isolates	O
+based	O
+on	O
+the	O
+spike	O
+gene	O
+and	O
+protein	B-CHED
+sequence	O
+using	O
+Neighbor	O
+-	O
+Joining	O
+,	O
+maximum	O
+likelihood	O
+and	O
+Bayesian	O
+inference	O
+methods	O
+indicated	O
+that	O
+a	O
+recent	O
+human	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+isolate	O
+was	O
+closer	O
+to	O
+some	O
+human	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+from	O
+earlier	O
+epidemic	O
+phase	O
+than	O
+to	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+like	O
+viruses	B-SPEC
+isolated	O
+from	O
+wild	O
+animals	B-SPEC
+during	O
+previous	O
+epidemic	O
+phase	O
+.	O
+
+A	O
+reasonable	O
+judgment	O
+based	O
+on	O
+phylogenetic	O
+relationship	O
+and	O
+sequence	O
+variations	O
+it	O
+is	O
+likely	O
+that	O
+the	O
+recent	O
+human	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+isolate	O
+is	O
+closer	O
+to	O
+an	O
+unknown	O
+SARS	B-DISO
+-	O
+CoV	O
+predecessor	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+revealing	O
+severe	O
+pulmonary	B-ANAT
+leptospirosis	B-DISO
+].	O
+
+TITLE	O
+:	O
+Molecular	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+project	O
+'	O
+s	O
+curation	O
+strategy	O
+has	O
+three	O
+prongs	O
+:	O
+'	O
+breadth	O
+first	O
+'	O
+beginning	O
+with	O
+whole	O
+-	O
+genome	O
+and	O
+proteome	O
+curation	O
+using	O
+standardized	O
+protocols	O
+,	O
+a	O
+'	B-PROC
+targeted	I-PROC
+'	O
+approach	O
+addressing	O
+the	O
+specific	O
+needs	O
+of	O
+researchers	O
+and	O
+an	O
+integrative	O
+strategy	O
+to	O
+leverage	O
+high	O
+-	O
+throughput	O
+experimental	O
+data	O
+(	O
+e	O
+.	O
+g	O
+.	O
+microarrays	O
+,	O
+proteomics	O
+)	O
+and	O
+literature	O
+.	O
+
+The	O
+dimeric	O
+enzyme	O
+dissociated	O
+at	O
+guanidinium	B-CHED
+chloride	I-CHED
+concentration	O
+of	O
+<	O
+0	O
+.	O
+4	O
+M	O
+,	O
+at	O
+which	O
+the	O
+enzymatic	B-PROC
+activity	I-PROC
+loss	O
+showed	O
+close	O
+correlation	O
+with	O
+the	O
+subunit	O
+dissociation	B-DISO
+.	O
+
+We	O
+provide	O
+direct	O
+evidence	O
+for	O
+the	O
+functional	O
+role	O
+of	O
+C	O
+-	O
+terminal	O
+domain	O
+in	O
+stabilization	O
+of	O
+the	O
+catalytic	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+SARS	O
+coronavirus	B-SPEC
+main	O
+protease	O
+.	O
+
+Subsequent	O
+analysis	O
+revealed	O
+no	O
+differences	O
+in	O
+T	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+,	O
+IFN	B-PROC
+-	I-PROC
+gamma	I-PROC
+secretion	B-ANAT
+by	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+or	O
+CD8	B-PRGE
++	I-PRGE
+T	I-PRGE
+cell	O
+cytolytic	O
+activity	O
+.	O
+
+Adoptive	O
+transfer	O
+of	O
+splenocytes	O
+acquired	O
+from	O
+MHV	B-SPEC
+-	O
+immunized	O
+CXCL10	O
+(-/-)	O
+mice	B-SPEC
+into	O
+MHV	B-SPEC
+-	O
+infected	O
+RAG1	O
+(-/-)	O
+mice	B-SPEC
+resulted	O
+in	O
+T	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+into	O
+the	O
+CNS	B-CHED
+,	O
+reduced	O
+viral	O
+burden	O
+,	O
+and	O
+demyelination	B-DISO
+comparable	O
+to	O
+RAG1	B-PRGE
+(-/-)	O
+recipients	O
+of	O
+immune	O
+CXCL10	O
+(+/+)	O
+splenocytes	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+CoV	I-PRGE
+main	I-PRGE
+proteinase	B-PROC
+:	O
+The	O
+monomer	O
+-	O
+dimer	O
+equilibrium	B-PROC
+dissociation	B-DISO
+constant	O
+.	O
+
+A	O
+crucial	O
+step	O
+in	O
+containing	O
+infection	B-DISO
+is	O
+the	O
+prevention	O
+of	O
+the	O
+disease	O
+;	O
+efforts	O
+are	O
+directed	O
+toward	O
+this	O
+endpoint	O
+.	O
+
+In	O
+particular	O
+,	O
+this	O
+approach	O
+utilizes	O
+docking	B-PROC
+scores	O
+generated	O
+for	O
+already	O
+processed	O
+compounds	O
+to	O
+build	O
+predictive	O
+QSAR	O
+models	O
+that	O
+,	O
+in	O
+turn	O
+,	O
+assess	O
+hypothetical	O
+target	O
+binding	B-FUNC
+affinities	O
+for	O
+yet	O
+undocked	O
+entries	O
+.	O
+
+We	O
+demonstrate	O
+that	O
+progressive	O
+docking	B-PROC
+can	O
+reduce	O
+the	O
+amount	O
+of	O
+computations	O
+1	O
+.	O
+2	O
+-	O
+to	O
+2	O
+.	O
+6	O
+-	O
+fold	O
+(	O
+when	O
+compared	O
+to	O
+traditional	O
+docking	B-PROC
+),	O
+while	O
+maintaining	O
+80	O
+-	O
+99	O
+%	O
+hit	O
+recovery	O
+rates	O
+.	O
+
+TITLE	O
+:	O
+Anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+activity	O
+of	O
+nucleoside	B-CHED
+analogs	O
+having	O
+6	O
+-	O
+chloropurine	O
+as	O
+a	O
+nucleobase	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Awareness	O
+on	O
+SARS	B-DISO
+and	O
+public	O
+health	O
+emergencies	B-DISO
+among	O
+general	O
+publics	O
+].	O
+
+It	O
+is	O
+essential	O
+for	O
+the	O
+government	O
+to	O
+interact	O
+and	O
+communicate	O
+with	O
+the	O
+publics	O
+through	O
+media	B-ANAT
+,	O
+medical	O
+and	O
+related	O
+institutions	O
+when	O
+confronting	O
+with	O
+the	O
+public	O
+health	O
+emergencies	B-DISO
+.	O
+
+TITLE	O
+:	O
+Family	B-SPEC
+physicians	O
+'	O
+experiences	O
+,	O
+behaviour	B-PROC
+,	O
+and	O
+use	O
+of	O
+personal	O
+protection	O
+equipment	O
+during	O
+the	O
+SARS	O
+outbreak	O
+in	O
+Singapore	O
+:	O
+
+Dimerization	O
+inhibitors	B-CHED
+are	O
+usually	O
+targeted	B-PROC
+to	O
+the	O
+dimerization	O
+interface	O
+and	O
+need	O
+to	O
+compete	O
+with	O
+the	O
+attractive	O
+forces	O
+between	O
+subunits	O
+to	O
+be	O
+effective	O
+.	O
+
+We	O
+previously	O
+identified	O
+a	O
+cluster	O
+of	O
+conserved	O
+serine	B-CHED
+residues	O
+(	O
+Ser139	O
+,	O
+Ser144	O
+,	O
+and	O
+Ser147	O
+)	O
+located	O
+adjacent	O
+to	O
+the	O
+active	O
+site	O
+of	O
+3CLpro	O
+that	O
+could	O
+effectively	O
+be	O
+targeted	O
+to	O
+inactivate	O
+the	O
+protease	O
+[	O
+Bacha	O
+,	O
+U	O
+et	O
+al	O
+.	O
+(	O
+2004	O
+)	O
+Biochemistry	O
+43	O
+,	O
+4906	O
+-	O
+4912	O
+].	O
+
+Pulmonary	B-DISO
+edema	I-DISO
+is	O
+the	O
+most	O
+severe	O
+form	O
+of	O
+lung	B-ANAT
+involvement	O
+.	O
+
+Increased	O
+alveolar	B-ANAT
+capillary	B-PROC
+permeability	I-PROC
+leading	O
+to	O
+intravascular	O
+fluid	B-DISO
+loss	I-DISO
+into	O
+the	O
+lungs	B-ANAT
+is	O
+the	O
+main	O
+pathophysiologic	O
+mechanism	O
+.	O
+
+Clinically	O
+,	O
+patients	O
+usually	O
+present	O
+with	O
+acute	O
+breathlessness	B-DISO
+that	O
+can	O
+rapidly	O
+progress	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+either	O
+at	O
+disease	O
+presentation	O
+or	O
+,	O
+interestingly	O
+,	O
+after	O
+treatment	O
+when	O
+clinical	O
+improvement	O
+is	O
+taking	O
+place	O
+and	O
+the	O
+parasitemia	O
+is	O
+falling	O
+.	O
+
+Whilst	O
+this	O
+is	O
+increasingly	O
+being	O
+recognized	O
+in	O
+malaria	B-PATH
+-	O
+endemic	O
+countries	O
+,	O
+clinicians	O
+in	O
+temperate	O
+zones	O
+should	O
+be	O
+aware	O
+that	O
+malaria	B-PATH
+may	O
+be	O
+a	O
+possible	O
+cause	O
+of	O
+'	B-DISO
+pneumonia	I-DISO
+'	O
+in	O
+a	O
+visiting	O
+or	O
+returning	O
+child	O
+.	O
+
+Both	O
+treatments	O
+blocked	O
+virus	B-DISO
+infection	I-DISO
+and	O
+apoptosis	B-PATH
+,	O
+indicating	O
+that	O
+virus	B-SPEC
+-	O
+receptor	B-FUNC
+binding	I-FUNC
+is	O
+necessary	O
+but	O
+not	O
+sufficient	O
+for	O
+the	O
+apoptosis	B-PROC
+induction	I-PROC
+.	O
+
+We	O
+developed	O
+a	O
+novel	O
+PCR	O
+assay	O
+,	O
+the	O
+microarray	O
+-	O
+in	O
+-	O
+a	O
+-	O
+tube	O
+system	O
+,	O
+which	O
+integrates	O
+multiple	O
+PCR	O
+processes	O
+and	O
+DNA	O
+microarrays	O
+for	O
+multiple	O
+virus	B-SPEC
+detection	O
+.	O
+
+A	O
+5	O
+x	O
+5	O
+oligonucleotide	B-CHED
+microarray	O
+for	O
+detecting	O
+4	O
+respiratory	B-ANAT
+tract	I-ANAT
+viruses	B-SPEC
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+,	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+enterovirus	B-SPEC
+)	O
+with	O
+inner	O
+controls	O
+was	O
+arranged	O
+on	O
+the	O
+inner	O
+surface	O
+of	O
+a	O
+specially	O
+designed	O
+Eppendorf	O
+cap	B-DISO
+with	O
+a	O
+flat	O
+,	O
+optically	O
+transparent	O
+window	O
+.	O
+
+We	O
+were	O
+able	O
+to	O
+perform	O
+all	O
+detection	O
+processes	O
+in	O
+the	O
+encapsulated	O
+system	O
+without	O
+opening	O
+the	O
+cap	B-DISO
+.	O
+
+The	O
+4	O
+viruses	B-SPEC
+were	O
+successfully	O
+amplified	O
+by	O
+one	O
+-	O
+step	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+in	O
+the	O
+encapsulated	O
+tube	O
+.	O
+
+The	O
+microarray	O
+-	O
+in	O
+-	O
+a	O
+-	O
+tube	O
+system	O
+is	O
+a	O
+rapid	O
+,	O
+labor	B-PROC
+-	O
+saving	O
+tool	O
+for	O
+multiple	O
+virus	B-SPEC
+detection	O
+with	O
+several	O
+advantages	O
+,	O
+such	O
+as	O
+convenience	O
+,	O
+prevention	O
+of	O
+cross	O
+-	O
+contamination	O
+of	O
+the	O
+PCR	O
+products	O
+,	O
+and	O
+potential	O
+for	O
+multiple	O
+-	O
+gene	O
+detection	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+were	O
+able	O
+to	O
+perform	O
+all	O
+detection	O
+processes	O
+in	O
+the	O
+encapsulated	O
+system	O
+without	O
+opening	O
+the	O
+cap	B-DISO
+.	O
+
+The	O
+sensitivity	O
+of	O
+the	O
+system	O
+for	O
+virus	B-SPEC
+detection	O
+reached	O
+10	O
+(	O
+2	O
+)	O
+copies	O
+/	O
+microL	O
+.	O
+With	O
+the	O
+help	O
+of	O
+inner	O
+controls	O
+,	O
+the	O
+system	O
+provided	O
+reliable	O
+results	O
+without	O
+false	O
+negatives	O
+and	O
+false	O
+positives	O
+.	O
+
+Demographics	O
+,	O
+mechanism	O
+of	O
+injury	O
+(	O
+MOI	O
+),	O
+ISS	B-DISO
+,	O
+revised	O
+trauma	O
+score	O
+,	O
+Glasgow	O
+Coma	B-DISO
+score	O
+,	O
+hospital	O
+course	O
+,	O
+morbidity	O
+,	O
+requirement	O
+of	O
+additional	O
+procedures	O
+,	O
+mortality	O
+,	O
+and	O
+cost	O
+were	O
+compared	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+6	O
+,	O
+431	O
+patients	O
+,	O
+55	O
+(	O
+0	O
+.	O
+9	O
+%)	O
+developed	O
+AWS	B-DISO
+.	O
+
+Hemagglutination	B-PROC
+inhibition	B-PROC
+(	O
+HI	O
+)	O
+test	O
+has	O
+been	O
+used	O
+to	O
+determine	O
+the	O
+serotypes	O
+of	O
+IBV	B-SPEC
+as	O
+a	O
+substitute	O
+to	O
+the	O
+more	O
+laborious	O
+virus	B-PROC
+neutralization	I-PROC
+test	O
+and	O
+the	O
+more	O
+sophisticated	B-PRGE
+restriction	I-PRGE
+endonuclease	I-PRGE
+digestion	B-PROC
+or	O
+sequencing	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+In	O
+Jordan	O
+,	O
+no	O
+previous	O
+studies	O
+have	O
+been	O
+carried	O
+out	O
+to	O
+determine	O
+the	O
+involvement	O
+of	O
+IBV	B-SPEC
+in	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+chickens	B-SPEC
+,	O
+or	O
+the	O
+serotypes	O
+of	O
+IBV	B-SPEC
+that	O
+possibly	O
+exist	O
+.	O
+
+The	O
+HI	O
+test	O
+results	O
+indicated	O
+that	O
+the	O
+exposure	O
+of	O
+some	O
+of	O
+these	O
+flocks	O
+were	O
+to	O
+Ark	B-PRGE
+,	O
+DE	O
+-	O
+072	O
+,	O
+and	O
+Mass	O
+like	O
+serotypes	O
+.	O
+
+Mapping	O
+of	O
+the	O
+binding	B-FUNC
+region	O
+was	O
+achieved	O
+with	O
+several	O
+S1	O
+recombinant	O
+proteins	B-CHED
+.	O
+
+The	O
+molecular	O
+biology	O
+of	O
+coronaviruses	O
+and	O
+particular	O
+features	O
+of	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	O
+229E	O
+)	O
+indicate	O
+that	O
+HCoV	O
+229E	O
+-	O
+based	O
+vaccine	O
+vectors	O
+can	O
+become	O
+a	O
+new	O
+class	B-SPEC
+of	O
+highly	O
+efficient	O
+vaccines	O
+.	O
+
+Second	O
+,	O
+HCoV	B-PRGE
+229E	I-PRGE
+structural	I-PRGE
+genes	I-PRGE
+can	O
+be	O
+replaced	O
+by	O
+multiple	O
+transcriptional	B-PROC
+units	O
+encoding	O
+various	O
+antigens	O
+.	O
+
+These	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+containing	O
+HCoV	O
+229E	O
+-	O
+based	O
+vector	O
+RNA	O
+have	O
+the	O
+ability	O
+to	O
+transduce	O
+human	B-SPEC
+DCs	B-DISO
+and	O
+to	O
+mediate	O
+heterologous	O
+gene	B-PROC
+expression	I-PROC
+in	O
+these	O
+cells	B-COMP
+.	O
+
+It	O
+is	O
+thus	O
+most	O
+likely	O
+that	O
+pre	O
+-	O
+existing	O
+immunity	B-PROC
+against	O
+HCoV	O
+229E	O
+will	O
+not	O
+significantly	O
+impact	O
+on	O
+the	O
+vaccination	O
+efficiency	O
+if	O
+HCoV	O
+229E	O
+-	O
+based	O
+vectors	O
+are	O
+used	O
+in	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+First	O
+,	O
+the	O
+liposomes	O
+entrapping	O
+DIP	B-DISO
+were	O
+prepared	O
+by	O
+film	O
+hydration	O
+for	O
+treating	O
+ARDS	B-DISO
+.	O
+
+Furthermore	O
+,	O
+DIP	B-DISO
+liposomes	O
+alleviated	O
+the	O
+ALI	O
+induced	O
+by	O
+LPS	B-DISO
+significantly	O
+.	O
+
+TITLE	O
+:	O
+Bronchoalveolar	O
+lavage	O
+with	O
+diluted	O
+porcine	B-SPEC
+surfactant	B-CHED
+in	O
+mechanically	O
+ventilated	O
+term	O
+infants	O
+with	O
+meconium	O
+aspiration	O
+syndrome	O
+.	O
+
+Only	O
+one	O
+patient	O
+required	O
+nitric	B-CHED
+oxide	I-CHED
+therapy	O
+for	O
+transient	O
+pulmonary	B-DISO
+hypertension	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Chinese	O
+medicine	B-CHED
+(	O
+CM	O
+)	O
+has	O
+been	O
+used	O
+to	O
+control	O
+infectious	B-DISO
+diseases	I-DISO
+for	O
+thousands	O
+of	O
+years	O
+.	O
+
+The	O
+initial	O
+findings	O
+seemed	O
+to	O
+indicate	O
+a	O
+favorable	O
+effect	O
+of	O
+CM	O
+on	O
+management	O
+of	O
+SARS	B-DISO
+.	O
+
+Additionally	O
+,	O
+the	O
+combined	O
+protocol	O
+improved	O
+arterial	B-ANAT
+oxyhemoglobin	B-CHED
+saturation	O
+significantly	O
+at	O
+day	O
+22	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+All	O
+of	O
+the	O
+clinical	O
+data	O
+and	O
+survival	O
+time	O
+during	O
+72	O
+hours	O
+were	O
+collected	O
+and	O
+analyzed	O
+,	O
+including	O
+the	O
+collection	O
+of	O
+bronchioalveolar	O
+lavage	O
+fluid	O
+(	O
+BALF	O
+)	O
+for	O
+the	O
+determination	O
+of	O
+total	O
+protein	B-CHED
+(	O
+TP	O
+),	O
+total	O
+phospholipids	B-CHED
+(	O
+TPL	O
+),	O
+disaturated	O
+phosphatidyl	B-CHED
+choline	B-CHED
+(	O
+DSPC	O
+),	O
+and	O
+measurement	O
+of	O
+alveolar	B-ANAT
+tension	B-DISO
+.	O
+
+The	O
+in	O
+vivo	O
+function	O
+of	O
+collectrin	B-PRGE
+was	O
+unclear	O
+.	O
+
+Here	O
+we	O
+report	O
+that	O
+targeted	B-PROC
+disruption	O
+of	O
+collectrin	B-PRGE
+in	O
+mice	B-SPEC
+results	O
+in	O
+a	O
+severe	O
+defect	O
+in	O
+renal	B-ANAT
+amino	B-PROC
+acid	I-PROC
+uptake	I-PROC
+owing	O
+to	O
+downregulation	B-PROC
+of	O
+apical	O
+amino	B-CHED
+acid	I-CHED
+transporters	O
+in	O
+the	O
+kidney	B-ANAT
+.	O
+
+The	O
+concerted	O
+and	O
+cooperative	O
+response	O
+for	O
+the	O
+treatment	O
+of	O
+the	O
+SARS	B-DISO
+disease	O
+has	O
+been	O
+proved	O
+to	O
+be	O
+a	O
+triumph	O
+of	O
+global	O
+public	O
+health	O
+and	O
+provides	O
+a	O
+new	O
+paradigm	O
+for	O
+the	O
+detection	O
+and	O
+control	O
+of	O
+future	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+threats	O
+.	O
+
+Inhibitors	B-CHED
+with	O
+IC50	O
+values	O
+as	O
+low	O
+as	O
+60	O
+nM	O
+have	O
+been	O
+reported	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+first	O
+appeared	O
+in	O
+2002	O
+in	O
+China	O
+,	O
+which	O
+fastly	O
+affected	O
+about	O
+8000	O
+patients	O
+over	O
+29	O
+countries	O
+and	O
+caused	O
+774	O
+fatalities	O
+.	O
+
+As	O
+its	O
+pathogen	O
+was	O
+identified	O
+as	O
+a	O
+new	O
+kind	O
+of	O
+coronavirus	B-SPEC
+(	O
+SARS_CoV	O
+),	O
+its	O
+genome	O
+was	O
+quickly	O
+sequenced	O
+on	O
+several	O
+isolates	O
+.	O
+
+Theoretical	O
+models	O
+,	O
+either	O
+Logistic	O
+model	O
+or	O
+SIR	O
+model	O
+,	O
+were	O
+developed	O
+to	O
+describe	O
+the	O
+transmission	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+recorded	O
+difference	O
+of	O
+SARS	B-DISO
+spreading	O
+in	O
+Beijing	O
+and	O
+Hong	O
+Kong	O
+was	O
+also	O
+reasonably	O
+analyzed	O
+according	O
+to	O
+these	O
+models	O
+.	O
+
+TITLE	O
+:	O
+Drug	O
+design	O
+targeting	B-PROC
+the	O
+main	O
+protease	O
+,	O
+the	O
+Achilles	B-ANAT
+'	O
+heel	B-ANAT
+of	O
+coronaviruses	O
+.	O
+
+Finally	O
+,	O
+a	O
+brief	O
+introduction	O
+is	O
+given	O
+for	O
+how	O
+to	O
+use	O
+computer	O
+-	O
+generated	O
+graphs	O
+to	O
+rapidly	O
+diagnose	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Attenuated	O
+Salmonella	B-DISO
+have	O
+been	O
+used	O
+as	O
+vectors	O
+to	O
+deliver	O
+foreign	O
+antigens	B-CHED
+as	O
+live	O
+vaccines	O
+.	O
+
+In	O
+vivo	O
+protection	O
+experiments	O
+on	O
+newborn	O
+piglets	O
+have	O
+,	O
+in	O
+addition	O
+,	O
+demonstrated	O
+a	O
+strong	O
+reduction	O
+of	O
+virus	B-SPEC
+titre	O
+in	O
+infected	O
+tissues	B-ANAT
+of	O
+animals	B-SPEC
+treated	O
+orally	B-ANAT
+with	O
+TGEV	B-SPEC
+-	O
+specific	O
+SIPs	B-PROC
+.	O
+
+In	O
+the	O
+meantime	O
+,	O
+decisive	O
+progress	O
+in	O
+the	O
+knowledge	O
+about	O
+the	O
+structure	O
+and	O
+further	O
+characteristics	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+have	O
+been	O
+made	O
+,	O
+including	O
+the	O
+likely	O
+virus	B-SPEC
+reservoir	O
+and	O
+the	O
+ways	O
+of	O
+spread	O
+.	O
+
+Effective	O
+vaccines	O
+and	O
+antiviral	B-CHED
+agents	I-CHED
+are	O
+being	O
+developed	O
+.	O
+
+The	O
+HCoV	B-PRGE
+-	I-PRGE
+NL63	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	B-CHED
+mediates	O
+virion	B-COMP
+attachment	O
+to	O
+cells	B-COMP
+and	O
+subsequent	O
+fusion	O
+of	O
+the	O
+viral	O
+and	O
+cellular	B-COMP
+membranes	B-ANAT
+.	O
+
+Limited	O
+proteolysis	B-PROC
+studies	O
+of	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+S2	O
+fusion	O
+core	O
+identify	O
+an	O
+alpha	O
+-	O
+helical	O
+domain	O
+composed	O
+of	O
+a	O
+trimer	O
+of	O
+the	O
+HR	O
+segments	O
+N57	O
+and	O
+C42	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+this	O
+structure	O
+is	O
+unusually	O
+stable	O
+,	O
+with	O
+an	O
+apparent	O
+melting	O
+temperature	O
+of	O
+78	O
+degrees	O
+C	O
+in	O
+the	O
+presence	O
+of	O
+the	O
+denaturant	O
+guanidine	B-CHED
+hydrochloride	B-CHED
+at	O
+5	O
+M	O
+concentration	O
+.	O
+
+This	O
+study	O
+also	O
+suggests	O
+a	O
+potential	O
+strategy	O
+for	O
+the	O
+development	B-PROC
+of	O
+improved	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+fusion	O
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+immunomodulators	O
+,	O
+interferons	O
+and	O
+known	O
+in	O
+vitro	O
+SARS	B-DISO
+-	O
+coV	O
+inhibitors	B-CHED
+for	O
+inhibition	B-PROC
+of	O
+SARS	B-DISO
+-	O
+coV	O
+replication	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+In	O
+summary	O
+,	O
+the	O
+data	O
+suggest	O
+that	O
+induction	O
+of	O
+IFN	B-PRGE
+by	O
+mismatched	O
+dsRNA	B-CHED
+or	O
+actual	O
+treatment	O
+with	O
+exogenous	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+can	O
+inhibit	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+mice	B-SPEC
+.	O
+
+Herein	O
+we	O
+describe	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+several	O
+classes	O
+of	O
+nucleoside	B-CHED
+analogues	I-CHED
+evaluated	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+Vero	O
+76	O
+cells	B-COMP
+,	O
+some	O
+of	O
+which	O
+exhibited	O
+moderate	O
+activity	O
+.	O
+
+Dengue	B-SPEC
+virus	I-SPEC
+-	O
+specific	O
+probes	O
+with	O
+predicted	O
+solution	O
+-	O
+phase	O
+DeltaG	O
+of	O
+folding	O
+in	O
+500	O
+mM	O
+buffered	O
+NaCl	B-CHED
+of	O
+approximately	O
+-	O
+4	O
+kcal	O
+/	O
+mol	O
+performed	O
+better	O
+than	O
+those	O
+with	O
+DeltaG	O
+>	O
+-	O
+2	O
+or	O
+<	O
+-	O
+6	O
+kcal	O
+/	O
+mol	O
+.	O
+
+Though	O
+they	O
+may	O
+be	O
+viewed	O
+as	O
+extreme	O
+events	O
+,	O
+scenarios	O
+such	O
+as	O
+the	O
+re	O
+-	O
+emergence	O
+of	O
+SARS	B-DISO
+,	O
+the	O
+affliction	O
+posed	O
+by	O
+the	O
+H5N1	B-DISO
+strain	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+and	O
+the	O
+threat	O
+of	O
+a	O
+bioterrorist	O
+attack	O
+have	O
+all	O
+been	O
+described	O
+.	O
+
+In	O
+cockerels	O
+,	O
+IBV	B-SPEC
+multiplies	O
+first	O
+in	O
+the	O
+Harderian	B-ANAT
+gland	I-ANAT
+,	O
+then	O
+simultaneously	O
+in	O
+the	O
+trachea	B-DISO
+and	O
+kidney	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Histopathology	O
+of	O
+two	O
+serotypes	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+laying	O
+hens	O
+vaccinated	O
+in	O
+the	O
+rearing	O
+phase	O
+.	O
+
+We	O
+used	O
+a	O
+well	O
+-	O
+established	O
+recombinant	O
+vaccinia	B-SPEC
+virus	I-SPEC
+(	O
+VV	O
+)-	O
+based	O
+expression	B-PROC
+system	O
+that	O
+lacks	O
+the	O
+viral	B-PRGE
+IFN	I-PRGE
+antagonist	I-PRGE
+E3L	I-PRGE
+to	O
+screen	O
+viral	O
+genes	O
+for	O
+their	O
+ability	O
+to	O
+rescue	O
+the	O
+IFN	B-PRGE
+sensitivity	O
+of	O
+the	O
+mutant	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+small	O
+envelope	O
+protein	B-CHED
+(	O
+E	O
+)	O
+plays	O
+a	O
+role	O
+of	O
+central	O
+importance	O
+in	O
+the	O
+assembly	O
+of	O
+coronaviruses	O
+.	O
+
+To	O
+investigate	O
+whether	O
+different	O
+working	O
+conditions	O
+in	O
+the	O
+hospital	O
+led	O
+to	O
+different	O
+psychological	B-DISO
+effects	O
+on	O
+healthcare	O
+workers	O
+,	O
+the	O
+psychological	B-DISO
+effect	O
+on	O
+emergency	B-DISO
+department	O
+staff	O
+in	O
+the	O
+high	O
+-	O
+risk	O
+ward	O
+was	O
+compared	O
+with	O
+that	O
+on	O
+psychiatric	O
+ward	O
+staff	O
+in	O
+the	O
+medium	O
+-	O
+risk	O
+ward	O
+.	O
+
+No	O
+significant	O
+difference	O
+in	O
+CHQ	B-CHED
+score	O
+was	O
+observed	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+was	O
+a	O
+traumatic	O
+experience	O
+for	O
+healthcare	O
+providers	O
+in	O
+Taiwan	O
+.	O
+
+TITLE	O
+:	O
+Preliminary	O
+crystallographic	O
+analysis	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+main	O
+protease	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+IBV	B-SPEC
+M	O
+(	O
+pro	B-CHED
+)	O
+was	O
+overexpressed	O
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+X	O
+-	O
+ray	B-SPEC
+diffraction	O
+data	O
+were	O
+collected	O
+in	O
+-	O
+house	O
+to	O
+2	O
+.	O
+7	O
+A	O
+resolution	O
+from	O
+a	O
+single	O
+crystal	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Contact	O
+tracing	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+control	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+but	O
+little	O
+is	O
+known	O
+yet	O
+about	O
+its	O
+effectiveness	O
+.	O
+
+TITLE	O
+:	O
+Baculovirus	B-SPEC
+surface	O
+display	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+protein	B-CHED
+and	O
+immunogenicity	O
+of	O
+the	O
+displayed	O
+protein	O
+in	O
+mice	B-SPEC
+models	O
+.	O
+
+Subcutaneous	O
+injection	O
+with	O
+purified	O
+S	O
+-	O
+displayed	O
+baculoviruses	O
+without	O
+adjuvant	B-CHED
+elicited	O
+highly	O
+effective	O
+production	O
+of	O
+specific	O
+and	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+mice	B-SPEC
+.	O
+
+rFVIIa	O
+reduced	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+/	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+coagulopathic	O
+patients	O
+(	O
+3	O
+%	O
+versus	O
+20	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+004	O
+),	O
+whereas	O
+thromboembolic	B-DISO
+events	I-DISO
+were	O
+equally	O
+present	O
+in	O
+both	O
+groups	O
+(	O
+3	O
+%	O
+versus	O
+4	O
+%,	O
+P	O
+=	O
+1	O
+.	O
+00	O
+).	O
+
+ABSTRACT	O
+:	O
+Cytomegalovirus	O
+(	O
+CMV	B-SPEC
+)	O
+infection	B-DISO
+is	O
+associated	O
+with	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+In	O
+immunocompetent	O
+individuals	O
+,	O
+the	O
+infection	B-DISO
+is	O
+usually	O
+subclinical	O
+but	O
+it	O
+can	O
+sometimes	O
+be	O
+life	O
+threatening	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+performed	O
+intra	O
+-	O
+hospital	O
+syndromic	O
+surveillance	O
+to	O
+rapidly	O
+detect	O
+nosocomial	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+outbreaks	O
+in	O
+both	O
+inpatients	O
+and	O
+health	O
+care	O
+workers	O
+in	O
+a	O
+hospital	O
+.	O
+
+Furthermore	O
+,	O
+some	O
+insectivorous	O
+bat	B-ENZY
+species	B-SPEC
+may	O
+be	O
+important	O
+reservoirs	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+whereas	O
+Ebola	B-SPEC
+virus	I-SPEC
+has	O
+been	O
+detected	O
+in	O
+some	O
+megachiropteran	O
+fruit	O
+bats	B-SPEC
+.	O
+
+Thus	O
+far	O
+,	O
+European	B-SPEC
+bat	I-SPEC
+lyssavirus	I-SPEC
+(	O
+EBLV	O
+)	O
+is	O
+the	O
+only	O
+zoonotic	O
+virus	B-SPEC
+that	O
+has	O
+been	O
+detected	O
+in	O
+bats	B-SPEC
+in	O
+Europe	O
+.	O
+
+New	O
+zoonotic	O
+viruses	B-SPEC
+may	O
+emerge	O
+from	O
+bat	B-ENZY
+reservoirs	O
+and	O
+known	O
+ones	O
+may	O
+spread	O
+to	O
+a	O
+wider	O
+geographical	O
+range	O
+.	O
+
+With	O
+the	O
+knowledge	O
+generated	O
+from	O
+this	O
+kind	O
+of	O
+research	O
+,	O
+a	O
+rapid	O
+response	O
+system	O
+can	O
+be	O
+set	O
+up	O
+to	O
+enhance	O
+public	O
+health	O
+awareness	O
+of	O
+emerging	O
+zoonotic	O
+viruses	B-SPEC
+of	O
+bats	B-SPEC
+.	O
+
+The	O
+purified	O
+protein	B-CHED
+was	O
+characterized	O
+using	O
+circular	O
+dichroism	O
+,	O
+size	O
+exclusion	O
+chromatography	O
+,	O
+and	O
+multi	O
+-	O
+angle	O
+light	O
+scattering	O
+.	O
+
+TITLE	O
+:	O
+Production	O
+of	O
+authentic	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+with	O
+enhanced	O
+activity	O
+:	O
+application	O
+as	O
+a	O
+novel	O
+tag	B-DISO
+-	O
+cleavage	B-PROC
+endopeptidase	O
+for	O
+protein	B-CHED
+overproduction	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+additional	O
+residues	O
+at	O
+the	O
+N	O
+terminus	O
+,	O
+but	O
+not	O
+at	O
+the	O
+C	O
+terminus	O
+,	O
+of	O
+M	O
+(	O
+pro	B-CHED
+)	O
+are	O
+detrimental	O
+to	O
+enzyme	B-FUNC
+activity	I-FUNC
+.	O
+
+To	O
+explain	O
+this	O
+,	O
+the	O
+crystal	B-ANAT
+structures	O
+of	O
+WT	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+and	O
+its	O
+complex	O
+with	O
+a	O
+Michael	O
+acceptor	B-CHED
+inhibitor	B-CHED
+were	O
+determined	O
+to	O
+1	O
+.	O
+6	O
+Angstroms	O
+and	O
+1	O
+.	O
+95	O
+Angstroms	O
+resolution	O
+respectively	O
+.	O
+
+RESULTS	O
+:	O
+Old	O
+age	O
+(	O
+over	O
+60	O
+years	O
+)	O
+was	O
+found	O
+to	O
+be	O
+significantly	O
+associated	O
+with	O
+SARS	B-DISO
+-	O
+related	O
+deaths	B-PROC
+in	O
+the	O
+univariate	O
+analysis	O
+.	O
+
+We	O
+investigated	O
+the	O
+combination	O
+of	O
+type	B-PRGE
+I	I-PRGE
+IFNs	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+or	I-PRGE
+-	I-PRGE
+beta	I-PRGE
+)	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+for	O
+antiviral	B-CHED
+activity	O
+and	O
+found	O
+that	O
+such	O
+combinations	O
+synergistically	O
+inhibited	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+using	O
+yield	O
+reduction	O
+assay	O
+and	O
+the	O
+isobologram	O
+and	O
+combination	O
+index	O
+methods	O
+of	O
+Chou	O
+and	O
+Talalay	O
+for	O
+evaluation	O
+.	O
+
+The	O
+highly	O
+synergistic	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+action	O
+of	O
+type	B-PRGE
+I	I-PRGE
+IFNs	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+parallels	O
+the	O
+marked	O
+increase	O
+in	O
+2	O
+'-	O
+5	O
+'-	O
+oligoadenylate	B-PRGE
+synthetase	I-PRGE
+and	O
+p56	B-PRGE
+mRNAs	I-PRGE
+following	O
+exposure	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+to	O
+either	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+or	I-PRGE
+-	I-PRGE
+beta	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+compared	O
+with	O
+the	O
+transcriptional	B-PROC
+levels	O
+obtained	O
+after	O
+stimulation	O
+with	O
+either	O
+IFN	B-PRGE
+alone	O
+.	O
+
+TITLE	O
+:	O
+Aurintricarboxylic	O
+acid	O
+inhibits	O
+the	O
+early	O
+stage	O
+of	O
+vaccinia	B-SPEC
+virus	B-PROC
+replication	I-PROC
+by	O
+targeting	B-PROC
+both	O
+cellular	O
+and	O
+viral	O
+factors	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+is	O
+a	O
+zoonotic	O
+virus	B-SPEC
+that	O
+crossed	O
+the	O
+species	B-SPEC
+barrier	O
+,	O
+most	O
+likely	O
+originating	O
+from	O
+bats	B-SPEC
+or	O
+from	O
+other	O
+species	B-SPEC
+including	O
+civets	B-SPEC
+,	O
+raccoon	B-SPEC
+dogs	I-SPEC
+,	O
+domestic	B-SPEC
+cats	I-SPEC
+,	O
+swine	B-SPEC
+,	O
+and	O
+rodents	B-SPEC
+.	O
+
+Using	O
+Venezuelan	B-SPEC
+equine	I-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+replicon	O
+particles	O
+(	O
+VRP	B-PRGE
+)	O
+expressing	O
+the	O
+2003	O
+epidemic	O
+Urbani	O
+SARS	B-DISO
+-	O
+CoV	O
+strain	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+(	O
+VRP	B-PRGE
+-	I-PRGE
+S	I-PRGE
+)	O
+or	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+from	O
+the	O
+same	O
+strain	O
+(	O
+VRP	O
+-	O
+N	O
+),	O
+we	O
+demonstrate	O
+that	O
+VRP	B-PRGE
+-	I-PRGE
+S	I-PRGE
+,	O
+but	O
+not	O
+VRP	O
+-	O
+N	O
+vaccines	O
+provide	O
+complete	O
+short	O
+-	O
+and	O
+long	O
+-	O
+term	O
+protection	O
+against	O
+homologous	O
+strain	O
+challenge	O
+in	O
+young	O
+and	O
+senescent	O
+mice	B-SPEC
+.	O
+
+To	O
+test	O
+VRP	O
+vaccine	O
+efficacy	O
+against	O
+a	O
+heterologous	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+we	O
+used	O
+phylogenetic	O
+analyses	O
+,	O
+synthetic	O
+biology	O
+,	O
+and	O
+reverse	O
+genetics	O
+to	O
+construct	O
+a	O
+chimeric	O
+virus	B-SPEC
+(	O
+icGDO3	O
+-	O
+S	O
+)	O
+encoding	O
+a	O
+synthetic	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+gene	I-PRGE
+of	O
+the	O
+most	O
+genetically	O
+divergent	O
+human	B-SPEC
+strain	O
+,	O
+GDO3	O
+,	O
+which	O
+clusters	B-CHED
+among	O
+the	O
+zoonotic	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+icGD03	O
+-	O
+S	O
+replicated	O
+efficiently	O
+in	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+young	O
+and	O
+senescent	O
+mice	B-SPEC
+,	O
+and	O
+was	O
+highly	O
+resistant	O
+to	O
+neutralization	O
+with	O
+antisera	O
+directed	O
+against	O
+the	O
+Urbani	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+encodes	O
+a	O
+single	O
+ORF4	O
+protein	B-CHED
+between	O
+the	O
+spike	O
+and	O
+the	O
+envelope	B-COMP
+genes	O
+.	O
+
+All	O
+CCU	O
+isolates	O
+are	O
+only	O
+98	O
+%	O
+identical	O
+to	O
+the	O
+Dutch	O
+isolates	O
+at	O
+the	O
+nucleotide	B-CHED
+level	O
+,	O
+but	O
+more	O
+closely	O
+related	O
+to	O
+the	O
+prototype	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+(>	O
+98	O
+%).	O
+
+For	O
+the	O
+follow	O
+-	O
+up	O
+study	O
+,	O
+the	O
+rats	B-SPEC
+exposed	O
+for	O
+3	O
+days	O
+were	O
+scanned	O
+using	O
+CT	O
+and	O
+their	O
+pathology	B-DISO
+was	O
+examined	O
+at	O
+7	O
+,	O
+14	O
+,	O
+and	O
+28	O
+days	O
+.	O
+
+The	O
+pathological	O
+findings	O
+in	O
+this	O
+period	O
+,	O
+the	O
+grades	O
+of	O
+vascular	B-ANAT
+congestion	B-DISO
+,	O
+tracheobronchial	O
+exfoliation	O
+,	O
+and	O
+alveolar	B-DISO
+rupture	I-DISO
+were	O
+significant	O
+.	O
+
+Interestingly	O
+,	O
+no	O
+apparent	O
+evidence	O
+for	O
+colocalization	O
+of	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+with	O
+lipid	B-COMP
+rafts	I-COMP
+in	O
+the	O
+membrane	B-COMP
+of	O
+Vero	O
+E6	O
+cells	B-COMP
+was	O
+obtained	O
+.	O
+
+The	O
+clinical	O
+presentation	O
+of	O
+SARS	B-DISO
+in	O
+patients	O
+older	O
+than	O
+12	O
+years	O
+of	O
+age	O
+was	O
+similar	O
+to	O
+that	O
+in	O
+adults	O
+.	O
+
+ABSTRACT	O
+:	O
+Leptospirosis	B-DISO
+is	O
+a	O
+globally	O
+distributed	O
+zoonosis	B-DISO
+of	O
+major	O
+public	O
+health	O
+importance	O
+and	O
+is	O
+associated	O
+with	O
+severe	O
+disease	O
+manifestations	O
+such	O
+as	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+pulmonary	B-DISO
+haemorrhage	I-DISO
+syndrome	B-DISO
+.	O
+
+Patients	O
+with	O
+severe	O
+leptospirosis	B-DISO
+had	O
+significantly	O
+higher	O
+NO	O
+levels	O
+compared	O
+to	O
+healthy	O
+individuals	O
+(	O
+30	O
+.	O
+82	O
++/-	O
+10	O
+.	O
+90	O
+microM	O
+versus	O
+3	O
+.	O
+86	O
++/-	O
+1	O
+.	O
+34	O
+microM	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+indicating	O
+that	O
+this	O
+immune	O
+mediator	O
+plays	O
+a	O
+role	O
+in	O
+the	O
+underlying	O
+systemic	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+The	O
+structural	O
+data	O
+further	O
+suggest	O
+that	O
+the	O
+binding	B-FUNC
+of	O
+APE	B-SPEC
+to	O
+M	O
+(	O
+pro	B-CHED
+)	O
+follows	O
+an	O
+induced	O
+-	O
+fit	B-DISO
+model	O
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+canine	I-DISO
+hepatitis	I-DISO
+:	O
+an	O
+""""	O
+old	O
+""""	O
+disease	O
+reemerging	O
+in	O
+Italy	O
+.	O
+
+The	O
+most	O
+worrying	O
+factors	O
+were	O
+the	O
+severity	O
+of	O
+consciousness	B-DISO
+disorders	I-DISO
+,	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+the	O
+metabolic	B-DISO
+acidosis	I-DISO
+,	O
+and	O
+the	O
+refractory	B-DISO
+shock	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Ten	O
+patients	O
+were	O
+included	O
+for	O
+severe	O
+imported	O
+malaria	B-PATH
+.	O
+
+TITLE	O
+:	O
+Mass	O
+casualty	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+prospective	O
+large	O
+-	O
+animal	B-SPEC
+study	O
+was	O
+performed	O
+to	O
+evaluate	O
+the	O
+contribution	O
+of	O
+arterio	B-ANAT
+-	I-ANAT
+venous	I-ANAT
+extracorporeal	O
+lung	B-ANAT
+assist	O
+(	O
+AV	O
+-	O
+ECLA	O
+)	O
+to	O
+pulmonary	B-PROC
+gas	B-ENZY
+exchange	I-PROC
+in	O
+a	O
+porcine	B-SPEC
+lavage	O
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+model	O
+.	O
+
+After	O
+a	O
+stabilization	O
+period	O
+of	O
+60	O
+min	O
+,	O
+the	O
+femoral	B-ANAT
+artery	I-ANAT
+and	O
+vein	B-ANAT
+were	O
+cannulated	O
+and	O
+a	O
+low	O
+-	O
+resistance	B-PROC
+membrane	B-COMP
+lung	B-ANAT
+was	O
+interposed	O
+.	O
+
+Under	O
+apnoeic	B-DISO
+oxygenation	B-PROC
+,	O
+variations	O
+of	O
+sweep	O
+-	O
+gas	B-ENZY
+flow	O
+were	O
+performed	O
+every	O
+20	O
+min	O
+in	O
+order	B-SPEC
+to	O
+evaluate	O
+the	O
+membrane	B-COMP
+lung	B-ANAT
+'	O
+s	O
+efficacy	O
+,	O
+in	O
+terms	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+(	O
+CO2	B-CHED
+)	O
+removal	O
+and	O
+oxygen	B-CHED
+(	O
+O2	O
+)	O
+uptake	O
+.	O
+
+TITLE	O
+:	O
+Novel	O
+beta	O
+-	O
+barrel	O
+fold	O
+in	O
+the	O
+nuclear	O
+magnetic	O
+resonance	O
+structure	O
+of	O
+the	O
+replicase	B-PRGE
+nonstructural	O
+protein	O
+1	O
+from	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+structure	O
+is	O
+analyzed	O
+in	O
+a	O
+search	O
+for	O
+possible	O
+correlations	O
+with	O
+the	O
+recently	O
+reported	O
+activity	O
+of	O
+nsp1	O
+in	O
+the	O
+degradation	O
+of	O
+mRNA	B-CHED
+.	O
+
+Our	O
+results	O
+indicating	O
+that	O
+the	O
+IgM	B-PRGE
+response	O
+appears	O
+earlier	O
+than	O
+IgG	B-PRGE
+after	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+consistent	O
+with	O
+those	O
+for	O
+other	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Delayed	O
+presentation	O
+of	O
+amniotic	B-DISO
+fluid	I-DISO
+embolism	I-DISO
+:	O
+lessons	O
+from	O
+a	O
+case	O
+diagnosed	O
+at	O
+autopsy	O
+.	O
+
+Her	O
+blood	B-PROC
+pressure	I-PROC
+was	O
+elevated	O
+(	O
+systolic	O
+150	O
+-	O
+180	O
+mm	O
+Hg	O
+,	O
+diastolic	O
+90	O
+-	O
+110	O
+mm	O
+Hg	O
+)	O
+throughout	O
+the	O
+admission	O
+.	O
+
+It	O
+was	O
+more	O
+intense	O
+in	O
+the	O
+patients	O
+with	O
+MODS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Oxygen	B-PROC
+metabolism	I-PROC
+abnormality	O
+was	O
+found	O
+after	O
+trauma	O
+,	O
+and	O
+it	O
+was	O
+correlated	O
+with	O
+ISS	B-DISO
+,	O
+RTS	B-DISO
+,	O
+injured	O
+organ	B-ANAT
+or	O
+region	O
+and	O
+number	O
+of	O
+injured	O
+organs	B-ANAT
+,	O
+shock	O
+,	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+)	O
+and	O
+respiratory	B-DISO
+complications	I-DISO
+.	O
+
+Later	O
+on	O
+,	O
+viral	O
+nucleocapsids	O
+have	O
+to	O
+be	O
+transported	O
+to	O
+the	O
+budding	B-PATH
+sites	O
+in	O
+the	O
+Golgi	B-COMP
+region	O
+where	O
+the	O
+viral	O
+glycoproteins	B-CHED
+accumulate	O
+and	O
+particle	O
+formation	B-PROC
+occurs	O
+.	O
+
+The	O
+patients	O
+were	O
+then	O
+followed	O
+up	O
+to	O
+note	O
+any	O
+subsequent	O
+development	B-PROC
+of	O
+complications	O
+.	O
+
+It	O
+was	O
+found	O
+to	O
+be	O
+significant	O
+at	O
+5	O
+%	O
+level	O
+of	O
+significance	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+by	O
+chi	B-CHED
+square	O
+test	O
+.	O
+
+The	O
+optimum	O
+diagnostic	O
+procedure	O
+is	O
+examination	O
+of	O
+thick	O
+and	O
+thin	O
+blood	B-ANAT
+films	O
+by	O
+an	O
+expert	O
+to	O
+detect	O
+and	O
+speciate	O
+the	O
+malarial	O
+parasites	O
+;	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+malaria	O
+can	O
+be	O
+diagnosed	O
+almost	O
+as	O
+accurately	O
+using	O
+rapid	O
+diagnostic	O
+tests	O
+(	O
+RDTs	O
+)	O
+which	O
+detect	O
+plasmodial	O
+antigens	B-CHED
+or	O
+enzymes	O
+,	O
+although	O
+RDTs	O
+for	O
+other	O
+Plasmodium	B-SPEC
+species	B-SPEC
+are	O
+not	O
+as	O
+reliable	O
+.	O
+
+This	O
+must	O
+be	O
+avoided	O
+or	O
+given	O
+with	O
+caution	O
+under	O
+expert	O
+supervision	O
+in	O
+patients	O
+with	O
+glucose	B-DISO
+-	I-DISO
+6	I-DISO
+-	I-DISO
+phosphate	B-CHED
+dehydrogenase	I-DISO
+deficiency	I-DISO
+(	O
+G6PD	B-PRGE
+),	O
+in	O
+whom	O
+it	O
+may	O
+cause	O
+severe	O
+haemolysis	B-DISO
+.	O
+
+An	O
+acute	O
+attack	O
+of	O
+malaria	B-PATH
+does	O
+not	O
+confer	O
+protection	O
+from	O
+future	O
+attacks	O
+:	O
+individuals	O
+who	O
+have	O
+had	O
+malaria	B-PATH
+should	O
+take	O
+effective	O
+anti	O
+-	O
+mosquito	B-SPEC
+precautions	O
+and	O
+chemoprophylaxis	O
+during	O
+future	O
+visits	O
+to	O
+endemic	O
+areas	O
+.	O
+
+TITLE	O
+:	O
+Serological	O
+and	O
+molecular	O
+evidence	O
+that	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+is	O
+circulating	O
+in	O
+Italy	O
+.	O
+
+Positive	O
+results	O
+were	O
+obtained	O
+from	O
+the	O
+lungs	B-ANAT
+of	O
+a	O
+dog	B-SPEC
+of	O
+the	O
+Apulia	O
+region	O
+that	O
+was	O
+co	O
+-	O
+infected	O
+with	O
+canine	O
+parvovirus	B-DISO
+type	O
+2	O
+.	O
+
+In	O
+multivariable	O
+analysis	O
+exposures	O
+for	O
+at	O
+least	O
+30	O
+min	O
+at	O
+a	O
+distance	O
+of	O
+<	O
+or	O
+=	O
+1	O
+m	O
+increased	O
+the	O
+likelihood	O
+of	O
+becoming	O
+a	O
+SARS	B-DISO
+case	O
+20	O
+.	O
+4	O
+-	O
+fold	O
+(	O
+95	O
+%	O
+CI	O
+11	O
+.	O
+8	O
+-	O
+35	O
+.	O
+1	O
+).	O
+
+TITLE	O
+:	O
+A	O
+mouse	B-SPEC
+-	O
+adapted	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+causes	O
+disease	O
+and	O
+mortality	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+Older	O
+(	O
+12	O
+-	O
+to	O
+14	O
+-	O
+mo	O
+-	O
+old	O
+)	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+develop	O
+clinical	O
+illness	O
+and	O
+pneumonitis	B-DISO
+,	O
+but	O
+they	O
+can	O
+be	O
+hard	O
+to	O
+procure	O
+,	O
+and	O
+immune	O
+senescence	O
+complicates	O
+pathogenesis	B-DISO
+studies	O
+.	O
+
+These	O
+observations	O
+suggest	O
+that	O
+mice	B-SPEC
+infected	O
+with	O
+MA15	O
+die	O
+from	O
+an	O
+overwhelming	O
+viral	B-DISO
+infection	I-DISO
+with	O
+extensive	O
+,	O
+virally	O
+mediated	O
+destruction	O
+of	O
+pneumocytes	B-ANAT
+and	O
+ciliated	O
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+This	O
+virus	B-SPEC
+will	O
+be	O
+of	O
+value	O
+as	O
+a	O
+stringent	O
+challenge	O
+in	O
+evaluation	O
+of	O
+the	O
+efficacy	O
+of	O
+vaccines	O
+and	O
+antivirals	B-CHED
+.	O
+
+HKU1	O
+-	O
+specific	O
+MAb	O
+may	O
+contribute	O
+to	O
+the	O
+rapid	O
+diagnosis	O
+of	O
+HKU1	O
+infections	B-DISO
+currently	O
+performed	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+RESULTS	O
+:	O
+Overall	O
+,	O
+48	O
+/	O
+426	O
+(	O
+11	O
+.	O
+3	O
+%)	O
+patients	O
+were	O
+found	O
+to	O
+be	O
+infected	O
+by	O
+hCoV	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ARTI	O
+).	O
+
+The	O
+nsps	O
+assemble	O
+with	O
+membranes	B-ANAT
+to	O
+generate	O
+double	O
+membrane	B-COMP
+vesicles	B-COMP
+,	O
+which	O
+are	O
+the	O
+sites	O
+of	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+MHV	B-SPEC
+nsp3	B-PRGE
+contains	O
+multiple	O
+domains	O
+including	O
+two	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+domains	I-PRGE
+,	O
+PLP1	B-PRGE
+and	O
+PLP2	B-PRGE
+,	O
+and	O
+a	O
+predicted	O
+transmembrane	B-COMP
+(	O
+TM	O
+)	O
+domain	O
+.	O
+
+RESULTS	O
+:	O
+CSF	B-ANAT
+IgG	B-PRGE
+(	O
+range	O
+of	O
+titers	O
+,	O
+1	O
+:	O
+32	O
+to	O
+1	O
+:	O
+4	O
+,	O
+096	O
+)	O
+was	O
+detected	O
+in	O
+12	O
+cats	B-SPEC
+,	O
+including	O
+6	O
+cats	B-SPEC
+with	O
+neurologic	O
+manifestation	O
+of	O
+FIP	B-DISO
+,	O
+4	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+not	O
+involving	O
+the	O
+CNS	B-CHED
+,	O
+and	O
+2	O
+cats	B-SPEC
+with	O
+brain	B-DISO
+tumors	I-DISO
+.	O
+
+Surprisingly	O
+,	O
+IgA	B-PRGE
+plasma	B-ANAT
+cells	I-ANAT
+infiltrate	B-DISO
+inflamed	O
+tissues	B-ANAT
+in	O
+acute	O
+Kawasaki	B-DISO
+disease	I-DISO
+,	O
+including	O
+the	O
+coronary	B-ANAT
+artery	I-ANAT
+,	O
+and	O
+are	O
+oligoclonal	O
+,	O
+or	O
+antigen	B-CHED
+-	O
+driven	O
+.	O
+
+Our	O
+objectives	O
+are	O
+to	O
+quickly	O
+interpret	O
+symptoms	O
+of	O
+emergency	B-DISO
+patients	O
+to	O
+identify	O
+likely	O
+syndromes	B-DISO
+and	O
+to	O
+improve	O
+population	O
+-	O
+wide	O
+disease	O
+outbreak	O
+detection	O
+.	O
+
+Combining	O
+these	O
+conditional	O
+probabilities	O
+with	O
+misdiagnosis	O
+error	O
+rates	O
+and	O
+incidence	O
+rates	O
+via	O
+Bayes	O
+theorem	O
+,	O
+the	O
+probability	O
+of	O
+each	O
+syndrome	B-DISO
+is	O
+estimated	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+examined	O
+long	O
+-	O
+term	O
+outcome	O
+of	O
+pulmonary	B-PROC
+function	I-PROC
+,	O
+exercise	O
+capacity	O
+and	O
+health	O
+-	O
+related	O
+quality	O
+of	O
+life	O
+(	O
+HRQoL	O
+)	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+caused	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Except	O
+for	O
+diffusion	B-PRGE
+capacity	I-PRGE
+adjusted	I-PRGE
+for	I-PRGE
+haemoglobin	I-PRGE
+concentration	I-PRGE
+(	O
+DLCO	O
+)	O
+measured	O
+at	O
+12	O
+months	O
+,	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+pulmonary	B-PROC
+function	I-PROC
+measurement	O
+between	O
+those	O
+who	O
+had	O
+mechanical	O
+ventilation	O
+and	O
+those	O
+who	O
+did	O
+not	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+causative	O
+agent	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+identified	O
+as	O
+a	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+following	O
+the	O
+outbreak	O
+of	O
+2002	O
+-	O
+2003	O
+.	O
+
+It	O
+was	O
+recently	O
+demonstrated	O
+that	O
+the	O
+protein	B-CHED
+forms	O
+ion	B-FUNC
+channels	I-FUNC
+.	O
+
+We	O
+investigated	O
+the	O
+importance	O
+of	O
+the	O
+hydrophobic	O
+domain	O
+of	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+A59	O
+E	O
+protein	B-CHED
+.	O
+
+Alanine	B-CHED
+scanning	O
+insertion	O
+mutagenesis	B-PROC
+was	O
+used	O
+to	O
+examine	O
+the	O
+effect	O
+of	O
+disruption	O
+of	O
+the	O
+domain	O
+on	O
+virus	B-SPEC
+production	O
+in	O
+the	O
+context	O
+of	O
+the	O
+virus	B-SPEC
+genome	O
+by	O
+using	O
+a	O
+MHV	B-SPEC
+A59	O
+infectious	B-DISO
+clone	O
+.	O
+
+We	O
+characterized	O
+the	O
+structures	O
+of	O
+N	O
+-	O
+NTD	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+two	O
+crystal	B-ANAT
+forms	O
+,	O
+at	O
+1	O
+.	O
+17	O
+A	O
+(	O
+monoclinic	O
+)	O
+and	O
+at	O
+1	O
+.	O
+85	O
+A	O
+(	O
+cubic	O
+),	O
+respectively	O
+,	O
+resolved	O
+by	O
+molecular	O
+replacement	O
+using	O
+the	O
+homologous	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+structure	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+nonfluorescent	O
+low	O
+-	O
+cost	O
+,	O
+low	O
+-	O
+density	O
+oligonucleotide	B-CHED
+array	O
+was	O
+designed	O
+for	O
+detecting	O
+the	O
+whole	O
+coronavirus	B-SPEC
+genus	B-SPEC
+after	O
+reverse	B-PROC
+transcription	I-PROC
+(	O
+RT	O
+)-	O
+PCR	O
+.	O
+
+These	O
+assays	O
+will	O
+be	O
+useful	O
+not	O
+only	O
+for	O
+routine	O
+SARS	B-DISO
+coronavirus	B-SPEC
+diagnostics	O
+but	O
+also	O
+for	O
+epidemiological	O
+and	O
+antibody	B-COMP
+kinetic	O
+studies	O
+.	O
+
+Ninety	O
+SARS	B-DISO
+-	O
+care	O
+task	O
+force	O
+members	O
+(	O
+SARS	B-DISO
+HCWs	O
+)	O
+and	O
+82	O
+control	O
+subjects	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+an	O
+empirical	O
+model	O
+to	O
+aid	O
+in	O
+designing	O
+airborne	O
+infection	B-DISO
+isolation	O
+rooms	O
+.	O
+
+The	O
+cleavage	B-PROC
+efficiency	O
+of	O
+SPP	B-ENZY
+is	O
+inversely	O
+proportional	O
+to	O
+the	O
+length	O
+of	O
+C	O
+-	O
+terminal	O
+extension	O
+of	O
+the	O
+signal	O
+peptide	B-CHED
+:	O
+the	O
+longer	O
+the	O
+extension	O
+,	O
+the	O
+less	O
+efficiency	O
+the	O
+cleavage	B-PROC
+is	O
+.	O
+
+Thus	O
+,	O
+our	O
+results	O
+suggest	O
+that	O
+both	O
+sequences	O
+of	O
+the	O
+signal	O
+peptide	B-CHED
+and	O
+the	O
+E	O
+.	O
+R	O
+.-	O
+associated	O
+domain	O
+are	O
+important	O
+for	O
+the	O
+signal	O
+peptide	B-CHED
+cleavage	B-PROC
+of	O
+HCV	B-PRGE
+core	I-PRGE
+protein	B-CHED
+by	O
+SPP	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+,	O
+Avian	B-DISO
+Flu	I-DISO
+and	O
+other	O
+infectious	B-DISO
+and	O
+potentially	O
+highly	O
+transmissible	O
+diseases	O
+are	O
+threats	O
+to	O
+the	O
+entire	O
+healthcare	O
+workforce	O
+.	O
+
+19	O
+%	O
+was	O
+calculated	O
+for	O
+B	B-SPEC
+.	I-SPEC
+subtilis	I-SPEC
+.	O
+
+We	O
+illustrate	O
+the	O
+use	O
+of	O
+DNA	O
+skews	O
+for	O
+characterization	O
+of	O
+poxvirus	O
+and	O
+coronavirus	B-SPEC
+genomes	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+have	O
+overlapping	O
+specificities	O
+but	O
+distinct	O
+functions	O
+in	O
+viral	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+New	O
+respiratory	O
+viruses	O
+associated	O
+with	O
+pneumonia	B-DISO
+have	O
+in	O
+the	O
+past	O
+few	O
+years	O
+been	O
+detected	O
+in	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+(	O
+CCoV	O
+)	O
+is	O
+widespread	O
+in	O
+dogs	O
+in	O
+several	O
+countries	O
+and	O
+causes	O
+mild	O
+enteric	O
+illness	O
+evolving	O
+to	O
+severe	O
+enteritis	B-DISO
+in	O
+young	O
+pups	O
+.	O
+
+Starting	O
+from	O
+24h	O
+after	O
+CCoV	O
+infection	B-DISO
+,	O
+cells	B-COMP
+morphology	O
+appeared	O
+dramatically	O
+changed	O
+,	O
+with	O
+cells	B-COMP
+rounding	O
+and	O
+detachment	B-DISO
+from	O
+culture	O
+surface	O
+.	O
+
+TITLE	O
+:	O
+Using	O
+models	O
+to	O
+identify	O
+routes	O
+of	O
+nosocomial	B-DISO
+infection	I-DISO
+:	O
+a	O
+large	O
+hospital	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+.	O
+
+Previous	O
+studies	O
+have	O
+described	O
+the	O
+general	O
+pathology	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+of	O
+SARS	B-DISO
+patients	O
+and	O
+have	O
+identified	O
+some	O
+of	O
+the	O
+cell	B-COMP
+types	O
+infected	O
+by	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+have	O
+performed	O
+double	O
+labeling	O
+combining	O
+in	O
+situ	O
+hybridization	B-PROC
+with	O
+immunohistochemistry	O
+and	O
+alternating	O
+each	O
+of	O
+these	O
+techniques	O
+separately	O
+in	O
+consecutive	O
+sections	O
+to	O
+evaluate	O
+the	O
+viral	O
+distribution	O
+on	O
+various	O
+cell	B-COMP
+types	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+seven	O
+patients	O
+affected	O
+with	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+metapneumovirus	O
+was	O
+identified	O
+in	O
+2001	O
+as	O
+a	O
+respiratory	O
+-	O
+tract	O
+pathogen	O
+that	O
+has	O
+been	O
+classified	O
+as	O
+a	O
+new	O
+genera	O
+in	O
+family	B-SPEC
+Paramyxoviridae	I-SPEC
+.	O
+
+Human	B-SPEC
+metapneumovirus	I-SPEC
+was	O
+identified	O
+in	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+amplification	B-DISO
+of	O
+the	O
+viral	O
+fusion	O
+and	O
+nucleocapsid	B-COMP
+genes	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+followed	O
+by	O
+sequencing	O
+and	O
+phylogenetic	O
+analysis	O
+.	O
+
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+in	O
+2003	O
+and	O
+current	O
+concerns	O
+about	O
+the	O
+risk	O
+of	O
+an	O
+avian	B-DISO
+influenza	I-DISO
+(	O
+H5N1	B-DISO
+)	O
+pandemic	O
+,	O
+have	O
+made	O
+a	O
+review	O
+of	O
+this	O
+area	O
+timely	O
+.	O
+
+The	O
+panel	O
+systematically	O
+assessed	O
+40	O
+original	O
+studies	O
+through	O
+both	O
+individual	O
+assessment	O
+and	O
+a	O
+2	O
+-	O
+day	O
+face	O
+-	O
+to	O
+-	O
+face	B-DISO
+consensus	O
+meeting	O
+.	O
+
+There	O
+is	O
+insufficient	O
+data	O
+to	O
+specify	O
+and	O
+quantify	O
+the	O
+minimum	O
+ventilation	O
+requirements	O
+in	O
+hospitals	O
+,	O
+schools	O
+,	O
+offices	O
+,	O
+homes	O
+and	O
+isolation	O
+rooms	O
+in	O
+relation	O
+to	O
+spread	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+via	O
+the	O
+airborne	O
+route	O
+.	O
+
+Isolation	O
+of	O
+Pasteurella	B-SPEC
+multocida	I-SPEC
+was	O
+associated	O
+with	O
+increased	O
+concentrations	O
+of	O
+all	O
+tested	O
+acute	O
+phase	O
+proteins	B-CHED
+.	O
+
+However	O
+,	O
+the	O
+antigens	B-CHED
+used	O
+in	O
+these	O
+assays	O
+differed	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+have	O
+expressed	B-PROC
+and	O
+purified	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+structural	O
+proteins	B-CHED
+and	O
+their	O
+fragments	O
+and	O
+developed	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assays	O
+(	O
+ELISAs	O
+)	O
+that	O
+detect	O
+antibodies	B-COMP
+against	O
+the	O
+SARS	B-DISO
+N	O
+,	O
+N	O
+(	O
+1	O
+),	O
+N	O
+(	O
+2	O
+),	O
+S	O
+(	O
+1	O
+),	O
+S	O
+(	O
+C	O
+),	O
+S	O
+(	O
+2	O
+),	O
+and	O
+M	O
+proteins	B-CHED
+as	O
+well	O
+as	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+and	O
+229E	O
+N	O
+proteins	B-CHED
+.	O
+
+These	O
+assays	O
+were	O
+used	O
+to	O
+screen	O
+58	O
+samples	O
+from	O
+SARS	B-DISO
+convalescent	O
+patients	O
+,	O
+40	O
+serial	O
+serum	B-COMP
+specimens	O
+from	O
+patients	O
+at	O
+different	O
+phases	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+,	O
+and	O
+88	O
+plasma	B-ANAT
+specimens	O
+from	O
+normal	O
+blood	B-ANAT
+donors	O
+.	O
+
+Using	O
+sensitive	O
+polymerase	O
+chain	O
+reactions	O
+,	O
+we	O
+studied	O
+the	O
+spectrum	O
+of	O
+atypical	O
+bacteria	B-SPEC
+and	O
+respiratory	O
+viruses	B-SPEC
+in	O
+travelers	O
+fulfilling	O
+the	O
+case	O
+definition	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Influenza	B-DISO
+and	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+were	O
+most	O
+prevalent	O
+,	O
+at	O
+14	O
+.	O
+2	O
+%	O
+and	O
+15	O
+.	O
+5	O
+%,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Globalization	O
+and	O
+infectious	B-DISO
+diseases	I-DISO
+].	O
+
+Most	O
+commercial	O
+mAbs	O
+studied	O
+as	O
+antiviral	B-CHED
+agents	I-CHED
+in	O
+the	O
+clinic	O
+have	O
+either	O
+directly	O
+or	O
+indirectly	O
+targeted	B-PROC
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+or	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+infections	B-DISO
+.	O
+
+Challenges	O
+remaining	O
+for	O
+the	O
+application	O
+of	O
+siRNA	O
+in	O
+vivo	O
+for	O
+SARS	B-DISO
+prevention	O
+and	O
+treatment	O
+include	O
+the	O
+specificity	O
+of	O
+the	O
+siRNAs	O
+and	O
+the	O
+efficiency	O
+of	O
+delivery	O
+.	O
+
+TITLE	O
+:	O
+Selective	O
+adaptation	B-PROC
+and	O
+human	B-SPEC
+rights	O
+to	O
+health	O
+in	O
+China	O
+.	O
+
+This	O
+chip	O
+does	O
+not	O
+require	O
+DNA	O
+labeling	O
+,	O
+and	O
+the	O
+hybridization	B-PROC
+signal	O
+can	O
+be	O
+detected	O
+as	O
+an	O
+anodic	O
+current	O
+.	O
+
+We	O
+also	O
+demonstrated	O
+that	O
+another	O
+unusual	O
+pathway	B-PROC
+,	O
+the	O
+calcium	B-CHED
+-	O
+independent	O
+PI3K	B-PRGE
+/	I-PRGE
+PKC	B-DISO
+epsilon	I-PRGE
+/	O
+JNK	B-FUNC
+/	O
+CREB	B-PRGE
+pathway	B-PROC
+,	O
+functioned	O
+in	O
+cooperation	O
+with	O
+the	O
+calcium	B-CHED
+-	O
+dependent	O
+pathway	O
+to	O
+induce	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+expression	B-PROC
+upon	O
+stimulation	O
+by	O
+spike	O
+protein	B-CHED
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+diverse	O
+coronaviruses	O
+are	O
+endemic	O
+in	O
+different	O
+bat	B-ENZY
+species	B-SPEC
+,	O
+with	O
+repeated	O
+introductions	O
+to	O
+other	O
+animals	B-SPEC
+and	O
+occasional	O
+establishment	O
+in	O
+other	O
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Development	B-PROC
+of	O
+vaccine	O
+adjuvants	B-CHED
+using	O
+polymeric	O
+nanoparticles	B-CHED
+and	O
+their	O
+potential	O
+applications	O
+for	O
+anti	O
+-	O
+HIV	O
+vaccine	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+development	B-PROC
+of	O
+a	O
+prophylactic	O
+/	O
+therapeutic	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+vaccine	O
+based	O
+on	O
+recombinant	O
+proteins	B-CHED
+is	O
+needed	O
+for	O
+the	O
+control	O
+of	O
+the	O
+worldwide	O
+AIDS	O
+epidemic	O
+.	O
+
+Core	O
+-	O
+corona	B-CHED
+type	O
+polymeric	O
+nanospheres	O
+have	O
+applications	O
+in	O
+various	O
+technological	O
+and	O
+biomedical	O
+fields	O
+,	O
+because	O
+their	O
+chemical	O
+structures	O
+and	O
+particle	O
+size	O
+can	O
+be	O
+easily	O
+controlled	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+focused	O
+on	O
+the	O
+development	B-PROC
+of	O
+a	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+vaccine	O
+using	O
+polymeric	O
+nanoparticles	B-CHED
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+study	O
+on	O
+using	O
+thermal	O
+texture	O
+maps	O
+in	O
+SARS	B-DISO
+diagnosis	O
+.	O
+
+We	O
+conclude	O
+that	O
+TTM	B-DISO
+is	O
+able	O
+to	O
+depict	O
+the	O
+position	O
+,	O
+morphology	O
+,	O
+and	O
+progress	O
+of	O
+lesions	O
+with	O
+the	O
+same	O
+degree	O
+of	O
+success	O
+as	O
+CT	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Impact	O
+of	O
+SARS	B-DISO
+on	O
+Childbirth	B-PROC
+Education	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+analysis	O
+of	O
+Brazilian	O
+infectious	B-DISO
+bronchitis	B-DISO
+field	O
+isolates	O
+by	O
+reverse	B-PROC
+transcription	B-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+,	O
+restriction	O
+fragment	O
+length	O
+polymorphism	B-PROC
+,	O
+and	O
+partial	O
+sequencing	O
+of	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+.	O
+
+N	B-PRGE
+gene	I-PRGE
+RFLP	O
+profiles	O
+,	O
+cDNA	O
+sequences	O
+,	O
+and	O
+predicted	O
+amino	B-CHED
+acid	I-CHED
+composition	O
+were	O
+used	O
+for	O
+the	O
+construction	O
+of	O
+dendrograms	O
+.	O
+
+Roosters	O
+were	O
+vaccinated	O
+at	O
+2	O
+,	O
+6	O
+,	O
+10	O
+,	O
+and	O
+14	O
+wk	O
+of	O
+age	O
+and	O
+the	O
+epididymal	B-ANAT
+region	O
+was	O
+observed	O
+at	O
+27	O
+wk	O
+of	O
+age	O
+.	O
+
+Histologically	O
+,	O
+immune	O
+cells	B-COMP
+were	O
+seen	O
+in	O
+the	O
+interstitium	B-ANAT
+of	O
+efferent	B-ANAT
+ductules	I-ANAT
+containing	O
+stones	O
+.	O
+
+We	O
+conclude	O
+that	O
+use	O
+of	O
+a	O
+killed	O
+vaccine	O
+does	O
+not	O
+reduce	O
+the	O
+incidence	O
+of	O
+epididymal	B-ANAT
+stones	O
+.	O
+
+ABSTRACT	O
+:	O
+Anticipated	O
+psychological	B-DISO
+responses	O
+and	O
+perceptions	O
+of	O
+risk	O
+have	O
+not	O
+been	O
+examined	O
+prior	O
+to	O
+the	O
+outbreak	O
+of	O
+an	O
+epidemic	O
+.	O
+
+Dissemination	O
+of	O
+accurate	O
+,	O
+timely	O
+information	O
+would	O
+reduce	O
+unnecessary	O
+distress	O
+and	O
+unwanted	O
+behaviors	B-PROC
+.	O
+
+Most	O
+anticipated	O
+at	O
+least	O
+1	O
+of	O
+the	O
+7	O
+studied	O
+stress	O
+-	O
+related	O
+responses	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+panic	O
+)	O
+or	O
+the	O
+adoption	O
+of	O
+at	O
+least	O
+1	O
+of	O
+the	O
+5	O
+studied	O
+preventive	O
+behavioral	B-PROC
+measures	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+avoiding	O
+going	O
+out	O
+).	O
+
+TITLE	O
+:	O
+Long	O
+pentraxin	O
+3	O
+in	O
+pulmonary	B-DISO
+infection	I-DISO
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+causative	O
+viruses	B-SPEC
+in	O
+patients	O
+with	O
+PVOD	B-DISO
+.	O
+
+Rhinoviruses	B-SPEC
+were	O
+also	O
+confirmed	O
+in	O
+four	O
+patients	O
+by	O
+nucleotide	B-CHED
+sequences	O
+.	O
+
+Olfactory	B-PROC
+testing	O
+did	O
+not	O
+show	O
+significant	O
+improvement	O
+at	O
+4	O
+,	O
+8	O
+,	O
+11	O
+,	O
+and	O
+24	O
+weeks	O
+after	O
+the	O
+first	O
+visit	O
+in	O
+the	O
+four	O
+patients	O
+,	O
+although	O
+results	O
+of	O
+acoustic	O
+rhinometry	O
+significantly	O
+improved	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+that	O
+bats	B-SPEC
+have	O
+played	O
+in	O
+the	O
+emergence	O
+of	O
+several	O
+new	O
+infectious	O
+diseases	O
+has	O
+been	O
+under	O
+review	O
+.	O
+
+Bats	B-SPEC
+have	O
+been	O
+identified	O
+as	O
+the	O
+reservoir	O
+hosts	B-COMP
+of	O
+newly	O
+emergent	O
+viruses	B-SPEC
+such	O
+as	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+Hendra	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+like	O
+coronaviruses	O
+.	O
+
+This	O
+article	O
+expands	O
+on	O
+recent	O
+findings	O
+about	O
+bats	B-SPEC
+and	O
+viruses	B-SPEC
+and	O
+their	O
+relevance	O
+to	O
+human	B-SPEC
+infections	B-DISO
+.	O
+
+Finally	O
+,	O
+we	O
+attempt	O
+to	O
+predict	O
+where	O
+,	O
+when	O
+,	O
+and	O
+why	O
+we	O
+may	O
+see	O
+the	O
+emergence	O
+of	O
+new	O
+chiropteran	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+therapeutic	O
+effect	O
+of	O
+Caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+inhibitors	B-CHED
+(	O
+ICE	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+on	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+in	O
+experimental	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+).	O
+
+The	O
+wet	O
+/	O
+dry	O
+weight	O
+ratios	O
+and	O
+histopathological	O
+changes	O
+of	O
+the	O
+lungs	B-ANAT
+were	O
+also	O
+evaluated	O
+.	O
+
+Intrapulmonary	O
+expression	B-PROC
+of	O
+Caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+and	O
+IL	B-PRGE
+-	I-PRGE
+18	I-PRGE
+mRNA	B-CHED
+were	O
+observed	O
+in	O
+the	O
+HC	O
+group	O
+,	O
+while	O
+they	O
+were	O
+increased	O
+significantly	O
+in	O
+the	O
+SAP	B-PRGE
+-	I-PRGE
+S	I-PRGE
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+,	O
+vs	O
+HC	O
+).	O
+
+The	O
+expression	B-PROC
+of	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+and	O
+IL	B-PRGE
+-	I-PRGE
+18	I-PRGE
+mRNA	B-CHED
+were	O
+decreased	O
+significantly	O
+in	O
+the	O
+SAP	B-PRGE
+-	I-PRGE
+ICE	I-PRGE
+-	I-PRGE
+I	I-PRGE
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+,	O
+vs	O
+SAP	B-PRGE
+-	I-PRGE
+S	I-PRGE
+),	O
+whereas	O
+Caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+mRNA	B-PROC
+expression	B-PROC
+had	O
+no	O
+significant	O
+difference	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+Serum	B-PRGE
+IL	I-PRGE
+-	I-PRGE
+1beta	I-PRGE
+levels	O
+in	O
+SAP	B-PRGE
+-	I-PRGE
+S	I-PRGE
+group	I-PRGE
+were	O
+276	O
+.	O
+77	O
++/-	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+are	O
+infections	B-DISO
+that	O
+cause	O
+a	O
+severe	O
+viral	B-DISO
+pneumonia	I-DISO
+leading	O
+to	O
+acute	O
+respiratory	B-DISO
+dysfunction	I-DISO
+syndrome	B-DISO
+and	O
+carry	O
+a	O
+high	O
+case	O
+-	O
+fatality	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+Enhancing	O
+the	O
+precision	O
+of	O
+infrared	O
+thermodetector	O
+for	O
+medicine	B-CHED
+by	O
+two	O
+-	O
+channel	O
+measuring	O
+technique	O
+and	O
+mulriple	O
+linear	O
+interpolation	O
+algorithm	O
+.	O
+
+Association	O
+rule	O
+mining	O
+was	O
+applied	O
+first	O
+but	O
+results	O
+showed	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+between	O
+the	O
+locations	O
+of	O
+the	O
+lesions	O
+or	O
+infiltrate	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+outbreaks	O
+and	O
+bioterrorism	O
+attacks	O
+warrant	O
+urgent	O
+public	O
+health	O
+and	O
+medical	O
+responses	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+cytokine	O
+mRNA	B-PROC
+expression	B-PROC
+profiles	O
+predict	O
+Morbillivirus	B-SPEC
+disease	O
+outcome	O
+in	O
+ferrets	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+immunosuppression	O
+is	O
+a	O
+hallmark	O
+of	O
+Morbillivirus	B-DISO
+infections	I-DISO
+.	O
+
+These	O
+mice	B-SPEC
+can	O
+be	O
+used	O
+to	O
+analyze	O
+the	O
+human	B-SPEC
+immune	B-PROC
+response	I-PROC
+in	O
+vivo	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+identification	O
+of	O
+four	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strains	O
+in	O
+China	O
+and	O
+analyses	O
+of	O
+their	O
+S1	O
+glycoprotein	O
+gene	O
+.	O
+
+ABSTRACT	O
+:	O
+Between	O
+2003	O
+and	O
+2005	O
+,	O
+four	O
+strains	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+isolated	O
+from	O
+the	O
+vaccinated	O
+chicken	B-SPEC
+flocks	O
+in	O
+China	O
+.	O
+
+The	O
+identity	O
+of	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+gene	O
+between	O
+the	O
+four	O
+Chinese	O
+IBV	B-SPEC
+isolates	O
+and	O
+14	O
+strains	O
+of	O
+other	O
+IBVs	O
+varied	O
+from	O
+70	O
+.	O
+06	O
+to	O
+81	O
+.	O
+59	O
+%.	O
+
+Increased	O
+levels	O
+of	O
+measured	O
+molecules	O
+(	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+,	O
+p	O
+<	O
+0	O
+.	O
+02	O
+,	O
+sE	O
+-	O
+Selectin	B-PROC
+,	O
+p	O
+<	O
+0	O
+.	O
+02	O
+,	O
+sL	O
+-	O
+Selectin	B-PROC
+,	O
+p	O
+=	O
+0	O
+.	O
+06	O
+,	O
+sICAM	O
+-	O
+1	O
+,	O
+p	O
+<	O
+0	O
+.	O
+03	O
+)	O
+were	O
+demonstrated	O
+among	O
+survivors	O
+in	O
+the	O
+sepsis	B-DISO
+and	O
+ARDS	B-DISO
+groups	O
+of	O
+patients	O
+and	O
+were	O
+positively	O
+correlated	O
+with	O
+length	O
+of	O
+stay	O
+(	O
+p	O
+<	O
+0	O
+.	O
+04	O
+)	O
+and	O
+mechanical	O
+ventilation	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Severely	O
+obese	B-DISO
+patients	O
+were	O
+more	O
+likely	O
+to	O
+be	O
+discharged	O
+to	O
+a	O
+rehabilitation	O
+or	O
+skilled	O
+nursing	B-PROC
+facility	O
+than	O
+to	O
+home	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+presentation	O
+with	O
+more	O
+severe	O
+hypoxemia	O
+,	O
+the	O
+ARDS	O
+,	O
+is	O
+a	O
+challenging	O
+entity	O
+for	O
+clinical	O
+investigation	O
+because	O
+,	O
+like	O
+many	O
+critical	B-DISO
+illness	I-DISO
+syndromes	B-DISO
+,	O
+it	O
+lacks	O
+an	O
+accepted	O
+diagnostic	O
+test	O
+and	O
+relies	O
+on	O
+a	O
+constellation	O
+of	O
+clinical	B-DISO
+findings	I-DISO
+for	O
+diagnosis	O
+.	O
+
+If	O
+new	O
+mutants	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+do	O
+initiate	O
+another	O
+epidemic	O
+,	O
+administration	O
+of	O
+prophylactic	O
+antibodies	B-COMP
+to	O
+risk	O
+groups	O
+may	O
+supplement	O
+the	O
+stringent	O
+isolation	O
+procedures	O
+that	O
+contained	O
+the	O
+first	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Assuming	O
+a	O
+basic	O
+reproduction	B-PROC
+number	O
+R	O
+(	O
+0	O
+)=	O
+3	O
+,	O
+admission	O
+of	O
+patients	O
+to	O
+hospital	O
+within	O
+4	O
+.	O
+3	O
+days	O
+of	O
+symptom	B-DISO
+onset	O
+is	O
+necessary	O
+to	O
+achieve	O
+outbreak	O
+control	O
+without	O
+the	O
+need	O
+to	O
+further	O
+reduce	O
+community	O
+-	O
+based	O
+transmission	O
+.	O
+
+Hyperoncotic	O
+albumin	B-PRGE
+given	O
+alone	O
+or	O
+with	O
+furosemide	B-CHED
+produced	O
+only	O
+transient	O
+improvement	O
+in	O
+oxygenation	O
+and	O
+haemodynamics	O
+,	O
+which	O
+was	O
+statistically	O
+significant	O
+only	O
+in	O
+the	O
+patients	O
+given	O
+albumin	B-PRGE
+alone	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Perioperative	O
+respiratory	B-DISO
+complications	I-DISO
+in	O
+pediatric	O
+patients	O
+with	O
+mediastinal	B-ANAT
+masses	O
+:	O
+a	O
+report	O
+of	O
+2	O
+cases	O
+].	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+important	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+which	O
+caused	O
+by	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+and	O
+the	O
+study	O
+of	O
+its	O
+pathogenesis	B-DISO
+is	O
+needed	O
+for	O
+the	O
+treatment	O
+and	O
+prevention	O
+of	O
+this	O
+disease	O
+.	O
+
+Construction	O
+of	O
+the	O
+genomic	O
+full	O
+-	O
+length	O
+cDNA	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+BJ01	I-PRGE
+stain	O
+successfully	O
+and	O
+study	O
+of	O
+the	O
+biological	O
+characteristics	O
+of	O
+the	O
+rescued	O
+virus	B-SPEC
+will	O
+provide	O
+a	O
+useful	O
+tool	O
+serving	O
+for	O
+the	O
+discovery	O
+of	O
+molecular	O
+pathogenesis	B-DISO
+and	O
+development	B-PROC
+of	O
+candidate	O
+vaccines	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+Antiviral	B-CHED
+activity	O
+was	O
+analysed	O
+by	O
+determining	O
+infective	O
+virus	B-SPEC
+titres	O
+by	O
+TCID50	O
+,	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+by	O
+Northern	O
+blot	O
+analysis	O
+and	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+,	O
+and	O
+viral	O
+protein	O
+synthesis	O
+by	O
+SDS	B-DISO
+-	O
+PAGE	O
+analysis	O
+after	O
+35S	O
+-	O
+methionine	B-CHED
+-	O
+labelling	O
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-PRGE
+-	I-PRGE
+Coronavirus	B-SPEC
+Membrane	B-COMP
+protein	B-CHED
+induces	O
+apoptosis	B-PATH
+through	O
+modulating	O
+the	O
+Akt	B-PRGE
+survival	O
+pathway	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+understand	O
+the	O
+association	O
+between	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+meteorological	O
+factors	O
+and	O
+air	B-CHED
+pollution	O
+.	O
+
+Of	O
+the	O
+6727	O
+close	O
+contacts	O
+,	O
+135	O
+(	O
+2	O
+.	O
+0	O
+%)	O
+later	O
+developed	O
+clinical	O
+symptoms	O
+and	O
+were	O
+diagnosed	O
+as	O
+probable	O
+SARS	B-DISO
+cases	O
+.	O
+
+In	O
+univariate	O
+analyses	O
+,	O
+daily	O
+average	O
+temperature	O
+(	O
+DAT	O
+),	O
+daily	O
+average	O
+air	B-CHED
+pressure	O
+(	O
+DAAP	O
+),	O
+and	O
+daily	O
+average	O
+relative	O
+humidity	O
+(	O
+DARH	O
+)	O
+were	O
+inversely	O
+associated	O
+with	O
+secondary	O
+attack	O
+rate	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+);	O
+a	O
+significant	O
+positive	O
+association	O
+was	O
+found	O
+for	O
+daily	O
+hours	O
+of	O
+sunshine	O
+(	O
+DHS	B-DISO
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+typing	O
+by	O
+molecular	O
+techniques	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+children	O
+hospitalized	O
+for	O
+acute	O
+respiratory	O
+infection	O
+in	O
+Rome	O
+,	O
+Italy	O
+.	O
+
+Two	O
+hundred	O
+twenty	O
+-	O
+seven	O
+children	O
+were	O
+enrolled	O
+in	O
+the	O
+study	O
+with	O
+a	O
+diagnosis	O
+of	O
+asthma	B-PATH
+,	O
+bronchiolitis	B-DISO
+,	O
+bronchopneumonia	B-DISO
+,	O
+or	O
+laringo	O
+-	O
+tracheo	O
+bronchitis	B-DISO
+.	O
+
+All	O
+of	O
+them	O
+were	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+infections	B-DISO
+or	O
+mixed	B-DISO
+infections	I-DISO
+:	O
+P	O
+.	O
+f	O
+.	O
+and	O
+another	O
+species	B-SPEC
+of	O
+the	O
+parasite	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+follow	O
+up	O
+study	O
+of	O
+total	O
+IgM	B-PRGE
+,	O
+IgG	B-PRGE
+,	O
+nucleoprotein	O
+and	O
+spike	O
+protein	B-CHED
+antibodies	B-COMP
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+in	O
+patients	O
+with	O
+SARS	B-DISO
+].	O
+
+146	O
+cases	O
+,	O
+all	O
+clinically	O
+diagnosed	O
+as	O
+SARS	B-DISO
+with	O
+positive	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+,	O
+were	O
+followed	O
+up	O
+.	O
+
+Then	O
+,	O
+the	O
+positive	O
+rate	O
+of	O
+IgM	B-PRGE
+went	O
+down	O
+gradually	O
+to	O
+8	O
+.	O
+2	O
+%	O
+(	O
+6	O
+/	O
+73	O
+)	O
+until	O
+550	O
+days	O
+after	O
+the	O
+onset	O
+.	O
+
+When	O
+N	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+and	O
+S	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+were	O
+tested	O
+40	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+the	O
+disease	O
+at	O
+three	O
+different	O
+times	O
+,	O
+the	O
+positive	O
+rate	O
+of	O
+N	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+(	O
+92	O
+.	O
+5	O
+%,	O
+37	O
+/	O
+40	O
+)	O
+was	O
+higher	O
+than	O
+that	O
+of	O
+S	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+(	O
+67	O
+.	O
+5	O
+%,	O
+27	O
+/	O
+40	O
+),	O
+but	O
+the	O
+two	O
+structure	O
+protein	B-CHED
+antibodies	B-COMP
+were	O
+always	O
+lower	O
+than	O
+the	O
+total	O
+IgG	B-PRGE
+.	O
+In	O
+SARS	B-DISO
+patients	O
+with	O
+definite	O
+clinical	O
+and	O
+etiological	O
+diagnosis	O
+,	O
+the	O
+highest	O
+positive	O
+rate	O
+of	O
+the	O
+antibodies	B-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+found	O
+at	O
+21	O
+-	O
+40	O
+days	O
+after	O
+the	O
+onset	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+of	O
+2002	O
+and	O
+2003	O
+occurred	O
+as	O
+a	O
+result	O
+of	O
+zoonotic	O
+transmission	O
+.	O
+
+Convalescence	O
+-	O
+phase	O
+sera	B-COMP
+from	O
+humans	B-SPEC
+were	O
+similarly	O
+ineffective	O
+against	O
+the	O
+dominant	O
+civet	B-SPEC
+pseudovirus	O
+.	O
+
+Samples	O
+were	O
+tested	O
+for	O
+antibodies	B-COMP
+to	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+,	O
+Dirofilaria	B-SPEC
+immitis	I-SPEC
+,	O
+feline	B-SPEC
+panleukopenia	I-SPEC
+virus	I-SPEC
+,	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+,	O
+feline	B-SPEC
+coronavirus	B-SPEC
+,	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+Toxoplasma	B-SPEC
+gondii	I-SPEC
+and	O
+for	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+(	O
+FeLV	O
+)	O
+antigen	B-CHED
+.	O
+
+TITLE	O
+:	O
+Group	O
+2	O
+coronaviruses	O
+prevent	O
+immediate	B-PRGE
+early	I-PRGE
+interferon	I-PRGE
+induction	O
+by	O
+protection	O
+of	O
+viral	O
+RNA	O
+from	O
+host	O
+cell	O
+recognition	O
+.	O
+
+Infection	B-DISO
+of	O
+fibroblasts	B-ANAT
+with	O
+the	O
+murine	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+and	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+did	O
+not	O
+result	O
+in	O
+nuclear	B-PROC
+translocation	I-PROC
+of	O
+interferon	B-PRGE
+-	I-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF3	B-PRGE
+),	O
+a	O
+key	O
+transcription	B-PROC
+factor	O
+involved	O
+in	O
+IFN	B-PRGE
+induction	O
+,	O
+and	O
+induction	O
+of	O
+IFN	B-PRGE
+mRNA	I-PRGE
+transcription	B-PROC
+.	O
+
+Studies	O
+in	O
+highly	O
+pathogenic	O
+viruses	O
+such	O
+as	O
+SARS	B-DISO
+coronavirus	B-SPEC
+should	O
+be	O
+utmost	O
+cautious	O
+.	O
+
+ABSTRACT	O
+:	O
+Epidemiologic	O
+studies	O
+have	O
+shown	O
+that	O
+there	O
+is	O
+an	O
+association	O
+between	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+and	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+analyze	O
+the	O
+thrombotic	O
+risk	O
+,	O
+assessed	O
+by	O
+platelet	B-PROC
+aggregation	I-PROC
+and	O
+aspirin	B-CHED
+non	O
+-	O
+responsiveness	O
+,	O
+in	O
+patients	O
+with	O
+an	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+complicated	O
+by	O
+an	O
+infection	B-DISO
+.	O
+
+The	O
+subgroups	O
+of	O
+patients	O
+with	O
+persistent	B-DISO
+fever	I-DISO
+,	O
+urinary	B-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+and	O
+pneumonia	B-DISO
+all	O
+had	O
+a	O
+higher	O
+level	O
+of	O
+aggregates	O
+than	O
+the	O
+group	O
+of	O
+patients	O
+without	O
+an	O
+infection	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+007	O
+,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+,	O
+and	O
+P	O
+=	O
+0	O
+.	O
+01	O
+,	O
+respectively	O
+).	O
+
+The	O
+spread	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+,	O
+brought	O
+to	O
+light	O
+substantial	O
+weaknesses	B-DISO
+in	O
+the	O
+country	O
+'	O
+s	O
+public	O
+-	O
+health	O
+system	O
+.	O
+
+The	O
+ultramicroscopic	O
+changes	O
+in	O
+the	O
+infundibulum	B-ANAT
+and	O
+magnum	O
+were	O
+compared	O
+with	O
+control	O
+hens	O
+which	O
+had	O
+eggs	O
+at	O
+different	O
+positions	O
+in	O
+the	O
+oviduct	B-ANAT
+.	O
+
+No	O
+pathological	O
+changes	O
+were	O
+recorded	O
+during	O
+2	O
+-	O
+8	O
+days	O
+post	O
+-	O
+infection	B-DISO
+(	O
+p	O
+.	O
+i	O
+.).	O
+
+,	O
+there	O
+was	O
+no	O
+cilia	B-COMP
+loss	O
+and	O
+lymphoid	O
+nodules	B-DISO
+were	O
+observed	O
+in	O
+the	O
+muscularis	B-ANAT
+layer	I-ANAT
+of	O
+the	O
+infundibulum	B-ANAT
+and	O
+magnum	O
+of	O
+some	O
+hens	O
+from	O
+both	O
+infected	O
+groups	O
+.	O
+
+An	O
+additional	O
+threat	O
+to	O
+the	O
+conservation	O
+of	O
+maned	O
+wolves	O
+is	O
+the	O
+risk	O
+of	O
+morbidity	O
+and	O
+mortality	O
+due	O
+to	O
+infectious	B-DISO
+and	I-DISO
+parasitic	I-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+Ranpirnase	O
+:	O
+amphibian	B-PRGE
+ribonuclease	B-FUNC
+A	I-FUNC
+,	O
+P	O
+-	O
+30	O
+protein	B-CHED
+-	O
+alfacell	O
+.	O
+
+Development	B-PROC
+for	O
+these	O
+indications	O
+has	O
+been	O
+discontinued	O
+.	O
+
+No	O
+further	O
+development	B-PROC
+has	O
+been	O
+reported	O
+.	O
+
+It	O
+also	O
+increased	O
+the	O
+lung	B-ANAT
+weight	O
+/	O
+bodyweight	O
+ratio	O
+,	O
+lung	B-ANAT
+weight	O
+gain	O
+,	O
+exhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+),	O
+the	O
+protein	B-CHED
+concentration	O
+in	O
+bronchoalveolar	O
+lavage	O
+and	O
+microvascular	B-PROC
+permeability	I-PROC
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+the	O
+inflammatory	B-DISO
+responses	I-DISO
+and	O
+ALI	O
+following	O
+infusion	O
+of	O
+LPS	B-DISO
+are	O
+due	O
+to	O
+the	O
+production	O
+of	O
+NO	O
+,	O
+free	O
+radicals	B-CHED
+and	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+through	O
+the	O
+iNOS	O
+system	O
+.	O
+
+In	O
+many	O
+cases	O
+,	O
+coronavirus	B-SPEC
+-	O
+receptor	B-PROC
+interactions	I-PROC
+are	O
+well	O
+understood	O
+.	O
+
+Feline	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+fAPN	O
+)	O
+serves	O
+as	O
+a	O
+functional	O
+receptor	O
+for	O
+most	O
+group	O
+1	O
+coronaviruses	O
+including	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+),	O
+canine	O
+coronavirus	B-SPEC
+,	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+).	O
+
+To	O
+account	O
+for	O
+the	O
+previous	O
+suggestion	O
+that	O
+fAPN	O
+could	O
+serve	O
+as	O
+an	O
+IBV	B-SPEC
+receptor	O
+,	O
+we	O
+show	O
+that	O
+feline	B-SPEC
+cells	B-COMP
+can	O
+be	O
+infected	O
+with	O
+the	O
+prototype	O
+strain	O
+of	O
+IBV	B-SPEC
+(	O
+Mass	O
+41	O
+),	O
+but	O
+with	O
+low	O
+susceptibility	O
+compared	O
+to	O
+primary	O
+chick	O
+kidney	B-ANAT
+cells	B-COMP
+.	O
+
+We	O
+conclude	O
+that	O
+fAPN	O
+is	O
+not	O
+a	O
+functional	O
+receptor	O
+for	O
+IBV	B-SPEC
+,	O
+the	O
+identity	O
+of	O
+which	O
+is	O
+currently	O
+under	O
+investigation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+conclude	O
+that	O
+fAPN	O
+is	O
+not	O
+a	O
+functional	O
+receptor	O
+for	O
+IBV	B-SPEC
+,	O
+the	O
+identity	O
+of	O
+which	O
+is	O
+currently	O
+under	O
+investigation	O
+.	O
+
+ABSTRACT	O
+:	O
+Because	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Taiwan	O
+in	O
+2003	O
+was	O
+worsened	O
+by	O
+hospital	B-DISO
+infections	I-DISO
+,	O
+we	O
+analyzed	O
+229	O
+questionnaires	O
+(	O
+84	O
+.	O
+8	O
+%	O
+of	O
+270	O
+sent	O
+)	O
+completed	O
+by	O
+surveyed	O
+healthcare	O
+workers	O
+who	O
+cared	O
+for	O
+patients	O
+with	O
+SARS	B-DISO
+in	O
+3	O
+types	O
+of	O
+hospitals	O
+,	O
+to	O
+identify	O
+surveillance	O
+problems	O
+.	O
+
+Under	O
+the	O
+positive	O
+selection	O
+pressure	O
+of	O
+human	B-SPEC
+host	B-COMP
+,	O
+certain	O
+mutated	O
+lineages	O
+of	O
+the	O
+virus	B-SPEC
+became	O
+readily	O
+transmissible	O
+between	O
+humans	B-SPEC
+and	O
+thus	O
+caused	O
+the	O
+epidemic	O
+of	O
+2002	O
+-	O
+2003	O
+.	O
+
+Myt1	B-PRGE
+expressing	O
+cells	B-COMP
+proliferated	O
+most	O
+extensively	O
+during	O
+active	O
+demyelination	B-DISO
+and	O
+subsequently	O
+accumulated	O
+to	O
+maximal	O
+levels	O
+during	O
+early	O
+remyelination	B-PROC
+.	O
+
+In	O
+MHV	B-SPEC
+lesions	O
+,	O
+Myt1	B-PRGE
+was	O
+not	O
+expressed	B-PROC
+in	O
+astrocytes	B-ANAT
+,	O
+lymphocytes	B-ANAT
+,	O
+or	O
+macrophage	B-ANAT
+/	O
+microglial	B-ANAT
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+cause	O
+respiratory	B-ANAT
+tract	I-ANAT
+infection	I-DISO
+and	O
+a	O
+coryzal	O
+syndrome	O
+.	O
+
+A	O
+third	O
+patient	O
+presented	O
+with	O
+an	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+but	O
+coronavirus	B-SPEC
+was	O
+not	O
+isolated	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+description	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+with	O
+coronavirus	B-SPEC
+in	O
+HIV	B-DISO
+patients	O
+.	O
+
+Both	O
+patients	O
+with	O
+coronavirus	B-SPEC
+required	O
+prolonged	O
+admission	O
+to	O
+hospital	O
+and	O
+extensive	O
+investigations	O
+because	O
+they	O
+were	O
+HIV	B-DISO
+infected	O
+.	O
+
+TITLE	O
+:	O
+Heterologous	O
+viral	O
+RNA	O
+export	O
+elements	O
+improve	O
+expression	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+and	O
+protective	O
+efficacy	O
+of	O
+DNA	O
+vaccines	O
+against	O
+SARS	B-DISO
+.	O
+
+Upon	O
+immunization	O
+of	O
+mice	B-SPEC
+with	O
+low	O
+doses	O
+(	O
+2	O
+microg	O
+)	O
+of	O
+naked	O
+DNA	O
+,	O
+only	O
+intron	O
+and	O
+WPRE	O
+-	O
+containing	O
+vectors	O
+could	O
+induce	O
+neutralizing	O
+anti	O
+-	O
+S	O
+antibodies	B-COMP
+and	O
+provide	O
+protection	O
+against	O
+challenge	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Our	O
+observations	O
+are	O
+likely	O
+to	O
+be	O
+useful	O
+for	O
+the	O
+construction	O
+of	O
+plasmid	O
+and	O
+viral	O
+vectors	O
+designed	O
+for	O
+optimal	O
+expression	O
+of	O
+intronless	O
+genes	O
+derived	O
+from	O
+cytoplasmic	B-COMP
+RNA	O
+viruses	B-SPEC
+.	O
+
+High	O
+mortality	O
+in	O
+melioidosis	B-DISO
+associated	O
+with	O
+bacteremic	O
+pneumonia	B-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+Although	O
+rhAPC	O
+has	O
+been	O
+reported	O
+to	O
+reduce	O
+the	O
+mortality	O
+of	O
+severe	O
+septic	B-DISO
+shock	I-DISO
+caused	O
+by	O
+various	O
+pathogens	O
+,	O
+to	O
+our	O
+best	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+rhAPC	O
+application	O
+in	O
+life	O
+-	O
+threatening	O
+melioidosis	B-DISO
+.	O
+
+Applying	O
+this	O
+method	O
+to	O
+SARS	B-DISO
+RNA	O
+sequence	O
+analysis	O
+,	O
+the	O
+characteristic	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+differing	O
+from	O
+Non	O
+-	O
+SARS	B-DISO
+is	O
+discovered	O
+.	O
+
+The	O
+result	O
+shows	O
+that	O
+the	O
+characteristic	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+classifiable	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+serum	B-COMP
+and	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+of	O
+a	O
+patient	O
+with	O
+recurrent	O
+acute	O
+episodes	O
+of	O
+respiratory	O
+crises	O
+,	O
+autonomic	B-ANAT
+symptoms	O
+and	O
+total	O
+insomnia	B-DISO
+(	O
+agrypnia	B-SPEC
+),	O
+we	O
+identified	O
+a	O
+novel	O
+anti	B-PRGE
+-	I-PRGE
+neural	I-PRGE
+complement	I-PRGE
+fixing	I-PRGE
+antibody	I-PRGE
+directed	O
+against	O
+GABA	B-PRGE
+(	I-PRGE
+B	I-PRGE
+)	I-PRGE
+receptor	I-PRGE
+(	O
+GABA	B-CHED
+(	O
+B	O
+)	O
+R	O
+).	O
+
+Patient	O
+purified	O
+IgG	B-PRGE
+recognized	O
+a	O
+band	B-ANAT
+of	O
+approximately	O
+110	O
+kDa	O
+on	O
+protein	B-CHED
+extracts	O
+of	O
+mouse	B-ANAT
+cerebellum	I-ANAT
+,	O
+cortex	B-ANAT
+and	O
+brainstem	B-ANAT
+and	O
+immunolabelled	O
+cultured	O
+Chinese	B-SPEC
+hamster	I-SPEC
+ovary	B-ANAT
+(	O
+CHO	B-FUNC
+)	O
+cells	B-COMP
+,	O
+transfected	O
+with	O
+human	B-SPEC
+GABA	B-CHED
+(	O
+B	O
+)	O
+R1	O
+and	O
+rat	B-SPEC
+GABA	B-PRGE
+(	I-PRGE
+B	I-PRGE
+)	I-PRGE
+R2	I-PRGE
+receptors	I-PRGE
+.	O
+
+At	O
+T1	O
+more	O
+patients	O
+indicated	O
+satisfaction	O
+for	O
+understanding	O
+the	O
+doctor	O
+'	O
+s	O
+plans	O
+(	O
+p	O
+-	O
+value	O
+is	O
+0	O
+.	O
+001	O
+),	O
+while	O
+at	O
+T2	O
+,	O
+more	O
+patients	O
+indicated	O
+satisfaction	O
+for	O
+being	O
+told	O
+how	O
+to	O
+care	O
+for	O
+their	O
+condition	B-DISO
+(	O
+p	O
+-	O
+value	O
+is	O
+0	O
+.	O
+04	O
+).	O
+
+TITLE	O
+:	O
+Biologic	O
+,	O
+antigenic	O
+,	O
+and	O
+full	O
+-	O
+length	O
+genomic	O
+characterization	O
+of	O
+a	O
+bovine	B-SPEC
+-	O
+like	O
+coronavirus	B-SPEC
+isolated	O
+from	O
+a	O
+giraffe	O
+.	O
+
+Detailed	O
+sequence	O
+analysis	O
+of	O
+the	O
+GiCoV	B-PRGE
+-	I-PRGE
+OH3	I-PRGE
+spike	I-PRGE
+gene	I-PRGE
+demonstrated	O
+the	O
+presence	O
+of	O
+a	O
+deletion	O
+in	O
+the	O
+variable	O
+region	O
+of	O
+the	O
+S1	O
+subunit	O
+(	O
+from	O
+amino	B-CHED
+acid	I-CHED
+543	O
+to	O
+amino	B-CHED
+acid	I-CHED
+547	O
+),	O
+which	O
+is	O
+a	O
+region	O
+associated	O
+with	O
+pathogenicity	O
+and	O
+tissue	B-PROC
+tropism	B-PROC
+for	O
+other	O
+CoVs	O
+.	O
+
+Coexpression	O
+of	O
+the	O
+SCoV	O
+S	O
+,	O
+M	O
+,	O
+E	O
+,	O
+and	O
+6	O
+proteins	B-CHED
+was	O
+sufficient	O
+for	O
+incorporation	O
+of	O
+the	O
+6	O
+protein	B-CHED
+into	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+.	O
+
+The	O
+epidemic	O
+was	O
+halted	O
+in	O
+2003	O
+by	O
+a	O
+highly	O
+effective	O
+global	O
+public	O
+health	O
+response	O
+,	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+currently	O
+not	O
+circulating	O
+in	O
+humans	B-SPEC
+.	O
+
+HCoV	O
+-	O
+NL63	O
+and	O
+HCoV	O
+-	O
+HKU1	O
+were	O
+identified	O
+shortly	O
+after	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Reliability	O
+of	O
+soiled	O
+bedding	O
+transfer	O
+for	O
+detection	O
+of	O
+mouse	B-SPEC
+parvovirus	B-DISO
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	O
+.	O
+
+Transfer	O
+of	O
+soiled	O
+bedding	O
+between	O
+mice	B-SPEC
+in	O
+static	O
+cages	O
+induced	O
+seroconversion	O
+of	O
+sentinel	O
+mice	B-SPEC
+most	O
+reliably	O
+during	O
+peak	O
+viral	B-DISO
+shedding	I-DISO
+(	O
+1	O
+wk	O
+PI	O
+for	O
+MPV	B-SPEC
+and	O
+3	O
+d	O
+PI	O
+for	O
+MHV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Production	O
+and	O
+characterization	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+to	O
+(	O
+poly100	O
+)	O
+S1	O
+protein	B-CHED
+of	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+sepsis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+a	O
+controversial	O
+means	O
+of	O
+life	O
+support	O
+,	O
+particularly	O
+in	O
+adults	O
+.	O
+
+The	O
+imino	B-CHED
+protons	O
+of	O
+U48	O
+in	O
+the	O
+wild	O
+-	O
+type	O
+RNA	O
+,	O
+and	O
+G48	O
+in	O
+the	O
+U48G	B-PRGE
+SL2	I-PRGE
+mutant	I-PRGE
+RNA	I-PRGE
+,	O
+are	O
+significantly	O
+protected	O
+from	O
+exchange	O
+with	O
+solvent	O
+,	O
+consistent	O
+with	O
+a	O
+hydrogen	B-CHED
+bonding	O
+interaction	O
+critical	O
+to	O
+the	O
+hairpin	O
+loop	O
+architecture	O
+.	O
+
+This	O
+concern	O
+makes	O
+it	O
+important	O
+to	O
+review	O
+the	O
+most	O
+current	O
+guidelines	O
+for	O
+the	O
+management	O
+of	O
+viral	O
+respiratory	B-DISO
+diseases	I-DISO
+in	O
+pregnancy	O
+.	O
+
+Long	O
+-	O
+term	O
+exposure	O
+of	O
+HIV	B-DISO
+to	O
+CBAs	O
+in	O
+cell	B-COMP
+culture	O
+results	O
+in	O
+the	O
+progressive	O
+deletion	O
+of	O
+N	O
+-	O
+glycans	O
+of	O
+HIV	B-DISO
+gpl20	O
+in	O
+an	O
+attempt	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+escape	O
+drug	O
+pressure	O
+.	O
+
+The	O
+latter	O
+phenomenon	O
+will	O
+result	O
+in	O
+creating	O
+'	O
+holes	O
+'	O
+in	O
+the	O
+protective	O
+glycan	B-CHED
+shield	O
+of	O
+the	O
+HIV	B-PRGE
+envelope	B-COMP
+,	O
+whereby	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+may	O
+become	O
+triggered	O
+to	O
+produce	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+previously	O
+hidden	O
+immunogenic	O
+epitopes	O
+of	O
+gp120	B-PRGE
+.	O
+
+In	O
+addition	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+may	O
+also	O
+qualify	O
+to	O
+be	O
+treated	O
+by	O
+CBAs	O
+.	O
+
+The	O
+computed	O
+tomography	O
+severe	O
+index	O
+(	O
+CTSI	O
+)	O
+was	O
+used	O
+to	O
+assess	O
+the	O
+severity	O
+of	O
+the	O
+pancreatitis	B-DISO
+.	O
+
+Patients	O
+with	O
+more	O
+than	O
+50	O
+%	O
+necrosis	B-PROC
+had	O
+more	O
+pulmonary	B-ANAT
+dysfunction	O
+and	O
+needed	O
+ventilatory	O
+support	O
+.	O
+
+Similarly	O
+,	O
+the	O
+onset	O
+of	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+also	O
+correlated	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+but	O
+,	O
+unlike	O
+consolidation	O
+,	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+correlated	O
+with	O
+mortality	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Among	O
+the	O
+respiratory	B-DISO
+complications	I-DISO
+developing	O
+during	O
+the	O
+course	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+consolidation	O
+and	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+correlate	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+while	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+alone	O
+leads	O
+to	O
+poor	O
+survival	O
+.	O
+
+Similar	O
+analyses	O
+showed	O
+that	O
+education	O
+level	O
+,	O
+variables	O
+related	O
+to	O
+perceived	O
+efficacy	O
+,	O
+perceived	O
+major	O
+local	O
+outbreak	O
+and	O
+such	O
+were	O
+significantly	O
+associated	O
+with	O
+various	O
+behaviors	B-PROC
+directed	O
+towards	O
+protecting	O
+others	O
+.	O
+
+The	O
+patient	O
+was	O
+discharged	O
+alive	O
+and	O
+in	O
+good	O
+condition	B-DISO
+at	O
+the	O
+19th	O
+day	O
+after	O
+admission	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+any	O
+other	O
+known	O
+etiology	O
+,	O
+multiple	O
+defibrillation	O
+shocks	B-DISO
+may	O
+have	O
+played	O
+a	O
+role	O
+in	O
+the	O
+genesis	O
+of	O
+ALI	O
+in	O
+our	O
+patient	O
+,	O
+but	O
+this	O
+remains	O
+speculative	O
+.	O
+
+TITLE	O
+:	O
+Why	O
+G3139	O
+works	O
+poorly	O
+in	O
+cancer	B-DISO
+trials	O
+but	O
+might	O
+work	O
+well	O
+against	O
+HIV	B-DISO
+.	O
+
+Viral	O
+RNA	O
+was	O
+isolated	O
+at	O
+post	O
+mortem	O
+from	O
+the	O
+jejunum	B-ANAT
+and	O
+liver	B-ANAT
+of	O
+a	O
+cat	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+A	O
+consensus	O
+sequence	O
+of	O
+the	O
+jejunum	B-ANAT
+-	O
+derived	O
+genomic	O
+RNA	O
+(	O
+FCoV	O
+C1Je	O
+)	O
+was	O
+determined	O
+from	O
+overlapping	O
+cDNA	O
+fragments	O
+produced	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+amplification	B-DISO
+.	O
+
+RT	O
+-	O
+PCR	O
+products	O
+were	O
+sequenced	O
+by	O
+a	O
+reiterative	O
+sequencing	O
+strategy	O
+and	O
+the	O
+genomic	O
+RNA	O
+termini	O
+were	O
+determined	O
+using	O
+a	O
+rapid	O
+amplification	B-DISO
+of	O
+cDNA	O
+ends	O
+PCR	O
+strategy	O
+.	O
+
+DRAK2	B-PRGE
+,	O
+a	O
+lymphoid	O
+-	O
+restricted	O
+serine	B-PRGE
+/	I-PRGE
+threonine	B-CHED
+kinase	I-PRGE
+,	O
+prevents	O
+spurious	O
+T	B-PROC
+cell	I-PROC
+activation	I-PROC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+further	O
+characterize	O
+the	O
+molecular	O
+mechanisms	O
+governing	O
+T	B-PROC
+cell	I-PROC
+activation	I-PROC
+and	O
+accumulation	O
+within	O
+the	O
+CNS	O
+in	O
+response	O
+to	O
+viral	B-DISO
+infection	I-DISO
+,	O
+MHV	B-SPEC
+was	O
+instilled	O
+into	O
+the	O
+CNS	B-CHED
+of	O
+Drak2	B-PRGE
+-	O
+/	O
+-	O
+mice	B-SPEC
+.	O
+
+However	O
+,	O
+all	O
+bursa	B-SPEC
+of	O
+Fabrícius	O
+tissues	B-ANAT
+analysed	O
+were	O
+negative	O
+.	O
+
+ABSTRACT	O
+:	O
+Attenuated	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccines	O
+are	O
+available	O
+but	O
+the	O
+relationship	O
+between	O
+sequence	O
+and	O
+virulence	B-PROC
+is	O
+not	O
+clear	O
+.	O
+
+TITLE	O
+:	O
+Positive	O
+rate	O
+of	O
+serum	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+immunoglobulin	B-PROC
+G	I-PRGE
+antibody	B-COMP
+among	O
+healthcare	O
+workers	O
+.	O
+
+Information	O
+on	O
+environmental	O
+and	O
+administrative	O
+factors	O
+was	O
+obtained	O
+through	O
+visits	O
+to	O
+the	O
+wards	O
+and	O
+interviews	O
+with	O
+ward	O
+managers	O
+or	O
+nursing	B-PROC
+officers	O
+.	O
+
+Our	O
+results	O
+revealed	O
+that	O
+factors	O
+that	O
+were	O
+associated	O
+with	O
+the	O
+ward	O
+environment	O
+and	O
+administration	O
+were	O
+important	O
+in	O
+nosocomial	O
+outbreaks	O
+of	O
+SARS	B-DISO
+.	O
+
+Phosphorylation	B-PROC
+is	O
+one	O
+of	O
+the	O
+most	O
+common	O
+post	O
+-	O
+translation	B-PROC
+modifications	O
+that	O
+plays	O
+important	O
+regulatory	O
+roles	O
+in	O
+modulating	O
+protein	B-CHED
+functions	O
+.	O
+
+TITLE	O
+:	O
+Computational	O
+simulation	O
+of	O
+interactions	O
+between	O
+SARS	B-DISO
+coronavirus	B-SPEC
+spike	O
+mutants	O
+and	O
+host	B-COMP
+species	B-SPEC
+-	O
+specific	O
+receptors	O
+.	O
+
+And	O
+the	O
+predictions	O
+further	O
+indicate	O
+that	O
+some	O
+viral	O
+prototypes	O
+might	O
+utilize	O
+the	O
+rat	B-SPEC
+ACE2	O
+while	O
+rats	B-SPEC
+might	O
+serve	O
+as	O
+a	O
+vector	O
+or	O
+reservoir	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+The	O
+molecular	O
+and	O
+cellular	B-COMP
+basis	O
+for	O
+how	O
+SARS	B-DISO
+CoV	O
+impacts	O
+the	O
+host	B-COMP
+immune	B-ANAT
+system	I-ANAT
+resulting	O
+in	O
+severe	O
+SARS	B-DISO
+,	O
+however	O
+,	O
+has	O
+not	O
+been	O
+elucidated	O
+.	O
+
+The	O
+variable	O
+clinical	O
+course	O
+of	O
+SARS	B-DISO
+may	O
+be	O
+the	O
+result	O
+of	O
+complex	O
+programs	O
+of	O
+host	B-COMP
+responses	O
+against	O
+the	O
+infectious	B-DISO
+agent	O
+.	O
+
+TITLE	O
+:	O
+Computational	O
+characterization	O
+and	O
+design	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+receptor	I-PRGE
+recognition	O
+and	O
+antibody	B-FUNC
+neutralization	O
+.	O
+
+Based	O
+on	O
+those	O
+complex	O
+structures	O
+,	O
+we	O
+conduct	B-PROC
+computational	O
+characterization	O
+and	O
+design	O
+of	O
+RBD	O
+-	O
+mediated	O
+receptor	O
+recognition	O
+and	O
+antibody	B-COMP
+neutralization	O
+.	O
+
+Recent	O
+field	O
+isolates	O
+display	O
+distinctive	O
+genetic	B-PROC
+divergence	I-PROC
+from	O
+the	O
+prototype	O
+enteric	O
+BCoV	O
+strains	O
+--	O
+Mebus	O
+,	O
+Quebec	O
+,	O
+Kakegawa	O
+,	O
+F15	O
+and	O
+LY138	O
+--	O
+and	O
+have	O
+diverged	O
+in	O
+three	O
+different	O
+aspects	O
+over	O
+8	O
+years	O
+.	O
+
+Prospective	O
+randomized	O
+clinical	O
+trial	O
+in	O
+the	O
+14	O
+-	O
+bed	B-DISO
+ICU	O
+of	O
+a	O
+750	O
+-	O
+bed	B-DISO
+university	O
+hospital	O
+.	O
+
+Patients	O
+were	O
+randomly	O
+assigned	O
+to	O
+either	O
+surfactant	B-CHED
+administration	O
+(	O
+n	O
+=	O
+8	O
+)	O
+or	O
+standard	O
+treatment	O
+(	O
+n	O
+=	O
+8	O
+).	O
+
+A	O
+single	O
+dose	O
+of	O
+natural	O
+bovine	B-SPEC
+surfactant	B-CHED
+was	O
+instilled	O
+bronchoscopically	O
+in	O
+the	O
+involved	O
+lung	B-ANAT
+areas	O
+;	O
+each	O
+segmental	B-ANAT
+bronchus	I-ANAT
+received	O
+(	O
+200	O
+/	O
+19	O
+)	O
+mg	O
+/	O
+kg	O
+body	B-ANAT
+weight	O
+.	O
+
+After	O
+primary	O
+successful	O
+resuscitation	O
+the	O
+baby	O
+died	B-PROC
+after	O
+49	O
+days	O
+due	O
+to	O
+large	O
+intracranial	B-ANAT
+hemorrages	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+are	O
+basic	O
+proteins	B-CHED
+that	O
+encapsulate	O
+viral	O
+genomic	O
+RNA	O
+to	O
+form	O
+part	O
+of	O
+the	O
+virus	B-ANAT
+structure	I-ANAT
+.	O
+
+RNA	O
+has	O
+been	O
+shown	O
+to	O
+bind	B-FUNC
+to	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+),	O
+although	O
+recently	O
+the	O
+C	O
+-	O
+terminal	O
+half	O
+of	O
+the	O
+protein	B-CHED
+has	O
+also	O
+been	O
+implicated	O
+in	O
+RNA	B-FUNC
+binding	I-FUNC
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+(	O
+CTD	O
+),	O
+spanning	O
+residues	O
+248	O
+-	O
+365	O
+(	O
+NP248	O
+-	O
+365	O
+),	O
+had	O
+stronger	O
+nucleic	B-CHED
+acid	I-CHED
+-	O
+binding	B-PROC
+activity	I-PROC
+than	O
+the	O
+NTD	O
+.	O
+
+TITLE	O
+:	O
+The	O
+hypothalamic	B-ANAT
+pituitary	I-ANAT
+adrenal	I-ANAT
+axis	I-ANAT
+in	O
+sepsis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Adverse	O
+events	O
+associated	O
+with	O
+high	O
+-	O
+dose	O
+ribavirin	B-CHED
+:	O
+evidence	O
+from	O
+the	O
+Toronto	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Understanding	O
+of	O
+the	O
+mechanisms	O
+by	O
+which	O
+local	O
+inflammation	B-DISO
+in	O
+the	O
+pancreas	B-ANAT
+leads	O
+to	O
+end	O
+-	O
+organ	B-ANAT
+injury	O
+is	O
+crucial	O
+for	O
+the	O
+development	B-PROC
+of	O
+new	O
+therapeutic	O
+strategies	O
+.	O
+
+RESULTS	O
+:	O
+Modulation	O
+of	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+using	O
+a	O
+combination	O
+of	O
+immunomodulatory	O
+agents	O
+may	O
+decrease	O
+the	O
+incidence	O
+of	O
+severe	O
+pancreatitis	O
+-	O
+related	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pathogenicity	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+is	O
+known	O
+to	O
+depend	O
+on	O
+macrophage	B-ANAT
+tropism	B-PROC
+,	O
+and	O
+this	O
+macrophage	B-ANAT
+infection	B-DISO
+is	O
+enhanced	O
+by	O
+mediation	O
+via	O
+anti	O
+-	O
+S	O
+antibody	B-COMP
+(	O
+antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+,	O
+ADE	B-CHED
+).	O
+
+For	O
+upregulation	B-PROC
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+fAPN	O
+in	O
+macrophages	B-ANAT
+,	O
+viral	B-PROC
+replication	I-PROC
+in	O
+macrophages	B-ANAT
+is	O
+necessary	O
+,	O
+and	O
+their	O
+expressions	O
+were	O
+increased	O
+by	O
+ADE	B-CHED
+of	O
+FIPV	O
+infection	B-DISO
+.	O
+
+These	O
+findings	O
+suggested	O
+that	O
+FIPV	O
+replication	O
+in	O
+macrophages	B-ANAT
+increases	O
+TNF	B-PROC
+-	I-PROC
+alpha	I-PROC
+production	I-PROC
+in	O
+macrophages	B-ANAT
+,	O
+and	O
+the	O
+produced	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+acts	O
+and	O
+upregulates	O
+fAPN	O
+expression	B-PROC
+,	O
+increasing	O
+FIPV	O
+sensitivity	O
+.	O
+
+The	O
+characteristic	O
+tache	B-DISO
+noire	I-DISO
+was	O
+observed	O
+on	O
+the	O
+lateral	B-ANAT
+region	I-ANAT
+of	O
+the	O
+thigh	B-ANAT
+and	O
+elevated	O
+IgM	B-COMP
+antibody	B-PROC
+titres	O
+against	O
+R	B-SPEC
+.	I-SPEC
+conorii	I-SPEC
+were	O
+detected	O
+by	O
+an	O
+indirect	O
+immunofluorescence	O
+test	O
+.	O
+
+EP	O
+was	O
+originally	O
+regarded	O
+as	O
+simply	O
+a	O
+way	O
+to	O
+administer	O
+pyruvate	B-CHED
+anion	B-CHED
+,	O
+whilst	O
+avoiding	O
+some	O
+of	O
+the	O
+problems	O
+associated	O
+with	O
+the	O
+instability	O
+of	O
+pyruvate	B-CHED
+in	O
+aqueous	O
+solutions	O
+.	O
+
+The	O
+SARS	B-DISO
+coronavirus	B-SPEC
+targets	O
+the	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+resulting	O
+in	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+.	O
+
+It	O
+seems	O
+that	O
+both	O
+abnormal	O
+immune	B-PROC
+responses	I-PROC
+and	O
+injury	O
+to	O
+immune	O
+cells	B-COMP
+may	O
+be	O
+key	O
+factors	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+this	O
+new	O
+disease	O
+.	O
+
+The	O
+C	B-PRGE
+-	I-PRGE
+terminal	I-PRGE
+ORF1a	I-PRGE
+protein	I-PRGE
+nsp10	I-PRGE
+colocalizes	O
+with	O
+viral	B-PROC
+replication	I-PROC
+complexes	O
+,	O
+but	O
+its	O
+role	O
+in	O
+transcription	B-PROC
+/	O
+replication	O
+is	O
+not	O
+well	O
+defined	O
+.	O
+
+Mapping	O
+the	O
+mutations	O
+onto	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+nsp10	O
+identified	O
+a	O
+central	B-ANAT
+core	I-ANAT
+resistant	O
+to	O
+mutation	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+),	O
+a	O
+common	O
+human	B-SPEC
+respiratory	O
+pathogen	O
+,	O
+is	O
+associated	O
+with	O
+both	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+disease	O
+in	O
+children	O
+and	O
+adults	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+replicase	I-PRGE
+proteins	B-CHED
+in	O
+pathogenesis	B-DISO
+.	O
+
+Evidence	O
+for	O
+change	O
+within	O
+the	O
+ORF1ab	O
+coding	O
+sequence	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+as	O
+well	O
+as	O
+evidence	O
+from	O
+studies	O
+with	O
+other	O
+coronaviruses	O
+,	O
+indicates	O
+that	O
+it	O
+is	O
+likely	O
+that	O
+the	O
+ORF1ab	O
+proteins	B-CHED
+play	B-DISO
+roles	I-DISO
+in	O
+virus	B-DISO
+pathogenesis	B-PROC
+distinct	O
+from	O
+or	O
+in	O
+addition	O
+to	O
+functions	O
+directly	O
+involved	O
+in	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Volunteers	O
+from	O
+employees	O
+of	O
+the	O
+animal	B-SPEC
+market	O
+were	O
+recruited	O
+and	O
+their	O
+serum	B-COMP
+specific	O
+antibody	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+determined	O
+by	O
+enzyme	O
+linked	O
+immunesorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+method	O
+.	O
+
+The	O
+prevalence	O
+of	O
+specific	O
+antibody	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+employees	O
+of	O
+the	O
+animal	B-SPEC
+market	O
+were	O
+somehow	O
+related	O
+with	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+palm	B-ANAT
+civet	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Positive	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+specific	I-PRGE
+IgG	B-COMP
+antibody	I-COMP
+was	O
+found	O
+25	O
+.	O
+61	O
+%	O
+(	O
+n	O
+=	O
+328	O
+),	O
+13	O
+.	O
+03	O
+%	O
+(	O
+n	O
+=	O
+238	O
+),	O
+12	O
+.	O
+59	O
+%	O
+(	O
+n	O
+=	O
+135	O
+),	O
+5	O
+.	O
+04	O
+%	O
+(	O
+n	O
+=	O
+139	O
+)	O
+and	O
+9	O
+.	O
+43	O
+%	O
+(	O
+n	O
+=	O
+53	O
+)	O
+among	O
+volunteers	O
+,	O
+which	O
+were	O
+sampled	O
+in	O
+May	O
+2003	O
+,	O
+Dec	B-CHED
+.	O
+2003	O
+,	O
+Jan	O
+.	O
+2004	O
+,	O
+July	O
+2004	O
+and	O
+June	O
+2005	O
+respectively	O
+.	O
+
+Canine	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+CECoV	O
+)	O
+is	O
+a	O
+widespread	O
+pathogen	O
+of	O
+dogs	B-SPEC
+,	O
+responsible	O
+for	O
+mild	O
+to	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+pups	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+establish	O
+the	O
+seroprevalence	O
+of	O
+CRCoV	O
+in	O
+Italy	O
+and	O
+its	O
+relationship	O
+to	O
+CECoV	B-PRGE
+type	I-PRGE
+II	I-PRGE
+seroprevalence	O
+.	O
+
+Acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+are	O
+responsible	O
+for	O
+considerable	O
+morbidity	O
+and	O
+mortality	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+No	O
+pathogens	O
+can	O
+be	O
+detected	O
+in	O
+a	O
+relatively	O
+large	O
+proportion	O
+of	O
+patients	O
+with	O
+respiratory	B-DISO
+disease	I-DISO
+,	O
+partially	O
+owing	O
+to	O
+limitations	O
+of	O
+current	O
+diagnostic	O
+assays	O
+but	O
+also	O
+since	O
+some	O
+infections	B-DISO
+are	O
+caused	O
+by	O
+as	O
+yet	O
+unknown	O
+pathogens	O
+.	O
+
+Consistent	O
+with	O
+the	O
+deletion	O
+of	O
+AE2	O
+cells	B-COMP
+,	O
+the	O
+amount	O
+of	O
+surfactant	B-CHED
+proteins	B-CHED
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+was	O
+greatly	O
+reduced	O
+in	O
+the	O
+DT	O
+-	O
+treated	O
+transgenic	B-SPEC
+mice	I-SPEC
+.	O
+
+Compared	O
+with	O
+the	O
+mice	B-SPEC
+in	O
+which	O
+both	O
+AE2	O
+cells	B-COMP
+and	O
+macrophages	B-ANAT
+were	O
+deleted	O
+by	O
+DT	O
+administration	O
+,	O
+the	O
+DT	O
+-	O
+treated	O
+LysM	B-PRGE
+-	I-PRGE
+DTR	I-PRGE
+mice	B-SPEC
+with	O
+DT	O
+-	O
+resistant	O
+macrophages	B-ANAT
+showed	O
+less	O
+severe	O
+lung	B-ANAT
+injury	O
+with	O
+a	O
+reduced	O
+amount	O
+of	O
+hepatocyte	B-PROC
+growth	B-PROC
+factor	I-PROC
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+.	O
+
+We	O
+herein	O
+present	O
+a	O
+case	O
+of	O
+woman	O
+admitted	O
+to	O
+the	O
+emergency	B-DISO
+room	O
+for	O
+acute	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+It	O
+resulted	O
+in	O
+pulmonary	B-ANAT
+parenchymal	O
+compression	O
+associated	O
+with	O
+reduced	O
+chest	B-ANAT
+wall	I-ANAT
+compliance	O
+and	O
+increased	O
+pulmonary	O
+pressure	O
+.	O
+
+Fewer	O
+than	O
+10	O
+%	O
+of	O
+the	O
+respondents	O
+thought	O
+that	O
+dentists	O
+ran	O
+a	O
+high	O
+risk	O
+of	O
+contracting	O
+SARS	B-DISO
+.	O
+
+Previously	O
+,	O
+SARS	B-PRGE
+CoV	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CLpro	O
+)	O
+has	O
+been	O
+demonstrated	O
+to	O
+induce	O
+apoptosis	B-PATH
+via	O
+the	O
+activation	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+caspase	B-PRGE
+-	I-PRGE
+9	I-PRGE
+(	O
+Lin	B-PRGE
+,	O
+C	O
+.	O
+W	O
+.,	O
+Lin	B-CHED
+,	O
+K	O
+.	O
+H	O
+.,	O
+Hsieh	O
+,	O
+T	O
+.	O
+H	O
+.,	O
+Shiu	O
+,	O
+S	O
+.	O
+Y	O
+.	O
+et	O
+al	O
+.,	O
+FEMS	O
+Immunol	O
+.	O
+
+Functional	O
+classification	O
+of	O
+identified	O
+up	O
+-	O
+regulated	O
+proteins	B-CHED
+indicated	O
+that	O
+protein	B-PROC
+metabolism	I-PROC
+and	I-PROC
+modification	I-PROC
+,	O
+particularly	O
+in	O
+the	O
+ubiquitin	B-PROC
+proteasome	B-PROC
+pathway	I-PROC
+,	O
+was	O
+the	O
+main	O
+biological	B-PROC
+process	I-PROC
+occurring	O
+in	O
+SARS	B-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+-	O
+expressing	O
+cells	B-COMP
+.	O
+
+In	O
+addition	O
+,	O
+confocal	O
+image	O
+analysis	O
+has	O
+shown	O
+release	B-PATH
+of	O
+mitochondrial	B-COMP
+apoptogenic	O
+apoptosis	B-PATH
+-	O
+inducing	O
+factor	O
+and	O
+cytochrome	B-PROC
+c	I-PROC
+into	O
+the	O
+cytosol	B-COMP
+.	O
+
+Our	O
+results	O
+revealed	O
+that	O
+SARS	B-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+could	O
+be	O
+considered	O
+to	O
+induce	O
+mitochondrial	B-COMP
+-	O
+mediated	O
+apoptosis	B-PATH
+.	O
+
+The	O
+binding	B-FUNC
+required	O
+Ca	O
+(	O
+2	O
++)	O
+and	O
+was	O
+inhibited	O
+by	O
+maltose	B-CHED
+.	O
+
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+binds	B-FUNC
+and	O
+activates	O
+macrophages	B-ANAT
+but	O
+not	O
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+DCs	B-DISO
+).	O
+
+Quarantining	O
+only	O
+persons	O
+with	O
+known	O
+exposure	O
+to	O
+people	O
+infected	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+could	O
+have	O
+reduced	O
+the	O
+number	O
+of	O
+persons	O
+quarantined	O
+by	O
+approximately	O
+64	O
+%.	O
+
+Many	O
+patients	O
+with	O
+AI	O
+H5N1	B-DISO
+are	O
+critically	B-DISO
+ill	I-DISO
+either	O
+at	O
+presentation	O
+or	O
+shortly	O
+thereafter	O
+.	O
+
+Although	O
+treating	O
+the	O
+infected	O
+patient	O
+with	O
+AI	O
+H5N1	B-DISO
+is	O
+a	O
+priority	O
+,	O
+safeguarding	O
+healthcare	O
+workers	O
+and	O
+other	O
+patients	O
+must	O
+be	O
+considered	O
+of	O
+equal	O
+priority	O
+.	O
+
+The	O
+acquisition	O
+of	O
+infections	B-DISO
+in	O
+the	O
+tropics	O
+,	O
+including	O
+community	O
+-	O
+acquired	O
+pneumonias	B-DISO
+,	O
+has	O
+been	O
+described	O
+for	O
+several	O
+centuries	O
+.	O
+
+A	O
+number	O
+of	O
+microorganisms	O
+may	O
+produce	O
+pneumonia	B-DISO
+in	O
+people	O
+who	O
+live	O
+or	O
+have	O
+traveled	O
+to	O
+tropical	O
+zones	O
+.	O
+
+TITLE	O
+:	O
+How	O
+to	O
+diagnose	O
+and	O
+manage	O
+common	O
+parasitic	O
+pneumonias	B-DISO
+.	O
+
+A	O
+polymerase	O
+chain	O
+reaction	O
+that	O
+can	O
+differentiate	O
+pathogenic	O
+Entamoeba	B-SPEC
+histolytica	I-SPEC
+from	O
+nonpathogenic	O
+species	B-SPEC
+has	O
+been	O
+reported	O
+.	O
+
+Parasitic	O
+pneumonia	B-DISO
+can	O
+sometimes	O
+be	O
+life	O
+threatening	O
+.	O
+
+If	O
+proper	O
+diagnosis	O
+is	O
+made	O
+early	O
+,	O
+the	O
+pneumonia	B-DISO
+can	O
+be	O
+treated	O
+successfully	O
+with	O
+currently	O
+available	O
+drugs	O
+.	O
+
+Forty	O
+-	O
+five	O
+patients	O
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+for	O
+the	O
+study	O
+cohort	O
+(	O
+severe	O
+thoracic	B-DISO
+trauma	O
+and	O
+femoral	B-ANAT
+fracture	O
+stabilized	O
+with	O
+unreamed	O
+intramedullary	O
+nailing	O
+[	O
+IMN	O
+]	O
+within	O
+the	O
+first	O
+24	O
+hours	O
+)	O
+and	O
+107	O
+patients	O
+were	O
+selected	O
+for	O
+the	O
+control	O
+cohort	O
+(	O
+severe	O
+thoracic	B-DISO
+trauma	O
+without	O
+any	O
+lower	B-ANAT
+extremity	I-ANAT
+fracture	O
+).	O
+
+Both	O
+cohorts	O
+were	O
+comparable	O
+with	O
+regard	O
+to	O
+demographic	O
+data	O
+,	O
+ISS	B-DISO
+,	O
+AIS	B-DISO
+score	O
+in	O
+the	O
+thoracic	B-ANAT
+region	I-ANAT
+,	O
+and	O
+incidence	O
+and	O
+severity	O
+of	O
+brain	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Neutrophil	B-ANAT
+-	O
+derived	O
+S100A12	B-PRGE
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Additional	O
+in	O
+vivo	O
+and	O
+in	O
+vitro	O
+experiments	O
+were	O
+performed	O
+to	O
+further	O
+analyze	O
+the	O
+contribution	O
+of	O
+S100A12	B-PRGE
+to	O
+pulmonary	B-DISO
+inflammation	I-DISO
+.	O
+
+S100A12	B-PRGE
+was	O
+also	O
+analyzed	O
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+from	O
+eight	O
+healthy	O
+subjects	O
+after	O
+challenge	O
+with	O
+lipopolysaccharide	B-CHED
+and	O
+compared	O
+with	O
+eight	O
+controls	O
+who	O
+received	O
+placebo	O
+inhalation	B-PROC
+.	O
+
+Several	O
+types	O
+of	O
+vaccines	O
+have	O
+been	O
+developed	O
+including	O
+inactivated	O
+viruses	B-SPEC
+,	O
+subunit	O
+vaccines	O
+,	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+),	O
+DNA	O
+vaccines	O
+,	O
+heterologous	O
+expression	B-PROC
+systems	O
+,	O
+and	O
+vaccines	O
+derived	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+by	O
+reverse	O
+genetics	O
+.	O
+
+The	O
+production	O
+of	O
+effective	O
+and	O
+safe	O
+vaccines	O
+to	O
+prevent	O
+SARS	B-DISO
+has	O
+led	O
+to	O
+the	O
+development	B-PROC
+of	O
+promising	O
+vaccine	O
+candidates	O
+,	O
+in	O
+contrast	O
+to	O
+the	O
+design	O
+of	O
+vaccines	O
+for	O
+other	O
+coronaviruses	O
+,	O
+that	O
+in	O
+general	O
+has	O
+been	O
+less	O
+successful	O
+.	O
+
+TITLE	O
+:	O
+Manipulation	O
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+genome	O
+for	O
+vaccine	O
+development	B-PROC
+and	O
+analysis	O
+of	O
+the	O
+accessory	O
+proteins	O
+.	O
+
+Our	O
+current	O
+molecularly	O
+cloned	O
+IBV	B-SPEC
+,	O
+strain	O
+Beaudette	O
+,	O
+is	O
+non	O
+-	O
+pathogenic	O
+,	O
+so	O
+we	O
+do	O
+not	O
+know	O
+what	O
+effect	O
+the	O
+absence	O
+of	O
+these	O
+proteins	B-CHED
+would	O
+have	O
+on	O
+pathogenicity	O
+.	O
+
+Replacing	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+of	O
+Beaudette	O
+with	O
+that	O
+from	O
+the	O
+pathogenic	O
+M41	O
+strain	O
+resulted	O
+in	O
+a	O
+recombinant	O
+virus	B-SPEC
+that	O
+was	O
+still	O
+non	O
+-	O
+pathogenic	O
+but	O
+which	O
+did	O
+induce	O
+protection	O
+against	O
+challenge	O
+with	O
+M41	O
+.	O
+
+ABSTRACT	O
+:	O
+Positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+and	O
+inspired	B-PROC
+oxygen	B-CHED
+fraction	O
+(	O
+F	O
+(	O
+IO	O
+(	O
+2	O
+)))	O
+are	O
+the	O
+primary	O
+means	O
+of	O
+improving	O
+P	O
+(	O
+aO	O
+(	O
+2	O
+))	O
+during	O
+mechanical	O
+ventilation	O
+.	O
+
+HFOV	O
+(	O
+8	O
+-	O
+10	O
+Hz	O
+)	O
+was	O
+started	O
+using	O
+a	O
+recruitment	B-DISO
+strategy	O
+and	O
+oxygenation	B-PROC
+improved	O
+within	O
+2	O
+h	O
+.	O
+After	O
+5	O
+days	O
+,	O
+the	O
+patient	O
+was	O
+switched	O
+back	B-ANAT
+to	O
+CV	O
+uneventfully	O
+and	O
+av	O
+-	O
+ECLA	O
+was	O
+removed	O
+after	O
+8	O
+days	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+combination	O
+of	O
+two	O
+innovative	O
+treatment	O
+modalities	O
+resulted	O
+in	O
+rapid	O
+stabilization	O
+and	O
+improvement	O
+of	O
+gas	B-ENZY
+exchange	O
+during	O
+severe	O
+ARDS	B-DISO
+refractory	O
+to	O
+conventional	O
+lung	B-ANAT
+protective	O
+ventilation	O
+.	O
+
+The	O
+authors	O
+prospectively	O
+investigated	O
+avian	B-DISO
+flu	I-DISO
+and	O
+SARS	B-DISO
+between	O
+March	O
+2005	O
+and	O
+April	O
+2006	O
+.	O
+
+This	O
+may	O
+be	O
+due	O
+to	O
+the	O
+mass	O
+campaign	O
+of	O
+influenza	B-DISO
+vaccination	O
+or	O
+seasonal	O
+variation	O
+.	O
+
+TITLE	O
+:	O
+Blastomycosis	B-DISO
+in	O
+solid	O
+organ	B-ANAT
+transplant	I-ANAT
+recipients	O
+.	O
+
+From	O
+1986	O
+to	O
+2004	O
+,	O
+we	O
+identified	O
+11	O
+cases	O
+of	O
+post	O
+-	O
+transplant	B-ANAT
+blastomycosis	B-DISO
+with	O
+64	O
+%	O
+occurring	O
+between	O
+2000	O
+and	O
+2004	O
+.	O
+
+Opportunistic	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+were	O
+common	O
+,	O
+occurring	O
+in	O
+36	O
+%	O
+of	O
+patients	O
+.	O
+
+None	O
+of	O
+the	O
+surviving	O
+patients	O
+relapsed	O
+or	O
+received	O
+routine	O
+secondary	O
+antifungal	B-CHED
+prophylaxis	O
+.	O
+
+Two	O
+targets	O
+of	O
+possible	O
+antiviral	B-CHED
+intervention	O
+were	O
+identified	O
+in	O
+the	O
+replication	O
+cycle	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+first	O
+target	O
+is	O
+located	O
+early	O
+in	O
+the	O
+replication	O
+cycle	O
+,	O
+most	O
+probably	O
+viral	O
+attachment	O
+,	O
+and	O
+the	O
+second	O
+target	O
+is	O
+located	O
+at	O
+the	O
+end	O
+of	O
+the	O
+infectious	B-DISO
+virus	B-SPEC
+cycle	O
+.	O
+
+Based	O
+on	O
+phylogenetic	O
+data	O
+and	O
+structure	O
+probing	O
+,	O
+we	O
+have	O
+identified	O
+a	O
+95	O
+-	O
+nt	O
+hairpin	O
+within	O
+the	O
+190	O
+-	O
+nt	O
+PS	O
+domain	O
+which	O
+is	O
+conserved	O
+in	O
+all	O
+group	O
+IIa	O
+coronaviruses	O
+but	O
+not	O
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+group	O
+IIb	O
+),	O
+group	O
+I	O
+coronaviruses	O
+,	O
+or	O
+group	O
+III	O
+coronaviruses	O
+.	O
+
+The	O
+homology	O
+of	O
+the	O
+nucleotides	B-CHED
+and	O
+amino	B-CHED
+acids	I-CHED
+among	O
+the	O
+five	O
+isolates	O
+were	O
+76	O
+.	O
+7	O
+%-	O
+92	O
+.	O
+1	O
+%	O
+and	O
+73	O
+.	O
+9	O
+%-	O
+89	O
+.	O
+5	O
+%,	O
+respectively	O
+,	O
+indicating	O
+a	O
+great	O
+variation	O
+in	O
+S1	O
+genes	O
+of	O
+the	O
+isolates	O
+.	O
+
+In	O
+a	O
+subset	O
+of	O
+176	O
+patients	O
+who	O
+had	O
+a	O
+complete	O
+blood	B-ANAT
+cell	I-ANAT
+count	O
+performed	O
+,	O
+the	O
+strongest	O
+predictors	O
+were	O
+temperature	O
+>	O
+or	O
+=	O
+38	O
+degrees	O
+C	O
+(	O
+OR	O
+=	O
+15	O
+.	O
+5	O
+),	O
+lymphocyte	B-ANAT
+count	O
+<	O
+1000	O
+(	O
+OR	O
+=	O
+9	O
+.	O
+3	O
+)	O
+and	O
+abnormal	O
+chest	B-ANAT
+x	O
+-	O
+ray	B-SPEC
+(	O
+OR	O
+=	O
+5	O
+.	O
+7	O
+).	O
+
+Diarrhea	B-DISO
+was	O
+a	O
+powerful	O
+negative	O
+predictor	O
+(	O
+OR	O
+=	O
+0	O
+.	O
+03	O
+)	O
+of	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Of	O
+821	O
+patients	O
+,	O
+205	O
+had	O
+confirmed	O
+SARS	B-DISO
+,	O
+35	O
+undetermined	O
+SARS	B-DISO
+and	O
+581	O
+non	O
+-	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Quasispecies	O
+of	O
+bovine	B-SPEC
+enteric	O
+and	O
+respiratory	O
+coronaviruses	O
+based	O
+on	O
+complete	O
+genome	O
+sequences	O
+and	O
+genetic	O
+changes	O
+after	O
+tissue	O
+culture	O
+adaptation	B-PROC
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+BCoV	O
+evolves	O
+through	O
+quasispecies	O
+development	B-PROC
+,	O
+and	O
+that	O
+enteric	O
+BCoV	O
+isolates	O
+are	O
+more	O
+prone	O
+to	O
+genetic	O
+changes	O
+and	O
+may	O
+mutate	B-PROC
+to	O
+resemble	O
+respiratory	O
+BCoV	O
+strains	O
+after	O
+tissue	B-ANAT
+culture	O
+passage	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+a	O
+devastating	O
+enteric	O
+disease	O
+with	O
+acute	B-DISO
+diarrhea	I-DISO
+,	O
+dehydration	B-DISO
+and	O
+significant	O
+mortality	O
+in	O
+swine	B-SPEC
+,	O
+thereby	O
+incurring	O
+heavy	O
+economic	O
+losses	O
+in	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Immunogenicity	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+DNA	O
+vaccine	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+delivered	O
+by	O
+attenuated	O
+Salmonella	B-SPEC
+typhimurium	O
+].	O
+
+The	O
+immunized	O
+mice	B-SPEC
+showed	O
+no	O
+clinic	O
+symptom	O
+.	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+immunized	O
+orally	B-ANAT
+with	O
+SL7207	O
+harboring	O
+recombinant	O
+plasmid	O
+at	O
+the	O
+dosage	O
+of	O
+109	O
+and	O
+boosted	O
+two	O
+weeks	O
+later	O
+with	O
+the	O
+same	O
+dose	O
+,	O
+for	O
+a	O
+total	O
+of	O
+three	O
+times	O
+.	O
+
+Most	O
+of	O
+the	O
+cases	O
+of	O
+NMO	B-CHED
+in	O
+Cuba	O
+are	O
+of	O
+the	O
+relapsing	O
+form	O
+,	O
+but	O
+this	O
+case	O
+report	O
+is	O
+the	O
+first	O
+one	O
+with	O
+monophasic	O
+NMO	B-CHED
+and	O
+DS	O
+with	O
+a	O
+very	O
+aggressive	B-DISO
+course	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+high	O
+-	O
+frequency	O
+oscillation	O
+(	O
+HFO	O
+)	O
+improves	O
+oxygenation	B-PROC
+relative	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+).	O
+
+A	O
+total	O
+of	O
+14	O
+patients	O
+with	O
+early	O
+(<	O
+72	O
+hrs	B-DISO
+in	O
+duration	O
+),	O
+severe	O
+(	O
+PaO2	O
+/	O
+FiO2	O
+of	O
+<	O
+150	O
+mm	O
+Hg	O
+and	O
+prerecruitment	O
+oxygenation	B-PROC
+index	O
+of	O
+22	O
+.	O
+8	O
++/-	O
+
+HFO	O
+sessions	O
+were	O
+preceded	O
+and	O
+followed	O
+by	O
+ARDS	O
+Network	O
+CMV	B-SPEC
+.	O
+
+Four	O
+recruitment	B-DISO
+maneuvers	O
+were	O
+performed	O
+during	O
+the	O
+study	O
+period	O
+.	O
+
+During	O
+HFO	O
+sessions	O
+,	O
+mean	O
+airway	B-ANAT
+pressure	O
+was	O
+set	O
+at	O
+1	O
+cm	O
+H2O	B-CHED
+above	O
+the	O
+point	O
+of	O
+maximal	O
+curvature	O
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+expiratory	B-PROC
+pressure	O
+-	O
+volume	O
+curve	O
+.	O
+
+TITLE	O
+:	O
+Randomization	O
+in	O
+clinical	O
+trials	O
+of	O
+titrated	O
+therapies	O
+:	O
+unintended	O
+consequences	O
+of	O
+using	O
+fixed	B-ANAT
+treatment	O
+protocols	O
+.	O
+
+The	O
+practice	O
+misalignments	B-DISO
+created	O
+by	O
+such	O
+designs	O
+may	O
+have	O
+unintended	O
+effects	O
+on	O
+trial	O
+results	O
+and	O
+safety	O
+.	O
+
+Publications	O
+before	O
+TRICC	O
+indicated	O
+that	O
+clinicians	O
+used	O
+higher	O
+transfusion	O
+thresholds	O
+in	O
+patients	O
+with	O
+ischemic	B-DISO
+heart	I-DISO
+disease	I-DISO
+compared	O
+with	O
+younger	O
+,	O
+healthier	O
+patients	O
+(	O
+p	O
+=	O
+.	O
+001	O
+).	O
+
+Thirty	O
+-	O
+day	O
+mortality	O
+was	O
+different	O
+and	O
+opposite	O
+in	O
+the	O
+liberal	O
+compared	O
+with	O
+the	O
+restrictive	O
+arm	B-ANAT
+depending	O
+on	O
+presence	O
+(	O
+21	O
+vs	O
+.	O
+26	O
+%)	O
+or	O
+absence	O
+(	O
+25	O
+vs	O
+.	O
+16	O
+%)	O
+of	O
+ischemic	B-DISO
+heart	I-DISO
+disease	I-DISO
+(	O
+p	O
+=	O
+.	O
+03	O
+).	O
+
+Characterizing	O
+current	O
+practice	O
+,	O
+incorporating	O
+current	O
+practice	O
+controls	O
+,	O
+and	O
+using	O
+alternative	O
+trial	O
+designs	O
+to	O
+minimize	O
+practice	O
+misalignments	B-DISO
+should	O
+improve	O
+trial	O
+safety	O
+and	O
+interpretability	O
+.	O
+
+ABSTRACT	O
+:	O
+Post	O
+-	O
+emetic	O
+spontaneous	B-DISO
+rupture	I-DISO
+of	O
+the	O
+esophagus	B-ANAT
+(	O
+Boerhaave	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+)	O
+is	O
+still	O
+a	O
+life	O
+-	O
+threatening	O
+condition	B-DISO
+,	O
+despite	O
+recent	O
+advances	O
+in	O
+thoracic	B-DISO
+surgery	O
+and	O
+critical	O
+care	O
+medicine	B-CHED
+.	O
+
+Emergency	B-DISO
+T	O
+-	O
+tube	O
+drainage	B-ANAT
+was	O
+therefore	O
+scheduled	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Role	O
+of	O
+endothelial	B-DISO
+dysfunction	I-DISO
+in	O
+the	O
+development	B-PROC
+of	O
+severe	B-DISO
+sepsis	I-DISO
+--	O
+the	O
+pathomechanism	O
+,	O
+evaluation	O
+by	O
+laboratory	O
+tests	O
+and	O
+new	O
+therapeutic	O
+strategies	O
+].	O
+
+E	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+,	O
+an	O
+endothelial	B-PRGE
+leukocyte	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+,	O
+is	O
+released	O
+from	O
+the	O
+endothelial	B-ANAT
+cell	I-ANAT
+membrane	O
+by	O
+the	O
+action	O
+of	O
+TNF	B-PRGE
+and	O
+exists	O
+as	O
+soluble	O
+E	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+in	O
+plasma	B-ANAT
+.	O
+
+Early	O
+detection	O
+of	O
+increases	O
+in	O
+plasma	B-ANAT
+levels	O
+of	O
+soluble	O
+E	O
+selectin	B-PROC
+by	O
+a	O
+rapid	O
+assay	O
+system	O
+,	O
+developed	O
+by	O
+the	O
+authors	O
+,	O
+enables	O
+early	O
+effective	O
+treatment	O
+of	O
+patients	O
+with	O
+sepsis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+association	O
+between	O
+weather	O
+and	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+transmission	O
+in	O
+Beijing	O
+and	O
+Hong	O
+Kong	O
+in	O
+the	O
+2003	O
+epidemic	O
+was	O
+studied	O
+to	O
+examine	O
+the	O
+effect	O
+of	O
+weather	O
+on	O
+SARS	B-DISO
+transmission	O
+.	O
+
+The	O
+study	O
+suggests	O
+that	O
+weather	O
+might	O
+be	O
+a	O
+contributory	O
+factor	O
+in	O
+the	O
+2003	O
+SARS	B-DISO
+epidemic	O
+,	O
+in	O
+particular	O
+in	O
+the	O
+transmission	O
+among	O
+the	O
+community	O
+members	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+results	O
+indicate	O
+that	O
+there	O
+were	O
+inverse	O
+association	O
+between	O
+the	O
+number	O
+of	O
+daily	O
+cases	O
+and	O
+maximum	O
+and	O
+/	O
+or	O
+minimum	O
+temperatures	O
+whereas	O
+air	O
+pressure	O
+was	O
+found	O
+to	O
+be	O
+positively	O
+associated	O
+with	O
+SARS	B-DISO
+transmission	O
+.	O
+
+Diseases	O
+with	O
+a	O
+limited	O
+reduction	O
+were	O
+acute	O
+conditions	O
+,	O
+difficult	O
+mental	B-DISO
+disorders	I-DISO
+,	O
+or	O
+procedures	O
+that	O
+could	O
+not	O
+be	O
+postponed	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+the	O
+disease	O
+categories	O
+with	O
+the	O
+smallest	O
+reduction	O
+were	O
+allergic	B-DISO
+reactions	I-DISO
+(-	O
+4	O
+%),	O
+skin	B-DISO
+infections	I-DISO
+(-	O
+6	O
+%),	O
+and	O
+anxiety	O
+(-	O
+10	O
+%)	O
+in	O
+ambulatory	O
+care	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+(+	O
+40	O
+%),	O
+delivery	O
+(-	O
+2	O
+%),	O
+and	O
+fractures	O
+of	O
+lower	B-ANAT
+limbs	I-ANAT
+(-	O
+5	O
+%)	O
+in	O
+inpatient	O
+care	O
+.	O
+
+The	O
+receptors	O
+of	O
+those	O
+two	O
+viruses	B-SPEC
+have	O
+been	O
+identified	O
+and	O
+their	O
+cell	B-COMP
+entry	O
+mechanism	O
+has	O
+been	O
+actively	O
+investigated	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Epidemiological	O
+investigation	O
+on	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+occurring	O
+in	O
+intensive	O
+care	O
+units	O
+in	O
+Beijing	O
+from	O
+1998	O
+to	O
+2003	O
+].	O
+
+The	O
+mean	O
+interval	O
+between	O
+onset	O
+of	O
+the	O
+primary	B-DISO
+disease	I-DISO
+and	O
+onset	O
+of	O
+ARDS	B-DISO
+was	O
+(	O
+61	O
+.	O
+8	O
++/-	O
+43	O
+.	O
+7	O
+)	O
+hours	O
+.	O
+
+It	O
+has	O
+no	O
+homology	O
+with	O
+known	O
+proteins	B-CHED
+and	O
+its	O
+function	O
+in	O
+SARS	B-DISO
+CoV	O
+replication	O
+has	O
+not	O
+been	O
+determined	O
+.	O
+
+The	O
+N	O
+-	O
+terminal	O
+part	O
+of	O
+the	O
+9b	O
+protein	B-CHED
+was	O
+used	O
+to	O
+raise	O
+polyclonal	O
+antibodies	B-COMP
+in	O
+rabbits	B-SPEC
+,	O
+and	O
+these	O
+antibodies	B-COMP
+could	O
+detect	O
+9b	B-PRGE
+protein	I-PRGE
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+Twenty	O
+-	O
+eight	O
+virus	B-SPEC
+-	O
+specific	O
+TCC	B-COMP
+and	O
+7	O
+myelin	B-COMP
+-	O
+specific	O
+TCC	B-COMP
+were	O
+obtained	O
+from	O
+six	O
+healthy	O
+donors	O
+.	O
+
+The	O
+ELSO	O
+registry	O
+currently	O
+includes	O
+31	O
+,	O
+340	O
+ECMO	O
+cases	O
+,	O
+of	O
+which	O
+151	O
+were	O
+post	O
+-	O
+LTx	O
+patients	O
+with	O
+primary	B-DISO
+graft	I-DISO
+dysfunction	I-DISO
+(	O
+PGD	B-CHED
+).	O
+
+It	O
+was	O
+also	O
+discontinued	O
+in	O
+29	O
+patients	O
+with	O
+multiorgan	B-DISO
+failure	I-DISO
+,	O
+in	O
+22	O
+patients	O
+that	O
+died	B-PROC
+with	O
+no	O
+further	O
+specification	O
+,	O
+and	O
+in	O
+7	O
+patients	O
+for	O
+other	O
+reasons	O
+.	O
+
+It	O
+has	O
+tremendous	O
+values	O
+for	O
+both	O
+drug	O
+discovery	O
+and	O
+basic	O
+research	O
+to	O
+develop	O
+a	O
+solid	O
+bioinformatical	O
+tool	O
+for	O
+guiding	O
+peptide	O
+reagent	B-CHED
+design	O
+.	O
+
+An	O
+iterative	O
+double	O
+least	O
+square	O
+technique	O
+is	O
+developed	O
+for	O
+the	O
+solution	O
+of	O
+the	O
+three	O
+-	O
+dimensional	O
+simultaneous	O
+linear	O
+equation	O
+set	O
+to	O
+determine	O
+the	O
+amino	B-CHED
+acid	I-CHED
+position	O
+coefficients	O
+of	O
+peptide	B-CHED
+sequence	O
+and	O
+the	O
+physicochemical	O
+parameter	O
+coefficients	O
+of	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+alternately	O
+.	O
+
+Using	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+as	O
+a	O
+model	O
+,	O
+we	O
+will	O
+review	O
+the	O
+current	O
+knowledge	O
+of	O
+the	O
+interplay	O
+between	O
+coronavirus	B-DISO
+infection	I-DISO
+and	O
+the	O
+host	B-COMP
+innate	O
+immune	B-ANAT
+system	I-ANAT
+in	O
+vivo	O
+,	O
+and	O
+then	O
+discuss	O
+the	O
+mechanisms	O
+by	O
+which	O
+specific	O
+gene	O
+products	O
+antagonize	O
+the	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+in	O
+cell	B-COMP
+culture	O
+models	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+,	O
+human	B-PRGE
+angiotensin	B-CHED
+1	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+hACE2	O
+),	O
+was	O
+detected	O
+exclusively	O
+on	O
+the	O
+apical	O
+surface	O
+of	O
+cells	B-COMP
+in	O
+polarized	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+and	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	O
+cultures	O
+(	O
+HAE	B-PRGE
+),	O
+indicating	O
+that	O
+hACE2	O
+was	O
+accessible	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+after	O
+lumenal	O
+airway	B-ANAT
+delivery	O
+.	O
+
+To	O
+assess	O
+infectivity	O
+in	O
+ciliated	O
+airway	B-ANAT
+cultures	O
+derived	O
+from	O
+susceptible	O
+animal	B-SPEC
+species	B-SPEC
+we	O
+generated	O
+a	O
+recombinant	O
+SARS	B-DISO
+-	O
+CoV	O
+by	O
+deletion	O
+of	O
+open	O
+reading	O
+frame	O
+7a	O
+/	O
+7b	O
+(	O
+ORF	O
+7a	O
+/	O
+7b	O
+)	O
+and	O
+insertion	O
+of	O
+the	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	B-CHED
+)	O
+resulting	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+GFP	B-CHED
+.	O
+
+Efficient	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+of	O
+ciliated	B-ANAT
+cell	I-ANAT
+-	O
+types	O
+in	O
+HAE	O
+provides	O
+a	O
+useful	O
+in	O
+vitro	O
+model	O
+of	O
+human	B-SPEC
+lung	B-ANAT
+origin	O
+to	O
+study	O
+characteristics	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+review	O
+,	O
+we	O
+summarize	O
+the	O
+researches	O
+on	O
+animal	O
+reservoirs	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Masked	B-SPEC
+palm	I-SPEC
+civets	I-SPEC
+were	O
+suspected	O
+as	O
+the	O
+origin	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+and	O
+was	O
+confirmed	O
+as	O
+the	O
+direct	O
+origin	O
+of	O
+SARS	B-DISO
+cases	O
+with	O
+mild	O
+symptom	B-DISO
+in	O
+2004	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+apoptosis	B-PATH
+effect	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+on	O
+cultured	B-ANAT
+cell	I-ANAT
+lines	O
+and	O
+to	O
+explore	O
+the	O
+possible	O
+pathway	B-PROC
+of	O
+apoptosis	B-PATH
+.	O
+
+Apoptosis	B-PATH
+induced	O
+by	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+N	I-PRGE
+protein	B-CHED
+under	O
+starvation	O
+of	O
+serum	B-COMP
+of	O
+COS	B-ANAT
+-	I-ANAT
+1	I-ANAT
+cells	B-COMP
+was	O
+monitored	O
+by	O
+Annexin	B-PRGE
+V	I-PRGE
+and	O
+electron	O
+microscopy	O
+assays	O
+.	O
+
+SARS	B-PRGE
+coronavirus	B-SPEC
+M	I-PRGE
+,	O
+S	B-PRGE
+protein	I-PRGE
+can	O
+not	O
+induce	O
+apoptosis	B-PATH
+in	O
+COS	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+HepG2	O
+and	O
+Huh	O
+-	O
+7	O
+and	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+N	I-PRGE
+protein	B-CHED
+can	O
+not	O
+induce	O
+apoptosis	B-PATH
+in	O
+HepG2	O
+and	O
+Huh	O
+-	O
+7	O
+by	O
+methods	O
+used	O
+in	O
+this	O
+study	O
+.	O
+
+Endotracheal	O
+intubation	O
+was	O
+done	O
+on	O
+the	O
+second	O
+hospital	O
+day	O
+in	O
+the	O
+Pediatric	O
+Intensive	O
+Care	O
+Unit	O
+(	O
+PICU	B-SPEC
+)	O
+due	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+manifested	O
+by	O
+hypercapnia	B-DISO
+and	O
+hypoxemia	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+is	O
+of	O
+paramount	O
+importance	O
+for	O
+modern	O
+intensive	O
+care	O
+since	O
+it	O
+is	O
+one	O
+of	O
+the	O
+most	O
+frequent	O
+conditions	O
+necessitating	O
+admission	O
+to	O
+an	O
+ICU	O
+.	O
+
+Although	O
+there	O
+are	O
+no	O
+currently	O
+approved	O
+antiviral	B-CHED
+agents	I-CHED
+for	O
+clinical	O
+use	O
+,	O
+our	O
+increased	O
+understanding	O
+of	O
+the	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+should	O
+lead	O
+to	O
+new	O
+intervention	O
+strategies	O
+.	O
+
+Clinicians	O
+should	O
+appreciate	O
+the	O
+potential	O
+for	O
+the	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+resistance	B-PROC
+to	O
+influenza	B-DISO
+antivirals	B-CHED
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviral	O
+infection	B-DISO
+of	O
+New	O
+World	O
+camelids	O
+was	O
+first	O
+identified	O
+in	O
+1998	O
+in	O
+llamas	O
+and	O
+alpacas	B-SPEC
+with	O
+severe	B-DISO
+diarrhea	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+145	O
+point	B-PROC
+mutations	I-PROC
+and	O
+one	O
+nucleotide	B-CHED
+deletion	O
+were	O
+found	O
+relative	O
+to	O
+the	O
+BCoV	B-PRGE
+ENT	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Critical	O
+assessment	O
+of	O
+the	O
+diagnostic	O
+value	O
+of	O
+feline	B-PRGE
+alpha1	I-PRGE
+-	I-PRGE
+acid	I-PRGE
+glycoprotein	B-CHED
+for	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+using	O
+the	O
+likelihood	O
+ratios	O
+approach	O
+.	O
+
+Serum	B-COMP
+AGP	O
+levels	O
+from	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+(	O
+group	O
+1	O
+;	O
+n	O
+=	O
+58	O
+)	O
+and	O
+without	O
+FIP	B-DISO
+(	O
+group	O
+2	O
+;	O
+n	O
+=	O
+104	O
+)	O
+were	O
+evaluated	O
+.	O
+
+In	O
+addition	O
+,	O
+MHV	B-SPEC
+was	O
+able	O
+to	O
+significantly	O
+decrease	O
+the	O
+level	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+protein	I-PRGE
+induced	O
+by	O
+both	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+)	O
+and	O
+Sendai	B-SPEC
+virus	I-SPEC
+infections	B-DISO
+,	O
+without	O
+targeting	B-PROC
+it	O
+for	O
+proteasomal	O
+degradation	O
+and	O
+without	O
+altering	O
+the	O
+nuclear	B-PROC
+translocation	I-PROC
+of	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+or	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+mRNA	I-PRGE
+production	O
+or	O
+stability	O
+.	O
+
+Furthermore	O
+,	O
+MHV	B-SPEC
+replication	O
+is	O
+highly	O
+resistant	O
+to	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+action	O
+,	O
+as	O
+indicated	O
+by	O
+unimpaired	O
+MHV	B-SPEC
+replication	O
+in	O
+L2	O
+cells	B-COMP
+pretreated	O
+with	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+an	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+averted	O
+in	O
+2004	O
+,	O
+many	O
+novel	O
+coronaviruses	O
+have	O
+been	O
+recognized	O
+from	O
+different	O
+species	B-SPEC
+,	O
+including	O
+humans	B-SPEC
+.	O
+
+Bats	B-SPEC
+have	O
+provided	O
+the	O
+most	O
+diverse	O
+assemblages	O
+of	O
+coronaviruses	O
+,	O
+suggesting	O
+that	O
+they	O
+may	O
+be	O
+the	O
+natural	O
+reservoir	O
+.	O
+
+TITLE	O
+:	O
+Seroprevalence	O
+of	O
+selected	O
+infectious	B-DISO
+agents	O
+in	O
+a	O
+free	O
+-	O
+ranging	O
+,	O
+low	O
+-	O
+density	O
+lion	B-SPEC
+population	O
+in	O
+the	O
+Central	O
+Kalahari	O
+Game	O
+Reserves	O
+in	O
+Botswana	O
+.	O
+
+Canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+and	O
+feline	B-SPEC
+calicivirus	I-SPEC
+occurred	O
+with	O
+a	O
+low	O
+prevalence	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+case	O
+of	O
+a	O
+young	O
+man	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+,	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+sepsis	B-DISO
+is	O
+reported	O
+.	O
+
+Treatment	O
+with	O
+antibiotics	B-CHED
+and	O
+various	O
+modes	O
+of	O
+mechanical	O
+ventilation	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+were	O
+unsuccessful	O
+.	O
+
+The	O
+overall	O
+downward	O
+trend	O
+of	O
+the	O
+infection	B-DISO
+curve	O
+after	O
+early	O
+May	O
+corresponds	O
+well	O
+to	O
+the	O
+date	O
+(	O
+May	O
+10	O
+)	O
+when	O
+changes	O
+in	O
+the	O
+review	O
+and	O
+classification	O
+procedure	O
+were	O
+implemented	O
+by	O
+the	O
+SARS	B-DISO
+Prevention	O
+and	O
+Extrication	O
+Committee	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+compare	O
+the	O
+diagnostic	O
+accuracy	O
+of	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+physicians	O
+with	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+case	O
+definition	O
+in	O
+a	O
+large	O
+community	O
+-	O
+based	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+cohort	O
+.	O
+
+In	O
+addition	O
+,	O
+immunofluorescence	O
+assays	O
+for	O
+detection	O
+of	O
+pAPN	O
+and	O
+PEDV	B-SPEC
+antigens	B-CHED
+,	O
+together	O
+with	O
+neutralization	O
+assays	O
+using	O
+antibodies	B-COMP
+against	O
+pAPN	O
+,	O
+further	O
+confirmed	O
+the	O
+correlation	O
+between	O
+pAPN	O
+expression	B-PROC
+and	O
+viral	B-PROC
+replication	I-PROC
+in	O
+pAPN	O
+-	O
+transfected	O
+MDCK	B-ANAT
+cells	I-ANAT
+.	O
+
+103	O
+adult	O
+patients	O
+with	O
+ARDS	B-DISO
+(	O
+white	O
+Germans	O
+).	O
+
+In	O
+the	O
+seven	O
+unvaccinated	O
+groups	O
+,	O
+CDV	B-CHED
+titers	O
+were	O
+low	O
+and	O
+occurred	O
+in	O
+20	O
+-	O
+100	O
+%	O
+of	O
+the	O
+animals	B-SPEC
+;	O
+antibody	B-COMP
+titers	O
+against	O
+CPV	B-SPEC
+were	O
+found	O
+in	O
+seven	O
+of	O
+eight	O
+areas	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+the	O
+first	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+of	O
+the	O
+21st	O
+century	O
+that	O
+has	O
+been	O
+highly	O
+transmissible	O
+and	O
+fatal	O
+and	O
+was	O
+caused	O
+by	O
+a	O
+previously	O
+unknown	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+It	O
+is	O
+hence	O
+necessary	O
+to	O
+understand	O
+the	O
+biology	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+to	O
+deal	O
+adequately	O
+with	O
+the	O
+next	O
+outbreak	O
+,	O
+whenever	O
+it	O
+happens	O
+.	O
+
+The	O
+remaining	O
+12	O
+ORFs	O
+encode	O
+the	O
+4	O
+structural	O
+proteins	B-CHED
+:	O
+spike	O
+,	O
+membrane	B-COMP
+,	O
+nucleocapsid	B-COMP
+and	O
+envelope	B-COMP
+;	O
+and	O
+eight	O
+accessory	O
+proteins	B-CHED
+.	O
+
+The	O
+viral	B-COMP
+genome	I-COMP
+and	O
+its	O
+expression	B-PROC
+within	O
+the	O
+host	B-COMP
+cell	I-COMP
+undergoes	O
+extensive	O
+translational	B-PROC
+and	O
+enzymatic	O
+processing	O
+to	O
+form	O
+the	O
+4	O
+structural	O
+,	O
+8	O
+accessory	O
+and	O
+16	O
+nonstructural	O
+proteins	B-CHED
+.	O
+
+Two	O
+conflicting	O
+cellular	B-COMP
+programs	O
+,	O
+apoptosis	B-PATH
+to	O
+eliminate	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+and	O
+survival	O
+to	O
+delay	O
+apoptosis	B-PATH
+by	O
+producing	O
+antiviral	B-CHED
+cytokines	O
+,	O
+occur	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+Agents	O
+being	O
+developed	O
+to	O
+target	O
+these	O
+signaling	B-PROC
+cascades	O
+may	O
+be	O
+important	O
+for	O
+the	O
+design	O
+of	O
+anti	O
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+drugs	O
+.	O
+
+The	O
+cleavage	B-PROC
+could	O
+be	O
+blocked	O
+by	O
+a	O
+PC	O
+-	O
+inhibitor	B-CHED
+,	O
+alpha1	B-PRGE
+-	I-PRGE
+PDX	I-PRGE
+,	O
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+4	O
+weeks	O
+later	O
+,	O
+the	O
+patient	O
+presented	O
+again	O
+with	O
+a	O
+clinical	O
+relapse	O
+of	O
+severe	O
+hemoptysis	B-DISO
+and	O
+respiratory	B-DISO
+insufficiency	I-DISO
+after	O
+smoke	O
+exposition	O
+.	O
+
+He	O
+was	O
+under	O
+intermittent	O
+hemodialysis	O
+until	O
+laboratory	O
+measurements	O
+showed	O
+improved	O
+renal	B-PROC
+function	I-PROC
+.	O
+
+It	O
+is	O
+important	O
+to	O
+consider	O
+that	O
+in	O
+patients	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+GBM	I-PRGE
+disease	I-PRGE
+antibody	B-COMP
+-	O
+negative	O
+relapses	O
+are	O
+possible	O
+.	O
+
+TITLE	O
+:	O
+Modelling	O
+respiratory	B-DISO
+infection	I-DISO
+control	O
+measure	O
+effects	O
+.	O
+
+We	O
+show	O
+that	O
+a	O
+combination	O
+of	O
+assigned	O
+effective	O
+public	O
+health	O
+interventions	O
+and	O
+enhanced	O
+engineering	O
+control	O
+measures	O
+would	O
+have	O
+a	O
+high	O
+probability	O
+for	O
+containing	O
+airborne	O
+infection	B-DISO
+.	O
+
+We	O
+conclude	O
+that	O
+SLVI	O
+within	O
+the	O
+BCoV	B-PRGE
+nsp1	I-PRGE
+coding	I-PRGE
+region	I-PRGE
+is	O
+a	O
+higher	O
+-	O
+order	B-SPEC
+cis	B-DISO
+-	O
+replication	O
+element	O
+for	O
+DI	B-PRGE
+RNA	I-PRGE
+and	O
+postulate	O
+that	O
+it	O
+functions	O
+similarly	O
+in	O
+the	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+For	O
+Canada	O
+,	O
+a	O
+similar	O
+catalyst	B-CHED
+stemmed	O
+from	O
+the	O
+lessons	O
+learned	B-PROC
+during	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+.	O
+
+Pneumococci	O
+should	O
+be	O
+considered	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+any	O
+young	O
+woman	O
+who	O
+develops	O
+peritonitis	B-DISO
+without	O
+an	O
+obvious	O
+cause	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+avian	O
+coronavirus	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+major	O
+economic	O
+pathogen	O
+of	O
+domestic	O
+poultry	O
+that	O
+,	O
+despite	O
+vaccination	O
+,	O
+causes	O
+mortality	O
+and	O
+significant	O
+losses	O
+in	O
+production	O
+.	O
+
+During	O
+replication	O
+of	O
+the	O
+RNA	O
+genome	O
+there	O
+is	O
+a	O
+high	O
+frequency	O
+of	O
+mutation	O
+and	O
+recombination	B-PROC
+,	O
+which	O
+has	O
+given	O
+rise	O
+to	O
+many	O
+strains	O
+of	O
+IBV	B-SPEC
+and	O
+results	O
+in	O
+the	O
+potential	O
+for	O
+new	O
+and	O
+emerging	O
+strains	O
+.	O
+
+Literature	O
+was	O
+searched	O
+through	O
+PubMed	O
+,	O
+Cochrane	O
+Library	O
+,	O
+Wan	O
+Fang	B-ANAT
+database	O
+and	O
+Google	O
+.	O
+
+Self	O
+-	O
+reported	O
+hand	O
+-	O
+washing	O
+compliance	O
+increased	O
+in	O
+the	O
+first	O
+phase	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+and	O
+maintained	O
+a	O
+high	O
+level	O
+22	O
+months	O
+after	O
+the	O
+outbreak	O
+.	O
+
+The	O
+importance	O
+of	O
+family	B-SPEC
+support	O
+and	O
+'	O
+significant	O
+female	O
+others	O
+'	O
+in	O
+hand	O
+hygiene	O
+promotion	O
+are	O
+noted	O
+.	O
+
+Morbid	B-DISO
+obesity	I-DISO
+was	O
+not	O
+associated	O
+with	O
+increased	O
+mortality	O
+(	O
+OR	O
+0	O
+.	O
+810	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+353	O
+to	O
+1	O
+.	O
+856	O
+).	O
+
+The	O
+use	O
+of	O
+colloids	O
+and	O
+steroids	B-CHED
+may	O
+be	O
+beneficial	O
+,	O
+but	O
+other	O
+new	O
+therapies	O
+such	O
+as	O
+insulin	B-PRGE
+and	O
+activated	O
+protein	B-CHED
+C	O
+still	O
+need	O
+further	O
+assessment	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+further	O
+characterize	O
+the	O
+functional	O
+properties	O
+of	O
+this	O
+protein	B-CHED
+,	O
+we	O
+initiated	O
+studies	O
+to	O
+check	O
+its	O
+RNA	B-FUNC
+binding	I-FUNC
+activity	O
+.	O
+
+This	O
+RNA	B-FUNC
+binding	I-FUNC
+motif	O
+of	O
+3a	O
+does	O
+not	O
+share	O
+homology	O
+with	O
+any	O
+other	O
+known	O
+RNA	B-FUNC
+binding	I-FUNC
+protein	B-CHED
+and	O
+may	O
+have	O
+an	O
+important	O
+role	O
+in	O
+viral	B-PROC
+capsid	I-PROC
+assembly	I-PROC
+and	O
+pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+recent	O
+advances	O
+in	O
+critical	O
+care	O
+management	O
+,	O
+the	O
+mortality	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+high	O
+.	O
+
+Bronchial	B-ANAT
+rupture	O
+and	O
+mediastinal	B-DISO
+emphysema	I-DISO
+was	O
+found	O
+in	O
+one	O
+of	O
+them	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+analysis	O
+of	O
+hyperoxic	O
+acute	O
+lung	B-ANAT
+injury	O
+survival	O
+in	O
+reciprocal	O
+intercross	O
+mice	B-SPEC
+.	O
+
+Concomitantly	O
+,	O
+phosphorylation	B-PROC
+of	O
+the	O
+eukaryotic	B-PRGE
+translation	I-PRGE
+initiation	I-PRGE
+factor	I-PRGE
+2alpha	I-PRGE
+was	O
+increased	O
+in	O
+MHV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+Cross	O
+-	O
+species	B-SPEC
+transmission	O
+:	O
+last	O
+obstacle	O
+before	O
+pandemic	O
+].	O
+
+The	O
+improvement	O
+of	O
+epidemiological	O
+surveillance	O
+has	O
+allowed	O
+live	O
+monitoring	O
+of	O
+epidemic	O
+progresses	O
+,	O
+while	O
+new	O
+molecular	O
+biological	O
+tools	O
+have	O
+allowed	O
+analysis	O
+of	O
+the	O
+various	O
+steps	O
+required	O
+for	O
+viral	O
+adaptation	B-PROC
+to	O
+their	O
+new	O
+hosts	B-COMP
+.	O
+
+We	O
+collected	O
+fecal	B-ANAT
+specimens	O
+from	O
+monkeys	B-SPEC
+with	O
+diarrhea	B-DISO
+that	O
+were	O
+housed	O
+in	O
+two	O
+primate	B-SPEC
+colonies	O
+,	O
+the	O
+Institute	O
+of	O
+Laboratory	O
+Animal	B-SPEC
+Sciences	O
+,	O
+Beijing	O
+,	O
+China	O
+and	O
+the	O
+Yerkes	O
+National	O
+Primate	B-SPEC
+Research	O
+Center	O
+,	O
+Georgia	O
+,	O
+USA	O
+.	O
+
+Our	O
+findings	O
+indicate	O
+endemic	O
+infections	B-DISO
+with	O
+enteric	O
+viruses	B-SPEC
+in	O
+monkeys	B-SPEC
+of	O
+both	O
+colonies	O
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+cycle	I-PATH
+arrest	I-PROC
+and	O
+apoptosis	B-PATH
+induced	O
+by	O
+the	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+the	O
+absence	O
+of	O
+p53	O
+.	O
+
+This	O
+study	O
+provides	O
+basic	O
+information	O
+for	O
+the	O
+design	O
+of	O
+DNA	O
+vaccines	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+Complete	O
+records	O
+for	O
+blood	B-ANAT
+transfusions	O
+were	O
+available	O
+for	O
+61	O
+patients	O
+:	O
+90	O
+%	O
+had	O
+penetrating	O
+trauma	O
+,	O
+17	O
+received	O
+rFVIIa	O
+early	O
+,	O
+and	O
+44	O
+received	O
+it	O
+late	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+enteric	O
+syndrome	B-DISO
+was	O
+observed	O
+in	O
+quail	O
+(	O
+Coturnix	B-SPEC
+coturnix	I-SPEC
+)	O
+semi	O
+-	O
+intensively	O
+reared	O
+for	O
+restocking	O
+in	O
+Apulia	O
+(	O
+southern	O
+Italy	O
+).	O
+
+Mortality	O
+occurred	O
+particularly	O
+in	O
+young	O
+birds	B-SPEC
+.	O
+
+The	O
+same	O
+patient	O
+subsequently	O
+required	O
+laryngeal	B-ANAT
+exclusion	O
+and	O
+tracheostomy	O
+.	O
+
+Of	O
+139	O
+patients	O
+treated	O
+for	O
+dysphagia	B-DISO
+secondary	O
+to	O
+muscular	B-DISO
+dystrophy	I-DISO
+,	O
+haematoma	B-DISO
+formation	B-PROC
+or	O
+infection	B-DISO
+occurred	O
+in	O
+four	O
+,	O
+and	O
+eight	O
+patients	O
+developed	O
+postoperative	O
+pulmonary	B-DISO
+complications	I-DISO
+,	O
+four	O
+of	O
+whom	O
+died	B-PROC
+from	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Two	O
+patients	O
+with	O
+myogenic	O
+dysphagia	B-DISO
+required	O
+laryngeal	B-ANAT
+exclusion	O
+with	O
+a	O
+permanent	O
+tracheostomy	O
+.	O
+
+TITLE	O
+:	O
+Animal	B-SPEC
+models	O
+and	O
+vaccines	O
+for	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+We	O
+invited	O
+SARS	B-DISO
+survivors	O
+from	O
+the	O
+same	O
+hospitals	O
+(	O
+non	O
+-	O
+health	O
+care	O
+workers	O
+,	O
+n	O
+=	O
+63	O
+;	O
+health	O
+care	O
+workers	O
+,	O
+n	O
+=	O
+33	O
+)	O
+to	O
+complete	O
+the	O
+PSS	B-DISO
+-	O
+10	O
+again	O
+in	O
+2004	O
+.	O
+
+The	O
+situation	O
+of	O
+health	O
+care	O
+worker	O
+SARS	B-DISO
+survivors	O
+is	O
+particularly	O
+worrying	O
+.	O
+
+PSS	B-DISO
+-	O
+10	O
+scores	O
+were	O
+also	O
+obtained	O
+from	O
+matched	O
+community	O
+control	O
+subjects	O
+during	O
+the	O
+outbreak	O
+(	O
+n	O
+=	O
+145	O
+)	O
+and	O
+again	O
+in	O
+2004	O
+(	O
+n	O
+=	O
+112	O
+).	O
+
+We	O
+recruited	O
+high	O
+-	O
+risk	O
+health	O
+care	O
+workers	O
+who	O
+practised	O
+respiratory	O
+medicine	B-CHED
+and	O
+compared	O
+them	O
+with	O
+nonrespiratory	O
+medicine	B-CHED
+workers	O
+,	O
+who	O
+formed	O
+the	O
+low	O
+-	O
+risk	O
+health	O
+care	O
+worker	O
+control	O
+group	O
+.	O
+
+Health	O
+care	O
+workers	O
+who	O
+were	O
+at	O
+high	O
+risk	O
+of	O
+contracting	O
+SARS	B-DISO
+appear	O
+not	O
+only	O
+to	O
+have	O
+chronic	O
+stress	O
+but	O
+also	O
+higher	O
+levels	O
+of	O
+depression	B-DISO
+and	O
+anxiety	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+our	O
+global	O
+world	O
+,	O
+the	O
+increasing	O
+complexity	O
+of	O
+social	O
+relations	O
+and	O
+transport	B-PROC
+infrastructures	O
+are	O
+key	O
+factors	O
+in	O
+the	O
+spread	O
+of	O
+epidemics	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3a	O
+protein	B-CHED
+and	O
+the	O
+assembly	O
+of	O
+coronavirus	O
+-	O
+like	O
+particles	O
+in	O
+the	O
+baculovirus	B-SPEC
+expression	B-PROC
+system	O
+.	O
+
+Using	O
+the	O
+same	O
+expression	B-PROC
+system	O
+,	O
+two	O
+structural	O
+proteins	B-CHED
+,	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+envelope	B-COMP
+(	O
+E	O
+),	O
+were	O
+co	O
+-	O
+expressed	B-PROC
+to	O
+form	O
+SARS	B-DISO
+-	O
+CoV	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+within	O
+an	O
+insect	B-SPEC
+cell	B-COMP
+.	O
+
+A	O
+fully	O
+matured	O
+S	B-PRGE
+glycoprotein	I-PRGE
+will	O
+be	O
+modified	O
+with	O
+complex	O
+oligosaccharides	B-CHED
+which	O
+makes	O
+it	O
+resistant	O
+to	O
+cleavage	B-PROC
+by	O
+EndoH	O
+but	O
+not	O
+by	O
+N	O
+-	O
+Gly	B-CHED
+F	O
+.	O
+By	O
+exploiting	O
+this	O
+characteristic	O
+,	O
+it	O
+is	O
+then	O
+possible	O
+to	O
+determine	O
+which	O
+forms	O
+of	O
+the	O
+immunoprecipitated	O
+S	B-PRGE
+protein	I-PRGE
+are	O
+properly	O
+processed	O
+by	O
+the	O
+host	O
+cell	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Modelling	O
+epidemics	O
+:	O
+the	O
+case	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Canada	O
+].	O
+
+However	O
+,	O
+with	O
+almost	O
+30	O
+%	O
+of	O
+the	O
+medicated	O
+hypertensive	O
+patients	O
+harboring	O
+an	O
+uncontrolled	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+a	O
+need	O
+for	O
+new	O
+drugs	O
+and	O
+new	O
+targets	O
+appears	O
+necessary	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+will	O
+compare	O
+the	O
+structures	O
+,	O
+distributions	O
+and	O
+properties	O
+of	O
+ACE	B-PRGE
+and	O
+its	O
+new	O
+homologue	O
+in	O
+the	O
+context	O
+of	O
+cardiovascular	B-PROC
+function	I-PROC
+,	O
+focusing	O
+on	O
+the	O
+autocrine	B-PROC
+/	O
+paracrine	B-PROC
+cardiac	B-ANAT
+and	O
+brain	B-ANAT
+renin	B-PRGE
+-	O
+angiotensin	B-CHED
+systems	O
+and	O
+we	O
+will	O
+present	O
+recent	O
+data	O
+from	O
+the	O
+literature	O
+and	O
+our	O
+laboratory	O
+offering	O
+a	O
+new	O
+perspective	O
+on	O
+this	O
+potential	O
+target	O
+for	O
+the	O
+treatment	O
+of	O
+cardiovascular	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+major	O
+neutralizing	O
+epitope	B-CHED
+was	O
+located	O
+on	O
+the	O
+D2	O
+peptide	B-CHED
+,	O
+and	O
+the	O
+amino	B-CHED
+acid	I-CHED
+residue	I-CHED
+was	O
+fine	O
+mapped	O
+to	O
+434	O
+-	O
+453	O
+.	O
+
+TITLE	O
+:	O
+GxxxG	O
+motif	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+glycoprotein	B-CHED
+transmembrane	B-ANAT
+domain	O
+is	O
+not	O
+involved	O
+in	O
+trimerization	O
+and	O
+is	O
+not	O
+important	O
+for	O
+entry	O
+.	O
+
+All	O
+viruses	B-SPEC
+replicated	O
+efficiently	O
+,	O
+but	O
+none	O
+produced	O
+clinical	O
+disease	O
+or	O
+death	B-PROC
+in	O
+young	O
+animals	B-SPEC
+.	O
+
+In	O
+contrast	O
+,	O
+severe	O
+clinical	O
+disease	O
+,	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+,	O
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+,	O
+alveolitis	B-DISO
+,	O
+and	O
+death	B-PROC
+were	O
+noted	O
+in	O
+12	O
+-	O
+month	O
+-	O
+old	O
+mice	B-SPEC
+inoculated	O
+with	O
+the	O
+palm	B-ANAT
+civet	B-SPEC
+HC	O
+/	O
+SZ	O
+/	O
+61	O
+/	O
+03	O
+strain	O
+or	O
+early	O
+-	O
+human	B-SPEC
+-	O
+phase	O
+GZ02	O
+variants	O
+but	O
+not	O
+with	O
+related	O
+middle	O
+-	O
+and	O
+late	O
+-	O
+phase	O
+epidemic	O
+or	O
+raccoon	B-SPEC
+dog	I-SPEC
+strains	O
+.	O
+
+TITLE	O
+:	O
+Simultaneous	O
+detection	O
+and	O
+high	O
+-	O
+throughput	O
+identification	O
+of	O
+a	O
+panel	O
+of	O
+RNA	O
+viruses	B-SPEC
+causing	O
+respiratory	B-ANAT
+tract	I-ANAT
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+presentations	O
+for	O
+viral	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+are	O
+often	O
+nonspecific	O
+,	O
+and	O
+a	O
+rapid	O
+,	O
+high	O
+-	O
+throughput	O
+laboratory	O
+technique	O
+that	O
+can	O
+detect	O
+a	O
+panel	O
+of	O
+common	O
+viral	O
+pathogens	O
+is	O
+clinically	O
+desirable	O
+.	O
+
+We	O
+evaluated	O
+two	O
+multiplex	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+products	O
+coupled	O
+with	O
+microarray	O
+-	O
+based	O
+systems	O
+for	O
+simultaneous	O
+detection	O
+of	O
+common	O
+respiratory	B-ANAT
+tract	I-ANAT
+viral	O
+pathogens	O
+.	O
+
+An	O
+investigator	O
+attended	O
+the	O
+lobby	O
+daily	O
+to	O
+screen	O
+patients	O
+with	O
+symptoms	O
+for	O
+SARS	B-DISO
+.	O
+
+The	O
+EMOPDs	O
+in	O
+key	O
+hospitals	O
+need	O
+be	O
+able	O
+to	O
+screen	O
+for	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+especially	O
+in	O
+view	O
+of	O
+the	O
+threats	O
+from	O
+SARS	B-DISO
+and	O
+Avian	B-DISO
+influenza	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+demand	O
+for	O
+rapid	O
+and	O
+simple	O
+development	B-PROC
+of	O
+a	O
+vaccine	O
+against	O
+a	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+is	O
+increasing	O
+worldwide	O
+.	O
+
+The	O
+system	O
+is	O
+characterized	O
+by	O
+a	O
+new	O
+low	O
+-	O
+resistance	B-PROC
+gas	B-ENZY
+exchange	O
+membrane	B-COMP
+that	O
+is	O
+integrated	O
+in	O
+an	O
+arterial	B-ANAT
+-	O
+venous	B-ANAT
+bypass	O
+established	O
+by	O
+cannulation	O
+of	O
+the	O
+femoral	B-ANAT
+artery	I-ANAT
+and	O
+vein	B-ANAT
+.	O
+
+Ventilator	O
+settings	O
+were	O
+able	O
+to	O
+be	O
+adjusted	O
+to	O
+the	O
+decreased	O
+pulmonary	B-PROC
+gas	B-ENZY
+exchange	I-PROC
+needs	O
+,	O
+making	O
+protective	O
+lung	B-ANAT
+strategies	O
+possible	O
+.	O
+
+TITLE	O
+:	O
+What	O
+'	O
+s	O
+new	O
+in	O
+surfactant	B-CHED
+?	O
+
+Ideally	O
+,	O
+surfactant	B-CHED
+would	O
+be	O
+administered	O
+without	O
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+Ongoing	O
+research	O
+is	O
+essential	O
+to	O
+continue	O
+to	O
+improve	O
+therapeutic	O
+prospects	O
+for	O
+children	O
+with	O
+serious	O
+respiratory	B-DISO
+disease	I-DISO
+involving	O
+disturbances	O
+in	O
+surfactant	B-CHED
+.	O
+
+Apart	O
+from	O
+supportive	O
+treatment	O
+with	O
+artificial	O
+ventilation	O
+the	O
+medical	O
+treatment	O
+included	O
+the	O
+use	O
+of	O
+Acyclovir	B-CHED
+and	O
+polyclonal	B-PRGE
+immunoglobulins	I-PRGE
+in	O
+the	O
+early	O
+phase	O
+and	O
+corticosteroids	B-CHED
+in	O
+the	O
+late	O
+phase	O
+.	O
+
+Nsp2	B-PRGE
+,	O
+nsp8	O
+and	O
+ORF9b	O
+showed	O
+a	O
+wide	O
+range	O
+of	O
+interactions	O
+with	O
+other	O
+viral	O
+proteins	B-CHED
+.	O
+
+However	O
+,	O
+it	O
+can	O
+be	O
+expected	O
+to	O
+be	O
+important	O
+for	O
+the	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interplay	O
+and	O
+for	O
+pathogenicity	O
+,	O
+due	O
+to	O
+its	O
+large	O
+number	O
+of	O
+interactions	O
+,	O
+by	O
+enhancing	O
+the	O
+global	O
+stability	O
+of	O
+the	O
+SARS	B-DISO
+proteome	O
+network	O
+,	O
+or	O
+play	O
+some	O
+unrealized	O
+role	O
+in	O
+regulating	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Protective	O
+effect	O
+of	O
+rupatadine	O
+against	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+rabbits	B-SPEC
+].	O
+
+ALI	O
+was	O
+induced	O
+by	O
+oleic	B-CHED
+acid	I-CHED
+in	O
+rabbits	B-SPEC
+.	O
+
+Both	O
+features	O
+can	O
+be	O
+evoked	O
+by	O
+pneumolysin	O
+(	O
+PLY	B-PRGE
+),	O
+an	O
+important	O
+virulence	B-PROC
+factor	O
+of	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+.	O
+
+Intravascular	O
+PLY	O
+,	O
+but	O
+not	O
+the	O
+pneumolysoid	O
+Pd	O
+-	O
+B	O
+(	O
+PLY	B-PRGE
+with	O
+a	O
+Trp	B-PRGE
+-	I-PRGE
+Phe	B-CHED
+substitution	O
+at	O
+position	O
+433	O
+),	O
+caused	O
+an	O
+impressive	O
+dose	O
+-	O
+dependent	O
+increase	O
+in	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+and	O
+increased	O
+PAF	B-DISO
+in	O
+lung	B-ANAT
+homogenates	O
+,	O
+as	O
+detected	O
+by	O
+reversed	O
+-	O
+phase	O
+high	O
+-	O
+performance	O
+liquid	O
+chromatography	O
+coupled	O
+to	O
+tandem	O
+mass	O
+spectrometry	O
+.	O
+
+PAF	B-DISO
+significantly	O
+contributed	O
+to	O
+PLY	O
+-	O
+induced	O
+acute	O
+injury	O
+in	O
+murine	B-SPEC
+lungs	B-ANAT
+.	O
+
+In	O
+this	O
+latter	O
+respect	O
+control	O
+may	O
+in	O
+part	O
+be	O
+achieved	O
+through	O
+the	O
+sub	O
+-	O
+cellular	B-PROC
+localisation	I-PROC
+of	O
+the	O
+protein	B-CHED
+.	O
+
+It	O
+plays	O
+important	O
+roles	O
+in	O
+virion	B-PROC
+assembly	I-PROC
+and	O
+morphogenesis	B-PROC
+,	O
+alteration	O
+of	O
+the	O
+membrane	B-PROC
+permeability	I-PROC
+of	O
+host	B-COMP
+cells	B-COMP
+and	O
+virus	B-SPEC
+-	O
+host	B-COMP
+cell	I-COMP
+interaction	O
+.	O
+
+We	O
+expressed	B-PROC
+the	O
+two	O
+proteins	B-CHED
+as	O
+fusion	O
+proteins	B-CHED
+in	O
+the	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+system	O
+to	O
+demonstrate	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+and	O
+tested	O
+the	O
+same	O
+using	O
+a	O
+yeast	B-SPEC
+genetic	O
+cross	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinical	O
+picture	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+an	O
+over	O
+-	O
+exuberant	O
+immune	B-PROC
+response	I-PROC
+with	O
+lung	B-ANAT
+lymphomononuclear	O
+cells	B-COMP
+infilteration	O
+and	O
+proliferation	B-DISO
+that	O
+may	O
+account	O
+for	O
+tissue	B-ANAT
+damage	O
+more	O
+than	O
+the	O
+direct	O
+effect	O
+of	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Cleavage	B-PROC
+of	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+by	I-PRGE
+protease	I-PRGE
+factor	I-PRGE
+Xa	I-PRGE
+is	O
+associated	O
+with	O
+viral	O
+infectivity	O
+.	O
+
+Also	O
+,	O
+the	O
+protease	O
+Factor	O
+Xa	O
+,	O
+a	O
+target	O
+of	O
+Ben	B-DISO
+-	O
+HCl	B-CHED
+abundantly	O
+expressed	B-PROC
+in	O
+infected	O
+cells	B-COMP
+,	O
+was	O
+able	O
+to	O
+cleave	O
+the	O
+recombinant	O
+and	O
+pseudoviral	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+into	O
+S1	O
+and	O
+S2	O
+subunits	O
+,	O
+and	O
+the	O
+cleavage	B-PROC
+was	O
+inhibited	O
+by	O
+Ben	B-PRGE
+-	I-PRGE
+HCl	B-CHED
+.	O
+
+Limitations	O
+on	O
+access	O
+to	O
+medical	O
+services	O
+during	O
+the	O
+2003	O
+SARS	B-DISO
+outbreak	O
+in	O
+Toronto	O
+had	O
+no	O
+observable	O
+impact	O
+on	O
+short	O
+-	O
+term	O
+population	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+international	O
+outbreak	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+2002	O
+-	O
+2003	O
+highlighted	O
+the	O
+need	O
+to	O
+develop	O
+pretested	O
+human	B-SPEC
+vaccine	O
+vectors	O
+that	O
+can	O
+be	O
+used	O
+in	O
+a	O
+rapid	O
+response	O
+against	O
+newly	O
+emerging	O
+pathogens	O
+.	O
+
+A	O
+wider	O
+implication	O
+is	O
+that	O
+runting	O
+coupled	O
+with	O
+steatorrhea	B-DISO
+are	O
+phenotypic	O
+criteria	O
+to	O
+suspect	O
+pancreatic	B-DISO
+disease	I-DISO
+that	O
+could	O
+be	O
+used	O
+in	O
+the	O
+context	O
+of	O
+a	O
+mouse	B-SPEC
+N	B-CHED
+-	I-CHED
+ethyl	I-CHED
+-	I-CHED
+N	I-CHED
+-	I-CHED
+nitrosourea	I-CHED
+-	O
+mutagenesis	B-PROC
+program	O
+to	O
+identify	O
+potential	O
+mutants	O
+with	O
+defects	O
+in	O
+pancreas	B-PROC
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Argatroban	B-CHED
+in	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+We	O
+report	O
+here	O
+the	O
+first	O
+successful	O
+expression	O
+and	O
+purification	O
+of	O
+an	O
+arterivirus	B-SPEC
+RdRp	B-FUNC
+that	O
+is	O
+catalytically	O
+active	O
+in	O
+the	O
+absence	O
+of	O
+other	O
+viral	O
+or	O
+cellular	B-COMP
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+is	O
+not	O
+understood	O
+how	O
+immune	O
+inflammation	B-DISO
+influences	O
+the	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+fact	O
+that	O
+the	O
+majority	O
+of	O
+SARS	B-DISO
+patients	O
+recover	B-PROC
+after	O
+relatively	O
+moderate	O
+illness	O
+suggests	O
+that	O
+the	O
+prevailing	O
+notion	O
+of	O
+deficient	O
+type	O
+I	O
+IFN	B-PRGE
+-	O
+mediated	O
+immunity	B-PROC
+,	O
+with	O
+hypercytokinemia	O
+driving	O
+a	O
+poor	O
+clinical	O
+course	O
+,	O
+is	O
+oversimplified	O
+.	O
+
+The	O
+majority	O
+of	O
+SARS	B-DISO
+patients	O
+resolved	O
+IFN	B-PRGE
+responses	O
+at	O
+crisis	O
+and	O
+expressed	B-PROC
+adaptive	O
+immune	O
+genes	O
+.	O
+
+We	O
+examined	O
+whether	O
+polymorphisms	B-PROC
+of	O
+RANTES	B-PRGE
+,	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+and	O
+Mig	B-PRGE
+affect	O
+the	O
+susceptibility	O
+to	O
+and	O
+outcome	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+CONCLUSIONS	O
+:	O
+RANTES	O
+-	O
+28	O
+G	O
+allele	O
+plays	O
+a	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+second	O
+exemplar	O
+involves	O
+the	O
+newly	O
+appreciated	O
+complexity	O
+of	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+as	O
+a	O
+regulator	O
+of	O
+the	O
+cardiovascular	B-ANAT
+system	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Differentiation	B-PROC
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+type	O
+I	O
+and	O
+II	O
+infections	B-DISO
+by	O
+virus	B-PROC
+neutralization	I-PROC
+test	O
+.	O
+
+A	O
+total	O
+of	O
+79	O
+cat	B-SPEC
+sera	B-COMP
+collected	O
+in	O
+the	O
+years	O
+between	O
+2004	O
+and	O
+2005	O
+were	O
+examined	O
+to	O
+evaluate	O
+seroprevalence	O
+by	O
+the	O
+VN	O
+test	O
+,	O
+showing	O
+the	O
+following	O
+results	O
+:	O
+(	O
+1	O
+)	O
+50	O
+cats	B-SPEC
+(	O
+63	O
+.	O
+3	O
+%)	O
+were	O
+sero	O
+-	O
+positive	O
+to	O
+FCoV	O
+;	O
+(	O
+2	O
+)	O
+of	O
+the	O
+50	O
+FCoV	O
+positive	O
+cat	B-SPEC
+serum	B-COMP
+samples	O
+,	O
+49	O
+(	O
+98	O
+%)	O
+showed	O
+significantly	O
+higher	O
+titers	O
+to	O
+type	O
+I	O
+virus	B-SPEC
+and	O
+only	O
+one	O
+(	O
+2	O
+%)	O
+for	O
+type	O
+II	O
+virus	B-SPEC
+.	O
+
+The	O
+antigen	O
+target	O
+in	O
+Goodpasture	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+is	O
+type	O
+IV	O
+collagen	B-COMP
+,	O
+the	O
+major	O
+component	O
+of	O
+basement	B-COMP
+membranes	I-COMP
+.	O
+
+Sequence	O
+analysis	O
+revealed	O
+that	O
+the	O
+VL	B-PRGE
+gene	I-PRGE
+was	O
+composed	O
+of	O
+VL3h	O
+(	O
+V	O
+lambda	O
+subgroup	O
+)	O
+and	O
+JL2	O
+regions	O
+and	O
+the	O
+VH	B-PRGE
+gene	I-PRGE
+was	O
+composed	O
+of	O
+VH1	B-PRGE
+-	I-PRGE
+69	I-PRGE
+(	O
+VH1	B-PRGE
+subgroup	O
+),	O
+D2	O
+-	O
+15	O
+,	O
+D3	O
+-	O
+22	O
+and	O
+JH6	O
+regions	O
+.	O
+
+Although	O
+much	O
+of	O
+the	O
+cytokine	B-PROC
+signaling	I-PROC
+responsible	O
+for	O
+the	O
+initial	O
+phase	O
+of	O
+ALI	O
+has	O
+been	O
+elaborated	O
+,	O
+relatively	O
+little	O
+is	O
+known	O
+about	O
+the	O
+mechanisms	O
+governing	O
+the	O
+recruitment	B-DISO
+of	O
+neutrophils	B-ANAT
+from	O
+the	O
+bone	B-ANAT
+marrow	I-ANAT
+to	O
+the	O
+lung	B-ANAT
+in	O
+the	O
+later	O
+period	O
+of	O
+this	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+papillomavirus	I-SPEC
+prevalence	O
+and	O
+type	O
+distribution	O
+in	O
+male	O
+anogenital	O
+sites	O
+and	O
+semen	B-ANAT
+.	O
+
+The	O
+penile	B-ANAT
+shaft	O
+was	O
+the	O
+site	O
+most	O
+likely	O
+to	O
+be	O
+HPV	O
+positive	O
+and	O
+harbored	O
+the	O
+greatest	O
+proportion	O
+of	O
+multiple	O
+type	O
+and	O
+oncogenic	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+report	O
+,	O
+we	O
+describe	O
+a	O
+case	O
+of	O
+pneumonia	B-DISO
+due	O
+to	O
+an	O
+infection	B-DISO
+with	O
+human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)-	O
+OC43	O
+in	O
+a	O
+pediatric	O
+leukemia	B-DISO
+patient	O
+with	O
+Down	B-DISO
+syndrome	I-DISO
+and	O
+febrile	B-DISO
+neutropenia	I-DISO
+.	O
+
+The	O
+coagulation	B-PROC
+profile	O
+was	O
+associated	O
+with	O
+clinical	O
+,	O
+epidemiological	O
+and	O
+CT	O
+findings	O
+.	O
+
+Univariate	O
+and	O
+multivariate	O
+analyses	O
+were	O
+used	O
+to	O
+check	O
+the	O
+association	O
+between	O
+coagulopathy	B-DISO
+and	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Sickle	O
+hemoglobin	O
+(	O
+Hb	O
+S	O
+;	O
+betaGlu	O
+6	O
+Val	B-CHED
+)	O
+is	O
+due	O
+to	O
+an	O
+A	O
+>	O
+T	O
+transversion	B-DISO
+in	O
+codon	O
+6	O
+of	O
+the	O
+beta	B-PRGE
+-	I-PRGE
+globin	I-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+protective	O
+immunity	B-PROC
+of	O
+rBCG	O
+-	O
+S1	O
+was	O
+identified	O
+in	O
+vaccinated	O
+chickens	B-SPEC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+detect	O
+the	O
+location	O
+of	O
+expressed	B-PROC
+protein	B-CHED
+,	O
+the	O
+yellow	O
+and	O
+green	O
+fluorescence	O
+of	O
+the	O
+recombinant	O
+strain	O
+pNZ8112	O
+-	O
+Sa	O
+/	O
+NZ9000	O
+was	O
+detected	O
+by	O
+the	O
+IFA	O
+experiments	O
+,	O
+which	O
+indicated	O
+that	O
+the	O
+expressed	B-PROC
+recombinant	O
+protein	B-CHED
+was	O
+secreted	B-PROC
+and	O
+located	O
+on	O
+the	O
+surface	O
+of	O
+the	O
+bacterium	B-SPEC
+cell	B-COMP
+.	O
+
+It	O
+was	O
+showed	O
+that	O
+the	O
+mice	B-SPEC
+immunized	O
+with	O
+pNZ8112	O
+-	O
+Sa	O
+/	O
+NZ9000	O
+recombinant	O
+strain	O
+had	O
+produced	O
+clear	O
+antibody	B-COMP
+level	O
+anti	O
+TGEV	B-SPEC
+,	O
+and	O
+which	O
+had	O
+provided	O
+important	O
+substance	O
+foundation	O
+and	O
+explored	O
+the	O
+feasibility	O
+of	O
+Lactobacillus	B-SPEC
+as	O
+oral	B-ANAT
+vaccine	O
+.	O
+
+Significant	O
+SEAP	O
+activity	O
+could	O
+be	O
+detected	O
+in	O
+the	O
+culture	O
+medium	O
+only	O
+after	O
+cell	O
+-	O
+cell	B-COMP
+fusion	O
+occurred	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+psittacosis	B-DISO
+with	O
+wandering	O
+infiltrates	B-DISO
+developing	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+Finally	O
+,	O
+elevated	O
+antibody	B-COMP
+titers	O
+against	O
+Chlamydophila	B-SPEC
+psittasi	O
+confirmed	O
+a	O
+diagnosis	O
+of	O
+Psittacosis	B-DISO
+.	O
+
+Sequential	O
+chest	B-ANAT
+computed	O
+tomography	O
+scans	O
+in	O
+this	O
+case	O
+indicate	O
+that	O
+absorption	O
+of	O
+marginal	O
+air	B-CHED
+-	O
+space	O
+consolidation	O
+with	O
+extended	O
+central	O
+ground	O
+glass	O
+attenuation	O
+in	O
+concordance	O
+with	O
+a	O
+new	O
+infiltrate	B-DISO
+on	O
+another	O
+lung	B-ANAT
+field	I-ANAT
+appeared	O
+to	O
+create	O
+wandering	O
+infiltrate	B-DISO
+.	O
+
+Both	O
+viral	O
+RNA	O
+and	O
+viral	B-PROC
+protein	I-PROC
+synthesis	I-PROC
+were	O
+affected	O
+with	O
+subsequent	O
+loss	O
+of	O
+progeny	O
+virus	B-SPEC
+production	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+multicentre	O
+retrospective	O
+study	O
+was	O
+undertaken	O
+to	O
+examine	O
+patients	O
+with	O
+interstitial	O
+lung	B-ANAT
+disease	O
+(	O
+ILD	O
+)	O
+with	O
+the	O
+initial	O
+clinical	O
+manifestation	O
+of	O
+an	O
+anti	B-PRGE
+-	I-PRGE
+synthetase	I-PRGE
+syndrome	I-PRGE
+(	O
+anti	O
+-	O
+Jo	O
+-	O
+1	O
+antibodies	B-COMP
+),	O
+and	O
+to	O
+analyse	O
+the	O
+characteristics	O
+and	O
+long	O
+-	O
+term	O
+outcome	O
+of	O
+these	O
+patients	O
+according	O
+to	O
+their	O
+clinical	O
+presentation	O
+(	O
+acute	O
+or	O
+gradual	O
+onset	O
+),	O
+treatment	O
+and	O
+adverse	O
+events	O
+related	O
+to	O
+treatment	O
+.	O
+
+32	O
+patients	O
+,	O
+15	O
+(	O
+47	O
+%)	O
+presenting	O
+with	O
+acute	O
+onset	O
+and	O
+associated	O
+respiratory	B-DISO
+insufficiency	I-DISO
+(	O
+group	O
+A	O
+)	O
+and	O
+17	O
+(	O
+53	O
+%)	O
+with	O
+gradual	O
+onset	O
+(	O
+group	O
+G	O
+)	O
+were	O
+examined	O
+.	O
+
+Myositis	B-DISO
+was	O
+diagnosed	O
+at	O
+admission	O
+in	O
+only	O
+31	O
+%	O
+of	O
+cases	O
+and	O
+was	O
+observed	O
+during	O
+follow	O
+-	O
+up	O
+in	O
+56	O
+%	O
+of	O
+cases	O
+,	O
+but	O
+the	O
+prevalence	O
+did	O
+not	O
+differ	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+AM	O
+decreased	O
+the	O
+numbers	O
+of	O
+total	O
+cells	B-COMP
+and	O
+neutrophils	B-ANAT
+and	O
+the	O
+levels	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+CINC	B-CHED
+in	O
+BALF	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+identified	O
+the	O
+expression	B-PROC
+of	O
+inducible	B-PRGE
+nitric	I-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+(	O
+iNOS	B-PRGE
+)	O
+using	O
+immunohistochemical	O
+stain	O
+.	O
+
+Biochemical	O
+determinations	O
+indicated	O
+hypoxia	B-DISO
+,	O
+hyperglycaemia	B-DISO
+,	O
+increased	O
+nitrite	B-CHED
+/	O
+nitrate	B-CHED
+,	O
+methyl	B-CHED
+guanidine	B-CHED
+and	O
+other	O
+factors	O
+.	O
+
+Animals	B-SPEC
+were	O
+subjected	O
+to	O
+heterologous	O
+prime	O
+-	O
+boost	O
+using	O
+vectors	O
+from	O
+human	B-SPEC
+serotype	O
+5	O
+and	O
+chimpanzee	B-SPEC
+derived	O
+adenoviruses	B-SPEC
+(	O
+human	B-SPEC
+AdHu5	O
+and	O
+chimpanzee	B-SPEC
+AdC7	O
+)	O
+expressing	O
+spike	O
+protein	B-CHED
+followed	O
+by	O
+intranasal	O
+challenge	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Vaccination	O
+led	O
+to	O
+a	O
+substantial	O
+reduction	O
+in	O
+viral	O
+load	O
+and	O
+prevented	O
+the	O
+severe	O
+pneumonia	B-DISO
+seen	O
+in	O
+unvaccinated	O
+animals	B-SPEC
+.	O
+
+So	O
+far	O
+antivirals	B-CHED
+are	O
+hardly	O
+available	O
+to	O
+combat	B-CHED
+infections	B-DISO
+with	O
+viruses	B-SPEC
+of	O
+this	O
+order	B-SPEC
+.	O
+
+Lectins	O
+,	O
+which	O
+bind	B-FUNC
+to	O
+N	O
+-	O
+linked	O
+oligosaccharide	B-CHED
+elements	O
+of	O
+enveloped	O
+viruses	B-SPEC
+,	O
+can	O
+be	O
+considered	O
+as	O
+a	O
+conceptionally	O
+new	O
+class	B-SPEC
+of	O
+virus	B-SPEC
+inhibitors	B-CHED
+.	O
+
+The	O
+presence	O
+of	O
+carbohydrate	B-CHED
+-	O
+binding	B-FUNC
+agents	O
+strongly	O
+inhibited	O
+coronaviruses	O
+(	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+,	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+,	O
+feline	B-SPEC
+coronaviruses	O
+serotypes	O
+I	O
+and	O
+II	O
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+),	O
+arteriviruses	B-SPEC
+(	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+and	O
+porcine	B-SPEC
+respiratory	I-SPEC
+and	I-SPEC
+reproductive	I-SPEC
+syndrome	B-DISO
+virus	I-SPEC
+)	O
+and	O
+torovirus	B-SPEC
+(	O
+equine	B-SPEC
+Berne	O
+virus	B-SPEC
+).	O
+
+Unfortunately	O
+,	O
+neither	O
+corticosteroids	B-CHED
+nor	O
+any	O
+other	O
+currently	O
+available	O
+therapy	O
+modifies	O
+the	O
+long	O
+-	O
+term	O
+outcome	O
+of	O
+preschool	O
+wheeze	B-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+secondary	O
+to	O
+intra	B-DISO
+-	I-DISO
+abdominal	B-ANAT
+hypertension	I-DISO
+and	O
+abdominal	O
+decompression	O
+in	O
+extensively	O
+burned	O
+patients	O
+.	O
+
+9	O
+.	O
+9	O
+cm	O
+H2O	B-CHED
+),	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+(	O
+51	O
+.	O
+4	O
++/-	O
+
+7	O
+.	O
+0	O
+cm	O
+H2O	B-CHED
+),	O
+and	O
+abdominal	B-ANAT
+perfusion	O
+pressure	O
+(	O
+51	O
+.	O
+3	O
++/-	O
+
+These	O
+results	O
+show	O
+that	O
+the	O
+WD	O
+-	O
+BCoV	O
+has	O
+dual	O
+tropism	B-PROC
+and	O
+induces	O
+pathological	O
+changes	O
+in	O
+both	O
+the	O
+digestive	B-PROC
+and	O
+respiratory	B-ANAT
+tracts	I-ANAT
+of	O
+calves	O
+.	O
+
+Subjects	O
+with	O
+an	O
+apnea	B-DISO
+-	O
+hypopnea	O
+index	O
+(	O
+AHI	O
+)	O
+>	O
+or	O
+=	O
+15	O
+/	O
+h	O
+underwent	O
+a	O
+second	O
+polysomnography	O
+with	O
+CPAP	O
+.	O
+
+CPAP	O
+significantly	O
+improved	O
+rapid	B-PROC
+eye	I-PROC
+movement	I-PROC
+(	O
+REM	B-PROC
+)	O
+duration	O
+(	O
+p	O
+<	O
+0	O
+.	O
+005	O
+),	O
+AHI	O
+(	O
+p	O
+<	O
+0	O
+.	O
+005	O
+),	O
+arousal	O
+indexes	O
+(	O
+p	O
+<	O
+0	O
+.	O
+005	O
+),	O
+and	O
+percentage	O
+of	O
+total	O
+sleep	B-PROC
+time	O
+(	O
+TST	O
+)	O
+with	O
+oxygen	B-CHED
+saturation	O
+(	O
+SpO2	O
+)	O
+<	O
+90	O
+%	O
+(	O
+p	O
+<	O
+0	O
+.	O
+005	O
+)	O
+in	O
+both	O
+groups	O
+.	O
+
+CPAP	O
+significantly	O
+improves	O
+AHI	O
+,	O
+REM	B-PROC
+duration	O
+,	O
+arousal	O
+indexes	O
+,	O
+and	O
+nocturnal	O
+oxygen	B-CHED
+desaturation	O
+.	O
+
+Some	O
+subjects	O
+with	O
+OHS	B-DISO
+continued	O
+to	O
+have	O
+nocturnal	O
+desaturation	O
+despite	O
+the	O
+control	O
+of	O
+upper	B-DISO
+airway	I-DISO
+obstruction	I-DISO
+;	O
+other	O
+mechanisms	O
+may	O
+contribute	O
+.	O
+
+Such	O
+plasmids	O
+are	O
+stably	O
+maintained	O
+,	O
+even	O
+in	O
+rich	O
+medium	O
+,	O
+so	O
+optimising	O
+biomass	O
+production	O
+and	O
+yields	O
+of	O
+recombinant	O
+protein	B-CHED
+.	O
+
+Plasmid	O
+copy	O
+numbers	O
+are	O
+also	O
+increased	O
+by	O
+limiting	O
+selective	O
+MOB1	B-PRGE
+and	O
+CDC28	B-PRGE
+gene	I-PRGE
+expression	O
+prior	O
+to	O
+induction	O
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+entry	O
+by	O
+enveloped	O
+viruses	B-SPEC
+:	O
+redox	B-PROC
+considerations	O
+for	O
+HIV	B-DISO
+and	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+.	O
+
+We	O
+discuss	O
+these	O
+findings	O
+and	O
+their	O
+implication	O
+for	O
+anti	O
+-	O
+HIV	B-DISO
+therapy	O
+.	O
+
+Sixty	O
+-	O
+one	O
+patients	O
+with	O
+PRIS	O
+have	O
+been	O
+recorded	O
+in	O
+the	O
+literature	O
+,	O
+with	O
+deaths	B-PROC
+in	O
+20	O
+paediatric	O
+and	O
+18	O
+adult	O
+patients	O
+.	O
+
+It	O
+is	O
+proposed	O
+that	O
+the	O
+syndrome	B-DISO
+may	O
+be	O
+caused	O
+by	O
+either	O
+a	O
+direct	O
+mitochondrial	B-COMP
+respiratory	I-COMP
+chain	I-COMP
+inhibition	B-PROC
+or	O
+impaired	B-DISO
+mitochondrial	B-COMP
+fatty	B-PATH
+acid	I-PATH
+metabolism	I-PATH
+mediated	O
+by	O
+propofol	B-CHED
+.	O
+
+TITLE	O
+:	O
+First	O
+isolation	O
+of	O
+cytopathogenic	O
+bovine	B-SPEC
+torovirus	I-SPEC
+in	O
+cell	B-COMP
+culture	O
+from	O
+a	O
+calf	B-ANAT
+with	O
+diarrhea	B-DISO
+.	O
+
+An	O
+antiserum	O
+against	O
+bovine	B-SPEC
+torovirus	I-SPEC
+(	O
+BToV	O
+)	O
+reacted	O
+with	O
+the	O
+infected	O
+cells	B-COMP
+by	O
+immunofluorescence	O
+and	O
+neutralized	O
+the	O
+isolate	O
+.	O
+
+In	O
+a	O
+serological	O
+survey	O
+of	O
+serum	B-COMP
+samples	O
+from	O
+355	O
+calves	O
+at	O
+33	O
+farms	O
+,	O
+92	O
+%	O
+of	O
+calves	O
+were	O
+positive	O
+for	O
+neutralizing	O
+antibodies	B-COMP
+to	O
+the	O
+isolate	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+a	O
+significant	O
+number	O
+of	O
+patients	O
+with	O
+severe	O
+brain	O
+injury	O
+develop	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+only	O
+intracranial	B-ANAT
+risk	O
+factors	O
+have	O
+previously	O
+been	O
+studied	O
+.	O
+
+In	O
+addition	O
+to	O
+a	O
+lower	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+(	O
+odds	O
+ratio	O
+0	O
+.	O
+98	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+0	O
+.	O
+98	O
+-	O
+0	O
+.	O
+99	O
+),	O
+the	O
+use	O
+of	O
+high	O
+tidal	O
+volume	O
+(	O
+odds	O
+ratio	O
+5	O
+.	O
+4	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+54	O
+-	O
+19	O
+.	O
+24	O
+)	O
+and	O
+relatively	O
+high	O
+respiratory	O
+rate	O
+(	O
+odds	O
+ratio	O
+1	O
+.	O
+8	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+13	O
+-	O
+2	O
+.	O
+86	O
+)	O
+were	O
+independent	O
+predictors	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+p	O
+<	O
+.	O
+01	O
+).	O
+
+However	O
+,	O
+patients	O
+with	O
+SARS	B-DISO
+homozygous	O
+for	O
+ICAM3	B-PRGE
+Gly143	O
+showed	O
+significant	O
+association	O
+with	O
+higher	O
+lactate	O
+dehydrogenase	O
+levels	O
+(	O
+P	O
+=.	O
+0067	O
+;	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+4	O
+.	O
+31	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+{	O
+CI	O
+},	O
+1	O
+.	O
+37	O
+-	O
+13	O
+.	O
+56	O
+])	O
+and	O
+lower	O
+total	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+counts	O
+(	O
+P	O
+=.	O
+022	O
+;	O
+OR	O
+,	O
+0	O
+.	O
+30	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+10	O
+-	O
+0	O
+.	O
+89	O
+])	O
+on	O
+admission	O
+.	O
+
+Nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+was	O
+collected	O
+and	O
+assessed	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+and	O
+viral	O
+culture	O
+.	O
+
+Both	O
+infections	B-DISO
+have	O
+crossed	O
+the	O
+species	B-SPEC
+barrier	O
+to	O
+infect	O
+humans	B-SPEC
+.	O
+
+The	O
+first	O
+outbreak	O
+of	O
+human	B-SPEC
+cases	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+was	O
+reported	O
+in	O
+1997	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Current	O
+evidence	O
+suggests	O
+that	O
+the	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+is	O
+rather	O
+inefficient	O
+,	O
+but	O
+mutation	O
+might	O
+occur	O
+in	O
+the	O
+future	O
+resulting	O
+in	O
+improved	O
+transmission	O
+and	O
+possibly	O
+a	O
+pandemic	O
+in	O
+humans	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+seroprevalence	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strains	O
+in	O
+commercial	O
+poultry	O
+in	O
+Pakistan	O
+.	O
+
+By	O
+utilizing	O
+such	O
+diagnostic	O
+techniques	O
+it	O
+is	O
+possible	O
+to	O
+conduct	B-PROC
+a	O
+detailed	O
+epidemiological	O
+study	O
+to	O
+determine	O
+the	O
+full	O
+economic	O
+impact	O
+of	O
+this	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+focus	O
+formation	B-PROC
+assay	O
+(	O
+FFA	B-CHED
+)	O
+for	O
+detection	O
+and	O
+titration	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+in	O
+a	O
+micro	O
+-	O
+culture	O
+system	O
+using	O
+Vero	B-ANAT
+cells	I-ANAT
+and	O
+PAP	B-DISO
+staining	O
+technique	O
+was	O
+evaluated	O
+.	O
+
+A	O
+linear	O
+correlation	O
+between	O
+the	O
+virus	B-SPEC
+dilution	O
+and	O
+virus	B-SPEC
+titer	O
+determined	O
+by	O
+FFA	B-CHED
+was	O
+observed	O
+between	O
+the	O
+range	O
+of	O
+10	O
+and	O
+30	O
+foci	O
+per	O
+well	O
+.	O
+
+In	O
+addition	O
+,	O
+FFA	B-CHED
+had	O
+higher	O
+sensitivity	O
+for	O
+detecting	O
+field	O
+isolates	O
+of	O
+PEDV	B-SPEC
+as	O
+well	O
+as	O
+positive	O
+identification	O
+of	O
+the	O
+virus	B-SPEC
+with	O
+the	O
+antibody	B-COMP
+specific	O
+reaction	O
+.	O
+
+ABSTRACT	O
+:	O
+Restrictions	O
+on	O
+the	O
+nonurgent	O
+use	O
+of	O
+hospital	O
+services	O
+were	O
+imposed	O
+in	O
+March	O
+2003	O
+to	O
+control	O
+an	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Toronto	O
+,	O
+Ont	B-CHED
+.	O
+
+The	O
+rates	O
+of	O
+elective	O
+cardiac	B-ANAT
+procedures	O
+declined	O
+by	O
+up	O
+to	O
+66	O
+%	O
+in	O
+Toronto	O
+and	O
+by	O
+71	O
+%	O
+in	O
+the	O
+comparison	O
+regions	O
+;	O
+the	O
+rates	O
+of	O
+urgent	O
+and	O
+semi	O
+-	O
+urgent	O
+procedures	O
+declined	O
+little	O
+or	O
+increased	O
+.	O
+
+Moreover	O
+,	O
+we	O
+determined	O
+that	O
+IgG	B-PRGE
+receptors	I-PRGE
+(	O
+FcgammaRs	O
+)	O
+mediate	O
+activity	O
+of	O
+anti	O
+-	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+:	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+complexes	O
+.	O
+
+We	O
+detected	O
+complexes	O
+between	O
+anti	O
+-	O
+KC	O
+autoantibodies	O
+and	O
+KC	O
+in	O
+lung	B-ANAT
+lavages	O
+and	O
+tissues	B-ANAT
+of	O
+mice	B-SPEC
+treated	O
+with	O
+LPS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-PROC
+replication	I-PROC
+in	O
+the	O
+chicken	B-SPEC
+embryo	B-ANAT
+related	O
+cell	B-ANAT
+line	I-ANAT
+.	O
+
+Extra	O
+-	O
+cellular	B-COMP
+virus	B-SPEC
+was	O
+measured	O
+by	O
+virus	B-SPEC
+titration	O
+performed	O
+on	O
+chicken	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+and	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+,	O
+and	O
+respective	O
+titres	O
+ranged	O
+from	O
+4	O
+.	O
+0	O
+to	O
+6	O
+.	O
+0	O
+log10	O
+EID50	O
+/	O
+ml	O
+on	O
+embryonated	O
+chicken	O
+eggs	O
+,	O
+and	O
+from	O
+2	O
+.	O
+0	O
+to	O
+6	O
+.	O
+0	O
+log10	O
+TCID50	O
+/	O
+ml	O
+on	O
+both	O
+CER	B-CHED
+cells	B-COMP
+and	O
+chicken	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+studied	O
+from	O
+24	O
+to	O
+120	O
+h	O
+p	O
+.	O
+i	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+temporal	O
+importance	O
+of	O
+prognostic	O
+indicators	O
+for	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+not	O
+been	O
+studied	O
+.	O
+
+While	O
+age	O
+,	O
+pulse	B-PROC
+rate	I-PROC
+and	O
+neutrophil	B-ANAT
+count	O
+consistently	O
+remained	O
+significant	O
+prognosticators	O
+during	O
+the	O
+first	O
+10	O
+days	O
+of	O
+illness	O
+,	O
+the	O
+prognostic	O
+impact	O
+of	O
+other	O
+derangements	O
+was	O
+more	O
+time	O
+-	O
+course	O
+dependent	O
+.	O
+
+TITLE	O
+:	O
+Do	O
+glucocorticoids	B-CHED
+decrease	O
+mortality	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+?	O
+
+ABSTRACT	O
+:	O
+Glucocorticoids	O
+have	O
+been	O
+shown	O
+to	O
+improve	O
+survival	O
+when	O
+used	O
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+TITLE	O
+:	O
+Leptin	B-PRGE
+treatment	O
+ameliorates	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+rats	B-SPEC
+with	O
+cerulein	B-CHED
+-	O
+induced	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+effect	O
+of	O
+exogenous	O
+leptin	B-PRGE
+on	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+in	O
+cerulein	B-CHED
+-	O
+induced	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+AP	O
+).	O
+
+All	O
+of	O
+the	O
+chest	B-ANAT
+x	O
+-	O
+rays	B-SPEC
+were	O
+normal	O
+on	O
+the	O
+day	O
+of	O
+the	O
+chlorine	B-CHED
+inhalation	B-PROC
+.	O
+
+TITLE	O
+:	O
+One	O
+-	O
+year	O
+outcomes	O
+and	O
+health	O
+care	O
+utilization	O
+in	O
+survivors	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+evaluated	O
+117	O
+SARS	B-DISO
+survivors	O
+from	O
+Toronto	O
+,	O
+Ontario	O
+.	O
+
+During	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+informal	O
+caregivers	O
+reported	O
+a	O
+decline	O
+of	O
+1	O
+.	O
+6	O
+SD	O
+below	O
+normal	O
+on	O
+the	O
+mental	O
+component	O
+score	O
+of	O
+the	O
+SF	O
+-	O
+36	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+is	O
+an	O
+important	O
+deterrent	O
+of	O
+severe	O
+viral	B-DISO
+infection	I-DISO
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+Retention	B-PROC
+of	O
+import	O
+factors	O
+at	O
+the	O
+ER	O
+/	O
+Golgi	B-COMP
+membrane	I-COMP
+leads	O
+to	O
+a	O
+loss	O
+of	O
+STAT1	B-PRGE
+transport	I-PRGE
+into	O
+the	O
+nucleus	B-COMP
+in	O
+response	O
+to	O
+interferon	B-PATH
+signaling	B-PROC
+,	O
+thus	O
+blocking	B-DISO
+the	O
+expression	B-PROC
+of	O
+STAT1	B-PRGE
+-	O
+activated	O
+genes	O
+that	O
+establish	O
+an	O
+antiviral	O
+state	O
+.	O
+
+The	O
+assay	O
+detected	O
+influenza	B-DISO
+A	I-PATH
+and	O
+B	O
+viruses	O
+;	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+subtypes	O
+H1	O
+,	O
+H3	O
+,	O
+and	O
+H5	O
+(	O
+including	O
+subtype	O
+H5N1	B-DISO
+of	O
+the	O
+Asian	O
+lineage	O
+);	O
+parainfluenza	B-DISO
+virus	B-SPEC
+types	O
+1	O
+,	O
+2	O
+,	O
+3	O
+,	O
+and	O
+4	O
+;	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+types	O
+A	O
+and	O
+B	O
+;	O
+adenovirus	B-DISO
+;	O
+metapneumovirus	B-SPEC
+;	O
+rhinovirus	B-SPEC
+;	O
+enterovirus	B-SPEC
+;	O
+and	O
+coronaviruses	O
+OC43	O
+,	O
+229E	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+,	O
+NL63	O
+,	O
+and	O
+HKU1	O
+.	O
+
+After	O
+resolution	O
+of	O
+discordant	O
+results	O
+by	O
+using	O
+a	O
+second	O
+unique	O
+PCR	O
+assay	O
+and	O
+by	O
+using	O
+a	O
+combined	O
+reference	O
+standard	O
+of	O
+positivity	O
+,	O
+the	O
+RVP	O
+test	O
+detected	O
+180	O
+of	O
+183	O
+true	O
+positives	O
+,	O
+for	O
+a	O
+sensitivity	O
+of	O
+98	O
+.	O
+5	O
+%,	O
+whereas	O
+DFA	B-CHED
+and	O
+culture	O
+detected	O
+only	O
+126	O
+of	O
+183	O
+true	O
+positives	O
+,	O
+for	O
+a	O
+sensitivity	O
+of	O
+68	O
+.	O
+8	O
+%.	O
+
+The	O
+RVP	O
+test	O
+should	O
+improve	O
+the	O
+capabilities	O
+of	O
+hospital	O
+and	O
+public	O
+health	O
+laboratories	O
+for	O
+diagnosing	O
+viral	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+should	O
+assist	O
+public	O
+health	O
+agencies	O
+in	O
+identifying	O
+etiologic	O
+agents	O
+in	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+Attenuated	O
+Salmonella	B-SPEC
+enterica	I-SPEC
+serovar	O
+Typhi	O
+strains	O
+have	O
+been	O
+considered	O
+to	O
+be	O
+attractive	O
+as	O
+potential	O
+live	O
+oral	B-ANAT
+delivery	O
+vector	O
+vaccines	O
+because	O
+of	O
+their	O
+ability	O
+to	O
+elicit	O
+the	O
+full	O
+array	O
+of	O
+immune	B-PROC
+responses	I-PROC
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Open	O
+reading	O
+frame	O
+8a	O
+of	O
+the	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+not	O
+only	O
+promotes	O
+viral	O
+replication	O
+but	O
+also	O
+induces	O
+apoptosis	B-PATH
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+etiologic	O
+role	O
+of	O
+recently	O
+identified	O
+respiratory	O
+viruses	O
+for	O
+acute	O
+wheezing	B-DISO
+in	O
+children	O
+is	O
+not	O
+yet	O
+clear	O
+.	O
+
+Viruses	B-SPEC
+were	O
+found	O
+in	O
+61	O
+.	O
+5	O
+%	O
+(	O
+142	O
+/	O
+231	O
+)	O
+of	O
+the	O
+study	O
+population	O
+and	O
+a	O
+single	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+45	O
+.	O
+5	O
+%	O
+(	O
+105	O
+/	O
+231	O
+)	O
+of	O
+the	O
+study	O
+population	O
+.	O
+
+Rhinovirus	O
+(	O
+33	O
+.	O
+3	O
+%),	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+hRSV	B-SPEC
+;	O
+13	O
+.	O
+8	O
+%),	O
+and	O
+hBoV	O
+(	O
+13	O
+.	O
+8	O
+%)	O
+were	O
+the	O
+most	O
+frequently	O
+detected	O
+viruses	B-SPEC
+.	O
+
+In	O
+children	O
+with	O
+acute	O
+wheezing	B-DISO
+,	O
+rhinovirus	B-SPEC
+,	O
+hRSV	B-SPEC
+,	O
+and	O
+hBoV	O
+were	O
+most	O
+frequently	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+pandemic	O
+caught	O
+the	O
+world	O
+by	O
+surprise	O
+in	O
+2003	O
+and	O
+spread	O
+rapidly	O
+within	O
+a	O
+relatively	O
+short	O
+period	O
+of	O
+time	O
+.	O
+
+TITLE	O
+:	O
+Mechanisms	O
+and	O
+clinical	O
+consequences	O
+of	O
+critical	B-DISO
+illness	I-DISO
+associated	O
+adrenal	B-DISO
+insufficiency	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Adrenal	O
+insufficiency	O
+is	O
+being	O
+diagnosed	O
+with	O
+increasing	O
+frequency	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Activation	O
+of	O
+the	O
+hypothalamic	B-ANAT
+-	I-ANAT
+pituitary	I-ANAT
+-	I-ANAT
+adrenal	I-ANAT
+axis	I-ANAT
+with	O
+the	O
+production	O
+of	O
+cortisol	B-CHED
+is	O
+a	O
+fundamental	O
+component	O
+of	O
+the	O
+stress	B-PATH
+response	I-PATH
+and	O
+is	O
+essential	O
+for	O
+survival	O
+of	O
+the	O
+host	B-COMP
+.	O
+
+Both	O
+inhibitors	B-CHED
+form	O
+an	O
+unusual	O
+thiiranium	O
+ring	O
+with	O
+the	O
+nucleophilic	O
+sulfur	B-CHED
+atom	I-CHED
+of	O
+Cys145	O
+,	O
+trapping	O
+the	O
+enzyme	O
+'	O
+s	O
+catalytic	O
+residues	O
+in	O
+configurations	O
+similar	O
+to	O
+the	O
+intermediate	O
+states	O
+proposed	O
+to	O
+exist	O
+during	O
+the	O
+hydrolysis	O
+of	O
+native	O
+substrates	O
+.	O
+
+Astrocytes	B-ANAT
+in	O
+the	O
+adult	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+up	O
+-	O
+regulated	O
+class	B-SPEC
+I	O
+surface	O
+expression	B-PROC
+,	O
+albeit	O
+delayed	O
+compared	O
+with	O
+microglia	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+a	O
+blood	B-ANAT
+sample	I-ANAT
+was	O
+taken	O
+from	O
+each	O
+calf	B-ANAT
+upon	O
+enrollment	O
+in	O
+the	O
+study	O
+,	O
+for	O
+assessment	O
+of	O
+maternal	O
+antibody	B-COMP
+transfer	O
+and	O
+for	O
+polymerase	O
+chain	O
+reaction	O
+testing	O
+for	O
+persistent	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+odds	O
+of	O
+diarrhea	B-DISO
+in	O
+calves	O
+shedding	O
+oocysts	O
+that	O
+had	O
+been	O
+allowed	O
+to	O
+remain	O
+with	O
+their	O
+dams	O
+for	O
+more	O
+than	O
+an	O
+hour	O
+were	O
+higher	O
+than	O
+the	O
+odds	O
+of	O
+diarrhea	B-DISO
+in	O
+shedding	O
+calves	O
+that	O
+had	O
+been	O
+separated	O
+from	O
+their	O
+dams	O
+within	O
+an	O
+hour	O
+after	O
+birth	B-PROC
+.	O
+
+Although	O
+public	O
+health	O
+procedures	O
+have	O
+been	O
+effective	O
+in	O
+combating	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+,	O
+concern	O
+remains	O
+about	O
+the	O
+possibility	O
+of	O
+a	O
+recurrence	B-DISO
+.	O
+
+One	O
+promising	O
+approach	O
+is	O
+to	O
+develop	O
+small	O
+molecule	O
+inhibitors	B-CHED
+of	O
+the	O
+essential	O
+major	O
+polyprotein	O
+processing	O
+protease	O
+3Clpro	O
+.	O
+
+Finally	O
+,	O
+we	O
+report	O
+the	O
+successful	O
+rational	O
+improvement	O
+of	O
+this	O
+scaffold	O
+with	O
+second	O
+generation	O
+inhibitors	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Presenting	O
+symptoms	O
+,	O
+clinical	O
+course	O
+and	O
+paraclinical	O
+findings	O
+in	O
+childhood	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+(	O
+GBS	B-DISO
+)	O
+have	O
+rarely	O
+been	O
+investigated	O
+prospectively	O
+.	O
+
+Clinical	B-DISO
+findings	I-DISO
+were	O
+recorded	O
+using	O
+an	O
+ordinal	O
+GBS	B-DISO
+score	O
+and	O
+additional	O
+scores	O
+for	O
+arm	B-ANAT
+,	O
+cranial	B-ANAT
+nerve	I-ANAT
+and	O
+vegetative	O
+function	O
+,	O
+and	O
+pain	O
+.	O
+
+All	O
+but	O
+eight	O
+were	O
+treated	O
+with	O
+I	B-PRGE
+.	I-PRGE
+V	I-PRGE
+.	I-PRGE
+immunoglobulin	I-PRGE
+.	O
+
+Improvement	O
+began	O
+on	O
+day	O
+13	O
+after	O
+the	O
+first	O
+symptom	B-DISO
+(	O
+median	O
+).	O
+
+No	O
+studies	O
+have	O
+examined	O
+how	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+loads	O
+in	O
+different	O
+organs	B-ANAT
+with	O
+respect	O
+to	O
+time	O
+,	O
+post	O
+-	O
+mortem	O
+.	O
+
+The	O
+ratio	O
+reached	O
+the	O
+highest	O
+value	O
+of	O
+equal	O
+to	O
+or	O
+greater	O
+than	O
+one	O
+for	O
+lung	B-ANAT
+and	O
+small	B-ANAT
+bowel	I-ANAT
+,	O
+whereas	O
+those	O
+for	O
+heart	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+and	O
+kidney	B-ANAT
+were	O
+always	O
+less	O
+than	O
+one	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+occupational	O
+lung	B-ANAT
+infections	B-DISO
+.	O
+
+Regular	O
+training	O
+should	O
+be	O
+provided	O
+by	O
+all	O
+health	O
+care	O
+institutions	O
+on	O
+infection	B-DISO
+control	O
+measures	O
+and	O
+the	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+.	O
+
+Neurological	O
+examination	O
+showed	O
+facial	B-DISO
+weakness	I-DISO
+,	O
+lingual	B-ANAT
+atrophy	B-DISO
+and	O
+bulbar	B-DISO
+palsy	I-DISO
+,	O
+which	O
+necessitated	O
+the	O
+use	O
+of	O
+a	O
+feeding	O
+tube	O
+and	O
+ventilatory	O
+support	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+of	O
+CXC	O
+chemokine	O
+ligand	B-PROC
+10	O
+from	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+genome	O
+results	O
+in	O
+protection	O
+from	O
+viral	O
+-	O
+induced	O
+neurological	O
+and	O
+liver	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+outcomes	O
+of	O
+patients	O
+with	O
+head	O
+and	O
+neck	O
+cancer	B-SPEC
+and	O
+severe	O
+acute	O
+illnesses	O
+,	O
+and	O
+to	O
+identify	O
+characteristics	O
+associated	O
+with	O
+hospital	O
+mortality	O
+.	O
+
+The	O
+main	O
+sites	O
+of	O
+primary	B-DISO
+tumor	I-DISO
+were	O
+oral	B-ANAT
+cavity	I-ANAT
+(	O
+30	O
+%),	O
+larynx	B-DISO
+(	O
+25	O
+%),	O
+pharynx	B-ANAT
+(	O
+14	O
+%)	O
+and	O
+thyroid	B-ANAT
+(	O
+9	O
+%).	O
+
+EPC	B-PRGE
+were	O
+localized	O
+in	O
+vessel	B-ANAT
+walls	O
+as	O
+well	O
+as	O
+in	O
+destructed	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+Virtually	O
+no	O
+cells	B-COMP
+were	O
+found	O
+in	O
+the	O
+right	B-ANAT
+lung	I-ANAT
+or	O
+in	O
+other	O
+organs	B-ANAT
+.	O
+
+However	O
+,	O
+few	O
+EPC	O
+were	O
+found	O
+in	O
+subcutaneous	O
+Matrigel	O
+in	O
+transplanted	B-ANAT
+rats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+caused	O
+a	O
+worldwide	O
+epidemic	O
+in	O
+late	O
+2002	O
+/	O
+early	O
+2003	O
+and	O
+a	O
+second	O
+outbreak	O
+in	O
+the	O
+winter	O
+of	O
+2003	O
+/	O
+2004	O
+by	O
+an	O
+independent	O
+animal	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+These	O
+antibodies	B-COMP
+also	O
+protected	O
+mice	B-SPEC
+challenged	O
+with	O
+the	O
+Urbani	O
+or	O
+recombinant	O
+viruses	B-SPEC
+bearing	O
+the	O
+GD03	O
+and	O
+SZ16	O
+spike	O
+(	O
+S	O
+)	O
+glycoproteins	B-CHED
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+C5a	I-PRGE
+treatment	O
+immediately	O
+after	O
+trauma	O
+ameliorated	O
+these	O
+peaks	O
+.	O
+
+However	O
+,	O
+as	O
+suggested	O
+in	O
+the	O
+Naylor	O
+report	O
+,	O
+issuing	O
+a	O
+travel	O
+advisory	O
+does	O
+not	O
+keep	O
+infected	O
+individuals	O
+from	O
+leaving	O
+Toronto	O
+and	O
+such	O
+individuals	O
+account	O
+for	O
+5	O
+of	O
+6	O
+cases	O
+where	O
+SARS	B-DISO
+was	O
+spread	O
+from	O
+Canada	O
+.	O
+
+The	O
+2003	O
+-	O
+04	O
+California	B-SPEC
+variant	O
+viruses	B-SPEC
+were	O
+not	O
+compared	O
+with	O
+variants	O
+isolated	O
+in	O
+California	B-SPEC
+during	O
+1970s	O
+and	O
+1980s	O
+because	O
+,	O
+to	O
+our	O
+knowledge	O
+,	O
+no	O
+genetic	O
+information	O
+is	O
+available	O
+and	O
+those	O
+viruses	B-SPEC
+are	O
+no	O
+longer	O
+obtainable	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+the	O
+effectiveness	O
+of	O
+two	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccine	O
+programs	O
+for	O
+preventing	O
+disease	O
+caused	O
+by	O
+a	O
+California	O
+IBV	B-SPEC
+field	O
+isolate	O
+.	O
+
+The	O
+virus	B-SPEC
+caused	O
+late	O
+-	O
+onset	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+increased	O
+airsacculitis	B-DISO
+condemnation	O
+in	O
+affected	O
+flocks	O
+despite	O
+the	O
+use	O
+of	O
+an	O
+established	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccination	O
+program	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+aMPV	O
+),	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+are	O
+important	O
+respiratory	O
+pathogens	O
+of	O
+chickens	B-SPEC
+.	O
+
+Despite	O
+therapy	O
+that	O
+included	O
+intravenous	O
+antibiotics	B-CHED
+,	O
+intravenous	O
+immune	O
+globulin	O
+and	O
+other	O
+supportive	O
+measures	O
+,	O
+the	O
+patient	O
+succumbed	O
+to	O
+his	O
+illness	O
+.	O
+
+As	O
+rates	O
+of	O
+CA	O
+-	O
+MRSA	B-DISO
+increase	O
+worldwide	O
+,	O
+physicians	O
+should	O
+be	O
+aware	O
+of	O
+the	O
+potential	O
+for	O
+MRSA	B-DISO
+to	O
+cause	O
+life	O
+-	O
+threatening	O
+infections	B-DISO
+in	O
+patients	O
+presenting	O
+to	O
+Canadian	O
+emergency	B-DISO
+departments	O
+(	O
+EDs	B-DISO
+).	O
+
+In	O
+previous	O
+studies	O
+,	O
+intravenously	O
+administered	O
+PAMP	O
+had	O
+variable	O
+effects	O
+on	O
+specific	O
+primary	O
+and	O
+secondary	O
+immune	B-PROC
+responses	I-PROC
+of	O
+poultry	O
+to	O
+systemically	O
+administered	O
+antigens	B-CHED
+.	O
+
+The	O
+N	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+peptide	B-CHED
+N220	I-PRGE
+shows	O
+a	O
+high	O
+binding	B-FUNC
+affinity	O
+towards	O
+human	B-SPEC
+MHC	B-PROC
+class	B-SPEC
+I	O
+in	O
+T2	O
+-	O
+cells	B-COMP
+,	O
+and	O
+is	O
+capable	O
+of	O
+activating	O
+cytotoxic	O
+T	B-ANAT
+-	I-ANAT
+cells	I-ANAT
+in	O
+human	B-SPEC
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+).	O
+
+TITLE	O
+:	O
+Global	O
+infectious	B-DISO
+disease	I-DISO
+surveillance	O
+and	O
+health	O
+intelligence	O
+.	O
+
+ABSTRACT	O
+:	O
+TRALI	O
+is	O
+a	O
+rare	O
+but	O
+serious	O
+complication	B-DISO
+associated	O
+with	O
+transfusion	O
+,	O
+and	O
+known	O
+to	O
+occur	O
+following	O
+infusion	O
+of	O
+all	O
+types	O
+of	O
+plasma	B-ANAT
+-	O
+containing	O
+blood	B-ANAT
+products	O
+.	O
+
+One	O
+notable	O
+exception	O
+is	O
+ACE2	O
+residue	O
+354	O
+,	O
+at	O
+the	O
+boundary	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+binding	B-FUNC
+site	I-PRGE
+,	O
+whose	O
+alteration	O
+markedly	O
+inhibited	O
+utilization	O
+by	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+but	O
+not	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+proteins	B-CHED
+.	O
+
+Although	O
+continuous	O
+translation	B-PROC
+and	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+ORF1ab	O
+by	O
+Mpro	O
+is	O
+required	O
+for	O
+replication	O
+,	O
+it	O
+is	O
+unknown	O
+whether	O
+specific	O
+cleavage	B-PROC
+events	O
+within	O
+the	O
+polyprotein	O
+are	O
+dispensable	O
+.	O
+
+Through	O
+use	O
+of	O
+an	O
+MHV	B-SPEC
+reverse	O
+genetics	O
+system	O
+,	O
+in	O
+-	O
+frame	O
+deletions	O
+of	O
+the	O
+coding	O
+sequences	O
+for	O
+nsp7	O
+to	O
+nsp10	O
+,	O
+or	O
+ablation	O
+of	O
+their	O
+flanking	O
+Mpro	O
+cleavage	B-PROC
+sites	O
+,	O
+were	O
+made	O
+and	O
+the	O
+effects	O
+upon	O
+replication	O
+were	O
+determined	O
+.	O
+
+Disruption	O
+of	O
+the	O
+cleavage	B-PROC
+sites	O
+was	O
+lethal	O
+with	O
+the	O
+exception	O
+of	O
+that	O
+of	O
+the	O
+nsp9	O
+-	O
+nsp10	O
+site	O
+,	O
+which	O
+resulted	O
+in	O
+a	O
+mutant	B-DISO
+virus	B-SPEC
+with	O
+attenuated	O
+replication	O
+.	O
+
+Passage	O
+of	O
+the	O
+attenuated	O
+nsp9	O
+-	O
+nsp10	O
+cleavage	B-PROC
+mutant	B-DISO
+increased	O
+fitness	O
+to	O
+near	O
+-	O
+wild	O
+-	O
+type	O
+kinetics	O
+without	O
+reversion	O
+to	O
+a	O
+virus	B-SPEC
+capable	O
+of	O
+processing	O
+nsp9	O
+-	O
+nsp10	O
+.	O
+
+The	O
+mutant	B-DISO
+virus	B-SPEC
+was	O
+not	O
+viable	O
+,	O
+suggesting	O
+that	O
+the	O
+uncleaved	O
+protein	B-CHED
+may	O
+be	O
+essential	O
+for	O
+replication	O
+or	O
+proteolytic	B-PROC
+processing	I-PROC
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+-	O
+penetrating	O
+peptide	B-CHED
+-	O
+morpholino	O
+conjugates	O
+alter	O
+pre	B-PROC
+-	I-PROC
+mRNA	I-PROC
+splicing	I-PROC
+of	O
+DMD	B-DISO
+(	O
+Duchenne	B-DISO
+muscular	B-ANAT
+dystrophy	I-DISO
+)	O
+and	O
+inhibit	O
+murine	B-SPEC
+coronavirus	I-SPEC
+replication	O
+in	O
+vivo	O
+.	O
+
+Shortening	O
+the	O
+CPP	O
+length	O
+,	O
+modifying	O
+it	O
+with	O
+a	O
+mannosylated	O
+serine	B-CHED
+moiety	O
+or	O
+replacing	O
+it	O
+with	O
+the	O
+R	O
+(	O
+9	O
+)	O
+F	O
+(	O
+2	O
+)	O
+CPP	O
+significantly	O
+decreased	O
+the	O
+efficacy	O
+of	O
+the	O
+resulting	O
+PPMO	O
+(	O
+CPP	O
+-	O
+PMO	O
+conjugate	O
+).	O
+
+The	O
+purified	O
+proteins	B-CHED
+mixed	O
+with	O
+complete	O
+Freund	O
+adjuvant	B-CHED
+were	O
+injected	O
+into	O
+Balb	O
+/	O
+c	O
+mice	B-SPEC
+three	O
+times	O
+at	O
+a	O
+two	O
+-	O
+week	O
+interval	O
+.	O
+
+High	O
+titer	O
+antibody	B-COMP
+was	O
+detected	O
+in	O
+the	O
+serum	B-COMP
+of	O
+immunized	O
+Balb	O
+/	O
+c	O
+mice	B-SPEC
+,	O
+and	O
+mice	B-SPEC
+immunized	O
+with	O
+S1	B-PRGE
+protein	I-PRGE
+produced	O
+high	B-PRGE
+titer	I-PRGE
+IgG1	I-PRGE
+,	O
+IgG2a	B-COMP
+,	O
+IgG2b	B-COMP
+and	O
+IgG3	B-COMP
+,	O
+while	O
+those	O
+immunized	O
+with	O
+S2	B-PRGE
+protein	I-PRGE
+produced	O
+high	B-PRGE
+titer	I-PRGE
+IgG1	I-PRGE
+,	O
+IgG2a	B-COMP
+,	O
+but	O
+lower	O
+titer	O
+IgG2b	B-PRGE
+and	O
+IgG3	B-COMP
+.	O
+
+Measures	O
+currently	O
+used	O
+for	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+include	O
+isolation	O
+,	O
+ribavirin	B-CHED
+,	O
+corticosteroid	B-CHED
+therapy	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+results	O
+suggest	O
+that	O
+the	O
+chicken	B-SPEC
+scFv	O
+phage	O
+display	O
+system	O
+can	O
+be	O
+a	O
+potential	O
+model	O
+for	O
+mass	O
+production	O
+of	O
+high	O
+-	O
+affinity	O
+antibodies	B-COMP
+against	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+most	O
+striking	O
+difference	O
+between	O
+the	O
+subgenomic	O
+mRNA8	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+isolated	O
+from	O
+human	B-SPEC
+and	O
+some	O
+animal	B-SPEC
+species	B-SPEC
+is	O
+the	O
+deletion	O
+of	O
+29	O
+nucleotides	B-CHED
+,	O
+resulting	O
+in	O
+splitting	O
+of	O
+a	O
+single	O
+ORF	O
+(	O
+ORF8	O
+)	O
+into	O
+two	O
+ORFs	O
+(	O
+ORF8a	O
+and	O
+ORF8b	O
+).	O
+
+TITLE	O
+:	O
+Retrospective	O
+analysis	O
+on	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+ICU	O
+.	O
+
+Totally	O
+,	O
+131	O
+patients	O
+(	O
+2	O
+.	O
+5	O
+%)	O
+developed	O
+ARDS	B-DISO
+,	O
+among	O
+whom	O
+,	O
+12	O
+patients	O
+were	O
+excluded	O
+from	O
+this	O
+study	O
+because	O
+they	O
+died	B-PROC
+within	O
+24	O
+hours	O
+and	O
+other	O
+4	O
+patients	O
+were	O
+also	O
+excluded	O
+for	O
+their	O
+incomplete	O
+information	O
+.	O
+
+ARDS	B-DISO
+is	O
+a	O
+frequent	O
+syndrome	B-DISO
+in	O
+this	O
+cohort	O
+.	O
+
+RESULTS	O
+:	O
+Totally	O
+,	O
+131	O
+patients	O
+(	O
+2	O
+.	O
+5	O
+%)	O
+developed	O
+ARDS	B-DISO
+,	O
+among	O
+whom	O
+,	O
+12	O
+patients	O
+were	O
+excluded	O
+from	O
+this	O
+study	O
+because	O
+they	O
+died	B-PROC
+within	O
+24	O
+hours	O
+and	O
+other	O
+4	O
+patients	O
+were	O
+also	O
+excluded	O
+for	O
+their	O
+incomplete	O
+information	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+clarify	O
+the	O
+molecular	O
+basis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+adaptation	B-PROC
+to	O
+different	O
+host	B-COMP
+species	B-SPEC
+,	O
+we	O
+serially	O
+passaged	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+rat	B-SPEC
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)-	O
+expressing	O
+cells	B-COMP
+.	O
+
+This	O
+indicates	O
+that	O
+the	O
+expression	O
+system	O
+of	O
+the	O
+plant	B-SPEC
+is	O
+capable	O
+of	O
+generating	O
+a	O
+sizable	O
+amount	O
+of	O
+antigen	B-CHED
+,	O
+possibly	O
+allowing	O
+for	O
+the	O
+successful	O
+development	B-PROC
+of	O
+an	O
+edible	O
+vaccine	O
+.	O
+
+TITLE	O
+:	O
+Biomarker	B-CHED
+discovery	O
+in	O
+infectious	B-DISO
+diseases	I-DISO
+using	O
+SELDI	O
+.	O
+
+It	O
+has	O
+been	O
+used	O
+to	O
+discover	O
+serum	B-COMP
+or	O
+tissue	B-ANAT
+protein	B-CHED
+signatures	O
+and	O
+biomarkers	O
+for	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+the	O
+fields	O
+of	O
+virology	O
+(	O
+hepatitis	B-DISO
+B	I-DISO
+and	O
+C	O
+viruses	B-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+human	B-SPEC
+T	B-DISO
+-	I-DISO
+cell	I-DISO
+leukemia	I-DISO
+virus	B-SPEC
+-	O
+1	O
+and	O
+BK	B-SPEC
+virus	I-SPEC
+),	O
+parasitology	O
+(	O
+trypanosomiasis	B-DISO
+)	O
+and	O
+bacteriology	O
+(	O
+intra	O
+-	O
+amniotic	B-ANAT
+inflammation	B-DISO
+,	O
+tuberculosis	B-PATH
+and	O
+bacterial	B-DISO
+endocarditis	I-DISO
+).	O
+
+Careful	O
+attention	O
+to	O
+experimental	O
+design	O
+,	O
+sample	O
+handling	O
+and	O
+storage	B-PROC
+,	O
+and	O
+the	O
+use	O
+of	O
+appropriate	O
+internal	O
+controls	O
+is	O
+crucial	O
+to	O
+success	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+specific	O
+abietane	B-CHED
+-	O
+type	O
+diterpenoids	B-CHED
+and	O
+lignoids	O
+exhibit	O
+strong	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+effects	O
+.	O
+
+Each	O
+of	O
+these	O
+plasmids	O
+was	O
+intradermally	O
+administered	O
+to	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+in	O
+three	O
+separate	O
+immunizations	O
+.	O
+
+TITLE	O
+:	O
+Activation	O
+of	O
+human	B-SPEC
+monocytes	B-ANAT
+after	O
+infection	B-DISO
+by	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+.	O
+
+Moreover	O
+,	O
+productive	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+of	O
+primary	O
+monocytes	B-ANAT
+and	O
+of	O
+the	O
+THP	B-CHED
+-	O
+1	O
+monocytic	B-ANAT
+cell	B-ANAT
+line	I-ANAT
+led	O
+to	O
+their	O
+activation	O
+,	O
+as	O
+indicated	O
+by	O
+the	O
+production	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+mediators	O
+,	O
+including	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+CCL5	B-PRGE
+,	O
+CXCL10	B-PRGE
+and	O
+CXCL11	B-PRGE
+and	O
+MMP	B-PRGE
+-	I-PRGE
+9	I-PRGE
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MHV	B-SPEC
+induce	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+stress	O
+and	O
+Cxcl2	B-PRGE
+mRNA	I-PRGE
+transcription	B-PROC
+during	O
+infection	B-DISO
+in	O
+vitro	O
+.	O
+
+Data	O
+on	O
+morbidity	O
+and	O
+mortality	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+,	O
+atypical	B-DISO
+pneumonia	I-DISO
+)	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+are	O
+analyzed	O
+and	O
+compared	O
+with	O
+World	O
+Health	O
+Organization	O
+data	O
+on	O
+human	B-DISO
+influenza	I-DISO
+.	O
+
+The	O
+patient	O
+'	O
+s	O
+medical	O
+history	O
+included	O
+a	O
+post	O
+-	O
+rheumatic	B-DISO
+mitral	I-DISO
+stenosis	I-DISO
+.	O
+
+Transesophageal	O
+echocardiography	O
+showed	O
+a	O
+severe	O
+mitral	B-DISO
+stenosis	I-DISO
+,	O
+mild	O
+mitral	B-DISO
+insufficiency	I-DISO
+,	O
+and	O
+diminished	O
+left	B-PROC
+ventricular	I-PROC
+function	I-PROC
+,	O
+hypokinetic	B-DISO
+,	O
+dilated	O
+right	B-ANAT
+ventricle	I-ANAT
+,	O
+and	O
+a	O
+severe	O
+tricuspid	B-DISO
+regurgitation	I-DISO
+.	O
+
+This	O
+decision	O
+was	O
+totally	O
+justified	O
+by	O
+the	O
+unfeasible	O
+CPB	O
+weaning	B-PROC
+off	O
+.	O
+
+Early	O
+use	O
+of	O
+cardiorespiratory	O
+support	O
+with	O
+veno	O
+-	O
+arterial	B-ANAT
+ECMO	O
+allows	O
+pulmonary	B-ANAT
+and	O
+right	B-ANAT
+heart	I-ANAT
+recovery	O
+after	O
+cardiac	B-ANAT
+surgery	O
+,	O
+thus	O
+avoiding	O
+the	O
+use	O
+of	O
+inotropic	O
+drugs	O
+and	O
+complex	O
+ventilatory	O
+support	O
+.	O
+
+Apelin	B-PRGE
+is	O
+also	O
+a	O
+catalytic	O
+substrate	O
+for	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+,	O
+the	O
+key	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+receptor	O
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+generation	O
+of	O
+Apelin	B-PRGE
+gene	I-PRGE
+-	O
+targeted	B-PROC
+mice	B-SPEC
+.	O
+
+Apelin	B-PRGE
+mutant	B-DISO
+mice	B-SPEC
+are	O
+viable	O
+and	O
+fertile	B-PROC
+,	O
+appear	O
+healthy	O
+,	O
+and	O
+exhibit	O
+normal	O
+body	B-ANAT
+weight	O
+,	O
+water	B-CHED
+and	O
+food	B-PROC
+intake	I-PROC
+,	O
+heart	B-ANAT
+rates	O
+,	O
+and	O
+heart	B-ANAT
+morphology	O
+.	O
+
+Intriguingly	O
+,	O
+aged	O
+Apelin	O
+knockout	O
+mice	B-SPEC
+developed	O
+progressive	O
+impairment	B-DISO
+of	O
+cardiac	B-ANAT
+contractility	O
+associated	O
+with	O
+systolic	B-DISO
+dysfunction	I-DISO
+in	O
+the	O
+absence	O
+of	O
+histological	O
+abnormalities	O
+.	O
+
+This	O
+study	O
+evaluated	O
+the	O
+incidence	O
+of	O
+ALI	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+mechanically	O
+ventilated	O
+CDS	B-DISO
+.	O
+
+The	O
+criteria	O
+for	O
+ARDS	O
+were	O
+met	B-CHED
+in	O
+11	O
+of	O
+24	O
+CDS	B-DISO
+(	O
+46	O
+%)	O
+and	O
+in	O
+21	O
+of	O
+317	O
+of	O
+controls	O
+(	O
+7	O
+%;	O
+OR	O
+11	O
+.	O
+9	O
+,	O
+95	O
+%	O
+CI	O
+4	O
+.	O
+8	O
+-	O
+29	O
+.	O
+8	O
+).	O
+
+After	O
+the	O
+cat	B-SPEC
+died	B-PROC
+,	O
+a	O
+pathological	O
+examination	O
+revealed	O
+nonsuppurative	O
+encephalomyelitis	B-DISO
+.	O
+
+The	O
+graphs	O
+of	O
+characteristic	O
+distributions	O
+of	O
+dinucleotide	B-CHED
+GC	O
+for	O
+the	O
+coding	O
+sequences	O
+of	O
+the	O
+first	O
+exon	O
+of	O
+beta	B-PRGE
+-	I-PRGE
+globin	I-PRGE
+gene	I-PRGE
+of	O
+eleven	O
+different	O
+species	B-SPEC
+and	O
+the	O
+construction	O
+of	O
+phylogenetic	O
+tree	O
+of	O
+twenty	O
+four	O
+coronavirus	B-SPEC
+genomes	O
+illustrate	O
+the	O
+utility	O
+of	O
+the	O
+approach	O
+.	O
+
+TITLE	O
+:	O
+Immune	B-PROC
+responses	I-PROC
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+induced	O
+by	O
+virus	B-SPEC
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+in	O
+mice	O
+.	O
+
+ABSTRACT	O
+:	O
+Virus	B-PRGE
+-	I-PRGE
+like	I-PRGE
+particles	I-PRGE
+(	O
+VLPs	B-ANAT
+)	O
+represent	O
+a	O
+promising	O
+vaccine	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+CoV	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+recombinant	O
+baculovirus	B-SPEC
+vAcS	O
+and	O
+vAcME	O
+were	O
+constructed	O
+to	O
+express	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+the	O
+M	O
+and	O
+E	O
+proteins	B-CHED
+of	O
+SARS	B-DISO
+CoV	O
+,	O
+respectively	O
+.	O
+
+Our	O
+findings	O
+demonstrate	O
+that	O
+SARS	B-PRGE
+CoV	I-PRGE
+VLPs	B-ANAT
+are	O
+immunogenic	O
+and	O
+can	O
+elicit	O
+strong	O
+SARS	B-DISO
+CoV	O
+-	O
+specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+mice	B-SPEC
+.	O
+
+After	O
+the	O
+onset	O
+of	O
+severe	B-DISO
+preeclampsia	I-DISO
+,	O
+the	O
+pregnancy	O
+was	O
+terminated	O
+but	O
+the	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+continued	O
+to	O
+worsen	O
+.	O
+
+AGP	B-PRGE
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+diagnosis	O
+of	O
+feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+)	O
+and	O
+may	O
+also	O
+be	O
+useful	O
+also	O
+in	O
+studies	O
+of	O
+FIP	B-DISO
+pathogenesis	B-DISO
+.	O
+
+There	O
+are	O
+accumulating	O
+data	O
+that	O
+some	O
+of	O
+these	O
+new	O
+pathogens	O
+are	O
+responsible	O
+for	O
+a	O
+substantial	O
+proportion	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+diseases	I-DISO
+,	O
+particularly	O
+in	O
+children	O
+.	O
+
+Data	O
+obtained	O
+with	O
+truncated	O
+ISG15	B-PRGE
+and	O
+hybrid	O
+Ub	O
+/	O
+ISG15	B-PRGE
+substrates	O
+indicate	O
+that	O
+both	O
+the	O
+N	O
+-	O
+and	O
+C	O
+-	O
+terminal	O
+Ub	O
+-	O
+like	O
+domains	O
+of	O
+ISG15	B-PRGE
+contribute	O
+to	O
+this	O
+preference	O
+.	O
+
+In	O
+both	O
+patients	O
+,	O
+the	O
+frequency	O
+of	O
+CD4	B-PRGE
+(+)	O
+memory	B-PROC
+T	B-ANAT
+-	I-ANAT
+cells	I-ANAT
+to	O
+virus	B-SPEC
+structural	O
+proteins	B-CHED
+and	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+IgG	I-PRGE
+levels	O
+were	O
+low	O
+by	O
+12	O
+months	O
+after	O
+infection	B-DISO
+.	O
+
+This	O
+report	O
+expands	O
+our	O
+understanding	O
+of	O
+the	O
+specificity	O
+and	O
+duration	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+CD4	I-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+immune	B-PROC
+responses	I-PROC
+.	O
+
+Electron	O
+microscopy	O
+studies	O
+of	O
+rTGEV	O
+-	O
+DeltaE	O
+infected	O
+BHK	O
+-	O
+pAPN	O
+-	O
+E	O
+(-)	O
+cells	B-COMP
+showed	O
+that	O
+only	O
+immature	O
+intracellular	B-COMP
+virions	B-COMP
+were	O
+assembled	O
+.	O
+
+These	O
+changes	O
+were	O
+associated	O
+with	O
+a	O
+loss	O
+in	O
+total	O
+protein	B-CHED
+content	O
+of	O
+claudin	O
+5	O
+and	O
+redistribution	O
+of	O
+ZO	O
+-	O
+1	O
+from	O
+the	O
+cytoskeleton	B-COMP
+to	O
+the	O
+membrane	B-COMP
+and	O
+the	O
+cytosolic	B-COMP
+and	O
+nuclear	O
+fractions	O
+.	O
+
+The	O
+effect	O
+of	O
+nsp1	B-PRGE
+on	O
+MHV	B-SPEC
+replication	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+was	O
+analyzed	O
+using	O
+a	O
+recombinant	O
+MHV	B-SPEC
+encoding	O
+a	O
+deletion	O
+in	O
+the	O
+nsp1	B-PRGE
+-	I-PRGE
+coding	I-PRGE
+sequence	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+likely	O
+mediated	O
+by	O
+disproportional	O
+immune	B-PROC
+responses	I-PROC
+and	O
+the	O
+ability	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+circumvent	O
+innate	B-PROC
+immunity	I-PROC
+.	O
+
+Our	O
+studies	O
+emphasize	O
+that	O
+the	O
+induction	O
+of	O
+early	O
+IFN	B-PRGE
+signaling	B-PROC
+may	O
+be	O
+critical	O
+to	O
+confer	O
+protection	O
+against	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+highlight	O
+the	O
+strength	O
+of	O
+combining	O
+functional	O
+genomics	O
+with	O
+immunohistochemistry	O
+to	O
+further	O
+unravel	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+Multiplex	O
+real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+)-	O
+PCR	O
+was	O
+developed	O
+for	O
+simultaneous	O
+differential	O
+quantification	O
+of	O
+each	O
+virus	B-SPEC
+in	O
+a	O
+single	O
+reaction	O
+tube	O
+,	O
+using	O
+Cy5	O
+-	O
+and	O
+FAM	O
+-	O
+labeled	O
+TaqMan	O
+-	O
+probes	O
+based	O
+on	O
+sequences	O
+from	O
+the	O
+TGEV	B-SPEC
+and	O
+PEDV	B-SPEC
+nucleocapsid	B-COMP
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+Angiosarcoma	B-DISO
+is	O
+a	O
+rare	O
+soft	O
+-	O
+tissue	B-ANAT
+neoplasm	B-DISO
+that	O
+occurs	O
+most	O
+often	O
+in	O
+the	O
+skin	B-ANAT
+and	O
+the	O
+subcutaneous	B-ANAT
+tissues	I-ANAT
+but	O
+very	O
+rarely	O
+in	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Attachment	O
+and	O
+internalization	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+in	O
+feline	B-SPEC
+blood	B-ANAT
+monocytes	I-ANAT
+and	O
+Crandell	O
+feline	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+.	O
+
+The	O
+effects	O
+of	O
+dialysis	B-SPEC
+dosage	O
+were	O
+evaluated	O
+in	O
+this	O
+population	O
+,	O
+with	O
+the	O
+use	O
+of	O
+either	O
+classic	O
+or	O
+slow	O
+low	O
+-	O
+efficiency	O
+hemodialysis	O
+,	O
+and	O
+two	O
+periods	O
+/	O
+treatment	O
+plans	O
+were	O
+compared	O
+:	O
+2002	O
+to	O
+2003	O
+/	O
+delayed	O
+,	O
+alternate	O
+-	O
+day	O
+dialysis	B-SPEC
+(	O
+DAdD	O
+group	O
+;	O
+n	O
+=	O
+15	O
+)	O
+and	O
+2004	O
+to	O
+2005	O
+/	O
+prompt	O
+and	O
+daily	O
+dialysis	B-SPEC
+(	O
+PaDD	O
+group	O
+;	O
+n	O
+=	O
+18	O
+).	O
+
+Mean	O
+serum	B-COMP
+urea	B-CHED
+during	O
+the	O
+dialysis	B-SPEC
+period	O
+was	O
+significantly	O
+lower	O
+in	O
+the	O
+PaDD	O
+group	O
+than	O
+in	O
+the	O
+DAdD	O
+group	O
+.	O
+
+Of	O
+the	O
+PaDD	O
+group	O
+patients	O
+,	O
+three	O
+(	O
+16	O
+.	O
+7	O
+%)	O
+died	B-PROC
+,	O
+compared	O
+with	O
+10	O
+(	O
+66	O
+.	O
+7	O
+%)	O
+of	O
+the	O
+DAdD	O
+group	O
+patients	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+this	O
+result	O
+,	O
+it	O
+is	O
+believed	O
+that	O
+alternate	O
+-	O
+day	O
+hemodialysis	O
+is	O
+no	O
+longer	O
+appropriate	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+Weil	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Prone	O
+position	O
+to	O
+treat	O
+bronchopleural	B-DISO
+fistula	I-DISO
+in	O
+post	O
+-	O
+operative	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Prone	O
+position	O
+associated	O
+with	O
+lung	B-ANAT
+protective	O
+strategy	O
+was	O
+implemented	O
+during	O
+16	O
+-	O
+18	O
+h	O
+daily	O
+and	O
+after	O
+the	O
+change	O
+of	O
+position	O
+PaO2	O
+/	O
+FiO2	O
+increased	O
+of	O
+35	O
+%	O
+and	O
+PaCO2	O
+-	O
+PetCO2	O
+decreased	O
+about	O
+40	O
+%;	O
+at	O
+4th	O
+day	O
+under	O
+treatment	O
+,	O
+the	O
+subcutaneous	O
+emphysema	O
+and	O
+pneumothorax	B-DISO
+could	O
+not	O
+be	O
+detected	O
+either	O
+clinically	O
+or	O
+radiologically	O
+.	O
+
+Our	O
+5	O
+-	O
+year	O
+ARDS	B-DISO
+and	O
+1	O
+-	O
+year	O
+SARS	B-DISO
+study	O
+retention	B-PROC
+rates	O
+were	O
+86	O
+%	O
+and	O
+91	O
+%,	O
+respectively	O
+,	O
+using	O
+these	O
+methods	O
+.	O
+
+This	O
+dynamic	O
+behavior	O
+did	O
+not	O
+arise	O
+in	O
+a	O
+SARS	B-DISO
+model	O
+without	O
+asymptomatic	O
+infective	O
+class	B-SPEC
+studied	O
+by	O
+Hsu	O
+and	O
+Hsieh	O
+(	O
+SIAM	O
+J	O
+.	O
+Appl	O
+.	O
+
+The	O
+Virochip	O
+detected	O
+viruses	B-SPEC
+in	O
+a	O
+higher	O
+proportion	O
+of	O
+samples	O
+(	O
+65	O
+%)	O
+than	O
+did	O
+culture	O
+isolation	O
+(	O
+17	O
+%)	O
+while	O
+exhibiting	O
+high	O
+concordance	O
+(	O
+98	O
+%)	O
+with	O
+and	O
+comparable	O
+sensitivity	O
+(	O
+97	O
+%)	O
+and	O
+specificity	O
+(	O
+98	O
+%)	O
+to	O
+pathogen	O
+-	O
+specific	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+Virochip	O
+detected	O
+viruses	B-SPEC
+in	O
+a	O
+higher	O
+proportion	O
+of	O
+samples	O
+(	O
+65	O
+%)	O
+than	O
+did	O
+culture	O
+isolation	O
+(	O
+17	O
+%)	O
+while	O
+exhibiting	O
+high	O
+concordance	O
+(	O
+98	O
+%)	O
+with	O
+and	O
+comparable	O
+sensitivity	O
+(	O
+97	O
+%)	O
+and	O
+specificity	O
+(	O
+98	O
+%)	O
+to	O
+pathogen	O
+-	O
+specific	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pathogenesis	B-DISO
+of	O
+2	O
+strains	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+T	O
+and	O
+N1	O
+/	O
+88	O
+strains	O
+)	O
+was	O
+studied	O
+in	O
+the	O
+eggshell	O
+-	O
+forming	O
+regions	O
+of	O
+the	O
+oviduct	B-ANAT
+of	O
+commercial	O
+laying	O
+hens	O
+.	O
+
+Recently	O
+,	O
+carbohydrate	B-CHED
+-	O
+binding	B-FUNC
+agents	O
+(	O
+CBA	B-CHED
+)	O
+were	O
+shown	O
+to	O
+possess	B-DISO
+antiviral	B-CHED
+activity	O
+towards	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+The	O
+membrane	B-COMP
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+suppresses	O
+NF	B-PROC
+-	I-PROC
+kappaB	I-PROC
+activation	I-PROC
+.	O
+
+The	O
+molecular	O
+mechanism	O
+of	O
+SARS	B-DISO
+pathogenesis	B-DISO
+remains	O
+elusive	O
+.	O
+
+Further	O
+investigation	O
+showed	O
+M	O
+protein	B-CHED
+suppressed	O
+Cox	B-PRGE
+-	I-PRGE
+2	I-PRGE
+expression	B-PROC
+using	O
+a	O
+luciferase	B-ENZY
+reporter	O
+gene	O
+assay	O
+,	O
+RT	O
+-	O
+PCR	O
+and	O
+Western	O
+blot	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+Priming	O
+with	O
+SARS	B-PRGE
+CoV	I-PRGE
+S	I-PRGE
+DNA	I-PRGE
+and	O
+boosting	O
+with	O
+SARS	B-PRGE
+CoV	I-PRGE
+S	I-PRGE
+epitopes	I-PRGE
+specific	O
+for	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	O
+cells	O
+promote	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+used	O
+swine	B-SPEC
+testicle	B-ANAT
+(	O
+ST	O
+)	O
+cells	B-COMP
+infected	O
+with	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+an	O
+indirect	O
+immunofluorescent	O
+assay	O
+with	O
+antibodies	B-COMP
+against	O
+TGEV	B-SPEC
+spike	O
+and	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+to	O
+screen	O
+small	O
+-	O
+molecule	O
+compounds	O
+that	O
+inhibit	O
+TGEV	B-SPEC
+replication	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+show	O
+that	O
+nonpathogenic	O
+SIV	B-DISO
+infection	B-DISO
+of	O
+sooty	B-SPEC
+mangabeys	I-SPEC
+(	O
+SMs	B-DISO
+),	O
+a	O
+natural	O
+host	B-COMP
+species	B-SPEC
+for	O
+SIV	B-DISO
+,	O
+is	O
+also	O
+associated	O
+with	O
+an	O
+early	O
+,	O
+severe	O
+,	O
+and	O
+persistent	O
+depletion	O
+of	O
+memory	B-PROC
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+from	O
+the	O
+intestinal	B-ANAT
+and	O
+respiratory	O
+mucosa	B-ANAT
+.	O
+
+Continuing	O
+research	O
+will	O
+lead	O
+to	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+regulation	B-PROC
+of	I-PROC
+cell	I-PROC
+death	I-PROC
+during	O
+viral	B-DISO
+infection	I-DISO
+and	O
+the	O
+identification	O
+of	O
+novel	O
+antiviral	B-CHED
+targets	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+could	O
+inhibit	O
+both	O
+virus	B-SPEC
+-	O
+and	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)-	O
+dependent	O
+signaling	B-PROC
+,	O
+two	O
+key	O
+steps	O
+of	O
+the	O
+antiviral	B-PROC
+response	I-PROC
+.	O
+
+There	O
+were	O
+31	O
+(	O
+59	O
+.	O
+6	O
+%)	O
+males	O
+and	O
+ages	O
+ranged	O
+between	O
+14	O
+months	O
+and	O
+12	O
+years	O
+[	O
+median	O
+(	O
+SD	O
+)	O
+6	O
+.	O
+5	O
+(	O
+2	O
+.	O
+49	O
+)	O
+years	O
+];	O
+ACS	B-FUNC
+occurred	O
+fairly	O
+evenly	O
+in	O
+those	O
+aged	O
+between	O
+2	O
+and	O
+10	O
+years	O
+.	O
+
+Cross	O
+-	O
+sectional	O
+Web	B-DISO
+-	O
+based	O
+survey	O
+.	O
+
+Of	O
+the	O
+790	O
+of	O
+2	O
+,	O
+985	O
+(	O
+27	O
+%)	O
+of	O
+physicians	O
+who	O
+responded	O
+,	O
+15	O
+%,	O
+6	O
+%,	O
+and	O
+28	O
+%	O
+never	O
+used	O
+sedation	B-DISO
+,	O
+analgesia	B-DISO
+,	O
+or	O
+hand	O
+restraints	O
+any	O
+of	O
+the	O
+time	O
+for	O
+NPPV	O
+patients	O
+,	O
+respectively	O
+,	O
+and	O
+the	O
+large	O
+majority	O
+reported	O
+using	O
+these	O
+interventions	O
+in	O
+<	O
+or	O
+=	O
+25	O
+%	O
+of	O
+patients	O
+.	O
+
+Europeans	O
+were	O
+less	O
+likely	O
+to	O
+use	O
+a	O
+benzodiazepine	B-CHED
+alone	O
+(	O
+25	O
+%	O
+vs	O
+.	O
+39	O
+%,	O
+p	O
+<	O
+.	O
+001	O
+)	O
+but	O
+more	O
+likely	O
+to	O
+use	O
+an	O
+opioid	O
+alone	O
+(	O
+37	O
+%	O
+vs	O
+.	O
+26	O
+%,	O
+p	O
+<	O
+.	O
+009	O
+).	O
+
+We	O
+review	O
+the	O
+strong	O
+evidence	O
+supporting	O
+the	O
+use	O
+of	O
+noninvasive	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+to	O
+prevent	O
+intubation	O
+in	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+exacerbations	O
+or	O
+acute	B-DISO
+cardiogenic	I-DISO
+pulmonary	I-DISO
+edema	I-DISO
+,	O
+and	O
+in	O
+immunocompromised	O
+patients	O
+,	O
+as	O
+well	O
+as	O
+to	O
+facilitate	O
+extubation	O
+in	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+who	O
+require	O
+initial	O
+intubation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Noninvasive	O
+ventilation	O
+has	O
+assumed	O
+an	O
+important	O
+role	O
+in	O
+managing	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+This	O
+outbreak	O
+led	O
+to	O
+the	O
+strengthening	O
+of	O
+surveillance	O
+for	O
+respiratory	O
+viruses	B-SPEC
+and	O
+to	O
+new	O
+national	O
+recommendations	O
+for	O
+influenza	B-DISO
+vaccination	O
+in	O
+Colombia	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+pancreatitis	O
+represents	O
+a	O
+spectrum	O
+of	O
+disease	O
+,	O
+ranging	O
+from	O
+a	O
+mild	O
+,	O
+transitory	O
+illness	O
+to	O
+a	O
+severe	O
+,	O
+rapidly	O
+progressive	O
+hemorrhagic	O
+form	O
+,	O
+with	O
+massive	B-DISO
+necrosis	I-DISO
+and	O
+mortality	O
+rates	O
+of	O
+up	O
+to	O
+24	O
+%.	O
+
+To	O
+better	O
+describe	O
+outpatient	O
+fatalities	O
+due	O
+to	O
+acute	B-DISO
+pancreatitis	I-DISO
+that	O
+present	O
+as	O
+sudden	O
+,	O
+unexpected	O
+death	B-PROC
+,	O
+we	O
+retrospectively	O
+reviewed	O
+the	O
+autopsy	O
+files	O
+at	O
+the	O
+Institute	O
+of	O
+Legal	O
+Medicine	B-CHED
+,	O
+University	O
+of	O
+Hamburg	O
+,	O
+Germany	O
+,	O
+from	O
+2000	O
+-	O
+2004	O
+.	O
+
+Contrary	O
+to	O
+the	O
+clinical	O
+observations	O
+of	O
+a	O
+clear	O
+seasonal	O
+variation	O
+in	O
+the	O
+onset	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+we	O
+found	O
+no	O
+correlation	O
+between	O
+death	B-PROC
+due	O
+to	O
+acute	B-DISO
+pancreatitis	I-DISO
+and	O
+a	O
+specific	O
+month	O
+or	O
+season	O
+.	O
+
+Conversely	O
+,	O
+in	O
+the	O
+present	O
+study	O
+,	O
+the	O
+majority	O
+of	O
+affected	O
+individuals	O
+died	B-PROC
+during	O
+the	O
+very	O
+early	O
+phase	O
+of	O
+the	O
+disease	O
+.	O
+
+While	O
+gallstones	B-DISO
+represent	O
+the	O
+main	O
+etiologic	O
+factor	O
+in	O
+most	O
+larger	O
+clinical	O
+series	O
+,	O
+biliary	O
+etiology	O
+seems	O
+to	O
+play	O
+only	O
+a	O
+minor	O
+role	O
+in	O
+outpatient	O
+deaths	B-PROC
+undergoing	O
+medicolegal	O
+autopsies	O
+.	O
+
+ABSTRACT	O
+:	O
+Babesiosis	B-DISO
+is	O
+a	O
+tick	B-SPEC
+-	O
+borne	O
+illness	O
+caused	O
+by	O
+the	O
+protozoan	O
+Babesia	O
+microti	O
+.	O
+
+The	O
+evolution	B-PROC
+was	O
+complicated	O
+:	O
+pneumothorax	B-DISO
+(	O
+3	O
+cases	O
+),	O
+hypokaliemia	O
+(	O
+3	O
+cases	O
+),	O
+inappropriate	O
+secretion	O
+of	O
+ADH	B-FUNC
+syndrome	B-DISO
+(	O
+1	O
+case	O
+).	O
+
+ABSTRACT	O
+:	O
+Transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+(	O
+TRALI	B-DISO
+)	O
+is	O
+a	O
+serious	O
+clinical	O
+syndrome	B-DISO
+associated	O
+with	O
+the	O
+transfusion	O
+of	O
+plasma	B-ANAT
+-	O
+containing	O
+blood	B-ANAT
+components	I-ANAT
+.	O
+
+Most	O
+of	O
+the	O
+donors	O
+implicated	O
+in	O
+cases	O
+of	O
+TRALI	B-DISO
+are	O
+multiparous	O
+women	O
+.	O
+
+Greater	O
+knowledge	O
+regarding	O
+TRALI	B-DISO
+on	O
+the	O
+part	O
+of	O
+clinicians	O
+could	O
+be	O
+crucial	O
+in	O
+preventing	O
+and	O
+treating	O
+this	O
+severe	O
+complication	O
+of	O
+blood	O
+transfusion	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+porcine	B-SPEC
+group	B-SPEC
+A	I-SPEC
+rotavirus	I-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+on	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+pathogenicity	O
+in	O
+piglets	O
+.	O
+
+No	O
+significant	O
+differences	O
+in	O
+mean	O
+VH	O
+:	O
+CD	O
+ratio	O
+and	O
+clinical	O
+symptoms	O
+(	O
+diarrhea	O
+,	O
+vomiting	B-DISO
+,	O
+dehydration	B-DISO
+,	O
+and	O
+anorexia	B-DISO
+)	O
+were	O
+observed	O
+between	O
+the	O
+PEDV	B-SPEC
+/	O
+PGAR	O
+-	O
+infected	O
+and	O
+PEDV	B-SPEC
+-	O
+infected	O
+groups	O
+of	O
+piglets	O
+at	O
+1	O
+,	O
+2	O
+and	O
+3	O
+DPI	O
+;	O
+however	O
+,	O
+at	O
+2	O
+and	O
+3	O
+DPI	O
+,	O
+PGAR	O
+was	O
+detected	O
+in	O
+all	O
+fecal	B-ANAT
+samples	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+virus	B-SPEC
+isolation	O
+.	O
+
+In	O
+addition	O
+to	O
+the	O
+four	O
+beta	O
+-	O
+strands	O
+and	O
+two	O
+alpha	O
+-	O
+helices	B-SPEC
+that	O
+are	O
+common	O
+to	O
+ubiquitin	B-PROC
+-	O
+like	O
+folds	O
+,	O
+the	O
+globular	O
+domain	O
+of	O
+nsp3a	O
+contains	O
+two	O
+short	O
+helices	B-SPEC
+representing	O
+a	O
+feature	O
+that	O
+has	O
+not	O
+previously	O
+been	O
+observed	O
+in	O
+these	O
+proteins	B-CHED
+.	O
+
+These	O
+prospectively	O
+collected	O
+data	O
+were	O
+compared	O
+with	O
+data	O
+of	O
+a	O
+matched	O
+,	O
+retrospective	O
+group	O
+without	O
+NAC	B-COMP
+treatment	O
+.	O
+
+Although	O
+factors	O
+contributing	O
+to	O
+the	O
+highly	O
+pathogenic	O
+nature	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+remain	O
+poorly	O
+understood	O
+,	O
+it	O
+has	O
+been	O
+reported	O
+that	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+does	O
+not	O
+induce	O
+type	O
+I	O
+interferons	O
+(	O
+IFNs	O
+)	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+The	O
+relationship	O
+between	O
+breastfeeding	B-PROC
+and	O
+cardiovascular	B-DISO
+diseases	I-DISO
+was	O
+unclear	O
+.	O
+
+TITLE	O
+:	O
+A	O
+qualitative	O
+study	O
+of	O
+the	O
+duty	O
+to	O
+care	O
+in	O
+communicable	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+TITLE	O
+:	O
+5	O
+'-	O
+O	O
+-	O
+masked	O
+2	B-CHED
+'-	I-CHED
+deoxyadenosine	I-CHED
+analogues	O
+as	O
+lead	B-CHED
+compounds	I-CHED
+for	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+)	O
+therapeutic	O
+agents	O
+.	O
+
+Among	O
+these	O
+,	O
+several	O
+5	O
+'-	O
+O	O
+-	O
+masked	O
+analogues	O
+of	O
+6	O
+-	O
+chloropurine	O
+-	O
+2	O
+'-	O
+deoxyriboside	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+5	O
+'-	O
+O	O
+-	O
+benzoyl	B-CHED
+,	O
+5	O
+'-	O
+O	O
+-	O
+p	O
+-	O
+methoxybenzoyl	O
+,	O
+and	O
+5	O
+'-	O
+O	O
+-	O
+benzyl	B-CHED
+analogues	O
+)	O
+were	O
+found	O
+to	O
+exhibit	O
+effective	O
+anti	O
+-	O
+HCV	B-SPEC
+activity	O
+.	O
+
+TITLE	O
+:	O
+Conductance	O
+and	O
+amantadine	B-CHED
+binding	B-FUNC
+of	O
+a	O
+pore	B-COMP
+formed	O
+by	O
+a	O
+lysine	B-CHED
+-	O
+flanked	O
+transmembrane	B-COMP
+domain	O
+of	O
+SARS	O
+coronavirus	B-SPEC
+envelope	B-COMP
+protein	B-CHED
+.	O
+
+We	O
+have	O
+shown	O
+previously	O
+that	O
+the	O
+topology	O
+of	O
+the	O
+alpha	O
+-	O
+helical	O
+putative	O
+TM	O
+domain	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+(	O
+ETM	O
+),	O
+flanked	O
+by	O
+two	O
+lysine	B-CHED
+residues	O
+at	O
+C	O
+and	O
+N	O
+termini	O
+to	O
+improve	O
+solubility	O
+,	O
+is	O
+consistent	O
+with	O
+a	O
+regular	O
+TM	O
+alpha	O
+-	O
+helix	O
+,	O
+with	O
+orientational	O
+parameters	O
+in	O
+lipid	B-ANAT
+bilayers	I-ANAT
+that	O
+are	O
+consistent	O
+with	O
+a	O
+homopentameric	O
+model	O
+.	O
+
+Results	O
+obtained	O
+from	O
+single	O
+or	O
+double	O
+mutants	O
+indicate	O
+that	O
+the	O
+organization	O
+of	O
+the	O
+transmembrane	B-COMP
+pore	B-COMP
+is	O
+consistent	O
+with	O
+our	O
+previously	O
+reported	O
+pentameric	O
+alpha	O
+-	O
+helical	O
+bundle	O
+model	O
+.	O
+
+Challenging	O
+this	O
+is	O
+the	O
+position	O
+that	O
+purging	B-DISO
+can	O
+,	O
+at	O
+best	O
+,	O
+only	O
+adapt	O
+a	O
+population	O
+to	O
+a	O
+particular	O
+environment	O
+;	O
+novel	O
+selective	O
+regimes	O
+will	O
+always	O
+uncover	O
+additional	O
+inbreeding	B-PROC
+load	O
+.	O
+
+We	O
+investigated	O
+factors	O
+affecting	O
+mortality	O
+in	O
+a	O
+population	O
+of	O
+naked	B-SPEC
+mole	I-SPEC
+-	I-SPEC
+rats	I-SPEC
+struck	B-DISO
+by	O
+a	O
+spontaneous	O
+,	O
+lethal	O
+coronavirus	B-SPEC
+outbreak	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+loss	O
+of	O
+genetic	O
+diversity	O
+through	O
+inbreeding	B-PROC
+may	O
+render	O
+populations	O
+vulnerable	O
+to	O
+local	O
+extinction	O
+from	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+even	O
+when	O
+other	O
+inbreeding	B-PROC
+depression	B-DISO
+symptoms	I-DISO
+are	O
+absent	O
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+FEV1	O
+/	O
+FVC	B-PROC
+,	O
+total	O
+lung	B-PROC
+capacity	I-PROC
+(	O
+TLC	O
+),	O
+diffusing	O
+capacity	O
+of	O
+the	O
+lung	B-ANAT
+for	O
+carbon	B-CHED
+monoxide	I-CHED
+(	O
+DLCO	O
+)	O
+between	O
+the	O
+two	O
+groups	O
+(	O
+all	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+PDC	B-DISO
+of	O
+patients	O
+showed	O
+up	O
+-	O
+regulated	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+7	I-PRGE
+mRNA	I-PRGE
+levels	O
+and	O
+evidence	O
+of	O
+in	O
+vivo	O
+activation	O
+(	O
+CD80	B-PRGE
+)	O
+and	O
+maturation	B-PROC
+(	O
+CD83	B-PRGE
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+current	O
+H5N1	B-DISO
+epidemic	O
+may	O
+be	O
+considered	O
+a	O
+prepandemic	O
+paradigm	O
+that	O
+needs	O
+thorough	O
+investigation	O
+.	O
+
+Furthermore	O
+,	O
+administration	O
+of	O
+MSCs	B-FUNC
+transfected	O
+with	O
+pANGPT1	O
+resulted	O
+in	O
+nearly	O
+complete	O
+reversal	O
+of	O
+LPS	B-DISO
+-	O
+induced	O
+increases	O
+in	O
+lung	B-ANAT
+permeability	O
+as	O
+assessed	O
+by	O
+reductions	O
+in	O
+IgM	B-PRGE
+and	O
+albumin	B-PRGE
+levels	O
+in	O
+BAL	B-ENZY
+(	O
+96	O
+%,	O
+CI	O
+6	O
+%-	O
+185	O
+%;	O
+and	O
+74	O
+%,	O
+CI	O
+23	O
+%-	O
+126	O
+%,	O
+respectively	O
+).	O
+
+Fluorescently	O
+tagged	O
+MSCs	B-FUNC
+were	O
+detected	O
+in	O
+the	O
+lung	B-ANAT
+tissues	I-ANAT
+by	O
+confocal	O
+microscopy	O
+and	O
+flow	O
+cytometry	O
+in	O
+both	O
+naïve	O
+and	O
+LPS	B-DISO
+-	O
+injured	O
+animals	B-SPEC
+up	O
+to	O
+3	O
+d	O
+.	O
+Treatment	O
+with	O
+MSCs	B-FUNC
+alone	O
+significantly	O
+reduced	O
+LPS	B-DISO
+-	O
+induced	O
+acute	O
+pulmonary	B-DISO
+inflammation	I-DISO
+in	O
+mice	B-SPEC
+,	O
+while	O
+administration	O
+of	O
+pANGPT1	O
+-	O
+transfected	O
+MSCs	B-FUNC
+resulted	O
+in	O
+a	O
+further	O
+improvement	O
+in	O
+both	O
+alveolar	B-ANAT
+inflammation	B-DISO
+and	O
+permeability	O
+.	O
+
+RT	O
+-	O
+PCR	O
+and	O
+nested	O
+PCR	O
+using	O
+the	O
+primer	O
+pairs	O
+specific	O
+to	O
+the	O
+nucleocapsid	B-COMP
+gene	O
+,	O
+BCoVs	O
+detected	O
+the	O
+BCoVs	O
+in	O
+56	O
+(	O
+15	O
+.	O
+6	O
+%)	O
+of	O
+359	O
+diarrhoeic	O
+faecal	B-ANAT
+samples	O
+.	O
+
+Primary	O
+rat	B-SPEC
+alveolar	B-ANAT
+type	O
+II	O
+cells	B-COMP
+were	O
+transdifferentiated	O
+into	O
+the	O
+type	B-ANAT
+I	I-ANAT
+cell	I-ANAT
+phenotype	O
+.	O
+
+Dual	O
+immunolabeling	O
+of	O
+type	O
+I	O
+cells	B-COMP
+for	O
+viral	B-PRGE
+antigen	I-PRGE
+and	I-PRGE
+CXC	I-PRGE
+chemokines	I-PRGE
+showed	O
+that	O
+chemokines	O
+were	O
+expressed	B-PROC
+primarily	O
+by	O
+uninfected	O
+cells	B-COMP
+.	O
+
+Virus	B-SPEC
+-	O
+induced	O
+chemokine	O
+expression	B-PROC
+was	O
+reduced	O
+by	O
+the	O
+IL	B-PRGE
+-	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+antagonist	B-PROC
+,	O
+suggesting	O
+that	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+produced	O
+by	O
+infected	O
+cells	B-COMP
+induces	O
+uninfected	O
+cells	B-COMP
+to	O
+express	O
+chemokines	O
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+multiplex	O
+nested	O
+PCR	O
+for	O
+detection	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+high	O
+speed	O
+of	O
+fast	B-FUNC
+PCR	O
+(	O
+within	O
+35	O
+min	O
+)	O
+greatly	O
+improved	O
+the	O
+efficiency	O
+of	O
+these	O
+assays	O
+.	O
+
+However	O
+,	O
+often	O
+patients	O
+with	O
+acute	O
+,	O
+severe	O
+brain	B-ANAT
+injury	O
+demonstrate	O
+intracranial	B-DISO
+hypertension	I-DISO
+(	O
+hICP	O
+)	O
+due	O
+to	O
+a	O
+variety	O
+of	O
+injuries	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+traumatic	O
+brain	B-ANAT
+injury	O
+,	O
+mass	B-DISO
+lesion	I-DISO
+,	O
+acute	O
+hydrocephalus	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Ultraviolet	O
+(	O
+UV	O
+)	O
+germicidal	O
+air	B-CHED
+disinfection	O
+is	O
+an	O
+engineering	O
+method	O
+used	O
+to	O
+control	O
+the	O
+airborne	O
+transmission	O
+of	O
+pathogenic	O
+microorganisms	O
+in	O
+high	O
+-	O
+risk	O
+settings	O
+.	O
+
+We	O
+confirmed	O
+that	O
+the	O
+UV	O
+disinfection	O
+rate	O
+differs	O
+greatly	O
+between	O
+viral	O
+aerosols	O
+and	O
+viruses	B-SPEC
+suspended	O
+in	O
+liquid	O
+.	O
+
+While	O
+its	O
+clinical	O
+manifestations	O
+have	O
+been	O
+extensively	O
+studied	O
+,	O
+its	O
+pathogenesis	B-DISO
+is	O
+not	O
+yet	O
+fully	O
+understood	O
+.	O
+
+A	O
+limited	O
+number	O
+of	O
+autopsy	O
+studies	O
+have	O
+revealed	O
+that	O
+the	O
+lungs	B-ANAT
+and	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+are	O
+the	O
+organs	B-ANAT
+that	O
+sustain	O
+the	O
+most	O
+severe	O
+damage	O
+.	O
+
+We	O
+used	O
+the	O
+previously	O
+-	O
+isolated	O
+anti	B-PRGE
+-	I-PRGE
+DNA	I-PRGE
+scFv	I-PRGE
+,	O
+3D8	O
+,	O
+as	O
+a	O
+target	O
+protein	B-CHED
+.	O
+
+Complexes	O
+containing	O
+the	O
+mRNA	B-CHED
+pseudoknot	O
+exhibited	O
+a	O
+higher	O
+efficiency	O
+of	O
+affinity	O
+selection	O
+than	O
+that	O
+those	O
+without	O
+,	O
+indicating	O
+that	O
+the	O
+pseudoknot	O
+improves	O
+stability	O
+of	O
+the	O
+mRNA	B-PRGE
+-	I-PRGE
+ribosome	B-COMP
+-	I-PRGE
+antibody	B-COMP
+complex	O
+in	O
+a	O
+eukaryotic	O
+translation	O
+system	O
+.	O
+
+Thus	O
+,	O
+in	O
+order	B-SPEC
+to	O
+improve	O
+the	O
+efficiency	O
+of	O
+selection	O
+,	O
+this	O
+relatively	O
+short	O
+pseudoknot	O
+sequence	O
+could	O
+be	O
+incorporated	O
+into	O
+ribosome	B-COMP
+display	O
+.	O
+
+The	O
+abdomen	B-ANAT
+was	O
+the	O
+most	O
+common	O
+site	O
+of	O
+infections	B-DISO
+(	O
+72	O
+.	O
+3	O
+%),	O
+followed	O
+by	O
+lung	B-ANAT
+(	O
+52	O
+.	O
+8	O
+%).	O
+
+Other	O
+than	O
+the	O
+microbiological	O
+patterns	O
+,	O
+the	O
+incidence	O
+,	O
+mortality	O
+,	O
+and	O
+major	O
+characteristics	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+in	O
+Chinese	O
+surgical	O
+intensive	O
+care	O
+units	O
+are	O
+close	O
+to	O
+those	O
+documented	O
+in	O
+developed	O
+countries	O
+.	O
+
+When	O
+the	O
+cat	B-SPEC
+was	O
+gently	O
+restrained	O
+for	O
+blood	B-ANAT
+sampling	O
+,	O
+the	O
+skin	B-ANAT
+on	O
+the	O
+dorsal	O
+neck	B-ANAT
+tore	O
+,	O
+leaving	O
+a	O
+15	O
+cm	O
+x	O
+7	O
+cm	O
+flap	B-ANAT
+of	O
+skin	B-ANAT
+.	O
+
+Clinicopathological	O
+abnormalities	O
+included	O
+nonregenerative	O
+anaemia	B-DISO
+,	O
+hypoalbuminaemia	O
+,	O
+increased	O
+globulin	O
+concentration	O
+,	O
+and	O
+mildly	O
+elevated	O
+aspartate	B-PRGE
+aminotransferase	I-PRGE
+and	O
+alkaline	B-PRGE
+phosphatase	I-PRGE
+activities	O
+.	O
+
+Recently	O
+,	O
+horseshoe	B-SPEC
+bats	I-SPEC
+in	O
+the	O
+genus	B-SPEC
+Rhinolophus	I-SPEC
+have	O
+been	O
+identified	O
+as	O
+natural	O
+reservoir	O
+of	O
+SARS	B-DISO
+-	O
+like	O
+coronaviruses	O
+.	O
+
+13	O
+,	O
+17	O
+and	O
+13	O
+sera	B-COMP
+samples	O
+were	O
+collected	O
+in	O
+the	O
+5th	O
+,	O
+20th	O
+and	O
+35th	O
+month	O
+after	O
+onset	O
+.	O
+
+Results	O
+showed	O
+that	O
+despite	O
+the	O
+fact	O
+that	O
+the	O
+positive	O
+rates	O
+of	O
+ELISA	O
+antibody	B-COMP
+were	O
+100	O
+%,	O
+82	O
+.	O
+4	O
+%	O
+and	O
+84	O
+.	O
+6	O
+%	O
+respectively	O
+,	O
+the	O
+neutralizing	O
+antibody	B-COMP
+was	O
+still	O
+positive	O
+for	O
+all	O
+the	O
+samples	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Results	O
+of	O
+the	O
+study	O
+indicated	O
+that	O
+the	O
+neutralizing	O
+antibody	B-COMP
+of	O
+SARS	B-DISO
+cases	O
+could	O
+last	O
+for	O
+at	O
+least	O
+three	O
+years	O
+,	O
+but	O
+the	O
+sera	B-COMP
+specific	O
+antibody	B-COMP
+in	O
+SARS	B-DISO
+cases	O
+decreased	O
+gradually	O
+when	O
+time	O
+went	O
+by	O
+.	O
+
+A	O
+42	O
+-	O
+year	O
+-	O
+old	O
+kidney	B-ANAT
+transplant	I-ANAT
+recipient	O
+experienced	O
+on	O
+postoperative	O
+day	O
+10	O
+a	O
+dehiscence	B-PROC
+of	O
+the	O
+ureterovesical	O
+anastomosis	B-DISO
+,	O
+associated	O
+with	O
+a	O
+7	O
+-	O
+cm	O
+longitudinal	O
+tear	B-ANAT
+graft	B-ANAT
+on	O
+the	O
+lower	O
+pole	B-ANAT
+of	O
+the	O
+kidney	B-ANAT
+and	O
+an	O
+ureteral	O
+ischemia	B-DISO
+.	O
+
+A	O
+subtotal	O
+colectomy	O
+with	O
+Hartmann	O
+'	O
+s	O
+procedure	O
+was	O
+performed	O
+,	O
+but	O
+the	O
+patient	O
+died	B-PROC
+13	O
+days	O
+later	O
+of	O
+a	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Structural	O
+analysis	O
+of	O
+the	O
+inhibitor	B-CHED
+-	O
+bound	O
+X	O
+-	O
+ray	B-SPEC
+structure	O
+revealed	O
+high	O
+binding	B-FUNC
+affinity	O
+toward	O
+the	O
+enzyme	O
+.	O
+
+In	O
+-	O
+frame	O
+partial	O
+or	O
+complete	O
+deletions	O
+of	O
+nsp4	B-PRGE
+;	O
+deletions	O
+of	O
+TM1	O
+,	O
+-	O
+2	O
+,	O
+and	O
+-	O
+3	O
+;	O
+and	O
+alanine	B-CHED
+substitutions	O
+of	O
+multiple	O
+conserved	O
+,	O
+clustered	O
+,	O
+charged	O
+residues	O
+in	O
+nsp4	O
+resulted	O
+in	O
+viruses	B-SPEC
+that	O
+were	O
+nonrecoverable	O
+,	O
+viruses	B-SPEC
+highly	O
+impaired	B-DISO
+in	O
+growth	B-PROC
+and	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+and	O
+viruses	B-SPEC
+that	O
+were	O
+nearly	O
+wild	O
+type	O
+in	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+Primary	O
+coenzyme	O
+Q	O
+(	O
+10	O
+)	O
+(	O
+CoQ	B-CHED
+(	O
+10	O
+))	O
+deficiency	O
+includes	O
+a	O
+group	O
+of	O
+rare	O
+autosomal	B-COMP
+recessive	O
+disorders	O
+primarily	O
+characterized	O
+by	O
+neurological	O
+and	O
+muscular	B-ANAT
+symptoms	O
+.	O
+
+Rarely	O
+,	O
+glomerular	B-ANAT
+involvement	O
+has	O
+been	O
+reported	O
+.	O
+
+Of	O
+the	O
+14	O
+recipients	O
+,	O
+the	O
+data	O
+from	O
+11	O
+were	O
+evaluable	B-DISO
+for	O
+engraftment	B-PROC
+after	O
+TLI	O
+-	O
+based	O
+reconditioning	O
+because	O
+3	O
+adults	O
+died	O
+early	O
+(	O
+at	O
+Day	O
+2	O
+,	O
+5	O
+,	O
+and	O
+15	O
+)	O
+after	O
+the	O
+second	O
+transplantation	O
+of	O
+infectious	B-DISO
+complications	O
+.	O
+
+Engraftment	B-PROC
+in	O
+4	O
+adults	O
+was	O
+seen	O
+after	O
+a	O
+median	O
+of	O
+12	O
+days	O
+(	O
+range	O
+,	O
+10	O
+-	O
+18	O
+)	O
+and	O
+occurred	O
+after	O
+a	O
+median	O
+of	O
+10	O
+days	O
+(	O
+range	O
+,	O
+9	O
+-	O
+32	O
+)	O
+in	O
+the	O
+7	O
+children	O
+.	O
+
+Despite	O
+engraftment	B-PROC
+in	O
+the	O
+4	O
+remaining	O
+adults	O
+,	O
+1	O
+died	B-PROC
+of	O
+fatal	O
+graft	B-ANAT
+-	O
+vs	O
+.-	O
+host	B-COMP
+disease	O
+,	O
+1	O
+of	O
+infectious	B-DISO
+complications	O
+,	O
+1	O
+of	O
+disease	O
+relapse	B-DISO
+,	O
+and	O
+1	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+on	O
+a	O
+5	O
+-	O
+week	O
+-	O
+old	O
+male	O
+infant	O
+with	O
+recurrent	O
+respiratory	O
+distress	O
+since	O
+birth	B-PROC
+and	O
+congenital	O
+thymic	B-DISO
+hyperplasia	I-DISO
+.	O
+
+Seventeen	O
+HSS	B-DISO
+patients	O
+were	O
+hospitalized	O
+in	O
+a	O
+pediatric	O
+outpatient	O
+clinic	O
+of	O
+a	O
+major	O
+academic	O
+medical	O
+center	O
+in	O
+Hong	O
+Kong	O
+,	O
+between	O
+March	O
+20	O
+and	O
+May	O
+28	O
+,	O
+2003	O
+,	O
+during	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Discovery	O
+of	O
+herpesviruses	B-SPEC
+in	O
+bats	B-SPEC
+.	O
+
+The	O
+sequences	O
+of	O
+six	O
+bat	B-ENZY
+GHV	O
+were	O
+similarly	O
+related	O
+to	O
+members	O
+of	O
+the	O
+gammaherpesvirus	O
+genera	O
+Percavirus	B-SPEC
+and	O
+Rhadinovirus	B-SPEC
+.	O
+
+The	O
+seventh	O
+GHV	O
+was	O
+related	O
+to	O
+the	O
+porcine	B-SPEC
+lymphotropic	O
+herpesvirus	B-SPEC
+1	O
+(	O
+genus	B-SPEC
+Macavirus	B-SPEC
+).	O
+
+In	O
+COPD	O
+exacerbations	O
+with	O
+moderate	O
+to	O
+severe	O
+hypercapnic	B-DISO
+encephalopathy	I-DISO
+,	O
+the	O
+use	O
+of	O
+NPPV	O
+performed	O
+by	O
+an	O
+experienced	O
+team	O
+compared	O
+to	O
+CMV	B-SPEC
+leads	O
+to	O
+similar	O
+short	O
+and	O
+long	O
+-	O
+term	O
+survivals	O
+with	O
+a	O
+reduced	O
+nosocomial	B-DISO
+infection	I-DISO
+rate	O
+and	O
+duration	O
+of	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Cyclophosphamide	B-CHED
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Recently	O
+identified	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+are	O
+important	O
+pathogens	O
+in	O
+community	O
+-	O
+based	O
+illness	O
+in	O
+children	O
+,	O
+particularly	O
+in	O
+those	O
+who	O
+attend	O
+child	O
+care	O
+.	O
+
+Influenza	B-SPEC
+virus	I-SPEC
+and	O
+adenovirus	B-DISO
+illnesses	O
+had	O
+the	O
+greatest	O
+impact	O
+,	O
+with	O
+fever	B-PROC
+in	O
+more	O
+than	O
+three	O
+quarters	O
+and	O
+requiring	O
+,	O
+on	O
+average	O
+,	O
+>	O
+1	O
+local	O
+doctor	O
+visit	O
+per	O
+illness	O
+.	O
+
+TITLE	O
+:	O
+RNA	B-PROC
+interference	I-PROC
+and	O
+antiviral	B-CHED
+therapy	O
+.	O
+
+RNAi	B-PROC
+uses	O
+short	O
+double	O
+-	O
+stranded	O
+RNA	O
+(	O
+dsRNA	B-CHED
+)	O
+to	O
+trigger	O
+degradation	O
+or	O
+translation	B-PROC
+repression	O
+of	O
+homologous	B-PRGE
+RNA	I-PRGE
+targets	I-PRGE
+in	O
+a	O
+sequence	O
+-	O
+specific	O
+manner	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+cell	B-COMP
+-	O
+passage	O
+canine	O
+coronavirus	B-SPEC
+vaccine	O
+providing	O
+sterilising	O
+immunity	B-PROC
+.	O
+
+Two	O
+seronegative	O
+and	O
+virus	B-SPEC
+-	O
+negative	O
+dogs	B-SPEC
+served	O
+as	O
+unvaccinated	O
+controls	O
+.	O
+
+Faecal	B-ANAT
+samples	O
+were	O
+collected	O
+daily	O
+from	O
+the	O
+vaccinated	O
+dogs	B-SPEC
+after	O
+the	O
+first	O
+and	O
+second	O
+inoculations	O
+.	O
+
+In	O
+doing	O
+this	O
+,	O
+some	O
+unfounded	O
+beliefs	O
+related	O
+to	O
+influenza	B-DISO
+vaccines	O
+and	O
+antiviral	B-CHED
+treatment	O
+and	O
+prophylaxis	O
+are	O
+explored	O
+.	O
+
+TITLE	O
+:	O
+Cytosine	B-CHED
+deamination	O
+and	O
+selection	O
+of	O
+CpG	O
+suppressed	O
+clones	O
+are	O
+the	O
+two	O
+major	O
+independent	O
+biological	O
+forces	O
+that	O
+shape	O
+codon	O
+usage	O
+bias	O
+in	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Using	O
+the	O
+complete	O
+genome	O
+sequences	O
+of	O
+19	O
+coronavirus	B-SPEC
+genomes	O
+,	O
+we	O
+analyzed	O
+the	O
+codon	O
+usage	O
+bias	B-SPEC
+,	O
+dinucleotide	B-CHED
+relative	O
+abundance	O
+and	O
+cytosine	B-CHED
+deamination	O
+in	O
+coronavirus	B-SPEC
+genomes	O
+.	O
+
+,	O
+numerous	O
+researchers	O
+around	O
+the	O
+world	O
+have	O
+been	O
+working	O
+relentlessly	O
+to	O
+understand	O
+the	O
+biology	O
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+As	O
+in	O
+other	O
+coronaviruses	O
+,	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+crucial	O
+structural	O
+components	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Hence	O
+major	O
+attention	O
+has	O
+been	O
+focused	O
+on	O
+characterization	O
+of	O
+this	O
+protein	B-CHED
+.	O
+
+In	O
+addition	O
+,	O
+many	O
+reports	O
+also	O
+suggest	O
+that	O
+this	O
+protein	B-CHED
+interferes	O
+with	O
+different	O
+cellular	B-COMP
+pathways	B-PROC
+,	O
+thus	O
+implying	O
+it	O
+to	O
+be	O
+a	O
+key	O
+regulatory	O
+component	O
+of	O
+the	O
+virus	B-SPEC
+too	O
+.	O
+
+It	O
+was	O
+found	O
+that	O
+low	B-PRGE
+-	I-PRGE
+avidity	I-PRGE
+IgG	I-PRGE
+antibodies	I-PRGE
+were	O
+detected	O
+in	O
+15	O
+/	O
+15	O
+(	O
+100	O
+%),	O
+1	O
+/	O
+5	O
+(	O
+20	O
+%),	O
+and	O
+0	O
+/	O
+8	O
+(	O
+0	O
+%)	O
+serum	B-COMP
+samples	O
+collected	O
+during	O
+the	O
+first	O
+,	O
+third	O
+,	O
+and	O
+ninth	O
+months	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+,	O
+respectively	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+assays	O
+to	O
+detect	O
+low	B-PRGE
+-	I-PRGE
+avidity	I-PRGE
+antibody	I-PRGE
+may	O
+be	O
+useful	O
+for	O
+discriminating	O
+early	O
+from	O
+late	O
+antibody	B-PROC
+responses	I-PROC
+and	O
+also	O
+for	O
+distinguishing	O
+anamnestic	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+antibody	B-PROC
+responses	I-PROC
+from	O
+primary	O
+specific	O
+responses	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Healthcare	O
+workers	O
+who	O
+had	O
+been	O
+actively	O
+involved	O
+in	O
+SARS	B-DISO
+work	O
+were	O
+more	O
+""""	O
+positive	O
+""""	O
+in	O
+responding	O
+to	O
+the	O
+impending	O
+avian	B-SPEC
+influenza	B-DISO
+epidemic	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Historical	O
+sources	O
+for	O
+the	O
+use	O
+of	O
+Glycyrrhiza	B-SPEC
+species	B-SPEC
+include	O
+ancient	O
+manuscripts	O
+from	O
+China	O
+,	O
+India	O
+and	O
+Greece	O
+.	O
+
+Three	O
+samples	O
+from	O
+mother	O
+-	O
+child	O
+couples	O
+,	O
+maternal	O
+vaginal	B-ANAT
+(	O
+VM	O
+)	O
+and	O
+respiratory	O
+(	O
+RM	O
+)	O
+samples	O
+during	O
+labor	B-PROC
+;	O
+newborn	O
+gastric	B-ANAT
+sample	O
+(	O
+GNN	O
+),	O
+were	O
+assessed	O
+for	O
+viral	O
+analysis	O
+using	O
+real	O
+time	O
+RT	O
+-	O
+PCR	O
+for	O
+the	O
+detection	O
+of	O
+HCoV	O
+229	O
+-	O
+E	O
+and	O
+OC43	O
+.	O
+
+For	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+the	O
+percentages	O
+of	O
+seropositive	O
+individuals	O
+were	O
+45	O
+.	O
+2	O
+%	O
+for	O
+infants	O
+<	O
+2	O
+months	O
+old	O
+;	O
+11	O
+.	O
+1	O
+%	O
+for	O
+infants	O
+2	O
+-	O
+3	O
+months	O
+old	O
+;	O
+4	O
+.	O
+7	O
+%	O
+for	O
+infants	O
+4	O
+-	O
+5	O
+months	O
+old	O
+;	O
+28	O
+.	O
+6	O
+-	O
+40	O
+.	O
+0	O
+%	O
+for	O
+infants	O
+6	O
+-	O
+12	O
+months	O
+old	O
+;	O
+25	O
+.	O
+0	O
+-	O
+70	O
+.	O
+3	O
+%	O
+for	O
+individuals	O
+1	O
+-	O
+20	O
+years	O
+old	O
+.	O
+
+Infection	B-DISO
+with	O
+these	O
+viruses	B-SPEC
+is	O
+common	O
+in	O
+childhood	O
+though	O
+the	O
+prevalence	O
+of	O
+these	O
+viruses	O
+may	O
+vary	O
+from	O
+year	O
+to	O
+year	O
+.	O
+
+The	O
+complete	O
+N	O
+and	O
+E	O
+gene	O
+sequences	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+were	O
+amplified	O
+from	O
+clinical	O
+sample	O
+by	O
+RT	O
+-	O
+PCR	O
+,	O
+then	O
+were	O
+cloned	O
+into	O
+the	O
+pCF	O
+-	O
+T	O
+and	O
+pUCm	O
+-	O
+T	O
+vectors	O
+respectively	O
+and	O
+sequenced	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+recombinant	O
+plasmids	O
+pCF	O
+-	O
+T	O
+-	O
+8081	O
+N	O
+and	O
+pUCm	O
+-	O
+T	O
+-	O
+8081	O
+E	O
+were	O
+successfully	O
+constructed	O
+and	O
+sequenced	O
+,	O
+and	O
+the	O
+data	O
+predicted	O
+by	O
+bioinformatics	O
+are	O
+helpful	O
+for	O
+the	O
+further	O
+analysis	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Expression	B-PROC
+of	O
+recombinant	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+in	O
+vaccinia	B-SPEC
+virus	I-SPEC
+and	O
+analysis	O
+of	O
+its	O
+immunogenicity	O
+].	O
+
+HeLa	B-ANAT
+cells	I-ANAT
+infected	O
+with	O
+rWR	O
+-	O
+SARS	B-DISO
+-	O
+S	O
+also	O
+showed	O
+high	O
+sensitivity	O
+in	O
+detecting	O
+specific	O
+serum	B-COMP
+antibody	B-COMP
+by	O
+indirect	O
+immunofluoresence	O
+assay	O
+(	O
+IFA	O
+).	O
+
+The	O
+M	O
+genes	O
+of	O
+twenty	O
+isolates	O
+were	O
+composed	O
+of	O
+672	O
+to	O
+681	O
+nucleotides	B-CHED
+,	O
+encoding	O
+polypeptides	B-CHED
+of	O
+223	O
+to	O
+226	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+.	O
+
+There	O
+were	O
+deletions	O
+or	O
+insertions	O
+in	O
+the	O
+M	O
+gene	O
+of	O
+Chinese	O
+isolates	O
+at	O
+amino	B-CHED
+acid	I-CHED
+position	O
+2	O
+to	O
+6	O
+,	O
+leading	O
+to	O
+the	O
+loss	O
+or	O
+gain	O
+of	O
+a	O
+glycosylation	B-PROC
+site	O
+.	O
+
+Furthermore	O
+,	O
+recombination	O
+especially	O
+the	O
+recombination	B-PROC
+between	O
+field	O
+isolates	O
+and	O
+vaccine	O
+strains	O
+had	O
+been	O
+observed	O
+while	O
+comparing	O
+the	O
+phylogeny	O
+of	O
+M	O
+genes	O
+with	O
+those	O
+of	O
+S1	O
+and	O
+N	O
+genes	O
+.	O
+
+We	O
+estimated	O
+the	O
+duration	O
+time	O
+until	O
+10	O
+beds	O
+in	O
+negative	O
+pressure	O
+rooms	O
+in	O
+Chiyoda	O
+-	O
+ku	O
+,	O
+one	O
+of	O
+the	O
+23	O
+wards	O
+in	O
+Tokyo	O
+,	O
+were	O
+fully	O
+occupied	O
+with	O
+SARS	B-DISO
+-	O
+infected	O
+patients	O
+.	O
+
+There	O
+is	O
+a	O
+possibility	O
+that	O
+an	O
+epidemic	O
+will	O
+occur	O
+with	O
+the	O
+isolation	O
+of	O
+the	O
+index	O
+case	O
+even	O
+at	O
+early	O
+days	O
+if	O
+the	O
+infection	B-DISO
+is	O
+transmitted	B-DISO
+outside	O
+the	O
+hospital	O
+.	O
+
+With	O
+improved	O
+prenatal	O
+and	O
+obstetrical	O
+care	O
+and	O
+improved	O
+/	O
+less	O
+invasive	O
+ventilatory	O
+support	O
+,	O
+severe	O
+BPD	O
+is	O
+now	O
+rarely	O
+seen	O
+in	O
+infants	O
+born	O
+after	O
+32	O
+weeks	O
+gestational	O
+age	O
+,	O
+but	O
+it	O
+is	O
+still	O
+the	O
+most	O
+frequent	O
+complication	B-DISO
+to	O
+severe	O
+prematurity	O
+.	O
+
+Selected	O
+recent	O
+publications	O
+on	O
+BPD	B-DISO
+,	O
+with	O
+focus	O
+on	O
+etiology	O
+,	O
+prophylaxis	O
+,	O
+management	O
+and	O
+more	O
+recent	O
+diagnostic	O
+criteria	O
+form	O
+the	O
+basis	O
+for	O
+the	O
+article	O
+and	O
+discussions	O
+.	O
+
+As	O
+a	O
+consequence	O
+,	O
+present	O
+strategies	O
+for	O
+prevention	O
+or	O
+treatment	O
+of	O
+BPD	B-DISO
+have	O
+so	O
+far	O
+been	O
+of	O
+only	O
+limited	O
+success	O
+.	O
+
+ABSTRACT	O
+:	O
+Bacterial	O
+and	O
+viral	O
+upper	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+URI	O
+)	O
+produce	O
+highly	O
+variable	O
+clinical	O
+symptoms	O
+that	O
+cannot	O
+be	O
+used	O
+to	O
+identify	O
+the	O
+etiologic	O
+agent	O
+.	O
+
+The	O
+assay	O
+was	O
+developed	O
+to	O
+detect	O
+four	O
+bacterial	O
+pathogens	O
+(	O
+Bordetella	B-SPEC
+pertussis	I-SPEC
+,	O
+Streptococcus	B-SPEC
+pyogenes	I-SPEC
+,	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+)	O
+and	O
+9	O
+viral	O
+pathogens	O
+(	O
+adenovirus	B-DISO
+4	O
+,	O
+coronavirus	B-SPEC
+OC43	O
+,	O
+229E	O
+and	O
+HK	O
+,	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+parainfluenza	B-DISO
+types	O
+1	O
+,	O
+2	O
+,	O
+and	O
+3	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+mNsp15	O
+is	O
+required	O
+for	O
+optimal	O
+infection	B-DISO
+by	O
+MHV	B-SPEC
+.	O
+
+Here	O
+,	O
+the	O
+lymphopenia	O
+can	O
+be	O
+documented	O
+as	O
+an	O
+important	O
+characteristic	O
+of	O
+blood	B-ANAT
+picture	O
+in	O
+the	O
+patients	O
+with	O
+SARS	B-DISO
+or	O
+it	O
+can	O
+indicate	O
+that	O
+""""	O
+SARS	B-DISO
+is	O
+a	O
+viral	O
+-	O
+induced	O
+lymphopenia	B-DISO
+disease	O
+"""."	O
+
+TITLE	O
+:	O
+Cold	B-PROC
+antibody	B-COMP
+autoimmune	B-DISO
+hemolytic	I-DISO
+anemias	I-DISO
+.	O
+
+In	O
+contrast	O
+,	O
+there	O
+were	O
+significantly	O
+weaker	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+,	O
+as	O
+well	O
+as	O
+less	O
+antibody	B-PROC
+production	I-PROC
+than	O
+in	O
+the	O
+control	O
+groups	O
+.	O
+
+It	O
+is	O
+still	O
+tradition	O
+in	O
+certain	O
+parts	O
+of	O
+the	O
+Middle	O
+East	O
+and	O
+is	O
+gaining	O
+popularity	O
+in	O
+the	O
+United	O
+Kingdom	B-SPEC
+,	O
+the	O
+United	O
+States	O
+,	O
+and	O
+The	O
+Netherlands	O
+to	O
+curb	B-DISO
+excessive	O
+crying	O
+.	O
+
+To	O
+overcome	O
+the	O
+problems	O
+we	O
+encountered	O
+in	O
+the	O
+existing	O
+databases	O
+during	O
+comparative	O
+sequence	O
+analysis	O
+,	O
+we	O
+built	O
+a	O
+comprehensive	O
+database	O
+,	O
+CoVDB	O
+(	O
+http	O
+://	O
+covdb	O
+.	O
+microbiology	O
+.	O
+hku	O
+.	O
+hk	O
+),	O
+of	O
+annotated	O
+coronavirus	B-SPEC
+genes	O
+and	O
+genomes	O
+.	O
+
+We	O
+analyzed	O
+this	O
+cross	O
+-	O
+reactivity	O
+by	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+and	O
+Western	O
+blot	O
+analysis	O
+using	O
+specific	O
+antisera	O
+to	O
+animal	B-SPEC
+CoVs	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+SARS	B-DISO
+patient	O
+convalescent	O
+-	O
+phase	O
+or	O
+negative	O
+sera	B-COMP
+.	O
+
+The	O
+observed	O
+cross	O
+-	O
+reactivity	O
+is	O
+not	O
+a	O
+consequence	O
+of	O
+a	O
+higher	O
+level	O
+of	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+porcine	B-SPEC
+CoV	O
+nucleoproteins	O
+,	O
+because	O
+sequence	O
+comparisons	O
+indicated	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+has	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+similar	O
+to	O
+that	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+N	O
+protein	B-CHED
+and	O
+shares	O
+a	O
+higher	O
+level	O
+of	O
+identity	O
+with	O
+bovine	B-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+within	O
+the	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+region	O
+.	O
+
+We	O
+speculate	O
+that	O
+during	O
+natural	O
+infection	B-DISO
+,	O
+antibodies	B-COMP
+target	O
+similar	O
+short	O
+antigenic	O
+sites	O
+within	O
+the	O
+N	O
+proteins	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+porcine	B-PRGE
+group	I-PRGE
+1	I-PRGE
+CoVs	I-PRGE
+that	O
+are	O
+exposed	O
+to	O
+an	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+antibodies	B-COMP
+are	O
+necessary	O
+to	O
+prevent	O
+cytotoxic	B-ANAT
+T	I-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+escape	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+a	O
+coronavirus	O
+.	O
+
+The	O
+prevalence	O
+of	O
+the	O
+CD14	B-PRGE
+-	I-PRGE
+159CC	I-PRGE
+polymorphism	B-PROC
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+patients	O
+with	O
+severe	O
+SARS	B-DISO
+than	O
+in	O
+the	O
+those	O
+with	O
+mild	O
+SARS	B-DISO
+or	O
+controls	O
+(	O
+31	O
+%	O
+versus	O
+15	O
+%	O
+[	O
+mild	O
+SARS	B-DISO
+]	O
+or	O
+20	O
+%	O
+[	O
+controls	O
+];	O
+mild	O
+SARS	B-DISO
+:	O
+P	O
+=	O
+0	O
+.	O
+029	O
+;	O
+odds	O
+ratio	O
+,	O
+2	O
+.	O
+74	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+15	O
+to	O
+6	O
+.	O
+57	O
+;	O
+controls	O
+,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+;	O
+odds	O
+ratio	O
+,	O
+2	O
+.	O
+41	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+05	O
+to	O
+5	O
+.	O
+54	O
+),	O
+and	O
+both	O
+CD14	B-PRGE
+-	I-PRGE
+159CC	I-PRGE
+and	O
+FcgammaRIIA	O
+-	O
+RR131	O
+are	O
+risk	O
+genotypes	O
+for	O
+severe	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Virus	B-SPEC
+isolation	O
+,	O
+hemagglutination	B-PROC
+and	O
+receptor	O
+-	O
+destroying	O
+enzyme	B-FUNC
+activity	I-FUNC
+showed	O
+that	O
+the	O
+buffalo	O
+coronavirus	B-SPEC
+(	O
+BuCoV	O
+)	O
+is	O
+closely	O
+related	O
+to	O
+BCoV	O
+but	O
+possesses	B-DISO
+some	O
+different	O
+biological	O
+properties	O
+.	O
+
+However	O
+,	O
+the	O
+presence	O
+of	O
+T	B-ANAT
+lymphocytes	I-ANAT
+or	O
+anti	O
+-	O
+viral	O
+antibody	B-COMP
+can	O
+induce	O
+disease	O
+in	O
+infected	O
+immunodeficient	B-DISO
+mice	B-SPEC
+.	O
+
+The	O
+univariate	O
+analysis	O
+and	O
+multivariate	O
+analysis	O
+demonstrated	O
+that	O
+the	O
+clinical	O
+conditions	O
+such	O
+as	O
+elder	B-SPEC
+age	O
+,	O
+shock	O
+,	O
+dyspnea	B-DISO
+,	O
+abnormal	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+,	O
+hemopneumothorax	B-DISO
+,	O
+pulmonary	B-ANAT
+contusion	O
+,	O
+flail	B-DISO
+chest	I-DISO
+,	O
+coexisting	O
+pulmonary	B-DISO
+diseases	I-DISO
+,	O
+multiple	O
+abdominal	B-ANAT
+injury	O
+and	O
+high	O
+ISS	B-DISO
+score	O
+were	O
+the	O
+independent	O
+high	O
+risk	O
+factors	O
+related	O
+to	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+prevalence	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+among	O
+blunt	O
+trauma	O
+patients	O
+with	O
+severe	O
+traumatic	O
+brain	B-ANAT
+injury	O
+(	O
+TBI	O
+)	O
+and	O
+to	O
+determine	O
+if	O
+ARDS	B-DISO
+is	O
+associated	O
+with	O
+higher	O
+mortality	O
+,	O
+morbidity	O
+and	O
+worse	O
+discharge	B-ANAT
+outcome	O
+.	O
+
+Outcomes	O
+including	O
+complications	O
+,	O
+mortality	O
+and	O
+discharge	B-ANAT
+disability	O
+were	O
+compared	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+There	O
+were	O
+no	O
+differences	O
+between	O
+the	O
+two	O
+groups	O
+with	O
+respect	O
+to	O
+age	O
+,	O
+sex	O
+,	O
+ISS	B-DISO
+,	O
+Glasgow	O
+coma	B-DISO
+score	O
+(	O
+GCS	O
+),	O
+head	B-ANAT
+,	O
+abdomen	B-ANAT
+and	O
+extremity	B-ANAT
+AIS	B-DISO
+.	O
+
+The	O
+TBI	B-DISO
++	I-DISO
+ARDS	I-DISO
+group	O
+had	O
+significantly	O
+more	O
+patients	O
+with	O
+chest	B-ANAT
+AIS	B-DISO
+>	O
+or	O
+=	O
+3	O
+(	O
+57	O
+.	O
+1	O
+%	O
+versus	O
+32	O
+.	O
+1	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+03	O
+).	O
+
+During	O
+study	O
+year	O
+1	O
+,	O
+43	O
+(	O
+5	O
+.	O
+9	O
+%)	O
+of	O
+734	O
+patients	O
+with	O
+pneumonia	B-DISO
+had	O
+HCoV	O
+infections	B-DISO
+;	O
+72	O
+.	O
+1	O
+%	O
+of	O
+the	O
+infections	B-DISO
+were	O
+with	O
+OC43	O
+.	O
+
+ABSTRACT	O
+:	O
+Development	B-PROC
+of	O
+vaccines	O
+to	O
+prevent	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+limited	O
+by	O
+the	O
+lack	O
+of	O
+well	O
+-	O
+characterized	O
+animal	B-SPEC
+models	O
+.	O
+
+All	O
+of	O
+the	O
+ferrets	B-SPEC
+cleared	O
+the	O
+virus	B-SPEC
+by	O
+day	O
+14	O
+,	O
+1	O
+week	O
+earlier	O
+if	O
+vaccinated	O
+.	O
+
+The	O
+ferret	B-SPEC
+may	O
+provide	O
+another	O
+useful	O
+model	O
+for	O
+evaluating	O
+SARS	B-DISO
+vaccine	O
+safety	O
+and	O
+efficacy	O
+.	O
+
+These	O
+putative	O
+lung	B-ANAT
+stem	B-ANAT
+/	O
+progenitor	B-ANAT
+cells	I-ANAT
+can	O
+also	O
+be	O
+identified	O
+in	O
+some	O
+non	O
+-	O
+SARS	B-DISO
+individuals	O
+and	O
+can	O
+be	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+ex	O
+vivo	O
+.	O
+
+Infection	B-DISO
+of	O
+these	O
+cells	B-COMP
+may	O
+contribute	O
+to	O
+the	O
+loss	O
+of	O
+lung	B-ANAT
+repair	B-PROC
+capacity	O
+that	O
+leads	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+as	O
+clinically	O
+observed	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+airway	B-ANAT
+pressure	O
+limitation	O
+,	O
+acute	O
+cor	O
+pulmonale	O
+persists	O
+in	O
+a	O
+minority	O
+of	O
+ARDS	B-DISO
+patients	O
+.	O
+
+The	O
+diagnosis	O
+of	O
+DRESS	O
+was	O
+immediately	O
+suspected	O
+as	O
+the	O
+patient	O
+had	O
+been	O
+treated	O
+for	O
+acne	B-DISO
+with	O
+minocycline	B-CHED
+for	O
+28	O
+days	O
+,	O
+and	O
+IV	O
+corticosteroids	B-CHED
+(	O
+2	O
+mmg	O
+/	O
+kg	O
+/	O
+day	O
+)	O
+were	O
+initiated	O
+.	O
+
+The	O
+outcome	O
+was	O
+uncertain	O
+for	O
+the	O
+following	O
+6	O
+weeks	O
+with	O
+serious	O
+disturbance	O
+of	O
+hepatic	O
+and	O
+renal	B-PROC
+function	I-PROC
+.	O
+
+Respiratory	O
+physicians	O
+should	O
+be	O
+aware	O
+of	O
+this	O
+syndrome	B-DISO
+as	O
+lung	B-ANAT
+involvement	O
+can	O
+be	O
+serious	O
+and	O
+may	O
+precede	O
+cutaneous	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+Factors	O
+associated	O
+with	O
+critical	O
+-	O
+care	O
+healthcare	O
+workers	O
+'	O
+adherence	O
+to	O
+recommended	O
+barrier	O
+precautions	O
+during	O
+the	O
+Toronto	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+.	O
+
+All	O
+patients	O
+with	O
+SARS	B-DISO
+who	O
+required	O
+intubation	O
+during	O
+the	O
+Toronto	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+.	O
+
+The	O
+8a	O
+polypeptide	B-CHED
+is	O
+likely	O
+to	O
+remain	O
+in	O
+the	O
+cytoplasm	B-COMP
+,	O
+as	O
+it	O
+is	O
+too	O
+small	O
+for	O
+its	O
+signal	O
+sequence	O
+to	O
+function	O
+and	O
+will	O
+therefore	O
+be	O
+directly	O
+released	O
+from	O
+the	O
+ribosome	B-COMP
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+the	O
+phosphorylated	O
+form	O
+of	O
+the	O
+IBV	B-SPEC
+N	O
+protein	B-CHED
+plays	O
+a	O
+role	O
+in	O
+virus	B-SPEC
+biology	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+main	I-PRGE
+proteinase	I-PRGE
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+),	I-PRGE
+is	O
+widely	O
+considered	O
+to	O
+be	O
+a	O
+major	O
+drug	O
+target	O
+for	O
+the	O
+development	B-PROC
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+treatment	O
+.	O
+
+The	O
+docking	B-PROC
+results	O
+suggest	O
+two	O
+major	O
+modes	O
+for	O
+the	O
+initial	O
+binding	B-FUNC
+of	O
+these	O
+inhibitors	B-CHED
+to	O
+the	O
+active	O
+site	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+).	I-PRGE
+
+Reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+on	O
+the	O
+partial	O
+ORF3	O
+gene	O
+including	O
+51	O
+nucleotide	B-CHED
+deletions	O
+revealed	O
+that	O
+all	O
+PEDVs	O
+fell	O
+into	O
+two	O
+types	O
+,	O
+wild	O
+-	O
+and	O
+attenuated	O
+-	O
+type	O
+PEDVs	O
+.	O
+
+The	O
+virtue	O
+ethics	O
+movement	B-PROC
+stresses	O
+the	O
+need	O
+to	O
+consider	O
+not	O
+only	O
+rules	O
+and	O
+outcomes	O
+but	O
+also	O
+the	O
+character	O
+of	O
+the	O
+individual	O
+(	O
+s	O
+)	O
+involved	O
+.	O
+
+Previously	O
+,	O
+it	O
+was	O
+thought	O
+that	O
+direct	O
+transmission	B-PROC
+of	I-PROC
+virus	I-PROC
+from	O
+bird	B-SPEC
+to	O
+human	B-SPEC
+could	O
+not	O
+take	O
+place	O
+,	O
+but	O
+it	O
+came	O
+to	O
+be	O
+true	O
+in	O
+1997	O
+,	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+In	O
+severe	O
+cases	O
+death	B-PROC
+occurs	O
+due	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiple	O
+organ	B-ANAT
+involvement	O
+.	O
+
+Herein	O
+,	O
+we	O
+show	O
+that	O
+""""	O
+immature	O
+""""	O
+F4	O
+/	O
+80	O
+(+)	O
+Ly	O
+-	O
+6C	O
+(	O
+hi	O
+)	O
+monocytes	B-ANAT
+are	O
+the	O
+first	O
+cells	B-COMP
+,	O
+along	O
+with	O
+neutrophils	B-ANAT
+,	O
+to	O
+enter	O
+the	O
+MHV	B-SPEC
+-	O
+JHM	O
+-	O
+infected	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+).	O
+
+Furthermore	O
+,	O
+CDllc	O
+(+)	O
+and	O
+F4	O
+/	O
+80	O
+(+)	O
+macrophages	B-ANAT
+and	O
+microglia	B-ANAT
+are	O
+localized	O
+to	O
+areas	O
+of	O
+demyelination	B-DISO
+,	O
+in	O
+some	O
+instances	O
+directly	O
+associated	O
+with	O
+damaged	O
+axons	B-COMP
+.	O
+
+Complete	O
+protection	O
+by	O
+IBV	B-SPEC
+vaccination	O
+was	O
+provided	O
+by	O
+the	O
+homologous	O
+strain	O
+but	O
+sufficient	O
+respiratory	O
+protection	O
+was	O
+not	O
+provided	O
+by	O
+the	O
+commercial	O
+vaccines	O
+.	O
+
+A	O
+major	O
+nosocomial	O
+hMPV	B-SPEC
+outbreak	O
+involving	O
+HCWs	O
+occurred	O
+during	O
+the	O
+early	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+The	O
+median	O
+and	O
+mean	O
+amount	O
+subjects	O
+reported	O
+being	O
+willing	O
+to	O
+pay	O
+for	O
+a	O
+SARS	B-DISO
+vaccine	O
+was	O
+US	O
+$	O
+1762	O
+and	O
+US	O
+$	O
+720	O
+,	O
+respectively	O
+.	O
+
+We	O
+found	O
+that	O
+they	O
+efficiently	O
+inhibited	O
+SCoV	O
+infection	B-DISO
+of	O
+the	O
+protease	O
+-	O
+mediated	O
+cell	B-COMP
+surface	I-COMP
+pathway	B-PROC
+but	O
+had	O
+little	O
+effect	O
+on	O
+the	O
+endosomal	O
+pathway	B-PROC
+.	O
+
+This	O
+finding	O
+suggests	O
+that	O
+sHRPs	O
+may	O
+effectively	O
+prevent	O
+infection	O
+in	O
+the	O
+lungs	B-ANAT
+,	O
+where	O
+SCoV	O
+infection	B-DISO
+could	O
+be	O
+enhanced	O
+by	O
+proteases	O
+produced	O
+in	O
+this	O
+organ	B-ANAT
+.	O
+
+This	O
+is	O
+the	O
+first	O
+observation	O
+that	O
+HRP	B-PRGE
+exhibits	O
+different	O
+effects	O
+on	O
+virus	B-SPEC
+that	O
+takes	O
+the	O
+endosomal	O
+pathway	B-PROC
+and	O
+virus	B-SPEC
+that	O
+enters	O
+directly	O
+from	O
+the	O
+cell	B-COMP
+surface	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pathogenesis	B-DISO
+and	O
+optimal	O
+treatments	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+are	O
+unclear	O
+,	O
+although	O
+corticosteroids	B-CHED
+were	O
+used	O
+to	O
+reduce	O
+lung	B-ANAT
+and	O
+systemic	O
+inflammation	B-DISO
+.	O
+
+Because	O
+the	O
+pulmonary	B-DISO
+pathology	I-DISO
+of	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	B-SPEC
+)	O
+in	O
+pigs	B-SPEC
+resembles	O
+SARS	B-DISO
+,	O
+we	O
+used	O
+PRCV	B-SPEC
+as	O
+a	O
+model	O
+to	O
+clarify	O
+the	O
+effects	O
+of	O
+the	O
+corticosteroid	B-CHED
+dexamethasone	B-CHED
+(	O
+DEX	O
+)	O
+on	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)-	O
+induced	O
+pneumonia	B-DISO
+.	O
+
+In	O
+PRCV	O
+/	O
+DEX	O
+pigs	B-SPEC
+,	O
+significantly	O
+milder	O
+pneumonia	B-DISO
+,	O
+fewer	O
+PRCV	O
+-	O
+positive	O
+cells	B-COMP
+,	O
+and	O
+lower	O
+viral	O
+RNA	O
+titers	O
+were	O
+present	O
+in	O
+lungs	B-ANAT
+early	O
+at	O
+PID	B-DISO
+2	O
+;	O
+however	O
+,	O
+at	O
+PID	B-DISO
+4	O
+,	O
+10	O
+,	O
+and	O
+21	O
+,	O
+severe	O
+bronchointerstitial	O
+pneumonia	B-DISO
+,	O
+significantly	O
+higher	O
+numbers	O
+of	O
+PRCV	O
+-	O
+positive	O
+cells	B-COMP
+,	O
+and	O
+higher	O
+viral	O
+RNA	O
+titers	O
+were	O
+observed	O
+compared	O
+to	O
+results	O
+for	O
+PRCV	O
+/	O
+PBS	B-DISO
+pigs	B-SPEC
+.	O
+
+The	O
+six	O
+case	O
+-	O
+control	O
+studies	O
+suggested	O
+that	O
+implementing	O
+barriers	O
+to	O
+transmission	O
+,	O
+isolation	O
+,	O
+and	O
+hygienic	O
+measures	O
+are	O
+effective	O
+at	O
+containing	O
+respiratory	O
+virus	B-SPEC
+epidemics	O
+.	O
+
+TITLE	O
+:	O
+Trauma	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+differs	O
+clinically	O
+and	O
+biologically	O
+from	O
+acute	O
+lung	B-ANAT
+injury	O
+due	O
+to	O
+other	O
+clinical	O
+disorders	O
+.	O
+
+Compared	O
+with	O
+patients	O
+with	O
+other	O
+clinical	O
+risks	O
+for	O
+lung	B-ANAT
+injury	O
+,	O
+trauma	O
+patients	O
+were	O
+younger	O
+and	O
+generally	O
+less	O
+acutely	O
+and	O
+chronically	B-DISO
+ill	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+CXCL2	B-PRGE
+polymorphism	B-PROC
+is	O
+associated	O
+with	O
+better	O
+outcomes	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+An	O
+exploratory	O
+analysis	O
+of	O
+the	O
+effect	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+on	O
+mortality	O
+showed	O
+a	O
+relative	O
+risk	O
+of	O
+2	O
+.	O
+60	O
+in	O
+the	O
+HC	O
+group	O
+(	O
+p	O
+=	O
+.	O
+0004	O
+),	O
+while	O
+in	O
+the	O
+nonhomozygote	O
+carriers	O
+(	O
+NHC	B-DISO
+)	O
+group	O
+the	O
+relative	O
+risk	O
+was	O
+3	O
+.	O
+34	O
+(	O
+p	O
+=	O
+.	O
+0001	O
+).	O
+
+Our	O
+data	O
+suggest	O
+that	O
+a	O
+tandem	O
+repeat	O
+polymorphism	B-PROC
+(	O
+AC	O
+)	O
+n	O
+at	O
+position	O
+-	O
+665	O
+in	O
+the	O
+CXCL2	B-PRGE
+gene	I-PRGE
+may	O
+be	O
+an	O
+independent	O
+predictor	O
+of	O
+mortality	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Six	O
+-	O
+month	O
+survival	O
+of	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+:	O
+prospective	O
+cohort	O
+study	O
+.	O
+
+Multiple	O
+logistic	O
+regression	O
+analysis	O
+identified	O
+underlying	O
+Charlson	O
+comorbidity	O
+score	O
+(	O
+odds	O
+ratio	O
+3	O
+.	O
+11	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+2	O
+.	O
+01	O
+-	O
+5	O
+.	O
+05	O
+)	O
+for	O
+each	O
+point	O
+increase	O
+,	O
+transfer	O
+admission	O
+from	O
+the	O
+floor	O
+or	O
+outside	O
+hospital	O
+(	O
+odds	O
+ratio	O
+3	O
+.	O
+75	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+41	O
+-	O
+10	O
+.	O
+99	O
+),	O
+day	O
+3	O
+cardiovascular	B-ANAT
+failure	O
+(	O
+odds	O
+ratio	O
+3	O
+.	O
+30	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+19	O
+-	O
+9	O
+.	O
+92	O
+),	O
+and	O
+day	O
+3	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+(	O
+odds	O
+ratio	O
+0	O
+.	O
+94	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+0	O
+.	O
+88	O
+-	O
+0	O
+.	O
+99	O
+)	O
+as	O
+significant	O
+predictors	O
+of	O
+6	O
+-	O
+month	O
+mortality	O
+.	O
+
+With	O
+the	O
+implementation	O
+of	O
+recent	O
+advances	O
+in	O
+mechanical	O
+ventilation	O
+and	O
+supportive	O
+care	O
+,	O
+premorbid	O
+condition	B-DISO
+is	O
+the	O
+most	O
+important	O
+determinant	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+survival	O
+.	O
+
+However	O
+,	O
+in	O
+contrast	O
+to	O
+control	O
+animals	B-SPEC
+,	O
+animals	B-SPEC
+with	O
+lower	O
+tidal	O
+volumes	O
+and	O
+interventional	O
+lung	B-ANAT
+assist	O
+had	O
+severe	O
+ventilation	O
+/	O
+perfusion	O
+mismatch	O
+,	O
+as	O
+indicated	O
+by	O
+increased	O
+perfusion	O
+to	O
+lung	B-ANAT
+areas	O
+with	O
+a	O
+low	O
+ventilation	O
+/	O
+perfusion	O
+ratio	O
+(	O
+p	O
+<	O
+.	O
+05	O
+).	O
+
+Rapid	O
+progress	O
+was	O
+made	O
+in	O
+describing	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+,	O
+evolution	B-PROC
+and	O
+lifecycle	O
+.	O
+
+Only	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+recently	O
+been	O
+introduced	O
+to	O
+the	O
+human	B-SPEC
+population	O
+;	O
+the	O
+other	O
+two	O
+have	O
+been	O
+circulating	O
+in	O
+humans	B-SPEC
+for	O
+a	O
+long	O
+time	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+Orf3a	O
+protein	B-CHED
+interacts	O
+with	O
+caveolin	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+orf3a	O
+(	O
+also	O
+called	O
+X1	O
+or	O
+U274	O
+)	O
+gene	O
+is	O
+the	O
+largest	O
+unique	O
+open	O
+reading	O
+frame	O
+in	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+genome	O
+and	O
+has	O
+been	O
+proposed	O
+to	O
+encode	O
+a	O
+protein	B-CHED
+with	O
+three	O
+transmembrane	B-COMP
+domains	O
+and	O
+a	O
+large	O
+cytoplasmic	B-ANAT
+domain	I-ANAT
+.	O
+
+By	O
+using	O
+various	O
+biochemical	O
+,	O
+biophysical	O
+and	O
+genetic	O
+techniques	O
+,	O
+interaction	O
+of	O
+the	O
+3a	O
+protein	B-CHED
+with	O
+caveolin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+is	O
+demonstrated	O
+.	O
+
+Illness	O
+usually	O
+is	O
+characterized	O
+by	O
+intermittent	O
+periods	B-PROC
+of	O
+fever	B-PROC
+,	O
+fatigue	B-DISO
+,	O
+and	O
+muscle	B-DISO
+aches	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+report	O
+describes	O
+a	O
+case	O
+of	O
+feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+)	O
+in	O
+a	O
+castrated	O
+cat	B-SPEC
+which	O
+first	O
+presented	O
+with	O
+the	O
+unusual	O
+sign	O
+of	O
+priapism	B-DISO
+.	O
+
+One	O
+month	O
+after	O
+the	O
+first	O
+examination	O
+,	O
+the	O
+cat	B-SPEC
+died	B-PROC
+.	O
+
+At	O
+necropsy	O
+,	O
+histopathological	O
+evaluation	O
+of	O
+organs	B-ANAT
+showed	O
+inflammatory	O
+granulomatous	B-DISO
+lesions	I-DISO
+compatible	O
+with	O
+non	O
+-	O
+effusive	O
+FIP	B-DISO
+and	O
+coronavirus	B-SPEC
+-	O
+specific	O
+polymerase	O
+chain	O
+reaction	O
+confirmed	O
+the	O
+diagnosis	O
+.	O
+
+Semen	B-ANAT
+was	O
+collected	O
+daily	O
+from	O
+17	O
+to	O
+27	O
+weeks	O
+of	O
+age	O
+,	O
+and	O
+semen	B-ANAT
+quality	O
+was	O
+assessed	O
+frequently	O
+by	O
+analysing	O
+sperm	O
+concentration	O
+,	O
+viability	O
+,	O
+motility	B-PROC
+,	O
+and	O
+ability	O
+to	O
+reach	B-PROC
+and	O
+interact	O
+with	O
+the	O
+ovum	B-ANAT
+in	O
+vivo	O
+.	O
+
+Acrosome	B-COMP
+damage	O
+was	O
+increased	O
+in	O
+vaccinated	O
+cockerels	O
+in	O
+week	O
+22	O
+,	O
+and	O
+decreased	O
+in	O
+weeks	O
+25	O
+and	O
+27	O
+when	O
+compared	O
+to	O
+controls	O
+,	O
+which	O
+correlate	O
+to	O
+the	O
+period	O
+of	O
+epididymal	B-ANAT
+stone	B-ANAT
+development	B-PROC
+.	O
+
+There	O
+were	O
+no	O
+differences	O
+across	O
+treatment	O
+groups	O
+in	O
+sperm	B-PROC
+mobility	I-PROC
+through	O
+Accudenz	O
+or	O
+in	O
+numbers	O
+of	O
+sperm	B-ANAT
+holes	O
+in	O
+perivitelline	O
+membranes	B-ANAT
+of	O
+eggs	O
+following	O
+insemination	B-PROC
+with	O
+semen	B-ANAT
+from	O
+27	O
+-	O
+week	O
+-	O
+old	O
+cockerels	O
+.	O
+
+No	O
+differences	O
+were	O
+observed	O
+in	O
+viability	O
+or	O
+acrosome	B-COMP
+integrity	O
+between	O
+cockerels	O
+with	O
+and	O
+without	O
+epididymal	B-ANAT
+stones	O
+within	O
+treatment	O
+groups	O
+.	O
+
+Diagnosis	O
+is	O
+based	O
+on	O
+a	O
+finding	O
+of	O
+elevated	O
+serum	B-COMP
+levels	O
+of	O
+components	O
+that	O
+are	O
+normally	O
+found	O
+within	O
+the	O
+muscle	B-ANAT
+cell	I-ANAT
+,	O
+chiefly	O
+muscle	B-ANAT
+enzymes	O
+and	O
+myoglobin	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+changes	O
+of	O
+health	O
+related	O
+behavior	O
+and	O
+influencing	O
+factor	O
+during	O
+and	O
+after	O
+the	O
+prevalence	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+as	O
+to	O
+providing	O
+evidence	O
+for	O
+inducing	O
+public	O
+health	O
+related	O
+behavior	O
+to	O
+cope	O
+with	O
+the	O
+emergent	O
+infectious	B-DISO
+public	O
+health	O
+hazards	O
+.	O
+
+However	O
+,	O
+the	O
+induction	O
+of	O
+cellular	B-COMP
+RNA	B-PROC
+synthesis	I-PROC
+in	O
+growing	O
+NIH	B-ANAT
+3T3	I-ANAT
+cells	I-ANAT
+did	O
+not	O
+result	O
+in	O
+an	O
+increase	O
+of	O
+either	O
+viral	O
+RNA	O
+amplification	B-DISO
+or	O
+CPE	O
+.	O
+
+However	O
+,	O
+toxin	O
+positive	O
+stools	B-ANAT
+were	O
+more	O
+common	O
+among	O
+nondiarrheic	O
+calves	O
+,	O
+but	O
+diarrheic	O
+calves	O
+were	O
+nearly	O
+twice	O
+as	O
+likely	O
+to	O
+be	O
+culture	O
+positive	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+total	O
+RNA	O
+was	O
+isolated	O
+,	O
+extracted	O
+from	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+WHU	I-PRGE
+strain	O
+and	O
+converted	O
+into	O
+cDNA	O
+.	O
+
+In	O
+vitro	O
+cleavage	B-PROC
+was	O
+performed	O
+using	O
+an	O
+in	O
+vitro	O
+transcribed	O
+5	O
+'	O
+UTR	O
+RNA	O
+substrate	O
+.	O
+
+High	O
+-	O
+frequency	O
+oscillation	O
+(	O
+HFO	O
+)	O
+exerts	B-PROC
+beneficial	O
+effects	O
+on	O
+gas	B-ENZY
+exchange	O
+in	O
+neonates	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+We	O
+examined	O
+whether	O
+continuous	O
+negative	O
+extrathoracic	O
+pressure	O
+(	O
+CNEP	O
+)	O
+combined	O
+with	O
+HFO	O
+would	O
+be	O
+effective	O
+for	O
+treating	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+an	O
+animal	B-SPEC
+model	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Changes	O
+and	O
+significance	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+fibrinogen	B-COMP
+level	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+The	O
+mean	O
+value	O
+of	O
+plasma	B-ANAT
+fibrinogen	B-COMP
+(	O
+x	O
++/-	O
+
+theses	O
+results	O
+suggested	O
+that	O
+elevation	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+fibrinogen	B-COMP
+in	O
+SARS	B-DISO
+patients	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+development	B-PROC
+and	O
+progress	O
+of	O
+the	O
+disease	O
+and	O
+its	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Mice	B-SPEC
+transgenic	O
+for	O
+human	B-SPEC
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+provide	O
+a	O
+model	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+The	O
+hACE2	B-PRGE
+gene	I-PRGE
+was	O
+expressed	B-PROC
+in	O
+lung	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+and	O
+intestine	B-ANAT
+.	O
+
+We	O
+also	O
+evaluated	O
+the	O
+responses	O
+of	O
+wild	O
+-	O
+type	O
+and	O
+transgenic	B-SPEC
+mice	I-SPEC
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+inoculation	O
+.	O
+
+The	O
+molecular	O
+cause	O
+of	O
+the	O
+unusually	O
+high	O
+human	B-SPEC
+pathogenicity	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+still	O
+unknown	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+syndrome	B-DISO
+with	O
+preoperative	O
+chronomodulated	O
+chemoradiotherapy	O
+in	O
+patients	O
+with	O
+esophageal	O
+cancer	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+showed	O
+that	O
+mutation	O
+of	O
+the	O
+dimer	O
+-	O
+interface	O
+residue	O
+Gly	B-CHED
+-	O
+11	O
+to	O
+alanine	B-CHED
+entirely	O
+abolished	O
+the	O
+activity	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+Five	O
+active	O
+metal	B-CHED
+-	O
+conjugated	O
+inhibitors	B-CHED
+(	O
+PMA	B-CHED
+,	O
+TDT	B-FUNC
+,	O
+EPDTC	O
+,	O
+JMF1586	O
+and	O
+JMF1600	O
+)	O
+bound	O
+with	O
+the	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+were	O
+analyzed	O
+crystallographically	O
+.	O
+
+For	O
+anti	O
+-	O
+SARS	B-DISO
+drug	O
+design	O
+,	O
+this	O
+Zn	O
+(	O
+2	O
++)-	O
+centered	O
+coordination	B-PROC
+pattern	O
+would	O
+serve	O
+as	O
+a	O
+starting	O
+platform	O
+for	O
+inhibitor	B-CHED
+optimization	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+mechanisms	O
+of	O
+primary	O
+and	O
+secondary	O
+mucosal	B-PROC
+immunity	I-PROC
+using	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	O
+as	O
+a	O
+model	O
+system	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Bad	O
+bats	B-SPEC
+?].	O
+
+Probably	O
+because	O
+of	O
+their	O
+particular	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+bats	B-SPEC
+can	O
+be	O
+considered	O
+an	O
+important	O
+reservoir	O
+for	O
+new	O
+emerging	O
+viral	B-DISO
+diseases	I-DISO
+like	O
+SARS	B-DISO
+-	O
+Coronavirus	B-SPEC
+,	O
+Marburg	O
+fever	B-PROC
+,	O
+Ebola	O
+fever	B-PROC
+and	O
+Nipah	B-SPEC
+virus	I-SPEC
+encephalitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Federal	O
+,	O
+provincial	O
+and	O
+municipal	O
+leaders	O
+in	O
+Canada	O
+have	O
+adopted	O
+a	O
+culture	O
+of	O
+preparedness	O
+with	O
+the	O
+development	B-PROC
+and	O
+update	O
+of	O
+emergency	B-DISO
+plans	O
+in	O
+anticipation	O
+of	O
+different	O
+types	O
+of	O
+disasters	O
+.	O
+
+As	O
+evident	O
+during	O
+the	O
+2003	O
+global	O
+outbreak	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+it	O
+is	O
+important	O
+to	O
+provide	O
+support	O
+for	O
+health	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+who	O
+are	O
+vulnerable	O
+during	O
+infectious	B-DISO
+outbreak	O
+scenarios	O
+.	O
+
+RESULTS	O
+:	O
+Emergency	B-DISO
+plans	O
+were	O
+comprised	O
+of	O
+a	O
+predominance	O
+of	O
+informational	O
+and	O
+instrumental	O
+supports	O
+,	O
+yet	O
+few	O
+emotional	O
+or	O
+social	O
+support	O
+mechanisms	O
+.	O
+
+Z	B-PRGE
+protein	I-PRGE
+was	O
+used	O
+as	O
+antigen	B-CHED
+to	O
+immunize	O
+the	O
+rabbit	B-SPEC
+and	O
+anti	B-PRGE
+-	I-PRGE
+Z	I-PRGE
+sera	I-PRGE
+was	O
+collected	O
+.	O
+
+Then	O
+the	O
+antigenic	O
+property	O
+of	O
+Z	B-PRGE
+protein	I-PRGE
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+was	O
+analyzed	O
+by	O
+dot	O
+-	O
+blot	O
+and	O
+ELISA	O
+assay	O
+.	O
+
+ELISA	O
+analysis	O
+indicated	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antigen	B-CHED
+prepared	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+lysates	O
+can	O
+be	O
+detected	O
+by	O
+anti	B-PRGE
+-	I-PRGE
+Z	I-PRGE
+sera	I-PRGE
+.	O
+
+This	O
+study	O
+was	O
+conducted	O
+to	O
+determine	O
+whether	O
+iNO	O
+therapy	O
+improves	O
+oxygenation	B-PROC
+in	O
+such	O
+infants	O
+.	O
+
+Rotavirus	B-SPEC
+was	O
+the	O
+only	O
+virus	B-SPEC
+detected	O
+prior	O
+to	O
+placement	O
+(	O
+7	O
+of	O
+16	O
+samples	O
+examined	O
+).	O
+
+All	O
+of	O
+the	O
+commercial	O
+flocks	O
+were	O
+positive	O
+for	O
+rotavirus	B-SPEC
+and	O
+astrovirus	O
+from	O
+2	O
+until	O
+6	O
+wk	O
+of	O
+age	O
+,	O
+and	O
+most	O
+were	O
+intermittently	O
+positive	O
+until	O
+12	O
+wk	O
+of	O
+age	O
+,	O
+when	O
+the	O
+birds	B-SPEC
+were	O
+processed	O
+.	O
+
+Intestinal	B-ANAT
+samples	O
+collected	O
+at	O
+1	O
+,	O
+2	O
+,	O
+and	O
+3	O
+wk	O
+of	O
+age	O
+from	O
+these	O
+turkeys	B-SPEC
+were	O
+free	O
+of	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+disease	B-DISO
+progression	I-DISO
+in	O
+vaccinated	O
+chickens	B-SPEC
+after	O
+challenge	O
+was	O
+evaluated	O
+in	O
+a	O
+single	O
+commercial	O
+line	O
+of	O
+layer	B-ANAT
+chickens	B-SPEC
+presenting	O
+two	O
+different	O
+major	B-PROC
+histocompatibility	I-PROC
+complex	I-PROC
+(	O
+MHC	B-PROC
+)	O
+B	O
+complex	O
+genotypes	O
+.	O
+
+TITLE	O
+:	O
+Sequence	O
+analysis	O
+of	O
+the	O
+S1	B-PRGE
+glycoprotein	I-PRGE
+gene	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+:	O
+identification	O
+of	O
+a	O
+novel	O
+phylogenetic	O
+group	O
+in	O
+Korea	O
+.	O
+
+However	O
+,	O
+a	O
+mild	O
+inflammatory	B-DISO
+response	I-DISO
+in	O
+local	O
+injection	O
+site	O
+and	O
+a	O
+moderate	O
+immune	B-PROC
+response	I-PROC
+against	O
+this	O
+antibody	B-COMP
+in	O
+the	O
+successively	O
+injected	O
+animals	B-SPEC
+were	O
+observed	O
+,	O
+which	O
+however	O
+recovered	O
+3	O
+weeks	O
+after	O
+the	O
+last	O
+injection	O
+.	O
+
+The	O
+significant	O
+difference	O
+in	O
+clinical	O
+presentation	O
+between	O
+the	O
+three	O
+coronavirus	B-SPEC
+groups	O
+was	O
+the	O
+very	O
+low	O
+association	O
+between	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illness	O
+and	O
+HKU1	O
+detection	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+recent	O
+advances	O
+in	O
+intensive	O
+care	O
+medicine	O
+,	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+its	O
+more	O
+severe	O
+form	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+pose	O
+major	O
+therapeutic	O
+problems	O
+.	O
+
+TITLE	O
+:	O
+Safety	O
+and	O
+immunogenicity	O
+from	O
+a	O
+phase	O
+I	O
+trial	O
+of	O
+inactivated	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+vaccine	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+on	O
+bystander	O
+willingness	O
+to	O
+perform	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+(	O
+CPR	B-ENZY
+)--	O
+is	O
+compression	O
+-	O
+only	O
+preferred	O
+to	O
+standard	O
+CPR	B-ENZY
+?	O
+
+The	O
+preferred	O
+type	O
+of	O
+SCPR	O
+in	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+era	B-CHED
+was	O
+assessed	O
+.	O
+
+Persons	O
+who	O
+attended	O
+a	O
+CPR	B-ENZY
+course	O
+from	O
+January	O
+2000	O
+through	O
+February	O
+2003	O
+answered	O
+a	O
+structured	O
+questionnaire	O
+.	O
+
+TITLE	O
+:	O
+Interaction	O
+of	O
+a	O
+peptide	B-CHED
+from	O
+the	O
+pre	O
+-	O
+transmembrane	B-COMP
+domain	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+with	O
+phospholipid	B-CHED
+membranes	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+envelope	B-COMP
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+,	O
+a	O
+Class	B-SPEC
+I	O
+viral	O
+fusion	O
+protein	B-CHED
+,	O
+is	O
+responsible	O
+for	O
+the	O
+fusion	O
+between	O
+the	O
+membranes	B-ANAT
+of	O
+the	O
+virus	B-SPEC
+and	O
+the	O
+target	B-ANAT
+cell	I-ANAT
+.	O
+
+All	O
+four	O
+pseudoknots	O
+cause	O
+-	O
+1	O
+programmed	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+.	O
+
+In	O
+order	O
+to	O
+investigate	O
+the	O
+potential	O
+role	O
+of	O
+proinflammatory	O
+cytokines	O
+in	O
+disease	O
+severity	O
+after	O
+coinfection	B-DISO
+,	O
+a	O
+second	O
+experiment	O
+was	O
+performed	O
+to	O
+examine	O
+cytokine	O
+transcription	B-PROC
+in	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+from	O
+single	O
+and	O
+dually	O
+infected	O
+pigs	B-SPEC
+.	O
+
+A	O
+total	O
+of	O
+48	O
+pigs	B-SPEC
+were	O
+divided	O
+equally	O
+into	O
+groups	O
+as	O
+above	O
+,	O
+but	O
+4	O
+pigs	B-SPEC
+from	O
+each	O
+group	O
+were	O
+euthanized	O
+at	O
+1	O
+,	O
+4	O
+and	O
+10	O
+days	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+Recombinant	B-PRGE
+PPV	I-PRGE
+NIa	B-SPEC
+protease	I-PRGE
+expressed	B-PROC
+and	O
+purified	O
+from	O
+Escherichia	B-SPEC
+coli	I-SPEC
+demonstrated	O
+efficient	O
+and	O
+specific	O
+processing	O
+of	O
+recombinant	O
+GFP	O
+and	O
+SARS	O
+-	O
+CoV	O
+nucleocapsid	B-COMP
+protein	B-CHED
+,	O
+with	O
+site	O
+F	O
+(	O
+N	O
+V	O
+V	O
+V	O
+H	O
+Q	O
+black	O
+triangle	O
+down	O
+A	O
+)	O
+for	O
+PPV	B-PRGE
+NIa	B-SPEC
+protease	I-PRGE
+artificially	O
+inserted	O
+between	O
+the	O
+fusion	O
+tags	O
+and	O
+the	O
+target	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+'	O
+Social	O
+evils	O
+'	O
+and	O
+harm	O
+reduction	O
+:	O
+the	O
+evolving	O
+policy	O
+environment	O
+for	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+prevention	O
+among	O
+injection	O
+drug	O
+users	O
+in	O
+China	O
+and	O
+Vietnam	O
+.	O
+
+These	O
+included	O
+the	O
+emergence	O
+of	O
+effective	O
+'	O
+champions	O
+'	O
+for	O
+such	O
+policies	O
+,	O
+an	O
+ethos	O
+of	O
+pragmatism	O
+and	O
+receptivity	O
+to	O
+evidence	O
+,	O
+growing	O
+collaboration	O
+across	O
+public	O
+health	O
+,	O
+police	O
+and	O
+other	O
+sectors	O
+,	O
+the	O
+influence	O
+of	O
+contingent	O
+events	O
+such	O
+as	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+and	O
+pressure	O
+from	O
+donors	O
+and	O
+international	O
+organizations	O
+to	O
+adopt	O
+best	O
+practice	O
+in	O
+HIV	B-DISO
+prevention	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+provided	O
+valuable	O
+lessons	O
+for	O
+protecting	O
+health	O
+workers	O
+during	O
+an	O
+influenza	B-DISO
+pandemic	O
+or	O
+other	O
+public	O
+health	O
+crisis	O
+.	O
+
+Given	O
+our	O
+recent	O
+experience	O
+of	O
+living	O
+through	O
+the	O
+consequences	O
+of	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Ontario	O
+and	O
+BC	O
+,	O
+one	O
+would	O
+think	O
+that	O
+we	O
+would	O
+be	O
+more	O
+than	O
+willing	O
+this	O
+time	O
+around	O
+to	O
+err	O
+on	O
+the	O
+side	O
+of	O
+caution	O
+and	O
+be	O
+as	O
+prepared	O
+as	O
+possible	O
+to	O
+deal	O
+with	O
+the	O
+next	O
+emerging	O
+infectious	B-DISO
+agent	O
+that	O
+comes	O
+our	O
+way	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+experience	O
+with	O
+the	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+Canada	O
+and	O
+the	O
+global	O
+threat	O
+of	O
+the	O
+H5N1	B-DISO
+virus	B-SPEC
+(	O
+avian	B-SPEC
+""""	O
+flu	B-DISO
+""")"	O
+have	O
+increased	O
+the	O
+appetite	B-PROC
+for	O
+and	O
+urgency	O
+of	O
+pandemic	O
+planning	O
+as	O
+a	O
+policy	O
+issue	O
+.	O
+
+A	O
+pandemic	O
+plan	B-DISO
+that	O
+does	O
+not	O
+consider	O
+healthcare	O
+outside	O
+of	O
+the	O
+institutional	O
+setting	O
+is	O
+incomplete	O
+and	O
+will	O
+be	O
+likely	O
+to	O
+fail	O
+.	O
+
+TITLE	O
+:	O
+Predictability	O
+and	O
+epidemic	O
+pathways	B-PROC
+in	O
+global	O
+outbreaks	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+:	O
+the	O
+SARS	B-DISO
+case	O
+study	O
+.	O
+
+The	O
+presented	O
+computational	O
+approach	O
+shows	O
+that	O
+the	O
+integration	B-PROC
+of	O
+long	O
+-	O
+range	O
+mobility	O
+and	O
+demographic	O
+data	O
+provides	O
+epidemic	O
+models	O
+with	O
+a	O
+predictive	O
+power	O
+that	O
+can	O
+be	O
+consistently	O
+tested	O
+and	O
+theoretically	O
+motivated	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+presented	O
+computational	O
+approach	O
+shows	O
+that	O
+the	O
+integration	B-PROC
+of	O
+long	O
+-	O
+range	O
+mobility	O
+and	O
+demographic	O
+data	O
+provides	O
+epidemic	O
+models	O
+with	O
+a	O
+predictive	O
+power	O
+that	O
+can	O
+be	O
+consistently	O
+tested	O
+and	O
+theoretically	O
+motivated	O
+.	O
+
+All	O
+pups	O
+seroconverted	O
+for	O
+CCoV	O
+,	O
+as	O
+shown	O
+by	O
+the	O
+high	O
+optical	O
+density	O
+values	O
+and	O
+antibody	B-COMP
+titres	O
+detected	O
+by	O
+ELISA	O
+and	O
+virusneutralisation	O
+tests	O
+,	O
+respectively	O
+.	O
+
+Sequencing	O
+of	O
+the	O
+V51	B-PRGE
+spike	I-PRGE
+gene	I-PRGE
+,	O
+the	O
+mediator	O
+of	O
+virus	B-SPEC
+entry	O
+,	O
+revealed	O
+13	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+relative	O
+to	O
+the	O
+originating	O
+MHV	B-SPEC
+A59	O
+strain	O
+.	O
+
+The	O
+second	O
+class	B-SPEC
+of	O
+suppressor	O
+was	O
+mapped	O
+to	O
+the	O
+extreme	O
+3	O
+'	O
+end	O
+of	O
+the	O
+genome	O
+,	O
+a	O
+result	O
+which	O
+pointed	O
+to	O
+the	O
+existence	O
+of	O
+a	O
+direct	O
+base	O
+-	O
+pairing	O
+interaction	O
+between	O
+loop	O
+1	O
+of	O
+the	O
+pseudoknot	O
+and	O
+the	O
+genomic	O
+terminus	O
+.	O
+
+The	O
+latter	O
+finding	O
+was	O
+strongly	O
+supported	O
+by	O
+phylogenetic	O
+evidence	O
+and	O
+by	O
+the	O
+construction	O
+of	O
+a	O
+deletion	O
+mutant	B-DISO
+that	O
+reduced	O
+the	O
+3	O
+'	O
+UTR	O
+to	O
+its	O
+minimal	O
+essential	O
+elements	O
+.	O
+
+The	O
+CLEIA	O
+was	O
+capable	O
+of	O
+detecting	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+at	O
+1	O
+.	O
+56	O
+pg	O
+/	O
+ml	O
+and	O
+viral	O
+N	O
+protein	B-CHED
+in	O
+SARS	B-DISO
+CoV	O
+cell	B-COMP
+culture	O
+lysates	O
+at	O
+0	O
+.	O
+087	O
+of	O
+50	O
+%	O
+tissue	B-ANAT
+culture	O
+infective	O
+doses	O
+/	O
+ml	O
+.	O
+
+In	O
+addition	O
+,	O
+an	O
+evaluation	O
+with	O
+18	O
+SARS	B-DISO
+-	O
+positive	O
+NPA	B-CHED
+samples	O
+,	O
+all	O
+confirmed	O
+SARS	B-DISO
+positive	O
+by	O
+quantitative	O
+PCR	O
+and	O
+antibodies	B-COMP
+to	O
+SARS	B-DISO
+CoV	O
+,	O
+revealed	O
+that	O
+all	O
+(	O
+18	O
+/	O
+18	O
+)	O
+were	O
+found	O
+positive	O
+by	O
+the	O
+CLEIA	O
+;	O
+thus	O
+,	O
+the	O
+sensitivity	O
+of	O
+detection	O
+was	O
+100	O
+%.	O
+
+When	O
+we	O
+tested	O
+20	O
+SARS	B-DISO
+-	O
+negative	O
+NPA	B-CHED
+samples	O
+,	O
+the	O
+CLEIA	O
+was	O
+shown	O
+to	O
+have	O
+high	O
+specificity	O
+(	O
+100	O
+%).	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+several	O
+virucidal	O
+agents	O
+on	O
+inactivation	B-DISO
+of	O
+influenza	B-DISO
+,	O
+Newcastle	B-DISO
+disease	I-DISO
+,	O
+and	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+viruses	B-SPEC
+in	O
+the	O
+allantoic	B-ANAT
+fluid	I-ANAT
+of	O
+chicken	B-SPEC
+eggs	O
+.	O
+
+That	O
+is	O
+,	O
+although	O
+sodium	O
+hypochlorite	B-CHED
+and	O
+sodium	B-CHED
+hydroxide	I-CHED
+are	O
+generally	O
+known	O
+as	O
+strong	O
+virucidal	O
+agents	O
+,	O
+they	O
+do	O
+not	O
+sufficiently	O
+inactivate	O
+viruses	B-SPEC
+in	O
+allantoic	B-ANAT
+fluid	I-ANAT
+.	O
+
+TITLE	O
+:	O
+A	O
+resource	O
+-	O
+based	O
+perspective	O
+on	O
+retention	B-PROC
+strategies	O
+for	O
+nurse	O
+epidemiologists	O
+.	O
+
+In	O
+the	O
+light	O
+of	O
+possible	O
+staff	O
+shortages	O
+,	O
+retention	B-PROC
+strategies	O
+for	O
+epidemiologists	O
+have	O
+gained	O
+importance	O
+.	O
+
+RESULTS	O
+:	O
+Cimicifuga	B-SPEC
+rhizoma	O
+,	O
+Meliae	O
+cortex	B-ANAT
+,	O
+Coptidis	O
+rhizoma	O
+,	O
+Phellodendron	B-SPEC
+cortex	B-ANAT
+and	O
+Sophora	B-SPEC
+subprostrata	O
+radix	B-SPEC
+decreased	O
+the	O
+MHV	B-SPEC
+production	O
+and	O
+the	O
+intracellular	B-COMP
+viral	O
+RNA	O
+and	O
+protein	B-PROC
+expression	B-PROC
+with	O
+EC50	O
+values	O
+ranging	O
+from	O
+2	O
+.	O
+0	O
+to	O
+27	O
+.	O
+5	O
+microg	O
+/	O
+ml	O
+.	O
+
+The	O
+cause	O
+of	O
+SARS	B-DISO
+was	O
+identified	O
+as	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	O
+).	O
+
+Although	O
+there	O
+are	O
+currently	O
+no	O
+confirmed	O
+reports	O
+of	O
+the	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+from	O
+asymptomatic	O
+individuals	O
+,	O
+recent	O
+research	O
+data	O
+indicate	O
+that	O
+transfusion	O
+-	O
+transmitted	B-DISO
+SARS	B-DISO
+-	O
+CoV	O
+is	O
+at	O
+least	O
+theoretically	O
+possible	O
+.	O
+
+Many	O
+patients	O
+with	O
+evidence	O
+of	O
+PTSD	B-DISO
+after	O
+critical	B-DISO
+illness	I-DISO
+have	O
+been	O
+treated	O
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+).	O
+
+A	O
+high	O
+number	O
+of	O
+these	O
+traumatic	O
+memories	O
+from	O
+the	O
+ICU	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+a	O
+significant	O
+risk	O
+factor	O
+for	O
+the	O
+later	O
+development	B-PROC
+of	O
+PTSD	B-DISO
+in	O
+long	O
+-	O
+term	O
+survivors	O
+.	O
+
+In	O
+addition	O
+,	O
+patients	O
+in	O
+the	O
+ICU	O
+are	O
+often	O
+treated	O
+with	O
+stress	O
+hormones	B-CHED
+like	O
+epinephrine	B-CHED
+,	O
+norepinephrine	B-CHED
+,	O
+or	O
+cortisol	B-CHED
+.	O
+
+The	O
+number	O
+of	O
+the	O
+above	O
+-	O
+mentioned	O
+categories	O
+of	O
+traumatic	O
+memory	B-PROC
+increased	O
+with	O
+the	O
+totally	O
+administered	O
+dosages	O
+of	O
+catecholamines	B-CHED
+and	O
+cortisol	B-CHED
+,	O
+and	O
+the	O
+evaluation	O
+of	O
+these	O
+categories	O
+at	O
+different	O
+time	O
+points	O
+after	O
+discharge	B-ANAT
+from	O
+the	O
+ICU	O
+showed	O
+better	O
+memory	B-PROC
+consolidation	O
+with	O
+higher	O
+dosages	O
+of	O
+stress	O
+hormones	B-CHED
+administered	O
+.	O
+
+Conversely	O
+,	O
+the	O
+prolonged	O
+administration	O
+of	O
+beta	B-CHED
+-	I-CHED
+adrenergic	I-CHED
+antagonists	I-CHED
+during	O
+the	O
+recovery	O
+phase	O
+after	O
+cardiac	B-ANAT
+surgery	O
+resulted	O
+in	O
+a	O
+lower	O
+number	O
+of	O
+traumatic	O
+memories	O
+and	O
+a	O
+lower	O
+incidence	O
+of	O
+stress	B-DISO
+symptoms	I-DISO
+at	O
+6	O
+months	O
+after	O
+surgery	O
+.	O
+
+Moreover	O
+,	O
+elevated	O
+levels	O
+of	O
+CXCL9	B-PRGE
+and	O
+CXCL10	B-PRGE
+gene	I-PRGE
+expression	O
+were	O
+detected	O
+in	O
+retinal	B-CHED
+tissue	B-ANAT
+.	O
+
+Although	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+and	O
+the	O
+chemokines	O
+were	O
+detected	O
+in	O
+CD	O
+-	O
+1	O
+mice	B-SPEC
+,	O
+they	O
+were	O
+at	O
+significantly	O
+lower	O
+levels	O
+compared	O
+to	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+The	O
+pathogenic	O
+mechanisms	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+remain	O
+poorly	O
+understood	O
+.	O
+
+After	O
+intratracheal	O
+(	O
+i	O
+.	O
+t	O
+.)	O
+inoculation	O
+,	O
+virus	B-SPEC
+antigen	B-CHED
+-	O
+positive	O
+alveolar	B-ANAT
+cells	B-COMP
+and	O
+macrophages	B-ANAT
+were	O
+found	O
+in	O
+lung	B-ANAT
+and	O
+infectious	B-DISO
+virus	B-SPEC
+was	O
+detected	O
+in	O
+lymphoid	O
+and	O
+intestinal	B-ANAT
+tissues	B-ANAT
+.	O
+
+Few	O
+data	O
+about	O
+the	O
+molecular	O
+epidemiology	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+in	O
+developing	O
+countries	O
+,	O
+such	O
+as	O
+Jordan	O
+,	O
+are	O
+available	O
+.	O
+
+HRSV	B-SPEC
+was	O
+detected	O
+in	O
+43	O
+%	O
+(	O
+140	O
+/	O
+326	O
+)	O
+of	O
+the	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+.	O
+
+(	O
+14	O
+/	O
+312	O
+:	O
+4	O
+.	O
+5	O
+%),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+8	O
+/	O
+326	O
+:	O
+2	O
+.	O
+5	O
+%),	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+(	O
+4	O
+/	O
+325	O
+:	O
+1	O
+.	O
+2	O
+%),	O
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+2	O
+/	O
+323	O
+:	O
+0	O
+.	O
+6	O
+%).	O
+
+ABSTRACT	O
+:	O
+The	O
+DNA	O
+hypomethylating	O
+agent	O
+azacitidine	B-CHED
+was	O
+approved	O
+by	O
+the	O
+United	O
+States	O
+Food	O
+and	O
+Drug	O
+Administration	O
+after	O
+the	O
+drug	O
+demonstrated	O
+superiority	O
+over	O
+the	O
+best	O
+supportive	O
+care	O
+for	O
+treatment	O
+of	O
+myelodysplastic	B-DISO
+syndrome	I-DISO
+in	O
+patients	O
+unable	O
+to	O
+undergo	O
+stem	B-ANAT
+cell	I-ANAT
+transplantation	O
+.	O
+
+The	O
+nine	O
+antiviral	B-CHED
+agents	I-CHED
+comprised	O
+six	O
+synthetic	O
+small	O
+-	O
+molecule	O
+compounds	O
+,	O
+one	O
+peptide	B-CHED
+,	O
+one	O
+monoclonal	O
+antibody	B-COMP
+and	O
+a	O
+vaccine	O
+.	O
+
+Search	O
+strategy	O
+of	O
+the	O
+Cochrane	O
+Library	O
+,	O
+Medline	O
+,	O
+OldMedline	O
+,	O
+Embase	O
+,	O
+and	O
+CINAHL	O
+,	O
+without	O
+language	O
+restriction	O
+,	O
+for	O
+any	O
+intervention	O
+to	O
+prevent	O
+transmission	O
+of	O
+respiratory	O
+viruses	B-SPEC
+(	O
+isolation	O
+,	O
+quarantine	O
+,	O
+social	O
+distancing	O
+,	O
+barriers	O
+,	O
+personal	O
+protection	O
+,	O
+and	O
+hygiene	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+led	O
+to	O
+a	O
+renewed	O
+interest	O
+in	O
+studying	O
+the	O
+role	O
+of	O
+accessory	O
+proteins	B-CHED
+in	O
+regulating	O
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+the	O
+natural	O
+host	B-COMP
+.	O
+
+We	O
+conclude	O
+by	O
+providing	O
+some	O
+questions	O
+for	O
+future	O
+studies	O
+that	O
+will	O
+greatly	O
+advance	O
+our	O
+knowledge	O
+about	O
+the	O
+biological	O
+significance	O
+and	O
+contributions	O
+of	O
+the	O
+accessory	O
+proteins	B-CHED
+in	O
+the	O
+development	O
+of	O
+SARS	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+We	O
+solved	O
+the	O
+structure	O
+of	O
+a	O
+catalytically	O
+inactive	O
+mutant	B-DISO
+version	O
+of	O
+Nsp15	O
+,	O
+which	O
+was	O
+crystallized	O
+as	O
+a	O
+hexamer	O
+.	O
+
+More	O
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+survive	O
+ICU	O
+admission	O
+and	O
+are	O
+less	O
+likely	O
+to	O
+be	O
+admitted	O
+to	O
+the	O
+ICU	O
+for	O
+related	O
+infections	B-DISO
+;	O
+in	O
+most	O
+cases	O
+,	O
+they	O
+need	O
+critical	O
+care	O
+for	O
+problems	O
+unrelated	O
+to	O
+HIV	O
+infection	O
+or	O
+for	O
+conditions	O
+related	O
+to	O
+HAART	O
+toxicity	O
+.	O
+
+Compound	O
+5	O
+was	O
+also	O
+moderately	O
+active	O
+against	O
+VEE	O
+and	O
+Tacaribe	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+test	O
+for	O
+constant	O
+fatality	O
+rate	O
+of	O
+an	O
+emerging	O
+epidemic	O
+:	O
+with	O
+applications	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Hong	O
+Kong	O
+and	O
+Beijing	O
+.	O
+
+As	O
+acid	O
+-	O
+fast	B-FUNC
+bacilli	B-SPEC
+were	O
+positive	O
+in	O
+urine	B-ANAT
+(	O
+Gaffky	O
+8	O
+)	O
+and	O
+sputum	B-ANAT
+(	O
+Gaffky	O
+1	O
+),	O
+we	O
+diagnosed	O
+as	O
+miliary	B-DISO
+tuberculosis	I-DISO
+and	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+International	O
+research	O
+networks	O
+in	O
+viral	O
+structural	O
+proteomics	O
+:	O
+again	O
+,	O
+lessons	O
+from	O
+SARS	B-DISO
+.	O
+
+The	O
+efforts	O
+and	O
+results	O
+by	O
+the	O
+international	O
+scientific	O
+community	O
+to	O
+the	O
+SARS	B-DISO
+outbreak	O
+are	O
+serving	O
+as	O
+an	O
+example	O
+and	O
+roadmap	O
+of	O
+a	O
+rapid	O
+response	O
+using	O
+modern	O
+research	O
+methods	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+in	O
+human	B-SPEC
+epithelial	O
+lung	B-ANAT
+cells	B-COMP
+(	O
+L132	O
+)	O
+by	O
+chloroquine	B-CHED
+:	O
+involvement	O
+of	O
+p38	B-FUNC
+MAPK	B-FUNC
+and	O
+ERK	B-FUNC
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+CQ	O
+affects	O
+the	O
+activation	O
+of	O
+MAPKs	O
+,	O
+involved	O
+in	O
+the	O
+replication	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+acute	B-DISO
+infectious	I-DISO
+disease	I-DISO
+with	O
+significant	O
+mortality	O
+.	O
+
+The	O
+promoting	O
+effect	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+on	O
+the	O
+transcriptional	B-PROC
+responses	O
+of	O
+TGF	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+is	O
+Smad3	B-PRGE
+-	O
+specific	O
+.	O
+
+These	O
+findings	O
+provide	O
+evidence	O
+of	O
+a	O
+novel	O
+mechanism	O
+whereby	O
+N	O
+protein	O
+modulates	O
+TGF	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+signaling	B-PROC
+to	O
+block	O
+apoptosis	B-PATH
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+host	B-COMP
+cells	B-COMP
+and	O
+meanwhile	O
+promote	O
+tissue	B-ANAT
+fibrosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Evidence	O
+of	O
+the	O
+recombinant	O
+origin	O
+of	O
+a	O
+bat	B-ENZY
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+like	O
+coronavirus	B-SPEC
+and	O
+its	O
+implications	O
+on	O
+the	O
+direct	O
+ancestor	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Based	O
+on	O
+this	O
+relatively	O
+short	O
+window	O
+period	O
+,	O
+we	O
+speculate	O
+that	O
+this	O
+uncharacterized	O
+SLCoV	O
+lineage	O
+may	O
+contain	O
+the	O
+direct	O
+ancestor	O
+of	O
+SCoV	O
+.	O
+This	O
+study	O
+sheds	O
+light	O
+on	O
+the	O
+possible	O
+host	B-COMP
+bat	B-ENZY
+species	B-SPEC
+of	O
+the	O
+direct	O
+ancestor	O
+of	O
+SCoV	O
+,	O
+providing	O
+valuable	O
+information	O
+on	O
+the	O
+scope	O
+and	O
+focus	O
+of	O
+surveillance	O
+for	O
+the	O
+origin	O
+of	O
+SCoV	O
+.	O
+
+RESULTS	O
+:	O
+Key	O
+recommendations	O
+,	O
+listed	O
+by	O
+category	O
+,	O
+include	O
+:	O
+early	O
+goal	O
+-	O
+directed	O
+resuscitation	O
+of	O
+the	O
+septic	O
+patient	O
+during	O
+the	O
+first	O
+6	O
+hrs	B-DISO
+after	O
+recognition	O
+(	O
+1C	O
+);	O
+blood	B-ANAT
+cultures	O
+prior	O
+to	O
+antibiotic	B-CHED
+therapy	O
+(	O
+1C	O
+);	O
+imaging	O
+studies	O
+performed	O
+promptly	O
+to	O
+confirm	O
+potential	O
+source	O
+of	O
+infection	B-DISO
+(	O
+1C	O
+);	O
+administration	O
+of	O
+broad	O
+-	O
+spectrum	O
+antibiotic	B-CHED
+therapy	O
+within	O
+1	O
+hr	O
+of	O
+diagnosis	O
+of	O
+septic	B-DISO
+shock	I-DISO
+(	O
+1B	O
+)	O
+and	O
+severe	B-DISO
+sepsis	I-DISO
+without	I-DISO
+septic	I-DISO
+shock	I-DISO
+(	O
+1D	O
+);	O
+reassessment	O
+of	O
+antibiotic	B-CHED
+therapy	O
+with	O
+microbiology	O
+and	O
+clinical	O
+data	O
+to	O
+narrow	O
+coverage	O
+,	O
+when	O
+appropriate	O
+(	O
+1C	O
+);	O
+a	O
+usual	O
+7	O
+-	O
+10	O
+days	O
+of	O
+antibiotic	B-CHED
+therapy	O
+guided	O
+by	O
+clinical	O
+response	O
+(	O
+1D	O
+);	O
+source	O
+control	O
+with	O
+attention	O
+to	O
+the	O
+balance	B-PROC
+of	O
+risks	O
+and	O
+benefits	O
+of	O
+the	O
+chosen	O
+method	O
+(	O
+1C	O
+);	O
+administration	O
+of	O
+either	O
+crystalloid	B-COMP
+or	O
+colloid	B-ANAT
+fluid	O
+resuscitation	O
+(	O
+1B	O
+);	O
+fluid	O
+challenge	O
+to	O
+restore	O
+mean	O
+circulating	O
+filling	O
+pressure	O
+(	O
+1C	O
+);	O
+reduction	O
+in	O
+rate	O
+of	O
+fluid	O
+administration	O
+with	O
+rising	O
+filing	O
+pressures	O
+and	O
+no	O
+improvement	O
+in	O
+tissue	B-ANAT
+perfusion	O
+(	O
+1D	O
+);	O
+vasopressor	O
+preference	O
+for	O
+norepinephrine	B-CHED
+or	O
+dopamine	B-CHED
+to	O
+maintain	O
+an	O
+initial	O
+target	O
+of	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+>	O
+or	O
+=	O
+65	O
+mm	O
+Hg	O
+(	O
+1C	O
+);	O
+dobutamine	B-CHED
+inotropic	O
+therapy	O
+when	O
+cardiac	B-ANAT
+output	O
+remains	O
+low	O
+despite	O
+fluid	O
+resuscitation	O
+and	O
+combined	O
+inotropic	O
+/	O
+vasopressor	O
+therapy	O
+(	O
+1C	O
+);	O
+stress	O
+-	O
+dose	O
+steroid	B-CHED
+therapy	O
+given	O
+only	O
+in	O
+septic	B-DISO
+shock	I-DISO
+after	O
+blood	B-PROC
+pressure	I-PROC
+is	O
+identified	O
+to	O
+be	O
+poorly	O
+responsive	O
+to	O
+fluid	O
+and	O
+vasopressor	O
+therapy	O
+(	O
+2C	O
+);	O
+recombinant	B-PRGE
+activated	I-PRGE
+protein	I-PRGE
+C	I-PRGE
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+clinical	O
+assessment	O
+of	O
+high	O
+risk	O
+for	O
+death	B-PROC
+(	O
+2B	O
+except	O
+2C	O
+for	O
+post	O
+-	O
+operative	O
+patients	O
+).	O
+
+Recommendations	O
+specific	O
+to	O
+pediatric	O
+severe	B-DISO
+sepsis	I-DISO
+include	O
+:	O
+greater	O
+use	O
+of	O
+physical	O
+examination	O
+therapeutic	O
+end	O
+points	O
+(	O
+2C	O
+);	O
+dopamine	B-CHED
+as	O
+the	O
+first	O
+drug	O
+of	O
+choice	O
+for	O
+hypotension	O
+(	O
+2C	O
+);	O
+steroids	B-CHED
+only	O
+in	O
+children	O
+with	O
+suspected	O
+or	O
+proven	O
+adrenal	B-DISO
+insufficiency	I-DISO
+(	O
+2C	O
+);	O
+a	O
+recommendation	O
+against	O
+the	O
+use	O
+of	O
+recombinant	B-PRGE
+activated	I-PRGE
+protein	I-PRGE
+C	I-PRGE
+in	O
+children	O
+(	O
+1B	O
+).	O
+
+Before	O
+and	O
+after	O
+the	O
+experiment	O
+,	O
+the	O
+cytokines	O
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+of	O
+the	O
+survival	O
+mice	B-SPEC
+were	O
+determined	O
+,	O
+and	O
+RNA	O
+was	O
+extracted	O
+from	O
+survival	O
+mouse	B-SPEC
+liver	B-ANAT
+tissue	I-ANAT
+for	O
+the	O
+analysis	O
+of	O
+the	O
+differential	B-PROC
+gene	I-PROC
+expression	I-PROC
+by	O
+a	O
+36	O
+kb	O
+mouse	O
+oligonucleotide	B-CHED
+DNA	O
+array	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+the	O
+I	O
+/	O
+D	O
+polymorphism	B-PROC
+also	O
+confers	O
+susceptibility	O
+to	O
+sepsis	B-DISO
+and	O
+is	O
+a	O
+predisposing	O
+factor	O
+for	O
+morbidity	O
+and	O
+mortality	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+ACE	B-PRGE
+I	I-PRGE
+/	I-PRGE
+D	I-PRGE
+polymorphism	B-PROC
+was	O
+not	O
+associated	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+susceptibility	O
+or	O
+mortality	O
+.	O
+
+Previously	O
+proposed	O
+mechanisms	O
+of	O
+IMS	O
+include	O
+different	O
+susceptibility	O
+of	O
+various	O
+cholinergic	O
+receptors	O
+,	O
+muscle	B-DISO
+necrosis	B-PROC
+,	O
+prolonged	O
+acetylcholinesterase	B-PRGE
+inhibition	B-PROC
+,	O
+inadequate	O
+oxime	B-CHED
+therapy	O
+,	O
+downregulation	B-PROC
+or	O
+desensitization	B-PROC
+of	O
+postsynaptic	O
+acetylcholine	B-CHED
+receptors	O
+,	O
+failure	O
+of	O
+postsynaptic	O
+acetylcholine	B-CHED
+release	B-PATH
+,	O
+and	O
+oxidative	B-DISO
+stress	I-DISO
+-	O
+related	O
+myopathy	B-DISO
+.	O
+
+Although	O
+IMS	O
+is	O
+well	O
+recognized	O
+as	O
+a	O
+disorder	O
+of	O
+neuromuscular	B-COMP
+junctions	I-COMP
+,	O
+its	O
+exact	O
+etiology	O
+,	O
+incidence	O
+,	O
+and	O
+risk	O
+factors	O
+are	O
+not	O
+clearly	O
+defined	O
+because	O
+existing	O
+studies	O
+are	O
+largely	O
+small	O
+-	O
+scale	O
+case	O
+series	O
+and	O
+do	O
+not	O
+employ	O
+a	O
+consistent	O
+and	O
+rigorous	O
+definition	O
+of	O
+IMS	O
+.	O
+
+Thirty	O
+-	O
+five	O
+patients	O
+(	O
+6	O
+female	O
+,	O
+29	O
+male	O
+,	O
+mean	O
+age	O
+36	O
+years	O
+)	O
+underwent	O
+surgical	O
+repair	B-PROC
+.	O
+
+Two	O
+patients	O
+were	O
+operated	O
+upon	O
+without	O
+cardiopulmonary	B-ANAT
+bypass	O
+.	O
+
+In	O
+39	O
+patients	O
+(	O
+5	O
+female	O
+,	O
+34	O
+male	O
+,	O
+mean	O
+age	O
+36	O
+years	O
+)	O
+thoracic	B-DISO
+endografts	O
+were	O
+implanted	O
+.	O
+
+RESULTS	O
+:	O
+Hospital	O
+mortality	O
+was	O
+20	O
+%	O
+(	O
+7	O
+of	O
+35	O
+patients	O
+)	O
+in	O
+the	O
+surgical	O
+group	O
+and	O
+7	O
+.	O
+7	O
+%	O
+(	O
+3	O
+of	O
+39	O
+patients	O
+)	O
+in	O
+the	O
+endovascular	B-ANAT
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+Transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+(	O
+TRALI	B-DISO
+)	O
+is	O
+a	O
+leading	O
+cause	O
+of	O
+transfusion	O
+-	O
+associated	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+relationship	O
+between	O
+antibodies	B-COMP
+detected	O
+in	O
+patients	O
+'	O
+and	O
+/	O
+or	O
+donors	O
+'	O
+sera	B-COMP
+and	O
+the	O
+clinical	O
+features	O
+of	O
+acute	O
+non	O
+-	O
+haemolytic	O
+transfusion	B-DISO
+reactions	I-DISO
+(	O
+ANHTRs	O
+),	O
+and	O
+to	O
+determine	O
+any	O
+gender	O
+-	O
+related	O
+difference	O
+.	O
+
+ANHTRs	O
+range	O
+from	O
+urticaria	B-DISO
+to	O
+transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+(	O
+TRALI	B-DISO
+).	O
+
+Antibodies	B-COMP
+to	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+(	O
+HLA	B-PRGE
+),	O
+granulocytes	B-ANAT
+,	O
+platelets	B-ANAT
+,	O
+and	O
+/	O
+or	O
+plasma	B-ANAT
+proteins	B-CHED
+are	O
+implicated	O
+in	O
+some	O
+of	O
+the	O
+ANHTRs	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+group	O
+1	O
+coronavirus	B-SPEC
+antigen	B-CHED
+in	O
+multisystemic	O
+granulomatous	B-DISO
+lesions	I-DISO
+in	O
+ferrets	B-SPEC
+(	O
+Mustela	B-SPEC
+putorius	I-SPEC
+furo	I-SPEC
+).	O
+
+Four	O
+main	O
+types	O
+of	O
+lesions	O
+were	O
+observed	O
+:	O
+diffuse	O
+granulomatous	B-DISO
+inflammation	I-DISO
+on	O
+serosal	B-ANAT
+surfaces	O
+;	O
+granulomas	B-DISO
+with	O
+areas	O
+of	O
+necrosis	B-PROC
+;	O
+granulomas	B-DISO
+without	O
+necrosis	B-PROC
+;	O
+and	O
+granulomas	B-DISO
+with	O
+neutrophils	B-ANAT
+.	O
+
+These	O
+antibodies	B-COMP
+were	O
+shown	O
+to	O
+have	O
+a	O
+specific	O
+affinity	O
+to	O
+the	O
+GPRLQPY	O
+motif	O
+,	O
+as	O
+demonstrated	O
+by	O
+non	O
+-	O
+reactivity	O
+with	O
+a	O
+peptide	B-CHED
+that	O
+lacks	O
+this	O
+motif	O
+.	O
+
+TITLE	O
+:	O
+Heterologous	O
+expression	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORF10	I-PRGE
+and	O
+X5	O
+genes	O
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+Streptomyces	B-SPEC
+lividans	I-SPEC
+TK24	O
+.	O
+
+The	O
+predicted	O
+unknown	O
+proteins	B-CHED
+(	O
+PUPs	O
+)	O
+encoded	O
+by	O
+the	O
+accessory	O
+genes	O
+,	O
+which	O
+are	O
+considered	O
+to	O
+be	O
+unique	O
+to	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+,	O
+might	O
+play	O
+important	O
+roles	O
+in	O
+the	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+This	O
+work	O
+makes	O
+it	O
+possible	O
+to	O
+study	O
+the	O
+structure	O
+and	O
+potential	O
+functions	O
+of	O
+proteins	B-CHED
+encoding	O
+by	O
+these	O
+two	O
+genes	O
+.	O
+
+TITLE	O
+:	O
+Calmodulin	B-PRGE
+interacts	O
+with	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+and	O
+inhibits	O
+shedding	O
+of	O
+its	O
+ectodomain	O
+.	O
+
+We	O
+also	O
+show	O
+that	O
+calmodulin	B-PRGE
+associates	O
+with	O
+ACE2	B-PRGE
+and	O
+that	O
+this	O
+interaction	O
+is	O
+decreased	O
+by	O
+calmodulin	B-PRGE
+inhibitors	B-CHED
+.	O
+
+A	O
+SARS	B-DISO
+-	O
+related	O
+lesion	O
+in	O
+each	O
+zone	O
+was	O
+scored	O
+using	O
+a	O
+four	O
+-	O
+point	O
+scale	O
+:	O
+zero	O
+to	O
+three	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+severity	O
+of	O
+abnormalities	O
+quantified	O
+on	O
+chest	B-ANAT
+radiographs	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+correlates	O
+with	O
+the	O
+clinical	O
+parameters	O
+.	O
+
+The	O
+majority	O
+of	O
+reported	O
+cases	O
+of	O
+gasoline	O
+intoxication	O
+involve	O
+oral	B-ANAT
+ingestion	O
+or	O
+inhalation	B-PROC
+.	O
+
+Data	O
+are	O
+scarce	O
+on	O
+complications	O
+and	O
+outcomes	O
+following	O
+hydrocarbon	B-CHED
+poisoning	O
+by	O
+intravenous	O
+injection	O
+.	O
+
+Gas	B-PRGE
+exchange	O
+was	O
+severely	O
+impaired	B-DISO
+and	O
+a	O
+chest	B-ANAT
+x	O
+-	O
+ray	B-SPEC
+indicated	O
+chemical	B-DISO
+pneumonitis	I-DISO
+.	O
+
+However	O
+,	O
+aerosolization	O
+of	O
+these	O
+anticoagulants	B-CHED
+in	O
+combination	O
+significantly	O
+attenuated	O
+all	O
+the	O
+observed	O
+pulmonary	B-ANAT
+pathophysiology	O
+.	O
+
+We	O
+found	O
+that	O
+the	O
+region	O
+of	O
+S1	O
+signed	O
+as	O
+S1D	O
+(	O
+aa	O
+636789	O
+)	O
+was	O
+able	O
+to	O
+react	O
+with	O
+PEDV	B-SPEC
+antiserum	O
+and	O
+to	O
+elicit	O
+formation	B-PROC
+of	O
+neutralization	O
+antibodies	B-COMP
+in	O
+mice	B-SPEC
+.	O
+
+Moreover	O
+,	O
+the	O
+immune	O
+serum	B-COMP
+against	O
+S1D	O
+showed	O
+the	O
+binding	B-FUNC
+ability	O
+to	O
+the	O
+native	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+of	O
+PEDV	B-SPEC
+.	O
+
+Strikingly	O
+,	O
+one	O
+mutation	O
+,	O
+an	O
+A1006V	O
+substitution	O
+,	O
+which	O
+consistently	O
+appeared	O
+first	O
+in	O
+four	O
+independently	O
+passaged	O
+viruses	B-SPEC
+,	O
+was	O
+the	O
+main	O
+determinant	O
+of	O
+the	O
+resistance	B-PROC
+phenotype	O
+,	O
+suggesting	O
+that	O
+only	O
+limited	O
+options	O
+exist	O
+for	O
+escape	O
+from	O
+the	O
+inhibitory	O
+effect	O
+of	O
+the	O
+HR2	O
+peptide	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+we	O
+report	O
+the	O
+complete	O
+sequence	O
+and	O
+genome	O
+organization	O
+of	O
+the	O
+serotype	O
+I	O
+feline	O
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+strain	O
+Black	O
+.	O
+
+Furthermore	O
+,	O
+a	O
+reverse	O
+genetic	O
+system	O
+was	O
+established	O
+for	O
+this	O
+FCoV	O
+strain	O
+by	O
+cloning	O
+a	O
+full	O
+-	O
+length	O
+cDNA	O
+copy	O
+into	O
+vaccinia	B-SPEC
+virus	I-SPEC
+.	O
+
+Since	O
+the	O
+introduction	O
+20	O
+years	O
+ago	O
+of	O
+solvent	B-CHED
+-	O
+detergent	B-CHED
+treatment	O
+,	O
+very	O
+effective	O
+against	O
+enveloped	O
+viruses	B-SPEC
+(	O
+HIV	B-DISO
+,	O
+HBV	B-DISO
+,	O
+HCV	B-SPEC
+,	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+SARS	B-DISO
+,	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+etc	O
+),	O
+there	O
+have	O
+been	O
+no	O
+known	O
+cases	O
+of	O
+transmission	O
+of	O
+this	O
+type	O
+of	O
+pathogens	O
+by	O
+products	O
+manufactured	O
+according	O
+to	O
+this	O
+procedure	O
+.	O
+
+Although	O
+there	O
+is	O
+no	O
+evidence	O
+for	O
+the	O
+transmission	O
+of	O
+classic	O
+transmissible	B-DISO
+spongiform	I-DISO
+encephalopathies	I-DISO
+(	O
+TSEs	O
+)	O
+through	O
+blood	B-ANAT
+or	O
+blood	B-ANAT
+-	O
+products	O
+transfusion	O
+,	O
+four	O
+possible	O
+cases	O
+have	O
+been	O
+reported	O
+in	O
+the	O
+United	O
+Kingdom	B-SPEC
+involving	O
+transmission	O
+by	O
+non	O
+-	O
+leukoreduced	O
+blood	B-ANAT
+components	I-ANAT
+of	O
+the	O
+agent	O
+that	O
+causes	O
+variant	B-DISO
+Creutzfeldt	I-DISO
+-	I-DISO
+Jakob	I-DISO
+Disease	I-DISO
+(	O
+vCJD	B-DISO
+),	O
+a	O
+disease	O
+linked	O
+to	O
+the	O
+outbreak	O
+of	O
+bovine	B-DISO
+spongiform	I-DISO
+encephalopathy	I-DISO
+(	O
+BSE	B-DISO
+)	O
+which	O
+took	O
+place	O
+in	O
+that	O
+country	O
+.	O
+
+However	O
+,	O
+there	O
+are	O
+no	O
+cases	O
+of	O
+human	B-SPEC
+TSE	O
+(	O
+classic	O
+or	O
+variant	O
+)	O
+transmission	O
+by	O
+plasma	B-ANAT
+-	O
+derived	O
+products	O
+.	O
+
+Experiments	O
+by	O
+Grifols	O
+and	O
+other	O
+groups	O
+show	O
+that	O
+the	O
+capacity	O
+of	O
+the	O
+production	O
+processes	O
+to	O
+eliminate	O
+vCJD	B-DISO
+agent	O
+models	O
+is	O
+many	O
+orders	O
+of	O
+magnitude	O
+greater	O
+than	O
+the	O
+maximum	O
+expected	O
+load	O
+of	O
+the	O
+agent	O
+.	O
+
+In	O
+IFN	B-PRGE
+-	I-PRGE
+gammaR1	I-PRGE
+(-/-)	I-PRGE
+RAG1	I-PRGE
+(-/-)	O
+recipients	O
+,	O
+demyelination	B-DISO
+is	O
+decreased	O
+,	O
+but	O
+not	O
+eliminated	O
+,	O
+while	O
+viral	O
+titers	O
+are	O
+significantly	O
+increased	O
+when	O
+compared	O
+to	O
+IFN	O
+-	O
+gammaR1	O
+(+/+)	O
+RAG1	B-PRGE
+(-/-)	O
+recipients	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+RNA	O
+aptamers	O
+against	O
+SCV	B-SPEC
+NTPase	B-PRGE
+/	O
+Helicase	B-PRGE
+(	O
+nsP10	O
+)	O
+were	O
+isolated	O
+from	O
+RNA	O
+library	O
+containing	O
+random	O
+sequences	O
+of	O
+40	O
+nts	B-ANAT
+using	O
+in	O
+vitro	O
+selection	O
+technique	O
+.	O
+
+Organophosphate	O
+compounds	O
+inhibit	O
+acetylcholinesterase	B-PRGE
+resulting	O
+in	O
+acute	O
+toxicity	O
+.	O
+
+Treatment	O
+involves	O
+supportive	O
+care	O
+and	O
+avoiding	O
+exogenous	O
+sympathomimetic	B-CHED
+agents	O
+.	O
+
+Ethylene	B-CHED
+dibromide	I-CHED
+-	O
+a	O
+highly	O
+toxic	O
+,	O
+fumigant	B-CHED
+pesticide	I-CHED
+-	O
+produces	O
+oral	B-DISO
+ulcerations	I-DISO
+,	O
+followed	O
+by	O
+liver	B-ANAT
+and	O
+renal	B-DISO
+toxicity	I-DISO
+,	O
+and	O
+is	O
+almost	O
+uniformly	O
+fatal	O
+.	O
+
+Faecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+200	O
+healthy	O
+dogs	B-SPEC
+and	O
+examined	O
+by	O
+electron	O
+microscopy	O
+for	O
+presence	O
+of	O
+viral	B-COMP
+particles	I-COMP
+.	O
+
+Long	O
+-	O
+term	O
+corticotherapy	O
+represents	O
+a	O
+risk	O
+for	O
+Pneumocystis	B-DISO
+pneumonia	I-DISO
+.	O
+
+In	O
+three	O
+patients	O
+,	O
+the	O
+test	O
+for	O
+cytomegalovirus	B-SPEC
+was	O
+also	O
+positive	O
+in	O
+the	O
+bronchoalveolar	O
+lavage	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Development	B-PROC
+and	O
+application	O
+of	O
+a	O
+safe	O
+SARS	B-DISO
+-	O
+CoV	O
+neutralization	O
+assay	O
+based	O
+on	O
+lentiviral	O
+vectors	O
+pseudotyped	O
+with	O
+SARS	O
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+].	O
+
+In	O
+addition	O
+culture	O
+of	O
+secretions	B-ANAT
+from	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+is	O
+not	O
+useful	O
+since	O
+the	O
+normal	O
+flora	O
+includes	O
+the	O
+bacteria	B-SPEC
+commonly	O
+responsible	O
+for	O
+pneumonia	B-DISO
+.	O
+
+The	O
+results	O
+can	O
+well	O
+explain	O
+the	O
+earlier	O
+governmental	O
+finding	O
+that	O
+DNA	O
+strings	O
+of	O
+SARS	O
+Corono	O
+-	O
+Virus	B-SPEC
+were	O
+detected	O
+within	O
+the	O
+sampled	O
+deposits	O
+on	O
+the	O
+window	O
+sills	O
+of	O
+the	O
+upper	O
+floors	O
+of	O
+the	O
+two	O
+index	O
+patients	O
+'	O
+flats	O
+.	O
+
+With	O
+respect	O
+to	O
+the	O
+former	O
+,	O
+considerations	O
+should	O
+be	O
+given	O
+to	O
+minimize	O
+the	O
+inter	O
+-	O
+flat	O
+airflow	B-PROC
+via	O
+windows	O
+flush	B-DISO
+with	O
+façade	O
+for	O
+high	O
+-	O
+rise	O
+buildings	O
+with	O
+natural	O
+ventilation	O
+;	O
+and	O
+with	O
+respect	O
+to	O
+the	O
+latter	O
+,	O
+more	O
+targeted	B-PROC
+and	O
+earlier	O
+intervention	O
+can	O
+be	O
+implemented	O
+in	O
+case	O
+of	O
+any	O
+highly	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+TITLE	O
+:	O
+Structures	O
+of	O
+two	O
+coronavirus	B-SPEC
+main	O
+proteases	O
+:	O
+implications	O
+for	O
+substrate	O
+binding	B-FUNC
+and	O
+antiviral	B-CHED
+drug	I-CHED
+design	O
+.	O
+
+A	O
+monomeric	O
+form	O
+of	O
+IBV	B-SPEC
+M	O
+(	O
+pro	B-CHED
+)	O
+was	O
+identified	O
+for	O
+the	O
+first	O
+time	O
+in	O
+CoV	B-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+structures	O
+.	O
+
+A	O
+comparison	O
+of	O
+these	O
+two	O
+structures	O
+to	O
+other	O
+available	O
+M	O
+(	O
+pro	B-CHED
+)	O
+structures	O
+provides	O
+new	O
+insights	O
+for	O
+the	O
+design	O
+of	O
+substrate	O
+-	O
+based	O
+inhibitors	B-CHED
+targeting	B-PROC
+CoV	B-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+s	I-PRGE
+.	O
+
+Furthermore	O
+,	O
+all	O
+S	O
+proteins	B-CHED
+analyzed	O
+were	O
+posttranslationally	O
+cleaved	B-ANAT
+into	O
+the	O
+subunits	O
+S1	O
+and	O
+S2	O
+.	O
+
+The	O
+epidemic	O
+,	O
+icSZ16	O
+-	O
+S	O
+K479N	O
+,	O
+and	O
+icSZ16	O
+-	O
+S	O
+K479N	O
+D22	O
+viruses	B-SPEC
+replicate	O
+similarly	O
+in	O
+the	O
+BALB	O
+/	O
+c	O
+mouse	B-ANAT
+lung	I-ANAT
+,	O
+highlighting	O
+the	O
+potential	O
+use	O
+of	O
+these	O
+zoonotic	O
+spike	O
+SARS	B-DISO
+-	O
+CoVs	O
+to	O
+assess	O
+vaccine	O
+or	O
+serotherapy	O
+efficacy	O
+in	O
+vivo	O
+.	O
+
+The	O
+model	O
+was	O
+then	O
+tested	O
+prospectively	O
+through	O
+media	B-ANAT
+harvesting	O
+based	O
+on	O
+keywords	O
+corresponding	O
+to	O
+the	O
+model	O
+parameters	O
+.	O
+
+Further	O
+studies	O
+revealed	O
+that	O
+the	O
+effect	O
+of	O
+fibroblast	B-PROC
+proliferation	B-DISO
+is	O
+biphasic	O
+,	O
+with	O
+the	O
+promitogenic	O
+effect	O
+of	O
+PGE2	B-CHED
+noted	O
+at	O
+concentrations	O
+close	O
+to	O
+that	O
+detected	O
+in	O
+pulmonary	B-DISO
+edema	I-DISO
+fluid	O
+from	O
+ALI	O
+patients	O
+.	O
+
+0	O
+.	O
+8	O
+days	O
+after	O
+5	O
+pneumonectomies	O
+and	O
+2	O
+lobectomies	O
+,	O
+a	O
+severe	O
+(	O
+Murray	O
+score	O
+,	O
+2	O
+.	O
+9	O
++/-	O
+0	O
+.	O
+3	O
+)	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+unresponsive	O
+to	O
+4	O
++/-	O
+
+This	O
+study	O
+examines	O
+the	O
+inhibitory	O
+effects	O
+of	O
+lipids	B-CHED
+extracted	O
+and	O
+purified	O
+chromatographically	O
+from	O
+TB	O
+on	O
+the	O
+surface	O
+-	O
+active	O
+function	O
+of	O
+lavaged	O
+bovine	B-SPEC
+lung	B-ANAT
+surfactant	B-CHED
+(	O
+LS	O
+)	O
+and	O
+a	O
+clinically	O
+relevant	O
+calf	B-ANAT
+lung	B-ANAT
+surfactant	B-CHED
+extract	O
+(	O
+CLSE	O
+).	O
+
+Concentration	O
+dependence	B-DISO
+studies	O
+showed	O
+that	O
+LS	O
+was	O
+also	O
+inhibited	O
+significantly	O
+by	O
+total	O
+TB	O
+lipids	B-CHED
+at	O
+0	O
+.	O
+075	O
+mg	O
+/	O
+ml	O
+,	O
+with	O
+a	O
+smaller	O
+activity	O
+decrease	O
+apparent	O
+even	O
+at	O
+0	O
+.	O
+00375	O
+mg	O
+/	O
+ml	O
+.	O
+
+In	O
+contrast	O
+,	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Caco	O
+-	O
+2	O
+cells	B-COMP
+,	O
+which	O
+show	O
+a	O
+moderate	O
+cytopathic	B-DISO
+effect	I-DISO
+and	O
+a	O
+low	O
+viral	O
+titer	O
+,	O
+this	O
+processing	O
+of	O
+N	O
+was	O
+not	O
+observed	O
+.	O
+
+In	O
+transfected	O
+Vero	O
+E6	O
+and	O
+A549	O
+cells	B-COMP
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+was	O
+localized	O
+both	O
+in	O
+the	O
+cytoplasm	B-COMP
+and	O
+nucleus	B-COMP
+,	O
+whereas	O
+in	O
+Caco	O
+-	O
+2	O
+and	O
+N2a	O
+cells	B-COMP
+,	O
+nearly	O
+no	O
+nuclear	O
+localization	B-PROC
+was	O
+observed	O
+.	O
+
+To	O
+date	O
+,	O
+12	O
+structures	O
+have	O
+been	O
+determined	O
+by	O
+X	O
+-	O
+ray	B-SPEC
+crystallography	O
+or	O
+NMR	O
+from	O
+the	O
+28	O
+proteins	B-CHED
+encoded	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+One	O
+key	O
+protein	B-CHED
+,	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+main	O
+protease	O
+(	O
+M	O
+(	O
+pro	B-CHED
+)),	O
+has	O
+been	O
+the	O
+focus	O
+of	O
+considerable	O
+structure	O
+-	O
+based	O
+drug	O
+discovery	O
+efforts	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+CC	O
+chemokine	B-PRGE
+receptor	I-PRGE
+1	I-PRGE
+(	O
+CCR1	B-PRGE
+)	O
+in	O
+host	B-PROC
+defense	I-PROC
+and	O
+disease	O
+development	B-PROC
+was	O
+determined	O
+in	O
+a	O
+model	O
+of	O
+viral	O
+-	O
+induced	O
+neurologic	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Preparation	O
+of	O
+armored	O
+RNA	O
+as	O
+a	O
+control	O
+for	O
+multiplex	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+detection	O
+of	O
+influenza	O
+virus	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+intended	O
+to	O
+evaluate	O
+the	O
+diagnostic	O
+usefulness	O
+of	O
+a	O
+multiplex	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+PCR	O
+(	O
+mRT	B-ANAT
+-	O
+PCR	O
+)	O
+assay	O
+kit	B-FUNC
+under	O
+dual	O
+priming	O
+oligonucleotide	B-CHED
+system	O
+(	O
+DPO	O
+)	O
+for	O
+the	O
+childhood	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Favorable	O
+outcome	O
+of	O
+gemcitabine	B-CHED
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+gemcitabine	B-CHED
+-	O
+induced	O
+ARDS	B-DISO
+in	O
+a	O
+72	O
+-	O
+year	O
+old	O
+patient	O
+treated	O
+with	O
+gemcitabine	B-CHED
+and	O
+cisplatin	B-CHED
+for	O
+a	O
+bladder	B-PATH
+cancer	B-SPEC
+without	O
+lung	B-DISO
+metastasis	I-DISO
+.	O
+
+Administration	O
+of	O
+high	O
+doses	O
+of	O
+corticosteroids	B-CHED
+led	O
+to	O
+a	O
+prompt	O
+symptomatic	O
+improvement	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+pulmonary	B-DISO
+oedema	I-DISO
+following	O
+therapeutic	O
+embolization	O
+with	O
+Onyx	B-SPEC
+for	O
+cerebral	B-ANAT
+arteriovenous	I-DISO
+malformation	I-DISO
+.	O
+
+Ethylene	B-CHED
+vinyl	B-CHED
+alcohol	O
+copolymer	B-CHED
+dissolved	O
+in	O
+dimethyl	B-CHED
+sulfoxide	I-CHED
+(	O
+DMSO	B-CHED
+),	O
+which	O
+was	O
+approved	O
+by	O
+the	O
+US	O
+FDA	O
+in	O
+July	O
+2005	O
+,	O
+is	O
+used	O
+as	O
+an	O
+embolic	O
+agent	O
+for	O
+cerebral	B-DISO
+arteriovenous	I-DISO
+malformation	I-DISO
+(	O
+AVM	B-DISO
+).	O
+
+It	O
+is	O
+a	O
+biocompatible	O
+liquid	O
+polymer	B-CHED
+that	O
+precipitates	O
+and	O
+solidifies	O
+on	O
+contact	O
+with	O
+blood	B-ANAT
+,	O
+thus	O
+forming	O
+a	O
+soft	O
+and	O
+spongy	O
+embolus	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+ARDS	B-DISO
+following	O
+therapeutic	O
+embolization	O
+with	O
+ethylene	B-CHED
+vinyl	B-CHED
+alcohol	O
+copolymer	B-CHED
+for	O
+cerebral	B-ANAT
+AVM	B-DISO
+under	O
+general	O
+anaesthesia	B-DISO
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+and	O
+hypoxaemia	O
+developed	O
+in	O
+the	O
+patient	O
+following	O
+extubation	O
+of	O
+the	O
+trachea	B-DISO
+.	O
+
+One	O
+,	O
+KT2	B-PRGE
+(	O
+KT2	B-PRGE
+-	I-PRGE
+L	I-PRGE
+),	O
+was	O
+passaged	O
+128	O
+times	O
+(	O
+KT2	B-PRGE
+-	I-PRGE
+H	I-PRGE
+)	O
+in	O
+swine	B-SPEC
+testicular	O
+cells	B-COMP
+.	O
+
+Compared	O
+to	O
+the	O
+original	O
+KT2	O
+-	O
+L	O
+strain	O
+,	O
+the	O
+KT2	B-PRGE
+-	I-PRGE
+H	I-PRGE
+strain	O
+differed	O
+by	O
+2	O
+.	O
+2	O
+and	O
+3	O
+.	O
+9	O
+%	O
+in	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+,	O
+respectively	O
+.	O
+
+Another	O
+Korean	O
+TGEV	B-SPEC
+isolate	O
+(	O
+DAE	O
+)	O
+was	O
+related	O
+to	O
+a	O
+strain	O
+from	O
+China	O
+and	O
+one	O
+from	O
+the	O
+USA	O
+.	O
+
+The	O
+Korean	O
+TGEV	B-SPEC
+isolates	O
+appear	O
+to	O
+have	O
+evolved	O
+from	O
+a	O
+separate	O
+lineage	O
+of	O
+TGEV	B-SPEC
+strain	O
+.	O
+
+TITLE	O
+:	O
+Responses	O
+of	O
+Chinese	O
+elderly	O
+to	O
+the	O
+threat	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+a	O
+Canadian	O
+community	O
+.	O
+
+RESULTS	O
+:	O
+Participants	O
+experienced	O
+a	O
+5	O
+-	O
+stage	O
+process	O
+of	O
+protecting	O
+self	O
+,	O
+family	B-SPEC
+,	O
+and	O
+others	O
+,	O
+responding	O
+according	O
+to	O
+the	O
+perceived	O
+threat	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Febrile	B-PROC
+respiratory	O
+illnesses	O
+with	O
+respiratory	O
+failure	O
+are	O
+one	O
+of	O
+the	O
+most	O
+common	O
+reasons	O
+for	O
+admission	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Recognition	O
+of	O
+these	O
+agents	O
+occurs	O
+largely	O
+based	O
+on	O
+epidemiological	O
+clues	O
+,	O
+and	O
+management	O
+consists	O
+of	O
+antibiotics	B-CHED
+,	O
+antivirals	B-CHED
+,	O
+supportive	O
+care	O
+,	O
+and	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+.	O
+
+Transthoracic	O
+echocardiography	O
+was	O
+performed	O
+for	O
+pulmonary	B-DISO
+hypertension	I-DISO
+assessment	O
+via	O
+measurement	O
+of	O
+tricuspid	O
+regurgitant	O
+jet	O
+velocity	O
+and	O
+was	O
+repeated	O
+when	O
+possible	O
+after	O
+resolution	O
+.	O
+
+All	O
+112	O
+infants	O
+who	O
+had	O
+an	O
+ARI	B-CHED
+had	O
+cough	B-DISO
+,	O
+and	O
+39	O
+(	O
+35	O
+%)	O
+had	O
+wheeze	B-DISO
+.	O
+
+Learning	B-PROC
+from	O
+the	O
+SARS	B-DISO
+epidemic	O
+pointed	O
+to	O
+the	O
+importance	O
+of	O
+quality	O
+nursing	B-PROC
+practice	O
+considerations	O
+that	O
+minimize	O
+cross	O
+-	O
+transmission	O
+of	O
+infection	B-DISO
+while	O
+maximizing	O
+patient	O
+-	O
+focused	O
+care	O
+.	O
+
+Hence	O
+,	O
+a	O
+modular	O
+nursing	B-PROC
+model	O
+was	O
+adopted	O
+.	O
+
+Data	O
+collection	O
+tools	O
+to	O
+evaluate	O
+modular	O
+nursing	B-PROC
+practice	O
+included	O
+a	O
+work	O
+sampling	O
+observation	O
+checklist	O
+,	O
+focused	O
+group	O
+interviews	O
+with	O
+nurses	O
+,	O
+questionnaires	O
+addressing	O
+nurses	O
+'	O
+perceived	O
+competence	O
+and	O
+caring	O
+attributes	O
+,	O
+a	O
+patient	O
+satisfaction	O
+questionnaire	O
+,	O
+and	O
+a	O
+hand	O
+hygiene	O
+audit	O
+.	O
+
+ABSTRACT	O
+:	O
+3C	O
+-	O
+like	O
+protease	O
+(	O
+3CL	O
+pro	B-CHED
+)	O
+plays	O
+pivotal	O
+roles	O
+in	O
+the	O
+life	O
+cycle	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+only	O
+the	O
+dimeric	O
+protease	O
+is	O
+proposed	O
+as	O
+the	O
+functional	O
+form	O
+.	O
+
+Seven	O
+residues	O
+on	O
+the	O
+dimer	O
+interface	O
+were	O
+selected	O
+for	O
+evaluating	O
+their	O
+contributions	O
+to	O
+dimer	O
+stability	O
+and	O
+catalytic	B-FUNC
+activity	I-FUNC
+by	O
+biophysical	O
+and	O
+biochemical	O
+methods	O
+.	O
+
+These	O
+residues	O
+are	O
+involved	O
+in	O
+dimerization	O
+through	O
+hydrogen	B-CHED
+bonding	O
+and	O
+broadly	O
+located	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+finger	B-ANAT
+,	O
+the	O
+alpha	B-PRGE
+-	I-PRGE
+helix	I-PRGE
+A	I-PRGE
+'	I-PRGE
+of	I-PRGE
+domain	I-PRGE
+I	I-PRGE
+,	O
+and	O
+the	O
+oxyanion	O
+loop	O
+near	O
+the	O
+S1	O
+substrate	O
+-	O
+binding	B-FUNC
+subsite	O
+in	O
+domain	O
+II	O
+.	O
+
+One	O
+hundred	O
+twenty	O
+sera	B-COMP
+collected	O
+from	O
+cats	B-SPEC
+belonging	O
+to	O
+catteries	O
+or	O
+community	O
+shelters	O
+and	O
+to	O
+households	O
+were	O
+tested	O
+for	O
+FCoV	B-PRGE
+type	I-PRGE
+I	I-PRGE
+and	I-PRGE
+II	I-PRGE
+antibodies	I-PRGE
+.	O
+
+SPEF	O
+contains	O
+condition	B-DISO
+-	O
+specific	O
+nutrients	B-CHED
+to	O
+modulate	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+TITLE	O
+:	O
+Importance	O
+of	O
+conserved	O
+cysteine	B-CHED
+residues	O
+in	O
+the	O
+coronavirus	B-PRGE
+envelope	B-COMP
+protein	B-CHED
+.	O
+
+Single	O
+-	O
+substitution	O
+viruses	B-SPEC
+exhibited	O
+growth	B-PROC
+characteristics	O
+virtually	O
+identical	O
+to	O
+those	O
+of	O
+the	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+,	O
+while	O
+the	O
+double	O
+-	O
+substitution	O
+mutations	O
+gave	O
+rise	O
+to	O
+viruses	O
+with	O
+less	O
+robust	O
+growth	B-PROC
+phenotypes	O
+indicated	O
+by	O
+smaller	O
+plaques	B-DISO
+and	O
+decreased	O
+virus	B-SPEC
+yields	O
+.	O
+
+Mutant	B-DISO
+E	O
+proteins	B-CHED
+localized	O
+properly	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+A	O
+comparison	O
+of	O
+intracellular	B-COMP
+and	O
+extracellular	B-COMP
+virus	B-SPEC
+yields	O
+suggested	O
+that	O
+release	B-PATH
+is	O
+only	O
+slightly	O
+impaired	B-DISO
+.	O
+
+Both	O
+native	B-PRGE
+E	I-PRGE
+and	I-PRGE
+E	I-PRGE
+.	I-PRGE
+T	I-PRGE
+proteins	B-CHED
+localized	O
+at	O
+identical	O
+perinuclear	O
+locations	O
+,	O
+and	O
+both	O
+copurified	O
+with	O
+M	O
+proteins	B-CHED
+,	O
+but	O
+E	O
+.	O
+T	O
+was	O
+entirely	O
+incompetent	O
+for	O
+VLP	B-COMP
+production	O
+.	O
+
+Studies	O
+in	O
+the	O
+populations	O
+of	O
+Hong	O
+Kong	O
+and	O
+Taiwan	O
+showed	O
+an	O
+association	O
+of	O
+human	B-PRGE
+leucocyte	B-ANAT
+antigen	B-CHED
+(	O
+HLA	B-PRGE
+)	O
+polymorphisms	B-PROC
+with	O
+the	O
+development	B-PROC
+and	O
+/	O
+or	O
+severity	O
+of	O
+SARS	B-DISO
+,	O
+respectively	O
+.	O
+
+Although	O
+the	O
+allelic	O
+frequencies	O
+of	O
+A23	O
+,	O
+A34	O
+,	O
+B60	O
+,	O
+DRB1	O
+*	O
+12	O
+in	O
+the	O
+SARS	B-DISO
+group	O
+were	O
+slightly	O
+higher	O
+,	O
+and	O
+A33	O
+,	O
+-	O
+B58	O
+and	O
+-	O
+B61	O
+were	O
+lower	O
+than	O
+in	O
+the	O
+controls	O
+,	O
+no	O
+statistical	O
+significance	O
+was	O
+found	O
+when	O
+the	O
+Pc	O
+value	O
+was	O
+considered	O
+.	O
+
+Balb	O
+/	O
+c	O
+mice	B-SPEC
+inoculated	O
+with	O
+a	O
+mixture	B-CHED
+of	O
+chimeric	O
+VLPs	B-ANAT
+and	O
+alum	O
+twice	O
+at	O
+an	O
+interval	O
+of	O
+four	O
+weeks	O
+were	O
+protected	O
+from	O
+SCoV	O
+challenge	O
+,	O
+as	O
+indicated	O
+by	O
+the	O
+absence	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+The	O
+same	O
+groups	O
+of	O
+mice	B-SPEC
+had	O
+high	O
+levels	O
+of	O
+SCoV	O
+-	O
+specific	O
+neutralizing	O
+antibodies	B-COMP
+,	O
+while	O
+mice	B-SPEC
+in	O
+the	O
+negative	O
+control	O
+groups	O
+,	O
+which	O
+were	O
+not	O
+immunized	O
+with	O
+chimeric	O
+VLPs	B-ANAT
+,	O
+failed	O
+to	O
+manifest	O
+neutralizing	O
+antibodies	B-COMP
+,	O
+suggesting	O
+that	O
+SCoV	O
+-	O
+specific	O
+neutralizing	O
+antibodies	B-COMP
+are	O
+important	O
+for	O
+the	O
+suppression	B-DISO
+of	O
+viral	O
+replication	O
+within	O
+the	O
+lungs	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Knowledge	O
+of	O
+immunodominant	O
+regions	O
+in	O
+major	O
+viral	O
+antigens	B-CHED
+is	O
+important	O
+for	O
+rational	O
+design	O
+of	O
+effective	O
+vaccines	O
+and	O
+diagnostic	O
+tests	O
+.	O
+
+Using	O
+a	O
+membrane	B-COMP
+-	O
+strip	O
+based	O
+Western	O
+blot	O
+approach	O
+,	O
+the	O
+reactivity	O
+of	O
+each	O
+antigen	B-CHED
+fragment	O
+against	O
+a	O
+panel	O
+of	O
+animal	B-SPEC
+sera	B-COMP
+was	O
+determined	O
+.	O
+
+Immunodominant	O
+regions	O
+containing	O
+linear	O
+epitopes	O
+,	O
+which	O
+reacted	O
+with	O
+sera	O
+from	O
+all	O
+the	O
+species	B-SPEC
+tested	O
+,	O
+were	O
+identified	O
+for	O
+both	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+A	O
+line	O
+immunoassay	O
+utilizing	O
+recombinant	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+human	O
+coronaviruses	O
+.	O
+
+Possibly	O
+,	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+antibody	B-PROC
+responses	I-PROC
+were	O
+observed	O
+using	O
+229E	O
+and	O
+OC43	O
+serum	B-COMP
+pairs	O
+.	O
+
+This	O
+coronavirus	B-SPEC
+strain	O
+-	O
+specific	O
+line	O
+immunoassay	O
+represents	O
+a	O
+powerful	O
+tool	O
+for	O
+serologic	O
+diagnostics	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+is	O
+no	O
+therapy	O
+with	O
+proven	O
+efficacy	O
+to	O
+treat	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+No	O
+effect	O
+of	O
+FeIFN	B-PRGE
+-	I-PRGE
+omega	I-PRGE
+on	O
+survival	O
+time	O
+or	O
+quality	O
+of	O
+life	O
+could	O
+be	O
+demonstrated	O
+in	O
+this	O
+study	O
+.	O
+
+The	O
+inhibition	B-PROC
+effect	O
+of	O
+siRNAs	O
+significantly	O
+differed	O
+among	O
+various	O
+genes	O
+and	O
+sites	O
+on	O
+the	O
+virus	B-SPEC
+genome	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+for	O
+potent	O
+cross	O
+-	O
+neutralizing	O
+human	B-SPEC
+monoclonal	O
+antibody	B-COMP
+protection	O
+against	O
+lethal	O
+human	O
+and	O
+zoonotic	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+challenge	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+emerged	O
+in	O
+2002	O
+,	O
+and	O
+detailed	O
+phylogenetic	O
+and	O
+epidemiological	O
+analyses	O
+have	O
+suggested	O
+that	O
+it	O
+originated	O
+from	O
+animals	B-SPEC
+.	O
+
+Both	O
+S227	O
+.	O
+14	O
+and	O
+S230	O
+.	O
+15	O
+completely	O
+protected	O
+young	O
+and	O
+old	O
+mice	B-SPEC
+from	O
+weight	O
+loss	O
+and	O
+virus	B-PROC
+replication	I-PROC
+in	O
+the	O
+lungs	B-ANAT
+for	O
+all	O
+viruses	B-SPEC
+tested	O
+,	O
+while	O
+S109	O
+.	O
+8	O
+completely	O
+protected	O
+mice	B-SPEC
+from	O
+weight	O
+loss	O
+and	O
+clinical	O
+signs	O
+in	O
+the	O
+presence	O
+of	O
+viral	O
+titers	O
+.	O
+
+They	O
+have	O
+a	O
+nonsegmented	O
+negative	O
+-	O
+stranded	O
+RNA	O
+genome	O
+and	O
+can	O
+cause	O
+a	O
+number	O
+of	O
+diseases	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+The	O
+chimeric	O
+virus	B-SPEC
+extends	O
+the	O
+coding	O
+capacity	O
+of	O
+NDV	B-SPEC
+by	O
+30	O
+%,	O
+suggesting	O
+that	O
+the	O
+two	O
+-	O
+segmented	O
+NDV	B-SPEC
+can	O
+be	O
+used	O
+for	O
+development	B-PROC
+of	O
+vaccines	O
+or	O
+gene	O
+therapy	O
+vectors	O
+carrying	O
+long	O
+and	O
+multiple	O
+transgenes	O
+.	O
+
+Alanine	B-CHED
+substitutions	O
+for	O
+one	O
+or	O
+two	O
+of	O
+the	O
+six	O
+aromatic	O
+residues	O
+in	O
+the	O
+JMD	O
+did	O
+not	O
+alter	O
+the	O
+surface	O
+expression	B-PROC
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+proteins	B-CHED
+with	O
+a	O
+deletion	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+19	O
+amino	B-CHED
+acids	I-CHED
+(	O
+S	O
+Delta19	O
+)	O
+or	O
+reduce	O
+binding	B-FUNC
+to	O
+soluble	O
+human	B-PRGE
+ACE2	I-PRGE
+(	O
+hACE2	O
+).	O
+
+The	O
+aromatic	B-CHED
+amino	I-CHED
+acids	I-CHED
+in	O
+the	O
+JMD	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+play	O
+critical	O
+roles	O
+in	O
+receptor	O
+-	O
+dependent	O
+virus	B-SPEC
+-	O
+cell	B-COMP
+and	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+therapeutic	O
+effect	O
+of	O
+alanyl	O
+-	O
+glutamine	B-CHED
+dipeptide	B-CHED
+(	O
+AGD	O
+)	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+)	O
+in	O
+early	O
+and	O
+advanced	O
+stage	O
+.	O
+
+The	O
+infection	B-DISO
+rate	O
+(	O
+7	O
+.	O
+9	O
+%	O
+vs	O
+26	O
+.	O
+3	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+operation	O
+rate	O
+(	O
+13	O
+.	O
+2	O
+%	O
+vs	O
+34	O
+.	O
+2	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+mortality	O
+(	O
+5	O
+.	O
+3	O
+%	O
+vs	O
+21	O
+.	O
+1	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+early	O
+treatment	O
+group	O
+were	O
+lower	O
+than	O
+in	O
+the	O
+late	O
+treatment	O
+group	O
+.	O
+
+Nurses	O
+who	O
+were	O
+vaccinated	O
+in	O
+2006	O
+were	O
+more	O
+likely	O
+to	O
+get	O
+vaccinated	O
+in	O
+2007	O
+(	O
+P	O
+<.	O
+01	O
+);	O
+56	O
+%	O
+of	O
+the	O
+nurses	O
+perceived	O
+influenza	B-DISO
+vaccine	O
+as	O
+being	O
+effective	O
+against	O
+influenza	B-DISO
+.	O
+
+TITLE	O
+:	O
+DNA	O
+hybridization	B-PROC
+biosensors	O
+using	O
+polylysine	B-CHED
+modified	O
+SPCEs	O
+.	O
+
+Both	O
+genosensors	O
+rely	O
+on	O
+the	O
+hybridization	B-PROC
+of	O
+the	O
+oligonucleotide	B-CHED
+target	O
+with	O
+its	O
+complementary	O
+probe	O
+,	O
+which	O
+is	O
+immobilized	O
+on	O
+positively	O
+charged	O
+polylysine	B-CHED
+modified	O
+screen	O
+-	O
+printed	O
+carbon	B-CHED
+electrodes	O
+(	O
+SPCEs	O
+),	O
+through	O
+electrostatic	O
+interactions	O
+.	O
+
+Using	O
+30	O
+min	O
+of	O
+hybridization	B-PROC
+time	O
+,	O
+a	O
+detection	O
+limit	O
+of	O
+8	O
+pM	O
+is	O
+calculated	O
+for	O
+the	O
+enzymatic	O
+genosensor	O
+.	O
+
+In	O
+the	O
+few	O
+studies	O
+of	O
+the	O
+long	O
+-	O
+term	O
+pulmonary	B-ANAT
+sequelae	O
+,	O
+it	O
+seems	O
+that	O
+certain	O
+children	O
+surviving	O
+meconium	B-DISO
+aspiration	I-DISO
+syndrome	I-DISO
+keep	O
+an	O
+obstructive	O
+syndrome	B-DISO
+.	O
+
+Patients	O
+admitted	O
+during	O
+an	O
+L1	O
+designation	O
+with	O
+a	O
+severe	O
+head	O
+,	O
+chest	B-ANAT
+,	O
+or	O
+abdominal	B-ANAT
+or	O
+pelvic	B-ANAT
+injury	O
+diagnosis	O
+had	O
+a	O
+significant	O
+decrease	O
+in	O
+mortality	O
+(	O
+9	O
+.	O
+96	O
+%	O
+vs	O
+14	O
+.	O
+51	O
+%	O
+[	O
+P	O
+=	O
+.	O
+005	O
+],	O
+7	O
+.	O
+14	O
+%	O
+vs	O
+11	O
+.	O
+27	O
+%	O
+[	O
+P	O
+=	O
+.	O
+01	O
+],	O
+and	O
+6	O
+.	O
+76	O
+%	O
+vs	O
+17	O
+.	O
+05	O
+%	O
+[	O
+P	O
+=	O
+.	O
+002	O
+],	O
+respectively	O
+),	O
+as	O
+did	O
+patients	O
+who	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+during	O
+their	O
+hospital	O
+stay	O
+(	O
+9	O
+.	O
+51	O
+%	O
+vs	O
+26	O
+.	O
+87	O
+%;	O
+P	O
+=	O
+.	O
+02	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+Cox	O
+model	O
+has	O
+been	O
+the	O
+mainstay	O
+of	O
+survival	O
+analysis	O
+in	O
+the	O
+critically	B-DISO
+ill	I-DISO
+and	O
+time	O
+-	O
+dependent	O
+covariates	O
+have	O
+infrequently	O
+been	O
+incorporated	O
+into	O
+survival	O
+analysis	O
+.	O
+
+The	O
+conserved	O
+intergenic	O
+motif	O
+(	O
+ATAAAC	O
+),	O
+as	O
+previously	O
+recognized	O
+in	O
+Br1	O
+/	O
+87	O
+,	O
+was	O
+found	O
+in	O
+the	O
+5	O
+nucleotides	B-CHED
+upstream	O
+of	O
+the	O
+initiator	O
+ATG	O
+of	O
+M	O
+protein	B-CHED
+genes	O
+of	O
+six	O
+Chinese	O
+PEDV	B-SPEC
+isolates	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+the	O
+phylogenetic	O
+relationship	O
+of	O
+M	B-PRGE
+protein	I-PRGE
+genes	I-PRGE
+,	O
+six	O
+Chinese	O
+PEDV	B-SPEC
+isolates	O
+composed	O
+of	O
+a	O
+separate	O
+cluster	O
+including	O
+one	O
+Chinese	O
+strain	O
+JS	O
+-	O
+2004	O
+-	O
+02	O
+,	O
+however	O
+,	O
+not	O
+including	O
+the	O
+Chinese	O
+strain	O
+LJB	O
+/	O
+03	O
+.	O
+
+Understanding	O
+the	O
+risks	O
+involved	O
+and	O
+the	O
+airway	B-ANAT
+techniques	O
+required	O
+for	O
+each	O
+possible	O
+scenario	O
+will	O
+be	O
+key	O
+to	O
+planning	O
+and	O
+preparation	O
+.	O
+
+More	O
+than	O
+twelve	O
+peaks	O
+were	O
+differentially	O
+expressed	B-PROC
+in	O
+SARS	B-DISO
+patients	O
+with	O
+one	O
+at	O
+m	O
+/	O
+z	O
+of	O
+11	O
+,	O
+695	O
+(	O
+later	O
+identified	O
+to	O
+be	O
+serum	B-PRGE
+amyloid	B-DISO
+A	I-PRGE
+protein	B-CHED
+),	O
+which	O
+had	O
+increase	O
+in	O
+peak	O
+intensity	O
+correlating	O
+with	O
+the	O
+extent	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+induced	O
+pneumonia	B-DISO
+as	O
+defined	O
+by	O
+a	O
+serial	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+opacity	B-DISO
+score	O
+.	O
+
+Likewise	O
+,	O
+patent	O
+applications	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protease	B-PROC
+inhibitors	I-PROC
+and	O
+interferon	B-PRGE
+and	O
+mismatched	O
+dsRNA	B-CHED
+also	O
+need	O
+to	O
+be	O
+watched	O
+for	O
+potential	O
+application	O
+in	O
+treatment	O
+and	O
+prevention	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Here	O
+,	O
+we	O
+review	O
+the	O
+recent	O
+advances	O
+and	O
+inventions	O
+that	O
+target	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+humans	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+epidemic	O
+that	O
+spread	O
+worldwide	O
+in	O
+early	O
+2003	O
+.	O
+
+The	O
+association	O
+with	O
+potentially	O
+injurious	O
+ventilator	O
+settings	O
+,	O
+in	O
+particular	O
+large	O
+tidal	O
+volumes	O
+,	O
+suggests	O
+that	O
+additional	O
+lung	B-ANAT
+injury	O
+in	O
+mechanically	O
+ventilated	O
+patients	O
+without	O
+ALI	O
+/	O
+ARDS	B-DISO
+is	O
+,	O
+in	O
+part	O
+,	O
+a	O
+preventable	O
+complication	B-DISO
+.	O
+
+Treatment	O
+of	O
+cells	B-COMP
+with	O
+either	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+or	O
+spike	O
+-	O
+bearing	O
+pseudoviruses	O
+resulted	O
+in	O
+the	O
+translocation	B-DISO
+of	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+the	O
+functional	O
+receptor	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+from	O
+the	O
+cell	B-COMP
+surface	I-COMP
+to	O
+endosomes	O
+.	O
+
+Forty	O
+seven	O
+cases	O
+with	O
+severe	O
+dyspnea	B-DISO
+history	O
+were	O
+reviewed	O
+and	O
+retrospective	O
+analysis	O
+performed	O
+.	O
+
+Sera	B-COMP
+were	O
+negative	O
+for	O
+antibodies	B-COMP
+against	O
+the	O
+other	O
+six	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+inhibits	O
+host	B-COMP
+cell	I-COMP
+translation	B-PROC
+by	O
+interaction	O
+with	O
+eIF3f	B-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-DISO
+-	O
+CoV	O
+ferret	B-SPEC
+model	O
+in	O
+an	O
+infection	B-DISO
+-	O
+challenge	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Phase	O
+I	O
+human	B-SPEC
+clinical	O
+studies	O
+involving	O
+therapeutics	O
+for	O
+emerging	O
+and	O
+biodefense	O
+pathogens	O
+with	O
+low	O
+incidence	O
+,	O
+such	O
+as	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+requires	O
+at	O
+a	O
+minimum	O
+preclinical	O
+evaluation	O
+of	O
+efficacy	O
+in	O
+two	O
+well	O
+-	O
+characterized	O
+and	O
+robust	O
+animal	B-SPEC
+models	O
+.	O
+
+Thus	O
+,	O
+a	O
+ferret	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+model	O
+was	O
+evaluated	O
+over	O
+a	O
+period	O
+of	O
+58	O
+days	O
+following	O
+extensive	O
+optimization	O
+and	O
+characterization	O
+of	O
+the	O
+model	O
+in	O
+order	B-SPEC
+to	O
+validate	O
+clinical	O
+,	O
+histopathological	O
+,	O
+virological	O
+and	O
+immunological	O
+endpoints	O
+.	O
+
+Numerous	O
+reports	O
+have	O
+implied	O
+that	O
+the	O
+fecal	B-ANAT
+microflora	O
+may	O
+contribute	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+NEC	O
+.	O
+
+Indications	O
+for	O
+surgery	O
+include	O
+clinical	O
+deterioration	O
+,	O
+perforation	O
+,	O
+peritonitis	B-DISO
+,	O
+obstruction	B-DISO
+,	O
+and	O
+abdominal	B-ANAT
+mass	O
+.	O
+
+Eighteen	O
+infants	O
+(	O
+78	O
+.	O
+2	O
+%)	O
+required	O
+high	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+with	O
+a	O
+rapid	O
+and	O
+persistant	O
+improvement	O
+of	O
+oxygenation	B-PROC
+parameters	O
+.	O
+
+TITLE	O
+:	O
+Steady	O
+-	O
+state	O
+and	O
+pre	O
+-	O
+steady	O
+-	O
+state	O
+kinetic	O
+evaluation	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+3CLpro	O
+cysteine	B-PRGE
+protease	I-PRGE
+:	O
+development	B-PROC
+of	O
+an	O
+ion	O
+-	O
+pair	O
+model	O
+for	O
+catalysis	O
+.	O
+
+Steady	O
+-	O
+state	O
+solvent	B-CHED
+isotope	O
+effect	O
+(	O
+SIE	O
+)	O
+studies	O
+showed	O
+an	O
+inverse	O
+SIE	O
+for	O
+the	O
+amide	B-CHED
+but	O
+not	O
+ester	B-CHED
+substrates	O
+.	O
+
+Proton	B-CHED
+inventory	O
+(	O
+PI	O
+)	O
+studies	O
+on	O
+amide	B-CHED
+peptide	B-CHED
+hydrolysis	O
+were	O
+consistent	O
+with	O
+two	O
+proton	B-CHED
+-	O
+transfer	O
+reactions	O
+in	O
+the	O
+transition	B-DISO
+state	O
+while	O
+the	O
+ester	B-CHED
+data	O
+was	O
+consistent	O
+with	O
+a	O
+single	O
+proton	B-CHED
+-	O
+transfer	O
+reaction	O
+.	O
+
+There	O
+are	O
+currently	O
+no	O
+known	O
+immune	O
+correlates	O
+of	O
+protection	O
+against	O
+HIV	B-DISO
+.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+a	O
+31	O
+-	O
+year	O
+-	O
+old	O
+female	O
+who	O
+developed	O
+respiratory	B-DISO
+distress	I-DISO
+with	O
+unilateral	O
+pulmonary	B-DISO
+oedema	I-DISO
+and	O
+left	O
+ventricular	B-ANAT
+(	O
+LV	O
+)	O
+dysfunction	O
+in	O
+the	O
+context	O
+of	O
+neurological	O
+sequelae	O
+and	O
+diagnostic	O
+evaluation	O
+consistent	O
+with	O
+acute	O
+MS	O
+exacerbation	O
+.	O
+
+TITLE	O
+:	O
+The	O
+-	O
+1082	O
+interleukin	B-PRGE
+-	I-PRGE
+10	I-PRGE
+polymorphism	B-PROC
+is	O
+associated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+after	O
+major	O
+trauma	O
+:	O
+a	O
+prospective	O
+cohort	O
+study	O
+.	O
+
+TITLE	O
+:	O
+The	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+inhibits	O
+B23	O
+phosphorylation	B-PROC
+.	O
+
+Nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+encapsidates	O
+the	O
+viral	O
+RNA	O
+and	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+virus	B-PROC
+particle	I-PROC
+assembly	I-PROC
+and	O
+release	B-PATH
+.	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+for	O
+severe	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+disease	O
+in	O
+children	O
+with	O
+cancer	B-DISO
+:	O
+the	O
+importance	O
+of	O
+lymphopenia	O
+and	O
+young	O
+age	O
+.	O
+
+Fifty	O
+-	O
+eight	O
+patients	O
+met	B-CHED
+the	O
+study	O
+criteria	O
+.	O
+
+Of	O
+all	O
+patients	O
+with	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+31	O
+%	O
+died	B-PROC
+as	O
+a	O
+result	O
+of	O
+respiratory	B-DISO
+syncytial	I-DISO
+virus	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+inoculation	O
+of	O
+testis	O
+samples	O
+into	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+via	O
+the	O
+allantoic	O
+cavity	B-DISO
+resulted	O
+in	O
+curled	O
+,	O
+hemorrhagic	O
+,	O
+and	O
+stunted	O
+embryos	B-ANAT
+typical	O
+of	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+The	O
+NDV	B-PRGE
++	I-PRGE
+Ark	I-PRGE
+vaccines	O
+used	O
+were	O
+commercial	O
+vaccines	O
+manufactured	O
+as	O
+single	O
+entity	O
+products	O
+that	O
+were	O
+administered	O
+by	O
+eyedrop	O
+to	O
+opposite	O
+eyes	B-ANAT
+of	O
+each	O
+chicken	O
+.	O
+
+In	O
+the	O
+C2	O
++	O
+Mass	O
+vaccination	O
+trial	O
+,	O
+IBV	B-SPEC
+immunity	B-PROC
+after	O
+challenge	O
+was	O
+reduced	O
+,	O
+but	O
+it	O
+did	O
+not	O
+seem	O
+to	O
+be	O
+a	O
+result	O
+of	O
+reduced	O
+Mass	O
+vaccine	O
+growth	B-PROC
+or	O
+the	O
+ability	O
+of	O
+the	O
+Mass	O
+vaccine	O
+to	O
+induce	O
+serum	B-COMP
+IBV	B-SPEC
+antibody	B-COMP
+.	O
+
+However	O
+,	O
+interference	O
+with	O
+NDV	B-SPEC
+replication	O
+was	O
+not	O
+reflected	O
+in	O
+a	O
+reduction	O
+in	O
+Newcastle	B-DISO
+disease	I-DISO
+challenge	O
+of	O
+immunity	B-PROC
+findings	O
+when	O
+combination	O
+Mass	O
++	O
+NDV	B-SPEC
+products	O
+manufactured	O
+by	O
+vaccine	O
+companies	O
+were	O
+tested	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+,	O
+which	O
+is	O
+characterized	O
+by	O
+respiratory	O
+,	O
+reproductive	B-PROC
+,	O
+and	O
+renal	B-ANAT
+signs	O
+.	O
+
+Birds	B-SPEC
+were	O
+presenting	O
+watery	O
+diarrhea	O
+and	O
+poor	O
+general	O
+condition	B-DISO
+but	O
+were	O
+without	O
+respiratory	O
+,	O
+renal	B-ANAT
+,	O
+or	O
+reproductive	B-PROC
+signs	O
+.	O
+
+Using	O
+an	O
+epidemiologic	O
+model	O
+,	O
+we	O
+simulated	O
+exportation	O
+of	O
+cases	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+like	O
+and	O
+influenza	B-DISO
+-	O
+like	O
+epidemics	O
+in	O
+a	O
+population	O
+for	O
+which	O
+a	O
+small	O
+proportion	O
+travel	O
+more	O
+frequently	O
+than	O
+the	O
+rest	B-FUNC
+.	O
+
+To	O
+determine	O
+whether	O
+bats	B-SPEC
+in	O
+North	O
+America	O
+also	O
+harbor	O
+coronaviruses	O
+,	O
+we	O
+used	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+to	O
+detect	O
+coronavirus	B-SPEC
+RNA	O
+in	O
+bats	B-SPEC
+.	O
+
+Because	O
+of	O
+the	O
+potential	O
+for	O
+bat	B-ENZY
+coronaviruses	O
+to	O
+cause	O
+disease	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+,	O
+further	O
+surveillance	O
+and	O
+characterization	O
+of	O
+bat	B-ENZY
+coronaviruses	O
+in	O
+North	O
+America	O
+are	O
+needed	O
+.	O
+
+Therefore	O
+,	O
+we	O
+conducted	O
+a	O
+population	O
+-	O
+based	O
+survey	O
+of	O
+persons	O
+'	O
+precautionary	O
+actions	O
+in	O
+response	O
+to	O
+a	O
+hypothetical	O
+influenza	B-DISO
+pandemic	O
+.	O
+
+We	O
+detected	O
+antibody	B-COMP
+reactive	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antigen	B-CHED
+in	O
+47	O
+(	O
+6	O
+.	O
+7	O
+%)	O
+of	O
+705	O
+bat	B-ENZY
+serum	B-COMP
+specimens	O
+comprising	O
+26	O
+species	B-SPEC
+collected	O
+in	O
+Africa	O
+;	O
+thus	O
+,	O
+African	O
+bats	B-SPEC
+may	O
+harbor	O
+agents	O
+related	O
+to	O
+putative	O
+group	O
+4	O
+CoV	O
+.	O
+
+ABSTRACT	O
+:	O
+Broad	O
+-	O
+spectrum	O
+analysis	O
+for	O
+pathogens	O
+in	O
+patients	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+is	O
+becoming	O
+more	O
+relevant	O
+as	O
+the	O
+number	O
+of	O
+potential	O
+infectious	B-DISO
+agents	O
+is	O
+still	O
+increasing	O
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+new	O
+multiparameter	O
+RespiFinder	O
+assay	O
+,	O
+which	O
+is	O
+based	O
+on	O
+the	O
+multiplex	O
+ligation	O
+-	O
+dependent	O
+probe	O
+amplification	B-DISO
+(	O
+MLPA	O
+)	O
+technology	O
+.	O
+
+This	O
+assay	O
+detects	O
+15	O
+respiratory	O
+viruses	B-SPEC
+in	O
+one	O
+reaction	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+late	O
+2002	O
+,	O
+cases	O
+of	O
+life	O
+-	O
+threatening	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+no	O
+identifiable	O
+cause	O
+were	O
+reported	O
+from	O
+Guangdong	O
+Province	O
+,	O
+China	O
+,	O
+and	O
+they	O
+were	O
+followed	O
+by	O
+reports	O
+from	O
+other	O
+countries	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+studies	O
+have	O
+suggested	O
+that	O
+bats	O
+are	O
+the	O
+natural	O
+reservoir	O
+of	O
+a	O
+range	O
+of	O
+coronaviruses	O
+(	O
+CoVs	O
+),	O
+and	O
+that	O
+rhinolophid	O
+bats	B-SPEC
+harbor	O
+viruses	B-SPEC
+closely	O
+related	O
+to	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+CoV	O
+,	O
+which	O
+caused	O
+an	O
+outbreak	O
+of	O
+respiratory	O
+illness	O
+in	O
+humans	B-SPEC
+during	O
+2002	O
+-	O
+2003	O
+.	O
+
+These	O
+shifts	O
+may	O
+be	O
+due	O
+to	O
+either	O
+virus	B-SPEC
+biologic	O
+traits	O
+or	O
+host	B-COMP
+behavioral	B-PROC
+traits	O
+.	O
+
+Thus	O
+,	O
+SARS	B-DISO
+patients	O
+might	O
+be	O
+susceptible	O
+to	O
+reinfection	O
+>	O
+or	O
+=	O
+3	O
+years	O
+after	O
+initial	O
+exposure	O
+.	O
+
+TITLE	O
+:	O
+Anti	B-PRGE
+-	I-PRGE
+interleukin	I-PRGE
+-	I-PRGE
+8	I-PRGE
+autoantibody	I-PRGE
+:	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+immune	O
+complexes	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+This	O
+report	O
+studied	O
+the	O
+cardiovascular	B-ANAT
+changes	O
+in	O
+fatal	O
+cases	O
+of	O
+leptospirosis	B-DISO
+in	O
+Mumbai	O
+city	O
+,	O
+India	O
+in	O
+the	O
+year	O
+2005	O
+.	O
+
+The	O
+majority	O
+(	O
+86	O
+%)	O
+were	O
+adults	O
+;	O
+all	O
+presented	O
+as	O
+acute	O
+febrile	B-DISO
+illness	I-DISO
+that	O
+terminated	O
+with	O
+severe	O
+respiratory	B-DISO
+insufficiency	I-DISO
+.	O
+
+We	O
+sequenced	O
+the	O
+spike	O
+glycoprotein	B-CHED
+of	O
+12	O
+IBV	B-SPEC
+vaccines	O
+(	O
+5	O
+different	O
+serotypes	O
+from	O
+3	O
+different	O
+manufacturers	O
+)	O
+directly	O
+from	O
+the	O
+vaccine	O
+vial	O
+,	O
+then	O
+compared	O
+that	O
+sequence	O
+with	O
+reisolated	O
+viruses	B-SPEC
+from	O
+vaccinated	O
+and	O
+contact	O
+-	O
+exposed	O
+birds	B-SPEC
+over	O
+time	O
+.	O
+
+This	O
+information	O
+is	O
+also	O
+valuable	O
+for	O
+the	O
+development	B-PROC
+of	O
+safer	O
+modified	O
+live	O
+coronavirus	B-SPEC
+vaccines	O
+.	O
+
+Multivariable	O
+Cox	O
+proportional	O
+hazards	O
+analysis	O
+showed	O
+significant	O
+risks	O
+for	O
+BOS	B-DISO
+were	O
+highest	O
+B	O
+grade	O
+(	O
+relative	O
+risk	O
+[	O
+RR	O
+],	O
+1	O
+.	O
+62	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+31	O
+-	O
+2	O
+.	O
+00	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+longer	O
+ischemic	O
+time	O
+(	O
+RR	O
+,	O
+1	O
+.	O
+00	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+00	O
+-	O
+1	O
+.	O
+00	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+and	O
+recent	O
+year	O
+of	O
+transplant	B-ANAT
+(	O
+RR	O
+,	O
+0	O
+.	O
+93	O
+;	O
+CI	O
+,	O
+0	O
+.	O
+87	O
+-	O
+1	O
+.	O
+00	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+whereas	O
+risks	O
+for	O
+death	B-PROC
+were	O
+BOS	B-DISO
+as	O
+a	O
+time	O
+-	O
+dependent	O
+covariable	O
+(	O
+RR	O
+,	O
+19	O
+.	O
+10	O
+;	O
+CI	O
+,	O
+11	O
+.	O
+07	O
+-	O
+32	O
+.	O
+96	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+highest	O
+B	O
+grade	O
+(	O
+RR	O
+,	O
+1	O
+.	O
+36	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+07	O
+-	O
+1	O
+.	O
+72	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+patient	O
+clinically	O
+showed	O
+hypotension	O
+tachypnea	B-DISO
+and	O
+increasing	O
+dyspnea	B-DISO
+.	O
+
+In	O
+conclusion	O
+,	O
+although	O
+rare	O
+and	O
+associated	O
+with	O
+specific	O
+risk	O
+factors	O
+,	O
+hypophosphatemia	B-DISO
+should	O
+be	O
+suspected	O
+in	O
+patients	O
+who	O
+develop	O
+unexplained	O
+ARDS	B-DISO
+.	O
+
+Factors	O
+influencing	O
+progression	O
+to	O
+fibroproliferative	O
+ARDS	B-DISO
+vs	O
+.	O
+resolution	O
+and	O
+reconstitution	O
+of	O
+the	O
+normal	O
+pulmonary	B-ANAT
+parenchymal	O
+architecture	O
+are	O
+poorly	O
+understood	O
+.	O
+
+Understanding	O
+the	O
+mechanisms	O
+leading	O
+to	O
+and	O
+regulating	O
+fibroproliferative	O
+changes	O
+may	O
+contribute	O
+to	O
+the	O
+development	B-PROC
+of	O
+novel	O
+early	O
+therapeutic	O
+interventions	O
+in	O
+ARDS	B-DISO
+/	O
+ALI	O
+patients	O
+.	O
+
+All	O
+experimental	O
+data	O
+indicated	O
+that	O
+oxidative	B-DISO
+stress	I-DISO
+in	O
+host	B-COMP
+cells	B-COMP
+is	O
+an	O
+important	O
+factor	O
+in	O
+HCoV	O
+229E	O
+infectivity	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+crisis	O
+exposed	O
+serious	O
+deficiencies	O
+in	O
+China	O
+'	O
+s	O
+public	O
+health	O
+system	O
+and	O
+willingness	O
+to	O
+report	O
+outbreaks	O
+of	O
+threats	O
+to	O
+public	O
+health	O
+.	O
+
+The	O
+pIRES	O
+-	O
+S1	O
+,	O
+pIRES	B-PRGE
+-	I-PRGE
+IL2	I-PRGE
+and	O
+pIRES	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+/	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+2	I-PRGE
+plasmid	O
+expressing	O
+or	O
+co	O
+-	O
+expressing	O
+S1	O
+and	O
+IL	B-PRGE
+-	I-PRGE
+2	I-PRGE
+gene	I-PRGE
+were	O
+constructed	O
+.	O
+
+The	O
+7	O
+-	O
+day	O
+-	O
+old	O
+chickens	B-SPEC
+were	O
+immunized	O
+intramuscularly	O
+with	O
+plasmids	O
+encapsulated	O
+by	O
+liposome	O
+and	O
+boosted	O
+three	O
+weeks	O
+later	O
+.	O
+
+The	O
+costs	O
+of	O
+death	B-PROC
+and	O
+morbidity	O
+in	O
+lost	B-CHED
+wages	O
+,	O
+lost	B-CHED
+taxes	O
+,	O
+and	O
+rehabilitative	O
+costs	O
+,	O
+let	O
+alone	O
+the	O
+emotional	O
+costs	O
+,	O
+are	O
+enormous	O
+.	O
+
+Use	O
+of	O
+inhaled	O
+nitric	B-CHED
+oxide	I-CHED
+in	O
+patients	O
+with	O
+severe	O
+traumatic	O
+brain	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+will	O
+show	O
+a	O
+benefit	O
+through	O
+improved	O
+physiological	O
+parameters	O
+,	O
+a	O
+decrease	O
+in	O
+biochemical	O
+markers	O
+of	O
+inflammation	B-DISO
+and	O
+brain	B-ANAT
+injury	O
+,	O
+thus	O
+leading	O
+to	O
+better	O
+outcomes	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+exerted	B-PROC
+a	O
+massive	O
+toll	O
+on	O
+Hong	O
+Kong	O
+'	O
+s	O
+healthcare	O
+system	O
+in	O
+2003	O
+.	O
+
+Personal	O
+reflective	O
+essays	O
+written	O
+in	O
+2004	O
+by	O
+seven	O
+senior	O
+nurses	O
+studying	O
+a	O
+part	O
+-	O
+time	O
+Masters	O
+in	O
+Nursing	B-PROC
+degree	O
+at	O
+a	O
+Hong	O
+Kong	O
+university	O
+were	O
+analysed	O
+using	O
+a	O
+form	O
+of	O
+content	O
+analysis	O
+.	O
+
+Rhinovirus	B-SPEC
+and	O
+adenovirus	B-DISO
+were	O
+most	O
+frequently	O
+detected	O
+during	O
+URI	O
+.	O
+
+Young	O
+age	O
+was	O
+the	O
+most	O
+important	O
+predictor	O
+of	O
+AOM	B-DISO
+that	O
+complicated	O
+URI	B-PRGE
+.	O
+
+MDMA	B-CHED
+is	O
+a	O
+major	O
+cause	O
+of	O
+acute	O
+severe	O
+hyponatraemia	O
+and	O
+also	O
+has	O
+been	O
+linked	O
+with	O
+hepatic	B-ANAT
+syndromes	B-DISO
+.	O
+
+However	O
+,	O
+steroid	B-CHED
+seem	O
+to	O
+shorten	O
+the	O
+length	O
+of	O
+hospital	O
+stay	O
+.	O
+
+ABSTRACT	O
+:	O
+Lipid	B-COMP
+rafts	I-COMP
+often	O
+serve	O
+as	O
+an	O
+entry	O
+site	O
+for	O
+certain	O
+viruses	O
+.	O
+
+MbetaCD	O
+-	O
+treatment	O
+inhibited	O
+infectivity	O
+of	O
+pseudotyped	O
+SARS	B-DISO
+-	O
+CoV	O
+by	O
+90	O
+%.	O
+
+Resuscitation	O
+included	O
+early	O
+administration	O
+of	O
+antidote	B-CHED
+by	O
+emergency	B-DISO
+medical	O
+personnel	O
+as	O
+well	O
+as	O
+high	O
+-	O
+dose	O
+atropine	B-CHED
+.	O
+
+TITLE	O
+:	O
+Misrepresentation	O
+of	O
+health	O
+risks	O
+by	O
+mass	O
+media	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+The	O
+number	O
+of	O
+media	B-ANAT
+reports	O
+inversely	O
+correlated	O
+with	O
+the	O
+actual	O
+number	O
+of	O
+deaths	B-PROC
+for	O
+the	O
+health	O
+risks	O
+evaluated	O
+.	O
+
+TITLE	O
+:	O
+Cytokine	O
+responses	O
+in	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+-	O
+infected	O
+pigs	B-SPEC
+treated	O
+with	O
+corticosteroids	B-CHED
+as	O
+a	O
+model	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+future	O
+glucocorticoid	B-CHED
+treatment	O
+of	O
+SARS	B-DISO
+patients	O
+should	O
+be	O
+reconsidered	O
+in	O
+the	O
+context	O
+of	O
+potential	O
+local	O
+immunosuppression	B-PROC
+of	O
+immune	B-PROC
+responses	I-PROC
+in	O
+lung	B-ANAT
+and	O
+systemic	O
+Th1	O
+cytokine	O
+-	O
+biased	O
+suppression	B-DISO
+.	O
+
+Despite	O
+their	O
+relative	O
+seclusion	O
+from	O
+the	O
+rest	B-FUNC
+of	O
+the	O
+world	O
+,	O
+cats	B-SPEC
+and	O
+dogs	B-SPEC
+of	O
+Isabela	O
+were	O
+exposed	O
+to	O
+many	O
+pathogens	O
+found	O
+in	O
+mainland	O
+South	O
+America	O
+.	O
+
+While	O
+the	O
+upper	O
+region	O
+of	O
+SL1	B-PRGE
+is	O
+required	O
+to	O
+be	O
+paired	O
+,	O
+we	O
+observe	O
+strong	O
+genetic	B-PROC
+selection	I-PROC
+against	O
+viruses	B-SPEC
+that	O
+contain	O
+a	O
+deletion	O
+of	O
+A35	O
+,	O
+an	O
+extrahelical	O
+nucleotide	B-CHED
+that	O
+destabilizes	O
+SL1	B-PRGE
+,	O
+in	O
+favor	O
+of	O
+genomes	O
+that	O
+contain	O
+a	O
+diverse	O
+panel	O
+of	O
+destabilizing	O
+second	O
+-	O
+site	O
+mutations	O
+,	O
+due	O
+to	O
+introduction	O
+of	O
+a	O
+noncanonical	O
+base	B-FUNC
+pair	I-FUNC
+near	O
+A35	O
+.	O
+
+Thermal	O
+denaturation	B-PROC
+and	O
+imino	B-CHED
+proton	B-CHED
+solvent	B-CHED
+exchange	O
+experiments	O
+reveal	O
+that	O
+the	O
+lower	O
+half	O
+of	O
+SL1	B-PRGE
+is	O
+unstable	O
+and	O
+that	O
+second	O
+-	O
+site	O
+SL1	B-PRGE
+-	I-PRGE
+DeltaA35	I-PRGE
+substitutions	O
+are	O
+characterized	O
+by	O
+one	O
+or	O
+more	O
+features	O
+of	O
+the	O
+wild	B-PRGE
+-	I-PRGE
+type	I-PRGE
+SL1	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Development	B-PROC
+of	O
+vaccines	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+crucial	O
+in	O
+the	O
+prevention	O
+of	O
+SARS	B-DISO
+reemergence	O
+.	O
+
+Other	O
+neurological	O
+diagnoses	O
+present	O
+in	O
+this	O
+study	O
+were	O
+Rett	B-DISO
+syndrome	I-DISO
+,	O
+neuromuscular	B-DISO
+disease	I-DISO
+and	O
+meningomyelocele	B-DISO
+.	O
+
+Among	O
+children	O
+that	O
+did	O
+not	O
+develop	O
+ARI	B-CHED
+,	O
+the	O
+predominant	O
+motor	O
+pattern	O
+was	O
+:	O
+28	O
+with	O
+quadriplegia	B-DISO
+,	O
+38	O
+diplegia	B-DISO
+,	O
+10	O
+hemiplegia	B-DISO
+,	O
+12	O
+with	O
+involuntary	B-DISO
+movement	I-DISO
+(	O
+choeroathethosis	O
+)	O
+and	O
+six	O
+without	O
+motor	O
+involvement	O
+.	O
+
+However	O
+,	O
+the	O
+sizes	O
+of	O
+the	O
+corresponding	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+of	O
+some	O
+genes	O
+varied	O
+among	O
+the	O
+virus	B-SPEC
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+prospective	O
+2	O
+-	O
+year	O
+analysis	O
+including	O
+322	O
+infant	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+(	O
+ARD	B-ENZY
+)	O
+hospitalized	O
+in	O
+a	O
+pediatric	O
+department	O
+in	O
+northern	O
+Italy	O
+was	O
+carried	O
+out	O
+to	O
+evaluate	O
+the	O
+role	O
+as	O
+respiratory	O
+pathogens	O
+or	O
+co	O
+-	O
+pathogens	O
+of	O
+recently	O
+identified	O
+viruses	B-SPEC
+.	O
+
+The	O
+neurovirulent	O
+spike	O
+gene	O
+chimera	B-DISO
+SJHM	O
+/	O
+RA59	O
+induces	O
+high	O
+levels	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+macrophages	B-ANAT
+in	O
+the	O
+brain	B-ANAT
+compared	O
+to	O
+the	O
+attenuated	O
+SA59	O
+/	O
+RJHM	O
+chimera	B-DISO
+.	O
+
+TITLE	O
+:	O
+Viral	B-PROC
+infections	I-PROC
+in	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+.	O
+
+There	O
+is	O
+increasing	O
+evidence	O
+that	O
+implicates	O
+viral	B-DISO
+infections	I-DISO
+as	O
+a	O
+major	O
+risk	O
+factor	O
+for	O
+exacerbations	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+.	O
+
+Coronavirus	B-SPEC
+,	O
+influenza	B-DISO
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+parainfluenza	B-DISO
+,	O
+adenovirus	B-DISO
+,	O
+and	O
+metapneumovirus	B-SPEC
+are	O
+other	O
+important	O
+viral	O
+causes	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+exacerbations	O
+.	O
+
+The	O
+use	O
+of	O
+biomarkers	O
+represents	O
+an	O
+exciting	O
+new	O
+potential	O
+diagnostic	O
+tool	O
+that	O
+may	O
+lend	O
+new	O
+insights	O
+into	O
+the	O
+pathogenesis	B-DISO
+of	O
+viral	B-DISO
+infections	I-DISO
+in	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+infection	I-DISO
+modulates	O
+the	O
+unfolded	O
+protein	B-CHED
+response	O
+and	O
+mediates	O
+sustained	O
+translational	B-PROC
+repression	I-PROC
+.	O
+
+We	O
+hypothesized	O
+that	O
+the	O
+association	O
+and	O
+intense	O
+utilization	O
+of	O
+the	O
+ER	O
+during	O
+viral	B-PROC
+replication	I-PROC
+would	O
+induce	O
+the	O
+cellular	B-COMP
+unfolded	O
+protein	B-CHED
+response	O
+(	O
+UPR	O
+),	O
+a	O
+signal	B-PROC
+transduction	I-PROC
+cascade	O
+that	O
+acts	O
+to	O
+modulate	O
+translation	B-PROC
+,	O
+membrane	B-COMP
+biosynthesis	B-PROC
+,	O
+and	O
+the	O
+levels	O
+of	O
+ER	O
+chaperones	O
+.	O
+
+Our	O
+study	O
+results	O
+help	O
+to	O
+clarify	O
+previously	O
+published	O
+controversial	O
+claims	O
+about	O
+the	O
+role	O
+of	O
+the	O
+N	O
+-	O
+finger	B-ANAT
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+M	O
+(	O
+pro	B-CHED
+)	O
+dimerization	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+nsp1	B-PRGE
+suppresses	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+,	O
+including	O
+that	O
+of	O
+type	O
+I	O
+interferon	O
+,	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+Both	O
+a	O
+SARS	B-DISO
+-	O
+CoV	O
+mutant	B-DISO
+virus	B-SPEC
+,	O
+encoding	O
+the	O
+nsp1	B-PRGE
+-	I-PRGE
+mt	I-PRGE
+protein	I-PRGE
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+mt	I-PRGE
+),	O
+and	O
+a	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+WT	O
+)	O
+replicated	O
+efficiently	O
+and	O
+exhibited	O
+similar	O
+one	O
+-	O
+step	O
+growth	B-PROC
+kinetics	O
+in	O
+susceptible	O
+cells	B-COMP
+.	O
+
+Both	O
+viruses	B-SPEC
+accumulated	O
+similar	O
+amounts	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+mRNAs	O
+and	O
+nsp1	B-PRGE
+protein	I-PRGE
+in	O
+infected	O
+cells	B-COMP
+,	O
+whereas	O
+the	O
+amounts	O
+of	O
+endogenous	O
+host	B-COMP
+mRNAs	O
+were	O
+clearly	O
+higher	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+mt	O
+-	O
+infected	O
+cells	O
+than	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+WT	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+in	O
+both	O
+the	O
+presence	O
+and	O
+absence	O
+of	O
+actinomycin	B-CHED
+D	I-CHED
+.	O
+Further	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+WT	I-PRGE
+replication	O
+strongly	O
+inhibited	O
+host	B-COMP
+protein	B-PROC
+synthesis	I-PROC
+,	O
+whereas	O
+host	B-PRGE
+protein	B-PROC
+synthesis	I-PROC
+inhibition	I-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+mt	O
+-	O
+infected	O
+cells	B-COMP
+was	O
+not	O
+as	O
+efficient	O
+as	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+WT	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+RNase	B-PRGE
+-	I-PRGE
+resistant	I-PRGE
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+containing	I-PRGE
+long	I-PRGE
+chimeric	I-PRGE
+RNA	I-PRGE
+sequences	I-PRGE
+produced	O
+by	O
+two	O
+-	O
+plasmid	O
+coexpression	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+75	O
+-	O
+year	O
+-	O
+old	O
+previously	O
+healthy	O
+man	O
+presented	O
+for	O
+elective	O
+resection	O
+of	O
+rectal	B-DISO
+cancer	I-DISO
+under	O
+general	B-PROC
+anesthesia	I-PROC
+.	O
+
+This	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+appeared	O
+to	O
+be	O
+due	O
+to	O
+increased	O
+permeability	O
+rather	O
+than	O
+pulmonary	B-DISO
+congestion	I-DISO
+as	O
+indicated	O
+by	O
+chest	B-ANAT
+radiography	O
+,	O
+pulmonary	B-ANAT
+artery	I-ANAT
+occlusion	O
+pressure	O
+,	O
+echocardiogram	O
+,	O
+and	O
+the	O
+protein	B-CHED
+-	O
+rich	O
+edema	B-DISO
+fluid	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+the	O
+9	O
+.	O
+36	O
+kb	O
+C	O
+-	O
+terminal	O
+region	O
+of	O
+canine	O
+coronavirus	B-SPEC
+1	O
+-	O
+71	O
+strain	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+total	O
+of	O
+9	O
+.	O
+36	O
+kb	O
+nucleotides	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+one	O
+-	O
+third	O
+genome	O
+of	O
+the	O
+canine	O
+Coronavirus	B-SPEC
+(	O
+CCV	B-DISO
+)	O
+1	O
+-	O
+71	O
+strain	O
+,	O
+including	O
+all	O
+the	O
+structural	O
+protein	B-CHED
+genes	O
+and	O
+some	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+(	O
+nsp	O
+)	O
+genes	O
+were	O
+cloned	O
+and	O
+sequenced	O
+.	O
+
+Relationships	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+gene	I-PRGE
+polymorphisms	O
+with	O
+interstitial	B-DISO
+lung	B-ANAT
+fibrosis	I-DISO
+and	O
+femoral	B-ANAT
+head	I-ANAT
+osteonecrosis	B-DISO
+were	O
+carried	O
+out	O
+in	O
+two	O
+case	O
+-	O
+case	O
+studies	O
+in	O
+discharged	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+inhibition	B-PROC
+is	O
+selective	O
+because	O
+these	O
+compounds	O
+do	O
+not	O
+exert	B-PROC
+significant	O
+inhibitory	O
+effects	O
+against	O
+other	O
+cysteine	B-CHED
+proteases	I-PRGE
+,	O
+including	O
+SARS	B-DISO
+-	O
+CoV	O
+3CLpro	O
+and	O
+several	O
+cathepsins	O
+.	O
+
+TITLE	O
+:	O
+Thrombopoietin	B-PRGE
+levels	O
+increased	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Amiodarone	B-CHED
+alters	O
+late	O
+endosomes	O
+and	O
+inhibits	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+at	O
+a	O
+post	O
+-	O
+endosomal	O
+level	O
+.	O
+
+We	O
+found	O
+that	O
+(	O
+1	O
+)	O
+amiodarone	B-CHED
+associates	O
+with	O
+different	O
+cell	B-COMP
+membranes	I-COMP
+and	O
+accumulates	O
+in	O
+acidic	O
+organelles	B-COMP
+;	O
+(	O
+2	O
+)	O
+the	O
+diethylamino	O
+-	O
+beta	O
+-	O
+ethoxy	B-CHED
+group	I-CHED
+is	O
+an	O
+important	O
+determinant	O
+of	O
+uptake	O
+;	O
+(	O
+3	O
+)	O
+vacuoles	B-COMP
+forming	O
+upon	O
+exposure	O
+to	O
+amiodarone	B-CHED
+are	O
+enlarged	O
+late	O
+endosomes	O
+;	O
+(	O
+4	O
+)	O
+amiodarone	B-CHED
+inhibits	O
+the	O
+spreading	O
+in	O
+vitro	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+;	O
+and	O
+(	O
+5	O
+)	O
+trypsin	B-PRGE
+cleavage	B-PROC
+of	O
+the	O
+viral	O
+spike	O
+protein	B-CHED
+before	O
+infection	B-DISO
+,	O
+which	O
+permits	B-SPEC
+virus	B-SPEC
+entry	O
+through	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+,	O
+does	O
+not	O
+impair	O
+amiodarone	B-CHED
+antiviral	B-CHED
+activity	O
+.	O
+
+TITLE	O
+:	O
+Protective	O
+effect	O
+of	O
+hydrogen	B-CHED
+sulfide	I-CHED
+in	O
+a	O
+murine	B-SPEC
+model	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+combined	O
+burn	O
+and	O
+smoke	O
+inhalation	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+hypothesized	O
+that	O
+a	O
+parenteral	O
+formulation	O
+of	O
+H2S	B-CHED
+would	O
+reduce	O
+the	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+burn	O
+and	O
+smoke	O
+inhalation	B-PROC
+in	O
+a	O
+novel	O
+murine	B-SPEC
+model	O
+.	O
+
+In	O
+conclusion	O
+,	O
+these	O
+results	O
+suggest	O
+that	O
+H2S	B-CHED
+exerts	B-PROC
+protective	O
+effects	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+at	O
+least	O
+in	O
+part	O
+through	O
+the	O
+activation	O
+of	O
+anti	O
+-	O
+inflammatory	O
+and	O
+antioxidant	B-CHED
+pathways	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Molecular	B-PROC
+mimicry	I-PROC
+,	O
+defined	O
+as	O
+similar	O
+structures	O
+shared	O
+by	O
+molecules	O
+from	O
+dissimilar	O
+genes	O
+or	O
+proteins	B-CHED
+,	O
+is	O
+a	O
+general	O
+strategy	O
+used	O
+by	O
+pathogens	O
+to	O
+infect	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+new	O
+human	B-SPEC
+respiratory	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+Endotoxemia	O
+and	O
+endotoxin	O
+tolerance	B-DISO
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+A	O
+comprehensive	O
+clinical	O
+and	O
+genetic	O
+analysis	O
+of	O
+influenza	B-DISO
+B	O
+viruses	B-SPEC
+-	O
+associated	O
+important	O
+diseases	O
+was	O
+lacking	O
+.	O
+
+ABSTRACT	O
+:	O
+Ovarian	B-ANAT
+hyperstimulation	I-DISO
+syndrome	I-DISO
+(	O
+OHSS	O
+)	O
+is	O
+an	O
+iatrogenic	O
+complication	B-DISO
+,	O
+the	O
+basis	O
+for	O
+which	O
+is	O
+a	O
+hyperergic	O
+uncontrolled	O
+ovarian	B-ANAT
+response	O
+to	O
+gonadotropins	O
+in	O
+the	O
+ovulation	B-PROC
+stimulation	O
+cycles	O
+and	O
+assisted	O
+procreation	B-PROC
+programs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+masked	B-SPEC
+palm	I-SPEC
+civet	I-SPEC
+(	O
+Paguma	B-SPEC
+larvata	I-SPEC
+)	O
+has	O
+been	O
+suspected	O
+to	O
+be	O
+the	O
+host	B-COMP
+of	O
+a	O
+SARS	B-DISO
+-	O
+like	O
+CoV	O
+virus	B-SPEC
+that	O
+causes	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+There	O
+was	O
+a	O
+significant	O
+difference	O
+in	O
+ELISA	O
+antibody	B-COMP
+levels	O
+elicited	O
+by	O
+either	O
+monocistronic	O
+or	O
+bicistronic	O
+DNA	O
+vaccines	O
+.	O
+
+Some	O
+of	O
+these	O
+studies	O
+have	O
+also	O
+shown	O
+anti	O
+-	O
+inflammatory	O
+effects	O
+of	O
+treatment	O
+targeting	B-PROC
+at	O
+coagulation	B-PROC
+.	O
+
+NK	B-ANAT
+cells	I-ANAT
+are	O
+recruited	O
+normally	O
+in	O
+the	O
+liver	B-ANAT
+and	O
+produce	O
+interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+gamma	O
+to	O
+control	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Phenotypic	O
+analysis	O
+of	O
+intrahepatic	O
+mononuclear	B-ANAT
+cells	I-ANAT
+revealed	O
+that	O
+apoptotic	O
+NK	O
+and	O
+NK	O
+T	B-ANAT
+cells	I-ANAT
+increased	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+the	O
+L2	O
+-	O
+MHV3	O
+,	O
+but	O
+were	O
+minor	O
+in	O
+51	O
+.	O
+6	O
+-	O
+MHV3	O
+-	O
+and	O
+CL12	O
+-	O
+MHV3	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+Future	O
+work	O
+should	O
+include	O
+the	O
+isolation	O
+and	O
+molecular	O
+characterization	O
+of	O
+IBV	B-SPEC
+in	O
+the	O
+region	O
+to	O
+adopt	O
+a	O
+suitable	O
+vaccination	O
+program	O
+using	O
+the	O
+common	O
+field	O
+serotypes	O
+as	O
+vaccines	O
+to	O
+protect	O
+against	O
+IBV	B-SPEC
+-	O
+caused	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Lessons	O
+from	O
+SARS	B-DISO
+:	O
+a	O
+new	O
+potential	O
+therapy	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+with	O
+angiotensin	O
+converting	O
+enzyme	O
+2	O
+(	O
+ACE2	B-PRGE
+)].	O
+
+Interestingly	O
+,	O
+a	O
+novel	O
+homologue	O
+of	O
+angiotensin	B-CHED
+converting	O
+-	O
+enzyme	O
+(	O
+ACE	B-PRGE
+),	O
+termed	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+receptor	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ACE	B-PRGE
+and	O
+ACE2	B-PRGE
+share	O
+homology	O
+in	O
+their	O
+catalytic	O
+domain	O
+and	O
+provide	O
+different	O
+key	O
+functions	O
+in	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+.	O
+
+Notably	O
+,	O
+injection	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+Spike	O
+into	O
+mice	B-SPEC
+worsens	O
+acute	O
+lung	B-ANAT
+failure	O
+in	O
+vivo	O
+that	O
+can	O
+be	O
+attenuated	O
+by	O
+blocking	B-DISO
+the	O
+renin	B-PRGE
+-	O
+angiotensin	B-CHED
+pathway	B-PROC
+,	O
+suggesting	O
+the	O
+activation	O
+of	O
+pulmonary	B-ANAT
+RAS	B-CHED
+influences	O
+the	O
+pathogenesis	B-DISO
+of	O
+ARDS	B-DISO
+and	O
+SARS	B-DISO
+.	O
+
+However	O
+,	O
+both	O
+alcohol	O
+-	O
+fed	O
+animals	B-SPEC
+and	O
+otherwise	O
+healthy	O
+alcoholic	O
+humans	B-SPEC
+do	O
+not	O
+have	O
+pulmonary	B-DISO
+edema	I-DISO
+at	O
+baseline	O
+,	O
+even	O
+though	O
+their	O
+lungs	B-ANAT
+are	O
+highly	O
+susceptible	O
+to	O
+acute	O
+edematous	B-DISO
+injury	O
+in	O
+response	O
+to	O
+inflammatory	O
+stresses	O
+.	O
+
+Chronic	O
+alcohol	O
+ingestion	O
+increases	O
+expression	B-PROC
+of	O
+apical	O
+sodium	O
+channels	O
+in	O
+the	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+;	O
+however	O
+,	O
+its	O
+effects	O
+on	O
+the	O
+Na	O
+,	O
+K	B-PRGE
+-	I-PRGE
+ATPase	I-PRGE
+complex	O
+that	O
+drives	O
+sodium	O
+and	O
+fluid	B-PROC
+transport	I-PROC
+out	O
+of	O
+the	O
+alveolar	B-ANAT
+space	O
+have	O
+not	O
+been	O
+examined	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+chronic	O
+alcohol	O
+ingestion	O
+,	O
+which	O
+is	O
+known	O
+to	O
+increase	O
+alveolar	B-ANAT
+epithelial	O
+paracellular	O
+permeability	O
+,	O
+actually	O
+increases	O
+the	O
+expression	B-PROC
+of	O
+Na	B-PRGE
+,	I-PRGE
+K	I-PRGE
+-	I-PRGE
+ATPase	I-PRGE
+in	O
+the	O
+lung	B-ANAT
+as	O
+a	O
+compensatory	O
+mechanism	O
+.	O
+
+Infected	O
+animals	B-SPEC
+become	O
+less	O
+aggressive	B-DISO
+and	O
+develop	O
+pyrexia	B-PROC
+,	O
+lethargy	B-DISO
+and	O
+diarrhoea	B-DISO
+.	O
+
+The	O
+present	O
+study	O
+describes	O
+the	O
+spectrum	O
+of	O
+histopathological	O
+changes	O
+in	O
+the	O
+lung	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+lymph	B-ANAT
+node	I-ANAT
+,	O
+liver	B-ANAT
+,	O
+small	B-ANAT
+intestine	I-ANAT
+,	O
+kidney	B-ANAT
+and	O
+cerebrum	B-ANAT
+of	O
+civets	B-SPEC
+infected	O
+experimentally	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+In	O
+-	O
+situ	O
+hybridization	B-PROC
+(	O
+ISH	B-DISO
+)	O
+with	O
+probes	O
+specific	O
+for	O
+the	O
+RNA	B-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+demonstrated	O
+viral	O
+RNA	O
+in	O
+the	O
+lung	B-ANAT
+,	O
+small	B-ANAT
+intestine	I-ANAT
+and	O
+cerebrum	B-ANAT
+only	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+residues	O
+in	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+that	O
+are	O
+critical	O
+for	O
+the	O
+RBD	B-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+receptor	I-PRGE
+interaction	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+NL63	O
+),	O
+a	O
+member	O
+of	O
+the	O
+group	O
+I	O
+coronaviruses	O
+,	O
+may	O
+cause	O
+acute	O
+respiratory	B-DISO
+diseases	I-DISO
+in	O
+young	O
+children	O
+and	O
+immunocompromised	O
+adults	O
+.	O
+
+Like	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+NL63	O
+also	O
+employs	O
+the	O
+human	B-PRGE
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+hACE2	O
+)	O
+receptor	O
+for	O
+cellular	B-COMP
+entry	O
+.	O
+
+These	O
+findings	O
+may	O
+be	O
+very	O
+important	O
+for	O
+understanding	O
+the	O
+mechanism	O
+of	O
+ADE	B-CHED
+of	O
+FIPV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+neutralising	O
+antibodies	B-COMP
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+by	O
+recombinant	O
+measles	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Live	O
+attenuated	O
+recombinant	O
+measles	B-PATH
+viruses	B-SPEC
+(	O
+rMV	O
+)	O
+expressing	O
+a	O
+codon	O
+-	O
+optimised	O
+spike	O
+glycoprotein	B-CHED
+(	O
+S	O
+)	O
+or	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+were	O
+generated	O
+(	O
+rMV	O
+-	O
+S	O
+and	O
+rMV	O
+-	O
+N	O
+).	O
+
+Both	O
+recombinant	O
+viruses	B-SPEC
+stably	O
+expressed	B-PROC
+the	O
+corresponding	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+,	O
+grew	O
+to	O
+similar	O
+end	O
+titres	O
+as	O
+the	O
+parental	O
+strain	O
+and	O
+induced	O
+high	O
+antibody	B-COMP
+titres	O
+against	O
+MV	O
+and	O
+the	O
+vectored	O
+SARS	B-DISO
+-	O
+CoV	O
+antigens	B-CHED
+(	O
+S	O
+and	O
+N	O
+)	O
+in	O
+transgenic	B-SPEC
+mice	I-SPEC
+susceptible	O
+to	O
+measles	B-PATH
+infection	B-DISO
+.	O
+
+Planning	O
+for	O
+future	O
+outbreaks	O
+should	O
+take	O
+into	O
+account	O
+the	O
+need	O
+to	O
+(	O
+1	O
+)	O
+develop	O
+systems	O
+that	O
+enable	O
+rapid	O
+two	O
+-	O
+way	O
+communication	O
+between	O
+public	O
+health	O
+officials	O
+and	O
+homeless	O
+service	O
+providers	O
+,	O
+(	O
+2	O
+)	O
+ensure	O
+that	O
+homeless	O
+service	O
+providers	O
+have	O
+access	O
+to	O
+infection	B-DISO
+control	O
+supplies	O
+and	O
+staff	O
+training	O
+,	O
+(	O
+3	O
+)	O
+prepare	O
+for	O
+possible	O
+homeless	O
+shelter	O
+closures	O
+due	O
+to	O
+staff	O
+shortages	O
+or	O
+high	O
+attack	O
+rates	O
+among	O
+clients	O
+,	O
+and	O
+(	O
+4	O
+)	O
+plan	O
+for	O
+where	O
+and	O
+how	O
+clinically	O
+ill	B-DISO
+homeless	O
+individuals	O
+will	O
+be	O
+isolated	O
+and	O
+treated	O
+.	O
+
+The	O
+Toronto	O
+SARS	B-DISO
+experience	O
+provided	O
+insights	O
+that	O
+are	O
+relevant	O
+to	O
+response	O
+planning	O
+for	O
+future	O
+outbreaks	O
+in	O
+cities	O
+with	O
+substantial	O
+numbers	O
+of	O
+homeless	O
+individuals	O
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+SW1	O
+to	O
+be	O
+a	O
+novel	O
+virus	B-SPEC
+distantly	O
+related	O
+to	O
+but	O
+most	O
+similar	O
+to	O
+group	O
+III	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+smoke	O
+inhalation	O
+injury	O
+victims	O
+frequently	O
+develop	O
+severe	O
+hypoxemia	O
+and	O
+are	O
+at	O
+increased	O
+risk	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+no	O
+early	O
+prognostic	O
+tests	O
+are	O
+currently	O
+available	O
+.	O
+
+Partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+(	O
+Pao2	O
+)	O
+and	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+Fio2	O
+)	O
+were	O
+recorded	O
+approximately	O
+every	O
+6	O
+hours	O
+from	O
+intubated	O
+smoke	O
+inhalation	B-PROC
+victims	O
+admitted	O
+to	O
+a	O
+regional	O
+burn	O
+center	O
+.	O
+
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+increased	O
+sharply	O
+in	O
+the	O
+first	O
+6	O
+.	O
+5	O
+hours	O
+postexposure	O
+(	O
+P	O
+<	O
+.	O
+001	O
+),	O
+and	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+in	O
+the	O
+first	O
+6	O
+.	O
+1	O
+hours	O
+(	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+On	O
+a	O
+neutralization	O
+assay	O
+,	O
+neutralizing	O
+activity	O
+with	O
+the	O
+IP	O
+immunization	O
+protocol	O
+was	O
+detected	O
+in	O
+sera	B-COMP
+and	O
+mucosal	B-ANAT
+secretions	B-ANAT
+(	O
+from	O
+the	O
+saliva	B-ANAT
+and	O
+genital	B-ANAT
+tract	O
+),	O
+but	O
+sera	B-COMP
+from	O
+the	O
+IN	O
+protocol	O
+failed	O
+to	O
+show	O
+any	O
+neutralizing	O
+activity	O
+.	O
+
+Patients	O
+were	O
+recruited	O
+from	O
+cases	O
+of	O
+snakebites	O
+admitted	O
+to	O
+the	O
+emergency	B-DISO
+care	O
+unit	O
+of	O
+Kottayam	O
+Medical	O
+College	O
+between	O
+May	O
+2005	O
+and	O
+December	O
+2006	O
+.	O
+
+Higher	O
+rates	O
+of	O
+complications	O
+were	O
+seen	O
+in	O
+those	O
+with	O
+severe	O
+coagulopathy	B-DISO
+(	O
+OR	O
+=	O
+8	O
+.	O
+0	O
+),	O
+leucocytosis	B-DISO
+(	O
+OR	O
+=	O
+3	O
+.	O
+7	O
+)	O
+and	O
+those	O
+who	O
+received	O
+SAV	O
+late	O
+.	O
+
+Eleven	O
+of	O
+59	O
+episodes	O
+(	O
+18	O
+.	O
+6	O
+%)	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Platypnea	O
+-	O
+orthodeoxia	O
+is	O
+a	O
+syndrome	B-DISO
+characterized	O
+by	O
+dyspnea	B-DISO
+and	O
+hypoxemia	O
+on	O
+adoption	O
+of	O
+an	O
+upright	O
+posture	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+orthodeoxia	O
+),	O
+and	O
+by	O
+the	O
+absence	O
+or	O
+reduction	O
+of	O
+symptoms	O
+and	O
+of	O
+hypoxemia	O
+in	O
+a	O
+supine	O
+position	O
+.	O
+
+Diagnosis	O
+of	O
+platypnea	B-DISO
+-	O
+orthodeoxia	O
+syndrome	B-DISO
+was	O
+demonstrated	O
+by	O
+O2	O
+saturation	O
+and	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+in	O
+the	O
+supine	O
+and	O
+upright	O
+positions	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Establishment	O
+of	O
+a	O
+system	O
+for	O
+determination	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+(	O
+RDV	B-SPEC
+method	O
+),	O
+and	O
+its	O
+application	O
+].	O
+
+Using	O
+the	O
+RDV	B-SPEC
+system	O
+,	O
+it	O
+is	O
+possible	O
+to	O
+obtain	O
+viral	O
+nucleic	B-CHED
+acid	I-CHED
+sequences	O
+within	O
+2	O
+days	O
+.	O
+
+All	O
+markers	O
+except	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+were	O
+significantly	O
+different	O
+between	O
+survivors	O
+and	O
+nonsurvivors	O
+.	O
+
+1	O
+.	O
+1	O
+ml	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+and	O
+the	O
+plateau	O
+pressure	O
+was	O
+25	O
++/-	O
+
+Lower	O
+levels	O
+of	O
+protein	B-CHED
+C	O
+were	O
+independently	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+death	B-PROC
+(	O
+odds	O
+ratio	O
+=	O
+0	O
+.	O
+5	O
+),	O
+a	O
+result	O
+that	O
+nearly	O
+reached	O
+statistical	O
+significance	O
+(	O
+P	O
+=	O
+0	O
+.	O
+06	O
+).	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+phagocytic	B-ANAT
+cells	I-ANAT
+in	O
+enhanced	O
+susceptibility	O
+of	O
+broilers	O
+to	O
+colibacillosis	B-DISO
+after	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Colibacillosis	B-DISO
+results	O
+from	O
+infection	B-DISO
+with	O
+avian	B-SPEC
+pathogenic	O
+Escherichia	B-SPEC
+coli	I-SPEC
+bacteria	B-SPEC
+.	O
+
+Inoculation	O
+with	O
+IBV	O
+induced	O
+extended	O
+and	O
+more	O
+severe	O
+colibacillosis	B-DISO
+than	O
+with	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+alone	O
+.	O
+
+Bactericidal	B-PROC
+activity	I-PROC
+of	O
+PBMC	O
+in	O
+IBV	B-SPEC
+-	O
+inoculated	O
+animals	B-SPEC
+at	O
+7dpi	O
+was	O
+lower	O
+than	O
+in	O
+PBS	B-DISO
+-	O
+and	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+-	O
+inoculated	O
+birds	B-SPEC
+,	O
+but	O
+phagocytic	O
+capacity	O
+and	O
+recruitment	B-DISO
+were	O
+not	O
+severely	O
+impaired	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Detection	O
+of	O
+the	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+human	B-SPEC
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+as	O
+a	O
+SARS	B-DISO
+coronavirus	B-SPEC
+functional	I-PRGE
+receptor	I-PRGE
+in	O
+human	B-SPEC
+femoral	B-ANAT
+head	I-ANAT
+].	O
+
+SARS	B-DISO
+-	O
+COV	O
+can	O
+not	O
+infect	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+tissue	B-ANAT
+and	O
+lead	O
+to	O
+avascular	B-DISO
+necrosis	I-DISO
+of	I-DISO
+the	I-DISO
+femoral	B-ANAT
+head	I-ANAT
+directly	O
+by	O
+the	O
+spike	O
+glycoprotein	B-CHED
+,	O
+and	O
+mechanism	O
+of	O
+the	O
+virus	B-SPEC
+for	O
+causing	O
+avascular	B-DISO
+necrosis	B-PROC
+needs	O
+further	O
+investigation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+-	O
+COV	O
+can	O
+not	O
+infect	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+tissue	B-ANAT
+and	O
+lead	O
+to	O
+avascular	B-DISO
+necrosis	I-DISO
+of	I-DISO
+the	I-DISO
+femoral	B-ANAT
+head	I-ANAT
+directly	O
+by	O
+the	O
+spike	O
+glycoprotein	B-CHED
+,	O
+and	O
+mechanism	O
+of	O
+the	O
+virus	B-SPEC
+for	O
+causing	O
+avascular	B-DISO
+necrosis	I-DISO
+needs	O
+further	O
+investigation	O
+.	O
+
+Two	O
+hundred	O
+and	O
+forty	O
+two	O
+nasal	B-ANAT
+swabs	O
+were	O
+collected	O
+from	O
+238	O
+children	O
+(	O
+median	O
+age	O
+12	O
+.	O
+4	O
+months	O
+).	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+co	O
+-	O
+circulation	B-PROC
+of	O
+hMPV	B-SPEC
+and	O
+HCoV	O
+NL63	O
+A	O
+and	O
+B	O
+lineages	O
+,	O
+although	O
+only	O
+HBoV	B-PRGE
+genotype	I-PRGE
+st2	I-PRGE
+was	O
+found	O
+.	O
+
+Viruses	B-SPEC
+are	O
+an	O
+important	O
+cause	O
+of	O
+wheezing	B-DISO
+in	O
+preschool	O
+children	O
+;	O
+hMPV	B-SPEC
+,	O
+HCoV	O
+NL63	O
+,	O
+and	O
+HBoV	O
+are	O
+less	O
+common	O
+than	O
+the	O
+usual	O
+respiratory	O
+pathogens	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+is	O
+a	O
+common	O
+cause	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+in	O
+children	O
+,	O
+predominantly	O
+presenting	O
+with	O
+mild	O
+symptoms	O
+.	O
+
+ABSTRACT	O
+:	O
+Cell	B-ANAT
+clone	I-ANAT
+
+TITLE	O
+:	O
+Acardiac	B-DISO
+twin	I-DISO
+fetus	B-ANAT
+with	O
+severe	O
+hydrops	B-DISO
+fetalis	I-DISO
+and	O
+bilateral	O
+talipes	O
+varus	B-DISO
+deformity	I-DISO
+.	O
+
+TRAPS	B-DISO
+is	O
+characterized	O
+by	O
+the	O
+hemodynamic	B-PROC
+dependence	B-DISO
+of	O
+a	O
+""""	O
+recipient	O
+""""	O
+twin	O
+from	O
+a	O
+""""	O
+pump	O
+""""	O
+twin	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+test	O
+the	O
+hypothesis	O
+that	O
+PBL	O
+is	O
+an	O
+effective	O
+method	O
+for	O
+preparing	O
+multidisciplinary	O
+learner	O
+groups	O
+at	O
+community	O
+health	O
+centers	O
+(	O
+CHCs	O
+)	O
+for	O
+pandemics	O
+,	O
+quantitative	O
+and	O
+qualitative	O
+methods	O
+were	O
+utilized	O
+to	O
+evaluate	O
+the	O
+conduct	B-PROC
+of	O
+a	O
+PBL	O
+case	O
+of	O
+a	O
+hypothetical	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+at	O
+two	O
+CHCs	O
+in	O
+Hawaii	O
+,	O
+with	O
+multidisciplinary	O
+health	O
+professional	O
+and	O
+student	O
+participants	O
+.	O
+
+Lemierre	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+is	O
+characterized	O
+by	O
+severe	O
+infection	B-DISO
+,	O
+with	O
+pharyngitis	B-DISO
+,	O
+sepsis	B-DISO
+and	O
+thrombosis	B-DISO
+of	O
+the	O
+internal	B-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+,	O
+and	O
+is	O
+most	O
+frequently	O
+associated	O
+with	O
+upper	O
+airway	B-ANAT
+infection	B-DISO
+with	O
+Fusobacterium	B-SPEC
+necrophorum	I-SPEC
+,	O
+often	O
+preceded	O
+by	O
+infection	B-DISO
+with	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+which	O
+enables	O
+bacteria	B-SPEC
+growing	O
+in	O
+the	O
+oral	B-ANAT
+cavity	I-ANAT
+to	O
+invade	O
+.	O
+
+Pulmonary	O
+coccidioidomycosis	O
+occurs	O
+in	O
+95	O
+%	O
+of	O
+all	O
+cases	O
+and	O
+can	O
+be	O
+divided	O
+into	O
+three	O
+main	O
+categories	O
+:	O
+primary	O
+,	O
+complicated	O
+,	O
+and	O
+residual	O
+pulmonary	B-DISO
+coccidioidomycosis	I-DISO
+.	O
+
+The	O
+primary	B-DISO
+infection	I-DISO
+occurs	O
+with	O
+inhalation	B-PROC
+of	O
+airborne	O
+arthroconidia	O
+.	O
+
+The	O
+third	O
+category	O
+of	O
+residual	B-DISO
+disease	I-DISO
+comprises	O
+only	O
+two	O
+entities	O
+:	O
+pulmonary	B-ANAT
+nodule	B-DISO
+and	O
+fibrosis	B-DISO
+.	O
+
+Laboratory	O
+investigations	O
+have	O
+demonstrated	O
+that	O
+these	O
+two	O
+emerging	O
+infections	B-DISO
+have	O
+similar	O
+features	O
+;	O
+and	O
+understanding	O
+the	O
+pathophysiological	O
+mechanisms	O
+of	O
+the	O
+disease	O
+causation	O
+will	O
+lead	O
+to	O
+insight	O
+into	O
+standard	O
+and	O
+novel	O
+treatments	O
+for	O
+these	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pandemic	O
+planning	O
+in	O
+China	O
+:	O
+applying	O
+lessons	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Public	O
+health	O
+response	O
+to	O
+avian	B-DISO
+influenza	I-DISO
+and	O
+pandemic	O
+preparedness	O
+benefit	O
+significantly	O
+from	O
+the	O
+experience	O
+of	O
+responses	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Proteins	B-CHED
+packaged	O
+during	O
+virus	B-PROC
+assembly	I-PROC
+may	O
+subsequently	O
+form	O
+the	O
+first	O
+line	O
+of	O
+attack	O
+and	O
+host	B-COMP
+manipulation	O
+upon	O
+infection	B-DISO
+.	O
+
+Surprisingly	O
+,	O
+the	O
+hub	O
+with	O
+the	O
+most	O
+potential	O
+connections	O
+was	O
+not	O
+the	O
+viral	O
+M	O
+protein	B-CHED
+but	O
+the	O
+nonstructural	B-PRGE
+protein	I-PRGE
+3	I-PRGE
+(	O
+nsp3	B-PRGE
+),	O
+which	O
+is	O
+one	O
+of	O
+the	O
+novel	O
+virion	B-COMP
+components	O
+identified	O
+by	O
+mass	O
+spectrometry	O
+.	O
+
+Using	O
+recombinant	B-PRGE
+protein	I-PRGE
+domains	I-PRGE
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+,	O
+we	O
+identified	O
+two	O
+additional	O
+RNA	O
+-	O
+binding	B-FUNC
+domains	O
+of	O
+nsp3	B-PRGE
+.	O
+
+We	O
+also	O
+identified	O
+a	O
+novel	O
+cysteine	B-CHED
+-	O
+coordinated	O
+metal	B-CHED
+ion	O
+-	O
+binding	B-FUNC
+domain	O
+.	O
+
+TITLE	O
+:	O
+Predicting	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+efficiency	O
+.	O
+
+TITLE	O
+:	O
+Application	O
+of	O
+siRNA	O
+against	O
+SARS	B-DISO
+in	O
+the	O
+rhesus	B-SPEC
+macaque	I-SPEC
+model	O
+.	O
+
+The	O
+GFP	O
+spots	B-DISO
+expanded	O
+as	O
+rings	O
+from	O
+5	O
+dpi	O
+,	O
+then	O
+fused	O
+to	O
+each	O
+other	O
+,	O
+and	O
+most	O
+fluorescence	O
+faded	O
+out	O
+at	O
+10	O
+-	O
+12	O
+dpi	O
+.	O
+
+ALSV	O
+labeled	O
+with	O
+two	O
+different	O
+fluorescent	O
+proteins	B-CHED
+(	O
+CFP	B-PRGE
+-	O
+ALSV	O
+and	O
+YFP	O
+-	O
+ALSV	O
+)	O
+were	O
+used	O
+to	O
+investigate	O
+the	O
+distribution	O
+of	O
+identical	O
+,	O
+but	O
+differently	O
+labeled	O
+viruses	O
+in	O
+mixed	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+characterize	O
+species	O
+and	O
+quantitative	O
+composition	O
+of	O
+intestinal	B-ANAT
+microflora	O
+in	O
+lingering	O
+and	O
+complicated	O
+course	O
+of	O
+community	O
+pneumonia	B-DISO
+(	O
+CP	O
+).	O
+
+Compared	O
+to	O
+healthy	O
+controls	O
+,	O
+CP	O
+patients	O
+'	O
+intestine	B-ANAT
+contains	O
+low	O
+content	O
+of	O
+bifidobacteria	O
+(	O
+100	O
+-	O
+fold	O
+),	O
+nonpathogenic	O
+enterococci	O
+and	O
+escherichia	B-SPEC
+with	O
+normal	O
+enzymatic	B-PROC
+activity	I-PROC
+(	O
+10	O
+-	O
+fold	O
+and	O
+more	O
+).	O
+
+This	O
+dictates	O
+the	O
+necessity	O
+to	O
+conduct	B-PROC
+fecal	B-ANAT
+microflora	O
+analysis	O
+in	O
+patients	O
+with	O
+CP	O
+irrespective	O
+of	O
+intestinal	B-DISO
+diseases	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Long	O
+-	O
+term	O
+administration	O
+of	O
+antibiotics	B-CHED
+in	O
+patients	O
+with	O
+lingering	O
+and	O
+complicated	O
+CP	O
+destroys	O
+balance	B-PROC
+of	O
+intestinal	B-ANAT
+microflora	O
+and	O
+thus	O
+influences	O
+the	O
+course	O
+of	O
+CP	O
+.	O
+
+Clinical	O
+management	O
+algorithm	O
+for	O
+HFO	O
+that	O
+minimized	O
+delivered	O
+tidal	O
+volumes	O
+by	O
+encouraging	O
+the	O
+use	O
+of	O
+the	O
+highest	O
+frequency	O
+that	O
+allowed	O
+acceptable	O
+clearance	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+.	O
+
+11	O
+cm	O
+H2O	B-CHED
+.	O
+
+Survival	O
+to	O
+hospital	O
+discharge	B-ANAT
+among	O
+this	O
+severely	O
+ill	B-DISO
+cohort	O
+was	O
+37	O
+%.	O
+
+The	O
+mechanism	O
+and	O
+therapeutic	O
+regimen	O
+of	O
+ARDS	B-DISO
+and	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+ALI	O
+remain	O
+undefined	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+changes	O
+in	O
+lung	B-ANAT
+variables	O
+for	O
+the	O
+measure	O
+of	O
+ALI	O
+,	O
+inflammatory	O
+mediators	O
+,	O
+and	O
+neutrophil	B-ANAT
+-	O
+derived	O
+substances	O
+.	O
+
+The	O
+inducible	O
+nitric	B-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+was	O
+up	O
+-	O
+regulated	O
+.	O
+
+To	O
+establish	O
+specific	O
+diagnostic	O
+methods	O
+,	O
+we	O
+generated	O
+nine	O
+clones	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+to	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+NP	O
+)	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Serological	O
+cross	O
+-	O
+reactivity	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+human	B-PRGE
+CoV	I-PRGE
+-	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+was	O
+investigated	O
+by	O
+peptide	B-CHED
+spot	B-SPEC
+assay	O
+.	O
+
+Eight	O
+residents	O
+died	B-PROC
+,	O
+six	O
+with	O
+pneumonia	B-DISO
+.	O
+
+No	O
+staff	O
+members	O
+developed	O
+pneumonia	B-DISO
+.	O
+
+Notably	O
+,	O
+sera	B-COMP
+demonstrated	O
+cross	O
+-	O
+reactivity	O
+against	O
+nucleocapsid	B-COMP
+peptide	B-CHED
+sequences	O
+common	O
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+In	O
+this	O
+study	O
+,	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+PCR	O
+sequencing	O
+of	O
+the	O
+RNA	O
+genome	O
+of	O
+an	O
+isolate	O
+of	O
+the	O
+MHV	B-PRGE
+ts	I-PRGE
+virus	B-SPEC
+Alb	I-PRGE
+ts6	I-PRGE
+,	O
+referred	O
+to	O
+as	O
+Alb	B-PRGE
+/	O
+ts	O
+/	O
+nsp5	B-PRGE
+/	O
+V148A	O
+,	O
+identified	O
+a	O
+putative	O
+ts	O
+mutation	O
+in	O
+nsp5	B-PRGE
+(	O
+T10651C	O
+,	O
+Val148Ala	O
+),	O
+the	O
+viral	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	I-PRGE
+(	O
+3CLpro	O
+).	O
+
+ABSTRACT	O
+:	O
+Fibrin	B-DISO
+deposition	I-DISO
+was	O
+universal	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+SARS	B-DISO
+patients	O
+and	O
+fgl2	B-PRGE
+prothrombinase	I-PRGE
+gene	I-PRGE
+,	O
+a	O
+novel	O
+procoagulant	O
+,	O
+was	O
+demonstrated	O
+to	O
+express	O
+highly	O
+in	O
+a	O
+clinically	O
+relevant	O
+SARS	B-DISO
+model	O
+.	O
+
+M	O
+,	O
+N	O
+and	O
+S2	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+detected	O
+by	O
+western	O
+blotting	O
+and	O
+immunohistochemistry	O
+analysis	O
+.	O
+
+Further	O
+assays	O
+demonstrated	O
+that	O
+expression	B-PROC
+of	O
+hfgl2	B-PRGE
+gene	I-PRGE
+was	O
+related	O
+with	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+but	O
+not	O
+with	O
+M	O
+or	O
+S2	O
+protein	B-CHED
+in	O
+THP	B-CHED
+-	O
+1	O
+cells	B-COMP
+and	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+samples	O
+did	O
+not	O
+undergo	O
+cell	B-COMP
+culture	O
+passage	O
+prior	O
+to	O
+PCR	O
+amplification	B-DISO
+and	O
+sequencing	O
+.	O
+
+The	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+entire	O
+S1	O
+gene	O
+showed	O
+that	O
+the	O
+BCoV	O
+Brazilian	O
+strains	O
+were	O
+more	O
+distant	O
+from	O
+the	O
+Mebus	O
+strain	O
+(	O
+97	O
+.	O
+8	O
+%	O
+identity	O
+for	O
+nucleotides	B-CHED
+and	O
+96	O
+.	O
+8	O
+%	O
+identity	O
+for	O
+amino	B-CHED
+acids	I-CHED
+)	O
+and	O
+more	O
+similar	O
+to	O
+the	O
+BCoV	B-PRGE
+-	I-PRGE
+ENT	I-PRGE
+strain	O
+(	O
+98	O
+.	O
+7	O
+%	O
+for	O
+nucleotides	B-CHED
+and	O
+98	O
+.	O
+7	O
+%	O
+for	O
+amino	B-CHED
+acids	I-CHED
+).	O
+
+We	O
+measured	O
+the	O
+effectiveness	O
+of	O
+immunization	O
+with	O
+the	O
+single	O
+-	O
+cycle	O
+vaccine	O
+in	O
+mice	B-SPEC
+.	O
+
+105	O
+of	O
+the	O
+12	O
+018	O
+patients	O
+(	O
+1	O
+.	O
+44	O
+%)	O
+were	O
+diagnosed	O
+as	O
+with	O
+ARDS	B-DISO
+.	O
+
+Logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+infiltration	B-DISO
+shadows	O
+in	O
+2	O
+-	O
+3	O
+quadrants	O
+,	O
+pediatric	O
+critical	B-DISO
+illness	I-DISO
+score	O
+(	O
+PCIS	O
+),	O
+and	O
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+(	O
+PaCO2	O
+)	O
+at	O
+the	O
+onset	O
+of	O
+ARDS	B-DISO
+were	O
+independently	O
+associated	O
+with	O
+the	O
+mortality	O
+.	O
+
+Young	O
+age	O
+and	O
+ongoing	O
+lactation	B-PROC
+,	O
+but	O
+not	O
+sex	O
+or	O
+existing	O
+gravidity	O
+,	O
+correlated	O
+significantly	O
+with	O
+coronavirus	B-SPEC
+detection	O
+.	O
+
+Nine	O
+flavonoids	B-CHED
+(	O
+2	O
+,	O
+3	O
+,	O
+6	O
+,	O
+8	O
+,	O
+10	O
+-	O
+13	O
+,	O
+15	O
+)	O
+were	O
+found	O
+to	O
+show	O
+inhibitory	O
+effects	O
+towards	O
+the	O
+CP	O
+and	O
+AP	O
+of	O
+complement	O
+system	O
+,	O
+luteolin	B-CHED
+(	O
+10	O
+)	O
+was	O
+the	O
+most	O
+potent	O
+with	O
+the	O
+CH50	O
+and	O
+AP50	O
+values	O
+of	O
+0	O
+.	O
+19	O
+and	O
+0	O
+.	O
+17	O
+mM	O
+.	O
+The	O
+bioactive	O
+flavonoids	B-CHED
+were	O
+mainly	O
+derived	O
+from	O
+Herba	O
+Houttuyniae	O
+,	O
+Flos	B-SPEC
+Chrysanthemi	O
+Indici	O
+and	O
+Herba	O
+Artemisiae	O
+Scopariae	O
+.	O
+
+Luteolin	B-CHED
+could	O
+be	O
+a	O
+potential	O
+anticomplementary	O
+agent	O
+.	O
+
+RESULTS	O
+:	O
+15	O
+compounds	O
+,	O
+including	O
+chlorogenic	B-CHED
+acid	I-CHED
+(	O
+1	O
+),	O
+rutin	B-CHED
+(	O
+2	O
+),	O
+hyperoside	B-CHED
+(	O
+3	O
+),	O
+p	O
+-	O
+hydroxyacephenone	O
+(	O
+4	O
+),	O
+scopoletin	B-CHED
+(	O
+5	O
+),	O
+quercitrin	B-CHED
+(	O
+6	O
+)	O
+(	O
+3R	O
+,	O
+4R	O
+,	O
+6S	O
+)-	O
+3	O
+,	O
+6	O
+-	O
+dihydroxy	O
+-	O
+1	O
+-	O
+menthene	O
+(	O
+7	O
+),	O
+acaciin	O
+(	O
+8	O
+),	O
+scoparone	O
+(	O
+9	O
+),	O
+luteolin	B-CHED
+(	O
+10	O
+),	O
+quercetin	B-CHED
+(	O
+11	O
+),	O
+apigenin	B-CHED
+(	O
+12	O
+),	O
+acacetin	B-CHED
+(	O
+13	O
+),	O
+aristolactam	O
+(	O
+14	O
+),	O
+and	O
+apigenin	B-CHED
+-	O
+7	O
+,	O
+4	O
+'-	O
+dimethyl	B-CHED
+ether	I-CHED
+(	O
+15	O
+)	O
+were	O
+isolated	O
+and	O
+identified	O
+.	O
+
+Nine	O
+flavonoids	B-CHED
+(	O
+2	O
+,	O
+3	O
+,	O
+6	O
+,	O
+8	O
+,	O
+10	O
+-	O
+13	O
+,	O
+15	O
+)	O
+were	O
+found	O
+to	O
+show	O
+inhibitory	O
+effects	O
+towards	O
+the	O
+CP	O
+and	O
+AP	O
+of	O
+complement	O
+system	O
+,	O
+luteolin	B-CHED
+(	O
+10	O
+)	O
+was	O
+the	O
+most	O
+potent	O
+with	O
+the	O
+CH50	O
+and	O
+AP50	O
+values	O
+of	O
+0	O
+.	O
+19	O
+and	O
+0	O
+.	O
+17	O
+mM	O
+.	O
+The	O
+bioactive	O
+flavonoids	B-CHED
+were	O
+mainly	O
+derived	O
+from	O
+Herba	O
+Houttuyniae	O
+,	O
+Flos	B-SPEC
+Chrysanthemi	O
+Indici	O
+and	O
+Herba	O
+Artemisiae	O
+Scopariae	O
+.	O
+
+What	O
+was	O
+believed	O
+to	O
+be	O
+the	O
+end	O
+of	O
+the	O
+Toronto	O
+SARS	B-DISO
+outbreak	O
+led	O
+the	O
+Provincial	O
+Operations	O
+Centre	O
+(	O
+POC	O
+)	O
+to	O
+issue	O
+a	O
+directive	O
+allowing	O
+a	O
+more	O
+relaxed	O
+use	O
+of	O
+infection	B-DISO
+-	O
+control	O
+precautions	O
+during	O
+the	O
+beginning	O
+of	O
+Phase	O
+2	O
+of	O
+the	O
+outbreak	O
+.	O
+
+Staff	O
+members	O
+who	O
+worked	O
+the	O
+evening	O
+shift	O
+or	O
+the	O
+morning	O
+shift	O
+and	O
+therefore	O
+likely	O
+attended	O
+a	O
+nursing	B-PROC
+appreciation	O
+breakfast	O
+were	O
+five	O
+times	O
+more	O
+likely	O
+to	O
+acquire	O
+SARS	B-DISO
+than	O
+those	O
+who	O
+did	O
+not	O
+attend	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+quantify	O
+and	O
+compare	O
+interferon	O
+-	O
+gamma	O
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+concentrations	O
+in	O
+the	O
+serum	B-COMP
+of	O
+clinically	O
+normal	O
+cats	B-SPEC
+infected	O
+with	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	B-SPEC
+)	O
+with	O
+its	O
+concentration	O
+in	O
+the	O
+sera	B-COMP
+and	O
+effusions	B-DISO
+of	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+a	O
+disease	O
+associated	O
+with	O
+infection	B-DISO
+with	O
+a	O
+mutated	O
+form	O
+of	O
+FCoV	B-SPEC
+.	O
+Clinically	O
+normal	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+living	O
+in	O
+catteries	O
+with	O
+a	O
+high	O
+prevalence	O
+of	O
+FIP	B-DISO
+had	O
+the	O
+highest	O
+serum	B-COMP
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+concentrations	O
+.	O
+
+Moreover	O
+,	O
+the	O
+concentration	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+effusions	B-DISO
+than	O
+in	O
+the	O
+serum	B-COMP
+of	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+probably	O
+due	O
+to	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+production	O
+within	O
+lesions	O
+.	O
+
+Following	O
+the	O
+identification	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+associated	O
+coronavirus	B-SPEC
+,	O
+two	O
+other	O
+newly	O
+detected	O
+coronaviruses	O
+,	O
+NL63	O
+and	O
+HKU1	O
+,	O
+have	O
+been	O
+linked	O
+to	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Epidemics	O
+that	O
+recently	O
+affected	O
+the	O
+world	O
+of	O
+work	O
+are	O
+zoonoses	B-DISO
+,	O
+such	O
+as	O
+cases	O
+of	O
+SARS	B-DISO
+in	O
+healthcare	O
+staff	O
+Dutch	O
+poultry	O
+workers	O
+infected	O
+with	O
+the	O
+avian	B-SPEC
+virus	B-SPEC
+A	O
+/	O
+H7N7	O
+in	O
+2003	O
+,	O
+the	O
+current	O
+threat	O
+of	O
+avian	B-PRGE
+flu	I-PRGE
+A	I-PRGE
+/	O
+H5N1	B-DISO
+to	O
+poultry	O
+workers	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+viral	O
+cause	O
+of	O
+laryngeal	O
+croup	B-DISO
+by	O
+use	O
+of	O
+highly	O
+sensitive	O
+methods	O
+,	O
+and	O
+including	O
+recently	O
+recognized	O
+viruses	B-SPEC
+in	O
+the	O
+analysis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Acute	O
+laryngeal	B-ANAT
+croup	B-DISO
+is	O
+most	O
+often	O
+associated	O
+with	O
+PIV	O
+,	O
+RSV	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+and	O
+enterovirus	B-SPEC
+.	O
+
+Sepsis	B-DISO
+is	O
+still	O
+a	O
+vital	O
+risk	O
+factor	O
+referring	O
+to	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+,	O
+infection	B-DISO
+,	I-DISO
+secondary	I-DISO
+multiple	O
+organ	B-ANAT
+dysfunction	O
+,	O
+etc	O
+.	O
+
+High	O
+-	O
+performance	O
+liquid	O
+chromatography	O
+analysis	O
+demonstrated	O
+that	O
+nsp16	O
+mediates	O
+methyl	O
+transfer	O
+from	O
+AdoMet	B-CHED
+to	O
+the	O
+2	O
+'	O
+O	O
+position	O
+of	O
+the	O
+first	O
+transcribed	O
+nucleotide	B-CHED
+,	O
+thus	O
+converting	O
+(	O
+7Me	O
+)	O
+GpppAC	O
+(	O
+3	O
+-	O
+6	O
+)	O
+into	O
+(	O
+7Me	O
+)	O
+GpppA	O
+(	O
+2	O
+')(	O
+O	O
+)(	O
+Me	O
+)	O
+C	O
+(	O
+3	O
+-	O
+6	O
+).	O
+
+Our	O
+results	O
+suggest	O
+that	O
+coronavirus	B-SPEC
+mRNA	B-CHED
+carries	O
+a	O
+cap	B-DISO
+-	O
+1	O
+,	O
+onto	O
+which	O
+2	O
+'	O
+O	O
+methylation	B-PROC
+follows	O
+an	O
+order	B-SPEC
+of	O
+events	O
+in	O
+which	O
+2	O
+'	O
+O	O
+-	O
+methyl	B-CHED
+transfer	O
+must	O
+be	O
+preceded	O
+by	O
+guanine	B-CHED
+N7	O
+methylation	B-PROC
+,	O
+with	O
+the	O
+latter	O
+step	O
+being	O
+performed	O
+by	O
+a	O
+yet	O
+-	O
+unknown	O
+N7	O
+-	O
+specific	O
+MTase	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Virus	O
+-	O
+specific	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+are	O
+critical	O
+for	O
+protection	O
+against	O
+neurotropic	O
+coronaviruses	O
+;	O
+however	O
+,	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+infection	B-DISO
+with	O
+the	O
+recombinant	O
+JHM	O
+(	O
+RJHM	O
+)	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+elicits	O
+a	O
+weak	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+in	O
+the	O
+brain	B-ANAT
+and	O
+causes	O
+lethal	O
+encephalomyelitis	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+full	O
+genomic	O
+sequences	O
+of	O
+bat	B-PRGE
+CoVs	I-PRGE
+1A	I-PRGE
+,	O
+1B	O
+and	O
+HKU8	O
+.	O
+
+These	O
+findings	O
+highlight	O
+that	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+of	O
+some	O
+coronaviruses	O
+might	O
+be	O
+common	O
+events	O
+in	O
+nature	O
+.	O
+
+TITLE	O
+:	O
+Procalcitonin	O
+is	O
+a	O
+valuable	O
+prognostic	O
+marker	O
+in	O
+ARDS	B-DISO
+caused	O
+by	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+Of	O
+the	O
+22	O
+patients	O
+with	O
+ARDS	B-DISO
+caused	O
+by	O
+CAP	B-DISO
+and	O
+enrolled	O
+in	O
+the	O
+study	O
+,	O
+17	O
+(	O
+77	O
+.	O
+3	O
+%)	O
+were	O
+alive	O
+14	O
+days	O
+after	O
+admission	O
+and	O
+five	O
+(	O
+22	O
+.	O
+7	O
+%)	O
+had	O
+died	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+PCT	B-DISO
+analysed	O
+within	O
+72	O
+h	O
+of	O
+the	O
+onset	O
+of	O
+ARDS	B-DISO
+predicted	O
+mortality	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+caused	O
+by	O
+severe	O
+CAP	B-DISO
+.	O
+
+The	O
+pursuit	O
+of	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+.	O
+
+The	O
+present	O
+commentary	O
+reviews	O
+aspects	O
+of	O
+this	O
+work	O
+,	O
+with	O
+particular	O
+attention	O
+to	O
+the	O
+implementation	O
+of	O
+low	O
+-	O
+tidal	O
+-	O
+volume	O
+/	O
+lung	B-ANAT
+-	O
+protective	O
+ventilatory	O
+strategies	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+oxidative	B-DISO
+stress	I-DISO
+and	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+4	I-PRGE
+signaling	B-PROC
+as	O
+a	O
+key	O
+pathway	B-PROC
+of	O
+acute	O
+lung	O
+injury	O
+.	O
+
+Adding	O
+a	O
+propylamino	O
+group	O
+to	O
+give	O
+promazine	B-CHED
+reduced	O
+virus	B-SPEC
+yields	O
+(	O
+VYR	O
+assay	O
+)	O
+with	O
+an	O
+EC	O
+(	O
+90	O
+)=	O
+8	O
+.	O
+3	O
++/-	O
+2	O
+.	O
+8	O
+microM	O
+,	O
+but	O
+without	O
+selectivity	O
+.	O
+
+Intraperitoneal	O
+treatment	O
+with	O
+promazine	B-CHED
+using	O
+a	O
+prophylactic	O
+(-	O
+4h	O
+)/	O
+therapeutic	O
+regimen	O
+of	O
+1	O
+,	O
+10	O
+,	O
+or	O
+50mg	O
+/(	O
+kg	O
+day	O
+)	O
+did	O
+not	O
+reduce	O
+virus	B-SPEC
+lung	B-ANAT
+titers	O
+at	O
+day	O
+3	O
+,	O
+yet	O
+prolonged	O
+virus	B-PROC
+replication	I-PROC
+to	O
+14	O
+days	O
+.	O
+
+During	O
+the	O
+viral	O
+and	O
+host	B-COMP
+cellular	B-PROC
+membrane	I-PROC
+fusion	I-PROC
+,	O
+HR1	O
+and	O
+HR2	O
+form	O
+6	O
+-	O
+helix	O
+bundle	O
+,	O
+positioning	O
+the	O
+fusion	O
+peptide	B-CHED
+closely	O
+to	O
+the	O
+C	O
+-	O
+terminal	O
+region	O
+of	O
+ectodomain	O
+to	O
+drive	O
+apposition	O
+and	O
+subsequent	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+the	O
+Trp	O
+-	O
+rich	O
+region	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+is	O
+essential	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+infectivity	O
+.	O
+
+This	O
+observation	O
+was	O
+expanded	O
+by	O
+profiling	O
+the	O
+inhibitory	O
+activity	O
+of	O
+the	O
+nonselective	O
+isopeptidase	O
+inhibitor	B-CHED
+NSC	O
+632839	O
+against	O
+DUBs	O
+and	O
+deSUMOylases	O
+.	O
+
+Preincubation	O
+of	O
+CCV2	O
+-	O
+2	O
+mAb	O
+with	O
+FCoV	B-PRGE
+antigen	I-PRGE
+suppressed	O
+the	O
+immunostaining	O
+.	O
+
+In	O
+contrast	O
+,	O
+none	O
+or	O
+only	O
+a	O
+few	O
+cells	B-COMP
+were	O
+positive	O
+for	O
+the	O
+FIPV3	O
+-	O
+70	O
+mAb	O
+.	O
+
+These	O
+findings	O
+provide	O
+evidence	O
+for	O
+antigenic	O
+heterogeneity	O
+in	O
+coronavirus	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+in	O
+FIP	B-DISO
+lesions	O
+,	O
+a	O
+result	O
+that	O
+is	O
+in	O
+line	O
+with	O
+molecular	O
+observations	O
+.	O
+
+Frequent	O
+hematologic	O
+findings	O
+were	O
+mild	O
+anemia	B-DISO
+,	O
+thrombocytopenia	O
+,	O
+and	O
+hypergammaglobulinemia	B-DISO
+.	O
+
+We	O
+sought	O
+to	O
+determine	O
+the	O
+effect	O
+of	O
+mechanical	O
+ventilation	O
+in	O
+the	O
+prone	O
+position	O
+on	O
+mortality	O
+,	O
+oxygenation	B-PROC
+,	O
+duration	O
+of	O
+ventilation	O
+and	O
+adverse	O
+events	O
+in	O
+patients	O
+with	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+features	O
+,	O
+pathogenesis	B-DISO
+and	O
+immunobiology	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+These	O
+subjects	O
+developed	O
+respiratory	B-DISO
+distress	I-DISO
+shortly	O
+after	O
+admission	O
+,	O
+and	O
+expired	O
+following	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+At	O
+autopsy	O
+,	O
+generalised	B-DISO
+lymphadenopathy	I-DISO
+was	O
+observed	O
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+summarize	O
+data	O
+on	O
+the	O
+prevalence	O
+of	O
+depressive	O
+,	O
+posttraumatic	B-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+),	O
+and	O
+other	O
+anxiety	O
+syndromes	B-DISO
+amongst	O
+survivors	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+potential	O
+risk	O
+factors	O
+for	O
+these	O
+syndromes	B-DISO
+,	O
+and	O
+their	O
+relationships	O
+to	O
+quality	O
+of	O
+life	O
+.	O
+
+As	O
+several	O
+years	O
+have	O
+now	O
+passed	O
+,	O
+it	O
+is	O
+possible	O
+to	O
+interrogate	O
+national	O
+statistics	O
+that	O
+have	O
+become	O
+available	O
+since	O
+the	O
+outbreak	O
+to	O
+provide	O
+a	O
+more	O
+accurate	O
+estimate	O
+of	O
+the	O
+actual	O
+macro	O
+-	O
+economic	O
+impact	O
+of	O
+SARS	B-DISO
+.	O
+
+Estimates	O
+and	O
+models	O
+produced	O
+at	O
+the	O
+time	O
+of	O
+the	O
+outbreak	O
+suggested	O
+that	O
+SARS	B-DISO
+could	O
+have	O
+a	O
+catastrophic	O
+effect	O
+on	O
+the	O
+global	O
+economy	O
+.	O
+
+TITLE	O
+:	O
+Childhood	O
+scrub	B-DISO
+typhus	I-DISO
+in	O
+eastern	O
+Taiwan	O
+:	O
+ten	O
+-	O
+year	O
+experience	O
+from	O
+a	O
+medical	O
+center	O
+.	O
+
+Most	O
+reports	O
+have	O
+been	O
+concerned	O
+about	O
+mainly	O
+adult	O
+patients	O
+,	O
+whereas	O
+serologic	O
+surveys	O
+suggested	O
+that	O
+as	O
+many	O
+as	O
+one	O
+-	O
+half	O
+of	O
+cases	O
+of	O
+scrub	B-DISO
+typhus	I-DISO
+might	O
+be	O
+in	O
+children	O
+.	O
+
+We	O
+conducted	O
+a	O
+retrospective	O
+study	O
+of	O
+childhood	O
+scrub	B-DISO
+typhus	I-DISO
+in	O
+our	O
+hospital	O
+from	O
+January	O
+1997	O
+to	O
+December	O
+2006	O
+.	O
+
+Fever	B-PROC
+and	O
+chigger	B-SPEC
+bite	B-PROC
+history	O
+were	O
+presented	O
+in	O
+all	O
+15	O
+cases	O
+,	O
+and	O
+eschar	B-DISO
+lesion	O
+was	O
+identified	O
+in	O
+12	O
+patients	O
+(	O
+80	O
+%).	O
+
+Three	O
+patients	O
+(	O
+20	O
+%)	O
+had	O
+meningoencephalitis	B-DISO
+,	O
+and	O
+two	O
+(	O
+13	O
+%)	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+were	O
+confirmed	O
+by	O
+bone	B-ANAT
+marrow	I-ANAT
+biopsy	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+oxygenation	B-PROC
+parameters	O
+,	O
+protein	B-CHED
+and	O
+histological	O
+data	O
+were	O
+similar	O
+,	O
+except	O
+for	O
+the	O
+fact	O
+that	O
+significantly	O
+more	O
+normal	O
+alveoli	B-ANAT
+were	O
+observed	O
+upon	O
+protective	O
+ventilation	O
+.	O
+
+This	O
+case	O
+suggests	O
+that	O
+the	O
+initial	O
+neuropathological	O
+changes	O
+in	O
+PSP	B-DISO
+is	O
+located	O
+in	O
+the	O
+dorsal	O
+brainstem	B-ANAT
+.	O
+
+Ultrastructural	O
+analysis	O
+of	O
+globoid	O
+-	O
+shaped	O
+tangles	O
+in	O
+the	O
+brainstem	B-ANAT
+revealed	O
+the	O
+presence	O
+of	O
+straight	O
+and	O
+paired	O
+helicoidal	O
+filaments	O
+compatible	O
+with	O
+a	O
+PSP	B-DISO
+.	O
+
+Bottom	O
+ashes	O
+were	O
+dominated	O
+by	O
+low	O
+molecular	O
+weight	O
+PAHs	B-CHED
+(	O
+LM	O
+-	O
+PAH	B-DISO
+;	O
+containing	O
+two	O
+-	O
+to	O
+three	O
+-	O
+ringed	O
+PAHs	B-CHED
+)	O
+and	O
+medium	O
+molecular	O
+weight	O
+PAHs	B-CHED
+(	O
+MM	O
+-	O
+PAH	B-DISO
+;	O
+containing	O
+four	O
+-	O
+ringed	O
+PAHs	B-CHED
+),	O
+while	O
+fly	B-SPEC
+ashes	O
+were	O
+abundant	O
+in	O
+MM	B-PRGE
+-	I-PRGE
+PAH	I-PRGE
+and	O
+high	O
+molecular	O
+weight	O
+PAHs	B-CHED
+(	O
+HM	O
+-	O
+PAH	B-DISO
+,	O
+containing	O
+five	O
+-	O
+to	O
+six	O
+-	O
+ringed	O
+PAHs	B-CHED
+).	O
+
+Humoral	O
+(	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+,	O
+ELISA	O
+)	O
+and	O
+cellular	B-COMP
+(	O
+by	O
+cell	B-PROC
+proliferation	B-DISO
+and	O
+CD4	B-PRGE
+(+):	O
+CD8	B-PRGE
+(+)	O
+assay	O
+)	O
+immunity	B-PROC
+was	O
+detected	O
+by	O
+using	O
+recombinant	O
+N1	O
+and	O
+N3	O
+specific	O
+antigen	B-CHED
+.	O
+
+The	O
+study	O
+of	O
+associations	O
+between	O
+important	O
+SARS	B-DISO
+characteristics	O
+considerably	O
+enhanced	O
+the	O
+mainstream	O
+epidemic	O
+analysis	O
+and	O
+improved	O
+the	O
+understanding	O
+of	O
+the	O
+relationships	O
+between	O
+the	O
+observed	O
+epidemic	O
+determinants	O
+.	O
+
+CoPPIX	O
+or	O
+ZnPPIX	O
+(	O
+an	O
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+inhibitor	B-CHED
+)	O
+was	O
+administered	O
+to	O
+mice	B-SPEC
+24	O
+h	O
+prior	O
+to	O
+LPS	B-DISO
+exposure	O
+.	O
+
+In	O
+addition	O
+,	O
+CoPPIX	O
+was	O
+also	O
+believed	O
+to	O
+have	O
+down	O
+-	O
+regulated	O
+the	O
+expression	B-PROC
+of	O
+LPS	B-DISO
+-	O
+induced	O
+proinflammatory	O
+cytokines	O
+,	O
+including	O
+early	B-PRGE
+proinflammatory	I-PRGE
+cytokine	I-PRGE
+TNF	I-PRGE
+-	I-PRGE
+a	I-PRGE
+,	O
+and	O
+late	B-PRGE
+proinflammatory	I-PRGE
+cytokine	I-PRGE
+Hmgb1	I-PRGE
+.	O
+
+Increasingly	O
+,	O
+however	O
+,	O
+it	O
+is	O
+becoming	O
+apparent	O
+that	O
+certain	O
+pyruvate	B-CHED
+esters	B-CHED
+,	O
+including	O
+ethyl	B-CHED
+pyruvate	B-CHED
+,	O
+have	O
+pharmacological	O
+effects	O
+,	O
+such	O
+as	O
+suppression	B-DISO
+of	O
+inflammation	B-DISO
+,	O
+which	O
+are	O
+distinct	O
+from	O
+those	O
+exerted	B-PROC
+by	O
+pyruvate	B-CHED
+anion	B-CHED
+.	O
+
+We	O
+characterized	O
+the	O
+clinical	O
+features	O
+of	O
+Nipah	B-SPEC
+virus	I-SPEC
+-	O
+infected	O
+individuals	O
+affected	O
+by	O
+these	O
+outbreaks	O
+.	O
+
+Fever	B-PROC
+,	O
+altered	B-DISO
+mental	I-DISO
+status	I-DISO
+,	O
+headache	B-DISO
+,	I-DISO
+cough	I-DISO
+,	O
+respiratory	B-DISO
+difficulty	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+and	O
+convulsions	B-DISO
+were	O
+the	O
+most	O
+common	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+;	O
+clinical	O
+and	O
+radiographic	O
+features	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+of	O
+Nipah	O
+illness	O
+were	O
+identified	O
+during	O
+the	O
+fourth	O
+outbreak	O
+.	O
+
+Among	O
+those	O
+who	O
+died	B-PROC
+,	O
+death	B-PROC
+occurred	O
+a	O
+median	O
+of	O
+6	O
+days	O
+(	O
+range	O
+,	O
+2	O
+-	O
+36	O
+days	O
+)	O
+after	O
+the	O
+onset	O
+of	O
+illness	O
+.	O
+
+As	O
+a	O
+relatively	O
+late	O
+rescue	O
+therapy	O
+after	O
+failure	O
+of	O
+CMV	B-SPEC
+,	O
+HFOV	O
+may	O
+improve	O
+PaCO2	O
+and	O
+PaO2	O
+/	O
+FiO2	O
+in	O
+children	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Blood	B-ANAT
+and	O
+turbinate	B-ANAT
+wash	O
+samples	O
+,	O
+and	O
+lung	B-ANAT
+tissue	I-ANAT
+were	O
+collected	O
+from	O
+each	O
+animal	B-SPEC
+at	O
+different	O
+time	O
+points	O
+after	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infection	B-DISO
+for	O
+determining	O
+the	O
+growth	B-PROC
+curve	O
+of	O
+virus	B-SPEC
+,	O
+if	O
+any	O
+,	O
+by	O
+the	O
+standard	O
+infectivity	O
+assay	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Methods	O
+of	O
+data	O
+collection	O
+and	O
+analysis	O
+for	O
+the	O
+economic	O
+evaluation	O
+alongside	O
+a	O
+national	O
+,	O
+multi	O
+-	O
+centre	O
+trial	O
+in	O
+the	O
+UK	O
+:	O
+conventional	O
+ventilation	O
+or	O
+ECMO	O
+for	O
+Severe	O
+Adult	O
+Respiratory	B-DISO
+Failure	I-DISO
+(	O
+CESAR	O
+).	O
+
+Lymphopenia	B-DISO
+can	O
+be	O
+caused	O
+by	O
+glucocorticoids	B-CHED
+,	O
+and	O
+thus	O
+any	O
+debilitating	O
+condition	B-DISO
+has	O
+the	O
+potential	O
+to	O
+induce	O
+lymphopenia	B-DISO
+via	O
+stress	O
+mechanism	O
+involving	O
+the	O
+hypothalamic	B-ANAT
+-	I-ANAT
+pituitary	I-ANAT
+-	I-ANAT
+adrenal	I-ANAT
+axis	I-ANAT
+.	O
+
+Because	O
+of	O
+the	O
+insidious	O
+presentation	O
+,	O
+SARS	O
+was	O
+treated	O
+with	O
+antibacterial	O
+,	O
+antiviral	B-CHED
+and	O
+supra	O
+-	O
+physiological	O
+doses	O
+of	O
+glucocorticoids	B-CHED
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+protein	B-CHED
+6	O
+accelerates	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+infections	B-DISO
+by	O
+more	O
+than	O
+one	O
+mechanism	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	B-CHED
+6	I-PRGE
+increases	O
+MHV	B-SPEC
+neurovirulence	O
+and	O
+accelerates	O
+MHV	B-SPEC
+infection	B-DISO
+kinetics	O
+in	O
+tissue	B-ANAT
+culture	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+analysis	O
+of	O
+major	O
+species	B-SPEC
+barriers	O
+between	O
+humans	B-SPEC
+and	O
+palm	B-ANAT
+civets	B-SPEC
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Late	O
+respiratory	B-PROC
+function	I-PROC
+complications	O
+following	O
+burns	O
+].	O
+
+The	O
+presence	O
+of	O
+both	O
+restrictive	O
+and	O
+obstructive	O
+defects	O
+led	O
+to	O
+the	O
+suggestion	O
+of	O
+alternative	O
+underlying	O
+mechanisms	O
+such	O
+as	O
+the	O
+pulmonary	B-ANAT
+consequences	O
+of	O
+ARDS	B-DISO
+and	O
+extensive	O
+dermal	O
+scars	B-DISO
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+replication	O
+/	O
+transcription	B-PROC
+complexes	O
+are	O
+membrane	B-COMP
+-	O
+protected	O
+and	O
+need	O
+a	O
+host	B-COMP
+factor	O
+for	O
+activity	O
+in	O
+vitro	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+pelleted	O
+RTC	O
+required	O
+the	O
+addition	O
+of	O
+a	O
+cytoplasmic	B-PRGE
+host	B-COMP
+factor	I-PRGE
+for	O
+reconstitution	O
+of	O
+its	O
+in	O
+vitro	O
+activity	O
+.	O
+
+The	O
+RTC	O
+appeared	O
+to	O
+be	O
+protected	O
+by	O
+membranes	B-ANAT
+,	O
+as	O
+newly	O
+synthesized	O
+viral	O
+RNA	O
+and	O
+several	O
+replicase	B-PRGE
+/	I-PRGE
+transcriptase	I-PRGE
+subunits	I-PRGE
+were	O
+protease	O
+-	O
+and	O
+nuclease	O
+-	O
+resistant	O
+and	O
+became	O
+susceptible	O
+to	O
+degradation	O
+only	O
+upon	O
+addition	O
+of	O
+a	O
+non	O
+-	O
+ionic	O
+detergent	B-CHED
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+E	B-PRGE
+gene	I-PRGE
+might	O
+be	O
+a	O
+virulence	B-PROC
+factor	O
+influencing	O
+replication	O
+level	O
+,	O
+tissue	B-PROC
+tropism	B-PROC
+and	O
+pathogenicity	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+suggesting	O
+that	O
+DeltaE	O
+attenuated	O
+viruses	B-SPEC
+are	O
+promising	O
+vaccine	O
+candidates	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+of	O
+fatal	O
+risk	O
+factors	O
+for	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+:	O
+a	O
+report	O
+of	O
+141	O
+cases	O
+].	O
+
+All	O
+the	O
+patients	O
+were	O
+divided	O
+into	O
+2	O
+groups	O
+,	O
+the	O
+death	B-PROC
+group	O
+and	O
+the	O
+survival	O
+group	O
+.	O
+
+There	O
+were	O
+significant	O
+differences	O
+between	O
+the	O
+two	O
+groups	O
+in	O
+age	O
+,	O
+body	B-ANAT
+mass	O
+index	O
+,	O
+length	O
+of	O
+stay	O
+,	O
+APACHE	O
+II	O
+score	O
+,	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+)	O
+and	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+Total	O
+hepatectomy	O
+with	O
+temporary	O
+portocaval	O
+shunt	O
+was	O
+employed	O
+as	O
+a	O
+bridging	O
+procedure	O
+before	O
+liver	O
+transplantation	O
+,	O
+in	O
+the	O
+setting	O
+of	O
+fulminant	B-DISO
+hepatic	I-DISO
+failure	I-DISO
+with	O
+""""	O
+toxic	O
+liver	B-ANAT
+syndrome	B-DISO
+""";"	O
+acute	O
+,	O
+severe	O
+,	O
+and	O
+extensive	O
+liver	B-DISO
+necrosis	B-PROC
+associated	O
+with	O
+cardiovascular	B-ANAT
+shock	O
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+with	O
+or	O
+without	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+The	O
+distribution	O
+of	O
+the	O
+different	O
+HCoV	O
+species	B-SPEC
+varies	O
+according	O
+to	O
+the	O
+geographic	O
+area	O
+and	O
+season	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+responsible	O
+of	O
+the	O
+first	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+of	O
+this	O
+millennium	O
+,	O
+infecting	O
+more	O
+than	O
+8000	O
+people	O
+between	O
+November	O
+2002	O
+and	O
+July	O
+2003	O
+.	O
+
+The	O
+detection	O
+of	O
+these	O
+viruses	B-SPEC
+is	O
+difficult	O
+and	O
+mainly	O
+based	O
+on	O
+molecular	O
+assays	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+Forty	O
+-	O
+seven	O
+(	O
+26	O
+.	O
+4	O
+%)	O
+of	O
+178	O
+NPAs	O
+were	O
+positive	O
+:	O
+18	O
+rhinovirus	O
+,	O
+15	O
+hMPV	B-SPEC
+,	O
+4	B-PRGE
+RSV	I-PRGE
+A	I-PRGE
+,	I-PRGE
+3	I-PRGE
+coronavirus	B-SPEC
+OC43	I-PRGE
+,	I-PRGE
+3	I-PRGE
+influenza	B-SPEC
+virus	I-SPEC
+A	I-PRGE
+,	I-PRGE
+2	I-PRGE
+adenovirus	B-DISO
+,	I-PRGE
+1	I-PRGE
+coronavirus	B-SPEC
+NL63	I-PRGE
+,	I-PRGE
+and	I-PRGE
+1	I-PRGE
+RSV	B-SPEC
+B	I-PRGE
+.	O
+Based	O
+on	O
+maximum	O
+identity	O
+,	O
+each	O
+of	O
+the	O
+sequences	O
+indicating	O
+rhinovirus	B-SPEC
+,	O
+hMPV	B-SPEC
+,	O
+and	O
+coronavirus	B-SPEC
+OC43	O
+matched	O
+to	O
+the	O
+corresponding	O
+viruses	B-SPEC
+with	O
+homology	O
+of	O
+94	O
+-	O
+98	O
+%,	O
+96	O
+-	O
+99	O
+%,	O
+and	O
+98	O
+-	O
+100	O
+%,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+epidemic	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+swept	O
+through	O
+the	O
+globe	B-ANAT
+with	O
+more	O
+than	O
+8000	O
+reported	O
+probable	O
+cases	O
+.	O
+
+We	O
+were	O
+the	O
+third	O
+group	O
+in	O
+the	O
+world	O
+to	O
+release	B-PATH
+the	O
+complete	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+sequence	O
+(	O
+isolate	O
+CUHK	O
+-	O
+W1	O
+)	O
+on	O
+the	O
+world	O
+-	O
+wide	O
+web	B-DISO
+.	O
+
+The	O
+reviewed	O
+data	O
+obtained	O
+from	O
+representative	O
+patients	O
+from	O
+the	O
+hospital	O
+and	O
+community	O
+outbreaks	O
+has	O
+documented	O
+the	O
+evolution	B-PROC
+of	O
+the	O
+virus	B-SPEC
+in	O
+this	O
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+The	O
+laboratory	O
+diagnosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+emerging	O
+laboratory	O
+tests	O
+for	O
+an	O
+emerging	O
+pathogen	O
+.	O
+
+Measurement	O
+of	O
+biochemical	O
+markers	O
+of	O
+bone	B-PROC
+metabolism	B-PROC
+demonstrated	O
+significant	O
+but	O
+transient	O
+increase	O
+in	O
+bone	B-PROC
+resorption	B-PROC
+from	O
+Day	O
+28	O
+-	O
+44	O
+after	O
+onset	O
+of	O
+fever	B-PROC
+,	O
+when	O
+pulse	B-PROC
+steroid	B-CHED
+was	O
+most	O
+frequently	O
+given	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+febrile	O
+respiratory	O
+illness	O
+(	O
+FRI	O
+)	O
+leading	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+is	O
+a	O
+common	O
+reason	O
+for	O
+admission	O
+to	O
+the	O
+ICU	O
+.	O
+
+Emerging	O
+viral	O
+infectious	B-DISO
+diseases	I-DISO
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+avian	B-DISO
+influenza	I-DISO
+present	O
+with	O
+acute	O
+FRIs	O
+progressing	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+public	O
+health	O
+interventions	O
+in	O
+controlling	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+:	O
+modelling	O
+of	O
+intervention	O
+scenarios	O
+.	O
+
+Tracing	O
+casual	O
+contacts	O
+and	O
+measures	O
+aiming	O
+to	O
+decrease	O
+social	O
+interaction	O
+were	O
+less	O
+effective	O
+in	O
+reducing	O
+the	O
+number	O
+of	O
+SARS	B-DISO
+cases	O
+.	O
+
+The	O
+study	O
+emphasizes	O
+the	O
+importance	O
+of	O
+early	O
+identification	O
+and	O
+isolation	O
+of	O
+SARS	B-DISO
+cases	O
+to	O
+reduce	O
+the	O
+number	O
+of	O
+people	O
+getting	O
+infected	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immunogenicity	O
+and	O
+protective	O
+efficacy	O
+of	O
+a	O
+live	O
+attenuated	O
+vaccine	O
+consisting	O
+of	O
+a	O
+recombinant	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+lacking	O
+the	O
+E	B-PRGE
+gene	I-PRGE
+(	O
+rSARS	O
+-	O
+CoV	O
+-	O
+DeltaE	O
+)	O
+were	O
+studied	O
+using	O
+hamsters	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Traumatic	O
+mitral	B-DISO
+regurgitation	I-DISO
+with	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+].	O
+
+A	O
+44	O
+-	O
+year	O
+-	O
+old	O
+,	O
+small	O
+-	O
+statured	O
+female	O
+with	O
+cretinism	B-DISO
+had	O
+a	O
+traffic	O
+accident	O
+.	O
+
+Eleven	O
+days	O
+after	O
+the	O
+accident	O
+,	O
+she	O
+was	O
+admitted	O
+to	O
+our	O
+hospital	O
+with	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+by	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+.	O
+
+Therefore	O
+,	O
+it	O
+will	O
+be	O
+useful	O
+in	O
+screening	O
+binding	B-FUNC
+candidates	O
+for	O
+a	O
+given	O
+RNA	O
+target	O
+motif	O
+with	O
+one	O
+chip	O
+.	O
+
+However	O
+,	O
+intraperitoneal	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+injection	O
+protected	O
+adult	O
+mice	B-SPEC
+from	O
+the	O
+lethal	O
+respiratory	O
+illness	O
+.	O
+
+TITLE	O
+:	O
+Combination	O
+of	O
+functionalized	O
+nanoparticles	B-CHED
+and	O
+polymerase	O
+chain	O
+reaction	O
+-	O
+based	O
+method	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+gene	O
+detection	O
+.	O
+
+The	O
+full	O
+-	O
+length	O
+genome	O
+was	O
+27	O
+,	O
+632	O
+nucleotides	B-CHED
+plus	O
+the	O
+3	O
+'	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+.	O
+
+Comparison	O
+between	O
+patients	O
+and	O
+close	O
+contacts	O
+showed	O
+that	O
+individuals	O
+with	O
+the	O
++	O
+1664	O
+C	O
+/	O
+T	O
+(	O
+CT	O
+and	O
+TT	O
+)	O
+genotype	O
+had	O
+a	O
+2	O
+.	O
+09	O
+-	O
+fold	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+90	O
+-	O
+7	O
+.	O
+16	O
+)	O
+and	O
+2	O
+.	O
+34	O
+-	O
+fold	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+79	O
+-	O
+13	O
+.	O
+37	O
+)	O
+increased	O
+risk	O
+of	O
+developing	O
+SARS	B-DISO
+,	O
+respectively	O
+.	O
+
+Each	O
+year	O
+our	O
+country	O
+is	O
+stricken	O
+by	O
+flu	B-DISO
+epidemics	O
+,	O
+but	O
+at	O
+some	O
+points	O
+of	O
+time	O
+unexpected	O
+new	O
+flu	B-DISO
+viruses	B-SPEC
+may	O
+cause	O
+a	O
+worldwide	O
+pandemic	O
+.	O
+
+Viruses	B-SPEC
+take	O
+all	O
+opportunities	O
+in	O
+our	O
+changing	O
+world	O
+and	O
+have	O
+many	O
+more	O
+surprises	O
+in	O
+store	O
+for	O
+us	O
+.	O
+
+TITLE	O
+:	O
+Immunomodulatory	O
+and	O
+anti	O
+-	O
+SARS	B-DISO
+activities	O
+of	O
+Houttuynia	B-SPEC
+cordata	I-SPEC
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+oral	B-ANAT
+acute	O
+toxicity	O
+test	O
+demonstrated	O
+that	O
+HC	O
+was	O
+non	O
+-	O
+toxic	O
+to	O
+laboratory	O
+animals	B-SPEC
+following	O
+oral	B-ANAT
+administration	O
+at	O
+16	O
+g	O
+/	O
+kg	O
+.	O
+
+RESULTS	O
+:	O
+Results	O
+showed	O
+that	O
+HC	O
+water	B-CHED
+extract	O
+could	O
+stimulate	O
+the	O
+proliferation	B-DISO
+of	O
+mouse	B-SPEC
+splenic	B-ANAT
+lymphocytes	B-ANAT
+significantly	O
+and	O
+dose	O
+-	O
+dependently	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+dysfunction	I-DISO
+in	O
+sleep	B-DISO
+apnea	I-DISO
+associated	O
+with	O
+quetiapine	B-CHED
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+work	O
+is	O
+to	O
+report	O
+on	O
+moderate	O
+to	O
+severe	O
+respiratory	B-DISO
+dysfunction	I-DISO
+after	O
+normal	O
+oral	B-ANAT
+doses	O
+of	O
+quetiapine	B-CHED
+in	O
+two	O
+obese	B-DISO
+patients	O
+with	O
+sleep	B-DISO
+apnea	I-DISO
+syndrome	I-DISO
+(	O
+SAS	O
+).	O
+
+TITLE	O
+:	O
+Staff	O
+perception	O
+and	O
+institutional	O
+reporting	O
+:	O
+two	O
+views	O
+of	O
+infection	B-DISO
+control	O
+compliance	O
+in	O
+British	O
+Columbia	O
+and	O
+Ontario	O
+three	O
+years	O
+after	O
+an	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+.	O
+
+The	O
+pattern	O
+of	O
+BVDV	B-SPEC
+immunolabeling	O
+revealed	O
+both	O
+similarities	O
+and	O
+differences	O
+compared	O
+with	O
+previous	O
+studies	O
+in	O
+postnatal	O
+calves	O
+,	O
+suggesting	O
+that	O
+viral	B-DISO
+infection	I-DISO
+in	O
+the	O
+brain	B-ANAT
+is	O
+a	O
+dynamic	O
+and	O
+progressive	O
+rather	O
+than	O
+static	O
+process	O
+.	O
+
+Approximately	O
+one	O
+third	O
+of	O
+Canadian	O
+nurses	O
+identified	O
+job	B-DISO
+strain	I-DISO
+and	O
+poor	O
+health	O
+,	O
+related	O
+to	O
+their	O
+work	O
+environment	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+envelope	B-COMP
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+,	O
+a	O
+Class	B-SPEC
+I	O
+viral	O
+fusion	O
+protein	B-CHED
+,	O
+is	O
+responsible	O
+for	O
+the	O
+fusion	O
+between	O
+the	O
+membranes	B-ANAT
+of	O
+the	O
+virus	B-SPEC
+and	O
+the	O
+target	B-ANAT
+cell	I-ANAT
+.	O
+
+From	O
+fluorescence	O
+and	O
+infrared	O
+spectroscopies	O
+,	O
+the	O
+peptide	B-CHED
+ability	O
+to	O
+induce	O
+membrane	B-COMP
+leakage	B-DISO
+,	O
+aggregation	O
+and	O
+fusion	O
+,	O
+as	O
+well	O
+as	O
+its	O
+affinity	O
+toward	O
+specific	O
+phospholipids	B-CHED
+,	O
+was	O
+assessed	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+cellular	B-COMP
+signals	O
+triggered	O
+by	O
+the	O
+interaction	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+with	O
+ACE2	B-PRGE
+are	O
+positively	O
+involved	O
+in	O
+viral	O
+entry	O
+but	O
+lead	O
+to	O
+tissue	B-ANAT
+damage	O
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+of	O
+humans	B-SPEC
+with	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+results	O
+in	O
+substantial	O
+morbidity	O
+and	O
+mortality	O
+,	O
+with	O
+death	B-PROC
+resulting	O
+primarily	O
+from	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+This	O
+extensive	O
+neuronal	O
+infection	B-DISO
+is	O
+the	O
+main	O
+cause	O
+of	O
+death	B-PROC
+because	O
+intracranial	O
+inoculation	O
+with	O
+low	O
+doses	O
+of	O
+virus	B-SPEC
+results	O
+in	O
+a	O
+uniformly	O
+lethal	O
+disease	O
+even	O
+though	O
+little	O
+infection	B-DISO
+is	O
+detected	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+and	O
+229E	O
+seroconversion	O
+in	O
+children	O
+.	O
+
+Methylprednisolone	B-CHED
+in	O
+a	O
+dose	O
+of	O
+1	O
+mg	O
+x	O
+kg	O
+(-	O
+1	O
+)	O
+x	O
+day	O
+(-	O
+1	O
+)	O
+for	O
+>	O
+or	O
+=	O
+14	O
+days	O
+is	O
+recommended	O
+in	O
+patients	O
+with	O
+severe	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Glucocorticoids	B-CHED
+should	O
+be	O
+weaned	B-PROC
+and	O
+not	O
+stopped	O
+abruptly	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+identification	O
+and	O
+characterization	O
+of	O
+B	O
+-	O
+cell	O
+epitopes	O
+play	O
+an	O
+important	O
+role	O
+in	O
+vaccine	O
+design	O
+,	O
+immunodiagnostic	O
+tests	O
+,	O
+and	O
+antibody	B-PROC
+production	I-PROC
+.	O
+
+Therefore	O
+,	O
+computational	O
+tools	O
+for	O
+reliably	O
+predicting	O
+linear	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+are	O
+highly	O
+desirable	O
+.	O
+
+Based	O
+on	O
+the	O
+results	O
+of	O
+our	O
+computational	O
+experiments	O
+,	O
+we	O
+propose	O
+BCPred	O
+,	O
+a	O
+novel	O
+method	O
+for	O
+predicting	O
+linear	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+using	O
+the	O
+subsequence	O
+kernel	O
+.	O
+
+Analysis	O
+of	O
+the	O
+data	O
+sets	O
+used	O
+and	O
+the	O
+results	O
+of	O
+this	O
+comparison	O
+show	O
+that	O
+conclusions	O
+about	O
+the	O
+relative	O
+performance	O
+of	O
+different	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitope	B-CHED
+prediction	O
+methods	O
+drawn	O
+on	O
+the	O
+basis	O
+of	O
+experiments	O
+using	O
+data	O
+sets	O
+of	O
+unique	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+are	O
+likely	O
+to	O
+yield	O
+overly	O
+optimistic	O
+estimates	O
+of	O
+performance	O
+of	O
+evaluated	O
+methods	O
+.	O
+
+Maintaining	O
+and	O
+enhancing	O
+mental	O
+well	O
+being	O
+of	O
+the	O
+public	O
+over	O
+the	O
+period	O
+of	O
+epidemic	O
+is	O
+as	O
+important	O
+as	O
+curbing	B-DISO
+the	O
+spread	O
+of	O
+the	O
+epidemic	O
+.	O
+
+Canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+)	O
+is	O
+a	O
+new	O
+coronavirus	B-SPEC
+of	O
+dogs	B-SPEC
+,	O
+which	O
+is	O
+widespread	O
+in	O
+North	O
+America	O
+,	O
+Japan	O
+,	O
+and	O
+several	O
+European	O
+countries	O
+.	O
+
+In	O
+the	O
+H5N1	B-DISO
+/	O
+PR8	O
+-	O
+5B19	O
+virus	B-SPEC
+,	O
+the	O
+HA	O
+cleavage	B-PROC
+site	O
+was	O
+modified	O
+to	O
+resemble	O
+that	O
+of	O
+low	O
+-	O
+pathogenic	O
+avian	B-SPEC
+strains	O
+and	O
+a	O
+portion	O
+of	O
+the	O
+NA	O
+stalk	B-DISO
+region	O
+was	O
+replaced	O
+by	O
+the	O
+immunodominant	O
+5B19	O
+epitope	B-CHED
+of	O
+the	O
+S2	B-PRGE
+glycoprotein	I-PRGE
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+H5N1	B-DISO
+/	O
+PR8	O
+-	O
+5B19	O
+is	O
+not	O
+lethal	O
+to	O
+embryonated	O
+eggs	O
+or	O
+chickens	B-SPEC
+.	O
+
+This	O
+viral	O
+super	O
+-	O
+group	O
+,	O
+known	O
+for	O
+decades	O
+,	O
+has	O
+still	O
+to	O
+face	B-DISO
+the	O
+full	O
+force	O
+of	O
+a	O
+molecular	O
+biology	O
+onslaught	O
+.	O
+
+Early	O
+findings	O
+from	O
+infection	B-DISO
+studies	O
+and	O
+use	O
+of	O
+inefficient	O
+detection	O
+methods	O
+have	O
+shaped	O
+the	O
+way	O
+we	O
+think	O
+of	O
+'	B-DISO
+common	I-DISO
+cold	I-DISO
+'	O
+viruses	B-SPEC
+today	O
+.	O
+
+The	O
+finding	O
+of	O
+many	O
+divergent	O
+and	O
+previously	O
+unrecognized	O
+HRV	O
+strains	O
+has	O
+drawn	O
+attention	O
+and	O
+resources	O
+back	B-ANAT
+to	O
+the	O
+most	O
+widespread	O
+and	O
+frequent	O
+infectious	B-DISO
+agent	O
+of	O
+humans	B-SPEC
+;	O
+providing	O
+us	O
+the	O
+chance	O
+to	O
+seize	O
+the	O
+advantage	O
+in	O
+a	O
+decades	O
+-	O
+long	O
+cold	B-DISO
+war	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Role	O
+of	O
+AQP	B-PRGE
+-	I-PRGE
+4	I-PRGE
+in	O
+pulmonary	B-ANAT
+water	B-CHED
+metabolism	B-PROC
+in	O
+rats	B-SPEC
+in	O
+early	O
+stage	O
+of	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+acute	O
+lung	O
+injury	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+capacity	O
+of	O
+alveolar	B-ANAT
+type	O
+II	O
+(	O
+AT	O
+II	O
+)	O
+cells	B-COMP
+for	O
+water	B-CHED
+and	O
+sodium	B-PROC
+transport	I-PROC
+in	O
+rats	B-SPEC
+with	O
+early	O
+-	O
+stage	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+AT	O
+II	O
+cells	B-COMP
+were	O
+isolated	O
+and	O
+purified	O
+from	O
+rats	B-SPEC
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+induced	O
+by	O
+oleic	B-CHED
+acid	I-CHED
+,	O
+and	O
+their	O
+morphology	O
+was	O
+observed	O
+using	O
+electron	O
+microscopy	O
+and	O
+optical	O
+microscopy	O
+.	O
+
+Smith	O
+lung	B-ANAT
+injury	O
+score	O
+and	O
+EVLW	O
+in	O
+ALI	O
+group	O
+were	O
+significantly	O
+higher	O
+in	O
+ALI	O
+group	O
+than	O
+in	O
+the	O
+control	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+level	O
+of	O
+APQ	B-PRGE
+-	I-PRGE
+4	I-PRGE
+whole	O
+-	O
+cell	B-COMP
+currents	O
+was	O
+decreased	O
+in	O
+AT	O
+II	O
+cell	B-COMP
+membrane	I-COMP
+and	O
+increased	O
+in	O
+cytoplasm	B-COMP
+in	O
+ALI	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+Microscopic	O
+examination	O
+and	O
+blood	B-PROC
+gas	B-ENZY
+analysis	O
+indicated	O
+severe	O
+injury	O
+of	O
+the	O
+lung	B-ANAT
+tissues	I-ANAT
+in	O
+ALI	O
+group	O
+.	O
+
+A	O
+commercial	O
+ELISA	O
+kit	B-FUNC
+for	O
+detecting	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibody	B-COMP
+was	O
+modified	O
+for	O
+detecting	O
+coronavirus	B-SPEC
+antibodies	B-COMP
+in	O
+bat	B-ENZY
+serum	B-COMP
+samples	O
+.	O
+
+The	O
+second	O
+antibody	B-COMP
+in	O
+the	O
+kit	B-FUNC
+was	O
+replaced	O
+with	O
+horseradish	B-PRGE
+peroxidase	B-ENZY
+-	I-PRGE
+conjugated	B-CHED
+protein	I-CHED
+-	I-PRGE
+A	I-PRGE
+(	O
+HRP	B-PRGE
+-	I-PRGE
+SPA	I-PRGE
+)	O
+based	O
+on	O
+the	O
+characteristics	O
+of	O
+binding	B-FUNC
+between	O
+Staphylococcus	B-PRGE
+aureus	I-PRGE
+protein	B-CHED
+A	I-PRGE
+(	O
+SPA	B-PRGE
+)	O
+and	O
+mammal	B-PRGE
+IgG	I-PRGE
+Fc	I-PRGE
+fragment	I-PRGE
+.	O
+
+The	O
+test	O
+results	O
+of	O
+the	O
+positive	O
+and	O
+negative	O
+controls	O
+in	O
+the	O
+kit	B-FUNC
+and	O
+the	O
+serum	B-COMP
+samples	O
+from	O
+convalescent	O
+;	O
+patient	O
+were	O
+consistent	O
+with	O
+expectation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+SPA	O
+-	O
+ELISA	O
+method	O
+is	O
+applicable	O
+for	O
+detecting	O
+coronavirus	B-SPEC
+antibody	B-COMP
+in	O
+bat	B-ENZY
+sera	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+failure	I-DISO
+may	O
+develop	O
+during	O
+the	O
+later	O
+stages	O
+of	O
+pregnancy	O
+and	O
+is	O
+usually	O
+associated	O
+with	O
+tocolysis	O
+or	O
+other	O
+co	O
+-	O
+existing	O
+conditions	O
+such	O
+as	O
+pneumonia	B-DISO
+,	O
+sepsis	B-DISO
+,	O
+pre	B-DISO
+-	I-DISO
+eclampsia	I-DISO
+or	O
+amniotic	B-DISO
+fluid	I-DISO
+embolism	I-DISO
+syndrome	B-DISO
+.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+a	O
+34	O
+-	O
+year	O
+-	O
+old	O
+healthy	O
+woman	O
+with	O
+a	O
+twin	O
+pregnancy	O
+at	O
+31	O
+weeks	O
+and	O
+6	O
+days	O
+who	O
+experienced	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+a	O
+few	O
+hours	O
+after	O
+administration	O
+of	O
+tocolysis	O
+(	O
+ritodrine	O
+),	O
+due	O
+to	O
+preterm	B-DISO
+premature	I-DISO
+rupture	I-DISO
+of	I-DISO
+the	I-DISO
+membranes	I-DISO
+.	O
+
+As	O
+there	O
+was	O
+no	O
+evidence	O
+for	O
+drug	O
+-	O
+or	O
+infection	O
+-	O
+related	O
+thromboembolic	O
+or	O
+myocardial	O
+causes	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+we	O
+conclude	O
+that	O
+our	O
+patient	O
+experienced	O
+a	O
+rare	O
+type	O
+of	O
+non	O
+-	O
+fatal	O
+amniotic	B-DISO
+fluid	I-DISO
+embolism	I-DISO
+.	O
+
+RESULTS	O
+:	O
+As	O
+a	O
+first	O
+-	O
+stage	O
+therapy	O
+,	O
+devascularization	O
+of	O
+internal	O
+iliac	B-ANAT
+arteries	I-ANAT
+was	O
+performed	O
+in	O
+29	O
+patients	O
+with	O
+pelvic	B-ANAT
+fractures	O
+combined	O
+with	O
+massive	B-DISO
+bleeding	I-DISO
+,	O
+including	O
+ligation	O
+of	O
+bilateral	O
+internal	O
+iliac	B-ANAT
+arteries	I-ANAT
+in	O
+21	O
+patients	O
+and	O
+embolization	O
+of	O
+bilateral	O
+internal	O
+iliac	B-ANAT
+arteries	I-ANAT
+in	O
+8	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+is	O
+a	O
+highly	O
+contagious	O
+infection	B-DISO
+,	O
+caused	O
+by	O
+new	O
+coronavirus	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Immunopathological	O
+mechanisms	O
+responsible	O
+for	O
+the	O
+reaction	O
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+have	O
+not	O
+yet	O
+been	O
+fully	O
+elucidated	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+nucleotide	B-CHED
+sequence	O
+of	O
+polyprotein	O
+gene	O
+1	O
+and	O
+genome	O
+organization	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+ClustalW	O
+analysis	O
+revealed	O
+88	O
+.	O
+99	O
+%	O
+identity	O
+and	O
+96	O
+.	O
+99	O
+%	O
+similarity	O
+for	O
+pp1ab	O
+between	O
+TCoV	O
+and	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+at	O
+the	O
+amino	B-CHED
+acid	I-CHED
+level	O
+.	O
+
+A	O
+total	O
+of	O
+13	O
+ORFs	O
+were	O
+predicted	O
+for	O
+TCoV	O
+.	O
+Five	O
+subgenomic	O
+RNAs	O
+were	O
+detected	O
+from	O
+ATCC	O
+-	O
+infected	O
+turkey	B-SPEC
+small	B-ANAT
+intestines	I-ANAT
+by	O
+Northern	O
+blotting	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+organ	B-ANAT
+that	O
+is	O
+affected	O
+first	O
+and	O
+most	O
+severely	O
+in	O
+intraabdominal	O
+sepsis	B-DISO
+is	O
+the	O
+lung	B-ANAT
+.	O
+
+Oxygen	B-CHED
+radicals	I-CHED
+and	O
+active	O
+neutrophils	B-ANAT
+in	O
+the	O
+lung	B-ANAT
+are	O
+important	O
+sources	O
+for	O
+severe	O
+pulmonary	B-DISO
+inflammation	I-DISO
+leading	O
+to	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+leflunomide	B-CHED
+,	O
+an	O
+immunomodulatory	O
+agent	O
+,	O
+on	O
+oxidant	B-CHED
+/	O
+antioxidant	B-CHED
+status	O
+with	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+level	O
+and	O
+myeloperoxidase	B-PRGE
+(	O
+MPO	B-FUNC
+)	O
+activity	O
+in	O
+rats	B-SPEC
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+ALI	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+65	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+was	O
+admitted	O
+because	O
+of	O
+high	O
+grade	O
+fever	B-PROC
+and	O
+cough	B-DISO
+after	O
+3	O
+days	O
+of	O
+gathering	O
+edible	O
+wild	O
+plants	B-SPEC
+.	O
+
+His	O
+high	O
+grade	O
+fever	B-PROC
+escalated	O
+after	O
+changing	O
+the	O
+antibiotics	B-CHED
+(	O
+imipenem	B-CHED
+with	O
+erythromycin	B-CHED
+).	O
+
+Careful	O
+anamnesis	B-PROC
+and	O
+physical	O
+examinations	O
+are	O
+most	O
+important	O
+for	O
+the	O
+diagnosis	O
+of	O
+Tsutsugamushi	B-DISO
+disease	I-DISO
+.	O
+
+From	O
+those	O
+,	O
+142	O
+(	O
+37	O
+.	O
+6	O
+%)	O
+met	B-CHED
+criteria	O
+for	O
+SPRF	O
+.	O
+
+In	O
+these	O
+we	O
+could	O
+find	O
+12	O
+(	O
+23	O
+%)	O
+patients	O
+that	O
+met	B-CHED
+criteria	O
+for	O
+that	O
+entity	O
+.	O
+
+Intramuscular	O
+immunization	O
+of	O
+mice	B-SPEC
+with	O
+this	O
+vaccine	O
+was	O
+sufficient	O
+to	O
+induce	O
+specific	O
+prime	O
+as	O
+well	O
+as	O
+a	O
+long	B-PROC
+-	I-PROC
+term	I-PROC
+memory	I-PROC
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+to	O
+at	O
+least	O
+two	O
+candidate	O
+epitopes	O
+,	O
+S	O
+(	O
+437	O
+-	O
+459	O
+)	O
+and	O
+M	O
+(	O
+1	O
+-	O
+20	O
+).	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+albumin	B-PRGE
+quotient	O
+and	O
+IgG	B-PRGE
+index	O
+to	O
+differentiate	O
+blood	B-ANAT
+-	O
+vs	O
+brain	B-ANAT
+-	O
+derived	O
+proteins	B-CHED
+in	O
+the	O
+cerebrospinal	O
+fluid	O
+of	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+CSF	B-PRGE
+-	I-PRGE
+total	I-PRGE
+protein	B-CHED
+(	O
+TP	O
+)	O
+was	O
+measured	O
+and	O
+albumin	B-PRGE
+and	O
+IgG	B-PRGE
+concentrations	O
+were	O
+measured	O
+in	O
+paired	O
+CSF	B-ANAT
+/	O
+serum	B-COMP
+samples	O
+;	O
+Q	O
+(	O
+alb	O
+)	O
+and	O
+IgG	B-PRGE
+index	O
+were	O
+calculated	O
+.	O
+
+The	O
+Q	O
+(	O
+alb	O
+)	O
+and	O
+IgG	B-PRGE
+index	O
+did	O
+not	O
+identify	O
+a	O
+CSF	B-ANAT
+protein	B-CHED
+pattern	O
+specific	O
+for	O
+BBB	B-CHED
+dysfunction	O
+or	O
+intrathecal	B-ANAT
+IgG	B-PRGE
+synthesis	B-PROC
+in	O
+cats	B-SPEC
+with	O
+CNS	B-CHED
+-	O
+FIP	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Evaluation	O
+of	O
+the	O
+protection	O
+conferred	O
+by	O
+several	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+attenuated	O
+vaccines	O
+against	O
+the	O
+field	O
+strain	O
+CK	O
+/	O
+CH	O
+/	O
+LDL	O
+/	O
+97	O
+I	O
+in	O
+China	O
+].	O
+
+The	O
+organ	O
+samples	O
+at	O
+5	O
+days	O
+post	O
+challenge	O
+showed	O
+that	O
+the	O
+viral	O
+detection	O
+rates	O
+were	O
+50	O
+%-	O
+90	O
+%	O
+and	O
+10	O
+%-	O
+30	O
+%	O
+for	O
+trachea	B-DISO
+and	O
+kidney	B-ANAT
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Fifty	O
+-	O
+one	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+cats	O
+10	O
+weeks	O
+to	O
+13	O
+years	O
+of	O
+age	O
+were	O
+infected	O
+with	O
+a	O
+cat	B-SPEC
+-	O
+to	O
+-	O
+cat	B-SPEC
+fecal	B-ANAT
+-	O
+oral	B-ANAT
+passed	O
+strain	O
+of	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+).	O
+
+Twenty	O
+-	O
+nine	O
+of	O
+these	O
+cats	B-SPEC
+were	O
+FECV	B-SPEC
+naïve	O
+before	O
+infection	B-DISO
+and	O
+followed	O
+sequentially	O
+for	O
+fecal	B-ANAT
+virus	B-DISO
+shedding	I-DISO
+and	O
+antibody	B-PROC
+responses	I-PROC
+over	O
+a	O
+period	O
+of	O
+8	O
+-	O
+48	O
+months	O
+.	O
+
+FECV	B-SPEC
+shedding	O
+remained	O
+at	O
+high	O
+levels	O
+for	O
+2	O
+-	O
+10	O
+months	O
+before	O
+eventually	O
+evolving	O
+into	O
+one	O
+of	O
+three	O
+excretion	B-PROC
+patterns	O
+.	O
+
+Eleven	O
+cats	B-SPEC
+shed	O
+the	O
+virus	B-SPEC
+persistently	O
+at	O
+varying	O
+levels	O
+over	O
+an	O
+observation	O
+period	O
+of	O
+9	O
+-	O
+24	O
+months	O
+.	O
+
+Eleven	O
+cats	B-SPEC
+appeared	O
+to	O
+have	O
+periods	B-PROC
+of	O
+virus	B-DISO
+shedding	I-DISO
+interlaced	O
+with	O
+periods	B-PROC
+of	O
+non	O
+-	O
+shedding	O
+(	O
+intermittent	O
+or	O
+recurrent	O
+shedders	O
+),	O
+and	O
+seven	O
+cats	O
+ceased	O
+shedding	O
+after	O
+5	O
+-	O
+19	O
+months	O
+(	O
+average	O
+12	O
+months	O
+).	O
+
+There	O
+was	O
+no	O
+change	O
+in	O
+the	O
+patterns	O
+of	O
+virus	B-DISO
+shedding	I-DISO
+among	O
+cats	B-SPEC
+that	O
+were	O
+excreting	O
+FECV	B-SPEC
+at	O
+the	O
+time	O
+of	O
+a	O
+secondary	O
+challenge	O
+exposure	O
+.	O
+
+For	O
+common	O
+upper	O
+respiratory	O
+viruses	B-SPEC
+that	O
+cause	O
+vURIs	O
+,	O
+to	O
+determine	O
+the	O
+relative	O
+frequencies	O
+of	O
+virus	B-SPEC
+detection	O
+by	O
+PCR	O
+in	O
+subjects	O
+with	O
+and	O
+without	O
+CFLIs	O
+.	O
+
+About	O
+85	O
+%	O
+of	O
+RSV	B-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+and	O
+adenovirus	B-DISO
+detections	O
+were	O
+associated	O
+with	O
+a	O
+CFLI	O
+,	O
+whereas	O
+less	O
+than	O
+62	O
+%	O
+of	O
+other	O
+virus	B-SPEC
+detections	O
+were	O
+associated	O
+with	O
+CFLI	O
+.	O
+
+RESULTS	O
+:	O
+Virus	B-SPEC
+was	O
+detected	O
+in	O
+415	O
+of	O
+956	O
+independent	O
+assays	O
+:	O
+425	O
+CFLI	O
+episodes	O
+and	O
+531	O
+non	O
+-	O
+CFLI	O
+periods	B-PROC
+were	O
+sampled	O
+;	O
+samples	O
+from	O
+270	O
+(	O
+64	O
+%)	O
+CFLI	O
+episodes	O
+and	O
+145	O
+(	O
+27	O
+%)	O
+non	O
+-	O
+CFLI	O
+periods	B-PROC
+contained	O
+virus	B-SPEC
+detected	O
+by	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+of	O
+a	O
+SARS	B-DISO
+coronavirus	B-SPEC
+-	O
+derived	O
+peptide	B-CHED
+bound	O
+to	O
+the	O
+human	B-SPEC
+major	B-ANAT
+histocompatibility	I-ANAT
+complex	I-ANAT
+class	B-SPEC
+I	I-PRGE
+molecule	I-PRGE
+HLA	B-ANAT
+-	O
+B	O
+*	O
+1501	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+(	O
+HLA	B-PRGE
+)	O
+class	B-SPEC
+I	O
+system	O
+comprises	O
+a	O
+highly	O
+polymorphic	O
+set	O
+of	O
+molecules	O
+that	O
+specifically	O
+bind	B-FUNC
+and	O
+present	O
+peptides	B-CHED
+to	O
+cytotoxic	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+envelope	B-PRGE
+glycoproteins	B-CHED
+of	O
+the	O
+class	B-PRGE
+I	I-PRGE
+family	B-SPEC
+,	O
+which	O
+include	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+),	O
+influenza	B-DISO
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+mediate	O
+viral	O
+entry	O
+by	O
+first	O
+binding	B-FUNC
+to	O
+their	O
+cellular	B-COMP
+receptors	O
+and	O
+subsequently	O
+inducing	O
+fusion	O
+of	O
+the	O
+viral	O
+and	O
+cellular	B-COMP
+membranes	B-ANAT
+.	O
+
+A	O
+model	O
+for	O
+viral	O
+entry	O
+is	O
+presented	O
+in	O
+which	O
+S2	O
+-	O
+HR2	O
+is	O
+in	O
+a	O
+dynamic	O
+equilibrium	B-PROC
+between	O
+an	O
+ensemble	O
+of	O
+unstructured	O
+monomers	O
+in	O
+the	O
+transition	B-DISO
+state	O
+and	O
+a	O
+structured	O
+trimer	O
+in	O
+the	O
+prefusion	O
+state	O
+.	O
+
+2	O
+alveolar	B-ANAT
+lavages	O
+over	O
+90	O
++/-	O
+
+Malaria	B-PATH
+was	O
+the	O
+most	O
+frequent	O
+diagnosis	O
+(	O
+49	O
+.	O
+1	O
+%),	O
+which	O
+was	O
+especially	O
+encountered	O
+in	O
+patients	O
+returning	O
+from	O
+sub	O
+-	O
+Saharan	O
+Africa	O
+(	O
+95	O
+.	O
+6	O
+%),	O
+without	O
+adequate	O
+chemoprophylaxis	O
+(	O
+78	O
+.	O
+2	O
+%).	O
+
+After	O
+the	O
+animals	B-SPEC
+were	O
+euthanized	O
+at	O
+4	O
+hours	O
+treatment	O
+time	O
+point	O
+,	O
+the	O
+right	B-ANAT
+middle	I-ANAT
+lobe	I-ANAT
+of	O
+rabbit	B-SPEC
+lung	B-ANAT
+was	O
+harvested	O
+for	O
+the	O
+examination	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+p73	B-PRGE
+contents	O
+and	O
+relative	O
+values	O
+,	O
+as	O
+well	O
+as	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+p73	B-PRGE
+.	O
+
+Compared	O
+with	O
+CMV	B-SPEC
+or	O
+CMV	O
++	O
+PS	O
+,	O
+HFOV	O
+or	O
+HFOV	O
++	O
+PS	O
+can	O
+decrease	O
+the	O
+concentration	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+p73	B-PRGE
+,	O
+reduce	O
+the	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+p73	B-PRGE
+in	O
+the	O
+lung	B-ANAT
+homogenates	O
+,	O
+as	O
+a	O
+result	O
+lung	B-ANAT
+tissue	I-ANAT
+apoptosis	B-PATH
+in	O
+inhalation	B-PROC
+injury	O
+may	O
+be	O
+suppressed	O
+.	O
+
+TITLE	O
+:	O
+Mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+type	O
+2	O
+enters	O
+cells	B-COMP
+through	O
+a	O
+clathrin	B-PRGE
+-	O
+mediated	O
+endocytic	O
+pathway	B-PROC
+independent	O
+of	O
+Eps15	O
+.	O
+
+Interestingly	O
+,	O
+when	O
+the	O
+cells	B-COMP
+transiently	O
+overexpressed	O
+a	O
+dominant	O
+-	O
+negative	O
+form	O
+(	O
+DIII	O
+)	O
+of	O
+Eps15	B-PRGE
+,	O
+which	O
+is	O
+thought	O
+to	O
+be	O
+an	O
+essential	O
+component	O
+of	O
+the	O
+clathrin	B-PRGE
+pathway	B-PROC
+,	O
+viral	O
+gene	B-PROC
+expression	I-PROC
+and	O
+infectivity	O
+were	O
+unaffected	O
+,	O
+although	O
+DIII	O
+expression	B-PROC
+blocked	O
+transferrin	B-PRGE
+uptake	O
+and	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	B-DISO
+infection	I-DISO
+,	O
+which	O
+are	O
+dependent	O
+on	O
+clathrin	B-PROC
+-	I-PROC
+mediated	I-PROC
+endocytosis	B-PATH
+.	O
+
+Some	O
+bat	B-ENZY
+astroviruses	O
+may	O
+be	O
+phylogenetically	O
+related	O
+to	O
+human	B-SPEC
+astroviruses	O
+,	O
+and	O
+further	O
+studies	O
+with	O
+a	O
+wider	O
+range	O
+of	O
+bat	B-ENZY
+species	B-SPEC
+in	O
+different	O
+geographic	O
+locations	O
+are	O
+warranted	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+hemagglutinin	O
+-	O
+esterases	B-FUNC
+(	O
+HEs	B-DISO
+)	O
+are	O
+a	O
+family	B-SPEC
+of	O
+viral	B-PRGE
+envelope	I-PRGE
+glycoproteins	B-CHED
+that	O
+mediate	O
+reversible	O
+attachment	O
+to	O
+O	O
+-	O
+acetylated	O
+sialic	B-CHED
+acids	I-CHED
+by	O
+acting	O
+both	O
+as	O
+lectins	O
+and	O
+as	O
+receptor	O
+-	O
+destroying	O
+enzymes	O
+(	O
+RDEs	O
+).	O
+
+We	O
+show	O
+that	O
+CoV	O
+HE	O
+arose	O
+from	O
+an	O
+influenza	B-DISO
+C	O
+-	O
+like	O
+HE	B-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+(	O
+HEF	O
+).	O
+
+We	O
+now	O
+show	O
+that	O
+MHV	B-SPEC
+replication	O
+is	O
+sensitive	O
+to	O
+brefeldin	B-CHED
+A	I-CHED
+(	O
+BFA	O
+).	O
+
+Consistently	O
+,	O
+expression	B-PROC
+of	O
+a	O
+dominant	B-DISO
+-	I-DISO
+negative	I-DISO
+mutant	I-DISO
+of	O
+ARF1	B-PRGE
+,	O
+known	O
+to	O
+mimic	O
+the	O
+action	O
+of	O
+the	O
+drug	O
+,	O
+inhibited	O
+MHV	B-SPEC
+infection	B-DISO
+profoundly	O
+.	O
+
+TITLE	O
+:	O
+Endocytosis	B-PROC
+of	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+together	O
+with	O
+virus	B-SPEC
+receptor	I-PRGE
+ACE2	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Cell	O
+entry	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+mediated	O
+by	O
+the	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+.	O
+
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+with	O
+the	O
+clinical	O
+picture	O
+of	O
+compartment	B-DISO
+syndrome	I-DISO
+is	O
+a	O
+reperfusion	O
+injury	O
+that	O
+is	O
+a	O
+cyclic	O
+event	O
+.	O
+
+Due	O
+to	O
+edema	B-DISO
+reducing	O
+thoracic	B-DISO
+compliance	O
+,	O
+producing	O
+severe	O
+encephalopathy	B-DISO
+and	O
+leading	O
+to	O
+severe	O
+ischemia	B-DISO
+with	O
+generation	O
+of	O
+significant	O
+quantities	O
+of	O
+reactive	O
+oxygen	B-CHED
+free	O
+radicals	B-CHED
+as	O
+well	O
+peroxidation	O
+products	O
+released	O
+from	O
+the	O
+intestine	B-ANAT
+,	O
+liver	B-ANAT
+and	I-ANAT
+spleen	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Transmission	O
+electron	O
+microscopy	O
+(	O
+of	O
+ultrathin	O
+sections	O
+)	O
+was	O
+used	O
+to	O
+examine	O
+the	O
+biomass	O
+of	O
+lung	O
+tissue	O
+in	O
+the	O
+immunodeficiency	B-DISO
+minipigs	O
+experimentally	O
+infected	O
+with	O
+Pneumocystis	B-SPEC
+carinii	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+frequency	O
+and	O
+types	O
+of	O
+respiratory	O
+viruses	B-SPEC
+circulating	O
+in	O
+Boston	O
+long	O
+-	O
+term	O
+care	O
+facilities	O
+(	O
+LTCFs	O
+)	O
+during	O
+a	O
+3	O
+-	O
+year	O
+period	O
+.	O
+
+At	O
+least	O
+one	O
+infectious	B-DISO
+agent	O
+was	O
+identified	O
+in	O
+76	O
+children	O
+(	O
+89	O
+.	O
+4	O
+%).	O
+
+RSV	B-SPEC
+was	O
+the	O
+most	O
+frequently	O
+detected	O
+pathogen	O
+and	O
+its	O
+prevalence	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+of	O
+the	O
+other	O
+pathogens	O
+in	O
+both	O
+age	O
+groups	O
+,	O
+and	O
+significantly	O
+higher	O
+in	O
+the	O
+children	O
+aged	O
+3	O
+-	O
+12	O
+months	O
+than	O
+in	O
+those	O
+aged	O
+<	O
+3	O
+months	O
+.	O
+
+Viral	O
+load	O
+was	O
+significantly	O
+higher	O
+in	O
+children	O
+with	O
+than	O
+in	O
+those	O
+without	O
+recurrent	O
+wheezing	B-DISO
+.	O
+
+TITLE	O
+:	O
+Solution	O
+structure	O
+of	O
+the	O
+c	B-PRGE
+-	I-PRGE
+terminal	I-PRGE
+dimerization	I-PRGE
+domain	I-PRGE
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+solved	O
+by	O
+the	O
+SAIL	O
+-	O
+NMR	O
+method	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+of	O
+the	O
+main	O
+protease	O
+from	O
+a	O
+global	O
+infectious	B-DISO
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+HCoV	O
+-	O
+HKU1	O
+.	O
+
+Severe	O
+burn	O
+is	O
+associated	O
+with	O
+a	O
+distinct	O
+serum	B-COMP
+cytokine	O
+profile	O
+and	O
+alterations	O
+in	O
+cytokines	O
+that	O
+contribute	O
+to	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+The	O
+number	O
+of	O
+days	O
+on	O
+the	O
+ventilator	O
+,	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+rates	O
+,	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+(	O
+PaO2	O
+)/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+FiO2	O
+)	O
+ratio	O
+and	O
+incidence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+were	O
+recorded	O
+for	O
+those	O
+patients	O
+.	O
+
+This	O
+report	O
+describes	O
+the	O
+usage	O
+of	O
+two	O
+short	O
+peptides	B-CHED
+from	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+nucleocapsid	B-COMP
+(	O
+SARS	B-DISO
+-	O
+N	O
+)	O
+protein	B-CHED
+as	O
+protein	B-CHED
+tags	O
+.	O
+
+The	O
+SARS	B-DISO
+peptide	B-CHED
+antibody	B-COMP
+system	O
+described	O
+presents	O
+an	O
+alternative	O
+tagging	O
+opportunity	O
+in	O
+the	O
+growing	O
+field	O
+of	O
+protein	B-CHED
+science	O
+.	O
+
+TITLE	O
+:	O
+Randomized	O
+clinical	O
+trial	O
+of	O
+activated	O
+protein	B-CHED
+C	O
+for	O
+the	O
+treatment	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Microvascular	O
+injury	O
+,	O
+inflammation	O
+,	O
+and	O
+coagulation	B-PROC
+play	O
+critical	O
+roles	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+Eligible	O
+subjects	O
+were	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+who	O
+met	B-CHED
+the	O
+American	O
+/	O
+European	O
+consensus	O
+criteria	O
+for	O
+ALI	O
+.	O
+
+APC	B-COMP
+increased	O
+plasma	B-PRGE
+protein	B-CHED
+C	I-PRGE
+levels	O
+(	O
+P	O
+=	O
+0	O
+.	O
+002	O
+)	O
+and	O
+decreased	O
+pulmonary	B-PROC
+dead	B-PROC
+space	I-PROC
+fraction	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+The	O
+results	O
+of	O
+this	O
+trial	O
+do	O
+not	O
+support	O
+a	O
+large	O
+clinical	O
+trial	O
+of	O
+APC	B-COMP
+for	O
+ALI	O
+in	O
+the	O
+absence	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+high	O
+disease	O
+severity	O
+.	O
+
+No	O
+randomized	O
+controlled	O
+trials	O
+with	O
+a	O
+specific	O
+anti	O
+-	O
+coronavirus	B-SPEC
+agent	O
+have	O
+been	O
+conducted	O
+with	O
+respect	O
+to	O
+therapy	O
+or	O
+prophylaxis	O
+.	O
+
+Prophylaxis	O
+with	O
+interferon	B-PRGE
+or	O
+hyperimmune	O
+globulin	O
+may	O
+be	O
+considered	O
+for	O
+unprotected	O
+exposure	O
+.	O
+
+TITLE	O
+:	O
+QM	O
+/	O
+QM	O
+studies	O
+for	O
+Michael	O
+reaction	O
+in	O
+coronavirus	B-SPEC
+main	O
+protease	O
+(	O
+3CL	O
+Pro	B-CHED
+).	O
+
+The	O
+third	O
+and	O
+fourth	O
+most	O
+common	O
+genotypes	O
+were	O
+two	O
+new	O
+economically	O
+important	O
+field	O
+types	O
+:	O
+Italy02	O
+,	O
+and	O
+a	O
+virus	B-SPEC
+similar	O
+to	O
+genotypes	O
+originally	O
+detected	O
+in	O
+China	O
+called	O
+QX	O
+.	O
+
+The	O
+virus	O
+subpopulations	O
+within	O
+each	O
+vaccine	O
+selected	O
+by	O
+chickens	B-SPEC
+are	O
+similar	O
+in	O
+their	O
+S1	O
+gene	O
+sequences	O
+,	O
+but	O
+distinct	O
+in	O
+the	O
+3	O
+'	O
+portion	O
+of	O
+the	O
+S2	O
+subunit	O
+gene	O
+for	O
+each	O
+of	O
+the	O
+three	O
+vaccines	O
+.	O
+
+Sequence	O
+comparisons	O
+provided	O
+no	O
+evidence	O
+to	O
+support	O
+that	O
+ArkDPI	O
+-	O
+like	O
+field	O
+isolates	O
+were	O
+derived	O
+directly	O
+from	O
+host	B-COMP
+-	O
+selected	O
+vaccine	O
+virus	B-SPEC
+subpopulations	O
+.	O
+
+On	O
+day	O
+4	O
+,	O
+she	O
+complained	O
+of	O
+progressive	O
+dyspnea	B-DISO
+and	O
+dysphonia	O
+after	O
+removal	O
+of	O
+the	O
+endotracheal	O
+tube	O
+.	O
+
+However	O
+,	O
+laryngeal	B-ANAT
+electromyography	O
+(	O
+LEMG	O
+)	O
+findings	O
+were	O
+consistent	O
+with	O
+bilateral	O
+laryngeal	B-DISO
+paralysis	I-DISO
+suggesting	O
+the	O
+vagus	B-ANAT
+nerve	I-ANAT
+involvement	O
+.	O
+
+TITLE	O
+:	O
+Generation	O
+of	O
+a	O
+protective	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+following	O
+coronavirus	B-DISO
+infection	I-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	B-DISO
+system	I-ANAT
+is	O
+not	O
+dependent	O
+on	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+/	O
+23	O
+signaling	B-PROC
+.	O
+
+Therefore	O
+,	O
+therapeutic	O
+targeting	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+and	O
+/	O
+or	O
+IL	B-FUNC
+-	I-FUNC
+23	I-FUNC
+for	O
+the	O
+treatment	O
+of	O
+autoimmune	B-DISO
+diseases	I-DISO
+may	O
+offer	O
+unique	O
+advantages	O
+by	O
+reducing	O
+disease	O
+severity	O
+without	O
+muting	O
+protective	O
+responses	O
+following	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Type	O
+I	O
+interferons	O
+(	O
+IFN	B-PRGE
+)	O
+include	O
+multiple	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+subtypes	O
+which	O
+exhibit	O
+considerable	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+and	O
+activate	O
+the	O
+same	O
+cell	B-COMP
+-	O
+surface	O
+receptor	O
+.	O
+
+In	O
+vivo	O
+,	O
+whereas	O
+A	O
+/	O
+J	O
+mice	B-SPEC
+are	O
+highly	O
+permissive	O
+for	O
+both	O
+MHV	B-SPEC
+-	O
+1	O
+and	O
+CVB3	O
+infections	B-DISO
+and	O
+mount	O
+a	O
+poor	O
+IFN	B-PRGE
+response	O
+,	O
+C57B1	O
+/	O
+6	O
+mice	B-SPEC
+are	O
+relatively	O
+resistant	O
+to	O
+both	O
+virus	B-SPEC
+infections	B-DISO
+and	O
+mount	O
+a	O
+vigorous	O
+IFN	B-PRGE
+response	O
+.	O
+
+The	O
+extent	O
+of	O
+IFN	B-PRGE
+response	O
+to	O
+viral	B-DISO
+infection	I-DISO
+influences	O
+the	O
+subsequent	O
+biological	O
+outcome	O
+:	O
+a	O
+robust	O
+IFN	B-PRGE
+response	O
+prescribes	O
+a	O
+level	O
+of	O
+resistance	B-PROC
+,	O
+whereas	O
+a	O
+poor	O
+IFN	B-PRGE
+response	O
+contributes	O
+towards	O
+a	O
+permissive	O
+phenotype	O
+for	O
+infection	B-DISO
+.	O
+
+Turkey	B-SPEC
+coronavirus	B-SPEC
+was	O
+detected	O
+in	O
+experimentally	O
+infected	O
+embryo	B-ANAT
+tissues	B-ANAT
+and	O
+also	O
+in	O
+field	O
+samples	O
+in	O
+100	O
+%	O
+of	O
+ileum	B-ANAT
+-	O
+cecal	B-ANAT
+junction	O
+and	O
+ceca	O
+by	O
+the	O
+3	O
+detection	O
+procedures	O
+.	O
+
+TITLE	O
+:	O
+Prospective	O
+community	O
+-	O
+based	O
+cluster	O
+census	O
+and	O
+case	O
+-	O
+control	O
+study	O
+of	O
+stillbirths	B-DISO
+and	O
+neonatal	O
+deaths	O
+in	O
+the	O
+West	O
+Bank	O
+and	O
+Gaza	B-SPEC
+Strip	O
+.	O
+
+ABSTRACT	O
+:	O
+Obstetric	O
+complications	O
+and	O
+newborn	O
+illnesses	O
+amenable	O
+to	O
+basic	O
+medical	O
+interventions	O
+underlie	O
+most	O
+perinatal	O
+deaths	B-PROC
+.	O
+
+A	O
+total	O
+of	O
+113	O
+of	O
+116	O
+married	O
+women	O
+15	O
+-	O
+49	O
+years	O
+old	O
+with	O
+a	O
+stillbirth	B-DISO
+or	O
+neonatal	B-DISO
+death	I-DISO
+and	O
+813	O
+randomly	O
+selected	O
+women	O
+with	O
+a	O
+surviving	O
+neonate	O
+were	O
+interviewed	O
+,	O
+and	O
+obstetric	O
+and	O
+newborn	O
+care	O
+records	O
+of	O
+women	O
+with	O
+a	O
+stillbirth	B-DISO
+or	O
+neonatal	O
+death	O
+were	O
+abstracted	O
+.	O
+
+Stillbirths	B-DISO
+are	O
+not	O
+officially	O
+reportable	O
+in	O
+the	O
+West	O
+Bank	O
+and	O
+Gaza	B-SPEC
+Strip	O
+and	O
+this	O
+is	O
+the	O
+first	O
+time	O
+that	O
+perinatal	O
+mortality	O
+has	O
+been	O
+examined	O
+.	O
+
+Pathological	O
+mechanisms	O
+and	O
+potential	O
+treatments	O
+for	O
+ON	O
+have	O
+been	O
+studied	O
+via	O
+experimental	O
+autoimmune	B-DISO
+MS	O
+models	O
+.	O
+
+In	O
+contrast	O
+,	O
+MHV	B-SPEC
+-	O
+2	O
+,	O
+a	O
+nondemyelinating	O
+MHV	B-SPEC
+strain	O
+,	O
+does	O
+not	O
+induce	O
+ON	O
+.	O
+
+Zoonotic	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+completely	O
+dependent	O
+on	O
+ACE2	B-PRGE
+for	O
+entry	O
+.	O
+
+Structural	O
+modeling	O
+predicted	O
+two	O
+distinct	O
+biochemical	O
+interaction	O
+networks	O
+by	O
+which	O
+zoonotic	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+architecture	O
+can	O
+productively	O
+engage	O
+hACE2	O
+,	O
+but	O
+only	O
+the	O
+Urbani	O
+mutational	O
+repertoire	O
+promoted	O
+efficient	O
+usage	O
+of	O
+both	O
+hACE2	O
+and	O
+cACE2	O
+binding	B-FUNC
+interfaces	O
+.	O
+
+ABSTRACT	O
+:	O
+Complement	O
+staining	O
+as	O
+a	O
+predictor	O
+of	O
+antibody	O
+-	O
+mediated	O
+rejection	O
+(	O
+AMR	O
+)	O
+after	O
+lung	B-ANAT
+transplantation	O
+continues	O
+to	O
+be	O
+debated	O
+.	O
+
+Mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+)	O
+and	O
+MBL	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+serine	I-PRGE
+protease	I-PRGE
+2	I-PRGE
+(	O
+MASP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+deficiencies	O
+are	O
+common	O
+primary	O
+immunodeficiencies	B-DISO
+the	O
+clinical	O
+penetrance	O
+of	O
+which	O
+remains	O
+controversial	O
+.	O
+
+However	O
+,	O
+in	O
+a	O
+multivariate	O
+analysis	O
+MBL	O
+insufficiency	O
+was	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+the	O
+most	O
+severe	O
+forms	O
+of	O
+sepsis	B-DISO
+(	O
+P	O
+=	O
+.	O
+007	O
+),	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+P	O
+=	O
+.	O
+009	O
+),	O
+multiorgan	O
+dysfunction	O
+syndrome	B-DISO
+(	O
+P	O
+=	O
+.	O
+036	O
+),	O
+intensive	O
+care	O
+unit	O
+admission	O
+(	O
+P	O
+=	O
+.	O
+020	O
+),	O
+and	O
+death	B-PROC
+(	O
+P	O
+=	O
+.	O
+003	O
+).	O
+
+No	O
+one	O
+can	O
+accurately	O
+predict	O
+if	O
+and	O
+when	O
+a	O
+given	O
+virus	B-SPEC
+will	O
+become	O
+a	O
+pandemic	O
+virus	B-SPEC
+.	O
+
+SARS	B-DISO
+illustrated	O
+dramatically	O
+the	O
+potential	O
+of	O
+air	B-CHED
+travel	O
+and	O
+globalization	O
+for	O
+the	O
+dissemination	O
+of	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+All	O
+infected	O
+cats	B-SPEC
+and	O
+ferrets	B-SPEC
+had	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+associated	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antigen	B-CHED
+expression	B-PROC
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antigen	B-CHED
+expression	B-PROC
+occurred	O
+mainly	O
+in	O
+type	O
+I	O
+and	O
+II	O
+pneumocytes	B-ANAT
+and	O
+serous	O
+cells	B-COMP
+of	O
+tracheo	O
+-	O
+bronchial	B-ANAT
+submucosal	O
+glands	B-ANAT
+of	O
+cats	B-SPEC
+and	O
+in	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+of	O
+ferrets	B-SPEC
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+pathology	B-DISO
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+cats	B-SPEC
+and	O
+ferrets	B-SPEC
+resembles	O
+that	O
+in	O
+humans	B-SPEC
+except	O
+that	O
+syncytia	B-ANAT
+and	O
+hyaline	B-DISO
+membranes	B-ANAT
+were	O
+not	O
+observed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+effectiveness	O
+of	O
+combined	O
+treatment	O
+with	O
+methylprednisolone	B-CHED
+and	O
+cyclophosphamide	B-CHED
+in	O
+oral	B-ANAT
+paraquat	O
+poisoning	O
+.	O
+
+When	O
+k	O
+>	O
+3	O
+,	O
+our	O
+method	O
+still	O
+works	O
+and	O
+gets	O
+convergent	O
+phylogenetic	O
+topology	O
+but	O
+the	O
+RE	O
+gives	O
+degenerate	B-DISO
+results	O
+.	O
+
+When	O
+this	O
+occurs	O
+,	O
+it	O
+can	O
+be	O
+difficult	O
+to	O
+distinguish	O
+GBS	B-DISO
+from	O
+critical	B-DISO
+illness	I-DISO
+neuropathy	B-DISO
+(	O
+CIN	B-DISO
+).	O
+
+Electrodiagnostic	O
+studies	O
+showed	O
+severe	O
+axonal	O
+polyneuropathy	B-DISO
+,	O
+with	O
+denervation	O
+in	O
+all	O
+extremities	B-ANAT
+.	O
+
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+in	O
+trauma	O
+patients	O
+is	O
+rare	O
+and	O
+is	O
+limited	O
+to	O
+case	O
+reports	O
+following	O
+head	B-ANAT
+trauma	O
+.	O
+
+This	O
+case	O
+also	O
+highlights	O
+the	O
+similarities	O
+and	O
+the	O
+subtle	O
+differences	O
+between	O
+GBS	B-DISO
+and	O
+CIN	B-DISO
+.	O
+
+Increased	O
+fluid	O
+administration	O
+,	O
+oxygen	B-CHED
+toxicity	O
+,	O
+and	O
+yet	O
+unidentified	O
+factors	O
+may	O
+contribute	O
+to	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+multiorgan	B-DISO
+failure	I-DISO
+and	O
+death	B-PROC
+.	O
+
+In	O
+summary	O
+,	O
+(	O
+a	O
+)	O
+DC	O
+-	O
+SIGN	O
+acts	O
+as	O
+a	O
+capture	O
+or	O
+attachment	O
+molecule	O
+for	O
+avian	O
+H5N1	B-DISO
+virus	B-SPEC
+,	O
+and	O
+(	O
+b	O
+)	O
+DC	O
+-	O
+SIGN	O
+mediates	O
+infections	B-DISO
+in	O
+cis	B-DISO
+and	O
+in	O
+trans	O
+.	O
+
+ABSTRACT	O
+:	O
+Experimental	O
+and	O
+clinical	O
+studies	O
+support	O
+the	O
+key	O
+role	O
+of	O
+interleukin	O
+6	O
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+),	O
+a	O
+potent	O
+proinflammatory	O
+cytokine	O
+,	O
+in	O
+the	O
+development	B-PROC
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+Here	O
+we	O
+aimed	O
+to	O
+validate	O
+the	O
+association	O
+of	O
+the	O
+IL6	B-PRGE
+gene	I-PRGE
+with	O
+ALI	O
+in	O
+a	O
+case	O
+-	O
+control	O
+sample	O
+from	O
+Spain	O
+.	O
+
+In	O
+most	O
+cases	O
+the	O
+results	O
+show	O
+flexibility	O
+in	O
+the	O
+P4	O
+position	O
+,	O
+very	O
+high	O
+specificity	O
+for	O
+arginine	O
+in	O
+the	O
+P3	O
+position	O
+and	O
+glycine	B-CHED
+in	O
+the	O
+P2	O
+position	O
+,	O
+in	O
+accord	O
+with	O
+the	O
+sequence	O
+of	O
+the	O
+natural	O
+substrate	O
+,	O
+ubiquitin	B-PROC
+.	O
+
+Together	O
+,	O
+our	O
+results	O
+reveal	O
+the	O
+importance	O
+of	O
+the	O
+dual	O
+features	O
+of	O
+(	O
+1	O
+)	O
+substrate	O
+specificity	O
+and	O
+(	O
+2	O
+)	O
+the	O
+mechanism	O
+of	O
+ubiquitin	B-FUNC
+binding	I-FUNC
+in	O
+determining	O
+deubiquitination	B-PROC
+by	O
+this	O
+group	O
+of	O
+proteases	O
+.	O
+
+ABSTRACT	O
+:	O
+Five	O
+known	O
+human	B-SPEC
+coronaviruses	O
+infect	O
+the	O
+human	B-SPEC
+respiratory	B-ANAT
+tract	I-ANAT
+:	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	O
+-	O
+HKU1	O
+.	O
+
+The	O
+ORF1a	B-PRGE
+gene	I-PRGE
+clustering	O
+in	O
+phylogenetic	O
+trees	O
+did	O
+not	O
+match	O
+with	O
+that	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+Determination	O
+of	O
+the	O
+active	O
+regions	O
+that	O
+allow	O
+viral	O
+escape	O
+from	O
+neutralization	O
+would	O
+enable	O
+the	O
+use	O
+of	O
+these	O
+antibodies	B-COMP
+for	O
+future	O
+passive	O
+immunotherapy	O
+.	O
+
+We	O
+identified	O
+several	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+,	O
+including	O
+Y442F	O
+and	O
+V601G	O
+in	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+and	O
+D757N	O
+and	O
+A834V	O
+in	O
+the	O
+S2	O
+region	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+terminal	B-DISO
+disease	I-DISO
+of	O
+cats	B-SPEC
+caused	O
+by	O
+systemic	B-DISO
+infection	I-DISO
+with	O
+a	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+).	O
+
+The	O
+compounds	O
+are	O
+highly	O
+potent	O
+against	O
+SARS	B-DISO
+3CL	O
+(	O
+pro	B-CHED
+)	O
+with	O
+K	O
+(	O
+i	O
+)'	O
+s	O
+as	O
+low	O
+as	O
+300	O
+nM	O
+.	O
+The	O
+crystal	O
+structure	O
+of	O
+the	O
+complex	O
+of	O
+one	O
+of	O
+the	O
+compounds	O
+with	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+indicates	O
+that	O
+this	O
+inhibitor	B-CHED
+forms	O
+a	O
+thioether	B-CHED
+linkage	B-PROC
+between	O
+the	O
+halomethyl	O
+carbon	B-CHED
+of	O
+the	O
+warhead	O
+and	O
+the	O
+catalytic	O
+Cys	B-CHED
+145	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+Akinesia	B-DISO
+,	O
+an	O
+unusual	O
+complication	B-DISO
+in	O
+Parkinson	B-PATH
+'	I-PATH
+s	I-PATH
+Disease	I-PATH
+:	O
+a	O
+case	O
+report	O
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+case	O
+of	O
+a	O
+67	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+PD	O
+who	O
+rapidly	O
+developed	O
+a	O
+severe	O
+akinetic	O
+state	O
+with	O
+rise	O
+of	O
+temperature	O
+(	O
+39	O
+degrees	O
+C	O
+)	O
+and	O
+creatine	B-CHED
+phosphokinase	O
+concentration	O
+(	O
+up	O
+to	O
+5000	O
+mg	O
+/	O
+dL	O
+).	O
+
+TITLE	O
+:	O
+A	O
+second	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S2	I-PRGE
+glycoprotein	B-CHED
+internal	O
+membrane	B-COMP
+-	O
+active	O
+peptide	B-CHED
+.	O
+
+The	O
+S2	O
+domain	O
+of	O
+protein	B-PRGE
+S	I-PRGE
+has	O
+been	O
+suggested	O
+to	O
+have	O
+two	O
+fusion	O
+peptides	B-CHED
+,	O
+one	O
+located	O
+at	O
+its	O
+N	O
+-	O
+terminus	O
+,	O
+downstream	O
+of	O
+the	O
+furin	B-PRGE
+cleavage	B-PROC
+,	O
+and	O
+another	O
+,	O
+more	O
+internal	O
+,	O
+located	O
+immediately	O
+upstream	O
+of	O
+the	O
+HR1	O
+.	O
+
+These	O
+data	O
+support	O
+its	O
+role	O
+in	O
+SARS	B-DISO
+-	O
+mediated	O
+membrane	B-PROC
+fusion	I-PROC
+and	O
+suggest	O
+that	O
+the	O
+regions	O
+where	O
+this	O
+peptide	B-CHED
+resides	O
+might	O
+assist	O
+the	O
+fusion	O
+peptide	B-CHED
+and	O
+/	O
+or	O
+the	O
+pretransmembrane	O
+segment	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+glycoprotein	B-CHED
+in	O
+the	O
+fusion	O
+process	O
+.	O
+
+The	O
+indications	O
+for	O
+ECLS	O
+were	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+n	O
+=	O
+23	O
+),	O
+acute	B-DISO
+myocarditis	I-DISO
+(	O
+n	O
+=	O
+10	O
+)	O
+and	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+(	O
+n	O
+=	O
+12	O
+).	O
+
+The	O
+communications	O
+effort	B-PROC
+has	O
+also	O
+been	O
+made	O
+more	O
+difficult	O
+by	O
+the	O
+confusion	B-DISO
+and	O
+cacophony	O
+in	O
+the	O
+media	B-ANAT
+and	O
+claims	O
+by	O
+experts	O
+and	O
+politicians	O
+worldwide	O
+.	O
+
+Successful	O
+replication	O
+was	O
+achieved	O
+as	O
+evident	O
+from	O
+continuous	O
+expression	B-PROC
+of	O
+eGFP	O
+detected	O
+by	O
+both	O
+fluorescence	O
+and	O
+Western	O
+blot	O
+.	O
+
+TITLE	O
+:	O
+A	O
+rapid	O
+point	O
+of	O
+care	O
+immunoswab	O
+assay	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+detection	O
+.	O
+
+Studies	O
+in	O
+human	B-SPEC
+beings	O
+and	O
+animals	B-SPEC
+have	O
+shown	O
+increased	O
+urinary	O
+fractional	O
+excretion	B-PROC
+of	O
+potassium	B-CHED
+and	O
+sodium	O
+,	O
+as	O
+well	O
+as	O
+an	O
+increased	O
+potassium	B-CHED
+/	O
+sodium	O
+ratio	O
+,	O
+suggesting	O
+increased	O
+distal	O
+potassium	B-CHED
+secretion	B-PROC
+caused	O
+by	O
+increased	O
+distal	O
+sodium	O
+delivery	O
+consequent	O
+to	O
+functional	O
+impairment	B-DISO
+of	O
+proximal	O
+sodium	O
+reabsorption	O
+.	O
+
+Confirming	O
+these	O
+findings	O
+,	O
+Western	O
+blot	O
+studies	O
+have	O
+shown	O
+lower	O
+renal	B-ANAT
+expression	B-PROC
+of	O
+the	O
+sodium	O
+/	O
+hydrogen	B-CHED
+exchanger	B-PROC
+isoform	O
+3	O
+and	O
+of	O
+aquaporin	B-PRGE
+2	I-PRGE
+,	O
+together	O
+with	O
+higher	O
+renal	B-ANAT
+expression	B-PROC
+of	O
+the	O
+Na	B-PRGE
+-	I-PRGE
+K	I-PRGE
+-	I-PRGE
+2Cl	I-PRGE
+cotransporter	I-PRGE
+NKCC2	I-PRGE
+,	O
+in	O
+infected	O
+animals	B-SPEC
+.	O
+
+For	O
+critically	B-DISO
+ill	I-DISO
+leptospirosis	B-DISO
+patients	O
+,	O
+the	O
+following	O
+are	O
+recommended	O
+:	O
+daily	O
+hemodialysis	O
+,	O
+low	O
+daily	O
+net	O
+fluid	O
+intake	O
+(	O
+because	O
+of	O
+the	O
+risk	O
+for	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+),	O
+and	O
+lung	B-ANAT
+-	O
+protective	O
+strategies	O
+(	O
+low	O
+tidal	O
+volumes	O
+and	O
+high	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressures	O
+after	O
+recruitment	B-DISO
+maneuvers	O
+).	O
+
+ABSTRACT	O
+:	O
+Programmed	O
+ribosomal	B-COMP
+frameshifting	I-PROC
+(	O
+PRF	O
+)	O
+is	O
+one	O
+of	O
+the	O
+multiple	O
+translational	O
+recoding	O
+processes	O
+that	O
+fundamentally	O
+alters	O
+triplet	O
+decoding	O
+of	O
+the	O
+messenger	B-CHED
+RNA	I-CHED
+by	O
+the	O
+elongating	O
+ribosome	B-COMP
+.	O
+
+During	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+there	O
+was	O
+a	O
+21	O
+%	O
+decrease	O
+in	O
+the	O
+number	O
+of	O
+patient	O
+consultations	O
+and	O
+a	O
+15	O
+%	O
+reduction	O
+in	O
+the	O
+number	O
+of	O
+patients	O
+treated	O
+with	O
+RT	O
+.	O
+
+Bordetella	B-SPEC
+bronchiseptica	I-SPEC
+(	O
+B	O
+.	O
+b	O
+.)	O
+was	O
+most	O
+frequently	O
+detected	O
+from	O
+nasal	B-ANAT
+and	O
+oropharynx	B-ANAT
+sites	O
+of	O
+7	O
+dogs	B-SPEC
+(	O
+10	O
+.	O
+3	O
+%).	O
+
+ABSTRACT	O
+:	O
+The	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+remains	O
+poorly	O
+understood	O
+.	O
+
+The	O
+observed	O
+difference	O
+in	O
+DC	O
+-	O
+stimulating	O
+activity	O
+between	O
+BVLPs	O
+and	O
+SARS	B-PRGE
+CoV	I-PRGE
+VLPs	B-ANAT
+was	O
+very	O
+likely	O
+due	O
+to	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+central	O
+domain	O
+of	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+contains	O
+several	O
+arginine	B-CHED
+/	O
+serine	B-CHED
+(	O
+RS	O
+)	O
+dipeptides	B-CHED
+,	O
+the	O
+biological	O
+significance	O
+of	O
+which	O
+has	O
+not	O
+been	O
+well	O
+investigated	O
+.	O
+
+The	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+lacking	O
+the	O
+RS	O
+motif	O
+formed	O
+high	O
+-	O
+order	B-SPEC
+RNP	B-COMP
+complexes	O
+,	O
+which	O
+may	O
+also	O
+account	O
+for	O
+its	O
+enhanced	O
+stress	B-COMP
+granule	I-COMP
+localization	B-PROC
+.	O
+
+Taken	O
+together	O
+,	O
+phosphorylation	B-PROC
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+CoV	B-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+modulates	O
+its	O
+activity	O
+in	O
+translation	B-PROC
+control	O
+and	O
+also	O
+interferes	O
+with	O
+its	O
+oligomerization	O
+and	O
+aggregation	O
+in	O
+stress	O
+granules	O
+.	O
+
+However	O
+,	O
+the	O
+cellular	B-COMP
+targets	O
+leading	O
+to	O
+3a	O
+protein	B-CHED
+-	O
+mediated	O
+apoptosis	B-PATH
+have	O
+not	O
+been	O
+fully	O
+characterized	O
+.	O
+
+Tachyphylaxis	B-PROC
+to	O
+NNMBAs	O
+is	O
+associated	O
+with	O
+adverse	O
+outcomes	O
+including	O
+inadequate	O
+ventilation	O
+,	O
+increased	O
+risk	O
+of	O
+dose	O
+-	O
+dependent	O
+side	O
+effects	O
+,	O
+and	O
+increased	O
+drug	O
+costs	O
+.	O
+
+Patients	O
+who	O
+develop	O
+tachyphylaxis	B-PROC
+to	O
+one	O
+NNMBA	O
+should	O
+be	O
+treated	O
+with	O
+another	O
+NNMBA	O
+if	O
+neuromuscular	B-DISO
+blockade	I-DISO
+(	O
+NMB	O
+)	O
+is	O
+still	O
+indicated	O
+.	O
+
+During	O
+PECLA	O
+therapy	O
+,	O
+48	O
+.	O
+7	O
+%	O
+of	O
+patients	O
+died	B-PROC
+,	O
+mainly	O
+as	O
+a	O
+result	O
+of	O
+multiorgan	B-DISO
+failure	I-DISO
+after	O
+a	O
+mean	O
+interval	O
+of	O
+4	O
+.	O
+8	O
++/-	O
+
+Since	O
+1993	O
+,	O
+more	O
+than	O
+1800	O
+cases	O
+of	O
+suspected	O
+PE	O
+have	O
+been	O
+submitted	O
+for	O
+examination	O
+by	O
+negative	O
+stain	O
+electron	O
+microscopy	O
+;	O
+this	O
+has	O
+involved	O
+more	O
+than	O
+2400	O
+individual	O
+results	O
+,	O
+because	O
+in	O
+many	O
+cases	O
+more	O
+than	O
+one	O
+virus	B-SPEC
+was	O
+identified	O
+;	O
+at	O
+least	O
+1500	O
+individual	O
+results	O
+were	O
+positive	O
+for	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Enteric	O
+viruses	B-SPEC
+detected	O
+by	O
+molecular	O
+methods	O
+in	O
+commercial	O
+chicken	B-SPEC
+and	O
+turkey	B-SPEC
+flocks	O
+in	O
+the	O
+United	O
+States	O
+between	O
+2005	O
+and	O
+2006	O
+.	O
+
+ABSTRACT	O
+:	O
+Intestinal	O
+samples	O
+collected	O
+from	O
+43	O
+commercial	O
+broiler	O
+and	O
+33	O
+commercial	O
+turkey	B-SPEC
+flocks	O
+from	O
+all	O
+regions	O
+of	O
+the	O
+United	O
+States	O
+during	O
+2005	O
+and	O
+2006	O
+were	O
+examined	O
+for	O
+the	O
+presence	O
+of	O
+astrovirus	O
+,	O
+rotavirus	B-SPEC
+,	O
+reovirus	B-SPEC
+,	O
+and	O
+coronavirus	B-SPEC
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+),	O
+and	O
+for	O
+the	O
+presence	O
+of	O
+groups	O
+1	O
+and	O
+2	O
+adenovirus	B-DISO
+by	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+A	O
+case	O
+of	O
+catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+presenting	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+as	O
+the	O
+initial	O
+manifestation	O
+.	O
+
+These	O
+studies	O
+implicate	O
+PBEF	O
+as	O
+a	O
+key	O
+inflammatory	O
+mediator	O
+intimately	O
+involved	O
+in	O
+both	O
+the	O
+development	B-PROC
+and	O
+severity	O
+of	O
+ventilator	O
+-	O
+induced	O
+ALI	O
+.	O
+
+To	O
+determine	O
+the	O
+pathway	B-PROC
+by	O
+which	O
+MHV	B-SPEC
+is	O
+recognized	O
+in	O
+macrophages	B-ANAT
+,	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+mRNA	I-PRGE
+expression	B-PROC
+was	O
+quantified	O
+following	O
+MHV	B-SPEC
+infection	B-DISO
+of	O
+a	O
+panel	O
+of	O
+primary	O
+bone	B-ANAT
+marrow	I-ANAT
+-	I-ANAT
+derived	I-ANAT
+macrophages	I-ANAT
+generated	O
+from	O
+mice	B-SPEC
+lacking	O
+different	O
+pattern	O
+recognition	O
+receptors	O
+(	O
+PRRs	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+HBV	B-DISO
+)	O
+constitutes	O
+a	O
+serious	O
+menace	O
+to	O
+man	B-CHED
+.	O
+
+Plasmid	B-PRGE
+pIRES2	I-PRGE
+-	I-PRGE
+EGFP	I-PRGE
+-	I-PRGE
+HBs	I-PRGE
+which	O
+expressed	B-PROC
+enhanced	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+as	O
+reporter	O
+for	O
+the	O
+expression	B-PROC
+of	O
+hepatitis	B-PRGE
+B	I-PRGE
+virus	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+was	O
+successfully	O
+constructed	O
+and	O
+confirmed	O
+by	O
+PCR	B-PRGE
+,	O
+EcoR	O
+I	O
+and	O
+Sal	B-PRGE
+I	I-PRGE
+digestion	B-PROC
+,	O
+and	O
+DNA	O
+sequencing	O
+.	O
+
+Others	O
+,	O
+such	O
+as	O
+adenovirus	B-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+coronavirus	B-SPEC
+,	O
+Hantavirus	B-SPEC
+,	O
+and	O
+the	O
+viral	B-DISO
+hemorrhagic	I-DISO
+fevers	I-DISO
+(	O
+VHFs	B-DISO
+),	O
+are	O
+rare	O
+but	O
+have	O
+an	O
+immense	O
+public	O
+health	O
+impact	O
+.	O
+
+Therefore	O
+,	O
+a	O
+basic	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+viral	O
+entry	O
+,	O
+replication	O
+,	O
+and	O
+host	B-PROC
+response	I-PROC
+is	O
+important	O
+for	O
+clinical	O
+diagnosis	O
+and	O
+initiating	O
+therapeutic	O
+options	O
+.	O
+
+During	O
+pulmonary	B-ANAT
+tissue	B-ANAT
+injury	O
+an	O
+endogenous	O
+secretory	B-PROC
+isoform	O
+of	O
+RAGE	B-PRGE
+called	O
+EsRAGE	O
+is	O
+noticed	O
+at	O
+high	O
+levels	O
+in	O
+broncho	B-ANAT
+-	I-ANAT
+alveolar	I-ANAT
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+and	O
+plasma	B-ANAT
+.	O
+
+This	O
+study	O
+would	O
+pave	O
+a	O
+way	O
+for	O
+potential	O
+vaccine	O
+development	B-PROC
+by	O
+generation	O
+of	O
+attenuated	O
+IBV	B-SPEC
+from	O
+field	O
+isolates	O
+through	O
+manipulation	O
+of	O
+the	O
+nsp10	O
+-	O
+nsp11	O
+/	O
+12	O
+cleavage	B-PROC
+site	O
+.	O
+
+Similar	O
+approaches	O
+would	O
+be	O
+also	O
+applicable	O
+to	O
+other	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spread	O
+of	O
+a	O
+virus	O
+--	O
+whether	O
+in	O
+a	O
+human	B-SPEC
+population	O
+,	O
+computer	O
+network	O
+or	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-COMP
+--	O
+is	O
+closely	O
+tied	O
+to	O
+the	O
+spatial	O
+(	O
+graph	O
+)	O
+topology	O
+of	O
+the	O
+interactions	O
+among	O
+the	O
+possible	O
+infectives	O
+.	O
+
+Radionuclide	O
+bone	B-ANAT
+scintigraphy	O
+is	O
+valuable	O
+in	O
+early	O
+diagnosis	O
+of	O
+osteonecrosis	B-DISO
+in	O
+SARS	B-DISO
+patients	O
+in	O
+convalescence	O
+.	O
+
+ARDS	B-DISO
+was	O
+most	O
+often	O
+associated	O
+with	O
+pneumonia	O
+or	O
+aspiration	B-DISO
+,	O
+sepsis	B-DISO
+,	O
+and	O
+trauma	O
+or	O
+surgery	O
+.	O
+
+rSP	O
+-	O
+C	O
+surfactant	B-CHED
+improved	O
+oxygenation	B-PROC
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+irrespective	O
+of	O
+the	O
+predisposition	O
+.	O
+
+Samples	O
+also	O
+were	O
+tested	O
+for	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+antigens	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+new	O
+5	O
+-	O
+alkyl	O
+-	O
+2	O
+-	O
+benzylsulfanylpyrimidin	O
+-	O
+4	O
+(	O
+3H	O
+)-	O
+ones	O
+(	O
+5a	O
+-	O
+y	O
+)	O
+bearing	O
+different	O
+substituted	O
+arylmethyl	O
+moieties	O
+at	O
+the	O
+C	O
+-	O
+6	O
+position	O
+of	O
+the	O
+pyrimidine	B-CHED
+core	O
+have	O
+been	O
+synthesized	O
+and	O
+evaluated	O
+for	O
+their	O
+in	O
+vitro	O
+activities	O
+against	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+and	O
+HIV	B-SPEC
+-	I-SPEC
+2	I-SPEC
+in	O
+MT	O
+-	O
+4	O
+cell	B-COMP
+cultures	O
+.	O
+
+The	O
+majority	O
+of	O
+the	O
+title	O
+compounds	O
+showed	O
+moderate	O
+to	O
+good	O
+activities	O
+against	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+with	O
+an	O
+IC	O
+(	O
+50	O
+)	O
+range	O
+from	O
+6	O
+.	O
+67	O
+microM	O
+to	O
+0	O
+.	O
+12	O
+microM	O
+.	O
+Among	O
+them	O
+,	O
+6	O
+-(	O
+3	O
+,	O
+5	O
+-	O
+dimethylbenzyl	O
+)	O
+analogue	O
+5q	O
+exhibited	O
+the	O
+most	O
+potent	O
+anti	O
+-	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+activity	O
+(	O
+IC	O
+(	O
+50	O
+)=	O
+0	O
+.	O
+12	O
+microM	O
+,	O
+SI	O
+>	O
+2642	O
+),	O
+which	O
+was	O
+about	O
+40	O
+-	O
+fold	O
+more	O
+active	O
+than	O
+the	O
+reference	O
+compounds	O
+1	B-CHED
+-[(	I-CHED
+2	I-CHED
+-	I-CHED
+hydroxyethoxy	I-CHED
+)	I-CHED
+methyl	I-CHED
+]-	I-CHED
+6	I-CHED
+-(	I-CHED
+phenylsulfanyl	I-CHED
+)	I-CHED
+thymine	I-CHED
+(	O
+HEPT	B-CHED
+)	O
+and	O
+2	B-CHED
+',	I-CHED
+3	I-CHED
+'-	I-CHED
+dideoxyinosine	I-CHED
+(	O
+DDI	B-CHED
+).	O
+
+TITLE	O
+:	O
+Genomic	O
+analysis	O
+and	O
+geographic	O
+visualization	O
+of	O
+H5N1	B-DISO
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+and	O
+organisms	O
+present	O
+critical	O
+issues	O
+of	O
+national	O
+security	O
+public	O
+health	O
+,	O
+and	O
+economic	O
+welfare	O
+.	O
+
+This	O
+was	O
+achieved	O
+using	O
+hybridization	O
+chain	O
+reaction	O
+(	O
+HCR	B-PRGE
+)	O
+as	O
+a	O
+signal	O
+amplifier	O
+on	O
+a	O
+water	B-CHED
+-	O
+soluble	O
+self	O
+-	O
+assembled	O
+DNA	O
+nanoarray	O
+carrying	O
+detection	O
+probes	O
+.	O
+
+In	O
+summary	O
+,	O
+this	O
+work	O
+provides	O
+proof	O
+-	O
+of	O
+-	O
+concept	O
+that	O
+HCR	B-PRGE
+can	O
+occur	O
+efficiently	O
+on	O
+DNA	O
+-	O
+tile	O
+-	O
+based	O
+nanoarrays	O
+,	O
+thus	O
+facilitating	O
+more	O
+sensitive	O
+detection	O
+.	O
+
+Rats	B-SPEC
+were	O
+pretreated	O
+with	O
+empty	O
+liposomes	O
+,	O
+NAC	B-COMP
+,	O
+or	O
+L	B-PRGE
+-	I-PRGE
+NAC	I-PRGE
+(	O
+25mg	O
+/	O
+kg	O
+body	B-ANAT
+weight	O
+,	O
+iv	O
+);	O
+4h	O
+later	O
+were	O
+challenged	O
+with	O
+LPS	B-DISO
+(	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+,	O
+LPS	B-DISO
+0111	O
+:	O
+B4	O
+)	O
+and	O
+sacrificed	O
+20h	O
+later	O
+.	O
+
+The	O
+LPS	B-DISO
+challenge	O
+also	O
+increased	O
+pulmonary	B-PRGE
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+and	O
+chloramine	O
+concentrations	O
+indicative	O
+of	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+and	O
+activation	O
+of	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+Our	O
+results	O
+suggested	O
+that	O
+the	O
+delivery	O
+of	O
+NAC	B-COMP
+as	O
+a	O
+liposomal	O
+formulation	O
+improved	O
+its	O
+prophylactic	O
+effectiveness	O
+against	O
+LPS	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+injuries	O
+.	O
+
+ABSTRACT	O
+:	O
+Critical	O
+illness	O
+is	O
+generally	O
+hallmarked	O
+by	O
+activation	O
+of	O
+the	O
+hypothalamic	B-ANAT
+-	I-ANAT
+pituitary	I-ANAT
+-	I-ANAT
+adrenal	I-ANAT
+axis	I-ANAT
+.	O
+
+The	O
+development	B-PROC
+of	O
+very	O
+high	O
+levels	O
+of	O
+cortisol	B-CHED
+has	O
+been	O
+associated	O
+with	O
+severe	O
+illness	O
+and	O
+a	O
+raised	O
+risk	O
+of	O
+death	B-PROC
+.	O
+
+Likewise	O
+,	O
+a	O
+response	O
+that	O
+is	O
+inadequate	O
+relative	O
+to	O
+the	O
+degree	O
+of	O
+stress	O
+,	O
+termed	O
+relative	O
+adrenal	B-DISO
+insufficiency	I-DISO
+(	O
+also	O
+known	O
+as	O
+critical	O
+-	O
+illness	O
+-	O
+related	O
+corticosteroid	B-CHED
+insufficiency	O
+)	O
+has	O
+been	O
+associated	O
+with	O
+increased	O
+mortality	O
+.	O
+
+Moderate	O
+doses	O
+have	O
+been	O
+advocated	O
+,	O
+however	O
+,	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+inflammatory	O
+conditions	O
+,	O
+such	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+septic	O
+shock	B-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Polymorphisms	B-PROC
+in	O
+the	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+lectin	I-PRGE
+genes	I-PRGE
+cluster	O
+in	O
+chromosome	B-ANAT
+19	I-ANAT
+and	O
+predisposition	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+Because	O
+cystatins	O
+added	O
+to	O
+cell	B-COMP
+cultures	O
+can	O
+inhibit	O
+polio	B-DISO
+,	O
+herpes	B-DISO
+simplex	I-DISO
+and	O
+coronavirus	B-SPEC
+replication	O
+,	O
+which	O
+are	O
+intracellular	B-COMP
+processes	O
+,	O
+the	O
+internalization	O
+and	O
+intracellular	B-COMP
+regulation	B-PROC
+of	O
+cysteine	B-PRGE
+proteases	I-PRGE
+by	O
+cystatin	B-PRGE
+C	I-PRGE
+should	O
+be	O
+considered	O
+.	O
+
+It	O
+was	O
+functionally	O
+intact	O
+and	O
+extracts	O
+of	O
+cells	B-COMP
+exposed	O
+to	O
+cystatin	B-PRGE
+C	I-PRGE
+showed	O
+a	O
+higher	O
+capacity	O
+to	O
+inhibit	O
+papain	B-ENZY
+and	O
+cathepsin	B-PRGE
+B	I-PRGE
+than	O
+control	O
+cells	B-COMP
+(	O
+decrease	O
+in	O
+enzyme	B-FUNC
+activity	I-FUNC
+of	O
+34	O
+%	O
+and	O
+37	O
+%,	O
+respectively	O
+).	O
+
+Later	O
+,	O
+we	O
+screened	O
+his	O
+sera	B-COMP
+for	O
+antibodies	B-COMP
+to	O
+anti	B-PRGE
+-	I-PRGE
+aminoacyl	I-PRGE
+tRNA	I-PRGE
+synthetase	I-PRGE
+to	O
+diagnose	O
+anti	B-PRGE
+-	I-PRGE
+aminoacyl	I-PRGE
+tRNA	I-PRGE
+synthetase	I-PRGE
+syndrome	B-DISO
+because	O
+anti	O
+-	O
+PL	O
+-	O
+12	O
+antibodies	B-COMP
+were	O
+positive	O
+.	O
+
+A	O
+variety	O
+of	O
+socio	O
+-	O
+demographic	O
+factors	O
+,	O
+notably	O
+gender	O
+,	O
+previous	O
+outbreak	O
+experience	O
+(	O
+particularly	O
+with	O
+SARS	B-DISO
+),	O
+full	O
+-	O
+time	O
+vs	O
+.	O
+part	O
+-	O
+time	O
+job	O
+status	O
+,	O
+and	O
+region	O
+of	O
+employment	O
+also	O
+were	O
+related	O
+to	O
+perceptions	O
+of	O
+risk	O
+.	O
+
+ABSTRACT	O
+:	O
+Among	O
+the	O
+deaths	B-PROC
+due	O
+to	O
+trauma	O
+,	O
+about	O
+one	O
+half	O
+of	O
+the	O
+patients	O
+suffer	B-DISO
+from	O
+road	O
+traffic	O
+injury	O
+(	O
+RTI	B-DISO
+).	O
+
+This	O
+study	O
+aimed	O
+to	O
+sieve	O
+distinctive	O
+risk	O
+factors	O
+in	O
+our	O
+RTI	B-DISO
+population	O
+,	O
+meanwhile	O
+,	O
+we	O
+also	O
+hypothesize	O
+that	O
+there	O
+may	O
+exist	O
+significantly	O
+different	O
+risk	O
+factors	O
+in	O
+these	O
+patients	O
+.	O
+
+Patients	O
+identified	O
+as	O
+severe	O
+RTI	B-DISO
+with	O
+post	O
+-	O
+traumatic	O
+ARDS	B-DISO
+were	O
+enrolled	O
+in	O
+a	O
+prospectively	O
+maintained	O
+database	O
+between	O
+May	O
+2002	O
+and	O
+April	O
+2007	O
+and	O
+observed	O
+.	O
+
+The	O
+unadjusted	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+and	O
+95	O
+%	O
+confidence	O
+intervals	O
+(	O
+CI	O
+)	O
+of	O
+mortality	O
+were	O
+associated	O
+with	O
+six	O
+risk	O
+factors	O
+out	O
+of	O
+23	O
+:	O
+APACHE	O
+II	O
+score	O
+,	O
+duration	O
+of	O
+trauma	O
+factor	O
+,	O
+pulmonary	B-ANAT
+contusion	O
+,	O
+aspiration	B-DISO
+of	O
+gastric	B-ANAT
+contents	I-ANAT
+,	O
+sepsis	B-DISO
+and	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+This	O
+study	O
+showed	O
+that	O
+ApNPV	O
+significantly	O
+enhanced	O
+inflammatory	O
+cytokine	O
+mRNA	B-PROC
+expression	B-PROC
+in	O
+chicken	B-SPEC
+PBMC	O
+and	O
+HD	O
+11	O
+cells	B-COMP
+through	O
+the	O
+clathrin	B-PRGE
+-	O
+dependent	O
+endocytic	O
+and	O
+endosomal	O
+maturation	B-PROC
+pathway	B-PROC
+,	O
+and	O
+up	O
+-	O
+regulated	O
+nitric	B-CHED
+oxide	I-CHED
+production	O
+in	O
+HD	O
+11	O
+cells	B-COMP
+.	O
+
+CoV	O
+primarily	O
+infects	O
+the	O
+upper	O
+respiratory	O
+and	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+;	O
+however	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+a	O
+unique	O
+pathogenesis	B-DISO
+because	O
+it	O
+infects	O
+both	O
+the	O
+upper	O
+and	O
+lower	O
+respiratory	B-ANAT
+tracts	I-ANAT
+and	O
+leads	O
+to	O
+human	B-SPEC
+respiratory	B-DISO
+diseases	I-DISO
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+has	O
+shown	O
+containing	O
+14	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+and	O
+8	O
+of	O
+them	O
+encode	O
+novel	O
+proteins	B-CHED
+.	O
+
+Importantly	O
+,	O
+the	O
+protein	B-CHED
+level	O
+of	O
+ER	B-PRGE
+chaperon	I-PRGE
+protein	I-PRGE
+,	O
+GRP94	B-PRGE
+,	O
+was	O
+up	O
+-	O
+regulated	O
+when	O
+ORF	B-PRGE
+-	I-PRGE
+6	I-PRGE
+was	O
+overexpressed	O
+.	O
+
+We	O
+produced	O
+mammalian	B-SPEC
+expression	B-PROC
+vectors	O
+encoding	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+accessory	O
+proteins	B-CHED
+with	O
+or	O
+without	O
+the	O
+fluorescence	O
+protein	B-FUNC
+tag	B-DISO
+and	O
+cell	B-ANAT
+lines	I-ANAT
+with	O
+stable	O
+expression	B-PROC
+of	O
+these	O
+proteins	B-CHED
+.	O
+
+Lymphopaenia	O
+in	O
+SARS	B-DISO
+patients	O
+is	O
+likely	O
+to	O
+result	O
+from	O
+indirect	O
+mechanisms	O
+secondary	O
+to	O
+the	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+This	O
+was	O
+supported	O
+by	O
+in	O
+vitro	O
+binding	B-FUNC
+studies	O
+that	O
+demonstrated	O
+homozygous	O
+L	O
+-	O
+SIGN	O
+,	O
+compared	O
+to	O
+heterozygous	O
+,	O
+had	O
+higher	O
+binding	B-FUNC
+capacity	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+with	O
+higher	O
+proteasome	B-PATH
+-	O
+dependent	O
+viral	O
+degradation	O
+.	O
+
+We	O
+have	O
+demonstrated	O
+for	O
+the	O
+first	O
+time	O
+that	O
+the	O
+helicase	O
+of	O
+a	O
+ribonucleic	B-CHED
+acid	I-CHED
+virus	B-SPEC
+,	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+is	O
+a	O
+valid	O
+target	O
+for	O
+drug	O
+development	B-PROC
+.	O
+
+These	O
+compounds	O
+can	O
+potentially	O
+be	O
+used	O
+to	O
+target	O
+other	O
+viruses	B-SPEC
+.	O
+
+Intranasal	O
+vaccination	O
+using	O
+inactivated	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+vaccine	O
+with	O
+adjuvant	B-CHED
+can	O
+induce	O
+strong	O
+systemic	O
+(	O
+serum	B-COMP
+immunoglobulin	B-PROC
+[	O
+Ig	O
+]	O
+G	O
+)	O
+and	O
+respiratory	B-ANAT
+tract	I-ANAT
+local	O
+(	O
+tracheal	O
+-	O
+lung	B-ANAT
+wash	O
+fluid	O
+IgA	B-PRGE
+)	O
+antibody	B-PROC
+responses	I-PROC
+with	O
+neutralising	O
+activity	O
+.	O
+
+A	O
+single	O
+dose	O
+of	O
+RBD	O
+-	O
+rAAV	O
+vaccination	O
+can	O
+induce	O
+adequate	O
+neutralising	O
+antibody	B-COMP
+against	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Intranasal	O
+vaccination	O
+with	O
+RBD	O
+-	O
+rAAV	O
+induced	O
+local	O
+IgA	B-PRGE
+and	O
+systemic	O
+IgG	B-PRGE
+neutralising	O
+antibodies	B-COMP
+and	O
+specific	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+,	O
+able	O
+to	O
+protect	O
+against	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+animal	B-SPEC
+models	O
+.	O
+
+When	O
+compared	O
+with	O
+the	O
+RBD	O
+-	O
+rAAV	O
+prime	O
+/	O
+boost	O
+vaccination	O
+,	O
+RBD	O
+-	O
+rAAV	O
+prime	O
+/	O
+RBD	O
+-	O
+peptide	O
+boost	O
+induced	O
+similar	O
+levels	O
+of	O
+Th1	O
+and	O
+neutralising	O
+antibody	B-PROC
+responses	I-PROC
+that	O
+protected	O
+vaccinated	O
+mice	B-SPEC
+from	O
+subsequent	O
+SARS	B-DISO
+-	O
+CoV	O
+challenges	O
+,	O
+but	O
+stronger	O
+Th2	O
+and	O
+CTL	B-ANAT
+responses	O
+.	O
+
+Overall	O
+,	O
+our	O
+findings	O
+suggest	O
+that	O
+the	O
+inactivated	O
+vaccine	O
+,	O
+RBD	O
+-	O
+Fc	O
+and	O
+RBD	O
+-	O
+rAAV	O
+,	O
+can	O
+be	O
+further	O
+developed	O
+into	O
+effective	O
+and	O
+safe	O
+vaccines	O
+against	O
+SARS	B-DISO
+and	O
+that	O
+intranasal	O
+vaccination	O
+may	O
+be	O
+the	O
+preferred	O
+route	O
+of	O
+administration	O
+.	O
+
+Other	O
+viruses	B-SPEC
+that	O
+cause	O
+myocarditis	B-DISO
+are	O
+adenovirus	B-DISO
+and	O
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+Histological	O
+examination	O
+was	O
+undertaken	O
+to	O
+detect	O
+myocardial	B-DISO
+inflammation	I-DISO
+.	O
+
+After	O
+exclusion	O
+of	O
+other	O
+possible	O
+causes	O
+of	O
+death	B-PROC
+,	O
+the	O
+results	O
+indicated	O
+that	O
+viral	B-PATH
+myocarditis	I-PATH
+was	O
+the	O
+cause	O
+of	O
+death	B-PROC
+in	O
+patients	O
+with	O
+adenovirus	B-DISO
+infection	I-DISO
+.	O
+
+Other	O
+common	O
+causes	O
+of	O
+diarrhea	B-DISO
+in	O
+adult	O
+camelids	O
+were	O
+not	O
+detected	O
+.	O
+
+Both	O
+patients	O
+died	B-PROC
+despite	O
+full	O
+supportive	O
+therapy	O
+;	O
+the	O
+first	O
+due	O
+to	O
+pulmonary	B-DISO
+haemorrhage	I-DISO
+,	O
+the	O
+second	O
+due	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+refractory	O
+to	O
+high	O
+frequency	O
+oscillatory	O
+ventilation	O
+.	O
+
+Further	O
+research	O
+into	O
+appropriate	O
+therapy	O
+for	O
+patients	O
+with	O
+acute	O
+severe	O
+forms	O
+of	O
+the	O
+disease	O
+who	O
+require	O
+intensive	O
+organ	B-ANAT
+support	O
+is	O
+required	O
+.	O
+
+This	O
+study	O
+considers	O
+250	O
+autopsies	O
+of	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+patients	O
+who	O
+died	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+describes	O
+the	O
+demographic	O
+data	O
+,	O
+etiology	O
+,	O
+and	O
+histological	O
+pulmonary	B-ANAT
+findings	O
+of	O
+the	O
+various	O
+pathologies	O
+.	O
+
+Odds	O
+ratio	O
+of	O
+the	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+-	O
+associated	O
+diseases	O
+developing	O
+a	O
+specific	O
+histopathological	O
+pattern	O
+was	O
+determined	O
+by	O
+logistic	O
+regression	O
+.	O
+
+In	O
+one	O
+year	O
+after	O
+beginning	O
+of	O
+treatment	O
+with	O
+TMZ	O
+(	O
+35	O
+mg	O
+)	O
+number	O
+of	O
+weekly	O
+pain	O
+attacks	O
+was	O
+decreased	O
+in	O
+patients	O
+of	O
+1st	O
+group	O
+vs	O
+.	O
+2nd	O
+group	O
+(	O
+at	O
+the	O
+average	O
+-	O
+50	O
+.	O
+8	O
+%	O
+-	O
+29	O
+.	O
+3	O
+%	O
+vs	O
+.	O
++	O
+12	O
+.	O
+5	O
+%	O
++	O
+16	O
+.	O
+6	O
+%	O
+respectively	O
+);	O
+significant	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+decrease	O
+in	O
+duration	O
+of	O
+painless	O
+myocardial	B-DISO
+ischemia	I-DISO
+was	O
+registered	O
+.	O
+
+Thus	O
+,	O
+long	O
+-	O
+term	O
+(	O
+not	O
+less	O
+then	O
+1	O
+year	O
+)	O
+use	O
+of	O
+TMZ	O
+(	O
+35	O
+mg	O
+)	O
+in	O
+combined	O
+treatment	O
+assists	O
+to	O
+normalization	O
+of	O
+cardiovascular	B-ANAT
+indices	O
+,	O
+decreases	O
+cardiovascular	B-ANAT
+complication	B-DISO
+occurrence	O
+,	O
+improves	O
+disease	O
+prognosis	O
+and	O
+do	O
+not	O
+has	O
+negative	O
+side	O
+-	O
+effects	O
+.	O
+
+Rapid	O
+improvement	O
+of	O
+PaO2	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+from	O
+172	O
+mmHg	O
+(	O
+NIV	O
+)	O
+to	O
+310	O
+mmHg	O
+with	O
+HFO	O
+.	O
+
+In	O
+contrast	O
+with	O
+previous	O
+studies	O
+,	O
+we	O
+successfully	O
+used	O
+lung	B-ANAT
+protective	O
+ventilation	O
+with	O
+HFO	O
+immediately	O
+.	O
+
+In	O
+this	O
+review	O
+we	O
+will	O
+discuss	O
+mechanisms	O
+of	O
+pulmonary	B-ANAT
+endothelial	B-DISO
+dysfunction	I-DISO
+and	O
+edema	B-DISO
+generation	O
+in	O
+the	O
+lung	B-ANAT
+with	O
+special	O
+emphasis	O
+on	O
+the	O
+interplay	O
+between	O
+the	O
+endothelium	O
+,	O
+the	O
+immune	O
+and	O
+hemostatic	B-PROC
+systems	O
+,	O
+and	O
+highlight	O
+how	O
+these	O
+principles	O
+apply	O
+in	O
+the	O
+context	O
+of	O
+defined	O
+disorders	O
+and	O
+specific	O
+insults	O
+implicated	O
+in	O
+ALI	O
+pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+production	O
+of	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+constitutes	O
+a	O
+relevant	O
+and	O
+safe	O
+model	O
+to	O
+study	O
+molecular	O
+determinants	O
+of	O
+virion	B-COMP
+egress	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+both	O
+E	O
+and	O
+N	O
+proteins	B-CHED
+must	O
+be	O
+coexpressed	O
+with	O
+M	B-PRGE
+protein	I-PRGE
+for	O
+the	O
+efficient	O
+production	O
+and	O
+release	B-PATH
+of	O
+VLPs	B-ANAT
+by	O
+transfected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+was	O
+controlled	O
+,	O
+repeated	O
+transmission	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+over	O
+several	O
+years	O
+makes	O
+the	O
+development	B-PROC
+of	O
+a	O
+SARS	B-DISO
+vaccine	O
+desirable	O
+.	O
+
+Both	O
+the	O
+whole	O
+killed	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+(	O
+with	O
+and	O
+without	O
+alum	O
+)	O
+and	O
+adenovirus	B-DISO
+-	O
+based	O
+vectors	O
+encoding	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+and	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+induced	O
+neutralizing	O
+antibody	B-PROC
+responses	I-PROC
+and	O
+reduced	O
+viral	B-PROC
+replication	I-PROC
+and	O
+shedding	O
+in	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+progression	O
+of	O
+virus	B-SPEC
+to	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+),	O
+a	O
+coronavirus	B-SPEC
+that	O
+causes	O
+a	O
+lethal	O
+chronic	B-DISO
+disease	I-DISO
+in	O
+cats	B-SPEC
+,	O
+enters	O
+feline	B-SPEC
+monocytes	B-ANAT
+via	O
+endocytosis	B-PATH
+.	O
+
+The	O
+caveolae	B-COMP
+-	O
+mediated	O
+pathway	B-PROC
+could	O
+be	O
+excluded	O
+based	O
+on	O
+the	O
+inability	O
+of	O
+genistein	B-CHED
+and	O
+DN	B-PRGE
+caveolin	I-PRGE
+-	I-PRGE
+1	I-PRGE
+to	O
+inhibit	O
+virus	B-SPEC
+uptake	O
+and	O
+lack	O
+of	O
+co	O
+-	O
+localization	B-PROC
+between	O
+FIPV	O
+and	O
+caveolin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+Antiviral	B-CHED
+activity	O
+of	O
+arbidol	O
+and	O
+its	O
+derivatives	O
+against	O
+the	O
+pathogen	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+cell	B-COMP
+cultures	O
+].	O
+
+TITLE	O
+:	O
+The	O
+obesity	B-DISO
+-	I-DISO
+hypoventilation	I-DISO
+syndrome	I-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+the	O
+acute	O
+trauma	O
+patient	O
+.	O
+
+In	O
+the	O
+acute	O
+trauma	O
+patient	O
+,	O
+these	O
+include	O
+spinal	O
+immobilization	O
+,	O
+supine	O
+positioning	O
+,	O
+and	O
+the	O
+administration	O
+of	O
+sedative	B-CHED
+and	O
+analgesic	B-CHED
+medications	O
+.	O
+
+Such	O
+patients	O
+will	O
+not	O
+be	O
+able	O
+to	O
+adequately	O
+increase	O
+ventilation	O
+in	O
+response	O
+to	O
+mounting	O
+hypercapnia	B-DISO
+.	O
+
+TITLE	O
+:	O
+An	O
+immunosuppressed	O
+Syrian	B-SPEC
+golden	I-SPEC
+hamster	I-SPEC
+model	O
+for	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+small	O
+animal	O
+models	O
+have	O
+been	O
+developed	O
+for	O
+the	O
+study	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+replication	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+Syrian	B-SPEC
+golden	I-SPEC
+hamsters	I-SPEC
+are	O
+among	O
+the	O
+best	O
+small	O
+animal	B-SPEC
+models	O
+,	O
+though	O
+little	O
+clinical	O
+illness	O
+and	O
+no	O
+mortality	O
+are	O
+observed	O
+after	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Purification	O
+,	O
+crystallization	O
+and	O
+preliminary	O
+crystallographic	O
+analysis	O
+of	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	O
+nsp3	B-PRGE
+ADRP	B-PRGE
+domain	O
+.	O
+
+One	O
+of	O
+them	O
+,	O
+nsp3	B-PRGE
+,	O
+contains	O
+an	O
+ADRP	B-PRGE
+(	O
+adenosine	B-CHED
+diphosphate	B-CHED
+-	O
+ribose	B-CHED
+-	O
+1	O
+'-	O
+phosphatase	B-FUNC
+)	O
+domain	O
+which	O
+was	O
+revealed	O
+in	O
+recent	O
+studies	O
+to	O
+have	O
+ADP	B-PRGE
+-	I-PRGE
+ribose	B-CHED
+-	I-PRGE
+1	I-PRGE
+'-	I-PRGE
+monophosphatase	I-PRGE
+(	O
+Appr	O
+-	O
+1	O
+'-	O
+pase	O
+)	O
+activity	O
+.	O
+
+Appr	O
+-	O
+1	O
+'-	O
+pase	O
+catalyzes	O
+the	O
+conversion	O
+of	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+-	O
+1	O
+'-	O
+monophosphate	O
+(	O
+Appr	O
+-	O
+1	O
+'-	O
+p	O
+)	O
+to	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+in	O
+the	O
+tRNA	B-FUNC
+-	O
+splicing	B-PROC
+pathway	B-PROC
+.	O
+
+2	O
+.	O
+4	O
+mL	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+.	O
+
+TITLE	O
+:	O
+[	O
+New	O
+respiratory	O
+viruses	B-SPEC
+in	O
+children	O
+2	O
+months	O
+to	O
+3	O
+years	O
+old	O
+with	O
+recurrent	O
+wheeze	B-DISO
+].	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viruses	O
+are	O
+associated	O
+with	O
+respiratory	O
+exacerbations	O
+,	O
+more	O
+frequently	O
+Respiratory	B-SPEC
+Syncytial	I-SPEC
+Virus	I-SPEC
+in	O
+infants	O
+and	O
+Rhinovirus	B-SPEC
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+The	O
+studies	O
+on	O
+the	O
+aetiology	O
+of	O
+diarrhoea	B-DISO
+in	O
+neonatal	O
+calves	O
+and	O
+determination	O
+of	O
+virulence	B-PROC
+gene	O
+markers	O
+of	O
+Escherichia	O
+coli	O
+strains	O
+by	O
+multiplex	O
+PCR	O
+.	O
+
+Faeces	B-ANAT
+were	O
+taken	O
+from	O
+the	O
+rectums	B-ANAT
+of	O
+all	O
+the	O
+calves	O
+and	O
+were	O
+subjected	O
+to	O
+bacterial	O
+culture	O
+.	O
+
+Furthermore	O
+,	O
+only	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+was	O
+isolated	O
+from	O
+all	O
+18	O
+faeces	O
+samples	O
+of	O
+healthy	O
+calves	O
+.	O
+
+A	O
+total	O
+of	O
+15	O
+rotavirus	B-SPEC
+,	O
+11	O
+coronavirus	B-SPEC
+and	O
+11	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+K99	O
+were	O
+detected	O
+in	O
+diarrhoeic	O
+calves	O
+by	O
+the	O
+antigen	B-CHED
+ELISA	O
+.	O
+
+K99	O
+,	O
+F41	O
+,	O
+STa	B-PRGE
+,	O
+Stx1	B-PRGE
+and	O
+Stx2	B-PRGE
+were	O
+found	O
+as	O
+the	O
+most	O
+common	O
+virulence	B-PROC
+gene	O
+markers	O
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+strains	O
+isolated	O
+from	O
+calves	O
+with	O
+diarrhoea	B-DISO
+.	O
+
+Multiplex	O
+PCR	O
+may	O
+be	O
+useful	O
+for	O
+characterization	O
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolated	O
+from	O
+calves	O
+.	O
+
+The	O
+nucleolar	B-ANAT
+trafficking	B-PROC
+of	O
+wild	O
+type	O
+viral	O
+proteins	B-CHED
+and	O
+chimeric	O
+proteins	B-CHED
+,	O
+which	O
+contain	O
+altered	O
+NoLSs	O
+,	O
+were	O
+compared	O
+to	O
+investigate	O
+the	O
+role	O
+of	O
+NoLSs	O
+in	O
+dynamic	O
+nucleolar	B-ANAT
+trafficking	B-PROC
+.	O
+
+A	O
+total	O
+of	O
+158	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+specimens	O
+collected	O
+from	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+Beijing	O
+were	O
+screened	O
+for	O
+the	O
+presence	O
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+and	O
+HKU1	O
+by	O
+using	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+and	O
+conventional	O
+RT	O
+-	O
+PCR	O
+method	O
+.	O
+
+The	O
+fluorescence	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+method	O
+detected	O
+six	O
+specimens	O
+positive	O
+for	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+,	O
+five	O
+specimens	O
+positive	O
+for	O
+human	O
+coronavirus	O
+HKU1	O
+;	O
+and	O
+conventional	O
+RT	O
+-	O
+PCR	O
+method	O
+detected	O
+three	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+positive	O
+and	O
+three	O
+HCoV	O
+-	O
+HKU1	O
+positive	O
+,	O
+respectively	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+is	O
+to	O
+investigate	O
+changes	O
+of	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+production	O
+occurring	O
+over	O
+the	O
+first	O
+48	O
+h	O
+after	O
+infection	B-DISO
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+)	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+and	O
+to	O
+compare	O
+these	O
+changes	O
+to	O
+those	O
+induced	O
+by	O
+well	O
+-	O
+established	O
+IFN	B-PRGE
+-	O
+inducing	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+vesicular	B-DISO
+stomatitis	I-DISO
+(	O
+VSV	O
+)	O
+and	O
+Newcastle	O
+viruses	B-SPEC
+(	O
+NDV	B-SPEC
+).	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+IFN	B-PRGE
+contained	O
+in	O
+the	O
+supernatant	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+PBMCs	O
+was	O
+lower	O
+than	O
+those	O
+induced	O
+by	O
+VSV	O
+and	O
+NDV	B-SPEC
+.	O
+
+Characterization	O
+of	O
+the	O
+profile	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+subtypes	O
+genes	O
+expression	B-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+PBMCs	O
+demonstrated	O
+that	O
+the	O
+level	O
+of	O
+IFN	O
+-	O
+alpha2	O
+and	O
+-	O
+6	O
+subtypes	O
+were	O
+higher	O
+compared	O
+to	O
+other	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+subtypes	O
+namely	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+alpha5	I-PRGE
+,	O
+-	O
+8	O
+,	O
+-	O
+10	O
+,	O
+-	O
+13	O
+/	O
+1	O
+,	O
+-	O
+17	O
+,	O
+and	O
+-	O
+21	O
+.	O
+
+These	O
+findings	O
+suggest	O
+either	O
+that	O
+the	O
+acutely	O
+infected	O
+pigs	B-SPEC
+did	O
+not	O
+aerosolize	O
+the	O
+viruses	B-SPEC
+or	O
+that	O
+the	O
+quantity	O
+of	O
+virus	B-SPEC
+excreted	O
+was	O
+below	O
+the	O
+detection	O
+threshold	O
+of	O
+current	O
+sampling	O
+or	O
+assay	O
+systems	O
+,	O
+or	O
+both	O
+,	O
+at	O
+the	O
+individual	O
+-	O
+pig	O
+level	O
+.	O
+
+Histopathological	O
+examination	O
+of	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+revealed	O
+severe	O
+granulomatous	B-DISO
+inflammation	I-DISO
+associated	O
+with	O
+large	O
+numbers	O
+of	O
+encapsulated	O
+yeast	B-SPEC
+cells	B-COMP
+.	O
+
+grubii	O
+yeast	B-SPEC
+cells	B-COMP
+.	O
+
+Here	O
+we	O
+describe	O
+a	O
+discovery	O
+platform	O
+that	O
+utilizes	O
+self	O
+-	O
+inactivating	O
+(	O
+SIN	B-PROC
+)	O
+lentiviral	O
+vectors	O
+for	O
+the	O
+surface	O
+display	O
+of	O
+high	O
+-	O
+affinity	O
+single	O
+-	O
+chain	O
+variable	O
+region	O
+(	O
+scFv	O
+)	O
+antibody	B-COMP
+fragments	O
+on	O
+human	B-SPEC
+cells	B-COMP
+and	O
+lentivirus	B-SPEC
+particles	O
+.	O
+
+Finally	O
+,	O
+the	O
+scFvFc	O
+displaying	O
+human	B-SPEC
+cells	B-COMP
+could	O
+be	O
+used	O
+directly	O
+in	O
+functional	O
+biological	O
+screens	O
+with	O
+remarkable	O
+sensitivity	O
+.	O
+
+These	O
+data	O
+demonstrated	O
+the	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+37	O
+genes	O
+and	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+nine	O
+genes	O
+,	O
+including	O
+those	O
+involved	O
+in	O
+cell	B-PROC
+signaling	I-PROC
+,	O
+inflammation	B-DISO
+,	O
+and	O
+gene	B-PROC
+transcription	I-PROC
+in	O
+SOD3	B-PRGE
+-/-	O
+mice	B-SPEC
+compared	O
+with	O
+either	O
+mice	B-SPEC
+with	O
+acute	O
+SOD3	B-PRGE
+reduction	O
+or	O
+wild	O
+-	O
+type	O
+controls	O
+.	O
+
+The	O
+M	O
+gene	O
+is	O
+of	O
+687	O
+bp	O
+in	O
+length	O
+encoding	O
+the	O
+M	O
+protein	B-CHED
+of	O
+228	O
+amino	B-CHED
+acids	I-CHED
+with	O
+a	O
+predicted	O
+molecular	O
+weight	O
+of	O
+25	O
+.	O
+4	O
+kDa	O
+.	O
+
+However	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+protein	B-CHED
+is	O
+co	O
+-	O
+localized	O
+almost	O
+entirely	O
+with	O
+S	O
+,	O
+E	O
+,	O
+or	O
+NC	B-PRGE
+protein	I-PRGE
+when	O
+co	O
+-	O
+expressed	B-PROC
+in	O
+the	O
+cells	B-COMP
+.	O
+
+Exposure	O
+to	O
+live	O
+birds	B-SPEC
+,	O
+perceived	O
+similar	O
+symptoms	O
+between	O
+influenza	B-DISO
+and	O
+bird	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+H5N1	B-DISO
+avian	B-DISO
+influenza	I-DISO
+,	O
+that	O
+bird	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+avian	B-DISO
+influenza	I-DISO
+was	O
+more	O
+lethal	O
+than	O
+SARS	B-DISO
+were	O
+predictive	O
+use	O
+of	O
+face	B-DISO
+mask	O
+when	O
+having	O
+ILI	O
+symptoms	O
+(	O
+OR	O
+=	O
+4	O
+.	O
+25	O
+-	O
+8	O
+.	O
+34	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Inhibitor	B-CHED
+10	O
+with	O
+a	O
+5	O
+-	O
+chloropyridinyl	O
+ester	B-CHED
+at	O
+position	O
+4	O
+of	O
+the	O
+indole	B-CHED
+ring	O
+is	O
+the	O
+most	O
+potent	O
+inhibitor	B-CHED
+with	O
+a	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+IC	I-PRGE
+(	O
+50	O
+)	O
+value	O
+of	O
+30	O
+nM	O
+and	O
+an	O
+antiviral	B-CHED
+EC	O
+(	O
+50	O
+)	O
+value	O
+of	O
+6	O
+.	O
+9	O
+microM	O
+.	O
+Molecular	O
+docking	B-PROC
+studies	O
+have	O
+provided	O
+possible	O
+binding	B-FUNC
+modes	O
+of	O
+these	O
+inhibitors	B-CHED
+.	O
+
+Sixty	O
+-	O
+six	O
+(	O
+40	O
+.	O
+4	O
+%)	O
+out	O
+of	O
+163	O
+patients	O
+developed	O
+79	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+Infectious	B-DISO
+etiology	O
+was	O
+the	O
+leading	O
+cause	O
+(	O
+92	O
+.	O
+4	O
+%).	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+replication	O
+is	O
+supported	O
+by	O
+a	O
+reticulovesicular	O
+network	O
+of	O
+modified	O
+endoplasmic	B-ANAT
+reticulum	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Utilization	O
+of	O
+DC	O
+-	O
+SIGN	O
+for	O
+entry	O
+of	O
+feline	B-SPEC
+coronaviruses	O
+into	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+We	O
+showed	O
+that	O
+entry	O
+of	O
+the	O
+serotype	O
+II	O
+feline	B-SPEC
+coronavirus	B-SPEC
+strains	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+WSU	O
+79	O
+-	O
+1146	O
+and	O
+DF2	O
+into	O
+nonpermissive	O
+mouse	B-SPEC
+3T3	O
+cells	B-COMP
+can	O
+be	O
+rescued	O
+by	O
+the	O
+expression	B-PROC
+of	O
+human	B-PRGE
+DC	I-PRGE
+-	I-PRGE
+SIGN	I-PRGE
+(	O
+hDC	B-PRGE
+-	I-PRGE
+SIGN	I-PRGE
+)	O
+and	O
+that	O
+infection	B-DISO
+of	O
+a	O
+permissive	O
+feline	B-SPEC
+cell	B-ANAT
+line	I-ANAT
+(	O
+Crandall	O
+-	O
+Reese	O
+feline	B-SPEC
+kidney	B-ANAT
+)	O
+was	O
+markedly	O
+enhanced	O
+by	O
+the	O
+overexpression	B-PROC
+of	O
+hDC	B-PRGE
+-	I-PRGE
+SIGN	I-PRGE
+.	O
+
+When	O
+blastocysts	B-ANAT
+were	O
+injected	O
+with	O
+10	O
+(-	O
+5	O
+)	O
+TCID	O
+(	O
+50	O
+)	O
+MMVp	O
+,	O
+all	O
+four	O
+recipients	O
+and	O
+14	O
+pups	O
+from	O
+four	O
+litters	O
+remained	O
+seronegative	O
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+the	O
+receptor	O
+that	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+utilizes	O
+for	O
+target	B-ANAT
+cell	I-ANAT
+entry	O
+and	O
+,	O
+therefore	O
+,	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+SARS	B-DISO
+pathogenesis	B-DISO
+.	O
+
+Rh	B-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+,	O
+however	O
+,	O
+is	O
+more	O
+polymorphic	O
+than	O
+hu	O
+-	O
+ACE2	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+three	O
+cases	O
+of	O
+patients	O
+(	O
+at	O
+the	O
+age	O
+of	O
+56	O
+years	O
+,	O
+49	O
+years	O
+and	O
+74	O
+years	O
+respectively	O
+)	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+),	O
+complicated	O
+by	O
+intra	O
+-	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+)	O
+and	O
+respiratory	B-DISO
+insufficiency	I-DISO
+with	O
+limitations	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+ACS	B-FUNC
+was	O
+discussed	O
+followed	O
+by	O
+a	O
+short	O
+review	O
+of	O
+the	O
+literature	O
+.	O
+
+Our	O
+cases	O
+show	O
+that	O
+DL	O
+may	O
+help	O
+patients	O
+with	O
+SAP	O
+to	O
+recover	B-PROC
+from	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+prime	O
+-	O
+boost	O
+vaccination	O
+protocol	O
+optimizes	O
+immune	B-PROC
+responses	I-PROC
+against	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+prevalences	O
+of	O
+C	O
+parvum	O
+,	O
+rotavirus	B-SPEC
+,	O
+BCV	B-SPEC
+and	O
+E	O
+coli	O
+k99	O
+were	O
+55	O
+.	O
+0	O
+per	O
+cent	O
+,	O
+58	O
+.	O
+7	O
+per	O
+cent	O
+,	O
+7	O
+.	O
+8	O
+per	O
+cent	O
+and	O
+5	O
+.	O
+5	O
+per	O
+cent	O
+,	O
+respectively	O
+.	O
+
+Malarial	O
+ALI	O
+/	O
+ARDS	B-DISO
+is	O
+more	O
+common	O
+in	O
+adults	O
+than	O
+in	O
+children	O
+.	O
+
+Increased	O
+alveolar	B-ANAT
+capillary	B-PROC
+permeability	I-PROC
+resulting	O
+in	O
+intravascular	O
+fluid	B-DISO
+loss	I-DISO
+into	O
+the	O
+lungs	B-ANAT
+appears	O
+to	O
+be	O
+the	O
+key	O
+pathophysiologic	O
+mechanism	O
+.	O
+
+In	O
+malaria	B-PATH
+,	O
+ARDS	B-DISO
+can	O
+develop	O
+either	O
+at	O
+initial	O
+presentation	O
+or	O
+after	O
+initiation	O
+of	O
+treatment	O
+when	O
+the	O
+parasitaemia	O
+is	O
+falling	O
+and	O
+the	O
+patient	O
+is	O
+improving	O
+.	O
+
+Careful	O
+attention	O
+must	O
+be	O
+paid	O
+to	O
+haemodynamic	O
+stabilisation	O
+and	O
+optimising	O
+fluid	B-PROC
+balance	I-PROC
+.	O
+
+By	O
+contrast	O
+,	O
+salt	B-CHED
+and	O
+water	B-CHED
+retention	B-PROC
+can	O
+be	O
+severe	O
+and	O
+complicated	O
+with	O
+hypertension	B-DISO
+,	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+or	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Decompensated	O
+pulmonary	B-DISO
+hypertension	I-DISO
+].	O
+
+The	O
+particular	O
+clinical	O
+picture	O
+and	O
+the	O
+associated	O
+hemodynamics	B-PROC
+determine	O
+this	O
+condition	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Cholesterol	B-CHED
+present	O
+in	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+of	O
+target	B-ANAT
+cells	I-ANAT
+has	O
+been	O
+shown	O
+to	O
+be	O
+important	O
+for	O
+the	O
+infection	B-DISO
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+We	O
+show	O
+that	O
+cholesterol	B-DISO
+depletion	I-DISO
+by	O
+treatment	O
+with	O
+methyl	B-CHED
+-	O
+beta	B-CHED
+-	I-CHED
+cyclodextrin	I-CHED
+(	O
+m	O
+beta	O
+CD	O
+)	O
+affects	O
+infection	B-DISO
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+to	O
+the	O
+same	O
+extent	O
+as	O
+infection	B-DISO
+by	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+-	O
+based	O
+pseudotypes	O
+containing	O
+the	O
+surface	O
+glycoprotein	B-PRGE
+S	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+VSV	O
+-	O
+Delta	O
+G	O
+-	O
+S	O
+).	O
+
+We	O
+found	O
+that	O
+ACE2	B-PRGE
+of	O
+both	O
+Vero	O
+E6	O
+and	O
+Caco	O
+-	O
+2	O
+cells	B-COMP
+co	O
+-	O
+purifies	O
+with	O
+marker	O
+proteins	B-CHED
+of	O
+detergent	B-CHED
+-	O
+resistant	O
+membranes	O
+supporting	O
+the	O
+notion	O
+that	O
+cholesterol	B-CHED
+-	O
+rich	O
+microdomains	O
+provide	O
+a	O
+platform	O
+facilitating	O
+the	O
+efficient	O
+interaction	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+with	O
+the	O
+cellular	B-COMP
+receptor	O
+ACE2	B-PRGE
+.	O
+
+Alternate	O
+encoding	O
+or	O
+duplication	B-DISO
+of	O
+the	O
+nsp2	B-PRGE
+gene	I-PRGE
+sequence	I-PRGE
+resulted	O
+in	O
+differences	O
+in	O
+nsp2	B-PRGE
+expression	B-PROC
+,	O
+processing	O
+,	O
+and	O
+localization	B-PROC
+,	O
+was	O
+neutral	O
+or	O
+detrimental	O
+to	O
+replication	O
+,	O
+and	O
+did	O
+not	O
+complement	O
+an	O
+ORF1a	O
+Deltansp2	O
+replication	O
+defect	O
+.	O
+
+TITLE	O
+:	O
+New	O
+respiratory	O
+viruses	B-SPEC
+of	O
+humans	B-SPEC
+.	O
+
+This	O
+study	O
+demonstrates	O
+that	O
+real	O
+-	O
+time	O
+PCR	O
+can	O
+increase	O
+the	O
+number	O
+of	O
+microbiological	O
+detections	O
+of	O
+respiratory	O
+pathogens	O
+,	O
+mainly	O
+as	O
+a	O
+result	O
+of	O
+detection	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+numbers	O
+of	O
+NK	B-ANAT
+cells	I-ANAT
+in	O
+their	O
+livers	B-ANAT
+,	O
+spleens	B-ANAT
+,	O
+blood	B-ANAT
+and	O
+bone	B-ANAT
+marrow	I-ANAT
+and	O
+the	O
+expression	B-PROC
+of	O
+CD69	B-PRGE
+on	O
+liver	B-ANAT
+NK	B-ANAT
+cells	I-ANAT
+at	O
+0	O
+,	O
+24	O
+,	O
+48	O
+and	O
+70	O
+h	O
+after	O
+MHV	B-SPEC
+-	O
+3	O
+infection	B-DISO
+were	O
+analyzed	O
+by	O
+flow	O
+cytometry	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+CD69	B-PRGE
+on	O
+liver	B-ANAT
+NK	B-ANAT
+cells	I-ANAT
+was	O
+highly	O
+up	O
+-	O
+regulated	O
+after	O
+the	O
+infection	B-DISO
+and	O
+the	O
+cytotoxic	O
+activity	O
+of	O
+hepatic	B-ANAT
+NK	B-ANAT
+cells	I-ANAT
+at	O
+48	O
+h	O
+was	O
+also	O
+significantly	O
+enhanced	O
+.	O
+
+Recruited	O
+NK	B-ANAT
+cells	I-ANAT
+remarkably	O
+express	O
+CD69	B-PRGE
+,	O
+enhance	O
+cytotoxic	O
+activity	O
+and	O
+IFN	B-PRGE
+gamma	I-PRGE
+production	O
+,	O
+which	O
+correlate	O
+with	O
+the	O
+disease	O
+severity	O
+of	O
+fulminant	O
+viral	B-DISO
+hepatitis	I-DISO
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+liver	B-ANAT
+NK	B-ANAT
+cells	I-ANAT
+may	O
+play	O
+a	O
+pivotal	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+fulminant	O
+viral	B-DISO
+hepatitis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Psychological	B-DISO
+resilience	O
+and	O
+dysfunction	O
+among	O
+hospitalized	O
+survivors	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+:	O
+a	O
+latent	O
+class	O
+approach	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+virus	B-SPEC
+is	O
+a	O
+member	O
+of	O
+the	O
+Coronaviridae	B-SPEC
+(	O
+CoV	O
+)	O
+family	B-SPEC
+that	O
+first	O
+appeared	O
+in	O
+the	O
+Guangdong	O
+Province	O
+of	O
+China	O
+in	O
+2002	O
+and	O
+was	O
+recognized	O
+as	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+in	O
+March	O
+2003	O
+.	O
+
+Nine	O
+subjects	O
+completed	O
+the	O
+3	O
+dose	O
+vaccination	O
+schedule	O
+and	O
+were	O
+evaluated	O
+for	O
+vaccine	O
+safety	O
+and	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+TITLE	O
+:	O
+Bovine	B-SPEC
+and	O
+human	B-SPEC
+-	O
+derived	O
+passive	O
+immunization	O
+could	O
+help	O
+slow	O
+a	O
+future	O
+avian	B-DISO
+influenza	I-DISO
+pandemic	O
+.	O
+
+This	O
+paper	O
+proposes	O
+that	O
+should	O
+such	O
+occur	O
+before	O
+effective	O
+vaccines	O
+and	O
+antiviral	B-CHED
+drugs	I-CHED
+are	O
+available	O
+,	O
+the	O
+outbreak	O
+could	O
+be	O
+significantly	O
+slowed	O
+by	O
+consumption	O
+of	O
+raw	O
+milk	O
+produced	O
+by	O
+herds	O
+of	O
+pathogen	O
+-	O
+free	O
+lactating	O
+cows	B-SPEC
+intranasally	O
+inoculated	O
+with	O
+heat	O
+-	O
+sterilized	O
+sputa	O
+pooled	O
+from	O
+avian	B-DISO
+influenza	I-DISO
+patients	O
+,	O
+supplemented	O
+by	O
+parenteral	O
+serum	B-COMP
+immune	O
+globulin	O
+from	O
+the	O
+same	O
+cows	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Design	O
+and	O
+synthesis	B-PROC
+of	O
+cinanserin	O
+analogs	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3CL	O
+protease	O
+inhibitors	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+3CL	B-PRGE
+protease	I-PRGE
+is	O
+an	O
+attractive	O
+target	O
+for	O
+the	O
+development	B-PROC
+of	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Genome	O
+-	O
+wide	O
+analysis	O
+of	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+and	O
+involvement	O
+of	O
+viral	O
+proteins	B-CHED
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+.	O
+
+The	O
+interactions	O
+between	O
+the	O
+multifunctional	O
+nsp10	O
+and	O
+nsp14	O
+or	O
+nsp16	O
+,	O
+which	O
+are	O
+the	O
+unique	O
+proteins	B-CHED
+found	O
+in	O
+the	O
+members	O
+of	O
+Nidovirales	B-SPEC
+with	O
+large	O
+RNA	O
+genomes	O
+including	O
+coronaviruses	O
+and	O
+toroviruses	B-SPEC
+,	O
+may	O
+have	O
+important	O
+implication	O
+for	O
+the	O
+mechanisms	O
+of	O
+replication	O
+/	O
+transcription	B-PROC
+complex	O
+assembly	O
+and	O
+functions	O
+of	O
+these	O
+viruses	O
+.	O
+
+TITLE	O
+:	O
+Variation	O
+in	O
+the	O
+myosin	B-PRGE
+light	I-PRGE
+chain	I-PRGE
+kinase	I-PRGE
+gene	I-PRGE
+is	O
+associated	O
+with	O
+development	B-PROC
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+after	O
+major	O
+trauma	O
+.	O
+
+Ninety	O
+-	O
+one	O
+of	O
+the	O
+273	O
+subjects	O
+(	O
+33	O
+%)	O
+met	B-CHED
+criteria	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+within	O
+5	O
+days	O
+of	O
+traumatic	O
+insult	O
+.	O
+
+We	O
+used	O
+chi	B-CHED
+(	O
+2	O
+),	O
+analysis	O
+of	O
+variance	O
+,	O
+and	O
+analysis	O
+of	O
+covariance	O
+analyses	O
+to	O
+test	O
+for	O
+differences	O
+between	O
+the	O
+1999	O
+and	O
+2005	O
+samples	O
+for	O
+infection	B-DISO
+control	O
+program	O
+components	O
+and	O
+ARO	O
+rates	O
+.	O
+
+Clostridium	B-SPEC
+difficile	I-SPEC
+-	O
+associated	O
+diarrhea	B-DISO
+rates	O
+trended	O
+up	O
+from	O
+1999	O
+to	O
+2005	O
+(	O
+F	O
+=	O
+2	O
+.	O
+9	O
+,	O
+P	O
+=	O
+.	O
+09	O
+).	O
+
+However	O
+,	O
+the	O
+proportion	O
+of	O
+ICPs	O
+in	O
+hospitals	O
+certified	O
+by	O
+the	O
+Certification	O
+Board	O
+of	O
+Infection	B-DISO
+Control	O
+decreased	O
+from	O
+53	O
+%	O
+(	O
+SD	O
+,	O
+46	O
+)	O
+in	O
+1999	O
+to	O
+38	O
+%	O
+(	O
+SD	O
+,	O
+36	O
+)	O
+in	O
+2005	O
+(	O
+F	O
+=	O
+8	O
+.	O
+7	O
+,	O
+P	O
+=	O
+.	O
+004	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+prevalence	O
+of	O
+antibodies	O
+to	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+and	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+)	O
+infections	B-DISO
+was	O
+studied	O
+in	O
+20	O
+conventional	O
+and	O
+20	O
+organic	O
+dairy	O
+herds	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+absence	O
+of	O
+the	O
+A1	O
+allele	O
+also	O
+appeared	O
+to	O
+be	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+odds	O
+ratio	O
+=	O
+3	O
+.	O
+1	O
+,	O
+confidence	O
+interval	O
+,	O
+0	O
+.	O
+99	O
+-	O
+9	O
+.	O
+67	O
+).	O
+
+In	O
+children	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+,	O
+absence	O
+of	O
+the	O
+A1	O
+allele	O
+at	O
+the	O
+interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+antagonist	B-PROC
+intron	O
+2	O
+polymorphic	O
+site	O
+is	O
+associated	O
+with	O
+increased	O
+risk	O
+for	O
+more	O
+severe	O
+lung	B-ANAT
+injury	O
+,	O
+as	O
+measured	O
+by	O
+the	O
+need	O
+for	O
+positive	O
+pressure	O
+ventilation	O
+or	O
+the	O
+development	B-PROC
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+nucleotide	B-CHED
+sequences	O
+of	O
+the	O
+isolates	O
+showed	O
+that	O
+they	O
+were	O
+closely	O
+related	O
+to	O
+each	O
+other	O
+,	O
+and	O
+formed	O
+a	O
+separate	O
+cluster	O
+apart	O
+from	O
+the	O
+U	O
+.	O
+S	O
+.	O
+A	O
+.	O
+and	O
+European	O
+strains	O
+.	O
+
+TITLE	O
+:	O
+Fatal	O
+pulmonary	B-DISO
+edema	I-DISO
+after	O
+acute	O
+occupational	O
+exposure	O
+to	O
+nitric	B-CHED
+acid	I-CHED
+.	O
+
+We	O
+established	O
+that	O
+two	O
+of	O
+the	O
+three	O
+hydrophobic	O
+domains	O
+in	O
+nsp3	B-PRGE
+and	O
+six	O
+of	O
+the	O
+seven	O
+in	O
+nsp6	O
+are	O
+membrane	B-COMP
+spanning	O
+.	O
+
+Control	O
+of	O
+neurotropic	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+requires	O
+the	O
+collaboration	O
+of	O
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+with	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+providing	O
+direct	O
+perforin	B-PRGE
+and	I-PRGE
+gamma	I-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)-	O
+mediated	O
+antiviral	B-CHED
+activity	O
+.	O
+
+To	O
+distinguish	O
+bystander	O
+from	O
+direct	O
+antiviral	B-CHED
+contributions	O
+of	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+virus	B-SPEC
+clearance	O
+and	O
+pathology	B-DISO
+,	O
+memory	B-PROC
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+purified	O
+from	O
+wild	O
+type	O
+(	O
+wt	O
+),	O
+perforin	B-PRGE
+-	O
+deficient	O
+(	O
+PKO	O
+),	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	O
+deficient	O
+(	O
+GKO	O
+)	O
+immune	O
+donors	O
+were	O
+transferred	O
+to	O
+immunodeficient	B-DISO
+SCID	B-DISO
+mice	B-SPEC
+prior	O
+to	O
+CNS	B-CHED
+challenge	O
+.	O
+
+All	O
+three	O
+donor	B-CHED
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+populations	O
+controlled	O
+CNS	B-CHED
+virus	B-PROC
+replication	I-PROC
+at	O
+8	O
+days	O
+postinfection	O
+,	O
+indicating	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	O
+and	O
+perforin	O
+-	O
+independent	O
+antiviral	B-CHED
+function	O
+.	O
+
+TITLE	O
+:	O
+Bovine	B-SPEC
+-	O
+like	O
+coronaviruses	O
+isolated	O
+from	O
+four	O
+species	B-SPEC
+of	O
+captive	O
+wild	O
+ruminants	B-SPEC
+are	O
+homologous	O
+to	O
+bovine	O
+coronaviruses	O
+,	O
+based	O
+on	O
+complete	O
+genomic	O
+sequences	O
+.	O
+
+The	O
+fecal	B-ANAT
+samples	O
+from	O
+the	O
+sambar	B-SPEC
+deer	I-SPEC
+,	O
+the	O
+waterbuck	B-SPEC
+,	O
+and	O
+the	O
+white	B-SPEC
+-	I-SPEC
+tailed	I-SPEC
+deer	I-SPEC
+were	O
+collected	O
+during	O
+winter	B-DISO
+dysentery	I-DISO
+outbreaks	O
+and	O
+sporadic	O
+diarrhea	B-DISO
+cases	O
+in	O
+1993	O
+and	O
+1994	O
+(	O
+H	O
+.	O
+Tsunemitsu	O
+,	O
+Z	O
+.	O
+R	O
+.	O
+el	O
+-	O
+Kanawati	O
+,	O
+D	O
+.	O
+R	O
+.	O
+Smith	O
+,	O
+H	O
+.	O
+H	O
+.	O
+Reed	O
+,	O
+and	O
+L	O
+.	O
+J	O
+.	O
+Saif	O
+,	O
+J	O
+.	O
+Clin	O
+.	O
+
+Further	O
+investigation	O
+into	O
+similarities	O
+and	O
+pathways	B-PROC
+common	O
+in	O
+AEs	O
+of	O
+various	O
+fibrotic	O
+lung	B-DISO
+diseases	I-DISO
+may	O
+yield	O
+additional	O
+insight	O
+into	O
+this	O
+recently	O
+recognized	O
+syndrome	B-DISO
+.	O
+
+Lung	B-ANAT
+biopsy	O
+at	O
+the	O
+time	O
+of	O
+the	O
+AE	O
+,	O
+explant	O
+,	O
+or	O
+autopsy	O
+revealed	O
+organizing	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+superimposed	O
+on	O
+fibrotic	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+Getting	O
+out	O
+of	O
+coma	B-DISO
+the	O
+patient	O
+started	O
+to	O
+complain	O
+of	O
+severe	B-DISO
+pain	I-DISO
+in	O
+the	O
+right	B-ANAT
+arm	I-ANAT
+,	O
+which	O
+clinically	O
+worsened	O
+on	O
+passive	O
+stretching	O
+of	O
+the	O
+limb	B-ANAT
+,	O
+with	O
+the	O
+loss	B-DISO
+of	I-DISO
+sensation	I-DISO
+and	O
+weakness	B-DISO
+.	O
+
+Despite	O
+therapy	O
+his	O
+urine	B-DISO
+output	I-DISO
+decreased	I-DISO
+.	O
+
+METHODOLOGY	O
+:	O
+Twenty	O
+-	O
+three	O
+patients	O
+were	O
+tested	O
+for	O
+DPD	B-DISO
+deficiency	I-DISO
+after	O
+excessive	O
+toxicities	O
+from	O
+5	B-CHED
+-	I-CHED
+FU	I-CHED
+and	O
+/	O
+or	O
+capecitabine	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+DPD	B-DISO
+deficiency	I-DISO
+was	O
+observed	O
+in	O
+several	O
+ethnicities	O
+.	O
+
+S1	O
+was	O
+secreted	B-PROC
+into	O
+the	O
+medium	O
+.	O
+
+Management	O
+of	O
+excessive	O
+inflammation	B-DISO
+may	O
+be	O
+possible	O
+through	O
+control	O
+of	O
+key	O
+inflammatory	O
+pathways	B-PROC
+such	O
+as	O
+those	O
+mediated	O
+by	O
+the	O
+important	O
+interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+associated	I-PRGE
+kinase	I-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+IRAK	B-PRGE
+-	I-PRGE
+1	I-PRGE
+).	O
+
+Following	O
+LPS	O
+stimulation	O
+,	O
+the	O
+anti	O
+-	O
+inflammatory	O
+activity	O
+of	O
+ASODN	O
+against	O
+the	O
+IRAK	B-PRGE
+-	I-PRGE
+1	I-PRGE
+gene	I-PRGE
+expression	O
+is	O
+evidenced	O
+by	O
+the	O
+lower	O
+expression	B-PROC
+of	O
+inflammatory	O
+chemokines	O
+,	O
+cytokines	O
+and	O
+acute	O
+-	O
+phase	O
+proteins	B-CHED
+compared	O
+to	O
+control	O
+cells	B-COMP
+.	O
+
+With	O
+wider	O
+application	O
+of	O
+molecular	O
+techniques	O
+,	O
+novel	O
+viruses	B-SPEC
+are	O
+being	O
+described	O
+and	O
+old	O
+viruses	B-SPEC
+are	O
+found	O
+to	O
+have	O
+new	O
+significance	O
+in	O
+different	O
+epidemiological	O
+and	O
+clinical	O
+settings	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+death	B-PROC
+in	O
+heartworm	O
+-	O
+infected	O
+cats	B-SPEC
+:	O
+unraveling	O
+the	O
+puzzle	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+the	O
+acute	O
+death	O
+syndrome	B-DISO
+in	O
+feline	B-SPEC
+heartworm	B-DISO
+disease	I-DISO
+is	O
+widely	O
+recognized	O
+,	O
+its	O
+pathogenesis	B-DISO
+remains	O
+a	O
+mystery	O
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+role	O
+of	O
+the	O
+physical	O
+form	O
+of	O
+antigen	B-CHED
+(	O
+Ag	B-CHED
+)	O
+in	O
+the	O
+ensuing	O
+reaction	O
+when	O
+Dirofilaria	B-SPEC
+immitis	I-SPEC
+-	O
+sensitized	O
+cats	B-SPEC
+are	O
+challenged	O
+by	O
+intravenous	O
+(	O
+IV	O
+)	O
+administration	O
+of	O
+heartworm	O
+Ag	B-CHED
+.	O
+
+Healthy	O
+D	B-SPEC
+.	I-SPEC
+immitis	I-SPEC
+-	O
+naive	O
+cats	B-SPEC
+(	O
+n	O
+=	O
+23	O
+)	O
+were	O
+sensitized	O
+using	O
+subcutaneous	O
+injections	O
+of	O
+adjuvanted	O
+D	B-SPEC
+.	I-SPEC
+immitis	I-SPEC
+Ag	O
+administered	O
+weekly	O
+for	O
+6	O
+weeks	O
+.	O
+
+Dyspnea	B-DISO
+increased	O
+significantly	O
+after	O
+challenge	O
+in	O
+all	O
+three	O
+groups	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+;	O
+p	O
+=	O
+0	O
+.	O
+04	O
+,	O
+and	O
+p	O
+=	O
+0	O
+.	O
+002	O
+,	O
+respectively	O
+),	O
+and	O
+blood	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+dropped	O
+post	O
+-	O
+challenge	O
+in	O
+the	O
+Dead	B-PROC
+Worm	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+the	O
+20	O
+ng	O
+/	O
+mL	O
+Ag	O
+(	O
+p	O
+=	O
+0	O
+.	O
+002	O
+)	O
+groups	O
+.	O
+
+Clinical	O
+observations	O
+included	O
+dyspnea	B-DISO
+,	O
+gastrointestinal	O
+signs	O
+(	O
+retching	B-DISO
+,	O
+defecation	B-PROC
+,	O
+or	O
+flatulence	B-DISO
+),	O
+urination	B-PROC
+,	O
+and	O
+less	O
+commonly	O
+,	O
+hemorrhage	B-DISO
+from	O
+the	O
+nostrils	B-ANAT
+or	O
+anus	B-ANAT
+,	O
+or	O
+cutaneous	O
+swelling	B-DISO
+(	O
+general	O
+or	O
+specifically	O
+facial	B-ANAT
+).	O
+
+The	O
+most	O
+common	O
+and	O
+reliable	O
+hematologic	O
+change	O
+associated	O
+with	O
+severe	O
+clinical	O
+effects	O
+of	O
+D	B-SPEC
+.	I-SPEC
+immitis	I-SPEC
+Ag	O
+challenge	O
+was	O
+increased	O
+hematocrit	O
+,	O
+which	O
+was	O
+statistically	O
+higher	O
+after	O
+challenge	O
+than	O
+at	O
+baseline	O
+in	O
+the	O
+Dead	B-PROC
+Worm	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+012	O
+).	O
+
+We	O
+report	O
+this	O
+case	O
+to	O
+highlight	O
+the	O
+diagnostic	O
+difficulty	O
+in	O
+children	O
+suffering	B-DISO
+from	O
+GBS	B-DISO
+who	O
+have	O
+respiratory	O
+involvement	O
+as	O
+the	O
+main	O
+clinical	B-DISO
+findings	I-DISO
+on	O
+presentation	O
+.	O
+
+Unexplained	O
+weakness	B-DISO
+,	O
+together	O
+with	O
+respiratory	O
+involvement	O
+and	O
+associated	O
+dysautonomia	B-DISO
+,	O
+should	O
+support	O
+the	O
+possibility	O
+of	O
+GBS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+liver	B-ANAT
+pathology	B-DISO
+is	O
+dependent	O
+on	O
+ADP	B-PRGE
+-	I-PRGE
+ribose	B-CHED
+-	I-PRGE
+1	I-PRGE
+''-	I-PRGE
+phosphatase	B-FUNC
+,	O
+a	O
+viral	O
+function	O
+conserved	O
+in	O
+the	O
+alpha	O
+-	O
+like	O
+supergroup	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+infection	O
+of	O
+the	O
+liver	B-ANAT
+can	O
+lead	O
+to	O
+severe	O
+tissue	B-ANAT
+damage	O
+when	O
+high	O
+levels	O
+of	O
+viral	B-PROC
+replication	I-PROC
+and	O
+spread	O
+in	O
+the	O
+organ	B-ANAT
+are	O
+coupled	O
+with	O
+strong	O
+induction	O
+of	O
+inflammatory	B-DISO
+responses	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Virus	B-SPEC
+infections	B-DISO
+are	O
+the	O
+most	O
+common	O
+human	B-SPEC
+diseases	O
+,	O
+particularly	O
+acute	O
+respiratory	O
+infections	O
+(	O
+mostly	O
+in	O
+children	O
+and	O
+young	O
+adults	O
+).	O
+
+In	O
+women	O
+with	O
+cervical	B-ANAT
+changes	O
+,	O
+by	O
+application	O
+of	O
+hybridization	B-PROC
+technique	O
+in	O
+situ	O
+,	O
+the	O
+most	O
+frequently	O
+identified	O
+virus	B-SPEC
+genotypes	O
+are	O
+human	B-SPEC
+papilloma	B-DISO
+viruses	B-SPEC
+16	O
+and	O
+18	O
+(	O
+in	O
+21	O
+.	O
+67	O
+%),	O
+genotypes	O
+6	O
+and	O
+11	O
+in	O
+8	O
+.	O
+33	O
+%	O
+and	O
+genotypes	O
+31	O
+,	O
+33	O
+and	O
+35	O
+in	O
+3	O
+.	O
+33	O
+%	O
+examined	O
+women	O
+.	O
+
+We	O
+characterised	O
+the	O
+patient	O
+population	O
+suffering	B-DISO
+from	O
+in	O
+-	O
+hospital	O
+PE	O
+and	O
+identified	O
+perioperative	O
+risk	O
+factors	O
+associated	O
+with	O
+PE	O
+using	O
+nationally	O
+representative	O
+data	O
+.	O
+
+Twelve	O
+healthy	O
+pigs	B-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+two	O
+groups	O
+according	O
+to	O
+the	O
+body	B-ANAT
+posture	O
+during	O
+mechanical	O
+ventilation	O
+after	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+:	O
+supine	O
+position	O
+group	O
+and	O
+prone	O
+position	O
+group	O
+.	O
+
+In	O
+supine	O
+group	O
+the	O
+dorsal	O
+regions	O
+of	O
+the	O
+lungs	B-ANAT
+showed	O
+more	O
+severe	O
+injury	O
+than	O
+that	O
+in	O
+prone	O
+group	O
+(	O
+12	O
+.	O
+00	O
++/-	O
+1	O
+.	O
+69	O
+vs	O
+.	O
+6	O
+.	O
+03	O
++/-	O
+1	O
+.	O
+56	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+In	O
+supine	O
+group	O
+the	O
+dorsal	O
+regions	O
+of	O
+the	O
+lungs	B-ANAT
+showed	O
+more	O
+severe	O
+injury	O
+than	O
+that	O
+in	O
+prone	O
+group	O
+(	O
+12	O
+.	O
+00	O
++/-	O
+1	O
+.	O
+69	O
+vs	O
+.	O
+6	O
+.	O
+03	O
++/-	O
+1	O
+.	O
+56	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Papular	O
+cutaneous	O
+lesions	O
+in	O
+a	O
+cat	B-SPEC
+associated	O
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+After	O
+internalization	O
+,	O
+the	O
+viral	B-PRGE
+antigen	I-PRGE
+-	I-PRGE
+antibody	B-COMP
+complexes	O
+passed	O
+through	O
+the	O
+early	O
+endosomes	O
+,	O
+where	O
+they	O
+resided	O
+only	O
+briefly	O
+,	O
+and	O
+accumulated	O
+in	O
+the	O
+late	O
+endosomes	O
+.	O
+
+In	O
+both	O
+assays	O
+,	O
+we	O
+find	O
+that	O
+the	O
+NL63	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+has	O
+a	O
+weaker	O
+interaction	O
+with	O
+ACE	B-PRGE
+-	I-PRGE
+2	I-PRGE
+than	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+,	O
+particularly	O
+in	O
+solution	O
+binding	B-FUNC
+,	O
+but	O
+the	O
+residues	O
+required	O
+for	O
+contact	O
+are	O
+similar	O
+.	O
+
+This	O
+newly	O
+discovered	O
+enzymatic	B-PROC
+activity	I-PROC
+places	O
+PP11	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteins	I-PRGE
+in	O
+a	O
+completely	O
+new	O
+perspective	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	O
+disease	O
+derived	O
+from	O
+wild	O
+animals	O
+and	O
+is	O
+highly	O
+pathogenic	O
+with	O
+a	O
+high	O
+mortality	O
+.	O
+
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+SARS	B-DISO
+coronavirus	B-SPEC
+was	O
+identified	O
+to	O
+be	O
+a	O
+causative	O
+agent	O
+for	O
+SARS	B-DISO
+.	O
+
+The	O
+lower	O
+limits	O
+of	O
+the	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+)	O
+of	O
+the	O
+R	O
+of	O
+IBV	B-SPEC
+H120	O
+vaccine	O
+,	O
+and	O
+of	O
+IBV	B-SPEC
+M41	O
+,	O
+were	O
+significantly	O
+<	O
+1	O
+.	O
+
+These	O
+findings	O
+increase	O
+our	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+infections	I-DISO
+unique	O
+to	O
+Asia	O
+.	O
+
+Pulmonary	B-DISO
+eosinophilia	I-DISO
+,	O
+endemic	O
+in	O
+parts	O
+of	O
+Asia	O
+,	O
+could	O
+occur	O
+with	O
+a	O
+wide	O
+range	O
+of	O
+tropical	O
+infections	B-DISO
+.	O
+
+To	O
+measure	O
+exposure	O
+rates	O
+to	O
+these	O
+four	O
+coronavirus	B-SPEC
+strains	O
+(	O
+229E	O
+,	O
+HKU1	O
+,	O
+NL63	O
+,	O
+and	O
+OC43	O
+),	O
+we	O
+devised	O
+an	O
+immunoassay	O
+based	O
+on	O
+amino	O
+-	O
+and	O
+carboxy	B-CHED
+-	O
+terminally	O
+tagged	O
+recombinant	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+antigens	B-CHED
+.	O
+
+The	O
+proportion	O
+of	O
+seropositive	O
+adults	O
+for	O
+each	O
+coronavirus	B-SPEC
+was	O
+as	O
+follows	O
+:	O
+229E	O
+,	O
+91	O
+.	O
+3	O
+%;	O
+HKU1	O
+,	O
+59	O
+.	O
+2	O
+%;	O
+NL63	O
+,	O
+91	O
+.	O
+8	O
+%;	O
+and	O
+OC43	O
+,	O
+90	O
+.	O
+8	O
+%.	O
+
+No	O
+evidence	O
+of	O
+a	O
+significant	O
+serological	O
+response	O
+to	O
+the	O
+feline	B-SPEC
+coronavirus	B-SPEC
+was	O
+observed	O
+.	O
+
+The	O
+incidence	O
+of	O
+tuberculosis	B-PATH
+and	O
+the	O
+proportion	O
+of	O
+disseminated	O
+disease	O
+increase	O
+with	O
+more	O
+severe	O
+immuno	O
+-	O
+suppression	B-DISO
+.	O
+
+It	O
+is	O
+essential	O
+that	O
+physicians	O
+who	O
+care	O
+for	O
+patients	O
+during	O
+the	O
+post	O
+extubation	O
+period	O
+are	O
+aware	O
+of	O
+this	O
+severe	O
+and	O
+life	O
+threatening	O
+cause	O
+of	O
+stridor	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+It	O
+is	O
+essential	O
+that	O
+physicians	O
+who	O
+care	O
+for	O
+patients	O
+during	O
+the	O
+post	O
+extubation	O
+period	O
+are	O
+aware	O
+of	O
+this	O
+severe	O
+and	O
+life	O
+threatening	O
+cause	O
+of	O
+stridor	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+association	O
+of	O
+a	O
+previous	O
+history	O
+of	O
+varicella	O
+virus	B-DISO
+infection	I-DISO
+with	O
+multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+)	O
+and	O
+its	O
+subtypes	O
+.	O
+
+Patients	O
+with	O
+a	O
+history	O
+of	O
+VZV	B-SPEC
+infection	B-DISO
+had	O
+a	O
+threefold	O
+risk	O
+increase	O
+of	O
+having	O
+MS	O
+.	O
+
+TITLE	O
+:	O
+Prevention	O
+of	O
+cytotoxic	B-ANAT
+T	I-ANAT
+cell	I-ANAT
+escape	O
+using	O
+a	O
+heteroclitic	O
+subdominant	O
+viral	O
+T	B-ANAT
+cell	I-ANAT
+determinant	O
+.	O
+
+We	O
+used	O
+the	O
+consensus	O
+peptide	B-CHED
+-	O
+binding	B-FUNC
+motif	O
+for	O
+the	O
+Major	B-PRGE
+Histocompatibility	I-PRGE
+Complex	I-PRGE
+molecule	I-PRGE
+H	I-PRGE
+-	I-PRGE
+2K	I-PRGE
+(	I-PRGE
+b	I-PRGE
+)	I-PRGE
+to	O
+design	O
+a	O
+heteroclitic	O
+version	O
+of	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+specific	O
+subdominant	O
+S598	O
+determinant	O
+.	O
+
+Collectively	O
+,	O
+our	O
+findings	O
+provide	O
+a	O
+basis	O
+for	O
+the	O
+enhanced	O
+immunogenicity	O
+of	O
+an	O
+engineered	O
+determinant	O
+that	O
+will	O
+serve	O
+as	O
+a	O
+template	O
+for	O
+guiding	O
+the	O
+development	B-PROC
+of	O
+heteroclitic	O
+T	B-ANAT
+cell	I-ANAT
+determinants	O
+with	O
+applications	O
+in	O
+prevention	O
+of	O
+CTL	B-ANAT
+escape	O
+in	O
+chronic	O
+viral	B-DISO
+infections	I-DISO
+as	O
+well	O
+as	O
+in	O
+tumor	B-DISO
+immunity	I-DISO
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+and	O
+zoonotic	O
+infections	B-DISO
+in	O
+women	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+N	O
+-	O
+aryl	O
+-	O
+O	O
+-(	O
+2	O
+-	O
+phthalimidoethyl	O
+)	O
+thiocarbamates	O
+(	O
+C	O
+-	O
+TCs	B-DISO
+)	O
+and	O
+their	O
+imide	B-CHED
+ring	O
+-	O
+opened	O
+congeners	O
+(	O
+O	O
+-	O
+TCs	B-DISO
+)	O
+as	O
+non	O
+-	O
+nucleoside	B-CHED
+HIV	B-CHED
+-	I-CHED
+1	I-CHED
+reverse	B-PROC
+transcriptase	I-PROC
+inhibitors	I-PROC
+were	O
+further	O
+investigated	O
+.	O
+
+The	O
+role	O
+of	O
+stereochemistry	B-PROC
+and	O
+tert	B-CHED
+-	I-CHED
+butyl	I-CHED
+substitution	O
+of	O
+the	O
+phthalimidoethyl	O
+moiety	O
+on	O
+activity	O
+was	O
+also	O
+investigated	O
+.	O
+
+Docking	B-PROC
+simulations	O
+helped	O
+to	O
+rationalize	O
+the	O
+SARs	B-DISO
+.	O
+
+TITLE	O
+:	O
+LNA	B-CHED
+probe	O
+-	O
+based	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+for	O
+the	O
+detection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+from	O
+the	O
+oviduct	B-ANAT
+of	O
+unvaccinated	O
+and	O
+vaccinated	O
+laying	O
+hens	O
+.	O
+
+The	O
+present	O
+test	O
+will	O
+be	O
+useful	O
+for	O
+the	O
+rapid	O
+identification	O
+of	O
+IBV	B-SPEC
+directly	O
+from	O
+clinical	O
+samples	O
+.	O
+
+We	O
+constructed	O
+truncated	O
+recombinant	O
+N	O
+proteins	B-CHED
+(	O
+N1	O
+[	O
+1	O
+-	O
+422	O
+aa	O
+],	O
+N2	O
+[	O
+1	O
+-	O
+109	O
+aa	O
+],	O
+and	O
+N3	O
+[	O
+110	O
+-	O
+422	O
+aa	O
+])	O
+and	O
+determined	O
+their	O
+antigenicity	O
+by	O
+Western	O
+blotting	O
+using	O
+convalescent	O
+SARS	B-DISO
+serum	B-COMP
+.	O
+
+The	O
+recombinants	O
+containing	O
+N1	O
+and	O
+N3	O
+reacted	O
+with	O
+convalescent	O
+SARS	B-DISO
+serum	B-COMP
+in	O
+Western	O
+blotting	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+middle	O
+or	O
+C	O
+-	O
+terminal	O
+region	O
+of	O
+the	O
+SARS	O
+N	O
+protein	B-CHED
+is	O
+important	O
+for	O
+eliciting	O
+antibodies	B-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+during	O
+the	O
+immune	B-PROC
+response	I-PROC
+,	O
+and	O
+ELISA	O
+reactions	O
+using	O
+N1	O
+or	O
+N3	O
+may	O
+be	O
+a	O
+valuable	O
+tool	O
+for	O
+SARS	B-DISO
+diagnosis	O
+.	O
+
+TITLE	O
+:	O
+PLP2	B-PRGE
+,	O
+a	O
+potent	O
+deubiquitinase	B-PROC
+from	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+strongly	O
+inhibits	O
+cellular	B-COMP
+type	B-PROC
+I	I-PROC
+interferon	I-PROC
+production	I-PROC
+.	O
+
+After	O
+purification	O
+by	O
+affinity	O
+chromatography	O
+,	O
+the	O
+protein	B-CHED
+identities	O
+were	O
+confirmed	O
+by	O
+western	O
+blot	O
+analysis	O
+,	O
+N	O
+-	O
+terminal	O
+sequencing	O
+and	O
+mass	O
+spectrometry	O
+.	O
+
+Operative	O
+procedures	O
+included	O
+thoracotomy	O
+with	O
+radical	B-CHED
+surgical	O
+debridement	O
+of	O
+the	O
+mediastinum	B-ANAT
+and	O
+excision	O
+of	O
+necrotic	B-PROC
+tissue	B-ANAT
+associated	O
+with	O
+transcervical	O
+surgical	O
+debridement	O
+and	O
+drainage	B-ANAT
+.	O
+
+Most	O
+commonly	O
+,	O
+it	O
+is	O
+instituted	O
+in	O
+an	O
+emergency	B-DISO
+or	O
+urgent	O
+situation	O
+after	O
+failure	O
+of	O
+other	O
+treatment	O
+modalities	O
+.	O
+
+The	O
+indications	O
+for	O
+veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+are	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+most	O
+commonly	O
+due	O
+to	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+pneumonia	B-DISO
+,	O
+trauma	O
+or	O
+primary	B-DISO
+graft	I-DISO
+failure	I-DISO
+following	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+epidemic	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+occurred	O
+in	O
+Taiwan	O
+from	O
+April	O
+to	O
+July	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+,	O
+classified	O
+as	O
+a	O
+group	O
+I	O
+coronavirus	B-SPEC
+,	O
+utilizes	O
+human	B-SPEC
+aminopeptidase	B-PRGE
+N	I-PRGE
+(	O
+APN	B-PRGE
+)	O
+as	O
+a	O
+receptor	O
+;	O
+however	O
+,	O
+its	O
+entry	O
+mechanism	O
+has	O
+not	O
+yet	O
+been	O
+fully	O
+elucidated	O
+.	O
+
+For	O
+helicase	B-PRGE
+,	O
+spike	O
+,	O
+and	O
+nucleocapsid	B-COMP
+,	O
+they	O
+were	O
+also	O
+clustered	O
+with	O
+a	O
+CoV	O
+recently	O
+discovered	O
+in	O
+Asian	O
+leopard	B-SPEC
+cats	I-SPEC
+,	O
+for	O
+which	O
+the	O
+complete	O
+genome	O
+sequence	O
+was	O
+not	O
+available	O
+.	O
+
+Expressed	B-PROC
+nucleocapsid	B-PRGE
+gene	I-PRGE
+produced	O
+two	O
+distinct	O
+proteins	B-CHED
+(	O
+52	O
+and	O
+43	O
+kDa	O
+);	O
+their	O
+specificity	O
+was	O
+confirmed	O
+by	O
+Western	O
+blotting	O
+using	O
+two	O
+different	O
+monoclonal	O
+antibodies	B-COMP
+.	O
+
+Recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+was	O
+purified	O
+and	O
+used	O
+as	O
+an	O
+antigen	B-CHED
+to	O
+develop	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+for	O
+the	O
+serological	O
+detection	O
+of	O
+TCoV	O
+that	O
+was	O
+then	O
+validated	O
+using	O
+experimentally	O
+derived	O
+turkey	B-SPEC
+serum	B-COMP
+.	O
+
+Similarly	O
+,	O
+a	O
+high	O
+field	O
+prevalence	O
+was	O
+found	O
+in	O
+the	O
+turkeys	B-SPEC
+from	O
+Arkansas	O
+,	O
+for	O
+which	O
+64	O
+.	O
+2	O
+%	O
+of	O
+the	O
+serum	B-COMP
+samples	O
+tested	O
+seropositive	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+develop	O
+,	O
+deliver	O
+,	O
+and	O
+evaluate	O
+a	O
+participatory	O
+leadership	O
+training	O
+program	O
+for	O
+emergency	B-DISO
+response	O
+.	O
+
+Survival	O
+in	O
+MHV	B-SPEC
+-	O
+CXCL9	O
+-	O
+infected	O
+CXCL9	O
+-/-	O
+mice	B-SPEC
+was	O
+associated	O
+with	O
+reduced	O
+viral	O
+burden	O
+within	O
+the	O
+brain	B-ANAT
+that	O
+coincided	O
+with	O
+increased	O
+T	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+.	O
+
+Because	O
+sera	B-PRGE
+endotoxins	I-PRGE
+were	O
+elevated	O
+,	O
+she	O
+was	O
+treated	O
+by	O
+endotoxin	O
+adsorption	O
+therapy	O
+on	O
+hospital	O
+day	O
+3	O
+.	O
+
+All	O
+were	O
+thought	O
+to	O
+be	O
+well	O
+after	O
+birth	B-PROC
+.	O
+
+Seven	O
+infants	O
+became	O
+severely	O
+encephalopathic	O
+,	O
+with	O
+severely	O
+abnormal	O
+EEG	O
+/	O
+aEEG	O
+recorded	O
+within	O
+12	O
+h	O
+.	O
+MRI	O
+showed	O
+acute	O
+severe	O
+hypoxic	B-DISO
+-	O
+ischaemic	O
+injury	O
+.	O
+
+Macro	O
+domains	O
+are	O
+also	O
+encoded	O
+by	O
+a	O
+set	O
+of	O
+positive	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+that	O
+replicate	O
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+animal	B-SPEC
+cells	B-COMP
+,	O
+including	O
+coronaviruses	O
+and	O
+alphaviruses	B-SPEC
+.	O
+
+We	O
+have	O
+here	O
+characterized	O
+three	O
+novel	O
+human	B-PRGE
+macro	I-PRGE
+domain	I-PRGE
+proteins	B-CHED
+that	O
+were	O
+found	O
+to	O
+reside	O
+either	O
+in	O
+the	O
+cytoplasm	B-COMP
+and	O
+nucleus	B-COMP
+[	O
+macro	O
+domain	O
+protein	B-CHED
+2	O
+(	O
+MDO2	O
+)	O
+and	O
+ganglioside	B-CHED
+-	O
+induced	O
+differentiation	B-PROC
+-	O
+associated	O
+protein	B-CHED
+2	O
+]	O
+or	O
+in	O
+mitochondria	B-COMP
+[	O
+macro	O
+domain	O
+protein	B-CHED
+1	O
+(	O
+MDO1	O
+)],	O
+and	O
+compared	O
+them	O
+with	O
+viral	O
+macro	O
+domains	O
+from	O
+Semliki	B-SPEC
+Forest	I-SPEC
+virus	I-SPEC
+,	O
+hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+with	O
+a	O
+yeast	B-SPEC
+macro	O
+protein	B-CHED
+,	O
+Poa1p	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+heptad	O
+repeats	O
+(	O
+HR1	O
+and	O
+HR2	O
+)	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+are	O
+highly	O
+conserved	O
+regions	O
+forming	O
+a	O
+critical	O
+6	O
+-	O
+helix	O
+bundle	O
+during	O
+the	O
+fusion	O
+step	O
+of	O
+virus	B-SPEC
+entry	O
+and	O
+are	O
+attractive	O
+targets	O
+of	O
+entry	O
+inhibitors	B-CHED
+.	O
+
+A	O
+human	O
+-	O
+mouse	B-SPEC
+chimeric	O
+antibody	B-COMP
+,	O
+based	O
+upon	O
+the	O
+original	O
+murine	B-SPEC
+mAb	O
+,	O
+was	O
+also	O
+constructed	O
+and	O
+shown	O
+to	O
+possess	B-DISO
+good	O
+neutralizing	O
+activity	O
+and	O
+high	O
+affinity	O
+.	O
+
+However	O
+,	O
+other	O
+unknown	O
+surface	O
+proteins	B-CHED
+on	O
+A549	O
+cells	B-COMP
+may	O
+be	O
+concomitantly	O
+utilized	O
+by	O
+S	B-PRGE
+glycoprotein	I-PRGE
+of	O
+HCoV	O
+-	O
+HKU1	O
+during	O
+viral	O
+entry	O
+.	O
+
+We	O
+have	O
+developed	O
+twin	O
+assays	O
+(	O
+slide	O
+agglutination	B-PROC
+test	O
+[	O
+SAT	O
+]	O
+for	O
+CPV	B-PRGE
+antigen	B-CHED
+and	O
+slide	O
+inhibition	B-PROC
+test	O
+[	O
+SIT	O
+]	O
+for	O
+CPV	B-SPEC
+antibody	B-COMP
+)	O
+that	O
+are	O
+sensitive	O
+,	O
+specific	O
+,	O
+cost	O
+-	O
+effective	O
+,	O
+generic	O
+for	O
+all	O
+genotypes	O
+of	O
+CPV	B-SPEC
+,	O
+and	O
+provide	O
+instant	O
+results	O
+for	O
+CPV	B-PRGE
+antigen	B-CHED
+detection	O
+in	O
+feces	B-ANAT
+and	O
+antibody	B-COMP
+quantification	O
+in	O
+serum	B-COMP
+.	O
+
+SAT	B-PRGE
+-	O
+SIT	B-PRGE
+technology	O
+will	O
+find	O
+applications	O
+in	O
+rapid	O
+screening	O
+of	O
+samples	O
+for	O
+other	O
+hemagglutinating	O
+emerging	O
+viruses	B-SPEC
+of	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+(	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Broadening	O
+of	O
+neutralization	O
+activity	O
+to	O
+directly	O
+block	O
+a	O
+dominant	O
+antibody	B-COMP
+-	O
+driven	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+evolution	B-PROC
+pathway	B-PROC
+.	O
+
+In	O
+vitro	O
+immune	O
+pressure	O
+on	O
+this	O
+epitope	B-CHED
+using	O
+2002	O
+/	O
+03	O
+strain	O
+-	O
+specific	O
+nAb	B-PRGE
+80R	I-PRGE
+recapitulated	O
+a	O
+dominant	O
+escape	O
+mutation	O
+that	O
+was	O
+present	O
+in	O
+all	O
+2003	O
+/	O
+04	O
+animal	B-SPEC
+and	O
+human	B-SPEC
+viruses	B-SPEC
+.	O
+
+The	O
+average	O
+emergency	B-DISO
+service	O
+volume	O
+was	O
+4382	O
++/-	O
+
+The	O
+MAPE	O
+of	O
+the	O
+ARIMA	O
+(	O
+2	O
+,	O
+1	O
+,	O
+0	O
+)	O
+model	O
+for	O
+the	O
+pre	O
+-	O
+SARS	B-DISO
+year	O
+was	O
+6	O
+.	O
+9	O
+%,	O
+and	O
+43	O
+.	O
+2	O
+%,	O
+10	O
+.	O
+6	O
+%,	O
+6	O
+.	O
+2	O
+%	O
+for	O
+following	O
+3	O
+years	O
+.	O
+
+ABSTRACT	O
+:	O
+hSARS	O
+-	O
+CoV	O
+is	O
+the	O
+causative	O
+agent	O
+for	O
+SARS	B-DISO
+infection	B-DISO
+.	O
+
+Several	O
+structural	O
+analogues	O
+of	O
+Q7R	O
+,	O
+quercetin	B-CHED
+,	O
+apigenin	B-CHED
+,	O
+luteolin	B-CHED
+and	O
+catechin	B-CHED
+,	O
+also	O
+showed	O
+moderate	O
+anti	O
+-	O
+PEDV	B-SPEC
+activity	O
+.	O
+
+Q7R	O
+could	O
+be	O
+considered	O
+as	O
+a	O
+lead	O
+compound	O
+for	O
+development	B-PROC
+of	O
+anti	O
+-	O
+PEDV	B-SPEC
+drugs	O
+to	O
+may	O
+be	O
+used	O
+to	O
+during	O
+the	O
+early	O
+stage	O
+of	O
+PEDV	B-SPEC
+replication	O
+and	O
+the	O
+structure	O
+-	O
+activity	O
+data	O
+of	O
+Q7R	O
+may	O
+usefully	O
+guideline	O
+to	O
+design	O
+other	O
+related	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+No	O
+clear	O
+difference	O
+existed	O
+between	O
+the	O
+single	O
+and	O
+dual	O
+infected	O
+birds	B-SPEC
+with	O
+respect	O
+to	O
+inflammatory	O
+reactions	O
+in	O
+the	O
+lung	B-ANAT
+,	O
+which	O
+had	O
+disappeared	O
+within	O
+7	O
+days	O
+,	O
+except	O
+for	O
+the	O
+presence	O
+of	O
+more	O
+follicles	B-ANAT
+in	O
+dual	O
+infected	O
+birds	B-SPEC
+.	O
+
+Moreover	O
+,	O
+a	O
+preceding	O
+infection	B-DISO
+with	O
+vaccine	O
+or	O
+virulent	O
+IBV	B-SPEC
+does	O
+not	O
+seem	O
+to	O
+impair	O
+the	O
+clearance	O
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+of	O
+broilers	O
+,	O
+but	O
+rather	O
+induces	O
+an	O
+exaggerated	O
+inflammatory	B-DISO
+response	I-DISO
+in	O
+the	O
+airsacs	O
+only	O
+,	O
+which	O
+seems	O
+to	O
+be	O
+the	O
+mechanism	O
+behind	O
+the	O
+pattern	O
+of	O
+airsacculitis	B-DISO
+in	O
+commercial	O
+poultry	O
+in	O
+the	O
+field	O
+.	O
+
+Although	O
+SARS	B-DISO
+likely	O
+stems	B-ANAT
+from	O
+overexuberant	O
+host	B-COMP
+inflammatory	B-DISO
+responses	I-DISO
+,	O
+the	O
+exact	O
+mechanism	O
+leading	O
+to	O
+the	O
+detrimental	O
+outcome	O
+in	O
+patients	O
+remains	O
+unknown	O
+.	O
+
+To	O
+study	O
+this	O
+,	O
+we	O
+established	O
+highly	O
+polarized	O
+human	B-SPEC
+lung	B-ANAT
+epithelial	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+by	O
+using	O
+the	O
+Transwell	O
+culture	O
+system	O
+.	O
+
+Well	O
+-	O
+trained	O
+technologists	O
+and	O
+microbiologists	O
+,	O
+and	O
+the	O
+introduction	O
+of	O
+new	O
+technologies	O
+,	O
+will	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+a	O
+wide	O
+variety	O
+of	O
+molecular	O
+tests	O
+for	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+at	O
+public	O
+health	O
+laboratories	O
+geographically	O
+distant	O
+from	O
+Toronto	O
+,	O
+thus	O
+enhancing	O
+overall	O
+laboratory	O
+testing	O
+capacity	O
+in	O
+the	O
+province	O
+of	O
+Ontario	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+acidosis	O
+can	O
+become	O
+a	O
+serious	O
+problem	O
+during	O
+protective	O
+ventilation	O
+of	O
+severe	O
+lung	B-ANAT
+failure	O
+.	O
+
+In	O
+a	O
+cohort	O
+of	O
+96	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+haemodynamic	O
+parameters	O
+,	O
+oxygen	B-CHED
+consumption	O
+and	O
+carbon	B-CHED
+dioxide	I-CHED
+production	O
+as	O
+well	O
+as	O
+gas	B-ENZY
+transfer	O
+through	O
+the	O
+iLA	B-PRGE
+were	O
+analysed	O
+.	O
+
+Interventional	O
+lung	B-ANAT
+assist	O
+eliminates	O
+approximately	O
+50	O
+%	O
+of	O
+calculated	O
+total	O
+carbon	B-CHED
+dioxide	I-CHED
+production	O
+with	O
+rapid	O
+normalisation	O
+of	O
+respiratory	B-DISO
+acidosis	I-DISO
+.	O
+
+A	O
+real	O
+-	O
+time	O
+PCR	O
+assay	O
+was	O
+developed	O
+for	O
+the	O
+detection	O
+of	O
+CRCoV	O
+.	O
+The	O
+assay	O
+was	O
+validated	O
+against	O
+cell	B-COMP
+culture	O
+grown	O
+virus	B-SPEC
+and	O
+shown	O
+to	O
+have	O
+a	O
+high	O
+level	O
+of	O
+sensitivity	O
+.	O
+
+A	O
+range	O
+of	O
+tissue	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+dogs	B-SPEC
+at	O
+a	O
+re	O
+-	O
+homing	O
+centre	O
+with	O
+a	O
+history	O
+of	O
+endemic	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+conclusion	O
+,	O
+CRCoV	O
+appears	O
+to	O
+infect	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+preferentially	O
+.	O
+
+Avicel	O
+,	O
+agarose	B-CHED
+and	O
+carboxymethyl	B-CHED
+-	O
+cellulose	B-CHED
+overlays	O
+proved	O
+suitable	O
+for	O
+plaque	B-DISO
+assays	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+virus	B-SPEC
+stock	O
+of	O
+increased	O
+infectivity	O
+will	O
+be	O
+beneficial	O
+in	O
+antiviral	B-CHED
+screening	O
+,	O
+animal	B-SPEC
+modelling	O
+of	O
+disease	O
+,	O
+and	O
+other	O
+experimental	O
+tasks	O
+.	O
+
+National	O
+strategies	O
+include	O
+source	O
+surveillance	O
+and	O
+control	O
+,	O
+adequate	O
+stockpiles	O
+of	O
+anti	O
+-	O
+viral	O
+agents	O
+,	O
+timely	O
+production	O
+of	O
+flu	B-DISO
+vaccines	O
+and	O
+healthcare	O
+system	O
+readiness	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Techniques	O
+of	O
+extracorporeal	O
+lung	B-ANAT
+support	O
+].	O
+
+Consequently	O
+,	O
+vaccine	O
+-	O
+induced	O
+enhancement	O
+has	O
+been	O
+a	O
+major	O
+stumble	O
+block	O
+in	O
+the	O
+development	O
+of	O
+certain	O
+flavi	O
+-,	O
+corona	B-CHED
+-,	O
+paramyxo	O
+-,	O
+and	O
+lentivirus	B-SPEC
+vaccines	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+substitution	B-PROC
+mutation	I-PROC
+of	O
+a	O
+conserved	O
+Gly	B-CHED
+(	O
+G98	O
+)	O
+residue	O
+in	O
+the	O
+C	O
+-	O
+terminal	O
+alpha	O
+-	O
+helix	O
+domain	O
+with	O
+an	O
+Asp	B-CHED
+greatly	O
+destabilized	O
+the	O
+IBV	B-SPEC
+nsp9	I-PRGE
+homodimer	I-PRGE
+and	O
+abolished	O
+its	O
+RNA	O
+-	O
+binding	O
+activity	O
+.	O
+
+Meanwhile	O
+,	O
+mutations	O
+of	O
+some	O
+positively	O
+charged	O
+residues	O
+in	O
+the	O
+beta	O
+-	O
+barrel	O
+regions	O
+of	O
+the	O
+IBV	B-PRGE
+nsp9	I-PRGE
+protein	B-CHED
+significantly	O
+reduced	O
+its	O
+RNA	O
+-	O
+binding	B-PROC
+activity	I-PROC
+,	O
+but	O
+with	O
+no	O
+obvious	O
+effect	O
+on	O
+dimerization	O
+of	O
+the	O
+protein	B-CHED
+.	O
+
+Introduction	O
+of	O
+these	O
+mutations	O
+into	O
+the	O
+viral	B-COMP
+genome	I-COMP
+showed	O
+only	O
+mild	O
+to	O
+moderate	O
+effects	O
+on	O
+the	O
+growth	B-PROC
+and	O
+infectivity	O
+of	O
+the	O
+rescued	O
+mutant	B-DISO
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+)	O
+polyprotein	O
+was	O
+predicted	O
+to	O
+be	O
+cleaved	B-ANAT
+into	O
+15	O
+non	O
+-	O
+structural	O
+proteins	B-CHED
+(	O
+nsp2	B-PRGE
+to	O
+nsp16	O
+),	O
+but	O
+none	O
+of	O
+these	O
+nsps	O
+have	O
+been	O
+characterized	O
+.	O
+
+TCoV	O
+nsp15	O
+consists	O
+of	O
+338	O
+residues	O
+and	O
+shares	O
+40	O
+%	O
+sequence	O
+similarity	O
+to	O
+U	O
+-	O
+specific	O
+Nidovirales	B-SPEC
+endoribonuclease	O
+(	O
+NendoU	O
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+No	O
+divalent	O
+metal	B-CHED
+ion	O
+was	O
+required	O
+for	O
+in	O
+vitro	O
+enzymatic	B-PROC
+activity	I-PROC
+of	O
+the	O
+TCoV	O
+nsp15	O
+.	O
+
+The	O
+active	O
+form	O
+of	O
+the	O
+TCoV	O
+nsp15	O
+was	O
+a	O
+homohexamer	O
+and	O
+disulfide	B-CHED
+bond	O
+was	O
+essential	O
+for	O
+the	O
+enzymatic	B-PROC
+activity	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Propagation	O
+of	O
+new	O
+human	O
+respiratory	O
+virus	B-SPEC
+pathogens	O
+in	O
+established	O
+cell	B-ANAT
+lines	I-ANAT
+is	O
+hampered	O
+by	O
+a	O
+lack	O
+of	O
+predictability	O
+regarding	O
+cell	B-ANAT
+line	I-ANAT
+permissivity	O
+and	O
+by	O
+availability	O
+of	O
+suitable	O
+antibody	B-COMP
+reagents	B-CHED
+to	O
+detect	O
+infection	B-DISO
+in	O
+cell	B-ANAT
+lines	I-ANAT
+that	O
+do	O
+not	O
+exhibit	O
+significant	O
+cytopathic	B-DISO
+effect	I-DISO
+.	O
+
+The	O
+goal	O
+of	O
+the	O
+experiments	O
+described	O
+here	O
+was	O
+to	O
+determine	O
+if	O
+propagation	O
+and	O
+identification	O
+of	O
+a	O
+human	B-SPEC
+respiratory	O
+virus	B-SPEC
+may	O
+be	O
+achieved	O
+through	O
+inoculation	O
+of	O
+HAE	O
+cultures	O
+followed	O
+by	O
+whole	O
+transcriptome	O
+amplification	O
+(	O
+WTA	O
+)	O
+and	O
+sequence	O
+analysis	O
+.	O
+
+Initial	O
+propagation	O
+of	O
+human	B-SPEC
+respiratory	O
+secretions	B-ANAT
+onto	O
+HAE	O
+cultures	O
+followed	O
+by	O
+TEM	B-COMP
+and	O
+WTA	O
+of	O
+culture	O
+supernatant	O
+may	O
+be	O
+a	O
+useful	O
+approach	O
+for	O
+visualization	O
+and	O
+detection	O
+of	O
+new	O
+human	B-SPEC
+respiratory	O
+pathogens	O
+that	O
+have	O
+eluded	O
+identification	O
+by	O
+traditional	O
+approaches	O
+.	O
+
+TITLE	O
+:	O
+Treatment	O
+of	O
+accidental	O
+hypothermia	O
+with	O
+cardiopulmonary	B-ANAT
+bypass	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+The	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+showed	O
+some	O
+signs	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+spite	O
+of	O
+normal	O
+blood	B-PROC
+gas	B-ENZY
+values	O
+.	O
+
+Intriguingly	O
+,	O
+only	O
+the	O
+non	O
+-	O
+G	O
+-	O
+quadruplex	O
+aptamers	O
+showed	O
+specific	O
+inhibition	B-PROC
+of	O
+helicase	B-PRGE
+activities	O
+,	O
+whereas	O
+the	O
+G	O
+-	O
+quadruplex	O
+aptamers	O
+did	O
+not	O
+inhibit	O
+helicase	B-PRGE
+activities	O
+.	O
+
+This	O
+study	O
+used	O
+a	O
+broad	O
+capture	O
+,	O
+rapid	O
+and	O
+sensitive	O
+method	O
+(	O
+multiplex	O
+PCR	O
+assay	O
+)	O
+to	O
+detect	O
+20	O
+different	O
+respiratory	O
+pathogens	O
+including	O
+influenza	B-PATH
+A	I-PATH
+subtypes	O
+H1	O
+,	O
+H3	O
+,	O
+and	O
+H5	O
+;	O
+influenza	B-DISO
+B	O
+;	O
+parainfluenza	B-DISO
+types	O
+1	O
+,	O
+2	O
+,	O
+3	O
+,	O
+and	O
+4	O
+;	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+groups	O
+A	O
+and	O
+B	O
+;	O
+adenoviruses	B-SPEC
+;	O
+human	B-SPEC
+rhinoviruses	B-SPEC
+;	O
+enteroviruses	B-SPEC
+;	O
+human	B-SPEC
+metapneumoviruses	B-SPEC
+;	O
+human	B-SPEC
+coronaviruses	O
+OC43	O
+,	O
+229E	O
+,	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+;	O
+Chlamydophila	B-SPEC
+pneumoniae	I-SPEC
+;	O
+Legionella	B-SPEC
+pneumophila	I-SPEC
+;	O
+and	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+;	O
+from	O
+respiratory	O
+specimens	O
+of	O
+475	O
+children	O
+hospitalized	O
+over	O
+a	O
+12	O
+-	O
+month	O
+period	O
+for	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+However	O
+,	O
+in	O
+some	O
+patients	O
+,	O
+long	O
+-	O
+term	O
+durability	O
+is	O
+limited	O
+due	O
+to	O
+fibrous	O
+and	O
+cellular	B-COMP
+accumulations	O
+on	O
+the	O
+gas	B-ENZY
+exchange	O
+surface	O
+which	O
+can	O
+increase	O
+resistance	B-PROC
+to	O
+blood	B-PROC
+flow	I-PROC
+and	O
+diffusion	O
+path	O
+.	O
+
+Recent	O
+advances	O
+in	O
+molecular	O
+microbiology	O
+have	O
+made	O
+it	O
+possible	O
+to	O
+diagnose	O
+a	O
+growing	O
+number	O
+of	O
+community	O
+-	O
+acquired	O
+viral	O
+pathogens	O
+infecting	O
+transplant	B-ANAT
+recipients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Isolation	O
+and	O
+genomic	O
+sequence	O
+analysis	O
+of	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+].	O
+
+Experimental	O
+infection	B-DISO
+of	O
+dogs	B-SPEC
+with	O
+a	O
+TGEV	B-SPEC
+-	O
+like	O
+isolate	O
+induced	O
+mild	O
+gastroenteritis	B-DISO
+without	O
+any	O
+systemic	O
+involvement	O
+.	O
+
+The	O
+ability	O
+to	O
+design	O
+and	O
+recover	B-PROC
+pathogens	O
+reconstituted	O
+from	O
+synthesized	O
+cDNAs	O
+has	O
+the	O
+potential	O
+to	O
+overcome	O
+these	O
+obstacles	O
+by	O
+allowing	O
+studies	O
+of	O
+replication	O
+and	O
+pathogenesis	B-DISO
+without	O
+identification	O
+of	O
+reservoir	O
+species	B-SPEC
+or	O
+cultivation	O
+of	O
+primary	O
+isolates	O
+.	O
+
+TITLE	O
+:	O
+The	O
+expression	B-PROC
+and	O
+antigenicity	O
+of	O
+a	O
+truncated	O
+spike	O
+-	O
+nucleocapsid	B-COMP
+fusion	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+Genes	O
+encoding	O
+truncated	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+and	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+of	O
+SARSCoV	O
+were	O
+cloned	O
+into	O
+the	O
+expression	B-PROC
+vector	O
+pQE30	O
+and	O
+fusionally	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+M15	O
+.	O
+
+This	O
+polypeptide	B-CHED
+cocktail	O
+was	O
+also	O
+used	O
+to	O
+set	O
+up	O
+an	O
+ELISA	O
+-	O
+based	O
+IgG	B-PRGE
+-	I-PRGE
+plus	I-PRGE
+-	I-PRGE
+IgM	I-PRGE
+antibody	I-PRGE
+detection	O
+test	O
+,	O
+which	O
+showed	O
+99	O
+%	O
+specificity	O
+and	O
+90	O
+%	O
+sensitivity	O
+upon	O
+evaluation	O
+using	O
+sera	B-COMP
+from	O
+100	O
+healthy	O
+negative	O
+controls	O
+and	O
+20	O
+SARS	B-DISO
+patients	O
+.	O
+
+Nasal	B-ANAT
+secretions	B-ANAT
+from	O
+58	O
+patients	O
+with	O
+symptoms	O
+of	O
+a	O
+common	B-DISO
+cold	I-DISO
+,	O
+from	O
+three	O
+clinical	O
+centers	O
+(	O
+Amsterdam	O
+,	O
+Lodz	O
+,	O
+Oslo	O
+),	O
+were	O
+obtained	O
+by	O
+four	O
+different	O
+methods	O
+:	O
+swab	O
+,	O
+aspirate	B-ANAT
+,	O
+brush	O
+,	O
+and	O
+wash	O
+.	O
+
+In	O
+each	O
+patient	O
+all	O
+four	O
+sampling	O
+procedures	O
+were	O
+performed	O
+and	O
+patient	O
+discomfort	B-DISO
+was	O
+evaluated	O
+by	O
+a	O
+visual	B-DISO
+discomfort	I-DISO
+scale	O
+(	O
+scale	O
+1	O
+-	O
+5	O
+)	O
+after	O
+each	O
+procedure	O
+.	O
+
+During	O
+their	O
+hospitalization	O
+,	O
+40	O
+(	O
+57	O
+%)	O
+developed	O
+abnormal	O
+x	O
+-	O
+ray	B-SPEC
+findings	O
+,	O
+74	O
+%	O
+of	O
+those	O
+within	O
+the	O
+first	O
+day	O
+.	O
+
+TITLE	O
+:	O
+B	B-ANAT
+-	I-ANAT
+cell	B-COMP
+activation	I-PROC
+in	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+by	O
+FIP	B-DISO
+-	O
+virus	B-SPEC
+-	O
+induced	O
+B	B-ANAT
+-	I-ANAT
+cell	B-COMP
+differentiation	I-PROC
+/	O
+survival	O
+factors	O
+.	O
+
+In	O
+pneumonia	B-DISO
+severity	O
+score	O
+,	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+film	O
+score	O
+was	O
+higher	O
+in	O
+the	O
+group	O
+of	O
+fatalities	O
+than	O
+in	O
+the	O
+survival	O
+group	O
+.	O
+
+In	O
+the	O
+survival	O
+cases	O
+,	O
+sivelestat	O
+had	O
+been	O
+administered	O
+earlier	O
+than	O
+in	O
+the	O
+cases	O
+that	O
+died	B-PROC
+.	O
+
+Thus	O
+,	O
+we	O
+discuss	O
+the	O
+biochemistry	O
+of	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+protease	I-PRGE
+,	O
+inhibitor	B-CHED
+development	B-PROC
+,	O
+clinical	O
+use	O
+of	O
+inhibitors	B-CHED
+,	O
+and	O
+evolution	B-PROC
+of	O
+resistance	B-PROC
+.	O
+
+At	O
+this	O
+time	O
+,	O
+interest	O
+in	O
+developing	O
+inhibitors	B-CHED
+is	O
+limited	O
+to	O
+viruses	B-SPEC
+that	O
+cause	O
+chronic	B-DISO
+disease	I-DISO
+,	O
+viruses	B-SPEC
+that	O
+have	O
+the	O
+potential	O
+to	O
+cause	O
+large	O
+-	O
+scale	O
+epidemics	O
+,	O
+or	O
+viruses	B-SPEC
+that	O
+are	O
+sufficiently	O
+ubiquitous	O
+that	O
+treating	O
+an	O
+acute	B-DISO
+infection	I-DISO
+would	O
+be	O
+beneficial	O
+even	O
+if	O
+the	O
+infection	B-DISO
+was	O
+ultimately	O
+self	O
+-	O
+limiting	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pharyngeal	B-ANAT
+-	O
+cervical	B-ANAT
+-	O
+brachial	O
+variant	O
+of	O
+Guillain	B-DISO
+-	I-DISO
+Barre	I-DISO
+syndrome	I-DISO
+(	O
+GBS	B-DISO
+)	O
+is	O
+rare	O
+.	O
+
+The	O
+most	O
+striking	O
+immunological	O
+finding	O
+was	O
+the	O
+presence	O
+of	O
+positive	O
+IgG	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+GQ1b	I-PRGE
+,	O
+IgM	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+GMI	I-PRGE
+and	O
+IgM	B-PRGE
+anti	O
+-	O
+asialo	B-CHED
+GM1	I-CHED
+titres	O
+.	O
+
+After	O
+cross	O
+-	O
+foster	O
+rederivation	O
+,	O
+mice	B-SPEC
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+Helicobacter	B-SPEC
+spp	B-ENZY
+.	O
+
+The	O
+use	O
+of	O
+cross	O
+-	O
+foster	O
+rederivation	O
+alone	O
+was	O
+unsuccessful	O
+for	O
+the	O
+elimination	B-PROC
+of	O
+Syphacia	B-SPEC
+obvelata	I-SPEC
+.	O
+
+We	O
+demonstrated	O
+a	O
+strategy	O
+,	O
+tetramer	O
+-	O
+guided	O
+epitope	B-CHED
+mapping	O
+,	O
+that	O
+specific	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cell	I-ANAT
+epitopes	O
+can	O
+be	O
+identified	O
+by	O
+using	O
+PBMC	O
+from	O
+subjects	O
+that	O
+have	O
+not	O
+been	O
+exposed	O
+to	O
+the	O
+infectious	B-DISO
+organism	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+innate	O
+immune	O
+system	O
+guards	O
+against	O
+virus	B-DISO
+infection	I-DISO
+through	O
+a	O
+variety	O
+of	O
+mechanisms	O
+including	O
+mobilization	O
+of	O
+the	O
+host	B-COMP
+interferon	B-PRGE
+system	O
+,	O
+which	O
+attacks	O
+viral	O
+products	O
+mainly	O
+at	O
+a	O
+posttranscriptional	O
+level	O
+.	O
+
+Interestingly	O
+,	O
+cells	O
+lacking	O
+an	O
+interferon	B-PRGE
+response	O
+were	O
+drug	O
+resistant	O
+,	O
+suggesting	O
+that	O
+the	O
+compounds	O
+block	O
+interactions	O
+between	O
+NS1	B-DISO
+and	O
+the	O
+interferon	B-PRGE
+system	O
+.	O
+
+The	O
+effects	O
+of	O
+the	O
+compounds	O
+were	O
+specific	O
+to	O
+NS1	B-DISO
+,	O
+because	O
+they	O
+had	O
+no	O
+effect	O
+on	O
+the	O
+ability	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+papainlike	O
+protease	B-PRGE
+protein	I-PRGE
+to	O
+block	O
+beta	B-PRGE
+interferon	I-PRGE
+promoter	I-PRGE
+activation	O
+.	O
+
+These	O
+data	O
+demonstrate	O
+that	O
+the	O
+function	O
+of	O
+NS1	B-DISO
+can	O
+be	O
+modulated	O
+by	O
+chemical	O
+inhibitors	B-CHED
+and	O
+that	O
+such	O
+inhibitors	B-CHED
+will	O
+be	O
+useful	O
+as	O
+probes	O
+of	O
+biological	B-PROC
+function	I-PROC
+and	O
+as	O
+starting	O
+points	O
+for	O
+clinical	O
+drug	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Mechanisms	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+pathogenesis	B-DISO
+and	O
+innate	O
+immunomodulation	B-PROC
+.	O
+
+These	O
+viruses	B-SPEC
+have	O
+broad	O
+or	O
+specific	O
+host	B-COMP
+ranges	O
+,	O
+suggesting	O
+the	O
+possibility	O
+of	O
+novel	O
+strategies	O
+for	O
+targeting	B-PROC
+and	O
+regulating	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+following	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Using	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+as	O
+a	O
+model	O
+,	O
+we	O
+review	O
+the	O
+current	O
+literature	O
+on	O
+the	O
+ability	O
+of	O
+coronaviruses	O
+to	O
+interact	O
+with	O
+and	O
+modify	O
+the	O
+host	B-COMP
+intracellular	I-COMP
+environment	O
+during	O
+infection	O
+.	O
+
+Patients	O
+with	O
+positive	O
+results	O
+of	O
+either	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+or	O
+antibody	B-COMP
+to	O
+SARS	B-DISO
+coronavirus	B-SPEC
+were	O
+defined	O
+as	O
+SARS	B-DISO
+cases	O
+and	O
+others	O
+with	O
+negative	O
+results	O
+as	O
+control	O
+cases	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+lowest	O
+lymphocyte	B-ANAT
+count	O
+and	O
+the	O
+ratio	O
+of	O
+Pao	B-PROC
+(	O
+2	O
+)	O
+to	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+were	O
+lower	O
+in	O
+the	O
+SARS	B-DISO
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+review	O
+the	O
+epidemiology	O
+of	O
+pediatric	O
+multiple	O
+organ	O
+dysfunction	O
+syndrome	O
+(	O
+MODS	B-DISO
+)	O
+and	O
+summarize	O
+current	O
+concepts	O
+regarding	O
+the	O
+pathophysiology	O
+of	O
+shock	O
+,	O
+organ	B-ANAT
+dysfunction	O
+,	O
+and	O
+nosocomial	B-DISO
+infections	I-DISO
+in	O
+this	O
+population	O
+.	O
+
+Descriptive	O
+scores	O
+to	O
+estimate	O
+the	O
+severity	O
+of	O
+pediatric	O
+MODS	B-DISO
+have	O
+been	O
+validated	O
+.	O
+
+Unbalanced	O
+inflammatory	O
+processes	O
+and	O
+activation	B-PROC
+of	I-PROC
+coagulation	I-PROC
+may	O
+lead	O
+to	O
+the	O
+development	B-PROC
+of	O
+capillary	B-ANAT
+leak	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Nevertheless	O
+,	O
+further	O
+studies	O
+are	O
+needed	O
+to	O
+more	O
+clearly	O
+evaluate	O
+what	O
+is	O
+the	O
+long	O
+-	O
+term	O
+outcome	O
+of	O
+pediatric	O
+MODS	B-DISO
+.	O
+
+An	O
+alternative	O
+indirect	O
+immunoperoxidase	O
+assay	O
+(	O
+IPA	B-CHED
+)	O
+is	O
+herein	O
+described	O
+for	O
+the	O
+detection	O
+and	O
+titration	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+Susceptible	O
+cells	B-COMP
+are	O
+inoculated	O
+with	O
+serial	O
+logarithmic	O
+dilutions	O
+of	O
+samples	O
+in	O
+a	O
+96	O
+-	O
+well	O
+plate	O
+.	O
+
+This	O
+represents	O
+the	O
+dilution	O
+of	O
+a	O
+virus	B-SPEC
+-	O
+containing	O
+sample	O
+at	O
+which	O
+half	O
+of	O
+a	O
+series	O
+of	O
+laboratory	O
+wells	O
+contain	O
+replicating	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+new	O
+viruses	B-SPEC
+by	O
+VIDISCA	O
+.	O
+
+In	O
+this	O
+chapter	O
+we	O
+describe	O
+the	O
+use	O
+of	O
+these	O
+oligonucleotides	B-CHED
+in	O
+a	O
+one	O
+-	O
+step	O
+(	O
+single	O
+-	O
+tube	O
+)	O
+RT	O
+-	O
+PCR	O
+,	O
+and	O
+describe	O
+the	O
+procedure	O
+that	O
+we	O
+used	O
+to	O
+extract	O
+RNA	O
+from	O
+turkey	O
+feces	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+sequence	O
+characterization	O
+of	O
+the	O
+3	O
+'-	O
+end	O
+of	O
+coronavirus	B-SPEC
+genomes	O
+harboring	O
+the	O
+highly	O
+conserved	O
+RNA	O
+motif	O
+s2m	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+sugar	O
+residues	O
+involved	O
+in	O
+the	O
+binding	B-FUNC
+of	O
+TGEV	B-SPEC
+to	O
+porcine	B-SPEC
+brush	B-COMP
+border	I-COMP
+membranes	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+most	O
+often	O
+infect	O
+the	O
+respiratory	O
+or	O
+intestinal	B-ANAT
+tract	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Systematic	O
+assembly	O
+and	O
+genetic	O
+manipulation	O
+of	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+A59	O
+genome	O
+.	O
+
+By	O
+adding	O
+the	O
+type	O
+IIs	O
+restriction	O
+site	O
+in	O
+the	O
+proper	O
+orientation	O
+,	O
+subsequent	O
+digestion	B-PROC
+removes	O
+the	O
+restriction	O
+site	O
+and	O
+leaves	O
+a	O
+sticky	O
+end	O
+comprising	O
+the	O
+mutation	O
+of	O
+interest	O
+ready	O
+to	O
+ligate	O
+to	O
+a	O
+second	O
+fragment	O
+generated	O
+in	O
+parallel	O
+as	O
+its	O
+complement	O
+.	O
+
+Vaccinia	B-SPEC
+virus	I-SPEC
+as	O
+a	O
+vector	O
+for	O
+the	O
+full	O
+-	O
+length	O
+IBV	B-SPEC
+cDNA	O
+has	O
+the	O
+advantage	O
+that	O
+modifications	O
+can	O
+be	O
+introduced	O
+into	O
+the	O
+IBV	B-SPEC
+cDNA	O
+using	O
+homologous	B-PATH
+recombination	I-PATH
+,	O
+a	O
+method	O
+frequently	O
+used	O
+to	O
+insert	O
+and	O
+delete	O
+sequences	O
+from	O
+the	O
+vaccinia	B-SPEC
+virus	I-SPEC
+genome	O
+.	O
+
+They	O
+have	O
+been	O
+applied	O
+to	O
+the	O
+generation	O
+of	O
+recombinant	O
+coronaviruses	O
+,	O
+selectable	O
+replicon	O
+RNAs	O
+,	O
+and	O
+coronavirus	B-SPEC
+-	O
+based	O
+vectors	O
+for	O
+heterologous	O
+gene	B-PROC
+expression	I-PROC
+.	O
+
+Initially	O
+,	O
+the	O
+vaccinia	B-SPEC
+virus	I-SPEC
+-	O
+based	O
+reverse	O
+genetic	O
+system	O
+was	O
+established	O
+for	O
+the	O
+generation	O
+of	O
+recombinant	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+.	O
+
+Recombinant	O
+viruses	B-SPEC
+are	O
+then	O
+isolated	O
+on	O
+the	O
+basis	O
+of	O
+their	O
+regained	O
+natural	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+murine	B-SPEC
+or	O
+feline	B-SPEC
+)	O
+cell	B-COMP
+tropism	B-PROC
+.	O
+
+The	O
+hybridomas	B-ANAT
+produce	O
+monoclonal	O
+antibodies	B-COMP
+that	O
+recognize	O
+viral	B-ANAT
+component	I-ANAT
+molecules	O
+,	O
+including	O
+the	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+and	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+),	O
+enabling	O
+the	O
+immunological	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+by	O
+immunofluorescence	O
+staining	O
+,	O
+immunoblot	O
+,	O
+or	O
+an	O
+antigen	B-CHED
+-	O
+capture	O
+ELISA	O
+system	O
+.	O
+
+In	O
+addition	O
+,	O
+several	O
+S	B-PRGE
+protein	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+antibodies	B-COMP
+are	O
+shown	O
+to	O
+have	O
+in	O
+vitro	O
+neutralization	O
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+a	O
+group	O
+3	O
+coronavirus	B-SPEC
+,	O
+produces	O
+three	O
+proteins	B-CHED
+(	O
+IBV	B-SPEC
+E	O
+,	O
+IBV	B-SPEC
+3a	O
+,	O
+and	O
+IBV	B-SPEC
+3b	O
+)	O
+from	O
+subgenomic	O
+mRNA	B-CHED
+3	O
+during	O
+infection	B-DISO
+.	O
+
+The	O
+developing	O
+embryo	B-ANAT
+and	O
+its	O
+membranes	B-ANAT
+provide	O
+the	O
+diversity	O
+of	O
+cell	B-COMP
+types	O
+that	O
+are	O
+needed	O
+for	O
+successful	O
+replication	O
+of	O
+a	O
+wide	O
+variety	O
+of	O
+different	O
+viruses	B-SPEC
+.	O
+
+Within	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+,	O
+the	O
+embryonated	O
+egg	B-ANAT
+has	O
+been	O
+used	O
+as	O
+a	O
+host	B-COMP
+system	O
+primarily	O
+for	O
+two	O
+group	O
+3	O
+coronaviruses	O
+,	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+),	O
+but	O
+it	O
+also	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+suitable	O
+for	O
+pheasant	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+lethal	O
+pathology	B-DISO
+associated	O
+with	O
+FIP	B-DISO
+(	O
+granulomatous	B-DISO
+inflammation	I-DISO
+and	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+lymphopenia	B-DISO
+)	O
+is	O
+thought	O
+to	O
+be	O
+mediated	O
+by	O
+aberrant	O
+modulation	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+due	O
+to	O
+infection	B-DISO
+of	O
+cells	B-COMP
+such	O
+as	O
+monocytes	B-ANAT
+and	O
+macrophages	B-ANAT
+.	O
+
+Overproduction	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+occurs	O
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+and	O
+has	O
+been	O
+suggested	O
+to	O
+play	O
+a	O
+significant	O
+role	O
+in	O
+the	O
+disease	O
+process	O
+.	O
+
+TITLE	O
+:	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	O
+mediated	O
+suppression	B-DISO
+of	O
+coronavirus	B-SPEC
+replication	O
+in	O
+glial	B-ANAT
+-	O
+committed	O
+progenitor	B-ANAT
+cells	B-COMP
+.	O
+
+Also	O
+,	O
+direct	O
+treatment	O
+of	O
+infected	O
+glial	B-ANAT
+cultures	O
+with	O
+recombinant	O
+mouse	B-SPEC
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+or	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+inhibits	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	O
+mediated	O
+control	O
+of	O
+JHMV	O
+replication	O
+is	O
+dampened	O
+in	O
+glial	B-ANAT
+cultures	O
+derived	O
+from	O
+the	O
+neural	O
+progenitor	B-ANAT
+cells	I-ANAT
+of	O
+type	B-PRGE
+I	I-PRGE
+receptor	I-PRGE
+knock	O
+-	O
+out	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+is	O
+a	O
+critical	O
+syndrome	B-DISO
+associated	O
+with	O
+respiratory	B-DISO
+dysfunction	I-DISO
+,	O
+and	O
+neutrophils	B-ANAT
+are	O
+considered	O
+to	O
+be	O
+central	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+ALI	O
+.	O
+
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+were	O
+fed	O
+a	O
+standard	O
+diet	O
+either	O
+with	O
+casein	B-PRGE
+as	O
+the	O
+nitrogen	B-CHED
+source	O
+or	O
+with	O
+25	O
+%	O
+of	O
+total	O
+nitrogen	B-CHED
+replaced	O
+by	O
+Gln	B-CHED
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+effectiveness	O
+of	O
+,	O
+and	O
+complications	O
+associated	O
+with	O
+High	O
+Frequency	O
+Oscillatory	O
+Ventilation	O
+(	O
+HFOV	O
+)	O
+in	O
+burn	O
+patients	O
+with	O
+the	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+who	O
+have	O
+had	O
+a	O
+smoke	O
+inhalation	B-PROC
+injury	O
+,	O
+and	O
+to	O
+compare	O
+with	O
+those	O
+without	O
+an	O
+inhalation	B-PROC
+injury	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+the	O
+traveler	O
+in	O
+emerging	O
+infections	B-DISO
+and	O
+magnitude	O
+of	O
+travel	O
+.	O
+
+Enteral	O
+tube	O
+feeding	O
+was	O
+initiated	O
+at	O
+small	O
+volumes	O
+providing	O
+4	O
+.	O
+4	O
+kcal	O
+x	O
+kg	O
+(-	O
+1	O
+)	O
+x	O
+d	O
+(-	O
+1	O
+)	O
+and	O
+gradually	O
+increased	O
+over	O
+48	O
+h	O
+to	O
+29	O
+kcal	O
+x	O
+kg	O
+(-	O
+1	O
+)	O
+x	O
+d	O
+(-	O
+1	O
+)	O
+(	O
+based	O
+on	O
+adjusted	O
+body	B-ANAT
+weight	O
+).	O
+
+The	O
+patient	O
+then	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+requiring	O
+intubation	O
+and	O
+ventilatory	O
+support	O
+.	O
+
+Seven	O
+of	O
+the	O
+57	O
+specimens	O
+(	O
+12	O
+.	O
+3	O
+%)	O
+were	O
+found	O
+to	O
+be	O
+co	O
+-	O
+infected	O
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+,	O
+and	O
+19	O
+of	O
+44	O
+(	O
+43	O
+.	O
+2	O
+%)	O
+specimens	O
+which	O
+were	O
+negative	O
+by	O
+culture	O
+were	O
+positive	O
+by	O
+the	O
+multiplex	O
+PCR	O
+.	O
+
+Similar	O
+malnutrition	B-DISO
+-	O
+attributable	O
+fractions	O
+were	O
+seen	O
+for	O
+the	O
+major	O
+causes	O
+of	O
+severe	O
+disease	O
+(	O
+severe	O
+malaria	B-PATH
+,	O
+gastroenteritis	B-DISO
+,	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+HIV	B-DISO
+,	O
+and	O
+invasive	O
+bacterial	B-DISO
+disease	I-DISO
+).	O
+
+The	O
+aim	O
+of	O
+the	O
+current	O
+study	O
+is	O
+to	O
+quantify	O
+HPV	O
+-	O
+16	O
+viral	O
+load	O
+in	O
+male	O
+anogenital	O
+specimens	O
+and	O
+to	O
+explore	O
+its	O
+correlates	O
+with	O
+anatomic	B-ANAT
+sites	I-ANAT
+.	O
+
+This	O
+assumes	O
+that	O
+clinical	O
+knowledge	O
+and	O
+therapeutic	O
+strategies	O
+can	O
+be	O
+transferred	O
+between	O
+seemingly	O
+disparate	O
+disorders	O
+,	O
+such	O
+as	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+skin	B-DISO
+diseases	I-DISO
+and	O
+platelet	B-DISO
+disorders	I-DISO
+,	O
+or	O
+combined	O
+to	O
+develop	O
+novel	O
+pharmacological	O
+approaches	O
+.	O
+
+Susceptible	O
+cells	B-COMP
+are	O
+inoculated	O
+with	O
+serial	O
+logarithmic	O
+dilutions	O
+of	O
+virus	B-SPEC
+-	O
+containing	O
+samples	O
+in	O
+a	O
+96	O
+-	O
+well	O
+plate	O
+format	O
+.	O
+
+This	O
+represents	O
+the	O
+dilution	O
+of	O
+a	O
+virus	B-SPEC
+-	O
+containing	O
+sample	O
+at	O
+which	O
+half	O
+of	O
+a	O
+series	O
+of	O
+laboratory	O
+wells	O
+contain	O
+infectious	B-DISO
+replicating	O
+virus	B-SPEC
+.	O
+
+The	O
+genetic	O
+absence	O
+of	O
+MyD88	B-PRGE
+resulted	O
+in	O
+enhanced	O
+pulmonary	B-DISO
+pathology	I-DISO
+and	O
+greater	O
+than	O
+90	O
+%	O
+mortality	O
+by	O
+day	O
+6	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+MyD88	B-PRGE
+(-/-)	O
+mice	B-SPEC
+had	O
+significantly	O
+higher	O
+viral	O
+loads	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+throughout	O
+the	O
+course	O
+of	O
+infection	B-DISO
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+MyD88	B-PRGE
+-	O
+mediated	O
+innate	O
+immune	O
+signaling	B-PROC
+and	O
+inflammatory	B-ANAT
+cell	I-ANAT
+recruitment	B-DISO
+to	O
+the	O
+lung	B-ANAT
+are	O
+required	O
+for	O
+protection	O
+from	O
+lethal	O
+rMA15	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Globalisation	O
+and	O
+blood	B-ANAT
+safety	O
+.	O
+
+Similarly	O
+,	O
+the	O
+monopolization	O
+of	O
+technology	O
+,	O
+through	O
+patent	O
+enforcement	O
+which	O
+puts	O
+access	O
+beyond	O
+the	O
+reach	B-PROC
+of	O
+developing	O
+countries	O
+,	O
+can	O
+have	O
+an	O
+effect	O
+on	O
+blood	B-ANAT
+safety	O
+.	O
+
+Treatment	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+FGL2	I-PRGE
+antibody	I-PRGE
+completely	O
+inhibited	O
+Treg	O
+activity	O
+and	O
+protected	O
+susceptible	O
+BALB	O
+/	O
+cJ	O
+mice	B-SPEC
+against	O
+MHV	B-SPEC
+-	O
+3	O
+-	O
+liver	B-ANAT
+injury	O
+and	O
+mortality	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+demonstrates	O
+that	O
+FGL2	B-PRGE
+is	O
+an	O
+important	O
+effector	B-CHED
+cytokine	O
+of	O
+Tregs	O
+that	O
+contributes	O
+to	O
+susceptibility	O
+to	O
+MHV	B-SPEC
+-	O
+3	O
+-	O
+induced	O
+FH	O
+.	O
+
+An	O
+important	O
+finding	O
+of	O
+this	O
+study	O
+was	O
+the	O
+significantly	O
+lower	O
+average	O
+daily	O
+weight	O
+gain	O
+among	O
+virus	B-SPEC
+-	O
+inoculated	O
+groups	O
+of	O
+chickens	B-SPEC
+during	O
+the	O
+acute	O
+phase	O
+of	O
+infection	B-DISO
+.	O
+
+Reported	O
+associations	O
+between	O
+circumcision	O
+and	O
+HPV	O
+infection	B-DISO
+in	O
+men	O
+have	O
+been	O
+inconsistent	O
+.	O
+
+The	O
+breakdown	B-DISO
+of	O
+suspected	O
+causative	O
+pathogens	O
+was	O
+as	O
+follows	O
+:	O
+24	O
+.	O
+4	O
+%	O
+were	O
+Streptococcus	O
+pneumoniae	O
+,	O
+14	O
+.	O
+8	O
+%	O
+were	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+11	O
+.	O
+3	O
+%	O
+were	O
+Haemophilus	B-SPEC
+influenzae	I-SPEC
+,	O
+and	O
+1	O
+.	O
+4	O
+%	O
+were	O
+Chlamydophila	B-SPEC
+pneumoniae	I-SPEC
+.	O
+
+Computed	O
+tomography	O
+revealed	O
+interstitial	B-DISO
+lung	B-ANAT
+fibrosis	I-DISO
+which	O
+was	O
+attributed	O
+to	O
+the	O
+toxic	O
+effects	O
+of	O
+nitrofurantoin	B-CHED
+(	O
+50	O
+mg	O
+/	O
+d	O
+)	O
+that	O
+the	O
+patient	O
+used	O
+for	O
+approximately	O
+one	O
+year	O
+for	O
+recurrent	B-DISO
+urinary	I-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+A	O
+82	O
+-	O
+year	O
+-	O
+old	O
+female	O
+patient	O
+used	O
+moxifloxacin	B-CHED
+(	O
+400	O
+mg	O
+/	O
+d	O
+)	O
+for	O
+febrile	B-PROC
+bronchopulmonary	B-DISO
+infection	I-DISO
+for	O
+one	O
+week	O
+.	O
+
+During	O
+this	O
+therapy	O
+,	O
+confusion	B-DISO
+and	O
+severe	O
+dementia	B-DISO
+presented	O
+and	O
+remained	O
+for	O
+more	O
+than	O
+two	O
+months	O
+after	O
+discontinuation	O
+.	O
+
+The	O
+demential	O
+syndrome	B-DISO
+appears	O
+to	O
+be	O
+possibly	O
+related	O
+to	O
+the	O
+fluoroquinolone	O
+use	O
+.	O
+
+The	O
+results	O
+demonstrated	O
+that	O
+all	O
+of	O
+the	O
+examined	O
+viruses	B-SPEC
+maintained	O
+the	O
+typical	O
+IBV	B-SPEC
+genome	O
+organization	O
+as	O
+5	B-PRGE
+'-	I-PRGE
+S	I-PRGE
+-	I-PRGE
+3a	I-PRGE
+-	I-PRGE
+3b	I-PRGE
+-	I-PRGE
+E	I-PRGE
+-	I-PRGE
+M	I-PRGE
+-	I-PRGE
+5a	I-PRGE
+-	I-PRGE
+5b	I-PRGE
+-	I-PRGE
+N	I-PRGE
+-	I-PRGE
+UTR	I-PRGE
+-	I-PRGE
+3	I-PRGE
+'.	O
+
+All	O
+of	O
+the	O
+recombinants	O
+showed	O
+chimeric	O
+IBV	B-SPEC
+genome	O
+arrangements	O
+originated	O
+from	O
+Taiwan	O
+and	O
+China	O
+-	O
+like	O
+parental	O
+strains	O
+.	O
+
+Comparative	O
+sequence	O
+analysis	O
+of	O
+Ark	B-PRGE
+DPI	O
+with	O
+other	O
+IBV	B-SPEC
+strains	O
+shows	O
+striking	O
+similarity	O
+to	O
+the	O
+Conn	O
+,	O
+Gray	O
+,	O
+JMK	O
+,	O
+and	O
+Ark	B-PRGE
+99	I-PRGE
+,	O
+which	O
+were	O
+circulating	O
+during	O
+that	O
+time	O
+period	O
+.	O
+
+Among	O
+non	O
+-	O
+structural	O
+genes	O
+,	O
+the	O
+5	O
+'	O
+untranslated	O
+region	O
+(	O
+UTR	O
+),	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	I-PRGE
+(	I-PRGE
+3CLpro	I-PRGE
+)	I-PRGE
+and	I-PRGE
+the	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+sequences	O
+are	O
+100	O
+%	O
+identical	O
+to	O
+the	O
+Gray	O
+strain	O
+.	O
+
+Independent	O
+recombination	B-PROC
+events	O
+may	O
+have	O
+occurred	O
+in	O
+the	O
+entire	O
+genome	O
+of	O
+Ark	O
+DPI	O
+,	O
+involving	O
+four	O
+different	O
+IBV	B-SPEC
+strains	O
+,	O
+suggesting	O
+that	O
+genomic	O
+RNA	O
+recombination	B-PROC
+may	O
+occur	O
+in	O
+any	O
+part	O
+of	O
+the	O
+genome	O
+at	O
+number	O
+of	O
+sites	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+in	O
+T	B-ANAT
+cell	I-ANAT
+survival	O
+was	O
+examined	O
+during	O
+chronic	O
+CNS	B-CHED
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Similar	O
+numbers	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+retained	O
+in	O
+the	O
+CNS	B-PRGE
+of	I-PRGE
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+(-/-)	O
+and	O
+wt	O
+mice	B-SPEC
+,	O
+consistent	O
+with	O
+loss	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+2	I-PRGE
+/	I-PRGE
+15	I-PRGE
+receptor	I-PRGE
+(	O
+CD122	B-PRGE
+)	O
+expression	B-PROC
+.	O
+
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+persistently	O
+infected	O
+CNS	B-CHED
+are	O
+thus	O
+characterized	O
+by	O
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+independent	O
+,	O
+low	O
+level	O
+proliferation	B-DISO
+and	O
+an	O
+activated	O
+/	O
+memory	B-PROC
+phenotype	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+is	O
+a	O
+highly	O
+phosphorylated	O
+protein	B-CHED
+required	O
+for	O
+viral	B-PROC
+replication	I-PROC
+,	O
+but	O
+whether	O
+its	O
+phosphorylation	B-PROC
+and	O
+the	O
+related	O
+kinases	O
+are	O
+involved	O
+in	O
+the	O
+viral	B-PROC
+life	I-PROC
+cycle	I-PROC
+is	O
+unknown	O
+.	O
+
+We	O
+found	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+N	O
+protein	B-CHED
+to	O
+be	O
+an	O
+appropriate	O
+system	O
+to	O
+address	O
+this	O
+issue	O
+.	O
+
+This	O
+study	O
+,	O
+thus	O
+,	O
+provides	O
+new	O
+avenues	O
+to	O
+further	O
+investigate	O
+the	O
+specific	O
+role	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+phosphorylation	O
+in	O
+CoV	O
+replication	O
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+analyses	O
+revealed	O
+that	O
+the	O
+reduction	O
+of	O
+GCN2	B-PRGE
+protein	I-PRGE
+was	O
+not	O
+due	O
+to	O
+decreased	O
+transcription	B-PROC
+or	O
+stability	O
+of	O
+GCN2	O
+mRNA	O
+.	O
+
+Surprisingly	O
+,	O
+the	O
+knockdown	O
+of	O
+PKR	B-PRGE
+neither	O
+enhanced	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+nor	O
+abrogated	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+induced	O
+eIF2alpha	B-PRGE
+phosphorylation	B-PROC
+.	O
+
+However	O
+,	O
+virus	B-PROC
+replication	I-PROC
+was	O
+not	O
+impaired	B-DISO
+by	O
+these	O
+events	O
+,	O
+suggesting	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+possesses	B-DISO
+a	O
+mechanism	O
+to	O
+overcome	O
+the	O
+inhibitory	O
+effects	O
+of	O
+phosphorylated	O
+eIF2alpha	B-PRGE
+on	O
+viral	B-PATH
+mRNA	I-PATH
+translation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+LSECtin	I-PRGE
+(	O
+liver	B-ANAT
+and	O
+lymph	B-PRGE
+node	I-PRGE
+sinusoidal	I-PRGE
+endothelial	B-PRGE
+cell	I-PRGE
+C	I-PRGE
+-	I-PRGE
+type	I-PRGE
+lectin	I-PRGE
+,	O
+CLEC4G	B-PRGE
+)	O
+is	O
+a	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+lectin	I-PRGE
+encoded	O
+within	O
+the	O
+L	O
+-	O
+SIGN	O
+/	O
+DC	O
+-	O
+SIGN	O
+/	O
+CD23	B-PRGE
+gene	I-PRGE
+cluster	I-PRGE
+.	O
+
+Moreover	O
+,	O
+knockdown	O
+of	O
+PU	B-PRGE
+.	I-PRGE
+1	I-PRGE
+through	O
+the	O
+use	O
+of	O
+small	O
+interfering	O
+RNA	O
+led	O
+to	O
+a	O
+decrease	O
+in	O
+LSECtin	B-PRGE
+mRNA	I-PRGE
+levels	O
+in	O
+THP	B-CHED
+-	O
+1	O
+and	O
+monocyte	B-ANAT
+-	O
+derived	O
+dendritic	B-ANAT
+cells	B-COMP
+,	O
+thus	O
+confirming	O
+the	O
+involvement	O
+of	O
+PU	B-PRGE
+.	I-PRGE
+1	I-PRGE
+in	O
+the	O
+myeloid	O
+expression	B-PROC
+of	O
+the	O
+lectin	B-PRGE
+.	O
+
+Coexpression	O
+of	O
+either	O
+S	O
+or	O
+E	O
+protein	B-CHED
+with	O
+human	B-PRGE
+alpha	I-PRGE
+-,	I-PRGE
+beta	I-PRGE
+-,	I-PRGE
+and	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+ENaC	I-PRGE
+in	O
+Xenopus	B-SPEC
+oocytes	B-ANAT
+led	O
+to	O
+significant	O
+decreases	O
+of	O
+both	O
+amiloride	B-CHED
+-	O
+sensitive	O
+Na	O
+(+)	O
+currents	O
+and	O
+gamma	B-PRGE
+-	I-PRGE
+ENaC	I-PRGE
+protein	I-PRGE
+levels	O
+at	O
+their	O
+plasma	B-COMP
+membranes	I-COMP
+.	O
+
+TITLE	O
+:	O
+PIRO	O
+score	O
+for	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+:	O
+a	O
+new	O
+prediction	O
+rule	O
+for	O
+assessment	O
+of	O
+severity	O
+in	O
+intensive	O
+care	O
+unit	O
+patients	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outcomes	O
+of	O
+feline	O
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+infection	B-DISO
+vary	O
+greatly	O
+from	O
+asymptomatic	O
+or	O
+mild	O
+enteric	O
+infection	B-DISO
+to	O
+fatal	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+Analysis	O
+of	O
+partial	O
+S	O
+gene	O
+sequences	O
+of	O
+the	O
+local	O
+type	O
+I	O
+and	O
+II	O
+FCoVs	O
+strains	O
+revealed	O
+that	O
+type	O
+I	O
+viruses	O
+were	O
+more	O
+genetically	O
+divergent	O
+(	O
+6	O
+.	O
+2	O
+-	O
+11	O
+.	O
+7	O
+%)	O
+than	O
+type	O
+II	O
+viruses	B-SPEC
+(	O
+0	O
+.	O
+6	O
+-	O
+3	O
+.	O
+2	O
+%)	O
+within	O
+the	O
+5	O
+-	O
+year	O
+study	O
+period	O
+.	O
+
+This	O
+report	O
+provides	O
+an	O
+update	O
+on	O
+pediatric	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+Toronto	O
+,	O
+Ontario	O
+,	O
+Canada	O
+,	O
+that	O
+includes	O
+microbiological	O
+findings	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+our	O
+clinical	O
+case	O
+definition	O
+,	O
+6	O
+of	O
+8	O
+microbiologically	O
+confirmed	O
+case	O
+had	O
+been	O
+classified	O
+as	O
+having	O
+probable	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+SARS	O
+-	O
+CoV	O
+has	O
+four	O
+major	O
+structural	O
+proteins	B-CHED
+:	O
+the	O
+N	O
+,	O
+S	O
+,	O
+M	O
+,	O
+and	O
+E	O
+proteins	B-CHED
+.	O
+
+Co	O
+-	O
+immunoprecipitation	O
+analyses	O
+demonstrated	O
+an	O
+interaction	O
+between	O
+the	O
+N	O
+and	O
+M	O
+proteins	B-CHED
+,	O
+suggesting	O
+that	O
+N	B-PRGE
+protein	I-PRGE
+binds	B-FUNC
+directly	O
+to	O
+M	B-PRGE
+protein	I-PRGE
+to	O
+be	O
+incorporated	O
+into	O
+VLP	B-COMP
+.	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+-	O
+dependent	O
+enhancement	O
+occurs	O
+upon	O
+re	O
+-	O
+infection	B-DISO
+with	O
+the	O
+identical	O
+serotype	O
+virus	B-SPEC
+in	O
+feline	O
+infectious	O
+peritonitis	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+importance	O
+of	O
+differences	O
+in	O
+FIPV	O
+serotype	O
+on	O
+the	O
+induction	O
+of	O
+ADE	B-CHED
+remains	O
+unclear	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+whether	O
+the	O
+same	O
+or	O
+different	O
+serotype	O
+of	O
+FIPV	O
+induces	O
+ADE	B-CHED
+in	O
+cats	B-SPEC
+.	O
+
+Specific	O
+pathogen	O
+-	O
+free	O
+cats	B-SPEC
+were	O
+passively	O
+immunized	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+type	I-PRGE
+I	I-PRGE
+or	I-PRGE
+II	I-PRGE
+FIPV	I-PRGE
+antibodies	I-PRGE
+,	O
+and	O
+we	O
+investigated	O
+the	O
+induction	O
+of	O
+ADE	B-CHED
+following	O
+subcutaneous	O
+inoculation	O
+with	O
+type	O
+I	O
+FIPV	O
+.	O
+
+IRF3	B-PRGE
+translocation	B-DISO
+was	O
+independent	O
+of	O
+p38	B-PRGE
+kinase	B-FUNC
+activity	I-FUNC
+,	O
+indicating	O
+that	O
+IRF3	B-PRGE
+and	O
+p38	B-FUNC
+kinase	O
+are	O
+distinct	O
+pathways	O
+leading	O
+to	O
+cytokine	B-PROC
+production	I-PROC
+by	O
+H5N1	B-DISO
+virus	B-SPEC
+.	O
+
+A	O
+more	O
+precise	O
+identification	O
+of	O
+the	O
+differences	O
+in	O
+the	O
+regulation	B-PROC
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+could	O
+provide	O
+novel	O
+targets	O
+for	O
+the	O
+design	O
+of	O
+therapeutic	O
+strategies	O
+for	O
+severe	O
+human	B-SPEC
+H5N1	B-DISO
+influenza	I-DISO
+and	O
+also	O
+for	O
+treating	O
+other	O
+causes	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Perceived	O
+threat	O
+of	O
+SARS	B-DISO
+in	O
+case	O
+of	O
+an	O
+outbreak	O
+in	O
+the	O
+country	O
+was	O
+higher	O
+than	O
+that	O
+of	O
+other	O
+diseases	O
+.	O
+
+The	O
+McNemar	O
+and	O
+Chi	B-CHED
+-	O
+squared	O
+test	O
+,	O
+standard	O
+Pearson	O
+correlation	O
+,	O
+ANOVA	O
+,	O
+intraclass	O
+correlation	O
+coefficient	O
+(	O
+ICC	B-DISO
+),	O
+and	O
+receiver	O
+operating	O
+characteristic	O
+curve	O
+(	O
+ROC	O
+)	O
+analysis	O
+were	O
+used	O
+to	O
+calculate	O
+the	O
+alarm	O
+temperature	O
+for	O
+each	O
+imager	O
+.	O
+
+In	O
+addition	O
+,	O
+other	O
+classically	O
+non	O
+-	O
+enteric	O
+viruses	B-SPEC
+(	O
+such	O
+as	O
+HIV	B-DISO
+and	O
+influenza	B-DISO
+)	O
+may	O
+also	O
+have	O
+enteric	O
+effects	O
+that	O
+are	O
+crucial	O
+in	O
+their	O
+pathogeneses	B-DISO
+.	O
+
+Another	O
+patient	O
+was	O
+intubated	O
+within	O
+the	O
+first	O
+24	O
+h	O
+because	O
+of	O
+ARDS	B-DISO
+.	O
+
+At	O
+presentation	O
+,	O
+all	O
+patients	O
+but	O
+two	O
+had	O
+a	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+<	O
+300	O
+,	O
+while	O
+ARDS	B-DISO
+was	O
+present	O
+in	O
+17	O
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+15	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+of	O
+inhibition	B-PROC
+specificities	O
+of	O
+3C	O
+and	O
+3C	O
+-	O
+like	O
+proteases	O
+by	O
+zinc	B-CHED
+-	O
+coordinating	O
+and	O
+peptidomimetic	O
+compounds	O
+.	O
+
+As	O
+shown	O
+in	O
+the	O
+present	O
+study	O
+,	O
+some	O
+of	O
+these	O
+compounds	O
+were	O
+also	O
+found	O
+to	O
+be	O
+active	O
+against	O
+3C	O
+(	O
+pro	B-CHED
+)	O
+of	O
+CV	O
+strain	O
+B3	O
+(	O
+CVB3	O
+).	O
+
+Nitrile	B-CHED
+oxides	B-CHED
+were	O
+generated	O
+in	O
+situ	O
+from	O
+oximes	B-CHED
+using	O
+a	O
+commercial	O
+bleaching	O
+agent	O
+;	O
+their	O
+cycloaddition	O
+with	O
+5	O
+-	O
+ethynyl	B-CHED
+-	O
+2	B-CHED
+'-	I-CHED
+deoxyuridine	I-CHED
+yielded	O
+isoxazoles	B-CHED
+possessing	O
+activity	O
+against	O
+herpes	B-SPEC
+simplex	I-SPEC
+viruses	I-SPEC
+1	O
+and	O
+2	O
+,	O
+Encephalomyocarditis	B-SPEC
+virus	I-SPEC
+,	O
+Coxsackie	O
+B3	O
+,	O
+and	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+;	O
+these	O
+isoxazoles	B-CHED
+were	O
+,	O
+however	O
+,	O
+inactive	O
+against	O
+corona	B-CHED
+virus	B-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+HIV	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+cost	O
+nearly	O
+800	O
+lives	O
+.	O
+
+Consequently	O
+,	O
+the	O
+antisera	O
+exhibited	O
+neutralization	O
+activity	O
+in	O
+an	O
+in	O
+vitro	O
+infection	B-DISO
+inhibition	B-PROC
+assay	O
+.	O
+
+Here	O
+we	O
+compared	O
+the	O
+IBV	B-SPEC
+strains	O
+Beaudette	O
+,	O
+4	O
+/	O
+91	O
+,	O
+Italy02	O
+,	O
+and	O
+QX	O
+for	O
+their	O
+sialic	B-CHED
+acid	I-CHED
+-	O
+binding	B-FUNC
+properties	O
+.	O
+
+There	O
+were	O
+only	O
+slight	O
+differences	O
+between	O
+the	O
+four	O
+strains	O
+,	O
+indicating	O
+the	O
+universal	O
+usage	O
+of	O
+sialic	B-CHED
+acids	I-CHED
+as	O
+receptor	O
+determinants	O
+by	O
+IBV	B-SPEC
+.	O
+
+Their	O
+aptitude	O
+to	O
+evolve	O
+by	O
+genetic	B-PROC
+recombination	I-PROC
+and	O
+/	O
+or	O
+point	B-PROC
+mutation	I-PROC
+is	O
+recognized	O
+,	O
+thus	O
+giving	O
+rise	O
+to	O
+new	O
+viral	O
+genotypes	O
+and	O
+mutants	O
+with	O
+different	O
+tissues	B-ANAT
+or	O
+host	B-COMP
+tropism	B-PROC
+.	O
+
+A	O
+large	O
+proportion	O
+of	O
+the	O
+Hong	O
+Kong	O
+elderly	O
+population	O
+has	O
+not	O
+undergone	O
+influenza	B-DISO
+vaccination	O
+.	O
+
+To	O
+investigate	O
+any	O
+differences	O
+in	O
+attitudes	O
+toward	O
+influenza	B-DISO
+vaccination	O
+among	O
+Hong	O
+Kong	O
+elderly	O
+people	O
+with	O
+different	O
+levels	O
+of	O
+cognitive	O
+and	O
+physical	O
+functioning	O
+.	O
+
+In	O
+the	O
+end	O
+,	O
+we	O
+had	O
+four	O
+rule	O
+sets	O
+using	O
+mean	O
+airway	B-ANAT
+pressure	O
+,	O
+plateau	O
+pressure	O
+,	O
+total	O
+respiratory	O
+rate	O
+and	O
+oxygen	B-CHED
+saturation	O
+(	O
+SpO	O
+(	O
+2	O
+)),	O
+where	O
+the	O
+specificity	O
+/	O
+sensitivity	O
+rates	O
+were	O
+either	O
+80	O
+%/	O
+60	O
+%	O
+or	O
+90	O
+%/	O
+50	O
+%.	O
+
+Finally	O
+,	O
+to	O
+investigate	O
+whether	O
+calmodulin	B-PRGE
+has	O
+any	O
+effect	O
+on	O
+ACE2	B-PRGE
+ectodomain	I-PRGE
+shedding	O
+in	O
+cells	B-COMP
+that	O
+endogenously	O
+express	O
+the	O
+enzyme	O
+,	O
+cells	B-COMP
+from	O
+a	O
+human	B-SPEC
+liver	B-ANAT
+cell	I-ANAT
+line	O
+(	O
+Huh	O
+-	O
+7	O
+)	O
+expressing	O
+ACE2	B-PRGE
+were	O
+incubated	O
+with	O
+calmodulin	B-PRGE
+-	O
+specific	O
+inhibitors	B-CHED
+,	O
+trifluoperazine	B-CHED
+and	O
+calmidazolium	O
+.	O
+
+Using	O
+a	O
+cross	O
+-	O
+sectional	O
+survey	O
+,	O
+EMTs	O
+in	O
+Toronto	O
+,	O
+Ont	B-CHED
+.,	O
+were	O
+surveyed	O
+1	O
+year	O
+after	O
+the	O
+SARS	B-DISO
+outbreak	O
+during	O
+mandatory	O
+training	O
+on	O
+the	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+in	O
+airway	B-ANAT
+management	O
+during	O
+the	O
+outbreak	O
+and	O
+just	O
+before	O
+taking	O
+the	O
+survey	O
+.	O
+
+Conversely	O
+,	O
+72	O
+.	O
+9	O
+%	O
+of	O
+the	O
+respondents	O
+reported	O
+that	O
+they	O
+never	O
+used	O
+the	O
+open	O
+face	B-DISO
+hood	O
+.	O
+
+ABSTRACT	O
+:	O
+Picornaviruses	B-SPEC
+(	O
+PV	O
+)	O
+and	O
+coronaviruses	O
+(	O
+CoV	O
+)	O
+are	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+which	O
+infect	O
+millions	O
+of	O
+people	O
+worldwide	O
+each	O
+year	O
+,	O
+resulting	O
+in	O
+a	O
+wide	O
+range	O
+of	O
+clinical	O
+outcomes	O
+.	O
+
+Using	O
+computer	O
+modeling	O
+,	O
+the	O
+structural	O
+features	O
+of	O
+these	O
+compounds	O
+as	O
+individual	O
+and	O
+common	O
+protease	B-PROC
+inhibitors	I-PROC
+were	O
+elucidated	O
+to	O
+enhance	O
+our	O
+knowledge	O
+for	O
+developing	O
+anti	B-CHED
+-	I-CHED
+viral	I-CHED
+agents	I-CHED
+against	O
+PV	O
+and	O
+CoV	O
+.	O
+
+In	O
+the	O
+present	O
+trial	O
+,	O
+the	O
+effects	O
+of	O
+vaccine	O
+strains	O
+A3	O
+and	O
+Vic	B-PRGE
+S	I-PRGE
+on	O
+the	O
+oviduct	B-ANAT
+of	O
+laying	O
+hens	O
+were	O
+assessed	O
+by	O
+histopathology	O
+,	O
+electron	O
+microscopy	O
+,	O
+serology	O
+and	O
+also	O
+by	O
+determining	O
+the	O
+presence	O
+and	O
+persistence	O
+of	O
+viral	O
+RNA	O
+in	O
+the	O
+oviduct	B-ANAT
+by	O
+real	O
+time	O
+PCR	O
+following	O
+the	O
+experimental	O
+infection	B-DISO
+.	O
+
+Birds	B-SPEC
+were	O
+either	O
+unvaccinated	O
+or	O
+vaccinated	O
+with	O
+both	O
+A3	O
+and	O
+Vic	B-PRGE
+S	I-PRGE
+and	O
+then	O
+mock	O
+-	O
+infected	O
+,	O
+challenged	O
+with	O
+the	O
+same	O
+attenuated	O
+strains	O
+,	O
+either	O
+A3	O
+or	O
+Vic	O
+S	O
+.	O
+Some	O
+respiratory	O
+signs	O
+were	O
+observed	O
+,	O
+but	O
+were	O
+mild	O
+and	O
+short	O
+-	O
+lived	O
+.	O
+
+Microscopic	O
+lesions	O
+were	O
+not	O
+recorded	O
+in	O
+the	O
+isthmus	O
+,	O
+tubular	O
+shell	B-ANAT
+gland	I-ANAT
+or	O
+shell	B-ANAT
+gland	I-ANAT
+pouch	O
+.	O
+
+Recent	O
+studies	O
+have	O
+demonstrated	O
+that	O
+antioxidants	B-CHED
+reduced	O
+pulmonary	B-DISO
+inflammation	I-DISO
+in	O
+different	O
+models	O
+of	O
+lung	B-ANAT
+damage	O
+.	O
+
+This	O
+novel	O
+phenotype	O
+suggests	O
+a	O
+strategy	O
+to	O
+investigate	O
+the	O
+function	O
+of	O
+the	O
+MHV	B-PRGE
+-	I-PRGE
+A59	I-PRGE
+ns2	B-DISO
+protein	B-CHED
+involving	O
+the	O
+search	O
+for	O
+organ	B-ANAT
+-	O
+specific	O
+proteins	B-CHED
+or	O
+RNAs	O
+that	O
+react	O
+differentially	O
+to	O
+wild	O
+-	O
+type	O
+and	O
+mutant	B-DISO
+ns2	B-DISO
+proteins	B-CHED
+.	O
+
+Consisting	O
+of	O
+five	O
+domains	O
+,	O
+Nsp3	B-PRGE
+is	O
+the	O
+largest	O
+of	O
+these	O
+(	O
+180	O
+-	O
+210	O
+kDa	O
+).	O
+
+However	O
+,	O
+the	O
+incidence	O
+of	O
+AE	O
+in	O
+CVD	B-DISO
+-	O
+IP	O
+and	O
+its	O
+clinical	O
+characteristics	O
+remain	O
+to	O
+be	O
+fully	O
+determined	O
+.	O
+
+Initiation	O
+of	O
+iLA	B-PRGE
+followed	O
+an	O
+algorithm	O
+for	O
+screening	O
+,	O
+careful	O
+evaluation	O
+and	O
+insertion	O
+technique	O
+.	O
+
+TITLE	O
+:	O
+Hypercapnia	B-DISO
+in	O
+late	O
+-	O
+phase	O
+ALI	O
+/	O
+ARDS	B-DISO
+:	O
+providing	O
+spontaneous	O
+breathing	B-PROC
+using	O
+pumpless	O
+extracorporeal	O
+lung	O
+assist	O
+.	O
+
+Median	O
+reduction	O
+in	O
+pCO	B-DISO
+(	O
+2	O
+)	O
+was	O
+50	O
+%	O
+following	O
+institution	O
+of	O
+p	O
+-	O
+ECLA	O
+.	O
+
+p	O
+-	O
+ECLA	O
+treatment	O
+supported	O
+control	O
+of	O
+breathing	B-PROC
+pattern	O
+while	O
+sedation	B-DISO
+requirements	O
+were	O
+reduced	O
+and	O
+facilitated	O
+the	O
+implementation	O
+of	O
+assisted	O
+spontaneous	O
+breathing	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+case	O
+of	O
+new	O
+outbreaks	O
+of	O
+SARS	B-DISO
+/	O
+avian	B-DISO
+flu	I-DISO
+in	O
+China	O
+,	O
+local	O
+authorities	O
+in	O
+the	O
+UK	O
+and	O
+The	O
+Netherlands	O
+can	O
+best	O
+reach	B-PROC
+Chinese	O
+people	O
+through	O
+informal	O
+networks	O
+and	O
+British	O
+/	O
+Dutch	O
+TV	O
+,	O
+while	O
+trying	O
+to	O
+improve	O
+confidence	O
+in	O
+information	O
+from	O
+the	O
+government	O
+.	O
+
+METHODS	O
+:	O
+The	O
+participants	O
+of	O
+the	O
+study	O
+,	O
+who	O
+used	O
+a	O
+modified	O
+SARS	B-DISO
+Psychosocial	O
+Research	O
+Consortium	O
+survey	O
+,	O
+were	O
+drawn	O
+from	O
+Internet	O
+panels	O
+in	O
+Finland	O
+(	O
+n	O
+=	O
+308	O
+)	O
+and	O
+the	O
+Netherlands	O
+(	O
+n	O
+=	O
+373	O
+)	O
+in	O
+June	O
+2003	O
+.	O
+
+Multiple	O
+logistic	O
+regression	O
+analyses	O
+were	O
+used	O
+to	O
+calculate	O
+odds	O
+ratios	O
+(	O
+with	O
+95	O
+%	O
+confidence	O
+intervals	O
+)	O
+to	O
+compare	O
+Finns	O
+with	O
+the	O
+Dutch	O
+for	O
+various	O
+levels	O
+of	O
+perceptions	O
+and	O
+behaviors	B-PROC
+.	O
+
+In	O
+recent	O
+years	O
+,	O
+TCoV	O
+has	O
+been	O
+increasingly	O
+recognized	O
+in	O
+North	O
+America	O
+as	O
+an	O
+important	O
+pathogen	O
+of	O
+young	O
+turkeys	B-SPEC
+,	O
+resulting	O
+in	O
+economic	O
+loss	O
+due	O
+to	O
+impaired	B-DISO
+growth	B-PROC
+and	O
+poor	O
+feed	O
+conversion	O
+.	O
+
+These	O
+studies	O
+have	O
+raised	O
+additional	O
+questions	O
+regarding	O
+the	O
+classification	O
+of	O
+TCoV	O
+;	O
+particularly	O
+,	O
+whether	O
+IBV	B-SPEC
+and	O
+TCoV	O
+are	O
+taxonomically	O
+distinct	O
+viruses	B-SPEC
+,	O
+or	O
+whether	O
+TCoV	O
+is	O
+merely	O
+a	O
+variant	O
+of	O
+IBV	B-SPEC
+.	O
+
+TCoV	O
+is	O
+readily	O
+distinguished	O
+from	O
+IBV	B-SPEC
+based	O
+on	O
+antigenic	O
+and	O
+biological	O
+differences	O
+,	O
+and	O
+these	O
+differences	O
+suggest	O
+that	O
+TCoV	O
+should	O
+be	O
+considered	O
+a	O
+distinct	O
+virus	B-SPEC
+species	B-SPEC
+.	O
+
+A	O
+uniform	O
+,	O
+informative	O
+system	O
+for	O
+naming	O
+IBV	B-SPEC
+isolates	O
+would	O
+be	O
+very	O
+helpful	O
+.	O
+
+To	O
+date	O
+,	O
+no	O
+genetic	O
+features	O
+have	O
+been	O
+found	O
+that	O
+are	O
+unique	O
+to	O
+turkey	B-SPEC
+isolates	O
+and	O
+to	O
+pheasant	O
+isolates	O
+that	O
+would	O
+permit	B-SPEC
+unequivocal	O
+differentiation	B-PROC
+from	O
+IBVs	O
+.	O
+
+Should	O
+the	O
+avian	B-SPEC
+coronaviruses	O
+from	O
+turkeys	B-SPEC
+,	O
+pheasants	O
+and	O
+other	O
+birds	B-SPEC
+each	O
+be	O
+considered	O
+as	O
+distinct	O
+coronavirus	B-SPEC
+species	B-SPEC
+?	O
+
+This	O
+suggested	O
+naming	O
+system	O
+for	O
+isolates	O
+is	O
+essentially	O
+neutral	O
+with	O
+regard	O
+to	O
+whether	O
+viruses	B-SPEC
+from	O
+different	O
+bird	B-SPEC
+species	B-SPEC
+should	O
+be	O
+considered	O
+as	O
+different	O
+coronavirus	B-SPEC
+species	B-SPEC
+or	O
+simply	O
+as	O
+variants	O
+of	O
+just	O
+one	O
+avian	B-SPEC
+coronavirus	I-SPEC
+species	B-SPEC
+.	O
+
+In	O
+my	O
+opinion	O
+an	O
+informative	O
+nomenclature	O
+for	O
+avian	B-SPEC
+coronavirus	I-SPEC
+isolates	O
+is	O
+required	O
+now	O
+,	O
+to	O
+improve	O
+communication	O
+,	O
+and	O
+need	O
+not	O
+be	O
+delayed	O
+until	O
+a	O
+decision	O
+on	O
+the	O
+definition	O
+of	O
+coronavirus	B-SPEC
+species	B-SPEC
+has	O
+been	O
+made	O
+.	O
+
+Negative	O
+contrast	O
+electron	O
+microscopy	O
+of	O
+caecal	O
+contents	O
+revealed	O
+virus	B-COMP
+particles	I-COMP
+,	O
+which	O
+in	O
+size	O
+and	O
+morphology	O
+had	O
+the	O
+appearance	O
+of	O
+a	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+-	O
+induced	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+occurs	O
+via	O
+activation	O
+of	O
+the	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+pathway	B-PROC
+in	O
+human	B-SPEC
+monocyte	B-ANAT
+macrophages	B-ANAT
+in	O
+vitro	O
+.	O
+
+We	O
+confirmed	O
+cytokine	O
+mRNA	B-CHED
+increases	O
+by	O
+real	O
+-	O
+time	O
+quantitative	O
+(	O
+q	O
+)	O
+RT	O
+-	O
+PCR	O
+or	O
+ELISA	O
+.	O
+
+A	O
+PCR	O
+test	O
+amplifying	O
+the	O
+lktC	O
+-	O
+artJ	O
+intergenic	O
+region	O
+was	O
+evaluated	O
+and	O
+shown	O
+to	O
+be	O
+specific	O
+for	O
+the	O
+two	O
+species	B-SPEC
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+and	O
+Mannheimia	B-SPEC
+glucosida	I-SPEC
+.	O
+
+All	O
+90	O
+aspirations	O
+were	O
+also	O
+analyzed	O
+for	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+),	O
+parainfluenza	B-DISO
+-	O
+3	O
+virus	B-SPEC
+,	O
+and	O
+bovine	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+by	O
+antigen	B-CHED
+ELISA	O
+.	O
+
+A	O
+higher	O
+percentage	O
+of	O
+the	O
+samples	O
+were	O
+positive	O
+for	O
+all	O
+bacterial	O
+species	B-SPEC
+in	O
+the	O
+group	O
+of	O
+diseased	O
+animals	B-SPEC
+compared	O
+to	O
+the	O
+clinically	O
+healthy	O
+animals	B-SPEC
+,	O
+however	O
+this	O
+difference	O
+was	O
+only	O
+significant	O
+for	O
+M	B-SPEC
+.	I-SPEC
+dispar	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+bovirhinis	I-SPEC
+.	O
+
+Among	O
+the	O
+diseased	O
+calves	O
+in	O
+these	O
+two	O
+herds	O
+a	O
+significant	O
+increase	O
+in	O
+haptoglobin	B-PRGE
+and	O
+serum	B-PRGE
+amyloid	B-DISO
+A	I-PRGE
+levels	O
+was	O
+observed	O
+compared	O
+to	O
+the	O
+healthy	O
+calves	O
+.	O
+
+For	O
+H	B-SPEC
+.	I-SPEC
+somni	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+,	O
+a	O
+higher	O
+percentage	O
+of	O
+the	O
+samples	O
+were	O
+found	O
+positive	O
+by	O
+PCR	O
+than	O
+by	O
+cultivation	O
+,	O
+whereas	O
+the	O
+opposite	O
+result	O
+was	O
+found	O
+for	O
+P	B-SPEC
+.	I-SPEC
+multocida	I-SPEC
+.	O
+
+For	O
+H	B-SPEC
+.	I-SPEC
+somni	I-SPEC
+a	O
+similar	O
+association	O
+with	O
+disease	O
+status	O
+was	O
+only	O
+observed	O
+for	O
+cultivation	O
+and	O
+not	O
+for	O
+PCR	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+orally	B-ANAT
+DNA	O
+vaccine	O
+evoked	O
+vigorous	O
+T	B-ANAT
+cell	I-ANAT
+response	O
+and	O
+a	O
+weak	O
+antibody	B-FUNC
+production	I-PROC
+.	O
+
+Two	O
+randomized	O
+controlled	O
+trials	O
+showed	O
+that	O
+the	O
+systematic	O
+early	O
+use	O
+of	O
+NMBAs	O
+is	O
+associated	O
+with	O
+a	O
+sustained	O
+improvement	O
+in	O
+oxygenation	B-PROC
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Twenty	O
+-	O
+one	O
+rabbits	B-SPEC
+were	O
+operatively	O
+prepared	O
+and	O
+randomly	O
+divided	O
+into	O
+sham	O
+,	O
+control	O
+,	O
+or	O
+APC	B-COMP
+groups	O
+(	O
+n	O
+=	O
+7	O
+in	O
+each	O
+group	O
+).	O
+
+RESULTS	O
+:	O
+In	O
+comparison	O
+with	O
+nontreatment	O
+in	O
+the	O
+control	O
+group	O
+,	O
+the	O
+infusion	O
+of	O
+APC	B-COMP
+significantly	O
+reduced	O
+the	O
+increase	O
+of	O
+thrombomodulin	B-PRGE
+level	I-PRGE
+(	O
+TM	O
+;	O
+control	O
+group	O
+was	O
+(	O
+0	O
+.	O
+68	O
++/-	O
+0	O
+.	O
+06	O
+)	O
+ng	O
+/	O
+ml	O
+,	O
+vs	O
+APC	B-COMP
+group	O
+of	O
+(	O
+0	O
+.	O
+62	O
++/-	O
+
+Thrombocytopenia	O
+was	O
+observed	O
+in	O
+5	O
+(	O
+12	O
+.	O
+5	O
+%)	O
+patients	O
+,	O
+and	O
+multi	O
+-	O
+organ	B-ANAT
+dysfunction	O
+was	O
+detected	O
+in	O
+19	O
+(	O
+47	O
+.	O
+5	O
+%)	O
+patients	O
+.	O
+
+The	O
+detection	O
+rates	O
+were	O
+as	O
+follows	O
+:	O
+respiratory	O
+syncytial	O
+virus	O
+(	O
+RSV	B-SPEC
+)	O
+was	O
+the	O
+most	O
+commonly	O
+detected	O
+in	O
+52	O
+.	O
+7	O
+%	O
+(	O
+87	O
+/	O
+165	O
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+)	O
+in	O
+15	O
+.	O
+8	O
+%,	O
+human	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+(	O
+hCoV	O
+)	O
+in	O
+5	O
+.	O
+5	O
+%,	O
+adenovirus	B-DISO
+in	O
+9	O
+.	O
+7	O
+%,	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+hBoV	O
+)	O
+in	O
+5	O
+.	O
+5	O
+%,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+in	O
+3	O
+.	O
+6	O
+%,	O
+rhinovirus	B-SPEC
+(	O
+RV	O
+)	O
+in	O
+4	O
+.	O
+2	O
+%,	O
+and	O
+the	O
+influenza	B-SPEC
+virus	I-SPEC
+in	O
+3	O
+%	O
+of	O
+the	O
+patients	O
+with	O
+ALRIs	O
+.	O
+
+Using	O
+the	O
+social	O
+amplification	B-DISO
+of	O
+risk	O
+framework	O
+,	O
+we	O
+show	O
+that	O
+,	O
+while	O
+other	O
+countries	O
+displayed	O
+social	O
+amplification	B-DISO
+of	O
+risk	O
+,	O
+Canada	O
+experienced	O
+a	O
+social	O
+attenuation	O
+of	O
+risk	O
+.	O
+
+TITLE	O
+:	O
+The	O
+epidemiology	O
+of	O
+,	O
+and	O
+risk	O
+factors	O
+for	O
+,	O
+mortality	O
+from	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+in	O
+a	O
+tertiary	O
+-	O
+care	O
+university	O
+hospital	O
+setting	O
+.	O
+
+Hospital	O
+-	O
+acquired	O
+infections	B-DISO
+accounted	O
+for	O
+55	O
+.	O
+6	O
+%	O
+of	O
+patients	O
+with	O
+Gram	O
+-	O
+negative	O
+bacteria	B-SPEC
+predominant	O
+(	O
+68	O
+%).	O
+
+To	O
+differentiate	O
+the	O
+genotypes	O
+without	O
+sequencing	O
+,	O
+a	O
+simple	O
+technique	O
+-	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+-	O
+polymerase	O
+chain	O
+reaction	O
+/	O
+restriction	O
+fragment	O
+length	O
+polymorphism	B-PROC
+analysis	O
+(	O
+RT	O
+-	O
+PCR	O
+/	O
+RFLP	O
+)-	O
+was	O
+developed	O
+.	O
+
+CONCLUSIONS	O
+:	O
+IHC	O
+can	O
+be	O
+an	O
+additional	O
+useful	O
+tool	O
+for	O
+diagnosis	O
+of	O
+IBV	B-SPEC
+infection	B-DISO
+in	O
+chickens	B-SPEC
+and	O
+allows	O
+further	O
+studies	O
+to	O
+foster	O
+a	O
+deeper	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+infections	B-DISO
+with	O
+IBV	B-SPEC
+strains	O
+of	O
+different	O
+virulence	B-PROC
+.	O
+
+Bacterial	O
+agents	O
+include	O
+Legionella	B-SPEC
+species	B-SPEC
+,	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+Chlamydophila	B-SPEC
+species	B-SPEC
+,	O
+and	O
+Coxiella	B-SPEC
+burnetii	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+a	O
+mandatory	O
+infection	B-DISO
+control	O
+education	O
+program	O
+on	O
+nosocomial	O
+acquisition	O
+of	O
+methicillin	B-CHED
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+.	O
+
+The	O
+rate	O
+of	O
+nosocomial	O
+acquisition	O
+of	O
+MRSA	B-DISO
+colonization	O
+or	O
+infection	B-DISO
+decreased	O
+after	O
+SARS	B-DISO
+and	O
+was	O
+further	O
+reduced	O
+in	O
+association	O
+with	O
+a	O
+hospital	O
+-	O
+wide	O
+education	O
+program	O
+.	O
+
+TITLE	O
+:	O
+Large	O
+mixed	B-DISO
+germ	I-DISO
+cell	I-DISO
+tumor	I-DISO
+in	O
+a	O
+young	O
+patient	O
+presenting	O
+as	O
+an	O
+intrapulmonary	O
+mass	O
+.	O
+
+Histology	O
+confirmed	O
+a	O
+teratoma	B-DISO
+with	O
+mature	O
+and	O
+immature	O
+components	O
+accompanied	O
+by	O
+residual	O
+seminomatous	O
+tumor	B-ANAT
+cells	B-COMP
+.	O
+
+Enteral	O
+administration	O
+of	O
+fish	B-SPEC
+oil	O
+,	O
+antioxidants	B-CHED
+and	O
+physiologic	O
+amounts	O
+of	O
+arginine	B-CHED
+improve	O
+oxygenation	B-PROC
+and	O
+clinical	O
+outcomes	O
+in	O
+ICU	O
+patients	O
+with	O
+impaired	B-DISO
+oxygenation	B-PROC
+.	O
+
+The	O
+genetically	O
+engineered	O
+attenuated	O
+form	O
+of	O
+the	O
+virus	B-SPEC
+or	O
+viral	O
+vector	O
+vaccine	O
+encoding	O
+for	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+glycoprotein	B-CHED
+has	O
+been	O
+shown	O
+to	O
+elicit	O
+protective	O
+immunity	B-PROC
+in	O
+vaccinated	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+highlight	O
+the	O
+case	O
+of	O
+a	O
+patient	O
+with	O
+acute	O
+respiratory	O
+failure	O
+,	O
+whose	O
+diagnosis	O
+of	O
+Boerhaave	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+only	O
+became	O
+apparent	O
+after	O
+a	O
+trial	O
+of	O
+non	O
+-	O
+invasive	O
+ventilation	O
+.	O
+
+A	O
+68	O
+-	O
+year	O
+-	O
+old	O
+female	O
+presented	O
+with	O
+a	O
+clinical	O
+picture	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+and	O
+exacerbation	O
+of	O
+asthma	B-PATH
+that	O
+was	O
+supported	O
+by	O
+radiological	O
+evidence	O
+of	O
+a	O
+large	O
+left	O
+-	O
+sided	O
+pleural	B-DISO
+effusion	I-DISO
+.	O
+
+TITLE	O
+:	O
+Functional	O
+screen	O
+reveals	O
+SARS	B-DISO
+coronavirus	B-SPEC
+nonstructural	O
+protein	B-CHED
+nsp14	O
+as	O
+a	O
+novel	O
+cap	B-DISO
+N7	I-PRGE
+methyltransferase	I-PRGE
+.	O
+
+A	O
+survey	O
+using	O
+a	O
+self	O
+-	O
+administered	O
+questionnaire	O
+was	O
+conducted	O
+on	O
+300	O
+printing	O
+company	O
+workers	O
+in	O
+Beijing	O
+,	O
+China	O
+,	O
+which	O
+was	O
+under	O
+mass	O
+isolation	O
+following	O
+the	O
+2003	O
+SARS	B-DISO
+outbreak	O
+,	O
+in	O
+the	O
+7	O
+-	O
+8	O
+months	O
+after	O
+the	O
+isolation	O
+was	O
+lifted	O
+.	O
+
+P	B-SPEC
+.	I-SPEC
+jirovecii	I-SPEC
+was	O
+detected	O
+in	O
+26	O
+/	O
+128	O
+,	O
+bacteria	B-SPEC
+in	O
+10	O
+,	O
+fungi	B-SPEC
+in	O
+four	O
+,	O
+Influenza	B-PATH
+A	I-PATH
+in	O
+two	O
+patients	O
+.	O
+
+Human	B-SPEC
+bocavirus	I-SPEC
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+are	O
+rarely	O
+involved	O
+in	O
+atypical	B-DISO
+pneumonia	I-DISO
+in	O
+immunocompromised	O
+adult	O
+patients	O
+with	O
+suspected	O
+PCP	B-DISO
+,	O
+but	O
+may	O
+contribute	O
+to	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Preliminary	O
+data	O
+suggest	O
+that	O
+patients	O
+with	O
+vasodilatory	O
+shock	O
+after	O
+cardiac	B-ANAT
+surgery	O
+and	O
+patients	O
+with	O
+liver	B-DISO
+cirrhosis	I-DISO
+and	O
+sepsis	B-DISO
+can	O
+benefit	O
+from	O
+corticosteroids	B-CHED
+.	O
+
+Critical	B-DISO
+illness	I-DISO
+-	O
+related	O
+corticosteroid	B-CHED
+insufficiency	O
+can	O
+also	O
+occur	O
+in	O
+patients	O
+with	O
+trauma	O
+,	O
+traumatic	O
+brain	B-ANAT
+injury	O
+,	O
+acute	B-DISO
+pancreatitis	I-DISO
+and	O
+burn	O
+injuries	O
+,	O
+but	O
+data	O
+from	O
+clinical	O
+trials	O
+on	O
+these	O
+target	O
+groups	O
+are	O
+insufficient	O
+at	O
+present	O
+.	O
+
+We	O
+reviewed	O
+the	O
+existing	O
+studies	O
+on	O
+fever	B-PROC
+screening	O
+by	O
+NCIT	O
+to	O
+estimate	O
+their	O
+efficacy	O
+under	O
+the	O
+hypothesis	O
+of	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+When	O
+we	O
+fixed	B-ANAT
+fever	B-PROC
+prevalence	O
+at	O
+1	O
+%	O
+in	O
+all	O
+studies	O
+to	O
+allow	O
+comparisons	O
+,	O
+the	O
+derived	O
+PPV	O
+varied	O
+from	O
+3	O
+.	O
+5	O
+%	O
+to	O
+65	O
+.	O
+4	O
+%	O
+and	O
+NPV	O
+was	O
+>	O
+or	O
+=	O
+99	O
+%.	O
+
+The	O
+low	O
+PPV	B-CHED
+suggests	O
+limited	O
+efficacy	O
+of	O
+NCIT	O
+to	O
+detect	O
+symptomatic	O
+passengers	O
+at	O
+the	O
+early	O
+stages	O
+of	O
+a	O
+pandemic	O
+influenza	B-DISO
+,	O
+when	O
+fever	B-PROC
+prevalence	O
+among	O
+passengers	O
+would	O
+be	O
+=	O
+or	O
+<	O
+1	O
+%.	O
+
+To	O
+examine	O
+,	O
+compare	O
+and	O
+contrast	O
+the	O
+functional	O
+characteristics	O
+of	O
+hmAbs	O
+with	O
+the	O
+potential	O
+for	O
+prophylaxis	O
+and	O
+treatment	O
+of	O
+diseases	O
+caused	O
+by	O
+SARS	B-PRGE
+CoV	I-PRGE
+,	O
+HeV	B-SPEC
+and	O
+NiV	O
+.	O
+A	O
+review	O
+of	O
+relevant	O
+literature	O
+.	O
+
+The	O
+critical	O
+nature	O
+of	O
+ALI	O
+and	O
+ARDS	B-DISO
+,	O
+compounded	O
+by	O
+the	O
+impact	O
+of	O
+phenotypic	O
+heterogeneity	O
+,	O
+has	O
+rendered	O
+the	O
+amassing	O
+of	O
+sufficiently	O
+powered	O
+studies	O
+especially	O
+challenging	O
+.	O
+
+To	O
+identify	O
+sequence	O
+changes	O
+responsible	O
+for	O
+the	O
+attenuation	O
+of	O
+IBV	B-SPEC
+,	O
+complete	O
+genome	O
+sequences	O
+of	O
+both	O
+virulent	O
+and	O
+attenuated	O
+Ark	O
+DPI	O
+viruses	B-SPEC
+were	O
+obtained	O
+.	O
+
+Twenty	O
+-	O
+one	O
+long	O
+-	O
+term	O
+survivors	O
+of	O
+severe	O
+ARDS	B-DISO
+and	O
+ECMO	O
+were	O
+studied	O
+in	O
+a	O
+follow	O
+-	O
+up	O
+program	O
+including	O
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+(	O
+HRCT	O
+)	O
+of	O
+the	O
+lungs	B-ANAT
+,	O
+extensive	O
+pulmonary	B-PROC
+function	I-PROC
+tests	O
+,	O
+pulmonary	B-ANAT
+scintigraphy	O
+and	O
+the	O
+pulmonary	B-DISO
+disease	I-DISO
+-	O
+specific	O
+St	O
+George	O
+'	O
+s	O
+Respiratory	O
+Questionnaire	O
+(	O
+SGRQ	O
+).	O
+
+CONCLUSIONS	O
+:	O
+The	O
+majority	O
+of	O
+ECMO	O
+-	O
+treated	O
+ARDS	B-DISO
+patients	O
+have	O
+good	O
+physical	O
+and	O
+social	O
+functioning	O
+.	O
+
+Clinical	O
+outcomes	O
+were	O
+worse	O
+in	O
+the	O
+lung	B-ANAT
+transplant	B-ANAT
+group	O
+and	O
+included	O
+a	O
+greater	O
+need	O
+for	O
+intensive	O
+care	O
+unit	O
+treatment	O
+(	O
+80	O
+%	O
+vs	O
+.	O
+20	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+02	O
+),	O
+longer	O
+length	O
+of	O
+hospital	O
+stay	O
+(	O
+21	O
+vs	O
+.	O
+5	O
+days	O
+,	O
+P	O
+=	O
+0	O
+.	O
+02	O
+),	O
+and	O
+propensity	O
+to	O
+develop	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+60	O
+%	O
+vs	O
+.	O
+10	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+TITLE	O
+:	O
+Aryl	O
+diketoacids	O
+(	O
+ADK	O
+)	O
+selectively	O
+inhibit	O
+duplex	O
+DNA	O
+-	O
+unwinding	O
+activity	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+NTPase	I-PRGE
+/	O
+helicase	B-PRGE
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+results	O
+suggest	O
+that	O
+there	O
+might	O
+be	O
+ADK	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+binding	I-PRGE
+site	I-PRGE
+in	O
+the	O
+SCV	B-SPEC
+Hel	O
+,	O
+which	O
+warrants	O
+further	O
+investigations	O
+with	O
+diverse	O
+ADKs	O
+to	O
+provide	O
+valuable	O
+insights	O
+into	O
+rational	O
+design	O
+of	O
+specific	O
+SCV	B-SPEC
+Hel	O
+inhibitors	O
+.	O
+
+TITLE	O
+:	O
+Differential	O
+characteristics	O
+of	O
+the	O
+early	O
+stage	O
+of	O
+lung	B-DISO
+inflammation	I-DISO
+induced	O
+by	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+Nucleocapsid	B-ANAT
+protein	B-CHED
+related	O
+to	O
+age	O
+in	O
+the	O
+mouse	B-SPEC
+.	O
+
+Specimens	O
+were	O
+tested	O
+for	O
+respiratory	O
+viruses	B-SPEC
+by	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+One	O
+hundred	O
+twenty	O
+-	O
+four	O
+out	O
+of	O
+237	O
+samples	O
+(	O
+52	O
+.	O
+3	O
+%)	O
+were	O
+positive	O
+for	O
+one	O
+or	O
+more	O
+viruses	B-SPEC
+.	O
+
+The	O
+sequence	O
+diversity	O
+suggests	O
+that	O
+bats	B-SPEC
+are	O
+well	O
+-	O
+established	O
+reservoirs	O
+for	O
+and	O
+likely	O
+sources	O
+of	O
+coronaviruses	O
+for	O
+many	O
+species	B-SPEC
+,	O
+including	O
+humans	B-SPEC
+.	O
+
+There	O
+were	O
+3	O
+women	O
+and	O
+1	O
+man	B-CHED
+with	O
+an	O
+average	O
+age	O
+of	O
+26	O
++/-	O
+
+Each	O
+patient	O
+received	O
+HBO	O
+treatment	O
+for	O
+100	O
+sessions	O
+and	O
+oral	B-ANAT
+alendronate	B-CHED
+for	O
+one	O
+year	O
+.	O
+
+At	O
+the	O
+4	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+,	O
+significant	O
+improvements	O
+in	O
+pain	O
+score	O
+and	O
+Harris	O
+hip	B-ANAT
+score	O
+were	O
+observed	O
+in	O
+all	O
+cases	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+None	O
+required	O
+surgical	O
+intervention	O
+including	O
+hip	B-ANAT
+replacement	O
+.	O
+
+MRI	O
+showed	O
+a	O
+trend	O
+of	O
+reduction	O
+in	O
+bone	B-DISO
+marrow	I-DISO
+edema	I-DISO
+and	O
+the	O
+size	O
+of	O
+the	O
+lesion	O
+,	O
+but	O
+no	O
+changes	O
+in	O
+the	O
+stage	O
+of	O
+the	O
+lesion	O
+.	O
+
+TITLE	O
+:	O
+Fatal	O
+outcome	O
+after	O
+insufficient	O
+spine	B-COMP
+fixation	O
+for	O
+pyogenic	O
+thoracic	B-DISO
+spondylodiscitis	B-DISO
+:	O
+an	O
+imperative	O
+for	O
+360	O
+degrees	O
+fusion	O
+of	O
+the	O
+infected	O
+spine	O
+.	O
+
+Clinically	O
+,	O
+the	O
+patient	O
+showed	O
+a	O
+deteriorating	O
+spastic	B-DISO
+paraparesis	I-DISO
+of	O
+her	O
+lower	B-ANAT
+extremities	I-ANAT
+.	O
+
+Despite	O
+the	O
+successful	O
+salvage	O
+procedure	O
+,	O
+the	O
+patient	O
+deteriorated	O
+in	O
+the	O
+postoperative	O
+phase	O
+,	O
+when	O
+she	O
+developed	O
+multiple	O
+complications	O
+including	O
+pneumonia	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+bacterial	B-DISO
+meningitis	I-DISO
+,	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+,	O
+followed	O
+by	O
+septic	B-DISO
+shock	I-DISO
+with	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+a	O
+lethal	O
+outcome	O
+within	O
+two	O
+weeks	O
+after	O
+revision	O
+surgery	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+a	O
+previously	O
+unknown	O
+coronavirus	O
+infection	O
+,	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+demonstrated	O
+that	O
+fecally	O
+contaminated	O
+liquid	O
+droplets	O
+are	O
+a	O
+potential	O
+vehicle	O
+for	O
+the	O
+spread	O
+of	O
+a	O
+respiratory	O
+virus	B-SPEC
+to	O
+large	O
+numbers	O
+of	O
+people	O
+.	O
+
+ABSTRACT	O
+:	O
+Application	O
+of	O
+glucocorticoids	B-CHED
+in	O
+sepsis	B-DISO
+or	O
+severe	O
+infection	B-DISO
+is	O
+disputable	O
+in	O
+clinic	O
+.	O
+
+In	O
+this	O
+experiment	O
+,	O
+we	O
+studied	O
+the	O
+effect	O
+of	O
+dexamethasone	B-CHED
+on	O
+nitric	B-CHED
+oxide	I-CHED
+synthases	O
+and	O
+whether	O
+dexamethasone	B-CHED
+could	O
+attenuate	O
+endotoxin	O
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+SD	O
+rats	B-SPEC
+received	O
+5	O
+mg	O
+/	O
+kg	O
+lipopolisaccharide	O
+(	O
+LPS	B-DISO
+)	O
+injection	O
+.	O
+
+In	O
+conclusion	O
+,	O
+dexamethasone	B-CHED
+could	O
+effectively	O
+attenuate	O
+endotoxin	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+through	O
+inhibiting	O
+iNOS	B-PRGE
+expression	B-PROC
+and	O
+activation	O
+in	O
+the	O
+very	O
+early	O
+stage	O
+of	O
+ALI	O
+.	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+fragment	O
+expression	B-PROC
+and	O
+purification	O
+.	O
+
+TITLE	O
+:	O
+Thermostability	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+RNA	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+:	O
+experiments	O
+and	O
+numerical	O
+simulations	O
+.	O
+
+Histological	O
+examination	O
+of	O
+liver	B-ANAT
+samples	O
+showed	O
+tissue	B-ANAT
+damages	O
+but	O
+without	O
+significant	O
+differences	O
+between	O
+the	O
+animals	B-SPEC
+submitted	O
+to	O
+MHV	B-DISO
++	I-DISO
+CCl	I-DISO
+(	O
+4	O
+)	O
+and	O
+controls	O
+,	O
+which	O
+were	O
+either	O
+infected	O
+by	O
+MHV	B-SPEC
+without	O
+CCl	B-DISO
+(	O
+4	O
+),	O
+or	O
+poisoned	O
+by	O
+CCl	B-DISO
+(	O
+4	O
+)	O
+in	O
+the	O
+absence	O
+of	O
+MHV	B-SPEC
+infection	B-DISO
+.	O
+
+A	O
+recombinant	O
+adenovirus	B-DISO
+encoding	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+rAd	B-PRGE
+-	I-PRGE
+N	I-PRGE
+)	O
+was	O
+constructed	O
+.	O
+
+Other	O
+branches	O
+of	O
+the	O
+UPR	O
+pathways	B-PROC
+controlled	O
+by	O
+IRE1	B-PRGE
+and	O
+ATF6	B-PRGE
+proteins	I-PRGE
+,	O
+respectively	O
+,	O
+are	O
+not	O
+involved	O
+.	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+cytokine	O
+and	O
+chemokine	O
+gene	B-PROC
+polymorphisms	I-PROC
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+polymorphisms	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+,	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+,	O
+Mig	B-PRGE
+and	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+are	O
+not	O
+associated	O
+with	O
+SARS	B-PRGE
+susceptibility	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Differential	O
+stepwise	O
+evolution	B-PROC
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+functional	I-PRGE
+proteins	B-CHED
+in	O
+different	O
+host	B-COMP
+species	B-SPEC
+.	O
+
+These	O
+results	O
+support	O
+the	O
+hypothesis	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+originated	O
+from	O
+bats	B-SPEC
+and	O
+that	O
+the	O
+spill	O
+over	O
+into	O
+civets	B-SPEC
+and	O
+humans	B-SPEC
+were	O
+more	O
+recent	O
+events	O
+.	O
+
+A	O
+review	O
+of	O
+Hong	O
+Kong	O
+'	O
+s	O
+infectious	B-DISO
+disease	I-DISO
+legislation	O
+was	O
+conducted	O
+with	O
+a	O
+view	O
+to	O
+updating	O
+the	O
+legal	O
+framework	O
+for	O
+the	O
+prevention	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+in	O
+order	B-SPEC
+to	O
+strengthen	O
+the	O
+capacity	O
+of	O
+law	O
+to	O
+support	O
+strategy	O
+in	O
+the	O
+control	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+This	O
+previously	O
+healthy	O
+8	O
+-	O
+month	O
+-	O
+old	O
+boy	O
+presented	O
+with	O
+acute	O
+superior	O
+limb	B-DISO
+weakness	I-DISO
+,	O
+absent	B-DISO
+tendon	I-DISO
+reflexes	B-PROC
+,	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Spinal	O
+magnetic	O
+resonance	O
+imaging	O
+showed	O
+an	O
+extensive	O
+cervical	B-ANAT
+demyelinating	O
+lesion	O
+.	O
+
+Afterward	O
+,	O
+sural	B-ANAT
+nerve	I-ANAT
+biopsy	O
+showed	O
+a	O
+mild	O
+neuropathy	B-DISO
+,	O
+but	O
+muscle	B-ANAT
+biopsy	O
+revealed	O
+abnormalities	O
+compatible	O
+with	O
+severe	O
+critical	B-DISO
+illness	I-DISO
+myopathy	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+nsp1	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+a	O
+group	O
+2b	O
+CoV	O
+,	O
+suppresses	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+by	O
+promoting	O
+host	B-COMP
+mRNA	B-PROC
+degradation	I-PROC
+and	O
+translation	B-PROC
+inhibition	B-PROC
+.	O
+
+This	O
+commentary	O
+introduces	O
+the	O
+technique	O
+of	O
+network	O
+analysis	O
+as	O
+a	O
+framework	O
+for	O
+the	O
+following	O
+:	O
+(	O
+1	O
+)	O
+understanding	O
+how	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+move	B-PROC
+between	O
+hospitals	O
+,	O
+(	O
+2	O
+)	O
+defining	O
+the	O
+roles	O
+hospitals	O
+play	O
+in	O
+regional	O
+care	O
+delivery	O
+,	O
+and	O
+(	O
+3	O
+)	O
+suggesting	O
+systematic	O
+improvements	O
+that	O
+may	O
+benefit	O
+population	O
+health	O
+.	O
+
+Continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+CRRT	O
+)	O
+has	O
+become	O
+the	O
+preferred	O
+method	O
+of	O
+renal	B-ANAT
+support	O
+in	O
+these	O
+patients	O
+though	O
+there	O
+is	O
+limited	O
+data	O
+to	O
+support	O
+its	O
+safety	O
+.	O
+
+Furthermore	O
+,	O
+exacerbations	O
+of	O
+cerebral	B-DISO
+edema	I-DISO
+have	O
+been	O
+reported	O
+.	O
+
+Fifteen	O
+consecutive	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+previously	O
+unresponsive	O
+to	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+adjustment	O
+,	O
+were	O
+treated	O
+with	O
+PPV	B-CHED
+.	O
+
+3	O
+vs	O
+37	O
++/-	O
+6	O
+,	O
+P	O
+<	O
+.	O
+0001	O
+)	O
+with	O
+extended	O
+PPV	B-CHED
+.	O
+
+Little	O
+is	O
+written	O
+in	O
+the	O
+Emergency	B-DISO
+Medicine	B-CHED
+literature	O
+regarding	O
+this	O
+clinical	O
+entity	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+a	O
+brief	O
+review	O
+of	O
+BACM	O
+from	O
+the	O
+current	O
+literature	O
+is	O
+provided	O
+,	O
+as	O
+well	O
+as	O
+tools	O
+to	O
+aid	O
+in	O
+differentiating	O
+it	O
+from	O
+more	O
+severe	O
+but	O
+similar	O
+disorders	O
+such	O
+as	O
+rhabdomyolysis	B-DISO
+and	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+.	O
+
+Corticosteroid	B-CHED
+and	O
+calcitonin	B-PRGE
+were	O
+prescribed	O
+to	O
+reduce	O
+the	O
+plasma	B-ANAT
+calcium	B-CHED
+.	O
+
+TITLE	O
+:	O
+Helminthic	O
+eosinophilic	B-DISO
+meningitis	I-DISO
+:	O
+emerging	O
+zoonotic	O
+diseases	O
+in	O
+the	O
+South	O
+.	O
+
+Baylisascariasis	O
+,	O
+a	O
+raccoon	B-SPEC
+zoonosis	B-DISO
+,	O
+caused	O
+by	O
+the	O
+raccoon	B-SPEC
+roundworm	B-DISO
+,	O
+Baylisascaris	B-SPEC
+procyonis	I-SPEC
+,	O
+has	O
+extended	O
+its	O
+US	O
+distribution	O
+range	O
+from	O
+suburban	O
+neighborhoods	O
+in	O
+the	O
+northern	O
+US	O
+to	O
+the	O
+Southeast	O
+and	O
+West	O
+Coast	O
+since	O
+the	O
+1980s	O
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+poses	O
+a	O
+threat	O
+to	O
+the	O
+blood	B-PROC
+supply	I-PROC
+but	O
+has	O
+never	O
+been	O
+transmitted	B-DISO
+in	O
+a	O
+transfusion	O
+.	O
+
+Prions	O
+also	O
+have	O
+been	O
+transmitted	B-DISO
+by	O
+a	O
+blood	B-ANAT
+transfusion	O
+.	O
+
+After	O
+adjusting	O
+for	O
+age	O
+,	O
+gender	O
+,	O
+marital	O
+status	O
+,	O
+educational	O
+level	O
+,	O
+professional	O
+title	O
+,	O
+and	O
+the	O
+department	O
+in	O
+which	O
+an	O
+individual	O
+worked	O
+,	O
+the	O
+results	O
+of	O
+a	O
+multivariate	O
+logistic	O
+regression	O
+analysis	O
+indicated	O
+that	O
+incidence	O
+of	O
+SARS	O
+among	O
+HCWs	O
+was	O
+significantly	O
+and	O
+positively	O
+associated	O
+with	O
+:	O
+performing	O
+tracheal	O
+intubations	O
+for	O
+SARS	B-DISO
+patients	O
+,	O
+methods	O
+used	O
+for	O
+air	B-CHED
+ventilation	O
+in	O
+wards	O
+,	O
+avoiding	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+interaction	O
+with	O
+SARS	B-DISO
+patients	O
+,	O
+the	O
+number	O
+of	O
+pairs	O
+of	O
+gloves	O
+worn	O
+by	O
+HCWs	O
+,	O
+and	O
+caring	O
+for	O
+serious	O
+SARS	B-DISO
+cases	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Some	O
+measures	O
+,	O
+particularly	O
+good	O
+air	B-CHED
+ventilation	O
+in	O
+SARS	B-DISO
+wards	O
+,	O
+may	O
+be	O
+effective	O
+in	O
+minimizing	O
+or	O
+preventing	O
+SARS	B-DISO
+transmission	O
+among	O
+HCWs	O
+in	O
+hospitals	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+showed	O
+co	O
+-	O
+purification	O
+of	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+from	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+with	O
+actin	B-PRGE
+.	O
+
+Introduction	O
+of	O
+the	O
+A159	O
+-	O
+K160	O
+mutation	O
+into	O
+an	O
+infectious	B-DISO
+IBV	B-SPEC
+clone	O
+system	O
+blocks	O
+the	O
+infectivity	O
+of	O
+the	O
+clone	O
+,	O
+although	O
+viral	O
+RNA	B-PROC
+replication	I-PROC
+and	O
+subgenomic	O
+mRNA	B-PROC
+transcription	B-PROC
+were	O
+actively	O
+detected	O
+.	O
+
+This	O
+study	O
+reveals	O
+an	O
+essential	O
+function	O
+of	O
+actin	B-PRGE
+in	O
+the	O
+replication	O
+cycle	O
+of	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Timely	O
+identification	O
+of	O
+optimal	O
+control	O
+strategies	O
+for	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+In	O
+future	O
+outbreaks	O
+of	O
+new	O
+human	B-SPEC
+diseases	O
+transmitted	B-DISO
+via	O
+close	O
+interpersonal	O
+contact	O
+,	O
+it	O
+should	O
+be	O
+possible	O
+to	O
+identify	O
+the	O
+optimal	O
+intervention	O
+early	O
+enough	O
+to	O
+facilitate	O
+effective	O
+decision	O
+-	O
+making	O
+.	O
+
+We	O
+conclude	O
+that	O
+transduction	B-PROC
+of	O
+antigen	B-ANAT
+-	I-ANAT
+presenting	I-ANAT
+cells	B-COMP
+within	O
+the	O
+CNS	B-CHED
+is	O
+a	O
+likely	O
+cause	O
+of	O
+this	O
+response	O
+and	O
+that	O
+caution	O
+is	O
+warranted	O
+when	O
+foreign	O
+transgenes	O
+are	O
+used	O
+as	O
+reporters	O
+in	O
+gene	O
+therapy	O
+studies	O
+with	O
+vectors	O
+with	O
+broader	O
+tropism	B-PROC
+than	O
+AAV2	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+26	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+developed	O
+acute	B-DISO
+disseminated	I-DISO
+encephalomyelitis	I-DISO
+(	O
+ADEM	O
+)	O
+after	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+infection	B-DISO
+,	O
+and	O
+was	O
+admitted	O
+after	O
+developing	O
+disturbed	O
+consciousness	O
+.	O
+
+ADEM	O
+following	O
+mixed	B-DISO
+infection	I-DISO
+with	O
+measles	B-PATH
+and	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+is	O
+rare	O
+,	O
+and	O
+it	O
+is	O
+not	O
+clear	O
+whether	O
+an	O
+additional	O
+infection	B-DISO
+with	O
+measles	B-PATH
+influenced	O
+the	O
+onset	O
+of	O
+ADEM	O
+after	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+infection	B-DISO
+.	O
+
+Moreover	O
+,	O
+such	O
+infection	B-DISO
+was	O
+accompanied	O
+by	O
+a	O
+more	O
+profound	O
+immune	B-DISO
+suppression	I-DISO
+in	O
+the	O
+former	O
+,	O
+as	O
+evidenced	O
+by	O
+the	O
+extensive	O
+loss	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+compromised	O
+responses	O
+to	O
+concanavalin	O
+A	O
+stimulation	O
+,	O
+and	O
+absence	O
+of	O
+inflammatory	O
+infiltrates	B-DISO
+within	O
+the	O
+brain	B-ANAT
+.	O
+
+We	O
+also	O
+found	O
+that	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+partially	O
+effective	O
+in	O
+attenuating	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+lethality	O
+-	O
+resistant	O
+AC22	O
+mice	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+the	O
+bacterially	O
+expressed	B-PROC
+nsp11	O
+proteins	O
+of	O
+two	O
+arteriviruses	B-SPEC
+,	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+and	O
+porcine	B-SPEC
+respiratory	I-SPEC
+and	I-SPEC
+reproductive	I-SPEC
+syndrome	B-DISO
+virus	I-SPEC
+,	O
+possess	B-DISO
+pyrimidine	B-CHED
+-	O
+specific	O
+endoribonuclease	B-FUNC
+activity	I-FUNC
+.	O
+
+RNA	O
+cleavage	B-PROC
+was	O
+independent	O
+of	O
+divalent	O
+cations	B-CHED
+in	O
+vitro	O
+and	O
+was	O
+greatly	O
+reduced	O
+by	O
+replacement	O
+of	O
+residues	O
+previously	O
+implicated	O
+in	O
+catalysis	O
+.	O
+
+Our	O
+data	O
+provide	O
+the	O
+first	O
+biochemical	O
+evidence	O
+of	O
+endoribonuclease	B-FUNC
+activity	I-FUNC
+associated	O
+with	O
+arterivirus	B-SPEC
+nsp11	O
+and	O
+support	O
+the	O
+conclusion	O
+that	O
+this	O
+remarkable	O
+RNA	O
+-	O
+processing	O
+enzyme	O
+,	O
+whose	O
+substrate	O
+in	O
+the	O
+infected	O
+cell	B-COMP
+remains	O
+to	O
+be	O
+identified	O
+,	O
+distinguishes	O
+nidoviruses	B-SPEC
+from	O
+all	O
+other	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Recombinant	B-PRGE
+Ov	I-PRGE
+-	I-PRGE
+ASP	I-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+a	O
+Th1	O
+-	O
+biased	O
+protein	B-CHED
+adjuvant	B-CHED
+derived	O
+from	O
+the	O
+helminth	O
+Onchocerca	B-SPEC
+volvulus	B-DISO
+,	O
+can	O
+directly	O
+bind	B-FUNC
+and	O
+activate	O
+antigen	B-ANAT
+-	I-ANAT
+presenting	I-ANAT
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+Prokaryotic	O
+expression	B-PROC
+of	O
+S2	O
+extracellular	B-COMP
+domain	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+and	O
+its	O
+fusion	O
+with	O
+Hela	O
+cell	O
+membrane	O
+].	O
+
+When	O
+incubated	O
+with	O
+Hela	B-ANAT
+cells	I-ANAT
+,	O
+the	O
+purified	O
+protein	B-CHED
+could	O
+not	O
+internalize	O
+through	O
+membrane	B-COMP
+fusion	I-PROC
+.	O
+
+The	O
+expression	O
+plasmid	O
+containing	O
+S2ED	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+Cov	I-PRGE
+S	I-PRGE
+protein	B-CHED
+and	O
+EGFP	O
+sequence	O
+is	O
+constructed	O
+successfully	O
+.	O
+
+Isolation	O
+of	O
+Fusobacterium	B-SPEC
+necrophorum	I-SPEC
+from	O
+the	O
+blood	B-ANAT
+culture	O
+and	O
+the	O
+contrast	O
+-	O
+enhanced	O
+scan	O
+revealed	O
+thrombosis	B-DISO
+and	O
+thrombophlebitis	B-DISO
+in	O
+the	O
+left	B-ANAT
+internal	I-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+.	O
+
+Considerable	O
+progress	O
+has	O
+been	O
+made	O
+since	O
+SARS	B-DISO
+in	O
+addressing	O
+these	O
+limitations	O
+,	O
+including	O
+the	O
+creation	O
+of	O
+the	O
+new	O
+Public	O
+Health	O
+Agency	O
+of	O
+Canada	O
+.	O
+
+The	O
+RT	O
+-	O
+PCR	O
+tests	O
+were	O
+negative	O
+to	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+/	O
+B	O
+,	O
+adenovirus	B-DISO
+,	O
+RSV	B-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+Nipah	B-SPEC
+virus	I-SPEC
+and	O
+Legionella	B-SPEC
+.	O
+
+Blood	B-ANAT
+culture	O
+was	O
+negative	O
+in	O
+all	O
+except	O
+patient	O
+no	O
+.	O
+1	O
+,	O
+who	O
+was	O
+found	O
+positive	O
+for	O
+coagulase	O
+-	O
+negative	O
+staphylococci	O
+.	O
+
+TITLE	O
+:	O
+Multiple	O
+-	O
+type	O
+human	B-DISO
+papillomavirus	I-DISO
+infection	I-DISO
+in	O
+male	O
+anogenital	O
+sites	O
+:	O
+prevalence	O
+and	O
+associated	O
+factors	O
+.	O
+
+Detection	O
+of	O
+multiple	O
+HPV	O
+types	O
+in	O
+this	O
+study	O
+of	O
+primarily	O
+asymptomatic	O
+men	O
+was	O
+common	O
+,	O
+particularly	O
+at	O
+external	O
+genital	B-ANAT
+sites	O
+.	O
+
+ABSTRACT	O
+:	O
+Surfactant	B-CHED
+treatment	O
+in	O
+preterm	O
+infants	O
+and	O
+term	O
+newborns	O
+with	O
+ARDS	B-DISO
+-	O
+like	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+has	O
+become	O
+part	O
+of	O
+an	O
+individualised	O
+treatment	O
+strategy	O
+in	O
+many	O
+intensive	O
+care	O
+units	O
+around	O
+the	O
+world	O
+.	O
+
+The	O
+structure	O
+of	O
+the	O
+M	O
+(	O
+pro	B-CHED
+)-	O
+C	O
+monomer	O
+is	O
+almost	O
+identical	O
+to	O
+that	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+in	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+M	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+).	I-PRGE
+
+Introduction	O
+of	O
+a	O
+furin	B-PRGE
+cleavage	B-PROC
+site	O
+at	O
+the	O
+S2	O
+'	O
+position	O
+allowed	O
+trypsin	B-PRGE
+-	O
+independent	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+,	O
+which	O
+was	O
+strongly	O
+increased	O
+by	O
+the	O
+presence	O
+of	O
+a	O
+second	O
+furin	B-ENZY
+cleavage	B-PROC
+site	O
+at	O
+the	O
+S1	O
+-	O
+S2	O
+position	O
+.	O
+
+Both	O
+the	O
+transmembrane	B-COMP
+domains	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+are	O
+required	O
+to	O
+interact	O
+with	O
+M	B-PRGE
+protein	I-PRGE
+,	O
+while	O
+either	O
+of	O
+the	O
+hydrophilic	O
+regions	O
+(	O
+a	O
+.	O
+a	O
+.	O
+
+These	O
+observations	O
+could	O
+explain	O
+the	O
+failure	O
+of	O
+the	O
+Massachusetts	O
+serotype	O
+vaccination	O
+programmes	O
+to	O
+control	O
+IBV	B-SPEC
+in	O
+these	O
+flocks	O
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+shedding	I-DISO
+and	O
+serum	B-COMP
+antibody	B-PROC
+responses	I-PROC
+during	O
+experimental	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+infections	I-DISO
+in	O
+young	O
+turkey	O
+poults	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+course	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+young	O
+turkey	B-SPEC
+poults	O
+was	O
+examined	O
+using	O
+a	O
+field	O
+isolate	O
+(	O
+TCoV	B-SPEC
+-	O
+MG10	O
+)	O
+from	O
+a	O
+diarrhoeal	B-DISO
+disease	I-DISO
+outbreak	O
+on	O
+a	O
+commercial	O
+turkey	B-SPEC
+farm	O
+in	O
+Ontario	O
+,	O
+Canada	O
+.	O
+
+Two	O
+-	O
+day	O
+-	O
+old	O
+and	O
+28	O
+-	O
+day	O
+-	O
+old	O
+poults	O
+were	O
+inoculated	O
+orally	B-ANAT
+with	O
+TCoV	O
+-	O
+MG10	O
+to	O
+examine	O
+the	O
+effect	O
+of	O
+age	O
+on	O
+viral	B-DISO
+shedding	I-DISO
+and	O
+serum	B-COMP
+antibody	B-PROC
+responses	I-PROC
+to	O
+the	O
+virus	B-SPEC
+.	O
+
+The	O
+pattern	O
+of	O
+cloacal	B-ANAT
+TCoV	O
+shedding	O
+was	O
+examined	O
+by	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+amplification	B-DISO
+of	O
+the	O
+nucleocapsid	B-COMP
+gene	O
+fragment	O
+.	O
+
+TCoV	B-PRGE
+serum	I-PRGE
+antibody	B-PROC
+responses	I-PROC
+were	O
+assessed	O
+with	O
+two	O
+recently	O
+developed	O
+TCoV	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assays	O
+that	O
+used	O
+TCoV	O
+nucleocapsid	B-COMP
+and	O
+S1	O
+polypeptides	B-CHED
+as	O
+coating	O
+antigens	B-CHED
+.	O
+
+Within	O
+S	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+mediates	O
+the	O
+interaction	O
+with	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+host	B-COMP
+cell	I-COMP
+receptor	I-PRGE
+.	O
+
+Reported	O
+here	O
+is	O
+the	O
+X	O
+-	O
+ray	B-SPEC
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+RBD	O
+in	O
+complex	O
+with	O
+the	O
+Fab	B-PRGE
+of	O
+a	O
+neutralizing	O
+mouse	B-PRGE
+monoclonal	I-PRGE
+antibody	B-COMP
+,	O
+F26G19	O
+,	O
+elicited	O
+by	O
+immunization	O
+with	O
+chemically	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+RBD	O
+-	O
+F26G19	O
+Fab	B-PRGE
+complex	I-PRGE
+represents	O
+the	O
+first	O
+example	O
+of	O
+the	O
+structural	O
+characterization	O
+of	O
+an	O
+antibody	B-COMP
+elicited	O
+by	O
+an	O
+immune	B-PROC
+response	I-PROC
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+or	O
+any	O
+fragment	O
+of	O
+it	O
+.	O
+
+TITLE	O
+:	O
+Minimally	O
+cultured	O
+bone	B-ANAT
+marrow	I-ANAT
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+ameliorate	O
+fibrotic	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Multiple	O
+organ	O
+damage	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+is	O
+common	O
+;	O
+however	O
+,	O
+the	O
+pathogenesis	B-DISO
+remains	O
+controversial	O
+.	O
+
+Abundant	O
+ACE2	O
+immunostaining	O
+was	O
+found	O
+in	O
+lung	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+and	O
+islets	O
+of	O
+pancreas	B-ANAT
+,	O
+but	O
+not	O
+in	O
+hepatocytes	B-ANAT
+.	O
+
+MHV	B-SPEC
+-	O
+3	O
+infected	O
+CD4	B-PRGE
+-	O
+CD8	B-PRGE
+-	O
+T	B-ANAT
+cells	I-ANAT
+showed	O
+significant	O
+cytotoxic	O
+effect	O
+on	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+,	O
+but	O
+not	O
+on	O
+infected	O
+hepatocytes	B-ANAT
+or	O
+MCMV	B-SPEC
+infected	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+Jordanian	O
+chickens	B-SPEC
+:	O
+seroprevalence	O
+and	O
+detection	O
+.	O
+
+In	O
+addition	O
+,	O
+51	O
+commercial	O
+chicken	B-SPEC
+flocks	O
+(	O
+25	O
+broilers	O
+,	O
+15	O
+layers	B-ANAT
+,	O
+and	O
+11	O
+broiler	O
+breeders	O
+)	O
+suffering	B-DISO
+from	O
+respiratory	B-DISO
+disease	I-DISO
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+IBV	B-SPEC
+,	O
+using	O
+the	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+IL	B-PRGE
+-	I-PRGE
+12p40	I-PRGE
+mRNA	I-PRGE
+rapidly	O
+increases	O
+after	O
+neurotropic	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+-	O
+producing	O
+cells	B-COMP
+never	O
+exceeded	O
+background	O
+levels	O
+,	O
+supporting	O
+a	O
+redundant	O
+role	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+23	I-FUNC
+in	O
+pathogenesis	B-DISO
+.	O
+
+Reduced	O
+morbidity	O
+in	O
+infected	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+deficient	O
+mice	B-SPEC
+was	O
+also	O
+not	O
+associated	O
+with	O
+altered	O
+recruitment	B-DISO
+or	O
+composition	O
+of	O
+inflammatory	B-ANAT
+cells	I-ANAT
+.	O
+
+However	O
+,	O
+gamma	B-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+levels	O
+and	O
+virus	B-SPEC
+-	O
+specific	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+secreting	I-PRGE
+CD4	I-PRGE
+and	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+were	O
+all	O
+reduced	O
+in	O
+the	O
+central	O
+nervous	O
+systems	O
+(	O
+CNS	B-CHED
+)	O
+of	O
+infected	O
+p35	B-COMP
+(-/-)	O
+mice	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+although	O
+transforming	B-PRGE
+growth	I-PRGE
+factor	I-PRGE
+beta	I-PRGE
+mRNA	B-CHED
+was	O
+not	O
+affected	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+was	O
+increased	O
+in	O
+the	O
+CNS	B-CHED
+in	O
+the	O
+absence	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+.	O
+
+Most	O
+neonates	O
+receiving	O
+ECMO	O
+suffer	B-DISO
+from	O
+meconium	B-DISO
+aspiration	I-DISO
+syndrome	I-DISO
+(	O
+MAS	B-COMP
+),	O
+congenital	B-DISO
+diaphragmatic	I-DISO
+hernia	I-DISO
+(	O
+CDH	B-DISO
+),	O
+sepsis	B-DISO
+or	O
+persistent	B-DISO
+pulmonary	I-DISO
+hypertension	I-DISO
+(	O
+PPH	B-FUNC
+).	O
+
+In	O
+a	O
+prospective	O
+population	O
+-	O
+based	O
+study	O
+(	O
+n	O
+=	O
+224	O
+)	O
+174	O
+five	O
+-	O
+year	O
+-	O
+old	O
+survivors	O
+born	O
+between	O
+1993	O
+and	O
+2000	O
+and	O
+treated	O
+in	O
+the	O
+two	O
+designated	O
+ECMO	O
+centres	O
+in	O
+the	O
+Netherlands	O
+(	O
+Radboud	O
+University	O
+Medical	O
+Centre	O
+Nijmegen	O
+and	O
+Sophia	O
+Children	O
+'	O
+s	O
+Hospital	O
+,	O
+Erasmus	O
+MC	O
+-	O
+University	O
+Medical	O
+Center	O
+Rotterdam	O
+)	O
+were	O
+invited	O
+to	O
+undergo	O
+follow	O
+-	O
+up	O
+assessment	O
+including	O
+a	O
+paediatric	O
+assessment	O
+,	O
+the	O
+movement	O
+assessment	O
+battery	O
+for	O
+children	O
+(	O
+MABC	O
+),	O
+the	O
+revised	O
+Amsterdam	O
+intelligence	O
+test	O
+(	O
+RAKIT	O
+)	O
+and	O
+the	O
+child	O
+behaviour	B-PROC
+checklist	O
+(	O
+CBCL	O
+).	O
+
+Chi	B-CHED
+-	O
+squared	O
+tests	O
+showed	O
+adverse	O
+outcome	O
+in	O
+MABC	O
+scores	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+compared	O
+with	O
+the	O
+reference	O
+population	O
+in	O
+children	O
+with	O
+CDH	B-DISO
+,	O
+sepsis	B-DISO
+and	O
+PPH	B-FUNC
+,	O
+but	O
+not	O
+in	O
+children	O
+with	O
+MAS	B-COMP
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+diversity	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+Feline	B-SPEC
+Coronavirus	B-SPEC
+sequences	O
+from	O
+Portugal	O
+.	O
+
+Results	O
+of	O
+the	O
+recombinant	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+-	O
+based	O
+ELISA	O
+were	O
+validated	O
+with	O
+Western	O
+blot	O
+,	O
+immunofluorescence	O
+analysis	O
+and	O
+flow	O
+cytometry	O
+.	O
+
+We	O
+showed	O
+that	O
+virus	B-SPEC
+-	O
+infected	O
+macrophages	B-ANAT
+overproduce	O
+neutrophil	O
+survival	O
+factors	O
+,	O
+and	O
+these	O
+factors	O
+act	O
+on	O
+neutrophils	B-ANAT
+and	O
+up	O
+-	O
+regulate	O
+their	O
+survival	O
+.	O
+
+After	O
+treatment	O
+of	O
+A549	O
+cells	B-COMP
+with	O
+EtP	B-CHED
+,	O
+a	O
+substantial	O
+reduction	O
+in	O
+the	O
+cytokine	O
+-	O
+induced	O
+adhesion	B-DISO
+of	O
+neutrophils	B-ANAT
+to	O
+monolayers	O
+was	O
+noted	O
+,	O
+whereas	O
+sodium	B-PRGE
+pyruvate	I-PRGE
+(	I-PRGE
+NaP	B-PROC
+)	I-PRGE
+conferred	O
+no	O
+reduction	O
+.	O
+
+This	O
+suggested	O
+that	O
+genetic	B-PROC
+recombination	I-PROC
+between	O
+the	O
+virus	B-SPEC
+strains	O
+classified	O
+into	O
+different	O
+genetic	O
+groups	O
+had	O
+occurred	O
+in	O
+poultry	O
+,	O
+and	O
+that	O
+recombinant	O
+viruses	B-SPEC
+might	O
+be	O
+epidemic	O
+in	O
+Japan	O
+.	O
+
+Miliary	B-DISO
+tuberculosis	I-DISO
+should	O
+be	O
+kept	O
+in	O
+mind	O
+as	O
+a	O
+cause	O
+of	O
+ARDS	B-DISO
+.	O
+
+The	O
+reduction	O
+in	O
+absolute	O
+risk	O
+of	O
+death	B-PROC
+was	O
+approximately	O
+4	O
+%.	O
+
+Preliminary	O
+results	O
+from	O
+recent	O
+studies	O
+suggest	O
+these	O
+drugs	O
+up	O
+-	O
+regulate	O
+the	O
+production	O
+of	O
+interferons	O
+(-	O
+alpha	O
+,	O
+-	O
+beta	O
+,	O
+and	O
+-	O
+gamma	O
+),	O
+and	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+but	O
+downregulate	O
+some	O
+proinflammatory	O
+cytokines	O
+including	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+.	O
+
+The	O
+clinical	O
+safety	O
+of	O
+these	O
+drugs	O
+and	O
+their	O
+efficacy	O
+in	O
+pre	O
+-	O
+clinical	O
+studies	O
+may	O
+provide	O
+sufficient	O
+justification	O
+for	O
+regulatory	O
+agencies	O
+to	O
+consider	O
+their	O
+fast	B-FUNC
+track	O
+development	B-PROC
+for	O
+use	O
+in	O
+future	O
+outbreaks	O
+of	O
+pandemic	O
+influenza	B-DISO
+or	O
+of	O
+other	O
+emerging	O
+respiratory	O
+pathogens	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+assess	O
+the	O
+role	O
+of	O
+activated	O
+neutrophils	B-ANAT
+,	O
+pro	B-CHED
+-	O
+and	O
+anti	O
+-	O
+inflammatory	O
+cytokines	O
+and	O
+adhesion	B-DISO
+molecules	O
+at	O
+the	O
+onset	O
+and	O
+development	B-PROC
+of	O
+respiratory	B-DISO
+complications	I-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+we	O
+measured	O
+the	O
+serum	B-COMP
+levels	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+(	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+beta	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+and	O
+anti	O
+-	O
+inflammatory	O
+(	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+ra	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+)	O
+cytokines	O
+in	O
+51	O
+AP	O
+patients	O
+who	O
+had	O
+been	O
+diagnosed	O
+with	O
+pancreatitis	B-DISO
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+with	O
+and	O
+without	O
+the	O
+development	B-PROC
+of	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Increase	O
+in	O
+the	O
+concentrations	O
+of	O
+adhesion	B-DISO
+molecules	O
+preceded	O
+the	O
+development	B-PROC
+of	O
+pulmonary	B-DISO
+infiltration	I-DISO
+with	O
+respiratory	B-DISO
+failure	I-DISO
+symptoms	O
+,	O
+which	O
+provoked	O
+endothelial	B-DISO
+dysfunction	I-DISO
+and	O
+determined	O
+the	O
+capillary	B-ANAT
+surface	O
+permeability	O
+for	O
+neutrophils	B-ANAT
+and	O
+monocytes	B-ANAT
+.	O
+
+Notably	O
+,	O
+nsp1	B-PRGE
+specifically	O
+binds	B-FUNC
+SLIII	O
+and	O
+its	O
+flanking	O
+sequences	O
+in	O
+the	O
+5	O
+'	O
+UTR	O
+with	O
+approximately	O
+2	O
+.	O
+5	O
+muM	B-SPEC
+affinity	O
+.	O
+
+Additionally	O
+,	O
+under	O
+conditions	O
+enabling	O
+expression	B-PROC
+of	O
+nsp1	B-PRGE
+from	O
+DI	O
+RNA	O
+-	O
+encoded	O
+subgenomic	O
+mRNA	B-CHED
+,	O
+DI	B-PRGE
+RNA	I-PRGE
+levels	O
+were	O
+greatly	O
+reduced	O
+,	O
+but	O
+there	O
+was	O
+only	O
+a	O
+slight	O
+transient	O
+reduction	O
+in	O
+viral	O
+RNA	O
+levels	O
+.	O
+
+ABSTRACT	O
+:	O
+Carcinoembryonic	O
+antigen	O
+-	O
+related	O
+cell	B-PROC
+adhesion	B-DISO
+molecule	O
+1	O
+(	O
+CEACAM1	B-PRGE
+)	O
+regulates	O
+intestinal	B-ANAT
+immunological	O
+homeostasis	B-PROC
+.	O
+
+However	O
+,	O
+precise	O
+expression	B-PROC
+patterns	O
+of	O
+CEACAM1	B-PRGE
+isoforms	I-PRGE
+remain	O
+poorly	O
+understood	O
+in	O
+the	O
+intestinal	B-ANAT
+epithelia	O
+.	O
+
+Among	O
+them	O
+,	O
+CEACAM1	O
+(	O
+a	O
+)-	O
+4C1	O
+was	O
+the	O
+major	O
+secreted	B-PROC
+isoform	O
+in	O
+vivo	O
+due	O
+to	O
+the	O
+soluble	O
+/	O
+secreted	B-PROC
+CEACAM1	O
+(	O
+a	O
+)	O
+with	O
+a	O
+frameshift	B-DISO
+sequence	O
+in	O
+the	O
+C	O
+-	O
+terminus	O
+,	O
+specific	O
+for	O
+CEACAM1	O
+(	O
+a	O
+)-	O
+2C1	O
+and	O
+-	O
+4C1	O
+.	O
+
+TITLE	O
+:	O
+Translational	B-PROC
+control	O
+of	O
+the	O
+subgenomic	O
+RNAs	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+focus	O
+on	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLP	B-PRGE
+),	O
+which	O
+engages	O
+and	O
+antagonizes	O
+the	O
+IFN	B-PRGE
+induction	O
+and	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+signaling	B-PROC
+pathways	B-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+SR	O
+-	O
+rich	O
+motif	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+is	O
+important	O
+for	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+mutated	O
+infectious	B-DISO
+clone	O
+showed	O
+reduced	O
+level	O
+of	O
+genome	O
+transcription	B-PROC
+and	O
+significantly	O
+reduced	O
+levels	O
+of	O
+the	O
+infectious	B-DISO
+virions	B-COMP
+.	O
+
+The	O
+best	O
+docking	B-PROC
+score	O
+and	O
+binding	B-FUNC
+energy	O
+for	O
+6MP	O
+and	O
+6TG	O
+is	O
+against	O
+ubiquitin	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+protease	I-PRGE
+(	I-PRGE
+USP	B-FUNC
+)	I-PRGE
+14	I-PRGE
+,	O
+suggesting	O
+that	O
+6MP	O
+and	O
+6TG	O
+are	O
+potential	O
+inhibitors	B-CHED
+of	O
+USP14	B-PRGE
+.	O
+
+The	O
+data	O
+of	O
+the	O
+patient	O
+infected	O
+by	O
+the	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+admitted	O
+to	O
+People	O
+'	O
+s	O
+Hospital	O
+of	O
+Guizhou	O
+Province	O
+on	O
+January	O
+15	O
+,	O
+2009	O
+,	O
+were	O
+analyzed	O
+and	O
+summarized	O
+.	O
+
+The	O
+patient	O
+,	O
+a	O
+29	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+,	O
+had	O
+been	O
+healthy	O
+in	O
+the	O
+past	O
+,	O
+but	O
+had	O
+exposed	O
+to	O
+the	O
+environment	O
+of	O
+bird	B-DISO
+flu	I-DISO
+before	O
+illness	O
+.	O
+
+The	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+improved	O
+day	O
+by	O
+day	O
+without	O
+developing	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Furthermore	O
+,	O
+this	O
+approach	O
+determines	O
+the	O
+subcellular	O
+localization	B-PROC
+of	O
+the	O
+recombinant	O
+protein	B-CHED
+in	O
+plant	B-SPEC
+cells	B-COMP
+,	O
+providing	O
+information	O
+on	O
+optimal	O
+subcellular	O
+targeting	B-PROC
+for	O
+production	O
+in	O
+plant	B-SPEC
+bioreactors	O
+.	O
+
+Two	O
+foldable	O
+fragments	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+were	O
+identified	O
+,	O
+which	O
+coincide	O
+with	O
+various	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+peptides	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+1	O
+-	O
+year	O
+-	O
+old	O
+child	O
+born	O
+with	O
+agenesis	B-DISO
+of	O
+the	O
+right	B-ANAT
+lung	I-ANAT
+who	O
+sustained	O
+an	O
+episode	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+related	O
+to	O
+a	O
+postpneumonectomy	O
+-	O
+like	O
+syndrome	B-DISO
+,	O
+with	O
+severe	O
+mediastinal	B-ANAT
+shift	O
+and	O
+subsequent	O
+stretching	O
+and	O
+stenosis	B-DISO
+of	O
+the	O
+left	B-ANAT
+main	I-ANAT
+bronchus	I-ANAT
+.	O
+
+Analysis	O
+of	O
+virus	B-SPEC
+-	O
+susceptible	O
+target	B-ANAT
+cells	I-ANAT
+in	O
+vivo	O
+revealed	O
+that	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+expression	B-PROC
+was	O
+regulated	O
+in	O
+a	O
+cell	B-COMP
+type	I-COMP
+-	O
+dependent	O
+manner	O
+.	O
+
+Depending	O
+on	O
+the	O
+localization	B-PROC
+and	O
+the	O
+size	O
+of	O
+the	O
+mediastinal	B-ANAT
+tumour	B-DISO
+,	O
+the	O
+clinical	O
+presentation	O
+is	O
+variable	O
+ranging	O
+from	O
+a	O
+complete	O
+lack	O
+of	O
+symptoms	O
+to	O
+severe	O
+cardiorespiratory	O
+problems	O
+.	O
+
+We	O
+have	O
+found	O
+it	O
+helpful	O
+to	O
+assign	O
+'	O
+severity	O
+grade	O
+'	O
+(	O
+using	O
+a	O
+three	O
+-	O
+grade	O
+clinical	O
+classification	O
+scale	O
+:	O
+'	O
+safe	O
+',	O
+'	O
+uncertain	O
+',	O
+'	O
+unsafe	O
+'),	O
+whereby	O
+each	O
+stage	O
+triggers	O
+appropriate	O
+action	O
+in	O
+terms	O
+of	O
+staffing	O
+and	O
+apparatus	B-ANAT
+,	O
+such	O
+as	O
+the	O
+provision	O
+of	O
+alternatives	O
+for	O
+airway	B-ANAT
+management	O
+,	O
+cardiopulmonary	B-ANAT
+bypass	O
+and	O
+additional	O
+specialists	O
+.	O
+
+Tumour	B-DISO
+compression	I-DISO
+on	O
+the	O
+airways	O
+or	O
+the	O
+great	B-ANAT
+vessels	I-ANAT
+may	O
+create	O
+a	O
+critical	O
+respiratory	O
+and	O
+/	O
+or	O
+haemodynamic	O
+situation	O
+,	O
+and	O
+therefore	O
+the	O
+standard	O
+of	O
+intraoperative	O
+management	O
+includes	O
+induction	O
+of	O
+anaesthesia	B-DISO
+in	O
+the	O
+operating	O
+theatre	O
+on	O
+an	O
+adjustable	O
+surgical	O
+table	O
+,	O
+the	O
+use	O
+of	O
+short	O
+-	O
+acting	O
+anaesthetics	B-CHED
+,	O
+avoidance	O
+of	O
+muscle	B-CHED
+relaxants	I-CHED
+and	O
+maintenance	O
+of	O
+spontaneous	O
+respiration	B-PROC
+.	O
+
+In	O
+the	O
+case	O
+of	O
+patients	O
+classified	O
+as	O
+'	O
+safe	O
+'	O
+or	O
+'	O
+uncertain	O
+',	O
+a	O
+preoperative	O
+consensus	O
+with	O
+the	O
+surgeons	O
+should	O
+be	O
+reached	O
+as	O
+to	O
+the	O
+anaesthetic	B-CHED
+approach	O
+and	O
+the	O
+management	O
+of	O
+possible	O
+complications	O
+.	O
+
+He	O
+had	O
+been	O
+known	O
+to	O
+have	O
+ingested	O
+2	O
+ml	O
+of	O
+pure	B-FUNC
+GBL	O
+every	O
+half	O
+an	O
+hour	O
+.	O
+
+The	O
+nsp6	O
+-	O
+specific	O
+peptide	B-CHED
+antiserum	O
+detected	O
+the	O
+replicase	B-PRGE
+intermediate	O
+p150	B-PRGE
+(	O
+nsp4	B-PRGE
+to	O
+nsp11	O
+)	O
+and	O
+two	O
+nsp6	O
+products	O
+of	O
+approximately	O
+23	O
+and	O
+25	O
+kDa	O
+.	O
+
+Analysis	O
+of	O
+nsp6	O
+transmembrane	B-COMP
+topology	O
+revealed	O
+six	O
+membrane	B-COMP
+-	O
+spanning	O
+segments	O
+and	O
+a	O
+conserved	O
+hydrophobic	O
+domain	O
+in	O
+the	O
+C	O
+-	O
+terminal	O
+cytosolic	B-COMP
+tail	O
+.	O
+
+The	O
+veterinary	O
+literature	O
+contains	O
+numerous	O
+reports	O
+detailing	O
+the	O
+impact	O
+of	O
+systemic	O
+disease	O
+on	O
+the	O
+nervous	B-ANAT
+system	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Thymosin	B-PRGE
+alpha	I-PRGE
+(	O
+1	O
+)	O
+(	O
+Talpha	O
+(	O
+1	O
+)),	O
+a	O
+synthetic	O
+version	O
+of	O
+a	O
+thymic	O
+-	O
+derived	O
+biological	O
+response	O
+modifier	O
+was	O
+the	O
+first	O
+of	O
+the	O
+thymosins	O
+in	O
+clinical	O
+use	O
+.	O
+
+Talpha	O
+(	O
+1	O
+)	O
+is	O
+also	O
+in	O
+late	O
+-	O
+stage	O
+clinical	O
+testing	O
+in	O
+the	O
+United	O
+States	O
+and	O
+Europe	O
+for	O
+hepatitis	B-PATH
+C	I-PATH
+and	O
+stage	B-DISO
+IV	I-DISO
+melanoma	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+of	O
+Strongyloides	B-SPEC
+stercoralis	I-SPEC
+hyperinfection	O
+syndrome	B-DISO
+in	O
+a	O
+renal	B-ANAT
+transplant	B-ANAT
+recipient	O
+complicated	O
+by	O
+septic	B-DISO
+shock	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+Klebsiella	B-SPEC
+pneumoniae	I-SPEC
+superinfection	B-DISO
+.	O
+
+The	O
+patient	O
+was	O
+treated	O
+successfully	O
+with	O
+drotrecogin	O
+alfa	O
+(	O
+activated	O
+),	O
+parenteral	O
+ivermectin	B-CHED
+,	O
+albendazole	B-CHED
+,	O
+and	O
+piperacillin	B-CHED
+/	O
+tazobactam	O
+.	O
+
+However	O
+,	O
+whether	O
+9b	B-PRGE
+protein	I-PRGE
+is	O
+a	O
+structural	O
+component	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+particles	O
+remains	O
+unknown	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+demonstrate	O
+that	O
+9b	O
+protein	B-CHED
+is	O
+translated	O
+from	O
+bicistronic	O
+mRNA9	O
+via	O
+leaky	O
+ribosome	B-COMP
+scanning	O
+and	O
+it	O
+is	O
+incorporated	O
+into	O
+both	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+and	O
+purified	O
+SARS	B-DISO
+-	O
+CoV	O
+virions	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Targeted	B-PROC
+treatment	O
+of	O
+inflammatory	B-DISO
+diseases	I-DISO
+of	I-DISO
+the	I-DISO
+central	I-DISO
+nervous	I-DISO
+system	I-DISO
+(	O
+CNS	B-CHED
+)	O
+remains	O
+problematic	O
+due	O
+to	O
+the	O
+complex	O
+pathogenesis	B-DISO
+of	O
+these	O
+disorders	O
+and	O
+difficulty	O
+in	O
+drug	O
+delivery	O
+.	O
+
+Although	O
+immunosuppressive	B-CHED
+agents	I-CHED
+are	O
+usually	O
+effective	O
+,	O
+some	O
+severe	O
+cases	O
+remain	O
+difficult	O
+to	O
+treat	O
+.	O
+
+TITLE	O
+:	O
+Determining	O
+SARS	B-DISO
+sub	O
+-	O
+clinical	B-DISO
+infection	I-DISO
+:	O
+a	O
+longitudinal	O
+seroepidemiological	O
+study	O
+in	O
+recovered	O
+SARS	O
+patients	O
+and	O
+controls	O
+after	O
+an	O
+outbreak	O
+in	O
+a	O
+general	O
+hospital	O
+.	O
+
+Serum	B-COMP
+samples	O
+taken	O
+at	O
+various	O
+times	O
+were	O
+tested	O
+for	O
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+;	O
+dynamic	O
+serological	O
+changes	O
+in	O
+these	O
+antibodies	B-COMP
+were	O
+described	O
+.	O
+
+The	O
+positive	O
+responses	O
+of	O
+IgM	B-PRGE
+and	O
+IgG	B-PRGE
+antibodies	I-PRGE
+in	O
+sera	B-COMP
+against	O
+SARS	B-DISO
+virus	B-SPEC
+from	O
+the	O
+first	O
+week	O
+to	O
+the	O
+sixth	O
+week	O
+after	O
+onset	O
+of	O
+the	O
+illness	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+were	O
+measured	O
+.	O
+
+Our	O
+results	O
+also	O
+suggest	O
+that	O
+sub	O
+-	O
+clinical	B-DISO
+infection	I-DISO
+,	O
+if	O
+it	O
+exists	O
+,	O
+is	O
+very	O
+rare	O
+.	O
+
+Protein	B-CHED
+sequence	O
+analysis	O
+reveals	O
+that	O
+3a	O
+possesses	B-DISO
+three	O
+major	O
+protein	B-CHED
+signatures	O
+,	O
+the	O
+cysteine	B-CHED
+-	O
+rich	O
+,	O
+Yxx	B-PRGE
+phi	I-PRGE
+and	O
+diacidic	O
+domains	O
+.	O
+
+We	O
+showed	O
+that	O
+3a	O
+proteins	B-CHED
+carrying	O
+respective	O
+mutations	O
+in	O
+these	O
+protein	O
+domains	O
+exhibit	O
+reduced	O
+pro	B-CHED
+-	O
+apoptotic	O
+activities	O
+,	O
+indicating	O
+the	O
+importance	O
+of	O
+these	O
+domains	O
+on	O
+3a	O
+'	O
+s	O
+pro	B-CHED
+-	O
+apoptotic	O
+function	O
+.	O
+
+We	O
+demonstrate	O
+unique	O
+shuttling	O
+behavior	O
+of	O
+ORF	B-PRGE
+3b	I-PRGE
+,	O
+whereby	O
+the	O
+protein	B-CHED
+initially	O
+accumulates	O
+in	O
+the	O
+nucleus	B-COMP
+and	O
+subsequently	O
+translocates	O
+to	O
+mitochondria	B-COMP
+.	O
+
+Following	O
+nuclear	O
+localization	B-PROC
+,	O
+ORF	O
+3b	O
+traffics	O
+to	O
+the	O
+outer	B-COMP
+membrane	I-COMP
+of	O
+mitochondria	B-COMP
+via	O
+a	O
+predicted	O
+amphipathic	O
+alpha	O
+-	O
+helix	O
+.	O
+
+The	O
+findings	O
+reported	O
+here	O
+reveal	O
+that	O
+for	O
+multilocalized	O
+proteins	B-CHED
+,	O
+consideration	O
+of	O
+the	O
+spatiotemporal	O
+distribution	O
+may	O
+be	O
+crucial	O
+for	O
+understanding	O
+viral	O
+protein	B-CHED
+behavior	O
+and	O
+function	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+data	O
+do	O
+not	O
+suggest	O
+a	O
+role	O
+for	O
+MASP2	B-PRGE
+polymorphisms	B-PROC
+in	O
+SARS	B-PRGE
+susceptibility	I-PRGE
+in	O
+northern	O
+and	O
+southern	O
+China	O
+.	O
+
+Infectious	B-DISO
+-	O
+Bronchitis	B-DISO
+-	O
+Virus	B-SPEC
+(	O
+IBV	B-SPEC
+)-	O
+related	O
+variants	O
+were	O
+found	O
+in	O
+7	O
+of	O
+35	O
+sample	O
+pools	O
+,	O
+from	O
+100	O
+wild	O
+mallards	B-SPEC
+(	O
+Anas	B-SPEC
+platyrhynchos	I-SPEC
+).	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+animal	B-SPEC
+models	O
+for	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Unfortunately	O
+,	O
+no	O
+single	O
+animal	B-SPEC
+model	O
+of	O
+ARDS	B-DISO
+replicates	O
+the	O
+complex	O
+pathophysiological	O
+changes	O
+seen	O
+in	O
+patients	O
+.	O
+
+The	O
+gene	O
+that	O
+encodes	O
+HCoV	O
+-	O
+HKU1	O
+nsp9	O
+was	O
+cloned	O
+and	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+the	O
+protein	B-CHED
+was	O
+subjected	O
+to	O
+crystallization	O
+trials	O
+.	O
+
+The	O
+crystals	B-ANAT
+diffracted	O
+to	O
+2	O
+.	O
+7	O
+A	O
+resolution	O
+and	O
+belonged	O
+to	O
+space	O
+group	O
+P2	O
+(	O
+1	O
+)	O
+2	O
+(	O
+1	O
+)	O
+2	O
+,	O
+with	O
+unit	O
+-	O
+cell	B-COMP
+parameters	O
+a	O
+=	O
+83	O
+.	O
+5	O
+,	O
+b	O
+=	O
+88	O
+.	O
+4	O
+,	O
+c	O
+=	O
+31	O
+.	O
+2	O
+A	O
+,	O
+alpha	O
+=	O
+beta	O
+=	O
+gamma	O
+=	O
+90	O
+degrees	O
+and	O
+two	O
+molecules	O
+per	O
+asymmetric	O
+unit	O
+.	O
+
+We	O
+performed	O
+a	O
+retrospective	O
+cohort	O
+study	O
+comparing	O
+a	O
+population	O
+of	O
+patients	O
+managed	O
+with	O
+early	O
+and	O
+aggressive	B-DISO
+CVVH	O
+compared	O
+with	O
+historical	O
+controls	O
+managed	O
+conservatively	O
+before	O
+the	O
+availability	O
+of	O
+CVVH	O
+.	O
+
+Overall	O
+,	O
+the	O
+28	O
+-	O
+day	O
+mortality	O
+was	O
+significantly	O
+lower	O
+in	O
+the	O
+CVVH	O
+arm	B-ANAT
+(	O
+n	O
+=	O
+29	O
+)	O
+compared	O
+with	O
+controls	O
+(	O
+n	O
+=	O
+28	O
+)	O
+(	O
+38	O
+%	O
+vs	O
+.	O
+71	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+011	O
+)	O
+as	O
+was	O
+the	O
+in	O
+-	O
+hospital	O
+mortality	O
+(	O
+62	O
+%	O
+vs	O
+.	O
+86	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+3CL	O
+(	O
+pro	B-PRGE
+))	O
+is	O
+vital	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+and	O
+is	O
+a	O
+promising	O
+drug	O
+target	O
+.	O
+
+Neither	O
+the	O
+juxtamembrane	B-COMP
+stalk	B-DISO
+region	O
+,	O
+transmembrane	B-COMP
+domain	O
+,	O
+nor	O
+the	O
+cytosolic	B-ANAT
+domain	I-ANAT
+was	O
+needed	O
+for	O
+constitutive	O
+ACE2	O
+release	B-PATH
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+envelope	B-COMP
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+is	O
+responsible	O
+for	O
+the	O
+fusion	O
+between	O
+the	O
+membranes	B-ANAT
+of	O
+the	O
+virus	B-SPEC
+and	O
+the	O
+target	B-ANAT
+cell	I-ANAT
+.	O
+
+Although	O
+there	O
+was	O
+significant	O
+positive	O
+correlation	O
+with	O
+a	O
+TCoV	O
+-	O
+N	O
+protein	O
+-	O
+based	O
+ELISA	O
+,	O
+there	O
+was	O
+little	O
+to	O
+no	O
+correlation	O
+with	O
+the	O
+whole	O
+IBV	B-SPEC
+antigen	B-CHED
+-	O
+based	O
+ELISA	O
+when	O
+field	O
+sera	B-COMP
+were	O
+tested	O
+for	O
+antibodies	B-COMP
+against	O
+TCoV	O
+.	O
+
+Moreover	O
+,	O
+identification	O
+of	O
+the	O
+risk	O
+factors	O
+associated	O
+with	O
+the	O
+spreading	O
+of	O
+bacteria	B-SPEC
+causing	O
+diarrhea	B-DISO
+may	O
+be	O
+helpful	O
+for	O
+construction	O
+of	O
+suitable	O
+methods	O
+for	O
+prevention	O
+and	O
+control	O
+.	O
+
+To	O
+explore	O
+other	O
+domain	O
+interactions	O
+of	O
+the	O
+MHV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+,	O
+we	O
+expressed	B-PROC
+a	O
+series	O
+of	O
+segments	O
+of	O
+the	O
+MHV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+as	O
+fusions	O
+with	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	O
+)	O
+during	O
+the	O
+course	O
+of	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+found	O
+that	O
+two	O
+of	O
+these	O
+GFP	O
+-	O
+N	O
+-	O
+domain	O
+fusion	O
+proteins	B-CHED
+were	O
+selectively	O
+packaged	O
+into	O
+virions	B-COMP
+as	O
+the	O
+result	O
+of	O
+tight	O
+binding	B-FUNC
+to	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+in	O
+the	O
+viral	O
+nucleocapsid	O
+,	O
+in	O
+a	O
+manner	O
+that	O
+did	O
+not	O
+involve	O
+association	O
+with	O
+either	O
+M	O
+protein	B-CHED
+or	O
+RNA	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+upregulation	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+cytokines	O
+promotes	O
+lethal	O
+disease	O
+in	O
+an	O
+aged	O
+-	O
+mouse	O
+model	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+produce	O
+more	O
+severe	O
+disease	O
+in	O
+the	O
+elderly	O
+,	O
+yet	O
+the	O
+molecular	O
+mechanisms	O
+governing	O
+age	O
+-	O
+related	O
+susceptibility	O
+remain	O
+poorly	O
+studied	O
+.	O
+
+However	O
+,	O
+these	O
+effective	O
+results	O
+in	O
+the	O
+animal	B-SPEC
+models	O
+are	O
+not	O
+equally	O
+adoptive	O
+to	O
+those	O
+in	O
+randomized	O
+,	O
+controlled	O
+trials	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+chimeric	O
+DNA	O
+-	O
+RNA	O
+hammerhead	O
+ribozyme	O
+targeting	B-PROC
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+Here	O
+we	O
+used	O
+CHO	B-FUNC
+-	O
+K1	O
+cells	B-COMP
+to	O
+establish	O
+a	O
+cell	B-ANAT
+line	I-ANAT
+for	O
+stable	O
+expression	B-PROC
+of	O
+a	O
+193	O
+-	O
+mer	O
+(	O
+residues	O
+318	O
+-	O
+510	O
+)	O
+RBD	O
+(	O
+RBD193	O
+-	O
+CHO	B-FUNC
+)	O
+and	O
+determined	O
+its	O
+antigenicity	O
+and	O
+immunogenicity	O
+.	O
+
+More	O
+importantly	O
+,	O
+N	B-PRGE
+protein	I-PRGE
+did	O
+not	O
+modulate	O
+the	O
+expression	B-PROC
+of	O
+FGL2	B-PRGE
+mRNA	I-PRGE
+or	O
+protein	B-CHED
+in	O
+transfected	O
+or	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	O
+.	O
+
+Unraveling	O
+the	O
+mechanism	B-PROC
+of	I-PROC
+action	I-PROC
+of	O
+these	O
+agents	O
+could	O
+contribute	O
+to	O
+the	O
+development	B-PROC
+of	O
+novel	O
+therapeutic	O
+strategies	O
+to	O
+combat	B-CHED
+permeability	O
+edema	B-DISO
+.	O
+
+Furthermore	O
+,	O
+the	O
+localization	B-PROC
+of	O
+pAPN	O
+on	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+of	O
+swine	B-SPEC
+was	O
+analyzed	O
+by	O
+immunohistochemistry	O
+.	O
+
+5x10	O
+(	O
+6	O
+)	O
+CFU	O
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+expressing	O
+scFvs	O
+against	O
+PEDV	O
+showed	O
+promising	O
+result	O
+of	O
+94	O
+%	O
+foci	O
+reduction	O
+compared	O
+to	O
+wild	O
+type	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+Isatis	B-SPEC
+indigotica	I-SPEC
+posses	O
+a	O
+valuable	O
+virucidal	O
+effect	O
+in	O
+disease	O
+control	O
+of	O
+pseudorabies	B-SPEC
+virus	B-DISO
+infection	I-DISO
+in	O
+swine	B-SPEC
+.	O
+
+This	O
+Review	O
+focuses	O
+on	O
+recent	O
+advances	O
+in	O
+our	O
+understanding	O
+of	O
+the	O
+mechanisms	O
+of	O
+coronavirus	B-SPEC
+replication	O
+,	O
+interactions	O
+with	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+and	O
+disease	O
+pathogenesis	B-DISO
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+gene	O
+showed	O
+the	O
+four	O
+isolates	O
+were	O
+highly	O
+related	O
+to	O
+each	O
+other	O
+(>	O
+or	O
+=	O
+99	O
+.	O
+6	O
+%	O
+nucleotide	B-CHED
+identity	O
+;	O
+>	O
+or	O
+=	O
+98	O
+.	O
+9	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+).	O
+
+268	O
+.	O
+3	O
+mg	O
+/	O
+L	O
+,	O
+P	O
+=	O
+0	O
+.	O
+003	O
+),	O
+tumors	B-DISO
+(	O
+522	O
+.	O
+5	O
++/-	O
+
+However	O
+,	O
+within	O
+the	O
+large	O
+Nsp3	B-PRGE
+(	O
+1922	O
+amino	B-CHED
+-	I-CHED
+acid	I-CHED
+residues	I-CHED
+),	O
+the	O
+structure	O
+and	O
+function	O
+of	O
+the	O
+so	O
+-	O
+called	O
+SARS	B-DISO
+-	O
+unique	O
+domain	O
+(	O
+SUD	O
+)	O
+have	O
+remained	O
+elusive	O
+.	O
+
+As	O
+there	O
+is	O
+no	O
+evidence	O
+for	O
+Nsp3	B-PRGE
+entering	O
+the	O
+nucleus	B-COMP
+of	O
+the	O
+host	B-COMP
+cell	I-COMP
+,	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genomic	O
+RNA	O
+or	O
+host	B-COMP
+-	O
+cell	B-COMP
+mRNA	B-CHED
+containing	O
+long	O
+G	O
+-	O
+stretches	B-DISO
+may	O
+be	O
+targets	O
+of	O
+SUD	O
+.	O
+
+The	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+is	O
+devoid	O
+of	O
+G	O
+-	O
+stretches	B-DISO
+longer	O
+than	O
+5	O
+-	O
+6	O
+nucleotides	B-CHED
+,	O
+but	O
+more	O
+extended	O
+G	O
+-	O
+stretches	B-DISO
+are	O
+found	O
+in	O
+the	O
+3	O
+'-	O
+nontranslated	O
+regions	O
+of	O
+mRNAs	O
+coding	O
+for	O
+certain	O
+host	B-COMP
+-	O
+cell	B-COMP
+proteins	B-CHED
+involved	O
+in	O
+apoptosis	B-PATH
+or	O
+signal	B-PROC
+transduction	I-PROC
+,	O
+and	O
+have	O
+been	O
+shown	O
+to	O
+bind	B-FUNC
+to	O
+SUD	O
+in	O
+vitro	O
+.	O
+
+Therefore	O
+,	O
+SUD	O
+may	O
+be	O
+involved	O
+in	O
+controlling	O
+the	O
+host	B-COMP
+cell	I-COMP
+'	O
+s	O
+response	O
+to	O
+the	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+SP	O
+-	O
+D	O
+significantly	O
+correlated	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+IgG	I-PRGE
+(	O
+r	O
+(	O
+2	O
+)	O
+=	O
+0	O
+.	O
+5995	O
+,	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+The	O
+significant	O
+correlation	O
+between	O
+plasma	B-ANAT
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+and	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+antibodies	B-COMP
+support	O
+the	O
+role	O
+for	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+in	O
+interlinking	O
+innate	O
+and	O
+adaptive	O
+immune	O
+pathways	B-PROC
+.	O
+
+It	O
+suggests	O
+that	O
+nonhuman	O
+coronaviruses	O
+may	O
+be	O
+attractive	O
+new	O
+therapeutic	O
+agents	O
+against	O
+human	B-SPEC
+tumors	B-DISO
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+a	O
+highly	O
+conserved	O
+domain	O
+within	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+S2	O
+domain	O
+with	O
+characteristics	O
+of	O
+a	O
+viral	O
+fusion	O
+peptide	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+viral	O
+fusion	O
+proteins	B-CHED
+are	O
+primed	O
+by	O
+proteolytic	B-PROC
+cleavage	B-PROC
+near	O
+their	O
+fusion	O
+peptides	B-CHED
+.	O
+
+Mutagenesis	B-PROC
+studies	O
+of	O
+these	O
+residues	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+,	O
+followed	O
+by	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+and	O
+pseudotyped	O
+virion	B-COMP
+infectivity	O
+assays	O
+,	O
+showed	O
+a	O
+critical	O
+role	O
+for	O
+residues	O
+L803	O
+,	O
+L804	O
+,	O
+and	O
+F805	O
+in	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+TITLE	O
+:	O
+Hospitalization	O
+for	O
+ambulatory	O
+-	O
+care	O
+-	O
+sensitive	O
+conditions	O
+in	O
+Taiwan	O
+following	O
+the	O
+SARS	B-DISO
+outbreak	O
+:	O
+a	O
+population	O
+-	O
+based	O
+interrupted	O
+time	O
+series	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2003	O
+,	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+resulted	O
+in	O
+8096	O
+probable	O
+cases	O
+and	O
+774	O
+deaths	B-PROC
+in	O
+26	O
+countries	O
+.	O
+
+Hospitalization	O
+for	O
+respiratory	O
+conditions	O
+was	O
+significantly	O
+lower	O
+than	O
+the	O
+predicted	O
+values	O
+,	O
+whereas	O
+hospitalization	O
+for	O
+diabetes	B-DISO
+was	O
+significantly	O
+higher	O
+than	O
+the	O
+predicted	O
+values	O
+after	O
+the	O
+outbreak	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Admission	O
+rates	O
+for	O
+most	O
+ACSCs	O
+,	O
+except	O
+for	O
+diabetes	B-DISO
+,	O
+did	O
+not	O
+change	O
+in	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+period	O
+.	O
+
+Other	O
+agents	O
+responsible	O
+for	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+include	O
+Coronavirus	B-SPEC
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+),	O
+Bocavirus	B-SPEC
+,	O
+and	O
+others	O
+.	O
+
+ABSTRACT	O
+:	O
+Excessive	O
+immune	B-PROC
+response	I-PROC
+is	O
+believed	O
+to	O
+play	O
+a	O
+role	O
+in	O
+the	O
+development	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+CONCLUSIONS	O
+:	O
+In	O
+this	O
+study	O
+in	O
+healthy	O
+Chinese	O
+male	O
+volunteers	O
+,	O
+the	O
+dispersible	O
+tablet	O
+formulation	O
+and	O
+the	O
+200	O
+-	O
+mg	O
+capsule	B-COMP
+formulation	O
+of	O
+arbidol	O
+met	B-CHED
+the	O
+SFDA	O
+'	O
+s	O
+regulatory	O
+definition	O
+of	O
+bioequivalence	O
+based	O
+on	O
+the	O
+rate	O
+and	O
+extent	O
+of	O
+absorption	O
+.	O
+
+It	O
+is	O
+classically	O
+considered	O
+an	O
+endemic	O
+mycosis	B-DISO
+,	O
+even	O
+though	O
+the	O
+fungus	B-SPEC
+has	O
+an	O
+opportunistic	O
+behavior	O
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+People	O
+acquired	O
+the	O
+infection	B-DISO
+through	O
+the	O
+inhalation	B-PROC
+of	O
+conidial	O
+forms	O
+present	O
+in	O
+the	O
+environmental	O
+,	O
+such	O
+as	O
+caves	O
+dwelling	O
+bats	B-SPEC
+and	O
+soils	O
+inhabited	O
+by	O
+chickens	B-SPEC
+.	O
+
+The	O
+clinical	O
+features	O
+may	O
+vary	O
+from	O
+asymptomatic	B-DISO
+infections	I-DISO
+to	O
+disseminated	O
+severe	O
+forms	O
+that	O
+affect	O
+patients	O
+with	O
+acquired	B-DISO
+immunodeficiency	I-DISO
+syndrome	I-DISO
+or	O
+hematological	B-DISO
+malignancies	I-DISO
+and	O
+allograft	O
+recipients	O
+.	O
+
+The	O
+diagnosis	O
+is	O
+based	O
+on	O
+the	O
+detection	O
+of	O
+the	O
+fungus	B-SPEC
+in	O
+organic	O
+fluids	B-ANAT
+(	O
+sputum	B-ANAT
+,	O
+blood	B-ANAT
+,	O
+liquor	B-ANAT
+)	O
+or	O
+tissues	B-ANAT
+(	O
+histopathological	O
+assays	O
+),	O
+in	O
+the	O
+culture	O
+of	O
+biological	O
+samples	O
+and	O
+serological	O
+assays	O
+.	O
+
+Part	O
+I	O
+of	O
+II	O
+--	O
+viral	O
+entry	O
+inhibitors	B-CHED
+.	O
+
+Samples	O
+were	O
+screened	O
+by	O
+RT	O
+-	O
+PCR	O
+to	O
+detect	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+).	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infections	B-DISO
+in	O
+hospitalised	O
+children	O
+in	O
+Africa	O
+.	O
+
+The	O
+presence	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+the	O
+heart	B-ANAT
+was	O
+also	O
+associated	O
+with	O
+marked	O
+reductions	O
+in	O
+ACE2	B-PRGE
+protein	I-PRGE
+expression	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+characterised	O
+by	O
+lung	O
+inflammation	O
+with	O
+severe	O
+hypoxia	B-DISO
+,	O
+which	O
+usually	O
+develops	O
+over	O
+4	O
+-	O
+48	O
+hours	O
+and	O
+persists	O
+for	O
+days	O
+or	O
+weeks	O
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+estimation	O
+methods	O
+are	O
+developed	O
+using	O
+a	O
+constant	O
+cure	O
+-	O
+death	B-PROC
+hazard	O
+ratio	O
+.	O
+
+ABSTRACT	O
+:	O
+Development	O
+of	O
+cancer	B-DISO
+after	O
+transplantation	O
+has	O
+rapidly	O
+became	O
+one	O
+of	O
+the	O
+leading	O
+causes	O
+of	O
+death	B-PROC
+in	O
+kidney	B-ANAT
+transplant	I-ANAT
+recipients	O
+with	O
+functioning	O
+grafts	B-ANAT
+.	O
+
+These	O
+preliminary	O
+data	O
+demonstrated	O
+a	O
+high	O
+incidence	O
+of	O
+HPV	O
+infection	O
+in	O
+renal	B-ANAT
+transplant	B-ANAT
+recipients	O
+.	O
+
+The	O
+HPV	O
+test	O
+is	O
+useful	O
+to	O
+monitor	O
+patients	O
+at	O
+higher	O
+risk	O
+of	O
+anogenital	O
+malignant	B-DISO
+neoplasms	I-DISO
+by	O
+identifying	O
+the	O
+cytologic	O
+anomalies	O
+at	O
+an	O
+earlier	O
+stage	O
+.	O
+
+Compared	O
+with	O
+hospitalizations	O
+without	O
+any	O
+hypertensive	O
+disorders	O
+,	O
+the	O
+risk	O
+of	O
+severe	O
+obstetric	O
+complications	O
+ranged	O
+from	O
+3	O
+.	O
+3	O
+to	O
+34	O
+.	O
+8	O
+for	O
+hospitalizations	O
+with	O
+eclampsia	B-DISO
+/	O
+severe	B-DISO
+preeclampsia	I-DISO
+and	O
+from	O
+1	O
+.	O
+4	O
+to	O
+2	O
+.	O
+2	O
+for	O
+gestational	B-DISO
+hypertension	I-DISO
+.	O
+
+CARV	O
+-	O
+infection	B-DISO
+did	O
+not	O
+influence	O
+BOS	B-DISO
+progression	O
+in	O
+88	O
+patients	O
+with	O
+prior	O
+BOS	B-DISO
+(	O
+P	O
+0	O
+.	O
+45	O
+).	O
+
+After	O
+paramyxovirus	O
+infection	B-DISO
+,	O
+8	O
+of	O
+24	O
+patients	O
+developed	O
+new	O
+-	O
+onset	O
+BOS	B-DISO
+,	O
+whereas	O
+no	O
+case	O
+was	O
+recorded	O
+after	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+After	O
+paramyxovirus	O
+infection	B-DISO
+,	O
+8	O
+of	O
+24	O
+patients	O
+developed	O
+new	O
+-	O
+onset	O
+BOS	B-DISO
+,	O
+whereas	O
+no	O
+case	O
+was	O
+recorded	O
+after	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Researchers	O
+routinely	O
+adopt	O
+molecular	O
+clock	O
+assumptions	O
+in	O
+conducting	O
+sequence	O
+analyses	O
+to	O
+estimate	O
+dates	O
+for	O
+viral	O
+origins	O
+in	O
+humans	B-SPEC
+.	O
+
+In	O
+the	O
+dog	B-SPEC
+,	O
+infection	B-DISO
+with	O
+the	O
+coronavirus	B-SPEC
+type	O
+2	O
+is	O
+associated	O
+with	O
+respiratory	O
+signs	O
+,	O
+while	O
+infection	B-DISO
+of	O
+a	O
+highly	O
+pathogenic	O
+strain	O
+of	O
+the	O
+coronavirus	B-SPEC
+type	O
+1	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+cause	O
+of	O
+mortality	O
+in	O
+puppies	O
+.	O
+
+TITLE	O
+:	O
+Protective	O
+mechanisms	O
+of	O
+activated	O
+protein	B-CHED
+C	O
+in	O
+severe	O
+inflammatory	O
+disorders	O
+.	O
+
+The	O
+pathophysiology	O
+of	O
+both	O
+diseases	O
+states	O
+involves	O
+uncontrolled	O
+inflammation	B-DISO
+,	O
+enhanced	O
+coagulation	B-PROC
+and	O
+compromised	O
+fibrinolysis	B-PROC
+.	O
+
+Several	O
+other	O
+clinical	O
+trials	O
+evaluating	O
+recombinant	O
+human	B-SPEC
+APC	B-COMP
+have	O
+been	O
+completed	O
+,	O
+including	O
+studies	O
+in	O
+children	O
+and	O
+less	O
+severely	O
+ill	B-DISO
+adults	O
+with	O
+sepsis	B-DISO
+as	O
+well	O
+as	O
+a	O
+study	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+data	O
+are	O
+helpful	O
+for	O
+using	O
+antivirals	B-CHED
+efficiently	O
+.	O
+
+Recognition	O
+and	O
+treatment	O
+of	O
+pulmonary	B-DISO
+aspergillosis	I-DISO
+is	O
+difficult	O
+and	O
+may	O
+require	O
+multi	O
+drug	O
+therapy	O
+.	O
+
+The	O
+investigation	O
+was	O
+not	O
+only	O
+performed	O
+to	O
+establish	O
+a	O
+new	O
+rapid	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+model	O
+,	O
+but	O
+also	O
+to	O
+provide	O
+the	O
+elicitation	O
+for	O
+mechanism	O
+of	O
+ALI	O
+changed	O
+into	O
+the	O
+rapid	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Rhabdomyolysis	O
+is	O
+a	O
+skeletal	B-ANAT
+muscle	I-ANAT
+injury	O
+with	O
+cell	B-ANAT
+components	I-ANAT
+'	O
+release	B-PATH
+to	O
+plasma	B-ANAT
+.	O
+
+Male	O
+patient	O
+,	O
+32	O
+year	O
+-	O
+old	O
+,	O
+presented	O
+with	O
+discomfort	B-DISO
+followed	O
+by	O
+syncope	B-DISO
+after	O
+running	O
+2	O
+,	O
+350	O
+m	O
+in	O
+a	O
+fitness	O
+race	O
+.	O
+
+Patient	O
+died	B-PROC
+before	O
+any	O
+specific	O
+investigation	O
+of	O
+malignant	B-DISO
+hyperthermia	I-DISO
+,	O
+but	O
+it	O
+is	O
+important	O
+to	O
+look	O
+for	O
+susceptibility	O
+for	O
+this	O
+syndrome	B-DISO
+within	O
+the	O
+family	B-SPEC
+to	O
+avoid	O
+potentially	O
+life	O
+-	O
+threatening	O
+anesthetic	O
+events	O
+.	O
+
+Unlike	O
+in	O
+a	O
+constant	O
+environment	O
+,	O
+the	O
+final	O
+epidemic	O
+size	O
+may	O
+not	O
+be	O
+an	O
+increasing	O
+function	O
+of	O
+the	O
+basic	O
+reproduction	B-PROC
+number	O
+R	O
+(	O
+0	O
+)	O
+or	O
+of	O
+the	O
+initial	O
+fraction	O
+of	O
+infected	O
+people	O
+.	O
+
+Significant	O
+cell	B-COMP
+-	O
+mediated	O
+immune	B-PROC
+responses	I-PROC
+were	O
+characterized	O
+by	O
+cytotoxic	B-ANAT
+T	I-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+(	O
+51	O
+)	O
+Cr	O
+release	B-PATH
+assay	O
+and	O
+interferon	B-PROC
+-	I-PROC
+gamma	I-PROC
+secretion	B-ANAT
+ELISPOT	O
+assay	O
+against	O
+RMA	O
+-	O
+S	O
+target	B-ANAT
+cells	I-ANAT
+presenting	O
+predicted	O
+MHC	B-PRGE
+class	B-SPEC
+I	I-PRGE
+H2	I-PRGE
+-	I-PRGE
+Kb	I-PRGE
+epitopes	I-PRGE
+,	O
+including	O
+those	O
+spanning	O
+residues	O
+884	O
+-	O
+891	O
+and	O
+1116	O
+-	O
+1123	O
+within	O
+the	O
+S2	O
+subunit	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+.	O
+
+Instead	O
+of	O
+comparing	O
+the	O
+frequencies	O
+of	O
+k	O
+-	O
+words	O
+in	O
+biological	O
+sequences	O
+directly	O
+,	O
+we	O
+considered	O
+the	O
+k	O
+-	O
+word	O
+frequency	O
+distribution	O
+under	O
+Gaussian	O
+model	O
+which	O
+gives	O
+the	O
+different	O
+expression	B-PROC
+levels	O
+of	O
+k	O
+-	O
+words	O
+.	O
+
+While	O
+most	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+are	O
+healthy	O
+or	O
+display	O
+only	O
+a	O
+mild	O
+enteritis	B-DISO
+,	O
+some	O
+go	O
+on	O
+to	O
+develop	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+,	O
+a	O
+disease	O
+that	O
+is	O
+especially	O
+common	O
+in	O
+young	O
+cats	B-SPEC
+and	O
+multi	O
+-	O
+cat	B-SPEC
+environments	O
+.	O
+
+The	O
+'	O
+wet	O
+'	O
+or	O
+effusive	O
+form	O
+,	O
+characterised	O
+by	O
+polyserositis	B-DISO
+(	O
+abdominal	B-ANAT
+and	O
+/	O
+or	O
+thoracic	B-DISO
+effusion	B-DISO
+)	O
+and	O
+vasculitis	B-DISO
+,	O
+and	O
+the	O
+'	O
+dry	O
+'	O
+or	O
+non	O
+-	O
+effusive	O
+form	O
+(	O
+pyogranulomatous	O
+lesions	O
+in	O
+organs	B-ANAT
+)	O
+reflect	O
+clinical	O
+extremes	O
+of	O
+a	O
+continuum	O
+.	O
+
+Three	O
+cats	B-SPEC
+with	O
+dry	O
+form	O
+FIP	B-DISO
+were	O
+treated	O
+with	O
+Polyprenyl	O
+Immunostimulant	B-CHED
+.	O
+
+Further	O
+studies	O
+are	O
+necessary	O
+to	O
+assess	O
+the	O
+potential	O
+of	O
+the	O
+Polyprenyl	O
+Immunostimulant	B-CHED
+.	O
+
+TITLE	O
+:	O
+The	O
+development	B-PROC
+of	O
+a	O
+non	O
+-	O
+contact	O
+screening	O
+system	O
+for	O
+rapid	O
+medical	O
+inspection	O
+at	O
+a	O
+quarantine	O
+depot	O
+using	O
+a	O
+laser	O
+Doppler	O
+blood	B-ANAT
+-	O
+flow	O
+meter	O
+,	O
+microwave	O
+radar	O
+and	O
+infrared	O
+thermography	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	B-SPEC
+to	O
+conduct	B-PROC
+fast	B-FUNC
+screening	O
+of	O
+passengers	O
+with	O
+infections	B-DISO
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+or	O
+pandemic	O
+influenza	B-DISO
+at	O
+a	O
+quarantine	O
+depot	O
+,	O
+we	O
+developed	O
+a	O
+non	O
+-	O
+contact	O
+screening	O
+system	O
+with	O
+self	O
+-	O
+produced	O
+program	O
+to	O
+conduct	B-PROC
+a	O
+human	B-SPEC
+screening	O
+within	O
+five	O
+seconds	O
+,	O
+via	O
+a	O
+linear	O
+discriminant	O
+function	O
+from	O
+non	O
+-	O
+contact	O
+derived	O
+variables	O
+,	O
+i	O
+.	O
+e	O
+.	O
+palmer	O
+pulse	B-PROC
+derived	O
+from	O
+a	O
+laser	B-SPEC
+Doppler	O
+blood	B-ANAT
+-	O
+flow	O
+meter	O
+,	O
+respiration	B-PROC
+rate	O
+determined	O
+by	O
+a	O
+10	O
+-	O
+GHz	O
+microwave	O
+radar	O
+,	O
+and	O
+facial	B-ANAT
+temperature	O
+measured	O
+by	O
+thermography	O
+.	O
+
+As	O
+emerging	O
+'	O
+new	O
+'	O
+respiratory	O
+viruses	O
+are	O
+identified	O
+in	O
+many	O
+wild	O
+and	O
+domestic	O
+animals	B-SPEC
+,	O
+issues	O
+of	O
+interspecies	O
+transmission	O
+have	O
+become	O
+of	O
+increasing	O
+concern	O
+.	O
+
+High	O
+containment	O
+pathogens	O
+pose	O
+a	O
+significant	O
+threat	O
+to	O
+public	O
+health	O
+systems	O
+,	O
+as	O
+well	O
+as	O
+a	O
+major	O
+research	O
+challenge	O
+,	O
+because	O
+of	O
+limited	O
+experience	O
+in	O
+case	O
+management	O
+,	O
+lack	O
+of	O
+appropriate	O
+resources	O
+in	O
+affected	O
+areas	O
+and	O
+a	O
+limited	O
+number	O
+of	O
+animal	B-SPEC
+research	O
+facilities	O
+in	O
+developed	O
+countries	O
+.	O
+
+The	O
+large	O
+fluctuation	B-DISO
+of	O
+scarlet	B-DISO
+fever	I-DISO
+cases	O
+between	O
+2000	O
+and	O
+2006	O
+was	O
+associated	O
+with	O
+the	O
+shuffling	O
+of	O
+six	O
+prevalent	O
+emm	O
+clones	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+of	O
+treatments	O
+and	O
+deceased	B-PROC
+cases	O
+of	O
+severe	O
+adverse	O
+drug	O
+reactions	O
+--	O
+analysis	O
+of	O
+46	O
+cases	O
+of	O
+Stevens	O
+-	O
+Johnson	O
+syndrome	O
+and	O
+toxic	B-DISO
+epidermal	I-DISO
+necrolysis	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+Systemic	O
+administration	O
+of	O
+corticosteroid	B-CHED
+,	O
+plasmapheresis	O
+and	O
+high	B-PRGE
+-	I-PRGE
+dose	I-PRGE
+immunoglobulin	I-PRGE
+therapy	O
+(	O
+IVIG	O
+)	O
+are	O
+the	O
+main	O
+treatment	O
+of	O
+Stevens	B-DISO
+-	I-DISO
+Johnson	I-DISO
+syndrome	I-DISO
+(	O
+SJS	B-DISO
+)	O
+and	O
+toxic	B-DISO
+epidermal	I-DISO
+necrolysis	I-DISO
+(	O
+TEN	O
+).	O
+
+RESULTS	O
+:	O
+Corticosteroid	B-CHED
+was	O
+administered	O
+systemically	O
+in	O
+all	O
+cases	O
+except	O
+one	O
+case	O
+of	O
+TEN	O
+which	O
+developed	O
+methicillin	B-CHED
+resistant	O
+staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+MRSA	B-DISO
+)	O
+pneumoniae	O
+before	O
+the	O
+onset	O
+of	O
+the	O
+eruption	B-DISO
+.	O
+
+Two	O
+of	O
+the	O
+liposomal	O
+peptides	B-CHED
+were	O
+effective	O
+for	O
+peptide	B-CHED
+-	O
+specific	O
+CTL	B-ANAT
+induction	O
+,	O
+and	O
+one	O
+of	O
+them	O
+was	O
+efficient	O
+for	O
+the	O
+clearance	O
+of	O
+vaccinia	B-SPEC
+virus	I-SPEC
+expressing	O
+epitopes	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+suggesting	O
+that	O
+the	O
+surface	O
+-	O
+linked	O
+liposomal	O
+peptide	B-CHED
+might	O
+offer	O
+an	O
+effective	O
+CTL	B-ANAT
+-	O
+based	O
+vaccine	O
+against	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+matrix	B-PRGE
+metalloproteinase	I-PRGE
+-	I-PRGE
+9	I-PRGE
+with	O
+doxycycline	B-CHED
+reduces	O
+pancreatitis	B-DISO
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+.	O
+
+We	O
+have	O
+previously	O
+demonstrated	O
+that	O
+pulmonary	B-ANAT
+injury	O
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+is	O
+mediated	O
+by	O
+PMN	B-PRGE
+-	I-PRGE
+derived	I-PRGE
+matrix	I-PRGE
+metalloproteinase	I-PRGE
+-	I-PRGE
+9	I-PRGE
+(	O
+MMP	B-PRGE
+-	I-PRGE
+9	I-PRGE
+).	O
+
+Eighteen	O
+rats	B-SPEC
+were	O
+randomized	O
+into	O
+three	O
+groups	O
+:	O
+severe	O
+pancreatitis	B-DISO
+(	O
+SAP	B-DISO
+),	O
+severe	O
+pancreatitis	B-DISO
++	O
+doxycycline	B-CHED
+(	O
+SAP	O
++	O
+Dox	O
+)	O
+(	O
+30	O
+mg	O
+/	O
+kg	O
+body	B-ANAT
+mass	O
+)	O
+or	O
+control	O
+.	O
+
+stimulation	O
+with	O
+cerulein	B-CHED
+.	O
+
+Active	O
+MMP	B-PRGE
+-	I-PRGE
+9	I-PRGE
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+was	O
+measured	O
+with	O
+fluorescent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+Addition	O
+of	O
+doxycycline	B-CHED
+significantly	O
+reduced	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+-	O
+induced	O
+PMN	B-PROC
+transmigration	O
+across	O
+Matrigel	O
+membrane	B-COMP
+(	O
+12	O
+.	O
+6	O
++/-	O
+2	O
+.	O
+6	O
+vs	O
+.	O
+20	O
+.	O
+1	O
++/-	O
+
+0	O
+.	O
+51	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+),	O
+atelectasis	B-DISO
+(	O
+1	O
+.	O
+67	O
++/-	O
+0	O
+.	O
+52	O
+vs	O
+.	O
+2	O
+.	O
+33	O
++/-	O
+0	O
+.	O
+52	O
+;	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+(	O
+2	O
+.	O
+5	O
++/-	O
+0	O
+.	O
+55	O
+vs	O
+.	O
+1	O
+.	O
+83	O
++/-	O
+0	O
+.	O
+41	O
+;	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+SAP	B-PRGE
++	I-PRGE
+Dox	I-PRGE
+vs	I-PRGE
+.	I-PRGE
+SAP	I-PRGE
+.	O
+
+The	O
+epidemiological	O
+investigation	O
+of	O
+EIDs	O
+associated	O
+with	O
+wildlife	O
+requires	O
+a	O
+trans	O
+-	O
+disciplinary	O
+approach	O
+that	O
+includes	O
+an	O
+understanding	O
+of	O
+the	O
+ecology	O
+of	O
+the	O
+wildlife	O
+species	B-SPEC
+,	O
+and	O
+an	O
+understanding	O
+of	O
+human	B-SPEC
+behaviours	O
+that	O
+increase	O
+risk	O
+of	O
+exposure	O
+.	O
+
+Cases	O
+reported	O
+from	O
+Asia	O
+suggest	O
+that	O
+maternal	O
+and	O
+fetal	B-ANAT
+outcomes	O
+are	O
+worsened	O
+by	O
+SARS	B-DISO
+during	O
+pregnancy	O
+.	O
+
+(	O
+III	B-PRGE
+-	I-PRGE
+C	I-PRGE
+)	O
+3	O
+.	O
+
+Either	O
+regional	O
+or	O
+general	O
+anaesthesia	B-DISO
+may	O
+be	O
+appropriate	O
+for	O
+delivery	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+A	O
+multidisciplinary	O
+team	O
+,	O
+consisting	O
+of	O
+obstetricians	O
+,	O
+nurses	O
+,	O
+pediatricians	O
+,	O
+infection	B-DISO
+control	O
+specialists	O
+,	O
+respiratory	O
+therapists	O
+,	O
+and	O
+anaesthesiologists	O
+,	O
+should	O
+be	O
+identified	O
+in	O
+each	O
+unit	O
+and	O
+be	O
+responsible	O
+for	O
+the	O
+unit	O
+organization	O
+and	O
+implementation	O
+of	O
+SARS	B-DISO
+management	O
+protocols	O
+.	O
+
+Regional	O
+health	O
+authorities	O
+in	O
+conjunction	O
+with	O
+hospital	O
+staff	O
+should	O
+consider	O
+designating	O
+specific	O
+facilities	O
+or	O
+health	O
+care	O
+units	O
+,	O
+including	O
+primary	O
+,	O
+secondary	O
+,	O
+or	O
+tertiary	O
+health	O
+care	O
+centres	O
+,	O
+to	O
+care	O
+for	O
+patients	O
+with	O
+SARS	B-DISO
+or	O
+similar	O
+illnesses	O
+.	O
+
+ABSTRACT	O
+:	O
+Massive	O
+hemoptysis	O
+,	O
+an	O
+extremely	O
+life	O
+-	O
+threatening	O
+condition	B-DISO
+with	O
+a	O
+high	O
+mortality	O
+,	O
+requires	O
+prompt	O
+diagnosis	O
+.	O
+
+Pheochromocytoma	B-DISO
+describes	O
+various	O
+clinical	O
+manifestations	O
+attributable	O
+to	O
+the	O
+excessive	O
+secretion	B-PROC
+of	O
+catecholamine	B-CHED
+by	O
+the	O
+tumor	B-DISO
+,	O
+however	O
+the	O
+disease	O
+is	O
+not	O
+typically	O
+included	O
+the	O
+differential	O
+diagnoses	O
+of	O
+massive	O
+hemoptysis	B-DISO
+.	O
+
+Therefore	O
+,	O
+massive	O
+hemoptysis	B-DISO
+should	O
+be	O
+considered	O
+as	O
+a	O
+possible	O
+presenting	O
+symptom	B-DISO
+of	O
+pheochromocytoma	B-DISO
+,	O
+especially	O
+in	O
+patients	O
+with	O
+severe	O
+paroxysmal	B-DISO
+hypertension	I-DISO
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+analysis	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+4	O
+/	O
+91	O
+type	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolated	O
+in	O
+Japan	O
+.	O
+
+HEV	B-SPEC
+infected	O
+nerve	B-ANAT
+cells	I-ANAT
+but	O
+did	O
+not	O
+infect	O
+non	O
+-	O
+neuronal	O
+cells	B-COMP
+,	O
+whereas	O
+PRV	B-DISO
+infected	O
+both	O
+cell	B-COMP
+types	O
+.	O
+
+By	O
+using	O
+cytoskeletal	B-COMP
+inhibitors	B-CHED
+,	O
+it	O
+was	O
+suggested	O
+that	O
+propagation	O
+of	O
+HEV	B-SPEC
+and	O
+PRV	B-DISO
+within	O
+and	O
+among	O
+nerve	B-ANAT
+cells	I-ANAT
+depended	O
+on	O
+microtubules	B-COMP
+and	O
+intermediate	B-COMP
+filaments	I-COMP
+of	O
+nerve	B-ANAT
+cells	I-ANAT
+,	O
+indicating	O
+that	O
+the	O
+viruses	B-SPEC
+may	O
+be	O
+transported	O
+between	O
+the	O
+cell	B-COMP
+body	I-COMP
+and	O
+axonal	O
+terminals	O
+of	O
+neurons	B-ANAT
+by	O
+fast	B-PROC
+axonal	I-PROC
+flow	I-PROC
+.	O
+
+The	O
+peripheral	B-ANAT
+blood	I-ANAT
+smear	O
+in	O
+these	O
+patients	O
+showed	O
+WBC	B-ANAT
+agglutinates	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+pathogens	O
+in	O
+respiratory	B-ANAT
+tract	I-ANAT
+illnesses	O
+during	O
+the	O
+first	O
+year	O
+of	O
+life	O
+:	O
+a	O
+birth	B-PROC
+cohort	O
+study	O
+.	O
+
+Although	O
+RSV	B-DISO
+infections	I-DISO
+seemed	O
+to	O
+be	O
+responsible	O
+for	O
+the	O
+most	O
+severe	O
+symptoms	O
+compared	O
+with	O
+HRV	O
+,	O
+the	O
+overall	O
+burden	O
+of	O
+disease	O
+was	O
+highest	O
+for	O
+HRV	O
+infections	B-DISO
+.	O
+
+These	O
+findings	O
+may	O
+explain	O
+the	O
+increased	O
+lung	B-ANAT
+infiltrations	O
+and	O
+lymphoid	O
+depletion	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+The	O
+impact	O
+on	O
+neonatal	O
+mortality	O
+of	O
+shifting	O
+childbirth	B-PROC
+services	O
+among	O
+levels	O
+of	O
+hospitals	O
+:	O
+Taiwan	O
+'	O
+s	O
+experience	O
+.	O
+
+Based	O
+on	O
+a	O
+pre	O
+-	O
+SARS	B-DISO
+sample	O
+from	O
+January	O
+1998	O
+to	O
+December	O
+2002	O
+,	O
+we	O
+estimated	O
+a	O
+linear	O
+regression	O
+model	O
+which	O
+included	O
+""""	O
+trend	O
+","""	O
+a	O
+continuous	O
+variable	O
+representing	O
+the	O
+effect	O
+of	O
+yearly	O
+changes	O
+,	O
+and	O
+two	O
+binary	O
+variables	O
+,	O
+""""	O
+month	O
+""""	O
+and	O
+""""	O
+county	O
+","""	O
+controlling	O
+for	O
+seasonal	O
+and	O
+county	O
+-	O
+specific	O
+effects	O
+.	O
+
+We	O
+compared	O
+the	O
+differences	O
+between	O
+observed	O
+mortality	O
+rates	O
+of	O
+the	O
+SARS	B-DISO
+period	O
+and	O
+predicted	O
+rates	O
+to	O
+examine	O
+whether	O
+the	O
+shifting	O
+in	O
+maternity	O
+services	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+significantly	O
+affected	O
+neonatal	O
+mortality	O
+rates	O
+.	O
+
+TITLE	O
+:	O
+The	O
+application	O
+of	O
+phosphoramidate	B-CHED
+ProTide	B-CHED
+technology	O
+to	O
+the	O
+potent	O
+anti	O
+-	O
+HCV	B-SPEC
+compound	O
+4	O
+'-	O
+azidocytidine	O
+(	O
+R1479	O
+).	O
+
+We	O
+herein	O
+report	O
+detailed	O
+SARs	B-DISO
+for	O
+each	O
+of	O
+the	O
+regions	O
+of	O
+the	O
+ProTide	B-CHED
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+chloroquine	B-CHED
+can	O
+be	O
+highly	O
+effective	O
+against	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+in	O
+newborn	O
+mice	B-SPEC
+and	O
+may	O
+be	O
+considered	O
+as	O
+a	O
+future	O
+drug	O
+against	O
+HCoVs	O
+.	O
+
+TITLE	O
+:	O
+The	O
+economic	O
+impact	O
+of	O
+SARS	B-DISO
+in	O
+Beijing	O
+,	O
+China	O
+.	O
+
+Probable	O
+SARS	B-DISO
+cases	O
+occurring	O
+between	O
+November	O
+2002	O
+and	O
+May	O
+2003	O
+in	O
+mainland	O
+China	O
+were	O
+compiled	O
+from	O
+different	O
+sources	O
+and	O
+geo	O
+-	O
+coded	O
+into	O
+a	O
+geographical	O
+information	O
+database	O
+based	O
+on	O
+onset	O
+location	O
+.	O
+
+TITLE	O
+:	O
+Duration	O
+of	O
+symptom	B-DISO
+onset	O
+to	O
+hospital	O
+admission	O
+and	O
+admission	O
+to	O
+discharge	B-ANAT
+or	O
+death	B-PROC
+in	O
+SARS	B-DISO
+in	O
+mainland	O
+China	O
+:	O
+a	O
+descriptive	O
+study	O
+.	O
+
+The	O
+average	O
+duration	O
+of	O
+onset	O
+of	O
+symptoms	O
+to	O
+hospital	O
+admission	O
+was	O
+3	O
+.	O
+8	O
+days	O
+,	O
+of	O
+admission	O
+to	O
+discharge	B-ANAT
+for	O
+those	O
+who	O
+survived	O
+was	O
+29	O
+.	O
+7	O
+days	O
+,	O
+while	O
+admission	O
+to	O
+death	B-PROC
+for	O
+casualties	O
+was	O
+17	O
+.	O
+4	O
+days	O
+.	O
+
+The	O
+sole	B-ANAT
+factor	O
+explaining	O
+AVN	O
+in	O
+the	O
+hip	B-ANAT
+was	O
+the	O
+total	O
+dose	O
+of	O
+corticosteroids	B-CHED
+received	O
+.	O
+
+The	O
+sole	B-ANAT
+factor	O
+explaining	O
+AVN	O
+in	O
+the	O
+hip	B-ANAT
+was	O
+the	O
+total	O
+dose	O
+of	O
+corticosteroids	B-CHED
+received	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+fatality	O
+of	O
+SARS	B-DISO
+in	O
+mainland	O
+China	O
+and	O
+associated	O
+risk	O
+factors	O
+.	O
+
+The	O
+definition	O
+of	O
+probable	O
+SARS	B-DISO
+case	O
+was	O
+consistent	O
+with	O
+the	O
+definition	O
+for	O
+clinically	O
+confirmed	O
+SARS	B-DISO
+issued	O
+by	O
+the	O
+Ministry	O
+of	O
+Health	O
+of	O
+the	O
+People	O
+'	O
+s	O
+Republic	O
+of	O
+China	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+overall	O
+CFR	O
+was	O
+6	O
+.	O
+4	O
+%	O
+among	O
+5327	O
+probable	O
+SARS	B-DISO
+cases	O
+in	O
+mainland	O
+China	O
+.	O
+
+All	O
+existing	O
+Chinese	O
+SARS	B-DISO
+data	O
+sources	O
+were	O
+integrated	O
+in	O
+one	O
+final	O
+database	O
+.	O
+
+Significant	O
+toxicity	O
+of	O
+neonicotinoids	O
+can	O
+occur	O
+following	O
+large	O
+amount	O
+of	O
+oral	B-ANAT
+ingestion	O
+.	O
+
+Patients	O
+with	O
+LC	O
+are	O
+at	O
+risk	O
+for	O
+gastric	B-ANAT
+aspiration	B-DISO
+at	O
+the	O
+time	O
+of	O
+trauma	O
+,	O
+but	O
+the	O
+combined	O
+insults	O
+have	O
+not	O
+been	O
+well	O
+-	O
+studied	O
+in	O
+animal	B-SPEC
+models	O
+.	O
+
+Unwitnessed	O
+gastric	B-ANAT
+aspiration	B-DISO
+has	O
+the	O
+potential	O
+to	O
+contribute	O
+to	O
+more	O
+severe	O
+forms	O
+of	O
+LC	O
+injury	O
+associated	O
+with	O
+progression	O
+to	O
+ALI	O
+/	O
+ARDS	B-DISO
+and	O
+pneumonia	B-DISO
+in	O
+patients	O
+with	O
+thoracic	B-DISO
+trauma	O
+.	O
+
+Multiplex	O
+PCR	O
+tests	O
+sentinel	O
+the	O
+appearance	O
+of	O
+pandemic	O
+influenza	B-SPEC
+viruses	I-SPEC
+including	O
+H1N1	O
+swine	B-SPEC
+influenza	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+turn	O
+of	O
+the	O
+century	O
+seven	O
+new	O
+respiratory	O
+viruses	B-SPEC
+have	O
+infected	O
+man	B-CHED
+and	O
+two	O
+of	O
+these	O
+have	O
+resulted	O
+in	O
+worldwide	O
+epidemics	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+review	O
+article	O
+describes	O
+the	O
+pathophysiological	O
+aspects	O
+of	O
+acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+induced	O
+by	O
+combined	O
+burn	O
+and	O
+smoke	O
+inhalation	B-PROC
+and	O
+examines	O
+various	O
+therapeutic	O
+approaches	O
+.	O
+
+Nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+is	O
+generated	O
+by	O
+both	O
+inducible	O
+and	O
+constitutive	O
+isoforms	O
+of	O
+nitric	B-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+(	O
+NOS	B-PRGE
+).	O
+
+Recently	O
+,	O
+neuronal	O
+NOS	O
+emerged	O
+as	O
+a	O
+major	O
+component	O
+within	O
+the	O
+pathogenesis	B-DISO
+of	O
+ARDS	B-DISO
+.	O
+
+Pathologic	O
+laughter	O
+,	O
+on	O
+the	O
+other	O
+hand	O
+,	O
+is	O
+observed	O
+primarily	O
+in	O
+various	O
+neurologic	B-DISO
+diseases	I-DISO
+in	O
+adults	O
+.	O
+
+In	O
+the	O
+present	O
+case	O
+,	O
+a	O
+child	O
+manifested	O
+transient	O
+mutism	B-DISO
+and	O
+pathologic	O
+laughter	O
+during	O
+a	O
+severe	O
+cerebellitis	B-DISO
+.	O
+
+Headache	B-DISO
+,	O
+vertigo	B-DISO
+,	O
+and	O
+impaired	B-DISO
+consciousness	I-DISO
+developed	O
+during	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+rN	B-PRGE
+protein	I-PRGE
+in	O
+the	O
+agrobacteria	O
+-	O
+infiltrated	B-DISO
+plant	B-SPEC
+leaf	O
+accumulated	O
+up	O
+to	O
+a	O
+concentration	O
+of	O
+79	O
+microg	O
+per	O
+g	O
+fresh	B-ANAT
+leaf	O
+weight	O
+at	O
+3	O
+days	O
+post	O
+infiltration	B-DISO
+.	O
+
+However	O
+,	O
+it	O
+is	O
+critical	O
+to	O
+determine	O
+whether	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+specific	O
+memory	B-PROC
+T	B-ANAT
+cells	I-ANAT
+can	O
+persist	O
+for	O
+long	O
+periods	B-PROC
+of	O
+time	O
+.	O
+
+Forty	O
+patients	O
+of	O
+SAP	O
+-	O
+ARDS	B-DISO
+were	O
+equally	O
+randomized	O
+into	O
+the	O
+early	O
+-	O
+treated	O
+group	O
+(	O
+ET	O
+)	O
+and	O
+the	O
+late	O
+-	O
+treated	O
+group	O
+(	O
+LT	O
+),	O
+CQCQD	O
+was	O
+administered	O
+to	O
+them	O
+immediately	O
+and	O
+3	O
+days	O
+later	O
+after	O
+hospitalization	O
+respectively	O
+.	O
+
+The	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Heath	O
+Evaluation	O
+II	O
+(	O
+APACHE	O
+I	O
+)	O
+scores	O
+,	O
+the	O
+incidence	O
+and	O
+sustained	O
+time	O
+of	O
+complications	O
+,	O
+the	O
+occurrence	O
+of	O
+infection	B-DISO
+,	O
+requirement	O
+of	O
+operation	O
+shifting	O
+on	O
+day	O
+7	O
+,	O
+as	O
+well	O
+as	O
+the	O
+duration	O
+resided	O
+in	O
+hospital	O
+and	O
+mortality	O
+in	O
+patients	O
+were	O
+observed	O
+and	O
+compared	O
+.	O
+
+But	O
+further	O
+study	O
+with	O
+large	O
+samples	O
+for	O
+explore	O
+its	O
+impact	O
+on	O
+the	O
+infection	B-DISO
+incidence	O
+and	O
+the	O
+mortality	O
+is	O
+needed	O
+.	O
+
+At	O
+international	O
+level	O
+cross	O
+-	O
+border	B-ANAT
+co	O
+-	O
+operation	O
+and	O
+information	O
+exchange	O
+on	O
+infection	B-DISO
+control	O
+is	O
+the	O
+key	O
+to	O
+pandemic	O
+mitigation	O
+and	O
+containment	O
+.	O
+
+To	O
+provide	O
+the	O
+clinician	O
+with	O
+a	O
+summary	O
+of	O
+the	O
+literature	O
+on	O
+the	O
+epidemiology	O
+,	O
+diagnosis	O
+,	O
+and	O
+an	O
+evidence	O
+-	O
+base	O
+for	O
+management	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+in	O
+children	O
+.	O
+
+Promising	O
+therapies	O
+based	O
+on	O
+adult	O
+trials	O
+include	O
+use	O
+of	O
+corticosteroids	B-CHED
+for	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+fibrosis	B-DISO
+,	O
+use	O
+of	O
+4	O
+to	O
+6	O
+mL	O
+/	O
+kg	O
+tidal	O
+volumes	O
+and	O
+restrictive	O
+fluid	O
+management	O
+.	O
+
+TITLE	O
+:	O
+2	O
+-	O
+Arylbenzimidazoles	O
+as	O
+antiviral	B-CHED
+and	O
+antiproliferative	O
+agents	O
+--	O
+Part	O
+2	O
+.	O
+
+Four	O
+putative	O
+recombination	B-PROC
+sites	O
+were	O
+found	O
+at	O
+the	O
+5	O
+'-	O
+end	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+,	O
+namely	O
+at	O
+nt	O
+53	O
+,	O
+75	O
+,	O
+425	O
+,	O
+991	O
+.	O
+
+The	O
+CCoV	B-PRGE
+1	I-PRGE
+-	I-PRGE
+71	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+sequence	I-PRGE
+was	O
+found	O
+to	O
+be	O
+similar	O
+to	O
+those	O
+of	O
+other	O
+CCoVs	O
+except	O
+for	O
+several	O
+N	O
+-	O
+glycosylation	B-PROC
+sites	O
+at	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+the	O
+S	O
+protein	O
+,	O
+which	O
+could	O
+be	O
+related	O
+to	O
+the	O
+differences	O
+in	O
+virulence	B-PROC
+and	O
+cell	B-COMP
+tropism	B-PROC
+in	O
+individual	O
+CCoVs	O
+.	O
+
+76	O
+strains	O
+carried	O
+the	O
+Panton	B-PRGE
+-	I-PRGE
+Valentine	I-PRGE
+leukocidin	I-PRGE
+gene	I-PRGE
+.	O
+
+Chickens	B-SPEC
+were	O
+challenged	O
+with	O
+virulent	O
+IBV	B-SPEC
+at	O
+3	O
+weeks	O
+after	O
+the	O
+booster	O
+immunization	O
+and	O
+observed	O
+for	O
+2	O
+weeks	O
+.	O
+
+In	O
+addition	O
+,	O
+vaccination	O
+with	O
+pVAX	B-PRGE
+-	I-PRGE
+chGM	I-PRGE
+-	I-PRGE
+CSF	I-PRGE
+and	O
+pVAX	O
+-	O
+S1	O
+provided	O
+86	O
+.	O
+7	O
+%	O
+protection	O
+(	O
+13	O
+/	O
+15	O
+)	O
+against	O
+IBV	B-SPEC
+challenge	O
+.	O
+
+It	O
+is	O
+suggested	O
+that	O
+N	B-PRGE
+protein	I-PRGE
+may	O
+be	O
+related	O
+to	O
+the	O
+excessive	O
+secretion	B-PROC
+of	O
+proinflammatory	O
+cytokines	O
+during	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+at	O
+the	O
+acute	O
+phase	O
+.	O
+
+METHODS	O
+:	O
+Under	O
+the	O
+condition	B-DISO
+of	O
+the	O
+establishment	O
+of	O
+dendrtic	O
+cells	B-COMP
+(	O
+DC	B-COMP
+)	O
+culture	O
+method	O
+,	O
+we	O
+used	O
+recombinant	O
+adenovirus	O
+to	O
+infect	O
+mature	O
+DC	B-COMP
+to	O
+make	O
+clear	O
+the	O
+development	B-PROC
+changes	O
+in	O
+mRNA	B-CHED
+levels	O
+and	O
+secreted	B-PROC
+protein	B-CHED
+levels	O
+of	O
+proinflammatory	O
+cytokines	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+by	O
+using	O
+RT	O
+-	O
+PCR	O
+and	O
+ELISA	O
+.	O
+
+Among	O
+all	O
+hosts	B-COMP
+,	O
+the	O
+diversity	O
+of	O
+coronaviruses	O
+is	O
+most	O
+evidenced	O
+in	O
+bats	B-SPEC
+and	O
+birds	B-SPEC
+,	O
+which	O
+may	O
+be	O
+a	O
+result	O
+of	O
+their	O
+species	B-SPEC
+diversity	O
+,	O
+ability	O
+to	O
+fly	B-SPEC
+,	O
+environmental	O
+pressures	O
+,	O
+and	O
+habits	O
+of	O
+roosting	O
+and	O
+flocking	O
+.	O
+
+The	O
+present	O
+evidence	O
+supports	O
+that	O
+bat	B-ENZY
+coronaviruses	O
+are	O
+the	O
+gene	O
+pools	O
+of	O
+group	O
+1	O
+and	O
+2	O
+coronaviruses	O
+,	O
+whereas	O
+bird	B-SPEC
+coronaviruses	O
+are	O
+the	O
+gene	O
+pools	O
+of	O
+group	O
+3	O
+coronaviruses	O
+.	O
+
+With	O
+the	O
+increasing	O
+number	O
+of	O
+coronaviruses	O
+,	O
+more	O
+and	O
+more	O
+closely	O
+related	O
+coronaviruses	O
+from	O
+distantly	O
+related	O
+animals	B-SPEC
+have	O
+been	O
+observed	O
+,	O
+which	O
+were	O
+results	O
+of	O
+recent	O
+interspecies	O
+jumping	O
+and	O
+may	O
+be	O
+the	O
+cause	O
+of	O
+disastrous	O
+outbreaks	O
+of	O
+zoonotic	O
+diseases	O
+.	O
+
+Adult	O
+male	O
+Sprague	B-SPEC
+-	I-SPEC
+Dawley	I-SPEC
+rats	I-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+three	O
+groups	O
+:	O
+control	O
+,	O
+lipopolysaccharide	B-CHED
+,	O
+and	O
+lipopolysaccharide	B-CHED
++	O
+dobutamine	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Synthesis	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+cells	B-COMP
+and	O
+characterization	O
+of	O
+the	O
+active	O
+exoribonuclease	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+].	O
+
+The	O
+recombinant	O
+nspl4	O
+proteins	B-CHED
+with	O
+either	O
+GST	B-PRGE
+fusion	O
+or	O
+6	O
+-	O
+histidine	B-CHED
+tag	B-DISO
+were	O
+shown	O
+to	O
+possess	B-DISO
+ribonuclease	B-FUNC
+activity	I-FUNC
+but	O
+nspl4	O
+with	O
+a	O
+short	O
+MGHHHHHHGS	O
+tag	B-DISO
+sequence	O
+at	O
+the	O
+N	O
+-	O
+terminus	O
+increased	O
+the	O
+solubility	O
+of	O
+nspl4	B-PRGE
+protein	I-PRGE
+and	O
+facilitated	O
+the	O
+protein	B-CHED
+purification	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+the	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+cleaved	B-ANAT
+into	O
+S1	O
+and	O
+S2	O
+subunits	O
+at	O
+the	O
+furin	B-PRGE
+consensus	O
+motif	O
+RRFRR	O
+(	O
+537	O
+)/	O
+S	O
+in	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Furthermore	O
+,	O
+sequence	O
+analysis	O
+of	O
+CoV	O
+S	O
+proteins	B-CHED
+by	O
+multiple	O
+alignments	O
+showed	O
+conservation	O
+of	O
+an	O
+XXXR	O
+/	O
+S	O
+motif	O
+,	O
+cleavable	O
+by	O
+either	O
+furin	B-PRGE
+or	O
+other	O
+trypsin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+,	O
+at	O
+a	O
+position	O
+equivalent	O
+to	O
+the	O
+second	O
+IBV	B-PRGE
+furin	B-ENZY
+site	I-PRGE
+.	O
+
+Though	O
+viral	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+are	O
+reported	O
+triggers	O
+for	O
+exacerbations	O
+,	O
+information	O
+on	O
+these	O
+infections	B-DISO
+with	O
+asthma	B-PATH
+is	O
+sparse	O
+in	O
+Caribbean	O
+territories	O
+.	O
+
+In	O
+a	O
+cross	O
+-	O
+sectional	O
+study	O
+of	O
+70	O
+wheezing	B-DISO
+children	O
+attending	O
+the	O
+emergency	B-DISO
+department	O
+for	O
+nebulisation	O
+and	O
+80	O
+stable	O
+control	O
+subjects	O
+(	O
+2	O
+to	O
+16	O
+yr	O
+of	O
+age	O
+)	O
+in	O
+the	O
+asthma	B-PATH
+clinic	O
+,	O
+nasal	B-ANAT
+specimens	O
+were	O
+collected	O
+during	O
+the	O
+dry	O
+(	O
+n	O
+=	O
+38	O
+,	O
+January	O
+to	O
+May	O
+)	O
+and	O
+rainy	O
+(	O
+n	O
+=	O
+112	O
+,	O
+June	O
+to	O
+December	O
+)	O
+seasons	O
+.	O
+
+A	O
+multitarget	O
+,	O
+sensitive	O
+,	O
+specific	O
+high	O
+-	O
+throughput	O
+Respiratory	O
+MultiCode	O
+assay	O
+tested	O
+for	O
+respiratory	O
+-	O
+virus	B-SPEC
+sequences	O
+for	O
+eight	O
+distinct	O
+groups	O
+:	O
+human	B-SPEC
+rhinovirus	I-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+metapneumovirus	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+coronavirus	B-SPEC
+,	O
+and	O
+enterovirus	B-SPEC
+.	O
+
+Acute	O
+asthmatics	B-DISO
+were	O
+thrice	O
+as	O
+likely	O
+to	O
+be	O
+infected	O
+with	O
+a	O
+respiratory	O
+virus	B-SPEC
+(	O
+OR	O
+=	O
+2	O
+.	O
+5	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+2	O
+-	O
+5	O
+.	O
+3	O
+).	O
+
+Strong	O
+odds	O
+for	O
+rhinoviral	O
+infection	B-DISO
+were	O
+observed	O
+among	O
+nebulised	O
+children	O
+compared	O
+with	O
+stable	O
+asthmatics	B-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+005	O
+,	O
+OR	O
+=	O
+3	O
+.	O
+6	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+4	O
+-	O
+9	O
+.	O
+3	O
+,).	O
+
+Emergent	O
+wheezing	B-DISO
+illnesses	O
+during	O
+childhood	O
+can	O
+be	O
+linked	O
+to	O
+infection	B-DISO
+with	O
+rhinovirus	B-SPEC
+in	O
+Trinidad	O
+'	O
+s	O
+tropical	O
+environment	O
+.	O
+
+Further	O
+clinical	O
+and	O
+virology	O
+investigations	O
+are	O
+recommended	O
+on	O
+the	O
+role	O
+of	O
+infections	B-DISO
+with	O
+the	O
+rhinovirus	B-SPEC
+in	O
+Caribbean	O
+childhood	O
+wheeze	B-DISO
+.	O
+
+The	O
+drill	B-SPEC
+did	O
+not	O
+generate	O
+a	O
+statistical	O
+signal	O
+in	O
+the	O
+NYC	O
+-	O
+DOHMH	O
+SaTScan	O
+analysis	O
+.	O
+
+RESULTS	O
+:	O
+Records	O
+from	O
+42	O
+patients	O
+(	O
+95	O
+%)	O
+were	O
+successfully	O
+transmitted	B-DISO
+to	O
+the	O
+NYC	O
+-	O
+DOHMH	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+outbreak	O
+of	O
+SARS	B-DISO
+can	O
+be	O
+regarded	O
+as	O
+a	O
+mental	O
+health	O
+catastrophe	O
+.	O
+
+The	O
+administration	O
+of	O
+phenobarbital	O
+in	O
+this	O
+patient	O
+allowed	O
+improved	O
+symptom	B-DISO
+control	O
+,	O
+minimized	O
+the	O
+potential	O
+for	O
+propylene	B-CHED
+glycol	I-CHED
+toxicity	O
+,	O
+was	O
+not	O
+associated	O
+with	O
+respiratory	B-DISO
+depression	I-DISO
+,	O
+and	O
+facilitated	O
+successful	O
+weaning	B-PROC
+of	O
+benzodiazepines	B-CHED
+.	O
+
+RESULTS	O
+:	O
+Forty	O
+-	O
+six	O
+patients	O
+(	O
+92	O
+%)	O
+were	O
+able	O
+to	O
+use	O
+MDI	B-DISO
+with	O
+spacer	O
+effectively	O
+.	O
+
+AFM	O
+and	O
+SPR	O
+imaging	O
+analyses	O
+demonstrated	O
+that	O
+anti	O
+-	O
+SCVme	O
+specifically	O
+bound	O
+to	O
+the	O
+fusion	O
+protein	B-CHED
+immobilized	O
+onto	O
+the	O
+gold	O
+-	O
+micropatterned	O
+chip	O
+,	O
+implying	O
+that	O
+appropriate	O
+orientation	O
+of	O
+bound	O
+fusion	O
+protein	B-CHED
+by	O
+GBP	B-PRGE
+resulted	O
+in	O
+optimal	O
+exposure	O
+of	O
+the	O
+SCVme	O
+domain	O
+to	O
+the	O
+assay	O
+solution	O
+,	O
+resulting	O
+in	O
+efficient	O
+capture	O
+of	O
+anti	O
+-	O
+SCVme	O
+antibody	B-COMP
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+antibodies	B-COMP
+in	O
+cats	B-SPEC
+in	O
+Bursa	B-SPEC
+province	O
+,	O
+Turkey	B-SPEC
+,	O
+by	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+The	O
+serum	B-COMP
+samples	O
+were	O
+initially	O
+tested	O
+with	O
+the	O
+virus	B-SPEC
+neutralisation	O
+(	O
+VN	O
+)	O
+test	O
+and	O
+the	O
+results	O
+were	O
+then	O
+compared	O
+with	O
+the	O
+ELISA	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+study	O
+of	O
+synonymous	O
+codon	O
+usage	O
+variations	O
+between	O
+the	O
+nucleocapsid	B-COMP
+and	O
+spike	O
+genes	O
+of	O
+coronavirus	O
+,	O
+and	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+lectin	I-PRGE
+domain	I-PRGE
+genes	I-PRGE
+of	O
+human	B-SPEC
+and	O
+mouse	B-SPEC
+.	O
+
+Findings	O
+indicate	O
+that	O
+the	O
+nucleocapsid	B-COMP
+genes	O
+of	O
+CoVs	O
+were	O
+affected	O
+from	O
+the	O
+synonymous	O
+codon	O
+usage	O
+bias	B-SPEC
+than	O
+spike	O
+genes	O
+,	O
+and	O
+the	O
+CTLDs	O
+of	O
+human	B-SPEC
+and	O
+mouse	B-SPEC
+partially	O
+overlapped	O
+with	O
+the	O
+nucleocapsid	B-COMP
+genes	O
+of	O
+CoVs	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+observed	O
+that	O
+CTLDs	O
+which	O
+showed	O
+the	O
+similar	O
+relative	O
+synonymous	O
+codon	O
+usage	O
+(	O
+RSCU	O
+)	O
+patterns	O
+with	O
+CoVs	O
+were	O
+commonly	O
+derived	O
+from	O
+the	O
+human	B-ANAT
+chromosome	B-COMP
+12	O
+,	O
+and	O
+mouse	B-SPEC
+chromosome	B-ANAT
+6	I-ANAT
+and	O
+12	O
+,	O
+suggesting	O
+that	O
+there	O
+might	O
+be	O
+a	O
+specific	O
+genomic	O
+region	O
+or	O
+chromosomes	B-COMP
+which	O
+show	O
+a	O
+more	O
+similar	O
+synonymous	O
+codon	O
+usage	O
+pattern	O
+with	O
+viral	O
+genes	O
+.	O
+
+Late	O
+in	O
+the	O
+study	O
+,	O
+94	O
+skin	B-ANAT
+samples	O
+(	O
+ear	B-ANAT
+notches	O
+)	O
+were	O
+tested	O
+for	O
+Bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+BVDV	B-SPEC
+)	O
+by	O
+immunohistochemistry	O
+(	O
+IHC	O
+).	O
+
+Viruses	B-SPEC
+recovered	O
+by	O
+cell	B-COMP
+culture	O
+were	O
+BVDV	B-SPEC
+-	O
+1a	O
+noncytopathic	O
+(	O
+NCP	B-FUNC
+;	O
+2	O
+.	O
+7	O
+%),	O
+BVDV	B-SPEC
+-	O
+1a	O
+cytopathic	O
+(	O
+CP	O
+)	O
+vaccine	O
+strain	O
+(	O
+1	O
+.	O
+8	O
+%),	O
+BVDV	O
+-	O
+1b	O
+NCP	B-FUNC
+(	O
+2	O
+.	O
+7	O
+%),	O
+BVDV	B-SPEC
+-	O
+2a	O
+NCP	B-FUNC
+(	O
+3	O
+.	O
+2	O
+%),	O
+BVDV	B-SPEC
+-	O
+2b	O
+CP	O
+(	O
+0	O
+.	O
+5	O
+%),	O
+and	O
+Bovine	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+(	O
+2	O
+.	O
+3	O
+%).	O
+
+Bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+IHC	O
+testing	O
+was	O
+positive	O
+in	O
+5	O
+.	O
+3	O
+%	O
+of	O
+the	O
+animals	B-SPEC
+.	O
+
+Statistically	O
+significant	O
+relationships	O
+were	O
+present	O
+among	O
+the	O
+agents	O
+,	O
+lesions	O
+,	O
+and	O
+the	O
+animal	B-SPEC
+treatment	O
+,	O
+disease	O
+onset	O
+,	O
+and	O
+mortality	O
+data	O
+.	O
+
+Clinical	O
+illnesses	O
+observed	O
+in	O
+this	O
+study	O
+were	O
+lengthier	O
+than	O
+those	O
+reported	O
+16	O
+-	O
+20	O
+years	O
+ago	O
+,	O
+based	O
+on	O
+fatal	O
+disease	O
+onset	O
+,	O
+treatment	O
+interval	O
+,	O
+and	O
+day	O
+of	O
+death	B-PROC
+.	O
+
+We	O
+describe	O
+the	O
+clinical	O
+and	O
+epidemiologic	O
+characteristics	O
+of	O
+persons	O
+hospitalized	O
+for	O
+pneumonia	B-DISO
+at	O
+the	O
+national	O
+tertiary	O
+hospital	O
+for	O
+respiratory	O
+illnesses	O
+in	O
+Mexico	O
+City	O
+who	O
+had	O
+laboratory	O
+-	O
+confirmed	O
+S	O
+-	O
+OIV	O
+infection	B-DISO
+,	O
+also	O
+known	O
+as	O
+swine	B-DISO
+flu	I-DISO
+.	O
+
+Within	O
+7	O
+days	O
+after	O
+contact	O
+with	O
+the	O
+initial	O
+case	O
+patients	O
+,	O
+a	O
+mild	O
+or	O
+moderate	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+developed	O
+in	O
+22	O
+health	O
+care	O
+workers	O
+;	O
+they	O
+were	O
+treated	O
+with	O
+oseltamivir	B-CHED
+,	O
+and	O
+none	O
+were	O
+hospitalized	O
+.	O
+
+A	O
+male	O
+L	B-SPEC
+.	I-SPEC
+pardalis	I-SPEC
+and	O
+a	O
+female	O
+L	B-SPEC
+.	I-SPEC
+tigrinus	I-SPEC
+were	O
+positive	O
+for	O
+FeLV	O
+proviral	O
+DNA	O
+,	O
+and	O
+identities	O
+of	O
+PCR	O
+products	O
+were	O
+confirmed	O
+by	O
+sequencing	O
+.	O
+
+Pretreatment	O
+of	O
+Penn	O
+-	O
+98	O
+-	O
+1	O
+with	O
+trypsin	B-PRGE
+reversed	O
+its	O
+properties	O
+in	O
+syncytium	B-PROC
+formation	I-PROC
+,	O
+virus	B-SPEC
+production	O
+,	O
+and	O
+genome	O
+transport	B-PROC
+to	O
+the	O
+ER	O
+.	O
+
+ABSTRACT	O
+:	O
+Intranasal	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+type	O
+1	O
+(	O
+MHV	B-SPEC
+-	O
+1	O
+)	O
+infection	B-DISO
+of	O
+mice	B-SPEC
+induces	O
+lung	B-ANAT
+pathology	B-DISO
+similar	O
+to	O
+that	O
+observed	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+show	O
+that	O
+an	O
+intact	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+system	O
+and	O
+the	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+are	O
+required	O
+for	O
+controlling	O
+MHV	B-SPEC
+-	O
+1	O
+replication	O
+and	O
+preventing	O
+morbidity	O
+and	O
+mortality	O
+in	O
+resistant	O
+C57BL	O
+/	O
+6J	O
+mice	B-SPEC
+after	O
+infection	B-DISO
+.	O
+
+In	O
+A	O
+/	O
+J	O
+and	O
+C3H	O
+/	O
+HeJ	O
+mice	B-SPEC
+,	O
+which	O
+are	O
+highly	O
+susceptible	O
+to	O
+MHV	B-SPEC
+-	O
+1	O
+-	O
+induced	O
+disease	O
+,	O
+we	O
+demonstrate	O
+that	O
+both	O
+CD4	B-PRGE
+and	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+contribute	O
+to	O
+morbidity	O
+during	O
+primary	B-DISO
+infection	I-DISO
+,	O
+and	O
+memory	B-PROC
+responses	O
+can	O
+enhance	O
+morbidity	O
+and	O
+mortality	O
+during	O
+subsequent	O
+reexposure	O
+to	O
+MHV	B-SPEC
+-	O
+1	O
+.	O
+
+TITLE	O
+:	O
+Acquisition	O
+of	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+activity	O
+by	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+in	O
+spike	O
+protein	B-CHED
+determines	O
+the	O
+infectivity	O
+of	O
+a	O
+coronavirus	O
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+host	B-COMP
+and	O
+cell	B-COMP
+specificities	O
+are	O
+determined	O
+by	O
+specific	O
+interactions	O
+between	O
+the	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+and	O
+host	B-COMP
+cell	I-COMP
+receptor	O
+(	O
+s	O
+).	O
+
+TITLE	O
+:	O
+Intragastric	O
+administration	O
+of	O
+attenuated	O
+Salmonella	B-DISO
+typhimurium	O
+harbouring	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+DNA	O
+vaccine	O
+induced	O
+specific	O
+antibody	B-PROC
+production	I-PROC
+.	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+inoculated	O
+orally	B-ANAT
+with	O
+SL7207	O
+(	O
+pVAX	O
+-	O
+S	O
+)	O
+at	O
+different	O
+dosages	O
+,	O
+the	O
+bacterium	B-SPEC
+was	O
+safe	O
+to	O
+mice	B-SPEC
+at	O
+dosage	O
+of	O
+2x10	O
+(	O
+9	O
+)	O
+CFU	O
+and	O
+eventually	O
+eliminated	O
+from	O
+the	O
+spleen	B-ANAT
+and	O
+liver	B-ANAT
+at	O
+week	O
+4	O
+post	O
+-	O
+immunization	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immunogenicity	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+DNA	I-PRGE
+vaccine	O
+and	O
+the	O
+immunoregulatory	O
+activity	O
+of	O
+interleukin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+)	O
+were	O
+investigated	O
+.	O
+
+DNA	O
+vaccine	O
+plasmids	O
+,	O
+pcDNA	O
+-	O
+N	O
+and	O
+pcDNA	O
+-	O
+IL2	B-PRGE
+,	O
+were	O
+constructed	O
+and	O
+inoculated	O
+into	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+with	O
+or	O
+without	O
+pcDNA	O
+-	O
+IL2	B-PRGE
+by	O
+intramuscular	O
+injection	O
+.	O
+
+During	O
+the	O
+vaccination	O
+course	O
+,	O
+the	O
+candidate	O
+peptide	B-CHED
+vaccines	O
+induced	O
+strong	O
+humoral	O
+and	O
+cellular	B-COMP
+response	O
+,	O
+and	O
+provided	O
+up	O
+to	O
+80	O
+.	O
+0	O
+%	O
+immune	O
+protection	O
+,	O
+while	O
+all	O
+non	O
+-	O
+immunized	O
+chickens	B-SPEC
+in	O
+the	O
+negative	O
+control	O
+group	O
+manifested	O
+obvious	O
+typical	O
+symptoms	O
+and	O
+died	B-PROC
+after	O
+virus	B-SPEC
+challenge	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+monitor	O
+and	O
+study	O
+the	O
+molecular	O
+epidemiology	O
+,	O
+evolution	B-PROC
+and	O
+pathogenicity	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+(	O
+IBVs	B-SPEC
+)	O
+in	O
+China	O
+in	O
+recent	O
+years	O
+and	O
+further	O
+our	O
+knowledge	O
+of	O
+the	O
+evolution	B-PROC
+of	O
+IBVs	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Three	O
+types	O
+of	O
+IBV	B-SPEC
+have	O
+been	O
+cocirculating	O
+in	O
+chicken	B-SPEC
+flocks	O
+in	O
+China	O
+in	O
+recent	O
+years	O
+.	O
+
+After	O
+adjusting	O
+for	O
+physiology	O
+,	O
+injury	O
+severity	O
+,	O
+and	O
+transfusion	O
+,	O
+etomidate	B-CHED
+use	O
+remained	O
+associated	O
+with	O
+ARDS	B-DISO
+(	O
+aOR	B-FUNC
+=	O
+3	O
+.	O
+9	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+24	O
+-	O
+12	O
+.	O
+0	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Single	O
+-	O
+dose	O
+etomidate	B-CHED
+for	O
+RSI	B-DISO
+in	O
+severely	O
+injured	O
+trauma	O
+patients	O
+is	O
+associated	O
+with	O
+increased	O
+ARDS	B-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+,	O
+in	O
+part	O
+,	O
+because	O
+of	O
+an	O
+effect	O
+of	O
+etomidate	B-CHED
+on	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+We	O
+have	O
+previously	O
+shown	O
+for	O
+the	O
+coronavirus	B-SPEC
+species	B-SPEC
+responsible	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+that	O
+the	O
+transmembrane	B-COMP
+domain	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+(	O
+ETM	O
+)	O
+forms	O
+pentameric	O
+alpha	O
+-	O
+helical	O
+bundles	O
+that	O
+are	O
+likely	O
+responsible	O
+for	O
+the	O
+observed	O
+channel	B-FUNC
+activity	I-FUNC
+.	O
+
+Full	B-PRGE
+length	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+displayed	O
+channel	B-FUNC
+activity	I-FUNC
+when	O
+transiently	O
+expressed	B-PROC
+in	O
+human	B-SPEC
+embryonic	B-ANAT
+kidney	B-ANAT
+293	O
+(	O
+HEK	O
+-	O
+293	O
+)	O
+cells	B-COMP
+in	O
+a	O
+whole	O
+-	O
+cell	B-COMP
+patch	O
+clamp	O
+set	O
+-	O
+up	O
+.	O
+
+In	O
+those	O
+models	O
+,	O
+vagal	O
+nerve	B-ANAT
+transaction	O
+and	O
+splenectomy	O
+decreased	O
+cytokine	O
+release	B-PATH
+and	O
+protected	O
+against	O
+lung	B-ANAT
+injury	O
+and	O
+mortality	O
+.	O
+
+Groups	O
+were	O
+compared	O
+controlling	O
+for	O
+age	O
+,	O
+gender	O
+,	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+),	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+and	O
+ED	O
+base	O
+deficit	B-DISO
+(	O
+BD	O
+)	O
+using	O
+multiple	O
+regression	O
+analyses	O
+.	O
+
+Nsp4	B-PRGE
+is	O
+localized	O
+to	O
+the	O
+ER	B-COMP
+membrane	I-COMP
+when	O
+expressed	B-PROC
+alone	O
+but	O
+is	O
+recruited	O
+into	O
+the	O
+replication	O
+complex	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+Department	O
+for	O
+International	O
+Development	B-PROC
+(	O
+DfID	O
+).	O
+
+Most	O
+physicians	O
+and	O
+general	O
+practitioners	O
+will	O
+encounter	O
+returned	O
+travellers	O
+with	O
+fever	O
+and	O
+the	O
+majority	O
+of	O
+travel	O
+-	O
+related	O
+infection	B-DISO
+is	O
+associated	O
+with	O
+travel	O
+to	O
+the	O
+tropics	O
+.	O
+
+TITLE	O
+:	O
+Immunogenicity	O
+difference	O
+between	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+the	O
+bat	B-ENZY
+SARS	B-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+spike	O
+(	O
+S	O
+)	O
+proteins	O
+.	O
+
+Functions	O
+of	O
+lung	O
+,	O
+heart	B-ANAT
+,	O
+liver	B-ANAT
+and	O
+kidney	B-ANAT
+recovered	O
+.	O
+
+Although	O
+the	O
+transmission	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+to	O
+airline	O
+passengers	O
+inside	O
+an	O
+aircraft	O
+is	O
+a	O
+rare	O
+occurrence	O
+,	O
+it	O
+is	O
+essential	O
+to	O
+implement	O
+entry	O
+and	O
+exit	O
+screening	O
+procedures	O
+at	O
+airports	O
+within	O
+the	O
+context	O
+of	O
+the	O
+International	O
+Health	O
+Regulations	O
+(	O
+IHR	O
+)	O
+in	O
+order	B-SPEC
+to	O
+slow	O
+down	O
+the	O
+spread	O
+of	O
+infection	B-DISO
+,	O
+especially	O
+during	O
+the	O
+early	O
+phases	O
+of	O
+a	O
+pandemic	O
+event	O
+.	O
+
+Despite	O
+the	O
+severe	O
+complications	O
+in	O
+his	O
+clinical	O
+course	O
+,	O
+including	O
+diabetic	B-DISO
+ketoacidosis	I-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+ARDS	B-DISO
+,	O
+detection	O
+of	O
+Legionella	B-SPEC
+pneumophila	I-SPEC
+by	O
+a	O
+urinary	O
+antigen	B-CHED
+test	O
+,	O
+Gimenez	O
+stain	O
+and	O
+sputum	B-ANAT
+culture	O
+made	O
+prompt	O
+and	O
+proper	O
+administration	O
+of	O
+antibiotics	B-CHED
+possible	O
+,	O
+finally	O
+yielding	O
+a	O
+desirable	O
+outcome	O
+.	O
+
+Although	O
+viruses	B-SPEC
+are	O
+known	O
+to	O
+affect	O
+host	B-COMP
+survival	O
+in	O
+populations	O
+,	O
+this	O
+has	O
+not	O
+been	O
+previously	O
+evaluated	O
+in	O
+the	O
+context	O
+of	O
+host	B-COMP
+group	O
+selection	O
+.	O
+
+Viruses	B-SPEC
+were	O
+not	O
+considered	O
+in	O
+such	O
+models	O
+.	O
+
+Yet	O
+many	O
+viruses	B-SPEC
+establish	O
+species	B-SPEC
+-	O
+specific	O
+persistent	O
+,	O
+inapparent	O
+infections	B-DISO
+that	O
+are	O
+stable	O
+on	O
+an	O
+evolutionary	O
+time	O
+scale	O
+.	O
+
+This	O
+virus	O
+-	O
+centric	O
+re	O
+-	O
+examination	O
+concludes	O
+that	O
+viruses	B-SPEC
+can	O
+indeed	O
+affect	O
+and	O
+promote	O
+relative	O
+group	O
+selection	O
+.	O
+
+This	O
+report	O
+summarizes	O
+the	O
+clinical	O
+characteristics	O
+of	O
+a	O
+series	O
+of	O
+10	O
+patients	O
+with	O
+novel	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+virus	B-PROC
+infection	I-PROC
+and	O
+ARDS	B-DISO
+at	O
+a	O
+tertiary	O
+-	O
+care	O
+ICU	O
+in	O
+Michigan	O
+.	O
+
+P	O
+-	O
+TMA	B-CHED
+Cl	O
+significantly	O
+decreased	O
+P	O
+(	O
+DA	O
+)	O
+in	O
+normal	O
+and	O
+inflamed	O
+cells	B-COMP
+and	O
+attenuated	O
+pressure	O
+-	O
+induced	O
+increases	O
+in	O
+L	O
+(	O
+p	O
+).	O
+
+Unmodified	O
+and	O
+SeMet	O
+-	O
+substituted	O
+proteins	O
+were	O
+crystallized	O
+under	O
+similar	O
+conditions	O
+,	O
+resulting	O
+in	O
+tetragonal	O
+crystals	B-ANAT
+that	O
+belonged	O
+to	O
+space	O
+group	O
+P4	O
+(	O
+3	O
+).	O
+
+ABSTRACT	O
+:	O
+An	O
+ideal	O
+animal	O
+model	O
+for	O
+hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+(	O
+HEV	B-SPEC
+)	O
+research	O
+is	O
+still	O
+unavailable	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+search	O
+for	O
+the	O
+pharmacophore	O
+space	O
+around	O
+the	O
+diketoacid	O
+core	O
+,	O
+three	O
+classes	O
+of	O
+dihydroxychromone	O
+derivatives	O
+were	O
+prepared	O
+.	O
+
+Based	O
+on	O
+SAR	B-CHED
+study	O
+,	O
+an	O
+extended	O
+feature	O
+of	O
+the	O
+pharmacophore	O
+model	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+NTPase	B-ENZY
+/	O
+helicase	B-PRGE
+was	O
+proposed	O
+which	O
+is	O
+constituted	O
+of	O
+a	O
+diketoacid	O
+core	O
+,	O
+a	O
+hydrophobic	O
+arylmethyl	O
+substituent	O
+,	O
+and	O
+a	O
+free	O
+catechol	B-CHED
+unit	O
+.	O
+
+ABSTRACT	O
+:	O
+Raccoon	B-SPEC
+dog	I-SPEC
+is	O
+one	O
+of	O
+the	O
+suspected	O
+intermediate	O
+hosts	B-COMP
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+full	O
+genome	O
+of	O
+the	O
+IBADAN	O
+reference	O
+strain	O
+(	O
+NGA	O
+/	O
+A116E7	O
+/	O
+2006	O
+)	O
+had	O
+a	O
+genetic	O
+distance	O
+of	O
+9	O
+.	O
+7	O
+-	O
+16	O
+.	O
+4	O
+%	O
+at	O
+the	O
+nucleotide	B-CHED
+level	O
+with	O
+all	O
+available	O
+fully	O
+sequenced	O
+strains	O
+.	O
+
+In	O
+addition	O
+,	O
+differential	O
+signals	O
+are	O
+required	O
+for	O
+trafficking	B-PROC
+and	O
+retention	B-PROC
+of	O
+virus	B-SPEC
+-	O
+specific	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+during	O
+chronic	O
+demyelination	B-DISO
+in	O
+JHMV	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Lower	O
+respiratory	O
+tract	O
+infections	O
+are	O
+the	O
+leading	O
+cause	O
+of	O
+death	B-PROC
+in	O
+children	O
+worldwide	O
+.	O
+
+The	O
+majority	O
+of	O
+HCoV	O
+infections	B-DISO
+occurred	O
+during	O
+winter	O
+months	O
+,	O
+and	O
+over	O
+62	O
+%	O
+were	O
+in	O
+previously	O
+healthy	O
+children	O
+.	O
+
+Recombinant	O
+L	B-SPEC
+.	I-SPEC
+lactis	I-SPEC
+,	O
+expressing	O
+the	O
+SN	B-PRGE
+protein	I-PRGE
+,	O
+was	O
+constructed	O
+with	O
+the	O
+pNZ8112	O
+plasmid	O
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+field	O
+vaccination	O
+coverage	O
+and	O
+persistence	O
+of	O
+Arkansas	O
+-	O
+type	O
+viruses	B-SPEC
+in	O
+commercial	O
+broilers	O
+.	O
+
+Protection	O
+studies	O
+conducted	O
+on	O
+birds	B-SPEC
+vaccinated	O
+with	O
+Arkansas	O
+-	O
+and	O
+Delaware	O
+-	O
+type	O
+vaccines	O
+and	O
+removed	O
+from	O
+the	O
+field	O
+at	O
+21	O
+days	O
+postvaccination	O
+showed	O
+complete	O
+protection	O
+against	O
+challenge	O
+with	O
+Delaware	O
+(	O
+except	O
+for	O
+one	O
+bird	B-SPEC
+),	O
+whereas	O
+protection	O
+against	O
+Arkansas	O
+challenge	O
+was	O
+between	O
+37	O
+.	O
+5	O
+%	O
+and	O
+62	O
+.	O
+5	O
+%.	O
+
+ABSTRACT	O
+:	O
+The	O
+understanding	O
+of	O
+innate	O
+immune	B-PROC
+modulation	I-PROC
+by	O
+pathogens	O
+and	O
+immune	O
+-	O
+modulating	O
+agents	O
+,	O
+including	O
+synthetic	O
+oligodeoxynucleotides	O
+(	O
+CpG	O
+ODNs	O
+),	O
+has	O
+offered	O
+several	O
+new	O
+approaches	O
+to	O
+improve	O
+prophylactic	O
+and	O
+therapeutic	O
+strategies	O
+against	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+However	O
+,	O
+in	O
+this	O
+regard	O
+not	O
+much	O
+work	O
+has	O
+been	O
+done	O
+in	O
+avian	B-SPEC
+medicine	B-CHED
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+analyzed	O
+the	O
+kinetics	O
+of	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+),	O
+cytokine	O
+,	O
+and	O
+chemokine	O
+mRNA	B-PROC
+expression	B-PROC
+in	O
+chicken	B-SPEC
+embryonic	B-ANAT
+spleen	B-ANAT
+at	O
+6	O
+hr	O
+,	O
+24	O
+hr	O
+,	O
+48	O
+hr	O
+,	O
+and	O
+72	O
+hr	O
+after	O
+administration	O
+of	O
+CpG	O
+ODN	O
+2007	O
+(	O
+B	O
+-	O
+class	B-SPEC
+)	O
+in	O
+18	O
+-	O
+day	O
+-	O
+old	O
+chicken	B-SPEC
+embryos	B-ANAT
+.	O
+
+Moreover	O
+,	O
+the	O
+infection	B-DISO
+was	O
+blocked	O
+by	O
+antibodies	B-COMP
+against	O
+pAPN	O
+,	O
+implying	O
+the	O
+critical	O
+role	O
+of	O
+pAPN	O
+during	O
+virus	B-SPEC
+entry	O
+.	O
+
+ABSTRACT	O
+:	O
+Patients	O
+who	O
+are	O
+diagnosed	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+)	O
+usually	O
+have	O
+ventilation	O
+-	O
+perfusion	O
+mismatch	O
+,	O
+severe	O
+decrease	O
+in	O
+lung	B-PROC
+capacity	I-PROC
+,	O
+and	O
+gas	B-ENZY
+exchange	O
+abnormalities	O
+.	O
+
+Significant	O
+expression	O
+levels	O
+were	O
+identified	O
+for	O
+ANPEP	O
+(	O
+a	O
+receptor	O
+for	O
+CoV	O
+),	O
+as	O
+well	O
+as	O
+inhibition	B-PROC
+of	O
+the	O
+STAT1	B-PRGE
+pathway	B-PROC
+,	O
+IFNs	O
+production	O
+and	O
+CXCL10	B-PRGE
+(	O
+a	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+recruiter	O
+).	O
+
+TITLE	O
+:	O
+NMR	O
+assignment	O
+of	O
+the	O
+domain	O
+513	O
+-	O
+651	O
+from	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+nonstructural	O
+protein	B-CHED
+nsp3	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Sequence	O
+-	O
+specific	O
+NMR	O
+assignments	O
+of	O
+an	O
+internal	O
+domain	O
+of	O
+the	O
+protein	O
+nsp3	B-PRGE
+,	O
+nsp3	B-PRGE
+(	I-PRGE
+513	I-PRGE
+-	I-PRGE
+651	I-PRGE
+),	I-PRGE
+which	O
+is	O
+a	O
+part	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+replicase	B-PRGE
+polyprotein	O
+,	O
+have	O
+been	O
+determined	O
+,	O
+using	O
+triple	O
+-	O
+resonance	O
+NMR	O
+experiments	O
+with	O
+the	O
+uniformly	O
+[(	O
+13	O
+)	O
+C	O
+,(	O
+15	O
+)	O
+N	O
+]-	O
+labeled	O
+protein	B-CHED
+.	O
+
+RCE	O
+appears	O
+to	O
+be	O
+a	O
+safe	O
+and	O
+effective	O
+treatment	O
+for	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+and	O
+ACS	B-FUNC
+.	O
+
+RESULTS	O
+:	O
+Sixty	O
+-	O
+two	O
+percent	O
+of	O
+the	O
+patients	O
+had	O
+at	O
+least	O
+one	O
+previous	O
+episode	O
+of	O
+ACS	B-FUNC
+.	O
+
+Many	O
+patients	O
+in	O
+the	O
+severe	O
+complication	B-DISO
+category	O
+had	O
+multiple	O
+severe	O
+complications	O
+.	O
+
+Despite	O
+prompt	O
+diagnosis	O
+and	O
+appropriate	O
+treatment	O
+with	O
+antimicrobial	B-CHED
+agents	O
+active	O
+against	O
+Legionella	B-SPEC
+,	O
+the	O
+lethal	O
+complications	O
+of	O
+Legionella	B-DISO
+pneumonia	I-DISO
+are	O
+septic	B-DISO
+shock	I-DISO
+/	O
+MODS	B-DISO
+and	O
+interstitial	B-DISO
+pneumonia	I-DISO
+/	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+interstitial	B-DISO
+pneumonia	I-DISO
+complicating	O
+RS3PE	B-DISO
+syndrome	I-DISO
+in	O
+which	O
+soluble	O
+interleukin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+receptor	I-PRGE
+(	O
+sIL	B-PRGE
+-	I-PRGE
+2R	I-PRGE
+)	O
+proved	O
+useful	O
+for	O
+assessing	O
+symptoms	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+patient	O
+was	O
+a	O
+70	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+who	O
+had	O
+been	O
+given	O
+a	O
+diagnosis	O
+of	O
+remitting	B-DISO
+seronegative	I-DISO
+symmetrical	I-DISO
+synovitis	I-DISO
+with	I-DISO
+pitting	I-DISO
+edema	I-DISO
+(	O
+RS3PE	O
+)	O
+syndrome	B-DISO
+and	O
+had	O
+been	O
+placed	O
+on	O
+low	O
+-	O
+dose	O
+steroid	B-CHED
+therapy	O
+in	O
+the	O
+Department	O
+of	O
+Orthopedics	O
+.	O
+
+During	O
+treatment	O
+,	O
+sudden	O
+fever	B-PROC
+,	O
+hypoxemia	O
+and	O
+chest	B-ANAT
+radiography	O
+-	O
+confirmed	O
+interstitial	B-ANAT
+shadows	O
+throughout	O
+the	O
+lung	B-ANAT
+fields	O
+were	O
+noted	O
+,	O
+and	O
+the	O
+patient	O
+was	O
+referred	O
+to	O
+the	O
+Department	O
+of	O
+Internal	O
+Medicine	B-CHED
+.	O
+
+TITLE	O
+:	O
+Host	B-COMP
+-	O
+pathogen	O
+interactions	O
+during	O
+coronavirus	B-DISO
+infection	I-DISO
+of	O
+primary	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+nonstructural	O
+protein	B-CHED
+2	O
+interacts	O
+with	O
+a	O
+host	B-COMP
+protein	B-CHED
+complex	I-ANAT
+involved	O
+in	O
+mitochondrial	B-PROC
+biogenesis	B-PROC
+and	O
+intracellular	B-COMP
+signaling	B-PROC
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+nsp2	B-PRGE
+may	O
+be	O
+involved	O
+in	O
+the	O
+disruption	O
+of	O
+intracellular	B-COMP
+host	B-COMP
+signaling	B-PROC
+during	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+These	O
+data	O
+,	O
+together	O
+with	O
+high	O
+-	O
+field	O
+relaxation	O
+and	O
+heteronuclear	O
+NOE	O
+,	O
+provide	O
+evidence	O
+for	O
+correlated	O
+rigid	B-DISO
+-	O
+body	B-ANAT
+motions	O
+of	O
+the	O
+entire	O
+beta	O
+-	O
+hairpin	O
+,	O
+and	O
+corresponding	O
+motions	O
+of	O
+adjacent	O
+loops	O
+with	O
+a	O
+time	O
+constant	O
+of	O
+0	O
+.	O
+8	O
+ns	O
+(	O
+mesodynamics	O
+).	O
+
+Chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+is	O
+the	O
+first	O
+cause	O
+of	O
+cor	B-DISO
+pulmonale	I-DISO
+,	O
+far	O
+before	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+and	O
+obesity	B-DISO
+-	I-DISO
+hypoventilation	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Nonthrombotic	O
+pulmonary	B-DISO
+embolism	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Nonthrombotic	O
+pulmonary	B-DISO
+embolism	I-DISO
+(	O
+NTPE	O
+)	O
+is	O
+defined	O
+as	O
+embolisation	O
+to	O
+the	O
+pulmonary	O
+circulation	B-PROC
+of	O
+different	O
+cell	B-COMP
+types	O
+(	O
+adipocytes	B-ANAT
+,	O
+haematopoietic	B-ANAT
+,	O
+amniotic	B-ANAT
+,	O
+trophoblastic	O
+or	O
+tumour	B-DISO
+),	O
+bacteria	B-SPEC
+,	O
+fungi	B-SPEC
+,	O
+foreign	O
+material	O
+or	O
+gas	B-ENZY
+.	O
+
+Profiling	O
+of	O
+IFNAR	B-PRGE
+-/-	O
+mice	B-SPEC
+allowed	O
+us	O
+to	O
+identify	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+-	O
+independent	O
+and	O
+-	O
+dependent	O
+responses	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+rapid	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assays	O
+,	O
+specific	O
+for	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+and	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+were	O
+evaluated	O
+for	O
+the	O
+detection	O
+of	O
+these	O
+viruses	B-SPEC
+in	O
+clinical	O
+respiratory	B-ANAT
+samples	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+the	O
+last	O
+year	O
+there	O
+have	O
+been	O
+more	O
+studies	O
+determining	O
+predisposition	O
+to	O
+severe	O
+bronchiolitis	B-DISO
+and	O
+its	O
+consequences	O
+.	O
+
+The	O
+impact	O
+of	O
+'	O
+other	O
+'	O
+viruses	B-SPEC
+(	O
+RSV	B-SPEC
+,	O
+influenza	B-DISO
+,	O
+adenovirus	B-DISO
+,	O
+parainfluenza	B-DISO
+,	O
+rhinovirus	B-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+[	O
+hMPV	B-SPEC
+],	O
+coronavirus	B-SPEC
+,	O
+boca	B-DISO
+-	O
+virus	B-SPEC
+,	O
+enterovirus	B-SPEC
+,	O
+paraechovirus	O
+)	O
+has	O
+been	O
+investigated	O
+.	O
+
+The	O
+gene	O
+that	O
+encodes	O
+a	O
+double	B-PRGE
+-	I-PRGE
+mutant	I-PRGE
+IBV	B-SPEC
+nsp2	I-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+domain	I-PRGE
+(	O
+residues	O
+9	O
+-	O
+393	O
+of	O
+the	O
+polyprotein	O
+,	O
+with	O
+mutations	O
+Q132L	O
+and	O
+L270F	O
+)	O
+was	O
+cloned	O
+and	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+the	O
+protein	B-CHED
+was	O
+subjected	O
+to	O
+crystallization	O
+trials	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+threat	O
+of	O
+outbreak	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+such	O
+as	O
+non	O
+-	O
+seasonal	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+),	O
+commonly	O
+referred	O
+to	O
+as	O
+Swine	B-DISO
+Flu	I-DISO
+,	O
+can	O
+provoke	O
+the	O
+implementation	O
+of	O
+public	O
+health	O
+control	O
+measures	O
+such	O
+as	O
+quarantine	O
+.	O
+
+The	O
+age	O
+-	O
+specific	O
+reference	O
+ranges	O
+of	O
+normal	O
+oral	B-ANAT
+temperature	O
+from	O
+this	O
+study	O
+for	O
+students	O
+<	O
+or	O
+=	O
+12	O
+years	O
+old	O
+and	O
+>	O
+12	O
+years	O
+old	O
+were	O
+35	O
+.	O
+7	O
+degrees	O
+C	O
+to	O
+37	O
+.	O
+7	O
+degrees	O
+C	O
+and	O
+35	O
+.	O
+6	O
+degrees	O
+C	O
+to	O
+37	O
+.	O
+4	O
+degrees	O
+C	O
+,	O
+respectively	O
+.	O
+
+Compared	O
+to	O
+low	O
+PEEP	B-CHED
+,	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+ratio	O
+and	O
+alveolar	B-ANAT
+recruitment	B-DISO
+were	O
+increased	O
+with	O
+high	O
+PEEP	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+is	O
+critical	O
+for	O
+host	B-PROC
+defence	I-PROC
+against	O
+respiratory	O
+coronaviruses	O
+(	O
+CoVs	O
+).	O
+
+Outbreaks	O
+of	O
+the	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+and	O
+avian	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+are	O
+but	O
+recent	O
+examples	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+in	O
+human	B-SPEC
+serum	B-COMP
+using	O
+a	O
+localized	O
+surface	O
+plasmon	O
+coupled	O
+fluorescence	O
+fiber	B-ANAT
+-	O
+optic	B-ANAT
+biosensor	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+work	O
+,	O
+the	O
+inhibitory	O
+activity	O
+of	O
+pyridine	B-CHED
+N	I-CHED
+-	I-CHED
+oxide	I-CHED
+derivatives	O
+against	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+predicted	O
+in	O
+terms	O
+of	O
+quantitative	O
+structure	O
+-	O
+activity	O
+relationship	O
+(	O
+QSAR	O
+)	O
+models	O
+.	O
+
+Comparison	O
+of	O
+the	O
+results	O
+of	O
+the	O
+proposed	O
+model	O
+with	O
+those	O
+of	O
+GA	O
+-	O
+PLS	B-DISO
+-	O
+ANFIS	O
+shows	O
+that	O
+the	O
+shuffling	O
+MARS	O
+-	O
+ANFIS	O
+model	O
+is	O
+superior	O
+and	O
+can	O
+be	O
+considered	O
+as	O
+a	O
+tool	O
+for	O
+predicting	O
+the	O
+inhibitory	O
+behavior	O
+of	O
+SARS	B-DISO
+drug	O
+-	O
+like	O
+molecules	O
+.	O
+
+Members	O
+of	O
+the	O
+GBF	B-PRGE
+/	O
+Gea	B-SPEC
+and	O
+BIG	B-PRGE
+/	O
+Sec7	B-PRGE
+subfamilies	O
+are	O
+large	O
+proteins	B-CHED
+on	O
+the	O
+order	B-SPEC
+of	O
+200	O
+kDa	O
+,	O
+and	O
+they	O
+possess	B-DISO
+multiple	O
+homology	O
+domains	O
+.	O
+
+This	O
+study	O
+was	O
+designed	O
+to	O
+profile	O
+the	O
+tolerability	O
+of	O
+RCIM	O
+by	O
+reviewing	O
+narratively	O
+all	O
+randomized	O
+,	O
+double	O
+-	O
+blind	B-DISO
+,	O
+placebo	O
+-	O
+controlled	O
+clinical	O
+trials	O
+and	O
+open	O
+-	O
+label	B-CHED
+studies	O
+as	O
+well	O
+as	O
+data	O
+from	O
+postmarketing	O
+surveillance	O
+studies	O
+representing	O
+>	O
+30	O
+million	O
+prescriptions	O
+.	O
+
+RCIM	O
+should	O
+not	O
+be	O
+used	O
+in	O
+case	O
+of	O
+acute	O
+streptococcal	O
+glomerulonephritis	B-DISO
+,	O
+acquired	B-DISO
+immune	I-DISO
+deficiency	I-DISO
+syndrome	I-DISO
+,	O
+severe	O
+viral	B-DISO
+disease	I-DISO
+,	O
+or	O
+severe	O
+autoimmune	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Multiply	O
+organ	B-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+tramadol	O
+intoxication	O
+alone	O
+.	O
+
+ABSTRACT	O
+:	O
+Tramadol	O
+is	O
+a	O
+synthetic	O
+,	O
+centrally	O
+acting	O
+analgesic	O
+for	O
+the	O
+treatment	O
+of	O
+moderate	O
+to	O
+severe	B-DISO
+pain	I-DISO
+.	O
+
+A	O
+normal	O
+-	O
+dose	O
+tramadol	O
+has	O
+less	O
+adverse	B-DISO
+effects	I-DISO
+than	O
+other	O
+opioids	O
+.	O
+
+With	O
+a	O
+history	O
+of	O
+tramadol	O
+abuse	B-DISO
+for	O
+6	O
+months	O
+,	O
+the	O
+patient	O
+was	O
+found	O
+unconsciousness	O
+in	O
+bed	B-DISO
+8	O
+hours	O
+before	O
+hospitalization	O
+.	O
+
+A	O
+toxicologic	O
+analysis	O
+showed	O
+a	O
+tramadol	O
+blood	B-ANAT
+concentration	O
+of	O
+9	O
+.	O
+5	O
+mg	O
+/	O
+L	O
+without	O
+toxic	O
+levels	O
+of	O
+other	O
+drugs	O
+.	O
+
+Preference	O
+will	O
+be	O
+given	O
+to	O
+rRBD	B-PRGE
+expressed	B-PROC
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+for	O
+future	O
+evaluation	O
+of	O
+the	O
+vaccine	O
+efficacy	O
+in	O
+a	O
+non	O
+-	O
+human	B-SPEC
+primate	B-SPEC
+model	O
+of	O
+SARS	B-DISO
+because	O
+of	O
+its	O
+ability	O
+to	O
+refold	O
+into	O
+a	O
+native	O
+conformation	O
+more	O
+readily	O
+and	O
+to	O
+induce	O
+higher	O
+level	O
+of	O
+neutralizing	O
+antibody	B-PROC
+responses	I-PROC
+than	O
+those	O
+expressed	B-PROC
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+insect	B-SPEC
+cells	B-COMP
+.	O
+
+3a	O
+/	O
+X1	O
+also	O
+enhanced	O
+RANKL	O
+expression	B-PROC
+in	O
+mouse	B-SPEC
+stromal	O
+ST2	B-ANAT
+cells	B-COMP
+.	O
+
+The	O
+initial	O
+chest	B-ANAT
+radiograph	O
+in	O
+both	O
+of	O
+these	O
+cases	O
+showed	O
+diffuse	O
+axial	O
+interstitial	B-ANAT
+pattern	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+and	O
+spread	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+and	O
+the	O
+subsequent	O
+identification	O
+of	O
+its	O
+animal	B-SPEC
+origin	O
+study	O
+have	O
+heightened	O
+the	O
+world	O
+'	O
+s	O
+awareness	O
+of	O
+animal	B-SPEC
+-	O
+borne	O
+or	O
+zoonotic	O
+pathogens	O
+.	O
+
+The	O
+878	O
+-	O
+bp	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+covering	O
+a	O
+hypervariable	O
+region	O
+was	O
+amplified	O
+and	O
+sequenced	O
+.	O
+
+IBV	B-SPEC
+isolates	O
+in	O
+group	O
+I	O
+were	O
+not	O
+related	O
+to	O
+other	O
+IBV	B-SPEC
+strains	O
+published	O
+in	O
+the	O
+GenBank	O
+database	O
+.	O
+
+Group	O
+1	O
+nucleotide	B-CHED
+sequence	O
+identities	O
+were	O
+less	O
+than	O
+85	O
+%	O
+and	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+identities	O
+less	O
+than	O
+84	O
+%	O
+in	O
+common	O
+with	O
+IBVs	O
+published	O
+in	O
+the	O
+GenBank	O
+database	O
+.	O
+
+The	O
+clinical	O
+disease	O
+profile	O
+suggested	O
+that	O
+the	O
+pandas	B-DISO
+may	O
+have	O
+suffered	B-DISO
+a	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Therefore	O
+,	O
+a	O
+series	O
+of	O
+detection	O
+including	O
+virus	B-SPEC
+isolation	O
+,	O
+electron	O
+microscopy	O
+,	O
+cytobiological	O
+assay	O
+,	O
+serum	B-COMP
+neutralization	O
+and	O
+RT	O
+-	O
+PCR	O
+were	O
+used	O
+to	O
+identify	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Elucidation	O
+of	O
+the	O
+stability	O
+and	O
+functional	O
+regions	O
+of	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	I-PRGE
+nucleocapsid	B-ANAT
+protein	B-CHED
+.	O
+
+The	O
+primary	O
+function	O
+of	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+nucleocapsid	B-PRGE
+protein	B-CHED
+(	O
+N	B-PRGE
+protein	I-PRGE
+)	O
+is	O
+to	O
+recognize	O
+viral	O
+genomic	O
+RNA	O
+,	O
+which	O
+leads	O
+to	O
+ribonucleocapsid	O
+formation	B-PROC
+.	O
+
+This	O
+study	O
+may	O
+benefit	O
+the	O
+understanding	O
+of	O
+the	O
+mechanism	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+nucleocapsid	B-COMP
+formation	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+Common	O
+household	O
+disinfectants	B-CHED
+and	O
+antiseptics	O
+were	O
+effective	O
+at	O
+inactivating	O
+MHV	B-SPEC
+,	O
+a	O
+possible	O
+surrogate	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+from	O
+surfaces	O
+when	O
+used	O
+as	O
+directed	O
+.	O
+
+Recent	O
+studies	O
+have	O
+demonstrated	O
+that	O
+significant	O
+axonal	O
+injury	O
+also	O
+occurs	O
+in	O
+MS	O
+patients	O
+and	O
+correlates	O
+with	O
+neurological	O
+dysfunction	O
+,	O
+but	O
+it	O
+is	O
+not	O
+known	O
+whether	O
+this	O
+neuronal	O
+damage	O
+is	O
+a	O
+primary	B-DISO
+disease	I-DISO
+process	O
+,	O
+or	O
+occurs	O
+only	O
+secondary	O
+to	O
+demyelination	B-DISO
+.	O
+
+The	O
+pathogenic	O
+properties	O
+of	O
+genetically	O
+engineered	O
+isogenic	O
+spike	O
+protein	B-CHED
+recombinant	O
+demyelinating	O
+and	O
+nondemyelinating	O
+strains	O
+of	O
+MHV	B-SPEC
+were	O
+compared	O
+.	O
+
+Studies	O
+demonstrate	O
+that	O
+a	O
+demyelinating	O
+strain	O
+of	O
+MHV	B-SPEC
+causes	O
+concomitant	O
+axonal	O
+loss	O
+and	O
+macrophage	B-ANAT
+-	O
+mediated	O
+demyelination	B-DISO
+.	O
+
+Despite	O
+the	O
+autopsy	O
+findings	O
+,	O
+all	O
+intravital	O
+specimens	O
+collected	O
+(	O
+blood	B-ANAT
+,	O
+urine	B-ANAT
+,	O
+and	O
+tracheal	B-ANAT
+mucus	I-ANAT
+)	O
+and	O
+all	O
+clinical	O
+Candida	B-SPEC
+antigen	B-CHED
+tests	O
+were	O
+unsuspicious	O
+.	O
+
+Suppression	B-DISO
+of	O
+immune	B-PROC
+response	I-PROC
+and	O
+possible	O
+previous	O
+gastric	B-ANAT
+Candida	B-SPEC
+colonization	O
+may	O
+contribute	O
+to	O
+hazardous	O
+outcomes	O
+.	O
+
+The	O
+2002	O
+-	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+,	O
+where	O
+27	O
+%	O
+of	O
+cases	O
+were	O
+healthcare	O
+workers	O
+,	O
+was	O
+used	O
+as	O
+an	O
+example	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+2002	O
+/	O
+3	O
+,	O
+a	O
+prototype	O
+virus	B-SPEC
+was	O
+isolated	O
+from	O
+a	O
+patient	O
+in	O
+Frankfurt	O
+/	O
+Germany	O
+(	O
+strain	O
+Frankfurt	O
+-	O
+1	O
+).	O
+
+To	O
+study	O
+the	O
+role	O
+of	O
+ORF	B-PRGE
+7b	I-PRGE
+in	O
+the	O
+context	O
+of	O
+virus	B-PROC
+replication	I-PROC
+,	O
+we	O
+cloned	O
+a	O
+full	O
+genome	O
+cDNA	O
+copy	O
+of	O
+Frankfurt	O
+-	O
+1	O
+in	O
+a	O
+bacterial	O
+artificial	O
+chromosome	B-COMP
+downstream	O
+of	O
+a	O
+T7	B-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+promoter	I-PRGE
+.	O
+
+In	O
+CaCo	O
+-	O
+2	O
+and	O
+HUH7	O
+cells	B-COMP
+,	O
+but	O
+not	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+the	O
+variant	O
+carrying	O
+the	O
+ORF	O
+7b	O
+deletion	O
+had	O
+a	O
+replicative	O
+advantage	O
+against	O
+the	O
+parental	O
+virus	B-SPEC
+(	O
+4	O
+-	O
+and	O
+6	O
+-	O
+fold	O
+increase	O
+of	O
+virus	B-SPEC
+RNA	O
+in	O
+supernatant	O
+,	O
+respectively	O
+).	O
+
+In	O
+Syrian	B-SPEC
+Golden	I-SPEC
+Hamsters	I-SPEC
+inoculated	O
+intranasally	O
+with	O
+10e4	O
+plaque	B-DISO
+forming	O
+units	O
+of	O
+either	O
+virus	B-SPEC
+,	O
+mean	O
+titers	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+and	O
+viral	O
+RNA	O
+in	O
+the	O
+lungs	B-ANAT
+after	O
+24	O
+h	O
+were	O
+increased	O
+23	O
+-	O
+and	O
+94	O
+.	O
+8	O
+-	O
+fold	O
+,	O
+respectively	O
+,	O
+with	O
+the	O
+deleted	O
+virus	B-SPEC
+.	O
+
+Upon	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+of	O
+both	O
+viruses	B-SPEC
+are	O
+activated	O
+for	O
+membrane	B-PROC
+fusion	I-PROC
+by	O
+proteases	O
+,	O
+such	O
+as	O
+trypsin	B-PRGE
+,	O
+present	O
+in	O
+the	O
+environment	O
+,	O
+facilitating	O
+virus	B-SPEC
+entry	O
+from	O
+the	O
+cell	B-COMP
+surface	I-COMP
+.	O
+
+In	O
+contrast	O
+,	O
+in	O
+the	O
+absence	O
+of	O
+extracellular	B-COMP
+proteases	O
+,	O
+these	O
+viruses	B-SPEC
+can	O
+enter	O
+cells	B-COMP
+via	O
+an	O
+endosomal	O
+pathway	B-PROC
+and	O
+utilize	O
+endosomal	O
+cathepsins	O
+for	O
+S	B-PRGE
+protein	I-PRGE
+activation	O
+.	O
+
+We	O
+demonstrate	O
+that	O
+the	O
+MHV	B-PRGE
+-	I-PRGE
+2	I-PRGE
+S	I-PRGE
+protein	B-CHED
+uses	O
+multistep	O
+conformational	O
+changes	O
+for	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+Liposome	O
+-	O
+binding	B-FUNC
+assays	O
+indicate	O
+that	O
+the	O
+receptor	O
+-	O
+bound	O
+virions	B-COMP
+are	O
+associated	O
+with	O
+the	O
+target	O
+membrane	B-COMP
+through	O
+hydrophobic	B-PROC
+interactions	I-PROC
+.	O
+
+Molecular	O
+analysis	O
+detected	O
+mutations	O
+in	O
+the	O
+CD40L	B-PRGE
+gene	I-PRGE
+(	O
+Hyper	B-PRGE
+-	I-PRGE
+IgM	I-PRGE
+syndrome	I-PRGE
+Type	I-PRGE
+1	I-PRGE
+).	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+at	O
+the	O
+Hajj	O
+:	O
+etiologies	O
+and	O
+outcomes	O
+.	O
+
+RESULTS	O
+:	O
+Severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+accounts	O
+for	O
+25	O
+.	O
+4	O
+%	O
+of	O
+admission	O
+to	O
+the	O
+ICU	O
+during	O
+Hajj	O
+.	O
+
+Calculation	O
+of	O
+the	O
+ratio	O
+of	O
+the	O
+cumulative	O
+number	O
+of	O
+deaths	B-PROC
+to	O
+cases	O
+during	O
+the	O
+course	O
+of	O
+an	O
+epidemic	O
+tends	O
+to	O
+result	O
+in	O
+a	O
+biased	O
+CFR	O
+.	O
+
+At	O
+48	O
+hours	O
+,	O
+LBP	O
+levels	O
+were	O
+significantly	O
+higher	O
+in	O
+ARDS	B-DISO
+patients	O
+than	O
+in	O
+ALI	O
+patients	O
+(	O
+112	O
+.	O
+5	O
++/-	O
+71	O
+.	O
+8	O
+microg	O
+/	O
+ml	O
+vs	O
+.	O
+76	O
+.	O
+6	O
++/-	O
+55	O
+.	O
+9	O
+microg	O
+/	O
+ml	O
+,	O
+P	O
+=	O
+0	O
+.	O
+0001	O
+).	O
+
+While	O
+comparing	O
+the	O
+interactions	O
+that	O
+humans	B-SPEC
+and	O
+bats	B-SPEC
+establish	O
+with	O
+Lyssavirus	B-SPEC
+,	O
+scientists	O
+try	O
+to	O
+understand	O
+the	O
+molecular	O
+basis	O
+ofpathogenicity	O
+in	O
+man	B-CHED
+,	O
+a	O
+indispensable	O
+prerequisite	O
+to	O
+identify	O
+antiviral	B-CHED
+targets	O
+in	O
+a	O
+perspective	O
+of	O
+therapy	O
+.	O
+
+One	O
+of	O
+the	O
+mechanisms	O
+that	O
+can	O
+help	O
+resolving	O
+infection	B-DISO
+is	O
+antibody	B-COMP
+-	O
+dependent	O
+,	O
+complement	O
+-	O
+mediated	O
+lysis	B-DISO
+(	O
+ADCML	O
+)	O
+of	O
+infected	O
+cells	B-COMP
+.	O
+
+ADCML	O
+assays	O
+,	O
+using	O
+FIPV	O
+strain	O
+79	O
+-	O
+1146	O
+and	O
+its	O
+deletion	O
+mutant	B-DISO
+strain	O
+Delta	O
+3abc	O
+/	O
+Delta	O
+7ab	O
+,	O
+were	O
+performed	O
+on	O
+:	O
+(	O
+i	O
+)	O
+CrFK	O
+cells	B-COMP
+that	O
+show	O
+surface	O
+-	O
+expressed	B-PROC
+viral	O
+antigens	B-CHED
+,	O
+(	O
+ii	O
+)	O
+monocytes	B-ANAT
+without	O
+surface	O
+-	O
+expressed	B-PROC
+viral	O
+proteins	B-CHED
+due	O
+to	O
+retention	B-PROC
+and	O
+(	O
+iii	O
+)	O
+monocytes	B-ANAT
+with	O
+surface	B-PRGE
+-	I-PRGE
+expressed	I-PRGE
+viral	I-PRGE
+proteins	B-CHED
+since	O
+the	O
+antibody	B-COMP
+-	O
+mediated	O
+internalization	O
+of	O
+these	O
+proteins	B-CHED
+was	O
+blocked	O
+.	O
+
+As	O
+expected	O
+,	O
+no	O
+ADCML	O
+was	O
+detected	O
+of	O
+the	O
+monocytes	B-ANAT
+without	O
+surface	O
+-	O
+expressed	B-PROC
+viral	O
+antigens	B-CHED
+.	O
+
+Although	O
+essential	O
+for	O
+efficient	O
+de	O
+-	O
+O	O
+-	O
+acetylation	B-PROC
+of	O
+Sias	O
+,	O
+this	O
+interaction	O
+is	O
+not	O
+required	O
+for	O
+catalysis	O
+nor	O
+does	O
+it	O
+affect	O
+substrate	O
+specificity	O
+.	O
+
+In	O
+fact	O
+,	O
+the	O
+distinct	O
+preference	O
+of	O
+the	O
+porcine	B-SPEC
+torovirus	I-SPEC
+enzyme	O
+for	O
+9	O
+-	O
+mono	B-DISO
+-	O
+over	O
+7	O
+,	O
+9	O
+-	O
+di	O
+-	O
+O	O
+-	O
+acetylated	O
+Sias	O
+can	O
+be	O
+explained	O
+from	O
+a	O
+single	O
+-	O
+residue	O
+difference	O
+with	O
+HEs	B-DISO
+of	O
+more	O
+promiscuous	O
+specificity	O
+.	O
+
+TITLE	O
+:	O
+Revisiting	O
+steroid	B-CHED
+treatment	O
+for	O
+septic	B-DISO
+shock	I-DISO
+:	O
+molecular	O
+actions	O
+and	O
+clinical	O
+effects	O
+--	O
+a	O
+review	O
+.	O
+
+But	O
+in	O
+4	O
+non	O
+-	O
+survival	O
+patients	O
+,	O
+the	O
+number	O
+of	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+kept	O
+continuously	O
+in	O
+lower	O
+level	O
+.	O
+
+Discontinuance	O
+of	O
+immunosuppressive	B-CHED
+agents	I-CHED
+in	O
+severe	O
+CMV	B-SPEC
+pneumonia	B-DISO
+patients	O
+was	O
+safe	O
+.	O
+
+CONCLUSIONS	O
+:	O
+CMV	B-SPEC
+pneumonia	B-DISO
+is	O
+associated	O
+with	O
+lower	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+level	O
+in	O
+kidney	B-ANAT
+transplant	I-ANAT
+recipients	O
+.	O
+
+The	O
+spectrum	O
+of	O
+interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+gamma	O
+responses	O
+of	O
+Balb	O
+/	O
+c	O
+mice	B-SPEC
+immunized	O
+against	O
+two	O
+different	O
+forms	O
+of	O
+SARS	B-DISO
+CoV	O
+-	O
+N	O
+plasmid	O
+was	O
+then	O
+analyzed	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+this	O
+study	O
+,	O
+four	O
+different	O
+plasmids	O
+were	O
+constructed	O
+:	O
+(	O
+i	O
+)	O
+DNA	O
+encoding	O
+the	O
+unmodified	O
+N	O
+(	O
+p	O
+-	O
+N	O
+)	O
+or	O
+N	O
+(	O
+70	O
+-	O
+122	O
+)	O
+(	O
+p	O
+-	O
+N	O
+(	O
+70	O
+-	O
+122	O
+))	O
+as	O
+an	O
+endogenous	O
+cytoplasmic	B-COMP
+protein	B-CHED
+or	O
+(	O
+ii	O
+)	O
+DNA	O
+encoding	O
+a	O
+lysosome	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+membrane	B-COMP
+protein	B-CHED
+(	O
+LAMP	B-PRGE
+)	O
+chimera	B-DISO
+with	O
+N	O
+(	O
+p	O
+-	O
+LAMP	B-CHED
+/	O
+N	O
+)	O
+or	O
+N	O
+(	O
+70	O
+-	O
+122	O
+)	O
+(	O
+p	O
+-	O
+LAMP	B-CHED
+/	O
+N	O
+(	O
+70	O
+-	O
+122	O
+)).	O
+
+These	O
+findings	O
+show	O
+that	O
+DNA	O
+vaccines	O
+,	O
+even	O
+epitope	B-CHED
+-	O
+based	O
+DNA	O
+vaccines	O
+using	O
+LAMP	O
+as	O
+chimera	B-DISO
+,	O
+can	O
+elicit	O
+both	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+TITLE	O
+:	O
+A	O
+real	O
+-	O
+time	O
+TaqMan	O
+RT	O
+-	O
+PCR	O
+assay	O
+with	O
+an	O
+internal	O
+amplification	B-DISO
+control	O
+for	O
+rapid	O
+detection	O
+of	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+in	O
+swine	B-SPEC
+fecal	B-ANAT
+samples	O
+.	O
+
+TITLE	O
+:	O
+Airborne	O
+virus	B-SPEC
+capture	O
+and	O
+inactivation	B-DISO
+by	O
+an	O
+electrostatic	O
+particle	O
+collector	O
+.	O
+
+This	O
+article	O
+examines	O
+the	O
+pedagogical	O
+innovations	O
+that	O
+allow	O
+clinical	O
+teaching	O
+to	O
+continue	O
+without	O
+medical	O
+students	O
+examining	O
+actual	O
+patients	O
+,	O
+and	O
+proposes	O
+a	O
+contingency	O
+plan	B-DISO
+in	O
+the	O
+event	O
+of	O
+future	O
+outbreaks	O
+that	O
+may	O
+necessitate	O
+similar	O
+containment	O
+measures	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Study	O
+on	O
+interaction	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+and	O
+MAP19	O
+].	O
+
+Using	O
+a	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+screen	O
+with	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+as	O
+a	O
+bait	O
+,	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+found	O
+to	O
+interact	O
+with	O
+MAP19	B-PRGE
+,	O
+a	O
+non	O
+-	O
+enzymatic	O
+protein	B-CHED
+of	O
+MASP	B-PRGE
+(	O
+mannan	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+serine	B-CHED
+protease	I-PRGE
+).	O
+
+SARS	B-DISO
+-	O
+CoV	O
+N	O
+greatly	O
+increased	O
+the	O
+amount	O
+of	O
+MAP19	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Antigen	B-CHED
+-	O
+capture	O
+blocking	B-DISO
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+based	O
+on	O
+a	O
+baculovirus	B-SPEC
+recombinant	O
+antigen	O
+to	O
+differentiate	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+from	O
+Porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+antibodies	B-COMP
+.	O
+
+These	O
+results	O
+indicated	O
+that	O
+truncated	O
+recombinant	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+is	O
+a	O
+suitable	O
+alternative	O
+to	O
+the	O
+complete	O
+virus	B-SPEC
+as	O
+antigen	B-CHED
+in	O
+ELISA	O
+assays	O
+.	O
+
+After	O
+hybridization	O
+,	O
+the	O
+microarrays	O
+were	O
+scanned	O
+,	O
+and	O
+the	O
+hybridization	B-PROC
+pattern	O
+agreed	O
+perfectly	O
+with	O
+the	O
+known	O
+location	O
+of	O
+each	O
+probe	O
+.	O
+
+Carcinoembryonic	B-PRGE
+cell	I-PRGE
+adhesion	B-DISO
+antigen	B-CHED
+1a	I-PRGE
+(	O
+CEACAM1a	O
+)	O
+is	O
+the	O
+specific	O
+receptor	O
+for	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+a	O
+coronavirus	B-SPEC
+known	O
+to	O
+induce	O
+acute	B-DISO
+viral	I-DISO
+hepatitis	I-DISO
+in	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+production	O
+of	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+by	O
+infiltrating	B-DISO
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cells	B-COMP
+in	O
+liver	B-ANAT
+is	O
+involved	O
+in	O
+the	O
+control	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infection	B-DISO
+.	O
+
+The	O
+objectives	O
+of	O
+this	O
+study	O
+were	O
+to	O
+identify	O
+the	O
+mechanisms	O
+used	O
+by	O
+MHV	B-SPEC
+type	O
+3	O
+to	O
+modulate	O
+the	O
+production	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+by	O
+NK	B-ANAT
+cells	I-ANAT
+during	O
+the	O
+acute	B-DISO
+hepatitis	I-DISO
+in	O
+susceptible	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+.	O
+
+Ex	O
+vivo	O
+and	O
+in	O
+vitro	O
+experiments	O
+revealed	O
+that	O
+NK	B-ANAT
+cells	I-ANAT
+,	O
+expressing	O
+carcinoembryonic	O
+antigen	B-CHED
+-	O
+related	O
+cell	B-PROC
+adhesion	B-DISO
+molecules	O
+(	O
+CEACAM	O
+)	O
+1a	O
+(	O
+the	O
+MHV	B-PRGE
+receptor	I-PRGE
+),	O
+can	O
+produce	O
+a	O
+higher	O
+level	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+in	O
+the	O
+presence	O
+of	O
+both	O
+L2	O
+-	O
+MHV3	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+12	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+)/	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+.	O
+
+In	O
+bronchial	B-ANAT
+alveolar	I-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+)	O
+a	O
+neutrophil	B-ANAT
+influx	O
+increased	O
+the	O
+population	O
+of	O
+neutrophils	O
+to	O
+45	O
+%	O
+compared	O
+with	O
+6	O
+%	O
+of	O
+the	O
+cells	B-COMP
+in	O
+control	O
+samples	O
+on	O
+day	O
+2	O
+after	O
+mock	O
+inoculation	O
+.	O
+
+The	O
+concentrations	O
+of	O
+chemokines	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+LIX	B-PRGE
+and	O
+CINC	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+BALF	O
+increased	O
+on	O
+day	O
+4	O
+p	O
+.	O
+i	O
+.,	O
+but	O
+returned	O
+to	O
+control	O
+levels	O
+by	O
+day	O
+8	O
+.	O
+
+Mainland	O
+China	O
+had	O
+three	O
+outbreaks	O
+of	O
+SARS	B-DISO
+between	O
+November	O
+2002	O
+-	O
+May	O
+2004	O
+and	O
+suffered	B-DISO
+the	O
+greatest	O
+impact	O
+on	O
+morbidity	O
+and	O
+mortality	O
+worldwide	O
+.	O
+
+Researchers	O
+expect	O
+that	O
+global	O
+infections	B-DISO
+,	O
+like	O
+SARS	B-DISO
+,	O
+will	O
+persist	O
+and	O
+escalate	O
+in	O
+the	O
+future	O
+.	O
+
+It	O
+is	O
+important	O
+to	O
+access	O
+the	O
+guidance	O
+from	O
+nurses	O
+who	O
+cared	O
+for	O
+SARS	B-DISO
+patients	O
+in	O
+China	O
+and	O
+to	O
+uncover	O
+instructive	O
+messages	O
+which	O
+can	O
+be	O
+useful	O
+when	O
+facing	O
+global	O
+infections	B-DISO
+in	O
+the	O
+future	O
+.	O
+
+Data	O
+were	O
+collected	O
+in	O
+2003	O
+,	O
+within	O
+the	O
+three	O
+months	O
+following	O
+the	O
+nurses	O
+'	O
+quarantine	O
+necessitated	O
+by	O
+caring	O
+for	O
+SARS	B-DISO
+patients	O
+.	O
+
+RESULTS	O
+:	O
+Chinese	O
+nurses	O
+faced	O
+personal	O
+challenge	O
+,	O
+focused	O
+on	O
+the	O
+essence	B-CHED
+of	O
+care	O
+and	O
+experienced	O
+self	O
+-	O
+growth	B-PROC
+while	O
+caring	O
+for	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Spike	O
+and	O
+nucleocapsid	B-COMP
+are	O
+structural	O
+proteins	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+major	O
+targets	O
+for	O
+cytotoxic	B-ANAT
+T	I-ANAT
+lymphocytes	I-ANAT
+(	O
+CTLs	O
+).	O
+
+In	O
+contrast	O
+,	O
+non	O
+-	O
+structural	O
+proteins	B-CHED
+encoded	O
+by	O
+two	O
+-	O
+thirds	O
+of	O
+viral	B-COMP
+genome	I-COMP
+are	O
+poorly	O
+characterized	O
+for	O
+cell	B-PROC
+-	I-PROC
+mediated	I-PROC
+immunity	I-PROC
+.	O
+
+Further	O
+,	O
+CTLs	O
+induced	O
+by	O
+the	O
+seven	O
+liposomal	O
+peptides	B-CHED
+lysed	B-DISO
+an	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0201	I-PRGE
+positive	O
+cell	B-ANAT
+line	I-ANAT
+expressing	O
+naturally	O
+processed	O
+,	O
+pp1a	B-PRGE
+-	I-PRGE
+derived	I-PRGE
+peptides	I-PRGE
+.	O
+
+We	O
+previously	O
+generated	O
+human	B-SPEC
+mAbs	O
+specific	O
+to	O
+the	O
+S1	O
+region	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+and	O
+clinical	O
+presentations	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+infections	B-DISO
+in	O
+hong	O
+kong	O
+children	O
+.	O
+
+However	O
+,	O
+the	O
+epidemiology	O
+and	O
+clinical	O
+course	O
+of	O
+this	O
+newly	O
+identified	O
+virus	B-SPEC
+have	O
+not	O
+been	O
+fully	O
+elucidated	O
+.	O
+
+In	O
+the	O
+12	O
+-	O
+month	O
+retrospective	O
+part	O
+of	O
+the	O
+study	O
+,	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+was	O
+used	O
+to	O
+detect	O
+HCoVs	O
+in	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+NPAs	O
+).	O
+
+Positive	O
+samples	O
+were	O
+sequenced	O
+to	O
+confirm	O
+the	O
+identity	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+to	O
+determine	O
+its	O
+phylogenetic	O
+relationship	O
+with	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+strains	O
+found	O
+elsewhere	O
+.	O
+
+From	O
+2005	O
+to	O
+2007	O
+,	O
+the	O
+peak	O
+season	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+was	O
+in	O
+September	O
+-	O
+October	O
+,	O
+which	O
+was	O
+earlier	O
+than	O
+the	O
+peak	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infections	B-DISO
+(	O
+December	O
+-	O
+January	O
+).	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+-	O
+infected	O
+patients	O
+were	O
+younger	O
+and	O
+more	O
+likely	O
+to	O
+have	O
+croup	B-DISO
+,	O
+febrile	B-DISO
+convulsions	I-DISO
+,	O
+and	O
+acute	B-DISO
+gastroenteritis	I-DISO
+.	O
+
+The	O
+aims	O
+of	O
+the	O
+current	O
+study	O
+were	O
+to	O
+estimate	O
+the	O
+prevalence	O
+of	O
+enteropathogens	O
+in	O
+calves	O
+in	O
+Norwegian	O
+dairy	O
+herds	O
+,	O
+evaluate	O
+the	O
+clinical	O
+consequences	O
+of	O
+protozoal	O
+infections	O
+,	O
+and	O
+identify	O
+risk	O
+factors	O
+for	O
+diarrhea	B-DISO
+.	O
+
+Diarrheic	O
+samples	O
+(	O
+n	O
+=	O
+191	O
+)	O
+were	O
+assayed	O
+for	O
+rotavirus	B-PRGE
+group	I-PRGE
+A	I-PRGE
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+),	O
+Cryptosporidium	B-SPEC
+,	O
+and	O
+Escherichia	B-SPEC
+coli	I-SPEC
+F5	O
+by	O
+antigen	B-CHED
+ELISA	O
+.	O
+
+Rotavirus	B-SPEC
+and	O
+Cryptosporidium	B-SPEC
+were	O
+the	O
+most	O
+commonly	O
+detected	O
+enteropathogens	O
+in	O
+diarrheic	O
+samples	O
+.	O
+
+Seroprevalences	O
+for	O
+parainfluenza	B-DISO
+virus	B-SPEC
+3	O
+,	O
+BCoV	O
+,	O
+BRSV	B-SPEC
+,	O
+and	O
+D	B-SPEC
+.	I-SPEC
+viviparus	I-SPEC
+at	O
+the	O
+calf	B-ANAT
+level	O
+were	O
+50	O
+.	O
+2	O
+,	O
+39	O
+.	O
+3	O
+,	O
+31	O
+.	O
+2	O
+,	O
+and	O
+4	O
+.	O
+3	O
+%,	O
+respectively	O
+.	O
+
+ALI	O
+-	O
+P	O
+and	O
+ALI	O
+-	O
+EX	O
+were	O
+induced	O
+by	O
+injection	O
+into	O
+the	O
+trachea	B-DISO
+(	O
+0	O
+.	O
+5	O
+mg	O
+/	O
+kg	O
+)	O
+and	O
+intraperitoneally	O
+(	O
+20	O
+mg	O
+/	O
+kg	O
+)	O
+24	O
+hours	O
+prior	O
+to	O
+tissue	B-ANAT
+collection	O
+.	O
+
+However	O
+,	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+glycogen	O
+content	O
+in	O
+the	O
+diaphragm	B-ANAT
+in	O
+the	O
+ALI	O
+-	O
+EX	O
+and	O
+ALI	O
+-	O
+P	O
+groups	O
+or	O
+in	O
+the	O
+gastrocnemius	B-ANAT
+,	O
+heart	B-ANAT
+and	O
+kidney	B-ANAT
+in	O
+the	O
+ALI	O
+-	O
+P	O
+group	O
+when	O
+compared	O
+to	O
+the	O
+respective	O
+controls	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+1	O
+,	O
+473	O
+patients	O
+,	O
+50	O
+%	O
+survived	O
+to	O
+discharge	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Orf	O
+9b	O
+was	O
+amplified	O
+by	O
+PCR	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+and	O
+cloned	O
+into	O
+the	O
+Nco	B-PRGE
+I	I-PRGE
+and	I-PRGE
+Bam	I-PRGE
+HI	I-PRGE
+sites	I-PRGE
+of	O
+the	O
+pET32c	O
+expression	B-PROC
+vector	O
+,	O
+and	O
+then	O
+recombinant	O
+plasmid	O
+pET32c	B-PRGE
+-	I-PRGE
+Orf	I-PRGE
+9b	I-PRGE
+was	O
+constructed	O
+.	O
+
+After	O
+being	O
+cleaved	B-ANAT
+by	O
+rEK	O
+,	O
+Orf	B-PRGE
+9b	I-PRGE
+protein	I-PRGE
+with	O
+MW	O
+11	O
+kD	O
+was	O
+separated	O
+and	O
+collected	O
+.	O
+
+A	O
+plan	B-DISO
+was	O
+designed	O
+to	O
+increase	O
+the	O
+hospital	O
+'	O
+s	O
+surge	O
+capacity	O
+,	O
+reallocate	O
+resources	O
+and	O
+guarantee	O
+bio	O
+-	O
+safety	O
+.	O
+
+oseltamivir	B-CHED
+,	O
+ampicillin	B-CHED
+-	O
+sulbactam	B-CHED
+,	O
+and	O
+clarithromycin	B-CHED
+.	O
+
+Oseltamivir	B-CHED
+and	O
+antibiotics	B-CHED
+were	O
+administered	O
+.	O
+
+Data	O
+selection	O
+Studies	O
+of	O
+any	O
+intervention	O
+to	O
+prevent	O
+the	O
+transmission	O
+of	O
+respiratory	O
+viruses	B-SPEC
+(	O
+isolation	O
+,	O
+quarantine	O
+,	O
+social	O
+distancing	O
+,	O
+barriers	O
+,	O
+personal	O
+protection	O
+,	O
+and	O
+hygiene	O
+).	O
+
+The	O
+highest	O
+quality	O
+cluster	O
+randomised	O
+trials	O
+suggested	O
+that	O
+spread	O
+of	O
+respiratory	O
+viruses	B-SPEC
+can	O
+be	O
+prevented	O
+by	O
+hygienic	O
+measures	O
+in	O
+younger	O
+children	O
+and	O
+within	O
+households	O
+.	O
+
+Evidence	O
+that	O
+the	O
+more	O
+uncomfortable	O
+and	O
+expensive	O
+N95	O
+masks	O
+were	O
+superior	O
+to	O
+simple	O
+surgical	O
+masks	O
+was	O
+limited	O
+,	O
+but	O
+they	O
+caused	O
+skin	B-DISO
+irritation	I-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+triggered	O
+by	O
+honeybee	B-SPEC
+sting	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+Electrocardiographic	O
+and	O
+biochemical	O
+markers	O
+were	O
+consistent	O
+with	O
+an	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+enhanced	O
+protection	O
+appears	O
+to	O
+be	O
+dependent	O
+upon	O
+the	O
+prior	O
+development	B-PROC
+of	O
+inducible	O
+bronchus	B-ANAT
+-	I-ANAT
+associated	I-ANAT
+lymphoid	I-ANAT
+tissue	I-ANAT
+(	O
+iBALT	O
+)	O
+in	O
+the	O
+lung	B-ANAT
+in	O
+response	O
+to	O
+the	O
+PCN	B-CHED
+treatment	O
+and	O
+to	O
+be	O
+mediated	O
+through	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cell	I-ANAT
+and	O
+B	B-ANAT
+cell	I-ANAT
+dependent	O
+mechanisms	O
+.	O
+
+This	O
+microarray	O
+-	O
+based	O
+method	O
+used	O
+the	O
+highly	O
+conserved	O
+consensus	O
+primers	O
+to	O
+synthesize	O
+specifically	O
+the	O
+virus	O
+cDNA	O
+and	O
+could	O
+identify	O
+effectively	O
+Chikungunya	B-SPEC
+virus	I-SPEC
+,	O
+Japanese	B-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+,	O
+Yellow	B-SPEC
+fever	I-SPEC
+virus	I-SPEC
+,	O
+Dengue	B-SPEC
+virus	I-SPEC
+,	O
+Tick	B-DISO
+borne	I-DISO
+encephalitis	I-DISO
+virus	B-SPEC
+,	O
+and	O
+H5N1	B-DISO
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+proinflammatory	O
+cytokines	O
+,	O
+such	O
+as	O
+tumor	O
+necrosis	O
+factor	O
+alpha	O
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+and	O
+interleukin	B-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+),	O
+are	O
+differentially	O
+induced	O
+in	O
+primary	O
+mouse	B-SPEC
+astrocytes	B-ANAT
+by	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+and	O
+MHV	B-SPEC
+-	O
+2	O
+.	O
+
+However	O
+,	O
+the	O
+signaling	B-PROC
+events	O
+that	O
+trigger	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+induction	O
+in	O
+these	O
+cells	B-COMP
+upon	O
+MHV	B-SPEC
+infection	B-DISO
+remain	O
+unknown	O
+.	O
+
+These	O
+results	O
+illustrate	O
+the	O
+complexity	O
+of	O
+the	O
+regulatory	O
+mechanism	O
+by	O
+which	O
+MHV	B-SPEC
+induces	O
+proinflammatory	O
+cytokines	O
+in	O
+primary	O
+astrocytes	B-ANAT
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+level	O
+of	O
+phosphorylated	O
+PKR	O
+was	O
+greatly	O
+reduced	O
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+the	O
+development	B-PROC
+of	O
+a	O
+real	O
+-	O
+time	O
+TaqMan	O
+RT	O
+-	O
+PCR	O
+targeting	B-PROC
+the	O
+highly	O
+conserved	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+gene	O
+of	O
+IBV	B-SPEC
+and	O
+including	O
+an	O
+internal	O
+PCR	O
+control	O
+is	O
+described	O
+.	O
+
+When	O
+tracheal	O
+and	O
+cloacal	B-ANAT
+swabs	O
+from	O
+clinical	O
+specimens	O
+were	O
+tested	O
+directly	O
+,	O
+50	O
+%	O
+more	O
+samples	O
+were	O
+positive	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+than	O
+by	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+RT	O
+-	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+Bid	O
+cleavage	B-PROC
+,	O
+cytochrome	B-PRGE
+c	I-PRGE
+release	B-PATH
+and	O
+caspase	B-PROC
+activation	I-PROC
+in	O
+canine	O
+coronavirus	B-SPEC
+-	O
+induced	O
+apoptosis	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+demonstrated	O
+that	O
+the	O
+inhibition	O
+of	O
+apoptosis	B-PATH
+by	O
+caspase	B-PRGE
+inhibitors	B-CHED
+did	O
+not	O
+affect	O
+CCoV	O
+replication	O
+,	O
+suggesting	O
+that	O
+apoptosis	B-PATH
+does	O
+not	O
+play	O
+a	O
+role	O
+in	O
+facilitating	O
+viral	B-PROC
+release	I-PROC
+.	O
+
+We	O
+show	O
+here	O
+that	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+)	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+from	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+a	O
+virus	B-SPEC
+most	O
+closely	O
+related	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+employs	O
+aromatic	B-CHED
+amino	I-CHED
+acid	I-CHED
+-	O
+nucleobase	B-CHED
+stacking	O
+interactions	O
+with	O
+a	O
+triple	O
+adenosine	B-CHED
+motif	O
+to	O
+mediate	O
+high	O
+-	O
+affinity	O
+binding	B-FUNC
+to	O
+single	O
+-	O
+stranded	O
+RNAs	O
+containing	O
+the	O
+transcriptional	B-PROC
+regulatory	O
+sequence	O
+(	O
+TRS	B-DISO
+)	O
+or	O
+its	O
+complement	O
+(	O
+cTRS	O
+).	O
+
+Viruses	B-SPEC
+harboring	O
+Y127A	O
+N	O
+mutation	O
+are	O
+strongly	O
+selected	O
+against	O
+and	O
+Y127A	O
+N	O
+does	O
+not	O
+support	O
+an	O
+accessory	O
+function	O
+in	O
+MHV	B-SPEC
+replication	O
+.	O
+
+High	O
+-	O
+dose	O
+pulse	B-PROC
+therapy	O
+with	O
+methylprednisolone	B-CHED
+induced	O
+a	O
+marked	O
+improvement	O
+in	O
+pulmonary	B-ANAT
+conditions	O
+.	O
+
+TITLE	O
+:	O
+Protection	O
+of	O
+chickens	B-SPEC
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+by	O
+a	O
+recombinant	O
+fowlpox	B-SPEC
+virus	I-SPEC
+co	O
+-	O
+expressing	O
+IBV	O
+-	O
+S1	O
+and	O
+chicken	B-SPEC
+IFNgamma	O
+.	O
+
+Compared	O
+to	O
+those	O
+of	O
+the	O
+rFPV	O
+-	O
+IBVS1	O
+and	O
+the	O
+attenuated	O
+live	O
+IB	O
+vaccine	O
+groups	O
+,	O
+chickens	O
+in	O
+the	O
+rFPV	O
+-	O
+IBVS1	O
+-	O
+ChIFNgamma	O
+group	O
+eliminated	O
+virus	B-SPEC
+more	O
+quickly	O
+and	O
+decreased	O
+the	O
+presence	O
+of	O
+viral	O
+antigen	B-CHED
+more	O
+significantly	O
+in	O
+renal	B-ANAT
+tissue	I-ANAT
+.	O
+
+Examination	O
+of	O
+affected	O
+tissues	B-ANAT
+revealed	O
+abnormalities	O
+in	O
+the	O
+liver	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+lung	B-ANAT
+and	O
+trachea	B-DISO
+of	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+the	O
+attenuated	O
+live	O
+IB	O
+vaccine	O
+and	O
+the	O
+rFPV	O
+-	O
+IBVS1	O
+vaccine	O
+.	O
+
+TITLE	O
+:	O
+De	O
+novo	O
+recruitment	B-DISO
+of	O
+antigen	B-CHED
+-	O
+experienced	O
+and	O
+naive	O
+T	B-ANAT
+cells	I-ANAT
+contributes	O
+to	O
+the	O
+long	O
+-	O
+term	O
+maintenance	O
+of	O
+antiviral	O
+T	B-ANAT
+cell	I-ANAT
+populations	O
+in	O
+the	O
+persistently	O
+infected	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+.	O
+
+Both	O
+virus	B-SPEC
+-	O
+specific	O
+CD4	B-PRGE
+and	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+are	O
+functional	O
+,	O
+as	O
+assessed	O
+by	O
+cytokine	O
+expression	B-PROC
+and	O
+degranulation	O
+after	O
+peptide	B-CHED
+exposure	O
+.	O
+
+TITLE	O
+:	O
+Genetics	O
+and	O
+pathogenesis	B-DISO
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+.	O
+
+Uncertainty	O
+remains	O
+regarding	O
+whether	O
+genetically	O
+distinctive	O
+avirulent	O
+and	O
+virulent	O
+forms	O
+coexist	O
+or	O
+whether	O
+an	O
+avirulent	O
+form	O
+mutates	O
+in	O
+vivo	O
+,	O
+causing	O
+FIP	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+5	O
+membrane	O
+protein	B-CHED
+amino	B-CHED
+acid	I-CHED
+residues	O
+with	O
+functional	O
+potential	O
+differentiated	B-PROC
+healthy	O
+cats	B-SPEC
+from	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+The	O
+ATE	B-DISO
+medium	O
+,	O
+which	O
+contains	O
+chicken	B-SPEC
+embryo	B-ANAT
+extract	O
+and	O
+fetal	B-ANAT
+bovine	B-SPEC
+serum	B-COMP
+,	O
+supports	O
+the	O
+growth	B-PROC
+of	O
+ciliated	O
+cells	B-ANAT
+,	I-ANAT
+goblet	I-ANAT
+cells	B-COMP
+and	O
+basal	B-ANAT
+cells	I-ANAT
+from	O
+chicken	B-SPEC
+tracheas	B-ANAT
+on	O
+fibronectin	B-PRGE
+-	O
+or	O
+matrigel	O
+-	O
+coated	O
+dishes	O
+.	O
+
+We	O
+further	O
+show	O
+that	O
+ATE	B-DISO
+cells	B-COMP
+support	O
+the	O
+replication	O
+and	O
+spread	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+Interestingly	O
+,	O
+immunocytostaining	O
+revealed	O
+that	O
+basal	B-ANAT
+cells	I-ANAT
+are	O
+resistant	O
+to	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+Every	O
+country	O
+with	O
+an	O
+intensive	O
+poultry	O
+industry	O
+has	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+Sentinel	O
+bird	B-SPEC
+studies	O
+were	O
+carried	O
+out	O
+in	O
+southern	O
+Ontario	O
+and	O
+IBV	B-SPEC
+has	O
+been	O
+isolated	O
+from	O
+layer	B-ANAT
+flocks	O
+.	O
+
+ABSTRACT	O
+:	O
+Airway	B-ANAT
+pressure	O
+-	O
+release	B-PATH
+ventilation	O
+(	O
+APRV	O
+)	O
+is	O
+a	O
+novel	O
+mode	O
+of	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+that	O
+has	O
+several	O
+advantages	O
+over	O
+low	O
+-	O
+tidal	O
+-	O
+volume	O
+,	O
+assist	O
+-	O
+control	O
+ventilation	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+specifically	O
+,	O
+lower	O
+airway	B-ANAT
+pressures	O
+,	O
+lower	O
+minute	O
+ventilation	O
+,	O
+minimal	O
+effects	O
+on	O
+cardio	O
+-	O
+circulatory	B-PROC
+function	O
+,	O
+ability	O
+to	O
+spontaneously	O
+breathe	O
+throughout	O
+the	O
+entire	O
+ventilatory	O
+cycle	O
+,	O
+and	O
+decreased	O
+sedation	B-DISO
+requirements	O
+.	O
+
+We	O
+present	O
+2	O
+cases	O
+of	O
+pregnant	O
+women	O
+with	O
+severe	O
+life	O
+-	O
+threatening	O
+ARDS	B-DISO
+who	O
+were	O
+successfully	O
+managed	O
+with	O
+APRV	O
+.	O
+
+TITLE	O
+:	O
+Design	O
+and	O
+efficient	O
+synthesis	B-PROC
+of	O
+novel	O
+arylthiourea	O
+derivatives	O
+as	O
+potent	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+inhibitors	O
+.	O
+
+The	O
+role	O
+of	O
+RNase	B-PRGE
+L	I-PRGE
+in	O
+viral	O
+encephalomyelitis	B-DISO
+was	O
+explored	O
+based	O
+on	O
+its	O
+functions	O
+in	O
+inhibiting	O
+translation	B-PROC
+,	O
+inducing	O
+apoptosis	B-PATH
+,	O
+and	O
+propagating	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+pathway	B-PROC
+through	O
+RNA	B-PATH
+degradation	I-PATH
+intermediates	O
+.	O
+
+Infection	B-DISO
+of	O
+RNase	B-PRGE
+L	I-PRGE
+deficient	O
+(	O
+RL	O
+(-/-))	O
+mice	B-SPEC
+with	O
+a	O
+sub	O
+-	O
+lethal	O
+,	O
+demyelinating	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+variant	O
+revealed	O
+that	O
+the	O
+majority	O
+of	O
+mice	B-SPEC
+succumbed	O
+to	O
+infection	B-DISO
+by	O
+day	O
+12	O
+p	O
+.	O
+i	O
+.	O
+
+The	O
+unique	O
+phenotype	O
+of	O
+infected	O
+RL	O
+(-/-)	O
+mice	B-SPEC
+was	O
+rather	O
+manifested	O
+in	O
+earlier	O
+onset	O
+and	O
+increased	O
+severity	O
+of	O
+demyelination	B-DISO
+and	O
+axonal	O
+damage	O
+in	O
+brain	B-ANAT
+stem	I-ANAT
+and	O
+spinal	B-ANAT
+cord	I-ANAT
+without	O
+evidence	O
+for	O
+enhanced	O
+neuronal	O
+infection	B-DISO
+.	O
+
+A	O
+/	O
+H5N1	B-DISO
+nucleic	B-CHED
+acid	I-CHED
+was	O
+detected	O
+by	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+in	O
+a	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+.	O
+
+The	O
+prominent	O
+clinical	O
+features	O
+included	O
+fever	B-PROC
+,	O
+cough	B-DISO
+and	O
+dyspnea	B-DISO
+.	O
+
+Extensive	O
+multiple	O
+lobular	O
+infiltrates	B-DISO
+developed	O
+quickly	O
+,	O
+followed	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+multi	O
+-	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+The	O
+data	O
+of	O
+a	O
+patient	O
+with	O
+A	O
+/	O
+H5N1	B-DISO
+infection	B-DISO
+complicated	O
+with	O
+bronchopleural	B-DISO
+fistula	I-DISO
+was	O
+collected	O
+and	O
+analyzed	O
+.	O
+
+The	O
+origins	O
+of	O
+SCoV	O
+have	O
+been	O
+mysterious	O
+and	O
+controversial	O
+,	O
+until	O
+the	O
+recent	O
+discovery	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+like	I-PRGE
+CoV	I-PRGE
+(	O
+SLCoV	O
+)	O
+in	O
+bats	B-SPEC
+and	O
+the	O
+proposal	O
+of	O
+bats	B-SPEC
+as	O
+the	O
+natural	O
+reservior	O
+of	O
+the	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+.	O
+
+Finally	O
+,	O
+we	O
+also	O
+discussed	O
+how	O
+the	O
+discoveries	O
+of	O
+SCoV	O
+and	O
+SLCoV	O
+expanded	O
+our	O
+knowledge	O
+on	O
+the	O
+evolution	O
+of	O
+the	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+as	O
+well	O
+as	O
+its	O
+implications	O
+on	O
+the	O
+possible	O
+future	O
+re	O
+-	O
+emergence	O
+of	O
+SCoV	O
+.	O
+
+We	O
+have	O
+previously	O
+shown	O
+that	O
+nitric	B-CHED
+oxide	I-CHED
+inhibits	O
+the	O
+replication	O
+cycle	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+vitro	O
+by	O
+an	O
+unknown	O
+mechanism	O
+.	O
+
+Secondly	O
+,	O
+NO	O
+or	O
+its	O
+derivatives	O
+cause	O
+a	O
+reduction	O
+in	O
+viral	O
+RNA	O
+production	O
+in	O
+the	O
+early	O
+steps	O
+of	O
+viral	B-PROC
+replication	I-PROC
+,	O
+and	O
+this	O
+could	O
+possibly	O
+be	O
+due	O
+to	O
+an	O
+effect	O
+on	O
+one	O
+or	O
+both	O
+of	O
+the	O
+cysteine	B-PRGE
+proteases	I-PRGE
+encoded	O
+in	O
+Orf1a	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+Chest	B-ANAT
+radiographs	O
+seem	O
+warranted	O
+when	O
+one	O
+or	O
+more	O
+of	O
+the	O
+following	O
+are	O
+present	O
+:	O
+age	O
+>	O
+or	O
+=	O
+40	O
+;	O
+dementia	B-DISO
+;	O
+a	O
+positive	O
+physical	O
+examination	O
+;	O
+hemoptysis	B-DISO
+;	O
+associated	O
+abnormalities	O
+(	O
+leukocytosis	B-DISO
+,	O
+hypoxemia	O
+);	O
+or	O
+other	O
+risk	O
+factors	O
+,	O
+including	O
+coronary	B-DISO
+artery	I-DISO
+disease	I-DISO
+,	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+,	O
+or	O
+drug	O
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Palmitate	B-CHED
+adducts	O
+are	O
+generally	O
+required	O
+for	O
+protein	B-CHED
+-	O
+mediated	O
+fusions	O
+,	O
+but	O
+their	O
+precise	O
+roles	O
+in	O
+the	O
+process	O
+are	O
+unclear	O
+.	O
+
+Substituting	O
+alanines	O
+for	O
+the	O
+cysteines	O
+that	O
+are	O
+subject	O
+to	O
+palmitoylation	B-PROC
+had	O
+effects	O
+on	O
+both	O
+S	O
+incorporation	O
+into	O
+virions	B-COMP
+and	O
+S	O
+-	O
+mediated	O
+membrane	B-PROC
+fusions	I-PROC
+.	O
+
+Fever	B-PROC
+,	O
+headache	B-DISO
+and	O
+myalgia	B-DISO
+after	O
+exposure	O
+to	O
+a	O
+rodent	B-SPEC
+-	O
+contaminated	O
+environment	O
+raised	O
+clinical	O
+suspicion	O
+.	O
+
+Non	O
+-	O
+cardiac	B-ANAT
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+hydrothorax	B-DISO
+,	O
+neutrophilia	O
+with	O
+band	B-ANAT
+forms	O
+26	O
+%,	O
+high	O
+hematocrit	O
+,	O
+thrombocytopenia	O
+,	O
+and	O
+elevated	O
+liver	B-ANAT
+enzymes	O
+were	O
+observed	O
+.	O
+
+Hantavirus	O
+IgM	B-COMP
+antibody	B-PROC
+-	O
+capture	O
+ELISA	O
+was	O
+positive	O
+,	O
+while	O
+tests	O
+for	O
+dengue	B-DISO
+,	O
+leptospirosis	B-DISO
+and	O
+yellow	B-DISO
+fever	I-DISO
+were	O
+negative	O
+.	O
+
+The	O
+prognosis	O
+for	O
+HPS	B-DISO
+is	O
+ominous	O
+and	O
+misdiagnoses	O
+may	O
+increase	O
+mortality	O
+.	O
+
+Serum	B-COMP
+samples	O
+from	O
+251	O
+dogs	B-SPEC
+of	O
+varying	O
+age	O
+,	O
+breed	B-PROC
+and	O
+clinical	O
+histories	O
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+antibodies	B-COMP
+to	O
+CRCoV	O
+and	O
+CIV	B-SPEC
+,	O
+using	O
+indirect	O
+fluorescent	O
+antibody	B-COMP
+(	O
+IFA	O
+)	O
+analysis	O
+.	O
+
+Seventy	O
+-	O
+three	O
+of	O
+the	O
+251	O
+samples	O
+(	O
+29	O
+%)	O
+were	O
+seropositive	O
+for	O
+CRCoV	O
+.	O
+Dogs	B-SPEC
+<	O
+2	O
+years	O
+old	O
+were	O
+less	O
+likely	O
+to	O
+be	O
+seropositive	O
+for	O
+CRCoV	O
+than	O
+older	O
+dogs	B-SPEC
+.	O
+
+Although	O
+infection	B-DISO
+with	O
+A	B-SPEC
+.	I-SPEC
+lumbricoides	I-SPEC
+is	O
+rare	O
+in	O
+the	O
+United	O
+States	O
+,	O
+it	O
+may	O
+become	O
+manifest	O
+with	O
+severe	O
+consequences	O
+in	O
+the	O
+postoperative	O
+period	O
+.	O
+
+TITLE	O
+:	O
+Controlling	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+:	O
+Lessons	O
+from	O
+mathematical	O
+modelling	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Automatic	O
+control	O
+and	O
+safety	O
+concepts	O
+for	O
+extracorporeal	O
+lung	B-ANAT
+support	O
+].	O
+
+To	O
+increase	O
+safety	O
+and	O
+reliability	O
+of	O
+devices	O
+,	O
+the	O
+oxygenator	O
+design	O
+was	O
+optimized	O
+integrating	O
+new	O
+plasma	B-ANAT
+-	O
+resistant	O
+composite	O
+membranes	B-ANAT
+and	O
+new	O
+blood	B-ANAT
+pumps	O
+are	O
+used	O
+with	O
+longer	O
+durability	O
+and	O
+reduced	O
+blood	B-ANAT
+cell	I-ANAT
+damage	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+shown	O
+that	O
+mice	O
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+develop	O
+autoantibodies	O
+(	O
+autoAb	O
+)	O
+to	O
+liver	B-ANAT
+and	O
+kidney	B-ANAT
+fumarylacetoacetate	B-PRGE
+hydrolase	I-PRGE
+(	O
+FAH	B-PRGE
+).	O
+
+Data	O
+indicated	O
+that	O
+neither	O
+the	O
+FAH	B-PRGE
+minimal	I-PRGE
+epitopes	I-PRGE
+nor	O
+the	O
+key	O
+residues	O
+important	O
+for	O
+binding	B-FUNC
+to	O
+Ab	O
+from	O
+MHV	B-SPEC
+-	O
+infected	O
+mice	B-SPEC
+have	O
+their	O
+counterparts	O
+in	O
+the	O
+viral	O
+proteins	B-CHED
+.	O
+
+Reverse	O
+genetics	O
+analyses	O
+demonstrated	O
+a	O
+major	O
+role	O
+for	O
+the	O
+viral	O
+hemagglutinin	O
+in	O
+this	O
+cell	B-COMP
+tropism	B-PROC
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+analysis	O
+of	O
+canine	O
+group	O
+2	O
+coronavirus	B-SPEC
+in	O
+Korean	O
+dogs	B-SPEC
+.	O
+
+The	O
+small	O
+open	O
+reading	O
+frames	O
+situated	O
+between	O
+the	O
+spike	O
+and	O
+envelope	B-COMP
+genes	O
+of	O
+the	O
+three	O
+Korean	O
+CRCoV	O
+isolates	O
+were	O
+found	O
+to	O
+encode	O
+three	O
+nonstructural	O
+proteins	B-CHED
+(	O
+4	O
+.	O
+9	O
+kDa	O
+,	O
+2	O
+.	O
+7	O
+kDa	O
+,	O
+and	O
+12	O
+.	O
+8	O
+kDa	O
+in	O
+size	O
+),	O
+as	O
+were	O
+the	O
+British	O
+(	O
+CRCoV	O
+G9142	O
+)	O
+and	O
+Italian	O
+(	O
+CRCoV	O
+240	O
+-	O
+05	O
+)	O
+strains	O
+.	O
+
+The	O
+dynamic	O
+properties	O
+of	O
+the	O
+different	O
+states	O
+,	O
+which	O
+are	O
+stabilized	O
+under	O
+different	O
+experimental	O
+conditions	O
+,	O
+extend	O
+the	O
+current	O
+model	O
+of	O
+viral	B-COMP
+membrane	I-COMP
+fusion	O
+and	O
+give	O
+insight	O
+into	O
+the	O
+design	O
+of	O
+structure	O
+-	O
+based	O
+antagonists	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+particular	O
+,	O
+as	O
+well	O
+as	O
+other	O
+enveloped	O
+viruses	B-SPEC
+such	O
+as	O
+HIV	B-DISO
+.	O
+
+TITLE	O
+:	O
+Hemocompatibility	O
+of	O
+a	O
+miniaturized	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+a	O
+pumpless	O
+interventional	O
+lung	O
+assist	O
+in	O
+experimental	O
+lung	B-ANAT
+injury	O
+.	O
+
+An	O
+interventional	O
+lung	B-ANAT
+assist	O
+using	O
+arteriovenous	O
+perfusion	O
+of	O
+a	O
+low	O
+-	O
+resistance	B-PROC
+oxygenator	O
+without	O
+a	O
+blood	B-ANAT
+pump	O
+(	O
+Novalung	O
+,	O
+Hechingen	O
+,	O
+Germany	O
+)	O
+or	O
+a	O
+miniaturized	O
+ECMO	O
+with	O
+reduced	O
+filling	O
+volume	O
+and	O
+a	O
+diagonal	O
+blood	B-ANAT
+pump	O
+(	O
+Deltastream	O
+,	O
+Medos	O
+AG	O
+,	O
+Stolberg	O
+,	O
+Germany	O
+)	O
+could	O
+optimize	O
+hemocompatibility	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+prevalence	O
+of	O
+14	O
+viruses	O
+in	O
+infants	O
+with	O
+bronchiolitis	B-DISO
+and	O
+to	O
+study	O
+demographic	O
+and	O
+clinical	O
+differences	O
+in	O
+those	O
+with	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+hBoV	O
+)	O
+and	O
+rhinovirus	B-SPEC
+(	O
+RV	O
+)	O
+infection	B-DISO
+.	O
+
+The	O
+most	O
+frequently	O
+detected	O
+viruses	B-SPEC
+were	O
+RSV	B-SPEC
+(	O
+41	O
+.	O
+2	O
+%),	O
+hBoV	O
+(	O
+12	O
+.	O
+2	O
+%)	O
+and	O
+RV	O
+(	O
+8	O
+.	O
+8	O
+%).	O
+
+Although	O
+the	O
+major	O
+pathogen	O
+responsible	O
+for	O
+bronchiolitis	B-DISO
+remains	O
+RSV	B-SPEC
+,	O
+the	O
+infection	B-DISO
+can	O
+also	O
+be	O
+caused	O
+by	O
+RV	O
+and	O
+hBoV	O
+.	O
+Demographic	O
+characteristics	O
+and	O
+clinical	O
+severity	O
+of	O
+the	O
+disease	O
+may	O
+depend	O
+on	O
+the	O
+number	O
+of	O
+viruses	B-SPEC
+or	O
+on	O
+the	O
+specific	O
+virus	B-SPEC
+detected	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+57	O
+.	O
+2	O
+%	O
+of	O
+the	O
+182	O
+infants	O
+.	O
+
+Observational	O
+study	O
+of	O
+58	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+at	O
+6	O
+hospitals	O
+between	O
+March	O
+24	O
+and	O
+June	O
+1	O
+,	O
+2009	O
+.	O
+
+Critical	O
+illness	O
+occurred	O
+in	O
+58	O
+of	O
+899	O
+patients	O
+(	O
+6	O
+.	O
+5	O
+%)	O
+admitted	O
+to	O
+the	O
+hospital	O
+with	O
+confirmed	O
+,	O
+probable	O
+,	O
+or	O
+suspected	O
+2009	O
+influenza	B-DISO
+(	O
+A	O
+)	O
+H1N1	O
+.	O
+
+After	O
+adjusting	O
+for	O
+a	O
+reduced	O
+opportunity	O
+of	O
+patients	O
+dying	B-PROC
+early	O
+to	O
+receive	O
+neuraminidase	B-PROC
+inhibitors	I-PROC
+,	O
+neuraminidase	B-CHED
+inhibitor	I-CHED
+treatment	O
+(	O
+vs	O
+no	O
+treatment	O
+)	O
+was	O
+associated	O
+with	O
+improved	O
+survival	O
+(	O
+odds	O
+ratio	O
+,	O
+8	O
+.	O
+5	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+2	O
+-	O
+62	O
+.	O
+8	O
+).	O
+
+The	O
+median	O
+time	O
+from	O
+symptom	B-DISO
+onset	O
+to	O
+hospital	O
+admission	O
+was	O
+4	O
+days	O
+(	O
+interquartile	O
+range	O
+[	O
+IQR	O
+],	O
+2	O
+-	O
+7	O
+days	O
+)	O
+and	O
+from	O
+hospitalization	O
+to	O
+ICU	O
+admission	O
+was	O
+1	O
+day	O
+(	O
+IQR	O
+,	O
+0	O
+-	O
+2	O
+days	O
+).	O
+
+Neuraminidase	B-PROC
+inhibitors	I-PROC
+were	O
+administered	O
+to	O
+152	O
+patients	O
+(	O
+90	O
+.	O
+5	O
+%).	O
+
+It	O
+caused	O
+an	O
+epidemic	O
+of	O
+critical	B-DISO
+illness	I-DISO
+and	O
+some	O
+patients	O
+developed	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+were	O
+treated	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+Incidence	O
+,	O
+clinical	O
+features	O
+,	O
+degree	O
+of	O
+pulmonary	B-ANAT
+dysfunction	O
+,	O
+technical	O
+characteristics	O
+,	O
+duration	O
+of	O
+ECMO	O
+,	O
+complications	O
+,	O
+and	O
+survival	O
+.	O
+
+Sixty	O
+-	O
+eight	O
+patients	O
+with	O
+severe	O
+influenza	B-DISO
+-	O
+associated	O
+ARDS	B-DISO
+were	O
+treated	O
+with	O
+ECMO	O
+,	O
+of	O
+whom	O
+61	O
+had	O
+either	O
+confirmed	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+(	O
+n	O
+=	O
+53	O
+)	O
+or	O
+influenza	B-PATH
+A	I-PATH
+not	O
+subtyped	O
+(	O
+n	O
+=	O
+8	O
+),	O
+representing	O
+an	O
+incidence	O
+rate	O
+of	O
+2	O
+.	O
+6	O
+ECMO	O
+cases	O
+per	O
+million	O
+population	O
+.	O
+
+By	O
+using	O
+""""	O
+rest	B-FUNC
+""""	O
+ventilator	O
+settings	O
+and	O
+venovenous	O
+ECLS	O
+,	O
+the	O
+patient	O
+remained	O
+stable	O
+for	O
+a	O
+total	O
+of	O
+6	O
+.	O
+5	O
+days	O
+(	O
+160	O
+hours	O
+)	O
+when	O
+he	O
+was	O
+successfully	O
+transitioned	O
+to	O
+a	O
+conventional	O
+ventilator	O
+and	O
+decannulated	O
+.	O
+
+ECLS	O
+should	O
+be	O
+considered	O
+early	O
+as	O
+a	O
+viable	O
+supportive	O
+modality	O
+after	O
+inhalational	O
+injury	O
+in	O
+patients	O
+failing	O
+advanced	O
+ARDS	B-DISO
+management	O
+strategies	O
+.	O
+
+A	O
+history	O
+of	O
+breastfeeding	B-PROC
+was	O
+associated	O
+with	O
+a	O
+reduction	O
+in	O
+the	O
+risk	O
+of	O
+acute	B-DISO
+otitis	I-DISO
+media	I-DISO
+,	O
+nonspecific	O
+gastroenteritis	B-DISO
+,	O
+severe	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+atopic	B-DISO
+dermatitis	I-DISO
+,	O
+asthma	B-PATH
+(	O
+young	O
+children	O
+),	O
+obesity	B-DISO
+,	O
+type	O
+1	O
+and	O
+2	O
+diabetes	B-DISO
+,	O
+childhood	B-DISO
+leukemia	I-DISO
+,	O
+and	O
+sudden	B-DISO
+infant	I-DISO
+death	I-DISO
+syndrome	I-DISO
+.	O
+
+Complete	O
+physical	O
+and	O
+ophthalmic	B-CHED
+examinations	O
+were	O
+performed	O
+for	O
+each	O
+dog	B-SPEC
+.	O
+
+A	O
+search	O
+of	O
+the	O
+protein	B-CHED
+structure	O
+database	O
+indicates	O
+that	O
+the	O
+globular	O
+domain	O
+of	O
+the	O
+NAB	O
+represents	O
+a	O
+new	O
+fold	O
+,	O
+with	O
+a	O
+parallel	O
+four	O
+-	O
+strand	O
+beta	O
+-	O
+sheet	O
+holding	O
+two	O
+alpha	O
+-	O
+helices	O
+of	O
+three	O
+and	O
+four	O
+turns	O
+that	O
+are	O
+oriented	O
+antiparallel	O
+to	O
+the	O
+beta	O
+-	O
+strands	O
+.	O
+
+Testing	O
+by	O
+direct	O
+fluorescent	O
+antigen	B-CHED
+detection	O
+(	O
+DFA	B-CHED
+)	O
+and	O
+various	O
+in	O
+-	O
+house	O
+nucleic	B-CHED
+acid	I-CHED
+amplification	B-DISO
+tests	O
+(	O
+NATs	O
+)	O
+for	O
+common	O
+respiratory	O
+viruses	B-SPEC
+provided	O
+an	O
+etiological	O
+diagnosis	O
+in	O
+177	O
+outbreaks	O
+(	O
+72	O
+.	O
+5	O
+%),	O
+with	O
+524	O
+samples	O
+testing	O
+positive	O
+(	O
+47	O
+.	O
+3	O
+%)	O
+for	O
+a	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+The	O
+prevalence	O
+of	O
+neuroleptic	B-DISO
+malignant	I-DISO
+syndrome	I-DISO
+is	O
+between	O
+0	O
+.	O
+02	O
+%	O
+and	O
+2	O
+.	O
+44	O
+%	O
+for	O
+patients	O
+taking	O
+neuroleptics	B-CHED
+and	O
+it	O
+is	O
+not	O
+necessary	O
+to	O
+fulfil	O
+all	O
+cardinal	B-SPEC
+features	O
+characterizing	O
+the	O
+syndrome	B-DISO
+to	O
+be	O
+diagnosed	O
+with	O
+neuroleptic	B-DISO
+malignant	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+22	O
+-	O
+year	O
+-	O
+old	O
+Caucasian	O
+man	B-CHED
+was	O
+admitted	O
+unconscious	O
+with	O
+a	O
+body	B-ANAT
+temperature	O
+of	O
+42	O
+degrees	O
+C	O
+,	O
+elevated	O
+serum	B-PRGE
+creatine	B-CHED
+phosphokinase	I-PRGE
+,	O
+tachycardia	O
+and	O
+hypotonic	B-DISO
+blood	B-PROC
+pressure	I-PROC
+.	O
+
+In	O
+our	O
+case	O
+the	O
+only	O
+residual	O
+impairment	B-DISO
+for	O
+the	O
+patient	O
+is	O
+dysarthria	B-DISO
+with	O
+corresponding	O
+symmetric	O
+cerebellar	B-ANAT
+pyramidal	B-ANAT
+cell	I-ANAT
+destruction	O
+demonstrated	O
+by	O
+increased	O
+signal	O
+intensity	O
+in	O
+T2	O
+-	O
+weighted	O
+magnetic	O
+resonance	O
+imaging	O
+,	O
+most	O
+likely	O
+caused	O
+by	O
+the	O
+excessive	O
+hyperthermia	B-PROC
+.	O
+
+One	O
+month	O
+after	O
+the	O
+last	O
+dose	O
+of	O
+rrituximab	O
+,	O
+she	O
+presented	O
+with	O
+recurrence	O
+of	O
+severe	O
+hemolysis	B-DISO
+and	O
+received	O
+two	O
+more	O
+doses	O
+of	O
+rrituximab	O
+.	O
+
+TITLE	O
+:	O
+A	O
+case	O
+of	O
+benign	O
+acute	O
+childhood	O
+myositis	B-DISO
+associated	O
+with	O
+influenza	B-DISO
+A	I-DISO
+(	I-DISO
+H1N1	I-DISO
+)	I-DISO
+virus	B-PROC
+infection	I-PROC
+.	O
+
+It	O
+is	O
+characterized	O
+by	O
+acute	O
+-	O
+onset	O
+difficulty	O
+in	O
+walking	O
+as	O
+a	O
+result	O
+of	O
+severe	O
+bilateral	O
+calf	B-DISO
+pain	I-DISO
+and	O
+by	O
+elevated	O
+muscle	B-ANAT
+enzymes	O
+including	O
+creatinine	B-PRGE
+kinase	I-PRGE
+.	O
+
+A	O
+total	O
+of	O
+187	O
+clinical	O
+tissues	B-ANAT
+samples	O
+(	O
+88	O
+blood	B-ANAT
+,	O
+62	O
+kidney	B-ANAT
+and	O
+37	O
+lung	B-ANAT
+)	O
+were	O
+evaluated	O
+and	O
+compared	O
+to	O
+conventional	O
+RT	O
+-	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+A	O
+two	O
+-	O
+pronged	O
+strategy	O
+to	O
+suppress	B-PRGE
+host	I-PRGE
+protein	B-PROC
+synthesis	I-PROC
+by	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+Nsp1	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+nsp1	B-PRGE
+protein	I-PRGE
+suppresses	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+,	O
+including	O
+type	B-PROC
+I	I-PROC
+interferon	I-PROC
+production	I-PROC
+,	O
+by	O
+promoting	O
+host	B-COMP
+mRNA	B-PROC
+degradation	I-PROC
+and	O
+inhibiting	O
+host	B-COMP
+translation	B-PROC
+,	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+We	O
+present	O
+evidence	O
+that	O
+nsp1	B-PRGE
+uses	O
+a	O
+novel	O
+,	O
+two	O
+-	O
+pronged	O
+strategy	O
+to	O
+inhibit	O
+host	B-COMP
+translation	B-PROC
+and	O
+gene	B-PROC
+expression	I-PROC
+.	O
+
+We	O
+speculate	O
+that	O
+the	O
+mRNAs	O
+that	O
+underwent	O
+the	O
+nsp1	O
+-	O
+mediated	O
+modification	O
+are	O
+marked	O
+for	O
+rapid	O
+turnover	O
+by	O
+the	O
+host	B-COMP
+RNA	B-PATH
+degradation	I-PATH
+machinery	O
+.	O
+
+ABSTRACT	O
+:	O
+For	O
+therapy	O
+of	O
+blunt	O
+thoracic	B-DISO
+trauma	O
+in	O
+multiple	O
+injured	O
+patients	O
+,	O
+some	O
+studies	O
+have	O
+recommended	O
+prophylactic	O
+ventilation	O
+with	O
+kinetic	O
+therapy	O
+for	O
+3	O
+-	O
+5	O
+days	O
+.	O
+
+The	O
+mean	O
+time	O
+of	O
+ventilation	O
+was	O
+98	O
+.	O
+4	O
+h	O
+and	O
+in	O
+patients	O
+without	O
+head	B-ANAT
+injury	O
+71	O
+.	O
+3	O
+h	O
+.	O
+Out	O
+of	O
+22	O
+patients	O
+4	O
+had	O
+to	O
+be	O
+reintubated	O
+which	O
+had	O
+to	O
+be	O
+repeated	O
+for	O
+2	O
+patients	O
+.	O
+
+Our	O
+findings	O
+indicate	O
+that	O
+even	O
+with	O
+early	O
+and	O
+aggressive	O
+weaning	B-PROC
+from	O
+a	O
+respirator	O
+with	O
+extensive	O
+lung	B-ANAT
+contusions	O
+an	O
+adequate	O
+therapy	O
+of	O
+thorax	B-ANAT
+trauma	O
+is	O
+possible	O
+without	O
+having	O
+a	O
+higher	O
+incidence	O
+of	O
+complications	O
+.	O
+
+Transmission	O
+electron	O
+microscopic	O
+(	O
+TEM	B-COMP
+)	O
+studies	O
+of	O
+NL63	O
+infected	O
+LLCMK2	O
+cells	B-COMP
+revealed	O
+that	O
+virions	B-COMP
+are	O
+spherical	O
+,	O
+spiked	O
+,	O
+and	O
+range	O
+from	O
+75	O
+to	O
+115	O
+nm	O
+in	O
+diameter	O
+.	O
+
+Murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+nsp4	B-PRGE
+is	I-PRGE
+glycosylated	I-PRGE
+at	I-PRGE
+residues	I-PRGE
+Asn176	I-PRGE
+(	O
+N176	O
+)	O
+and	O
+N237	O
+during	O
+plasmid	O
+expression	B-PROC
+of	O
+nsp4	B-PRGE
+in	O
+cells	B-COMP
+.	O
+
+The	O
+degree	O
+of	O
+altered	O
+DMV	O
+morphology	O
+directly	O
+correlated	O
+with	O
+the	O
+extent	O
+of	O
+impairment	B-DISO
+in	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+virus	B-SPEC
+growth	B-PROC
+of	O
+the	O
+nsp4	B-PRGE
+mutant	I-PRGE
+viruses	B-SPEC
+.	O
+
+In	O
+relation	O
+to	O
+gene	O
+3	O
+,	O
+samples	O
+showed	O
+a	O
+greater	O
+relationship	O
+with	O
+chicken	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+while	O
+gene	O
+5	O
+showed	O
+greater	O
+identity	O
+with	O
+pheasant	O
+coronavirus	B-SPEC
+(	O
+PhCoV	O
+).	O
+
+These	O
+data	O
+demonstrated	O
+,	O
+for	O
+the	O
+first	O
+time	O
+in	O
+Tunisia	O
+,	O
+the	O
+cocirculation	O
+of	O
+IBV	B-SPEC
+variant	O
+serotypes	O
+along	O
+with	O
+the	O
+Massachusetts	O
+type	O
+,	O
+causing	O
+severe	O
+clinical	O
+diseases	O
+and	O
+high	O
+economic	O
+losses	O
+to	O
+the	O
+poultry	O
+industry	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+report	O
+describes	O
+the	O
+identification	O
+of	O
+a	O
+novel	O
+linear	O
+B	O
+-	O
+cell	O
+epitope	B-CHED
+at	O
+the	O
+C	O
+-	O
+terminus	O
+of	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+Alignment	O
+and	O
+comparison	O
+of	O
+the	O
+15E2	O
+-	O
+defined	O
+epitope	B-CHED
+sequence	O
+with	O
+the	O
+sequences	O
+of	O
+other	O
+corona	B-CHED
+-	O
+viruses	B-SPEC
+indicated	O
+that	O
+the	O
+epitope	B-CHED
+is	O
+well	O
+conserved	O
+among	O
+chicken	B-SPEC
+and	O
+turkey	B-SPEC
+coronaviruses	O
+.	O
+
+Strain	O
+v2163	O
+increased	O
+IL	O
+-	O
+1alpha	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+MIP	B-PRGE
+-	I-PRGE
+1alpha	I-PRGE
+,	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+and	O
+RANTES	O
+in	O
+mice	B-SPEC
+,	O
+and	O
+high	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+expression	B-PROC
+correlated	O
+with	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+initiated	O
+by	O
+specific	O
+interactions	O
+between	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+and	O
+its	O
+receptor	O
+ACE2	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+are	O
+part	O
+of	O
+a	O
+devastating	O
+syndrome	B-DISO
+characterized	O
+by	O
+acute	O
+onset	O
+,	O
+hypoxemia	O
+,	O
+and	O
+bilateral	O
+infiltrates	B-DISO
+on	O
+chest	B-ANAT
+x	O
+-	O
+rays	B-SPEC
+.	O
+
+The	O
+most	O
+common	O
+cause	O
+is	O
+sepsis	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+application	O
+of	O
+genomics	O
+to	O
+emerging	O
+zoonotic	O
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+Genomics	O
+tools	O
+such	O
+as	O
+high	O
+-	O
+throughput	O
+sequencing	O
+,	O
+mRNA	B-PROC
+expression	B-PROC
+profiling	O
+,	O
+and	O
+microarray	O
+-	O
+based	O
+analysis	O
+of	O
+single	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+are	O
+providing	O
+unprecedented	O
+ways	O
+to	O
+analyze	O
+the	O
+diversity	O
+of	O
+the	O
+genomes	O
+of	O
+emerging	O
+pathogens	O
+as	O
+well	O
+as	O
+the	O
+molecular	O
+basis	O
+of	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+them	O
+.	O
+
+The	O
+ultimate	O
+challenge	O
+is	O
+to	O
+link	O
+pathogen	O
+and	O
+host	B-COMP
+genomics	O
+data	O
+with	O
+biological	O
+outcomes	O
+of	O
+zoonotic	O
+transmission	O
+and	O
+to	O
+translate	O
+the	O
+integrated	O
+data	O
+into	O
+novel	O
+intervention	O
+strategies	O
+that	O
+eventually	O
+will	O
+allow	O
+the	O
+effective	O
+control	O
+of	O
+newly	O
+emerging	O
+infectious	O
+diseases	O
+.	O
+
+Despite	O
+marked	O
+differences	O
+in	O
+infection	B-DISO
+,	O
+antibody	B-PROC
+responses	I-PROC
+were	O
+observed	O
+in	O
+all	O
+animals	B-SPEC
+irrespective	O
+of	O
+age	O
+,	O
+with	O
+older	O
+pigs	B-SPEC
+tending	O
+to	O
+seroconvert	O
+sooner	O
+and	O
+achieve	O
+higher	O
+antibody	B-COMP
+levels	O
+than	O
+3	O
+-	O
+week	O
+-	O
+old	O
+animals	B-SPEC
+.	O
+
+To	O
+understand	O
+the	O
+mechanism	O
+by	O
+which	O
+a	O
+virus	B-SPEC
+escapes	O
+from	O
+antibody	B-PROC
+-	I-PROC
+mediated	I-PROC
+neutralization	I-PROC
+,	O
+we	O
+have	O
+investigated	O
+the	O
+interactions	O
+of	O
+non	O
+-	O
+neutralizing	O
+and	O
+neutralizing	O
+antibodies	B-COMP
+at	O
+an	O
+epitope	B-CHED
+cluster	O
+on	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+This	O
+transient	O
+selection	O
+could	O
+lead	O
+to	O
+high	O
+virulence	B-PROC
+in	O
+emerging	O
+pathogens	O
+.	O
+
+Pathogens	O
+that	O
+are	O
+moderately	O
+evolvable	O
+,	O
+highly	O
+transmissible	O
+,	O
+and	O
+highly	O
+virulent	O
+at	O
+equilibrium	B-PROC
+could	O
+briefly	O
+double	O
+their	O
+virulence	B-PROC
+during	O
+an	O
+epidemic	O
+;	O
+thus	O
+,	O
+epidemic	O
+-	O
+phase	O
+selection	O
+could	O
+contribute	O
+significantly	O
+to	O
+the	O
+virulence	O
+of	O
+emerging	O
+pathogens	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+further	O
+assess	O
+the	O
+potential	O
+significance	O
+of	O
+this	O
+mechanism	O
+,	O
+we	O
+bring	O
+together	O
+data	O
+from	O
+the	O
+literature	O
+for	O
+the	O
+shapes	O
+of	O
+tradeoff	O
+curves	O
+for	O
+several	O
+pathogens	O
+(	O
+myxomatosis	O
+,	O
+HIV	B-DISO
+,	O
+and	O
+a	O
+parasite	O
+of	O
+Daphnia	B-SPEC
+)	O
+and	O
+the	O
+level	O
+of	O
+genetic	O
+variation	O
+for	O
+virulence	B-PROC
+for	O
+one	O
+(	O
+myxomatosis	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+objective	O
+of	O
+this	O
+investigation	O
+is	O
+to	O
+review	O
+existing	O
+research	O
+pertaining	O
+to	O
+cognitive	O
+impairment	O
+and	O
+decline	O
+following	O
+critical	B-DISO
+illness	I-DISO
+and	O
+describe	O
+a	O
+case	O
+involving	O
+a	O
+49	O
+-	O
+year	O
+-	O
+old	O
+female	O
+with	O
+sepsis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+with	O
+no	O
+prior	O
+neurologic	O
+history	O
+who	O
+,	O
+compared	O
+to	O
+baseline	O
+neuropsychological	O
+test	O
+data	O
+,	O
+experienced	O
+dramatic	O
+cognitive	B-DISO
+decline	I-DISO
+and	O
+brain	B-DISO
+atrophy	I-DISO
+following	O
+treatment	O
+in	O
+the	O
+medical	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+at	O
+Vanderbilt	O
+University	O
+Medical	O
+Center	O
+.	O
+
+Initial	O
+diffusion	O
+tensor	O
+brain	B-ANAT
+magnetic	O
+resonance	O
+imaging	O
+(	O
+DT	O
+-	O
+MRI	O
+)	O
+at	O
+the	O
+end	O
+of	O
+ICU	O
+hospitalization	O
+showed	O
+diffuse	O
+abnormal	O
+hyperintense	O
+areas	O
+involving	O
+predominately	O
+white	B-ANAT
+matter	I-ANAT
+in	O
+both	O
+hemispheres	O
+and	O
+the	O
+left	O
+cerebellum	B-ANAT
+.	O
+
+A	O
+brain	B-ANAT
+MRI	O
+nearly	O
+4	O
+years	O
+after	O
+ICU	O
+discharge	B-ANAT
+demonstrated	O
+interval	O
+development	B-PROC
+of	O
+profound	O
+and	O
+generalized	O
+atrophy	B-DISO
+with	O
+sulcal	O
+widening	O
+and	O
+ventricular	B-ANAT
+enlargement	B-DISO
+.	O
+
+Survivors	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+a	O
+systemic	O
+critical	B-DISO
+illness	I-DISO
+,	O
+often	O
+report	O
+poor	O
+quality	O
+of	O
+life	O
+based	O
+on	O
+responses	O
+to	O
+standardized	O
+questionnaires	O
+.	O
+
+The	O
+diverse	O
+and	O
+unique	O
+experiences	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+survivors	O
+reflect	O
+the	O
+global	O
+impact	O
+of	O
+severe	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+We	O
+have	O
+identified	O
+symptom	B-DISO
+domains	O
+important	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+who	O
+are	O
+not	O
+well	O
+represented	O
+in	O
+existing	O
+health	O
+outcomes	O
+measures	O
+.	O
+
+Diagnostic	O
+criteria	O
+were	O
+microscopic	O
+or	O
+macroscopic	O
+haematuria	O
+,	O
+decreased	O
+C3	O
+fraction	O
+of	O
+the	O
+complement	O
+and	O
+evidence	O
+of	O
+recent	O
+streptococcal	B-DISO
+infection	I-DISO
+.	O
+
+Signs	O
+of	O
+previous	O
+respiratory	B-DISO
+infections	I-DISO
+were	O
+clearly	O
+evident	O
+in	O
+40	O
+%	O
+of	O
+the	O
+children	O
+.	O
+
+Systematic	O
+detection	O
+and	O
+treatment	O
+of	O
+group	B-SPEC
+A	I-SPEC
+Streptococcus	I-SPEC
+should	O
+be	O
+intensified	O
+.	O
+
+ABSTRACT	O
+:	O
+Disruption	O
+of	O
+fibrinolytic	O
+homeostasis	B-PROC
+participates	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+severe	O
+lung	B-DISO
+diseases	I-DISO
+like	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+(	O
+IPF	O
+)	O
+and	O
+plastic	B-DISO
+bronchitis	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+male	O
+mice	B-SPEC
+had	O
+higher	O
+BALF	B-PRGE
+mtPA	I-PRGE
+concentrations	O
+.	O
+
+TITLE	O
+:	O
+Plasmodium	B-SPEC
+vivax	I-SPEC
+malaria	B-PATH
+:	O
+an	O
+unusual	O
+presentation	O
+.	O
+
+A	O
+diagnosis	O
+of	O
+Plasmodium	B-DISO
+vivax	I-DISO
+malaria	B-PATH
+was	O
+established	O
+by	O
+a	O
+positive	O
+Plasmodium	B-SPEC
+LDH	B-PRGE
+immunochromatographic	O
+assay	O
+while	O
+a	O
+negative	O
+PfHRP2	O
+based	O
+assay	O
+ruled	O
+out	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+malaria	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+first	O
+series	O
+of	O
+indigenous	O
+European	O
+patients	O
+with	O
+severe	O
+leptospirosis	O
+in	O
+need	O
+of	O
+intensive	O
+care	O
+because	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+coma	B-DISO
+and	O
+shock	O
+.	O
+
+ABSTRACT	O
+:	O
+Otitis	B-DISO
+media	I-DISO
+typically	O
+presents	O
+as	O
+either	O
+acute	O
+otitis	O
+media	O
+(	O
+AOM	B-DISO
+),	O
+with	O
+symptoms	O
+including	O
+fever	B-PROC
+,	O
+otalgia	B-DISO
+,	O
+otorrhoea	O
+or	O
+irritability	O
+and	O
+short	O
+duration	O
+;	O
+or	O
+as	O
+otitis	B-DISO
+media	I-DISO
+with	I-DISO
+effusion	B-ANAT
+(	O
+OME	O
+),	O
+which	O
+is	O
+often	O
+asymptomatic	O
+and	O
+characterised	O
+by	O
+accumulation	O
+of	O
+fluid	O
+in	O
+the	O
+middle	B-ANAT
+ear	I-ANAT
+.	O
+
+These	O
+include	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+parainfluenza	B-DISO
+and	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Unraveling	O
+the	O
+complexities	O
+of	O
+the	O
+interferon	B-PRGE
+response	O
+during	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+a	O
+virus	B-SPEC
+that	O
+causes	O
+severe	O
+lung	B-ANAT
+damage	O
+,	O
+encodes	O
+an	O
+array	O
+of	O
+proteins	B-CHED
+able	O
+to	O
+inhibit	O
+induction	O
+and	O
+signaling	B-PROC
+of	O
+type	B-PRGE
+-	I-PRGE
+I	I-PRGE
+interferons	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genome	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+contains	O
+eight	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+that	O
+encode	O
+novel	O
+proteins	B-CHED
+.	O
+
+Electron	O
+microscopy	O
+of	O
+infected	O
+cells	B-COMP
+revealed	O
+a	O
+role	O
+for	O
+ORF	B-PRGE
+3a	I-PRGE
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+induced	O
+vesicle	B-PROC
+formation	I-PROC
+,	O
+a	O
+prominent	O
+feature	O
+of	O
+cells	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+Finally	O
+,	O
+overexpression	B-PROC
+of	O
+ADP	B-PRGE
+-	I-PRGE
+ribosylation	I-PRGE
+factor	I-PRGE
+1	I-PRGE
+(	O
+Arf1	B-PRGE
+),	O
+a	O
+small	B-PRGE
+GTPase	I-PRGE
+essential	O
+for	O
+the	O
+maintenance	O
+of	O
+the	O
+Golgi	B-COMP
+apparatus	I-COMP
+,	O
+restored	O
+Golgi	B-COMP
+morphology	O
+during	O
+infection	B-DISO
+.	O
+
+When	O
+the	O
+secretory	B-PROC
+pathway	I-PROC
+was	O
+disrupted	O
+by	O
+brefeldin	B-CHED
+A	I-CHED
+(	O
+BFA	O
+)	O
+treatment	O
+at	O
+the	O
+start	O
+of	O
+infection	B-DISO
+,	O
+RVN	O
+formation	B-PROC
+and	O
+viral	O
+RTC	O
+activity	O
+were	O
+not	O
+blocked	O
+and	O
+continued	O
+up	O
+to	O
+11	O
+h	O
+postinfection	O
+,	O
+although	O
+RNA	B-PROC
+synthesis	I-PROC
+was	O
+reduced	O
+by	O
+ca	O
+.	O
+
+Confocal	O
+microscopy	O
+studies	O
+showed	O
+that	O
+early	O
+secretory	O
+pathway	O
+components	O
+are	O
+not	O
+associated	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+induced	O
+replication	O
+sites	O
+,	O
+although	O
+our	O
+studies	O
+revealed	O
+that	O
+infection	B-DISO
+induces	O
+a	O
+remarkable	O
+redistribution	O
+of	O
+the	O
+translocon	B-COMP
+subunit	O
+Sec61alpha	O
+.	O
+
+TITLE	O
+:	O
+Hyperimmunoglobulin	B-DISO
+E	I-DISO
+syndrome	I-DISO
+with	O
+a	O
+novel	O
+STAT3	B-PRGE
+mutation	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+35	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+severe	O
+eczematous	O
+dermatitis	O
+and	O
+recurrent	O
+staphylococcal	B-DISO
+skin	I-DISO
+infections	I-DISO
+,	O
+some	O
+of	O
+which	O
+required	O
+hospitalization	O
+,	O
+is	O
+presented	O
+.	O
+
+CONCLUSIONS	O
+:	O
+PTSD	B-DISO
+occurs	O
+in	O
+a	O
+significant	O
+percentage	O
+of	O
+subjects	O
+who	O
+recover	B-PROC
+from	O
+SARS	B-DISO
+,	O
+and	O
+the	O
+occurrence	O
+of	O
+PTSD	B-DISO
+predicts	O
+persistent	O
+psychological	B-DISO
+distress	I-DISO
+and	O
+diminished	O
+social	O
+functioning	O
+in	O
+the	O
+4	O
+years	O
+after	O
+SARS	B-DISO
+treatment	O
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+no	O
+previous	O
+reports	O
+have	O
+examined	O
+the	O
+long	O
+-	O
+term	O
+recovery	O
+of	O
+patients	O
+who	O
+have	O
+had	O
+this	O
+condition	B-DISO
+.	O
+
+Although	O
+previous	O
+investigations	O
+focused	O
+mainly	O
+on	O
+viruses	B-SPEC
+such	O
+as	O
+hepatitis	B-PATH
+C	I-PATH
+and	O
+HIV	B-DISO
+,	O
+it	O
+is	O
+now	O
+becoming	O
+clear	O
+that	O
+other	O
+microbes	O
+associate	O
+with	O
+tetraspanins	O
+,	O
+using	O
+TEMs	O
+as	O
+a	O
+'	O
+gateway	O
+'	O
+to	O
+infection	B-DISO
+.	O
+
+Low	O
+-	O
+dose	O
+corticosteroids	B-CHED
+administered	O
+within	O
+14	O
+days	O
+of	O
+disease	O
+onset	O
+may	O
+reduce	O
+all	O
+-	O
+cause	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Respiratory	B-DISO
+complications	I-DISO
+of	O
+accidental	O
+drownings	O
+in	O
+children	O
+].	O
+
+Age	O
+at	O
+the	O
+moment	O
+of	O
+the	O
+accident	O
+,	O
+sex	O
+,	O
+history	O
+of	O
+accident	O
+,	O
+hospitable	O
+care	O
+,	O
+thoracic	B-DISO
+imaging	O
+and	O
+neurological	O
+outcome	O
+of	O
+the	O
+children	O
+were	O
+studied	O
+.	O
+
+Drowning	O
+in	O
+fresh	B-ANAT
+water	O
+,	O
+especially	O
+in	O
+contaminated	O
+fresh	B-ANAT
+water	B-CHED
+(	O
+canal	B-ANAT
+,	O
+WC	O
+,	O
+etc	O
+.),	O
+induced	O
+atelectasis	B-DISO
+(	O
+10	O
+.	O
+8	O
+%),	O
+whereas	O
+drowning	O
+in	O
+sea	O
+water	B-CHED
+induced	O
+diffuse	O
+infiltrates	B-DISO
+(	O
+8	O
+.	O
+4	O
+%).	O
+
+TITLE	O
+:	O
+Crystal	B-ANAT
+structure	O
+of	O
+NL63	B-PRGE
+respiratory	I-PRGE
+coronavirus	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+complexed	O
+with	O
+its	O
+human	O
+receptor	O
+.	O
+
+Both	O
+affinity	O
+-	O
+purified	O
+anti	B-PRGE
+-	I-PRGE
+CD134	I-PRGE
+and	O
+anti	O
+-	O
+SU	O
+antibodies	B-COMP
+blocked	O
+FIV	B-SPEC
+infection	B-DISO
+ex	O
+vivo	O
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+CD134	I-PRGE
+binding	B-FUNC
+caused	O
+displacement	O
+of	O
+SU	O
+from	O
+the	O
+surface	O
+of	O
+the	O
+cell	B-COMP
+and	O
+inhibition	B-PROC
+of	O
+infection	B-DISO
+.	O
+
+Prone	O
+and	O
+supine	O
+patients	O
+from	O
+the	O
+entire	O
+study	O
+population	O
+had	O
+similar	O
+28	O
+-	O
+day	O
+(	O
+31	O
+.	O
+0	O
+%	O
+vs	O
+32	O
+.	O
+8	O
+%;	O
+relative	O
+risk	O
+[	O
+RR	O
+],	O
+0	O
+.	O
+97	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+0	O
+.	O
+84	O
+-	O
+1	O
+.	O
+13	O
+;	O
+P	O
+=	O
+.	O
+72	O
+)	O
+and	O
+6	O
+-	O
+month	O
+(	O
+47	O
+.	O
+0	O
+%	O
+vs	O
+52	O
+.	O
+3	O
+%;	O
+RR	O
+,	O
+0	O
+.	O
+90	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+73	O
+-	O
+1	O
+.	O
+11	O
+;	O
+P	O
+=	O
+.	O
+33	O
+)	O
+mortality	O
+rates	O
+,	O
+despite	O
+significantly	O
+higher	O
+complication	B-DISO
+rates	O
+in	O
+the	O
+prone	O
+group	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+have	O
+analyzed	O
+the	O
+phenotypes	O
+of	O
+recombinant	O
+FCoVs	O
+that	O
+are	O
+based	O
+on	O
+the	O
+genetic	O
+background	O
+of	O
+type	O
+I	O
+FCoV	O
+strain	O
+Black	O
+but	O
+encode	O
+the	O
+type	O
+II	O
+FCoV	O
+strain	O
+79	O
+-	O
+1146	O
+S	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Cellular	B-ANAT
+immune	I-PROC
+responses	I-PROC
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+senescent	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+:	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+are	O
+important	O
+in	O
+control	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+characterized	O
+the	O
+cellular	B-PROC
+immune	I-PROC
+response	I-PROC
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+12	O
+-	O
+to	O
+14	O
+-	O
+month	O
+-	O
+old	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+,	O
+a	O
+model	O
+that	O
+mimics	O
+features	O
+of	O
+the	O
+human	B-SPEC
+disease	O
+.	O
+
+The	O
+disease	O
+,	O
+which	O
+quickly	O
+spread	O
+worldwide	O
+over	O
+a	O
+period	O
+of	O
+4	O
+months	O
+spanning	O
+late	O
+2002	O
+and	O
+early	O
+2003	O
+,	O
+infected	O
+over	O
+8	O
+,	O
+000	O
+individuals	O
+and	O
+killed	O
+nearly	O
+800	O
+before	O
+it	O
+was	O
+successfully	O
+contained	O
+by	O
+aggressive	B-DISO
+public	O
+health	O
+intervention	O
+strategies	O
+.	O
+
+Here	O
+,	O
+we	O
+described	O
+PF	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+H5N1	B-DISO
+virus	B-SPEC
+.	O
+
+Eight	O
+-	O
+week	O
+-	O
+old	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+inoculated	O
+intranasally	O
+with	O
+1	O
+x	O
+101	O
+MID50	O
+of	O
+A	O
+/	O
+Chicken	B-SPEC
+/	O
+Hebei	O
+/	O
+108	O
+/	O
+2002	O
+(	O
+H5N1	B-DISO
+)	O
+viruses	B-SPEC
+.	O
+
+The	O
+dramatically	O
+elevated	O
+hydroxyproline	B-CHED
+levels	O
+in	O
+H5N1	B-DISO
+-	O
+infected	O
+mice	B-SPEC
+showed	O
+deposition	O
+of	O
+collagen	B-COMP
+in	O
+lungs	B-ANAT
+,	O
+and	O
+confirmed	O
+fibrosis	B-DISO
+of	O
+lungs	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+H5N1	B-DISO
+-	O
+inoculated	O
+mice	B-SPEC
+presented	O
+two	O
+stages	O
+of	O
+pulmonary	B-DISO
+disease	I-DISO
+over	O
+a	O
+30	O
+-	O
+d	O
+period	O
+after	O
+infection	B-DISO
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+the	O
+vaccines	O
+used	O
+for	O
+these	O
+giant	B-SPEC
+pandas	B-DISO
+do	O
+not	O
+elicit	O
+consistent	O
+antibody	B-COMP
+titers	O
+.	O
+
+In	O
+the	O
+aftermath	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+although	O
+significant	O
+progress	O
+towards	O
+understanding	O
+the	O
+underlying	O
+molecular	O
+mechanism	O
+of	O
+the	O
+infection	B-DISO
+has	O
+been	O
+made	O
+,	O
+a	O
+large	O
+gap	O
+still	O
+remains	O
+in	O
+our	O
+knowledge	O
+regarding	O
+how	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+interacts	O
+with	O
+the	O
+host	B-COMP
+cell	I-COMP
+at	O
+the	O
+onset	O
+of	O
+infection	B-DISO
+.	O
+
+Upregulated	O
+BASC	O
+miRNAs	O
+-	O
+17	O
+*,	O
+-	O
+574	O
+-	O
+5p	O
+,	O
+and	O
+-	O
+214	O
+are	O
+co	O
+-	O
+opted	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+to	O
+suppress	O
+its	O
+own	O
+replication	O
+and	O
+evade	O
+immune	B-PROC
+elimination	I-PROC
+until	O
+successful	O
+transmission	O
+takes	O
+place	O
+.	O
+
+The	O
+designed	O
+primers	O
+and	O
+probe	O
+were	O
+specific	O
+for	O
+TCoV	O
+.	O
+Other	O
+non	O
+-	O
+TCoV	O
+avian	B-SPEC
+viruses	B-SPEC
+and	O
+bacteria	B-SPEC
+were	O
+not	O
+amplified	O
+by	O
+RRT	O
+-	O
+PCR	O
+.	O
+
+The	O
+viral	O
+RNA	O
+in	O
+the	O
+intestine	B-ANAT
+segments	O
+reached	O
+the	O
+highest	O
+level	O
+,	O
+6x10	O
+(	O
+15	O
+)	O
+copies	O
+/	O
+microl	O
+,	O
+in	O
+the	O
+jejunum	B-ANAT
+at	O
+5	O
+DPI	O
+.	O
+
+The	O
+average	O
+amount	O
+of	O
+TCoV	B-PRGE
+RNA	I-PRGE
+in	O
+the	O
+cloacal	B-ANAT
+fecal	B-ANAT
+samples	O
+was	O
+10	O
+times	O
+higher	O
+than	O
+that	O
+in	O
+the	O
+fecal	B-ANAT
+droppings	B-ANAT
+on	O
+the	O
+floor	O
+.	O
+
+Taken	O
+together	O
+,	O
+the	O
+results	O
+indicated	O
+that	O
+the	O
+developed	O
+RRT	O
+-	O
+PCR	O
+assay	O
+is	O
+rapid	O
+,	O
+sensitive	O
+,	O
+and	O
+specific	O
+for	O
+detection	O
+,	O
+differentiation	B-PROC
+,	O
+and	O
+quantitation	O
+of	O
+TCoV	O
+in	O
+the	O
+turkey	B-SPEC
+tissues	B-ANAT
+and	O
+should	O
+be	O
+helpful	O
+in	O
+monitoring	O
+the	O
+progression	O
+of	O
+TCoV	O
+induced	O
+acute	O
+enteritis	B-DISO
+in	O
+the	O
+turkey	B-SPEC
+flocks	O
+.	O
+
+A	O
+retrospective	O
+analysis	O
+was	O
+conducted	O
+among	O
+225	O
+SARS	B-DISO
+patients	O
+treated	O
+in	O
+our	O
+in	O
+2003	O
+.	O
+
+High	O
+Performance	O
+Liquid	O
+Chromatography	O
+(	O
+HPLC	O
+)	O
+and	O
+amino	B-CHED
+acid	I-CHED
+sequencing	O
+analyses	O
+identified	O
+two	O
+arginine	B-CHED
+residues	O
+(	O
+R667	O
+and	O
+R797	O
+)	O
+as	O
+potential	O
+protease	O
+cleavage	B-PROC
+site	O
+(	O
+s	O
+).	O
+
+The	O
+effect	O
+of	O
+protease	O
+-	O
+dependent	O
+enhancement	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+was	O
+demonstrated	O
+with	O
+ACE2	B-PRGE
+expressing	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+16HBE	O
+.	O
+
+From	O
+June	O
+24	O
+through	O
+12	O
+July	O
+2009	O
+,	O
+13	O
+patients	O
+with	O
+suspected	O
+H1N1	O
+pneumonia	B-DISO
+and	O
+ALI	O
+-	O
+ARDS	B-DISO
+were	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+of	O
+a	O
+tertiary	O
+care	O
+hospital	O
+.	O
+
+Patients	O
+with	O
+and	O
+without	O
+confirmed	O
+H1N1	B-DISO
+influenza	I-DISO
+had	O
+similar	O
+disease	O
+severity	O
+at	O
+presentation	O
+and	O
+a	O
+comparable	O
+response	O
+to	O
+treatment	O
+.	O
+
+Survivors	O
+were	O
+discharged	O
+home	O
+without	O
+oxygen	B-CHED
+supplementation	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+52	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+presented	O
+with	O
+unproductive	O
+cough	O
+,	O
+fever	B-PROC
+and	O
+chill	B-DISO
+in	O
+our	O
+emergency	B-DISO
+department	O
+.	O
+
+Self	O
+-	O
+medication	O
+with	O
+amoxicillin	B-CHED
+over	O
+3	O
+days	O
+failed	O
+to	O
+improve	O
+his	O
+condition	B-DISO
+.	O
+
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+was	O
+diagnosed	O
+.	O
+
+Therefore	O
+,	O
+the	O
+diagnostic	O
+and	O
+treatment	O
+algorithms	O
+need	O
+to	O
+be	O
+reconsidered	O
+in	O
+order	B-SPEC
+to	O
+rapidly	O
+diagnose	O
+and	O
+treat	O
+infections	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+incidence	O
+of	O
+influenza	B-DISO
+(	O
+A	O
+/	O
+H1N1	O
+)	O
+has	O
+increased	O
+in	O
+Germany	O
+and	O
+severe	O
+and	O
+lethal	O
+courses	O
+have	O
+occurred	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+tumor	B-DISO
+lysis	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+7	O
+-	O
+month	O
+-	O
+old	O
+with	O
+hepatoblastoma	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+tumor	B-DISO
+lysis	B-PROC
+syndrome	I-DISO
+(	O
+TLS	O
+)	O
+is	O
+characterized	O
+by	O
+the	O
+triad	B-COMP
+of	O
+hyperuricemia	B-DISO
+,	O
+hyperkalemia	O
+,	O
+and	O
+hyperphosphatemia	B-DISO
+and	O
+is	O
+caused	O
+by	O
+the	O
+death	B-PROC
+of	O
+tumor	B-ANAT
+cells	B-COMP
+and	O
+release	B-PATH
+of	O
+intracellular	B-COMP
+contents	O
+into	O
+the	O
+circulation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Severe	O
+late	O
+-	O
+onset	O
+nosocomial	B-DISO
+pneumonia	I-DISO
+caused	O
+by	O
+Chlamydophila	B-SPEC
+pneumoniae	I-SPEC
+.	O
+
+The	O
+recently	O
+identified	O
+virus	B-SPEC
+variant	O
+CPV	B-SPEC
+-	O
+2c	O
+was	O
+predominant	O
+in	O
+Italy	O
+and	O
+Germany	O
+and	O
+present	O
+at	O
+high	O
+rates	O
+in	O
+Spain	O
+and	O
+France	O
+but	O
+was	O
+not	O
+detected	O
+in	O
+the	O
+UK	O
+or	O
+Belgium	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+novel	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pandemic	O
+,	O
+some	O
+patients	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+or	O
+severe	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+despite	O
+the	O
+use	O
+of	O
+conventional	O
+management	O
+.	O
+
+Because	O
+of	O
+compromised	O
+cardiopulmonary	B-ANAT
+function	O
+,	O
+venoarterial	O
+ECMO	O
+support	O
+was	O
+started	O
+4	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+and	O
+he	O
+was	O
+transferred	O
+to	O
+Hospital	O
+B	O
+on	O
+July	O
+25	O
+,	O
+2009	O
+.	O
+
+Observed	O
+ICU	O
+admissions	O
+were	O
+15	O
+-	O
+fold	O
+greater	O
+than	O
+expected	O
+for	O
+those	O
+with	O
+BMI	O
+>	O
+or	O
+=	O
+40	O
+kg	O
+/	O
+m2	O
+(	O
+standardized	O
+morbidity	O
+ratio	O
+15	O
+.	O
+8	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+8	O
+.	O
+3	O
+-	O
+23	O
+.	O
+4	O
+)	O
+and	O
+1	O
+.	O
+5	O
+-	O
+fold	O
+greater	O
+than	O
+expected	O
+among	O
+those	O
+with	O
+BMI	O
+of	O
+30	O
+to	O
+39	O
+kg	O
+/	O
+m	O
+(	O
+2	O
+)	O
+for	O
+age	O
+-	O
+adjusted	O
+and	O
+sex	O
+-	O
+adjusted	O
+rates	O
+for	O
+Salt	B-CHED
+Lake	B-SPEC
+County	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+/	O
+renal	B-ANAT
+interaction	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+kidney	B-ANAT
+injury	O
+contributes	O
+to	O
+the	O
+development	B-PROC
+of	O
+acute	O
+lung	O
+injury	O
+and	O
+vice	O
+-	O
+versa	O
+.	O
+
+An	O
+increasing	O
+body	B-ANAT
+of	O
+evidence	O
+suggests	O
+that	O
+kidney	B-ANAT
+and	O
+lung	B-ANAT
+interact	O
+(	O
+crosstalk	B-PROC
+)	O
+during	O
+severe	O
+insults	O
+,	O
+such	O
+as	O
+shock	O
+,	O
+trauma	O
+,	O
+and	O
+sepsis	B-DISO
+,	O
+due	O
+to	O
+a	O
+loss	O
+of	O
+the	O
+normal	O
+balance	B-PROC
+of	O
+immune	O
+,	O
+inflammatory	O
+and	O
+soluble	O
+mediators	O
+.	O
+
+At	O
+44	O
+days	O
+of	O
+age	O
+,	O
+poults	O
+infected	O
+at	O
+2	O
+or	O
+28	O
+days	O
+of	O
+age	O
+weighed	O
+only	O
+68	O
+.	O
+1	O
+%	O
+or	O
+77	O
+.	O
+7	O
+%,	O
+respectively	O
+,	O
+compared	O
+with	O
+uninfected	O
+turkeys	B-SPEC
+of	O
+the	O
+same	O
+age	O
+on	O
+the	O
+same	O
+diet	O
+,	O
+a	O
+mean	O
+difference	O
+in	O
+body	B-ANAT
+weights	O
+of	O
+683	O
+or	O
+477g	O
+,	O
+respectively	O
+.	O
+
+Strain	O
+793	O
+/	O
+B	O
+had	O
+the	O
+least	O
+capacity	O
+to	O
+invade	O
+the	O
+investigated	O
+organs	B-ANAT
+,	O
+while	O
+it	O
+produced	O
+a	O
+good	O
+humoral	O
+response	O
+as	O
+measured	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Due	O
+to	O
+their	O
+paucity	O
+in	O
+blood	B-ANAT
+,	O
+we	O
+utilized	O
+novel	O
+fluorescent	O
+-	O
+activated	O
+cell	B-COMP
+sorting	B-PROC
+procedures	O
+to	O
+isolate	O
+them	O
+from	O
+PBMC	O
+.	O
+
+In	O
+addition	O
+to	O
+being	O
+a	O
+potent	O
+source	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+other	O
+properties	O
+of	O
+these	O
+porcine	B-SPEC
+CD4	B-PRGE
+(	O
+hi	O
+)	O
+CD172	O
+(	O
+lo	O
+)	O
+cells	B-COMP
+including	O
+their	O
+morphological	O
+transition	B-DISO
+from	O
+a	O
+plasma	B-ANAT
+cell	I-ANAT
+-	O
+like	O
+shape	O
+during	O
+quiescence	O
+to	O
+one	O
+resembling	O
+a	O
+dendritic	B-ANAT
+cell	B-COMP
+(	O
+DC	O
+)	O
+after	O
+activation	O
+by	O
+TGEV	B-SPEC
+and	O
+their	O
+relatively	O
+strong	O
+constitutive	O
+expression	B-PROC
+of	O
+interferon	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+7	I-PRGE
+(	O
+IRF	B-PRGE
+-	I-PRGE
+7	I-PRGE
+)	O
+conformed	O
+to	O
+the	O
+expectations	O
+of	O
+genuine	O
+pDCs	O
+.	O
+
+Notably	O
+,	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+)	O
+failed	O
+to	O
+provoke	O
+the	O
+pDCs	O
+to	O
+secrete	B-PROC
+any	O
+of	O
+the	O
+measured	O
+cytokines	O
+except	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+.	O
+
+Major	O
+histopathological	O
+changes	O
+in	O
+infected	O
+lungs	B-ANAT
+included	O
+diffuse	O
+pneumonia	B-DISO
+and	O
+alveolar	B-ANAT
+damage	O
+,	O
+with	O
+neutrophil	B-ANAT
+-	O
+dominant	O
+inflammatory	O
+cellular	B-ANAT
+infiltration	B-DISO
+,	O
+interstitial	B-ANAT
+and	O
+alveolar	B-DISO
+edema	I-DISO
+,	O
+hemorrhage	B-DISO
+,	O
+and	O
+severe	O
+bronchiolitis	B-DISO
+/	O
+peribronchiolitis	O
+.	O
+
+Our	O
+data	O
+show	O
+that	O
+H9N2	O
+viral	B-DISO
+infection	I-DISO
+resulted	O
+in	O
+ARDS	B-DISO
+in	O
+mice	B-SPEC
+,	O
+and	O
+this	O
+may	O
+facilitate	O
+studies	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+future	O
+potential	O
+H9N2	O
+disease	O
+in	O
+humans	B-SPEC
+.	O
+
+Adult	B-DISO
+onset	I-DISO
+Still	I-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+(	O
+AOSD	O
+),	O
+a	O
+diagnosis	O
+considered	O
+in	O
+this	O
+patient	O
+,	O
+is	O
+a	O
+rare	B-DISO
+disease	I-DISO
+with	O
+unknown	O
+prevalence	O
+,	O
+pathogenesis	B-DISO
+and	O
+etiology	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+failure	O
+and	O
+its	O
+most	O
+severe	O
+form	O
+,	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+are	O
+relatively	O
+common	O
+in	O
+the	O
+ICU	O
+setting	O
+and	O
+have	O
+a	O
+high	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Multivariate	O
+analysis	O
+found	O
+2	O
+independent	O
+factors	O
+related	O
+to	O
+severe	O
+pulmonary	B-DISO
+involvement	I-DISO
+:	O
+dyspnoea	B-DISO
+(	O
+OR	O
+10	O
+.	O
+18	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+and	O
+oliguria	B-DISO
+/	O
+anuria	B-DISO
+(	O
+OR	O
+4	O
+.	O
+87	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0009	O
+).	O
+
+(	O
+3	O
+)	O
+The	O
+respective	O
+PIP	B-CHED
+in	O
+the	O
+4	O
+groups	O
+was	O
+(	O
+33	O
++/-	O
+
+Interestingly	O
+,	O
+N	B-PRGE
+protein	I-PRGE
+and	O
+its	O
+deletion	O
+mutants	O
+with	O
+RNA	O
+chaperone	B-PROC
+activity	I-PROC
+enhanced	O
+template	O
+switching	O
+in	O
+a	O
+retrovirus	B-SPEC
+-	O
+derived	O
+heterologous	O
+system	O
+,	O
+reinforcing	O
+the	O
+concept	O
+that	O
+TGEV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+is	O
+an	O
+RNA	B-PROC
+chaperone	I-PROC
+that	O
+could	O
+be	O
+involved	O
+in	O
+template	O
+switching	O
+.	O
+
+TITLE	O
+:	O
+Seroprevalences	O
+to	O
+viral	O
+pathogens	O
+in	O
+free	O
+-	O
+ranging	O
+and	O
+captive	O
+cheetahs	B-SPEC
+(	O
+Acinonyx	B-SPEC
+jubatus	I-SPEC
+)	O
+on	O
+Namibian	O
+Farmland	O
+.	O
+
+Eight	O
+of	O
+11	O
+other	O
+wild	O
+carnivores	B-SPEC
+were	O
+seropositive	O
+for	O
+at	O
+least	O
+one	O
+of	O
+the	O
+viruses	B-SPEC
+,	O
+including	O
+the	O
+first	O
+record	O
+of	O
+an	O
+FIV	B-SPEC
+-	O
+like	O
+infection	B-DISO
+in	O
+a	O
+wild	O
+felid	B-SPEC
+west	O
+of	O
+the	O
+Kalahari	O
+,	O
+the	O
+caracal	B-SPEC
+(	O
+Felis	B-SPEC
+caracal	I-SPEC
+).	O
+
+Total	O
+RNAs	O
+extracted	O
+from	O
+virus	B-SPEC
+were	O
+reverse	O
+transcribed	O
+,	O
+followed	O
+by	O
+multi	O
+-	O
+PCR	O
+amplification	B-DISO
+and	O
+labeled	O
+with	O
+Cy3	O
+-	O
+dCTP	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+potential	O
+risk	O
+factors	O
+of	O
+affecting	O
+progression	O
+from	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+severe	O
+trauma	O
+population	O
+.	O
+
+We	O
+performed	O
+serial	O
+measurements	O
+of	O
+Clara	B-ANAT
+cell	I-ANAT
+protein	B-CHED
+(	O
+CC16	O
+),	O
+soluble	O
+receptor	O
+for	O
+advanced	O
+glycation	O
+end	O
+products	O
+(	O
+sRAGE	O
+),	O
+surfactant	B-PRGE
+protein	B-CHED
+D	I-PRGE
+(	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+)	O
+and	O
+Krebs	B-PRGE
+von	I-PRGE
+den	I-PRGE
+Lungen	I-PRGE
+(	O
+KL	O
+-	O
+6	O
+)	O
+in	O
+plasma	B-ANAT
+of	O
+patients	O
+with	O
+VAP	O
+and	O
+mechanically	O
+ventilated	O
+control	O
+patients	O
+without	O
+VAP	O
+.	O
+
+ALI	O
+/	O
+ARDS	B-DISO
+was	O
+diagnosed	O
+using	O
+the	O
+criteria	O
+of	O
+the	O
+North	O
+-	O
+American	O
+European	O
+consensus	O
+conference	O
+.	O
+
+Of	O
+note	O
+,	O
+levels	O
+of	O
+CC16	O
+increased	O
+2	O
+days	O
+before	O
+ALI	O
+/	O
+ARDS	B-DISO
+diagnosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Ribavirin	O
+and	O
+corticosteroids	B-CHED
+were	O
+used	O
+widely	O
+as	O
+front	O
+-	O
+line	O
+treatments	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+;	O
+however	O
+,	O
+previous	O
+evaluations	O
+were	O
+inconclusive	O
+.	O
+
+Only	O
+FCV	B-CHED
+RNA	O
+was	O
+present	O
+in	O
+significantly	O
+more	O
+cats	B-SPEC
+with	O
+FGS	B-DISO
+(	O
+40	O
+.	O
+5	O
+%)	O
+than	O
+control	O
+cats	O
+(	O
+0	O
+%).	O
+
+ABSTRACT	O
+:	O
+To	O
+gauge	O
+Singapore	O
+physicians	O
+'	O
+perceptions	O
+of	O
+the	O
+national	O
+response	O
+to	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+using	O
+a	O
+questionnaire	O
+survey	O
+.	O
+
+TITLE	O
+:	O
+Cost	O
+-	O
+effectiveness	O
+analysis	O
+of	O
+hospital	B-DISO
+infection	I-DISO
+control	O
+response	O
+to	O
+an	O
+epidemic	O
+respiratory	O
+virus	O
+threat	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+influenza	B-PATH
+A	I-PATH
+pandemic	O
+(	O
+H1N1	O
+)	O
+2009	O
+prompted	O
+many	O
+countries	O
+in	O
+Asia	O
+,	O
+previously	O
+strongly	O
+affected	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+to	O
+respond	O
+with	O
+stringent	O
+measures	O
+,	O
+particularly	O
+in	O
+preventing	O
+outbreaks	O
+in	O
+hospitals	O
+.	O
+
+RESULTS	O
+:	O
+Two	O
+datasets	O
+have	O
+been	O
+used	O
+as	O
+test	O
+beds	O
+,	O
+one	O
+dataset	O
+includes	O
+patients	O
+of	O
+nasopharyngeal	B-DISO
+carcinoma	I-DISO
+with	O
+different	O
+responses	O
+to	O
+chemotherapy	O
+drug	O
+,	O
+and	O
+the	O
+other	O
+consists	O
+of	O
+patients	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+influenza	B-DISO
+,	O
+and	O
+control	O
+normals	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+derived	O
+networks	O
+can	O
+effectively	O
+capture	O
+the	O
+unique	O
+regulatory	O
+patterns	O
+of	O
+protein	B-CHED
+markers	O
+associated	O
+with	O
+different	O
+patient	O
+groups	O
+and	O
+hence	O
+can	O
+be	O
+used	O
+for	O
+disease	O
+classification	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+of	O
+the	O
+X	O
+(	O
+ADRP	O
+)	O
+domain	O
+of	O
+nsp3	B-PRGE
+from	O
+feline	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+In	O
+the	O
+tetragonal	O
+crystal	B-ANAT
+form	O
+,	O
+glycerol	B-CHED
+-	I-CHED
+3	I-CHED
+-	I-CHED
+phosphate	I-CHED
+was	O
+observed	O
+in	O
+the	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+-	O
+binding	B-FUNC
+site	O
+.	O
+
+However	O
+,	O
+the	O
+structure	O
+with	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+bound	O
+was	O
+determined	O
+in	O
+the	O
+cubic	O
+crystal	B-ANAT
+form	O
+at	O
+3	O
+.	O
+9	O
+A	O
+resolution	O
+.	O
+
+To	O
+demonstrate	O
+this	O
+possibility	O
+,	O
+we	O
+here	O
+tested	O
+the	O
+effects	O
+of	O
+TACE	B-ENZY
+inhibitors	B-CHED
+on	O
+viral	O
+entry	O
+.	O
+
+We	O
+engineered	O
+recombinant	O
+Lactobacillus	B-SPEC
+casei	I-SPEC
+,	O
+producing	O
+biologically	O
+active	O
+canine	O
+granulocyte	B-PRGE
+macrophage	B-ANAT
+colony	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+cGM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+),	O
+and	O
+investigated	O
+its	O
+possibility	O
+as	O
+a	O
+good	O
+probiotic	O
+agent	O
+for	O
+dogs	B-SPEC
+.	O
+
+After	O
+the	O
+administration	O
+of	O
+CCV	B-DISO
+vaccine	O
+,	O
+CCV	B-DISO
+-	O
+specific	O
+IgG	B-PRGE
+in	O
+serum	B-COMP
+increased	O
+more	O
+in	O
+the	O
+group	O
+supplemented	O
+with	O
+L	B-SPEC
+.	I-SPEC
+casei	I-SPEC
+expressing	O
+cGM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+than	O
+the	O
+other	O
+two	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+last	O
+2	O
+years	O
+,	O
+several	O
+reports	O
+have	O
+dealt	O
+with	O
+recruitment	O
+/	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+selection	O
+.	O
+
+The	O
+highest	O
+opening	O
+pressures	O
+are	O
+required	O
+to	O
+open	O
+the	O
+most	O
+dependent	O
+lung	B-ANAT
+regions	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+(	O
+BRD	O
+)	O
+research	O
+has	O
+provided	O
+significant	O
+understanding	O
+of	O
+the	O
+disease	O
+over	O
+the	O
+past	O
+26	O
+years	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+induce	O
+in	O
+infected	O
+cells	O
+the	O
+formation	B-PROC
+of	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+(	O
+DMVs	O
+)	O
+in	O
+which	O
+the	O
+replication	O
+-	O
+transcription	B-PROC
+complexes	O
+(	O
+RTCs	O
+)	O
+are	O
+anchored	O
+.	O
+
+TITLE	O
+:	O
+A	O
+single	O
+tyrosine	B-CHED
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+membrane	B-COMP
+protein	B-CHED
+cytoplasmic	B-COMP
+tail	I-ANAT
+is	O
+important	O
+for	O
+efficient	O
+interaction	O
+with	O
+spike	O
+protein	B-CHED
+.	O
+
+Mutating	O
+Y	O
+(	O
+195	O
+)	O
+also	O
+disrupted	O
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+-	O
+M	O
+interaction	O
+in	O
+vitro	O
+.	O
+
+Importantly	O
+,	O
+expression	B-PROC
+of	O
+the	O
+JHM	O
+nucleocapsid	B-COMP
+in	O
+the	O
+context	O
+of	O
+the	O
+A59	O
+genome	O
+conferred	O
+increased	O
+mortality	O
+and	O
+spread	O
+of	O
+viral	O
+antigen	B-CHED
+in	O
+the	O
+mouse	B-ANAT
+central	I-ANAT
+nervous	B-DISO
+system	I-ANAT
+compared	O
+to	O
+the	O
+parental	O
+A59	O
+strain	O
+,	O
+while	O
+having	O
+little	O
+effect	O
+on	O
+the	O
+induction	O
+of	O
+hepatitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Short	O
+-	O
+term	O
+follow	O
+-	O
+up	O
+studies	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+survivors	O
+suggested	O
+that	O
+their	O
+physical	O
+conditions	O
+continuously	O
+improved	O
+in	O
+the	O
+first	O
+year	O
+but	O
+that	O
+their	O
+mental	O
+health	O
+did	O
+not	O
+.	O
+
+Psychiatric	O
+morbidities	O
+and	O
+chronic	O
+fatigue	B-DISO
+persisted	O
+and	O
+continued	O
+to	O
+be	O
+clinically	O
+significant	O
+among	O
+the	O
+survivors	O
+at	O
+the	O
+4	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+.	O
+
+Optimization	O
+of	O
+the	O
+treatment	O
+of	O
+mental	O
+health	O
+morbidities	O
+by	O
+a	O
+multidisciplinary	O
+approach	O
+with	O
+a	O
+view	O
+for	O
+long	O
+-	O
+term	O
+rehabilitation	O
+,	O
+especially	O
+targeting	B-PROC
+psychiatric	O
+and	O
+fatigue	B-DISO
+problems	O
+and	O
+functional	O
+and	O
+occupational	O
+rehabilitation	O
+,	O
+would	O
+be	O
+needed	O
+.	O
+
+Specific	O
+parameters	O
+assessed	O
+in	O
+the	O
+innate	O
+pulmonary	B-ANAT
+inflammatory	B-DISO
+response	I-DISO
+were	O
+leukocytes	B-ANAT
+,	O
+macrophages	B-ANAT
+,	O
+and	O
+polymorphonuclear	B-ANAT
+neutrophils	I-ANAT
+(	O
+PMNs	O
+)	O
+in	O
+BAL	B-ENZY
+;	O
+whole	O
+lung	B-PRGE
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+;	O
+and	O
+a	O
+series	O
+of	O
+cytokines	O
+or	O
+chemokines	O
+present	O
+in	O
+BAL	B-ENZY
+at	O
+5	O
+or	O
+24	O
+hours	O
+after	O
+injury	O
+:	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+1beta	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+macrophage	B-PRGE
+inflammatory	I-PRGE
+protein	B-CHED
+-	I-PRGE
+2	I-PRGE
+,	O
+cytokine	O
+-	O
+induced	O
+neutrophil	B-ANAT
+chemoattractant	O
+-	O
+1	O
+,	O
+and	O
+monocyte	B-PRGE
+chemoattractant	I-PRGE
+protein	B-CHED
+-	I-PRGE
+1	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+,	O
+immortalisation	O
+and	O
+characterisation	O
+of	O
+pteropid	O
+bat	B-ENZY
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+Black	O
+flying	B-SPEC
+foxes	I-SPEC
+(	O
+Pteropus	B-SPEC
+alecto	I-SPEC
+)	O
+were	O
+captured	O
+from	O
+the	O
+wild	O
+and	O
+transported	O
+live	O
+to	O
+the	O
+laboratory	O
+for	O
+primary	O
+cell	B-COMP
+culture	O
+preparation	O
+using	O
+a	O
+variety	O
+of	O
+different	O
+methods	O
+and	O
+culture	O
+media	B-ANAT
+.	O
+
+The	O
+present	O
+authors	O
+,	O
+in	O
+collaboration	O
+with	O
+Vietnamese	O
+hospital	O
+staff	O
+,	O
+performed	O
+a	O
+fact	O
+-	O
+finding	O
+survey	O
+of	O
+nosocomial	B-DISO
+infection	I-DISO
+control	O
+in	O
+hospitals	O
+in	O
+northern	O
+Vietnam	O
+and	O
+compared	O
+the	O
+results	O
+with	O
+those	O
+of	O
+a	O
+survey	O
+conducted	O
+4	O
+years	O
+previously	O
+.	O
+
+All	O
+patients	O
+were	O
+imported	O
+cases	O
+,	O
+representing	O
+an	O
+important	O
+epidemiological	O
+factor	O
+and	O
+future	O
+medical	O
+issue	O
+,	O
+though	O
+they	O
+were	O
+not	O
+malnourished	B-DISO
+nor	O
+affected	O
+by	O
+chronic	B-DISO
+diseases	I-DISO
+.	O
+
+We	O
+conclude	O
+that	O
+early	O
+respiratory	O
+assessment	O
+and	O
+timely	O
+PICU	B-SPEC
+referral	O
+is	O
+of	O
+mainstem	O
+importance	O
+in	O
+the	O
+youngest	O
+infants	O
+with	O
+measles	B-PATH
+-	O
+induced	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Chinese	O
+rufous	O
+horseshoe	B-SPEC
+bat	I-SPEC
+(	O
+Rhinolophus	B-SPEC
+sinicus	I-SPEC
+)	O
+has	O
+been	O
+suggested	O
+to	O
+carry	O
+the	O
+direct	O
+ancestor	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SCoV	O
+),	O
+and	O
+the	O
+diversity	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+like	I-PRGE
+CoVs	I-PRGE
+(	O
+SLCoV	O
+)	O
+within	O
+this	O
+Rhinolophus	B-SPEC
+species	B-SPEC
+is	O
+therefore	O
+worth	O
+investigating	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrate	O
+the	O
+remarkable	O
+diversity	O
+of	O
+SLCoVs	O
+in	O
+R	B-SPEC
+.	I-SPEC
+sinicus	I-SPEC
+and	O
+identify	O
+a	O
+strain	O
+with	O
+the	O
+same	O
+pattern	O
+of	O
+phylogenetic	O
+incongruence	O
+(	O
+i	O
+.	O
+e	O
+.	O
+an	O
+indication	O
+of	O
+recombination	B-PROC
+)	O
+as	O
+reported	O
+previously	O
+in	O
+another	O
+SLCoV	O
+strain	O
+.	O
+
+Outcome	O
+of	O
+severe	O
+blunt	O
+trauma	O
+in	O
+dogs	B-SPEC
+treated	O
+with	O
+intensive	O
+care	O
+is	O
+very	O
+good	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+could	O
+represent	O
+an	O
+important	O
+treatment	O
+option	O
+,	O
+if	O
+complications	O
+were	O
+reduced	O
+by	O
+new	O
+technical	O
+developments	O
+.	O
+
+Ventilatory	O
+parameters	O
+were	O
+reduced	O
+to	O
+a	O
+highly	O
+protective	O
+mode	O
+,	O
+allowing	O
+a	O
+fast	B-FUNC
+reduction	O
+of	O
+tidal	O
+volume	O
+from	O
+495	O
+(	O
+401	O
+to	O
+570	O
+)	O
+mL	O
+to	O
+336	O
+(	O
+292	O
+to	O
+404	O
+)	O
+mL	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+of	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+from	O
+36	O
+(	O
+32	O
+to	O
+40	O
+)	O
+cmH2O	O
+to	O
+31	O
+(	O
+28	O
+to	O
+35	O
+)	O
+cmH2O	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+with	O
+a	O
+new	O
+miniaturized	O
+device	O
+supports	O
+gas	B-ENZY
+transfer	O
+effectively	O
+,	O
+allows	O
+for	O
+highly	O
+protective	O
+ventilation	O
+and	O
+is	O
+very	O
+reliable	O
+.	O
+
+Plasmodium	B-DISO
+falciparum	I-DISO
+malaria	B-PATH
+and	O
+to	O
+some	O
+extent	O
+malaria	B-PATH
+caused	O
+by	O
+other	O
+species	B-SPEC
+of	O
+Plasmodium	B-SPEC
+can	O
+lead	O
+to	O
+many	O
+complications	O
+such	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+severe	B-DISO
+anemia	I-DISO
+,	O
+thrombocytopenia	O
+,	O
+and	O
+bleeding	B-DISO
+complications	O
+.	O
+
+There	O
+has	O
+been	O
+significant	O
+progress	O
+in	O
+the	O
+understanding	O
+of	O
+pathogenesis	B-DISO
+of	O
+severe	O
+malaria	B-PATH
+over	O
+the	O
+last	O
+decade	O
+.	O
+
+Outcome	O
+measures	O
+were	O
+days	O
+on	O
+mechanical	O
+ventilation	O
+,	O
+days	O
+required	O
+in	O
+ICU	O
+,	O
+days	O
+required	O
+in	O
+hospital	O
+,	O
+incidence	O
+of	O
+fistulas	O
+/	O
+leakages	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+mortality	O
+.	O
+
+We	O
+did	O
+not	O
+find	O
+significant	O
+differences	O
+in	O
+morbidity	O
+or	O
+mortality	O
+when	O
+we	O
+compared	O
+DPA	B-CHED
+versus	O
+diversion	O
+surgical	O
+treatment	O
+.	O
+
+RESULTS	O
+:	O
+There	O
+were	O
+34	O
+patients	O
+subjected	O
+to	O
+DPA	B-PRGE
+and	O
+78	O
+to	O
+diversion	O
+.	O
+
+Due	O
+to	O
+lack	O
+of	O
+effective	O
+drugs	O
+,	O
+3C	O
+(	O
+pro	B-CHED
+)	O
+has	O
+served	O
+as	O
+an	O
+excellent	O
+target	O
+for	O
+anti	O
+-	O
+viral	O
+intervention	O
+and	O
+considerable	O
+efforts	O
+have	O
+been	O
+made	O
+in	O
+the	O
+development	B-PROC
+of	O
+inhibitors	B-CHED
+.	O
+
+Readers	O
+will	O
+rapidly	O
+gain	O
+an	O
+overview	O
+of	O
+the	O
+individual	O
+and	O
+dual	O
+3C	O
+(	O
+pro	B-CHED
+)	O
+inhibitors	B-CHED
+and	O
+the	O
+structural	O
+basis	O
+for	O
+discriminating	O
+them	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+genetic	O
+analysis	O
+revealed	O
+no	O
+predominant	O
+new	O
+strains	O
+of	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	O
+circulating	O
+in	O
+South	O
+China	O
+during	O
+2004	O
+-	O
+2008	O
+.	O
+
+Patients	O
+with	O
+severe	O
+illness	O
+or	O
+underlying	O
+medical	O
+conditions	O
+that	O
+increase	O
+the	O
+risk	O
+of	O
+more	O
+severe	O
+disease	O
+should	O
+be	O
+treated	O
+with	O
+oseltamivir	B-CHED
+or	O
+zanamivir	B-CHED
+as	O
+soon	O
+as	O
+possible	O
+,	O
+without	O
+waiting	O
+for	O
+the	O
+results	O
+of	O
+laboratory	O
+tests	O
+.	O
+
+Lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+strategy	O
+with	O
+a	O
+low	O
+tidal	O
+volume	O
+and	O
+adequate	O
+pressure	O
+,	O
+in	O
+addition	O
+to	O
+a	O
+conservative	O
+fluid	O
+management	O
+approach	O
+,	O
+is	O
+recommended	O
+when	O
+treating	O
+adult	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Low	O
+-	O
+dose	O
+corticosteroids	B-CHED
+may	O
+be	O
+considered	O
+in	O
+the	O
+treatment	O
+of	O
+refractory	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+Although	O
+the	O
+evidence	O
+base	O
+of	O
+most	O
+non	O
+pharmaceutical	B-CHED
+interventions	O
+(	O
+NPIs	O
+)	O
+and	O
+personal	O
+protection	O
+measures	O
+is	O
+debated	O
+,	O
+it	O
+appears	O
+on	O
+the	O
+basis	O
+of	O
+past	O
+experience	O
+that	O
+NPIs	O
+implemented	O
+the	O
+most	O
+systematically	O
+,	O
+the	O
+earliest	O
+,	O
+and	O
+for	O
+the	O
+longest	O
+time	O
+could	O
+reduce	O
+overall	O
+mortality	O
+rates	O
+and	O
+spread	O
+out	O
+epidemic	O
+peaks	O
+.	O
+
+Adequate	O
+,	O
+transparent	O
+,	O
+and	O
+targeted	B-PROC
+communication	O
+on	O
+the	O
+part	O
+of	O
+public	O
+health	O
+authorities	O
+would	O
+be	O
+also	O
+of	O
+crucial	O
+importance	O
+in	O
+the	O
+event	O
+of	O
+a	O
+serious	O
+influenza	O
+pandemic	O
+.	O
+
+On	O
+univariate	O
+analysis	O
+6	O
+variables	O
+were	O
+associated	O
+with	O
+EOVAP	O
+:	O
+early	O
+enteral	O
+feeding	O
+,	O
+barbiturate	B-CHED
+use	O
+,	O
+immunosuppression	B-PROC
+,	O
+mean	O
+Simplified	O
+Acute	O
+Physiology	O
+Score	O
+2	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+initial	O
+neurosurgery	O
+procedures	O
+.	O
+
+Methicillin	B-CHED
+-	O
+susceptible	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+was	O
+the	O
+most	O
+common	O
+pathogen	O
+involved	O
+in	O
+EOVAP	O
+(	O
+46	O
+%).	O
+
+Moreover	O
+,	O
+the	O
+addition	O
+of	O
+vitamin	B-CHED
+K3	I-CHED
+before	O
+and	O
+after	O
+LPS	B-DISO
+administration	O
+attenuated	O
+the	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+in	O
+an	O
+animal	B-SPEC
+model	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+occurs	O
+in	O
+the	O
+setting	O
+of	O
+acute	O
+severe	O
+illness	O
+complicated	O
+by	O
+systemic	O
+inflammation	B-DISO
+.	O
+
+Despite	O
+marked	O
+efforts	O
+,	O
+little	O
+therapeutic	O
+progress	O
+has	O
+been	O
+made	O
+,	O
+and	O
+the	O
+mortality	O
+rate	O
+of	O
+ARDS	B-DISO
+remains	O
+high	O
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+of	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+have	O
+recently	O
+emerged	O
+through	O
+zoonotic	O
+transmission	O
+to	O
+become	O
+serious	O
+human	B-SPEC
+pathogens	O
+.	O
+
+The	O
+pathogenic	O
+agent	O
+responsible	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+is	O
+a	O
+member	O
+of	O
+this	O
+large	O
+family	B-SPEC
+of	O
+positive	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+that	O
+cause	O
+a	O
+spectrum	O
+of	O
+disease	O
+in	O
+humans	B-SPEC
+,	O
+other	O
+mammals	B-SPEC
+,	O
+and	O
+birds	B-SPEC
+.	O
+
+Finally	O
+,	O
+we	O
+show	O
+that	O
+GRFT	O
+treatment	O
+has	O
+a	O
+positive	O
+effect	O
+on	O
+morbidity	O
+and	O
+mortality	O
+in	O
+a	O
+lethal	O
+infection	B-DISO
+model	O
+using	O
+a	O
+mouse	B-SPEC
+-	O
+adapted	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+also	O
+specifically	O
+inhibits	O
+deleterious	O
+aspects	O
+of	O
+the	O
+host	B-COMP
+immunological	O
+response	O
+to	O
+SARS	B-DISO
+infection	B-DISO
+in	O
+mammals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Clearly	O
+air	O
+travel	O
+,	O
+by	O
+transporting	O
+infectious	B-DISO
+individuals	O
+from	O
+one	O
+geographic	O
+location	O
+to	O
+another	O
+,	O
+significantly	O
+affects	O
+the	O
+rate	O
+of	O
+spread	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+).	O
+
+Specifically	O
+,	O
+0	O
+-	O
+1	O
+infections	B-DISO
+could	O
+occur	O
+during	O
+a	O
+5	O
+hour	O
+flight	B-PROC
+,	O
+1	O
+-	O
+3	O
+during	O
+an	O
+11	O
+hour	O
+flight	B-PROC
+and	O
+2	O
+-	O
+5	O
+during	O
+a	O
+17	O
+hour	O
+flight	B-PROC
+.	O
+
+Introduction	O
+of	O
+lysine	B-CHED
+residues	O
+in	O
+the	O
+hydrophobic	O
+stretch	O
+of	O
+S	O
+also	O
+resulted	O
+in	O
+a	O
+block	O
+of	O
+entry	O
+,	O
+suggesting	O
+the	O
+borders	O
+of	O
+the	O
+actual	O
+transmembrane	B-COMP
+domain	O
+.	O
+
+Surprisingly	O
+,	O
+replacement	O
+of	O
+a	O
+glycine	B-CHED
+residue	I-CHED
+,	O
+situated	O
+close	O
+to	O
+the	O
+aromatic	O
+domain	O
+,	O
+with	O
+a	O
+lysine	B-CHED
+residue	I-CHED
+was	O
+tolerated	O
+,	O
+whereas	O
+the	O
+introduction	O
+of	O
+a	O
+lysine	B-CHED
+adjacent	O
+to	O
+the	O
+glycine	B-CHED
+,	O
+was	O
+not	O
+.	O
+
+Pharmacologic	O
+strategies	O
+(	O
+including	O
+steroids	B-CHED
+)	O
+investigated	O
+for	O
+the	O
+treatment	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+are	O
+also	O
+reviewed	O
+.	O
+
+Not	O
+surprisingly	O
+,	O
+tempol	O
+substantially	O
+preserved	O
+the	O
+integrity	O
+of	O
+the	O
+CNS	B-CHED
+,	O
+including	O
+the	O
+blood	B-PROC
+-	I-PROC
+brain	I-PROC
+barrier	I-PROC
+.	O
+
+Furthermore	O
+,	O
+treatment	O
+with	O
+tempol	O
+decreased	O
+CNS	B-CHED
+viral	O
+titers	O
+,	O
+macrophage	B-ANAT
+and	O
+T	B-ANAT
+lymphocyte	I-ANAT
+infiltration	B-DISO
+,	O
+and	O
+levels	O
+of	O
+markers	O
+of	O
+inflammation	B-DISO
+,	O
+such	O
+as	O
+expression	B-PROC
+of	O
+inducible	O
+nitric	B-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+,	O
+transcription	B-PROC
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+,	O
+and	O
+protein	B-CHED
+nitration	O
+.	O
+
+Inspiratory	B-PROC
+pressure	O
+at	O
+the	O
+beginning	O
+of	O
+mechanical	O
+ventilation	O
+was	O
+a	O
+predictor	O
+of	O
+mortality	O
+within	O
+28	O
+days	O
+and	O
+of	O
+a	O
+longer	O
+course	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Should	O
+prone	O
+positioning	O
+be	O
+routinely	O
+used	O
+for	O
+lung	B-ANAT
+protection	O
+during	O
+mechanical	O
+ventilation	O
+?	O
+
+Day	O
+100	O
+cumulative	O
+incidence	O
+estimate	O
+was	O
+22	O
+.	O
+3	O
+%	O
+for	O
+HRV	O
+and	O
+11	O
+.	O
+1	O
+%	O
+for	O
+HCoV	O
+.	O
+Median	O
+duration	O
+of	O
+viral	B-DISO
+shedding	I-DISO
+was	O
+3	O
+weeks	O
+;	O
+prolonged	O
+shedding	O
+of	O
+at	O
+least	O
+3	O
+months	O
+occurred	O
+in	O
+6	O
+of	O
+45	O
+patients	O
+with	O
+HRV	O
+and	O
+3	O
+of	O
+22	O
+with	O
+HCoV	O
+.	O
+Six	O
+patients	O
+with	O
+HRV	O
+and	O
+9	O
+with	O
+HCoV	O
+were	O
+asymptomatic	O
+.	O
+
+In	O
+October	O
+2009	O
+,	O
+it	O
+was	O
+found	O
+that	O
+he	O
+had	O
+developed	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+secondary	O
+to	O
+novel	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+.	O
+
+Importantly	O
+,	O
+the	O
+initial	O
+specimen	O
+evaluated	O
+by	O
+real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+was	O
+negative	O
+for	O
+novel	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+.	O
+
+The	O
+patient	O
+was	O
+successfully	O
+weaned	B-PROC
+from	O
+ECMO	O
+after	O
+24	O
+days	O
+,	O
+extubated	O
+at	O
+6	O
+weeks	O
+,	O
+and	O
+continues	O
+to	O
+make	O
+steady	O
+rehabilitative	O
+progress	O
+.	O
+
+Early	O
+suspicion	O
+for	O
+infection	B-DISO
+and	O
+initiation	O
+of	O
+treatment	O
+,	O
+even	O
+with	O
+negative	O
+testing	O
+,	O
+is	O
+essential	O
+for	O
+cardiothoracic	O
+transplant	B-ANAT
+recipients	O
+during	O
+the	O
+current	O
+pandemic	O
+of	O
+novel	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+.	O
+
+Thus	O
+,	O
+to	O
+induce	O
+a	O
+maximal	O
+protective	O
+effect	O
+,	O
+it	O
+is	O
+desirable	O
+to	O
+apply	O
+vaccines	O
+by	O
+the	O
+mucosal	B-ANAT
+route	O
+where	O
+virus	B-SPEC
+infections	B-DISO
+start	O
+.	O
+
+However	O
+the	O
+mucosal	B-ANAT
+antigen	B-CHED
+-	O
+specific	B-PROC
+immune	I-PROC
+response	I-PROC
+is	O
+weak	O
+because	O
+most	O
+protein	B-CHED
+antigens	B-CHED
+can	O
+evoke	O
+only	O
+a	O
+weak	O
+immune	B-PROC
+response	I-PROC
+when	O
+they	O
+are	O
+applied	O
+mucosally	O
+.	O
+
+In	O
+this	O
+regards	O
+,	O
+we	O
+have	O
+created	O
+a	O
+mutant	B-PRGE
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+),	O
+mTNF	O
+-	O
+K90R	O
+,	O
+that	O
+exhibits	O
+high	O
+bioactivity	O
+and	O
+resistance	B-PROC
+to	O
+proteases	O
+.	O
+
+Some	O
+of	O
+the	O
+viral	O
+antigen	B-CHED
+-	O
+positive	O
+inflammatory	B-ANAT
+cells	I-ANAT
+found	O
+in	O
+the	O
+subarachnoidal	B-ANAT
+space	O
+during	O
+the	O
+early	O
+phase	O
+of	O
+infection	B-DISO
+reacted	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+F4	I-PRGE
+/	I-PRGE
+80	I-PRGE
+or	O
+anti	B-PRGE
+-	I-PRGE
+CD11b	I-PRGE
+monoclonal	I-PRGE
+antibodies	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+descriptive	O
+distribution	O
+and	O
+phylogeny	O
+of	O
+feline	O
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+were	O
+studied	O
+in	O
+cats	B-SPEC
+suspected	O
+of	O
+having	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+in	O
+Malaysia	O
+.	O
+
+Ascitic	B-ANAT
+fluids	I-ANAT
+and	O
+/	O
+or	O
+biopsy	O
+samples	O
+were	O
+subjected	O
+to	O
+a	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+targeted	B-PROC
+for	O
+a	O
+conserved	O
+region	O
+of	O
+3	O
+'	O
+untranslated	O
+region	O
+(	O
+3	O
+'	O
+UTR	O
+)	O
+of	O
+the	O
+FCoV	O
+genome	O
+.	O
+
+ABSTRACT	O
+:	O
+After	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Hong	O
+Kong	O
+,	O
+the	O
+importance	O
+of	O
+preventing	O
+nosocomial	O
+transmission	O
+of	O
+respiratory	O
+viruses	B-SPEC
+has	O
+become	O
+a	O
+top	O
+priority	O
+in	O
+infection	B-DISO
+control	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+believe	O
+that	O
+cyclosporine	B-CHED
+is	O
+a	O
+cornerstone	O
+for	O
+the	O
+treatment	O
+of	O
+Still	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+.	O
+
+The	O
+imaging	O
+emphasizes	O
+the	O
+importance	O
+of	O
+CT	O
+angiography	O
+to	O
+understanding	O
+the	O
+three	O
+-	O
+dimensional	O
+relationships	O
+resulting	O
+in	O
+bronchial	B-DISO
+compression	I-DISO
+.	O
+
+We	O
+retrospectively	O
+reviewed	O
+medical	O
+charts	O
+and	O
+laboratory	O
+results	O
+ofall	O
+patients	O
+who	O
+tested	O
+positively	O
+for	O
+H1N1	O
+by	O
+viral	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+on	O
+nasopharyngeal	B-ANAT
+smear	O
+or	O
+endobronchial	O
+secretions	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+identification	O
+of	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+-	I-SPEC
+related	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARSr	O
+-	O
+CoV	O
+)	O
+in	O
+Rhinolophus	B-SPEC
+Chinese	O
+horseshoe	B-SPEC
+bats	I-SPEC
+(	O
+SARSr	O
+-	O
+Rh	O
+-	O
+BatCoV	O
+)	O
+in	O
+China	O
+,	O
+the	O
+evolutionary	O
+and	O
+possible	O
+recombination	B-PROC
+origin	O
+of	O
+SARSr	O
+-	O
+CoV	O
+remains	O
+undetermined	O
+.	O
+
+A	O
+tagging	O
+exercise	O
+of	O
+511	O
+bats	B-SPEC
+showed	O
+migration	B-PROC
+distances	O
+from	O
+1	O
+.	O
+86	O
+to	O
+17	O
+km	O
+.	O
+
+However	O
+,	O
+lower	O
+body	O
+weights	O
+were	O
+observed	O
+in	O
+bats	B-SPEC
+positive	O
+for	O
+SARSr	O
+-	O
+Rh	O
+-	O
+BatCoV	O
+,	O
+but	O
+not	O
+Rh	O
+-	O
+BatCoV	O
+HKU2	O
+.	O
+
+Complete	O
+genome	O
+sequencing	O
+of	O
+10	O
+SARSr	O
+-	O
+Rh	O
+-	O
+BatCoV	O
+strains	O
+showed	O
+frequent	O
+recombination	B-PROC
+between	O
+different	O
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+which	O
+belong	O
+to	O
+group	O
+1	O
+coronaviruses	O
+,	O
+are	O
+important	O
+viral	O
+pathogens	O
+in	O
+pigs	B-SPEC
+causing	O
+lethal	O
+diarrhea	B-DISO
+.	O
+
+Moreover	O
+,	O
+the	O
+only	O
+APN	B-PRGE
+inhibitor	B-CHED
+blocking	B-DISO
+the	O
+protease	B-PROC
+activity	I-PROC
+site	O
+had	O
+no	O
+obvious	O
+negative	O
+effect	O
+on	O
+viral	B-DISO
+infection	I-DISO
+,	O
+indicating	O
+that	O
+the	O
+enzymatic	O
+role	O
+of	O
+APN	B-PRGE
+is	O
+dispensable	O
+for	O
+the	O
+process	O
+of	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+following	O
+were	O
+used	O
+to	O
+determine	O
+patient	O
+characteristics	O
+:	O
+sequential	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+score	O
+,	O
+14	O
+;	O
+simplified	O
+acute	O
+physiology	O
+score	O
+II	O
+,	O
+41	O
+;	O
+and	O
+Murray	O
+score	O
+,	O
+4	O
+.	O
+
+However	O
+,	O
+with	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+40	O
+cases	O
+(	O
+93	O
+%)	O
+were	O
+positive	O
+for	O
+rotavirus	B-SPEC
+,	O
+36	O
+(	O
+84	O
+%)	O
+for	O
+TAstV	O
+-	O
+2	O
+,	O
+and	O
+17	O
+(	O
+40	O
+%)	O
+for	O
+reovirus	B-SPEC
+.	O
+
+Biopsy	O
+-	O
+proven	O
+acute	O
+rejection	O
+(>	O
+or	O
+=	O
+grade	O
+2	O
+)	O
+or	O
+decline	O
+in	O
+forced	B-PROC
+expiratory	I-PROC
+volume	I-PROC
+in	O
+1	O
+sec	B-CHED
+>	O
+or	O
+=	O
+20	O
+%	O
+occurred	O
+in	O
+16	O
+of	O
+48	O
+(	O
+33	O
+.	O
+3	O
+%)	O
+patients	O
+within	O
+3	O
+months	O
+of	O
+RVI	O
+when	O
+compared	O
+with	O
+3	O
+of	O
+45	O
+(	O
+6	O
+.	O
+7	O
+%)	O
+RVI	O
+-	O
+negative	O
+patients	O
+within	O
+a	O
+comparable	O
+time	O
+frame	O
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+In	O
+a	O
+significant	O
+percentage	O
+of	O
+patients	O
+,	O
+symptomatic	O
+or	O
+asymptomatic	O
+viral	B-DISO
+infection	I-DISO
+is	O
+a	O
+trigger	O
+for	O
+acute	O
+rejection	O
+and	O
+obliterative	B-DISO
+bronchiolitis	I-DISO
+/	O
+BOS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Community	O
+-	O
+acquired	O
+RVIs	O
+are	O
+frequently	O
+detected	O
+in	O
+BAL	B-ENZY
+samples	O
+from	O
+lung	B-ANAT
+transplant	B-ANAT
+patients	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+open	I-PRGE
+reading	I-PRGE
+frame	I-PRGE
+3	I-PRGE
+encodes	O
+a	O
+virion	B-COMP
+-	O
+incorporated	O
+N	O
+-	O
+glycosylated	O
+membrane	B-ANAT
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+pathogenic	I-PRGE
+coronavirus	B-SPEC
+NL63	I-PRGE
+(	O
+hCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+)	O
+is	O
+a	O
+group	O
+1	O
+(	O
+alpha	O
+)	O
+coronavirus	B-SPEC
+commonly	O
+associated	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+In	O
+addition	O
+to	O
+known	O
+non	O
+-	O
+structural	O
+and	O
+structural	O
+proteins	B-CHED
+all	O
+coronaviruses	O
+have	O
+one	O
+or	O
+more	O
+accessory	O
+proteins	B-CHED
+whose	O
+functions	O
+are	O
+mostly	O
+unknown	O
+.	O
+
+By	O
+fluorescence	O
+microscopy	O
+of	O
+differently	O
+tagged	O
+envelope	B-COMP
+(	O
+E	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+proteins	B-CHED
+it	O
+was	O
+shown	O
+that	O
+ORF	B-PRGE
+3	I-PRGE
+protein	I-PRGE
+colocalizes	O
+extensively	O
+with	O
+E	O
+and	O
+M	O
+within	O
+the	O
+ERGIC	B-COMP
+.	O
+
+We	O
+give	O
+evidence	O
+that	O
+ORF	B-PRGE
+3	I-PRGE
+protein	I-PRGE
+is	O
+a	O
+structural	O
+N	O
+-	O
+glycosylated	O
+and	O
+virion	B-COMP
+-	O
+incorporated	O
+protein	B-CHED
+.	O
+
+Analysis	O
+of	O
+purified	O
+viral	B-COMP
+particles	I-COMP
+revealed	O
+that	O
+ORF	B-PRGE
+3	I-PRGE
+protein	I-PRGE
+is	O
+incorporated	O
+into	O
+virions	B-COMP
+and	O
+is	O
+therefore	O
+an	O
+additional	O
+structural	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+sequence	O
+analysis	O
+of	O
+the	O
+distal	O
+one	O
+-	O
+third	O
+of	O
+the	O
+genomes	O
+of	O
+a	O
+systemic	O
+and	O
+an	O
+enteric	O
+ferret	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Enhanced	O
+macrophage	B-ANAT
+tropism	B-PROC
+and	O
+the	O
+resulting	O
+induction	O
+of	O
+pyogranulomatous	O
+lesions	O
+are	O
+shared	O
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+infection	B-DISO
+in	O
+cats	B-SPEC
+,	O
+but	O
+are	O
+not	O
+features	O
+of	O
+ferret	B-SPEC
+enteric	I-SPEC
+coronavirus	I-SPEC
+(	O
+FRECV	O
+)	O
+infection	B-DISO
+.	O
+
+Comparative	O
+sequence	O
+analysis	O
+of	O
+the	O
+distal	O
+one	O
+-	O
+third	O
+of	O
+the	O
+genomes	O
+of	O
+one	O
+FRSCV	O
+and	O
+one	O
+FRECV	O
+strain	O
+showed	O
+that	O
+these	O
+two	O
+ferret	B-SPEC
+coronaviruses	O
+share	O
+>	O
+96	O
+%	O
+nucleotide	B-CHED
+sequence	O
+identities	O
+in	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+),	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+and	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+genes	O
+(	O
+partial	O
+polymerase	O
+,	O
+open	O
+reading	O
+frames	O
+[	O
+ORFs	O
+]	O
+3	O
+and	O
+7b	O
+).	O
+
+TITLE	O
+:	O
+Construction	O
+of	O
+an	O
+implicit	O
+membrane	B-COMP
+environment	O
+for	O
+the	O
+lattice	O
+Monte	O
+Carlo	O
+simulation	O
+of	O
+transmembrane	B-ANAT
+protein	B-CHED
+.	O
+
+It	O
+was	O
+found	O
+that	O
+the	O
+coil	O
+-	O
+helix	O
+transition	O
+of	O
+the	O
+transmembrane	B-COMP
+segment	O
+occurred	O
+earlier	O
+than	O
+the	O
+coil	O
+-	O
+globule	O
+transition	B-DISO
+of	O
+the	O
+two	O
+terminal	O
+domains	O
+.	O
+
+The	O
+infection	O
+,	O
+which	O
+affects	O
+younger	O
+patients	O
+than	O
+seasonal	O
+influenza	B-DISO
+,	O
+presents	O
+most	O
+often	O
+under	O
+a	O
+benign	O
+form	O
+.	O
+
+ABSTRACT	O
+:	O
+Nucleic	B-CHED
+acid	I-CHED
+amplification	B-DISO
+techniques	O
+have	O
+improved	O
+the	O
+diagnostic	O
+possibilities	O
+in	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+although	O
+their	O
+clinical	O
+applicability	O
+is	O
+not	O
+yet	O
+fully	O
+defined	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+diagnostic	O
+performance	O
+and	O
+clinical	O
+use	O
+of	O
+a	O
+novel	O
+multiplex	O
+PCR	O
+method	O
+in	O
+adults	O
+with	O
+community	O
+-	O
+acquired	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+,	O
+and	O
+the	O
+impact	O
+of	O
+duration	O
+of	O
+symptoms	O
+on	O
+detection	O
+rates	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swab	I-ANAT
+samples	O
+were	O
+prospectively	O
+collected	O
+from	O
+209	O
+adult	O
+outpatients	O
+with	O
+respiratory	B-DISO
+infections	I-DISO
+and	O
+100	O
+asymptomatic	O
+controls	O
+.	O
+
+The	O
+two	O
+deaths	B-PROC
+were	O
+due	O
+to	O
+multiorgan	B-DISO
+failure	I-DISO
+,	O
+which	O
+occurred	O
+while	O
+the	O
+patients	O
+were	O
+on	O
+ECLS	O
+.	O
+
+Internal	O
+struggle	O
+consisted	O
+of	O
+3	O
+themes	O
+:	O
+(	O
+1	O
+)	O
+struggle	O
+with	O
+being	O
+quarantined	O
+,	O
+(	O
+2	O
+)	O
+struggle	O
+with	O
+emotional	O
+turmoil	O
+,	O
+and	O
+(	O
+3	O
+)	O
+struggle	O
+with	O
+possible	O
+SARS	B-DISO
+diagnosis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+These	O
+results	O
+will	O
+contribute	O
+to	O
+sensitizing	O
+health	O
+care	O
+professionals	O
+to	O
+empathize	O
+with	O
+quarantined	O
+persons	O
+while	O
+providing	O
+quality	O
+quarantine	O
+care	O
+and	O
+other	O
+infection	B-DISO
+control	O
+measures	O
+.	O
+
+The	O
+current	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pandemic	O
+is	O
+fortunately	O
+not	O
+associated	O
+with	O
+as	O
+high	O
+a	O
+mortality	O
+rate	O
+as	O
+the	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+),	O
+another	O
+potential	O
+pandemic	O
+candidate	O
+virus	B-SPEC
+.	O
+
+Regional	O
+cooperation	O
+with	O
+the	O
+Palestinian	O
+Authority	O
+and	O
+Jordan	O
+before	O
+and	O
+after	O
+this	O
+pandemic	O
+influenza	B-DISO
+outbreak	O
+is	O
+noted	O
+.	O
+
+Therefore	O
+,	O
+we	O
+hypothesize	O
+that	O
+FcgammaRs	O
+such	O
+as	O
+FcgammaRIIa	O
+could	O
+contribute	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+In	O
+particular	O
+,	O
+it	O
+provides	O
+insights	O
+in	O
+the	O
+role	O
+of	O
+each	O
+CoV	O
+-	O
+induced	O
+structure	O
+and	O
+reveals	O
+that	O
+LVCVs	O
+are	O
+ERGIC	B-COMP
+/	O
+Golgi	B-COMP
+compartments	B-ANAT
+that	O
+expand	O
+to	O
+accommodate	O
+an	O
+increasing	O
+production	O
+of	O
+viral	B-COMP
+particles	I-COMP
+.	O
+
+We	O
+also	O
+showed	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+that	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+lambdas	I-PRGE
+were	O
+capable	O
+of	O
+exerting	B-PROC
+previously	O
+unrecognized	O
+,	O
+non	O
+-	O
+redundant	O
+,	O
+and	O
+complementary	O
+abilities	O
+to	O
+limit	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+,	O
+even	O
+though	O
+their	O
+expression	B-PROC
+could	O
+not	O
+be	O
+detected	O
+in	O
+infected	O
+2B4	O
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+until	O
+48	O
+hrs	B-DISO
+p	O
+.	O
+i	O
+.	O
+
+Collectively	O
+,	O
+our	O
+results	O
+highlight	O
+the	O
+mechanics	O
+of	O
+the	O
+sequential	O
+events	O
+of	O
+antiviral	B-CHED
+signaling	B-PROC
+pathway	I-PROC
+/	O
+s	O
+triggered	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+identify	O
+novel	O
+cellular	B-COMP
+targets	O
+for	O
+future	O
+studies	O
+,	O
+aiming	O
+at	O
+advancing	O
+strategies	O
+against	O
+SARS	B-DISO
+.	O
+
+This	O
+syndrome	B-DISO
+is	O
+characterized	O
+by	O
+acute	O
+respiratory	O
+signs	O
+,	O
+high	O
+fever	B-PROC
+,	O
+and	O
+occasional	O
+sudden	B-DISO
+death	I-DISO
+,	O
+and	O
+has	O
+mostly	O
+been	O
+observed	O
+in	O
+pregnant	O
+alpacas	B-SPEC
+(	O
+Vicugna	B-SPEC
+pacos	I-SPEC
+),	O
+although	O
+all	O
+signalments	O
+have	O
+been	O
+affected	O
+.	O
+
+The	O
+coronavirus	O
+identity	O
+was	O
+confirmed	O
+in	O
+tissue	B-ANAT
+culture	O
+by	O
+transmission	O
+electron	O
+microscopy	O
+and	O
+by	O
+sequence	O
+analysis	O
+of	O
+a	O
+conserved	O
+region	O
+within	O
+the	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+The	O
+majority	O
+of	O
+laboratory	O
+studies	O
+identified	O
+both	O
+mask	O
+types	O
+as	O
+having	O
+a	O
+range	O
+of	O
+filtration	O
+efficiency	O
+,	O
+yet	O
+N95	O
+masks	O
+afford	O
+superior	O
+protection	O
+against	O
+particles	O
+of	O
+a	O
+similar	O
+size	O
+to	O
+influenza	B-DISO
+.	O
+
+Later	O
+,	O
+the	O
+disease	O
+was	O
+complicated	O
+by	O
+acute	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Treatment	O
+with	O
+antibiotics	B-CHED
+(	O
+erythromycin	B-CHED
+,	O
+rifampicin	B-CHED
+,	O
+azithromycin	B-CHED
+)	O
+combined	O
+with	O
+ARDS	B-DISO
+treatment	O
+led	O
+to	O
+a	O
+clinical	O
+recovery	O
+of	O
+the	O
+patient	O
+together	O
+with	O
+complete	O
+resolution	O
+of	O
+inflammatory	O
+lesions	O
+seen	O
+on	O
+chest	B-ANAT
+radiography	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+susceptibility	O
+to	O
+botanical	O
+oleoresins	O
+and	O
+essential	O
+oils	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+.	O
+
+Treatment	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+with	O
+QR448	O
+(	O
+a	O
+)	O
+reduced	O
+the	O
+virus	B-SPEC
+titer	O
+as	O
+measured	O
+in	O
+two	O
+laboratory	O
+host	B-COMP
+systems	O
+,	O
+Vero	O
+E6	O
+cells	B-COMP
+and	O
+embryonating	O
+eggs	O
+.	O
+
+Anti	O
+-	O
+IBV	B-SPEC
+activity	O
+of	O
+QR448	O
+(	O
+a	O
+)	O
+was	O
+greater	O
+prior	O
+to	O
+virus	O
+attachment	O
+and	O
+entry	O
+indicating	O
+that	O
+the	O
+effect	O
+is	O
+virucidal	O
+.	O
+
+Mean	O
+patient	O
+age	O
+was	O
+44	O
+years	O
+,	O
+and	O
+mean	O
+body	B-ANAT
+mass	O
+index	O
+was	O
+25	O
+.	O
+7	O
+kg	O
+/	O
+m	O
+(	O
+2	O
+).	O
+
+33	O
+mm	O
+Hg	O
+)	O
+and	O
+a	O
+mean	O
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+of	O
+68	O
++/-	O
+
+3	O
+days	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+patients	O
+were	O
+hemodynamically	O
+stabilized	O
+.	O
+
+Twelve	O
+patients	O
+(	O
+66	O
+.	O
+7	O
+%)	O
+could	O
+be	O
+weaned	B-PROC
+,	O
+with	O
+a	O
+30	O
+-	O
+day	O
+mortality	O
+of	O
+55	O
+.	O
+6	O
+%.	O
+
+Norepinephrine	B-CHED
+dosage	O
+could	O
+be	O
+reduced	O
+significantly	O
+within	O
+24	O
+hours	O
+(	O
+3	O
+.	O
+2	O
++/-	O
+1	O
+.	O
+8	O
+versus	O
+1	O
+.	O
+5	O
++/-	O
+
+This	O
+gave	O
+a	O
+simple	O
+answer	O
+to	O
+the	O
+long	O
+-	O
+standing	B-PROC
+question	O
+of	O
+why	O
+epidemics	O
+woould	O
+appear	O
+suddenly	O
+and	O
+then	O
+disappear	O
+just	O
+as	O
+suddenly	O
+without	O
+having	O
+infected	O
+an	O
+entire	O
+population	O
+.	O
+
+This	O
+cross	O
+-	O
+sectional	O
+study	O
+sought	O
+to	O
+determine	O
+the	O
+prevalence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+related	O
+psychiatric	O
+and	O
+posttraumatic	O
+morbidities	O
+and	O
+associated	O
+coping	O
+styles	O
+within	O
+the	O
+general	O
+population	O
+visiting	O
+community	O
+health	O
+care	O
+services	O
+.	O
+
+These	O
+findings	O
+could	O
+potentially	O
+inform	O
+the	O
+development	B-PROC
+of	O
+practical	O
+community	O
+mental	O
+health	O
+programs	O
+for	O
+future	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+Of	O
+the	O
+415	O
+community	O
+health	O
+care	O
+setting	O
+respondents	O
+,	O
+we	O
+found	O
+significant	O
+rates	O
+of	O
+SARS	B-DISO
+-	O
+related	O
+psychiatric	O
+(	O
+22	O
+.	O
+9	O
+%)	O
+and	O
+posttraumatic	O
+morbidities	O
+(	O
+25	O
+.	O
+8	O
+%).	O
+
+In	O
+order	B-SPEC
+to	O
+elucidate	O
+the	O
+possible	O
+mechanism	O
+responsible	O
+for	O
+the	O
+antiviral	B-CHED
+activity	O
+,	O
+the	O
+induction	O
+of	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+release	B-PATH
+as	O
+well	O
+as	O
+the	O
+attachment	O
+ability	O
+of	O
+LAB	B-PRGE
+on	O
+the	O
+cell	B-ANAT
+lines	I-ANAT
+was	O
+investigated	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+ability	O
+of	O
+the	O
+examined	O
+LAB	O
+strains	O
+to	O
+attach	O
+to	O
+the	O
+cell	B-ANAT
+line	I-ANAT
+monolayers	O
+was	O
+LAB	O
+strain	O
+but	O
+not	O
+cell	B-ANAT
+line	I-ANAT
+specific	O
+.	O
+
+TITLE	O
+:	O
+The	O
+N	O
+-	O
+terminal	O
+region	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+protein	B-CHED
+6	O
+induces	O
+membrane	B-ANAT
+rearrangement	B-PROC
+and	O
+enhances	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Here	O
+,	O
+we	O
+demonstrate	O
+that	O
+p6	O
+has	O
+an	O
+N	O
+-	O
+terminal	O
+region	O
+-	O
+cytoplasm	B-COMP
+-	O
+C	O
+-	O
+terminal	O
+region	O
+-	O
+cytoplasm	B-COMP
+configuration	O
+with	O
+residues	O
+2	O
+to	O
+37	O
+likely	O
+membrane	B-COMP
+embedded	O
+.	O
+
+Consistent	O
+with	O
+a	O
+role	O
+in	O
+virus	B-PROC
+replication	I-PROC
+,	O
+p6	O
+partially	O
+colocalized	O
+with	O
+nonstructural	O
+protein	O
+3	O
+(	O
+nsp3	B-PRGE
+),	O
+a	O
+marker	O
+for	O
+virus	B-PROC
+replication	I-PROC
+complexes	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+strain	O
+of	O
+H1N1	B-DISO
+influenza	I-DISO
+,	O
+also	O
+known	O
+as	O
+swine	B-DISO
+flu	I-DISO
+was	O
+confirmed	O
+in	O
+the	O
+UK	O
+in	O
+May	O
+2009	O
+and	O
+has	O
+spread	O
+to	O
+over	O
+100	O
+countries	O
+around	O
+the	O
+world	O
+causing	O
+the	O
+World	O
+Health	O
+Organization	O
+to	O
+declare	O
+a	O
+global	O
+flu	B-DISO
+pandemic	O
+.	O
+
+There	O
+is	O
+evidence	O
+that	O
+greater	O
+levels	O
+of	O
+perceived	O
+susceptibility	O
+to	O
+and	O
+perceived	O
+severity	O
+of	O
+the	O
+diseases	O
+and	O
+greater	O
+belief	O
+in	O
+the	O
+effectiveness	O
+of	O
+recommended	O
+behaviours	O
+to	O
+protect	O
+against	O
+the	O
+disease	O
+are	O
+important	O
+predictors	O
+of	O
+behaviour	B-PROC
+.	O
+
+There	O
+is	O
+also	O
+evidence	O
+that	O
+greater	O
+levels	O
+of	O
+state	B-DISO
+anxiety	I-DISO
+and	O
+greater	O
+trust	O
+in	O
+authorities	O
+are	O
+associated	O
+with	O
+behaviour	B-PROC
+.	O
+
+There	O
+is	O
+also	O
+evidence	O
+that	O
+greater	O
+levels	O
+of	O
+state	B-DISO
+anxiety	I-DISO
+and	O
+greater	O
+trust	O
+in	O
+authorities	O
+are	O
+associated	O
+with	O
+behaviour	B-PROC
+.	O
+
+TITLE	O
+:	O
+Immunization	O
+with	O
+an	O
+attenuated	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+deleted	O
+in	O
+E	O
+protein	B-CHED
+protects	O
+against	O
+lethal	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+hACE2	O
+Tg	O
+mice	B-SPEC
+,	O
+which	O
+express	O
+the	O
+human	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+,	O
+are	O
+extremely	O
+susceptible	O
+to	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+isolation	O
+of	O
+the	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+identified	O
+as	O
+the	O
+cause	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+and	O
+the	O
+detection	O
+of	O
+2	O
+new	O
+human	B-SPEC
+CoVs	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	O
+-	O
+HKU1	O
+)	O
+have	O
+led	O
+to	O
+studies	O
+of	O
+the	O
+epidemiology	O
+and	O
+clinical	O
+and	O
+socioeconomic	O
+effects	O
+of	O
+infections	B-DISO
+caused	O
+by	O
+all	O
+HCoVs	O
+,	O
+including	O
+those	O
+known	O
+since	O
+the	O
+late	O
+1960s	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+).	O
+
+HCoV	O
+infections	B-DISO
+can	O
+be	O
+associated	O
+with	O
+respiratory	O
+and	O
+extrarespiratory	O
+manifestations	O
+,	O
+including	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+involvement	O
+.	O
+
+Furthermore	O
+,	O
+unlike	O
+other	O
+RNA	O
+viruses	B-SPEC
+,	O
+HCoVs	O
+can	O
+easily	O
+mutate	B-PROC
+and	O
+recombine	O
+when	O
+different	O
+strains	O
+infect	O
+the	O
+same	O
+cells	B-COMP
+and	O
+give	O
+rise	O
+to	O
+a	O
+novel	O
+virus	B-SPEC
+with	O
+unpredictable	O
+host	B-COMP
+ranges	O
+and	O
+pathogenicity	O
+.	O
+
+The	O
+first	O
+publications	O
+of	O
+patients	O
+admitted	O
+in	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+for	O
+severe	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+often	O
+associated	O
+to	O
+an	O
+ARDS	B-DISO
+reported	O
+a	O
+mortality	O
+rate	O
+from	O
+15	O
+to	O
+40	O
+%.	O
+
+Indeed	O
+,	O
+the	O
+highest	O
+mortality	O
+rates	O
+(	O
+30	O
+-	O
+40	O
+%)	O
+have	O
+been	O
+reported	O
+by	O
+in	O
+Mexico	O
+which	O
+were	O
+affected	O
+the	O
+first	O
+by	O
+pandemic	O
+flu	B-DISO
+and	O
+which	O
+were	O
+not	O
+prepared	O
+.	O
+
+TITLE	O
+:	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+associated	O
+syndromes	B-DISO
+.	O
+
+The	O
+viruses	B-SPEC
+responsible	O
+for	O
+enteric	O
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+are	O
+closely	O
+related	O
+antigenically	O
+and	O
+genetically	O
+.	O
+
+During	O
+a	O
+six	O
+week	O
+period	O
+in	O
+the	O
+fall	O
+of	O
+2009	O
+,	O
+16	O
+patients	O
+were	O
+admitted	O
+to	O
+intensive	O
+care	O
+in	O
+Iceland	O
+with	O
+confirmed	O
+H1N1	O
+infection	B-DISO
+.	O
+
+12	O
+needed	O
+mechanical	O
+ventilation	O
+and	O
+two	O
+extra	O
+corporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+He	O
+was	O
+originally	O
+admitted	O
+for	O
+an	O
+elective	O
+renal	B-ANAT
+biopsy	O
+for	O
+diagnosis	O
+of	O
+renal	B-ANAT
+pathology	B-DISO
+.	O
+
+Subcutaneous	O
+low	O
+molecular	O
+weight	O
+heparin	B-CHED
+and	O
+intravenous	O
+methylprednisolone	B-CHED
+were	O
+given	O
+to	O
+treat	O
+the	O
+presumed	O
+pulmonary	B-DISO
+embolism	I-DISO
+and	O
+the	O
+underlying	O
+nephrotic	B-DISO
+syndrome	I-DISO
+.	O
+
+Our	O
+data	O
+in	O
+tissue	B-ANAT
+culture	O
+indicate	O
+that	O
+inhibition	B-PROC
+of	O
+N	B-PROC
+-	I-PROC
+glycan	I-PROC
+processing	I-PROC
+may	O
+be	O
+considered	O
+as	O
+a	O
+therapeutic	O
+strategy	O
+against	O
+SARS	B-DISO
+CoV	O
+infections	B-DISO
+.	O
+
+Analysis	O
+of	O
+TB	O
+programme	O
+data	O
+from	O
+clinics	O
+taking	O
+part	O
+in	O
+two	O
+consecutive	O
+randomised	O
+trials	O
+of	O
+educational	O
+outreach	O
+aimed	O
+at	O
+improving	O
+respiratory	O
+and	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+/	O
+acquired	O
+immune	O
+-	O
+deficiency	O
+syndrome	B-DISO
+care	O
+based	O
+on	O
+the	O
+Practical	O
+Approach	O
+to	O
+Lung	B-ANAT
+Health	O
+.	O
+
+Interestingly	O
+,	O
+the	O
+tree	O
+topology	O
+based	O
+on	O
+the	O
+nucleotide	B-CHED
+sequences	O
+representing	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+or	O
+the	O
+S1	B-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+region	I-PRGE
+most	O
+nearly	O
+resembled	O
+the	O
+full	O
+S	O
+gene	O
+-	O
+based	O
+phylogenetic	O
+tree	O
+.	O
+
+TITLE	O
+:	O
+Automated	O
+detection	O
+of	O
+conformational	O
+epitopes	O
+using	O
+phage	O
+display	O
+Peptide	B-CHED
+sequences	O
+.	O
+
+The	O
+molecular	O
+pathways	B-PROC
+,	O
+however	O
+,	O
+that	O
+cause	O
+virus	B-SPEC
+-	O
+induced	O
+ALI	O
+/	O
+ARDS	B-DISO
+in	O
+aged	O
+individuals	O
+are	O
+ill	B-DISO
+-	O
+defined	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+(	O
+EBV	B-SPEC
+)	O
+negative	O
+Hodgkin	B-ANAT
+'	I-ANAT
+s	I-ANAT
+cell	I-ANAT
+lines	O
+and	O
+classical	O
+EBV	B-SPEC
+-	O
+negative	O
+Hodgkin	B-DISO
+'	I-DISO
+s	I-DISO
+lymphoma	I-DISO
+(	O
+HL	O
+),	O
+Reed	B-ANAT
+-	I-ANAT
+Sternberg	I-ANAT
+cells	I-ANAT
+(	O
+RS	O
+cells	B-COMP
+)	O
+represent	O
+end	O
+-	O
+stage	O
+tumor	B-ANAT
+cells	B-COMP
+,	O
+in	O
+which	O
+further	O
+nuclear	B-PROC
+division	I-PROC
+becomes	O
+impossible	O
+because	O
+of	O
+sustained	O
+telomere	B-COMP
+loss	O
+,	O
+shortening	O
+and	O
+aggregation	O
+.	O
+
+We	O
+performed	O
+a	O
+3D	O
+telomere	B-COMP
+analysis	O
+after	O
+quantitative	O
+fluorescent	O
+in	O
+situ	O
+hybridization	B-PROC
+on	O
+5	O
+mum	B-SPEC
+tissue	B-ANAT
+sections	O
+on	O
+two	O
+LMP1	B-PRGE
+-	O
+expressing	O
+HL	O
+cases	O
+and	O
+showed	O
+highly	O
+significant	O
+telomere	B-DISO
+shortening	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+formation	B-PROC
+of	O
+telomere	B-COMP
+aggregates	O
+in	O
+RS	O
+cells	B-COMP
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+when	O
+compared	O
+with	O
+the	O
+mononuclear	O
+precursor	O
+Hodgkin	O
+cells	B-COMP
+(	O
+H	O
+cells	B-COMP
+).	O
+
+We	O
+conclude	O
+that	O
+RS	O
+cells	B-COMP
+irrespective	O
+of	O
+LMP1	B-PRGE
+expression	B-PROC
+are	O
+end	O
+-	O
+stage	O
+tumor	B-ANAT
+cells	B-COMP
+in	O
+which	O
+the	O
+extent	O
+of	O
+their	O
+inability	O
+to	O
+divide	O
+further	O
+is	O
+proportional	O
+to	O
+the	O
+increase	O
+of	O
+very	O
+short	O
+telomeres	B-COMP
+,	O
+telomere	B-COMP
+loss	O
+,	O
+aggregate	O
+formation	B-PROC
+and	O
+the	O
+generation	O
+of	O
+'	B-ANAT
+ghost	I-ANAT
+'	O
+nuclei	B-CHED
+.	O
+
+Rotenone	B-CHED
+or	O
+1	B-CHED
+-	I-CHED
+methyl	I-CHED
+-	I-CHED
+4	I-CHED
+-	I-CHED
+phenyl	I-CHED
+-	I-CHED
+1	I-CHED
+,	I-CHED
+2	I-CHED
+,	I-CHED
+3	I-CHED
+,	I-CHED
+6	I-CHED
+-	I-CHED
+tetrahydropyridine	I-CHED
+(	O
+MPTP	B-CHED
+)	O
+inhibit	O
+the	O
+mitochondrial	B-PRGE
+complex	B-COMP
+I	I-COMP
+and	O
+they	O
+cause	O
+the	O
+death	B-PROC
+of	O
+substantia	B-ANAT
+nigra	I-ANAT
+dopaminergic	B-ANAT
+neurons	I-ANAT
+,	O
+thereby	O
+providing	O
+acute	O
+murine	B-SPEC
+models	O
+of	O
+Parkinson	B-PATH
+'	I-PATH
+s	I-PATH
+disease	I-PATH
+.	O
+
+As	O
+a	O
+result	O
+,	O
+we	O
+have	O
+studied	O
+the	O
+effects	O
+of	O
+hexokinase	B-PRGE
+II	I-PRGE
+gene	I-PRGE
+transfer	O
+in	O
+vivo	O
+using	O
+a	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+)	O
+amplicon	O
+vector	O
+.	O
+
+TITLE	O
+:	O
+Escape	O
+from	O
+human	B-SPEC
+monoclonal	O
+antibody	B-COMP
+neutralization	O
+affects	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+fitness	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+emerged	O
+as	O
+a	O
+human	B-SPEC
+disease	O
+in	O
+2002	O
+.	O
+
+Detailed	O
+phylogenetic	O
+analysis	O
+and	O
+epidemiologic	O
+studies	O
+have	O
+suggested	O
+that	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+originated	O
+from	O
+animals	B-SPEC
+.	O
+
+Finally	O
+,	O
+we	O
+showed	O
+that	O
+escape	O
+from	O
+neutralization	O
+usually	O
+attenuates	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+7a	O
+protein	B-CHED
+is	O
+present	O
+in	O
+the	O
+virus	B-COMP
+particle	I-COMP
+and	O
+has	O
+been	O
+shown	O
+to	O
+interact	O
+with	O
+several	O
+host	B-COMP
+proteins	B-CHED
+;	O
+thereby	O
+implicating	O
+it	O
+as	O
+being	O
+involved	O
+in	O
+several	O
+pathogenic	O
+processes	O
+including	O
+apoptosis	B-PATH
+,	O
+inhibition	B-PROC
+of	O
+cellular	B-COMP
+protein	B-PROC
+synthesis	I-PROC
+,	O
+and	O
+activation	O
+of	O
+p38	B-FUNC
+mitogen	B-CHED
+activated	O
+protein	B-ENZY
+kinase	I-ENZY
+.	O
+
+Ap4A	B-PRGE
+-	I-PRGE
+hydrolase	I-PRGE
+is	O
+responsible	O
+for	O
+metabolizing	O
+the	O
+""""	O
+allarmone	O
+""""	O
+nucleotide	B-CHED
+Ap4A	O
+and	O
+therefore	O
+likely	O
+involved	O
+in	O
+regulation	B-PROC
+of	I-PROC
+cell	I-PROC
+proliferation	B-DISO
+,	O
+DNA	B-PATH
+replication	I-PATH
+,	O
+RNA	B-PROC
+processing	I-PROC
+,	O
+apoptosis	B-PATH
+and	O
+DNA	B-PROC
+repair	I-PROC
+.	O
+
+During	O
+the	O
+current	O
+pandemic	O
+of	O
+H1N1	B-DISO
+influenza	I-DISO
+,	O
+few	O
+cases	O
+of	O
+H1N1	O
+have	O
+been	O
+reported	O
+in	O
+pregnancy	O
+.	O
+
+Other	O
+measures	O
+included	O
+traffic	O
+control	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+19	O
+%),	O
+availability	O
+of	O
+an	O
+outbreak	O
+standard	O
+operation	O
+protocol	O
+(	O
+12	O
+%),	O
+mandatory	O
+temperature	O
+screening	O
+(	O
+9	O
+%),	O
+establishing	O
+a	O
+hand	O
+washing	O
+setup	O
+at	O
+each	O
+hospital	O
+checkpoint	B-PROC
+(	O
+3	O
+%),	O
+adding	O
+simplified	O
+isolation	O
+rooms	O
+(	O
+3	O
+%),	O
+and	O
+a	O
+standardized	O
+patient	O
+transfer	O
+protocol	O
+(	O
+3	O
+%).	O
+
+Illness	O
+severity	O
+was	O
+measured	O
+using	O
+score	O
+for	O
+neonatal	O
+acute	O
+physiology	O
+(	O
+SNAP	B-FUNC
+).	O
+
+There	O
+was	O
+also	O
+an	O
+inverse	O
+correlation	O
+between	O
+lowest	O
+measured	O
+fT	O
+(	O
+4	O
+)	O
+and	O
+highest	O
+mean	O
+airway	B-ANAT
+pressure	O
+,	O
+oxygenation	B-PROC
+index	O
+,	O
+and	O
+A	O
+-	O
+a	O
+gradient	O
+.	O
+
+K2p170	O
+also	O
+had	O
+no	O
+virulence	B-PROC
+reversion	O
+after	O
+five	O
+back	B-ANAT
+passages	O
+in	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+can	O
+form	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+when	O
+coexpressed	O
+with	O
+nucleocapsid	B-PRGE
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+or	I-PRGE
+envelope	B-COMP
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+proteins	B-CHED
+,	O
+suggesting	O
+a	O
+pivotal	O
+role	O
+for	O
+M	O
+in	O
+virion	B-PROC
+assembly	I-PROC
+.	O
+
+Fusion	O
+proteins	O
+containing	O
+M	O
+amino	O
+-	O
+terminal	O
+50	O
+residues	O
+encompassing	O
+the	O
+first	O
+transmembrane	B-COMP
+domain	O
+were	O
+found	O
+to	O
+be	O
+sufficient	O
+for	O
+membrane	B-COMP
+binding	B-FUNC
+,	O
+multimerization	O
+,	O
+and	O
+Golgi	B-COMP
+retention	B-PROC
+.	O
+
+RESULTS	O
+:	O
+GBS	B-DISO
+affected	O
+predominantly	O
+young	O
+adult	O
+males	O
+living	O
+in	O
+rural	O
+areas	O
+.	O
+
+In	O
+ALI	O
+/	O
+ARDS	B-DISO
+patients	O
+,	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+and	O
+KL	O
+-	O
+6	O
+levels	O
+increased	O
+over	O
+time	O
+,	O
+which	O
+was	O
+attenuated	O
+by	O
+lung	B-ANAT
+-	O
+protective	O
+mechanical	O
+ventilation	O
+using	O
+lower	O
+tidal	O
+volumes	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+for	O
+both	O
+biological	O
+markers	O
+).	O
+
+The	O
+Delphi	O
+technique	O
+was	O
+employed	O
+,	O
+which	O
+comprised	O
+a	O
+pilot	O
+round	O
+,	O
+two	O
+written	O
+rounds	O
+and	O
+a	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+meeting	O
+.	O
+
+The	O
+typical	O
+histopathological	O
+features	O
+of	O
+syndrome	B-DISO
+overlapping	O
+the	O
+first	O
+exudative	O
+phase	O
+into	O
+the	O
+second	O
+proliferate	O
+phase	O
+were	O
+observed	O
+.	O
+
+The	O
+genomic	O
+organizations	O
+of	O
+many	O
+other	O
+frameshifting	O
+viruses	B-SPEC
+,	O
+including	O
+the	O
+coronaviruses	O
+,	O
+are	O
+very	O
+different	O
+,	O
+in	O
+that	O
+their	O
+upstream	O
+open	O
+reading	O
+frames	O
+encode	O
+nonstructural	O
+proteins	B-CHED
+,	O
+the	O
+frameshift	B-DISO
+-	O
+dependent	O
+downstream	O
+open	O
+reading	O
+frames	O
+encode	O
+enzymes	O
+involved	O
+in	O
+transcription	B-PROC
+and	O
+replication	O
+,	O
+and	O
+their	O
+structural	O
+proteins	B-CHED
+are	O
+encoded	O
+by	O
+subgenomic	O
+mRNAs	O
+.	O
+
+Second	O
+,	O
+a	O
+series	O
+of	O
+frameshift	B-DISO
+-	O
+promoting	O
+mRNA	B-CHED
+pseudoknot	O
+mutants	O
+was	O
+employed	O
+to	O
+demonstrate	O
+that	O
+the	O
+frameshift	B-DISO
+signals	O
+of	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+have	O
+evolved	O
+to	O
+promote	O
+optimal	O
+frameshift	B-DISO
+efficiencies	O
+.	O
+
+In	O
+the	O
+present	O
+contribution	O
+,	O
+functional	O
+aspects	O
+of	O
+the	O
+target	O
+proteases	O
+,	O
+their	O
+structural	O
+properties	O
+,	O
+drug	O
+design	O
+strategies	O
+,	O
+resulting	O
+inhibitors	B-CHED
+,	O
+and	O
+resistance	B-PROC
+management	O
+are	O
+reviewed	O
+and	O
+discussed	O
+by	O
+means	O
+of	O
+the	O
+four	O
+essential	O
+representative	O
+cases	O
+of	O
+HIV	B-DISO
+,	O
+HCV	B-SPEC
+,	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+the	O
+flaviviruses	B-SPEC
+Dengue	B-DISO
+and	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+life	O
+-	O
+threatening	O
+amniotic	B-DISO
+fluid	I-DISO
+embolism	I-DISO
+,	O
+where	O
+chest	B-ANAT
+CT	O
+in	O
+the	O
+acute	O
+phase	O
+was	O
+obtained	O
+.	O
+
+TITLE	O
+:	O
+Neutralizing	O
+epitopes	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	B-CHED
+cluster	I-PRGE
+independent	O
+of	O
+repertoire	O
+,	O
+antigen	B-CHED
+structure	O
+or	O
+mAb	O
+technology	O
+.	O
+
+The	O
+genome	O
+of	O
+PEDV	B-SPEC
+was	O
+not	O
+detected	O
+after	O
+the	O
+amplification	B-DISO
+step	O
+but	O
+it	O
+was	O
+detected	O
+in	O
+the	O
+second	O
+round	O
+of	O
+PCR	O
+,	O
+yielding	O
+amplicon	O
+with	O
+size	O
+of	O
+291	O
+bp	O
+.	O
+
+Multiplex	O
+nested	O
+RT	O
+-	O
+PCR	O
+can	O
+detect	O
+TGEV	B-SPEC
+,	O
+PRV	B-DISO
+-	O
+A	O
+,	O
+and	O
+PEDV	B-SPEC
+up	O
+to	O
+concentration	O
+10	O
+(	O
+2	O
+)	O
+TCID	O
+(	O
+50	O
+)/	O
+mL	O
+,	O
+10	O
+(	O
+1	O
+)	O
+TCID	O
+(	O
+50	O
+)/	O
+mL	O
+,	O
+and	O
+27	O
+.	O
+2	O
+microg	O
+/	O
+microl	O
+of	O
+RNA	O
+,	O
+respectively	O
+.	O
+
+Fifty	O
+-	O
+six	O
+patients	O
+have	O
+been	O
+transplanted	B-ANAT
+with	O
+a	O
+5	O
+-	O
+year	O
+survival	O
+of	O
+55	O
+%.	O
+
+Eighteen	O
+(	O
+32	O
+%)	O
+developed	O
+BOS	B-DISO
+,	O
+at	O
+a	O
+mean	O
+age	O
+at	O
+diagnosis	O
+of	O
+57	O
+years	O
+(	O
+range	O
+16	O
+-	O
+74	O
+).	O
+
+The	O
+main	O
+cause	O
+of	O
+death	B-PROC
+was	O
+respiratory	B-DISO
+insufficiency	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Significance	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+inhalation	B-PROC
+(	O
+NO	O
+)	O
+in	O
+preterm	O
+infants	O
+<	O
+34	O
+weeks	O
+of	O
+gestation	B-PROC
+].	O
+
+However	O
+,	O
+early	O
+prophylactic	O
+use	O
+of	O
+iNO	B-PRGE
+in	O
+preterm	O
+infants	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+seems	O
+to	O
+improve	O
+survival	O
+without	O
+BPD	B-DISO
+or	O
+severe	O
+cerebral	B-ANAT
+damage	O
+.	O
+
+It	O
+is	O
+caused	O
+by	O
+a	O
+mutated	O
+,	O
+highly	O
+contagious	O
+coronavirus	B-SPEC
+,	O
+and	O
+it	O
+is	O
+more	O
+common	O
+in	O
+indoor	O
+cats	B-SPEC
+in	O
+multicat	O
+households	O
+.	O
+
+This	O
+paper	O
+presents	O
+a	O
+subset	O
+of	O
+data	O
+from	O
+a	O
+programme	O
+of	O
+research	O
+which	O
+examined	O
+various	O
+stakeholder	O
+experiences	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreaks	O
+of	O
+2003	O
+.	O
+
+Twenty	O
+-	O
+one	O
+(	O
+n	O
+=	O
+21	O
+)	O
+child	O
+and	O
+adolescent	O
+participants	O
+were	O
+interviewed	O
+from	O
+a	O
+variety	O
+of	O
+medical	O
+areas	O
+including	O
+cardiac	B-ANAT
+(	O
+n	O
+=	O
+2	O
+),	O
+critical	O
+care	O
+(	O
+n	O
+=	O
+2	O
+),	O
+organ	B-ANAT
+transplant	I-ANAT
+(	O
+n	O
+=	O
+4	O
+),	O
+respiratory	O
+medicine	B-CHED
+(	O
+n	O
+=	O
+8	O
+)	O
+and	O
+infectious	B-DISO
+diseases	I-DISO
+(	O
+patients	O
+diagnosed	O
+with	O
+suspected	O
+or	O
+probable	O
+SARS	O
+;	O
+n	O
+=	O
+5	O
+).	O
+
+PCV2	O
+,	O
+M	B-SPEC
+.	I-SPEC
+hyopneumoniae	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+hyorhinis	I-SPEC
+and	O
+Pasteurella	B-SPEC
+multocida	I-SPEC
+were	O
+detected	O
+most	O
+frequently	O
+among	O
+the	O
+PRDC	O
+affected	O
+swine	B-SPEC
+and	O
+the	O
+diversity	O
+and	O
+number	O
+of	O
+pathogens	O
+were	O
+higher	O
+in	O
+these	O
+animals	B-SPEC
+compared	O
+with	O
+controls	O
+.	O
+
+One	O
+such	O
+multifunctional	O
+domain	O
+is	O
+the	O
+coronavirus	B-SPEC
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLP	B-PRGE
+),	O
+which	O
+processes	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+polyprotein	I-PRGE
+,	O
+has	O
+deubiquitinating	B-PROC
+(	O
+DUB	O
+)	O
+activity	O
+,	O
+and	O
+antagonizes	O
+the	O
+induction	O
+of	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+).	O
+
+Group	O
+3	O
+was	O
+used	O
+as	O
+a	O
+control	O
+and	O
+inoculated	O
+with	O
+sterile	B-DISO
+PBS	B-DISO
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+no	O
+distinct	O
+pathological	O
+changes	O
+were	O
+found	O
+in	O
+chick	O
+embryos	O
+after	O
+they	O
+were	O
+inoculated	O
+with	O
+SIAMP	O
+-	O
+IBV	B-SPEC
+intermixture	O
+and	O
+the	O
+mortality	O
+was	O
+reduced	O
+remarkably	O
+compared	O
+with	O
+the	O
+IBV	B-SPEC
+-	O
+infected	O
+group	O
+.	O
+
+These	O
+results	O
+indicated	O
+that	O
+SIAMP	O
+can	O
+inhibit	O
+virus	B-PROC
+replication	I-PROC
+and	O
+reduce	O
+tissue	B-ANAT
+injury	O
+caused	O
+by	O
+IBV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Delayed	O
+onset	O
+of	O
+severe	O
+neonatal	O
+toxoplasmosis	B-PATH
+.	O
+
+Most	O
+recently	O
+,	O
+an	O
+inhalable	O
+insulin	O
+formulation	O
+was	O
+shown	O
+to	O
+effectively	O
+reduce	O
+glucose	B-CHED
+concentrations	O
+with	O
+minimal	O
+impact	O
+on	O
+long	O
+-	O
+term	O
+pulmonary	B-PROC
+function	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+study	O
+tested	O
+the	O
+model	O
+of	O
+perceived	O
+support	O
+from	O
+medical	O
+staff	O
+and	O
+family	O
+/	O
+friends	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+survivors	O
+'	O
+mental	O
+health	O
+as	O
+mediated	O
+by	O
+self	O
+-	O
+care	O
+self	O
+-	O
+efficacy	O
+.	O
+
+The	O
+study	O
+is	O
+the	O
+first	O
+attempt	O
+in	O
+understanding	O
+long	O
+-	O
+term	O
+psychological	B-DISO
+adjustment	O
+of	O
+SARS	B-DISO
+survivors	O
+.	O
+
+The	O
+patient	O
+responded	O
+to	O
+pulse	B-PROC
+steroid	B-CHED
+therapy	O
+and	O
+recovered	O
+from	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+To	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+report	O
+describing	O
+the	O
+details	O
+of	O
+ARDS	B-DISO
+following	O
+PCT	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+H1N1	O
+-	O
+Associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+A	O
+case	O
+series	O
+.	O
+
+We	O
+investigated	O
+the	O
+detection	O
+rate	O
+and	O
+epidemiological	O
+features	O
+of	O
+infection	B-DISO
+with	O
+coronavirus	B-SPEC
+in	O
+children	O
+receiving	O
+hospital	O
+care	O
+for	O
+acute	O
+gastro	B-ANAT
+-	O
+enteritis	B-DISO
+in	O
+Maddina	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+Especially	O
+patients	O
+with	O
+the	O
+obesity	B-DISO
+hypoventilation	I-DISO
+syndrome	I-DISO
+(	O
+OHS	B-DISO
+)	O
+will	O
+have	O
+frequent	O
+night	O
+time	O
+desaturations	O
+of	O
+significant	O
+duration	O
+below	O
+50	O
+%	O
+Sa	O
+O	O
+(	O
+2	O
+),	O
+but	O
+do	O
+still	O
+cope	O
+with	O
+their	O
+daytime	O
+jobs	O
+.	O
+
+The	O
+latter	O
+is	O
+mainly	O
+being	O
+determined	O
+by	O
+oxygen	B-CHED
+delivery	O
+(	O
+DO2	O
+)	O
+which	O
+is	O
+being	O
+calculated	O
+by	O
+multiplying	O
+cardiac	B-ANAT
+output	O
+(	O
+CO	O
+)	O
+and	O
+oxygen	B-PROC
+content	I-PROC
+(	O
+CaO2	B-CHED
+).	O
+
+In	O
+case	O
+of	O
+acute	O
+hypoxemia	O
+that	O
+evolves	O
+within	O
+minutes	O
+the	O
+organism	O
+can	O
+shift	O
+the	O
+oxygen	B-FUNC
+binding	I-FUNC
+curve	O
+by	O
+changing	O
+2	O
+-	O
+3	O
+-	O
+DGP	O
+erythrocytic	B-ANAT
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+central	O
+lung	B-DISO
+cancer	B-SPEC
+,	O
+lobectomy	O
+can	O
+be	O
+achieved	O
+without	O
+pneumonectomy	O
+by	O
+surgical	O
+reconstruction	O
+of	O
+the	O
+pulmonary	B-ANAT
+artery	I-ANAT
+(	O
+PA	O
+).	O
+
+In	O
+our	O
+series	O
+,	O
+PA	O
+reconstruction	O
+with	O
+end	O
+-	O
+to	O
+-	O
+end	O
+anastomosis	B-DISO
+was	O
+performed	O
+in	O
+18	O
+patients	O
+(	O
+52	O
+.	O
+9	O
+%).	O
+
+CONCLUSIONS	O
+:	O
+In	O
+our	O
+department	O
+,	O
+PA	O
+reconstruction	O
+has	O
+been	O
+more	O
+frequently	O
+and	O
+actively	O
+performed	O
+for	O
+patients	O
+with	O
+central	O
+lung	B-DISO
+cancer	B-SPEC
+,	O
+especially	O
+for	O
+some	O
+patients	O
+with	O
+a	O
+lower	O
+lobe	B-ANAT
+tumor	B-DISO
+.	O
+
+Chickenpox	B-DISO
+in	O
+adults	O
+causes	O
+severe	O
+systemic	O
+manifestations	O
+leading	O
+to	O
+high	O
+frequency	O
+of	O
+complications	O
+with	O
+increased	O
+mortality	O
+rate	O
+,	O
+particularly	O
+in	O
+the	O
+older	O
+age	O
+group	O
+and	O
+in	O
+smokers	O
+who	O
+develops	O
+varicella	B-DISO
+pneumonia	I-DISO
+and	O
+require	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+the	O
+gene	O
+3	O
+region	O
+sequences	O
+of	O
+Chinese	O
+field	O
+strains	O
+of	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+this	O
+study	O
+indicated	O
+the	O
+presence	O
+of	O
+different	O
+TGEV	B-SPEC
+strains	O
+within	O
+the	O
+same	O
+pig	B-SPEC
+herds	O
+in	O
+China	O
+.	O
+
+Structure	O
+probing	O
+confirmed	O
+the	O
+existence	O
+of	O
+these	O
+hairpins	O
+in	O
+the	O
+group	O
+I	O
+Human	B-SPEC
+coronavirus	I-SPEC
+-	O
+229E	O
+and	O
+the	O
+group	O
+II	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+On	O
+admission	O
+,	O
+patients	O
+had	O
+severe	O
+hypoxemia	O
+(	O
+Pa	O
+(	O
+O	O
+(	O
+2	O
+))/	O
+Fi	O
+(	O
+O	O
+(	O
+2	O
+))	O
+140	O
+[	O
+87	O
+-	O
+200	O
+]),	O
+extensive	O
+lung	B-ANAT
+radiologic	O
+infiltrates	B-DISO
+(	O
+2	O
+.	O
+87	O
++/-	O
+
+In	O
+addition	O
+,	O
+other	O
+diseases	O
+such	O
+as	O
+malaria	B-PATH
+,	O
+tuberculosis	B-PATH
+,	O
+and	O
+bacterial	B-DISO
+pneumonia	I-DISO
+are	O
+increasingly	O
+resistant	O
+to	O
+antimicrobial	B-CHED
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Study	O
+on	O
+the	O
+influences	O
+of	O
+palindromes	O
+in	O
+protein	B-CHED
+coding	O
+sequences	O
+on	O
+the	O
+folding	O
+rates	O
+of	O
+peptide	B-CHED
+chains	O
+.	O
+
+The	O
+results	O
+indicated	O
+that	O
+the	O
+folding	O
+rates	O
+show	O
+significant	O
+positive	O
+linear	O
+correlation	O
+for	O
+alpha	O
+-	O
+helices	B-SPEC
+and	O
+negative	O
+linear	O
+correlation	O
+for	O
+beta	O
+-	O
+strands	O
+with	O
+the	O
+average	O
+polarities	O
+.	O
+
+Our	O
+analysis	O
+indicated	O
+that	O
+this	O
+kind	O
+of	O
+effects	O
+mostly	O
+comes	O
+from	O
+the	O
+information	O
+palindrome	O
+structure	O
+itself	O
+or	O
+from	O
+the	O
+synonymous	O
+codon	O
+usage	O
+,	O
+but	O
+not	O
+from	O
+the	O
+translation	B-PROC
+information	O
+from	O
+codons	O
+to	O
+amino	B-CHED
+acids	I-CHED
+.	O
+
+The	O
+report	O
+prepared	O
+by	O
+the	O
+study	O
+group	O
+was	O
+discussed	O
+by	O
+members	O
+of	O
+Working	O
+Groups	O
+who	O
+met	B-CHED
+three	O
+times	O
+in	O
+Italy	O
+.	O
+
+We	O
+present	O
+a	O
+comparative	O
+epidemiologic	O
+analysis	O
+of	O
+SARS	B-DISO
+,	O
+based	O
+on	O
+an	O
+integrated	O
+dataset	O
+with	O
+3	O
+,	O
+336	O
+SARS	B-DISO
+patients	O
+from	O
+Hong	O
+Kong	O
+,	O
+Beijing	O
+and	O
+Taiwan	O
+,	O
+epidemiological	O
+and	O
+clinical	O
+characteristics	O
+such	O
+as	O
+incubation	O
+,	O
+onset	O
+-	O
+to	O
+-	O
+admission	O
+,	O
+onset	O
+-	O
+to	O
+-	O
+discharge	B-ANAT
+and	O
+onset	O
+-	O
+to	O
+-	O
+death	B-PROC
+periods	B-PROC
+,	O
+case	O
+fatality	O
+ratios	O
+(	O
+CFRs	O
+)	O
+and	O
+presenting	O
+symptoms	O
+are	O
+described	O
+and	O
+compared	O
+between	O
+regions	O
+.	O
+
+Our	O
+findings	O
+underline	O
+the	O
+importance	O
+of	O
+a	O
+common	O
+data	O
+collection	O
+platform	O
+,	O
+especially	O
+in	O
+an	O
+emerging	O
+epidemic	O
+,	O
+in	O
+order	B-SPEC
+to	O
+identify	O
+and	O
+explain	O
+consistencies	O
+and	O
+differences	O
+in	O
+the	O
+eventual	O
+clinical	O
+and	O
+public	O
+health	O
+outcomes	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+,	O
+which	O
+is	O
+becoming	O
+increasingly	O
+important	O
+in	O
+our	O
+highly	O
+interconnected	O
+world	O
+.	O
+
+Presence	O
+of	O
+pre	O
+-	O
+existing	O
+comorbid	O
+conditions	O
+was	O
+also	O
+associated	O
+with	O
+greater	O
+mortality	O
+(	O
+AOR	B-FUNC
+:	O
+1	O
+.	O
+74	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+:	O
+1	O
+.	O
+36	O
+,	O
+2	O
+.	O
+21	O
+).	O
+
+We	O
+show	O
+that	O
+Tregs	O
+dampen	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+mediated	O
+by	O
+transferred	O
+JHMV	O
+-	O
+immune	O
+splenocytes	O
+in	O
+infected	O
+RAG1	O
+(-/-)	O
+mice	B-SPEC
+by	O
+decreasing	O
+T	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+,	O
+dendritic	B-ANAT
+cell	B-COMP
+activation	O
+,	O
+and	O
+proinflammatory	O
+cytokine	O
+/	O
+chemokine	B-PROC
+production	I-PROC
+,	O
+without	O
+inducing	O
+apoptosis	B-PATH
+.	O
+
+The	O
+response	O
+(	O
+or	O
+output	O
+)	O
+of	O
+interest	O
+is	O
+the	O
+control	O
+reproduction	B-PROC
+number	O
+,	O
+which	O
+is	O
+an	O
+epidemiological	O
+threshold	O
+governing	O
+the	O
+persistence	O
+or	O
+elimination	B-PROC
+of	O
+SARS	B-DISO
+in	O
+a	O
+given	O
+population	O
+.	O
+
+QYD	O
+could	O
+markedly	O
+improve	O
+the	O
+prognosis	O
+of	O
+SAP	O
+patients	O
+by	O
+way	O
+of	O
+lowering	O
+the	O
+blood	B-ANAT
+levels	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+efficacy	O
+in	O
+the	O
+treated	O
+group	O
+was	O
+also	O
+superior	O
+to	O
+that	O
+in	O
+the	O
+control	O
+group	O
+in	O
+terms	O
+of	O
+reducing	O
+mortality	O
+,	O
+operation	O
+transferring	O
+rate	O
+,	O
+and	O
+blood	B-ANAT
+levels	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+on	O
+the	O
+7th	O
+and	O
+9th	O
+day	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+A	O
+simple	O
+and	O
+rapid	O
+strip	O
+test	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+.	O
+
+The	O
+detection	O
+time	O
+of	O
+IBV	B-PRGE
+IgG	I-PRGE
+by	O
+the	O
+GICA	O
+was	O
+less	O
+than	O
+10	O
+min	O
+,	O
+whereas	O
+the	O
+HI	O
+test	O
+and	O
+the	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+require	O
+1	O
+-	O
+2	O
+hr	O
+.	O
+
+3	O
+.	O
+126	O
+APL	B-DISO
+,	O
+IgG	O
+at	O
+5	O
+.	O
+184	O
++/-	O
+
+TITLE	O
+:	O
+[	O
+Cell	B-ANAT
+entry	O
+mechanisms	O
+of	O
+coronaviruses	O
+].	O
+
+ABSTRACT	O
+:	O
+Mathematical	O
+modeling	O
+can	O
+be	O
+used	O
+for	O
+the	O
+development	O
+and	O
+implementation	O
+of	O
+infection	B-DISO
+control	O
+policy	O
+to	O
+combat	B-CHED
+outbreaks	O
+and	O
+epidemics	O
+of	O
+communicable	O
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+This	O
+provides	O
+insights	O
+in	O
+the	O
+strengths	O
+,	O
+limitations	O
+,	O
+and	O
+weaknesses	B-DISO
+of	O
+the	O
+various	O
+models	O
+,	O
+and	O
+demonstrates	O
+their	O
+potential	O
+for	O
+supporting	O
+policy	O
+and	O
+decision	O
+making	O
+.	O
+
+This	O
+study	O
+was	O
+designed	O
+to	O
+explore	O
+the	O
+efficacy	O
+of	O
+dual	O
+short	O
+hairpin	O
+RNA	O
+(	O
+shRNA	O
+)	O
+interference	O
+with	O
+fgl2	B-PRGE
+and	O
+TNFR1	B-PRGE
+in	O
+the	O
+treatment	O
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+3	O
+(	O
+MHV	B-SPEC
+-	O
+3	O
+)-	O
+induced	O
+fulminant	B-DISO
+hepatitis	I-DISO
+in	O
+mice	B-SPEC
+.	O
+
+In	O
+vivo	O
+hydrodynamic	O
+delivery	O
+of	O
+dual	O
+-	O
+interference	O
+shRNA	O
+plasmids	O
+for	O
+mfgl2	O
+and	O
+mTNFR1	O
+significantly	O
+decreased	O
+mfgl2	O
+and	O
+mTNFR1	O
+expression	B-PROC
+;	O
+markedly	O
+ameliorated	O
+fibrin	B-DISO
+deposition	I-DISO
+,	O
+hepatocyte	B-ANAT
+necrosis	B-PROC
+,	O
+and	O
+apoptosis	B-PATH
+;	O
+and	O
+prolonged	O
+survival	O
+against	O
+fulminant	O
+viral	B-DISO
+hepatitis	I-DISO
+induced	O
+by	O
+MHV	B-SPEC
+-	O
+3	O
+in	O
+BALB	O
+/	O
+cJ	O
+mice	B-SPEC
+compared	O
+with	O
+mfgl2	O
+or	O
+TNFR1	B-PRGE
+single	I-PRGE
+-	I-PRGE
+gene	I-PRGE
+interference	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+rAd	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+led	O
+to	O
+dramatic	O
+augmentation	O
+of	O
+humoral	O
+and	O
+cellular	B-COMP
+responses	O
+in	O
+birds	B-SPEC
+vaccinated	O
+in	O
+ovo	B-SPEC
+followed	O
+by	O
+an	O
+intramuscular	O
+inoculation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+pandemic	O
+affected	O
+South	O
+Africa	O
+late	O
+during	O
+the	O
+2009	O
+Southern	O
+hemisphere	O
+winter	O
+and	O
+placed	O
+an	O
+extra	O
+burden	O
+on	O
+a	O
+health	O
+care	O
+system	O
+already	O
+dealing	O
+with	O
+a	O
+high	O
+prevalence	O
+of	O
+chronic	O
+lung	B-DISO
+diseases	I-DISO
+and	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+infection	B-DISO
+.	O
+
+Of	O
+these	O
+,	O
+15	O
+were	O
+female	O
+and	O
+16	O
+had	O
+identifiable	O
+risk	O
+factors	O
+for	O
+severe	O
+disease	O
+,	O
+including	O
+pregnancy	O
+(	O
+n	O
+=	O
+6	O
+),	O
+type	B-DISO
+2	I-DISO
+diabetes	I-DISO
+mellitus	I-DISO
+(	O
+n	O
+=	O
+6	O
+),	O
+obesity	B-DISO
+(	O
+n	O
+=	O
+4	O
+),	O
+HIV	B-PATH
+infection	I-PATH
+(	O
+n	O
+=	O
+3	O
+),	O
+immunosuppressive	O
+therapy	O
+(	O
+n	O
+=	O
+3	O
+)	O
+and	O
+active	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+(	O
+n	O
+=	O
+2	O
+).	O
+
+In	O
+the	O
+present	O
+work	O
+,	O
+the	O
+authors	O
+investigated	O
+an	O
+outbreak	O
+of	O
+enteritis	B-DISO
+in	O
+puppies	O
+from	O
+a	O
+Greek	O
+kennel	O
+for	O
+the	O
+presence	O
+of	O
+CCoV	O
+.	O
+Dogs	B-SPEC
+were	O
+presented	O
+with	O
+clinical	O
+signs	O
+of	O
+diarrhea	B-DISO
+,	O
+anorexia	B-DISO
+,	O
+weakness	B-DISO
+,	O
+depression	B-DISO
+,	O
+dehydration	B-DISO
+,	O
+and	O
+1	O
+death	B-PROC
+.	O
+
+Positive	O
+sera	B-COMP
+were	O
+obtained	O
+from	O
+6	O
+-	O
+week	O
+-	O
+old	O
+,	O
+female	O
+C57BL	O
+/	O
+6JJcl	O
+mice	B-SPEC
+inoculated	O
+orally	B-ANAT
+with	O
+MNV	O
+-	O
+S7	O
+.	O
+
+We	O
+also	O
+used	O
+this	O
+ELISA	O
+system	O
+to	O
+evaluate	O
+77	O
+murine	B-SPEC
+serum	B-COMP
+samples	O
+obtained	O
+from	O
+15	O
+conventional	O
+mouse	B-SPEC
+rooms	O
+in	O
+research	O
+facilities	O
+in	O
+Japan	O
+and	O
+found	O
+that	O
+approximately	O
+half	O
+of	O
+the	O
+serum	B-COMP
+samples	O
+contained	O
+antibody	B-COMP
+to	O
+MNV	O
+-	O
+S7	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+the	O
+MNV	O
+infection	B-DISO
+is	O
+more	O
+prevalent	O
+than	O
+other	O
+infections	B-DISO
+such	O
+as	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+and	O
+Mycoplasma	B-SPEC
+pulmonis	I-SPEC
+in	O
+conventional	O
+mouse	B-SPEC
+colonies	O
+in	O
+Japan	O
+,	O
+as	O
+is	O
+the	O
+case	O
+in	O
+other	O
+areas	O
+of	O
+the	O
+world	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+method	O
+is	O
+practical	O
+for	O
+rating	O
+the	O
+severity	O
+of	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+outbreak	O
+,	O
+though	O
+it	O
+should	O
+be	O
+optimized	O
+.	O
+
+ABSTRACT	O
+:	O
+Assessment	O
+of	O
+the	O
+risks	O
+posed	O
+by	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+on	O
+surfaces	O
+requires	O
+data	O
+on	O
+survival	O
+of	O
+this	O
+virus	B-SPEC
+on	O
+environmental	O
+surfaces	O
+and	O
+on	O
+how	O
+survival	O
+is	O
+affected	O
+by	O
+environmental	O
+variables	O
+,	O
+such	O
+as	O
+air	B-CHED
+temperature	O
+(	O
+AT	O
+)	O
+and	O
+relative	O
+humidity	O
+(	O
+RH	O
+).	O
+
+The	O
+Chinese	O
+vaccine	O
+strain	O
+H165	O
+of	O
+TGEV	B-SPEC
+was	O
+derived	O
+from	O
+a	O
+virulent	O
+field	O
+strain	O
+H16	O
+by	O
+serial	O
+passage	O
+in	O
+vitro	O
+.	O
+
+Data	O
+from	O
+the	O
+SARS	B-DISO
+outbreak	O
+illustrated	O
+that	O
+if	O
+hospitals	O
+are	O
+seen	O
+as	O
+sources	O
+of	O
+contagion	O
+,	O
+many	O
+patients	O
+with	O
+non	O
+-	O
+bioterrorism	O
+-	O
+related	O
+healthcare	O
+needs	O
+may	O
+delay	O
+seeking	O
+help	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+potent	O
+,	O
+prolonged	O
+inhibition	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+with	O
+IFN	B-PRGE
+-	I-PRGE
+alfacon	I-PRGE
+1	I-PRGE
+was	O
+observed	O
+.	O
+
+Surprisingly	O
+,	O
+the	O
+recombinant	B-PRGE
+N	I-PRGE
+gene	I-PRGE
+is	O
+found	O
+in	O
+all	O
+of	O
+tested	O
+TW	O
+IBV	B-SPEC
+isolates	O
+,	O
+suggesting	O
+that	O
+a	O
+recombination	B-PROC
+event	O
+gave	O
+origin	O
+to	O
+a	O
+founder	B-DISO
+lineage	O
+.	O
+
+The	O
+diagnosis	O
+of	O
+mtDNA	B-COMP
+-	O
+associated	O
+Leigh	B-DISO
+syndrome	I-DISO
+is	O
+established	O
+clinically	O
+in	O
+a	O
+proband	O
+with	O
+progressive	O
+neurologic	O
+disease	O
+with	O
+motor	O
+and	O
+intellectual	O
+developmental	B-DISO
+delay	I-DISO
+,	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+of	O
+brain	B-ANAT
+stem	I-ANAT
+and	O
+/	O
+or	O
+basal	B-DISO
+ganglia	I-DISO
+disease	I-DISO
+,	O
+raised	O
+lactate	B-CHED
+concentration	O
+in	O
+blood	B-ANAT
+and	O
+/	O
+or	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+,	O
+and	O
+any	O
+one	O
+of	O
+the	O
+following	O
+:	O
+Characteristic	O
+features	O
+on	O
+brain	B-ANAT
+imaging	O
+.	O
+
+In	O
+most	O
+cases	O
+,	O
+the	O
+mother	O
+has	O
+a	O
+much	O
+lower	O
+proportion	O
+of	O
+abnormal	O
+mtDNA	B-COMP
+than	O
+the	O
+proband	O
+and	O
+usually	O
+remains	O
+asymptomatic	O
+or	O
+develops	O
+only	O
+mild	O
+symptoms	O
+.	O
+
+In	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+pandemic	O
+H1N1	O
+,	O
+kidney	B-ANAT
+injury	O
+,	O
+kidney	B-DISO
+failure	I-DISO
+,	O
+and	O
+the	O
+need	O
+for	O
+dialysis	B-SPEC
+are	O
+common	O
+and	O
+associated	O
+with	O
+an	O
+increase	O
+in	O
+mortality	O
+and	O
+length	O
+of	O
+intensive	O
+care	O
+unit	O
+stay	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+pandemic	O
+H1N1	O
+group	O
+was	O
+composed	O
+of	O
+50	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+pandemic	O
+H1N1	O
+with	O
+severe	O
+respiratory	O
+syndrome	B-DISO
+(	O
+47	O
+confirmed	O
+cases	O
+,	O
+3	O
+probable	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+methods	O
+of	O
+repeated	O
+immunization	O
+with	O
+inactivated	O
+vaccines	O
+have	O
+been	O
+used	O
+widely	O
+to	O
+increase	O
+antibody	B-COMP
+protection	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+The	O
+chickens	B-SPEC
+were	O
+immunized	O
+primely	O
+on	O
+day	O
+7	O
+and	O
+boosted	O
+2	O
+weeks	O
+later	O
+.	O
+
+After	O
+that	O
+,	O
+distribution	O
+of	O
+the	O
+DNA	O
+vaccine	O
+in	O
+vivo	O
+,	O
+the	O
+percentage	O
+of	O
+CD4	B-PRGE
++	I-PRGE
+CD3	I-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+CD3	I-PRGE
++	I-PRGE
+subgroups	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+T	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+,	O
+and	O
+the	O
+specific	O
+IgG	B-PRGE
+and	O
+virus	B-SPEC
+neutralizing	O
+antibodies	B-COMP
+were	O
+measured	O
+.	O
+
+The	O
+results	O
+demonstrated	O
+that	O
+priming	O
+with	O
+a	O
+DNA	B-PRGE
+vaccine	I-PRGE
+encoding	I-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+(	O
+pVAX1	O
+-	O
+N	O
+)	O
+and	O
+boosting	O
+with	O
+the	O
+inactivated	O
+IBV	B-SPEC
+vaccine	O
+led	O
+to	O
+the	O
+dramatic	O
+augmentation	O
+of	O
+humoral	O
+and	O
+cellular	B-COMP
+responses	O
+,	O
+and	O
+provided	O
+up	O
+to	O
+86	O
+.	O
+7	O
+%	O
+rate	O
+of	O
+immune	O
+protection	O
+,	O
+providing	O
+an	O
+effective	O
+approach	O
+to	O
+protect	O
+chickens	B-SPEC
+from	O
+IBV	B-SPEC
+.	O
+
+Currently	O
+,	O
+we	O
+are	O
+investigating	O
+immune	O
+and	O
+endocrine	B-CHED
+interactions	O
+in	O
+the	O
+chicken	B-SPEC
+,	O
+in	O
+particular	O
+the	O
+cells	B-COMP
+and	O
+molecules	O
+that	O
+are	O
+known	O
+to	O
+be	O
+involved	O
+in	O
+such	O
+interactions	O
+in	O
+mammals	B-SPEC
+.	O
+
+We	O
+have	O
+evaluated	O
+the	O
+effects	O
+of	O
+corticosterone	B-CHED
+administration	O
+in	O
+drinking	B-PROC
+water	B-CHED
+on	O
+peripheral	O
+lymphocyte	B-ANAT
+and	O
+heterophil	B-ANAT
+cytokine	O
+and	O
+chemokine	O
+gene	O
+profiles	O
+.	O
+
+Messenger	B-CHED
+RNA	I-CHED
+expression	O
+levels	O
+of	O
+transforming	B-PRGE
+growth	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+beta4	I-PRGE
+(	O
+TGF	B-PRGE
+-	I-PRGE
+beta4	I-PRGE
+)	O
+are	O
+also	O
+upregulated	O
+in	O
+cortisosterone	O
+-	O
+treated	O
+birds	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Predictive	O
+factors	O
+for	O
+the	O
+outcome	O
+of	O
+noninvasive	O
+ventilation	O
+in	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Children	O
+(	O
+age	O
+range	O
+,	O
+1	O
+month	O
+-	O
+16	O
+yrs	O
+)	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+who	O
+received	O
+noninvasive	O
+ventilation	O
+during	O
+a	O
+4	O
+-	O
+year	O
+period	O
+.	O
+
+Nine	O
+(	O
+19	O
+.	O
+1	O
+%)	O
+of	O
+47	O
+patients	O
+needed	O
+tracheal	O
+intubation	O
+between	O
+the	O
+third	O
+and	O
+87th	O
+hour	O
+after	O
+the	O
+start	O
+of	O
+treatment	O
+(	O
+33	O
+.	O
+6	O
+±	O
+29	O
+.	O
+6	O
+hrs	B-DISO
+).	O
+
+The	O
+failure	O
+group	O
+had	O
+a	O
+higher	O
+rate	O
+of	O
+breathing	B-PROC
+assistance	O
+,	O
+both	O
+initial	O
+and	O
+maximal	O
+.	O
+
+In	O
+the	O
+multivariant	O
+analysis	O
+,	O
+only	O
+maximum	O
+mean	O
+airway	B-ANAT
+pressure	O
+and	O
+Fio2	O
+formed	O
+part	O
+of	O
+the	O
+success	O
+/	O
+failure	O
+discriminant	O
+function	O
+with	O
+a	O
+cutoff	O
+point	O
+of	O
+11	O
+.	O
+5	O
+and	O
+0	O
+.	O
+57	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Poliovirus	B-PRGE
+2B	I-PRGE
+protein	B-CHED
+is	O
+a	O
+well	O
+-	O
+known	O
+viroporin	O
+implicated	O
+in	O
+plasma	B-COMP
+membrane	I-COMP
+permeabilization	O
+to	O
+ions	B-CHED
+and	O
+low	O
+-	O
+molecular	O
+-	O
+weight	O
+compounds	O
+during	O
+infection	B-DISO
+.	O
+
+Expression	B-PROC
+of	O
+2B	O
+induced	O
+permeabilization	O
+of	O
+neighbouring	O
+cell	B-ANAT
+lines	I-ANAT
+other	O
+than	O
+BHK	O
+.	O
+
+The	O
+data	O
+presented	O
+herein	O
+show	O
+that	O
+(	O
+1	O
+)	O
+ligand	B-PROC
+presentation	O
+does	O
+not	O
+disrupt	O
+ELP	O
+(	O
+BC	O
+)	O
+self	O
+-	O
+assembly	O
+;	O
+(	O
+2	O
+)	O
+both	O
+multivalent	O
+ligand	B-PROC
+presentation	O
+and	O
+upregulated	O
+receptor	B-PROC
+expression	I-PROC
+are	O
+needed	O
+for	O
+receptor	O
+-	O
+mediated	O
+interaction	O
+;	O
+(	O
+3	O
+)	O
+increased	O
+size	O
+of	O
+the	O
+hydrophobic	O
+segment	O
+of	O
+the	O
+block	B-CHED
+copolymer	I-CHED
+promotes	O
+multivalent	O
+interaction	O
+with	O
+membrane	B-COMP
+receptors	O
+,	O
+potentially	O
+due	O
+to	O
+changes	O
+in	O
+the	O
+nanoscale	O
+architecture	O
+of	O
+the	O
+micelle	O
+;	O
+and	O
+(	O
+4	O
+)	O
+nanoscale	O
+presentation	O
+of	O
+the	O
+ligand	B-PROC
+is	O
+important	O
+,	O
+as	O
+presentation	O
+of	O
+the	O
+ligand	B-PROC
+by	O
+micrometer	O
+-	O
+sized	O
+aggregates	O
+of	O
+an	O
+ELP	O
+showed	O
+a	O
+low	O
+level	O
+of	O
+binding	B-FUNC
+/	O
+uptake	O
+by	O
+receptor	O
+-	O
+positive	O
+cells	B-COMP
+compared	O
+to	O
+its	O
+presentation	O
+on	O
+the	O
+corona	B-CHED
+of	O
+a	O
+micelle	O
+.	O
+
+Complete	O
+untethering	O
+of	O
+the	O
+diseased	O
+pericardium	B-ANAT
+should	O
+be	O
+performed	O
+with	O
+active	O
+prevention	O
+of	O
+postoperative	B-DISO
+complications	I-DISO
+.	O
+
+Relapse	B-DISO
+occurred	O
+in	O
+one	O
+case	O
+because	O
+of	O
+incomplete	O
+pericardial	B-ANAT
+resection	O
+.	O
+
+The	O
+relative	O
+contributions	O
+of	O
+the	O
+various	O
+IFN	B-PRGE
+subtypes	I-PRGE
+to	O
+innate	B-PROC
+immunity	I-PROC
+against	O
+virus	B-SPEC
+infections	B-DISO
+remain	O
+elusive	O
+.	O
+
+Of	O
+them	O
+,	O
+669	O
+had	O
+a	O
+history	O
+of	O
+close	O
+contact	O
+with	O
+symptomatic	O
+SARS	B-DISO
+patients	O
+,	O
+101	O
+developed	O
+symptoms	O
+with	O
+a	O
+rate	O
+of	O
+15	O
+.	O
+1	O
+%,	O
+363	O
+had	O
+a	O
+history	O
+of	O
+close	O
+contact	O
+with	O
+patients	O
+in	O
+their	O
+incubation	O
+period	O
+,	O
+none	O
+of	O
+whom	O
+developed	O
+symptoms	O
+(	O
+0	O
+%).	O
+
+Preservation	O
+of	O
+SB	O
+was	O
+provided	O
+by	O
+4	O
+different	O
+modes	O
+:	O
+Unassisted	O
+SB	O
+was	O
+enabled	O
+by	O
+biphasic	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+BIPAP	O
+),	O
+moderate	O
+inspiratory	B-PROC
+assist	O
+was	O
+provided	O
+by	O
+pressure	O
+support	O
+(	O
+PS	O
+)	O
+and	O
+volume	O
+-	O
+assured	O
+pressure	O
+support	O
+(	O
+VAPS	O
+),	O
+maximum	O
+assist	O
+was	O
+ensured	O
+by	O
+assist	O
+control	O
+(	O
+A	O
+/	O
+C	O
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+the	O
+sensitivity	O
+of	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+methods	O
+for	O
+the	O
+detection	O
+of	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+avian	B-SPEC
+reovirus	I-SPEC
+(	O
+ARV	O
+),	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AIV	O
+)	O
+and	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+was	O
+compared	O
+to	O
+the	O
+sensitivity	O
+of	O
+the	O
+corresponding	O
+serological	O
+tests	O
+described	O
+in	O
+the	O
+European	O
+Pharmacopoeia	O
+(	O
+Ph	O
+.	O
+
+Two	O
+weeks	O
+later	O
+,	O
+serum	B-COMP
+samples	O
+from	O
+each	O
+animal	B-SPEC
+were	O
+tested	O
+for	O
+antibodies	B-COMP
+using	O
+an	O
+Idexx	O
+enzyme	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+ABSTRACT	O
+:	O
+Airway	O
+pressure	O
+release	B-PATH
+ventilation	O
+(	O
+APRV	O
+)	O
+is	O
+a	O
+ventilatory	O
+mode	O
+that	O
+allows	O
+unsupported	O
+spontaneous	O
+breathing	B-PROC
+at	O
+any	O
+phase	O
+of	O
+the	O
+ventilatory	O
+cycle	O
+with	O
+high	O
+mean	O
+airway	B-ANAT
+pressures	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+use	O
+of	O
+APRV	O
+might	O
+produce	O
+potential	O
+beneficial	O
+effects	O
+on	O
+oxygenation	B-PROC
+,	O
+reducing	O
+mortality	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+comparison	O
+with	O
+synchronized	O
+intermittent	O
+mandatory	O
+ventilation	O
+(	O
+SIMV	O
+)	O
+as	O
+a	O
+conventional	O
+mode	O
+of	O
+ventilation	O
+.	O
+
+Use	O
+of	O
+APRV	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	O
+appears	O
+to	O
+be	O
+associated	O
+with	O
+improvements	O
+in	O
+oxygenation	B-PROC
+,	O
+and	O
+a	O
+trend	O
+toward	O
+lower	O
+mortality	O
+in	O
+ICU	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+85	O
+BAL	B-ENZY
+samples	O
+from	O
+82	O
+patients	O
+,	O
+median	O
+viral	O
+loads	O
+were	O
+as	O
+follows	O
+:	O
+for	O
+RSV	B-SPEC
+(	O
+n	O
+=	O
+35	O
+),	O
+2	O
+.	O
+6	O
+x	O
+10	O
+(	O
+6	O
+)	O
+copies	O
+/	O
+mL	O
+;	O
+for	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+n	O
+=	O
+35	O
+),	O
+4	O
+.	O
+9	O
+x	O
+10	O
+(	O
+7	O
+)	O
+copies	O
+/	O
+mL	O
+;	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+n	O
+=	O
+9	O
+),	O
+6	O
+.	O
+8	O
+x	O
+10	O
+(	O
+5	O
+)	O
+copies	O
+/	O
+mL	O
+;	O
+for	O
+MPV	B-SPEC
+(	O
+n	O
+=	O
+7	O
+),	O
+3	O
+.	O
+9	O
+x	O
+10	O
+(	O
+7	O
+)	O
+copies	O
+/	O
+mL	O
+;	O
+and	O
+for	O
+CoV	O
+(	O
+n	O
+=	O
+4	O
+),	O
+1	O
+.	O
+8	O
+x	O
+10	O
+(	O
+5	O
+)	O
+copies	O
+/	O
+mL	O
+.	O
+Quantitative	O
+viral	O
+load	O
+was	O
+not	O
+associated	O
+with	O
+mechanical	O
+ventilation	O
+or	O
+death	B-PROC
+.	O
+
+We	O
+enrolled	O
+six	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+-	O
+ARDS	B-DISO
+babies	O
+,	O
+five	O
+ARDS	B-DISO
+babies	O
+,	O
+and	O
+six	O
+control	O
+infants	O
+.	O
+
+Children	O
+were	O
+stratified	O
+for	O
+age	O
+,	O
+type	O
+of	O
+patient	O
+,	O
+and	O
+cause	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+956	O
+(	O
+49	O
+.	O
+2	O
+%)	O
+patients	O
+required	O
+MV	O
+via	O
+an	O
+endotracheal	O
+tube	O
+;	O
+673	O
+(	O
+34	O
+.	O
+6	O
+%)	O
+were	O
+ventilated	O
+for	O
+>	O
+24	O
+hrs	B-DISO
+.	O
+
+The	O
+overall	O
+mortality	O
+was	O
+6	O
+.	O
+7	O
+%	O
+with	O
+highest	O
+rates	O
+for	O
+heart	B-DISO
+disease	I-DISO
+(	O
+nonoperative	O
+),	O
+sepsis	B-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+26	O
+.	O
+1	O
+%,	O
+22	O
+.	O
+2	O
+%,	O
+and	O
+16	O
+.	O
+7	O
+%	O
+respectively	O
+).	O
+
+Controlled	O
+MV	O
+and	O
+pressure	O
+support	O
+ventilation	O
++	O
+synchronized	O
+intermittent	O
+mandatory	O
+ventilation	O
+were	O
+the	O
+most	O
+frequently	O
+used	O
+modes	O
+of	O
+ventilatory	O
+assistance	O
+during	O
+PICU	B-SPEC
+stay	O
+.	O
+
+Despite	O
+improved	O
+surveillance	O
+and	O
+quarantine	O
+measures	O
+,	O
+we	O
+find	O
+ourselves	O
+in	O
+the	O
+midst	O
+of	O
+a	O
+H1N1	B-DISO
+influenza	I-DISO
+pandemic	O
+.	O
+
+35kg	O
+pigs	B-SPEC
+were	O
+maintained	O
+under	O
+general	O
+anaesthesia	B-DISO
+and	O
+invasively	O
+monitored	O
+.	O
+
+Animals	B-SPEC
+surviving	O
+28	O
+hours	O
+were	O
+euthanased	O
+.	O
+
+26	O
+.	O
+9	O
+mPa	O
+/	O
+s	O
+/	O
+m3	O
+)	O
+observed	O
+may	O
+reflect	O
+the	O
+development	B-PROC
+of	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Liver	B-DISO
+damage	I-DISO
+was	O
+confirmed	O
+by	O
+deterioration	O
+in	O
+pH	O
+(	O
+7	O
+.	O
+23	O
++/-	O
+0	O
+.	O
+05	O
+vs	O
+7	O
+.	O
+45	O
++/-	O
+
+Animals	B-SPEC
+displayed	O
+evidence	O
+of	O
+renal	B-DISO
+impairment	I-DISO
+;	O
+mean	O
+creatinine	B-CHED
+levels	O
+280	O
+.	O
+2	O
++/-	O
+
+RESULTS	O
+:	O
+Cytochrome	B-PROC
+p450	I-PROC
+levels	O
+in	O
+phenobarbital	B-CHED
+pre	O
+-	O
+treated	O
+animals	B-SPEC
+were	O
+significantly	O
+higher	O
+than	O
+non	O
+pre	O
+-	O
+treated	O
+animals	B-SPEC
+(	O
+300	O
+vs	O
+100	O
+pmol	O
+/	O
+mg	O
+protein	B-CHED
+).	O
+
+The	O
+CC	O
+-	O
+induced	O
+PE	O
+was	O
+attributed	O
+to	O
+overactivation	O
+of	O
+the	O
+medullary	B-ANAT
+sympathetic	O
+mechanism	O
+.	O
+
+Fat	B-DISO
+embolism	I-DISO
+syndrome	I-DISO
+(	O
+FES	O
+)	O
+is	O
+a	O
+serious	O
+clinical	O
+problem	O
+in	O
+patients	O
+suffering	B-DISO
+from	O
+long	B-ANAT
+bone	I-ANAT
+fractures	O
+.	O
+
+Later	O
+study	O
+also	O
+found	O
+that	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+and	O
+myeloperoxidase	B-PRGE
+were	O
+elevated	O
+following	O
+fat	B-DISO
+embolism	I-DISO
+.	O
+
+N	B-CHED
+-	I-CHED
+acetylcysteine	I-CHED
+(	O
+an	O
+antioxidant	B-CHED
+),	O
+and	O
+NOS	O
+inhibitors	B-CHED
+such	O
+as	O
+Nomega	O
+nitro	B-CHED
+-	O
+L	B-CHED
+-	I-CHED
+arginine	I-CHED
+methyl	B-CHED
+ester	B-CHED
+(	O
+L	O
+-	O
+NAME	B-SPEC
+),	O
+S	O
+-	O
+methylisothiourea	O
+(	O
+SMT	O
+)	O
+or	O
+L	O
+-	O
+N6	O
+(	O
+1	O
+-	O
+iminoethyl	O
+)-	O
+lysine	B-CHED
+(	O
+L	O
+-	O
+Nil	O
+)	O
+were	O
+able	O
+to	O
+abrogate	O
+the	O
+FES	O
+or	O
+the	O
+fat	B-DISO
+embolism	I-DISO
+-	O
+induced	O
+changes	O
+.	O
+
+TITLE	O
+:	O
+CD209	B-PRGE
+(	O
+DC	O
+-	O
+SIGN	O
+)	O
+-	O
+336A	O
+>	O
+G	O
+promoter	O
+polymorphism	B-PROC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Hong	O
+Kong	O
+Chinese	O
+.	O
+
+High	O
+LDH	O
+levels	O
+are	O
+known	O
+to	O
+be	O
+an	O
+independent	O
+predictor	O
+for	O
+poor	O
+clinical	O
+outcome	O
+,	O
+probably	O
+related	O
+to	O
+tissue	B-ANAT
+destruction	O
+from	O
+immune	O
+hyperactivity	O
+.	O
+
+ABSTRACT	O
+:	O
+Scrub	O
+typhus	O
+is	O
+an	O
+important	O
+cause	O
+of	O
+acute	O
+undifferentiated	O
+febrile	B-PROC
+illnesses	O
+in	O
+the	O
+Indian	O
+subcontinent	O
+.	O
+
+Given	O
+the	O
+telltale	O
+presence	O
+of	O
+an	O
+eschar	B-DISO
+(	O
+evident	O
+in	O
+45	O
+.	O
+5	O
+%),	O
+the	O
+characteristic	O
+clinical	O
+profile	O
+and	O
+the	O
+dramatic	O
+therapeutic	O
+response	O
+to	O
+a	O
+cheap	O
+,	O
+yet	O
+effective	O
+,	O
+drug	O
+such	O
+as	O
+doxycycline	B-CHED
+,	O
+medical	O
+practitioners	O
+in	O
+the	O
+region	O
+should	O
+have	O
+ample	O
+opportunity	O
+to	O
+reach	B-PROC
+an	O
+early	O
+diagnosis	O
+and	O
+initiate	O
+treatment	O
+which	O
+could	O
+,	O
+potentially	O
+,	O
+reduce	O
+the	O
+mortality	O
+and	O
+morbidity	O
+associated	O
+with	O
+scrub	B-DISO
+typhus	I-DISO
+.	O
+
+Proteins	B-CHED
+from	O
+the	O
+four	O
+viruses	B-SPEC
+were	O
+purified	O
+and	O
+spotted	O
+onto	O
+an	O
+aldehyde	B-CHED
+group	I-CHED
+-	O
+modified	O
+glass	O
+slide	O
+at	O
+2mg	O
+/	O
+ml	O
+.	O
+
+In	O
+conclusion	O
+,	O
+this	O
+protein	B-CHED
+chip	O
+can	O
+be	O
+used	O
+to	O
+differentiate	O
+the	O
+antibodies	B-COMP
+induced	O
+by	O
+the	O
+four	O
+avian	B-SPEC
+viruses	B-SPEC
+.	O
+
+HCoV	O
+-	O
+HKU1	O
+can	O
+be	O
+identified	O
+in	O
+stool	B-ANAT
+samples	O
+from	O
+children	O
+and	O
+adults	O
+with	O
+gastrointestinal	B-DISO
+disease	I-DISO
+,	O
+with	O
+most	O
+individuals	O
+having	O
+respiratory	O
+findings	O
+as	O
+well	O
+.	O
+
+Of	O
+these	O
+samples	O
+,	O
+4	O
+patients	O
+(	O
+1	O
+.	O
+3	O
+%,	O
+2	O
+adult	O
+;	O
+2	O
+pediatric	O
+)	O
+screened	O
+positive	O
+for	O
+the	O
+presence	O
+of	O
+a	O
+coronavirus	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+past	O
+experiences	O
+in	O
+the	O
+SARS	B-DISO
+outbreak	O
+not	O
+only	O
+led	O
+the	O
+participants	O
+to	O
+remember	O
+their	O
+stigmatization	O
+experiences	O
+in	O
+this	O
+H1N1	O
+pandemic	O
+,	O
+but	O
+also	O
+aroused	O
+the	O
+memory	B-PROC
+of	O
+the	O
+general	O
+Hong	O
+Kong	O
+population	O
+that	O
+chronic	O
+renal	O
+disease	O
+patients	O
+were	O
+""""	O
+dangerous	O
+""""	O
+and	O
+""""	O
+polluted	O
+","""	O
+which	O
+could	O
+further	O
+contribute	O
+to	O
+their	O
+stigmatization	O
+in	O
+this	O
+H1N1	O
+pandemic	O
+.	O
+
+Recent	O
+advances	O
+in	O
+phylogenetic	O
+methods	O
+can	O
+infer	O
+more	O
+in	O
+-	O
+depth	O
+information	O
+about	O
+the	O
+patterns	O
+of	O
+virus	B-SPEC
+emergence	O
+,	O
+adding	O
+to	O
+the	O
+conventional	O
+approaches	O
+in	O
+viral	O
+epidemiology	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+clinical	O
+feature	O
+,	O
+treatment	O
+and	O
+outcome	O
+of	O
+respiratory	O
+failure	O
+in	O
+patients	O
+with	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+infection	B-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+adults	O
+.	O
+
+Compared	O
+with	O
+survivors	O
+,	O
+acute	O
+kidney	B-ANAT
+injury	O
+and	O
+barotrauma	O
+occurred	O
+more	O
+frequently	O
+in	O
+non	O
+-	O
+survivors	O
+(	O
+42	O
+.	O
+9	O
+%	O
+vs	O
+.	O
+27	O
+.	O
+3	O
+%,	O
+28	O
+.	O
+6	O
+%	O
+vs	O
+.	O
+9	O
+.	O
+1	O
+%,	O
+both	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+the	O
+most	O
+common	O
+manifestation	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+infection	B-DISO
+in	O
+adult	O
+.	O
+
+Failure	O
+to	O
+obtain	O
+satisfactory	O
+oxygenation	B-PROC
+with	O
+high	O
+-	O
+level	O
+ventilation	O
+settings	O
+within	O
+the	O
+first	O
+7	O
+-	O
+days	O
+,	O
+onset	O
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+and	O
+barotrauma	O
+,	O
+and	O
+continuous	O
+need	O
+for	O
+vasopressors	O
+portend	O
+a	O
+poor	O
+prognosis	O
+.	O
+
+Fifty	O
+-	O
+three	O
+patients	O
+were	O
+complicated	O
+with	O
+pneumonia	B-DISO
+(	O
+70	O
+.	O
+67	O
+%)	O
+and	O
+41	O
+patients	O
+with	O
+pre	O
+-	O
+existing	O
+medical	O
+conditions	O
+(	O
+54	O
+.	O
+67	O
+%),	O
+65	O
+patients	O
+with	O
+fever	B-PROC
+(	O
+86	O
+.	O
+67	O
+%),	O
+63	O
+patients	O
+with	O
+cough	B-DISO
+and	O
+sputum	B-ANAT
+(	O
+84	O
+.	O
+00	O
+%),	O
+61	O
+patients	O
+with	O
+dyspnea	B-DISO
+(	O
+81	O
+.	O
+33	O
+%),	O
+1	O
+patients	O
+with	O
+meningitis	B-DISO
+as	O
+the	O
+main	O
+manifestation	O
+,	O
+2	O
+patients	O
+with	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+and	O
+left	B-DISO
+heart	I-DISO
+failure	I-DISO
+,	O
+28	O
+patients	O
+with	O
+leucopenia	B-DISO
+(	O
+37	O
+.	O
+33	O
+%),	O
+28	O
+patients	O
+with	O
+myocardial	O
+enzyme	O
+abnormalities	O
+(	O
+37	O
+.	O
+33	O
+%),	O
+23	O
+patients	O
+with	O
+blood	B-ANAT
+glucose	B-CHED
+abnormalities	O
+(	O
+30	O
+.	O
+67	O
+%),	O
+8	O
+patients	O
+with	O
+coagulopathy	B-DISO
+(	O
+10	O
+.	O
+67	O
+%),	O
+4	O
+patients	O
+with	O
+lipid	B-CHED
+abnormalities	O
+(	O
+5	O
+.	O
+33	O
+%),	O
+51	O
+patients	O
+with	O
+increased	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+68	O
+.	O
+00	O
+%).	O
+
+Except	O
+1	O
+patient	O
+out	O
+of	O
+75	O
+patients	O
+died	B-PROC
+,	O
+and	O
+the	O
+rest	B-FUNC
+were	O
+cured	O
+.	O
+
+Among	O
+coagulation	B-PROC
+parameters	O
+kaolin	O
+-	O
+kefalin	O
+time	O
+(	O
+69	O
+s	O
+)	O
+and	O
+D	O
+-	O
+dimers	O
+(	O
+2000	O
+-	O
+4000	O
+/	O
+ul	O
+.)	O
+were	O
+abnormal	O
+.	O
+
+We	O
+describe	O
+a	O
+78	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+who	O
+presented	O
+with	O
+a	O
+two	O
+-	O
+day	O
+history	O
+of	O
+progressive	O
+generalised	O
+weakness	B-DISO
+and	O
+left	B-ANAT
+facial	I-ANAT
+nerve	I-ANAT
+palsy	O
+,	O
+preceded	O
+by	O
+a	O
+flu	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+lasting	O
+for	O
+one	O
+week	O
+.	O
+
+Seven	O
+days	O
+after	O
+completion	O
+of	O
+immunoglobulin	B-PROC
+treatment	O
+,	O
+plasma	B-ANAT
+exchange	O
+was	O
+started	O
+with	O
+an	O
+exchange	O
+of	O
+about	O
+three	O
+litres	O
+of	O
+plasma	O
+every	O
+day	O
+for	O
+three	O
+days	O
+and	O
+every	O
+second	O
+day	O
+on	O
+two	O
+further	O
+occasions	O
+.	O
+
+Based	O
+on	O
+the	O
+crystal	B-ANAT
+structures	O
+,	O
+a	O
+key	O
+residue	O
+,	O
+Glu	B-CHED
+-	O
+166	O
+,	O
+which	O
+is	O
+responsible	O
+for	O
+recognizing	O
+the	O
+Gln	B-CHED
+-	O
+P1	O
+of	O
+the	O
+substrate	O
+and	O
+binding	B-FUNC
+to	O
+Ser	B-COMP
+-	O
+1	O
+of	O
+another	O
+protomer	O
+,	O
+will	O
+interact	O
+with	O
+Asn	B-CHED
+-	O
+142	O
+and	O
+block	O
+the	O
+S1	O
+subsite	O
+entrance	O
+in	O
+the	O
+monomer	O
+.	O
+
+This	O
+demonstrates	O
+that	O
+Glu	B-CHED
+-	O
+166	O
+plays	O
+a	O
+pivotal	O
+role	O
+in	O
+connecting	O
+the	O
+substrate	O
+binding	B-FUNC
+site	O
+with	O
+the	O
+dimer	O
+interface	O
+.	O
+
+A	O
+prevailing	O
+hypothesis	O
+is	O
+that	O
+the	O
+highly	O
+pathogenic	O
+virus	B-SPEC
+isolates	O
+cause	O
+a	O
+severe	O
+cytokinemia	O
+precipitating	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+.	O
+
+Extrapulmonary	O
+pathology	B-DISO
+may	O
+thus	O
+contribute	O
+to	O
+the	O
+morbidities	O
+induced	O
+by	O
+H5N1	B-DISO
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+report	O
+describes	O
+the	O
+identification	O
+of	O
+a	O
+novel	O
+linear	O
+B	O
+-	O
+cell	O
+epitope	B-CHED
+at	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+the	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+.	O
+
+We	O
+propose	O
+that	O
+this	O
+motif	O
+is	O
+a	O
+linear	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitope	B-CHED
+of	O
+N	O
+protein	B-CHED
+,	O
+and	O
+is	O
+the	O
+core	O
+sequence	O
+for	O
+reactivity	O
+,	O
+as	O
+demonstrated	O
+by	O
+binding	B-FUNC
+of	O
+2D2	O
+to	O
+the	O
+truncated	O
+peptides	B-CHED
+and	O
+different	O
+IBV	B-SPEC
+strains	O
+.	O
+
+The	O
+identified	O
+epitope	B-CHED
+might	O
+be	O
+useful	O
+for	O
+clinical	O
+applications	O
+and	O
+as	O
+a	O
+tool	O
+for	O
+further	O
+study	O
+of	O
+the	O
+structure	O
+and	O
+function	O
+of	O
+the	O
+IBV	B-SPEC
+N	O
+protein	B-CHED
+.	O
+
+RBD219	O
+-	O
+CHO	B-FUNC
+protein	B-CHED
+elicited	O
+potent	O
+protective	O
+immunity	O
+that	O
+protected	O
+all	O
+vaccinated	O
+mice	B-SPEC
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+challenge	O
+.	O
+
+Ultraviolet	O
+germicidal	O
+irradiation	O
+is	O
+underused	O
+at	O
+present	O
+,	O
+despite	O
+good	O
+evidence	O
+of	O
+safety	O
+and	O
+efficacy	O
+in	O
+elimination	B-PROC
+of	O
+airborne	O
+respiratory	O
+infectious	B-DISO
+agents	O
+including	O
+TB	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Benefit	O
+of	O
+the	O
+stabilization	O
+of	O
+long	O
+-	O
+bone	B-ANAT
+fractures	O
+in	O
+polytraumatized	O
+patients	O
+].	O
+
+RESULTS	O
+:	O
+The	O
+patient	O
+group	O
+whose	O
+fractures	O
+were	O
+stabilized	O
+after	O
+48	O
+hours	O
+had	O
+more	O
+clinical	O
+complications	O
+,	O
+alterations	O
+of	O
+lung	B-ANAT
+parameters	O
+and	O
+a	O
+longer	O
+hospital	O
+stay	O
+.	O
+
+There	O
+is	O
+no	O
+complete	O
+evidence	O
+showing	O
+that	O
+early	O
+stabilization	O
+of	O
+long	B-ANAT
+bones	I-ANAT
+in	O
+patients	O
+with	O
+moderate	O
+or	O
+severe	O
+head	B-ANAT
+trauma	O
+worsens	O
+or	O
+improves	O
+the	O
+outcomes	O
+.	O
+
+The	O
+Chinese	O
+Government	O
+has	O
+carried	O
+out	O
+a	O
+series	O
+of	O
+emergency	B-DISO
+preparedness	O
+education	O
+and	O
+training	O
+programmes	O
+to	O
+improve	O
+the	O
+emergency	B-DISO
+preparedness	O
+capability	O
+of	O
+rural	O
+public	O
+health	O
+personnel	O
+nationwide	O
+.	O
+
+Cardiopulmonary	B-DISO
+failure	I-DISO
+was	O
+treated	O
+effectively	O
+with	O
+ECMO	O
+and	O
+systemic	O
+gas	B-ENZY
+exchange	O
+and	O
+blood	B-PROC
+flow	I-PROC
+improved	O
+rapidly	O
+within	O
+2	O
+h	O
+on	O
+ECMO	O
+in	O
+all	O
+patients	O
+(	O
+median	O
+OR	O
+69	O
+(	O
+52	O
+-	O
+263	O
+)	O
+mmHg	O
+,	O
+median	O
+paCO	O
+(	O
+2	O
+)	O
+41	O
+(	O
+22	O
+-	O
+85	O
+)	O
+mmHg	O
+.	O
+
+Initially	O
+heparin	B-CHED
+-	O
+free	O
+ECMO	O
+support	O
+can	O
+improve	O
+therapy	O
+and	O
+outcome	O
+even	O
+in	O
+disastrous	O
+trauma	O
+patients	O
+with	O
+coexisting	O
+bleeding	B-DISO
+shock	O
+.	O
+
+Tidal	O
+volumes	O
+ranged	O
+between	O
+8	O
+.	O
+64	O
+and	O
+9	O
+.	O
+16	O
+and	O
+the	O
+average	O
+PEEP	B-CHED
+varied	O
+from	O
+2	O
+.	O
+5	O
+to	O
+5	O
+.	O
+5	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+.	O
+There	O
+were	O
+substantial	O
+differences	O
+in	O
+the	O
+average	O
+Fio	O
+(	O
+2	O
+)	O
+and	O
+PIP	B-CHED
+among	O
+the	O
+groups	O
+,	O
+59	O
+%	O
+to	O
+91	O
+%	O
+and	O
+22	O
+to	O
+29	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+,	O
+respectively	O
+.	O
+
+The	O
+average	O
+Fio	O
+(	O
+2	O
+)	O
+and	O
+PIP	B-CHED
+were	O
+significantly	O
+escalated	O
+depending	O
+on	O
+the	O
+P	O
+/	O
+F	O
+ratio	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Similar	O
+ventilation	O
+strategies	O
+in	O
+mL	O
+/	O
+kg	O
+PBW	O
+and	O
+PEEP	B-CHED
+were	O
+used	O
+among	O
+patients	O
+regardless	O
+of	O
+P	O
+/	O
+F	O
+ratio	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+pathogenesis	B-DISO
+is	O
+regulated	O
+by	O
+a	O
+STAT1	B-PRGE
+dependent	O
+but	O
+a	O
+type	O
+I	O
+,	O
+II	O
+and	O
+III	O
+interferon	B-PRGE
+receptor	I-PRGE
+independent	O
+mechanism	O
+.	O
+
+We	O
+performed	O
+the	O
+screening	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+and	O
+sequencing	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+gene	O
+fragments	O
+derived	O
+from	O
+conventional	O
+PCR	O
+.	O
+
+Finally	O
+,	O
+demographic	O
+and	O
+clinical	O
+data	O
+associated	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+were	O
+examined	O
+retrospectively	O
+.	O
+
+The	O
+main	O
+clinical	O
+manifestations	O
+were	O
+noted	O
+as	O
+:	O
+headache	B-DISO
+(	O
+in	O
+70	O
+.	O
+9	O
+%),	O
+sore	B-DISO
+throat	I-DISO
+(	O
+69	O
+%),	O
+chills	B-DISO
+(	O
+68	O
+%),	O
+cough	B-DISO
+(	O
+33	O
+%),	O
+sputum	B-ANAT
+(	O
+21	O
+.	O
+3	O
+%),	O
+rhinorrhea	B-DISO
+(	O
+21	O
+.	O
+4	O
+%),	O
+nasal	B-ANAT
+obstruction	B-DISO
+(	O
+16	O
+.	O
+5	O
+%),	O
+and	O
+a	O
+few	O
+of	O
+patients	O
+were	O
+visible	O
+as	O
+vomiting	B-DISO
+(	O
+6	O
+.	O
+8	O
+%),	O
+dyspnea	B-DISO
+(	O
+3	O
+.	O
+9	O
+%),	O
+diarrhea	B-DISO
+(	O
+in	O
+1	O
+.	O
+9	O
+%).	O
+
+The	O
+rate	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+in	O
+adult	O
+patients	O
+was	O
+found	O
+no	O
+relative	O
+with	O
+age	O
+and	O
+gender	O
+.	O
+
+Logistic	O
+regression	O
+indicated	O
+that	O
+compared	O
+with	O
+the	O
+persons	O
+with	O
+the	O
+thoughts	O
+of	O
+nothing	O
+serious	O
+of	O
+SARS	B-DISO
+,	O
+without	O
+any	O
+dread	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+knowing	O
+nothing	O
+about	O
+prevention	O
+of	O
+SARS	B-DISO
+,	O
+the	O
+perceived	O
+stress	O
+was	O
+significantly	O
+related	O
+with	O
+perceiving	O
+of	O
+the	O
+thread	O
+to	O
+certain	O
+extent	O
+(	O
+beta	O
+=	O
+0	O
+.	O
+41	O
+,	O
+Wald	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+4	O
+.	O
+84	O
+,	O
+P	O
+=	O
+0	O
+.	O
+03	O
+),	O
+worrying	O
+little	O
+about	O
+the	O
+epidemic	O
+(	O
+beta	O
+=	O
+0	O
+.	O
+50	O
+,	O
+Wald	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+6	O
+.	O
+69	O
+,	O
+P	O
+=	O
+0	O
+.	O
+01	O
+),	O
+worrying	O
+about	O
+it	O
+to	O
+certain	O
+extent	O
+(	O
+beta	O
+=	O
+1	O
+.	O
+39	O
+,	O
+Wald	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+48	O
+.	O
+59	O
+,	O
+P	O
+=	O
+0	O
+.	O
+00	O
+)	O
+and	O
+scared	O
+so	O
+much	O
+(	O
+beta	O
+=	O
+1	O
+.	O
+77	O
+,	O
+Wald	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+53	O
+.	O
+59	O
+,	O
+P	O
+=	O
+0	O
+.	O
+00	O
+),	O
+and	O
+knowing	O
+little	O
+about	O
+the	O
+prevention	O
+(	O
+beta	O
+=	O
+0	O
+.	O
+74	O
+,	O
+Wald	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+4	O
+.	O
+48	O
+,	O
+P	O
+=	O
+0	O
+.	O
+03	O
+),	O
+knowing	O
+something	O
+about	O
+prevention	O
+(	O
+beta	O
+=	O
+-	O
+0	O
+.	O
+98	O
+,	O
+Wald	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+8	O
+.	O
+29	O
+,	O
+P	O
+=	O
+0	O
+.	O
+00	O
+)	O
+and	O
+knowing	O
+the	O
+prevention	O
+very	O
+well	O
+(	O
+beta	O
+=	O
+-	O
+1	O
+.	O
+18	O
+,	O
+Wald	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+10	O
+.	O
+66	O
+,	O
+P	O
+=	O
+0	O
+.	O
+00	O
+).	O
+
+The	O
+5	O
+-	O
+fluoro	B-CHED
+derivative	O
+inhibited	O
+the	O
+HCV	B-SPEC
+RNA	B-PROC
+synthesis	I-PROC
+at	O
+6	O
+mug	O
+/	O
+ml	O
+,	O
+without	O
+toxicity	O
+at	O
+a	O
+concentration	O
+up	O
+to	O
+42	O
+mug	O
+/	O
+ml	O
+in	O
+Huh	O
+5	O
+-	O
+2	O
+cells	B-COMP
+.	O
+
+The	O
+faecal	B-ANAT
+samples	O
+were	O
+pooled	O
+in	O
+groups	O
+of	O
+five	O
+.	O
+
+The	O
+presence	O
+of	O
+two	O
+or	O
+three	O
+different	O
+viruses	B-SPEC
+in	O
+combination	O
+may	O
+affect	O
+the	O
+dynamics	O
+of	O
+turkey	B-SPEC
+health	O
+and	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+,	O
+in	O
+spite	O
+of	O
+vaccination	O
+,	O
+still	O
+a	O
+major	O
+cause	O
+of	O
+respiratory	B-DISO
+problems	I-DISO
+in	O
+broilers	O
+and	O
+of	O
+poor	O
+egg	B-ANAT
+production	O
+in	O
+breeders	O
+and	O
+layers	B-ANAT
+in	O
+many	O
+parts	O
+of	O
+the	O
+world	O
+.	O
+
+In	O
+the	O
+first	O
+,	O
+the	O
+results	O
+of	O
+the	O
+alpha	B-PRGE
+-	I-PRGE
+IBV	I-PRGE
+IgM	I-PRGE
+enzyme	I-PRGE
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+on	O
+post	O
+-	O
+vaccination	O
+sera	B-COMP
+were	O
+compared	O
+with	O
+the	O
+efficacy	O
+of	O
+the	O
+IBV	B-SPEC
+vaccination	O
+against	O
+homologous	O
+challenge	O
+of	O
+the	O
+same	O
+broilers	O
+.	O
+
+The	O
+aim	O
+was	O
+to	O
+identify	O
+factors	O
+that	O
+might	O
+be	O
+associated	O
+positively	O
+or	O
+negatively	O
+with	O
+the	O
+IgM	B-PRGE
+response	O
+and	O
+thereby	O
+with	O
+the	O
+expected	O
+level	O
+of	O
+protection	O
+against	O
+homologous	O
+challenge	O
+under	O
+field	O
+conditions	O
+.	O
+
+inoculation	O
+with	O
+the	O
+M	O
+.	O
+synoviae	O
+EAA	O
+strain	O
+if	O
+preceded	O
+by	O
+an	O
+infection	B-DISO
+with	O
+IBV	B-SPEC
+.	O
+
+Vaccines	O
+have	O
+remained	O
+unaltered	O
+for	O
+many	O
+years	O
+but	O
+new	O
+ones	O
+are	O
+being	O
+developed	O
+to	O
+counter	B-CHED
+vaccine	O
+side	O
+effects	O
+and	O
+reversion	O
+and	O
+reactivation	B-PROC
+of	I-PROC
+latent	I-PROC
+virus	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+early	O
+stages	O
+of	O
+infection	B-DISO
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+produces	O
+more	O
+severe	O
+perturbation	O
+of	O
+host	B-COMP
+cell	I-COMP
+gene	B-PROC
+expression	I-PROC
+in	O
+a	O
+human	B-SPEC
+epithelial	B-ANAT
+cell	I-ANAT
+line	O
+of	O
+liver	B-ANAT
+origin	O
+than	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+The	O
+promotion	O
+of	O
+personal	O
+protective	O
+health	O
+practices	O
+must	O
+take	O
+into	O
+account	O
+background	O
+perceptions	O
+of	O
+risk	O
+and	O
+psychological	B-DISO
+responses	O
+in	O
+the	O
+community	O
+-	O
+at	O
+-	O
+large	O
+.	O
+
+Population	O
+psycho	O
+-	O
+behavioural	O
+factors	O
+in	O
+Hong	O
+Kong	O
+and	O
+Singapore	O
+are	O
+shown	O
+to	O
+be	O
+an	O
+important	O
+potential	O
+vector	O
+for	O
+the	O
+transmission	O
+of	O
+an	O
+infectious	B-DISO
+agent	O
+.	O
+
+Three	O
+different	O
+recHE	O
+molecules	O
+were	O
+constructed	O
+:	O
+one	O
+representing	O
+a	O
+high	O
+virulent	O
+isolate	O
+,	O
+one	O
+a	O
+low	O
+virulent	O
+,	O
+while	O
+in	O
+the	O
+third	O
+a	O
+Ser	O
+(	O
+32	O
+)	O
+to	O
+Ala	B-CHED
+(	O
+32	O
+)	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+was	O
+introduced	O
+in	O
+the	O
+enzymatic	O
+catalytic	O
+site	O
+as	O
+inferred	O
+from	O
+the	O
+model	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+Ser	B-COMP
+(	O
+32	O
+)	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+totally	O
+abolished	O
+enzymatic	B-PROC
+activity	I-PROC
+while	O
+receptor	B-FUNC
+binding	I-FUNC
+increased	O
+,	O
+as	O
+observed	O
+by	O
+agglutination	B-PROC
+of	O
+Atlantic	B-PRGE
+salmon	I-PRGE
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Mechanistic	O
+study	O
+of	O
+the	O
+reaction	O
+of	O
+thiol	B-CHED
+-	O
+containing	O
+enzymes	O
+with	O
+alpha	O
+,	O
+beta	O
+-	O
+unsaturated	O
+carbonyl	B-CHED
+substrates	O
+by	O
+computation	O
+and	O
+chemoassays	O
+.	O
+
+There	O
+is	O
+a	O
+long	O
+history	O
+of	O
+investigations	O
+concluding	O
+that	O
+,	O
+if	O
+used	O
+properly	O
+,	O
+UVGI	O
+can	O
+be	O
+safe	O
+and	O
+highly	O
+effective	O
+in	O
+disinfecting	O
+the	O
+air	B-CHED
+,	O
+thereby	O
+preventing	O
+transmission	O
+of	O
+a	O
+variety	O
+of	O
+airborne	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Nasal	B-ANAT
+administration	O
+has	O
+emerged	O
+as	O
+a	O
+promising	O
+and	O
+attractive	O
+route	O
+for	O
+vaccination	O
+,	O
+especially	O
+for	O
+the	O
+prophylaxis	O
+of	O
+respiratory	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+mRT	B-ANAT
+-	O
+PCR	O
+assay	O
+accurately	O
+detected	O
+and	O
+discriminated	O
+vaccine	O
+viruses	B-SPEC
+from	O
+wildtype	O
+strains	O
+in	O
+the	O
+field	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+is	O
+little	O
+information	O
+on	O
+the	O
+role	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+in	O
+innate	B-PROC
+immunity	I-PROC
+to	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infections	B-DISO
+.	O
+
+We	O
+detected	O
+a	O
+large	O
+increase	O
+in	O
+NO	O
+levels	O
+in	O
+BAL	B-ENZY
+fluids	B-ANAT
+of	O
+PRCV	O
+-	O
+infected	O
+pigs	B-SPEC
+,	O
+but	O
+not	O
+in	O
+PRRSV	B-SPEC
+-	O
+infected	O
+pigs	B-SPEC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+in	O
+vivo	O
+study	O
+to	O
+report	O
+the	O
+synergistic	O
+interaction	O
+between	O
+a	O
+virus	B-SPEC
+and	O
+LTA	O
+in	O
+enhancing	O
+the	O
+severity	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+the	O
+pig	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+More	O
+than	O
+200	O
+of	O
+the	O
+documented	O
+zoonoses	O
+represent	O
+a	O
+high	O
+proportion	O
+of	O
+the	O
+infectious	B-DISO
+diseases	I-DISO
+that	O
+cause	O
+cases	O
+of	O
+morbidity	O
+and	O
+mortality	O
+and	O
+almost	O
+75	O
+%	O
+are	O
+emerging	O
+infections	B-DISO
+.	O
+
+Immigration	O
+and	O
+tourism	O
+are	O
+human	B-SPEC
+activities	O
+that	O
+are	O
+included	O
+in	O
+the	O
+broader	O
+field	O
+of	O
+human	B-SPEC
+migration	B-PROC
+and	O
+travel	O
+.	O
+
+The	O
+migration	B-PROC
+of	O
+humans	B-SPEC
+has	O
+provided	O
+the	O
+route	O
+of	O
+spread	O
+for	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+zoonoses	B-DISO
+(	O
+for	O
+example	O
+,	O
+plague	B-DISO
+,	O
+yellow	B-DISO
+fever	I-DISO
+,	O
+monkey	B-DISO
+pox	I-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+).	O
+
+ATF3	B-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+have	O
+greater	O
+sensitivity	O
+to	O
+mechanical	O
+ventilation	O
+alone	O
+or	O
+in	O
+conjunction	O
+with	O
+inhaled	B-PROC
+endotoxin	O
+,	O
+as	O
+demonstrated	O
+by	O
+increased	O
+cell	B-COMP
+infiltration	B-DISO
+and	O
+proinflammatory	O
+cytokines	O
+in	O
+the	O
+lung	B-ANAT
+and	O
+bronchoalveolar	O
+lavage	O
+,	O
+and	O
+increased	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+indices	O
+of	O
+tissue	B-ANAT
+injury	O
+.	O
+
+The	O
+RFLP	O
+analysis	O
+identified	O
+a	O
+change	O
+in	O
+the	O
+cleavage	B-PROC
+sites	O
+of	O
+AclI	O
+at	O
+passages	O
+155	O
+and	O
+165	O
+.	O
+
+The	O
+G3	O
+Chinese	O
+TGEVs	O
+possessed	O
+several	O
+specific	O
+nucleotides	B-CHED
+and	O
+amino	B-CHED
+acids	I-CHED
+that	O
+were	O
+not	O
+found	O
+in	O
+the	O
+G1	O
+and	O
+G2	O
+Chinese	O
+TGEVs	O
+or	O
+the	O
+other	O
+reference	O
+TGEVs	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+viral	B-DISO
+infection	I-DISO
+detected	O
+by	O
+PCR	O
+and	O
+RT	O
+-	O
+PCR	O
+in	O
+patients	O
+with	O
+acute	O
+exacerbation	O
+of	O
+COPD	O
+:	O
+a	O
+systematic	O
+review	O
+.	O
+
+picornavirus	B-SPEC
+was	O
+the	O
+most	O
+commonly	O
+detected	O
+virus	B-SPEC
+with	O
+WMP	O
+17	O
+.	O
+3	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+7	O
+.	O
+2	O
+-	O
+27	O
+.	O
+3	O
+),	O
+followed	O
+by	O
+influenza	B-DISO
+;	O
+7	O
+.	O
+4	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+2	O
+.	O
+9	O
+-	O
+12	O
+.	O
+0	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+;	O
+5	O
+.	O
+3	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+6	O
+-	O
+9	O
+.	O
+0	O
+),	O
+corona	B-CHED
+viruses	B-SPEC
+;	O
+3	O
+.	O
+1	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+4	O
+-	O
+5	O
+.	O
+8	O
+),	O
+parainfluenza	B-DISO
+;	O
+2	O
+.	O
+6	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+4	O
+-	O
+4	O
+.	O
+8	O
+),	O
+adenovirus	B-DISO
+;	O
+1	O
+.	O
+1	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+-	O
+1	O
+.	O
+1	O
+to	O
+3	O
+.	O
+3	O
+),	O
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+;	O
+0	O
+.	O
+7	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+-	O
+0	O
+.	O
+3	O
+to	O
+1	O
+.	O
+8	O
+).	O
+
+Picorna	O
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+detected	O
+in	O
+Western	O
+countries	O
+whereas	O
+influenza	B-DISO
+was	O
+most	O
+common	O
+in	O
+Asia	O
+.	O
+
+The	O
+peak	O
+coincided	O
+with	O
+the	O
+majority	O
+of	O
+SARS	B-DISO
+cases	O
+being	O
+reported	O
+in	O
+April	O
+2003	O
+.	O
+
+In	O
+this	O
+paper	O
+we	O
+examine	O
+the	O
+mechanism	O
+of	O
+how	O
+the	O
+SARS	B-DISO
+outbreak	O
+resulted	O
+in	O
+a	O
+higher	O
+completed	B-DISO
+suicide	I-DISO
+rate	O
+especially	O
+among	O
+older	O
+adults	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+SARS	B-DISO
+-	O
+related	O
+older	O
+adult	O
+suicide	O
+victims	O
+were	O
+more	O
+likely	O
+to	O
+be	O
+afraid	O
+of	O
+contracting	O
+the	O
+disease	O
+and	O
+had	O
+fears	O
+of	O
+disconnection	O
+.	O
+
+In	O
+addition	O
+,	O
+it	O
+is	O
+important	O
+to	O
+alert	O
+family	B-SPEC
+members	O
+to	O
+vulnerable	O
+individuals	O
+who	O
+are	O
+at	O
+potential	O
+risk	O
+because	O
+of	O
+their	O
+illnesses	O
+or	O
+anxieties	O
+.	O
+
+RESULTS	O
+:	O
+SARS	B-DISO
+-	O
+related	O
+older	O
+adult	O
+suicide	O
+victims	O
+were	O
+more	O
+likely	O
+to	O
+be	O
+afraid	O
+of	O
+contracting	O
+the	O
+disease	O
+and	O
+had	O
+fears	O
+of	O
+disconnection	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+provide	O
+an	O
+overview	O
+of	O
+the	O
+epidemiology	O
+of	O
+novel	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+human	B-SPEC
+bocavirus	I-SPEC
+,	O
+new	O
+subtypes	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+NL63	O
+and	O
+HKU1	O
+),	O
+KI	O
+virus	B-SPEC
+,	O
+WU	O
+virus	B-SPEC
+,	O
+and	O
+Melaka	O
+virus	B-SPEC
+in	O
+the	O
+Philippines	O
+,	O
+a	O
+tropical	O
+country	O
+.	O
+
+Human	B-PRGE
+metapneumovirus	I-PRGE
+,	I-PRGE
+human	B-SPEC
+bocavirus	I-SPEC
+,	I-PRGE
+human	B-SPEC
+coronavirus	I-SPEC
+HKU1	I-SPEC
+,	O
+KI	O
+virus	B-SPEC
+,	O
+and	O
+WU	O
+virus	B-SPEC
+were	O
+detected	O
+for	O
+the	O
+first	O
+time	O
+in	O
+the	O
+Philippines	O
+;	O
+Melaka	O
+virus	B-SPEC
+was	O
+not	O
+found	O
+.	O
+
+The	O
+coronavirus	B-PRGE
+main	I-PRGE
+protease	I-PRGE
+,	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+),	I-PRGE
+is	O
+a	O
+key	O
+target	O
+for	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+development	B-PROC
+because	O
+of	O
+its	O
+critical	O
+role	O
+in	O
+viral	B-PROC
+maturation	I-PROC
+and	O
+high	O
+degree	O
+of	O
+structural	O
+conservation	O
+among	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Alveolar	B-ANAT
+dead	B-PROC
+-	O
+space	O
+response	O
+to	O
+activated	B-PRGE
+protein	I-PRGE
+C	I-PRGE
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+complicated	O
+case	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+from	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+in	O
+which	O
+we	O
+measured	O
+the	O
+ratio	O
+of	O
+physiologic	O
+dead	B-PROC
+space	O
+to	O
+tidal	O
+volume	O
+(	O
+V	O
+(	O
+D	O
+)/	O
+V	O
+(	O
+T	O
+))	O
+with	O
+volumetric	O
+capnography	O
+prior	O
+to	O
+,	O
+during	O
+,	O
+and	O
+after	O
+therapy	O
+with	O
+human	B-SPEC
+recombinant	O
+activated	O
+protein	B-CHED
+C	O
+.	O
+Previous	O
+studies	O
+hypothesized	O
+that	O
+early	O
+in	O
+ARDS	B-DISO
+,	O
+elevated	O
+V	O
+(	O
+D	O
+)/	O
+V	O
+(	O
+T	O
+)	O
+primarily	O
+reflects	O
+increased	O
+alveolar	B-ANAT
+V	O
+(	O
+D	O
+),	O
+probably	O
+caused	O
+by	O
+pronounced	O
+thrombi	B-DISO
+formation	B-PROC
+in	O
+the	O
+pulmonary	B-ANAT
+microvasculature	B-PROC
+.	O
+
+Thus	O
+,	O
+improved	O
+alveolar	B-ANAT
+perfusion	O
+persisted	O
+despite	O
+signs	O
+of	O
+alveolar	B-ANAT
+de	O
+-	O
+recruitment	B-DISO
+.	O
+
+TITLE	O
+:	O
+In	O
+vitro	O
+reconstitution	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+mRNA	B-CHED
+cap	B-DISO
+methylation	B-PROC
+.	O
+
+We	O
+show	O
+that	O
+mRNA	B-CHED
+cap	B-DISO
+methylation	B-PROC
+requires	O
+a	O
+third	O
+viral	O
+protein	B-CHED
+,	O
+nsp10	O
+,	O
+which	O
+acts	O
+as	O
+an	O
+essential	O
+trigger	O
+to	O
+complete	O
+RNA	O
+cap	B-DISO
+-	O
+1	O
+formation	B-PROC
+.	O
+
+The	O
+obligate	O
+sequence	O
+of	O
+methylation	B-PROC
+events	O
+is	O
+initiated	O
+by	O
+nsp14	O
+,	O
+which	O
+first	O
+methylates	O
+capped	O
+RNA	O
+transcripts	O
+to	O
+generate	O
+cap	O
+-	O
+0	O
+(	O
+7Me	O
+)	O
+GpppA	O
+-	O
+RNAs	O
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+induces	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+in	O
+oligodendrocytes	B-ANAT
+through	O
+recognition	O
+by	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+MDA5	B-PRGE
+.	O
+
+We	O
+show	O
+that	O
+MHV	B-SPEC
+infection	B-DISO
+activated	O
+both	O
+transcription	B-PROC
+factors	O
+,	O
+the	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+)	O
+and	O
+nuclear	B-PRGE
+factor	I-PRGE
+kappaB	I-PRGE
+(	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+),	O
+as	O
+evidenced	O
+by	O
+phosphorylation	B-PROC
+and	O
+nuclear	B-PROC
+translocation	I-PROC
+of	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+an	O
+increased	O
+promoter	O
+binding	B-PROC
+activity	I-PROC
+for	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+.	O
+Furthermore	O
+,	O
+the	O
+cytoplasmic	B-PRGE
+pattern	I-PRGE
+recognition	I-PRGE
+receptor	I-PRGE
+retinoic	B-CHED
+acid	I-CHED
+-	O
+inducible	O
+gene	B-PRGE
+I	I-PRGE
+(	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+was	O
+induced	O
+by	O
+MHV	B-SPEC
+infection	B-DISO
+.	O
+
+Knockdown	O
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+by	O
+small	O
+interfering	O
+RNAs	O
+blocked	O
+the	O
+activation	O
+of	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+subsequent	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+production	O
+induced	O
+by	O
+MHV	B-SPEC
+infection	B-DISO
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+MHV	B-SPEC
+is	O
+recognized	O
+by	O
+both	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+MDA5	B-PRGE
+and	O
+induces	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+through	O
+the	O
+activation	O
+of	O
+the	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+Kolobow	O
+and	O
+Gattinoni	O
+were	O
+the	O
+first	O
+to	O
+introduce	O
+extracorporeal	O
+support	O
+,	O
+with	O
+the	O
+intent	O
+to	O
+separate	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+from	O
+oxygen	B-CHED
+uptake	O
+;	O
+they	O
+hypothesized	O
+that	O
+to	O
+allow	O
+the	O
+lung	B-ANAT
+to	O
+'	B-FUNC
+rest	I-FUNC
+'	O
+oxygenation	B-PROC
+via	O
+mechanical	O
+ventilation	O
+could	O
+be	O
+dissociated	O
+from	O
+decarboxylation	O
+via	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+.	O
+
+The	O
+focus	O
+was	O
+that	O
+,	O
+in	O
+case	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+CO	O
+(	O
+2	O
+)	O
+extraction	O
+facilitates	O
+a	O
+reduction	O
+in	O
+ventilatory	O
+support	O
+and	O
+oxygenation	O
+is	O
+maintained	O
+by	O
+simple	O
+diffusion	O
+across	O
+the	O
+patient	O
+'	O
+s	O
+alveoli	B-ANAT
+,	O
+called	O
+'	B-DISO
+apneic	I-DISO
+oxygenation	B-PROC
+'.	O
+
+ABSTRACT	O
+:	O
+The	O
+year	O
+2009	O
+was	O
+characterized	O
+by	O
+a	O
+pandemic	O
+with	O
+a	O
+new	O
+virus	O
+,	O
+the	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+.	O
+
+Severe	O
+falciparum	B-DISO
+malaria	I-DISO
+is	O
+an	O
+important	O
+cause	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+in	O
+Indian	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+patients	O
+.	O
+
+Jaundice	B-DISO
+with	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+was	O
+the	O
+most	O
+common	O
+presentation	O
+(	O
+13	O
+.	O
+28	O
+percent	O
+),	O
+followed	O
+by	O
+cerebral	B-DISO
+malaria	B-PATH
+with	O
+jaundice	B-DISO
+and	O
+ARF	B-DISO
+(	O
+6	O
+.	O
+37	O
+percent	O
+),	O
+and	O
+jaundice	B-DISO
+,	O
+ARF	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+(	O
+5	O
+.	O
+31	O
+percent	O
+).	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+AMAN	O
+variant	O
+of	O
+GBS	B-DISO
+associated	O
+with	O
+proven	O
+H1N1	B-DISO
+influenza	B-PATH
+A	I-PATH
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+zoonoses	B-DISO
+on	O
+human	B-SPEC
+health	O
+.	O
+
+An	O
+underlying	O
+condition	B-DISO
+was	O
+present	O
+in	O
+83	O
+%	O
+of	O
+the	O
+patients	O
+.	O
+
+None	O
+of	O
+them	O
+had	O
+bronchiolitis	B-DISO
+on	O
+PICU	B-SPEC
+admission	O
+;	O
+12	O
+(	O
+40	O
+%)	O
+had	O
+bilateral	B-DISO
+pneumonia	I-DISO
+;	O
+15	O
+(	O
+50	O
+%)	O
+had	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+and	O
+nine	O
+(	O
+30	O
+%)	O
+had	O
+shock	O
+.	O
+
+When	O
+both	O
+groups	O
+were	O
+compared	O
+,	O
+patients	O
+with	O
+influenza	B-PATH
+A	I-PATH
+pH1N1	O
+infection	B-DISO
+were	O
+older	O
+;	O
+pneumonia	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+shock	O
+were	O
+more	O
+frequently	O
+seen	O
+at	O
+the	O
+time	O
+of	O
+PICU	B-SPEC
+admission	O
+,	O
+although	O
+length	O
+of	O
+stay	O
+and	O
+mortality	O
+were	O
+similar	O
+.	O
+
+The	O
+RT	O
+-	O
+nPCR	O
+method	O
+can	O
+be	O
+used	O
+to	O
+effectively	O
+detect	O
+and	O
+differentiate	O
+wild	O
+-	O
+type	O
+CDV	B-CHED
+-	O
+infected	O
+dogs	B-SPEC
+from	O
+dogs	B-SPEC
+vaccinated	O
+with	O
+CDV	B-CHED
+vaccine	O
+,	O
+and	O
+thus	O
+can	O
+be	O
+used	O
+in	O
+clinical	O
+detection	O
+and	O
+epidemiological	O
+surveillance	O
+.	O
+
+The	O
+usefulness	O
+of	O
+procalcitonin	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+as	O
+indicators	O
+of	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+viral	B-DISO
+infection	I-DISO
+in	O
+this	O
+setting	O
+also	O
+needs	O
+to	O
+be	O
+evaluated	O
+.	O
+
+In	O
+our	O
+study	O
+,	O
+serum	B-COMP
+procalcitonin	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+did	O
+not	O
+discriminate	O
+virus	B-SPEC
+-	O
+associated	O
+exacerbations	O
+from	O
+others	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+feline	O
+infectious	O
+peritonitis	O
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+is	O
+a	O
+mutated	O
+form	O
+of	O
+the	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FeCV	B-SPEC
+)	O
+that	O
+can	O
+present	O
+with	O
+a	O
+variety	O
+of	O
+clinical	O
+signs	O
+.	O
+
+Although	O
+none	O
+of	O
+these	O
+ultrasonographic	O
+findings	O
+are	O
+specific	O
+for	O
+FIPV	O
+infection	B-DISO
+,	O
+a	O
+combination	O
+of	O
+these	O
+findings	O
+should	O
+increase	O
+the	O
+index	O
+of	O
+suspicion	O
+for	O
+FIPV	O
+infection	B-DISO
+when	O
+considered	O
+along	O
+with	O
+appropriate	O
+clinical	O
+signs	O
+.	O
+
+One	O
+alternative	O
+to	O
+the	O
+use	O
+of	O
+soyabean	O
+oil	O
+is	O
+its	O
+partial	O
+replacement	O
+by	O
+fish	B-SPEC
+oil	O
+,	O
+which	O
+contains	O
+n	O
+-	O
+3	O
+fatty	B-CHED
+acids	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+3C	O
+-	O
+like	O
+proteinase	B-PROC
+(	O
+3CLpro	O
+),	O
+located	O
+in	O
+nonstructural	B-PRGE
+protein	I-PRGE
+5	I-PRGE
+(	O
+nsp5	B-PRGE
+),	O
+processes	O
+the	O
+replicase	B-PRGE
+polyproteins	I-PRGE
+1a	I-PRGE
+and	I-PRGE
+1ab	I-PRGE
+(	O
+pp1a	B-PRGE
+and	O
+pp1ab	O
+)	O
+at	O
+11	O
+specific	O
+sites	O
+to	O
+produce	O
+12	O
+mature	O
+nonstructural	O
+proteins	B-CHED
+(	O
+nsp5	B-PRGE
+to	O
+nsp16	O
+).	O
+
+Here	O
+,	O
+we	O
+investigate	O
+the	O
+effects	O
+of	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+at	O
+the	O
+P1	O
+position	O
+of	O
+3CLpro	O
+cleavage	B-PROC
+sites	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+on	O
+the	O
+cleavage	B-PROC
+efficiency	O
+and	O
+viral	B-PROC
+replication	I-PROC
+by	O
+in	O
+vitro	O
+cleavage	B-PROC
+assays	O
+and	O
+reverse	O
+genetic	O
+approaches	O
+.	O
+
+The	O
+serum	B-COMP
+levels	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+IL	B-PRGE
+-	I-PRGE
+4	I-PRGE
+in	I-PRGE
+groups	I-PRGE
+1	I-PRGE
+-	I-PRGE
+4	I-PRGE
+were	O
+higher	O
+than	O
+those	O
+in	O
+groups	O
+5	O
+and	O
+6	O
+.	O
+
+Therapeutic	O
+plasma	B-ANAT
+exchange	O
+was	O
+used	O
+as	O
+a	O
+rescue	O
+strategy	O
+.	O
+
+This	O
+very	O
+limited	O
+case	O
+series	O
+suggest	O
+there	O
+may	O
+be	O
+a	O
+role	O
+for	O
+therapeutic	O
+plasma	B-ANAT
+exchange	O
+as	O
+a	O
+rescue	O
+therapy	O
+in	O
+severe	O
+shock	O
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+related	O
+to	O
+pH1N1	O
+that	O
+has	O
+not	O
+responded	O
+to	O
+traditional	O
+therapy	O
+.	O
+
+We	O
+identified	O
+and	O
+analyzed	O
+all	O
+published	O
+articles	O
+on	O
+the	O
+epidemiology	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+Hong	O
+Kong	O
+or	O
+Toronto	O
+.	O
+
+To	O
+facilitate	O
+information	O
+dissemination	O
+,	O
+journal	O
+managers	O
+should	O
+reengineer	O
+their	O
+fast	B-FUNC
+-	O
+track	O
+channels	O
+,	O
+which	O
+should	O
+be	O
+adapted	O
+to	O
+the	O
+purpose	O
+of	O
+an	O
+emerging	O
+outbreak	O
+,	O
+taking	O
+into	O
+account	O
+the	O
+requirement	O
+of	O
+high	O
+standards	O
+of	O
+quality	O
+for	O
+scientific	O
+journals	O
+and	O
+competition	O
+with	O
+other	O
+online	O
+resources	O
+.	O
+
+Pulmonary	B-ANAT
+pseudocysts	B-DISO
+are	O
+reported	O
+in	O
+adults	O
+recovering	O
+from	O
+ARDS	B-DISO
+,	O
+usually	O
+in	O
+non	O
+-	O
+dependent	O
+lung	B-ANAT
+regions	O
+.	O
+
+TITLE	O
+:	O
+Two	O
+fatal	O
+cases	O
+of	O
+hidden	O
+pneumonia	B-DISO
+in	O
+young	O
+people	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+lung	B-DISO
+disease	I-DISO
+characterized	O
+by	O
+inflammation	B-DISO
+of	O
+the	O
+lung	B-ANAT
+parenchyma	I-ANAT
+leading	O
+to	O
+impaired	B-DISO
+gas	I-DISO
+exchange	I-DISO
+.	O
+
+In	O
+both	O
+cases	O
+the	O
+cause	O
+of	O
+death	B-PROC
+was	O
+cardio	B-DISO
+-	I-DISO
+respiratory	I-DISO
+failure	I-DISO
+following	O
+an	O
+acute	O
+bilateral	B-DISO
+pneumonia	I-DISO
+with	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+and	O
+ARDS	B-DISO
+associated	O
+with	O
+sepsis	B-DISO
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+.	O
+
+Although	O
+many	O
+tools	O
+have	O
+been	O
+developed	O
+for	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+,	O
+false	O
+-	O
+positive	O
+reactions	O
+in	O
+negative	O
+sera	B-COMP
+may	O
+occur	O
+because	O
+of	O
+cross	O
+-	O
+reactivity	O
+with	O
+other	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+viruses	B-SPEC
+(	O
+IBVs	O
+)	O
+isolated	O
+from	O
+commercial	O
+layer	B-ANAT
+flocks	O
+kept	O
+in	O
+Ibaraki	O
+Prefecture	O
+in	O
+2009	O
+were	O
+genetically	O
+and	O
+serologically	O
+characterized	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrate	O
+that	O
+the	O
+-	O
+123A	O
+minor	O
+allele	O
+provided	O
+stronger	O
+binding	B-FUNC
+affinity	O
+to	O
+nuclear	O
+proteins	B-CHED
+extracted	O
+from	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+-	O
+untreated	O
+cells	B-COMP
+than	O
+did	O
+the	O
+wild	O
+-	O
+type	O
+allele	O
+,	O
+whereas	O
+the	O
+-	O
+88T	O
+allele	O
+showed	O
+preferential	O
+binding	B-FUNC
+after	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+stimulation	O
+.	O
+
+Rarely	O
+,	O
+patients	O
+develop	O
+severe	O
+pulmonary	B-DISO
+infection	I-DISO
+that	O
+progresses	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+has	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+Updated	O
+guidelines	O
+from	O
+the	O
+Infectious	O
+Diseases	O
+Society	O
+of	O
+America	O
+are	O
+available	O
+to	O
+aid	O
+clinicians	O
+in	O
+the	O
+management	O
+of	O
+the	O
+various	O
+forms	O
+of	O
+blastomycosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Infidelity	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Nsp14	I-PRGE
+-	I-PRGE
+exonuclease	I-PRGE
+mutant	B-DISO
+virus	B-PROC
+replication	I-PROC
+is	O
+revealed	O
+by	O
+complete	O
+genome	O
+sequencing	O
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+RNA	O
+viruses	O
+lack	O
+the	O
+mechanisms	O
+to	O
+recognize	O
+and	O
+correct	O
+mutations	O
+that	O
+arise	O
+during	O
+genome	O
+replication	O
+,	O
+resulting	O
+in	O
+quasispecies	O
+diversity	O
+that	O
+is	O
+required	O
+for	O
+pathogenesis	B-DISO
+and	O
+adaptation	B-PROC
+.	O
+
+Using	O
+novel	O
+bioinformatic	O
+tools	O
+and	O
+deep	O
+sequencing	O
+across	O
+the	O
+full	O
+-	O
+length	O
+genome	O
+following	O
+10	O
+population	O
+passages	O
+in	O
+vitro	O
+,	O
+we	O
+demonstrate	O
+retention	B-PROC
+of	O
+ExoN	O
+mutations	O
+and	O
+continued	O
+increased	O
+diversity	O
+and	O
+mutational	O
+load	O
+compared	O
+to	O
+wild	O
+-	O
+type	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+results	O
+define	O
+a	O
+novel	O
+genetic	O
+and	O
+bioinformatics	O
+model	O
+for	O
+introduction	O
+and	O
+identification	O
+of	O
+multi	O
+-	O
+allelic	O
+mutations	O
+in	O
+replication	O
+competent	O
+viruses	B-SPEC
+that	O
+will	O
+be	O
+powerful	O
+tools	O
+for	O
+testing	O
+the	O
+effects	O
+of	O
+decreased	O
+fidelity	O
+and	O
+increased	O
+quasispecies	O
+diversity	O
+on	O
+viral	B-PROC
+replication	I-PROC
+,	O
+pathogenesis	B-DISO
+,	O
+and	O
+evolution	B-PROC
+.	O
+
+The	O
+parameters	O
+were	O
+compared	O
+with	O
+a	O
+control	O
+group	O
+(	O
+n	O
+=	O
+8	O
+),	O
+receiving	O
+only	O
+PRCV	B-PRGE
+-	I-PRGE
+LPS	I-PRGE
+.	O
+
+Anti	O
+-	O
+Toxoplasma	B-SPEC
+gondii	I-SPEC
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+47	O
+/	O
+194	O
+samples	O
+(	O
+24	O
+.	O
+2	O
+%);	O
+anti	O
+-	O
+Leishmania	B-SPEC
+infantum	I-SPEC
+antibodies	B-COMP
+in	O
+1	O
+/	O
+180	O
+cats	B-SPEC
+(	O
+0	O
+.	O
+6	O
+%);	O
+intestinal	B-DISO
+parasites	I-DISO
+in	O
+23	O
+/	O
+74	O
+samples	O
+(	O
+Toxocara	B-SPEC
+cati	I-SPEC
+,	O
+Isospora	B-SPEC
+felis	I-SPEC
+,	O
+Ancylostoma	B-SPEC
+tubaeforme	I-SPEC
+,	O
+Dipylidium	B-SPEC
+caninum	I-SPEC
+,	O
+Uncinaria	B-SPEC
+stenocephala	I-SPEC
+,	O
+Toxascaris	B-SPEC
+leonina	I-SPEC
+)	O
+and	O
+Otodectes	B-SPEC
+cynotis	I-SPEC
+in	O
+4	O
+/	O
+182	O
+cats	B-SPEC
+(	O
+2	O
+.	O
+2	O
+%);	O
+dermatophyte	B-SPEC
+fungi	B-SPEC
+were	O
+isolated	O
+in	O
+40	O
+/	O
+136	O
+samples	O
+(	O
+29	O
+.	O
+4	O
+%);	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+23	O
+/	O
+226	O
+samples	O
+(	O
+10	O
+.	O
+2	O
+%);	O
+feline	O
+leukaemia	B-DISO
+virus	B-SPEC
+antigen	B-CHED
+in	O
+14	O
+/	O
+198	O
+samples	O
+(	O
+7	O
+.	O
+1	O
+%);	O
+and	O
+feline	B-SPEC
+coronavirus	B-SPEC
+RNA	O
+in	O
+9	O
+/	O
+127	O
+samples	O
+(	O
+7	O
+.	O
+1	O
+%).	O
+
+Our	O
+results	O
+revealed	O
+that	O
+zoonotic	O
+agents	O
+,	O
+namely	O
+dermatophyte	B-SPEC
+fungi	B-SPEC
+and	O
+Toxocara	B-SPEC
+cati	I-SPEC
+were	O
+present	O
+in	O
+stray	O
+cat	B-SPEC
+colonies	O
+in	O
+the	O
+investigated	O
+counties	O
+.	O
+
+Overall	O
+the	O
+low	O
+frequency	O
+of	O
+major	O
+pathogens	O
+suggests	O
+a	O
+balanced	O
+relationship	O
+between	O
+host	B-COMP
+and	O
+agents	O
+.	O
+
+In	O
+the	O
+cathepsin	B-PRGE
+L	I-PRGE
+inhibition	B-PROC
+assay	O
+,	O
+the	O
+oxocarbazate	O
+caused	O
+a	O
+time	O
+-	O
+dependent	O
+17	O
+-	O
+fold	O
+drop	O
+in	O
+IC	O
+(	O
+50	O
+)	O
+from	O
+6	O
+.	O
+9	O
+nM	O
+(	O
+no	O
+preincubation	O
+)	O
+to	O
+0	O
+.	O
+4	O
+nM	O
+(	O
+4	O
+-	O
+h	O
+preincubation	O
+).	O
+
+A	O
+transient	O
+kinetic	O
+analysis	O
+using	O
+a	O
+single	O
+-	O
+step	O
+competitive	B-PROC
+inhibition	I-PROC
+model	O
+provided	O
+rate	O
+constants	O
+of	O
+k	O
+(	O
+on	O
+)	O
+=	O
+153	O
+,	O
+000	O
+M	O
+(-	O
+1	O
+)	O
+s	O
+(-	O
+1	O
+)	O
+and	O
+k	O
+(	O
+off	O
+)	O
+=	O
+4	O
+.	O
+40	O
+x	O
+10	O
+(-	O
+5	O
+)	O
+s	O
+(-	O
+1	O
+)	O
+(	O
+K	O
+(	O
+i	O
+)	O
+=	O
+0	O
+.	O
+29	O
+nM	O
+).	O
+
+These	O
+included	O
+proteins	B-CHED
+regulated	O
+by	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+-	O
+and	O
+AP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+dependent	O
+pathways	B-PROC
+and	O
+proteins	B-CHED
+involved	O
+in	O
+the	O
+cytoskeleton	B-COMP
+and	O
+molecular	O
+motors	O
+.	O
+
+This	O
+research	O
+is	O
+the	O
+first	O
+application	O
+of	O
+SILAC	O
+to	O
+study	O
+total	O
+host	B-COMP
+cell	I-COMP
+proteome	O
+changes	O
+in	O
+response	O
+to	O
+positive	O
+sense	B-PROC
+RNA	B-DISO
+virus	I-DISO
+infection	I-DISO
+and	O
+illustrates	O
+the	O
+versatility	O
+of	O
+this	O
+technique	O
+as	O
+applied	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+research	O
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+neutrophil	I-PRGE
+cytoplasmic	B-COMP
+antibody	B-COMP
+(	O
+ANCA	B-PRGE
+)	O
+associated	O
+vasculitis	B-DISO
+""""	O
+and	O
+glomerular	B-ANAT
+basement	I-ANAT
+membrane	I-ANAT
+"("""	O
+Goodpasture	O
+'	O
+s	O
+""")"	O
+disease	O
+are	O
+the	O
+commonest	O
+causes	O
+but	O
+other	O
+pathologies	O
+including	O
+systemic	B-PATH
+lupus	I-PATH
+erythematosus	I-PATH
+and	O
+the	O
+anti	B-DISO
+-	I-DISO
+phospholipid	I-DISO
+syndrome	I-DISO
+are	O
+also	O
+implicated	O
+.	O
+
+TITLE	O
+:	O
+Indications	O
+for	O
+blood	B-ANAT
+purification	O
+in	O
+critical	O
+care	O
+.	O
+
+As	O
+an	O
+artificial	O
+kidney	B-ANAT
+,	O
+continuous	O
+blood	B-ANAT
+purification	O
+(	O
+such	O
+as	O
+continuous	O
+hemofiltration	O
+and	O
+continuous	O
+hemodiafiltration	O
+,	O
+CHDF	O
+)	O
+is	O
+widely	O
+applied	O
+in	O
+intensive	O
+care	O
+units	O
+.	O
+
+However	O
+,	O
+our	O
+understanding	O
+of	O
+the	O
+pathophysiology	O
+of	O
+sepsis	B-DISO
+has	O
+changed	O
+since	O
+the	O
+concept	O
+of	O
+pattern	O
+recognition	O
+receptors	O
+and	O
+pathogen	O
+-	O
+associated	O
+molecular	O
+patterns	O
+was	O
+introduced	O
+.	O
+
+Of	O
+126	O
+eligible	O
+patients	O
+,	O
+99	O
+survived	O
+>	O
+or	O
+=	O
+3	O
+months	O
+after	O
+critical	B-DISO
+illness	I-DISO
+;	O
+long	O
+-	O
+term	O
+cognitive	O
+outcomes	O
+were	O
+obtained	O
+for	O
+77	O
+(	O
+78	O
+%)	O
+patients	O
+.	O
+
+At	O
+3	O
+-	O
+mo	O
+and	O
+12	O
+-	O
+mo	O
+follow	O
+-	O
+up	O
+,	O
+79	O
+%	O
+and	O
+71	O
+%	O
+of	O
+survivors	O
+had	O
+cognitive	B-DISO
+impairment	I-DISO
+,	O
+respectively	O
+(	O
+with	O
+62	O
+%	O
+and	O
+36	O
+%	O
+being	O
+severely	O
+impaired	O
+).	O
+
+Duration	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+alternatively	O
+,	O
+was	O
+not	O
+associated	O
+with	O
+long	O
+-	O
+term	O
+cognitive	B-DISO
+impairment	I-DISO
+(	O
+p	O
+=.	O
+20	O
+and	O
+.	O
+58	O
+).	O
+
+In	O
+this	O
+study	O
+of	O
+mechanically	O
+ventilated	O
+medical	O
+intensive	O
+care	O
+unit	O
+patients	O
+,	O
+duration	O
+of	O
+delirium	B-DISO
+(	O
+which	O
+is	O
+potentially	O
+modifiable	O
+)	O
+was	O
+independently	O
+associated	O
+with	O
+long	O
+-	O
+term	O
+cognitive	B-DISO
+impairment	I-DISO
+,	O
+a	O
+common	O
+public	O
+health	O
+problem	O
+among	O
+intensive	O
+care	O
+unit	O
+survivors	O
+.	O
+
+TITLE	O
+:	O
+Prone	O
+positioning	O
+improves	O
+survival	O
+in	O
+severe	O
+ARDS	B-DISO
+:	O
+a	O
+pathophysiologic	O
+review	O
+and	O
+individual	O
+patient	O
+meta	O
+-	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Prone	O
+positioning	O
+has	O
+been	O
+used	O
+for	O
+over	O
+30	O
+years	O
+in	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+all	O
+data	O
+suggest	O
+that	O
+long	O
+-	O
+term	O
+prone	O
+positioning	O
+may	O
+expose	O
+patients	O
+with	O
+less	O
+severe	O
+ARDS	B-DISO
+to	O
+unnecessary	O
+complications	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+the	O
+public	O
+health	O
+control	O
+measures	O
+implemented	O
+in	O
+Singapore	O
+to	O
+limit	O
+the	O
+spread	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+-	O
+2009	O
+)	O
+and	O
+mitigate	O
+its	O
+social	O
+effects	O
+.	O
+
+Contact	O
+tracing	O
+and	O
+QOs	O
+tapered	O
+off	O
+,	O
+and	O
+border	B-ANAT
+temperature	O
+screening	O
+ended	O
+.	O
+
+Documenting	O
+the	O
+measures	O
+taken	O
+and	O
+lessons	O
+learnt	O
+provides	O
+a	O
+learning	B-PROC
+opportunity	O
+for	O
+both	O
+doctors	O
+and	O
+policy	O
+makers	O
+,	O
+and	O
+can	O
+help	O
+fortify	O
+Singapore	O
+'	O
+s	O
+ability	O
+to	O
+respond	O
+to	O
+future	O
+major	O
+disease	O
+outbreaks	O
+.	O
+
+Furthermore	O
+,	O
+these	O
+therapies	O
+are	O
+already	O
+used	O
+clinically	O
+for	O
+other	O
+conditions	O
+and	O
+could	O
+readily	O
+be	O
+tested	O
+in	O
+clinical	O
+studies	O
+of	O
+alcoholics	O
+at	O
+high	O
+risk	O
+for	O
+ARDS	B-DISO
+and	O
+/	O
+or	O
+with	O
+severe	O
+lung	B-ANAT
+infections	B-DISO
+.	O
+
+The	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+NP	O
+)	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+may	O
+be	O
+critical	O
+for	O
+pathogenicity	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+intermittent	O
+noninvasive	O
+ventilation	O
+for	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+in	O
+adults	O
+with	O
+sickle	B-ANAT
+cell	B-COMP
+disease	I-DISO
+:	O
+a	O
+pilot	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Alveolar	B-ANAT
+hypoxia	B-DISO
+and	O
+hypoxic	B-DISO
+vasoconstriction	B-DISO
+lead	O
+to	O
+trapping	O
+of	O
+sickle	B-ANAT
+cells	I-ANAT
+within	O
+the	O
+pulmonary	B-ANAT
+vasculature	I-ANAT
+.	O
+
+NIV	O
+promptly	O
+lowered	O
+the	O
+respiratory	O
+rate	O
+,	O
+raised	O
+PaO2	O
+,	O
+and	O
+decreased	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-CHED
+gradient	O
+((	O
+A	O
+-	O
+a	O
+)	O
+O2	O
+),	O
+which	O
+remained	O
+unchanged	O
+with	O
+oxygen	B-CHED
+alone	O
+.	O
+
+PaCO2significantly	O
+worsened	O
+only	O
+in	O
+the	O
+oxygen	B-CHED
+group	O
+.	O
+
+RESULTS	O
+:	O
+Seventy	O
+-	O
+one	O
+consecutive	O
+ACS	B-FUNC
+episodes	O
+in	O
+67	O
+patients	O
+were	O
+randomly	O
+allocated	O
+to	O
+oxygen	B-CHED
+(	O
+n	O
+=	O
+36	O
+)	O
+or	O
+NIV	O
+(	O
+n	O
+=	O
+35	O
+)	O
+for	O
+3	O
+days	O
+in	O
+a	O
+medical	O
+step	O
+-	O
+down	O
+unit	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+serious	O
+and	O
+fatal	O
+pulmonary	B-ANAT
+manifestation	O
+.	O
+
+TITLE	O
+:	O
+Varicella	B-DISO
+zoster	I-DISO
+virus	I-SPEC
+in	O
+progressive	O
+forms	O
+of	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+Both	O
+,	O
+the	O
+molecular	O
+and	O
+the	O
+ultrastructural	O
+evidence	O
+of	O
+VZV	B-SPEC
+became	O
+negative	O
+in	O
+the	O
+same	O
+patients	O
+at	O
+the	O
+time	O
+of	O
+remission	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+we	O
+investigated	O
+the	O
+role	O
+of	O
+the	O
+UPS	O
+in	O
+different	O
+steps	O
+of	O
+the	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infection	B-DISO
+cycle	O
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+viruses	B-SPEC
+,	O
+including	O
+coronaviruses	O
+(	O
+CoVs	O
+),	O
+depend	O
+on	O
+a	O
+functional	O
+cellular	B-COMP
+proteasome	B-PATH
+for	O
+efficient	O
+infection	B-DISO
+in	O
+vitro	O
+.	O
+
+No	O
+patients	O
+on	O
+V	O
+-	O
+A	O
+ECLS	O
+support	O
+after	O
+cardiac	B-DISO
+arrest	I-DISO
+survived	O
+(	O
+N	O
+=	O
+4	O
+).	O
+
+We	O
+constructed	O
+a	O
+large	O
+protein	B-CHED
+containing	O
+the	O
+cyan	O
+fluorescent	O
+protein	B-CHED
+(	O
+C	O
+),	O
+the	O
+N	O
+-	O
+terminal	O
+flanking	O
+substrate	O
+peptide	B-CHED
+of	O
+SARS	B-DISO
+3CL	O
+(	O
+pro	B-CHED
+)	O
+(	O
+XX	O
+),	O
+SARS	B-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+(	I-PRGE
+3CLP	I-PRGE
+),	I-PRGE
+and	O
+the	O
+yellow	O
+fluorescent	O
+protein	B-CHED
+(	O
+Y	O
+)	O
+to	O
+study	O
+the	O
+autoprocessing	O
+of	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+using	O
+fluorescence	O
+resonance	O
+energy	B-PROC
+transfer	I-PROC
+.	O
+
+As	O
+many	O
+viral	O
+proteases	O
+undergo	O
+a	O
+similar	O
+maturation	B-PROC
+process	O
+,	O
+this	O
+model	O
+might	O
+be	O
+generally	O
+applicable	O
+.	O
+
+Another	O
+area	O
+in	O
+middle	O
+-	O
+west	O
+Sweden	O
+(	O
+Värmland	O
+-	O
+Dalarna	O
+)	O
+had	O
+also	O
+a	O
+lower	O
+prevalence	O
+for	O
+BRSV	B-SPEC
+(	O
+7	O
+.	O
+9	O
+%).	O
+
+These	O
+compounds	O
+are	O
+inhibitors	B-CHED
+of	O
+the	O
+HCV	B-PRGE
+NS3	B-DISO
+serine	B-CHED
+protease	I-PRGE
+,	O
+and	O
+structural	O
+studies	O
+show	O
+that	O
+they	O
+inhibit	O
+the	O
+NS3	B-PRGE
+protease	I-PRGE
+by	O
+trapping	O
+the	O
+Ser	B-COMP
+-	O
+139	O
+hydroxyl	B-CHED
+group	I-CHED
+in	O
+the	O
+active	O
+site	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+unique	O
+domain	O
+:	O
+three	O
+-	O
+domain	O
+molecular	O
+architecture	O
+in	O
+solution	O
+and	O
+RNA	B-FUNC
+binding	I-FUNC
+.	O
+
+ABSTRACT	O
+:	O
+Nonstructural	O
+protein	B-CHED
+3	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+includes	O
+a	O
+""""	O
+SARS	B-DISO
+-	O
+unique	O
+domain	O
+""""	O
+(	O
+SUD	O
+)	O
+consisting	O
+of	O
+three	O
+globular	O
+domains	O
+separated	O
+by	O
+short	O
+linker	O
+peptide	B-CHED
+segments	O
+.	O
+
+SUD	O
+-	O
+C	O
+adopts	O
+a	O
+frataxin	O
+like	O
+fold	O
+and	O
+has	O
+structural	O
+similarity	O
+to	O
+DNA	O
+-	O
+binding	B-FUNC
+domains	O
+of	O
+DNA	O
+-	O
+modifying	O
+enzymes	O
+.	O
+
+Overall	O
+,	O
+the	O
+present	O
+data	O
+provide	O
+evidence	O
+for	O
+molecular	O
+mechanisms	O
+involving	O
+the	O
+concerted	O
+actions	O
+of	O
+SUD	O
+-	O
+M	O
+and	O
+SUD	O
+-	O
+C	O
+,	O
+which	O
+result	O
+in	O
+specific	O
+RNA	B-FUNC
+binding	I-FUNC
+that	O
+might	O
+be	O
+unique	O
+to	O
+the	O
+SUD	O
+and	O
+,	O
+thus	O
+,	O
+to	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+,	O
+docking	B-PROC
+studies	O
+,	O
+and	O
+evaluation	O
+of	O
+pyrimidines	B-CHED
+as	O
+inhibitors	B-CHED
+of	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+examines	O
+how	O
+companies	O
+'	O
+pandemic	O
+response	O
+planning	O
+has	O
+evolved	O
+from	O
+the	O
+2002	O
+SARS	B-DISO
+epidemic	O
+through	O
+to	O
+the	O
+H1N1	O
+pandemic	O
+that	O
+emerged	O
+in	O
+2009	O
+.	O
+
+The	O
+does	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+corresponding	O
+to	O
+10	O
+%	O
+and	O
+50	O
+%	O
+responses	O
+(	O
+illness	O
+)	O
+were	O
+estimated	O
+at	O
+43	O
+and	O
+280	O
+PFU	B-CHED
+,	O
+respectively	O
+.	O
+
+The	O
+estimated	O
+dose	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+for	O
+apartment	O
+residents	O
+during	O
+the	O
+outbreak	O
+,	O
+which	O
+was	O
+back	B-ANAT
+-	O
+calculated	O
+from	O
+the	O
+reported	O
+number	O
+of	O
+cases	O
+,	O
+ranged	O
+from	O
+16	O
+to	O
+160	O
+PFU	B-CHED
+/	O
+person	O
+,	O
+depending	O
+on	O
+the	O
+floor	O
+.	O
+
+The	O
+lung	B-PRGE
+ET	I-PRGE
+-	I-PRGE
+1	I-PRGE
+level	O
+in	O
+the	O
+VT20	O
+group	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+in	O
+the	O
+VT6	O
+group	O
+and	O
+VT10	O
+group	O
+(	O
+both	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+while	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+lung	B-ANAT
+NO	O
+levels	O
+between	O
+two	O
+groups	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+Test	O
+PCR	O
+for	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+was	O
+the	O
+basis	O
+in	O
+diagnostics	O
+procedures	O
+of	O
+the	O
+new	O
+pandemic	O
+influenza	B-DISO
+confirmation	O
+.	O
+
+Oseltamivir	B-CHED
+safety	O
+and	O
+tolerability	O
+were	O
+verified	O
+in	O
+patients	O
+with	O
+new	O
+variant	O
+infection	B-DISO
+A	O
+/	O
+H1N1	O
+.	O
+
+Illness	O
+-	O
+related	O
+fatalities	O
+have	O
+been	O
+recorded	O
+among	O
+individuals	O
+hospitalized	O
+in	O
+The	O
+Hospital	O
+For	O
+Infectious	B-DISO
+Diseases	I-DISO
+in	O
+Warsaw	O
+,	O
+Poland	O
+.	O
+
+Two	O
+woman	O
+with	O
+clinically	O
+-	O
+relevant	O
+obesity	B-DISO
+have	O
+developed	O
+rapid	O
+progression	O
+of	O
+respiratory	B-DISO
+insufficiency	I-DISO
+and	O
+were	O
+still	O
+on	O
+mechanical	O
+ventilation	O
+.	O
+
+In	O
+a	O
+sample	O
+of	O
+Kenyan	O
+infants	O
+and	O
+children	O
+admitted	O
+with	O
+severe	O
+pneumonia	B-DISO
+to	O
+a	O
+rural	O
+hospital	O
+,	O
+RSV	B-SPEC
+was	O
+the	O
+predominant	O
+viral	O
+pathogen	O
+.	O
+
+Compared	O
+with	O
+well	O
+control	O
+participants	O
+,	O
+detection	O
+of	O
+RSV	B-PRGE
+was	O
+associated	O
+with	O
+severe	O
+disease	O
+(	O
+5	O
+%	O
+[	O
+corrected	O
+]	O
+in	O
+control	O
+participants	O
+;	O
+adjusted	O
+odds	O
+ratio	O
+,	O
+6	O
+.	O
+11	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+65	O
+-	O
+22	O
+.	O
+6	O
+])	O
+while	O
+collectively	O
+,	O
+other	O
+respiratory	O
+viruses	B-SPEC
+were	O
+not	O
+associated	O
+with	O
+severe	O
+disease	O
+(	O
+23	O
+%	O
+in	O
+control	O
+participants	O
+;	O
+adjusted	O
+odds	O
+ratio	O
+,	O
+1	O
+.	O
+27	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+64	O
+-	O
+2	O
+.	O
+52	O
+]).	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+2003	O
+Toronto	O
+SARS	O
+outbreak	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+transmitted	B-DISO
+in	O
+hospitals	O
+despite	O
+adherence	O
+to	O
+infection	B-DISO
+control	O
+procedures	O
+.	O
+
+All	O
+HCWs	O
+who	O
+provided	O
+care	O
+to	O
+intubated	O
+SARS	B-DISO
+patients	O
+during	O
+treatment	O
+or	O
+transportation	O
+and	O
+who	O
+entered	O
+a	O
+patient	O
+room	O
+or	O
+had	O
+direct	O
+patient	O
+contact	O
+from	O
+24	O
+hours	O
+before	O
+to	O
+4	O
+hours	O
+after	O
+intubation	O
+were	O
+eligible	O
+for	O
+this	O
+study	O
+.	O
+
+In	O
+multivariate	O
+GEE	O
+logistic	O
+regression	O
+models	O
+,	O
+presence	O
+in	O
+the	O
+room	O
+during	O
+fiberoptic	O
+intubation	O
+(	O
+OR	O
+=	O
+2	O
+.	O
+79	O
+,	O
+p	O
+=	O
+.	O
+004	O
+)	O
+or	O
+ECG	O
+(	O
+OR	O
+=	O
+3	O
+.	O
+52	O
+,	O
+p	O
+=	O
+.	O
+002	O
+),	O
+unprotected	O
+eye	B-ANAT
+contact	O
+with	O
+secretions	B-ANAT
+(	O
+OR	O
+=	O
+7	O
+.	O
+34	O
+,	O
+p	O
+=	O
+.	O
+001	O
+),	O
+patient	O
+APACHE	O
+II	O
+score	O
+>	O
+or	O
+=	O
+20	O
+(	O
+OR	O
+=	O
+17	O
+.	O
+05	O
+,	O
+p	O
+=	O
+.	O
+009	O
+)	O
+and	O
+patient	O
+Pa0	O
+(	O
+2	O
+)/	O
+Fi0	O
+(	O
+2	O
+)	O
+ratio	O
+<	O
+or	O
+=	O
+59	O
+(	O
+OR	O
+=	O
+8	O
+.	O
+65	O
+,	O
+p	O
+=	O
+.	O
+001	O
+)	O
+were	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+In	O
+CART	O
+analyses	O
+,	O
+the	O
+four	O
+covariates	O
+which	O
+explained	O
+the	O
+greatest	O
+amount	O
+of	O
+variation	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+transmission	O
+were	O
+covariates	O
+representing	O
+individual	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+the	O
+case	O
+of	O
+an	O
+immunosuppressed	O
+transplant	B-ANAT
+recipient	O
+with	O
+disseminated	B-DISO
+blastomycosis	I-DISO
+(	O
+cutaneous	O
+,	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+,	O
+and	O
+pulmonary	B-DISO
+infection	I-DISO
+)	O
+complicated	O
+by	O
+septic	B-DISO
+shock	I-DISO
+and	O
+severe	O
+,	O
+refractory	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+that	O
+improved	O
+markedly	O
+and	O
+rapidly	O
+after	O
+the	O
+addition	O
+of	O
+corticosteroids	B-CHED
+to	O
+the	O
+antifungal	B-CHED
+regimen	O
+.	O
+
+ABSTRACT	O
+:	O
+Sanjad	O
+--	O
+Sakati	B-DISO
+syndrome	I-DISO
+(	O
+SSS	O
+)	O
+is	O
+a	O
+genetic	B-DISO
+disease	I-DISO
+confined	O
+to	O
+Arab	O
+populations	O
+in	O
+the	O
+Middle	O
+-	O
+East	O
+countries	O
+and	O
+characterized	O
+by	O
+hypoparathyroidism	B-DISO
+,	O
+hypocalcaemia	B-DISO
+and	O
+hyperphosphataemia	B-DISO
+,	O
+severe	O
+intrauterine	B-ANAT
+and	O
+postnatal	O
+growth	B-DISO
+failure	I-DISO
+,	O
+respiratory	B-DISO
+infection	I-DISO
+susceptibility	O
+prone	O
+,	O
+dwarfism	B-DISO
+,	O
+mental	B-DISO
+retardation	I-DISO
+,	O
+seizures	B-DISO
+,	O
+craniofacial	B-ANAT
+dysmorphic	B-DISO
+features	I-DISO
+as	O
+retromicrognathia	O
+and	O
+abnormal	O
+dentition	B-ANAT
+.	O
+
+Plaque	B-DISO
+removal	O
+,	O
+restorations	O
+and	O
+extractions	O
+of	O
+infected	O
+teeth	B-ANAT
+were	O
+performed	O
+.	O
+
+We	O
+propose	O
+a	O
+novel	O
+mechanism	O
+whereby	O
+SARS	B-DISO
+-	O
+CoV	O
+fusion	O
+protein	B-PROC
+function	I-PROC
+can	O
+be	O
+controlled	O
+by	O
+spatial	O
+regulation	B-PROC
+of	O
+the	O
+proteolytic	O
+priming	O
+site	O
+,	O
+with	O
+important	O
+implications	O
+for	O
+viral	B-DISO
+pathogenesis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Avoidance	O
+behaviors	B-PROC
+and	O
+negative	O
+psychological	B-DISO
+responses	O
+in	O
+the	O
+general	O
+population	O
+in	O
+the	O
+initial	O
+stage	O
+of	O
+the	O
+H1N1	O
+pandemic	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Such	O
+avoidance	O
+behaviors	B-PROC
+could	O
+greatly	O
+impact	O
+daily	O
+routines	O
+of	O
+the	O
+community	O
+and	O
+the	O
+local	O
+economy	O
+.	O
+
+RESULTS	O
+:	O
+This	O
+study	O
+found	O
+that	O
+76	O
+.	O
+5	O
+%	O
+of	O
+the	O
+respondents	O
+currently	O
+avoided	O
+going	O
+out	O
+or	O
+visiting	O
+crowded	O
+places	O
+or	O
+hospitals	O
+,	O
+whilst	O
+15	O
+%	O
+felt	O
+much	O
+worried	O
+about	O
+contracting	O
+H1N1	O
+and	O
+6	O
+%	O
+showed	O
+signs	O
+of	O
+emotional	B-DISO
+distress	I-DISO
+.	O
+
+TITLE	O
+:	O
+Duodenal	B-ANAT
+perforation	I-DISO
+due	O
+to	O
+a	O
+kink	O
+in	O
+a	O
+nasojejunal	O
+feeding	O
+tube	O
+in	O
+a	O
+patient	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+:	O
+a	O
+case	O
+report	O
+.	O
+
+Uniformed	O
+Service	O
+Nurses	O
+'	O
+devoted	O
+to	O
+caring	O
+for	O
+patients	O
+with	O
+SARS	B-DISO
+during	O
+the	O
+outbreak	O
+made	O
+significant	O
+contributions	O
+to	O
+the	O
+prevention	O
+and	O
+control	O
+of	O
+SARS	B-DISO
+.	O
+
+Lung	B-ANAT
+tissue	I-ANAT
+was	O
+submitted	O
+for	O
+viral	O
+and	O
+bacteriological	O
+analyses	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+,	O
+and	O
+autopsy	O
+was	O
+conducted	O
+on	O
+all	O
+patients	O
+who	O
+died	B-PROC
+.	O
+
+All	O
+deaths	B-PROC
+occurred	O
+due	O
+to	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Other	O
+lung	B-ANAT
+findings	O
+were	O
+necrotizing	B-DISO
+bronchiolitis	I-DISO
+or	O
+extensive	O
+hemorrhage	B-DISO
+.	O
+
+Phosphorylation	B-PROC
+levels	O
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+induced	O
+by	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+,	O
+bacterial	B-PRGE
+lipopolysaccharide	I-PRGE
+,	I-PRGE
+muramyl	B-CHED
+dipeptide	I-CHED
+,	I-PRGE
+Escherichia	B-SPEC
+coli	I-SPEC
+,	I-PRGE
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+,	O
+and	O
+Staphylococcus	B-SPEC
+epidermidis	I-SPEC
+were	O
+significantly	O
+lower	O
+in	O
+patients	O
+'	O
+monocytes	B-ANAT
+than	O
+monocytes	B-ANAT
+of	O
+healthy	O
+reference	O
+subjects	O
+,	O
+whereas	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+p38	B-FUNC
+phosphorylation	B-PROC
+levels	O
+were	O
+normal	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	B-PROC
+)	O
+in	O
+the	O
+treatment	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+controversial	O
+,	O
+notwithstanding	O
+the	O
+recent	O
+publication	O
+of	O
+the	O
+results	O
+of	O
+the	O
+CESAR	O
+(	O
+Conventional	O
+Ventilation	O
+or	O
+ECMO	B-PROC
+for	O
+Severe	O
+Adult	O
+Respiratory	B-DISO
+Failure	I-DISO
+)	O
+trial	O
+.	O
+
+Critically	O
+ill	O
+patients	O
+with	O
+H1N1	O
+infection	B-DISO
+frequently	O
+exhibit	O
+right	B-ANAT
+heart	I-ANAT
+dilatation	B-DISO
+and	O
+failure	O
+.	O
+
+We	O
+will	O
+assess	O
+the	O
+temporal	O
+patterns	O
+of	O
+healthcare	O
+utilization	O
+rates	O
+before	O
+,	O
+during	O
+and	O
+after	O
+the	O
+SARS	B-DISO
+restrictions	O
+in	O
+different	O
+regions	O
+using	O
+administrative	O
+health	O
+databases	O
+and	O
+longitudinal	O
+data	O
+analysis	O
+methods	O
+(	O
+generalized	O
+estimating	O
+equations	O
+).	O
+
+Interestingly	O
+,	O
+21	O
+of	O
+the	O
+total	O
+host	B-COMP
+proteins	B-CHED
+have	O
+not	O
+been	O
+reported	O
+to	O
+be	O
+present	O
+in	O
+virions	B-COMP
+of	O
+other	O
+virus	B-SPEC
+families	O
+,	O
+such	O
+as	O
+major	O
+vault	O
+protein	B-CHED
+,	O
+TENP	B-PRGE
+protein	I-PRGE
+,	O
+ovalbumin	B-PRGE
+,	O
+and	O
+scavenger	B-PRGE
+receptor	I-PRGE
+protein	B-CHED
+.	O
+
+Treatment	O
+with	O
+anti	O
+-	O
+CXCL12	O
+[	O
+stromal	O
+derived	O
+factor	O
+-	O
+1alpha	O
+,	O
+(	O
+SDF	O
+-	O
+1alpha	O
+)]	O
+blocking	B-DISO
+serum	B-COMP
+resulted	O
+in	O
+a	O
+marked	O
+impairment	B-DISO
+in	O
+migration	B-PROC
+and	O
+proliferation	B-DISO
+of	O
+engrafted	O
+stem	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+global	O
+health	O
+and	O
+global	O
+health	O
+surveillance	O
+have	O
+received	O
+unprecedented	O
+recognition	O
+of	O
+their	O
+importance	O
+because	O
+of	O
+the	O
+newly	O
+emerging	O
+and	O
+reemerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+new	O
+cycles	O
+of	O
+pandemics	O
+,	O
+and	O
+the	O
+threats	O
+of	O
+bioterrorism	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+,	O
+in	O
+apparent	O
+contrast	O
+to	O
+human	B-SPEC
+and	O
+ungulate	O
+host	B-COMP
+range	O
+variants	O
+of	O
+Betacoronavirus	B-SPEC
+-	O
+1	O
+,	O
+murine	B-SPEC
+coronaviruses	O
+actually	O
+bind	B-FUNC
+to	O
+O	O
+-	O
+Ac	O
+-	O
+Sias	O
+via	O
+HE	O
+exclusively	O
+.	O
+
+Downregulation	B-PROC
+of	O
+LC3	O
+,	O
+but	O
+not	O
+inactivation	B-DISO
+of	O
+host	B-COMP
+cell	I-COMP
+autophagy	B-PROC
+,	O
+protects	O
+cells	B-COMP
+from	O
+CoV	O
+infection	B-DISO
+.	O
+
+Open	O
+reading	O
+frame	O
+3	O
+(	O
+ORF3	O
+)	O
+is	O
+the	O
+only	O
+accessory	O
+gene	O
+in	O
+the	O
+PEDV	B-SPEC
+genome	O
+.	O
+
+The	O
+entire	O
+ORF3	O
+genes	O
+of	O
+12	O
+PEDV	B-SPEC
+field	O
+strains	O
+and	O
+one	O
+vaccine	O
+strain	O
+were	O
+sequenced	O
+.	O
+
+Incubation	O
+of	O
+the	O
+GA08	O
+strain	O
+of	O
+IBV	B-SPEC
+at	O
+56	O
+degrees	O
+C	O
+and	O
+passage	O
+in	O
+embryonated	O
+eggs	O
+was	O
+used	O
+as	O
+a	O
+method	O
+to	O
+fast	B-FUNC
+track	O
+the	O
+attenuation	O
+process	O
+.	O
+
+Severe	O
+viral	B-DISO
+pneumonia	I-DISO
+predominated	O
+in	O
+these	O
+patients	O
+,	O
+mean	O
+APACHE	O
+was	O
+18	O
+,	O
+average	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+on	O
+admission	O
+was	O
+74	O
+.	O
+9	O
+,	O
+100	O
+%	O
+had	O
+multisystemic	O
+involvement	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+swine	O
+influenza	O
+(	O
+H1N1	O
+)	O
+outbreak	O
+in	O
+2009	O
+highlighted	O
+the	O
+ethical	O
+and	O
+legal	O
+pressures	O
+facing	O
+general	O
+practitioners	O
+and	O
+health	O
+workers	O
+in	O
+emergency	B-DISO
+departments	O
+in	O
+determining	O
+the	O
+nature	O
+and	O
+limits	O
+of	O
+their	O
+obligations	O
+to	O
+their	O
+patients	O
+and	O
+the	O
+public	O
+.	O
+
+TITLE	O
+:	O
+Amiodarone	B-CHED
+:	O
+review	O
+of	O
+pulmonary	B-PROC
+effects	I-PROC
+and	O
+toxicity	O
+.	O
+
+ABSTRACT	O
+:	O
+Amiodarone	B-CHED
+,	O
+a	O
+bi	O
+-	O
+iodinated	O
+benzofuran	B-CHED
+derivative	O
+,	O
+is	O
+,	O
+because	O
+of	O
+its	O
+high	O
+effectiveness	O
+,	O
+one	O
+of	O
+the	O
+most	O
+widely	O
+used	O
+antiarrhythmic	O
+agents	O
+.	O
+
+Amiodarone	B-CHED
+-	O
+related	O
+adverse	O
+pulmonary	B-PROC
+effects	I-PROC
+may	O
+develop	O
+as	O
+early	O
+as	O
+from	O
+the	O
+first	O
+few	O
+days	O
+of	O
+treatment	O
+to	O
+several	O
+years	O
+later	O
+.	O
+
+Pulmonary	B-DISO
+involvement	I-DISO
+falls	O
+into	O
+two	O
+categories	O
+of	O
+different	O
+grades	O
+of	O
+clinical	O
+significance	O
+:	O
+(	O
+i	O
+)	O
+the	O
+ubiquitous	O
+'	B-DISO
+lipoid	I-DISO
+pneumonia	I-DISO
+',	O
+the	O
+so	O
+-	O
+called	O
+'	B-CHED
+amiodarone	I-CHED
+effect	O
+',	O
+which	O
+is	O
+usually	O
+asymptomatic	O
+;	O
+and	O
+(	O
+ii	O
+)	O
+the	O
+more	O
+appropriately	O
+named	O
+'	B-CHED
+amiodarone	I-CHED
+toxicity	O
+',	O
+which	O
+includes	O
+several	O
+distinct	O
+clinical	O
+entities	O
+related	O
+to	O
+the	O
+differing	O
+patterns	O
+of	O
+lung	B-ANAT
+inflammatory	B-DISO
+reaction	I-DISO
+,	O
+such	O
+as	O
+eosinophilic	B-DISO
+pneumonia	I-DISO
+,	O
+chronic	O
+organizing	B-DISO
+pneumonia	I-DISO
+,	O
+acute	B-DISO
+fibrinous	I-DISO
+organizing	I-DISO
+pneumonia	I-DISO
+,	O
+nodules	B-DISO
+or	O
+mass	O
+-	O
+like	O
+lesions	O
+,	O
+nonspecific	B-DISO
+interstitial	I-DISO
+pneumonia	I-DISO
+-	O
+like	O
+and	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+-	O
+like	O
+interstitial	B-DISO
+pneumonia	I-DISO
+,	O
+desquamative	B-DISO
+interstitial	I-DISO
+pneumonia	I-DISO
+,	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+diffuse	O
+alveolar	B-ANAT
+haemorrhage	B-DISO
+.	O
+
+Discontinuation	O
+of	O
+the	O
+drug	O
+,	O
+control	O
+of	O
+risk	O
+factors	O
+and	O
+,	O
+in	O
+the	O
+more	O
+severe	O
+cases	O
+,	O
+corticosteroids	B-CHED
+may	O
+be	O
+of	O
+therapeutic	O
+value	O
+.	O
+
+There	O
+were	O
+additional	O
+longer	O
+-	O
+term	O
+differences	O
+in	O
+detection	O
+frequencies	O
+between	O
+seasons	O
+,	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+predominant	O
+in	O
+the	O
+first	O
+and	O
+third	O
+seasons	O
+and	O
+HCoV	O
+-	O
+HKU1	O
+dominating	O
+in	O
+the	O
+second	O
+(	O
+see	O
+Results	O
+for	O
+definitions	O
+of	O
+seasons	O
+).	O
+
+ABSTRACT	O
+:	O
+Intranasal	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+1	O
+(	O
+MHV	B-SPEC
+-	O
+1	O
+)	O
+infection	B-DISO
+of	O
+susceptible	O
+mouse	B-SPEC
+strains	O
+mimics	O
+some	O
+important	O
+pathologic	O
+features	O
+observed	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+coronavirus	B-SPEC
+-	O
+infected	O
+humans	B-SPEC
+.	O
+
+Homology	O
+analysis	O
+of	O
+the	O
+sequences	O
+of	O
+S1	O
+genes	O
+of	O
+the	O
+19	O
+isolates	O
+and	O
+37	O
+reference	O
+IBV	B-SPEC
+strains	O
+revealed	O
+that	O
+the	O
+identity	O
+of	O
+the	O
+nucleotides	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+the	O
+S1	O
+genes	O
+between	O
+the	O
+15	O
+LX4	O
+-	O
+type	O
+isolates	O
+and	O
+other	O
+IBV	B-SPEC
+strains	O
+were	O
+71	O
+.	O
+9	O
+-	O
+99	O
+.	O
+3	O
+%	O
+and	O
+72	O
+.	O
+1	O
+-	O
+99	O
+.	O
+1	O
+%,	O
+respectively	O
+,	O
+while	O
+those	O
+of	O
+the	O
+analyzed	O
+IBV	B-SPEC
+of	O
+LX4	O
+type	O
+were	O
+96	O
+.	O
+0	O
+-	O
+99	O
+.	O
+9	O
+%	O
+and	O
+94	O
+.	O
+3	O
+-	O
+99	O
+.	O
+8	O
+%,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+clarify	O
+the	O
+prevalence	O
+of	O
+canine	O
+coronavirus	O
+(	O
+CCoV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+Japan	O
+,	O
+faecal	B-ANAT
+samples	O
+from	O
+109	O
+dogs	B-SPEC
+with	O
+diarrhoea	B-DISO
+were	O
+examined	O
+for	O
+CCoV	B-SPEC
+RNA	O
+together	O
+with	O
+canine	O
+parvovirus	B-PRGE
+type	I-PRGE
+2	I-PRGE
+(	O
+CPV	B-SPEC
+-	O
+2	O
+)	O
+DNA	O
+.	O
+
+The	O
+detection	O
+rates	O
+of	O
+CCoV	O
+and	O
+CPV	B-SPEC
+-	O
+2	O
+for	O
+dogs	B-SPEC
+aged	O
+less	O
+than	O
+1	O
+year	O
+were	O
+66	O
+.	O
+3	O
+%	O
+and	O
+43	O
+.	O
+8	O
+%,	O
+while	O
+those	O
+for	O
+dogs	B-SPEC
+aged	O
+1	O
+year	O
+or	O
+older	O
+were	O
+6	O
+.	O
+9	O
+%	O
+and	O
+10	O
+.	O
+3	O
+%,	O
+respectively	O
+,	O
+which	O
+were	O
+significantly	O
+different	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+and	O
+p	O
+=	O
+0	O
+.	O
+0003	O
+,	O
+respectively	O
+),	O
+indicating	O
+not	O
+CPV	B-SPEC
+-	O
+2	O
+but	O
+CCoV	O
+is	O
+an	O
+important	O
+diarrhoea	B-DISO
+-	O
+causing	O
+organism	O
+in	O
+juvenile	O
+dogs	B-SPEC
+.	O
+
+The	O
+viruses	B-SPEC
+causing	O
+acute	B-DISO
+bronchiolitis	I-DISO
+in	O
+the	O
+community	O
+were	O
+hRSV	B-SPEC
+(	O
+42	O
+%),	O
+rhinovirus	B-SPEC
+(	O
+19	O
+.	O
+5	O
+%),	O
+coronavirus	B-SPEC
+(	O
+8	O
+%),	O
+PIV	O
+(	O
+3	O
+.	O
+5	O
+%),	O
+and	O
+hMPV	B-SPEC
+(	O
+2	O
+.	O
+5	O
+%).	O
+
+Of	O
+the	O
+hRSV	B-SPEC
+cases	O
+,	O
+48	O
+.	O
+2	O
+%	O
+were	O
+detected	O
+in	O
+November	O
+and	O
+December	O
+and	O
+44	O
+.	O
+5	O
+%	O
+in	O
+January	O
+and	O
+February	O
+.	O
+
+PIV1	O
+infections	B-DISO
+occurred	O
+every	O
+2	O
+years	O
+in	O
+the	O
+fall	O
+.	O
+
+PIV3	O
+infections	B-DISO
+were	O
+observed	O
+every	O
+year	O
+during	O
+the	O
+fall	O
+and	O
+winter	O
+,	O
+with	O
+peaks	O
+of	O
+infections	B-DISO
+in	O
+the	O
+spring	O
+in	O
+the	O
+years	O
+without	O
+PIV1	O
+.	O
+
+Peripheral	B-ANAT
+blood	I-ANAT
+monocytes	B-ANAT
+(	O
+CD14	B-PRGE
+(+)),	O
+T	B-ANAT
+lymphocytes	I-ANAT
+(	O
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+))	O
+and	O
+B	B-ANAT
+lymphocytes	I-ANAT
+(	O
+CD21	B-PRGE
+(+))	O
+were	O
+studied	O
+by	O
+flow	O
+cytometry	O
+within	O
+5	O
+days	O
+post	O
+-	O
+infection	B-DISO
+(	O
+p	O
+.	O
+i	O
+.)	O
+and	O
+at	O
+later	O
+time	O
+points	O
+.	O
+
+In	O
+particular	O
+,	O
+while	O
+the	O
+CD8	B-PRGE
+(+)	O
+and	O
+the	O
+B	B-ANAT
+lymphocytes	I-ANAT
+returned	O
+to	O
+baseline	O
+levels	O
+by	O
+day	O
+7	O
+p	O
+.	O
+i	O
+.,	O
+the	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+remained	O
+significantly	O
+low	O
+until	O
+day	O
+30	O
+p	O
+.	O
+i	O
+.	O
+and	O
+recovered	O
+completely	O
+only	O
+at	O
+day	O
+60	O
+p	O
+.	O
+i	O
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+of	O
+crush	B-DISO
+syndrome	I-DISO
+caused	O
+by	O
+prolonged	O
+limb	B-ANAT
+compression	O
+longer	O
+than	O
+24	O
+h	O
+in	O
+the	O
+Sichuan	O
+earthquake	O
+.	O
+
+Adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+developed	O
+in	O
+four	O
+patients	O
+and	O
+required	O
+mechanical	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+CD200	O
+,	O
+a	O
+type	B-PRGE
+I	I-PRGE
+membrane	I-PRGE
+glycoprotein	B-CHED
+,	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+prevention	O
+of	O
+inflammatory	O
+disorders	O
+,	O
+graft	B-PROC
+rejection	I-PROC
+,	O
+autoimmune	B-DISO
+diseases	I-DISO
+and	O
+spontaneous	O
+fetal	B-ANAT
+loss	O
+.	O
+
+Direct	O
+binding	B-FUNC
+of	O
+SF2	B-PRGE
+/	O
+ASF	B-DISO
+to	O
+the	O
+ESE	O
+site	O
+was	O
+confirmed	O
+by	O
+RNA	O
+electrophoretic	O
+mobility	O
+shift	O
+assay	O
+(	O
+EMSA	O
+).	O
+
+Taken	O
+together	O
+,	O
+our	O
+data	O
+suggest	O
+for	O
+the	O
+first	O
+time	O
+that	O
+SF2	B-PRGE
+/	O
+ASF	B-DISO
+regulates	O
+the	O
+function	O
+of	O
+CD200	B-PRGE
+by	O
+controlling	O
+CD200	B-PRGE
+alternative	B-PROC
+splicing	I-PROC
+,	O
+through	O
+direct	O
+binding	B-FUNC
+to	O
+an	O
+ESE	O
+located	O
+in	O
+exon	O
+2	O
+of	O
+CD200	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+recognition	O
+that	O
+acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+can	O
+elevate	O
+pulmonary	B-ANAT
+artery	I-ANAT
+(	O
+PA	O
+)	O
+pressure	O
+and	O
+right	O
+ventricular	B-ANAT
+afterload	O
+,	O
+the	O
+impact	O
+of	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+dysfunction	O
+on	O
+outcomes	O
+of	O
+these	O
+patients	O
+is	O
+not	O
+well	O
+defined	O
+.	O
+
+We	O
+searched	O
+the	O
+PubMed	O
+database	O
+for	O
+clinical	O
+trials	O
+that	O
+examined	O
+the	O
+use	O
+of	O
+the	O
+following	O
+therapies	O
+in	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+recruitment	B-DISO
+maneuvers	O
+,	O
+high	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+prone	O
+position	O
+,	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+,	O
+glucocorticoids	B-CHED
+,	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+,	O
+buffer	B-CHED
+therapy	O
+,	O
+and	O
+extracorporeal	O
+life	O
+support	O
+.	O
+
+Self	O
+-	O
+administered	O
+questionnaires	O
+were	O
+used	O
+to	O
+assess	O
+nurses	O
+'	O
+acceptance	O
+of	O
+vaccination	O
+against	O
+seasonal	O
+flu	B-DISO
+and	O
+H1N1	O
+.	O
+
+TITLE	O
+:	O
+Malaria	B-DISO
+in	O
+pregnancy	O
+:	O
+update	O
+on	O
+emergency	B-DISO
+management	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+is	O
+a	O
+report	O
+of	O
+the	O
+effectiveness	O
+of	O
+a	O
+purpose	O
+-	O
+designed	O
+education	O
+program	O
+in	O
+improving	O
+undergraduate	O
+nursing	O
+students	O
+'	O
+understanding	O
+and	O
+practice	O
+of	O
+infection	B-DISO
+control	O
+precautions	O
+.	O
+
+CONCLUSIONS	O
+:	O
+To	O
+improve	O
+nursing	B-PROC
+students	O
+'	O
+capacity	O
+in	O
+responding	O
+to	O
+infectious	B-DISO
+epidemics	O
+,	O
+an	O
+educational	O
+programme	O
+that	O
+integrates	O
+the	O
+theme	O
+of	O
+infection	B-DISO
+precautions	O
+,	O
+learning	B-PROC
+theory	O
+and	O
+teaching	O
+strategies	O
+is	O
+recommended	O
+for	O
+all	O
+nursing	B-PROC
+institutes	O
+.	O
+
+If	O
+the	O
+risks	O
+of	O
+hospital	O
+and	O
+community	O
+infection	B-DISO
+are	O
+equal	O
+,	O
+95	O
+%	O
+of	O
+patients	O
+who	O
+develop	O
+symptoms	O
+of	O
+adenovirus	B-DISO
+infection	I-DISO
+within	O
+5	O
+days	O
+of	O
+hospital	O
+admission	O
+will	O
+have	O
+been	O
+infected	O
+in	O
+the	O
+community	O
+,	O
+as	O
+will	O
+95	O
+%	O
+of	O
+patients	O
+who	O
+develop	O
+symptoms	O
+within	O
+3	O
+days	O
+for	O
+human	B-SPEC
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+2	O
+.	O
+5	O
+days	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+1	O
+day	O
+for	O
+influenza	B-PATH
+A	I-PATH
+,	O
+0	O
+.	O
+5	O
+day	O
+for	O
+influenza	B-DISO
+B	O
+,	O
+12	O
+days	O
+for	O
+measles	B-PATH
+,	O
+2	O
+days	O
+for	O
+parainfluenza	B-DISO
+,	O
+4	O
+days	O
+for	O
+respiratory	B-DISO
+syncytial	I-DISO
+virus	I-DISO
+infection	I-DISO
+,	O
+and	O
+1	O
+.	O
+5	O
+days	O
+for	O
+rhinovirus	B-DISO
+infection	I-DISO
+.	O
+
+This	O
+work	O
+shows	O
+how	O
+a	O
+detailed	O
+understanding	O
+of	O
+the	O
+incubation	O
+period	O
+can	O
+be	O
+an	O
+effective	O
+tool	O
+for	O
+identifying	O
+the	O
+source	O
+of	O
+infection	B-DISO
+,	O
+ultimately	O
+ensuring	O
+patient	O
+safety	O
+.	O
+
+RESULTS	O
+:	O
+If	O
+the	O
+risks	O
+of	O
+hospital	O
+and	O
+community	O
+infection	B-DISO
+are	O
+equal	O
+,	O
+95	O
+%	O
+of	O
+patients	O
+who	O
+develop	O
+symptoms	O
+of	O
+adenovirus	B-DISO
+infection	I-DISO
+within	O
+5	O
+days	O
+of	O
+hospital	O
+admission	O
+will	O
+have	O
+been	O
+infected	O
+in	O
+the	O
+community	O
+,	O
+as	O
+will	O
+95	O
+%	O
+of	O
+patients	O
+who	O
+develop	O
+symptoms	O
+within	O
+3	O
+days	O
+for	O
+human	B-SPEC
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+2	O
+.	O
+5	O
+days	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+1	O
+day	O
+for	O
+influenza	B-PATH
+A	I-PATH
+,	O
+0	O
+.	O
+5	O
+day	O
+for	O
+influenza	B-DISO
+B	O
+,	O
+12	O
+days	O
+for	O
+measles	B-PATH
+,	O
+2	O
+days	O
+for	O
+parainfluenza	B-DISO
+,	O
+4	O
+days	O
+for	O
+respiratory	B-DISO
+syncytial	I-DISO
+virus	I-DISO
+infection	I-DISO
+,	O
+and	O
+1	O
+.	O
+5	O
+days	O
+for	O
+rhinovirus	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+bilateral	B-DISO
+pneumonia	I-DISO
+in	O
+an	O
+80	O
+year	O
+old	O
+caucasian	O
+man	B-CHED
+who	O
+developed	O
+very	O
+rapidly	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+with	O
+a	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+of	O
+55	O
+,	O
+requiring	O
+mechanical	O
+ventilation	O
+and	O
+adrenergic	O
+support	O
+.	O
+
+There	O
+was	O
+an	O
+increased	O
+eosinophilia	B-DISO
+in	O
+both	O
+blood	B-ANAT
+and	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+experimentally	O
+the	O
+pathogenicity	O
+and	O
+tissue	B-ANAT
+distribution	O
+of	O
+the	O
+recently	O
+emerged	O
+QX	O
+-	O
+like	O
+strain	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+with	O
+the	O
+widespread	O
+M41	O
+and	O
+793	O
+/	O
+B	O
+serotypes	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Replication	O
+of	O
+the	O
+isolates	O
+in	O
+the	O
+alimentary	B-ANAT
+tract	I-ANAT
+was	O
+detected	O
+,	O
+but	O
+the	O
+infection	B-DISO
+did	O
+not	O
+cause	O
+significant	O
+gut	B-ANAT
+lesions	O
+.	O
+
+Dilation	B-DISO
+of	O
+the	O
+oviduct	B-ANAT
+with	O
+accumulation	O
+of	O
+serum	B-COMP
+-	O
+like	O
+fluid	O
+in	O
+the	O
+lumen	B-ANAT
+of	O
+this	O
+structure	O
+,	O
+reported	O
+previously	O
+from	O
+field	O
+cases	O
+of	O
+QX	O
+-	O
+like	O
+IBV	B-SPEC
+infection	B-DISO
+,	O
+was	O
+observed	O
+following	O
+experimental	O
+infection	B-DISO
+with	O
+all	O
+of	O
+the	O
+five	O
+QX	O
+-	O
+like	O
+strains	O
+.	O
+
+For	O
+coronaviruses	O
+,	O
+it	O
+was	O
+long	O
+speculated	O
+that	O
+replication	O
+of	O
+the	O
+giant	B-DISO
+RNA	O
+genome	O
+and	O
+transcription	B-PROC
+of	O
+multiple	O
+subgenomic	O
+mRNA	B-CHED
+species	B-SPEC
+by	O
+a	O
+unique	O
+discontinuous	O
+transcription	B-PROC
+mechanism	O
+may	O
+require	O
+host	B-COMP
+cofactors	B-CHED
+.	O
+
+Furthermore	O
+,	O
+the	O
+endogenous	B-PRGE
+DDX1	I-PRGE
+protein	I-PRGE
+was	O
+found	O
+to	O
+be	O
+relocated	O
+from	O
+the	O
+nucleus	O
+to	O
+the	O
+cytoplasm	B-COMP
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+A	O
+single	O
+asparagine	B-CHED
+-	O
+linked	O
+glycosylation	B-PROC
+site	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+glycoprotein	B-CHED
+facilitates	O
+inhibition	B-PROC
+by	O
+mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+through	O
+multiple	O
+mechanisms	O
+.	O
+
+ABSTRACT	O
+:	O
+Mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+)	O
+is	O
+a	O
+serum	B-COMP
+protein	B-CHED
+that	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+host	B-COMP
+defenses	O
+as	O
+an	O
+opsonin	O
+and	O
+through	O
+activation	O
+of	O
+the	O
+complement	O
+system	O
+.	O
+
+MBL	B-PRGE
+was	O
+found	O
+to	O
+selectively	O
+bind	B-FUNC
+to	O
+retroviral	B-SPEC
+particles	O
+pseudotyped	O
+with	O
+SARS	B-DISO
+-	O
+S	O
+.	O
+Unlike	O
+several	O
+other	O
+viral	O
+envelopes	O
+to	O
+which	O
+MBL	B-PRGE
+can	O
+bind	B-FUNC
+,	O
+both	O
+recombinant	O
+and	O
+plasma	B-ANAT
+-	O
+derived	O
+human	B-SPEC
+MBL	O
+directly	O
+inhibited	O
+SARS	B-DISO
+-	O
+S	O
+-	O
+mediated	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Naturally	O
+occurring	O
+recombination	B-PROC
+between	O
+distant	O
+strains	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+It	O
+was	O
+concluded	O
+that	O
+novel	O
+IBVs	O
+,	O
+which	O
+have	O
+not	O
+been	O
+detected	O
+since	O
+1993	O
+,	O
+and	O
+which	O
+are	O
+phylogenically	O
+more	O
+distant	O
+from	O
+classical	O
+IBVs	O
+than	O
+turkey	B-SPEC
+coronaviruses	O
+,	O
+might	O
+still	O
+be	O
+circulating	O
+and	O
+contributing	O
+to	O
+the	O
+evolution	B-PROC
+of	O
+IBV	B-SPEC
+in	O
+Australia	O
+.	O
+
+In	O
+all	O
+domestic	B-SPEC
+cats	I-SPEC
+of	O
+different	O
+breeds	B-PROC
+:	O
+female	O
+Abyssinian	O
+,	O
+female	O
+American	O
+shorthair	O
+,	O
+male	O
+Cornish	O
+Rex	B-FUNC
+,	O
+female	O
+European	O
+Burmese	O
+,	O
+female	O
+Persian	O
+,	O
+female	O
+Siamese	O
+,	O
+a	O
+male	O
+Ragdoll	O
+and	O
+a	O
+female	O
+African	O
+wildcat	O
+were	O
+sequenced	O
+lightly	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+classical	O
+epidemiological	O
+framework	O
+is	O
+used	O
+to	O
+provide	O
+a	O
+preliminary	O
+cost	O
+analysis	O
+of	O
+the	O
+effects	O
+of	O
+quarantine	O
+and	O
+isolation	O
+on	O
+the	O
+dynamics	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+for	O
+which	O
+no	O
+treatment	O
+or	O
+immediate	O
+diagnosis	O
+tools	O
+are	O
+available	O
+.	O
+
+Taking	O
+the	O
+context	O
+of	O
+the	O
+2003	O
+SARS	B-DISO
+outbreak	O
+in	O
+Hong	O
+Kong	O
+as	O
+an	O
+example	O
+,	O
+we	O
+use	O
+a	O
+simple	O
+cost	O
+function	O
+to	O
+compare	O
+the	O
+total	O
+cost	O
+of	O
+each	O
+mixed	O
+(	O
+quarantine	O
+and	O
+isolation	O
+)	O
+control	O
+strategy	O
+from	O
+a	O
+public	O
+health	O
+resource	O
+allocation	O
+perspective	O
+.	O
+
+Coronavirus	B-SPEC
+S	O
+proteins	B-CHED
+are	O
+palmitoylated	O
+,	O
+which	O
+may	O
+affect	O
+function	O
+.	O
+
+Surprisingly	O
+,	O
+however	O
+,	O
+palmitoylation	B-PROC
+of	O
+S	O
+was	O
+not	O
+required	O
+for	O
+interaction	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Monitoring	O
+of	O
+perceptions	O
+,	O
+anticipated	O
+behavioral	B-PROC
+,	O
+and	O
+psychological	B-DISO
+responses	O
+related	O
+to	O
+H5N1	B-DISO
+influenza	I-DISO
+.	O
+
+Starting	O
+in	O
+2005	O
+through	O
+to	O
+2008	O
+,	O
+respondents	O
+perceived	O
+a	O
+decreasing	O
+level	O
+of	O
+susceptibility	O
+,	O
+severity	O
+,	O
+and	O
+anticipated	O
+stress	O
+towards	O
+a	O
+hypothetical	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+H5N1	B-DISO
+outbreak	O
+,	O
+possibly	O
+due	O
+to	O
+the	O
+low	O
+efficiency	O
+of	O
+transmission	O
+.	O
+
+We	O
+sought	O
+to	O
+determine	O
+the	O
+effects	O
+of	O
+telbivudine	B-CHED
+on	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+particularly	O
+on	O
+cytokine	B-PROC
+production	I-PROC
+and	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+,	O
+using	O
+an	O
+animal	B-SPEC
+model	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+3	O
+(	O
+MHV	B-SPEC
+-	O
+3	O
+)-	O
+induced	O
+hepatitis	B-DISO
+.	O
+
+In	O
+vivo	O
+survival	O
+was	O
+enhanced	O
+in	O
+telbivudine	B-CHED
+-	O
+treated	O
+mice	B-SPEC
+,	O
+with	O
+marked	O
+normalization	O
+in	O
+clinical	O
+conditions	O
+and	O
+histological	O
+lesions	O
+.	O
+
+Furthermore	O
+,	O
+telbivudine	B-CHED
+treatment	O
+enhanced	O
+the	O
+ability	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+to	O
+undergo	O
+proliferation	B-DISO
+and	O
+secrete	B-PROC
+cytokines	O
+but	O
+did	O
+not	O
+affect	O
+cytotoxicity	B-DISO
+of	O
+infected	O
+hepatocytes	B-ANAT
+.	O
+
+Of	O
+note	O
+,	O
+we	O
+found	O
+that	O
+telbivudine	B-CHED
+treatment	O
+suppressed	O
+programmed	O
+death	B-PROC
+ligand	B-PROC
+1	O
+expression	B-PROC
+on	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+We	O
+calculated	O
+three	O
+winter	O
+and	O
+annual	O
+excess	O
+influenza	B-DISO
+-	O
+associated	O
+mortalities	O
+[	O
+pneumonia	B-DISO
+and	I-DISO
+influenza	I-DISO
+(	O
+P	O
+&	O
+I	O
+),	O
+respiratory	O
+and	O
+circulatory	B-PROC
+,	O
+and	O
+all	O
+-	O
+cause	O
+]	O
+from	O
+the	O
+1999	O
+-	O
+2000	O
+through	O
+the	O
+2006	O
+-	O
+2007	O
+influenza	B-DISO
+seasons	O
+.	O
+
+Furthermore	O
+,	O
+vaccine	O
+-	O
+mismatched	O
+H3N2	B-CHED
+viruses	B-SPEC
+circulating	O
+in	O
+the	O
+years	O
+with	O
+high	O
+excess	O
+P	O
+&	O
+I	O
+mortality	O
+exhibited	O
+both	O
+a	O
+lower	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+percentage	O
+of	O
+HA1	B-COMP
+between	O
+vaccine	O
+and	O
+circulating	O
+strains	O
+and	O
+a	O
+higher	O
+numbers	O
+of	O
+variations	O
+at	O
+epitope	B-CHED
+B	O
+.	O
+Our	O
+model	O
+can	O
+help	O
+future	O
+decision	O
+makers	O
+to	O
+estimate	O
+excess	O
+P	O
+&	O
+I	O
+mortality	O
+effectively	O
+,	O
+select	O
+and	O
+test	O
+virus	B-SPEC
+strains	O
+for	O
+antigenic	B-PROC
+variation	I-PROC
+,	O
+and	O
+evaluate	O
+public	O
+health	O
+strategy	O
+effectiveness	O
+.	O
+
+Moreover	O
+,	O
+CXCR2	B-PRGE
+neutralization	O
+was	O
+associated	O
+with	O
+an	O
+increase	O
+in	O
+the	O
+severity	O
+of	O
+demyelination	B-DISO
+that	O
+was	O
+independent	O
+of	O
+viral	O
+recrudescence	O
+or	O
+modulation	O
+of	O
+neuroinflammation	O
+.	O
+
+Rather	O
+,	O
+blocking	O
+CXCR2	B-PRGE
+was	O
+associated	O
+with	O
+increased	O
+numbers	O
+of	O
+apoptotic	O
+cells	B-COMP
+primarily	O
+within	O
+white	B-ANAT
+matter	I-ANAT
+tracts	B-ANAT
+,	O
+suggesting	O
+that	O
+oligodendrocytes	B-ANAT
+were	O
+affected	O
+.	O
+
+Mice	B-SPEC
+subjected	O
+to	O
+intestinal	B-ANAT
+I	O
+/	O
+R	O
+injury	O
+showed	O
+histologic	O
+and	O
+functional	O
+evidence	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+decreased	O
+survival	O
+compared	O
+with	O
+sham	O
+-	O
+operated	O
+animals	B-SPEC
+.	O
+
+Commercially	O
+available	O
+vaccines	O
+are	O
+only	O
+partially	O
+effective	O
+in	O
+protection	O
+against	O
+PRRSV	B-SPEC
+.	O
+
+Partial	O
+protection	O
+in	O
+challenged	O
+animals	B-SPEC
+was	O
+observed	O
+,	O
+as	O
+vaccinated	O
+pigs	B-SPEC
+showed	O
+decreased	O
+lung	B-ANAT
+damage	O
+when	O
+compared	O
+with	O
+the	O
+non	O
+-	O
+vaccinated	O
+ones	O
+.	O
+
+However	O
+,	O
+when	O
+the	O
+two	O
+agents	O
+were	O
+added	O
+together	O
+to	O
+FCoV	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+a	O
+synergistic	O
+antiviral	B-CHED
+effect	O
+defined	O
+by	O
+complete	O
+blockage	O
+of	O
+viral	B-PROC
+replication	I-PROC
+was	O
+observed	O
+.	O
+
+TITLE	O
+:	O
+Host	B-COMP
+intraspatial	O
+selection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+populations	O
+.	O
+
+Five	O
+new	O
+predominant	O
+populations	O
+designated	O
+component	O
+(	O
+C	O
+)	O
+1	O
+through	O
+C5	O
+,	O
+showing	O
+distinct	O
+nonsynonymous	O
+changes	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+nucleotide	B-CHED
+changes	O
+resulting	O
+in	O
+different	O
+amino	B-CHED
+acids	I-CHED
+encoded	O
+and	O
+thus	O
+in	O
+a	O
+phenotypic	O
+change	O
+of	O
+the	O
+predominant	O
+virus	B-SPEC
+population	O
+,	O
+were	O
+detected	O
+in	O
+the	O
+tissues	B-ANAT
+or	O
+fluids	B-ANAT
+of	O
+individual	O
+vaccinated	O
+chickens	B-SPEC
+.	O
+
+These	O
+results	O
+indicate	O
+for	O
+the	O
+first	O
+time	O
+that	O
+IBV	B-SPEC
+undergoes	O
+intraspatial	O
+variation	O
+during	O
+host	B-PROC
+invasion	B-DISO
+,	O
+i	O
+.	O
+e	O
+.,	O
+the	O
+dominant	O
+genotype	O
+/	O
+phenotype	O
+further	O
+changes	O
+during	O
+host	B-PROC
+invasion	B-DISO
+as	O
+the	O
+microenvironment	O
+of	O
+distinct	O
+tissues	B-ANAT
+exerts	B-PROC
+selective	O
+pressure	O
+on	O
+the	O
+replicating	O
+virus	B-SPEC
+population	O
+.	O
+
+No	O
+consistent	O
+antigenic	O
+or	O
+genetic	B-PROC
+markers	I-PROC
+have	O
+been	O
+identified	O
+to	O
+discriminate	O
+BCoVs	O
+from	O
+the	O
+different	O
+clinical	O
+syndromes	B-DISO
+.	O
+
+This	O
+article	O
+focuses	O
+on	O
+respiratory	O
+BCoV	O
+infections	B-DISO
+including	O
+viral	O
+characteristics	O
+;	O
+epidemiology	O
+and	O
+interspecies	O
+transmission	O
+;	O
+diagnosis	O
+,	O
+pathogenesis	O
+,	O
+and	O
+clinical	O
+signs	O
+;	O
+and	O
+immunity	B-PROC
+and	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Calf	B-ANAT
+diarrhea	B-DISO
+is	O
+a	O
+major	O
+economic	O
+burden	O
+to	O
+the	O
+bovine	B-SPEC
+industry	O
+.	O
+
+Since	O
+multiple	O
+infectious	B-DISO
+agents	O
+can	O
+be	O
+involved	O
+in	O
+calf	B-ANAT
+diarrhea	B-DISO
+,	O
+and	O
+the	O
+detection	O
+of	O
+each	O
+of	O
+the	O
+causative	O
+agents	O
+by	O
+traditional	O
+methods	O
+is	O
+laborious	O
+and	O
+expensive	O
+,	O
+a	O
+panel	O
+of	O
+2	O
+multiplex	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+assays	O
+was	O
+developed	O
+for	O
+rapid	O
+and	O
+simultaneous	O
+detection	O
+of	O
+the	O
+5	O
+major	O
+bovine	B-SPEC
+enteric	O
+pathogens	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+[	O
+BCoV	O
+;	O
+formally	O
+known	O
+as	O
+Betacoronavirus	B-SPEC
+1	I-SPEC
+],	O
+group	O
+A	O
+Bovine	B-SPEC
+rotavirus	B-SPEC
+[	O
+BRV	B-DISO
+],	O
+Salmonella	B-PRGE
+spp	B-ENZY
+.,	I-PRGE
+Escherichia	B-SPEC
+coli	I-SPEC
+K99	I-PRGE
+(+),	I-PRGE
+and	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+).	O
+
+The	O
+purpose	O
+of	O
+this	O
+article	O
+is	O
+to	O
+describe	O
+the	O
+clinical	O
+course	O
+and	O
+outcome	O
+of	O
+drowning	O
+cases	O
+related	O
+to	O
+current	O
+US	O
+military	O
+combat	B-CHED
+operations	O
+.	O
+
+Survivor	O
+long	O
+-	O
+term	O
+morbidity	O
+was	O
+often	O
+related	O
+to	O
+the	O
+sequelae	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+hypoxic	B-DISO
+encephalopathy	I-DISO
+.	O
+
+Drowning	O
+associated	O
+with	O
+combat	B-CHED
+operations	O
+was	O
+associated	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+cardiovascular	B-ANAT
+shock	O
+.	O
+
+Survivor	O
+long	O
+-	O
+term	O
+morbidity	O
+was	O
+often	O
+related	O
+to	O
+the	O
+sequelae	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+hypoxic	B-DISO
+encephalopathy	I-DISO
+.	O
+
+Duration	O
+of	O
+antiviral	B-CHED
+therapy	O
+,	O
+the	O
+timing	O
+of	O
+steroid	B-CHED
+introduction	O
+,	O
+and	O
+moving	B-PROC
+away	O
+from	O
+standard	O
+ventilation	O
+techniques	O
+in	O
+ARDS	B-DISO
+may	O
+be	O
+key	O
+points	O
+in	O
+disease	O
+management	O
+.	O
+
+TITLE	O
+:	O
+Putative	O
+probiotic	O
+Lactobacillus	B-SPEC
+spp	B-ENZY
+.	O
+
+from	O
+porcine	B-SPEC
+gastrointestinal	B-ANAT
+tract	I-ANAT
+inhibit	O
+transmissible	O
+gastroenteritis	O
+coronavirus	B-SPEC
+and	O
+enteric	O
+bacterial	O
+pathogens	O
+.	O
+
+The	O
+evolution	B-PROC
+was	O
+favorable	O
+,	O
+and	O
+the	O
+patient	O
+was	O
+discharged	O
+after	O
+14	O
+days	O
+.	O
+
+The	O
+prevalence	O
+,	O
+clinical	O
+predictors	O
+and	O
+inflammatory	O
+mediator	O
+profile	O
+of	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+in	O
+serious	O
+acute	O
+respiratory	O
+illness	O
+were	O
+investigated	O
+.	O
+
+Sequential	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluids	B-ANAT
+from	O
+all	O
+patients	O
+hospitalised	O
+with	O
+acute	O
+respiratory	O
+illness	O
+over	O
+12	O
+months	O
+(	O
+n	O
+=	O
+283	O
+)	O
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+17	O
+respiratory	O
+viruses	B-SPEC
+by	O
+multiplex	O
+PCR	O
+assay	O
+and	O
+for	O
+newly	O
+discovered	O
+respiratory	O
+viruses	B-SPEC
+(	O
+bocavirus	B-SPEC
+,	O
+WU	O
+and	O
+KI	O
+polyomaviruses	B-SPEC
+)	O
+by	O
+single	O
+-	O
+target	O
+PCR	O
+.	O
+
+The	O
+presence	O
+of	O
+respiratory	O
+virus	B-SPEC
+was	O
+associated	O
+with	O
+increased	O
+levels	O
+of	O
+interferon	B-PRGE
+gamma	I-PRGE
+-	O
+inducible	O
+protein	B-CHED
+10	O
+(	O
+IP	O
+-	O
+10	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+eotaxin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+p	O
+=	O
+0	O
+.	O
+017	O
+)	O
+in	O
+BAL	B-ENZY
+.	O
+
+RESULTS	O
+:	O
+39	O
+respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+37	O
+(	O
+13	O
+.	O
+1	O
+%	O
+of	O
+total	O
+)	O
+patients	O
+by	O
+molecular	O
+testing	O
+,	O
+including	O
+rhinovirus	B-SPEC
+(	O
+n	O
+=	O
+13	O
+),	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+n	O
+=	O
+8	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+n	O
+=	O
+6	O
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+n	O
+=	O
+3	O
+),	O
+coronavirus	B-SPEC
+NL63	O
+(	O
+n	O
+=	O
+2	O
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+n	O
+=	O
+2	O
+),	O
+adenovirus	B-DISO
+(	O
+n	O
+=	O
+1	O
+)	O
+and	O
+newly	O
+discovered	O
+viruses	B-SPEC
+(	O
+n	O
+=	O
+4	O
+).	O
+
+The	O
+presence	O
+of	O
+respiratory	O
+virus	B-SPEC
+was	O
+associated	O
+with	O
+increased	O
+levels	O
+of	O
+interferon	B-PRGE
+gamma	I-PRGE
+-	O
+inducible	O
+protein	B-CHED
+10	O
+(	O
+IP	O
+-	O
+10	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+eotaxin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+p	O
+=	O
+0	O
+.	O
+017	O
+)	O
+in	O
+BAL	B-ENZY
+.	O
+
+ABSTRACT	O
+:	O
+Food	O
+-	O
+and	O
+waterborne	O
+viruses	O
+pose	O
+serious	O
+health	O
+risks	O
+to	O
+humans	B-SPEC
+and	O
+were	O
+associated	O
+with	O
+many	O
+outbreaks	O
+worldwide	O
+.	O
+
+The	O
+virus	B-SPEC
+detection	O
+limit	O
+by	O
+SERS	O
+using	O
+gold	B-CHED
+substrates	O
+reached	O
+a	O
+titer	O
+of	O
+10	O
+(	O
+2	O
+).	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+here	O
+investigation	O
+into	O
+the	O
+genetic	O
+basis	O
+of	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+strain	O
+1	O
+(	O
+MHV	B-SPEC
+-	O
+1	O
+)	O
+pneumovirulence	O
+.	O
+
+Challenge	O
+studies	O
+in	O
+mice	B-SPEC
+demonstrated	O
+that	O
+expression	B-PROC
+of	O
+the	O
+MHV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+within	O
+the	O
+MHV	B-SPEC
+-	O
+A59	O
+background	O
+(	O
+rA59	O
+/	O
+S	O
+(	O
+MHV	B-SPEC
+-	O
+1	O
+))	O
+increased	O
+the	O
+pneumovirulence	O
+of	O
+MHV	B-SPEC
+-	O
+A59	O
+,	O
+and	O
+mice	B-SPEC
+infected	O
+with	O
+this	O
+recombinant	O
+virus	B-SPEC
+developed	O
+pulmonary	B-ANAT
+lesions	O
+that	O
+were	O
+similar	O
+to	O
+those	O
+observed	O
+with	O
+MHV	B-SPEC
+-	O
+1	O
+,	O
+although	O
+rA59	O
+/	O
+S	O
+(	O
+MHV	O
+-	O
+1	O
+)	O
+was	O
+significantly	O
+less	O
+virulent	O
+.	O
+
+The	O
+combination	O
+of	O
+experimental	O
+X	O
+-	O
+ray	B-SPEC
+structural	O
+information	O
+and	O
+aspherical	O
+atomic	O
+electron	O
+density	O
+data	O
+from	O
+theoretical	O
+calculations	O
+resulted	O
+in	O
+properties	O
+like	O
+the	O
+electrostatic	O
+potential	O
+and	O
+the	O
+Hirshfeld	O
+surface	O
+which	O
+allowed	O
+a	O
+study	O
+of	O
+electronic	O
+complementarity	O
+and	O
+the	O
+identification	O
+of	O
+sites	O
+and	O
+strengths	O
+of	O
+drug	O
+-	O
+receptor	B-PROC
+interactions	I-PROC
+.	O
+
+Electron	O
+microscopic	O
+analysis	O
+indicated	O
+that	O
+viral	O
+inactivation	B-DISO
+by	O
+PPs	B-DISO
+was	O
+primarily	O
+a	O
+consequence	O
+of	O
+virion	B-COMP
+structural	O
+damage	O
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+of	O
+acute	O
+heroin	B-CHED
+overdose	O
+requiring	O
+intensive	O
+care	O
+unit	O
+admission	O
+.	O
+
+ABSTRACT	O
+:	O
+Heroin	B-CHED
+use	O
+carries	O
+a	O
+large	O
+burden	O
+of	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+1	O
+days	O
+,	O
+while	O
+two	O
+patients	O
+succumbed	O
+because	O
+of	O
+anoxemic	O
+encephalopathy	B-DISO
+and	O
+brain	B-DISO
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+Mutations	O
+in	O
+the	O
+spike	O
+glycoprotein	B-CHED
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+modulate	O
+disease	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+from	O
+encephalitis	B-DISO
+to	O
+flaccid	B-DISO
+paralysis	I-DISO
+and	O
+demyelination	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+etiology	O
+of	O
+most	O
+neurodegenerative	B-DISO
+diseases	I-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+remains	O
+unknown	O
+and	O
+likely	O
+involves	O
+a	O
+combination	O
+of	O
+genetic	O
+susceptibility	O
+and	O
+environmental	O
+triggering	O
+factors	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+mutations	O
+in	O
+the	O
+viral	O
+spike	O
+glycoprotein	O
+,	O
+reproducibly	O
+acquired	O
+during	O
+viral	O
+persistence	O
+in	O
+human	B-SPEC
+neural	B-ANAT
+cell	I-ANAT
+cultures	O
+,	O
+led	O
+to	O
+a	O
+drastically	O
+modified	O
+virus	B-SPEC
+-	O
+induced	O
+neuropathology	B-DISO
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+,	O
+characterized	O
+by	O
+flaccid	B-DISO
+paralysis	I-DISO
+and	O
+demyelination	B-DISO
+.	O
+
+Moreover	O
+,	O
+recombinant	O
+virus	B-SPEC
+harboring	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+mutations	O
+retained	O
+its	O
+neurotropism	B-DISO
+,	O
+productively	O
+infecting	O
+neurons	B-ANAT
+.	O
+
+The	O
+recognizing	O
+of	O
+a	O
+specific	O
+serum	B-COMP
+against	O
+pAPN	O
+to	O
+these	O
+proteins	B-CHED
+was	O
+investigated	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+and	O
+immunoblotting	O
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+three	O
+truncated	O
+pAPNs	O
+positively	O
+reacted	O
+with	O
+the	O
+specific	O
+antiserum	O
+and	O
+the	O
+major	O
+binding	B-FUNC
+regions	O
+of	O
+pAPN	O
+were	O
+limited	O
+in	O
+regions	O
+36aa	O
+-	O
+223aa	O
+,	O
+349aa	O
+-	O
+591aa	O
+and	O
+592	O
+-	O
+963aa	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Toronto	O
+,	O
+outpatient	O
+clinics	O
+at	O
+SickKids	O
+Hospital	O
+were	O
+closed	O
+to	O
+prevent	O
+further	O
+disease	B-DISO
+transmission	I-DISO
+.	O
+
+We	O
+compared	O
+the	O
+diagnostic	O
+accuracy	O
+(	O
+identification	O
+of	O
+developmental	B-DISO
+delay	I-DISO
+),	O
+and	O
+patient	O
+management	O
+(	O
+referral	O
+for	O
+therapy	O
+or	O
+communication	O
+of	O
+a	O
+new	O
+diagnosis	O
+)	O
+of	O
+the	O
+strategies	O
+used	O
+during	O
+SARS	B-DISO
+,	O
+April	O
+/	O
+May	O
+2003	O
+,	O
+to	O
+the	O
+standard	O
+assessment	O
+methods	O
+used	O
+for	O
+patients	O
+seen	O
+in	O
+April	O
+/	O
+May	O
+2005	O
+(	O
+non	O
+-	O
+SARS	O
+).	O
+
+There	O
+were	O
+95	O
+patients	O
+in	O
+the	O
+SARS	B-DISO
+group	O
+and	O
+99	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+NNFU	O
+clinic	O
+staff	O
+mailed	O
+ASQ	O
+to	O
+27	O
+families	O
+during	O
+SARS	B-DISO
+,	O
+17	O
+(	O
+63	O
+%)	O
+were	O
+returned	O
+,	O
+and	O
+8	O
+of	O
+the	O
+17	O
+were	O
+then	O
+contacted	O
+by	O
+telephone	O
+.	O
+
+There	O
+was	O
+a	O
+significant	O
+under	O
+identification	O
+of	O
+developmental	B-DISO
+delay	I-DISO
+during	O
+SARS	B-DISO
+(	O
+18	O
+%	O
+versus	O
+45	O
+%).	O
+
+Poor	O
+advanced	O
+planning	O
+led	O
+to	O
+a	O
+haphazard	O
+assessment	O
+of	O
+patients	O
+during	O
+this	O
+infectious	B-DISO
+disease	I-DISO
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Endocrine	B-CHED
+cells	B-COMP
+of	O
+the	O
+adenohypophysis	B-ANAT
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+This	O
+phenomenon	O
+suggests	O
+that	O
+the	O
+adenohypophyseal	O
+endocrine	B-CHED
+cells	B-COMP
+in	O
+SARS	B-DISO
+patients	O
+may	O
+be	O
+damaged	O
+.	O
+
+The	O
+immunohistochemistry	O
+and	O
+quantitative	O
+image	O
+results	O
+showed	O
+that	O
+compared	O
+with	O
+control	O
+cases	O
+,	O
+both	O
+the	O
+number	O
+of	O
+positive	O
+cells	O
+and	O
+the	O
+staining	O
+intensity	O
+of	O
+immunoreactivity	B-PROC
+for	O
+growth	B-FUNC
+hormone	I-FUNC
+,	O
+TSH	B-PRGE
+,	O
+and	O
+adrenocorticotrophic	O
+hormone	B-CHED
+in	O
+these	O
+cells	B-COMP
+were	O
+remarkably	O
+decreased	O
+,	O
+while	O
+that	O
+of	O
+PRL	B-PRGE
+,	O
+FSH	B-PRGE
+,	O
+and	O
+LH	O
+were	O
+significantly	O
+increased	O
+in	O
+all	O
+SARS	B-DISO
+cases	O
+studied	O
+.	O
+
+Besides	O
+,	O
+potential	O
+recombination	B-PROC
+events	O
+associated	O
+with	O
+H120	O
+were	O
+found	O
+in	O
+five	O
+IBV	B-SPEC
+strains	O
+including	O
+H52	O
+,	O
+KQ6	O
+,	O
+SAIBK	O
+,	O
+Ark	B-PRGE
+DPI	I-PRGE
+11	I-PRGE
+,	O
+and	O
+Ark	O
+DPI	O
+101	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+explore	O
+the	O
+post	O
+-	O
+crisis	O
+psychological	B-DISO
+distress	I-DISO
+among	O
+residents	O
+in	O
+Taiwan	O
+after	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+Psychological	B-DISO
+distress	I-DISO
+was	O
+measured	O
+by	O
+a	O
+question	O
+related	O
+to	O
+subject	O
+'	O
+s	O
+changes	O
+in	O
+perception	O
+of	O
+life	O
+,	O
+plus	O
+the	O
+five	O
+-	O
+item	O
+Brief	O
+Symptom	B-DISO
+Rating	O
+Scale	O
+.	O
+
+About	O
+9	O
+.	O
+2	O
+%	O
+of	O
+the	O
+participants	O
+reported	O
+that	O
+their	O
+perceptions	O
+of	O
+life	O
+became	O
+more	O
+pessimistic	O
+following	O
+the	O
+SARS	B-DISO
+crisis	O
+.	O
+
+Of	O
+the	O
+155	O
+cases	O
+,	O
+136	O
+(	O
+87	O
+.	O
+7	O
+%)	O
+had	O
+abnormal	O
+SPE	O
+results	O
+,	O
+most	O
+commonly	O
+due	O
+to	O
+a	O
+polyclonal	O
+increase	O
+in	O
+gamma	B-PRGE
+globulins	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Description	O
+of	O
+the	O
+first	O
+acute	O
+bovine	B-SPEC
+diarrhea	B-DISO
+virus	B-SPEC
+-	O
+2	O
+outbreak	O
+in	O
+Israel	O
+.	O
+
+Implementation	O
+of	O
+infection	B-DISO
+control	O
+targeting	B-PROC
+this	O
+pathogen	O
+is	O
+required	O
+in	O
+tertiary	O
+hospitals	O
+in	O
+Thailand	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+management	O
+of	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+an	O
+emerging	O
+challenge	O
+,	O
+especially	O
+during	O
+the	O
+2009	O
+pandemic	O
+.	O
+
+25	O
+percent	O
+of	O
+the	O
+patients	O
+had	O
+good	O
+health	O
+prior	O
+to	O
+the	O
+infection	B-DISO
+.	O
+
+The	O
+efficiency	O
+of	O
+RMs	O
+may	O
+be	O
+affected	O
+by	O
+different	O
+factors	O
+,	O
+including	O
+the	O
+nature	O
+and	O
+extent	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+capability	O
+of	O
+increasing	O
+inspiratory	B-PROC
+transpulmonary	O
+pressures	O
+,	O
+patient	O
+positioning	O
+and	O
+cardiac	B-ANAT
+preload	O
+.	O
+
+We	O
+assessed	O
+the	O
+sublingual	B-ANAT
+microcirculation	B-PROC
+in	O
+seven	O
+consecutive	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+related	O
+to	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+.	O
+
+Three	O
+patients	O
+had	O
+bacterial	O
+superinfection	B-DISO
+.	O
+
+Histopathological	O
+changes	O
+in	O
+lungs	B-ANAT
+from	O
+2	O
+of	O
+these	O
+seals	B-SPEC
+included	O
+a	O
+necrotizing	O
+lymphocytic	O
+and	O
+histocytic	O
+lobar	B-DISO
+pneumonia	I-DISO
+with	O
+intra	O
+-	O
+lesional	O
+bacteria	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Chlamydiae	O
+induce	O
+persistent	O
+infections	B-DISO
+,	O
+which	O
+have	O
+been	O
+associated	O
+with	O
+a	O
+wide	O
+range	O
+of	O
+chronic	B-DISO
+diseases	I-DISO
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+Women	O
+also	O
+perceived	O
+the	O
+effectiveness	O
+of	O
+hand	O
+washing	O
+to	O
+be	O
+lower	O
+,	O
+and	O
+illness	O
+severity	O
+and	O
+personal	O
+susceptibility	O
+to	O
+H1N1	O
+infection	B-DISO
+to	O
+be	O
+higher	O
+.	O
+
+This	O
+short	O
+review	O
+describes	O
+the	O
+pathologic	O
+features	O
+of	O
+SARS	B-DISO
+in	O
+relation	O
+to	O
+their	O
+clinical	O
+presentation	O
+in	O
+human	B-SPEC
+cases	O
+.	O
+
+It	O
+also	O
+looks	O
+at	O
+animal	B-SPEC
+susceptibility	O
+after	O
+experimental	O
+infection	B-DISO
+,	O
+animal	B-SPEC
+models	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+the	O
+pathogenesis	B-DISO
+of	O
+this	O
+disease	O
+.	O
+
+It	O
+seems	O
+that	O
+adaptation	B-PROC
+of	O
+the	O
+virus	B-SPEC
+within	O
+the	O
+host	B-COMP
+animal	B-SPEC
+and	O
+the	O
+subsequent	O
+abnormal	O
+immune	B-PROC
+responses	I-PROC
+may	O
+be	O
+key	O
+factors	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+this	O
+new	O
+and	O
+fatal	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+proteases	O
+produced	O
+in	O
+the	O
+lung	B-ANAT
+during	O
+inflammation	B-DISO
+could	O
+also	O
+play	O
+an	O
+important	O
+role	O
+for	O
+exacerbation	O
+of	O
+SARS	B-DISO
+in	O
+animals	B-SPEC
+.	O
+
+We	O
+transduced	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+-	O
+displayed	O
+recombinant	O
+baculovirus	B-SPEC
+(	O
+SSDRB	O
+),	O
+vAtEpGS688	O
+,	O
+into	O
+peripheral	O
+B	B-ANAT
+cells	I-ANAT
+and	O
+B	O
+lymphoma	B-ANAT
+cells	B-COMP
+.	O
+
+SSDRB	O
+-	O
+mediated	O
+changes	O
+in	O
+gene	B-PROC
+expression	I-PROC
+profiles	O
+of	O
+B	O
+lymphoma	B-ANAT
+cells	B-COMP
+were	O
+analyzed	O
+by	O
+microarray	O
+.	O
+
+These	O
+macrophage	B-ANAT
+-	O
+like	O
+cells	B-COMP
+were	O
+defective	O
+in	O
+phagocytosis	B-PROC
+of	O
+red	O
+fluorescent	O
+beads	O
+.	O
+
+In	O
+conclusion	O
+,	O
+our	O
+results	O
+suggest	O
+that	O
+conversion	O
+of	O
+B	B-ANAT
+cells	I-ANAT
+to	O
+macrophage	B-ANAT
+-	O
+like	O
+cells	B-COMP
+,	O
+similar	O
+to	O
+a	O
+pathophysiological	O
+response	O
+,	O
+could	O
+be	O
+mediated	O
+by	O
+a	O
+devastating	O
+viral	O
+ligand	B-PROC
+,	O
+in	O
+particular	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+virus	B-SPEC
+,	O
+or	O
+in	O
+combination	O
+with	O
+severe	O
+local	O
+hypoxia	B-DISO
+,	O
+which	O
+is	O
+a	O
+condition	B-DISO
+often	O
+observed	O
+in	O
+afflicted	O
+lungs	B-ANAT
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Transmission	O
+electron	O
+microscopy	O
+showed	O
+that	O
+,	O
+compared	O
+to	O
+revertant	O
+virus	B-SPEC
+,	O
+the	O
+number	O
+of	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+in	O
+MHV	B-SPEC
+-	O
+Brts31	O
+-	O
+infected	O
+cells	B-COMP
+is	O
+reduced	O
+at	O
+the	O
+nonpermissive	O
+temperature	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+encode	O
+two	O
+classes	O
+of	O
+cysteine	B-PRGE
+proteases	I-PRGE
+,	O
+which	O
+have	O
+narrow	O
+substrate	O
+specificities	O
+and	O
+either	O
+a	O
+chymotrypsin	B-PRGE
+-	O
+or	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+fold	O
+.	O
+
+We	O
+identify	O
+both	O
+conserved	O
+and	O
+unique	O
+structural	O
+features	O
+likely	O
+controlling	O
+the	O
+interaction	O
+of	O
+PL1	B-PRGE
+(	O
+pro	B-CHED
+)	O
+with	O
+cofactors	B-CHED
+and	O
+substrates	O
+,	O
+including	O
+the	O
+tentative	O
+mapping	O
+of	O
+substrate	O
+pocket	O
+residues	O
+.	O
+
+Serum	B-COMP
+DNA	O
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+),	O
+and	O
+malonaldehyde	B-CHED
+(	O
+MDA	B-CHED
+)	O
+concentrations	O
+were	O
+measured	O
+and	O
+were	O
+found	O
+to	O
+be	O
+significantly	O
+higher	O
+in	O
+patients	O
+with	O
+moderate	O
+and	O
+severe	O
+OSAHS	B-DISO
+groups	O
+than	O
+those	O
+in	O
+the	O
+mild	O
+OSAHS	B-DISO
+and	O
+control	O
+groups	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+aspects	O
+of	O
+human	B-SPEC
+infection	B-DISO
+by	O
+the	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+].	O
+
+A	O
+new	O
+type	O
+of	O
+medicine	B-CHED
+has	O
+appeared	O
+,	O
+in	O
+the	O
+form	O
+of	O
+on	O
+-	O
+board	O
+medical	O
+assistance	O
+.	O
+
+TITLE	O
+:	O
+Cooperative	O
+translocation	B-DISO
+enhances	O
+the	O
+unwinding	O
+of	O
+duplex	O
+DNA	O
+by	O
+SARS	B-DISO
+coronavirus	B-SPEC
+helicase	I-PRGE
+nsP13	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	B-DISO
+viruses	I-SPEC
+continue	O
+to	O
+cause	O
+yearly	O
+epidemics	O
+and	O
+occasional	O
+pandemics	O
+in	O
+humans	O
+.	O
+
+In	O
+recent	O
+years	O
+,	O
+the	O
+threat	O
+of	O
+a	O
+possible	O
+influenza	B-DISO
+pandemic	O
+arising	O
+from	O
+the	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+virus	B-SPEC
+has	O
+prompted	O
+the	O
+development	B-PROC
+of	O
+comprehensive	O
+pandemic	O
+preparedness	O
+programs	O
+in	O
+many	O
+countries	O
+.	O
+
+Respiratory	B-DISO
+failure	I-DISO
+is	O
+the	O
+major	O
+complication	B-DISO
+,	O
+and	O
+patients	O
+may	O
+progress	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+There	O
+is	O
+currently	O
+no	O
+proven	O
+effective	O
+treatment	O
+of	O
+SARS	B-DISO
+,	O
+so	O
+early	O
+recognition	O
+,	O
+isolation	O
+,	O
+and	O
+stringent	O
+infection	B-DISO
+control	O
+are	O
+the	O
+key	O
+to	O
+controlling	O
+this	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+.	O
+
+which	O
+is	O
+widely	O
+used	O
+as	O
+an	O
+antiinflammatory	B-CHED
+agent	I-CHED
+in	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+.	O
+
+The	O
+pretreatment	O
+of	O
+cells	B-COMP
+with	O
+forsythoside	O
+A	O
+,	O
+adding	O
+forsythoside	O
+A	O
+post	O
+infection	B-DISO
+of	O
+cells	B-COMP
+,	O
+and	O
+treatment	O
+of	O
+virus	B-SPEC
+with	O
+forsythoside	O
+A	O
+were	O
+analysed	O
+.	O
+
+The	O
+inhibitory	O
+effect	O
+of	O
+forsythoside	O
+A	O
+was	O
+confirmed	O
+by	O
+infecting	O
+primary	O
+chicken	B-SPEC
+embryo	B-ANAT
+kidney	B-ANAT
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Ferret	B-SPEC
+coronavirus	B-SPEC
+-	O
+associated	O
+diseases	O
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+characterization	O
+of	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+-	I-SPEC
+related	I-SPEC
+coronavirus	I-SPEC
+in	O
+European	O
+bats	O
+and	O
+classification	O
+of	O
+coronaviruses	O
+based	O
+on	O
+partial	O
+RNA	O
+-	O
+dependent	O
+RNA	B-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+sequences	O
+.	O
+
+We	O
+conducted	O
+an	O
+evaluation	O
+of	O
+CoV	O
+in	O
+rhinolophid	O
+and	O
+vespertilionid	O
+bat	B-ENZY
+species	B-SPEC
+common	O
+in	O
+Europe	O
+.	O
+
+Rhinolophids	O
+carried	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+related	O
+CoV	O
+at	O
+high	O
+frequencies	O
+and	O
+concentrations	O
+(	O
+26	O
+%	O
+of	O
+animals	B-SPEC
+are	O
+positive	O
+;	O
+up	O
+to	O
+2	O
+.	O
+4	O
+×	O
+10	O
+(	O
+8	O
+)	O
+copies	O
+per	O
+gram	O
+of	O
+feces	B-ANAT
+),	O
+as	O
+well	O
+as	O
+two	O
+Alphacoronavirus	B-SPEC
+clades	O
+,	O
+one	O
+novel	O
+and	O
+one	O
+related	O
+to	O
+the	O
+HKU2	O
+clade	O
+.	O
+
+Criteria	O
+for	O
+defining	O
+separate	O
+RGU	O
+in	O
+mammalian	B-SPEC
+CoV	O
+were	O
+a	O
+>	O
+4	O
+.	O
+8	O
+%	O
+amino	B-CHED
+acid	I-CHED
+distance	O
+for	O
+alphacoronaviruses	O
+and	O
+a	O
+>	O
+6	O
+.	O
+3	O
+%	O
+distance	O
+for	O
+betacoronaviruses	O
+.	O
+
+After	O
+amplification	B-DISO
+by	O
+Bst	B-PRGE
+enzyme	I-PRGE
+at	O
+a	O
+constant	O
+temperature	O
+of	O
+65	O
+degrees	O
+C	O
+,	O
+a	O
+laddering	O
+of	O
+bright	O
+products	O
+was	O
+visible	O
+following	O
+electrophoresis	O
+on	O
+a	O
+2	O
+%	O
+agarose	B-CHED
+gel	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+determine	O
+the	O
+prevalence	O
+of	O
+CPV	B-SPEC
+and	O
+CECoV	O
+in	O
+dogs	B-SPEC
+presenting	O
+with	O
+severe	B-DISO
+diarrhoea	I-DISO
+to	O
+PDSA	O
+PetAid	O
+hospitals	O
+throughout	O
+the	O
+UK	O
+.	O
+
+All	O
+samples	O
+were	O
+tested	O
+for	O
+CPV	B-SPEC
+using	O
+a	O
+long	O
+range	O
+PCR	O
+and	O
+for	O
+CECoV	O
+using	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Analysis	O
+showed	O
+that	O
+animals	B-SPEC
+with	O
+no	O
+history	O
+of	O
+vaccination	O
+were	O
+more	O
+likely	O
+to	O
+be	O
+CPV	B-SPEC
+positive	O
+,	O
+with	O
+greatest	O
+effect	O
+in	O
+younger	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+cross	O
+-	O
+sectional	O
+study	O
+was	O
+conducted	O
+to	O
+evaluate	O
+the	O
+association	O
+between	O
+herd	O
+-	O
+level	O
+characteristics	O
+,	O
+management	O
+routines	O
+and	O
+farm	O
+-	O
+level	O
+antibody	O
+status	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+and	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+)	O
+in	O
+257	O
+Swedish	O
+dairy	O
+herds	O
+.	O
+
+Surfactant	B-CHED
+replacement	O
+with	O
+calfactant	O
+is	O
+a	O
+rational	O
+,	O
+useful	O
+,	O
+and	O
+potentially	O
+lifesaving	O
+treatment	O
+for	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+drowning	O
+.	O
+
+ABSTRACT	O
+:	O
+Sensitivity	O
+and	O
+specificity	O
+of	O
+respiratory	O
+change	O
+in	O
+pulse	B-PROC
+pressure	I-PROC
+(	O
+DeltaPP	O
+)	O
+to	O
+predict	O
+preload	O
+dependency	O
+has	O
+been	O
+questioned	O
+at	O
+small	O
+tidal	O
+volumes	O
+(	O
+VT	O
+)	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+suffering	B-DISO
+from	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Sixteen	O
+deeply	O
+sedated	O
+mechanically	O
+ventilated	O
+pigs	B-SPEC
+were	O
+successively	O
+ventilated	O
+with	O
+VT	O
+of	O
+10	O
+ml	O
+/	O
+kg	O
+at	O
+a	O
+respiratory	O
+rate	O
+of	O
+15	O
+breaths	O
+/	O
+min	O
+(	O
+RR15	O
+)	O
+and	O
+VT	O
+of	O
+6	O
+ml	O
+/	O
+kg	O
+at	O
+RR15	O
+and	O
+RR25	O
+.	O
+
+Two	O
+of	O
+6	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+had	O
+increased	O
+macro	O
+-	O
+CK1	B-PRGE
+and	O
+increased	O
+CK	B-FUNC
+-	I-FUNC
+BB	I-FUNC
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+within	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+proteome	O
+have	O
+been	O
+identified	O
+,	O
+one	O
+of	O
+them	O
+being	O
+between	O
+non	O
+-	O
+structural	O
+proteins	B-CHED
+nsp10	O
+and	O
+nsp16	O
+.	O
+
+TITLE	O
+:	O
+A	O
+fulminant	O
+case	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+associated	O
+with	O
+Mycoplasma	B-DISO
+pneumoniae	I-SPEC
+infection	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+caused	O
+by	O
+mycoplasmas	B-SPEC
+is	O
+very	O
+rare	O
+.	O
+
+This	O
+report	O
+describes	O
+a	O
+severe	O
+case	O
+of	O
+atypical	B-DISO
+pneumonia	I-DISO
+due	O
+to	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+in	O
+a	O
+formerly	O
+healthy	O
+young	O
+woman	O
+who	O
+developed	O
+high	O
+grade	O
+fever	B-PROC
+and	O
+cough	B-DISO
+leading	O
+to	O
+severe	O
+disseminated	O
+lung	B-DISO
+disease	I-DISO
+and	O
+finally	O
+to	O
+fatal	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+the	O
+successful	O
+use	O
+of	O
+perioperative	O
+non	O
+-	O
+invasive	O
+mechanical	O
+ventilation	O
+in	O
+a	O
+morbidly	O
+obese	O
+pregnant	O
+woman	O
+with	O
+bronchial	B-DISO
+asthma	B-PATH
+,	O
+severe	B-DISO
+preeclampsia	I-DISO
+and	O
+pulmonary	B-DISO
+edema	I-DISO
+undergoing	O
+an	O
+emergency	B-DISO
+cesarean	O
+delivery	O
+with	O
+spinal	O
+anesthesia	B-DISO
+.	O
+
+STAT1	B-PRGE
+-/-	O
+mice	B-SPEC
+exhibited	O
+dysregulation	O
+of	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+and	O
+macrophage	B-PROC
+differentiation	I-PROC
+,	O
+leading	O
+to	O
+a	O
+TH2	O
+-	O
+biased	O
+immune	B-PROC
+response	I-PROC
+and	O
+the	O
+development	B-PROC
+of	O
+alternatively	O
+activated	O
+macrophages	B-ANAT
+that	O
+mediate	O
+a	O
+profibrotic	O
+environment	O
+within	O
+the	O
+lung	B-ANAT
+.	O
+
+Recombination	B-PROC
+analysis	O
+using	O
+eight	O
+Ro	O
+-	O
+BatCoV	O
+HKU9	O
+genomes	O
+showed	O
+possible	O
+recombination	O
+events	O
+between	O
+strains	O
+from	O
+different	O
+bat	B-ENZY
+individuals	O
+,	O
+which	O
+may	O
+have	O
+allowed	O
+for	O
+the	O
+generation	O
+of	O
+different	O
+genotypes	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+disease	O
+in	O
+Tunisia	O
+:	O
+seroprevalence	O
+,	O
+pathogenicity	O
+and	O
+compatibility	O
+studies	O
+of	O
+vaccine	O
+-	O
+field	O
+isolates	O
+].	O
+
+ABSTRACT	O
+:	O
+A	O
+sero	O
+-	O
+epidemiological	O
+study	O
+was	O
+carried	O
+out	O
+on	O
+5660	O
+sera	B-COMP
+collected	O
+,	O
+between	O
+2006	O
+and	O
+2008	O
+,	O
+from	O
+different	O
+flocks	O
+in	O
+different	O
+regions	O
+of	O
+the	O
+country	O
+.	O
+
+TITLE	O
+:	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cell	I-ANAT
+response	O
+in	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0201	I-PRGE
+transgenic	B-SPEC
+mice	I-SPEC
+is	O
+elicited	O
+by	O
+epitopes	O
+from	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Cytotoxic	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+lymphocytes	I-ANAT
+(	O
+CTLs	O
+)	O
+play	O
+an	O
+important	O
+role	O
+in	O
+antiviral	B-CHED
+immunity	B-PROC
+.	O
+
+The	O
+lymphocytes	B-ANAT
+from	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+,	O
+spleens	B-ANAT
+and	O
+lungs	B-ANAT
+were	O
+stimulated	O
+with	O
+the	O
+cognate	O
+peptides	B-CHED
+.	O
+
+The	O
+phenotype	O
+of	O
+the	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+was	O
+characterized	O
+based	O
+on	O
+the	O
+expression	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+.	O
+
+Sophorae	O
+radix	B-SPEC
+,	O
+Acanthopanacis	O
+cortex	B-ANAT
+,	O
+Sanguisorbae	O
+radix	B-SPEC
+and	O
+Torilis	B-SPEC
+fructus	O
+might	O
+be	O
+considered	O
+as	O
+promising	O
+novel	O
+anti	O
+-	O
+coronavirus	B-SPEC
+drug	O
+candidates	O
+.	O
+
+ABSTRACT	O
+:	O
+Panton	B-PRGE
+-	I-PRGE
+Valentine	I-PRGE
+leukocidin	I-PRGE
+expressing	O
+Staphylococcus	B-DISO
+aureus	I-DISO
+pneumonia	I-DISO
+,	O
+an	O
+infection	B-DISO
+that	O
+affects	O
+predominantly	O
+young	O
+people	O
+,	O
+has	O
+a	O
+mortality	O
+rate	O
+of	O
+>	O
+70	O
+%	O
+despite	O
+aggressive	B-DISO
+conventional	O
+management	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+a	O
+variant	O
+virus	B-SPEC
+from	O
+ascitic	B-ANAT
+fluid	I-ANAT
+of	O
+subacute	O
+granulomatous	O
+serositis	B-DISO
+in	O
+interferon	O
+-	O
+gamma	O
+-	O
+deficient	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+persistently	O
+infected	O
+with	O
+murine	B-SPEC
+coronavirus	I-SPEC
+strain	O
+JHM	O
+.	O
+
+Viruses	B-SPEC
+were	O
+isolated	O
+from	O
+ascites	O
+at	O
+25	O
+d	O
+post	O
+-	O
+infection	B-DISO
+and	O
+cloned	O
+by	O
+limiting	O
+dilution	O
+on	O
+DBT	B-CHED
+cells	B-COMP
+;	O
+one	O
+variant	O
+was	O
+named	O
+25V16G	O
+.	O
+
+Nucleotide	B-CHED
+sequencing	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+of	O
+25V16G	O
+and	O
+JHMV	O
+revealed	O
+a	O
+deletion	O
+of	O
+29	O
+amino	B-CHED
+acids	I-CHED
+encompassing	O
+S	O
+(	O
+511	O
+-	O
+539	O
+),	O
+which	O
+covers	O
+a	O
+major	O
+cytotoxic	B-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+(	O
+CTL	B-ANAT
+)	O
+epitope	B-CHED
+in	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+,	O
+and	O
+two	O
+point	B-PROC
+mutations	I-PROC
+resulting	O
+in	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+25V16G	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+104	O
+children	O
+suffering	B-DISO
+from	O
+HCMV	O
+infection	B-DISO
+,	O
+in	O
+an	O
+effort	B-PROC
+to	O
+find	O
+any	O
+association	O
+between	O
+MBL	O
+and	O
+HCMV	O
+infection	B-DISO
+of	O
+children	O
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+pathophysiological	O
+effects	O
+of	O
+intratracheal	O
+instillation	O
+of	O
+budesonide	B-CHED
+and	O
+exogenous	O
+surfactant	B-CHED
+in	O
+a	O
+neonatal	O
+surfactant	B-CHED
+-	O
+depleted	O
+piglet	O
+model	O
+.	O
+
+The	O
+additional	O
+use	O
+of	O
+budesonide	B-CHED
+does	O
+not	O
+disturb	O
+the	O
+function	O
+of	O
+the	O
+exogenous	O
+surfactant	B-CHED
+.	O
+
+Histophilus	B-SPEC
+somni	I-SPEC
+was	O
+detected	O
+in	O
+2	O
+/	O
+40	O
+(	O
+5	O
+%)	O
+cases	O
+,	O
+while	O
+bovine	B-SPEC
+herpesvirus	I-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+bovine	B-DISO
+viral	I-DISO
+diarrhoea	I-DISO
+virus	B-SPEC
+and	O
+parainfluenza	B-DISO
+virus	B-SPEC
+-	O
+3	O
+were	O
+each	O
+found	O
+in	O
+1	O
+/	O
+40	O
+(	O
+2	O
+.	O
+5	O
+%)	O
+case	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+case	O
+-	O
+control	O
+study	O
+was	O
+designed	O
+to	O
+investigate	O
+the	O
+role	O
+of	O
+different	O
+Cryptosporidium	O
+spp	B-ENZY
+.	O
+
+Faecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+preweaned	O
+calves	O
+,	O
+young	O
+stock	O
+and	O
+cows	B-SPEC
+.	O
+
+Molecular	O
+diagnostics	O
+were	O
+used	O
+to	O
+identify	O
+Cryptosporidium	B-SPEC
+species	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+expressed	B-PROC
+a	O
+truncated	O
+gene	O
+encoding	O
+the	O
+N	O
+terminal	O
+half	O
+of	O
+TGEV	B-PRGE
+S	I-PRGE
+gene	I-PRGE
+(	O
+designated	O
+S1	B-PRGE
+gene	I-PRGE
+)	O
+in	O
+a	O
+prokaryotic	O
+system	O
+.	O
+
+TITLE	O
+:	O
+Culturing	O
+the	O
+unculturable	O
+:	O
+human	B-SPEC
+coronavirus	I-SPEC
+HKU1	I-SPEC
+infects	O
+,	O
+replicates	O
+,	O
+and	O
+produces	O
+progeny	O
+virions	O
+in	O
+human	B-SPEC
+ciliated	O
+airway	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+cultures	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+critical	O
+to	O
+develop	O
+suitable	O
+in	O
+vitro	O
+platforms	O
+to	O
+isolate	O
+and	O
+characterize	O
+the	O
+replication	O
+kinetics	O
+and	O
+pathogenesis	B-DISO
+of	O
+recently	O
+identified	O
+human	B-SPEC
+pathogens	O
+.	O
+
+We	O
+propose	O
+that	O
+the	O
+HAE	O
+model	O
+provides	O
+a	O
+ready	O
+platform	O
+for	O
+molecular	O
+studies	O
+and	O
+characterization	O
+of	O
+HCoV	O
+-	O
+HKU1	O
+and	O
+in	O
+general	O
+serves	O
+as	O
+a	O
+robust	O
+technology	O
+for	O
+the	O
+recovery	O
+,	O
+amplification	B-DISO
+,	O
+adaptation	B-PROC
+,	O
+and	O
+characterization	O
+of	O
+novel	O
+coronaviruses	O
+and	O
+other	O
+respiratory	O
+viruses	B-SPEC
+from	O
+clinical	O
+material	O
+.	O
+
+Coinfections	B-DISO
+with	O
+>	O
+or	O
+=	O
+2	O
+viruses	B-SPEC
+were	O
+found	O
+in	O
+20	O
+(	O
+11	O
+%)	O
+patients	O
+.	O
+
+Patients	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+were	O
+younger	O
+than	O
+those	O
+who	O
+were	O
+positive	O
+for	O
+PIV1	O
+(	O
+median	O
+age	O
+13	O
+months	O
+versus	O
+21	O
+months	O
+,	O
+P	O
+=	O
+0	O
+.	O
+006	O
+)	O
+and	O
+had	O
+shorter	O
+fever	B-PROC
+duration	O
+than	O
+influenza	B-DISO
+A	I-DISO
+virus	B-PROC
+infection	I-PROC
+(	O
+median	O
+1	O
+.	O
+5	O
+days	O
+versus	O
+4	O
+days	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+).	O
+
+RESULTS	O
+:	O
+Viruses	B-SPEC
+were	O
+identified	O
+in	O
+147	O
+(	O
+80	O
+.	O
+8	O
+%)	O
+of	O
+the	O
+182	O
+croup	B-DISO
+patients	O
+.	O
+
+Before	O
+ECMO	O
+,	O
+patients	O
+had	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+median	O
+(	O
+IQR	O
+)	O
+PaO₂	O
+to	O
+FiO₂	O
+ratio	O
+of	O
+52	O
+(	O
+50	O
+-	O
+60	O
+)	O
+mmHg	O
+and	O
+PaCO₂	O
+of	O
+85	O
+(	O
+69	O
+-	O
+91	O
+)	O
+mmHg	O
+.	O
+
+ECMO	O
+may	O
+be	O
+an	O
+effective	O
+salvage	O
+treatment	O
+for	O
+patients	O
+with	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)-	O
+related	O
+ARDS	B-DISO
+presenting	O
+rapid	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+particularly	O
+when	O
+provided	O
+by	O
+a	O
+mobile	O
+team	O
+allowing	O
+early	O
+cannulation	O
+prior	O
+to	O
+transfer	O
+to	O
+a	O
+reference	O
+centre	O
+.	O
+
+This	O
+study	O
+aimed	O
+at	O
+developing	O
+a	O
+multiplex	O
+semi	O
+-	O
+nested	O
+RT	O
+-	O
+PCR	O
+for	O
+simultaneous	O
+detection	O
+of	O
+BCoV	O
+(	O
+N	B-PRGE
+gene	I-PRGE
+)	O
+and	O
+group	B-SPEC
+A	I-SPEC
+rotavirus	I-SPEC
+(	O
+VP1	O
+gene	O
+)	O
+with	O
+the	O
+addition	O
+of	O
+an	O
+internal	O
+control	O
+(	O
+mRNA	B-CHED
+ND5	O
+).	O
+
+The	O
+pregnant	O
+females	O
+infected	O
+with	O
+PEDV	B-SPEC
+during	O
+the	O
+first	O
+30	O
+days	O
+of	O
+pregnancy	O
+had	O
+a	O
+12	O
+.	O
+6	O
+percentage	O
+point	O
+decrease	O
+of	O
+FR	O
+(	O
+91	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+78	O
+.	O
+5	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+003	O
+),	O
+a	O
+5	O
+.	O
+7	O
+percentage	O
+point	O
+increase	O
+of	O
+RR	O
+(	O
+3	O
+.	O
+5	O
+%	O
+vs	O
+.	O
+9	O
+.	O
+2	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+01	O
+),	O
+a	O
+1	O
+.	O
+3	O
+percentage	O
+point	O
+increase	O
+of	O
+AR	O
+(	O
+2	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+3	O
+.	O
+4	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+01	O
+)	O
+and	O
+a	O
+2	O
+.	O
+0	O
+percentage	O
+point	O
+increase	O
+of	O
+MM	O
+(	O
+3	O
+.	O
+5	O
+%	O
+vs	O
+.	O
+5	O
+.	O
+6	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+SB	O
+increased	O
+in	O
+the	O
+pregnant	O
+females	O
+that	O
+were	O
+infected	O
+with	O
+PEDV	B-SPEC
+during	O
+91	O
+-	O
+120	O
+days	O
+of	O
+pregnancy	O
+(	O
+1	O
+.	O
+8	O
+percentage	O
+points	O
+,	O
+4	O
+.	O
+5	O
+%	O
+vs	O
+.	O
+6	O
+.	O
+2	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+01	O
+).	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+phenanthroindolizines	O
+and	O
+phenanthroquinolizidines	O
+as	O
+novel	O
+potent	O
+anti	O
+-	O
+coronaviral	O
+agents	O
+for	O
+porcine	B-SPEC
+enteropathogenic	O
+coronavirus	B-SPEC
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+potent	O
+compounds	O
+showed	O
+50	O
+%	O
+maximal	O
+effective	O
+concentration	O
+(	O
+EC₅₀	O
+)	O
+values	O
+ranging	O
+from	O
+8	O
+to	O
+1468	O
+nM	O
+as	O
+determined	O
+by	O
+immunofluorescent	O
+assay	O
+of	O
+the	O
+expression	B-PROC
+of	O
+TGEV	B-SPEC
+N	O
+and	O
+S	O
+proteins	B-CHED
+and	O
+by	O
+real	O
+time	O
+-	O
+quantitative	O
+PCR	O
+analysis	O
+of	O
+viral	O
+yields	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+potent	O
+tylophorine	O
+compounds	O
+exerted	O
+profound	O
+anti	O
+-	O
+TGEV	B-SPEC
+replication	O
+activity	O
+and	O
+thereby	O
+blocked	O
+the	O
+TGEV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+and	O
+subsequent	O
+cytopathic	B-DISO
+effect	I-DISO
+in	O
+ST	O
+cells	B-COMP
+.	O
+
+Analysis	O
+of	O
+the	O
+structure	O
+-	O
+activity	O
+relations	O
+indicated	O
+that	O
+the	O
+most	O
+active	O
+tylophorine	O
+analogues	O
+were	O
+compounds	O
+with	O
+a	O
+hydroxyl	B-CHED
+group	I-CHED
+at	O
+the	O
+C14	O
+position	O
+of	O
+the	O
+indolizidine	O
+moiety	O
+or	O
+at	O
+the	O
+C3	O
+position	O
+of	O
+the	O
+phenanthrene	B-CHED
+moiety	O
+and	O
+that	O
+the	O
+quinolizidine	B-CHED
+counterparts	O
+were	O
+more	O
+potent	O
+than	O
+indolizidines	O
+.	O
+
+More	O
+severe	O
+LPS	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+and	O
+vascular	B-ANAT
+leak	O
+were	O
+observed	O
+in	O
+ANP	O
+knockout	O
+mice	B-SPEC
+.	O
+
+In	O
+rescue	O
+experiments	O
+,	O
+ANP	B-PRGE
+injection	O
+significantly	O
+reduced	O
+lung	B-ANAT
+injury	O
+in	O
+Nppa	O
+(-/-)	O
+mice	B-SPEC
+caused	O
+by	O
+LPS	B-DISO
+.	O
+
+Our	O
+data	O
+suggest	O
+a	O
+direct	O
+role	O
+for	O
+ANP	B-PRGE
+in	O
+endothelial	B-ANAT
+barrier	O
+regulation	B-PROC
+via	O
+modulation	O
+of	O
+small	B-PRGE
+GTPase	I-PRGE
+signaling	B-PROC
+.	O
+
+RESULTS	O
+:	O
+45	O
+patients	O
+with	O
+severe	O
+manifestations	O
+of	O
+infectious	B-DISO
+mononucleosis	I-DISO
+received	O
+antivirals	B-CHED
+(	O
+as	O
+an	O
+adjunct	O
+to	O
+steroids	B-CHED
+in	O
+26	O
+of	O
+them	O
+).	O
+
+Here	O
+we	O
+investigated	O
+,	O
+using	O
+recombinant	O
+murine	B-SPEC
+coronaviruses	O
+expressing	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	O
+)-	O
+tagged	O
+versions	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+the	O
+dynamics	O
+of	O
+its	O
+interactions	O
+with	O
+the	O
+RTCs	O
+and	O
+the	O
+domain	O
+(	O
+s	O
+)	O
+involved	O
+.	O
+
+Using	O
+fluorescent	O
+recovery	O
+after	O
+photobleaching	O
+,	O
+we	O
+showed	O
+that	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+unlike	O
+the	O
+nonstructural	O
+protein	B-CHED
+2	O
+,	O
+is	O
+dynamically	O
+associated	O
+with	O
+the	O
+RTCs	O
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+receptors	O
+are	O
+differentially	O
+expressed	B-PROC
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+and	O
+play	O
+virus	O
+strain	O
+-	O
+dependent	O
+roles	O
+in	O
+neuronal	O
+spread	O
+.	O
+
+Quantification	O
+of	O
+mRNA	B-CHED
+for	O
+the	O
+ceacam1a	B-PRGE
+-	I-PRGE
+related	I-PRGE
+genes	I-PRGE
+ceacam2	I-PRGE
+and	O
+psg16	O
+(	O
+bCEA	O
+),	O
+which	O
+encode	O
+proposed	O
+alternative	O
+MHV	B-SPEC
+receptors	O
+,	O
+revealed	O
+low	O
+ceacam2	O
+expression	B-PROC
+in	O
+microglia	B-ANAT
+and	O
+oligodendrocytes	B-ANAT
+and	O
+psg16	O
+expression	B-PROC
+exclusively	O
+in	O
+neurons	B-ANAT
+;	O
+however	O
+,	O
+only	O
+CEACAM2	O
+mediated	O
+infection	B-DISO
+in	O
+human	B-SPEC
+293T	O
+cells	B-COMP
+.	O
+
+Haematological	O
+and	O
+biochemical	O
+abnormalities	O
+in	O
+FIP	B-DISO
+cases	O
+are	O
+also	O
+non	O
+-	O
+specific	O
+.	O
+
+Reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+has	O
+been	O
+used	O
+to	O
+detect	O
+FCoV	O
+and	O
+is	O
+rapid	O
+and	O
+sensitive	O
+,	O
+but	O
+results	O
+must	O
+be	O
+interpreted	O
+in	O
+the	O
+context	O
+of	O
+clinical	O
+findings	O
+.	O
+
+The	O
+assay	O
+established	O
+in	O
+this	O
+study	O
+was	O
+found	O
+to	O
+detect	O
+only	O
+the	O
+TGEV	B-SPEC
+and	O
+no	O
+cross	B-PROC
+-	I-PROC
+reaction	I-PROC
+with	O
+other	O
+viruses	B-SPEC
+,	O
+demonstrating	O
+its	O
+high	O
+specificity	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+global	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+led	O
+to	O
+an	O
+intense	O
+and	O
+effective	O
+global	O
+response	O
+that	O
+stopped	O
+the	O
+spread	O
+of	O
+the	O
+disease	O
+by	O
+July	O
+2003	O
+.	O
+
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+(	O
+IAH	B-FUNC
+)	O
+and	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+)	O
+are	O
+increasingly	O
+recognized	O
+and	O
+treatable	O
+complications	O
+of	O
+severe	O
+illness	O
+in	O
+medical	O
+patients	O
+,	O
+and	O
+are	O
+independent	O
+predictors	O
+of	O
+mortality	O
+.	O
+
+However	O
+,	O
+ACS	B-FUNC
+has	O
+been	O
+only	O
+rarely	O
+described	O
+in	O
+this	O
+population	O
+.	O
+
+Her	O
+clinical	O
+course	O
+worsened	O
+abruptly	O
+,	O
+with	O
+new	O
+shock	O
+,	O
+worsening	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+,	O
+increased	O
+peak	O
+airway	O
+pressures	O
+and	O
+reduced	O
+tidal	O
+volumes	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+H1N1	O
+(	O
+2009	O
+)	O
+influenza	B-DISO
+among	O
+healthcare	O
+workers	O
+in	O
+a	O
+tertiary	O
+care	O
+center	O
+in	O
+Saudi	O
+Arabia	O
+:	O
+a	O
+6	O
+-	O
+month	O
+surveillance	O
+study	O
+.	O
+
+None	O
+of	O
+these	O
+HCWs	O
+died	B-PROC
+,	O
+and	O
+all	O
+recovered	O
+fully	O
+without	O
+hospital	O
+admission	O
+.	O
+
+Early	O
+protection	O
+appears	O
+to	O
+be	O
+mediated	O
+partly	O
+through	O
+the	O
+inhibition	B-PROC
+of	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+pathway	B-PROC
+activation	O
+.	O
+
+Abrupt	O
+cessation	O
+of	O
+intrathecal	B-ANAT
+baclofen	B-CHED
+infusion	O
+has	O
+been	O
+associated	O
+with	O
+a	O
+severe	O
+withdrawal	B-DISO
+syndrome	I-DISO
+comprised	O
+of	O
+dystonia	B-DISO
+,	O
+autonomic	B-DISO
+dysfunction	I-DISO
+,	O
+hyperthermia	B-PROC
+,	O
+end	O
+-	O
+organ	B-DISO
+failure	I-DISO
+and	O
+sometimes	O
+death	B-PROC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+prevent	O
+premature	O
+interruption	O
+of	O
+folding	O
+,	O
+ERAD	B-PROC
+regulators	O
+and	O
+effectors	O
+such	O
+as	O
+EDEM1	B-PRGE
+and	O
+OS	B-PRGE
+-	I-PRGE
+9	I-PRGE
+are	O
+selectively	O
+cleared	O
+from	O
+the	O
+ER	O
+in	O
+so	O
+-	O
+called	O
+EDEMosomes	O
+to	O
+downregulate	O
+the	O
+degradative	O
+activity	O
+.	O
+
+While	O
+it	O
+seems	O
+clear	O
+that	O
+CoVs	O
+hijack	O
+ER	O
+-	O
+derived	O
+host	O
+cell	B-COMP
+membranes	I-COMP
+for	O
+replication	O
+,	O
+the	O
+mechanism	O
+by	O
+which	O
+these	O
+DMVs	O
+are	O
+assembled	O
+has	O
+remained	O
+completely	O
+mysterious	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+antioxidative	O
+and	O
+antiviral	B-CHED
+properties	O
+of	O
+flowering	B-PROC
+cherry	O
+cultivars	O
+(	O
+Prunus	B-SPEC
+yedoensis	I-SPEC
+,	O
+Prunus	B-SPEC
+sargentii	I-SPEC
+,	O
+Prunus	B-SPEC
+lannesiana	O
+,	O
+and	O
+Prunus	B-SPEC
+cerasus	I-SPEC
+)	O
+in	O
+Korea	O
+were	O
+investigated	O
+.	O
+
+The	O
+incidence	O
+of	O
+MRSA	B-DISO
+infection	I-DISO
+in	O
+the	O
+ICU	O
+was	O
+monitored	O
+during	O
+3	O
+different	O
+phases	O
+:	O
+the	O
+baseline	O
+period	O
+(	O
+phase	O
+1	O
+);	O
+after	O
+ICU	O
+renovation	O
+(	O
+phase	O
+2	O
+)	O
+and	O
+after	O
+implementation	O
+of	O
+a	O
+hand	O
+hygiene	O
+campaign	O
+with	O
+alcohol	O
+-	O
+based	O
+hand	O
+rub	O
+(	O
+phase	O
+3	O
+).	O
+
+Among	O
+the	O
+types	O
+of	O
+genomes	O
+being	O
+rapidly	O
+sequenced	O
+are	O
+those	O
+of	O
+microbial	O
+and	O
+viral	O
+genomes	O
+responsible	O
+for	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Therefore	O
+,	O
+accurate	O
+and	O
+efficient	O
+gene	O
+prediction	O
+programs	O
+are	O
+highly	O
+desired	O
+for	O
+rapid	O
+and	O
+cost	O
+effective	O
+surveillance	O
+of	O
+RNA	O
+viruses	B-SPEC
+through	O
+full	O
+genome	O
+sequencing	O
+.	O
+
+we	O
+have	O
+developed	O
+VIGOR	O
+(	O
+Viral	B-COMP
+Genome	I-COMP
+ORF	O
+Reader	O
+),	O
+a	O
+web	B-DISO
+application	O
+tool	O
+for	O
+gene	O
+prediction	O
+in	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+rotavirus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+subtypes	O
+.	O
+
+VIGOR	O
+detects	O
+protein	B-CHED
+coding	O
+regions	O
+based	O
+on	O
+sequence	O
+similarity	O
+searches	O
+and	O
+can	O
+accurately	O
+detect	O
+genome	O
+specific	O
+features	O
+such	O
+as	O
+frame	O
+shifts	O
+,	O
+overlapping	O
+genes	O
+,	O
+embedded	O
+genes	O
+,	O
+and	O
+can	O
+predict	O
+mature	O
+peptides	B-CHED
+within	O
+the	O
+context	O
+of	O
+a	O
+single	O
+polypeptide	B-CHED
+open	O
+reading	O
+frame	O
+.	O
+
+Genotyping	O
+capability	O
+for	O
+influenza	B-DISO
+and	O
+rotavirus	B-SPEC
+is	O
+built	O
+into	O
+the	O
+program	O
+.	O
+
+TITLE	O
+:	O
+Trimethoprim	B-CHED
+/	I-CHED
+Sulfamethoxazole	I-CHED
+pharmacokinetics	B-PROC
+in	O
+two	O
+patients	O
+undergoing	O
+continuous	O
+venovenous	O
+hemodiafiltration	O
+.	O
+
+A	O
+77	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+was	O
+admitted	O
+for	O
+aortic	B-ANAT
+root	I-ANAT
+replacement	O
+and	O
+developed	O
+septic	B-DISO
+shock	I-DISO
+and	O
+nosocomial	B-DISO
+pneumonia	I-DISO
+due	O
+to	O
+Stenotrophomonas	B-SPEC
+maltophilia	I-SPEC
+.	O
+
+Twenty	O
+-	O
+two	O
+(	O
+13	O
+%)	O
+newborns	O
+in	O
+the	O
+CPAP	O
+group	O
+subsequently	O
+required	O
+ETT	O
+ventilation	O
+within	O
+24	O
+h	O
+:	O
+these	O
+babies	O
+had	O
+higher	O
+initial	O
+oxygen	B-CHED
+requirements	O
+than	O
+those	O
+successfully	O
+transported	O
+on	O
+CPAP	B-PRGE
+alone	O
+.	O
+
+PEDV	B-SPEC
+obtained	O
+after	O
+ten	O
+passages	O
+through	O
+the	O
+brains	B-ANAT
+(	O
+MK	B-PRGE
+-	I-PRGE
+p10	I-PRGE
+)	O
+had	O
+increased	O
+virulence	B-PROC
+for	O
+mice	B-SPEC
+,	O
+and	O
+its	O
+fusion	O
+activity	O
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+exceeded	O
+that	O
+of	O
+the	O
+original	O
+strain	O
+.	O
+
+However	O
+,	O
+the	O
+replication	O
+kinetics	O
+of	O
+MK	O
+and	O
+MK	B-PRGE
+-	I-PRGE
+p10	I-PRGE
+did	O
+not	O
+differ	O
+from	O
+each	O
+other	O
+in	O
+the	O
+brain	B-ANAT
+and	O
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+.	O
+
+One	O
+of	O
+these	O
+(	O
+an	O
+H	O
+-	O
+to	O
+-	O
+R	O
+substitution	O
+at	O
+residue	O
+1	O
+,	O
+381	O
+)	O
+was	O
+first	O
+detected	O
+in	O
+PEDV	B-SPEC
+isolated	O
+after	O
+eight	O
+passages	O
+,	O
+and	O
+both	O
+this	O
+virus	B-SPEC
+(	O
+MK	O
+-	O
+p8	O
+)	O
+and	O
+MK	O
+-	O
+p10	B-PRGE
+showed	O
+enhanced	O
+syncytium	B-PROC
+formation	I-PROC
+relative	O
+to	O
+the	O
+original	O
+MK	O
+strain	O
+and	O
+viruses	O
+isolated	O
+after	O
+two	O
+,	O
+four	O
+,	O
+and	O
+six	O
+passages	O
+,	O
+suggesting	O
+the	O
+possibility	O
+that	O
+the	O
+H	O
+-	O
+to	O
+-	O
+R	O
+mutation	O
+was	O
+responsible	O
+for	O
+this	O
+activity	O
+.	O
+
+Advances	O
+in	O
+the	O
+standardisation	O
+of	O
+care	O
+for	O
+ARDS	O
+patients	O
+involving	O
+innovative	O
+therapeutic	O
+procedures	O
+such	O
+as	O
+extracorporeal	O
+gas	B-PRGE
+exchange	I-PRGE
+systems	I-PRGE
+will	O
+lead	O
+to	O
+a	O
+further	O
+improvement	O
+in	O
+ARDS	B-DISO
+management	O
+and	O
+outcome	O
+.	O
+
+These	O
+demonstrated	O
+that	O
+specific	O
+rather	O
+than	O
+generic	O
+changes	O
+occurred	O
+in	O
+the	O
+nucleolar	B-ANAT
+proteome	O
+in	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Using	O
+multiplex	O
+PCR	O
+/	O
+RT	O
+-	O
+PCR	O
+methods	O
+for	O
+the	O
+detection	O
+of	O
+18	O
+respiratory	O
+viruses	B-SPEC
+,	O
+the	O
+circulation	B-PROC
+of	O
+those	O
+viruses	B-SPEC
+during	O
+3	O
+consecutive	O
+dry	O
+seasons	O
+in	O
+Cambodia	O
+was	O
+described	O
+.	O
+
+No	O
+significant	O
+differences	O
+were	O
+observed	O
+in	O
+frequency	O
+and	O
+in	O
+virus	B-SPEC
+copy	O
+numbers	O
+for	O
+rhinovirus	B-SPEC
+detection	O
+between	O
+symptomatic	O
+and	O
+asymptomatic	O
+groups	O
+.	O
+
+The	O
+link	O
+between	O
+the	O
+presence	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+the	O
+origin	O
+of	O
+the	O
+illness	O
+is	O
+therefore	O
+unclear	O
+.	O
+
+Among	O
+patients	O
+who	O
+developed	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+there	O
+was	O
+no	O
+evidence	O
+to	O
+support	O
+a	O
+difference	O
+in	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+to	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+Pao	B-PROC
+(	O
+2	O
+)/	O
+Fio	O
+(	O
+2	O
+))	O
+(	O
+P	O
+=	O
+.	O
+33	O
+),	O
+lung	B-ANAT
+injury	O
+score	O
+(	O
+P	O
+=	O
+.	O
+67	O
+),	O
+or	O
+mortality	O
+(	O
+P	O
+=	O
+.	O
+78	O
+)	O
+by	O
+race	O
+.	O
+
+Following	O
+MHV	B-SPEC
+infection	B-DISO
+,	O
+T3	O
+-	O
+and	O
+T9	O
+-	O
+injured	O
+mice	B-SPEC
+exhibited	O
+increased	O
+mortality	O
+in	O
+comparison	O
+to	O
+un	O
+-	O
+injured	O
+and	O
+laminectomy	O
+controls	O
+.	O
+
+Infection	B-DISO
+at	O
+all	O
+dosages	O
+resulted	O
+in	O
+significantly	O
+higher	O
+viral	O
+titer	O
+in	O
+both	O
+T3	O
+-	O
+and	O
+T9	O
+-	O
+injured	O
+mice	B-SPEC
+compared	O
+to	O
+un	O
+-	O
+injured	O
+controls	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+still	O
+significant	O
+mortality	O
+associated	O
+with	O
+antineutrophil	B-PRGE
+cytoplasmic	I-PRGE
+antibody	B-COMP
+-	O
+associated	O
+vasculitis	B-DISO
+.	O
+
+Herein	O
+,	O
+we	O
+report	O
+successful	O
+lung	B-ANAT
+transplantation	O
+for	O
+a	O
+patient	O
+with	O
+life	O
+-	O
+threatening	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+as	O
+a	O
+consequence	O
+of	O
+this	O
+pulmonary	B-DISO
+renal	B-ANAT
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+15	O
+-	O
+year	O
+analysis	O
+of	O
+molecular	O
+epidemiology	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+coronavirus	B-SPEC
+in	O
+China	O
+.	O
+
+Nine	O
+types	O
+were	O
+found	O
+according	O
+to	O
+sequence	O
+analysis	O
+and	O
+phylogenetic	O
+study	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+Factors	O
+contributing	O
+to	O
+the	O
+continual	O
+emergence	O
+include	O
+mutations	O
+,	O
+insertions	O
+and	O
+deletions	O
+in	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+genes	I-PRGE
+;	O
+recombination	B-PROC
+between	O
+local	O
+IBV	B-SPEC
+strains	O
+circulating	O
+in	O
+chicken	B-SPEC
+flocks	O
+in	O
+China	O
+;	O
+and	O
+recombination	B-PROC
+between	O
+local	O
+strains	O
+and	O
+vaccine	O
+strains	O
+.	O
+
+All	O
+treated	O
+groups	O
+received	O
+an	O
+additional	O
+14	O
+.	O
+4	O
+μg	O
+every	O
+4	O
+hrs	B-DISO
+for	O
+the	O
+24	O
+-	O
+hr	O
+study	O
+period	O
+.	O
+
+TITLE	O
+:	O
+Brachial	B-DISO
+neuritis	I-DISO
+masquerading	O
+as	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+.	O
+
+Cardiac	B-ANAT
+investigations	O
+were	O
+unremarkable	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+undergoing	O
+mechanical	O
+ventilation	O
+for	O
+the	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+may	O
+improve	O
+oxygenation	B-PROC
+and	O
+decrease	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+but	O
+may	O
+also	O
+cause	O
+muscle	B-DISO
+weakness	I-DISO
+.	O
+
+The	O
+hazard	O
+ratio	O
+for	O
+death	B-PROC
+at	O
+90	O
+days	O
+in	O
+the	O
+cisatracurium	O
+group	O
+,	O
+as	O
+compared	O
+with	O
+the	O
+placebo	O
+group	O
+,	O
+was	O
+0	O
+.	O
+68	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+0	O
+.	O
+48	O
+to	O
+0	O
+.	O
+98	O
+;	O
+P	O
+=	O
+0	O
+.	O
+04	O
+),	O
+after	O
+adjustment	O
+for	O
+both	O
+the	O
+baseline	O
+PaO2	O
+:	O
+FIO2	O
+and	O
+plateau	O
+pressure	O
+and	O
+the	O
+Simplified	O
+Acute	O
+Physiology	O
+II	O
+score	O
+.	O
+
+Meanwhile	O
+,	O
+a	O
+rapid	O
+and	O
+efficient	O
+strategy	O
+is	O
+presented	O
+for	O
+the	O
+determination	O
+of	O
+naturally	O
+presented	O
+CTL	B-ANAT
+epitopes	O
+in	O
+the	O
+context	O
+of	O
+given	O
+HLA	B-PRGE
+alleles	I-PRGE
+of	I-PRGE
+interest	I-PRGE
+from	I-PRGE
+long	I-PRGE
+immunogenic	I-PRGE
+overlapping	I-PRGE
+peptides	B-CHED
+.	O
+
+Over	O
+half	O
+of	O
+the	O
+severe	O
+cases	O
+had	O
+underlying	O
+conditions	O
+,	O
+in	O
+which	O
+pregnancy	O
+and	O
+morbid	B-DISO
+obesity	I-DISO
+were	O
+regarded	O
+as	O
+major	O
+risk	O
+factors	O
+.	O
+
+Further	O
+studies	O
+are	O
+needed	O
+for	O
+better	O
+clinical	O
+management	O
+of	O
+the	O
+severe	O
+cases	O
+of	O
+the	O
+latest	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+causes	O
+tremendous	O
+economic	O
+losses	O
+associated	O
+with	O
+production	O
+inefficiencies	O
+and	O
+mortality	O
+in	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)/	O
+high	O
+-	O
+resolution	O
+melt	O
+(	O
+HRM	O
+)	O
+curve	O
+analysis	O
+protocol	O
+was	O
+developed	O
+in	O
+our	O
+laboratory	O
+to	O
+differentiate	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+virus	B-SPEC
+reference	O
+strains	O
+.	O
+
+Thirty	O
+Sprague	O
+Dawley	O
+(	O
+SD	O
+)	O
+rats	B-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+three	O
+groups	O
+:	O
+sham	O
+operation	O
+(	O
+SO	O
+)	O
+group	O
+,	O
+model	O
+group	O
+and	O
+QYT	O
+group	O
+,	O
+with	O
+10	O
+rats	B-SPEC
+in	O
+each	O
+group	O
+.	O
+
+Compared	O
+with	O
+SO	O
+group	O
+,	O
+the	O
+levels	O
+of	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+(	O
+PaO	B-PROC
+(	O
+2	O
+))	O
+and	O
+pH	O
+value	O
+in	O
+model	O
+group	O
+were	O
+significantly	O
+decreased	O
+[	O
+PaO	B-PROC
+(	O
+2	O
+)	O
+(	O
+mm	O
+Hg	O
+,	O
+1	O
+mm	O
+Hg	O
+=	O
+0	O
+.	O
+133	O
+kPa	O
+):	O
+79	O
+.	O
+24	O
+±	O
+5	O
+.	O
+84	O
+vs	O
+.	O
+96	O
+.	O
+78	O
+±	O
+3	O
+.	O
+81	O
+,	O
+pH	O
+value	O
+:	O
+7	O
+.	O
+269	O
+±	O
+0	O
+.	O
+054	O
+vs	O
+.	O
+7	O
+.	O
+391	O
+±	O
+0	O
+.	O
+054	O
+],	O
+arterial	B-ANAT
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+(	O
+PaCO	O
+(	O
+2	O
+)),	O
+the	O
+serum	B-COMP
+levels	O
+of	O
+AMY	O
+,	O
+W	O
+/	O
+D	O
+ratio	O
+and	O
+the	O
+serum	B-COMP
+levels	O
+of	O
+sPLA	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+were	O
+significantly	O
+increased	O
+[	O
+PaCO	O
+(	O
+2	O
+)	O
+(	O
+mm	O
+Hg	O
+):	O
+47	O
+.	O
+57	O
+±	O
+2	O
+.	O
+55	O
+vs	O
+.	O
+27	O
+.	O
+69	O
+±	O
+1	O
+.	O
+02	O
+,	O
+AMY	O
+(	O
+U	O
+/	O
+L	O
+):	O
+7	O
+144	O
+.	O
+19	O
+±	O
+727	O
+.	O
+91	O
+vs	O
+.	O
+1	O
+193	O
+.	O
+41	O
+±	O
+192	O
+.	O
+54	O
+,	O
+W	O
+/	O
+D	O
+ratio	O
+:	O
+8	O
+.	O
+57	O
+±	O
+2	O
+.	O
+45	O
+vs	O
+.	O
+3	O
+.	O
+70	O
+±	O
+0	O
+.	O
+90	O
+,	O
+sPLA	O
+(	O
+2	O
+)	O
+(	O
+nmol	O
+×	O
+min	O
+(-	O
+1	O
+)	O
+×	O
+ml	O
+(-	O
+1	O
+)):	O
+45	O
+.	O
+13	O
+±	O
+6	O
+.	O
+05	O
+vs	O
+.	O
+29	O
+.	O
+94	O
+±	O
+6	O
+.	O
+39	O
+],	O
+the	O
+expression	B-PROC
+of	O
+sPLA	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+II	I-PRGE
+mRNA	I-PRGE
+(	O
+1	O
+.	O
+28	O
+±	O
+0	O
+.	O
+21	O
+vs	O
+.	O
+0	O
+.	O
+80	O
+±	O
+0	O
+.	O
+08	O
+)	O
+and	O
+protein	B-CHED
+were	O
+significantly	O
+increased	O
+(	O
+all	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Comparing	O
+these	O
+results	O
+with	O
+some	O
+obtained	O
+previously	O
+with	O
+chlorhexidine	B-CHED
+and	O
+hexamidine	O
+,	O
+(	O
+i	O
+)	O
+these	O
+two	O
+calixarenes	B-CHED
+did	O
+not	O
+show	O
+any	O
+cytotoxicity	B-DISO
+contrary	O
+to	O
+chlorhexidine	B-CHED
+and	O
+hexamidine	O
+,	O
+(	O
+ii	O
+)	O
+C	O
+[	O
+4	O
+]	O
+S	O
+showed	O
+as	O
+did	O
+hexamidine	O
+,	O
+a	O
+very	O
+weak	O
+activity	O
+against	O
+HCoV	O
+229E	O
+,	O
+and	O
+(	O
+iii	O
+)	O
+the	O
+C	B-PRGE
+[	I-PRGE
+4	I-PRGE
+]	I-PRGE
+S	I-PRGE
+-	I-PRGE
+BTZ	I-PRGE
+showed	O
+a	O
+stronger	O
+activity	O
+than	O
+chlorhexidine	O
+,	O
+i	O
+.	O
+e	O
+.	O
+2	O
+.	O
+7	O
+and	O
+1	O
+.	O
+4log₁₀	O
+reduction	O
+in	O
+viral	O
+titer	O
+after	O
+5min	O
+of	O
+contact	O
+with	O
+10	O
+⁻	O
+³mol	O
+L	O
+⁻	O
+¹	O
+solutions	O
+of	O
+C	O
+[	O
+4	O
+]	O
+S	O
+-	O
+BTZ	O
+and	O
+chlorhexidine	B-CHED
+,	O
+respectively	O
+.	O
+
+This	O
+case	O
+is	O
+being	O
+presented	O
+to	O
+emphasize	O
+its	O
+recognition	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+complications	O
+arising	O
+from	O
+acute	B-DISO
+severe	I-DISO
+asthma	I-DISO
+and	O
+to	O
+present	O
+its	O
+management	O
+strategy	O
+in	O
+detail	O
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+E	I-PRGE
+protein	B-CHED
+interacts	O
+with	O
+PALS1	B-PRGE
+and	O
+alters	O
+tight	B-PROC
+junction	I-PROC
+formation	I-PROC
+and	O
+epithelial	O
+morphogenesis	O
+.	O
+
+Here	O
+we	O
+report	O
+that	O
+the	O
+carboxy	B-CHED
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+small	I-PRGE
+envelope	B-COMP
+protein	B-CHED
+(	O
+E	O
+)	O
+binds	B-FUNC
+to	O
+human	B-PRGE
+PALS1	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Severe	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+caused	O
+by	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+and	O
+other	O
+pathogens	O
+:	O
+report	O
+of	O
+a	O
+case	O
+successfully	O
+managed	O
+by	O
+serial	O
+surveillance	O
+cultures	O
+of	O
+endotracheal	O
+aspirates	O
+.	O
+
+ABSTRACT	O
+:	O
+Local	O
+prevalences	O
+of	O
+individual	O
+diseases	O
+influence	O
+the	O
+prioritization	O
+of	O
+the	O
+differential	O
+diagnoses	O
+of	O
+a	O
+clinical	O
+syndrome	O
+of	O
+acute	O
+undifferentiated	O
+febrile	B-DISO
+illness	I-DISO
+(	O
+AFI	O
+).	O
+
+ABSTRACT	O
+:	O
+Caffeine	B-DISO
+is	O
+a	O
+silver	B-CHED
+bullet	O
+in	O
+neonatology	O
+.	O
+
+In	O
+mice	B-SPEC
+infected	O
+with	O
+gliatropic	O
+demyelinating	O
+coronavirus	B-SPEC
+,	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+expression	B-PROC
+on	O
+oligodendroglia	B-ANAT
+delays	O
+virus	B-SPEC
+control	O
+,	O
+but	O
+also	O
+dampens	O
+clinical	O
+disease	O
+.	O
+
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+deficiency	O
+did	O
+not	O
+affect	O
+peripheral	O
+T	O
+or	O
+B	B-PROC
+cell	I-PROC
+activation	I-PROC
+or	O
+alter	O
+the	O
+magnitude	O
+or	O
+composition	O
+of	O
+CNS	B-CHED
+-	O
+infiltrating	B-DISO
+cells	B-COMP
+.	O
+
+However	O
+,	O
+higher	O
+levels	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+mRNA	I-PRGE
+in	O
+CNS	B-CHED
+-	O
+infiltrating	B-DISO
+virus	B-SPEC
+-	O
+specific	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+as	O
+well	O
+as	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+contributed	O
+to	O
+elevated	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+protein	I-PRGE
+in	O
+the	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+(-/-)	O
+CNS	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+)	O
+are	O
+severe	O
+forms	O
+of	O
+bilateral	O
+lung	B-DISO
+inflammation	I-DISO
+with	O
+poor	O
+clinical	O
+outcomes	O
+.	O
+
+We	O
+sequenced	O
+and	O
+analyzed	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+and	O
+hemagglutinin	O
+/	O
+esterase	B-PRGE
+(	O
+HE	O
+)	O
+genes	O
+of	O
+these	O
+viruses	B-SPEC
+and	O
+compared	O
+the	O
+nucleotide	B-CHED
+(	O
+nt	O
+)	O
+and	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+(	O
+aa	O
+)	O
+sequences	O
+with	O
+those	O
+of	O
+other	O
+bovine	B-SPEC
+CoV	O
+(	O
+BcoV	O
+)	O
+strains	O
+.	O
+
+Avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AIV	O
+)	O
+infections	B-DISO
+may	O
+be	O
+asymptomatic	O
+or	O
+present	O
+as	O
+mild	O
+conjunctivitis	B-DISO
+in	O
+humans	B-SPEC
+;	O
+however	O
+,	O
+H5N1	B-DISO
+infections	B-DISO
+may	O
+present	O
+as	O
+severe	O
+pneumonia	B-DISO
+progressing	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+syndrome	B-DISO
+,	O
+multiorgan	O
+dysfunction	O
+syndrome	B-DISO
+and	O
+death	B-PROC
+.	O
+
+Immunofluorescence	O
+analysis	O
+indicated	O
+that	O
+the	O
+anti	O
+-	O
+PEDV	B-SPEC
+-	O
+M	O
+antibody	B-COMP
+reacted	O
+with	O
+PEDV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+if	O
+morbidity	O
+in	O
+young	O
+children	O
+admitted	O
+to	O
+a	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+(	O
+PICU	O
+with	O
+a	O
+laboratory	O
+proven	O
+diagnosis	O
+of	O
+influenza	B-DISO
+and	O
+parainfluenza	B-DISO
+infection	B-DISO
+)	O
+had	O
+increased	O
+.	O
+
+Parainfluenza	B-DISO
+type	O
+3	O
+(	O
+n	O
+=	O
+9	O
+)	O
+was	O
+the	O
+commonest	O
+subtype	O
+of	O
+parainfluenza	B-DISO
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Porcine	B-DISO
+reproductive	I-DISO
+and	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	I-SPEC
+-	O
+induced	O
+immunosuppression	B-PROC
+exacerbates	O
+the	O
+inflammatory	O
+response	O
+to	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+in	O
+pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immunogenicity	O
+and	O
+efficacy	O
+of	O
+β	O
+-	O
+propiolactone	B-CHED
+(	O
+BPL	O
+)	O
+inactivated	O
+whole	O
+virion	B-COMP
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+WI	O
+-	O
+SARS	B-DISO
+)	O
+vaccine	O
+was	O
+evaluated	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+and	O
+golden	O
+Syrian	B-SPEC
+hamsters	I-SPEC
+.	O
+
+Two	O
+doses	O
+of	O
+WI	O
+-	O
+SARS	B-DISO
+with	O
+and	O
+without	O
+Adjuvant	B-CHED
+Systems	O
+were	O
+highly	O
+efficacious	O
+in	O
+mice	B-SPEC
+.	O
+
+In	O
+hamsters	B-SPEC
+,	O
+two	O
+doses	O
+of	O
+WI	O
+-	O
+SARS	B-DISO
+with	O
+and	O
+without	O
+AS01	O
+(	O
+B	O
+)	O
+were	O
+immunogenic	O
+,	O
+and	O
+two	O
+doses	O
+of	O
+2	O
+μg	O
+of	O
+WI	O
+-	O
+SARS	B-DISO
+with	O
+and	O
+without	O
+the	O
+adjuvant	B-CHED
+provided	O
+complete	O
+protection	O
+from	O
+early	O
+challenge	O
+.	O
+
+Enhanced	O
+disease	O
+was	O
+not	O
+observed	O
+in	O
+the	O
+lungs	B-ANAT
+or	O
+liver	B-ANAT
+of	O
+hamsters	B-SPEC
+following	O
+SARS	B-DISO
+-	O
+CoV	O
+challenge	O
+,	O
+regardless	O
+of	O
+the	O
+level	O
+of	O
+serum	B-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Hemorrhagic	O
+shock	O
+and	O
+resuscitation	O
+induce	O
+immunosuppression	B-PROC
+.	O
+
+CD4	B-PRGE
+(+)	O
+CD25	O
+(+)	O
+Foxp3	O
+(+)	O
+regulatory	B-ANAT
+T	I-ANAT
+Cells	I-ANAT
+(	O
+Foxp3	O
+(+)	O
+Tregs	O
+),	O
+iNOS	O
+and	O
+cytokines	O
+may	O
+affect	O
+these	O
+severe	O
+conditions	O
+such	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+after	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+resuscitation	O
+.	O
+
+Immune	O
+condition	B-DISO
+may	O
+be	O
+restored	O
+by	O
+hypertonic	O
+saline	O
+resuscitation	O
+that	O
+inhibits	O
+pro	B-CHED
+-	O
+inflammatory	O
+effects	O
+of	O
+cytokine	O
+.	O
+
+At	O
+6h	O
+,	O
+NOS2	B-PRGE
+in	O
+HS	O
+wild	O
+group	O
+was	O
+significantly	O
+lower	O
+than	O
+in	O
+2LR	O
+wild	O
+group	O
+.	O
+
+Plasma	B-ANAT
+levels	O
+of	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+increased	O
+at	O
+2	O
+h	O
+.	O
+Both	O
+in	O
+wild	O
+type	O
+and	O
+iNOS	O
+knockout	O
+mice	B-SPEC
+,	O
+hypertonic	O
+saline	O
+resuscitation	O
+decreased	O
+plasma	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+and	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+levels	O
+at	O
+2	O
+h	O
+;	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+spleen	B-ANAT
+and	O
+thymus	B-SPEC
+decreased	O
+at	O
+24	O
+,	O
+48	O
+,	O
+and	O
+72	O
+h	O
+,	O
+and	O
+Foxp3	O
+(+)	O
+Tregs	O
+in	O
+spleen	B-ANAT
+at	O
+48	O
+h	O
+increased	O
+,	O
+however	O
+,	O
+hypertonic	O
+saline	O
+resuscitation	O
+did	O
+not	O
+affect	O
+the	O
+Foxp3	O
+(+).	O
+
+Published	O
+data	O
+on	O
+trends	O
+in	O
+the	O
+epidemiology	O
+and	O
+management	O
+of	O
+respiratory	B-DISO
+diseases	I-DISO
+and	O
+are	O
+summarized	O
+;	O
+finally	O
+,	O
+the	O
+limitations	O
+of	O
+available	O
+data	O
+and	O
+projections	O
+for	O
+the	O
+future	O
+of	O
+respiratory	O
+health	O
+in	O
+the	O
+region	O
+are	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+an	O
+intensive	O
+care	O
+unit	O
+during	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+2009	O
+pandemia	O
+].	O
+
+This	O
+study	O
+seeks	O
+to	O
+describe	O
+attitudes	O
+and	O
+perceived	O
+practices	O
+of	O
+pediatric	O
+intensivists	O
+regarding	O
+the	O
+use	O
+of	O
+noninvasive	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+in	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Respondents	O
+reported	O
+use	O
+of	O
+noninvasive	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+for	O
+acute	O
+respiratory	O
+failure	O
+in	O
+lower	O
+airway	B-DISO
+disease	I-DISO
+(	O
+70	O
+%),	O
+asthma	B-PATH
+(	O
+51	O
+%),	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+43	O
+%),	O
+and	O
+upper	B-DISO
+airway	I-DISO
+obstruction	I-DISO
+(	O
+31	O
+%).	O
+
+These	O
+findings	O
+may	O
+help	O
+direct	O
+further	O
+studies	O
+of	O
+noninvasive	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+in	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Each	O
+group	O
+received	O
+oxygen	B-CHED
+therapy	O
+,	O
+NIV	O
+using	O
+a	O
+vented	O
+mask	O
+system	O
+and	O
+a	O
+modified	O
+circuit	O
+with	O
+non	O
+-	O
+vented	O
+mask	O
+and	O
+exhalation	B-PROC
+filter	O
+,	O
+and	O
+nebulised	O
+saline	O
+.	O
+
+ABSTRACT	O
+:	O
+Mass	O
+exposure	O
+to	O
+explosions	O
+,	O
+infectious	B-DISO
+agents	O
+,	O
+foodborne	O
+illnesses	O
+,	O
+chemicals	O
+or	O
+radiological	O
+materials	O
+may	O
+require	O
+mass	O
+decontamination	O
+that	O
+have	O
+critical	O
+psychosocial	O
+implications	O
+for	O
+the	O
+public	O
+and	O
+for	O
+both	O
+traditional	O
+and	O
+non	O
+-	O
+traditional	O
+responders	O
+in	O
+terms	O
+of	O
+impact	O
+and	O
+of	O
+response	O
+.	O
+
+Implication	O
+for	O
+responders	O
+,	O
+healthcare	O
+and	O
+emergency	O
+infrastructure	O
+,	O
+public	O
+behaviour	B-PROC
+,	O
+screening	O
+processes	O
+,	O
+risk	O
+communication	O
+and	O
+media	B-ANAT
+management	O
+are	O
+described	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-PRGE
+small	I-PRGE
+envelope	B-COMP
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+protein	B-CHED
+plays	O
+a	O
+crucial	O
+,	O
+but	O
+poorly	O
+defined	O
+,	O
+role	O
+in	O
+the	O
+assembly	O
+of	O
+virions	B-COMP
+.	O
+
+We	O
+subsequently	O
+constructed	O
+an	O
+E	O
+gene	B-DISO
+deletion	I-DISO
+(	O
+ΔE	O
+)	O
+mutant	B-DISO
+that	O
+was	O
+only	O
+minimally	O
+viable	O
+.	O
+
+Severe	O
+respiratory	O
+syndrome	B-DISO
+was	O
+present	O
+in	O
+645	O
+ICU	O
+patients	O
+.	O
+
+ICU	O
+length	O
+of	O
+stay	O
+was	O
+3	O
+days	O
+longer	O
+in	O
+patients	O
+who	O
+had	O
+coinfection	B-DISO
+than	O
+in	O
+patients	O
+who	O
+did	O
+not	O
+(	O
+11	O
+[	O
+interquartile	O
+range	O
+,	O
+5	O
+-	O
+23	O
+]	O
+vs	O
+8	O
+[	O
+interquartile	O
+range	O
+4	O
+-	O
+17	O
+],	O
+P	O
+=.	O
+01	O
+).	O
+
+The	O
+duration	O
+of	O
+ECMO	O
+support	O
+was	O
+significantly	O
+shorter	O
+in	O
+group	O
+A	O
+than	O
+in	O
+group	B-DISO
+B	I-DISO
+(	O
+111	O
+±	O
+68	O
+hr	O
+vs	O
+.	O
+380	O
+±	O
+233	O
+hr	O
+,	O
+p	O
+=	O
+0	O
+.	O
+011	O
+).	O
+
+In	O
+all	O
+cases	O
+,	O
+vivax	B-DISO
+malaria	I-DISO
+was	O
+diagnosed	O
+by	O
+peripheral	B-ANAT
+blood	I-ANAT
+film	O
+(	O
+PBF	O
+)	O
+examination	O
+.	O
+
+Three	O
+additional	O
+authentic	O
+flavones	B-CHED
+(	O
+apigenin	B-CHED
+,	O
+luteolin	B-PRGE
+and	I-PRGE
+quercetin	B-CHED
+)	O
+were	O
+tested	O
+to	O
+establish	O
+the	O
+basic	O
+structure	O
+-	O
+activity	O
+relationship	O
+of	O
+biflavones	O
+.	O
+
+TITLE	O
+:	O
+Spectrum	O
+of	O
+hypokalaemic	B-DISO
+periodic	I-DISO
+paralysis	I-DISO
+in	O
+a	O
+tertiary	O
+care	O
+centre	O
+in	O
+India	O
+.	O
+
+Patients	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+,	O
+porphyria	B-DISO
+,	O
+polio	B-DISO
+and	O
+non	O
+-	O
+polio	B-DISO
+enterovirus	B-DISO
+infection	I-DISO
+and	O
+myositis	B-DISO
+were	O
+excluded	O
+.	O
+
+CONCLUSIONS	O
+:	O
+43	O
+.	O
+3	O
+%	O
+of	O
+patients	O
+with	O
+hypokalaemic	O
+paralysis	O
+had	O
+a	O
+secondary	O
+cause	O
+for	O
+their	O
+condition	B-DISO
+.	O
+
+Lymphocytes	B-ANAT
+may	O
+play	O
+a	O
+role	O
+in	O
+resolution	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+no	O
+effective	O
+pharmacologic	O
+therapy	O
+,	O
+although	O
+cell	O
+-	O
+based	O
+therapy	O
+and	O
+other	O
+therapies	O
+currently	O
+being	O
+tested	O
+in	O
+clinical	O
+trials	O
+may	O
+provide	O
+novel	O
+treatments	O
+for	O
+ARDS	B-DISO
+.	O
+
+The	O
+currently	O
+available	O
+extracorporeal	O
+lung	O
+assist	O
+systems	O
+are	O
+described	O
+in	O
+this	O
+article	O
+,	O
+including	O
+high	O
+flow	O
+systems	O
+such	O
+as	O
+traditional	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+CO₂	O
+removal	O
+systems	O
+(	O
+interventional	O
+lung	B-ANAT
+assist	O
+or	O
+iLA	O
+,	O
+with	O
+or	O
+without	O
+associated	O
+centrifugal	O
+pumps	O
+),	O
+and	O
+the	O
+new	O
+low	O
+flow	O
+and	O
+less	O
+invasive	O
+systems	O
+under	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Identifying	O
+genetic	B-PROC
+markers	I-PROC
+of	O
+adaptation	B-PROC
+for	O
+surveillance	O
+of	O
+viral	O
+host	B-COMP
+jumps	O
+.	O
+
+TITLE	O
+:	O
+Transfusion	O
+requirements	O
+after	O
+cardiac	B-ANAT
+surgery	O
+:	O
+the	O
+TRACS	O
+randomized	O
+controlled	O
+trial	O
+.	O
+
+To	O
+define	O
+whether	O
+a	O
+restrictive	O
+perioperative	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+transfusion	O
+strategy	O
+is	O
+as	O
+safe	O
+as	O
+a	O
+liberal	O
+strategy	O
+in	O
+patients	O
+undergoing	O
+elective	O
+cardiac	B-ANAT
+surgery	O
+.	O
+
+Among	O
+patients	O
+undergoing	O
+cardiac	B-ANAT
+surgery	O
+,	O
+the	O
+use	O
+of	O
+a	O
+restrictive	O
+perioperative	O
+transfusion	O
+strategy	O
+compared	O
+with	O
+a	O
+more	O
+liberal	O
+strategy	O
+resulted	O
+in	O
+noninferior	O
+rates	O
+of	O
+the	O
+combined	O
+outcome	O
+of	O
+30	O
+-	O
+day	O
+all	O
+-	O
+cause	O
+mortality	O
+and	O
+severe	O
+morbidity	O
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+the	O
+induction	O
+of	O
+humoral	O
+responses	O
+directed	O
+against	O
+human	O
+autoantigens	O
+during	O
+acute	O
+inflammation	B-DISO
+.	O
+
+In	O
+some	O
+cases	O
+,	O
+the	O
+patient	O
+autoantibody	O
+titers	O
+remained	O
+elevated	O
+through	O
+the	O
+last	O
+serum	B-ANAT
+sample	I-ANAT
+collected	O
+.	O
+
+RESULTS	O
+:	O
+From	O
+screening	O
+patient	O
+plasma	B-ANAT
+,	O
+57	O
+%	O
+of	O
+ARDS	B-DISO
+and	O
+46	O
+%	O
+of	O
+septic	O
+patients	O
+without	O
+ARDS	B-DISO
+demonstrated	O
+at	O
+least	O
+one	O
+statistically	O
+significant	O
+elevated	O
+autoantibody	O
+compared	O
+to	O
+the	O
+controls	O
+.	O
+
+In	O
+some	O
+cases	O
+,	O
+the	O
+patient	O
+autoantibody	O
+titers	O
+remained	O
+elevated	O
+through	O
+the	O
+last	O
+serum	B-ANAT
+sample	I-ANAT
+collected	O
+.	O
+
+The	O
+substrate	O
+sequences	O
+were	O
+inserted	O
+between	O
+cyan	O
+and	O
+yellow	O
+fluorescent	O
+proteins	B-CHED
+so	O
+that	O
+the	O
+cleavage	B-PROC
+rates	O
+were	O
+monitored	O
+by	O
+in	O
+vitro	O
+fluorescence	O
+resonance	O
+energy	B-PROC
+transfer	I-PROC
+.	O
+
+Noteworthy	O
+,	O
+solvent	B-CHED
+exposed	O
+sites	O
+such	O
+as	O
+P5	O
+,	O
+P3	O
+and	O
+P3	O
+'	O
+positions	O
+favour	O
+positively	O
+charged	O
+residues	O
+over	O
+negatively	O
+charged	O
+one	O
+,	O
+suggesting	O
+that	O
+electrostatic	O
+interactions	O
+may	O
+play	O
+a	O
+role	O
+in	O
+catalysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Cholesterol	B-CHED
+is	O
+a	O
+major	O
+constituent	O
+of	O
+detergent	B-CHED
+-	O
+resistant	O
+membrane	B-COMP
+microdomains	O
+(	O
+DRMs	O
+).	O
+
+Though	O
+S	B-PRGE
+protein	I-PRGE
+was	O
+not	O
+solubilized	O
+by	O
+cold	B-DISO
+non	O
+-	O
+ionic	O
+detergents	B-CHED
+,	O
+this	O
+behavior	O
+was	O
+unchanged	O
+when	O
+cholesterol	B-CHED
+was	O
+depleted	O
+from	O
+viral	B-COMP
+membrane	I-COMP
+by	O
+methyl	B-CHED
+-	O
+β	O
+-	O
+cyclodextrin	B-CHED
+(	O
+MβCD	O
+)	O
+and	O
+the	O
+protein	B-CHED
+did	O
+not	O
+comigrate	O
+with	O
+cellular	B-COMP
+DRM	B-DISO
+marker	O
+proteins	B-CHED
+in	O
+flotation	O
+analyses	O
+.	O
+
+TITLE	O
+:	O
+Construction	O
+and	O
+immunogenicity	O
+of	O
+a	O
+recombinant	O
+fowlpox	B-DISO
+vaccine	O
+coexpressing	O
+S1	B-PRGE
+glycoprotein	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+chicken	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+.	O
+
+The	O
+ratios	O
+of	O
+CD4	B-PRGE
+(+)	O
+to	O
+CD8	B-PRGE
+(+)	I-PRGE
+in	I-PRGE
+chickens	I-PRGE
+immunized	O
+with	O
+rFPV	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+/	I-PRGE
+IL18	I-PRGE
+were	O
+significantly	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+than	O
+in	O
+those	O
+immunized	O
+with	O
+rFPV	O
+-	O
+S1	O
+.	O
+
+Many	O
+laboratory	O
+animal	B-SPEC
+models	O
+of	O
+poxviral	O
+disease	O
+have	O
+been	O
+developed	O
+over	O
+the	O
+years	O
+to	O
+study	O
+host	B-PROC
+response	I-PROC
+and	O
+to	O
+evaluate	O
+new	O
+therapeutics	O
+and	O
+vaccines	O
+for	O
+the	O
+treatment	O
+or	O
+prevention	O
+of	O
+human	B-SPEC
+smallpox	B-DISO
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+of	O
+the	O
+eukaryotic	B-ANAT
+cell	I-ANAT
+lines	O
+for	O
+inducible	O
+control	O
+of	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+gene	B-PROC
+expression	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	B-SPEC
+to	O
+establish	O
+the	O
+eukaryotic	B-ANAT
+cell	I-ANAT
+lines	O
+for	O
+inducible	O
+control	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+gene	B-PROC
+expression	I-PROC
+.	O
+
+The	O
+co	O
+-	O
+localization	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoVN	O
+and	O
+CXCL16	B-PRGE
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+HEK293FT	O
+cells	B-COMP
+was	O
+also	O
+shown	O
+using	O
+confocal	O
+laser	B-SPEC
+scanning	O
+microscopy	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genomic	O
+sequence	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+TS	O
+and	O
+3	O
+'	O
+end	O
+sequence	O
+characterization	O
+following	O
+cell	O
+culture	O
+.	O
+
+Of	O
+them	O
+,	O
+3	O
+cases	O
+(	O
+10	O
+.	O
+3	O
+%)	O
+were	O
+abnormal	O
+,	O
+showed	O
+symmetrical	O
+long	O
+T1	O
+and	O
+T2	O
+signal	O
+shadow	O
+in	O
+bilateral	O
+thalamus	B-ANAT
+and	O
+longer	O
+T1	O
+and	O
+T2	O
+signals	O
+in	O
+the	O
+between	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+late	O
+March	O
+2009	O
+,	O
+an	O
+outbreak	O
+of	O
+influenza	O
+A	O
+virus	B-PROC
+infection	I-PROC
+was	O
+detected	O
+in	O
+Mexico	O
+with	O
+subsequent	O
+cases	O
+observed	O
+in	O
+many	O
+other	O
+countries	O
+.	O
+
+She	O
+was	O
+admitted	O
+with	O
+a	O
+5	O
+-	O
+day	O
+history	O
+of	O
+febrile	B-DISO
+syndrome	I-DISO
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+with	O
+extensive	O
+bilateral	B-DISO
+pneumonia	I-DISO
+and	O
+acute	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+that	O
+required	O
+admission	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+TITLE	O
+:	O
+Transfusion	O
+-	O
+related	O
+Plasmodium	B-DISO
+ovale	I-DISO
+malaria	B-PATH
+complicated	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+a	O
+non	O
+-	O
+endemic	O
+country	O
+.	O
+
+The	O
+patient	O
+remained	O
+intubated	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+for	O
+16	O
+days	O
+,	O
+and	O
+was	O
+later	O
+extubated	O
+successfully	O
+with	O
+a	O
+clear	O
+chest	B-ANAT
+x	O
+-	O
+ray	B-SPEC
+after	O
+a	O
+total	O
+of	O
+one	O
+month	O
+hospitalization	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+targets	O
+the	O
+initial	O
+step	O
+,	O
+probably	O
+the	O
+cellular	B-COMP
+PRRs	B-DISO
+(	O
+pattern	O
+recognition	O
+receptors	O
+)-	O
+RNAs	O
+-	O
+recognition	O
+step	O
+in	O
+the	O
+innate	O
+immune	O
+pathways	B-PROC
+,	O
+to	O
+suppress	O
+IFN	O
+expression	B-PROC
+responses	O
+.	O
+
+(	O
+i	O
+)	O
+Most	O
+were	O
+similarly	O
+regulated	O
+in	O
+response	O
+to	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+.	O
+
+(	O
+iii	O
+)	O
+Over	O
+40	O
+%	O
+were	O
+similarly	O
+regulated	O
+in	O
+vitro	O
+in	O
+response	O
+to	O
+both	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+and	O
+interferon	B-PRGE
+treatment	O
+.	O
+
+A	O
+potential	O
+strategy	O
+for	O
+the	O
+management	O
+of	O
+such	O
+patients	O
+involves	O
+goal	O
+-	O
+oriented	O
+manipulation	O
+of	O
+cardiac	B-ANAT
+output	O
+and	O
+,	O
+if	O
+necessary	O
+,	O
+hemoglobin	B-PRGE
+concentration	O
+,	O
+to	O
+compensate	O
+for	O
+hypoxemia	O
+and	O
+maintain	O
+a	O
+normal	O
+(	O
+but	O
+not	O
+supranormal	O
+)	O
+value	O
+of	O
+oxygen	B-CHED
+delivery	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+features	O
+of	O
+severe	O
+new	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+in	O
+pregnant	O
+women	O
+].	O
+
+To	O
+protect	O
+against	O
+future	O
+emerging	O
+strains	O
+,	O
+vaccine	O
+platforms	O
+should	O
+induce	O
+broad	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+immunity	B-PROC
+that	O
+is	O
+sufficient	O
+to	O
+protect	O
+from	O
+homologous	O
+and	O
+heterologous	O
+challenge	O
+in	O
+all	O
+ages	O
+.	O
+
+TITLE	O
+:	O
+Leptospirosis	B-DISO
+:	O
+An	O
+Unusual	O
+Cause	O
+of	O
+ARDS	B-DISO
+.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+a	O
+severe	O
+leptospirosis	B-DISO
+.	O
+
+Bedside	O
+open	O
+lung	B-ANAT
+biopsy	O
+was	O
+only	O
+consistent	O
+with	O
+a	O
+postinfectious	O
+BOOP	B-DISO
+.	O
+
+Seropositivity	O
+for	O
+influenza	B-DISO
+B	O
+was	O
+significantly	O
+associated	O
+with	O
+a	O
+history	O
+of	O
+suicide	B-DISO
+attempt	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+history	O
+of	O
+psychotic	B-DISO
+symptoms	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+005	O
+).	O
+
+The	O
+need	O
+for	O
+these	O
+studies	O
+is	O
+additionally	O
+supported	O
+by	O
+the	O
+high	O
+incidence	O
+of	O
+these	O
+viral	B-DISO
+infections	I-DISO
+,	O
+the	O
+high	O
+prevalence	O
+of	O
+mood	B-DISO
+disorders	I-DISO
+,	O
+and	O
+resilience	O
+of	O
+suicide	O
+epidemics	O
+.	O
+
+Neonatal	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+is	O
+still	O
+a	O
+common	O
+cause	O
+of	O
+hospitalization	O
+in	O
+China	O
+.	O
+
+This	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+pathogenesis	B-DISO
+,	O
+clinical	O
+characteristics	O
+and	O
+management	O
+strategies	O
+of	O
+RDS	O
+in	O
+full	O
+-	O
+term	O
+neonates	O
+,	O
+with	O
+the	O
+aim	O
+of	O
+developing	O
+a	O
+working	O
+protocol	O
+for	O
+improving	O
+the	O
+outcome	O
+in	O
+full	O
+-	O
+term	O
+neonates	O
+with	O
+RDS	O
+.	O
+
+(	O
+4	O
+)	O
+Complications	O
+included	O
+multiple	B-DISO
+organ	I-DISO
+system	I-DISO
+failure	I-DISO
+(	O
+MOSF	O
+)	O
+in	O
+49	O
+patients	O
+,	O
+persistent	B-DISO
+pulmonary	I-DISO
+hypertension	I-DISO
+of	I-DISO
+newborn	I-DISO
+(	O
+PPHN	O
+)	O
+in	O
+25	O
+patients	O
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+in	O
+18	O
+patients	O
+,	O
+severe	O
+hyperkalemia	O
+in	O
+25	O
+patients	O
+,	O
+severe	O
+metabolic	B-DISO
+acidosis	I-DISO
+in	O
+6	O
+cases	O
+,	O
+severe	O
+myocardial	O
+injury	O
+in	O
+9	O
+cases	O
+,	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+in	O
+3	O
+cases	O
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+in	O
+14	O
+patients	O
+and	O
+shock	O
+in	O
+12	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+gene	B-PROC
+expression	I-PROC
+events	O
+in	O
+ferrets	B-SPEC
+in	O
+response	O
+to	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+versus	O
+direct	O
+interferon	O
+-	O
+alpha2b	O
+stimulation	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+human	B-SPEC
+enterovirus	B-SPEC
+71	O
+infections	B-DISO
+in	O
+France	O
+,	O
+2000	O
+-	O
+2009	O
+.	O
+
+We	O
+studied	O
+the	O
+APACHE	O
+III	O
+database	O
+and	O
+cTnT	O
+levels	O
+from	O
+patients	O
+admitted	O
+consecutively	O
+to	O
+the	O
+ICU	O
+at	O
+Mayo	B-SPEC
+Clinic	O
+,	O
+Rochester	O
+,	O
+Minnesota	O
+.	O
+
+Here	O
+we	O
+determine	O
+the	O
+impact	O
+of	O
+ectopic	B-PROC
+expression	I-PROC
+of	O
+ISG20	B-PRGE
+on	O
+replication	O
+of	O
+several	O
+positive	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+from	O
+distinct	O
+viral	O
+families	O
+.	O
+
+The	O
+closely	O
+related	O
+cellular	B-COMP
+exonucleases	O
+,	O
+ISG20L1	B-PRGE
+and	O
+ISG20L2	B-PRGE
+,	O
+did	O
+not	O
+inhibit	O
+HCV	B-SPEC
+replication	O
+.	O
+
+Together	O
+,	O
+these	O
+data	O
+may	O
+help	O
+better	O
+understand	O
+the	O
+antiviral	B-CHED
+specificity	O
+and	O
+action	O
+of	O
+ISG20	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Investigation	O
+of	O
+the	O
+influence	O
+of	O
+EPs	B-PRGE
+®	I-PRGE
+7630	O
+,	O
+a	O
+herbal	O
+drug	O
+preparation	O
+from	O
+Pelargonium	B-SPEC
+sidoides	O
+,	O
+on	O
+replication	O
+of	O
+a	O
+broad	O
+panel	O
+of	O
+respiratory	O
+viruses	O
+.	O
+
+In	O
+children	O
+<	O
+5	O
+years	O
+of	O
+age	O
+,	O
+the	O
+proportion	O
+of	O
+severe	O
+malaria	O
+attributable	O
+to	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+rose	B-SPEC
+to	O
+67	O
+.	O
+4	O
+%	O
+(	O
+31	O
+/	O
+46	O
+)	O
+compared	O
+with	O
+30	O
+.	O
+4	O
+%	O
+(	O
+14	O
+/	O
+46	O
+)	O
+of	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+(	O
+OR	O
+=	O
+4	O
+.	O
+7	O
+[	O
+95	O
+%	O
+CI	O
+=	O
+2	O
+.	O
+6	O
+-	O
+8	O
+.	O
+6	O
+],	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+2	O
+.	O
+2	O
+%	O
+(	O
+1	O
+/	O
+46	O
+)	O
+of	O
+mixed	B-DISO
+infection	I-DISO
+(	O
+OR	O
+=	O
+92	O
+[	O
+95	O
+%	O
+CI	O
+=	O
+24	O
+.	O
+6	O
+-	O
+339	O
+.	O
+9	O
+],	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Needs	O
+and	O
+values	O
+assessments	O
+were	O
+undertaken	O
+by	O
+international	O
+experts	O
+in	O
+pandemic	O
+infection	B-DISO
+control	O
+and	O
+local	O
+healthcare	O
+workers	O
+.	O
+
+Despite	O
+the	O
+equivocal	O
+evidence	O
+for	O
+the	O
+efficacy	O
+of	O
+surgical	O
+and	O
+N95	O
+masks	O
+and	O
+the	O
+provision	O
+of	O
+algorithms	O
+appropriate	O
+for	O
+the	O
+level	O
+of	O
+risk	O
+according	O
+to	O
+clinical	O
+care	O
+during	O
+a	O
+pandemic	O
+,	O
+clinicians	O
+still	O
+demanded	O
+N95	O
+masks	O
+plus	O
+face	B-DISO
+shields	O
+in	O
+combination	O
+with	O
+prophylaxis	O
+and	O
+novel	O
+vaccination	O
+.	O
+
+Since	O
+immunohistochemistry	O
+(	O
+IHC	O
+)	O
+includes	O
+most	O
+of	O
+these	O
+features	O
+,	O
+its	O
+sensitivity	O
+,	O
+specificity	O
+,	O
+predictive	O
+positive	O
+value	O
+(	O
+PPV	B-CHED
+)	O
+and	O
+predictive	O
+negative	O
+value	O
+(	O
+PNV	O
+)	O
+for	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+(	O
+WNv	B-DISO
+)	O
+screening	O
+were	O
+compared	O
+to	O
+those	O
+of	O
+the	O
+gold	B-CHED
+standard	O
+,	O
+RT	O
+-	O
+PCR	O
+testing	O
+of	O
+kidney	B-ANAT
+tissue	B-ANAT
+in	O
+dead	B-PROC
+birds	B-SPEC
+.	O
+
+Fixed	B-ANAT
+tissue	B-ANAT
+sections	O
+were	O
+screened	O
+by	O
+IHC	O
+using	O
+polyclonal	O
+antibodies	B-COMP
+,	O
+and	O
+frozen	O
+kidney	B-ANAT
+tissues	B-ANAT
+were	O
+tested	O
+with	O
+RT	O
+-	O
+PCR	O
+.	O
+
+The	O
+present	O
+study	O
+showed	O
+that	O
+IHC	O
+is	O
+as	O
+equally	O
+effective	O
+as	O
+RT	O
+-	O
+PCR	O
+in	O
+screening	O
+for	O
+WNv	B-DISO
+in	O
+dead	B-PROC
+birds	B-SPEC
+.	O
+
+Therefore	O
+,	O
+IHC	O
+can	O
+effectively	O
+serve	O
+as	O
+a	O
+competent	O
+screening	O
+technique	O
+for	O
+those	O
+disease	O
+surveillance	O
+agencies	O
+that	O
+lack	O
+expensive	O
+RT	O
+-	O
+PCR	O
+technology	O
+while	O
+promoting	O
+safer	O
+biohazardous	O
+conditions	O
+,	O
+except	O
+at	O
+the	O
+initial	O
+stage	O
+of	O
+tissue	B-ANAT
+collection	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+E	O
+protein	B-CHED
+plays	O
+an	O
+important	O
+role	O
+in	O
+virus	B-PROC
+assembly	I-PROC
+.	O
+
+Genetic	O
+variations	O
+,	O
+including	O
+whole	O
+-	O
+gene	B-PROC
+deletions	I-PROC
+,	O
+are	O
+key	O
+to	O
+IBV	B-SPEC
+evolution	B-PROC
+.	O
+
+Australian	O
+subgroup	O
+2	O
+IBVs	O
+contain	O
+sequence	B-PROC
+insertions	I-PROC
+and	O
+multiple	O
+gene	B-PROC
+deletions	I-PROC
+that	O
+have	O
+resulted	O
+in	O
+a	O
+substantial	O
+genomic	O
+divergence	O
+from	O
+international	O
+IBVs	O
+.	O
+
+Open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+found	O
+throughout	O
+the	O
+genome	O
+of	O
+Australian	O
+IBVs	O
+were	O
+analogous	O
+in	O
+sequence	O
+and	O
+position	O
+to	O
+TCoV	O
+ORFs	O
+,	O
+except	O
+for	O
+ORF	B-PRGE
+4b	I-PRGE
+,	O
+which	O
+appeared	O
+to	O
+be	O
+translocated	O
+to	O
+a	O
+different	O
+position	O
+in	O
+the	O
+subgroup	O
+2	O
+strains	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+analysis	O
+of	O
+soft	O
+multicomponent	O
+nanoparticle	B-CHED
+clusters	B-CHED
+.	O
+
+When	O
+compared	O
+to	O
+culture	O
+,	O
+the	O
+xTAG	B-PRGE
+PRV	I-PRGE
+showed	O
+a	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+100	O
+%	O
+and	O
+91	O
+%,	O
+compared	O
+to	O
+MultiCode	O
+-	O
+PLx	O
+with	O
+89	O
+%	O
+and	O
+87	O
+%,	O
+and	O
+ResPlex	O
+II	O
+with	O
+89	O
+%	O
+and	O
+94	O
+%,	O
+respectively	O
+.	O
+
+Co	B-DISO
+-	I-DISO
+infection	I-DISO
+was	O
+detected	O
+in	O
+a	O
+small	O
+subset	O
+of	O
+patient	O
+specimens	O
+.	O
+
+Each	O
+panel	O
+showed	O
+differences	O
+in	O
+sensitivities	O
+for	O
+individual	O
+viruses	B-SPEC
+.	O
+
+Each	O
+panel	O
+showed	O
+differences	O
+in	O
+sensitivities	O
+for	O
+individual	O
+viruses	B-SPEC
+.	O
+
+The	O
+body	B-ANAT
+temperature	O
+was	O
+higher	O
+than	O
+39	O
+°	O
+C	O
+accompanied	O
+by	O
+chill	B-DISO
+and	O
+low	O
+blood	B-PROC
+pressure	I-PROC
+at	O
+the	O
+onset	O
+of	O
+the	O
+illness	O
+.	O
+
+Twenty	O
+-	O
+one	O
+viruses	B-SPEC
+,	O
+including	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+HCoV	O
+-	O
+HKU1	O
+,	O
+and	O
+RSV	B-SPEC
+were	O
+tested	O
+.	O
+
+Among	O
+children	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+73	O
+.	O
+0	O
+%	O
+tested	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+other	O
+virus	B-SPEC
+,	O
+compared	O
+with	O
+41	O
+.	O
+2	O
+%	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+40	O
+.	O
+3	O
+%	O
+with	O
+RSV	B-SPEC
+(	O
+P	O
+=	O
+0	O
+.	O
+03	O
+and	O
+P	O
+<	O
+0	O
+.	O
+01	O
+,	O
+respectively	O
+).	O
+
+Lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+LRTI	B-DISO
+)	O
+was	O
+half	O
+as	O
+common	O
+in	O
+children	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+(	O
+48	O
+.	O
+6	O
+%)	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+(	O
+47	O
+.	O
+1	O
+%)	O
+as	O
+in	O
+children	O
+with	O
+RSV	B-SPEC
+(	O
+82	O
+.	O
+3	O
+%)	O
+(	O
+both	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Neither	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+nor	O
+HCoV	O
+-	O
+HKU1	O
+was	O
+detected	O
+.	O
+
+Sequence	O
+analysis	O
+showed	O
+that	O
+the	O
+detected	O
+viruses	B-SPEC
+are	O
+gamma	O
+-	O
+coronaviruses	O
+related	O
+to	O
+IBV	B-SPEC
+.	O
+
+These	O
+cytokines	O
+,	O
+except	O
+TNFα	O
+,	O
+had	O
+a	O
+positive	O
+correlation	O
+with	O
+the	O
+admission	O
+delay	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+and	O
+a	O
+negative	O
+correlation	O
+with	O
+the	O
+PaO	B-PROC
+(	O
+2	O
+):	O
+FiO	O
+(	O
+2	O
+)	O
+ratio	O
+.	O
+
+Few	O
+HCWs	O
+(	O
+6	O
+.	O
+6	O
+%)	O
+had	O
+restricted	O
+their	O
+social	O
+contacts	O
+and	O
+fewer	O
+(	O
+3	O
+.	O
+8	O
+%)	O
+felt	O
+isolated	O
+by	O
+their	O
+family	B-SPEC
+members	O
+and	O
+friends	O
+because	O
+of	O
+their	O
+hospital	O
+work	O
+,	O
+while	O
+a	O
+low	O
+percentage	O
+(	O
+4	O
+.	O
+3	O
+%)	O
+indented	O
+to	O
+take	O
+a	O
+leave	O
+to	O
+avoid	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Trends	O
+in	O
+importation	O
+of	O
+communicable	B-DISO
+diseases	I-DISO
+into	O
+Singapore	O
+.	O
+
+Non	O
+-	O
+invasive	O
+ventilation	O
+is	O
+now	O
+considered	O
+first	O
+-	O
+line	O
+intervention	O
+for	O
+different	O
+causes	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+may	O
+be	O
+considered	O
+in	O
+the	O
+context	O
+of	O
+H1N1	O
+pandemic	O
+.	O
+
+Treatment	O
+of	O
+early	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+associated	O
+with	O
+H1N1	O
+using	O
+non	O
+-	O
+invasive	O
+ventilation	O
+could	O
+be	O
+tried	O
+rapidly	O
+identifying	O
+those	O
+who	O
+fail	O
+without	O
+delaying	O
+endotracheal	O
+intubation	O
+.	O
+
+ABSTRACT	O
+:	O
+By	O
+revisiting	O
+the	O
+air	B-CHED
+distribution	O
+and	O
+bioaerosol	O
+dispersion	O
+in	O
+Ward	O
+8A	O
+where	O
+the	O
+largest	O
+nosocomial	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+occurred	O
+in	O
+Hong	O
+Kong	O
+in	O
+2003	O
+,	O
+we	O
+found	O
+an	O
+interesting	O
+phenomenon	O
+.	O
+
+Although	O
+all	O
+the	O
+cubicles	O
+were	O
+in	O
+'	O
+positive	O
+pressure	O
+'	O
+towards	O
+the	O
+corridor	O
+,	O
+the	O
+virus	B-SPEC
+-	O
+containing	O
+bioaerosols	O
+generated	O
+from	O
+the	O
+index	O
+patient	O
+'	O
+s	O
+cubicle	O
+were	O
+still	O
+transmitted	B-DISO
+to	O
+other	O
+cubicles	O
+,	O
+which	O
+cannot	O
+be	O
+explained	O
+in	O
+a	O
+traditional	O
+manner	O
+.	O
+
+TITLE	O
+:	O
+Eosinophilic	O
+infiltrate	B-DISO
+in	O
+a	O
+patient	O
+with	O
+severe	O
+Legionella	B-DISO
+pneumonia	I-DISO
+as	O
+a	O
+levofloxacin	B-CHED
+-	O
+related	O
+complication	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+The	O
+severe	O
+lung	B-ANAT
+injury	O
+was	O
+accompanied	O
+by	O
+elevated	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+,	O
+cell	B-PROC
+death	I-PROC
+,	O
+and	O
+fibrin	B-DISO
+deposition	I-DISO
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+Comparison	O
+of	O
+the	O
+highly	O
+virulent	O
+JHM	O
+isolate	O
+,	O
+JHM	O
+.	O
+SD	O
+,	O
+with	O
+less	O
+virulent	O
+JHM	O
+isolates	O
+and	O
+with	O
+A59	O
+has	O
+been	O
+used	O
+to	O
+determine	O
+the	O
+mechanisms	O
+and	O
+genes	O
+responsible	O
+for	O
+high	O
+neuropathogenicity	O
+of	O
+MHV	B-SPEC
+.	O
+
+Further	O
+data	O
+suggest	O
+that	O
+neither	O
+the	O
+internal	O
+(	O
+I	O
+)	O
+protein	B-CHED
+nor	O
+nonstructural	O
+proteins	B-CHED
+ns4	B-DISO
+,	O
+and	O
+ns2	B-DISO
+are	O
+significant	O
+contributors	O
+to	O
+neurovirulence	O
+.	O
+
+TITLE	O
+:	O
+Nucleic	B-ANAT
+acid	I-CHED
+amplification	B-DISO
+-	O
+based	O
+diagnosis	O
+of	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+Nucleic	B-CHED
+acid	I-CHED
+amplification	B-DISO
+tests	O
+(	O
+NATs	O
+)	O
+that	O
+first	O
+appeared	O
+two	O
+decades	O
+ago	O
+have	O
+been	O
+developed	O
+for	O
+both	O
+conventional	O
+and	O
+emerging	O
+viruses	B-SPEC
+and	O
+now	O
+form	O
+the	O
+backbone	B-ANAT
+of	O
+the	O
+clinical	O
+laboratory	O
+.	O
+
+Tramadol	O
+and	O
+tapentadol	O
+hydrochloride	B-CHED
+are	O
+novel	O
+in	O
+that	O
+their	O
+analgesic	B-CHED
+actions	O
+occur	O
+at	O
+multiple	O
+sites	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+demonstrate	O
+that	O
+the	O
+combination	O
+of	O
+Zn	O
+(	O
+2	O
++)	O
+and	O
+PT	O
+at	O
+low	O
+concentrations	O
+(	O
+2	O
+µM	O
+Zn	O
+(	O
+2	O
++)	O
+and	O
+2	O
+µM	O
+PT	O
+)	O
+inhibits	O
+the	O
+replication	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+(	O
+EAV	B-SPEC
+)	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+,	O
+therefore	O
+,	O
+was	O
+to	O
+analyze	O
+perioperative	O
+demographics	O
+and	O
+pulmonary	B-ANAT
+outcomes	O
+of	O
+patients	O
+with	O
+SA	O
+after	O
+orthopedic	O
+and	O
+general	O
+surgical	O
+procedures	O
+using	O
+a	O
+population	O
+-	O
+based	O
+sample	O
+.	O
+
+Orthopedic	O
+and	O
+general	O
+surgical	O
+procedures	O
+were	O
+included	O
+and	O
+discharges	B-ANAT
+with	O
+a	O
+diagnosis	O
+code	O
+for	O
+SA	O
+were	O
+identified	O
+.	O
+
+SA	O
+was	O
+associated	O
+with	O
+a	O
+significantly	O
+higher	O
+adjusted	O
+OR	O
+of	O
+developing	O
+pulmonary	B-DISO
+complications	I-DISO
+after	O
+both	O
+orthopedic	O
+and	O
+general	O
+surgical	O
+procedures	O
+,	O
+respectively	O
+,	O
+with	O
+the	O
+exception	O
+of	O
+PE	O
+(	O
+OR	O
+for	O
+aspiration	B-DISO
+pneumonia	I-DISO
+:	O
+1	O
+.	O
+41	O
+[	O
+1	O
+.	O
+35	O
+,	O
+1	O
+.	O
+47	O
+]	O
+and	O
+1	O
+.	O
+37	O
+[	O
+1	O
+.	O
+33	O
+,	O
+1	O
+.	O
+41	O
+];	O
+for	O
+ARDS	B-DISO
+:	O
+2	O
+.	O
+39	O
+[	O
+2	O
+.	O
+28	O
+,	O
+2	O
+.	O
+51	O
+]	O
+and	O
+1	O
+.	O
+58	O
+[	O
+1	O
+.	O
+54	O
+,	O
+1	O
+.	O
+62	O
+];	O
+for	O
+PE	O
+:	O
+OR	O
+1	O
+.	O
+22	O
+[	O
+1	O
+.	O
+15	O
+,	O
+1	O
+.	O
+29	O
+]	O
+and	O
+0	O
+.	O
+90	O
+[	O
+0	O
+.	O
+84	O
+,	O
+0	O
+.	O
+97	O
+];	O
+for	O
+intubation	O
+/	O
+mechanical	O
+ventilation	O
+:	O
+5	O
+.	O
+20	O
+[	O
+5	O
+.	O
+05	O
+,	O
+5	O
+.	O
+37	O
+]	O
+and	O
+1	O
+.	O
+95	O
+[	O
+1	O
+.	O
+91	O
+,	O
+1	O
+.	O
+98	O
+]).	O
+
+After	O
+their	O
+characterization	O
+,	O
+three	O
+MAbs	O
+were	O
+selected	O
+in	O
+order	B-SPEC
+to	O
+develop	O
+a	O
+differential	O
+DAS	O
+-	O
+ELISA	O
+.	O
+
+TITLE	O
+:	O
+Total	O
+liquid	O
+ventilation	O
+provides	O
+superior	O
+respiratory	O
+support	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+in	O
+a	O
+large	O
+animal	B-SPEC
+model	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Survival	O
+at	O
+24	O
+hours	O
+in	O
+the	O
+TLV	O
+and	O
+CMV	B-SPEC
+groups	O
+were	O
+100	O
+%	O
+and	O
+40	O
+%,	O
+respectively	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+2	O
+'-	O
+O	O
+methylation	B-PROC
+of	O
+the	O
+viral	O
+mRNA	B-CHED
+cap	B-DISO
+evades	O
+host	B-COMP
+restriction	O
+by	O
+IFIT	B-PRGE
+family	I-PRGE
+members	I-PRGE
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+a	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+(	O
+WNV	B-DISO
+)	O
+mutant	B-DISO
+(	O
+E218A	O
+)	O
+that	O
+lacks	O
+2	O
+'-	O
+O	O
+MTase	B-PRGE
+activity	O
+was	O
+attenuated	O
+in	O
+wild	O
+-	O
+type	O
+primary	O
+cells	B-COMP
+and	O
+mice	B-SPEC
+but	O
+was	O
+pathogenic	O
+in	O
+the	O
+absence	O
+of	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+signalling	B-PROC
+.	O
+
+Our	O
+results	O
+demonstrate	O
+that	O
+the	O
+2	O
+'-	O
+O	O
+methylation	B-PROC
+of	O
+the	O
+5	O
+'	O
+cap	B-DISO
+of	O
+viral	O
+RNA	O
+functions	O
+to	O
+subvert	O
+innate	O
+host	B-COMP
+antiviral	B-CHED
+responses	O
+through	O
+escape	O
+of	O
+IFIT	O
+-	O
+mediated	O
+suppression	B-DISO
+,	O
+and	O
+suggest	O
+an	O
+evolutionary	O
+explanation	O
+for	O
+2	O
+'-	O
+O	O
+methylation	B-PROC
+of	O
+cellular	B-COMP
+mRNA	B-CHED
+:	O
+to	O
+distinguish	O
+self	O
+from	O
+non	O
+-	O
+self	O
+RNA	O
+.	O
+
+The	O
+viral	B-PRGE
+peptidase	I-PRGE
+activation	O
+described	O
+here	O
+could	O
+be	O
+related	O
+to	O
+the	O
+crowded	O
+intracellular	B-COMP
+environment	O
+and	O
+indicates	O
+a	O
+further	O
+fine	O
+-	O
+tuning	O
+mechanism	O
+for	O
+biological	B-PROC
+control	I-PROC
+,	O
+particularly	O
+in	O
+the	O
+microenvironment	O
+of	O
+the	O
+vesicles	B-COMP
+that	O
+are	O
+induced	O
+in	O
+host	B-COMP
+cells	B-COMP
+during	O
+positive	O
+strand	O
+RNA	B-DISO
+virus	I-DISO
+infection	I-DISO
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+application	O
+of	O
+AUC	O
+to	O
+protein	B-CHED
+size	O
+-	O
+and	O
+-	O
+shape	O
+distribution	O
+analysis	O
+and	O
+structure	O
+-	O
+and	O
+-	O
+function	O
+analysis	O
+in	O
+the	O
+presence	O
+of	O
+ligands	O
+or	O
+lipids	B-CHED
+.	O
+
+Using	O
+band	B-ANAT
+-	O
+sedimentation	O
+velocity	O
+,	O
+quaternary	O
+structural	O
+changes	O
+and	O
+an	O
+enzyme	O
+'	O
+s	O
+catalytic	B-FUNC
+activity	I-FUNC
+can	O
+be	O
+observed	O
+simultaneously	O
+.	O
+
+This	O
+provides	O
+direct	O
+insights	O
+into	O
+the	O
+correlation	O
+between	O
+quaternary	O
+structure	O
+and	O
+catalytic	B-FUNC
+activity	I-FUNC
+of	O
+the	O
+enzyme	O
+.	O
+
+The	O
+sedimentation	O
+velocity	O
+data	O
+for	O
+the	O
+protein	B-CHED
+with	O
+or	O
+without	O
+lipid	B-CHED
+were	O
+evaluated	O
+using	O
+the	O
+c	O
+(	O
+s	O
+,	O
+f	O
+(	O
+r	O
+))	O
+two	O
+-	O
+dimensional	O
+distribution	O
+model	O
+,	O
+which	O
+provides	O
+a	O
+precise	O
+and	O
+quantitative	O
+means	O
+of	O
+analyzing	O
+the	O
+protein	B-CHED
+'	O
+s	O
+conformational	O
+changes	O
+.	O
+
+TITLE	O
+:	O
+Predictors	O
+of	O
+pandemic	O
+(	O
+H1N1	O
+)	O
+2009	O
+virus	B-SPEC
+positivity	O
+and	O
+adverse	O
+outcomes	O
+among	O
+hospitalized	O
+patients	O
+with	O
+a	O
+compatible	O
+syndrome	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+pandemic	O
+(	O
+H1N1	O
+)	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+was	O
+identified	O
+in	O
+2009	O
+.	O
+
+A	O
+significant	O
+number	O
+of	O
+relatively	O
+young	O
+and	O
+previously	O
+healthy	O
+positive	O
+patients	O
+might	O
+develop	O
+severe	O
+disease	O
+associated	O
+with	O
+a	O
+robust	O
+inflammatory	B-DISO
+reaction	I-DISO
+and	O
+significant	O
+lymphopenia	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+179	O
+examined	O
+hospitalized	O
+patients	O
+suspected	O
+of	O
+having	O
+pandemic	O
+(	O
+H1N1	O
+)	O
+2009	O
+infection	B-DISO
+65	O
+(	O
+36	O
+%)	O
+were	O
+found	O
+positive	O
+.	O
+
+USA	O
+,	O
+nationwide	O
+hospital	O
+discharge	B-ANAT
+data	O
+.	O
+
+adjusted	O
+odds	O
+ratios	O
+describing	O
+the	O
+associations	O
+between	O
+chronic	O
+maternal	O
+heart	B-DISO
+disease	I-DISO
+and	O
+severe	O
+obstetric	O
+complications	O
+were	O
+obtained	O
+from	O
+multivariable	O
+logistic	O
+models	O
+.	O
+
+The	O
+contribution	O
+of	O
+chronic	B-DISO
+heart	I-DISO
+disease	I-DISO
+to	O
+severe	O
+morbidity	O
+was	O
+estimated	O
+using	O
+adjusted	O
+population	O
+-	O
+attributable	O
+fractions	O
+.	O
+
+In	O
+2004	O
+-	O
+2006	O
+,	O
+64	O
+.	O
+5	O
+%	O
+of	O
+the	O
+cases	O
+of	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+,	O
+57	O
+.	O
+5	O
+%	O
+of	O
+the	O
+instances	O
+of	O
+cardiac	B-DISO
+arrest	I-DISO
+/	O
+ventricular	B-DISO
+fibrillation	I-DISO
+,	O
+27	O
+.	O
+8	O
+%	O
+of	O
+in	O
+-	O
+hospital	O
+mortality	O
+and	O
+26	O
+.	O
+0	O
+%	O
+of	O
+the	O
+cases	O
+of	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+were	O
+associated	O
+with	O
+hospitalisations	O
+with	O
+chronic	B-DISO
+heart	I-DISO
+disease	I-DISO
+.	O
+
+in	O
+the	O
+USA	O
+chronic	B-DISO
+heart	I-DISO
+disease	I-DISO
+among	O
+women	O
+hospitalised	O
+during	O
+pregnancy	O
+may	O
+have	O
+increased	O
+in	O
+severity	O
+from	O
+1995	O
+to	O
+2006	O
+.	O
+
+RESULTS	O
+:	O
+in	O
+2004	O
+-	O
+2006	O
+,	O
+about	O
+1	O
+.	O
+4	O
+%	O
+of	O
+delivery	O
+hospitalisations	O
+were	O
+complicated	O
+with	O
+chronic	B-DISO
+heart	I-DISO
+disease	I-DISO
+.	O
+
+In	O
+2004	O
+-	O
+2006	O
+,	O
+64	O
+.	O
+5	O
+%	O
+of	O
+the	O
+cases	O
+of	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+,	O
+57	O
+.	O
+5	O
+%	O
+of	O
+the	O
+instances	O
+of	O
+cardiac	B-DISO
+arrest	I-DISO
+/	O
+ventricular	B-DISO
+fibrillation	I-DISO
+,	O
+27	O
+.	O
+8	O
+%	O
+of	O
+in	O
+-	O
+hospital	O
+mortality	O
+and	O
+26	O
+.	O
+0	O
+%	O
+of	O
+the	O
+cases	O
+of	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+were	O
+associated	O
+with	O
+hospitalisations	O
+with	O
+chronic	B-DISO
+heart	I-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+may	O
+cause	O
+a	O
+lethal	O
+infection	B-DISO
+in	O
+cats	B-SPEC
+.	O
+
+Antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+(	O
+ADE	B-CHED
+)	O
+of	O
+FIPV	O
+infection	B-DISO
+has	O
+been	O
+recognized	O
+,	O
+and	O
+cellular	B-PROC
+immunity	I-PROC
+is	O
+considered	O
+to	O
+play	O
+an	O
+important	O
+role	O
+in	O
+preventing	O
+the	O
+onset	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+whether	O
+or	O
+not	O
+the	O
+T	O
+helper	O
+(	O
+Th	O
+)	O
+1	O
+epitope	B-CHED
+was	O
+present	O
+in	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+2	O
+domain	O
+was	O
+investigated	O
+,	O
+the	O
+ADE	B-CHED
+epitope	B-CHED
+being	O
+thought	O
+to	O
+be	O
+absent	O
+from	O
+this	O
+domain	O
+.	O
+
+It	O
+was	O
+shown	O
+that	O
+FP	B-PRGE
+-	I-PRGE
+HR2	I-PRGE
+protein	I-PRGE
+induced	O
+marked	O
+Th1	O
+-	O
+and	O
+Th2	O
+-	O
+type	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+Five	O
+and	O
+16	O
+peptides	B-CHED
+which	O
+included	O
+the	O
+Th1	O
+and	O
+Th2	O
+epitopes	O
+,	O
+respectively	O
+,	O
+were	O
+identified	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+the	O
+identification	O
+of	O
+Th1	B-PRGE
+epitopes	I-PRGE
+in	O
+the	O
+S2	O
+domain	O
+of	O
+FIPV	O
+has	O
+important	O
+implications	O
+in	O
+the	O
+cat	B-SPEC
+.	O
+
+Severe	O
+,	O
+asymmetrical	O
+ventricular	B-ANAT
+dilation	B-DISO
+associated	O
+with	O
+hydrocephalus	B-DISO
+,	O
+cerebellar	B-ANAT
+and	O
+brainstem	B-ANAT
+hypoplasia	B-DISO
+,	O
+and	O
+punctuate	O
+calcifications	B-PROC
+of	O
+the	O
+thalamus	B-ANAT
+,	O
+third	O
+and	O
+fourth	B-ANAT
+ventricles	I-ANAT
+,	O
+around	O
+the	O
+aqueduct	B-ANAT
+,	O
+were	O
+observed	O
+on	O
+computed	O
+tomography	O
+(	O
+CT	O
+).	O
+
+The	O
+expressions	O
+of	O
+NF	O
+-	O
+κB	O
+and	O
+AQP4	B-PRGE
+in	O
+the	O
+liver	B-ANAT
+and	O
+stomach	B-ANAT
+were	O
+determined	O
+using	O
+immunohistochemistry	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+and	O
+CD4	B-PRGE
+(+)/	O
+CD8	B-PRGE
+(+)	O
+ratio	O
+in	O
+the	O
+virus	B-SPEC
+and	O
+model	O
+groups	O
+were	O
+significantly	O
+higher	O
+than	O
+those	O
+in	O
+the	O
+damp	B-CHED
+-	O
+heat	O
+and	O
+control	O
+groups	O
+,	O
+while	O
+the	O
+expression	B-PROC
+of	O
+AQP4	B-PRGE
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+model	O
+and	O
+damp	B-CHED
+-	O
+heat	O
+groups	O
+than	O
+in	O
+the	O
+other	O
+groups	O
+.	O
+
+Compared	O
+with	O
+the	O
+control	O
+group	O
+,	O
+the	O
+model	O
+group	O
+showed	O
+a	O
+significantly	O
+higher	O
+ratio	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+/	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+4	I-PRGE
+.	O
+
+Therefore	O
+,	O
+the	O
+aim	O
+of	O
+this	O
+paper	O
+was	O
+to	O
+give	O
+a	O
+critical	O
+review	O
+of	O
+these	O
+meta	B-SPEC
+-	O
+analyses	O
+.	O
+
+From	O
+November	O
+2009	O
+to	O
+March	O
+2010	O
+,	O
+a	O
+total	O
+of	O
+239	O
+pig	B-SPEC
+tissue	B-ANAT
+samples	O
+from	O
+91	O
+farms	O
+were	O
+tested	O
+by	O
+nested	O
+RT	O
+-	O
+PCR	O
+.	O
+
+The	O
+detection	O
+rate	O
+of	O
+suckling	O
+pigs	B-SPEC
+,	O
+weaning	B-PROC
+pigs	B-SPEC
+,	O
+growers	O
+and	O
+finishers	O
+were	O
+14	O
+.	O
+3	O
+%	O
+(	O
+12	O
+/	O
+84	O
+),	O
+6	O
+.	O
+5	O
+%	O
+(	O
+7	O
+/	O
+107	O
+),	O
+7	O
+%	O
+(	O
+3	O
+/	O
+43	O
+),	O
+and	O
+0	O
+%	O
+(	O
+0	O
+/	O
+5	O
+),	O
+respectively	O
+.	O
+
+During	O
+initial	O
+examinations	O
+of	O
+patients	O
+,	O
+physicians	O
+must	O
+rule	O
+out	O
+other	O
+neurologic	B-DISO
+disorders	I-DISO
+or	O
+conditions	O
+that	O
+resemble	O
+Fisher	B-DISO
+syndrome	I-DISO
+,	O
+such	O
+as	O
+vitamin	B-DISO
+B1	I-DISO
+deficiency	I-DISO
+(	O
+Wernicke	B-DISO
+'	I-DISO
+s	I-DISO
+encephalopathy	I-DISO
+),	O
+vascular	B-DISO
+disease	I-DISO
+,	O
+multiple	B-DISO
+sclerosis	I-DISO
+,	O
+collagen	B-DISO
+disease	I-DISO
+,	O
+Behçet	O
+disease	O
+,	O
+sarcoidosis	B-DISO
+,	O
+neoplasm	B-DISO
+of	I-DISO
+the	I-DISO
+brainstem	I-DISO
+,	O
+and	O
+infectious	B-DISO
+diseases	I-DISO
+such	O
+as	O
+diphtheria	B-DISO
+,	O
+botulism	O
+,	O
+and	O
+viral	B-DISO
+infections	I-DISO
+(	O
+eg	O
+,	O
+herpes	B-DISO
+encephalitis	I-DISO
+).	O
+
+Sixty	O
+-	O
+seven	O
+(	O
+30	O
+.	O
+5	O
+%)	O
+of	O
+the	O
+patients	O
+died	B-PROC
+in	O
+ICU	O
+and	O
+75	O
+(	O
+34	O
+.	O
+1	O
+%)	O
+whilst	O
+in	O
+hospital	O
+.	O
+
+One	O
+hundred	O
+twenty	O
+-	O
+six	O
+(	O
+57	O
+.	O
+3	O
+%)	O
+patients	O
+received	O
+corticosteroid	B-CHED
+therapy	O
+on	O
+admission	O
+to	O
+ICU	O
+.	O
+
+Patients	O
+who	O
+received	O
+corticosteroids	B-CHED
+had	O
+significantly	O
+higher	O
+ICU	O
+mortality	O
+than	O
+patients	O
+who	O
+did	O
+not	O
+(	O
+46	O
+.	O
+0	O
+%	O
+versus	O
+18	O
+.	O
+1	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+;	O
+OR	O
+3	O
+.	O
+8	O
+,	O
+CI	B-PRGE
+2	I-PRGE
+.	I-PRGE
+1	I-PRGE
+-	I-PRGE
+7	I-PRGE
+.	I-PRGE
+2	I-PRGE
+).	O
+
+When	O
+only	O
+patients	O
+developing	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+were	O
+analyzed	O
+,	O
+similar	O
+results	O
+were	O
+observed	O
+.	O
+
+From	O
+a	O
+collection	O
+of	O
+250	O
+samples	O
+,	O
+seven	O
+CPV	B-SPEC
+strains	O
+and	O
+three	O
+CCoV	O
+strains	O
+were	O
+identified	O
+in	O
+symptomatic	O
+Irish	O
+dogs	B-SPEC
+.	O
+
+Three	O
+CPV	B-SPEC
+strains	O
+were	O
+characterized	O
+as	O
+CPV	B-SPEC
+-	O
+2a	O
+,	O
+while	O
+four	O
+others	O
+were	O
+characterized	O
+as	O
+CPV	B-SPEC
+-	O
+2b	O
+.	O
+
+ABSTRACT	O
+:	O
+Fat	B-PRGE
+embolism	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+severe	O
+complication	O
+of	O
+long	B-ANAT
+bone	I-ANAT
+fractures	O
+,	O
+corresponding	O
+to	O
+the	O
+obstruction	B-DISO
+of	O
+small	B-ANAT
+vessels	I-ANAT
+by	O
+microdroplets	O
+of	O
+fat	O
+,	O
+originating	O
+from	O
+medulla	B-ANAT
+ossium	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+for	O
+chronic	B-DISO
+post	I-DISO
+-	I-DISO
+traumatic	I-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+)	O
+in	O
+SARS	B-DISO
+survivors	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+study	O
+of	O
+PTSD	B-DISO
+at	O
+30	O
+months	O
+post	O
+-	O
+SARS	B-DISO
+showed	O
+that	O
+the	O
+predictive	O
+value	O
+of	O
+acute	O
+medical	O
+variables	O
+may	O
+fade	O
+out	O
+.	O
+
+TITLE	O
+:	O
+Integrated	O
+capillary	B-ANAT
+electrophoresis	O
+microsystem	O
+for	O
+multiplex	O
+analysis	O
+of	O
+human	B-SPEC
+respiratory	O
+viruses	O
+.	O
+
+When	O
+a	O
+two	O
+-	O
+step	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+amplification	B-DISO
+is	O
+employed	O
+,	O
+the	O
+device	O
+can	O
+detect	O
+ribonucleic	B-CHED
+acid	I-CHED
+(	O
+RNA	O
+)	O
+analogues	O
+of	O
+all	O
+four	O
+viral	O
+targets	O
+with	O
+detection	O
+limits	O
+in	O
+the	O
+range	O
+of	O
+25	O
+-	O
+100	O
+copies	O
+/	O
+reactor	O
+.	O
+
+When	O
+size	O
+-	O
+based	O
+separation	B-DISO
+is	O
+combined	O
+with	O
+four	O
+-	O
+color	O
+detection	O
+,	O
+this	O
+platform	O
+provides	O
+excellent	O
+product	O
+discrimination	O
+,	O
+making	O
+it	O
+readily	O
+extendable	O
+to	O
+higher	O
+-	O
+order	B-SPEC
+multiplex	O
+assays	O
+.	O
+
+Sepsis	B-DISO
+was	O
+the	O
+main	O
+cause	O
+of	O
+death	B-PROC
+after	O
+LT	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+activity	O
+of	O
+NEP	B-PRGE
+in	O
+the	O
+BALF	O
+of	O
+LPS	B-DISO
+-	O
+treated	O
+mice	B-SPEC
+was	O
+increased	O
+.	O
+
+In	O
+this	O
+experimental	O
+and	O
+clinical	O
+study	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+the	O
+activity	O
+of	O
+NEP	O
+was	O
+significantly	O
+decreased	O
+in	O
+plasma	B-ANAT
+and	O
+increased	O
+in	O
+the	O
+alveolar	B-ANAT
+air	I-ANAT
+space	O
+.	O
+
+It	O
+is	O
+expected	O
+that	O
+the	O
+proliferation	B-DISO
+of	O
+Internet	O
+-	O
+based	O
+reports	O
+has	O
+resulted	O
+in	O
+greater	O
+communication	O
+and	O
+improved	O
+surveillance	O
+and	O
+reporting	O
+frameworks	O
+,	O
+especially	O
+with	O
+the	O
+revision	O
+of	O
+the	O
+World	O
+Health	O
+Organization	O
+'	O
+s	O
+(	O
+WHO	O
+)	O
+International	O
+Health	O
+Regulations	O
+(	O
+IHR	O
+2005	O
+),	O
+which	O
+went	O
+into	O
+force	O
+in	O
+2007	O
+.	O
+
+TITLE	O
+:	O
+Simultaneous	O
+detection	O
+and	O
+differentiation	B-PROC
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+other	O
+respiratory	O
+viral	O
+pathogens	O
+.	O
+
+In	O
+this	O
+chapter	O
+,	O
+we	O
+describe	O
+several	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+protocols	O
+for	O
+detecting	O
+SARS	B-DISO
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Bedside	O
+lung	B-ANAT
+mechanics	O
+predict	O
+survival	O
+in	O
+hypoplastic	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+compare	O
+two	O
+inpatient	O
+symptom	B-DISO
+-	O
+triggered	O
+pharmacological	O
+treatments	O
+of	O
+acute	O
+alcohol	B-DISO
+withdrawal	I-DISO
+(	O
+AWS	B-DISO
+)	O
+(	O
+clomethiazole	O
+vs	O
+.	O
+clonazepam	B-CHED
+).	O
+
+Because	O
+of	O
+a	O
+need	O
+for	O
+extra	O
+precautions	O
+against	O
+complications	O
+such	O
+as	O
+seizures	B-DISO
+and	O
+severe	O
+respiratory	O
+complaints	O
+,	O
+patients	O
+with	O
+a	O
+history	O
+of	O
+withdrawal	B-DISO
+seizures	I-DISO
+or	O
+complications	O
+with	O
+clomethiazole	O
+in	O
+their	O
+history	O
+were	O
+automatically	O
+assigned	O
+to	O
+the	O
+clonazepam	B-CHED
+group	O
+.	O
+
+The	O
+remaining	O
+patients	O
+were	O
+alternately	O
+assigned	O
+either	O
+to	O
+the	O
+clonazepam	B-CHED
+group	O
+(	O
+n	O
+=	O
+38	O
+altogether	O
+)	O
+or	O
+the	O
+clomethiazole	O
+group	O
+(	O
+n	O
+=	O
+36	O
+).	O
+
+Rescue	O
+medication	O
+could	O
+consist	O
+of	O
+adding	O
+either	O
+extra	O
+clonazepam	B-CHED
+or	O
+clomethiazole	O
+.	O
+
+Effectiveness	O
+was	O
+measured	O
+by	O
+Clinical	O
+Global	O
+Impression	O
+Scale	O
+,	O
+Revised	O
+Clinical	O
+Institute	O
+Withdrawal	B-DISO
+Assessment	O
+for	O
+Alcohol	O
+Scale	O
+,	O
+Mainz	O
+Alcohol	B-DISO
+Withdrawal	I-DISO
+Scale	O
+,	O
+Essen	O
+Self	O
+-	O
+Assessment	O
+-	O
+Alcohol	B-DISO
+Withdrawal	I-DISO
+and	O
+attrition	B-DISO
+rate	O
+.	O
+
+Both	O
+reduced	O
+the	O
+severity	O
+of	O
+initial	O
+withdrawal	B-DISO
+symptoms	I-DISO
+below	O
+20	O
+%	O
+up	O
+to	O
+the	O
+ending	O
+of	O
+withdrawal	B-DISO
+medications	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+is	O
+a	O
+mainstay	O
+in	O
+the	O
+ventilatory	O
+management	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+our	O
+burn	O
+center	O
+.	O
+
+Sodium	B-CHED
+bicarbonate	I-CHED
+(	O
+50	O
+ml	O
+8	O
+.	O
+4	O
+%)	O
+only	O
+for	O
+excessive	O
+hyperkaliemia	O
+,	O
+metabolic	B-DISO
+acidosis	I-DISO
+,	O
+or	O
+intoxication	O
+with	O
+tricyclic	B-CHED
+antidepressants	I-CHED
+.	O
+
+Most	O
+effective	O
+improvement	O
+of	O
+outcome	O
+by	O
+prevention	O
+of	O
+full	O
+cardiorespiratory	B-DISO
+arrest	I-DISO
+.	O
+
+Foreign	O
+body	B-ANAT
+airway	B-DISO
+obstruction	I-DISO
+with	O
+insufficient	O
+cough	B-DISO
+:	O
+alternate	O
+back	B-ANAT
+blows	O
+and	O
+chest	B-ANAT
+compressions	O
+(	O
+infants	O
+),	O
+or	O
+abdominal	B-ANAT
+compressions	O
+(	O
+children	O
+>	O
+1	O
+year	O
+).	O
+
+Defibrillation	O
+(	O
+4	O
+J	O
+/	O
+kgBW	O
+;	O
+monophasic	O
+or	O
+biphasic	O
+)	O
+followed	O
+by	O
+2	O
+min	O
+CPR	B-ENZY
+,	O
+then	O
+ECG	O
+and	O
+pulse	B-PROC
+check	O
+.	O
+
+In	O
+STEMI	B-DISO
+define	O
+reperfusion	O
+strategy	O
+depending	O
+on	O
+duration	O
+of	O
+symptoms	O
+until	O
+PCI	O
+,	O
+age	O
+and	O
+location	O
+of	O
+infarction	B-DISO
+.	O
+
+Any	O
+CPR	B-ENZY
+training	O
+is	O
+better	O
+than	O
+nothing	O
+;	O
+simplification	O
+of	O
+contents	O
+and	O
+processes	O
+is	O
+the	O
+main	O
+aim	O
+.	O
+
+Diagnosis	O
+of	O
+IMAM	O
+was	O
+based	O
+on	O
+the	O
+infiltration	B-DISO
+of	O
+CD68	B-PRGE
++	I-PRGE
+macrophages	B-ANAT
+into	O
+biopsied	O
+specimens	O
+,	O
+particularly	O
+the	O
+fascia	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Profile	O
+of	O
+patients	O
+of	O
+leptospirosis	B-DISO
+in	O
+sub	O
+-	O
+Himalayan	O
+region	O
+of	O
+North	O
+India	O
+.	O
+
+We	O
+present	O
+here	O
+a	O
+case	O
+series	O
+of	O
+13	O
+patients	O
+who	O
+were	O
+positive	O
+for	O
+leptospirosis	B-DISO
+either	O
+by	O
+IgM	B-PRGE
+Elisa	O
+or	O
+PCR	O
+method	O
+.	O
+
+All	O
+had	O
+contact	O
+with	O
+animals	B-SPEC
+or	O
+contaminated	O
+environment	O
+.	O
+
+Leptospirosis	B-DISO
+was	O
+unexpectedly	O
+found	O
+to	O
+be	O
+positive	O
+in	O
+many	O
+of	O
+our	O
+patients	O
+who	O
+were	O
+having	O
+pyrexia	B-PROC
+during	O
+the	O
+monsoons	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+the	O
+RT	O
+-	O
+LAMP	O
+amplified	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+with	O
+high	O
+specificity	O
+,	O
+efficiency	O
+,	O
+and	O
+rapidity	O
+at	O
+isothermal	O
+condition	B-DISO
+.	O
+
+The	O
+structural	O
+modifications	O
+induced	O
+by	O
+tryptophan	B-CHED
+oxidation	B-PROC
+were	O
+severe	O
+,	O
+with	O
+a	O
+reduction	O
+in	O
+helical	O
+extent	O
+from	O
+approximately	O
+three	O
+helical	O
+turns	O
+to	O
+,	O
+at	O
+most	O
+,	O
+one	O
+turn	O
+,	O
+and	O
+were	O
+observed	O
+in	O
+a	O
+variety	O
+of	O
+solvent	B-CHED
+environments	O
+,	O
+including	O
+sodium	B-CHED
+dodecyl	I-CHED
+sulfate	I-CHED
+(	O
+SDS	B-DISO
+)	O
+micelles	O
+,	O
+dodecyl	B-CHED
+phosphocholine	B-CHED
+(	O
+DPC	B-CHED
+)	O
+micelles	O
+,	O
+and	O
+a	O
+40	O
+%	O
+hexafluoro	B-CHED
+-	I-CHED
+2	I-CHED
+-	I-CHED
+propanol	I-CHED
+(	O
+HFIP	B-CHED
+)	O
+aqueous	O
+solution	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+the	O
+simultaneous	O
+triggering	O
+of	O
+both	O
+takotsubo	B-DISO
+cardiomyopathy	I-DISO
+and	O
+myasthenic	B-DISO
+crisis	I-DISO
+by	O
+the	O
+physiologic	O
+consequences	O
+of	O
+a	O
+state	O
+of	O
+severe	O
+emotional	B-DISO
+stress	I-DISO
+.	O
+
+The	O
+autopsy	O
+revealed	O
+widespread	O
+asphyxia	B-DISO
+syndrome	B-DISO
+and	O
+erosive	B-DISO
+gastritis	I-DISO
+.	O
+
+The	O
+latency	O
+and	O
+the	O
+brutality	O
+of	O
+clinical	O
+picture	O
+degradation	O
+seem	O
+to	O
+be	O
+in	O
+consideration	O
+of	O
+systemic	O
+poisoning	O
+by	O
+vanadium	O
+leading	O
+to	O
+inhibition	B-PROC
+of	O
+the	O
+cellular	B-COMP
+respiratory	B-PROC
+process	I-PROC
+.	O
+
+We	O
+investigated	O
+how	O
+M	O
+structure	O
+and	O
+organization	O
+is	O
+related	O
+to	O
+virus	B-SPEC
+shape	O
+and	O
+size	O
+using	O
+cryo	O
+-	O
+electron	O
+microscopy	O
+,	O
+tomography	O
+and	O
+statistical	O
+analysis	O
+.	O
+
+Analysis	O
+of	O
+several	O
+types	O
+of	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+and	O
+virions	B-COMP
+revealed	O
+that	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+N	B-PRGE
+protein	I-PRGE
+and	O
+genomic	O
+RNA	O
+each	O
+help	O
+to	O
+regulate	O
+virion	B-COMP
+size	O
+and	O
+variation	O
+,	O
+presumably	O
+through	O
+interactions	O
+with	O
+M	O
+.	O
+These	O
+findings	O
+provide	O
+insight	O
+into	O
+how	O
+M	O
+protein	O
+functions	O
+to	O
+promote	O
+virus	B-PROC
+assembly	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+common	O
+and	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+resulting	O
+from	O
+both	O
+direct	O
+(	O
+eg	O
+,	O
+pneumonia	B-DISO
+)	O
+and	O
+indirect	O
+(	O
+eg	O
+,	O
+sepsis	B-DISO
+)	O
+pulmonary	B-ANAT
+insults	O
+.	O
+
+It	O
+is	O
+a	O
+common	O
+cause	O
+of	O
+admission	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+due	O
+to	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+requiring	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+is	O
+associated	O
+with	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+In	O
+some	O
+patients	O
+,	O
+ARDS	B-DISO
+leads	O
+to	O
+the	O
+development	B-PROC
+of	O
+life	O
+-	O
+threatening	O
+refractory	O
+hypoxemia	O
+.	O
+
+It	O
+proved	O
+that	O
+this	O
+method	O
+is	O
+sensitive	O
+for	O
+clinical	O
+fecal	B-ANAT
+samples	O
+and	O
+is	O
+worth	O
+applying	O
+to	O
+laboratory	O
+diagnosis	O
+for	O
+BCoV	O
+and	O
+group	O
+A	O
+BRV	B-DISO
+.	O
+
+TITLE	O
+:	O
+Genetically	O
+diverse	O
+coronaviruses	O
+in	O
+captive	O
+bird	B-SPEC
+populations	O
+in	O
+a	O
+Brazilian	O
+zoological	O
+park	B-DISO
+.	O
+
+This	O
+study	O
+demonstrates	O
+the	O
+inactivation	B-DISO
+of	O
+a	O
+virus	B-SPEC
+using	O
+the	O
+streamer	O
+corona	B-CHED
+discharge	B-ANAT
+process	O
+(	O
+SCDP	O
+)	O
+with	O
+MS2	O
+phage	O
+as	O
+a	O
+surrogate	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+elucidate	O
+the	O
+mechanism	O
+of	O
+MS2	O
+phage	O
+inactivation	O
+,	O
+potentially	O
+lethal	O
+factors	O
+that	O
+can	O
+be	O
+generated	O
+by	O
+the	O
+SCDP	O
+were	O
+selected	O
+,	O
+and	O
+their	O
+roles	O
+in	O
+the	O
+inactivation	B-DISO
+of	O
+MS2	O
+phage	O
+were	O
+examined	O
+.	O
+
+The	O
+shockwave	O
+generated	O
+upon	O
+plasma	B-ANAT
+channel	O
+formation	B-PROC
+appears	O
+to	O
+be	O
+the	O
+most	O
+important	O
+factor	O
+responsible	O
+for	O
+MS2	O
+phage	O
+inactivation	B-DISO
+.	O
+
+There	O
+are	O
+some	O
+publications	O
+concerning	O
+the	O
+course	O
+of	O
+the	O
+pandemic	O
+influenza	B-DISO
+among	O
+pediatric	O
+population	O
+but	O
+mostly	O
+from	O
+hospital	O
+or	O
+from	O
+emergency	B-DISO
+units	O
+.	O
+
+In	O
+patients	O
+who	O
+met	B-CHED
+ILI	O
+criteria	O
+,	O
+nasopharyngeal	B-ANAT
+swabs	O
+were	O
+taken	O
+for	O
+RIDT	O
+and	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Two	O
+children	O
+received	O
+treatment	O
+with	O
+oseltamivir	B-CHED
+(	O
+one	O
+boy	O
+with	O
+congenital	B-DISO
+heart	I-DISO
+defect	I-DISO
+and	O
+Down	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+and	O
+another	O
+with	O
+severe	O
+bronchial	B-DISO
+asthma	B-PATH
+).	O
+
+There	O
+remains	O
+,	O
+therefore	O
+,	O
+a	O
+need	O
+for	O
+evidence	O
+-	O
+based	O
+treatment	O
+to	O
+inform	O
+both	O
+military	O
+and	O
+civilian	O
+medical	O
+response	O
+teams	O
+on	O
+the	O
+most	O
+appropriate	O
+treatment	O
+for	O
+chemically	B-DISO
+induced	I-DISO
+lung	B-ANAT
+injury	O
+.	O
+
+To	O
+this	O
+end	O
+,	O
+we	O
+implement	O
+a	O
+memetic	O
+algorithm	O
+for	O
+the	O
+problem	O
+and	O
+demonstrate	O
+the	O
+effectiveness	O
+of	O
+the	O
+arithmetic	O
+-	O
+harmonic	O
+cut	O
+on	O
+a	O
+number	O
+of	O
+datasets	O
+including	O
+a	O
+cancer	B-DISO
+type	O
+dataset	O
+and	O
+a	O
+corona	B-CHED
+virus	B-SPEC
+dataset	O
+.	O
+
+ABSTRACT	O
+:	O
+Transgenic	O
+plants	B-SPEC
+have	O
+been	O
+used	O
+as	O
+a	O
+safe	O
+and	O
+economic	O
+expression	B-PROC
+system	O
+for	O
+the	O
+production	O
+of	O
+edible	O
+vaccines	O
+.	O
+
+A	O
+synthetic	O
+cholera	B-PRGE
+toxin	I-PRGE
+B	I-PRGE
+subunit	I-PRGE
+gene	I-PRGE
+(	O
+CTB	B-PRGE
+)	O
+was	O
+fused	O
+with	O
+a	O
+synthetic	O
+neutralizing	O
+epitope	B-CHED
+gene	O
+of	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+sCTB	O
+-	O
+sCOE	O
+),	O
+and	O
+the	O
+sCTB	O
+-	O
+sCOE	O
+fusion	O
+gene	O
+was	O
+introduced	O
+into	O
+a	O
+plant	B-SPEC
+expression	B-PROC
+vector	O
+under	O
+the	O
+control	O
+of	O
+the	O
+ubiquitin	B-PRGE
+promoter	I-PRGE
+.	O
+
+The	O
+biological	O
+activity	O
+of	O
+CTB	B-PRGE
+-	I-PRGE
+COE	I-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+to	O
+its	O
+receptor	O
+,	O
+G	O
+(	O
+M1	O
+)-	O
+ganglioside	B-CHED
+,	O
+in	O
+transgenic	O
+plants	B-SPEC
+was	O
+confirmed	O
+via	O
+G	O
+(	O
+M1	O
+)-	O
+ELISA	O
+with	O
+anti	O
+-	O
+cholera	B-DISO
+toxin	O
+and	O
+anti	O
+-	O
+COE	O
+antibody	B-COMP
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Several	O
+techniques	O
+are	O
+available	O
+to	O
+improve	O
+oxygenation	B-PROC
+in	O
+severely	O
+hypoxemic	O
+patients	O
+.	O
+
+Randomized	O
+trials	O
+failed	O
+to	O
+prove	O
+survival	O
+benefits	O
+with	O
+the	O
+use	O
+of	O
+high	O
+levels	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+or	O
+prone	O
+positioning	O
+.	O
+
+Special	O
+antibody	B-COMP
+titer	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+of	O
+14	O
+patients	O
+from	O
+5	O
+different	O
+families	O
+and	O
+their	O
+10	O
+kinfolks	O
+continuously	O
+tested	O
+by	O
+IFA	O
+and	O
+antigen	B-CHED
+-	O
+capturing	O
+ELISA	O
+methods	O
+.	O
+
+Immunochemical	O
+staining	O
+with	O
+monoclonal	O
+antibody	B-COMP
+(	O
+mAb	O
+)	O
+against	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+used	O
+to	O
+determine	O
+the	O
+stomach	B-ANAT
+and	O
+enteric	O
+tissues	O
+among	O
+5	O
+SARS	B-DISO
+patients	O
+with	O
+their	O
+nucleocapsid	B-COMP
+antibody	B-COMP
+titer	O
+ascended	O
+obviously	O
+after	O
+1	O
+(	O
+st	O
+)-	O
+7	O
+(	O
+th	O
+)	O
+year	O
+.	O
+
+Regarding	O
+the	O
+IgM	B-PRGE
+titer	O
+,	O
+it	O
+disappeared	O
+in	O
+most	O
+of	O
+the	O
+SARS	B-DISO
+patients	O
+1	O
+year	O
+later	O
+.	O
+
+3	O
+cases	O
+showed	O
+N	B-PRGE
+protein	I-PRGE
+antibody	B-COMP
+positive	O
+in	O
+the	O
+serum	B-COMP
+,	O
+and	O
+positive	O
+immunohistochemical	O
+expression	B-PROC
+in	O
+most	O
+of	O
+the	O
+cytoplasm	B-COMP
+in	O
+the	O
+gastric	B-ANAT
+tissue	I-ANAT
+mucous	B-ANAT
+gland	I-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+By	O
+testing	O
+the	O
+special	O
+IgG	B-PRGE
+,	I-PRGE
+IgM	I-PRGE
+,	I-PRGE
+nucleocapsid	I-PRGE
+antibody	B-COMP
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+of	O
+the	O
+14	O
+family	B-SPEC
+clustering	O
+cases	O
+,	O
+we	O
+found	O
+that	O
+they	O
+all	O
+decreased	O
+in	O
+the	O
+7	O
+(	O
+th	O
+)	O
+year	O
+,	O
+and	O
+most	O
+of	O
+them	O
+disappeared	O
+.	O
+
+ABSTRACT	O
+:	O
+Three	O
+cats	O
+were	O
+evaluated	O
+at	O
+a	O
+veterinary	O
+teaching	O
+hospital	O
+for	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+(	O
+CHF	B-DISO
+)	O
+secondary	O
+to	O
+hyperviscosity	B-DISO
+syndrome	I-DISO
+from	O
+plasma	B-ANAT
+cell	I-ANAT
+neoplasia	B-DISO
+.	O
+
+Multiple	B-DISO
+myeloma	I-DISO
+or	O
+plasma	B-ANAT
+cell	I-ANAT
+neoplasia	B-DISO
+was	O
+diagnosed	O
+based	O
+on	O
+cytopathology	O
+and	O
+post	O
+mortem	O
+examination	O
+.	O
+
+However	O
+,	O
+systemic	O
+corticosteroid	B-CHED
+was	O
+not	O
+associated	O
+with	O
+improving	O
+28	O
+-	O
+day	O
+and	O
+3	O
+-	O
+month	O
+survival	O
+rates	O
+.	O
+
+To	O
+our	O
+knowledge	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+Type	B-DISO
+1	I-DISO
+diabetes	I-DISO
+in	O
+this	O
+age	O
+group	O
+and	O
+the	O
+first	O
+report	O
+of	O
+transient	O
+neonatal	B-DISO
+diabetes	I-DISO
+mellitus	I-DISO
+in	O
+horses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+as	O
+a	O
+prominent	O
+cause	O
+of	O
+childhood	O
+acute	O
+flaccid	B-DISO
+paralysis	I-DISO
+in	O
+post	O
+polio	B-DISO
+eradication	O
+era	B-CHED
+in	O
+Egypt	O
+.	O
+
+The	O
+present	O
+authors	O
+have	O
+previously	O
+demonstrated	O
+that	O
+antigens	B-CHED
+chemically	O
+coupled	O
+to	O
+the	O
+surface	O
+of	O
+liposomes	O
+made	O
+using	O
+unsaturated	B-CHED
+fatty	I-CHED
+acids	I-CHED
+are	O
+cross	O
+-	O
+presented	O
+by	O
+APCs	B-DISO
+via	O
+MHC	B-PRGE
+class	B-SPEC
+I	I-PRGE
+to	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+induce	O
+antigen	B-CHED
+-	O
+specific	O
+CTLs	O
+.	O
+
+The	O
+HCoV	B-PRGE
+-	I-PRGE
+HKU1	I-PRGE
+pol	I-PRGE
+gene	I-PRGE
+sequences	I-PRGE
+shared	O
+a	O
+95	O
+.	O
+8	O
+%	O
+-	O
+99	O
+.	O
+6	O
+%	O
+nucleotide	B-CHED
+identity	O
+with	O
+the	O
+human	B-PRGE
+coronavirus	I-PRGE
+-	I-PRGE
+HKU1	I-PRGE
+strain	O
+,	O
+whereas	O
+the	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+was	O
+90	O
+.	O
+7	O
+%	O
+-	O
+99	O
+.	O
+3	O
+%.	O
+
+The	O
+clinical	O
+presentations	O
+of	O
+HCoV	O
+-	O
+HKU1	O
+positive	O
+children	O
+included	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+sputum	B-PROC
+production	I-PROC
+,	O
+diarrhea	B-DISO
+,	O
+vomiting	B-DISO
+;	O
+pharynx	B-ANAT
+engorgement	B-DISO
+,	O
+crackles	B-DISO
+,	O
+and	O
+wheezing	B-DISO
+.	O
+
+Human	B-PRGE
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+infection	B-DISO
+exists	O
+in	O
+children	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+Lanzhou	O
+region	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Human	B-PRGE
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+infection	B-DISO
+exists	O
+in	O
+children	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+Lanzhou	O
+region	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+pAPN	O
+)	O
+is	O
+a	O
+cellular	B-COMP
+receptor	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+a	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Small	O
+molecules	O
+,	O
+especially	O
+peptides	B-CHED
+are	O
+an	O
+expanding	O
+area	O
+for	O
+therapy	O
+or	O
+diagnostic	O
+assays	O
+for	O
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+Three	O
+chemically	O
+synthesized	O
+peptides	B-CHED
+recognizing	O
+the	O
+pAPN	O
+showed	O
+effective	O
+inhibition	B-PROC
+ability	O
+to	O
+TGEV	B-SPEC
+infection	B-DISO
+in	O
+vitro	O
+.	O
+
+A	O
+putative	O
+TxxF	O
+motif	O
+was	O
+identified	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+TGEV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Interferon	O
+interplay	O
+helps	O
+tissue	B-ANAT
+cells	B-COMP
+to	O
+cope	O
+with	O
+SARS	B-DISO
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+the	O
+causative	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+is	O
+a	O
+versatile	O
+pathogen	O
+armed	O
+with	O
+a	O
+host	B-COMP
+of	O
+factors	O
+countering	O
+the	O
+antiviral	B-CHED
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+system	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+host	B-COMP
+factors	O
+involved	O
+in	O
+coronavirus	B-SPEC
+replication	O
+by	O
+quantitative	O
+proteomics	O
+analysis	O
+.	O
+
+Comparison	O
+of	O
+the	O
+protein	B-CHED
+profiles	O
+of	O
+Golgi	B-COMP
+-	O
+enriched	O
+fractions	O
+of	O
+cells	B-COMP
+that	O
+were	O
+either	O
+mock	O
+infected	O
+or	O
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+revealed	O
+the	O
+significant	O
+depletion	O
+or	O
+enrichment	O
+of	O
+116	O
+proteins	B-CHED
+.	O
+
+Although	O
+ribosomal	B-PRGE
+/	I-PRGE
+nucleic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+proteins	B-CHED
+were	O
+enriched	O
+in	O
+the	O
+Golgi	B-COMP
+-	O
+fractions	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+,	O
+proteins	B-CHED
+annotated	O
+to	O
+localize	O
+to	O
+several	O
+organelles	B-COMP
+of	O
+the	O
+secretory	B-PROC
+pathway	I-PROC
+were	O
+overrepresented	O
+among	O
+the	O
+proteins	B-CHED
+that	O
+were	O
+depleted	O
+from	O
+these	O
+fractions	O
+upon	O
+infection	B-DISO
+.	O
+
+Overexpression	B-PROC
+of	O
+these	O
+proteins	B-CHED
+,	O
+on	O
+the	O
+other	O
+hand	O
+,	O
+had	O
+a	O
+negative	O
+effect	O
+on	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Overall	O
+,	O
+our	O
+study	O
+shows	O
+that	O
+the	O
+SILAC	O
+approach	O
+is	O
+a	O
+suitable	O
+tool	O
+to	O
+study	O
+host	B-COMP
+-	O
+pathogen	O
+interactions	O
+and	O
+to	O
+identify	O
+host	B-COMP
+proteins	B-CHED
+involved	O
+in	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Intensive	O
+passages	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+its	O
+natural	O
+host	B-COMP
+may	O
+enhance	O
+the	O
+appearance	O
+of	O
+mutations	O
+and	O
+therefore	O
+may	O
+contribute	O
+to	O
+any	O
+attenuated	O
+form	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+characterize	O
+the	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+TMK22	O
+strain	O
+after	O
+passages	O
+in	O
+piglets	O
+from	O
+1992	O
+until	O
+2007	O
+.	O
+
+Although	O
+these	O
+deletions	O
+were	O
+positioned	O
+at	O
+the	O
+beginning	O
+of	O
+the	O
+antigenic	O
+site	O
+B	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+no	O
+clinical	O
+differences	O
+were	O
+observed	O
+in	O
+piglets	O
+infected	O
+experimentally	O
+either	O
+with	O
+the	O
+native	O
+virus	B-SPEC
+or	O
+the	O
+mutated	O
+one	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+report	O
+that	O
+the	O
+S	O
+protein	B-CHED
+deletion	O
+did	O
+not	O
+affect	O
+the	O
+virus	B-SPEC
+'	O
+s	O
+pathogenicity	O
+.	O
+
+TITLE	O
+:	O
+North	O
+American	O
+porcine	B-DISO
+reproductive	B-PROC
+and	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+viruses	B-SPEC
+inhibit	O
+type	B-PRGE
+I	I-PRGE
+interferon	B-PROC
+production	I-PROC
+by	O
+plasmacytoid	B-ANAT
+dendritic	I-ANAT
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Fulminant	B-DISO
+hepatitis	I-DISO
+can	O
+cause	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+and	O
+death	B-PROC
+in	O
+both	O
+humans	B-SPEC
+and	O
+mice	B-SPEC
+.	O
+
+In	O
+IFN	B-PRGE
+-	I-PRGE
+γR	I-PRGE
+(-/-)	O
+mice	B-SPEC
+,	O
+Th17	O
+response	O
+is	O
+enhanced	O
+and	O
+the	O
+elevated	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+production	I-PROC
+contributes	O
+to	O
+severe	O
+liver	B-DISO
+damage	I-DISO
+as	O
+well	O
+as	O
+detrimental	O
+inflammation	B-DISO
+because	O
+neutralization	O
+of	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+effectively	O
+suppresses	O
+inflammation	B-DISO
+and	O
+protects	O
+mice	B-SPEC
+from	O
+liver	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+produces	O
+a	O
+series	O
+of	O
+subgenomic	O
+RNAs	O
+for	O
+viral	O
+protein	B-PROC
+expression	B-PROC
+.	O
+
+Meanwhile	O
+,	O
+the	O
+distribution	O
+patterns	O
+of	O
+HK	O
+and	O
+EGFP	O
+expressed	B-PROC
+by	O
+the	O
+recombinant	O
+viruses	B-SPEC
+were	O
+similar	O
+to	O
+those	O
+in	O
+cells	B-COMP
+transfected	O
+with	O
+a	O
+eukaryotic	O
+expression	B-PROC
+vector	O
+.	O
+
+TITLE	O
+:	O
+A	O
+type	O
+-	O
+specific	O
+blocking	B-DISO
+ELISA	O
+for	O
+the	O
+detection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+antibody	B-COMP
+.	O
+
+The	O
+percentage	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+-,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+-	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+-	O
+producing	O
+cells	B-COMP
+were	O
+higher	O
+in	O
+PEI	B-CHED
+/	O
+pci	B-PRGE
+-	O
+S	O
+vaccinated	O
+mice	B-SPEC
+than	O
+in	O
+control	O
+mice	B-SPEC
+.	O
+
+These	O
+results	O
+showed	O
+that	O
+intranasal	O
+immunization	O
+with	O
+PEI	B-CHED
+/	O
+pci	O
+-	O
+S	O
+nanoparticles	B-CHED
+induce	O
+antigen	B-CHED
+specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+The	O
+percentage	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+-,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+-	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+-	O
+producing	O
+cells	B-COMP
+were	O
+higher	O
+in	O
+PEI	B-CHED
+/	O
+pci	B-PRGE
+-	O
+S	O
+vaccinated	O
+mice	B-SPEC
+than	O
+in	O
+control	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+of	O
+communicable	O
+respiratory	B-DISO
+infections	I-DISO
+and	O
+facemasks	O
+.	O
+
+Fluorescein	B-CHED
+-	O
+KCl	B-CHED
+solution	O
+was	O
+sprayed	B-DISO
+onto	O
+the	O
+faces	B-ANAT
+of	O
+participants	O
+wearing	O
+the	O
+facemasks	O
+and	O
+performing	O
+intermittent	O
+exercises	O
+on	O
+a	O
+treadmill	O
+in	O
+a	O
+climatic	O
+chamber	B-ANAT
+.	O
+
+Using	O
+the	O
+same	O
+filters	O
+as	O
+normal	O
+surgical	O
+masks	O
+,	O
+facemasks	O
+A	O
+and	O
+B	O
+provided	O
+more	O
+effective	O
+respiratory	O
+protection	O
+against	O
+communicable	O
+respiratory	B-DISO
+infections	I-DISO
+such	O
+as	O
+influenza	B-DISO
+and	O
+SARS	B-DISO
+by	O
+the	O
+location	O
+of	O
+the	O
+breathing	B-PROC
+pathway	B-PROC
+to	O
+the	O
+back	B-ANAT
+of	O
+the	O
+facemasks	O
+.	O
+
+RESULTS	O
+:	O
+Experimental	O
+results	O
+showed	O
+that	O
+when	O
+droplets	O
+spread	O
+onto	O
+a	O
+person	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+over	O
+short	O
+distances	O
+,	O
+92	O
+.	O
+3	O
+%	O
+to	O
+99	O
+.	O
+5	O
+%	O
+of	O
+droplets	O
+were	O
+blocked	O
+by	O
+the	O
+front	O
+surface	O
+of	O
+the	O
+facemask	O
+,	O
+whereas	O
+only	O
+0	O
+.	O
+5	O
+%	O
+to	O
+7	O
+.	O
+7	O
+%	O
+of	O
+droplets	O
+reached	O
+the	O
+back	B-ANAT
+of	O
+the	O
+facemask	O
+.	O
+
+ABSTRACT	O
+:	O
+Patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+often	O
+require	O
+prolonged	O
+sessions	O
+of	O
+prone	O
+position	O
+(	O
+PP	O
+)	O
+because	O
+of	O
+refractory	O
+hypoxemia	O
+.	O
+
+PP	O
+is	O
+not	O
+associated	O
+with	O
+a	O
+significant	O
+change	O
+in	O
+the	O
+oropharyngeal	B-ANAT
+tract	O
+cross	O
+-	O
+section	O
+in	O
+healthy	O
+individuals	O
+.	O
+
+TITLE	O
+:	O
+Structures	O
+of	O
+the	O
+N	O
+-	O
+and	O
+C	O
+-	O
+terminal	O
+domains	O
+of	O
+MHV	B-PRGE
+-	I-PRGE
+A59	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+corroborate	O
+a	O
+conserved	O
+RNA	O
+-	O
+protein	O
+binding	O
+mechanism	O
+in	O
+coronavirus	B-SPEC
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+crystal	B-ANAT
+structures	O
+of	O
+the	O
+two	O
+proteolytically	O
+resistant	O
+N	O
+-	O
+(	O
+NTD	O
+)	O
+and	O
+C	O
+-	O
+terminal	O
+(	O
+CTD	O
+)	O
+domains	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+from	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+After	O
+complete	O
+removal	O
+of	O
+the	O
+extension	O
+peptide	B-CHED
+from	O
+the	O
+dimer	O
+,	O
+the	O
+mature	O
+M	O
+(	O
+pro	B-CHED
+)	O
+self	O
+-	O
+assembles	O
+into	O
+a	O
+novel	O
+super	O
+-	O
+active	O
+octamer	O
+(	O
+AO	O
+-	O
+M	O
+(	O
+pro	B-CHED
+)).	O
+
+Thus	O
+,	O
+during	O
+the	O
+initial	O
+period	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+this	O
+novel	O
+active	O
+form	O
+AOM	B-DISO
+(	O
+pro	B-CHED
+)	O
+should	O
+play	O
+a	O
+major	O
+role	O
+in	O
+cleaving	O
+polyproteins	O
+as	O
+the	O
+protein	B-CHED
+level	O
+is	O
+extremely	O
+low	O
+.	O
+
+TITLE	O
+:	O
+New	O
+nsp8	B-PRGE
+isoform	I-PRGE
+suggests	O
+mechanism	O
+for	O
+tuning	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+This	O
+specific	O
+proteolysis	B-PROC
+may	O
+indicate	O
+one	O
+possible	O
+mechanism	O
+by	O
+which	O
+coronaviruses	O
+to	O
+switch	O
+from	O
+viral	O
+infection	O
+to	O
+genome	O
+replication	O
+and	O
+viral	B-PROC
+assembly	I-PROC
+stages	O
+.	O
+
+However	O
+,	O
+the	O
+auto	O
+-	O
+processing	O
+mechanism	O
+of	O
+M	O
+(	O
+pro	B-CHED
+),	O
+i	O
+.	O
+e	O
+.	O
+its	O
+own	O
+release	B-PATH
+from	O
+the	O
+polyproteins	O
+through	O
+autocleavage	O
+,	O
+remains	O
+unclear	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+caused	O
+enteric	O
+disease	O
+with	O
+devastating	O
+impact	O
+since	O
+the	O
+first	O
+identification	O
+of	O
+PEDV	B-SPEC
+in	O
+1992	O
+in	O
+Korea	O
+.	O
+
+HMGB1	B-PRGE
+was	O
+a	O
+sole	B-ANAT
+independent	O
+correlate	O
+of	O
+sRAGE	O
+.	O
+
+RESULTS	O
+:	O
+Compared	O
+with	O
+age	O
+-	O
+and	O
+sex	O
+-	O
+matched	O
+control	O
+subjects	O
+,	O
+blood	B-PROC
+pressure	I-PROC
+levels	O
+were	O
+lower	O
+and	O
+KL	O
+-	O
+6	O
+,	O
+high	O
+mobility	O
+group	O
+box	O
+1	O
+(	O
+HMGB1	B-PRGE
+),	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+and	O
+sRAGE	O
+levels	O
+were	O
+higher	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Sequence	O
+analysis	O
+and	O
+BLAST	B-ANAT
+homology	O
+search	O
+in	O
+GenBank	O
+data	O
+base	O
+indicate	O
+that	O
+two	O
+of	O
+the	O
+farms	O
+were	O
+infected	O
+with	O
+the	O
+4	O
+/	O
+91	O
+strain	O
+,	O
+one	O
+with	O
+an	O
+unidentified	O
+IBV	B-SPEC
+and	O
+five	O
+were	O
+infected	O
+with	O
+Sul	O
+/	O
+01	O
+/	O
+09	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+(	O
+ADE	B-CHED
+)	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+infection	B-DISO
+has	O
+been	O
+recognized	O
+in	O
+experimentally	O
+infected	O
+cats	B-SPEC
+,	O
+and	O
+cellular	B-PROC
+immunity	I-PROC
+is	O
+considered	O
+to	O
+play	O
+an	O
+important	O
+role	O
+in	O
+preventing	O
+the	O
+onset	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+synthesized	O
+eighty	O
+-	O
+one	O
+kinds	O
+of	O
+peptides	B-CHED
+derived	O
+from	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+2	O
+domain	O
+of	O
+type	B-PRGE
+I	I-PRGE
+FIPV	I-PRGE
+KU	I-PRGE
+-	I-PRGE
+2	I-PRGE
+strain	O
+,	O
+the	O
+S2	O
+domain	O
+of	O
+type	O
+II	O
+FIPV	O
+79	O
+-	O
+1146	O
+strain	O
+,	O
+and	O
+the	O
+nucleocapcid	O
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+FIPV	O
+KU	O
+-	O
+2	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+recombinant	O
+fowlpox	B-SPEC
+virus	I-SPEC
+expressing	O
+infectious	B-DISO
+bronchitis	B-PRGE
+virus	B-SPEC
+S1	I-PRGE
+gene	I-PRGE
+and	O
+chicken	B-SPEC
+interferon	I-PRGE
+-	I-PRGE
+γ	I-PRGE
+gene	I-PRGE
+for	O
+immune	O
+protection	O
+against	O
+heterologous	O
+strains	O
+.	O
+
+To	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+the	O
+recombinant	O
+fowlpox	B-SPEC
+virus	I-SPEC
+vaccine	O
+against	O
+heterotypic	O
+IBV	B-SPEC
+strains	O
+,	O
+60	O
+4	O
+-	O
+week	O
+-	O
+old	O
+Specific	O
+-	O
+Pathogen	O
+-	O
+Free	O
+(	O
+SPF	O
+)	O
+chickens	B-SPEC
+were	O
+inoculated	O
+with	O
+this	O
+vaccine	O
+and	O
+3	O
+weeks	O
+post	O
+inoculation	O
+challenged	O
+with	O
+the	O
+homotypic	O
+IBV	B-SPEC
+strain	O
+LX4	O
+and	O
+the	O
+heterotypic	O
+IBV	B-SPEC
+strains	O
+LHB	O
+,	O
+LHLJ04XI	O
+,	O
+LTJ95I	O
+and	O
+LSC99I	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+5	O
+'	O
+cap	B-DISO
+structures	O
+of	O
+higher	O
+eukaryote	B-SPEC
+mRNAs	O
+have	O
+ribose	B-CHED
+2	O
+'-	O
+O	O
+-	O
+methylation	B-PROC
+.	O
+
+Likewise	O
+,	O
+many	O
+viruses	B-SPEC
+that	O
+replicate	O
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+eukaryotes	B-SPEC
+have	O
+evolved	O
+2	O
+'-	O
+O	O
+-	O
+methyltransferases	O
+to	O
+autonomously	O
+modify	O
+their	O
+mRNAs	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+2	O
+'-	O
+O	O
+-	O
+methylation	B-PROC
+of	O
+viral	O
+mRNA	B-CHED
+was	O
+critically	O
+involved	O
+in	O
+subverting	O
+the	O
+induction	O
+of	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Soluble	O
+form	O
+of	O
+the	O
+receptor	O
+for	O
+advanced	O
+glycation	O
+end	O
+products	O
+is	O
+a	O
+marker	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+but	O
+not	O
+of	O
+severe	O
+sepsis	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Levels	O
+of	O
+sRAGE	O
+were	O
+correlated	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+severity	O
+and	O
+decreased	O
+over	O
+time	O
+but	O
+were	O
+not	O
+associated	O
+with	O
+outcome	O
+.	O
+
+sRAGE	O
+levels	O
+were	O
+elevated	O
+during	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+regardless	O
+of	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+have	O
+caused	O
+a	O
+global	O
+effort	B-PROC
+for	O
+development	B-PROC
+of	O
+fast	B-FUNC
+and	O
+accurate	O
+detection	O
+techniques	O
+.	O
+
+Four	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+)	O
+against	O
+the	O
+N	O
+-	O
+terminal	O
+half	O
+of	O
+spike	O
+protein	B-CHED
+(	O
+S1	O
+protein	B-CHED
+)	O
+of	O
+TGEV	B-SPEC
+were	O
+identified	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+bocavirus	I-SPEC
+is	O
+a	O
+recently	O
+described	O
+respiratory	O
+pathogen	O
+.	O
+
+A	O
+case	O
+of	O
+a	O
+life	O
+-	O
+threatening	O
+human	O
+bocavirus	O
+infection	B-DISO
+of	O
+a	O
+previously	O
+healthy	O
+pediatric	O
+patient	O
+is	O
+described	O
+.	O
+
+TITLE	O
+:	O
+Antigenic	O
+modules	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+S1	O
+region	O
+of	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+spike	O
+protein	O
+.	O
+
+The	O
+most	O
+N	O
+-	O
+terminal	O
+portion	O
+of	O
+the	O
+S1	O
+region	O
+,	O
+which	O
+comprises	O
+antigenic	O
+sites	O
+C	O
+and	O
+B	O
+,	O
+is	O
+needed	O
+for	O
+the	O
+enteric	O
+tropism	B-PROC
+of	O
+TGEV	B-SPEC
+,	O
+whereas	O
+the	O
+major	O
+antigenic	O
+site	O
+A	O
+at	O
+the	O
+C	O
+-	O
+terminal	O
+moiety	O
+is	O
+required	O
+for	O
+both	O
+respiratory	O
+and	O
+enteric	O
+cell	B-COMP
+tropism	B-PROC
+,	O
+and	O
+is	O
+engaged	O
+in	O
+recognition	O
+of	O
+the	O
+aminopeptidase	B-PRGE
+N	I-PRGE
+(	O
+APN	O
+)	O
+receptor	O
+.	O
+
+The	O
+organization	O
+of	O
+the	O
+four	O
+modules	O
+in	O
+the	O
+S1	O
+region	O
+of	O
+the	O
+TGEV	B-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+is	O
+discussed	O
+.	O
+
+Herein	O
+are	O
+presented	O
+three	O
+cases	O
+of	O
+severe	O
+European	O
+Puumala	B-SPEC
+hantavirus	I-SPEC
+infection	O
+that	O
+meet	O
+the	O
+HPS	B-DISO
+case	O
+definition	O
+.	O
+
+The	O
+clinical	O
+and	O
+pathological	O
+findings	O
+were	O
+similar	O
+to	O
+those	O
+found	O
+in	O
+American	O
+hantavirus	B-SPEC
+patients	O
+.	O
+
+Consequently	O
+,	O
+hantavirus	B-DISO
+infection	I-DISO
+should	O
+be	O
+considered	O
+as	O
+a	O
+cause	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+in	O
+all	O
+endemic	O
+areas	O
+worldwide	O
+.	O
+
+Autopsy	O
+revealed	O
+a	O
+predominantly	O
+lymphocytic	B-DISO
+myocarditis	I-DISO
+in	O
+the	O
+absence	O
+of	O
+a	O
+significant	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Cough	B-DISO
+hypersensitivity	B-DISO
+syndrome	I-DISO
+:	O
+a	O
+distinct	O
+clinical	O
+entity	O
+.	O
+
+Two	O
+patients	O
+most	O
+likely	O
+had	O
+pre	O
+-	O
+existent	O
+cardiac	B-ANAT
+pathologies	O
+,	O
+and	O
+three	O
+required	O
+catecholamine	B-CHED
+therapy	O
+to	O
+maintain	O
+hemodynamic	B-PROC
+function	O
+.	O
+
+In	O
+38	O
+healthy	O
+individuals	O
+,	O
+nasal	B-ANAT
+inoculation	O
+with	O
+human	B-SPEC
+rhinovirus	I-SPEC
+-	I-PRGE
+16	I-PRGE
+(	O
+HRV	O
+-	O
+16	O
+)	O
+was	O
+performed	O
+.	O
+
+The	O
+supernatants	O
+efficiently	O
+killed	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+and	O
+vaccine	O
+failure	O
+in	O
+pregnancy	O
+.	O
+
+CONCLUSIONS	O
+:	O
+With	O
+the	O
+expectation	O
+that	O
+2009	O
+H1N1	O
+will	O
+continue	O
+to	O
+cause	O
+disease	O
+in	O
+the	O
+immediate	O
+future	O
+,	O
+the	O
+virus	B-SPEC
+has	O
+been	O
+included	O
+as	O
+a	O
+component	O
+of	O
+the	O
+2010	O
+-	O
+2011	O
+seasonal	O
+influenza	B-DISO
+vaccine	O
+.	O
+
+Trypsin	B-PRGE
+treatment	O
+of	O
+receptor	O
+-	O
+associated	O
+SARS	B-DISO
+-	O
+CoV	O
+pseudovirions	O
+,	O
+which	O
+bypasses	O
+their	O
+dependence	B-DISO
+on	I-DISO
+lysosomal	B-PRGE
+cathepsin	B-ENZY
+L	I-ENZY
+,	O
+also	O
+bypassed	O
+IFITM	O
+-	O
+mediated	O
+restriction	O
+.	O
+
+However	O
+,	O
+the	O
+isolates	O
+formed	O
+a	O
+new	O
+gene	O
+cluster	O
+that	O
+was	O
+distinguished	O
+from	O
+the	O
+two	O
+distinct	O
+K	O
+-	O
+II	O
+subgroups	O
+(	O
+KM91	O
+-	O
+like	O
+and	O
+QX	B-PRGE
+-	I-PRGE
+like	I-PRGE
+).	O
+
+For	O
+MHV	B-SPEC
+,	O
+log	O
+(	O
+10	O
+)	O
+reduction	O
+factors	O
+were	O
+3	O
+.	O
+9	O
+for	O
+70	O
+%	O
+ethanol	B-CHED
+,	O
+1	O
+.	O
+3	O
+for	O
+phenolic	O
+,	O
+1	O
+.	O
+7	O
+for	O
+OPA	B-CHED
+,	O
+0	O
+.	O
+62	O
+for	O
+1	O
+:	O
+100	O
+hypochlorite	B-CHED
+,	O
+2	O
+.	O
+7	O
+for	O
+62	O
+%	O
+ethanol	B-CHED
+,	O
+and	O
+2	O
+.	O
+0	O
+for	O
+71	O
+%	O
+ethanol	B-CHED
+.	O
+
+The	O
+herd	O
+status	O
+regarding	O
+the	O
+calves	O
+'	O
+passive	O
+transfer	O
+(	O
+total	O
+protein	B-CHED
+),	O
+levels	O
+of	O
+α	O
+-	O
+tocopherol	B-CHED
+,	O
+β	O
+-	O
+carotene	B-CHED
+and	O
+retinol	B-CHED
+,	O
+and	O
+excretion	B-PROC
+of	O
+faecal	B-ANAT
+pathogens	O
+(	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.,	O
+Escherichia	B-SPEC
+coli	I-SPEC
+F5	O
+,	O
+rota	O
+and	O
+corona	B-CHED
+virus	B-SPEC
+)	O
+was	O
+evaluated	O
+based	O
+on	O
+targeted	B-PROC
+sampling	O
+of	O
+high	O
+risk	O
+calf	B-ANAT
+groups	O
+;	O
+in	O
+each	O
+herd	O
+,	O
+blood	B-ANAT
+and	O
+faecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+calves	O
+1	O
+-	O
+7	O
+and	O
+1	O
+-	O
+14	O
+days	O
+old	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Critically	B-DISO
+ill	I-DISO
+children	O
+with	O
+pandemic	O
+influenza	B-DISO
+(	O
+H1N1	O
+)	O
+in	O
+pediatric	O
+intensive	O
+care	O
+units	O
+in	O
+Turkey	B-SPEC
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+rapidly	O
+decimated	O
+the	O
+region	O
+'	O
+s	O
+tourist	O
+industry	O
+.	O
+
+The	O
+Virochip	O
+successfully	O
+detected	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+)	O
+in	O
+serum	B-COMP
+containing	O
+6	O
+.	O
+10	O
+×	O
+10	O
+(	O
+2	O
+)	O
+viral	O
+copies	O
+per	O
+microliter	O
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+in	O
+lung	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+containing	O
+2	O
+.	O
+08	O
+×	O
+10	O
+(	O
+6	O
+)	O
+viral	O
+copies	O
+per	O
+microliter	O
+.	O
+
+Collectively	O
+,	O
+the	O
+data	O
+in	O
+this	O
+report	O
+demonstrate	O
+that	O
+the	O
+Virochip	O
+can	O
+successfully	O
+detect	O
+pathogenic	O
+viruses	B-SPEC
+frequently	O
+found	O
+in	O
+swine	B-SPEC
+in	O
+a	O
+variety	O
+of	O
+solid	O
+and	O
+liquid	O
+specimens	O
+,	O
+such	O
+as	O
+turbinate	B-ANAT
+tissue	B-ANAT
+homogenate	O
+and	O
+lung	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+as	O
+well	O
+as	O
+antemortem	O
+samples	O
+,	O
+such	O
+as	O
+serum	B-COMP
+.	O
+
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+treatment	O
+significantly	O
+induced	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+UBC	B-PRGE
+E2	I-PRGE
+-	I-PRGE
+25k	I-PRGE
+,	O
+but	O
+not	O
+ERK1	B-FUNC
+,	O
+causing	O
+time	O
+-	O
+dependent	O
+decrease	O
+of	O
+ERK1	B-FUNC
+,	O
+but	O
+not	O
+ERK2	B-FUNC
+,	O
+in	O
+PLpro	O
+-	O
+expressing	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+with	O
+a	O
+low	O
+tidal	O
+volume	O
+,	O
+plateau	O
+pressure	O
+<	O
+30	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+.	O
+oxygen	B-CHED
+saturation	O
+>	O
+90	O
+%	O
+and	O
+permissive	O
+hypercapnia	B-DISO
+results	O
+in	O
+reduction	O
+of	O
+the	O
+mortality	O
+rate	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+sedation	B-DISO
+should	O
+be	O
+interrupted	O
+daily	O
+,	O
+with	O
+phases	O
+of	O
+awakenings	O
+and	O
+,	O
+if	O
+possible	O
+,	O
+spontaneous	O
+breathing	B-PROC
+.	O
+
+In	O
+silico	O
+bioinformatic	O
+experiments	O
+were	O
+used	O
+to	O
+select	O
+an	O
+optimum	O
+annotation	O
+strategy	O
+for	O
+discovering	O
+human	B-SPEC
+viruses	B-SPEC
+in	O
+virome	O
+data	O
+sets	O
+and	O
+applied	O
+to	O
+annotate	O
+a	O
+class	B-SPEC
+B	O
+biosolid	O
+virome	O
+.	O
+
+Five	O
+10	O
+-	O
+week	O
+-	O
+old	O
+beagle	O
+pups	O
+were	O
+administered	O
+(	O
+three	O
+weeks	O
+apart	O
+)	O
+two	O
+vaccine	O
+doses	O
+,	O
+whereas	O
+two	O
+animals	B-SPEC
+served	O
+as	O
+unvaccinated	O
+controls	O
+.	O
+
+Serum	B-COMP
+antibodies	B-COMP
+against	O
+CCoV	O
+were	O
+detected	O
+in	O
+vaccinates	O
+starting	O
+from	O
+study	O
+day	O
+14	O
+(	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+)	O
+or	O
+28	O
+(	O
+by	O
+virus	O
+neutralisation	O
+test	O
+).	O
+
+The	O
+developed	O
+vaccine	O
+may	O
+help	O
+control	O
+the	O
+CCoV	B-PRGE
+-	I-PRGE
+IIb	I-PRGE
+-	O
+induced	O
+disease	O
+(	O
+and	O
+active	O
+virus	B-SPEC
+circulation	B-PROC
+)	O
+in	O
+environments	O
+,	O
+such	O
+as	O
+kennels	O
+and	O
+shelters	O
+,	O
+where	O
+the	O
+pathogenic	O
+potential	O
+of	O
+this	O
+virus	B-SPEC
+is	O
+greater	O
+as	O
+a	O
+consequence	O
+of	O
+predisposing	O
+factors	O
+and	O
+concurrent	O
+infections	B-DISO
+.	O
+
+However	O
+,	O
+the	O
+isolate	O
+had	O
+a	O
+185	O
+-	O
+nucleotide	O
+deletion	O
+from	O
+four	O
+bases	B-CHED
+after	O
+the	O
+3	O
+'-	O
+terminal	O
+end	O
+of	O
+the	O
+spike	O
+gene	O
+,	O
+resulting	O
+in	O
+the	O
+absence	O
+of	O
+the	O
+open	O
+reading	O
+frame	O
+predicted	O
+to	O
+encode	O
+a	O
+4	O
+.	O
+7	O
+-	O
+kDa	O
+nonstructural	O
+protein	B-CHED
+in	O
+strain	O
+NC99	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+young	O
+patient	O
+with	O
+36	O
+weeks	O
+pregnancy	O
+,	O
+and	O
+an	O
+acute	O
+respiratory	O
+infection	O
+with	O
+severe	O
+bronchospasm	B-DISO
+,	O
+who	O
+developed	O
+an	O
+occipital	B-DISO
+headache	I-DISO
+and	O
+neck	B-DISO
+pain	I-DISO
+on	O
+the	O
+third	O
+day	O
+of	O
+inadvertent	O
+dural	O
+puncture	O
+during	O
+placement	O
+of	O
+combined	O
+epidural	B-ANAT
+spinal	O
+anaesthesia	B-DISO
+for	O
+caesarian	O
+section	O
+.	O
+
+Very	O
+premature	O
+infants	O
+have	O
+more	O
+severe	O
+diseases	O
+and	O
+also	O
+'	O
+late	O
+preterm	O
+infants	O
+'	O
+may	O
+be	O
+more	O
+susceptible	O
+to	O
+the	O
+infection	B-DISO
+.	O
+
+The	O
+risk	O
+of	O
+hospitalization	O
+was	O
+significantly	O
+60	O
+%	O
+reduced	O
+in	O
+breastfed	O
+babies	O
+and	O
+four	O
+folds	O
+significantly	O
+increased	O
+during	O
+the	O
+RSV	B-SPEC
+season	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Development	B-PROC
+of	O
+serological	O
+detection	O
+assays	O
+for	O
+human	B-SPEC
+coronavirus	I-SPEC
+HKU1	I-SPEC
+infection	B-DISO
+and	O
+its	O
+application	O
+].	O
+
+The	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+HCoV	O
+-	O
+HKU1	O
+was	O
+expressed	B-PROC
+in	O
+E	O
+.	O
+Coli	B-PRGE
+,	O
+anti	O
+-	O
+N	O
+antibody	B-COMP
+assay	O
+was	O
+established	O
+using	O
+Western	O
+Blotting	O
+with	O
+turn	O
+-	O
+based	O
+membrane	B-COMP
+.	O
+
+We	O
+analyzed	O
+anti	O
+-	O
+S	O
+and	O
+anti	O
+-	O
+N	O
+antibody	B-COMP
+among	O
+100	O
+normal	O
+adult	O
+serum	B-COMP
+.	O
+
+Either	O
+detection	O
+of	O
+HCoV	O
+-	O
+HKU1	O
+S	O
+or	O
+N	O
+antibodies	B-COMP
+achieved	O
+good	O
+results	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+role	O
+of	O
+oxidative	B-DISO
+stress	I-DISO
+,	O
+alveolar	B-ANAT
+antioxidant	B-CHED
+status	O
+and	O
+multiple	O
+organ	B-ANAT
+injury	O
+in	O
+ARDS	B-DISO
+induced	O
+by	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)	O
+in	O
+rats	B-SPEC
+.	O
+
+A	O
+prospective	O
+cohort	O
+genetic	O
+association	O
+study	O
+of	O
+lung	B-ANAT
+injury	O
+in	O
+children	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+The	O
+optimization	O
+,	O
+sensitivity	O
+,	O
+and	O
+specificity	O
+of	O
+the	O
+RT	B-PRGE
+-	I-PRGE
+LAMP	I-PRGE
+were	O
+investigated	O
+.	O
+
+Our	O
+findings	O
+also	O
+have	O
+implications	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+early	O
+diagnosis	O
+and	O
+prevention	O
+.	O
+
+Research	O
+in	O
+wounded	O
+military	O
+showed	O
+that	O
+a	O
+high	O
+ratio	O
+of	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+to	O
+packed	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+(	O
+FFP	O
+:	O
+PRBC	O
+)	O
+seemed	O
+to	O
+have	O
+a	O
+positive	O
+effect	O
+on	O
+survival	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+past	O
+decade	O
+saw	O
+emerging	O
+infections	B-DISO
+such	O
+as	O
+SARS	O
+,	O
+avian	B-SPEC
+and	O
+pandemic	O
+influenza	B-DISO
+,	O
+food	O
+-	O
+borne	O
+infections	B-DISO
+and	O
+the	O
+bioterror	O
+threat	O
+.	O
+
+TITLE	O
+:	O
+Cross	O
+-	O
+crystal	B-ANAT
+averaging	O
+with	O
+search	O
+models	O
+to	O
+improve	O
+molecular	O
+replacement	O
+phases	O
+.	O
+
+TITLE	O
+:	O
+Computed	O
+tomography	O
+findings	O
+from	O
+patients	O
+with	O
+ARDS	B-DISO
+due	O
+to	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+-	O
+associated	O
+pneumonia	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+patients	O
+presented	O
+with	O
+a	O
+mixture	B-CHED
+of	O
+bilateral	O
+patchy	O
+consolidations	O
+and	O
+ground	O
+glass	O
+opacities	B-DISO
+.	O
+
+TITLE	O
+:	O
+Early	O
+prognosis	O
+after	O
+severe	O
+traumatic	O
+brain	B-ANAT
+injury	O
+with	O
+minor	O
+or	O
+absent	O
+computed	O
+tomography	O
+scan	O
+lesions	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+prognostic	O
+value	O
+of	O
+corpus	O
+callosum	O
+lesions	O
+(	O
+CCL	B-DISO
+)	O
+and	O
+brain	B-ANAT
+stem	I-ANAT
+lesions	O
+(	O
+BSL	O
+)	O
+in	O
+diffuse	O
+axonal	O
+injury	O
+(	O
+DAI	O
+)	O
+patients	O
+.	O
+
+Four	O
+variables	O
+affected	O
+time	O
+to	O
+recovery	O
+of	O
+consciousness	O
+:	O
+age	O
+(	O
+hazard	O
+ratio	O
+,	O
+0	O
+.	O
+98	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+97	O
+-	O
+0	O
+.	O
+99	O
+;	O
+p	O
+=	O
+0	O
+.	O
+009	O
+),	O
+bilateral	O
+absence	O
+of	O
+light	O
+reflexes	B-PROC
+(	O
+hazard	O
+ratio	O
+,	O
+0	O
+.	O
+51	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+27	O
+-	O
+0	O
+.	O
+97	O
+;	O
+p	O
+=	O
+0	O
+.	O
+041	O
+),	O
+multiplicity	O
+of	O
+CCL	B-DISO
+(	O
+hazard	O
+ratio	O
+,	O
+0	O
+.	O
+40	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+25	O
+-	O
+0	O
+.	O
+66	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+total	O
+GCS	O
+on	O
+admission	O
+(	O
+hazard	O
+ratio	O
+,	O
+1	O
+.	O
+45	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+23	O
+-	O
+1	O
+.	O
+71	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Pandemic	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+was	O
+a	O
+serious	O
+health	O
+problem	O
+during	O
+the	O
+winter	O
+of	O
+2009	O
+-	O
+2010	O
+in	O
+Turkey	B-SPEC
+.	O
+
+The	O
+most	O
+common	O
+risk	O
+factors	O
+for	O
+severe	O
+H1N1	O
+infection	B-DISO
+were	O
+obesity	B-DISO
+(	O
+33	O
+%),	O
+COPD	B-DISO
+(	O
+16	O
+%),	O
+and	O
+pregnancy	O
+(	O
+11	O
+%).	O
+
+ABSTRACT	O
+:	O
+Sixteen	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+field	O
+isolates	O
+obtained	O
+from	O
+vaccinated	O
+commercial	O
+broiler	O
+chickens	B-SPEC
+showing	O
+clinical	O
+respiratory	B-DISO
+disease	I-DISO
+were	O
+characterized	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+sequence	O
+analysis	O
+of	O
+the	O
+hypervariable	O
+region	O
+of	O
+the	O
+S1	B-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+gene	I-PRGE
+.	O
+
+Protection	O
+was	O
+evaluated	O
+at	O
+5	O
+and	O
+7	O
+days	O
+postchallenge	O
+by	O
+scoring	O
+clinical	O
+signs	O
+and	O
+quantifying	O
+the	O
+challenge	O
+virus	B-SPEC
+load	O
+in	O
+the	O
+trachea	B-DISO
+using	O
+real	O
+-	O
+time	O
+PCR	O
+(	O
+qPCR	O
+).	O
+
+In	O
+addition	O
+,	O
+the	O
+viral	O
+load	O
+of	O
+the	O
+vaccine	O
+viruses	B-SPEC
+(	O
+ILTV	B-SPEC
+,	O
+NDV	B-SPEC
+,	O
+and	O
+IBV	B-SPEC
+)	O
+was	O
+quantified	O
+3	O
+and	O
+5	O
+days	O
+postvaccination	O
+also	O
+using	O
+qPCR	O
+.	O
+
+TITLE	O
+:	O
+The	O
+benzodiazepine	B-CHED
+Midazolam	O
+mitigates	O
+the	O
+breathing	B-PROC
+defects	O
+of	O
+Mecp2	B-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+.	O
+
+Mecp2	B-PRGE
+(-/	O
+y	O
+)	O
+mice	B-SPEC
+also	O
+develop	O
+early	O
+GABA	B-CHED
+deficits	O
+.	O
+
+The	O
+most	O
+widely	O
+used	O
+scales	B-ANAT
+are	O
+the	O
+PSI	O
+/	O
+Fine	O
+and	O
+CURB	B-DISO
+-	O
+65	O
+scales	B-ANAT
+,	O
+which	O
+have	O
+been	O
+widely	O
+validated	O
+and	O
+are	O
+easy	O
+to	O
+calculate	O
+in	O
+clinical	O
+practice	O
+.	O
+
+Etiologic	O
+diagnosis	O
+of	O
+pneumonia	B-DISO
+continues	O
+to	O
+pose	O
+a	O
+challenge	O
+to	O
+clinicians	O
+.	O
+
+Experience	O
+has	O
+also	O
+been	O
+gained	O
+in	O
+antiviral	B-CHED
+treatment	O
+and	O
+complications	O
+,	O
+especially	O
+bacterial	O
+superinfection	B-DISO
+as	O
+the	O
+main	O
+unfavorable	O
+event	O
+in	O
+viral	B-DISO
+pneumonias	I-DISO
+.	O
+
+Fever	B-PROC
+screening	O
+stations	O
+,	O
+triage	O
+of	O
+fever	B-PROC
+patients	O
+,	O
+separating	O
+SARS	B-DISO
+patients	O
+from	O
+other	O
+patients	O
+,	O
+separation	B-DISO
+of	O
+entrances	O
+and	O
+passageways	O
+between	O
+patients	O
+and	O
+HCWs	O
+,	O
+and	O
+increasing	O
+hand	O
+-	O
+washing	O
+facilities	O
+all	O
+demonstrated	O
+a	O
+protective	O
+effect	O
+for	O
+HCWs	O
+(	O
+univariate	O
+analysis	O
+;	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+show	O
+that	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+a	O
+potent	O
+anti	O
+-	O
+inflammatory	O
+cytokine	O
+,	O
+is	O
+produced	O
+transiently	O
+at	O
+the	O
+peak	O
+of	O
+infection	B-DISO
+by	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+in	O
+the	O
+brains	B-ANAT
+of	O
+coronavirus	B-SPEC
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+A	O
+highly	O
+integrated	O
+extracorporeal	O
+membrane	B-COMP
+oxygenator	O
+(	O
+HEXMO	O
+)	O
+was	O
+developed	O
+to	O
+reduce	O
+filling	O
+volume	O
+and	O
+simplify	O
+management	O
+.	O
+
+In	O
+the	O
+remaining	O
+five	O
+experiments	O
+,	O
+the	O
+oxygenation	B-PROC
+increased	O
+significantly	O
+(	O
+arterial	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+[	O
+SaO2	B-PROC
+]	O
+from	O
+79	O
+±	O
+5	O
+%	O
+before	O
+HEXMO	O
+to	O
+92	O
+%	O
+±	O
+11	O
+%	O
+after	O
+4	O
+hours	O
+)	O
+facilitated	O
+by	O
+a	O
+mean	O
+oxygen	B-CHED
+transfer	O
+of	O
+66	O
+±	O
+29	O
+ml	O
+/	O
+dl	O
+through	O
+the	O
+oxygenator	O
+.	O
+
+The	O
+plasmatic	O
+coagulation	B-PROC
+was	O
+only	O
+mildly	O
+activated	O
+without	O
+significant	O
+platelet	B-ANAT
+consumption	O
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+the	O
+inhibitory	O
+effect	O
+of	O
+siRNA	O
+on	O
+the	O
+isolated	O
+N	B-PRGE
+gene	I-PRGE
+expression	O
+might	O
+be	O
+influenced	O
+by	O
+the	O
+sequence	O
+context	O
+around	O
+the	O
+targeted	B-PROC
+sites	O
+.	O
+
+Distinguishing	O
+cellular	B-COMP
+and	O
+biomolecular	O
+evidence	O
+for	O
+several	O
+VIDs	O
+suggests	O
+that	O
+environmental	O
+conditions	O
+conducive	O
+to	O
+chronic	O
+dietary	O
+Se	O
+deprivation	O
+could	O
+be	O
+monitored	O
+for	O
+bioindicators	O
+of	O
+incipient	O
+viral	O
+virulence	O
+and	O
+subsequent	O
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Nursing	B-PROC
+students	O
+'	O
+anxiety	O
+and	O
+clinical	O
+performance	O
+.	O
+
+Anxiety	O
+was	O
+induced	O
+by	O
+showing	O
+a	O
+video	O
+of	O
+interviews	O
+with	O
+frontline	O
+nurses	O
+and	O
+doctors	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+,	O
+China	O
+;	O
+calmness	O
+was	O
+induced	O
+by	O
+a	O
+video	O
+of	O
+a	O
+nursing	B-PROC
+student	O
+'	O
+s	O
+pleasant	O
+orientation	O
+to	O
+a	O
+clinical	O
+placement	O
+site	O
+.	O
+
+However	O
+,	O
+the	O
+function	O
+of	O
+3CLpro	O
+in	O
+host	B-COMP
+cells	B-COMP
+remains	O
+unknown	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+protein	O
+levels	O
+of	O
+NF	B-PRGE
+-	I-PRGE
+kB	I-PRGE
+decreased	O
+in	O
+3CLpro	O
+-	O
+transfected	O
+A549	O
+cells	B-COMP
+when	O
+compared	O
+to	O
+EGFP	O
+transfected	O
+cells	B-COMP
+.	O
+
+In	O
+contrast	O
+,	O
+other	O
+proinflammatory	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+including	O
+osteopontin	B-PRGE
+and	O
+CCL3	B-PRGE
+,	O
+were	O
+upregulated	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+African	B-SPEC
+green	I-SPEC
+monkeys	I-SPEC
+to	O
+a	O
+significantly	O
+greater	O
+extent	O
+than	O
+in	O
+macaques	B-SPEC
+.	O
+
+Induction	O
+of	O
+distinct	O
+proinflammatory	O
+genes	O
+after	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+different	O
+nonhuman	O
+primate	B-SPEC
+species	B-SPEC
+needs	O
+to	O
+be	O
+taken	O
+into	O
+account	O
+when	O
+analyzing	O
+outcomes	O
+of	O
+intervention	O
+strategies	O
+in	O
+these	O
+species	B-SPEC
+.	O
+
+Western	O
+blot	O
+analysis	O
+revealed	O
+that	O
+SARS	B-DISO
+S	O
+was	O
+cleaved	B-ANAT
+into	O
+several	O
+fragments	O
+upon	O
+coexpression	O
+of	O
+TMPRSS2	O
+(	O
+cis	B-DISO
+-	O
+cleavage	B-PROC
+)	O
+and	O
+upon	O
+contact	O
+between	O
+SARS	B-DISO
+S	O
+-	O
+expressing	O
+cells	B-COMP
+and	O
+TMPRSS2	O
+-	O
+positive	O
+cells	O
+(	O
+trans	O
+-	O
+cleavage	B-PROC
+).	O
+
+Among	O
+the	O
+7	O
+,	O
+872	O
+assembled	O
+sequences	O
+that	O
+were	O
+identified	O
+as	O
+from	O
+human	B-SPEC
+genome	O
+,	O
+578	O
+non	O
+-	O
+coding	O
+genes	O
+were	O
+revealed	O
+by	O
+BLAST	O
+search	O
+.	O
+
+Mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+is	O
+a	O
+widely	O
+studied	O
+model	O
+system	O
+for	O
+Coronavirus	B-SPEC
+replication	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+most	O
+IBV	B-SPEC
+strains	O
+that	O
+have	O
+circulated	O
+in	O
+China	O
+in	O
+recent	O
+years	O
+belong	O
+to	O
+the	O
+genotype	O
+of	O
+QX	O
+-	O
+like	O
+strains	O
+,	O
+and	O
+that	O
+they	O
+could	O
+be	O
+grouped	O
+further	O
+into	O
+two	O
+clusters	B-CHED
+,	O
+regardless	O
+of	O
+the	O
+level	O
+of	O
+genetic	O
+variation	O
+displayed	O
+.	O
+
+No	O
+lesions	O
+were	O
+observed	O
+if	O
+the	O
+chickens	B-SPEC
+had	O
+been	O
+vaccinated	O
+at	O
+7	O
+days	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+first	O
+successful	O
+use	O
+of	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+for	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+an	O
+infant	O
+with	O
+DiGeorge	B-DISO
+anomaly	I-DISO
+,	O
+following	O
+thymus	B-SPEC
+transplantation	O
+.	O
+
+TITLE	O
+:	O
+Patient	O
+-	O
+ventilator	O
+interaction	O
+during	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+the	O
+role	O
+of	O
+spontaneous	O
+breathing	B-PROC
+:	O
+part	O
+1	O
+:	O
+respiratory	B-ANAT
+muscle	I-ANAT
+function	O
+during	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+Historically	O
+,	O
+the	O
+term	O
+""""	O
+disuse	B-DISO
+atrophy	I-DISO
+""""	O
+has	O
+described	O
+a	O
+situation	O
+wherein	O
+sustained	O
+inactivity	O
+of	O
+the	O
+respiratory	B-ANAT
+muscles	I-ANAT
+(	O
+ie	O
+,	O
+passive	B-PROC
+ventilation	I-PROC
+)	O
+results	O
+in	O
+deconditioning	O
+and	O
+weakness	B-DISO
+.	O
+
+TITLE	O
+:	O
+Patient	O
+-	O
+ventilator	O
+interaction	O
+during	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+the	O
+role	O
+of	O
+spontaneous	O
+breathing	B-PROC
+:	O
+part	O
+2	O
+:	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+.	O
+
+Thus	O
+,	O
+APRV	O
+/	O
+BIPAP	O
+should	O
+reduce	O
+requirements	O
+for	O
+sedation	B-DISO
+and	O
+muscle	B-ANAT
+paralysis	O
+,	O
+and	O
+thereby	O
+reduce	O
+the	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+Studies	O
+on	O
+sedation	B-DISO
+use	O
+have	O
+serious	O
+methodological	O
+limitations	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+can	O
+cause	O
+a	O
+lethal	O
+disease	O
+in	O
+cats	B-SPEC
+,	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+Then	O
+,	O
+the	O
+difference	O
+in	O
+epitope	B-CHED
+which	O
+those	O
+MAbs	O
+recognise	O
+was	O
+demonstrated	O
+by	O
+competitive	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+neutralisation	O
+tests	O
+.	O
+
+Subsequently	O
+,	O
+quantitative	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	O
+chain	O
+reaction	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+51	O
+immune	O
+-	O
+related	O
+and	O
+four	O
+internal	O
+reference	O
+genes	O
+were	O
+developed	O
+.	O
+
+In	O
+conclusion	O
+,	O
+these	O
+new	O
+assays	O
+will	O
+greatly	O
+improve	O
+the	O
+use	O
+of	O
+the	O
+hamster	B-SPEC
+as	O
+an	O
+important	O
+small	O
+animal	B-SPEC
+model	O
+in	O
+infectious	B-DISO
+disease	I-DISO
+research	O
+.	O
+
+Rescue	O
+therapies	O
+are	O
+utilized	O
+in	O
+younger	O
+patients	O
+with	O
+more	O
+severe	O
+oxygenation	B-PROC
+deficits	O
+.	O
+
+A	O
+total	O
+of	O
+575	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+admitted	O
+to	O
+the	O
+medical	O
+or	O
+surgical	O
+intensive	O
+care	O
+unit	O
+of	O
+an	O
+academic	O
+tertiary	O
+-	O
+care	O
+hospital	O
+.	O
+
+Catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+(	O
+CAPS	O
+),	O
+in	O
+contradistinction	O
+to	O
+APS	B-DISO
+,	O
+is	O
+defined	O
+as	O
+three	O
+or	O
+more	O
+organs	B-ANAT
+affected	O
+by	O
+thrombotic	B-DISO
+microangiopathy	I-DISO
+in	O
+patients	O
+demonstrating	O
+aPL	B-DISO
+and	O
+can	O
+result	O
+in	O
+mortality	O
+up	O
+to	O
+50	O
+%.	O
+
+Both	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+(	O
+DIC	B-DISO
+)	O
+and	O
+CAPS	O
+share	O
+similar	O
+characteristics	O
+encompassing	O
+thrombotic	B-DISO
+microangiopathy	I-DISO
+,	O
+bleeding	B-DISO
+,	O
+thromboembolism	B-DISO
+,	O
+and	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+For	O
+the	O
+killing	O
+reaction	O
+,	O
+these	O
+cells	B-COMP
+have	O
+an	O
+extensive	O
+machinery	O
+of	O
+cytotoxic	O
+effector	B-CHED
+mechanisms	O
+including	O
+phagocytosis	B-PROC
+,	O
+production	O
+of	O
+toxic	O
+oxygen	B-CHED
+metabolites	B-CHED
+,	O
+initiated	O
+by	O
+a	O
+membrane	B-COMP
+bound	O
+nicotinamide	B-CHED
+adenine	I-CHED
+dinucleotide	I-CHED
+phosphate	I-CHED
+(	O
+NADPH	B-CHED
+)	O
+oxidase	B-PRGE
+,	O
+and	O
+degranulation	O
+of	O
+cytotoxic	O
+proteins	B-CHED
+(	O
+for	O
+reviews	O
+see	O
+1	O
+,	O
+2	O
+).	O
+
+We	O
+analyzed	O
+the	O
+data	O
+collected	O
+in	O
+a	O
+cohort	O
+of	O
+patients	O
+with	O
+GBS	B-DISO
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+of	O
+our	O
+university	O
+hospital	O
+between	O
+1996	O
+and	O
+2009	O
+.	O
+
+Sixty	O
+-	O
+one	O
+patients	O
+with	O
+severe	O
+GBS	B-DISO
+were	O
+studied	O
+.	O
+
+The	O
+lack	O
+of	O
+foot	B-ANAT
+flexion	B-PROC
+ability	O
+at	O
+ICU	O
+admission	O
+and	O
+at	O
+the	O
+end	O
+of	O
+immunotherapy	O
+was	O
+significantly	O
+associated	O
+with	O
+MV	O
+length	O
+>	O
+15	O
+days	O
+(	O
+positive	O
+predictive	O
+value	O
+:	O
+82	O
+%;	O
+odds	O
+ratio	O
+:	O
+5	O
+.	O
+4	O
+[	O
+1	O
+.	O
+2	O
+-	O
+23	O
+.	O
+8	O
+]	O
+and	O
+82	O
+%;	O
+6	O
+.	O
+4	O
+[	O
+1	O
+.	O
+4	O
+-	O
+28	O
+.	O
+8	O
+],	O
+respectively	O
+).	O
+
+Combined	O
+with	O
+a	O
+sciatic	O
+motor	O
+conduction	B-PROC
+block	O
+,	O
+it	O
+may	O
+be	O
+a	O
+strong	O
+argument	O
+to	O
+perform	O
+an	O
+early	O
+tracheotomy	O
+.	O
+
+Then	O
+,	O
+UDA	B-CHED
+was	O
+tested	O
+for	O
+efficacy	O
+in	O
+a	O
+lethal	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+BALB	O
+/	O
+c	O
+mouse	B-SPEC
+model	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+mode	O
+of	O
+action	O
+of	O
+UDA	B-CHED
+in	O
+vitro	O
+was	O
+further	O
+investigated	O
+using	O
+live	O
+SARS	B-DISO
+-	O
+CoV	O
+Urbani	O
+strain	O
+virus	B-SPEC
+and	O
+retroviral	B-SPEC
+particles	O
+pseudotyped	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+(	O
+S	O
+).	O
+
+To	O
+establish	O
+the	O
+reciprocal	O
+binding	B-FUNC
+of	O
+CCoV	O
+on	O
+plasma	B-COMP
+membrane	I-COMP
+,	O
+A72	O
+cells	B-COMP
+on	O
+a	O
+permeable	O
+support	O
+were	O
+preincubated	O
+with	O
+a	O
+mAb	O
+specific	O
+for	O
+CCoV	O
+.	O
+Infection	B-DISO
+from	O
+the	O
+apical	O
+side	O
+was	O
+blocked	O
+by	O
+mAb	O
+applied	O
+to	O
+that	O
+side	O
+;	O
+in	O
+contrast	O
+,	O
+such	O
+treatment	O
+on	O
+the	O
+basolateral	O
+side	O
+had	O
+no	O
+effect	O
+on	O
+the	O
+infectious	O
+process	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+LJB	O
+/	O
+03	O
+strain	O
+was	O
+isolated	O
+from	O
+the	O
+feces	B-ANAT
+of	O
+piglets	O
+suspected	O
+to	O
+be	O
+suffering	B-DISO
+from	O
+a	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+Heilongjiang	O
+Province	O
+,	O
+and	O
+was	O
+identified	O
+by	O
+immunofluorescence	O
+test	O
+,	O
+immunelectronmicroscopy	O
+,	O
+RT	O
+-	O
+PCR	O
+and	O
+indirect	O
+ELISA	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+previously	O
+shown	O
+to	O
+be	O
+associated	O
+with	O
+catarrhal	O
+gastroenteritis	B-DISO
+in	O
+mink	B-SPEC
+(	O
+Mustela	B-SPEC
+vison	I-SPEC
+)	O
+was	O
+identified	O
+by	O
+electron	O
+microscopy	O
+in	O
+mink	B-SPEC
+faeces	B-ANAT
+from	O
+two	O
+fur	O
+farms	O
+in	O
+Wisconsin	O
+and	O
+Minnesota	O
+in	O
+1998	O
+.	O
+
+A	O
+pan	B-COMP
+-	O
+coronavirus	B-SPEC
+and	O
+a	O
+genus	B-SPEC
+-	O
+specific	O
+RT	O
+-	O
+PCR	O
+assay	O
+were	O
+used	O
+initially	O
+to	O
+demonstrate	O
+that	O
+the	O
+newly	O
+discovered	O
+mink	B-SPEC
+CoVs	O
+(	O
+MCoVs	O
+)	O
+were	O
+members	O
+of	O
+the	O
+genus	B-SPEC
+Alphacoronavirus	B-SPEC
+.	O
+
+The	O
+two	O
+compounds	O
+were	O
+found	O
+to	O
+inhibit	O
+IBV	B-SPEC
+with	O
+an	O
+IC₅₀	O
+of	O
+0	O
+.	O
+98	O
+±	O
+0	O
+.	O
+25	O
+and	O
+1	O
+.	O
+32	O
+±	O
+0	O
+.	O
+11	O
+mM	O
+.	O
+The	O
+MTT	B-CHED
+assay	O
+showed	O
+that	O
+the	O
+inhibitions	O
+of	O
+(-)-	O
+pinenes	O
+against	O
+IBV	B-SPEC
+appear	O
+to	O
+occur	O
+moderately	O
+before	O
+entering	O
+the	O
+cell	B-COMP
+but	O
+are	O
+much	O
+stronger	O
+occur	O
+after	O
+penetration	O
+of	O
+the	O
+virus	B-SPEC
+into	O
+the	O
+cell	B-COMP
+.	O
+
+Five	O
+of	O
+the	O
+7	O
+patients	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+immunogenicity	O
+of	O
+recombinant	O
+GapA	B-PRGE
+(+)	O
+Mycoplasma	B-SPEC
+gallisepticum	I-SPEC
+vaccine	O
+strain	O
+ts	O
+-	O
+11	O
+expressing	O
+infectious	O
+bronchitis	B-PRGE
+virus	B-SPEC
+-	I-PRGE
+S1	I-PRGE
+glycoprotein	B-CHED
+and	I-PRGE
+chicken	B-SPEC
+interleukin	I-PRGE
+-	I-PRGE
+6	I-PRGE
+.	O
+
+To	O
+improve	O
+the	O
+functionality	O
+of	O
+the	O
+vaccine	O
+and	O
+investigate	O
+its	O
+potential	O
+as	O
+a	O
+delivery	O
+vector	O
+for	O
+foreign	O
+antigens	B-CHED
+and	O
+immunomodulatory	O
+proteins	B-CHED
+,	O
+we	O
+developed	O
+a	O
+derivative	O
+of	O
+ts	O
+-	O
+11	O
+expressing	O
+infectious	B-DISO
+bronchitis	B-PRGE
+virus	B-SPEC
+-	I-PRGE
+S1	I-PRGE
+glycoprotein	B-CHED
+(	O
+IBV	B-SPEC
+-	O
+S1	O
+)	O
+and	O
+releasing	O
+chicken	B-SPEC
+interleukin	O
+-	O
+6	O
+into	O
+the	O
+extracellular	B-COMP
+milieu	O
+(	O
+MG	O
+ts	O
+-	O
+11	O
+C3	O
+(+	O
+CS	O
+))	O
+using	O
+a	O
+transposon	O
+-	O
+based	O
+delivery	O
+vector	O
+.	O
+
+Drugs	O
+that	O
+inhibit	O
+the	O
+ion	O
+channel	O
+formed	O
+by	O
+the	O
+3a	O
+protein	B-CHED
+can	O
+be	O
+expected	O
+to	O
+inhibit	O
+virus	B-SPEC
+release	B-PATH
+,	O
+and	O
+would	O
+be	O
+a	O
+source	O
+for	O
+the	O
+development	B-PROC
+of	O
+novel	O
+therapeutic	O
+agents	O
+.	O
+
+Here	O
+we	O
+demonstrate	O
+that	O
+emodin	B-CHED
+can	O
+inhibit	O
+the	O
+3a	O
+ion	O
+channel	O
+of	O
+coronavirus	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+as	O
+well	O
+as	O
+virus	B-SPEC
+release	B-PATH
+from	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+with	O
+a	O
+K1	O
+/	O
+2	O
+value	O
+of	O
+about	O
+20	O
+μM	O
+.	O
+We	O
+suggest	O
+that	O
+viral	O
+ion	B-FUNC
+channels	I-FUNC
+,	O
+in	O
+general	O
+,	O
+may	O
+be	O
+a	O
+good	O
+target	O
+for	O
+the	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+TITLE	O
+:	O
+Cutting	O
+edge	O
+:	O
+attrition	B-DISO
+of	O
+Plasmodium	B-SPEC
+-	O
+specific	O
+memory	B-PROC
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+results	O
+in	O
+decreased	O
+protection	O
+that	O
+is	O
+rescued	O
+by	O
+booster	O
+immunization	O
+.	O
+
+Treatment	O
+includes	O
+early	O
+admission	O
+to	O
+a	O
+burn	O
+unit	O
+,	O
+where	O
+treatment	O
+with	O
+precise	O
+fluid	O
+,	O
+electrolyte	O
+,	O
+protein	B-CHED
+,	O
+and	O
+energy	O
+supplementation	O
+,	O
+moderate	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+expert	O
+wound	O
+care	O
+can	O
+be	O
+provided	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+retrieval	O
+program	O
+was	O
+developed	O
+in	O
+New	O
+South	O
+Wales	O
+(	O
+NSW	O
+),	O
+Australia	O
+to	O
+provide	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+support	O
+(	O
+ECMO	O
+)	O
+for	O
+the	O
+safe	O
+transport	B-PROC
+of	O
+adults	O
+with	O
+severe	O
+,	O
+acute	O
+respiratory	O
+or	O
+cardiac	B-DISO
+failure	I-DISO
+.	O
+
+Two	O
+other	O
+patients	O
+died	B-PROC
+after	O
+referral	O
+but	O
+before	O
+ECMO	O
+support	O
+could	O
+be	O
+established	O
+.	O
+
+TITLE	O
+:	O
+PLP2	B-PRGE
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+targets	O
+TBK1	B-FUNC
+to	O
+negatively	O
+regulate	O
+cellular	B-COMP
+type	O
+I	O
+interferon	O
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SCoV	O
+)	O
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+have	O
+evolved	O
+strategies	O
+to	O
+disable	O
+the	O
+innate	O
+immune	B-ANAT
+system	I-ANAT
+for	O
+productive	O
+replication	O
+and	O
+spread	O
+of	O
+infection	B-DISO
+.	O
+
+Albeit	O
+promiscuous	O
+in	O
+deubiquitinating	B-PROC
+cellular	B-COMP
+proteins	B-CHED
+,	O
+PLP2	B-PRGE
+inactivated	O
+TBK1	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+response	O
+in	O
+TNF	B-PRGE
+receptor	I-PRGE
+associated	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+TRAF3	B-PRGE
+)	O
+deficient	O
+cells	B-COMP
+,	O
+suggesting	O
+that	O
+targeting	B-PROC
+TBK1	B-FUNC
+would	O
+be	O
+sufficient	O
+for	O
+PLP2	B-PRGE
+to	O
+inhibit	O
+IRF3	B-PRGE
+activation	O
+.	O
+
+Age	O
+was	O
+51	O
+±	O
+16	O
+years	O
+,	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+74	O
+±	O
+19	O
+,	O
+and	O
+PaCO	O
+(	O
+2	O
+)	O
+54	O
+±	O
+10	O
+mmHg	O
+.	O
+
+The	O
+60	O
+-	O
+day	O
+mortality	O
+was	O
+19	O
+%	O
+and	O
+death	B-PROC
+occurred	O
+after	O
+12	O
+±	O
+5	O
+days	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+is	O
+a	O
+leading	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+worldwide	O
+,	O
+especially	O
+among	O
+young	O
+children	O
+.	O
+
+Human	O
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+have	O
+only	O
+recently	O
+been	O
+shown	O
+to	O
+cause	O
+both	O
+lower	O
+and	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+To	O
+date	O
+,	O
+five	O
+coronaviruses	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	O
+HKU	O
+-	O
+1	O
+)	O
+that	O
+infect	O
+humans	B-SPEC
+have	O
+been	O
+identified	O
+,	O
+four	O
+of	O
+which	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	O
+-	O
+HKU	O
+-	O
+1	O
+)	O
+circulate	O
+continuously	O
+in	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+describe	O
+baseline	O
+characteristics	O
+,	O
+development	B-PROC
+of	O
+VAHS	O
+,	O
+related	O
+treatments	O
+and	O
+associated	O
+mortality	O
+rate	O
+of	O
+consecutive	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+confirmed	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+At	O
+48	O
+h	O
+post	O
+-	O
+infection	B-DISO
+,	O
+only	O
+a	O
+few	O
+siRNA	O
+-	O
+treated	O
+cells	B-COMP
+were	O
+positive	O
+for	O
+viral	B-PRGE
+antigen	I-PRGE
+staining	O
+,	O
+whereas	O
+most	O
+untreated	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+were	O
+positive	O
+.	O
+
+RESULTS	O
+:	O
+Examination	O
+of	O
+CPE	O
+demonstrated	O
+that	O
+the	O
+four	O
+siRNAs	O
+were	O
+capable	O
+of	O
+protecting	O
+cells	B-COMP
+against	O
+PHE	B-CHED
+-	O
+CoV	O
+invasion	B-DISO
+with	O
+very	O
+high	O
+specificity	O
+and	O
+efficiency	O
+.	O
+
+We	O
+report	O
+two	O
+extremely	O
+rare	O
+cases	O
+of	O
+prenatal	O
+diagnosis	O
+of	O
+PRS	B-DISO
+and	O
+SS	O
+,	O
+prematurely	O
+identified	O
+by	O
+prenatal	O
+ultrasonography	O
+and	O
+successively	O
+managed	O
+by	O
+oculists	O
+ophthalmogists	O
+.	O
+
+To	O
+this	O
+aim	O
+,	O
+we	O
+designed	O
+,	O
+through	O
+a	O
+bioinformatic	O
+approach	O
+,	O
+8	O
+potentially	O
+immunogenic	O
+peptides	B-CHED
+from	O
+the	O
+protein	B-CHED
+N	O
+corresponding	O
+to	O
+sequences	O
+of	O
+residues	O
+14	O
+,	O
+182	O
+,	O
+198	O
+detected	O
+only	O
+in	O
+FCoVs	O
+from	O
+FIP	B-DISO
+cats	B-SPEC
+(	O
+virulent	O
+strains	O
+),	O
+only	O
+in	O
+FCoVs	O
+from	O
+healthy	O
+cats	B-SPEC
+(	O
+avirulent	O
+strains	O
+)	O
+and	O
+both	O
+in	O
+FIP	B-DISO
+and	O
+in	O
+healthy	O
+cats	B-SPEC
+(	O
+mixed	O
+strains	O
+).	O
+
+The	O
+combined	O
+approach	O
+employed	O
+in	O
+this	O
+study	O
+allowed	O
+us	O
+to	O
+identify	O
+potentially	O
+immunogenic	O
+peptides	B-CHED
+of	O
+FCoV	O
+N	O
+protein	B-CHED
+that	O
+can	O
+modulate	O
+the	O
+production	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+especially	O
+in	O
+cats	B-SPEC
+with	O
+a	O
+""""	O
+pre	O
+-	O
+activated	O
+""""	O
+cell	B-COMP
+mediated	O
+response	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+summarize	O
+RNA	O
+-	O
+RNA	O
+and	O
+RNA	O
+-	O
+protein	B-CHED
+interactions	O
+that	O
+represent	O
+modest	O
+examples	O
+of	O
+complex	O
+quaternary	O
+RNA	O
+-	O
+protein	B-CHED
+structures	O
+required	O
+for	O
+the	O
+fine	O
+-	O
+tuning	O
+of	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Organs	B-ANAT
+and	O
+tissues	B-ANAT
+from	O
+deceased	B-PROC
+patients	O
+were	O
+histologically	O
+studied	O
+;	O
+chest	B-ANAT
+computed	O
+tomography	O
+,	O
+body	B-ANAT
+plethysmography	O
+,	O
+fibrobronchoscopy	O
+,	O
+breath	B-ANAT
+test	O
+,	O
+and	O
+6	O
+-	O
+minute	O
+walk	O
+test	O
+were	O
+performed	O
+in	O
+the	O
+late	O
+period	O
+.	O
+
+The	O
+significance	O
+of	O
+this	O
+structure	O
+in	O
+the	O
+context	O
+of	O
+a	O
+previous	O
+mutagenesis	B-PROC
+analysis	O
+of	O
+SL2	B-PRGE
+function	O
+in	O
+replication	O
+of	O
+the	O
+related	O
+group	O
+2	O
+coronavirus	B-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+is	O
+discussed	O
+.	O
+
+Information	O
+remains	O
+limited	O
+about	O
+the	O
+comparative	O
+protein	B-PROC
+expression	B-PROC
+profiles	O
+of	O
+chicken	B-SPEC
+embryonic	B-ANAT
+tissues	B-ANAT
+in	O
+response	O
+to	O
+IBV	B-SPEC
+infection	B-DISO
+in	O
+ovo	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+17	O
+differentially	O
+expressed	B-PROC
+proteins	B-CHED
+from	O
+tracheal	O
+tissues	B-ANAT
+and	O
+19	O
+differentially	O
+expressed	B-PROC
+proteins	B-CHED
+from	O
+kidney	B-ANAT
+tissues	B-ANAT
+were	O
+identified	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Canadian	O
+Critical	O
+Care	O
+Trials	O
+Group	O
+project	O
+in	O
+collaboration	O
+with	O
+the	O
+international	O
+forum	O
+for	O
+acute	O
+care	O
+trialists	O
+-	O
+Collaborative	O
+H1N1	O
+Adjuvant	B-CHED
+Treatment	O
+pilot	O
+trial	O
+(	O
+CHAT	B-SPEC
+):	O
+study	O
+protocol	O
+and	O
+design	O
+of	O
+a	O
+randomized	O
+controlled	O
+trial	O
+.	O
+
+ABSTRACT	O
+:	O
+Swine	B-SPEC
+origin	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+infection	B-DISO
+(	O
+H1N1	O
+)	O
+emerged	O
+in	O
+early	O
+2009	O
+and	O
+rapidly	O
+spread	O
+to	O
+humans	B-SPEC
+.	O
+
+For	O
+most	O
+infected	O
+individuals	O
+,	O
+symptoms	O
+were	O
+mild	O
+and	O
+self	O
+-	O
+limited	O
+;	O
+however	O
+,	O
+a	O
+small	O
+number	O
+developed	O
+a	O
+more	O
+severe	O
+clinical	O
+syndrome	B-DISO
+characterized	O
+by	O
+profound	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+hospital	O
+mortality	O
+ranging	O
+from	O
+10	O
+to	O
+30	O
+%.	O
+
+Multiple	O
+observational	O
+studies	O
+have	O
+suggested	B-PRGE
+that	I-PRGE
+HMGCoA	I-PRGE
+reductase	I-PRGE
+inhibitors	I-PRGE
+(	O
+statins	O
+)	O
+can	O
+exert	B-PROC
+a	O
+class	B-SPEC
+effect	O
+in	O
+attenuating	O
+inflammation	B-DISO
+.	O
+
+TITLE	O
+:	O
+Structure	O
+and	O
+functional	O
+relevance	O
+of	O
+a	O
+transcription	B-PROC
+-	O
+regulating	O
+sequence	O
+involved	O
+in	O
+coronavirus	B-SPEC
+discontinuous	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+The	O
+nascent	O
+minus	O
+-	O
+stranded	O
+RNA	O
+would	O
+then	O
+be	O
+transferred	O
+by	O
+a	O
+template	O
+switch	O
+process	O
+to	O
+the	O
+TRS	B-DISO
+-	O
+L	O
+,	O
+which	O
+acts	O
+as	O
+the	O
+acceptor	B-CHED
+RNA	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+etiology	O
+of	O
+influenza	B-DISO
+-	O
+like	O
+illnesses	O
+in	O
+Antananarivo	O
+,	O
+Madagascar	O
+,	O
+July	O
+2008	O
+to	O
+June	O
+2009	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+Madagascar	O
+,	O
+despite	O
+an	O
+influenza	O
+surveillance	O
+established	O
+since	O
+1978	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+etiology	O
+and	O
+prevalence	O
+of	O
+viruses	B-SPEC
+other	O
+than	O
+influenza	B-DISO
+causing	O
+influenza	B-DISO
+-	O
+like	O
+illnesses	O
+(	O
+ILIs	O
+).	O
+
+We	O
+screened	O
+these	O
+specimens	O
+using	O
+five	O
+multiplex	O
+real	O
+time	O
+Reverse	B-PROC
+Transcription	I-PROC
+and	O
+/	O
+or	O
+Polymerase	O
+Chain	O
+Reaction	O
+assays	O
+for	O
+detection	O
+of	O
+14	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+We	O
+detected	O
+respiratory	O
+viruses	B-SPEC
+in	O
+235	O
+/	O
+313	O
+(	O
+75	O
+.	O
+1	O
+%)	O
+samples	O
+.	O
+
+In	O
+this	O
+age	O
+group	O
+,	O
+compared	O
+to	O
+those	O
+≥	O
+5	O
+years	O
+,	O
+the	O
+risk	O
+of	O
+detecting	O
+more	O
+than	O
+one	O
+virus	B-SPEC
+was	O
+higher	O
+(	O
+OR	O
+=	O
+1	O
+.	O
+9	O
+),	O
+as	O
+was	O
+the	O
+risk	O
+of	O
+detecting	O
+of	O
+RSV	B-SPEC
+(	O
+OR	O
+=	O
+10	O
+.	O
+1	O
+)	O
+and	O
+adenovirus	B-DISO
+(	O
+OR	O
+=	O
+4	O
+.	O
+7	O
+).	O
+
+Previously	O
+,	O
+the	O
+extra	O
+domain	O
+was	O
+demonstrated	O
+to	O
+regulate	O
+the	O
+catalysis	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+by	O
+controlling	O
+its	O
+dimerization	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+observation	O
+on	O
+the	O
+effect	O
+of	O
+dexamethasone	B-CHED
+and	O
+Chinese	O
+herbal	O
+decoction	O
+for	O
+purgation	O
+in	O
+severe	O
+acute	O
+pancreatitis	O
+patients	O
+.	O
+
+The	O
+breeding	B-PROC
+success	O
+of	O
+the	O
+colony	O
+was	O
+significantly	O
+better	O
+in	O
+2010	O
+than	O
+in	O
+2008	O
+,	O
+in	O
+spite	O
+of	O
+stronger	O
+amplification	B-DISO
+of	O
+coronaviruses	O
+and	O
+astroviruses	O
+in	O
+2010	O
+,	O
+suggesting	O
+that	O
+these	O
+viruses	B-SPEC
+had	O
+little	O
+pathogenic	O
+influence	O
+on	O
+bats	B-SPEC
+.	O
+
+However	O
+,	O
+the	O
+general	O
+correlation	O
+of	O
+virus	B-SPEC
+and	O
+bat	B-ENZY
+population	O
+dynamics	O
+suggests	O
+that	O
+bats	O
+control	O
+infections	B-DISO
+similar	O
+to	O
+other	O
+mammals	B-SPEC
+and	O
+that	O
+they	O
+may	O
+well	O
+experience	O
+epidemics	O
+of	O
+viruses	B-SPEC
+under	O
+certain	O
+circumstances	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+date	O
+,	O
+the	O
+SARS	O
+coronavirus	B-SPEC
+is	O
+the	O
+only	O
+known	O
+highly	O
+pathogenic	O
+human	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Changes	O
+in	O
+attitudes	O
+toward	O
+wildlife	O
+and	O
+wildlife	O
+meats	O
+in	O
+Hunan	O
+Province	O
+,	O
+central	O
+China	O
+,	O
+before	O
+and	O
+after	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+.	O
+
+Although	O
+palm	B-ANAT
+civet	B-SPEC
+was	O
+suspected	O
+to	O
+be	O
+the	O
+carrier	O
+of	O
+SARS	B-DISO
+,	O
+it	O
+was	O
+interesting	O
+to	O
+note	O
+that	O
+,	O
+after	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+the	O
+proportion	O
+of	O
+people	O
+surveyed	O
+who	O
+ate	B-DISO
+palm	B-ANAT
+civets	B-SPEC
+had	O
+declined	O
+only	O
+slightly	O
+.	O
+
+Furthermore	O
+,	O
+many	O
+piglets	O
+were	O
+seropositive	O
+to	O
+PHEV	O
+,	O
+indicating	O
+the	O
+possible	O
+transfer	O
+of	O
+maternal	O
+antibodies	B-COMP
+via	O
+the	O
+colostrum	B-ANAT
+.	O
+
+Nine	O
+of	O
+the	O
+37	O
+cattle	B-SPEC
+infected	O
+with	O
+bovine	B-SPEC
+kobuvirus	I-SPEC
+were	O
+confirmed	O
+to	O
+have	O
+a	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+other	O
+viruses	B-SPEC
+including	O
+bovine	B-SPEC
+rotavirus	B-SPEC
+(	O
+n	O
+=	O
+3	O
+),	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+n	O
+=	O
+1	O
+),	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+n	O
+=	O
+1	O
+),	O
+and	O
+both	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+n	O
+=	O
+4	O
+).	O
+
+ABSTRACT	O
+:	O
+Infections	B-DISO
+caused	O
+by	O
+human	B-SPEC
+rhinoviruses	B-SPEC
+(	O
+HRVs	O
+)	O
+are	O
+important	O
+triggers	O
+of	O
+wheezing	B-DISO
+in	O
+young	O
+children	O
+.	O
+
+Wheezy	B-DISO
+illness	O
+has	O
+increasingly	O
+been	O
+recognised	O
+as	O
+an	O
+important	O
+cause	O
+of	O
+morbidity	O
+in	O
+African	O
+children	O
+,	O
+but	O
+there	O
+is	O
+little	O
+information	O
+on	O
+the	O
+contribution	O
+of	O
+HRV	O
+to	O
+this	O
+.	O
+
+The	O
+presence	O
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+human	B-SPEC
+bocavirus	I-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+NL63	O
+was	O
+assessed	O
+in	O
+all	O
+samples	O
+using	O
+PCR	O
+-	O
+based	O
+assays	O
+.	O
+
+Categorical	O
+characteristics	O
+were	O
+analysed	O
+using	O
+Fisher	B-SPEC
+'	O
+s	O
+Exact	O
+test	O
+.	O
+
+Providing	O
+a	O
+core	O
+component	O
+of	O
+the	O
+front	O
+line	O
+response	O
+to	O
+disasters	O
+,	O
+paramedics	O
+potentially	O
+expose	O
+themselves	O
+to	O
+a	O
+variety	O
+of	O
+health	O
+and	O
+safety	O
+risks	O
+,	O
+including	O
+physical	O
+injury	O
+,	O
+death	B-PROC
+,	O
+communicable	B-DISO
+disease	I-DISO
+,	O
+and	O
+psychological	B-DISO
+effects	O
+.	O
+
+TITLE	O
+:	O
+Kartagener	B-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+a	O
+66	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+chronic	O
+recurrent	O
+upper	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+,	O
+pseudomonal	B-DISO
+pneumonia	I-DISO
+,	O
+and	O
+chronic	O
+bronchiectasis	B-DISO
+who	O
+presented	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+She	O
+expired	O
+on	O
+ventilator	O
+with	O
+refractory	O
+respiratory	O
+and	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Simultaneous	O
+multiple	O
+assay	O
+(	O
+Luminex	O
+xTAG	O
+respiratory	O
+viral	O
+panel	O
+FAST	B-FUNC
+assay	O
+)	O
+efficacy	O
+in	O
+human	B-SPEC
+respiratory	O
+virus	B-SPEC
+detection	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+discontinuous	O
+transcription	B-PROC
+mechanism	O
+is	O
+driven	O
+by	O
+long	O
+-	O
+distance	O
+RNA	O
+-	O
+RNA	O
+interactions	O
+between	O
+transcription	B-PROC
+-	O
+regulating	O
+sequences	O
+(	O
+TRSs	O
+)	O
+located	O
+at	O
+the	O
+5	O
+'	O
+terminal	O
+leader	O
+(	O
+TRS	B-DISO
+-	O
+L	O
+)	O
+and	O
+also	O
+preceding	O
+each	O
+mRNA	B-PRGE
+-	I-PRGE
+coding	I-PRGE
+sequence	I-PRGE
+(	O
+TRS	B-DISO
+-	O
+B	O
+).	O
+
+The	O
+hot	B-DISO
+spot	I-DISO
+consists	O
+of	O
+a	O
+salt	B-CHED
+bridge	O
+surrounded	O
+by	O
+hydrophobic	O
+tunnel	O
+walls	O
+.	O
+
+Furthermore	O
+,	O
+NL63	O
+-	O
+CoV	O
+RBD	O
+inhibits	O
+hACE2	O
+-	O
+dependent	O
+transduction	B-PROC
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+,	O
+a	O
+successful	O
+application	O
+of	O
+the	O
+hot	B-DISO
+spot	I-DISO
+theory	O
+that	O
+has	O
+the	O
+potential	O
+to	O
+become	O
+a	O
+new	O
+antiviral	B-CHED
+strategy	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+structural	O
+features	O
+of	O
+the	O
+hot	B-DISO
+spot	I-DISO
+on	O
+hACE2	O
+were	O
+among	O
+the	O
+driving	O
+forces	O
+for	O
+the	O
+convergent	O
+evolution	B-PROC
+of	O
+NL63	O
+-	O
+CoV	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Nucleic	B-CHED
+acid	I-CHED
+tests	O
+are	O
+sensitive	O
+and	O
+specific	O
+and	O
+provide	O
+a	O
+rapid	O
+diagnosis	O
+,	O
+making	O
+them	O
+invaluable	O
+for	O
+patient	O
+and	O
+outbreak	O
+management	O
+.	O
+
+Targets	O
+not	O
+detected	O
+by	O
+the	O
+RVP	O
+Fast	B-FUNC
+assay	O
+included	O
+primarily	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+parainfluenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+2	I-SPEC
+,	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Soluble	B-PRGE
+receptor	I-PRGE
+-	I-PRGE
+resistant	I-PRGE
+mutant	I-PRGE
+7	I-PRGE
+(	O
+ssr7	O
+)	O
+is	O
+isolated	O
+from	O
+a	O
+highly	O
+neurovirulent	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+JHMV	O
+cl	O
+-	O
+2	O
+strain	O
+(	O
+cl	O
+-	O
+2	O
+).	O
+
+srr7	O
+exhibits	O
+lower	O
+virulence	B-PROC
+than	O
+its	O
+maternal	O
+strain	O
+in	O
+infected	O
+mice	B-SPEC
+,	O
+which	O
+is	O
+typically	O
+manifested	O
+in	O
+a	O
+longer	O
+lifespan	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrate	O
+that	O
+the	O
+next	O
+viral	O
+spread	O
+was	O
+observed	O
+in	O
+glial	B-COMP
+fibrillary	I-COMP
+acidic	I-COMP
+protein	I-COMP
+-	O
+positive	O
+cells	B-COMP
+or	O
+nestin	O
+-	O
+positive	O
+progenitor	B-ANAT
+cells	I-ANAT
+which	O
+take	O
+up	O
+positions	O
+in	O
+the	O
+subventricular	O
+zone	O
+(	O
+SVZ	O
+).	O
+
+Antigenic	O
+and	O
+genomic	O
+characterizations	O
+of	O
+the	O
+virus	B-SPEC
+(	O
+isolate	O
+PHEV	O
+-	O
+JLsp09	O
+)	O
+were	O
+based	O
+on	O
+multiplex	O
+PCR	O
+and	O
+negative	O
+staining	O
+electron	O
+microscopy	O
+and	O
+sequence	O
+analysis	O
+of	O
+the	O
+Hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+(	O
+HE	O
+)	O
+gene	O
+.	O
+
+Mice	B-SPEC
+were	O
+infected	O
+with	O
+the	O
+isolated	O
+virus	B-SPEC
+.	O
+
+The	O
+detection	O
+limit	O
+of	O
+the	O
+reaction	O
+was	O
+10	O
+(	O
+3	O
+)	O
+plasmid	O
+copies	O
+and	O
+1	O
+.	O
+17	O
+×	O
+10	O
+(-	O
+3	O
+)	O
+TCID	O
+(	O
+50	O
+)	O
+of	O
+the	O
+tissue	B-ANAT
+culture	O
+propagated	O
+virus	B-SPEC
+.	O
+
+However	O
+,	O
+three	O
+fecal	B-ANAT
+and	O
+two	O
+nasal	B-ANAT
+samples	O
+tested	O
+negative	O
+in	O
+gel	O
+-	O
+based	O
+assay	O
+were	O
+positive	O
+for	O
+the	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Because	O
+gene	B-PROC
+expression	I-PROC
+is	O
+an	O
+intermediate	O
+phenotype	O
+that	O
+resides	O
+between	O
+the	O
+DNA	O
+sequence	O
+variation	O
+and	O
+the	O
+higher	O
+level	O
+cellular	B-COMP
+or	O
+whole	O
+-	O
+body	B-ANAT
+phenotypes	O
+,	O
+the	O
+illustration	O
+of	O
+gene	B-PROC
+expression	I-PROC
+regulatory	O
+networks	O
+potentially	O
+could	O
+enhance	O
+understanding	O
+of	O
+disease	O
+susceptibility	O
+and	O
+the	O
+development	B-PROC
+of	O
+inflammatory	O
+lung	B-ANAT
+syndromes	B-DISO
+.	O
+
+MicroRNAs	O
+(	O
+miRNAs	O
+)	O
+have	O
+emerged	O
+as	O
+a	O
+novel	O
+class	B-SPEC
+of	O
+gene	O
+regulators	O
+that	O
+play	O
+critical	O
+roles	O
+in	O
+complex	O
+diseases	O
+including	O
+ALI	O
+.	O
+
+None	O
+of	O
+the	O
+pathogens	O
+tested	O
+for	O
+was	O
+a	O
+significant	O
+factor	O
+in	O
+the	O
+final	O
+multivariable	O
+model	O
+suggesting	O
+that	O
+in	O
+this	O
+predominantly	O
+vaccinated	O
+population	O
+,	O
+diarrhoea	B-DISO
+may	O
+be	O
+more	O
+associated	O
+with	O
+lifestyle	O
+risk	O
+factors	O
+than	O
+specific	O
+pathogens	O
+.	O
+
+RT	O
+-	O
+PCR	O
+was	O
+used	O
+to	O
+detect	O
+the	O
+following	O
+pathogens	O
+:	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+and	O
+B	O
+,	O
+parainfluenza	B-DISO
+1	O
+-	O
+4	O
+,	O
+adenovirus	B-DISO
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+rhinovirus	I-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+OC43	O
+,	O
+229E	O
+,	O
+NL63	O
+),	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+,	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Legionella	B-SPEC
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Modeling	O
+and	O
+public	O
+health	O
+emergency	B-DISO
+responses	O
+:	O
+lessons	O
+from	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+highly	O
+contagious	O
+respiratory	O
+coronavirus	B-SPEC
+of	O
+domestic	O
+chickens	B-SPEC
+.	O
+
+These	O
+preliminary	O
+data	O
+provide	O
+important	O
+clues	O
+regarding	O
+potential	O
+mechanisms	O
+for	O
+IBV	B-SPEC
+tissue	B-PROC
+tropism	B-PROC
+and	O
+spread	O
+and	O
+show	O
+that	O
+the	O
+nature	O
+of	O
+the	O
+virus	B-SPEC
+isolate	O
+influences	O
+the	O
+early	O
+progression	O
+of	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+We	O
+present	O
+an	O
+adult	O
+who	O
+contracted	O
+H1N1	O
+infection	B-DISO
+followed	O
+by	O
+fulminant	O
+myocarditis	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+severe	O
+traumatic	O
+brain	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Resilience	O
+training	O
+for	O
+hospital	O
+workers	O
+in	O
+anticipation	O
+of	O
+an	O
+influenza	B-DISO
+pandemic	O
+.	O
+
+METHODS	O
+:	O
+The	O
+intervention	O
+we	O
+describe	O
+emerged	O
+from	O
+the	O
+recognition	O
+that	O
+an	O
+expected	O
+influenza	B-DISO
+pandemic	O
+indicated	O
+a	O
+need	O
+to	O
+build	O
+resilience	O
+to	O
+maintain	O
+the	O
+health	O
+of	O
+individuals	O
+within	O
+the	O
+organization	O
+and	O
+to	O
+protect	O
+the	O
+capacity	O
+of	O
+the	O
+organization	O
+to	O
+respond	O
+to	O
+extraordinary	O
+demands	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+RNA	B-PROC
+replication	I-PROC
+and	O
+transcription	B-PROC
+complex	O
+of	O
+coronaviruses	O
+is	O
+associated	O
+with	O
+an	O
+elaborate	O
+reticulovesicular	O
+network	O
+(	O
+RVN	O
+)	O
+of	O
+modified	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+.	O
+
+Sequential	O
+Organ	B-ANAT
+Failure	I-DISO
+Assessment	O
+(	O
+SOFA	O
+)	O
+score	O
+of	O
+patients	O
+with	O
+and	O
+without	O
+H1N1	O
+infection	B-DISO
+was	O
+comparable	O
+;	O
+7	O
+.	O
+8	O
+±	O
+3	O
+.	O
+5	O
+and	O
+6	O
+.	O
+6	O
+±	O
+3	O
+.	O
+1	O
+on	O
+day	O
+1	O
+and	O
+7	O
+.	O
+2	O
+±	O
+4	O
+.	O
+5	O
+and	O
+6	O
+.	O
+5	O
+±	O
+3	O
+.	O
+1	O
+on	O
+day	O
+3	O
+,	O
+respectively	O
+.	O
+
+There	O
+was	O
+a	O
+mean	O
+delay	O
+of	O
+5	O
+.	O
+7	O
+±	O
+3	O
+.	O
+1	O
+days	O
+in	O
+initiation	O
+of	O
+antivirals	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+variable	O
+learning	B-PROC
+rate	O
+has	O
+been	O
+demonstrated	O
+for	O
+training	O
+artificial	O
+neural	B-PROC
+network	I-PROC
+and	O
+predicting	O
+BNB	O
+for	O
+small	O
+datasets	O
+.	O
+
+Cannulation	O
+is	O
+associated	O
+with	O
+a	O
+risk	O
+of	O
+vascular	B-ANAT
+damage	O
+or	O
+cardiac	B-ANAT
+perforation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+suggest	O
+that	O
+the	O
+technique	O
+may	O
+mitigate	O
+the	O
+risk	O
+of	O
+guidewire	O
+looping	O
+during	O
+insertion	O
+of	O
+the	O
+dilators	O
+/	O
+cannula	B-SPEC
+and	O
+thereby	O
+reduce	O
+the	O
+risk	O
+of	O
+perforation	O
+of	O
+the	O
+right	B-ANAT
+ventricle	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Lessons	O
+learned	B-PROC
+from	O
+international	O
+responses	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+A	O
+rapid	O
+spread	O
+of	O
+SARS	B-DISO
+around	O
+the	O
+world	O
+occurred	O
+at	O
+its	O
+onset	O
+,	O
+facilitated	O
+greatly	O
+by	O
+air	B-CHED
+travel	O
+.	O
+
+TITLE	O
+:	O
+Chronic	O
+widespread	O
+musculoskeletal	O
+pain	O
+,	O
+fatigue	B-DISO
+,	O
+depression	B-DISO
+and	O
+disordered	O
+sleep	B-PROC
+in	O
+chronic	O
+post	O
+-	O
+SARS	O
+syndrome	B-DISO
+;	O
+a	O
+case	O
+-	O
+controlled	O
+study	O
+.	O
+
+11	O
+.	O
+8	O
+yrs	O
+.)	O
+who	O
+fulfilled	O
+criteria	O
+for	O
+fibromyalgia	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Chronic	O
+post	O
+-	O
+SARS	B-DISO
+is	O
+characterized	O
+by	O
+persistent	O
+fatigue	B-DISO
+,	O
+diffuse	O
+myalgia	B-DISO
+,	O
+weakness	B-DISO
+,	O
+depression	B-DISO
+,	O
+and	O
+nonrestorative	O
+sleep	B-PROC
+with	O
+associated	O
+REM	B-PROC
+-	O
+related	O
+apneas	B-DISO
+/	O
+hypopneas	O
+,	O
+an	O
+elevated	O
+sleep	B-PROC
+EEG	O
+cyclical	O
+alternating	O
+pattern	O
+,	O
+and	O
+alpha	O
+EEG	O
+sleep	B-PROC
+anomaly	O
+.	O
+
+Finally	O
+,	O
+SARS	B-DISO
+-	O
+S	O
+-	O
+driven	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+was	O
+independent	O
+of	O
+cathepsin	B-PRGE
+L	I-PRGE
+,	O
+a	O
+protease	O
+essential	O
+for	O
+virus	B-SPEC
+-	O
+cell	B-PROC
+fusion	I-PROC
+.	O
+
+HRCT	O
+findings	O
+of	O
+the	O
+lungs	B-ANAT
+for	O
+all	O
+patients	O
+were	O
+retrospectively	O
+reviewed	O
+by	O
+two	O
+independent	O
+radiologists	O
+.	O
+
+Bronchiectasis	B-DISO
+was	O
+not	O
+seen	O
+.	O
+
+Ground	O
+glass	O
+opacities	B-DISO
+,	O
+interlobular	O
+septal	O
+thickening	O
+and	O
+consolidations	O
+were	O
+consistent	O
+HRCT	O
+manifestations	O
+in	O
+both	O
+metapneumovirus	B-DISO
+infection	I-DISO
+and	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+secondary	O
+to	O
+H1N1	O
+viral	B-DISO
+infection	I-DISO
+has	O
+been	O
+a	O
+worldwide	O
+medical	O
+and	O
+organizational	O
+challenge	O
+.	O
+
+ABSTRACT	O
+:	O
+Three	O
+hundred	O
+sera	B-COMP
+were	O
+collected	O
+from	O
+horses	O
+in	O
+various	O
+parts	O
+of	O
+Mongolia	O
+in	O
+2007	O
+and	O
+seroepidemiological	O
+surveys	O
+for	O
+several	O
+equine	B-SPEC
+viruses	B-SPEC
+performed	O
+on	O
+them	O
+.	O
+
+Respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+61	O
+of	O
+166	O
+episodes	O
+(	O
+36	O
+.	O
+7	O
+%).	O
+
+For	O
+this	O
+to	O
+occur	O
+,	O
+the	O
+viral	B-PRGE
+envelope	I-PRGE
+proteins	B-CHED
+must	O
+be	O
+efficiently	O
+targeted	B-PROC
+to	O
+the	O
+Golgi	B-COMP
+region	O
+of	O
+the	O
+secretory	B-PROC
+pathway	I-PROC
+.	O
+
+Through	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+,	O
+we	O
+demonstrate	O
+that	O
+a	O
+predicted	O
+beta	O
+-	O
+hairpin	O
+structural	O
+motif	O
+in	O
+the	O
+tail	O
+is	O
+sufficient	O
+for	O
+Golgi	B-COMP
+complex	I-COMP
+localization	B-PROC
+of	O
+a	O
+reporter	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+Ebola	B-SPEC
+virus	I-SPEC
+entry	O
+by	O
+a	O
+C	O
+-	O
+peptide	B-CHED
+targeted	B-PROC
+to	O
+endosomes	O
+.	O
+
+Infection	B-DISO
+by	O
+other	O
+viruses	B-SPEC
+employing	O
+similar	O
+viral	O
+entry	O
+mechanisms	O
+(	O
+such	O
+as	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+)	O
+can	O
+be	O
+inhibited	O
+with	O
+synthetic	O
+peptides	B-CHED
+corresponding	O
+to	O
+the	O
+native	O
+CHR	B-DISO
+sequence	O
+"("""	O
+C	O
+-	O
+peptides	B-CHED
+""")."	O
+
+We	O
+conducted	O
+a	O
+three	O
+-	O
+year	O
+prospective	O
+descriptive	O
+study	O
+of	O
+severe	O
+respiratory	O
+illness	O
+among	O
+children	O
+from	O
+2	O
+months	O
+to	O
+13	O
+years	O
+of	O
+age	O
+within	O
+the	O
+largest	O
+referral	O
+hospital	O
+for	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+southern	O
+Vietnam	O
+.	O
+
+Nasopharyngeal	O
+and	O
+rectal	O
+swabs	O
+revealed	O
+pandemic	O
+2009	O
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+by	O
+reverse	O
+-	O
+transcriptase	B-PROC
+-	O
+polymerase	O
+-	O
+chain	O
+-	O
+reaction	O
+assay	O
+.	O
+
+To	O
+gain	O
+baseline	O
+data	O
+on	O
+infectious	B-DISO
+agents	O
+in	O
+this	O
+area	O
+,	O
+including	O
+those	O
+with	O
+zoonotic	O
+potential	O
+,	O
+we	O
+collected	O
+blood	B-ANAT
+and	O
+stool	B-ANAT
+samples	O
+from	O
+107	O
+dogs	B-SPEC
+in	O
+5	O
+remote	O
+communities	O
+in	O
+May	O
+and	O
+September	O
+2007	O
+.	O
+
+No	O
+dogs	B-SPEC
+showed	O
+evidence	O
+of	O
+exposure	O
+to	O
+Ehrlichia	O
+canis	O
+,	O
+Anaplasma	B-SPEC
+phagocytophilum	I-SPEC
+,	O
+Borrelia	B-SPEC
+burgdorferi	I-SPEC
+,	O
+Dirofilaria	B-SPEC
+immitis	I-SPEC
+,	O
+or	O
+Cryptococcus	B-SPEC
+gattii	I-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Expression	B-PROC
+of	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+using	O
+an	O
+infectious	B-DISO
+cDNA	O
+clone	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+].	O
+
+Metformin	B-CHED
+was	O
+approved	O
+in	O
+Europe	O
+in	O
+1957	O
+,	O
+and	O
+it	O
+is	O
+used	O
+for	O
+the	O
+treatment	O
+of	O
+non	B-DISO
+-	I-DISO
+insulin	I-DISO
+-	I-DISO
+dependent	I-DISO
+diabetes	I-DISO
+mellitus	I-DISO
+for	O
+more	O
+than	O
+50	O
+years	O
+.	O
+
+It	O
+is	O
+a	O
+rare	O
+but	O
+dangerous	O
+metabolic	B-PROC
+complication	B-DISO
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+up	O
+to	O
+50	O
+%	O
+that	O
+can	O
+result	O
+from	O
+the	O
+accumulation	O
+of	O
+lactates	O
+.	O
+
+It	O
+is	O
+characterized	O
+by	O
+an	O
+increased	O
+serum	B-COMP
+lactate	B-CHED
+level	O
+(>	O
+5	O
+mmol	O
+/	O
+L	O
+or	O
+>	O
+45	O
+mg	O
+/	O
+dL	O
+),	O
+decreased	O
+blood	B-ANAT
+pH	O
+(<	O
+7	O
+.	O
+35	O
+),	O
+and	O
+electrolyte	B-DISO
+imbalance	I-DISO
+with	O
+an	O
+increased	O
+anion	B-CHED
+gap	O
+.	O
+
+The	O
+estimated	O
+incidence	O
+of	O
+this	O
+syndrome	B-DISO
+is	O
+2	O
+-	O
+9	O
+cases	O
+per	O
+100	O
+000	O
+patients	O
+.	O
+
+Currently	O
+,	O
+there	O
+are	O
+no	O
+standardized	O
+guidelines	O
+for	O
+metformin	B-CHED
+administration	O
+during	O
+the	O
+perioperative	O
+period	O
+,	O
+and	O
+published	O
+data	O
+remain	O
+controversial	O
+.	O
+
+Concerns	O
+have	O
+been	O
+raised	O
+for	O
+the	O
+use	O
+of	O
+metformin	B-CHED
+in	O
+patients	O
+with	O
+cardiovascular	B-ANAT
+,	O
+renal	B-ANAT
+,	O
+hepatic	B-ANAT
+,	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Overall	O
+,	O
+PIKA	B-PRGE
+could	O
+be	O
+a	O
+good	O
+mucosal	B-ANAT
+adjuvant	B-CHED
+candidate	O
+for	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+for	O
+use	O
+in	O
+possible	O
+future	O
+pandemic	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+corticosteroids	B-CHED
+in	O
+severe	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+their	O
+controversial	O
+role	O
+,	O
+corticosteroids	B-CHED
+are	O
+often	O
+administered	O
+to	O
+patients	O
+with	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+secondary	O
+to	O
+viral	B-DISO
+pneumonia	I-DISO
+.	O
+
+Patients	O
+were	O
+then	O
+followed	O
+for	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+.	O
+
+An	O
+acute	O
+exacerbation	B-DISO
+of	I-DISO
+idiopathic	I-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+is	O
+an	O
+episode	O
+of	O
+acute	O
+respiratory	O
+worsening	O
+without	O
+an	O
+identifiable	O
+etiology	O
+.	O
+
+Four	O
+of	O
+forty	O
+-	O
+three	O
+patients	O
+with	O
+acute	O
+exacerbation	B-DISO
+of	I-DISO
+idiopathic	I-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+had	O
+evidence	O
+of	O
+common	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+(	O
+parainfluenza	B-DISO
+[	O
+n	O
+=	O
+1	O
+],	O
+rhinovirus	B-SPEC
+[	O
+n	O
+=	O
+2	O
+],	O
+coronavirus	B-SPEC
+[	O
+n	O
+=	O
+1	O
+]);	O
+no	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+the	O
+bronchoalveolar	O
+lavage	O
+from	O
+stable	O
+patients	O
+.	O
+
+TTV	B-SPEC
+infection	B-DISO
+was	O
+significantly	O
+more	O
+common	O
+in	O
+patients	O
+with	O
+acute	O
+exacerbation	O
+than	O
+stable	O
+controls	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0003	O
+),	O
+but	O
+present	O
+in	O
+a	O
+similar	O
+percentage	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+controls	O
+.	O
+
+Deep	O
+sequencing	O
+of	O
+a	O
+subset	O
+of	O
+acute	O
+exacerbation	O
+cases	O
+confirmed	O
+the	O
+presence	O
+of	O
+TTV	B-SPEC
+but	O
+did	O
+not	O
+identify	O
+additional	O
+viruses	B-SPEC
+.	O
+
+Shock	O
+wave	O
+pressure	O
+at	O
+1	O
+917	O
+.	O
+3	O
+mm	O
+Hg	O
+(	O
+group	O
+C	O
+)	O
+produced	O
+extensive	O
+contusion	O
+from	O
+grade	O
+4	O
+to	O
+grade	O
+5	O
+as	O
+assessed	O
+with	O
+AIS	B-DISO
+.	O
+
+The	O
+rabbits	B-SPEC
+survived	O
+in	O
+poor	O
+general	O
+condition	B-DISO
+,	O
+and	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+(	O
+PaO	B-PROC
+(	O
+2	O
+))	O
+lowered	O
+within	O
+6	O
+hours	O
+.	O
+
+TITLE	O
+:	O
+Vascular	B-ANAT
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PRGE
+(	O
+VEGF	B-PRGE
+),	O
+produced	O
+by	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+virus	B-SPEC
+-	O
+infected	O
+monocytes	B-ANAT
+and	O
+macrophages	B-ANAT
+,	O
+induces	O
+vascular	B-PROC
+permeability	I-PROC
+and	O
+effusion	B-DISO
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+The	O
+effusion	B-DISO
+in	O
+body	B-ANAT
+cavity	I-ANAT
+is	O
+commonly	O
+associated	O
+with	O
+FIP	B-DISO
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+validation	O
+of	O
+RT	O
+-	O
+PCR	O
+tests	O
+for	O
+the	O
+detection	O
+and	O
+S1	O
+genotyping	O
+of	O
+infectious	B-DISO
+bronchitis	O
+virus	B-SPEC
+and	O
+other	O
+closely	O
+related	O
+gammacoronaviruses	O
+within	O
+clinical	O
+samples	O
+.	O
+
+A	O
+total	O
+of	O
+323	O
+field	O
+samples	O
+were	O
+tested	O
+;	O
+176	O
+samples	O
+were	O
+positive	O
+using	O
+the	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+method	O
+,	O
+but	O
+only	O
+three	O
+were	O
+positive	O
+by	O
+virus	B-SPEC
+isolation	O
+.	O
+
+This	O
+method	O
+was	O
+developed	O
+to	O
+provide	O
+a	O
+tool	O
+to	O
+inform	O
+vaccination	O
+decisions	O
+and	O
+for	O
+ongoing	O
+surveillance	O
+to	O
+detect	O
+new	O
+and	O
+emerging	O
+strains	O
+of	O
+IBV	B-SPEC
+within	O
+the	O
+UK	O
+.	O
+
+The	O
+causes	O
+of	O
+death	B-PROC
+were	O
+MOF	B-DISO
+(	O
+57	O
+.	O
+1	O
+%),	O
+septic	B-DISO
+shock	I-DISO
+(	O
+21	O
+.	O
+4	O
+%)	O
+and	O
+refractory	O
+hypoxaemia	O
+(	O
+21	O
+.	O
+4	O
+%).	O
+
+Learning	B-PROC
+from	O
+viruses	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+The	O
+results	O
+of	O
+multinomial	O
+regression	O
+analyses	O
+showed	O
+that	O
+,	O
+with	O
+other	O
+relevant	O
+factors	O
+controlled	O
+for	O
+,	O
+being	O
+single	O
+,	O
+having	O
+been	O
+quarantined	O
+during	O
+the	O
+outbreak	O
+,	O
+having	O
+been	O
+exposed	O
+to	O
+other	O
+traumatic	O
+events	O
+before	O
+SARS	B-DISO
+,	O
+and	O
+perceived	O
+SARS	B-DISO
+-	O
+related	O
+risk	O
+level	O
+during	O
+the	O
+outbreak	O
+were	O
+found	O
+to	O
+increase	O
+the	O
+odds	O
+of	O
+having	O
+a	O
+high	O
+level	O
+of	O
+depressive	B-DISO
+symptoms	I-DISO
+3	O
+years	O
+later	O
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+delivery	O
+and	O
+long	O
+-	O
+term	O
+persistence	O
+of	O
+transgene	O
+expression	B-PROC
+in	O
+the	O
+brain	B-ANAT
+by	O
+a	O
+135	O
+-	O
+kb	O
+iBAC	O
+-	O
+FXN	O
+genomic	O
+DNA	O
+expression	O
+vector	O
+.	O
+
+We	O
+constructed	O
+genomic	O
+DNA	O
+-	O
+reporter	O
+fusion	O
+vectors	O
+carrying	O
+a	O
+complete	O
+135	O
+kb	O
+FXN	O
+genomic	O
+locus	O
+with	O
+an	O
+insertion	O
+of	O
+the	O
+Escherichia	B-PRGE
+coli	I-PRGE
+lacZ	I-PRGE
+gene	I-PRGE
+at	O
+the	O
+ATG	O
+start	O
+codon	O
+(	O
+iBAC	O
+-	O
+FXN	B-PRGE
+-	O
+lacZ	B-PRGE
+).	O
+
+SHSY5Y	O
+human	B-SPEC
+neuroblastoma	B-DISO
+cells	B-COMP
+transduced	O
+by	O
+iBAC	O
+-	O
+FXN	B-PRGE
+-	O
+lacZ	B-PRGE
+showed	O
+high	O
+efficiency	O
+of	O
+vector	O
+delivery	O
+and	O
+LacZ	B-PRGE
+expression	B-PROC
+.	O
+
+TITLE	O
+:	O
+An	O
+unusual	O
+case	O
+of	O
+neuralgic	B-DISO
+amyotrophy	I-DISO
+presenting	O
+with	O
+bilateral	O
+phrenic	B-ANAT
+nerve	I-ANAT
+and	O
+vocal	B-ANAT
+cord	I-ANAT
+paresis	I-DISO
+.	O
+
+A	O
+55	O
+-	O
+year	O
+-	O
+old	O
+male	O
+presented	O
+with	O
+orthopnea	B-DISO
+and	O
+aphonia	B-DISO
+after	O
+an	O
+episode	O
+of	O
+bilateral	O
+shoulder	B-DISO
+pain	I-DISO
+preceded	O
+by	O
+an	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+An	O
+electromyography	O
+of	O
+the	O
+upper	B-ANAT
+limb	I-ANAT
+muscles	B-ANAT
+and	O
+nerve	B-PROC
+conduction	B-PROC
+studies	O
+did	O
+not	O
+reveal	O
+signs	O
+of	O
+denervation	O
+.	O
+
+TITLE	O
+:	O
+Overview	O
+of	O
+the	O
+winter	O
+wave	O
+of	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+v	O
+in	O
+Vojvodina	O
+,	O
+Serbia	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+epidemiological	O
+data	O
+for	O
+pandemic	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+v	O
+in	O
+the	O
+Autonomous	O
+Province	O
+of	O
+Vojvodina	O
+,	O
+Serbia	O
+,	O
+during	O
+the	O
+season	O
+of	O
+2009	O
+/	O
+2010	O
+and	O
+to	O
+assess	O
+whether	O
+including	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+(	O
+SARI	O
+)	O
+hospitalization	O
+data	O
+to	O
+the	O
+surveillance	O
+system	O
+gives	O
+a	O
+more	O
+complete	O
+picture	O
+of	O
+the	O
+impact	O
+of	O
+influenza	B-DISO
+during	O
+the	O
+pandemic	O
+.	O
+
+From	O
+September	O
+2009	O
+to	O
+September	O
+2010	O
+,	O
+the	O
+Institute	O
+of	O
+Public	O
+Health	O
+of	O
+Vojvodina	O
+conducted	O
+sentinel	O
+surveillance	O
+of	O
+influenza	B-DISO
+-	O
+like	O
+illnesses	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+in	O
+all	O
+hospitalized	O
+patients	O
+with	O
+SARI	O
+and	O
+virological	O
+surveillance	O
+of	O
+population	O
+of	O
+Vojvodina	O
+according	O
+to	O
+the	O
+European	O
+Centers	O
+for	O
+Disease	O
+Control	O
+technical	O
+document	O
+.	O
+
+Nasal	B-ANAT
+/	O
+throat	B-ANAT
+swabs	O
+were	O
+obtained	O
+for	O
+polymerase	O
+chain	O
+reaction	O
+test	O
+from	O
+315	O
+hospitalized	O
+patients	O
+and	O
+20	O
+non	O
+-	O
+hospitalized	O
+patients	O
+,	O
+and	O
+145	O
+(	O
+46	O
+%)	O
+and	O
+15	O
+(	O
+75	O
+%)	O
+specimens	O
+,	O
+respectively	O
+,	O
+tested	O
+positive	O
+on	O
+A	O
+(	O
+H1N1	O
+)	O
+v	O
+.	O
+
+Faecal	B-ANAT
+samples	O
+from	O
+84	O
+Australian	O
+dairy	O
+and	O
+dairy	O
+beef	O
+properties	O
+(	O
+597	O
+samples	O
+)	O
+were	O
+screened	O
+for	O
+rotavirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+using	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+,	O
+for	O
+Salmonella	B-PRGE
+spp	B-ENZY
+.	O
+
+Of	O
+laboratory	O
+arboviral	O
+infections	B-DISO
+,	O
+15	O
+.	O
+7	O
+%	O
+were	O
+acquired	O
+percutaneously	O
+,	O
+whereas	O
+41	O
+.	O
+6	O
+%	O
+of	O
+hospital	B-DISO
+infections	I-DISO
+were	O
+percutaneous	O
+.	O
+
+Using	O
+a	O
+newly	O
+designed	O
+real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+specific	O
+for	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+gene	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+turkey	B-SPEC
+coronaviruses	O
+(	O
+TCoV	O
+),	O
+coronaviruses	O
+were	O
+identified	O
+in	O
+37	O
+%	O
+of	O
+the	O
+intestinal	B-ANAT
+samples	O
+collected	O
+from	O
+diseased	O
+turkey	B-SPEC
+flocks	O
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+that	O
+both	O
+the	O
+NA	O
+TCoV	O
+and	O
+French	O
+TCoV	O
+(	O
+Fr	O
+TCoV	O
+)	O
+lineages	O
+included	O
+some	O
+IBV	B-SPEC
+relatives	O
+,	O
+which	O
+were	O
+however	O
+different	O
+in	O
+the	O
+two	O
+lineages	O
+.	O
+
+These	O
+strains	O
+shared	O
+five	O
+specific	O
+amino	O
+acid	O
+substitutions	O
+that	O
+became	O
+fixed	B-ANAT
+during	O
+the	O
+period	O
+of	O
+surveillance	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viruses	O
+may	O
+persist	O
+in	O
+the	O
+airways	O
+of	O
+asthmatics	B-DISO
+between	O
+episodes	O
+of	O
+clinical	O
+worsening	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Patients	O
+with	O
+clinically	O
+stable	O
+asthma	B-PATH
+and	O
+healthy	O
+controls	O
+have	O
+similar	O
+detection	O
+rates	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+samples	O
+from	O
+nasopharynx	B-ANAT
+,	O
+sputum	B-ANAT
+and	O
+exhaled	B-ANAT
+air	B-CHED
+.	O
+
+This	O
+report	O
+documents	O
+a	O
+confirmed	O
+case	O
+of	O
+methicillin	B-CHED
+-	O
+sensitive	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+strain	O
+harboring	O
+Panton	O
+-	O
+Valentine	O
+leukocidin	O
+genes	O
+from	O
+Trinidad	O
+and	O
+Tobago	O
+.	O
+
+A	O
+13	O
+-	O
+year	O
+-	O
+old	O
+Trinidadian	O
+boy	O
+of	O
+African	O
+descent	O
+presented	O
+with	O
+upper	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+gastroenteritis	B-DISO
+-	O
+like	O
+syptoms	O
+.	O
+
+An	O
+autopsy	O
+revealed	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+histological	O
+tissue	B-ANAT
+stains	O
+of	O
+several	O
+organs	B-ANAT
+were	O
+also	O
+performed	O
+and	O
+showed	O
+involvement	O
+of	O
+his	O
+lungs	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+kidneys	B-ANAT
+and	O
+thymus	B-SPEC
+,	O
+which	O
+showed	O
+Hassal	O
+'	O
+s	O
+corpuscles	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+characteristics	O
+of	O
+human	B-SPEC
+bocavirus	I-SPEC
+infection	B-DISO
+in	O
+90	O
+children	O
+].	O
+
+The	O
+multiple	O
+RT	O
+-	O
+PCR	O
+method	O
+was	O
+used	O
+to	O
+detect	O
+HBoV	O
+and	O
+six	O
+other	O
+common	O
+respiratory	B-ANAT
+tract	I-ANAT
+viruses	B-SPEC
+.	O
+
+Legionellosis	B-PATH
+,	O
+foodborne	O
+diseases	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+bovine	B-DISO
+spongiform	I-DISO
+encephalopathy	I-DISO
+(	O
+BSE	B-DISO
+),	O
+bioterrorism	O
+,	O
+meningococcal	O
+meningitis	B-DISO
+,	I-DISO
+tuberculosis	I-DISO
+,	O
+heat	O
+waves	O
+,	O
+and	O
+influenza	B-DISO
+epidemics	O
+were	O
+found	O
+to	O
+be	O
+cause	O
+for	O
+most	O
+public	O
+health	O
+crises	O
+.	O
+
+Our	O
+results	O
+support	O
+the	O
+strategy	O
+of	O
+targeting	B-PROC
+the	O
+eIF4F	B-PRGE
+complex	I-PRGE
+to	O
+block	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+illness	O
+is	O
+defined	O
+as	O
+one	O
+or	O
+more	O
+of	O
+the	O
+following	O
+:	O
+cough	B-DISO
+,	O
+sputum	B-PROC
+production	I-PROC
+,	O
+chest	B-DISO
+pain	I-DISO
+,	O
+or	O
+dyspnea	B-DISO
+(	O
+with	O
+or	O
+without	O
+fever	B-PROC
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+Southern	O
+hemisphere	O
+,	O
+Réunion	O
+Island	O
+acts	O
+as	O
+a	O
+sentinel	O
+for	O
+infections	O
+preferentially	O
+occurring	O
+during	O
+the	O
+austral	O
+winter	O
+that	O
+are	O
+likely	O
+to	O
+reach	B-PROC
+the	O
+Northern	O
+hemisphere	O
+a	O
+few	O
+months	O
+later	O
+.	O
+
+Within	O
+the	O
+study	O
+period	O
+,	O
+12	O
+patients	O
+died	B-PROC
+(	O
+48	O
+%)	O
+mainly	O
+of	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+patient	O
+was	O
+resuscitated	O
+but	O
+suffered	B-DISO
+septic	B-DISO
+shock	I-DISO
+and	O
+severe	O
+hypoxemia	O
+refractory	O
+to	O
+advanced	O
+mechanical	O
+ventilatory	O
+strategies	O
+.	O
+
+Aeromonas	B-SPEC
+hydrophila	I-SPEC
+was	O
+isolated	O
+as	O
+the	O
+causative	O
+pathogen	O
+of	O
+severe	O
+bilateral	B-DISO
+pneumonia	I-DISO
+.	O
+
+TITLE	O
+:	O
+Phylogenetic	O
+distribution	O
+and	O
+predominant	O
+genotype	O
+of	O
+the	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+China	O
+during	O
+2008	O
+-	O
+2009	O
+.	O
+
+To	O
+learn	B-PROC
+more	O
+about	O
+the	O
+molecular	O
+evolutionary	O
+characteristics	O
+of	O
+the	O
+circulating	O
+field	O
+strains	O
+,	O
+the	O
+coding	O
+region	O
+of	O
+major	O
+spike	O
+1	O
+(	O
+S1	O
+)	O
+protein	B-CHED
+gene	O
+of	O
+these	O
+strains	O
+was	O
+RT	O
+-	O
+PCR	O
+amplified	O
+and	O
+sequenced	O
+.	O
+
+Compared	O
+to	O
+the	O
+published	O
+representative	O
+strains	O
+,	O
+nucleotides	B-CHED
+and	O
+amino	B-CHED
+acids	I-CHED
+sequence	O
+analysis	O
+indicated	O
+that	O
+the	O
+S1	O
+genes	O
+of	O
+these	O
+strains	O
+and	O
+the	O
+reference	O
+strains	O
+displayed	O
+homologies	O
+ranging	O
+from	O
+75	O
+.	O
+1	O
+%	O
+to	O
+99	O
+.	O
+8	O
+%	O
+and	O
+from	O
+73	O
+.	O
+1	O
+%	O
+to	O
+99	O
+.	O
+8	O
+%	O
+respectively	O
+.	O
+
+The	O
+cardinal	B-SPEC
+clinical	O
+feature	O
+of	O
+ARDS	B-DISO
+,	O
+refractory	O
+arterial	B-ANAT
+hypoxemia	O
+,	O
+is	O
+the	O
+result	O
+of	O
+protein	B-CHED
+-	O
+rich	O
+alveolar	B-DISO
+edema	I-DISO
+with	O
+impaired	B-DISO
+surfactant	B-CHED
+function	O
+,	O
+due	O
+to	O
+vascular	B-ANAT
+leakage	B-DISO
+and	O
+vascular	B-ANAT
+dysfunction	O
+with	O
+consequently	O
+impaired	B-DISO
+matching	O
+of	O
+ventilation	O
+to	O
+perfusion	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+RNA	B-PROC
+synthesis	I-PROC
+is	O
+a	O
+sophisticated	O
+process	O
+performed	O
+by	O
+a	O
+viral	O
+multienzymatic	O
+replicase	B-PRGE
+complex	O
+,	O
+together	O
+with	O
+cellular	B-COMP
+factors	O
+.	O
+
+To	O
+study	O
+the	O
+replication	O
+of	O
+coronavirus	B-SPEC
+genome	O
+,	O
+six	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+)	O
+specific	O
+for	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+RdRp	B-FUNC
+were	O
+generated	O
+and	O
+characterized	O
+.	O
+
+The	O
+TGEV	B-SPEC
+RdRp	B-FUNC
+was	O
+recognized	O
+by	O
+these	O
+mAbs	O
+in	O
+the	O
+context	O
+of	O
+virus	B-DISO
+infection	I-DISO
+by	O
+immunofluorescence	O
+analysis	O
+and	O
+Western	O
+blot	O
+.	O
+
+Under	O
+similar	O
+conditions	O
+,	O
+high	O
+-	O
+pathogenic	O
+avian	B-DISO
+influenza	I-DISO
+H7N1	O
+was	O
+the	O
+most	O
+resistant	O
+,	O
+with	O
+D	O
+values	O
+of	O
+3	O
+.	O
+0	O
+and	O
+1	O
+.	O
+4	O
+h	O
+.	O
+MS2	O
+was	O
+more	O
+resistant	O
+than	O
+the	O
+viruses	B-SPEC
+to	O
+all	O
+treatments	O
+and	O
+proved	O
+to	O
+be	O
+a	O
+suitable	O
+indicator	B-CHED
+of	O
+viral	O
+inactivation	B-DISO
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+viruses	B-SPEC
+in	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+:	O
+a	O
+critical	O
+review	O
+and	O
+pooled	O
+analysis	O
+of	O
+clinical	O
+studies	O
+.	O
+
+We	O
+found	O
+a	O
+pooled	O
+incidence	O
+of	O
+18	O
+%	O
+(	O
+9	O
+/	O
+50	O
+)	O
+of	O
+bronchiolitis	O
+obliterans	O
+syndrome	B-DISO
+(	O
+BOS	B-DISO
+)	O
+in	O
+virus	B-SPEC
+-	O
+positive	O
+cases	O
+compared	O
+to	O
+11	O
+.	O
+6	O
+%	O
+(	O
+37	O
+/	O
+319	O
+)	O
+in	O
+virus	B-SPEC
+-	O
+negative	O
+cases	O
+;	O
+however	O
+,	O
+limited	O
+number	O
+of	O
+BOS	B-DISO
+events	O
+did	O
+not	O
+allow	O
+to	O
+confirm	O
+the	O
+association	O
+.	O
+
+The	O
+average	O
+time	O
+from	O
+the	O
+beginning	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+to	O
+the	O
+admission	O
+in	O
+hospital	O
+was	O
+3	O
+days	O
+(	O
+0	O
+-	O
+16	O
+days	O
+)	O
+and	O
+from	O
+the	O
+moment	O
+of	O
+hospitalization	O
+to	O
+the	O
+Intensive	O
+Care	O
+Unit	O
+(	O
+ICU	O
+)	O
+admission	O
+was	O
+2	O
+days	O
+(	O
+0	O
+-	O
+5	O
+days	O
+).	O
+
+Antiviral	B-CHED
+therapy	O
+was	O
+applied	O
+to	O
+43	O
+(	O
+43	O
+.	O
+3	O
+%)	O
+patients	O
+in	O
+the	O
+first	O
+48	O
+hours	O
+from	O
+the	O
+onset	O
+of	O
+the	O
+disease	O
+,	O
+of	O
+whom	O
+only	O
+one	O
+(	O
+3	O
+.	O
+4	O
+)	O
+developed	O
+ARDS	B-DISO
+.	O
+
+Novel	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+is	O
+most	O
+commonly	O
+manifested	O
+as	O
+a	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+,	O
+which	O
+usually	O
+affects	O
+young	O
+healthy	O
+adults	O
+.	O
+
+Children	O
+with	O
+a	O
+higher	O
+severity	O
+score	O
+had	O
+greater	O
+chance	O
+to	O
+develop	O
+asthma	B-PATH
+in	O
+the	O
+next	O
+2	O
+years	O
+(	O
+p	O
+=	O
+0	O
+.	O
+042	O
+).	O
+
+In	O
+addition	O
+,	O
+measurement	O
+of	O
+plasma	B-COMP
+membrane	I-COMP
+voltage	B-FUNC
+gated	I-FUNC
+ion	I-FUNC
+channel	I-FUNC
+activity	I-FUNC
+by	O
+whole	O
+-	O
+cell	B-COMP
+patch	O
+clamp	O
+suggested	O
+that	O
+E	B-PRGE
+protein	I-PRGE
+was	O
+not	O
+present	O
+in	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+.	O
+
+A	O
+topological	O
+conformation	O
+in	O
+which	O
+SARS	O
+-	O
+CoV	O
+E	O
+protein	B-CHED
+amino	O
+terminus	O
+is	O
+oriented	O
+towards	O
+the	O
+lumen	B-ANAT
+of	O
+intracellular	B-COMP
+membranes	B-ANAT
+and	O
+carboxy	B-CHED
+terminus	O
+faces	B-ANAT
+cell	B-COMP
+cytoplasm	B-COMP
+is	O
+proposed	O
+.	O
+
+This	O
+case	O
+report	O
+reveals	O
+a	O
+patient	O
+with	O
+ARDS	B-DISO
+secondary	O
+to	O
+influenza	B-PATH
+A	I-PATH
+with	O
+deteriorating	O
+clinical	O
+status	O
+,	O
+who	O
+improved	O
+tremendously	O
+after	O
+intravenous	O
+immunoglobulin	B-PROC
+G	O
+(	O
+IV	O
+IgG	O
+).	O
+
+TITLE	O
+:	O
+Shifting	O
+hierarchies	O
+of	O
+interleukin	B-PRGE
+-	I-PRGE
+10	I-PRGE
+-	O
+producing	O
+T	B-ANAT
+cell	I-ANAT
+populations	O
+in	O
+the	O
+central	B-ANAT
+nervous	B-DISO
+system	I-ANAT
+during	O
+acute	O
+and	O
+persistent	O
+viral	O
+encephalomyelitis	O
+.	O
+
+ABSTRACT	O
+:	O
+Interleukin	B-PRGE
+-	I-PRGE
+10	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+)	O
+mRNA	B-CHED
+is	O
+rapidly	O
+upregulated	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+following	O
+infection	B-DISO
+with	O
+neurotropic	O
+coronavirus	B-SPEC
+and	O
+remains	O
+elevated	O
+during	O
+persistent	B-DISO
+infection	I-DISO
+.	O
+
+Infection	B-DISO
+of	O
+transgenic	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+/	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	O
+)	O
+reporter	O
+mice	B-SPEC
+revealed	O
+that	O
+CNS	B-CHED
+-	O
+infiltrating	B-DISO
+T	B-ANAT
+cells	I-ANAT
+were	O
+the	O
+major	O
+source	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+with	O
+minimal	O
+IL	B-PROC
+-	I-PROC
+10	I-PROC
+production	I-PROC
+by	O
+macrophages	B-ANAT
+and	O
+resident	O
+microglia	B-ANAT
+.	O
+
+Unlike	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+a	O
+large	O
+proportion	O
+of	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+within	O
+the	O
+CNS	B-CHED
+retained	O
+IL	B-PROC
+-	I-PROC
+10	I-PROC
+production	I-PROC
+throughout	O
+persistence	O
+.	O
+
+Moreover	O
+,	O
+a	O
+shift	O
+from	O
+predominant	O
+IL	B-PROC
+-	I-PROC
+10	I-PROC
+production	I-PROC
+by	O
+CD25	B-PRGE
+(+)	I-PRGE
+CD4	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+to	O
+CD25	B-PRGE
+(-)	I-PRGE
+CD4	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+suggests	O
+that	O
+a	O
+transition	B-DISO
+to	O
+nonclassical	O
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+precedes	O
+and	O
+is	O
+retained	O
+during	O
+CNS	B-CHED
+viral	O
+persistence	O
+.	O
+
+The	O
+systematic	O
+review	O
+covered	O
+over	O
+3	O
+,	O
+700	O
+peer	O
+-	O
+reviewed	O
+articles	O
+and	O
+grey	O
+literature	O
+for	O
+the	O
+following	O
+diseases	O
+:	O
+tuberculosis	B-PATH
+,	O
+influenza	B-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+invasive	O
+meningococcal	B-DISO
+disease	I-DISO
+,	O
+measles	B-PATH
+,	O
+rubella	B-DISO
+,	O
+diphtheria	B-DISO
+,	O
+Ebola	O
+and	O
+Marburg	O
+haemorrhagic	O
+fevers	B-DISO
+,	I-DISO
+Lassa	I-DISO
+fever	B-PROC
+,	O
+smallpox	B-DISO
+and	O
+anthrax	B-DISO
+.	O
+
+Using	O
+PRRSV	B-SPEC
+,	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+,	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+pseudorabies	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+as	O
+coating	O
+antigens	B-CHED
+,	O
+a	O
+virus	B-SPEC
+-	O
+based	O
+ELISA	O
+was	O
+established	O
+.	O
+
+During	O
+chronic	B-DISO
+inflammation	I-DISO
+,	O
+we	O
+found	O
+that	O
+inhibiting	O
+glycogen	B-PRGE
+synthase	I-PRGE
+kinase	I-PRGE
+-	I-PRGE
+3β	I-PRGE
+activity	O
+with	O
+lithium	B-CHED
+reduced	O
+tau	B-CHED
+phosphorylation	B-PROC
+and	O
+the	O
+accumulation	O
+of	O
+insoluble	O
+tau	B-CHED
+and	O
+reversed	O
+memory	B-PROC
+impairments	O
+.	O
+
+Taken	O
+together	O
+,	O
+infectious	B-DISO
+agents	O
+that	O
+trigger	O
+central	B-DISO
+nervous	I-DISO
+system	I-DISO
+inflammation	I-DISO
+may	O
+serve	O
+as	O
+a	O
+comorbidity	O
+for	O
+AD	O
+,	O
+leading	O
+to	O
+cognitive	B-DISO
+impairments	I-DISO
+by	O
+a	O
+mechanism	O
+that	O
+involves	O
+exacerbation	O
+of	O
+tau	B-CHED
+pathological	O
+characteristics	O
+.	O
+
+Also	O
+,	O
+PaO₂	B-PRGE
+/	O
+Fio₂	O
+may	O
+increase	O
+when	O
+Fio2	O
+is	O
+raised	O
+from	O
+moderate	O
+to	O
+high	O
+levels	O
+,	O
+suggesting	O
+that	O
+patients	O
+with	O
+similar	O
+PaO₂	B-PRGE
+/	O
+Fio₂	O
+ratios	O
+but	O
+different	O
+Fio₂	O
+levels	O
+have	O
+different	O
+risks	O
+of	O
+mortality	O
+.	O
+
+At	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Network	O
+hospitals	O
+,	O
+the	O
+addition	O
+of	O
+baseline	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+would	O
+not	O
+have	O
+increased	O
+the	O
+value	O
+of	O
+PaO₂	B-PRGE
+/	O
+Fio₂	O
+for	O
+predicting	O
+mortality	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+.	O
+
+The	O
+monomeric	O
+form	O
+of	O
+M	O
+(	O
+pro	B-CHED
+)	O
+is	O
+enzymatically	O
+inactive	O
+,	O
+and	O
+it	O
+is	O
+activated	O
+through	O
+homo	B-SPEC
+-	O
+dimerization	O
+which	O
+is	O
+strongly	O
+affected	O
+by	O
+extra	O
+residues	O
+to	O
+both	O
+ends	O
+of	O
+the	O
+mature	O
+enzyme	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+patient	O
+who	O
+had	O
+received	O
+a	O
+liver	B-ANAT
+transplant	B-ANAT
+.	O
+
+Following	O
+transfer	O
+to	O
+the	O
+ICU	O
+,	O
+continuous	O
+hemodialysis	O
+was	O
+introduced	O
+to	O
+reduce	O
+excessive	O
+blood	B-ANAT
+volume	O
+.	O
+
+ECMO	O
+was	O
+successfully	O
+weaned	B-PROC
+on	O
+POD	O
+88	O
+.	O
+
+LocaPep	O
+is	O
+a	O
+computer	O
+program	O
+developed	O
+to	O
+localize	O
+epitopes	O
+using	O
+a	O
+new	O
+clusters	B-CHED
+algorithm	O
+that	O
+focuses	O
+on	O
+protein	B-CHED
+surface	O
+properties	O
+.	O
+
+Positive	O
+selection	O
+was	O
+not	O
+detected	O
+and	O
+mutation	O
+rates	O
+ranged	O
+from	O
+10	O
+(-	O
+4	O
+)	O
+to	O
+10	O
+(-	O
+6	O
+)	O
+substitutions	O
+/	O
+site	O
+/	O
+year	O
+for	O
+Mass	O
+and	O
+Conn	O
+IBV	B-SPEC
+types	O
+where	O
+attenuated	O
+live	O
+vaccines	O
+are	O
+routinely	O
+used	O
+to	O
+control	O
+the	O
+disease	O
+.	O
+
+Lower	O
+levels	O
+of	O
+genetic	O
+diversity	O
+among	O
+the	O
+Mass	O
+and	O
+Conn	O
+viruses	B-SPEC
+as	O
+well	O
+as	O
+sequence	O
+similarities	O
+with	O
+vaccine	O
+virus	O
+genomes	O
+suggest	O
+that	O
+the	O
+origin	O
+of	O
+the	O
+Mass	O
+and	O
+all	O
+but	O
+one	O
+of	O
+the	O
+Conn	O
+viruses	B-SPEC
+was	O
+likely	O
+vaccine	O
+virus	B-SPEC
+that	O
+had	O
+been	O
+circulating	O
+in	O
+the	O
+field	O
+for	O
+an	O
+unknown	O
+but	O
+apparently	O
+short	O
+period	O
+of	O
+time	O
+.	O
+
+The	O
+genetic	O
+data	O
+also	O
+identified	O
+a	O
+recombinant	O
+IBV	B-SPEC
+isolate	O
+with	O
+7	O
+breakpoints	O
+distributed	O
+across	O
+the	O
+entire	O
+genome	O
+suggesting	O
+that	O
+viruses	B-SPEC
+within	O
+the	O
+same	O
+serotype	O
+can	O
+have	O
+a	O
+high	O
+degree	O
+of	O
+genetic	O
+variability	O
+outside	O
+of	O
+the	O
+spike	O
+gene	O
+.	O
+
+When	O
+expressed	B-PROC
+in	O
+Xenopus	B-SPEC
+oocytes	B-ANAT
+the	O
+protein	B-CHED
+forms	O
+channels	O
+.	O
+
+Based	O
+on	O
+bioinformatics	O
+approaches	O
+the	O
+topology	O
+has	O
+been	O
+identified	O
+to	O
+include	O
+three	O
+transmembrane	B-COMP
+domains	O
+(	O
+TMDs	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+more	O
+severe	O
+form	O
+,	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+,	O
+are	O
+complex	O
+illnesses	O
+involving	O
+the	O
+interplay	O
+of	O
+both	O
+environmental	O
+(	O
+such	O
+as	O
+mechanical	O
+ventilation	O
+)	O
+and	O
+genetic	O
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+Cultivation	O
+of	O
+the	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+strain	O
+ARRHIAH	O
+in	O
+the	O
+continuous	O
+RBT	O
+versus	O
+MDBK	O
+and	O
+Taurus	O
+cell	B-COMP
+cultures	O
+made	O
+it	O
+possible	O
+to	O
+reduce	O
+the	O
+time	O
+taken	O
+to	O
+reproduce	O
+the	O
+virus	B-SPEC
+and	O
+to	O
+increase	O
+its	O
+hemagglutination	B-PROC
+titer	O
+.	O
+
+Evaluation	O
+of	O
+the	O
+method	O
+showed	O
+that	O
+the	O
+test	O
+is	O
+specific	O
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+that	O
+it	O
+does	O
+not	O
+cross	O
+-	O
+react	O
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+viral	B-PRGE
+RNA	I-PRGE
+replicase	I-PRGE
+polyproteins	I-PRGE
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+are	O
+encoded	O
+by	O
+the	O
+two	O
+overlapping	O
+open	O
+reading	O
+frames	O
+1a	O
+and	O
+1b	O
+,	O
+which	O
+are	O
+connected	O
+by	O
+a	O
+-	O
+1	O
+PRF	O
+signal	O
+.	O
+
+Treatment	O
+of	O
+cells	B-COMP
+,	O
+which	O
+were	O
+transfected	O
+with	O
+a	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+replicon	I-PRGE
+expressing	I-PRGE
+firefly	I-PRGE
+luciferase	I-PRGE
+,	O
+with	O
+the	O
+PNA	B-CHED
+fused	O
+to	O
+a	O
+cell	B-COMP
+-	O
+penetrating	O
+peptide	B-CHED
+(	O
+CPP	O
+)	O
+resulted	O
+in	O
+suppression	B-DISO
+of	O
+the	O
+replication	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+replicon	O
+,	O
+with	O
+a	O
+50	O
+%	O
+inhibitory	O
+concentration	O
+of	O
+4	O
+.	O
+4μM	O
+.	O
+There	O
+was	O
+no	O
+induction	O
+of	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+responses	O
+by	O
+PNA	B-CHED
+treatment	O
+,	O
+suggesting	O
+that	O
+the	O
+effect	O
+of	O
+PNA	B-CHED
+is	O
+not	O
+due	O
+to	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+viruses	B-SPEC
+in	O
+used	O
+ventilation	O
+filters	O
+from	O
+two	O
+large	O
+public	O
+buildings	O
+.	O
+
+Representative	O
+pieces	O
+of	O
+each	O
+filter	O
+were	O
+cut	O
+and	O
+eluted	O
+with	O
+a	O
+buffer	B-CHED
+solution	O
+.	O
+
+Attempts	O
+were	O
+made	O
+to	O
+detect	O
+viruses	B-SPEC
+by	O
+inoculation	O
+of	O
+these	O
+eluates	O
+in	O
+cell	B-COMP
+cultures	O
+(	O
+Vero	O
+,	O
+MDCK	O
+,	O
+and	O
+RK	O
+-	O
+13	O
+)	O
+and	O
+specific	O
+pathogen	O
+-	O
+free	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+existing	O
+building	O
+HVAC	O
+filters	O
+may	O
+be	O
+used	O
+as	O
+a	O
+method	O
+of	O
+detection	O
+for	O
+airborne	O
+viruses	B-SPEC
+.	O
+
+In	O
+case	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+non	O
+-	O
+invasive	O
+ventilation	O
+is	O
+the	O
+preferred	O
+mode	O
+of	O
+ventilatory	O
+support	O
+because	O
+invasive	O
+ventilation	O
+is	O
+associated	O
+with	O
+poor	O
+outcomes	O
+.	O
+
+Pigs	B-SPEC
+experimentally	O
+infected	O
+with	O
+the	O
+34th	O
+-	O
+or	O
+61st	O
+-	O
+passaged	O
+virus	B-SPEC
+,	O
+but	O
+not	O
+the	O
+100th	O
+-	O
+passaged	O
+virus	O
+,	O
+exhibited	O
+diarrhea	B-DISO
+,	O
+indicating	O
+an	O
+attenuation	O
+of	O
+the	O
+83P	O
+-	O
+5	O
+at	O
+the	O
+100th	O
+passage	O
+.	O
+
+This	O
+increase	O
+in	O
+activity	O
+correlates	O
+with	O
+the	O
+activation	O
+of	O
+ERK	O
+and	O
+JNK	B-PROC
+pathways	I-PROC
+.	O
+
+Furthermore	O
+,	O
+3b	O
+expression	B-PROC
+potentiates	O
+AP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+driven	I-PRGE
+promoter	I-PRGE
+activity	I-PRGE
+of	I-PRGE
+proinflammatory	I-PRGE
+cytokine	I-PRGE
+MCP	I-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+suggesting	O
+a	O
+plausible	O
+role	O
+for	O
+3b	O
+as	O
+a	O
+virulence	B-PROC
+factor	O
+that	O
+might	O
+function	O
+by	O
+upregulating	O
+AP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+dependent	O
+cytokine	O
+levels	O
+in	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+We	O
+have	O
+previously	O
+reported	O
+that	O
+ADAM17	B-PRGE
+is	O
+able	O
+to	O
+mediate	O
+the	O
+cleavage	B-PROC
+secretion	B-PROC
+of	O
+the	O
+ectodomain	O
+of	O
+human	B-SPEC
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+a	O
+functional	O
+receptor	O
+for	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Prior	O
+studies	O
+using	O
+recombinant	O
+MHV	B-SPEC
+strains	O
+that	O
+differ	O
+only	O
+in	O
+the	O
+spike	O
+gene	O
+,	O
+which	O
+encodes	O
+a	O
+glycoprotein	B-CHED
+involved	O
+in	O
+virus	B-SPEC
+-	O
+host	O
+cell	B-COMP
+attachment	I-COMP
+,	O
+demonstrated	O
+that	O
+spike	O
+mediates	O
+anterograde	B-PROC
+axonal	I-PROC
+transport	I-PROC
+of	O
+virus	B-SPEC
+to	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+.	O
+
+A	O
+demyelinating	O
+MHV	B-SPEC
+strain	O
+induces	O
+optic	B-DISO
+neuritis	I-DISO
+,	O
+but	O
+whether	O
+this	O
+is	O
+due	O
+to	O
+the	O
+retrograde	B-PROC
+axonal	I-PROC
+transport	I-PROC
+of	O
+viral	B-COMP
+particles	I-COMP
+to	O
+the	O
+retina	B-ANAT
+or	O
+due	O
+to	O
+traumatic	O
+disruption	O
+of	O
+retinal	B-ANAT
+ganglion	B-DISO
+cell	B-COMP
+axons	B-COMP
+during	O
+intracranial	B-ANAT
+inoculation	O
+is	O
+not	O
+known	O
+.	O
+
+Using	O
+recombinant	O
+isogenic	O
+MHV	B-SPEC
+strains	O
+,	O
+we	O
+examined	O
+the	O
+ability	O
+of	O
+recombinant	O
+MHV	B-SPEC
+to	O
+induce	O
+optic	B-DISO
+neuritis	I-DISO
+by	O
+retrograde	O
+spread	O
+from	O
+the	O
+brain	B-ANAT
+through	O
+the	O
+optic	B-ANAT
+nerve	I-ANAT
+into	O
+the	O
+eye	B-ANAT
+after	O
+intracranial	B-ANAT
+inoculation	O
+.	O
+
+In	O
+multivariate	O
+analysis	O
+,	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+the	O
+del	O
+/	O
+del	O
+genotype	O
+also	O
+had	O
+increased	O
+60	O
+day	O
+mortality	O
+(	O
+HR	O
+1	O
+.	O
+54	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+01	O
+-	O
+2	O
+.	O
+36	O
+)	O
+and	O
+more	O
+severe	O
+daily	O
+organ	B-ANAT
+dysfunction	O
+(	O
+P	O
+<.	O
+001	O
+)	O
+when	O
+compared	O
+to	O
+ARDS	B-DISO
+patients	O
+with	O
+other	O
+genotypes	O
+.	O
+
+The	O
+inhibitory	O
+effect	O
+of	O
+LiCl	O
+against	O
+TGEV	B-SPEC
+infection	B-DISO
+and	O
+transcription	B-PROC
+was	O
+confirmed	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+real	O
+-	O
+time	O
+PCR	O
+targeting	B-PROC
+viral	O
+S	O
+and	O
+3CL	B-PRGE
+-	I-PRGE
+protease	I-PRGE
+genes	I-PRGE
+.	O
+
+The	O
+time	O
+-	O
+of	O
+-	O
+addition	O
+effect	O
+of	O
+the	O
+drug	O
+on	O
+TGEV	B-SPEC
+infection	B-DISO
+indicated	O
+that	O
+LiCl	B-CHED
+acted	O
+on	O
+the	O
+initial	O
+and	O
+late	O
+stage	O
+of	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+Moreover	O
+,	O
+immunofluorescence	O
+(	O
+IF	O
+)	O
+and	O
+flow	O
+cytometry	O
+analyses	O
+based	O
+on	O
+staining	O
+of	O
+Annexin	B-PRGE
+V	I-PRGE
+and	O
+propidium	B-CHED
+iodide	I-CHED
+staining	O
+of	O
+nuclei	B-CHED
+indicated	O
+that	O
+early	O
+and	O
+late	O
+cell	B-COMP
+apoptosis	B-PATH
+induced	O
+by	O
+TGEV	B-SPEC
+was	O
+inhibited	O
+efficiently	O
+.	O
+
+17	O
+pigs	B-SPEC
+,	O
+in	O
+which	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+was	O
+induced	O
+by	O
+saline	O
+lavage	O
+,	O
+were	O
+studied	O
+.	O
+
+ABSTRACT	O
+:	O
+Six	O
+years	O
+have	O
+passed	O
+since	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Protocol	O
+for	O
+recombinant	O
+RBD	O
+-	O
+based	O
+SARS	B-DISO
+vaccines	O
+:	O
+protein	B-CHED
+preparation	O
+,	O
+animal	B-SPEC
+vaccination	O
+and	O
+neutralization	O
+detection	O
+.	O
+
+Compared	O
+with	O
+the	O
+lipid	B-CHED
+transfection	B-PROC
+method	O
+,	O
+this	O
+modified	O
+calcium	B-CHED
+phosphate	I-CHED
+transfection	B-PROC
+method	O
+is	O
+cheaper	O
+,	O
+easier	O
+to	O
+handle	O
+,	O
+and	O
+has	O
+the	O
+potential	O
+to	O
+reach	B-PROC
+high	O
+efficacy	O
+once	O
+a	O
+transfection	B-PROC
+complex	O
+with	O
+suitable	O
+size	O
+and	O
+shape	O
+is	O
+formed	O
+.	O
+
+This	O
+assay	O
+is	O
+relatively	O
+safe	O
+,	O
+does	O
+not	O
+involve	O
+an	O
+infectious	B-DISO
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+and	O
+can	O
+be	O
+performed	O
+without	O
+the	O
+requirement	O
+of	O
+a	O
+biosafety	O
+-	O
+3	O
+laboratory	O
+.	O
+
+The	O
+protocol	O
+described	O
+here	O
+can	O
+also	O
+be	O
+used	O
+to	O
+design	O
+and	O
+study	O
+recombinant	O
+subunit	O
+vaccines	O
+against	O
+other	O
+viruses	B-SPEC
+with	O
+class	B-PRGE
+I	I-PRGE
+fusion	I-PRGE
+proteins	B-CHED
+,	O
+for	O
+example	O
+,	O
+HIV	B-DISO
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+Ebola	B-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+as	O
+well	O
+as	O
+Nipah	O
+and	O
+Handra	O
+viruses	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+methods	O
+for	O
+generating	O
+a	O
+pseudovirus	O
+and	O
+subsequently	O
+establishing	O
+a	O
+pseudovirus	O
+neutralization	O
+assay	O
+can	O
+be	O
+applied	O
+to	O
+all	O
+these	O
+viruses	B-SPEC
+.	O
+
+Thus	O
+,	O
+small	O
+molecules	O
+interacting	O
+with	O
+high	O
+affinity	O
+and	O
+selectivity	O
+with	O
+the	O
+RNA	O
+pseudoknot	O
+in	O
+the	O
+-	O
+1	O
+RF	O
+site	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+SARS	B-PRGE
+-	I-PRGE
+pseudoknot	I-PRGE
+)	O
+would	O
+disrupt	O
+-	O
+1	O
+RF	O
+and	O
+be	O
+fatal	O
+to	O
+viral	O
+infectivity	O
+and	O
+production	O
+.	O
+
+Findings	O
+indicate	O
+a	O
+strong	O
+correlation	O
+between	O
+the	O
+scale	O
+of	O
+SARS	B-DISO
+infections	B-DISO
+and	O
+level	O
+of	O
+rumour	O
+activities	O
+across	O
+regions	O
+.	O
+
+Our	O
+particular	O
+typology	O
+of	O
+SARS	B-DISO
+-	O
+incurred	O
+rumours	O
+leads	O
+us	O
+to	O
+identify	O
+four	O
+distinct	O
+types	O
+of	O
+rumours	O
+:	O
+legendary	O
+rumours	O
+;	O
+aetiological	O
+narratives	O
+;	O
+proto	O
+-	O
+memorates	O
+;	O
+and	O
+bogies	O
+.	O
+
+5H10	O
+has	O
+potential	O
+for	O
+use	O
+in	O
+prevention	O
+and	O
+treatment	O
+of	O
+SARS	B-DISO
+if	O
+it	O
+reemerges	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+course	O
+of	O
+ICU	O
+patients	O
+with	O
+severe	O
+pandemic	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pneumonia	B-DISO
+:	O
+single	O
+center	O
+experience	O
+with	O
+proning	O
+and	O
+pressure	O
+release	O
+ventilation	O
+.	O
+
+A	O
+single	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+experience	O
+with	O
+management	O
+of	O
+laboratory	O
+-	O
+confirmed	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+ARDS	B-DISO
+with	O
+a	O
+combination	O
+of	O
+proning	O
+and	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+(	O
+APRV	O
+)	O
+is	O
+described	O
+.	O
+
+Following	O
+proning	O
+in	O
+patients	O
+on	O
+APRV	O
+,	O
+improvement	O
+of	O
+hypoxemia	O
+and	O
+hemodynamic	B-PROC
+status	O
+was	O
+achieved	O
+.	O
+
+TITLE	O
+:	O
+Ultrastructure	O
+of	O
+Felis	B-SPEC
+catus	I-SPEC
+whole	O
+fetus	B-ANAT
+(	O
+Fcwf	O
+-	O
+4	O
+)	O
+cell	B-COMP
+culture	O
+following	O
+infection	B-DISO
+with	O
+feline	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+consists	O
+of	O
+two	O
+biotypes	O
+based	O
+on	O
+their	O
+growth	B-PROC
+in	O
+cell	B-COMP
+culture	O
+and	O
+their	O
+antigenicity	O
+.	O
+
+The	O
+current	O
+study	O
+shows	O
+that	O
+novel	O
+DNA	O
+vaccines	O
+delivered	O
+by	O
+attenuated	O
+S	O
+.	O
+Typhimurium	O
+may	O
+be	O
+promising	O
+candidates	O
+for	O
+the	O
+prevention	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+).	O
+These	O
+vaccines	O
+are	O
+efficacious	O
+,	O
+easily	O
+produced	O
+economically	O
+,	O
+and	O
+able	O
+to	O
+be	O
+delivered	O
+orally	B-ANAT
+and	O
+nasally	O
+rather	O
+than	O
+injected	O
+.	O
+
+The	O
+discovery	O
+of	O
+a	O
+protein	B-CHED
+distinct	O
+from	O
+a	O
+viral	O
+RdRp	B-FUNC
+that	O
+regulates	O
+replication	O
+fidelity	O
+also	O
+raises	O
+the	O
+possibility	O
+that	O
+RNA	O
+genome	O
+replication	O
+fidelity	O
+may	O
+be	O
+adaptable	O
+to	O
+differing	O
+replication	O
+environments	O
+and	O
+selective	O
+pressures	O
+,	O
+rather	O
+than	O
+being	O
+a	O
+fixed	B-ANAT
+determinant	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+characterization	O
+of	O
+a	O
+neutralizing	O
+-	O
+epitope	B-CHED
+-	O
+containing	O
+spike	O
+protein	B-CHED
+fragment	O
+in	O
+turkey	O
+coronavirus	B-SPEC
+.	O
+
+It	O
+raises	O
+unanswered	O
+questions	O
+regarding	O
+when	O
+,	O
+if	O
+ever	O
+,	O
+careproviders	O
+should	O
+provide	O
+active	O
+euthanasia	O
+to	O
+patients	O
+who	O
+are	O
+incompetent	O
+,	O
+and	O
+when	O
+,	O
+if	O
+ever	O
+,	O
+careproviders	O
+should	O
+give	O
+their	O
+own	O
+food	O
+and	O
+water	B-CHED
+to	O
+patients	O
+or	O
+others	O
+who	O
+may	O
+otherwise	O
+soon	O
+die	O
+without	O
+them	O
+.	O
+
+IL	O
+-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+and	O
+IL	B-PRGE
+-	I-PRGE
+10	I-PRGE
+mRNA	B-PROC
+expression	B-PROC
+in	O
+rat	B-SPEC
+lungs	B-ANAT
+was	O
+measured	O
+quantitatively	O
+by	O
+the	O
+RT	O
+-	O
+PCR	O
+method	O
+and	O
+confirmed	O
+by	O
+morphometric	O
+studies	O
+of	O
+the	O
+lungs	B-ANAT
+.	O
+
+Compared	O
+with	O
+untreated	O
+rats	B-SPEC
+,	O
+the	O
+lungs	B-ANAT
+of	O
+rats	B-SPEC
+treated	O
+with	O
+DCQD	O
+showed	O
+significantly	O
+lower	O
+levels	O
+of	O
+proinflammatory	O
+cytokine	B-PRGE
+IL	I-PRGE
+-	I-PRGE
+1β	I-PRGE
+and	O
+IL	B-PRGE
+-	I-PRGE
+6	I-PRGE
+mRNA	B-CHED
+.	O
+
+DCQD	O
+has	O
+good	O
+prospects	O
+in	O
+the	O
+treatment	O
+for	O
+SAP	O
+because	O
+it	O
+did	O
+shorten	O
+the	O
+average	O
+time	O
+that	O
+patients	O
+suffered	B-DISO
+ARDS	B-DISO
+in	O
+the	O
+clinic	O
+.	O
+
+First	O
+,	O
+the	O
+effects	O
+of	O
+blocking	B-DISO
+the	O
+potential	O
+receptor	O
+(	O
+s	O
+)	O
+were	O
+studied	O
+for	O
+the	O
+processes	O
+of	O
+attachment	O
+and	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Mixed	O
+virus	B-SPEC
+infections	B-DISO
+can	O
+cause	O
+livestock	O
+losses	O
+that	O
+are	O
+more	O
+devastating	O
+than	O
+those	O
+caused	O
+by	O
+single	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+This	O
+speciation	O
+was	O
+later	O
+confirmed	O
+by	O
+16S	B-PRGE
+RNA	I-PRGE
+gene	B-DISO
+amplification	I-DISO
+.	O
+
+Multiple	O
+low	O
+micromolar	O
+inhibitors	B-CHED
+of	O
+the	O
+enzyme	O
+were	O
+identified	O
+through	O
+this	O
+search	O
+,	O
+one	O
+of	O
+which	O
+also	O
+showed	O
+activity	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+a	O
+whole	O
+cell	B-COMP
+CPE	O
+assay	O
+.	O
+
+Because	O
+it	O
+has	O
+been	O
+proposed	O
+that	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+is	O
+stimulated	O
+by	O
+alarm	O
+signals	O
+called	O
+damage	O
+-	O
+associated	O
+molecular	O
+patterns	O
+or	O
+alarmins	O
+,	O
+we	O
+investigated	O
+the	O
+participation	O
+of	O
+uric	B-CHED
+acid	I-CHED
+and	O
+high	B-PRGE
+-	I-PRGE
+mobility	I-PRGE
+group	I-PRGE
+box	I-PRGE
+protein	I-PRGE
+1	I-PRGE
+(	O
+HMGB1	B-PRGE
+)	O
+in	O
+the	O
+autoimmune	B-DISO
+response	I-DISO
+elicited	O
+by	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+ABSTRACT	O
+:	O
+Pneumonia	O
+is	O
+still	O
+one	O
+of	O
+the	O
+most	O
+frequent	O
+causes	O
+of	O
+death	B-PROC
+in	O
+the	O
+elderly	O
+.	O
+
+Serum	B-COMP
+sES	O
+levels	O
+were	O
+measured	O
+in	O
+27	O
+pneumonia	B-DISO
+patients	O
+,	O
+who	O
+were	O
+enrolled	O
+between	O
+April	O
+2006	O
+and	O
+September	O
+2007	O
+.	O
+
+CONCLUSIONS	O
+:	O
+sES	B-PRGE
+may	O
+be	O
+a	O
+useful	O
+biomarker	B-CHED
+for	O
+discriminating	O
+complicating	O
+ALI	O
+/	O
+cALI	O
+in	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+proteases	O
+in	O
+the	O
+release	B-PATH
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+from	O
+infected	O
+cells	B-COMP
+.	O
+
+However	O
+,	O
+the	O
+potential	O
+role	O
+of	O
+proteases	O
+in	O
+the	O
+infection	B-DISO
+process	O
+remains	O
+unclear	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+explore	O
+this	O
+,	O
+we	O
+used	O
+two	O
+different	O
+approaches	O
+:	O
+we	O
+infected	O
+either	O
+Vero	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+presence	O
+of	O
+trypsin	B-PRGE
+or	O
+Vero	B-ANAT
+cells	I-ANAT
+that	O
+constitutively	O
+express	O
+the	O
+membrane	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+protease	I-PRGE
+TMPRSS2	I-PRGE
+(	O
+Vero	O
+/	O
+TMPRSS2	O
+cells	B-COMP
+).	O
+
+When	O
+infected	O
+Vero	B-ANAT
+cells	I-ANAT
+were	O
+cultured	O
+for	O
+3	O
+days	O
+in	O
+the	O
+absence	O
+of	O
+trypsin	O
+but	O
+were	O
+then	O
+treated	O
+transiently	O
+with	O
+trypsin	B-PRGE
+,	O
+infectious	B-DISO
+viruses	B-SPEC
+were	O
+immediately	O
+released	O
+from	O
+infected	O
+cells	B-COMP
+.	O
+
+Thus	O
+,	O
+the	O
+present	O
+study	O
+indicates	O
+that	O
+proteases	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+release	B-PATH
+of	O
+PEDV	B-SPEC
+virions	B-COMP
+clustered	O
+on	O
+cells	B-COMP
+after	O
+replication	O
+occurs	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+splenic	B-ANAT
+cells	B-COMP
+during	O
+the	O
+early	O
+phase	O
+of	O
+infection	B-DISO
+with	O
+neuropathogenic	O
+mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+The	O
+population	O
+of	O
+viral	O
+antigen	B-CHED
+-	O
+positive	O
+splenic	B-ANAT
+cells	B-COMP
+was	O
+only	O
+slightly	O
+higher	O
+in	O
+cl	O
+-	O
+2	O
+infection	B-DISO
+than	O
+in	O
+srr7	O
+infection	B-DISO
+,	O
+but	O
+the	O
+cells	B-COMP
+showing	O
+viral	O
+production	O
+were	O
+present	O
+in	O
+numbers	O
+significantly	O
+higher	O
+in	O
+cl	O
+-	O
+2	O
+infection	B-DISO
+compared	O
+with	O
+srr7	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Long	O
+-	O
+term	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+with	O
+minimal	O
+ventilatory	O
+support	O
+:	O
+a	O
+new	O
+paradigm	O
+for	O
+severe	O
+ARDS	O
+?	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+patient	O
+with	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+and	O
+severe	O
+ARDS	B-DISO
+(	O
+PaO2	O
+/	O
+FiO2	O
+<	O
+100	O
+mmHg	O
+)	O
+who	O
+was	O
+initially	O
+managed	O
+with	O
+advanced	O
+up	O
+-	O
+to	O
+-	O
+date	O
+treatments	O
+(	O
+protective	O
+ventilation	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+ECMO	O
+)	O
+but	O
+failed	O
+to	O
+improve	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+current	O
+scientific	O
+evidence	O
+supports	O
+a	O
+link	O
+between	O
+VILI	O
+and	O
+the	O
+development	B-PROC
+of	O
+extrapulmonary	O
+organ	B-ANAT
+dysfunction	O
+,	O
+similar	O
+to	O
+how	O
+most	O
+severe	O
+cases	O
+of	O
+sepsis	B-DISO
+are	O
+clinically	O
+manifested	O
+.	O
+
+In	O
+addition	O
+,	O
+functional	O
+genomics	O
+approaches	O
+using	O
+a	O
+gene	O
+array	O
+methodology	O
+to	O
+measure	O
+lung	B-ANAT
+gene	B-PROC
+expression	I-PROC
+have	O
+identified	O
+differential	O
+patterns	O
+of	O
+gene	B-PROC
+expression	I-PROC
+in	O
+animal	B-SPEC
+models	O
+of	O
+VILI	O
+,	O
+similar	O
+to	O
+those	O
+gene	O
+pathways	B-PROC
+activated	O
+during	O
+experimental	O
+and	O
+clinical	B-DISO
+sepsis	I-DISO
+.	O
+
+In	O
+this	O
+line	O
+of	O
+thought	O
+,	O
+we	O
+hypothesize	O
+that	O
+injurious	O
+mechanical	O
+ventilation	O
+could	O
+be	O
+responsible	O
+for	O
+the	O
+perpetuation	O
+and	O
+worsening	O
+of	O
+sepsis	B-DISO
+in	O
+some	O
+patients	O
+and	O
+for	O
+the	O
+development	B-PROC
+of	O
+a	O
+sepsis	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+in	O
+others	O
+.	O
+
+One	O
+hundred	O
+and	O
+four	O
+patients	O
+(	O
+15	O
+-	O
+96	O
+years	O
+)	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+pH1N1	O
+infection	B-DISO
+seen	O
+at	O
+the	O
+Emergency	B-DISO
+Department	O
+from	O
+July	O
+to	O
+December	O
+2009	O
+who	O
+underwent	O
+chest	B-ANAT
+radiographs	O
+were	O
+studied	O
+.	O
+
+Initial	O
+chest	B-ANAT
+radiographs	O
+show	O
+acute	O
+abnormalities	O
+in	O
+all	O
+patients	O
+with	O
+severe	O
+disease	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+kidney	O
+transplantation	O
+from	O
+HBcAb	O
+-	O
+positive	O
+donors	O
+is	O
+safe	O
+with	O
+a	O
+low	O
+rate	O
+of	O
+HBV	B-DISO
+transmission	O
+.	O
+
+ABSTRACT	O
+:	O
+Outbreaks	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+,	O
+H1N1	O
+)	O
+and	O
+measles	B-PATH
+viruses	B-SPEC
+in	O
+recent	O
+years	O
+have	O
+raised	O
+serious	O
+concerns	O
+about	O
+the	O
+measures	O
+available	O
+to	O
+control	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+infectious	B-DISO
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+Starting	O
+from	O
+a	O
+Pplat	O
+/	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+of	O
+40	O
+/	O
+25	O
+,	O
+we	O
+sequentially	O
+increased	O
+airway	B-ANAT
+pressure	O
+in	O
+5	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+steps	O
+until	O
+a	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+of	O
+350	O
+mmHg	O
+or	O
+a	O
+Pplat	O
+/	O
+PEEP	B-CHED
+of	O
+60	O
+/	O
+40	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+was	O
+reached	O
+.	O
+
+The	O
+respiratory	B-PROC
+mechanics	I-PROC
+and	O
+hemodynamics	B-PROC
+were	O
+monitored	O
+at	O
+each	O
+phase	O
+and	O
+during	O
+the	O
+two	O
+-	O
+hour	O
+follow	O
+-	O
+up	O
+.	O
+
+Two	O
+hours	O
+after	O
+the	O
+RM	O
+,	O
+the	O
+PaO	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)/	I-PRGE
+FiO	I-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+was	O
+higher	O
+than	O
+at	O
+baseline	O
+(	O
+187	O
+±	O
+102	O
+versus	O
+339	O
+±	O
+136	O
+mmHg	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Both	O
+foals	O
+required	O
+whole	B-ANAT
+blood	I-ANAT
+transfusions	O
+,	O
+and	O
+were	O
+treated	O
+with	O
+the	O
+antimicrobial	B-CHED
+combination	O
+of	O
+rifampin	B-CHED
+and	O
+a	O
+macrolide	B-CHED
+(	O
+eg	O
+,	O
+clarithromycin	B-CHED
+,	O
+erythromycin	B-CHED
+,	O
+or	O
+azithromycin	B-CHED
+).	O
+
+Both	O
+foals	O
+survived	O
+,	O
+and	O
+required	O
+prolonged	O
+antimicrobial	B-CHED
+therapy	O
+.	O
+
+TITLE	O
+:	O
+Autoimmune	B-DISO
+hepatitis	I-DISO
+-	O
+like	O
+disease	O
+in	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+A59	O
+.	O
+
+However	O
+,	O
+the	O
+adjuvant	B-CHED
+did	O
+not	O
+expand	O
+the	O
+time	O
+of	O
+the	O
+symptoms	O
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+patients	O
+infected	O
+with	O
+highly	O
+pathogenic	O
+avian	O
+influenza	B-DISO
+A	I-DISO
+/	I-DISO
+H5N1	I-DISO
+virus	B-SPEC
+develop	O
+severe	O
+pneumonia	B-DISO
+resulting	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+with	O
+extrarespiratory	O
+disease	O
+as	O
+an	O
+uncommon	O
+complication	B-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+characterized	O
+lesions	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+of	O
+ferrets	B-SPEC
+(	O
+n	O
+=	O
+8	O
+)	O
+inoculated	O
+intranasally	O
+with	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+/	O
+Indonesia	O
+/	O
+5	O
+/	O
+2005	O
+(	O
+H5N1	B-DISO
+).	O
+
+These	O
+findings	O
+indicate	O
+that	O
+influenza	B-DISO
+A	I-DISO
+/	I-DISO
+H5N1	I-DISO
+virus	B-SPEC
+spread	O
+directly	O
+from	O
+nasal	B-ANAT
+cavity	I-ANAT
+to	O
+brain	B-ANAT
+,	O
+and	O
+that	O
+CNS	B-DISO
+lesions	I-DISO
+contributed	O
+more	O
+than	O
+pulmonary	B-ANAT
+lesions	O
+to	O
+the	O
+pathogenicity	O
+of	O
+influenza	B-DISO
+A	I-DISO
+/	I-DISO
+H5N1	I-DISO
+virus	B-DISO
+infection	I-DISO
+in	O
+ferrets	B-SPEC
+.	O
+
+Pathologically	O
+ARDS	B-DISO
+is	O
+characterised	O
+by	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+,	O
+alveolar	B-ANAT
+capillary	B-ANAT
+leakage	B-DISO
+,	O
+and	O
+protein	B-CHED
+rich	O
+pulmonary	B-DISO
+oedema	I-DISO
+leading	O
+to	O
+the	O
+clinical	O
+manifestation	O
+of	O
+poor	O
+lung	B-PROC
+compliance	I-PROC
+,	O
+severe	O
+hypoxaemia	O
+,	O
+and	O
+bilateral	O
+infiltrates	B-DISO
+on	O
+chest	B-ANAT
+radiograph	O
+.	O
+
+ABSTRACT	O
+:	O
+Delayed	O
+acute	O
+abdominal	O
+compartment	O
+syndrome	O
+(	O
+ACS	B-FUNC
+)	O
+due	O
+to	O
+retroperitoneal	B-ANAT
+bleeding	B-DISO
+is	O
+rare	O
+.	O
+
+Abdominal	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+was	O
+normal	O
+on	O
+admission	O
+.	O
+
+The	O
+abdomen	B-ANAT
+was	O
+temporarily	O
+closed	O
+using	O
+saline	O
+IV	O
+bags	O
+sandwiched	O
+between	O
+two	O
+layers	B-ANAT
+of	O
+Steri	B-SPEC
+-	O
+Drape	O
+.	O
+
+Life	O
+-	O
+threatening	O
+delayed	O
+retroperitoneal	B-ANAT
+bleeding	B-DISO
+may	O
+occur	O
+suddenly	O
+two	O
+weeks	O
+after	O
+trauma	O
+causing	O
+ACS	B-FUNC
+.	O
+
+TITLE	O
+:	O
+Host	B-COMP
+and	O
+viral	O
+ecology	O
+determine	O
+bat	B-ENZY
+rabies	B-DISO
+seasonality	O
+and	O
+maintenance	O
+.	O
+
+Patients	O
+with	O
+cardiopulmonary	B-ANAT
+comorbidities	O
+and	O
+acute	O
+GBS	B-DISO
+-	O
+like	O
+onset	O
+of	O
+CIDP	B-DISO
+may	O
+be	O
+at	O
+higher	O
+risk	O
+of	O
+ventilatory	B-DISO
+failure	I-DISO
+which	O
+typically	O
+responds	O
+to	O
+'	O
+standard	O
+'	O
+treatments	O
+of	O
+CIDP	B-DISO
+.	O
+
+TITLE	O
+:	O
+Viral	O
+-	O
+bacterial	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+in	O
+Australian	O
+Indigenous	O
+children	O
+with	O
+acute	B-DISO
+otitis	I-DISO
+media	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+366	O
+nasopharyngeal	B-ANAT
+swabs	O
+from	O
+114	O
+Indigenous	O
+children	O
+were	O
+retrospectively	O
+examined	O
+.	O
+
+Histopathological	O
+diagnosis	O
+of	O
+FHV	O
+-	O
+1	O
+dermatitis	B-DISO
+is	O
+based	O
+on	O
+the	O
+detection	O
+of	O
+the	O
+intranuclear	B-COMP
+inclusion	I-COMP
+bodies	O
+.	O
+
+However	O
+,	O
+the	O
+epidemiological	O
+data	O
+regarding	O
+the	O
+MS	O
+occurrence	O
+rate	O
+following	O
+herpes	B-DISO
+zoster	I-DISO
+are	O
+still	O
+scanty	O
+.	O
+
+It	O
+should	O
+be	O
+remembered	O
+that	O
+close	O
+collaboration	O
+is	O
+required	O
+with	O
+the	O
+haematology	O
+department	O
+,	O
+particularly	O
+in	O
+those	O
+patients	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+or	O
+stroke	B-DISO
+,	O
+so	O
+that	O
+prompt	O
+arrangements	O
+can	O
+be	O
+made	O
+if	O
+exchange	O
+transfusion	O
+is	O
+required	O
+.	O
+
+ABSTRACT	O
+:	O
+Enteral	O
+nutrition	B-PROC
+(	O
+EN	O
+)	O
+with	O
+eicosapentaenoic	B-CHED
+acid	I-CHED
+(	O
+EPA	B-CHED
+)/	O
+γ	O
+-	O
+linolenic	B-CHED
+acid	I-CHED
+(	O
+GLA	B-CHED
+)	O
+is	O
+recommended	O
+for	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+severe	O
+lung	B-ANAT
+injury	O
+.	O
+
+Patients	O
+were	O
+continuously	O
+tube	O
+-	O
+fed	O
+at	O
+a	O
+minimum	O
+of	O
+75	O
+%	O
+of	O
+basal	O
+energy	B-PROC
+expenditure	I-PROC
+×	O
+1	O
+.	O
+3	O
+.	O
+
+The	O
+ITT	O
+analysis	O
+demonstrated	O
+that	O
+patients	O
+in	O
+the	O
+study	O
+group	O
+developed	O
+cardiovascular	B-ANAT
+failure	O
+(	O
+36	O
+.	O
+2	O
+%	O
+versus	O
+21	O
+%,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+0381	O
+)	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+39	O
+.	O
+6	O
+%	O
+versus	O
+24	O
+.	O
+6	O
+%,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+0362	O
+)	O
+less	O
+often	O
+than	O
+the	O
+control	O
+group	O
+.	O
+
+Sometimes	O
+,	O
+the	O
+pericardial	O
+effusion	O
+can	O
+be	O
+easily	O
+related	O
+to	O
+a	O
+known	O
+underlying	O
+disease	O
+,	O
+such	O
+as	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+,	O
+cardiac	B-ANAT
+surgery	O
+,	O
+end	B-DISO
+-	I-DISO
+stage	I-DISO
+renal	I-DISO
+disease	I-DISO
+or	O
+widespread	O
+metastatic	B-DISO
+neoplasm	I-DISO
+.	O
+
+Patients	O
+with	O
+chronic	O
+massive	O
+idiopathic	O
+pericardial	B-DISO
+effusion	I-DISO
+should	O
+also	O
+be	O
+submitted	O
+to	O
+pericardial	B-ANAT
+drainage	B-ANAT
+because	O
+of	O
+the	O
+risk	O
+of	O
+developing	O
+unexpected	O
+tamponade	O
+.	O
+
+Purulent	B-DISO
+pericarditis	I-DISO
+should	O
+be	O
+drained	O
+surgically	O
+,	O
+usually	O
+through	O
+subxiphoid	O
+pericardiotomy	O
+.	O
+
+Massive	O
+chronic	O
+idiopathic	O
+pericardial	B-DISO
+effusions	I-DISO
+do	O
+not	O
+respond	O
+to	O
+medical	O
+treatment	O
+and	O
+tend	O
+to	O
+recur	O
+after	O
+pericardiocentesis	O
+,	O
+so	O
+wide	O
+anterior	O
+pericardiectomy	O
+is	O
+finally	O
+necessary	O
+in	O
+many	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+-	O
+bound	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+spike	O
+protein	B-CHED
+cleaved	B-ANAT
+by	O
+trypsin	B-PRGE
+induces	O
+membrane	B-ANAT
+fusion	I-PROC
+.	O
+
+The	O
+present	O
+study	O
+describes	O
+the	O
+mode	O
+of	O
+action	O
+of	O
+trypsin	B-PRGE
+in	O
+enhancing	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+during	O
+different	O
+stage	O
+of	O
+the	O
+virus	B-SPEC
+life	O
+cycle	O
+.	O
+
+These	O
+findings	O
+strongly	O
+suggest	O
+that	O
+the	O
+PEDV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+may	O
+undergo	O
+a	O
+conformational	B-PROC
+change	I-PROC
+after	O
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+cleavage	B-PROC
+by	O
+exogenous	O
+trypsin	B-PRGE
+,	O
+which	O
+induces	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+have	O
+evolved	O
+diverse	O
+mechanisms	O
+to	O
+recognize	O
+different	O
+receptors	O
+for	O
+their	O
+cross	O
+-	O
+species	O
+transmission	O
+and	O
+host	B-COMP
+-	O
+range	O
+expansion	O
+.	O
+
+Critical	O
+contacts	O
+at	O
+the	O
+interface	O
+have	O
+been	O
+confirmed	O
+by	O
+mutagenesis	B-PROC
+,	O
+providing	O
+a	O
+structural	O
+basis	O
+for	O
+viral	O
+and	O
+host	B-COMP
+specificities	O
+of	O
+coronavirus	O
+/	O
+CEACAM1	O
+interactions	O
+.	O
+
+Median	O
+length	O
+of	O
+hospitalization	O
+was	O
+shorter	O
+for	O
+hemoglobin	B-DISO
+SC	I-DISO
+episodes	O
+when	O
+compared	O
+to	O
+hemoglobin	B-DISO
+SS	I-DISO
+episodes	O
+(	O
+3	O
+.	O
+0	O
+vs	O
+.	O
+5	O
+.	O
+0	O
+days	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Asthma	B-PATH
+and	O
+wheezing	B-DISO
+may	O
+represent	O
+more	O
+significant	O
+risk	O
+factors	O
+for	O
+the	O
+development	B-PROC
+of	O
+ACS	B-FUNC
+in	O
+children	O
+with	O
+hemoglobin	B-DISO
+SC	I-DISO
+disease	I-DISO
+.	O
+
+Dyspnoea	B-DISO
+,	O
+pulmonary	B-ANAT
+,	O
+and	O
+systemic	O
+congestion	B-DISO
+often	O
+characterize	O
+AHFS	O
+due	O
+to	O
+acutely	O
+elevated	O
+intracardiac	B-ANAT
+filling	O
+pressures	O
+and	O
+fluid	B-DISO
+overload	I-DISO
+.	O
+
+Although	O
+these	O
+agents	O
+are	O
+indicated	O
+in	O
+patients	O
+with	O
+chronic	O
+,	O
+severe	O
+heart	B-DISO
+failure	I-DISO
+with	O
+reduced	O
+ejection	O
+fraction	O
+(	O
+HF	O
+/	O
+REF	O
+)	O
+and	O
+in	O
+patients	O
+with	O
+HF	O
+/	O
+REF	O
+post	O
+-	O
+myocardial	B-DISO
+infarction	I-DISO
+(	O
+MI	O
+),	O
+they	O
+have	O
+not	O
+been	O
+systematically	O
+studied	O
+in	O
+patients	O
+with	O
+AHFS	O
+.	O
+
+TITLE	O
+:	O
+Reversible	O
+cerebral	B-DISO
+vasoconstriction	B-PROC
+syndrome	B-DISO
+with	O
+increased	B-DISO
+intracranial	I-DISO
+pressure	I-DISO
+,	O
+probably	O
+related	O
+to	O
+altitude	O
+changes	O
+and	O
+windy	O
+winter	O
+travelling	O
+.	O
+
+Lumbar	B-ANAT
+puncture	O
+revealed	O
+the	O
+opening	O
+pressure	O
+of	O
+240	O
+mmH2O	O
+but	O
+normal	O
+CSF	O
+profiles	O
+.	O
+
+Blood	B-ANAT
+tests	O
+,	O
+including	O
+complete	O
+blood	B-ANAT
+count	O
+,	O
+protein	B-PRGE
+C	I-PRGE
+,	O
+protein	B-PRGE
+S	I-PRGE
+,	O
+antithrombin	B-PRGE
+III	I-PRGE
+,	O
+high	B-PRGE
+-	I-PRGE
+sensitivity	I-PRGE
+C	I-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+immunologic	O
+and	O
+antibody	B-COMP
+profiles	O
+were	O
+normal	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+contribution	O
+of	O
+viruses	O
+to	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+disease	O
+in	O
+sub	O
+-	O
+Saharan	O
+Africa	O
+where	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+may	O
+exacerbate	O
+respiratory	B-DISO
+infections	I-DISO
+is	O
+not	O
+well	O
+defined	O
+.	O
+
+A	O
+higher	O
+HIV	B-DISO
+sero	O
+-	O
+prevalence	O
+was	O
+noticed	O
+in	O
+patients	O
+with	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+although	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+were	O
+not	O
+associated	O
+with	O
+more	O
+severe	O
+disease	O
+.	O
+
+RSV	B-SPEC
+,	O
+hPMV	O
+,	O
+PIV	O
+-	O
+3	O
+,	O
+and	O
+influenza	B-SPEC
+viruses	I-SPEC
+had	O
+defined	O
+seasons	O
+while	O
+rhinovirus	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+occurred	O
+year	O
+round	O
+in	O
+this	O
+temporal	B-ANAT
+region	I-ANAT
+of	O
+sub	O
+-	O
+Saharan	O
+Africa	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+66	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+hepatitis	B-SPEC
+C	I-SPEC
+related	O
+liver	B-DISO
+cirrhosis	I-DISO
+presented	O
+to	O
+our	O
+hospital	O
+for	O
+dyspnoea	B-DISO
+and	O
+cyanosis	B-DISO
+.	O
+
+To	O
+study	O
+gene	O
+7	O
+function	O
+,	O
+a	O
+recombinant	O
+TGEV	B-SPEC
+virus	B-SPEC
+lacking	O
+gene	O
+7	O
+was	O
+engineered	O
+(	O
+rTGEV	O
+-	O
+Δ7	O
+).	O
+
+These	O
+results	O
+suggested	O
+that	O
+the	O
+removal	O
+of	O
+gene	O
+7	O
+promoted	O
+an	O
+intensified	O
+dsRNA	B-CHED
+-	O
+activated	O
+host	B-COMP
+antiviral	B-PROC
+response	I-PROC
+.	O
+
+We	O
+postulated	O
+that	O
+TGEV	B-PRGE
+protein	B-CHED
+7	I-PRGE
+may	O
+counteract	O
+host	B-COMP
+antiviral	B-PROC
+response	I-PROC
+by	O
+its	O
+association	O
+with	O
+PP1c	B-PRGE
+.	O
+
+The	O
+cells	B-COMP
+grew	O
+well	O
+and	O
+showed	O
+susceptibility	O
+to	O
+a	O
+wide	O
+variety	O
+of	O
+viruses	B-SPEC
+derived	O
+from	O
+ovine	O
+,	O
+bovine	B-SPEC
+,	O
+and	O
+porcine	B-SPEC
+species	B-SPEC
+,	O
+including	O
+orf	B-SPEC
+virus	I-SPEC
+,	O
+maedi	B-DISO
+visna	I-DISO
+virus	O
+,	O
+bovine	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+,	O
+bovine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+3	I-SPEC
+,	O
+bovine	B-PRGE
+viral	I-PRGE
+diarrhea	I-PRGE
+viruses	B-SPEC
+1	I-PRGE
+and	I-PRGE
+2	I-PRGE
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+,	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+bovine	B-SPEC
+enterovirus	I-SPEC
+,	O
+suid	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+,	O
+and	O
+porcine	B-SPEC
+enterovirus	B-SPEC
+.	O
+
+While	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+derived	O
+from	O
+the	O
+nephropathogenic	O
+IBV	B-SPEC
+strain	O
+B1648	O
+also	O
+hardly	O
+displayed	O
+binding	B-FUNC
+to	O
+respiratory	B-ANAT
+tract	I-ANAT
+cells	B-COMP
+,	O
+distinct	O
+binding	B-FUNC
+to	O
+kidney	B-ANAT
+cells	B-COMP
+was	O
+observed	O
+,	O
+but	O
+only	O
+after	O
+the	O
+removal	O
+of	O
+sialic	B-CHED
+acid	I-CHED
+from	O
+S1	O
+.	O
+
+A	O
+'	O
+low	O
+-	O
+grade	O
+'	O
+inflammatory	O
+stimulus	O
+in	O
+utero	B-ANAT
+may	O
+'	O
+prime	O
+'	O
+the	O
+fetal	B-ANAT
+lung	I-ANAT
+for	O
+accelerated	O
+maturation	B-PROC
+of	O
+the	O
+surfactant	B-CHED
+system	O
+,	O
+especially	O
+in	O
+conjunction	O
+with	O
+prenatal	O
+steroids	B-CHED
+,	O
+and	O
+may	O
+protect	O
+the	O
+preterm	O
+infant	O
+from	O
+developing	O
+moderate	O
+to	O
+severe	O
+RDS	O
+.	O
+
+Whenever	O
+surfactant	B-CHED
+inactivation	B-DISO
+is	O
+suspected	O
+,	O
+higher	O
+or	O
+repetitive	O
+doses	O
+of	O
+natural	O
+surfactant	B-CHED
+may	O
+help	O
+to	O
+overcome	O
+surfactant	B-CHED
+inactivation	B-DISO
+and	O
+to	O
+restore	O
+lung	B-PROC
+function	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Avian	O
+influenza	O
+H5N1	B-DISO
+and	O
+pandemic	O
+(	O
+H1N1	O
+)	O
+2009	O
+viruses	B-SPEC
+are	O
+known	O
+to	O
+induce	O
+viral	B-DISO
+pneumonia	I-DISO
+and	O
+subsequent	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+with	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+DAD	O
+).	O
+
+DAD	B-PRGE
+with	O
+alveolar	B-ANAT
+collapse	B-DISO
+was	O
+observed	O
+in	O
+all	O
+dead	B-PROC
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Beyond	O
+the	O
+black	O
+box	O
+:	O
+drug	O
+-	O
+and	O
+device	O
+-	O
+associated	O
+hypersensitivity	B-DISO
+events	O
+.	O
+
+Adverse	O
+event	O
+reports	O
+identified	O
+three	O
+health	O
+care	O
+workers	O
+who	O
+developed	O
+nevirapine	B-CHED
+-	O
+associated	O
+Stevens	B-DISO
+-	I-DISO
+Johnson	I-DISO
+syndrome	I-DISO
+following	O
+occupational	O
+exposure	O
+to	O
+HIV	B-DISO
+-	O
+infected	O
+blood	B-ANAT
+or	O
+blood	B-ANAT
+products	O
+;	O
+four	O
+persons	O
+with	O
+localized	O
+hypersensitivity	B-DISO
+and	O
+fatal	O
+cardiac	O
+events	O
+associated	O
+with	O
+rapamycin	B-CHED
+-	O
+or	O
+paclitaxel	B-CHED
+-	O
+coated	O
+coronary	B-ANAT
+artery	I-ANAT
+stent	O
+placements	O
+;	O
+and	O
+six	O
+persons	O
+with	O
+breast	B-DISO
+cancer	B-SPEC
+who	O
+developed	O
+severe	O
+or	O
+fatal	O
+anaphylaxis	B-DISO
+after	O
+receiving	O
+adjuvant	B-CHED
+chemotherapy	O
+with	O
+Cremophor	O
+-	O
+EL	O
+containing	O
+paclitaxel	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+is	O
+a	O
+key	O
+structural	O
+protein	B-CHED
+of	O
+coronaviruses	O
+including	O
+,	O
+the	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+Rabbit	B-SPEC
+polyclonal	O
+antiserum	O
+was	O
+generated	O
+using	O
+recombinant	O
+S	O
+-	O
+AD	O
+(	O
+rS	O
+-	O
+AD	O
+)	O
+protein	B-CHED
+.	O
+
+In	O
+contrast	O
+to	O
+prior	O
+studies	O
+showing	O
+no	O
+activity	O
+with	O
+bacterially	O
+produced	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+results	O
+indicated	O
+that	O
+polyclonal	O
+serum	B-COMP
+recognized	O
+TGEV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+and	O
+reduced	O
+infection	B-DISO
+by	O
+100	O
+%.	O
+
+This	O
+qRT	O
+-	O
+PCR	O
+assay	O
+was	O
+used	O
+to	O
+screen	O
+nucleic	B-CHED
+acids	I-CHED
+extracted	O
+from	O
+498	O
+ticks	B-SPEC
+collected	O
+in	O
+the	O
+Republic	O
+of	O
+Chad	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+in	O
+the	O
+management	O
+of	O
+early	O
+smoke	O
+inhalation	B-PROC
+injury	O
+has	O
+not	O
+been	O
+studied	O
+.	O
+
+Six	O
+uninjured	O
+pigs	B-SPEC
+received	O
+conventional	O
+mechanical	O
+ventilation	O
+for	O
+48	O
+hrs	B-DISO
+and	O
+served	O
+as	O
+time	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+TNF	O
+-	O
+α	O
+and	O
+its	O
+two	O
+receptors	O
+(	O
+TNFR1	B-PRGE
+and	I-PRGE
+2	I-PRGE
+)	O
+are	O
+known	O
+to	O
+stimulate	O
+dendritic	B-ANAT
+cell	B-COMP
+(	O
+DC	O
+)	O
+maturation	B-PROC
+and	O
+T	B-ANAT
+cell	I-ANAT
+response	O
+.	O
+
+Correspondingly	O
+,	O
+virus	B-SPEC
+-	O
+specific	O
+CD8	B-PRGE
+T	B-ANAT
+cell	I-ANAT
+response	O
+was	O
+dramatically	O
+diminished	O
+in	O
+TNFR1	B-PRGE
+(-/-)	O
+mice	B-SPEC
+.	O
+
+Rainfall	O
+simulations	O
+on	O
+stream	O
+banks	O
+resulted	O
+in	O
+greater	O
+(	O
+<	O
+0	O
+.	O
+10	O
+)	O
+proportions	O
+of	O
+applied	O
+precipitation	B-PROC
+and	O
+amounts	O
+of	O
+sediment	O
+and	O
+P	O
+transported	O
+in	O
+runoff	O
+from	O
+bare	O
+sites	O
+than	O
+from	O
+vegetated	O
+sites	O
+across	O
+grazing	O
+treatments	O
+.	O
+
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+was	O
+tolerated	O
+well	O
+;	O
+no	O
+adverse	B-DISO
+effects	I-DISO
+or	O
+severe	O
+hyperinflation	B-DISO
+and	O
+hemodynamic	B-PROC
+compromise	O
+were	O
+observed	O
+.	O
+
+RESULTS	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+was	O
+tolerated	O
+well	O
+;	O
+no	O
+adverse	B-DISO
+effects	I-DISO
+or	O
+severe	O
+hyperinflation	B-DISO
+and	O
+hemodynamic	B-PROC
+compromise	O
+were	O
+observed	O
+.	O
+
+TITLE	O
+:	O
+Gene	O
+N	O
+proximal	O
+and	O
+distal	O
+RNA	O
+motifs	O
+regulate	O
+coronavirus	B-PRGE
+nucleocapsid	B-COMP
+mRNA	B-PROC
+transcription	B-PROC
+.	O
+
+The	O
+extension	O
+of	O
+complementarity	O
+between	O
+these	O
+two	O
+sequences	O
+increased	O
+N	B-PRGE
+gene	I-PRGE
+transcription	O
+.	O
+
+According	O
+to	O
+the	O
+proposed	O
+working	O
+model	O
+for	O
+N	B-PRGE
+gene	I-PRGE
+transcriptional	B-PROC
+activation	I-PROC
+,	O
+the	O
+long	O
+-	O
+distance	O
+RNA	O
+-	O
+RNA	O
+interaction	O
+relocates	O
+the	O
+distant	O
+active	O
+domain	O
+in	O
+close	O
+proximity	O
+with	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+TRS	B-DISO
+,	O
+which	O
+probably	O
+increases	O
+the	O
+frequency	O
+of	O
+template	O
+switching	O
+during	O
+the	O
+synthesis	B-PROC
+of	O
+negative	O
+RNA	O
+.	O
+
+ABSTRACT	O
+:	O
+Endothelial	B-ANAT
+cells	B-COMP
+(	O
+ECs	O
+),	O
+forming	O
+a	O
+semi	O
+-	O
+permeable	O
+barrier	O
+between	O
+the	O
+interior	O
+space	O
+of	O
+blood	B-ANAT
+vessels	I-ANAT
+and	O
+underlying	O
+tissues	B-ANAT
+,	O
+control	O
+such	O
+diverse	O
+processes	O
+as	O
+vascular	B-ANAT
+tone	O
+,	O
+homeostasis	B-PROC
+,	O
+adhesion	B-DISO
+of	O
+platelets	B-ANAT
+,	O
+and	O
+leukocytes	B-ANAT
+to	O
+the	O
+vascular	B-ANAT
+wall	O
+and	O
+permeability	O
+of	O
+vascular	B-ANAT
+wall	O
+for	O
+cells	B-COMP
+and	O
+fluids	B-ANAT
+.	O
+
+It	O
+is	O
+now	O
+well	O
+accepted	O
+that	O
+extracellular	B-COMP
+purines	B-CHED
+and	O
+pyrimidines	B-CHED
+are	O
+promising	O
+and	O
+physiologically	O
+relevant	O
+barrier	O
+-	O
+protective	B-CHED
+agents	I-CHED
+and	O
+their	O
+effects	O
+are	O
+mediated	O
+by	O
+interaction	O
+with	O
+cell	O
+surface	O
+P2Y	B-PRGE
+receptors	I-PRGE
+which	O
+belong	O
+to	O
+the	O
+superfamily	B-SPEC
+of	O
+G	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+-	I-PRGE
+coupled	I-PRGE
+receptors	I-PRGE
+.	O
+
+The	O
+treatment	O
+proposed	O
+for	O
+leptospirotic	O
+pneumonitis	B-DISO
+includes	O
+just	O
+care	O
+for	O
+patients	O
+in	O
+critical	O
+condition	B-DISO
+.	O
+
+This	O
+is	O
+a	O
+randomized	O
+double	O
+-	O
+blind	B-DISO
+clinical	O
+trial	O
+to	O
+test	O
+the	O
+efficacy	O
+of	O
+pulse	B-PROC
+treatment	O
+with	O
+methylprednisolone	B-CHED
+in	O
+patients	O
+with	O
+leptospirotic	O
+pneumonitis	B-DISO
+,	O
+compared	O
+with	O
+a	O
+placebo	O
+.	O
+
+The	O
+secondary	O
+end	O
+-	O
+points	O
+are	O
+:	O
+evolution	B-PROC
+of	O
+lung	B-DISO
+disease	I-DISO
+;	O
+the	O
+occurrence	O
+of	O
+nosocomial	O
+respiratory	B-DISO
+infection	I-DISO
+;	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+;	O
+duration	O
+of	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+stay	O
+;	O
+duration	O
+of	O
+hospital	O
+stay	O
+;	O
+occurrence	O
+of	O
+other	O
+infection	B-DISO
+-	O
+related	O
+complications	O
+;	O
+other	B-DISO
+respiratory	I-DISO
+complications	I-DISO
+;	O
+and	O
+adverse	B-DISO
+effects	I-DISO
+of	O
+methylprednisolone	B-CHED
+.	O
+
+This	O
+strategy	O
+allowed	O
+fistula	B-DISO
+healing	B-PROC
+in	O
+3	O
+patients	O
+.	O
+
+If	O
+correctly	O
+timed	O
+,	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+can	O
+provide	O
+a	O
+therapeutic	O
+bridge	O
+to	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+and	O
+allow	O
+bronchial	B-DISO
+fistula	I-DISO
+healing	B-PROC
+in	O
+case	O
+of	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Viral	O
+genetic	O
+determinants	O
+specifically	O
+associated	O
+with	O
+FIPV	O
+pathogenesis	B-DISO
+have	O
+not	O
+yet	O
+been	O
+discovered	O
+.	O
+
+Epidemiologic	O
+data	O
+suggests	O
+that	O
+the	O
+genetic	O
+background	O
+of	O
+the	O
+cat	B-SPEC
+contributes	O
+to	O
+the	O
+manifestation	O
+of	O
+FIP	B-DISO
+.	O
+
+This	O
+study	O
+was	O
+performed	O
+to	O
+evaluate	O
+the	O
+incidence	O
+and	O
+outcomes	O
+of	O
+RVD	B-PROC
+in	O
+septic	B-DISO
+shock	I-DISO
+patients	O
+.	O
+
+It	O
+is	O
+unknown	O
+whether	O
+the	O
+human	B-SPEC
+immune	B-ANAT
+system	I-ANAT
+could	O
+tolerate	O
+invasion	B-DISO
+with	O
+a	O
+plant	B-SPEC
+virus	B-SPEC
+.	O
+
+We	O
+observed	O
+suspected	O
+TMV	B-SPEC
+virions	B-COMP
+in	O
+HeLa	B-ANAT
+cells	I-ANAT
+by	O
+TEM	B-COMP
+(	O
+transmission	O
+electron	O
+microscopy	O
+).	O
+
+pECLA	O
+was	O
+accompanied	O
+by	O
+a	O
+significant	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+increase	O
+in	O
+the	O
+PaO2	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+P	O
+/	O
+F	O
+)	O
+ratio	O
+from	O
+100	O
+.	O
+0	O
+(	O
+28	O
+.	O
+9	O
+)	O
+(	O
+pre	O
+-	O
+pECLA	O
+)	O
+to	O
+191	O
+.	O
+1	O
+(	O
+114	O
+.	O
+3	O
+)	O
+mmHg	O
+after	O
+7	O
+days	O
+of	O
+treatment	O
+.	O
+
+Major	O
+complications	O
+were	O
+two	O
+inadvertent	O
+decannulations	O
+in	O
+the	O
+first	O
+two	O
+patients	O
+treated	O
+;	O
+there	O
+was	O
+one	O
+minor	O
+bleeding	B-DISO
+event	O
+in	O
+a	O
+patient	O
+seen	O
+subsequently	O
+.	O
+
+TITLE	O
+:	O
+The	O
+preventive	O
+role	O
+of	O
+higher	O
+PEEP	B-CHED
+in	O
+treating	O
+severely	O
+hypoxemic	O
+ARDS	B-DISO
+.	O
+
+WNv	B-PRGE
+antigen	B-CHED
+was	O
+detected	O
+in	O
+brain	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+gonads	B-ANAT
+,	O
+intestine	B-ANAT
+,	O
+lung	B-ANAT
+,	O
+and	O
+pancreas	B-ANAT
+.	O
+
+The	O
+spleen	B-ANAT
+was	O
+found	O
+to	O
+be	O
+positive	O
+in	O
+all	O
+infected	O
+crows	B-SPEC
+,	O
+followed	O
+by	O
+kidney	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+and	O
+duodenum	B-ANAT
+(	O
+95	O
+%	O
+each	O
+).	O
+
+CONCLUSIONS	O
+:	O
+More	O
+than	O
+one	O
+tissue	B-ANAT
+sample	I-ANAT
+is	O
+suggested	O
+to	O
+screen	O
+WNv	B-DISO
+infection	B-DISO
+using	O
+IHC	O
+technique	O
+.	O
+
+ABSTRACT	O
+:	O
+Antibody	B-COMP
+-	O
+enhanced	O
+replication	O
+(	O
+AER	B-COMP
+)	O
+of	O
+dengue	B-DISO
+type	O
+-	O
+2	O
+virus	B-SPEC
+(	O
+DENV	O
+-	O
+2	O
+)	O
+strains	O
+and	O
+production	O
+of	O
+antibody	B-COMP
+-	O
+enhanced	O
+disease	O
+(	O
+AED	B-CHED
+)	O
+was	O
+tested	O
+in	O
+out	O
+-	O
+bred	O
+mice	B-SPEC
+.	O
+
+This	O
+DENV	B-PRGE
+-	I-PRGE
+2	I-PRGE
+AER	I-PRGE
+/	I-PRGE
+AED	B-CHED
+was	O
+blocked	O
+by	O
+high	O
+concentrations	O
+of	O
+only	O
+the	O
+NG	B-PRGE
+-	I-PRGE
+C	I-PRGE
+NS1	I-PRGE
+glycoprotein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Lithium	O
+carbonate	O
+is	O
+a	O
+widely	O
+administered	O
+antimanic	B-CHED
+drug	I-CHED
+used	O
+for	O
+the	O
+treatment	O
+of	O
+bipolar	O
+disorder	B-DISO
+,	I-DISO
+schizoaffective	I-DISO
+disorder	O
+,	O
+and	O
+depression	B-DISO
+.	O
+
+Her	O
+chest	B-ANAT
+x	O
+-	O
+rays	B-SPEC
+showed	O
+new	O
+bilateral	O
+pulmonary	O
+edema	O
+,	O
+the	O
+computed	O
+tomography	O
+scan	O
+showed	O
+extensive	O
+alveolar	B-ANAT
+consolidation	O
+and	O
+V	O
+/	O
+Q	O
+scan	O
+of	O
+low	O
+probability	O
+for	O
+pulmonary	B-DISO
+embolism	I-DISO
+.	O
+
+The	O
+patients	O
+were	O
+treated	O
+with	O
+saline	O
+hydration	O
+(	O
+50	O
+%)	O
+or	O
+hemodialysis	O
+(	O
+50	O
+%),	O
+indicating	O
+that	O
+hemodialysis	O
+may	O
+be	O
+a	O
+permissive	O
+factor	O
+in	O
+lithium	B-CHED
+-	O
+associated	O
+ARDS	B-DISO
+development	B-PROC
+rather	O
+than	O
+a	O
+required	O
+component	O
+.	O
+
+We	O
+assessed	O
+non	O
+-	O
+RCTs	O
+for	O
+potential	O
+confounders	O
+and	O
+classified	O
+them	O
+as	O
+low	O
+,	O
+medium	O
+and	O
+high	O
+risk	O
+of	O
+bias	B-SPEC
+.	O
+
+The	O
+highest	O
+quality	O
+cluster	O
+-	O
+RCTs	O
+suggest	O
+respiratory	O
+virus	B-SPEC
+spread	O
+can	O
+be	O
+prevented	O
+by	O
+hygienic	O
+measures	O
+,	O
+such	O
+as	O
+handwashing	O
+,	O
+especially	O
+around	O
+younger	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Super	O
+-	O
+spreaders	O
+in	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+In	O
+addition	O
+to	O
+retroviruses	O
+,	O
+many	O
+structural	O
+proteins	B-CHED
+of	O
+unrelated	O
+viruses	B-SPEC
+,	O
+including	O
+influenza	B-DISO
+M1	O
+,	O
+NEP	O
+and	O
+NP	O
+proteins	B-CHED
+,	O
+38	O
+Borna	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+N	O
+and	O
+P	O
+proteins28	O
+,	O
+56	O
+and	O
+coronavirus	B-SPEC
+N	O
+protein	B-CHED
+,	O
+23	O
+,	O
+57	O
+undergo	O
+nuclear	O
+localization	B-PROC
+and	O
+bind	B-FUNC
+viral	O
+RNAs	O
+to	O
+form	O
+viral	O
+ribonuclear	O
+protein	B-CHED
+(	O
+RNP	B-COMP
+)	O
+complexes	O
+that	O
+are	O
+exported	O
+from	O
+the	O
+nucleus	B-COMP
+for	O
+packaging	O
+into	O
+virus	B-COMP
+particles	I-COMP
+.	O
+
+We	O
+propose	O
+that	O
+association	O
+of	O
+the	O
+viral	O
+RNA	O
+induces	O
+a	O
+conformational	B-PROC
+change	I-PROC
+in	O
+Gag	B-PRGE
+that	O
+reveals	O
+its	O
+nuclear	B-PROC
+export	I-PROC
+signal	O
+(	O
+NES	B-SPEC
+)	O
+and	O
+prepares	O
+that	O
+complex	O
+for	O
+its	O
+journey	O
+to	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+for	O
+budding	B-PATH
+.	O
+
+break	O
+-	O
+down	O
+in	O
+infection	B-DISO
+control	O
+procedures	O
+3	O
+.)	O
+
+Staffing	O
+demands	O
+and	O
+loss	O
+of	O
+income	O
+were	O
+noted	O
+as	O
+pressures	O
+to	O
+attend	O
+work	O
+when	O
+unwell	B-DISO
+.	O
+
+The	O
+reason	O
+for	O
+this	O
+emerging	O
+debate	O
+is	O
+twofold	O
+:	O
+the	O
+recent	O
+occurrence	O
+of	O
+pandemic	O
+viruses	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+H1N1	O
+,	O
+and	O
+the	O
+emergence	O
+of	O
+highly	O
+resistant	O
+strains	O
+of	O
+infectious	B-DISO
+pathogens	O
+such	O
+as	O
+multi	O
+and	O
+extensively	B-DISO
+drug	I-DISO
+-	I-DISO
+resistant	I-DISO
+tuberculosis	I-DISO
+(	O
+TB	O
+).	O
+
+A	O
+retrospective	O
+study	O
+on	O
+62	O
+severe	O
+and	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+was	O
+conducted	O
+in	O
+Shanghai	O
+Public	O
+Health	O
+Clinical	O
+Center	O
+.	O
+
+Severe	O
+illness	O
+from	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+in	O
+Shanghai	O
+occurred	O
+among	O
+young	O
+individuals	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+case	O
+of	O
+novel	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+and	O
+Evans	B-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+description	O
+of	O
+a	O
+third	O
+syndrome	B-DISO
+associated	O
+with	O
+a	O
+same	O
+TSFM	O
+mutation	O
+gives	O
+support	O
+to	O
+the	O
+broad	O
+clinical	O
+and	O
+genetic	O
+heterogeneity	O
+of	O
+mitochondrial	B-PROC
+translation	B-PROC
+deficiencies	O
+in	O
+human	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+interstitial	B-ANAT
+pneumonia	I-DISO
+(	O
+AIP	B-DISO
+)	O
+encompasses	O
+a	O
+spectrum	O
+of	O
+pulmonary	B-DISO
+disorders	I-DISO
+characterized	O
+by	O
+involvement	O
+of	O
+the	O
+lung	B-ANAT
+interstitium	B-ANAT
+and	O
+distal	O
+airways	O
+(	O
+bronchioles	B-ANAT
+and	O
+alveoli	B-ANAT
+).	O
+
+TITLE	O
+:	O
+Recombinational	O
+histories	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+and	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+induction	O
+of	O
+antigen	B-PRGE
+specific	I-PRGE
+memory	B-PROC
+CD8	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+vivo	O
+is	O
+very	O
+important	O
+to	O
+new	O
+vaccines	O
+against	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+aimed	O
+to	O
+evaluate	O
+the	O
+immune	B-PROC
+responses	I-PROC
+of	O
+peptide	B-CHED
+-	O
+specific	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+induced	O
+by	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0201	I-PRGE
+restricted	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+S	O
+epitopes	O
+plus	O
+CpG	O
+oligodeoxynucleotide	O
+(	O
+CpG	O
+ODN	O
+),	O
+PolyI	O
+:	O
+C	O
+and	O
+R848	O
+as	O
+adjuvants	B-CHED
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+peptide	B-CHED
+-	O
+specific	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+(+)	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+distributed	O
+throughout	O
+the	O
+lymphoid	O
+and	O
+non	O
+-	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Foxp3	O
+(+)	O
+CD4	B-PRGE
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+(	O
+T	B-ANAT
+reg	I-ANAT
+cells	B-COMP
+)	O
+are	O
+important	O
+in	O
+limiting	O
+immunopathology	B-DISO
+in	O
+infections	B-DISO
+.	O
+
+Using	O
+MHC	B-PRGE
+class	B-SPEC
+II	I-PRGE
+/	I-PRGE
+peptide	B-CHED
+tetramers	I-PRGE
+and	O
+intracellular	B-COMP
+cytokine	O
+staining	O
+,	O
+we	O
+identify	O
+T	B-ANAT
+reg	I-ANAT
+cells	B-COMP
+recognizing	O
+two	O
+virus	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+CD4	I-PRGE
+T	B-ANAT
+cell	I-ANAT
+epitopes	I-PRGE
+in	O
+the	O
+coronavirus	B-SPEC
+-	O
+infected	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+as	O
+well	O
+as	O
+naive	O
+T	B-ANAT
+cell	I-ANAT
+precursor	O
+pools	O
+.	O
+
+Identification	O
+of	O
+T	B-PRGE
+reg	I-PRGE
+cell	B-COMP
+target	O
+epitopes	O
+by	O
+cytokine	B-PROC
+production	I-PROC
+is	O
+also	O
+applicable	O
+in	O
+autoimmune	B-DISO
+disease	I-DISO
+because	O
+myelin	B-PRGE
+oligodendrocyte	B-ANAT
+glycoprotein	B-CHED
+-	I-PRGE
+specific	I-PRGE
+Foxp3	I-PRGE
+(+)	I-PRGE
+T	B-ANAT
+reg	I-ANAT
+cells	B-COMP
+express	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+at	O
+the	O
+peak	O
+of	O
+disease	O
+in	O
+mice	B-SPEC
+with	O
+experimental	O
+autoimmune	B-DISO
+encephalomyelitis	B-DISO
+.	O
+
+Autopsy	O
+findings	O
+failed	O
+to	O
+show	O
+influenza	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+or	O
+lupus	B-DISO
+pneumonitis	I-DISO
+.	O
+
+Electron	O
+microscopy	O
+showed	O
+viral	B-COMP
+particles	I-COMP
+consistent	O
+with	O
+CoV	O
+HKU1	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+both	O
+at	O
+autopsy	O
+and	O
+from	O
+a	O
+previous	O
+biopsy	O
+.	O
+
+Fluorescence	O
+double	O
+-	O
+staining	O
+revealed	O
+that	O
+FGL2	B-PRGE
+and	O
+PD	B-PRGE
+-	I-PRGE
+1	I-PRGE
+were	O
+not	O
+co	O
+-	O
+expressed	B-PROC
+on	O
+the	O
+same	O
+cells	B-COMP
+,	O
+while	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+demonstrated	O
+that	O
+higher	O
+levels	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+mRNA	I-PRGE
+transcription	B-PROC
+occurred	O
+in	O
+PD	O
+-	O
+1	O
+-	O
+deficient	O
+mice	B-SPEC
+in	O
+response	O
+to	O
+MHV	B-SPEC
+-	O
+3	O
+infection	B-DISO
+.	O
+
+Conversely	O
+,	O
+in	O
+vivo	O
+blockade	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+led	O
+to	O
+efficient	O
+inhibition	B-PROC
+of	O
+FGL2	B-PRGE
+expression	B-PROC
+,	O
+greatly	O
+attenuated	O
+the	O
+development	B-PROC
+of	O
+tissue	B-ANAT
+lesions	O
+,	O
+and	O
+ultimately	O
+reduced	O
+mortality	O
+.	O
+
+In	O
+addition	O
+,	O
+mutation	O
+of	O
+MHV	B-SPEC
+nonstructural	B-PRGE
+protein	I-PRGE
+2	I-PRGE
+(	O
+ns2	B-DISO
+)	O
+abrogates	O
+the	O
+ability	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+replicate	O
+in	O
+the	O
+liver	B-ANAT
+and	O
+induce	O
+hepatitis	B-DISO
+but	O
+does	O
+not	O
+affect	O
+replication	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+).	O
+
+ABSTRACT	O
+:	O
+Low	O
+micromolar	O
+,	O
+non	O
+-	O
+cytotoxic	O
+concentrations	O
+of	O
+cyclosporin	O
+A	O
+(	O
+CsA	B-DISO
+)	O
+strongly	O
+affected	O
+the	O
+replication	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+in	O
+cell	B-COMP
+culture	O
+,	O
+as	O
+was	O
+evident	O
+from	O
+the	O
+strong	O
+inhibition	B-PROC
+of	O
+GFP	B-PRGE
+reporter	I-PRGE
+gene	I-PRGE
+expression	O
+and	O
+a	O
+reduction	O
+of	O
+up	O
+to	O
+4	O
+logs	O
+in	O
+progeny	O
+titres	O
+.	O
+
+Upon	O
+high	O
+-	O
+multiplicity	O
+infection	B-DISO
+,	O
+CsA	B-DISO
+treatment	O
+rendered	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+and	O
+protein	B-PROC
+synthesis	I-PROC
+almost	O
+undetectable	O
+,	O
+suggesting	O
+an	O
+early	O
+block	O
+in	O
+replication	O
+.	O
+
+We	O
+wished	O
+to	O
+determine	O
+the	O
+potential	O
+for	O
+pulmonary	B-ANAT
+overexpression	B-PROC
+of	O
+the	O
+extracellular	B-COMP
+isoform	O
+of	O
+superoxide	B-PRGE
+dismutase	I-PRGE
+(	O
+EC	B-PRGE
+-	I-PRGE
+SOD	I-PRGE
+)	O
+to	O
+reduce	O
+the	O
+severity	O
+of	O
+endotoxin	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Animals	B-SPEC
+were	O
+randomly	O
+allocated	O
+to	O
+undergo	O
+intratracheal	O
+instillation	O
+of	O
+(	O
+1	O
+)	O
+surfactant	B-CHED
+alone	O
+(	O
+vehicle	O
+);	O
+(	O
+2	O
+)	O
+adeno	B-SPEC
+-	I-SPEC
+associated	I-SPEC
+virus	I-SPEC
+(	O
+AAV	B-SPEC
+)	O
+vectors	O
+containing	O
+a	O
+null	O
+transgene	O
+(	O
+AAV	B-SPEC
+-	O
+null	O
+);	O
+and	O
+(	O
+3	O
+)	O
+adeno	B-SPEC
+-	I-SPEC
+associated	I-SPEC
+virus	I-SPEC
+vectors	O
+containing	O
+the	O
+EC	B-PRGE
+-	I-PRGE
+SOD	I-PRGE
+transgene	I-PRGE
+(	O
+AAV	B-PRGE
+-	I-PRGE
+EC	I-PRGE
+-	I-PRGE
+SOD	B-FUNC
+)	O
+and	O
+endotoxin	O
+was	O
+subsequently	O
+administered	O
+intratracheally	O
+.	O
+
+Two	O
+additional	O
+groups	O
+were	O
+randomized	O
+to	O
+receive	O
+(	O
+1	O
+)	O
+vehicle	O
+or	O
+(	O
+2	O
+)	O
+AAV	O
+-	O
+EC	O
+-	O
+SOD	B-FUNC
+,	O
+and	O
+to	O
+undergo	O
+sham	O
+(	O
+vehicle	O
+)	O
+injury	O
+.	O
+
+Finally	O
+,	O
+mention	O
+is	O
+made	O
+to	O
+the	O
+recent	O
+discovery	O
+of	O
+ACE2	B-PRGE
+as	O
+a	O
+receptor	O
+for	O
+the	O
+SARS	B-DISO
+Corona	B-CHED
+Virus	B-SPEC
+.	O
+
+The	O
+detection	O
+of	O
+previously	O
+known	O
+viruses	B-SPEC
+has	O
+also	O
+improved	O
+.	O
+
+The	O
+new	O
+viruses	B-SPEC
+cause	O
+respiratory	B-DISO
+symptoms	I-DISO
+like	O
+the	O
+common	B-DISO
+cold	I-DISO
+,	O
+cough	B-DISO
+,	O
+bronchitis	B-DISO
+,	O
+bronchiolitis	B-DISO
+,	O
+exacerbations	O
+of	O
+asthma	B-PATH
+and	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+and	O
+pneumonia	B-DISO
+.	O
+
+Fifty	O
+-	O
+six	O
+patients	O
+had	O
+PCR	O
+-	O
+confirmed	O
+P	B-SPEC
+.	I-SPEC
+knowlesi	I-SPEC
+monoinfection	O
+and	O
+clinical	O
+records	O
+available	O
+for	O
+review	O
+.	O
+
+Patients	O
+with	O
+uncomplicated	O
+disease	O
+received	O
+chloroquine	B-CHED
+,	O
+quinine	B-CHED
+,	O
+or	O
+artemether	B-CHED
+-	O
+lumefantrine	B-CHED
+,	O
+and	O
+those	O
+with	O
+severe	O
+disease	O
+received	O
+intravenous	O
+quinine	B-CHED
+or	O
+artesunate	B-CHED
+.	O
+
+P	B-SPEC
+.	I-SPEC
+knowlesi	I-SPEC
+is	O
+a	O
+major	O
+cause	O
+of	O
+severe	O
+and	O
+fatal	O
+malaria	B-PATH
+in	O
+Sabah	O
+.	O
+
+TITLE	O
+:	O
+Chimeric	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+S	O
+glycoprotein	B-CHED
+and	O
+influenza	B-DISO
+matrix	O
+1	O
+efficiently	O
+form	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+that	O
+protect	O
+mice	B-SPEC
+against	O
+challenge	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+the	O
+cause	O
+of	O
+the	O
+global	O
+pandemic	O
+in	O
+2003	O
+that	O
+infected	O
+over	O
+8000	O
+people	O
+in	O
+8	O
+months	O
+.	O
+
+Vaccines	O
+against	O
+SARS	B-DISO
+are	O
+still	O
+not	O
+available	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+an	O
+80	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+who	O
+presented	O
+with	O
+fever	B-PROC
+,	O
+lung	B-ANAT
+infiltrates	B-DISO
+,	O
+peripheral	B-ANAT
+blood	I-ANAT
+eosinophilia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+patient	O
+had	O
+a	O
+past	O
+medical	O
+history	O
+of	O
+AEP	O
+induced	O
+by	O
+sertraline	B-CHED
+and	O
+a	O
+recent	O
+medical	O
+history	O
+of	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+on	O
+the	O
+context	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+during	O
+treatment	O
+with	O
+venlafaxine	B-CHED
+.	O
+
+We	O
+included	O
+190	O
+consecutive	O
+adults	O
+treated	O
+with	O
+high	O
+-	O
+frequency	O
+oscillation	O
+and	O
+retrospectively	O
+abstracted	O
+data	O
+on	O
+patient	O
+demographics	O
+,	O
+gas	B-ENZY
+exchange	O
+,	O
+hemodynamics	B-PROC
+,	O
+settings	O
+during	O
+conventional	O
+ventilation	O
+and	O
+high	O
+-	O
+frequency	O
+oscillation	O
+,	O
+adjunctive	O
+therapies	O
+,	O
+and	O
+outcomes	O
+.	O
+
+Most	O
+patients	O
+treated	O
+with	O
+high	O
+-	O
+frequency	O
+oscillation	O
+have	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+severe	O
+hypoxemia	O
+that	O
+modestly	O
+improves	O
+2	O
+hrs	B-DISO
+after	O
+high	O
+-	O
+frequency	O
+oscillation	O
+application	O
+.	O
+
+To	O
+this	O
+end	O
+,	O
+the	O
+various	O
+efficacious	O
+anti	O
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+therapies	O
+recently	O
+published	O
+from	O
+2007	O
+to	O
+2010	O
+are	O
+reviewed	O
+in	O
+this	O
+article	O
+.	O
+
+Interestingly	O
+,	O
+although	O
+some	O
+of	O
+these	O
+viruses	B-SPEC
+are	O
+related	O
+to	O
+other	O
+European	O
+BatCoV	O
+,	O
+or	O
+to	O
+Asian	O
+CoV	O
+,	O
+some	O
+of	O
+the	O
+viruses	B-SPEC
+found	O
+in	O
+Spain	O
+cluster	O
+in	O
+new	O
+groups	O
+of	O
+α	O
+and	O
+β	O
+CoV	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+advances	O
+in	O
+critical	O
+care	O
+facilities	O
+and	O
+ventilation	O
+therapies	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+rates	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+:	O
+25	O
+(	O
+50	O
+%),	O
+27	O
+(	O
+54	O
+%),	O
+36	O
+(	O
+72	O
+%)	O
+of	O
+50	O
+sera	B-COMP
+were	O
+indentified	O
+as	O
+anti	O
+-	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+antibody	B-COMP
+positive	O
+when	O
+the	O
+antigen	B-CHED
+was	O
+from	O
+Nf	O
+,	O
+Np	O
+and	O
+Cp	O
+,	O
+respectively	O
+.	O
+
+Our	O
+study	O
+provides	O
+the	O
+foundation	O
+for	O
+development	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+serological	O
+detection	O
+reagents	B-CHED
+and	O
+an	O
+experimental	O
+tool	O
+for	O
+immunological	O
+research	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Anti	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+antibodies	B-COMP
+trigger	O
+infection	B-DISO
+of	O
+human	B-SPEC
+immune	O
+cells	B-COMP
+via	O
+a	O
+pH	O
+-	O
+and	O
+cysteine	B-PRGE
+protease	I-PRGE
+-	O
+independent	O
+FcγR	O
+pathway	B-PROC
+.	O
+
+Vaccination	O
+is	O
+a	O
+major	O
+strategy	O
+for	O
+containing	O
+resurgence	O
+of	O
+SARS	B-DISO
+in	O
+humans	B-SPEC
+,	O
+and	O
+a	O
+number	O
+of	O
+vaccine	O
+candidates	O
+have	O
+been	O
+tested	O
+in	O
+experimental	O
+animal	B-SPEC
+models	O
+.	O
+
+We	O
+previously	O
+reported	O
+that	O
+antibody	B-COMP
+elicited	O
+by	O
+a	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+candidate	O
+based	O
+on	O
+recombinant	O
+full	O
+-	O
+length	O
+Spike	O
+-	O
+protein	B-CHED
+trimers	O
+potentiated	O
+infection	B-DISO
+of	O
+human	B-SPEC
+B	O
+cell	B-ANAT
+lines	I-ANAT
+despite	O
+eliciting	O
+in	O
+vivo	O
+a	O
+neutralizing	O
+and	O
+protective	O
+immune	B-PROC
+response	I-PROC
+in	O
+rodents	B-SPEC
+.	O
+
+Healthcare	O
+workers	O
+'	O
+willingness	O
+to	O
+work	O
+is	O
+a	O
+concern	O
+worldwide	O
+since	O
+SARS	B-DISO
+;	O
+Concerns	O
+related	O
+to	O
+work	O
+in	O
+the	O
+isolation	O
+wards	O
+among	O
+healthcare	O
+workers	O
+'	O
+who	O
+continue	O
+to	O
+work	O
+during	O
+the	O
+novel	O
+H1N1	O
+pandemic	O
+is	O
+unknown	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+conductance	O
+levels	O
+remained	O
+relatively	O
+unchanged	O
+when	O
+indoor	O
+air	B-CHED
+or	O
+clean	O
+air	B-CHED
+samples	O
+were	O
+delivered	O
+.	O
+
+Quantitative	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+qPCR	O
+)	O
+tests	O
+revealed	O
+that	O
+higher	O
+virus	B-SPEC
+concentrations	O
+in	O
+the	O
+air	B-CHED
+samples	O
+generally	O
+corresponded	O
+to	O
+higher	O
+conductance	O
+levels	O
+in	O
+the	O
+SiNW	O
+devices	O
+.	O
+
+Although	O
+the	O
+drivers	O
+for	O
+virus	B-SPEC
+emergence	O
+remain	O
+poorly	O
+understood	O
+,	O
+the	O
+rate	O
+of	O
+discovery	O
+of	O
+new	O
+viruses	B-SPEC
+is	O
+accelerating	O
+.	O
+
+Only	O
+6	O
+(	O
+14	O
+.	O
+3	O
+%)	O
+of	O
+the	O
+schools	O
+with	O
+influenza	B-DISO
+specific	O
+Web	B-DISO
+sites	O
+had	O
+information	O
+for	O
+parents	O
+,	O
+with	O
+23	O
+(	O
+54	O
+.	O
+8	O
+%)	O
+providing	O
+information	O
+specifically	O
+for	O
+faculty	O
+and	O
+staff	O
+,	O
+and	O
+24	O
+(	O
+57	O
+.	O
+1	O
+%)	O
+providing	O
+information	O
+specifically	O
+to	O
+students	O
+.	O
+
+Coronavirus	B-SPEC
+HKU1	O
+were	O
+detected	O
+in	O
+12	O
+patients	O
+(	O
+1	O
+.	O
+03	O
+%)	O
+out	O
+of	O
+the	O
+1165	O
+children	O
+.	O
+
+The	O
+most	O
+common	O
+clinical	O
+diagnosis	O
+was	O
+bronchopneumonia	B-DISO
+(	O
+83	O
+.	O
+33	O
+%).	O
+
+Similarity	O
+of	O
+coronavirus	B-SPEC
+HKU1	O
+with	O
+those	O
+published	O
+in	O
+the	O
+GenBank	O
+at	O
+nucleotide	B-CHED
+levels	O
+was	O
+98	O
+.	O
+18	O
+%	O
+-	O
+100	O
+%.	O
+
+A	O
+cytokine	O
+-	O
+mediated	O
+inflammatory	B-DISO
+response	I-DISO
+has	O
+been	O
+well	O
+documented	O
+in	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Serum	B-COMP
+and	O
+bronchoalveolar	O
+lavage	O
+samples	O
+were	O
+obtained	O
+from	O
+three	O
+mechanically	O
+ventilated	O
+patients	O
+diagnosed	O
+with	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+pneumonia	B-DISO
+by	O
+bronchoscopic	O
+bronchoalveolar	O
+lavage	O
+.	O
+
+RESULTS	O
+:	O
+High	O
+levels	O
+of	O
+C	B-PRGE
+Reactive	I-PRGE
+Protein	I-PRGE
+,	O
+Procalcitonin	O
+below	O
+1	O
+ng	O
+/	O
+ml	O
+and	O
+absence	O
+of	O
+leukocytosis	B-DISO
+were	O
+common	O
+findings	O
+in	O
+all	O
+patients	O
+.	O
+
+We	O
+have	O
+previously	O
+identified	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+and	O
+residues	O
+important	O
+for	O
+RBD	O
+-	O
+hACE2	O
+association	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+3	O
+'-	O
+untranslated	O
+region	O
+(	O
+UTR	O
+)	O
+of	O
+the	O
+group	O
+2	O
+coronavirus	B-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+genome	O
+contains	O
+a	O
+predicted	O
+bulged	O
+stem	B-ANAT
+-	O
+loop	O
+(	O
+designated	O
+P0ab	O
+),	O
+a	O
+conserved	O
+cis	B-DISO
+-	O
+acting	O
+pseudoknot	O
+(	O
+PK	O
+),	O
+and	O
+a	O
+more	O
+distal	O
+stem	B-ANAT
+-	O
+loop	O
+(	O
+designated	O
+P2	O
+).	O
+
+Degradation	O
+through	O
+autophagy	B-PROC
+can	O
+provide	O
+an	O
+innate	O
+defence	O
+against	O
+virus	B-DISO
+infection	I-DISO
+,	O
+or	O
+conversely	O
+autophagosomes	O
+can	O
+promote	O
+infection	B-DISO
+by	O
+facilitating	O
+assembly	O
+of	O
+replicase	B-PRGE
+proteins	I-PRGE
+.	O
+
+We	O
+demonstrate	O
+that	O
+the	O
+avian	B-SPEC
+coronavirus	I-SPEC
+,	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+activates	O
+autophagy	B-PROC
+.	O
+
+The	O
+vesicles	B-COMP
+recruited	O
+double	O
+FYVE	B-PRGE
+-	I-PRGE
+domain	I-PRGE
+containing	I-PRGE
+protein	I-PRGE
+(	O
+DFCP	O
+)	O
+indicating	O
+localised	O
+concentration	O
+of	O
+phosphatidylinositol	B-CHED
+3	O
+phosphate	B-CHED
+,	O
+and	O
+therefore	O
+shared	O
+many	O
+features	O
+with	O
+omegasomes	O
+formed	O
+from	O
+the	O
+ER	O
+in	O
+response	B-PROC
+to	I-PROC
+starvation	I-PROC
+.	O
+
+The	O
+coronavirus	B-SPEC
+nsp6	O
+proteins	B-CHED
+activated	O
+omegasome	O
+and	O
+autophagosome	B-PROC
+formation	I-PROC
+independently	O
+of	O
+starvation	O
+,	O
+but	O
+activation	O
+did	O
+not	O
+involve	O
+direct	O
+inhibition	B-PROC
+of	O
+mTOR	B-PRGE
+signalling	B-PROC
+,	O
+activation	O
+of	O
+sirtuin1	O
+or	O
+induction	O
+of	O
+ER	O
+stress	O
+.	O
+
+During	O
+neurotropic	O
+coronavirus	B-SPEC
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+induced	O
+encephalomyelitis	B-DISO
+,	O
+MMP9	B-PRGE
+activity	O
+is	O
+restricted	O
+to	O
+neutrophils	B-ANAT
+.	O
+
+Depletion	O
+of	O
+neutrophils	B-ANAT
+reduced	O
+CNS	B-CHED
+accumulation	O
+of	O
+monocytes	B-ANAT
+and	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+albeit	O
+without	O
+affecting	O
+overall	O
+pathogenesis	B-DISO
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+this	O
+assay	O
+offers	O
+a	O
+reliable	O
+method	O
+to	O
+detect	O
+HCoV	O
+-	O
+OC43	O
+infection	B-DISO
+and	O
+may	O
+be	O
+a	O
+useful	O
+tool	O
+in	O
+coronavirus	B-SPEC
+seroepidemiological	O
+studies	O
+.	O
+
+Despite	O
+their	O
+similarities	O
+,	O
+these	O
+proteins	B-CHED
+are	O
+involved	O
+in	O
+distinct	O
+RNA	O
+-	O
+processing	O
+pathways	B-PROC
+in	O
+different	O
+organisms	O
+.	O
+
+There	O
+was	O
+one	O
+plastic	B-DISO
+bronchitis	I-DISO
+patient	O
+.	O
+
+However	O
+,	O
+there	O
+was	O
+no	O
+difference	O
+in	O
+pain	O
+or	O
+ACS	B-FUNC
+rate	O
+,	O
+lung	B-PROC
+function	I-PROC
+,	O
+or	O
+risk	O
+of	O
+death	B-PROC
+between	O
+adults	O
+with	O
+and	O
+without	O
+a	O
+doctor	O
+-	O
+diagnosis	O
+of	O
+asthma	B-PATH
+.	O
+
+TITLE	O
+:	O
+Engineering	O
+T	B-ANAT
+cells	I-ANAT
+specific	O
+for	O
+a	O
+dominant	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+CD8	B-PRGE
+T	B-ANAT
+cell	I-ANAT
+epitope	B-CHED
+.	O
+
+To	O
+reconstitute	O
+such	O
+a	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cell	B-COMP
+response	O
+,	O
+we	O
+isolated	O
+the	O
+alpha	B-PRGE
+and	I-PRGE
+beta	I-PRGE
+T	I-PRGE
+cell	I-PRGE
+receptors	I-PRGE
+of	O
+the	O
+HLA	B-PRGE
+-	I-PRGE
+B	I-PRGE
+*	I-PRGE
+40	I-PRGE
+:	O
+01	O
+-	O
+restricted	O
+SARS	B-DISO
+-	O
+specific	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+New	O
+modalities	O
+such	O
+as	O
+brain	B-ANAT
+magnetic	O
+resonance	O
+imaging	O
+(	O
+MRI	O
+)	O
+and	O
+continuous	O
+electroencephalography	O
+are	O
+being	O
+evaluated	O
+.	O
+
+In	O
+the	O
+most	O
+severe	O
+case	O
+,	O
+extensive	O
+embolization	O
+was	O
+associated	O
+pulmonary	B-ANAT
+damage	O
+consistent	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Although	O
+clinical	O
+criteria	O
+diagnostic	O
+of	O
+FES	O
+were	O
+not	O
+investigated	O
+at	O
+the	O
+time	O
+of	O
+death	B-PROC
+,	O
+this	O
+severe	O
+case	O
+may	O
+represent	O
+the	O
+fulminant	O
+form	O
+of	O
+FES	O
+,	O
+which	O
+occurs	O
+within	O
+12	O
+h	O
+after	O
+trauma	O
+.	O
+
+FE	O
+and	O
+FES	O
+represent	O
+important	O
+research	O
+confounders	O
+and	O
+FES	O
+should	O
+be	O
+considered	O
+as	O
+a	O
+differential	O
+diagnosis	O
+for	O
+clinical	O
+complications	O
+subsequent	O
+to	O
+skeletal	B-ANAT
+trauma	O
+.	O
+
+The	O
+seawater	O
+aspiration	B-DISO
+group	O
+also	O
+presented	O
+with	O
+severe	O
+pulmonary	B-DISO
+edema	I-DISO
+which	O
+was	O
+paralleled	O
+with	O
+over	O
+expressed	B-PROC
+AQP1	B-PRGE
+and	O
+AQP5	B-PRGE
+.	O
+
+In	O
+conclusion	O
+,	O
+E2	O
+treatment	O
+could	O
+effectively	O
+attenuate	O
+seawater	O
+aspiration	B-DISO
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+rats	B-SPEC
+by	O
+the	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+AQP1	B-PRGE
+and	O
+AQP5	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Inhibitors	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+entry	O
+--	O
+identification	O
+using	O
+an	O
+internally	O
+-	O
+controlled	O
+dual	O
+envelope	B-COMP
+pseudovirion	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+the	O
+management	O
+of	O
+a	O
+38	O
+-	O
+yr	O
+-	O
+old	O
+patient	O
+with	O
+known	O
+Marfan	O
+syndrome	O
+who	O
+presented	O
+with	O
+acute	O
+Stanford	O
+type	O
+A	O
+dissection	O
+of	O
+the	O
+aorta	B-ANAT
+in	O
+the	O
+34	O
+(	O
+th	O
+)	O
+week	O
+of	O
+pregnancy	O
+.	O
+
+Hospitals	O
+must	O
+establish	O
+systems	O
+to	O
+assure	O
+timely	O
+assessment	O
+,	O
+multidisciplinary	O
+care	O
+,	O
+and	O
+possibly	O
+a	O
+plan	B-DISO
+for	O
+transfer	O
+to	O
+a	O
+higher	O
+level	O
+of	O
+care	O
+to	O
+provide	O
+highest	O
+quality	O
+care	O
+to	O
+the	O
+perinatal	O
+patient	O
+presenting	O
+with	O
+a	O
+severe	O
+respiratory	O
+condition	B-DISO
+to	O
+promote	O
+optimal	O
+outcomes	O
+for	O
+the	O
+woman	O
+and	O
+the	O
+fetus	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+alternative	O
+treatments	O
+have	O
+been	O
+proposed	O
+to	O
+decrease	O
+mortality	O
+of	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+).	O
+
+Though	O
+randomized	O
+trials	O
+failed	O
+to	O
+prove	O
+survival	O
+benefits	O
+with	O
+the	O
+use	O
+of	O
+prone	O
+positioning	O
+or	O
+HFOV	O
+,	O
+recent	O
+meta	B-SPEC
+-	O
+analyses	O
+have	O
+shown	O
+,	O
+for	O
+both	O
+treatments	O
+,	O
+a	O
+decrease	O
+in	O
+mortality	O
+in	O
+the	O
+subpopulation	O
+of	O
+more	O
+severe	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Searches	O
+of	O
+MEDLINE	O
+(	O
+1975	O
+-	O
+May	O
+2011	O
+),	O
+EMBASE	O
+(	O
+1980	O
+-	O
+May	O
+2011	O
+),	O
+and	O
+Cumulative	O
+Index	O
+to	O
+Nursing	B-PROC
+and	O
+Allied	O
+Health	O
+Literature	O
+(	O
+1981	O
+-	O
+May	O
+2011	O
+)	O
+were	O
+conducted	O
+to	O
+identify	O
+observational	O
+and	O
+interventional	O
+studies	O
+evaluating	O
+the	O
+efficacy	O
+or	O
+safety	O
+of	O
+NMBAs	O
+for	O
+management	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+status	B-DISO
+asthmaticus	I-DISO
+,	O
+elevated	B-DISO
+intracranial	I-DISO
+pressure	I-DISO
+(	O
+ICP	B-DISO
+),	O
+and	O
+therapeutic	O
+hypothermia	O
+.	O
+
+Recent	O
+data	O
+on	O
+ARDS	B-DISO
+demonstrated	O
+that	O
+early	O
+application	O
+of	O
+NMBAs	O
+improved	O
+adjusted	O
+90	O
+-	O
+day	O
+survival	O
+for	O
+patients	O
+with	O
+severe	O
+lung	B-ANAT
+injury	O
+.	O
+
+New	O
+data	O
+are	O
+available	O
+regarding	O
+the	O
+use	O
+of	O
+these	O
+agents	O
+for	O
+treatment	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+and	O
+status	B-DISO
+asthmaticus	I-DISO
+,	O
+management	O
+of	O
+elevated	O
+ICP	B-DISO
+,	O
+and	O
+provision	O
+of	O
+therapeutic	O
+hypothermia	O
+after	O
+cardiac	B-DISO
+arrest	I-DISO
+.	O
+
+The	O
+study	O
+of	O
+infectious	O
+disease	O
+has	O
+depended	O
+on	O
+strategies	O
+for	O
+integrating	O
+patterns	O
+of	O
+observed	O
+disease	O
+incidence	O
+with	O
+mechanistic	O
+process	O
+models	O
+since	O
+John	O
+Snow	O
+first	O
+mapped	O
+cholera	B-DISO
+cases	O
+around	O
+a	O
+London	O
+water	B-CHED
+pump	O
+in	O
+1854	O
+.	O
+
+Still	O
+,	O
+zoonotic	O
+and	O
+vector	O
+-	O
+borne	O
+diseases	O
+increasingly	O
+affect	O
+human	B-SPEC
+populations	O
+,	O
+and	O
+methods	O
+used	O
+to	O
+successfully	O
+characterize	O
+directly	O
+transmitted	B-DISO
+diseases	O
+are	O
+often	O
+insufficient	O
+.	O
+
+We	O
+present	O
+a	O
+conceptual	O
+framework	O
+for	O
+data	O
+-	O
+model	O
+fusion	O
+in	O
+infectious	B-DISO
+disease	I-DISO
+research	O
+that	O
+addresses	O
+these	O
+fundamental	O
+challenges	O
+using	O
+a	O
+hierarchical	O
+state	O
+-	O
+space	O
+structure	O
+to	O
+(	O
+1	O
+)	O
+integrate	O
+multiple	O
+data	O
+sources	O
+and	O
+spatial	O
+scales	B-ANAT
+to	O
+inform	O
+latent	O
+parameters	O
+,	O
+(	O
+2	O
+)	O
+partition	O
+uncertainty	O
+in	O
+process	O
+and	O
+observation	O
+models	O
+,	O
+and	O
+(	O
+3	O
+)	O
+explicitly	O
+build	O
+upon	O
+existing	O
+ecological	O
+and	O
+epidemiological	O
+understanding	O
+.	O
+
+Given	O
+the	O
+constraints	O
+inherent	O
+in	O
+the	O
+study	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+and	O
+the	O
+urgent	O
+need	O
+for	O
+progress	O
+,	O
+fusion	O
+of	O
+data	O
+and	O
+expertise	O
+via	O
+this	O
+type	O
+of	O
+conceptual	O
+framework	O
+should	O
+prove	O
+an	O
+indispensable	O
+tool	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+prevalence	O
+of	O
+respiratory	O
+pathogens	O
+in	O
+diseased	O
+veal	O
+calves	O
+was	O
+determined	O
+in	O
+24	O
+respiratory	B-DISO
+disease	I-DISO
+outbreaks	O
+in	O
+15	O
+herds	O
+in	O
+Belgium	O
+.	O
+
+Vaccination	O
+programmes	O
+using	O
+different	O
+combinations	O
+of	O
+heterologous	O
+live	O
+vaccines	O
+at	O
+day	O
+0	O
+or	O
+at	O
+days	O
+0	O
+and	O
+14	O
+induced	O
+a	O
+reasonable	O
+to	O
+high	O
+level	O
+of	O
+protection	O
+in	O
+the	O
+trachea	B-DISO
+,	O
+kidney	B-ANAT
+,	O
+oviduct	B-ANAT
+and	O
+air	B-ANAT
+sacs	B-DISO
+against	O
+challenge	O
+with	O
+the	O
+D388	O
+strain	O
+at	O
+28	O
+days	O
+of	O
+age	O
+.	O
+
+However	O
+,	O
+for	O
+very	O
+early	O
+protection	O
+,	O
+maternally	O
+-	O
+derived	O
+D388	O
+-	O
+neutralizing	O
+antibodies	B-COMP
+were	O
+shown	O
+to	O
+be	O
+very	O
+important	O
+.	O
+
+Moreover	O
+,	O
+HR1	O
+and	O
+HR2	O
+derived	O
+free	O
+peptides	B-CHED
+are	O
+inhibitors	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+entry	O
+.	O
+
+TITLE	O
+:	O
+Microwave	O
+assisted	O
+organic	O
+synthesis	B-PROC
+(	O
+MAOS	O
+)	O
+of	O
+small	O
+molecules	O
+as	O
+potential	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+integrase	B-PROC
+inhibitors	B-CHED
+.	O
+
+Thirteen	O
+patients	O
+with	O
+isolated	O
+blunt	O
+chest	B-ANAT
+injury	O
+[	O
+abbreviated	O
+injury	O
+score	O
+(	O
+AIS	B-DISO
+)	O
+2	O
+-	O
+5	O
+]	O
+were	O
+included	O
+.	O
+
+Blunt	O
+chest	B-ANAT
+injury	O
+resulted	O
+in	O
+the	O
+activation	O
+of	O
+circulating	O
+neutrophils	O
+,	O
+as	O
+characterized	O
+by	O
+a	O
+decreased	O
+expression	B-PROC
+of	O
+l	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+(	O
+CD62L	B-PRGE
+),	O
+CXCR2	B-PRGE
+(	O
+CD182b	O
+)	O
+and	O
+C5aR	B-PRGE
+(	O
+CD88	B-PRGE
+)	O
+compared	O
+to	O
+control	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+has	O
+been	O
+recognized	O
+as	O
+a	O
+consequence	O
+of	O
+blood	O
+transfusion	O
+(	O
+BT	O
+)	O
+since	O
+1978	O
+;	O
+the	O
+Food	O
+and	O
+Drug	O
+Administration	O
+,	O
+has	O
+classified	O
+it	O
+as	O
+the	O
+third	O
+BT	O
+mortality	O
+issue	O
+,	O
+in	O
+2004	O
+,	O
+and	O
+in	O
+first	O
+place	O
+related	O
+with	O
+ALI	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+transfusion	B-DISO
+associated	I-DISO
+circulatory	I-DISO
+overload	I-DISO
+(	O
+TACO	B-DISO
+)	O
+and	O
+transfusion	B-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+(	O
+TRALI	B-DISO
+).	O
+
+Antileukocyte	O
+antibodies	B-COMP
+in	O
+blood	B-ANAT
+donors	O
+plasma	B-ANAT
+,	O
+caused	O
+TRALI	B-DISO
+in	O
+89	O
+%	O
+of	O
+cases	O
+;	O
+also	O
+it	O
+has	O
+been	O
+found	O
+antigen	O
+specificity	O
+against	O
+leukocyte	B-PRGE
+blood	B-ANAT
+receptor	I-PRGE
+in	O
+59	O
+%.	O
+
+The	O
+UCI	O
+patients	O
+who	O
+received	O
+a	O
+BT	O
+have	O
+ALI	O
+as	O
+a	O
+complication	B-DISO
+in	O
+40	O
+%	O
+of	O
+cases	O
+.	O
+
+The	O
+prevalence	O
+of	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+was	O
+3	O
+.	O
+2	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+-	O
+6	O
+.	O
+6	O
+)	O
+with	O
+a	O
+1	O
+.	O
+7	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+-	O
+3	O
+.	O
+2	O
+)	O
+prevalence	O
+of	O
+H5N1	B-DISO
+being	O
+detected	O
+.	O
+
+Positive	O
+cases	O
+of	O
+H5N1	B-DISO
+virus	B-SPEC
+were	O
+found	O
+in	O
+two	O
+out	O
+of	O
+three	O
+vultures	O
+in	O
+Ouagadougou	O
+,	O
+and	O
+in	O
+three	O
+out	O
+of	O
+203	O
+local	O
+chickens	B-SPEC
+in	O
+the	O
+Western	O
+Region	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+part	O
+of	O
+our	O
+ongoing	O
+surveillance	O
+program	O
+,	O
+40	O
+field	O
+strains	O
+of	O
+avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+isolated	O
+from	O
+dead	B-PROC
+or	O
+diseased	O
+chicken	B-SPEC
+flocks	O
+in	O
+different	O
+areas	O
+of	O
+China	O
+between	O
+2009	O
+and	O
+2010	O
+.	O
+
+TITLE	O
+:	O
+Report	O
+of	O
+the	O
+'	O
+mechanisms	O
+of	O
+lung	B-ANAT
+injury	O
+and	O
+immunomodulator	B-CHED
+interventions	O
+in	O
+influenza	B-DISO
+'	O
+workshop	O
+,	O
+21	O
+March	O
+2010	O
+,	O
+Ventura	O
+,	O
+California	O
+,	O
+USA	O
+.	O
+
+In	O
+addition	O
+,	O
+therapeutic	O
+agents	O
+that	O
+target	O
+host	B-PROC
+response	I-PROC
+proteins	B-CHED
+and	O
+pathways	B-PROC
+were	O
+identified	O
+and	O
+investigational	O
+agents	O
+in	O
+development	B-PROC
+reviewed	O
+.	O
+
+However	O
+,	O
+a	O
+better	O
+understanding	O
+of	O
+common	O
+cell	B-COMP
+signalling	B-PROC
+pathways	B-PROC
+associated	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+caused	O
+by	O
+influenza	B-DISO
+and	O
+other	O
+pathogens	O
+is	O
+necessary	O
+to	O
+understand	O
+immunopathologic	O
+causes	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+We	O
+conducted	O
+a	O
+molecular	O
+epidemiology	O
+study	O
+to	O
+investigate	O
+different	O
+genotypes	O
+and	O
+potential	O
+recombination	B-PROC
+in	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+.	O
+
+Twenty	O
+-	O
+nine	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+strains	O
+from	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+,	O
+collected	O
+from	O
+2004	O
+to	O
+2011	O
+,	O
+were	O
+subjected	O
+to	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+),	O
+spike	O
+,	O
+and	O
+nucleocapsid	B-COMP
+gene	O
+analysis	O
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+at	O
+least	O
+three	O
+distinct	O
+clusters	B-CHED
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+although	O
+10	O
+unusual	O
+strains	O
+displayed	O
+incongruent	O
+phylogenetic	O
+positions	O
+between	O
+RdRp	B-FUNC
+and	O
+spike	O
+genes	O
+.	O
+
+This	O
+represents	O
+the	O
+first	O
+study	O
+to	O
+describe	O
+natural	O
+recombination	B-PROC
+in	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+the	O
+evolution	B-PROC
+of	O
+different	O
+genotypes	O
+over	O
+time	O
+,	O
+leading	O
+to	O
+the	O
+emergence	O
+of	O
+novel	O
+genotype	O
+D	O
+,	O
+which	O
+is	O
+associated	O
+with	O
+pneumonia	B-DISO
+in	O
+our	O
+elderly	O
+population	O
+.	O
+
+Partial	O
+sequencing	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+revealed	O
+153	O
+vaccine	O
+strains	O
+and	O
+49	O
+field	O
+isolates	O
+of	O
+several	O
+genetic	O
+groups	O
+.	O
+
+No	O
+patient	O
+developed	O
+a	O
+reaction	O
+meeting	O
+the	O
+study	O
+definition	O
+of	O
+a	O
+severe	O
+complication	B-DISO
+.	O
+
+The	O
+cleavage	B-PROC
+efficiency	O
+for	O
+the	O
+substrate	O
+with	O
+serine	B-CHED
+in	O
+the	O
+P2	O
+position	O
+was	O
+160	O
+-	O
+times	O
+lower	O
+than	O
+that	O
+for	O
+the	O
+original	O
+substrate	O
+(	O
+P2	B-CHED
+=	I-CHED
+Leu	I-CHED
+);	O
+furthermore	O
+,	O
+the	O
+substrate	O
+with	O
+aspartic	B-CHED
+acid	I-CHED
+in	O
+the	O
+P2	O
+position	O
+was	O
+not	O
+cleaved	B-ANAT
+at	O
+all	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+and	O
+solid	O
+organ	B-ANAT
+transplant	I-ANAT
+recipients	O
+.	O
+
+The	O
+disorder	O
+is	O
+mainly	O
+caused	O
+by	O
+a	O
+delayed	O
+resorption	B-PROC
+of	O
+foetal	O
+lung	B-ANAT
+fluid	O
+.	O
+
+ABSTRACT	O
+:	O
+Sustained	O
+high	O
+-	O
+efficiency	O
+daily	O
+diafiltration	O
+using	O
+a	O
+mediator	O
+-	O
+adsorbing	O
+membrane	B-COMP
+(	O
+SHEDD	O
+-	O
+fA	O
+)	O
+is	O
+an	O
+effective	O
+,	O
+intensive	O
+modality	O
+for	O
+sepsis	B-DISO
+treatment	O
+.	O
+
+SHEDD	O
+-	O
+fA	O
+was	O
+initiated	O
+after	O
+adequate	O
+fluid	O
+resuscitation	O
+and	O
+catecholamine	B-CHED
+support	O
+had	O
+been	O
+provided	O
+.	O
+
+A	O
+large	O
+(	O
+2	O
+.	O
+1	O
+m	O
+(	O
+2	O
+))	O
+polymethylmethacrylate	B-CHED
+membrane	B-COMP
+dialyzer	O
+was	O
+placed	O
+in	O
+the	O
+blood	B-ANAT
+circuit	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+sialodacryoadenitis	O
+virus	B-DISO
+infection	I-DISO
+on	O
+axonal	O
+regeneration	B-PROC
+.	O
+
+Active	O
+SDAV	O
+infection	B-DISO
+severely	O
+impaired	B-DISO
+nerve	B-PROC
+regeneration	B-PROC
+and	O
+negated	O
+the	O
+positive	O
+effect	O
+of	O
+FK506	O
+on	O
+nerve	B-PROC
+regeneration	B-PROC
+in	O
+rats	B-SPEC
+.	O
+
+We	O
+have	O
+assessed	O
+the	O
+detection	O
+rate	O
+of	O
+a	O
+multiplex	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+test	O
+,	O
+with	O
+emphasis	O
+on	O
+epidemiology	O
+and	O
+seasonal	O
+distribution	O
+of	O
+the	O
+most	O
+common	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+Seven	O
+thousand	O
+eight	O
+hundred	O
+and	O
+fifty	O
+-	O
+three	O
+nasopharyngeal	B-ANAT
+samples	O
+from	O
+7220	O
+patients	O
+(	O
+age	O
+range	O
+0	O
+-	O
+98	O
+y	O
+,	O
+median	O
+22	O
+y	O
+)	O
+obtained	O
+during	O
+36	O
+consecutive	O
+months	O
+(	O
+November	O
+2006	O
+-	O
+October	O
+2009	O
+),	O
+were	O
+analyzed	O
+with	O
+a	O
+multiplex	O
+PCR	O
+panel	O
+including	O
+influenza	B-PATH
+A	I-PATH
+(	O
+IfA	O
+)	O
+and	O
+B	O
+(	O
+IfB	O
+)	O
+virus	B-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+1	O
+-	O
+3	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+),	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	O
+)	O
+OC43	O
+,	O
+NL63	O
+,	O
+and	O
+229E	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+),	O
+adenovirus	B-DISO
+(	O
+AdV	O
+),	O
+enterovirus	B-SPEC
+(	O
+EV	O
+),	O
+and	O
+2	O
+bacteria	B-SPEC
+--	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Chlamydophila	B-SPEC
+pneumoniae	I-SPEC
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+total	O
+samples	O
+,	O
+44	O
+.	O
+5	O
+%	O
+(	O
+n	O
+=	O
+3496	O
+)	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+1	O
+agent	O
+,	O
+with	O
+HRV	O
+being	O
+the	O
+most	O
+common	O
+(	O
+n	O
+=	O
+1482	O
+,	O
+38	O
+.	O
+0	O
+%),	O
+followed	O
+by	O
+RSV	B-SPEC
+(	O
+n	O
+=	O
+526	O
+,	O
+13	O
+.	O
+5	O
+%)	O
+and	O
+IfA	O
+(	O
+n	O
+=	O
+403	O
+,	O
+10	O
+.	O
+3	O
+%).	O
+
+ABSTRACT	O
+:	O
+A	O
+shotgun	O
+proteomics	O
+approach	O
+was	O
+used	O
+to	O
+characterize	O
+and	O
+compare	O
+the	O
+proteins	B-CHED
+that	O
+lead	O
+to	O
+the	O
+formation	B-PROC
+of	O
+a	O
+rich	O
+""""	O
+protein	B-CHED
+corona	B-CHED
+""""	O
+adsorbed	O
+onto	O
+the	O
+surfaces	O
+of	O
+cationic	O
+liposomes	O
+(	O
+CLs	B-DISO
+),	O
+lipoplexes	O
+,	O
+and	O
+lipid	B-CHED
+/	O
+polycation	B-CHED
+/	O
+DNA	O
+(	O
+LPD	O
+)	O
+complexes	O
+,	O
+when	O
+they	O
+come	O
+into	O
+contact	O
+with	O
+plasma	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+cause	O
+a	O
+high	O
+percentage	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonias	O
+.	O
+
+The	O
+advent	O
+of	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+other	O
+molecular	O
+techniques	O
+has	O
+been	O
+associated	O
+with	O
+the	O
+detection	O
+of	O
+a	O
+higher	O
+prevalence	O
+of	O
+common	O
+respiratory	O
+viruses	B-SPEC
+than	O
+previously	O
+suspected	O
+.	O
+
+The	O
+results	O
+of	O
+the	O
+current	O
+study	O
+demonstrated	O
+a	O
+decrease	O
+in	O
+the	O
+activity	O
+of	O
+the	O
+complex	B-COMP
+I	I-COMP
+by	O
+31	O
+and	O
+48	O
+%	O
+at	O
+18	O
+and	O
+24	O
+h	O
+respectively	O
+after	O
+the	O
+thioacetamide	B-CHED
+injection	O
+.	O
+
+The	O
+inhibition	B-PROC
+of	O
+the	O
+respiratory	O
+complexes	O
+III	O
+and	O
+I	O
+and	O
+pyruvate	B-PATH
+dehydrogenase	I-PATH
+might	O
+lead	O
+to	O
+the	O
+increased	O
+production	O
+of	O
+free	B-CHED
+radical	I-CHED
+resulting	O
+in	O
+oxidative	B-DISO
+stress	I-DISO
+and	O
+cerebral	B-ANAT
+energy	O
+disturbances	O
+thereby	O
+leading	O
+to	O
+mitochondrial	B-PROC
+swelling	B-DISO
+and	O
+further	O
+contributing	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+FHF	B-DISO
+.	O
+
+TITLE	O
+:	O
+Disease	O
+burden	O
+of	O
+the	O
+most	O
+commonly	O
+detected	O
+respiratory	O
+viruses	B-SPEC
+in	O
+hospitalized	O
+patients	O
+calculated	O
+using	O
+the	O
+disability	O
+adjusted	O
+life	O
+year	O
+(	O
+DALY	O
+)	O
+model	O
+.	O
+
+Diagnostic	O
+testing	O
+results	O
+from	O
+samples	O
+collected	O
+over	O
+three	O
+years	O
+for	O
+adenovirus	B-DISO
+(	O
+AdV	O
+),	O
+influenzas	B-DISO
+A	O
+and	O
+B	O
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+1	O
+,	O
+2	O
+and	O
+3	O
+(	O
+PIV	O
+-	O
+1	O
+,	O
+-	O
+2	O
+and	O
+-	O
+3	O
+),	O
+respiratory	O
+syncytial	O
+virus	O
+(	O
+HRSV	B-SPEC
+),	O
+and	O
+previously	O
+published	O
+retrospective	O
+screening	O
+for	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+rhinoviruses	B-SPEC
+,	O
+and	O
+four	O
+respiratory	O
+coronaviruses	O
+were	O
+applied	O
+to	O
+the	O
+DALY	O
+model	O
+.	O
+
+These	O
+analyses	O
+provide	O
+a	O
+framework	O
+which	O
+can	O
+be	O
+used	O
+to	O
+identify	O
+where	O
+finite	O
+resources	O
+should	O
+be	O
+directed	O
+in	O
+respiratory	O
+therapeutics	O
+and	O
+vaccine	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Physiological	O
+techniques	O
+for	O
+detecting	O
+expiratory	B-PROC
+flow	O
+limitation	O
+during	O
+tidal	O
+breathing	B-PROC
+.	O
+
+In	O
+fact	O
+,	O
+EFL	O
+(	O
+T	O
+)	O
+occurs	O
+commonly	O
+in	O
+COPD	B-DISO
+patients	O
+(	O
+mainly	O
+in	O
+Global	O
+Initiative	O
+for	O
+Chronic	B-DISO
+Obstructive	I-DISO
+Lung	I-DISO
+Disease	I-DISO
+III	O
+and	O
+IV	O
+stage	O
+),	O
+in	O
+whom	O
+the	O
+latter	O
+symptoms	O
+are	O
+common	O
+,	O
+but	O
+is	O
+not	O
+exclusive	O
+to	O
+COPD	B-DISO
+,	O
+since	O
+it	O
+can	O
+also	O
+be	O
+detected	O
+in	O
+other	O
+pulmonary	B-ANAT
+and	O
+nonpulmonary	O
+diseases	O
+like	O
+asthma	B-PATH
+,	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+,	O
+heart	B-DISO
+failure	I-DISO
+and	O
+obesity	B-DISO
+,	O
+etc	O
+.	O
+
+During	O
+days	O
+1	O
+-	O
+10	O
+post	O
+-	O
+randomisation	O
+,	O
+P	O
+(	O
+a	O
+,	O
+O	O
+(	O
+2	O
+))/	O
+F	O
+(	O
+I	O
+,	O
+O	O
+(	O
+2	O
+))),	O
+oxygenation	B-PROC
+index	O
+,	O
+plateau	O
+pressure	O
+and	O
+respiratory	O
+compliance	O
+were	O
+improved	O
+in	O
+the	O
+HFO	O
+-	O
+TGI	O
+group	O
+versus	O
+the	O
+CMV	B-SPEC
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+for	O
+group	O
+×	O
+time	O
+).	O
+
+However	O
+,	O
+the	O
+most	O
+lung	B-ANAT
+protective	O
+tidal	O
+volume	O
+in	O
+association	O
+with	O
+hypercapnia	B-DISO
+is	O
+unknown	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+SARS	B-DISO
+pseudovirus	O
+cell	B-COMP
+entry	O
+by	O
+lactoferrin	B-PRGE
+binding	B-FUNC
+to	O
+heparan	B-CHED
+sulfate	I-CHED
+proteoglycans	B-CHED
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+outbreaks	O
+and	O
+pregnancy	O
+:	O
+occupational	O
+health	O
+and	O
+safety	O
+concerns	O
+of	O
+Canadian	O
+nurses	O
+.	O
+
+Nurses	O
+'	O
+fears	O
+of	O
+fertility	B-DISO
+risks	O
+posed	O
+by	O
+exposure	O
+to	O
+infectious	B-DISO
+agents	O
+or	O
+anti	O
+-	O
+infective	O
+therapy	O
+and	O
+prophylaxis	O
+are	O
+not	O
+well	O
+supported	O
+by	O
+the	O
+literature	O
+,	O
+with	O
+the	O
+former	O
+not	O
+biologically	O
+plausible	O
+and	O
+the	O
+latter	O
+lacking	O
+sufficient	O
+data	O
+.	O
+
+In	O
+our	O
+prospective	O
+non	O
+-	O
+controlled	O
+trial	O
+,	O
+we	O
+enrolled	O
+patients	O
+with	O
+severe	O
+neurological	B-DISO
+symptoms	I-DISO
+and	O
+confirmed	O
+recent	O
+E	O
+coli	O
+O104	O
+:	O
+H4	O
+infection	B-DISO
+without	O
+other	O
+acute	O
+bacterial	B-DISO
+infection	I-DISO
+or	O
+raised	O
+procalcitonin	O
+concentrations	O
+.	O
+
+Composite	O
+neurological	B-DISO
+symptom	I-DISO
+scores	O
+increased	O
+in	O
+the	O
+3	O
+days	O
+before	O
+immunoadsorption	O
+to	O
+3	O
+·	O
+0	O
+(	O
+SD	O
+1	O
+·	O
+1	O
+,	O
+p	O
+=	O
+0	O
+·	O
+038	O
+),	O
+and	O
+improved	O
+to	O
+1	O
+·	O
+0	O
+(	O
+1	O
+·	O
+2	O
+,	O
+p	O
+=	O
+0	O
+·	O
+0006	O
+)	O
+3	O
+days	O
+after	O
+immunoadsorption	O
+.	O
+
+Five	O
+patients	O
+who	O
+were	O
+intubated	O
+were	O
+weaned	B-PROC
+within	O
+48	O
+h	O
+,	O
+two	O
+within	O
+4	O
+days	O
+,	O
+and	O
+two	O
+patients	O
+needed	O
+continued	O
+ventilation	O
+for	O
+respiratory	B-DISO
+problems	I-DISO
+.	O
+
+Mutations	O
+in	O
+MTU1	B-PRGE
+are	O
+associated	O
+with	O
+acute	O
+infantile	O
+liver	B-DISO
+failure	I-DISO
+,	O
+and	O
+this	O
+has	O
+been	O
+ascribed	O
+to	O
+a	O
+transient	O
+lack	O
+of	O
+cysteine	B-CHED
+,	O
+the	O
+sulfur	B-CHED
+donor	B-CHED
+for	O
+the	O
+thiouridylation	O
+reaction	O
+,	O
+resulting	O
+in	O
+a	O
+mitochondrial	B-PROC
+translation	B-PROC
+defect	O
+during	O
+early	O
+development	B-PROC
+.	O
+
+The	O
+draft	O
+chicken	B-PRGE
+genome	O
+was	O
+first	O
+scanned	O
+using	O
+human	B-SPEC
+sPLA2	O
+sequences	O
+to	O
+identify	O
+chicken	B-PRGE
+sPLA2s	I-PRGE
+(	O
+ChPLA2	O
+),	O
+chicken	B-SPEC
+total	O
+mRNA	B-CHED
+were	O
+isolated	O
+and	O
+RT	O
+-	O
+PCR	O
+experiments	O
+were	O
+performed	O
+to	O
+amplify	O
+and	O
+then	O
+sequence	O
+orthologous	O
+cDNAs	O
+.	O
+
+ABSTRACT	O
+:	O
+Face	O
+masks	O
+or	O
+respirators	O
+are	O
+commonly	O
+worn	O
+by	O
+medical	O
+professionals	O
+and	O
+patients	O
+for	O
+protection	O
+against	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+and	O
+the	O
+spread	O
+of	O
+illnesses	O
+,	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+pandemic	O
+influenza	B-DISO
+(	O
+H1N1	O
+).	O
+
+Breathing	B-PROC
+discomfort	B-DISO
+due	O
+to	O
+increased	O
+breathing	B-PROC
+resistance	B-PROC
+is	O
+known	O
+to	O
+be	O
+a	O
+problem	O
+with	O
+the	O
+use	O
+of	O
+N95	O
+respirators	O
+but	O
+there	O
+is	O
+a	O
+lack	O
+of	O
+scientific	O
+data	O
+to	O
+quantify	O
+this	O
+effect	O
+.	O
+
+Nasal	B-ANAT
+airflow	B-PROC
+resistance	B-PROC
+during	O
+inspiration	B-PROC
+and	I-PROC
+expiration	I-PROC
+was	O
+measured	O
+using	O
+a	O
+standard	O
+rhinomanometry	O
+and	O
+nasal	B-ANAT
+spirometry	O
+.	O
+
+The	O
+results	O
+showed	O
+a	O
+mean	O
+increment	O
+of	O
+126	O
+and	O
+122	O
+%	O
+in	O
+inspiratory	O
+and	O
+expiratory	B-PROC
+flow	O
+resistances	O
+,	O
+respectively	O
+,	O
+with	O
+the	O
+use	O
+of	O
+N95	O
+respirators	O
+.	O
+
+hmAbs	O
+may	O
+be	O
+used	O
+therapeutically	O
+without	O
+the	O
+drawbacks	O
+of	O
+chimeric	O
+or	O
+animal	B-SPEC
+Abs	O
+.	O
+
+TITLE	O
+:	O
+Non	O
+-	O
+cancer	B-DISO
+effects	O
+of	O
+chemical	O
+agents	O
+on	O
+children	O
+'	O
+s	O
+health	O
+.	O
+
+Maternal	O
+smoking	O
+during	O
+pregnancy	O
+is	O
+a	O
+risk	O
+factor	O
+for	O
+preterm	B-DISO
+birth	I-DISO
+,	O
+foetal	O
+growth	O
+deficit	B-DISO
+and	O
+SIDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Surveillance	O
+using	O
+serological	O
+and	O
+molecular	O
+methods	O
+for	O
+the	O
+detection	O
+of	O
+infectious	B-DISO
+agents	O
+in	O
+captive	O
+Brazilian	O
+neotropic	O
+and	O
+exotic	O
+felids	O
+.	O
+
+infections	B-DISO
+were	O
+detected	O
+.	O
+
+Analysis	O
+of	O
+the	O
+consensus	O
+full	O
+-	O
+length	O
+genome	O
+for	O
+three	O
+different	O
+IBV	B-SPEC
+serotypes	O
+(	O
+Ark	B-PRGE
+,	O
+GA98	O
+,	O
+and	O
+Mass41	O
+)	O
+showed	O
+that	O
+passage	O
+in	O
+embryonated	O
+eggs	O
+,	O
+to	O
+attenuate	O
+the	O
+viruses	B-SPEC
+for	O
+chickens	B-SPEC
+,	O
+resulted	O
+in	O
+34	O
+.	O
+75	O
+-	O
+43	O
+.	O
+66	O
+%	O
+of	O
+all	O
+the	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+occurring	O
+in	O
+nsp	B-PRGE
+3	I-PRGE
+within	O
+a	O
+virus	B-SPEC
+type	O
+,	O
+whereas	O
+changes	O
+in	O
+the	O
+spike	O
+glycoprotein	B-CHED
+,	O
+thought	O
+to	O
+be	O
+the	O
+most	O
+variable	O
+protein	B-CHED
+in	O
+IBV	B-SPEC
+,	O
+ranged	O
+from	O
+5	O
+.	O
+8	O
+to	O
+13	O
+.	O
+4	O
+%	O
+of	O
+all	O
+changes	O
+.	O
+
+Prior	O
+to	O
+infection	B-DISO
+,	O
+cultured	B-ANAT
+cells	I-ANAT
+were	O
+either	O
+treated	O
+with	O
+neuraminidase	B-PRGE
+to	O
+deplete	O
+sialic	B-CHED
+acids	I-CHED
+from	O
+the	O
+cell	B-COMP
+surface	I-COMP
+,	O
+or	O
+mock	O
+-	O
+treated	O
+.	O
+
+In	O
+a	O
+second	O
+approach	O
+,	O
+pre	O
+-	O
+treatment	O
+of	O
+the	O
+virus	B-SPEC
+with	O
+porcine	B-PRGE
+intestinal	B-ANAT
+mucin	I-PRGE
+was	O
+performed	O
+,	O
+followed	O
+by	O
+the	O
+plaque	O
+assay	O
+after	O
+a	O
+5	O
+min	O
+adsorption	O
+time	O
+.	O
+
+Nasopharyngeal	B-ANAT
+specimens	O
+from	O
+children	O
+less	O
+than	O
+16	O
+years	O
+old	O
+who	O
+were	O
+suffering	B-DISO
+from	O
+acute	O
+respiratory	B-DISO
+diseases	I-DISO
+were	O
+tested	O
+for	O
+hMPV	B-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Clinical	B-DISO
+findings	I-DISO
+of	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+culture	O
+-	O
+negative	O
+shock	O
+were	O
+established	O
+in	O
+7	O
+children	O
+infected	O
+with	O
+hMPV	B-SPEC
+and	O
+having	O
+hematologic	B-DISO
+malignancies	I-DISO
+,	O
+myelofibrosis	B-DISO
+,	O
+Gaucher	B-DISO
+disease	I-DISO
+,	O
+and	O
+congenital	B-DISO
+immunodeficiency	I-DISO
+;	O
+2	O
+of	O
+the	O
+7	O
+patients	O
+died	B-PROC
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+All	O
+children	O
+infected	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+had	O
+underlying	O
+conditions	O
+;	O
+1	O
+of	O
+the	O
+4	O
+patients	O
+developed	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+recombinant	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+expressing	O
+a	O
+heterologous	O
+spike	O
+gene	O
+belonging	O
+to	O
+the	O
+4	O
+/	O
+91	O
+serotype	O
+.	O
+
+A	O
+degree	O
+of	O
+heterologous	O
+protection	O
+against	O
+M41	B-PRGE
+challenge	I-PRGE
+was	O
+observed	O
+,	O
+albeit	O
+at	O
+a	O
+lower	O
+level	O
+.	O
+
+The	O
+primary	O
+endpoint	O
+occurred	O
+in	O
+271	O
+PAC	B-DISO
+patients	O
+versus	O
+196	O
+without	O
+PAC	B-DISO
+(	O
+21	O
+.	O
+3	O
+%	O
+vs	O
+.	O
+15	O
+.	O
+4	O
+%;	O
+adjusted	O
+odds	O
+ratio	O
+[	O
+AOR	B-FUNC
+],	O
+1	O
+.	O
+68	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+24	O
+to	O
+2	O
+.	O
+26	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+A	O
+randomized	O
+controlled	O
+trial	O
+with	O
+defined	O
+hemodynamic	B-PROC
+goals	O
+would	O
+be	O
+ideal	O
+to	O
+either	O
+confirm	O
+or	O
+refute	O
+our	O
+findings	O
+.	O
+
+Use	O
+of	O
+PAC	B-DISO
+was	O
+also	O
+associated	O
+with	O
+prolonged	O
+intensive	O
+care	O
+unit	O
+stay	O
+(	O
+14	O
+.	O
+5	O
+%	O
+vs	O
+10	O
+.	O
+1	O
+%;	O
+AOR	B-FUNC
+,	O
+1	O
+.	O
+55	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+06	O
+to	O
+2	O
+.	O
+27	O
+;	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+We	O
+present	O
+a	O
+report	O
+of	O
+its	O
+clinical	O
+and	O
+epidemiological	O
+characteristics	O
+in	O
+children	O
+and	O
+adults	O
+in	O
+Panama	B-SPEC
+.	O
+
+The	O
+overall	O
+incident	O
+rate	O
+was	O
+23	O
+.	O
+35	O
+cases	O
+of	O
+pandemic	O
+influenza	B-DISO
+per	O
+100	O
+,	O
+000	O
+habitants	O
+,	O
+with	O
+the	O
+highest	O
+incidence	O
+found	O
+in	O
+the	O
+age	O
+group	O
+between	O
+10	O
+to	O
+14	O
+years	O
+of	O
+age	O
+(	O
+58	O
+.	O
+67	O
+cases	O
+per	O
+100	O
+,	O
+000	O
+habitants	O
+).	O
+
+Fever	B-PROC
+and	O
+cough	B-DISO
+were	O
+the	O
+most	O
+frequent	O
+symptoms	O
+reported	O
+in	O
+all	O
+age	O
+groups	O
+.	O
+
+RESULTS	O
+:	O
+From	O
+26	O
+April	O
+2009	O
+to	O
+11	O
+January	O
+2010	O
+,	O
+confirmed	O
+cases	O
+of	O
+pandemic	O
+2009	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+reached	O
+806	O
+.	O
+
+Since	O
+the	O
+RNA	O
+pseudoknot	O
+located	O
+in	O
+the	O
+frameshifting	O
+region	O
+of	O
+IBV	B-SPEC
+was	O
+used	O
+as	O
+bait	O
+for	O
+cellular	B-COMP
+RBPs	O
+,	O
+we	O
+tested	O
+whether	O
+ANXA2	B-PRGE
+could	O
+regulate	O
+the	O
+frameshfting	O
+of	O
+IBV	B-SPEC
+pseudoknot	O
+RNA	O
+by	O
+dual	O
+luciferase	B-ENZY
+assay	O
+.	O
+
+TITLE	O
+:	O
+Novel	O
+system	O
+for	O
+detecting	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+using	O
+an	O
+ssDNA	O
+aptamer	O
+.	O
+
+Enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+analysis	O
+was	O
+then	O
+used	O
+to	O
+identify	O
+the	O
+aptamer	O
+with	O
+the	O
+highest	O
+binding	B-FUNC
+affinity	O
+to	O
+the	O
+SARS	B-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+Using	O
+this	O
+approach	O
+,	O
+an	O
+ssDNA	O
+aptamer	O
+that	O
+binds	O
+to	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+with	O
+a	O
+K	O
+(	O
+d	O
+)	O
+of	O
+4	O
+.	O
+93	O
+±	O
+0	O
+.	O
+30nM	O
+was	O
+identified	O
+.	O
+
+In	O
+other	O
+conditions	O
+,	O
+such	O
+as	O
+tuberculosis	B-PATH
+,	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+,	O
+acute	O
+lung	B-DISO
+aspiration	I-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+CS	O
+are	O
+often	O
+used	O
+empirically	O
+despite	O
+the	O
+lack	O
+of	O
+clear	O
+evidence	O
+of	O
+their	O
+benefit	O
+.	O
+
+These	O
+have	O
+been	O
+reduced	O
+,	O
+but	O
+not	O
+eliminated	O
+,	O
+with	O
+the	O
+use	O
+of	O
+the	O
+inhaled	B-PROC
+route	O
+.	O
+
+Possible	O
+enterococcal	B-DISO
+infection	I-DISO
+pathways	B-PROC
+and	O
+mechanisms	O
+of	O
+ARDS	B-DISO
+development	B-PROC
+are	O
+discussed	O
+.	O
+
+Subtle	O
+structural	O
+differences	O
+in	O
+the	O
+S2	O
+and	O
+S3	O
+pockets	O
+of	O
+these	O
+proteases	O
+make	O
+inhibitors	B-CHED
+selective	O
+,	O
+but	O
+some	O
+dual	O
+inhibitors	B-CHED
+have	O
+been	O
+discovered	O
+.	O
+
+Our	O
+findings	O
+as	O
+summarized	O
+in	O
+the	O
+present	O
+review	O
+provide	O
+new	O
+potential	O
+anti	O
+-	O
+coronavirus	B-SPEC
+and	O
+anti	O
+-	O
+picornavirus	B-SPEC
+therapeutic	O
+agents	O
+and	O
+a	O
+clue	O
+to	O
+convert	O
+3CLpro	O
+inhibitors	O
+into	O
+3Cpro	O
+inhibitors	B-CHED
+and	O
+vice	O
+versa	O
+.	O
+
+The	O
+facemask	O
+was	O
+challenged	O
+by	O
+both	O
+pseudo	O
+-	O
+steady	O
+and	O
+highly	O
+transient	O
+emissions	B-ANAT
+generated	O
+by	O
+an	O
+expiratory	B-PROC
+process	O
+where	O
+parameters	O
+,	O
+such	O
+as	O
+separation	B-DISO
+distance	O
+between	O
+manikins	O
+,	O
+emission	B-ANAT
+velocity	O
+and	O
+expiratory	B-PROC
+duration	O
+,	O
+were	O
+controlled	O
+and	O
+measured	O
+systematically	O
+.	O
+
+It	O
+was	O
+also	O
+observed	O
+that	O
+the	O
+separation	B-DISO
+between	O
+the	O
+source	O
+and	O
+the	O
+manikin	O
+was	O
+the	O
+most	O
+influential	O
+parameter	O
+affecting	O
+facemask	O
+protection	O
+.	O
+
+While	O
+a	O
+variety	O
+of	O
+vaccine	O
+platforms	O
+have	O
+shown	O
+efficacy	O
+in	O
+young	O
+-	O
+animal	B-SPEC
+models	O
+and	O
+against	O
+homologous	O
+viral	O
+strains	O
+,	O
+vaccine	O
+efficacy	O
+has	O
+not	O
+been	O
+thoroughly	O
+evaluated	O
+using	O
+highly	O
+pathogenic	O
+variants	O
+that	O
+replicate	O
+the	O
+acute	O
+end	O
+stage	O
+lung	B-DISO
+disease	I-DISO
+phenotypes	O
+seen	O
+during	O
+the	O
+human	B-SPEC
+epidemic	O
+.	O
+
+Using	O
+an	O
+adjuvanted	O
+and	O
+an	O
+unadjuvanted	O
+double	O
+-	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+DIV	B-PRGE
+)	O
+vaccine	O
+,	O
+we	O
+demonstrate	O
+an	O
+eosinophilic	O
+immunopathology	B-DISO
+in	O
+aged	O
+mice	B-SPEC
+comparable	O
+to	O
+that	O
+seen	O
+in	O
+mice	B-SPEC
+immunized	O
+with	O
+the	O
+SARS	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+,	O
+and	O
+poor	O
+protection	O
+against	O
+a	O
+nonlethal	O
+heterologous	O
+challenge	O
+.	O
+
+In	O
+young	O
+and	O
+1	O
+-	O
+year	O
+-	O
+old	O
+animals	O
+,	O
+we	O
+demonstrate	O
+that	O
+adjuvanted	O
+DIV	O
+vaccine	O
+provides	O
+protection	O
+against	O
+lethal	O
+disease	O
+in	O
+young	O
+animals	B-SPEC
+following	O
+homologous	O
+and	O
+heterologous	O
+challenge	O
+,	O
+although	O
+enhanced	O
+immune	O
+pathology	B-DISO
+and	O
+eosinophilia	B-DISO
+are	O
+evident	O
+following	O
+heterologous	O
+challenge	O
+.	O
+
+In	O
+contrast	O
+,	O
+DIV	O
+vaccines	O
+(	O
+both	O
+adjuvanted	O
+and	O
+unadjuvanted	O
+)	O
+performed	O
+poorly	O
+in	O
+aged	O
+-	O
+animal	B-SPEC
+models	O
+.	O
+
+Patterns	O
+of	O
+muscle	B-DISO
+weakness	I-DISO
+involved	O
+limb	B-ANAT
+,	O
+trunk	B-ANAT
+,	O
+bulbar	B-ANAT
+,	O
+respiratory	O
+,	O
+facial	B-ANAT
+and	O
+extraocular	B-ANAT
+muscles	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Predictive	O
+value	O
+of	O
+bronchoscopy	O
+in	O
+assessing	O
+the	O
+severity	O
+of	O
+inhalation	B-PROC
+injury	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+authors	O
+evaluated	O
+whether	O
+bronchoscopic	O
+grading	O
+of	O
+injury	O
+clinically	O
+correlated	O
+with	O
+indices	O
+of	O
+gas	B-ENZY
+exchange	O
+over	O
+the	O
+first	O
+72	O
+hours	O
+or	O
+predicted	O
+differences	O
+in	O
+hospitalization	O
+outcomes	O
+.	O
+
+They	O
+conducted	O
+a	O
+single	O
+-	O
+center	O
+retrospective	O
+review	O
+of	O
+all	O
+mechanically	O
+ventilated	O
+adults	O
+with	O
+suspected	O
+inhalation	B-PROC
+injury	O
+and	O
+thermal	O
+injury	O
+over	O
+an	O
+18	O
+-	O
+month	O
+period	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+,	O
+with	O
+fatal	O
+outcome	O
+,	O
+of	O
+a	O
+man	B-CHED
+of	O
+19	O
+years	O
+with	O
+no	O
+previous	O
+history	O
+other	O
+than	O
+an	O
+addiction	B-DISO
+to	O
+cannabis	B-DISO
+using	O
+""""	O
+bang	O
+"""."	O
+
+Bronchoalveolar	O
+lavage	O
+revealed	O
+massive	O
+alveolar	B-ANAT
+haemorrhage	B-DISO
+.	O
+
+Investigations	O
+for	O
+infection	B-DISO
+and	O
+immunological	O
+disorder	O
+were	O
+negative	O
+and	O
+toxicology	O
+was	O
+negative	O
+except	O
+for	O
+cannabis	B-DISO
+.	O
+
+Autopsy	O
+showed	O
+toxic	O
+alveolar	B-ANAT
+haemorrhage	B-DISO
+.	O
+
+The	O
+GBS	B-DISO
+represents	O
+a	O
+hospital	O
+frequency	O
+of	O
+0	O
+.	O
+45	O
+%	O
+o	O
+.	O
+
+The	O
+course	O
+of	O
+the	O
+disease	O
+is	O
+often	O
+mild	O
+and	O
+severe	O
+scars	B-DISO
+are	O
+only	O
+encountered	O
+in	O
+5	O
+to	O
+10	O
+%	O
+of	O
+cases	O
+.	O
+
+A	O
+specific	O
+therapy	O
+by	O
+intravenous	O
+polyvalent	B-PRGE
+immunoglobulin	I-PRGE
+was	O
+prescribed	O
+for	O
+14	O
+patients	O
+.	O
+
+The	O
+evolution	B-PROC
+was	O
+favourable	O
+in	O
+10	O
+cases	O
+with	O
+total	O
+recovery	O
+three	O
+cases	O
+of	O
+drop	B-DISO
+foot	I-DISO
+gait	I-DISO
+were	O
+observed	O
+,	O
+seven	O
+patients	O
+were	O
+lost	B-CHED
+to	O
+follow	O
+up	O
+and	O
+two	O
+patients	O
+are	O
+dead	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+GB	O
+syndrome	B-DISO
+is	O
+the	O
+most	O
+frequent	O
+cause	O
+of	O
+child	O
+acute	O
+primitive	O
+distal	O
+paralysis	O
+,	O
+since	O
+acute	B-DISO
+polio	I-DISO
+has	O
+been	O
+eradicated	O
+.	O
+
+Previous	O
+studies	O
+have	O
+demonstrated	O
+absolute	O
+requirement	O
+of	O
+NF	O
+-	O
+κB	O
+activation	O
+for	O
+efficient	O
+replication	O
+of	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+and	O
+HSV	B-SPEC
+-	O
+2	O
+and	O
+inhibition	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+activation	O
+has	O
+been	O
+shown	O
+to	O
+suppress	O
+HSV	B-DISO
+infection	I-DISO
+.	O
+
+At	O
+150	O
+and	O
+450	O
+μg	O
+/	O
+ml	O
+,	O
+HCWE	O
+blocked	O
+infectious	B-DISO
+HSV	B-SPEC
+-	O
+2	O
+production	O
+by	O
+more	O
+than	O
+3	O
+and	O
+4	O
+logs	O
+,	O
+respectively	O
+.	O
+
+Although	O
+activation	O
+of	O
+NF	B-PRGE
+-	I-PRGE
+κB	I-PRGE
+and	I-PRGE
+Erk	I-PRGE
+MAPK	B-FUNC
+has	O
+been	O
+implicated	O
+for	O
+HSV	B-SPEC
+replication	O
+and	O
+growth	B-PROC
+,	O
+HCWE	O
+showed	O
+no	O
+effect	O
+on	O
+HSV	B-SPEC
+-	O
+2	O
+-	O
+induced	O
+Erk	B-FUNC
+activation	O
+.	O
+
+Herein	O
+,	O
+we	O
+show	O
+that	O
+a	O
+single	O
+point	B-PROC
+mutation	I-PROC
+in	O
+the	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+(	O
+Y241H	O
+),	O
+acquired	O
+during	O
+viral	O
+persistence	O
+in	O
+human	B-SPEC
+neural	O
+cells	B-COMP
+,	O
+led	O
+to	O
+a	O
+hind	O
+-	O
+limb	B-ANAT
+paralytic	O
+disease	O
+in	O
+infected	O
+mice	B-SPEC
+.	O
+
+As	O
+activation	O
+of	O
+the	O
+p38	B-FUNC
+MAPK	B-FUNC
+pathway	B-PROC
+and	O
+induction	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+may	O
+have	O
+multiple	O
+pathogenic	O
+effects	O
+on	O
+the	O
+whole	O
+host	B-COMP
+as	O
+well	O
+as	O
+on	O
+individual	O
+infected	O
+cells	B-COMP
+,	O
+regulation	B-PROC
+of	O
+the	O
+p38	B-PRGE
+MAPK	B-FUNC
+and	O
+DUSP1	B-PRGE
+feedback	O
+loop	O
+by	O
+IBV	B-SPEC
+may	O
+modulate	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Once	O
+more	O
+fully	O
+implemented	O
+,	O
+an	O
+evaluation	O
+will	O
+be	O
+initiated	O
+to	O
+determine	O
+the	O
+degree	O
+to	O
+which	O
+these	O
+public	O
+health	O
+competencies	O
+are	O
+being	O
+achieved	O
+by	O
+family	B-SPEC
+medicine	B-CHED
+graduates	O
+,	O
+especially	O
+whether	O
+they	O
+attained	O
+the	O
+knowledge	O
+,	O
+skills	O
+,	O
+and	O
+confidence	O
+necessary	O
+to	O
+effectively	O
+face	B-DISO
+diverse	O
+public	O
+health	O
+situations	O
+-	O
+from	O
+common	O
+to	O
+emergent	O
+.	O
+
+Moreover	O
+,	O
+this	O
+synergy	O
+was	O
+blocked	O
+by	O
+an	O
+IκB	B-PRGE
+kinase	I-PRGE
+inhibitor	O
+,	O
+BAY	O
+11	O
+-	O
+7082	O
+.	O
+
+TITLE	O
+:	O
+Quercetin	B-CHED
+7	O
+-	O
+rhamnoside	B-CHED
+reduces	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-PROC
+replication	I-PROC
+via	O
+independent	O
+pathway	B-PROC
+of	O
+viral	O
+induced	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+.	O
+
+Antiviral	B-CHED
+activity	O
+of	O
+antioxidants	B-CHED
+such	O
+as	O
+NAC	B-COMP
+,	O
+pyrrolidine	B-CHED
+dithiocarbamate	O
+(	O
+PDTC	O
+),	O
+and	O
+the	O
+vitamin	B-CHED
+E	I-CHED
+derivative	O
+,	O
+trolox	O
+,	O
+were	O
+hardly	O
+noticed	O
+.	O
+
+The	O
+average	O
+PC	O
+volume	O
+percentage	O
+was	O
+21	O
+.	O
+86	O
+%	O
+±	O
+13	O
+.	O
+90	O
+%	O
+(	O
+range	O
+,	O
+5	O
+.	O
+6	O
+%	O
+to	O
+61	O
+.	O
+0	O
+%),	O
+which	O
+was	O
+inconsistently	O
+correlated	O
+with	O
+the	O
+admission	O
+partial	O
+pressure	O
+of	O
+oxygen	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+(	O
+R	O
+(	O
+2	O
+)	O
+=	O
+0	O
+.	O
+083	O
+).	O
+
+APE1	B-PRGE
+does	O
+not	O
+cleave	O
+strong	O
+doublestranded	O
+regions	O
+of	O
+RNA	O
+and	O
+it	O
+has	O
+a	O
+strong	O
+preference	O
+for	O
+3	O
+'	O
+of	O
+pyrimidine	B-CHED
+,	O
+especially	O
+towards	O
+UA	O
+,	O
+CA	O
+,	O
+and	O
+UG	O
+sites	O
+at	O
+single	O
+-	O
+stranded	O
+or	O
+weakly	O
+paired	O
+regions	O
+.	O
+
+ABSTRACT	O
+:	O
+Pre	B-DISO
+-	I-DISO
+eclampsia	I-DISO
+/	O
+Eclampsia	B-DISO
+is	O
+one	O
+of	O
+the	O
+leading	O
+causes	O
+of	O
+maternal	O
+and	O
+perinatal	B-DISO
+morbidity	I-DISO
+and	O
+mortality	O
+in	O
+sub	O
+-	O
+Saharan	O
+Africa	O
+including	O
+Nigeria	O
+.	O
+
+Activation	O
+of	O
+viral	B-COMP
+glycoprotein	I-COMP
+(	O
+GP	O
+)	O
+by	O
+protease	O
+also	O
+has	O
+been	O
+reported	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+The	O
+most	O
+distinctive	O
+difference	O
+between	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+the	O
+stage	O
+during	O
+virus	B-PROC
+replication	I-PROC
+in	O
+which	O
+viral	O
+glycoproteins	B-CHED
+are	O
+cleaved	B-ANAT
+by	O
+proteases	O
+.	O
+
+TITLE	O
+:	O
+Referral	O
+to	O
+an	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+center	O
+and	O
+mortality	O
+among	O
+patients	O
+with	O
+severe	O
+2009	O
+influenza	O
+A	O
+(	O
+H1N1	O
+).	O
+
+ECMO	O
+was	O
+used	O
+to	O
+treat	O
+patients	O
+with	O
+ARDS	B-DISO
+during	O
+the	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pandemic	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+80	O
+ECMO	O
+-	O
+referred	O
+patients	O
+,	O
+69	O
+received	O
+ECMO	O
+(	O
+86	O
+.	O
+3	O
+%)	O
+and	O
+22	O
+died	B-PROC
+(	O
+27	O
+.	O
+5	O
+%)	O
+prior	O
+to	O
+discharge	B-ANAT
+from	O
+the	O
+hospital	O
+.	O
+
+CONCLUSIONS	O
+:	O
+For	O
+patients	O
+with	O
+H1N1	O
+-	O
+related	O
+ARDS	B-DISO
+,	O
+referral	O
+and	O
+transfer	O
+to	O
+an	O
+ECMO	O
+center	O
+was	O
+associated	O
+with	O
+lower	O
+hospital	O
+mortality	O
+compared	O
+with	O
+matched	O
+non	O
+-	O
+ECMO	O
+-	O
+referred	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+cause	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+occasionally	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+diseases	O
+.	O
+
+A	O
+46	O
+-	O
+year	O
+-	O
+old	O
+female	O
+,	O
+health	O
+care	O
+worker	O
+with	O
+diabetes	B-DISO
+and	O
+presenting	O
+with	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+was	O
+admitted	O
+to	O
+the	O
+hospital	O
+.	O
+
+During	O
+9	O
+days	O
+of	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+symptoms	I-DISO
+,	O
+the	O
+patient	O
+had	O
+diabetes	B-DISO
+decompensation	O
+,	O
+haemorrhagic	B-DISO
+pneumonia	I-DISO
+,	O
+rhabdomyolysis	B-DISO
+,	O
+respiratory	O
+and	O
+renal	B-DISO
+failure	I-DISO
+,	O
+pericarditis	B-DISO
+,	O
+and	O
+brain	B-DISO
+edema	I-DISO
+and	O
+died	B-PROC
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+study	O
+is	O
+to	O
+review	O
+a	O
+single	O
+institution	O
+'	O
+s	O
+experience	O
+with	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+and	O
+compare	O
+patient	O
+characteristics	O
+,	O
+outcomes	O
+,	O
+and	O
+complications	O
+with	O
+other	O
+reported	O
+studies	O
+of	O
+HFOV	O
+use	O
+in	O
+burn	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Patient	O
+data	O
+were	O
+collected	O
+,	O
+including	O
+demographics	O
+,	O
+percentage	O
+of	O
+TBSA	O
+burn	O
+,	O
+percentage	O
+of	O
+full	O
+-	O
+thickness	O
+burn	O
+,	O
+mechanisms	O
+of	O
+burn	O
+,	O
+settings	O
+on	O
+conventional	O
+mechanical	O
+ventilation	O
+and	O
+HFOV	O
+,	O
+and	O
+blood	B-PROC
+gas	B-ENZY
+data	O
+before	O
+initiation	O
+of	O
+HFOV	O
+and	O
+at	O
+1	O
+,	O
+3	O
+,	O
+6	O
+,	O
+12	O
+,	O
+24	O
+,	O
+72	O
+(	O
+3	O
+days	O
+),	O
+120	O
+(	O
+5	O
+days	O
+),	O
+168	O
+(	O
+7	O
+days	O
+),	O
+240	O
+(	O
+10	O
+days	O
+),	O
+and	O
+336	O
+hours	O
+(	O
+14	O
+days	O
+).	O
+
+Flame	O
+burn	O
+was	O
+responsible	O
+for	O
+92	O
+.	O
+9	O
+%	O
+of	O
+the	O
+deaths	B-PROC
+,	O
+followed	O
+by	O
+5	O
+.	O
+3	O
+%	O
+of	O
+deaths	B-PROC
+due	O
+to	O
+chemical	O
+burns	O
+and	O
+1	O
+.	O
+8	O
+%	O
+to	O
+scalding	O
+.	O
+
+The	O
+eyes	B-ANAT
+are	O
+typically	O
+involved	O
+in	O
+TEN	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-DISO
+complications	I-DISO
+together	O
+with	O
+surgical	O
+complications	O
+are	O
+the	O
+most	O
+frequent	O
+causes	O
+for	O
+morbidity	O
+and	O
+mortality	O
+after	O
+thoracoabdominal	O
+esophagectomy	O
+.	O
+
+Thus	O
+,	O
+the	O
+choice	O
+of	O
+the	O
+thoracotomy	O
+method	O
+during	O
+the	O
+thoracoabdominal	O
+esophagectomy	O
+and	O
+the	O
+resultant	O
+cytokine	O
+levels	O
+may	O
+contribute	O
+to	O
+the	O
+occurrence	O
+of	O
+postoperative	O
+pulmonary	B-DISO
+complications	I-DISO
+and	O
+may	O
+have	O
+an	O
+impact	O
+on	O
+the	O
+extent	O
+and	O
+severity	O
+of	O
+the	O
+surgical	O
+stress	O
+.	O
+
+Monoclonal	O
+antibodies	B-COMP
+have	O
+been	O
+generated	O
+for	O
+direct	O
+antigen	B-CHED
+detection	O
+in	O
+NPA	B-CHED
+.	O
+
+For	O
+antibody	B-COMP
+detection	O
+,	O
+Escherichia	B-SPEC
+coli	I-SPEC
+BL21	B-ANAT
+and	O
+baculovirus	B-SPEC
+-	O
+expressed	B-PROC
+recombinant	O
+nucleocapsid	B-COMP
+of	O
+HCoV	O
+-	O
+HKU1	O
+have	O
+been	O
+used	O
+for	O
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+detection	O
+in	O
+sera	B-COMP
+of	O
+patients	O
+and	O
+normal	O
+individuals	O
+,	O
+using	O
+Western	O
+blot	O
+and	O
+enzyme	O
+-	O
+linked	O
+immunoassay	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+genomics	O
+and	O
+bioinformatics	O
+analysis	O
+.	O
+
+Coronaviruses	O
+possess	B-DISO
+the	O
+largest	O
+genomes	O
+(	O
+26	O
+.	O
+4	O
+to	O
+31	O
+.	O
+7	O
+kb	O
+)	O
+among	O
+all	O
+known	O
+RNA	O
+viruses	B-SPEC
+,	O
+with	O
+G	O
++	O
+C	O
+contents	O
+varying	O
+from	O
+32	O
+%	O
+to	O
+43	O
+%.	O
+
+A	O
+fourth	O
+genus	B-SPEC
+,	O
+Deltacoronavirus	O
+,	O
+which	O
+includes	O
+bulbul	B-SPEC
+coronavirus	B-SPEC
+HKU11	O
+,	O
+thrush	B-PRGE
+coronavirus	B-SPEC
+HKU12	I-PRGE
+and	I-PRGE
+munia	I-PRGE
+coronavirus	B-SPEC
+HKU13	I-PRGE
+,	O
+is	O
+emerging	O
+.	O
+
+However	O
+,	O
+there	O
+are	O
+limited	O
+data	O
+available	O
+on	O
+the	O
+frequency	O
+and	O
+extent	O
+of	O
+recombination	B-PROC
+in	O
+coronaviruses	O
+in	O
+nature	O
+and	O
+particularly	O
+for	O
+the	O
+avian	B-SPEC
+gamma	O
+-	O
+coronaviruses	O
+where	O
+only	O
+recently	O
+the	O
+emergence	O
+of	O
+a	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+has	O
+been	O
+attributed	O
+solely	O
+to	O
+recombination	B-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+full	O
+-	O
+length	O
+genomes	O
+of	O
+eight	O
+avian	B-SPEC
+gamma	O
+-	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+were	O
+sequenced	O
+and	O
+along	O
+with	O
+other	O
+full	O
+-	O
+length	O
+IBV	B-SPEC
+genomes	O
+available	O
+from	O
+GenBank	O
+were	O
+analyzed	O
+for	O
+recombination	B-PROC
+.	O
+
+Areas	O
+that	O
+have	O
+the	O
+highest	O
+occurrence	O
+of	O
+recombination	B-PROC
+are	O
+located	O
+in	O
+regions	O
+of	O
+the	O
+genome	O
+that	O
+code	O
+for	O
+nonstructural	O
+proteins	O
+2	O
+,	O
+3	O
+and	O
+16	O
+,	O
+and	O
+the	O
+structural	O
+spike	O
+glycoprotein	B-CHED
+.	O
+
+Among	O
+viruses	B-SPEC
+detectable	O
+by	O
+both	O
+commercial	O
+assays	O
+(	O
+adenovirus	B-DISO
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+1	O
+to	O
+3	O
+,	O
+and	O
+respiratory	O
+syncytial	O
+virus	O
+),	O
+the	O
+FilmArray	O
+and	O
+Prodesse	O
+assays	O
+showed	O
+good	O
+overall	O
+agreement	O
+(	O
+181	O
+/	O
+192	O
+[	O
+94	O
+.	O
+3	O
+%];	O
+kappa	O
+=	O
+0	O
+.	O
+87	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+79	O
+to	O
+0	O
+.	O
+94	O
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+present	O
+study	O
+,	O
+the	O
+detection	O
+of	O
+a	O
+pantropic	O
+canine	O
+coronavirus	O
+(	O
+CCoV	O
+)	O
+strain	O
+in	O
+a	O
+dog	B-SPEC
+with	O
+lethal	O
+diarrhoea	B-DISO
+is	O
+reported	O
+.	O
+
+The	O
+high	O
+binding	B-FUNC
+site	O
+plasticity	O
+is	O
+a	O
+major	O
+challenge	O
+in	O
+computational	O
+drug	O
+discovery	O
+/	O
+design	O
+efforts	O
+.	O
+
+Only	O
+aMD	B-DISO
+simulation	O
+,	O
+starting	O
+from	O
+the	O
+closed	O
+loop	O
+conformation	O
+,	O
+reproduced	O
+the	O
+180	O
+°	O
+ϕ	O
+-	O
+ψ	O
+dihedral	O
+rotation	O
+back	B-ANAT
+to	O
+the	O
+open	O
+loop	O
+state	O
+.	O
+
+Nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+comparisons	O
+have	O
+shown	O
+that	O
+the	O
+recent	O
+isolates	O
+bear	B-SPEC
+98	O
+.	O
+97	O
+%	O
+genetic	O
+similarity	O
+with	O
+strains	O
+of	O
+the	O
+QX	B-PRGE
+-	I-PRGE
+like	I-PRGE
+genotype	I-PRGE
+.	O
+
+Remarkably	O
+,	O
+a	O
+strong	O
+positive	O
+selection	O
+pressure	O
+was	O
+determined	O
+,	O
+mostly	O
+involving	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+insertion	O
+/	O
+deletion	O
+polymorphism	B-PROC
+is	O
+associated	O
+with	O
+severe	O
+hypoxemia	O
+in	O
+pediatric	O
+ARDS	O
+.	O
+
+Plasma	B-ANAT
+angiotensin	B-CHED
+-	O
+II	O
+concentration	O
+was	O
+measured	O
+by	O
+immunoassay	O
+at	O
+admission	O
+.	O
+
+ACE	B-PRGE
+I	I-PRGE
+/	I-PRGE
+D	I-PRGE
+polymorphism	B-PROC
+modified	O
+angiotensin	B-CHED
+-	O
+II	O
+levels	O
+in	O
+pediatric	O
+ARDS	B-DISO
+,	O
+but	O
+its	O
+pathogenic	O
+role	O
+is	O
+not	O
+well	O
+understood	O
+and	O
+needs	O
+to	O
+be	O
+addressed	O
+in	O
+future	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+following	O
+sepsis	B-DISO
+after	O
+stereotactic	O
+aspiration	B-DISO
+for	O
+spontaneous	O
+pontine	B-ANAT
+hemorrhage	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+52	O
+-	O
+year	O
+-	O
+old	O
+female	O
+was	O
+treated	O
+with	O
+CT	O
+-	O
+guided	O
+stereotactic	O
+aspiration	B-DISO
+for	O
+acute	O
+spontaneous	O
+pontine	B-DISO
+hemorrhage	I-DISO
+.	O
+
+As	O
+sepsis	B-DISO
+was	O
+stabilized	O
+,	O
+she	O
+developed	O
+flaccid	O
+weakness	B-DISO
+and	O
+autonomic	B-DISO
+dysfunction	I-DISO
+on	O
+postoperative	O
+day	O
+21	O
+.	O
+
+After	O
+confirming	O
+reactivity	O
+of	O
+the	O
+recombinant	B-PRGE
+protein	I-PRGE
+pAPN	I-PRGE
+-	I-PRGE
+C	I-PRGE
+to	O
+antibody	B-COMP
+against	O
+native	O
+pAPN	O
+,	O
+polyclonal	O
+antibody	B-COMP
+against	O
+the	O
+recombinant	B-PRGE
+protein	I-PRGE
+pAPN	I-PRGE
+-	I-PRGE
+C	I-PRGE
+was	O
+prepared	O
+in	O
+rabbit	B-SPEC
+using	O
+purified	O
+protein	B-CHED
+as	O
+immunogen	B-CHED
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+monoclonal	I-PRGE
+antibodies	B-COMP
+developed	O
+using	O
+a	O
+prokaryotic	O
+expressed	B-PROC
+protein	B-CHED
+.	O
+
+To	O
+express	O
+and	O
+purify	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+protein	B-CHED
+)	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+generate	O
+MAbs	O
+against	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+gene	O
+encoding	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+separated	O
+into	O
+two	O
+parts	O
+according	O
+to	O
+the	O
+prediction	O
+of	O
+epitopes	O
+and	O
+cloned	O
+into	O
+pET32a	O
+(+),	O
+respectively	O
+.	O
+
+Expression	B-PROC
+of	O
+the	O
+target	O
+proteins	B-CHED
+were	O
+induced	O
+by	O
+M	O
+isopropyl	B-CHED
+-	O
+β	O
+-	O
+thio	B-CHED
+-	O
+D	O
+-	O
+galactopyranoside	O
+(	O
+IPTG	B-CHED
+)	O
+and	O
+purified	O
+by	O
+a	O
+single	O
+-	O
+step	O
+affinity	O
+chromatography	O
+on	O
+a	O
+Ni	O
+-	O
+NTA	B-CHED
+column	B-ANAT
+.	O
+
+We	O
+review	O
+several	O
+approaches	O
+referred	O
+to	O
+as	O
+""""	O
+rescue	O
+""""	O
+therapies	O
+for	O
+severe	O
+hypoxemia	O
+,	O
+including	O
+lung	B-ANAT
+-	O
+recruitment	B-DISO
+maneuvers	O
+,	O
+ventilation	O
+modes	O
+,	O
+prone	O
+positioning	O
+,	O
+inhaled	B-PROC
+vasodilator	B-CHED
+therapy	O
+,	O
+and	O
+the	O
+use	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Noninvasive	O
+ventilation	O
+for	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Few	O
+studies	O
+have	O
+been	O
+performed	O
+on	O
+noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+to	O
+treat	O
+hypoxic	B-DISO
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Overall	O
+,	O
+the	O
+high	O
+rate	O
+of	O
+NIV	O
+failure	O
+suggests	O
+a	O
+cautious	O
+approach	O
+to	O
+NIV	O
+use	O
+in	O
+patients	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+including	O
+early	O
+initiation	O
+,	O
+intensive	O
+monitoring	O
+,	O
+and	O
+prompt	O
+intubation	O
+if	O
+signs	O
+of	O
+NIV	O
+failure	O
+emerge	O
+.	O
+
+TITLE	O
+:	O
+Crosstalk	B-PROC
+between	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+to	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+after	O
+vaccination	O
+and	O
+challenge	O
+of	O
+chickens	O
+varying	O
+in	O
+serum	B-COMP
+mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+concentrations	O
+.	O
+
+MBL	B-PRGE
+selectively	O
+binds	B-FUNC
+distinct	O
+chemical	O
+patterns	O
+,	O
+including	O
+carbohydrates	B-CHED
+expressed	B-PROC
+on	O
+all	O
+kinds	O
+of	O
+pathogens	O
+.	O
+
+The	O
+primary	O
+IBV	B-SPEC
+infection	B-DISO
+induced	I-DISO
+changes	O
+in	O
+circulating	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+populations	O
+and	O
+in	O
+the	O
+specific	O
+antibody	B-PROC
+responses	I-PROC
+.	O
+
+Serum	B-COMP
+MBL	O
+levels	O
+also	O
+influenced	O
+IBV	B-SPEC
+vaccine	O
+-	O
+induced	O
+changes	O
+in	O
+circulating	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+populations	O
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+morbidly	O
+obese	B-DISO
+,	O
+37	O
+-	O
+year	O
+-	O
+old	O
+,	O
+AH1N1	O
+-	O
+infected	O
+woman	O
+,	O
+who	O
+was	O
+admitted	O
+to	O
+a	O
+regional	O
+hospital	O
+because	O
+of	O
+rapidly	O
+progressing	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+HFOV	O
+was	O
+instituted	O
+for	O
+48	O
+h	O
+,	O
+resulting	O
+in	O
+a	O
+marked	O
+improvement	O
+in	O
+gas	B-ENZY
+exchange	O
+,	O
+however	O
+any	O
+manipulations	O
+caused	O
+immediate	O
+deterioration	O
+in	O
+the	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+ORF3b	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+a	O
+nuclear	O
+localization	B-PROC
+signal	O
+(	O
+NLS	B-DISO
+)	O
+at	O
+its	O
+C	O
+terminus	O
+and	O
+antagonizes	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+function	O
+by	O
+modulating	O
+the	O
+activity	O
+of	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF3	B-PRGE
+).	O
+
+Some	O
+HCoV	O
+strains	O
+,	O
+including	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+can	O
+invade	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+,	O
+where	O
+they	O
+infect	O
+neurons	B-ANAT
+,	O
+with	O
+unclear	O
+consequences	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+based	O
+design	O
+,	O
+synthesis	B-PROC
+,	O
+and	O
+evaluation	O
+of	O
+peptide	B-CHED
+-	O
+mimetic	O
+SARS	B-PRGE
+3CL	I-PRGE
+protease	B-CHED
+inhibitors	I-CHED
+.	O
+
+The	O
+electrical	O
+signals	O
+allow	O
+synchronization	O
+of	O
+ventilation	O
+to	O
+spontaneous	O
+breathing	B-PROC
+efforts	O
+of	O
+a	O
+child	O
+,	O
+as	O
+well	O
+as	O
+permitting	O
+pressure	O
+assistance	O
+proportional	O
+to	O
+the	O
+electrical	O
+signal	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+determined	O
+the	O
+effect	O
+of	O
+sample	O
+mishandling	O
+on	O
+the	O
+performance	O
+of	O
+ELISAs	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+avian	B-SPEC
+encephalomyelitis	I-SPEC
+virus	I-SPEC
+(	O
+AEV	O
+)	O
+and	O
+chicken	B-SPEC
+anaemia	I-SPEC
+virus	I-SPEC
+(	O
+CAV	B-SPEC
+)	O
+in	O
+the	O
+serum	B-COMP
+of	O
+chickens	B-SPEC
+.	O
+
+The	O
+IBV	B-SPEC
+ELISA	O
+appeared	O
+to	O
+be	O
+most	O
+susceptible	O
+to	O
+the	O
+effects	O
+of	O
+serum	B-COMP
+maltreatment	O
+.	O
+
+Immunohistochemistry	O
+was	O
+strongly	O
+positive	O
+for	O
+IBV	B-PRGE
+antigen	B-CHED
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+tubular	O
+epithelial	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+kidneys	B-ANAT
+and	O
+also	O
+in	O
+the	O
+epithelium	B-ANAT
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+salivary	B-ANAT
+glands	I-ANAT
+,	O
+proventriculus	B-ANAT
+,	O
+intestine	B-ANAT
+,	O
+and	O
+bursa	B-ANAT
+of	I-ANAT
+Fabricius	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Between	O
+2006	O
+and	O
+2009	O
+,	O
+seven	O
+strains	O
+of	O
+infectious	O
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+isolated	O
+from	O
+vaccinated	O
+chicken	B-SPEC
+flocks	O
+on	O
+different	O
+chicken	B-SPEC
+farms	O
+in	O
+China	O
+.	O
+
+The	O
+homology	O
+of	O
+the	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+among	O
+the	O
+seven	O
+isolates	O
+was	O
+81	O
+.	O
+7	O
+%-	O
+99	O
+.	O
+7	O
+%	O
+and	O
+79	O
+.	O
+0	O
+%-	O
+99	O
+.	O
+4	O
+%,	O
+respectively	O
+.	O
+
+As	O
+most	O
+detected	O
+enteric	O
+viruses	B-SPEC
+have	O
+been	O
+directly	O
+demonstrated	O
+in	O
+healthy	O
+turkey	B-SPEC
+flocks	O
+as	O
+well	O
+,	O
+the	O
+epidemiology	O
+of	O
+this	O
+disease	O
+complex	O
+remains	O
+unclear	O
+,	O
+suggesting	O
+that	O
+a	O
+certain	O
+combination	O
+of	O
+pathogens	O
+,	O
+environmental	O
+factors	O
+,	O
+or	O
+both	O
+are	O
+necessary	O
+for	O
+the	O
+development	B-PROC
+of	O
+clinical	O
+signs	O
+.	O
+
+To	O
+help	O
+in	O
+the	O
+evaluation	O
+of	O
+each	O
+case	O
+we	O
+used	O
+a	O
+decision	O
+-	O
+support	O
+tool	O
+that	O
+was	O
+previously	O
+developed	O
+for	O
+ventilator	O
+allocation	O
+during	O
+an	O
+influenza	B-DISO
+pandemic	O
+.	O
+
+In	O
+patients	O
+with	O
+H1N1	O
+pneumonia	B-DISO
+,	O
+post	O
+-	O
+ARDS	B-DISO
+pulmonary	B-DISO
+fibrosis	I-DISO
+is	O
+not	O
+a	O
+rare	O
+complication	B-DISO
+.	O
+
+We	O
+found	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp16	I-PRGE
+MTase	I-PRGE
+methylated	O
+m7GpppA	O
+-	O
+RNA	O
+but	O
+not	O
+m7GpppG	O
+-	O
+RNA	O
+,	O
+which	O
+is	O
+in	O
+contrast	O
+with	O
+nsp14	O
+MTase	O
+that	O
+functions	O
+in	O
+a	O
+sequence	O
+-	O
+independent	O
+manner	O
+.	O
+
+We	O
+demonstrated	O
+that	O
+nsp10	O
+is	O
+required	O
+for	O
+nsp16	O
+to	O
+bind	B-FUNC
+both	O
+m7GpppA	B-PRGE
+-	I-PRGE
+RNA	I-PRGE
+substrate	O
+and	O
+SAM	B-DISO
+cofactor	B-CHED
+.	O
+
+TITLE	O
+:	O
+Estimating	O
+the	O
+Causal	O
+Effect	O
+of	O
+Low	O
+Tidal	O
+Volume	O
+Ventilation	O
+on	O
+Survival	O
+in	O
+Patients	O
+with	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+.	O
+
+Using	O
+a	O
+transient	O
+transfection	B-PROC
+system	O
+,	O
+ORF6	O
+'	O
+s	O
+ability	O
+to	O
+suppress	O
+the	O
+expression	B-PROC
+of	O
+co	O
+-	O
+transfected	O
+expression	B-PROC
+constructs	O
+was	O
+measured	O
+in	O
+a	O
+quantitative	O
+manner	O
+.	O
+
+While	O
+ORF6	O
+does	O
+not	O
+have	O
+a	O
+global	O
+effect	O
+on	O
+protein	B-PROC
+synthesis	I-PROC
+,	O
+quantitative	O
+real	O
+-	O
+time	O
+PCR	O
+revealed	O
+that	O
+it	O
+down	O
+-	O
+regulated	O
+the	O
+mRNA	B-CHED
+level	O
+of	O
+the	O
+co	O
+-	O
+transfected	O
+myc	B-PRGE
+-	I-PRGE
+nsp8	I-PRGE
+gene	I-PRGE
+.	O
+
+Twenty	O
+-	O
+five	O
+stress	B-PATH
+response	I-PATH
+genes	O
+were	O
+preferentially	O
+upregulated	O
+during	O
+infection	B-DISO
+in	O
+the	O
+absence	O
+of	O
+the	O
+E	B-PRGE
+gene	I-PRGE
+.	O
+
+Administration	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+in	O
+trans	O
+reduced	O
+the	O
+stress	B-PATH
+response	I-PATH
+in	O
+cells	B-COMP
+infected	O
+with	O
+rSARS	O
+-	O
+CoV	O
+-	O
+ΔE	O
+or	O
+with	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+or	O
+treated	O
+with	O
+drugs	O
+,	O
+such	O
+as	O
+tunicamycin	B-CHED
+and	O
+thapsigargin	B-CHED
+that	O
+elicit	O
+cell	B-COMP
+stress	O
+by	O
+different	O
+mechanisms	O
+.	O
+
+In	O
+2009	O
+serologic	O
+responses	O
+to	O
+either	O
+pandemic	O
+H1N1	O
+(	O
+2009	O
+)	O
+vaccine	O
+(	O
+n	O
+=	O
+36	O
+)	O
+or	O
+pandemic	O
+H1N1	O
+(	O
+2009	O
+)	O
+infection	B-DISO
+(	O
+n	O
+=	O
+2	O
+)	O
+were	O
+studied	O
+in	O
+38	O
+HSCT	O
+recipients	O
+.	O
+
+Responses	O
+were	O
+measured	O
+with	O
+a	O
+standard	O
+hemagglutination	B-PROC
+-	O
+inhibition	B-PROC
+assay	O
+.	O
+
+Little	O
+is	O
+known	O
+about	O
+the	O
+epidemiology	O
+of	O
+this	O
+syndrome	B-DISO
+.	O
+
+The	O
+relationship	O
+between	O
+severe	O
+AH	O
+strata	O
+and	O
+need	O
+for	O
+MV	O
+was	O
+graded	O
+in	O
+the	O
+most	O
+pronounced	O
+way	O
+in	O
+respiratory	O
+and	O
+circulatory	B-PROC
+conditions	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+ABSTRACT	O
+:	O
+Uniquely	O
+among	O
+RNA	O
+viruses	O
+,	O
+replication	O
+of	O
+the	O
+~	O
+30	O
+-	O
+kb	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+genome	O
+is	O
+believed	O
+to	O
+involve	O
+two	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+activities	O
+.	O
+
+The	O
+latter	O
+activity	O
+is	O
+,	O
+however	O
+,	O
+~	O
+20	O
+-	O
+fold	O
+weaker	O
+than	O
+that	O
+of	O
+the	O
+primer	O
+-	O
+dependent	O
+nsp12	O
+-	O
+RdRp	B-FUNC
+at	O
+equal	O
+monomer	O
+concentrations	O
+.	O
+
+Wire	O
+-	O
+enforced	O
+cannulae	O
+(	O
+13	O
+-	O
+15	O
+Fr	O
+)	O
+were	O
+inserted	O
+under	O
+ultrasound	O
+guidance	O
+and	O
+connected	O
+to	O
+iLA	B-PRGE
+.	O
+
+iLA	B-PRGE
+showed	O
+effective	O
+CO	O
+(	O
+2	O
+)	O
+removal	O
+,	O
+allowed	O
+for	O
+reducing	O
+the	O
+invasiveness	O
+of	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+from	O
+various	O
+causes	O
+even	O
+using	O
+a	O
+small	O
+-	O
+sized	O
+catheter	O
+and	O
+was	O
+safe	O
+in	O
+small	O
+body	B-ANAT
+-	O
+sized	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+:	O
+not	O
+only	O
+an	O
+enteric	O
+pathogen	O
+.	O
+
+The	O
+enteric	O
+FCoV	O
+,	O
+referred	O
+to	O
+as	O
+feline	B-SPEC
+enteric	O
+virus	B-SPEC
+(	O
+FECV	B-SPEC
+),	O
+is	O
+considered	O
+a	O
+mostly	O
+benign	O
+biotype	O
+infecting	O
+the	O
+gut	B-ANAT
+,	O
+whereas	O
+the	O
+FIP	B-DISO
+virus	B-SPEC
+biotype	O
+is	O
+considered	O
+the	O
+highly	O
+pathogenic	O
+etiologic	O
+agent	O
+for	O
+FIP	B-DISO
+.	O
+
+Current	O
+laboratory	O
+tests	O
+are	O
+unable	O
+to	O
+distinguish	O
+between	O
+virus	B-SPEC
+biotypes	O
+of	O
+FCoV	O
+.	O
+FECV	B-SPEC
+is	O
+highly	O
+contagious	O
+and	O
+easily	O
+spreads	O
+in	O
+multicat	O
+environments	O
+;	O
+therefore	O
+,	O
+the	O
+challenges	O
+to	O
+animal	B-SPEC
+shelters	O
+are	O
+tremendous	O
+.	O
+
+Neuromuscular	O
+blocking	B-DISO
+agents	O
+(	O
+NMBAs	O
+)	O
+are	O
+used	O
+to	O
+facilitate	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+have	O
+been	O
+shown	O
+to	O
+improve	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+survival	O
+in	O
+adult	O
+patients	O
+with	O
+early	O
+ARDS	B-DISO
+who	O
+were	O
+randomized	O
+to	O
+receive	O
+either	O
+a	O
+48	O
+-	O
+hr	O
+infusion	O
+of	O
+the	O
+NMBA	O
+,	O
+cisatracurium	O
+,	O
+or	O
+a	O
+placebo	O
+.	O
+
+Eligible	O
+patients	O
+were	O
+>	O
+18	O
+yr	O
+with	O
+an	O
+intubated	O
+trachea	O
+and	O
+ventilated	O
+lungs	B-ANAT
+for	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Their	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+)	O
+ratio	O
+was	O
+<	O
+150	O
+at	O
+a	O
+tidal	O
+volume	O
+of	O
+6	O
+-	O
+8	O
+mL	O
+·	O
+kg	O
+(-	O
+1	O
+)	O
+ideal	O
+body	B-ANAT
+weight	O
+and	O
+a	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+≥	O
+5	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+for	O
+<	O
+48	O
+hr	O
+.	O
+
+It	O
+was	O
+determined	O
+a	O
+priori	O
+that	O
+this	O
+would	O
+be	O
+adjusted	O
+for	O
+imbalance	B-DISO
+in	O
+key	O
+risk	O
+factors	O
+at	O
+baseline	O
+,	O
+as	O
+derived	O
+from	O
+Cox	O
+regression	O
+.	O
+
+This	O
+outcome	O
+did	O
+not	O
+reach	B-PROC
+statistical	O
+significance	O
+(	O
+P	O
+=	O
+0	O
+.	O
+08	O
+).	O
+
+The	O
+cisatracurium	O
+group	O
+also	O
+had	O
+significantly	O
+more	O
+ventilator	O
+-	O
+free	O
+days	O
+,	O
+more	O
+days	O
+outside	O
+of	O
+the	O
+ICU	O
+,	O
+and	O
+more	O
+days	O
+free	O
+of	O
+organ	B-ANAT
+-	O
+failure	O
+.	O
+
+A	O
+prospective	O
+observational	O
+study	O
+of	O
+children	O
+under	O
+eighteen	O
+years	O
+old	O
+,	O
+confirmed	O
+having	O
+the	O
+2009	O
+pandemic	O
+influenza	B-DISO
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+by	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+-	O
+polymerase	O
+-	O
+chain	O
+-	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+admitted	O
+at	O
+Queen	O
+Sirikit	O
+National	O
+Institute	O
+of	O
+Child	O
+Health	O
+,	O
+Bangkok	O
+,	O
+Thailand	O
+during	O
+one	O
+year	O
+,	O
+from	O
+1st	O
+June	O
+2009	O
+to	O
+31st	O
+May	O
+2010	O
+.	O
+
+Radiographic	O
+findings	O
+included	O
+diffuse	O
+interstitial	B-ANAT
+,	O
+alveolar	B-ANAT
+infiltrates	B-DISO
+and	O
+some	O
+in	O
+lobar	O
+distributions	O
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+-	O
+host	B-COMP
+interactome	O
+:	O
+identification	O
+of	O
+cyclophilins	O
+as	O
+target	O
+for	O
+pan	B-COMP
+-	O
+coronavirus	B-SPEC
+inhibitors	B-CHED
+.	O
+
+After	O
+exposure	O
+to	O
+hyperoxia	B-DISO
+,	O
+the	O
+wet	O
+/	O
+dry	O
+weight	O
+ratio	O
+remained	O
+stable	O
+before	O
+day	O
+2	O
+but	O
+increased	O
+significantly	O
+after	O
+day	O
+3	O
+.	O
+
+Some	O
+of	O
+viruses	B-SPEC
+found	O
+in	O
+animals	B-SPEC
+,	O
+and	O
+particularly	O
+rotaviruses	B-SPEC
+,	O
+can	O
+also	O
+infect	O
+humans	B-SPEC
+.	O
+
+Quinoline	B-CHED
+derivatives	O
+were	O
+also	O
+tested	O
+against	O
+representatives	O
+of	O
+other	O
+RNA	O
+virus	B-SPEC
+families	O
+containing	O
+single	O
+-	O
+stranded	O
+,	O
+either	O
+positive	O
+-	O
+sense	B-PROC
+(	O
+ssRNA	O
+(+))	O
+or	O
+negative	O
+-	O
+sense	B-PROC
+(	O
+RNA	O
+(-)),	O
+and	O
+double	O
+-	O
+stranded	O
+genomes	O
+(	O
+dsRNA	B-CHED
+),	O
+as	O
+well	O
+as	O
+against	O
+representatives	O
+of	O
+two	O
+DNA	O
+virus	B-SPEC
+families	O
+.	O
+
+Some	O
+quinolines	B-CHED
+showed	O
+moderate	O
+,	O
+although	O
+selective	O
+activity	O
+against	O
+CVB	O
+-	O
+5	O
+,	O
+Reo	O
+-	O
+1	O
+and	O
+RSV	O
+.	O
+
+New	O
+International	O
+Health	O
+Regulations	O
+(	O
+IHR	O
+),	O
+applied	O
+first	O
+during	O
+the	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+outbreak	O
+,	O
+demonstrated	O
+improvement	O
+.	O
+
+Establishment	O
+of	O
+a	O
+joint	B-ANAT
+WHO	O
+-	O
+WTO	O
+committee	O
+to	O
+adjudicate	O
+these	O
+conflicts	O
+might	O
+better	O
+achieve	O
+that	O
+balance	B-PROC
+.	O
+
+ARDS	B-DISO
+is	O
+a	O
+clinically	O
+important	O
+complication	B-DISO
+of	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+a	O
+significant	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+the	O
+risk	O
+of	O
+HAIs	O
+before	O
+and	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Such	O
+comparison	O
+is	O
+intended	O
+to	O
+provide	O
+a	O
+surrogate	O
+measure	O
+of	O
+the	O
+influence	O
+that	O
+strict	O
+enforcement	O
+of	O
+infection	B-DISO
+control	O
+strategies	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+may	O
+have	O
+had	O
+on	O
+the	O
+risk	O
+of	O
+HAIs	O
+.	O
+
+The	O
+rate	O
+of	O
+HAIs	O
+was	O
+higher	O
+in	O
+the	O
+pre	O
+-	O
+SARS	O
+period	O
+than	O
+the	O
+SARS	B-DISO
+period	O
+.	O
+
+The	O
+rate	O
+of	O
+HAIs	O
+in	O
+the	O
+pre	O
+-	O
+SARS	B-DISO
+period	O
+was	O
+14	O
+.	O
+5	O
+%	O
+as	O
+opposed	O
+to	O
+9	O
+%	O
+during	O
+the	O
+SARS	B-DISO
+period	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+findings	O
+suggest	O
+that	O
+strict	O
+enforcement	O
+of	O
+infection	B-DISO
+control	O
+strategies	O
+may	O
+have	O
+a	O
+positive	O
+impact	O
+on	O
+the	O
+efforts	O
+to	O
+minimise	O
+the	O
+risk	O
+of	O
+HAIs	O
+.	O
+
+TITLE	O
+:	O
+Thiazolides	O
+as	O
+novel	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+The	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+thiazolides	O
+against	O
+HCV	B-SPEC
+are	O
+less	O
+predictable	O
+than	O
+against	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+HBV	B-DISO
+),	O
+though	O
+an	O
+electron	O
+-	O
+withdrawing	O
+group	O
+at	O
+C	O
+(	O
+5	O
+')	O
+generally	O
+correlates	O
+with	O
+potency	O
+.	O
+
+We	O
+show	O
+here	O
+that	O
+the	O
+5	O
+'-	O
+Cl	O
+analogue	B-CHED
+4	I-CHED
+has	O
+closely	O
+comparable	O
+in	O
+vitro	O
+activity	O
+and	O
+a	O
+good	O
+cell	B-COMP
+safety	O
+index	O
+.	O
+
+ABSTRACT	O
+:	O
+Neurological	B-DISO
+disease	I-DISO
+is	O
+a	O
+relatively	O
+common	O
+reason	O
+for	O
+referral	O
+,	O
+constituting	O
+approximately	O
+10	O
+%	O
+of	O
+the	O
+feline	B-SPEC
+referral	O
+caseload	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+causes	O
+severe	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+characterized	O
+by	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+and	O
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+.	O
+
+This	O
+pathology	B-DISO
+often	O
+progresses	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+(	O
+such	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+[	O
+ARDS	B-DISO
+])	O
+and	O
+atypical	B-DISO
+pneumonia	I-DISO
+in	O
+humans	B-SPEC
+,	O
+with	O
+characteristic	O
+age	O
+-	O
+related	O
+mortality	O
+rates	O
+approaching	O
+50	O
+%	O
+or	O
+more	O
+in	O
+immunosenescent	O
+populations	O
+.	O
+
+The	O
+mutations	O
+in	O
+S	O
+likely	O
+increase	O
+recognition	O
+of	O
+the	O
+mouse	B-SPEC
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+receptor	O
+not	O
+only	O
+in	O
+MA15	O
+but	O
+also	O
+in	O
+two	O
+additional	O
+,	O
+independently	O
+isolated	O
+mouse	B-SPEC
+-	O
+adapted	O
+SARS	B-DISO
+-	O
+CoVs	O
+.	O
+
+In	O
+contrast	O
+to	O
+the	O
+findings	O
+for	O
+young	O
+animals	B-SPEC
+,	O
+mutations	O
+to	O
+revert	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+sequence	O
+in	O
+nsp9	O
+and	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+were	O
+not	O
+sufficient	O
+to	O
+significantly	O
+attenuate	O
+the	O
+virus	B-SPEC
+compared	O
+to	O
+other	O
+combinations	O
+of	O
+mouse	B-SPEC
+-	O
+adapted	O
+mutations	O
+in	O
+12	O
+-	O
+month	O
+-	O
+old	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Four	O
+new	O
+tetromycin	O
+derivatives	O
+,	O
+tetromycins	O
+1	O
+-	O
+4	O
+and	O
+a	O
+previously	O
+known	O
+one	O
+,	O
+tetromycin	O
+B	O
+(	O
+5	O
+)	O
+were	O
+isolated	O
+from	O
+Streptomyces	O
+axinellae	O
+Pol001	O
+(	O
+T	O
+)	O
+cultivated	O
+from	O
+the	O
+Mediterranean	O
+sponge	B-SPEC
+Axinella	B-SPEC
+polypoides	I-SPEC
+.	O
+
+All	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+prefer	O
+Gln	O
+at	O
+P1	O
+position	O
+,	O
+Leu	B-CHED
+at	O
+P2	O
+position	O
+,	O
+basic	O
+residues	O
+at	O
+P3	O
+position	O
+,	O
+small	O
+hydrophobic	O
+residues	O
+at	O
+P4	O
+position	O
+,	O
+and	O
+small	O
+residues	O
+at	O
+P1	O
+'	O
+and	O
+P2	O
+'	O
+positions	O
+.	O
+
+By	O
+combining	O
+the	O
+most	O
+favorable	O
+residues	O
+at	O
+P3	O
+to	O
+P5	O
+positions	O
+,	O
+we	O
+identified	O
+super	O
+-	O
+active	O
+substrate	O
+sequences	O
+'	O
+VARLQ	O
+↓	O
+SGF	O
+'	O
+that	O
+can	O
+be	O
+cleaved	B-ANAT
+efficiently	O
+by	O
+all	O
+3CL	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+with	O
+relative	O
+activity	O
+of	O
+1	O
+.	O
+7	O
+to	O
+3	O
+.	O
+2	O
+,	O
+and	O
+'	O
+VPRLQ	O
+↓	O
+SGF	O
+'	O
+that	O
+can	O
+be	O
+cleaved	B-ANAT
+specifically	O
+by	O
+IBV	B-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+with	O
+relative	O
+activity	O
+of	O
+4	O
+.	O
+3	O
+.	O
+
+As	O
+reported	O
+,	O
+numerous	O
+cases	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+were	O
+also	O
+seen	O
+among	O
+young	O
+previously	O
+healthy	O
+people	O
+.	O
+
+All	O
+patients	O
+were	O
+older	O
+than	O
+30	O
+but	O
+younger	O
+than	O
+50	O
+years	O
+,	O
+had	O
+clinical	O
+and	O
+radiological	O
+evidence	O
+of	O
+an	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+needed	O
+invasive	O
+ventilatory	O
+support	O
+.	O
+
+Four	O
+patients	O
+needed	O
+an	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+due	O
+to	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+global	O
+respiratory	B-DISO
+insufficiency	I-DISO
+that	O
+could	O
+not	O
+be	O
+treated	O
+by	O
+conservative	O
+ventilatory	O
+support	O
+.	O
+
+One	O
+other	O
+patient	O
+died	B-PROC
+due	O
+to	O
+a	O
+subarachnoidal	B-ANAT
+bleeding	B-DISO
+under	O
+the	O
+anticoagulatory	O
+regime	O
+during	O
+ECMO	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+Prone	O
+positioning	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+):	O
+when	O
+and	O
+how	O
+?	O
+
+Compared	O
+with	O
+the	O
+control	O
+group	O
+,	O
+the	O
+levels	O
+of	O
+secreted	B-PROC
+IgA	B-PRGE
+decreased	O
+significantly	O
+at	O
+42	O
+d	O
+of	O
+age	O
+in	O
+the	O
+chickens	B-SPEC
+that	O
+were	O
+treated	O
+with	O
+LPS	B-DISO
+or	O
+CPM	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+ABSTRACT	O
+:	O
+An	O
+experimental	O
+study	O
+was	O
+conducted	O
+to	O
+determine	O
+the	O
+comparative	O
+pathogenicity	O
+of	O
+type	O
+-	O
+2	O
+turkey	O
+astrovirus	O
+(	O
+TAstV	O
+-	O
+2	O
+)	O
+obtained	O
+from	O
+turkey	B-SPEC
+flocks	O
+afflicted	O
+with	O
+poult	O
+enteritis	B-DISO
+syndrome	B-DISO
+(	O
+PES	B-ANAT
+)	O
+and	O
+from	O
+turkey	B-SPEC
+flocks	O
+displaying	O
+no	O
+apparent	O
+signs	O
+of	O
+infection	B-DISO
+.	O
+
+Group	O
+C	O
+served	O
+as	O
+a	O
+negative	O
+control	O
+and	O
+was	O
+given	O
+PBS	B-DISO
+.	O
+
+These	O
+results	O
+provide	O
+a	O
+preliminary	O
+indication	O
+that	O
+TAstV	O
+-	O
+2	O
+from	O
+PES	B-ANAT
+birds	B-SPEC
+may	O
+be	O
+more	O
+pathogenic	O
+than	O
+TAstV	O
+-	O
+2	O
+from	O
+apparently	O
+healthy	O
+poults	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+a	O
+highly	O
+infectious	B-DISO
+pneumonia	B-DISO
+that	O
+emerged	O
+in	O
+southern	O
+China	O
+early	O
+in	O
+2003	O
+.	O
+
+SARS	B-DISO
+patients	O
+were	O
+almost	O
+universally	O
+steroid	B-CHED
+naive	O
+with	O
+no	O
+other	O
+known	O
+predisposition	O
+to	O
+osteonecrosis	B-DISO
+.	O
+
+Osteonecrosis	B-DISO
+most	O
+commonly	O
+affected	O
+the	O
+proximal	B-ANAT
+femur	I-ANAT
+and	O
+femoral	B-ANAT
+condyles	B-ANAT
+and	O
+was	O
+most	O
+strongly	O
+related	O
+to	O
+cumulative	O
+steroid	B-CHED
+dose	O
+and	O
+duration	O
+of	O
+steroid	B-CHED
+therapy	O
+.	O
+
+It	O
+has	O
+a	O
+heterogeneous	O
+aetiology	O
+with	O
+wide	O
+-	O
+ranging	O
+pulmonary	B-ANAT
+and	O
+extra	O
+-	O
+pulmonary	B-ANAT
+causes	O
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+-	O
+binding	B-PROC
+activity	I-PROC
+of	O
+the	O
+truncated	O
+C	O
+subunit	O
+of	O
+porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+A	O
+majority	O
+of	O
+identified	O
+microRNAs	O
+(	O
+miRNAs	O
+)	O
+showed	O
+divergent	O
+changes	O
+in	O
+expression	B-PROC
+across	O
+mouse	B-SPEC
+strains	O
+with	O
+respect	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+infections	B-DISO
+and	O
+responded	O
+differently	O
+to	O
+a	O
+highly	O
+pathogenic	O
+reconstructed	O
+1918	O
+virus	B-SPEC
+compared	O
+to	O
+a	O
+minimally	O
+pathogenic	O
+seasonal	O
+influenza	O
+virus	O
+isolate	O
+.	O
+
+The	O
+small	O
+RNAs	O
+identified	O
+also	O
+included	O
+many	O
+non	O
+-	O
+miRNA	O
+small	O
+RNAs	O
+,	O
+such	O
+as	O
+small	O
+nucleolar	B-ANAT
+RNAs	O
+(	O
+snoRNAs	O
+),	O
+in	O
+addition	O
+to	O
+nonannotated	O
+small	O
+RNAs	O
+.	O
+
+These	O
+findings	O
+represent	O
+the	O
+first	O
+integrated	O
+sequencing	O
+analysis	O
+of	O
+the	O
+response	O
+of	O
+host	B-COMP
+small	O
+RNAs	O
+to	O
+virus	B-DISO
+infection	I-DISO
+and	O
+show	O
+that	O
+small	O
+RNAs	O
+are	O
+an	O
+integrated	O
+component	O
+of	O
+complex	O
+networks	O
+involved	O
+in	O
+regulating	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+infection	B-DISO
+.	O
+
+Multimodal	O
+therapies	O
+for	O
+ARDS	B-DISO
+were	O
+effective	O
+.	O
+
+TITLE	O
+:	O
+Involvement	O
+of	O
+FOXO	B-PRGE
+transcription	I-PRGE
+factors	I-PRGE
+,	O
+TRAIL	B-PRGE
+-	O
+FasL	B-PRGE
+/	O
+Fas	B-DISO
+,	O
+and	O
+sirtuin	O
+proteins	B-CHED
+family	B-SPEC
+in	O
+canine	O
+coronavirus	O
+type	O
+II	O
+-	O
+induced	O
+apoptosis	B-PATH
+.	O
+
+with	O
+a	O
+decrease	O
+of	O
+both	O
+proteins	B-CHED
+at	O
+the	O
+end	O
+of	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Combined	O
+recombinant	B-PRGE
+human	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+C	I-PRGE
+and	O
+ceftazidime	B-CHED
+prevent	O
+the	O
+onset	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+experimental	O
+animal	B-SPEC
+study	O
+investigates	O
+the	O
+effects	O
+of	O
+combined	O
+recombinant	B-PRGE
+human	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+C	I-PRGE
+(	O
+rhAPC	O
+)	O
+and	O
+ceftazidime	B-CHED
+on	O
+cardiopulmonary	B-ANAT
+function	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Compared	O
+with	O
+injured	O
+controls	O
+,	O
+the	O
+treatment	O
+group	O
+had	O
+a	O
+significantly	O
+higher	O
+PaO₂	B-PRGE
+/	O
+FIO₂	O
+ratio	O
+,	O
+and	O
+the	O
+onset	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+was	O
+prevented	O
+.	O
+
+This	O
+study	O
+determined	O
+the	O
+virus	B-SPEC
+susceptibility	O
+of	O
+primary	O
+cultures	O
+of	O
+human	B-SPEC
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+(	O
+AMs	B-DISO
+).	O
+
+The	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+of	O
+AMs	B-DISO
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+was	O
+evaluated	O
+for	O
+cytokine	B-PROC
+production	I-PROC
+and	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+gene	B-PROC
+expression	I-PROC
+.	O
+
+TITLE	O
+:	O
+Thoracic	B-ANAT
+computerized	O
+tomographic	O
+(	O
+CT	O
+)	O
+findings	O
+in	O
+2009	O
+influenza	B-DISO
+A	I-DISO
+(	I-DISO
+H1N1	I-DISO
+)	I-DISO
+virus	B-PROC
+infection	I-PROC
+in	O
+Isfahan	O
+,	O
+Iran	O
+.	O
+
+Propentofylline	O
+(	O
+PPF	B-CHED
+)	O
+can	O
+decrease	O
+vasculitis	B-DISO
+,	O
+and	O
+therefore	O
+prolong	O
+survival	O
+time	O
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+and	O
+increase	O
+their	O
+quality	O
+of	O
+life	O
+.	O
+
+There	O
+was	O
+no	O
+statistically	O
+significant	O
+difference	O
+in	O
+the	O
+survival	O
+time	O
+of	O
+cats	B-SPEC
+treated	O
+with	O
+PPF	B-CHED
+(	O
+8	O
+days	O
+,	O
+95	O
+%	O
+CI	O
+5	O
+.	O
+4	O
+-	O
+10	O
+.	O
+6	O
+)	O
+versus	O
+placebo	O
+(	O
+7	O
+.	O
+5	O
+days	O
+,	O
+95	O
+%	O
+CI	O
+4	O
+.	O
+4	O
+-	O
+9	O
+.	O
+6	O
+).	O
+
+There	O
+was	O
+neither	O
+a	O
+difference	O
+in	O
+quality	O
+of	O
+life	O
+(	O
+day	O
+7	O
+,	O
+P	O
+=	O
+.	O
+892	O
+),	O
+in	O
+the	O
+amount	O
+of	O
+effusion	B-DISO
+(	O
+day	O
+7	O
+,	O
+P	O
+=	O
+.	O
+710	O
+),	O
+the	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+)	O
+concentration	O
+(	O
+day	O
+7	O
+,	O
+P	O
+=	O
+.	O
+355	O
+),	O
+nor	O
+in	O
+any	O
+other	O
+variable	O
+investigated	O
+in	O
+this	O
+study	O
+,	O
+including	O
+a	O
+complete	O
+blood	B-ANAT
+count	O
+,	O
+and	O
+a	O
+small	O
+animal	B-SPEC
+biochemistry	O
+profile	O
+.	O
+
+RESULTS	O
+:	O
+There	O
+was	O
+no	O
+statistically	O
+significant	O
+difference	O
+in	O
+the	O
+survival	O
+time	O
+of	O
+cats	B-SPEC
+treated	O
+with	O
+PPF	B-CHED
+(	O
+8	O
+days	O
+,	O
+95	O
+%	O
+CI	O
+5	O
+.	O
+4	O
+-	O
+10	O
+.	O
+6	O
+)	O
+versus	O
+placebo	O
+(	O
+7	O
+.	O
+5	O
+days	O
+,	O
+95	O
+%	O
+CI	O
+4	O
+.	O
+4	O
+-	O
+9	O
+.	O
+6	O
+).	O
+
+Organisational	O
+implementation	O
+of	O
+infection	B-DISO
+control	O
+measures	O
+,	O
+avoidance	O
+of	O
+patients	O
+and	O
+complying	O
+with	O
+personal	O
+protective	O
+equipment	O
+were	O
+identified	O
+as	O
+risk	O
+-	O
+mitigating	O
+strategies	O
+.	O
+
+RESULTS	O
+:	O
+Findings	O
+indicated	O
+that	O
+healthcare	O
+workers	O
+perceived	O
+personal	O
+and	O
+familial	O
+health	O
+risks	O
+and	O
+stigmatisation	O
+from	O
+their	O
+exposure	O
+to	O
+emerging	O
+acute	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+but	O
+the	O
+majority	O
+were	O
+accepting	O
+of	O
+these	O
+risks	O
+.	O
+
+We	O
+also	O
+review	O
+the	O
+functions	O
+of	O
+coronavirus	B-SPEC
+proteins	B-CHED
+,	O
+structural	O
+,	O
+enzymatic	O
+,	O
+and	O
+accessory	O
+,	O
+with	O
+an	O
+emphasis	O
+on	O
+roles	O
+in	O
+pathogenesis	O
+.	O
+
+Nonstructural	O
+proteins	B-CHED
+include	O
+the	O
+small	O
+accessory	O
+proteins	B-CHED
+that	O
+are	O
+not	O
+at	O
+all	O
+conserved	O
+between	O
+MHV	B-SPEC
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+the	O
+16	O
+conserved	O
+proteins	B-CHED
+encoded	O
+in	O
+the	O
+replicase	B-PRGE
+locus	I-PRGE
+,	O
+many	O
+of	O
+which	O
+have	O
+enzymatic	O
+activities	O
+in	O
+RNA	B-PROC
+metabolism	I-PROC
+or	O
+protein	B-PROC
+processing	I-PROC
+in	O
+addition	O
+to	O
+functions	O
+in	O
+antagonizing	O
+host	B-PROC
+response	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+can	O
+be	O
+induced	O
+by	O
+viral	B-DISO
+diseases	I-DISO
+,	O
+with	O
+two	O
+virus	B-SPEC
+types	O
+being	O
+responsible	O
+:	O
+respiratory	O
+viruses	B-SPEC
+that	O
+cause	O
+community	O
+-	O
+acquired	O
+viral	B-DISO
+pneumonia	I-DISO
+and	O
+Herpesviridae	B-SPEC
+that	O
+cause	O
+nosocomial	O
+viral	B-DISO
+pneumonia	I-DISO
+.	O
+
+Other	O
+than	O
+antiviral	B-CHED
+drug	I-CHED
+(	O
+mainly	O
+oseltamivir	B-CHED
+)	O
+administration	O
+and	O
+avoidance	O
+of	O
+corticosteroids	B-CHED
+,	O
+management	O
+of	O
+ARDS	B-DISO
+due	O
+to	O
+these	O
+viruses	B-SPEC
+does	O
+not	O
+differ	O
+from	O
+that	O
+for	O
+ARDS	B-DISO
+caused	O
+by	O
+other	O
+diseases	O
+.	O
+
+HSV	B-SPEC
+is	O
+frequently	O
+recovered	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+of	O
+mechanically	O
+ventilated	O
+patients	O
+and	O
+can	O
+sometimes	O
+be	O
+responsible	O
+for	O
+HSV	B-SPEC
+bronchopneumonitis	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+have	O
+been	O
+detected	O
+in	O
+children	O
+with	O
+upper	O
+and	O
+lower	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+but	O
+little	O
+is	O
+known	O
+about	O
+their	O
+relationship	O
+with	O
+severe	O
+respiratory	O
+illness	O
+.	O
+
+Hospitalized	O
+children	O
+testing	O
+positive	O
+for	O
+HCoV	O
+alone	O
+tended	O
+to	O
+be	O
+less	O
+ill	B-DISO
+than	O
+those	O
+infected	O
+with	O
+other	O
+viruses	B-SPEC
+,	O
+whereas	O
+those	O
+coinfected	O
+with	O
+HCoV	O
+and	O
+other	O
+viruses	B-SPEC
+were	O
+clinically	O
+similar	O
+to	O
+those	O
+infected	O
+with	O
+other	O
+viruses	B-SPEC
+alone	O
+.	O
+
+ECMO	O
+was	O
+introduced	O
+in	O
+a	O
+patient	O
+with	O
+severe	O
+heart	O
+failure	O
+caused	O
+by	O
+fulminant	O
+myocarditis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	O
+phase	O
+proteins	B-CHED
+as	O
+a	O
+tool	O
+for	O
+differential	O
+diagnosis	O
+of	O
+wasting	B-DISO
+diseases	I-DISO
+in	O
+growing	O
+pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+concentrations	O
+of	O
+haptoglobin	B-PRGE
+(	O
+Hp	O
+),	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+)	O
+and	O
+serum	B-PRGE
+amyloid	B-DISO
+A	I-PRGE
+(	O
+SAA	B-PRGE
+)	O
+were	O
+measured	O
+in	O
+wasted	B-DISO
+pigs	B-SPEC
+,	O
+first	O
+to	O
+evaluate	O
+their	O
+usefulness	O
+in	O
+the	O
+diagnosis	O
+of	O
+infectious	B-DISO
+,	O
+wasting	B-DISO
+diseases	I-DISO
+in	O
+pigs	B-SPEC
+,	O
+and	O
+second	O
+,	O
+to	O
+evaluate	O
+whether	O
+their	O
+concentrations	O
+can	O
+distinguish	O
+the	O
+lymphoid	O
+depletion	O
+score	O
+in	O
+the	O
+lymph	B-ANAT
+tissues	B-ANAT
+of	O
+wasted	B-DISO
+affected	O
+pigs	B-SPEC
+.	O
+
+T	B-ANAT
+cells	I-ANAT
+are	O
+necessary	O
+for	O
+viral	O
+clearance	O
+,	O
+and	O
+many	O
+age	O
+-	O
+dependent	O
+intrinsic	O
+T	B-ANAT
+cell	I-ANAT
+defects	O
+have	O
+been	O
+documented	O
+.	O
+
+They	O
+show	O
+that	O
+migration	B-PROC
+of	O
+respiratory	O
+DCs	B-DISO
+from	O
+the	O
+site	O
+of	O
+virus	B-PROC
+replication	I-PROC
+to	O
+the	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+in	O
+response	O
+to	O
+infection	B-DISO
+with	O
+several	O
+different	O
+respiratory	O
+viruses	B-SPEC
+is	O
+markedly	O
+diminished	O
+with	O
+increasing	O
+age	O
+.	O
+
+It	O
+comprised	O
+of	O
+three	O
+sections	O
+:	O
+(	O
+1	O
+)	O
+Section	O
+A	O
+was	O
+the	O
+introduction	O
+;	O
+(	O
+2	O
+)	O
+Section	O
+B	O
+asked	O
+for	O
+the	O
+respondent	O
+'	O
+s	O
+personal	O
+information	O
+;	O
+and	O
+(	O
+3	O
+)	O
+Section	O
+C	O
+comprised	O
+the	O
+major	O
+part	O
+of	O
+the	O
+questionnaire	O
+and	O
+was	O
+intended	O
+to	O
+gather	O
+information	O
+regarding	O
+the	O
+hospital	O
+'	O
+s	O
+general	O
+emergency	B-DISO
+management	O
+situation	O
+.	O
+
+No	O
+hospital	O
+had	O
+an	O
+established	O
+emergency	B-DISO
+management	O
+department	O
+or	O
+full	O
+-	O
+time	O
+staff	O
+for	O
+emergency	B-DISO
+management	O
+.	O
+
+A	O
+total	O
+of	O
+15	O
+-	O
+45	O
+%	O
+of	O
+the	O
+hospitals	O
+had	O
+established	O
+a	O
+hospital	O
+emergency	B-DISO
+management	O
+committee	O
+,	O
+performed	O
+a	O
+vulnerability	O
+analysis	O
+,	O
+or	O
+evaluated	O
+emergency	B-DISO
+management	O
+regularly	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+survey	O
+response	O
+rate	O
+was	O
+44	O
+%,	O
+accounting	O
+for	O
+29	O
+%	O
+of	O
+total	O
+hospitals	O
+that	O
+the	O
+study	O
+targeted	B-PROC
+.	O
+
+No	O
+amplification	B-DISO
+was	O
+achieved	O
+for	O
+the	O
+uninfected	O
+cells	B-COMP
+,	O
+cells	B-COMP
+infected	O
+with	O
+canine	O
+parvovirus	B-DISO
+,	O
+canine	O
+coronavirus	B-SPEC
+,	O
+or	O
+canine	B-SPEC
+adenovirus	I-SPEC
+.	O
+
+These	O
+results	O
+suggested	O
+that	O
+the	O
+CDV	B-CHED
+genotype	O
+Asia	O
+-	O
+1	O
+is	O
+circulating	O
+currently	O
+in	O
+domestic	O
+dogs	B-SPEC
+in	O
+China	O
+.	O
+
+Early	O
+initiation	O
+of	O
+neuraminidase	O
+inhibitor	O
+and	O
+the	O
+implementation	O
+of	O
+guidelines	O
+for	O
+management	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+should	O
+be	O
+considered	O
+.	O
+
+Treatment	O
+for	O
+pneumonia	B-DISO
+outside	O
+the	O
+home	O
+was	O
+sought	O
+by	O
+92	O
+%	O
+of	O
+the	O
+children	O
+<	O
+5	O
+years	O
+old	O
+and	O
+73	O
+%	O
+of	O
+the	O
+persons	O
+aged	O
+five	O
+years	O
+and	O
+older	O
+.	O
+
+The	O
+acceleration	O
+of	O
+the	O
+epithelial	O
+repair	B-PROC
+process	O
+in	O
+the	O
+injured	O
+lung	B-ANAT
+may	O
+provide	O
+an	O
+effective	O
+therapeutic	O
+target	O
+.	O
+
+TITLE	O
+:	O
+Chronic	B-DISO
+fatigue	I-DISO
+syndrome	I-DISO
+:	O
+acute	B-DISO
+infection	I-DISO
+and	O
+history	O
+of	O
+physical	O
+activity	O
+affect	O
+resting	B-ANAT
+levels	O
+and	O
+response	O
+to	O
+exercise	O
+of	O
+plasma	B-ANAT
+oxidant	B-CHED
+/	O
+antioxidant	B-CHED
+status	O
+and	O
+heat	B-PROC
+shock	I-PROC
+proteins	B-CHED
+.	O
+
+A	O
+combination	O
+of	O
+sport	O
+practice	O
+and	O
+infection	B-DISO
+was	O
+noted	O
+in	O
+11	O
+patients	O
+(	O
+group	O
+IV	O
+).	O
+
+This	O
+case	O
+highlights	O
+the	O
+importance	O
+of	O
+biochemical	O
+profiling	O
+in	O
+patients	O
+presenting	O
+with	O
+possible	O
+drug	B-DISO
+use	I-DISO
+,	O
+even	O
+in	O
+the	O
+absence	O
+of	O
+significant	O
+symptoms	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+has	O
+a	O
+high	O
+mutation	O
+rate	O
+,	O
+leading	O
+to	O
+various	O
+neuropathologies	O
+after	O
+infection	B-DISO
+.	O
+
+To	O
+confirm	O
+MHVR	O
+-	O
+independence	O
+in	O
+vitro	O
+,	O
+we	O
+used	O
+a	O
+combination	O
+of	O
+spinoculation	O
+and	O
+ultraviolet	O
+radiation	O
+to	O
+detect	O
+distinct	O
+plaque	B-DISO
+formation	B-PROC
+(	O
+SpinoPlaque	O
+(	O
+UV	O
++))	O
+afrer	O
+infection	B-DISO
+of	O
+BHK	O
+cells	B-COMP
+,	O
+which	O
+do	O
+not	O
+express	O
+MHVR	O
+.	O
+
+Infection	B-DISO
+with	O
+the	O
+mutant	B-DISO
+viruses	B-SPEC
+was	O
+100	O
+%	O
+correlated	O
+with	O
+SpinoPlaque	O
+(	O
+UV	O
++)	O
+formation	B-PROC
+.	O
+
+This	O
+is	O
+in	O
+contrast	O
+to	O
+infection	B-DISO
+with	O
+srr7	O
+,	O
+which	O
+does	O
+not	O
+from	O
+SpinoPlaque	O
+(	O
+UV	O
++).	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+due	O
+to	O
+Acinetobacter	B-SPEC
+baumannii	I-SPEC
+].	O
+
+Administering	O
+oxygen	B-CHED
+via	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+is	O
+,	O
+however	O
+,	O
+limited	O
+in	O
+respiratory	B-DISO
+diseases	I-DISO
+such	O
+as	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+,	O
+pneumoconiosis	B-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+or	O
+following	O
+the	O
+inhalation	B-PROC
+of	O
+asphyxiating	O
+poisons	O
+.	O
+
+In	O
+combination	O
+with	O
+their	O
+superior	O
+isolation	O
+efficiency	O
+,	O
+MDCK	B-ANAT
+cells	I-ANAT
+appear	O
+highly	O
+suitable	O
+to	O
+be	O
+used	O
+as	O
+an	O
+alternative	O
+to	O
+embryonated	O
+eggs	O
+to	O
+isolate	O
+and	O
+propagate	O
+influenza	B-DISO
+vaccine	O
+candidate	O
+viruses	B-SPEC
+.	O
+
+The	O
+compound	O
+1	O
+,	O
+evaluated	O
+in	O
+HepG	B-PRGE
+2	I-PRGE
+.	I-PRGE
+2	I-PRGE
+.	O
+15	O
+cells	B-COMP
+expressing	O
+permanently	O
+HBV	B-DISO
+,	O
+significantly	O
+reduced	O
+the	O
+levels	O
+of	O
+HBV	B-DISO
+antigens	B-CHED
+and	O
+HBV	B-DISO
+DNA	O
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+and	O
+time	O
+-	O
+dependent	O
+manner	O
+.	O
+
+Eight	O
+(	O
+4	O
+for	O
+Campylobacter	B-SPEC
+jejuni	I-SPEC
+,	O
+2	O
+for	O
+Campylobacter	B-SPEC
+coli	I-SPEC
+,	O
+1	O
+for	O
+Norovirus	B-SPEC
+genogroup	O
+II	O
+,	O
+and	O
+1	O
+for	O
+both	O
+Campylobacter	B-SPEC
+coli	I-SPEC
+and	O
+enterotoxigenic	O
+Escherichia	B-SPEC
+coli	I-SPEC
+)	O
+of	O
+10	O
+samples	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+1	O
+enteric	O
+pathogen	O
+.	O
+
+The	O
+nuclear	O
+receptor	O
+farnesoid	B-PRGE
+X	I-PRGE
+receptor	I-PRGE
+(	O
+FXR	B-PRGE
+)	O
+is	O
+expressed	B-PROC
+in	O
+pulmonary	B-ANAT
+artery	I-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+expression	B-PROC
+of	O
+a	O
+constitutively	O
+active	O
+FXR	B-PRGE
+repressed	O
+the	O
+expression	B-PROC
+of	O
+proinflammatory	O
+genes	O
+and	O
+improved	O
+lung	B-ANAT
+permeability	O
+and	O
+lung	B-ANAT
+regeneration	B-PROC
+in	O
+FXR	O
+-/-	O
+mice	B-SPEC
+.	O
+
+Determination	O
+of	O
+etiology	O
+,	O
+infection	B-DISO
+,	O
+fat	B-DISO
+embolism	I-DISO
+or	O
+hypoventilation	B-DISO
+,	O
+is	O
+difficult	O
+,	O
+as	O
+a	O
+self	O
+-	O
+perpetuating	O
+vicious	O
+circle	O
+is	O
+ongoing	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+indicate	O
+a	O
+reduced	O
+immune	B-PROC
+response	I-PROC
+to	O
+MF59	O
+-	O
+adjuvanted	O
+seasonal	O
+influenza	B-DISO
+vaccine	O
+in	O
+JIA	O
+children	O
+and	O
+adolescents	O
+treated	O
+with	O
+etanercept	O
+in	O
+comparison	O
+with	O
+those	O
+treated	O
+with	O
+DMARDs	O
+and	O
+healthy	O
+controls	O
+.	O
+
+The	O
+shRNAs	O
+were	O
+transiently	O
+transfected	O
+into	O
+a	O
+porcine	B-SPEC
+kidney	B-ANAT
+cell	I-ANAT
+line	O
+,	O
+PK	O
+-	O
+15	O
+,	O
+to	O
+determine	O
+whether	O
+these	O
+constructs	O
+inhibited	O
+PHEV	O
+production	O
+.	O
+
+Next	O
+,	O
+stable	O
+transfection	B-PROC
+of	O
+shN2	B-PRGE
+was	O
+used	O
+to	O
+produce	O
+two	O
+siRNA	O
+stably	O
+expressing	O
+PK	O
+-	O
+15	O
+cell	B-ANAT
+clones	I-ANAT
+(	O
+shN2	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+shN2	B-PRGE
+-	I-PRGE
+2	I-PRGE
+),	O
+and	O
+these	O
+two	O
+lines	O
+were	O
+infected	O
+with	O
+PHEV	O
+.	O
+
+These	O
+results	O
+indicated	O
+that	O
+RNAi	B-PROC
+targeting	B-PROC
+of	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+could	O
+facilitate	O
+studies	O
+of	O
+the	O
+specific	O
+function	O
+of	O
+viral	O
+genes	O
+associated	O
+with	O
+PHEV	O
+replication	O
+and	O
+may	O
+have	O
+potential	O
+therapeutic	O
+applications	O
+.	O
+
+Severe	O
+illness	O
+is	O
+characterized	O
+by	O
+a	O
+loss	O
+of	O
+total	O
+body	B-ANAT
+protein	B-CHED
+mass	O
+,	O
+mainly	O
+from	O
+the	O
+skeletal	B-ANAT
+muscle	I-ANAT
+.	O
+
+Simultaneously	O
+,	O
+protein	B-CHED
+intake	O
+should	O
+be	O
+between	O
+1	O
+.	O
+2	O
+and	O
+1	O
+.	O
+5	O
+g	O
+/	O
+kg	O
+/	O
+day	O
+.	O
+
+Glutamine	B-CHED
+(	O
+0	O
+.	O
+2	O
+-	O
+0	O
+.	O
+4	O
+g	O
+/	O
+kg	O
+/	O
+day	O
+of	O
+L	B-CHED
+-	I-CHED
+glutamine	I-CHED
+)	O
+should	O
+be	O
+added	O
+to	O
+enteral	O
+nutrition	B-PROC
+in	O
+burn	O
+and	O
+trauma	O
+patients	O
+(	O
+ESPEN	O
+guidelines	O
+2006	O
+)	O
+and	O
+to	O
+parenteral	O
+nutrition	B-PROC
+,	O
+in	O
+the	O
+form	O
+of	O
+dipeptides	B-CHED
+,	O
+in	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+patients	O
+in	O
+general	O
+(	O
+ESPEN	O
+guidelines	O
+2009	O
+).	O
+
+We	O
+have	O
+developed	O
+VIRsiRNAdb	O
+,	O
+a	O
+manually	O
+curated	O
+database	O
+having	O
+comprehensive	O
+details	O
+of	O
+1358	O
+siRNA	O
+/	O
+shRNA	O
+targeting	B-PROC
+viral	B-COMP
+genome	I-COMP
+regions	O
+.	O
+
+VIRsiRNAdb	O
+would	O
+prove	O
+useful	O
+for	O
+researchers	O
+in	O
+picking	O
+up	O
+the	O
+best	O
+viral	O
+siRNA	O
+for	O
+antiviral	B-CHED
+therapeutics	O
+development	B-PROC
+and	O
+also	O
+for	O
+developing	O
+better	O
+viral	O
+siRNA	O
+design	O
+tools	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+protocol	O
+for	O
+the	O
+cessation	O
+of	O
+sedation	B-DISO
+in	O
+brain	B-ANAT
+-	O
+injured	O
+patients	O
+].	O
+
+If	O
+an	O
+opioid	O
+withdrawal	B-DISO
+syndrome	I-DISO
+occurred	O
+,	O
+patients	O
+received	O
+a	O
+48	O
+-	O
+hour	O
+continuous	O
+infusion	O
+of	O
+buprenorphine	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+in	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+adults	O
+.	O
+
+HFOV	O
+theoretically	O
+meets	O
+the	O
+goals	O
+of	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+.	O
+
+Large	O
+,	O
+prospective	O
+,	O
+randomized	O
+controlled	O
+trials	O
+such	O
+as	O
+the	O
+ongoing	O
+OSCAR	O
+and	O
+OSCILLATE	O
+trials	O
+will	O
+help	O
+further	O
+define	O
+the	O
+role	O
+of	O
+HFOV	O
+in	O
+adult	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+study	O
+'	O
+s	O
+objective	O
+was	O
+to	O
+report	O
+a	O
+case	O
+and	O
+review	O
+the	O
+literature	O
+on	O
+the	O
+use	O
+of	O
+extracorporeal	O
+life	O
+support	O
+in	O
+the	O
+face	B-DISO
+of	O
+severe	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Meconium	B-ANAT
+aspiration	I-DISO
+syndrome	I-DISO
+(	O
+MAS	O
+)	O
+is	O
+a	O
+common	O
+cause	O
+of	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+in	O
+term	O
+infants	O
+,	O
+with	O
+an	O
+associated	O
+highly	O
+variable	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+This	O
+disorder	O
+can	O
+be	O
+life	O
+threatening	O
+,	O
+often	O
+complicated	O
+by	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+pulmonary	B-ANAT
+air	B-CHED
+leaks	O
+,	O
+and	O
+PPHN	O
+.	O
+
+TITLE	O
+:	O
+Yeast	B-SPEC
+based	O
+small	O
+molecule	O
+screen	O
+for	O
+inhibitors	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+coronavirus	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+emerged	O
+in	O
+2002	O
+,	O
+resulting	O
+in	O
+roughly	O
+8000	O
+cases	O
+worldwide	O
+and	O
+10	O
+%	O
+mortality	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLP	B-PRGE
+)	O
+is	O
+an	O
+attractive	O
+target	O
+for	O
+pharmaceutical	B-CHED
+development	B-PROC
+because	O
+it	O
+is	O
+essential	O
+for	O
+virus	B-PROC
+replication	I-PROC
+and	O
+is	O
+conserved	O
+among	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+BToV	O
+was	O
+the	O
+only	O
+enteric	O
+pathogen	O
+detected	O
+in	O
+these	O
+outbreaks	O
+,	O
+as	O
+determined	O
+by	O
+electron	O
+microscopy	O
+,	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+,	O
+bacteria	B-SPEC
+and	O
+parasite	O
+tests	O
+of	O
+fecal	B-ANAT
+samples	O
+,	O
+and	O
+antibody	B-COMP
+tests	O
+with	O
+paired	O
+sera	B-COMP
+.	O
+
+Furthermore	O
+,	O
+we	O
+isolated	O
+a	O
+BToV	O
+strain	O
+,	O
+designated	O
+Niigata	O
+(	O
+TC	O
+),	O
+from	O
+a	O
+fecal	B-ANAT
+sample	O
+using	O
+a	O
+human	B-SPEC
+rectal	B-DISO
+tumor	I-DISO
+cell	O
+line	O
+.	O
+
+In	O
+addition	O
+,	O
+our	O
+findings	O
+indicate	O
+that	O
+the	O
+HE	B-PRGE
+protein	I-PRGE
+of	O
+BToV	O
+may	O
+not	O
+be	O
+necessary	O
+for	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Pulmonary	B-DISO
+disease	I-DISO
+can	O
+range	O
+from	O
+asymptomatic	B-DISO
+infection	I-DISO
+to	O
+rapidly	O
+severe	O
+and	O
+fatal	O
+disease	O
+.	O
+
+Most	O
+cases	O
+will	O
+present	O
+as	O
+pneumonia	B-DISO
+,	O
+either	O
+acute	O
+or	O
+chronic	O
+,	O
+or	O
+as	O
+a	O
+lung	B-ANAT
+mass	O
+.	O
+
+Detection	O
+of	O
+urinary	O
+Blastomyces	B-PRGE
+antigen	B-CHED
+is	O
+a	O
+recent	O
+addition	O
+to	O
+diagnostic	O
+options	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+frequency	O
+of	O
+epidemiological	O
+threats	O
+(	O
+H5N1	B-DISO
+influenza	I-DISO
+,	O
+SARS	B-DISO
+,	O
+etc	O
+.)	O
+in	O
+modern	O
+world	O
+calls	O
+for	O
+the	O
+development	B-PROC
+of	O
+new	O
+flexible	O
+technologies	O
+for	O
+manufacturing	O
+efficacious	O
+vaccines	O
+and	O
+rapid	O
+reorientation	O
+of	O
+their	O
+production	O
+as	O
+appropriate	O
+.	O
+
+The	O
+main	O
+objective	O
+was	O
+to	O
+decide	O
+on	O
+the	O
+best	O
+-	O
+performing	O
+testing	O
+approach	O
+for	O
+the	O
+detection	O
+of	O
+influenza	B-SPEC
+viruses	I-SPEC
+A	O
+and	O
+B	O
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+types	O
+1	O
+to	O
+3	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+Chlamydophila	B-SPEC
+pneumoniae	I-SPEC
+,	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+and	O
+Legionella	B-SPEC
+pneumophila	I-SPEC
+by	O
+nucleic	B-CHED
+acid	I-CHED
+amplification	B-DISO
+techniques	O
+(	O
+NAATs	O
+).	O
+
+In	O
+this	O
+study	O
+chicks	O
+and	O
+old	O
+hens	O
+were	O
+infected	O
+by	O
+oculo	O
+-	O
+nasal	B-ANAT
+route	O
+with	O
+Italy	O
+02	O
+serotype	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+nsp1	I-PRGE
+protein	B-CHED
+induces	O
+template	O
+-	O
+dependent	O
+endonucleolytic	O
+cleavage	B-PROC
+of	O
+mRNAs	O
+:	O
+viral	O
+mRNAs	O
+are	O
+resistant	O
+to	O
+nsp1	O
+-	O
+induced	O
+RNA	O
+cleavage	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SCoV	O
+)	O
+nonstructural	O
+protein	B-CHED
+(	O
+nsp	O
+)	O
+1	O
+,	O
+a	O
+potent	O
+inhibitor	B-CHED
+of	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+,	O
+possesses	B-DISO
+a	O
+unique	O
+mode	O
+of	O
+action	O
+:	O
+it	O
+binds	B-FUNC
+to	O
+40S	O
+ribosomes	B-COMP
+to	O
+inactivate	O
+their	O
+translation	B-PROC
+functions	O
+and	O
+induces	O
+host	B-COMP
+mRNA	B-PROC
+degradation	I-PROC
+.	O
+
+Our	O
+previous	O
+study	O
+demonstrated	O
+that	O
+nsp1	B-PRGE
+induces	O
+RNA	B-PROC
+modification	I-PROC
+near	O
+the	O
+5	O
+'-	O
+end	O
+of	O
+a	O
+reporter	O
+mRNA	B-CHED
+having	O
+a	O
+short	O
+5	O
+'	O
+untranslated	O
+region	O
+and	O
+RNA	O
+cleavage	B-PROC
+in	O
+the	O
+encephalomyocarditis	B-SPEC
+virus	I-SPEC
+internal	O
+ribosome	B-COMP
+entry	O
+site	O
+(	O
+IRES	O
+)	O
+region	O
+of	O
+a	O
+dicistronic	O
+RNA	O
+template	O
+,	O
+but	O
+not	O
+in	O
+those	O
+IRES	O
+elements	O
+from	O
+hepatitis	B-PATH
+C	I-PATH
+or	O
+cricket	B-SPEC
+paralysis	O
+viruses	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+RSV	B-SPEC
+was	O
+the	O
+main	O
+pathogen	O
+of	O
+ARI	B-CHED
+,	O
+and	O
+the	O
+new	O
+-	O
+found	O
+virus	B-SPEC
+MPV	B-SPEC
+was	O
+also	O
+another	O
+crucial	O
+pathogen	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+causes	O
+an	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+of	O
+domestic	O
+fowl	O
+that	O
+affects	O
+poultry	O
+of	O
+all	O
+ages	O
+causing	O
+economic	O
+problems	O
+for	O
+the	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+These	O
+interactions	O
+lead	O
+to	O
+the	O
+formation	B-PROC
+of	O
+viral	B-PROC
+replication	I-PROC
+complexes	O
+,	O
+which	O
+produce	O
+new	O
+viral	O
+RNA	O
+progeny	O
+in	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+The	O
+remaining	O
+12	O
+patients	O
+were	O
+transferred	O
+on	O
+veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+with	O
+extracorporeal	B-ANAT
+blood	I-ANAT
+flow	O
+2	O
+.	O
+7	O
+±	O
+1	O
+L	O
+·	O
+min	O
+⁻	O
+¹	O
+,	O
+gas	B-ENZY
+flow	O
+3	O
+.	O
+8	O
+±	O
+1	O
+.	O
+8	O
+L	O
+·	O
+min	O
+⁻	O
+¹	O
+,	O
+and	O
+FiO₂	O
+1	O
+.	O
+
+These	O
+assays	O
+are	O
+now	O
+being	O
+multiplexed	O
+with	O
+primary	O
+detection	O
+and	O
+subtyping	O
+assays	O
+,	O
+especially	O
+in	O
+the	O
+case	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+	O
+Fighting	O
+against	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+China	O
+.	O
+
+In	O
+1985	O
+,	O
+Dr	O
+.	O
+Yin	O
+sucessfully	O
+isolated	O
+the	O
+hepatitis	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+after	O
+which	O
+,	O
+in	O
+2002	O
+,	O
+he	O
+developed	O
+the	O
+first	O
+proprietary	O
+inactivated	O
+hepatitis	B-DISO
+A	I-DISO
+vaccine	O
+in	O
+China	O
+and	O
+soon	O
+launched	O
+it	O
+into	O
+the	O
+China	O
+market	O
+.	O
+
+They	O
+are	O
+now	O
+simpler	O
+,	O
+safer	O
+,	O
+require	O
+less	O
+anticoagulation	B-PROC
+and	O
+are	O
+associated	O
+with	O
+fewer	O
+bleeding	B-DISO
+complications	O
+.	O
+
+Comparing	O
+infection	B-DISO
+frequencies	O
+in	O
+children	O
+who	O
+have	O
+mild	O
+infections	B-DISO
+with	O
+frequencies	O
+in	O
+children	O
+needing	O
+hospital	O
+uptake	O
+will	O
+determine	O
+whether	O
+infection	B-DISO
+by	O
+one	O
+of	O
+the	O
+four	O
+HCoVs	O
+leads	O
+to	O
+more	O
+severe	O
+disease	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+sequence	O
+of	O
+seroconversions	O
+can	O
+reveal	O
+whether	O
+infection	B-DISO
+by	O
+one	O
+HCoV	O
+protects	O
+from	O
+infection	B-DISO
+by	O
+other	O
+HCoVs	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+majority	O
+of	O
+healthy	O
+children	O
+seroconverted	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+(	O
+n	O
+=	O
+19	O
+)	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+(	O
+n	O
+=	O
+17	O
+),	O
+less	O
+for	O
+HCoV	O
+-	O
+HKU1	O
+(	O
+n	O
+=	O
+9	O
+)	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+(	O
+n	O
+=	O
+5	O
+).	O
+
+Inclusion	O
+criteria	O
+included	O
+randomised	O
+controlled	O
+trials	O
+and	O
+quasi	O
+-	O
+experimental	O
+and	O
+observational	O
+studies	O
+of	O
+humans	B-SPEC
+published	O
+in	O
+English	O
+with	O
+an	O
+outcome	O
+of	O
+laboratory	O
+-	O
+confirmed	O
+or	O
+clinically	O
+-	O
+diagnosed	O
+influenza	B-DISO
+and	O
+other	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+One	O
+hospital	O
+-	O
+based	O
+trial	O
+found	O
+a	O
+lower	O
+rate	O
+of	O
+clinical	O
+respiratory	O
+illness	O
+associated	O
+with	O
+non	O
+-	O
+fit	B-DISO
+-	O
+tested	O
+N95	O
+respirator	O
+use	O
+compared	O
+with	O
+medical	O
+masks	O
+.	O
+
+None	O
+of	O
+the	O
+studies	O
+established	O
+a	O
+conclusive	O
+relationship	O
+between	O
+mask	O
+/	O
+respirator	O
+use	O
+and	O
+protection	O
+against	O
+influenza	B-PATH
+infection	B-DISO
+.	O
+
+This	O
+signature	O
+comprised	O
+57	O
+genes	O
+including	O
+a	O
+subnetwork	O
+of	O
+chemokines	O
+,	O
+implicating	O
+dysregulated	O
+cell	B-COMP
+recruitment	B-DISO
+in	O
+injury	O
+.	O
+
+Finally	O
+,	O
+our	O
+electron	O
+tomograms	O
+revealed	O
+a	O
+network	O
+of	O
+nucleocapsid	B-COMP
+protein	B-CHED
+-	O
+containing	O
+protein	B-CHED
+tubules	O
+that	O
+appears	O
+to	O
+be	O
+intertwined	O
+with	O
+the	O
+RVN	O
+.	O
+
+The	O
+finding	O
+of	O
+high	O
+rates	O
+of	O
+rhinovirus	B-DISO
+infection	I-DISO
+corresponds	O
+to	O
+their	O
+frequent	O
+occurrence	O
+in	O
+adults	O
+.	O
+
+Ergothioneine	B-CHED
+should	O
+be	O
+considered	O
+for	O
+additional	O
+testing	O
+as	O
+a	O
+potential	O
+therapy	O
+for	O
+treating	O
+and	O
+preventing	O
+ARDS	B-DISO
+.	O
+
+Dengue	B-DISO
+vaccine	O
+development	B-PROC
+using	O
+traditional	O
+approaches	O
+has	O
+not	O
+been	O
+satisfactory	O
+in	O
+terms	O
+of	O
+inducing	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Among	O
+different	O
+coronavirus	O
+genera	O
+,	O
+the	O
+receptor	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+S1	I-PRGE
+subunits	I-PRGE
+of	O
+their	O
+spike	O
+proteins	B-CHED
+differ	O
+in	O
+primary	O
+,	O
+secondary	O
+,	O
+and	O
+tertiary	O
+structures	O
+.	O
+
+Our	O
+patient	O
+experienced	O
+nephrotic	B-DISO
+syndrome	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+caused	O
+by	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	B-DISO
+virus	I-DISO
+infection	I-DISO
+at	O
+5	O
+years	O
+of	O
+age	O
+.	O
+
+The	O
+BPEX	O
+Pig	B-SPEC
+Health	O
+Scheme	O
+(	O
+BPHS	O
+)	O
+is	O
+a	O
+monitoring	O
+system	O
+,	O
+which	O
+informs	O
+producers	O
+of	O
+gross	O
+lesions	O
+in	O
+their	O
+pigs	B-SPEC
+'	O
+carcasses	O
+at	O
+slaughter	O
+,	O
+enabling	O
+farm	O
+-	O
+level	O
+decisions	O
+to	O
+be	O
+made	O
+.	O
+
+Principal	O
+component	O
+analysis	O
+(	O
+PCA	B-DISO
+)	O
+performed	O
+on	O
+BPHS	B-PRGE
+reports	I-PRGE
+generated	O
+three	O
+principal	O
+components	O
+,	O
+explaining	O
+71	O
+%	O
+of	O
+the	O
+total	O
+variance	O
+.	O
+
+The	O
+study	O
+found	O
+statistical	O
+associations	O
+between	O
+levels	O
+of	O
+pleurisy	B-DISO
+recorded	O
+by	O
+BPHS	O
+at	O
+slaughter	O
+and	O
+the	O
+presence	O
+H1N2	O
+and	O
+PRRSV	B-SPEC
+in	O
+the	O
+herd	O
+.	O
+
+The	O
+reports	O
+were	O
+combined	O
+with	O
+data	O
+regarding	O
+the	O
+presence	O
+/	O
+absence	O
+of	O
+several	O
+pathogens	O
+in	O
+the	O
+herd	O
+and	O
+potential	O
+farm	O
+-	O
+level	O
+risk	O
+factors	O
+for	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+BCV	B-SPEC
+was	O
+identified	O
+in	O
+lung	B-ANAT
+samples	O
+[	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+collection	O
+]	O
+as	O
+well	O
+as	O
+in	O
+nasal	B-ANAT
+swabs	O
+.	O
+
+Bovine	B-SPEC
+coronavirus	B-SPEC
+was	O
+isolated	O
+from	O
+both	O
+healthy	O
+and	O
+sick	O
+calves	O
+,	O
+but	O
+not	O
+from	O
+sick	O
+calves	O
+after	O
+4	O
+d	O
+arrival	O
+at	O
+the	O
+feedlot	O
+.	O
+
+To	O
+approach	O
+the	O
+subject	O
+,	O
+we	O
+investigated	O
+immunological	O
+etiology	O
+focused	O
+on	O
+cytokines	O
+and	O
+an	O
+acute	O
+lung	B-ANAT
+damage	O
+factor	O
+in	O
+influenza	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+by	O
+using	O
+a	O
+PR	O
+-	O
+8	O
+(	O
+A	O
+/	O
+H1N1	O
+)-	O
+infected	O
+mouse	B-SPEC
+model	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+aerobic	O
+capacity	O
+of	O
+children	O
+3	O
+years	O
+after	O
+they	O
+were	O
+diagnosed	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+In	O
+girls	O
+,	O
+ventilatory	O
+efficiency	O
+(	O
+ventilatory	O
+equivalents	O
+for	O
+oxygen	B-CHED
+and	O
+carbon	B-CHED
+dioxide	I-CHED
+)	O
+and	O
+perfusion	O
+of	O
+the	O
+lungs	B-ANAT
+(	O
+end	O
+-	O
+tidal	O
+partial	O
+carbon	B-CHED
+dioxide	I-CHED
+pressure	O
+)	O
+had	O
+not	O
+increased	O
+further	O
+compared	O
+with	O
+the	O
+values	O
+measured	O
+at	O
+15	O
+months	O
+.	O
+
+EVLW	O
+was	O
+measured	O
+within	O
+6	O
+hours	O
+of	O
+ICU	O
+admission	O
+and	O
+indexed	O
+to	O
+actual	O
+body	B-ANAT
+weight	O
+(	O
+EVLW	O
+/	O
+ABW	O
+),	O
+predicted	O
+body	B-ANAT
+weight	O
+(	O
+EVLW	O
+/	O
+PBW	O
+)	O
+and	O
+pulmonary	B-ANAT
+blood	B-ANAT
+volume	O
+(	O
+EVLW	O
+/	O
+PBV	O
+).	O
+
+The	O
+relationship	O
+of	O
+these	O
+indices	O
+to	O
+the	O
+diagnosis	O
+and	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+and	O
+ICU	O
+mortality	O
+were	O
+studied	O
+.	O
+
+Clinical	O
+signs	O
+(	O
+dyspnea	B-DISO
+,	O
+lethargy	B-DISO
+,	O
+and	O
+weakness	B-DISO
+)	O
+started	O
+very	O
+acutely	O
+.	O
+
+Vaccination	O
+with	O
+rS1	O
+,	O
+rN	O
+,	O
+or	O
+H120	O
+induced	O
+a	O
+cellular	B-ANAT
+immune	I-PROC
+response	I-PROC
+as	O
+demonstrated	O
+by	O
+in	O
+vitro	O
+ChIFN	O
+-	O
+γ	O
+production	O
+by	O
+splenocytes	O
+of	O
+vaccinated	O
+birds	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+develops	O
+in	O
+a	O
+minority	O
+of	O
+patients	O
+with	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+,	O
+and	O
+is	O
+characterized	O
+by	O
+acute	O
+thrombotic	O
+microvasculopathy	O
+with	O
+multiorganic	O
+involvement	O
+(	O
+three	O
+or	O
+more	O
+organs	B-ANAT
+).	O
+
+The	O
+authors	O
+present	O
+a	O
+clinical	O
+case	O
+of	O
+catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+,	O
+diagnosed	O
+in	O
+a	O
+patient	O
+with	O
+abdominal	B-DISO
+pain	I-DISO
+and	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Mean	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+increased	O
+from	O
+125	O
+(±	O
+43	O
+)	O
+to	O
+300	O
+(±	O
+103	O
+;	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+after	O
+MRS	B-DISO
+and	O
+was	O
+sustained	O
+above	O
+300	O
+throughout	O
+seven	O
+days	O
+.	O
+
+The	O
+potentially	O
+recruitable	O
+lung	B-ANAT
+was	O
+estimated	O
+at	O
+45	O
+%	O
+(	O
+IQR	O
+:	O
+25	O
+to	O
+53	O
+).	O
+
+To	O
+further	O
+validate	O
+the	O
+hypothesis	O
+and	O
+understand	O
+initial	O
+immune	B-PROC
+responses	I-PROC
+to	O
+different	O
+viruses	B-SPEC
+,	O
+two	O
+phage	O
+-	O
+displayed	O
+human	B-SPEC
+cord	B-ANAT
+blood	I-ANAT
+-	O
+derived	O
+IgM	B-PRGE
+libraries	O
+were	O
+constructed	O
+which	O
+contained	O
+mostly	O
+germline	O
+antibodies	B-COMP
+or	O
+antibodies	B-COMP
+with	O
+very	O
+low	O
+level	O
+of	O
+somatic	O
+hypermutations	O
+.	O
+
+Despite	O
+a	O
+high	O
+sequence	O
+and	O
+combinatorial	O
+diversity	O
+observed	O
+in	O
+the	O
+cord	B-ANAT
+blood	I-ANAT
+-	O
+derived	O
+IgM	B-COMP
+antibody	B-PROC
+repertoire	O
+,	O
+no	O
+enrichment	O
+for	O
+binders	O
+of	O
+Envs	O
+was	O
+observed	O
+in	O
+contrast	O
+to	O
+considerable	O
+specific	O
+enrichments	O
+produced	O
+with	O
+panning	O
+against	O
+RBD	O
+and	O
+sG	O
+;	O
+one	O
+of	O
+the	O
+selected	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+against	O
+the	O
+RBD	O
+)	O
+was	O
+of	O
+high	O
+(	O
+nM	O
+)	O
+affinity	O
+with	O
+only	O
+few	O
+somatic	B-DISO
+mutations	I-DISO
+.	O
+
+These	O
+results	O
+further	O
+support	O
+and	O
+expand	O
+our	O
+initial	O
+hypothesis	O
+for	O
+fundamental	O
+differences	O
+in	O
+immune	B-PROC
+responses	I-PROC
+leading	O
+to	O
+elicitation	O
+of	O
+bnAbs	O
+against	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+compared	O
+to	O
+SARS	B-PRGE
+CoV	I-PRGE
+and	O
+Hendra	B-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Spontaneous	O
+breathing	B-PROC
+activity	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Clearly	O
+,	O
+further	O
+clinical	O
+and	O
+experimental	O
+investigations	O
+on	O
+the	O
+use	O
+of	O
+different	O
+ventilation	O
+modes	O
+of	O
+supported	O
+/	O
+unsupported	O
+spontaneous	O
+breathing	B-PROC
+in	I-PROC
+ALI	O
+/	O
+ARDS	B-DISO
+are	O
+needed	O
+.	O
+
+Recent	O
+reports	O
+suggest	O
+that	O
+permissive	O
+hypercapnia	B-DISO
+,	O
+therapeutic	O
+paralysis	O
+,	O
+sedation	B-DISO
+,	O
+and	O
+controlled	O
+hypothermia	O
+could	O
+potentially	O
+improve	O
+important	O
+clinical	O
+outcomes	O
+.	O
+
+When	O
+adding	O
+microbes	O
+to	O
+these	O
+cultures	O
+,	O
+bacteria	B-SPEC
+and	O
+virus	B-SPEC
+differed	O
+in	O
+two	O
+major	O
+respects	O
+;	O
+Firstly	O
+,	O
+all	O
+enveloped	O
+viruses	B-SPEC
+,	O
+but	O
+none	O
+of	O
+the	O
+bacteria	B-SPEC
+,	O
+blocked	O
+Th2	B-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+13	I-FUNC
+)	O
+production	O
+by	O
+cord	B-DISO
+CD4	B-PRGE
+(+)	O
+cells	B-COMP
+.	O
+
+Secondly	O
+,	O
+all	O
+Gram	B-SPEC
+-	I-SPEC
+positive	I-SPEC
+bacteria	I-SPEC
+,	O
+but	O
+none	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+induced	O
+IL	B-PRGE
+-	I-PRGE
+12p40	I-PRGE
+responses	O
+,	O
+but	O
+the	O
+IL	B-PRGE
+-	I-PRGE
+12p40	I-PRGE
+responses	O
+did	O
+not	O
+affect	O
+Th1	O
+cytokine	B-PROC
+production	I-PROC
+(	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+).	O
+
+These	O
+data	O
+imply	O
+that	O
+enveloped	O
+virus	B-SPEC
+can	O
+deviate	O
+Th2	O
+responses	O
+in	O
+human	B-SPEC
+cord	B-DISO
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+A	O
+systematic	O
+review	O
+of	O
+the	O
+Brazilian	O
+indexed	O
+and	O
+non	O
+-	O
+indexed	O
+literature	O
+on	O
+complicated	O
+cases	O
+of	O
+vivax	B-DISO
+malaria	I-DISO
+was	O
+performed	O
+including	O
+published	O
+articles	O
+,	O
+masters	O
+'	O
+dissertations	O
+,	O
+doctoral	O
+theses	O
+and	O
+national	O
+congresses	O
+'	O
+abstracts	O
+.	O
+
+We	O
+show	O
+here	O
+that	O
+whereas	O
+antibody	B-COMP
+-	O
+or	O
+B	B-ANAT
+cell	I-ANAT
+-	O
+deficient	O
+mice	B-SPEC
+failed	O
+to	O
+contain	O
+MHV	B-SPEC
+CNS	B-DISO
+infection	I-DISO
+and	O
+developed	O
+progressive	O
+demyelinating	B-DISO
+disease	I-DISO
+,	O
+germline	O
+IgM	B-PRGE
+produced	O
+in	O
+activation	O
+-	O
+induced	O
+cytidine	B-ENZY
+deaminase	I-ENZY
+-	O
+deficient	O
+mice	B-SPEC
+(	O
+aicda	O
+(-/-))	O
+provided	O
+long	O
+-	O
+term	O
+protection	O
+against	O
+the	O
+chronic	O
+multiple	O
+sclerosis	O
+-	O
+like	O
+disease	O
+.	O
+
+Mice	B-SPEC
+were	O
+inoculated	O
+with	O
+A	O
+/	O
+swine	B-SPEC
+/	O
+Shandong	O
+/	O
+731	O
+/	O
+2009	O
+(	O
+SD	O
+/	O
+09	O
+),	O
+which	O
+was	O
+a	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+variant	O
+with	O
+a	O
+G222D	O
+mutation	O
+in	O
+the	O
+hemagglutinin	O
+.	O
+
+These	O
+results	O
+suggested	O
+that	O
+we	O
+successfully	O
+established	O
+an	O
+ARDS	B-DISO
+mouse	B-SPEC
+model	O
+induced	O
+by	O
+a	O
+virulent	O
+2009	O
+H1N1	O
+variant	O
+without	O
+previous	O
+adaptation	B-PROC
+,	O
+which	O
+may	O
+be	O
+of	O
+benefit	O
+for	O
+evaluating	O
+the	O
+pathogenesis	B-DISO
+or	O
+therapy	O
+of	O
+human	B-DISO
+ARDS	I-DISO
+caused	O
+by	O
+2009	O
+H1N1	O
+virus	B-SPEC
+.	O
+
+In	O
+contrast	O
+,	O
+an	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+)	O
+showed	O
+that	O
+depalmitylated	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SCoV	O
+)	O
+S	O
+proteins	B-CHED
+still	O
+co	O
+-	O
+localized	O
+with	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+in	O
+the	O
+budding	B-PATH
+site	O
+.	O
+
+This	O
+indicated	O
+that	O
+these	O
+palmitylated	O
+cysteines	O
+are	O
+essential	O
+for	O
+S	O
+incorporation	O
+,	O
+but	O
+are	O
+not	O
+involved	O
+in	O
+S	O
+co	O
+-	O
+localization	B-PROC
+mediated	O
+by	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+.	O
+
+A	O
+growing	O
+understanding	O
+of	O
+the	O
+complexity	O
+of	O
+the	O
+pathophysiology	O
+of	O
+ARDS	B-DISO
+,	O
+coupled	O
+with	O
+advances	O
+in	O
+stem	B-ANAT
+cell	I-ANAT
+biology	O
+,	O
+has	O
+lead	O
+to	O
+a	O
+renewed	O
+interest	O
+in	O
+the	O
+therapeutic	O
+potential	O
+of	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+for	O
+ARDS	B-DISO
+.	O
+
+Recent	O
+evidence	O
+suggests	O
+that	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+can	O
+modulate	O
+the	O
+immune	B-PROC
+response	I-PROC
+to	O
+reduce	O
+injury	O
+and	O
+also	O
+increase	O
+resistance	B-PROC
+to	O
+infection	B-DISO
+,	O
+while	O
+also	O
+facilitating	O
+regeneration	B-PROC
+and	O
+repair	B-PROC
+of	O
+the	O
+injured	O
+lung	B-ANAT
+.	O
+
+We	O
+also	O
+summarise	O
+existing	O
+pre	O
+-	O
+clinical	O
+evidence	O
+,	O
+evaluate	O
+the	O
+potential	O
+and	O
+pitfalls	O
+of	O
+using	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+for	O
+treatment	O
+,	O
+and	O
+examine	O
+the	O
+likely	O
+future	O
+directions	O
+for	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+in	O
+ARDS	B-DISO
+.	O
+
+Serious	O
+impacts	O
+on	O
+susceptible	O
+populations	O
+most	O
+frequently	O
+occur	O
+when	O
+generalist	O
+pathogens	O
+are	O
+maintained	O
+within	O
+populations	O
+of	O
+abundant	O
+(	O
+often	O
+domestic	O
+)	O
+""""	O
+reservoir	O
+""""	O
+hosts	B-COMP
+,	O
+and	O
+spill	O
+over	O
+into	O
+less	O
+abundant	O
+host	B-COMP
+species	B-SPEC
+.	O
+
+If	O
+this	O
+is	O
+the	O
+case	O
+,	O
+disease	O
+control	O
+directed	O
+at	O
+the	O
+reservoir	O
+host	B-COMP
+might	O
+be	O
+most	O
+appropriate	O
+.	O
+
+Domestic	O
+dog	B-SPEC
+contact	O
+was	O
+associated	O
+with	O
+exposure	O
+to	O
+canine	O
+parvovirus	B-DISO
+,	O
+Ehrlichia	B-SPEC
+canis	I-SPEC
+,	O
+Neospora	B-SPEC
+caninum	I-SPEC
+and	O
+perhaps	O
+rabies	B-SPEC
+virus	I-SPEC
+,	O
+but	O
+not	O
+with	O
+exposure	O
+to	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+or	O
+canine	O
+coronavirus	B-SPEC
+.	O
+
+Ten	O
+of	O
+them	O
+suffered	B-DISO
+from	O
+pathological	B-DISO
+fractures	I-DISO
+,	O
+and	O
+10	O
+from	O
+chylopericardium	B-DISO
+and	O
+/	O
+or	O
+chylous	B-DISO
+ascites	I-DISO
+.	O
+
+The	O
+publications	O
+do	O
+not	O
+specify	O
+the	O
+ultimate	O
+cause	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Respiratory	B-DISO
+failure	I-DISO
+and	O
+infection	B-DISO
+are	O
+aggravated	O
+by	O
+immunosuppression	B-PROC
+,	O
+malnutrition	B-DISO
+and	O
+the	O
+non	O
+-	O
+restrictive	O
+use	O
+of	O
+central	O
+catheters	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Recommendations	O
+of	O
+the	O
+Infectious	B-DISO
+Diseases	I-DISO
+Work	O
+Group	O
+(	O
+GTEI	O
+)	O
+of	O
+the	O
+Spanish	O
+Society	O
+of	O
+Intensive	O
+and	O
+Critical	O
+Care	O
+Medicine	O
+and	O
+Coronary	B-ANAT
+Units	O
+(	O
+SEMICYUC	O
+)	O
+and	O
+the	O
+Infections	B-DISO
+in	O
+Critically	B-DISO
+Ill	I-DISO
+Patients	O
+Study	O
+Group	O
+(	O
+GEIPC	O
+)	O
+of	O
+the	O
+Spanish	O
+Society	O
+of	O
+Infectious	B-DISO
+Diseases	I-DISO
+and	O
+Clinical	O
+Microbiology	O
+(	O
+SEIMC	O
+)	O
+for	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+in	O
+seriously	O
+ill	B-DISO
+adults	O
+admitted	O
+to	O
+the	O
+Intensive	O
+Care	O
+Unit	O
+].	O
+
+Indirect	O
+methods	O
+for	O
+detecting	O
+antibodies	B-COMP
+are	O
+only	O
+of	O
+epidemiological	O
+interest	O
+.	O
+
+New	O
+antiviral	B-CHED
+drugs	I-CHED
+,	O
+especially	O
+those	O
+formulated	O
+for	O
+intravenous	O
+administration	O
+,	O
+may	O
+be	O
+the	O
+best	O
+choice	O
+in	O
+future	O
+epidemics	O
+.	O
+
+Patients	O
+with	O
+a	O
+high	O
+suspicion	O
+of	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+infection	B-DISO
+must	O
+continue	O
+with	O
+antiviral	B-CHED
+treatment	O
+,	O
+regardless	O
+of	O
+the	O
+negative	O
+results	O
+of	O
+initial	O
+tests	O
+,	O
+unless	O
+an	O
+alternative	O
+diagnosis	O
+can	O
+be	O
+established	O
+or	O
+clinical	O
+criteria	O
+suggest	O
+a	O
+low	O
+probability	O
+of	O
+influenza	B-DISO
+.	O
+
+The	O
+microbiological	O
+findings	O
+and	O
+clinical	O
+or	O
+laboratory	O
+test	O
+variables	O
+may	O
+decide	O
+withdrawal	B-DISO
+or	O
+not	O
+of	O
+antibiotic	B-CHED
+treatment	O
+.	O
+
+Pneumococcal	O
+vaccination	O
+is	O
+recommended	O
+as	O
+a	O
+preventive	O
+measure	O
+in	O
+the	O
+population	O
+at	O
+risk	O
+of	O
+suffering	B-DISO
+severe	O
+complications	O
+.	O
+
+Noninvasive	O
+mechanical	O
+ventilation	O
+cannot	O
+be	O
+considered	O
+a	O
+technique	O
+of	O
+choice	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+though	O
+it	O
+may	O
+be	O
+useful	O
+in	O
+experienced	O
+centers	O
+and	O
+in	O
+cases	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+associated	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+exacerbation	O
+or	O
+heart	B-DISO
+failure	I-DISO
+.	O
+
+Female	O
+BLM	B-DISO
+WT	O
+mice	B-SPEC
+had	O
+mild	O
+fibrosis	B-DISO
+and	O
+displayed	O
+a	O
+possible	O
+compensatory	O
+upregulation	B-PROC
+of	O
+the	O
+AT2	B-PRGE
+receptor	I-PRGE
+.	O
+
+These	O
+counties	O
+account	O
+for	O
+an	O
+important	O
+part	O
+of	O
+the	O
+Croatian	O
+commercial	O
+pig	B-SPEC
+production	O
+and	O
+have	O
+a	O
+high	O
+density	O
+of	O
+wild	B-SPEC
+boars	I-SPEC
+.	O
+
+Antibodies	B-COMP
+to	O
+all	O
+of	O
+the	O
+infectious	B-DISO
+pathogens	O
+except	O
+SVDV	O
+were	O
+detected	O
+.	O
+
+These	O
+observations	O
+give	O
+some	O
+insights	O
+into	O
+the	O
+pathogenesis	B-DISO
+of	O
+coronavirus	B-DISO
+infection	I-DISO
+and	O
+are	O
+thought	O
+to	O
+help	O
+understand	O
+the	O
+interactions	O
+between	O
+sensory	B-ANAT
+neurons	I-ANAT
+and	O
+their	O
+satellite	O
+cells	B-COMP
+.	O
+
+Sputum	B-ANAT
+culture	O
+revealed	O
+the	O
+presence	O
+of	O
+MRSA	B-DISO
+,	O
+and	O
+HSV	B-SPEC
+was	O
+isolated	O
+in	O
+broncho	O
+-	O
+alveoler	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluid	O
+.	O
+
+Using	O
+gene	O
+knockdown	O
+technology	O
+,	O
+we	O
+demonstrate	O
+that	O
+phosphatidylinositol	B-PRGE
+4	I-PRGE
+-	I-PRGE
+kinase	I-PRGE
+IIIβ	I-PRGE
+(	O
+PI4KB	B-PRGE
+)	O
+is	O
+required	O
+for	O
+cellular	B-COMP
+entry	O
+by	O
+pseudoviruses	O
+bearing	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+protein	B-CHED
+and	O
+that	O
+the	O
+cell	B-COMP
+entry	O
+mediated	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+is	O
+strongly	O
+inhibited	O
+by	O
+knockdown	O
+of	O
+PI4KB	B-PRGE
+.	O
+
+The	O
+current	O
+study	O
+aims	O
+at	O
+identifying	O
+novel	O
+host	B-COMP
+cellular	B-COMP
+interactors	O
+of	O
+the	O
+3b	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Virus	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+and	O
+viral	O
+mechanisms	O
+that	O
+regulate	O
+this	O
+cell	B-PROC
+death	I-PROC
+program	O
+are	O
+key	O
+issues	O
+in	O
+understanding	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+and	O
+viral	B-DISO
+pathogenesis	I-DISO
+.	O
+
+Interestingly	O
+,	O
+the	O
+onset	O
+of	O
+apoptosis	O
+occurred	O
+earlier	O
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+mammalian	B-SPEC
+cells	B-COMP
+silenced	O
+with	O
+short	O
+interfering	O
+RNA	O
+targeting	B-PROC
+Mcl	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+siMcl	O
+-	O
+1	O
+),	O
+and	O
+was	O
+delayed	O
+in	O
+cells	B-COMP
+silenced	O
+with	O
+siBak	O
+.	O
+
+OSAS	B-DISO
+is	O
+traditionally	O
+diagnosed	O
+using	O
+polysomnography	O
+,	O
+which	O
+requires	O
+a	O
+whole	O
+night	O
+stay	O
+at	O
+the	O
+sleep	B-PROC
+laboratory	O
+of	O
+a	O
+hospital	O
+,	O
+with	O
+multiple	O
+electrodes	O
+attached	O
+to	O
+the	O
+patient	O
+'	O
+s	O
+body	B-ANAT
+.	O
+
+In	O
+this	O
+method	O
+,	O
+first	O
+segmentation	B-PROC
+is	O
+done	O
+to	O
+eliminate	O
+the	O
+silence	O
+parts	O
+.	O
+
+Applying	O
+a	O
+natural	O
+experiment	O
+design	O
+to	O
+the	O
+Taiwan	O
+population	O
+between	O
+2000	O
+and	O
+2004	O
+,	O
+which	O
+includes	O
+the	O
+2003	O
+SARS	B-DISO
+epidemic	O
+when	O
+an	O
+average	O
+20	O
+%	O
+decline	O
+in	O
+health	O
+care	O
+utilization	O
+occurred	O
+,	O
+this	O
+study	O
+examines	O
+the	O
+association	O
+between	O
+a	O
+decline	O
+in	O
+health	O
+care	O
+utilization	O
+and	O
+health	O
+outcomes	O
+measured	O
+by	O
+cause	O
+-	O
+specific	O
+mortality	O
+rates	O
+.	O
+
+Although	O
+air	B-CHED
+travel	O
+contributed	O
+to	O
+dissemination	O
+in	O
+these	O
+two	O
+pandemics	O
+,	O
+the	O
+travel	O
+restrictions	O
+,	O
+quarantines	O
+,	O
+and	O
+heightened	O
+vigilance	O
+which	O
+resulted	O
+had	O
+an	O
+impact	O
+on	O
+maritime	O
+health	O
+.	O
+
+Most	O
+of	O
+the	O
+data	O
+for	O
+maritime	O
+influenza	B-DISO
+outbreaks	O
+focus	O
+on	O
+seasonal	O
+influenza	B-DISO
+on	O
+cruise	O
+ships	O
+,	O
+but	O
+influenza	B-DISO
+among	O
+crew	O
+members	O
+occurs	O
+due	O
+to	O
+close	O
+working	O
+conditions	O
+and	O
+is	O
+potentially	O
+preventable	O
+with	O
+staff	O
+vaccination	O
+programs	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+examined	O
+coronavirus	B-SPEC
+stability	O
+on	O
+lettuce	O
+surfaces	O
+.	O
+
+A	O
+cell	B-COMP
+culture	O
+adapted	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+,	O
+diluted	O
+in	O
+growth	B-PROC
+media	B-ANAT
+or	O
+in	O
+bovine	B-SPEC
+fecal	B-ANAT
+suspensions	O
+to	O
+simulate	O
+fecal	B-ANAT
+contamination	O
+was	O
+used	O
+to	O
+spike	O
+romaine	O
+lettuce	O
+.	O
+
+Thus	O
+,	O
+it	O
+is	O
+possible	O
+that	O
+contaminated	O
+vegetables	O
+may	O
+be	O
+potential	O
+vehicles	O
+for	O
+coronavirus	B-SPEC
+zoonotic	O
+transmission	O
+to	O
+humans	B-SPEC
+.	O
+
+The	O
+peptide	B-CHED
+also	O
+inhibits	O
+proliferation	B-DISO
+of	O
+coronavirus	B-SPEC
+NL63	O
+.	O
+
+Peptide	B-CHED
+(	O
+438	O
+)	O
+YKYRYL	O
+(	O
+443	O
+)	O
+is	O
+part	O
+of	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Peptide	B-CHED
+libraries	O
+were	O
+screened	O
+by	O
+surface	O
+plasmon	O
+resonance	O
+(	O
+SPR	O
+)	O
+to	O
+identify	O
+RBD	O
+binding	B-FUNC
+epitopes	O
+.	O
+
+TITLE	O
+:	O
+Alcohol	O
+worsens	O
+acute	O
+lung	B-ANAT
+injury	O
+by	O
+inhibiting	O
+alveolar	B-ANAT
+sodium	B-PROC
+transport	I-PROC
+through	O
+the	O
+adenosine	B-CHED
+A1	I-PRGE
+receptor	I-PRGE
+.	O
+
+Alcohol	O
+decreases	O
+alveolar	B-ANAT
+fluid	O
+clearance	O
+and	O
+impairs	O
+survival	O
+from	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Physical	O
+examination	O
+showed	O
+fine	O
+bilateral	O
+basal	O
+crackles	B-DISO
+.	O
+
+inoculation	O
+,	O
+while	O
+FIPVs	O
+with	O
+intact	O
+3c	O
+genes	O
+were	O
+shed	O
+in	O
+the	O
+feces	B-ANAT
+following	O
+oronasal	O
+but	O
+not	O
+i	O
+.	O
+p	O
+.	O
+
+An	O
+attempt	O
+to	O
+trace	O
+FIPV	O
+isolates	O
+back	B-ANAT
+to	O
+enteric	O
+strains	O
+existing	O
+in	O
+the	O
+shelter	O
+was	O
+only	O
+partially	O
+successful	O
+due	O
+to	O
+the	O
+large	O
+region	O
+over	O
+which	O
+shelter	O
+cats	B-SPEC
+and	O
+kittens	O
+originated	O
+,	O
+housing	O
+conditions	O
+prior	O
+to	O
+acquisition	O
+,	O
+and	O
+rapid	O
+movement	B-PROC
+through	O
+the	O
+shelter	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+identify	O
+potential	O
+therapeutic	O
+targets	O
+,	O
+we	O
+asked	O
+here	O
+whether	O
+common	O
+molecular	O
+mechanisms	O
+can	O
+be	O
+identified	O
+that	O
+are	O
+relevant	O
+in	O
+different	O
+models	O
+of	O
+the	O
+direct	O
+form	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Further	O
+mechanisms	O
+including	O
+TNF	B-PRGE
+,	O
+DARC	B-PRGE
+,	O
+HMGB1	B-PRGE
+,	O
+PARP	B-PRGE
+,	O
+GADD45	B-PRGE
+and	O
+collagenase	B-PRGE
+are	O
+under	O
+investigation	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+recognize	O
+the	O
+etiological	O
+agent	O
+responsible	O
+for	O
+severe	O
+acute	O
+respiratory	O
+failure	O
+(	O
+ARF	B-DISO
+)	O
+in	O
+patients	O
+in	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+)	O
+is	O
+important	O
+to	O
+determine	O
+their	O
+treatment	O
+and	O
+prognosis	O
+,	O
+and	O
+to	O
+avoid	O
+the	O
+excessive	O
+use	O
+of	O
+antibiotics	B-CHED
+.	O
+
+Mini	O
+bronchoalveolar	O
+lavage	O
+(	O
+mini	O
+BAL	B-ENZY
+)	O
+is	O
+a	O
+blind	B-DISO
+,	O
+non	O
+bronchoscopic	O
+procedure	O
+,	O
+used	O
+to	O
+obtain	O
+samples	O
+from	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+from	O
+patients	O
+on	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+).	O
+
+To	O
+assess	O
+the	O
+feasibility	O
+,	O
+complications	O
+and	O
+preliminary	O
+results	O
+of	O
+mini	O
+BAL	B-ENZY
+among	O
+patients	O
+with	O
+severe	O
+ARF	B-DISO
+on	O
+MV	O
+.	O
+
+RESULTS	O
+:	O
+At	O
+baseline	O
+:	O
+APACHE	O
+II	O
+score	O
+of	O
+22	O
+±	O
+6	O
+,	O
+7	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+was	O
+176	O
+.	O
+6	O
+±	O
+48	O
+.	O
+6	O
+and	O
+the	O
+oxygenation	B-PROC
+index	O
+was	O
+9	O
+.	O
+74	O
+±	O
+3	O
+.	O
+78	O
+.	O
+
+There	O
+is	O
+clear	O
+overlap	O
+between	O
+the	O
+pathogenesis	B-DISO
+of	O
+CRS	B-DISO
+and	O
+asthma	B-PATH
+.	O
+
+RESULTS	O
+:	O
+No	O
+respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+any	O
+of	O
+the	O
+samples	O
+.	O
+
+A	O
+50	O
+-	O
+year	O
+-	O
+old	O
+female	O
+,	O
+after	O
+presenting	O
+with	O
+diarrhea	B-DISO
+and	O
+abdominal	B-DISO
+pain	I-DISO
+,	O
+developed	O
+pancolitis	B-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+and	O
+thrombocytopenia	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+impact	O
+of	O
+these	O
+mutations	O
+on	O
+receptor	O
+recognition	O
+,	O
+an	O
+important	O
+determinant	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+pathogenesis	B-DISO
+.	O
+
+These	O
+results	O
+not	O
+only	O
+illustrate	O
+the	O
+detailed	O
+mechanisms	O
+of	O
+host	B-COMP
+receptor	O
+adaptation	B-PROC
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+but	O
+also	O
+provide	O
+a	O
+molecular	O
+and	O
+structural	O
+basis	O
+for	O
+tracking	O
+future	O
+SARS	B-DISO
+-	O
+CoV	O
+evolution	B-PROC
+in	O
+animals	B-SPEC
+.	O
+
+The	O
+data	O
+show	O
+that	O
+the	O
+shift	O
+from	O
+9	O
+-	O
+O	O
+-	O
+to	O
+4	B-PRGE
+-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+Ac	I-PRGE
+-	I-PRGE
+Sia	I-PRGE
+receptor	I-PRGE
+usage	O
+primarily	O
+entailed	O
+a	O
+change	O
+in	O
+ligand	B-PROC
+binding	B-FUNC
+topology	O
+and	O
+,	O
+surprisingly	O
+,	O
+only	O
+modest	O
+changes	O
+in	O
+receptor	O
+-	O
+binding	O
+site	O
+architecture	O
+.	O
+
+TITLE	O
+:	O
+Seroepidemiology	O
+of	O
+respiratory	O
+(	O
+group	O
+2	O
+)	O
+canine	O
+coronavirus	B-SPEC
+,	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+Bordetella	O
+bronchiseptica	O
+infections	B-DISO
+in	O
+urban	O
+dogs	B-SPEC
+in	O
+a	O
+humane	O
+shelter	O
+and	O
+in	O
+rural	O
+dogs	B-SPEC
+in	O
+small	O
+communities	O
+.	O
+
+Rural	O
+dogs	B-SPEC
+were	O
+0	O
+.	O
+421	O
+times	O
+(	O
+P	O
+≤	O
+0	O
+.	O
+0001	O
+)	O
+less	O
+likely	O
+to	O
+be	O
+positive	O
+for	O
+CRCoV	O
+than	O
+dogs	B-SPEC
+admitted	O
+to	O
+the	O
+shelter	O
+.	O
+
+Seroconversion	O
+to	O
+CRCoV	O
+was	O
+common	O
+in	O
+dogs	B-SPEC
+in	O
+the	O
+shelter	O
+,	O
+but	O
+was	O
+not	O
+associated	O
+(	O
+P	O
+=	O
+0	O
+.	O
+18	O
+)	O
+with	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+With	O
+changing	O
+spectrum	O
+of	O
+clinical	O
+presentation	O
+in	O
+malaria	B-PATH
+,	O
+pulmonary	B-ANAT
+system	I-ANAT
+involvement	O
+has	O
+always	O
+been	O
+under	O
+diagnosed	O
+.	O
+
+STUDY	O
+DESIGN	O
+&	O
+DESCRIPTION	O
+OF	O
+THE	O
+PATIENTS	O
+:	O
+Our	O
+study	O
+was	O
+conducted	O
+during	O
+2007	O
+to	O
+2009	O
+in	O
+200	O
+cases	O
+of	O
+severe	O
+malaria	B-PATH
+[	O
+Pf	O
+,	O
+Pv	O
+,	O
+and	O
+mixed	O
+(	O
+Pf	O
++	O
+Pv	O
+)]	O
+with	O
+pulmonary	B-DISO
+involvement	I-DISO
+.	O
+
+Metabolic	B-DISO
+acidosis	I-DISO
+and	O
+low	O
+oxygen	B-CHED
+saturation	O
+was	O
+observed	O
+in	O
+7	O
+%	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Aryl	O
+diketoacid	O
+(	O
+ADK	O
+)	O
+is	O
+well	O
+known	O
+for	O
+antiviral	B-CHED
+activity	O
+which	O
+can	O
+be	O
+enhanced	O
+by	O
+introduction	O
+of	O
+an	O
+aromatic	O
+arylmethyl	O
+substituent	O
+.	O
+
+Overexpression	B-PROC
+of	O
+pRb	B-PRGE
+delayed	O
+the	O
+viral	O
+protein	B-CHED
+production	O
+by	O
+wild	O
+-	O
+type	O
+MHV	B-SPEC
+but	O
+not	O
+by	O
+vLC	B-ANAT
+.	O
+
+We	O
+have	O
+cloned	O
+a	O
+novel	O
+full	O
+-	O
+length	O
+isoform	O
+of	O
+psg16	O
+that	O
+is	O
+also	O
+expressed	B-PROC
+in	O
+the	O
+brain	B-ANAT
+,	O
+placenta	B-ANAT
+,	O
+and	O
+retina	B-ANAT
+but	O
+,	O
+like	O
+the	O
+truncated	O
+form	O
+,	O
+lacks	O
+MHV	B-PRGE
+receptor	B-FUNC
+activity	I-FUNC
+when	O
+expressed	B-PROC
+on	O
+293T	O
+cells	B-COMP
+,	O
+suggesting	O
+that	O
+PSG16	O
+does	O
+not	O
+mediate	O
+CEACAM1a	O
+-	O
+independent	O
+spread	O
+of	O
+MHV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Enhancement	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+murine	I-PRGE
+colon	B-DISO
+cancer	B-SPEC
+immunity	B-PROC
+by	O
+fusion	O
+of	O
+a	O
+SARS	B-DISO
+fragment	O
+to	O
+a	O
+low	O
+-	O
+immunogenic	O
+carcinoembryonic	O
+antigen	O
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+is	O
+widely	O
+understood	O
+that	O
+tumor	B-ANAT
+cells	B-COMP
+express	O
+tumor	B-DISO
+-	O
+associated	O
+antigens	B-CHED
+(	O
+TAAs	O
+),	O
+of	O
+which	O
+many	O
+are	O
+usually	O
+in	O
+low	O
+immunogenicity	O
+;	O
+for	O
+example	O
+,	O
+carcinoembryonic	B-PRGE
+antigen	I-PRGE
+(	O
+CEA	B-PRGE
+)	O
+is	O
+specifically	O
+expressed	B-PROC
+on	O
+human	B-SPEC
+colon	B-DISO
+cancer	B-ANAT
+cells	B-COMP
+and	O
+is	O
+viewed	O
+as	O
+a	O
+low	O
+-	O
+immunogenic	O
+TAA	B-DISO
+.	O
+
+He	O
+was	O
+hypothermic	O
+,	O
+unresponsive	O
+with	O
+bilateral	O
+mydriasis	B-DISO
+,	O
+and	O
+had	O
+poor	O
+oxygen	B-CHED
+saturation	O
+.	O
+
+He	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+requiring	O
+high	O
+frequency	O
+percussive	O
+ventilation	O
+.	O
+
+He	O
+completely	O
+recovered	O
+from	O
+the	O
+respiratory	O
+and	O
+cardiac	B-DISO
+failure	I-DISO
+.	O
+
+Among	O
+the	O
+most	O
+frequent	O
+causes	O
+for	O
+admission	O
+are	O
+exacerbation	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+or	O
+with	O
+criteria	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+This	O
+support	O
+should	O
+alleviate	O
+the	O
+catabolic	B-PROC
+effects	O
+of	O
+the	O
+disease	O
+,	O
+avoid	O
+calorie	B-DISO
+overload	I-DISO
+and	O
+,	O
+in	O
+selected	O
+patients	O
+,	O
+to	O
+use	O
+omega	O
+-	O
+3	O
+fatty	O
+acid	O
+-	O
+and	O
+antioxidant	B-CHED
+-	O
+enriched	O
+diets	O
+,	O
+which	O
+could	O
+improve	O
+outcome	O
+.	O
+
+In	O
+young	O
+children	O
+,	O
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+infection	B-DISO
+is	O
+associated	O
+with	O
+a	O
+high	O
+rate	O
+of	O
+febrile	B-DISO
+seizures	I-DISO
+(	O
+50	O
+%).	O
+
+This	O
+study	O
+also	O
+revealed	O
+a	O
+previously	O
+unknown	O
+diversity	O
+of	O
+coronaviruses	O
+in	O
+bats	O
+,	O
+which	O
+are	O
+important	O
+natural	O
+reservoir	O
+for	O
+coronaviruses	O
+including	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+like	O
+viruses	B-SPEC
+.	O
+
+Using	O
+the	O
+'	O
+pancoronavirus	O
+'	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+,	O
+detection	O
+rates	O
+were	O
+0	O
+.	O
+6	O
+%	O
+for	O
+HCoVNL63	O
+,	O
+1	O
+.	O
+2	O
+%	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+0	O
+.	O
+5	O
+%	O
+for	O
+HCoV	O
+-	O
+HKU1	O
+,	O
+and	O
+0	O
+.	O
+2	O
+%	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+Antibody	B-COMP
+-	O
+mediated	O
+infection	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+triggers	O
+entry	O
+into	O
+human	B-SPEC
+haematopoietic	B-ANAT
+cells	B-COMP
+via	O
+an	O
+FcγR	O
+-	O
+dependent	O
+and	O
+ACE2	B-PRGE
+-,	O
+pH	O
+-,	O
+cysteine	B-CHED
+-	O
+protease	O
+-	O
+independent	O
+pathways	B-PROC
+.	O
+
+Occurrence	O
+of	O
+immune	O
+-	O
+mediated	O
+enhancement	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+raises	O
+safety	O
+concerns	O
+regarding	O
+the	O
+use	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+in	O
+humans	B-SPEC
+and	O
+enables	O
+new	O
+ways	O
+to	O
+investigate	O
+SARS	B-DISO
+pathogenesis	B-DISO
+(	O
+tropism	B-PROC
+and	O
+immune	B-PROC
+response	I-PROC
+deregulation	O
+).	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+is	O
+an	O
+enveloped	O
+single	O
+-	O
+stranded	O
+RNA	O
+virus	O
+,	O
+of	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+and	O
+the	O
+order	B-SPEC
+Nidovirales	I-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+Effects	O
+of	O
+Temperature	O
+and	O
+Relative	O
+Humidity	O
+on	O
+the	O
+Viability	O
+of	O
+the	O
+SARS	B-DISO
+Coronavirus	B-SPEC
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)	O
+NL63	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+CoV	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+(	O
+PLP	B-PRGE
+)	O
+antagonize	O
+innate	O
+immune	O
+signaling	B-PROC
+mediated	O
+by	O
+STING	B-PRGE
+(	O
+stimulator	B-PRGE
+of	I-PRGE
+interferon	I-PRGE
+genes	I-PRGE
+,	O
+also	O
+known	O
+as	O
+MITA	B-PRGE
+/	O
+ERIS	B-PRGE
+/	O
+MYPS	O
+).	O
+
+TITLE	O
+:	O
+Risk	O
+assessment	O
+of	O
+airborne	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+aircraft	O
+cabins	O
+.	O
+
+Deterministic	O
+and	O
+probabilistic	O
+approaches	O
+were	O
+used	O
+to	O
+quantify	O
+the	O
+risks	O
+based	O
+on	O
+the	O
+amount	O
+of	O
+inhaled	B-PROC
+influenza	B-DISO
+virus	I-SPEC
+RNA	O
+particles	O
+and	O
+quanta	O
+,	O
+respectively	O
+.	O
+
+The	O
+probabilistic	O
+approach	O
+indicated	O
+that	O
+the	O
+number	O
+of	O
+secondary	O
+infection	O
+cases	O
+can	O
+be	O
+reduced	O
+from	O
+3	O
+to	O
+0	O
+and	O
+20	O
+to	O
+11	O
+,	O
+for	O
+influenza	B-DISO
+cases	O
+if	O
+N95	O
+respirator	O
+masks	O
+are	O
+used	O
+by	O
+the	O
+passengers	O
+.	O
+
+Between	O
+2005	O
+-	O
+2007	O
+,	O
+95	O
+pet	O
+and	O
+10	O
+feral	O
+cats	B-SPEC
+tested	O
+negative	O
+by	O
+indirect	O
+immunofluorescence	O
+antibody	B-COMP
+(	O
+IFA	O
+)	O
+analysis	O
+using	O
+two	O
+strains	O
+of	O
+type	B-PRGE
+II	I-PRGE
+FCoV	I-PRGE
+,	O
+two	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+assays	O
+,	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+and	O
+rapid	O
+immunomigration	O
+test	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+pDCs	O
+facilitate	O
+CD4	B-PRGE
+(+)	O
+helper	B-ANAT
+T	I-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+to	O
+persistent	O
+viruses	B-SPEC
+independently	O
+of	O
+direct	O
+antigen	B-PROC
+presentation	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+clinical	O
+presentation	O
+and	O
+case	O
+management	O
+of	O
+a	O
+dog	B-SPEC
+that	O
+developed	O
+ascending	O
+flaccid	B-DISO
+paralysis	I-DISO
+after	O
+being	O
+envenomated	O
+by	O
+a	O
+Southern	B-SPEC
+Pacific	I-SPEC
+rattlesnake	I-SPEC
+.	O
+
+RESULTS	O
+:	O
+In	O
+6	O
+cases	O
+,	O
+pulse	B-PROC
+blood	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+[	O
+SpO	O
+(	O
+2	O
+)]	O
+was	O
+elevated	O
+(	O
+0	O
+.	O
+45	O
+-	O
+0	O
+.	O
+92	O
+up	O
+to	O
+0	O
+.	O
+94	O
+-	O
+1	O
+.	O
+00	O
+),	O
+PEEP	B-CHED
+level	O
+[	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+,	O
+1	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+=	O
+0	O
+.	O
+098	O
+kPa	O
+]	O
+and	O
+[	O
+FiO	O
+(	O
+2	O
+)]	O
+were	O
+lowered	O
+[	O
+PEEP	B-CHED
+:	O
+10	O
+.	O
+0	O
+-	O
+22	O
+.	O
+0	O
+down	O
+to	O
+4	O
+.	O
+0	O
+-	O
+15	O
+.	O
+0	O
+;	O
+FiO	O
+(	O
+2	O
+):	O
+1	O
+.	O
+00	O
+down	O
+to	O
+0	O
+.	O
+30	O
+-	O
+0	O
+.	O
+60	O
+]	O
+after	O
+treatment	O
+with	O
+ECMO	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+effects	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+on	O
+mortality	O
+in	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+[	O
+The	O
+application	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+critically	B-DISO
+ill	I-DISO
+patient	O
+].	O
+
+A	O
+retrospective	O
+observational	O
+study	O
+of	O
+9	O
+patients	O
+treated	O
+in	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+of	O
+Peking	O
+University	O
+Third	O
+Hospital	O
+and	O
+Beijing	O
+Ditan	B-CHED
+Hospital	O
+from	O
+October	O
+1	O
+,	O
+2007	O
+to	O
+December	O
+26	O
+,	O
+2009	O
+with	O
+ECMO	O
+for	O
+various	O
+diseases	O
+was	O
+conducted	O
+.	O
+
+The	O
+mean	O
+amount	O
+of	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+suspension	O
+administered	O
+per	O
+patients	O
+was	O
+(	O
+15	O
+.	O
+1	O
+±	O
+9	O
+.	O
+9	O
+)	O
+U	O
+,	O
+and	O
+length	O
+of	O
+ICU	O
+stay	O
+was	O
+(	O
+18	O
+.	O
+9	O
+±	O
+15	O
+.	O
+7	O
+)	O
+days	O
+.	O
+
+Blood	B-ANAT
+routine	O
+,	O
+electrolytes	O
+,	O
+blood	B-PROC
+gas	B-ENZY
+analysis	O
+,	O
+hepatic	B-ANAT
+and	O
+renal	B-PROC
+function	I-PROC
+tests	O
+and	O
+cardiac	B-ANAT
+enzymes	O
+were	O
+examined	O
+before	O
+and	O
+after	O
+treatment	O
+.	O
+
+Respiratory	B-ANAT
+system	I-ANAT
+could	O
+be	O
+mainly	O
+injured	O
+as	O
+the	O
+result	O
+of	O
+exposure	O
+to	O
+phosgene	B-CHED
+and	O
+leading	O
+to	O
+ARDS	B-DISO
+.	O
+
+Sixteen	O
+patients	O
+totally	O
+recovered	O
+,	O
+1	O
+patient	O
+died	B-PROC
+,	O
+and	O
+the	O
+cure	O
+rate	O
+was	O
+94	O
+.	O
+12	O
+%.	O
+
+ABSTRACT	O
+:	O
+Nonstructural	O
+proteins	B-CHED
+7	O
+and	O
+8	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+have	O
+previously	O
+been	O
+shown	O
+by	O
+X	O
+-	O
+ray	B-SPEC
+crystallography	O
+to	O
+form	O
+an	O
+8	O
+:	O
+8	O
+hexadecamer	O
+.	O
+
+We	O
+present	O
+here	O
+the	O
+2	O
+.	O
+6	O
+-	O
+Å	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+Nsp7	O
+:	O
+Nsp8	B-PRGE
+complex	I-PRGE
+,	O
+which	O
+is	O
+a	O
+2	O
+:	O
+1	O
+heterotrimer	O
+containing	O
+two	O
+copies	O
+of	O
+the	O
+α	O
+-	O
+helical	O
+Nsp7	O
+with	O
+conformational	O
+differences	O
+between	O
+them	O
+,	O
+and	O
+one	O
+copy	O
+of	O
+Nsp8	O
+that	O
+consists	O
+of	O
+an	O
+α	B-PRGE
+/	I-PRGE
+β	I-PRGE
+domain	I-PRGE
+and	O
+a	O
+long	O
+-	O
+α	O
+-	O
+helix	O
+domain	O
+.	O
+
+TITLE	O
+:	O
+The	O
+First	O
+Case	O
+of	O
+Feline	B-DISO
+Infectious	I-DISO
+Peritonitis	I-DISO
+-	O
+like	O
+Pyogranuloma	B-DISO
+in	O
+a	O
+Ferret	B-SPEC
+Infected	O
+by	O
+Coronavirus	B-SPEC
+in	O
+Japan	O
+.	O
+
+Histopathologically	O
+,	O
+multifocal	O
+granulomas	B-DISO
+consisting	O
+of	O
+necrotic	B-PROC
+foci	O
+,	O
+macrophages	B-ANAT
+,	O
+fibroblasts	B-ANAT
+and	O
+plentiful	O
+fibrous	O
+connective	B-ANAT
+tissues	I-ANAT
+were	O
+observed	O
+in	O
+the	O
+mesenteric	B-ANAT
+mass	O
+.	O
+
+TITLE	O
+:	O
+Fatal	O
+outbreaks	O
+in	O
+dogs	B-SPEC
+associated	O
+with	O
+pantropic	O
+canine	O
+coronavirus	B-SPEC
+in	O
+France	O
+and	O
+Belgium	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Three	O
+years	O
+surveillance	O
+of	O
+viral	O
+etiology	O
+of	O
+acute	B-DISO
+lower	I-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+children	O
+from	O
+2007	O
+to	O
+2010	O
+].	O
+
+ABSTRACT	O
+:	O
+Viruses	O
+are	O
+common	O
+pathogens	O
+of	O
+acute	B-DISO
+lower	I-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+ALRTI	O
+)	O
+in	O
+children	O
+.	O
+
+Mixed	B-DISO
+infections	I-DISO
+with	O
+two	O
+or	O
+more	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+substantial	O
+proportion	O
+of	O
+patients	O
+with	O
+ALRTI	O
+,	O
+but	O
+further	O
+studies	O
+are	O
+needed	O
+to	O
+explore	O
+the	O
+clinical	O
+significance	O
+of	O
+mixed	B-DISO
+infection	I-DISO
+with	O
+viruses	B-SPEC
+in	O
+patients	O
+with	O
+ALRTI	O
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+(	O
+RT	O
+)	O
+PCR	O
+methods	O
+were	O
+applied	O
+to	O
+detect	O
+common	O
+respiratory	O
+viruses	B-SPEC
+including	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+),	O
+influenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+A	I-SPEC
+,	O
+B	O
+and	O
+C	O
+(	O
+IFA	O
+,	O
+IFB	B-PRGE
+,	O
+IFC	B-PRGE
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+type	O
+1	O
+-	O
+4	O
+,	O
+adenovirus	B-DISO
+(	O
+ADV	O
+),	O
+enterovirus	B-SPEC
+(	O
+EV	O
+),	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCOV	O
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+)	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBOV	O
+).	O
+
+Among	O
+virus	B-SPEC
+-	O
+positive	O
+dogs	B-SPEC
+,	O
+dogs	B-SPEC
+with	O
+parvovirus	B-DISO
+infection	I-DISO
+were	O
+significantly	O
+younger	O
+when	O
+compared	O
+to	O
+dogs	B-SPEC
+infected	O
+with	O
+other	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+Parvovirus	B-DISO
+-	O
+infected	O
+patients	O
+also	O
+showed	O
+significantly	O
+lower	O
+leukocyte	B-ANAT
+and	O
+erythrocyte	B-ANAT
+counts	O
+as	O
+well	O
+as	O
+hematocrit	O
+,	O
+total	O
+protein	B-CHED
+,	O
+and	O
+albumin	B-PRGE
+levels	O
+compared	O
+to	O
+all	O
+other	O
+groups	O
+.	O
+
+Young	O
+dogs	B-SPEC
+are	O
+more	O
+likely	O
+to	O
+suffer	B-DISO
+from	O
+viral	B-DISO
+enteritis	I-DISO
+.	O
+
+As	O
+an	O
+effective	O
+measure	O
+of	O
+respiratory	O
+supports	O
+,	O
+ECMO	O
+may	O
+provide	O
+pulmonary	B-ANAT
+rest	B-FUNC
+and	O
+improve	O
+gas	B-ENZY
+exchanges	O
+in	O
+severe	O
+ARDS	B-DISO
+induced	O
+by	O
+novel	B-DISO
+H1N1	I-DISO
+Influenza	I-DISO
+.	O
+
+Respiratory	B-ANAT
+samples	I-ANAT
+from	O
+3	O
+,	O
+525	O
+patients	O
+with	O
+respiratory	O
+syndrome	B-DISO
+,	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+(	O
+CSF	B-ANAT
+)	O
+from	O
+340	O
+patients	O
+with	O
+neurologic	O
+syndrome	B-DISO
+as	O
+well	O
+as	O
+CSF	B-ANAT
+and	O
+plasma	B-ANAT
+samples	O
+from	O
+five	O
+neonatal	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+like	O
+illness	O
+collected	O
+from	O
+October	O
+2008	O
+to	O
+2010	O
+were	O
+tested	O
+retrospectively	O
+using	O
+HPeV	O
+-	O
+specific	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+,	O
+stable	O
+and	O
+reproducible	O
+acute	O
+lung	B-ANAT
+injury	O
+model	O
+induced	O
+by	O
+oleic	B-CHED
+acid	I-CHED
+in	O
+immature	O
+piglet	O
+.	O
+
+A	O
+good	O
+ALI	O
+model	O
+will	O
+help	O
+us	O
+to	O
+gain	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+real	O
+pathophysiological	O
+picture	O
+and	O
+to	O
+evaluate	O
+novel	O
+treatment	O
+approaches	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+more	O
+accurately	O
+and	O
+liberally	O
+.	O
+
+Mean	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+heart	B-ANAT
+rate	O
+(	O
+HR	O
+),	O
+cardiac	B-ANAT
+output	O
+(	O
+CO	O
+),	O
+central	O
+venous	B-PROC
+pressure	I-PROC
+(	O
+CVP	O
+)	O
+and	O
+left	O
+atrial	B-ANAT
+pressure	O
+(	O
+LAP	B-DISO
+)	O
+were	O
+sharply	O
+decreased	O
+after	O
+oleic	B-CHED
+acid	I-CHED
+given	O
+,	O
+while	O
+the	O
+mean	O
+pulmonary	B-ANAT
+arterial	B-PROC
+pressure	I-PROC
+(	O
+MPAP	O
+)	O
+was	O
+increased	O
+in	O
+comparison	O
+with	O
+baseline	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+lung	B-ANAT
+histology	O
+showed	O
+severe	O
+inflammation	B-DISO
+,	O
+hyaline	B-DISO
+membranes	B-ANAT
+,	O
+intra	O
+-	O
+alveolar	B-ANAT
+and	O
+interstitial	B-ANAT
+hemorrhage	B-DISO
+.	O
+
+The	O
+virus	B-SPEC
+mainly	O
+infects	O
+respiratory	B-ANAT
+epithelium	I-ANAT
+,	O
+but	O
+can	O
+be	O
+also	O
+detected	O
+in	O
+other	O
+organs	B-ANAT
+.	O
+
+Recently	O
+,	O
+it	O
+has	O
+been	O
+shown	O
+that	O
+the	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+lectins	I-PRGE
+DC	I-PRGE
+-	O
+SIGN	O
+/	O
+L	O
+-	O
+SIGN	O
+can	O
+promote	O
+entry	O
+of	O
+several	O
+coronaviruses	O
+.	O
+
+Our	O
+findings	O
+demonstrated	O
+that	O
+even	O
+in	O
+the	O
+absence	O
+of	O
+avian	O
+-	O
+specific	O
+receptor	O
+,	O
+DC	B-PRGE
+-	I-PRGE
+SIGN	I-PRGE
+-	I-PRGE
+like	I-PRGE
+lectins	I-PRGE
+are	O
+capable	O
+of	O
+mediating	O
+efficient	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+An	O
+online	O
+questionnaire	O
+was	O
+designed	O
+and	O
+electronically	O
+distributed	O
+to	O
+the	O
+staff	O
+of	O
+a	O
+teaching	O
+medical	O
+institution	O
+in	O
+the	O
+United	O
+Kingdom	B-SPEC
+.	O
+
+METHODS	O
+:	O
+An	O
+online	O
+questionnaire	O
+was	O
+designed	O
+and	O
+electronically	O
+distributed	O
+to	O
+the	O
+staff	O
+of	O
+a	O
+teaching	O
+medical	O
+institution	O
+in	O
+the	O
+United	O
+Kingdom	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Increasing	O
+concerns	O
+about	O
+the	O
+spread	O
+of	O
+airborne	O
+pathogens	O
+such	O
+as	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+novel	O
+swine	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+have	O
+attracted	O
+public	O
+attention	O
+to	O
+bioaerosols	O
+and	O
+protection	O
+against	O
+them	O
+.	O
+
+The	O
+airborne	O
+pathogens	O
+are	O
+likely	O
+to	O
+be	O
+expelled	O
+from	O
+coughing	B-DISO
+or	O
+speaking	O
+,	O
+so	O
+the	O
+physical	O
+data	O
+of	O
+the	O
+exhaled	B-PROC
+particles	O
+plays	O
+a	O
+key	O
+role	O
+in	O
+analyzing	O
+the	O
+pathway	B-PROC
+of	O
+airborne	O
+viruses	B-SPEC
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+analyze	O
+the	O
+initial	O
+velocity	O
+and	O
+the	O
+angle	O
+of	O
+the	O
+exhaled	B-PROC
+airflow	B-PROC
+from	O
+coughing	B-DISO
+and	O
+speaking	O
+of	O
+17	O
+males	O
+and	O
+9	O
+females	O
+using	O
+Particle	O
+Image	O
+Velocimetry	O
+(	O
+PIV	O
+)	O
+and	O
+acrylic	O
+indoor	O
+chamber	B-ANAT
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+average	O
+initial	O
+coughing	B-DISO
+velocity	O
+was	O
+15	O
+.	O
+3	O
+m	O
+/	O
+s	O
+for	O
+the	O
+males	O
+and	O
+10	O
+.	O
+6	O
+m	O
+/	O
+s	O
+for	O
+the	O
+females	O
+,	O
+while	O
+the	O
+average	O
+initial	O
+speaking	O
+velocity	O
+was	O
+4	O
+.	O
+07	O
+m	O
+/	O
+s	O
+and	O
+2	O
+.	O
+31	O
+m	O
+/	O
+s	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Positive	O
+-	O
+strand	O
+RNA	O
+virus	B-SPEC
+genomes	O
+are	O
+translated	O
+into	O
+polyproteins	O
+that	O
+are	O
+processed	O
+by	O
+viral	O
+proteases	O
+to	O
+yield	O
+functional	O
+intermediate	O
+and	O
+mature	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Primary	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+limits	O
+replication	O
+but	O
+not	O
+lung	B-ANAT
+inflammation	I-DISO
+upon	O
+homologous	O
+rechallenge	O
+.	O
+
+We	O
+previously	O
+reported	O
+that	O
+synthetic	O
+θ	O
+-	O
+defensins	B-PATH
+called	O
+retrocyclins	O
+can	O
+neutralize	O
+and	O
+aggregate	O
+various	O
+strains	O
+of	O
+IAV	O
+and	O
+increase	O
+IAV	O
+uptake	O
+by	O
+neutrophils	B-ANAT
+.	O
+
+The	O
+novel	O
+peptides	B-CHED
+also	O
+allowed	O
+for	O
+systemic	O
+substitution	O
+of	O
+key	O
+residues	O
+to	O
+evaluate	O
+the	O
+role	O
+of	O
+charge	O
+or	O
+hydrophobicity	O
+on	O
+antiviral	B-CHED
+activity	O
+.	O
+
+The	O
+new	O
+peptides	B-CHED
+acted	O
+at	O
+an	O
+early	O
+phase	O
+of	O
+viral	B-DISO
+infection	I-DISO
+,	O
+and	O
+,	O
+when	O
+combined	O
+with	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+protein	B-CHED
+D	O
+,	O
+their	O
+antiviral	B-CHED
+effects	O
+were	O
+additive	O
+.	O
+
+TITLE	O
+:	O
+Spectrum	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+in	O
+tertiary	O
+care	O
+hospital	O
+at	O
+Kolkata	O
+.	O
+
+This	O
+was	O
+a	O
+retrospective	O
+analysis	O
+of	O
+139	O
+children	O
+with	O
+severe	O
+GBS	B-DISO
+admitted	O
+to	O
+our	O
+respiratory	O
+care	O
+unit	O
+managed	O
+with	O
+the	O
+IVIg	O
+as	O
+an	O
+adjunct	O
+intervention	O
+to	O
+conventional	O
+supportive	O
+and	O
+respiratory	O
+care	O
+.	O
+
+In	O
+our	O
+case	O
+series	O
+of	O
+139	O
+cases	O
+,	O
+motor	O
+weakness	B-DISO
+was	O
+the	O
+most	O
+common	O
+presenting	O
+feature	O
+.	O
+
+On	O
+admission	O
+,	O
+a	O
+majority	O
+(	O
+61	O
+.	O
+54	O
+%)	O
+were	O
+in	O
+Hughes	O
+neurological	B-DISO
+disability	I-DISO
+grading	O
+stage	O
+V	O
+;	O
+all	O
+had	O
+limb	B-DISO
+weakness	I-DISO
+at	O
+the	O
+peak	O
+deficit	B-DISO
+,	O
+autonomic	B-ANAT
+disturbance	O
+was	O
+seen	O
+in	O
+35	O
+.	O
+8	O
+%,	O
+and	O
+bulbar	B-DISO
+palsy	I-DISO
+in	O
+52	O
+%.	O
+
+Although	O
+IVIg	O
+may	O
+be	O
+useful	O
+in	O
+the	O
+treatment	O
+of	O
+GBS	B-DISO
+,	O
+the	O
+key	O
+issue	O
+is	O
+excellent	O
+intensive	O
+care	O
+unit	O
+management	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+our	O
+case	O
+series	O
+of	O
+139	O
+cases	O
+,	O
+motor	O
+weakness	B-DISO
+was	O
+the	O
+most	O
+common	O
+presenting	O
+feature	O
+.	O
+
+ABSTRACT	O
+:	O
+ARDS	B-DISO
+remains	O
+a	O
+lethal	O
+complication	O
+after	O
+major	O
+lung	B-ANAT
+resections	O
+.	O
+
+The	O
+detection	O
+specificity	O
+of	O
+the	O
+new	O
+assay	O
+was	O
+proven	O
+by	O
+positive	O
+amplification	B-DISO
+from	O
+a	O
+set	O
+of	O
+nine	O
+different	O
+FCoV	O
+strains	O
+and	O
+negative	O
+from	O
+the	O
+tested	O
+non	O
+-	O
+coronaviral	O
+targets	O
+.	O
+
+Examination	O
+of	O
+faecal	B-ANAT
+samples	O
+of	O
+healthy	O
+young	O
+cats	B-SPEC
+,	O
+organ	B-ANAT
+samples	O
+of	O
+perished	O
+animals	B-SPEC
+,	O
+which	O
+suffered	B-DISO
+from	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+,	O
+and	O
+cat	B-SPEC
+leukocytes	B-ANAT
+from	O
+uncertain	O
+clinical	O
+cases	O
+were	O
+also	O
+subjected	O
+to	O
+the	O
+assay	O
+.	O
+
+GCG	B-PRGE
+showed	O
+a	O
+competitive	B-PROC
+inhibition	I-PROC
+pattern	O
+with	O
+K	O
+(	O
+i	O
+)	O
+value	O
+of	O
+25	O
+±	O
+1	O
+.	O
+7	O
+μM	O
+.	O
+In	O
+molecular	O
+docking	O
+experiments	O
+,	O
+GCG	B-PRGE
+displayed	O
+a	O
+binding	B-FUNC
+energy	O
+of	O
+-	O
+14	O
+kcal	O
+mol	O
+(-	O
+1	O
+)	O
+to	O
+the	O
+active	O
+site	O
+of	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+and	O
+the	O
+galloyl	O
+moiety	O
+at	O
+3	O
+-	O
+OH	O
+position	O
+was	O
+required	O
+for	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+inhibition	B-PROC
+activity	O
+.	O
+
+ECMO	O
+by	O
+itself	O
+did	O
+not	O
+impact	O
+on	O
+the	O
+pharmacokinetics	B-PROC
+of	O
+OC	O
+.	O
+
+RESULTS	O
+:	O
+OC	O
+Cmax	O
+(	O
+1029	O
+±	O
+478	O
+ng	O
+/	O
+mL	O
+)	O
+and	O
+area	O
+under	O
+the	O
+curve	O
+(	O
+9	O
+.	O
+00	O
+±	O
+4	O
+.	O
+52	O
+mcg	O
+·	O
+h	O
+/	O
+mL	O
+)	O
+for	O
+patients	O
+on	O
+ECMO	O
+with	O
+preserved	O
+renal	B-PROC
+function	I-PROC
+were	O
+comparable	O
+with	O
+those	O
+of	O
+healthy	O
+volunteers	O
+or	O
+noncritically	O
+ill	B-DISO
+patients	O
+.	O
+
+The	O
+sequence	O
+data	O
+indicate	O
+that	O
+this	O
+PEDV	B-SPEC
+variant	O
+prevails	O
+in	O
+China	O
+.	O
+
+The	O
+pDNA	O
+loaded	O
+biotinylated	O
+chitosan	B-CHED
+nanoparticles	B-CHED
+were	O
+targeted	B-PROC
+with	O
+bifunctional	O
+fusion	O
+protein	B-CHED
+(	O
+bfFp	O
+)	O
+vector	O
+for	O
+achieving	O
+DC	O
+selective	O
+targeting	O
+.	O
+
+The	O
+overall	O
+infectious	B-DISO
+diseases	I-DISO
+burden	O
+experienced	O
+a	O
+dramatic	O
+drop	O
+during	O
+1975	O
+-	O
+1995	O
+,	O
+but	O
+since	O
+then	O
+,	O
+it	O
+reverted	O
+and	O
+maintained	O
+a	O
+gradual	O
+upward	O
+trend	O
+to	O
+date	O
+.	O
+
+Tuberculosis	B-PATH
+,	O
+as	O
+a	O
+bacterial	B-DISO
+infection	I-DISO
+,	O
+has	O
+re	O
+-	O
+emerged	O
+since	O
+the	O
+1990s	O
+and	O
+has	O
+become	O
+prevalent	O
+in	O
+the	O
+country	O
+.	O
+
+Together	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+),	O
+they	O
+account	O
+for	O
+39	O
+%	O
+of	O
+all	O
+death	B-PROC
+cases	O
+due	O
+to	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+China	O
+in	O
+2008	O
+.	O
+
+The	O
+drugs	O
+are	O
+at	O
+present	O
+applicable	O
+all	O
+over	O
+the	O
+world	O
+in	O
+retrovirus	B-SPEC
+therapy	O
+of	O
+HIV	B-DISO
+infected	O
+subjects	O
+.	O
+
+The	O
+search	O
+for	O
+efficient	O
+Russian	O
+unspecific	O
+medicines	O
+for	O
+control	O
+of	O
+SARS	B-DISO
+is	O
+actual	O
+.	O
+
+The	O
+new	O
+viruses	B-SPEC
+cause	O
+respiratory	O
+illnesses	O
+such	O
+as	O
+common	O
+cold	O
+,	O
+bronchitis	B-DISO
+,	O
+bronchiolitis	B-DISO
+,	O
+exacerbations	O
+of	O
+asthma	B-PATH
+and	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+and	O
+pneumonia	B-DISO
+.	O
+
+Rarely	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+may	O
+occur	O
+.	O
+
+TITLE	O
+:	O
+Treatment	O
+of	O
+sepsis	B-DISO
+and	O
+ARDS	B-DISO
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+interventional	O
+lung	B-ANAT
+assist	O
+membrane	B-COMP
+ventilator	O
+in	O
+a	O
+patient	O
+with	O
+acute	B-DISO
+lymphoblastic	I-DISO
+leukemia	I-DISO
+.	O
+
+Viral	O
+proteins	B-CHED
+target	O
+highly	O
+central	O
+human	B-SPEC
+proteins	B-CHED
+,	O
+which	O
+are	O
+precisely	O
+the	O
+Achilles	B-ANAT
+'	O
+heel	B-ANAT
+of	O
+the	O
+human	B-SPEC
+interactome	O
+.	O
+
+The	O
+intrinsic	O
+structural	O
+disorder	O
+is	O
+a	O
+distinctive	O
+feature	O
+of	O
+viral	O
+hubs	O
+in	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactomes	O
+.	O
+
+Host	B-COMP
+proteins	B-CHED
+that	O
+are	O
+strongly	O
+targeted	B-PROC
+by	O
+a	O
+virus	B-SPEC
+seem	O
+to	O
+be	O
+particularly	O
+attractive	O
+for	O
+other	O
+viruses	B-SPEC
+.	O
+
+To	O
+define	O
+the	O
+epidemiological	O
+profile	O
+and	O
+the	O
+clinical	O
+characteristics	O
+associated	O
+with	O
+HBoV	O
+infection	B-DISO
+in	O
+a	O
+population	O
+of	O
+children	O
+hospitalized	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+Samples	O
+were	O
+tested	O
+for	O
+HBoV	O
+by	O
+PCR	O
+amplifying	O
+a	O
+part	O
+of	O
+the	O
+NS1	B-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+most	O
+common	O
+symptoms	O
+were	O
+fever	B-PROC
+,	O
+cough	B-DISO
+and	O
+various	O
+degrees	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+All	O
+children	O
+were	O
+clinically	O
+diagnosed	O
+as	O
+having	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+mainly	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+laryngotracheobronchitis	I-DISO
+,	O
+and	O
+recovered	O
+uneventfully	O
+.	O
+
+MP	O
+pneumonia	B-DISO
+has	O
+been	O
+reported	O
+in	O
+10	O
+to	O
+40	O
+%	O
+of	O
+cases	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+and	O
+shows	O
+an	O
+even	O
+higher	O
+proportion	O
+during	O
+epidemics	O
+.	O
+
+MP	O
+infection	B-DISO
+is	O
+usually	O
+a	O
+mild	O
+and	O
+self	O
+-	O
+limiting	O
+disease	O
+without	O
+specific	O
+treatment	O
+,	O
+and	O
+if	O
+needed	O
+,	O
+macrolides	B-CHED
+are	O
+generally	O
+used	O
+as	O
+a	O
+first	O
+-	O
+choice	O
+drug	O
+for	O
+children	O
+.	O
+
+The	O
+immunopathogenesis	O
+of	O
+MP	O
+pneumonia	B-DISO
+is	O
+believed	O
+to	O
+be	O
+a	O
+hyperimmune	O
+reaction	O
+of	O
+the	O
+host	B-COMP
+to	O
+the	O
+insults	O
+from	O
+MP	O
+infection	B-DISO
+,	O
+including	O
+cytokine	O
+overproduction	O
+and	O
+immune	B-PROC
+cell	I-PROC
+activation	I-PROC
+(	O
+T	B-ANAT
+cells	I-ANAT
+).	O
+
+In	O
+the	O
+last	O
+few	O
+years	O
+,	O
+it	O
+has	O
+been	O
+discovered	O
+that	O
+the	O
+association	O
+between	O
+coronaviruses	O
+and	O
+bats	B-SPEC
+is	O
+a	O
+worldwide	O
+phenomenon	O
+,	O
+and	O
+it	O
+has	O
+been	O
+hypothesised	O
+that	O
+all	O
+mammalian	B-SPEC
+coronaviruses	O
+were	O
+derived	O
+from	O
+ancestral	O
+viruses	B-SPEC
+residing	O
+in	O
+bats	B-SPEC
+.	O
+
+The	O
+study	O
+included	O
+a	O
+total	O
+of	O
+75	O
+subjects	O
+;	O
+there	O
+were	O
+25	O
+adult	O
+patients	O
+with	O
+acute	O
+severe	O
+FM	O
+and	O
+ARF	B-DISO
+,	O
+25	O
+adult	O
+patients	O
+with	O
+uncomplicated	O
+FM	O
+without	O
+ARF	B-DISO
+,	O
+and	O
+25	O
+age	O
+-	O
+and	O
+sex	O
+-	O
+matched	O
+healthy	O
+subjects	O
+who	O
+served	O
+as	O
+controls	O
+.	O
+
+Sixty	O
+percent	O
+recovered	O
+and	O
+40	O
+%	O
+died	B-PROC
+.	O
+
+The	O
+mean	O
+serum	B-COMP
+malondialdehyde	B-CHED
+(	O
+MDA	B-CHED
+)	O
+levels	O
+were	O
+0	O
+.	O
+82	O
+±	O
+0	O
+.	O
+43	O
+μmol	O
+/	O
+L	O
+,	O
+2	O
+.	O
+97	O
+±	O
+1	O
+.	O
+11	O
+μmol	O
+/	O
+L	O
+,	O
+and	O
+6	O
+.	O
+86	O
+±	O
+2	O
+.	O
+62	O
+μmol	O
+/	O
+L	O
+,	O
+respectively	O
+,	O
+in	O
+healthy	O
+controls	O
+,	O
+in	O
+patients	O
+with	O
+uncomplicated	O
+FM	O
+,	O
+and	O
+in	O
+those	O
+with	O
+severe	O
+FM	O
+with	O
+ARF	O
+.	O
+
+Also	O
+,	O
+we	O
+observed	O
+a	O
+high	O
+occurrence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+involvement	O
+among	O
+the	O
+patients	O
+who	O
+expired	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+pathophysiology	O
+and	O
+therapeutic	O
+options	O
+.	O
+
+Despite	O
+intense	O
+ongoing	O
+research	O
+on	O
+the	O
+pathophysiology	O
+and	O
+treatment	O
+of	O
+ARDS	B-DISO
+,	O
+mortality	O
+remains	O
+high	O
+.	O
+
+Viral	O
+culture	O
+detected	O
+only	O
+one	O
+case	O
+of	O
+RV	O
+infection	B-DISO
+,	O
+while	O
+multiplex	O
+PCR	O
+detected	O
+eight	O
+,	O
+suggesting	O
+that	O
+screening	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+using	O
+multiplex	O
+PCR	O
+is	O
+better	O
+than	O
+the	O
+conventional	O
+culture	O
+method	O
+.	O
+
+Ten	O
+adult	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+secondary	O
+to	O
+H1N1	O
+infection	B-DISO
+(	O
+Pao	B-PROC
+(	O
+2	O
+)/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+,	O
+69	O
+mm	O
+Hg	O
+[	O
+56	O
+-	O
+84	O
+];	O
+Murray	O
+score	O
+,	O
+3	O
+.	O
+5	O
+[	O
+3	O
+.	O
+5	O
+-	O
+3	O
+.	O
+8	O
+])	O
+were	O
+included	O
+,	O
+and	O
+60	O
+%	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+Six	O
+patients	O
+were	O
+treated	O
+during	O
+the	O
+first	O
+postpandemic	O
+influenza	B-DISO
+season	O
+.	O
+
+Viral	O
+pathogens	O
+were	O
+detected	O
+in	O
+52	O
+.	O
+88	O
+%	O
+(	O
+220	O
+/	O
+416	O
+)	O
+of	O
+patient	O
+samples	O
+,	O
+and	O
+7	O
+.	O
+21	O
+%	O
+(	O
+30	O
+/	O
+416	O
+)	O
+of	O
+patients	O
+tested	O
+positive	O
+for	O
+more	O
+than	O
+one	O
+virus	B-SPEC
+.	O
+
+Further	O
+observations	O
+suggest	O
+that	O
+the	O
+zinc	B-CHED
+-	O
+binding	B-FUNC
+domain	O
+may	O
+start	O
+to	O
+unfold	O
+during	O
+the	O
+first	O
+transition	B-DISO
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+characterization	O
+of	O
+a	O
+novel	O
+Betacoronavirus	B-SPEC
+subgroup	O
+A	O
+coronavirus	B-SPEC
+,	O
+rabbit	B-SPEC
+coronavirus	B-SPEC
+HKU14	I-PRGE
+,	O
+from	O
+domestic	B-SPEC
+rabbits	I-SPEC
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+that	O
+RbCoV	O
+HKU14	O
+formed	O
+a	O
+distinct	O
+branch	B-ANAT
+among	O
+Betacoronavirus	B-SPEC
+subgroup	O
+A	O
+coronaviruses	O
+,	O
+being	O
+most	O
+closely	O
+related	O
+to	O
+but	O
+separate	O
+from	O
+the	O
+species	B-SPEC
+Betacoronavirus	B-SPEC
+1	I-SPEC
+.	O
+
+Younger	O
+cats	B-SPEC
+were	O
+significantly	O
+over	O
+-	O
+represented	O
+among	O
+FIP	B-DISO
+cases	O
+.	O
+
+This	O
+opens	O
+further	O
+avenues	O
+to	O
+investigate	O
+the	O
+role	O
+of	O
+genetic	O
+factors	O
+in	O
+FIP	B-DISO
+.	O
+
+Deoxynivalenol	O
+(	O
+DON	O
+)	O
+is	O
+known	O
+to	O
+modulate	O
+immune	B-PROC
+function	I-PROC
+,	O
+but	O
+only	O
+a	O
+few	O
+studies	O
+have	O
+investigated	O
+the	O
+effect	O
+of	O
+DON	O
+on	O
+the	O
+vaccinal	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+The	O
+feeding	O
+of	O
+contaminated	O
+diets	O
+altered	O
+the	O
+immune	B-PROC
+response	I-PROC
+in	O
+broilers	O
+by	O
+reducing	O
+the	O
+total	O
+lymphocyte	B-ANAT
+count	O
+.	O
+
+It	O
+was	O
+concluded	O
+that	O
+broiler	O
+performance	O
+and	O
+some	O
+blood	B-ANAT
+and	O
+immunological	O
+parameters	O
+were	O
+adversely	O
+affected	O
+by	O
+feeding	O
+diets	O
+contaminated	O
+with	O
+the	O
+Fusarium	B-SPEC
+mycotoxin	B-CHED
+DON	O
+.	O
+
+When	O
+left	O
+untreated	O
+,	O
+the	O
+mortality	O
+rate	O
+for	O
+scrub	B-DISO
+typhus	I-DISO
+will	O
+be	O
+increased	O
+.	O
+
+In	O
+contrast	O
+,	O
+all	O
+80	O
+fecal	B-ANAT
+samples	O
+lacking	O
+the	O
+five	O
+target	O
+viruses	B-SPEC
+from	O
+normal	O
+adult	O
+cattle	B-SPEC
+were	O
+negative	O
+in	O
+the	O
+multiplex	O
+assay	O
+.	O
+
+We	O
+analyzed	O
+in	O
+this	O
+study	O
+the	O
+impact	O
+of	O
+Tregs	O
+on	O
+the	O
+development	B-PROC
+of	O
+acute	O
+viral	O
+encephalomyelitis	B-DISO
+,	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+antiviral	B-CHED
+protection	O
+,	O
+and	O
+prevention	O
+of	O
+CNS	B-CHED
+autoimmunity	B-DISO
+following	O
+intranasal	O
+infection	B-DISO
+with	O
+the	O
+gliatropic	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+.	O
+
+Dissection	O
+of	O
+the	O
+underlying	O
+immunopathological	O
+mechanisms	O
+revealed	O
+the	O
+elaborate	O
+Treg	O
+-	O
+dependent	O
+regulation	B-PROC
+of	O
+self	O
+-	O
+reactive	O
+CD4	B-PRGE
+(+)	O
+T	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+within	O
+the	O
+CNS	B-CHED
+-	O
+draining	O
+lymph	B-ANAT
+node	I-ANAT
+and	O
+downtuning	O
+of	O
+CXCR3	B-PRGE
+expression	B-PROC
+on	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Barth	B-DISO
+syndrome	I-DISO
+in	O
+a	O
+female	O
+patient	O
+.	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+BTHS	B-DISO
+confirmed	O
+by	O
+TAZ	B-PRGE
+gene	I-PRGE
+analysis	O
+in	O
+a	O
+female	O
+patient	O
+.	O
+
+This	O
+case	O
+highlights	O
+that	O
+the	O
+diagnosis	O
+of	O
+BTHS	B-DISO
+should	O
+also	O
+be	O
+suspected	O
+in	O
+female	O
+patients	O
+presenting	O
+a	O
+phenotype	O
+similar	O
+to	O
+affected	O
+boys	O
+.	O
+
+A	O
+preliminary	O
+structure	O
+-	O
+activity	O
+relationship	O
+study	O
+(	O
+SARs	B-DISO
+)	O
+revealed	O
+the	O
+necessity	O
+of	O
+the	O
+biflavonoid	B-CHED
+skeleton	B-ANAT
+,	O
+the	O
+influence	O
+of	O
+number	O
+and	O
+position	O
+of	O
+methoxylations	O
+,	O
+and	O
+the	O
+importance	O
+of	O
+a	O
+free	O
+rotation	O
+of	O
+the	O
+linkage	B-PROC
+between	O
+the	O
+two	O
+apigenin	B-CHED
+monomers	O
+of	O
+the	O
+biflavonoids	B-CHED
+.	O
+
+(	O
+i	O
+)	O
+To	O
+elucidate	O
+the	O
+clinical	O
+aspects	O
+of	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+,	O
+(	O
+ii	O
+)	O
+to	O
+develop	O
+a	O
+simple	O
+diagnostic	O
+algorithm	O
+in	O
+order	B-SPEC
+to	O
+separate	O
+DAH	O
+from	O
+other	O
+important	O
+pulmonary	B-DISO
+diseases	I-DISO
+with	O
+similar	O
+clinical	O
+picture	O
+and	O
+comparably	O
+high	O
+mortality	O
+.	O
+
+This	O
+test	O
+should	O
+be	O
+performed	O
+in	O
+all	O
+patients	O
+with	O
+pulmonary	B-ANAT
+opacities	B-DISO
+in	O
+order	B-SPEC
+to	O
+separate	O
+ARDS	B-DISO
+/	O
+ALI	O
+from	O
+DAH	O
+.	O
+
+TITLE	O
+:	O
+Doxycycline	B-CHED
+treatment	O
+attenuates	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+virulent	O
+influenza	B-DISO
+H3N2	B-CHED
+virus	B-SPEC
+:	O
+involvement	O
+of	O
+matrix	O
+metalloproteinases	O
+.	O
+
+We	O
+have	O
+provided	O
+evidence	O
+for	O
+the	O
+involvement	O
+of	O
+recruited	O
+neutrophils	B-ANAT
+,	O
+their	O
+toxic	O
+enzymes	O
+such	O
+as	O
+myeloperoxidase	B-PRGE
+and	O
+matrix	O
+metalloproteinases	O
+(	O
+MMPs	O
+),	O
+and	O
+neutrophil	B-ANAT
+extracellular	B-COMP
+traps	B-DISO
+in	O
+aggravating	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+damage	O
+.	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+infected	O
+with	O
+a	O
+sublethal	O
+dose	O
+of	O
+mouse	B-SPEC
+-	O
+adapted	O
+virulent	O
+influenza	B-PATH
+A	I-PATH
+/	O
+Aichi	O
+/	O
+2	O
+/	O
+68	O
+(	O
+H3N2	B-CHED
+)	O
+virus	B-SPEC
+,	O
+and	O
+administered	O
+daily	O
+with	O
+20mg	O
+/	O
+kg	O
+or	O
+60	O
+mg	O
+/	O
+kg	O
+DOX	O
+orally	B-ANAT
+.	O
+
+Twelve	O
+patients	O
+had	O
+pneumonia	B-DISO
+and	O
+sepsis	B-DISO
+with	O
+progression	O
+to	O
+ARDS	B-DISO
+.	O
+
+The	O
+range	O
+of	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+was	O
+42	O
+-	O
+69	O
+.	O
+9	O
+,	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-CHED
+gradient	O
+(	O
+AaDO	O
+(	O
+2	O
+))	O
+602	O
+-	O
+645	O
+,	O
+and	O
+oxygenation	B-PROC
+index	O
+(	O
+OI	O
+)	O
+27	O
+.	O
+4	O
+-	O
+68	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+multiple	O
+cysteine	O
+as	O
+well	O
+as	O
+charged	O
+residues	O
+concurrently	O
+improves	O
+the	O
+membrane	B-COMP
+-	O
+associated	O
+functions	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+viral	B-PROC
+replication	I-PROC
+and	O
+cytopathogenesis	O
+.	O
+
+Feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+p27	O
+antigen	O
+was	O
+detected	O
+in	O
+13	O
+/	O
+50	O
+serum	B-COMP
+/	O
+lung	B-ANAT
+tissue	I-ANAT
+extract	O
+samples	O
+(	O
+26	O
+%),	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+2	O
+/	O
+26	O
+serum	B-COMP
+/	O
+lung	B-ANAT
+tissue	I-ANAT
+extract	O
+samples	O
+(	O
+7	O
+.	O
+7	O
+%),	O
+feline	B-SPEC
+coronavirus	B-SPEC
+RNA	O
+was	O
+present	O
+in	O
+6	O
+/	O
+29	O
+stool	B-ANAT
+samples	O
+(	O
+20	O
+.	O
+7	O
+%)	O
+and	O
+feline	B-SPEC
+parvovirus	I-SPEC
+DNA	O
+in	O
+2	O
+/	O
+29	O
+stool	B-ANAT
+samples	O
+(	O
+6	O
+.	O
+9	O
+%).	O
+
+Canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+RNA	O
+was	O
+not	O
+detected	O
+.	O
+
+Postoperatively	O
+she	O
+had	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+successfully	O
+treated	O
+by	O
+the	O
+anesthetic	O
+care	O
+team	O
+Causes	O
+for	O
+the	O
+complication	B-DISO
+are	O
+discussed	O
+.	O
+
+After	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+resuscitation	O
+,	O
+median	O
+survival	O
+time	O
+in	O
+obstetric	O
+rabbits	O
+(	O
+3	O
+days	O
+)	O
+was	O
+significantly	O
+shorter	O
+(	O
+p	O
+<.	O
+05	O
+)	O
+than	O
+that	O
+in	O
+nonobstetric	O
+rabbits	B-SPEC
+(	O
+5	O
+days	O
+).	O
+
+The	O
+mechanism	O
+may	O
+be	O
+through	O
+upregulation	B-PROC
+of	O
+the	O
+signal	B-PROC
+transductions	I-PROC
+of	O
+the	O
+nuclear	O
+factor	O
+-	O
+κB	O
+pathways	B-PROC
+.	O
+
+Given	O
+the	O
+genetic	O
+diversity	O
+of	O
+respiratory	O
+viruses	B-SPEC
+and	O
+the	O
+emergence	O
+of	O
+drug	O
+resistant	O
+strains	O
+,	O
+the	O
+targeted	B-PROC
+disruption	O
+of	O
+human	B-SPEC
+host	B-COMP
+-	O
+virus	B-SPEC
+interactions	O
+is	O
+a	O
+potential	O
+therapeutic	O
+strategy	O
+for	O
+treating	O
+multi	O
+-	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Our	O
+study	O
+suggests	O
+that	O
+multiple	O
+and	O
+diverse	O
+respiratory	O
+viruses	B-SPEC
+invoke	O
+several	O
+common	O
+host	B-PROC
+response	I-PROC
+pathways	B-PROC
+.	O
+
+The	O
+expression	B-PROC
+of	O
+KCTD9	B-PRGE
+protein	I-PRGE
+was	O
+mainly	O
+evidenced	O
+in	O
+infiltrative	O
+mononuclear	B-ANAT
+cells	I-ANAT
+of	O
+liver	B-ANAT
+as	O
+shown	O
+by	O
+immunohistochemistry	O
+.	O
+
+ABSTRACT	O
+:	O
+Cystic	O
+lymphangioma	O
+is	O
+a	O
+rare	O
+lesion	O
+of	O
+the	O
+mediastinum	B-ANAT
+.	O
+
+We	O
+present	O
+a	O
+patient	O
+with	O
+an	O
+antenatally	O
+detected	O
+mediastinal	B-ANAT
+mass	O
+that	O
+appeared	O
+to	O
+regress	O
+during	O
+foetal	O
+life	O
+and	O
+was	O
+not	O
+demonstrated	O
+on	O
+early	O
+postnatal	O
+imaging	O
+.	O
+
+Acute	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+at	O
+two	O
+months	O
+of	O
+age	O
+precipitated	O
+surgery	O
+with	O
+subsequent	O
+diagnosis	O
+of	O
+lymphangioma	B-DISO
+.	O
+
+Compared	O
+with	O
+256	O
+patients	O
+without	O
+pneumonia	B-DISO
+,	O
+these	O
+195	O
+patients	O
+with	O
+pneumonia	B-DISO
+were	O
+more	O
+likely	O
+to	O
+be	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+52	O
+%	O
+vs	O
+16	O
+%),	O
+have	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+;	O
+26	O
+%	O
+vs	O
+2	O
+%),	O
+have	O
+sepsis	B-DISO
+(	O
+18	O
+%	O
+vs	O
+3	O
+%),	O
+and	O
+die	O
+(	O
+17	O
+%	O
+vs	O
+2	O
+%;	O
+P	O
+<	O
+.	O
+0001	O
+).	O
+
+One	O
+hundred	O
+eighteen	O
+(	O
+61	O
+%)	O
+of	O
+the	O
+patients	O
+with	O
+pneumonia	B-DISO
+had	O
+≥	O
+1	O
+underlying	O
+condition	B-DISO
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+accurate	O
+pneumonia	B-DISO
+diagnostics	O
+,	O
+patients	O
+hospitalized	O
+with	O
+suspected	O
+influenza	B-DISO
+and	O
+lung	B-ANAT
+infiltrates	B-DISO
+on	O
+chest	B-ANAT
+radiography	O
+should	O
+receive	O
+early	O
+and	O
+aggressive	B-DISO
+treatment	O
+with	O
+antibiotics	B-CHED
+and	O
+influenza	B-DISO
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+Patients	O
+with	O
+pneumonia	B-DISO
+,	O
+when	O
+compared	O
+with	O
+patients	O
+without	O
+pneumonia	B-DISO
+,	O
+were	O
+equally	O
+likely	O
+to	O
+receive	O
+influenza	B-DISO
+antiviral	B-CHED
+agents	I-CHED
+(	O
+78	O
+%	O
+vs	O
+79	O
+%)	O
+but	O
+less	O
+likely	O
+to	O
+receive	O
+antiviral	B-CHED
+agents	I-CHED
+within	O
+≤	O
+2	O
+days	O
+of	O
+illness	O
+onset	O
+(	O
+28	O
+%	O
+vs	O
+50	O
+%;	O
+P	O
+<	O
+.	O
+0001	O
+).	O
+
+TITLE	O
+:	O
+Prolonged	O
+use	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+combined	O
+with	O
+prone	O
+positioning	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+and	O
+invasive	B-DISO
+Aspergillosis	I-DISO
+.	O
+
+Early	O
+in	O
+infection	B-DISO
+,	O
+nascent	O
+viral	O
+RNA	O
+and	O
+nsp	O
+'	O
+s	O
+colocalized	O
+with	O
+or	O
+occurred	O
+adjacent	O
+to	O
+dsRNA	B-CHED
+foci	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+signatures	O
+of	O
+recurrent	O
+positive	O
+selection	O
+in	O
+the	O
+bat	B-PRGE
+ACE2	I-PRGE
+gene	I-PRGE
+map	O
+almost	O
+perfectly	O
+to	O
+known	O
+SARS	B-DISO
+-	O
+CoV	O
+interaction	O
+surfaces	O
+.	O
+
+Both	O
+viruses	B-SPEC
+showed	O
+similar	O
+replication	O
+kinetics	O
+in	O
+established	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+Although	O
+the	O
+horizontal	O
+propagation	O
+of	O
+viruses	B-SPEC
+feeds	O
+the	O
+continuous	O
+emergence	O
+of	O
+novel	O
+pathogenic	O
+viruses	B-SPEC
+,	O
+the	O
+genetic	O
+variation	O
+of	O
+cellular	B-COMP
+receptors	O
+can	O
+represent	O
+a	O
+challenging	O
+barrier	O
+.	O
+
+So	O
+the	O
+question	O
+'	O
+Are	O
+bats	B-SPEC
+different	O
+,	O
+special	O
+or	O
+exceptional	O
+?'	O
+has	O
+become	O
+a	O
+focal	O
+point	O
+in	O
+the	O
+field	O
+of	O
+virology	O
+,	O
+bat	B-ENZY
+biology	O
+and	O
+virus	B-SPEC
+-	O
+host	B-COMP
+co	O
+-	O
+evolution	B-PROC
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+three	O
+diagnostic	O
+techniques	O
+for	O
+detection	O
+of	O
+rotavirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+in	O
+calf	B-ANAT
+faeces	O
+in	O
+Australia	O
+.	O
+
+A	O
+subset	O
+of	O
+samples	O
+was	O
+screened	O
+using	O
+qRT	O
+-	O
+PCR	O
+,	O
+ELISA	O
+and	O
+a	O
+commercial	O
+LAT	B-ENZY
+dipstick	O
+(	O
+132	O
+faecal	B-ANAT
+samples	O
+were	O
+tested	O
+for	O
+coronavirus	B-SPEC
+and	O
+122	O
+samples	O
+for	O
+rotavirus	B-SPEC
+).	O
+
+There	O
+was	O
+also	O
+poor	O
+agreement	O
+between	O
+the	O
+LAT	B-PRGE
+and	O
+qRT	O
+-	O
+PCR	O
+assays	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+586	O
+samples	O
+tested	O
+,	O
+131	O
+(	O
+22	O
+.	O
+39	O
+%)	O
+and	O
+468	O
+(	O
+79	O
+.	O
+86	O
+%)	O
+were	O
+positive	O
+for	O
+coronavirus	B-SPEC
+and	O
+group	B-SPEC
+A	I-SPEC
+rotavirus	I-SPEC
+,	O
+respectively	O
+,	O
+using	O
+qRT	O
+-	O
+PCR	O
+.	O
+
+The	O
+resultant	O
+antibodies	B-COMP
+had	O
+a	O
+higher	O
+titer	O
+than	O
+antibodies	B-COMP
+produced	O
+in	O
+response	O
+to	O
+native	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Olig1	B-PRGE
+function	O
+is	O
+required	O
+for	O
+remyelination	B-PROC
+potential	O
+of	O
+transplanted	B-ANAT
+neural	O
+progenitor	B-ANAT
+cells	B-COMP
+in	O
+a	O
+model	O
+of	O
+viral	O
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+We	O
+have	O
+previously	O
+shown	O
+that	O
+transplantation	O
+of	O
+neural	O
+progenitor	B-ANAT
+cells	I-ANAT
+(	O
+NPCs	O
+)	O
+into	O
+mice	B-SPEC
+persistently	O
+infected	O
+with	O
+the	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+results	O
+in	O
+enhanced	O
+differentiation	B-PROC
+into	O
+oligodendrocyte	B-ANAT
+progenitor	B-ANAT
+cells	I-ANAT
+(	O
+OPCs	O
+)	O
+that	O
+is	O
+associated	O
+with	O
+remyelination	B-PROC
+and	O
+axonal	O
+sparing	O
+.	O
+
+However	O
+,	O
+only	O
+recipients	O
+of	O
+wild	O
+type	O
+NPCs	O
+exhibited	O
+extensive	O
+remyelination	B-PROC
+compared	O
+to	O
+mice	B-SPEC
+receiving	O
+Olig1	O
+-/-	O
+NPCs	O
+.	O
+
+In	O
+vivo	O
+characterization	O
+of	O
+NPCs	O
+revealed	O
+that	O
+Olig1	B-PRGE
++/+	I-PRGE
+NPCs	I-PRGE
+preferentially	O
+differentiated	B-PROC
+into	O
+NG2	O
+-	O
+positive	O
+OPCs	O
+and	O
+formed	O
+processes	O
+expressing	O
+myelin	B-PRGE
+basic	I-PRGE
+protein	B-CHED
+that	O
+encircled	O
+axons	B-COMP
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+majority	O
+of	O
+transplanted	B-ANAT
+Olig1	B-PRGE
+-/-	O
+NPCs	O
+differentiated	B-PROC
+into	O
+GFAP	O
+-	O
+positive	O
+cells	B-COMP
+consistent	O
+with	O
+the	O
+astrocyte	B-ANAT
+lineage	O
+.	O
+
+Clinical	O
+usefulness	O
+of	O
+ECMO	O
+was	O
+documented	O
+in	O
+many	O
+cases	O
+of	O
+severe	O
+ARDS	B-DISO
+secondary	O
+to	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+2009	O
+infection	B-DISO
+.	O
+
+Five	O
+other	O
+patients	O
+developed	O
+late	O
+respiratory	B-DISO
+failure	I-DISO
+after	O
+24	O
+hours	O
+of	O
+ingestion	O
+,	O
+and	O
+all	O
+of	O
+them	O
+showed	O
+progressive	O
+RNS	B-DISO
+changes	O
+indicating	O
+severe	O
+IMS	O
+prior	O
+to	O
+intubation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+normal	O
+RNS	B-DISO
+in	O
+all	O
+patients	O
+developing	O
+early	O
+respiratory	B-DISO
+failure	I-DISO
+suggests	O
+that	O
+it	O
+is	O
+due	O
+to	O
+a	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+and	O
+muscarinic	O
+effect	O
+.	O
+
+TITLE	O
+:	O
+The	O
+differential	O
+clinical	O
+impact	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+species	B-SPEC
+in	O
+children	O
+with	O
+cystic	B-DISO
+fibrosis	I-DISO
+.	O
+
+Samples	O
+positive	O
+for	O
+HCoV	O
+were	O
+submitted	O
+for	O
+nucleotide	B-CHED
+sequencing	O
+to	O
+determine	O
+the	O
+species	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+common	O
+complication	B-DISO
+in	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+The	O
+authors	O
+propose	O
+that	O
+increasing	O
+the	O
+concentration	O
+of	O
+the	O
+inoculum	O
+without	O
+changing	O
+the	O
+bacterial	O
+dose	O
+will	O
+lead	O
+to	O
+severe	B-DISO
+sepsis	I-DISO
+with	O
+pronounced	O
+pulmonary	B-ANAT
+lesions	O
+.	O
+
+Since	O
+no	O
+correlation	O
+was	O
+observed	O
+between	O
+local	O
+and	O
+systemic	O
+levels	O
+of	O
+inflammatory	O
+cytokines	O
+,	O
+this	O
+finding	O
+could	O
+indicate	O
+an	O
+ability	O
+of	O
+the	O
+porcine	B-SPEC
+lung	B-ANAT
+to	O
+compartmentalize	O
+the	O
+local	O
+inflammatory	B-DISO
+response	I-DISO
+and	O
+thus	O
+restrict	O
+systemic	O
+contribution	O
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+,	O
+structure	O
+-	O
+activity	O
+relationships	O
+and	O
+biological	O
+evaluation	O
+of	O
+caudatin	O
+derivatives	O
+as	O
+novel	O
+anti	O
+-	O
+hepatitis	O
+B	O
+virus	O
+agents	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+drugs	I-CHED
+on	O
+colibacillosis	B-DISO
+lesions	O
+in	O
+broilers	O
+after	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+and	O
+subsequent	O
+Escherichia	B-DISO
+coli	I-DISO
+infection	I-DISO
+.	O
+
+To	O
+assess	O
+the	O
+effect	O
+of	O
+anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+drugs	I-CHED
+on	O
+lesions	O
+due	O
+to	O
+colibacillosis	B-DISO
+.	O
+
+Broilers	O
+of	O
+four	O
+groups	O
+were	O
+treated	O
+from	O
+day	O
+28	O
+up	O
+to	O
+and	O
+including	O
+day	O
+39	O
+orally	B-ANAT
+on	O
+a	O
+daily	O
+basis	O
+with	O
+either	O
+carbasalate	O
+calcium	B-CHED
+(	O
+4	O
+×	O
+12	O
+.	O
+5	O
+mg	O
+),	O
+meloxicam	O
+(	O
+2	O
+×	O
+0	O
+.	O
+5	O
+mg	O
+),	O
+acetaminophen	B-CHED
+(	O
+4	O
+×	O
+2	O
+.	O
+5	O
+mg	O
+),	O
+or	O
+dexamethasone	B-CHED
+(	O
+1	O
+×	O
+1	O
+.	O
+0	O
+mg	O
+).	O
+
+RESULTS	O
+:	O
+All	O
+broilers	O
+in	O
+the	O
+dexamethasone	B-CHED
+group	O
+died	B-PROC
+.	O
+
+Vitamin	B-CHED
+D	I-CHED
+levels	O
+were	O
+associated	O
+with	O
+pulmonary	B-PROC
+function	I-PROC
+(	O
+forced	B-PROC
+expiratory	I-PROC
+volume	I-PROC
+in	O
+1	O
+second	O
+[	O
+FEV	B-SPEC
+(	O
+1	O
+)]),	O
+but	O
+not	O
+associated	O
+with	O
+either	O
+rates	O
+of	O
+acute	B-DISO
+pain	I-DISO
+or	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+episodes	O
+.	O
+
+Further	O
+studies	O
+are	O
+needed	O
+to	O
+be	O
+able	O
+to	O
+compare	O
+outcomes	O
+in	O
+those	O
+with	O
+deficiency	O
+to	O
+those	O
+with	O
+sufficiency	O
+,	O
+as	O
+well	O
+as	O
+to	O
+treating	O
+patients	O
+with	O
+SCA	B-ANAT
+with	O
+vitamin	B-CHED
+D	I-CHED
+to	O
+better	O
+establish	O
+a	O
+possible	O
+link	O
+,	O
+if	O
+any	O
+,	O
+between	O
+vitamin	B-CHED
+D	I-CHED
+and	O
+SCA	B-ANAT
+morbidity	O
+.	O
+
+To	O
+investigate	O
+single	O
+-	O
+chain	O
+fragment	O
+variable	O
+(	O
+scFv	O
+)	O
+repertoire	O
+against	O
+pAPN	O
+,	O
+the	O
+genes	O
+encoding	O
+the	O
+immunoglobulin	B-PRGE
+light	I-PRGE
+chain	I-PRGE
+variable	I-PRGE
+region	I-PRGE
+(	O
+VL	O
+)	O
+and	O
+heavy	O
+chain	O
+variable	O
+region	O
+(	O
+VH	O
+)	O
+were	O
+amplified	O
+by	O
+reverse	O
+transcript	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+using	O
+a	O
+series	O
+of	O
+degenerate	B-DISO
+primers	O
+from	O
+the	O
+spleen	B-ANAT
+of	O
+BABL	O
+/	O
+c	O
+mice	B-SPEC
+immunized	O
+with	O
+native	O
+pAPN	O
+.	O
+
+The	O
+effectiveness	O
+of	O
+the	O
+scFv	O
+library	O
+against	O
+pAPN	O
+was	O
+verified	O
+further	O
+by	O
+phage	O
+ELISA	O
+using	O
+the	O
+recombinant	O
+protein	B-CHED
+of	O
+the	O
+pAPN	B-PRGE
+C	I-PRGE
+subunit	I-PRGE
+as	I-PRGE
+coating	I-PRGE
+antigen	I-PRGE
+.	O
+
+Univariate	O
+analysis	O
+revealed	O
+no	O
+significant	O
+pre	O
+-	O
+ECMO	O
+risk	O
+factor	O
+for	O
+treatment	O
+failure	O
+but	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+concentration	O
+at	O
+the	O
+time	O
+of	O
+ECMO	O
+differed	O
+significantly	O
+among	O
+patients	O
+who	O
+did	O
+versus	O
+did	O
+not	O
+survive	O
+after	O
+ECMO	O
+.	O
+
+Histopathologically	O
+,	O
+lymphoid	B-ANAT
+organs	I-ANAT
+(	O
+bursa	B-ANAT
+of	I-ANAT
+Fabricius	I-ANAT
+,	O
+spleen	B-ANAT
+,	O
+thymus	B-SPEC
+,	O
+caecal	O
+tonsils	B-ANAT
+and	O
+Harderian	O
+glands	B-ANAT
+)	O
+showed	O
+moderate	O
+to	O
+severe	O
+necrosis	B-PROC
+(	O
+lymphocytolysis	O
+)	O
+and	O
+extensive	O
+lymphocyte	B-ANAT
+depletion	O
+in	O
+all	O
+the	O
+toxin	O
+groups	O
+(	O
+T	O
+-	O
+2	O
+and	O
+T	O
+-	O
+2	B-SPEC
++	I-SPEC
+IBV	I-SPEC
+groups	O
+)	O
+where	O
+the	O
+severity	O
+and	O
+extent	O
+of	O
+the	O
+lesions	O
+were	O
+more	O
+in	O
+T	O
+-	O
+2	B-SPEC
++	I-SPEC
+IBV	I-SPEC
+group	O
+.	O
+
+The	O
+patient	O
+decompensated	O
+,	O
+developing	O
+intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+with	O
+renal	B-ANAT
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	O
+)	O
+is	O
+a	O
+lethal	O
+immunopathological	O
+disease	O
+caused	O
+by	O
+feline	B-SPEC
+coronaviruses	O
+(	O
+FCoVs	O
+).	O
+
+Virus	B-SPEC
+sequence	O
+analyses	O
+from	O
+FIP	B-DISO
+-	O
+diseased	O
+cats	B-SPEC
+revealed	O
+that	O
+the	O
+3c	B-PRGE
+gene	I-PRGE
+stop	O
+codon	O
+of	O
+strain	O
+79	O
+-	O
+1146	O
+has	O
+changed	O
+to	O
+restore	O
+a	O
+full	O
+-	O
+length	O
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+type	B-PRGE
+II	I-PRGE
+transmembrane	I-PRGE
+protease	I-PRGE
+TMPRSS2	I-PRGE
+activates	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+on	O
+the	O
+cell	B-COMP
+surface	I-COMP
+following	O
+receptor	B-FUNC
+binding	I-FUNC
+during	O
+viral	O
+entry	O
+into	O
+cells	B-COMP
+.	O
+
+Simultaneous	O
+treatment	O
+of	O
+the	O
+cells	B-COMP
+with	O
+camostat	O
+and	O
+EST	O
+[(	O
+23	O
+,	O
+25	O
+)	O
+trans	O
+-	O
+epoxysuccinyl	O
+-	O
+L	O
+-	O
+leucylamindo	O
+-	O
+3	O
+-	O
+methylbutane	O
+ethyl	B-CHED
+ester	B-CHED
+],	O
+a	O
+cathepsin	B-PRGE
+inhibitor	B-CHED
+,	O
+efficiently	O
+prevented	O
+both	O
+cell	O
+entry	O
+and	O
+the	O
+multistep	O
+growth	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+human	B-SPEC
+Calu	O
+-	O
+3	O
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Title	O
+compounds	O
+were	O
+also	O
+tested	O
+against	O
+RNA	O
+viruses	B-SPEC
+representative	O
+of	O
+other	O
+single	O
+-	O
+stranded	O
+,	O
+positive	O
+-	O
+sense	B-PROC
+(	O
+ssRNA	O
+(+))	O
+negative	O
+-	O
+sense	B-PROC
+(	O
+RNA	O
+(-)),	O
+or	O
+double	O
+-	O
+stranded	O
+(	O
+dsRNA	B-CHED
+)	O
+genomes	O
+,	O
+as	O
+well	O
+as	O
+against	O
+representatives	O
+of	O
+two	O
+DNA	O
+virus	B-SPEC
+families	O
+.	O
+
+Interestingly	O
+,	O
+35	O
+was	O
+moderately	O
+active	O
+also	O
+against	O
+RSV	B-SPEC
+(	O
+EC	O
+(	O
+50	O
+)	O
+=	O
+25	O
+μM	O
+).	O
+
+ABSTRACT	O
+:	O
+Shenzhen	O
+,	O
+a	O
+city	O
+located	O
+on	O
+the	O
+border	B-ANAT
+between	O
+Mainland	O
+China	O
+and	O
+Hong	O
+Kong	O
+,	O
+is	O
+populated	O
+primarily	O
+by	O
+internal	O
+Chinese	O
+migrants	O
+.	O
+
+Apparent	O
+farm	O
+seroprevalence	O
+rates	O
+for	O
+PPV	B-CHED
+,	O
+PCV2	O
+and	O
+Lawsonia	B-SPEC
+intracellularis	I-SPEC
+were	O
+56	O
+.	O
+3	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+39	O
+-	O
+73	O
+%),	O
+21	O
+.	O
+9	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+8	O
+-	O
+36	O
+%)	O
+and	O
+78	O
+.	O
+1	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+64	O
+-	O
+92	O
+%),	O
+respectively	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+possible	O
+that	O
+the	O
+rearing	O
+of	O
+wild	B-SPEC
+boars	I-SPEC
+in	O
+fenced	O
+estates	O
+may	O
+predispose	O
+them	O
+to	O
+particular	O
+infections	B-DISO
+,	O
+as	O
+reflected	O
+in	O
+higher	O
+antibody	B-COMP
+titres	O
+.	O
+
+However	O
+,	O
+mice	B-SPEC
+that	O
+were	O
+vaccinated	O
+twice	O
+with	O
+the	O
+DNA	O
+vaccine	O
+and	O
+boosted	O
+with	O
+the	O
+IPV	B-DISO
+could	O
+mount	O
+a	O
+sufficient	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+against	O
+live	O
+PHE	B-CHED
+-	O
+CoV	O
+,	O
+with	O
+little	O
+variation	O
+in	O
+IgG1	B-COMP
+and	O
+IgG2a	B-COMP
+levels	O
+,	O
+and	O
+showed	O
+high	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+.	O
+
+For	O
+this	O
+,	O
+the	O
+quality	O
+of	O
+stools	B-ANAT
+was	O
+evaluated	O
+on	O
+154	O
+puppies	O
+between	O
+4	O
+and	O
+8	O
+weeks	O
+of	O
+age	O
+(	O
+100	O
+from	O
+small	O
+breeds	B-PROC
+and	O
+54	O
+from	O
+large	O
+breeds	B-PROC
+).	O
+
+In	O
+large	O
+breeds	B-PROC
+,	O
+the	O
+ADG	O
+was	O
+significantly	O
+reduced	O
+under	O
+a	O
+fecal	B-ANAT
+score	O
+of	O
+5	O
+whatever	O
+the	O
+age	O
+of	O
+the	O
+puppy	O
+.	O
+
+Whereas	O
+a	O
+high	O
+viral	O
+load	O
+of	O
+canine	O
+parvovirus	B-DISO
+type	O
+2	O
+significantly	O
+impacted	B-DISO
+feces	B-ANAT
+quality	O
+,	O
+no	O
+effect	O
+was	O
+recorded	O
+for	O
+canine	O
+coronavirus	B-SPEC
+.	O
+
+This	O
+study	O
+provides	O
+an	O
+objective	O
+threshold	O
+for	O
+evaluation	O
+of	O
+fecal	B-ANAT
+quality	O
+in	O
+weaning	B-PROC
+puppies	O
+.	O
+
+It	O
+also	O
+emphasizes	O
+the	O
+importance	O
+to	O
+be	O
+given	O
+to	O
+age	O
+and	O
+breed	B-PROC
+size	O
+in	O
+that	O
+evaluation	O
+.	O
+
+This	O
+prospective	O
+epidemiologic	O
+study	O
+was	O
+done	O
+in	O
+all	O
+the	O
+339	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+included	O
+in	O
+a	O
+multicenter	O
+randomized	O
+,	O
+placebo	O
+-	O
+controlled	O
+double	O
+-	O
+blind	B-DISO
+trial	O
+of	O
+cisatracurium	B-CHED
+besylate	I-CHED
+in	O
+severe	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Tracheostomy	O
+,	O
+enteral	O
+nutrition	B-PROC
+,	O
+and	O
+the	O
+use	O
+of	O
+a	O
+subglottic	B-ANAT
+secretion	B-PROC
+-	O
+drainage	B-ANAT
+device	O
+were	O
+protective	O
+.	O
+
+Additionally	O
+computed	O
+tomography	O
+techniques	O
+to	O
+assess	O
+the	O
+pulmonary	B-ANAT
+situation	O
+and	O
+recruitment	B-DISO
+potential	O
+as	O
+well	O
+as	O
+bed	B-DISO
+-	O
+side	O
+techniques	O
+to	O
+adjust	O
+PEEP	B-CHED
+on	O
+the	O
+ward	O
+have	O
+been	O
+modified	O
+and	O
+improved	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+paper	O
+was	O
+to	O
+develop	O
+a	O
+prognostic	O
+index	O
+for	O
+severe	O
+complications	O
+among	O
+hospitalized	O
+patients	O
+with	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+2009	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+conducted	O
+a	O
+prospective	O
+observational	O
+cohort	O
+study	O
+of	O
+618	O
+inpatients	O
+with	O
+2009	O
+H1N1	B-DISO
+virus	I-DISO
+infection	I-DISO
+admitted	O
+to	O
+36	O
+Spanish	O
+hospitals	O
+between	O
+July	O
+2009	O
+and	O
+February	O
+2010	O
+.	O
+
+We	O
+developed	O
+a	O
+composite	O
+index	O
+of	O
+severe	O
+in	O
+-	O
+hospital	O
+complications	O
+(	O
+SIHC	O
+),	O
+which	O
+included	O
+:	O
+mortality	O
+,	O
+mechanical	O
+ventilation	O
+,	O
+septic	B-DISO
+shock	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+requirement	O
+for	O
+resuscitation	O
+maneuvers	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+a	O
+commercial	O
+rapid	O
+test	O
+kit	B-FUNC
+for	O
+detecting	O
+bovine	B-SPEC
+enteric	O
+pathogens	O
+in	O
+feces	B-ANAT
+.	O
+
+In	O
+comparison	O
+to	O
+mrtPCR	O
+,	O
+the	O
+diagnostic	O
+sensitivity	O
+of	O
+Bovine	B-SPEC
+Enterichek	O
+was	O
+60	O
+.	O
+0	O
+%,	O
+42	O
+.	O
+3	O
+%,	O
+71	O
+.	O
+4	O
+%,	O
+and	O
+81	O
+.	O
+5	O
+%,	O
+and	O
+the	O
+diagnostic	O
+specificity	O
+was	O
+51	O
+.	O
+4	O
+%,	O
+100	O
+%,	O
+100	O
+%,	O
+and	O
+98	O
+.	O
+6	O
+%	O
+for	O
+BCV	B-SPEC
+-	O
+1	O
+,	O
+RV	O
+-	O
+A	O
+,	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+K99	O
+(	O
++	O
+),	O
+and	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+,	O
+respectively	O
+.	O
+
+However	O
+,	O
+test	O
+results	O
+for	O
+BCV	B-SPEC
+-	O
+1	O
+by	O
+the	O
+kit	B-FUNC
+should	O
+be	O
+interpreted	O
+with	O
+caution	O
+due	O
+to	O
+low	O
+specificity	O
+and	O
+sensitivity	O
+of	O
+the	O
+kit	B-FUNC
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+a	O
+fusion	O
+protein	B-CHED
+linking	O
+a	O
+fragment	O
+(	O
+residues	O
+39	O
+-	O
+272	O
+)	O
+of	O
+murine	B-SPEC
+calreticulin	B-PRGE
+(	O
+CRT	B-PRGE
+)	O
+to	O
+S450	O
+-	O
+650	O
+in	O
+a	O
+prokaryotic	O
+expression	B-PROC
+system	O
+was	O
+created	O
+.	O
+
+ABSTRACT	O
+:	O
+Mucosal	B-ANAT
+surfaces	O
+are	O
+common	O
+sites	O
+of	O
+pathogen	O
+colonization	O
+/	O
+entry	O
+.	O
+
+Effective	O
+mucosal	B-PROC
+immunity	I-PROC
+by	O
+vaccination	O
+should	O
+provide	O
+protection	O
+at	O
+this	O
+primary	B-DISO
+infection	I-DISO
+site	O
+.	O
+
+Our	O
+aim	O
+was	O
+to	O
+develop	O
+a	O
+new	O
+vaccination	O
+strategy	O
+that	O
+elicits	O
+a	O
+mucosal	B-PROC
+immune	I-PROC
+response	I-PROC
+.	O
+
+A	O
+needle	O
+-	O
+free	O
+delivery	O
+approach	O
+is	O
+a	O
+convenient	O
+and	O
+cost	O
+effective	O
+method	O
+of	O
+vaccine	O
+administration	O
+,	O
+especially	O
+for	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+economic	O
+animals	B-SPEC
+.	O
+
+This	O
+report	O
+describes	O
+the	O
+first	O
+complete	O
+genome	O
+sequences	O
+of	O
+virulent	O
+PEDV	B-SPEC
+and	O
+its	O
+attenuated	O
+counterpart	O
+,	O
+which	O
+will	O
+provide	O
+important	O
+insights	O
+into	O
+the	O
+molecular	O
+basis	O
+of	O
+the	O
+attenuation	O
+of	O
+PEDV	B-SPEC
+.	O
+
+We	O
+previously	O
+identified	O
+the	O
+antiviral	B-CHED
+activities	O
+of	O
+the	O
+scorpion	B-SPEC
+-	O
+venom	O
+-	O
+peptide	B-CHED
+-	O
+derived	O
+mucroporin	O
+-	O
+M1	O
+for	O
+three	O
+RNA	O
+viruses	B-SPEC
+(	O
+measles	B-PATH
+viruses	B-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+and	O
+H5N1	B-DISO
+).	O
+
+Binding	B-FUNC
+assay	O
+of	O
+Kn2	O
+-	O
+7	O
+to	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+PV	O
+by	O
+Octet	O
+Red	O
+system	O
+suggested	O
+the	O
+anti	O
+-	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+activity	O
+was	O
+correlated	O
+with	O
+a	O
+direct	O
+interaction	O
+between	O
+Kn2	B-PRGE
+-	I-PRGE
+7	I-PRGE
+and	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+envelope	B-COMP
+.	O
+
+Histopathology	O
+seen	O
+in	O
+animals	B-SPEC
+given	O
+one	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccines	O
+was	O
+uniformly	O
+a	O
+Th2	O
+-	O
+type	O
+immunopathology	B-DISO
+with	O
+prominent	O
+eosinophil	B-ANAT
+infiltration	B-DISO
+,	O
+confirmed	O
+with	O
+special	O
+eosinophil	B-ANAT
+stains	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+integrity	O
+of	O
+the	O
+vascular	O
+wall	O
+and	O
+its	O
+intrinsic	O
+basement	B-COMP
+membrane	I-COMP
+structures	O
+ensure	O
+that	O
+plasma	B-ANAT
+and	O
+the	O
+corpuscular	O
+elements	O
+of	O
+the	O
+blood	B-ANAT
+remain	O
+confined	O
+to	O
+the	O
+intravascular	O
+milieu	O
+and	O
+can	O
+enter	O
+into	O
+the	O
+extravascular	O
+compartment	B-ANAT
+in	O
+a	O
+well	O
+controlled	O
+fashion	O
+in	O
+cases	O
+of	O
+tissue	B-ANAT
+infection	B-DISO
+or	O
+inflammation	B-DISO
+.	O
+
+While	O
+participants	O
+were	O
+generally	O
+knowledgeable	O
+about	O
+influenza	B-DISO
+transmission	O
+,	O
+they	O
+were	O
+unable	O
+to	O
+accurately	O
+define	O
+what	O
+'	O
+pandemic	O
+influenza	B-DISO
+'	O
+meant	O
+.	O
+
+Not	O
+surprisingly	O
+,	O
+it	O
+was	O
+uncommon	O
+for	O
+participants	O
+to	O
+identify	O
+university	O
+students	O
+as	O
+being	O
+at	O
+risk	O
+of	O
+catching	B-DISO
+pandemic	O
+influenza	B-DISO
+.	O
+
+Given	O
+the	O
+high	O
+levels	O
+of	O
+interaction	O
+that	O
+occurs	O
+in	O
+a	O
+university	O
+setting	O
+,	O
+it	O
+is	O
+really	O
+important	O
+that	O
+students	O
+are	O
+informed	O
+about	O
+disease	B-DISO
+transmission	I-DISO
+and	O
+about	O
+risk	O
+of	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+genetic	O
+and	O
+biological	O
+characterisation	O
+of	O
+a	O
+novel	O
+pantropic	O
+canine	O
+coronavirus	O
+(	O
+CCoV	O
+),	O
+strain	O
+450	O
+/	O
+07	O
+,	O
+which	O
+caused	O
+the	O
+death	B-PROC
+of	O
+a	O
+60	O
+-	O
+day	O
+-	O
+old	O
+miniature	O
+pinscher	O
+.	O
+
+There	O
+are	O
+currently	O
+four	O
+commercially	O
+available	O
+vaccines	O
+in	O
+Australia	O
+to	O
+protect	O
+chickens	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+An	O
+in	O
+vivo	O
+investigation	O
+involved	O
+5	O
+groups	O
+of	O
+20	O
+chickens	O
+each	O
+and	O
+found	O
+that	O
+VicS	B-PRGE
+-	I-PRGE
+del	I-PRGE
+grew	O
+to	O
+a	O
+significantly	O
+lesser	O
+extent	O
+in	O
+the	O
+chicken	B-SPEC
+tissues	B-ANAT
+collected	O
+than	O
+did	O
+VicS	O
+-	O
+v	O
+.	O
+
+These	O
+results	O
+indicate	O
+the	O
+potential	O
+for	O
+a	O
+cooperative	O
+,	O
+instead	O
+of	O
+an	O
+expected	O
+competitive	O
+,	O
+relationship	O
+between	O
+VicS	O
+-	O
+v	O
+and	O
+VicS	O
+-	O
+del	O
+to	O
+infect	O
+a	O
+host	B-COMP
+,	O
+which	O
+is	O
+reminiscent	O
+of	O
+RNA	O
+viral	O
+quasi	O
+-	O
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Cross	O
+sectional	O
+and	O
+longitudinal	O
+surveys	O
+of	O
+canine	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+infection	O
+in	O
+kennelled	O
+dogs	O
+:	O
+a	O
+molecular	O
+marker	O
+for	O
+biosecurity	O
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+studies	O
+have	O
+suggested	O
+that	O
+kennelled	O
+dogs	B-SPEC
+are	O
+more	O
+likely	O
+to	O
+test	O
+positive	O
+for	O
+CECoV	O
+than	O
+household	O
+pets	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+diversity	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+coronavirus	B-SPEC
+in	O
+recent	O
+years	O
+in	O
+China	O
+.	O
+
+Pathogenicity	O
+testing	O
+and	O
+sequence	O
+analysis	O
+of	O
+the	O
+3	O
+'	O
+terminal	O
+untranslated	O
+region	O
+revealed	O
+that	O
+TW	O
+II	O
+-	O
+type	O
+IBV	B-SPEC
+strains	O
+isolated	O
+in	O
+mainland	O
+China	O
+have	O
+a	O
+close	O
+relationship	O
+with	O
+the	O
+embryo	B-ANAT
+-	O
+passaged	O
+,	O
+attenuated	O
+TW2296	O
+/	O
+95	O
+.	O
+
+TITLE	O
+:	O
+Suppression	B-PROC
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+replication	O
+in	O
+vitro	O
+by	O
+cyclosporin	B-CHED
+A	I-CHED
+.	O
+ABSTRACT	O
+:	O
+The	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+is	O
+a	O
+member	O
+of	O
+the	O
+feline	B-SPEC
+coronavirus	B-SPEC
+family	B-SPEC
+that	O
+causes	O
+FIP	B-DISO
+,	O
+which	O
+is	O
+incurable	O
+and	O
+fatal	O
+in	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Right	O
+ventricular	O
+(	O
+RV	O
+)	O
+failure	O
+is	O
+characterized	O
+by	O
+an	O
+inability	O
+to	O
+pump	O
+blood	B-ANAT
+into	O
+the	O
+pulmonary	B-PROC
+circulation	B-PROC
+and	O
+can	O
+often	O
+lead	O
+to	O
+hemodynamic	B-DISO
+instability	I-DISO
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+61	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+no	O
+significant	O
+pulmonary	B-ANAT
+or	O
+cardiac	B-DISO
+disease	I-DISO
+who	O
+presented	O
+with	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+in	O
+the	O
+setting	O
+of	O
+opioid	O
+overdose	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+organization	O
+of	O
+the	O
+response	O
+to	O
+infectious	O
+disease	O
+outbreaks	O
+by	O
+public	O
+health	O
+agencies	O
+at	O
+the	O
+federal	O
+,	O
+state	O
+,	O
+and	O
+local	O
+levels	O
+has	O
+historically	O
+been	O
+based	O
+on	O
+traditional	O
+public	O
+health	O
+functions	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+epidemiology	O
+,	O
+surveillance	O
+,	O
+laboratory	O
+,	O
+infection	B-DISO
+control	O
+,	O
+and	O
+health	O
+communications	O
+).	O
+
+The	O
+topics	O
+are	O
+described	O
+mainly	O
+for	O
+palmitoylated	O
+proteins	B-CHED
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+but	O
+proteins	B-CHED
+of	O
+other	O
+important	O
+pathogens	O
+,	O
+such	O
+as	O
+the	O
+causative	O
+agents	O
+of	O
+AIDS	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+of	O
+model	O
+viruses	B-SPEC
+are	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+A	O
+human	B-SPEC
+coronavirus	I-SPEC
+responsible	O
+for	O
+the	O
+common	B-DISO
+cold	I-DISO
+massively	O
+kills	O
+dendritic	B-ANAT
+cells	B-COMP
+but	O
+not	O
+monocytes	B-ANAT
+.	O
+
+By	O
+the	O
+time	O
+this	O
+coronavirus	B-SPEC
+,	O
+labeled	O
+SCoV	O
+,	O
+apparently	O
+receded	O
+from	O
+human	B-SPEC
+hosts	B-COMP
+in	O
+July	O
+2003	O
+,	O
+nearly	O
+10	O
+percent	O
+of	O
+more	O
+than	O
+8	O
+,	O
+000	O
+individuals	O
+who	O
+fit	B-DISO
+the	O
+probable	O
+case	O
+definition	O
+had	O
+died	B-PROC
+of	O
+the	O
+disease	O
+now	O
+known	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+(	O
+World	O
+Health	O
+Organization	O
+[	O
+WHO	O
+],	O
+2003a	O
+).	O
+
+In	O
+sum	O
+,	O
+our	O
+results	O
+show	O
+that	O
+TMPRSS2	B-PRGE
+and	O
+HAT	B-PRGE
+are	O
+expressed	B-PROC
+by	O
+important	O
+influenza	B-DISO
+and	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+target	B-ANAT
+cells	I-ANAT
+and	O
+could	O
+thus	O
+support	O
+viral	O
+spread	O
+in	O
+the	O
+human	B-SPEC
+host	B-COMP
+.	O
+
+However	O
+,	O
+no	O
+commercial	O
+vaccines	O
+that	O
+are	O
+specific	O
+for	O
+this	O
+type	O
+of	O
+IBV	B-SPEC
+are	O
+currently	O
+available	O
+.	O
+
+Our	O
+results	O
+demonstrate	O
+that	O
+rMDV	O
+-	O
+S1	O
+is	O
+an	O
+effective	O
+and	O
+promising	O
+recombinant	O
+vaccine	O
+for	O
+the	O
+prevention	O
+of	O
+QX	O
+-	O
+like	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+Sequences	O
+analysis	O
+confirmed	O
+that	O
+the	O
+CoVs	O
+from	O
+Kenya	O
+bats	B-SPEC
+are	O
+divergent	O
+members	O
+of	O
+Alphacoronavirus	B-SPEC
+and	O
+Betacoronavirus	B-SPEC
+genera	O
+.	O
+
+BtKY27	O
+and	O
+BtKY33	O
+are	O
+members	O
+of	O
+the	O
+established	O
+bat	B-PRGE
+CoV	I-PRGE
+species	B-SPEC
+in	O
+Alphacoronavirus	B-SPEC
+genus	B-SPEC
+and	O
+BtKY06	O
+is	O
+a	O
+member	O
+of	O
+the	O
+established	O
+bat	O
+CoV	O
+species	B-SPEC
+in	O
+Betacoronavirus	B-SPEC
+genus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Aerosol	O
+generating	O
+procedures	O
+(	O
+AGPs	O
+)	O
+may	O
+expose	O
+health	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+to	O
+pathogens	O
+causing	O
+acute	O
+respiratory	O
+infections	O
+(	O
+ARIs	B-DISO
+),	O
+but	O
+the	O
+risk	O
+of	O
+transmission	O
+of	O
+ARIs	B-PRGE
+from	I-PRGE
+AGPs	I-PRGE
+is	O
+not	O
+fully	O
+known	O
+.	O
+
+We	O
+searched	O
+PubMed	O
+,	O
+EMBASE	O
+,	O
+MEDLINE	O
+,	O
+CINAHL	O
+,	O
+the	O
+Cochrane	O
+Library	O
+,	O
+University	O
+of	O
+York	O
+CRD	B-DISO
+databases	O
+,	O
+EuroScan	O
+,	O
+LILACS	B-SPEC
+,	O
+Indian	O
+Medlars	B-SPEC
+,	O
+Index	O
+Medicus	O
+for	O
+SE	O
+Asia	O
+,	O
+international	O
+health	O
+technology	O
+agencies	O
+and	O
+the	O
+Internet	O
+in	O
+all	O
+languages	O
+for	O
+articles	O
+from	O
+01	O
+/	O
+01	O
+/	O
+1990	O
+to	O
+22	O
+/	O
+10	O
+/	O
+2010	O
+.	O
+
+TITLE	O
+:	O
+Pathogenesis	B-PROC
+and	O
+tissue	B-ANAT
+distribution	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+isolate	O
+IRFIBV32	O
+(	O
+793	O
+/	O
+B	O
+serotype	O
+)	O
+in	O
+experimentally	O
+infected	O
+broiler	O
+chickens	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+distribution	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+isolate	O
+IRFIBV32	O
+(	O
+793	O
+/	O
+B	O
+serotype	O
+)	O
+in	O
+experimentally	O
+infected	O
+chicken	B-SPEC
+.	O
+
+Although	O
+it	O
+seems	O
+to	O
+have	O
+a	O
+benign	O
+course	O
+,	O
+it	O
+may	O
+also	O
+be	O
+lethal	O
+and	O
+severe	O
+in	O
+some	O
+cases	O
+,	O
+especially	O
+in	O
+the	O
+form	O
+of	O
+hydrops	B-DISO
+and	O
+/	O
+or	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+found	O
+that	O
+a	O
+transmembrane	B-COMP
+topology	O
+was	O
+required	O
+for	O
+disrupting	O
+the	O
+secretory	B-PROC
+pathway	I-PROC
+,	O
+but	O
+was	O
+less	O
+efficient	O
+for	O
+virus	B-COMP
+-	I-COMP
+like	I-COMP
+particle	I-COMP
+production	O
+.	O
+
+ARDS	B-DISO
+was	O
+successfully	O
+treated	O
+using	O
+emergency	B-DISO
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+within	O
+3	O
+h	O
+after	O
+the	O
+incident	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+is	O
+a	O
+pathogenic	O
+coronavirus	B-SPEC
+that	O
+emerged	O
+from	O
+a	O
+zoonotic	O
+reservoir	O
+,	O
+leading	O
+to	O
+global	O
+dissemination	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+myricetin	B-CHED
+and	O
+scutellarein	B-CHED
+as	O
+novel	O
+chemical	O
+inhibitors	B-CHED
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+helicase	I-PRGE
+,	O
+nsP13	O
+.	O
+
+Among	O
+all	O
+ROS	B-CHED
+-	O
+producing	O
+enzymes	O
+,	O
+the	O
+members	O
+of	O
+NADPH	B-PRGE
+oxidases	I-PRGE
+(	O
+NOXs	O
+),	O
+which	O
+are	O
+widely	O
+expressed	B-PROC
+in	O
+different	O
+lung	B-ANAT
+cell	B-COMP
+types	O
+,	O
+have	O
+been	O
+shown	O
+to	O
+participate	O
+in	O
+cellular	B-COMP
+processes	O
+involved	O
+in	O
+the	O
+maintenance	O
+of	O
+lung	B-ANAT
+integrity	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+summarize	O
+the	O
+current	O
+knowledge	O
+concerning	O
+some	O
+cellular	B-COMP
+aspects	O
+of	O
+NOXs	O
+localization	B-PROC
+and	O
+function	O
+in	O
+the	O
+lungs	B-ANAT
+,	O
+consider	O
+their	O
+contribution	O
+in	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+and	O
+discuss	O
+the	O
+place	O
+of	O
+NOX	O
+inhibitors	B-CHED
+as	O
+potential	O
+therapeutical	O
+target	O
+.	O
+
+Early	O
+following	O
+JHMV	O
+infection	B-DISO
+,	O
+ELR	O
+-	O
+positive	O
+chemokines	O
+contribute	O
+to	O
+host	B-PROC
+defense	I-PROC
+by	O
+attracting	O
+CXCR2	B-PRGE
+-	O
+expressing	O
+cells	B-COMP
+including	O
+polymorphonuclear	B-ANAT
+cells	I-ANAT
+to	O
+the	O
+CNS	B-CHED
+that	O
+aid	O
+in	O
+host	B-PROC
+defense	I-PROC
+through	O
+increasing	O
+the	O
+permeability	O
+the	O
+blood	B-ANAT
+-	O
+brain	B-ANAT
+-	O
+barrier	O
+(	O
+BBB	B-CHED
+).	O
+
+PEEP	B-CHED
+was	O
+applied	O
+and	O
+adjusted	O
+to	O
+appropriate	O
+levels	O
+on	O
+the	O
+basis	O
+of	O
+information	O
+obtained	O
+from	O
+continuous	O
+monitoring	O
+of	O
+cerebral	B-ANAT
+and	O
+systemic	O
+haemodynamics	O
+.	O
+
+The	O
+M	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+seven	O
+PEDV	B-SPEC
+isolates	O
+encompasses	O
+an	O
+open	O
+reading	O
+frame	O
+of	O
+681	O
+nucleotides	B-CHED
+,	O
+encoding	O
+a	O
+protein	B-CHED
+of	O
+226	O
+amino	B-CHED
+acids	I-CHED
+.	O
+
+When	O
+compared	O
+with	O
+other	O
+Chinese	O
+isolates	O
+and	O
+foreign	O
+isolates	O
+,	O
+the	O
+seven	O
+isolates	O
+showed	O
+high	O
+nucleotide	B-CHED
+identity	O
+with	O
+the	O
+Thailand	O
+isolate	O
+M	O
+-	O
+NIAH1005	O
+(	O
+99	O
+.	O
+6	O
+-	O
+99	O
+.	O
+9	O
+%)	O
+and	O
+Korea	O
+isolate	O
+PFF188	O
+(	O
+99	O
+.	O
+7	O
+-	O
+100	O
+%),	O
+but	O
+low	O
+identity	O
+with	O
+other	O
+Chinese	O
+isolates	O
+(	O
+96	O
+.	O
+6	O
+-	O
+99	O
+.	O
+1	O
+%)	O
+and	O
+with	O
+the	O
+vaccine	O
+strain	O
+CV777	O
+used	O
+in	O
+China	O
+(	O
+97	O
+.	O
+8	O
+-	O
+98	O
+.	O
+2	O
+%).	O
+
+ABSTRACT	O
+:	O
+Many	O
+viruses	B-SPEC
+are	O
+known	O
+to	O
+cause	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+);	O
+however	O
+,	O
+in	O
+nearly	O
+50	O
+%	O
+of	O
+patients	O
+,	O
+the	O
+etiologic	O
+agent	O
+remains	O
+unknown	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+the	O
+rhetorical	O
+construction	O
+of	O
+""""	O
+bad	O
+""""	O
+scientific	O
+work	O
+.	O
+
+Recent	O
+studies	O
+have	O
+indicated	O
+that	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+has	O
+functions	O
+during	O
+infection	B-DISO
+beyond	O
+assembly	O
+,	O
+including	O
+in	O
+virus	B-SPEC
+egress	O
+and	O
+in	O
+the	O
+host	B-COMP
+stress	B-PATH
+response	I-PATH
+.	O
+
+The	O
+review	O
+concludes	O
+by	O
+noting	O
+how	O
+understanding	O
+of	O
+coronavirus	B-SPEC
+entry	O
+informs	O
+antiviral	B-CHED
+therapies	O
+.	O
+
+Factor	B-PRGE
+VIII	I-PRGE
+(	O
+FVIII	O
+)	O
+levels	O
+were	O
+very	O
+low	O
+and	O
+evidence	O
+of	O
+FVIII	B-PRGE
+inhibitor	B-CHED
+was	O
+found	O
+.	O
+
+Abdominal	B-ANAT
+XR	O
+confirmed	O
+these	O
+findings	O
+.	O
+
+Within	O
+24	O
+hours	O
+of	O
+presentation	O
+,	O
+he	O
+became	O
+tachycardic	O
+and	O
+oliguric	O
+with	O
+orthostatic	B-PROC
+hypotension	O
+.	O
+
+Following	O
+two	O
+enemas	O
+,	O
+he	O
+acutely	O
+deteriorated	O
+with	O
+severe	O
+hypotension	O
+,	O
+marked	O
+tachycardia	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+,	O
+and	O
+a	O
+declining	O
+mental	O
+status	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+parechovirus	I-SPEC
+infections	B-DISO
+,	O
+Lyon	O
+,	O
+France	O
+,	O
+2008	O
+-	O
+10	O
+:	O
+evidence	O
+for	O
+severe	O
+cases	O
+.	O
+
+To	O
+determine	O
+the	O
+detection	O
+frequency	O
+of	O
+HPeV	O
+in	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+(	O
+CSF	B-ANAT
+)	O
+samples	O
+collected	O
+from	O
+children	O
+aged	O
+<	O
+5	O
+years	O
+hospitalized	O
+between	O
+2008	O
+and	O
+2010	O
+in	O
+the	O
+University	O
+Hospital	O
+of	O
+Lyon	O
+and	O
+to	O
+describe	O
+the	O
+clinical	O
+,	O
+virological	O
+and	O
+biological	O
+characteristics	O
+associated	O
+with	O
+HPeV	O
+infection	B-DISO
+.	O
+
+Three	O
+patients	O
+(	O
+2	O
+with	O
+septic	O
+shock	B-DISO
+syndrome	I-DISO
+,	O
+1	O
+with	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+)	O
+required	O
+hospitalization	O
+in	O
+an	O
+intensive	O
+care	O
+unit	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+caused	O
+by	O
+adenovirus	B-DISO
+type	O
+11	O
+in	O
+immunocompetent	O
+adults	O
+in	O
+Beijing	O
+.	O
+
+Patients	O
+with	O
+adenovirus	B-DISO
+pneumonia	B-DISO
+typically	O
+reported	O
+flu	B-DISO
+-	I-DISO
+like	I-DISO
+symptoms	I-DISO
+.	O
+
+Our	O
+identification	O
+of	O
+severe	O
+respiratory	O
+illness	O
+due	O
+to	O
+adenovirus	B-DISO
+,	O
+especially	O
+type	O
+11	O
+may	O
+highlight	O
+the	O
+need	O
+for	O
+rapid	O
+diagnosis	O
+and	O
+improved	O
+surveillance	O
+,	O
+which	O
+may	O
+assist	O
+with	O
+targeted	B-PROC
+development	B-PROC
+of	O
+antiviral	B-CHED
+agents	I-CHED
+or	O
+type	O
+-	O
+specific	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+in	O
+children	O
+carries	O
+a	O
+high	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+High	O
+frequency	O
+ventilation	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+are	O
+used	O
+as	O
+rescue	O
+modes	O
+of	O
+support	O
+in	O
+difficult	O
+situations	O
+.	O
+
+Rapid	O
+evolution	B-PROC
+of	O
+avian	B-SPEC
+coronavirus	I-SPEC
+IBV	B-SPEC
+makes	O
+this	O
+virus	B-SPEC
+extremely	O
+difficult	O
+to	O
+diagnose	O
+and	O
+control	O
+,	O
+but	O
+also	O
+makes	O
+it	O
+an	O
+excellent	O
+model	O
+system	O
+to	O
+study	O
+viral	O
+genetic	O
+diversity	O
+and	O
+the	O
+mechanisms	O
+behind	O
+the	O
+emergence	O
+of	O
+coronaviruses	O
+in	O
+their	O
+natural	O
+host	B-COMP
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+CCoV	O
+-	O
+A76	O
+represents	O
+a	O
+recombinant	O
+coronavirus	O
+form	O
+,	O
+with	O
+distinct	O
+host	B-COMP
+cell	I-COMP
+tropism	B-PROC
+.	O
+
+On	O
+the	O
+one	O
+hand	O
+these	O
+inhibitory	O
+signals	O
+prevent	O
+excessive	O
+immune	O
+mediated	O
+pathology	B-DISO
+but	O
+on	O
+the	O
+other	O
+hand	O
+they	O
+may	O
+impair	O
+clearance	O
+of	O
+the	O
+pathogen	O
+.	O
+
+MHV	B-SPEC
+clearance	O
+is	O
+known	O
+to	O
+be	O
+dependent	O
+on	O
+Toll	B-PRGE
+like	I-PRGE
+receptor	I-PRGE
+7	I-PRGE
+(	O
+TLR7	B-PRGE
+)-	O
+mediated	O
+type	B-PROC
+I	I-PROC
+IFN	I-PROC
+production	I-PROC
+and	O
+sex	O
+differences	O
+in	O
+TLR7	O
+responses	O
+previously	O
+have	O
+been	O
+reported	O
+for	O
+humans	B-SPEC
+.	O
+
+This	O
+hypothesis	O
+is	O
+supported	O
+by	O
+our	O
+findings	O
+that	O
+in	O
+vivo	O
+administration	O
+of	O
+synthetic	O
+TLR7	B-PRGE
+ligand	I-PRGE
+leads	O
+to	O
+enhanced	O
+type	B-PROC
+I	I-PROC
+IFN	I-PROC
+production	I-PROC
+,	O
+particularly	O
+in	O
+female	O
+Cd200	O
+(-/-)	O
+mice	B-SPEC
+and	O
+that	O
+CD200R	B-PRGE
+ligation	O
+inhibits	O
+TLR7	B-PRGE
+signaling	B-PROC
+in	O
+vitro	O
+.	O
+
+Our	O
+data	O
+predict	O
+a	O
+sex	O
+bias	B-SPEC
+in	O
+both	O
+beneficial	O
+and	O
+pathological	O
+immune	B-PROC
+responses	I-PROC
+to	O
+virus	B-DISO
+infection	I-DISO
+upon	O
+therapeutic	O
+targeting	B-PROC
+of	O
+CD200	B-PRGE
+-	O
+CD200R	B-PRGE
+.	O
+
+However	O
+,	O
+because	O
+it	O
+is	O
+a	O
+protein	B-CHED
+,	O
+the	O
+rOv	B-PRGE
+-	I-PRGE
+ASP	I-PRGE
+-	I-PRGE
+1	I-PRGE
+adjuvant	B-CHED
+may	O
+also	O
+induce	O
+anti	O
+-	O
+self	O
+-	O
+antibodies	B-COMP
+.	O
+
+When	O
+expressed	B-PROC
+as	O
+N	O
+-	O
+terminal	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescence	I-PRGE
+protein	I-PRGE
+(	O
+EGFP	O
+)	O
+fusion	O
+,	O
+it	O
+predominantly	O
+formed	O
+speckles	O
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+Expression	B-PROC
+of	O
+a	O
+small	O
+(	O
+35aa	O
+)	O
+sequence	O
+in	O
+Domain	O
+III	O
+alone	O
+was	O
+sufficient	O
+to	O
+form	O
+speckles	O
+for	O
+all	O
+3	O
+viral	O
+nsp15s	O
+.	O
+
+ABSTRACT	O
+:	O
+Hundreds	O
+of	O
+million	O
+people	O
+worldwide	O
+have	O
+been	O
+infected	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+the	O
+rate	O
+of	O
+global	O
+death	B-PROC
+from	O
+SARS	B-DISO
+has	O
+remarkably	O
+increased	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+a	O
+designed	O
+biochip	O
+could	O
+analyze	O
+inhibitors	B-CHED
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+using	O
+nanoparticle	B-CHED
+-	O
+based	O
+RNA	O
+oligonucleotide	B-CHED
+.	O
+
+Among	O
+the	O
+polyphenolic	O
+compounds	O
+examined	O
+,	O
+(-)-	O
+catechin	B-CHED
+gallate	B-CHED
+and	O
+(-)-	O
+gallocatechin	B-CHED
+gallate	B-CHED
+demonstrated	O
+a	O
+remarkable	O
+inhibition	B-PROC
+activity	O
+on	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+At	O
+a	O
+concentration	O
+of	O
+0	O
+.	O
+05	O
+μg	O
+mL	O
+(-	O
+1	O
+),	O
+(-)-	O
+catechin	B-CHED
+gallate	B-CHED
+and	O
+(-)-	O
+gallocatechin	B-CHED
+gallate	B-CHED
+showed	O
+more	O
+than	O
+40	O
+%	O
+inhibition	B-PROC
+activity	O
+on	O
+a	O
+nanoparticle	B-CHED
+-	O
+based	O
+RNA	O
+oligonucleotide	B-CHED
+biochip	O
+system	O
+.	O
+
+The	O
+clinical	O
+files	O
+of	O
+women	O
+having	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+attending	O
+the	O
+Monica	O
+Pretelini	O
+maternal	O
+-	O
+perinatal	O
+hospital	O
+'	O
+s	O
+(	O
+HMPMP	O
+)	O
+intensive	O
+care	O
+unit	O
+in	O
+Toluca	O
+,	O
+Mexico	O
+,	O
+were	O
+reviewed	O
+.	O
+
+The	O
+nsp14	B-PRGE
+protein	I-PRGE
+carries	O
+both	O
+exoribonuclease	O
+(	O
+ExoN	O
+)	O
+and	O
+(	B-PRGE
+guanine	I-PRGE
+-	I-PRGE
+N7	I-PRGE
+)-	I-PRGE
+methyltransferase	I-PRGE
+(	O
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+)	O
+activities	O
+.	O
+
+The	O
+B	B-PRGE
+and	I-PRGE
+T	I-PRGE
+lymphocyte	I-PRGE
+attenuator	I-PRGE
+(	O
+BTLA	B-PRGE
+)	O
+is	O
+an	O
+immunoglobulin	B-PRGE
+-	I-PRGE
+domain	I-PRGE
+-	I-PRGE
+containing	I-PRGE
+protein	B-CHED
+that	O
+has	O
+the	O
+capacity	O
+to	O
+maintain	O
+peripheral	O
+tolerance	B-DISO
+and	O
+limit	O
+immunopathological	O
+damage	O
+during	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+RESULTS	O
+:	O
+FGL2	B-PRGE
+production	O
+,	O
+liver	B-ANAT
+and	I-ANAT
+spleen	I-ANAT
+damage	O
+,	O
+and	O
+mortality	O
+were	O
+significantly	O
+reduced	O
+in	O
+BTLA	O
+-/-	O
+mice	B-SPEC
+infected	O
+with	O
+MHV	B-SPEC
+-	O
+3	O
+.	O
+
+These	O
+data	O
+demonstrate	O
+that	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+mediates	O
+detrimental	O
+clinical	O
+consequences	O
+in	O
+an	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+-	O
+deprived	O
+environment	O
+,	O
+independent	O
+of	O
+extensive	O
+neutrophil	B-ANAT
+accumulation	O
+or	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+upregulation	B-PROC
+.	O
+
+Furthermore	O
+,	O
+co	O
+-	O
+transfer	O
+of	O
+WT	O
+and	O
+GKO	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+prolonged	O
+survival	O
+in	O
+an	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+dependent	O
+manner	O
+,	O
+although	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+transcription	B-PROC
+was	O
+not	O
+reduced	O
+.	O
+
+In	O
+all	O
+cases	O
+,	O
+results	O
+showed	O
+that	O
+pVAX1	O
+-(	O
+PEDV	B-SPEC
+-	O
+S	O
+)	O
+and	O
+the	O
+combination	O
+of	O
+pVAX1	O
+-(	O
+PEDV	B-SPEC
+-	O
+S1	O
+)	O
+with	O
+pVAX1	O
+-(	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+)	O
+induced	O
+the	O
+strongest	O
+responses	O
+;	O
+however	O
+,	O
+pIL	B-PRGE
+-	I-PRGE
+18	I-PRGE
+had	O
+no	O
+adjuvant	B-CHED
+effects	O
+when	O
+given	O
+in	O
+combination	O
+with	O
+pVAX1	O
+-(	O
+PEDV	B-SPEC
+-	O
+S1	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+16	O
+-	O
+month	O
+old	O
+boy	O
+presented	O
+with	O
+a	O
+severe	O
+tumour	O
+lysis	O
+syndrome	O
+(	O
+TLS	O
+)	O
+complicating	O
+induction	O
+therapy	O
+for	O
+acute	B-DISO
+myeloid	I-DISO
+leukaemia	I-DISO
+.	O
+
+The	O
+present	O
+study	O
+aimed	O
+to	O
+develop	O
+a	O
+simple	O
+method	O
+to	O
+estimate	O
+the	O
+CFR	O
+based	O
+on	O
+readily	O
+available	O
+datasets	O
+,	O
+that	O
+is	O
+,	O
+confirmed	O
+cases	O
+and	O
+deaths	B-PROC
+,	O
+while	O
+addressing	O
+some	O
+of	O
+the	O
+known	O
+technical	O
+issues	O
+.	O
+
+Cytotoxic	O
+lung	B-ANAT
+injury	O
+may	O
+result	O
+from	O
+direct	O
+injury	O
+to	O
+pneumocytes	B-ANAT
+or	O
+the	O
+alveolar	B-ANAT
+capillary	B-ANAT
+endothelium	I-ANAT
+.	O
+
+Assessment	O
+of	O
+cell	O
+-	O
+mediated	O
+immunity	O
+has	O
+recently	O
+increased	O
+,	O
+because	O
+verifying	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+drug	O
+-	O
+sensitized	O
+lymphocytes	B-ANAT
+can	O
+aid	O
+in	O
+confirmation	O
+of	O
+drug	O
+-	O
+induced	O
+disease	O
+.	O
+
+Its	O
+application	O
+on	O
+bats	B-SPEC
+screening	O
+resulted	O
+in	O
+a	O
+prevalence	O
+of	O
+42	O
+%.	O
+
+TITLE	O
+:	O
+[	O
+Salmonella	B-SPEC
+enteritidis	O
+bacteraemia	B-DISO
+as	O
+clinical	O
+onset	O
+of	O
+acquired	B-DISO
+immune	I-DISO
+deficiency	I-DISO
+syndrome	I-DISO
+].	O
+
+As	O
+nsp10	O
+acts	O
+as	O
+an	O
+essential	O
+trigger	O
+to	O
+activate	O
+the	O
+2	O
+'-	O
+O	B-FUNC
+-	I-FUNC
+methyltransferase	I-FUNC
+activity	I-FUNC
+of	O
+nsp16	O
+,	O
+short	O
+peptides	B-CHED
+derived	O
+from	O
+nsp10	O
+may	O
+have	O
+inhibitory	O
+effect	O
+on	O
+viral	B-PRGE
+2	I-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+methyltransferase	I-PRGE
+activity	O
+.	O
+
+We	O
+further	O
+showed	O
+that	O
+two	O
+short	O
+peptides	B-CHED
+derived	O
+from	O
+the	O
+interaction	O
+domain	O
+of	O
+nsp10	O
+could	O
+inhibit	O
+the	O
+2	O
+'-	O
+O	B-FUNC
+-	I-FUNC
+methyltransferase	I-FUNC
+activity	I-FUNC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp16	I-PRGE
+/	O
+10	O
+complex	O
+,	O
+thus	O
+providing	O
+a	O
+novel	O
+strategy	O
+and	O
+proof	O
+-	O
+of	O
+-	O
+principle	O
+study	O
+for	O
+developing	O
+peptide	B-CHED
+inhibitors	B-CHED
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+The	O
+development	O
+of	O
+a	O
+severe	O
+and	O
+acute	O
+methemoglobinemia	B-DISO
+following	O
+the	O
+administration	O
+of	O
+MCP	B-FUNC
+is	O
+described	O
+in	O
+this	O
+case	O
+report	O
+.	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+,	O
+antiviral	B-CHED
+activity	O
+,	O
+and	O
+SARs	B-DISO
+of	O
+14	O
+-	O
+aminophenanthroindolizidines	O
+.	O
+
+TITLE	O
+:	O
+Treatment	O
+of	O
+336	O
+cases	O
+of	O
+chest	B-ANAT
+trauma	O
+.	O
+
+Among	O
+the	O
+dead	B-PROC
+cases	O
+,	O
+one	O
+died	B-PROC
+of	O
+hemorrhagic	B-DISO
+shock	I-DISO
+,	O
+three	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+three	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+and	O
+four	O
+of	O
+severe	O
+multiple	O
+traumas	O
+.	O
+
+TITLE	O
+:	O
+Carboplatin	B-CHED
+-	O
+induced	O
+hypersensitivity	B-DISO
+reaction	I-DISO
+.	O
+
+Precisely	O
+identifying	O
+the	O
+mat_peptide	O
+cleavage	B-PROC
+for	O
+some	O
+viruses	B-SPEC
+is	O
+a	O
+built	O
+-	O
+in	O
+feature	O
+of	O
+VIGOR	O
+.	O
+
+The	O
+gene	O
+predictions	O
+for	O
+these	O
+viruses	B-SPEC
+have	O
+been	O
+evaluated	O
+by	O
+testing	O
+from	O
+27	O
+to	O
+240	O
+genomes	O
+from	O
+GenBank	O
+.	O
+
+Early	O
+treatment	O
+with	O
+influenza	B-DISO
+antiviral	B-CHED
+agents	I-CHED
+was	O
+likely	O
+beneficial	O
+,	O
+especially	O
+when	O
+initiated	O
+≤	O
+2	O
+days	O
+after	O
+illness	O
+onset	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+majority	O
+(	O
+77	O
+%)	O
+of	O
+154	O
+patients	O
+hospitalized	O
+in	O
+an	O
+ICU	O
+were	O
+<	O
+50	O
+years	O
+of	O
+age	O
+,	O
+and	O
+65	O
+%	O
+had	O
+at	O
+least	O
+one	O
+underlying	O
+medical	O
+condition	B-DISO
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+antibodies	B-COMP
+in	O
+Japanese	O
+domestic	B-SPEC
+cats	I-SPEC
+during	O
+the	O
+past	O
+decade	O
+.	O
+
+This	O
+report	O
+describes	O
+three	O
+cases	O
+of	O
+prolonged	O
+heparin	B-CHED
+-	O
+free	O
+venovenous	O
+ECMO	O
+in	O
+multiple	O
+injured	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+with	O
+severe	O
+TBI	O
+failing	O
+conventional	O
+mechanical	O
+ventilation	O
+.	O
+:	O
+Using	O
+this	O
+strategy	O
+,	O
+neither	O
+ECMO	O
+-	O
+associated	O
+bleeding	B-DISO
+nor	O
+clotting	B-PROC
+of	O
+the	O
+extracorporeal	O
+circuit	O
+occurred	O
+.	O
+
+Based	O
+on	O
+our	O
+experience	O
+,	O
+we	O
+recommend	O
+the	O
+use	O
+of	O
+heparin	B-CHED
+-	O
+free	O
+ECMO	O
+in	O
+multiple	O
+injured	O
+patients	O
+with	O
+pulmonary	B-DISO
+failure	I-DISO
+that	O
+is	O
+not	O
+successfully	O
+controlled	O
+by	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+even	O
+if	O
+severe	O
+TBI	O
+is	O
+present	O
+.	O
+
+ABSTRACT	O
+:	O
+Dengue	B-DISO
+infection	B-DISO
+is	O
+now	O
+known	O
+to	O
+present	O
+with	O
+wide	O
+spectrum	O
+of	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+manifestation	O
+of	O
+novel	O
+swine	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+(	O
+S	O
+-	O
+OIV	O
+)	O
+infection	B-DISO
+in	O
+immunocompromised	O
+patients	O
+:	O
+initial	O
+findings	O
+with	O
+multidetector	O
+computed	O
+tomography	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+initial	O
+multidetector	O
+computed	O
+tomographic	O
+(	O
+MDCT	O
+)	O
+findings	O
+of	O
+novel	O
+swine	O
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+(	O
+S	O
+-	O
+OIV	O
+)	O
+infection	B-DISO
+in	O
+immunocompromised	O
+patients	O
+and	O
+to	O
+evaluate	O
+whether	O
+or	O
+not	O
+identification	O
+of	O
+certain	O
+abnormalities	O
+can	O
+help	O
+predict	O
+patients	O
+who	O
+are	O
+at	O
+risk	O
+for	O
+a	O
+severe	O
+clinical	O
+course	O
+.	O
+
+This	O
+retrospective	O
+study	O
+included	O
+13	O
+patients	O
+with	O
+confirmed	O
+S	O
+-	O
+OIV	O
+infection	B-DISO
+suffering	B-DISO
+from	O
+an	O
+underlying	O
+immunodeficiency	B-DISO
+or	O
+who	O
+were	O
+receiving	O
+immunosuppressive	O
+therapy	O
+.	O
+
+Bilateral	O
+opacities	B-DISO
+with	O
+extensive	O
+involvement	O
+of	O
+the	O
+lung	B-ANAT
+parenchyma	I-ANAT
+were	O
+most	O
+predictive	O
+of	O
+a	O
+severe	O
+clinical	O
+course	O
+.	O
+
+Because	O
+antiviral	B-CHED
+drugs	I-CHED
+are	O
+only	O
+effective	O
+early	O
+in	O
+infection	B-DISO
+,	O
+new	O
+agents	O
+are	O
+needed	O
+to	O
+treat	O
+nonvaccinated	O
+patients	O
+presenting	O
+with	O
+late	O
+-	O
+stage	O
+disease	O
+,	O
+particularly	O
+those	O
+who	O
+develop	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Air	B-CHED
+transportation	O
+for	O
+those	O
+with	O
+severe	O
+injuries	O
+and	O
+diseases	O
+played	O
+a	O
+crucial	O
+role	O
+in	O
+decreasing	O
+the	O
+mortality	O
+and	O
+morbidity	O
+.	O
+
+Characteristic	O
+factors	O
+such	O
+as	O
+high	O
+altitude	O
+,	O
+low	O
+-	O
+oxygen	B-PROC
+content	I-PROC
+,	O
+local	O
+construction	O
+features	O
+,	O
+and	O
+lifestyle	O
+may	O
+contribute	O
+to	O
+complex	O
+injuries	O
+and	O
+illnesses	O
+.	O
+
+PP	O
+also	O
+significantly	O
+complicates	O
+burn	O
+care	O
+by	O
+making	O
+skin	B-ANAT
+protection	O
+and	O
+wound	O
+care	O
+more	O
+difficult	O
+.	O
+
+This	O
+led	O
+to	O
+a	O
+National	O
+Institute	O
+of	O
+Health	O
+Consensus	O
+Development	B-PROC
+Conference	O
+which	O
+concluded	O
+that	O
+FFP	O
+should	O
+be	O
+given	O
+to	O
+only	O
+those	O
+patients	O
+who	O
+had	O
+a	O
+documented	O
+coagulopathy	B-DISO
+as	O
+evidenced	O
+by	O
+a	O
+prolongation	O
+of	O
+the	O
+prothrombin	B-PRGE
+time	O
+and	O
+the	O
+partial	O
+thromboplastin	B-PRGE
+time	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	B-DISO
+is	O
+easily	O
+overlooked	O
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+),	O
+particularly	O
+in	O
+patients	O
+with	O
+alternative	O
+causes	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+or	O
+in	O
+those	O
+who	O
+acquire	O
+influenza	B-DISO
+during	O
+their	O
+ICU	O
+stay	O
+.	O
+
+The	O
+small	O
+size	O
+,	O
+unique	O
+structure	O
+,	O
+and	O
+multiple	O
+host	B-PROC
+defense	I-PROC
+activities	O
+of	O
+θ	O
+-	O
+defensins	B-PATH
+make	O
+them	O
+intriguing	O
+potential	O
+therapeutic	O
+agents	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+do	O
+this	O
+,	O
+we	O
+felt	O
+it	O
+necessary	O
+to	O
+summarize	O
+the	O
+knowledge	O
+acquired	O
+previously	O
+,	O
+since	O
+the	O
+since	O
+the	O
+disease	O
+was	O
+first	O
+identified	O
+in	O
+the	O
+1930s	O
+.	O
+
+The	O
+virus	B-SPEC
+exists	O
+in	O
+the	O
+form	O
+of	O
+many	O
+,	O
+ever	O
+changing	O
+,	O
+serotypic	O
+or	O
+genotypic	O
+variants	O
+,	O
+some	O
+of	O
+which	O
+have	O
+global	O
+distribution	O
+whilst	O
+others	O
+are	O
+found	O
+only	O
+in	O
+more	O
+local	O
+areas	O
+.	O
+
+However	O
+,	O
+disorder	O
+shows	O
+a	O
+sharp	O
+increase	O
+associated	O
+with	O
+the	O
+transition	B-DISO
+from	O
+prokaryotic	O
+to	O
+eukaryotic	B-ANAT
+cells	I-ANAT
+.	O
+
+As	O
+a	O
+result	O
+,	O
+we	O
+identified	O
+2	O
+alternative	O
+amino	B-CHED
+acid	I-CHED
+differences	O
+in	O
+the	O
+putative	O
+fusion	O
+peptide	B-CHED
+of	O
+the	O
+spike	O
+protein	B-CHED
+that	O
+together	O
+distinguish	O
+FIPV	O
+from	O
+FECV	B-SPEC
+in	O
+>	O
+95	O
+%	O
+of	O
+cases	O
+.	O
+
+In	O
+conclusion	O
+,	O
+pdm	B-PRGE
+H1N1	I-PRGE
+2009	O
+infection	B-DISO
+-	O
+associated	O
+encephalopathy	B-DISO
+was	O
+a	O
+critical	O
+disease	O
+in	O
+children	O
+,	O
+with	O
+rapidly	O
+progressive	O
+characteristics	O
+similar	O
+to	O
+those	O
+of	O
+seasonal	O
+influenza	B-DISO
+-	O
+associated	O
+encephalopathy	B-DISO
+.	O
+
+A	O
+specific	O
+decrease	O
+for	O
+ACE2	B-PRGE
+protein	I-PRGE
+level	O
+was	O
+observed	O
+when	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+was	O
+cultured	O
+at	O
+34	O
+°	O
+C	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+etiology	O
+in	O
+Chinese	O
+adults	O
+with	O
+acute	B-DISO
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+infection	I-DISO
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assays	O
+.	O
+
+Although	O
+many	O
+researchers	O
+have	O
+explored	O
+the	O
+combination	O
+of	O
+proteins	B-CHED
+with	O
+organic	O
+polymers	B-CHED
+,	O
+far	O
+fewer	O
+investigations	O
+have	O
+explored	O
+nucleic	B-CHED
+acid	I-CHED
+/	O
+polymer	B-CHED
+hybrids	O
+,	O
+known	O
+as	O
+DNA	O
+block	B-CHED
+copolymers	I-CHED
+(	O
+DBCs	O
+).	O
+
+DNA	O
+as	O
+a	O
+polymer	B-CHED
+block	O
+provides	O
+several	O
+advantages	O
+over	O
+other	O
+biopolymers	B-CHED
+.	O
+
+A	O
+screen	O
+utilizing	O
+a	O
+recombinant	O
+Vesicular	B-SPEC
+Stomatitis	I-SPEC
+Virus	I-SPEC
+(	O
+VSV	O
+)	O
+encoding	O
+Zaire	B-SPEC
+ebolavirus	I-SPEC
+GP	O
+identified	O
+four	O
+Chinese	B-SPEC
+Hamster	I-SPEC
+Ovary	B-ANAT
+(	O
+CHO	B-FUNC
+)	O
+cell	B-ANAT
+lines	I-ANAT
+resistant	O
+to	O
+GP	O
+-	O
+mediated	O
+viral	O
+entry	O
+.	O
+
+Conversely	O
+,	O
+expression	B-PROC
+of	O
+the	O
+recently	O
+described	O
+ebolavirus	B-SPEC
+host	B-COMP
+entry	I-PRGE
+factor	I-PRGE
+Niemann	I-PRGE
+-	I-PRGE
+Pick	I-PRGE
+Type	I-PRGE
+C1	I-PRGE
+(	O
+NPC1	O
+)	O
+restored	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+nasopharyngeal	B-ANAT
+flocked	O
+swabs	O
+and	O
+nasopharyngeal	B-ANAT
+wash	O
+collection	O
+methods	O
+for	O
+respiratory	O
+virus	O
+detection	O
+in	O
+hospitalized	O
+children	O
+using	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+TITLE	O
+:	O
+Microparticles	O
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pathophysiology	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+most	O
+severe	O
+form	O
+,	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+is	O
+characterized	O
+by	O
+increased	O
+vascular	B-ANAT
+and	O
+epithelial	O
+permeability	O
+,	O
+hypercoagulation	O
+and	O
+hypofibrinolysis	O
+,	O
+inflammation	B-DISO
+,	O
+and	O
+immune	B-PROC
+modulation	I-PROC
+.	O
+
+Peak	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+activity	O
+often	O
+appeared	O
+during	O
+the	O
+summer	O
+and	O
+autumn	O
+in	O
+Chongqing	O
+area	O
+.	O
+
+The	O
+diagnosis	O
+included	O
+bronchial	B-DISO
+pneumonia	I-DISO
+,	O
+bronchitis	B-DISO
+,	O
+interstitial	B-DISO
+pneumonia	I-DISO
+and	O
+bronchiolitis	B-DISO
+.	O
+
+PTX3	B-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+(	O
+129	O
+/	O
+SvEv	O
+/	O
+C57BL6	O
+/	O
+J	O
+)	O
+and	O
+their	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+littermates	O
+were	O
+intranasally	O
+infected	O
+MHV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+.	O
+
+Cytokine	O
+expression	B-PROC
+,	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+leukocyte	B-ANAT
+infiltration	B-DISO
+and	O
+inflammatory	B-DISO
+responses	I-DISO
+were	O
+examined	O
+in	O
+vivo	O
+.	O
+
+C	O
+-	O
+arm	B-ANAT
+CT	O
+guidance	O
+was	O
+used	O
+to	O
+confirm	O
+gas	B-ENZY
+filling	O
+of	O
+the	O
+target	O
+vessels	B-ANAT
+.	O
+
+No	O
+serious	O
+complication	B-DISO
+occurred	O
+.	O
+
+TITLE	O
+:	O
+Life	O
+-	O
+threatening	O
+scrub	B-DISO
+typhus	I-DISO
+with	O
+hemophagocytosis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+an	O
+infant	O
+.	O
+
+Here	O
+,	O
+we	O
+present	O
+the	O
+case	O
+of	O
+an	O
+8	O
+-	O
+month	O
+-	O
+old	O
+boy	O
+with	O
+scrub	B-DISO
+typhus	I-DISO
+accompanied	O
+by	O
+hemophagocytic	B-DISO
+lymphohistiocytosis	I-DISO
+(	O
+HLH	B-DISO
+).	O
+
+The	O
+highest	O
+expression	B-PROC
+level	O
+of	O
+the	O
+COE	O
+-	O
+Co1	B-PRGE
+fusion	O
+protein	B-CHED
+reached	O
+0	O
+.	O
+083	O
+%	O
+of	O
+the	O
+total	O
+soluble	O
+protein	B-CHED
+according	O
+to	O
+quantitative	O
+densitometry	O
+of	O
+Western	O
+blot	O
+analysis	O
+.	O
+
+These	O
+results	O
+indicated	O
+that	O
+oral	B-ANAT
+immunization	O
+of	O
+plant	B-SPEC
+-	O
+produced	O
+COE	O
+-	O
+Co1	B-PRGE
+fusion	O
+protein	B-CHED
+could	O
+elicit	O
+efficient	O
+systemic	O
+and	O
+mucosal	B-PROC
+immune	I-PROC
+responses	I-PROC
+against	O
+the	O
+COE	B-PRGE
+antigen	I-PRGE
+.	O
+
+The	O
+approach	O
+was	O
+certainly	O
+effective	O
+as	O
+no	O
+secondary	O
+infections	O
+were	O
+reported	O
+in	O
+hospitals	O
+that	O
+used	O
+it	O
+during	O
+SARS	B-DISO
+.	O
+
+Using	O
+the	O
+example	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+Canada	O
+,	O
+the	O
+inter	O
+-	O
+relationships	O
+between	O
+evidence	O
+and	O
+ethics	O
+are	O
+explored	O
+.	O
+
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+,	O
+Simplified	O
+Acute	O
+Physiology	O
+Score	O
+II	O
+and	O
+Sepsis	O
+-	O
+Related	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+scoring	O
+systems	O
+were	O
+unable	O
+to	O
+predict	O
+the	O
+outcome	O
+of	O
+the	O
+patients	O
+with	O
+leptospirosis	B-DISO
+-	O
+associated	O
+severe	O
+pulmonary	B-ANAT
+hemorrhagic	O
+syndrome	B-DISO
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+PF4	B-PRGE
+and	O
+beta	B-PRGE
+-	I-PRGE
+TG	I-PRGE
+may	O
+also	O
+play	O
+similar	O
+roles	O
+in	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)-	O
+related	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+:	O
+preliminary	O
+experience	O
+from	O
+a	O
+single	O
+center	O
+.	O
+
+Four	O
+patients	O
+(	O
+44	O
+.	O
+4	O
+%)	O
+died	B-PROC
+while	O
+undergoing	O
+ECMO	O
+.	O
+
+Use	O
+of	O
+ECMO	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)-	O
+related	O
+ARDS	B-DISO
+is	O
+feasible	O
+and	O
+effective	O
+.	O
+
+Two	O
+hundred	O
+and	O
+three	O
+patients	O
+with	O
+high	B-DISO
+altitude	I-DISO
+pulmonary	I-DISO
+edema	I-DISO
+(	O
+HAPE	O
+)	O
+or	O
+high	B-DISO
+altitude	I-DISO
+cerebral	I-DISO
+edema	I-DISO
+(	O
+HACE	O
+)	O
+met	B-CHED
+inclusion	O
+criteria	O
+were	O
+included	O
+,	O
+and	O
+were	O
+randomly	O
+divided	O
+into	O
+Bundle	O
+treatment	O
+group	O
+(	O
+n	O
+=	O
+125	O
+)	O
+and	O
+conventional	O
+treatment	O
+control	O
+group	O
+(	O
+n	O
+=	O
+78	O
+).	O
+
+ABSTRACT	O
+:	O
+Bovine	O
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+is	O
+found	O
+worldwide	O
+and	O
+causes	O
+respiratory	B-DISO
+infections	I-DISO
+and	O
+diarrhoea	B-DISO
+in	O
+calves	O
+and	O
+adult	O
+cattle	B-SPEC
+.	O
+
+In	O
+the	O
+Southern	O
+and	O
+Central	O
+regions	O
+,	O
+several	O
+genotypes	O
+of	O
+BCoV	O
+circulated	O
+contemporaneously	O
+,	O
+indicating	O
+that	O
+in	O
+these	O
+regions	O
+,	O
+which	O
+had	O
+a	O
+higher	O
+density	O
+of	O
+cattle	O
+than	O
+the	O
+Northern	O
+regions	O
+,	O
+more	O
+extensive	O
+transmission	O
+of	O
+the	O
+virus	B-SPEC
+was	O
+occurring	O
+.	O
+
+TITLE	O
+:	O
+Regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+in	O
+arterivirus	B-SPEC
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+:	O
+do	O
+they	O
+protect	O
+against	O
+disease	O
+or	O
+enhance	O
+it	O
+?	O
+
+The	O
+hallmark	O
+of	O
+T	O
+(	O
+regs	O
+)	O
+is	O
+the	O
+expression	B-PROC
+of	O
+the	O
+forkhead	B-PRGE
+box	I-PRGE
+P3	I-PRGE
+(	O
+FoxP3	O
+)	O
+transcription	O
+factor	O
+.	O
+
+TITLE	O
+:	O
+Protective	O
+role	O
+of	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+Receptor	I-PRGE
+3	I-PRGE
+-	O
+induced	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+in	O
+murine	B-SPEC
+coronavirus	I-SPEC
+infection	O
+of	O
+macrophages	B-ANAT
+.	O
+
+All	O
+infants	O
+were	O
+treated	O
+with	O
+routine	O
+therapy	O
+for	O
+Pneumocystis	B-SPEC
+jiroveci	I-SPEC
+and	O
+bacterial	O
+coinfection	B-DISO
+.	O
+
+However	O
+,	O
+in	O
+addition	O
+,	O
+all	O
+infants	O
+received	O
+ganciclovir	O
+from	O
+admission	O
+until	O
+the	O
+cytomegalovirus	B-SPEC
+viral	O
+load	O
+result	O
+was	O
+demonstrated	O
+to	O
+be	O
+<	O
+log	O
+4	O
+.	O
+
+This	O
+may	O
+,	O
+however	O
+,	O
+be	O
+a	O
+marker	O
+of	O
+as	O
+yet	O
+undefined	O
+pathology	B-DISO
+.	O
+
+After	O
+6	O
+hours	O
+of	O
+HFNC	O
+O	O
+(	O
+2	O
+)	O
+therapy	O
+,	O
+nonresponders	O
+presented	O
+a	O
+lower	O
+Pao	B-PROC
+(	O
+2	O
+)/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+median	O
+,	O
+135	O
+[	O
+interquartile	O
+range	O
+,	O
+84	O
+-	O
+210	O
+]	O
+vs	O
+73	O
+[	O
+56	O
+-	O
+81	O
+]	O
+mm	O
+Hg	O
+P	O
+<	O
+.	O
+05	O
+)	O
+and	O
+needed	O
+higher	O
+oxygen	B-CHED
+flow	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+typhus	I-DISO
+in	O
+southern	O
+Taiwan	O
+during	O
+1992	O
+-	O
+2009	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+81	O
+cases	O
+of	O
+serologically	O
+documented	O
+murine	B-DISO
+typhus	I-DISO
+during	O
+1992	O
+-	O
+2009	O
+at	O
+four	O
+referral	O
+hospitals	O
+in	O
+southern	O
+Taiwan	O
+were	O
+analyzed	O
+.	O
+
+The	O
+high	O
+mortality	O
+could	O
+be	O
+due	O
+to	O
+the	O
+pre	O
+-	O
+existing	O
+clinical	O
+severity	O
+of	O
+cases	O
+prior	O
+to	O
+request	O
+for	O
+peramivir	O
+,	O
+but	O
+also	O
+raises	O
+questions	O
+about	O
+peramivir	O
+safety	O
+and	O
+effectiveness	O
+in	O
+hospitalized	O
+and	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+From	O
+1996	O
+to	O
+2010	O
+,	O
+19	O
+patient	O
+deaths	B-PROC
+with	O
+a	O
+clinical	O
+diagnosis	O
+of	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+infection	B-DISO
+occurred	O
+in	O
+a	O
+tertiary	O
+care	O
+center	O
+in	O
+the	O
+Brazilian	O
+Amazon	B-SPEC
+.	O
+
+Nested	O
+polymerase	O
+chain	O
+reaction	O
+was	O
+performed	O
+in	O
+paraffinized	O
+samples	O
+of	O
+spleen	B-ANAT
+and	O
+lung	B-ANAT
+to	O
+confirm	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+monoinfection	O
+.	O
+
+Spleen	B-ANAT
+rupture	O
+(	O
+3	O
+cases	O
+)	O
+and	O
+multiorgan	O
+dysfunction	O
+syndrome	B-DISO
+(	O
+3	O
+cases	O
+)	O
+were	O
+the	O
+second	O
+most	O
+common	O
+complications	O
+.	O
+
+Endotracheal	O
+intubation	O
+was	O
+performed	O
+but	O
+complicated	O
+by	O
+a	O
+distinct	O
+resistance	B-PROC
+.	O
+
+Fiberoptic	O
+bronchoscopy	O
+in	O
+the	O
+hospital	O
+finally	O
+showed	O
+a	O
+bulk	O
+of	O
+granulomatous	O
+tissue	B-ANAT
+located	O
+just	O
+above	O
+the	O
+tracheal	B-ANAT
+bifurcation	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+retrotranscription	O
+process	O
+,	O
+characteristic	O
+of	O
+all	O
+retroviruses	B-SPEC
+,	O
+the	O
+viral	O
+ssRNA	O
+genome	O
+is	O
+converted	O
+into	O
+integration	B-PROC
+-	O
+competent	O
+dsDNA	O
+.	O
+
+This	O
+paper	O
+describes	O
+the	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+function	O
+and	O
+molecular	O
+structure	O
+,	O
+illustrates	O
+the	O
+currently	O
+approved	O
+RTIs	O
+,	O
+and	O
+focuses	O
+on	O
+the	O
+mechanisms	O
+of	O
+action	O
+of	O
+the	O
+newer	O
+classes	O
+of	O
+RTIs	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+describe	O
+the	O
+clinical	O
+presentation	O
+,	O
+treatment	O
+,	O
+and	O
+outcome	O
+of	O
+pleural	B-DISO
+effusion	I-DISO
+associated	O
+with	O
+OHSS	B-DISO
+in	O
+three	O
+patients	O
+undergoing	O
+in	O
+vitro	O
+fertilization	B-PROC
+.	O
+
+The	O
+onset	O
+of	O
+symptomatic	O
+pleural	B-DISO
+effusion	I-DISO
+(	O
+bilateral	O
+in	O
+all	O
+cases	O
+)	O
+occurred	O
+,	O
+on	O
+average	O
+,	O
+43	O
+days	O
+(	O
+range	O
+,	O
+27	O
+-	O
+60	O
+days	O
+)	O
+after	O
+initiation	O
+of	O
+hormone	B-CHED
+therapy	O
+for	O
+ovulation	B-PROC
+induction	O
+.	O
+
+Additional	O
+m	B-ENZY
+-	I-ENZY
+calpain	I-ENZY
+knockdown	O
+experiments	O
+confirmed	O
+the	O
+dependence	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+on	O
+the	O
+activity	O
+of	O
+the	O
+cysteine	B-PRGE
+protease	I-PRGE
+m	B-ENZY
+-	I-ENZY
+calpain	I-ENZY
+.	O
+
+Taken	O
+together	O
+,	O
+we	O
+provide	O
+strong	O
+experimental	O
+evidence	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+unique	O
+replication	O
+requirements	O
+which	O
+are	O
+independent	O
+of	O
+functional	O
+UPS	O
+or	O
+autophagy	B-PROC
+pathways	B-PROC
+compared	O
+to	O
+other	O
+coronaviruses	O
+.	O
+
+V	O
+-	O
+type	O
+H	O
++	O
+ATPase	B-ENZY
+inhibition	B-PROC
+in	O
+the	O
+renal	B-ANAT
+tubule	I-ANAT
+has	O
+been	O
+demonstrated	O
+.	O
+
+We	O
+hypothesize	O
+that	O
+Cordyceps	B-SPEC
+has	O
+beneficial	O
+effects	O
+on	O
+lung	B-DISO
+fibrosis	I-DISO
+and	O
+the	O
+objective	O
+of	O
+this	O
+study	O
+is	O
+to	O
+explore	O
+the	O
+target	O
+(	O
+s	O
+)	O
+of	O
+Cordyceps	B-SPEC
+in	O
+the	O
+relief	O
+of	O
+lung	B-DISO
+fibrosis	I-DISO
+in	O
+animal	B-SPEC
+and	O
+cell	B-COMP
+models	O
+and	O
+to	O
+gain	O
+insight	O
+into	O
+its	O
+underlying	O
+mechanisms	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+the	O
+Berlin	O
+Definition	O
+.	O
+
+The	O
+model	O
+for	O
+CBP	B-PRGE
+was	O
+continuous	O
+veno	O
+-	O
+venous	B-ANAT
+hemofiltration	O
+dialysis	B-SPEC
+(	O
+CVVHDF	O
+).	O
+
+CBP	B-PRGE
+treatment	O
+persisted	O
+for	O
+at	O
+least	O
+8	O
+hours	O
+and	O
+replacement	O
++	O
+dialysis	B-SPEC
+fluid	O
+dose	O
+was	O
+35	O
+-	O
+100	O
+ml	O
+/(	O
+kg	O
+·	O
+h	O
+).	O
+
+CONCLUSIONS	O
+:	O
+CBP	B-PRGE
+adjuvant	B-CHED
+treatment	O
+for	O
+ALI	O
+/	O
+ARDS	B-DISO
+could	O
+reduce	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+improve	O
+PaO2	O
+/	O
+FiO2	O
+and	O
+Cdyn	O
+,	O
+and	O
+improve	O
+mechanical	O
+ventilation	O
+parameters	O
+.	O
+
+Demographics	O
+(	O
+body	B-ANAT
+weigh	O
+,	O
+age	O
+,	O
+gender	O
+,	O
+VSD	B-DISO
+diameter	O
+)	O
+and	O
+clinical	O
+characteristics	O
+(	O
+CPB	O
+time	O
+,	O
+oxygenation	B-PROC
+index	O
+,	O
+mean	O
+airway	B-ANAT
+pressure	O
+,	O
+pH	O
+and	O
+PCO2	O
+)	O
+of	O
+all	O
+the	O
+patients	O
+were	O
+collected	O
+,	O
+and	O
+statistical	O
+analysis	O
+was	O
+done	O
+to	O
+compare	O
+the	O
+data	O
+between	O
+treatment	O
+and	O
+control	O
+group	O
+.	O
+
+Demographics	O
+(	O
+body	B-ANAT
+weigh	O
+,	O
+age	O
+,	O
+gender	O
+,	O
+VSD	B-DISO
+diameter	O
+)	O
+and	O
+clinical	O
+characteristics	O
+(	O
+CPB	O
+time	O
+,	O
+oxygenation	B-PROC
+index	O
+,	O
+mean	O
+airway	B-ANAT
+pressure	O
+,	O
+pH	O
+and	O
+PCO2	O
+)	O
+of	O
+all	O
+the	O
+patients	O
+were	O
+collected	O
+,	O
+and	O
+statistical	O
+analysis	O
+was	O
+done	O
+to	O
+compare	O
+the	O
+data	O
+between	O
+treatment	O
+and	O
+control	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Mechanically	O
+ventilated	O
+children	O
+with	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+:	O
+results	O
+from	O
+the	O
+National	O
+Pediatric	O
+Intensive	O
+Care	O
+Registry	O
+in	O
+Japan	O
+.	O
+
+Forty	O
+-	O
+one	O
+patients	O
+(	O
+50	O
+%)	O
+had	O
+at	O
+least	O
+one	O
+underlying	O
+chronic	O
+condition	O
+,	O
+including	O
+31	O
+with	O
+asthma	B-PATH
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+occurred	O
+in	O
+79	O
+subjects	O
+(	O
+35	O
+%)	O
+belonging	O
+to	O
+the	O
+development	B-PROC
+cohort	O
+and	O
+in	O
+423	O
+subjects	O
+(	O
+24	O
+%)	O
+from	O
+the	O
+validation	O
+cohort	O
+.	O
+
+Multivariable	O
+predictors	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+trauma	O
+included	O
+subject	O
+age	O
+,	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+Score	O
+,	O
+injury	O
+severity	O
+score	O
+,	O
+and	O
+the	O
+presence	O
+of	O
+blunt	O
+traumatic	O
+injury	O
+,	O
+pulmonary	B-ANAT
+contusion	O
+,	O
+massive	O
+transfusion	O
+,	O
+and	O
+flail	B-DISO
+chest	I-DISO
+injury	O
+(	O
+area	O
+under	O
+the	O
+receiver	O
+operator	O
+characteristic	O
+curve	O
+0	O
+.	O
+79	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+0	O
+.	O
+73	O
+,	O
+0	O
+.	O
+85	O
+]).	O
+
+From	O
+July	O
+to	O
+October	O
+2009	O
+,	O
+101	O
+cases	O
+suspected	O
+of	O
+suffering	B-DISO
+from	O
+Pandemic	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+were	O
+admitted	O
+and	O
+isolated	O
+in	O
+Al	O
+Nahdha	O
+Hospital	O
+in	O
+Muscat	O
+.	O
+
+The	O
+most	O
+common	O
+presenting	O
+symptoms	O
+were	O
+fever	B-PROC
+(	O
+95	O
+%)	O
+and	O
+cough	B-DISO
+(	O
+94	O
+%).	O
+
+Fecal	B-ANAT
+samples	O
+collected	O
+within	O
+24	O
+hours	O
+after	O
+admission	O
+from	O
+50	O
+cats	B-SPEC
+with	O
+normal	O
+feces	B-ANAT
+and	O
+50	O
+cats	B-SPEC
+with	O
+diarrhea	B-DISO
+were	O
+tested	O
+by	O
+fecal	B-ANAT
+flotation	O
+,	O
+antigen	B-CHED
+testing	O
+,	O
+PCR	O
+assay	O
+,	O
+and	O
+electron	O
+microscopy	O
+for	O
+selected	O
+enteropathogens	O
+.	O
+
+Other	O
+enteropathogens	O
+identified	O
+in	O
+cats	B-SPEC
+with	O
+and	O
+without	O
+diarrhea	B-DISO
+included	O
+Clostridium	B-SPEC
+perfringens	I-SPEC
+enterotoxin	O
+A	O
+(	O
+42	O
+%	O
+and	O
+50	O
+%,	O
+respectively	O
+),	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+(	O
+10	O
+%	O
+and	O
+20	O
+%,	O
+respectively	O
+),	O
+Giardia	B-DISO
+spp	B-ENZY
+(	O
+20	O
+%	O
+and	O
+8	O
+%,	O
+respectively	O
+),	O
+Cystoisospora	B-SPEC
+spp	B-ENZY
+(	O
+14	O
+%	O
+and	O
+10	O
+%,	O
+respectively	O
+),	O
+hookworms	B-SPEC
+(	O
+10	O
+%	O
+and	O
+18	O
+%,	O
+respectively	O
+),	O
+ascarids	O
+(	O
+6	O
+%	O
+and	O
+16	O
+%,	O
+respectively	O
+),	O
+Salmonella	B-DISO
+spp	B-ENZY
+(	O
+6	O
+%	O
+and	O
+4	O
+%,	O
+respectively	O
+),	O
+astrovirus	O
+(	O
+8	O
+%	O
+and	O
+2	O
+%,	O
+respectively	O
+),	O
+feline	B-SPEC
+panleukopenia	I-SPEC
+virus	I-SPEC
+(	O
+4	O
+%	O
+and	O
+4	O
+%,	O
+respectively	O
+),	O
+calicivirus	O
+(	O
+0	O
+%	O
+and	O
+2	O
+%,	O
+respectively	O
+),	O
+and	O
+Spirometra	B-SPEC
+spp	B-ENZY
+(	O
+0	O
+%	O
+and	O
+2	O
+%,	O
+respectively	O
+).	O
+
+100	O
+dogs	B-SPEC
+evaluated	O
+at	O
+an	O
+open	O
+-	O
+admission	O
+municipal	O
+animal	B-SPEC
+shelter	O
+in	O
+Florida	O
+.	O
+
+Feces	B-ANAT
+were	O
+tested	O
+by	O
+fecal	B-ANAT
+flotation	O
+,	O
+antigen	B-CHED
+testing	O
+,	O
+PCR	O
+assay	O
+,	O
+and	O
+electron	O
+microscopy	O
+for	O
+selected	O
+enteropathogens	O
+.	O
+
+Dogs	B-SPEC
+with	O
+diarrhea	B-DISO
+were	O
+significantly	O
+more	O
+likely	O
+to	O
+be	O
+infected	O
+with	O
+≥	O
+1	O
+enteropathogens	O
+(	O
+96	O
+%)	O
+than	O
+were	O
+dogs	B-SPEC
+with	O
+normal	O
+feces	B-ANAT
+(	O
+78	O
+%).	O
+
+TITLE	O
+:	O
+Respiratory	O
+virus	B-SPEC
+detection	O
+in	O
+immunocompromised	O
+patients	O
+with	O
+FilmArray	O
+respiratory	O
+panel	O
+compared	O
+to	O
+conventional	O
+methods	O
+.	O
+
+It	O
+is	O
+classified	O
+as	O
+a	O
+class	B-SPEC
+I	O
+fusion	O
+protein	B-CHED
+,	O
+and	O
+is	O
+responsible	O
+for	O
+binding	B-FUNC
+to	O
+the	O
+receptor	O
+on	O
+the	O
+host	B-COMP
+cell	I-COMP
+as	O
+well	O
+as	O
+mediating	O
+the	O
+fusion	O
+of	O
+host	B-COMP
+and	O
+viral	O
+membranes	B-ANAT
+-	O
+A	O
+process	O
+driven	O
+by	O
+major	O
+conformational	O
+changes	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+Sixty	O
+-	O
+seven	O
+percent	O
+had	O
+an	O
+underlying	O
+medical	O
+conditions	O
+,	O
+including	O
+diabetes	B-DISO
+,	O
+obesity	B-DISO
+,	O
+heart	B-ANAT
+and	I-ANAT
+lung	I-ANAT
+diseases	O
+,	O
+and	O
+pregnancy	O
+.	O
+
+ABSTRACT	O
+:	O
+Zinc	O
+has	O
+been	O
+shown	O
+to	O
+mediate	O
+antiviral	B-CHED
+effects	O
+against	O
+certain	O
+viruses	B-SPEC
+.	O
+
+In	O
+common	O
+to	O
+other	O
+viroporins	B-PRGE
+,	I-PRGE
+coronavirus	I-PRGE
+envelope	B-COMP
+proteins	B-CHED
+increase	O
+membrane	B-PROC
+permeability	I-PROC
+to	O
+ions	B-CHED
+.	O
+
+Although	O
+an	O
+NMR	O
+-	O
+based	O
+model	O
+for	O
+the	O
+TM	O
+domain	O
+of	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+E	O
+)	O
+has	O
+been	O
+reported	O
+,	O
+structural	O
+data	O
+and	O
+biophysical	O
+studies	O
+of	O
+full	O
+length	O
+E	O
+proteins	B-CHED
+are	O
+not	O
+available	O
+because	O
+efficient	O
+expression	B-PROC
+and	O
+purification	O
+methods	O
+for	O
+these	O
+proteins	B-CHED
+are	O
+lacking	O
+.	O
+
+This	O
+is	O
+an	O
+approach	O
+that	O
+can	O
+be	O
+used	O
+in	O
+other	O
+difficult	O
+hydrophobic	O
+peptides	B-CHED
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+accessory	O
+proteins	B-CHED
+6	O
+and	O
+9b	O
+interact	O
+in	O
+vivo	O
+.	O
+
+The	O
+experiences	O
+of	O
+regional	O
+countries	O
+with	O
+prevention	O
+and	O
+control	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+SARS	B-DISO
+have	O
+reinforced	O
+the	O
+need	O
+for	O
+sustained	O
+,	O
+well	O
+-	O
+coordinated	O
+,	O
+multi	O
+-	O
+sector	O
+,	O
+multi	O
+-	O
+disciplinary	O
+,	O
+community	O
+-	O
+based	O
+actions	O
+to	O
+address	O
+emerging	O
+disease	O
+threats	O
+.	O
+'	O
+
+There	O
+were	O
+156	O
+cases	O
+:	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+105	O
+(	O
+67	O
+.	O
+3	O
+%),	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+39	O
+(	O
+25	O
+%)	O
+and	O
+mixed	B-DISO
+infections	I-DISO
+12	O
+(	O
+7	O
+.	O
+7	O
+%).	O
+
+Thrombocytopenia	O
+(	O
+platelet	B-ANAT
+count	O
+<	O
+150	O
+×	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+)	O
+was	O
+present	O
+in	O
+90	O
+(	O
+85	O
+.	O
+7	O
+%)	O
+patients	O
+with	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+mono	B-DISO
+-	O
+infection	B-DISO
+.	O
+
+We	O
+collected	O
+data	O
+on	O
+demographics	O
+,	O
+comorbidities	O
+,	O
+hemodynamic	B-PROC
+parameters	O
+,	O
+and	O
+ventilatory	O
+support	O
+used	O
+before	O
+ECLS	O
+.	O
+
+Overall	O
+,	O
+5	O
+of	O
+the	O
+8	O
+patients	O
+(	O
+63	O
+%)	O
+survived	O
+to	O
+discharge	B-ANAT
+.	O
+
+AGP	O
+-	O
+positive	O
+leucocytes	B-ANAT
+can	O
+be	O
+found	O
+in	O
+feline	B-SPEC
+blood	B-ANAT
+,	O
+especially	O
+during	O
+inflammation	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+broad	O
+spectrum	O
+of	O
+pathogens	O
+is	O
+causative	O
+for	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+but	O
+symptoms	O
+are	O
+mostly	O
+similar	O
+.	O
+
+The	O
+analytical	O
+sensitivity	O
+of	O
+three	O
+multiplex	O
+PCR	O
+assays	O
+,	O
+RespiFinder	O
+-	O
+19	O
+,	O
+RespiFinder	O
+-	O
+SMART	O
+-	O
+22	O
+and	O
+xTAG	O
+-	O
+Respiratory	O
+-	O
+Virus	B-SPEC
+-	O
+Panel	O
+-	O
+Fast	B-FUNC
+-	O
+Assay	O
+(	O
+RVP	O
+),	O
+were	O
+compared	O
+to	O
+monoplex	B-SPEC
+real	O
+-	O
+time	O
+PCR	O
+with	O
+quantified	O
+standardized	O
+control	O
+material	O
+.	O
+
+Concordant	O
+results	O
+were	O
+received	O
+for	O
+rhinovirus	B-SPEC
+,	O
+whereas	O
+the	O
+RVP	O
+detected	O
+influenzavirus	B-SPEC
+,	O
+RSV	B-SPEC
+and	O
+hMPV	B-SPEC
+more	O
+frequently	O
+in	O
+low	O
+concentrations	O
+.	O
+
+The	O
+detection	O
+of	O
+all	O
+13	O
+viruses	B-SPEC
+in	O
+one	O
+sample	O
+was	O
+only	O
+achieved	O
+using	O
+monoplex	B-SPEC
+PCR	O
+.	O
+
+To	O
+analyze	O
+possible	O
+competitive	O
+amplification	B-DISO
+reactions	O
+between	O
+the	O
+different	O
+viruses	B-SPEC
+,	O
+samples	O
+were	O
+further	O
+inoculated	O
+with	O
+only	O
+4	O
+different	O
+viruses	B-SPEC
+in	O
+one	O
+sample	O
+.	O
+
+ABSTRACT	O
+:	O
+Airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+(	O
+APRV	O
+)	O
+is	O
+an	O
+alternative	O
+approach	O
+to	O
+the	O
+low	O
+-	O
+tidal	O
+volume	O
+""""	O
+open	O
+-	O
+lung	B-ANAT
+""""	O
+ventilation	O
+strategy	O
+.	O
+
+APRV	O
+is	O
+associated	O
+with	O
+a	O
+higher	O
+mean	O
+airway	B-ANAT
+pressure	O
+than	O
+conventional	O
+ventilation	O
+and	O
+has	O
+therefore	O
+not	O
+been	O
+evaluated	O
+in	O
+patients	O
+with	O
+acute	O
+neurological	O
+injuries	O
+.	O
+
+The	O
+ion	O
+conductance	O
+was	O
+also	O
+controlled	O
+by	O
+the	O
+lipid	B-CHED
+composition	O
+of	O
+the	O
+membrane	B-COMP
+.	O
+
+Lipid	B-CHED
+charge	O
+also	O
+regulated	O
+the	O
+selectivity	O
+of	O
+a	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+E	I-PRGE
+protein	B-CHED
+derived	I-PRGE
+peptide	B-CHED
+.	O
+
+These	O
+results	O
+suggested	O
+that	O
+the	O
+lipids	B-CHED
+are	O
+functionally	O
+involved	O
+in	O
+E	O
+protein	O
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+,	O
+forming	O
+a	O
+protein	B-CHED
+-	O
+lipid	B-CHED
+pore	B-COMP
+,	O
+a	O
+novel	O
+concept	O
+for	O
+CoV	B-PRGE
+E	I-PRGE
+protein	I-PRGE
+ion	O
+channel	O
+entity	O
+.	O
+
+The	O
+epidemic	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+,	O
+re	O
+-	O
+emergence	O
+of	O
+a	O
+panzootic	O
+of	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+H5N1	B-DISO
+in	O
+2005	O
+,	O
+and	O
+the	O
+sudden	O
+emergence	O
+of	O
+pandemic	O
+H1N1	O
+in	O
+North	O
+America	O
+in	O
+2009	O
+all	O
+highlighted	O
+the	O
+importance	O
+of	O
+shared	O
+global	O
+responsibility	O
+for	O
+surveillance	O
+and	O
+disease	O
+control	O
+.	O
+
+To	O
+explore	O
+the	O
+distribution	O
+of	O
+BtCoVs	O
+in	O
+the	O
+Philippines	O
+,	O
+we	O
+collected	O
+179	O
+bats	B-SPEC
+and	O
+detected	O
+viral	O
+RNA	O
+from	O
+intestinal	B-ANAT
+or	O
+fecal	B-ANAT
+samples	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Experimental	O
+part	O
+of	O
+work	O
+was	O
+carried	O
+out	O
+on	O
+59	O
+mice	B-SPEC
+with	O
+induced	O
+peritonitis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+analysis	O
+of	O
+16	O
+Colorado	O
+human	B-SPEC
+NL63	O
+coronaviruses	O
+identifies	O
+a	O
+new	O
+genotype	O
+,	O
+high	O
+sequence	O
+diversity	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+spike	O
+gene	O
+and	O
+evidence	O
+of	O
+recombination	O
+.	O
+
+From	O
+1	O
+January	O
+2009	O
+to	O
+31	O
+December	O
+2011	O
+,	O
+92	O
+of	O
+9380	O
+respiratory	O
+specimens	O
+were	O
+found	O
+to	O
+be	O
+positive	O
+for	O
+NL63	B-PRGE
+RNA	I-PRGE
+by	O
+PCR	O
+,	O
+an	O
+overall	O
+prevalence	O
+of	O
+1	O
+%.	O
+
+Out	O
+of	O
+the	O
+studied	O
+172	O
+infants	O
+,	O
+33	O
+infants	O
+(	O
+19	O
+.	O
+2	O
+%)	O
+developed	O
+ROP	B-DISO
+in	O
+one	O
+or	O
+both	O
+eyes	B-ANAT
+;	O
+18	O
+(	O
+54	O
+.	O
+5	O
+%)	O
+cases	O
+stage	O
+1	O
+,	O
+9	O
+(	O
+27	O
+.	O
+3	O
+%)	O
+cases	O
+stage	O
+2	O
+,	O
+and	O
+6	O
+(	O
+18	O
+.	O
+2	O
+%)	O
+cases	O
+stage	O
+3	O
+.	O
+
+The	O
+prevalence	O
+of	O
+ROP	B-DISO
+in	O
+this	O
+study	O
+was	O
+19	O
+.	O
+2	O
+%;	O
+low	O
+gestational	O
+age	O
+,	O
+sepsis	B-DISO
+,	O
+oxygen	B-CHED
+therapy	O
+,	O
+and	O
+frequent	O
+blood	B-ANAT
+transfusions	O
+were	O
+significant	O
+risk	O
+factors	O
+for	O
+ROP	B-DISO
+.	O
+
+As	O
+this	O
+is	O
+a	O
+unit	O
+-	O
+based	O
+study	O
+,	O
+a	O
+comprehensive	O
+countrywide	O
+survey	O
+on	O
+ROP	B-DISO
+in	O
+Egypt	O
+is	O
+recommended	O
+to	O
+determine	O
+any	O
+regional	O
+differences	O
+in	O
+disease	O
+prevalence	O
+.	O
+
+There	O
+were	O
+no	O
+differences	O
+in	O
+venous	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+and	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+between	O
+the	O
+groups	O
+.	O
+
+Inspiratory	B-PROC
+P	O
+(	O
+el	O
+)/	O
+V	O
+curves	O
+recorded	O
+from	O
+PEEP	B-CHED
+or	O
+,	O
+even	O
+better	O
+,	O
+expiratory	B-PROC
+P	O
+(	O
+el	O
+)/	O
+V	O
+curves	O
+allow	O
+monitoring	O
+in	O
+ARDS	B-DISO
+.	O
+
+There	O
+were	O
+no	O
+differences	O
+in	O
+venous	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+and	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+between	O
+the	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Infections	B-DISO
+in	O
+pediatrics	O
+:	O
+old	O
+and	O
+new	O
+diseases	O
+.	O
+
+Finally	O
+,	O
+new	O
+emerging	O
+paediatric	O
+infectious	B-DISO
+diseases	I-DISO
+caused	O
+by	O
+newly	O
+discovered	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+human	B-SPEC
+bocavirus	I-SPEC
+,	O
+or	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+are	O
+explored	O
+.	O
+
+TITLE	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	O
+)	O
+is	O
+an	O
+important	O
+cause	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+that	O
+is	O
+often	O
+associated	O
+with	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Infections	B-DISO
+with	O
+human	B-SPEC
+coronaviruses	O
+NL63	O
+and	O
+OC43	O
+among	O
+hospitalised	O
+and	O
+outpatient	O
+individuals	O
+in	O
+São	O
+Paulo	O
+,	O
+Brazil	O
+.	O
+
+To	O
+identify	O
+the	O
+HCoVs	O
+,	O
+pancoronavirus	O
+and	O
+species	B-SPEC
+-	O
+specific	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+assays	O
+were	O
+performed	O
+.	O
+
+ABSTRACT	O
+:	O
+RNA	O
+virus	O
+evolution	B-PROC
+results	O
+from	O
+viral	B-PROC
+replication	I-PROC
+fidelity	O
+and	O
+mutational	O
+robustness	O
+in	O
+combination	O
+with	O
+selection	O
+.	O
+
+One	O
+clinical	O
+diagnostic	O
+criterion	O
+for	O
+ARDS	B-DISO
+is	O
+the	O
+P	O
+(	O
+a	O
+)	O
+O	O
+(	O
+2	O
+):	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+)	O
+ratio	O
+,	O
+which	O
+is	O
+an	O
+index	O
+of	O
+alveolar	B-ANAT
+gas	B-ENZY
+exchange	O
+.	O
+
+After	O
+15	O
+minutes	O
+exposure	O
+to	O
+room	O
+air	B-CHED
+(	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+)	O
+=	O
+0	O
+·	O
+21	O
+)	O
+or	O
+100	O
+%	O
+O	O
+(	O
+2	O
+)	O
+(	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+)	O
+=	O
+1	O
+·	O
+0	O
+),	O
+carotid	B-ANAT
+P	O
+(	O
+a	O
+)	O
+O	O
+(	O
+2	O
+)	O
+was	O
+measured	O
+.	O
+
+To	O
+determine	O
+influenza	B-DISO
+effects	O
+on	O
+P	O
+(	O
+a	O
+)	O
+O	O
+(	O
+2	O
+):	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+),	O
+mice	B-SPEC
+were	O
+challenged	O
+with	O
+10	O
+,	O
+000	O
+p	O
+.	O
+f	O
+..	O
+
+TITLE	O
+:	O
+[	O
+Breastfeeding	B-PROC
+:	O
+the	O
+importance	O
+of	O
+intervening	O
+].	O
+
+ABSTRACT	O
+:	O
+Breast	B-ANAT
+milk	I-ANAT
+is	O
+considered	O
+by	O
+the	O
+WHO	O
+the	O
+ideal	O
+food	O
+for	O
+the	O
+first	O
+months	O
+of	O
+life	O
+.	O
+
+We	O
+also	O
+found	O
+long	O
+-	O
+term	O
+benefits	O
+,	O
+such	O
+as	O
+for	O
+obesity	B-DISO
+(	O
+7	O
+-	O
+24	O
+%)	O
+and	O
+other	O
+cardiovascular	B-ANAT
+risk	O
+factors	O
+in	O
+adulthood	O
+.	O
+
+RESULTS	O
+:	O
+Breast	B-ANAT
+-	O
+feeding	O
+is	O
+clearly	O
+associated	O
+with	O
+benefits	O
+to	O
+the	O
+infant	O
+,	O
+including	O
+significant	O
+protective	O
+effects	O
+for	O
+gastrointestinal	B-DISO
+infections	I-DISO
+(	O
+64	O
+%),	O
+middle	B-ANAT
+ear	I-ANAT
+(	O
+23	O
+-	O
+50	O
+%),	O
+severe	O
+respiratory	B-DISO
+infections	I-DISO
+(	O
+73	O
+%)	O
+and	O
+for	O
+acute	B-DISO
+lymphocytic	I-DISO
+leukemia	I-DISO
+(	O
+19	O
+%)	O
+and	O
+sudden	B-DISO
+death	I-DISO
+syndrome	B-DISO
+in	O
+infants	O
+(	O
+36	O
+%).	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+immunostimulated	O
+with	O
+the	O
+purified	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+expressed	B-PROC
+by	O
+Bac	O
+-	O
+to	O
+-	O
+Bac	O
+baculovirus	B-SPEC
+expression	B-PROC
+system	O
+.	O
+
+mAbs	O
+against	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+MHV	O
+with	O
+high	O
+activity	O
+and	O
+specificity	O
+were	O
+prepared	O
+successfully	O
+,	O
+which	O
+provides	O
+a	O
+potential	O
+basis	O
+for	O
+further	O
+researches	O
+on	O
+N	B-PRGE
+protein	I-PRGE
+function	O
+and	O
+diagnostic	O
+methods	O
+.	O
+
+Western	O
+blotting	O
+showed	O
+that	O
+the	O
+mAbs	O
+specifically	O
+recognized	O
+certain	O
+antigenic	O
+epitope	B-CHED
+of	O
+N	O
+protein	B-CHED
+of	O
+MHV	B-SPEC
+.	O
+
+Both	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+were	O
+associated	O
+with	O
+decreased	O
+VFDs	O
+and	O
+increased	O
+28	O
+-	O
+day	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+and	O
+the	O
+more	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+represent	O
+a	O
+spectrum	O
+of	O
+lung	B-DISO
+disease	I-DISO
+characterized	O
+by	O
+the	O
+sudden	O
+onset	O
+of	O
+inflammatory	O
+pulmonary	B-ANAT
+edema	B-DISO
+secondary	I-DISO
+to	O
+myriad	O
+local	O
+or	O
+systemic	O
+insults	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+the	O
+prone	O
+position	O
+has	O
+been	O
+shown	O
+to	O
+improve	O
+survival	O
+of	O
+patients	O
+who	O
+are	O
+severely	O
+hypoxemic	O
+with	O
+an	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+to	O
+inspiratory	B-PROC
+oxygen	B-CHED
+fraction	O
+ratio	O
+(	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+))<	O
+100	O
+.	O
+
+However	O
+decision	O
+making	O
+about	O
+bronchoscopy	O
+in	O
+severe	O
+hypoxia	B-DISO
+should	O
+be	O
+even	O
+more	O
+cautious	O
+than	O
+in	O
+the	O
+supine	O
+patient	O
+,	O
+as	O
+dangerous	O
+delay	O
+in	O
+resuscitation	O
+manoeuvres	O
+due	O
+to	O
+postponed	O
+switching	O
+the	O
+patient	O
+to	O
+the	O
+supine	O
+position	O
+should	O
+always	O
+be	O
+prevented	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+distress	I-DISO
+develops	O
+in	O
+up	O
+to	O
+25	O
+%	O
+of	O
+adults	O
+and	O
+40	O
+%	O
+of	O
+children	O
+with	O
+severe	O
+falciparum	O
+malaria	O
+.	O
+
+Mechanical	O
+ventilation	O
+can	O
+save	O
+life	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+The	O
+use	O
+of	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+has	O
+helped	O
+to	O
+reduce	O
+mortality	O
+from	O
+malaria	B-PATH
+-	O
+induced	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+but	O
+permissive	O
+hypercapnia	B-DISO
+in	O
+unconscious	O
+patients	O
+is	O
+not	O
+recommended	O
+because	O
+increased	B-DISO
+intracranial	I-DISO
+pressure	I-DISO
+and	O
+cerebral	B-ANAT
+swelling	B-DISO
+may	O
+occur	O
+in	O
+cerebral	B-DISO
+malaria	B-PATH
+.	O
+
+Not	O
+detected	O
+were	O
+Coronavirus	B-SPEC
+,	O
+Cardiovirus	B-SPEC
+,	O
+Cosavirus	B-SPEC
+,	O
+Salivirus	B-SPEC
+,	O
+Sapovirus	B-SPEC
+,	O
+and	O
+Norovirus	B-SPEC
+.	O
+
+Four	O
+nonpolio	O
+enterovirus	B-SPEC
+genotypes	O
+were	O
+also	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+enveloped	O
+viruses	B-SPEC
+of	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+associated	O
+mostly	O
+with	O
+enteric	O
+and	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+10	O
+-	O
+20	O
+%	O
+of	O
+all	O
+common	B-DISO
+colds	I-DISO
+.	O
+
+Comparison	O
+of	O
+the	O
+RBDs	O
+of	O
+TGEV	B-SPEC
+and	O
+PRCV	O
+to	O
+those	O
+of	O
+other	O
+related	O
+CoVs	O
+,	O
+suggests	O
+that	O
+the	O
+conformation	O
+of	O
+the	O
+S	B-PRGE
+receptor	I-PRGE
+-	O
+binding	B-FUNC
+region	O
+determines	O
+cell	B-COMP
+entry	O
+receptor	O
+specificity	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+regulates	O
+immune	B-PROC
+function	I-PROC
+-	O
+related	O
+gene	B-PROC
+expression	I-PROC
+in	O
+human	B-SPEC
+monocytic	B-ANAT
+cells	B-COMP
+.	O
+
+However	O
+,	O
+topical	O
+antibiotics	B-CHED
+are	O
+rarely	O
+associated	O
+with	O
+the	O
+infection	B-DISO
+.	O
+
+However	O
+,	O
+monotherapy	O
+with	O
+NAIs	B-SPEC
+is	O
+insufficient	O
+for	O
+severe	O
+pneumonia	B-DISO
+secondary	O
+to	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+previously	O
+demonstrated	O
+that	O
+mice	B-SPEC
+infected	O
+with	O
+a	O
+lethal	O
+dose	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+develop	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+DAD	O
+)	O
+with	O
+alveolar	B-ANAT
+collapse	B-DISO
+similar	O
+to	O
+that	O
+seen	O
+in	O
+ARDS	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Therefore	O
+,	O
+the	O
+present	O
+study	O
+examined	O
+whether	O
+combination	O
+therapy	O
+of	O
+NAI	B-CHED
+with	O
+exogenous	O
+artificial	O
+surfactant	B-CHED
+affects	O
+mortality	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+The	O
+mice	B-SPEC
+were	O
+additionally	O
+administered	O
+exogenous	O
+artificial	O
+surfactant	B-CHED
+in	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+a	O
+new	O
+NAI	B-CHED
+,	O
+laninamivir	O
+octanoate	B-CHED
+.	O
+
+This	O
+combination	O
+could	O
+be	O
+effective	O
+for	O
+prevention	O
+of	O
+severe	O
+pneumonia	B-DISO
+secondary	O
+to	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+in	O
+humans	B-SPEC
+,	O
+which	O
+is	O
+not	O
+improved	O
+by	O
+NAI	B-CHED
+monotherapy	O
+.	O
+
+TITLE	O
+:	O
+Contribution	O
+of	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+to	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+3	O
+-	O
+induced	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Unique	O
+disorders	O
+appear	O
+episodically	O
+in	O
+human	B-SPEC
+populations	O
+and	O
+cause	O
+life	O
+-	O
+threatening	O
+systemic	O
+or	O
+neurological	O
+disease	O
+.	O
+
+Here	O
+,	O
+alignments	O
+of	O
+transmembrane	B-COMP
+domains	O
+(	O
+TMDs	O
+)	O
+of	O
+viral	O
+channel	O
+forming	O
+proteins	B-CHED
+with	O
+host	B-COMP
+ion	B-FUNC
+channels	I-FUNC
+and	O
+toxins	B-CHED
+are	O
+evaluated	O
+.	O
+
+The	O
+following	O
+representatives	O
+of	O
+polytopic	O
+viral	O
+channel	O
+proteins	B-CHED
+are	O
+chosen	O
+:	O
+(	O
+i	O
+)	O
+p7	O
+of	O
+HCV	B-SPEC
+and	O
+2B	O
+of	O
+Polio	B-DISO
+virus	B-SPEC
+(	O
+two	O
+TMDs	O
+)	O
+and	O
+(	O
+ii	O
+)	O
+3a	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+three	O
+TMDs	O
+).	O
+
+Using	O
+ClustalW2	O
+,	O
+each	O
+of	O
+the	O
+TMDs	O
+of	O
+the	O
+viral	O
+channels	O
+is	O
+aligned	O
+,	O
+and	O
+the	O
+overlap	O
+is	O
+mapped	O
+onto	O
+structural	O
+models	O
+of	O
+the	O
+host	B-COMP
+channels	O
+and	O
+toxins	B-CHED
+focusing	O
+on	O
+the	O
+pore	B-COMP
+-	O
+lining	O
+TMDs	O
+.	O
+
+ABSTRACT	O
+:	O
+Secretory	O
+and	O
+membrane	B-COMP
+proteins	B-CHED
+attain	O
+their	O
+native	O
+structure	O
+in	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+).	O
+
+Folding	O
+-	O
+defective	O
+polypeptides	B-CHED
+are	O
+selected	O
+for	O
+degradation	O
+by	O
+processes	O
+collectively	O
+defined	O
+as	O
+ER	O
+-	O
+associated	O
+degradation	O
+(	O
+ERAD	B-PROC
+).	O
+
+ABSTRACT	O
+:	O
+Clara	O
+cell	O
+protein	B-CHED
+16	O
+(	O
+CC16	B-PRGE
+)	O
+has	O
+recently	O
+gained	O
+acceptance	O
+as	O
+a	O
+blood	B-ANAT
+biomarker	B-CHED
+for	O
+detecting	O
+direct	O
+and	O
+indirect	O
+lung	B-ANAT
+injury	O
+.	O
+
+In	O
+the	O
+latter	O
+patients	O
+,	O
+median	O
+CC16	O
+serum	B-COMP
+levels	O
+were	O
+significantly	O
+elevated	O
+(	O
+14	O
+.	O
+5	O
+ng	O
+/	O
+mL	O
+)	O
+at	O
+the	O
+onset	O
+of	O
+pneumonia	B-DISO
+compared	O
+with	O
+their	O
+levels	O
+(	O
+7	O
+.	O
+3	O
+ng	O
+/	O
+mL	O
+)	O
+1	O
+day	O
+before	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+results	O
+confirm	O
+the	O
+previously	O
+described	O
+association	O
+between	O
+initial	O
+elevation	O
+in	O
+CC16	O
+serum	B-COMP
+levels	O
+and	O
+severe	O
+thoracic	B-DISO
+injury	O
+in	O
+patients	O
+with	O
+multiple	O
+injuries	O
+.	O
+
+The	O
+EPEC	O
+P86	O
+-	O
+1390	O
+and	O
+other	O
+well	O
+-	O
+characterised	O
+porcine	B-SPEC
+EPEC	O
+strains	O
+were	O
+applied	O
+to	O
+54	O
+pigs	B-SPEC
+,	O
+leaving	O
+41	O
+weaned	B-PROC
+pigs	B-SPEC
+as	O
+negative	O
+controls	O
+.	O
+
+A	O
+total	O
+of	O
+41	O
+weaned	B-PROC
+pigs	B-SPEC
+served	O
+as	O
+negative	O
+controls	O
+inoculated	O
+with	O
+a	O
+commensal	O
+porcine	B-SPEC
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+The	O
+highest	O
+IBV	B-SPEC
+codon	O
+adaptation	B-PROC
+index	O
+(	O
+CAI	O
+)	O
+value	O
+was	O
+0	O
+.	O
+7	O
+,	O
+indicating	O
+a	O
+distant	O
+virus	B-SPEC
+versus	O
+host	B-COMP
+synonymous	O
+codons	O
+usage	O
+.	O
+
+The	O
+low	O
+CAI	O
+values	O
+agree	O
+with	O
+a	O
+low	O
+S	B-PRGE
+protein	I-PRGE
+expression	B-PROC
+and	O
+considering	O
+that	O
+S	B-PRGE
+protein	I-PRGE
+is	O
+a	O
+determinant	O
+for	O
+attachment	O
+and	O
+neutralization	O
+,	O
+this	O
+could	O
+be	O
+a	O
+further	O
+mechanism	O
+besides	O
+mRNA	O
+transcription	B-PROC
+attenuation	O
+for	O
+a	O
+low	O
+expression	B-PROC
+of	O
+this	O
+protein	B-CHED
+leading	O
+to	O
+an	O
+immune	O
+camouflage	O
+.	O
+
+Although	O
+MV	O
+is	O
+necessary	O
+for	O
+the	O
+treatment	O
+of	O
+severe	O
+hypoxemia	O
+it	O
+causes	O
+damage	O
+not	O
+only	O
+in	O
+the	O
+lungs	B-ANAT
+but	O
+also	O
+in	O
+other	O
+organs	B-ANAT
+due	O
+to	O
+a	O
+secondary	O
+inflammatory	O
+process	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+6	O
+.	O
+91	O
+years	O
+);	O
+affiliated	O
+with	O
+Apnea	B-DISO
+Academy	O
+,	O
+(	O
+International	O
+School	O
+for	O
+Education	O
+and	O
+Research	O
+of	O
+Free	O
+-	O
+Diving	O
+).	O
+
+The	O
+source	O
+,	O
+a	O
+gamma	O
+unit	O
+containing	O
+Cobalt	B-CHED
+-	O
+60	O
+pencils	O
+,	O
+was	O
+improperly	O
+disposed	O
+of	O
+by	O
+a	O
+research	O
+institution	O
+in	O
+violation	O
+of	O
+national	O
+regulations	O
+for	O
+radiation	O
+protection	O
+and	O
+safety	O
+of	O
+radioactive	O
+sources	O
+.	O
+
+This	O
+event	O
+subsequently	O
+caused	O
+the	O
+most	O
+severe	O
+radiation	O
+accident	O
+reported	O
+in	O
+India	O
+to	O
+date	O
+,	O
+resulting	O
+in	O
+seven	O
+radiation	O
+injuries	O
+and	O
+one	O
+death	B-PROC
+.	O
+
+Texas	O
+Veterinary	O
+Medical	O
+Diagnostic	O
+Laboratory	O
+current	O
+methods	O
+for	O
+calf	B-ANAT
+diarrhea	B-DISO
+pathogen	O
+identification	O
+include	O
+electron	O
+microscopy	O
+(	O
+EM	O
+)	O
+for	O
+BCV	B-SPEC
+and	O
+BRV	B-DISO
+and	O
+a	O
+direct	O
+fluorescent	O
+antibody	B-COMP
+test	O
+(	O
+DFAT	O
+)	O
+for	O
+organism	O
+detection	O
+of	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.	O
+
+The	O
+results	O
+demonstrate	O
+that	O
+the	O
+newly	O
+developed	O
+assay	O
+can	O
+purify	O
+and	O
+subsequently	O
+detect	O
+BCV	B-SPEC
+,	O
+BRV	B-DISO
+,	O
+and	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.	O
+
+All	O
+compounds	O
+were	O
+highly	O
+effective	O
+against	O
+the	O
+majority	O
+of	O
+tested	O
+viruses	B-SPEC
+,	O
+with	O
+half	O
+-	O
+maximal	O
+inhibitory	O
+concentrations	O
+in	O
+the	O
+high	O
+nanomolar	O
+or	O
+low	O
+micromolar	O
+range	O
+in	O
+enzyme	O
+-	O
+and	O
+/	O
+or	O
+cell	B-COMP
+-	O
+based	O
+assays	O
+and	O
+with	O
+high	O
+therapeutic	O
+indices	O
+.	O
+
+Pseudotyped	O
+virus	B-SPEC
+carrying	O
+S	B-PRGE
+protein	I-PRGE
+(	O
+S	O
+-	O
+pseudovirus	O
+)	O
+produced	O
+by	O
+human	B-SPEC
+cells	B-COMP
+that	O
+were	O
+treated	O
+with	O
+small	O
+interfering	O
+RNA	O
+(	O
+siRNA	O
+)	O
+for	O
+calnexin	B-PRGE
+expression	B-PROC
+(	O
+calnexin	O
+siRNA	O
+-	O
+treated	O
+cells	B-COMP
+)	O
+showed	O
+significantly	O
+lower	O
+infectivity	O
+than	O
+S	O
+-	O
+pseudoviruses	O
+produced	O
+by	O
+untreated	O
+and	O
+control	O
+siRNA	O
+-	O
+treated	O
+cells	B-COMP
+.	O
+
+S	O
+-	O
+pseudovirus	O
+produced	O
+by	O
+calnexin	B-PRGE
+siRNA	I-PRGE
+-	O
+treated	O
+cells	B-COMP
+contained	O
+S	O
+protein	O
+modified	O
+with	O
+N	B-CHED
+-	I-CHED
+glycan	I-CHED
+side	O
+chains	O
+differently	O
+from	O
+other	O
+two	O
+S	O
+proteins	B-CHED
+and	O
+consisted	O
+of	O
+two	O
+kinds	O
+of	O
+viral	B-COMP
+particles	I-COMP
+:	O
+those	O
+of	O
+normal	O
+density	O
+with	O
+little	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+those	O
+of	O
+high	O
+density	O
+with	O
+abundant	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+S	O
+-	O
+pseudovirus	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+produced	O
+in	O
+the	O
+presence	O
+of	O
+α	B-PRGE
+-	I-PRGE
+glucosidase	I-PRGE
+inhibitors	B-CHED
+,	O
+which	O
+disrupt	O
+the	O
+interaction	O
+between	O
+calnexin	B-PRGE
+and	O
+its	O
+substrates	O
+,	O
+showed	O
+significantly	O
+lower	O
+infectivity	O
+than	O
+each	O
+virus	B-SPEC
+produced	O
+in	O
+the	O
+absence	O
+of	O
+those	O
+compounds	O
+.	O
+
+In	O
+S	O
+-	O
+pseudovirus	O
+,	O
+the	O
+incorporation	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+into	O
+viral	B-COMP
+particles	I-COMP
+was	O
+obviously	O
+inhibited	O
+.	O
+
+In	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+viral	O
+production	O
+was	O
+obviously	O
+inhibited	O
+.	O
+
+Intranasal	O
+pretreatment	O
+of	O
+aged	O
+mice	B-SPEC
+with	O
+poly	O
+(	O
+I	O
+·	O
+C	O
+)	O
+(	O
+a	O
+TLR3	B-PRGE
+agonist	B-CHED
+)	O
+and	O
+,	O
+to	O
+a	O
+lesser	O
+extent	O
+,	O
+CpG	O
+,	O
+R848	O
+,	O
+or	O
+lipopolysaccharide	B-CHED
+(	O
+TLR9	B-PRGE
+,	O
+TLR7	B-PRGE
+/	I-PRGE
+8	I-PRGE
+,	O
+or	O
+TLR4	B-PRGE
+agonists	B-CHED
+),	O
+provided	O
+a	O
+high	O
+level	O
+of	O
+protection	O
+[	O
+90	O
+%	O
+to	O
+100	O
+%	O
+survival	O
+rate	O
+after	O
+poly	O
+(	O
+I	O
+·	O
+C	O
+)	O
+treatment	O
+]	O
+against	O
+lethal	O
+MA15	O
+or	O
+IAV	O
+challenge	O
+and	O
+reduced	O
+pathological	O
+changes	O
+and	O
+virus	B-SPEC
+loads	O
+in	O
+the	O
+lungs	B-ANAT
+at	O
+early	O
+times	O
+after	O
+infection	B-DISO
+.	O
+
+From	O
+mRNA	B-CHED
+-	O
+1	O
+,	O
+1a	O
+as	O
+well	O
+as	O
+1a	O
++	O
+1b	O
+are	O
+translated	O
+;	O
+the	O
+latter	O
+1a	O
++	O
+1b	O
+results	O
+from	O
+the	O
+translation	B-PROC
+due	O
+to	O
+ribosomal	B-COMP
+frame	O
+-	O
+shifting	O
+facilitated	O
+by	O
+the	O
+pseudoknot	O
+structure	O
+.	O
+
+TITLE	O
+:	O
+One	O
+hundred	O
+ten	O
+days	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+a	O
+young	O
+woman	O
+with	O
+postpartum	O
+cerebral	O
+venous	B-ANAT
+thrombosis	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+antigen	B-CHED
+characteristics	O
+of	O
+different	O
+fragments	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+expressed	B-PROC
+in	O
+E	O
+.	O
+Coli	O
+and	O
+their	O
+application	O
+in	O
+the	O
+serological	O
+diagnosis	O
+.	O
+
+Western	O
+-	O
+Bolt	O
+results	O
+show	O
+that	O
+all	O
+the	O
+six	O
+fragments	O
+have	O
+reacted	O
+with	O
+the	O
+SARS	B-DISO
+patient	O
+convalescent	O
+sera	B-COMP
+,	O
+but	O
+the	O
+PN360	O
+and	O
+PN301	O
+showed	O
+obvious	O
+cross	B-PROC
+-	I-PROC
+reaction	I-PROC
+with	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+negative	O
+normal	O
+adults	O
+;	O
+sensitivity	O
+analysis	O
+using	O
+an	O
+ELISA	O
+coating	O
+with	O
+PN199	O
+,	O
+PN185	O
+,	O
+PN155b	O
+,	O
+PN125	O
+as	O
+antigen	O
+showed	O
+that	O
+the	O
+PN185	O
+and	O
+PN155b	O
+are	O
+better	O
+than	O
+PN125	O
+.	O
+
+RESULTS	O
+:	O
+An	O
+immunochromatographic	O
+strip	O
+was	O
+developed	O
+for	O
+the	O
+detection	O
+of	O
+PHE	B-CHED
+-	O
+CoV	O
+.	O
+The	O
+colloidal	B-CHED
+gold	I-CHED
+-	O
+labeled	O
+MAb	O
+4D4	O
+was	O
+used	O
+as	O
+the	O
+detection	O
+reagent	B-CHED
+,	O
+and	O
+the	O
+MAb	O
+1E2	O
+and	O
+goat	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+mouse	B-SPEC
+IgG	I-PRGE
+coated	O
+the	O
+strip	O
+'	O
+s	O
+test	O
+and	O
+control	O
+lines	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Moutan	O
+cortex	B-ANAT
+radicis	O
+improves	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+rats	B-SPEC
+through	O
+anti	O
+-	O
+inflammation	O
+.	O
+
+MCR	O
+was	O
+orally	B-ANAT
+administered	O
+before	O
+and	O
+after	O
+LPS	B-DISO
+was	O
+introduced	O
+into	O
+rats	B-SPEC
+(	O
+MCR	O
+-	O
+LPS	B-DISO
+group	O
+and	O
+LPS	B-DISO
+-	O
+MCR	O
+group	O
+,	O
+respectively	O
+).	O
+
+This	O
+report	O
+describes	O
+the	O
+complete	O
+genome	O
+sequence	O
+of	O
+GD	O
+-	O
+A	O
+,	O
+and	O
+the	O
+data	O
+will	O
+provide	O
+important	O
+insights	O
+into	O
+the	O
+variation	O
+of	O
+PEDV	B-SPEC
+field	O
+isolates	O
+in	O
+southern	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Zoonotic	O
+diseases	O
+continue	O
+to	O
+emerge	O
+and	O
+threaten	O
+both	O
+human	O
+and	O
+animal	B-SPEC
+health	O
+.	O
+
+All	O
+study	O
+subjects	O
+were	O
+negative	O
+for	O
+antibodies	B-COMP
+against	O
+CRCoV	O
+by	O
+this	O
+competitive	O
+ELISA	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+enrolled	O
+1006	O
+children	O
+less	O
+than	O
+5	O
+years	O
+of	O
+age	O
+of	O
+whom	O
+423	O
+(	O
+42	O
+%),	O
+428	O
+(	O
+42	O
+%)	O
+and	O
+155	O
+(	O
+16	O
+%)	O
+had	O
+pneumonia	B-DISO
+,	O
+bronchiolitis	B-DISO
+and	O
+unclassified	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+respectively	O
+.	O
+
+Patients	O
+may	O
+have	O
+ARDS	B-DISO
+if	O
+the	O
+onset	O
+is	O
+within	O
+1	O
+week	O
+of	O
+a	O
+known	O
+clinical	O
+insult	O
+or	O
+new	O
+/	O
+worsening	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+In	O
+general	O
+,	O
+little	O
+sequence	O
+changes	O
+were	O
+noted	O
+,	O
+most	O
+could	O
+be	O
+attributed	O
+to	O
+genetic	B-PROC
+drift	I-PROC
+,	O
+since	O
+the	O
+clinical	O
+isolates	O
+originate	O
+from	O
+2009	O
+to	O
+2010	O
+and	O
+VR740	O
+from	O
+1962	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+M	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)-	I-PRGE
+C	I-PRGE
+can	O
+reversibly	O
+interconvert	O
+between	O
+these	O
+two	O
+topological	O
+states	O
+under	O
+physiological	O
+conditions	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+inhibitory	O
+effect	O
+of	O
+short	O
+hairpin	O
+RNAs	O
+(	O
+shRNAs	O
+)	O
+targeting	B-PROC
+the	O
+ORF	B-PRGE
+7	I-PRGE
+gene	I-PRGE
+of	O
+TGEV	B-SPEC
+on	O
+virus	B-PROC
+replication	I-PROC
+was	O
+examined	O
+.	O
+
+Our	O
+results	O
+indicated	O
+that	O
+plasmid	O
+-	O
+transcribed	O
+shRNAs	O
+targeting	B-PROC
+the	O
+ORF	B-PRGE
+7	I-PRGE
+gene	I-PRGE
+in	O
+the	O
+TGEV	B-SPEC
+genome	O
+effectively	O
+inhibited	O
+expression	B-PROC
+of	O
+the	O
+viral	O
+target	O
+gene	O
+and	O
+viral	B-PROC
+replication	I-PROC
+in	O
+vitro	O
+.	O
+
+These	O
+findings	O
+provide	O
+evidence	O
+that	O
+the	O
+shRNAs	O
+have	O
+potential	O
+therapeutic	O
+application	O
+for	O
+treatment	O
+of	O
+TGE	B-DISO
+.	O
+
+SOFA	O
+scores	O
+over	O
+the	O
+first	O
+2	O
+weeks	O
+in	O
+the	O
+ICU	O
+indicate	O
+more	O
+severe	O
+organ	B-DISO
+failure	I-DISO
+in	O
+the	O
+noninfluenza	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+017	O
+).	O
+
+The	O
+noninfluenza	O
+group	O
+tended	O
+to	O
+have	O
+higher	O
+overall	O
+charges	O
+,	O
+including	O
+significantly	O
+higher	O
+cost	O
+of	O
+blood	B-ANAT
+products	O
+in	O
+the	O
+ICU	O
+.	O
+
+ALI	O
+/	O
+ARDS	B-DISO
+secondary	O
+to	O
+pandemic	O
+influenza	B-PATH
+infection	B-DISO
+is	O
+associated	O
+with	O
+more	O
+severe	O
+respiratory	O
+compromise	O
+but	O
+has	O
+lower	O
+overall	O
+acuity	O
+and	O
+better	O
+survival	O
+rates	O
+than	O
+ALI	O
+/	O
+ARDS	B-DISO
+due	O
+to	O
+other	O
+causes	O
+.	O
+
+Underlying	O
+conditions	O
+included	O
+hematologic	B-DISO
+malignancies	I-DISO
+(	O
+n	O
+=	O
+21	O
+),	O
+vasculitis	B-DISO
+(	O
+n	O
+=	O
+13	O
+),	O
+and	O
+solid	B-DISO
+tumors	I-DISO
+(	O
+n	O
+=	O
+13	O
+).	O
+
+Most	O
+patients	O
+were	O
+receiving	O
+systemic	O
+corticosteroids	B-CHED
+(	O
+n	O
+=	O
+63	O
+)	O
+and	O
+cytotoxic	O
+drugs	O
+(	O
+n	O
+=	O
+51	O
+).	O
+
+Pulmonary	B-ANAT
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+HSV	B-SPEC
+or	O
+CMV	B-SPEC
+may	O
+contribute	O
+to	O
+fatal	O
+outcome	O
+.	O
+
+The	O
+elevation	O
+of	O
+CK	O
+and	O
+CK	B-FUNC
+-	I-FUNC
+MB	I-FUNC
+in	O
+serum	B-COMP
+could	O
+not	O
+be	O
+judged	O
+as	O
+the	O
+criteria	O
+of	O
+myocardial	O
+damage	O
+in	O
+AOPP	O
+,	O
+the	O
+ratio	O
+of	O
+CK	B-FUNC
+-	I-FUNC
+MB	I-FUNC
+to	O
+CK	O
+were	O
+more	O
+valuable	O
+;	O
+the	O
+value	O
+of	O
+cTnI	B-PRGE
+in	O
+myocardial	O
+damage	O
+was	O
+still	O
+in	O
+suspect	O
+.	O
+
+To	O
+investigate	O
+possible	O
+interspecies	O
+transmission	O
+between	O
+the	O
+two	O
+bat	B-ENZY
+species	B-SPEC
+,	O
+the	O
+complete	O
+genomes	O
+of	O
+two	O
+Ro	O
+-	O
+BatCoV	O
+HKU10	O
+and	O
+six	O
+Hi	O
+-	O
+BatCoV	O
+HKU10	O
+strains	O
+were	O
+sequenced	O
+.	O
+
+Treatment	O
+with	O
+SB203580	O
+and	O
+U0126	B-CHED
+reduced	O
+PLpro	O
+-	O
+induced	O
+expression	B-PROC
+of	O
+TGF	O
+-	O
+β1	O
+,	O
+vimentin	B-COMP
+,	O
+and	O
+type	B-PRGE
+I	I-PRGE
+collagen	I-PRGE
+.	O
+
+Although	O
+swine	B-SPEC
+are	O
+widely	O
+recognized	O
+as	O
+a	O
+potential	O
+host	B-COMP
+for	O
+generating	O
+novel	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+and	O
+that	O
+some	O
+of	O
+these	O
+viruses	B-SPEC
+,	O
+including	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+2009	O
+,	O
+have	O
+been	O
+shown	O
+to	O
+be	O
+readily	O
+transmissible	O
+between	O
+humans	B-SPEC
+and	O
+swine	B-SPEC
+,	O
+only	O
+one	O
+study	O
+was	O
+found	O
+related	O
+to	O
+the	O
+modelling	O
+of	O
+influenza	B-DISO
+spread	O
+at	O
+the	O
+swine	B-SPEC
+-	O
+human	B-SPEC
+interface	O
+.	O
+
+NMBAs	O
+have	O
+been	O
+shown	O
+to	O
+improve	O
+oxygenation	B-PROC
+during	O
+severe	O
+ARDS	B-DISO
+in	O
+three	O
+randomized	O
+controlled	O
+trials	O
+.	O
+
+NMBAs	O
+have	O
+not	O
+been	O
+shown	O
+to	O
+be	O
+an	O
+independent	O
+risk	O
+factor	O
+of	O
+neuromyopathy	B-DISO
+in	O
+most	O
+studies	O
+.	O
+
+NMBAs	O
+are	O
+commonly	O
+used	O
+in	O
+ARDS	B-DISO
+(	O
+25	O
+-	O
+55	O
+%	O
+of	O
+patients	O
+),	O
+but	O
+the	O
+benefits	O
+and	O
+the	O
+risks	O
+of	O
+using	O
+these	O
+agents	O
+are	O
+controversial	O
+.	O
+
+NMBAs	O
+do	O
+not	O
+appear	O
+to	O
+be	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+ICU	O
+-	O
+acquired	O
+weakness	O
+if	O
+they	O
+are	O
+not	O
+given	O
+with	O
+corticosteroids	B-CHED
+or	O
+in	O
+patients	O
+with	O
+hyperglycaemia	B-DISO
+.	O
+
+We	O
+used	O
+mice	B-SPEC
+lacking	O
+functional	O
+receptors	O
+for	O
+both	O
+type	B-PRGE
+I	I-PRGE
+and	I-PRGE
+type	I-PRGE
+III	I-PRGE
+IFN	I-PRGE
+(	O
+double	O
+knockout	O
+,	O
+dKO	O
+)	O
+to	O
+evaluate	O
+the	O
+possibility	O
+that	O
+type	B-PRGE
+III	I-PRGE
+IFN	I-PRGE
+plays	O
+a	O
+decisive	O
+role	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protection	O
+.	O
+
+TITLE	O
+:	O
+Goal	O
+-	O
+oriented	O
+respiratory	O
+management	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+,	O
+based	O
+on	O
+relevant	O
+literature	O
+articles	O
+and	O
+the	O
+authors	O
+'	O
+clinical	O
+experience	O
+,	O
+presents	O
+a	O
+goal	O
+-	O
+oriented	O
+respiratory	O
+management	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+that	O
+can	O
+help	O
+improve	O
+clinicians	O
+'	O
+ability	O
+to	O
+care	O
+for	O
+these	O
+patients	O
+.	O
+
+Early	O
+recognition	O
+of	O
+ARDS	B-DISO
+modified	O
+risk	O
+factors	O
+and	O
+avoidance	O
+of	O
+aggravating	O
+factors	O
+during	O
+hospital	O
+stay	O
+such	O
+as	O
+nonprotective	O
+mechanical	O
+ventilation	O
+,	O
+multiple	O
+blood	B-ANAT
+products	O
+transfusions	O
+,	O
+positive	O
+fluid	B-PROC
+balance	I-PROC
+,	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+,	O
+and	O
+gastric	B-ANAT
+aspiration	B-DISO
+can	O
+help	O
+decrease	O
+its	O
+incidence	O
+.	O
+
+TITLE	O
+:	O
+WFDC1	B-PRGE
+/	O
+ps20	B-PRGE
+:	O
+a	O
+host	B-COMP
+factor	O
+that	O
+influences	O
+the	O
+neutrophil	B-ANAT
+response	O
+to	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	O
+)	O
+1	O
+infection	B-DISO
+.	O
+
+Herein	O
+we	O
+describe	O
+a	O
+contrasting	O
+role	O
+for	O
+ps20	O
+in	O
+limiting	O
+MHV	B-SPEC
+-	O
+1	O
+infection	B-DISO
+.	O
+
+Accordingly	O
+,	O
+we	O
+examined	O
+MHV	B-SPEC
+-	O
+1	O
+infection	B-DISO
+of	O
+neutrophils	B-ANAT
+and	O
+provide	O
+evidence	O
+that	O
+neutrophils	B-ANAT
+isolated	O
+from	O
+ps20	O
+(-/-)	O
+mice	B-SPEC
+are	O
+more	O
+susceptible	O
+to	O
+MHV	B-SPEC
+-	O
+1	O
+infection	B-DISO
+than	O
+neutrophils	B-ANAT
+isolated	O
+from	O
+ps20	O
+(+/+)	O
+mice	B-SPEC
+.	O
+
+The	O
+rate	O
+of	O
+antimicrobial	B-CHED
+resistance	B-PROC
+among	O
+Enterobacteriaceae	B-SPEC
+also	O
+increased	O
+significantly	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+After	O
+controlling	O
+for	O
+potentially	O
+confounding	O
+factors	O
+,	O
+the	O
+DAI	B-PRGE
+was	O
+an	O
+independent	O
+prognostic	O
+factor	O
+for	O
+both	O
+30	O
+-	O
+day	O
+mortality	O
+(	O
+OR	O
+2	O
+.	O
+51	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+1	O
+.	O
+99	O
+-	O
+3	O
+.	O
+17	O
+,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+in	O
+-	O
+hospital	O
+mortality	O
+(	O
+OR	O
+3	O
+.	O
+61	O
+,	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+10	O
+-	O
+3	O
+.	O
+25	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Furthermore	O
+,	O
+each	O
+of	O
+S366	O
+-	O
+374	O
+was	O
+replaced	O
+by	O
+alanine	B-CHED
+(	O
+A	O
+),	O
+lysine	B-CHED
+(	O
+K	O
+)	O
+or	O
+aspartic	B-CHED
+acid	I-CHED
+(	O
+D	O
+),	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+were	O
+able	O
+to	O
+treat	O
+a	O
+patient	O
+with	O
+acute	O
+exacerbation	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+who	O
+also	O
+suffered	B-DISO
+from	O
+sleep	B-DISO
+-	I-DISO
+disordered	I-DISO
+breathing	B-PROC
+by	O
+using	O
+the	O
+average	O
+volume	O
+-	O
+assured	O
+pressure	O
+support	O
+mode	O
+of	O
+a	O
+Respironics	O
+V60	O
+Ventilator	O
+(	O
+Philips	O
+Respironics	O
+:	O
+United	O
+States	O
+).	O
+
+During	O
+the	O
+initial	O
+exacerbation	O
+,	O
+his	O
+tidal	O
+volume	O
+was	O
+significantly	O
+lower	O
+during	O
+sleep	B-PROC
+(	O
+378	O
+.	O
+9	O
+±	O
+72	O
+.	O
+9mL	O
+)	O
+than	O
+while	O
+awake	O
+(	O
+446	O
+.	O
+5	O
+±	O
+63	O
+.	O
+3mL	O
+).	O
+
+A	O
+ventilator	O
+that	O
+allows	O
+ventilation	O
+to	O
+be	O
+maintained	O
+by	O
+automatically	O
+adjusting	O
+the	O
+inspiratory	B-PROC
+force	I-PROC
+to	O
+within	O
+an	O
+acceptable	O
+range	O
+was	O
+attached	O
+in	O
+average	O
+volume	O
+-	O
+assured	O
+pressure	O
+support	O
+mode	O
+,	O
+improving	O
+his	O
+sleep	B-PROC
+-	O
+related	O
+hypoventilation	B-DISO
+,	O
+which	O
+is	O
+often	O
+associated	O
+with	O
+the	O
+use	O
+of	O
+the	O
+Respironics	O
+V60	O
+Ventilator	O
+.	O
+
+Polysomnography	O
+performed	O
+while	O
+our	O
+patient	O
+was	O
+on	O
+noninvasive	O
+positive	O
+pressure	O
+ventilation	O
+revealed	O
+obstructive	B-DISO
+sleep	I-DISO
+apnea	I-DISO
+syndrome	I-DISO
+(	O
+apnea	B-DISO
+-	O
+hypopnea	O
+index	O
+=	O
+14	O
+),	O
+suggesting	O
+that	O
+his	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+was	O
+complicated	O
+by	O
+obstructive	B-DISO
+sleep	I-DISO
+apnea	I-DISO
+syndrome	I-DISO
+.	O
+
+On	O
+such	O
+occasions	O
+,	O
+the	O
+Respironics	O
+V60	O
+Ventilator	O
+,	O
+which	O
+is	O
+equipped	O
+with	O
+an	O
+average	O
+volume	O
+-	O
+assured	O
+pressure	O
+support	O
+mode	O
+,	O
+may	O
+be	O
+useful	O
+in	O
+improving	O
+gas	B-ENZY
+exchange	O
+and	O
+may	O
+achieve	O
+good	O
+patient	O
+compliance	O
+,	O
+because	O
+that	O
+mode	O
+allows	O
+ventilation	O
+to	O
+be	O
+maintained	O
+by	O
+automatically	O
+adjusting	O
+the	O
+inspiratory	B-PROC
+force	I-PROC
+to	O
+within	O
+an	O
+acceptable	O
+range	O
+whenever	O
+ventilation	O
+falls	O
+below	O
+target	O
+levels	O
+.	O
+
+The	O
+main	O
+clinical	O
+features	O
+included	O
+skin	B-ANAT
+purpura	B-DISO
+(	O
+100	O
+%),	O
+arthritis	B-DISO
+or	O
+arthralgia	B-DISO
+(	O
+66	O
+%),	O
+gastrointestinal	O
+manifestation	O
+(	O
+47	O
+%),	O
+orchitis	B-DISO
+(	O
+15	O
+%)	O
+of	O
+boys	O
+,	O
+and	O
+nephritis	B-DISO
+(	O
+24	O
+%).	O
+
+Eleven	O
+(	O
+14	O
+%)	O
+patients	O
+received	O
+corticosteroid	B-CHED
+therapy	O
+.	O
+
+TITLE	O
+:	O
+A	O
+framework	O
+for	O
+the	O
+study	O
+of	O
+zoonotic	O
+disease	O
+emergence	O
+and	O
+its	O
+drivers	O
+:	O
+spillover	O
+of	O
+bat	B-ENZY
+pathogens	O
+as	O
+a	O
+case	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+serious	O
+emerging	O
+zoonotic	O
+infections	O
+have	O
+recently	O
+arisen	O
+from	O
+bats	B-SPEC
+,	O
+including	O
+Ebola	O
+,	O
+Marburg	O
+,	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+,	O
+Hendra	O
+,	O
+Nipah	O
+,	O
+and	O
+a	O
+number	O
+of	O
+rabies	B-DISO
+and	O
+rabies	B-DISO
+-	O
+related	O
+viruses	B-SPEC
+,	O
+consistent	O
+with	O
+the	O
+overall	O
+observation	O
+that	O
+wildlife	O
+are	O
+an	O
+important	O
+source	O
+of	O
+emerging	O
+zoonoses	B-DISO
+for	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+Here	O
+we	O
+reported	O
+the	O
+complete	O
+genome	O
+sequences	O
+of	O
+two	O
+virulent	O
+IBV	B-SPEC
+variants	O
+from	O
+China	O
+,	O
+GX	B-PRGE
+-	I-PRGE
+YL5	I-PRGE
+and	O
+GX	O
+-	O
+YL9	O
+,	O
+belonging	O
+to	O
+different	O
+serotypes	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+diarrhea	B-DISO
+outbreak	O
+caused	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+been	O
+observed	O
+in	O
+China	O
+since	O
+December	O
+2010	O
+.	O
+
+Measurement	O
+data	O
+were	O
+processed	O
+with	O
+t	O
+test	O
+and	O
+randomized	O
+blocks	O
+analysis	O
+of	O
+variance	O
+,	O
+enumeration	O
+data	O
+were	O
+processed	O
+with	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+.	O
+
+Except	O
+for	O
+that	O
+of	O
+PBD	B-PRGE
+4	I-PRGE
+,	O
+there	O
+was	O
+no	O
+statistically	O
+significant	O
+difference	O
+between	O
+two	O
+groups	O
+in	O
+fluid	O
+intake	O
+(	O
+with	O
+F	O
+values	O
+from	O
+0	O
+.	O
+072	O
+to	O
+1	O
+.	O
+939	O
+,	O
+P	O
+values	O
+all	O
+above	O
+0	O
+.	O
+05	O
+).	O
+
+Fluid	B-PROC
+balance	I-PROC
+lowered	O
+in	O
+both	O
+groups	O
+,	O
+and	O
+it	O
+was	O
+the	O
+lowest	O
+on	O
+PBD	B-DISO
+10	O
+in	O
+control	O
+group	O
+and	O
+PBD	B-PRGE
+6	I-PRGE
+in	O
+treatment	O
+group	O
+.	O
+
+We	O
+revealed	O
+that	O
+administration	O
+of	O
+PGRN	O
+significantly	O
+reduced	O
+LPS	B-DISO
+-	O
+induced	O
+pulmonary	B-DISO
+inflammation	I-DISO
+,	O
+as	O
+reflected	O
+by	O
+reductions	O
+in	O
+total	O
+cell	B-COMP
+and	O
+neutrophil	B-ANAT
+counts	O
+,	O
+proinflammatory	O
+cytokines	O
+,	O
+as	O
+well	O
+as	O
+chemokines	O
+in	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluid	O
+.	O
+
+Consistently	O
+,	O
+we	O
+revealed	O
+a	O
+significant	O
+reduction	O
+of	O
+histopathology	O
+changes	O
+of	O
+lung	B-ANAT
+in	O
+mice	B-SPEC
+received	O
+PGRN	O
+treatment	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+were	O
+collected	O
+from	O
+a	O
+group	O
+of	O
+164	O
+children	O
+aged	O
+below	O
+3	O
+years	O
+who	O
+were	O
+hospitalized	O
+due	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+from	O
+May	O
+2009	O
+to	O
+July	O
+2010	O
+in	O
+Shanghai	O
+.	O
+
+Identified	O
+viruses	B-SPEC
+included	O
+37	O
+of	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+22	O
+.	O
+6	O
+%	O
+of	O
+cases	O
+),	O
+32	O
+of	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+19	O
+.	O
+5	O
+%),	O
+30	O
+of	O
+parainfluenzavirus	O
+-	O
+2	O
+(	O
+18	O
+.	O
+3	O
+%),	O
+23	O
+of	O
+parainfluenzavirus	O
+-	O
+3	O
+(	O
+14	O
+.	O
+0	O
+%),	O
+15	O
+of	O
+human	B-SPEC
+enterovirus	B-SPEC
+(	O
+9	O
+.	O
+1	O
+%),	O
+14	O
+each	O
+of	O
+parainfluenzavirus	O
+-	O
+1	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+B	O
+and	O
+adenovirus	B-DISO
+(	O
+8	O
+.	O
+5	O
+%),	O
+8	O
+of	O
+coronavirus	B-SPEC
+229E	O
+/	O
+NL63	O
+(	O
+4	O
+.	O
+9	O
+%),	O
+6	O
+of	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+3	O
+.	O
+7	O
+%),	O
+5	O
+each	O
+of	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+A	O
+(	O
+3	O
+.	O
+0	O
+%),	O
+3	O
+of	O
+parainfluenzavirus	O
+-	O
+4	O
+(	O
+1	O
+.	O
+8	O
+%),	O
+2	O
+of	O
+coronavirus	B-SPEC
+OC43	O
+/	O
+HKU1	O
+(	O
+1	O
+.	O
+2	O
+%),	O
+and	O
+1	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+0	O
+.	O
+6	O
+%).	O
+
+The	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+the	O
+mRT	B-ANAT
+-	O
+PCR	O
+were	O
+determined	O
+by	O
+comparing	O
+it	O
+to	O
+a	O
+rapid	O
+antigen	B-CHED
+test	O
+(	O
+RAT	B-SPEC
+)	O
+or	O
+immuno	O
+-	O
+chromatography	O
+test	O
+kit	B-FUNC
+and	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+in	O
+the	O
+detection	O
+of	O
+CDV	B-CHED
+,	O
+CRCoV	O
+and	O
+CIV	B-SPEC
+antigens	B-CHED
+present	O
+in	O
+100	O
+clinical	O
+samples	O
+(	O
+nasal	B-ANAT
+swabs	O
+and	O
+whole	O
+blood	B-ANAT
+samples	I-ANAT
+)	O
+from	O
+50	O
+dogs	B-SPEC
+with	O
+respiratory	B-DISO
+disease	I-DISO
+symptoms	O
+.	O
+
+This	O
+study	O
+revealed	O
+that	O
+mRT	B-ANAT
+-	O
+PCR	O
+had	O
+almost	O
+exactly	O
+the	O
+same	O
+performance	O
+or	O
+results	O
+were	O
+almost	O
+100	O
+%	O
+in	O
+agreement	O
+with	O
+that	O
+of	O
+RT	O
+-	O
+PCR	O
+and	O
+RAT	B-SPEC
+both	O
+in	O
+terms	O
+of	O
+the	O
+assay	O
+sensitivity	O
+and	O
+specificity	O
+which	O
+was	O
+more	O
+highly	O
+evident	O
+in	O
+detecting	O
+CIV	O
+,	O
+CDV	B-CHED
+and	O
+CRCoV	O
+antigens	B-CHED
+present	O
+in	O
+canine	O
+nasal	B-ANAT
+swab	O
+samples	O
+.	O
+
+Of	O
+the	O
+isolated	O
+diarylheptanoids	O
+,	O
+hirsutenone	O
+(	O
+2	O
+)	O
+showed	O
+the	O
+most	O
+potent	O
+PL	O
+(	O
+pro	B-CHED
+)	O
+inhibitory	O
+activity	O
+,	O
+with	O
+an	O
+inhibitory	O
+concentration	O
+(	O
+IC	O
+(	O
+50	O
+))	O
+value	O
+of	O
+4	O
+.	O
+1	O
+µM	O
+.	O
+Structure	O
+-	O
+activity	O
+analysis	O
+showed	O
+that	O
+catechol	B-CHED
+and	O
+α	O
+,	O
+β	O
+-	O
+unsaturated	O
+carbonyl	B-CHED
+moiety	O
+in	O
+the	O
+molecule	O
+were	O
+the	O
+key	O
+requirement	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+cysteine	B-CHED
+protease	I-PRGE
+inhibition	B-PROC
+.	O
+
+In	O
+the	O
+O2	O
+-	O
+PS	O
+group	O
+,	O
+the	O
+breathing	B-PROC
+rates	O
+and	O
+lung	B-ANAT
+injury	O
+scores	O
+were	O
+significantly	O
+lower	O
+than	O
+that	O
+of	O
+the	O
+air	B-CHED
+-	O
+PS	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	B-DISO
+diseases	I-DISO
+are	O
+important	O
+threats	O
+to	O
+public	O
+health	O
+worldwide	O
+.	O
+
+Abused	O
+children	O
+have	O
+to	O
+be	O
+considered	O
+as	O
+potentially	O
+immunologically	O
+impaired	B-DISO
+patients	O
+;	O
+therefore	O
+,	O
+it	O
+is	O
+very	O
+important	O
+to	O
+screen	O
+them	O
+for	O
+opportunistic	B-DISO
+infections	I-DISO
+.	O
+
+Moreover	O
+,	O
+a	O
+history	O
+of	O
+unusual	O
+or	O
+recurring	O
+infections	B-DISO
+may	O
+indicate	O
+abuse	B-DISO
+,	O
+especially	O
+neglect	O
+or	O
+malnutrition	B-DISO
+.	O
+
+Thus	O
+,	O
+there	O
+is	O
+a	O
+need	O
+for	O
+multidisciplinary	O
+cooperation	O
+to	O
+ensure	O
+the	O
+early	O
+identification	O
+and	O
+prevention	O
+of	O
+child	B-DISO
+abuse	I-DISO
+.	O
+
+TITLE	O
+:	O
+Potential	O
+cross	O
+-	O
+reactivity	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+nucleocapsid	O
+(	O
+N	O
+)-	O
+based	O
+IgG	B-PRGE
+ELISA	O
+assay	O
+for	O
+plasma	B-ANAT
+samples	O
+from	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+positive	O
+intravenous	O
+drug	O
+users	O
+(	O
+IDUs	O
+).	O
+
+ABSTRACT	O
+:	O
+to	O
+evaluate	O
+the	O
+specificity	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+-	O
+based	O
+IgG	B-PRGE
+ELISA	O
+assay	O
+for	O
+detection	O
+of	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+(	O
+IgG	B-PRGE
+)	O
+in	O
+plasma	B-ANAT
+samples	O
+obtained	O
+from	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+positive	O
+and	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+negative	O
+intravenous	O
+drug	O
+users	O
+(	O
+IDUs	O
+).	O
+
+The	O
+6x	O
+His	O
+-	O
+tagged	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+expressed	B-PROC
+by	O
+inducing	O
+the	O
+bacterial	O
+cells	B-COMP
+with	O
+isopropyl	B-CHED
+-	O
+1	O
+-	O
+thio	B-CHED
+-	O
+D	O
+-	O
+galactopyranoside	O
+(	O
+IPTG	B-CHED
+)	O
+and	O
+purified	O
+by	O
+Ni	O
+-	O
+NTA	B-CHED
+affinity	O
+resin	O
+.	O
+
+TITLE	O
+:	O
+Surveillance	O
+and	O
+genome	O
+analysis	O
+of	O
+human	B-SPEC
+bocavirus	I-SPEC
+in	O
+patients	O
+with	O
+respiratory	B-DISO
+infection	I-DISO
+in	O
+Guangzhou	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+understanding	O
+of	O
+disaster	O
+medicine	B-CHED
+and	O
+the	O
+health	O
+care	O
+system	O
+during	O
+mass	O
+-	O
+casualty	O
+events	O
+is	O
+vital	O
+to	O
+a	O
+successful	O
+disaster	O
+response	O
+,	O
+and	O
+has	O
+been	O
+recommended	O
+as	O
+an	O
+integral	O
+part	O
+of	O
+the	O
+medical	O
+curriculum	O
+by	O
+the	O
+Association	O
+of	O
+American	O
+Medical	O
+Colleges	O
+(	O
+AAMC	O
+).	O
+
+Of	O
+those	O
+schools	O
+that	O
+included	O
+disaster	O
+medicine	B-CHED
+in	O
+their	O
+curricula	O
+,	O
+20	O
+.	O
+7	O
+%	O
+offered	O
+disaster	O
+material	O
+as	O
+required	O
+course	O
+work	O
+,	O
+and	O
+17	O
+.	O
+2	O
+%	O
+offered	O
+it	O
+as	O
+elective	O
+course	O
+work	O
+.	O
+
+Only	O
+a	O
+small	O
+percentage	O
+of	O
+US	O
+medical	O
+schools	O
+currently	O
+include	O
+disaster	O
+medicine	B-CHED
+in	O
+their	O
+core	O
+curriculum	O
+,	O
+and	O
+even	O
+fewer	O
+medical	O
+schools	O
+have	O
+incorporated	O
+or	O
+adopted	O
+competency	O
+-	O
+based	O
+training	O
+within	O
+their	O
+disaster	O
+medicine	B-CHED
+lecture	O
+topics	O
+and	O
+curricula	O
+.	O
+
+ABSTRACT	O
+:	O
+Programmed	O
+-	O
+1	O
+frameshifting	O
+,	O
+whereby	O
+the	O
+reading	O
+frame	O
+of	O
+a	O
+ribosome	B-COMP
+on	O
+messenger	B-CHED
+RNA	I-CHED
+is	O
+shifted	O
+in	O
+order	B-SPEC
+to	O
+generate	O
+an	O
+alternate	O
+gene	O
+product	O
+,	O
+is	O
+often	O
+triggered	O
+by	O
+a	O
+pseudoknot	O
+structure	O
+in	O
+the	O
+mRNA	B-CHED
+in	O
+combination	O
+with	O
+an	O
+upstream	O
+slippery	O
+sequence	O
+.	O
+
+This	O
+result	O
+shows	O
+that	O
+there	O
+is	O
+a	O
+considerable	O
+incidence	O
+of	O
+viral	O
+pathogens	O
+in	O
+pulmonary	B-ANAT
+exacerbations	O
+in	O
+adult	O
+CF	O
+patients	O
+.	O
+
+Newly	O
+identified	O
+viruses	B-SPEC
+such	O
+as	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+human	B-SPEC
+bocavirus	I-SPEC
+,	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+were	O
+not	O
+detected	O
+in	O
+our	O
+population	O
+,	O
+except	O
+for	O
+1	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+.	O
+
+These	O
+observations	O
+support	O
+the	O
+hypothesis	O
+that	O
+human	B-SPEC
+CoVs	O
+are	O
+capable	O
+of	O
+establishing	O
+zoonotic	O
+-	O
+reverse	O
+zoonotic	O
+transmission	O
+cycles	O
+that	O
+may	O
+allow	O
+some	O
+CoVs	O
+to	O
+readily	O
+circulate	O
+and	O
+exchange	O
+genetic	O
+material	O
+between	O
+strains	O
+found	O
+in	O
+bats	B-SPEC
+and	O
+other	O
+mammals	B-SPEC
+,	O
+including	O
+humans	B-SPEC
+.	O
+
+These	O
+antibody	B-PROC
+responses	I-PROC
+are	O
+comparable	O
+to	O
+those	O
+induced	O
+by	O
+intranasal	O
+(	O
+i	O
+.	O
+n	O
+.)	O
+administration	O
+.	O
+
+immunization	O
+with	O
+rADV	O
+did	O
+not	O
+redirect	O
+the	O
+rADV	O
+vector	O
+to	O
+the	O
+olfactory	B-ANAT
+bulb	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+cellular	B-PRGE
+furin	B-ENZY
+content	O
+as	O
+a	O
+potential	O
+factor	O
+determining	O
+the	O
+susceptibility	O
+of	O
+cultured	O
+human	O
+and	O
+animal	B-SPEC
+cells	B-COMP
+to	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-DISO
+infection	I-DISO
+.	O
+
+In	O
+other	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+the	O
+virus	B-SPEC
+cannot	O
+be	O
+propagated	O
+beyond	O
+passage	O
+5	O
+.	O
+
+Cleavage	B-PROC
+of	O
+IBV	B-SPEC
+spike	O
+protein	B-CHED
+by	O
+furin	B-PRGE
+may	O
+contribute	O
+to	O
+the	O
+productive	O
+IBV	B-SPEC
+infection	B-DISO
+in	O
+these	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+rise	O
+in	O
+influenza	B-DISO
+morbidity	O
+became	O
+a	O
+topical	O
+problem	O
+again	O
+after	O
+the	O
+identification	O
+of	O
+a	O
+new	O
+H1N1	B-PRGE
+swl	I-PRGE
+strain	O
+in	O
+California	B-SPEC
+in	O
+2009	O
+.	O
+
+Coronavirus	B-SPEC
+NL63	O
+infection	B-DISO
+exists	O
+in	O
+hospitalized	O
+children	O
+with	O
+acute	B-DISO
+lower	I-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+Changsha	O
+.	O
+
+The	O
+peak	O
+of	O
+prevalence	O
+of	O
+the	O
+coronavirus	B-SPEC
+NL63	O
+was	O
+in	O
+summer	O
+.	O
+
+BCoV	O
+was	O
+detected	O
+in	O
+nasal	B-ANAT
+swabs	O
+and	O
+pulmonary	B-ANAT
+lesions	O
+using	O
+real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+assay	O
+and	O
+virus	B-SPEC
+isolation	O
+.	O
+
+RESULTS	O
+:	O
+BCoV	O
+was	O
+detected	O
+in	O
+nasal	B-ANAT
+swabs	O
+and	O
+pulmonary	B-ANAT
+lesions	O
+using	O
+real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+assay	O
+and	O
+virus	B-SPEC
+isolation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+is	O
+believed	O
+to	O
+be	O
+the	O
+first	O
+report	O
+of	O
+BCoV	O
+in	O
+association	O
+with	O
+bovine	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+complex	I-DISO
+in	O
+Australia	O
+.	O
+
+TITLE	O
+:	O
+Sigmoid	B-ANAT
+diverticulitis	B-DISO
+perforation	O
+in	O
+burns	O
+:	O
+case	O
+reports	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+.	O
+
+ABSTRACT	O
+:	O
+Burned	O
+patients	O
+are	O
+prone	O
+to	O
+develop	O
+severe	O
+intestinal	O
+complications	O
+because	O
+of	O
+decreased	O
+splanchnic	B-PROC
+circulation	I-PROC
+.	O
+
+Moreover	O
+,	O
+the	O
+severe	B-DISO
+sepsis	I-DISO
+group	O
+appeared	O
+to	O
+have	O
+a	O
+higher	O
+level	O
+of	O
+sCD163	O
+compared	O
+with	O
+that	O
+in	O
+the	O
+sepsis	B-DISO
+group	O
+(	O
+76	O
+.	O
+2	O
+;	O
+47	O
+.	O
+2	O
+-	O
+167	O
+.	O
+5	O
+ng	O
+/	O
+ml	O
+vs	O
+.	O
+74	O
+.	O
+2	O
+;	O
+46	O
+.	O
+2	O
+-	O
+131	O
+.	O
+6	O
+ng	O
+/	O
+ml	O
+),	O
+but	O
+this	O
+was	O
+not	O
+significant	O
+.	O
+
+We	O
+have	O
+shown	O
+that	O
+STAT1	B-PRGE
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+severity	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+pathogenesis	B-DISO
+and	O
+that	O
+it	O
+is	O
+independent	O
+of	O
+the	O
+role	O
+of	O
+STAT1	B-PRGE
+in	O
+interferon	B-PATH
+signaling	B-PROC
+.	O
+
+Mice	B-SPEC
+with	O
+STAT1	B-PRGE
+in	O
+either	O
+monocytes	B-ANAT
+and	O
+macrophages	B-ANAT
+(	O
+LysM	B-PRGE
+/	O
+STAT1	B-PRGE
+)	O
+or	O
+ciliated	O
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+FoxJ1	B-PRGE
+/	O
+STAT1	B-PRGE
+)	O
+deleted	O
+were	O
+created	O
+.	O
+
+STAT6	B-PRGE
+is	O
+essential	O
+for	O
+the	O
+development	B-PROC
+of	O
+AA	O
+macrophages	B-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+Treatment	O
+with	O
+inhaled	B-PROC
+epoprostenol	B-CHED
+improved	O
+gas	B-ENZY
+exchange	O
+in	O
+severely	O
+hypoxemic	O
+surgical	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+study	O
+of	O
+effect	O
+of	O
+penehyclidine	O
+hydrochloride	B-CHED
+and	O
+atropine	B-CHED
+sequential	O
+therapy	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	O
+organophosphorus	O
+pesticide	O
+poisoning	O
+].	O
+
+This	O
+work	O
+compared	O
+two	O
+different	O
+routes	O
+of	O
+infection	B-DISO
+(	O
+intratracheal	O
+versus	O
+eye	B-ANAT
+drop	O
+)	O
+in	O
+commercial	O
+pullets	O
+,	O
+looking	O
+for	O
+differences	O
+in	O
+the	O
+pathology	B-DISO
+(	O
+air	B-ANAT
+sac	B-COMP
+and	O
+tracheal	O
+lesion	O
+scores	O
+,	O
+and	O
+tracheal	O
+mucosal	B-ANAT
+thickness	O
+)	O
+and	O
+the	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+(	O
+measured	O
+by	O
+serum	B-COMP
+plate	O
+agglutination	B-PROC
+)	O
+of	O
+the	O
+host	B-COMP
+.	O
+
+The	O
+impact	O
+of	O
+concurrent	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccination	O
+on	O
+disease	O
+outcomes	O
+was	O
+also	O
+determined	O
+.	O
+
+However	O
+,	O
+tracheal	O
+mucosal	B-ANAT
+thicknesses	O
+of	O
+intratracheally	O
+challenged	O
+pullets	O
+were	O
+not	O
+statistically	O
+different	O
+from	O
+those	O
+of	O
+the	O
+eye	B-ANAT
+drop	O
+challenged	O
+or	O
+control	O
+pullets	O
+at	O
+two	O
+and	O
+three	O
+weeks	O
+post	O
+infection	B-DISO
+.	O
+
+Vaccination	O
+of	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+with	O
+the	O
+F	O
+-	O
+strain	O
+MG	O
+vaccine	O
+completely	O
+protected	O
+them	O
+against	O
+the	O
+effects	O
+of	O
+MG	O
+intratracheal	O
+infectious	B-DISO
+challenge	O
+,	O
+as	O
+evidenced	O
+by	O
+a	O
+lack	O
+of	O
+significant	O
+difference	O
+in	O
+air	B-ANAT
+sac	B-COMP
+and	O
+tracheal	O
+lesion	O
+scores	O
+and	O
+tracheal	O
+mucosal	B-ANAT
+thickness	O
+with	O
+those	O
+of	O
+unchallenged	O
+media	B-ANAT
+control	O
+chickens	B-SPEC
+.	O
+
+The	O
+motif	O
+195WAFYVR200	O
+was	O
+the	O
+minimal	O
+requirement	O
+for	O
+reactivity	O
+,	O
+as	O
+demonstrated	O
+by	O
+removing	O
+amino	B-CHED
+acids	I-CHED
+individually	O
+from	O
+both	O
+ends	O
+of	O
+the	O
+motif	O
+193TGWAFYVR200	O
+.	O
+
+Furthermore	O
+,	O
+this	O
+epitope	B-CHED
+was	O
+highly	O
+conserved	O
+among	O
+different	O
+PEDV	B-SPEC
+strains	O
+,	O
+as	O
+shown	O
+by	O
+alignment	O
+and	O
+comparison	O
+of	O
+sequences	O
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+innate	O
+interferon	B-PRGE
+responses	O
+during	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+a	O
+vaccination	O
+and	O
+reinfection	O
+ferret	O
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+terms	O
+of	O
+its	O
+highly	O
+pathogenic	O
+nature	O
+,	O
+there	O
+remains	O
+a	O
+significant	O
+need	O
+to	O
+further	O
+define	O
+the	O
+immune	O
+pathology	B-DISO
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+,	O
+as	O
+well	O
+as	O
+identify	O
+correlates	O
+of	O
+immunity	B-PROC
+to	O
+help	O
+develop	O
+vaccines	O
+for	O
+severe	O
+coronaviral	O
+infections	B-DISO
+.	O
+
+Factors	O
+found	O
+to	O
+be	O
+associated	O
+with	O
+less	O
+willingness	O
+were	O
+:	O
+being	O
+female	O
+,	O
+being	O
+in	O
+a	O
+supportive	O
+staff	O
+position	O
+,	O
+working	O
+part	O
+-	O
+time	O
+,	O
+the	O
+peak	O
+phase	O
+of	O
+the	O
+influenza	B-DISO
+emergency	B-DISO
+,	O
+concern	O
+for	O
+family	B-SPEC
+and	O
+loved	O
+ones	O
+,	O
+and	O
+personal	O
+obligations	O
+.	O
+
+Information	O
+from	O
+this	O
+review	O
+can	O
+guide	O
+emergency	B-DISO
+policy	O
+makers	O
+,	O
+planners	O
+,	O
+and	O
+implementers	O
+in	O
+both	O
+understanding	O
+and	O
+influencing	O
+the	O
+willingness	O
+of	O
+HCP	B-DISO
+to	O
+work	O
+during	O
+an	O
+influenza	B-DISO
+public	O
+health	O
+emergency	B-DISO
+.	O
+
+A	O
+liberal	O
+fluid	O
+strategy	O
+during	O
+the	O
+early	O
+phase	O
+of	O
+comorbid	O
+septic	B-DISO
+shock	I-DISO
+,	O
+balanced	O
+with	O
+a	O
+conservative	O
+fluid	O
+strategy	O
+in	O
+patients	O
+with	O
+ALI	O
+or	O
+ARDS	B-DISO
+during	O
+the	O
+postresuscitation	O
+phase	O
+,	O
+is	O
+the	O
+optimum	O
+approach	O
+for	O
+fluid	O
+management	O
+.	O
+
+Available	O
+evidence	O
+supports	O
+an	O
+early	O
+,	O
+short	O
+course	O
+of	O
+continuous	O
+-	O
+infusion	O
+cisatracurium	O
+in	O
+patients	O
+presenting	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+nonstructural	B-PRGE
+protein	I-PRGE
+1	I-PRGE
+(	O
+nsp1	B-PRGE
+)	O
+binds	B-FUNC
+to	O
+the	O
+40S	B-COMP
+ribosomal	I-COMP
+subunit	I-COMP
+and	O
+inhibits	O
+translation	B-PROC
+,	O
+and	O
+it	O
+also	O
+induces	O
+a	O
+template	O
+-	O
+dependent	O
+endonucleolytic	O
+cleavage	B-PROC
+of	O
+host	B-COMP
+mRNAs	O
+.	O
+
+nsp1	B-PRGE
+and	O
+nsp1	B-PRGE
+-	I-PRGE
+CD	I-PRGE
+had	O
+identical	O
+inhibitory	O
+effects	O
+on	O
+mRNA	B-CHED
+templates	O
+that	O
+are	O
+resistant	O
+to	O
+nsp1	B-PRGE
+-	O
+induced	O
+RNA	O
+cleavage	B-PROC
+,	O
+implying	O
+the	O
+validity	O
+of	O
+using	O
+nsp1	O
+-	O
+CD	O
+to	O
+dissect	O
+the	O
+translation	B-PROC
+inhibition	B-PROC
+function	O
+of	O
+nsp1	B-PRGE
+.	O
+
+We	O
+have	O
+also	O
+removed	O
+from	O
+the	O
+list	O
+of	O
+HHS	B-DISO
+and	O
+overlap	O
+select	O
+agents	O
+and	O
+toxins	B-CHED
+,	O
+or	O
+excluded	O
+from	O
+compliance	O
+with	O
+part	O
+73	O
+,	O
+the	O
+agents	O
+and	O
+toxins	B-CHED
+described	O
+in	O
+the	O
+Executive	O
+Summary	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+etiology	O
+of	O
+bronchiolitis	B-DISO
+among	O
+pediatric	O
+inpatients	O
+in	O
+northern	O
+Taiwan	O
+with	O
+emphasis	O
+on	O
+newly	O
+identified	O
+respiratory	O
+viruses	O
+.	O
+
+Human	B-SPEC
+bocavirus	I-SPEC
+(	O
+hBoV	O
+)	O
+was	O
+the	O
+second	O
+most	O
+common	O
+identified	O
+virus	B-SPEC
+(	O
+in	O
+19	O
+.	O
+5	O
+%),	O
+followed	O
+by	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+),	O
+rhinovirus	B-SPEC
+,	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+and	O
+coronavirus	B-SPEC
+OC43	O
+.	O
+
+Clinical	O
+characteristics	O
+were	O
+not	O
+significantly	O
+different	O
+among	O
+the	O
+children	O
+with	O
+bronchiolitis	B-DISO
+caused	O
+by	O
+different	O
+viruses	B-SPEC
+.	O
+
+No	O
+cross	O
+-	O
+reactivity	O
+was	O
+observed	O
+with	O
+coronaviruses	O
+OC43	O
+,	O
+NL63	O
+,	O
+229E	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+nor	O
+with	O
+92	O
+clinical	O
+specimens	O
+containing	O
+common	O
+human	B-SPEC
+respiratory	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genome	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+AYU	B-SPEC
+strain	O
+isolated	O
+in	O
+Shanghai	O
+,	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+multi	O
+-	O
+epitope	B-CHED
+based	O
+peptide	B-CHED
+EpiC	O
+in	O
+Lactococcus	B-SPEC
+lactis	I-SPEC
+for	O
+oral	B-ANAT
+immunization	O
+of	O
+chickens	B-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+for	O
+the	O
+detection	O
+of	O
+astrovirus	O
+,	O
+rotavirus	B-SPEC
+,	O
+and	O
+reovirus	B-SPEC
+in	O
+turkeys	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+was	O
+undertaken	O
+to	O
+develop	O
+and	O
+validate	O
+a	O
+multiplex	O
+reverse	O
+transcription	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+mRT	B-ANAT
+-	O
+PCR	O
+)	O
+for	O
+simultaneous	O
+detection	O
+of	O
+avian	B-PRGE
+rotavirus	B-SPEC
+,	I-PRGE
+turkey	B-SPEC
+astrovirus	I-SPEC
+-	I-PRGE
+2	I-PRGE
+(	O
+TAstV	O
+-	O
+2	O
+),	O
+and	O
+avian	B-SPEC
+reovirus	I-SPEC
+.	O
+
+Primers	O
+targeting	B-PROC
+the	O
+conserved	O
+regions	O
+of	O
+NSP4	B-PRGE
+gene	I-PRGE
+of	I-PRGE
+avian	I-PRGE
+rotavirus	B-SPEC
+,	I-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+of	O
+TAstV	O
+-	O
+2	O
+,	O
+and	O
+S4	B-PRGE
+gene	I-PRGE
+of	O
+avian	B-SPEC
+reovirus	I-SPEC
+were	O
+used	O
+.	O
+
+This	O
+mRT	B-ANAT
+-	O
+PCR	O
+was	O
+found	O
+to	O
+be	O
+specific	O
+as	O
+no	O
+amplification	B-DISO
+was	O
+observed	O
+with	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+,	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+,	O
+avian	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+and	O
+intestinal	B-ANAT
+contents	I-ANAT
+of	O
+uninfected	O
+turkey	B-SPEC
+poults	O
+.	O
+
+Of	O
+the	O
+120	O
+pooled	O
+samples	O
+tested	O
+,	O
+70	O
+%	O
+were	O
+positive	O
+for	O
+TAstV	O
+-	O
+2	O
+,	O
+45	O
+%	O
+for	O
+avian	O
+rotavirus	B-SPEC
+,	O
+and	O
+18	O
+%	O
+for	O
+avian	B-SPEC
+reovirus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Novel	O
+viruses	B-SPEC
+might	O
+be	O
+responsible	O
+for	O
+numerous	O
+disease	O
+cases	O
+with	O
+unknown	O
+etiology	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+en	O
+masse	O
+lobectomy	O
+,	O
+particularly	O
+considering	O
+the	O
+constellation	O
+of	O
+pulmonary	B-ANAT
+vessels	B-ANAT
+and	O
+the	O
+bronchus	B-SPEC
+.	O
+
+Lobectomy	O
+included	O
+the	O
+right	B-ANAT
+upper	I-ANAT
+lobe	I-ANAT
+in	O
+two	O
+cases	O
+,	O
+the	O
+right	B-ANAT
+middle	I-ANAT
+lobe	I-ANAT
+in	O
+three	O
+,	O
+the	O
+right	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+in	O
+two	O
+,	O
+the	O
+right	O
+middle	O
+-	O
+lower	O
+lobe	B-ANAT
+in	O
+two	O
+,	O
+and	O
+the	O
+left	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+in	O
+three	O
+.	O
+
+TITLE	O
+:	O
+Frequency	O
+of	O
+common	O
+viruses	B-SPEC
+in	O
+etiology	O
+of	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+Sensitivity	O
+of	O
+the	O
+PCR	O
+and	O
+cell	B-COMP
+culture	O
+methods	O
+for	O
+influenzavirus	B-SPEC
+infections	B-DISO
+were	O
+detected	O
+as	O
+100	O
+%	O
+and	O
+100	O
+%,	O
+respectively	O
+.	O
+
+Forty	O
+-	O
+eight	O
+patients	O
+were	O
+diagnosed	O
+with	O
+acute	O
+inflammatory	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+Though	O
+unspecific	O
+,	O
+it	O
+could	O
+be	O
+used	O
+in	O
+a	O
+panel	O
+of	O
+markers	O
+discerning	O
+COPD	B-DISO
+smokers	O
+from	O
+healthy	O
+nonsmokers	O
+.	O
+
+Geoffroy	B-SPEC
+'	I-SPEC
+s	I-SPEC
+cats	I-SPEC
+had	O
+detectable	O
+antibody	B-COMP
+to	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+),	O
+feline	B-SPEC
+calicivirus	I-SPEC
+(	O
+FCV	B-CHED
+),	O
+feline	B-SPEC
+coronavirus	B-SPEC
+,	O
+feline	B-SPEC
+panleukopenia	I-SPEC
+virus	I-SPEC
+(	O
+FPV	B-SPEC
+),	O
+Toxoplasma	B-SPEC
+gondii	I-SPEC
+,	O
+Leptospira	B-SPEC
+interrogans	I-SPEC
+(	O
+serovars	O
+Ictero	O
+/	O
+Icter	O
+and	O
+Ballum	O
+),	O
+and	O
+Dirofilaria	B-SPEC
+immitis	I-SPEC
+.	O
+
+We	O
+encourage	O
+continued	O
+monitoring	O
+for	O
+diseases	O
+in	O
+wild	O
+and	O
+domestic	O
+carnivores	B-SPEC
+as	O
+well	O
+as	O
+preventive	O
+health	O
+care	O
+for	O
+domestic	O
+animals	B-SPEC
+,	O
+particularly	O
+in	O
+park	B-DISO
+buffer	B-CHED
+zones	O
+where	O
+overlap	O
+is	O
+greatest	O
+.	O
+
+We	O
+performed	O
+clinical	O
+evaluations	O
+and	O
+investigated	O
+the	O
+presence	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+through	O
+serology	O
+and	O
+coprologic	O
+tests	O
+on	O
+maned	O
+wolves	O
+from	O
+Galheiro	O
+Natural	O
+Private	O
+Reserve	O
+,	O
+Perdizes	O
+City	O
+,	O
+Minas	O
+Gerais	O
+State	O
+,	O
+southeastern	O
+Brazil	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+exposure	O
+to	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+in	O
+Neotropical	O
+free	O
+-	O
+ranging	O
+wild	O
+canids	B-SPEC
+.	O
+
+Recently	O
+,	O
+new	O
+evidence	O
+has	O
+shown	O
+that	O
+paralytics	O
+hold	O
+more	O
+promise	O
+when	O
+used	O
+in	O
+carefully	O
+selected	O
+lung	B-ANAT
+injury	O
+patients	O
+for	O
+brief	O
+periods	B-PROC
+of	O
+time	O
+.	O
+
+Ultimately	O
+,	O
+we	O
+conclude	O
+that	O
+NMBAs	O
+should	O
+be	O
+considered	O
+a	O
+lung	B-ANAT
+protective	O
+adjuvant	B-CHED
+in	O
+early	O
+ARDS	B-DISO
+and	O
+that	O
+clinicians	O
+should	O
+consider	O
+using	O
+an	O
+alternative	O
+NMBA	O
+to	O
+the	O
+aminosteroids	O
+in	O
+septic	B-DISO
+shock	I-DISO
+with	O
+less	O
+severe	O
+lung	B-ANAT
+injury	O
+pending	O
+further	O
+studies	O
+.	O
+
+In	O
+contrast	O
+,	O
+phylogenetic	O
+analysis	O
+based	O
+on	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+showed	O
+that	O
+L748	O
+was	O
+more	O
+closely	O
+related	O
+to	O
+the	O
+SE17	O
+type	O
+,	O
+indicating	O
+that	O
+there	O
+had	O
+been	O
+exchange	O
+of	O
+S1	O
+genetic	O
+materials	O
+between	O
+Mass	O
+-	O
+and	O
+SE17	O
+-	O
+like	O
+viruses	B-SPEC
+.	O
+
+Since	O
+70	O
+%	O
+of	O
+all	O
+emerging	O
+infectious	B-DISO
+pathogens	O
+came	O
+from	O
+animals	B-SPEC
+,	O
+the	O
+emergence	O
+of	O
+this	O
+novel	O
+virus	B-SPEC
+may	O
+represent	O
+another	O
+instance	O
+of	O
+interspecies	O
+jumping	O
+of	O
+betacoronavirus	B-SPEC
+from	O
+animals	B-SPEC
+to	O
+human	B-SPEC
+similar	O
+to	O
+the	O
+group	O
+A	O
+coronavirus	B-SPEC
+OC43	O
+possibly	O
+from	O
+a	O
+bovine	B-SPEC
+source	O
+in	O
+the	O
+1890s	O
+and	O
+the	O
+group	B-DISO
+B	I-DISO
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+2003	O
+from	O
+bat	B-ENZY
+to	O
+civet	B-SPEC
+and	O
+human	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+lung	B-ANAT
+support	O
+technologies	O
+-	O
+bridge	O
+to	O
+recovery	O
+and	O
+bridge	O
+to	O
+lung	B-ANAT
+transplantation	O
+in	O
+adult	O
+patients	O
+:	O
+an	O
+evidence	O
+-	O
+based	O
+analysis	O
+.	O
+
+For	O
+these	O
+reasons	O
+,	O
+extracorporeal	O
+lung	B-ANAT
+support	O
+technologies	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+clinical	O
+management	O
+of	O
+patients	O
+with	O
+lung	O
+failure	O
+,	O
+allowing	O
+not	O
+only	O
+the	O
+transfer	O
+of	O
+oxygen	B-CHED
+and	O
+carbon	B-CHED
+dioxide	I-CHED
+(	O
+CO	O
+(	O
+2	O
+))	O
+but	O
+also	O
+buying	O
+the	O
+lungs	B-ANAT
+the	O
+time	O
+needed	O
+to	O
+rest	B-FUNC
+and	O
+heal	B-PROC
+.	O
+
+As	O
+a	O
+bridge	O
+to	O
+recovery	O
+after	O
+LTx	O
+-	O
+used	O
+as	O
+lung	B-ANAT
+support	O
+for	O
+patients	O
+with	O
+PGD	B-CHED
+or	O
+severe	O
+hypoxemia	O
+.	O
+
+Depending	O
+on	O
+the	O
+size	O
+of	O
+the	O
+arterial	B-ANAT
+cannula	B-SPEC
+used	O
+and	O
+the	O
+mean	O
+systemic	O
+arterial	B-PROC
+pressure	I-PROC
+,	O
+a	O
+blood	B-PROC
+flow	I-PROC
+of	O
+up	O
+to	O
+2	O
+.	O
+5	O
+L	O
+/	O
+min	O
+can	O
+be	O
+achieved	O
+(	O
+up	O
+to	O
+5	O
+.	O
+5	O
+L	O
+/	O
+min	O
+with	O
+an	O
+external	O
+pump	O
+).	O
+
+The	O
+GRADE	O
+system	O
+classifies	O
+the	O
+quality	O
+of	O
+a	O
+body	B-ANAT
+of	O
+evidence	O
+as	O
+high	O
+,	O
+moderate	O
+,	O
+low	O
+,	O
+or	O
+very	O
+low	O
+according	O
+to	O
+four	O
+key	O
+elements	O
+:	O
+study	O
+design	O
+,	O
+study	O
+quality	O
+,	O
+consistency	O
+across	O
+studies	O
+,	O
+and	O
+directness	O
+.	O
+
+Six	O
+hours	O
+after	O
+initiation	O
+of	O
+ILA	B-PRGE
+,	O
+the	O
+partial	O
+pressure	O
+of	O
+CO	O
+(	O
+2	O
+)	O
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+significantly	O
+decreased	O
+(	O
+P	O
+<	O
+.	O
+05	O
+)	O
+and	O
+arterial	B-ANAT
+blood	I-ANAT
+pH	O
+significantly	O
+improved	O
+(	O
+P	O
+<	O
+.	O
+05	O
+)	O
+and	O
+remained	O
+stable	O
+for	O
+one	O
+week	O
+(	O
+last	O
+time	O
+point	O
+reported	O
+).	O
+
+(	O
+ABSTRACT	O
+TRUNCATED	O
+)	O
+RESULTS	O
+:	O
+TRIALS	O
+ON	O
+ILA	O
+:	O
+Of	O
+the	O
+seven	O
+studies	O
+identified	O
+,	O
+six	O
+involved	O
+patients	O
+with	O
+ARDS	B-DISO
+caused	O
+by	O
+a	O
+range	O
+of	O
+underlying	O
+conditions	O
+;	O
+the	O
+seventh	O
+included	O
+only	O
+patients	O
+awaiting	O
+LTx	O
+.	O
+
+Therefore	O
+,	O
+when	O
+exposure	O
+to	O
+airborne	O
+infectious	B-DISO
+pathogens	O
+is	O
+a	O
+risk	O
+,	O
+the	O
+use	O
+of	O
+an	O
+in	O
+-	O
+room	O
+air	B-CHED
+cleaner	O
+to	O
+reduce	O
+the	O
+concentration	O
+of	O
+airborne	O
+pathogens	O
+and	O
+prevent	O
+the	O
+spread	O
+of	O
+airborne	O
+infectious	B-DISO
+diseases	I-DISO
+has	O
+been	O
+proposed	O
+as	O
+an	O
+alternative	O
+to	O
+renovating	O
+a	O
+HVAC	O
+system	O
+.	O
+
+Small	O
+drops	O
+of	O
+moisture	O
+carrying	O
+infectious	B-DISO
+pathogens	O
+are	O
+called	O
+droplet	O
+nuclei	B-CHED
+.	O
+
+Droplet	O
+nuclei	B-CHED
+are	O
+about	O
+1	O
+to	O
+5μm	O
+in	O
+diameter	O
+.	O
+
+Because	O
+droplet	O
+nuclei	B-CHED
+remain	O
+airborne	O
+for	O
+longer	O
+periods	B-PROC
+than	O
+do	O
+droplets	O
+,	O
+they	O
+are	O
+more	O
+amenable	O
+to	O
+engineering	O
+infection	B-DISO
+control	O
+methods	O
+than	O
+are	O
+droplets	O
+.	O
+
+(	O
+1	O
+)	O
+The	O
+functional	O
+unit	O
+is	O
+the	O
+hydroxyl	B-CHED
+,	O
+which	O
+is	O
+a	O
+molecule	O
+comprised	O
+of	O
+one	O
+oxygen	B-CHED
+molecule	I-CHED
+and	O
+one	O
+hydrogen	B-CHED
+atom	I-CHED
+.	O
+
+The	O
+GRADE	O
+system	O
+was	O
+used	O
+to	O
+summarize	O
+the	O
+quality	O
+of	O
+the	O
+body	B-ANAT
+of	O
+evidence	O
+comprised	O
+of	O
+1	O
+or	O
+more	O
+studies	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+maternal	O
+and	O
+perinatal	O
+outcomes	O
+in	O
+obstetric	O
+patients	O
+with	O
+severe	O
+sepsis	O
+and	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+It	O
+is	O
+possible	O
+that	O
+Chinese	O
+herbs	O
+combined	O
+with	O
+Western	O
+medicines	O
+may	O
+improve	O
+symptoms	O
+,	O
+quality	O
+of	O
+life	O
+and	O
+absorption	O
+of	O
+pulmonary	B-DISO
+infiltration	I-DISO
+,	O
+and	O
+decrease	O
+the	O
+corticosteroid	B-CHED
+dosage	O
+for	O
+SARS	B-DISO
+patients	O
+.	O
+
+Ten	O
+days	O
+after	O
+last	O
+exposure	O
+,	O
+none	O
+of	O
+64	O
+close	O
+contacts	O
+had	O
+developed	O
+severe	O
+disease	O
+,	O
+with	O
+13	O
+of	O
+64	O
+reporting	O
+mild	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+respiratory	O
+illness	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+in	O
+a	O
+patient	O
+transferred	O
+to	O
+the	O
+United	O
+Kingdom	O
+from	O
+the	O
+Middle	O
+East	O
+,	O
+September	O
+2012	O
+.	O
+
+ABSTRACT	O
+:	O
+Field	O
+epidemiology	O
+involves	O
+the	O
+implementation	O
+of	O
+quick	O
+and	O
+targeted	B-PROC
+public	O
+health	O
+interventions	O
+with	O
+the	O
+aid	O
+of	O
+epidemiological	O
+methods	O
+.	O
+
+Patients	O
+aged	O
+8	O
+days	O
+to	O
+13	O
+years	O
+old	O
+who	O
+were	O
+admitted	O
+to	O
+the	O
+Department	O
+of	O
+Pediatrics	O
+with	O
+severe	O
+pneumonia	B-DISO
+were	O
+enrolled	O
+for	O
+the	O
+study	O
+.	O
+
+Upon	O
+admission	O
+,	O
+polymerase	O
+chain	O
+reaction	O
+was	O
+performed	O
+using	O
+nasopharyngeal	B-ANAT
+swabs	O
+and	O
+blood	B-ANAT
+cultures	O
+to	O
+detect	O
+respiratory	O
+viruses	B-SPEC
+and	O
+bacteria	B-SPEC
+,	O
+respectively	O
+.	O
+
+Positivity	O
+only	O
+for	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+OR	O
+=	O
+4	O
+.	O
+3	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+3	O
+-	O
+14	O
+.	O
+6	O
+)	O
+was	O
+significantly	O
+associated	O
+with	O
+fatal	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+HIV	O
+-	O
+1	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+attracting	O
+targets	O
+for	O
+the	O
+development	B-PROC
+of	O
+early	O
+phase	O
+infection	B-DISO
+inhibitors	B-CHED
+.	O
+
+The	O
+frequencies	O
+of	O
+deviations	O
+from	O
+the	O
+treatment	O
+goals	O
+were	O
+:	O
+episodes	O
+of	O
+intracranial	B-DISO
+hypertension	I-DISO
+69	O
+.	O
+5	O
+%	O
+(	O
+of	O
+monitored	O
+patients	O
+),	O
+hypotension	O
+20	O
+.	O
+3	O
+%,	O
+anaemia	B-DISO
+77	O
+.	O
+4	O
+%,	O
+hyperglycaemia	B-DISO
+42	O
+.	O
+9	O
+%,	O
+hyponatremia	O
+34	O
+.	O
+6	O
+%,	O
+hypoalbuminemia	O
+30	O
+.	O
+8	O
+%	O
+and	O
+hyperthermia	B-PROC
+54	O
+.	O
+9	O
+%.	O
+
+Pulmonary	B-DISO
+complications	I-DISO
+were	O
+common	O
+(	O
+pneumonia	B-DISO
+72	O
+.	O
+2	O
+%,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+/	O
+acute	O
+lung	B-ANAT
+injury	O
+31	O
+.	O
+6	O
+%).	O
+
+A	O
+household	O
+survey	O
+was	O
+conducted	O
+in	O
+those	O
+cases	O
+with	O
+confirmed	O
+A	O
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+,	O
+to	O
+identify	O
+contacts	O
+and	O
+history	O
+related	O
+to	O
+influenza	B-SPEC
+virus	I-SPEC
+transmission	O
+.	O
+
+Clinical	O
+diagnosis	O
+relies	O
+on	O
+the	O
+following	O
+4	O
+criteria	O
+stated	O
+by	O
+the	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+:	O
+acute	O
+onset	O
+of	O
+impaired	B-DISO
+gas	I-DISO
+exchange	I-DISO
+,	O
+severe	O
+hypoxemia	O
+defined	O
+as	O
+a	O
+PaO2	O
+to	O
+FiO2	O
+ratio	O
+<	O
+300	O
+(	O
+PaO2	O
+in	O
+mmHg	O
+),	O
+bilateral	O
+diffuse	O
+infiltration	B-DISO
+on	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+;	O
+pulmonary	B-ANAT
+artery	I-ANAT
+wedge	O
+pressure	O
+of	O
+≤	O
+18	O
+mmHg	O
+to	O
+rule	O
+out	O
+cardiogenic	O
+causes	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+Because	O
+of	O
+the	O
+extent	O
+of	O
+surgery	O
+,	O
+patients	O
+undergoing	O
+bilateral	O
+total	O
+knee	B-ANAT
+arthroplasty	O
+may	O
+be	O
+at	O
+high	O
+risk	O
+of	O
+complications	O
+.	O
+
+The	O
+level	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+was	O
+measured	O
+at	O
+baseline	O
+and	O
+at	O
+six	O
+,	O
+ten	O
+,	O
+twenty	O
+-	O
+four	O
+,	O
+and	O
+forty	O
+-	O
+eight	O
+hours	O
+postoperatively	O
+.	O
+
+TITLE	O
+:	O
+Danger	O
+-	O
+associated	O
+molecular	O
+patterns	O
+(	O
+DAMPs	O
+)	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+This	O
+review	O
+describes	O
+the	O
+function	O
+and	O
+the	O
+management	O
+of	O
+ECMO	O
+-	O
+therapy	O
+in	O
+ARDS	B-DISO
+-	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Besides	O
+being	O
+a	O
+common	O
+threat	O
+to	O
+farm	O
+animals	O
+and	O
+poultry	O
+,	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+was	O
+responsible	O
+for	O
+the	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+in	O
+2002	O
+-	O
+4	O
+.	O
+
+The	O
+incubation	O
+period	O
+helps	O
+differential	O
+diagnosis	O
+,	O
+and	O
+up	O
+to	O
+two	O
+days	O
+is	O
+suggestive	O
+of	O
+influenza	B-DISO
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+A	I-PATH
+:	O
+From	O
+highly	O
+pathogenic	O
+H5N1	B-DISO
+to	O
+pandemic	O
+2009	O
+H1N1	O
+.	O
+
+Most	O
+patients	O
+have	O
+presented	O
+with	O
+severe	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+However	O
+,	O
+in	O
+the	O
+recent	O
+two	O
+years	O
+,	O
+there	O
+was	O
+no	O
+significant	O
+progress	O
+in	O
+the	O
+development	O
+of	O
+a	O
+new	O
+drug	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Institute	O
+for	O
+Quality	O
+and	O
+Efficiency	O
+in	O
+Health	O
+Care	O
+:	O
+Executive	O
+Summaries	O
+ABSTRACT	O
+:	O
+Gestational	B-DISO
+diabetes	I-DISO
+(	O
+GDM	B-DISO
+:	O
+gestational	B-DISO
+diabetes	I-DISO
+mellitus	I-DISO
+)	O
+is	O
+generally	O
+understood	O
+to	O
+mean	O
+any	O
+impaired	B-DISO
+glucose	I-DISO
+tolerance	I-DISO
+(	O
+IGT	O
+)	O
+first	O
+occurring	O
+or	O
+diagnosed	O
+during	O
+pregnancy	O
+.	O
+
+Gestational	B-DISO
+diabetes	I-DISO
+is	O
+viewed	O
+by	O
+many	O
+professional	O
+associations	O
+as	O
+a	O
+disorder	O
+that	O
+should	O
+be	O
+diagnosed	O
+and	O
+treated	O
+,	O
+and	O
+which	O
+should	O
+be	O
+systematically	O
+identified	O
+through	O
+general	O
+screening	O
+.	O
+
+the	O
+relationship	O
+between	O
+the	O
+results	O
+of	O
+an	O
+oral	B-ANAT
+glucose	B-PROC
+tolerance	B-DISO
+test	O
+(	O
+oGTT	O
+)	O
+and	O
+maternal	O
+/	O
+baby	O
+outcomes	O
+,	O
+and	O
+4	O
+.	O
+
+ABSTRACT	O
+:	O
+Calf	B-ANAT
+diarrhea	B-DISO
+is	O
+a	O
+multifactorial	O
+disease	O
+related	O
+to	O
+a	O
+combination	O
+of	O
+host	O
+and	O
+pathogen	O
+factors	O
+.	O
+
+TITLE	O
+:	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+-	O
+induced	O
+gene	O
+3	O
+negatively	O
+regulates	O
+neuroinflammation	O
+and	O
+T	B-ANAT
+cell	I-ANAT
+activation	I-PROC
+following	O
+coronavirus	O
+-	O
+induced	O
+encephalomyelitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+31	O
+-	O
+year	O
+-	O
+old	O
+pregnant	O
+woman	O
+presented	O
+with	O
+refractory	O
+severe	O
+hypercalcemia	O
+due	O
+to	O
+an	O
+advanced	O
+neuroendocrine	B-DISO
+tumor	I-DISO
+masquerading	O
+as	O
+hyperemesis	B-DISO
+gravidarum	I-DISO
+.	O
+
+Octreotide	B-CHED
+therapy	O
+and	O
+extensive	O
+tumor	B-DISO
+debulking	O
+surgery	O
+resulted	O
+in	O
+symptom	B-DISO
+control	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+heptide	O
+repeat	O
+(	O
+HR	O
+)	O
+region	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+induces	O
+neutralizing	O
+antibodies	B-COMP
+that	O
+block	O
+the	O
+postfusion	O
+core	O
+formation	B-PROC
+and	O
+inhibit	O
+virus	B-SPEC
+entry	O
+into	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+populations	O
+are	O
+rarely	O
+exposed	O
+to	O
+one	O
+pathogen	O
+alone	O
+.	O
+
+TITLE	O
+:	O
+Workforce	O
+integration	B-PROC
+of	O
+new	O
+graduate	O
+nurses	O
+:	O
+evaluation	O
+of	O
+a	O
+health	O
+human	B-SPEC
+resources	O
+employment	O
+policy	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+facilitators	O
+and	O
+barriers	O
+to	O
+policy	O
+implementation	O
+and	O
+assess	O
+the	O
+impact	O
+of	O
+the	O
+NGG	O
+on	O
+full	O
+-	O
+time	O
+employment	O
+and	O
+workforce	O
+integration	B-PROC
+of	O
+new	O
+graduate	O
+nurses	O
+in	O
+Ontario	O
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+-	O
+related	O
+pneumonia	B-DISO
+and	O
+other	O
+complications	O
+.	O
+
+The	O
+main	O
+complications	O
+reported	O
+in	O
+hospitalized	O
+adults	O
+with	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+were	O
+pneumonia	B-DISO
+(	O
+primary	O
+influenza	B-DISO
+pneumonia	I-DISO
+and	O
+concomitant	O
+/	O
+secondary	B-DISO
+bacterial	I-DISO
+pneumonia	I-DISO
+),	O
+exacerbations	O
+of	O
+chronic	O
+pulmonary	B-DISO
+diseases	I-DISO
+(	O
+mainly	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+and	O
+asthma	B-PATH
+),	O
+the	O
+need	O
+for	O
+intensive	O
+unit	O
+care	O
+admission	O
+(	O
+including	O
+mechanical	O
+ventilation	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+),	O
+nosocomial	B-DISO
+infections	I-DISO
+and	O
+acute	O
+cardiac	B-DISO
+events	I-DISO
+.	O
+
+While	O
+9	O
+(	O
+53	O
+%)	O
+of	O
+17	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+decedents	O
+with	O
+available	O
+data	O
+had	O
+obesity	B-DISO
+and	O
+7	O
+(	O
+17	O
+%)	O
+of	O
+40	O
+had	O
+diabetes	B-DISO
+,	O
+less	O
+than	O
+4	O
+%	O
+of	O
+surviving	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+case	O
+-	O
+patients	O
+had	O
+these	O
+pre	O
+-	O
+existing	O
+conditions	O
+(	O
+p	O
+≤	O
+0	O
+.	O
+001	O
+).	O
+
+Cats	B-SPEC
+were	O
+submitted	O
+to	O
+clinical	O
+evaluations	O
+and	O
+concomitant	O
+virus	B-SPEC
+excretion	B-PROC
+assessement	O
+.	O
+
+TITLE	O
+:	O
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+for	O
+the	O
+detection	O
+of	O
+rodent	B-SPEC
+coronaviruses	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+describe	O
+clinical	O
+,	O
+hematological	O
+and	O
+fecal	O
+PCR	O
+results	O
+from	O
+161	O
+horses	B-SPEC
+involved	O
+in	O
+outbreaks	O
+associated	O
+with	O
+ECoV	O
+.	O
+The	O
+outbreaks	O
+happened	O
+at	O
+four	O
+separate	O
+boarding	O
+facilities	O
+between	O
+November	O
+2011	O
+and	O
+April	O
+2012	O
+in	O
+the	O
+States	O
+of	O
+CA	O
+,	O
+TX	O
+,	O
+WI	O
+and	O
+MA	O
+.	O
+
+Four	O
+horses	B-SPEC
+from	O
+3	O
+different	O
+outbreaks	O
+were	O
+euthanized	O
+or	O
+died	B-PROC
+due	O
+to	O
+rapid	O
+progression	O
+of	O
+clinical	O
+signs	O
+.	O
+
+Alignments	O
+of	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+from	O
+a	O
+large	O
+number	O
+of	O
+IBV	B-SPEC
+isolates	O
+indicated	O
+that	O
+the	O
+two	O
+epitopes	O
+,	O
+especially	O
+(	O
+242	O
+)	O
+FGPRTK	O
+(	O
+247	O
+),	O
+were	O
+well	O
+conserved	O
+among	O
+IBV	B-SPEC
+strains	O
+.	O
+
+The	O
+novel	O
+mAbs	O
+and	O
+the	O
+epitopes	O
+identified	O
+will	O
+be	O
+useful	O
+for	O
+developing	O
+diagnostic	O
+assays	O
+for	O
+IBV	B-SPEC
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Extraordinary	O
+GU	O
+-	O
+rich	O
+single	O
+-	O
+strand	O
+RNA	O
+identified	O
+from	O
+SARS	B-DISO
+coronavirus	B-SPEC
+contributes	O
+an	O
+excessive	O
+innate	O
+immune	O
+response	O
+.	O
+
+This	O
+study	O
+not	O
+only	O
+presents	O
+new	O
+evidence	O
+about	O
+the	O
+immunopathologic	O
+damage	O
+caused	O
+by	O
+overactive	O
+inflammation	B-DISO
+during	O
+the	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+but	O
+also	O
+provides	O
+a	O
+useful	O
+clue	O
+for	O
+a	O
+new	O
+therapeutic	O
+strategy	O
+.	O
+
+TITLE	O
+:	O
+Formic	B-CHED
+acid	I-CHED
+poisoning	O
+in	O
+a	O
+tertiary	O
+care	O
+center	O
+in	O
+South	O
+India	O
+:	O
+A	O
+2	O
+-	O
+year	O
+retrospective	O
+analysis	O
+of	O
+clinical	O
+profile	O
+and	O
+predictors	O
+of	O
+mortality	O
+.	O
+
+This	O
+study	O
+highlights	O
+the	O
+magnitude	O
+and	O
+ill	B-DISO
+-	O
+effects	O
+of	O
+self	O
+-	O
+harm	O
+caused	O
+by	O
+a	O
+strong	O
+corrosive	O
+,	O
+readily	O
+available	O
+due	O
+to	O
+very	O
+few	O
+restrictions	O
+in	O
+its	O
+distribution	O
+.	O
+
+TITLE	O
+:	O
+New	O
+anthraquinone	B-CHED
+derivatives	O
+as	O
+inhibitors	B-CHED
+of	O
+the	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-ENZY
+transcriptase	I-ENZY
+-	O
+associated	O
+ribonuclease	B-ENZY
+H	I-ENZY
+function	O
+.	O
+
+We	O
+have	O
+assayed	O
+new	O
+AQ	O
+derivatives	O
+on	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RNase	B-PRGE
+H	I-PRGE
+activities	O
+in	O
+biochemical	O
+assays	O
+.	O
+
+While	O
+in	O
+first	O
+case	O
+severe	B-DISO
+pain	I-DISO
+in	O
+abdomen	B-ANAT
+with	O
+intermittent	O
+exacerbation	O
+was	O
+the	O
+only	O
+presentation	O
+,	O
+the	O
+second	O
+patient	O
+presented	O
+as	O
+accelerated	B-DISO
+hypertension	I-DISO
+and	O
+acute	O
+abdominal	B-ANAT
+crises	O
+in	O
+whom	O
+the	O
+clinical	O
+course	O
+was	O
+characterized	O
+by	O
+development	B-PROC
+of	O
+deep	O
+coma	B-DISO
+due	O
+to	O
+inappropriate	O
+secretion	B-PROC
+of	O
+antidiuretic	B-CHED
+hormone	I-CHED
+before	O
+she	O
+made	O
+complete	O
+recovery	O
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+complications	I-DISO
+are	O
+prevalent	O
+in	O
+the	O
+critically	O
+ill	O
+neurological	O
+population	O
+.	O
+
+Laboratory	O
+markers	O
+,	O
+interventions	O
+,	O
+medications	O
+,	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+)	O
+and	O
+sepsis	B-DISO
+criteria	O
+,	O
+length	O
+of	O
+stay	O
+,	O
+and	O
+hospital	O
+mortality	O
+as	O
+well	O
+as	O
+expected	O
+mortality	O
+,	O
+based	O
+on	O
+the	O
+SAPSII	O
+-	O
+expanded	O
+score	O
+,	O
+were	O
+assessed	O
+retrospectively	O
+.	O
+
+Whether	O
+central	O
+venous	B-ANAT
+lines	O
+and	O
+nonadherence	O
+to	O
+cardiac	B-ANAT
+care	O
+guidelines	O
+influence	O
+the	O
+mortality	O
+of	O
+patients	O
+with	O
+IAT	O
+should	O
+be	O
+investigated	O
+in	O
+further	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Biogenesis	B-PROC
+of	O
+the	O
+vaccinia	B-SPEC
+virus	I-SPEC
+membrane	B-COMP
+:	O
+genetic	O
+and	O
+ultrastructural	O
+analysis	O
+of	O
+the	O
+contributions	O
+of	O
+the	O
+A14	O
+and	O
+A17	O
+proteins	O
+.	O
+
+When	O
+the	O
+proteins	B-CHED
+are	O
+induced	O
+at	O
+12	O
+h	O
+postinfection	O
+(	O
+hpi	B-DISO
+),	O
+crescents	O
+appear	O
+at	O
+the	O
+periphery	O
+of	O
+the	O
+electron	O
+-	O
+dense	O
+virosomes	O
+,	O
+with	O
+the	O
+accumulated	O
+vesicles	B-COMP
+likely	O
+contributing	O
+to	O
+their	O
+formation	B-PROC
+.	O
+
+For	O
+A17	O
+,	O
+truncation	B-DISO
+or	O
+mutation	O
+of	O
+the	O
+N	O
+terminus	O
+of	O
+A17	O
+engendered	O
+a	O
+phenotype	O
+consistent	O
+with	O
+the	O
+N	O
+terminus	O
+of	O
+A17	O
+recruiting	O
+the	O
+D13	B-PRGE
+scaffold	I-PRGE
+protein	I-PRGE
+to	O
+nascent	O
+membranes	B-ANAT
+.	O
+
+In	O
+vivo	O
+,	O
+the	O
+biological	O
+competency	O
+of	O
+A17	O
+was	O
+reduced	O
+by	O
+mutations	O
+that	O
+prevented	O
+its	O
+serine	B-CHED
+-	O
+threonine	B-CHED
+phosphorylation	B-PROC
+and	O
+restored	O
+by	O
+phosphomimetic	O
+substitutions	O
+.	O
+
+ABSTRACT	O
+:	O
+Patients	O
+who	O
+developed	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+after	O
+infection	B-DISO
+with	O
+severe	O
+respiratory	O
+viruses	B-SPEC
+(	O
+e	O
+.	O
+g	O
+.,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+,	O
+H5N1	B-DISO
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+),	O
+exhibited	O
+unusually	O
+high	O
+levels	O
+of	O
+CXCL10	B-PRGE
+,	O
+which	O
+belongs	O
+to	O
+the	O
+non	O
+-	O
+ELR	O
+(	O
+glutamic	O
+-	O
+leucine	B-CHED
+-	O
+arginine	B-CHED
+)	O
+CXC	O
+chemokine	O
+superfamily	B-SPEC
+.	O
+
+CXCL10	B-PRGE
+may	O
+not	O
+be	O
+a	O
+bystander	O
+to	O
+the	O
+severe	O
+virus	B-DISO
+infection	I-DISO
+but	O
+may	O
+directly	O
+contribute	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+neutrophil	B-ANAT
+-	O
+mediated	O
+,	O
+excessive	O
+pulmonary	B-DISO
+inflammation	I-DISO
+.	O
+
+CXCL10	B-PRGE
+-	O
+CXCR3	B-PRGE
+acts	O
+in	O
+an	O
+autocrine	B-PROC
+fashion	O
+on	O
+the	O
+oxidative	B-PROC
+burst	I-PROC
+and	O
+chemotaxis	B-PROC
+in	O
+the	O
+inflamed	O
+neutrophils	B-ANAT
+,	O
+leading	O
+to	O
+fulminant	O
+pulmonary	B-DISO
+inflammation	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+core	O
+neutralizing	O
+epitope	B-CHED
+(	O
+COE	O
+)	O
+region	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+development	B-PROC
+of	O
+the	O
+subunit	O
+vaccine	O
+against	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+mice	B-SPEC
+immunized	O
+orogastrically	O
+with	O
+L	O
+.	O
+casei	O
+expressing	O
+COE	O
+or	O
+LTB	B-PRGE
+-	I-PRGE
+COE	I-PRGE
+produced	O
+secretory	B-PRGE
+immunoglobulin	B-PROC
+A	I-PRGE
+and	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+with	O
+the	O
+ability	O
+to	O
+neutralize	O
+PEDV	B-SPEC
+in	O
+sera	B-COMP
+and	O
+mucus	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Disseminated	O
+phaeohyphomycoses	O
+are	O
+rare	O
+infections	B-DISO
+caused	O
+by	O
+dematiaceous	O
+fungi	B-SPEC
+.	O
+
+We	O
+report	O
+herein	O
+an	O
+O	O
+gallopavum	O
+phaeohyphomycosis	B-DISO
+with	O
+involvement	O
+of	O
+skin	B-ANAT
+in	O
+a	O
+transplant	B-ANAT
+recipient	O
+.	O
+
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+showed	O
+no	O
+evidence	O
+of	O
+pneumonia	B-DISO
+.	O
+
+Additional	O
+intravenous	O
+therapy	O
+with	O
+tobramycin	B-CHED
+and	O
+imipenem	B-CHED
+was	O
+started	O
+upon	O
+detection	O
+of	O
+Enterobacter	B-SPEC
+clocae	O
+and	O
+Enterococci	O
+in	O
+the	O
+sputum	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+effect	O
+of	O
+Chaiqinchengqi	O
+decoction	O
+(	O
+CQCQD	O
+)	O
+on	O
+serum	O
+amyloid	B-DISO
+A	O
+(	O
+SAA	B-PRGE
+)	O
+in	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+)	O
+patients	O
+.	O
+
+SAA	O
+was	O
+positively	O
+correlated	O
+with	O
+serum	B-COMP
+CRP	B-PRGE
+(	O
+R	O
+=	O
+0	O
+.	O
+346	O
+,	O
+P	O
+=	O
+0	O
+.	O
+042	O
+),	O
+Ranson	O
+score	O
+(	O
+R	O
+=	O
+0	O
+.	O
+442	O
+,	O
+P	O
+=	O
+0	O
+.	O
+008	O
+)	O
+and	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+(	O
+R	O
+=	O
+0	O
+.	O
+359	O
+,	O
+P	O
+=	O
+0	O
+.	O
+034	O
+).	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+),	O
+which	O
+is	O
+characterized	O
+by	O
+severe	B-DISO
+diarrhea	I-DISO
+,	O
+dehydration	B-DISO
+and	O
+high	O
+mortality	O
+in	O
+the	O
+affected	O
+pigs	B-SPEC
+.	O
+
+PEDV	B-SPEC
+was	O
+detected	O
+in	O
+92	O
+.	O
+7	O
+%	O
+of	O
+the	O
+samples	O
+(	O
+267	O
+/	O
+288	O
+).	O
+
+The	O
+15	O
+M	O
+genes	O
+that	O
+were	O
+amplified	O
+shared	O
+99	O
+.	O
+6	O
+-	O
+100	O
+%	O
+nucleotide	B-CHED
+identity	O
+and	O
+99	O
+.	O
+1	O
+-	O
+100	O
+%	O
+amino	B-CHED
+acid	I-CHED
+similarity	O
+with	O
+each	O
+other	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+impact	O
+of	O
+A	O
+/	O
+H1	O
+/	O
+N1	O
+/	O
+09	O
+influenza	B-DISO
+in	O
+patients	O
+with	O
+cirrhosis	B-DISO
+:	O
+experience	O
+from	O
+a	O
+nosocomial	O
+cluster	O
+of	O
+infection	O
+.	O
+
+None	O
+of	O
+patients	O
+without	O
+cirrhosis	B-DISO
+died	B-PROC
+.	O
+
+This	O
+lesion	O
+is	O
+detected	O
+at	O
+slaughterhouses	O
+and	O
+is	O
+characterized	O
+by	O
+paleness	B-DISO
+and	O
+atrophy	B-DISO
+of	O
+the	O
+deep	B-ANAT
+pectoral	I-ANAT
+muscle	I-ANAT
+,	O
+including	O
+necrosis	B-PROC
+of	O
+the	O
+region	O
+,	O
+leading	O
+to	O
+condemnations	O
+of	O
+the	O
+breast	B-ANAT
+muscle	B-ANAT
+,	O
+a	O
+valuable	O
+meat	O
+cut	O
+in	O
+the	O
+market	O
+.	O
+
+The	O
+tracheal	O
+,	O
+cecal	B-ANAT
+tonsil	I-ANAT
+,	O
+and	O
+supracoracoid	O
+muscle	B-ANAT
+(	O
+with	O
+and	O
+without	O
+lesions	O
+)	O
+samples	O
+from	O
+the	O
+40	O
+broiler	O
+flocks	O
+were	O
+screened	O
+by	O
+RT	O
+-	O
+PCR	O
+to	O
+detect	O
+IBV	B-SPEC
+.	O
+
+Data	O
+from	O
+patients	O
+admitted	O
+for	O
+H1N1	O
+-	O
+associated	O
+ARDS	B-DISO
+to	O
+French	O
+ICUs	O
+were	O
+prospectively	O
+collected	O
+from	O
+2009	O
+to	O
+2011	O
+through	O
+the	O
+national	O
+REVA	O
+registry	O
+.	O
+
+This	O
+may	O
+be	O
+circumvented	O
+by	O
+having	O
+the	O
+participants	O
+collect	O
+their	O
+own	O
+nasal	B-ANAT
+swabs	O
+.	O
+
+We	O
+presented	O
+a	O
+male	O
+patient	O
+,	O
+aged	O
+50	O
+,	O
+hospitalized	O
+in	O
+the	O
+Emergency	B-DISO
+Center	O
+Kragujevac	O
+due	O
+to	O
+altered	B-DISO
+mental	I-DISO
+status	I-DISO
+(	O
+Glasgow	O
+Coma	B-DISO
+Score	O
+11	O
+),	O
+partial	O
+respiratory	B-DISO
+insufficiency	I-DISO
+(	O
+pO2	B-PROC
+7	O
+.	O
+5	O
+kPa	O
+,	O
+pCO2	O
+4	O
+.	O
+3	O
+kPa	O
+,	O
+SpO2	O
+89	O
+%),	O
+weakness	B-DISO
+of	O
+lower	B-ANAT
+extremities	I-ANAT
+and	O
+atypical	O
+electrocardiographic	O
+changes	O
+.	O
+
+Laboratory	O
+analyses	O
+,	O
+carried	O
+out	O
+immediately	O
+after	O
+the	O
+patient	O
+'	O
+s	O
+admission	O
+to	O
+the	O
+Emergency	B-DISO
+Center	O
+,	O
+registered	O
+the	O
+following	O
+disturbances	O
+:	O
+high	O
+hyperkalemia	O
+level	O
+(	O
+K	O
++	O
+9	O
+.	O
+9	O
+m	O
+mol	O
+/	O
+L	O
+),	O
+increased	O
+levels	O
+of	O
+urea	B-CHED
+(	O
+30	O
+.	O
+1	O
+mmol	O
+/	O
+L	O
+),	O
+creatinine	B-CHED
+(	O
+400	O
+micromol	O
+/	O
+L	O
+),	O
+creatine	B-CHED
+phosphokinase	O
+--	O
+CK	O
+(	O
+12	O
+,	O
+0350	O
+IU	O
+/	O
+L	O
+),	O
+CK	B-FUNC
+-	I-FUNC
+MB	I-FUNC
+(	O
+2500	O
+IU	O
+/	O
+L	O
+)	O
+and	O
+myoglobin	B-PRGE
+(	O
+57000	O
+microg	O
+/	O
+L	O
+),	O
+with	O
+normal	O
+levels	O
+of	O
+troponin	B-PRGE
+I	I-PRGE
+(<	O
+0	O
+.	O
+01	O
+microg	O
+/	O
+L	O
+),	O
+as	O
+well	O
+as	O
+signs	O
+of	O
+anemia	B-DISO
+(	O
+Hgb	O
+92	O
+g	O
+/	O
+L	O
+,	O
+Er	O
+3	O
+.	O
+61	O
+x	O
+10	O
+(	O
+12	O
+)/	O
+L	O
+),	O
+infection	B-DISO
+(	O
+C	O
+-	O
+reactive	O
+proteine	O
+184	O
+microg	O
+/	O
+mL	O
+,	O
+Le	O
+16	O
+.	O
+1	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+)	O
+and	O
+acidosis	B-DISO
+(	O
+base	O
+excess	O
+--	O
+18	O
+.	O
+4	O
+mmol	O
+/	O
+L	O
+,	O
+pH	O
+7	O
+.	O
+26	O
+.	O
+
+Normalization	O
+of	O
+kalemia	O
+and	O
+fast	B-FUNC
+regression	O
+of	O
+electrocardiographic	O
+changes	O
+were	O
+registered	O
+.	O
+
+Therefore	O
+,	O
+on	O
+the	O
+day	O
+30	O
+of	O
+hospitalization	O
+the	O
+above	O
+-	O
+knee	B-ANAT
+amputation	O
+of	O
+the	O
+right	B-ANAT
+leg	I-ANAT
+was	O
+performed	O
+,	O
+and	O
+on	O
+the	O
+day	O
+38	O
+the	O
+transmetatarsal	O
+amputation	O
+of	O
+the	O
+left	B-ANAT
+foot	I-ANAT
+was	O
+carried	O
+out	O
+.	O
+
+His	O
+respiratory	O
+condition	B-DISO
+improved	O
+,	O
+and	O
+he	O
+was	O
+weaned	B-PROC
+from	O
+V	O
+-	O
+V	O
+ECMO	O
+.	O
+
+This	O
+paper	O
+describes	O
+the	O
+experience	O
+of	O
+Toronto	B-PRGE
+2	I-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+1	I-PRGE
+dealing	O
+with	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+and	O
+later	O
+that	O
+year	O
+the	O
+Great	O
+Northeastern	O
+Blackout	B-DISO
+.	O
+
+Therefore	O
+,	O
+it	O
+is	O
+necessary	O
+to	O
+review	O
+the	O
+experience	O
+on	O
+rescue	O
+use	O
+of	O
+ECMO	O
+in	O
+critically	B-DISO
+ill	I-DISO
+pediatric	O
+patients	O
+.	O
+
+His	O
+motor	O
+function	O
+has	O
+been	O
+improved	O
+following	O
+orthopedic	O
+operation	O
+at	O
+one	O
+year	O
+after	O
+discharge	B-ANAT
+.	O
+
+METHODS	O
+:	O
+A	O
+retrospective	O
+analysis	O
+was	O
+done	O
+for	O
+patients	O
+who	O
+had	O
+been	O
+receiving	O
+ECMO	O
+treatment	O
+to	O
+rescue	O
+refractory	O
+cardiorespiratory	B-DISO
+failure	I-DISO
+from	O
+different	O
+causes	O
+in	O
+a	O
+hospital	O
+between	O
+July	O
+2007	O
+and	O
+May	O
+2011	O
+.	O
+
+CONCLUSIONS	O
+:	O
+ECMO	O
+is	O
+a	O
+justifiable	O
+alternative	O
+treatment	O
+for	O
+reversible	O
+severe	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+children	O
+.	O
+
+TITLE	O
+:	O
+Unusual	O
+presentation	O
+of	O
+sacrococcygeal	O
+teratomas	B-DISO
+and	O
+associated	O
+malformations	B-DISO
+in	O
+children	O
+:	O
+clinical	O
+experience	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+.	O
+
+ABSTRACT	O
+:	O
+Sacrococcygeal	O
+teratomas	O
+are	O
+the	O
+most	O
+common	O
+and	O
+best	O
+known	O
+extragonadal	O
+teratomas	B-DISO
+in	O
+neonates	O
+and	O
+infants	O
+,	O
+but	O
+they	O
+sometimes	O
+present	O
+unique	O
+,	O
+distinctive	O
+features	O
+unlike	O
+those	O
+commonly	O
+described	O
+,	O
+that	O
+can	O
+be	O
+considered	O
+exceptional	O
+and	O
+noteworthy	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+applicability	O
+of	O
+pulse	B-PROC
+pressure	I-PROC
+variation	O
+(	O
+ΔPP	O
+)	O
+to	O
+predict	O
+fluid	O
+responsiveness	O
+using	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+strategies	O
+is	O
+uncertain	O
+in	O
+clinical	O
+practice	O
+.	O
+
+The	O
+major	O
+clinical	O
+symptoms	O
+associated	O
+with	O
+HCoV	O
+-	O
+HKU1	O
+infection	B-DISO
+were	O
+examined	O
+statistically	O
+and	O
+sequence	O
+variations	O
+of	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+),	O
+spike	O
+,	O
+and	O
+nucleocapsid	B-COMP
+genes	O
+were	O
+also	O
+analyzed	O
+.	O
+
+CPAP	B-PRGE
+is	O
+a	O
+relatively	O
+low	O
+-	O
+cost	O
+,	O
+low	O
+-	O
+technology	O
+that	O
+is	O
+a	O
+safe	O
+method	O
+to	O
+decrease	O
+respiratory	O
+rate	O
+in	O
+children	O
+with	O
+nonspecific	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+The	O
+CK	O
+/	O
+CH	O
+/	O
+Zhejiang	O
+/	O
+06	O
+/	O
+10	O
+strain	O
+(	O
+IBV	B-SPEC
+-	O
+YX10	O
+)	O
+was	O
+isolated	O
+from	O
+a	O
+12	O
+-	O
+day	O
+-	O
+old	O
+broiler	O
+chicken	B-SPEC
+in	O
+a	O
+flock	O
+of	O
+chickens	B-SPEC
+with	O
+swollen	O
+speckled	O
+kidneys	B-ANAT
+and	O
+distended	O
+ureters	B-ANAT
+filled	O
+with	O
+uric	B-CHED
+acid	I-CHED
+in	O
+China	O
+in	O
+2010	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genome	O
+sequence	O
+of	O
+novel	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+strain	O
+GD	O
+-	O
+1	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+infection	B-DISO
+,	O
+which	O
+causes	O
+acute	B-DISO
+diarrhea	I-DISO
+and	O
+dehydration	B-DISO
+in	O
+suckling	O
+piglets	O
+,	O
+has	O
+become	O
+a	O
+serious	O
+problem	O
+for	O
+the	O
+swine	B-SPEC
+industry	O
+of	O
+China	O
+in	O
+recent	O
+years	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genome	O
+sequence	O
+of	O
+a	O
+virulent	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+strain	O
+.	O
+
+Although	O
+the	O
+putative	O
+causative	O
+virus	B-SPEC
+of	O
+the	O
+disease	O
+was	O
+not	O
+isolated	O
+,	O
+the	O
+genomic	O
+sequence	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+was	O
+consistently	O
+detected	O
+from	O
+feces	B-ANAT
+of	O
+diseased	O
+pigs	B-SPEC
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+Three	O
+assays	O
+were	O
+conducted	O
+:	O
+inhibition	O
+of	O
+cancer	B-ANAT
+cell	B-COMP
+proliferation	O
+,	O
+inhibition	B-PROC
+of	O
+TGEV	B-SPEC
+replication	O
+for	O
+anticoronavirus	O
+activity	O
+,	O
+and	O
+suppression	B-DISO
+of	O
+nitric	B-CHED
+oxide	I-CHED
+production	O
+in	O
+RAW264	O
+.	O
+7	O
+cells	B-COMP
+(	O
+a	O
+measure	O
+of	O
+anti	O
+-	O
+inflammation	B-DISO
+).	O
+
+We	O
+used	O
+data	O
+from	O
+a	O
+new	O
+sentinel	O
+surveillance	O
+system	O
+to	O
+investigate	O
+the	O
+seasonality	O
+and	O
+characteristics	O
+of	O
+influenza	B-DISO
+,	O
+including	O
+pandemic	O
+(	O
+pdm	O
+)	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+,	O
+in	O
+Zambia	O
+.	O
+
+Nasopharyngeal	B-ANAT
+and	O
+oropharyngeal	B-ANAT
+swabs	O
+and	O
+structured	O
+questionnaires	O
+were	O
+collected	O
+from	O
+eligible	O
+patients	O
+and	O
+samples	O
+were	O
+tested	O
+by	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+types	O
+and	O
+subtypes	O
+.	O
+
+While	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+enterovirus	B-SPEC
+,	O
+RSV	B-SPEC
+,	O
+and	O
+HMPV	B-SPEC
+had	O
+a	O
+defined	O
+period	O
+of	O
+circulation	B-PROC
+,	O
+the	O
+other	O
+viruses	B-SPEC
+were	O
+detected	O
+throughout	O
+the	O
+year	O
+.	O
+
+We	O
+found	O
+that	O
+respiratory	O
+viruses	B-SPEC
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+etiology	O
+of	O
+ILI	O
+in	O
+Cameroon	O
+,	O
+particularly	O
+in	O
+children	O
+<	O
+5	O
+years	O
+of	O
+age	O
+.	O
+
+While	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+enterovirus	B-SPEC
+,	O
+RSV	B-SPEC
+,	O
+and	O
+HMPV	B-SPEC
+had	O
+a	O
+defined	O
+period	O
+of	O
+circulation	B-PROC
+,	O
+the	O
+other	O
+viruses	B-SPEC
+were	O
+detected	O
+throughout	O
+the	O
+year	O
+.	O
+
+By	O
+establishing	O
+its	O
+complete	O
+genome	O
+sequence	O
+,	O
+HCoV	O
+-	O
+EMC	B-COMP
+/	O
+2012	O
+was	O
+characterized	O
+as	O
+a	O
+new	O
+genotype	O
+which	O
+is	O
+closely	O
+related	O
+to	O
+bat	B-ENZY
+coronaviruses	O
+that	O
+are	O
+distant	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+We	O
+expect	O
+that	O
+this	O
+information	O
+will	O
+be	O
+vital	O
+to	O
+rapid	O
+advancement	O
+of	O
+both	O
+clinical	O
+and	O
+vital	O
+research	O
+on	O
+this	O
+emerging	O
+pathogen	O
+.	O
+
+Exogenous	O
+surfactant	B-CHED
+replacement	O
+in	O
+animal	B-SPEC
+models	O
+of	O
+ARDS	B-DISO
+and	O
+neonatal	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+shows	O
+consistent	O
+improvements	O
+in	O
+gas	B-ENZY
+exchange	O
+and	O
+survival	O
+.	O
+
+Absence	O
+of	O
+phenotypic	O
+characterisation	O
+of	O
+patients	O
+,	O
+the	O
+lack	O
+of	O
+an	O
+ideal	O
+natural	O
+surfactant	B-CHED
+material	O
+with	O
+adequate	O
+surfactant	B-CHED
+proteins	B-CHED
+,	O
+coupled	O
+with	O
+uncertainty	O
+about	O
+optimal	O
+timing	O
+,	O
+dosing	O
+and	O
+delivery	O
+method	O
+are	O
+some	O
+of	O
+the	O
+limitations	O
+of	O
+published	O
+surfactant	B-CHED
+replacement	O
+clinical	O
+trials	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+and	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+)	O
+are	O
+two	O
+important	O
+coronaviruses	O
+of	O
+domestic	B-SPEC
+cat	I-SPEC
+worldwide	O
+.	O
+
+The	O
+present	O
+study	O
+indicated	O
+that	O
+type	B-PRGE
+I	I-PRGE
+FCoV	I-PRGE
+is	O
+more	O
+prevalent	O
+among	O
+cats	B-SPEC
+in	O
+Malaysia	O
+.	O
+
+Using	O
+the	O
+purified	O
+recombinant	O
+NP	O
+as	O
+an	O
+antigen	B-CHED
+,	O
+a	O
+polyclonal	O
+antibody	B-COMP
+from	O
+rabbit	B-SPEC
+serum	B-COMP
+with	O
+specificity	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+NP	O
+was	O
+generated	O
+;	O
+this	O
+antibody	B-COMP
+reacts	O
+specifically	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+NP	O
+and	O
+does	O
+not	O
+cross	O
+-	O
+react	O
+with	O
+other	O
+human	B-PRGE
+CoV	I-PRGE
+NPs	B-DISO
+(	O
+including	O
+those	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+by	O
+Western	O
+blot	O
+.	O
+
+The	O
+results	O
+revealed	O
+that	O
+strains	O
+ck	O
+/	O
+CH	O
+/	O
+LNM	O
+/	O
+091017	O
+and	O
+ck	O
+/	O
+CH	O
+/	O
+LDL	B-CHED
+/	O
+101212	O
+were	O
+closely	O
+related	O
+to	O
+the	O
+H120	O
+vaccine	O
+,	O
+which	O
+suggests	O
+that	O
+they	O
+might	O
+represent	O
+re	O
+-	O
+isolations	O
+of	O
+vaccine	O
+strains	O
+or	O
+variants	O
+of	O
+vaccine	O
+strains	O
+that	O
+have	O
+resulted	O
+from	O
+the	O
+accumulated	O
+point	B-PROC
+mutations	I-PROC
+after	O
+several	O
+passages	O
+in	O
+chickens	B-SPEC
+.	O
+
+IBV	B-SPEC
+Gray	O
+strain	O
+infection	B-DISO
+of	O
+MHC	B-PROC
+homozygous	O
+B12	B-PRGE
+and	O
+B19	O
+haplotype	O
+chicks	O
+resulted	O
+in	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+compared	O
+to	O
+chicks	O
+with	O
+B2	O
+/	O
+B2	O
+and	O
+B5	O
+/	O
+B5	O
+haplotypes	O
+.	O
+
+Demonstrating	O
+a	O
+dominant	B-PRGE
+B2	I-PRGE
+phenotype	I-PRGE
+,	O
+B2	O
+/	O
+B12	B-PRGE
+birds	B-SPEC
+were	O
+also	O
+more	O
+resistant	O
+to	O
+IBV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+N	O
+protein	B-CHED
+oligomerizes	O
+via	O
+its	O
+carboxyl	O
+terminus	O
+.	O
+
+Based	O
+on	O
+the	O
+protein	B-CHED
+disorder	O
+prediction	O
+system	O
+,	O
+a	O
+comprehensive	O
+series	O
+of	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+N	I-PRGE
+protein	B-CHED
+mutants	I-PRGE
+with	O
+truncated	O
+CTD	O
+was	O
+generated	O
+and	O
+systematically	O
+investigated	O
+by	O
+biophysical	O
+and	O
+biochemical	O
+analyses	O
+to	O
+clarify	O
+the	O
+role	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+tail	O
+of	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+N	I-PRGE
+protein	B-CHED
+in	O
+oligomerization	O
+.	O
+
+While	O
+many	O
+aspirates	B-ANAT
+were	O
+dilute	O
+and	O
+showed	O
+no	O
+mRNA	B-CHED
+signal	O
+,	O
+viral	B-DISO
+infection	I-DISO
+significantly	O
+increased	O
+the	O
+number	O
+of	O
+samples	O
+that	O
+were	O
+positive	O
+for	O
+IFN	B-PRGE
+-	I-PRGE
+λ1	I-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+λ2	I-PRGE
+/	I-PRGE
+3	I-PRGE
+,	O
+TLR3	B-PRGE
+,	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+,	O
+and	O
+IRF7	B-PRGE
+mRNA	I-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+accessory	O
+proteins	B-CHED
+in	O
+the	O
+replication	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+monocytes	B-ANAT
+.	O
+
+Although	O
+autophagy	B-PROC
+is	O
+not	O
+required	O
+,	O
+depletion	O
+of	O
+LC3	O
+markedly	O
+reduced	O
+the	O
+replication	O
+of	O
+EAV	B-SPEC
+.	O
+
+There	O
+are	O
+still	O
+many	O
+unknowns	O
+on	O
+the	O
+implication	O
+of	O
+cellular	B-COMP
+factors	O
+that	O
+regulate	O
+the	O
+entry	O
+process	O
+.	O
+
+ABSTRACT	O
+:	O
+Immune	O
+sera	B-COMP
+from	O
+convalescent	O
+patients	O
+have	O
+been	O
+shown	O
+to	O
+be	O
+effective	O
+in	O
+the	O
+treatment	O
+of	O
+patients	O
+infected	O
+with	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Virus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+making	O
+passive	O
+immune	O
+therapy	O
+with	O
+human	B-SPEC
+monoclonal	O
+antibodies	B-COMP
+an	O
+attractive	O
+treatment	O
+strategy	O
+for	O
+SARS	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+describe	O
+non	O
+-	O
+S1	O
+binding	B-FUNC
+neutralizing	O
+HmAbs	O
+that	O
+can	O
+specifically	O
+bind	B-FUNC
+to	O
+the	O
+conserved	O
+S2	O
+domain	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+Prospective	O
+studies	O
+with	O
+viral	O
+load	O
+determination	O
+and	O
+asymptomatic	O
+controls	O
+are	O
+needed	O
+to	O
+study	O
+the	O
+association	O
+of	O
+these	O
+emerging	O
+respiratory	O
+viruses	B-SPEC
+with	O
+LRTI	B-DISO
+in	O
+children	O
+with	O
+cancer	B-DISO
+and	O
+posthematopoietic	O
+stem	O
+cell	B-ANAT
+transplant	I-ANAT
+.	O
+
+These	O
+early	O
+successes	O
+can	O
+be	O
+attributed	O
+to	O
+population	O
+mobilization	O
+,	O
+mass	O
+campaigns	O
+and	O
+a	O
+focus	O
+on	O
+sanitation	O
+,	O
+hygiene	O
+,	O
+clean	O
+water	B-CHED
+and	O
+clean	O
+delivery	O
+,	O
+and	O
+occurred	O
+despite	O
+political	O
+instability	O
+and	O
+slow	O
+economic	O
+progress	O
+.	O
+
+TITLE	O
+:	O
+Fatal	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+a	O
+child	O
+with	O
+severe	B-DISO
+combined	I-DISO
+immunodeficiency	I-DISO
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+preparedness	O
+for	O
+severe	O
+pneumonia	B-DISO
+with	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+):	O
+experiences	O
+with	O
+cases	O
+in	O
+Vietnam	O
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+pandemics	O
+--	O
+eg	O
+,	O
+HIV	B-SPEC
+/	I-DISO
+AIDS	I-DISO
+,	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+,	O
+pandemic	O
+influenza	B-DISO
+--	O
+originate	O
+in	O
+animals	B-SPEC
+,	O
+are	O
+caused	O
+by	O
+viruses	B-SPEC
+,	O
+and	O
+are	O
+driven	O
+to	O
+emerge	O
+by	O
+ecological	O
+,	O
+behavioural	O
+,	O
+or	O
+socioeconomic	O
+changes	O
+.	O
+
+Despite	O
+their	O
+substantial	O
+effects	O
+on	O
+global	O
+public	O
+health	O
+and	O
+growing	O
+understanding	O
+of	O
+the	O
+process	O
+by	O
+which	O
+they	O
+emerge	O
+,	O
+no	O
+pandemic	O
+has	O
+been	O
+predicted	O
+before	O
+infecting	O
+human	B-SPEC
+beings	O
+.	O
+
+New	O
+mathematical	O
+modelling	O
+,	O
+diagnostic	O
+,	O
+communications	O
+,	O
+and	O
+informatics	O
+technologies	O
+can	O
+identify	O
+and	O
+report	O
+hitherto	O
+unknown	O
+microbes	O
+in	O
+other	O
+species	B-SPEC
+,	O
+and	O
+thus	O
+new	O
+risk	O
+assessment	O
+approaches	O
+are	O
+needed	O
+to	O
+identify	O
+microbes	O
+most	O
+likely	O
+to	O
+cause	O
+human	O
+disease	O
+.	O
+
+Using	O
+the	O
+Respiratory	O
+Virus	B-SPEC
+Panel	O
+these	O
+specimens	O
+tested	O
+positive	O
+for	O
+one	O
+or	O
+more	O
+respiratory	O
+virus	B-SPEC
+and	O
+negative	O
+for	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+.	O
+From	O
+our	O
+subset	O
+hMPV	B-SPEC
+was	O
+the	O
+fourth	O
+most	O
+common	O
+virus	B-SPEC
+(	O
+n	O
+=	O
+2	O
+,	O
+561	O
+)	O
+with	O
+373	O
+(	O
+15	O
+%)	O
+identified	O
+as	O
+mixed	B-DISO
+infection	I-DISO
+using	O
+DIAL	O
+.	O
+
+Mixed	B-DISO
+infection	I-DISO
+with	O
+hMPV	B-SPEC
+was	O
+most	O
+commonly	O
+found	O
+in	O
+infants	O
+less	O
+than	O
+6	O
+months	O
+old	O
+and	O
+ERV	O
+was	O
+most	O
+commonly	O
+found	O
+in	O
+mixed	B-DISO
+infection	I-DISO
+with	O
+hMPV	B-SPEC
+(	O
+230	O
+/	O
+373	O
+,	O
+56	O
+%)	O
+across	O
+all	O
+age	O
+groups	O
+.	O
+
+HCoV	O
+are	O
+now	O
+known	O
+to	O
+be	O
+involved	O
+in	O
+more	O
+serious	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+i	O
+.	O
+e	O
+.	O
+bronchitis	B-DISO
+,	O
+bronchiolitis	B-DISO
+or	O
+pneumonia	B-DISO
+,	O
+especially	O
+in	O
+young	O
+children	O
+and	O
+neonates	O
+,	O
+elderly	O
+people	O
+and	O
+immunosuppressed	O
+patients	O
+.	O
+
+Indeed	O
+,	O
+several	O
+studies	O
+have	O
+described	O
+the	O
+ability	O
+of	O
+HCoVs	O
+(	O
+i	O
+.	O
+e	O
+.	O
+HCoV	O
+229E	O
+,	O
+HCoV	O
+OC43	O
+(	O
+also	O
+known	O
+as	O
+betacoronavirus	B-SPEC
+1	I-SPEC
+),	O
+NL63	O
+,	O
+HKU1	O
+or	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+to	O
+survive	O
+in	O
+different	O
+environmental	O
+conditions	O
+(	O
+e	O
+.	O
+g	O
+.	O
+temperature	O
+and	O
+humidity	O
+),	O
+on	O
+different	O
+supports	O
+found	O
+in	O
+hospital	O
+settings	O
+such	O
+as	O
+aluminum	B-CHED
+,	O
+sterile	B-DISO
+sponges	B-SPEC
+or	O
+latex	O
+surgical	O
+gloves	O
+or	O
+in	O
+biological	O
+fluids	B-ANAT
+.	O
+
+ViPR	B-PRGE
+provides	O
+access	O
+to	O
+sequence	O
+records	O
+,	O
+gene	O
+and	O
+protein	B-CHED
+annotations	O
+,	O
+immune	O
+epitopes	O
+,	O
+3D	O
+structures	O
+,	O
+host	B-COMP
+factor	O
+data	O
+,	O
+and	O
+other	O
+data	O
+types	O
+through	O
+an	O
+intuitive	O
+web	B-DISO
+-	O
+based	O
+search	O
+interface	O
+.	O
+
+All	O
+of	O
+the	O
+data	O
+and	O
+integrated	O
+analysis	O
+and	O
+visualization	O
+tools	O
+in	O
+ViPR	B-PRGE
+are	O
+made	O
+available	O
+without	O
+charge	O
+as	O
+a	O
+service	O
+to	O
+the	O
+Coronaviridae	B-SPEC
+research	O
+community	O
+to	O
+facilitate	O
+the	O
+research	O
+and	O
+development	B-PROC
+of	O
+diagnostics	O
+,	O
+prophylactics	O
+,	O
+vaccines	O
+and	O
+therapeutics	O
+against	O
+these	O
+human	B-SPEC
+pathogens	O
+.	O
+
+Two	O
+variables	O
+significantly	O
+contributed	O
+to	O
+the	O
+detection	O
+of	O
+study	O
+pathogens	O
+:	O
+age	O
+(	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+1	O
+.	O
+21	O
+for	O
+each	O
+day	O
+older	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+12	O
+-	O
+1	O
+.	O
+30	O
+)	O
+and	O
+rhinorrhea	B-DISO
+(	O
+OR	O
+6	O
+.	O
+71	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+54	O
+-	O
+29	O
+.	O
+21	O
+).	O
+
+The	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+(	O
+pro	B-CHED
+))	O
+of	O
+coronaviruses	O
+is	O
+required	O
+for	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+polyproteins	O
+and	O
+viral	B-PROC
+replication	I-PROC
+,	O
+and	O
+is	O
+a	O
+promising	O
+target	O
+for	O
+the	O
+development	B-PROC
+of	O
+drugs	O
+against	O
+coronaviral	O
+infection	B-DISO
+.	O
+
+We	O
+have	O
+further	O
+showed	O
+that	O
+the	O
+peptidomimetic	B-CHED
+inhibitor	B-CHED
+,	O
+Cbz	B-CHED
+-	O
+AVLQ	O
+-	O
+CN	O
+,	O
+has	O
+broad	O
+-	O
+spectrum	O
+inhibition	B-PROC
+against	O
+3CL	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+from	O
+human	B-SPEC
+coronavirus	I-SPEC
+strains	O
+229E	O
+,	O
+NL63	O
+,	O
+OC43	O
+,	O
+HKU1	O
+,	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+,	O
+with	O
+IC	O
+(	O
+50	O
+)	O
+values	O
+ranging	O
+from	O
+1	O
+.	O
+3	O
+to	O
+3	O
+.	O
+7	O
+μM	O
+,	O
+but	O
+no	O
+detectable	O
+inhibition	B-PROC
+against	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+fibrinous	O
+and	O
+organizing	O
+pneumonia	O
+(	O
+AFOP	O
+)	O
+is	O
+a	O
+newly	O
+recognized	O
+form	O
+of	O
+diffuse	O
+lung	B-ANAT
+injury	O
+.	O
+
+He	O
+had	O
+clinical	O
+and	O
+radiologic	O
+improvement	O
+with	O
+a	O
+course	O
+of	O
+systemic	O
+corticosteroids	B-CHED
+.	O
+
+Retrospectively	O
+,	O
+we	O
+collected	O
+clinical	O
+data	O
+on	O
+all	O
+patients	O
+who	O
+were	O
+admitted	O
+to	O
+the	O
+ICU	O
+with	O
+confirmed	O
+or	O
+suspected	O
+diagnosis	O
+of	O
+severe	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+A	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+at	O
+4	O
+major	O
+tertiary	O
+care	O
+hospitals	O
+in	O
+Damascus	O
+,	O
+Syria	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	O
+onset	O
+pulmonary	B-DISO
+toxicity	I-DISO
+associated	O
+to	O
+amiodarone	B-CHED
+].	O
+
+During	O
+the	O
+administration	O
+,	O
+the	O
+patient	O
+developed	O
+hemodynamic	B-DISO
+instability	I-DISO
+and	O
+oxygen	B-CHED
+dessaturation	O
+that	O
+led	O
+to	O
+an	O
+electrical	O
+cardioversion	O
+with	O
+return	O
+of	O
+sinus	B-DISO
+rhythm	B-PROC
+.	O
+
+Expeditive	O
+therapeutic	O
+measures	O
+were	O
+undertaken	O
+,	O
+namely	O
+by	O
+initiation	O
+of	O
+non	O
+-	O
+invasive	O
+positive	O
+airway	B-ANAT
+pressure	O
+support	O
+,	O
+that	O
+attained	O
+a	O
+good	O
+result	O
+.	O
+
+Analysis	O
+of	O
+sequences	O
+of	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+fragments	O
+revealed	O
+strains	O
+in	O
+the	O
+genus	B-SPEC
+Alphacoronavirus	B-SPEC
+,	O
+including	O
+three	O
+distinct	O
+strains	O
+in	O
+hyenas	B-SPEC
+and	O
+one	O
+distinct	O
+strain	O
+in	O
+a	O
+jackal	O
+.	O
+
+To	O
+overcome	O
+this	O
+problem	O
+,	O
+a	O
+novel	O
+method	O
+for	O
+the	O
+detection	O
+of	O
+viruses	B-SPEC
+is	O
+described	O
+in	O
+the	O
+current	O
+manuscript	O
+.	O
+
+ABSTRACT	O
+:	O
+Measurement	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+antibody	B-COMP
+titres	O
+is	O
+utilised	O
+mainly	O
+for	O
+diagnosing	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+and	O
+for	O
+quarantine	O
+purposes	O
+.	O
+
+This	O
+syndrome	B-DISO
+largely	O
+accounts	O
+for	O
+the	O
+late	O
+mortality	O
+that	O
+arises	O
+and	O
+despite	O
+many	O
+theories	O
+,	O
+the	O
+pathological	O
+mechanism	O
+is	O
+not	O
+fully	O
+understood	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+noncanonically	O
+transcribed	O
+subgenomic	O
+mRNA	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+other	O
+gammacoronaviruses	O
+.	O
+
+We	O
+also	O
+demonstrated	O
+that	O
+noncanonical	O
+TRS	B-DISO
+-	O
+Bs	O
+may	O
+provide	O
+a	O
+mechanism	O
+by	O
+which	O
+coronaviruses	O
+can	O
+control	O
+protein	B-PROC
+expression	B-PROC
+levels	O
+by	O
+reducing	O
+sgmRNA	O
+synthesis	B-PROC
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+dynamic	O
+distribution	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+M41	O
+,	O
+H120	O
+,	O
+and	O
+SAIBK	O
+strains	O
+by	O
+quantitative	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+in	O
+SPF	O
+chickens	O
+.	O
+
+The	O
+pancreas	B-ANAT
+and	O
+the	O
+liver	B-ANAT
+are	O
+candidates	O
+for	O
+antigen	O
+detection	O
+.	O
+
+TITLE	O
+:	O
+Aerophagia	B-DISO
+in	O
+a	O
+toddler	O
+with	O
+gastric	B-ANAT
+pull	O
+-	O
+up	O
+:	O
+an	O
+unusual	O
+combination	O
+precipitating	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Aerophagia	B-DISO
+is	O
+a	O
+common	O
+disorder	O
+in	O
+adults	O
+as	O
+well	O
+as	O
+children	O
+,	O
+which	O
+often	O
+goes	B-SPEC
+unnoticed	O
+.	O
+
+One	O
+thousand	O
+two	O
+hundred	O
+ninety	O
+-	O
+seven	O
+patients	O
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+for	O
+the	O
+study	O
+,	O
+821	O
+(	O
+63	O
+.	O
+3	O
+%)	O
+were	O
+male	O
+,	O
+and	O
+mean	O
+age	O
+was	O
+58	O
+.	O
+5	O
+±	O
+19	O
+.	O
+2	O
+yrs	O
+.	O
+
+Mechanical	O
+ventilation	O
+was	O
+used	O
+in	O
+almost	O
+three	O
+fourths	O
+of	O
+the	O
+patients	O
+,	O
+whereas	O
+any	O
+type	O
+of	O
+renal	B-ANAT
+replacement	O
+therapy	O
+was	O
+used	O
+in	O
+173	O
+patients	O
+(	O
+13	O
+.	O
+3	O
+%).	O
+
+ABSTRACT	O
+:	O
+A	O
+multiplex	O
+PCR	O
+assay	O
+was	O
+developed	O
+and	O
+evaluated	O
+for	O
+its	O
+ability	O
+to	O
+simultaneously	O
+detect	O
+three	O
+viral	B-DISO
+infections	I-DISO
+of	O
+swine	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+influenza	B-DISO
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Outcome	O
+was	O
+better	O
+when	O
+the	O
+time	O
+of	O
+severe	O
+deoxygenation	O
+(	O
+Pao2	O
+<	O
+70	O
+mm	O
+Hg	O
+)	O
+despite	O
+maximally	O
+invasive	O
+respiratory	O
+support	O
+to	O
+ECMO	O
+implantation	B-PROC
+was	O
+less	O
+than	O
+6	O
+hours	O
+(	O
+odds	O
+ratio	O
+:	O
+2	O
+.	O
+4	O
+;	O
+p	O
+=	O
+0	O
+.	O
+05	O
+).	O
+
+Platypnea	B-DISO
+-	O
+orthodeoxia	O
+syndrome	B-DISO
+referring	O
+to	O
+abnormal	O
+oxygenation	B-PROC
+in	O
+the	O
+upright	O
+position	O
+has	O
+been	O
+correlated	O
+with	O
+reopening	O
+of	O
+foramen	B-ANAT
+ovale	I-ANAT
+and	O
+acute	O
+right	O
+-	O
+to	O
+-	O
+left	O
+intracardiac	B-ANAT
+shunt	O
+.	O
+
+However	O
+,	O
+unlike	O
+the	O
+earlier	O
+cases	O
+,	O
+and	O
+despite	O
+underlying	O
+chronic	B-DISO
+disease	I-DISO
+and	O
+a	O
+single	O
+kidney	B-ANAT
+,	O
+he	O
+survived	O
+his	O
+infection	B-DISO
+and	O
+has	O
+been	O
+discharged	O
+home	O
+.	O
+
+TITLE	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+in	O
+2012	O
+:	O
+20	O
+years	O
+after	O
+the	O
+institute	O
+of	O
+medicine	B-CHED
+report	O
+.	O
+
+The	O
+disease	O
+resembled	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+),	O
+causing	O
+a	O
+fatal	O
+epidemic	O
+in	O
+2002	O
+/	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+epidemiological	O
+features	O
+and	O
+types	O
+of	O
+human	O
+adenoviruses	B-SPEC
+(	O
+ADV	O
+)	O
+in	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+Nanjing	O
+area	O
+,	O
+China	O
+.	O
+
+Nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+and	O
+nasopharyngeal	B-ANAT
+swabs	O
+were	O
+collected	O
+from	O
+644	O
+outpatients	O
+or	O
+hospitalized	O
+pediatric	O
+patients	O
+with	O
+ARTI	O
+at	O
+the	O
+Children	O
+Hospital	O
+of	O
+Nanjing	O
+,	O
+Jiangsu	O
+Province	O
+,	O
+China	O
+,	O
+between	O
+August	O
+2010	O
+and	O
+July	O
+2011	O
+.	O
+
+ADV	O
+infection	B-DISO
+could	O
+occur	O
+in	O
+any	O
+season	O
+.	O
+
+There	O
+was	O
+a	O
+higher	O
+possibility	O
+of	O
+ADV	O
+infection	B-DISO
+from	O
+April	O
+to	O
+July	O
+in	O
+2011	O
+.	O
+
+A	O
+total	O
+of	O
+99	O
+of	O
+the	O
+171	O
+ADV	O
+-	O
+positive	O
+children	O
+(	O
+57	O
+.	O
+89	O
+%)	O
+were	O
+co	O
+-	O
+infected	O
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Although	O
+it	O
+can	O
+remain	O
+quiescent	O
+for	O
+extended	O
+time	O
+periods	B-PROC
+,	O
+the	O
+inflammatory	O
+and	O
+remodeling	O
+processes	O
+affect	O
+the	O
+bronchial	B-ANAT
+milieu	O
+and	O
+predispose	O
+to	O
+acute	O
+and	O
+occasionally	O
+severe	O
+clinical	O
+manifestations	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2007	O
+,	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+associated	O
+with	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+in	O
+alpacas	B-SPEC
+(	O
+Alpaca	B-SPEC
+Coronavirus	B-SPEC
+,	O
+ACoV	O
+)	O
+was	O
+isolated	O
+.	O
+
+The	O
+ACoV	O
+was	O
+genetically	O
+most	O
+similar	O
+to	O
+the	O
+common	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)	O
+229E	O
+with	O
+92	O
+.	O
+2	O
+%	O
+nucleotide	B-CHED
+identity	O
+over	O
+the	O
+entire	O
+genome	O
+.	O
+
+A	O
+comparison	O
+of	O
+spike	O
+gene	O
+sequences	O
+from	O
+ACoV	O
+and	O
+from	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+isolates	O
+recovered	O
+over	O
+a	O
+span	O
+of	O
+five	O
+decades	O
+showed	O
+the	O
+ACoV	O
+to	O
+be	O
+most	O
+similar	O
+to	O
+viruses	B-SPEC
+isolated	O
+in	O
+the	O
+1960	O
+'	O
+s	O
+to	O
+early	O
+1980	O
+'	O
+s	O
+.	O
+
+The	O
+Berlin	O
+definition	O
+resulted	O
+in	O
+the	O
+following	O
+modifications	O
+:	O
+a	O
+criterion	O
+of	O
+less	O
+than	O
+7	O
+days	O
+was	O
+used	O
+to	O
+define	O
+acute	O
+onset	O
+;	O
+the	O
+requirement	O
+of	O
+pulmonary	B-ANAT
+artery	I-ANAT
+wedge	O
+pressure	O
+was	O
+removed	O
+.	O
+
+Three	O
+-	O
+dimensional	O
+reconstructions	O
+identify	O
+DMVs	O
+as	O
+protrusions	B-DISO
+from	O
+the	O
+ER	B-COMP
+membrane	I-COMP
+into	O
+the	O
+cytosol	B-COMP
+,	O
+frequently	O
+connected	O
+to	O
+the	O
+ER	B-COMP
+membrane	I-COMP
+via	O
+a	O
+neck	B-ANAT
+-	O
+like	O
+structure	O
+.	O
+
+By	O
+contrast	O
+,	O
+the	O
+absence	O
+of	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+enhances	O
+CD8	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+function	O
+and	O
+accelerates	O
+viral	O
+control	O
+,	O
+but	O
+increases	O
+morbidity	O
+.	O
+
+The	O
+local	O
+requirement	O
+of	O
+CD4	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+help	O
+for	O
+CD8	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+function	O
+is	O
+not	O
+overcome	O
+if	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+inhibitory	O
+signals	O
+are	O
+lost	B-CHED
+.	O
+
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+-	O
+mediated	O
+restraint	O
+of	O
+CD4	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+activity	O
+is	O
+thus	O
+crucial	O
+to	O
+dampen	O
+both	O
+CD8	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+function	O
+and	O
+microglia	B-ANAT
+/	O
+macrophage	B-PROC
+activation	I-PROC
+,	O
+thereby	O
+providing	O
+protection	O
+from	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+bystander	O
+damage	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+is	O
+a	O
+high	O
+incidence	O
+of	O
+developing	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+pediatric	O
+patients	O
+with	O
+major	O
+burns	O
+,	O
+and	O
+this	O
+development	B-PROC
+leads	O
+to	O
+higher	O
+mortality	O
+.	O
+
+A	O
+single	O
+center	O
+,	O
+retrospective	O
+chart	O
+review	O
+of	O
+pediatric	O
+burn	O
+patients	O
+with	O
+ARDS	B-DISO
+from	O
+1996	O
+to	O
+2007	O
+was	O
+completed	O
+.	O
+
+Daily	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+(	O
+P	O
+(	O
+a	O
+)	O
+O	O
+(	O
+2	O
+)):	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+))	O
+and	O
+oxygenation	B-PROC
+index	O
+was	O
+calculated	O
+for	O
+each	O
+patient	O
+.	O
+
+TITLE	O
+:	O
+Worsening	O
+respiratory	B-PROC
+function	I-PROC
+in	O
+mechanically	O
+ventilated	O
+intensive	O
+care	O
+patients	O
+:	O
+feasibility	O
+and	O
+value	O
+of	O
+xenon	O
+-	O
+enhanced	O
+dual	O
+energy	O
+CT	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+feasibility	O
+and	O
+incremental	O
+diagnostic	O
+value	O
+of	O
+xenon	B-CHED
+-	O
+enhanced	O
+dual	O
+-	O
+energy	O
+CT	O
+in	O
+mechanically	O
+ventilated	O
+intensive	O
+care	O
+patients	O
+with	O
+worsening	O
+respiratory	B-PROC
+function	I-PROC
+.	O
+
+CT	O
+scans	O
+were	O
+performed	O
+using	O
+a	O
+dual	O
+-	O
+source	O
+CT	O
+scanner	O
+at	O
+an	O
+expiratory	B-PROC
+xenon	B-CHED
+concentration	O
+of	O
+30	O
+%.	O
+
+Ventilation	O
+defects	O
+on	O
+xenon	B-CHED
+images	O
+were	O
+matched	O
+to	O
+morphological	O
+findings	O
+on	O
+standard	O
+CT	O
+images	O
+and	O
+incremental	O
+diagnostic	O
+information	O
+of	O
+xenon	B-CHED
+ventilation	O
+images	O
+was	O
+recorded	O
+if	O
+present	O
+.	O
+
+In	O
+the	O
+visual	O
+CT	O
+analysis	O
+,	O
+the	O
+Xe	O
+-	O
+DECT	O
+ventilation	O
+defects	O
+matched	O
+with	O
+pathologic	O
+changes	O
+in	O
+lung	B-ANAT
+parenchyma	I-ANAT
+seen	O
+in	O
+the	O
+standard	O
+CT	O
+images	O
+in	O
+all	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Full	O
+genome	O
+analysis	O
+of	O
+a	O
+novel	O
+type	O
+II	O
+feline	B-SPEC
+coronavirus	B-SPEC
+NTU156	O
+.	O
+
+ABSTRACT	O
+:	O
+Infections	B-DISO
+by	O
+type	O
+II	O
+feline	O
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+have	O
+been	O
+shown	O
+to	O
+be	O
+significantly	O
+correlated	O
+with	O
+fatal	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+Two	O
+hMPV	B-SPEC
+subtypes	O
+were	O
+identified	O
+,	O
+A2	O
+(	O
+26	O
+.	O
+9	O
+%;	O
+7	O
+/	O
+26	O
+)	O
+and	O
+B2	O
+(	O
+73	O
+.	O
+1	O
+%;	O
+19	O
+/	O
+26	O
+)	O
+but	O
+no	O
+difference	O
+was	O
+observed	O
+between	O
+the	O
+patient	O
+groups	O
+in	O
+terms	O
+of	O
+age	O
+or	O
+immunosuppression	B-PROC
+level	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+mouse	B-SPEC
+-	O
+adapted	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+MK	B-PRGE
+-	I-PRGE
+p10	I-PRGE
+,	O
+showed	O
+higher	O
+neurovirulence	O
+in	O
+suckling	O
+mice	B-SPEC
+than	O
+a	O
+non	O
+-	O
+adapted	O
+MK	O
+strain	O
+.	O
+
+There	O
+was	O
+no	O
+difference	O
+in	O
+virus	B-SPEC
+growth	B-PROC
+,	O
+whereas	O
+clear	O
+differences	O
+between	O
+these	O
+two	O
+virus	B-SPEC
+infections	B-DISO
+existed	O
+in	O
+the	O
+type	O
+of	O
+target	B-ANAT
+cells	I-ANAT
+infected	O
+,	O
+the	O
+spread	O
+of	O
+virus	B-SPEC
+and	O
+the	O
+cytokine	O
+levels	O
+produced	O
+in	O
+the	O
+brain	B-ANAT
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+review	O
+is	O
+to	O
+bring	O
+together	O
+all	O
+the	O
+reported	O
+pulmonary	B-ANAT
+manifestations	O
+of	O
+leptospirosis	B-DISO
+and	O
+the	O
+recent	O
+trends	O
+in	O
+the	O
+management	O
+.	O
+
+ABSTRACT	O
+:	O
+Natural	O
+killer	O
+(	O
+NK	O
+)	O
+cells	O
+are	O
+cytotoxic	O
+lymphocytes	B-ANAT
+and	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+early	O
+defence	O
+against	O
+viruses	B-SPEC
+.	O
+
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+mRNA	I-PRGE
+and	O
+proteins	B-CHED
+were	O
+not	O
+rapidly	O
+induced	O
+whereas	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+production	O
+in	O
+lung	B-ANAT
+,	O
+measured	O
+by	O
+Elispot	O
+assay	O
+,	O
+increased	O
+over	O
+time	O
+at	O
+2	O
+and	O
+4	O
+dpi	O
+.	O
+
+ABSTRACT	O
+:	O
+BoCV	O
+isolated	O
+from	O
+respiratory	O
+tract	O
+,	O
+nasal	B-ANAT
+swab	O
+and	O
+broncho	B-ANAT
+alveolar	I-ANAT
+washing	O
+fluid	O
+samples	O
+were	O
+evaluated	O
+for	O
+genetic	O
+and	O
+antigenic	O
+differences	O
+.	O
+
+Currently	O
+available	O
+vaccines	O
+designed	O
+to	O
+control	O
+enteric	O
+disease	O
+are	O
+based	O
+on	O
+viruses	B-SPEC
+from	O
+one	O
+clade	O
+while	O
+viruses	B-SPEC
+isolated	O
+from	O
+respiratory	B-ANAT
+tracts	I-ANAT
+,	O
+in	O
+this	O
+study	O
+,	O
+belong	O
+to	O
+the	O
+other	O
+clade	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+characteristics	O
+of	O
+children	O
+with	O
+viral	O
+single	O
+-	O
+and	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+and	O
+a	O
+petechial	B-DISO
+rash	I-DISO
+.	O
+
+However	O
+,	O
+viruses	B-SPEC
+have	O
+also	O
+been	O
+associated	O
+with	O
+petechial	B-DISO
+rash	I-DISO
+.	O
+
+RESULTS	O
+:	O
+A	O
+viral	O
+pathogen	O
+was	O
+identified	O
+in	O
+67	O
+%	O
+of	O
+the	O
+analyzed	O
+58	O
+cases	O
+with	O
+petechial	B-DISO
+rash	I-DISO
+.	O
+
+A	O
+roadmap	O
+for	O
+the	O
+product	O
+development	O
+of	O
+the	O
+RBD	O
+-	O
+S	O
+SARS	B-DISO
+vaccine	O
+is	O
+outlined	O
+with	O
+a	O
+goal	O
+to	O
+manufacture	O
+the	O
+vaccine	O
+for	O
+clinical	O
+testing	O
+within	O
+the	O
+next	O
+5	O
+years	O
+.	O
+
+We	O
+therefore	O
+assessed	O
+the	O
+effects	O
+on	O
+gas	B-ENZY
+exchange	O
+and	O
+lung	B-ANAT
+mechanics	O
+and	O
+the	O
+possible	O
+detrimental	O
+effects	O
+of	O
+a	O
+sequential	O
+lung	B-ANAT
+RMs	O
+and	O
+decremental	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+titration	O
+in	O
+pediatric	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Efficacy	O
+was	O
+evaluated	O
+as	O
+changes	O
+in	O
+lung	B-PROC
+compliance	I-PROC
+(	O
+Cdyn	O
+)	O
+and	O
+gas	B-PRGE
+exchange	I-PRGE
+1	I-PRGE
+,	O
+12	O
+,	O
+and	O
+24	O
+hr	O
+after	O
+the	O
+RM	O
+.	O
+
+RMs	O
+and	O
+a	O
+decremental	O
+PEEP	B-CHED
+trial	O
+may	O
+improve	O
+lung	B-PROC
+function	I-PROC
+in	O
+pediatric	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+severe	O
+hypoxemia	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+included	O
+25	O
+patients	O
+,	O
+of	O
+median	O
+age	O
+5	O
+(	O
+1	O
+-	O
+16	O
+)	O
+months	O
+,	O
+median	O
+weight	O
+7	O
+.	O
+0	O
+(	O
+4	O
+.	O
+1	O
+-	O
+9	O
+.	O
+2	O
+)	O
+kg	O
+,	O
+median	O
+PaO2	O
+/	O
+FIO2	O
+117	O
+(	O
+96	O
+-	O
+139	O
+),	O
+and	O
+median	O
+Cdyn	O
+0	O
+.	O
+48	O
+(	O
+0	O
+.	O
+41	O
+-	O
+0	O
+.	O
+68	O
+)	O
+ml	O
+/	O
+cmH2	B-DISO
+O	O
+/	O
+kg	O
+at	O
+baseline	O
+.	O
+
+The	O
+etiological	O
+backgrounds	O
+of	O
+these	O
+infections	B-DISO
+remain	O
+unconfirmed	O
+in	O
+most	O
+clinical	O
+cases	O
+.	O
+
+Of	O
+the	O
+HCoV	O
+-	O
+positive	O
+children	O
+,	O
+70	O
+.	O
+3	O
+%	O
+had	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+Of	O
+the	O
+HCoV	O
+-	O
+positive	O
+children	O
+,	O
+70	O
+.	O
+3	O
+%	O
+had	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+is	O
+frequent	O
+in	O
+surgical	O
+and	O
+medical	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+has	O
+a	O
+serious	O
+impact	O
+on	O
+the	O
+function	O
+of	O
+respiratory	O
+as	O
+well	O
+as	O
+peripheral	O
+organs	B-ANAT
+.	O
+
+Additionally	O
+,	O
+KIOM	O
+198	O
+exhibited	O
+a	O
+similar	O
+extent	O
+of	O
+antiviral	B-CHED
+effect	O
+against	O
+other	O
+subtypes	O
+of	O
+Corona	B-CHED
+virus	B-SPEC
+such	O
+as	O
+sm98	O
+and	O
+TGE	B-DISO
+viruses	B-SPEC
+.	O
+
+Cytotoxicity	B-DISO
+results	O
+showed	O
+that	O
+KIOM	O
+198	O
+is	O
+nontoxic	O
+on	O
+the	O
+cells	B-COMP
+and	O
+suggest	O
+that	O
+it	O
+can	O
+be	O
+delivered	O
+safely	O
+for	O
+therapy	O
+.	O
+
+Furthermore	O
+,	O
+when	O
+we	O
+orally	O
+administered	O
+KIOM	O
+198	O
+to	O
+piglets	O
+and	O
+then	O
+infected	O
+them	O
+with	O
+PEDV	B-SPEC
+,	O
+the	O
+piglets	O
+did	O
+not	O
+show	O
+any	O
+disease	O
+symptoms	O
+like	O
+diarrhea	B-DISO
+and	O
+biopsy	O
+results	O
+showed	O
+clean	O
+intestine	B-ANAT
+,	O
+whereas	O
+control	O
+pigs	B-SPEC
+without	O
+KIOM	O
+198	O
+treatment	O
+exhibited	O
+PED	O
+-	O
+related	O
+severe	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+Abdominal	B-ANAT
+obesity	I-DISO
+and	O
+prolonged	O
+prone	O
+positioning	O
+increase	O
+risk	O
+of	O
+developing	O
+sclerosing	B-DISO
+cholangitis	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+influenza	B-PATH
+A	I-PATH
+-	O
+associated	O
+ARDS	B-DISO
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+obesity	B-DISO
+,	O
+intraperitoneal	O
+fat	O
+volume	O
+,	O
+and	O
+a	O
+longer	O
+cumulative	O
+duration	O
+spent	O
+in	O
+the	O
+prone	O
+position	O
+may	O
+put	O
+patients	O
+with	O
+ARDS	B-DISO
+at	O
+risk	O
+of	O
+developing	O
+SC	B-PRGE
+-	I-PRGE
+CIP	I-PRGE
+.	O
+
+First	O
+line	O
+hypoxaemic	O
+rescue	O
+therapies	O
+include	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+,	O
+prone	O
+positioning	O
+,	O
+alveolar	B-ANAT
+recruitment	B-DISO
+manoeuvres	O
+and	O
+high	O
+frequency	O
+oscillatory	O
+ventilation	O
+,	O
+which	O
+have	O
+all	O
+been	O
+shown	O
+to	O
+be	O
+effective	O
+in	O
+improving	O
+oxygenation	B-PROC
+.	O
+
+Non	O
+-	O
+specific	O
+reactions	O
+were	O
+not	O
+observed	O
+when	O
+other	O
+viruses	B-SPEC
+and	O
+bacteria	B-SPEC
+were	O
+used	O
+for	O
+evaluating	O
+the	O
+mnRT	O
+-	O
+PCR	O
+.	O
+
+Adoptive	O
+transfer	O
+of	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+from	O
+MHV	B-SPEC
+-	O
+3	O
+infected	O
+mice	B-SPEC
+led	O
+to	O
+a	O
+significant	O
+increase	O
+in	O
+mice	B-SPEC
+survival	O
+.	O
+
+The	O
+benefits	O
+of	O
+attempting	O
+to	O
+fully	O
+reverse	O
+arterial	B-ANAT
+hypoxemia	O
+may	O
+be	O
+outweighed	O
+by	O
+the	O
+harms	O
+associated	O
+with	O
+high	O
+concentrations	O
+of	O
+supplemental	O
+oxygen	B-CHED
+and	O
+invasive	O
+mechanical	O
+ventilation	O
+strategies	O
+.	O
+
+The	O
+aim	O
+of	O
+permissive	O
+hypoxemia	O
+is	O
+to	O
+minimize	O
+the	O
+possible	O
+harms	O
+caused	O
+by	O
+restoration	O
+of	O
+normoxemia	O
+while	O
+avoiding	O
+tissue	B-ANAT
+hypoxia	B-DISO
+.	O
+
+We	O
+also	O
+identified	O
+large	O
+clinical	O
+studies	O
+in	O
+patients	O
+with	O
+critical	B-DISO
+illness	I-DISO
+characterized	O
+by	O
+hypoxemia	O
+such	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+However	O
+,	O
+at	O
+present	O
+there	O
+is	O
+no	O
+direct	O
+evidence	O
+to	O
+support	O
+the	O
+immediate	O
+implementation	O
+of	O
+permissive	O
+hypoxemia	O
+and	O
+a	O
+comprehensive	O
+evaluation	O
+of	O
+its	O
+value	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+should	O
+be	O
+a	O
+high	O
+research	O
+priority	O
+.	O
+
+TITLE	O
+:	O
+Soft	O
+-	O
+X	O
+-	O
+ray	B-SPEC
+-	O
+enhanced	O
+electrostatic	O
+precipitation	B-PROC
+for	O
+protection	O
+against	O
+inhalable	O
+allergens	O
+,	O
+ultrafine	O
+particles	O
+,	O
+and	O
+microbial	O
+infections	O
+.	O
+
+Incorporating	O
+soft	O
+X	O
+-	O
+ray	B-SPEC
+irradiation	O
+as	O
+an	O
+in	O
+situ	O
+component	O
+of	O
+the	O
+electrostatic	O
+precipitation	B-PROC
+process	O
+greatly	O
+improves	O
+capture	O
+efficiency	O
+of	O
+ultrafine	O
+particles	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	O
+are	O
+being	O
+increasingly	O
+recognized	O
+as	O
+an	O
+important	O
+reservoir	O
+of	O
+zoonotic	O
+viruses	B-SPEC
+of	O
+different	O
+families	O
+,	O
+including	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+Hendra	B-SPEC
+virus	I-SPEC
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+.	O
+
+Several	O
+recent	O
+studies	O
+hypothesized	O
+that	O
+bats	B-SPEC
+,	O
+an	O
+ancient	O
+group	O
+of	O
+flying	O
+mammals	B-SPEC
+,	O
+are	O
+the	O
+major	O
+reservoir	O
+of	O
+several	O
+important	O
+RNA	O
+virus	B-SPEC
+families	O
+from	O
+which	O
+other	O
+mammalian	B-SPEC
+viruses	B-SPEC
+of	O
+livestock	O
+and	O
+humans	B-SPEC
+were	O
+derived	O
+.	O
+
+The	O
+question	O
+of	O
+whether	O
+bats	B-SPEC
+have	O
+unique	O
+biological	O
+features	O
+making	O
+them	O
+ideal	O
+reservoir	O
+hosts	B-COMP
+has	O
+been	O
+the	O
+subject	O
+of	O
+several	O
+recent	O
+reviews	O
+.	O
+
+Analysis	O
+of	O
+mutant	O
+viruses	B-SPEC
+resistant	O
+to	O
+neutralization	O
+by	O
+4H4	O
+revealed	O
+that	O
+the	O
+antigenic	O
+site	O
+of	O
+the	O
+Kakegawa	O
+strain	O
+maps	O
+to	O
+amino	B-CHED
+acid	I-CHED
+position	O
+284	O
+of	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Chemokine	O
+(	O
+C	O
+-	O
+C	O
+motif	O
+)	O
+ligand	B-PROC
+2	O
+(	O
+CCL2	B-CHED
+),	O
+a	O
+chemoattractant	O
+for	O
+macrophages	B-ANAT
+,	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+cells	B-COMP
+expressing	O
+CCR2	B-PRGE
+,	O
+is	O
+upregulated	O
+during	O
+acute	B-DISO
+and	I-DISO
+chronic	I-DISO
+inflammation	I-DISO
+.	O
+
+CCL2	B-PRGE
+Tg	O
+mice	B-SPEC
+mounted	O
+a	O
+dysregulated	O
+immune	B-PROC
+response	I-PROC
+,	O
+characterized	O
+by	O
+augmented	O
+accumulation	O
+of	O
+regulatory	O
+Foxp3	B-PRGE
+(+)	I-PRGE
+CD4	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+of	O
+nitric	O
+-	O
+oxide	B-CHED
+-	O
+and	O
+YM	O
+-	O
+1	O
+-	O
+expressing	O
+macrophages	B-ANAT
+and	O
+microglia	B-ANAT
+,	O
+suggestive	O
+of	O
+mixed	O
+M1	O
+/	O
+M2	O
+macrophage	B-PROC
+activation	I-PROC
+.	O
+
+Further	O
+,	O
+macrophages	B-ANAT
+from	O
+infected	O
+CCL2	B-PRGE
+Tg	I-PRGE
+brains	B-ANAT
+relative	O
+to	O
+non	O
+-	O
+Tg	O
+controls	O
+were	O
+less	O
+activated	O
+/	O
+mature	O
+,	O
+expressing	O
+lower	O
+levels	O
+of	O
+major	B-PRGE
+histocompatibility	I-PRGE
+complex	I-PRGE
+class	B-SPEC
+II	I-PRGE
+(	O
+MHC	B-PRGE
+-	I-PRGE
+II	I-PRGE
+),	O
+CD86	B-PRGE
+,	O
+and	O
+CD40	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+nsp1	B-PRGE
+has	O
+been	O
+shown	O
+to	O
+induce	O
+suppression	B-DISO
+of	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+and	O
+to	O
+interfere	O
+with	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+.	O
+
+During	O
+the	O
+study	O
+period	O
+,	O
+rhinovirus	B-SPEC
+was	O
+detected	O
+in	O
+20	O
+%	O
+and	O
+coronavirus	B-SPEC
+in	O
+6	O
+%	O
+of	O
+samples	O
+using	O
+FilmArray	O
+;	O
+these	O
+viruses	B-SPEC
+would	O
+not	O
+have	O
+been	O
+detected	O
+with	O
+DFA	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Oxygen	B-CHED
+is	O
+necessary	O
+for	O
+all	O
+aerobic	O
+life	O
+,	O
+and	O
+nothing	O
+is	O
+more	O
+important	O
+in	O
+respiratory	O
+care	O
+than	O
+its	O
+proper	O
+understanding	O
+,	O
+assessment	O
+,	O
+and	O
+administration	O
+.	O
+
+Severe	O
+hypoxemia	O
+in	O
+acute	O
+lung	O
+injury	O
+and	O
+ARDS	B-DISO
+can	O
+be	O
+improved	O
+by	O
+ventilation	O
+with	O
+PEEP	B-CHED
+,	O
+and	O
+also	O
+in	O
+many	O
+patients	O
+by	O
+various	O
+adjunctive	O
+techniques	O
+and	O
+alternative	O
+support	O
+strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+Cheetahs	B-SPEC
+(	O
+Acinonyx	B-SPEC
+jubatus	I-SPEC
+)	O
+are	O
+a	O
+highly	O
+threatened	O
+species	B-SPEC
+because	O
+of	O
+habitat	O
+loss	O
+,	O
+human	B-SPEC
+conflict	O
+,	O
+and	O
+high	O
+prevalence	O
+of	O
+disease	O
+in	O
+captivity	O
+.	O
+
+Forty	O
+-	O
+four	O
+percent	O
+(	O
+7	O
+/	O
+16	O
+)	O
+of	O
+cheetahs	B-SPEC
+had	O
+detectable	O
+FCoV	O
+in	O
+feces	B-ANAT
+,	O
+and	O
+the	O
+proportion	O
+of	O
+positive	O
+samples	O
+for	O
+individual	O
+animals	B-SPEC
+ranged	O
+from	O
+13	O
+to	O
+93	O
+%.	O
+
+We	O
+,	O
+therefore	O
+propose	O
+that	O
+the	O
+difference	O
+in	O
+the	O
+catalytic	O
+efficiency	O
+of	O
+these	O
+two	O
+constructs	O
+is	O
+due	O
+to	O
+the	O
+interference	O
+of	O
+ATP	O
+binding	O
+by	O
+the	O
+histidine	B-CHED
+tag	B-DISO
+at	O
+the	O
+amino	O
+—	O
+terminus	O
+of	O
+nsp13	O
+.	O
+
+Thirty	O
+-	O
+two	O
+(	O
+64	O
+%)	O
+were	O
+obese	B-DISO
+.	O
+
+Forty	O
+-	O
+eight	O
+patients	O
+(	O
+96	O
+%)	O
+experienced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+28	O
+(	O
+56	O
+%)	O
+septic	B-DISO
+shock	I-DISO
+,	O
+and	O
+27	O
+(	O
+54	O
+%)	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Viral	B-DISO
+shedding	I-DISO
+was	O
+readily	O
+detected	O
+from	O
+the	O
+oropharynx	B-ANAT
+up	O
+to	O
+10	O
+days	O
+post	O
+infection	B-DISO
+,	O
+but	O
+there	O
+was	O
+little	O
+or	O
+no	O
+evidence	O
+of	O
+rectal	O
+shedding	O
+.	O
+
+Immunomonitoring	O
+platforms	O
+typically	O
+concentrate	O
+on	O
+restriction	O
+elements	O
+associated	O
+with	O
+European	O
+ancestry	O
+,	O
+and	O
+such	O
+tools	O
+are	O
+scarce	O
+for	O
+Asian	B-PRGE
+HLA	I-PRGE
+variants	O
+.	O
+
+We	O
+report	O
+30	O
+novel	O
+irradiation	O
+-	O
+sensitive	O
+ligands	O
+,	O
+specifically	O
+targeting	B-PROC
+South	O
+East	O
+Asian	O
+populations	O
+,	O
+which	O
+provide	O
+93	O
+,	O
+63	O
+,	O
+and	O
+79	O
+%	O
+coverage	O
+for	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+,	I-PRGE
+-	I-PRGE
+B	I-PRGE
+,	O
+and	O
+-	O
+C	O
+,	O
+respectively	O
+.	O
+
+HLA	B-PRGE
+tetramers	I-PRGE
+with	O
+redirected	O
+specificity	O
+could	O
+detect	O
+antigen	B-CHED
+-	O
+specific	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+against	O
+human	B-SPEC
+cytomegalovirus	I-SPEC
+,	O
+hepatitis	B-DISO
+B	I-DISO
+(	O
+HBV	B-DISO
+),	O
+dengue	B-DISO
+virus	I-SPEC
+(	O
+DENV	O
+),	O
+and	O
+Epstein	O
+-	O
+Barr	O
+virus	O
+(	O
+EBV	O
+)	O
+infections	B-DISO
+.	O
+
+The	O
+potential	O
+of	O
+this	O
+population	O
+-	O
+centric	O
+HLA	B-ANAT
+library	O
+was	O
+demonstrated	O
+with	O
+the	O
+characterization	O
+of	O
+seven	O
+novel	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+,	O
+HBV	B-DISO
+,	O
+and	O
+DENV	O
+.	O
+
+Posthoc	O
+analysis	O
+revealed	O
+that	O
+the	O
+majority	O
+of	O
+responses	O
+would	O
+be	O
+more	O
+readily	O
+identified	O
+by	O
+our	O
+unbiased	O
+discovery	O
+approach	O
+than	O
+through	O
+the	O
+application	O
+of	O
+state	O
+-	O
+of	O
+-	O
+the	O
+-	O
+art	O
+epitope	B-CHED
+prediction	O
+.	O
+
+TITLE	O
+:	O
+Burden	O
+of	O
+Chronic	O
+Respiratory	B-DISO
+Diseases	I-DISO
+(	O
+CRD	B-DISO
+)	O
+in	O
+Middle	O
+East	O
+and	O
+North	O
+Africa	O
+(	O
+MENA	O
+).	O
+
+They	O
+are	O
+essentially	O
+represented	O
+by	O
+COPD	B-DISO
+,	O
+asthma	B-PATH
+,	O
+and	O
+allergic	O
+diseases	O
+.	O
+
+Swabs	O
+were	O
+tested	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+for	O
+15	O
+respiratory	O
+viruses	B-SPEC
+and	O
+subtypes	O
+.	O
+
+RESULTS	O
+:	O
+At	O
+least	O
+1	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+382	O
+(	O
+84	O
+%)	O
+of	O
+455	O
+new	O
+-	O
+onset	O
+illnesses	O
+with	O
+multiple	O
+viruses	B-SPEC
+identified	O
+in	O
+212	O
+(	O
+46	O
+%).	O
+
+Ten	O
+patients	O
+were	O
+successfully	O
+weaned	B-PROC
+from	O
+ECMO	O
+,	O
+of	O
+whom	O
+2	O
+died	B-PROC
+in	O
+ICU	O
+.	O
+
+Despite	O
+low	O
+potential	O
+toxicity	O
+of	O
+this	O
+herbicide	B-CHED
+,	O
+a	O
+number	O
+of	O
+fatalities	O
+and	O
+severe	O
+outcomes	O
+are	O
+reported	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+is	O
+to	O
+describe	O
+the	O
+clinical	O
+feature	O
+and	O
+determinate	O
+the	O
+utility	O
+of	O
+the	O
+glyphosate	B-CHED
+concentration	O
+in	O
+blood	B-ANAT
+and	O
+urine	B-ANAT
+and	O
+the	O
+dose	O
+taken	O
+for	O
+predicting	O
+clinical	O
+outcomes	O
+.	O
+
+Decreasing	O
+the	O
+ECMO	O
+flow	O
+from	O
+its	O
+baseline	O
+maximum	O
+value	O
+(	O
+5	O
+.	O
+8	O
+±	O
+0	O
+.	O
+8	O
+L	O
+/	O
+min	O
+)	O
+to	O
+40	O
+%	O
+less	O
+(	O
+2	O
+.	O
+4	O
+±	O
+0	O
+.	O
+3	O
+L	O
+/	O
+min	O
+)	O
+significantly	O
+decreased	O
+mean	O
+PaO2	O
+(	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+;	O
+88	O
+±	O
+24	O
+to	O
+45	O
+±	O
+9	O
+mm	O
+Hg	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+SaO2	B-PROC
+(	O
+oxygen	B-CHED
+saturation	O
+;	O
+97	O
+±	O
+2	O
+to	O
+82	O
+±	O
+10	O
+%;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+When	O
+the	O
+ECMO	O
+flow	O
+/	O
+cardiac	B-ANAT
+output	O
+was	O
+>	O
+60	O
+%,	O
+SaO2	B-PROC
+was	O
+always	O
+>	O
+90	O
+%.	O
+
+In	O
+a	O
+recent	O
+article	O
+,	O
+van	O
+Boheemen	O
+et	O
+al	O
+.	O
+demonstrated	O
+how	O
+state	O
+-	O
+of	O
+-	O
+the	O
+-	O
+art	O
+sequencing	O
+technology	O
+and	O
+bioinformatic	O
+analysis	O
+can	O
+quickly	O
+provide	O
+critical	O
+insight	O
+into	O
+the	O
+viral	B-COMP
+genome	I-COMP
+sequence	O
+,	O
+phylogeny	O
+,	O
+replication	O
+strategy	O
+,	O
+and	O
+potential	O
+drug	O
+and	O
+vaccine	O
+targets	O
+and	O
+generate	O
+tools	O
+to	O
+evaluate	O
+the	O
+possible	O
+epidemic	O
+risk	O
+associated	O
+with	O
+this	O
+novel	O
+human	O
+virus	B-SPEC
+.	O
+
+Virus	B-SPEC
+detection	O
+rates	O
+in	O
+KD	O
+patients	O
+and	O
+control	O
+subjects	O
+were	O
+32	O
+.	O
+7	O
+%	O
+and	O
+30	O
+.	O
+8	O
+%,	O
+respectively	O
+(	O
+P	O
+=	O
+0	O
+.	O
+811	O
+).	O
+
+Comparisons	O
+between	O
+the	O
+18	O
+patients	O
+with	O
+positive	O
+RT	O
+-	O
+PCR	O
+results	O
+and	O
+the	O
+other	O
+37	O
+KD	O
+patients	O
+revealed	O
+no	O
+significant	O
+differences	O
+in	O
+terms	O
+of	O
+clinical	B-DISO
+findings	I-DISO
+(	O
+including	O
+the	O
+prevalence	O
+of	O
+incomplete	O
+presentation	O
+of	O
+the	O
+disease	O
+)	O
+and	O
+coronary	B-ANAT
+artery	I-ANAT
+diameter	O
+.	O
+
+TITLE	O
+:	O
+Astrocyte	B-ANAT
+-	O
+derived	O
+CXCL10	B-PRGE
+drives	O
+accumulation	O
+of	O
+antibody	B-ANAT
+-	I-ANAT
+secreting	B-PROC
+cells	B-COMP
+in	O
+the	O
+central	B-ANAT
+nervous	B-DISO
+system	I-ANAT
+during	O
+viral	O
+encephalomyelitis	B-DISO
+.	O
+
+While	O
+CXCL10	B-PRGE
+was	O
+predominantly	O
+expressed	B-PROC
+by	O
+astrocytes	B-ANAT
+,	O
+CXCL9	B-PRGE
+expression	B-PROC
+was	O
+confined	O
+to	O
+the	O
+vasculature	B-ANAT
+/	O
+perivascular	B-ANAT
+spaces	I-ANAT
+.	O
+
+NMR	O
+chemical	O
+shift	O
+perturbation	O
+analysis	O
+reveals	O
+that	O
+the	O
+N	O
+-	O
+terminal	O
+region	O
+of	O
+an	O
+MHV	B-SPEC
+N	O
+SR	O
+-	O
+rich	O
+linker	O
+peptide	B-CHED
+(	O
+residues	O
+198	O
+to	O
+230	O
+)	O
+binds	B-FUNC
+to	O
+the	O
+acidic	O
+face	B-DISO
+of	O
+MHV	B-SPEC
+nsp3a	O
+containing	O
+the	O
+acidic	O
+α2	O
+helix	O
+with	O
+an	O
+affinity	O
+(	O
+expressed	B-PROC
+as	O
+K	O
+(	O
+a	O
+))	O
+of	O
+8	O
+.	O
+1	O
+×	O
+10	O
+(	O
+3	O
+)	O
+M	O
+(-	O
+1	O
+).	O
+
+These	O
+studies	O
+reveal	O
+that	O
+the	O
+SR	O
+-	O
+rich	O
+linker	O
+of	O
+MHV	B-SPEC
+N	O
+is	O
+necessary	O
+but	O
+not	O
+sufficient	O
+to	O
+maintain	O
+this	O
+high	O
+-	O
+affinity	O
+binding	B-FUNC
+to	O
+N	O
+.	O
+
+Intrathoracic	B-DISO
+goiters	I-DISO
+cause	O
+adjacent	O
+structure	O
+compression	O
+more	O
+frequently	O
+than	O
+the	O
+cervical	B-ANAT
+goiters	B-DISO
+,	O
+due	O
+to	O
+the	O
+limited	O
+space	O
+of	O
+the	O
+thoracic	B-ANAT
+cage	I-ANAT
+.	O
+
+Tracheal	O
+compression	O
+by	O
+(	O
+cervical	B-ANAT
+or	O
+thoracic	B-DISO
+)	O
+goiter	B-DISO
+is	O
+also	O
+an	O
+indication	O
+for	O
+resection	O
+;	O
+early	O
+tracheal	O
+decompression	O
+is	O
+recommended	O
+particularly	O
+in	O
+symptomatic	O
+patients	O
+.	O
+
+We	O
+hereby	O
+present	O
+successful	O
+and	O
+uncomplicated	O
+total	O
+thyroidectomy	O
+,	O
+through	O
+a	O
+median	O
+sternotomy	O
+,	O
+of	O
+a	O
+benign	O
+,	O
+gigantic	O
+,	O
+bilateral	O
+,	O
+retrovascular	O
+,	O
+posterior	O
+mediastinal	B-ANAT
+,	O
+intrathoracic	B-DISO
+goiter	I-DISO
+,	O
+encircling	O
+the	O
+trachea	B-DISO
+,	O
+and	O
+causing	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+in	O
+a	O
+63	O
+year	O
+old	O
+man	B-CHED
+with	O
+history	O
+of	O
+previous	O
+subtotal	O
+thyroidectomy	O
+.	O
+
+TITLE	O
+:	O
+Lower	O
+tidal	O
+volume	O
+strategy	O
+(≈	O
+3	O
+ml	O
+/	O
+kg	O
+)	O
+combined	O
+with	O
+extracorporeal	O
+CO2	B-CHED
+removal	O
+versus	O
+'	O
+conventional	O
+'	O
+protective	O
+ventilation	O
+(	O
+6	O
+ml	O
+/	O
+kg	O
+)	O
+in	O
+severe	O
+ARDS	O
+:	O
+the	O
+prospective	O
+randomized	O
+Xtravent	O
+-	O
+study	O
+.	O
+
+They	O
+were	O
+randomly	O
+assigned	O
+to	O
+receive	O
+a	O
+low	O
+V	O
+(	O
+T	O
+)	O
+ventilation	O
+(≈	O
+3	O
+ml	O
+/	O
+kg	O
+)	O
+combined	O
+with	O
+extracorporeal	O
+CO2	B-CHED
+elimination	B-PROC
+,	O
+or	O
+to	O
+a	O
+ARDSNet	O
+strategy	O
+(≈	O
+6	O
+ml	O
+/	O
+kg	O
+)	O
+without	O
+the	O
+extracorporeal	O
+device	O
+.	O
+
+Secondary	O
+outcome	O
+parameters	O
+were	O
+respiratory	O
+mechanics	O
+,	O
+gas	B-ENZY
+exchange	O
+,	O
+analgesic	B-CHED
+/	O
+sedation	B-DISO
+use	O
+,	O
+complications	O
+and	O
+hospital	O
+mortality	O
+.	O
+
+Ventilation	O
+with	O
+very	O
+low	O
+V	O
+(	O
+T	O
+)'	O
+s	O
+was	O
+easy	O
+to	O
+implement	O
+with	O
+extracorporeal	O
+CO2	B-CHED
+-	O
+removal	O
+.	O
+
+ABSTRACT	O
+:	O
+Refeeding	O
+syndrome	O
+is	O
+a	O
+potentially	O
+life	O
+-	O
+threatening	O
+condition	B-DISO
+characterised	O
+by	O
+severe	O
+intracellular	B-COMP
+electrolyte	O
+shifts	O
+,	O
+acute	O
+circulatory	B-PROC
+fluid	B-DISO
+overload	I-DISO
+and	O
+organ	B-DISO
+failure	I-DISO
+.	O
+
+Secondary	O
+outcome	O
+:	O
+analysis	O
+of	O
+the	O
+risk	O
+factors	O
+which	O
+predict	O
+the	O
+refeeding	B-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+presence	O
+of	O
+cyanosis	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+000	O
+;	O
+OR	O
+,	O
+351	O
+.	O
+7	O
+)	O
+and	O
+lung	B-DISO
+consolidation	I-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+006	O
+,	O
+OR	O
+,	O
+9	O
+.	O
+3	O
+)	O
+were	O
+independent	O
+risk	O
+factors	O
+associated	O
+with	O
+ICU	O
+admission	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+infection	B-DISO
+is	O
+rare	O
+but	O
+must	O
+be	O
+considered	O
+when	O
+the	O
+appropriate	O
+clinical	O
+and	O
+radiological	O
+pattern	O
+occurs	O
+.	O
+
+We	O
+investigated	O
+HBP	B-DISO
+in	O
+plasma	B-ANAT
+samples	O
+within	O
+36	O
+h	O
+from	O
+trauma	O
+in	O
+47	O
+patients	O
+admitted	O
+to	O
+a	O
+level	O
+one	O
+trauma	O
+centre	O
+with	O
+a	O
+mean	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+of	O
+26	O
+(	O
+21	O
+-	O
+34	O
+).	O
+
+We	O
+found	O
+no	O
+correlation	O
+between	O
+individual	O
+maximal	O
+plasma	B-PRGE
+HBP	B-DISO
+levels	O
+at	O
+admission	O
+and	O
+ISS	B-DISO
+,	O
+admission	O
+SOFA	O
+or	O
+APACHE	O
+II	O
+.	O
+
+These	O
+results	O
+provide	O
+a	O
+strong	O
+incentive	O
+for	O
+identifying	O
+the	O
+host	B-COMP
+cell	I-COMP
+receptor	O
+used	O
+by	O
+HCoV	O
+-	O
+EMC	B-COMP
+.	O
+
+Although	O
+induction	O
+of	O
+the	O
+heat	B-PROC
+shock	I-PROC
+response	I-PROC
+can	O
+restore	O
+alveolar	B-ANAT
+fluid	O
+clearance	O
+compromised	O
+by	O
+IL	O
+-	O
+1β	O
+following	O
+the	O
+onset	O
+of	O
+severe	O
+hemorrhagic	B-DISO
+shock	I-DISO
+in	O
+rats	B-SPEC
+,	O
+the	O
+mechanisms	O
+are	O
+not	O
+fully	O
+understood	O
+.	O
+
+Adenovirus	B-DISO
+serotype	O
+7	O
+and	O
+3	O
+can	O
+cause	O
+severe	O
+disease	O
+-	O
+even	O
+death	B-PROC
+-	O
+in	O
+children	O
+,	O
+especially	O
+those	O
+with	O
+underlying	O
+neurological	O
+diseases	O
+.	O
+
+Patients	O
+infected	O
+with	O
+adenovirus	B-DISO
+serotype	O
+7	O
+tended	O
+to	O
+have	O
+a	O
+higher	O
+case	O
+-	O
+fatality	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+Low	O
+plasma	B-ANAT
+citrulline	B-CHED
+levels	O
+are	O
+associated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+patients	O
+with	O
+severe	O
+sepsis	O
+.	O
+
+Low	O
+NOS	O
+substrate	O
+levels	O
+have	O
+been	O
+shown	O
+in	O
+other	O
+disease	O
+states	O
+to	O
+lead	O
+to	O
+NOS	O
+uncoupling	O
+and	O
+oxidative	O
+injury	O
+suggesting	O
+a	O
+potential	O
+mechanism	O
+for	O
+the	O
+association	O
+between	O
+low	O
+citrulline	B-CHED
+and	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	O
+-	O
+converting	O
+enzyme	O
+2	O
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+a	O
+negative	O
+regulator	O
+of	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+,	O
+and	O
+functions	O
+as	O
+the	O
+key	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+receptor	I-PRGE
+and	O
+stabilizer	B-PROC
+of	O
+neutral	O
+amino	B-PRGE
+acid	I-PRGE
+transporters	I-PRGE
+.	O
+
+Microtubule	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+protein	B-CHED
+1	I-PRGE
+light	I-PRGE
+chain	I-PRGE
+3	I-PRGE
+(	O
+MAP1LC3	B-PRGE
+/	O
+LC3	B-PRGE
+)	O
+is	O
+an	O
+important	O
+marker	O
+for	O
+autophagy	B-PROC
+and	O
+is	O
+used	O
+to	O
+follow	O
+autophagosome	B-PROC
+formation	I-PROC
+.	O
+
+Employing	O
+human	B-SPEC
+prostate	B-ANAT
+cancer	B-SPEC
+and	O
+melanoma	B-ANAT
+cell	B-COMP
+models	O
+,	O
+we	O
+found	O
+that	O
+the	O
+intensity	O
+and	O
+duration	O
+of	O
+STAT1	B-PRGE
+phosphorylation	B-PROC
+as	O
+well	O
+as	O
+the	O
+downstream	O
+activation	O
+of	O
+pathobiologically	O
+relevant	O
+genes	O
+were	O
+dose	O
+and	O
+particle	O
+dependent	O
+.	O
+
+TITLE	O
+:	O
+Severity	O
+and	O
+outcome	O
+associated	O
+with	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+infections	B-DISO
+among	O
+children	O
+.	O
+
+Subtype	O
+OC43	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+is	O
+the	O
+more	O
+prevalent	O
+human	B-SPEC
+coronavirus	I-SPEC
+in	O
+several	O
+parts	O
+of	O
+the	O
+world	O
+.	O
+
+We	O
+retrospectively	O
+identified	O
+patients	O
+with	O
+positive	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+respiratory	O
+specimens	O
+between	O
+December	O
+2009	O
+and	O
+December	O
+2010	O
+in	O
+a	O
+pediatric	O
+hospital	O
+in	O
+Montreal	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+was	O
+not	O
+more	O
+frequent	O
+in	O
+children	O
+with	O
+preexisting	O
+conditions	O
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+trials	O
+suggesting	O
+that	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+reduced	O
+mortality	O
+among	O
+adults	O
+with	O
+the	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+were	O
+limited	O
+by	O
+the	O
+use	O
+of	O
+outdated	O
+comparator	O
+ventilation	O
+strategies	O
+and	O
+small	O
+sample	O
+sizes	O
+.	O
+
+In	O
+a	O
+multicenter	O
+,	O
+randomized	O
+,	O
+controlled	O
+trial	O
+conducted	O
+at	O
+39	O
+intensive	O
+care	O
+units	O
+in	O
+five	O
+countries	O
+,	O
+we	O
+randomly	O
+assigned	O
+adults	O
+with	O
+new	O
+-	O
+onset	O
+,	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+to	O
+HFOV	O
+targeting	B-PROC
+lung	B-ANAT
+recruitment	B-DISO
+or	O
+to	O
+a	O
+control	O
+ventilation	O
+strategy	O
+targeting	B-PROC
+lung	B-ANAT
+recruitment	B-DISO
+with	O
+the	O
+use	O
+of	O
+low	O
+tidal	O
+volumes	O
+and	O
+high	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+.	O
+
+Due	O
+to	O
+the	O
+parallel	O
+HIV	B-DISO
+-	O
+and	O
+Hepatits	O
+B	O
+infection	B-DISO
+an	O
+antiretroviral	O
+therapy	O
+was	O
+initiated	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+summary	O
+the	O
+Puumala	O
+infection	B-DISO
+bears	B-SPEC
+the	O
+potential	O
+for	O
+a	O
+severe	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+which	O
+is	O
+not	O
+typical	O
+for	O
+this	O
+usually	O
+benign	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+was	O
+performed	O
+to	O
+characterize	O
+respiratory	O
+viral	O
+infections	O
+in	O
+pediatric	O
+patients	O
+undergoing	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+(	O
+HSCT	O
+).	O
+
+Among	O
+the	O
+89	O
+clinical	O
+episodes	O
+,	O
+frequently	O
+detected	O
+viruses	B-SPEC
+were	O
+rhinovirus	B-SPEC
+in	O
+25	O
+(	O
+28	O
+.	O
+1	O
+%),	O
+RSV	B-SPEC
+in	O
+23	O
+(	O
+25	O
+.	O
+8	O
+%),	O
+PIV	O
+-	O
+3	O
+in	O
+16	O
+(	O
+18	O
+.	O
+0	O
+%),	O
+adenovirus	B-DISO
+in	O
+12	O
+(	O
+13	O
+.	O
+5	O
+%),	O
+and	O
+hCoV	O
+in	O
+10	O
+(	O
+11	O
+.	O
+2	O
+%).	O
+
+Three	O
+patients	O
+died	B-PROC
+of	O
+respiratory	B-DISO
+failure	I-DISO
+caused	O
+by	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+adjuvanticity	B-PROC
+of	O
+Sargassum	B-SPEC
+pallidum	I-SPEC
+polysaccharides	B-CHED
+in	O
+Newcastle	B-DISO
+disease	I-DISO
+(	O
+ND	O
+),	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+(	O
+AI	O
+)	O
+was	O
+investigated	O
+by	O
+examining	O
+the	O
+antibody	B-COMP
+titers	O
+and	O
+lymphocyte	B-PROC
+proliferation	B-DISO
+following	O
+immunization	O
+in	O
+chickens	B-SPEC
+.	O
+
+The	O
+ND	O
+,	O
+IB	O
+and	O
+AI	O
+antibody	B-COMP
+titers	O
+and	O
+the	O
+lymphocyte	B-PROC
+proliferation	B-DISO
+were	O
+enhanced	O
+at	O
+30	O
+mg	O
+/	O
+mL	O
+SPP	B-ENZY
+.	O
+
+In	O
+conclusion	O
+,	O
+an	O
+appropriate	O
+dose	O
+of	O
+SPP	B-PRGE
+may	O
+be	O
+a	O
+safe	O
+and	O
+efficacious	O
+immune	O
+stimulator	O
+candidate	O
+that	O
+is	O
+suitable	O
+for	O
+vaccines	O
+to	O
+produce	O
+early	O
+and	O
+persistent	O
+prophylaxis	O
+.	O
+
+TITLE	O
+:	O
+Chronic	O
+-	O
+alcohol	O
+-	O
+abuse	B-DISO
+-	O
+induced	O
+oxidative	B-DISO
+stress	I-DISO
+in	O
+the	O
+development	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Alcohol	B-DISO
+abuse	I-DISO
+is	O
+also	O
+associated	O
+with	O
+a	O
+higher	O
+incidence	O
+of	O
+sepsis	B-DISO
+or	O
+pneumonia	B-DISO
+resulting	O
+in	O
+a	O
+higher	O
+rate	O
+of	O
+admittance	O
+to	O
+intensive	O
+care	O
+,	O
+longer	O
+inpatient	O
+stays	O
+,	O
+higher	O
+healthcare	O
+costs	O
+,	O
+and	O
+a	O
+2	O
+-	O
+4	O
+times	O
+greater	O
+mortality	O
+rate	O
+.	O
+
+Viral	O
+metagenome	O
+sequence	O
+annotations	O
+were	O
+reproducible	O
+and	O
+independent	O
+PCR	O
+-	O
+based	O
+identification	O
+of	O
+selected	O
+viruses	B-SPEC
+suggests	O
+that	O
+viral	O
+metagenomes	O
+were	O
+a	O
+conservative	O
+estimate	O
+of	O
+the	O
+true	O
+viral	O
+occurrence	O
+and	O
+diversity	O
+.	O
+
+ADORA2A	B-PRGE
+is	O
+protective	O
+against	O
+lung	B-ANAT
+injury	O
+after	O
+LPS	B-DISO
+and	O
+oxygen	B-CHED
+.	O
+
+Examination	O
+of	O
+sputum	B-ANAT
+and	O
+urine	B-ANAT
+revealed	O
+acid	O
+-	O
+fast	B-FUNC
+bacilli	B-SPEC
+,	O
+which	O
+were	O
+later	O
+confirmed	O
+as	O
+Mycobacterium	B-SPEC
+tuberculosis	I-SPEC
+sensitive	O
+to	O
+all	O
+drugs	O
+.	O
+
+We	O
+therefore	O
+diagnosed	O
+her	O
+with	O
+miliary	B-DISO
+tuberculosis	I-DISO
+complicated	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+(	O
+DIC	B-DISO
+).	O
+
+A	O
+recent	O
+report	O
+suggested	O
+that	O
+rTM	O
+is	O
+effective	O
+for	O
+DIC	B-DISO
+and	O
+ARDS	B-DISO
+secondary	O
+to	O
+sepsis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Surviving	O
+sepsis	B-DISO
+campaign	O
+:	O
+international	O
+guidelines	O
+for	O
+management	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+:	O
+2012	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+provide	O
+an	O
+update	O
+to	O
+the	O
+""""	O
+Surviving	O
+Sepsis	B-DISO
+Campaign	O
+Guidelines	O
+for	O
+Management	O
+of	O
+Severe	B-DISO
+Sepsis	I-DISO
+and	O
+Septic	B-DISO
+Shock	I-DISO
+","""	O
+last	O
+published	O
+in	O
+2008	O
+.	O
+
+A	O
+stand	O
+-	O
+alone	O
+meeting	O
+was	O
+held	O
+for	O
+all	O
+subgroup	O
+heads	B-ANAT
+,	O
+co	O
+-	O
+and	O
+vice	O
+-	O
+chairs	O
+,	O
+and	O
+selected	O
+individuals	O
+.	O
+
+Teleconferences	O
+and	O
+electronic	O
+-	O
+based	O
+discussion	O
+among	O
+subgroups	O
+and	O
+among	O
+the	O
+entire	O
+committee	O
+served	O
+as	O
+an	O
+integral	O
+part	O
+of	O
+the	O
+development	B-PROC
+.	O
+
+Key	O
+recommendations	O
+and	O
+suggestions	O
+,	O
+listed	O
+by	O
+category	O
+,	O
+include	O
+:	O
+early	O
+quantitative	O
+resuscitation	O
+of	O
+the	O
+septic	O
+patient	O
+during	O
+the	O
+first	O
+6	O
+hrs	B-DISO
+after	O
+recognition	O
+(	O
+1C	O
+);	O
+blood	B-ANAT
+cultures	O
+before	O
+antibiotic	B-CHED
+therapy	O
+(	O
+1C	O
+);	O
+imaging	O
+studies	O
+performed	O
+promptly	O
+to	O
+confirm	O
+a	O
+potential	O
+source	O
+of	O
+infection	B-DISO
+(	O
+UG	O
+);	O
+administration	O
+of	O
+broad	O
+-	O
+spectrum	O
+antimicrobials	B-CHED
+therapy	O
+within	O
+1	O
+hr	O
+of	O
+recognition	O
+of	O
+septic	B-DISO
+shock	I-DISO
+(	O
+1B	O
+)	O
+and	O
+severe	B-DISO
+sepsis	I-DISO
+without	I-DISO
+septic	I-DISO
+shock	I-DISO
+(	O
+1C	O
+)	O
+as	O
+the	O
+goal	O
+of	O
+therapy	O
+;	O
+reassessment	O
+of	O
+antimicrobial	B-CHED
+therapy	O
+daily	O
+for	O
+de	O
+-	O
+escalation	O
+,	O
+when	O
+appropriate	O
+(	O
+1B	O
+);	O
+infection	B-DISO
+source	O
+control	O
+with	O
+attention	O
+to	O
+the	O
+balance	B-PROC
+of	O
+risks	O
+and	O
+benefits	O
+of	O
+the	O
+chosen	O
+method	O
+within	O
+12	O
+hrs	B-DISO
+of	O
+diagnosis	O
+(	O
+1C	O
+);	O
+initial	O
+fluid	O
+resuscitation	O
+with	O
+crystalloid	B-COMP
+(	O
+1B	O
+)	O
+and	O
+consideration	O
+of	O
+the	O
+addition	O
+of	O
+albumin	B-PRGE
+in	O
+patients	O
+who	O
+continue	O
+to	O
+require	O
+substantial	O
+amounts	O
+of	O
+crystalloid	B-COMP
+to	O
+maintain	O
+adequate	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+(	O
+2C	O
+)	O
+and	O
+the	O
+avoidance	O
+of	O
+hetastarch	O
+formulations	O
+(	O
+1C	O
+);	O
+initial	O
+fluid	O
+challenge	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+tissue	B-ANAT
+hypoperfusion	O
+and	O
+suspicion	O
+of	O
+hypovolemia	O
+to	O
+achieve	O
+a	O
+minimum	O
+of	O
+30	O
+mL	O
+/	O
+kg	O
+of	O
+crystalloids	O
+(	O
+more	O
+rapid	O
+administration	O
+and	O
+greater	O
+amounts	O
+of	O
+fluid	O
+may	O
+be	O
+needed	O
+in	O
+some	O
+patients	O
+)	O
+(	O
+1C	O
+);	O
+fluid	O
+challenge	O
+technique	O
+continued	O
+as	O
+long	O
+as	O
+hemodynamic	B-PROC
+improvement	O
+,	O
+as	O
+based	O
+on	O
+either	O
+dynamic	O
+or	O
+static	O
+variables	O
+(	O
+UG	O
+);	O
+norepinephrine	B-CHED
+as	O
+the	O
+first	O
+-	O
+choice	O
+vasopressor	O
+to	O
+maintain	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+≥	O
+65	O
+mm	O
+Hg	O
+(	O
+1B	O
+);	O
+epinephrine	B-CHED
+when	O
+an	O
+additional	O
+agent	O
+is	O
+needed	O
+to	O
+maintain	O
+adequate	O
+blood	B-PROC
+pressure	I-PROC
+(	O
+2B	O
+);	O
+vasopressin	B-CHED
+(	O
+0	O
+.	O
+03	O
+U	O
+/	O
+min	O
+)	O
+can	O
+be	O
+added	O
+to	O
+norepinephrine	B-CHED
+to	O
+either	O
+raise	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+to	O
+target	O
+or	O
+to	O
+decrease	O
+norepinephrine	B-CHED
+dose	O
+but	O
+should	O
+not	O
+be	O
+used	O
+as	O
+the	O
+initial	O
+vasopressor	O
+(	O
+UG	O
+);	O
+dopamine	B-CHED
+is	O
+not	O
+recommended	O
+except	O
+in	O
+highly	O
+selected	O
+circumstances	O
+(	O
+2C	O
+);	O
+dobutamine	B-CHED
+infusion	O
+administered	O
+or	O
+added	O
+to	O
+vasopressor	O
+in	O
+the	O
+presence	O
+of	O
+a	O
+)	O
+myocardial	B-DISO
+dysfunction	I-DISO
+as	O
+suggested	O
+by	O
+elevated	O
+cardiac	B-ANAT
+filling	O
+pressures	O
+and	O
+low	O
+cardiac	B-ANAT
+output	O
+,	O
+or	O
+b	O
+)	O
+ongoing	O
+signs	O
+of	O
+hypoperfusion	O
+despite	O
+achieving	O
+adequate	O
+intravascular	O
+volume	O
+and	O
+adequate	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+(	O
+1C	O
+);	O
+avoiding	O
+use	O
+of	O
+intravenous	O
+hydrocortisone	B-CHED
+in	O
+adult	O
+septic	B-DISO
+shock	I-DISO
+patients	O
+if	O
+adequate	O
+fluid	O
+resuscitation	O
+and	O
+vasopressor	O
+therapy	O
+are	O
+able	O
+to	O
+restore	O
+hemodynamic	B-PROC
+stability	O
+(	O
+2C	O
+);	O
+hemoglobin	B-PRGE
+target	O
+of	O
+7	O
+-	O
+9	O
+g	O
+/	O
+dL	O
+in	O
+the	O
+absence	O
+of	O
+tissue	B-ANAT
+hypoperfusion	O
+,	O
+ischemic	O
+coronary	B-DISO
+artery	I-DISO
+disease	I-DISO
+,	O
+or	O
+acute	B-DISO
+hemorrhage	I-DISO
+(	O
+1B	O
+);	O
+low	O
+tidal	O
+volume	O
+(	O
+1A	O
+)	O
+and	O
+limitation	O
+of	O
+inspiratory	B-PROC
+plateau	O
+pressure	O
+(	O
+1B	O
+)	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+);	O
+application	O
+of	O
+at	O
+least	O
+a	O
+minimal	O
+amount	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+in	O
+ARDS	B-DISO
+(	O
+1B	O
+);	O
+higher	O
+rather	O
+than	O
+lower	O
+level	O
+of	O
+PEEP	B-CHED
+for	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+(	O
+2C	O
+);	O
+recruitment	B-DISO
+maneuvers	O
+in	O
+sepsis	B-DISO
+patients	O
+with	O
+severe	O
+refractory	O
+hypoxemia	O
+due	O
+to	O
+ARDS	B-DISO
+(	O
+2C	O
+);	O
+prone	O
+positioning	O
+in	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+patients	O
+with	O
+a	O
+PaO2	O
+/	O
+FIO2	O
+ratio	O
+of	O
+≤	O
+100	O
+mm	O
+Hg	O
+in	O
+facilities	O
+that	O
+have	O
+experience	O
+with	O
+such	O
+practices	O
+(	O
+2C	O
+);	O
+head	B-ANAT
+-	O
+of	O
+-	O
+bed	B-DISO
+elevation	O
+in	O
+mechanically	O
+ventilated	O
+patients	O
+unless	O
+contraindicated	O
+(	O
+1B	O
+);	O
+a	O
+conservative	O
+fluid	O
+strategy	O
+for	O
+patients	O
+with	O
+established	O
+ARDS	B-DISO
+who	O
+do	O
+not	O
+have	O
+evidence	O
+of	O
+tissue	B-ANAT
+hypoperfusion	O
+(	O
+1C	O
+);	O
+protocols	O
+for	O
+weaning	B-PROC
+and	O
+sedation	B-DISO
+(	O
+1A	O
+);	O
+minimizing	O
+use	O
+of	O
+either	O
+intermittent	O
+bolus	O
+sedation	B-DISO
+or	O
+continuous	O
+infusion	O
+sedation	B-DISO
+targeting	B-PROC
+specific	O
+titration	O
+endpoints	O
+(	O
+1B	O
+);	O
+avoidance	O
+of	O
+neuromuscular	O
+blockers	O
+if	O
+possible	O
+in	O
+the	O
+septic	O
+patient	O
+without	O
+ARDS	B-DISO
+(	O
+1C	O
+);	O
+a	O
+short	O
+course	O
+of	O
+neuromuscular	O
+blocker	O
+(	O
+no	O
+longer	O
+than	O
+48	O
+hrs	B-DISO
+)	O
+for	O
+patients	O
+with	O
+early	O
+ARDS	B-DISO
+and	O
+a	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+<	O
+150	O
+mm	O
+Hg	O
+(	O
+2C	O
+);	O
+a	O
+protocolized	O
+approach	O
+to	O
+blood	B-ANAT
+glucose	B-CHED
+management	O
+commencing	O
+insulin	B-PRGE
+dosing	O
+when	O
+two	O
+consecutive	O
+blood	B-ANAT
+glucose	B-CHED
+levels	O
+are	O
+>	O
+180	O
+mg	O
+/	O
+dL	O
+,	O
+targeting	B-PROC
+an	O
+upper	O
+blood	B-ANAT
+glucose	B-CHED
+≤	O
+180	O
+mg	O
+/	O
+dL	O
+(	O
+1A	O
+);	O
+equivalency	O
+of	O
+continuous	O
+veno	O
+-	O
+venous	B-ANAT
+hemofiltration	O
+or	O
+intermittent	O
+hemodialysis	O
+(	O
+2B	O
+);	O
+prophylaxis	O
+for	O
+deep	B-DISO
+vein	I-DISO
+thrombosis	I-DISO
+(	O
+1B	O
+);	O
+use	O
+of	O
+stress	B-DISO
+ulcer	I-DISO
+prophylaxis	O
+to	O
+prevent	O
+upper	B-DISO
+gastrointestinal	I-DISO
+bleeding	I-DISO
+in	O
+patients	O
+with	O
+bleeding	B-DISO
+risk	O
+factors	O
+(	O
+1B	O
+);	O
+oral	B-ANAT
+or	O
+enteral	O
+(	O
+if	O
+necessary	O
+)	O
+feedings	O
+,	O
+as	O
+tolerated	O
+,	O
+rather	O
+than	O
+either	O
+complete	O
+fasting	O
+or	O
+provision	O
+of	O
+only	O
+intravenous	O
+glucose	B-CHED
+within	O
+the	O
+first	O
+48	O
+hrs	B-DISO
+after	O
+a	O
+diagnosis	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+/	O
+septic	B-DISO
+shock	I-DISO
+(	O
+2C	O
+);	O
+and	O
+addressing	O
+goals	O
+of	O
+care	O
+,	O
+including	O
+treatment	O
+plans	O
+and	O
+end	O
+-	O
+of	O
+-	O
+life	O
+planning	O
+(	O
+as	O
+appropriate	O
+)	O
+(	O
+1B	O
+),	O
+as	O
+early	O
+as	O
+feasible	O
+,	O
+but	O
+within	O
+72	O
+hrs	B-DISO
+of	O
+intensive	O
+care	O
+unit	O
+admission	O
+(	O
+2C	O
+).	O
+
+Recombination	B-PROC
+analysis	O
+showed	O
+that	O
+Sczy3	O
+is	O
+a	O
+chimeric	O
+strain	O
+derived	O
+from	O
+LX4	O
+(	O
+major	O
+parental	O
+sequence	O
+)	O
+and	O
+H120	O
+(	O
+minor	O
+parental	O
+sequence	O
+)	O
+suggesting	O
+that	O
+recombination	B-PROC
+occurred	O
+in	O
+a	O
+region	O
+containing	O
+the	O
+3	O
+'	O
+terminal	O
+5a	O
+sequence	O
+(	O
+83	O
+nt	O
+),	O
+the	O
+5	O
+'	O
+terminal	O
+5b	O
+sequence	O
+(	O
+222	O
+nt	O
+),	O
+and	O
+the	O
+5	O
+'	O
+terminal	O
+nucleocapsid	O
+protein	B-CHED
+gene	O
+sequence	O
+(	O
+132	O
+nt	O
+).	O
+
+Mutations	O
+and	O
+intergenic	O
+recombination	B-PROC
+may	O
+have	O
+played	O
+an	O
+important	O
+role	O
+in	O
+the	O
+evolution	B-PROC
+of	O
+IBVs	O
+.	O
+
+TITLE	O
+:	O
+Surviving	O
+Sepsis	B-DISO
+Campaign	O
+:	O
+international	O
+guidelines	O
+for	O
+management	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+,	O
+2012	O
+.	O
+
+Key	O
+recommendations	O
+and	O
+suggestions	O
+,	O
+listed	O
+by	O
+category	O
+,	O
+include	O
+:	O
+early	O
+quantitative	O
+resuscitation	O
+of	O
+the	O
+septic	O
+patient	O
+during	O
+the	O
+first	O
+6	O
+h	O
+after	O
+recognition	O
+(	O
+1C	O
+);	O
+blood	B-ANAT
+cultures	O
+before	O
+antibiotic	B-CHED
+therapy	O
+(	O
+1C	O
+);	O
+imaging	O
+studies	O
+performed	O
+promptly	O
+to	O
+confirm	O
+a	O
+potential	O
+source	O
+of	O
+infection	B-DISO
+(	O
+UG	O
+);	O
+administration	O
+of	O
+broad	O
+-	O
+spectrum	O
+antimicrobials	B-CHED
+therapy	O
+within	O
+1	O
+h	O
+of	O
+the	O
+recognition	O
+of	O
+septic	B-DISO
+shock	I-DISO
+(	O
+1B	O
+)	O
+and	O
+severe	B-DISO
+sepsis	I-DISO
+without	I-DISO
+septic	I-DISO
+shock	I-DISO
+(	O
+1C	O
+)	O
+as	O
+the	O
+goal	O
+of	O
+therapy	O
+;	O
+reassessment	O
+of	O
+antimicrobial	B-CHED
+therapy	O
+daily	O
+for	O
+de	O
+-	O
+escalation	O
+,	O
+when	O
+appropriate	O
+(	O
+1B	O
+);	O
+infection	B-DISO
+source	O
+control	O
+with	O
+attention	O
+to	O
+the	O
+balance	B-PROC
+of	O
+risks	O
+and	O
+benefits	O
+of	O
+the	O
+chosen	O
+method	O
+within	O
+12	O
+h	O
+of	O
+diagnosis	O
+(	O
+1C	O
+);	O
+initial	O
+fluid	O
+resuscitation	O
+with	O
+crystalloid	B-COMP
+(	O
+1B	O
+)	O
+and	O
+consideration	O
+of	O
+the	O
+addition	O
+of	O
+albumin	B-PRGE
+in	O
+patients	O
+who	O
+continue	O
+to	O
+require	O
+substantial	O
+amounts	O
+of	O
+crystalloid	B-COMP
+to	O
+maintain	O
+adequate	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+(	O
+2C	O
+)	O
+and	O
+the	O
+avoidance	O
+of	O
+hetastarch	O
+formulations	O
+(	O
+1B	O
+);	O
+initial	O
+fluid	O
+challenge	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+tissue	B-ANAT
+hypoperfusion	O
+and	O
+suspicion	O
+of	O
+hypovolemia	O
+to	O
+achieve	O
+a	O
+minimum	O
+of	O
+30	O
+mL	O
+/	O
+kg	O
+of	O
+crystalloids	O
+(	O
+more	O
+rapid	O
+administration	O
+and	O
+greater	O
+amounts	O
+of	O
+fluid	O
+may	O
+be	O
+needed	O
+in	O
+some	O
+patients	O
+(	O
+1C	O
+);	O
+fluid	O
+challenge	O
+technique	O
+continued	O
+as	O
+long	O
+as	O
+hemodynamic	B-PROC
+improvement	O
+is	O
+based	O
+on	O
+either	O
+dynamic	O
+or	O
+static	O
+variables	O
+(	O
+UG	O
+);	O
+norepinephrine	B-CHED
+as	O
+the	O
+first	O
+-	O
+choice	O
+vasopressor	O
+to	O
+maintain	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+≥	O
+65	O
+mmHg	O
+(	O
+1B	O
+);	O
+epinephrine	B-CHED
+when	O
+an	O
+additional	O
+agent	O
+is	O
+needed	O
+to	O
+maintain	O
+adequate	O
+blood	B-PROC
+pressure	I-PROC
+(	O
+2B	O
+);	O
+vasopressin	B-CHED
+(	O
+0	O
+.	O
+03	O
+U	O
+/	O
+min	O
+)	O
+can	O
+be	O
+added	O
+to	O
+norepinephrine	B-CHED
+to	O
+either	O
+raise	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+to	O
+target	O
+or	O
+to	O
+decrease	O
+norepinephrine	B-CHED
+dose	O
+but	O
+should	O
+not	O
+be	O
+used	O
+as	O
+the	O
+initial	O
+vasopressor	O
+(	O
+UG	O
+);	O
+dopamine	B-CHED
+is	O
+not	O
+recommended	O
+except	O
+in	O
+highly	O
+selected	O
+circumstances	O
+(	O
+2C	O
+);	O
+dobutamine	B-CHED
+infusion	O
+administered	O
+or	O
+added	O
+to	O
+vasopressor	O
+in	O
+the	O
+presence	O
+of	O
+(	O
+a	O
+)	O
+myocardial	B-DISO
+dysfunction	I-DISO
+as	O
+suggested	O
+by	O
+elevated	O
+cardiac	B-ANAT
+filling	O
+pressures	O
+and	O
+low	O
+cardiac	B-ANAT
+output	O
+,	O
+or	O
+(	O
+b	O
+)	O
+ongoing	O
+signs	O
+of	O
+hypoperfusion	O
+despite	O
+achieving	O
+adequate	O
+intravascular	O
+volume	O
+and	O
+adequate	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+(	O
+1C	O
+);	O
+avoiding	O
+use	O
+of	O
+intravenous	O
+hydrocortisone	B-CHED
+in	O
+adult	O
+septic	B-DISO
+shock	I-DISO
+patients	O
+if	O
+adequate	O
+fluid	O
+resuscitation	O
+and	O
+vasopressor	O
+therapy	O
+are	O
+able	O
+to	O
+restore	O
+hemodynamic	B-PROC
+stability	O
+(	O
+2C	O
+);	O
+hemoglobin	B-PRGE
+target	O
+of	O
+7	O
+-	O
+9	O
+g	O
+/	O
+dL	O
+in	O
+the	O
+absence	O
+of	O
+tissue	B-ANAT
+hypoperfusion	O
+,	O
+ischemic	O
+coronary	B-DISO
+artery	I-DISO
+disease	I-DISO
+,	O
+or	O
+acute	B-DISO
+hemorrhage	I-DISO
+(	O
+1B	O
+);	O
+low	O
+tidal	O
+volume	O
+(	O
+1A	O
+)	O
+and	O
+limitation	O
+of	O
+inspiratory	B-PROC
+plateau	O
+pressure	O
+(	O
+1B	O
+)	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+);	O
+application	O
+of	O
+at	O
+least	O
+a	O
+minimal	O
+amount	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+in	O
+ARDS	B-DISO
+(	O
+1B	O
+);	O
+higher	O
+rather	O
+than	O
+lower	O
+level	O
+of	O
+PEEP	B-CHED
+for	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+(	O
+2C	O
+);	O
+recruitment	B-DISO
+maneuvers	O
+in	O
+sepsis	B-DISO
+patients	O
+with	O
+severe	O
+refractory	O
+hypoxemia	O
+due	O
+to	O
+ARDS	B-DISO
+(	O
+2C	O
+);	O
+prone	O
+positioning	O
+in	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+patients	O
+with	O
+a	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+ratio	O
+of	O
+≤	O
+100	O
+mm	O
+Hg	O
+in	O
+facilities	O
+that	O
+have	O
+experience	O
+with	O
+such	O
+practices	O
+(	O
+2C	O
+);	O
+head	B-ANAT
+-	O
+of	O
+-	O
+bed	B-DISO
+elevation	O
+in	O
+mechanically	O
+ventilated	O
+patients	O
+unless	O
+contraindicated	O
+(	O
+1B	O
+);	O
+a	O
+conservative	O
+fluid	O
+strategy	O
+for	O
+patients	O
+with	O
+established	O
+ARDS	B-DISO
+who	O
+do	O
+not	O
+have	O
+evidence	O
+of	O
+tissue	B-ANAT
+hypoperfusion	O
+(	O
+1C	O
+);	O
+protocols	O
+for	O
+weaning	B-PROC
+and	O
+sedation	B-DISO
+(	O
+1A	O
+);	O
+minimizing	O
+use	O
+of	O
+either	O
+intermittent	O
+bolus	O
+sedation	B-DISO
+or	O
+continuous	O
+infusion	O
+sedation	B-DISO
+targeting	B-PROC
+specific	O
+titration	O
+endpoints	O
+(	O
+1B	O
+);	O
+avoidance	O
+of	O
+neuromuscular	O
+blockers	O
+if	O
+possible	O
+in	O
+the	O
+septic	O
+patient	O
+without	O
+ARDS	B-DISO
+(	O
+1C	O
+);	O
+a	O
+short	O
+course	O
+of	O
+neuromuscular	O
+blocker	O
+(	O
+no	O
+longer	O
+than	O
+48	O
+h	O
+)	O
+for	O
+patients	O
+with	O
+early	O
+ARDS	B-DISO
+and	O
+a	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FI	O
+O	O
+(	O
+2	O
+)	O
+<	O
+150	O
+mm	O
+Hg	O
+(	O
+2C	O
+);	O
+a	O
+protocolized	O
+approach	O
+to	O
+blood	B-ANAT
+glucose	B-CHED
+management	O
+commencing	O
+insulin	B-PRGE
+dosing	O
+when	O
+two	O
+consecutive	O
+blood	B-ANAT
+glucose	B-CHED
+levels	O
+are	O
+>	O
+180	O
+mg	O
+/	O
+dL	O
+,	O
+targeting	B-PROC
+an	O
+upper	O
+blood	B-ANAT
+glucose	B-CHED
+≤	O
+180	O
+mg	O
+/	O
+dL	O
+(	O
+1A	O
+);	O
+equivalency	O
+of	O
+continuous	O
+veno	O
+-	O
+venous	B-ANAT
+hemofiltration	O
+or	O
+intermittent	O
+hemodialysis	O
+(	O
+2B	O
+);	O
+prophylaxis	O
+for	O
+deep	B-DISO
+vein	I-DISO
+thrombosis	I-DISO
+(	O
+1B	O
+);	O
+use	O
+of	O
+stress	B-DISO
+ulcer	I-DISO
+prophylaxis	O
+to	O
+prevent	O
+upper	B-DISO
+gastrointestinal	I-DISO
+bleeding	I-DISO
+in	O
+patients	O
+with	O
+bleeding	B-DISO
+risk	O
+factors	O
+(	O
+1B	O
+);	O
+oral	B-ANAT
+or	O
+enteral	O
+(	O
+if	O
+necessary	O
+)	O
+feedings	O
+,	O
+as	O
+tolerated	O
+,	O
+rather	O
+than	O
+either	O
+complete	O
+fasting	O
+or	O
+provision	O
+of	O
+only	O
+intravenous	O
+glucose	B-CHED
+within	O
+the	O
+first	O
+48	O
+h	O
+after	O
+a	O
+diagnosis	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+/	O
+septic	B-DISO
+shock	I-DISO
+(	O
+2C	O
+);	O
+and	O
+addressing	O
+goals	O
+of	O
+care	O
+,	O
+including	O
+treatment	O
+plans	O
+and	O
+end	O
+-	O
+of	O
+-	O
+life	O
+planning	O
+(	O
+as	O
+appropriate	O
+)	O
+(	O
+1B	O
+),	O
+as	O
+early	O
+as	O
+feasible	O
+,	O
+but	O
+within	O
+72	O
+h	O
+of	O
+intensive	O
+care	O
+unit	O
+admission	O
+(	O
+2C	O
+).	O
+
+For	O
+specimens	O
+with	O
+discrepant	O
+results	O
+,	O
+monoplex	B-SPEC
+PCR	O
+and	O
+sequencing	O
+of	O
+the	O
+target	O
+viruses	B-SPEC
+were	O
+performed	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+predisposition	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Patients	O
+older	O
+than	O
+18	O
+years	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+with	O
+the	O
+diagnosis	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+were	O
+prospectively	O
+included	O
+.	O
+
+After	O
+adjustment	O
+for	O
+those	O
+variables	O
+,	O
+the	O
+presence	O
+of	O
+the	O
+allele	O
+D	O
+of	O
+the	O
+ACE	B-PRGE
+gene	I-PRGE
+(	O
+odds	O
+ratio	O
+,	O
+4	O
+.	O
+75	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+02	O
+-	O
+22	O
+.	O
+20	O
+;	O
+P	O
+=	O
+0	O
+.	O
+048	O
+)	O
+was	O
+significantly	O
+associated	O
+with	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+accessory	O
+protein	B-CHED
+ORF6	O
+antagonizes	O
+interferon	B-PATH
+signaling	B-PROC
+by	O
+blocking	B-DISO
+karyopherin	B-PRGE
+-	O
+mediated	O
+nuclear	B-PROC
+import	I-PROC
+processes	O
+.	O
+
+By	O
+bioinformatic	O
+and	O
+systems	O
+biology	O
+approaches	O
+,	O
+we	O
+evaluated	O
+the	O
+impact	O
+of	O
+nuclear	B-PROC
+import	I-PROC
+antagonism	O
+on	O
+host	B-COMP
+expression	B-PROC
+networks	O
+by	O
+using	O
+human	B-SPEC
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+infected	O
+with	O
+either	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+or	O
+a	O
+mutant	B-DISO
+that	O
+does	O
+not	O
+express	O
+ORF6	B-PRGE
+protein	I-PRGE
+.	O
+
+Microarray	O
+analysis	O
+revealed	O
+significant	O
+changes	O
+in	O
+differential	B-PROC
+gene	I-PROC
+expression	I-PROC
+,	O
+with	O
+approximately	O
+twice	O
+as	O
+many	O
+upregulated	O
+genes	O
+in	O
+the	O
+mutant	B-DISO
+virus	B-SPEC
+samples	O
+by	O
+48	O
+h	O
+postinfection	O
+,	O
+despite	O
+identical	O
+viral	O
+titers	O
+.	O
+
+To	O
+evaluate	O
+the	O
+accuracy	O
+of	O
+these	O
+clinical	O
+criteria	O
+using	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+DAD	O
+)	O
+at	O
+autopsy	O
+as	O
+the	O
+reference	O
+standard	O
+.	O
+
+Glucocorticoids	B-CHED
+are	O
+the	O
+natural	O
+regulators	O
+of	O
+inflammation	B-DISO
+,	O
+and	O
+their	O
+production	O
+increases	O
+during	O
+infection	B-DISO
+.	O
+
+We	O
+have	O
+expanded	O
+on	O
+this	O
+meta	B-SPEC
+-	O
+analysis	O
+by	O
+including	O
+patients	O
+with	O
+CAP	B-DISO
+recruited	O
+in	O
+trials	O
+investigating	O
+prolonged	O
+low	O
+-	O
+dose	O
+glucocorticoid	B-CHED
+treatment	O
+in	O
+septic	B-DISO
+shock	I-DISO
+and	O
+/	O
+or	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+n	O
+=	O
+1	O
+,	O
+206	O
+).	O
+
+Our	O
+findings	O
+confirm	O
+a	O
+survival	O
+advantage	O
+for	O
+severe	O
+CAP	B-DISO
+(	O
+RR	O
+0	O
+.	O
+66	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+0	O
+.	O
+51	O
+-	O
+0	O
+.	O
+84	O
+;	O
+p	O
+=	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Breastfeeding	B-PROC
+is	O
+the	O
+reference	O
+against	O
+which	O
+alternative	O
+infant	O
+feeding	O
+models	O
+must	O
+be	O
+measured	O
+with	O
+regard	O
+to	O
+growth	O
+,	O
+development	B-PROC
+and	O
+other	O
+health	O
+outcomes	O
+.	O
+
+The	O
+results	O
+of	O
+a	O
+systematic	O
+review	O
+in	O
+which	O
+researchers	O
+examined	O
+the	O
+relationship	O
+between	O
+breastfeeding	B-PROC
+and	O
+early	B-DISO
+childhood	I-DISO
+caries	I-DISO
+were	O
+inconclusive	O
+.	O
+
+Patients	O
+had	O
+a	O
+significantly	O
+higher	O
+probability	O
+of	O
+HCoV	O
+detection	O
+in	O
+stool	B-ANAT
+(	O
+OR	O
+4	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+4	O
+-	O
+15	O
+.	O
+3	O
+;	O
+P	O
+=	O
+0	O
+.	O
+006	O
+)	O
+and	O
+also	O
+in	O
+stool	B-ANAT
+and	O
+/	O
+or	O
+NP	O
+(	O
+OR	O
+3	O
+.	O
+3	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+3	O
+-	O
+10	O
+.	O
+0	O
+;	O
+P	O
+=	O
+0	O
+.	O
+01	O
+)	O
+than	O
+healthy	O
+controls	O
+.	O
+
+All	O
+four	O
+HCoVs	O
+species	B-SPEC
+were	O
+detected	O
+in	O
+stool	B-ANAT
+and	O
+NP	O
+samples	O
+.	O
+
+Additionally	O
+,	O
+the	O
+prime	O
+-	O
+boost	O
+group	O
+also	O
+showed	O
+the	O
+highest	O
+level	O
+of	O
+IBV	O
+-	O
+specific	O
+cellular	B-DISO
+proliferation	I-DISO
+compared	O
+to	O
+the	O
+monovalent	O
+groups	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+but	O
+no	O
+significant	O
+difference	O
+was	O
+found	O
+compared	O
+to	O
+the	O
+multivalent	O
+DNA	O
+vaccine	O
+group	O
+,	O
+and	O
+the	O
+prime	O
+-	O
+boost	O
+group	O
+completely	O
+protected	O
+from	O
+followed	O
+viral	O
+challenge	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+N	O
+genes	O
+of	O
+15	O
+PEDV	B-SPEC
+strains	O
+were	O
+amplified	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+cloned	O
+into	O
+the	O
+pMT	B-PRGE
+-	I-PRGE
+19T	I-PRGE
+vector	O
+,	O
+sequenced	O
+,	O
+and	O
+compared	O
+to	O
+each	O
+other	O
+as	O
+well	O
+as	O
+to	O
+PEDV	B-SPEC
+reference	O
+strains	O
+.	O
+
+Alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+AEC	B-COMP
+)	O
+contribute	O
+importantly	O
+to	O
+normal	O
+alveolar	B-ANAT
+function	O
+,	O
+and	O
+AEC	B-COMP
+dysfunction	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+is	O
+associated	O
+with	O
+worse	O
+outcomes	O
+.	O
+
+Cytomix	O
+-	O
+stimulated	O
+PMN	B-PROC
+-	O
+dependent	O
+PMVEC	O
+hyper	O
+-	O
+permeability	O
+and	O
+trans	O
+-	O
+PMVEC	O
+PMN	B-PROC
+migration	B-PROC
+were	O
+also	O
+inhibited	O
+in	O
+the	O
+presence	O
+of	O
+A549	O
+cells	B-COMP
+or	O
+A549	O
+cell	B-COMP
+-	O
+conditioned	O
+medium	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+One	O
+hundred	O
+fifty	O
+-	O
+nine	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+including	O
+50	O
+patients	O
+with	O
+sepsis	B-DISO
+,	O
+57	O
+patients	O
+with	O
+severe	O
+trauma	O
+and	O
+52	O
+resuscitated	O
+after	O
+out	O
+-	O
+of	O
+-	O
+hospital	O
+cardiac	O
+arrest	O
+,	O
+were	O
+divided	O
+into	O
+three	O
+subgroups	O
+:	O
+including	O
+25	O
+ALI	O
+patients	O
+,	O
+101	O
+ARDS	B-DISO
+patients	O
+and	O
+22	O
+non	O
+-	O
+ALI	O
+/	O
+ARDS	B-DISO
+patients	O
+.	O
+
+There	O
+were	O
+also	O
+significant	O
+negative	O
+correlations	O
+between	O
+the	O
+minimal	O
+value	O
+of	O
+sVEGFR2	O
+,	O
+the	O
+maximal	O
+value	O
+of	O
+Ang1	B-PRGE
+and	O
+the	O
+ALI	O
+/	O
+ARDS	B-DISO
+group	O
+.	O
+
+Moreover	O
+,	O
+Ang2	B-PRGE
+and	O
+sVEGFR2	O
+also	O
+independently	O
+predicted	O
+the	O
+mortality	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Different	O
+serotypes	O
+and	O
+genetic	O
+types	O
+of	O
+the	O
+virus	B-SPEC
+have	O
+been	O
+identified	O
+worldwide	O
+and	O
+for	O
+the	O
+most	O
+part	O
+do	O
+not	O
+cross	O
+-	O
+protect	O
+.	O
+
+Genetic	O
+typing	O
+of	O
+IBV	B-SPEC
+,	O
+which	O
+involves	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+amplification	B-DISO
+and	O
+sequence	O
+analysis	O
+of	O
+the	O
+S1	B-PRGE
+glycoprotein	I-PRGE
+gene	O
+,	O
+has	O
+revolutionized	O
+diagnosis	O
+and	O
+identification	O
+of	O
+this	O
+virus	B-SPEC
+by	O
+making	O
+it	O
+possible	O
+to	O
+type	O
+and	O
+compare	O
+the	O
+relatedness	O
+of	O
+a	O
+large	O
+number	O
+of	O
+virus	O
+isolates	O
+in	O
+a	O
+short	O
+period	O
+of	O
+time	O
+.	O
+
+We	O
+observed	O
+lower	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+the	O
+vaccines	O
+that	O
+produced	O
+lower	O
+viral	O
+loads	O
+,	O
+which	O
+might	O
+contribute	O
+to	O
+the	O
+persistence	O
+of	O
+Ark	B-PRGE
+serotype	O
+IBV	B-SPEC
+vaccines	O
+observed	O
+in	O
+commercial	O
+flocks	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+draw	O
+an	O
+epidemiologic	O
+picture	O
+of	O
+aMPV	O
+presence	O
+in	O
+layer	B-ANAT
+flocks	O
+in	O
+Italy	O
+,	O
+a	O
+survey	O
+was	O
+performed	O
+on	O
+19	O
+flocks	O
+of	O
+pullets	O
+and	O
+layers	B-ANAT
+based	O
+on	O
+longitudinal	O
+studies	O
+or	O
+sporadic	O
+samplings	O
+.	O
+
+In	O
+two	O
+layer	B-ANAT
+flocks	O
+,	O
+egg	B-ANAT
+drops	O
+were	O
+observed	O
+and	O
+could	O
+be	O
+strongly	O
+linked	O
+to	O
+the	O
+presence	O
+of	O
+aMPV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Deubiquitinase	B-FUNC
+function	O
+of	O
+arterivirus	B-SPEC
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+2	I-PRGE
+suppresses	O
+the	O
+innate	B-PROC
+immune	I-PROC
+response	I-PROC
+in	O
+infected	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+The	O
+discovery	O
+of	O
+viruses	B-SPEC
+encoding	O
+deubiquitinating	B-PROC
+enzymes	O
+(	O
+DUBs	O
+)	O
+suggests	O
+they	O
+remove	O
+ubiquitin	B-PROC
+to	O
+evade	O
+ubiquitin	B-PROC
+-	O
+dependent	O
+antiviral	B-CHED
+responses	O
+;	O
+however	O
+,	O
+this	O
+has	O
+never	O
+been	O
+conclusively	O
+demonstrated	O
+in	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Arteriviruses	B-SPEC
+are	O
+economically	O
+important	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+that	O
+encode	O
+an	O
+ovarian	B-DISO
+tumor	I-DISO
+(	O
+OTU	O
+)	O
+domain	O
+DUB	O
+known	O
+as	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+2	I-PRGE
+(	O
+PLP2	B-PRGE
+).	O
+
+In	O
+patients	O
+with	O
+and	O
+without	O
+invasive	O
+mechanical	O
+ventilation	O
+,	O
+the	O
+baseline	O
+HBP	B-DISO
+levels	O
+were	O
+152	O
+ng	O
+/	O
+mL	O
+(	O
+72	O
+-	O
+237	O
+ng	O
+/	O
+mL	O
+)	O
+and	O
+83	O
+ng	O
+/	O
+mL	O
+(	O
+58	O
+-	O
+108	O
+ng	O
+/	O
+mL	O
+)	O
+(	O
+p	O
+0	O
+.	O
+088	O
+),	O
+respectively	O
+.	O
+
+The	O
+increase	O
+in	O
+HBP	B-DISO
+concentrations	O
+seems	O
+to	O
+be	O
+associated	O
+with	O
+more	O
+pronounced	O
+respiratory	B-DISO
+dysfunction	I-DISO
+.	O
+
+RESULTS	O
+:	O
+After	O
+delivery	O
+,	O
+lambs	B-SPEC
+developed	O
+severe	O
+RDS	O
+(	O
+inspiratory	B-PROC
+fraction	O
+of	O
+oxygen	B-CHED
+:	O
+1	O
+;	O
+pH	O
+<	O
+7	O
+.	O
+15	O
+;	O
+PaCO2	O
+>	O
+80	O
+mm	O
+Hg	O
+;	O
+PaO2	O
+<	O
+30	O
+mm	O
+Hg	O
+,	O
+mean	O
+dynamic	O
+compliance	O
+<	O
+0	O
+.	O
+08	O
+ml	O
+/	O
+cm	O
+H2O	B-CHED
+/	O
+kg	O
+).	O
+
+TITLE	O
+:	O
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+and	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Because	O
+of	O
+the	O
+increased	O
+rate	O
+of	O
+severe	O
+perioperative	O
+respiratory	B-DISO
+complications	I-DISO
+in	O
+patients	O
+with	O
+OSA	B-DISO
+,	O
+the	O
+American	O
+Society	O
+of	O
+Anesthesiologists	O
+issued	O
+practice	O
+guidelines	O
+for	O
+perioperative	O
+management	O
+.	O
+
+Strategies	O
+based	O
+on	O
+preoperative	O
+and	O
+immediate	O
+postoperative	O
+clinical	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+can	O
+help	O
+identify	O
+patients	O
+with	O
+a	O
+high	O
+likelihood	O
+of	O
+OSA	B-DISO
+,	O
+postoperative	O
+desaturations	O
+,	O
+and	O
+pulmonary	O
+complications	O
+.	O
+
+Evidence	O
+is	O
+emerging	O
+that	O
+early	O
+identification	O
+of	O
+modifiable	O
+risk	O
+factors	O
+and	O
+implementation	O
+of	O
+'	O
+protective	O
+'	O
+management	O
+strategies	O
+may	O
+lead	O
+to	O
+reduction	O
+of	O
+severe	O
+postoperative	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+accompanied	O
+by	O
+severe	O
+lung	B-DISO
+inflammation	I-DISO
+induced	O
+by	O
+various	O
+diseases	O
+.	O
+
+Despite	O
+the	O
+severity	O
+of	O
+symptoms	O
+,	O
+therapeutic	O
+strategies	O
+for	O
+this	O
+pathologic	O
+condition	B-DISO
+are	O
+still	O
+poorly	O
+developed	O
+.	O
+
+Interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+α	O
+is	O
+well	O
+known	O
+as	O
+an	O
+antiviral	B-CHED
+cytokine	O
+and	O
+low	O
+-	O
+dose	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+has	O
+been	O
+reported	O
+to	O
+show	O
+antiinflammatory	O
+effects	O
+.	O
+
+These	O
+mice	B-SPEC
+were	O
+then	O
+treated	O
+intranasally	O
+with	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+their	O
+survival	O
+,	O
+lung	B-ANAT
+weight	O
+,	O
+pathological	O
+findings	O
+,	O
+and	O
+cytokine	B-PROC
+production	I-PROC
+were	O
+evaluated	O
+.	O
+
+Administration	O
+of	O
+low	O
+-	O
+dose	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+prolonged	O
+survival	O
+of	O
+fulminant	O
+ARDS	B-DISO
+mice	B-SPEC
+,	O
+but	O
+higher	O
+doses	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+did	O
+not	O
+.	O
+
+Furthermore	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+production	O
+in	O
+the	O
+lungs	B-ANAT
+was	O
+significantly	O
+reduced	O
+in	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+-	O
+treated	O
+mice	B-SPEC
+,	O
+compared	O
+with	O
+control	O
+mice	B-SPEC
+,	O
+but	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	O
+)-	O
+α	O
+production	O
+was	O
+almost	O
+equivalent	O
+for	O
+both	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+Critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+(	O
+CIP	O
+)	O
+and	O
+critical	B-DISO
+illness	I-DISO
+myopathy	I-DISO
+(	O
+CIM	O
+)	O
+are	O
+complications	O
+causing	O
+weakness	B-DISO
+of	O
+respiratory	O
+and	O
+limb	B-ANAT
+muscles	B-ANAT
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+case	O
+expands	O
+our	O
+understanding	O
+of	O
+the	O
+complications	O
+of	O
+PNL	B-ENZY
+and	O
+underscores	O
+the	O
+importance	O
+of	O
+differentiating	O
+CIP	B-PRGE
+/	O
+CIM	B-PRGE
+from	O
+GBS	B-DISO
+in	O
+case	O
+of	O
+such	O
+patients	O
+developing	O
+weakness	B-DISO
+after	O
+the	O
+treatment	O
+.	O
+
+Between	O
+December	O
+2007	O
+and	O
+December	O
+2009	O
+,	O
+206	O
+fecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+dogs	B-SPEC
+with	O
+diarrhea	B-DISO
+from	O
+kennels	O
+,	O
+pet	O
+shops	O
+and	O
+veterinary	O
+clinics	O
+of	O
+different	O
+country	O
+regions	O
+.	O
+
+Trends	O
+in	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+according	O
+to	O
+sex	O
+,	O
+age	O
+,	O
+and	O
+period	O
+of	O
+infection	B-DISO
+were	O
+also	O
+analyzed	O
+.	O
+
+The	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+analysis	O
+showed	O
+17	O
+.	O
+1	O
+%	O
+of	O
+double	O
+infections	B-DISO
+and	O
+1	O
+.	O
+8	O
+%	O
+of	O
+triple	O
+infections	B-DISO
+.	O
+
+One	O
+-	O
+hundred	O
+and	O
+ninety	O
+hips	B-ANAT
+in	O
+117	O
+patients	O
+with	O
+more	O
+than	O
+7	O
+years	O
+of	O
+follow	O
+-	O
+up	O
+were	O
+studied	O
+.	O
+
+ABSTRACT	O
+:	O
+Virus	O
+-	O
+induced	O
+rhabdomyolysis	B-DISO
+rarely	O
+induces	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+discuss	O
+here	O
+a	O
+case	O
+of	O
+severe	O
+rhabdomyolysis	B-DISO
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+secondary	O
+to	O
+a	O
+cytomegalovirus	B-SPEC
+(	O
+CMV	B-SPEC
+)	O
+primary	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+mechanism	O
+of	O
+acute	O
+viral	O
+-	O
+induced	O
+rhabdomyolysis	B-DISO
+remains	O
+elusive	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+continuation	O
+of	O
+our	O
+efforts	O
+toward	O
+identification	O
+and	O
+optimization	O
+of	O
+novel	O
+non	O
+-	O
+nucleoside	O
+reverse	B-CHED
+transcriptase	I-CHED
+inhibitors	I-CHED
+(	O
+NNRTIs	O
+),	O
+we	O
+have	O
+employed	O
+a	O
+structure	O
+-	O
+based	O
+bioisosterism	O
+strategy	O
+,	O
+with	O
+which	O
+a	O
+new	O
+series	O
+of	O
+diarylpyridazine	O
+(	O
+DAPD	O
+)	O
+derivatives	O
+were	O
+synthesized	O
+and	O
+evaluated	O
+for	O
+their	O
+anti	O
+-	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+(	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+)	O
+activity	O
+.	O
+
+Rhinovirus	B-SPEC
+was	O
+the	O
+most	O
+common	O
+pathogen	O
+among	O
+those	O
+who	O
+died	B-PROC
+,	O
+although	O
+it	O
+did	O
+not	O
+have	O
+the	O
+highest	O
+case	O
+fatality	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+Viral	B-DISO
+pneumonitis	I-DISO
+is	O
+increased	O
+in	O
+obese	B-DISO
+patients	O
+during	O
+the	O
+first	O
+wave	O
+of	O
+pandemic	O
+A	O
+(	O
+H1N1	O
+)	O
+2009	O
+virus	O
+.	O
+
+Of	O
+173	O
+patients	O
+,	O
+100	O
+(	O
+57	O
+.	O
+8	O
+%),	O
+73	O
+(	O
+42	O
+.	O
+2	O
+%)	O
+and	O
+23	O
+(	O
+13	O
+.	O
+3	O
+%)	O
+had	O
+body	B-ANAT
+mass	O
+index	O
+(	O
+BMI	O
+)	O
+<	O
+30	O
+kg	O
+/	O
+m	O
+(	O
+2	O
+),	O
+≥	O
+30	O
+kg	O
+/	O
+m	O
+(	O
+2	O
+)	O
+(	O
+obese	B-DISO
+)	O
+and	O
+≥	O
+40	O
+kg	O
+/	O
+m	O
+(	O
+2	O
+)	O
+(	O
+morbidly	O
+obese	B-DISO
+)	O
+respectively	O
+.	O
+
+Among	O
+patients	O
+admitted	O
+to	O
+ICU	O
+during	O
+the	O
+first	O
+wave	O
+of	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+,	O
+obese	B-DISO
+and	O
+morbidly	O
+obese	B-DISO
+patients	O
+with	O
+severe	O
+infection	B-DISO
+were	O
+more	O
+likely	O
+to	O
+develop	O
+pneumonitis	B-DISO
+compared	O
+to	O
+non	O
+-	O
+obese	B-DISO
+patients	O
+,	O
+but	O
+mortality	O
+rates	O
+were	O
+not	O
+increased	O
+.	O
+
+More	O
+than	O
+one	O
+-	O
+half	O
+of	O
+patients	O
+experience	O
+severe	B-DISO
+pain	I-DISO
+,	O
+and	O
+about	O
+two	O
+-	O
+thirds	O
+have	O
+autonomic	B-ANAT
+symptoms	O
+,	O
+such	O
+as	O
+cardiac	B-DISO
+arrhythmias	I-DISO
+,	O
+blood	B-PROC
+pressure	I-PROC
+instability	O
+,	O
+or	O
+urinary	O
+retention	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+explore	O
+the	O
+perceptions	O
+of	O
+the	O
+highly	O
+specialized	O
+nurses	O
+who	O
+provided	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+therapy	O
+for	O
+the	O
+mostly	O
+young	O
+and	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+during	O
+the	O
+2009	O
+H1N1	O
+pandemic	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+pseudostratified	O
+HAE	O
+cultures	O
+derived	O
+from	O
+different	O
+donors	O
+are	O
+highly	O
+permissive	O
+to	O
+HCoV	O
+-	O
+EMC	B-COMP
+infection	B-DISO
+,	O
+and	O
+by	O
+using	O
+reverse	B-PROC
+transcription	I-PROC
+(	O
+RT	O
+)-	O
+PCR	O
+and	O
+RNAseq	O
+data	O
+,	O
+we	O
+experimentally	O
+determined	O
+the	O
+identity	O
+of	O
+seven	O
+HCoV	O
+-	O
+EMC	O
+subgenomic	O
+mRNAs	O
+.	O
+
+Importantly	O
+,	O
+type	O
+I	O
+and	O
+type	O
+III	O
+interferon	B-PRGE
+treatment	O
+can	O
+efficiently	O
+reduce	O
+HCoV	O
+-	O
+EMC	B-COMP
+replication	O
+in	O
+the	O
+human	B-SPEC
+airway	B-ANAT
+epithelium	B-ANAT
+,	O
+providing	O
+a	O
+possible	O
+avenue	O
+for	O
+treatment	O
+of	O
+emerging	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+This	O
+prospective	O
+study	O
+assessed	O
+the	O
+incidence	O
+,	O
+clinical	O
+spectrum	O
+,	O
+prognostic	O
+factors	O
+and	O
+outcome	O
+of	O
+AKI	O
+in	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+malaria	O
+.	O
+
+RESULTS	O
+:	O
+AKI	O
+occurred	O
+in	O
+63	O
+patients	O
+(	O
+32	O
+%),	O
+with	O
+maximum	O
+RIFLE	O
+class	B-SPEC
+R	O
+(	O
+Risk	O
+),	O
+class	B-SPEC
+I	O
+(	O
+Injury	O
+)	O
+and	O
+class	B-SPEC
+F	O
+(	O
+Failure	O
+)	O
+in	O
+27	O
+(	O
+43	O
+%),	O
+23	O
+(	O
+37	O
+%)	O
+and	O
+13	O
+(	O
+21	O
+%)	O
+patients	O
+,	O
+respectively	O
+.	O
+
+Patient	O
+characteristics	O
+,	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+cellularity	O
+,	O
+rates	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+colonization	O
+,	O
+acute	O
+rejection	O
+,	O
+and	O
+lymphocytic	O
+bronchiolitis	B-DISO
+were	O
+compared	O
+between	O
+BOS	B-DISO
+,	O
+RAS	B-PRGE
+,	O
+and	O
+stable	O
+patients	O
+.	O
+
+There	O
+were	O
+more	O
+patients	O
+with	O
+infection	B-DISO
+and	O
+pseudomonal	O
+colonizations	O
+in	O
+BOS	B-DISO
+and	O
+RAS	B-CHED
+compared	O
+with	O
+control	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0090	O
+and	O
+P	O
+=	O
+0	O
+.	O
+0034	O
+,	O
+respectively	O
+).	O
+
+BAL	B-ENZY
+neutrophilia	O
+in	O
+BOS	B-DISO
+and	O
+RAS	B-CHED
+were	O
+elevated	O
+at	O
+days	O
+360	O
+,	O
+540	O
+,	O
+and	O
+720	O
+versus	O
+control	O
+.	O
+
+One	O
+such	O
+model	O
+is	O
+differentiated	B-PROC
+normal	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+NHBE	O
+).	O
+
+Here	O
+,	O
+we	O
+detail	O
+the	O
+establishment	O
+of	O
+a	O
+polarized	O
+,	O
+liquid	O
+-	O
+covered	O
+culture	O
+(	O
+LCC	B-DISO
+)	O
+of	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+,	O
+focusing	O
+on	O
+the	O
+technical	O
+details	O
+of	O
+growing	O
+and	O
+culturing	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+,	O
+maintaining	O
+cells	B-COMP
+that	O
+have	O
+been	O
+cultured	O
+into	O
+LCC	B-DISO
+,	O
+and	O
+we	O
+present	O
+the	O
+method	O
+for	O
+performing	O
+respiratory	B-DISO
+virus	I-DISO
+infection	I-DISO
+of	O
+polarized	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+.	O
+
+To	O
+consistently	O
+obtain	O
+polarized	O
+Calu	O
+-	O
+3	O
+LCC	B-DISO
+,	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+must	O
+be	O
+carefully	O
+subcultured	O
+before	O
+culturing	O
+in	O
+Transwell	O
+inserts	O
+.	O
+
+Nowadays	O
+,	O
+four	O
+HCoVs	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+HCoV	O
+-	O
+HKU1	O
+,	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+are	O
+known	O
+to	O
+be	O
+circulating	O
+worldwide	O
+,	O
+causing	O
+upper	O
+and	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+nonhospitalized	O
+and	O
+hospitalized	O
+children	O
+.	O
+
+Studies	O
+of	O
+the	O
+fundamental	O
+aspects	O
+of	O
+these	O
+HCoV	O
+infections	B-DISO
+at	O
+the	O
+primary	O
+entry	O
+port	O
+,	O
+such	O
+as	O
+cell	B-COMP
+tropism	B-PROC
+,	O
+are	O
+seriously	O
+hampered	O
+by	O
+the	O
+lack	O
+of	O
+a	O
+universal	O
+culture	O
+system	O
+or	O
+suitable	O
+animal	B-SPEC
+models	O
+.	O
+
+After	O
+infectious	B-DISO
+challenge	O
+by	O
+TCoV	O
+,	O
+clinical	O
+signs	O
+and	O
+TCoV	O
+detected	O
+by	O
+immunofluorescence	O
+antibody	B-FUNC
+(	O
+IFA	O
+)	O
+assay	O
+were	O
+observed	O
+in	O
+less	O
+number	O
+of	O
+turkeys	B-SPEC
+in	O
+vaccination	O
+groups	O
+than	O
+that	O
+in	O
+challenge	O
+control	O
+groups	O
+.	O
+
+Comparing	O
+to	O
+the	O
+turkeys	B-SPEC
+in	O
+G1	O
+-	O
+750DP	O
+,	O
+significantly	O
+less	O
+TCoV	O
+were	O
+detected	O
+by	O
+IFA	O
+in	O
+the	O
+turkeys	B-SPEC
+in	O
+G2	O
+-	O
+100DPH	O
+receiving	O
+an	O
+extra	O
+dose	O
+of	O
+100μg	O
+DNA	O
+mixed	O
+with	O
+PEI	B-CHED
+and	O
+HA	O
+.	O
+
+Because	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+had	O
+been	O
+used	O
+successfully	O
+with	O
+pediatric	O
+patients	O
+who	O
+had	O
+no	O
+congenital	B-DISO
+heart	I-DISO
+defects	I-DISO
+,	O
+this	O
+therapy	O
+was	O
+used	O
+in	O
+our	O
+unit	O
+.	O
+
+This	O
+report	O
+aims	O
+to	O
+describe	O
+a	O
+single	O
+-	O
+center	O
+experience	O
+with	O
+HFOV	O
+in	O
+the	O
+management	O
+of	O
+ARDS	B-DISO
+after	O
+open	O
+heart	B-ANAT
+surgery	O
+with	O
+respect	O
+to	O
+mortality	O
+.	O
+
+The	O
+complications	O
+during	O
+HFOV	O
+included	O
+pneumothorax	B-DISO
+for	O
+22	O
+patients	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+role	O
+of	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cells	B-COMP
+and	O
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+(	O
+Tregs	O
+),	O
+central	O
+players	O
+in	O
+the	O
+innate	O
+and	O
+adaptive	O
+CMI	O
+respectively	O
+,	O
+was	O
+examined	O
+during	O
+natural	O
+FIPV	O
+infection	B-DISO
+.	O
+
+The	O
+New	O
+cluster	O
+1	O
+prevalent	O
+during	O
+2009	O
+and	O
+2010	O
+was	O
+not	O
+found	O
+in	O
+2011	O
+but	O
+QX	O
+-	O
+like	O
+viruses	B-SPEC
+became	O
+prevalent	O
+in	O
+2011	O
+.	O
+
+The	O
+recombination	B-PROC
+analysis	O
+revealed	O
+two	O
+new	O
+S	B-PRGE
+gene	I-PRGE
+recombinants	O
+,	O
+11036	O
+and	O
+11052	O
+which	O
+might	O
+have	O
+been	O
+derived	O
+from	O
+recombinations	B-PROC
+between	O
+the	O
+New	O
+cluster	O
+1	O
+and	O
+QX	O
+-	O
+like	O
+viruses	B-SPEC
+and	O
+between	O
+the	O
+K	O
+-	O
+I	O
+and	O
+H120	O
+(	O
+vaccine	O
+)	O
+viruses	B-SPEC
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Environmental	O
+stresses	O
+can	O
+alter	O
+immunoreactivity	O
+of	O
+biomarkers	O
+in	O
+stored	O
+tissue	B-ANAT
+sections	O
+.	O
+
+Immunoreactivity	B-PROC
+was	O
+compared	O
+with	O
+that	O
+in	O
+the	O
+corresponding	O
+1	O
+-	O
+day	O
+-	O
+old	O
+section	O
+and	O
+scored	O
+as	O
+4	O
+(<	O
+10	O
+%	O
+reduction	O
+),	O
+3	O
+(	O
+10	O
+%-	O
+25	O
+%	O
+reduction	O
+),	O
+2	O
+(	O
+26	O
+%-	O
+60	O
+%	O
+reduction	O
+),	O
+1	O
+(>	O
+60	O
+%	O
+reduction	O
+),	O
+or	O
+0	O
+(	O
+no	O
+reactivity	O
+).	O
+
+Consequently	O
+,	O
+corresponding	O
+SARs	B-DISO
+were	O
+increasingly	O
+obvious	O
+.	O
+
+A	O
+chest	B-ANAT
+tube	O
+was	O
+inserted	O
+and	O
+we	O
+observed	O
+immediate	O
+improvement	O
+in	O
+oxygen	B-CHED
+saturation	O
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+capable	O
+of	O
+lethal	O
+human	B-SPEC
+infections	B-DISO
+:	O
+an	O
+emerging	O
+picture	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+new	O
+virus	B-SPEC
+revealed	O
+that	O
+it	O
+was	O
+indeed	O
+a	O
+member	O
+of	O
+the	O
+same	O
+genus	B-SPEC
+as	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+By	O
+mid	O
+-	O
+February	O
+2013	O
+,	O
+12	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+had	O
+been	O
+reported	O
+with	O
+6	O
+fatalities	O
+.	O
+
+Multiple	O
+mucosal	B-ANAT
+surfaces	O
+were	O
+also	O
+affected	O
+.	O
+
+A	O
+chest	B-ANAT
+computed	O
+tomography	O
+revealed	O
+bilateral	O
+nonsegmental	O
+ground	O
+-	O
+glass	O
+opacities	O
+.	O
+
+Exposure	O
+to	O
+mixtures	O
+of	O
+ethenone	B-CHED
+and	O
+crotonaldehyde	B-CHED
+can	O
+cause	O
+severe	O
+pulmonary	B-ANAT
+injury	O
+leading	O
+to	O
+delayed	O
+ARDS	B-DISO
+.	O
+
+The	O
+MHV	B-SPEC
+PS	O
+is	O
+an	O
+RNA	O
+structure	O
+that	O
+maps	O
+to	O
+the	O
+region	O
+of	O
+the	O
+replicase	B-PRGE
+gene	I-PRGE
+encoding	O
+the	O
+nonstructural	O
+protein	B-CHED
+15	O
+subunit	O
+of	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+-	I-PRGE
+transcriptase	I-PRGE
+complex	O
+.	O
+
+Surprisingly	O
+,	O
+the	O
+PS	O
+was	O
+not	O
+essential	O
+for	O
+MHV	O
+viability	O
+,	O
+nor	O
+did	O
+its	O
+elimination	B-PROC
+have	O
+a	O
+severe	O
+effect	O
+on	O
+viral	O
+growth	B-PROC
+.	O
+
+However	O
+,	O
+the	O
+PS	O
+was	O
+found	O
+to	O
+provide	O
+a	O
+distinct	O
+selective	O
+advantage	O
+to	O
+MHV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Infections	B-DISO
+with	O
+human	B-SPEC
+coronavirus	I-SPEC
+EMC	B-COMP
+(	O
+HCoV	O
+-	O
+EMC	B-COMP
+)	O
+are	O
+associated	O
+with	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+However	O
+,	O
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+was	O
+markedly	O
+more	O
+sensitive	O
+to	O
+the	O
+antiviral	B-CHED
+state	O
+established	O
+by	O
+ectopic	O
+IFN	B-PRGE
+.	O
+
+Uncontrolled	O
+studies	O
+in	O
+adults	O
+have	O
+shown	O
+improvements	O
+in	O
+gas	B-ENZY
+exchange	O
+and	O
+lung	B-PROC
+compliance	I-PROC
+with	O
+partial	O
+liquid	O
+ventilation	O
+.	O
+
+To	O
+assess	O
+whether	O
+partial	O
+liquid	O
+ventilation	O
+reduces	O
+mortality	O
+or	O
+morbidity	O
+,	O
+or	O
+both	O
+,	O
+in	O
+children	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+We	O
+included	O
+randomized	O
+controlled	O
+trials	O
+(	O
+RCTs	O
+)	O
+which	O
+compared	O
+partial	O
+liquid	O
+ventilation	O
+with	O
+other	O
+forms	O
+of	O
+ventilation	O
+in	O
+children	O
+(	O
+aged	O
+28	O
+days	O
+to	O
+18	O
+years	O
+)	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Autoprocessing	O
+mechanism	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+)	O
+from	O
+its	O
+polyproteins	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+14	O
+kDa	O
+endocan	O
+fragment	O
+generated	O
+by	O
+cathepsin	B-PRGE
+G	I-PRGE
+,	O
+a	O
+novel	O
+circulating	O
+biomarker	B-CHED
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+septic	B-DISO
+syndrome	I-DISO
+,	O
+which	O
+is	O
+the	O
+most	O
+prevalent	O
+and	O
+lethal	O
+cause	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+remains	O
+one	O
+of	O
+the	O
+most	O
+frequent	O
+causes	O
+of	O
+admission	O
+and	O
+death	B-PROC
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICU	O
+).	O
+
+Endocan	O
+,	O
+specifically	O
+secreted	B-PROC
+by	O
+activated	O
+-	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+endothelial	I-ANAT
+cells	I-ANAT
+,	O
+is	O
+thought	O
+to	O
+play	O
+a	O
+key	O
+role	O
+in	O
+the	O
+control	O
+of	O
+the	O
+lung	B-ANAT
+inflammatory	B-DISO
+reaction	I-DISO
+.	O
+
+We	O
+demonstrate	O
+that	O
+cathepsin	B-PRGE
+G	I-PRGE
+(	O
+CG	O
+),	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+(	O
+NE	O
+),	O
+and	O
+to	O
+a	O
+lesser	O
+extent	O
+proteinase	B-PRGE
+3	I-PRGE
+(	O
+PR3	B-PRGE
+),	O
+degrade	O
+endocan	O
+.	O
+
+An	O
+immunoassay	O
+specific	O
+for	O
+p14	B-PRGE
+endocan	I-PRGE
+fragment	I-PRGE
+was	O
+then	O
+developed	O
+,	O
+and	O
+revealed	O
+increased	O
+plasma	B-ANAT
+levels	O
+of	O
+p14	B-PRGE
+in	O
+20	O
+out	O
+of	O
+55	O
+severe	O
+septic	O
+patients	O
+,	O
+ranging	O
+from	O
+0	O
+.	O
+52	O
+to	O
+10	O
+.	O
+40	O
+ng	O
+/	O
+mL	O
+versus	O
+undetectable	O
+p14	B-PRGE
+in	O
+plasma	B-ANAT
+from	O
+32	O
+control	O
+subjects	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0011	O
+).	O
+
+Taken	O
+together	O
+,	O
+the	O
+p14	B-PRGE
+endocan	O
+fragment	O
+represents	O
+a	O
+novel	O
+interesting	O
+biomarker	B-CHED
+which	O
+could	O
+participate	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+sepsis	B-DISO
+.	O
+
+We	O
+conducted	O
+a	O
+comprehensive	O
+9	O
+-	O
+year	O
+study	O
+on	O
+HCoVs	O
+by	O
+analyzing	O
+1137	O
+respiratory	B-ANAT
+samples	I-ANAT
+from	O
+four	O
+subsets	O
+of	O
+patients	O
+(	O
+asymptomatic	O
+,	O
+general	O
+community	O
+,	O
+with	O
+comorbidities	O
+,	O
+and	O
+hospitalized	O
+)	O
+in	O
+São	O
+Paulo	O
+,	O
+Brazil	O
+.	O
+
+The	O
+most	O
+frequently	O
+detected	O
+HCoV	O
+species	B-SPEC
+were	O
+NL63	O
+(	O
+50	O
+.	O
+0	O
+%)	O
+and	O
+OC43	O
+(	O
+27	O
+.	O
+3	O
+%).	O
+
+There	O
+were	O
+interseasonal	O
+differences	O
+in	O
+the	O
+detection	O
+frequencies	O
+,	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+being	O
+predominant	O
+in	O
+the	O
+year	O
+2004	O
+(	O
+61	O
+.	O
+5	O
+%)	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+(	O
+70	O
+.	O
+8	O
+%)	O
+in	O
+2008	O
+.	O
+
+Genetic	O
+analysis	O
+showed	O
+that	O
+each	O
+PEDV	B-SPEC
+group	O
+had	O
+several	O
+unique	O
+characteristics	O
+,	O
+which	O
+indicated	O
+that	O
+a	O
+specific	O
+group	O
+PEDVs	O
+may	O
+be	O
+differentiated	B-PROC
+from	O
+another	O
+group	O
+PEDVs	O
+.	O
+
+Finally	O
+,	O
+occupational	B-DISO
+lung	I-DISO
+disease	I-DISO
+,	O
+particularly	O
+hypersensitivity	B-DISO
+pneumonitis	I-DISO
+,	O
+silicosis	B-DISO
+,	O
+hard	O
+metal	B-CHED
+lung	B-ANAT
+,	O
+and	O
+chronic	B-DISO
+berylliosis	I-DISO
+are	O
+associated	O
+with	O
+pulmonary	B-DISO
+granuloma	B-PROC
+formation	I-PROC
+.	O
+
+TITLE	O
+:	O
+Streptococcus	B-SPEC
+agalactiae	I-SPEC
+infection	I-DISO
+in	O
+domestic	B-SPEC
+rabbits	I-SPEC
+,	O
+Oryctolagus	B-SPEC
+cuniculus	I-SPEC
+.	O
+
+A	O
+Gram	O
+-	O
+positive	O
+,	O
+chain	O
+-	O
+forming	O
+coccus	B-SPEC
+was	O
+isolated	O
+from	O
+the	O
+primary	O
+organs	B-ANAT
+and	O
+tissues	B-ANAT
+of	O
+diseased	O
+rabbits	B-SPEC
+and	O
+then	O
+identified	O
+as	O
+S	O
+.	O
+agalactiae	O
+by	O
+morphology	O
+,	O
+biochemical	O
+and	O
+physiological	O
+characteristics	O
+,	O
+16S	B-CHED
+rDNA	O
+and	O
+gyrB	B-PRGE
+gene	O
+sequences	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+EMC	B-COMP
+(	O
+hCoV	O
+-	O
+EMC	B-COMP
+),	O
+which	O
+recently	O
+emerged	O
+in	O
+Saudi	O
+Arabia	O
+,	O
+is	O
+highly	O
+pathogenic	O
+and	O
+could	O
+pose	O
+a	O
+significant	O
+threat	O
+to	O
+public	O
+health	O
+.	O
+
+Here	O
+we	O
+investigated	O
+the	O
+viral	O
+and	O
+cellular	B-COMP
+determinants	O
+governing	O
+hCoV	O
+-	O
+EMC	B-COMP
+entry	B-PROC
+into	I-PROC
+host	I-PROC
+cells	B-COMP
+.	O
+
+Collectively	O
+,	O
+our	O
+results	O
+indicate	O
+that	O
+hCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+uses	O
+a	O
+novel	O
+receptor	O
+for	O
+protease	O
+-	O
+activated	O
+entry	O
+into	O
+human	B-SPEC
+cells	B-COMP
+and	O
+might	O
+be	O
+capable	O
+of	O
+extrapulmonary	O
+spread	O
+.	O
+
+TITLE	O
+:	O
+Enteric	O
+viruses	B-SPEC
+in	O
+Brazilian	O
+turkey	B-SPEC
+flocks	O
+:	O
+single	O
+and	O
+multiple	O
+virus	B-DISO
+infection	I-DISO
+frequency	O
+according	O
+to	O
+age	O
+and	O
+clinical	O
+signs	O
+of	O
+intestinal	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Poult	O
+enteritis	B-DISO
+complex	O
+has	O
+been	O
+associated	O
+with	O
+enteritis	B-DISO
+and	O
+reduction	O
+in	O
+growth	B-PROC
+rates	O
+in	O
+commercial	O
+turkeys	B-SPEC
+worldwide	O
+.	O
+
+An	O
+average	O
+of	O
+3	O
+.	O
+20	O
+viruses	B-SPEC
+per	O
+sample	O
+was	O
+detected	O
+in	O
+turkeys	B-SPEC
+in	O
+the	O
+growing	O
+phase	O
+of	O
+the	O
+production	O
+cycle	O
+(	O
+1	O
+to	O
+4	O
+wk	O
+of	O
+age	O
+).	O
+
+Breeder	O
+hens	O
+(	O
+n	O
+=	O
+88	O
+)	O
+were	O
+randomly	O
+allotted	O
+to	O
+the	O
+control	O
+or	O
+HYPER	O
+groups	O
+and	O
+received	O
+common	O
+or	O
+thyroxine	B-CHED
+(	O
+T4	O
+)-	O
+added	O
+(	O
+1	O
+mg	O
+/	O
+L	O
+)	O
+water	B-CHED
+,	O
+respectively	O
+.	O
+
+Prevaccination	O
+antibody	B-COMP
+titers	O
+to	O
+Newcastle	O
+disease	B-DISO
+,	I-DISO
+infectious	I-DISO
+bronchitis	B-DISO
+,	O
+and	O
+infectious	B-DISO
+bursal	I-DISO
+disease	I-DISO
+virus	I-SPEC
+were	O
+higher	O
+in	O
+HYPER	O
+chicks	O
+during	O
+1	O
+wk	O
+of	O
+age	O
+,	O
+although	O
+not	O
+different	O
+in	O
+their	O
+dams	O
+.	O
+
+The	O
+present	O
+study	O
+suggests	O
+the	O
+likely	O
+occurrence	O
+of	O
+T	B-SPEC
+.	I-SPEC
+gondii	I-SPEC
+infection	B-DISO
+in	O
+bats	B-SPEC
+in	O
+China	O
+,	O
+and	O
+these	O
+bats	B-SPEC
+are	O
+new	O
+putative	O
+hosts	B-COMP
+for	O
+T	B-SPEC
+.	I-SPEC
+gondii	I-SPEC
+,	O
+which	O
+may	O
+pose	O
+a	O
+threat	O
+to	O
+human	B-SPEC
+health	O
+.	O
+
+Early	O
+OI	O
+(	O
+within	O
+3	O
+days	O
+)	O
+and	O
+SOFA	O
+score	O
+were	O
+predictors	O
+of	O
+mortality	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Leptospirosis	B-DISO
+-	O
+induced	O
+AKI	O
+is	O
+typically	O
+nonoliguric	O
+with	O
+a	O
+high	O
+frequency	O
+of	O
+hypokalemia	O
+.	O
+
+Antibiotic	B-CHED
+treatment	O
+is	O
+efficient	O
+in	O
+the	O
+early	O
+and	O
+late	O
+/	O
+severe	O
+phases	O
+and	O
+revert	O
+all	O
+kidney	B-ANAT
+transporters	O
+.	O
+
+In	O
+the	O
+Southern	O
+Regions	O
+the	O
+percentage	O
+of	O
+antibody	B-COMP
+-	O
+positive	O
+herds	O
+remained	O
+persistently	O
+high	O
+(	O
+75	O
+-	O
+100	O
+%),	O
+whereas	O
+in	O
+herds	O
+based	O
+in	O
+the	O
+Northern	O
+Region	O
+,	O
+the	O
+percentage	O
+of	O
+positive	O
+herds	O
+for	O
+BCV	B-SPEC
+and	O
+BRSV	B-SPEC
+was	O
+38	O
+-	O
+80	O
+%	O
+and	O
+0	O
+-	O
+80	O
+%,	O
+respectively	O
+,	O
+with	O
+antibody	B-COMP
+levels	O
+to	O
+BRSV	B-SPEC
+decreasing	O
+over	O
+time	O
+.	O
+
+Pooled	O
+milk	O
+samples	O
+of	O
+'	O
+home	O
+-	O
+bred	O
+'	O
+primiparous	O
+animals	B-SPEC
+were	O
+found	O
+to	O
+be	O
+most	O
+useful	O
+in	O
+terms	O
+of	O
+monitoring	O
+herd	O
+status	O
+but	O
+could	O
+gradually	O
+be	O
+replaced	O
+by	O
+bulk	O
+-	O
+tank	O
+sampling	O
+once	O
+freedom	O
+from	O
+infection	O
+was	O
+established	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+27	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+presented	O
+with	O
+acute	B-DISO
+dyspnea	I-DISO
+and	O
+a	O
+previous	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+with	O
+progressive	O
+dyspnoea	B-DISO
+and	O
+chest	B-DISO
+pain	I-DISO
+over	O
+2	O
+weeks	O
+.	O
+
+A	O
+myocardial	O
+biopsy	O
+was	O
+taken	O
+to	O
+exclude	O
+giant	B-DISO
+cell	I-DISO
+myocarditis	I-DISO
+.	O
+
+A	O
+drug	O
+-	O
+only	O
+circulatory	B-PROC
+support	O
+very	O
+often	O
+does	O
+not	O
+enable	O
+stabilization	O
+of	O
+a	O
+patient	O
+in	O
+progressive	O
+cardiogenic	O
+shock	O
+and	O
+cannot	O
+prevent	O
+multiorgan	O
+dysfunction	O
+.	O
+
+Therefore	O
+implantation	B-PROC
+of	O
+an	O
+assist	O
+device	O
+facilitates	O
+a	O
+""""	O
+bridging	O
+-	O
+to	O
+-	O
+recovery	O
+""""	O
+or	O
+a	O
+""""	O
+bridging	O
+-	O
+to	O
+transplant	B-ANAT
+""""	O
+concept	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+presenting	O
+with	O
+cardiogenic	B-DISO
+shock	I-DISO
+.	O
+
+In	O
+case	O
+of	O
+recovery	O
+continuous	O
+care	O
+in	O
+a	O
+specialized	O
+Heart	B-DISO
+Failure	I-DISO
+Clinic	O
+can	O
+help	O
+to	O
+maintain	O
+the	O
+clinical	O
+status	O
+and	O
+offer	O
+frequent	O
+reevaluation	O
+of	O
+cardiac	B-ANAT
+status	O
+and	O
+therapeutic	O
+concepts	O
+.	O
+
+Reconstitution	O
+of	O
+the	O
+peptides	B-CHED
+as	O
+TMD1	O
++	O
+TMD3	O
+as	O
+well	O
+as	O
+TMD2	O
++	O
+TMD3	O
+in	O
+a	O
+1	O
+:	O
+1	O
+mixture	B-CHED
+induces	O
+membrane	B-PROC
+activity	I-PROC
+for	O
+both	O
+mixtures	O
+.	O
+
+Expression	B-PROC
+of	O
+full	O
+length	O
+3a	O
+and	O
+reconstitution	O
+into	O
+artificial	O
+lipid	B-ANAT
+bilayers	I-ANAT
+reveal	O
+a	O
+weak	O
+cation	B-CHED
+selective	O
+(	O
+PK	B-PRGE
+≈	I-PRGE
+2	I-PRGE
+PCl	I-PRGE
+)	O
+rectifying	O
+channel	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+eosinophilic	I-DISO
+pneumonia	I-DISO
+is	O
+a	O
+severe	O
+and	O
+rapidly	O
+progressive	O
+lung	O
+disease	O
+that	O
+can	O
+cause	O
+fatal	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+of	O
+severe	O
+Cushing	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+developing	O
+into	O
+life	O
+-	O
+threatening	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+cryptococcus	B-SPEC
+and	O
+cytomegalovirus	B-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+soon	O
+after	O
+hypercortisolism	B-DISO
+treatment	O
+using	O
+metyrapone	B-CHED
+,	O
+an	O
+11	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+-	I-PRGE
+hydroxylase	I-PRGE
+inhibitor	B-CHED
+.	O
+
+TITLE	O
+:	O
+Dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+is	O
+a	O
+functional	O
+receptor	O
+for	O
+the	O
+emerging	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+EMC	B-COMP
+.	O
+
+Genetic	O
+sequence	O
+analyses	O
+have	O
+shown	O
+that	O
+this	O
+new	O
+virus	B-SPEC
+is	O
+different	O
+from	O
+any	O
+other	O
+known	O
+human	B-SPEC
+coronaviruses	O
+,	O
+including	O
+the	O
+one	O
+that	O
+caused	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Imaging	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Accurate	O
+diagnosis	O
+and	O
+differentiation	B-PROC
+from	O
+other	O
+treatable	O
+conditions	O
+is	O
+crucial	O
+.	O
+
+This	O
+publication	O
+addresses	O
+the	O
+clinical	O
+and	O
+radiological	O
+features	O
+of	O
+ARDS	B-DISO
+,	O
+a	O
+review	O
+of	O
+the	O
+imaging	O
+technology	O
+with	O
+illustrations	O
+and	O
+differential	O
+diagnosis	O
+.	O
+
+Five	O
+patients	O
+died	B-PROC
+.	O
+
+The	O
+relationship	O
+between	O
+ethnicity	O
+and	O
+immunity	B-PROC
+to	O
+severe	O
+disease	O
+is	O
+complex	O
+.	O
+
+Multivariate	O
+analysis	O
+showed	O
+that	O
+HFOV	O
+was	O
+more	O
+effective	O
+in	O
+younger	O
+patients	O
+,	O
+when	O
+instituted	O
+early	O
+,	O
+and	O
+in	O
+patients	O
+with	O
+milder	O
+respiratory	B-DISO
+acidosis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Crystal	B-ANAT
+structure	O
+-	O
+based	O
+exploration	O
+of	O
+the	O
+important	O
+role	O
+of	O
+Arg106	O
+in	O
+the	O
+RNA	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+human	O
+coronavirus	O
+OC43	O
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+We	O
+have	O
+solved	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+HCoV	B-PRGE
+-	I-PRGE
+OC43	I-PRGE
+N	I-PRGE
+protein	B-CHED
+(	O
+N	O
+-	O
+NTD	O
+)	O
+(	O
+residues	O
+58	O
+to	O
+195	O
+)	O
+to	O
+a	O
+resolution	O
+of	O
+2	O
+.	O
+0Å	O
+.	O
+
+The	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+N	O
+-	O
+NTD	O
+is	O
+a	O
+single	O
+domain	O
+protein	B-CHED
+composed	O
+of	O
+a	O
+five	O
+-	O
+stranded	O
+β	O
+-	O
+sheet	O
+core	O
+and	O
+a	O
+long	O
+extended	O
+loop	O
+,	O
+similar	O
+to	O
+that	O
+observed	O
+in	O
+the	O
+structures	O
+of	O
+N	O
+-	O
+NTDs	O
+from	O
+other	O
+coronaviruses	O
+.	O
+
+The	O
+results	O
+show	O
+that	O
+R106	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+interaction	O
+between	O
+the	O
+N	O
+protein	B-CHED
+and	O
+RNA	O
+.	O
+
+The	O
+results	O
+also	O
+indicate	O
+that	O
+the	O
+strength	O
+of	O
+N	O
+protein	B-CHED
+/	O
+RNA	O
+interactions	O
+is	O
+critical	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+survey	O
+was	O
+carried	O
+out	O
+in	O
+search	O
+for	O
+bat	B-ENZY
+coronaviruses	O
+in	O
+an	O
+urban	O
+maternity	O
+roost	O
+of	O
+about	O
+500	O
+specimens	O
+of	O
+two	O
+species	B-SPEC
+of	O
+insectivorous	O
+bats	B-SPEC
+,	O
+Molossus	B-SPEC
+molossus	I-SPEC
+and	O
+Tadarida	B-SPEC
+brasiliensis	I-SPEC
+,	O
+in	O
+Southern	O
+Brazil	O
+.	O
+
+CVVH	O
+was	O
+employed	O
+when	O
+the	O
+values	O
+of	O
+creatine	B-CHED
+phosphokinase	O
+(	O
+CPK	B-PRGE
+),	O
+myoglobin	B-PRGE
+(	O
+Mb	O
+),	O
+and	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+increased	O
+significantly	O
+.	O
+
+After	O
+emergency	B-DISO
+treatment	O
+and	O
+CVVH	O
+therapy	O
+,	O
+the	O
+values	O
+of	O
+CPK	B-PRGE
+,	O
+Mb	O
+,	O
+and	O
+LDH	B-PRGE
+in	O
+the	O
+blood	B-ANAT
+plasma	I-ANAT
+of	O
+the	O
+patients	O
+decreased	O
+significantly	O
+.	O
+
+This	O
+study	O
+highlights	O
+the	O
+significant	O
+burden	O
+of	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+complicated	B-DISO
+malaria	I-DISO
+with	O
+isolated	O
+complication	B-DISO
+like	O
+ARDS	B-DISO
+with	O
+high	O
+mortality	O
+rate	O
+of	O
+50	O
+%	O
+in	O
+present	O
+population	O
+.	O
+
+TITLE	O
+:	O
+Outcomes	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+patients	O
+on	O
+chronic	O
+antiplatelet	O
+treatment	O
+:	O
+a	O
+historical	O
+cohort	O
+study	O
+.	O
+
+Incidence	O
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+was	O
+similar	O
+between	O
+both	O
+groups	O
+(	O
+odds	O
+ratio	O
+1	O
+.	O
+08	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+0	O
+.	O
+73	O
+-	O
+1	O
+.	O
+59	O
+).	O
+
+Antiplatelet	O
+therapy	O
+was	O
+associated	O
+with	O
+a	O
+decreased	O
+incidence	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Initial	O
+ventilator	O
+settings	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Patients	O
+with	O
+a	O
+stiff	O
+chest	B-ANAT
+wall	I-ANAT
+may	O
+tolerate	O
+higher	O
+plateau	O
+pressure	O
+targets	O
+(	O
+approximately	O
+35	O
+cmH2O	O
+)	O
+while	O
+those	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+ventilator	O
+asynchrony	O
+may	O
+require	O
+a	O
+short	O
+-	O
+term	O
+neuromuscular	B-DISO
+blockade	I-DISO
+.	O
+
+TITLE	O
+:	O
+Do	O
+parameters	O
+used	O
+to	O
+clear	O
+noncritically	O
+injured	O
+polytrauma	O
+patients	O
+for	O
+extremity	B-ANAT
+surgery	O
+predict	O
+complications	O
+?	O
+
+(	O
+1	O
+)	O
+Patients	O
+with	O
+complications	O
+had	O
+a	O
+decreased	O
+initial	O
+Glasgow	O
+Coma	B-DISO
+Scale	O
+and	O
+tended	O
+to	O
+have	O
+a	O
+lower	O
+ISS	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Case	O
+report	O
+of	O
+the	O
+first	O
+world	O
+death	B-PROC
+due	O
+to	O
+a	O
+new	O
+strain	O
+of	O
+human	B-PRGE
+influenza	B-PATH
+A	I-PATH
+H1N1	I-PRGE
+virus	B-SPEC
+and	O
+behavior	O
+of	O
+human	O
+influenzae	O
+in	O
+pregnant	O
+women	O
+].	O
+
+RESULTS	O
+:	O
+Tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+on	O
+the	O
+fourth	O
+and	O
+seventh	O
+days	O
+,	O
+and	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+scores	O
+on	O
+the	O
+seventh	O
+day	O
+after	O
+treatment	O
+showed	O
+significant	O
+decrease	O
+in	O
+the	O
+somatostatin	B-PRGE
+,	O
+somatostatin	B-PRGE
++	I-PRGE
+ulinastatin	I-PRGE
+,	O
+somatostatin	B-PRGE
++	I-PRGE
+S	I-PRGE
+miltiorrhiza	I-PRGE
+and	O
+somatostatin	B-PRGE
++	O
+ulinastatin	B-PRGE
++	I-PRGE
+S	I-PRGE
+miltiorrhiza	O
+subgroups	O
+compared	O
+with	O
+the	O
+basic	O
+treatment	O
+subgroup	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+on	O
+clinical	O
+outcome	O
+of	O
+pediatric	O
+patients	O
+with	O
+acute	O
+cardiopulmonary	O
+failure	O
+:	O
+a	O
+single	O
+-	O
+center	O
+experience	O
+.	O
+
+ABSTRACT	O
+:	O
+Conventional	O
+therapy	O
+against	O
+acute	O
+pediatric	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+(	O
+APCPF	O
+)	O
+caused	O
+by	O
+a	O
+variety	O
+of	O
+disease	O
+entities	O
+remains	O
+unsatisfactory	O
+with	O
+extremely	O
+high	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Between	O
+August	O
+2006	O
+and	O
+May	O
+2011	O
+,	O
+a	O
+single	O
+-	O
+center	O
+cohort	O
+study	O
+was	O
+performed	O
+in	O
+pediatric	O
+patients	O
+who	O
+required	O
+ECMO	O
+support	O
+due	O
+to	O
+cardiogenic	B-DISO
+shock	I-DISO
+or	O
+severe	O
+hypoxemia	O
+.	O
+
+The	O
+indications	O
+included	O
+acute	O
+fulminant	O
+myocarditis	B-DISO
+(	O
+AFM	O
+)	O
+(	O
+n	O
+=	O
+6	O
+),	O
+congenital	B-DISO
+diaphragmatic	I-DISO
+hernia	I-DISO
+(	O
+CDH	B-DISO
+)	O
+(	O
+n	O
+=	O
+3	O
+),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+(	O
+n	O
+=	O
+6	O
+),	O
+enterovirus	B-SPEC
+71	O
+(	O
+n	O
+=	O
+3	O
+),	O
+viral	B-DISO
+sepsis	I-DISO
+(	O
+n	O
+=	O
+2	O
+),	O
+refractory	O
+ventricular	B-DISO
+fibrillation	I-DISO
+due	O
+to	O
+long	B-DISO
+QT	I-DISO
+syndrome	I-DISO
+(	O
+n	O
+=	O
+1	O
+),	O
+and	O
+pulmonary	B-DISO
+edema	I-DISO
+with	O
+brain	B-DISO
+herniation	I-DISO
+(	O
+n	O
+=	O
+1	O
+).	O
+
+Successful	O
+ECMO	O
+weaning	B-PROC
+with	O
+uneventful	O
+discharge	B-ANAT
+from	O
+hospital	O
+was	O
+noted	O
+in	O
+14	O
+(	O
+63	O
+.	O
+6	O
+%)	O
+patients	O
+,	O
+whereas	O
+in	O
+-	O
+hospital	O
+mortality	O
+despite	O
+successful	O
+ECMO	O
+weaning	B-PROC
+occurred	O
+in	O
+5	O
+patients	O
+(	O
+22	O
+.	O
+7	O
+%).	O
+
+Failure	O
+in	O
+ECMO	O
+weaning	B-PROC
+and	O
+in	O
+-	O
+hospital	O
+death	B-PROC
+was	O
+noted	O
+in	O
+3	O
+patients	O
+(	O
+13	O
+.	O
+6	O
+%).	O
+
+TITLE	O
+:	O
+Phylogenetic	O
+analysis	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+strains	O
+in	O
+an	O
+epizootic	O
+outbreak	O
+of	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+This	O
+prospective	O
+outbreak	O
+investigation	O
+was	O
+initiated	O
+during	O
+an	O
+outbreak	O
+of	O
+FIP	B-DISO
+in	O
+cats	B-SPEC
+within	O
+or	O
+rehomed	O
+from	O
+a	O
+rescue	O
+/	O
+rehoming	O
+center	O
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+that	O
+the	O
+FIP	B-DISO
+-	O
+associated	O
+strains	O
+of	O
+FCoV	O
+from	O
+the	O
+outbreak	O
+were	O
+very	O
+closely	O
+related	O
+to	O
+the	O
+fecally	O
+derived	O
+strains	O
+of	O
+FCoV	O
+from	O
+contemporary	O
+-	O
+asymptomatic	O
+cats	B-SPEC
+.	O
+
+Contact	O
+tracing	O
+identified	O
+two	O
+secondary	O
+cases	O
+among	O
+family	B-SPEC
+members	O
+without	O
+recent	O
+travel	O
+:	O
+one	O
+developed	O
+severe	O
+respiratory	O
+illness	O
+and	O
+died	B-PROC
+,	O
+the	O
+other	O
+an	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+fibroproliferative	O
+response	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+mechanisms	O
+and	O
+clinical	O
+significance	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+develop	O
+a	O
+nested	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+nested	O
+PCR	O
+)	O
+for	O
+the	O
+rapid	O
+detection	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+of	O
+pigs	B-SPEC
+.	O
+
+External	O
+primers	O
+were	O
+used	O
+to	O
+amplify	O
+a	O
+fragment	O
+of	O
+the	O
+expected	O
+size	O
+(	O
+441	O
+bp	O
+)	O
+in	O
+all	O
+the	O
+samples	O
+evaluated	O
+using	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+but	O
+with	O
+very	O
+low	O
+intensity	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+sudden	B-DISO
+death	B-PROC
+of	O
+three	O
+calves	O
+,	O
+one	O
+diarrheic	O
+calf	B-ANAT
+,	O
+and	O
+one	O
+aborted	B-ANAT
+fetus	I-ANAT
+from	O
+four	O
+farms	O
+in	O
+southern	O
+Brazil	O
+was	O
+investigated	O
+.	O
+
+H	B-SPEC
+.	I-SPEC
+somni	I-SPEC
+DNA	O
+was	O
+amplified	O
+in	O
+tissues	B-ANAT
+from	O
+all	O
+calves	O
+and	O
+the	O
+brain	B-ANAT
+of	O
+the	O
+aborted	B-ANAT
+fetus	I-ANAT
+with	O
+pathological	O
+alterations	O
+consistent	O
+with	O
+histophilosis	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+recombinant	O
+DNA	O
+plasmids	O
+increased	O
+the	O
+proliferation	B-DISO
+of	O
+T	B-ANAT
+lymphocytes	I-ANAT
+and	O
+the	O
+number	O
+of	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-ANAT
++	I-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+subgroups	O
+.	O
+
+The	O
+most	O
+potent	O
+derivative	O
+of	O
+this	O
+series	O
+inhibits	O
+TMPRSS2	O
+with	O
+a	O
+K	O
+(	O
+i	O
+)	O
+value	O
+of	O
+0	O
+.	O
+9	O
+nM	O
+and	O
+showed	O
+an	O
+efficient	O
+blockage	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+propagation	O
+in	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Younger	O
+patients	O
+had	O
+accidentally	O
+swallowed	O
+paraquat	B-CHED
+,	O
+whereas	O
+older	O
+patients	O
+had	O
+intentionally	O
+ingested	O
+paraquat	B-CHED
+.	O
+
+Secondary	O
+bacterial	B-DISO
+infections	I-DISO
+were	O
+common	O
+after	O
+hospitalization	O
+and	O
+included	O
+sepsis	B-DISO
+(	O
+33	O
+.	O
+3	O
+%),	O
+pneumonia	B-DISO
+(	O
+33	O
+.	O
+3	O
+%),	O
+and	O
+urinary	B-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+50	O
+.	O
+0	O
+%).	O
+
+Our	O
+data	O
+(	O
+mortality	O
+rate	O
+,	O
+33	O
+.	O
+3	O
+%)	O
+are	O
+comparable	O
+to	O
+the	O
+data	O
+of	O
+other	O
+published	O
+reports	O
+from	O
+other	O
+international	O
+poison	B-CHED
+centers	O
+.	O
+
+In	O
+the	O
+end	O
+,	O
+2	O
+patients	O
+(	O
+33	O
+.	O
+3	O
+%)	O
+died	B-PROC
+from	O
+multiple	O
+-	O
+organ	B-DISO
+failure	I-DISO
+,	O
+despite	O
+intensive	O
+resuscitation	O
+.	O
+
+Hypercapnia	B-DISO
+and	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+is	O
+often	O
+noted	O
+with	O
+lung	B-ANAT
+protective	O
+ventilation	O
+.	O
+
+Some	O
+clinicians	O
+argue	O
+that	O
+hypercapnia	B-DISO
+and	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+protect	O
+the	O
+lungs	B-ANAT
+and	O
+may	O
+be	O
+associated	O
+with	O
+improved	O
+outcomes	O
+.	O
+
+A	O
+recent	O
+cell	B-ANAT
+line	I-ANAT
+susceptibility	O
+study	O
+showed	O
+that	O
+HCoV	O
+-	O
+EMC	B-COMP
+can	O
+infect	O
+primate	B-SPEC
+,	O
+porcine	B-SPEC
+,	O
+and	O
+bat	B-ENZY
+cells	B-COMP
+and	O
+therefore	O
+may	O
+jump	O
+interspecies	O
+barriers	O
+.	O
+
+We	O
+found	O
+that	O
+HCoV	O
+-	O
+EMC	B-COMP
+can	O
+also	O
+infect	O
+civet	B-SPEC
+lung	B-ANAT
+fibroblast	B-ANAT
+and	O
+rabbit	B-SPEC
+kidney	B-ANAT
+cell	I-ANAT
+lines	O
+.	O
+
+These	O
+findings	O
+have	O
+important	O
+implications	O
+for	O
+the	O
+diagnosis	O
+,	O
+pathogenesis	B-DISO
+,	O
+and	O
+transmission	O
+of	O
+HCoV	O
+-	O
+EMC	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+with	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+is	O
+associated	O
+with	O
+the	O
+common	B-DISO
+cold	I-DISO
+and	O
+may	O
+result	O
+in	O
+pneumonia	B-DISO
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+Finally	O
+,	O
+immunohistochemistry	O
+revealed	O
+that	O
+TMPRSS2	B-PRGE
+is	O
+coexpressed	O
+with	O
+CD13	B-PRGE
+,	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+receptor	I-PRGE
+,	O
+in	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	O
+(	O
+HAE	O
+)	O
+cells	B-COMP
+,	O
+and	O
+that	O
+CD13	B-PRGE
+(+)	O
+TMPRSS2	O
+(+)	O
+cells	B-COMP
+are	O
+preferentially	O
+targeted	B-PROC
+by	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+suggesting	O
+that	O
+TMPRSS2	B-PRGE
+can	O
+activate	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+in	O
+infected	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+possess	O
+a	O
+cap	B-DISO
+structure	O
+at	O
+the	O
+5	O
+'	O
+ends	O
+of	O
+viral	O
+genomic	O
+RNA	O
+and	O
+subgenomic	O
+RNAs	O
+,	O
+which	O
+is	O
+generated	O
+through	O
+consecutive	O
+methylations	B-PROC
+by	O
+virally	O
+encoded	O
+guanine	B-PRGE
+-	I-PRGE
+N7	I-PRGE
+-	I-PRGE
+methyltransferase	I-PRGE
+(	O
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+)	I-PRGE
+and	I-PRGE
+2	I-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+methyltransferase	I-PRGE
+(	I-PRGE
+2	I-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+).	O
+
+The	O
+sequence	O
+motif	O
+DxGxPxA	O
+(	O
+amino	B-CHED
+acids	I-CHED
+[	O
+aa	O
+]	O
+331	O
+to	O
+338	O
+)	O
+was	O
+identified	O
+as	O
+the	O
+key	O
+part	O
+of	O
+the	O
+SAM	B-DISO
+-	O
+binding	B-FUNC
+site	O
+.	O
+
+TITLE	O
+:	O
+Virological	O
+and	O
+clinical	O
+characterizations	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+hospitalized	O
+children	O
+.	O
+
+Alcohol	O
+misuse	O
+was	O
+common	O
+with	O
+70	O
+(	O
+7	O
+%)	O
+of	O
+patients	O
+having	O
+Alcohol	B-DISO
+Use	I-DISO
+Disorders	I-DISO
+Identification	O
+Test	O
+scores	O
+in	O
+zone	B-ANAT
+3	I-ANAT
+and	O
+129	O
+(	O
+12	O
+%)	O
+patients	O
+in	O
+zone	O
+4	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+describe	O
+the	O
+experience	O
+with	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+in	O
+a	O
+Portuguese	O
+Pediatric	O
+Critical	O
+Care	O
+Unit	O
+,	O
+and	O
+to	O
+evaluate	O
+whether	O
+HFOV	O
+allowed	O
+improvement	O
+in	O
+oxygenation	B-PROC
+and	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+Previously	O
+,	O
+we	O
+have	O
+confirmed	O
+that	O
+the	O
+antiviral	O
+activities	O
+of	O
+the	O
+chromone	B-CHED
+derivatives	O
+were	O
+controlled	O
+by	O
+the	O
+type	O
+as	O
+well	O
+as	O
+the	O
+position	O
+of	O
+the	O
+substituents	O
+attached	O
+to	O
+the	O
+chromone	B-CHED
+core	O
+structure	O
+.	O
+
+The	O
+synthesized	O
+2	O
+-(	O
+3	O
+-	O
+amino	O
+-	O
+4	O
+-	O
+piperazinylphenyl	O
+)-	O
+chromones	O
+showed	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+corona	B-CHED
+virus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)-	O
+specific	O
+antiviral	B-CHED
+activity	O
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+2	O
+-	O
+pyridinylpiperazinylphenyl	O
+substituents	O
+provided	O
+the	O
+resulting	O
+chromone	B-CHED
+derivatives	O
+with	O
+selective	O
+antiviral	B-CHED
+activity	O
+.	O
+
+Polymyxin	B-CHED
+B	I-CHED
+-	O
+immobilized	O
+fiber	B-ANAT
+column	B-ANAT
+direct	O
+hemoperfusion	O
+(	O
+PMX	O
+-	O
+DHP	O
+)	O
+is	O
+a	O
+medical	O
+device	O
+that	O
+reduces	O
+blood	B-ANAT
+endotoxin	O
+levels	O
+in	O
+sepsis	B-DISO
+.	O
+
+Use	O
+of	O
+combination	O
+of	O
+bronchodilators	O
+and	O
+inhaled	B-PROC
+corticosteroids	B-CHED
+was	O
+more	O
+frequent	O
+in	O
+younger	O
+patients	O
+with	O
+more	O
+severe	O
+airways	B-DISO
+obstruction	I-DISO
+and	O
+lower	O
+CCI	O
+.	O
+
+TITLE	O
+:	O
+Tropism	B-PROC
+of	O
+and	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+to	O
+the	O
+novel	O
+human	B-SPEC
+betacoronavirus	B-SPEC
+lineage	O
+C	O
+virus	B-SPEC
+in	O
+human	O
+ex	O
+vivo	O
+respiratory	B-ANAT
+organ	I-ANAT
+cultures	O
+.	O
+
+The	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+elicited	O
+by	O
+HCoV	O
+-	O
+EMC	B-COMP
+were	O
+also	O
+investigated	O
+.	O
+
+While	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+productively	O
+replicated	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+replication	O
+in	O
+human	B-SPEC
+bronchial	B-ANAT
+tissue	B-ANAT
+was	O
+limited	O
+.	O
+
+Immunohistochemistry	O
+revealed	O
+that	O
+HCoV	O
+-	O
+EMC	B-COMP
+infected	O
+nonciliated	O
+bronchial	B-ANAT
+epithelium	I-ANAT
+,	O
+bronchiolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+endothelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Finally	O
+,	O
+the	O
+blocking	B-DISO
+of	O
+PS	O
+receptors	O
+on	O
+macrophages	B-ANAT
+inhibited	O
+the	O
+entry	O
+of	O
+Ebola	O
+VLPs	B-ANAT
+,	O
+suggesting	O
+that	O
+PS	O
+receptors	O
+can	O
+contribute	O
+to	O
+infection	B-DISO
+in	O
+physiologically	O
+relevant	O
+cells	B-COMP
+.	O
+
+The	O
+predictors	O
+of	O
+NIV	O
+failure	O
+were	O
+the	O
+severity	O
+of	O
+associated	O
+organ	B-ANAT
+dysfunctions	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+20	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+05	O
+to	O
+1	O
+.	O
+34	O
+),	O
+ARDS	B-DISO
+(	O
+OR	O
+,	O
+2	O
+.	O
+31	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+10	O
+to	O
+4	O
+.	O
+82	O
+)	O
+and	O
+positive	O
+fluid	B-PROC
+balance	I-PROC
+(	O
+OR	O
+,	O
+2	O
+.	O
+09	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+02	O
+to	O
+4	O
+.	O
+30	O
+).	O
+
+Overall	O
+ICU	O
+mortality	O
+during	O
+the	O
+two	O
+decades	O
+was	O
+37	O
+.	O
+3	O
+%	O
+(	O
+range	O
+25	O
+.	O
+0	O
+%-	O
+38	O
+.	O
+1	O
+%)	O
+between	O
+1995	O
+and	O
+2001	O
+and	O
+a	O
+non	O
+-	O
+significant	O
+increase	O
+in	O
+values	O
+between	O
+36	O
+.	O
+8	O
+%	O
+and	O
+58	O
+.	O
+3	O
+%	O
+during	O
+the	O
+time	O
+interval	O
+from	O
+2002	O
+und	B-CHED
+2005	O
+.	O
+
+The	O
+introduction	O
+of	O
+new	O
+modalities	O
+of	O
+ARDS	B-DISO
+treatment	O
+were	O
+associated	O
+with	O
+higher	O
+paO2	O
+/	O
+FIO2	O
+-	O
+ratios	O
+on	O
+ICU	O
+admittance	O
+but	O
+had	O
+no	O
+effect	O
+on	O
+short	O
+-	O
+term	O
+outcomes	O
+including	O
+duration	O
+of	O
+ICU	O
+therapy	O
+,	O
+mechanical	O
+ventilation	O
+or	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+mast	O
+cells	O
+(	O
+MCs	B-COMP
+)	O
+in	O
+allergic	B-DISO
+reactions	I-DISO
+and	O
+parasitic	O
+infections	B-DISO
+is	O
+well	O
+established	O
+.	O
+
+Thirty	O
+-	O
+four	O
+patients	O
+with	O
+at	O
+least	O
+5	O
+years	O
+of	O
+HIV	B-PATH
+infection	I-PATH
+and	O
+27	O
+healthy	O
+controls	O
+underwent	O
+magnetic	O
+resonance	O
+imaging	O
+(	O
+MRI	O
+)	O
+in	O
+a	O
+1	O
+.	O
+5	O
+T	O
+scanner	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+established	O
+a	O
+porcine	B-SPEC
+intestinal	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+(	O
+IEC	O
+)	O
+line	O
+which	O
+can	O
+stably	O
+express	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+Characterising	O
+the	O
+viruses	B-SPEC
+of	O
+candidate	O
+reservoir	O
+species	B-SPEC
+in	O
+geographical	O
+hot	B-DISO
+spots	I-DISO
+for	O
+viral	O
+emergence	O
+is	O
+a	O
+sensible	O
+approach	O
+to	O
+develop	O
+tools	O
+to	O
+predict	O
+,	O
+prevent	O
+,	O
+or	O
+contain	O
+emergence	O
+events	O
+.	O
+
+We	O
+identified	O
+a	O
+great	O
+abundance	O
+and	O
+diversity	O
+of	O
+novel	O
+herpes	B-DISO
+and	O
+papillomaviruses	O
+,	O
+described	O
+the	O
+isolation	O
+of	O
+a	O
+novel	O
+adenovirus	B-DISO
+,	O
+and	O
+detected	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+sequences	O
+of	O
+a	O
+chiropteran	O
+poxvirus	B-SPEC
+closely	O
+related	O
+with	O
+Molluscum	B-DISO
+contagiosum	I-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+ARDS	B-DISO
+induced	O
+by	O
+fusobacterial	O
+infections	B-DISO
+:	O
+a	O
+rare	O
+clinical	O
+presentation	O
+of	O
+Lemierre	B-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+poses	O
+a	O
+major	O
+challenge	O
+in	O
+intensive	O
+care	O
+settings	O
+.	O
+
+These	O
+habitat	O
+impacts	O
+could	O
+enhance	O
+disease	O
+risk	O
+by	O
+increasing	O
+contact	O
+with	O
+domestic	O
+animals	B-SPEC
+and	O
+by	O
+altering	O
+patterns	O
+of	O
+exposure	O
+to	O
+other	O
+wild	O
+felids	B-SPEC
+.	O
+
+Most	O
+mountain	O
+lions	B-SPEC
+sampled	O
+were	O
+killed	O
+because	O
+of	O
+depredation	O
+or	O
+public	O
+safety	O
+concerns	O
+and	O
+75	O
+%	O
+were	O
+adults	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+fatal	O
+immune	O
+-	O
+mediated	O
+vasculitis	B-DISO
+of	O
+felids	B-SPEC
+caused	O
+by	O
+a	O
+mutant	B-DISO
+form	O
+of	O
+a	O
+common	O
+feline	B-SPEC
+enteric	O
+virus	B-SPEC
+,	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+CMV	B-SPEC
+is	O
+frequent	O
+and	O
+severe	O
+in	O
+immunosuppressed	O
+infants	O
+but	O
+infrequent	O
+in	O
+full	O
+-	O
+term	O
+neonates	O
+and	O
+occurs	O
+more	O
+frequently	O
+after	O
+perinatal	O
+than	O
+after	O
+congenital	B-DISO
+infection	I-DISO
+,	O
+particularly	O
+in	O
+premature	O
+infants	O
+.	O
+
+The	O
+role	O
+of	O
+antiviral	B-CHED
+therapy	O
+remains	O
+to	O
+be	O
+elucidated	O
+.	O
+
+RESULTS	O
+:	O
+CMV	B-SPEC
+is	O
+frequent	O
+and	O
+severe	O
+in	O
+immunosuppressed	O
+infants	O
+but	O
+infrequent	O
+in	O
+full	O
+-	O
+term	O
+neonates	O
+and	O
+occurs	O
+more	O
+frequently	O
+after	O
+perinatal	O
+than	O
+after	O
+congenital	B-DISO
+infection	I-DISO
+,	O
+particularly	O
+in	O
+premature	O
+infants	O
+.	O
+
+RESULTS	O
+:	O
+Five	O
+common	O
+themes	O
+characterized	O
+respondents	O
+'	O
+experiences	O
+with	O
+pandemic	O
+planning	O
+and	O
+response	O
+:	O
+1	O
+)	O
+national	O
+pandemic	O
+influenza	B-DISO
+preparedness	O
+guidance	O
+has	O
+not	O
+fully	O
+penetrated	O
+to	O
+the	O
+level	O
+of	O
+pediatric	O
+emergency	B-DISO
+physician	O
+(	O
+EP	O
+)	O
+leaders	O
+,	O
+leading	O
+to	O
+variable	O
+states	O
+of	O
+preparedness	O
+;	O
+2	O
+)	O
+pediatric	O
+EDs	B-DISO
+that	O
+maintained	O
+strong	O
+relationships	O
+with	O
+local	O
+public	O
+health	O
+and	O
+other	O
+health	O
+care	O
+entities	O
+found	O
+those	O
+relationships	O
+to	O
+be	O
+beneficial	O
+to	O
+pandemic	O
+response	O
+;	O
+3	O
+)	O
+pediatric	O
+EP	O
+leaders	O
+reported	O
+difficulty	O
+reconciling	O
+public	O
+health	O
+guidance	O
+with	O
+the	O
+reality	O
+of	O
+ED	O
+practice	O
+;	O
+4	O
+)	O
+although	O
+many	O
+anticipated	O
+obstacles	O
+did	O
+not	O
+materialize	O
+,	O
+in	O
+some	O
+cases	O
+pediatric	O
+EP	O
+leaders	O
+experienced	O
+unexpected	O
+institutional	O
+challenges	O
+;	O
+and	O
+5	O
+)	O
+pediatric	O
+EP	O
+leaders	O
+described	O
+varied	O
+experiences	O
+with	O
+organizational	O
+learning	B-PROC
+following	O
+the	O
+H1N1	O
+pandemic	O
+experience	O
+.	O
+
+The	O
+first	O
+was	O
+a	O
+47	O
+-	O
+year	O
+-	O
+old	O
+female	O
+who	O
+was	O
+admitted	O
+with	O
+fracture	O
+of	O
+both	O
+tibial	B-ANAT
+bones	B-ANAT
+sustained	O
+during	O
+a	O
+road	O
+traffic	O
+accident	O
+.	O
+
+X	O
+-	O
+ray	B-SPEC
+and	O
+magnetic	O
+resonance	O
+imaging	O
+of	O
+the	O
+lumbosacral	B-ANAT
+spine	I-ANAT
+revealed	O
+fracture	O
+of	O
+L1	O
+and	O
+L2	O
+vertebrae	O
+.	O
+
+However	O
+,	O
+his	O
+condition	B-DISO
+gradually	O
+deteriorated	O
+as	O
+he	O
+developed	O
+aspiration	B-DISO
+pneumonia	I-DISO
+and	O
+sepsis	B-DISO
+with	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+finally	O
+expired	O
+.	O
+
+TITLE	O
+:	O
+Long	O
+-	O
+term	O
+membrane	B-COMP
+oxygenator	O
+use	O
+to	O
+support	O
+an	O
+infant	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+on	O
+biventricular	O
+assist	O
+device	O
+.	O
+
+Extended	O
+use	O
+may	O
+facilitate	O
+the	O
+prevention	O
+of	O
+ventilator	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+and	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+This	O
+therapy	O
+may	O
+be	O
+an	O
+attractive	O
+intermediate	O
+step	O
+in	O
+the	O
+transition	B-DISO
+from	O
+,	O
+or	O
+alternative	O
+to	O
+ECMO	O
+,	O
+in	O
+patients	O
+requiring	O
+VAD	O
+placement	O
+with	O
+associated	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+The	O
+emergence	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+EMC	B-COMP
+:	O
+how	O
+scared	O
+should	O
+we	O
+be	O
+?	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+immunogenic	O
+determinants	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+using	O
+a	O
+series	O
+of	O
+truncated	O
+expressed	B-PROC
+SSL	B-PRGE
+fragments	I-PRGE
+and	O
+SSL	O
+specific	O
+mouse	B-SPEC
+sera	B-COMP
+,	O
+we	O
+identified	O
+two	O
+immunogenic	O
+determinants	O
+for	O
+SSL	O
+.	O
+
+We	O
+previously	O
+showed	O
+that	O
+recombinant	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+(	O
+Urbani	O
+strain	O
+based	O
+)	O
+lacking	O
+envelope	B-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+protein	B-PROC
+expression	B-PROC
+(	O
+rU	O
+-	O
+ΔE	O
+)	O
+provided	O
+good	O
+but	O
+not	O
+perfect	O
+protection	O
+in	O
+young	O
+mice	B-SPEC
+against	O
+challenge	O
+with	O
+virulent	O
+mouse	B-SPEC
+-	O
+adapted	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+MA15	O
+).	O
+
+Immunization	O
+with	O
+this	O
+virus	B-SPEC
+completely	O
+protected	O
+mice	O
+of	O
+three	O
+ages	O
+from	O
+lethal	O
+disease	O
+and	O
+effected	O
+more	O
+-	O
+rapid	O
+virus	B-SPEC
+clearance	O
+.	O
+
+After	O
+challenge	O
+,	O
+inflammatory	B-DISO
+cell	I-DISO
+infiltration	I-DISO
+,	O
+edema	B-DISO
+,	O
+and	O
+lung	B-ANAT
+destruction	O
+were	O
+decreased	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+rMA15	O
+-	O
+ΔE	O
+-	O
+immunized	O
+mice	B-SPEC
+compared	O
+to	O
+those	O
+in	O
+rU	O
+-	O
+ΔE	O
+-	O
+immunized	O
+12	O
+-	O
+month	O
+-	O
+old	O
+mice	B-SPEC
+.	O
+
+This	O
+approach	O
+will	O
+be	O
+generally	O
+useful	O
+for	O
+development	B-PROC
+of	O
+vaccines	O
+protective	O
+against	O
+human	B-SPEC
+coronaviruses	O
+as	O
+well	O
+as	O
+against	O
+coronaviruses	O
+that	O
+cause	O
+disease	O
+in	O
+domestic	O
+and	O
+companion	O
+animals	B-SPEC
+.	O
+
+In	O
+March	O
+2013	O
+,	O
+three	O
+urban	O
+residents	O
+of	O
+Shanghai	O
+or	O
+Anhui	O
+,	O
+China	O
+,	O
+presented	O
+with	O
+rapidly	O
+progressing	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+were	O
+found	O
+to	O
+be	O
+infected	O
+with	O
+a	O
+novel	O
+reassortant	O
+avian	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+.	O
+
+Chest	B-ANAT
+radiography	O
+revealed	O
+diffuse	O
+opacities	B-DISO
+and	O
+consolidation	O
+.	O
+
+Complications	O
+included	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	O
+-	O
+phase	O
+concentrations	O
+of	O
+soluble	O
+fibrinogen	B-COMP
+inhibit	O
+neutrophil	B-ANAT
+adhesion	B-DISO
+under	O
+flow	O
+conditions	O
+in	O
+vitro	O
+through	O
+interactions	O
+with	O
+ICAM	O
+-	O
+1	O
+and	O
+MAC	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+CD11b	B-PRGE
+/	O
+CD18	B-PRGE
+).	O
+
+Soluble	O
+fibrinogen	B-COMP
+reduced	O
+MAC	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+dependent	O
+binding	B-FUNC
+of	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+-	O
+activated	O
+neutrophils	B-ANAT
+to	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+expressing	O
+cells	B-COMP
+under	O
+flow	O
+conditions	O
+.	O
+
+We	O
+propose	O
+a	O
+model	O
+in	O
+which	O
+the	O
+increased	O
+circulating	O
+concentrations	O
+of	O
+soluble	O
+fibrinogen	B-COMP
+found	O
+during	O
+the	O
+acute	B-DISO
+-	I-DISO
+phase	I-DISO
+response	I-DISO
+can	O
+act	O
+as	O
+a	O
+natural	O
+antagonist	B-PROC
+of	O
+leukocyte	B-ANAT
+recruitment	B-DISO
+,	O
+and	O
+therefore	O
+might	O
+contribute	O
+to	O
+the	O
+resolution	O
+of	O
+inflammation	B-DISO
+.	O
+
+Convalescent	O
+SARS	B-DISO
+sera	B-COMP
+may	O
+contain	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+antibodies	B-COMP
+against	O
+other	O
+betacoronaviruses	O
+and	O
+confound	O
+seroprevalence	O
+study	O
+for	O
+HCoV	O
+-	O
+EMC	B-COMP
+.	O
+
+However	O
+,	O
+the	O
+alcoholic	O
+lung	B-ANAT
+represents	O
+a	O
+clear	O
+example	O
+of	O
+environment	O
+-	O
+host	B-COMP
+interactions	O
+that	O
+should	O
+be	O
+well	O
+suited	O
+for	O
+such	O
+applications	O
+.	O
+
+The	O
+pulmonary	B-PROC
+function	I-PROC
+objectified	O
+a	O
+severe	O
+restrictive	O
+ventilatory	O
+defect	O
+in	O
+all	O
+cases	O
+.	O
+
+A	O
+patient	O
+had	O
+died	B-PROC
+in	O
+an	O
+array	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+one	O
+patient	O
+was	O
+lost	B-CHED
+to	O
+follow	O
+-	O
+up	O
+.	O
+
+TITLE	O
+:	O
+Synergy	O
+between	O
+stents	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+multitrauma	O
+patients	O
+with	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+injury	O
+.	O
+
+Sixty	O
+-	O
+two	O
+post	O
+-	O
+SARS	B-DISO
+patients	O
+with	O
+osteonecrosis	B-DISO
+were	O
+one	O
+group	O
+,	O
+and	O
+52	O
+age	O
+-	O
+and	O
+sex	O
+-	O
+matched	O
+healthy	O
+people	O
+were	O
+as	O
+normal	O
+controlled	O
+group	O
+.	O
+
+The	O
+plasma	B-ANAT
+PAI	B-PRGE
+activity	O
+was	O
+related	O
+to	O
+homozygote	O
+4G	O
+/	O
+4G	O
+genotype	O
+.	O
+
+All	O
+samples	O
+from	O
+the	O
+non	O
+-	O
+FIP	B-DISO
+cats	B-SPEC
+and	O
+25	O
+.	O
+26	O
+%	O
+of	O
+the	O
+samples	O
+from	O
+the	O
+FIP	B-DISO
+cats	B-SPEC
+were	O
+positive	O
+for	O
+the	O
+FCoV	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+gene	O
+.	O
+
+Of	O
+the	O
+cats	B-SPEC
+without	O
+FIP	B-DISO
+that	O
+harboured	O
+FECoV	O
+,	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+identities	O
+for	O
+the	O
+M	O
+gene	O
+were	O
+100	O
+%	O
+among	O
+cats	O
+(	O
+Cats	B-PRGE
+1	I-PRGE
+-	I-PRGE
+3	I-PRGE
+)	O
+from	O
+the	O
+same	O
+cattery	O
+,	O
+and	O
+the	O
+overall	O
+sequence	O
+identity	O
+for	O
+the	O
+M	O
+gene	O
+was	O
+≥	O
+91	O
+%.	O
+
+Among	O
+1	O
+,	O
+434	O
+persons	O
+exposed	O
+to	O
+chlorine	B-CHED
+gas	B-ENZY
+,	O
+92	O
+developed	O
+severe	O
+symptoms	O
+required	O
+hospital	O
+admission	O
+and	O
+21	O
+participated	O
+in	O
+the	O
+follow	O
+-	O
+up	O
+study	O
+at	O
+2	O
+months	O
+there	O
+after	O
+.	O
+
+Obstructive	O
+defect	O
+from	O
+spirometry	O
+was	O
+identified	O
+in	O
+2	O
+participants	O
+,	O
+one	O
+of	O
+which	O
+also	O
+had	O
+bronchial	B-ANAT
+hyper	O
+responsiveness	O
+(	O
+BHR	O
+)	O
+compatible	O
+with	O
+reactive	O
+airway	B-ANAT
+dysfunction	O
+syndrome	B-DISO
+(	O
+RADS	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+investigators	O
+present	O
+a	O
+series	O
+of	O
+adults	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+who	O
+were	O
+treated	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+at	O
+a	O
+regional	O
+referral	O
+center	O
+.	O
+
+Human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+has	O
+not	O
+been	O
+observed	O
+,	O
+but	O
+zoonotic	O
+infections	B-DISO
+of	O
+nrH7N9	O
+from	O
+birds	B-SPEC
+to	O
+humans	B-SPEC
+appear	O
+to	O
+be	O
+associated	O
+with	O
+live	O
+poultry	O
+markets	O
+.	O
+
+Thus	O
+,	O
+a	O
+combination	O
+of	O
+interferon	O
+-	O
+α2b	O
+and	O
+ribavirin	B-CHED
+,	O
+which	O
+are	O
+already	O
+commonly	O
+used	O
+in	O
+the	O
+clinic	O
+,	O
+may	O
+be	O
+useful	O
+for	O
+patient	O
+management	O
+in	O
+the	O
+event	O
+of	O
+future	O
+nCoV	O
+infections	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+blocked	O
+synthetic	O
+dsRNA	B-CHED
+-	O
+induced	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+by	O
+interfering	O
+with	O
+the	O
+activation	O
+of	O
+interferon	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF3	B-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+found	O
+in	O
+a	O
+diverse	O
+array	O
+of	O
+bat	B-ENZY
+and	O
+bird	B-SPEC
+species	B-SPEC
+,	O
+which	O
+are	O
+believed	O
+to	O
+act	O
+as	O
+natural	O
+hosts	B-COMP
+.	O
+
+TITLE	O
+:	O
+Airway	B-ANAT
+management	O
+in	O
+an	O
+infant	O
+with	O
+alobar	B-DISO
+holoprosencephaly	I-DISO
+and	O
+cebocephaly	B-DISO
+associated	O
+with	O
+maternal	O
+diabetes	O
+mellitus	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+different	O
+resuscitation	O
+fluid	O
+on	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Furthermore	O
+,	O
+incidence	O
+of	O
+respiratory	O
+and	O
+abdominal	B-DISO
+infection	I-DISO
+was	O
+significantly	O
+decreased	O
+in	O
+the	O
+SH	O
+and	O
+SHG	O
+groups	O
+,	O
+while	O
+no	O
+significant	O
+difference	O
+in	O
+sepsis	B-DISO
+was	O
+seen	O
+.	O
+
+Moreover	O
+,	O
+the	O
+serum	B-COMP
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+levels	O
+in	O
+the	O
+SH	O
+and	O
+SHG	O
+groups	O
+were	O
+obviously	O
+lower	O
+than	O
+in	O
+the	O
+NS	B-CHED
+group	I-CHED
+at	O
+each	O
+time	O
+point	O
+.	O
+
+Herein	O
+,	O
+DNA	O
+plasmid	O
+bearing	O
+TGEV	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+(	O
+the	O
+N	O
+terminal	O
+half	O
+of	O
+TGEV	B-PRGE
+S	I-PRGE
+gene	I-PRGE
+)	O
+was	O
+used	O
+to	O
+immunize	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+followed	O
+by	O
+generation	O
+of	O
+a	O
+monoclonal	O
+antibody	B-COMP
+(	O
+MAb	O
+)	O
+using	O
+the	O
+hybridoma	B-ANAT
+technique	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Study	O
+and	O
+application	O
+of	O
+transmission	O
+tracking	O
+analysis	O
+technique	O
+during	O
+incubation	O
+period	O
+of	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+develop	O
+a	O
+new	O
+transmission	O
+tracking	O
+analysis	O
+technique	O
+during	O
+incubation	O
+period	O
+of	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+and	O
+to	O
+discuss	O
+its	O
+practical	O
+value	O
+in	O
+the	O
+field	O
+survey	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+transmission	O
+tracking	O
+analysis	O
+technique	O
+was	O
+established	O
+based	O
+on	O
+the	O
+modeling	O
+platform	O
+ArcGIS	O
+Engine	O
+Developer	O
+Kit	B-FUNC
+9	O
+.	O
+3	O
+,	O
+using	O
+the	O
+techniques	O
+of	O
+address	O
+matching	O
+,	O
+shortest	O
+path	O
+analysis	O
+and	O
+buffer	B-CHED
+analysis	O
+,	O
+and	O
+programming	O
+by	O
+Visual	O
+C	O
+++.	O
+
+RESULTS	O
+:	O
+The	O
+single	O
+case	O
+transmission	O
+tracking	O
+analysis	O
+showed	O
+that	O
+the	O
+length	O
+of	O
+transmission	O
+track	O
+of	O
+case	O
+A	O
+was	O
+129	O
+.	O
+89	O
+km	O
+during	O
+April	O
+25th	O
+to	O
+29th	O
+in	O
+2003	O
+,	O
+including	O
+12	O
+tracing	O
+point	O
+and	O
+108	O
+intimate	O
+contacts	O
+,	O
+and	O
+the	O
+total	O
+area	O
+of	O
+buffer	B-CHED
+zone	O
+was	O
+7	O
+.	O
+11	O
+km	O
+(	O
+2	O
+)	O
+including	O
+81	O
+important	O
+institutes	O
+,	O
+naming	O
+72	O
+schools	O
+,	O
+6	O
+kindergartens	O
+and	O
+3	O
+gerocomiums	O
+.	O
+
+Although	O
+more	O
+than	O
+half	O
+of	O
+respondents	O
+stated	O
+they	O
+would	O
+almost	O
+never	O
+prescribe	O
+corticosteroids	B-CHED
+in	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+(	O
+81	O
+%),	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+,	O
+76	O
+%),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+,	O
+65	O
+%),	O
+and	O
+severe	O
+ARDS	B-DISO
+(	O
+51	O
+%),	O
+variability	O
+increased	O
+with	O
+severity	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TCoV	O
+has	O
+been	O
+associated	O
+with	O
+poult	O
+enteritis	B-DISO
+complex	O
+,	O
+a	O
+syndrome	B-DISO
+that	O
+severely	O
+affects	O
+turkey	B-SPEC
+production	O
+.	O
+
+TITLE	O
+:	O
+Involvement	O
+of	O
+high	B-PRGE
+mobility	I-PRGE
+group	I-PRGE
+box	I-PRGE
+1	I-PRGE
+and	O
+the	O
+therapeutic	O
+effect	O
+of	O
+recombinant	O
+thrombomodulin	B-PRGE
+in	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+therapeutic	O
+effect	O
+of	O
+rTM	O
+,	O
+and	O
+the	O
+contribution	O
+of	O
+T	O
+(	O
+reg	O
+)	O
+cells	B-COMP
+to	O
+this	O
+effect	O
+,	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+severe	O
+ARDS	B-DISO
+.	O
+
+HMGB1	B-PRGE
+was	O
+expressed	B-PROC
+in	O
+the	O
+infiltrating	B-DISO
+neutrophils	B-ANAT
+and	O
+macrophages	B-ANAT
+in	O
+lungs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+The	O
+impact	O
+of	O
+major	O
+operative	O
+fractures	O
+in	O
+blunt	O
+abdominal	B-ANAT
+injury	O
+.	O
+
+We	O
+hypothesize	O
+that	O
+operative	O
+fractures	O
+of	O
+the	O
+thoracolumbar	B-ANAT
+spine	I-ANAT
+,	O
+pelvis	B-ANAT
+,	O
+acetabulum	B-ANAT
+,	O
+or	O
+femur	B-ANAT
+increase	O
+systemic	O
+complications	O
+in	O
+patients	O
+with	O
+blunt	O
+abdominal	B-ANAT
+injury	O
+.	O
+
+A	O
+retrospective	O
+review	O
+of	O
+patients	O
+presenting	O
+to	O
+a	O
+Level	O
+I	O
+trauma	O
+center	O
+with	O
+abdominal	B-ANAT
+injury	O
+between	O
+2000	O
+and	O
+2006	O
+was	O
+performed	O
+.	O
+
+Logistic	O
+regression	O
+modeling	O
+demonstrates	O
+that	O
+the	O
+presence	O
+of	O
+an	O
+operative	O
+fracture	O
+increased	O
+the	O
+odds	O
+of	O
+developing	O
+at	O
+least	O
+one	O
+complication	B-DISO
+approximately	O
+three	O
+times	O
+(	O
+odds	O
+ratio	O
+,	O
+2	O
+.	O
+88	O
+,	O
+p	O
+=	O
+0	O
+.	O
+006	O
+),	O
+after	O
+controlling	O
+for	O
+presence	O
+of	O
+chest	B-ANAT
+injury	O
+and	O
+type	O
+of	O
+injured	O
+abdominal	B-ANAT
+organ	I-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+Operative	O
+fractures	O
+of	O
+the	O
+thoracolumbar	B-ANAT
+spine	I-ANAT
+,	O
+pelvis	B-ANAT
+,	O
+acetabulum	B-ANAT
+and	O
+femur	B-ANAT
+increase	O
+the	O
+risk	O
+of	O
+developing	O
+systemic	O
+complications	O
+in	O
+patients	O
+with	O
+blunt	O
+abdominal	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Complications	O
+in	O
+patients	O
+undergoing	O
+thoracotomy	O
+for	O
+lung	B-DISO
+carcinoma	I-DISO
+].	O
+
+Histories	O
+of	O
+heavy	O
+smoking	O
+,	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+,	O
+coexisting	O
+medical	O
+conditions	O
+,	O
+and	O
+the	O
+nature	O
+of	O
+the	O
+procedure	O
+contribute	O
+.	O
+
+This	O
+review	O
+was	O
+undertaken	O
+to	O
+evaluate	O
+and	O
+discuss	O
+major	O
+complications	O
+in	O
+patients	O
+undergoing	O
+thoracotomy	O
+for	O
+lung	O
+cancer	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Interstitial	B-ANAT
+lung	B-ANAT
+disease	I-DISO
+and	O
+profound	O
+hypoxaemia	O
+in	O
+a	O
+severely	O
+-	O
+malnourished	B-DISO
+child	O
+with	O
+very	O
+severe	O
+pneumonia	O
+and	O
+potential	O
+lymph	B-ANAT
+-	O
+node	B-ANAT
+tuberculosis	B-PATH
+:	O
+an	O
+uncommon	O
+but	O
+serious	O
+co	O
+-	O
+morbidity	O
+.	O
+
+Danish	O
+and	O
+American	O
+Birman	O
+cats	B-SPEC
+were	O
+closely	O
+related	O
+and	O
+the	O
+populations	O
+were	O
+therefore	O
+combined	O
+and	O
+analyzed	O
+in	O
+two	O
+manners	O
+:	O
+(	O
+1	O
+)	O
+all	O
+cases	O
+(	O
+FIP	B-DISO
+)	O
+vs	O
+.	O
+all	O
+controls	O
+(	O
+healthy	O
+)	O
+regardless	O
+of	O
+age	O
+,	O
+and	O
+(	O
+2	O
+)	O
+cases	O
+1½	O
+years	O
+of	O
+age	O
+and	O
+younger	O
+(	O
+most	O
+susceptible	O
+)	O
+vs	O
+.	O
+controls	O
+2	O
+years	O
+of	O
+age	O
+and	O
+older	O
+(	O
+most	O
+resistant	O
+).	O
+
+Five	O
+candidate	O
+genes	O
+ELMO1	B-PRGE
+,	O
+RRAGA	B-PRGE
+,	O
+TNFSF10	B-PRGE
+,	O
+ERAP1	B-PRGE
+and	O
+ERAP2	B-PRGE
+,	O
+all	O
+relevant	O
+to	O
+what	O
+is	O
+known	O
+about	O
+FIP	B-DISO
+virus	B-DISO
+pathogenesis	B-PROC
+,	O
+were	O
+identified	O
+but	O
+no	O
+single	O
+association	O
+was	O
+fully	O
+concordant	O
+with	O
+the	O
+disease	O
+phenotype	O
+.	O
+
+Electron	O
+microscopy	O
+of	O
+infected	O
+Vero	B-ANAT
+cells	I-ANAT
+revealed	O
+extensive	O
+membrane	B-COMP
+rearrangements	O
+,	O
+including	O
+the	O
+formation	B-PROC
+of	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+and	O
+convoluted	O
+membranes	B-ANAT
+,	O
+which	O
+have	O
+been	O
+implicated	O
+previously	O
+in	O
+the	O
+RNA	B-PROC
+synthesis	I-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+other	O
+CoVs	O
+.	O
+
+ABSTRACT	O
+:	O
+Anti	O
+-	O
+NMDA	O
+receptor	O
+encephalitis	O
+is	O
+a	O
+newly	O
+characterized	O
+severe	O
+neuroautoimmune	O
+syndrome	B-DISO
+with	O
+a	O
+progressive	O
+,	O
+clinical	O
+course	O
+.	O
+
+The	O
+finding	O
+of	O
+oligoclonal	O
+protein	B-CHED
+electrophoresis	O
+(>	O
+80	O
+%)	O
+and	O
+antibodies	B-COMP
+in	O
+serum	B-COMP
+and	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+directed	O
+against	O
+the	O
+NR1	O
+subunit	O
+of	O
+the	O
+NMDA	B-FUNC
+receptor	I-FUNC
+confirms	O
+the	O
+diagnosis	O
+.	O
+
+The	O
+upE	O
+and	O
+LNA	B-CHED
+-	O
+TZ1	O
+based	O
+assays	O
+were	O
+better	O
+than	O
+others	O
+.	O
+
+Bronchiolitis	B-DISO
+and	O
+pneumonia	B-DISO
+were	O
+the	O
+most	O
+frequent	O
+diagnoses	O
+in	O
+NL63	O
+positive	O
+patients	O
+and	O
+the	O
+major	O
+symptoms	O
+were	O
+fever	B-PROC
+and	O
+cough	B-DISO
+in	O
+our	O
+study	O
+.	O
+
+METHODS	O
+:	O
+From	O
+November	O
+2006	O
+to	O
+October	O
+2009	O
+,	O
+1169	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+NPA	B-CHED
+)	O
+were	O
+collected	O
+from	O
+children	O
+under	O
+14	O
+years	O
+old	O
+with	O
+ARTIs	O
+.	O
+
+CONCLUSIONS	O
+:	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+is	O
+an	O
+important	O
+pathogen	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+children	O
+in	O
+Lanzhou	O
+city	O
+.	O
+
+Here	O
+,	O
+the	O
+carboxy	B-CHED
+-	O
+terminal	O
+charge	O
+-	O
+rich	O
+motif	O
+in	O
+the	O
+endodomain	O
+was	O
+verified	O
+to	O
+be	O
+critical	O
+for	O
+the	O
+specificity	O
+of	O
+S	O
+assembly	O
+into	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+Interestingly	O
+,	O
+in	O
+TGEV	B-SPEC
+endodomain	O
+chimeras	O
+the	O
+reverting	O
+mutations	O
+resulted	O
+in	O
+stronger	O
+S	O
+incorporation	O
+into	O
+virions	B-COMP
+,	O
+and	O
+a	O
+net	O
+gain	O
+of	O
+negatively	O
+charged	O
+residues	O
+in	O
+the	O
+charge	O
+-	O
+rich	O
+motif	O
+accounted	O
+for	O
+the	O
+improvement	O
+.	O
+
+This	O
+study	O
+highlights	O
+the	O
+role	O
+of	O
+the	O
+above	O
+seven	O
+risk	O
+factors	O
+in	O
+the	O
+development	B-PROC
+of	O
+severe	O
+pneumonia	B-DISO
+in	O
+under	O
+-	O
+five	O
+children	O
+.	O
+
+Furthermore	O
+,	O
+lung	B-ANAT
+protective	O
+mechanical	O
+ventilation	O
+must	O
+be	O
+applied	O
+using	O
+low	O
+tidal	O
+volumes	O
+and	O
+limiting	O
+inspiratory	B-PROC
+pressures	O
+.	O
+
+TITLE	O
+:	O
+Mechanism	O
+for	O
+controlling	O
+the	O
+monomer	O
+-	O
+dimer	O
+conversion	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+main	I-PRGE
+protease	I-PRGE
+.	O
+
+This	O
+structural	O
+information	O
+offers	O
+valuable	O
+insights	O
+into	O
+the	O
+molecular	O
+mechanism	O
+associated	O
+with	O
+substrate	O
+-	O
+induced	O
+dimerization	O
+and	O
+has	O
+important	O
+implications	O
+with	O
+respect	O
+to	O
+the	O
+maturation	B-PROC
+of	O
+the	O
+enzyme	O
+.	O
+
+TITLE	O
+:	O
+The	O
+cellular	B-COMP
+interactome	O
+of	O
+the	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-PRGE
+virus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+and	O
+functional	O
+implications	O
+for	O
+virus	O
+biology	O
+.	O
+
+These	O
+functions	O
+are	O
+likely	O
+to	O
+be	O
+facilitated	O
+by	O
+interactions	O
+with	O
+host	B-COMP
+cell	I-COMP
+proteins	B-CHED
+.	O
+
+The	O
+potential	O
+interactome	O
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+N	O
+protein	B-CHED
+was	O
+mapped	O
+using	O
+stable	O
+isotope	O
+labeling	O
+with	O
+amino	B-CHED
+acids	I-CHED
+in	O
+cell	B-COMP
+culture	O
+(	O
+SILAC	O
+)	O
+coupled	O
+to	O
+a	O
+green	O
+fluorescent	O
+protein	B-CHED
+-	O
+nanotrap	O
+pulldown	O
+methodology	O
+and	O
+liquid	O
+chromatography	O
+-	O
+tandem	O
+mass	O
+spectrometry	O
+.	O
+
+An	O
+example	O
+is	O
+the	O
+stimulation	O
+of	O
+-	O
+1	O
+programmed	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+,	O
+leading	O
+to	O
+3	O
+'	O
+direction	O
+slippage	O
+of	O
+the	O
+reading	O
+-	O
+frame	O
+during	O
+elongation	O
+,	O
+by	O
+specific	O
+pseudoknot	O
+stimulators	O
+downstream	O
+of	O
+the	O
+frameshifting	O
+site	O
+.	O
+
+Murine	B-SPEC
+alveolar	B-ANAT
+cells	B-ANAT
+cultured	I-ANAT
+to	O
+maintain	O
+an	O
+ATII	O
+cell	B-COMP
+phenotype	O
+,	O
+determined	O
+by	O
+expression	B-PROC
+of	O
+LBP180	O
+,	O
+were	O
+susceptible	O
+to	O
+infection	B-DISO
+by	O
+all	O
+three	O
+viruses	B-SPEC
+.	O
+
+Both	O
+cell	B-COMP
+types	O
+had	O
+increased	O
+expression	B-PROC
+of	O
+IL	B-PRGE
+-	I-PRGE
+1β	I-PRGE
+mRNA	I-PRGE
+upon	O
+viral	B-DISO
+infection	I-DISO
+,	O
+though	O
+at	O
+different	O
+levels	O
+.	O
+
+In	O
+summary	O
+,	O
+ATI	O
+and	O
+ATII	O
+cells	B-COMP
+exhibited	O
+differential	O
+susceptibilities	O
+and	O
+cytokine	O
+responses	O
+to	O
+infection	B-DISO
+by	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+However	O
+,	O
+clinicians	O
+seeing	B-PROC
+pet	O
+rabbits	B-SPEC
+in	O
+North	O
+America	O
+infrequently	O
+encounter	O
+viral	B-DISO
+diseases	I-DISO
+although	O
+myxomatosis	O
+may	O
+be	O
+seen	O
+occasionally	O
+.	O
+
+The	O
+situation	O
+is	O
+different	O
+in	O
+Europe	O
+and	O
+Australia	O
+,	O
+where	O
+myxomatosis	O
+and	O
+rabbit	B-SPEC
+hemorrhagic	B-DISO
+disease	I-DISO
+are	O
+endemic	O
+.	O
+
+Enteric	O
+viruses	B-SPEC
+including	O
+lapine	O
+rotavirus	B-SPEC
+,	O
+rabbit	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+and	O
+rabbit	B-SPEC
+astrovirus	O
+are	O
+being	O
+acknowledged	O
+as	O
+contributors	O
+to	O
+the	O
+multifactorial	O
+enteritis	B-DISO
+complex	O
+of	O
+juvenile	O
+rabbits	O
+.	O
+
+This	O
+was	O
+a	O
+retrospective	O
+review	O
+of	O
+the	O
+management	O
+and	O
+outcome	O
+of	O
+patients	O
+with	O
+Legionella	B-SPEC
+-	O
+associated	O
+respiratory	B-DISO
+failure	I-DISO
+treated	O
+with	O
+ECMO	O
+support	O
+in	O
+a	O
+large	O
+ECMO	O
+center	O
+over	O
+the	O
+past	O
+10	O
+years	O
+.	O
+
+The	O
+main	O
+clinical	O
+signs	O
+of	O
+affected	O
+horses	B-SPEC
+were	O
+anorexia	B-DISO
+,	O
+pyrexia	B-PROC
+and	O
+leucopenia	B-DISO
+;	O
+gastrointestinal	B-DISO
+disease	I-DISO
+was	O
+observed	O
+in	O
+about	O
+10	O
+%	O
+of	O
+affected	O
+horses	B-SPEC
+.	O
+
+CHVHF	O
+is	O
+an	O
+effective	O
+adjuvant	B-CHED
+treatment	O
+for	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Compared	O
+with	O
+control	O
+group	O
+,	O
+the	O
+duration	O
+of	O
+MV	O
+and	O
+ICU	O
+stay	O
+were	O
+shortened	O
+in	O
+treatment	O
+group	O
+(	O
+duration	O
+of	O
+MV	O
+:	O
+12	O
+±	O
+4	O
+days	O
+vs	O
+.	O
+19	O
+±	O
+6	O
+days	O
+,	O
+ICU	O
+stay	O
+time	O
+:	O
+21	O
+±	O
+4	O
+days	O
+vs	O
+.	O
+33	O
+±	O
+8	O
+days	O
+,	O
+both	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+and	O
+percentage	O
+of	O
+successful	O
+weaning	B-PROC
+from	O
+MV	O
+and	O
+28	O
+-	O
+day	O
+survival	O
+rate	O
+were	O
+higher	O
+in	O
+treatment	O
+group	O
+(	O
+percentage	O
+of	O
+successful	O
+weaning	B-PROC
+from	O
+MV	O
+:	O
+81	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+64	O
+.	O
+3	O
+%,	O
+28	O
+-	O
+day	O
+survival	O
+rate	O
+:	O
+86	O
+.	O
+5	O
+%	O
+vs	O
+.	O
+71	O
+.	O
+4	O
+%,	O
+both	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+No	O
+evidence	O
+of	O
+sustained	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+has	O
+been	O
+found	O
+,	O
+and	O
+no	O
+human	B-SPEC
+cases	O
+of	O
+H7N9	O
+virus	O
+infection	O
+have	O
+been	O
+detected	O
+outside	O
+China	O
+,	O
+including	O
+the	O
+United	O
+States	O
+.	O
+
+From	O
+this	O
+work	O
+,	O
+we	O
+identified	O
+six	O
+classes	O
+of	O
+mutants	O
+that	O
+abolished	O
+,	O
+attenuated	O
+or	O
+increased	O
+nsp1	B-PRGE
+inhibition	B-PROC
+of	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+and	O
+/	O
+or	O
+antiviral	B-CHED
+signaling	B-PROC
+.	O
+
+We	O
+undertook	O
+a	O
+retrospective	O
+study	O
+to	O
+examine	O
+dengue	B-DISO
+death	B-PROC
+cases	O
+in	O
+our	O
+hospital	O
+from	O
+June	O
+2006	O
+to	O
+October	O
+2007	O
+with	O
+a	O
+view	O
+to	O
+determine	O
+if	O
+there	O
+have	O
+been	O
+changes	O
+in	O
+the	O
+presentation	O
+of	O
+severe	O
+to	O
+fatal	O
+dengue	B-DISO
+.	O
+
+Gastrointestinal	B-DISO
+pain	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+diarrhea	B-DISO
+,	O
+intravascular	O
+leakages	O
+and	O
+bleeding	B-DISO
+occurred	O
+in	O
+the	O
+majority	O
+of	O
+cases	O
+.	O
+
+In	O
+our	O
+cohort	O
+,	O
+dengue	B-DISO
+fatalities	O
+are	O
+seen	O
+primarily	O
+in	O
+adult	O
+females	O
+with	O
+secondary	O
+dengue	B-DISO
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+ascertain	O
+the	O
+metabolic	B-PROC
+changes	O
+in	O
+patients	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+SARS	B-DISO
+-	O
+related	O
+post	B-DISO
+-	I-DISO
+traumatic	I-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+)	O
+and	O
+elucidate	O
+the	O
+relationship	O
+between	O
+PTSD	B-DISO
+,	O
+SARS	B-DISO
+and	O
+brain	B-PROC
+metabolism	B-PROC
+.	O
+
+A	O
+total	O
+of	O
+58	O
+convalescent	O
+SARS	B-DISO
+patients	O
+were	O
+evaluated	O
+by	O
+the	O
+scores	O
+of	O
+impact	O
+of	O
+event	O
+scale	O
+(	O
+IES	B-CHED
+),	O
+self	O
+-	O
+rating	O
+anxiety	O
+scale	O
+(	O
+SAS	O
+)	O
+and	O
+self	O
+-	O
+rating	O
+depression	B-DISO
+scale	O
+(	O
+SDS	B-DISO
+),	O
+etc	O
+.	O
+
+There	O
+were	O
+18	O
+patients	O
+(	O
+M	O
+:	O
+F	O
+=	O
+6	O
+:	O
+12	O
+)	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+related	I-PRGE
+PTSD	B-DISO
+and	O
+26	O
+convalescent	O
+SARS	B-DISO
+patients	O
+without	O
+PTSD	B-DISO
+.	O
+
+SARS	B-DISO
+may	O
+also	O
+lead	O
+to	O
+the	O
+changes	O
+of	O
+brain	B-PROC
+metabolism	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+changes	O
+of	O
+brain	B-PROC
+metabolism	B-PROC
+in	O
+PTSD	B-DISO
+are	O
+caused	O
+by	O
+SARS	B-DISO
+.	O
+
+Based	O
+on	O
+available	O
+experimental	O
+data	O
+,	O
+the	O
+prediction	O
+accuracy	O
+is	O
+up	O
+to	O
+90	O
+%	O
+for	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+We	O
+suggest	O
+the	O
+use	O
+of	O
+epitope	B-CHED
+prediction	O
+methods	O
+in	O
+combination	O
+with	O
+3D	O
+structural	O
+modelling	O
+of	O
+peptide	O
+-	O
+MHC	B-PROC
+-	O
+TCR	B-COMP
+complex	O
+to	O
+identify	O
+MHC	B-PROC
+class	B-SPEC
+I	O
+restricted	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+for	O
+use	O
+in	O
+epitope	B-CHED
+based	O
+vaccines	O
+like	O
+HIV	B-DISO
+and	O
+human	B-SPEC
+cancers	B-DISO
+,	O
+which	O
+should	O
+provide	O
+a	O
+valuable	O
+step	O
+forward	O
+for	O
+the	O
+design	O
+of	O
+better	O
+vaccines	O
+and	O
+may	O
+provide	O
+in	O
+depth	O
+understanding	O
+about	O
+activation	O
+of	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitopes	I-PRGE
+by	O
+MHC	B-PRGE
+binding	B-FUNC
+peptides	B-CHED
+.	O
+
+Interestingly	O
+,	O
+special	O
+findings	O
+could	O
+render	O
+the	O
+diagnosis	O
+easier	O
+,	O
+such	O
+as	O
+greenish	O
+homogeneous	O
+cytoplasmic	B-ANAT
+inclusions	I-ANAT
+,	O
+surrounded	O
+by	O
+a	O
+fine	O
+clear	O
+halo	O
+in	O
+BAL	B-ENZY
+macrophages	B-ANAT
+.	O
+
+Therefore	O
+,	O
+although	O
+the	O
+diagnosis	O
+remains	O
+difficult	O
+before	O
+the	O
+onset	O
+of	O
+renal	B-ANAT
+involvement	O
+,	O
+the	O
+occurrence	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+mimicking	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+must	O
+alert	O
+the	O
+clinician	O
+for	O
+possible	O
+HPS	B-DISO
+,	O
+especially	O
+in	O
+endemic	O
+areas	O
+.	O
+
+Key	O
+components	O
+of	O
+such	O
+a	O
+strategy	O
+include	O
+avoiding	O
+lung	B-ANAT
+overdistension	O
+by	O
+limiting	O
+tidal	O
+volumes	O
+and	O
+airway	B-ANAT
+pressures	O
+,	O
+and	O
+the	O
+use	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+with	O
+or	O
+without	O
+lung	B-ANAT
+recruitment	B-DISO
+manoeuvres	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+therapy	O
+demonstrates	O
+promise	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+-	O
+but	O
+which	O
+cell	B-COMP
+is	O
+best	O
+?	O
+
+Recent	O
+studies	O
+involving	O
+the	O
+administration	O
+of	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+(	O
+MSCs	B-FUNC
+)	O
+for	O
+the	O
+treatment	O
+of	O
+experimental	O
+ALI	O
+/	O
+ARDS	B-DISO
+have	O
+shown	O
+promising	O
+results	O
+.	O
+
+Cor	B-DISO
+pulmonale	I-DISO
+was	O
+detected	O
+in	O
+49	O
+patients	O
+(	O
+prevalence	O
+of	O
+22	O
+%;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+16	O
+-	O
+27	O
+%).	O
+
+RESULTS	O
+:	O
+Cor	B-DISO
+pulmonale	I-DISO
+was	O
+detected	O
+in	O
+49	O
+patients	O
+(	O
+prevalence	O
+of	O
+22	O
+%;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+16	O
+-	O
+27	O
+%).	O
+
+then	O
+antibodies	B-COMP
+titers	O
+declined	O
+rapidly	O
+in	O
+some	O
+cases	O
+.	O
+
+Serum	B-COMP
+IgG	B-PRGE
+antibodies	I-PRGE
+has	O
+diagnostic	O
+value	O
+for	O
+SARS	B-DISO
+in	O
+the	O
+late	O
+course	O
+of	O
+disease	O
+and	O
+the	O
+antibodies	B-COMP
+present	O
+more	O
+than	O
+48	O
+months	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+infection	B-DISO
+induced	I-DISO
+apoptosis	B-PATH
+in	O
+several	O
+cell	B-ANAT
+lines	I-ANAT
+in	O
+vitro	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+activation	O
+of	O
+the	O
+protein	B-PRGE
+kinase	I-PRGE
+R	O
+-	O
+like	O
+ER	O
+kinase	O
+(	O
+PERK	B-PRGE
+)	O
+pathway	B-PROC
+of	O
+UPR	O
+in	O
+cells	B-COMP
+infected	O
+with	O
+the	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+its	O
+relationship	O
+with	O
+IBV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+.	O
+
+DMV	O
+/	O
+1639	O
+/	O
+11	O
+and	O
+PA	O
+/	O
+9579A	O
+/	O
+10	O
+were	O
+determined	O
+to	O
+be	O
+nephropathogenic	O
+in	O
+susceptible	O
+chickens	B-SPEC
+,	O
+yielding	O
+virus	B-SPEC
+reisolations	O
+from	O
+kidney	B-ANAT
+and	O
+inducing	O
+characteristic	O
+interstitial	B-DISO
+nephritis	I-DISO
+microscopic	O
+lesions	O
+.	O
+
+TITLE	O
+:	O
+Survival	O
+of	O
+Respiratory	O
+Viruses	B-SPEC
+on	O
+Fresh	B-ANAT
+Produce	O
+.	O
+
+Coronavirus	B-SPEC
+was	O
+recovered	O
+from	O
+lettuce	O
+with	O
+an	O
+efficiency	O
+of	O
+19	O
+.	O
+6	O
+%	O
+yet	O
+could	O
+not	O
+be	O
+recovered	O
+from	O
+strawberries	O
+.	O
+
+All	O
+three	O
+horses	B-SPEC
+were	O
+diagnosed	O
+with	O
+presumptive	O
+equine	B-SPEC
+atypical	O
+myopathy	B-DISO
+.	O
+
+Genomes	O
+carrying	O
+the	O
+original	O
+mutations	O
+in	O
+S3	O
+or	O
+S4	O
+plus	O
+compensatory	O
+mutations	O
+restoring	O
+base	B-FUNC
+pairing	I-FUNC
+were	O
+viable	O
+and	O
+had	O
+robust	O
+growth	B-PROC
+phenotypes	O
+.	O
+
+TITLE	O
+:	O
+The	O
+lung	B-ANAT
+microvascular	O
+endothelium	B-ANAT
+as	O
+a	O
+therapeutic	O
+target	O
+in	O
+severe	O
+influenza	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+epidemiological	O
+survey	O
+of	O
+porcine	O
+diarrheal	B-DISO
+disease	I-DISO
+prevalence	O
+between	O
+September	O
+2011	O
+and	O
+January	O
+2012	O
+revealed	O
+that	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+contributed	O
+to	O
+outbreaks	O
+of	O
+diarrhea	B-DISO
+in	O
+pig	B-SPEC
+farms	O
+in	O
+Shanghai	O
+,	O
+China	O
+.	O
+
+Six	O
+of	O
+them	O
+were	O
+affected	O
+by	O
+cblD	B-PRGE
+-	I-PRGE
+MMA	I-PRGE
+,	O
+but	O
+only	O
+three	O
+had	O
+a	O
+known	O
+clinical	O
+history	O
+.	O
+
+We	O
+evaluated	O
+the	O
+effect	O
+of	O
+early	O
+application	O
+of	O
+prone	O
+positioning	O
+on	O
+outcomes	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+The	O
+primary	O
+outcome	O
+was	O
+the	O
+proportion	O
+of	O
+patients	O
+who	O
+died	B-PROC
+from	O
+any	O
+cause	O
+within	O
+28	O
+days	O
+after	O
+inclusion	O
+.	O
+
+The	O
+incidence	O
+of	O
+complications	O
+did	O
+not	O
+differ	O
+significantly	O
+between	O
+the	O
+groups	O
+,	O
+except	O
+for	O
+the	O
+incidence	O
+of	O
+cardiac	B-ANAT
+arrests	O
+,	O
+which	O
+was	O
+higher	O
+in	O
+the	O
+supine	O
+group	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+malaria	B-PATH
+:	O
+is	O
+it	O
+always	O
+the	O
+prerogative	O
+of	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+?].	O
+
+Severity	O
+associated	O
+with	O
+the	O
+occurrence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+well	O
+-	O
+known	O
+complication	B-DISO
+of	O
+infection	B-DISO
+with	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+and	O
+can	O
+reach	B-PROC
+25	O
+%	O
+of	O
+infected	O
+adults	O
+.	O
+
+RSV	B-SPEC
+was	O
+the	O
+most	O
+common	O
+pathogens	O
+in	O
+patients	O
+under	O
+1	O
+year	O
+and	O
+showed	O
+seasonal	O
+variation	O
+with	O
+peaks	O
+during	O
+winter	O
+and	O
+spring	O
+.	O
+
+We	O
+also	O
+analyzed	O
+serum	B-COMP
+from	O
+non	O
+-	O
+lung	B-DISO
+disease	I-DISO
+intubated	O
+patients	O
+(	O
+controls	O
+)	O
+and	O
+sepsis	B-DISO
+-	O
+mediated	O
+ARDS	B-DISO
+patients	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+malaria	B-PATH
+with	O
+multi	O
+organ	B-ANAT
+involvement	O
+.	O
+
+No	O
+severe	O
+adverse	O
+event	O
+was	O
+observed	O
+related	O
+to	O
+CART	B-PRGE
+,	O
+and	O
+25	O
+.	O
+2	O
+-	O
+98	O
+.	O
+0	O
+(	O
+median	O
+30	O
+.	O
+2	O
+)	O
+grams	O
+of	O
+albumin	B-PRGE
+was	O
+collected	O
+and	O
+reinfused	O
+.	O
+
+Detailed	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+virus	B-SPEC
+genome	O
+(	O
+England	O
+/	O
+Qatar	O
+/	O
+2012	O
+)	O
+revealed	O
+its	O
+close	O
+relationship	O
+to	O
+European	O
+bat	B-ENZY
+coronaviruses	O
+circulating	O
+among	O
+the	O
+bat	B-ENZY
+species	B-SPEC
+of	O
+the	O
+Vespertilionidae	B-SPEC
+family	B-SPEC
+.	O
+
+Molecular	O
+clock	O
+analysis	O
+showed	O
+that	O
+the	O
+2	O
+human	B-SPEC
+infections	B-DISO
+of	O
+this	O
+betacoronavirus	B-SPEC
+in	O
+June	O
+2012	O
+(	O
+EMC	B-COMP
+/	O
+2012	O
+)	O
+and	O
+September	O
+2012	O
+(	O
+England	O
+/	O
+Qatar	O
+/	O
+2012	O
+)	O
+share	O
+a	O
+common	O
+virus	B-SPEC
+ancestor	O
+most	O
+likely	O
+considerably	O
+before	O
+early	O
+2012	O
+,	O
+suggesting	O
+the	O
+human	B-SPEC
+diversity	O
+is	O
+the	O
+result	O
+of	O
+multiple	O
+zoonotic	O
+events	O
+.	O
+
+Illness	O
+severity	O
+was	O
+determined	O
+using	O
+an	O
+ordinal	O
+bronchiolitis	B-DISO
+severity	O
+score	O
+.	O
+
+Common	O
+respiratory	O
+viruses	B-SPEC
+were	O
+identified	O
+by	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Among	O
+infants	O
+with	O
+bronchiolitis	B-DISO
+,	O
+76	O
+%	O
+had	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+18	O
+%	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+),	O
+10	O
+%	O
+influenza	B-DISO
+,	O
+2	O
+%	O
+coronavirus	B-SPEC
+,	O
+3	O
+%	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+and	O
+1	O
+%	O
+parainfluenza	B-DISO
+virus	B-SPEC
+.	O
+
+We	O
+searched	O
+Pubmed	O
+,	O
+Toxnet	O
+,	O
+Cochrane	O
+database	O
+and	O
+Embase	O
+from	O
+1966	O
+to	O
+September	O
+2012	O
+using	O
+the	O
+search	O
+terms	O
+(''	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	O
+'',	O
+'	O
+extracorporeal	O
+life	O
+support	O
+',	O
+'	O
+ECMO	O
+',	O
+'	O
+ECLS	O
+',	O
+'	O
+assist	O
+-	O
+device	O
+',	O
+and	O
+'	O
+intox	O
+*'	O
+or	O
+'	O
+poison	O
+*').	O
+
+The	O
+organ	B-ANAT
+support	O
+that	O
+can	O
+be	O
+applied	O
+with	O
+ECMO	O
+makes	O
+it	O
+especially	O
+useful	O
+in	O
+patients	O
+with	O
+severe	O
+poisoning	O
+as	O
+the	O
+clinical	O
+impact	O
+of	O
+the	O
+intoxication	O
+is	O
+often	O
+temporary	O
+;	O
+ECMO	O
+can	O
+be	O
+used	O
+as	O
+a	O
+'	O
+bridge	O
+to	O
+recovery	O
+'.	O
+
+In	O
+contrast	O
+,	O
+following	O
+intranasal	O
+or	O
+intracranial	B-ANAT
+inoculation	O
+,	O
+efficient	O
+replication	O
+of	O
+MHV	B-SPEC
+in	O
+the	O
+brain	B-ANAT
+is	O
+not	O
+dependent	O
+on	O
+an	O
+enzymatically	O
+active	O
+ns2	B-DISO
+.	O
+
+A59	O
+and	O
+ns2	B-PRGE
+-	I-PRGE
+H126R	I-PRGE
+replicated	O
+with	O
+similar	O
+kinetics	O
+in	O
+all	O
+cell	B-COMP
+types	O
+tested	O
+,	O
+except	O
+macrophages	B-ANAT
+and	O
+microglia	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Suppression	B-PROC
+of	O
+coronavirus	B-SPEC
+replication	O
+by	O
+cyclophilin	B-PROC
+inhibitors	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+infect	O
+a	O
+variety	O
+of	O
+mammalian	O
+and	O
+avian	B-SPEC
+species	B-SPEC
+and	O
+cause	O
+serious	O
+diseases	O
+in	O
+humans	B-SPEC
+,	O
+cats	B-SPEC
+,	O
+mice	B-SPEC
+,	O
+and	O
+birds	B-SPEC
+in	O
+the	O
+form	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+mouse	B-DISO
+hepatitis	I-DISO
+,	O
+and	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+,	O
+respectively	O
+.	O
+
+No	O
+effective	O
+vaccine	O
+or	O
+treatment	O
+has	O
+been	O
+developed	O
+for	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+or	O
+FIP	B-DISO
+virus	B-SPEC
+,	O
+both	O
+of	O
+which	O
+cause	O
+lethal	O
+diseases	O
+.	O
+
+We	O
+noted	O
+a	O
+significant	O
+reduction	O
+in	O
+M	O
+secretion	O
+due	O
+to	O
+serine	B-CHED
+replacement	O
+for	O
+C158	O
+,	O
+but	O
+not	O
+for	O
+C63	O
+or	O
+C85	O
+.	O
+
+He	O
+has	O
+focused	O
+his	O
+research	O
+on	O
+host	B-COMP
+-	O
+pathogen	O
+interactions	O
+at	O
+the	O
+molecular	O
+level	O
+.	O
+
+Research	O
+in	O
+his	O
+laboratory	O
+is	O
+focused	O
+on	O
+,	O
+but	O
+not	O
+restricted	O
+to	O
+,	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+Salmonella	B-DISO
+interactions	O
+with	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+He	O
+cofounded	O
+Inimex	O
+Pharmaceuticals	B-CHED
+,	O
+Inc	O
+.	O
+(	O
+BC	O
+,	O
+Canada	O
+),	O
+and	O
+is	O
+Director	O
+of	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Accelerated	O
+Vaccine	O
+Initiative	O
+.	O
+
+Despite	O
+the	O
+presence	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+high	O
+risk	O
+of	O
+mortality	O
+,	O
+all	O
+three	O
+patients	O
+survived	O
+with	O
+minimal	O
+long	O
+-	O
+term	O
+sequelae	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+guanine	B-PRGE
+-	I-PRGE
+N7	I-PRGE
+methyltransferase	B-FUNC
+activity	I-FUNC
+of	O
+coronavirus	B-SPEC
+nsp14	O
+on	O
+nucleotide	B-CHED
+GTP	B-CHED
+.	O
+
+Moreover	O
+,	O
+the	O
+accumulation	O
+of	O
+m7GTP	B-PRGE
+or	I-PRGE
+presence	I-PRGE
+of	I-PRGE
+protein	I-PRGE
+nsp14	I-PRGE
+could	O
+interfere	O
+with	O
+protein	O
+translation	B-PROC
+of	O
+cellular	B-COMP
+mRNAs	O
+.	O
+
+Anaesthesia	B-DISO
+for	O
+this	O
+long	O
+procedure	O
+involves	O
+advanced	O
+planning	O
+for	O
+airway	B-ANAT
+management	O
+,	O
+vascular	B-ANAT
+access	O
+,	O
+technique	O
+of	O
+anaesthesia	B-DISO
+,	O
+and	O
+fluid	O
+management	O
+.	O
+
+TITLE	O
+:	O
+Binding	B-FUNC
+and	O
+repressive	O
+activities	O
+of	O
+apolipoprotein	B-PRGE
+E3	I-PRGE
+and	I-PRGE
+E4	I-PRGE
+isoforms	I-PRGE
+on	O
+the	O
+human	B-SPEC
+ApoD	B-PRGE
+promoter	I-PRGE
+.	O
+
+Here	O
+,	O
+we	O
+identified	O
+several	O
+nuclear	O
+factors	O
+from	O
+the	O
+cortex	B-ANAT
+of	O
+control	O
+and	O
+OC43	O
+-	O
+infected	O
+mice	B-SPEC
+which	O
+bind	B-FUNC
+a	O
+fragment	O
+of	O
+the	O
+proximal	O
+ApoD	B-PRGE
+promoter	I-PRGE
+in	O
+vitro	O
+.	O
+
+Of	O
+interest	O
+,	O
+we	O
+detected	O
+apolipoprotein	B-PRGE
+E	I-PRGE
+(	O
+ApoE	B-PRGE
+).	O
+
+Consistent	O
+with	O
+these	O
+results	O
+,	O
+we	O
+also	O
+demonstrated	O
+by	O
+ChIP	O
+assay	O
+that	O
+E3	O
+and	O
+E4	O
+isoforms	O
+,	O
+but	O
+not	O
+E2	O
+,	O
+bind	B-FUNC
+the	O
+ApoD	B-PRGE
+promoter	I-PRGE
+.	O
+
+Moreover	O
+,	O
+using	O
+the	O
+Allen	O
+Brain	B-ANAT
+Atlas	B-ANAT
+in	O
+situ	O
+hybridization	B-PROC
+database	O
+,	O
+we	O
+observed	O
+an	O
+inverse	O
+correlation	O
+between	O
+ApoD	B-PRGE
+and	O
+ApoE	B-PRGE
+mRNA	I-PRGE
+expression	B-PROC
+during	O
+development	B-PROC
+and	O
+in	O
+several	O
+regions	O
+of	O
+the	O
+mouse	B-ANAT
+brain	I-ANAT
+,	O
+notably	O
+in	O
+the	O
+cortex	B-ANAT
+,	O
+hippocampus	B-SPEC
+,	O
+plexus	B-ANAT
+choroid	I-ANAT
+,	O
+and	O
+cerebellum	B-ANAT
+.	O
+
+This	O
+study	O
+was	O
+conducted	O
+to	O
+evaluate	O
+the	O
+distribution	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+patients	O
+with	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	B-DISO
+)	O
+through	O
+the	O
+first	O
+teaching	O
+hospital	O
+-	O
+based	O
+surveillance	O
+scheme	O
+for	O
+ILI	B-DISO
+in	O
+South	O
+Korea	O
+.	O
+
+Respiratory	O
+specimens	O
+were	O
+obtained	O
+from	O
+adult	O
+patients	O
+(≥	O
+18	O
+years	O
+)	O
+who	O
+visited	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+with	O
+ILI	O
+from	O
+week	O
+40	O
+,	O
+2011	O
+to	O
+week	O
+22	O
+,	O
+2012	O
+.	O
+
+The	O
+positive	O
+rate	O
+of	O
+respiratory	O
+viruses	B-SPEC
+was	O
+52	O
+.	O
+1	O
+%	O
+(	O
+1	O
+,	O
+033	O
+/	O
+1	O
+,	O
+983	O
+)	O
+and	O
+the	O
+total	O
+number	O
+of	O
+detected	O
+viruses	B-SPEC
+was	O
+1	O
+,	O
+100	O
+.	O
+
+This	O
+study	O
+is	O
+valuable	O
+as	O
+the	O
+first	O
+extensive	O
+laboratory	O
+surveillance	O
+of	O
+the	O
+epidemiology	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+ILI	O
+patients	O
+through	O
+a	O
+teaching	O
+hospital	O
+-	O
+based	O
+influenza	B-DISO
+surveillance	O
+system	O
+in	O
+South	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+Family	B-SPEC
+cluster	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+characterise	O
+the	O
+histopathological	O
+lesions	O
+and	O
+tissue	B-PROC
+tropism	B-PROC
+of	O
+Iranian	O
+isolate	O
+IR	O
+/	O
+773	O
+/	O
+2001	O
+(	O
+793	O
+/	O
+B	O
+)	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+different	O
+organs	B-ANAT
+of	O
+experimentally	O
+infected	O
+SPF	B-PRGE
+chickens	I-PRGE
+.	O
+
+The	O
+most	O
+obvious	O
+histopathological	O
+lesions	O
+were	O
+found	O
+in	O
+the	O
+trachea	B-DISO
+,	O
+kidney	B-ANAT
+,	O
+lungs	B-ANAT
+and	O
+bursa	B-ANAT
+of	I-ANAT
+Fabricius	I-ANAT
+.	O
+
+Amongst	O
+the	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+,	O
+histopathological	O
+changes	O
+were	O
+found	O
+most	O
+frequently	O
+in	O
+the	O
+bursa	B-ANAT
+of	I-ANAT
+Fabricius	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+most	O
+severe	O
+form	O
+,	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+were	O
+presciently	O
+described	O
+nearly	O
+two	O
+centuries	O
+ago	O
+by	O
+René	O
+Laennec	O
+,	O
+later	O
+to	O
+be	O
+described	O
+clinically	O
+in	O
+the	O
+1950s	O
+and	O
+1960s	O
+.	O
+
+Functional	O
+animal	B-SPEC
+models	O
+and	O
+clinically	O
+applicable	O
+case	O
+definitions	O
+for	O
+ALI	O
+and	O
+ARDS	B-DISO
+were	O
+instrumental	O
+in	O
+gaining	O
+these	O
+new	O
+insights	O
+.	O
+
+Although	O
+no	O
+specific	O
+pharmacological	O
+therapies	O
+for	O
+ALI	O
+and	O
+ARDS	B-DISO
+yet	O
+exist	O
+,	O
+outcomes	O
+have	O
+improved	O
+with	O
+advancements	O
+in	O
+respiratory	O
+and	O
+fluid	O
+-	O
+based	O
+supportive	O
+therapies	O
+,	O
+and	O
+methods	O
+to	O
+prevent	O
+the	O
+development	B-PROC
+or	O
+exacerbation	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+This	O
+article	O
+focuses	O
+on	O
+mechanisms	O
+of	O
+lung	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+,	O
+reviews	O
+major	O
+intracellular	B-COMP
+signaling	B-PROC
+cascades	O
+involved	O
+in	O
+endothelial	B-ANAT
+monolayer	O
+barrier	O
+preservation	O
+and	O
+summarizes	O
+a	O
+current	O
+knowledge	O
+regarding	O
+recently	O
+identified	O
+compounds	O
+which	O
+either	O
+reduce	O
+pulmonary	B-ANAT
+endothelial	B-ANAT
+barrier	O
+disruption	O
+and	O
+hyperpermeability	O
+,	O
+or	O
+reverse	O
+preexisting	O
+lung	B-ANAT
+vascular	B-ANAT
+barrier	O
+compromise	O
+induced	O
+by	O
+pathologic	O
+insults	O
+.	O
+
+The	O
+in	O
+vitro	O
+inhibitory	O
+activity	O
+(	O
+50	O
+%	O
+effective	O
+concentration	O
+)	O
+of	O
+the	O
+macrocyclic	O
+inhibitor	B-CHED
+toward	O
+enterovirus	B-PRGE
+3C	I-PRGE
+protease	I-PRGE
+(	O
+CVB3	O
+Nancy	O
+strain	O
+),	O
+and	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+norovirus	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+,	O
+was	O
+determined	O
+to	O
+be	O
+1	O
+.	O
+8	O
+,	O
+15	O
+.	O
+5	O
+and	O
+5	O
+.	O
+1	O
+μM	O
+,	O
+respectively	O
+.	O
+
+No	O
+secondary	B-DISO
+transmission	I-DISO
+was	O
+documented	O
+in	O
+hospital	O
+staff	O
+despite	O
+the	O
+absence	O
+of	O
+specific	O
+protective	O
+measures	O
+before	O
+the	O
+diagnosis	O
+of	O
+MERS	O
+-	O
+CoV	O
+was	O
+suspected	O
+.	O
+
+These	O
+cases	O
+illustrate	O
+the	O
+importance	O
+of	O
+the	O
+techniques	O
+of	O
+cell	B-COMP
+culture	O
+and	O
+electron	O
+microscopy	O
+in	O
+pathogen	O
+identification	O
+and	O
+recognition	O
+of	O
+emerging	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+Ten	O
+years	O
+have	O
+elapsed	O
+since	O
+the	O
+World	O
+Health	O
+Organization	O
+issued	O
+its	O
+first	O
+global	O
+alert	O
+for	O
+an	O
+unexplained	O
+illness	O
+named	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Improper	O
+management	O
+of	O
+hospital	O
+waste	O
+has	O
+been	O
+reported	O
+to	O
+be	O
+responsible	O
+for	O
+several	O
+acute	O
+outbreaks	O
+like	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+effect	O
+of	O
+burnt	O
+hospital	O
+wastes	O
+on	O
+the	O
+agricultural	O
+soil	O
+was	O
+conducted	O
+on	O
+soils	O
+sampled	O
+around	O
+farm	O
+settlement	O
+near	O
+Obafemi	O
+Awolowo	O
+University	O
+Teaching	O
+Hospital	O
+Complex	O
+,	O
+Ile	B-CHED
+-	O
+Ife	O
+,	O
+South	O
+West	O
+Nigeria	O
+.	O
+
+PIXE	O
+technique	O
+was	O
+employed	O
+with	O
+a	O
+1	O
+.	O
+7	O
+MV	O
+5SDH	O
+Tandem	O
+Pelletron	O
+accelerator	O
+available	O
+at	O
+Centre	O
+for	O
+Energy	O
+Research	O
+and	O
+Development	B-PROC
+O	O
+.	O
+A	O
+.	O
+U	O
+Ile	B-CHED
+-	O
+Ife	O
+,	O
+Nigeria	O
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+253	O
+consecutive	O
+patients	O
+hospitalized	O
+for	O
+acute	B-DISO
+pancreatitis	I-DISO
+in	O
+intensive	O
+care	O
+unit	O
+.	O
+
+RESULTS	O
+:	O
+Specific	O
+CT	O
+images	O
+of	O
+GC	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+included	O
+enlarged	O
+and	O
+high	O
+-	O
+tensioned	O
+gallbladder	B-ANAT
+,	O
+wall	O
+thickening	O
+,	O
+lumenal	O
+emphysema	B-DISO
+,	O
+discontinuous	O
+and	O
+/	O
+or	O
+irregular	O
+enhancement	O
+of	O
+mucosa	B-ANAT
+,	O
+and	O
+pericholecystic	O
+effusion	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pathogenesis	B-PROC
+of	O
+malaria	B-PATH
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Anyplex	O
+™	O
+II	O
+RV16	O
+[	O
+RV16	O
+]	O
+was	O
+designed	O
+for	O
+simultaneous	O
+detection	O
+of	O
+16	O
+respiratory	O
+viruses	B-SPEC
+using	O
+multiplex	O
+PCR	O
+coupled	O
+with	O
+TOCE	O
+™	O
+technology	O
+.	O
+
+Serology	O
+for	O
+feline	B-SPEC
+coronavirus	B-SPEC
+antibody	B-COMP
+was	O
+positive	O
+with	O
+an	O
+elevated	O
+alpha	B-PRGE
+-	I-PRGE
+1	I-PRGE
+acid	I-PRGE
+glycoprotein	I-PRGE
+.	O
+
+Immunocytochemistry	O
+for	O
+feline	B-SPEC
+coronavirus	B-SPEC
+was	O
+performed	O
+on	O
+the	O
+CSF	B-ANAT
+,	O
+with	O
+positive	O
+staining	O
+observed	O
+inside	O
+macrophages	B-ANAT
+.	O
+
+The	O
+affection	O
+of	O
+lung	B-ANAT
+can	O
+sometimes	O
+result	O
+in	O
+fatal	O
+outcome	O
+(	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+,	O
+secondary	B-DISO
+pulmonary	I-DISO
+hypertension	I-DISO
+).	O
+
+Intravenous	O
+immunoglobulins	O
+applied	O
+parenterally	O
+in	O
+a	O
+dose	O
+of	O
+2	O
+g	O
+/	O
+kg	O
+divided	O
+into	O
+multiple	O
+doses	O
+showed	O
+an	O
+excellent	O
+clinical	O
+effect	O
+in	O
+patients	O
+with	O
+affection	O
+of	O
+the	O
+esophagus	B-ANAT
+and	O
+throat	B-ANAT
+muscles	B-ANAT
+,	O
+in	O
+patients	O
+with	O
+pulmonary	B-ANAT
+affection	O
+and	O
+in	O
+patients	O
+with	O
+resistant	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+prepdominat	O
+agent	O
+causing	O
+severe	O
+entero	O
+-	O
+pathogenic	O
+diarrhea	B-DISO
+in	O
+swine	B-SPEC
+,	O
+there	O
+are	O
+no	O
+effective	O
+therapeutical	O
+treatment	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+,	O
+and	O
+biological	O
+evaluation	O
+of	O
+novel	O
+dipeptide	B-PRGE
+-	I-PRGE
+type	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	B-CHED
+inhibitors	I-CHED
+:	O
+structure	O
+-	O
+activity	O
+relationship	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+work	O
+describes	O
+the	O
+design	O
+,	O
+synthesis	B-PROC
+,	O
+and	O
+evaluation	O
+of	O
+low	O
+-	O
+molecular	O
+weight	O
+peptidic	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	B-PROC
+inhibitors	I-PROC
+.	O
+
+The	O
+inhibitors	B-CHED
+were	O
+designed	O
+based	O
+on	O
+the	O
+potent	O
+tripeptidic	O
+Z	O
+-	O
+Val	B-CHED
+-	O
+Leu	B-CHED
+-	O
+Ala	B-CHED
+(	O
+pyrrolidone	B-CHED
+-	O
+3	O
+-	O
+yl	O
+)-	O
+2	O
+-	O
+benzothiazole	B-CHED
+(	O
+8	O
+;	O
+Ki	O
+=	O
+4	O
+.	O
+1	O
+nM	O
+),	O
+in	O
+which	O
+the	O
+P3	O
+valine	B-CHED
+unit	O
+was	O
+substituted	O
+with	O
+a	O
+variety	O
+of	O
+distinct	O
+moieties	O
+.	O
+
+He	O
+was	O
+noted	O
+to	O
+have	O
+very	O
+-	O
+high	O
+triglyceride	B-CHED
+levels	O
+(>	O
+5000	O
+mg	O
+/	O
+dL	O
+)	O
+at	O
+admission	O
+.	O
+
+A	O
+magnetic	O
+resonance	O
+imaging	O
+revealed	O
+a	O
+severe	O
+Chiari	B-DISO
+malformation	I-DISO
+type	I-DISO
+I	I-DISO
+.	O
+The	O
+patient	O
+eventually	O
+required	O
+tracheostomy	O
+and	O
+prolonged	O
+mechanical	O
+ventilation	O
+.	O
+
+A	O
+21	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+severe	O
+head	B-ANAT
+injury	O
+after	O
+a	O
+car	B-COMP
+accident	O
+was	O
+endotracheally	O
+intubated	O
+,	O
+mechanically	O
+ventilated	O
+,	O
+and	O
+hemodynamically	O
+stabilized	O
+before	O
+transfer	O
+to	O
+our	O
+university	O
+hospital	O
+.	O
+
+Simultaneously	O
+,	O
+his	O
+intracranial	B-PROC
+pressure	I-PROC
+peaked	O
+and	O
+his	O
+pupils	B-DISO
+dilated	I-DISO
+,	O
+displaying	O
+no	O
+reflexes	B-PROC
+to	O
+light	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+protein	B-CHED
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+is	O
+a	O
+major	O
+target	O
+in	O
+the	O
+development	B-PROC
+of	O
+diagnostic	O
+assay	O
+and	O
+vaccine	O
+,	O
+it	O
+has	O
+a	O
+pivotal	O
+role	O
+in	O
+receptor	O
+attachment	O
+,	O
+viral	O
+entry	O
+and	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+The	O
+RBD	O
+(	O
+RL	O
+and	O
+RS	O
+)	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+were	O
+expressed	B-PROC
+majorly	O
+as	O
+inclusion	B-COMP
+body	I-COMP
+when	O
+expressed	B-PROC
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+BL21pLys	O
+S	O
+under	O
+different	O
+conditions	O
+.	O
+
+An	O
+Emergency	B-DISO
+Use	O
+Authorization	O
+(	O
+EUA	B-SPEC
+)	O
+was	O
+recently	O
+issued	O
+by	O
+the	O
+Food	O
+and	O
+Drug	O
+Administration	O
+(	O
+FDA	O
+)	O
+to	O
+allow	O
+for	O
+expanded	O
+availability	O
+of	O
+diagnostic	O
+testing	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+The	O
+latter	O
+function	O
+of	O
+N	O
+was	O
+shown	O
+to	O
+depend	O
+on	O
+both	O
+of	O
+the	O
+RNA	O
+-	O
+binding	B-FUNC
+domains	O
+of	O
+N	O
+,	O
+as	O
+well	O
+as	O
+on	O
+the	O
+serine	B-CHED
+-	O
+and	O
+arginine	B-CHED
+-	O
+rich	O
+central	O
+region	O
+of	O
+N	O
+,	O
+which	O
+binds	B-FUNC
+nsp3	B-PRGE
+.	O
+
+Our	O
+results	O
+support	O
+a	O
+model	O
+in	O
+which	O
+the	O
+N	O
+-	O
+nsp3	B-PRGE
+interaction	O
+serves	O
+to	O
+tether	O
+the	O
+genome	O
+to	O
+the	O
+newly	O
+translated	O
+replicase	B-PRGE
+-	I-PRGE
+transcriptase	I-PRGE
+complex	O
+at	O
+a	O
+very	O
+early	O
+stage	O
+of	O
+infection	B-DISO
+.	O
+
+The	O
+key	O
+clinical	O
+feature	O
+is	O
+refractory	O
+arterial	B-ANAT
+hypoxemia	O
+,	O
+which	O
+in	O
+severe	O
+cases	O
+necessitates	O
+the	O
+application	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Primary	O
+and	O
+acquired	O
+abdominal	B-ANAT
+pathology	O
+accounts	O
+for	O
+a	O
+significant	O
+proportion	O
+of	O
+sepsis	B-DISO
+and	O
+SIRS	B-DISO
+in	O
+the	O
+ICU	O
+population	O
+.	O
+
+There	O
+is	O
+only	O
+limited	O
+data	O
+on	O
+neotropical	O
+bat	B-ENZY
+CoVs	O
+.	O
+
+Consecutive	O
+inpatients	O
+admitted	O
+from	O
+the	O
+emergency	B-DISO
+department	O
+were	O
+included	O
+if	O
+they	O
+were	O
+≥	O
+18	O
+years	O
+of	O
+age	O
+,	O
+underwent	O
+a	O
+screening	O
+tool	O
+assessment	O
+at	O
+presentation	O
+and	O
+had	O
+a	O
+most	O
+responsible	O
+diagnosis	O
+that	O
+was	O
+cardiac	O
+,	O
+respiratory	O
+or	O
+infectious	B-DISO
+.	O
+
+FECV	B-SPEC
+causes	O
+subclinical	B-DISO
+infections	I-DISO
+;	O
+FIPV	O
+causes	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+a	O
+systemic	O
+and	O
+fatal	O
+disease	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+whether	O
+the	O
+PHEV	O
+-	O
+induced	O
+cytopathic	B-DISO
+effect	I-DISO
+(	O
+CPE	O
+)	O
+was	O
+caused	O
+by	O
+apoptosis	B-PATH
+.	O
+
+Replication	O
+of	O
+PHEV	O
+in	O
+a	O
+porcine	B-SPEC
+kidney	B-ANAT
+-	O
+derived	O
+cell	B-ANAT
+line	I-ANAT
+(	O
+PK	O
+-	O
+15	O
+cells	B-COMP
+)	O
+caused	O
+an	O
+extensive	O
+CPE	O
+,	O
+leading	O
+to	O
+the	O
+destruction	O
+of	O
+the	O
+entire	O
+monolayer	O
+and	O
+the	O
+death	B-PROC
+of	O
+the	O
+infected	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+exemplified	O
+by	O
+coronaviruses	O
+and	O
+influenza	O
+viruses	O
+,	O
+bats	B-SPEC
+and	O
+birds	B-SPEC
+are	O
+natural	O
+reservoirs	O
+for	O
+providing	O
+viral	O
+genes	O
+during	O
+evolution	B-PROC
+of	O
+new	O
+virus	B-SPEC
+species	B-SPEC
+and	O
+viruses	B-SPEC
+for	O
+interspecies	O
+transmission	O
+.	O
+
+Reports	O
+on	O
+the	O
+presence	O
+of	O
+viral	O
+aerosols	O
+in	O
+indoor	O
+air	B-CHED
+are	O
+scarce	O
+,	O
+however	O
+,	O
+despite	O
+the	O
+fact	O
+that	O
+viruses	B-SPEC
+are	O
+probably	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+infection	B-DISO
+acquired	O
+indoor	O
+.	O
+
+ABSTRACT	O
+:	O
+Diarrhoea	O
+caused	O
+by	O
+infectious	B-DISO
+agents	O
+is	O
+common	O
+in	O
+foals	O
+but	O
+there	O
+is	O
+no	O
+comprehensive	O
+molecular	O
+work	O
+-	O
+up	O
+of	O
+the	O
+relative	O
+prevalence	O
+of	O
+common	O
+agents	O
+and	O
+appearance	O
+of	O
+coinfections	B-DISO
+.	O
+
+Six	O
+of	O
+the	O
+8	O
+infectious	B-DISO
+agents	O
+were	O
+associated	O
+with	O
+the	O
+GI	O
+-	O
+diseased	O
+group	O
+,	O
+the	O
+other	O
+2	O
+were	O
+not	O
+(	O
+equine	B-SPEC
+coronavirus	B-SPEC
+and	O
+R	B-SPEC
+.	I-SPEC
+equi	I-SPEC
+).	O
+
+This	O
+conclusion	O
+was	O
+supported	O
+by	O
+the	O
+ultrastructure	O
+images	O
+of	O
+the	O
+early	O
+stage	O
+of	O
+DEV	O
+infection	O
+,	O
+which	O
+showed	O
+that	O
+the	O
+replication	O
+of	O
+virus	B-SPEC
+nucleic	B-CHED
+acid	I-CHED
+and	O
+the	O
+formation	B-PROC
+of	O
+the	O
+capsid	B-ANAT
+in	O
+the	O
+cell	B-COMP
+nucleus	I-COMP
+were	O
+suppressed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+study	O
+of	O
+complications	O
+of	O
+vivax	B-DISO
+malaria	I-DISO
+in	O
+comparison	O
+with	O
+falciparum	B-DISO
+malaria	I-DISO
+in	O
+Mumbai	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+have	O
+compared	O
+the	O
+complications	O
+in	O
+vivax	B-DISO
+malaria	I-DISO
+with	O
+those	O
+in	O
+falciparum	O
+or	O
+mixed	B-DISO
+malaria	I-DISO
+.	O
+
+1	O
+)	O
+To	O
+study	O
+various	O
+complications	O
+in	O
+adult	O
+inpatients	O
+of	O
+vivax	B-DISO
+malaria	I-DISO
+.	O
+
+RESULTS	O
+:	O
+680	O
+cases	O
+of	O
+malaria	B-PATH
+were	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+Overall	O
+24	O
+-	O
+hour	O
+KM	O
+survival	O
+for	O
+the	O
+HRR	B-PROC
+versus	O
+LRR	O
+was	O
+85	O
+.	O
+2	O
+%	O
+versus	O
+68	O
+.	O
+6	O
+%	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0004	O
+).	O
+
+Our	O
+MIA	O
+results	O
+support	O
+previous	O
+studies	O
+with	O
+decreased	O
+mortality	O
+in	O
+HRR	B-PROC
+group	O
+when	O
+compared	O
+with	O
+LRR	O
+.	O
+
+Within	O
+all	O
+MTPs	O
+with	O
+10	O
+or	O
+more	O
+units	O
+of	O
+PRBC	O
+,	O
+HRR	B-PROC
+was	O
+not	O
+a	O
+predictor	O
+of	O
+morbidity	O
+,	O
+but	O
+crystalloid	B-COMP
+volume	O
+was	O
+.	O
+
+Caution	O
+in	O
+overzealous	O
+use	O
+of	O
+crystalloid	B-COMP
+during	O
+HRR	B-PROC
+is	O
+warranted	O
+.	O
+
+TITLE	O
+:	O
+Hospital	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Vitamin	B-CHED
+D	I-CHED
+deficiency	I-DISO
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+evidence	O
+for	O
+the	O
+role	O
+of	O
+vitamin	B-CHED
+D	I-CHED
+in	O
+lung	B-DISO
+disease	I-DISO
+is	O
+growing	O
+-	O
+deficiency	O
+has	O
+been	O
+associated	O
+with	O
+impaired	B-DISO
+pulmonary	B-PROC
+function	I-PROC
+,	O
+increased	O
+incidence	O
+of	O
+viral	O
+and	O
+bacterial	B-DISO
+infections	I-DISO
+and	O
+inflammatory	B-DISO
+disease	I-DISO
+including	O
+asthma	B-PATH
+and	O
+COPD	B-DISO
+.	O
+
+From	O
+time	O
+of	O
+diagnosis	O
+,	O
+respiratory	O
+,	O
+faecal	B-ANAT
+,	O
+and	O
+urine	B-ANAT
+samples	O
+were	O
+obtained	O
+for	O
+virus	B-SPEC
+quantification	O
+.	O
+
+Stool	B-ANAT
+samples	O
+obtained	O
+on	O
+days	O
+12	O
+and	O
+16	O
+contained	O
+the	O
+virus	B-SPEC
+,	O
+with	O
+up	O
+to	O
+1031	O
+RNA	O
+copies	O
+per	O
+g	O
+(	O
+close	O
+to	O
+the	O
+lowest	O
+detection	O
+limit	O
+of	O
+the	O
+assay	O
+).	O
+
+TITLE	O
+:	O
+The	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+of	O
+the	O
+new	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+maps	O
+to	O
+a	O
+231	O
+-	O
+residue	O
+region	O
+in	O
+the	O
+spike	O
+protein	O
+that	O
+efficiently	O
+elicits	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+No	O
+other	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+were	O
+identified	O
+among	O
+the	O
+index	O
+case	O
+’	O
+s	O
+123	O
+contacts	O
+,	O
+nor	O
+among	O
+39	O
+contacts	O
+of	O
+the	O
+secondary	O
+case	O
+,	O
+during	O
+the	O
+10	O
+-	O
+day	O
+follow	O
+-	O
+up	O
+period	O
+.	O
+
+TITLE	O
+:	O
+Solution	O
+NMR	O
+analyses	O
+of	O
+the	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+carbohydrate	I-PRGE
+recognition	I-PRGE
+domain	I-PRGE
+of	O
+DC	B-PRGE
+-	I-PRGE
+SIGNR	I-PRGE
+protein	I-PRGE
+reveal	O
+different	O
+binding	O
+modes	O
+for	O
+HIV	B-DISO
+-	O
+derived	O
+oligosaccharides	B-CHED
+and	O
+smaller	O
+glycan	B-CHED
+fragments	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+lectin	I-PRGE
+DC	O
+-	O
+SIGNR	O
+(	O
+dendritic	B-ANAT
+cell	B-COMP
+-	O
+specific	O
+ICAM	B-PRGE
+-	I-PRGE
+3	I-PRGE
+-	I-PRGE
+grabbing	I-PRGE
+non	I-PRGE
+-	I-PRGE
+integrin	I-PRGE
+-	O
+related	O
+;	O
+also	O
+known	O
+as	O
+L	O
+-	O
+SIGN	O
+or	O
+CD299	O
+)	O
+is	O
+a	O
+promising	O
+drug	O
+target	O
+due	O
+to	O
+its	O
+ability	O
+to	O
+promote	O
+infection	B-DISO
+and	O
+/	O
+or	O
+within	O
+-	O
+host	B-COMP
+survival	O
+of	O
+several	O
+dangerous	O
+pathogens	O
+(	O
+e	O
+.	O
+g	O
+.	O
+HIV	B-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+))	O
+via	O
+interactions	O
+with	O
+their	O
+surface	O
+glycans	B-CHED
+.	O
+
+Treatment	O
+(	O
+hepatorenal	B-DISO
+syndrome	I-DISO
+)	O
+or	O
+prevention	O
+(	O
+renal	B-DISO
+failure	I-DISO
+after	O
+spontaneous	B-DISO
+bacterial	I-DISO
+peritonitis	I-DISO
+and	O
+post	O
+-	O
+paracentesis	O
+circulatory	B-PROC
+dysfunction	O
+after	O
+large	O
+volume	O
+paracentesis	O
+)	O
+of	O
+severe	O
+clinical	O
+complications	O
+in	O
+patients	O
+with	O
+cirrhosis	B-DISO
+and	O
+fluid	O
+resuscitation	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+when	O
+crystalloids	O
+and	O
+non	O
+-	O
+proteic	O
+colloids	O
+are	O
+not	O
+effective	O
+or	O
+contra	O
+-	O
+indicated	O
+,	O
+represents	O
+the	O
+major	O
+evidence	O
+-	O
+based	O
+clinical	O
+indications	O
+for	O
+HSA	O
+administration	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+):	O
+challenges	O
+in	O
+identifying	O
+its	O
+source	O
+and	O
+controlling	O
+its	O
+spread	O
+.	O
+
+Limited	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+has	O
+occurred	O
+within	O
+several	O
+clusters	B-CHED
+,	O
+as	O
+individuals	O
+without	O
+a	O
+recent	O
+travel	O
+history	O
+have	O
+become	O
+infected	O
+after	O
+exposure	O
+to	O
+an	O
+ill	B-DISO
+returned	O
+traveler	O
+.	O
+
+This	O
+case	O
+illustrates	O
+that	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+-	O
+induced	O
+ARDS	B-DISO
+is	O
+not	O
+uncommon	O
+and	O
+should	O
+be	O
+readily	O
+recognized	O
+by	O
+the	O
+treating	O
+physicians	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+current	O
+Chinese	O
+PEDV	B-SPEC
+isolates	O
+originated	O
+from	O
+either	O
+South	O
+Korean	O
+and	O
+/	O
+or	O
+Chinese	O
+ancestors	O
+that	O
+underwent	O
+some	O
+genetic	O
+variation	O
+,	O
+thereby	O
+forming	O
+a	O
+new	O
+PEDV	O
+genotype	O
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+presentation	O
+of	O
+patients	O
+with	O
+seasonal	O
+influenza	B-DISO
+and	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+-	O
+2009	O
+)	O
+requiring	O
+hospitalisation	O
+.	O
+
+Common	O
+presenting	O
+symptoms	O
+included	O
+fever	B-PROC
+in	O
+17	O
+(	O
+89	O
+.	O
+4	O
+%),	O
+cough	B-DISO
+in	O
+16	O
+(	O
+84	O
+.	O
+2	O
+%),	O
+myalgia	B-DISO
+in	O
+15	O
+(	O
+78	O
+.	O
+9	O
+%)	O
+and	O
+breathlessness	B-DISO
+in	O
+10	O
+(	O
+52	O
+.	O
+6	O
+%)	O
+patients	O
+.	O
+
+Autopsies	O
+were	O
+performed	O
+in	O
+5	O
+cases	O
+and	O
+revealed	O
+haemorrhagic	B-DISO
+pneumonia	I-DISO
+in	O
+2	O
+patients	O
+.	O
+
+We	O
+examined	O
+the	O
+efficacy	O
+of	O
+ET	O
+as	O
+an	O
+adjunct	O
+treatment	O
+for	O
+severe	O
+malaria	B-PATH
+using	O
+US	O
+surveillance	O
+data	O
+and	O
+reviewed	O
+the	O
+literature	O
+to	O
+update	O
+recommendations	O
+.	O
+
+""""	O
+Case	O
+reports	O
+and	O
+series	O
+,	O
+observational	O
+and	O
+case	O
+-	O
+control	O
+studies	O
+,	O
+and	O
+meta	B-SPEC
+-	O
+analysis	O
+were	O
+included	O
+.	O
+
+A	O
+high	O
+similarity	O
+was	O
+observed	O
+between	O
+BCoV	O
+,	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+)	O
+and	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+).	O
+
+ABSTRACT	O
+:	O
+Cryopreserved	O
+primary	O
+human	B-SPEC
+renal	B-ANAT
+proximal	B-ANAT
+tubule	I-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+RPTEC	O
+)	O
+were	O
+obtained	O
+from	O
+a	O
+commercial	O
+supplier	O
+for	O
+studies	O
+of	O
+Simian	B-SPEC
+virus	I-SPEC
+40	I-SPEC
+(	O
+SV40	B-SPEC
+).	O
+
+The	O
+authors	O
+gave	O
+an	O
+example	O
+of	O
+fatal	O
+course	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+S	O
+-	O
+OIV	O
+in	O
+young	O
+patient	O
+with	O
+severe	O
+VA	O
+-	O
+pneumonia	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+with	O
+progressive	O
+respiratory	B-DISO
+distress	I-DISO
+secondary	O
+to	O
+an	O
+metabolic	B-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+detection	O
+limit	O
+of	O
+the	O
+assay	O
+was	O
+8	O
+.	O
+2	O
+gene	O
+copies	O
+/	O
+μL	O
+based	O
+on	O
+in	O
+vitro	O
+transcribed	O
+RNA	O
+and	O
+0	O
+.	O
+1	O
+EID50	O
+/	O
+mL	O
+.	O
+The	O
+assay	O
+was	O
+able	O
+to	O
+detect	O
+all	O
+the	O
+IBV	B-SPEC
+strains	O
+assessed	O
+and	O
+discriminated	O
+well	O
+among	O
+the	O
+IBV	B-SPEC
+Mass	O
+.	O
+and	O
+the	O
+IBV	B-SPEC
+non	O
+-	O
+Mass	O
+.	O
+
+Hand	B-ANAT
+–	I-ANAT
+foot	I-ANAT
+syndrome	B-DISO
+was	O
+present	O
+in	O
+12	O
+.	O
+8	O
+%	O
+of	O
+patients	O
+,	O
+exclusively	O
+in	O
+those	O
+less	O
+than	O
+5	O
+years	O
+old	O
+.	O
+
+Pain	O
+crisis	O
+was	O
+particularly	O
+present	O
+in	O
+SCD	B-DISO
+children	O
+less	O
+than	O
+5	O
+years	O
+of	O
+age	O
+(	O
+74	O
+.	O
+5	O
+%	O
+vs	O
+25	O
+.	O
+6	O
+%,	O
+P	O
+,	O
+0	O
+.	O
+001	O
+).	O
+
+RESULTS	O
+:	O
+Thirty	O
+-	O
+five	O
+children	O
+with	O
+a	O
+diagnosis	O
+of	O
+severe	O
+malaria	B-PATH
+were	O
+enrolled	O
+[	O
+18	O
+(	O
+51	O
+·	O
+4	O
+%)	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+,	O
+nine	O
+(	O
+25	O
+·	O
+7	O
+%)	O
+mixed	B-DISO
+infection	I-DISO
+,	O
+eight	O
+(	O
+22	O
+·	O
+8	O
+%)	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+].	O
+
+We	O
+diagnosed	O
+Legionella	B-DISO
+pneumonia	I-DISO
+from	O
+his	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+imaging	O
+which	O
+showed	O
+bilateral	O
+lobe	B-ANAT
+consolidation	O
+excluding	O
+the	O
+left	B-ANAT
+upper	I-ANAT
+lobe	I-ANAT
+,	O
+and	O
+his	O
+sputum	B-ANAT
+culture	O
+yielded	O
+Legionella	B-SPEC
+pneumophilla	O
+serogroup	O
+1	O
+.	O
+
+His	O
+respiratory	O
+status	O
+gradually	O
+improved	O
+after	O
+that	O
+and	O
+he	O
+was	O
+weaned	B-PROC
+from	O
+ECMO	O
+on	O
+the	O
+7th	O
+day	O
+.	O
+
+In	O
+medicine	B-CHED
+,	O
+a	O
+definition	O
+or	O
+syndrome	B-DISO
+representing	O
+""""	O
+a	O
+constellation	O
+of	O
+symptomatology	O
+seen	O
+in	O
+association	O
+""""	O
+should	O
+stand	O
+the	O
+trial	O
+of	O
+time	O
+after	O
+it	O
+is	O
+coined	O
+.	O
+
+ABSTRACT	O
+:	O
+Pharmacological	O
+interventions	O
+are	O
+commonly	O
+considered	O
+in	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+.	O
+
+Fluid	O
+management	O
+with	O
+the	O
+goal	O
+to	O
+obtain	O
+zero	O
+fluid	B-PROC
+balance	I-PROC
+in	O
+ARDS	B-DISO
+patients	O
+without	O
+shock	O
+or	O
+renal	B-DISO
+failure	I-DISO
+significantly	O
+increases	O
+the	O
+number	O
+of	O
+days	O
+without	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+early	O
+use	O
+of	O
+high	O
+doses	O
+of	O
+corticosteroids	B-CHED
+for	O
+the	O
+prevention	O
+of	O
+ARDS	B-DISO
+in	O
+septic	B-DISO
+shock	I-DISO
+patients	O
+or	O
+in	O
+patients	O
+with	O
+confirmed	O
+ARDS	B-DISO
+significantly	O
+reduced	O
+the	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+but	O
+had	O
+no	O
+effect	O
+or	O
+even	O
+increased	O
+mortality	O
+.	O
+
+In	O
+the	O
+context	O
+of	O
+a	O
+persistent	O
+ARDS	B-DISO
+with	O
+histological	O
+proof	O
+of	O
+fibroproliferation	O
+,	O
+a	O
+corticosteroid	B-CHED
+treatment	O
+with	O
+a	O
+progressive	O
+decrease	O
+of	O
+doses	O
+can	O
+be	O
+proposed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+changing	O
+nature	O
+of	O
+death	B-PROC
+on	O
+the	O
+trauma	O
+service	O
+.	O
+
+Mortality	O
+caused	O
+by	O
+preexisting	O
+medical	O
+conditions	O
+has	O
+increased	O
+,	O
+while	O
+markedly	O
+fewer	O
+deaths	B-PROC
+resulted	O
+from	O
+the	O
+complications	O
+of	O
+injury	O
+.	O
+
+TITLE	O
+:	O
+Biological	O
+features	O
+of	O
+novel	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+.	O
+
+We	O
+discover	O
+that	O
+the	O
+H7N9	O
+virus	B-SPEC
+can	O
+bind	B-FUNC
+to	O
+both	O
+avian	B-SPEC
+-	O
+type	O
+(	O
+α2	O
+,	O
+3	O
+-	O
+linked	O
+sialic	B-CHED
+acid	I-CHED
+)	O
+and	O
+human	B-SPEC
+-	O
+type	O
+(	O
+α2	O
+,	O
+6	O
+-	O
+linked	O
+sialic	B-CHED
+acid	I-CHED
+)	O
+receptors	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+RTIs	O
+)	O
+are	O
+caused	O
+by	O
+a	O
+plethora	O
+of	O
+viral	O
+and	O
+bacterial	O
+pathogens	O
+.	O
+
+The	O
+FilmArray	O
+RP	O
+and	O
+Prodesse	O
+ProFLU	O
++/	O
+FAST	B-PRGE
++	I-PRGE
+assays	O
+were	O
+convenient	O
+to	O
+perform	O
+with	O
+regard	O
+to	O
+sensitivity	O
+,	O
+ease	O
+of	O
+use	O
+,	O
+and	O
+low	O
+percentages	O
+of	O
+invalid	O
+results	O
+.	O
+
+In	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+as	O
+a	O
+model	O
+,	O
+we	O
+previously	O
+reported	O
+that	O
+accessory	O
+gene	O
+7	O
+counteracts	O
+the	O
+host	B-COMP
+antiviral	B-PROC
+response	I-PROC
+by	O
+associating	O
+with	O
+the	O
+catalytic	O
+subunit	O
+of	O
+protein	B-PRGE
+phosphatase	B-FUNC
+1	I-PRGE
+(	O
+PP1c	B-PRGE
+).	O
+
+In	O
+the	O
+present	O
+work	O
+,	O
+the	O
+effect	O
+of	O
+the	O
+absence	O
+of	O
+gene	O
+7	O
+on	O
+the	O
+host	B-COMP
+cell	I-COMP
+,	O
+during	O
+infection	B-DISO
+,	O
+was	O
+further	O
+analyzed	O
+by	O
+transcriptomic	O
+analysis	O
+.	O
+
+Dipeptidyl	O
+peptidase	O
+-	O
+4	O
+(	O
+DPP4	B-PRGE
+)	O
+was	O
+recently	O
+identified	O
+as	O
+its	O
+receptor	O
+.	O
+
+Infection	B-DISO
+results	O
+in	O
+profound	O
+apoptosis	B-PATH
+within	O
+24	O
+h	O
+irrespective	O
+of	O
+its	O
+production	O
+of	O
+titers	O
+that	O
+are	O
+lower	O
+than	O
+those	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Together	O
+,	O
+our	O
+results	O
+provide	O
+new	O
+insights	O
+into	O
+the	O
+dissemination	O
+and	O
+pathogenesis	B-DISO
+of	O
+MERS	O
+-	O
+CoV	O
+and	O
+may	O
+indicate	O
+that	O
+the	O
+virus	B-SPEC
+differs	O
+markedly	O
+from	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+Using	O
+colored	O
+food	O
+dye	B-CHED
+as	O
+a	O
+tracer	B-CHED
+,	O
+the	O
+qualitative	O
+effects	O
+of	O
+door	O
+-	O
+opening	O
+motions	O
+on	O
+the	O
+dissemination	O
+of	O
+potentially	O
+contaminated	O
+air	B-CHED
+into	O
+and	O
+out	O
+of	O
+a	O
+single	O
+isolation	O
+room	O
+were	O
+visualized	O
+and	O
+filmed	O
+using	O
+Reynolds	O
+-	O
+number	O
+-	O
+equivalent	O
+,	O
+small	O
+-	O
+scale	O
+,	O
+water	B-CHED
+-	O
+tank	O
+models	O
+fitted	B-DISO
+with	O
+programmable	O
+door	O
+-	O
+opening	O
+and	O
+moving	B-PROC
+human	B-SPEC
+figure	O
+motions	O
+.	O
+
+The	O
+relative	O
+effect	O
+of	O
+the	O
+moving	B-PROC
+human	B-SPEC
+figure	O
+on	O
+spreading	O
+any	O
+potential	O
+contamination	O
+was	O
+greatest	O
+with	O
+the	O
+sliding	O
+doors	O
+,	O
+as	O
+the	O
+bulk	O
+airflows	O
+induced	O
+were	O
+large	O
+relative	O
+to	O
+those	O
+resulting	O
+from	O
+these	O
+door	O
+-	O
+opening	O
+motions	O
+.	O
+
+This	O
+report	O
+emphasizes	O
+that	O
+this	O
+fatal	O
+complication	B-DISO
+may	O
+occur	O
+with	O
+use	O
+of	O
+this	O
+drug	O
+.	O
+
+Clinicians	O
+need	O
+to	O
+be	O
+aware	O
+of	O
+this	O
+condition	B-DISO
+as	O
+prompt	O
+recognition	O
+and	O
+supportive	O
+management	O
+can	O
+prevent	O
+unwanted	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Poulvac	O
+IB	O
+®	O
+Primer	O
+is	O
+a	O
+lyophilized	O
+vaccine	O
+containing	O
+two	O
+attenuated	O
+infectious	B-DISO
+bronchitis	B-DISO
+strains	O
+in	O
+one	O
+vial	O
+,	O
+IB	O
+H120	O
+and	O
+IB	O
+D274	O
+.	O
+
+For	O
+quantification	O
+of	O
+the	O
+viral	O
+content	O
+of	O
+the	O
+vaccine	O
+,	O
+dilution	O
+series	O
+of	O
+the	O
+final	O
+product	O
+are	O
+inoculated	O
+in	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+not	O
+clear	O
+what	O
+the	O
+live	O
+virus	B-SPEC
+titre	O
+is	O
+for	O
+strain	O
+IB	O
+H120	O
+and	O
+for	O
+strain	O
+IB	O
+D274	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+determine	O
+end	O
+-	O
+points	O
+in	O
+the	O
+titration	O
+for	O
+each	O
+of	O
+the	O
+two	O
+strains	O
+,	O
+we	O
+collected	O
+the	O
+allantoic	O
+fluids	B-ANAT
+from	O
+each	O
+egg	B-ANAT
+after	O
+the	O
+incubation	O
+period	O
+and	O
+tested	O
+these	O
+for	O
+the	O
+presence	O
+of	O
+IB	O
+H120	O
+and	O
+IB	O
+D274	O
+by	O
+a	O
+strain	O
+specific	O
+reverse	O
+phase	O
+PCR	O
+.	O
+
+In	O
+multivariate	O
+analyses	O
+,	O
+four	O
+variables	O
+were	O
+significantly	O
+associated	O
+with	O
+an	O
+increased	O
+number	O
+of	O
+healthcare	O
+visits	O
+per	O
+ILI	O
+:	O
+non	O
+-	O
+Caucasian	O
+child	O
+,	O
+living	O
+in	O
+a	O
+detached	O
+house	O
+,	O
+both	O
+parents	O
+in	O
+employed	O
+work	O
+and	O
+having	O
+an	O
+ILI	O
+with	O
+one	O
+or	O
+more	O
+viruses	B-SPEC
+identified	O
+.	O
+
+At	O
+day	O
+30	O
+,	O
+one	O
+death	B-PROC
+had	O
+occurred	O
+in	O
+each	O
+group	O
+.	O
+
+The	O
+main	O
+factor	O
+associated	O
+with	O
+non	O
+-	O
+severe	O
+presentation	O
+was	O
+an	O
+early	O
+(<	O
+48	O
+h	O
+)	O
+implementation	O
+of	O
+oseltamivir	B-CHED
+treatment	O
+(	O
+P	O
+=	O
+0	O
+.	O
+038	O
+).	O
+
+Although	O
+the	O
+study	O
+failed	O
+to	O
+achieve	O
+its	O
+main	O
+objective	O
+,	O
+due	O
+mainly	O
+to	O
+the	O
+difficulty	O
+of	O
+carrying	O
+a	O
+study	O
+of	O
+this	O
+nature	O
+in	O
+the	O
+midst	O
+of	O
+a	O
+pandemic	O
+,	O
+it	O
+allowed	O
+the	O
+description	O
+of	O
+a	O
+panel	O
+of	O
+unusual	O
+and	O
+complicated	O
+forms	O
+and	O
+confirmed	O
+the	O
+added	O
+value	O
+of	O
+early	O
+oseltamivir	B-CHED
+treatment	O
+in	O
+limiting	O
+severity	O
+in	O
+hospitalized	O
+children	O
+and	O
+adults	O
+.	O
+
+Pregnant	O
+women	O
+are	O
+susceptible	O
+to	O
+certain	O
+infections	B-DISO
+because	O
+of	O
+alterations	O
+in	O
+their	O
+cell	B-PROC
+-	I-PROC
+mediated	I-PROC
+immunity	I-PROC
+.	O
+
+Pyelonephritis	B-DISO
+remains	O
+a	O
+common	O
+cause	O
+of	O
+sepsis	B-DISO
+during	O
+pregnancy	O
+,	O
+and	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+occurs	O
+more	O
+commonly	O
+than	O
+in	O
+the	O
+nonpregnant	O
+population	O
+.	O
+
+When	O
+the	O
+phage	O
+-	O
+ELISA	O
+was	O
+compared	O
+to	O
+conventional	O
+antibody	B-COMP
+-	O
+based	O
+ELISA	O
+for	O
+detecting	O
+infections	B-DISO
+,	O
+phage	O
+-	O
+ELISA	O
+exhibited	O
+greater	O
+sensitivity	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+pepTGEV	O
+-	O
+M7	O
+might	O
+be	O
+utilized	O
+for	O
+virus	B-SPEC
+-	O
+specific	O
+diagnostics	O
+and	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Interhuman	O
+transmissibility	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+:	O
+estimation	O
+of	O
+pandemic	O
+risk	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+new	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+shares	O
+many	O
+clinical	O
+,	O
+epidemiological	O
+,	O
+and	O
+virological	O
+similarities	O
+with	O
+that	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+.	O
+We	O
+aimed	O
+to	O
+estimate	O
+virus	B-SPEC
+transmissibility	O
+and	O
+the	O
+epidemic	O
+potential	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+to	O
+compare	O
+the	O
+results	O
+with	O
+similar	O
+findings	O
+obtained	O
+for	O
+prepandemic	O
+SARS	B-DISO
+.	O
+
+We	O
+retrieved	O
+data	O
+for	O
+MERS	O
+-	O
+CoV	O
+clusters	B-CHED
+from	O
+the	O
+WHO	O
+summary	O
+and	O
+subsequent	O
+reports	O
+,	O
+and	O
+published	O
+descriptions	O
+of	O
+cases	O
+,	O
+and	O
+took	O
+into	O
+account	O
+55	O
+of	O
+the	O
+64	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+reported	O
+as	O
+of	O
+June	O
+21	O
+,	O
+2013	O
+,	O
+excluding	O
+cases	O
+notified	O
+in	O
+the	O
+previous	O
+2	O
+weeks	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+basis	O
+of	O
+binding	B-FUNC
+between	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+MERS	O
+-	O
+CoV	O
+and	O
+its	O
+receptor	O
+CD26	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+newly	O
+emergent	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+can	O
+cause	O
+severe	O
+pulmonary	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+,	O
+representing	O
+the	O
+second	O
+example	O
+of	O
+a	O
+highly	O
+pathogenic	O
+coronavirus	B-SPEC
+,	O
+the	O
+first	O
+being	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+CD26	B-PRGE
+(	O
+also	O
+known	O
+as	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+,	O
+DPP4	B-PRGE
+)	O
+was	O
+recently	O
+identified	O
+as	O
+the	O
+cellular	B-COMP
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+engagement	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+with	O
+CD26	B-PRGE
+mediates	O
+viral	O
+attachment	O
+to	O
+host	B-COMP
+cells	B-COMP
+and	O
+virus	B-SPEC
+-	O
+cell	B-PROC
+fusion	I-PROC
+,	O
+thereby	O
+initiating	O
+infection	B-DISO
+.	O
+
+Furthermore	O
+,	O
+binding	B-FUNC
+between	O
+the	O
+RBD	O
+and	O
+CD26	B-PRGE
+is	O
+measured	O
+using	O
+real	O
+-	O
+time	O
+surface	O
+plasmon	O
+resonance	O
+with	O
+a	O
+dissociation	B-DISO
+constant	O
+of	O
+16	O
+.	O
+7	O
+nM	O
+.	O
+The	O
+viral	O
+RBD	O
+is	O
+composed	O
+of	O
+a	O
+core	O
+subdomain	O
+homologous	O
+to	O
+that	O
+of	O
+the	O
+SARS	O
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+,	O
+and	O
+a	O
+unique	O
+strand	O
+-	O
+dominated	O
+external	O
+receptor	B-FUNC
+binding	I-FUNC
+motif	O
+that	O
+recognizes	O
+blades	O
+IV	O
+and	O
+V	O
+of	O
+the	O
+CD26	B-PRGE
+β	I-PRGE
+-	O
+propeller	O
+.	O
+
+The	O
+atomic	O
+details	O
+at	O
+the	O
+interface	O
+between	O
+the	O
+two	O
+binding	B-FUNC
+entities	O
+reveal	O
+a	O
+surprising	O
+protein	B-CHED
+-	O
+protein	B-CHED
+contact	O
+mediated	O
+mainly	O
+by	O
+hydrophilic	O
+residues	O
+.	O
+
+From	O
+2006	O
+to	O
+2009	O
+,	O
+at	O
+least	O
+21	O
+%	O
+of	O
+117	O
+patients	O
+diagnosed	O
+with	O
+HV	O
+infection	B-DISO
+had	O
+HV	O
+Fever	B-PROC
+(	O
+HF	O
+)	O
+with	O
+no	O
+evidence	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+(	O
+no	O
+respiratory	B-DISO
+distress	I-DISO
+or	O
+radiographic	O
+lung	B-ANAT
+infiltrates	B-DISO
+),	O
+and	O
+44	O
+%	O
+of	O
+patients	O
+had	O
+very	O
+mild	O
+HPS	B-DISO
+(	O
+radiographic	O
+pulmonary	B-DISO
+edema	I-DISO
+but	O
+no	O
+respiratory	B-DISO
+insufficiency	I-DISO
+).	O
+
+Another	O
+patient	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+was	O
+admitted	O
+to	O
+the	O
+ICU	O
+.	O
+
+No	O
+patient	O
+died	B-PROC
+of	O
+AP	O
+during	O
+the	O
+study	O
+period	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+avian	O
+coronavirus	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+the	O
+respiratory	B-DISO
+disease	I-DISO
+infectious	B-DISO
+bronchitis	B-DISO
+of	O
+domestic	O
+fowl	O
+,	O
+and	O
+is	O
+controlled	O
+by	O
+routine	O
+vaccination	O
+.	O
+
+ABSTRACT	O
+:	O
+On	O
+29	O
+March	O
+2013	O
+,	O
+the	O
+Chinese	O
+Center	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+confirmed	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+human	O
+infection	B-DISO
+with	O
+an	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+does	O
+not	O
+replicate	O
+in	O
+Syrian	B-SPEC
+hamsters	I-SPEC
+.	O
+
+RESULTS	O
+:	O
+Compared	O
+to	O
+patients	O
+with	O
+mild	O
+ARDS	B-DISO
+,	O
+patients	O
+with	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+had	O
+higher	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+and	O
+sequential	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+scores	O
+on	O
+the	O
+day	O
+of	O
+enrollment	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+frequency	O
+oscillation	O
+and	O
+tracheal	O
+gas	B-ENZY
+insufflation	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+traumatic	O
+brain	B-ANAT
+injury	O
+:	O
+an	O
+interventional	O
+physiological	O
+study	O
+.	O
+
+Arterial	O
+/	O
+central	O
+-	O
+venous	B-ANAT
+blood	I-ANAT
+gases	O
+,	O
+hemodynamics	B-PROC
+,	O
+and	O
+ICP	B-DISO
+were	O
+recorded	O
+before	O
+,	O
+during	O
+(	O
+every	O
+4	O
+hours	O
+),	O
+and	O
+after	O
+HFO	O
+-	O
+TGI	O
+,	O
+and	O
+were	O
+analyzed	O
+by	O
+using	O
+repeated	O
+measures	O
+analysis	O
+of	O
+variance	O
+.	O
+
+Respiratory	B-PROC
+mechanics	I-PROC
+were	O
+assessed	O
+before	O
+and	O
+after	O
+HFO	O
+-	O
+TGI	O
+.	O
+
+After	O
+acid	O
+aspiration	B-DISO
+,	O
+computed	O
+tomography	O
+scans	O
+revealed	O
+that	O
+lung	B-ANAT
+density	O
+had	O
+increased	O
+in	O
+the	O
+injured	O
+regions	O
+and	O
+that	O
+these	O
+regions	O
+colocalized	O
+with	O
+areas	O
+of	O
+increased	O
+blood	B-PROC
+flow	I-PROC
+.	O
+
+Twenty	O
+-	O
+five	O
+children	O
+(	O
+1	O
+month	O
+<	O
+age	O
+<	O
+17	O
+years	O
+)	O
+admitted	O
+to	O
+a	O
+university	O
+hospital	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+with	O
+ARDS	B-DISO
+and	O
+submitted	O
+to	O
+HFOV	O
+for	O
+a	O
+minimum	O
+of	O
+48	O
+hours	O
+after	O
+failure	O
+of	O
+conventional	O
+mechanical	O
+ventilation	O
+were	O
+assessed	O
+.	O
+
+Twenty	O
+eight	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+ARDS	B-DISO
+,	O
+the	O
+mortality	O
+rate	O
+was	O
+52	O
+%	O
+(	O
+13	O
+/	O
+25	O
+).	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+encodes	O
+an	O
+extensively	O
+phosphorylated	O
+and	O
+highly	O
+basic	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+.	O
+
+Introduction	O
+of	O
+Ala	B-CHED
+substitutions	O
+at	O
+these	O
+two	O
+sites	O
+individually	O
+,	O
+in	O
+combination	O
+of	O
+the	O
+two	O
+and	O
+together	O
+with	O
+other	O
+two	O
+sites	O
+(	O
+Ser190	O
+and	O
+Ser192	O
+)	O
+into	O
+an	O
+infectious	B-DISO
+IBV	B-SPEC
+clone	O
+did	O
+not	O
+affect	O
+recovery	O
+of	O
+the	O
+recombinant	O
+viruses	B-SPEC
+containing	O
+the	O
+mutations	O
+.	O
+
+A	O
+mutant	B-DISO
+virus	B-SPEC
+(	O
+rIBV	O
+-	O
+Nm4	O
+)	O
+carrying	O
+the	O
+four	O
+Ala	B-CHED
+substitutions	O
+grew	O
+at	O
+a	O
+similar	O
+,	O
+if	O
+not	O
+better	O
+,	O
+growth	B-PROC
+rate	O
+as	O
+wild	O
+type	O
+virus	O
+.	O
+
+However	O
+,	O
+the	O
+burden	O
+of	O
+certain	O
+respiratory	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+coronaviruses	O
+,	O
+and	O
+the	O
+relevance	O
+of	O
+viral	O
+coinfections	B-DISO
+remain	O
+unclear	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+distribution	O
+and	O
+seasonal	O
+occurrences	O
+of	O
+respiratory	O
+viruses	B-SPEC
+detected	O
+by	O
+multiplex	O
+molecular	O
+assay	O
+in	O
+6	O
+,	O
+014	O
+samples	O
+from	O
+2008	O
+to	O
+2011	O
+in	O
+a	O
+French	O
+hospital	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+generalized	O
+exanthematous	O
+pustulosis	O
+(	O
+AGEP	B-DISO
+)	O
+is	O
+a	O
+severe	O
+cutaneous	O
+adverse	O
+reaction	O
+characterized	O
+by	O
+rash	B-DISO
+with	O
+sterile	B-DISO
+pustules	O
+,	O
+high	O
+fever	B-PROC
+and	O
+elevated	O
+circulating	O
+neutrophil	B-ANAT
+counts	O
+.	O
+
+Western	O
+blot	O
+analysis	O
+was	O
+used	O
+to	O
+validate	O
+the	O
+changes	O
+of	O
+alpha	B-PRGE
+tubulin	I-PRGE
+,	O
+keratin	B-PRGE
+19	I-PRGE
+,	O
+and	O
+prohibitin	B-PRGE
+during	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+we	O
+have	O
+performed	O
+the	O
+first	O
+analysis	O
+of	O
+the	O
+proteomic	O
+changes	O
+in	O
+host	B-COMP
+cell	I-COMP
+during	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+Western	O
+blot	O
+analysis	O
+was	O
+used	O
+to	O
+validate	O
+the	O
+changes	O
+of	O
+alpha	B-PRGE
+tubulin	I-PRGE
+,	O
+keratin	B-PRGE
+19	I-PRGE
+,	O
+and	O
+prohibitin	B-PRGE
+during	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+A	O
+dynamic	O
+respiratory	O
+control	O
+system	O
+is	O
+critical	O
+to	O
+successful	O
+adaptation	B-PROC
+in	O
+the	O
+face	B-DISO
+of	O
+progressive	O
+pulmonary	B-DISO
+pathology	I-DISO
+.	O
+
+Over	O
+time	O
+,	O
+adaptations	B-PROC
+of	O
+the	O
+respiratory	O
+control	O
+system	O
+to	O
+this	O
+disease	O
+include	O
+changes	O
+in	O
+the	O
+intrinsic	O
+properties	O
+of	O
+respiratory	B-ANAT
+muscles	I-ANAT
+,	O
+chemoreceptor	B-ANAT
+signaling	B-PROC
+,	O
+and	O
+central	O
+respiratory	O
+drive	O
+which	O
+increase	O
+motor	O
+output	O
+to	O
+the	O
+respiratory	B-ANAT
+muscles	I-ANAT
+.	O
+
+In	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+data	O
+indicating	O
+a	O
+protective	O
+effect	O
+of	O
+ASA	B-CHED
+are	O
+less	O
+convincing	O
+.	O
+
+Five	O
+hours	O
+after	O
+LPS	O
+,	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+)	O
+and	O
+plasma	B-ANAT
+were	O
+obtained	O
+.	O
+
+The	O
+28	O
+-	O
+day	O
+mortality	O
+and	O
+number	O
+of	O
+days	O
+free	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+were	O
+statistically	O
+similar	O
+between	O
+the	O
+groups	O
+.	O
+
+In	O
+this	O
+prospective	O
+multicenter	O
+study	O
+,	O
+200	O
+patients	O
+submitted	O
+to	O
+protective	O
+ventilation	O
+for	O
+early	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+[	O
+PaO₂	B-PRGE
+/	O
+F	O
+(	O
+I	O
+)	O
+O₂	O
+:	O
+115	O
+±	O
+39	O
+with	O
+F	O
+(	O
+I	O
+)	O
+O₂	O
+:	O
+1	O
+;	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+):	O
+10	O
+.	O
+6	O
+±	O
+3	O
+.	O
+1	O
+cmH2O	O
+]	O
+underwent	O
+transthoracic	O
+(	O
+TTE	O
+)	O
+and	O
+transesophageal	O
+echocardiography	O
+(	O
+TEE	O
+)	O
+<	O
+48	O
+h	O
+after	O
+admission	O
+.	O
+
+Plateau	O
+pressure	O
+(	O
+OR	O
+1	O
+.	O
+15	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+05	O
+-	O
+1	O
+.	O
+26	O
+;	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+and	O
+air	B-CHED
+leaks	O
+(	O
+OR	O
+5	O
+.	O
+48	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+30	O
+-	O
+22	O
+.	O
+99	O
+;	O
+p	O
+=	O
+0	O
+.	O
+02	O
+),	O
+but	O
+neither	O
+ACP	B-DISO
+nor	O
+PFO	B-CHED
+,	O
+were	O
+independently	O
+associated	O
+with	O
+outcome	O
+.	O
+
+We	O
+performed	O
+a	O
+retrospective	O
+study	O
+of	O
+all	O
+patients	O
+treated	O
+with	O
+ECLS	O
+at	O
+our	O
+institution	O
+for	O
+severe	O
+ARDS	B-DISO
+as	O
+a	O
+result	O
+of	O
+Legionella	B-DISO
+pneumonia	I-DISO
+from	O
+1994	O
+to	O
+2006	O
+.	O
+
+A	O
+total	O
+of	O
+twelve	O
+patients	O
+with	O
+a	O
+diagnosis	O
+of	O
+Legionella	B-DISO
+pneumonia	I-DISO
+were	O
+treated	O
+with	O
+veno	O
+-	O
+venous	B-ANAT
+(	O
+VV	O
+)	O
+ECLS	O
+over	O
+this	O
+time	O
+period	O
+.	O
+
+ABSTRACT	O
+:	O
+Microglia	B-ANAT
+are	O
+the	O
+resident	O
+macrophage	O
+-	O
+like	O
+populations	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+).	O
+
+Despite	O
+the	O
+fact	O
+that	O
+more	O
+than	O
+one	O
+FCoV	O
+was	O
+identified	O
+in	O
+this	O
+multi	O
+-	O
+cat	B-SPEC
+environment	O
+,	O
+the	O
+eight	O
+FIP	B-DISO
+cats	B-SPEC
+were	O
+invariably	O
+found	O
+to	O
+be	O
+infected	O
+with	O
+a	O
+type	O
+II	O
+FCoV	O
+.	O
+Sequence	O
+analysis	O
+revealed	O
+that	O
+the	O
+type	O
+II	O
+FIPV	O
+detected	O
+from	O
+fecal	O
+samples	O
+,	O
+body	B-ANAT
+effusions	B-DISO
+and	O
+granulomatous	O
+tissue	B-ANAT
+homogenates	O
+from	O
+the	O
+cats	B-SPEC
+that	O
+succumbed	O
+to	O
+FIP	B-DISO
+all	O
+harbored	O
+an	O
+identical	O
+recombination	B-PROC
+site	O
+in	O
+their	O
+S	O
+gene	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+antibody	B-COMP
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+evaluated	O
+at	O
+mucosal	B-ANAT
+sites	O
+of	O
+chickens	B-SPEC
+after	O
+immunization	O
+with	O
+various	O
+doses	O
+of	O
+an	O
+attenuated	O
+vaccine	O
+at	O
+1	O
+day	O
+of	O
+age	O
+.	O
+
+The	O
+correlation	O
+of	O
+these	O
+immune	B-PROC
+responses	I-PROC
+with	O
+protection	O
+of	O
+tracheal	O
+tissues	B-ANAT
+was	O
+evaluated	O
+after	O
+experimental	O
+infection	B-DISO
+of	O
+these	O
+birds	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Mobilization	O
+of	O
+endothelial	B-ANAT
+progenitor	B-ANAT
+cells	I-ANAT
+from	O
+bone	B-ANAT
+marrow	I-ANAT
+is	O
+impaired	B-DISO
+in	O
+a	O
+piglet	O
+model	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+The	O
+number	O
+of	O
+CD34KDR	O
+,	O
+KDRCD133	O
+,	O
+and	O
+CD34KDRCD133	O
+cells	B-COMP
+was	O
+higher	O
+in	O
+the	O
+acute	O
+lung	B-ANAT
+injury	O
+group	O
+than	O
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+group	O
+.	O
+
+TITLE	O
+:	O
+A	O
+sorghum	B-SPEC
+xylanase	B-PROC
+inhibitor	B-CHED
+-	I-PRGE
+like	I-PRGE
+protein	B-CHED
+with	O
+highly	O
+potent	O
+antifungal	B-CHED
+,	O
+antitumor	O
+and	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	O
+transcriptase	O
+inhibitory	O
+activities	O
+.	O
+
+XILP	O
+inhibited	O
+proliferation	B-DISO
+of	O
+various	O
+cancer	B-ANAT
+cell	B-COMP
+lines	O
+but	O
+did	O
+not	O
+do	O
+so	O
+in	O
+human	B-SPEC
+embryonic	B-ANAT
+liver	B-ANAT
+(	O
+WRL	O
+68	O
+)	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+was	O
+performed	O
+to	O
+clarify	O
+the	O
+acute	B-DISO
+phase	I-DISO
+response	I-DISO
+following	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+inoculation	O
+.	O
+
+In	O
+the	O
+serum	B-COMP
+the	O
+acute	O
+phase	O
+proteins	O
+(	O
+haptoglobin	B-PRGE
+and	O
+serum	B-COMP
+amyloid	B-DISO
+A	O
+),	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+(	O
+interferon	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+),	O
+and	O
+serum	B-COMP
+sialic	B-CHED
+acid	I-CHED
+(	O
+total	O
+,	O
+TSA	B-FUNC
+;	O
+lipid	B-CHED
+-	O
+bound	O
+,	O
+LBSA	O
+;	O
+and	O
+protein	B-CHED
+-	O
+bound	O
+,	O
+PBSA	O
+)	O
+concentrations	O
+were	O
+measured	O
+using	O
+validated	O
+standard	O
+procedures	O
+.	O
+
+All	O
+variables	O
+were	O
+significantly	O
+higher	O
+in	O
+the	O
+infected	O
+birds	B-SPEC
+after	O
+virus	B-SPEC
+inoculation	O
+compared	O
+with	O
+the	O
+healthy	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Peak	O
+Flow	O
+-	O
+test	O
+is	O
+a	O
+useful	O
+predictive	O
+factor	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+by	O
+its	O
+easy	O
+management	O
+.	O
+
+To	O
+understand	O
+the	O
+effect	O
+of	O
+transport	O
+-	O
+related	O
+infection	B-DISO
+on	O
+disease	O
+spread	O
+,	O
+an	O
+SEIRS	O
+(	O
+Susceptible	O
+,	O
+Exposed	O
+,	O
+Infectious	B-DISO
+,	O
+Recovered	O
+)	O
+epidemic	O
+model	O
+for	O
+two	O
+cities	O
+is	O
+formulated	O
+and	O
+analyzed	O
+.	O
+
+If	O
+the	O
+basic	O
+reproduction	B-PROC
+number	O
+is	O
+below	O
+unity	O
+,	O
+the	O
+disease	O
+-	O
+free	O
+equilibrium	B-PROC
+is	O
+locally	O
+asymptotically	O
+stable	O
+.	O
+
+Bacterially	O
+expressed	B-PROC
+VP3	O
+-	O
+CTD	O
+exhibited	O
+2	O
+',	O
+5	B-PROC
+'-	I-PROC
+PDE	I-PROC
+activity	I-PROC
+,	O
+which	O
+cleaved	B-ANAT
+2	O
+-	O
+5A	O
+in	O
+vitro	O
+.	O
+
+Acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+secondary	O
+to	O
+obstructive	B-DISO
+uropathy	I-DISO
+is	O
+rare	O
+.	O
+
+Among	O
+the	O
+potential	O
+viral	O
+drug	O
+targets	O
+,	O
+coronavirus	B-SPEC
+3C	B-PRGE
+like	I-PRGE
+proteases	I-PRGE
+(	O
+3Cl	O
+)	O
+have	O
+emerged	O
+as	O
+the	O
+most	O
+popular	O
+drug	O
+target	O
+.	O
+
+Twelve	O
+percent	O
+of	O
+the	O
+positive	O
+samples	O
+were	O
+positive	O
+for	O
+multiple	O
+analytes	O
+,	O
+with	O
+Rhino	O
+/	O
+Entero	O
+and	O
+RSV	B-SPEC
+being	O
+the	O
+most	O
+common	O
+combination	O
+.	O
+
+hMPV	B-SPEC
+peaked	O
+2	O
+months	O
+after	O
+RSV	B-SPEC
+,	O
+as	O
+has	O
+been	O
+observed	O
+recently	O
+in	O
+other	O
+studies	O
+.	O
+
+No	O
+evidence	O
+indicated	O
+that	O
+'	O
+high	O
+'-	O
+dose	O
+PLV	O
+either	O
+reduced	O
+mortality	O
+at	O
+28	O
+d	O
+(	O
+risk	O
+ratio	O
+(	O
+RR	O
+)	O
+1	O
+.	O
+21	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+)	O
+0	O
+.	O
+79	O
+to	O
+1	O
+.	O
+85	O
+,	O
+P	O
+=	O
+0	O
+.	O
+37	O
+)	O
+or	O
+increased	O
+the	O
+number	O
+of	O
+days	O
+free	O
+of	O
+CMV	B-SPEC
+at	O
+28	O
+d	O
+(	O
+mean	O
+difference	O
+(	O
+MD	O
+)	O
+-	O
+2	O
+.	O
+24	O
+,	O
+95	O
+%	O
+CI	O
+-	O
+4	O
+.	O
+71	O
+to	O
+0	O
+.	O
+23	O
+,	O
+P	O
+=	O
+0	O
+.	O
+08	O
+).	O
+
+Pooled	O
+estimates	O
+of	O
+effect	O
+for	O
+the	O
+following	O
+adverse	O
+events	O
+-	O
+hypoxia	B-DISO
+,	O
+pneumothorax	B-DISO
+,	O
+hypotension	O
+and	O
+cardiac	B-DISO
+arrest	I-DISO
+-	O
+all	O
+showed	O
+a	O
+nonsignificant	O
+trend	O
+towards	O
+a	O
+higher	O
+occurrence	O
+of	O
+these	O
+events	O
+in	O
+those	O
+treated	O
+with	O
+PLV	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+rare	O
+complication	B-DISO
+with	O
+gemcitabine	B-CHED
+,	O
+but	O
+is	O
+sometimes	O
+fatal	O
+.	O
+
+We	O
+describe	O
+a	O
+cured	O
+case	O
+of	O
+acute	O
+,	O
+severe	O
+gemcitabine	B-CHED
+-	O
+induced	O
+pulmonary	B-DISO
+toxicity	I-DISO
+.	O
+
+There	O
+was	O
+no	O
+increase	O
+in	O
+β	O
+-	O
+D	O
+-	O
+glucan	B-CHED
+,	O
+and	O
+cytomegalovirus	B-SPEC
+antigenemia	O
+assays	O
+were	O
+negative	O
+.	O
+
+Considering	O
+these	O
+data	O
+,	O
+we	O
+diagnosed	O
+eosinophilic	O
+pneumonia	O
+induced	O
+by	O
+gemcitabine	B-CHED
+.	O
+
+Physicians	O
+should	O
+be	O
+cognizant	O
+of	O
+the	O
+possible	O
+association	O
+of	O
+serious	O
+pulmonary	B-DISO
+toxicity	I-DISO
+with	O
+gemcitabine	B-CHED
+treatment	O
+.	O
+
+Understanding	O
+global	O
+population	O
+movements	B-PROC
+out	O
+of	O
+the	O
+Middle	O
+East	O
+through	O
+the	O
+end	O
+of	O
+this	O
+year	O
+'	O
+s	O
+Hajj	O
+could	O
+help	O
+direct	O
+anticipatory	O
+MERS	O
+-	O
+CoV	O
+surveillance	O
+and	O
+public	O
+health	O
+preparedness	O
+to	O
+mitigate	O
+its	O
+potential	O
+global	O
+health	O
+and	O
+economic	O
+impacts	O
+.	O
+
+RESULTS	O
+:	O
+16	O
+.	O
+8	O
+million	O
+travelers	O
+flew	O
+on	O
+commercial	O
+flights	O
+out	O
+of	O
+Saudi	O
+Arabia	O
+,	O
+Jordan	O
+,	O
+Qatar	O
+,	O
+and	O
+the	O
+United	O
+Arab	O
+Emirates	O
+between	O
+June	O
+and	O
+November	O
+2012	O
+,	O
+of	O
+which	O
+51	O
+.	O
+6	O
+%	O
+were	O
+destined	O
+for	O
+India	O
+(	O
+16	O
+.	O
+3	O
+%),	O
+Egypt	O
+(	O
+10	O
+.	O
+4	O
+%),	O
+Pakistan	O
+(	O
+7	O
+.	O
+8	O
+%),	O
+the	O
+United	O
+Kingdom	B-SPEC
+(	O
+4	O
+.	O
+3	O
+%),	O
+Kuwait	O
+(	O
+3	O
+.	O
+6	O
+%),	O
+Bangladesh	O
+(	O
+3	O
+.	O
+1	O
+%),	O
+Iran	O
+(	O
+3	O
+.	O
+1	O
+%)	O
+and	O
+Bahrain	O
+(	O
+2	O
+.	O
+9	O
+%).	O
+
+A	O
+variety	O
+of	O
+infectious	B-DISO
+agents	O
+are	O
+implicated	O
+in	O
+calf	B-ANAT
+diarrhea	B-DISO
+and	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+of	O
+multiple	O
+pathogens	O
+is	O
+not	O
+uncommon	O
+in	O
+diarrheic	O
+calves	O
+.	O
+
+Samples	O
+were	O
+tested	O
+by	O
+a	O
+panel	O
+of	O
+multiplex	O
+PCR	O
+assays	O
+for	O
+11	O
+enteric	O
+pathogens	O
+:	O
+bovine	B-SPEC
+rotavirus	B-SPEC
+group	I-SPEC
+A	I-SPEC
+(	O
+BRV	B-DISO
+-	O
+A	O
+),	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+),	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+BVDV	B-SPEC
+),	O
+bovine	B-SPEC
+enterovirus	I-SPEC
+(	O
+BEV	B-SPEC
+),	O
+bovine	B-SPEC
+norovirus	B-SPEC
+(	O
+BNoV	O
+),	O
+Nebovirus	B-SPEC
+,	O
+bovine	B-PRGE
+torovirus	I-PRGE
+(	I-PRGE
+BToV	I-PRGE
+)	I-PRGE
+Salmonella	B-DISO
+spp	B-ENZY
+.	O
+
+TITLE	O
+:	O
+Single	O
+particle	O
+assay	O
+of	O
+coronavirus	B-SPEC
+membrane	B-PROC
+fusion	I-PROC
+with	O
+proteinaceous	O
+receptor	O
+-	O
+embedded	O
+supported	O
+bilayers	O
+.	O
+
+Here	O
+we	O
+describe	O
+a	O
+general	O
+method	O
+to	O
+integrate	O
+proteinaceous	O
+receptors	O
+and	O
+cellular	B-COMP
+components	O
+into	O
+supported	O
+bilayers	O
+for	O
+SPT	B-FUNC
+fusion	O
+studies	O
+.	O
+
+SPT	B-FUNC
+is	O
+then	O
+used	O
+to	O
+identify	O
+fusion	O
+intermediates	O
+and	O
+measure	O
+membrane	O
+fusion	O
+kinetics	O
+for	O
+FCoV	O
+.	O
+Overall	O
+,	O
+the	O
+fusion	O
+results	O
+recapitulate	O
+what	O
+is	O
+observed	O
+in	O
+vivo	O
+,	O
+that	O
+coronavirus	B-SPEC
+entry	O
+requires	O
+binding	B-FUNC
+to	O
+specific	O
+receptors	O
+,	O
+a	O
+low	O
+-	O
+pH	O
+environment	O
+,	O
+and	O
+that	O
+membrane	B-PROC
+fusion	I-PROC
+is	O
+receptor	O
+-	O
+and	O
+protease	O
+-	O
+dependent	O
+.	O
+
+Moreover	O
+,	O
+the	O
+platform	O
+offers	O
+versatile	O
+,	O
+precise	O
+control	O
+over	O
+the	O
+sequence	O
+of	O
+triggers	O
+for	O
+fusion	O
+;	O
+these	O
+triggers	O
+may	O
+define	O
+the	O
+fusion	O
+pathway	B-PROC
+,	O
+tissue	B-PROC
+tropism	B-PROC
+,	O
+and	O
+pathogenicity	O
+of	O
+coronaviruses	O
+.	O
+
+Systematically	O
+varying	O
+these	O
+triggers	O
+in	O
+this	O
+platform	O
+provides	O
+a	O
+new	O
+route	O
+to	O
+study	O
+how	O
+viruses	B-SPEC
+rapidly	O
+adapt	O
+to	O
+other	O
+hosts	B-COMP
+,	O
+and	O
+to	O
+identify	O
+factors	O
+that	O
+led	O
+to	O
+the	O
+emergence	O
+of	O
+zoonotic	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+human	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+the	O
+newly	O
+emerging	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+infections	O
+in	O
+Jordan	O
+,	O
+April	O
+2012	O
+:	O
+epidemiological	O
+findings	O
+from	O
+a	O
+retrospective	O
+investigation	O
+.	O
+
+This	O
+paper	O
+describes	O
+the	O
+epidemiological	O
+findings	O
+of	O
+retrospective	O
+investigation	O
+carried	O
+out	O
+in	O
+November	O
+2012	O
+and	O
+highlights	O
+the	O
+likelihood	O
+of	O
+nosocomial	O
+transmission	O
+of	O
+nCoV	O
+infection	B-DISO
+in	O
+a	O
+health	O
+-	O
+care	O
+setting	O
+.	O
+
+Additional	O
+recommendations	O
+were	O
+made	O
+to	O
+improve	O
+surveillance	O
+capacity	O
+by	O
+acquiring	O
+the	O
+capacity	O
+to	O
+test	O
+for	O
+the	O
+virus	B-SPEC
+and	O
+enhance	O
+syndromic	O
+surveillance	O
+.	O
+
+TITLE	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+:	O
+the	O
+challenge	O
+of	O
+communicating	O
+about	O
+a	O
+virus	B-SPEC
+which	O
+one	O
+knows	O
+little	O
+about	O
+.	O
+
+TITLE	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+infection	O
+in	O
+the	O
+eastern	O
+mediterranean	O
+region	O
+:	O
+time	O
+to	O
+act	O
+.	O
+
+Opportunistic	O
+airborne	O
+transmission	O
+may	O
+occur	O
+when	O
+conducting	B-PROC
+highrisk	O
+aerosol	O
+generating	O
+procedures	O
+and	O
+airborne	O
+precautions	O
+will	O
+be	O
+required	O
+in	O
+this	O
+setting	O
+.	O
+
+General	O
+infection	B-DISO
+control	O
+measures	O
+effective	O
+for	O
+all	O
+respiratory	O
+viral	B-PROC
+infections	I-PROC
+are	O
+reviewed	O
+and	O
+followed	O
+by	O
+discussion	O
+on	O
+some	O
+of	O
+the	O
+common	O
+viruses	B-SPEC
+,	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+and	O
+the	O
+recently	O
+discovered	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+Although	O
+,	O
+nCoV	O
+emerged	O
+prior	O
+to	O
+the	O
+2012	O
+Hajj	O
+pilgrimage	O
+season	O
+,	O
+Muslims	O
+completed	O
+their	O
+religious	O
+duty	O
+without	O
+acquiring	O
+infections	B-DISO
+by	O
+nCoV	O
+.	O
+Clearly	O
+,	O
+the	O
+global	O
+nature	O
+of	O
+mass	O
+gatherings	O
+and	O
+their	O
+potential	O
+risks	O
+to	O
+international	O
+health	O
+make	O
+it	O
+imperative	O
+that	O
+research	O
+on	O
+such	O
+events	O
+and	O
+guidelines	O
+produced	O
+for	O
+their	O
+management	O
+are	O
+relevant	O
+to	O
+diverse	O
+contexts	O
+and	O
+are	O
+a	O
+collaborative	O
+effort	O
+between	O
+global	O
+experts	O
+.	O
+
+A	O
+total	O
+of	O
+30	O
+cases	O
+,	O
+of	O
+whom	O
+18	O
+have	O
+died	B-PROC
+,	O
+and	O
+at	O
+least	O
+3	O
+clusters	B-CHED
+have	O
+been	O
+detected	O
+to	O
+date	O
+(	O
+1	O
+cluster	O
+among	O
+health	O
+-	O
+care	O
+workers	O
+and	O
+another	O
+2	O
+clusters	B-CHED
+among	O
+family	B-SPEC
+members	O
+).	O
+
+To	O
+assess	O
+pulmonary	B-ANAT
+co	O
+-	O
+morbidities	O
+,	O
+we	O
+used	O
+infant	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+through	O
+the	O
+raised	O
+volume	O
+rapid	O
+thoracoabdominal	O
+compression	O
+technique	O
+as	O
+both	O
+an	O
+established	O
+study	O
+of	O
+early	O
+cystic	B-DISO
+fibrosis	I-DISO
+and	O
+also	O
+as	O
+a	O
+newer	O
+study	O
+of	O
+mechanism	O
+for	O
+early	O
+sickle	B-ANAT
+cell	I-ANAT
+lung	B-DISO
+disease	I-DISO
+.	O
+
+Infant	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+data	O
+demonstrated	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+lower	O
+airways	B-DISO
+obstruction	I-DISO
+,	O
+moderate	O
+air	B-DISO
+trapping	I-DISO
+,	O
+and	O
+no	O
+evidence	O
+of	O
+restrictive	B-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+At	O
+72	O
+hours	O
+post	O
+inoculation	O
+,	O
+HCoV	O
+-	O
+HKU1	O
+infection	B-DISO
+of	O
+type	O
+II	O
+cells	B-COMP
+induced	O
+increased	O
+levels	O
+of	O
+mRNAs	B-PRGE
+encoding	I-PRGE
+IL29	I-PRGE
+,	O
+CXCL10	B-PRGE
+,	O
+CCL5	B-PRGE
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+with	O
+no	O
+significant	O
+increases	O
+in	O
+the	O
+levels	O
+of	O
+IFNβ	O
+.	O
+
+We	O
+show	O
+that	O
+HLH	B-DISO
+may	O
+present	O
+by	O
+masquerading	O
+as	O
+surgical	O
+disease	O
+or	O
+as	O
+a	O
+postoperative	B-DISO
+complication	I-DISO
+leading	O
+to	O
+delays	O
+in	O
+diagnosis	O
+and	O
+treatment	O
+.	O
+
+Four	O
+children	O
+with	O
+different	O
+clinical	O
+presentations	O
+(	O
+1	O
+.	O
+neonatal	O
+abdominal	B-ANAT
+distension	B-DISO
+,	O
+2	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+explanation	O
+for	O
+their	O
+symptoms	O
+and	O
+deteriorating	O
+clinical	O
+condition	B-DISO
+,	O
+a	O
+total	O
+of	O
+six	O
+'	O
+negative	O
+'	O
+exploratory	O
+laparotomies	O
+were	O
+performed	O
+.	O
+
+This	O
+diagnosis	O
+should	O
+be	O
+considered	O
+in	O
+children	O
+with	O
+unexplained	O
+prolonged	O
+fever	B-PROC
+,	O
+hepatosplenomegaly	B-DISO
+and	O
+pancytopenia	B-DISO
+,	O
+especially	O
+if	O
+associated	O
+with	O
+high	O
+ferritin	B-PRGE
+levels	O
+.	O
+
+Most	O
+relevant	O
+citations	O
+were	O
+peer	O
+-	O
+reviewed	O
+journal	O
+articles	O
+(	O
+29	O
+/	O
+32	O
+,	O
+91	O
+%)	O
+published	O
+in	O
+2010	O
+-	O
+11	O
+(	O
+28	O
+/	O
+32	O
+,	O
+88	O
+%)	O
+and	O
+reported	O
+use	O
+of	O
+a	O
+Google	O
+program	O
+for	O
+surveillance	O
+of	O
+influenza	B-DISO
+.	O
+
+Most	O
+authors	O
+(	O
+21	O
+/	O
+32	O
+articles	O
+,	O
+66	O
+%)	O
+reported	O
+that	O
+social	O
+media	B-ANAT
+-	O
+based	O
+surveillance	O
+had	O
+comparable	O
+performance	O
+when	O
+compared	O
+to	O
+an	O
+existing	O
+surveillance	O
+program	O
+.	O
+
+The	O
+importance	O
+of	O
+this	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+ability	O
+during	O
+infection	B-DISO
+is	O
+,	O
+however	O
+,	O
+quite	O
+different	O
+.	O
+
+An	O
+infection	B-DISO
+with	O
+a	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+was	O
+confirmed	O
+and	O
+found	O
+to	O
+be	O
+the	O
+reason	O
+for	O
+rapidly	O
+progressive	O
+respiratory	B-DISO
+failure	I-DISO
+of	O
+our	O
+patient	O
+.	O
+
+After	O
+challenge	O
+,	O
+neither	O
+mortality	O
+nor	O
+notable	O
+clinical	O
+signs	O
+of	O
+MD	O
+,	O
+ND	O
+,	O
+or	O
+IB	O
+were	O
+observed	O
+in	O
+the	O
+vaccinated	O
+birds	B-SPEC
+.	O
+
+The	O
+experimental	O
+bivalent	O
+MDV	O
+vaccine	O
+proved	O
+efficacious	O
+against	O
+lethal	O
+MDV	O
+challenge	O
+and	O
+did	O
+not	O
+affect	O
+the	O
+efficacy	O
+of	O
+the	O
+NDV	O
+or	O
+IBV	B-SPEC
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+severe	O
+postoperative	B-DISO
+complications	I-DISO
+after	O
+cardiac	B-ANAT
+surgery	O
+on	O
+mortality	O
+in	O
+patients	O
+aged	O
+over	O
+80	O
+years	O
+.	O
+
+Between	O
+January	O
+1998	O
+and	O
+December	O
+2007	O
+,	O
+649	O
+patients	O
+aged	O
+over	O
+80	O
+years	O
+received	O
+isolated	O
+first	O
+-	O
+time	O
+coronary	B-ANAT
+artery	I-ANAT
+bypass	O
+graft	B-ANAT
+(	O
+CABG	O
+),	O
+isolated	O
+aortic	B-ANAT
+valve	I-ANAT
+replacement	O
+(	O
+AVR	O
+)	O
+or	O
+a	O
+combination	O
+of	O
+both	O
+in	O
+our	O
+institute	O
+.	O
+
+A	O
+multivariate	O
+analysis	O
+revealed	O
+that	O
+advanced	O
+age	O
+(	O
+OR	O
+1	O
+.	O
+130	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+1	O
+.	O
+017	O
+-	O
+1	O
+.	O
+256	O
+,	O
+p	O
+=	O
+0	O
+.	O
+023	O
+),	O
+low	O
+output	O
+syndrome	O
+(	O
+OR	O
+5	O
+.	O
+094	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+1	O
+.	O
+1635	O
+-	O
+15	O
+.	O
+871	O
+,	O
+p	O
+=	O
+0	O
+.	O
+005	O
+),	O
+renal	B-DISO
+failure	I-DISO
+(	O
+OR	O
+8	O
+.	O
+128	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+3	O
+.	O
+347	O
+-	O
+19	O
+.	O
+742	O
+,	O
+p	O
+=	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+sepsis	B-DISO
+(	O
+OR	O
+4	O
+.	O
+975	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+1	O
+.	O
+420	O
+-	O
+17	O
+.	O
+426	O
+,	O
+p	O
+=	O
+0	O
+.	O
+012	O
+)	O
+as	O
+independent	O
+risk	O
+factors	O
+.	O
+
+A	O
+multivariate	O
+analysis	O
+revealed	O
+that	O
+advanced	O
+age	O
+(	O
+OR	O
+1	O
+.	O
+130	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+1	O
+.	O
+017	O
+-	O
+1	O
+.	O
+256	O
+,	O
+p	O
+=	O
+0	O
+.	O
+023	O
+),	O
+low	O
+output	O
+syndrome	B-DISO
+(	O
+OR	O
+5	O
+.	O
+094	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+1	O
+.	O
+1635	O
+-	O
+15	O
+.	O
+871	O
+,	O
+p	O
+=	O
+0	O
+.	O
+005	O
+),	O
+renal	B-DISO
+failure	I-DISO
+(	O
+OR	O
+8	O
+.	O
+128	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+3	O
+.	O
+347	O
+-	O
+19	O
+.	O
+742	O
+,	O
+p	O
+=	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+sepsis	B-DISO
+(	O
+OR	O
+4	O
+.	O
+975	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+1	O
+.	O
+420	O
+-	O
+17	O
+.	O
+426	O
+,	O
+p	O
+=	O
+0	O
+.	O
+012	O
+)	O
+as	O
+independent	O
+risk	O
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+serious	O
+complication	B-DISO
+of	O
+sepsis	B-DISO
+,	O
+and	O
+sepsis	B-DISO
+-	O
+associated	O
+ARDS	B-DISO
+is	O
+associated	O
+with	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Elevated	O
+serum	B-COMP
+lactate	B-CHED
+levels	O
+in	O
+the	O
+ED	O
+and	O
+a	O
+recently	O
+validated	O
+clinical	O
+prediction	O
+score	O
+were	O
+independently	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+in	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+hepatic	O
+CD69	O
++	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cells	B-COMP
+in	O
+virus	B-SPEC
+-	O
+induced	O
+severe	O
+liver	B-ANAT
+injury	O
+and	O
+subsequent	O
+hepatic	B-DISO
+failure	I-DISO
+is	O
+not	O
+well	O
+defined	O
+.	O
+
+The	O
+correlation	O
+between	O
+the	O
+CD69	B-PRGE
+level	O
+in	O
+hepatic	B-ANAT
+NK	B-ANAT
+cells	I-ANAT
+and	O
+liver	B-ANAT
+injury	O
+was	O
+studied	O
+.	O
+
+Meanwhile	O
+,	O
+the	O
+CD69	B-PRGE
+expression	B-PROC
+in	O
+hepatic	B-ANAT
+NK	B-ANAT
+cells	I-ANAT
+was	O
+highly	O
+correlated	O
+with	O
+the	O
+serum	B-COMP
+level	O
+of	O
+ALT	B-FUNC
+and	O
+AST	B-PRGE
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+NKG2A	B-PRGE
+expression	B-PROC
+was	O
+increased	O
+in	O
+hepatic	B-ANAT
+CD69	O
+-	O
+NK	B-ANAT
+cells	I-ANAT
+but	O
+not	O
+in	O
+CD69	B-ANAT
++	I-ANAT
+NK	I-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+-	O
+specific	O
+phage	O
+displayed	O
+antigen	B-CHED
+library	O
+was	O
+biopanned	O
+and	O
+screened	O
+against	O
+two	O
+anti	O
+-	O
+S	O
+mAbs	O
+,	O
+S	O
+-	O
+M1	O
+and	O
+S	O
+-	O
+M2	O
+.	O
+
+TITLE	O
+:	O
+Anti	O
+-	O
+SARS	B-DISO
+coronavirus	B-SPEC
+agents	O
+:	O
+a	O
+patent	O
+review	O
+(	O
+2008	O
+-	O
+present	O
+).	O
+
+TITLE	O
+:	O
+The	O
+ORF4a	B-PRGE
+protein	I-PRGE
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+functions	O
+as	O
+a	O
+viroporin	O
+that	O
+regulates	O
+viral	O
+production	O
+.	O
+
+The	O
+ORF4a	O
+proteins	B-CHED
+formed	O
+homo	B-SPEC
+-	O
+oligomers	O
+through	O
+disulfide	B-CHED
+bridges	O
+and	O
+possessed	B-DISO
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+in	O
+both	O
+Xenopus	B-SPEC
+oocytes	B-ANAT
+and	O
+yeast	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+viral	O
+production	O
+decreased	O
+when	O
+the	O
+ORF4a	O
+protein	B-PROC
+expression	B-PROC
+was	O
+suppressed	O
+by	O
+siRNA	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+Collectively	O
+,	O
+this	O
+evidence	O
+indicates	O
+that	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+ORF4a	I-PRGE
+protein	B-CHED
+is	O
+functionally	O
+analogous	O
+to	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3a	I-PRGE
+protein	B-CHED
+,	O
+which	O
+also	O
+acts	O
+as	O
+a	O
+viroporin	O
+that	O
+regulates	O
+virus	B-SPEC
+production	O
+.	O
+
+TITLE	O
+:	O
+The	O
+PRESERVE	O
+mortality	O
+risk	O
+score	O
+and	O
+analysis	O
+of	O
+long	O
+-	O
+term	O
+outcomes	O
+after	O
+extracorporeal	O
+membrane	B-ANAT
+oxygenation	B-PROC
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Based	O
+on	O
+multivariable	O
+logistic	O
+regression	O
+analysis	O
+,	O
+the	O
+PRESERVE	O
+(	O
+PRedicting	O
+dEath	B-PROC
+for	O
+SEvere	O
+ARDS	B-DISO
+on	O
+VV	O
+-	O
+ECMO	O
+)	O
+score	O
+(	O
+0	O
+-	O
+14	O
+points	O
+)	O
+was	O
+constructed	O
+with	O
+eight	O
+pre	O
+-	O
+ECMO	O
+parameters	O
+,	O
+i	O
+.	O
+e	O
+.	O
+age	O
+,	O
+body	B-ANAT
+mass	O
+index	O
+,	O
+immunocompromised	O
+status	O
+,	O
+prone	O
+positioning	O
+,	O
+days	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+sepsis	B-DISO
+-	O
+related	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+,	O
+plateau	O
+pressure	O
+andpositive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+.	O
+
+The	O
+PRESERVE	O
+score	O
+might	O
+help	O
+ICU	O
+physicians	O
+select	O
+appropriate	O
+candidates	O
+for	O
+ECMO	O
+among	O
+severe	O
+ARDS	B-DISO
+patients	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+2144	O
+surveillance	O
+samples	O
+tested	O
+,	O
+1235	O
+(	O
+57	O
+.	O
+6	O
+%)	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+virus	B-SPEC
+.	O
+
+Cytologically	O
+assessed	O
+plasma	B-ANAT
+cell	I-ANAT
+number	O
+was	O
+correlated	O
+with	O
+keratic	O
+precipitates	O
+and	O
+disease	O
+duration	O
+.	O
+
+Aqueous	B-DISO
+humor	I-DISO
+cytology	O
+permitted	O
+diagnosis	O
+of	O
+neoplasia	B-DISO
+in	O
+dogs	B-SPEC
+with	O
+anterior	B-DISO
+uveitis	I-DISO
+but	O
+was	O
+generally	O
+not	O
+helpful	O
+in	O
+cats	B-SPEC
+.	O
+
+Poor	O
+correlation	O
+between	O
+clinical	O
+and	O
+cytologic	O
+assessment	O
+of	O
+cell	B-COMP
+numbers	O
+and	O
+type	O
+within	O
+the	O
+anterior	B-ANAT
+chamber	I-ANAT
+dictates	O
+that	O
+clinical	O
+grading	O
+should	O
+not	O
+be	O
+the	O
+sole	B-ANAT
+criterion	O
+for	O
+electing	O
+to	O
+perform	O
+aqueocentesis	O
+.	O
+
+RESULTS	O
+:	O
+Disease	O
+duration	O
+prior	O
+to	O
+aqueocentesis	O
+was	O
+not	O
+significantly	O
+different	O
+between	O
+dogs	B-SPEC
+with	O
+idiopathic	B-DISO
+anterior	I-DISO
+uveitis	I-DISO
+and	O
+those	O
+with	O
+an	O
+etiologic	O
+diagnosis	O
+,	O
+but	O
+was	O
+shorter	O
+in	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+than	O
+those	O
+with	O
+idiopathic	O
+uveitis	B-DISO
+.	O
+
+Thus	O
+whether	O
+aPC	B-COMP
+will	O
+continue	O
+to	O
+be	O
+used	O
+to	O
+modulate	O
+the	O
+acute	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+in	O
+humans	B-SPEC
+remains	O
+uncertain	O
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+of	O
+conventional	O
+mice	B-SPEC
+with	O
+a	O
+mouse	B-SPEC
+adapted	O
+(	O
+MA15	O
+)	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+reproduces	O
+many	O
+aspects	O
+of	O
+human	B-SPEC
+SARS	B-DISO
+such	O
+as	O
+pathological	O
+changes	O
+in	O
+lung	B-ANAT
+,	O
+viremia	B-DISO
+,	O
+neutrophilia	O
+,	O
+and	O
+lethality	O
+.	O
+
+No	O
+hospital	O
+or	O
+other	O
+social	O
+contacts	O
+are	O
+known	O
+to	O
+have	O
+acquired	O
+the	O
+infection	B-DISO
+.	O
+
+It	O
+appears	O
+that	O
+the	O
+index	O
+patient	O
+in	O
+this	O
+cluster	O
+acquired	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+whilst	O
+in	O
+hospital	O
+from	O
+an	O
+unrecognized	O
+mild	O
+or	O
+asymptomatic	O
+case	O
+.	O
+
+It	O
+appears	O
+that	O
+the	O
+index	O
+patient	O
+in	O
+this	O
+cluster	O
+acquired	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+whilst	O
+in	O
+hospital	O
+from	O
+an	O
+unrecognized	O
+mild	O
+or	O
+asymptomatic	O
+case	O
+.	O
+
+This	O
+is	O
+an	O
+open	O
+,	O
+controlled	O
+,	O
+non	O
+-	O
+randomized	O
+interventional	O
+study	O
+of	O
+ten	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+increasing	O
+levels	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+systematically	O
+increased	O
+strain	O
+along	O
+the	O
+sternovertebral	O
+axis	B-SPEC
+.	O
+
+The	O
+pathogenesis	B-DISO
+and	O
+potential	O
+threat	O
+of	O
+bat	B-ENZY
+-	O
+borne	O
+viruses	B-SPEC
+to	O
+public	O
+health	O
+remains	O
+largely	O
+unknown	O
+.	O
+
+Some	O
+of	O
+these	O
+viruses	B-SPEC
+have	O
+the	O
+potential	O
+for	O
+rapid	O
+and	O
+global	O
+spread	O
+with	O
+high	O
+morbidity	O
+and	O
+mortality	O
+,	O
+such	O
+as	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+outbreak	O
+.	O
+
+Femoral	B-ANAT
+venous	B-ANAT
+blood	I-ANAT
+and	O
+urine	B-ANAT
+had	O
+MDPV	O
+concentrations	O
+of	O
+39	O
+ng	O
+/	O
+mL	O
+and	O
+760	O
+ng	O
+/	O
+mL	O
+.	O
+The	O
+second	O
+fatality	O
+was	O
+a	O
+White	O
+man	B-CHED
+with	O
+a	O
+history	O
+of	O
+drug	O
+and	O
+bath	O
+salt	B-CHED
+abuse	B-DISO
+found	O
+dead	B-PROC
+at	O
+a	O
+scene	O
+in	O
+total	O
+disarray	O
+after	O
+exhibiting	O
+fits	B-DISO
+of	O
+anger	O
+and	O
+psychotic	B-DISO
+behavior	I-DISO
+.	O
+
+This	O
+unbiased	O
+approach	O
+produced	O
+a	O
+high	O
+-	O
+priority	O
+list	O
+of	O
+4	O
+genes	O
+in	O
+one	O
+pathway	B-PROC
+out	O
+of	O
+over	O
+3	O
+,	O
+500	O
+genes	O
+that	O
+were	O
+differentially	O
+expressed	B-PROC
+following	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+incidence	O
+and	O
+clinical	O
+impact	O
+of	O
+coronavirus	O
+(	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+elderly	O
+persons	O
+and	O
+those	O
+with	O
+underlying	O
+cardiopulmonary	B-DISO
+disease	I-DISO
+over	O
+a	O
+long	O
+duration	O
+is	O
+not	O
+well	O
+described	O
+.	O
+
+We	O
+determined	O
+the	O
+incidence	O
+and	O
+clinical	O
+impact	O
+of	O
+229E	O
+and	O
+OC43	O
+CoV	O
+in	O
+this	O
+population	O
+during	O
+4	O
+consecutive	O
+winters	O
+,	O
+and	O
+compared	O
+illnesses	O
+to	O
+influenza	B-PATH
+A	I-PATH
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Regulation	B-PROC
+of	O
+coronaviral	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+length	O
+during	O
+infection	B-DISO
+.	O
+
+Surprisingly	O
+,	O
+this	O
+length	O
+was	O
+found	O
+to	O
+vary	O
+throughout	O
+infection	B-DISO
+from	O
+~	O
+45	O
+nt	O
+immediately	O
+after	O
+virus	B-SPEC
+entry	O
+(	O
+at	O
+0	O
+to	O
+4	O
+hpi	B-DISO
+)	O
+to	O
+~	O
+65	O
+nt	O
+later	O
+on	O
+(	O
+at	O
+6	O
+h	O
+to	O
+9	O
+hpi	B-DISO
+)	O
+and	O
+from	O
+~	O
+65	O
+nt	O
+(	O
+at	O
+6	O
+h	O
+to	O
+9	O
+hpi	B-DISO
+)	O
+to	O
+~	O
+30	O
+nt	O
+(	O
+at	O
+120	O
+-	O
+144	O
+hpi	B-DISO
+).	O
+
+TITLE	O
+:	O
+Removing	O
+extra	O
+CO	O
+ABSTRACT	O
+:	O
+For	O
+patients	O
+experiencing	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+due	O
+to	O
+a	O
+severe	O
+exacerbation	O
+of	O
+chronic	O
+obstructive	O
+pulmonary	O
+disease	O
+(	O
+COPD	B-DISO
+),	O
+noninvasive	O
+positive	O
+pressure	O
+ventilation	O
+has	O
+been	O
+shown	O
+to	O
+significantly	O
+reduce	O
+mortality	O
+and	O
+hospital	O
+length	O
+of	O
+stay	O
+compared	O
+to	O
+respiratory	O
+support	O
+with	O
+invasive	O
+mechanical	O
+ventilation	O
+.	O
+
+RESULTS	O
+:	O
+By	O
+HA	O
+-	O
+RBS	B-DISO
+direct	O
+sequencing	O
+of	O
+respiratory	O
+specimens	O
+,	O
+D222G	O
+and	O
+D222N	O
+viral	O
+variants	O
+were	O
+identified	O
+in	O
+a	O
+higher	O
+proportion	O
+in	O
+ICU	O
+patients	O
+(	O
+n	O
+=	O
+8	O
+/	O
+24	O
+,	O
+33	O
+·	O
+3	O
+%)	O
+than	O
+in	O
+patients	O
+with	O
+mild	O
+disease	O
+(	O
+n	O
+=	O
+2	O
+/	O
+34	O
+,	O
+6	O
+%)	O
+or	O
+in	O
+outpatients	O
+(	O
+n	O
+=	O
+0	O
+/	O
+44	O
+)	O
+(	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+P	O
+<	O
+0	O
+·	O
+0001	O
+;	O
+OR	O
+38	O
+·	O
+5	O
+;	O
+CI	O
+95	O
+%	O
+4	O
+·	O
+494	O
+-	O
+329	O
+·	O
+9	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Viral	O
+etiology	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+among	O
+pediatric	O
+inpatients	O
+and	O
+outpatients	O
+from	O
+2010	O
+to	O
+2012	O
+in	O
+Beijing	O
+,	O
+China	O
+].	O
+
+One	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+or	O
+throat	B-ANAT
+swab	I-ANAT
+specimen	O
+was	O
+collected	O
+from	O
+each	O
+patient	O
+.	O
+
+Here	O
+we	O
+describe	O
+an	O
+alternative	O
+approach	O
+that	O
+involves	O
+no	O
+T	B-ANAT
+cell	I-ANAT
+stimulation	O
+or	O
+propagation	O
+in	O
+vitro	O
+.	O
+
+After	O
+demonstrating	O
+that	O
+these	O
+cells	B-COMP
+were	O
+functional	O
+and	O
+responded	O
+to	O
+epitope	B-CHED
+M133	O
+,	O
+these	O
+TCR	B-PRGE
+chains	I-PRGE
+were	O
+used	O
+to	O
+generate	O
+an	O
+epitope	B-CHED
+M133	O
+-	O
+specific	O
+TCR	B-PRGE
+Tg	I-PRGE
+mouse	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+neutralising	O
+serum	B-COMP
+antibodies	B-COMP
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+:	O
+a	O
+comparative	O
+serological	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+article	O
+presents	O
+a	O
+case	O
+study	O
+demonstrating	O
+various	O
+rescue	O
+therapies	O
+considered	O
+in	O
+the	O
+care	O
+of	O
+a	O
+patient	O
+with	O
+severe	O
+,	O
+refractory	O
+hypoxemia	O
+secondary	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+lessons	O
+learned	B-PROC
+from	O
+the	O
+pandemic	O
+outbreaks	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+H1N1	O
+capture	O
+key	O
+principles	O
+of	O
+virally	O
+mediated	O
+ALI	O
+.	O
+
+There	O
+are	O
+pathogen	O
+-	O
+specific	O
+pathways	B-PROC
+underlying	O
+virally	O
+mediated	O
+ALI	O
+that	O
+converge	O
+onto	O
+a	O
+common	O
+end	O
+pathway	B-PROC
+resulting	O
+in	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+.	O
+
+Our	O
+results	O
+demonstrate	O
+the	O
+utility	O
+of	O
+integrating	O
+diverse	O
+'	O
+omic	O
+datasets	O
+to	O
+predict	O
+and	O
+prioritize	O
+regulatory	O
+features	O
+conserved	O
+across	O
+multiple	O
+pathogen	O
+infection	B-DISO
+models	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+severe	O
+economic	O
+losses	O
+in	O
+the	O
+swine	B-SPEC
+industry	O
+in	O
+China	O
+and	O
+other	O
+Asian	O
+countries	O
+.	O
+
+The	O
+new	O
+PEDV	B-SPEC
+reverse	O
+genetics	O
+system	O
+will	O
+enable	O
+functional	O
+studies	O
+of	O
+the	O
+structural	O
+proteins	B-CHED
+and	O
+the	O
+accessory	B-PRGE
+ORF3	I-PRGE
+protein	I-PRGE
+and	O
+will	O
+allow	O
+the	O
+rational	O
+design	O
+and	O
+development	B-PROC
+of	O
+next	O
+generation	O
+PEDV	B-SPEC
+vaccines	O
+.	O
+
+In	O
+two	O
+recent	O
+papers	O
+,	O
+one	O
+published	O
+in	O
+Cell	B-COMP
+Research	O
+,	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+viral	B-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+domain	I-PRGE
+in	O
+complex	O
+with	O
+the	O
+host	B-COMP
+CD26	B-PRGE
+/	I-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+receptor	I-PRGE
+has	O
+now	O
+been	O
+characterized	O
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+-	O
+B	O
+associated	O
+rhabdomyolysis	B-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+nsp3	B-PRGE
+has	O
+membrane	B-COMP
+disordering	O
+and	O
+proliferation	B-DISO
+ability	O
+,	O
+both	O
+in	O
+its	O
+full	O
+-	O
+length	O
+form	O
+and	O
+in	O
+a	O
+C	O
+-	O
+terminal	O
+-	O
+truncated	O
+form	O
+.	O
+
+Systems	O
+biology	O
+provides	O
+an	O
+opportunity	O
+to	O
+explore	O
+and	O
+understand	O
+these	O
+multifaceted	O
+interactions	O
+based	O
+on	O
+integration	B-PROC
+and	O
+modeling	O
+of	O
+multiple	O
+biological	O
+parameters	O
+.	O
+
+Symptomatic	O
+treatment	O
+with	O
+protective	O
+ventilation	O
+,	O
+vasopressors	O
+,	O
+continuous	O
+heparin	B-CHED
+and	O
+insulin	B-PRGE
+was	O
+continued	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+shows	O
+that	O
+AKI	B-PRGE
+in	O
+scrub	B-DISO
+typhus	I-DISO
+is	O
+common	O
+and	O
+a	O
+severe	O
+disease	O
+.	O
+
+We	O
+performed	O
+a	O
+structured	O
+search	O
+on	O
+Pubmed	O
+,	O
+EMBASE	O
+,	O
+Lilacs	B-SPEC
+,	O
+and	O
+the	O
+Cochrane	O
+Library	O
+for	O
+randomized	O
+controlled	O
+trials	O
+and	O
+observational	O
+case	O
+-	O
+control	O
+studies	O
+with	O
+severity	O
+-	O
+paired	O
+patients	O
+,	O
+evaluating	O
+the	O
+use	O
+of	O
+ECMO	O
+on	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+adult	O
+patients	O
+.	O
+
+To	O
+increase	O
+our	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+disease	O
+caused	O
+by	O
+this	O
+virus	B-SPEC
+,	O
+we	O
+investigated	O
+the	O
+response	O
+of	O
+chickens	B-SPEC
+to	O
+2	O
+IBV	B-SPEC
+with	O
+different	O
+genotypes	O
+,	O
+KIIa	O
+and	O
+ChVI	O
+.	O
+
+In	O
+chickens	B-SPEC
+infected	O
+with	O
+this	O
+isolate	O
+,	O
+simultaneous	O
+peaks	O
+in	O
+the	O
+viral	O
+copy	O
+number	O
+and	O
+cytokine	B-PROC
+production	I-PROC
+were	O
+observed	O
+at	O
+7	O
+dpi	O
+in	O
+the	O
+trachea	B-DISO
+and	O
+9	O
+d	O
+postinoculation	O
+in	O
+the	O
+kidney	B-ANAT
+.	O
+
+It	O
+is	O
+now	O
+clear	O
+that	O
+MERS	O
+-	O
+CoV	O
+is	O
+transmissible	O
+from	O
+person	O
+to	O
+person	O
+,	O
+and	O
+its	O
+close	O
+relationship	O
+with	O
+several	O
+bat	B-ENZY
+coronaviruses	O
+suggests	O
+that	O
+these	O
+animals	B-SPEC
+may	O
+be	O
+the	O
+ultimate	O
+source	O
+of	O
+the	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+of	O
+feline	B-SPEC
+intestinal	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+cultures	O
+for	O
+the	O
+propagation	O
+and	O
+study	O
+of	O
+feline	O
+enteric	O
+coronaviruses	O
+.	O
+
+No	O
+infection	B-DISO
+was	O
+seen	O
+in	O
+cultures	O
+inoculated	O
+with	O
+FIPV	O
+tissue	B-ANAT
+homogenates	O
+.	O
+
+One	O
+of	O
+these	O
+RNA	O
+motifs	O
+was	O
+the	O
+stem	B-ANAT
+-	O
+loop	O
+SL5	O
+,	O
+a	O
+highly	O
+conserved	O
+motif	O
+in	O
+coronaviruses	O
+located	O
+at	O
+nucleotide	B-CHED
+positions	O
+106	O
+to	O
+136	O
+.	O
+
+Using	O
+TGEV	B-SPEC
+-	O
+derived	O
+defective	O
+minigenomes	O
+replicated	O
+in	O
+trans	O
+by	O
+a	O
+helper	O
+virus	B-SPEC
+,	O
+we	O
+have	O
+shown	O
+that	O
+TGEV	B-SPEC
+RNA	O
+packaging	O
+is	O
+a	O
+replication	O
+-	O
+independent	O
+process	O
+.	O
+
+The	O
+identification	O
+of	O
+well	O
+-	O
+defined	O
+RNA	O
+motifs	O
+within	O
+the	O
+TGEV	B-SPEC
+RNA	O
+genome	O
+that	O
+are	O
+essential	O
+for	O
+packaging	O
+will	O
+be	O
+useful	O
+for	O
+designing	O
+packaging	O
+-	O
+deficient	O
+biosafe	O
+coronavirus	B-SPEC
+-	O
+derived	O
+vectors	O
+and	O
+providing	O
+new	O
+targets	O
+for	O
+antiviral	B-CHED
+therapies	O
+.	O
+
+The	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+epidemic	O
+in	O
+2002	O
+-	O
+2003	O
+,	O
+and	O
+the	O
+recent	O
+emergence	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+April	O
+2012	O
+,	O
+emphasize	O
+the	O
+high	O
+probability	O
+of	O
+future	O
+zoonotic	O
+HCoV	O
+emergence	O
+causing	O
+severe	O
+and	O
+lethal	O
+human	B-SPEC
+disease	O
+.	O
+
+Together	O
+our	O
+results	O
+constitute	O
+direct	O
+evidence	O
+that	O
+CoV	O
+ExoN	O
+activity	O
+provides	O
+a	O
+critical	O
+proofreading	O
+function	O
+during	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+These	O
+toxins	B-CHED
+are	O
+able	O
+to	O
+impair	O
+endothelial	B-ANAT
+barrier	O
+function	O
+,	O
+either	O
+directly	O
+,	O
+or	O
+indirectly	O
+,	O
+by	O
+induction	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+mediators	O
+and	O
+neutrophil	B-ANAT
+sequestration	O
+.	O
+
+In	O
+this	O
+paper	O
+we	O
+present	O
+for	O
+the	O
+first	O
+time	O
+a	O
+case	O
+of	O
+von	B-DISO
+Hippel	I-DISO
+-	I-DISO
+Lindau	I-DISO
+disease	I-DISO
+associated	O
+with	O
+acute	B-PATH
+myeloid	I-PATH
+leukemia	I-PATH
+.	O
+
+It	O
+seems	O
+likely	O
+that	O
+development	B-PROC
+of	O
+acute	B-PATH
+myeloid	I-PATH
+leukemia	I-PATH
+in	O
+patient	O
+with	O
+VHL	B-DISO
+disease	O
+can	O
+be	O
+related	O
+to	O
+epigenetic	O
+alterations	O
+of	O
+the	O
+VHL	B-PRGE
+gene	I-PRGE
+,	O
+but	O
+further	O
+studies	O
+are	O
+needed	O
+.	O
+
+All	O
+used	O
+vaccines	O
+induced	O
+the	O
+rise	O
+of	O
+IgY	O
+antibody	B-COMP
+in	O
+egg	B-ANAT
+yolks	O
+.	O
+
+Immunization	O
+with	O
+C	O
+vaccine	O
+allowed	O
+to	O
+harvest	O
+eggs	O
+with	O
+satisfactory	O
+levels	O
+of	O
+E	O
+.	O
+coli	O
+,	O
+rotavirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+IgY	O
+antibodies	B-COMP
+which	O
+may	O
+be	O
+used	O
+to	O
+evaluate	O
+their	O
+protective	O
+effect	O
+by	O
+oral	B-ANAT
+administration	O
+in	O
+calves	O
+.	O
+
+Here	O
+,	O
+we	O
+simulate	O
+epidemic	O
+spread	O
+through	O
+various	O
+contact	O
+networks	O
+and	O
+fit	B-DISO
+spatial	O
+-	O
+based	O
+models	O
+in	O
+a	O
+Bayesian	O
+framework	O
+using	O
+Markov	O
+chain	O
+Monte	O
+Carlo	O
+methods	O
+.	O
+
+These	O
+spatial	O
+models	O
+are	O
+individual	O
+-	O
+level	O
+models	O
+which	O
+account	O
+for	O
+the	O
+spatio	O
+-	O
+temporal	O
+dynamics	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+Since	O
+then	O
+,	O
+researchers	O
+around	O
+the	O
+world	O
+,	O
+especially	O
+those	O
+in	O
+Asia	O
+where	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+first	O
+identified	O
+,	O
+have	O
+turned	O
+their	O
+focus	O
+to	O
+find	O
+novel	O
+coronaviruses	O
+infecting	O
+humans	B-SPEC
+,	O
+bats	B-SPEC
+,	O
+and	O
+other	O
+animals	B-SPEC
+.	O
+
+In	O
+2012	O
+,	O
+a	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+now	O
+called	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+has	O
+emerged	O
+in	O
+the	O
+Middle	O
+East	O
+to	O
+cause	O
+fatal	O
+human	B-SPEC
+infections	B-DISO
+in	O
+three	O
+continents	O
+.	O
+
+While	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+are	O
+genetically	O
+closely	O
+related	O
+to	O
+bat	B-ENZY
+coronaviruses	O
+,	O
+intermediate	O
+host	B-COMP
+(	O
+s	O
+)	O
+is	O
+(	O
+are	O
+)	O
+likely	O
+to	O
+be	O
+involved	O
+in	O
+the	O
+emergence	O
+and	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+of	O
+these	O
+novel	O
+human	B-SPEC
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+decade	O
+ago	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+caused	O
+a	O
+global	O
+pandemic	O
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+10	O
+%.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+coronavirus	B-SPEC
+is	O
+causing	O
+alarm	O
+among	O
+researchers	O
+and	O
+international	O
+health	O
+officials	O
+.	O
+
+Our	O
+results	O
+demonstrated	O
+that	O
+the	O
+generated	O
+MERS	O
+-	O
+CoV	O
+pseudovirus	O
+allows	O
+for	O
+single	O
+-	O
+cycle	O
+infection	B-DISO
+of	O
+a	O
+variety	O
+of	O
+cells	B-COMP
+expressing	O
+dipeptidyl	O
+peptidase	O
+-	O
+4	O
+(	O
+DPP4	B-PRGE
+),	O
+the	O
+confirmed	O
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+Consistent	O
+with	O
+the	O
+results	O
+from	O
+a	O
+live	O
+MERS	O
+-	O
+CoV	O
+-	O
+based	O
+inhibition	B-PROC
+assay	O
+,	O
+the	O
+antisera	O
+of	O
+mice	B-SPEC
+vaccinated	O
+with	O
+a	O
+recombinant	O
+protein	B-CHED
+containing	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+,	O
+residues	O
+377	O
+-	O
+662	O
+)	O
+of	O
+MERS	O
+-	O
+CoV	O
+S	O
+fused	O
+with	O
+Fc	O
+of	O
+human	B-SPEC
+IgG	B-PRGE
+exhibited	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+against	O
+infection	B-DISO
+of	O
+MERS	O
+-	O
+CoV	O
+pseudovirus	O
+.	O
+
+With	O
+the	O
+rapid	O
+advancement	O
+in	O
+the	O
+field	O
+of	O
+microglia	B-ANAT
+and	O
+astrocytic	B-ANAT
+neurobiology	O
+,	O
+the	O
+term	O
+neuroinflammation	O
+progressively	O
+started	O
+to	O
+denote	O
+chronic	O
+CNS	B-CHED
+cell	B-COMP
+-	O
+specific	O
+inflammation	B-DISO
+in	O
+MS	O
+.	O
+
+Median	O
+duration	O
+of	O
+MCS	B-COMP
+was	O
+4	O
+days	O
+(	O
+0	O
+-	O
+18	O
+days	O
+),	O
+12	O
+patients	O
+(	O
+75	O
+%)	O
+were	O
+weaned	B-PROC
+successfully	O
+from	O
+MCS	B-COMP
+,	O
+4	O
+of	O
+these	O
+children	O
+(	O
+25	O
+%)	O
+died	B-PROC
+after	O
+weaning	B-PROC
+,	O
+with	O
+a	O
+median	O
+survival	O
+time	O
+of	O
+15	O
+days	O
+(	O
+6	O
+-	O
+28	O
+days	O
+).	O
+
+Mean	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+before	O
+MCS	B-COMP
+was	O
+700	O
+(±	O
+384	O
+)	O
+U	O
+/	O
+l	O
+,	O
+and	O
+increased	O
+to	O
+a	O
+maximum	O
+of	O
+2279	O
+(±	O
+2635	O
+)	O
+U	O
+/	O
+l	O
+during	O
+MCS	B-COMP
+(	O
+P	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+The	O
+increase	O
+in	O
+plasma	B-ANAT
+-	O
+free	O
+haemoglobin	B-CHED
+correlated	O
+moderately	O
+with	O
+the	O
+duration	O
+of	O
+MCS	B-COMP
+(	O
+Pearson	O
+'	O
+s	O
+r	O
+:	O
+0	O
+.	O
+78	O
+).	O
+
+The	O
+increase	O
+in	O
+plasma	B-ANAT
+-	O
+free	O
+haemoglobin	B-CHED
+correlated	O
+moderately	O
+with	O
+the	O
+duration	O
+of	O
+MCS	B-COMP
+(	O
+Pearson	O
+'	O
+s	O
+r	O
+:	O
+0	O
+.	O
+78	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+occurrence	O
+of	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+traumatic	O
+brain	B-ANAT
+injury	O
+is	O
+not	O
+uncommon	O
+and	O
+is	O
+associated	O
+with	O
+an	O
+extremely	O
+high	O
+incidence	O
+of	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Data	O
+on	O
+severe	O
+forms	O
+of	O
+measles	B-PATH
+in	O
+adults	O
+are	O
+lacking	O
+.	O
+
+We	O
+performed	O
+a	O
+retrospective	O
+analysis	O
+of	O
+a	O
+cohort	O
+of	O
+36	O
+adults	O
+admitted	O
+to	O
+a	O
+total	O
+of	O
+64	O
+ICUs	O
+throughout	O
+France	O
+for	O
+complications	B-DISO
+of	I-DISO
+measles	I-DISO
+from	O
+January	O
+1	O
+,	O
+2009	O
+,	O
+to	O
+December	O
+31	O
+,	O
+2011	O
+.	O
+
+Among	O
+the	O
+26	O
+patients	O
+whose	O
+measles	B-PATH
+vaccination	O
+status	O
+was	O
+documented	O
+,	O
+none	O
+had	O
+received	O
+2	O
+injections	O
+.	O
+
+Of	O
+11	O
+patients	O
+who	O
+required	O
+mechanical	O
+ventilation	O
+,	O
+9	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Although	O
+GBS	B-DISO
+patients	O
+were	O
+historically	O
+cared	O
+for	O
+at	O
+tertiary	O
+referral	O
+centers	O
+,	O
+changing	O
+treatment	O
+practices	O
+have	O
+broadened	O
+the	O
+number	O
+of	O
+neurologists	O
+who	O
+care	O
+for	O
+the	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Positioning	O
+therapy	O
+may	O
+improve	O
+lung	B-ANAT
+recruitment	B-DISO
+and	O
+oxygenation	B-PROC
+and	O
+is	O
+part	O
+of	O
+the	O
+standard	O
+care	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Vaccinated	O
+mice	B-SPEC
+produced	O
+high	O
+levels	O
+of	O
+serum	B-COMP
+antibodies	B-COMP
+neutralizing	O
+MERS	O
+-	O
+CoV	O
+.	O
+Thus	O
+,	O
+MVA	B-CHED
+-	O
+MERS	O
+-	O
+S	O
+may	O
+serve	O
+for	O
+further	O
+development	B-PROC
+of	O
+an	O
+emergency	B-DISO
+vaccine	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Assessing	O
+activity	O
+and	O
+inhibition	B-PROC
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+papain	B-ENZY
+-	O
+like	O
+and	O
+3C	O
+-	O
+like	O
+proteases	O
+using	O
+luciferase	B-ENZY
+-	O
+based	O
+biosensors	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+associated	O
+with	O
+an	O
+outbreak	O
+of	O
+more	O
+than	O
+90	O
+cases	O
+of	O
+severe	O
+pneumonia	B-DISO
+with	O
+high	O
+mortality	O
+(	O
+greater	O
+than	O
+50	O
+%).	O
+
+To	O
+date	O
+,	O
+there	O
+are	O
+no	O
+antiviral	B-CHED
+drugs	I-CHED
+or	O
+specific	O
+therapies	O
+to	O
+treat	O
+MERS	O
+-	O
+CoV	O
+.	O
+To	O
+rapidly	O
+identify	O
+potential	O
+inhibitors	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+replication	O
+,	O
+we	O
+expressed	B-PROC
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLpro	O
+)	O
+and	O
+the	O
+3	B-PRGE
+-	I-PRGE
+chymotrypsin	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CLpro	O
+)	O
+from	O
+MERS	O
+-	O
+CoV	O
+and	O
+developed	O
+luciferase	B-ENZY
+-	O
+based	O
+biosensors	O
+to	O
+monitor	O
+protease	B-PROC
+activity	I-PROC
+in	O
+cells	B-COMP
+.	O
+
+Importantly	O
+,	O
+we	O
+found	O
+that	O
+a	O
+small	O
+-	O
+molecule	O
+inhibitor	B-CHED
+that	O
+blocks	O
+replication	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+CoV	O
+and	O
+murine	B-SPEC
+CoV	O
+also	O
+inhibits	O
+the	O
+activity	O
+of	O
+MERS	O
+-	O
+CoV	O
+3CLpro	O
+.	O
+
+TITLE	O
+:	O
+Risperidone	B-CHED
+-	O
+induced	O
+acute	B-DISO
+eosinophilic	I-DISO
+pneumonia	I-DISO
+.	O
+
+All	O
+evidence	O
+indicated	O
+risperidone	B-CHED
+as	O
+the	O
+most	O
+probable	O
+causal	O
+factor	O
+.	O
+
+The	O
+syndrome	B-DISO
+rapidly	O
+resolved	O
+after	O
+discontinuation	O
+of	O
+the	O
+drug	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+toxic	B-DISO
+epidermal	I-DISO
+necrolysis	I-DISO
+:	O
+clinical	O
+features	O
+and	O
+factors	O
+associated	O
+with	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+presentation	O
+and	O
+outcome	O
+of	O
+patients	O
+requiring	O
+mechanical	O
+ventilation	O
+and	O
+the	O
+characteristics	O
+of	O
+bronchial	B-ANAT
+epithelial	O
+lesions	O
+among	O
+ventilated	O
+patients	O
+are	O
+reported	O
+.	O
+
+TITLE	O
+:	O
+IL	B-FUNC
+-	I-FUNC
+21	I-FUNC
+optimizes	O
+T	B-ANAT
+cell	I-ANAT
+and	O
+humoral	O
+responses	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+during	O
+viral	B-DISO
+encephalitis	I-DISO
+.	O
+
+Therefore	O
+the	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+(	O
+1	O
+)	O
+to	O
+determine	O
+the	O
+prevalence	O
+of	O
+trichomonads	B-SPEC
+infecting	O
+puppies	O
+living	O
+in	O
+French	O
+breeding	B-PROC
+kennels	O
+,	O
+(	O
+2	O
+)	O
+to	O
+confirm	O
+the	O
+predominance	O
+of	O
+P	B-SPEC
+.	I-SPEC
+hominis	I-SPEC
+in	O
+dogs	B-SPEC
+,	O
+(	O
+3	O
+)	O
+to	O
+investigate	O
+the	O
+genetic	O
+diversity	O
+of	O
+P	B-SPEC
+.	I-SPEC
+hominis	I-SPEC
+isolates	O
+identified	O
+in	O
+the	O
+French	O
+canine	O
+population	O
+and	O
+(	O
+4	O
+)	O
+to	O
+evaluate	O
+the	O
+risk	O
+factors	O
+for	O
+infection	B-DISO
+by	O
+P	B-SPEC
+.	I-SPEC
+hominis	I-SPEC
+and	O
+the	O
+influence	O
+of	O
+the	O
+parasite	O
+on	O
+feces	B-ANAT
+consistency	O
+.	O
+
+Moreover	O
+,	O
+puppies	O
+from	O
+large	O
+breeding	B-PROC
+kennels	O
+,	O
+excreting	O
+a	O
+high	O
+level	O
+of	O
+G	B-SPEC
+.	I-SPEC
+intestinalis	I-SPEC
+and	O
+/	O
+or	O
+excreting	O
+a	O
+high	O
+level	O
+of	O
+C	B-SPEC
+.	I-SPEC
+canis	I-SPEC
+oocysts	O
+showed	O
+a	O
+higher	O
+probability	O
+of	O
+being	O
+positive	O
+for	O
+P	B-SPEC
+.	I-SPEC
+hominis	I-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Receptor	O
+recognition	O
+is	O
+a	O
+major	O
+determinant	O
+of	O
+the	O
+host	O
+range	O
+,	O
+cross	O
+-	O
+species	B-SPEC
+infections	B-DISO
+,	O
+and	O
+pathogenesis	B-DISO
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+Clinical	O
+management	O
+and	O
+infection	B-DISO
+control	O
+of	O
+SARS	B-DISO
+:	O
+lessons	O
+learned	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+Ki	O
+value	O
+of	O
+5h	O
+was	O
+in	O
+very	O
+good	O
+agreement	O
+with	O
+the	O
+binding	B-FUNC
+affinity	O
+(	O
+16	O
+nM	O
+)	O
+observed	O
+in	O
+isothermal	O
+titration	O
+calorimetry	O
+(	O
+ITC	O
+).	O
+
+Clinical	O
+and	O
+epidemiological	O
+data	O
+on	O
+287	O
+children	O
+(<	O
+6	O
+years	O
+old	O
+)	O
+admitted	O
+with	O
+adenovirus	B-DISO
+respiratory	B-DISO
+infections	I-DISO
+from	O
+2001	O
+to	O
+2004	O
+were	O
+reviewed	O
+.	O
+
+To	O
+better	O
+understand	O
+the	O
+genomic	O
+changes	O
+associated	O
+with	O
+viral	O
+adaptation	B-PROC
+,	O
+we	O
+sequenced	O
+the	O
+complete	O
+genomes	O
+of	O
+FIPV	O
+WSU	O
+79	O
+-	O
+1146	O
+at	O
+different	O
+tissue	B-ANAT
+passage	O
+levels	O
+:	O
+passage	O
+1	O
+,	O
+passage	O
+8	O
+,	O
+and	O
+passage	O
+50	O
+tissue	B-ANAT
+culture	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+:	O
+an	O
+overview	O
+.	O
+
+TITLE	O
+:	O
+Complications	O
+associated	O
+with	O
+Plasmodium	B-DISO
+vivax	I-DISO
+malaria	B-PATH
+:	O
+a	O
+retrospective	O
+study	O
+from	O
+a	O
+tertiary	O
+care	O
+hospital	O
+based	O
+in	O
+Western	O
+Uttar	O
+Pradesh	O
+,	O
+India	O
+.	O
+
+TITLE	O
+:	O
+Drug	O
+repurposing	O
+:	O
+a	O
+better	O
+approach	O
+for	O
+infectious	B-DISO
+disease	I-DISO
+drug	O
+discovery	O
+?	O
+
+ABSTRACT	O
+:	O
+The	O
+advent	O
+of	O
+publicly	O
+available	O
+databases	O
+containing	O
+system	O
+-	O
+wide	O
+phenotypic	O
+data	O
+of	O
+the	O
+host	O
+response	O
+to	O
+both	O
+drugs	O
+and	O
+pathogens	O
+,	O
+in	O
+conjunction	O
+with	O
+bioinformatics	O
+and	O
+computational	O
+methods	O
+now	O
+allows	O
+for	O
+in	O
+silico	O
+predictions	O
+of	O
+FDA	O
+-	O
+approved	O
+drugs	O
+as	O
+treatments	O
+against	O
+infection	B-DISO
+diseases	O
+.	O
+
+The	O
+rhesus	B-SPEC
+macaque	I-SPEC
+is	O
+the	O
+only	O
+known	O
+model	O
+organism	O
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+developing	O
+an	O
+acute	O
+localized	O
+to	O
+widespread	O
+pneumonia	B-DISO
+with	O
+transient	O
+clinical	O
+disease	O
+that	O
+recapitulates	O
+mild	O
+to	O
+moderate	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+Poly	O
+-	O
+γ	O
+-	O
+glutamic	B-CHED
+acid	I-CHED
+(	O
+γ	O
+-	O
+PGA	B-DISO
+)	O
+is	O
+an	O
+anionic	O
+polypeptide	B-CHED
+secreted	B-PROC
+by	O
+Bacillus	B-SPEC
+sp	I-SPEC
+.	O
+that	O
+has	O
+been	O
+shown	O
+to	O
+activate	O
+immune	O
+cells	B-COMP
+through	O
+interactions	O
+with	O
+toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+4	I-PRGE
+(	O
+TLR4	B-PRGE
+).	O
+
+Four	O
+H7N9	O
+avian	B-DISO
+influenza	I-DISO
+patients	O
+administered	O
+from	O
+April	O
+to	O
+June	O
+in	O
+2013	O
+in	O
+First	O
+Affiliated	O
+Hospital	O
+of	O
+Nanchang	O
+University	O
+were	O
+studied	O
+.	O
+
+During	O
+ventilation	O
+,	O
+patients	O
+'	O
+parameters	O
+,	O
+such	O
+as	O
+PEEP	B-CHED
+,	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+FiO2	B-CHED
+),	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+(	O
+PaO2	B-PROC
+),	O
+oxygenation	B-PROC
+index	O
+(	O
+PaO2	B-PROC
+/	O
+FiO2	B-CHED
+),	O
+cardiac	B-ANAT
+index	O
+(	O
+CI	O
+),	O
+systemic	B-PROC
+vascular	I-PROC
+resistance	I-PROC
+index	O
+(	O
+SVRI	O
+),	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+index	O
+(	O
+PVRI	O
+),	O
+EVLWI	O
+,	O
+and	O
+central	O
+venous	B-PROC
+pressure	I-PROC
+(	O
+CVP	O
+)	O
+were	O
+collected	O
+.	O
+
+All	O
+4	O
+H7N9	O
+avian	B-DISO
+influenza	I-DISO
+patients	O
+were	O
+complicated	O
+with	O
+ARDS	B-DISO
+,	O
+2	O
+patients	O
+were	O
+classified	O
+to	O
+severe	O
+ARDS	B-DISO
+and	O
+administered	O
+with	O
+comprehensive	O
+therapies	O
+,	O
+specially	O
+protected	O
+ventilation	O
+strategy	O
+;	O
+ventilation	O
+duration	O
+was	O
+9	O
+days	O
+and	O
+30	O
+days	O
+respectively	O
+,	O
+and	O
+PiCCO	O
+monitoring	O
+was	O
+9	O
+days	O
+and	O
+21	O
+days	O
+respectively	O
+.	O
+
+PEEP	B-CHED
+and	O
+FiO2	O
+of	O
+2	O
+patients	O
+were	O
+down	O
+-	O
+regulated	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+increased	O
+to	O
+334	O
+±	O
+64	O
+mm	O
+Hg	O
+and	O
+142	O
+±	O
+53	O
+mm	O
+Hg	O
+at	O
+weaning	B-PROC
+.	O
+
+Interestingly	O
+,	O
+the	O
+rMERS	O
+-	O
+CoV	O
+-	O
+ΔE	O
+genome	O
+replicated	O
+after	O
+cDNA	O
+clone	O
+was	O
+transfected	O
+into	O
+cells	B-COMP
+.	O
+
+None	O
+of	O
+the	O
+cells	B-COMP
+were	O
+sensitive	O
+to	O
+infection	B-DISO
+by	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+a	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+,	O
+or	O
+to	O
+infection	B-DISO
+mediated	O
+by	O
+the	O
+Spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+incorporated	O
+into	O
+pseudotypes	O
+based	O
+on	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+(	O
+VSV	O
+).	O
+
+The	O
+resistance	B-PROC
+to	O
+infection	B-DISO
+was	O
+overcome	O
+if	O
+cells	B-COMP
+were	O
+transfected	O
+to	O
+express	O
+the	O
+respective	O
+cellular	B-COMP
+receptor	O
+,	O
+porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+for	O
+TGEV	B-SPEC
+or	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+VSV	O
+pseudotypes	O
+containing	O
+the	O
+S	O
+proteins	O
+of	O
+two	O
+bat	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+related	I-PRGE
+CoV	I-PRGE
+(	O
+Bg08	O
+and	O
+Rp3	B-DISO
+)	O
+were	O
+unable	O
+to	O
+infect	O
+any	O
+of	O
+the	O
+six	O
+tested	O
+bat	B-ENZY
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+prospective	O
+study	O
+conducted	O
+from	O
+June	O
+2008	O
+to	O
+March	O
+2011	O
+was	O
+to	O
+characterise	O
+the	O
+incidence	O
+and	O
+outcomes	O
+of	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+LTR	O
+.	O
+
+One	O
+hundred	O
+and	O
+twelve	O
+LTR	O
+had	O
+903	O
+encounters	O
+:	O
+570	O
+(	O
+63	O
+%)	O
+were	O
+screening	O
+visits	O
+,	O
+124	O
+(	O
+14	O
+%)	O
+were	O
+routine	O
+post	O
+-	O
+transplantation	O
+follow	O
+-	O
+up	O
+and	O
+209	O
+(	O
+23	O
+%)	O
+were	O
+emergency	B-DISO
+visits	O
+.	O
+
+Infections	B-DISO
+were	O
+associated	O
+with	O
+transient	O
+lung	B-PROC
+function	I-PROC
+loss	O
+and	O
+high	O
+calcineurin	B-CHED
+inhibitor	I-CHED
+blood	B-ANAT
+levels	O
+.	O
+
+The	O
+hospitalisation	O
+rate	O
+was	O
+50	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+30	O
+%	O
+to	O
+70	O
+.	O
+9	O
+%)	O
+for	O
+influenza	B-DISO
+and	O
+parainfluenza	B-DISO
+and	O
+16	O
+.	O
+9	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+11	O
+.	O
+2	O
+%	O
+to	O
+23	O
+.	O
+9	O
+%)	O
+for	O
+other	O
+viruses	B-SPEC
+.	O
+
+There	O
+is	O
+a	O
+high	O
+incidence	O
+of	O
+viral	B-DISO
+infection	I-DISO
+in	O
+LTR	O
+;	O
+asymptomatic	O
+carriage	O
+is	O
+rare	O
+.	O
+
+RESULTS	O
+:	O
+One	O
+hundred	O
+and	O
+twelve	O
+LTR	O
+had	O
+903	O
+encounters	O
+:	O
+570	O
+(	O
+63	O
+%)	O
+were	O
+screening	O
+visits	O
+,	O
+124	O
+(	O
+14	O
+%)	O
+were	O
+routine	O
+post	O
+-	O
+transplantation	O
+follow	O
+-	O
+up	O
+and	O
+209	O
+(	O
+23	O
+%)	O
+were	O
+emergency	B-DISO
+visits	O
+.	O
+
+The	O
+sponge	B-SPEC
+model	O
+accounts	O
+for	O
+density	O
+distribution	O
+in	O
+prone	O
+position	O
+,	O
+for	O
+which	O
+the	O
+unloaded	O
+dorsal	O
+regions	O
+are	O
+recruited	O
+,	O
+while	O
+the	O
+loaded	O
+ventral	O
+region	O
+,	O
+collapses	O
+.	O
+
+Finally	O
+,	O
+and	O
+a	O
+series	O
+of	O
+clinical	O
+trials	O
+led	O
+to	O
+the	O
+conclusion	O
+that	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+the	O
+prone	O
+position	O
+provides	O
+a	O
+significant	O
+survival	O
+advantage	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+accessory	O
+protein	B-CHED
+4a	O
+is	O
+a	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+antagonist	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+cause	O
+epidemics	O
+of	O
+severe	O
+human	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+CoV	B-PRGE
+nsp5	I-PRGE
+has	O
+a	O
+conserved	O
+3	O
+-	O
+domain	O
+structure	O
+and	O
+catalytic	O
+residues	O
+.	O
+
+However	O
+,	O
+the	O
+experimental	O
+documentation	O
+of	O
+efficacy	O
+of	O
+vaporization	O
+of	O
+PFC	B-PRGE
+in	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+still	O
+lacking	O
+.	O
+
+Therefore	O
+,	O
+the	O
+non	O
+-	O
+invasive	O
+vaporization	O
+application	O
+technique	O
+would	O
+be	O
+a	O
+reasonable	O
+alternative	O
+to	O
+administer	O
+perfluorocarbons	O
+in	O
+severe	O
+lung	B-ANAT
+injury	O
+.	O
+
+Additionally	O
+,	O
+6	O
+h	O
+post	O
+treatment	O
+,	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+was	O
+significantly	O
+reduced	O
+in	O
+PFC	O
+group	O
+when	O
+compared	O
+with	O
+the	O
+control	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+and	O
+Cst	O
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+PFC	O
+group	O
+than	O
+in	O
+the	O
+control	O
+group	O
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+analyzed	O
+whether	O
+plasma	B-ANAT
+SP	O
+-	O
+D	O
+concentrations	O
+reflect	O
+rejection	O
+or	O
+infection	B-DISO
+of	O
+the	O
+lung	B-ANAT
+allograft	O
+.	O
+
+All	O
+patients	O
+with	O
+a	O
+plasma	B-ANAT
+SP	O
+-	O
+D	O
+level	O
+of	O
+>	O
+300	O
+ng	O
+/	O
+mL	O
+during	O
+pneumonia	B-DISO
+developed	O
+BOS	B-DISO
+III	O
+and	O
+/	O
+or	O
+died	B-PROC
+within	O
+6	O
+months	O
+of	O
+follow	O
+-	O
+up	O
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+determination	O
+of	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+levels	O
+in	O
+plasma	B-ANAT
+during	O
+pneumonia	B-DISO
+in	O
+LTRs	O
+may	O
+be	O
+of	O
+prognostic	O
+value	O
+and	O
+warrants	O
+further	O
+evaluation	O
+.	O
+
+Following	O
+the	O
+results	O
+of	O
+the	O
+initial	O
+genetic	O
+screening	O
+study	O
+,	O
+we	O
+prospectively	O
+followed	O
+aquaporin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+leukocyte	B-ANAT
+expression	B-PROC
+patterns	O
+in	O
+patients	O
+with	O
+ICU	O
+-	O
+acquired	O
+sepsis	B-DISO
+who	O
+subsequently	O
+developed	O
+septic	B-DISO
+shock	I-DISO
+(	O
+n	O
+=	O
+16	O
+)	O
+versus	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+who	O
+were	O
+discharged	O
+without	O
+developing	O
+sepsis	O
+(	O
+n	O
+=	O
+13	O
+).	O
+
+The	O
+latter	O
+could	O
+be	O
+abolished	O
+by	O
+blocking	B-DISO
+aquaporin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+with	O
+mercury	B-CHED
+and	O
+restored	O
+by	O
+incubation	O
+in	O
+β	O
+-	O
+mercaptoethanol	B-CHED
+,	O
+which	O
+abrogated	O
+the	O
+action	O
+of	O
+mercury	B-CHED
+inhibition	B-PROC
+.	O
+
+Patients	O
+were	O
+eligible	O
+if	O
+they	O
+(	O
+1	O
+)	O
+were	O
+intubated	O
+and	O
+mechanically	O
+ventilated	O
+patients	O
+in	O
+participating	O
+ICUs	O
+;	O
+(	O
+2	O
+)	O
+were	O
+within	O
+72	O
+hours	O
+of	O
+onset	O
+of	O
+ARDS	B-DISO
+;	O
+(	O
+3	O
+)	O
+fulfilled	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+definition	O
+for	O
+ARDS	B-DISO
+{	O
+acute	O
+-	O
+onset	O
+,	O
+severe	O
+hypoxaemic	O
+respiratory	B-DISO
+failure	I-DISO
+[	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+≤	O
+26	O
+.	O
+7	O
+kPa	O
+(	O
+200	O
+mmHg	O
+)]	O
+and	O
+bilateral	O
+infiltrates	B-DISO
+on	O
+the	O
+chest	B-ANAT
+radiograph	O
+in	O
+the	O
+absence	O
+of	O
+clinical	O
+evidence	O
+of	O
+left	O
+atrial	B-ANAT
+hypertension	B-DISO
+};	O
+and	O
+(	O
+4	O
+)	O
+were	O
+aged	O
+≥	O
+16	O
+years	O
+.	O
+
+The	O
+PEMS	O
+clinical	O
+features	O
+were	O
+characterized	O
+by	O
+watery	O
+to	O
+foamy	O
+faeces	B-ANAT
+,	O
+light	O
+brown	O
+-	O
+yellow	O
+in	O
+colour	O
+and	O
+low	O
+mortality	O
+rate	O
+.	O
+
+Meteorological	O
+data	O
+(	O
+rainfall	O
+and	O
+relative	O
+humidity	O
+)	O
+observed	O
+during	O
+along	O
+the	O
+study	O
+presented	O
+monthly	O
+average	O
+temperature	O
+ranging	O
+from	O
+39	O
+.	O
+3	O
+and	O
+31	O
+.	O
+2ºC	O
+,	O
+precipitation	B-PROC
+in	O
+rainy	O
+season	O
+from	O
+40	O
+to	O
+270	O
+.	O
+3	O
+mm	O
+/	O
+month	O
+,	O
+and	O
+no	O
+rain	O
+during	O
+dry	O
+season	O
+.	O
+
+The	O
+positive	O
+results	O
+of	O
+both	O
+virus	B-SPEC
+suggested	O
+that	O
+they	O
+can	O
+play	O
+an	O
+important	O
+role	O
+in	O
+enteric	O
+disorders	O
+,	O
+associated	O
+to	O
+low	O
+humidity	O
+and	O
+high	O
+temperatures	O
+frequently	O
+found	O
+in	O
+tropical	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+rescue	O
+therapy	O
+in	O
+a	O
+case	O
+of	O
+portopulmonary	B-DISO
+hypertension	I-DISO
+during	O
+liver	O
+transplantation	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+43	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+,	O
+scheduled	O
+for	O
+OLT	O
+due	O
+to	O
+alcoholic	B-DISO
+cirrhosis	I-DISO
+with	O
+hemosiderosis	B-DISO
+.	O
+
+Upon	O
+graft	B-ANAT
+reperfusion	O
+the	O
+hemodynamic	B-PROC
+profile	O
+was	O
+:	O
+mPAP	O
+47	O
+mm	O
+Hg	O
+,	O
+WP	O
+23	O
+mm	O
+Hg	O
+,	O
+CO	O
+14	O
+.	O
+2	O
+L	O
+/	O
+min	O
+,	O
+PVR	B-DISO
+135	O
+dyne	O
+s	O
+/	O
+cm	O
+(	O
+5	O
+),	O
+TPG	O
+24	O
+mm	O
+Hg	O
+,	O
+and	O
+at	O
+the	O
+end	O
+of	O
+surgery	O
+,	O
+mPAP	O
+39	O
+mm	O
+Hg	O
+,	O
+WP	O
+20	O
+mm	O
+Hg	O
+,	O
+CO	O
+10	O
+.	O
+6	O
+L	O
+/	O
+min	O
+,	O
+PVR	B-DISO
+123	O
+dyne	O
+s	O
+/	O
+cm	O
+(	O
+5	O
+),	O
+TPG	O
+19	O
+mm	O
+Hg	O
+.	O
+
+ECMO	O
+rescue	O
+therapy	O
+in	O
+this	O
+""""	O
+extreme	O
+""""	O
+case	O
+allowed	O
+us	O
+to	O
+correct	O
+hypoxemia	O
+responsible	O
+for	O
+worsening	O
+of	O
+pulmonary	B-DISO
+hypertension	I-DISO
+allowing	O
+time	O
+to	O
+reach	B-PROC
+the	O
+goal	O
+of	O
+vasodilatatory	O
+therapy	O
+.	O
+
+However	O
+,	O
+there	O
+are	O
+limited	O
+clinical	O
+data	O
+and	O
+guidelines	O
+for	O
+the	O
+management	O
+of	O
+influenza	B-DISO
+and	O
+other	O
+severe	O
+illness	O
+in	O
+these	O
+settings	O
+.	O
+
+While	O
+there	O
+are	O
+a	O
+variety	O
+of	O
+challenges	O
+to	O
+the	O
+management	O
+of	O
+the	O
+severely	O
+ill	B-DISO
+in	O
+resource	O
+-	O
+limited	O
+settings	O
+,	O
+several	O
+new	O
+international	O
+initiatives	O
+have	O
+begun	O
+to	O
+develop	O
+syndromic	O
+management	O
+strategies	O
+for	O
+these	O
+environments	O
+,	O
+including	O
+the	O
+World	O
+Health	O
+Organization	O
+'	O
+s	O
+Integrated	O
+Management	O
+of	O
+Adult	O
+and	O
+Adolescent	O
+Illness	O
+Program	O
+.	O
+
+Realizing	O
+a	O
+sustainable	O
+,	O
+global	O
+impact	O
+on	O
+death	O
+and	O
+suffering	B-DISO
+due	O
+to	O
+severe	O
+influenza	B-DISO
+and	O
+other	O
+severe	O
+illness	O
+necessitates	O
+an	O
+ongoing	O
+and	O
+concerted	O
+international	O
+effort	B-PROC
+to	O
+iteratively	O
+generate	O
+,	O
+implement	O
+,	O
+and	O
+evaluate	O
+best	O
+-	O
+practice	O
+management	O
+guidelines	O
+for	O
+use	O
+in	O
+resource	O
+-	O
+limited	O
+settings	O
+.	O
+
+ABSTRACT	O
+:	O
+to	O
+assess	O
+the	O
+epidemiological	O
+and	O
+genetic	O
+factors	O
+associated	O
+with	O
+severity	O
+of	O
+acute	B-DISO
+viral	I-DISO
+bronchiolitis	I-DISO
+(	O
+AVB	O
+)	O
+by	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+).	O
+
+the	O
+severity	O
+of	O
+AVB	O
+by	O
+RSV	B-SPEC
+is	O
+a	O
+phenomenon	O
+that	O
+depends	O
+on	O
+the	O
+varying	O
+degrees	O
+of	O
+interaction	O
+among	O
+epidemiological	O
+,	O
+environmental	O
+,	O
+and	O
+genetic	O
+variables	O
+.	O
+
+Alterations	O
+in	O
+actin	B-COMP
+cytoskeleton	I-COMP
+are	O
+shown	O
+to	O
+be	O
+crucial	O
+for	O
+NF	O
+-	O
+κB	O
+regulation	B-PROC
+and	O
+EC	O
+inflammation	B-DISO
+.	O
+
+Eighteen	O
+NDV	B-SPEC
+strains	O
+,	O
+fourteen	O
+AIV	O
+strains	O
+,	O
+and	O
+twelve	O
+other	O
+(	O
+negative	O
+control	O
+)	O
+strains	O
+viruses	B-SPEC
+were	O
+isolated	O
+from	O
+allantoic	O
+fluids	B-ANAT
+of	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+),	O
+embryonated	O
+eggs	O
+.	O
+
+The	O
+results	O
+obtained	O
+in	O
+this	O
+study	O
+show	O
+that	O
+by	O
+using	O
+duplex	O
+real	O
+-	O
+time	O
+PCR	O
+,	O
+it	O
+was	O
+possible	O
+to	O
+detect	O
+and	O
+distinguish	O
+both	O
+viruses	B-SPEC
+within	O
+less	O
+than	O
+three	O
+hours	O
+and	O
+with	O
+high	O
+sensitivity	O
+,	O
+even	O
+in	O
+case	O
+a	O
+bird	B-SPEC
+was	O
+co	O
+-	O
+infected	O
+.	O
+
+Additionally	O
+,	O
+the	O
+results	O
+show	O
+the	O
+applicability	O
+of	O
+the	O
+real	O
+-	O
+time	O
+PCR	O
+assay	O
+in	O
+laboratory	O
+practice	O
+for	O
+the	O
+identification	O
+and	O
+differentiation	B-PROC
+of	O
+Newcastle	B-DISO
+disease	I-DISO
+and	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+in	O
+birds	B-SPEC
+.	O
+
+TITLE	O
+:	O
+First	O
+infection	B-DISO
+by	O
+all	O
+four	O
+non	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+human	B-SPEC
+coronaviruses	O
+takes	O
+place	O
+during	O
+childhood	O
+.	O
+
+Both	O
+S	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+and	O
+S	B-PRGE
+-	I-PRGE
+IgM	I-PRGE
+antibodies	I-PRGE
+were	O
+detectable	O
+among	O
+children	O
+and	O
+increased	O
+with	O
+age	O
+,	O
+reaching	B-PROC
+a	O
+plateau	O
+at	O
+6	O
+years	O
+of	O
+age	O
+.	O
+
+The	O
+S1	B-PRGE
+subunit	I-PRGE
+of	O
+the	O
+spike	O
+is	O
+assumed	O
+to	O
+be	O
+required	O
+for	O
+virus	B-SPEC
+attachment	O
+.	O
+
+To	O
+further	O
+elucidate	O
+the	O
+role	O
+of	O
+S2	O
+the	O
+spike	O
+ectodomains	O
+of	O
+virulent	O
+IBV	B-SPEC
+M41	O
+and	O
+chimeras	O
+of	O
+M41	O
+and	O
+Beaudette	O
+were	O
+analyzed	O
+for	O
+their	O
+binding	B-FUNC
+to	O
+CAM	B-DISO
+,	O
+chicken	B-SPEC
+trachea	B-DISO
+and	O
+mammalian	B-ANAT
+cell	B-COMP
+lines	O
+.	O
+
+To	O
+elucidate	O
+the	O
+predictors	O
+of	O
+severe	O
+effects	O
+following	O
+acute	O
+glufosinate	B-CHED
+poisoning	O
+.	O
+
+The	O
+mechanism	O
+underlying	O
+the	O
+decreased	O
+FIPV	O
+replication	O
+caused	O
+by	O
+the	O
+3C	O
+protein	B-CHED
+was	O
+further	O
+investigated	O
+;	O
+neither	O
+the	O
+induction	O
+nor	O
+inhibition	B-PROC
+of	O
+autophagy	B-PROC
+rescued	O
+the	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+data	O
+suggest	O
+that	O
+the	O
+3C	O
+protein	O
+might	O
+have	O
+a	O
+virulence	B-PROC
+-	O
+suppressing	O
+effect	O
+in	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+.	O
+
+A	O
+range	O
+of	O
+personal	O
+protective	O
+equipment	O
+that	O
+provides	O
+different	O
+degrees	O
+of	O
+facial	B-ANAT
+and	O
+respiratory	O
+protection	O
+is	O
+available	O
+.	O
+
+To	O
+address	O
+this	O
+issue	O
+,	O
+the	O
+Scientific	O
+Development	B-PROC
+Committee	O
+of	O
+the	O
+Healthcare	O
+Infection	B-DISO
+Society	O
+established	O
+a	O
+short	O
+-	O
+life	O
+working	O
+group	O
+to	O
+develop	O
+guidance	O
+.	O
+
+In	O
+addition	O
+to	O
+confirming	O
+diagnosis	O
+,	O
+we	O
+generated	O
+the	O
+MERS	O
+-	O
+CoV	O
+genomic	O
+sequences	O
+obtained	O
+directly	O
+from	O
+patient	O
+samples	O
+to	O
+provide	O
+important	O
+information	O
+on	O
+MERS	O
+-	O
+CoV	O
+transmission	O
+,	O
+evolution	B-PROC
+,	O
+and	O
+origin	O
+.	O
+
+Full	O
+genome	O
+deep	O
+sequencing	O
+was	O
+done	O
+on	O
+nucleic	B-CHED
+acid	I-CHED
+extracted	O
+directly	O
+from	O
+PCR	O
+-	O
+confirmed	O
+clinical	O
+samples	O
+.	O
+
+TITLE	O
+:	O
+Defining	O
+CD8	B-PRGE
++	I-PRGE
+T	I-PRGE
+cell	I-PRGE
+determinants	I-PRGE
+during	O
+human	B-SPEC
+viral	B-DISO
+infection	I-DISO
+in	O
+populations	O
+of	O
+Asian	O
+ethnicity	O
+.	O
+
+These	O
+results	O
+highlight	O
+the	O
+limited	O
+applicability	O
+of	O
+the	O
+NetMHCpan	O
+algorithm	O
+for	O
+populations	O
+expressing	O
+HLA	O
+molecules	O
+for	O
+which	O
+there	O
+are	O
+little	O
+or	O
+no	O
+experimental	O
+binding	B-FUNC
+data	O
+,	O
+such	O
+as	O
+those	O
+of	O
+Asian	O
+ethnicity	O
+.	O
+
+Although	O
+,	O
+the	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+levels	O
+increased	O
+in	O
+sera	B-COMP
+of	O
+viral	B-DISO
+hepatitis	I-DISO
+patients	O
+in	O
+human	B-SPEC
+,	O
+the	O
+cellular	B-COMP
+sources	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+in	O
+viral	B-DISO
+hepatitis	I-DISO
+remained	O
+obscure	O
+.	O
+
+The	O
+LSEC	O
+and	O
+VEC	B-PRGE
+expressed	B-PROC
+inducible	O
+expression	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+following	O
+L2	O
+-	O
+MHV3	O
+infection	B-DISO
+but	O
+the	O
+hepatocyte	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+expression	B-PROC
+was	O
+only	O
+evident	O
+between	O
+24	O
+to	O
+32h	O
+of	O
+post	O
+infection	B-DISO
+.	O
+
+Interestingly	O
+,	O
+increased	O
+expression	B-PROC
+of	O
+genes	O
+involved	O
+in	O
+lipid	B-PROC
+transport	B-PROC
+,	O
+processing	O
+,	O
+and	O
+catabolism	B-PROC
+,	O
+including	O
+some	O
+with	O
+known	O
+roles	O
+in	O
+neurodegenerative	B-DISO
+diseases	I-DISO
+,	O
+coincided	O
+with	O
+demyelination	B-DISO
+.	O
+
+This	O
+study	O
+highlights	O
+the	O
+complexity	O
+of	O
+the	O
+host	B-COMP
+antiviral	B-PROC
+response	I-PROC
+,	O
+which	O
+accompany	O
+MHV	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+,	O
+and	O
+further	O
+supports	O
+previous	O
+findings	O
+that	O
+MHV	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+is	O
+immune	O
+-	O
+mediated	O
+.	O
+
+Interestingly	O
+,	O
+these	O
+data	O
+suggest	O
+a	O
+parallel	O
+between	O
+bone	B-ANAT
+reabsorption	O
+by	O
+osteoclasts	B-ANAT
+and	O
+myelin	B-COMP
+debris	O
+clearance	O
+by	O
+microglia	B-ANAT
+in	O
+the	O
+bone	B-ANAT
+and	O
+the	O
+CNS	B-CHED
+,	O
+respectively	O
+.	O
+
+Upon	O
+a	O
+combination	O
+of	O
+intratracheal	O
+,	O
+ocular	B-PROC
+,	O
+oral	B-ANAT
+,	O
+and	O
+intranasal	O
+inoculation	O
+with	O
+7	O
+×	O
+10	O
+(	O
+6	O
+)	O
+50	O
+%	O
+tissue	B-ANAT
+culture	O
+infectious	B-DISO
+dose	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+isolate	I-PRGE
+HCoV	I-PRGE
+-	I-PRGE
+EMC	I-PRGE
+/	I-PRGE
+2012	I-PRGE
+,	I-PRGE
+rhesus	B-SPEC
+macaques	I-SPEC
+developed	O
+a	O
+transient	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+MERS	O
+-	O
+CoV	O
+caused	O
+a	O
+multifocal	O
+,	O
+mild	O
+to	O
+marked	O
+interstitial	O
+pneumonia	O
+,	O
+with	O
+virus	B-PROC
+replication	I-PROC
+occurring	O
+mainly	O
+in	O
+alveolar	B-ANAT
+pneumocytes	B-ANAT
+.	O
+
+Notably	O
+,	O
+MERS	O
+-	O
+CoV	O
+induced	O
+significantly	O
+higher	O
+expression	B-PROC
+levels	O
+of	O
+interleukin	B-PRGE
+12	I-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+,	O
+and	O
+chemokines	O
+(	O
+IP	O
+-	O
+10	O
+/	O
+CXCL	O
+-	O
+10	O
+,	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+/	O
+CCL	B-DISO
+-	I-PRGE
+2	I-PRGE
+,	O
+MIP	O
+-	O
+1α	O
+/	O
+CCL	B-PRGE
+-	I-PRGE
+3	I-PRGE
+,	O
+RANTES	B-PRGE
+/	O
+CCL	B-PRGE
+-	I-PRGE
+5	I-PRGE
+,	O
+and	O
+interleukin	B-PRGE
+8	I-PRGE
+)	O
+than	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+expression	B-PROC
+of	O
+major	B-PRGE
+histocompatibility	I-PRGE
+complex	I-PRGE
+class	B-SPEC
+I	I-PRGE
+and	I-PRGE
+costimulatory	I-PRGE
+molecules	I-PRGE
+were	O
+significantly	O
+higher	O
+in	O
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+MDMs	O
+than	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+No	O
+coronavirus	B-SPEC
+was	O
+detected	O
+in	O
+LTS	O
+flocks	O
+and	O
+no	O
+corona	B-CHED
+-	O
+or	O
+reovirus	B-SPEC
+was	O
+detected	O
+in	O
+non	O
+-	O
+LTS	O
+flocks	O
+.	O
+
+Significantly	O
+lower	B-ANAT
+body	I-ANAT
+weights	O
+were	O
+seen	O
+in	O
+the	O
+challenged	O
+group	O
+starting	O
+at	O
+seven	O
+weeks	O
+of	O
+age	O
+and	O
+lasting	O
+until	O
+20	O
+weeks	O
+of	O
+age	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+obtained	O
+on	O
+days	O
+112	O
+and	O
+140	O
+were	O
+used	O
+for	O
+assessment	O
+of	O
+BCoV	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+serum	I-PRGE
+IgG1	B-COMP
+,	O
+IgG2	B-COMP
+,	O
+IgM	B-PRGE
+,	O
+and	O
+IgA	B-PRGE
+titers	O
+via	O
+an	O
+ELISA	O
+.	O
+
+Thus	O
+,	O
+low	O
+vitamin	B-CHED
+A	I-CHED
+diets	O
+may	O
+compromise	O
+the	O
+effectiveness	O
+of	O
+viral	O
+vaccines	O
+and	O
+render	O
+calves	O
+more	O
+susceptible	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+reported	O
+to	O
+cause	O
+human	B-SPEC
+infection	B-DISO
+in	O
+September	O
+2012	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+recently	O
+emerged	O
+as	O
+a	O
+severe	O
+worldwide	O
+public	O
+health	O
+concern	O
+.	O
+
+The	O
+virus	B-SPEC
+is	O
+highly	O
+pathogenic	O
+,	O
+manifesting	O
+in	O
+infected	O
+patients	O
+with	O
+an	O
+approximately	O
+50	O
+%	O
+fatality	O
+rate	O
+.	O
+
+With	O
+this	O
+notion	O
+,	O
+we	O
+further	O
+identified	O
+an	O
+HR2	O
+-	O
+based	O
+peptide	B-CHED
+that	O
+could	O
+potently	O
+inhibit	O
+MERS	O
+-	O
+CoV	O
+fusion	O
+and	O
+entry	O
+by	O
+using	O
+a	O
+pseudotyped	O
+-	O
+virus	B-SPEC
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+H1N1	O
+pandemic	O
+of	O
+2009	O
+and	O
+2010	O
+,	O
+the	O
+large	O
+number	O
+of	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+H1N1	O
+infection	B-DISO
+strained	O
+the	O
+capacities	O
+of	O
+treatment	O
+facilities	O
+for	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+around	O
+the	O
+world	O
+.	O
+
+During	O
+the	O
+pandemic	O
+,	O
+the	O
+German	O
+ARDS	B-DISO
+Network	O
+(	O
+a	O
+task	O
+force	O
+of	O
+the	O
+DIVI	O
+'	O
+s	O
+respiratory	B-DISO
+failure	I-DISO
+section	O
+)	O
+kept	O
+track	O
+of	O
+the	O
+availability	O
+of	O
+ECMO	O
+treatment	O
+facilities	O
+with	O
+a	O
+day	O
+-	O
+to	O
+-	O
+day	O
+,	O
+Internet	O
+-	O
+based	O
+capacity	O
+assessment	O
+.	O
+
+In	O
+cooperation	O
+with	O
+the	O
+Robert	O
+Koch	O
+Institute	O
+,	O
+epidemiological	O
+and	O
+clinical	O
+data	O
+were	O
+obtained	O
+on	O
+all	O
+patients	O
+treated	O
+for	O
+influenza	B-DISO
+in	O
+intensive	O
+care	O
+units	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Even	O
+persons	O
+without	O
+any	O
+other	O
+accompanying	O
+disease	O
+developed	O
+life	O
+-	O
+threatening	O
+respiratory	B-DISO
+failure	I-DISO
+as	O
+a	O
+result	O
+of	O
+H1N1	O
+infection	B-DISO
+,	O
+and	O
+many	O
+of	O
+these	O
+patients	O
+needed	O
+ECMO	O
+.	O
+
+Incidences	O
+of	O
+pneumonia	O
+,	O
+atelectasis	B-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+were	O
+assessed	O
+.	O
+
+The	O
+current	O
+trial	O
+identified	O
+clinically	O
+important	O
+findings	O
+that	O
+warrant	O
+further	O
+research	O
+to	O
+investigate	O
+zinc	B-CHED
+'	O
+s	O
+therapeutic	O
+effect	O
+for	O
+calf	B-ANAT
+diarrhea	B-DISO
+.	O
+
+Histopathological	O
+examination	O
+of	O
+specimens	O
+collected	O
+at	O
+postmortem	O
+confirmed	O
+FIP	O
+in	O
+10	O
+/	O
+17	O
+cases	O
+and	O
+ruled	O
+out	O
+FIP	B-DISO
+out	O
+in	O
+7	O
+/	O
+17	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+a	O
+novel	O
+spike	O
+pseudoparticle	O
+neutralisation	O
+assay	O
+(	O
+ppNT	O
+)	O
+for	O
+seroepidemiological	O
+studies	O
+on	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERSCoV	O
+)	O
+and	O
+apply	O
+this	O
+assay	O
+together	O
+with	O
+conventional	O
+microneutralisation	O
+(	O
+MN	O
+)	O
+tests	O
+to	O
+investigate	O
+1	O
+,	O
+343	O
+human	B-SPEC
+and	O
+625	O
+animal	B-SPEC
+sera	B-COMP
+.	O
+
+The	O
+X	O
+-	O
+ray	B-SPEC
+structure	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+bound	O
+with	O
+a	O
+ML300	O
+analog	O
+highlights	O
+a	O
+unique	O
+induced	O
+-	O
+fit	B-DISO
+reorganization	O
+of	O
+the	O
+S2	O
+-	O
+S4	O
+binding	B-FUNC
+pockets	O
+leading	O
+to	O
+the	O
+first	O
+sub	O
+-	O
+micromolar	O
+noncovalent	O
+3CLpro	O
+inhibitors	B-CHED
+retaining	O
+a	O
+single	O
+amide	B-CHED
+bond	O
+.	O
+
+ABSTRACT	O
+:	O
+Multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+)	O
+is	O
+an	O
+inflammatory	O
+demyelinating	B-DISO
+disease	I-DISO
+of	O
+the	O
+human	B-SPEC
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+).	O
+
+Neurotropic	O
+demyelinating	O
+strain	O
+of	O
+MHV	B-SPEC
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+or	O
+its	O
+isogenic	O
+recombinant	O
+strain	O
+RSA59	O
+)	O
+induces	O
+MS	O
+-	O
+like	O
+disease	O
+in	O
+mice	B-SPEC
+mediated	O
+by	O
+microglia	B-ANAT
+,	O
+along	O
+with	O
+a	O
+small	O
+population	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Our	O
+study	O
+directly	O
+compares	O
+CNS	B-CHED
+pathology	B-DISO
+in	O
+autoimmune	B-DISO
+and	O
+viral	O
+-	O
+induced	O
+MS	O
+models	O
+.	O
+
+Inflammation	B-DISO
+was	O
+restricted	O
+mainly	O
+to	O
+white	B-ANAT
+matter	I-ANAT
+at	O
+all	O
+times	O
+in	O
+EAE	O
+,	O
+whereas	O
+inflammation	B-DISO
+initially	O
+largely	O
+involved	O
+gray	B-ANAT
+matter	I-ANAT
+in	O
+acute	O
+MHV	B-SPEC
+-	O
+induced	O
+disease	O
+and	O
+then	O
+is	O
+subsequently	O
+localized	O
+only	O
+in	O
+white	B-ANAT
+matter	I-ANAT
+in	O
+the	O
+chronic	B-DISO
+disease	I-DISO
+phase	O
+.	O
+
+Their	O
+heterogeneity	O
+was	O
+investigated	O
+by	O
+analysis	O
+of	O
+the	O
+ORF3	O
+gene	O
+because	O
+of	O
+its	O
+potential	O
+function	O
+as	O
+a	O
+representation	O
+of	O
+virulence	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+increases	O
+mortality	O
+in	O
+patients	O
+with	O
+multiorgan	O
+dysfunction	O
+syndrome	B-DISO
+(	O
+MODS	B-DISO
+).	O
+
+Virus	B-SPEC
+CU	O
+evolves	O
+independently	O
+for	O
+each	O
+gene	O
+in	O
+a	O
+manner	O
+predicted	O
+by	O
+the	O
+protein	B-PROC
+function	I-PROC
+,	O
+with	O
+a	O
+balance	B-PROC
+between	O
+natural	O
+selection	O
+and	O
+mutation	O
+pressure	O
+,	O
+giving	O
+further	O
+molecular	O
+basis	O
+for	O
+the	O
+viruses	B-SPEC
+'	O
+ability	O
+to	O
+exploit	O
+the	O
+host	B-COMP
+'	O
+s	O
+cellular	B-COMP
+environment	O
+in	O
+a	O
+concerted	O
+virus	B-SPEC
+-	O
+host	B-COMP
+molecular	O
+evolution	B-PROC
+.	O
+
+Two	O
+time	O
+periods	B-PROC
+in	O
+2013	O
+were	O
+compared	O
+to	O
+identify	O
+changes	O
+in	O
+the	O
+epidemiology	O
+.	O
+
+Thirteen	O
+out	O
+of	O
+14	O
+known	O
+primary	O
+cases	O
+died	B-PROC
+.	O
+
+The	O
+incidence	O
+and	O
+number	O
+of	O
+viruses	B-SPEC
+known	O
+to	O
+cause	O
+pneumonia	B-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+have	O
+also	O
+expanded	O
+in	O
+recent	O
+years	O
+.	O
+
+This	O
+article	O
+provides	O
+an	O
+overview	O
+of	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+caused	O
+by	O
+coronavirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+and	O
+hantavirus	B-SPEC
+.	O
+
+Management	O
+of	O
+individual	O
+cases	O
+is	O
+mainly	O
+supportive	O
+and	O
+requires	O
+institution	O
+of	O
+appropriate	O
+infection	B-DISO
+control	O
+measures	O
+.	O
+
+Influenza	B-DISO
+is	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+associated	O
+with	O
+severe	O
+viral	B-DISO
+pneumonia	I-DISO
+,	O
+although	O
+other	O
+important	O
+causes	O
+include	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+metapneumonia	O
+virus	B-SPEC
+,	O
+and	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Generation	O
+,	O
+characterization	O
+and	O
+therapeutic	O
+potential	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+feline	I-PRGE
+TNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+MAbs	O
+for	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+Thus	O
+,	O
+the	O
+administration	O
+of	O
+a	O
+feline	B-SPEC
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+-	I-PRGE
+neutralizing	I-PRGE
+antibody	I-PRGE
+to	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+may	O
+reduce	O
+the	O
+disease	B-DISO
+progression	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+p53	B-PATH
+signaling	I-PATH
+pathway	I-PATH
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+regulation	B-PROC
+of	I-PROC
+cell	I-PROC
+cycle	I-PROC
+.	O
+
+Our	O
+previous	O
+studies	O
+have	O
+demonstrated	O
+that	O
+TGEV	B-SPEC
+infection	B-DISO
+induces	O
+the	O
+activation	O
+of	O
+p53	B-PATH
+signaling	I-PATH
+pathway	I-PATH
+.	O
+
+Further	O
+studies	O
+showed	O
+that	O
+inhibition	B-PROC
+of	O
+p53	B-PRGE
+signaling	B-PROC
+could	O
+attenuate	O
+the	O
+TGEV	B-SPEC
+-	O
+induced	O
+S	O
+-	O
+and	O
+G2	O
+/	O
+M	B-PROC
+-	I-PROC
+phase	I-PROC
+arrest	O
+by	O
+reversing	O
+the	O
+expression	B-PROC
+of	O
+p21	B-PRGE
+and	I-PRGE
+corresponding	I-PRGE
+cyclin	I-PRGE
+/	O
+cdk	B-FUNC
+.	O
+
+We	O
+used	O
+small	O
+compound	O
+-	O
+based	O
+forward	O
+chemical	O
+genetics	O
+to	O
+screen	O
+a	O
+chemical	O
+library	O
+of	O
+1280	O
+known	O
+drugs	O
+against	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+in	O
+Biosafety	O
+Level	O
+-	O
+2	O
+laboratory	O
+.	O
+
+We	O
+then	O
+assessed	O
+the	O
+anti	O
+-	O
+MERS	O
+-	O
+CoV	O
+activities	O
+of	O
+the	O
+identified	O
+compounds	O
+and	O
+of	O
+interferons	O
+,	O
+nelfinavir	O
+,	O
+and	O
+lopinavir	O
+because	O
+of	O
+their	O
+reported	O
+anti	O
+-	O
+coronavirus	B-SPEC
+activities	O
+in	O
+terms	O
+of	O
+cytopathic	B-DISO
+effect	I-DISO
+inhibition	B-PROC
+,	O
+viral	O
+yield	O
+reduction	O
+,	O
+and	O
+plaque	B-DISO
+reduction	O
+assays	O
+in	O
+Biosafety	O
+Level	O
+-	O
+3	O
+laboratory	O
+.	O
+
+Combination	O
+of	O
+mycophenolic	B-CHED
+acid	I-CHED
+and	O
+interferon	B-PRGE
+-	I-PRGE
+β1b	I-PRGE
+lowered	O
+the	O
+EC50	O
+of	O
+each	O
+drug	O
+by	O
+1	O
+-	O
+3	O
+times	O
+.	O
+
+Among	O
+264	O
+swabs	O
+from	O
+193	O
+outpatients	O
+,	O
+58	O
+(	O
+22	O
+%)	O
+resulted	O
+positive	O
+for	O
+61	O
+viruses	B-SPEC
+(	O
+influenza	B-DISO
+,	O
+n	O
+=	O
+20	O
+;	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+[	O
+RSV	B-SPEC
+],	O
+n	O
+=	O
+21	O
+;	O
+rhinovirus	B-SPEC
+,	O
+n	O
+=	O
+12	O
+;	O
+coronavirus	B-SPEC
+,	O
+n	O
+=	O
+4	O
+;	O
+adenovirus	B-DISO
+,	O
+n	O
+=	O
+3	O
+;	O
+parainfluenza	B-DISO
+,	O
+n	O
+=	O
+1	O
+).	O
+
+Furthermore	O
+,	O
+recent	O
+studies	O
+have	O
+suggested	O
+that	O
+the	O
+exacerbation	O
+of	O
+asthma	B-PATH
+,	O
+namely	O
+virus	B-SPEC
+-	O
+induced	O
+asthma	B-PATH
+,	O
+may	O
+be	O
+associated	O
+with	O
+a	O
+wide	O
+variety	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+of	O
+human	B-SPEC
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+virus	O
+entry	O
+and	O
+syncytia	B-ANAT
+formation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+the	O
+biology	O
+of	O
+the	O
+emerging	O
+human	B-SPEC
+group	O
+c	O
+betacoronavirus	B-SPEC
+,	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+MERS	O
+pseudovirions	O
+released	O
+from	O
+293T	O
+cells	B-COMP
+contained	O
+only	O
+uncleaved	O
+S	O
+,	O
+and	O
+pseudovirus	O
+entry	O
+was	O
+blocked	O
+by	O
+lysosomotropic	O
+reagents	B-CHED
+NH4Cl	B-CHED
+and	O
+bafilomycin	O
+and	O
+inhibitors	B-CHED
+of	O
+cathepsin	B-PRGE
+L	I-PRGE
+.	O
+However	O
+,	O
+when	O
+MERS	O
+pseudovirions	O
+with	O
+uncleaved	O
+S	O
+protein	O
+were	O
+adsorbed	O
+at	O
+4	O
+°	O
+C	O
+to	O
+Vero	O
+E6	O
+cells	B-COMP
+,	O
+brief	O
+trypsin	B-PRGE
+treatment	O
+at	O
+neutral	O
+pH	O
+triggered	O
+virus	B-SPEC
+entry	O
+at	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+and	O
+syncytia	B-ANAT
+formation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Assembly	O
+and	O
+immunogenicity	O
+of	O
+coronavirus	B-SPEC
+-	O
+like	O
+particles	O
+carrying	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+M	O
+and	O
+S	O
+proteins	B-CHED
+.	O
+
+Patients	O
+were	O
+categorized	O
+according	O
+to	O
+the	O
+two	O
+definitions	O
+,	O
+as	O
+follows	O
+:	O
+ALI	O
+,	O
+36	O
+;	O
+ARDS	O
+,	O
+185	O
+(	O
+for	O
+the	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+(	O
+AECC	O
+)	O
+definition	O
+);	O
+mild	O
+,	O
+36	O
+;	O
+moderate	O
+,	O
+97	O
+;	O
+severe	O
+ARDS	B-DISO
+,	O
+88	O
+(	O
+for	O
+BD	O
+).	O
+
+There	O
+was	O
+significant	O
+concordance	O
+between	O
+raters	O
+evaluating	O
+radiographs	O
+[	O
+ICC	B-DISO
+0	O
+.	O
+6	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+2	O
+-	O
+0	O
+.	O
+8	O
+)]	O
+and	O
+risk	O
+factors	O
+[	O
+ICC	B-DISO
+0	O
+.	O
+92	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+8	O
+-	O
+0	O
+.	O
+97	O
+)].	O
+
+RESULTS	O
+:	O
+Patients	O
+were	O
+categorized	O
+according	O
+to	O
+the	O
+two	O
+definitions	O
+,	O
+as	O
+follows	O
+:	O
+ALI	O
+,	O
+36	O
+;	O
+ARDS	B-DISO
+,	O
+185	O
+(	O
+for	O
+the	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+(	O
+AECC	O
+)	O
+definition	O
+);	O
+mild	O
+,	O
+36	O
+;	O
+moderate	O
+,	O
+97	O
+;	O
+severe	O
+ARDS	B-DISO
+,	O
+88	O
+(	O
+for	O
+BD	O
+).	O
+
+This	O
+review	O
+is	O
+aimed	O
+at	O
+the	O
+clinical	O
+neurologist	O
+in	O
+that	O
+it	O
+offers	O
+insights	O
+into	O
+potential	O
+adverse	O
+events	O
+of	O
+each	O
+of	O
+the	O
+approved	O
+MS	O
+therapeutics	O
+:	O
+interferon	B-PRGE
+beta	I-PRGE
+,	O
+glatiramer	O
+acetate	B-CHED
+,	O
+mitoxantrone	B-CHED
+,	O
+natalizumab	O
+,	O
+fingolimod	B-CHED
+and	O
+teriflunomide	B-CHED
+,	O
+as	O
+well	O
+as	O
+recently	O
+approved	O
+therapeutics	O
+such	O
+as	O
+dimethyl	B-CHED
+fumarate	B-CHED
+and	O
+alemtuzumab	O
+.	O
+
+Immunological	O
+assessments	O
+demonstrated	O
+decreased	O
+IgM	B-PRGE
+,	O
+increased	O
+IgE	B-DISO
+,	O
+T	O
+lymphocytepenia	O
+,	O
+especially	O
+in	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+,	O
+decreased	O
+PHA	B-DISO
+blastogenesis	B-PROC
+,	O
+and	O
+decreased	O
+CD27	B-PRGE
+(+)	I-PRGE
+CD19	I-PRGE
+(+)	O
+memory	B-PROC
+B	B-ANAT
+cells	I-ANAT
+.	O
+
+As	O
+far	O
+as	O
+we	O
+know	O
+,	O
+this	O
+is	O
+the	O
+first	O
+Japanese	O
+case	O
+of	O
+DOCK8	B-PRGE
+deficiency	O
+.	O
+
+We	O
+show	O
+that	O
+bat	B-PRGE
+DPP4	I-PRGE
+genes	I-PRGE
+have	O
+been	O
+subject	O
+to	O
+significant	O
+adaptive	O
+evolution	B-PROC
+,	O
+suggestive	O
+of	O
+a	O
+long	O
+-	O
+term	O
+arms	B-DISO
+-	O
+race	O
+between	O
+bats	B-SPEC
+and	O
+MERS	O
+related	O
+CoVs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+human	O
+coronavirus	O
+OC43	O
+is	O
+a	O
+major	O
+contributor	O
+to	O
+the	O
+common	B-DISO
+cold	I-DISO
+worldwide	O
+,	O
+though	O
+due	O
+to	O
+its	O
+low	O
+mortality	O
+rate	O
+,	O
+little	O
+research	O
+has	O
+focused	O
+on	O
+this	O
+human	B-SPEC
+pathogen	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+implement	O
+more	O
+strict	O
+entry	O
+screening	O
+in	O
+the	O
+epidemic	O
+seasons	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+we	O
+developed	O
+an	O
+infection	B-DISO
+screening	O
+system	O
+for	O
+airport	O
+quarantines	O
+using	O
+multi	O
+-	O
+parameter	O
+vital	O
+signs	O
+.	O
+
+MAb	O
+5E12	O
+not	O
+only	O
+reacted	O
+with	O
+rS1	B-PRGE
+protein	I-PRGE
+indirect	O
+ELISA	O
+and	O
+Western	O
+blot	O
+,	O
+but	O
+also	O
+recognized	O
+PEDV	B-SPEC
+transiently	O
+expressed	B-PROC
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+in	O
+indirect	O
+immunofluorescence	O
+examinations	O
+.	O
+
+Among	O
+them	O
+,	O
+18	O
+(	O
+6	O
+.	O
+5	O
+%)	O
+did	O
+not	O
+comply	O
+with	O
+the	O
+Berlin	O
+criterion	O
+PEEP	B-CHED
+≥	O
+5	O
+cmH2O	O
+and	O
+20	O
+(	O
+7	O
+.	O
+2	O
+%)	O
+had	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+≤	O
+200	O
+while	O
+on	O
+noninvasive	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Children	O
+with	O
+multiple	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+are	O
+older	O
+than	O
+those	O
+with	O
+single	O
+viruses	B-SPEC
+.	O
+
+Demographic	O
+data	O
+from	O
+37	O
+multiple	O
+infection	B-DISO
+periods	B-PROC
+in	O
+children	O
+<	O
+5	O
+years	O
+of	O
+age	O
+were	O
+compared	O
+to	O
+data	O
+from	O
+193	O
+episodes	O
+with	O
+single	O
+infections	B-DISO
+.	O
+
+No	O
+differences	O
+were	O
+found	O
+regarding	O
+duration	O
+of	O
+hospitalisation	O
+,	O
+oxygen	B-CHED
+treatment	O
+or	O
+admittance	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Children	O
+with	O
+multiple	O
+viral	O
+findings	O
+in	O
+their	O
+respiratory	O
+secretions	B-ANAT
+were	O
+older	O
+than	O
+those	O
+with	O
+a	O
+single	O
+detected	O
+virus	B-SPEC
+.	O
+
+Neither	O
+enterotoxigenic	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+,	O
+Clostridium	B-SPEC
+perfringens	I-SPEC
+type	O
+A	O
+or	O
+C	O
+,	O
+Clostridium	B-SPEC
+difficile	I-SPEC
+,	O
+rotavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+,	O
+Giardia	B-DISO
+spp	B-ENZY
+,	O
+Cystoisospora	B-SPEC
+suis	I-SPEC
+nor	O
+Strongyloides	B-SPEC
+ransomi	I-SPEC
+were	O
+associated	O
+with	O
+diarrhoea	B-DISO
+in	O
+the	O
+investigated	O
+outbreaks	O
+.	O
+
+The	O
+predominant	O
+histological	O
+lesions	O
+were	O
+villous	O
+atrophy	B-DISO
+in	O
+jejunum	B-ANAT
+and	O
+ileum	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+Four	O
+well	O
+-	O
+managed	O
+herds	O
+experiencing	O
+neonatal	B-DISO
+diarrhoea	I-DISO
+with	O
+no	O
+previously	O
+established	O
+laboratory	O
+conclusion	O
+and	O
+suspected	O
+to	O
+suffer	B-DISO
+from	O
+New	O
+Neonatal	O
+Porcine	B-SPEC
+Diarrhoea	B-DISO
+Syndrome	B-DISO
+,	O
+were	O
+selected	O
+.	O
+
+Spokespersons	O
+of	O
+health	O
+and	O
+medical	O
+institutions	O
+play	O
+an	O
+important	O
+role	O
+in	O
+media	B-ANAT
+relations	O
+during	O
+the	O
+crisis	O
+of	O
+a	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Spokespersons	O
+of	O
+health	O
+and	O
+medical	O
+institutions	O
+play	O
+an	O
+important	O
+role	O
+in	O
+media	B-ANAT
+relations	O
+during	O
+the	O
+crisis	O
+of	O
+a	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+Severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+that	O
+did	O
+not	O
+respond	O
+to	O
+optimal	O
+conventional	O
+treatment	O
+led	O
+us	O
+to	O
+employ	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+At	O
+one	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+he	O
+is	O
+in	O
+NYHA	O
+class	B-SPEC
+I	O
+with	O
+full	O
+functional	O
+autonomy	O
+.	O
+
+TITLE	O
+:	O
+Proteolytic	B-PROC
+activation	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+:	O
+cutting	O
+enzymes	O
+at	O
+the	O
+cutting	O
+edge	O
+of	O
+antiviral	O
+research	O
+.	O
+
+TITLE	O
+:	O
+Prospective	O
+evaluation	O
+for	O
+respiratory	O
+pathogens	O
+in	O
+children	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+and	O
+acute	O
+respiratory	O
+illness	O
+.	O
+
+Clinical	O
+characteristics	O
+and	O
+distribution	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+patients	O
+with	O
+and	O
+without	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+)	O
+were	O
+evaluated	O
+.	O
+
+The	O
+demographic	O
+characteristics	O
+of	O
+patients	O
+with	O
+and	O
+without	O
+ACS	B-FUNC
+were	O
+similar	O
+.	O
+
+RESULTS	O
+:	O
+Even	O
+after	O
+storage	B-PROC
+for	O
+21	O
+days	O
+,	O
+test	O
+results	O
+were	O
+comparable	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+Rivalta	O
+'	O
+s	O
+test	O
+seems	O
+to	O
+be	O
+a	O
+very	O
+robust	O
+test	O
+concerning	O
+storage	B-PROC
+conditions	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+refractory	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+severe	O
+malaria	O
+.	O
+
+In	O
+one	O
+patient	O
+,	O
+a	O
+bicaval	O
+dual	O
+-	O
+lumen	B-ANAT
+cannula	B-SPEC
+was	O
+inserted	O
+;	O
+in	O
+the	O
+two	O
+other	O
+patients	O
+,	O
+a	O
+two	O
+-	O
+site	O
+configuration	O
+was	O
+used	O
+.	O
+
+Females	O
+are	O
+also	O
+a	O
+mosaic	O
+of	O
+cells	B-COMP
+with	O
+genes	O
+from	O
+either	O
+paternal	O
+or	O
+maternal	O
+X	B-COMP
+chromosome	I-COMP
+.	O
+
+In	O
+light	O
+of	O
+recent	O
+functional	O
+,	O
+biochemical	O
+and	O
+structural	O
+findings	O
+,	O
+we	O
+review	O
+the	O
+inhibition	O
+mechanisms	O
+of	O
+RLRs	O
+recognition	O
+of	O
+dsRNA	B-CHED
+displayed	O
+by	O
+a	O
+number	O
+of	O
+highly	O
+pathogenic	O
+RNA	O
+viruses	B-SPEC
+with	O
+different	O
+disease	O
+phenotypes	O
+such	O
+as	O
+haemorrhagic	B-DISO
+fever	I-DISO
+(	O
+Ebola	O
+,	O
+Marburg	O
+,	O
+Lassa	B-DISO
+fever	I-DISO
+,	O
+Lujo	O
+,	O
+Machupo	O
+,	O
+Junin	O
+,	O
+Guanarito	O
+,	O
+Crimean	O
+-	O
+Congo	O
+,	O
+Rift	B-DISO
+Valley	I-DISO
+fever	I-DISO
+,	O
+dengue	B-DISO
+),	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+(	O
+influenza	B-DISO
+,	O
+SARS	B-DISO
+,	O
+Hendra	O
+,	O
+Hantaan	O
+,	O
+Sin	B-PROC
+Nombre	O
+,	O
+Andes	B-SPEC
+)	O
+and	O
+encephalitis	B-DISO
+(	O
+Nipah	O
+,	O
+West	O
+Nile	O
+).	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+known	O
+to	O
+infect	O
+humans	O
+and	O
+other	O
+animals	B-SPEC
+and	O
+cause	O
+respiratory	O
+and	O
+gastrointestinal	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+finding	O
+that	O
+the	O
+emergent	O
+U	O
+.	O
+S	O
+.	O
+PEDV	B-SPEC
+strains	O
+share	O
+unique	O
+genetic	O
+features	O
+at	O
+the	O
+5	O
+'-	O
+untranslated	O
+region	O
+with	O
+a	O
+bat	B-ENZY
+coronavirus	B-SPEC
+provided	O
+further	O
+support	O
+of	O
+the	O
+evolutionary	O
+origin	O
+of	O
+PEDV	B-SPEC
+from	O
+bats	B-SPEC
+and	O
+potential	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+.	O
+
+Detailed	O
+analyses	O
+of	O
+the	O
+full	O
+hedgehog	O
+intestine	B-ANAT
+showed	O
+the	O
+highest	O
+EriCoV	O
+concentrations	O
+in	O
+lower	B-ANAT
+gastrointestinal	I-ANAT
+tract	I-ANAT
+specimens	O
+,	O
+compatible	O
+with	O
+viral	B-PROC
+replication	I-PROC
+in	O
+the	O
+lower	O
+intestine	B-ANAT
+and	O
+fecal	B-ANAT
+-	O
+oral	B-ANAT
+transmission	O
+.	O
+
+Given	O
+the	O
+lack	O
+of	O
+related	O
+ongoing	O
+or	O
+recently	O
+completed	O
+randomized	O
+trials	O
+,	O
+new	O
+data	O
+addressing	O
+the	O
+effectiveness	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+severe	O
+hypoxemia	O
+will	O
+not	O
+be	O
+available	O
+for	O
+the	O
+foreseeable	O
+future	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+prone	O
+position	O
+,	O
+computed	O
+tomography	O
+scan	O
+densities	O
+redistribute	O
+from	O
+dorsal	O
+to	O
+ventral	O
+as	O
+the	O
+dorsal	O
+region	O
+tends	O
+to	O
+reexpand	O
+while	O
+the	O
+ventral	O
+zone	O
+tends	O
+to	O
+collapse	B-DISO
+.	O
+
+MAP	O
+recovery	O
+was	O
+delayed	O
+∼	O
+10	O
+s	O
+by	O
+5	B-CHED
+-	I-CHED
+HT	I-CHED
+deficiency	O
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Although	O
+intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+(	O
+IAH	B-FUNC
+)	O
+and	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+)	O
+are	O
+associated	O
+with	O
+substantial	O
+morbidity	O
+and	O
+mortality	O
+among	O
+critically	B-DISO
+ill	I-DISO
+adults	O
+,	O
+it	O
+remains	O
+unknown	O
+if	O
+prevention	O
+or	O
+treatment	O
+of	O
+these	O
+conditions	O
+improves	O
+patient	O
+outcomes	O
+.	O
+
+It	O
+is	O
+still	O
+not	O
+known	O
+what	O
+the	O
+source	O
+of	O
+the	O
+virus	B-SPEC
+is	O
+and	O
+what	O
+the	O
+best	O
+treatment	O
+modality	O
+should	O
+be	O
+.	O
+
+TITLE	O
+:	O
+Bats	B-SPEC
+,	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+and	O
+the	O
+rabies	B-DISO
+paradigm	O
+revisited	O
+.	O
+
+We	O
+also	O
+identified	O
+DMVs	O
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+that	O
+were	O
+observed	O
+as	O
+single	O
+individual	O
+DMVs	O
+or	O
+were	O
+connected	O
+to	O
+the	O
+ER	O
+via	O
+their	O
+outer	B-COMP
+membrane	I-COMP
+but	O
+not	O
+to	O
+the	O
+zippered	O
+ER	O
+.	O
+
+All	O
+positive	O
+-	O
+sense	B-PROC
+single	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+induce	O
+rearranged	O
+cellular	B-COMP
+membranes	B-ANAT
+,	O
+providing	O
+a	O
+platform	O
+for	O
+viral	B-COMP
+replication	I-COMP
+complex	I-COMP
+assembly	O
+and	O
+protecting	O
+viral	O
+RNA	O
+from	O
+cellular	B-COMP
+defenses	O
+.	O
+
+However	O
+,	O
+the	O
+role	O
+of	O
+DMVs	O
+and	O
+CMs	O
+in	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+remains	O
+unclear	O
+because	O
+these	O
+sealed	O
+vesicles	B-COMP
+lack	O
+a	O
+means	O
+of	O
+delivering	O
+viral	O
+RNA	O
+to	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+Significantly	O
+,	O
+spherules	O
+contain	O
+a	O
+channel	O
+connecting	O
+their	O
+interior	O
+to	O
+the	O
+cytoplasm	B-COMP
+and	O
+strongly	O
+resemble	O
+confirmed	O
+sites	O
+of	O
+RNA	B-PROC
+synthesis	I-PROC
+for	O
+other	O
+positive	O
+-	O
+sense	B-PROC
+RNA	O
+viruses	B-SPEC
+,	O
+making	O
+them	O
+ideal	O
+candidates	O
+for	O
+the	O
+site	O
+of	O
+IBV	B-SPEC
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+coincides	O
+with	O
+changes	O
+in	O
+the	O
+epidemiology	O
+of	O
+other	O
+viral	O
+pathogens	O
+causing	O
+acute	O
+respiratory	O
+tract	O
+infections	O
+in	O
+children	O
+.	O
+
+The	O
+RSV	B-SPEC
+and	O
+hMPV	B-SPEC
+epidemics	O
+of	O
+2009	O
+/	O
+2010	O
+erupted	O
+several	O
+weeks	O
+later	O
+than	O
+expected	O
+based	O
+on	O
+data	O
+collected	O
+in	O
+the	O
+PID	B-DISO
+-	O
+ARI	B-CHED
+-	O
+Network	O
+during	O
+the	O
+past	O
+10	O
+years	O
+,	O
+whereas	O
+in	O
+the	O
+2010	O
+/	O
+2011	O
+influenza	B-DISO
+season	O
+they	O
+occurred	O
+as	O
+expected	O
+.	O
+
+ABSTRACT	O
+:	O
+Hypoxemia	O
+is	O
+a	O
+feared	O
+complication	O
+of	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+,	O
+and	O
+high	O
+oxygen	B-CHED
+requirements	O
+will	O
+frequently	O
+lead	O
+to	O
+removal	O
+of	O
+patients	O
+from	O
+the	O
+transplant	B-ANAT
+list	O
+.	O
+
+Thirty	O
+-	O
+one	O
+(	O
+21	O
+%)	O
+had	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+17	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+[	O
+12	O
+%],	O
+9	O
+moderate	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+[	O
+12	O
+%],	O
+and	O
+5	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+)	O
+within	O
+the	O
+first	O
+72	O
+hours	O
+following	O
+admission	O
+.	O
+
+79	O
+.	O
+66	O
+%	O
+(	O
+141	O
+of	O
+177	O
+)	O
+pig	B-SPEC
+farms	O
+in	O
+29	O
+provinces	O
+(	O
+excluding	O
+Tibet	O
+and	O
+Hainan	O
+,	O
+China	O
+)	O
+and	O
+72	O
+.	O
+27	O
+%	O
+(	O
+417	O
+of	O
+577	O
+)	O
+samples	O
+were	O
+positive	O
+for	O
+PEDV	B-SPEC
+confirmed	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+Most	O
+field	O
+strains	O
+have	O
+nucleotide	B-CHED
+deletion	O
+and	O
+insertion	O
+regions	O
+,	O
+and	O
+show	O
+lower	O
+homologies	O
+(	O
+93	O
+.	O
+5	O
+%-	O
+94	O
+.	O
+2	O
+%)	O
+with	O
+Chinese	O
+classical	O
+strain	O
+CH	O
+/	O
+S	O
+,	O
+however	O
+higher	O
+homologies	O
+(	O
+97	O
+.	O
+1	O
+%-	O
+99	O
+.	O
+3	O
+%)	O
+with	O
+recent	O
+strain	O
+CHGD	O
+-	O
+1	O
+.	O
+
+TITLE	O
+:	O
+Real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+assay	O
+panel	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinical	O
+and	O
+laboratory	O
+findings	O
+in	O
+puppies	O
+naturally	O
+infected	O
+with	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCoV	O
+)	O
+and	O
+/	O
+or	O
+canine	O
+parvovirus	B-DISO
+(	O
+CPV	B-SPEC
+)	O
+were	O
+compared	O
+with	O
+findings	O
+in	O
+uninfected	O
+puppies	O
+.	O
+
+RESULTS	O
+:	O
+Using	O
+the	O
+five	O
+best	O
+-	O
+performing	O
+biomarkers	O
+(	O
+surfactant	B-CHED
+protein	B-PRGE
+-	I-PRGE
+D	I-PRGE
+(	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+),	O
+receptor	O
+for	O
+advanced	O
+glycation	O
+end	O
+-	O
+products	O
+(	O
+RAGE	O
+),	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+),	O
+club	B-PRGE
+cell	I-PRGE
+secretory	B-PROC
+protein	B-CHED
+(	O
+CC	O
+-	O
+16	O
+),	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+))	O
+the	O
+area	O
+under	O
+the	O
+receiver	O
+operator	O
+characteristic	O
+curve	O
+(	O
+AUC	O
+)	O
+was	O
+0	O
+.	O
+75	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+7	O
+to	O
+0	O
+.	O
+84	O
+)	O
+for	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+.	O
+
+Hypovolemia	O
+was	O
+defined	O
+as	O
+less	O
+than	O
+0	O
+%,	O
+euvolemia	O
+was	O
+defined	O
+as	O
+0	O
+%	O
+to	O
++	O
+16	O
+%,	O
+and	O
+hypervolemia	B-DISO
+was	O
+defined	O
+as	O
+greater	O
+than	O
++	O
+16	O
+%	O
+deviation	O
+from	O
+ideal	O
+BV	O
+.	O
+
+BNP	O
+and	O
+RVEDVI	O
+measurements	O
+obtained	O
+with	O
+BV	O
+analysis	O
+were	O
+evaluated	O
+with	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+and	O
+regression	O
+analysis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+critically	B-DISO
+ill	I-DISO
+surgical	O
+patients	O
+,	O
+BNP	O
+and	O
+RVEDVI	O
+were	O
+not	O
+associated	O
+with	O
+intravascular	O
+volume	O
+status	O
+,	O
+although	O
+they	O
+may	O
+be	O
+useful	O
+as	O
+indices	O
+that	O
+reflect	O
+increased	O
+cardiac	B-ANAT
+preload	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+are	O
+considered	O
+one	O
+of	O
+the	O
+most	O
+common	O
+respiratory	O
+viruses	B-SPEC
+associated	O
+with	O
+respiratory	B-ANAT
+tract	I-ANAT
+illnesses	O
+.	O
+
+The	O
+prevalence	O
+of	O
+HCoVs	O
+was	O
+higher	O
+among	O
+children	O
+with	O
+heart	O
+diseases	O
+(	O
+24	O
+.	O
+6	O
+%),	O
+patients	O
+under	O
+stem	B-ANAT
+cell	I-ANAT
+transplantation	O
+program	O
+(	O
+24	O
+.	O
+3	O
+%)	O
+and	O
+renal	B-ANAT
+transplanted	B-ANAT
+patients	O
+(	O
+20	O
+.	O
+2	O
+%).	O
+
+TITLE	O
+:	O
+Cardiopulmonary	B-ANAT
+involvement	O
+in	O
+Puumala	B-SPEC
+hantavirus	I-SPEC
+infection	O
+.	O
+
+Two	O
+-	O
+thirds	O
+of	O
+the	O
+patients	O
+experienced	O
+respiratory	O
+symptoms	O
+as	O
+dry	B-DISO
+cough	I-DISO
+or	O
+dyspnoea	B-DISO
+.	O
+
+In	O
+a	O
+majority	O
+of	O
+patients	O
+with	O
+PUUV	O
+-	O
+infection	B-DISO
+,	O
+both	O
+cardiac	B-ANAT
+and	O
+pulmonary	B-DISO
+involvement	I-DISO
+was	O
+demonstrated	O
+with	O
+implications	O
+on	O
+patients	O
+'	O
+recovery	O
+.	O
+
+RESULTS	O
+:	O
+Two	O
+-	O
+thirds	O
+of	O
+the	O
+patients	O
+experienced	O
+respiratory	B-DISO
+symptoms	I-DISO
+as	O
+dry	B-DISO
+cough	I-DISO
+or	O
+dyspnoea	B-DISO
+.	O
+
+In	O
+the	O
+most	O
+severe	O
+cases	O
+,	O
+it	O
+can	O
+cause	O
+pneumonia	B-DISO
+,	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+pulmonary	B-DISO
+hypertension	I-DISO
+,	O
+and	O
+death	B-PROC
+.	O
+
+RESULTS	O
+:	O
+IBV	B-SPEC
+infection	B-DISO
+contributed	O
+to	O
+differential	O
+expression	B-PROC
+of	O
+1777	O
+genes	O
+,	O
+of	O
+which	O
+876	O
+were	O
+up	O
+-	O
+regulated	O
+and	O
+901	O
+down	O
+-	O
+regulated	O
+in	O
+the	O
+kidney	B-ANAT
+compared	O
+to	O
+those	O
+of	O
+control	O
+chickens	B-SPEC
+and	O
+103	O
+associated	O
+with	O
+immune	O
+and	O
+inflammatory	B-DISO
+responses	I-DISO
+may	O
+play	O
+important	O
+roles	O
+in	O
+the	O
+host	B-PROC
+defense	B-PROC
+response	I-PROC
+during	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+Most	O
+of	O
+these	O
+genes	O
+were	O
+related	O
+and	O
+formed	O
+a	O
+large	O
+network	O
+,	O
+in	O
+which	O
+IL6	B-PRGE
+,	O
+STAT1	B-PRGE
+,	O
+MYD88	B-PRGE
+,	O
+IRF1	B-PRGE
+and	O
+NFKB2	B-PRGE
+were	O
+key	O
+genes	O
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+treated	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	O
+and	O
+brought	O
+to	O
+a	O
+referral	O
+center	O
+.	O
+
+Patients	O
+with	O
+an	O
+influenza	B-DISO
+pneumonia	I-DISO
+diagnosis	O
+and	O
+a	O
+SOFA	O
+score	O
+before	O
+ECMO	O
+of	O
+less	O
+than	O
+12	O
+had	O
+a	O
+mortality	O
+rate	O
+of	O
+22	O
+%.	O
+
+ABSTRACT	O
+:	O
+To	O
+document	O
+the	O
+clinical	O
+features	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+(	O
+GBS	B-DISO
+)	O
+in	O
+Australia	O
+,	O
+we	O
+performed	O
+a	O
+retrospective	O
+analysis	O
+of	O
+all	O
+patients	O
+admitted	O
+to	O
+several	O
+hospitals	O
+along	O
+the	O
+East	O
+Coast	O
+of	O
+Australia	O
+from	O
+2000	O
+to	O
+2012	O
+.	O
+
+Our	O
+results	O
+provide	O
+the	O
+strongest	O
+evidence	O
+to	O
+date	O
+that	O
+Chinese	O
+horseshoe	B-SPEC
+bats	I-SPEC
+are	O
+natural	O
+reservoirs	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+and	O
+that	O
+intermediate	O
+hosts	B-COMP
+may	O
+not	O
+be	O
+necessary	O
+for	O
+direct	O
+human	B-SPEC
+infection	B-DISO
+by	O
+some	O
+bat	B-ENZY
+SL	O
+-	O
+CoVs	O
+.	O
+
+The	O
+2007	O
+National	O
+Asthma	B-PATH
+Education	O
+and	O
+Prevention	O
+Program	O
+Expert	O
+Panel	O
+3	O
+provides	O
+guidelines	O
+for	O
+the	O
+treatment	O
+of	O
+uncontrolled	O
+asthma	B-PATH
+.	O
+
+Immunomodulation	B-PROC
+with	O
+drugs	O
+like	O
+omalizumab	O
+in	O
+IgE	B-DISO
+-	O
+mediated	O
+asthma	B-PATH
+syndromes	B-DISO
+is	O
+one	O
+important	O
+approach	O
+.	O
+
+TITLE	O
+:	O
+The	O
+unusual	O
+presentation	O
+of	O
+a	O
+usual	O
+organism	O
+-	O
+the	O
+changing	O
+spectrum	O
+of	O
+the	O
+clinical	O
+manifestations	O
+of	O
+Plasmodium	B-DISO
+vivax	I-DISO
+malaria	B-PATH
+in	O
+children	O
+:	O
+a	O
+retrospective	O
+study	O
+.	O
+
+Among	O
+all	O
+countries	O
+in	O
+the	O
+SE	O
+Asian	O
+region	O
+the	O
+highest	O
+number	O
+of	O
+cases	O
+and	O
+deaths	B-PROC
+are	O
+reported	O
+from	O
+India	O
+.	O
+
+However	O
+,	O
+in	O
+recent	O
+years	O
+,	O
+the	O
+spectrum	O
+of	O
+is	O
+shifting	O
+from	O
+being	O
+the	O
+cause	O
+of	O
+benign	O
+fever	B-PROC
+,	O
+to	O
+more	O
+severe	O
+complications	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Plasmodium	B-SPEC
+vivax	I-SPEC
+is	O
+emerging	O
+as	O
+a	O
+cause	O
+of	O
+severe	O
+malaria	B-PATH
+.	O
+
+Sequencing	O
+of	O
+the	O
+malaria	B-PATH
+parasite	O
+DNA	O
+from	O
+both	O
+cases	O
+,	O
+followed	O
+by	O
+multiple	O
+sequence	O
+alignment	O
+and	O
+phylogenetic	O
+tree	O
+construction	O
+suggested	O
+that	O
+the	O
+causative	O
+agent	O
+for	O
+both	O
+malaria	B-PATH
+cases	O
+was	O
+P	B-SPEC
+.	I-SPEC
+ovale	I-SPEC
+curtisi	I-SPEC
+.	O
+
+RESULTS	O
+:	O
+Sequencing	O
+of	O
+the	O
+malaria	B-PATH
+parasite	O
+DNA	O
+from	O
+both	O
+cases	O
+,	O
+followed	O
+by	O
+multiple	O
+sequence	O
+alignment	O
+and	O
+phylogenetic	O
+tree	O
+construction	O
+suggested	O
+that	O
+the	O
+causative	O
+agent	O
+for	O
+both	O
+malaria	B-PATH
+cases	O
+was	O
+P	B-SPEC
+.	I-SPEC
+ovale	I-SPEC
+curtisi	I-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+Plasmodium	B-SPEC
+ovale	I-SPEC
+is	O
+potentially	O
+capable	O
+of	O
+causing	O
+severe	O
+complications	O
+,	O
+if	O
+not	O
+death	B-PROC
+.	O
+
+As	O
+a	O
+strongly	O
+dissociated	O
+anion	B-CHED
+(	O
+pK	O
+'=	O
+3	O
+.	O
+7	O
+)	O
+directly	O
+changing	O
+the	O
+strong	O
+ion	O
+difference	O
+,	O
+lactate	B-CHED
+causes	O
+a	O
+reduction	O
+in	O
+the	O
+dependent	O
+anion	B-CHED
+[	O
+HCO3	O
+-]	O
+and	O
+a	O
+rise	O
+in	O
+[	O
+H	O
++],	O
+resulting	O
+in	O
+""""	O
+metabolic	B-PROC
+""""	O
+acidosis	B-DISO
+in	O
+the	O
+CSF	B-ANAT
+.	O
+
+Moreover	O
+,	O
+lactate	B-CHED
+and	O
+acidosis	B-DISO
+have	O
+been	O
+shown	O
+to	O
+cause	O
+astrocytic	B-ANAT
+swelling	B-DISO
+and	O
+to	O
+affect	O
+astrocytic	B-ANAT
+viability	O
+,	O
+potentially	O
+rendering	O
+astrocytes	B-ANAT
+more	O
+susceptible	O
+to	O
+AQP4	B-PRGE
+-	O
+Ab	O
+-	O
+mediated	O
+damage	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2002	O
+/	O
+2003	O
+,	O
+a	O
+novel	O
+coronavirus	O
+(	O
+CoV	O
+)	O
+caused	O
+a	O
+pandemic	O
+,	O
+infecting	O
+more	O
+than	O
+8000	O
+people	O
+,	O
+of	O
+whom	O
+nearly	O
+10	O
+%	O
+died	B-PROC
+.	O
+
+We	O
+also	O
+demonstrate	O
+a	O
+geographic	O
+bias	B-SPEC
+within	O
+available	O
+studies	O
+on	O
+bat	B-ENZY
+CoVs	O
+,	O
+and	O
+identify	O
+a	O
+critical	O
+lack	O
+of	O
+information	O
+from	O
+biodiversity	O
+hotspots	O
+in	O
+Africa	O
+,	O
+Asia	O
+and	O
+Latin	O
+America	O
+.	O
+
+This	O
+paper	O
+forms	O
+part	O
+of	O
+a	O
+symposium	O
+in	O
+Antiviral	B-CHED
+Research	O
+on	O
+""""	O
+from	O
+SARS	B-DISO
+to	O
+MERS	O
+:	O
+10years	O
+of	O
+research	O
+on	O
+highly	O
+pathogenic	O
+human	B-SPEC
+coronaviruses	O
+"""."	O
+
+This	O
+study	O
+fills	O
+a	O
+substantive	O
+gap	O
+in	O
+the	O
+knowledge	O
+on	O
+bat	B-ENZY
+-	O
+CoV	O
+ecology	O
+in	O
+Italy	O
+,	O
+and	O
+extends	O
+the	O
+current	O
+knowledge	O
+on	O
+clade	O
+2c	O
+betacoronaviruses	O
+with	O
+new	O
+sequences	O
+obtained	O
+from	O
+bats	B-SPEC
+that	O
+have	O
+not	O
+been	O
+previously	O
+described	O
+as	O
+hosts	B-COMP
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Biochemical	O
+analysis	O
+and	O
+application	O
+of	O
+molecular	O
+display	O
+technology	O
+on	O
+Candida	B-SPEC
+albicans	I-SPEC
+for	O
+diagnosing	O
+and	O
+preventing	O
+candidiasis	O
+.	O
+
+Three	O
+major	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+namely	O
+AIDS	O
+,	O
+malaria	B-PATH
+,	O
+and	O
+tuberculosis	B-PATH
+,	O
+are	O
+killing	O
+around	O
+8	O
+million	O
+people	O
+in	O
+the	O
+world	O
+annually	O
+.	O
+
+Given	O
+that	O
+ORF7	O
+encodes	O
+two	O
+proteins	B-CHED
+,	O
+7a	O
+and	O
+7b	O
+,	O
+it	O
+was	O
+further	O
+explored	O
+which	O
+of	O
+these	O
+proteins	B-CHED
+is	O
+active	O
+in	O
+this	O
+mechanism	O
+.	O
+
+ABSTRACT	O
+:	O
+Interferon	B-PRGE
+Lambda	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+λ	I-PRGE
+)	O
+is	O
+a	O
+type	O
+III	O
+interferon	B-PRGE
+which	O
+belongs	O
+to	O
+a	O
+novel	O
+family	B-SPEC
+of	O
+cytokines	O
+and	O
+possesses	B-DISO
+antiviral	B-CHED
+and	O
+antitumor	O
+properties	O
+.	O
+
+It	O
+is	O
+unique	O
+in	O
+its	O
+own	O
+class	B-SPEC
+of	O
+cytokines	O
+;	O
+because	O
+of	O
+the	O
+specificity	O
+towards	O
+its	O
+heterodimer	O
+receptors	O
+and	O
+its	O
+structural	O
+similarities	O
+with	O
+cytokines	O
+of	O
+other	O
+classes	O
+.	O
+
+TITLE	O
+:	O
+Bedside	O
+selection	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+in	O
+mild	O
+,	O
+moderate	O
+,	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Whole	O
+lung	B-ANAT
+CT	O
+scans	O
+were	O
+taken	O
+in	O
+static	O
+conditions	O
+at	O
+5	O
+and	O
+45	O
+cm	O
+H2O	B-CHED
+during	O
+an	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+/	O
+end	O
+-	O
+inspiratory	B-PROC
+pause	O
+to	O
+measure	O
+lung	B-ANAT
+recruitability	O
+.	O
+
+Positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+levels	O
+selected	O
+by	O
+the	O
+ExPress	O
+,	O
+stress	O
+index	O
+,	O
+and	O
+absolute	O
+esophageal	O
+pressures	O
+methods	O
+were	O
+unrelated	O
+with	O
+lung	B-ANAT
+recruitability	O
+,	O
+whereas	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+levels	O
+selected	O
+by	O
+the	O
+lung	B-ANAT
+open	O
+ventilation	O
+method	O
+showed	O
+a	O
+weak	O
+relationship	O
+with	O
+lung	B-ANAT
+recruitability	O
+(	O
+r	O
+=	O
+0	O
+.	O
+29	O
+;	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+The	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+selected	O
+by	O
+the	O
+different	O
+methods	O
+were	O
+unrelated	O
+to	O
+each	O
+other	O
+with	O
+the	O
+exception	O
+of	O
+the	O
+two	O
+methods	O
+based	O
+on	O
+lung	B-ANAT
+mechanics	O
+(	O
+ExPress	O
+and	O
+stress	O
+index	O
+).	O
+
+TITLE	O
+:	O
+Fatal	O
+colchicine	B-CHED
+poisoning	O
+by	O
+accidental	O
+ingestion	O
+of	O
+Colchicum	B-SPEC
+persicum	I-SPEC
+:	O
+a	O
+case	O
+report	O
+.	O
+
+The	O
+unknown	O
+cause	O
+of	O
+death	O
+was	O
+disclosed	O
+after	O
+determination	O
+of	O
+colchicine	B-CHED
+in	O
+the	O
+plant	B-SPEC
+and	O
+botanical	O
+identification	O
+as	O
+Colchicum	B-SPEC
+persicum	I-SPEC
+.	O
+
+The	O
+committee	O
+determined	O
+the	O
+most	O
+probable	O
+cause	O
+of	O
+death	B-PROC
+as	O
+acute	O
+cardiopulmonary	B-ANAT
+complications	O
+induced	O
+by	O
+colchicine	B-CHED
+poisoning	O
+and	O
+the	O
+manner	O
+of	O
+death	B-PROC
+as	O
+accidental	O
+.	O
+
+Virus	B-SPEC
+production	O
+in	O
+cell	B-COMP
+culture	O
+was	O
+confirmed	O
+by	O
+PEDV	B-SPEC
+-	O
+specific	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+immunofluorescence	O
+assays	O
+,	O
+and	O
+electron	O
+microscopy	O
+.	O
+
+These	O
+data	O
+indicated	O
+that	O
+activation	O
+of	O
+the	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathway	I-PROC
+represents	O
+a	O
+major	O
+contribution	O
+to	O
+the	O
+inflammation	B-DISO
+induced	O
+after	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+that	O
+NF	O
+-	O
+κB	O
+inhibitors	B-CHED
+are	O
+promising	O
+antivirals	B-CHED
+in	O
+infections	B-DISO
+caused	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+potentially	O
+other	O
+pathogenic	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+Although	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+induction	O
+by	O
+coronaviruses	O
+is	O
+modest	O
+,	O
+it	O
+effectively	O
+limits	O
+viral	O
+spread	O
+within	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+and	O
+protects	O
+against	O
+mortality	O
+.	O
+
+Bats	B-SPEC
+might	O
+play	O
+a	O
+role	O
+in	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+Real	O
+time	O
+RT	O
+-	O
+qPCR	O
+developed	O
+focusing	O
+on	O
+2	O
+up	O
+-	O
+regulated	O
+genes	O
+(	O
+PD	B-PRGE
+-	I-PRGE
+L1	I-PRGE
+and	O
+A3H	O
+)	O
+together	O
+with	O
+an	O
+apoptosis	B-PATH
+associated	O
+gene	O
+PD	O
+-	O
+1	O
+expressions	O
+in	O
+FIPV	O
+infected	O
+CRFK	O
+cells	B-COMP
+and	O
+in	O
+PBMCs	O
+from	O
+healthy	O
+and	O
+FIP	B-DISO
+diagnosed	O
+cats	B-SPEC
+produced	O
+concordant	O
+results	O
+with	O
+transcriptome	O
+data	O
+.	O
+
+Our	O
+aim	O
+is	O
+to	O
+verify	O
+if	O
+NAVA	O
+is	O
+feasible	O
+and	O
+safe	O
+in	O
+terms	O
+of	O
+physiological	O
+and	O
+clinical	O
+variables	O
+in	O
+infants	O
+recovering	O
+from	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+CD25	B-PRGE
+(+)	I-PRGE
+CD4	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+acute	O
+and	O
+persistent	O
+coronavirus	B-DISO
+infection	I-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	B-DISO
+system	I-ANAT
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+CNS	B-CHED
+inflammation	B-DISO
+,	O
+progression	O
+of	O
+viral	O
+control	O
+and	O
+viral	O
+persistence	O
+are	O
+relatively	O
+independent	O
+of	O
+CD25	B-PRGE
+(+)	I-PRGE
+CD4	I-PRGE
+(+)	I-PRGE
+Treg	O
+.	O
+
+Existing	O
+national	O
+guidelines	O
+do	O
+not	O
+present	O
+consistent	O
+or	O
+specific	O
+recommendations	O
+for	O
+the	O
+evaluation	O
+and	O
+treatment	O
+of	O
+individual	O
+asthma	B-PATH
+patients	O
+in	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+Acute	B-DISO
+severe	I-DISO
+asthma	I-DISO
+,	O
+refractory	O
+asthma	B-PATH
+,	O
+status	B-DISO
+asthmaticus	I-DISO
+,	O
+and	O
+near	O
+-	O
+fatal	O
+asthma	B-PATH
+all	O
+describe	O
+CAS	B-DISO
+where	O
+physical	O
+exhaustion	B-DISO
+from	O
+the	O
+overwhelming	O
+work	B-PROC
+of	I-PROC
+breathing	I-PROC
+leads	O
+to	O
+respiratory	B-DISO
+arrest	I-DISO
+and	O
+death	B-PROC
+from	O
+hypoxia	B-DISO
+or	O
+related	O
+complications	O
+.	O
+
+The	O
+authors	O
+of	O
+this	O
+supplement	O
+seek	O
+to	O
+emphasize	O
+the	O
+importance	O
+of	O
+early	O
+recognition	O
+,	O
+prompt	O
+and	O
+coordinated	O
+evaluation	O
+,	O
+and	O
+treatment	O
+of	O
+CAS	B-DISO
+in	O
+the	O
+emergency	B-DISO
+department	O
+,	O
+hospital	O
+,	O
+and	O
+intensive	O
+care	O
+units	O
+by	O
+experienced	O
+healthcare	O
+provider	O
+teams	O
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+receiving	O
+mechanical	O
+ventilation	O
+should	O
+receive	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+,	O
+whereby	O
+tidal	O
+volume	O
+is	O
+decreased	O
+to	O
+6	O
+ml	O
+/	O
+kg	O
+of	O
+their	O
+predicted	O
+weight	O
+and	O
+distending	O
+pressures	O
+are	O
+maintained	O
+≤	O
+30	O
+cm	O
+H2	O
+O	O
+,	O
+as	O
+well	O
+as	O
+increased	O
+inspired	B-PROC
+oxygen	B-CHED
+concentrations	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+to	O
+prevent	O
+atelectasis	O
+and	O
+support	O
+oxygenation	B-PROC
+.	O
+
+This	O
+commentary	O
+selectively	O
+reviews	O
+examples	O
+of	O
+where	O
+specific	O
+agents	O
+have	O
+provided	O
+promising	O
+clinical	O
+benefits	O
+in	O
+selected	O
+target	O
+populations	O
+and	O
+also	O
+considers	O
+potential	O
+therapeutics	O
+for	O
+emerging	O
+threats	O
+like	O
+the	O
+SARS	B-DISO
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronaviruses	O
+.	O
+
+A	O
+recent	O
+randomized	O
+controlled	O
+trial	O
+(	O
+RCT	O
+)	O
+comparing	O
+hyperimmune	O
+globulin	O
+prepared	O
+from	O
+convalescent	O
+plasma	B-ANAT
+against	O
+normal	O
+intravenous	O
+gammaglobulin	O
+(	O
+IVIG	O
+)	O
+manufactured	O
+before	O
+2009	O
+as	O
+control	O
+in	O
+patients	O
+with	O
+severe	O
+A	O
+(	O
+H1N1	B-PATH
+)	O
+pdm09	O
+infection	B-DISO
+on	O
+standard	O
+antiviral	B-CHED
+treatment	O
+has	O
+shown	O
+that	O
+the	O
+hyperimmune	O
+globulin	O
+group	O
+who	O
+received	O
+treatment	O
+within	O
+5	O
+days	O
+of	O
+symptom	O
+onset	O
+had	O
+a	O
+lower	O
+viral	O
+load	O
+and	O
+reduced	O
+mortality	O
+compared	O
+with	O
+the	O
+controls	O
+.	O
+
+Among	O
+patients	O
+with	O
+moderate	O
+ARDS	B-DISO
+,	O
+NIV	O
+failure	O
+was	O
+lower	O
+among	O
+those	O
+having	O
+a	O
+PaO2	O
+/	O
+FiO2	O
+>	O
+150	O
+mmHg	O
+(	O
+45	O
+%	O
+vs	O
+.	O
+74	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+canine	O
+coronavirus	B-SPEC
+strains	O
+circulating	O
+in	O
+Brazil	O
+.	O
+
+In	O
+this	O
+Review	O
+,	O
+we	O
+describe	O
+the	O
+emergence	O
+and	O
+identification	O
+of	O
+novel	O
+human	B-SPEC
+coronaviruses	O
+over	O
+the	O
+past	O
+10	O
+years	O
+,	O
+discuss	O
+their	O
+key	O
+biological	O
+features	O
+,	O
+including	O
+tropism	B-PROC
+and	O
+receptor	O
+use	O
+,	O
+and	O
+summarize	O
+approaches	O
+for	O
+developing	O
+broadly	O
+effective	O
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Investigation	O
+of	O
+anti	O
+-	O
+middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+antibodies	B-COMP
+in	O
+blood	B-ANAT
+donors	O
+and	O
+slaughterhouse	O
+workers	O
+in	O
+Jeddah	O
+and	O
+Makkah	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+fall	O
+2012	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+developed	O
+rhesus	B-SPEC
+macaques	I-SPEC
+as	O
+a	O
+model	O
+for	O
+MERS	O
+-	O
+CoV	O
+using	O
+intratracheal	O
+inoculation	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+blastomycosis	B-DISO
+infection	B-DISO
+in	O
+a	O
+patient	O
+with	O
+hypertension	B-DISO
+,	O
+cirrhosis	B-DISO
+and	O
+chronic	O
+pancreatitis	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+case	O
+of	O
+cardiac	B-ANAT
+blastomycosis	B-DISO
+who	O
+initially	O
+presented	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+In	O
+our	O
+patient	O
+,	O
+it	O
+was	O
+practically	O
+impossible	O
+to	O
+establish	O
+a	O
+diagnosis	O
+of	O
+cardiac	B-ANAT
+blastomycosis	B-DISO
+antemortem	O
+because	O
+of	O
+his	O
+previous	O
+cardiac	B-ANAT
+history	O
+related	O
+to	O
+alcoholic	B-DISO
+cardiomyopathy	I-DISO
+,	O
+which	O
+confounded	O
+the	O
+cardiac	B-ANAT
+findings	O
+.	O
+
+TITLE	O
+:	O
+Regulation	B-PROC
+of	O
+ROS	B-CHED
+in	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+-	O
+activated	O
+apoptotic	O
+signaling	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+TGEV	B-SPEC
+infection	B-DISO
+lowered	O
+mitochondrial	B-COMP
+transmembrane	B-PROC
+potential	I-PROC
+in	O
+PK	O
+-	O
+15	O
+cell	B-ANAT
+line	I-ANAT
+,	O
+which	O
+could	O
+be	O
+inhibited	O
+by	O
+ROS	B-CHED
+scavengers	B-SPEC
+,	O
+pyrrolidinedithiocarbamic	O
+(	O
+PDTC	O
+)	O
+and	O
+N	B-CHED
+-	I-CHED
+acetyl	I-CHED
+-	I-CHED
+l	I-CHED
+-	I-CHED
+cysteine	I-CHED
+(	O
+NAC	B-COMP
+).	O
+
+Expression	B-PROC
+of	O
+TMPRSS2	O
+increased	O
+cellular	B-COMP
+uptake	O
+of	O
+soluble	O
+SARS	B-PRGE
+-	I-PRGE
+S	I-PRGE
+,	O
+suggesting	O
+that	O
+protease	O
+-	O
+dependent	O
+augmentation	O
+of	O
+viral	O
+entry	O
+might	O
+be	O
+due	O
+to	O
+increased	O
+uptake	O
+of	O
+virions	B-COMP
+into	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+Furthermore	O
+,	O
+a	O
+single	O
+amino	B-CHED
+acid	I-CHED
+change	O
+in	O
+the	O
+viral	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+modulated	O
+virus	B-SPEC
+-	O
+induced	O
+neuropathology	B-DISO
+in	O
+mice	B-SPEC
+from	O
+an	O
+encephalitis	B-DISO
+to	O
+a	O
+neuropathology	B-DISO
+characterized	O
+by	O
+flaccid	B-DISO
+paralysis	I-DISO
+,	O
+which	O
+involves	O
+glutamate	B-CHED
+excitotoxicity	O
+.	O
+
+ABSTRACT	O
+:	O
+Myoclonic	O
+status	O
+epilepticus	O
+(	O
+MSE	O
+)	O
+within	O
+the	O
+first	O
+24	O
+hours	O
+after	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+(	O
+CPR	B-ENZY
+)	O
+predicts	O
+poor	O
+prognosis	O
+,	O
+enough	O
+to	O
+discontinue	O
+the	O
+treatment	O
+.	O
+
+Hemodynamics	B-PROC
+,	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+,	O
+and	O
+the	O
+plasma	B-ANAT
+levels	O
+of	O
+lactate	B-CHED
+,	O
+creatinine	B-CHED
+and	O
+potassium	B-CHED
+were	O
+measured	O
+at	O
+0	O
+,	O
+1	O
+,	O
+2	O
+,	O
+3	O
+,	O
+and	O
+4	O
+h	O
+after	O
+treatment	O
+.	O
+
+One	O
+hundred	O
+and	O
+three	O
+(	O
+89	O
+.	O
+6	O
+%)	O
+of	O
+115	O
+patients	O
+presented	O
+with	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+,	O
+and	O
+22	O
+(	O
+19	O
+.	O
+1	O
+%)	O
+of	O
+115	O
+proceeded	O
+to	O
+the	O
+stage	O
+of	O
+life	O
+threatening	O
+multiple	O
+organ	O
+failure	O
+.	O
+
+SFTSV	O
+infection	B-DISO
+may	O
+present	O
+with	O
+more	O
+severe	O
+symptoms	O
+and	O
+laboratory	O
+abnormalities	O
+than	O
+hitherto	O
+reported	O
+.	O
+
+TITLE	O
+:	O
+The	O
+lectin	B-PRGE
+ERGIC	I-PRGE
+-	I-PRGE
+53	I-PRGE
+goes	B-SPEC
+viral	O
+.	O
+
+ABSTRACT	O
+:	O
+Arenaviruses	B-SPEC
+and	O
+hantaviruses	B-SPEC
+cause	O
+severe	O
+human	B-SPEC
+disease	O
+.	O
+
+We	O
+identified	O
+human	B-SPEC
+proteins	B-CHED
+that	O
+interact	O
+with	O
+the	O
+glycoproteins	B-CHED
+(	O
+GPs	B-DISO
+)	O
+of	O
+a	O
+prototypic	O
+arenavirus	B-SPEC
+and	O
+hantavirus	B-SPEC
+and	O
+show	O
+that	O
+the	O
+lectin	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)-	O
+Golgi	B-COMP
+intermediate	O
+compartment	B-ANAT
+53	O
+kDa	O
+protein	B-CHED
+(	O
+ERGIC	B-COMP
+-	O
+53	O
+),	O
+a	O
+cargo	O
+receptor	O
+required	O
+for	O
+glycoprotein	B-CHED
+trafficking	B-PROC
+within	O
+the	O
+early	O
+exocytic	O
+pathway	B-PROC
+,	O
+associates	O
+with	O
+arenavirus	B-SPEC
+,	O
+hantavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+orthomyxovirus	B-SPEC
+,	O
+and	O
+filovirus	B-SPEC
+GPs	B-DISO
+.	O
+
+Thus	O
+,	O
+we	O
+have	O
+identified	O
+a	O
+class	B-SPEC
+of	O
+pathogen	O
+-	O
+derived	O
+ERGIC	B-COMP
+-	O
+53	O
+ligands	O
+,	O
+a	O
+lectin	B-PRGE
+-	O
+independent	O
+basis	O
+for	O
+their	O
+association	O
+with	O
+ERGIC	B-COMP
+-	O
+53	O
+,	O
+and	O
+a	O
+role	O
+for	O
+ERGIC	B-COMP
+-	O
+53	O
+in	O
+the	O
+propagation	O
+of	O
+several	O
+highly	O
+pathogenic	O
+RNA	O
+virus	B-SPEC
+families	O
+.	O
+
+Analysis	O
+of	O
+human	B-SPEC
+clusters	B-CHED
+indicated	O
+that	O
+chains	O
+of	O
+transmission	O
+were	O
+not	O
+self	O
+-	O
+sustaining	O
+when	O
+infection	B-DISO
+control	O
+was	O
+implemented	O
+,	O
+but	O
+that	O
+R	O
+in	O
+the	O
+absence	O
+of	O
+controls	O
+was	O
+in	O
+the	O
+range	O
+0	O
+·	O
+8	O
+-	O
+1	O
+·	O
+3	O
+.	O
+
+ABSTRACT	O
+:	O
+Ten	O
+years	O
+have	O
+elapsed	O
+since	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+outbreak	O
+,	O
+which	O
+resulted	O
+in	O
+more	O
+than	O
+8000	O
+cases	O
+worldwide	O
+with	O
+more	O
+than	O
+700	O
+deaths	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+more	O
+severe	O
+form	O
+,	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+have	O
+high	O
+mortality	O
+rates	O
+with	O
+few	O
+treatment	O
+options	O
+.	O
+
+Degradation	O
+of	O
+the	O
+glycosaminoglycan	B-CHED
+,	O
+hyaluronan	B-CHED
+(	O
+HA	B-CHED
+),	O
+is	O
+involved	O
+in	O
+reduction	O
+of	O
+the	O
+endothelial	B-ANAT
+glycocalyx	B-COMP
+,	O
+disruption	O
+of	O
+endothelial	B-ANAT
+cell	I-ANAT
+-	O
+cell	B-COMP
+contacts	O
+and	O
+activation	O
+of	O
+HA	B-PRGE
+binding	B-FUNC
+proteins	B-CHED
+upregulated	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+which	O
+promote	O
+a	O
+loss	O
+of	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+integrity	O
+.	O
+
+TITLE	O
+:	O
+Insufficient	O
+preparedness	O
+of	O
+primary	O
+care	O
+practices	O
+for	O
+pandemic	O
+influenza	B-DISO
+and	O
+the	O
+effect	O
+of	O
+a	O
+preparedness	O
+plan	O
+in	O
+Japan	O
+:	O
+a	O
+prefecture	O
+-	O
+wide	O
+cross	O
+-	O
+sectional	O
+study	O
+.	O
+
+Clinic	O
+-	O
+based	O
+PCPs	O
+were	O
+significantly	O
+less	O
+prepared	O
+than	O
+hospital	O
+-	O
+based	O
+PCPs	O
+to	O
+provide	O
+N95	O
+masks	O
+(	O
+OR	O
+0	O
+.	O
+34	O
+),	O
+gowns	O
+(	O
+OR	O
+0	O
+.	O
+15	O
+),	O
+and	O
+eye	B-ANAT
+protection	O
+(	O
+OR	O
+0	O
+.	O
+18	O
+).	O
+
+With	O
+regard	O
+to	O
+PPE	B-CHED
+availability	O
+,	O
+PCPs	O
+(	O
+especially	O
+clinic	O
+-	O
+based	O
+PCPs	O
+)	O
+were	O
+not	O
+adequately	O
+prepared	O
+for	O
+the	O
+influenza	B-DISO
+pandemic	O
+.	O
+
+CoV	O
+N	O
+proteins	B-CHED
+within	O
+but	O
+not	O
+across	O
+subgroups	O
+share	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+epitopes	O
+with	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+.	O
+
+Thus	O
+,	O
+we	O
+investigated	O
+the	O
+effect	O
+on	O
+oxygenation	B-PROC
+and	O
+the	O
+safety	O
+of	O
+PP	O
+during	O
+vvECMO	O
+.	O
+
+Retrospective	O
+quantitative	O
+analysis	O
+of	O
+CT	O
+scan	O
+images	O
+of	O
+148	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+100	O
+control	O
+subjects	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+wealth	O
+of	O
+information	O
+available	O
+for	O
+the	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+)-	O
+associated	O
+ribonuclease	B-PRGE
+H	I-PRGE
+(	O
+RNaseH	O
+)	O
+domain	O
+of	O
+lentiviruses	O
+,	O
+gammaretroviruses	B-SPEC
+and	O
+long	O
+terminal	O
+repeat	O
+containing	O
+retrotransposons	O
+,	O
+exploiting	O
+this	O
+information	O
+in	O
+the	O
+form	O
+of	O
+an	O
+RNaseH	O
+inhibitor	B-CHED
+with	O
+high	O
+specificity	O
+and	O
+low	O
+cellular	B-COMP
+toxicity	O
+has	O
+been	O
+disappointing	O
+.	O
+
+This	O
+review	O
+summarizes	O
+current	O
+progress	O
+towards	O
+development	B-PROC
+of	O
+both	O
+active	O
+site	O
+and	O
+allosteric	O
+RNaseH	O
+inhibitors	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Proteus	B-DISO
+syndrome	I-DISO
+is	O
+a	O
+rare	O
+genetic	O
+disease	O
+which	O
+is	O
+characterized	O
+by	O
+the	O
+overgrowth	O
+of	O
+tissues	B-ANAT
+,	O
+especially	O
+bone	B-ANAT
+,	O
+connective	O
+and	O
+adipose	B-ANAT
+tissue	I-ANAT
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+25	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+,	O
+diagnosed	O
+with	O
+the	O
+Proteus	B-DISO
+syndrome	I-DISO
+at	O
+the	O
+age	O
+of	O
+6	O
+months	O
+.	O
+
+Prominent	O
+among	O
+them	O
+is	O
+the	O
+effect	O
+that	O
+the	O
+disease	O
+has	O
+on	O
+lung	B-PROC
+growth	B-PROC
+and	O
+function	O
+.	O
+
+This	O
+research	O
+has	O
+provided	O
+significant	O
+new	O
+insight	O
+into	O
+many	O
+mechanisms	O
+used	O
+by	O
+the	O
+coronavirus	B-SPEC
+replication	O
+-	O
+transcription	B-PROC
+complex	O
+(	O
+RTC	O
+).	O
+
+TITLE	O
+:	O
+Rates	O
+of	O
+respiratory	O
+virus	B-SPEC
+-	O
+associated	O
+hospitalization	O
+in	O
+children	O
+aged	O
+<	O
+5	O
+years	O
+in	O
+rural	O
+northern	O
+India	O
+.	O
+
+Of	O
+245	O
+hospitalized	O
+children	O
+,	O
+respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+among	O
+98	O
+(	O
+40	O
+%),	O
+of	O
+whom	O
+92	O
+(	O
+94	O
+%)	O
+had	O
+fever	O
+or	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Using	O
+this	O
+model	O
+,	O
+MERS	O
+-	O
+CoV	O
+is	O
+placed	O
+into	O
+disorder	O
+group	O
+C	O
+,	O
+which	O
+consists	O
+of	O
+coronaviruses	O
+that	O
+have	O
+relatively	O
+hard	O
+inner	O
+and	O
+outer	O
+shells	B-ANAT
+.	O
+
+Oral	B-ANAT
+-	O
+urine	B-ANAT
+and	O
+saliva	B-ANAT
+transmission	O
+are	O
+also	O
+highly	O
+possible	O
+since	O
+both	O
+require	O
+harder	O
+protective	O
+shells	O
+.	O
+
+Nearly	O
+all	O
+symptomatic	O
+patients	O
+presented	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+1	O
+/	O
+3	O
+of	O
+patients	O
+also	O
+had	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+.	O
+
+Outbreaks	O
+have	O
+been	O
+extinguished	O
+without	O
+overly	O
+aggressive	B-DISO
+isolation	O
+and	O
+quarantine	O
+suggesting	O
+that	O
+transmission	B-PROC
+of	I-PROC
+virus	I-PROC
+may	O
+be	O
+stopped	O
+with	O
+implementation	O
+of	O
+appropriate	O
+infection	B-DISO
+control	O
+measures	O
+.	O
+
+Furthermore	O
+,	O
+miR	B-PRGE
+-	I-PRGE
+146a	I-PRGE
+delivery	I-PRGE
+or	O
+Akt2	B-PRGE
+silencing	O
+in	O
+WT	O
+mice	B-SPEC
+exposed	O
+to	O
+acid	O
+resulted	O
+in	O
+suppression	B-DISO
+of	O
+iNOS	O
+in	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+recent	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+pandemic	O
+,	O
+due	O
+to	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+many	O
+patients	O
+required	O
+treatment	O
+with	O
+alternative	O
+ventilator	O
+modalities	O
+including	O
+High	O
+Frequency	O
+Oscillatory	O
+Ventilation	O
+(	O
+HFOV	O
+).	O
+
+However	O
+,	O
+no	O
+experimental	O
+studies	O
+have	O
+been	O
+conducted	O
+to	O
+demonstrate	O
+TCoV	O
+pathogenesis	B-DISO
+in	O
+turkey	B-SPEC
+hens	O
+and	O
+its	O
+effect	O
+on	O
+reproductive	B-PROC
+performance	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+assessed	O
+the	O
+possible	O
+effect	O
+of	O
+TCoV	O
+on	O
+the	O
+reproductive	B-PROC
+performance	O
+of	O
+experimentally	O
+infected	O
+turkey	B-SPEC
+hens	O
+.	O
+
+In	O
+both	O
+experimental	O
+trials	O
+an	O
+average	O
+of	O
+28	O
+%-	O
+29	O
+%	O
+drop	O
+in	O
+egg	B-ANAT
+production	O
+was	O
+observed	O
+in	O
+TCoV	O
+-	O
+infected	O
+turkey	B-SPEC
+hens	O
+between	O
+4	O
+and	O
+7	O
+DPI	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+IBV	B-SPEC
+K40	O
+/	O
+09	O
+could	O
+be	O
+useful	O
+to	O
+ensure	O
+IBV	B-SPEC
+vaccine	O
+effectiveness	O
+owing	O
+to	O
+its	O
+cross	O
+-	O
+protective	O
+ability	O
+.	O
+
+TITLE	O
+:	O
+AVPdb	O
+:	O
+a	O
+database	O
+of	O
+experimentally	O
+validated	O
+antiviral	B-CHED
+peptides	B-CHED
+targeting	B-PROC
+medically	O
+important	O
+viruses	O
+.	O
+
+These	O
+combined	O
+results	O
+indicate	O
+that	O
+signaling	B-PROC
+through	O
+TNFR1	B-PRGE
+plays	O
+an	O
+essential	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+FH	O
+caused	O
+by	O
+MHV	B-SPEC
+-	O
+3	O
+infection	B-DISO
+,	O
+and	O
+interruption	O
+of	O
+this	O
+signaling	B-PROC
+pathway	I-PROC
+could	O
+be	O
+useful	O
+for	O
+clinical	O
+therapy	O
+.	O
+
+Consequently	O
+,	O
+new	O
+aptamer	O
+-	O
+based	O
+therapeutics	O
+have	O
+the	O
+potential	O
+to	O
+lead	O
+a	O
+revolution	O
+in	O
+the	O
+development	B-PROC
+of	O
+anti	B-CHED
+-	I-CHED
+infective	I-CHED
+drugs	I-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+recombinant	O
+IBV	B-SPEC
+is	O
+developed	O
+by	O
+replacing	O
+the	O
+ectodomain	O
+region	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+IBV	B-SPEC
+Beaudette	O
+strain	O
+with	O
+the	O
+corresponding	O
+fragment	O
+from	O
+H120	O
+strain	O
+,	O
+designated	O
+as	O
+rBeau	O
+-	O
+H120	O
+(	O
+S1e	O
+).	O
+
+The	O
+peak	O
+titer	O
+would	O
+reach	B-PROC
+10	O
+(	O
+5	O
+.	O
+9	O
+)	O
+50	O
+%	O
+(	O
+median	O
+)	O
+tissue	B-ANAT
+culture	O
+infective	O
+dose	O
+/	O
+mL	O
+at	O
+24	O
+h	O
+post	O
+-	O
+infection	O
+.	O
+
+Current	O
+evidence	O
+indicates	O
+that	O
+these	O
+viruses	B-SPEC
+may	O
+employ	O
+such	O
+strategies	O
+to	O
+avert	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+.	O
+
+As	O
+viral	O
+proteins	B-CHED
+interact	O
+with	O
+key	O
+regulators	O
+of	O
+the	O
+host	B-COMP
+nuclear	B-PROC
+transport	I-PROC
+machinery	O
+,	O
+viruses	B-SPEC
+have	O
+served	O
+as	O
+invaluable	O
+tools	O
+of	O
+discovery	O
+that	O
+led	O
+to	O
+the	O
+identification	O
+of	O
+novel	O
+constituents	O
+of	O
+nuclear	O
+transport	O
+pathways	B-PROC
+.	O
+
+Interestingly	O
+,	O
+both	O
+groups	O
+of	O
+Thai	O
+PEDV	B-SPEC
+isolates	O
+had	O
+a	O
+4	O
+-	O
+aa	O
+(	O
+GENQ	O
+)	O
+insertion	O
+between	O
+positions	O
+55	O
+and	O
+56	O
+,	O
+a	O
+1	O
+-	O
+aa	O
+insertion	O
+between	O
+positions	O
+135	O
+and	O
+136	O
+,	O
+and	O
+a	O
+2	O
+-	O
+aa	O
+deletion	O
+between	O
+positions	O
+155	O
+and	O
+156	O
+,	O
+making	O
+them	O
+identical	O
+to	O
+the	O
+Korean	O
+KNU	O
+series	O
+and	O
+isolates	O
+responsible	O
+for	O
+outbreaks	O
+in	O
+China	O
+in	O
+recent	O
+years	O
+.	O
+
+The	O
+14	O
+PEDV	B-SPEC
+isolates	O
+were	O
+classified	O
+as	O
+G1	O
+and	O
+showed	O
+a	O
+close	O
+relationship	O
+to	O
+some	O
+Chinese	O
+strains	O
+isolated	O
+previously	O
+in	O
+central	O
+China	O
+and	O
+differed	O
+genetically	O
+from	O
+recent	O
+isolates	O
+from	O
+southern	O
+China	O
+,	O
+Korean	O
+strains	O
+(	O
+SM98	O
+and	O
+DB1865	O
+,	O
+2012	O
+),	O
+the	O
+Chinese	O
+LZC	O
+strain	O
+(	O
+2007	O
+),	O
+and	O
+the	O
+vaccine	O
+strain	O
+(	O
+CV777	O
+)	O
+being	O
+used	O
+in	O
+China	O
+.	O
+
+There	O
+are	O
+still	O
+over	O
+2	O
+million	O
+deaths	B-PROC
+annually	O
+from	O
+tuberculosis	B-PATH
+,	O
+with	O
+most	O
+of	O
+these	O
+occurring	O
+in	O
+the	O
+developing	O
+world	O
+.	O
+
+Asthma	B-PATH
+,	O
+one	O
+of	O
+the	O
+most	O
+common	O
+chronic	B-DISO
+diseases	I-DISO
+in	O
+children	O
+,	O
+still	O
+accounts	O
+for	O
+significant	O
+mortality	O
+and	O
+morbidity	O
+,	O
+as	O
+well	O
+as	O
+high	O
+health	O
+care	O
+costs	O
+worldwide	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+identification	O
+of	O
+pathogens	O
+of	O
+viral	O
+(	O
+Rotavirus	O
+,	O
+Coronavirus	B-SPEC
+),	O
+parasitic	O
+(	O
+Toxocara	B-PRGE
+spp	B-ENZY
+.)	I-PRGE
+and	I-PRGE
+bacterial	I-PRGE
+(	I-PRGE
+Escherichia	B-SPEC
+coli	I-SPEC
+,	I-PRGE
+Salmonella	B-DISO
+spp	B-ENZY
+.,	O
+Rhodococcus	B-SPEC
+equi	I-SPEC
+)	O
+origin	O
+shed	O
+in	O
+feces	B-ANAT
+,	O
+and	O
+the	O
+virulence	B-PROC
+profile	O
+of	O
+R	B-SPEC
+.	I-SPEC
+equi	I-SPEC
+and	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolates	O
+were	O
+investigated	O
+in	O
+200	O
+samples	O
+of	O
+sand	O
+obtained	O
+from	O
+40	O
+parks	O
+,	O
+located	O
+in	O
+central	O
+region	O
+of	O
+state	O
+of	O
+Sao	O
+Paulo	O
+,	O
+Brazil	O
+,	O
+using	O
+different	O
+diagnostic	O
+methods	O
+.	O
+
+None	O
+of	O
+the	O
+R	B-SPEC
+.	I-SPEC
+equi	I-SPEC
+isolates	O
+showed	O
+a	O
+virulent	O
+(	O
+vapA	B-PRGE
+gene	I-PRGE
+)	O
+or	O
+intermediately	O
+virulent	O
+(	O
+vapB	B-PRGE
+gene	I-PRGE
+)	O
+profiles	O
+.	O
+
+The	O
+following	O
+genes	O
+encoding	O
+virulence	B-PROC
+factors	O
+were	O
+identified	O
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+:	O
+eae	O
+,	O
+bfp	B-PRGE
+,	O
+saa	B-PRGE
+,	O
+iucD	B-PRGE
+,	O
+papGI	O
+,	O
+sfa	B-PRGE
+and	O
+hly	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+mice	B-SPEC
+to	O
+DNA	O
+vaccines	O
+containing	O
+individual	O
+S	O
+or	O
+M	O
+genes	O
+of	O
+a	O
+new	O
+type	O
+of	O
+reovirus	B-SPEC
+(	O
+nRV	O
+)	O
+isolate	O
+from	O
+a	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patient	O
+in	O
+Beijing	O
+,	O
+China	O
+.	O
+
+We	O
+found	O
+that	O
+all	O
+DNA	O
+vaccines	O
+induced	O
+IgG	B-PRGE
+antibodies	B-COMP
+,	O
+predominantly	O
+of	O
+the	O
+IgG2a	B-COMP
+class	B-SPEC
+and	O
+S3	O
+DNA	O
+vaccine	O
+was	O
+the	O
+strongest	O
+inducer	O
+.	O
+
+TITLE	O
+:	O
+Extracting	O
+Computational	O
+and	O
+Semantic	O
+Features	O
+from	O
+Portable	O
+Chest	B-ANAT
+X	O
+-	O
+rays	B-SPEC
+for	O
+Diagnosis	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Our	O
+approach	O
+demonstrates	O
+the	O
+feasibility	O
+of	O
+using	O
+machine	O
+learning	B-PROC
+to	O
+identify	O
+radiographic	O
+criteria	O
+that	O
+are	O
+more	O
+consistent	O
+and	O
+accurate	O
+for	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+.	O
+
+In	O
+conclusion	O
+,	O
+multiple	O
+IBV	B-SPEC
+genotypes	O
+co	O
+-	O
+circulated	O
+;	O
+genetic	O
+diversity	O
+and	O
+positive	O
+selections	O
+existed	O
+in	O
+S1	O
+,	O
+M	O
+and	O
+N	O
+genes	O
+;	O
+4	O
+/	O
+91	O
+vaccine	O
+recombinants	O
+emerged	O
+in	O
+China	O
+.	O
+
+The	O
+addition	O
+of	O
+FOS	O
+to	O
+the	O
+vaccine	O
+also	O
+increased	O
+the	O
+number	O
+of	O
+circulating	O
+CD4	B-PRGE
++	I-PRGE
+cells	B-COMP
+in	O
+L10H	O
+chickens	B-SPEC
+compared	O
+to	O
+L10L	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+February	O
+2013	O
+,	O
+a	O
+novel	O
+reassortant	O
+H7N9	O
+virus	O
+associated	O
+with	O
+human	B-SPEC
+deaths	B-PROC
+,	O
+but	O
+no	O
+apparent	O
+outbreaks	O
+in	O
+poultry	O
+and	O
+wild	O
+birds	B-SPEC
+has	O
+emerged	O
+in	O
+eastern	O
+China	O
+.	O
+
+They	O
+presented	O
+with	O
+fever	B-PROC
+and	O
+rapidly	O
+progressive	O
+pneumonia	B-DISO
+that	O
+did	O
+not	O
+respond	O
+to	O
+antibiotics	B-CHED
+.	O
+
+Pulmonary	B-DISO
+fibrosis	I-DISO
+can	O
+be	O
+seen	O
+at	O
+late	O
+stage	O
+of	O
+the	O
+disease	O
+.	O
+
+In	O
+dairy	O
+herds	O
+,	O
+milk	O
+is	O
+more	O
+readily	O
+collected	O
+than	O
+serum	B-COMP
+.	O
+
+TITLE	O
+:	O
+Peptides	B-CHED
+corresponding	O
+to	O
+the	O
+predicted	O
+heptad	O
+repeat	O
+2	O
+domain	O
+of	O
+the	O
+feline	B-SPEC
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	I-PRGE
+are	O
+potent	O
+inhibitors	B-CHED
+of	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Hospitalized	O
+children	O
+<	O
+2	O
+years	O
+of	O
+age	O
+in	O
+Amman	O
+,	O
+Jordan	O
+,	O
+admitted	O
+for	O
+fever	O
+and	O
+/	O
+or	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+were	O
+tested	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+):	O
+MERS	O
+-	O
+CoV	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+(	O
+rRT	O
+-	O
+PCR	O
+).	O
+
+TITLE	O
+:	O
+Trends	O
+in	O
+influenza	B-DISO
+vaccination	O
+coverage	O
+in	O
+Portugal	O
+from	O
+1998	O
+to	O
+2010	O
+:	O
+effect	O
+of	O
+major	O
+pandemic	O
+threats	O
+.	O
+
+This	O
+article	O
+describes	O
+national	O
+trends	O
+in	O
+seasonal	O
+influenza	B-DISO
+vaccine	O
+(	O
+IV	O
+)	O
+coverage	O
+in	O
+Portugal	O
+from	O
+1998	O
+/	O
+99	O
+to	O
+2010	O
+/	O
+11	O
+,	O
+analyzes	O
+progress	O
+towards	O
+meeting	O
+WHO	O
+2010	O
+coverage	O
+goals	O
+,	O
+and	O
+addresses	O
+the	O
+effect	O
+of	O
+major	O
+public	O
+health	O
+threats	O
+of	O
+the	O
+last	O
+12	O
+years	O
+(	O
+SARS	B-DISO
+in	O
+2003	O
+/	O
+04	O
+,	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+in	O
+2005	O
+/	O
+06	O
+,	O
+and	O
+the	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+2009	O
+pandemic	O
+)	O
+on	O
+vaccination	O
+trends	O
+.	O
+
+3CL	O
+(	O
+pro	B-CHED
+)	O
+plays	O
+a	O
+pivotal	O
+role	O
+in	O
+the	O
+viral	B-PROC
+replication	I-PROC
+cycle	I-PROC
+and	O
+is	O
+a	O
+potential	O
+target	O
+for	O
+SARS	B-DISO
+inhibitor	B-CHED
+development	B-PROC
+.	O
+
+A	O
+series	O
+of	O
+isatin	B-CHED
+derivatives	O
+as	O
+possible	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+inhibitors	B-CHED
+was	O
+designed	O
+,	O
+synthesized	O
+,	O
+and	O
+evaluated	O
+by	O
+in	O
+vitro	O
+protease	O
+assay	O
+using	O
+fluorogenic	O
+substrate	O
+peptide	B-CHED
+,	O
+in	O
+which	O
+several	O
+showed	O
+potent	O
+inhibition	B-PROC
+against	O
+the	O
+3CL	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+).	I-PRGE
+
+ABSTRACT	O
+:	O
+The	O
+temporal	O
+and	O
+spatial	O
+distributions	O
+of	O
+the	O
+2003	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Amoy	O
+Gardens	O
+of	O
+Hong	O
+Kong	O
+was	O
+reexamined	O
+using	O
+all	O
+confirmed	O
+cases	O
+.	O
+
+Under	O
+these	O
+circumstances	O
+,	O
+clinicians	O
+urgently	O
+need	O
+clinical	O
+trials	O
+and	O
+formal	B-CHED
+indication	O
+,	O
+contraindication	O
+and	O
+rules	O
+for	O
+implementation	O
+to	O
+provide	O
+reproducible	O
+results	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+presents	O
+a	O
+novel	O
+emerging	O
+threat	O
+to	O
+public	O
+health	O
+worldwide	O
+.	O
+
+Several	O
+treatments	O
+for	O
+infected	O
+individuals	O
+have	O
+been	O
+suggested	O
+including	O
+IFN	B-PRGE
+,	O
+ribavirin	B-CHED
+and	O
+passive	O
+immunotherapy	O
+with	O
+convalescent	O
+plasma	B-ANAT
+.	O
+
+Ribavirin	B-CHED
+did	O
+not	O
+inhibit	O
+viral	B-PROC
+replication	I-PROC
+in	O
+vitro	O
+at	O
+a	O
+dose	O
+that	O
+would	O
+be	O
+applicable	O
+to	O
+current	O
+treatment	O
+protocols	O
+in	O
+humans	B-SPEC
+.	O
+
+To	O
+determine	O
+their	O
+role	O
+during	O
+RCoV	O
+infection	B-DISO
+,	O
+PMN	B-PROC
+were	O
+depleted	O
+and	O
+the	O
+effects	O
+on	O
+disease	B-DISO
+progression	I-DISO
+,	O
+viral	B-PROC
+replication	I-PROC
+,	O
+inflammatory	B-DISO
+response	I-DISO
+and	O
+lung	B-ANAT
+pathology	B-DISO
+were	O
+analysed	O
+.	O
+
+PMN	B-PROC
+-	O
+depleted	O
+animals	B-SPEC
+had	O
+fewer	O
+macrophages	B-ANAT
+and	O
+lymphocytes	B-ANAT
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+corresponding	O
+to	O
+lower	O
+chemokine	O
+levels	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+emerging	O
+respiratory	O
+infectious	B-DISO
+disease	I-DISO
+with	O
+high	O
+mortality	O
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+),	O
+is	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+recombinant	O
+S377	O
+-	O
+588	O
+-	O
+Fc	O
+is	O
+able	O
+to	O
+induce	O
+in	O
+the	O
+vaccinated	O
+mice	B-SPEC
+strong	O
+MERS	O
+-	O
+CoV	O
+S	O
+-	O
+specific	O
+antibodies	B-COMP
+,	O
+which	O
+blocks	O
+the	O
+binding	B-FUNC
+of	O
+RBD	O
+to	O
+DPP4	B-PRGE
+receptor	I-PRGE
+and	O
+effectively	O
+neutralizes	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+have	O
+employed	O
+a	O
+new	O
+dataset	O
+of	O
+1725	O
+viral	O
+siRNAs	O
+with	O
+experimentally	O
+verified	O
+quantitative	O
+efficacies	O
+tested	O
+under	O
+heterogeneous	O
+experimental	O
+conditions	O
+and	O
+targeting	B-PROC
+as	O
+many	O
+as	O
+37	O
+important	O
+human	B-SPEC
+viruses	B-SPEC
+including	O
+HIV	B-DISO
+,	O
+Influenza	B-DISO
+,	O
+HCV	B-SPEC
+,	O
+HBV	B-DISO
+,	O
+SARS	B-DISO
+etc	O
+.	O
+
+We	O
+hope	O
+this	O
+algorithm	O
+would	O
+be	O
+useful	O
+in	O
+predicting	O
+highly	O
+potent	O
+viral	O
+siRNA	O
+to	O
+aid	O
+siRNA	O
+based	O
+antiviral	B-CHED
+therapeutics	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Supine	O
+chest	B-ANAT
+compression	O
+:	O
+alternative	O
+to	O
+prone	O
+ventilation	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Chest	B-ANAT
+wall	I-ANAT
+compression	O
+was	O
+performed	O
+by	O
+2	O
+-	O
+kg	O
+weight	O
+in	O
+front	O
+of	O
+the	O
+chest	B-ANAT
+wall	I-ANAT
+bilaterally	O
+while	O
+the	O
+patient	O
+was	O
+in	O
+a	O
+supine	O
+position	O
+.	O
+
+Respiratory	B-PROC
+mechanics	I-PROC
+work	O
+to	O
+improve	O
+oxygenation	B-PROC
+almost	O
+as	O
+same	O
+as	O
+the	O
+mechanism	O
+proposed	O
+for	O
+prone	O
+position	O
+without	O
+any	O
+major	O
+adverse	B-DISO
+effects	I-DISO
+and	O
+serious	O
+complications	O
+.	O
+
+A	O
+structure	O
+-	O
+based	O
+VS	O
+approach	O
+integrating	O
+docking	B-PROC
+and	O
+pharmacophore	O
+based	O
+methods	O
+was	O
+employed	O
+to	O
+computationally	O
+screen	O
+621	O
+,	O
+000	O
+compounds	O
+from	O
+the	O
+ZINC	B-CHED
+library	O
+.	O
+
+Subsequently	O
+,	O
+a	O
+fluorescence	O
+-	O
+based	O
+enzymatic	O
+HTS	B-DISO
+assay	O
+was	O
+developed	O
+and	O
+optimized	O
+to	O
+experimentally	O
+screen	O
+approximately	O
+41	O
+,	O
+000	O
+compounds	O
+from	O
+four	O
+structurally	O
+diverse	O
+libraries	O
+chosen	O
+mainly	O
+based	O
+on	O
+the	O
+VS	O
+results	O
+.	O
+
+False	O
+positives	O
+from	O
+initial	O
+HTS	B-DISO
+hits	O
+were	O
+eliminated	O
+by	O
+a	O
+secondary	O
+orthogonal	O
+binding	B-FUNC
+analysis	O
+using	O
+surface	O
+plasmon	O
+resonance	O
+(	O
+SPR	O
+).	O
+
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+belonging	O
+to	O
+gamma	O
+-	O
+coronaviruses	O
+,	O
+causes	O
+a	O
+highly	O
+infectious	B-DISO
+respiratory	O
+viral	B-DISO
+disease	I-DISO
+and	O
+can	O
+result	O
+in	O
+catastrophic	O
+economic	O
+losses	O
+to	O
+the	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+However	O
+,	O
+PrP	B-PRGE
+during	O
+ECMO	O
+might	O
+be	O
+associated	O
+with	O
+complications	O
+such	O
+as	O
+dislocation	O
+of	O
+ECMO	O
+cannulae	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+newly	O
+emerged	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+becoming	O
+another	O
+""""	O
+SARS	B-DISO
+-	O
+like	O
+""""	O
+threat	O
+to	O
+the	O
+world	O
+.	O
+
+It	O
+has	O
+an	O
+extremely	O
+high	O
+death	B-PROC
+rate	O
+(∼	O
+50	O
+%)	O
+as	O
+there	O
+is	O
+no	O
+vaccine	O
+or	O
+efficient	O
+therapeutics	O
+.	O
+
+BacMam	O
+virus	B-SPEC
+,	O
+a	O
+modified	O
+baculovirus	B-SPEC
+mediating	O
+transgene	O
+expression	B-PROC
+under	O
+the	O
+control	O
+of	O
+a	O
+mammalian	B-SPEC
+promoter	O
+,	O
+has	O
+emerged	O
+as	O
+a	O
+versatile	O
+and	O
+safe	O
+vector	O
+during	O
+vaccine	O
+development	B-PROC
+.	O
+
+We	O
+showed	O
+that	O
+Ac	O
+-	O
+CMV	B-SPEC
+-	O
+S1	O
+induced	O
+excellent	O
+cellular	B-PROC
+immunity	I-PROC
+,	O
+but	O
+did	O
+not	O
+confer	O
+adequate	O
+protection	O
+in	O
+chickens	B-SPEC
+compared	O
+with	O
+the	O
+conventional	O
+inactivated	O
+vaccine	O
+.	O
+
+BacMam	O
+virus	B-SPEC
+-	O
+based	O
+surface	O
+display	O
+strategies	O
+could	O
+serve	O
+as	O
+effective	O
+tools	O
+in	O
+designing	O
+vaccines	O
+against	O
+IB	O
+and	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+Neutralising	O
+antibodies	B-COMP
+were	O
+found	O
+in	O
+all	O
+camel	B-SPEC
+sera	B-COMP
+while	O
+sera	B-COMP
+from	O
+goats	B-SPEC
+and	O
+cattle	B-SPEC
+tested	O
+negative	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+seroprevalence	O
+in	O
+domestic	O
+livestock	O
+in	O
+Saudi	O
+Arabia	O
+,	O
+2010	O
+to	O
+2013	O
+.	O
+
+Dromedary	B-SPEC
+camels	B-SPEC
+however	O
+,	O
+had	O
+a	O
+high	O
+prevalence	O
+of	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Gastroenteritis	O
+is	O
+one	O
+of	O
+the	O
+leading	O
+causes	O
+of	O
+morbidity	O
+and	O
+mortality	O
+among	O
+young	O
+and	O
+newborn	O
+animals	B-SPEC
+and	O
+is	O
+often	O
+caused	O
+by	O
+multiple	O
+intestinal	B-DISO
+infections	I-DISO
+,	O
+with	O
+rotavirus	B-SPEC
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+being	O
+the	O
+main	O
+viral	O
+causes	O
+in	O
+cattle	B-SPEC
+.	O
+
+To	O
+achieve	O
+this	O
+,	O
+eleven	O
+fecal	B-ANAT
+samples	O
+from	O
+dairy	O
+cows	B-SPEC
+with	O
+winter	B-DISO
+dysentery	I-DISO
+,	O
+three	O
+from	O
+calves	O
+,	O
+and	O
+two	O
+from	O
+horses	B-SPEC
+,	O
+all	O
+from	O
+Brazil	O
+,	O
+were	O
+analysed	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+establishment	O
+of	O
+persistent	O
+viral	B-DISO
+infection	I-DISO
+is	O
+often	O
+associated	O
+with	O
+the	O
+selection	O
+of	O
+one	O
+or	O
+more	O
+mutant	B-DISO
+viruses	B-SPEC
+.	O
+
+Therefore	O
+,	O
+this	O
+previously	O
+unidentified	O
+leaderless	O
+genome	O
+is	O
+associated	O
+with	O
+the	O
+attenuation	O
+of	O
+genome	O
+expression	B-PROC
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+microtubule	B-COMP
+disruption	O
+on	O
+neuronal	O
+spread	O
+and	O
+replication	O
+of	O
+demyelinating	O
+and	O
+nondemyelinating	O
+strains	O
+of	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+The	O
+impact	O
+of	O
+patient	O
+positioning	O
+on	O
+pressure	B-DISO
+ulcers	I-DISO
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+:	O
+results	O
+from	O
+a	O
+multicentre	O
+randomised	O
+controlled	O
+trial	O
+on	O
+prone	O
+positioning	O
+.	O
+
+ABSTRACT	O
+:	O
+Placing	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+in	O
+the	O
+prone	O
+position	O
+has	O
+been	O
+shown	O
+to	O
+improve	O
+survival	O
+as	O
+compared	O
+to	O
+the	O
+supine	O
+position	O
+.	O
+
+In	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+prone	O
+positioning	O
+was	O
+associated	O
+with	O
+a	O
+higher	O
+frequency	O
+of	O
+pressure	B-DISO
+ulcers	I-DISO
+than	O
+the	O
+supine	O
+position	O
+.	O
+
+Structures	O
+that	O
+shed	O
+light	O
+on	O
+the	O
+function	O
+and	O
+biological	O
+roles	O
+of	O
+the	O
+proteins	B-CHED
+in	O
+viral	B-PROC
+replication	I-PROC
+and	O
+pathogenesis	B-DISO
+are	O
+highlighted	O
+.	O
+
+Previous	O
+studies	O
+suggested	O
+dromedary	B-SPEC
+camels	B-SPEC
+were	O
+a	O
+reservoir	O
+for	O
+this	O
+virus	B-SPEC
+.	O
+
+We	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+from	O
+a	O
+farm	O
+in	O
+Qatar	O
+linked	O
+to	O
+two	O
+human	B-SPEC
+cases	O
+of	O
+the	O
+infection	B-DISO
+in	O
+October	O
+,	O
+2013	O
+.	O
+
+PCR	O
+positive	O
+samples	O
+were	O
+tested	O
+by	O
+different	O
+MERS	O
+-	O
+CoV	O
+specific	O
+PCRs	O
+and	O
+obtained	O
+sequences	O
+were	O
+used	O
+for	O
+phylogentic	O
+analysis	O
+together	O
+with	O
+sequences	O
+from	O
+the	O
+linked	O
+human	B-SPEC
+cases	O
+and	O
+other	O
+human	B-SPEC
+cases	O
+.	O
+
+TITLE	O
+:	O
+Yeast	B-SPEC
+-	O
+expressed	B-PROC
+recombinant	O
+protein	B-CHED
+of	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+with	O
+deglycosylated	O
+forms	O
+as	O
+a	O
+SARS	O
+vaccine	O
+candidate	O
+.	O
+
+More	O
+importantly	O
+,	O
+RBD219	O
+-	O
+N1	O
+induced	O
+significantly	O
+stronger	O
+RBD	O
+-	O
+specific	O
+antibody	B-PROC
+responses	I-PROC
+and	O
+a	O
+higher	O
+level	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+immunized	O
+mice	B-SPEC
+than	O
+RBD193	O
+-	O
+WT	O
+,	O
+RBD193	O
+-	O
+N1	O
+,	O
+RBD193	O
+-	O
+N3	O
+,	O
+or	O
+RBD219	O
+-	O
+WT	O
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+systematically	O
+review	O
+original	O
+research	O
+studies	O
+evaluating	O
+organ	B-ANAT
+-	O
+specific	O
+outcomes	O
+at	O
+28	O
+days	O
+or	O
+greater	O
+in	O
+patients	O
+surviving	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Two	O
+studies	O
+contributed	O
+the	O
+majority	O
+of	O
+patients	O
+and	O
+had	O
+consistent	O
+rates	O
+of	O
+1	O
+month	O
+organ	B-ANAT
+dysfunction	O
+for	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+(	O
+8	O
+%-	O
+9	O
+%),	O
+renal	B-ANAT
+(	O
+7	O
+%-	O
+8	O
+%),	O
+hepatic	B-ANAT
+(	O
+3	O
+%-	O
+7	O
+%),	O
+and	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+2	O
+%-	O
+5	O
+%).	O
+
+For	O
+organ	B-DISO
+failure	I-DISO
+resolution	O
+the	O
+rates	O
+were	O
+highly	O
+variable	O
+.	O
+
+Our	O
+review	O
+found	O
+variable	O
+rates	O
+of	O
+organ	B-ANAT
+dysfunction	O
+at	O
+1	O
+month	O
+after	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+MERS	O
+-	O
+CoV	O
+PLpro	O
+acts	O
+as	O
+a	O
+viral	O
+DUB	O
+and	O
+suppresses	O
+production	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+by	O
+an	O
+interfering	O
+IRF3	B-PRGE
+-	O
+mediated	O
+signalling	B-PROC
+pathway	I-PROC
+,	O
+in	O
+addition	O
+to	O
+recognizing	O
+and	O
+processing	O
+the	O
+CS	O
+at	O
+the	O
+N	O
+terminus	O
+of	O
+replicase	B-PRGE
+polyprotein	O
+to	O
+release	B-PATH
+the	O
+non	O
+-	O
+structural	O
+proteins	B-CHED
+.	O
+
+During	O
+diagnostic	O
+procedures	O
+based	O
+on	O
+the	O
+MSSCP	O
+genotyping	O
+it	O
+was	O
+observed	O
+that	O
+the	O
+WHO	O
+recommended	O
+RT	O
+-	O
+PCR	O
+kits	O
+and	O
+/	O
+or	O
+procedure	O
+of	O
+sample	O
+collection	O
+from	O
+patients	O
+for	O
+molecular	O
+investigation	O
+could	O
+lead	O
+to	O
+false	O
+positive	O
+A	O
+/	O
+H1N1	O
+pandemic	O
+strain	O
+detection	O
+because	O
+of	O
+the	O
+co	O
+-	O
+amplification	B-DISO
+during	O
+the	O
+RT	O
+-	O
+PCR	O
+fragments	O
+of	O
+the	O
+human	O
+genome	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+symptoms	O
+similar	O
+to	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+yet	O
+involving	O
+an	O
+additional	O
+component	O
+of	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+according	O
+to	O
+several	O
+published	O
+case	O
+reports	O
+.	O
+
+Adverse	B-DISO
+effects	I-DISO
+of	O
+HES	B-DISO
+on	O
+survival	O
+and	O
+organ	B-ANAT
+function	O
+have	O
+been	O
+reported	O
+.	O
+
+Three	O
+-	O
+day	O
+totals	O
+of	O
+administered	O
+resuscitation	O
+fluid	O
+(	O
+medians	O
+)	O
+were	O
+21	O
+,	O
+190	O
+mL	O
+in	O
+the	O
+lactated	O
+Ringer	O
+'	O
+s	O
+group	O
+and	O
+19	O
+,	O
+535	O
+mL	O
+in	O
+the	O
+HES	B-DISO
+group	O
+(	O
+HES	O
+:	O
+-	O
+1	O
+,	O
+213	O
+mL	O
+;	O
+P	O
+=	O
+0	O
+.	O
+39	O
+).	O
+
+There	O
+was	O
+no	O
+evidence	O
+that	O
+early	O
+fluid	O
+resuscitation	O
+with	O
+balanced	O
+HES	B-DISO
+130	O
+/	O
+0	O
+.	O
+4	O
+(	O
+6	O
+%)	O
+in	O
+addition	O
+to	O
+lactated	O
+Ringer	O
+'	O
+s	O
+solution	O
+would	O
+lead	O
+to	O
+a	O
+volume	O
+-	O
+sparing	O
+effect	O
+in	O
+severe	O
+burn	O
+injury	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+hypercytokinemia	O
+is	O
+associated	O
+with	O
+interferon	B-PRGE
+-	O
+induced	O
+transmembrane	B-COMP
+protein	B-CHED
+-	O
+3	O
+dysfunction	O
+and	O
+predictive	O
+of	O
+fatal	O
+H7N9	O
+infection	O
+.	O
+
+ABSTRACT	O
+:	O
+Treatment	O
+with	O
+positive	O
+airway	B-ANAT
+pressure	O
+devices	O
+improved	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+of	O
+obstructive	B-DISO
+sleep	I-DISO
+apnea	I-DISO
+syndrome	I-DISO
+(	O
+OSA	B-DISO
+);	O
+however	O
+,	O
+auto	O
+-	O
+adjusting	O
+positive	O
+pressure	O
+(	O
+APAP	B-CHED
+)	O
+device	O
+was	O
+not	O
+as	O
+effective	O
+as	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+CPAP	O
+)	O
+in	O
+reducing	O
+arterial	B-ANAT
+blood	I-ANAT
+pressure	O
+and	O
+insulin	B-DISO
+resistance	B-PROC
+.	O
+
+K2	O
+values	O
+were	O
+lower	O
+in	O
+APAP	B-CHED
+compared	O
+with	O
+those	O
+in	O
+CPAP	O
+and	O
+CON	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+CPAP	B-PRGE
+and	O
+CON	B-PRGE
+,	O
+LFnu	O
+and	O
+LF	O
+/	O
+HF	O
+,	O
+markers	O
+of	O
+sympathetic	O
+modulation	O
+,	O
+decreased	O
+from	O
+N2	O
+to	O
+N3	O
+and	O
+increased	O
+during	O
+REM	B-PROC
+sleep	B-PROC
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+while	O
+in	O
+APAP	B-CHED
+group	O
+,	O
+sympathetic	O
+modulation	O
+was	O
+significantly	O
+higher	O
+compared	O
+with	O
+those	O
+of	O
+CPAP	O
+and	O
+CON	O
+during	O
+all	O
+sleep	B-PROC
+stages	I-PROC
+.	O
+
+Therefore	O
+,	O
+potent	O
+reversible	O
+HNE	B-CHED
+inhibitors	B-CHED
+are	O
+promising	O
+alternatives	O
+to	O
+sivelestat	O
+.	O
+
+Molecular	O
+docking	B-PROC
+experiments	O
+indicated	O
+that	O
+the	O
+molecular	O
+scaffold	O
+,	O
+28	O
+-	O
+COOH	O
+,	O
+and	O
+a	O
+double	O
+bond	O
+at	O
+an	O
+appropriate	O
+location	O
+in	O
+the	O
+pentacyclic	O
+triterpenes	B-CHED
+are	O
+important	O
+for	O
+their	O
+inhibitory	O
+activity	O
+.	O
+
+The	O
+use	O
+of	O
+anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+agents	I-CHED
+to	O
+attenuate	O
+inflammatory	B-DISO
+response	I-DISO
+during	O
+acute	O
+systemic	O
+inflammatory	O
+reactions	O
+may	O
+improve	O
+survival	O
+rates	O
+.	O
+
+The	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+,	O
+including	O
+TNFα	O
+,	O
+IL	O
+-	O
+1β	O
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+were	O
+dose	O
+-	O
+dependently	O
+suppressed	O
+by	O
+FJU	O
+-	O
+C4	O
+both	O
+in	O
+mRNA	B-CHED
+and	O
+protein	B-CHED
+levels	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+the	O
+FJU	O
+-	O
+C4	O
+compound	O
+may	O
+act	O
+as	O
+a	O
+promising	O
+therapeutic	O
+agent	O
+against	O
+inflammatory	O
+diseases	O
+by	O
+inhibiting	O
+the	O
+p38MAPK	B-PRGE
+and	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+poses	O
+a	O
+severe	O
+threat	O
+to	O
+the	O
+poultry	O
+industry	O
+and	O
+causes	O
+heavy	O
+economic	O
+losses	O
+worldwide	O
+.	O
+
+Finally	O
+,	O
+the	O
+chimeric	O
+VLPs	B-ANAT
+induced	O
+significantly	O
+higher	O
+IL	B-PROC
+-	I-PROC
+4	I-PROC
+production	I-PROC
+in	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Few	O
+studies	O
+have	O
+examined	O
+the	O
+epidemiology	O
+of	O
+respiratory	O
+viral	O
+infections	O
+in	O
+large	O
+tertiary	O
+centres	O
+over	O
+more	O
+than	O
+one	O
+season	O
+in	O
+the	O
+era	B-CHED
+of	O
+molecular	O
+diagnosis	O
+.	O
+
+Respiratory	O
+virus	B-SPEC
+testing	O
+was	O
+performed	O
+using	O
+a	O
+large	O
+panel	O
+of	O
+real	O
+-	O
+time	O
+PCR	O
+or	O
+RT	O
+-	O
+PCR	O
+.	O
+
+In	O
+conclusion	O
+,	O
+we	O
+observed	O
+significant	O
+differences	O
+in	O
+viral	B-DISO
+infection	I-DISO
+rates	O
+and	O
+virus	B-SPEC
+types	O
+among	O
+age	O
+groups	O
+,	O
+clinical	O
+sample	O
+types	O
+and	O
+seasons	O
+.	O
+
+Laboratory	O
+tests	O
+demonstrated	O
+severe	O
+hemolytic	O
+anemia	B-DISO
+,	I-DISO
+profound	I-DISO
+thrombocytopenia	O
+,	O
+markedly	O
+elevated	O
+fibrin	O
+degradation	O
+products	O
+,	O
+and	O
+renal	B-DISO
+failure	I-DISO
+.	O
+
+The	O
+patient	O
+was	O
+diagnosed	O
+with	O
+CAPS	O
+with	O
+hemorrhagic	O
+manifestations	O
+in	O
+the	O
+setting	O
+of	O
+new	O
+-	O
+onset	O
+SLE	B-DISO
+.	O
+
+This	O
+review	O
+focuses	O
+on	O
+how	O
+to	O
+manage	O
+a	O
+calculated	O
+ventilation	O
+therapy	O
+of	O
+patients	O
+suffering	B-DISO
+from	O
+bronchial	B-ANAT
+obstruction	B-DISO
+and	O
+relevant	O
+patents	O
+.	O
+
+Further	O
+non	O
+-	O
+invasive	O
+ventilation	O
+can	O
+successfully	O
+support	O
+the	O
+weaning	B-PROC
+after	O
+a	O
+long	O
+-	O
+lasting	O
+ventilation	O
+therapy	O
+and	O
+improve	O
+the	O
+prognosis	O
+of	O
+COPD	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Aerobic	O
+and	O
+strength	O
+training	O
+in	O
+concomitant	O
+metabolic	B-DISO
+syndrome	I-DISO
+and	O
+type	B-DISO
+2	I-DISO
+diabetes	I-DISO
+.	O
+
+We	O
+observed	O
+a	O
+significant	O
+decrease	O
+in	O
+metabolic	B-DISO
+syndrome	I-DISO
+scores	O
+(	O
+P	O
+for	O
+trend	O
+=	O
+0	O
+.	O
+003	O
+)	O
+for	O
+AER	B-COMP
+(-	O
+0	O
+.	O
+59	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+-	O
+1	O
+.	O
+00	O
+to	O
+-	O
+0	O
+.	O
+21	O
+)	O
+and	O
+AER	B-COMP
++	O
+RES	O
+(-	O
+0	O
+.	O
+79	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+-	O
+1	O
+.	O
+40	O
+to	O
+-	O
+0	O
+.	O
+35	O
+),	O
+both	O
+being	O
+significant	O
+(	O
+P	O
+≤	O
+0	O
+.	O
+02	O
+)	O
+versus	O
+control	O
+(	O
+0	O
+.	O
+26	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+-	O
+0	O
+.	O
+58	O
+to	O
+0	O
+.	O
+40	O
+)	O
+and	O
+RES	O
+(-	O
+0	O
+.	O
+13	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+-	O
+1	O
+.	O
+00	O
+to	O
+0	O
+.	O
+24	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+indicated	O
+that	O
+China	O
+'	O
+s	O
+existing	O
+former	O
+mechanism	O
+for	O
+emergency	B-DISO
+management	O
+was	O
+very	O
+vulnerable	O
+.	O
+
+TITLE	O
+:	O
+Cytokine	O
+levels	O
+(	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+TGFβ	O
+)	O
+as	O
+potential	O
+biomarkers	O
+of	O
+systemic	O
+inflammatory	B-PROC
+response	I-PROC
+in	O
+trauma	O
+patients	O
+.	O
+
+SIRS	B-DISO
+may	O
+result	O
+in	O
+life	O
+threatening	O
+conditions	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+(	O
+MOF	B-DISO
+).	O
+
+Levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+were	O
+significantly	O
+lower	O
+in	O
+the	O
+injured	O
+groups	O
+as	O
+compared	O
+to	O
+the	O
+controls	O
+.	O
+
+Combined	O
+tissue	B-ANAT
+suppression	B-DISO
+from	O
+arterial	B-ANAT
+involvement	O
+and	O
+peripheral	B-DISO
+vasodilatation	I-DISO
+,	O
+perhaps	O
+,	O
+occur	O
+simultaneously	O
+.	O
+
+Currently	O
+,	O
+there	O
+is	O
+no	O
+specific	O
+therapy	O
+or	O
+vaccine	O
+with	O
+proven	O
+effectiveness	O
+for	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+While	O
+ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+may	O
+be	O
+effective	O
+in	O
+some	O
+patients	O
+,	O
+our	O
+practical	O
+experience	O
+suggests	O
+that	O
+critically	O
+ill	O
+patients	O
+with	O
+multiple	O
+comorbidities	O
+who	O
+are	O
+diagnosed	O
+late	O
+in	O
+the	O
+course	O
+of	O
+their	O
+illness	O
+may	O
+not	O
+benefit	O
+from	O
+combination	O
+antiviral	B-CHED
+therapy	O
+as	O
+preclinical	O
+data	O
+suggest	O
+.	O
+
+None	O
+of	O
+the	O
+patients	O
+responded	O
+to	O
+the	O
+supportive	O
+or	O
+therapeutic	O
+interventions	O
+and	O
+all	O
+died	B-PROC
+of	O
+their	O
+illness	O
+.	O
+
+Addressing	O
+censoring	O
+by	O
+considering	O
+the	O
+transmission	O
+dynamics	O
+in	O
+an	O
+exporting	O
+country	O
+,	O
+we	O
+demonstrate	O
+that	O
+the	O
+illness	O
+onset	O
+within	O
+2	O
+days	O
+from	O
+immigration	O
+is	O
+suggestive	O
+of	O
+influenza	B-DISO
+.	O
+
+It	O
+is	O
+vital	O
+to	O
+collect	O
+the	O
+information	O
+of	O
+the	O
+incubation	O
+period	O
+upon	O
+emergence	O
+of	O
+a	O
+novel	O
+infectious	O
+disease	O
+,	O
+and	O
+moreover	O
+,	O
+in	O
+our	O
+model	O
+,	O
+the	O
+fundamental	O
+transmission	O
+dynamics	O
+including	O
+the	O
+initial	O
+growth	B-PROC
+rate	O
+has	O
+to	O
+be	O
+explored	O
+to	O
+differentiate	O
+the	O
+disease	O
+diagnoses	O
+with	O
+non	O
+-	O
+specific	O
+symptoms	O
+.	O
+
+NPPV	O
+applied	O
+as	O
+the	O
+first	O
+-	O
+line	O
+intervention	O
+for	O
+ARDS	O
+following	O
+esophagectomy	O
+for	O
+esophageal	B-DISO
+cancer	I-DISO
+avoided	O
+intubation	O
+in	O
+30	O
+patients	O
+(	O
+30	O
+/	O
+64	O
+,	O
+48	O
+.	O
+4	O
+%).	O
+
+It	O
+is	O
+not	O
+understood	O
+whether	O
+HCoV	B-PRGE
+-	I-PRGE
+HKU1	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+has	O
+similar	O
+activity	O
+.	O
+
+Through	O
+PERK	B-PRGE
+kinase	I-PRGE
+they	O
+activated	O
+the	O
+transcription	B-PROC
+of	O
+UPR	O
+effector	B-CHED
+genes	O
+such	O
+as	O
+Grp78	B-PRGE
+,	O
+Grp94	B-PRGE
+and	O
+CHOP	B-PRGE
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+HCoV	O
+-	O
+HKU1	O
+S	O
+proteins	B-CHED
+use	O
+distinct	O
+UPR	O
+-	O
+activating	O
+domains	O
+to	O
+exert	B-PROC
+the	O
+same	O
+modulatory	O
+effects	O
+on	O
+UPR	O
+signaling	B-PROC
+.	O
+
+More	O
+cats	B-SPEC
+were	O
+negative	O
+for	O
+all	O
+8	O
+enteropathogens	O
+tested	O
+(	O
+12	O
+.	O
+7	O
+%)	O
+than	O
+expected	O
+.	O
+
+When	O
+exact	O
+combinations	O
+of	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+were	O
+examined	O
+,	O
+Tr	O
+tended	O
+to	O
+be	O
+found	O
+in	O
+combinations	O
+with	O
+Co	O
+,	O
+Cl	O
+,	O
+and	O
+Gi	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+encountered	O
+a	O
+case	O
+of	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+in	O
+late	B-DISO
+pregnancy	I-DISO
+due	O
+to	O
+influenza	B-DISO
+(	O
+H1N1	O
+)	O
+with	O
+refractory	O
+hypoxemia	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+The	O
+effects	O
+of	O
+Nigella	B-SPEC
+sativa	I-SPEC
+(	O
+Ns	O
+),	O
+Anthemis	B-SPEC
+hyalina	I-SPEC
+(	O
+Ah	O
+)	O
+and	O
+Citrus	B-SPEC
+sinensis	I-SPEC
+(	O
+Cs	O
+)	O
+extracts	O
+on	O
+the	O
+replication	O
+of	O
+coronavirus	O
+and	O
+the	O
+expression	B-PROC
+of	O
+TRP	B-PRGE
+genes	I-PRGE
+family	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Extracts	O
+of	O
+Anthemis	B-SPEC
+hyalina	I-SPEC
+(	O
+Ah	O
+),	O
+Nigella	B-SPEC
+sativa	I-SPEC
+(	O
+Ns	O
+)	O
+and	O
+peels	B-DISO
+of	O
+Citrus	B-SPEC
+sinensis	I-SPEC
+(	O
+Cs	O
+)	O
+have	O
+been	O
+used	O
+as	O
+folk	O
+medicine	B-CHED
+to	O
+fight	O
+antimicrobial	B-CHED
+diseases	O
+.	O
+
+To	O
+evaluate	O
+the	O
+effect	O
+of	O
+extracts	O
+of	O
+Ah	O
+,	O
+Ns	O
+and	O
+Cs	O
+on	O
+the	O
+replication	O
+of	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+and	O
+on	O
+the	O
+expression	B-PROC
+of	O
+TRP	B-PRGE
+genes	I-PRGE
+during	O
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+HeLa	B-ANAT
+-	O
+CEACAM1a	O
+(	O
+HeLa	B-ANAT
+-	O
+epithelial	O
+carcinoembryonic	B-PRGE
+antigen	I-PRGE
+-	I-PRGE
+related	I-PRGE
+cell	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+1a	I-PRGE
+)	O
+cells	B-COMP
+were	O
+inoculated	O
+with	O
+MHV	B-SPEC
+-	O
+A59	O
+(	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+A59	O
+)	O
+at	O
+moi	O
+of	O
+30	O
+.	O
+
+Total	O
+RNA	O
+was	O
+isolated	O
+from	O
+the	O
+infected	O
+cells	B-COMP
+and	O
+cDNA	O
+was	O
+synthesized	O
+.	O
+
+ABSTRACT	O
+:	O
+Neural	O
+precursor	O
+cells	O
+(	O
+NPCs	B-COMP
+)	O
+are	O
+the	O
+subject	O
+of	O
+intense	O
+investigation	O
+for	O
+their	O
+potential	O
+to	O
+treat	O
+neurodegenerative	B-DISO
+disorders	I-DISO
+,	O
+yet	O
+the	O
+consequences	O
+of	O
+neuroinvasive	O
+virus	B-DISO
+infection	I-DISO
+of	O
+NPCs	B-COMP
+remain	O
+unclear	O
+.	O
+
+Electron	O
+microscopy	O
+analyses	O
+indicate	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+virions	B-COMP
+are	O
+tethered	O
+to	O
+cell	B-COMP
+surfaces	O
+or	O
+intracellular	B-COMP
+membranes	B-ANAT
+by	O
+BST2	B-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+--	O
+forms	O
+and	O
+functions	O
+.	O
+
+BRSV	B-SPEC
+infection	B-DISO
+was	O
+detected	O
+either	O
+serologically	O
+and	O
+/	O
+or	O
+virologically	O
+in	O
+18	O
+(	O
+86	O
+%)	O
+of	O
+21	O
+outbreaks	O
+and	O
+in	O
+most	O
+cases	O
+as	O
+a	O
+single	O
+viral	O
+agent	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+use	O
+a	O
+real	O
+-	O
+time	O
+PCR	O
+diarrhea	B-DISO
+panel	O
+to	O
+survey	O
+the	O
+frequencies	O
+of	O
+pathogens	O
+and	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+in	O
+owned	O
+dogs	B-SPEC
+attended	O
+in	O
+a	O
+veterinary	O
+hospital	O
+with	O
+and	O
+without	O
+diarrhea	B-DISO
+,	O
+as	O
+well	O
+the	O
+frequency	O
+in	O
+different	O
+countries	O
+.	O
+
+CPV	B-SPEC
+-	O
+2	O
+was	O
+the	O
+most	O
+prevalent	O
+pathogen	O
+in	O
+the	O
+dual	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+,	O
+associated	O
+with	O
+CPA	O
+,	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.,	O
+or	O
+Giardia	B-DISO
+spp	B-ENZY
+.	O
+
+To	O
+screen	O
+for	O
+IBV	B-SPEC
+inhibition	B-PROC
+,	O
+cells	B-COMP
+and	O
+virus	B-SPEC
+were	O
+pretreated	O
+with	O
+extracts	O
+,	O
+followed	O
+by	O
+infection	B-DISO
+in	O
+the	O
+presence	O
+of	O
+extract	O
+.	O
+
+Viral	B-DISO
+cytopathic	I-DISO
+effect	I-DISO
+was	O
+assessed	O
+visually	O
+following	O
+an	O
+additional	O
+24	O
+h	O
+incubation	O
+with	O
+extract	O
+.	O
+
+However	O
+,	O
+treatment	O
+with	O
+S	B-SPEC
+.	I-SPEC
+nigra	I-SPEC
+extracts	O
+reduced	O
+virus	B-SPEC
+titers	O
+by	O
+four	O
+orders	O
+of	O
+magnitude	O
+at	O
+a	O
+multiplicity	O
+of	O
+infection	B-DISO
+(	O
+MOI	O
+)	O
+of	O
+1	O
+in	O
+a	O
+dose	O
+-	O
+responsive	O
+manner	O
+.	O
+
+Unfortunately	O
+,	O
+prior	O
+attempts	O
+involving	O
+direct	O
+oxygen	B-CHED
+ventilation	O
+or	O
+aqueous	O
+perfusates	O
+of	O
+fluorocarbons	B-CHED
+or	O
+hemoglobin	B-PRGE
+carriers	O
+have	O
+failed	O
+,	O
+leading	O
+many	O
+researchers	O
+to	O
+abandon	O
+the	O
+method	O
+.	O
+
+At	O
+basal	O
+state	O
+,	O
+loss	O
+of	O
+Cav1	B-PRGE
+and	O
+ADPN	B-PRGE
+resulted	O
+in	O
+a	O
+drastic	O
+increase	O
+of	O
+oxidative	B-DISO
+stress	I-DISO
+and	O
+resultant	O
+nitrative	O
+stress	O
+in	O
+DKO	O
+lungs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+The	O
+ORF4b	O
+-	O
+encoded	O
+accessory	O
+proteins	B-CHED
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+and	O
+two	O
+related	O
+bat	O
+coronaviruses	O
+localize	O
+to	O
+the	O
+nucleus	B-COMP
+and	O
+inhibit	O
+innate	O
+immune	O
+signalling	B-PROC
+.	O
+
+We	O
+report	O
+the	O
+first	O
+series	O
+of	O
+adult	O
+patients	O
+with	O
+ARF	B-DISO
+and	O
+HMs	B-DISO
+treated	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+Etiology	O
+of	O
+ARF	B-DISO
+was	O
+pneumonia	B-DISO
+(	O
+n	O
+=	O
+10	O
+),	O
+thoracic	B-DISO
+manifestation	O
+of	O
+NHL	B-DISO
+(	O
+n	O
+=	O
+2	O
+),	O
+sepsis	B-DISO
+of	O
+nonpulmonary	O
+origin	O
+(	O
+n	O
+=	O
+1	O
+),	O
+and	O
+transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+(	O
+n	O
+=	O
+1	O
+).	O
+
+There	O
+is	O
+very	O
+little	O
+information	O
+regarding	O
+extracorporeal	O
+life	O
+support	O
+in	O
+severe	O
+AlP	B-CHED
+poisoning	O
+.	O
+
+ABSTRACT	O
+:	O
+Programmed	O
+-	O
+1	O
+ribosomal	O
+frameshifting	O
+(-	O
+1	O
+PRF	O
+)	O
+stimulated	O
+by	O
+mRNA	B-CHED
+pseudoknots	O
+regulates	O
+gene	B-PROC
+expression	I-PROC
+in	O
+many	O
+viruses	B-SPEC
+,	O
+making	O
+pseudoknots	O
+potential	O
+targets	O
+for	O
+anti	O
+-	O
+viral	O
+drugs	O
+.	O
+
+Using	O
+single	O
+-	O
+molecule	O
+force	O
+spectroscopy	O
+to	O
+unfold	O
+pseudoknots	O
+mechanically	O
+,	O
+we	O
+found	O
+that	O
+the	O
+ligand	B-PROC
+binding	B-FUNC
+effectively	O
+abolished	O
+the	O
+formation	B-PROC
+of	O
+alternate	O
+conformers	O
+.	O
+
+This	O
+result	O
+extends	O
+the	O
+connection	O
+between	O
+-	O
+1	O
+PRF	O
+and	O
+conformational	O
+dynamics	O
+and	O
+,	O
+moreover	O
+,	O
+suggests	O
+that	O
+targeting	B-PROC
+the	O
+conformational	O
+dynamics	O
+of	O
+pseudoknots	O
+may	O
+be	O
+an	O
+effective	O
+strategy	O
+for	O
+anti	B-CHED
+-	I-CHED
+viral	I-CHED
+drug	I-CHED
+design	O
+.	O
+
+The	O
+apoptotic	O
+cells	B-COMP
+,	O
+indicated	O
+by	O
+caspase	B-PRGE
+3	I-PRGE
+-	O
+activation	O
+,	O
+were	O
+a	O
+mixed	O
+population	O
+of	O
+infected	O
+and	O
+a	O
+higher	O
+number	O
+of	O
+uninfected	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Lipid	B-CHED
+charge	O
+regulation	B-PROC
+of	O
+non	O
+-	O
+specific	O
+biological	O
+ion	B-FUNC
+channels	I-FUNC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+tested	O
+,	O
+using	O
+a	O
+low	O
+starting	O
+dilution	O
+,	O
+sequential	O
+serum	O
+samples	O
+from	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+sheep	B-SPEC
+and	O
+horses	B-SPEC
+collected	O
+in	O
+Dubai	O
+from	O
+February	O
+/	O
+April	O
+to	O
+October	O
+of	O
+2005	O
+and	O
+from	O
+dromedary	B-SPEC
+camels	B-SPEC
+for	O
+export	O
+/	O
+import	O
+testing	O
+between	O
+Canada	O
+and	O
+USA	O
+in	O
+2000	O
+-	O
+2001	O
+.	O
+
+We	O
+immunized	O
+cats	B-SPEC
+with	O
+peptides	B-CHED
+containing	O
+T	O
+-	O
+helper	O
+(	O
+Th	O
+)	O
+1	O
+epitopes	O
+derived	O
+from	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+the	O
+type	B-PRGE
+I	I-PRGE
+FIPV	I-PRGE
+KU	I-PRGE
+-	I-PRGE
+2	I-PRGE
+strain	O
+(	O
+NP7	O
+and	O
+NP8	O
+)	O
+with	O
+feline	B-SPEC
+CpG	O
+-	O
+oligodeoxynucleotides	O
+(	O
+fCpG	O
+-	O
+ODNs	O
+)	O
+as	O
+a	O
+vaccine	O
+adjuvant	B-CHED
+.	O
+
+Chest	B-ANAT
+tubes	O
+were	O
+used	O
+in	O
+44	O
+%,	O
+and	O
+21	O
+%	O
+required	O
+a	O
+tracheostomy	O
+.	O
+
+Patients	O
+with	O
+concurrent	O
+severe	O
+head	B-ANAT
+injury	O
+had	O
+higher	O
+rates	O
+of	O
+ventilatory	O
+support	O
+and	O
+ICU	O
+stay	O
+and	O
+had	O
+worse	O
+outcomes	O
+in	O
+every	O
+category	O
+compared	O
+with	O
+those	O
+without	O
+a	O
+head	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+protein	O
+coded	O
+by	O
+the	O
+open	O
+-	O
+reading	O
+-	O
+frame	O
+3a	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+has	O
+been	O
+demonstrated	O
+to	O
+form	O
+a	O
+cation	B-CHED
+-	O
+selective	O
+channel	O
+that	O
+may	O
+become	O
+expressed	B-PROC
+in	O
+the	O
+infected	O
+cell	B-COMP
+.	O
+
+Drugs	O
+that	O
+inhibit	O
+the	O
+ion	O
+channel	O
+can	O
+,	O
+therefore	O
+,	O
+inhibit	O
+virus	B-SPEC
+release	B-PATH
+,	O
+and	O
+they	O
+could	O
+be	O
+a	O
+source	O
+for	O
+development	B-PROC
+of	O
+novel	O
+therapeutic	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+We	O
+used	O
+the	O
+Xenopus	B-ANAT
+oocyte	I-ANAT
+with	O
+a	O
+heterologously	O
+expressed	B-PROC
+3a	B-PRGE
+protein	I-PRGE
+as	O
+a	O
+model	O
+system	O
+to	O
+test	O
+the	O
+efficacy	O
+of	O
+the	O
+flavonols	B-CHED
+.	O
+
+Some	O
+of	O
+these	O
+drugs	O
+turned	O
+out	O
+to	O
+be	O
+potent	O
+inhibitors	B-CHED
+of	O
+the	O
+3a	O
+channel	O
+.	O
+
+TITLE	O
+:	O
+Benign	B-DISO
+prostatic	I-DISO
+hyperplasia	I-DISO
+:	O
+a	O
+new	O
+metabolic	B-DISO
+disease	I-DISO
+?	O
+
+Management	O
+of	O
+emergency	B-DISO
+care	O
+.	O
+
+The	O
+MERS	O
+-	O
+CoV	O
+RT	O
+-	O
+RPA	O
+showed	O
+cross	O
+-	O
+detection	O
+neither	O
+of	O
+any	O
+of	O
+the	O
+RNAs	O
+of	O
+several	O
+coronaviruses	O
+and	O
+respiratory	O
+viruses	B-SPEC
+affecting	O
+humans	B-SPEC
+nor	O
+of	O
+the	O
+human	B-SPEC
+genome	O
+.	O
+
+The	O
+present	O
+case	O
+suggests	O
+that	O
+extreme	O
+leukocytosis	B-DISO
+may	O
+easily	O
+lead	O
+to	O
+ARDS	B-DISO
+,	O
+triggered	O
+by	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Saudi	O
+Arabian	O
+Ministry	O
+of	O
+Health	O
+implemented	O
+a	O
+pro	B-CHED
+-	O
+active	O
+surveillance	O
+programme	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+).	O
+
+Five	O
+thousand	O
+and	O
+65	O
+individuals	O
+were	O
+screened	O
+for	O
+MER	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+:	O
+hospitalized	O
+patients	O
+with	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+(	O
+n	O
+=	O
+2908	O
+,	O
+57	O
+.	O
+4	O
+%),	O
+healthcare	O
+worker	O
+(	O
+HCW	O
+)	O
+contacts	O
+(	O
+n	O
+=	O
+1695	O
+;	O
+33	O
+.	O
+5	O
+%),	O
+and	O
+family	B-SPEC
+contacts	O
+of	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+cases	O
+(	O
+n	O
+=	O
+462	O
+;	O
+9	O
+.	O
+1	O
+%).	O
+
+ABSTRACT	O
+:	O
+Recent	O
+years	O
+have	O
+seen	O
+progress	O
+in	O
+the	O
+development	B-PROC
+of	O
+statistically	O
+rigorous	O
+frameworks	O
+to	O
+infer	O
+outbreak	O
+transmission	O
+trees	O
+"("""	O
+who	O
+infected	O
+whom	O
+""")"	O
+from	O
+epidemiological	O
+and	O
+genetic	O
+data	O
+.	O
+
+Our	O
+approach	O
+identifies	O
+likely	O
+transmission	O
+events	O
+and	O
+infers	O
+dates	O
+of	O
+infections	B-DISO
+,	O
+unobserved	O
+cases	O
+and	O
+separate	O
+introductions	O
+of	O
+the	O
+disease	O
+.	O
+
+It	O
+also	O
+proves	O
+useful	O
+for	O
+inferring	O
+numbers	O
+of	O
+secondary	B-DISO
+infections	I-DISO
+and	O
+identifying	O
+heterogeneous	O
+infectivity	O
+and	O
+super	O
+-	O
+spreaders	O
+.	O
+
+TITLE	O
+:	O
+Network	O
+analysis	O
+reveals	O
+distinct	O
+clinical	O
+syndromes	B-DISO
+underlying	O
+acute	B-DISO
+mountain	I-DISO
+sickness	I-DISO
+.	O
+
+Different	O
+pathophysiological	O
+mechanisms	O
+are	O
+now	O
+thought	O
+to	O
+underlie	O
+headache	B-DISO
+and	O
+sleep	B-DISO
+disturbance	I-DISO
+during	O
+acute	O
+exposure	O
+to	O
+high	O
+altitude	O
+.	O
+
+Using	O
+a	O
+novel	O
+visual	O
+analogue	O
+scale	O
+(	O
+VAS	O
+),	O
+we	O
+sought	O
+to	O
+undertake	O
+a	O
+systematic	O
+exploration	O
+of	O
+the	O
+symptomatology	O
+of	O
+AMS	B-DISO
+using	O
+an	O
+unbiased	O
+,	O
+data	O
+-	O
+driven	O
+approach	O
+originally	O
+designed	O
+for	O
+analysis	O
+of	O
+gene	B-PROC
+expression	I-PROC
+.	O
+
+The	O
+post	O
+-	O
+mortem	O
+examination	O
+revealed	O
+bilateral	O
+pleural	O
+,	O
+pericardial	B-ANAT
+and	O
+peritoneal	B-ANAT
+effusions	I-ANAT
+as	O
+well	O
+as	O
+left	B-DISO
+ventricular	I-DISO
+hypertrophy	I-DISO
+with	O
+patchy	O
+myocardial	B-DISO
+fibrosis	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemic	O
+in	O
+mainland	O
+China	O
+dissected	O
+.	O
+
+An	O
+important	O
+finding	O
+from	O
+a	O
+cohort	O
+study	O
+was	O
+that	O
+many	O
+former	O
+SARS	B-DISO
+patients	O
+currently	O
+suffer	B-DISO
+from	O
+avascular	O
+osteonecrosis	B-DISO
+,	O
+as	O
+a	O
+consequence	O
+of	O
+the	O
+treatment	O
+with	O
+corticosteroids	B-CHED
+during	O
+their	O
+infection	B-DISO
+.	O
+
+The	O
+SARS	B-DISO
+epidemic	O
+provided	O
+valuable	O
+information	O
+and	O
+lessons	O
+relevant	O
+in	O
+controlling	O
+outbreaks	O
+of	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+and	O
+has	O
+led	O
+to	O
+fundamental	O
+reforms	O
+of	O
+the	O
+Chinese	O
+health	O
+system	O
+.	O
+
+The	O
+results	O
+indicated	O
+that	O
+the	O
+HP	O
+-	O
+PRRSV	B-SPEC
+-	O
+infected	O
+pigs	B-SPEC
+died	B-PROC
+and	O
+exhibited	O
+severe	O
+pathological	O
+changes	O
+of	O
+lungs	B-ANAT
+featuring	O
+increased	O
+neutrophils	B-ANAT
+,	O
+mast	B-ANAT
+cells	I-ANAT
+and	O
+mononuclear	O
+macrophages	B-ANAT
+,	O
+compared	O
+with	O
+the	O
+pigs	B-SPEC
+inoculated	O
+with	O
+low	O
+pathogenic	O
+(	O
+LP	O
+-)	O
+PRRSV	B-SPEC
+.	O
+
+In	O
+the	O
+majority	O
+of	O
+patients	O
+(	O
+14	O
+/	O
+17	O
+),	O
+multifocal	O
+areas	O
+of	O
+patchy	O
+consolidation	O
+were	O
+identified	O
+in	O
+the	O
+lower	O
+lung	B-ANAT
+zones	O
+on	O
+the	O
+initial	O
+CT	O
+.	O
+
+As	O
+the	O
+condition	B-DISO
+progressed	O
+,	O
+the	O
+patchy	O
+consolidation	O
+disappeared	O
+(	O
+10	O
+/	O
+13	O
+)	O
+and	O
+diffuse	O
+centrilobular	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+nodules	B-DISO
+started	O
+to	O
+predominate	O
+and	O
+persist	O
+.	O
+
+Most	O
+patients	O
+(	O
+92	O
+%)	O
+had	O
+extrapulmonary	O
+manifestations	O
+,	O
+including	O
+shock	O
+,	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+and	O
+thrombocytopenia	O
+.	O
+
+TITLE	O
+:	O
+Stillbirth	B-DISO
+during	O
+infection	B-DISO
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Work	O
+focused	O
+on	O
+enhancements	O
+to	O
+three	O
+interrelated	O
+priority	O
+areas	O
+and	O
+included	O
+achievements	O
+in	O
+1	O
+)	O
+establishing	O
+an	O
+emergency	O
+operations	O
+center	O
+(	O
+EOC	O
+)	O
+at	O
+the	O
+General	O
+Department	O
+of	O
+Preventive	O
+Medicine	B-CHED
+with	O
+training	O
+of	O
+personnel	O
+for	O
+public	O
+health	O
+emergency	B-DISO
+management	O
+;	O
+2	O
+)	O
+improving	O
+the	O
+nationwide	O
+laboratory	O
+system	O
+,	O
+including	O
+enhanced	O
+testing	O
+capability	O
+for	O
+several	O
+priority	O
+pathogens	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+those	O
+in	O
+Vietnam	O
+most	O
+likely	O
+to	O
+contribute	O
+to	O
+public	O
+health	O
+emergencies	B-DISO
+of	O
+international	O
+concern	O
+);	O
+and	O
+3	O
+)	O
+creating	O
+an	O
+emergency	B-DISO
+response	O
+information	O
+systems	O
+platform	O
+,	O
+including	O
+a	O
+demonstration	O
+of	O
+real	O
+-	O
+time	O
+reporting	O
+capability	O
+.	O
+
+Understanding	O
+this	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+provided	O
+an	O
+opportunity	O
+to	O
+design	O
+a	O
+successful	O
+live	O
+-	O
+attenuated	O
+vaccine	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+opens	O
+avenues	O
+for	O
+treatment	O
+and	O
+prevention	O
+of	O
+emerging	O
+CoVs	O
+and	O
+other	O
+RNA	B-DISO
+virus	I-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+other	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+older	O
+adults	O
+with	O
+moderate	O
+to	O
+severe	O
+influenza	O
+-	O
+like	O
+illness	O
+.	O
+
+Any	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+320	O
+/	O
+556	O
+(	O
+57	O
+.	O
+6	O
+%)	O
+ILI	O
+episodes	O
+:	O
+influenza	B-PATH
+A	I-PATH
+(	O
+104	O
+/	O
+556	O
+,	O
+18	O
+.	O
+7	O
+%),	O
+rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+(	O
+82	O
+/	O
+556	O
+,	O
+14	O
+.	O
+7	O
+%),	O
+coronavirus	B-SPEC
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+each	O
+32	O
+/	O
+556	O
+,	O
+5	O
+.	O
+6	O
+%).	O
+
+Generalized	O
+hypotonia	B-DISO
+,	O
+lactic	B-DISO
+acidosis	I-DISO
+,	O
+hyperammonemia	B-DISO
+and	O
+3	O
+-	O
+MGA	O
+were	O
+present	O
+in	O
+all	O
+since	O
+birth	B-PROC
+.	O
+
+TITLE	O
+:	O
+Flavivirus	B-SPEC
+RNA	B-PROC
+methylation	I-PROC
+.	O
+
+For	O
+antiviral	B-CHED
+development	B-PROC
+,	O
+a	O
+structural	O
+feature	O
+unique	O
+to	O
+the	O
+flavivirus	B-PRGE
+methyltransferase	I-PRGE
+was	O
+successfully	O
+used	O
+to	O
+design	O
+selective	O
+inhibitors	B-CHED
+that	O
+block	O
+viral	O
+methyltransferase	O
+without	O
+affecting	O
+host	O
+methyltransferases	O
+.	O
+
+Functionally	O
+,	O
+capping	B-PROC
+is	O
+essential	O
+for	O
+prevention	O
+of	O
+triphosphate	B-CHED
+-	O
+triggered	O
+innate	O
+immune	O
+activation	O
+;	O
+N	O
+-	O
+7	O
+methylation	B-PROC
+is	O
+critical	O
+for	O
+enhancement	O
+of	O
+viral	O
+translation	B-PROC
+;	O
+and	O
+2	O
+'-	O
+O	O
+methylation	B-PROC
+is	O
+important	O
+for	O
+subversion	O
+of	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+during	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Moreover	O
+,	O
+we	O
+showed	O
+that	O
+the	O
+expression	B-PROC
+of	O
+pulmonary	B-ANAT
+myeloperoxidase	B-PRGE
+(	O
+MPO	B-FUNC
+),	O
+intercellular	B-PRGE
+adhesion	I-PRGE
+molecule	I-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+of	O
+endothelial	B-ANAT
+cells	I-ANAT
+and	O
+CD11b	B-PRGE
+of	O
+polymorphonuclear	B-ANAT
+neutrophils	I-ANAT
+(	O
+PMN	B-PROC
+)	O
+induced	O
+by	O
+LPS	B-DISO
+were	O
+significantly	O
+decreased	O
+by	O
+PFC	O
+treatment	O
+in	O
+vivo	O
+.	O
+
+This	O
+study	O
+highlighted	O
+the	O
+difficulty	O
+in	O
+managing	O
+pain	O
+in	O
+neonates	O
+who	O
+are	O
+exposed	O
+to	O
+numerous	O
+painful	B-DISO
+procedures	O
+.	O
+
+The	O
+main	O
+diagnosis	O
+included	O
+prematurity	O
+and	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Mesenchymal	B-ANAT
+stromal	I-ANAT
+cell	I-ANAT
+therapies	O
+:	O
+potential	O
+and	O
+pitfalls	O
+for	O
+ARDS	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+MSCs	B-FUNC
+may	O
+be	O
+able	O
+to	O
+enhance	O
+the	O
+repair	B-PROC
+and	O
+resolution	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+MSCs	B-FUNC
+appear	O
+to	O
+restore	O
+epithelial	O
+and	O
+endothelial	B-ANAT
+function	O
+,	O
+via	O
+both	O
+paracrine	B-PROC
+and	O
+cell	B-COMP
+contact	O
+dependent	O
+effects	O
+.	O
+
+ARDS	B-DISO
+is	O
+frequently	O
+a	O
+component	O
+of	O
+a	O
+generalized	O
+process	O
+resulting	O
+in	O
+dysfunction	O
+and	O
+failure	O
+of	O
+multiple	O
+organs	B-ANAT
+.	O
+
+The	O
+fact	O
+that	O
+MSCs	B-FUNC
+are	O
+in	O
+clinical	O
+studies	O
+for	O
+a	O
+wide	O
+range	O
+of	O
+disease	O
+processes	O
+is	O
+a	O
+clear	O
+advantage	O
+for	O
+translating	O
+MSCs	B-FUNC
+to	O
+clinical	O
+testing	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+influence	O
+of	O
+age	O
+,	O
+gender	O
+and	O
+treatment	O
+with	O
+steroids	B-CHED
+on	O
+the	O
+incidence	O
+of	O
+osteonecrosis	B-DISO
+of	O
+the	O
+femoral	O
+head	O
+during	O
+the	O
+management	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+retrospective	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Corticosteroid	B-CHED
+use	O
+has	O
+been	O
+implicated	O
+in	O
+the	O
+development	B-PROC
+of	O
+osteonecrosis	B-DISO
+of	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+(	O
+ONFH	O
+).	O
+
+Polyomavirus	B-SPEC
+-	O
+KI	O
+(	O
+8	O
+.	O
+9	O
+%	O
+vs	O
+.	O
+4	O
+.	O
+8	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+002	O
+)	O
+and	O
+CoV	O
+-	O
+OC43	O
+(	O
+12	O
+.	O
+2	O
+%	O
+vs	O
+.	O
+3	O
+.	O
+6	O
+%;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+more	O
+prevalent	O
+in	O
+HIV	B-DISO
+-	O
+infected	O
+than	O
+-	O
+uninfected	O
+children	O
+.	O
+
+The	O
+high	O
+frequency	O
+of	O
+viral	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+illustrates	O
+the	O
+complexities	O
+in	O
+attributing	O
+causality	O
+to	O
+specific	O
+viruses	B-SPEC
+in	O
+the	O
+aetiology	O
+of	O
+LRTI	B-DISO
+and	O
+may	O
+indicate	O
+a	O
+synergetic	O
+role	O
+of	O
+viral	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+childhood	O
+LRTI	B-DISO
+.	O
+
+RESULTS	O
+:	O
+At	O
+least	O
+one	O
+of	O
+these	O
+viruses	B-SPEC
+were	O
+identified	O
+in	O
+274	O
+(	O
+53	O
+.	O
+0	O
+%)	O
+of	O
+517	O
+and	O
+in	O
+509	O
+(	O
+54	O
+.	O
+0	O
+%)	O
+of	O
+943	O
+LRTI	B-DISO
+-	O
+episodes	O
+in	O
+HIV	B-DISO
+-	O
+infected	O
+and	O
+-	O
+uninfected	O
+children	O
+,	O
+respectively	O
+.	O
+
+Following	O
+a	O
+clinical	O
+examination	O
+,	O
+we	O
+collected	O
+nasal	B-ANAT
+specimens	O
+from	O
+which	O
+the	O
+RT	O
+-	O
+PCR	O
+detection	O
+of	O
+10	O
+respiratory	O
+viruses	B-SPEC
+was	O
+performed	O
+through	O
+snapshot	O
+investigations	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+small	O
+molecule	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+Ebola	O
+,	O
+Hendra	O
+,	O
+and	O
+Nipah	O
+viruses	B-SPEC
+by	O
+using	O
+a	O
+novel	O
+high	O
+-	O
+throughput	O
+screening	O
+assay	O
+.	O
+
+We	O
+screened	O
+a	O
+library	O
+of	O
+5	O
+,	O
+000	O
+small	O
+molecules	O
+and	O
+discovered	O
+a	O
+small	O
+molecule	O
+that	O
+can	O
+inhibit	O
+the	O
+cathepsin	B-PRGE
+L	I-PRGE
+cleavage	B-PROC
+of	I-PRGE
+all	I-PRGE
+viral	I-PRGE
+peptides	B-CHED
+with	O
+minimal	O
+inhibition	B-PROC
+of	O
+cleavage	B-PROC
+of	O
+a	O
+host	B-COMP
+protein	B-CHED
+-	O
+derived	O
+peptide	O
+(	O
+pro	B-CHED
+-	O
+neuropeptide	O
+Y	O
+).	O
+
+Furthermore	O
+,	O
+we	O
+demonstrate	O
+that	O
+the	O
+small	O
+molecule	O
+is	O
+a	O
+mixed	O
+inhibitor	B-CHED
+of	O
+cathepsin	B-PRGE
+L	I-PRGE
+.	O
+Our	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+small	O
+molecule	O
+appears	O
+to	O
+be	O
+an	O
+ideal	O
+candidate	O
+for	O
+future	O
+optimization	O
+and	O
+development	B-PROC
+into	O
+a	O
+potent	O
+antiviral	B-CHED
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+Ebola	O
+,	O
+Hendra	O
+,	O
+and	O
+Nipah	O
+viruses	B-SPEC
+.	O
+
+N	B-PRGE
+protein	I-PRGE
+has	O
+also	O
+been	O
+proposed	O
+to	O
+participate	O
+in	O
+the	O
+replication	O
+and	O
+selective	O
+packaging	O
+of	O
+genomic	O
+RNA	O
+and	O
+the	O
+transcription	B-PROC
+and	O
+translation	B-PROC
+of	O
+subgenomic	O
+mRNA	B-CHED
+.	O
+
+Coronavirus	B-SPEC
+N	O
+proteins	B-CHED
+contain	O
+two	O
+structurally	O
+distinct	O
+RNA	O
+-	O
+binding	B-FUNC
+domains	O
+,	O
+an	O
+unusual	O
+characteristic	O
+among	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+As	O
+expected	O
+,	O
+the	O
+interaction	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+with	O
+M	B-PRGE
+protein	I-PRGE
+was	O
+not	O
+affected	O
+in	O
+either	O
+of	O
+the	O
+chimeric	O
+viruses	B-SPEC
+.	O
+
+The	O
+main	O
+finding	O
+is	O
+that	O
+the	O
+second	O
+of	O
+the	O
+two	O
+domains	O
+plays	O
+an	O
+essential	O
+role	O
+in	O
+recognizing	O
+the	O
+RNA	O
+structure	O
+that	O
+allows	O
+the	O
+selective	O
+packaging	O
+of	O
+genomic	O
+RNA	O
+into	O
+assembled	O
+virions	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+encode	O
+papain	O
+-	O
+like	O
+proteases	O
+(	O
+PLpro	O
+)	O
+that	O
+are	O
+often	O
+multifunctional	O
+enzymes	O
+with	O
+protease	B-PROC
+activity	I-PROC
+to	O
+process	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+polyprotein	I-PRGE
+and	O
+deubiquitinating	B-PROC
+(	O
+DUB	O
+)/	O
+deISGylating	O
+activity	O
+,	O
+which	O
+is	O
+hypothesized	O
+to	O
+modify	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+to	O
+infection	B-DISO
+.	O
+
+Initiation	O
+of	O
+the	O
+transcription	B-PROC
+of	O
+selected	O
+innate	O
+immune	O
+genes	O
+such	O
+as	O
+TLR3	B-PRGE
+,	O
+TLR7	B-PRGE
+,	O
+MyD88	B-PRGE
+,	O
+IL	O
+-	O
+1β	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+,	O
+as	O
+well	O
+as	O
+recruitment	B-DISO
+of	O
+macrophages	B-ANAT
+,	O
+were	O
+evident	O
+following	O
+an	O
+initial	O
+down	B-PROC
+regulation	I-PROC
+of	O
+some	O
+of	O
+the	O
+observed	O
+genes	O
+(	O
+TLR3	B-PRGE
+,	O
+IL	O
+-	O
+1β	O
+,	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+)	O
+in	O
+trachea	B-DISO
+and	O
+lung	B-ANAT
+.	O
+
+Moreover	O
+,	O
+how	O
+to	O
+select	O
+patients	O
+and	O
+the	O
+timing	O
+and	O
+indications	O
+for	O
+ECLS	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+remain	O
+unclear	O
+.	O
+
+The	O
+purpose	O
+of	O
+the	O
+study	O
+is	O
+to	O
+compare	O
+H1N1	O
+-	O
+induced	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+with	O
+ARDS	B-DISO
+due	O
+to	O
+other	O
+causes	O
+of	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+focusing	O
+on	O
+pulmonary	B-PROC
+function	I-PROC
+.	O
+
+This	O
+is	O
+a	O
+retrospective	O
+data	O
+analysis	O
+of	O
+adult	O
+ARDS	B-DISO
+patients	O
+between	O
+January	O
+2009	O
+and	O
+December	O
+2010	O
+in	O
+an	O
+ARDS	B-DISO
+referral	O
+center	O
+.	O
+
+Parameters	O
+of	O
+mechanical	O
+ventilation	O
+and	O
+pulmonary	B-PROC
+function	I-PROC
+were	O
+analyzed	O
+on	O
+day	O
+of	O
+admission	O
+and	O
+over	O
+the	O
+consecutive	O
+10	O
+days	O
+using	O
+a	O
+nonparametric	O
+analysis	O
+of	O
+longitudinal	O
+data	O
+in	O
+a	O
+2	O
+-	O
+factorial	O
+design	O
+.	O
+
+Gas	B-PRGE
+exchange	O
+was	O
+more	O
+severely	O
+impaired	B-DISO
+in	O
+patients	O
+with	O
+H1N1	O
+-	O
+ARDS	B-DISO
+over	O
+course	O
+of	O
+time	O
+.	O
+
+Despite	O
+significantly	O
+prolonged	O
+weaning	B-PROC
+off	O
+extracorporeal	O
+lung	B-ANAT
+support	O
+and	O
+intensive	O
+care	O
+unit	O
+stay	O
+in	O
+H1N1	O
+patients	O
+,	O
+the	O
+proportion	O
+of	O
+survivors	O
+did	O
+not	O
+differ	O
+significantly	O
+.	O
+
+ABSTRACT	O
+:	O
+Hantavirus	B-SPEC
+(	O
+Bunyaviridae	B-SPEC
+)	O
+cardiopulmonary	B-ANAT
+syndrome	B-DISO
+(	O
+HCPS	O
+)	O
+is	O
+an	O
+emerging	O
+health	O
+problem	O
+in	O
+South	O
+America	O
+due	O
+to	O
+urban	O
+growth	B-PROC
+and	O
+to	O
+the	O
+expansion	O
+of	O
+agriculture	O
+and	O
+cattle	B-SPEC
+-	O
+raising	O
+areas	O
+into	O
+ecosystems	O
+containing	O
+most	O
+of	O
+the	O
+species	B-SPEC
+of	O
+Sigmodontinae	B-SPEC
+rodents	B-SPEC
+that	O
+act	O
+as	O
+hantavirus	B-SPEC
+reservoirs	O
+.	O
+
+Person	O
+-	O
+to	O
+-	O
+person	O
+transmission	O
+of	O
+hantavirus	B-SPEC
+has	O
+also	O
+been	O
+reported	O
+in	O
+Argentina	B-SPEC
+and	O
+Chile	O
+.	O
+
+We	O
+have	O
+previously	O
+shown	O
+that	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+M	O
+protein	B-CHED
+suppresses	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+production	O
+by	O
+impeding	O
+the	O
+formation	B-PROC
+of	O
+functional	O
+TRAF3	B-PRGE
+-	I-PRGE
+containing	I-PRGE
+complex	I-PRGE
+.	O
+
+Extension	O
+of	O
+these	O
+studies	O
+to	O
+other	O
+coronaviruses	O
+and	O
+arteriviruses	B-SPEC
+led	O
+to	O
+the	O
+realization	O
+that	O
+viral	O
+protease	O
+/	O
+DUB	B-PRGE
+activity	O
+is	O
+conserved	O
+in	O
+many	O
+family	B-SPEC
+members	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+provide	O
+data	O
+of	O
+immunisation	O
+experiments	O
+with	O
+a	O
+recombinant	O
+FCoV	O
+pair	O
+differing	O
+only	O
+in	O
+the	O
+truncation	B-DISO
+(	O
+PBFIPV	O
+-	O
+DF	O
+-	O
+2	O
+)	O
+or	O
+completion	O
+(	O
+PBFIPV	O
+-	O
+DF	O
+-	O
+2	O
+-	O
+R3i	O
+)	O
+of	O
+their	O
+ORF3abc	O
+regions	O
+.	O
+
+Prolonged	O
+survival	O
+was	O
+observed	O
+in	O
+40	O
+%	O
+of	O
+the	O
+animals	B-SPEC
+,	O
+while	O
+60	O
+%	O
+showed	O
+fulminant	O
+disease	O
+course	O
+.	O
+
+The	O
+use	O
+of	O
+noninvasive	O
+ventilation	O
+as	O
+a	O
+preventive	O
+postextubation	O
+approach	O
+in	O
+patients	O
+at	O
+risk	O
+and	O
+rescue	O
+noninvasive	O
+ventilation	O
+in	O
+those	O
+developing	O
+respiratory	B-DISO
+failure	I-DISO
+remains	O
+under	O
+debate	O
+and	O
+is	O
+subject	O
+to	O
+ongoing	O
+research	O
+.	O
+
+Postoperative	O
+pulmonary	B-DISO
+complications	I-DISO
+are	O
+common	O
+,	O
+but	O
+severe	O
+complications	O
+are	O
+infrequent	O
+.	O
+
+Their	O
+reduction	O
+requires	O
+measures	O
+to	O
+prevent	O
+infection	B-DISO
+and	O
+mechanical	O
+ventilation	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+through	O
+the	O
+use	O
+of	O
+low	O
+tidal	O
+volumes	O
+and	O
+early	O
+extubation	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+):	O
+evidence	O
+and	O
+speculations	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+specificity	O
+and	O
+sensitivity	O
+of	O
+ICA	B-CHED
+(	O
+CJNP	O
+/	O
+TPA	B-FUNC
+)	O
+were	O
+equivalent	O
+to	O
+those	O
+of	O
+the	O
+reference	O
+ELISA	O
+.	O
+
+With	O
+co	O
+-	O
+localisation	B-PROC
+stainings	O
+,	O
+it	O
+was	O
+found	O
+that	O
+MLCK	B-FUNC
+and	O
+myosin	B-PRGE
+1	I-PRGE
+co	O
+-	O
+localise	O
+with	O
+antigens	B-CHED
+even	O
+before	O
+internalisation	O
+started	O
+.	O
+
+The	O
+most	O
+commonly	O
+diagnosed	O
+cause	O
+of	O
+death	B-PROC
+was	O
+respiratory	B-DISO
+disease	I-DISO
+(	O
+107	O
+/	O
+180	O
+,	O
+59	O
+.	O
+4	O
+%),	O
+followed	O
+by	O
+lameness	B-DISO
+(	O
+n	O
+=	O
+22	O
+,	O
+12	O
+.	O
+2	O
+%),	O
+ketosis	B-DISO
+(	O
+n	O
+=	O
+12	O
+,	O
+6	O
+.	O
+7	O
+%),	O
+septicemia	B-DISO
+(	O
+n	O
+=	O
+11	O
+,	O
+6	O
+.	O
+1	O
+%),	O
+and	O
+enteric	O
+disease	O
+(	O
+n	O
+=	O
+10	O
+,	O
+5	O
+.	O
+6	O
+%).	O
+
+An	O
+electrocardiogram	O
+recorded	O
+frequent	O
+monomorphic	O
+ventricular	B-DISO
+ectopic	I-DISO
+beats	I-DISO
+with	O
+bigeminy	O
+and	O
+trigeminy	B-DISO
+.	O
+
+The	O
+main	O
+factors	O
+predisposing	O
+to	O
+the	O
+development	B-PROC
+of	O
+such	O
+complications	O
+are	O
+autonomic	B-DISO
+disorder	I-DISO
+,	O
+hypoxemia	O
+,	O
+acidosis	B-DISO
+,	O
+and	O
+electrolyte	B-DISO
+imbalance	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+caused	O
+by	O
+the	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S2	I-PRGE
+is	O
+a	O
+potential	O
+drug	O
+target	O
+,	O
+as	O
+peptidomimetics	B-CHED
+against	O
+S2	O
+act	O
+as	O
+potent	O
+fusion	O
+inhibitors	B-CHED
+.	O
+
+The	O
+importance	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+hydrophobic	O
+residues	O
+led	O
+us	O
+to	O
+identify	O
+a	O
+42	O
+-	O
+residue	O
+substructure	O
+on	O
+the	O
+central	B-ANAT
+core	I-ANAT
+that	O
+is	O
+structurally	O
+conserved	O
+in	O
+all	O
+existing	O
+CoV	O
+S2	O
+fusion	O
+proteins	B-CHED
+(	O
+root	B-ANAT
+mean	O
+squared	O
+deviation	O
+=	O
+0	O
+.	O
+4	O
+Å	O
+).	O
+
+TITLE	O
+:	O
+Middle	O
+east	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+4a	O
+protein	B-CHED
+is	O
+a	O
+double	O
+-	O
+stranded	O
+RNA	O
+-	O
+binding	B-FUNC
+protein	B-CHED
+that	O
+suppresses	O
+PACT	B-DISO
+-	O
+induced	O
+activation	O
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+MDA5	B-PRGE
+in	O
+the	O
+innate	O
+antiviral	B-PROC
+response	I-PROC
+.	O
+
+Expression	B-PROC
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+4a	I-PRGE
+protein	I-PRGE
+suppressed	O
+the	O
+interferon	B-PROC
+production	I-PROC
+induced	O
+by	O
+poly	O
+(	O
+I	O
+·	O
+C	O
+)	O
+or	O
+Sendai	B-SPEC
+virus	I-SPEC
+.	O
+
+The	O
+correlation	O
+between	O
+EVLWI	O
+and	O
+intrathoracic	O
+blood	B-ANAT
+volume	O
+index	O
+(	O
+ITBVI	O
+),	O
+PVPI	O
+and	O
+OI	O
+was	O
+analyzed	O
+.	O
+
+The	O
+28	O
+-	O
+day	O
+mortality	O
+rate	O
+was	O
+gradually	O
+increased	O
+with	O
+severity	O
+categories	O
+of	O
+ARDS	B-DISO
+,	O
+and	O
+mortality	O
+in	O
+moderate	O
+and	O
+severe	O
+groups	O
+were	O
+significantly	O
+higher	O
+than	O
+that	O
+in	O
+mild	O
+group	O
+[	O
+54	O
+.	O
+5	O
+%	O
+(	O
+12	O
+/	O
+22	O
+),	O
+57	O
+.	O
+1	O
+%	O
+(	O
+8	O
+/	O
+14	O
+)	O
+vs	O
+.	O
+22	O
+.	O
+2	O
+%	O
+(	O
+4	O
+/	O
+18	O
+),	O
+both	O
+P	O
+<	O
+0	O
+.	O
+05	O
+].	O
+
+Combining	O
+the	O
+Berlin	O
+definition	O
+with	O
+EVLWI	O
+and	O
+PVPI	O
+,	O
+the	O
+severity	O
+of	O
+ARDS	B-DISO
+can	O
+be	O
+assessed	O
+accurately	O
+.	O
+
+Herein	O
+,	O
+four	O
+representative	O
+Ag	O
+NMs	B-DISO
+including	O
+spherical	O
+Ag	O
+nanoparticles	B-CHED
+(	O
+Ag	O
+NPs	B-DISO
+,	O
+NM	O
+-	O
+300	O
+),	O
+two	O
+kinds	O
+of	O
+silver	B-CHED
+nanowires	O
+(	O
+XFJ011	O
+)	O
+and	O
+silver	B-CHED
+colloids	O
+(	O
+XFJ04	O
+)	O
+were	O
+selected	O
+to	O
+study	O
+their	O
+inhibitory	O
+effect	O
+on	O
+TGEV	B-SPEC
+-	O
+induced	O
+host	B-COMP
+cell	I-COMP
+infection	B-DISO
+in	O
+vitro	O
+.	O
+
+No	O
+Th1	O
+epitope	B-CHED
+-	O
+containing	O
+peptide	B-CHED
+was	O
+identified	O
+in	O
+the	O
+peptides	B-CHED
+derived	O
+from	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+of	O
+type	B-PRGE
+I	I-PRGE
+FIPV	I-PRGE
+.	O
+
+Of	O
+the	O
+peptides	B-CHED
+derived	O
+from	O
+the	O
+S	O
+,	O
+M	O
+,	O
+and	O
+N	O
+proteins	B-CHED
+of	O
+FIPV	O
+,	O
+those	O
+that	O
+induced	O
+significantly	O
+stronger	O
+Th1	O
+activity	O
+than	O
+that	O
+of	O
+the	O
+FIPV	B-PRGE
+antigen	I-PRGE
+were	O
+rescreened	O
+,	O
+and	O
+4	O
+peptides	B-CHED
+were	O
+identified	O
+.	O
+
+Various	O
+synthetic	O
+peptides	B-CHED
+covering	O
+the	O
+potential	O
+binding	B-FUNC
+site	O
+helped	O
+to	O
+minimize	O
+further	O
+the	O
+binding	B-FUNC
+motif	O
+to	O
+10	O
+-	O
+25	O
+residues	O
+.	O
+
+However	O
+,	O
+the	O
+molecular	O
+organization	O
+and	O
+biochemical	B-PROC
+mechanisms	I-PROC
+of	O
+the	O
+viral	O
+capping	B-PROC
+apparatus	B-ANAT
+typically	O
+differ	O
+from	O
+its	O
+cellular	B-COMP
+counterpart	O
+,	O
+which	O
+makes	O
+viral	O
+capping	B-PROC
+enzymes	O
+attractive	O
+targets	O
+for	O
+drug	O
+discovery	O
+.	O
+
+Our	O
+previous	O
+work	O
+showed	O
+that	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+14	O
+represents	O
+a	O
+structurally	O
+novel	O
+and	O
+unique	O
+guanine	B-PRGE
+-	I-PRGE
+N7	I-PRGE
+-	I-PRGE
+methyltransferase	I-PRGE
+(	O
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+)	O
+that	O
+is	O
+able	O
+to	O
+functionally	O
+complement	O
+yeast	B-SPEC
+cellular	B-PRGE
+N7	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+yeast	B-SPEC
+-	O
+based	O
+system	O
+for	O
+identifying	O
+and	O
+screening	O
+inhibitors	O
+against	O
+coronavirus	B-SPEC
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+using	O
+both	O
+96	O
+-	O
+well	O
+and	O
+384	O
+-	O
+well	O
+microtiter	O
+plates	O
+.	O
+
+However	O
+,	O
+other	O
+compounds	O
+,	O
+such	O
+as	O
+ATA	B-SPEC
+and	O
+AdoHcy	B-CHED
+,	O
+did	O
+not	O
+exert	B-PROC
+an	O
+inhibitory	O
+effect	O
+within	O
+a	O
+cellular	B-COMP
+context	O
+.	O
+
+ABSTRACT	O
+:	O
+Papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLpro	O
+)	O
+is	O
+one	O
+of	O
+two	O
+cysteine	B-PRGE
+proteases	I-PRGE
+involved	O
+in	O
+the	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+the	O
+polyproteins	O
+of	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+One	O
+of	O
+the	O
+O	O
+atoms	B-CHED
+of	O
+the	O
+C	O
+-	O
+terminal	O
+Gly	B-CHED
+residue	O
+of	O
+Ub	O
+is	O
+located	O
+in	O
+the	O
+oxyanion	O
+hole	O
+consisting	O
+of	O
+the	O
+main	O
+-	O
+chain	O
+amides	B-CHED
+of	O
+residues	O
+112	O
+and	O
+113	O
+.	O
+
+By	O
+January	O
+9	O
+,	O
+2014	O
+,	O
+the	O
+disease	O
+had	O
+already	O
+struck	B-DISO
+178	O
+persons	O
+of	O
+whom	O
+75	O
+died	B-PROC
+from	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+diarrhoea	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+many	O
+strains	O
+of	O
+Betacoronavirus	B-SPEC
+more	O
+or	O
+less	O
+related	O
+to	O
+those	O
+responsible	O
+for	O
+the	O
+MERS	O
+disease	O
+in	O
+man	B-CHED
+have	O
+been	O
+isolated	O
+from	O
+bats	B-SPEC
+in	O
+Africa	O
+,	O
+Asia	O
+and	O
+Europe	O
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+the	O
+N	O
+-	O
+glycosylation	B-PROC
+of	O
+the	O
+Fc	O
+-	O
+portion	O
+of	O
+serum	B-COMP
+IgG	B-PRGE
+was	O
+investigated	O
+in	O
+patients	O
+with	O
+GBS	B-DISO
+before	O
+and	O
+after	O
+treatment	O
+with	O
+IVIg	O
+in	O
+relation	O
+to	O
+clinical	O
+course	O
+and	O
+outcome	O
+.	O
+
+Glycoforms	O
+of	O
+serum	B-PRGE
+IgG1	B-COMP
+and	O
+IgG2	B-COMP
+were	O
+determined	O
+separately	O
+by	O
+liquid	O
+chromatography	O
+mass	O
+spectrometry	O
+.	O
+
+TITLE	O
+:	O
+TGEV	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+induces	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+and	O
+apoptosis	B-PATH
+through	O
+activation	O
+of	O
+p53	B-PRGE
+signaling	B-PROC
+.	O
+
+We	O
+found	O
+that	O
+TGEV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+suppressed	O
+cell	B-PROC
+proliferation	B-DISO
+by	O
+causing	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+at	O
+the	O
+S	O
+and	O
+G2	O
+/	O
+M	B-PROC
+phases	I-PROC
+and	O
+apoptosis	B-PATH
+.	O
+
+Moreover	O
+,	O
+the	O
+expression	B-PROC
+of	O
+TGEV	B-PRGE
+N	I-PRGE
+gene	I-PRGE
+promoted	O
+translocation	B-DISO
+of	O
+Bax	B-PRGE
+to	O
+mitochondria	B-COMP
+,	O
+which	O
+in	O
+turn	O
+caused	O
+the	O
+release	B-PATH
+of	O
+cytochrome	B-PROC
+c	I-PROC
+,	O
+followed	O
+by	O
+activation	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+,	O
+resulting	O
+in	O
+cell	B-COMP
+apoptosis	B-PATH
+in	O
+the	O
+transfected	O
+PK	O
+-	O
+15	O
+cells	O
+following	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+.	O
+
+Further	O
+studies	O
+showed	O
+that	O
+p53	B-PRGE
+inhibitor	B-CHED
+attenuated	O
+TGEV	B-SPEC
+N	O
+protein	B-CHED
+induced	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+at	O
+S	O
+and	O
+G2	O
+/	O
+M	B-PROC
+phases	I-PROC
+and	O
+apoptosis	B-PATH
+through	O
+reversing	O
+the	O
+expression	B-PROC
+changes	O
+of	O
+cdc2	B-PRGE
+,	O
+cdk2	B-PRGE
+and	O
+cyclin	B-PRGE
+B1	I-PRGE
+and	O
+the	O
+translocation	B-DISO
+changes	O
+of	O
+Bax	B-PRGE
+and	O
+cytochrome	B-PROC
+c	I-PROC
+induced	O
+by	O
+TGEV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+World	O
+Health	O
+Organization	O
+,	O
+as	O
+well	O
+as	O
+several	O
+other	O
+national	O
+agencies	O
+,	O
+are	O
+still	O
+working	O
+on	O
+different	O
+clinical	O
+approaches	O
+to	O
+implement	O
+the	O
+most	O
+relevant	O
+treatment	O
+in	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+We	O
+compared	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+of	O
+two	O
+patients	O
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+to	O
+understand	O
+the	O
+underlying	O
+mechanisms	O
+involved	O
+in	O
+the	O
+response	O
+and	O
+propose	O
+potential	O
+therapeutic	O
+approaches	O
+.	O
+
+Finally	O
+,	O
+we	O
+confirm	O
+previous	O
+in	O
+vitro	O
+findings	O
+that	O
+MERS	O
+-	O
+CoV	O
+can	O
+drive	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+production	I-PROC
+in	O
+humans	B-SPEC
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+identified	O
+independent	O
+risk	O
+factors	O
+for	O
+developing	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Predictors	O
+for	O
+the	O
+development	B-PROC
+of	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+were	O
+inhalation	B-PROC
+injury	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+1	O
+.	O
+90	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+01	O
+-	O
+3	O
+.	O
+54	O
+;	O
+p	O
+=	O
+0	O
+.	O
+046	O
+),	O
+Injury	O
+Severity	O
+Score	O
+(	O
+ISS	B-DISO
+)	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+04	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+01	O
+-	O
+1	O
+.	O
+07	O
+;	O
+p	O
+=	O
+0	O
+.	O
+0021	O
+),	O
+pneumonia	B-DISO
+(	O
+OR	O
+,	O
+198	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+07	O
+-	O
+3	O
+.	O
+66	O
+;	O
+p	O
+=	O
+0	O
+.	O
+03	O
+),	O
+and	O
+transfusion	O
+of	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+(	O
+OR	O
+,	O
+1	O
+.	O
+32	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+01	O
+-	O
+1	O
+.	O
+72	O
+;	O
+p	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+A	O
+prototype	O
+coronavirus	B-SPEC
+was	O
+used	O
+to	O
+illustrate	O
+how	O
+the	O
+virus	B-SPEC
+fusion	O
+machinery	O
+can	O
+be	O
+controlled	O
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+variation	O
+and	O
+susceptibility	O
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+It	O
+is	O
+conservatively	O
+estimated	O
+that	O
+10	O
+%	O
+of	O
+Sri	O
+Lanka	B-SPEC
+'	O
+s	O
+population	O
+work	O
+as	O
+international	O
+labor	B-PROC
+migrants	O
+(	O
+1	O
+.	O
+8	O
+to	O
+2	O
+million	O
+workers	O
+),	O
+with	O
+93	O
+%	O
+residing	O
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+The	O
+strategies	O
+described	O
+here	O
+may	O
+be	O
+useful	O
+for	O
+other	O
+labor	B-PROC
+sending	O
+country	O
+contexts	O
+in	O
+Asia	O
+with	O
+a	O
+high	O
+frequency	O
+and	O
+volume	O
+of	O
+migrant	O
+workers	O
+to	O
+and	O
+from	O
+the	O
+Gulf	O
+region	O
+.	O
+
+Sera	B-COMP
+from	O
+noninfected	O
+and	O
+infected	O
+pigs	B-SPEC
+were	O
+used	O
+to	O
+set	O
+the	O
+median	O
+fluorescent	O
+intensity	O
+(	O
+MFI	O
+)	O
+cutoffs	O
+and	O
+as	O
+positive	O
+controls	O
+,	O
+respectively	O
+.	O
+
+Sixteen	O
+reactive	O
+plaques	B-DISO
+(	O
+52	O
+genes	O
+)	O
+were	O
+detected	O
+.	O
+
+Oral	B-ANAT
+valganciclovir	B-CHED
+treatment	O
+reduces	O
+the	O
+risk	O
+of	O
+hearing	B-DISO
+loss	I-DISO
+in	O
+congenital	B-DISO
+CMV	I-DISO
+infection	I-DISO
+.	O
+
+An	O
+outbreak	O
+of	O
+mould	O
+infections	B-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+has	O
+been	O
+described	O
+in	O
+the	O
+United	O
+States	O
+following	O
+injection	O
+of	O
+contaminated	O
+steroids	B-CHED
+.	O
+
+Therefore	O
+,	O
+development	B-PROC
+of	O
+effective	O
+vaccines	O
+is	O
+crucial	O
+for	O
+preventing	O
+its	O
+further	O
+spread	O
+and	O
+future	O
+pandemic	O
+.	O
+
+This	O
+study	O
+suggests	O
+the	O
+potential	O
+of	O
+developing	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RBD	I-PRGE
+protein	I-PRGE
+into	O
+an	O
+effective	O
+and	O
+safe	O
+mucosal	B-ANAT
+candidate	O
+vaccine	O
+for	O
+prevention	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+caused	O
+by	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+ABSTRACT	O
+:	O
+Community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+continues	O
+to	O
+be	O
+an	O
+important	O
+complication	B-DISO
+of	O
+HIV	B-PATH
+infection	I-PATH
+.	O
+
+Rates	O
+of	O
+pneumonia	B-DISO
+decrease	O
+with	O
+the	O
+use	O
+of	O
+antiretroviral	O
+therapy	O
+but	O
+continue	O
+to	O
+be	O
+higher	O
+than	O
+in	O
+HIV	B-DISO
+uninfected	O
+individuals	O
+.	O
+
+Immunization	O
+against	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+and	O
+smoking	O
+cessation	O
+can	O
+reduce	O
+this	O
+risk	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+for	O
+the	O
+identification	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	I-PRGE
+as	O
+an	O
+antiviral	B-CHED
+target	O
+.	O
+
+By	O
+targeting	B-PROC
+this	O
+pocket	O
+,	O
+we	O
+identified	O
+and	O
+developed	O
+a	O
+new	O
+coronavirus	B-SPEC
+N	O
+protein	B-CHED
+inhibitor	B-CHED
+,	O
+N	O
+-(	O
+6	O
+-	O
+oxo	B-CHED
+-	O
+5	O
+,	O
+6	O
+-	O
+dihydrophenanthridin	O
+-	O
+2	O
+-	O
+yl	O
+)(	O
+N	O
+,	O
+N	O
+-	O
+dimethylamino	O
+)	O
+acetamide	B-CHED
+hydrochloride	B-CHED
+(	O
+PJ34	O
+),	O
+using	O
+virtual	O
+screening	O
+;	O
+this	O
+inhibitor	B-CHED
+reduced	O
+the	O
+N	O
+protein	O
+'	O
+s	O
+RNA	O
+-	O
+binding	B-FUNC
+affinity	O
+and	O
+hindered	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+We	O
+also	O
+determined	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+N	B-PRGE
+-	I-PRGE
+NTD	I-PRGE
+-	I-PRGE
+PJ34	I-PRGE
+complex	I-PRGE
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+these	O
+findings	O
+,	O
+we	O
+propose	O
+guidelines	O
+for	O
+developing	O
+new	O
+N	O
+protein	B-CHED
+-	O
+based	O
+antiviral	B-CHED
+agents	I-CHED
+that	O
+target	O
+CoVs	O
+.	O
+
+The	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+developed	O
+with	O
+respect	O
+to	O
+CV	O
+effects	O
+established	O
+that	O
+small	O
+structural	O
+changes	O
+to	O
+the	O
+P2	O
+*	O
+subsite	O
+of	O
+the	O
+molecule	O
+had	O
+a	O
+significant	O
+impact	O
+on	O
+the	O
+CV	O
+profile	O
+of	O
+a	O
+given	O
+compound	O
+.	O
+
+Although	O
+the	O
+physicians	O
+generally	O
+focus	O
+their	O
+attention	O
+in	O
+avoid	O
+barotrauma	O
+--	O
+caused	O
+by	O
+oxygen	B-CHED
+supplement	O
+or	O
+jet	O
+ventilation	O
+through	O
+AEC	O
+--	O
+concern	O
+for	O
+insertion	O
+technique	O
+can	O
+minimize	O
+life	O
+threatening	O
+complications	O
+and	O
+increase	O
+the	O
+safety	O
+of	O
+AEC	O
+.	O
+
+Quantitative	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+qPCR	O
+)	O
+analyses	O
+allow	O
+sensitive	O
+detection	O
+of	O
+viral	O
+nucleic	B-CHED
+acids	I-CHED
+,	O
+but	O
+it	O
+is	O
+not	O
+clear	O
+to	O
+what	O
+extent	O
+specific	O
+viruses	B-SPEC
+contribute	O
+to	O
+disease	O
+because	O
+many	O
+viruses	B-SPEC
+have	O
+been	O
+detected	O
+in	O
+asymptomatic	O
+children	O
+.	O
+
+Better	O
+understanding	O
+of	O
+how	O
+to	O
+interpret	O
+viral	O
+findings	O
+is	O
+important	O
+to	O
+reduce	O
+unnecessary	O
+use	O
+of	O
+antibiotics	B-CHED
+.	O
+
+Metapneumovirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+,	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+were	O
+highly	O
+overrepresented	O
+in	O
+case	O
+patients	O
+.	O
+
+qPCR	O
+detection	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+metapneumovirus	B-SPEC
+,	O
+or	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+in	O
+children	O
+with	O
+ARI	B-CHED
+is	O
+likely	O
+to	O
+be	O
+causative	O
+of	O
+disease	O
+;	O
+detection	O
+of	O
+several	O
+other	O
+respiratory	O
+viruses	B-SPEC
+must	O
+be	O
+interpreted	O
+with	O
+caution	O
+due	O
+to	O
+high	O
+detection	O
+rates	O
+in	O
+asymptomatic	O
+children	O
+.	O
+
+Rhinovirus	B-SPEC
+was	O
+the	O
+most	O
+common	O
+finding	O
+in	O
+both	O
+case	O
+patients	O
+and	O
+control	O
+subjects	O
+(	O
+47	O
+.	O
+9	O
+%	O
+and	O
+21	O
+.	O
+5	O
+%,	O
+respectively	O
+),	O
+with	O
+a	O
+population	O
+-	O
+attributable	O
+proportion	O
+of	O
+0	O
+.	O
+39	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+:	O
+0	O
+.	O
+01	O
+to	O
+0	O
+.	O
+62	O
+).	O
+
+There	O
+appeared	O
+to	O
+be	O
+no	O
+significant	O
+seasonal	O
+influence	O
+on	O
+the	O
+frequency	O
+of	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.;	O
+but	O
+there	O
+was	O
+one	O
+for	O
+Eimeria	B-SPEC
+spp	B-ENZY
+.:	O
+the	O
+odds	O
+of	O
+being	O
+infected	O
+with	O
+Eimeria	B-SPEC
+spp	B-ENZY
+.	O
+
+and	O
+Rotavirus	B-SPEC
+are	O
+mostly	O
+relevant	O
+in	O
+young	O
+calves	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+fatal	O
+infectious	B-DISO
+diseases	I-DISO
+of	O
+cats	B-SPEC
+,	O
+the	O
+pathogenesis	B-DISO
+of	O
+which	O
+has	O
+not	O
+yet	O
+been	O
+fully	O
+revealed	O
+.	O
+
+The	O
+present	O
+review	O
+focuses	O
+on	O
+the	O
+biology	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+infection	B-DISO
+and	O
+the	O
+pathogenesis	B-DISO
+and	O
+pathological	O
+features	O
+of	O
+FIP	B-DISO
+.	O
+
+Advances	O
+have	O
+been	O
+made	O
+in	O
+the	O
+clinical	O
+diagnosis	O
+of	O
+FIP	B-DISO
+,	O
+based	O
+on	O
+the	O
+clinical	O
+pathologic	O
+findings	O
+,	O
+serologic	O
+testing	O
+,	O
+and	O
+detection	B-PROC
+of	I-PROC
+virus	I-PROC
+using	O
+molecular	O
+(	O
+polymerase	O
+chain	O
+reaction	O
+)	O
+or	O
+antibody	B-COMP
+-	O
+based	O
+methods	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	B-DISO
+)	O
+is	O
+proposed	O
+to	O
+be	O
+a	O
+zoonotic	O
+disease	O
+;	O
+however	O
+,	O
+the	O
+reservoir	O
+and	O
+mechanism	O
+for	O
+transmission	O
+of	O
+the	O
+causative	O
+agent	O
+,	O
+the	O
+MERS	B-DISO
+coronavirus	B-SPEC
+,	O
+are	O
+unknown	O
+.	O
+
+We	O
+found	O
+no	O
+evidence	O
+of	O
+infection	O
+in	O
+domestic	B-SPEC
+sheep	I-SPEC
+or	O
+domestic	B-SPEC
+goats	I-SPEC
+.	O
+
+It	O
+was	O
+provided	O
+on	O
+an	O
+emergency	B-DISO
+basis	O
+to	O
+11	O
+patients	O
+,	O
+urgently	O
+to	O
+5	O
+,	O
+and	O
+electively	O
+to	O
+3	O
+.	O
+
+It	O
+significantly	O
+increased	O
+costs	O
+by	O
+delaying	O
+imminent	O
+death	B-PROC
+and	O
+prolonging	O
+stay	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+institutional	O
+experience	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenator	O
+support	O
+for	O
+cardiac	B-ANAT
+indications	O
+in	O
+adult	O
+patients	O
+indicates	O
+poor	O
+survival	O
+.	O
+
+ABSTRACT	O
+:	O
+African	O
+trypanosomiasis	O
+is	O
+a	O
+parasitic	B-DISO
+infection	I-DISO
+sporadically	O
+imported	O
+to	O
+Europe	O
+by	O
+tourists	O
+or	O
+immigrants	O
+returning	O
+from	O
+endemic	O
+areas	O
+.	O
+
+On	O
+admission	O
+,	O
+his	O
+clinical	O
+status	O
+was	O
+severe	O
+,	O
+with	O
+high	O
+fever	B-PROC
+of	O
+41ºC	O
+,	O
+preceded	O
+by	O
+chills	B-DISO
+,	O
+bleeding	B-DISO
+from	O
+the	O
+gums	B-ANAT
+and	O
+oral	B-ANAT
+mucosa	I-ANAT
+,	O
+haemorrhages	B-DISO
+at	O
+the	O
+sites	O
+of	O
+venipuncture	O
+,	O
+numerous	O
+ecchymoses	O
+,	O
+fine	O
+-	O
+spotted	O
+skin	B-DISO
+rash	I-DISO
+,	O
+tachycardia	O
+,	O
+hepatosplenomegaly	B-DISO
+,	O
+dehydration	B-DISO
+,	O
+jaundice	B-DISO
+,	O
+dyspnoea	B-DISO
+,	O
+hypoxaemia	O
+,	O
+generalised	O
+oedema	O
+and	O
+oliguria	B-DISO
+.	O
+
+A	O
+severe	O
+clinical	O
+course	O
+of	O
+acute	O
+rhodesiense	B-DISO
+trypanosomiasis	I-DISO
+with	O
+renal	B-DISO
+failure	I-DISO
+,	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+syndrome	B-DISO
+,	O
+haemolysis	B-DISO
+,	O
+liver	B-DISO
+insufficiency	I-DISO
+and	O
+myocarditis	B-DISO
+was	O
+confirmed	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+study	O
+on	O
+the	O
+related	O
+markers	O
+of	O
+blood	B-PROC
+coagulation	I-PROC
+in	O
+the	O
+patients	O
+with	O
+ANFH	B-DISO
+after	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+common	O
+respiratory	O
+viruses	B-SPEC
+in	O
+tonsillar	B-ANAT
+tissue	I-ANAT
+of	O
+children	O
+with	O
+obstructive	B-DISO
+sleep	B-PROC
+apnea	I-DISO
+.	O
+
+Therefore	O
+,	O
+we	O
+examined	O
+tonsils	B-ANAT
+for	O
+the	O
+presence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+'	O
+nucleic	B-CHED
+acids	I-CHED
+in	O
+children	O
+with	O
+OSA	B-DISO
+,	O
+and	O
+in	O
+children	O
+without	O
+OSA	B-DISO
+(	O
+undergoing	O
+surgery	O
+for	O
+recurrent	O
+throat	B-ANAT
+infections	B-DISO
+(	O
+RI	O
+)).	O
+
+In	O
+contrast	O
+,	O
+no	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+RI	O
+samples	O
+(	O
+relative	O
+frequency	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+ABSTRACT	O
+:	O
+Few	O
+studies	O
+have	O
+investigated	O
+high	O
+-	O
+frequency	O
+percussive	O
+ventilation	O
+(	O
+HFPV	O
+)	O
+in	O
+adult	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+).	O
+
+HFPV	O
+caused	O
+rapid	O
+and	O
+sustained	O
+improvement	O
+of	O
+oxygenation	B-PROC
+and	O
+ventilation	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+involvement	O
+in	O
+leptospirosis	B-DISO
+most	O
+commonly	O
+occurs	O
+as	O
+aseptic	B-DISO
+meningitis	I-DISO
+,	O
+often	O
+asymptomatic	O
+,	O
+only	O
+with	O
+abnormal	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+findings	O
+.	O
+
+We	O
+investigated	O
+the	O
+clinical	O
+characteristics	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+in	O
+patients	O
+<	O
+5	O
+years	O
+of	O
+age	O
+during	O
+a	O
+recent	O
+coronavirus	B-SPEC
+season	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+partial	O
+spike	O
+(	O
+S	O
+),	O
+ORF3	O
+,	O
+and	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+genes	O
+amplified	O
+from	O
+these	O
+variants	O
+were	O
+sequenced	O
+and	O
+analyzed	O
+.	O
+
+It	O
+is	O
+possible	O
+that	O
+these	O
+mutations	O
+have	O
+changed	O
+the	O
+hydrophobicity	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+influenced	O
+the	O
+viral	O
+antigenicity	O
+and	O
+virulence	B-PROC
+.	O
+
+There	O
+is	O
+a	O
+lack	O
+of	O
+proven	O
+effective	O
+medications	O
+for	O
+therapy	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+current	O
+knowledge	O
+of	O
+therapeutic	O
+options	O
+for	O
+MERS	O
+-	O
+CoV	O
+is	O
+based	O
+on	O
+the	O
+experience	O
+from	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+from	O
+in	O
+vitro	O
+studies	O
+.	O
+
+In	O
+this	O
+article	O
+we	O
+review	O
+the	O
+different	O
+therapeutics	O
+available	O
+for	O
+MERS	O
+-	O
+CoV	O
+from	O
+SARS	B-DISO
+experience	O
+,	O
+in	O
+vitro	O
+and	O
+animal	B-SPEC
+studies	O
+of	O
+this	O
+emerging	O
+disease	O
+.	O
+
+Therefore	O
+,	O
+this	O
+review	O
+compares	O
+animal	B-SPEC
+models	O
+of	O
+SARS	B-DISO
+and	O
+influenza	B-DISO
+,	O
+with	O
+an	O
+emphasis	O
+on	O
+non	O
+-	O
+human	B-SPEC
+primates	B-SPEC
+,	O
+ferrets	B-SPEC
+and	O
+cats	B-SPEC
+.	O
+
+Nevertheless	O
+,	O
+the	O
+overall	O
+information	O
+obtained	O
+on	O
+SARs	B-DISO
+following	O
+the	O
+qHPV	O
+vaccine	O
+suggests	O
+a	O
+good	O
+safety	O
+profile	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+the	O
+AdvanSure	O
+™	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+compared	O
+with	O
+culture	O
+and	O
+Seeplex	O
+RV15	O
+for	O
+simultaneous	O
+detection	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+investigation	O
+was	O
+to	O
+determine	O
+whether	O
+the	O
+combination	O
+of	O
+NIV	O
+with	O
+administration	O
+of	O
+a	O
+neutrophil	B-CHED
+elastase	I-CHED
+inhibitor	I-CHED
+could	O
+improve	O
+outcome	O
+and	O
+respiratory	O
+conditions	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)-	O
+patients	O
+,	O
+according	O
+to	O
+the	O
+Berlin	O
+definition	O
+.	O
+
+Eight	O
+mild	O
+,	O
+17	O
+moderate	O
+,	O
+and	O
+10	O
+severe	O
+ARDS	B-DISO
+-	O
+patients	O
+were	O
+alive	O
+on	O
+day	O
+28	O
+after	O
+the	O
+induction	O
+of	O
+NIV	O
+.	O
+
+aMPV	O
+and	O
+THEV	O
+diagnostic	O
+swabs	O
+and	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+made	O
+once	O
+a	O
+week	O
+up	O
+to	O
+14	O
+weeks	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+On	O
+September	O
+20	O
+,	O
+2012	O
+,	O
+a	O
+Saudi	O
+Arabian	O
+physician	O
+reported	O
+the	O
+isolation	O
+of	O
+a	O
+novel	O
+coronavirus	O
+from	O
+a	O
+patient	O
+with	O
+pneumonia	B-DISO
+on	O
+ProMED	O
+-	O
+mail	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+originated	O
+in	O
+China	O
+'	O
+s	O
+Guangdong	O
+Province	O
+and	O
+affected	O
+more	O
+than	O
+8000	O
+patients	O
+in	O
+26	O
+countries	O
+before	O
+it	O
+was	O
+contained	O
+6	O
+months	O
+later	O
+.	O
+
+Here	O
+,	O
+we	O
+review	O
+the	O
+current	O
+state	O
+of	O
+knowledge	O
+on	O
+the	O
+epidemiology	O
+,	O
+ecology	O
+,	O
+molecular	O
+biology	O
+,	O
+clinical	O
+features	O
+,	O
+and	O
+intervention	O
+strategies	O
+of	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+in	O
+vivo	O
+analysis	O
+of	O
+recombinant	O
+type	O
+II	O
+feline	B-SPEC
+coronaviruses	O
+with	O
+truncated	O
+and	O
+completed	O
+ORF3	O
+region	O
+.	O
+
+ABSTRACT	O
+:	O
+Our	O
+previous	O
+in	O
+vitro	O
+comparative	O
+study	O
+on	O
+a	O
+feline	O
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+pair	O
+,	O
+differing	O
+only	O
+in	O
+the	O
+intactness	O
+of	O
+their	O
+ORF3abc	O
+regions	O
+,	O
+showed	O
+that	O
+the	O
+truncated	O
+ORF3abc	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+efficient	O
+macrophage	B-ANAT
+/	O
+monocyte	B-ANAT
+tropism	B-PROC
+of	O
+type	O
+II	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+).	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+association	O
+of	O
+the	O
+caspase	B-PRGE
+-	I-PRGE
+12	I-PRGE
+long	I-PRGE
+allele	I-PRGE
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+in	O
+people	O
+of	O
+African	O
+descent	O
+.	O
+
+Active	O
+full	O
+-	O
+length	O
+caspase	B-PRGE
+-	I-PRGE
+12	I-PRGE
+(	O
+CASP12L	O
+),	O
+confined	O
+to	O
+the	O
+people	O
+of	O
+African	O
+descent	O
+,	O
+has	O
+been	O
+associated	O
+with	O
+increased	O
+susceptibility	O
+to	O
+and	O
+mortality	O
+from	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Neither	O
+in	O
+the	O
+three	O
+individual	O
+CAP	B-PRGE
+cohorts	I-PRGE
+nor	O
+in	O
+the	O
+combined	O
+CAP	O
+cohorts	O
+,	O
+was	O
+mortality	O
+in	O
+CASP12L	O
+carriers	O
+significantly	O
+different	O
+from	O
+that	O
+in	O
+non	O
+-	O
+CASP12L	O
+carriers	O
+.	O
+
+Next	O
+generation	O
+sequencing	O
+technologies	O
+have	O
+been	O
+utilized	O
+for	O
+analysis	O
+of	O
+clinical	O
+and	O
+environmental	B-SPEC
+samples	I-SPEC
+to	O
+identify	O
+viral	O
+pathogens	O
+that	O
+may	O
+be	O
+present	O
+.	O
+
+The	O
+resultant	O
+cDNAs	O
+were	O
+amplified	O
+by	O
+primer	O
+-	O
+specific	O
+PCR	O
+,	O
+pooled	O
+,	O
+size	O
+fractionated	O
+and	O
+sequenced	O
+on	O
+the	O
+Ion	O
+Torrent	O
+PGM	B-FUNC
+platform	O
+.	O
+
+Oxygen	B-CHED
+saturation	O
+was	O
+increased	O
+to	O
+more	O
+than	O
+90	O
+%	O
+in	O
+24	O
+hours	O
+,	O
+which	O
+was	O
+maintained	O
+for	O
+3	O
+days	O
+when	O
+we	O
+were	O
+able	O
+to	O
+wean	B-PROC
+him	O
+from	O
+mechanical	O
+ventilation	O
+.	O
+
+After	O
+7	O
+days	O
+,	O
+the	O
+x	O
+-	O
+ray	B-SPEC
+film	O
+showed	O
+considerable	O
+clearing	O
+of	O
+shadows	O
+.	O
+
+Recent	O
+experiences	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+pandemic	O
+(	O
+H1N1	O
+)	O
+influenza	B-DISO
+in	O
+2009	O
+highlighted	O
+that	O
+health	O
+professionals	O
+may	O
+have	O
+difficulty	O
+in	O
+choosing	O
+the	O
+correct	O
+facial	B-ANAT
+and	O
+respiratory	O
+protection	O
+.	O
+
+Among	O
+the	O
+2	O
+,	O
+145	O
+patients	O
+enrolled	O
+,	O
+45	O
+%	O
+belonged	O
+to	O
+Group	O
+A	O
+,	O
+36	O
+%	O
+to	O
+Group	B-DISO
+B	I-DISO
+and	O
+20	O
+%	O
+to	O
+Group	O
+C	O
+.	O
+Patients	O
+in	O
+Group	O
+C	O
+were	O
+more	O
+severe	O
+than	O
+patients	O
+in	O
+Group	B-DISO
+B	I-DISO
+.	O
+Isolated	O
+ARF	B-DISO
+was	O
+correlated	O
+with	O
+age	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+COPD	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+multilobar	O
+infiltrates	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+identification	O
+of	O
+ARF	B-DISO
+and	O
+SS	O
+on	O
+hospital	O
+admission	O
+can	O
+help	O
+physicians	O
+in	O
+classifying	O
+CAP	B-DISO
+patients	O
+into	O
+three	O
+different	O
+clinical	O
+phenotypes	O
+.	O
+
+ABSTRACT	O
+:	O
+Fathead	B-SPEC
+minnow	I-SPEC
+nidovirus	B-SPEC
+(	O
+FHMNV	O
+)	O
+is	O
+a	O
+serious	O
+baitfish	O
+-	O
+pathogenic	O
+virus	B-SPEC
+in	O
+North	O
+America	O
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+generation	O
+of	O
+a	O
+mouse	B-SPEC
+model	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+.	O
+
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+recently	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+a	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+Given	O
+the	O
+ability	O
+of	O
+coronavirus	B-SPEC
+to	O
+rapidly	O
+adapt	O
+to	O
+new	O
+hosts	B-COMP
+,	O
+a	O
+major	O
+public	O
+health	O
+concern	O
+is	O
+that	O
+MERS	O
+-	O
+CoV	O
+will	O
+further	O
+adapt	O
+to	O
+replication	O
+in	O
+humans	B-SPEC
+,	O
+triggering	O
+a	O
+pandemic	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+mice	B-SPEC
+were	O
+sensitized	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+by	O
+prior	O
+transduction	B-PROC
+with	O
+adenoviral	B-SPEC
+vectors	O
+expressing	O
+the	O
+human	B-PRGE
+host	B-COMP
+-	I-PRGE
+cell	B-COMP
+receptor	I-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+.	O
+
+Clinical	O
+disease	O
+and	O
+histopathological	O
+changes	O
+were	O
+more	O
+severe	O
+in	O
+the	O
+absence	O
+of	O
+type	B-PRGE
+-	I-PRGE
+I	I-PRGE
+IFN	I-PRGE
+signaling	B-PROC
+whereas	O
+the	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+was	O
+required	O
+for	O
+virus	B-SPEC
+clearance	O
+.	O
+
+Using	O
+these	O
+mice	B-SPEC
+,	O
+we	O
+demonstrated	O
+the	O
+efficacy	O
+of	O
+a	O
+therapeutic	O
+intervention	O
+(	O
+poly	O
+I	O
+:	O
+C	O
+)	O
+and	O
+a	O
+potential	O
+vaccine	O
+[	O
+Venezuelan	B-DISO
+equine	I-DISO
+encephalitis	I-DISO
+replicon	O
+particles	O
+expressing	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+].	O
+
+We	O
+also	O
+found	O
+little	O
+protective	O
+cross	O
+-	O
+reactivity	O
+between	O
+MERS	O
+-	O
+CoV	O
+and	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+CoV	O
+.	O
+Our	O
+results	O
+demonstrate	O
+that	O
+this	O
+system	O
+will	O
+be	O
+useful	O
+for	O
+MERS	O
+-	O
+CoV	O
+studies	O
+and	O
+for	O
+the	O
+rapid	O
+development	B-PROC
+of	O
+relevant	O
+animal	B-SPEC
+models	O
+for	O
+emerging	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+By	O
+comparing	O
+what	O
+is	O
+known	O
+about	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+to	O
+what	O
+has	O
+recently	O
+been	O
+found	O
+for	O
+MERS	O
+-	O
+CoV	O
+,	O
+researchers	O
+are	O
+discovering	O
+similarities	O
+and	O
+differences	O
+that	O
+may	O
+be	O
+important	O
+for	O
+pathogenesis	B-DISO
+.	O
+
+Such	O
+drugs	O
+could	O
+also	O
+be	O
+effective	O
+for	O
+many	O
+other	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+the	O
+recently	O
+emerged	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+,	O
+because	O
+they	O
+are	O
+also	O
+activated	O
+by	O
+TMPRSS2	O
+in	O
+vitro	O
+.	O
+
+From	O
+Sep	O
+2009	O
+to	O
+Dec	B-CHED
+2010	O
+,	O
+a	O
+total	O
+of	O
+1032	O
+patients	O
+with	O
+serological	O
+evidence	O
+of	O
+dengue	B-DISO
+infection	B-DISO
+were	O
+admitted	O
+to	O
+our	O
+hospital	O
+.	O
+
+Dengue	B-DISO
+is	O
+associated	O
+with	O
+severe	O
+disease	O
+,	O
+and	O
+deaths	B-PROC
+do	O
+occur	O
+despite	O
+current	O
+supportive	O
+management	O
+.	O
+
+TITLE	O
+:	O
+Neuroleptic	B-CHED
+malignant	I-DISO
+-	O
+like	O
+syndrome	B-DISO
+with	O
+a	O
+slight	O
+elevation	O
+of	O
+creatine	B-PRGE
+-	I-PRGE
+kinase	I-PRGE
+levels	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+a	O
+patient	O
+with	O
+Parkinson	B-PATH
+'	I-PATH
+s	I-PATH
+disease	I-PATH
+.	O
+
+Likewise	O
+,	O
+the	O
+need	O
+for	O
+supportive	O
+care	O
+is	O
+essential	O
+,	O
+because	O
+its	O
+complications	O
+are	O
+severe	O
+,	O
+even	O
+such	O
+as	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Pathology	B-DISO
+was	O
+not	O
+fully	O
+elucidated	O
+.	O
+
+TITLE	O
+:	O
+A	O
+lysine	B-CHED
+-	O
+methionine	B-CHED
+exchange	O
+in	O
+a	O
+coronavirus	B-SPEC
+surface	O
+protein	B-CHED
+transforms	O
+a	O
+retention	B-PROC
+motif	O
+into	O
+an	O
+endocytosis	O
+signal	O
+.	O
+
+In	O
+accordance	O
+,	O
+biopsy	O
+of	O
+FH	O
+patients	O
+shows	O
+a	O
+dramatic	O
+increase	O
+of	O
+Fgl2	B-PRGE
+expression	B-PROC
+,	O
+which	O
+correlates	O
+with	O
+C5aR	B-PRGE
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+in	O
+the	O
+liver	B-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+These	O
+data	O
+provide	O
+evidence	O
+that	O
+mouse	B-SPEC
+susceptibility	O
+to	O
+MHV	B-SPEC
+-	O
+3	O
+-	O
+induced	O
+FH	O
+may	O
+rely	O
+on	O
+C5a	B-PRGE
+/	O
+C5aR	B-PRGE
+interactions	O
+,	O
+for	O
+which	O
+ERK1	B-PRGE
+/	I-PRGE
+2	I-PRGE
+and	O
+p38	B-FUNC
+pathways	B-PROC
+participate	O
+in	O
+up	O
+-	O
+regulating	O
+Fgl2	B-PRGE
+expression	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Rett	B-DISO
+syndrome	I-DISO
+(	O
+RS	O
+)	O
+causes	O
+severe	O
+cognitive	B-DISO
+impairment	I-DISO
+,	O
+loss	O
+of	O
+speech	B-PROC
+,	O
+epilepsy	B-DISO
+,	O
+and	O
+breathing	B-PROC
+disturbances	O
+with	O
+intermittent	O
+hypoxia	B-DISO
+.	O
+
+Furthermore	O
+,	O
+Trolox	O
+specifically	O
+attenuated	O
+the	O
+increased	O
+hypoxia	B-DISO
+susceptibility	O
+of	O
+Mecp2	B-PRGE
+(-)	O
+(/	O
+y	O
+)	O
+slices	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+treatment	O
+of	O
+influenza	B-DISO
+and	O
+acute	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+Baculovirus	B-SPEC
+is	O
+an	O
+efficient	O
+system	O
+for	O
+the	O
+gene	B-PROC
+expression	I-PROC
+that	O
+can	O
+be	O
+used	O
+for	O
+gene	O
+transfer	O
+to	O
+both	O
+insect	B-SPEC
+and	O
+different	O
+vertebrate	B-SPEC
+hosts	B-COMP
+.	O
+
+The	O
+nucleocapsid	B-COMP
+gene	O
+(	O
+N	O
+)	O
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+was	O
+cloned	O
+in	O
+a	O
+baculovirus	B-SPEC
+expression	B-PROC
+system	O
+for	O
+insect	B-SPEC
+cell	B-COMP
+expression	B-PROC
+.	O
+
+AM	O
+depletion	O
+resulted	O
+in	O
+a	O
+decreased	O
+number	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+CD4	B-PRGE
+T	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+lung	B-ANAT
+airways	O
+.	O
+
+In	O
+addition	O
+,	O
+a	O
+significant	O
+increase	O
+in	O
+the	O
+frequency	O
+and	O
+total	O
+number	O
+of	O
+Tregs	O
+in	O
+the	O
+lung	O
+tissue	O
+and	O
+lung	B-ANAT
+airways	O
+was	O
+observed	O
+following	O
+MHV	B-SPEC
+-	O
+1	O
+infection	B-DISO
+in	O
+mice	B-SPEC
+depleted	O
+of	O
+AM	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+distinct	O
+immune	B-PROC
+responses	I-PROC
+in	O
+the	O
+lung	B-ANAT
+and	O
+gut	B-ANAT
+during	O
+the	O
+primary	O
+and	O
+chronic	O
+stages	O
+of	O
+viral	B-DISO
+infection	I-DISO
+contribute	O
+to	O
+these	O
+differences	O
+.	O
+
+Bioinformatics	O
+analysis	O
+showed	O
+that	O
+IBV	B-SPEC
+,	O
+NDV	B-SPEC
+,	O
+and	O
+AIV	O
+H9	O
+induced	O
+similar	O
+core	O
+host	B-COMP
+responses	O
+involved	O
+in	O
+biosynthetic	B-PROC
+,	O
+catabolic	B-PROC
+,	O
+metabolic	B-PROC
+,	O
+signal	B-PROC
+transduction	I-PROC
+,	O
+transport	B-PROC
+,	O
+cytoskeleton	B-PROC
+organization	I-PROC
+,	O
+macromolecular	B-PROC
+complex	I-PROC
+assembly	I-PROC
+,	O
+cell	B-PROC
+death	I-PROC
+,	O
+response	B-PROC
+to	I-PROC
+stress	I-PROC
+,	O
+and	O
+immune	B-PROC
+system	I-PROC
+process	I-PROC
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+antigen	B-CHED
+on	O
+eggshell	B-PROC
+formation	I-PROC
+and	O
+immunoreaction	B-PROC
+in	O
+hen	O
+oviduct	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Organophosphate	O
+poisoning	O
+presenting	O
+with	O
+muscular	B-DISO
+weakness	I-DISO
+and	O
+abdominal	B-DISO
+pain	I-DISO
+--	O
+a	O
+case	O
+report	O
+.	O
+
+It	O
+leads	O
+to	O
+three	O
+main	O
+syndromes	B-DISO
+notably	O
+acute	O
+cholinergic	O
+syndrome	B-DISO
+,	O
+intermediate	B-DISO
+syndrome	I-DISO
+,	O
+and	O
+delayed	O
+polyneuropathy	B-DISO
+.	O
+
+It	O
+rarely	O
+causes	O
+cardiac	B-DISO
+arrhythmia	I-DISO
+,	O
+pancreatitis	B-DISO
+and	O
+hepatic	B-DISO
+dysfunction	I-DISO
+.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+a	O
+middle	O
+-	O
+aged	O
+Asian	O
+woman	O
+suffering	B-DISO
+from	O
+organophosphate	O
+poisoning	O
+with	O
+dual	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+Intersectin	B-PRGE
+-	I-PRGE
+1s	I-PRGE
+:	O
+an	O
+important	O
+regulator	O
+of	O
+cellular	B-COMP
+and	O
+molecular	O
+pathways	B-PROC
+in	O
+lung	B-ANAT
+injury	O
+.	O
+
+However	O
+,	O
+robust	O
+cluster	O
+-	O
+based	O
+estimates	O
+for	O
+low	O
+R0	O
+values	O
+are	O
+still	O
+desirable	O
+so	O
+as	O
+to	O
+help	O
+prioritise	O
+scarce	O
+resources	O
+between	O
+different	O
+emerging	O
+infections	B-DISO
+and	O
+to	O
+detect	O
+significant	O
+changes	O
+between	O
+clusters	B-CHED
+and	O
+over	O
+time	O
+.	O
+
+Once	O
+there	O
+,	O
+infection	B-DISO
+of	O
+CNS	B-CHED
+cells	B-COMP
+(	O
+neurotropism	B-DISO
+)	O
+could	O
+lead	O
+to	O
+human	B-SPEC
+health	O
+problems	O
+,	O
+such	O
+as	O
+encephalitis	B-DISO
+and	O
+long	O
+-	O
+term	O
+neurological	O
+diseases	O
+.	O
+
+We	O
+aimed	O
+to	O
+determine	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+nasal	B-ANAT
+carriage	O
+rate	O
+among	O
+pilgrims	O
+performing	O
+the	O
+2013	O
+Hajj	O
+and	O
+to	O
+describe	O
+the	O
+compliance	O
+with	O
+the	O
+Saudi	O
+Ministry	O
+of	O
+Health	O
+vaccine	O
+recommendations	O
+.	O
+
+CONCLUSIONS	O
+:	O
+There	O
+was	O
+no	O
+evidence	O
+of	O
+MERS	O
+-	O
+CoV	O
+nasal	B-ANAT
+carriage	O
+among	O
+Hajj	O
+pilgrims	O
+.	O
+
+Furthermore	O
+,	O
+age	O
+-	O
+dependent	O
+iron	O
+accumulation	O
+and	O
+lesion	O
+-	O
+associated	O
+iron	O
+liberation	O
+,	O
+as	O
+occurring	O
+in	O
+the	O
+human	B-SPEC
+brain	B-ANAT
+,	O
+were	O
+only	O
+minor	O
+in	O
+rodent	B-SPEC
+brains	B-ANAT
+.	O
+
+The	O
+amplification	B-DISO
+of	O
+oxidative	O
+injury	O
+,	O
+which	O
+has	O
+been	O
+suggested	O
+in	O
+MS	O
+,	O
+is	O
+only	O
+reflected	O
+to	O
+a	O
+limited	O
+degree	O
+in	O
+the	O
+studied	O
+rodent	B-SPEC
+models	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+uncovered	O
+a	O
+novel	O
+mechanism	O
+that	O
+may	O
+explain	O
+how	O
+SARS	B-DISO
+PLpro	O
+efficiently	O
+inhibits	O
+activation	O
+of	O
+the	O
+IRF3	B-PRGE
+pathway	B-PROC
+.	O
+
+Furthermore	O
+,	O
+SARS	B-DISO
+PLpro	O
+-	O
+TM	O
+reduces	O
+the	O
+levels	O
+of	O
+ubiquitinated	O
+forms	O
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+,	O
+STING	B-PRGE
+,	O
+TRAF3	B-PRGE
+,	O
+TBK1	B-FUNC
+,	O
+and	O
+IRF3	B-PRGE
+in	O
+the	O
+STING	B-PRGE
+-	O
+TRAF3	B-PRGE
+-	O
+TBK1	B-FUNC
+complex	O
+.	O
+
+These	O
+results	O
+collectively	O
+point	O
+to	O
+a	O
+new	O
+mechanism	O
+used	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+through	O
+which	O
+PLpro	O
+negatively	O
+regulates	O
+IRF3	B-PRGE
+activation	O
+by	O
+interaction	O
+with	O
+STING	B-PRGE
+-	O
+TRAF3	B-PRGE
+-	O
+TBK1	B-FUNC
+complex	O
+,	O
+yielding	O
+a	O
+SARS	B-DISO
+-	O
+CoV	O
+countermeasure	O
+against	O
+host	B-COMP
+innate	B-PROC
+immunity	I-PROC
+.	O
+
+Previous	O
+studies	O
+of	O
+coronavirus	B-SPEC
+replication	O
+complex	O
+organization	O
+and	O
+protein	B-CHED
+interactions	O
+have	O
+utilized	O
+protein	B-PROC
+overexpression	I-PROC
+studies	O
+and	O
+immunofluorescence	O
+of	O
+fixed	B-ANAT
+cells	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+tested	O
+whether	O
+reporter	O
+molecules	O
+could	O
+be	O
+expressed	B-PROC
+from	O
+the	O
+replicase	O
+polyprotein	O
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+as	O
+fusions	O
+with	O
+nonstructural	O
+protein	B-CHED
+2	O
+or	O
+3	O
+and	O
+whether	O
+such	O
+reporters	O
+could	O
+define	O
+the	O
+targeting	B-PROC
+and	O
+activity	O
+of	O
+replicase	B-PRGE
+proteins	I-PRGE
+during	O
+infection	B-DISO
+.	O
+
+Coronaviruses	O
+are	O
+a	O
+family	B-SPEC
+of	O
+enveloped	O
+,	O
+positive	O
+-	O
+sense	B-PROC
+RNA	O
+viruses	B-SPEC
+that	O
+are	O
+important	O
+agents	O
+of	O
+disease	O
+,	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+tested	O
+whether	O
+reporter	O
+molecules	O
+expressed	B-PROC
+from	O
+native	O
+locations	O
+within	O
+the	O
+replicase	B-PRGE
+polyprotein	O
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+as	O
+fusions	O
+with	O
+nonstructural	O
+proteins	B-CHED
+could	O
+define	O
+the	O
+expression	B-PROC
+and	O
+targeting	B-PROC
+of	O
+replicase	B-PRGE
+proteins	I-PRGE
+during	O
+infection	B-DISO
+in	O
+live	O
+cells	B-COMP
+.	O
+
+Although	O
+a	O
+small	O
+number	O
+of	O
+camels	B-SPEC
+have	O
+been	O
+found	O
+to	O
+have	O
+positive	O
+nasal	B-ANAT
+swabs	O
+by	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+to	O
+carry	O
+antibody	B-COMP
+against	O
+MERS	O
+-	O
+CoV	O
+,	O
+the	O
+transmission	O
+route	O
+and	O
+the	O
+intermediary	O
+animal	B-SPEC
+source	O
+remain	O
+uncertain	O
+amongst	O
+the	O
+sporadic	O
+primary	O
+cases	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+has	O
+emerged	O
+as	O
+an	O
+important	O
+physical	O
+trigger	O
+factor	O
+in	O
+takotsubo	B-DISO
+cardiomyopathy	I-DISO
+.	O
+
+Immature	O
+immune	B-ANAT
+system	I-ANAT
+and	O
+lack	O
+of	O
+fully	O
+established	O
+microbiota	B-SPEC
+at	O
+birth	B-PROC
+predispose	O
+neonatal	O
+piglets	O
+to	O
+infection	B-DISO
+with	O
+enteric	O
+pathogens	O
+.	O
+
+The	O
+microorganisms	O
+that	O
+for	O
+decades	O
+have	O
+been	O
+associated	O
+with	O
+enteritis	B-DISO
+and	O
+diarrhea	B-DISO
+in	O
+suckling	O
+piglets	O
+are	O
+:	O
+rotavirus	B-SPEC
+A	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+enterotoxigenic	O
+Escherichia	B-SPEC
+coli	I-SPEC
+(	O
+ETEC	O
+),	O
+Clostridium	B-SPEC
+perfringens	I-SPEC
+type	O
+C	O
+,	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.,	O
+Giardia	B-DISO
+spp	B-ENZY
+.,	O
+Cystoisospora	B-SPEC
+suis	I-SPEC
+and	O
+Strongyloides	B-SPEC
+ransomi	I-SPEC
+.	O
+
+Potentially	O
+pathogenic	O
+bacteria	B-SPEC
+have	O
+recently	O
+received	O
+focus	O
+in	O
+the	O
+research	O
+on	O
+the	O
+possible	O
+etiology	O
+of	O
+neonatal	O
+diarrhea	O
+not	O
+caused	O
+by	O
+common	O
+pathogens	O
+.	O
+
+Furthermore	O
+,	O
+an	O
+association	O
+between	O
+the	O
+presence	O
+of	O
+these	O
+bacteria	B-SPEC
+and	O
+histological	O
+lesions	O
+was	O
+evaluated	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Extrarespiratory	O
+manifestations	O
+of	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+:	O
+a	O
+case	O
+report	O
+].	O
+
+TITLE	O
+:	O
+Viral	O
+lung	B-ANAT
+infections	B-DISO
+:	O
+epidemiology	O
+,	O
+virology	O
+,	O
+clinical	O
+features	O
+,	O
+and	O
+management	O
+of	O
+avian	B-SPEC
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+has	O
+jumped	O
+species	B-SPEC
+barrier	O
+and	O
+caused	O
+severe	O
+human	B-SPEC
+infections	B-DISO
+.	O
+
+Most	O
+patients	O
+acquired	O
+the	O
+infection	B-DISO
+from	O
+direct	O
+contact	O
+with	O
+poultry	O
+or	O
+from	O
+a	O
+contaminated	O
+environment	O
+,	O
+although	O
+person	O
+-	O
+to	O
+-	O
+person	O
+transmission	O
+has	O
+likely	O
+occurred	O
+.	O
+
+Serum	B-COMP
+proinflammatory	O
+cytokines	O
+were	O
+similar	O
+in	O
+both	O
+age	O
+groups	O
+,	O
+whereas	O
+significantly	O
+lower	O
+levels	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+were	O
+detected	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+aged	O
+monkeys	B-SPEC
+at	O
+either	O
+5	O
+or	O
+10	O
+days	O
+post	O
+infection	B-DISO
+.	O
+
+Dendritic	B-ANAT
+cells	B-COMP
+and	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+showed	O
+age	O
+-	O
+dependent	O
+differences	O
+in	O
+activation	O
+and	O
+chemokine	O
+receptor	O
+profiles	O
+,	O
+while	O
+the	O
+CD8	B-PRGE
+T	I-PRGE
+cell	O
+and	O
+B	B-ANAT
+cell	I-ANAT
+responses	O
+were	O
+significantly	O
+reduced	O
+in	O
+the	O
+aged	O
+host	B-COMP
+.	O
+
+In	O
+examination	O
+of	O
+viral	O
+titers	O
+,	O
+significantly	O
+higher	O
+levels	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+detected	O
+in	O
+the	O
+nasal	B-ANAT
+swabs	O
+early	O
+,	O
+at	O
+day	O
+1	O
+post	O
+infection	B-DISO
+,	O
+in	O
+aged	O
+as	O
+compared	O
+to	O
+juvenile	O
+monkeys	B-SPEC
+,	O
+but	O
+virus	B-SPEC
+levels	O
+were	O
+only	O
+slightly	O
+higher	O
+in	O
+aged	O
+animals	B-SPEC
+by	O
+day	O
+3	O
+.	O
+
+Mice	B-SPEC
+deficient	O
+in	O
+the	O
+ISG15	B-PRGE
+deconjugating	I-PRGE
+enzyme	I-PRGE
+,	O
+ubiquitin	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+peptidase	I-PRGE
+-	I-PRGE
+18	I-PRGE
+(	O
+USP18	B-PRGE
+),	O
+accumulate	O
+high	O
+levels	O
+of	O
+ISG15	B-PRGE
+-	I-PRGE
+conjugated	I-PRGE
+proteins	I-PRGE
+and	O
+are	O
+hypersensitive	O
+to	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+demonstrate	O
+that	O
+an	O
+important	O
+host	B-COMP
+viral	O
+defense	O
+-	O
+the	O
+ISG15	B-PRGE
+pathway	B-PROC
+-	O
+is	O
+only	O
+partially	O
+effective	O
+in	O
+controlling	O
+severe	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+MMP	B-PRGE
+-	I-PRGE
+8	I-PRGE
+and	O
+TIMP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+levels	O
+were	O
+analyzed	O
+from	O
+blood	B-ANAT
+samples	I-ANAT
+taken	O
+on	O
+enrollment	O
+in	O
+the	O
+study	O
+and	O
+48	O
+hours	O
+later	O
+.	O
+
+MMP	B-PRGE
+-	I-PRGE
+8	I-PRGE
+and	O
+TIMP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+levels	O
+were	O
+compared	O
+between	O
+90	O
+-	O
+day	O
+survivors	O
+and	O
+nonsurvivors	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+and	O
+molecular	O
+characterization	O
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+in	O
+influenza	B-PATH
+a	I-PATH
+negative	O
+sample	O
+in	O
+Thailand	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+metapneumovirus	O
+(	O
+hMPV	B-SPEC
+)	O
+causes	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+.	O
+
+The	O
+role	O
+of	O
+hMPV	B-SPEC
+infections	B-DISO
+in	O
+all	O
+age	O
+groups	O
+in	O
+Thailand	O
+has	O
+not	O
+yet	O
+been	O
+investigated	O
+.	O
+
+Thus	O
+,	O
+the	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+prevalence	O
+of	O
+hMPV	B-SPEC
+infection	B-DISO
+in	O
+all	O
+age	O
+groups	O
+in	O
+Thailand	O
+during	O
+2011	O
+.	O
+
+Partially	O
+,	O
+F	B-PRGE
+gene	I-PRGE
+from	O
+hMPV	B-SPEC
+positive	O
+samples	O
+were	O
+sequenced	O
+and	O
+used	O
+for	O
+genotyping	O
+by	O
+phylogenetic	O
+tree	O
+analysis	O
+.	O
+
+The	O
+prevalence	O
+of	O
+hMPV	B-SPEC
+for	O
+all	O
+age	O
+groups	O
+was	O
+6	O
+.	O
+3	O
+%.	O
+
+We	O
+used	O
+serologic	O
+assays	O
+to	O
+analyze	O
+651	O
+dromedary	B-SPEC
+camel	B-SPEC
+serum	B-COMP
+samples	O
+from	O
+the	O
+United	O
+Arab	O
+Emirates	O
+;	O
+151	O
+of	O
+651	O
+samples	O
+were	O
+obtained	O
+in	O
+2003	O
+,	O
+well	O
+before	O
+onset	O
+of	O
+the	O
+current	O
+epidemic	O
+,	O
+and	O
+500	O
+serum	B-COMP
+samples	O
+were	O
+obtained	O
+in	O
+2013	O
+.	O
+
+Along	O
+with	O
+this	O
+coronavirus	B-SPEC
+,	O
+viruses	B-SPEC
+of	O
+at	O
+least	O
+8	O
+other	O
+families	O
+have	O
+been	O
+found	O
+to	O
+infect	O
+camels	B-SPEC
+.	O
+
+Infection	B-DISO
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+suspected	O
+on	O
+March	O
+21	O
+and	O
+confirmed	O
+on	O
+March	O
+23	O
+;	O
+the	O
+patient	O
+,	O
+who	O
+had	O
+contact	O
+with	O
+an	O
+ill	B-DISO
+camel	B-SPEC
+shortly	O
+before	O
+symptom	B-DISO
+onset	O
+,	O
+died	B-PROC
+on	O
+March	O
+26	O
+.	O
+
+Among	O
+contacts	O
+,	O
+the	O
+use	O
+of	O
+FFP2	O
+/	O
+FFP3	O
+face	B-DISO
+masks	O
+during	O
+aerosol	O
+exposure	O
+was	O
+more	O
+frequent	O
+after	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+was	O
+suspected	O
+than	O
+before	O
+.	O
+
+For	O
+SwIV	O
+,	O
+due	O
+to	O
+low	O
+virus	B-SPEC
+titre	O
+on	O
+the	O
+control	O
+discs	O
+,	O
+>	O
+3	O
+.	O
+8	O
+-	O
+log	O
+reduction	O
+was	O
+shown	O
+for	O
+the	O
+25	O
+-	O
+mL	O
+vaporized	O
+volume	O
+and	O
+>	O
+4	O
+-	O
+log	O
+reduction	O
+was	O
+shown	O
+for	O
+the	O
+27	O
+-	O
+mL	O
+and	O
+33	O
+-	O
+mL	O
+vaporized	O
+volumes	O
+.	O
+
+When	O
+allocated	O
+to	O
+serology	O
+-	O
+matched	O
+recipients	O
+,	O
+kidney	B-ANAT
+transplantation	O
+from	O
+donors	O
+with	O
+hepatitis	B-PATH
+C	I-PATH
+may	O
+result	O
+in	O
+an	O
+excellent	O
+short	O
+-	O
+term	O
+outcome	O
+and	O
+a	O
+significant	O
+reduction	O
+of	O
+time	O
+on	O
+the	O
+waiting	O
+list	O
+.	O
+
+These	O
+data	O
+also	O
+suggest	O
+that	O
+viral	O
+binding	B-FUNC
+and	O
+/	O
+or	O
+entry	O
+may	O
+be	O
+required	O
+for	O
+this	O
+effect	O
+.	O
+
+Under	O
+electron	O
+microscopy	O
+,	O
+BYD1	O
+-	O
+infected	O
+cells	B-COMP
+showed	O
+characteristics	O
+typical	O
+of	O
+apoptosis	B-PATH
+.	O
+
+Survival	O
+at	O
+day	O
+28	O
+and	O
+hemodynamic	B-PROC
+and	O
+respiratory	O
+parameters	O
+were	O
+analyzed	O
+and	O
+compared	O
+according	O
+to	O
+outcome	O
+and	O
+respiratory	O
+status	O
+.	O
+
+IMPORTANCE	O
+The	O
+2012	O
+outbreak	O
+of	O
+MERS	O
+-	O
+CoV	O
+raises	O
+the	O
+specter	O
+of	O
+another	O
+global	O
+epidemic	O
+,	O
+similar	O
+to	O
+the	O
+2003	O
+SARS	B-DISO
+-	O
+CoV	O
+epidemic	O
+.	O
+
+This	O
+study	O
+holds	O
+significance	O
+as	O
+a	O
+strategy	O
+to	O
+control	O
+newly	O
+emerging	O
+viruses	B-SPEC
+.	O
+
+We	O
+examined	O
+the	O
+entire	O
+agenda	O
+of	O
+published	O
+randomized	O
+controlled	O
+trials	O
+(	O
+RCTs	O
+)	O
+in	O
+ARDS	B-DISO
+that	O
+reported	O
+on	O
+mortality	O
+and	O
+of	O
+respective	O
+meta	B-SPEC
+-	O
+analyses	O
+.	O
+
+Among	O
+RCTs	O
+with	O
+more	O
+than	O
+50	O
+deaths	B-PROC
+in	O
+at	O
+least	O
+one	O
+treatment	O
+arm	B-ANAT
+(	O
+n	O
+=	O
+21	O
+),	O
+two	O
+showed	O
+a	O
+statistically	O
+significant	O
+mortality	O
+benefit	O
+of	O
+the	O
+intervention	O
+(	O
+lower	O
+tidal	O
+volumes	O
+and	O
+prone	O
+positioning	O
+),	O
+one	O
+showed	O
+a	O
+statistically	O
+significant	O
+mortality	O
+benefit	O
+only	O
+in	O
+adjusted	O
+analyses	O
+(	O
+cisatracurium	O
+),	O
+and	O
+one	O
+(	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+)	O
+showed	O
+a	O
+significant	O
+detrimental	O
+effect	O
+.	O
+
+Across	O
+29	O
+meta	B-SPEC
+-	O
+analyses	O
+,	O
+the	O
+most	O
+consistent	O
+evidence	O
+was	O
+seen	O
+for	O
+low	O
+tidal	O
+volumes	O
+and	O
+prone	O
+positioning	O
+in	O
+severe	O
+ARDS	B-DISO
+.	O
+
+A	O
+statistically	O
+significant	O
+survival	O
+benefit	O
+was	O
+observed	O
+in	O
+eight	O
+trials	O
+(	O
+seven	O
+interventions	O
+)	O
+and	O
+two	O
+trials	O
+reported	O
+an	O
+adverse	B-DISO
+effect	I-DISO
+on	O
+survival	O
+.	O
+
+Across	O
+29	O
+meta	B-SPEC
+-	O
+analyses	O
+,	O
+the	O
+most	O
+consistent	O
+evidence	O
+was	O
+seen	O
+for	O
+low	O
+tidal	O
+volumes	O
+and	O
+prone	O
+positioning	O
+in	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Herein	O
+,	O
+we	O
+show	O
+that	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+has	O
+only	O
+one	O
+TM	O
+domain	O
+in	O
+micelles	O
+,	O
+whereas	O
+the	O
+predicted	O
+β	O
+-	O
+coil	O
+-	O
+β	O
+motif	O
+forms	O
+a	O
+short	O
+membrane	B-COMP
+-	O
+bound	O
+α	O
+-	O
+helix	O
+connected	O
+by	O
+a	O
+disordered	O
+loop	O
+to	O
+the	O
+TM	O
+domain	O
+.	O
+
+A	O
+diagnosis	O
+of	O
+acute	O
+pulmonary	B-DISO
+thromboembolism	I-DISO
+was	O
+suggested	O
+by	O
+initial	O
+evaluation	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+endotoxin	O
+was	O
+infused	O
+intravenously	O
+into	O
+14	O
+sheep	B-SPEC
+from	O
+which	O
+6	O
+received	O
+different	O
+doses	O
+of	O
+adult	O
+stem	B-ANAT
+cells	I-ANAT
+by	O
+intrabronchial	O
+delivery	O
+to	O
+evaluate	O
+the	O
+effect	O
+of	O
+stem	B-ANAT
+cell	I-ANAT
+therapy	O
+.	O
+
+Other	O
+risk	O
+factors	O
+including	O
+flock	O
+size	O
+,	O
+flock	O
+type	O
+,	O
+flock	O
+age	O
+,	O
+chicken	B-SPEC
+breed	B-PROC
+and	O
+vaccination	O
+frequency	O
+were	O
+also	O
+assessed	O
+.	O
+
+Detection	O
+of	O
+IBV	B-SPEC
+in	O
+a	O
+flock	O
+,	O
+the	O
+farm	O
+type	O
+and	O
+flock	O
+size	O
+were	O
+identified	O
+as	O
+potential	O
+risk	O
+factors	O
+for	O
+the	O
+production	O
+of	O
+eggs	O
+with	O
+poor	O
+Haugh	O
+units	O
+.	O
+
+CONCLUSIONS	O
+:	O
+IBV	B-SPEC
+is	O
+prevalent	O
+in	O
+Australian	O
+layer	B-ANAT
+flocks	O
+,	O
+but	O
+infection	B-DISO
+was	O
+primarily	O
+subclinical	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+dose	O
+dietary	O
+zinc	B-CHED
+oxide	I-CHED
+mitigates	O
+infection	B-DISO
+with	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+in	O
+piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+Zinc	O
+(	O
+Zn	O
+)	O
+supplementation	O
+has	O
+been	O
+shown	O
+to	O
+reduce	O
+the	O
+incidence	O
+of	O
+diarrhea	B-DISO
+and	O
+to	O
+protect	O
+animals	B-SPEC
+from	O
+intestinal	B-DISO
+diseases	I-DISO
+,	O
+but	O
+the	O
+mechanisms	O
+of	O
+this	O
+protective	O
+effect	O
+against	O
+virus	B-DISO
+infection	I-DISO
+in	O
+vivo	O
+have	O
+not	O
+yet	O
+been	O
+elucidated	O
+.	O
+
+The	O
+other	O
+groups	O
+received	O
+the	O
+diet	O
+supplemented	O
+with	O
+ZnO	B-CHED
+at	O
+final	O
+concentrations	O
+of	O
+150	O
+mg	O
+Zn	O
+/	O
+kg	O
+diet	O
+(	O
+Znmed	O
+),	O
+or	O
+2	O
+,	O
+500	O
+mg	O
+/	O
+kg	O
+diet	O
+(	O
+Znhigh	O
+).	O
+
+This	O
+study	O
+was	O
+aimed	O
+to	O
+compare	O
+the	O
+strength	O
+of	O
+associations	O
+between	O
+different	O
+cognitive	O
+and	O
+affective	O
+measures	O
+of	O
+risk	O
+and	O
+self	O
+-	O
+reported	O
+protective	O
+behaviors	B-PROC
+in	O
+a	O
+series	O
+of	O
+ten	O
+cross	O
+-	O
+sectional	O
+surveys	O
+conducted	O
+throughout	O
+the	O
+first	O
+wave	O
+of	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+pandemic	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+year	O
+2013	O
+marks	O
+the	O
+10th	O
+anniversary	O
+of	O
+the	O
+outbreak	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Pathogenicity	O
+and	O
+molecular	O
+characteristics	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strains	O
+isolated	O
+from	O
+broilers	O
+showing	O
+diarrhoea	O
+and	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+IBV	B-SPEC
+variants	O
+were	O
+isolated	O
+from	O
+broiler	O
+flocks	O
+with	O
+enteric	O
+and	O
+respiratory	B-DISO
+problems	I-DISO
+in	O
+two	O
+regions	O
+of	O
+Brazil	O
+.	O
+
+The	O
+USP	B-FUNC
+-	O
+10	O
+isolate	O
+,	O
+of	O
+enteric	O
+origin	O
+,	O
+was	O
+inoculated	O
+via	O
+the	O
+oral	B-ANAT
+oroculonasal	O
+routes	O
+into	O
+IBV	B-SPEC
+-	O
+antibody	B-COMP
+-	O
+free	O
+broilers	O
+and	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+chickens	B-SPEC
+to	O
+determine	O
+tissue	B-PROC
+tropism	B-PROC
+and	O
+pathogenicity	O
+and	O
+compared	O
+with	O
+an	O
+IBV	B-SPEC
+variant	O
+(	O
+USP	B-FUNC
+-	O
+50	O
+)	O
+isolated	O
+from	O
+chickens	B-SPEC
+showing	O
+signs	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+only	O
+.	O
+
+Interestingly	O
+,	O
+we	O
+also	O
+found	O
+that	O
+2	O
+-	O
+DG	O
+treatment	O
+could	O
+affect	O
+virus	B-PROC
+assembly	I-PROC
+,	O
+which	O
+is	O
+similar	O
+to	O
+previous	O
+studies	O
+on	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+Adenovirus	B-DISO
+,	O
+bocavirus	B-SPEC
+-	O
+1	O
+,	O
+coronavirus	B-SPEC
+,	O
+enteroviruses	B-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+metapneumovirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+were	O
+detected	O
+using	O
+PCR	O
+.	O
+
+IL	O
+-	O
+37	O
+expression	B-PROC
+was	O
+positively	O
+associated	O
+with	O
+atopic	B-DISO
+dermatitis	I-DISO
+,	O
+whereas	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+13	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+28	I-FUNC
+,	O
+and	O
+Tbet	B-PRGE
+expressions	O
+were	O
+negatively	O
+associated	O
+with	O
+allergic	O
+diseases	O
+.	O
+
+Tonsillar	B-ANAT
+cytokine	O
+expression	B-PROC
+is	O
+closely	O
+related	O
+to	O
+existing	O
+viral	B-DISO
+infections	I-DISO
+,	O
+age	O
+,	O
+and	O
+allergic	O
+illnesses	O
+and	O
+shows	O
+distinct	O
+clusters	B-CHED
+between	O
+antiviral	B-CHED
+and	O
+immune	O
+regulatory	O
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+leading	O
+cause	O
+of	O
+mortality	O
+in	O
+burn	O
+patients	O
+.	O
+
+Recent	O
+reports	O
+showed	O
+a	O
+high	O
+prevalence	O
+of	O
+one	O
+main	O
+IBV	B-SPEC
+genotype	O
+(	O
+Brazil	O
+or	O
+BR	O
+-	O
+I	O
+)	O
+with	O
+low	O
+genetic	O
+diversity	O
+in	O
+commercial	O
+poultry	O
+flocks	O
+from	O
+Brazil	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+causes	O
+an	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+disease	O
+in	O
+chickens	B-SPEC
+and	O
+is	O
+highly	O
+contagious	O
+.	O
+
+TITLE	O
+:	O
+An	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+in	O
+quail	O
+with	O
+respiratory	O
+and	O
+reproductive	B-PROC
+signs	O
+.	O
+
+Although	O
+Avian	B-SPEC
+metapneumovirus	I-SPEC
+subtype	O
+B	O
+was	O
+found	O
+in	O
+two	O
+layers	B-ANAT
+samples	O
+,	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+was	O
+not	O
+found	O
+in	O
+quail	O
+or	O
+in	O
+hens	O
+.	O
+
+Based	O
+on	O
+DNA	O
+sequences	O
+for	O
+the	O
+3	O
+'-	O
+untranslated	O
+region	O
+and	O
+the	O
+gene	O
+encoding	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+,	O
+this	O
+avian	B-SPEC
+coronaviruses	O
+in	O
+quail	O
+is	O
+an	O
+IB	O
+virus	B-SPEC
+-	O
+like	O
+gammacoronavirus	B-SPEC
+.	O
+
+The	O
+demonstration	O
+of	O
+an	O
+endogeneous	O
+in	O
+vitro	O
+growth	B-PROC
+of	O
+myeloid	O
+progenitors	O
+although	O
+not	O
+very	O
+specific	O
+can	O
+help	O
+JMML	B-DISO
+diagnosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Positive	O
+-	O
+stranded	O
+viruses	B-SPEC
+synthesize	O
+their	O
+RNA	O
+in	O
+membrane	B-COMP
+-	O
+bound	O
+organelles	B-COMP
+,	O
+but	O
+it	O
+is	O
+not	O
+clear	O
+how	O
+this	O
+benefits	O
+the	O
+virus	B-SPEC
+or	O
+the	O
+host	B-COMP
+.	O
+
+For	O
+coronaviruses	O
+,	O
+these	O
+organelles	B-COMP
+take	O
+the	O
+form	O
+of	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+(	O
+DMVs	O
+)	O
+interconnected	O
+by	O
+a	O
+convoluted	O
+membrane	B-COMP
+network	O
+.	O
+
+22	O
+.	O
+2	O
+%	O
+of	O
+the	O
+patients	O
+were	O
+found	O
+to	O
+have	O
+live	O
+poultry	O
+contact	O
+history	O
+and	O
+80	O
+%	O
+were	O
+aged	O
+male	O
+patients	O
+with	O
+multiple	O
+co	O
+-	O
+morbidities	O
+including	O
+diabetes	B-DISO
+,	O
+hypertension	B-DISO
+and	O
+/	O
+or	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+).	O
+
+H7N9	O
+infection	B-DISO
+induced	I-DISO
+pneumonia	B-DISO
+of	O
+different	O
+severity	O
+ranging	O
+from	O
+mild	O
+to	O
+severe	O
+pneumonia	B-DISO
+or	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+to	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+After	O
+multivariate	O
+analysis	O
+,	O
+only	O
+CRP	B-PRGE
+level	O
+showed	O
+significant	O
+prediction	O
+of	O
+mortality	O
+(	O
+P	O
+=	O
+0	O
+.	O
+013	O
+)	O
+while	O
+results	O
+of	O
+prothrombin	B-PRGE
+time	I-PRGE
+(	O
+PT	O
+)	O
+analysis	O
+almost	O
+reached	O
+statistical	O
+significance	O
+(	O
+P	O
+=	O
+0	O
+.	O
+056	O
+).	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+an	O
+established	O
+method	O
+of	O
+treatment	O
+for	O
+extremely	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+ARDS	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+),	O
+for	O
+mechanical	O
+circulatory	B-PROC
+support	O
+after	O
+cardiac	B-ANAT
+surgery	O
+as	O
+well	O
+as	O
+advanced	O
+resuscitation	O
+technique	O
+in	O
+specific	O
+cases	O
+.	O
+
+One	O
+was	O
+for	O
+the	O
+detection	O
+of	O
+5	O
+type	O
+/	O
+subtypes	O
+of	O
+the	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+called	O
+Influenza	B-DISO
+Panel	O
+),	O
+the	O
+other	O
+was	O
+for	O
+the	O
+identification	O
+of	O
+14	O
+major	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+emerging	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+),	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+NL63	O
+,	O
+HKU1	O
+),	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBoV	O
+),	O
+and	O
+WU	B-SPEC
+polyomavirus	I-SPEC
+(	O
+WUPyV	O
+)	O
+(	O
+called	O
+Respiratory	O
+Panel	O
+).	O
+
+As	O
+determined	O
+by	O
+commercial	O
+multi	O
+-	O
+PCR	O
+kit	B-FUNC
+and	O
+conventional	O
+PCR	O
+(	O
+for	O
+HBoV	O
+and	O
+WUPyV	O
+),	O
+the	O
+diagnostic	O
+sensitivity	O
+of	O
+the	O
+Respiratory	O
+Panel	O
+for	O
+each	O
+viral	O
+targets	O
+ranged	O
+from	O
+50	O
+.	O
+0	O
+%	O
+to	O
+100	O
+.	O
+0	O
+%,	O
+the	O
+diagnostic	O
+specificity	O
+was	O
+96	O
+.	O
+2	O
+%-	O
+100	O
+.	O
+0	O
+%,	O
+and	O
+accordance	O
+rate	O
+was	O
+93	O
+.	O
+2	O
+%	O
+-	O
+100	O
+.	O
+0	O
+%,	O
+the	O
+kappa	O
+correlation	O
+of	O
+eight	O
+viral	O
+targets	O
+was	O
+>	O
+0	O
+.	O
+75	O
+.	O
+
+To	O
+test	O
+plans	O
+that	O
+were	O
+developed	O
+for	O
+mass	O
+prophylaxis	O
+scenarios	O
+,	O
+in	O
+April	O
+2013	O
+the	O
+Cook	O
+Country	O
+Department	O
+of	O
+Public	O
+Health	O
+(	O
+CCDPH	O
+)	O
+and	O
+the	O
+Triple	O
+Community	O
+(	O
+TripCom	O
+)	O
+Medical	O
+Reserve	O
+Corps	O
+(	O
+MRC	O
+)	O
+executed	O
+a	O
+full	O
+-	O
+scale	O
+mass	O
+prophylaxis	O
+exercise	O
+in	O
+response	O
+to	O
+a	O
+simulated	O
+anthrax	B-DISO
+bioterrorism	O
+attack	O
+.	O
+
+The	O
+exercise	O
+took	O
+place	O
+over	O
+2	O
+days	O
+and	O
+included	O
+the	O
+TripCom	O
+Point	O
+-	O
+of	O
+-	O
+Dispensing	O
+(	O
+POD	O
+)	O
+Management	O
+Team	O
+,	O
+volunteers	O
+from	O
+the	O
+TripCom	O
+MRC	O
+,	O
+and	O
+neighboring	O
+public	O
+health	O
+departments	O
+and	O
+MRCs	B-DISO
+.	O
+
+His	O
+post	O
+-	O
+operative	O
+recovery	O
+was	O
+complicated	O
+by	O
+myocardial	B-DISO
+infarction	I-DISO
+and	O
+stroke	B-DISO
+but	O
+he	O
+made	O
+a	O
+full	O
+recovery	O
+.	O
+
+This	O
+represents	O
+the	O
+first	O
+report	O
+of	O
+slide	O
+tracheoplasty	O
+and	O
+partial	B-DISO
+atrioventricular	I-DISO
+septal	I-DISO
+defect	I-DISO
+repair	B-PROC
+in	O
+a	O
+child	O
+following	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+.	O
+
+During	O
+a	O
+3	O
+month	O
+period	O
+,	O
+June	O
+to	O
+August	O
+2013	O
+,	O
+there	O
+were	O
+12	O
+positive	O
+MERS	O
+-	O
+CoV	O
+cases	O
+reported	O
+from	O
+the	O
+Hafr	O
+Al	O
+-	O
+Batin	O
+region	O
+district	O
+in	O
+the	O
+north	O
+east	O
+region	O
+of	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+A	O
+ruddy	B-SPEC
+turnstone	I-SPEC
+sample	O
+yielded	O
+sequences	O
+with	O
+homology	O
+to	O
+deltacoronaviruses	O
+.	O
+
+Examples	O
+are	O
+calcitonin	B-CHED
+-	O
+producing	O
+tumors	B-DISO
+,	I-DISO
+medullary	I-DISO
+C	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+thyroid	B-DISO
+carcinoma	I-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+secretions	B-ANAT
+of	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+were	O
+analyzed	O
+in	O
+children	O
+younger	O
+than	O
+21	O
+years	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+.	O
+
+Patients	O
+were	O
+treated	O
+at	O
+the	O
+Grupo	B-CHED
+em	O
+Defesa	O
+da	O
+Criança	O
+Com	B-CHED
+Câncer	O
+(	O
+Grendacc	O
+)	O
+and	O
+University	O
+Hospital	O
+(	O
+HU	O
+),	O
+Jundiaí	O
+,	O
+SP	O
+.	O
+
+Acute	B-DISO
+lymphocytic	I-DISO
+leukemia	I-DISO
+(	O
+42	O
+.	O
+3	O
+%)	O
+was	O
+the	O
+most	O
+prevalent	O
+neoplasia	B-DISO
+.	O
+
+Despite	O
+causing	O
+severe	O
+,	O
+and	O
+often	O
+refractory	O
+,	O
+hypoxaemia	O
+,	O
+the	O
+high	O
+mortality	O
+and	O
+long	O
+-	O
+term	O
+morbidity	O
+of	O
+ARDS	B-DISO
+results	O
+mainly	O
+from	O
+extra	O
+-	O
+pulmonary	B-ANAT
+organ	B-DISO
+failure	I-DISO
+;	O
+however	O
+the	O
+mechanism	O
+for	O
+this	O
+organ	B-ANAT
+crosstalk	B-PROC
+has	O
+not	O
+been	O
+determined	O
+.	O
+
+Flow	O
+cytometry	O
+of	O
+whole	O
+blood	B-ANAT
+samples	I-ANAT
+was	O
+used	O
+to	O
+assess	O
+transpulmonary	O
+neutrophil	B-ANAT
+priming	O
+gradients	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+sepsis	B-DISO
+and	O
+perioperative	O
+controls	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+correlation	O
+with	O
+resistance	O
+to	O
+illness	O
+following	O
+viral	B-DISO
+infection	I-DISO
+may	O
+be	O
+directly	O
+linked	O
+to	O
+a	O
+more	O
+vigorous	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+RT	O
+-	O
+qPCR	O
+results	O
+showed	O
+that	O
+the	O
+circular	O
+TFO	O
+RNAs	O
+,	O
+except	O
+TFO2	O
+,	O
+inhibit	O
+FIPV	O
+replication	O
+,	O
+where	O
+the	O
+viral	B-COMP
+genome	I-COMP
+copy	O
+numbers	O
+decreased	O
+significantly	O
+by	O
+5	O
+-	O
+fold	O
+log10	O
+from	O
+10	O
+(	O
+14	O
+)	O
+in	O
+the	O
+virus	B-SPEC
+-	O
+inoculated	O
+cells	B-COMP
+to	O
+10	O
+(	O
+9	O
+)	O
+in	O
+the	O
+circular	O
+TFO	O
+RNAs	O
+-	O
+transfected	O
+cells	B-COMP
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+circular	O
+TFOs	O
+have	O
+the	O
+potential	O
+to	O
+be	O
+further	O
+developed	O
+as	O
+antiviral	B-CHED
+agents	I-CHED
+against	O
+FIPV	O
+infection	B-DISO
+.	O
+
+Infectious	B-DISO
+respiratory	B-DISO
+tract	I-DISO
+diseases	I-DISO
+cause	O
+most	O
+mortality	O
+among	O
+infectious	B-DISO
+illnesses	O
+around	O
+the	O
+world	O
+.	O
+
+Many	O
+herbs	O
+have	O
+remarkable	O
+antiviral	B-CHED
+effects	O
+,	O
+therefore	O
+they	O
+are	O
+used	O
+as	O
+substitutes	O
+of	O
+antimicrobial	B-CHED
+drugs	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Liver	B-ANAT
+resection	O
+is	O
+increasingly	O
+performed	O
+in	O
+elderly	O
+patients	O
+who	O
+are	O
+suspected	O
+of	O
+increased	O
+postoperative	O
+morbidity	O
+(	O
+PM	O
+)	O
+and	O
+reduced	O
+overall	O
+survival	O
+(	O
+OS	O
+).	O
+
+ABSTRACT	O
+:	O
+Development	B-PROC
+of	O
+anti	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+agents	O
+is	O
+pivotal	O
+to	O
+prevent	O
+the	O
+reemergence	O
+of	O
+the	O
+life	O
+-	O
+threatening	O
+disease	O
+,	O
+SARS	B-DISO
+.	O
+
+Among	O
+these	O
+extracts	O
+,	O
+CBM	O
+and	O
+DBM	B-DISO
+also	O
+showed	O
+significant	O
+inhibition	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	B-PROC
+activity	I-PROC
+with	O
+IC50	O
+values	O
+of	O
+39	O
+μg	O
+/	O
+ml	O
+and	O
+44	O
+μg	O
+/	O
+ml	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+disease	O
+caused	O
+by	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+HPAI	B-FUNC
+)	O
+(	O
+H5N1	B-DISO
+)	O
+is	O
+associated	O
+with	O
+fulminant	O
+viral	B-DISO
+pneumonia	I-DISO
+and	O
+mortality	O
+rates	O
+in	O
+excess	O
+of	O
+60	O
+%.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+diversity	O
+of	O
+viral	O
+flora	O
+,	O
+we	O
+used	O
+metagenomics	O
+to	O
+study	O
+the	O
+viral	O
+communities	O
+in	O
+a	O
+pooled	O
+faecal	B-ANAT
+sample	O
+of	O
+27	O
+diarrhoeic	O
+piglets	O
+from	O
+intensive	O
+commercial	O
+farms	O
+in	O
+China	O
+.	O
+
+By	O
+contrast	O
+,	O
+healthy	O
+piglets	O
+shed	O
+a	O
+mean	O
+of	O
+3	O
+.	O
+2	O
+different	O
+viruses	B-SPEC
+.	O
+
+Specifically	O
+,	O
+when	O
+given	O
+to	O
+a	O
+person	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+a	O
+patient	O
+'	O
+s	O
+family	B-SPEC
+member	O
+or	O
+a	O
+health	O
+care	O
+worker	O
+)	O
+either	O
+before	O
+or	O
+after	O
+exposure	O
+to	O
+MERS	O
+-	O
+CoV	O
+,	O
+the	O
+humanized	O
+antibody	B-COMP
+may	O
+prevent	O
+or	O
+inhibit	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+thereby	O
+stopping	O
+the	O
+spread	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+diverse	O
+alphacoronaviruses	O
+and	O
+genomic	O
+characterization	O
+of	O
+a	O
+novel	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+from	O
+bats	B-SPEC
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Typical	O
+or	O
+atypical	B-DISO
+pneumonia	I-DISO
+and	O
+severe	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+PICU	B-SPEC
+.	O
+
+Confusing	O
+case	O
+definitions	O
+such	O
+as	O
+MERS	O
+(	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+)	O
+and	O
+SARI	O
+(	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+)	O
+were	O
+coined	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+:	O
+a	O
+case	O
+-	O
+control	O
+study	O
+of	O
+hospitalized	O
+patients	O
+.	O
+
+Few	O
+clinical	O
+predictors	O
+could	O
+enhance	O
+the	O
+ability	O
+to	O
+predict	O
+which	O
+patients	O
+with	O
+pneumonia	B-DISO
+would	O
+have	O
+MERS	O
+-	O
+CoV	O
+.	O
+However	O
+,	O
+further	O
+prospective	O
+analysis	O
+and	O
+matched	O
+case	O
+-	O
+control	O
+studies	O
+may	O
+shed	O
+light	O
+on	O
+other	O
+predictors	O
+of	O
+infection	B-DISO
+.	O
+
+Interestingly	O
+,	O
+we	O
+also	O
+found	O
+that	O
+a	O
+low	O
+day	O
+1	O
+albumin	B-PRGE
+level	O
+was	O
+an	O
+independent	O
+biomarker	B-CHED
+for	O
+predicting	O
+patient	O
+life	O
+dependence	B-DISO
+6	O
+months	O
+after	O
+a	O
+pneumonia	B-DISO
+event	O
+.	O
+
+However	O
+,	O
+the	O
+exact	O
+mechanisms	O
+responsible	O
+for	O
+pulmonary	B-DISO
+oedema	I-DISO
+remain	O
+unclear	O
+.	O
+
+With	O
+antimicrobial	B-CHED
+therapy	O
+and	O
+other	O
+supportive	O
+treatment	O
+,	O
+clinical	O
+symptoms	O
+and	O
+oxygenation	B-PROC
+of	O
+the	O
+patient	O
+improved	O
+gradually	O
+.	O
+
+Twenty	O
+-	O
+three	O
+days	O
+after	O
+hospitalization	O
+,	O
+blood	B-ANAT
+stream	O
+infection	B-DISO
+with	O
+multidrug	O
+-	O
+resistant	O
+Acinetobacter	B-SPEC
+Baumannii	I-SPEC
+occurred	O
+,	O
+which	O
+lead	O
+to	O
+septic	B-DISO
+shock	I-DISO
+and	O
+death	B-PROC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+cooperation	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibodies	B-COMP
+and	O
+phagocytic	B-ANAT
+cells	I-ANAT
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+elimination	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Productive	O
+replication	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+monocyte	B-ANAT
+-	O
+derived	O
+dendritic	B-COMP
+cells	B-COMP
+modulates	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+First	O
+,	O
+MERS	O
+-	O
+CoV	O
+productively	O
+infected	O
+Mo	B-PRGE
+-	I-PRGE
+DCs	I-PRGE
+while	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infection	B-DISO
+was	O
+abortive	O
+.	O
+
+Second	O
+,	O
+MERS	O
+-	O
+CoV	O
+induced	O
+significantly	O
+higher	O
+levels	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+,	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+,	O
+and	O
+RANTES	B-PRGE
+expression	B-PROC
+than	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Third	O
+,	O
+MERS	O
+-	O
+CoV	O
+-	O
+infection	B-DISO
+induced	I-DISO
+higher	O
+surface	O
+expression	B-PROC
+of	O
+MHC	B-PRGE
+class	B-SPEC
+II	I-PRGE
+(	O
+HLA	B-PRGE
+-	I-PRGE
+DR	I-PRGE
+)	O
+and	O
+the	O
+co	O
+-	O
+stimulatory	O
+molecule	O
+CD86	B-PRGE
+than	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infection	B-DISO
+.	O
+
+The	O
+kit	B-FUNC
+is	O
+a	O
+valuable	O
+tool	O
+for	O
+assisting	O
+in	O
+the	O
+rapid	O
+diagnosis	O
+,	O
+patient	O
+management	O
+and	O
+epidemiology	O
+of	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+cases	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+kit	B-FUNC
+is	O
+a	O
+valuable	O
+tool	O
+for	O
+assisting	O
+in	O
+the	O
+rapid	O
+diagnosis	O
+,	O
+patient	O
+management	O
+and	O
+epidemiology	O
+of	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Bacterial	O
+and	O
+viral	O
+etiology	O
+in	O
+hospitalized	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+with	O
+molecular	O
+methods	O
+and	O
+clinical	O
+evaluation	O
+.	O
+
+We	O
+aimed	O
+to	O
+evaluate	O
+the	O
+bacterial	O
+and	O
+viral	O
+etiology	O
+of	O
+hospitalized	O
+CAP	B-DISO
+cases	O
+and	O
+compare	O
+clinical	O
+and	O
+laboratory	O
+findings	O
+of	O
+patients	O
+with	O
+pure	B-FUNC
+bacterial	O
+and	O
+bacterial	O
+and	O
+viral	O
+(	O
+mixed	O
+)	O
+infections	B-DISO
+.	O
+
+The	O
+etiological	O
+identification	O
+rate	O
+in	O
+50	O
+patients	O
+for	O
+bacteria	B-SPEC
+,	O
+viruses	B-SPEC
+and	O
+mixed	O
+virus	B-SPEC
+-	O
+bacteria	B-SPEC
+combination	O
+by	O
+PCR	O
+were	O
+62	O
+%,	O
+4	O
+%,	O
+32	O
+%,	O
+respectively	O
+and	O
+60	O
+%	O
+in	O
+55	O
+patients	O
+by	O
+bacterial	O
+culture	O
+method	O
+.	O
+
+TITLE	O
+:	O
+Cytokine	B-DISO
+storm	I-DISO
+plays	O
+a	O
+direct	O
+role	O
+in	O
+the	O
+morbidity	O
+and	O
+mortality	O
+from	O
+influenza	B-SPEC
+virus	B-PROC
+infection	I-PROC
+and	O
+is	O
+chemically	O
+treatable	O
+with	O
+a	O
+single	O
+sphingosine	B-CHED
+-	I-CHED
+1	I-CHED
+-	I-CHED
+phosphate	I-CHED
+agonist	B-CHED
+molecule	O
+.	O
+
+Thus	O
+,	O
+we	O
+hypothesized	O
+that	O
+neutrophil	B-CHED
+elastase	I-CHED
+inhibitor	I-CHED
+attenuated	O
+ventilation	O
+-	O
+induced	O
+neutrophil	B-PROC
+recruitment	B-DISO
+and	O
+MIP	B-PROC
+-	I-PROC
+2	I-PROC
+production	I-PROC
+through	O
+inhibition	B-PROC
+of	O
+the	O
+NF	O
+-	O
+κB	O
+/	O
+NRF	B-PRGE
+pathway	B-PROC
+.	O
+
+Neutrophil	B-CHED
+elastase	I-CHED
+inhibitor	I-CHED
+ameliorated	O
+high	O
+-	O
+tidal	O
+-	O
+volume	O
+ventilation	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+,	O
+neutrophil	B-ANAT
+influx	O
+,	O
+production	O
+of	O
+MIP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+malondialdehyde	B-CHED
+,	O
+activation	O
+of	O
+NF	O
+-	O
+κB	O
+and	O
+NRF	B-PRGE
+,	O
+apoptotic	O
+epithelial	B-ANAT
+cell	I-ANAT
+death	O
+,	O
+and	O
+disruption	O
+of	O
+bronchial	B-ANAT
+microstructure	O
+in	O
+mice	B-SPEC
+.	O
+
+MV	O
+induced	O
+systemic	O
+leukocytopenia	B-DISO
+and	O
+liver	B-ANAT
+,	O
+gut	B-ANAT
+and	O
+kidney	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+with	O
+pneumonia	B-DISO
+.	O
+
+There	O
+is	O
+also	O
+emerging	O
+evidence	O
+that	O
+a	O
+lung	B-ANAT
+-	O
+protective	O
+strategy	O
+may	O
+benefit	O
+non	O
+-	O
+ARDS	B-DISO
+patients	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+contraindications	O
+,	O
+it	O
+is	O
+reasonable	O
+to	O
+consider	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+in	O
+non	O
+-	O
+ARDS	B-DISO
+patients	O
+as	O
+well	O
+,	O
+though	O
+the	O
+evidence	O
+supporting	O
+this	O
+practice	O
+is	O
+less	O
+conclusive	O
+.	O
+
+Once	O
+the	O
+patient	O
+demonstrates	O
+signs	O
+of	O
+recovery	O
+,	O
+the	O
+best	O
+approach	O
+to	O
+liberation	O
+from	O
+mechanical	O
+ventilation	O
+involves	O
+daily	O
+spontaneous	O
+breathing	B-PROC
+trials	O
+and	O
+protocolized	O
+assessment	O
+of	O
+readiness	O
+for	O
+extubation	O
+.	O
+
+ABSTRACT	O
+:	O
+Objective	O
+:	O
+We	O
+aimed	O
+to	O
+identify	O
+the	O
+role	O
+of	O
+major	O
+respiratory	O
+viruses	O
+in	O
+the	O
+aetiology	O
+of	O
+human	B-SPEC
+nasal	B-DISO
+polyps	I-DISO
+using	O
+polymerase	O
+chain	O
+reaction	O
+technique	O
+.	O
+
+As	O
+these	O
+viruses	B-SPEC
+approach	O
+the	O
+epithelial	O
+surfaces	O
+from	O
+the	O
+apical	O
+side	O
+,	O
+it	O
+is	O
+not	O
+surprising	O
+that	O
+coronavirus	B-SPEC
+cell	B-COMP
+receptors	O
+are	O
+exposed	O
+primarily	O
+on	O
+the	O
+apical	O
+domain	O
+of	O
+polarized	O
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+an	O
+attenuated	O
+TGEV	B-SPEC
+(	O
+STC3	O
+)	O
+and	O
+a	O
+virulent	O
+TGEV	B-SPEC
+(	O
+SHXB	O
+)	O
+were	O
+used	O
+to	O
+determine	O
+whether	O
+porcine	B-SPEC
+DCs	B-DISO
+play	O
+an	O
+important	O
+role	O
+in	O
+pathogenetic	O
+differences	O
+between	O
+these	O
+two	O
+TGEVs	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+immature	O
+and	O
+mature	O
+monocyte	B-ANAT
+-	O
+derived	O
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+Mo	O
+-	O
+DCs	B-DISO
+)	O
+were	O
+susceptible	O
+to	O
+infection	B-DISO
+with	O
+SHXB	O
+and	O
+STC3	O
+.	O
+
+These	O
+differences	O
+may	O
+underlie	O
+the	O
+pathogenesis	B-DISO
+of	O
+virulent	O
+and	O
+attenuated	O
+TGEV	B-SPEC
+in	O
+piglets	O
+,	O
+and	O
+could	O
+help	O
+us	O
+to	O
+develop	O
+a	O
+better	O
+strategy	O
+to	O
+prevent	O
+virulent	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Plasmodium	B-DISO
+vivax	I-DISO
+malaria	B-PATH
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+case	O
+associated	O
+with	O
+focal	O
+autochthonous	O
+transmission	O
+in	O
+Greece	O
+.	O
+
+TITLE	O
+:	O
+Spinal	B-ANAT
+cord	I-ANAT
+injury	O
+,	O
+immunodepression	O
+,	O
+and	O
+antigenic	O
+challenge	O
+.	O
+
+TITLE	O
+:	O
+Stability	O
+of	O
+infectious	B-DISO
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+transportation	O
+in	O
+spread	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+,	O
+United	O
+States	O
+.	O
+
+Salification	O
+,	O
+the	O
+most	O
+commonly	O
+employed	O
+method	O
+for	O
+modifying	O
+physical	O
+-	O
+chemical	O
+properties	O
+,	O
+did	O
+significantly	O
+increase	O
+antiviral	B-CHED
+activity	O
+,	O
+and	O
+different	O
+salt	B-CHED
+forms	O
+displayed	O
+different	O
+antiviral	B-CHED
+effect	O
+.	O
+
+IFITMs	O
+typically	O
+exert	B-PROC
+their	O
+antiviral	B-CHED
+function	O
+by	O
+inhibiting	O
+the	O
+entry	O
+of	O
+a	O
+broad	O
+spectrum	O
+of	O
+viruses	B-SPEC
+into	O
+their	O
+host	B-COMP
+cells	B-COMP
+,	O
+presumably	O
+by	O
+trapping	O
+and	O
+degrading	O
+invading	O
+virions	B-COMP
+within	O
+the	O
+endocytic	O
+compartments	B-ANAT
+.	O
+
+In	O
+contrast	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+uses	O
+IFN	B-PRGE
+-	O
+induced	O
+human	B-SPEC
+IFITM2	B-PRGE
+or	O
+IFITM3	B-PRGE
+as	O
+an	O
+entry	O
+factor	O
+to	O
+facilitate	O
+its	O
+infection	B-DISO
+of	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+was	O
+detected	O
+in	O
+185	O
+samples	O
+originating	O
+from	O
+chicken	B-SPEC
+flocks	O
+of	O
+various	O
+commodity	O
+groups	O
+in	O
+Canada	O
+.	O
+
+Flocks	O
+with	O
+clinical	O
+signs	O
+such	O
+as	O
+respiratory	O
+challenge	O
+,	O
+sudden	B-DISO
+death	I-DISO
+,	O
+egg	B-ANAT
+production	O
+problems	O
+,	O
+or	O
+nephropathogenic	O
+conditions	O
+,	O
+and	O
+randomly	O
+selected	O
+flocks	O
+sampled	O
+at	O
+slaughter	O
+as	O
+part	O
+of	O
+an	O
+Ontario	O
+broiler	O
+surveillance	O
+project	O
+,	O
+were	O
+included	O
+.	O
+
+However	O
+,	O
+the	O
+recent	O
+outbreaks	O
+of	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+production	O
+problems	O
+in	O
+Ontario	O
+chicken	B-SPEC
+flocks	O
+related	O
+to	O
+the	O
+incursion	O
+of	O
+IBV	B-SPEC
+strain	O
+4	O
+/	O
+91	O
+were	O
+not	O
+prevented	O
+by	O
+standard	O
+vaccination	O
+protocols	O
+.	O
+
+However	O
+,	O
+if	O
+only	O
+diarrhoeic	O
+on	O
+the	O
+day	O
+of	O
+birth	B-PROC
+,	O
+no	O
+negative	O
+effect	O
+on	O
+ADG	O
+was	O
+seen	O
+.	O
+
+In	O
+one	O
+of	O
+the	O
+herds	O
+,	O
+approximately	O
+25	O
+%	O
+of	O
+the	O
+diarrhoeic	O
+piglets	O
+vs	O
+.	O
+6	O
+%	O
+of	O
+the	O
+non	O
+-	O
+diarrhoeic	O
+piglets	O
+died	B-PROC
+,	O
+and	O
+74	O
+%	O
+of	O
+necropsied	O
+piglets	O
+were	O
+diagnosed	O
+with	O
+enteritis	B-DISO
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+the	O
+high	O
+mortality	O
+seen	O
+in	O
+this	O
+herd	O
+was	O
+due	O
+to	O
+diarrhoea	B-DISO
+.	O
+
+Antibodies	B-COMP
+against	O
+canine	O
+parvovirus	B-DISO
+were	O
+detected	O
+in	O
+71	O
+.	O
+6	O
+%	O
+(	O
+63	O
+/	O
+88	O
+)	O
+blood	B-ANAT
+samples	I-ANAT
+and	O
+the	O
+seroprevalence	O
+found	O
+for	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+was	O
+51	O
+.	O
+1	O
+%	O
+(	O
+45	O
+/	O
+88	O
+).	O
+
+RESULTS	O
+:	O
+To	O
+provide	O
+information	O
+regarding	O
+the	O
+health	O
+status	O
+of	O
+the	O
+canine	O
+population	O
+in	O
+Vila	B-SPEC
+do	O
+Maio	O
+,	O
+Maio	O
+Island	O
+,	O
+Cape	O
+Verde	O
+,	O
+53	O
+rectal	O
+swabs	O
+were	O
+collected	O
+from	O
+53	O
+stray	O
+dogs	B-SPEC
+during	O
+2010	O
+and	O
+93	O
+rectal	O
+swabs	O
+and	O
+88	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+collected	O
+from	O
+125	O
+stray	O
+dogs	B-SPEC
+in	O
+2011	O
+.	O
+
+The	O
+use	O
+of	O
+controlled	O
+mechanical	O
+ventilation	O
+with	O
+tidal	O
+volume	O
+>	O
+8	O
+mL	O
+/	O
+kg	O
+and	O
+without	O
+arrhythmias	B-DISO
+occurred	O
+in	O
+only	O
+2	O
+.	O
+9	O
+%	O
+of	O
+the	O
+patients	O
+at	O
+the	O
+time	O
+of	O
+fluid	O
+challenge	O
+episodes	O
+.	O
+
+Pearson	O
+chi	B-CHED
+-	O
+square	O
+test	O
+).	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+genetic	O
+characterization	O
+of	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+from	O
+domestic	O
+piglets	O
+in	O
+China	O
+.	O
+
+Coronavirus	B-SPEC
+-	O
+like	O
+particles	O
+were	O
+observed	O
+by	O
+electron	O
+microscopy	O
+.	O
+
+The	O
+recombinant	O
+virus	B-SPEC
+showed	O
+somewhat	O
+-	O
+reduced	O
+pathogenicity	O
+compared	O
+to	O
+the	O
+parental	O
+lentogenic	O
+LaSota	O
+strain	O
+but	O
+effectively	O
+elicited	O
+hemagglutination	B-PROC
+inhibition	B-PROC
+antibodies	B-COMP
+against	O
+NDV	B-SPEC
+and	O
+protected	O
+chickens	B-SPEC
+against	O
+lethal	O
+challenge	O
+with	O
+virulent	O
+NDV	B-SPEC
+/	O
+CA02	O
+.	O
+
+Challenge	O
+with	O
+virulent	O
+Ark	B-PRGE
+was	O
+performed	O
+at	O
+21	O
+days	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+Factors	O
+responsible	O
+for	O
+the	O
+persistence	O
+of	O
+Arkansas	O
+Delmarva	O
+Poultry	O
+Industry	O
+(	O
+ArkDPI	O
+)-	O
+derived	O
+infectious	B-DISO
+bronchitis	B-DISO
+vaccines	O
+in	O
+commercial	O
+flocks	O
+and	O
+the	O
+high	O
+frequency	O
+of	O
+isolation	O
+of	O
+ArkDPI	O
+-	O
+type	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+in	O
+respiratory	O
+cases	O
+are	O
+still	O
+unclear	O
+.	O
+
+One	O
+of	O
+the	O
+vaccines	O
+(	O
+coded	O
+vaccine	O
+B	O
+)	O
+produced	O
+significantly	O
+higher	O
+vaccine	O
+virus	B-SPEC
+heterogeneity	O
+in	O
+vaccinated	O
+chickens	B-SPEC
+than	O
+the	O
+other	O
+vaccine	O
+(	O
+coded	O
+A	O
+).	O
+
+Paired	O
+serum	B-COMP
+samples	O
+were	O
+obtained	O
+from	O
+patients	O
+with	O
+Kawasaki	B-DISO
+disease	I-DISO
+who	O
+had	O
+not	O
+been	O
+treated	O
+with	O
+γ	O
+-	O
+globulin	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+3a	O
+protein	B-CHED
+functions	O
+as	O
+an	O
+ion	O
+channel	O
+,	O
+induces	O
+apoptosis	B-PATH
+and	O
+is	O
+important	O
+for	O
+viral	B-DISO
+pathogenesis	I-DISO
+.	O
+
+However	O
+the	O
+3a	B-PRGE
+protein	I-PRGE
+with	O
+mutations	O
+within	O
+the	O
+EXD	O
+di	O
+-	O
+acidic	O
+motif	O
+(	O
+ΔEXD	O
+)	O
+showed	O
+an	O
+intracellular	B-COMP
+distribution	O
+similar	O
+to	O
+the	O
+wild	O
+type	O
+protein	B-CHED
+.	O
+
+The	O
+ΔYXXΦ	B-PRGE
+protein	I-PRGE
+also	O
+expressed	B-PROC
+at	O
+significantly	O
+lower	O
+levels	O
+compared	O
+to	O
+the	O
+wild	B-PRGE
+type	I-PRGE
+3a	I-PRGE
+protein	I-PRGE
+,	O
+which	O
+was	O
+reversed	O
+with	O
+Brefeldin	B-CHED
+A	I-CHED
+and	O
+Aprotinin	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+disease	O
+in	O
+children	O
+.	O
+
+Despite	O
+the	O
+global	O
+distribution	O
+of	O
+IBV	B-SPEC
+,	O
+Finland	O
+has	O
+been	O
+free	O
+of	O
+clinical	O
+cases	O
+for	O
+almost	O
+three	O
+decades	O
+.	O
+
+The	O
+increased	O
+human	B-SPEC
+cases	O
+and	O
+high	O
+mortality	O
+rate	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+make	O
+it	O
+essential	O
+to	O
+develop	O
+safe	O
+and	O
+effective	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+membrane	B-COMP
+(	O
+M	O
+)	O
+proteins	B-CHED
+are	O
+capable	O
+of	O
+interacting	O
+with	O
+nucleocapsid	B-PRGE
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+and	I-PRGE
+envelope	B-COMP
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+proteins	B-CHED
+.	O
+
+Changing	O
+all	O
+three	O
+E	O
+cysteine	B-CHED
+residues	O
+to	O
+alanines	O
+did	O
+not	O
+exert	B-PROC
+negative	O
+effects	O
+on	O
+E	O
+release	B-PATH
+,	O
+E	O
+association	O
+with	O
+N	O
+,	O
+or	O
+E	O
+enhancement	O
+of	O
+VLP	B-COMP
+production	O
+,	O
+suggesting	O
+that	O
+E	O
+palmitoylation	B-PROC
+modification	O
+or	O
+disulfide	B-CHED
+bond	O
+formation	B-PROC
+is	O
+not	O
+required	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+virus	B-PROC
+assembly	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+common	O
+,	O
+devastating	O
+complication	B-DISO
+of	O
+critical	B-DISO
+illness	I-DISO
+that	O
+is	O
+characterized	O
+by	O
+pulmonary	B-ANAT
+injury	O
+and	O
+inflammation	B-DISO
+.	O
+
+An	O
+electronic	O
+nose	B-ANAT
+can	O
+rapidly	O
+and	O
+non	O
+-	O
+invasively	O
+discriminate	O
+between	O
+patients	O
+with	O
+and	O
+without	O
+ARDS	B-DISO
+with	O
+modest	O
+accuracy	O
+.	O
+
+This	O
+implicates	O
+that	O
+breath	B-ANAT
+analysis	O
+may	O
+allow	O
+for	O
+rapid	O
+,	O
+bedside	O
+detection	O
+of	O
+ARDS	B-DISO
+,	O
+especially	O
+if	O
+our	O
+findings	O
+are	O
+reproduced	O
+using	O
+continuous	O
+exhaled	B-PROC
+breath	B-ANAT
+profiling	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+training	O
+cohort	O
+(	O
+40	O
+patients	O
+with	O
+ARDS	B-DISO
+versus	O
+66	O
+controls	O
+)	O
+the	O
+diagnostic	O
+model	O
+for	O
+ARDS	B-DISO
+showed	O
+a	O
+moderate	O
+discrimination	O
+,	O
+with	O
+an	O
+area	O
+under	O
+the	O
+receiver	O
+-	O
+operator	O
+characteristic	O
+curve	O
+(	O
+AUC	O
+-	O
+ROC	O
+)	O
+of	O
+0	O
+.	O
+72	O
+(	O
+95	O
+%-	O
+confidence	O
+interval	O
+(	O
+CI	O
+):	O
+0	O
+.	O
+63	O
+-	O
+0	O
+.	O
+82	O
+).	O
+
+TITLE	O
+:	O
+Is	O
+abdomen	B-ANAT
+release	B-PATH
+really	O
+necessary	O
+for	O
+prone	O
+ventilation	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+?	O
+
+This	O
+study	O
+aimed	O
+to	O
+retrospectively	O
+investigate	O
+the	O
+clinical	O
+status	O
+and	O
+outcomes	O
+in	O
+IPF	O
+patients	O
+receiving	O
+NIV	O
+for	O
+ARF	B-DISO
+and	O
+to	O
+identify	O
+those	O
+clinical	O
+and	O
+laboratory	O
+characteristics	O
+,	O
+which	O
+could	O
+be	O
+considered	O
+risk	O
+factors	O
+for	O
+its	O
+failure	O
+.	O
+
+The	O
+use	O
+of	O
+NIV	O
+was	O
+,	O
+nevertheless	O
+,	O
+found	O
+to	O
+be	O
+associated	O
+with	O
+clinical	O
+benefits	O
+in	O
+selected	O
+IPF	O
+patients	O
+,	O
+preventing	O
+the	O
+need	O
+for	O
+intubation	O
+and	O
+reducing	O
+the	O
+rate	O
+of	O
+complications	O
+/	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Early	O
+identification	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+forceful	O
+implementation	O
+of	O
+standardized	O
+therapy	O
+algorithms	O
+are	O
+the	O
+mandatory	O
+basis	O
+of	O
+an	O
+effective	O
+therapy	O
+to	O
+improve	O
+patient	O
+outcome	O
+.	O
+
+Recently	O
+,	O
+a	O
+new	O
+definition	O
+of	O
+ARDS	B-DISO
+was	O
+implemented	O
+,	O
+which	O
+simplified	O
+the	O
+diagnostic	O
+criteria	O
+for	O
+ARDS	B-DISO
+.	O
+
+Thus	O
+,	O
+bats	B-SPEC
+are	O
+thought	O
+to	O
+be	O
+natural	O
+hosts	B-COMP
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Bioinformatics	O
+insight	O
+into	O
+the	O
+spike	O
+glycoprotein	B-CHED
+gene	O
+of	O
+field	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+strains	O
+during	O
+2011	O
+-	O
+2013	O
+in	O
+Guangdong	O
+,	O
+China	O
+.	O
+
+This	O
+explains	O
+why	O
+there	O
+have	O
+been	O
+constant	O
+but	O
+infrequent	O
+outbreaks	O
+recently	O
+in	O
+comparison	O
+to	O
+late	O
+2010	O
+in	O
+which	O
+PEDV	B-SPEC
+outbreaks	O
+were	O
+more	O
+frequent	O
+and	O
+severe	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+human	B-SPEC
+neutralizing	O
+antibodies	B-COMP
+against	O
+MERS	O
+-	O
+CoV	O
+and	O
+their	O
+role	O
+in	O
+virus	B-SPEC
+adaptive	O
+evolution	O
+.	O
+
+Given	O
+the	O
+recent	O
+detection	B-PROC
+of	I-PROC
+virus	I-PROC
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+zoonotic	O
+transfer	O
+of	O
+MERS	O
+-	O
+CoV	O
+to	O
+humans	B-SPEC
+is	O
+suspected	O
+.	O
+
+We	O
+anticipate	O
+this	O
+model	O
+will	O
+advance	O
+our	O
+understanding	O
+of	O
+HPS	B-DISO
+pathogenesis	B-DISO
+and	O
+will	O
+greatly	O
+facilitate	O
+research	O
+toward	O
+the	O
+development	B-PROC
+of	O
+effective	O
+therapeutics	O
+and	O
+vaccines	O
+against	O
+hantaviral	O
+diseases	O
+.	O
+
+Mutagenesis	B-PROC
+analysis	O
+suggested	O
+that	O
+MERS	O
+-	O
+4	O
+and	O
+MERS	O
+-	O
+27	O
+recognized	O
+distinct	O
+regions	O
+in	O
+RBD	O
+.	O
+
+IMPORTANCE	O
+In	O
+most	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	B-DISO
+),	O
+the	O
+route	O
+for	O
+human	B-SPEC
+infection	B-DISO
+with	O
+the	O
+causative	O
+agent	O
+,	O
+MERS	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+),	O
+is	O
+unknown	O
+.	O
+
+After	O
+serial	O
+infections	B-DISO
+,	O
+mutant	B-DISO
+viruses	B-SPEC
+,	O
+in	O
+general	O
+,	O
+incorporated	O
+compensatory	O
+mutations	O
+within	O
+E	O
+gene	O
+that	O
+rendered	O
+active	O
+ion	B-FUNC
+channels	I-FUNC
+.	O
+
+In	O
+contrast	O
+,	O
+mice	B-SPEC
+infected	O
+with	O
+mutants	O
+lacking	O
+IC	O
+activity	O
+,	O
+which	O
+did	O
+not	O
+incorporate	O
+mutations	O
+within	O
+E	B-PRGE
+gene	I-PRGE
+during	O
+the	O
+experiment	O
+,	O
+recovered	O
+from	O
+disease	O
+and	O
+most	O
+survived	O
+.	O
+
+Knocking	O
+down	O
+E	O
+protein	B-CHED
+IC	O
+activity	O
+did	O
+not	O
+significantly	O
+affect	O
+virus	B-SPEC
+growth	B-PROC
+in	O
+infected	O
+mice	B-SPEC
+but	O
+decreased	O
+edema	B-DISO
+accumulation	O
+,	O
+the	O
+major	O
+determinant	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+leading	O
+to	O
+death	B-PROC
+.	O
+
+Reduced	O
+edema	B-DISO
+correlated	O
+with	O
+lung	B-ANAT
+epithelia	O
+integrity	O
+and	O
+proper	O
+localization	B-PROC
+of	O
+Na	B-PRGE
++/	I-PRGE
+K	I-PRGE
++	I-PRGE
+ATPase	I-PRGE
+,	O
+which	O
+participates	O
+in	O
+edema	B-DISO
+resolution	O
+.	O
+
+Importance	O
+:	O
+A	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+was	O
+found	O
+to	O
+infect	O
+humans	B-SPEC
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+in	O
+2012	O
+,	O
+just	O
+1	O
+decade	O
+after	O
+the	O
+appearance	O
+of	O
+the	O
+first	O
+highly	O
+pathogenic	O
+coronavirus	B-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+This	O
+augmented	O
+MHC	B-PROC
+binding	B-FUNC
+is	O
+likely	O
+to	O
+increase	O
+the	O
+half	O
+-	O
+life	O
+and	O
+surface	O
+density	O
+of	O
+the	O
+heteroclitic	O
+complex	O
+,	O
+but	O
+precisely	O
+how	O
+this	O
+enhanced	O
+T	B-ANAT
+cell	I-ANAT
+response	O
+occurs	O
+in	O
+vivo	O
+is	O
+not	O
+known	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+the	O
+detection	O
+rates	O
+of	O
+respiratory	O
+viruses	B-SPEC
+from	O
+nasopharyngeal	B-ANAT
+swabs	O
+and	O
+sputum	B-ANAT
+using	O
+a	O
+multiplex	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+However	O
+,	O
+the	O
+range	O
+of	O
+reagents	B-CHED
+available	O
+to	O
+measure	O
+the	O
+ferret	B-SPEC
+immune	B-PROC
+response	I-PROC
+is	O
+very	O
+limited	O
+.	O
+
+These	O
+new	O
+tools	O
+will	O
+allow	O
+a	O
+more	O
+comprehensive	O
+analysis	O
+of	O
+the	O
+ferret	B-SPEC
+immune	B-PROC
+responses	I-PROC
+following	O
+infection	B-DISO
+or	O
+in	O
+other	O
+disease	O
+states	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+Respiratory	O
+Infections	O
+(	O
+ARI	B-CHED
+)	O
+are	O
+some	O
+of	O
+the	O
+most	O
+common	O
+human	B-SPEC
+diseases	O
+worldwide	O
+.	O
+
+The	O
+most	O
+frequently	O
+detected	O
+pathogens	O
+were	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+768	O
+/	O
+2361	O
+,	O
+32	O
+.	O
+5	O
+%),	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+428	O
+/	O
+2361	O
+,	O
+18	O
+.	O
+1	O
+%),	O
+enterovirus	B-SPEC
+(	O
+138	O
+/	O
+2361	O
+,	O
+13	O
+.	O
+3	O
+%),	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+(	O
+267	O
+/	O
+2361	O
+,	O
+11	O
+.	O
+3	O
+%)	O
+and	O
+adenovirus	B-DISO
+(	O
+213	O
+/	O
+2361	O
+,	O
+9	O
+.	O
+0	O
+%).	O
+
+Therefore	O
+,	O
+it	O
+is	O
+a	O
+promising	O
+target	O
+for	O
+drug	O
+development	B-PROC
+.	O
+
+Five	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RHIs	B-SPEC
+inhibited	O
+PFV	B-CHED
+RNase	B-FUNC
+H	I-FUNC
+activity	I-FUNC
+at	O
+low	O
+-	O
+micromolar	O
+concentrations	O
+similar	O
+to	O
+those	O
+of	O
+HIV	O
+-	O
+1	O
+RNase	B-PRGE
+H	I-PRGE
+,	O
+suggesting	O
+pocket	O
+similarity	O
+of	O
+the	O
+RNase	B-PRGE
+H	I-PRGE
+domains	I-PRGE
+.	O
+
+We	O
+decided	O
+to	O
+insert	O
+a	O
+T	O
+-	O
+tube	O
+through	O
+the	O
+perforation	O
+and	O
+performed	O
+intercostal	B-ANAT
+muscle	I-ANAT
+flap	B-ANAT
+reinforcement	O
+.	O
+
+Oral	B-ANAT
+intake	O
+was	O
+started	O
+on	O
+day	O
+45	O
+and	O
+he	O
+was	O
+discharged	O
+on	O
+day	O
+71	O
+.	O
+
+Our	O
+study	O
+focused	O
+on	O
+the	O
+role	O
+of	O
+protease	B-PROC
+activity	I-PROC
+on	O
+infection	B-DISO
+by	O
+investigating	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+a	O
+PEDV	B-SPEC
+isolate	O
+(	O
+wtPEDV	O
+)	O
+using	O
+a	O
+reverse	O
+genetics	O
+system	O
+based	O
+on	O
+the	O
+trypsin	B-PRGE
+-	O
+independent	O
+cell	B-COMP
+culture	O
+-	O
+adapted	O
+strain	O
+DR13	O
+(	O
+caPEDV	O
+).	O
+
+CBF	B-PRGE
+velocity	O
+of	O
+middle	B-ANAT
+cerebral	I-ANAT
+artery	I-ANAT
+(	O
+MCA	B-CHED
+)	O
+was	O
+measured	O
+using	O
+transcranial	O
+Doppler	O
+(	O
+TCD	B-DISO
+),	O
+and	O
+breath	B-ANAT
+-	O
+holding	O
+index	O
+(	O
+BHI	O
+)	O
+was	O
+also	O
+calculated	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Prognostic	O
+significance	O
+of	O
+early	O
+lactate	B-CHED
+clearance	O
+rate	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+patients	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+].	O
+
+Patients	O
+were	O
+divided	O
+into	O
+the	O
+survival	O
+group	O
+(	O
+n	O
+=	O
+24	O
+)	O
+and	O
+the	O
+death	B-PROC
+group	O
+(	O
+n	O
+=	O
+19	O
+)	O
+.	O
+
+Early	O
+lactate	B-CHED
+clearance	O
+rate	O
+could	O
+be	O
+used	O
+as	O
+an	O
+important	O
+variable	O
+for	O
+evaluating	O
+the	O
+prognosis	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+patients	O
+on	O
+ECMO	O
+.	O
+
+Better	O
+characterization	O
+of	O
+patients	O
+who	O
+aspirate	B-ANAT
+may	O
+allow	O
+identification	O
+of	O
+potential	O
+risks	O
+for	O
+aspiration	B-DISO
+that	O
+could	O
+be	O
+used	O
+in	O
+future	O
+studies	O
+to	O
+mitigate	O
+the	O
+occurrence	O
+of	O
+aspiration	B-DISO
+and	O
+its	O
+devastating	O
+complications	O
+.	O
+
+Aspiration	B-DISO
+subjects	O
+were	O
+sicker	O
+(	O
+higher	O
+APACHE	O
+[	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+]	O
+II	O
+score	O
+),	O
+required	O
+more	O
+mechanical	O
+ventilation	O
+(	O
+54	O
+%	O
+vs	O
+32	O
+%,	O
+P	O
+<	O
+.	O
+0001	O
+),	O
+developed	O
+more	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+(	O
+12	O
+%	O
+vs	O
+3	O
+.	O
+8	O
+%,	O
+P	O
+<	O
+.	O
+0001	O
+),	O
+and	O
+were	O
+twofold	O
+more	O
+likely	O
+to	O
+die	O
+in	O
+-	O
+hospital	O
+,	O
+even	O
+after	O
+adjustment	O
+for	O
+severity	O
+of	O
+illness	O
+(	O
+OR	O
+=	O
+2	O
+.	O
+1	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+2	O
+-	O
+3	O
+.	O
+6	O
+).	O
+
+Findings	O
+from	O
+this	O
+study	O
+may	O
+facilitate	O
+the	O
+design	O
+of	O
+future	O
+clinical	O
+studies	O
+of	O
+aspiration	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Neither	O
+obesity	B-DISO
+nor	O
+gastroesophageal	B-DISO
+reflux	I-DISO
+was	O
+associated	O
+with	O
+aspiration	B-DISO
+.	O
+
+Our	O
+study	O
+showed	O
+that	O
+QTc	O
+is	O
+a	O
+potential	O
+predictor	O
+for	O
+adverse	O
+outcomes	O
+related	O
+to	O
+acute	O
+methadone	B-CHED
+intoxication	O
+.	O
+
+Risk	O
+factors	O
+for	O
+pneumothorax	B-DISO
+included	O
+:	O
+a	O
+)	O
+for	O
+the	O
+overall	O
+lpopulation	O
+-	O
+Score	O
+for	O
+Neonatal	O
+Acute	O
+Physiology	O
+,	O
+version	O
+II	O
+>	O
+20	O
+,	O
+surfactant	B-CHED
+use	O
+,	O
+and	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+b	O
+)	O
+for	O
+early	O
+preterm	O
+infants	O
+-	O
+chorioamnionitis	B-DISO
+;	O
+c	O
+)	O
+for	O
+moderate	O
+-	O
+late	O
+preterm	O
+infants	O
+-	O
+higher	O
+birth	B-PROC
+weight	O
+,	O
+male	O
+sex	O
+,	O
+rupture	O
+of	O
+membranes	B-ANAT
+>	O
+24	O
+hours	O
+,	O
+and	O
+outborn	O
+status	O
+;	O
+and	O
+d	O
+)	O
+for	O
+term	O
+infants	O
+-	O
+male	O
+sex	O
+,	O
+outborn	O
+status	O
+,	O
+and	O
+meconium	B-DISO
+aspiration	I-DISO
+in	O
+term	O
+neonates	O
+.	O
+
+In	O
+early	O
+preterm	O
+neonates	O
+,	O
+pneumothorax	B-DISO
+was	O
+associated	O
+with	O
+mortality	O
+,	O
+bronchopulmonary	B-DISO
+dysplasia	I-DISO
+,	O
+severe	O
+intraventricular	B-DISO
+hemorrhage	I-DISO
+,	O
+and	O
+prolonged	O
+NICU	O
+stay	O
+.	O
+
+Vergadi	O
+et	O
+al	O
+.	O
+are	O
+the	O
+first	O
+to	O
+demonstrate	O
+that	O
+depletion	O
+of	O
+Akt2	B-PRGE
+kinase	I-PRGE
+and	O
+microRNA	O
+-	O
+146a	O
+induction	O
+in	O
+mice	B-SPEC
+resulted	O
+in	O
+polarization	O
+of	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+towards	O
+an	O
+M2	O
+activation	O
+phenotype	O
+and	O
+resulted	O
+in	O
+less	O
+severe	O
+injury	O
+following	O
+acid	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+and	O
+L	B-SPEC
+.	I-SPEC
+intracellularis	I-SPEC
+was	O
+detected	O
+in	O
+12	O
+turkey	B-SPEC
+flocks	O
+.	O
+
+These	O
+results	O
+throw	O
+new	O
+light	O
+on	O
+the	O
+multiple	O
+etiology	O
+of	O
+enteritis	B-DISO
+in	O
+turkeys	B-SPEC
+.	O
+
+He	O
+died	B-PROC
+in	O
+several	O
+days	O
+because	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+prospectively	O
+included	O
+76	O
+consecutive	O
+patients	O
+with	O
+BMI	O
+>	O
+40	O
+kg	O
+/	O
+m2	O
+diagnosed	O
+with	O
+OHS	B-DISO
+and	O
+treated	O
+by	O
+NIV	O
+for	O
+ARF	B-DISO
+in	O
+a	O
+15	O
+-	O
+bed	B-DISO
+ICU	O
+of	O
+a	O
+tertiary	O
+hospital	O
+.	O
+
+Factors	O
+associated	O
+with	O
+NIV	O
+failure	O
+included	O
+pneumonia	B-DISO
+(	O
+n	O
+=	O
+12	O
+/	O
+13	O
+,	O
+92	O
+%	O
+vs	O
+n	O
+=	O
+9	O
+/	O
+63	O
+,	O
+14	O
+%;	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+high	O
+SOFA	O
+(	O
+10	O
+vs	O
+5	O
+;	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+SAPS2	O
+score	O
+(	O
+63	O
+vs	O
+39	O
+;	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+at	O
+admission	O
+.	O
+
+In	O
+the	O
+NIV	O
+success	O
+group	O
+(	O
+n	O
+=	O
+63	O
+),	O
+33	O
+patients	O
+(	O
+53	O
+%)	O
+experienced	O
+a	O
+delayed	O
+response	O
+to	O
+NIV	O
+(	O
+with	O
+persistent	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+during	O
+the	O
+first	O
+6	O
+hours	O
+).	O
+
+Multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+pneumonia	B-DISO
+were	O
+the	O
+main	O
+factors	O
+associated	O
+with	O
+NIV	O
+failure	O
+and	O
+death	B-PROC
+in	O
+morbidly	O
+obese	B-DISO
+patients	O
+in	O
+hypoxemic	O
+ARF	B-DISO
+.	O
+
+Of	O
+the	O
+33	O
+samples	O
+from	O
+healthy	O
+children	O
+,	O
+at	O
+least	O
+one	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+21	O
+(	O
+63	O
+.	O
+6	O
+%)	O
+and	O
+viral	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+were	O
+detected	O
+in	O
+seven	O
+(	O
+21	O
+.	O
+2	O
+%)	O
+samples	O
+.	O
+
+Our	O
+study	O
+aimed	O
+to	O
+determine	O
+the	O
+point	O
+prevalence	O
+of	O
+viruses	B-SPEC
+associated	O
+with	O
+exacerbations	O
+and	O
+evaluate	O
+clinical	O
+and	O
+investigational	O
+differences	O
+between	O
+virus	B-SPEC
+-	O
+positive	O
+and	O
+-	O
+negative	O
+exacerbations	O
+in	O
+children	O
+with	O
+bronchiectasis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+mid	O
+-	O
+March	O
+2014	O
+,	O
+the	O
+frequency	O
+with	O
+which	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+have	O
+been	O
+reported	O
+has	O
+increased	O
+,	O
+with	O
+the	O
+majority	O
+of	O
+recent	O
+cases	O
+reported	O
+from	O
+Saudi	O
+Arabia	O
+and	O
+United	O
+Arab	O
+Emirates	O
+(	O
+UAE	O
+).	O
+
+Here	O
+,	O
+we	O
+analyzed	O
+the	O
+role	O
+of	O
+the	O
+nuclear	B-PROC
+import	I-PROC
+factor	O
+importin	O
+-	O
+α7	O
+in	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+pulmonary	B-ANAT
+tropism	B-PROC
+by	O
+using	O
+various	O
+ex	O
+vivo	O
+imaging	O
+techniques	O
+(	O
+magnetic	O
+resonance	O
+imaging	O
+,	O
+confocal	O
+laser	B-SPEC
+scanning	O
+microscopy	O
+,	O
+and	O
+correlative	O
+light	O
+-	O
+electron	O
+microscopy	O
+).	O
+
+The	O
+ability	O
+of	O
+macrophages	B-ANAT
+to	O
+support	O
+or	O
+clear	O
+the	O
+virus	B-DISO
+infection	I-DISO
+,	O
+as	O
+well	O
+as	O
+the	O
+host	B-COMP
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+,	O
+did	O
+not	O
+significantly	O
+differ	O
+between	O
+WT	O
+and	O
+α7	O
+(-/-)	O
+mice	B-SPEC
+.	O
+
+However	O
+,	O
+cytokine	O
+and	O
+chemokine	O
+responses	O
+were	O
+generally	O
+elevated	O
+in	O
+WT	O
+mice	B-SPEC
+,	O
+likely	O
+reflective	O
+of	O
+increased	O
+viral	B-PROC
+replication	I-PROC
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+Using	O
+complementary	O
+ex	O
+vivo	O
+imaging	O
+approaches	O
+,	O
+we	O
+show	O
+that	O
+influenza	B-SPEC
+virus	B-PROC
+replication	I-PROC
+is	O
+restricted	O
+to	O
+the	O
+bronchial	B-ANAT
+epithelium	I-ANAT
+,	O
+followed	O
+by	O
+enhanced	O
+survival	O
+in	O
+importin	O
+-	O
+α7	O
+-	O
+deficient	O
+mice	B-SPEC
+.	O
+
+Hospital	O
+outcome	O
+was	O
+defined	O
+as	O
+death	B-PROC
+or	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+Like	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+MERS	O
+is	O
+caused	O
+by	O
+a	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Laboratory	O
+-	O
+confirmed	O
+case	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+Malaysia	O
+:	O
+preparedness	O
+and	O
+response	O
+,	O
+April	O
+2014	O
+.	O
+
+TITLE	O
+:	O
+Rapidly	O
+Progressing	O
+Severe	O
+Cutaneous	O
+Adverse	O
+Reaction	O
+With	O
+Acute	O
+Kidney	B-ANAT
+Injury	O
+After	O
+Drug	O
+Exposure	O
+:	O
+An	O
+Uncommon	O
+Presentation	O
+.	O
+
+The	O
+bioassay	O
+results	O
+showed	O
+that	O
+most	O
+of	O
+the	O
+synthesized	O
+compounds	O
+(	O
+such	O
+as	O
+4a	O
+,	O
+6a	O
+,	O
+7a	O
+,	O
+11a	O
+,	O
+14a	O
+,	O
+6b	O
+,	O
+and	O
+14b	O
+)	O
+exhibited	O
+good	O
+to	O
+excellent	O
+antiviral	B-CHED
+activity	O
+against	O
+TMV	B-SPEC
+both	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+.	O
+
+We	O
+analyzed	O
+samples	O
+from	O
+112	O
+patients	O
+infected	O
+with	O
+the	O
+recently	O
+discovered	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+Tracheal	O
+aspirates	B-ANAT
+yielded	O
+significantly	O
+higher	O
+MERS	O
+-	O
+CoV	O
+loads	O
+,	O
+compared	O
+with	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+specimens	O
+(	O
+P	O
+=	O
+.	O
+005	O
+)	O
+and	O
+sputum	B-ANAT
+specimens	O
+(	O
+P	O
+=	O
+.	O
+0001	O
+).	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+SSYA10	O
+-	O
+001	O
+as	O
+a	O
+replication	O
+inhibitor	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+mouse	B-SPEC
+hepatitis	I-DISO
+,	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronaviruses	O
+.	O
+
+A	O
+putative	O
+binding	B-FUNC
+pocket	O
+for	O
+SSYA10	O
+-	O
+001	O
+was	O
+identified	O
+and	O
+shown	O
+to	O
+be	O
+similar	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+MHV	B-PRGE
+helicases	I-PRGE
+.	O
+
+These	O
+studies	O
+show	O
+that	O
+it	O
+is	O
+possible	O
+to	O
+target	O
+multiple	O
+coronaviruses	O
+through	O
+broad	O
+-	O
+spectrum	O
+inhibitors	B-CHED
+.	O
+
+The	O
+2003	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+first	O
+demonstrated	O
+the	O
+potentially	O
+lethal	O
+consequences	O
+of	O
+zoonotic	O
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+compounds	O
+belong	O
+to	O
+13	O
+different	O
+classes	O
+of	O
+pharmaceuticals	B-CHED
+,	O
+including	O
+inhibitors	B-CHED
+of	O
+estrogen	B-CHED
+receptors	O
+used	O
+for	O
+cancer	B-DISO
+treatment	O
+and	O
+inhibitors	B-CHED
+of	O
+dopamine	B-PRGE
+receptor	I-PRGE
+used	O
+as	O
+antipsychotics	B-CHED
+.	O
+
+Although	O
+poorly	O
+understood	O
+,	O
+it	O
+has	O
+long	O
+been	O
+recognized	O
+that	O
+host	B-COMP
+regulation	B-PROC
+of	O
+virus	B-SPEC
+-	O
+associated	O
+disease	O
+severity	O
+is	O
+multigenic	O
+.	O
+
+The	O
+advent	O
+of	O
+systems	O
+genetic	O
+and	O
+biology	O
+resources	O
+provides	O
+new	O
+opportunities	O
+for	O
+deconvoluting	O
+the	O
+complex	O
+genetic	O
+interactions	O
+and	O
+expression	O
+networks	O
+that	O
+regulate	O
+pathogenic	O
+or	O
+protective	O
+host	B-PROC
+response	I-PROC
+patterns	O
+following	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Neural	O
+precursor	O
+cells	B-COMP
+(	O
+NPCs	O
+)	O
+offer	O
+a	O
+promising	O
+approach	O
+for	O
+treating	O
+demyelinating	B-DISO
+diseases	I-DISO
+.	O
+
+Our	O
+findings	O
+reveal	O
+focal	O
+axonal	O
+degeneration	B-DISO
+that	O
+occurs	O
+in	O
+the	O
+ventral	O
+side	O
+of	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+within	O
+1	O
+wk	O
+following	O
+intracranial	B-ANAT
+instillation	O
+with	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+).	O
+
+NPCs	O
+engrafted	O
+into	O
+spinal	O
+cords	O
+of	O
+JHMV	O
+-	O
+infected	O
+mice	B-SPEC
+exhibited	O
+diminished	O
+migration	B-PROC
+velocities	O
+and	O
+increased	O
+proliferation	B-DISO
+compared	O
+with	O
+transplanted	B-ANAT
+cells	B-COMP
+in	O
+noninfected	O
+mice	B-SPEC
+.	O
+
+The	O
+majority	O
+of	O
+studies	O
+carried	O
+out	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+attribute	O
+a	O
+dysregulated	O
+/	O
+exuberant	O
+innate	O
+response	O
+as	O
+a	O
+leading	O
+contributor	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	O
+mediated	O
+pathology	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+broad	O
+range	O
+and	O
+diversity	O
+of	O
+interferon	B-PRGE
+-	O
+stimulated	O
+genes	O
+(	O
+ISGs	O
+)	O
+function	O
+to	O
+induce	O
+an	O
+antiviral	B-CHED
+state	O
+within	O
+the	O
+host	B-COMP
+,	O
+impeding	O
+viral	B-DISO
+pathogenesis	I-DISO
+.	O
+
+The	O
+patient	O
+developed	O
+posttraumatic	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+,	O
+which	O
+began	O
+to	O
+resolve	O
+after	O
+72	O
+hours	O
+,	O
+and	O
+he	O
+started	O
+breathing	B-PROC
+spontaneously	O
+.	O
+
+After	O
+7	O
+days	O
+,	O
+he	O
+was	O
+weaned	B-PROC
+from	O
+vv	O
+-	O
+ECMO	O
+and	O
+recovered	O
+in	O
+a	O
+rehabilitation	O
+facility	O
+.	O
+
+Additionally	O
+,	O
+microarray	O
+analysis	O
+showed	O
+that	O
+genes	O
+associated	O
+with	O
+chemotaxis	B-PROC
+,	O
+eosinophil	B-PROC
+migration	B-PROC
+,	O
+eosinophilia	B-DISO
+,	O
+and	O
+cell	B-PROC
+movement	I-PROC
+and	O
+the	O
+polarization	O
+of	O
+Th2	B-ANAT
+cells	I-ANAT
+were	O
+upregulated	O
+in	O
+UV	O
+-	O
+V	O
+-	O
+immunized	O
+but	O
+not	O
+in	O
+UV	O
+-	O
+V	O
++	O
+TLR	O
+-	O
+immunized	O
+mice	B-SPEC
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+vaccine	O
+-	O
+induced	O
+eosinophil	B-ANAT
+immunopathology	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+upon	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+could	O
+be	O
+avoided	O
+by	O
+the	O
+TLR	O
+agonist	B-CHED
+adjuvants	B-CHED
+.	O
+
+Inactivated	O
+whole	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+-	I-SPEC
+related	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+vaccines	O
+induce	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+mouse	B-SPEC
+models	O
+;	O
+however	O
+,	O
+they	O
+also	O
+cause	O
+increased	O
+eosinophilic	O
+immunopathology	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+upon	O
+SARS	B-DISO
+-	O
+CoV	O
+challenge	O
+.	O
+
+Compounds	O
+were	O
+assayed	O
+on	O
+these	O
+enzyme	O
+activities	O
+,	O
+which	O
+highlighted	O
+dual	O
+inhibition	B-PROC
+properties	O
+in	O
+the	O
+low	O
+-	O
+micromolar	O
+range	O
+.	O
+
+Since	O
+PLUS	O
+is	O
+readily	O
+available	O
+,	O
+easily	O
+affordable	O
+,	O
+and	O
+biologically	O
+non	O
+-	O
+invasive	O
+,	O
+it	O
+is	O
+especially	O
+suitable	O
+for	O
+bedside	O
+clinical	O
+care	O
+in	O
+critically	B-DISO
+ill	I-DISO
+and	O
+unstable	O
+adult	O
+patients	O
+.	O
+
+After	O
+surgery	O
+,	O
+he	O
+developed	O
+a	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+extra	O
+-	O
+corporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+treatment	O
+was	O
+started	O
+.	O
+
+PLUS	O
+was	O
+performed	O
+daily	O
+to	O
+monitor	O
+the	O
+disease	O
+'	O
+s	O
+progression	O
+and	O
+response	O
+to	O
+treatment	O
+during	O
+lung	B-ANAT
+rest	B-FUNC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+emergence	O
+of	O
+zoonotic	O
+diseases	O
+such	O
+as	O
+Highly	O
+Pathogenic	O
+Avian	B-DISO
+Influenza	I-DISO
+(	O
+HPAI	B-FUNC
+)	O
+and	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+have	O
+contributed	O
+to	O
+dominant	O
+Global	O
+Health	O
+narratives	O
+around	O
+health	O
+securitisation	O
+and	O
+pandemic	O
+preparedness	O
+,	O
+calling	O
+for	O
+greater	O
+co	O
+-	O
+operation	O
+between	O
+the	O
+health	O
+,	O
+veterinary	O
+and	O
+environmental	O
+sectors	O
+in	O
+the	O
+ever	O
+-	O
+evolving	O
+One	O
+Health	O
+movement	B-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+3	O
+'-	O
+terminal	O
+55	O
+nucleotides	B-CHED
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+defective	O
+interfering	O
+RNA	O
+harbor	O
+cis	B-DISO
+-	O
+acting	O
+elements	O
+required	O
+for	O
+both	O
+negative	O
+-	O
+and	O
+positive	O
+-	O
+strand	O
+RNA	O
+synthesis	O
+.	O
+
+Here	O
+,	O
+we	O
+employed	O
+a	O
+method	O
+of	O
+head	B-ANAT
+-	O
+to	O
+-	O
+tail	O
+ligation	O
+and	O
+real	O
+-	O
+time	O
+quantitative	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+to	O
+detect	O
+and	O
+quantitate	O
+the	O
+synthesis	B-PROC
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+defective	O
+interfering	O
+(	O
+DI	O
+)	O
+RNA	O
+(-)	O
+strands	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+are	O
+a	O
+major	O
+cause	O
+of	O
+outpatient	O
+visits	O
+,	O
+yet	O
+only	O
+a	O
+portion	O
+is	O
+tested	O
+to	O
+determine	O
+the	O
+etiologic	O
+organism	O
+.	O
+
+No	O
+virus	B-SPEC
+was	O
+identified	O
+in	O
+267	O
+(	O
+40	O
+.	O
+3	O
+%)	O
+samples	O
+.	O
+
+In	O
+regression	O
+analyses	O
+,	O
+compared	O
+with	O
+non	O
+-	O
+viral	O
+illnesses	O
+,	O
+RSV	B-SPEC
+and	O
+hMPV	B-SPEC
+were	O
+significantly	O
+more	O
+frequent	O
+in	O
+children	O
+and	O
+less	O
+frequent	O
+in	O
+18	O
+-	O
+to	O
+49	O
+-	O
+year	O
+-	O
+olds	O
+than	O
+in	O
+those	O
+≥	O
+50	O
+years	O
+(	O
+P	O
+=	O
+0	O
+.	O
+01	O
+),	O
+fever	B-PROC
+was	O
+more	O
+common	O
+in	O
+hMPV	B-SPEC
+and	O
+influenza	B-DISO
+infections	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+008	O
+),	O
+nasal	B-DISO
+congestion	I-DISO
+was	O
+more	O
+frequent	O
+in	O
+CoV	O
+,	O
+HRV	O
+,	O
+hMPV	B-SPEC
+,	O
+influenza	B-DISO
+and	O
+RSV	B-DISO
+infections	I-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+),	O
+and	O
+body	B-ANAT
+mass	O
+index	O
+was	O
+higher	O
+among	O
+those	O
+with	O
+influenza	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+036	O
+).	O
+
+ABSTRACT	O
+:	O
+Since	O
+about	O
+a	O
+year	O
+,	O
+a	O
+new	O
+pulmonary	B-ANAT
+pathology	I-DISO
+occurred	O
+in	O
+Saudi	O
+Arabia	O
+and	O
+some	O
+cases	O
+are	O
+imported	O
+in	O
+Europa	O
+.	O
+
+Rhinovirus	B-SPEC
+C	O
+and	O
+human	B-PRGE
+bocavirus	I-PRGE
+type	I-PRGE
+1	I-PRGE
+have	O
+been	O
+commonly	O
+detected	O
+in	O
+infants	O
+and	O
+young	O
+children	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+and	O
+studies	O
+have	O
+shown	O
+a	O
+positive	O
+correlation	O
+between	O
+respiratory	O
+illness	O
+and	O
+high	O
+viral	O
+loads	O
+,	O
+mono	B-DISO
+-	O
+infection	B-DISO
+,	O
+viremia	B-DISO
+,	O
+and	O
+/	O
+or	O
+serologically	O
+-	O
+confirmed	O
+primary	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+level	O
+of	O
+social	O
+contact	O
+on	O
+dairy	O
+calf	B-ANAT
+behavior	O
+and	O
+health	O
+.	O
+
+No	O
+effect	O
+of	O
+treatment	O
+was	O
+found	O
+for	O
+clinical	O
+scores	O
+,	O
+levels	O
+of	O
+the	O
+5	O
+most	O
+common	O
+pathogens	O
+in	O
+feces	B-ANAT
+,	O
+or	O
+in	O
+development	B-PROC
+of	O
+serum	B-COMP
+antibodies	B-COMP
+against	O
+the	O
+3	O
+most	O
+common	O
+respiratory	O
+pathogens	O
+.	O
+
+Mild	O
+and	O
+moderate	O
+cases	O
+can	O
+be	O
+efficiently	O
+treated	O
+by	O
+NIV	O
+,	O
+but	O
+this	O
+is	O
+contra	O
+-	O
+indicated	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Therefore	O
+,	O
+we	O
+developed	O
+a	O
+cost	O
+-	O
+effective	O
+and	O
+compact	O
+(	O
+2	O
+.	O
+9	O
+×	O
+5	O
+.	O
+8	O
+×	O
+2	O
+.	O
+0	O
+cm	O
+)	O
+thermopile	O
+array	O
+for	O
+fever	B-PROC
+screening	O
+of	O
+patients	O
+with	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+the	O
+clinical	O
+setting	O
+.	O
+
+The	O
+maximum	O
+facial	B-ANAT
+temperature	O
+,	O
+measured	O
+by	O
+the	O
+array	O
+at	O
+0	O
+.	O
+3	O
+m	O
+from	O
+the	O
+subject	O
+,	O
+exhibited	O
+a	O
+positive	O
+correlation	O
+with	O
+axillary	B-ANAT
+temperature	O
+measured	O
+using	O
+a	O
+contact	O
+-	O
+type	O
+thermometer	O
+(	O
+r	O
+=	O
+0	O
+.	O
+71	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+the	O
+thermopile	O
+array	O
+in	O
+identifying	O
+the	O
+febrile	B-PROC
+subjects	O
+were	O
+80	O
+.	O
+5	O
+%	O
+and	O
+93	O
+.	O
+3	O
+%,	O
+respectively	O
+,	O
+setting	O
+the	O
+threshold	O
+cut	O
+-	O
+off	O
+of	O
+maximum	O
+facial	B-ANAT
+temperature	O
+at	O
+an	O
+appropriate	O
+value	O
+.	O
+
+The	O
+emergence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	I-DISO
+(	O
+HPAI	B-FUNC
+)	O
+H5N1	B-DISO
+,	O
+avian	B-DISO
+influenza	I-DISO
+H7N9	O
+,	O
+and	O
+severe	O
+fever	B-PROC
+with	O
+thrombocytopenia	O
+syndrome	B-DISO
+(	O
+SFTS	O
+),	O
+and	O
+the	O
+re	O
+-	O
+emergence	O
+of	O
+rabies	B-DISO
+,	O
+brucellosis	B-DISO
+,	O
+and	O
+other	O
+zoonoses	B-DISO
+have	O
+had	O
+a	O
+significant	O
+effect	O
+on	O
+the	O
+national	O
+economy	O
+and	O
+public	O
+health	O
+in	O
+China	O
+,	O
+and	O
+have	O
+affected	O
+other	O
+countries	O
+.	O
+
+α	B-PRGE
+-	I-PRGE
+Fodrin	I-PRGE
+protein	I-PRGE
+was	O
+used	O
+for	O
+further	O
+analysis	O
+and	O
+western	O
+blot	O
+reactivity	O
+was	O
+seen	O
+only	O
+in	O
+sera	B-COMP
+from	O
+virus	B-SPEC
+infected	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+These	O
+studies	O
+clearly	O
+identified	O
+both	O
+antibody	B-COMP
+and	O
+CD4	B-PRGE
+T	I-PRGE
+cell	O
+reactivities	O
+to	O
+α	O
+-	O
+fodrin	O
+in	O
+sera	B-COMP
+from	O
+virus	B-SPEC
+infected	O
+,	O
+retinal	B-CHED
+degenerative	B-DISO
+susceptible	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+group	B-DISO
+B	I-DISO
+Betacoronavirus	B-SPEC
+infection	B-DISO
+in	O
+little	B-SPEC
+Japanese	I-SPEC
+horseshoe	I-SPEC
+bats	I-SPEC
+in	O
+Iwate	O
+prefecture	O
+.	O
+
+Pathogenic	O
+trait	O
+of	O
+these	O
+bat	B-ENZY
+coronaviruses	O
+remained	O
+unexplored	O
+.	O
+
+ABSTRACT	O
+:	O
+Various	O
+infections	B-DISO
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+trigger	O
+B	B-ANAT
+cell	I-ANAT
+accumulation	O
+;	O
+however	O
+,	O
+the	O
+relative	O
+dynamics	O
+between	O
+viral	B-PROC
+replication	I-PROC
+and	O
+alterations	O
+in	O
+distinct	O
+B	B-ANAT
+cell	I-ANAT
+subsets	O
+are	O
+largely	O
+unknown	O
+.	O
+
+Using	O
+a	O
+glia	B-SPEC
+-	O
+tropic	O
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+which	O
+is	O
+initiated	O
+in	O
+the	O
+brain	B-ANAT
+but	O
+rapidly	O
+spreads	O
+to	O
+and	O
+predominantly	O
+persists	O
+in	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+,	O
+this	O
+study	O
+characterizes	O
+longitudinal	O
+changes	O
+in	O
+B	B-ANAT
+cell	I-ANAT
+subsets	O
+at	O
+both	O
+infected	O
+anatomical	B-ANAT
+sites	I-ANAT
+.	O
+
+Moreover	O
+,	O
+CNS	B-CHED
+viral	O
+persistence	O
+is	O
+a	O
+driving	O
+force	O
+promoting	O
+differentiated	B-PROC
+B	B-ANAT
+cells	I-ANAT
+with	O
+protective	O
+potential	O
+.	O
+
+A	O
+detailed	O
+analysis	O
+revealed	O
+that	O
+the	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+targets	O
+TBK1	B-FUNC
+by	O
+direct	O
+interaction	O
+and	O
+that	O
+this	O
+binding	B-FUNC
+sequesters	O
+the	O
+association	O
+between	O
+TBK1	B-FUNC
+and	O
+IRF3	B-PRGE
+,	O
+which	O
+in	O
+turn	O
+inhibits	O
+both	O
+IRF3	B-PRGE
+activation	O
+and	O
+type	B-PROC
+I	I-PROC
+IFN	I-PROC
+production	I-PROC
+.	O
+
+Together	O
+,	O
+our	O
+findings	O
+demonstrate	O
+a	O
+new	O
+mechanism	O
+evolved	O
+by	O
+PEDV	B-SPEC
+to	O
+circumvent	O
+the	O
+host	B-COMP
+'	O
+s	O
+antiviral	B-CHED
+immunity	B-PROC
+.	O
+
+This	O
+adds	O
+another	O
+layer	B-ANAT
+of	O
+complexity	O
+to	O
+the	O
+immune	B-PROC
+evasion	I-PROC
+strategies	O
+evolved	O
+by	O
+this	O
+economically	O
+important	O
+viral	O
+pathogen	O
+.	O
+
+TITLE	O
+:	O
+Targeting	B-PROC
+membrane	B-COMP
+-	O
+bound	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+reveals	O
+potent	O
+inhibition	B-PROC
+of	O
+diverse	O
+coronaviruses	O
+including	O
+the	O
+middle	O
+East	O
+respiratory	O
+syndrome	O
+virus	B-SPEC
+.	O
+
+Collectively	O
+,	O
+this	O
+study	O
+proposes	O
+an	O
+evolutionary	O
+conserved	O
+step	O
+in	O
+the	O
+life	O
+cycle	O
+of	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+,	O
+the	O
+recruitment	B-DISO
+of	O
+cellular	B-COMP
+membranes	B-ANAT
+for	O
+viral	B-PROC
+replication	I-PROC
+,	O
+as	O
+vulnerable	O
+and	O
+,	O
+most	O
+importantly	O
+,	O
+druggable	O
+target	O
+for	O
+antiviral	B-CHED
+intervention	O
+.	O
+
+TITLE	O
+:	O
+The	O
+first	O
+reported	O
+case	O
+of	O
+ureteral	O
+perforation	O
+in	O
+a	O
+patient	O
+with	O
+severe	O
+toxic	B-DISO
+epidermal	B-ANAT
+necrolysis	I-DISO
+syndrome	O
+.	O
+
+There	O
+have	O
+been	O
+descriptions	O
+of	O
+gastrointestinal	O
+,	O
+respiratory	O
+,	O
+vaginal	O
+,	O
+and	O
+ocular	B-PROC
+mucosal	B-ANAT
+involvement	O
+,	O
+including	O
+cases	O
+of	O
+corneal	O
+and	O
+colonic	B-ANAT
+perforation	O
+.	O
+
+ABSTRACT	O
+:	O
+Prone	O
+positioning	O
+has	O
+been	O
+used	O
+for	O
+many	O
+years	O
+in	O
+patients	O
+with	O
+acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+with	O
+no	O
+clear	O
+benefit	O
+for	O
+patient	O
+outcome	O
+.	O
+
+Meta	B-SPEC
+-	O
+analyses	O
+have	O
+suggested	O
+better	O
+survival	O
+in	O
+patients	O
+with	O
+an	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+(	O
+PaO2	O
+)/	O
+inspiratory	B-PROC
+oxygen	B-CHED
+fraction	O
+(	O
+FIO2	O
+)	O
+ratio	O
+<	O
+100	O
+mmHg	O
+.	O
+
+The	O
+aims	O
+of	O
+this	O
+article	O
+are	O
+to	O
+discuss	O
+:	O
+the	O
+rationale	O
+of	O
+prone	O
+positioning	O
+in	O
+patients	O
+with	O
+ALI	O
+/	O
+ARDS	O
+;	O
+the	O
+evidence	O
+of	O
+its	O
+use	O
+based	O
+on	O
+trial	O
+analysis	O
+;	O
+and	O
+the	O
+limitations	O
+of	O
+its	O
+use	O
+as	O
+well	O
+as	O
+the	O
+current	O
+place	O
+of	O
+prone	O
+positioning	O
+in	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Whereas	O
+resolution	O
+of	O
+alveolar	B-DISO
+edema	I-DISO
+in	O
+cardiogenic	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+can	O
+be	O
+rapid	O
+,	O
+the	O
+rate	O
+of	O
+edema	B-DISO
+resolution	O
+in	O
+most	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+markedly	O
+impaired	B-DISO
+,	O
+a	O
+finding	O
+that	O
+correlates	O
+with	O
+higher	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Tribulus	O
+terrestris	O
+fruits	O
+are	O
+well	O
+known	O
+for	O
+their	O
+usage	O
+in	O
+pharmaceutical	B-CHED
+preparations	O
+and	O
+food	O
+supplements	O
+.	O
+
+ABSTRACT	O
+:	O
+Activin	B-PROC
+A	O
+and	O
+its	O
+binding	B-FUNC
+protein	B-CHED
+follistatin	B-PRGE
+(	O
+FS	O
+)	O
+are	O
+increased	O
+in	O
+inflammatory	O
+disorders	O
+and	O
+sepsis	B-DISO
+.	O
+
+Our	O
+aim	O
+was	O
+to	O
+evaluate	O
+the	O
+levels	O
+of	O
+activin	B-PRGE
+A	I-PRGE
+,	O
+activin	B-PRGE
+B	I-PRGE
+,	O
+FS	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+their	O
+association	O
+with	O
+the	O
+severity	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+H1N1	O
+patients	O
+.	O
+
+No	O
+difference	O
+in	O
+baseline	O
+or	O
+highest	O
+activin	B-PRGE
+A	I-PRGE
+or	O
+activin	B-PRGE
+B	I-PRGE
+was	O
+found	O
+in	O
+patients	O
+with	O
+or	O
+without	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+or	O
+ARDS	B-DISO
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+for	O
+all	O
+).	O
+
+We	O
+have	O
+previously	O
+reported	O
+that	O
+antibodies	B-COMP
+elicited	O
+by	O
+a	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+candidate	O
+based	O
+on	O
+recombinant	O
+,	O
+full	O
+-	O
+length	O
+SARS	B-DISO
+-	O
+CoV	O
+Spike	O
+-	O
+protein	B-CHED
+trimers	O
+,	O
+trigger	O
+infection	B-DISO
+of	O
+immune	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+Macrophages	B-ANAT
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+however	O
+,	O
+did	O
+not	O
+support	O
+productive	O
+replication	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Purified	O
+anti	O
+-	O
+viral	O
+IgGs	O
+,	O
+but	O
+not	O
+other	O
+soluble	O
+factor	O
+(	O
+s	O
+)	O
+from	O
+heat	O
+-	O
+inactivated	O
+mouse	B-SPEC
+immune	O
+serum	B-COMP
+,	O
+were	O
+sufficient	O
+to	O
+enhance	O
+infection	B-DISO
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+human	B-SPEC
+macrophages	B-ANAT
+can	O
+be	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+as	O
+a	O
+result	O
+of	O
+IgG	B-PRGE
+-	O
+mediated	O
+ADE	B-CHED
+and	O
+indicate	O
+that	O
+this	O
+infection	B-DISO
+route	O
+requires	O
+signaling	B-PROC
+pathways	B-PROC
+activated	O
+downstream	O
+of	O
+binding	B-FUNC
+to	O
+FcγRII	O
+receptors	O
+.	O
+
+Furthermore	O
+,	O
+only	O
+FcγRII	O
+with	O
+intact	O
+cytoplasmic	B-COMP
+signaling	B-PROC
+domains	O
+were	O
+competent	O
+to	O
+sustain	O
+ADE	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoVpp	O
+infection	B-DISO
+,	O
+thus	O
+providing	O
+additional	O
+information	O
+on	O
+the	O
+role	O
+of	O
+downstream	O
+signaling	B-PROC
+by	O
+FcγRII	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+an	O
+immune	O
+-	O
+mediated	O
+,	O
+highly	O
+lethal	O
+disease	O
+caused	O
+by	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+infection	B-DISO
+.	O
+
+Since	O
+cellular	B-PROC
+immunity	I-PROC
+is	O
+thought	O
+to	O
+be	O
+critical	O
+in	O
+preventing	O
+FIP	B-DISO
+and	O
+because	O
+diseased	O
+cats	B-SPEC
+often	O
+show	O
+a	O
+significant	O
+decrease	O
+in	O
+interferon	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+)	O
+production	O
+,	O
+we	O
+investigated	O
+whether	O
+single	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+(	O
+SNP	O
+)	O
+in	O
+the	O
+feline	B-SPEC
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+gene	I-PRGE
+(	O
+fIFNG	O
+)	O
+are	O
+associated	O
+with	O
+the	O
+outcome	O
+of	O
+infection	B-DISO
+.	O
+
+On	O
+the	O
+Thai	O
+-	O
+Myanmar	O
+border	B-ANAT
+,	O
+all	O
+pregnant	O
+women	O
+are	O
+followed	O
+systematically	O
+with	O
+active	O
+weekly	O
+malaria	B-PATH
+screening	O
+.	O
+
+Over	O
+a	O
+27	O
+-	O
+year	O
+period	O
+of	O
+providing	O
+antenatal	O
+care	O
+,	O
+48	O
+,	O
+983	O
+have	O
+been	O
+prospectively	O
+followed	O
+until	O
+pregnancy	O
+outcome	O
+(	O
+miscarriage	B-DISO
+or	O
+delivery	O
+)	O
+and	O
+4	O
+,	O
+298	O
+women	O
+have	O
+had	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+detected	O
+at	O
+least	O
+once	O
+.	O
+
+The	O
+patient	O
+had	O
+a	O
+low	O
+body	B-ANAT
+mass	O
+index	O
+.	O
+
+Sensitive	O
+detection	O
+with	O
+nested	O
+PCR	O
+confirmed	O
+only	O
+the	O
+presence	O
+of	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+species	B-SPEC
+and	O
+concomitant	O
+infections	B-DISO
+such	O
+as	O
+tuberculosis	B-PATH
+and	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+were	O
+also	O
+ruled	O
+out	O
+.	O
+
+PP	O
+reduced	O
+mortality	O
+among	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+patients	O
+receiving	O
+relatively	O
+high	O
+PEEP	B-CHED
+levels	O
+.	O
+
+These	O
+results	O
+may	O
+also	O
+guide	O
+future	O
+acute	O
+lung	B-ANAT
+injury	O
+preclinical	O
+and	O
+clinical	O
+research	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+reduction	O
+in	O
+cell	B-COMP
+numbers	O
+in	O
+the	O
+spleens	B-ANAT
+of	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+after	O
+infection	B-DISO
+was	O
+not	O
+observed	O
+in	O
+the	O
+infected	O
+Fut9	B-PRGE
+(-/-)	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+IL	B-PRGE
+-	I-PRGE
+27	I-PRGE
+limits	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+viral	O
+clearance	O
+by	O
+promoting	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+enhances	O
+demyelination	B-DISO
+.	O
+
+Nevertheless	O
+,	O
+IL	O
+-	O
+27Rα	O
+(-/-)	O
+mice	B-SPEC
+exhibited	O
+decreased	O
+clinical	O
+disease	O
+during	O
+persistence	O
+,	O
+coincident	O
+with	O
+less	O
+severe	O
+demyelination	B-DISO
+,	O
+the	O
+hallmark	O
+tissue	B-ANAT
+damage	O
+associated	O
+with	O
+JHMV	O
+infection	B-DISO
+.	O
+
+Following	O
+the	O
+injury	O
+,	O
+sheep	B-SPEC
+were	O
+ventilated	O
+,	O
+resuscitated	O
+with	O
+lactated	O
+Ringer	O
+'	O
+s	O
+solution	O
+and	O
+studied	O
+for	O
+24	O
+h	O
+.	O
+The	O
+sheep	B-SPEC
+were	O
+randomly	O
+allocated	O
+to	O
+receive	O
+one	O
+of	O
+the	O
+following	O
+treatments	O
+intravenously	O
+over	O
+1	O
+h	O
+in	O
+one	O
+of	O
+the	O
+following	O
+groups	O
+:	O
+(	O
+1	O
+)	O
+control	O
+,	O
+PlasmaLyte	O
+A	O
+,	O
+n	O
+=	O
+8	O
+;	O
+(	O
+2	O
+)	O
+lower	O
+dose	O
+hMSCs	O
+,	O
+5	O
+×	O
+10	O
+(	O
+6	O
+)	O
+hMSCs	O
+/	O
+kg	O
+,	O
+n	O
+=	O
+7	O
+;	O
+and	O
+(	O
+3	O
+)	O
+higher	O
+-	O
+dose	O
+hMSCs	O
+,	O
+10	O
+×	O
+10	O
+(	O
+6	O
+)	O
+hMSCs	O
+/	O
+kg	O
+,	O
+n	O
+=	O
+4	O
+.	O
+
+The	O
+hMSCs	O
+had	O
+no	O
+adverse	B-DISO
+effects	I-DISO
+.	O
+
+Early	O
+recognition	O
+of	O
+the	O
+clinical	O
+symptoms	O
+allow	O
+the	O
+clinician	O
+to	O
+identify	O
+the	O
+syndrome	B-DISO
+and	O
+to	O
+undertake	O
+therapeutic	O
+measures	O
+that	O
+may	O
+reduce	O
+the	O
+morbidity	O
+and	O
+mortality	O
+associated	O
+with	O
+this	O
+complication	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+late	O
+2013	O
+,	O
+several	O
+outbreaks	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+infection	B-DISO
+have	O
+emerged	O
+in	O
+Taiwan	O
+.	O
+
+A	O
+total	O
+of	O
+68	O
+samples	O
+from	O
+25	O
+pig	B-SPEC
+farms	O
+were	O
+confirmed	O
+as	O
+positive	O
+for	O
+PEDV	B-SPEC
+and	O
+negative	O
+for	O
+rotavirus	B-SPEC
+and	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+by	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+,	O
+and	O
+the	O
+partial	O
+S	O
+gene	O
+of	O
+PEDV	B-SPEC
+was	O
+analyzed	O
+.	O
+
+ABSTRACT	O
+:	O
+Transplantation	O
+of	O
+major	B-PROC
+histocompatibility	I-PROC
+complex	I-PROC
+-	O
+mismatched	O
+mouse	B-SPEC
+neural	O
+precursor	O
+cells	B-COMP
+(	O
+NPCs	O
+)	O
+into	O
+mice	B-SPEC
+persistently	O
+infected	O
+with	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+results	O
+in	O
+rapid	O
+rejection	O
+that	O
+is	O
+mediated	O
+,	O
+in	O
+part	O
+,	O
+by	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+However	O
+,	O
+the	O
+contribution	O
+of	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+to	O
+allograft	B-PATH
+rejection	I-PATH
+in	O
+a	O
+model	O
+of	O
+viral	O
+-	O
+induced	O
+neurological	B-DISO
+disease	I-DISO
+has	O
+not	O
+been	O
+well	O
+defined	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+highly	O
+pathogenic	O
+human	O
+coronavirus	O
+(	O
+CoV	B-SPEC
+),	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	B-SPEC
+),	O
+has	O
+emerged	O
+in	O
+Jeddah	O
+and	O
+Saudi	O
+Arabia	O
+and	O
+quickly	O
+spread	O
+to	O
+some	O
+European	O
+countries	O
+since	O
+September	O
+2012	O
+.	O
+
+Circular	O
+dichroism	O
+and	O
+Tyr	B-CHED
+/	O
+Trp	B-ENZY
+fluorescence	O
+analyses	O
+indicated	O
+that	O
+the	O
+secondary	O
+and	O
+tertiary	O
+structure	O
+of	O
+MERS	O
+-	O
+CoV	O
+PLpro	O
+is	O
+well	O
+organized	O
+and	O
+folded	O
+.	O
+
+RESULTS	O
+:	O
+Circular	O
+dichroism	O
+and	O
+Tyr	B-CHED
+/	O
+Trp	B-ENZY
+fluorescence	O
+analyses	O
+indicated	O
+that	O
+the	O
+secondary	O
+and	O
+tertiary	O
+structure	O
+of	O
+MERS	O
+-	O
+CoV	O
+PLpro	O
+is	O
+well	O
+organized	O
+and	O
+folded	O
+.	O
+
+Etiological	O
+categories	O
+were	O
+primary	B-DISO
+infection	I-DISO
+-	O
+related	O
+ARDS	B-DISO
+(	O
+n	O
+=	O
+662	O
+,	O
+65	O
+.	O
+9	O
+%;	O
+385	O
+bacterial	B-DISO
+infections	I-DISO
+,	O
+213	O
+invasive	B-DISO
+aspergillosis	I-DISO
+,	O
+64	O
+Pneumocystis	B-DISO
+pneumonia	I-DISO
+);	O
+extrapulmonary	O
+septic	B-DISO
+shock	I-DISO
+-	O
+related	O
+ARDS	B-DISO
+(	O
+n	O
+=	O
+225	O
+,	O
+22	O
+.	O
+4	O
+%;	O
+33	O
+%	O
+candidemia	B-DISO
+);	O
+noninfectious	O
+ARDS	B-DISO
+(	O
+n	O
+=	O
+76	O
+,	O
+7	O
+.	O
+6	O
+%);	O
+and	O
+undetermined	O
+cause	O
+(	O
+n	O
+=	O
+41	O
+,	O
+4	O
+.	O
+1	O
+%).	O
+
+Solid	B-DISO
+tumors	I-DISO
+,	O
+primary	O
+ARDS	B-DISO
+,	O
+and	O
+later	O
+admission	O
+period	O
+were	O
+associated	O
+with	O
+lower	O
+mortality	O
+.	O
+
+Expression	B-PROC
+of	O
+human	B-SPEC
+DPP4	B-PRGE
+in	O
+nonsusceptible	O
+BHK	O
+and	O
+ferret	B-SPEC
+cells	B-COMP
+enabled	O
+MERS	O
+-	O
+CoV	O
+replication	O
+,	O
+whereas	O
+expression	B-PROC
+of	O
+hamster	B-SPEC
+or	O
+ferret	B-SPEC
+DPP4	B-PRGE
+did	O
+not	O
+.	O
+
+Expression	B-PROC
+of	O
+hamster	B-SPEC
+DPP4	B-PRGE
+containing	O
+the	O
+five	O
+human	B-SPEC
+DPP4	O
+amino	B-CHED
+acids	I-CHED
+rendered	O
+BHK	O
+cells	B-COMP
+susceptible	O
+to	O
+MERS	O
+-	O
+CoV	O
+,	O
+whereas	O
+expression	B-PROC
+of	O
+human	B-SPEC
+DPP4	B-PRGE
+containing	O
+the	O
+five	O
+hamster	B-SPEC
+DPP4	O
+amino	B-CHED
+acids	I-CHED
+did	O
+not	O
+.	O
+
+Using	O
+a	O
+combined	O
+modeling	O
+and	O
+experimental	O
+approach	O
+,	O
+we	O
+predict	O
+that	O
+,	O
+based	O
+on	O
+the	O
+ability	O
+of	O
+MERS	O
+-	O
+CoV	O
+to	O
+utilize	O
+the	O
+DPP4	B-PRGE
+of	O
+common	O
+Middle	O
+East	O
+livestock	O
+species	B-SPEC
+,	O
+such	O
+as	O
+camels	B-SPEC
+,	O
+goats	B-SPEC
+,	O
+sheep	B-SPEC
+,	O
+and	O
+cows	B-SPEC
+,	O
+these	O
+form	O
+a	O
+potential	O
+MERS	O
+-	O
+CoV	O
+intermediate	O
+host	B-COMP
+reservoir	O
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Diffuse	O
+alveolar	B-ANAT
+haemorrhage	B-DISO
+and	O
+severe	O
+hypoxemia	O
+from	O
+Strongyloides	B-SPEC
+stercoralis	I-SPEC
+hyperinfection	O
+syndrome	O
+.	O
+
+We	O
+discuss	O
+the	O
+clinical	O
+condition	B-DISO
+of	O
+Strongyloides	B-SPEC
+hyperinfection	O
+syndrome	B-DISO
+presenting	O
+with	O
+severe	O
+hypoxemia	O
+and	O
+complicated	O
+by	O
+severe	O
+diffuse	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+leading	O
+to	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Genetic	O
+variation	O
+between	O
+diverse	O
+mouse	B-SPEC
+species	B-SPEC
+is	O
+well	O
+-	O
+characterized	O
+,	O
+yet	O
+existing	O
+knowledge	O
+of	O
+the	O
+mouse	B-SPEC
+transcriptome	O
+comes	O
+largely	O
+from	O
+one	O
+mouse	B-SPEC
+strain	O
+(	O
+C57BL	O
+/	O
+6J	O
+).	O
+
+Of	O
+these	O
+novel	O
+transcripts	O
+,	O
+2150	O
+could	O
+be	O
+aligned	O
+to	O
+human	O
+or	O
+rat	B-SPEC
+genomes	O
+,	O
+but	O
+not	O
+to	O
+existing	O
+mouse	B-SPEC
+genomes	O
+,	O
+suggesting	O
+functionally	O
+conserved	O
+sequences	O
+not	O
+yet	O
+recorded	O
+in	O
+mouse	B-SPEC
+genomes	O
+.	O
+
+Host	B-COMP
+genetic	O
+variation	O
+drives	O
+the	O
+complexity	O
+and	O
+diversity	O
+of	O
+the	O
+host	B-PROC
+response	I-PROC
+by	O
+eliciting	O
+starkly	O
+different	O
+transcriptional	B-PROC
+profiles	O
+in	O
+response	O
+to	O
+a	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Due	O
+to	O
+its	O
+coordinatively	O
+unsaturated	O
+[	O
+Cu	O
+(	O
+Phen	B-CHED
+)](+)	O
+sites	O
+the	O
+dimeric	O
+iron	O
+complex	O
+is	O
+able	O
+to	O
+serve	O
+as	O
+a	O
+catalyst	B-CHED
+in	O
+the	O
+cyclopropanation	O
+of	O
+Z	O
+-	O
+cyclooctene	O
+using	O
+ethyl	B-CHED
+diazoacetate	O
+.	O
+
+Hospital	O
+-	O
+acquired	O
+infection	B-DISO
+and	O
+community	B-DISO
+-	I-DISO
+acquired	I-DISO
+infection	I-DISO
+are	O
+both	O
+possible	O
+.	O
+
+In	O
+the	O
+subgroup	O
+of	O
+viral	O
+exclusive	O
+infection	B-DISO
+,	O
+the	O
+mean	O
+age	O
+of	O
+severe	O
+cases	O
+was	O
+2	O
+.	O
+0	O
+years	O
+vs	O
+3	O
+.	O
+8	O
+years	O
+in	O
+mild	O
+and	O
+moderate	O
+cases	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Clinical	O
+data	O
+and	O
+laboratory	O
+findings	O
+including	O
+autoantibodies	O
+,	O
+immunoglobulin	B-PROC
+levels	O
+as	O
+well	O
+as	O
+number	O
+of	O
+T	O
+,	O
+B	O
+and	O
+NK	B-ANAT
+cells	I-ANAT
+were	O
+evaluated	O
+.	O
+
+Two	O
+cousins	O
+of	O
+PI	O
+had	O
+the	O
+same	O
+hypomorphic	O
+splice	O
+site	O
+mutation	O
+leading	O
+to	O
+a	O
+deletion	O
+of	O
+27	O
+amino	B-CHED
+acids	I-CHED
+,	O
+but	O
+normal	O
+FOXP3	B-PRGE
+protein	I-PRGE
+expression	B-PROC
+and	O
+normal	O
+suppressive	O
+capacity	O
+of	O
+T	B-PRGE
+reg	I-PRGE
+in	O
+a	O
+proliferation	B-DISO
+inhibition	B-PROC
+assay	O
+.	O
+
+Patient	O
+IV	O
+from	O
+another	O
+family	B-SPEC
+presented	O
+with	O
+chronic	B-DISO
+diarrhea	I-DISO
+without	O
+autoimmune	B-DISO
+manifestations	O
+and	O
+died	B-PROC
+due	O
+to	O
+ARDS	B-DISO
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+describe	O
+the	O
+chest	O
+CT	O
+findings	O
+in	O
+seven	O
+patients	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+The	O
+subpleural	O
+and	O
+peribronchovascular	O
+predilection	O
+of	O
+the	O
+abnormalities	O
+is	O
+suggestive	O
+of	O
+an	O
+organizing	B-DISO
+pneumonia	I-DISO
+pattern	O
+.	O
+
+We	O
+sought	O
+to	O
+corroborate	O
+our	O
+findings	O
+using	O
+data	O
+from	O
+a	O
+different	O
+trial	O
+of	O
+higher	O
+PEEP	B-CHED
+(	O
+ExPress	O
+,	O
+n	O
+=	O
+749	O
+).	O
+
+In	O
+order	B-SPEC
+to	O
+gain	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+epidemiology	O
+of	O
+MERS	O
+CoV	O
+,	O
+further	O
+investigation	O
+is	O
+warranted	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outcome	O
+of	O
+respiratory	B-DISO
+virus	I-DISO
+infection	I-DISO
+is	O
+determined	O
+by	O
+a	O
+complex	O
+interplay	O
+of	O
+viral	O
+and	O
+host	B-COMP
+factors	O
+.	O
+
+Here	O
+we	O
+systematically	O
+inferred	O
+the	O
+regulatory	O
+functions	O
+of	O
+host	B-COMP
+lncRNAs	O
+in	O
+response	O
+to	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+based	O
+on	O
+their	O
+similarity	O
+in	O
+expression	B-PROC
+with	O
+genes	O
+of	O
+known	O
+function	O
+.	O
+
+All	O
+of	O
+them	O
+received	O
+VIPC	O
+plan	B-DISO
+for	O
+early	O
+stage	O
+resuscitation	O
+and	O
+CRASHPLAN	O
+for	O
+further	O
+evaluations	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+ranks	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+RTI	B-DISO
+)	O
+as	O
+the	O
+second	O
+leading	O
+cause	O
+of	O
+death	B-PROC
+worldwide	O
+for	O
+children	O
+under	O
+5	O
+years	O
+of	O
+age	O
+.	O
+
+Human	B-SPEC
+coronavirus	I-SPEC
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+were	O
+the	O
+most	O
+common	O
+pathogens	O
+,	O
+tending	O
+to	O
+occur	O
+in	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Previously	O
+,	O
+we	O
+demonstrated	O
+that	O
+nsp3	B-PRGE
+and	O
+nsp4	B-PRGE
+interact	O
+and	O
+that	O
+their	O
+co	O
+-	O
+expression	B-PROC
+results	O
+in	O
+the	O
+relocalization	O
+of	O
+these	O
+proteins	B-CHED
+from	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+into	O
+discrete	O
+perinuclear	O
+foci	O
+.	O
+
+We	O
+now	O
+show	O
+that	O
+these	O
+foci	O
+correspond	O
+to	O
+areas	O
+of	O
+rearranged	O
+ER	O
+-	O
+derived	O
+membranes	B-ANAT
+,	O
+which	O
+display	O
+increased	O
+membrane	B-COMP
+curvature	O
+.	O
+
+TITLE	O
+:	O
+Differences	O
+in	O
+the	O
+tissue	B-PROC
+tropism	B-PROC
+to	O
+chicken	B-SPEC
+oviduct	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+between	O
+avian	B-SPEC
+coronavirus	I-SPEC
+IBV	B-SPEC
+strains	O
+QX	O
+and	O
+B1648	O
+are	O
+not	O
+related	O
+to	O
+the	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+properties	O
+of	O
+their	O
+spike	O
+proteins	B-CHED
+.	O
+
+We	O
+analysed	O
+infectivity	O
+and	O
+binding	B-FUNC
+properties	O
+of	O
+the	O
+QX	O
+strain	O
+and	O
+compared	O
+them	O
+with	O
+those	O
+of	O
+the	O
+nephropathogenic	O
+strain	O
+B1648	O
+.	O
+
+Binding	B-FUNC
+tests	O
+with	O
+isolated	O
+primary	O
+oviduct	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+soluble	O
+S1	O
+proteins	B-CHED
+revealed	O
+that	O
+S1	O
+proteins	B-CHED
+of	O
+two	O
+IBV	B-SPEC
+strains	O
+bound	O
+with	O
+the	O
+same	O
+efficiency	O
+to	O
+oviduct	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+molecular	O
+assays	O
+detected	O
+53	O
+and	O
+31	O
+CPV	B-SPEC
+-	O
+and	O
+CCoV	O
+-	O
+positive	O
+specimens	O
+,	O
+respectively	O
+,	O
+with	O
+mixed	O
+CPV	B-SPEC
+-	O
+CCoV	O
+infections	B-DISO
+diagnosed	O
+in	O
+28	O
+dogs	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+multiplex	O
+TaqMan	O
+probe	O
+-	O
+based	O
+real	O
+-	O
+time	O
+PCR	O
+for	O
+discrimination	O
+of	O
+variant	O
+and	O
+classical	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+October	O
+2010	O
+,	O
+porcine	B-SPEC
+diarrhea	B-DISO
+outbreaks	O
+have	O
+occurred	O
+widely	O
+,	O
+resulting	O
+in	O
+major	O
+losses	O
+in	O
+suckling	O
+piglets	O
+in	O
+China	O
+.	O
+
+The	O
+multiplex	O
+TaqMan	O
+probe	O
+-	O
+based	O
+real	O
+-	O
+time	O
+PCR	O
+should	O
+be	O
+a	O
+useful	O
+tool	O
+for	O
+quantifying	O
+viral	O
+load	O
+,	O
+detecting	O
+PEDV	B-SPEC
+,	O
+and	O
+differentiating	O
+variant	O
+from	O
+classical	O
+PEDV	B-SPEC
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+briefly	O
+review	O
+and	O
+discuss	O
+the	O
+different	O
+reverse	O
+genetic	O
+systems	O
+developed	O
+for	O
+CoVs	O
+,	O
+paying	O
+special	O
+attention	O
+to	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Identification	O
+of	O
+the	O
+genes	O
+underlying	O
+the	O
+diseases	O
+of	O
+alveolar	B-ANAT
+homeostasis	B-PROC
+is	O
+useful	O
+for	O
+the	O
+diagnosis	O
+of	O
+lung	B-DISO
+disease	I-DISO
+before	O
+and	O
+after	O
+birth	B-PROC
+.	O
+
+Three	O
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+with	O
+AIDS	O
+were	O
+admitted	O
+to	O
+ICU	O
+and	O
+were	O
+treated	O
+with	O
+ECMO	O
+:	O
+a	O
+21	O
+years	O
+old	O
+Caucasian	O
+female	O
+with	O
+congenital	B-DISO
+HIV	I-DISO
+infection	I-DISO
+presented	O
+with	O
+Pneumocystis	B-SPEC
+jirovecii	I-SPEC
+pneumonia	B-DISO
+(	O
+PJP	B-DISO
+);	O
+a	O
+38	O
+years	O
+old	O
+Caucasian	O
+female	O
+with	O
+HIV	B-DISO
+-	O
+HCV	B-SPEC
+infection	B-DISO
+and	O
+L	B-SPEC
+.	I-SPEC
+pneumophila	I-SPEC
+pneumonia	B-DISO
+;	O
+a	O
+24	O
+years	O
+old	O
+Caucasian	O
+male	O
+with	O
+fever	O
+,	O
+cough	B-DISO
+weight	O
+loss	O
+and	O
+PJP	B-DISO
+pneumonia	B-DISO
+.	O
+
+The	O
+last	O
+patient	O
+died	B-PROC
+with	O
+septic	B-DISO
+shock	I-DISO
+after	O
+three	O
+months	O
+of	O
+ICU	O
+stay	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+animals	B-SPEC
+rescued	O
+from	O
+hoarding	O
+frequently	O
+have	O
+a	O
+variety	O
+of	O
+medical	O
+conditions	O
+including	O
+respiratory	B-DISO
+infections	I-DISO
+,	O
+gastrointestinal	B-DISO
+disease	I-DISO
+,	O
+parasitism	B-PROC
+,	O
+malnutrition	B-DISO
+,	O
+and	O
+other	O
+evidence	O
+of	O
+neglect	O
+.	O
+
+Cats	B-SPEC
+were	O
+screened	O
+for	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+(	O
+FeLV	O
+)	O
+and	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+)	O
+in	O
+all	O
+four	O
+cases	O
+and	O
+for	O
+dermatophytosis	B-DISO
+in	O
+one	O
+case	O
+.	O
+
+Several	O
+randomized	O
+clinical	O
+trials	O
+and	O
+observational	O
+studies	O
+suggested	O
+that	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+associated	O
+with	O
+protective	O
+mechanical	O
+ventilation	O
+could	O
+improve	O
+outcome	O
+,	O
+but	O
+its	O
+efficacy	O
+remains	O
+uncertain	O
+.	O
+
+Meta	B-SPEC
+-	O
+analyses	O
+showed	O
+reduced	O
+28	O
+-	O
+day	O
+mortality	O
+with	O
+a	O
+48	O
+-	O
+hour	O
+infusion	O
+of	O
+cis	B-DISO
+-	O
+atracurium	B-CHED
+in	O
+early	O
+ARDS	B-DISO
+(	O
+relative	O
+risk	O
+0	O
+.	O
+66	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+0	O
+.	O
+50	O
+to	O
+0	O
+.	O
+87	O
+;	O
+431	O
+patients	O
+,	O
+138	O
+deaths	B-PROC
+).	O
+
+RESULTS	O
+:	O
+From	O
+13461	O
+citations	O
+,	O
+58	O
+trials	O
+(	O
+6635	O
+patients	O
+)	O
+of	O
+21	O
+classes	O
+of	O
+medications	O
+met	B-CHED
+selection	O
+criteria	O
+;	O
+26	O
+trials	O
+(	O
+3880	O
+patients	O
+)	O
+were	O
+published	O
+after	O
+2003	O
+.	O
+
+Inflammation	B-DISO
+-	O
+related	O
+gene	B-PROC
+expression	I-PROC
+was	O
+detected	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+,	O
+immunohistochemistry	O
+and	O
+Western	O
+blotting	O
+.	O
+
+Pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+,	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+and	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	O
+)-	O
+α	O
+,	O
+were	O
+also	O
+increased	O
+significantly	O
+at	O
+72	O
+h	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+were	O
+more	O
+often	O
+positive	O
+(	O
+56	O
+.	O
+6	O
+%,	O
+95	O
+%	O
+CI	O
+=	O
+37	O
+.	O
+3	O
+-	O
+72	O
+.	O
+4	O
+)	O
+compared	O
+to	O
+other	O
+groups	O
+(	O
+patients	O
+with	O
+malignant	B-DISO
+disease	I-DISO
+7	O
+.	O
+7	O
+%,	O
+95	O
+%	O
+CI	O
+=	O
+2	O
+.	O
+6	O
+-	O
+20	O
+.	O
+3	O
+;	O
+transplant	O
+patients	O
+7	O
+.	O
+7	O
+%,	O
+95	O
+%	O
+CI	O
+=	O
+2	O
+.	O
+2	O
+-	O
+24	O
+.	O
+1	O
+;	O
+patients	O
+with	O
+other	O
+diagnosis	O
+1	O
+.	O
+5	O
+%,	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+5	O
+-	O
+4	O
+.	O
+4	O
+).	O
+
+Our	O
+results	O
+indicate	O
+that	O
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+still	O
+represents	O
+the	O
+main	O
+risk	O
+group	O
+for	O
+P	B-SPEC
+.	I-SPEC
+jirovecii	I-SPEC
+infection	B-DISO
+.	O
+
+Virus	B-DISO
+infection	I-DISO
+was	O
+observed	O
+in	O
+lung	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+and	O
+brain	B-ANAT
+tissue	I-ANAT
+.	O
+
+RSV	B-SPEC
+was	O
+the	O
+most	O
+common	O
+etiology	O
+(	O
+17	O
+.	O
+0	O
+%)	O
+in	O
+young	O
+children	O
+aged	O
+<	O
+2	O
+years	O
+.	O
+
+All	O
+patients	O
+who	O
+were	O
+managed	O
+with	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+from	O
+1	O
+July	O
+2010	O
+to	O
+30	O
+June	O
+2013	O
+in	O
+the	O
+Intensive	O
+Care	O
+Unit	O
+.	O
+
+Of	O
+these	O
+,	O
+90	O
+.	O
+3	O
+%	O
+(	O
+28	O
+patients	O
+)	O
+presented	O
+with	O
+pneumonia	B-DISO
+as	O
+the	O
+cause	O
+of	O
+the	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+and	O
+22	O
+of	O
+them	O
+had	O
+identifiable	O
+causes	O
+.	O
+
+Among	O
+the	O
+22	O
+patients	O
+who	O
+had	O
+identifiable	O
+infective	O
+causes	O
+,	O
+those	O
+suffering	B-DISO
+from	O
+viral	B-DISO
+infection	I-DISO
+had	O
+lower	O
+intensive	O
+care	O
+unit	O
+and	O
+hospital	O
+mortality	O
+than	O
+those	O
+who	O
+had	O
+bacterial	B-DISO
+infection	I-DISO
+(	O
+8	O
+.	O
+3	O
+%	O
+vs	O
+20	O
+.	O
+0	O
+%).	O
+
+IN	O
+BOTH	B-PRGE
+PATIENTS	I-PRGE
+,	I-PRGE
+CHARACTERISTIC	I-PRGE
+LUNG	B-ANAT
+ULTRASOUND	I-PRGE
+FINDINGS	I-PRGE
+HAVE	I-PRGE
+BEEN	I-PRGE
+OBSERVED	I-PRGE
+AS	I-PRGE
+PREVIOUSLY	I-PRGE
+DESCRIBED	I-PRGE
+IN	I-PRGE
+VIRAL	I-PRGE
+PULMONARY	I-PRGE
+INFECTIONS	I-PRGE
+:	O
+subpleural	O
+consolidations	O
+associated	O
+or	O
+not	O
+with	O
+local	O
+pleural	B-DISO
+effusion	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+numerous	O
+,	O
+confluent	O
+,	O
+or	O
+coalescing	O
+B	O
+-	O
+lines	O
+leading	O
+to	O
+'	O
+white	O
+lung	B-ANAT
+'	O
+with	O
+corresponding	O
+pleural	O
+line	O
+thickening	O
+are	O
+associated	O
+with	O
+ARDS	B-DISO
+.	O
+
+Clinicians	O
+with	O
+access	O
+to	O
+point	O
+-	O
+of	O
+-	O
+care	O
+ultrasonography	O
+may	O
+use	O
+these	O
+findings	O
+as	O
+an	O
+alternative	O
+to	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+or	O
+CT	O
+scan	O
+.	O
+
+Coexisting	O
+consolidated	O
+pneumonia	B-DISO
+with	O
+sonographic	O
+air	B-CHED
+bronchograms	O
+was	O
+noted	O
+in	O
+one	O
+patient	O
+who	O
+did	O
+not	O
+survive	O
+.	O
+
+TITLE	O
+:	O
+Surfactant	B-CHED
+protein	B-CHED
+A	I-PRGE
+genetic	I-PRGE
+variants	I-PRGE
+associate	O
+with	O
+severe	O
+respiratory	B-DISO
+insufficiency	I-DISO
+in	O
+pandemic	O
+influenza	O
+A	O
+virus	B-PROC
+infection	I-PROC
+.	O
+
+The	O
+SFTPA2	B-PRGE
+haplotype	I-PRGE
+1A	I-PRGE
+(	I-PRGE
+1	I-PRGE
+)	I-PRGE
+was	O
+a	O
+protective	O
+variant	O
+.	O
+
+Our	O
+data	O
+suggest	O
+an	O
+effect	O
+of	O
+genetic	O
+variants	O
+of	O
+SFTPA2	B-PRGE
+on	O
+the	O
+severity	O
+of	O
+H1N1pdm	O
+infection	B-DISO
+and	O
+could	O
+pave	O
+the	O
+way	O
+for	O
+a	O
+potential	O
+treatment	O
+with	O
+haplotype	O
+-	O
+specific	O
+(	O
+1A	O
+(	O
+1	O
+))	O
+SP	O
+-	O
+A2	O
+for	O
+future	O
+IAV	O
+pandemics	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+single	O
+nucleotide	B-CHED
+polymorphism	B-PROC
+DNA	O
+microarray	O
+for	O
+the	O
+detection	O
+and	O
+genotyping	O
+of	O
+the	O
+SARS	O
+coronavirus	B-SPEC
+.	O
+
+No	O
+symptom	B-DISO
+was	O
+found	O
+in	O
+his	O
+135	O
+close	O
+contacts	O
+.	O
+
+We	O
+detected	O
+three	O
+PEDV	B-SPEC
+strains	O
+from	O
+ten	O
+small	B-ANAT
+intestine	I-ANAT
+samples	O
+from	O
+piglets	O
+with	O
+acute	B-DISO
+diarrhea	I-DISO
+and	O
+we	O
+determined	O
+the	O
+complete	O
+genome	O
+sequences	O
+of	O
+the	O
+reemerging	O
+Korean	O
+PEDV	B-SPEC
+field	O
+isolates	O
+,	O
+except	O
+for	O
+the	O
+noncoding	O
+regions	O
+from	O
+both	O
+ends	O
+.	O
+
+Specimens	O
+were	O
+tested	O
+by	O
+real	O
+time	O
+RT	O
+-	O
+PCR	O
+for	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+.	O
+Influenza	B-PATH
+A	I-PATH
+-	O
+positive	O
+specimens	O
+were	O
+subtyped	O
+for	O
+H1	O
+,	O
+H3	O
+,	O
+H5	O
+,	O
+and	O
+(	O
+beginning	O
+in	O
+May	O
+2009	O
+)	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+.	O
+
+In	O
+all	O
+,	O
+2	O
+,	O
+378	O
+(	O
+9	O
+.	O
+6	O
+%)	O
+SARI	O
+cases	O
+and	O
+2	O
+,	O
+041	O
+(	O
+14	O
+.	O
+6	O
+%)	O
+ILI	O
+cases	O
+were	O
+positive	O
+for	O
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+The	O
+potential	O
+for	O
+antiviral	B-CHED
+development	B-PROC
+is	O
+currently	O
+hindered	O
+by	O
+a	O
+poor	O
+understanding	O
+of	O
+RNA	O
+-	O
+driven	O
+molecular	O
+mechanisms	O
+,	O
+resulting	O
+from	O
+a	O
+lack	O
+of	O
+structural	O
+information	O
+on	O
+large	O
+RNAs	O
+and	O
+ribonucleoprotein	B-COMP
+complexes	O
+.	O
+
+Ongoing	O
+and	O
+future	O
+work	O
+will	O
+contribute	O
+to	O
+a	O
+more	O
+complete	O
+understanding	O
+of	O
+the	O
+lifecycles	O
+of	O
+retroviruses	B-SPEC
+and	O
+RNA	O
+viruses	B-SPEC
+and	O
+potentially	O
+lead	O
+to	O
+novel	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+RNA	O
+and	O
+neutralising	O
+antibodies	B-COMP
+in	O
+milk	O
+collected	O
+according	O
+to	O
+local	O
+customs	O
+from	O
+dromedary	O
+camels	B-SPEC
+,	O
+Qatar	O
+,	O
+April	O
+2014	O
+.	O
+
+At	O
+one	O
+location	O
+,	O
+evidence	O
+for	O
+active	O
+virus	B-DISO
+shedding	I-DISO
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+and	O
+/	O
+or	O
+faeces	B-ANAT
+was	O
+observed	O
+for	O
+7	O
+/	O
+12	O
+camels	B-SPEC
+;	O
+viral	O
+RNA	O
+was	O
+detected	O
+in	O
+milk	O
+of	O
+five	O
+of	O
+these	O
+seven	O
+camels	B-SPEC
+.	O
+
+No	O
+time	O
+evolution	B-PROC
+of	O
+the	O
+situation	O
+emerges	O
+.	O
+
+A	O
+protocol	O
+-	O
+driven	O
+ventilation	O
+using	O
+goal	O
+-	O
+oriented	O
+structural	O
+programming	O
+was	O
+implemented	O
+and	O
+used	O
+for	O
+4	O
+hours	O
+in	O
+seven	O
+pigs	B-SPEC
+with	O
+lavage	O
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Between	O
+January	O
+2013	O
+and	O
+February	O
+2014	O
+,	O
+we	O
+prospectively	O
+studied	O
+all	O
+patients	O
+with	O
+suspected	O
+clinical	O
+respiratory	B-DISO
+infection	I-DISO
+by	O
+taking	O
+throat	B-ANAT
+swabs	O
+and	O
+performing	O
+a	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+in	O
+search	O
+of	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Utility	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+antibody	B-COMP
+tests	O
+.	O
+
+The	O
+IFAT	O
+and	O
+ELISA	O
+tests	O
+were	O
+best	O
+for	O
+obtaining	O
+an	O
+antibody	B-COMP
+titre	O
+and	O
+for	O
+working	O
+in	O
+the	O
+presence	O
+of	O
+virus	B-SPEC
+.	O
+
+The	O
+most	O
+appropriate	O
+FCoV	O
+antibody	B-COMP
+test	O
+to	O
+use	O
+depends	O
+on	O
+the	O
+reason	O
+for	O
+testing	O
+:	O
+in	O
+excluding	O
+a	O
+diagnosis	O
+of	O
+FIP	B-DISO
+,	O
+sensitivity	O
+,	O
+specificity	O
+,	O
+small	O
+sample	O
+quantity	O
+,	O
+rapidity	O
+and	O
+ability	O
+to	O
+work	O
+in	O
+the	O
+presence	O
+of	O
+virus	B-SPEC
+all	O
+matter	O
+.	O
+
+TITLE	O
+:	O
+Plasmodium	B-SPEC
+vivax	I-SPEC
+malaria	B-PATH
+--	O
+is	O
+it	O
+really	O
+benign	O
+?	O
+
+Public	O
+health	O
+officials	O
+urge	O
+emergency	B-DISO
+personnel	O
+to	O
+pay	O
+strict	O
+attention	O
+to	O
+infection	B-DISO
+control	O
+practices	O
+,	O
+and	O
+to	O
+query	O
+patients	O
+who	O
+present	O
+with	O
+fever	B-PROC
+and	O
+respiratory	B-DISO
+distress	I-DISO
+about	O
+recent	O
+travel	O
+to	O
+the	O
+Arabian	O
+Peninsula	O
+and	O
+/	O
+or	O
+close	O
+contact	O
+with	O
+a	O
+person	O
+who	O
+has	O
+a	O
+confirmed	O
+or	O
+probable	O
+case	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+We	O
+collected	O
+1	O
+,	O
+254	O
+samples	O
+from	O
+patients	O
+diagnosed	O
+with	O
+respiratory	B-DISO
+infection	I-DISO
+in	O
+southern	O
+Thailand	O
+from	O
+July	O
+2009	O
+to	O
+January	O
+2011	O
+and	O
+screened	O
+for	O
+HCoV	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+genotyped	O
+by	O
+BLAST	B-ANAT
+analysis	O
+of	O
+nsp12	B-PRGE
+gene	I-PRGE
+.	O
+
+Since	O
+2012	O
+,	O
+the	O
+Saudi	O
+Ministry	O
+of	O
+Health	O
+(	O
+MoH	O
+)	O
+has	O
+required	O
+screening	O
+for	O
+MERS	O
+-	O
+CoV	O
+for	O
+all	O
+cases	O
+of	O
+severe	O
+pneumonia	B-DISO
+requiring	O
+hospitalization	O
+.	O
+
+Of	O
+these	O
+,	O
+bacterial	O
+pathogens	O
+were	O
+detected	O
+in	O
+84	O
+.	O
+6	O
+%	O
+(	O
+22	O
+/	O
+26	O
+)	O
+and	O
+viruses	B-SPEC
+in	O
+80	O
+.	O
+7	O
+%	O
+(	O
+21	O
+/	O
+26	O
+).	O
+
+RESULTS	O
+:	O
+Thirty	O
+-	O
+eight	O
+patients	O
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+;	O
+they	O
+were	O
+predominantly	O
+elderly	O
+(	O
+mean	O
+age	O
+58	O
+.	O
+6	O
+years	O
+,	O
+range	O
+25	O
+-	O
+83	O
+years	O
+)	O
+and	O
+male	O
+(	O
+68	O
+.	O
+4	O
+%),	O
+and	O
+all	O
+were	O
+from	O
+developing	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+babesiosis	B-DISO
+presenting	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+an	O
+immunocompetent	O
+patient	O
+.	O
+
+On	O
+arrival	O
+to	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+the	O
+patient	O
+was	O
+noted	O
+to	O
+be	O
+febrile	B-PROC
+with	O
+tachycardia	O
+,	O
+tachypnea	B-DISO
+,	O
+and	O
+hypoxia	B-DISO
+and	O
+was	O
+intubated	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Tick	B-SPEC
+-	O
+borne	O
+illness	O
+was	O
+suspected	O
+and	O
+Wright	O
+-	O
+Giemsa	O
+stained	O
+thin	O
+blood	B-ANAT
+smear	O
+confirmed	O
+the	O
+diagnosis	O
+of	O
+babesiosis	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+prevalence	O
+of	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+(	O
+CPIV	O
+),	O
+canine	B-SPEC
+adenovirus	I-SPEC
+type	O
+2	O
+(	O
+CAV	B-SPEC
+-	O
+2	O
+),	O
+canine	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+CIV	B-SPEC
+),	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+),	O
+canine	O
+herpes	B-SPEC
+virus	I-SPEC
+-	O
+1	O
+(	O
+CHV	O
+-	O
+1	O
+),	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+)	O
+and	O
+Bordetella	B-SPEC
+bronchiseptica	I-SPEC
+in	O
+dogs	B-SPEC
+with	O
+CIRD	O
+and	O
+to	O
+compare	O
+the	O
+data	O
+with	O
+findings	O
+in	O
+healthy	O
+dogs	B-SPEC
+.	O
+
+Nasal	B-ANAT
+and	O
+pharyngeal	B-ANAT
+swabs	O
+were	O
+collected	O
+from	O
+all	O
+dogs	B-SPEC
+and	O
+were	O
+analysed	O
+for	O
+CPIV	O
+,	O
+CAV	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+CIV	B-SPEC
+,	O
+CRCoV	O
+,	O
+CHV	O
+-	O
+1	O
+,	O
+CDV	B-CHED
+,	O
+and	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+by	O
+real	O
+-	O
+time	O
+PCR	O
+.	O
+
+Genbank	O
+sequences	O
+of	O
+six	O
+human	B-SPEC
+coronaviruses	O
+,	O
+including	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+HCoV	O
+-	O
+HKU1	O
+,	O
+were	O
+included	O
+as	O
+reference	O
+sequences	O
+.	O
+
+Viroporins	O
+,	O
+encoded	O
+by	O
+all	O
+common	O
+respiratory	O
+viruses	B-SPEC
+,	O
+are	O
+responsible	O
+for	O
+the	O
+changes	O
+in	O
+intracellular	B-COMP
+ion	B-PROC
+homeostasis	I-PROC
+that	O
+modulate	O
+inflammasome	O
+activation	O
+.	O
+
+ABSTRACT	O
+:	O
+Data	O
+on	O
+the	O
+efficacy	O
+of	O
+Peg	O
+-	O
+interferon	B-PRGE
+/	O
+ribavirin	B-CHED
+therapy	O
+for	O
+chronic	B-DISO
+hepatitis	I-DISO
+C	I-DISO
+are	O
+mostly	O
+derived	O
+from	O
+treatment	O
+of	O
+selected	O
+patients	O
+enrolled	O
+in	O
+clinical	O
+trials	O
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+AKAP7	I-PRGE
+has	O
+a	O
+2	O
+',	O
+5	B-ENZY
+'-	I-ENZY
+phosphodiesterase	I-ENZY
+domain	O
+that	O
+can	O
+complement	O
+an	O
+inactive	O
+murine	B-SPEC
+coronavirus	I-SPEC
+ns2	B-DISO
+gene	I-PRGE
+.	O
+
+We	O
+speculate	O
+that	O
+AKAP7	B-PRGE
+is	O
+the	O
+ancestral	O
+precursor	O
+of	O
+viral	O
+proteins	B-CHED
+,	O
+such	O
+as	O
+ns2	B-DISO
+and	O
+VP3	O
+,	O
+that	O
+degrade	O
+2	O
+-	O
+5A	O
+to	O
+evade	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+RNase	B-PRGE
+L	I-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+beyond	O
+ARDS	B-DISO
+.	O
+
+Adjunctive	O
+use	O
+of	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+INO	O
+)	O
+is	O
+well	O
+-	O
+defined	O
+as	O
+a	O
+rescue	O
+therapy	O
+in	O
+severe	O
+ARDS	B-DISO
+,	O
+but	O
+its	O
+specific	O
+role	O
+in	O
+intracranial	B-DISO
+hypertension	I-DISO
+is	O
+somewhat	O
+uncertain	O
+.	O
+
+The	O
+epidemiological	O
+profiles	O
+of	O
+the	O
+patients	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+were	O
+described	O
+.	O
+
+Partial	O
+S	O
+and	O
+N	O
+genes	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+circulating	O
+strains	O
+were	O
+sequenced	O
+followed	O
+by	O
+phylogenetic	O
+analysis	O
+and	O
+amino	B-CHED
+acid	I-CHED
+alignment	O
+.	O
+
+Phylogenetic	O
+analysis	O
+based	O
+on	O
+neighbour	O
+-	O
+joining	O
+method	O
+showed	O
+that	O
+at	O
+least	O
+three	O
+distinct	O
+clusters	O
+(	O
+A	O
+,	O
+B	O
+,	O
+C	O
+/	O
+D	O
+)	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+strains	O
+were	O
+circulating	O
+among	O
+adult	O
+patients	O
+with	O
+ARI	B-CHED
+in	O
+Beijing	O
+.	O
+
+IBV	B-SPEC
+NSP6	O
+also	O
+limited	O
+autophagosome	B-COMP
+and	O
+omegasome	O
+expansion	O
+in	O
+response	B-PROC
+to	I-PROC
+starvation	I-PROC
+and	O
+Torin1	O
+and	O
+could	O
+therefore	O
+limit	O
+the	O
+size	O
+of	O
+autophagosomes	O
+induced	O
+following	O
+inhibition	B-PROC
+of	O
+MTOR	B-PRGE
+signaling	B-PROC
+,	O
+as	O
+well	O
+as	O
+those	O
+induced	O
+independently	O
+by	O
+the	O
+NSP6	B-PRGE
+protein	I-PRGE
+itself	O
+.	O
+
+The	O
+molecule	O
+consists	O
+of	O
+a	O
+ubiquitin	B-PROC
+-	O
+like	O
+domain	O
+and	O
+a	O
+catalytic	O
+core	O
+domain	O
+.	O
+
+The	O
+catalytic	O
+domain	O
+displays	O
+an	O
+extended	O
+right	O
+-	O
+hand	O
+fold	O
+with	O
+a	O
+zinc	B-CHED
+ribbon	B-COMP
+and	O
+embraces	O
+a	O
+solvent	B-CHED
+-	O
+exposed	O
+substrate	O
+-	O
+binding	B-FUNC
+region	O
+.	O
+
+The	O
+overall	O
+structure	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PL	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+is	O
+similar	O
+to	O
+that	O
+of	O
+the	O
+corresponding	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+enzyme	I-PRGE
+,	O
+but	O
+the	O
+architecture	O
+of	O
+the	O
+oxyanion	O
+hole	O
+and	O
+of	O
+the	O
+S3	O
+as	O
+well	O
+as	O
+the	O
+S5	O
+specificity	O
+sites	O
+differ	O
+from	O
+the	O
+latter	O
+.	O
+
+This	O
+review	O
+makes	O
+an	O
+attempt	O
+to	O
+summarize	O
+the	O
+published	O
+knowledge	O
+on	O
+SARS	B-DISO
+-	O
+CoV	O
+accessory	O
+proteins	B-CHED
+,	O
+with	O
+an	O
+emphasis	O
+on	O
+their	O
+involvement	O
+in	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+.	O
+
+Here	O
+we	O
+also	O
+discuss	O
+the	O
+thermodynamic	O
+characterization	O
+in	O
+solution	O
+of	O
+the	O
+metal	B-CHED
+complexes	O
+of	O
+the	O
+most	O
+active	O
+ligands	O
+,	O
+affording	O
+to	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+for	O
+the	O
+first	O
+time	O
+this	O
+type	O
+of	O
+data	O
+for	O
+complexes	O
+with	O
+anti	O
+-	O
+HIV	B-DISO
+activity	O
+.	O
+
+However	O
+,	O
+the	O
+emergence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+and	O
+more	O
+recently	O
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+has	O
+impelled	O
+the	O
+development	B-PROC
+of	O
+such	O
+drugs	O
+.	O
+
+Severe	O
+Capnocytophaga	B-SPEC
+canimorsus	I-SPEC
+sepsis	B-DISO
+may	O
+be	O
+complicated	O
+by	O
+life	O
+-	O
+threatening	O
+nosocomial	B-DISO
+infection	I-DISO
+in	O
+immunocompromized	O
+patients	O
+.	O
+
+The	O
+prophylactic	O
+application	O
+of	O
+antibiotics	B-CHED
+after	O
+a	O
+dog	B-SPEC
+bite	B-PROC
+should	O
+be	O
+considered	O
+in	O
+high	O
+-	O
+risk	O
+individuals	O
+with	O
+immune	B-DISO
+deficiency	I-DISO
+in	O
+order	B-SPEC
+to	O
+prevent	O
+both	O
+Capnocytophyga	O
+canimorsus	O
+sepsis	B-DISO
+and	O
+serious	O
+nosocomial	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+diagnosis	O
+of	O
+leptospirosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Enforced	O
+expression	B-PROC
+of	O
+miR	B-PRGE
+-	I-PRGE
+125b	I-PRGE
+attenuates	O
+LPS	B-DISO
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+in	O
+a	O
+silversmith	O
+.	O
+
+On	O
+the	O
+day	O
+of	O
+onset	O
+of	O
+symptoms	O
+,	O
+while	O
+smelting	O
+silver	B-CHED
+he	O
+was	O
+exposed	O
+to	O
+golden	B-CHED
+yellow	I-CHED
+fumes	O
+for	O
+around	O
+15	O
+minutes	O
+,	O
+with	O
+the	O
+quantum	O
+of	O
+exposure	O
+more	O
+than	O
+any	O
+other	O
+day	O
+earlier	O
+.	O
+
+Adult	O
+mice	B-SPEC
+(	O
+C57BL	O
+/	O
+6J	O
+,	O
+8	O
+wk	O
+of	O
+age	O
+,	O
+n	O
+=	O
+146	O
+)	O
+were	O
+inoculated	O
+with	O
+a	O
+neurotropic	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+A59	O
+strain	O
+)	O
+and	O
+followed	O
+for	O
+4	O
+wk	O
+.	O
+
+Inoculation	O
+with	O
+the	O
+virus	B-SPEC
+caused	O
+a	O
+significant	O
+neural	O
+deficit	B-DISO
+in	O
+mice	B-SPEC
+with	O
+an	O
+average	O
+clinical	O
+symptom	B-DISO
+score	O
+of	O
+2	O
+.	O
+6	O
+±	O
+0	O
+.	O
+5	O
+at	O
+2	O
+wk	O
+.	O
+
+The	O
+purified	O
+recombinant	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+was	O
+found	O
+to	O
+mediate	O
+highly	O
+potent	O
+antibody	B-PROC
+responses	I-PROC
+in	O
+immunized	O
+rabbits	B-SPEC
+.	O
+
+Altogether	O
+,	O
+our	O
+results	O
+indicate	O
+that	O
+a	O
+caspase	B-PRGE
+-	O
+independent	O
+mitochondrial	B-COMP
+AIF	O
+-	O
+mediated	O
+pathway	B-PROC
+plays	O
+a	O
+central	O
+role	O
+in	O
+PEDV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+to	O
+facilitate	O
+viral	B-PROC
+replication	I-PROC
+and	O
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+CpG	O
+-	O
+ODNs	O
+induced	O
+changes	O
+in	O
+cytokine	O
+/	O
+chemokines	O
+genes	O
+expression	B-PROC
+associated	O
+with	O
+suppression	B-DISO
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-PROC
+replication	I-PROC
+in	O
+chicken	B-SPEC
+lungs	B-ANAT
+.	O
+
+CpG	O
+ODN	O
+and	O
+PBS	B-DISO
+inoculated	O
+embryos	B-ANAT
+were	O
+challenged	O
+with	O
+virulent	O
+IBV	B-SPEC
+on	O
+the	O
+19th	O
+ED	O
+.	O
+
+We	O
+evaluated	O
+the	O
+proportion	O
+of	O
+SARI	O
+/	O
+ARDS	B-DISO
+cases	O
+and	O
+deaths	B-PROC
+due	O
+to	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+infection	B-DISO
+and	O
+the	O
+impact	O
+of	O
+other	O
+respiratory	O
+viruses	B-SPEC
+during	O
+pandemic	O
+and	O
+postpandemic	O
+period	O
+(	O
+2009	O
+-	O
+2011	O
+)	O
+in	O
+northern	O
+Italy	O
+;	O
+additionally	O
+we	O
+searched	O
+for	O
+unknown	O
+viruses	B-SPEC
+in	O
+those	O
+cases	O
+for	O
+which	O
+diagnosis	O
+remained	O
+negative	O
+.	O
+
+VIDISCA	O
+-	O
+454	O
+enabled	O
+the	O
+identification	O
+of	O
+one	O
+previously	O
+undiagnosed	O
+measles	B-PATH
+infection	B-DISO
+.	O
+
+Different	O
+kinds	O
+of	O
+DNA	O
+vaccines	O
+are	O
+investigated	O
+to	O
+provide	O
+protection	O
+against	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+including	O
+tuberculosis	B-PATH
+,	O
+coronavirus	B-SPEC
+,	O
+influenza	B-DISO
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+etc	O
+.	O
+
+All	O
+samples	O
+tested	O
+negative	O
+for	O
+HEV	B-SPEC
+,	O
+RV	O
+and	O
+Salmonella	B-DISO
+,	O
+whereas	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+the	O
+highly	O
+stable	O
+porcine	B-PRGE
+circovirus	I-PRGE
+type	I-PRGE
+2	I-PRGE
+(	O
+PCV2	O
+)	O
+were	O
+detected	O
+in	O
+eight	O
+and	O
+12	O
+samples	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Microorganisms	O
+in	O
+respiratory	B-ANAT
+tract	I-ANAT
+of	O
+patients	O
+diagnosed	O
+with	O
+atypical	B-DISO
+pneumonia	I-DISO
+:	O
+results	O
+of	O
+a	O
+research	O
+based	O
+on	O
+the	O
+use	O
+of	O
+reverse	O
+transcription	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+DNA	O
+microarray	O
+method	O
+and	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Results	O
+indicated	O
+presence	O
+of	O
+infectious	B-DISO
+PEDV	B-SPEC
+in	O
+the	O
+air	B-CHED
+from	O
+experimentally	O
+infected	O
+pigs	B-SPEC
+and	O
+genetic	O
+material	O
+of	O
+PEDV	B-SPEC
+was	O
+detected	O
+up	O
+to	O
+10	O
+miles	O
+downwind	O
+from	O
+naturally	O
+infected	O
+farms	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+coccidioidomycosis	I-DISO
+:	O
+pictorial	O
+review	O
+of	O
+chest	B-ANAT
+radiographic	O
+and	O
+CT	O
+findings	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+clinical	O
+presentation	O
+and	O
+imaging	O
+abnormalities	O
+,	O
+pulmonary	B-ANAT
+involvement	I-DISO
+is	O
+categorized	O
+into	O
+acute	O
+,	O
+disseminated	O
+,	O
+and	O
+chronic	O
+forms	O
+,	O
+each	O
+with	O
+a	O
+spectrum	O
+of	O
+imaging	O
+findings	O
+.	O
+
+Pulmonary	B-ANAT
+findings	O
+are	O
+miliary	O
+nodules	B-DISO
+and	O
+confluent	O
+parenchymal	O
+opacities	B-DISO
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+surface	O
+Spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+is	O
+a	O
+major	O
+antigenic	B-CHED
+determinant	I-CHED
+in	O
+eliciting	O
+neutralizing	O
+antibody	B-PROC
+production	I-PROC
+during	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Dissecting	O
+virus	B-SPEC
+entry	O
+:	O
+replication	O
+-	O
+independent	O
+analysis	O
+of	O
+virus	B-SPEC
+binding	B-FUNC
+,	O
+internalization	O
+,	O
+and	O
+penetration	O
+using	O
+minimal	O
+complementation	O
+of	O
+β	O
+-	O
+galactosidase	O
+.	O
+
+ABSTRACT	O
+:	O
+Studies	O
+of	O
+viral	O
+entry	B-PROC
+into	I-PROC
+host	I-PROC
+cells	B-COMP
+often	O
+rely	O
+on	O
+the	O
+detection	O
+of	O
+post	O
+-	O
+entry	O
+parameters	O
+,	O
+such	O
+as	O
+viral	B-PROC
+replication	I-PROC
+or	O
+the	O
+expression	B-PROC
+of	O
+a	O
+reporter	O
+gene	O
+,	O
+rather	O
+than	O
+on	O
+measuring	O
+entry	O
+per	O
+se	O
+.	O
+
+Here	O
+we	O
+use	O
+it	O
+to	O
+confirm	O
+and	O
+extend	O
+current	O
+knowledge	O
+on	O
+the	O
+entry	O
+process	O
+of	O
+two	O
+enveloped	O
+viruses	O
+:	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+(	O
+VSV	O
+)	O
+and	O
+murine	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+Serum	B-COMP
+albumin	B-PRGE
+(	O
+OR	O
+,	O
+0	O
+.	O
+52	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+31	O
+-	O
+0	O
+.	O
+87	O
+)	O
+and	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+score	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+08	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+04	O
+-	O
+1	O
+.	O
+13	O
+)	O
+on	O
+admission	O
+were	O
+the	O
+most	O
+informative	O
+covariates	O
+for	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+in	O
+the	O
+regression	O
+model	O
+.	O
+
+Studies	O
+were	O
+commonly	O
+of	O
+low	O
+or	O
+very	O
+low	O
+quality	O
+,	O
+lacked	O
+control	O
+groups	O
+,	O
+and	O
+at	O
+moderate	O
+or	O
+high	O
+risk	O
+of	O
+bias	B-SPEC
+.	O
+
+Camelids	O
+may	O
+represent	O
+mixing	O
+vessels	B-ANAT
+for	O
+MERS	O
+-	O
+CoV	O
+and	O
+other	O
+mammalian	B-SPEC
+CoVs	O
+.	O
+
+Epidemiological	O
+and	O
+genomic	O
+studies	O
+show	O
+zoonotic	O
+transmission	O
+to	O
+humans	B-SPEC
+from	O
+camels	B-SPEC
+and	O
+possibly	O
+bats	B-SPEC
+.	O
+
+In	O
+contrast	O
+to	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+pandemic	O
+,	O
+very	O
+limited	O
+global	O
+spread	O
+of	O
+fatal	O
+MERS	O
+-	O
+CoV	O
+has	O
+occurred	O
+outside	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+Extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+(	O
+ECCO₂R	O
+)	O
+devices	O
+allow	O
+uncoupling	O
+of	O
+ventilation	O
+from	O
+oxygenation	B-PROC
+,	O
+thereby	O
+removing	O
+carbon	B-CHED
+dioxide	I-CHED
+and	O
+facilitating	O
+lower	O
+tidal	O
+volume	O
+ventilation	O
+.	O
+
+We	O
+performed	O
+a	O
+systematic	O
+review	O
+to	O
+assess	O
+efficacy	O
+,	O
+complication	B-DISO
+rates	O
+,	O
+and	O
+utility	O
+of	O
+ECCO₂R	O
+devices	O
+.	O
+
+Interestingly	O
+,	O
+the	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+length	O
+variation	O
+was	O
+similarly	O
+found	O
+in	O
+the	O
+avirulent	O
+IBV	B-SPEC
+strain	O
+H120	O
+in	O
+CEK	O
+cells	B-COMP
+,	O
+although	O
+the	O
+overall	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+length	O
+was	O
+shorter	O
+for	O
+this	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viruses	B-SPEC
+infections	B-DISO
+caused	O
+by	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+human	B-SPEC
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+hPIV	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+and	O
+coronaviruses	O
+are	O
+an	O
+eminent	O
+threat	O
+for	O
+public	O
+health	O
+.	O
+
+However	O
+,	O
+there	O
+are	O
+some	O
+practical	O
+and	O
+regulatory	O
+issues	O
+that	O
+need	O
+to	O
+be	O
+addressed	O
+in	O
+order	B-SPEC
+to	O
+develop	O
+MVA	B-CHED
+-	O
+based	O
+vaccines	O
+on	O
+short	O
+notice	O
+at	O
+the	O
+verge	O
+of	O
+a	O
+pandemic	O
+.	O
+
+We	O
+then	O
+conducted	O
+100	O
+-	O
+ns	O
+molecular	B-PROC
+dynamics	I-PROC
+(	O
+MD	O
+)	O
+simulations	O
+for	O
+both	O
+STI	O
+/	O
+A	O
+and	O
+WT	O
+,	O
+the	O
+longest	O
+reported	O
+so	O
+far	O
+for	O
+3CLpro	O
+.	O
+
+Most	O
+strikingly	O
+,	O
+the	O
+N214A	O
+mutation	O
+globally	O
+decouples	O
+this	O
+network	O
+while	O
+the	O
+STI	B-PRGE
+/	I-PRGE
+A	I-PRGE
+mutation	I-PRGE
+alters	O
+the	O
+correlation	O
+pattern	O
+.	O
+
+From	O
+2002	O
+to	O
+2011	O
+,	O
+surveillance	O
+of	O
+enteric	O
+pathogens	O
+was	O
+performed	O
+in	O
+cows	B-SPEC
+of	O
+various	O
+breed	B-PROC
+and	O
+age	O
+from	O
+302	O
+farms	O
+in	O
+which	O
+diarrhea	B-DISO
+had	O
+occurred	O
+in	O
+Yamagata	O
+Prefecture	O
+,	O
+Japan	O
+.	O
+
+Clinical	O
+symptoms	O
+(	O
+duration	O
+of	O
+epidemic	O
+,	O
+hematochezia	O
+and	O
+complications	O
+)	O
+caused	O
+by	O
+bovine	B-SPEC
+rotavirus	B-DISO
+infection	I-DISO
+were	O
+milder	O
+than	O
+those	O
+caused	O
+by	O
+bovine	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Between	O
+April	O
+2012	O
+and	O
+June	O
+2014	O
+,	O
+820	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+have	O
+been	O
+reported	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+Europe	O
+,	O
+North	O
+Africa	O
+,	O
+Southeast	O
+Asia	O
+,	O
+the	O
+Middle	O
+East	O
+,	O
+and	O
+the	O
+United	O
+States	O
+.	O
+
+Efforts	O
+to	O
+minimize	O
+bloodstream	B-PROC
+infections	B-DISO
+during	O
+the	O
+resuscitation	O
+must	O
+be	O
+increased	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+effects	O
+of	O
+treatment	O
+approach	O
+on	O
+the	O
+outcomes	O
+of	O
+newborns	O
+(	O
+birth	B-PROC
+weight	O
+[	O
+BW	O
+]	O
+<	O
+1	O
+,	O
+000	O
+g	O
+)	O
+with	O
+patent	B-DISO
+ductus	I-DISO
+arteriosus	I-DISO
+(	O
+PDA	B-DISO
+),	O
+from	O
+the	O
+Brazilian	O
+Neonatal	O
+Research	O
+Network	O
+(	O
+BNRN	O
+)	O
+on	O
+:	O
+death	B-PROC
+,	O
+bronchopulmonary	B-DISO
+dysplasia	I-DISO
+(	O
+BPD	B-DISO
+),	O
+severe	O
+intraventricular	B-DISO
+hemorrhage	I-DISO
+(	O
+IVH	O
+III	O
+/	O
+IV	O
+),	O
+retinopathy	B-DISO
+of	I-DISO
+prematurity	I-DISO
+requiring	O
+surgical	O
+(	O
+ROPsur	O
+),	O
+necrotizing	B-DISO
+enterocolitis	I-DISO
+requiring	O
+surgery	O
+(	O
+NECsur	O
+),	O
+and	O
+death	B-PROC
+/	O
+BPD	B-DISO
+.	O
+
+This	O
+was	O
+a	O
+multicentric	O
+,	O
+cohort	O
+study	O
+,	O
+retrospective	O
+data	O
+collection	O
+,	O
+including	O
+newborns	O
+(	O
+BW	O
+<	O
+1000	O
+g	O
+)	O
+with	O
+gestational	O
+age	O
+(	O
+GA	O
+)	O
+<	O
+33	O
+weeks	O
+and	O
+echocardiographic	O
+diagnosis	O
+of	O
+PDA	B-DISO
+,	O
+from	O
+16	O
+neonatal	O
+units	O
+of	O
+the	O
+BNRN	O
+from	O
+January	O
+1	O
+,	O
+2010	O
+to	O
+Dec	B-CHED
+31	O
+,	O
+2011	O
+.	O
+
+death	B-PROC
+,	O
+O2	O
+dependence	B-DISO
+at	O
+36	O
+weeks	O
+(	O
+BPD36wks	O
+),	O
+IVH	B-PRGE
+III	I-PRGE
+/	I-PRGE
+IV	I-PRGE
+,	O
+ROPsur	O
+,	O
+NECsur	O
+,	O
+and	O
+death	B-PROC
+/	O
+BPD36wks	O
+.	O
+
+A	O
+secondary	O
+analysis	O
+of	O
+a	O
+multicenter	O
+prospective	O
+cohort	O
+conducted	O
+in	O
+45	O
+Brazilian	O
+ICUs	O
+,	O
+including	O
+adult	O
+patients	O
+requiring	O
+ventilatory	O
+support	O
+and	O
+sedation	B-DISO
+in	O
+the	O
+first	O
+48	O
+hours	O
+of	O
+ICU	O
+admissions	O
+,	O
+was	O
+performed	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+genome	O
+in	O
+an	O
+air	B-CHED
+sample	O
+originating	O
+from	O
+a	O
+camel	O
+barn	O
+owned	O
+by	O
+an	O
+infected	O
+patient	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+serological	O
+and	O
+virological	O
+data	O
+suggest	O
+dromedary	B-SPEC
+camels	B-SPEC
+as	O
+the	O
+potential	O
+animal	B-SPEC
+reservoirs	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Recently	O
+,	O
+we	O
+isolated	O
+MERS	O
+-	O
+CoV	O
+from	O
+a	O
+camel	B-SPEC
+and	O
+its	O
+infected	O
+owner	O
+and	O
+provided	O
+evidence	O
+for	O
+the	O
+direct	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+from	O
+the	O
+infected	O
+camel	B-SPEC
+to	O
+the	O
+patient	O
+.	O
+
+Indeed	O
+,	O
+the	O
+S1	O
+sequence	O
+of	O
+the	O
+IBV	B-SPEC
+population	O
+previously	O
+designated	O
+C4	O
+(	O
+AdIBVS1	O
+.	O
+C4	O
+),	O
+which	O
+protected	O
+the	O
+most	O
+poorly	O
+,	O
+differs	O
+from	O
+the	O
+S1	O
+sequence	O
+of	O
+population	O
+C2	O
+(	O
+AdIBVS1	O
+.	O
+C2	O
+),	O
+which	O
+provided	O
+the	O
+highest	O
+protection	O
+,	O
+only	O
+at	O
+amino	B-CHED
+acid	I-CHED
+position	O
+56	O
+.	O
+
+Moreover	O
+,	O
+increased	O
+numbers	O
+of	O
+both	O
+IgA	B-PRGE
+and	O
+IgG	B-PRGE
+IBV	B-SPEC
+-	O
+specific	O
+antibody	B-COMP
+secreting	B-PROC
+lymphocytes	B-ANAT
+were	O
+detected	O
+in	O
+the	O
+spleen	B-ANAT
+after	O
+challenge	O
+.	O
+
+The	O
+increased	O
+response	O
+detected	O
+for	O
+both	O
+IgA	B-PRGE
+and	O
+IgG	B-PRGE
+lymphocytes	B-ANAT
+after	O
+challenge	O
+might	O
+be	O
+explained	O
+by	O
+vaccine	O
+-	O
+induced	O
+B	O
+memory	B-ANAT
+cells	B-COMP
+.	O
+
+The	O
+fact	O
+that	O
+a	O
+single	O
+vaccination	O
+with	O
+Ad	O
+/	O
+IBVS1	O
+.	O
+C2	O
+provides	O
+protection	O
+against	O
+IBV	B-SPEC
+challenge	O
+is	O
+promising	O
+,	O
+because	O
+Ad	O
+-	O
+vectored	O
+vaccines	O
+can	O
+be	O
+mass	O
+delivered	O
+by	O
+in	O
+ovo	B-SPEC
+inoculation	O
+using	O
+automated	O
+in	O
+ovo	B-SPEC
+injectors	O
+.	O
+
+To	O
+test	O
+this	O
+hypothesis	O
+,	O
+chickens	B-SPEC
+were	O
+ocularly	O
+vaccinated	O
+with	O
+a	O
+commercially	O
+available	O
+live	O
+attenuated	O
+IBV	B-SPEC
+Ark	O
+-	O
+Delmarva	O
+Poultry	O
+Industry	O
+vaccine	O
+strain	O
+and	O
+both	O
+mucosal	B-ANAT
+and	O
+systemic	O
+antibody	B-PROC
+responses	I-PROC
+were	O
+measured	O
+.	O
+
+Interestingly	O
+,	O
+the	O
+peak	O
+IgA	B-PRGE
+SFC	I-PRGE
+response	O
+occurred	O
+2	O
+days	O
+earlier	O
+in	O
+spleen	B-ANAT
+than	O
+in	O
+the	O
+head	B-ANAT
+-	O
+associated	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+despite	O
+ocular	B-PROC
+vaccination	O
+.	O
+
+IgA	B-COMP
+antibody	I-COMP
+levels	O
+were	O
+higher	O
+than	O
+IgG	B-COMP
+antibody	I-COMP
+levels	O
+throughout	O
+the	O
+primary	O
+response	O
+in	O
+tears	B-ANAT
+and	O
+were	O
+similar	O
+in	O
+magnitude	O
+in	O
+plasma	B-ANAT
+.	O
+
+This	O
+early	O
+increase	O
+is	O
+consistent	O
+with	O
+a	O
+mucosal	B-ANAT
+T	O
+-	O
+independent	O
+IgA	B-PRGE
+response	O
+to	O
+IBV	B-SPEC
+.	O
+
+In	O
+summary	O
+,	O
+ocular	B-PROC
+vaccination	O
+induced	O
+higher	O
+IgA	B-PRGE
+antibodies	I-PRGE
+in	O
+the	O
+primary	O
+IBV	B-SPEC
+response	O
+,	O
+while	O
+the	O
+memory	B-PROC
+response	O
+is	O
+dominated	O
+by	O
+IgG	B-PRGE
+antibodies	I-PRGE
+.	O
+
+This	O
+report	O
+details	O
+the	O
+subsequent	O
+sequence	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+TCoV	B-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+and	O
+the	O
+comparison	O
+of	O
+outbreak	O
+-	O
+associated	O
+isolates	O
+to	O
+sequences	O
+in	O
+the	O
+public	O
+database	O
+.	O
+
+We	O
+evaluated	O
+a	O
+simple	O
+method	O
+of	O
+processing	O
+sputum	B-ANAT
+samples	O
+in	O
+a	O
+fully	O
+automated	O
+respiratory	O
+viral	O
+panel	O
+RT	O
+-	O
+PCR	O
+assay	O
+(	O
+FilmArray	O
+).	O
+
+Archived	O
+sputum	B-ANAT
+and	O
+NTS	B-ANAT
+samples	O
+collected	O
+in	O
+2008	O
+-	O
+2012	O
+from	O
+hospitalized	O
+adults	O
+with	O
+RTI	B-DISO
+were	O
+evaluated	O
+.	O
+
+Quantitative	O
+RT	O
+-	O
+PCR	O
+revealed	O
+higher	O
+mean	O
+viral	O
+loads	O
+in	O
+dunked	O
+sputum	B-ANAT
+samples	O
+compared	O
+to	O
+NTS	B-ANAT
+samples	O
+for	O
+Flu	B-PRGE
+A	I-PRGE
+,	O
+RSV	B-SPEC
+,	O
+and	O
+HMPV	B-SPEC
+(	O
+P	O
+=	O
+0	O
+.	O
+0001	O
+,	O
+P	O
+=	O
+0	O
+.	O
+006	O
+,	O
+and	O
+P	O
+=	O
+0	O
+.	O
+011	O
+,	O
+respectively	O
+).	O
+
+However	O
+,	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibody	B-PROC
+response	I-PROC
+is	O
+short	O
+-	O
+lived	O
+in	O
+patients	O
+who	O
+have	O
+recovered	O
+from	O
+SARS	B-DISO
+,	O
+making	O
+it	O
+critical	O
+to	O
+develop	O
+additional	O
+vaccine	O
+strategies	O
+.	O
+
+Proteolytic	B-PROC
+activation	O
+of	O
+MERS	O
+-	O
+S	O
+during	O
+viral	O
+uptake	O
+into	O
+target	B-ANAT
+cells	I-ANAT
+has	O
+been	O
+demonstrated	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+MERS	O
+-	O
+S	O
+is	O
+processed	O
+by	O
+proprotein	O
+convertases	O
+in	O
+MERS	O
+-	O
+S	O
+-	O
+transfected	O
+and	O
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+and	O
+that	O
+several	O
+RXXR	O
+motifs	O
+located	O
+at	O
+the	O
+border	B-ANAT
+between	O
+the	O
+surface	O
+and	O
+transmembrane	B-COMP
+subunit	O
+of	O
+MERS	O
+-	O
+S	O
+are	O
+required	O
+for	O
+efficient	O
+proteolysis	O
+.	O
+
+However	O
+,	O
+blockade	O
+of	O
+proprotein	O
+convertases	O
+did	O
+not	O
+impact	O
+MERS	O
+-	O
+S	O
+-	O
+dependent	O
+transduction	B-PROC
+of	O
+target	B-ANAT
+cells	I-ANAT
+expressing	O
+high	O
+amounts	O
+of	O
+the	O
+viral	O
+receptor	O
+,	O
+DPP4	B-PRGE
+,	O
+and	O
+did	O
+not	O
+modulate	O
+MERS	O
+-	O
+CoV	O
+infectivity	O
+.	O
+
+These	O
+results	O
+show	O
+that	O
+MERS	O
+-	O
+S	O
+is	O
+a	O
+substrate	O
+for	O
+proprotein	O
+convertases	O
+and	O
+demonstrate	O
+that	O
+processing	O
+by	O
+these	O
+enzymes	O
+is	O
+dispensable	O
+for	O
+S	B-PRGE
+protein	I-PRGE
+activation	O
+.	O
+
+Efforts	O
+to	O
+inhibit	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+by	O
+targeting	B-PROC
+host	B-COMP
+cell	I-COMP
+proteases	O
+should	O
+therefore	O
+focus	O
+on	O
+enzymes	O
+that	O
+process	O
+MERS	O
+-	O
+S	O
+during	O
+viral	O
+uptake	O
+into	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+model	O
+in	O
+rat	B-SPEC
+.	O
+
+At	O
+the	O
+end	O
+,	O
+lungs	B-ANAT
+were	O
+excised	O
+for	O
+determination	O
+of	O
+pulmonary	B-ANAT
+water	B-CHED
+content	O
+and	O
+histological	O
+examination	O
+.	O
+
+Retained	O
+organisms	O
+were	O
+eluted	O
+from	O
+the	O
+filters	O
+by	O
+passing	O
+beef	O
+extract	O
+-	O
+glycine	B-CHED
+buffer	B-CHED
+(	O
+pH	O
+9	O
+.	O
+5	O
+)	O
+in	O
+the	O
+direction	O
+opposite	O
+of	O
+sample	O
+flow	O
+.	O
+
+TITLE	O
+:	O
+Immunogenicity	O
+,	O
+safety	O
+and	O
+tolerability	O
+of	O
+a	O
+bivalent	O
+human	B-SPEC
+papillomavirus	I-SPEC
+vaccine	O
+in	O
+adolescents	O
+with	O
+juvenile	O
+idiopathic	O
+arthritis	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+immunogenicity	O
+,	O
+safety	O
+and	O
+tolerability	O
+of	O
+the	O
+bivalent	O
+HPV	O
+vaccine	O
+in	O
+female	O
+patients	O
+with	O
+juvenile	B-DISO
+idiopathic	I-DISO
+arthritis	I-DISO
+(	O
+JIA	O
+).	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+increasing	O
+knowledge	O
+on	O
+the	O
+role	O
+of	O
+viruses	B-SPEC
+in	O
+exacerbations	O
+of	O
+COPD	B-DISO
+(	O
+AECOPD	O
+),	O
+it	O
+is	O
+less	O
+clear	O
+which	O
+viruses	B-SPEC
+are	O
+involved	O
+and	O
+to	O
+what	O
+extent	O
+they	O
+contribute	O
+to	O
+exacerbations	O
+.	O
+
+Seven	O
+of	O
+the	O
+eight	O
+analyzed	O
+viruses	B-SPEC
+had	O
+a	O
+higher	O
+prevalence	O
+in	O
+LRT	B-ANAT
+samples	O
+.	O
+
+Compared	O
+to	O
+venoarterial	O
+ECMO	O
+,	O
+in	O
+VV	O
+-	O
+ECMO	O
+,	O
+the	O
+rate	O
+of	O
+complications	O
+,	O
+such	O
+as	O
+thrombosis	B-DISO
+,	O
+bleeding	B-DISO
+,	O
+infection	B-DISO
+and	O
+ischemic	O
+events	O
+,	O
+is	O
+lower	O
+.	O
+
+Quantitative	O
+-	O
+PCR	O
+and	O
+immunofluorescence	O
+staining	O
+results	O
+indicate	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+capable	O
+of	O
+replication	O
+in	O
+HL	O
+-	O
+CZ	O
+cells	B-COMP
+,	O
+and	O
+of	O
+displaying	O
+virus	B-SPEC
+-	O
+induced	O
+cytopathic	B-DISO
+effects	I-DISO
+and	O
+increased	O
+levels	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+two	O
+days	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+Hospital	O
+outbreak	O
+and	O
+nosocomial	O
+transmission	O
+were	O
+reported	O
+,	O
+however	O
+,	O
+several	O
+issues	O
+remain	O
+on	O
+the	O
+viral	O
+excretion	B-PROC
+course	O
+.	O
+
+After	O
+the	O
+initial	O
+diagnosis	O
+,	O
+blood	B-ANAT
+,	O
+urine	B-ANAT
+,	O
+rectal	O
+and	O
+respiratory	B-ANAT
+samples	I-ANAT
+were	O
+collected	O
+regularly	O
+,	O
+aliquoted	O
+and	O
+stored	O
+at	O
+-	O
+80	O
+°	O
+C	O
+.	O
+
+Tracheal	O
+aspirations	O
+were	O
+positive	O
+until	O
+the	O
+33rd	O
+day	O
+,	O
+while	O
+nasopharyngeal	B-ANAT
+swabs	O
+were	O
+negative	O
+.	O
+
+TITLE	O
+:	O
+Heat	O
+inactivation	B-DISO
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Budd	O
+-	O
+Chiari	O
+-	O
+like	O
+syndrome	O
+is	O
+a	O
+rare	O
+phenomenon	O
+in	O
+veterinary	O
+medicine	B-CHED
+,	O
+and	O
+congenital	B-DISO
+malformations	I-DISO
+should	O
+be	O
+considered	O
+in	O
+young	O
+feline	B-SPEC
+patients	O
+with	O
+ascites	O
+.	O
+
+ABSTRACT	O
+:	O
+Israeli	O
+acute	O
+paralysis	O
+virus	O
+(	O
+IAPV	O
+)	O
+is	O
+a	O
+widespread	O
+RNA	O
+virus	B-SPEC
+of	O
+honey	B-SPEC
+bees	I-SPEC
+that	O
+has	O
+been	O
+linked	O
+with	O
+colony	O
+losses	O
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+has	O
+been	O
+demonstrated	O
+that	O
+,	O
+in	O
+addition	O
+to	O
+genomic	O
+RNA	O
+,	O
+sgmRNA	O
+is	O
+able	O
+to	O
+serve	O
+as	O
+a	O
+template	O
+for	O
+the	O
+synthesis	B-PROC
+of	O
+the	O
+negative	O
+-	O
+strand	O
+[(-)-	O
+strand	O
+]	O
+complement	O
+.	O
+
+(	O
+1	O
+)	O
+Deletion	O
+of	O
+the	O
+5	O
+'-	O
+terminal	O
+leader	O
+sequence	O
+on	O
+sgmRNA	O
+7	O
+decreased	O
+the	O
+synthesis	B-PROC
+of	O
+the	O
+(-)-	O
+strand	O
+sgmRNA	O
+complement	O
+.	O
+
+TITLE	O
+:	O
+Crystallization	O
+and	O
+preliminary	O
+crystallographic	O
+study	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+main	I-PRGE
+protease	I-PRGE
+in	O
+complex	O
+with	O
+an	O
+inhibitor	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+mainly	O
+infects	O
+younger	O
+children	O
+and	O
+causes	O
+cough	B-DISO
+,	O
+fever	B-PROC
+,	O
+rhinorrhoea	B-DISO
+,	O
+bronchiolitis	B-DISO
+and	O
+croup	B-DISO
+.	O
+
+Each	O
+polyprotein	O
+undergoes	O
+extensive	O
+proteolytic	B-PROC
+processing	I-PROC
+,	O
+resulting	O
+in	O
+functional	O
+subunits	O
+.	O
+
+This	O
+process	O
+is	O
+mainly	O
+mediated	O
+by	O
+its	O
+genome	O
+-	O
+encoded	O
+main	O
+protease	O
+,	O
+which	O
+is	O
+an	O
+attractive	O
+target	O
+for	O
+antiviral	B-CHED
+drug	I-CHED
+design	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+27	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+suddenly	O
+died	B-PROC
+in	O
+hospital	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+secondary	O
+to	O
+severe	O
+systemic	O
+vasculitis	B-DISO
+.	O
+
+Multi	O
+-	O
+phase	O
+post	O
+-	O
+mortem	O
+computed	O
+tomography	O
+angiography	O
+followed	O
+by	O
+scientific	O
+autopsy	O
+of	O
+the	O
+thoracic	B-DISO
+and	O
+abdominal	B-ANAT
+cavity	I-ANAT
+and	O
+histology	O
+was	O
+performed	O
+,	O
+illustrating	O
+the	O
+advantages	O
+and	O
+drawbacks	O
+of	O
+such	O
+techniques	O
+.	O
+
+MPMCTA	O
+revealed	O
+absence	O
+of	O
+opacification	O
+of	O
+the	O
+left	B-ANAT
+middle	I-ANAT
+cerebral	I-ANAT
+artery	I-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+determined	O
+the	O
+entry	O
+mechanism	O
+of	O
+PEDV	B-SPEC
+into	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+onset	O
+of	O
+epidemics	O
+caused	O
+by	O
+viruses	O
+such	O
+as	O
+Ebola	O
+,	O
+Marburg	O
+,	O
+Nipah	O
+,	O
+Lassa	O
+,	O
+coronavirus	B-SPEC
+,	O
+West	O
+-	O
+Nile	O
+encephalitis	B-DISO
+,	I-DISO
+Saint	I-DISO
+Louis	I-DISO
+encephalitis	B-DISO
+,	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+,	O
+dengue	B-DISO
+,	O
+yellow	B-DISO
+fever	I-DISO
+and	O
+Venezuelan	B-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+alerts	O
+about	O
+the	O
+risk	O
+these	O
+agents	O
+represent	O
+for	O
+the	O
+global	O
+health	O
+.	O
+
+Although	O
+chikungunya	B-DISO
+infection	B-DISO
+has	O
+a	O
+low	O
+mortality	O
+rate	O
+,	O
+its	O
+high	O
+attack	O
+ratio	O
+may	O
+collapse	B-DISO
+the	O
+health	O
+system	O
+during	O
+epidemics	O
+affecting	O
+a	O
+sensitive	O
+population	O
+.	O
+
+Because	O
+of	O
+the	O
+high	O
+sequence	O
+homology	O
+among	O
+FCoV	O
+,	O
+CCoV	O
+,	O
+and	O
+TGEV	B-SPEC
+,	O
+a	O
+nucleotide	B-CHED
+preceding	O
+the	O
+last	O
+pair	O
+of	O
+dissimilar	O
+nucleotides	B-CHED
+in	O
+S3	O
+and	O
+S4	O
+was	O
+substituted	O
+with	O
+an	O
+inosine	B-CHED
+to	O
+allow	O
+primer	O
+binding	B-FUNC
+.	O
+
+The	O
+respiratory	O
+viruses	B-SPEC
+detected	O
+using	O
+a	O
+multiplex	O
+real	O
+-	O
+time	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+kit	B-FUNC
+were	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+A	O
+/	O
+H1N1	O
+,	O
+A	O
+/	O
+H3N2	B-CHED
+,	O
+A	O
+/	O
+H5N1	B-DISO
+,	O
+and	O
+B	O
+),	O
+adenovirus	B-DISO
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+type	O
+1	O
+,	O
+2	O
+,	O
+3	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+type	O
+A	O
+,	O
+B	O
+),	O
+human	B-SPEC
+rhinovirus	I-SPEC
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+OC43	O
+/	O
+229E	O
+,	O
+NL63	O
+),	O
+human	B-SPEC
+bocavirus	I-SPEC
+,	O
+and	O
+enterovirus	B-SPEC
+.	O
+
+The	O
+most	O
+commonly	O
+detected	O
+virus	B-SPEC
+was	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+32	O
+.	O
+6	O
+%),	O
+followed	O
+by	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+26	O
+.	O
+8	O
+%).	O
+
+In	O
+particular	O
+,	O
+human	B-SPEC
+bocavirus	I-SPEC
+and	O
+enterovirus	B-SPEC
+have	O
+significant	O
+correlations	O
+with	O
+monthly	O
+patterns	O
+of	O
+KD	O
+occurrence	O
+(	O
+p	O
+=	O
+0	O
+.	O
+032	O
+and	O
+p	O
+=	O
+0	O
+.	O
+007	O
+,	O
+respectively	O
+)	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+correlated	O
+with	O
+KD	O
+occurrence	O
+with	O
+borderline	O
+significance	O
+(	O
+p	O
+=	O
+0	O
+.	O
+063	O
+).	O
+
+In	O
+contrast	O
+,	O
+MERS	O
+is	O
+relatively	O
+inefficiently	O
+transmitted	B-DISO
+to	O
+humans	B-SPEC
+but	O
+has	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+These	O
+data	O
+are	O
+consistent	O
+with	O
+observations	O
+in	O
+MS	O
+that	O
+axonal	O
+damage	O
+or	O
+Wallerian	B-DISO
+degeneration	I-DISO
+is	O
+occurring	O
+within	O
+the	O
+CNS	B-CHED
+contributing	O
+to	O
+the	O
+disability	O
+and	O
+disease	O
+severity	O
+.	O
+
+Ninety	O
+percent	O
+of	O
+the	O
+complications	O
+were	O
+related	O
+to	O
+transient	O
+hypoxemia	O
+,	O
+whereas	O
+bradycardia	B-DISO
+and	O
+hypotension	O
+each	O
+occurred	O
+in	O
+1	O
+patient	O
+.	O
+
+The	O
+mean	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+score	O
+was	O
+22	O
+(±	O
+7	O
+.	O
+5	O
+),	O
+whereas	O
+the	O
+median	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+was	O
+9	O
+(	O
+interquartile	O
+range	O
+,	O
+5	O
+-	O
+12	O
+).	O
+
+Quantitative	O
+PCR	O
+studies	O
+and	O
+fluorescence	O
+-	O
+activated	O
+cell	B-COMP
+sorting	B-PROC
+(	O
+FACS	O
+)	O
+analyses	O
+showed	O
+that	O
+RDS1759	O
+selectively	O
+inhibited	O
+reverse	B-PROC
+transcription	I-PROC
+in	O
+cell	B-COMP
+-	O
+based	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+virulence	B-PROC
+genes	O
+with	O
+main	O
+focus	O
+on	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+envelope	B-COMP
+gene	I-PRGE
+.	O
+
+Nevertheless	O
+,	O
+CoVs	O
+have	O
+evolved	O
+viral	O
+proteins	B-CHED
+that	O
+target	O
+different	O
+signaling	B-PROC
+pathways	B-PROC
+to	O
+counteract	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+Key	O
+CoV	O
+proteins	B-CHED
+involved	O
+in	O
+the	O
+regulation	B-PROC
+of	O
+these	O
+pathways	B-PROC
+and	O
+the	O
+proinflammatory	O
+immune	B-PROC
+response	I-PROC
+are	O
+revisited	O
+in	O
+this	O
+manuscript	O
+.	O
+
+In	O
+fact	O
+,	O
+after	O
+infection	B-DISO
+with	O
+viruses	B-SPEC
+in	O
+which	O
+this	O
+protein	B-CHED
+has	O
+been	O
+deleted	O
+,	O
+increased	O
+cellular	B-DISO
+stress	I-DISO
+and	O
+unfolded	B-PROC
+protein	I-PROC
+responses	I-PROC
+,	O
+apoptosis	B-PATH
+,	O
+and	O
+augmented	O
+host	B-COMP
+immune	B-PROC
+responses	I-PROC
+were	O
+observed	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+presence	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+activated	O
+a	O
+pathogenic	O
+inflammatory	B-DISO
+response	I-DISO
+that	O
+may	O
+cause	O
+death	B-PROC
+in	O
+animal	B-SPEC
+models	O
+and	O
+in	O
+humans	B-SPEC
+.	O
+
+Although	O
+E	B-PRGE
+protein	I-PRGE
+is	O
+not	O
+essential	O
+for	O
+CoV	O
+genome	O
+replication	O
+or	O
+subgenomic	O
+mRNA	B-PROC
+synthesis	I-PROC
+,	O
+it	O
+affects	O
+virus	B-SPEC
+morphogenesis	B-PROC
+,	O
+budding	B-PATH
+,	O
+assembly	O
+,	O
+intracellular	B-COMP
+trafficking	B-PROC
+,	O
+and	O
+virulence	B-PROC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+macropinocytosis	B-PROC
+likely	O
+facilitates	O
+CoV	O
+infection	B-DISO
+through	O
+enhanced	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-COMP
+spreading	O
+.	O
+
+Importance	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+),	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+CoV	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+,	O
+are	O
+critical	O
+emerging	O
+human	B-SPEC
+pathogens	O
+.	O
+
+Given	O
+the	O
+popularity	O
+of	O
+amlodipine	B-CHED
+and	O
+atenolol	B-CHED
+as	O
+antihypertensive	B-CHED
+drugs	I-CHED
+in	O
+this	O
+part	O
+of	O
+the	O
+world	O
+,	O
+it	O
+is	O
+likely	O
+that	O
+more	O
+such	O
+cases	O
+will	O
+be	O
+encountered	O
+in	O
+the	O
+future	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+January	O
+2014	O
+,	O
+approximately	O
+9	O
+months	O
+following	O
+the	O
+initial	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	B-DISO
+)	O
+in	O
+the	O
+USA	O
+,	O
+the	O
+first	O
+case	O
+of	O
+PED	B-DISO
+was	O
+confirmed	O
+in	O
+a	O
+swine	B-SPEC
+herd	O
+in	O
+south	O
+-	O
+western	O
+Ontario	O
+.	O
+
+These	O
+findings	O
+led	O
+us	O
+to	O
+conduct	B-PROC
+a	O
+bioassay	O
+experiment	O
+in	O
+which	O
+three	O
+PEDV	B-SPEC
+-	O
+positive	O
+SDPP	O
+samples	O
+(	O
+from	O
+a	O
+single	O
+lot	O
+)	O
+and	O
+two	O
+PEDV	B-SPEC
+-	O
+positive	O
+feed	O
+samples	O
+supplemented	O
+with	O
+this	O
+SDPP	O
+were	O
+used	O
+to	O
+orally	O
+inoculate	O
+3	O
+-	O
+week	O
+-	O
+old	O
+piglets	O
+.	O
+
+The	O
+standard	O
+therapy	O
+for	O
+SS	O
+is	O
+systemic	O
+corticosteroids	B-CHED
+.	O
+
+Histopathological	O
+examination	O
+suggested	O
+perivascular	O
+neutrophilic	B-PROC
+infiltration	B-DISO
+with	O
+scattered	O
+eosinophils	B-ANAT
+.	O
+
+However	O
+,	O
+the	O
+selection	O
+and	O
+consequences	O
+of	O
+inhibitor	B-CHED
+-	O
+resistant	O
+CoVs	O
+are	O
+unknown	O
+.	O
+
+Overall	O
+,	O
+our	O
+study	O
+provides	O
+the	O
+first	O
+analysis	O
+of	O
+the	O
+low	O
+barrier	O
+but	O
+high	O
+cost	O
+of	O
+resistance	B-PROC
+to	O
+a	O
+CoV	O
+3CLpro	O
+inhibitor	B-CHED
+,	O
+which	O
+will	O
+facilitate	O
+the	O
+further	O
+development	B-PROC
+of	O
+protease	B-PROC
+inhibitors	I-PROC
+as	O
+anti	O
+-	O
+coronavirus	B-SPEC
+therapeutics	O
+.	O
+
+However	O
+,	O
+this	O
+PLpro	O
+inhibitor	B-CHED
+was	O
+not	O
+sufficient	O
+to	O
+protect	O
+the	O
+mice	B-SPEC
+from	O
+lethal	O
+infection	B-DISO
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+MA15	I-PRGE
+,	O
+suggesting	O
+that	O
+further	O
+optimization	O
+of	O
+the	O
+delivery	O
+and	O
+stability	O
+of	O
+PLpro	O
+inhibitors	B-CHED
+is	O
+needed	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+demonstrate	O
+that	O
+the	O
+chimeric	O
+-	O
+virus	B-SPEC
+system	O
+can	O
+be	O
+adapted	O
+to	O
+study	O
+the	O
+proteases	O
+of	O
+emerging	O
+human	B-SPEC
+pathogens	O
+,	O
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+On	O
+DOI	O
+11	O
+,	O
+he	O
+presented	O
+to	O
+an	O
+Indiana	O
+hospital	O
+as	O
+dyspneic	O
+,	O
+hypoxic	B-DISO
+,	O
+and	O
+with	O
+a	O
+right	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+infiltrate	B-DISO
+on	O
+chest	B-ANAT
+radiography	O
+.	O
+
+These	O
+cells	B-COMP
+are	O
+more	O
+suppressive	O
+than	O
+bulk	O
+Tregs	O
+and	O
+provide	O
+a	O
+targeted	B-PROC
+approach	O
+to	O
+ameliorating	O
+immunopathological	O
+disease	O
+in	O
+infectious	B-DISO
+settings	O
+.	O
+
+The	O
+RT	B-PRGE
+-	I-PRGE
+LAMP	I-PRGE
+assay	O
+was	O
+capable	O
+of	O
+detecting	O
+as	O
+few	O
+as	O
+3	O
+.	O
+4	O
+copies	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+,	O
+and	O
+was	O
+highly	O
+specific	O
+,	O
+with	O
+no	O
+cross	B-PROC
+-	I-PROC
+reaction	I-PROC
+to	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+To	O
+increase	O
+the	O
+understanding	O
+of	O
+the	O
+mechanisms	O
+involved	O
+in	O
+these	O
+processes	O
+,	O
+we	O
+focused	O
+on	O
+the	O
+evaluation	O
+of	O
+local	O
+inflammatory	O
+and	O
+cell	B-COMP
+-	O
+mediated	O
+immune	B-PROC
+responses	I-PROC
+after	O
+challenge	O
+with	O
+the	O
+M41	O
+strain	O
+of	O
+IBV	B-SPEC
+,	O
+associating	O
+these	O
+responses	O
+with	O
+pathologic	O
+changes	O
+in	O
+the	O
+tracheal	B-ANAT
+mucosa	I-ANAT
+.	O
+
+At	O
+24	O
+h	O
+post	O
+-	O
+infection	B-DISO
+,	O
+inflammatory	O
+cytokines	O
+related	O
+genes	O
+were	O
+significantly	O
+upregulated	O
+,	O
+including	O
+peaks	O
+of	O
+TNFSF15	B-PRGE
+and	O
+TGFβ	B-PRGE
+mRNA	I-PRGE
+production	O
+,	O
+although	O
+no	O
+tracheal	O
+microscopic	O
+alterations	O
+were	O
+observed	O
+and	O
+only	O
+a	O
+slightly	O
+increase	O
+in	O
+viral	O
+load	O
+occurred	O
+.	O
+
+ABSTRACT	O
+:	O
+Mounting	O
+reports	O
+on	O
+severe	O
+Plasmodium	O
+vivax	O
+malaria	B-PATH
+from	O
+across	O
+the	O
+globe	B-ANAT
+have	O
+raised	O
+concerns	O
+among	O
+the	O
+scientific	O
+community	O
+.	O
+
+A	O
+Phase	O
+2b	O
+/	O
+3	O
+clinical	O
+trial	O
+recently	O
+published	O
+in	O
+The	O
+Lancet	O
+Infectious	B-DISO
+Diseases	I-DISO
+found	O
+that	O
+oral	B-ANAT
+administration	O
+of	O
+nitazoxanide	O
+600mg	O
+twice	O
+daily	O
+for	O
+five	O
+days	O
+reduced	O
+the	O
+duration	O
+of	O
+clinical	O
+symptoms	O
+and	O
+reduced	O
+viral	B-DISO
+shedding	I-DISO
+compared	O
+to	O
+placebo	O
+in	O
+persons	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+influenza	B-DISO
+.	O
+
+From	O
+a	O
+chemical	O
+perspective	O
+,	O
+nitazoxanide	O
+is	O
+the	O
+scaffold	O
+for	O
+a	O
+new	O
+class	B-SPEC
+of	O
+drugs	O
+called	O
+thiazolides	O
+.	O
+
+However	O
+,	O
+over	O
+the	O
+last	O
+decade	O
+it	O
+has	O
+become	O
+clear	O
+that	O
+aggressive	B-DISO
+fluid	O
+resuscitation	O
+leading	O
+to	O
+fluid	B-DISO
+overload	I-DISO
+is	O
+associated	O
+with	O
+increased	O
+morbidity	O
+and	O
+mortality	O
+across	O
+a	O
+diverse	O
+group	O
+of	O
+patients	O
+,	O
+including	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+as	O
+well	O
+as	O
+elective	O
+surgical	O
+and	O
+trauma	O
+patients	O
+and	O
+those	O
+with	O
+pancreatitis	B-DISO
+.	O
+
+A	O
+CVP	O
+>	O
+8	O
+mmHg	O
+has	O
+been	O
+demonstrated	O
+to	O
+decrease	O
+microcirculatory	O
+flow	O
+,	O
+as	O
+well	O
+as	O
+renal	B-PROC
+blood	B-ANAT
+flow	I-PROC
+and	O
+is	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+renal	B-DISO
+failure	I-DISO
+and	O
+death	B-PROC
+.	O
+
+This	O
+paper	O
+reviews	O
+the	O
+adverse	B-DISO
+effects	I-DISO
+of	O
+large	O
+volume	O
+resuscitation	O
+,	O
+a	O
+high	O
+CVP	O
+and	O
+the	O
+excessive	O
+use	O
+of	O
+normal	O
+saline	O
+.	O
+
+Results	O
+of	O
+a	O
+meta	B-SPEC
+-	O
+analysis	O
+using	O
+individual	O
+patient	O
+data	O
+from	O
+three	O
+randomized	O
+controlled	O
+trials	O
+suggest	O
+that	O
+higher	O
+PEEP	B-CHED
+should	O
+be	O
+used	O
+for	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+,	O
+whereas	O
+lower	O
+PEEP	B-CHED
+may	O
+be	O
+more	O
+appropriate	O
+in	O
+patients	O
+with	O
+mild	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+support	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+2008	O
+,	O
+severe	O
+cases	O
+of	O
+emerging	O
+human	O
+adenovirus	B-DISO
+type	O
+55	O
+(	O
+HAdV	O
+-	O
+55	O
+)	O
+in	O
+immunocompetent	O
+adults	O
+have	O
+been	O
+reported	O
+sporadically	O
+in	O
+China	O
+.	O
+
+We	O
+prospectively	O
+collected	O
+and	O
+analyzed	O
+clinical	O
+,	O
+laboratory	O
+,	O
+radiological	O
+characteristics	O
+,	O
+sequential	O
+tests	O
+of	O
+viral	O
+load	O
+in	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+blood	B-ANAT
+,	O
+treatments	O
+and	O
+outcomes	O
+.	O
+
+Mean	O
+durations	O
+from	O
+onset	O
+to	O
+a	O
+single	O
+-	O
+lobe	B-ANAT
+consolidation	O
+shown	O
+on	O
+chest	B-ANAT
+X	O
+-	O
+rays	B-SPEC
+(	O
+CXRs	O
+)	O
+and	O
+,	O
+from	O
+the	O
+first	O
+positive	O
+CXR	O
+to	O
+bilateral	O
+multilobar	O
+lung	B-ANAT
+infiltrates	B-DISO
+,	O
+were	O
+2	O
+days	O
+and	O
+4	O
+.	O
+8	O
+days	O
+,	O
+respectively	O
+.	O
+
+Four	O
+(	O
+80	O
+%)	O
+of	O
+the	O
+five	O
+patients	O
+died	B-PROC
+despite	O
+receiving	O
+appropriate	O
+respiratory	O
+support	O
+.	O
+
+Clinical	O
+and	O
+radiological	O
+features	O
+were	O
+collected	O
+in	O
+83	O
+patients	O
+with	O
+ILD	O
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+).	O
+
+Sequencing	O
+analysis	O
+of	O
+the	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+revealed	O
+that	O
+mutations	O
+in	O
+S	O
+might	O
+be	O
+a	O
+potential	O
+determinant	O
+of	O
+auxiliary	O
+targets	O
+for	O
+PEDV	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+emerged	O
+in	O
+North	O
+America	O
+in	O
+April	O
+2013	O
+and	O
+has	O
+since	O
+been	O
+identified	O
+in	O
+30	O
+U	O
+.	O
+S	O
+.	O
+States	O
+,	O
+Canada	O
+and	O
+Mexico	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+infectivity	O
+of	O
+PEDV	B-SPEC
+RNA	O
+present	O
+in	O
+commercial	O
+SDPP	O
+.	O
+
+Specifically	O
+,	O
+40	O
+3	O
+-	O
+week	O
+-	O
+old	O
+PEDV	B-SPEC
+naïve	O
+pigs	B-SPEC
+were	O
+randomly	O
+assigned	O
+to	O
+one	O
+of	O
+five	O
+treatment	O
+groups	O
+.	O
+
+All	O
+PEDV	B-SPEC
+-	O
+CONTROL	O
+pigs	B-SPEC
+began	O
+shedding	O
+PEDV	B-SPEC
+in	O
+feces	B-ANAT
+by	O
+dpi	B-PRGE
+3	I-PRGE
+and	O
+seroconverted	O
+between	O
+dpi	O
+7	O
+and	O
+14	O
+,	O
+whereas	O
+pigs	B-SPEC
+in	O
+NEG	O
+-	O
+CONTROL	O
+and	O
+SDPP	O
+-	O
+CONTROL	O
+groups	O
+remained	O
+PEDV	B-SPEC
+RNA	O
+negative	O
+and	O
+did	O
+not	O
+seroconvert	O
+to	O
+PEDV	B-SPEC
+for	O
+the	O
+study	O
+duration	O
+.	O
+
+Heliox	O
+may	O
+also	O
+enhance	O
+the	O
+bronchodilating	O
+effects	O
+of	O
+β	O
+-	O
+agonist	B-CHED
+administration	O
+for	O
+acute	B-DISO
+asthma	I-DISO
+.	O
+
+Nevertheless	O
+,	O
+many	O
+of	O
+these	O
+genes	O
+are	O
+still	O
+maintained	O
+in	O
+the	O
+virus	B-SPEC
+genome	O
+under	O
+selective	O
+pressure	O
+,	O
+suggesting	O
+that	O
+they	O
+might	O
+play	O
+a	O
+very	O
+important	O
+role	O
+in	O
+the	O
+survival	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+natural	O
+environment	O
+of	O
+the	O
+infected	O
+host	B-COMP
+.	O
+
+The	O
+most	O
+common	O
+risk	O
+factor	O
+was	O
+pneumonia	B-DISO
+[	O
+50	O
+(	O
+71	O
+%)].	O
+
+Adjunct	O
+therapies	O
+used	O
+in	O
+our	O
+patients	O
+included	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+[	O
+5	O
+(	O
+7	O
+%)],	O
+prone	O
+position	O
+[	O
+22	O
+(	O
+31	O
+%)],	O
+steroids	B-CHED
+[	O
+26	O
+(	O
+37	O
+%)],	O
+and	O
+neuromuscular	B-DISO
+blockade	I-DISO
+[	O
+26	O
+(	O
+37	O
+%)].	O
+
+Risk	O
+factors	O
+for	O
+mortality	O
+included	O
+having	O
+an	O
+underlying	O
+comorbidity	O
+,	O
+multiorgan	O
+dysfunction	O
+,	O
+a	O
+low	O
+PF	O
+ratio	O
+,	O
+and	O
+high	O
+OI	O
+at	O
+24	O
+h	O
+of	O
+ARDS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Risk	O
+factors	O
+for	O
+mortality	O
+included	O
+having	O
+an	O
+underlying	O
+comorbidity	O
+,	O
+multiorgan	O
+dysfunction	O
+,	O
+a	O
+low	O
+PF	O
+ratio	O
+,	O
+and	O
+high	O
+OI	O
+at	O
+24	O
+h	O
+of	O
+ARDS	B-DISO
+.	O
+
+Here	O
+we	O
+report	O
+that	O
+E	B-PRGE
+protein	I-PRGE
+PDZ	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+motif	I-PRGE
+(	O
+PBM	O
+),	O
+a	O
+domain	O
+involved	O
+in	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+,	O
+is	O
+a	O
+major	O
+determinant	O
+of	O
+virulence	B-PROC
+.	O
+
+Syntenin	B-PRGE
+redistributed	O
+from	O
+the	O
+nucleus	B-COMP
+to	O
+the	O
+cell	B-COMP
+cytoplasm	B-COMP
+during	O
+infection	B-DISO
+with	O
+viruses	B-SPEC
+containing	O
+the	O
+E	O
+protein	B-CHED
+PBM	O
+,	O
+activating	O
+p38	B-FUNC
+MAPK	B-FUNC
+and	O
+leading	O
+to	O
+the	O
+overexpression	O
+of	O
+inflammatory	O
+cytokines	O
+.	O
+
+Active	O
+p38	B-PRGE
+MAPK	B-FUNC
+was	O
+reduced	O
+in	O
+lungs	B-ANAT
+of	O
+mice	B-SPEC
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoVs	O
+lacking	O
+E	B-PRGE
+protein	I-PRGE
+PBM	O
+as	O
+compared	O
+with	O
+the	O
+parental	O
+virus	B-SPEC
+,	O
+leading	O
+to	O
+a	O
+decreased	O
+expression	B-PROC
+of	O
+inflammatory	O
+cytokines	O
+and	O
+to	O
+virus	B-SPEC
+attenuation	O
+.	O
+
+Expression	B-PROC
+of	O
+TMPRSS2	O
+is	O
+essential	O
+for	O
+the	O
+spread	O
+and	O
+pathogenesis	B-DISO
+of	O
+H1N1	B-DISO
+influenza	I-DISO
+viruses	O
+in	O
+mice	B-SPEC
+.	O
+
+We	O
+found	O
+that	O
+MSPL	B-PRGE
+and	O
+,	O
+to	O
+a	O
+lesser	O
+degree	O
+,	O
+DESC1	B-PRGE
+are	O
+expressed	B-PROC
+in	O
+human	B-SPEC
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+cleave	O
+and	O
+activate	O
+the	O
+spike	O
+proteins	B-CHED
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronaviruses	O
+for	O
+cell	B-COMP
+-	O
+cell	B-COMP
+and	O
+virus	B-SPEC
+-	O
+cell	B-PROC
+fusion	I-PROC
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+show	O
+that	O
+these	O
+proteases	O
+support	O
+the	O
+spread	O
+of	O
+all	O
+influenza	B-SPEC
+virus	I-SPEC
+subtypes	O
+previously	O
+pandemic	O
+in	O
+humans	O
+.	O
+
+Importance	O
+:	O
+Activation	O
+of	O
+influenza	B-SPEC
+viruses	I-SPEC
+by	O
+host	B-COMP
+cell	I-COMP
+proteases	O
+is	O
+essential	O
+for	O
+viral	O
+infectivity	O
+and	O
+the	O
+enzymes	O
+responsible	O
+are	O
+potential	O
+targets	O
+for	O
+antiviral	B-CHED
+intervention	O
+.	O
+
+A	O
+total	O
+of	O
+833	O
+cases	O
+from	O
+a	O
+teaching	O
+hospital	O
+was	O
+surveyed	O
+for	O
+prevalence	O
+of	O
+different	O
+FCoV	O
+infections	B-DISO
+.	O
+
+Characterisation	O
+of	O
+the	O
+bat	B-ENZY
+microRNA	O
+repertoire	O
+is	O
+an	O
+essential	O
+step	O
+towards	O
+understanding	O
+transcriptional	B-PROC
+regulation	I-PROC
+during	O
+viral	B-DISO
+infection	I-DISO
+,	O
+and	O
+will	O
+assist	O
+in	O
+the	O
+identification	O
+of	O
+mechanisms	O
+that	O
+enable	O
+bats	B-SPEC
+to	O
+act	O
+as	O
+natural	O
+virus	B-SPEC
+reservoirs	O
+.	O
+
+However	O
+,	O
+understanding	O
+of	O
+FIP	B-DISO
+pathogenesis	B-DISO
+is	O
+still	O
+incomplete	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+describe	O
+key	O
+features	O
+of	O
+the	O
+preparedness	O
+for	O
+the	O
+2014	O
+Hajj	O
+and	O
+Umra	O
+,	O
+review	O
+the	O
+recent	O
+impact	O
+of	O
+emerging	O
+viruses	B-SPEC
+such	O
+as	O
+Ebola	O
+in	O
+West	O
+Africa	O
+and	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+affected	O
+countries	O
+,	O
+and	O
+highlight	O
+the	O
+updated	O
+requirements	O
+and	O
+the	O
+required	O
+vaccines	O
+.	O
+
+From	O
+the	O
+31	O
+positive	O
+samples	O
+,	O
+only	O
+10	O
+gave	O
+positive	O
+results	O
+in	O
+molecular	O
+tests	O
+aimed	O
+at	O
+various	O
+IBV	B-SPEC
+genome	O
+fragments	O
+:	O
+five	O
+samples	O
+were	O
+positive	O
+for	O
+the	O
+RdRp	B-PRGE
+gene	I-PRGE
+,	O
+four	O
+for	O
+gene	O
+3	O
+,	O
+eight	O
+for	O
+gene	O
+N	O
+and	O
+eight	O
+for	O
+the	O
+3	O
+'-	O
+untranslated	O
+region	O
+fragment	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoV	O
+)	O
+have	O
+recently	O
+emerged	O
+as	O
+potentially	O
+serious	O
+pathogens	O
+that	O
+can	O
+cause	O
+significant	O
+human	B-SPEC
+morbidity	O
+and	O
+death	B-PROC
+.	O
+
+This	O
+severely	O
+limits	O
+host	B-COMP
+cell	I-COMP
+IFN	O
+responses	O
+.	O
+
+Since	O
+it	O
+has	O
+been	O
+reported	O
+that	O
+sepsis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+contribute	O
+to	O
+brain	B-DISO
+dysfunction	I-DISO
+,	O
+we	O
+investigated	O
+the	O
+brain	B-ANAT
+-	O
+lung	B-ANAT
+crosstalk	B-PROC
+using	O
+a	O
+combined	O
+experimental	O
+in	O
+vitro	O
+airway	B-ANAT
+epithelial	O
+and	O
+brain	B-ANAT
+cell	I-ANAT
+injury	O
+model	O
+.	O
+
+Conditioned	O
+medium	O
+at	O
+15	O
+%	O
+significantly	O
+increased	O
+apoptosis	B-PATH
+in	O
+brain	B-ANAT
+cell	I-ANAT
+cultures	O
+24	O
+h	O
+after	O
+treatment	O
+,	O
+whereas	O
+25	O
+%	O
+and	O
+50	O
+%	O
+significantly	O
+increased	O
+both	O
+necrosis	B-PROC
+and	O
+apoptosis	B-PATH
+.	O
+
+Our	O
+findings	O
+demonstrated	O
+that	O
+human	B-SPEC
+epithelial	O
+pulmonary	B-ANAT
+cells	B-COMP
+stimulated	O
+with	O
+bacterial	O
+lipopolysaccharide	B-CHED
+release	B-PATH
+inflammatory	O
+mediators	O
+that	O
+are	O
+able	O
+to	O
+induce	O
+a	O
+translational	B-PROC
+clinically	O
+relevant	O
+and	O
+harmful	O
+response	O
+in	O
+brain	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+FTY720	B-CHED
+(	O
+fingolimod	B-CHED
+)	O
+modulates	O
+the	O
+severity	O
+of	O
+viral	O
+-	O
+induced	O
+encephalomyelitis	B-DISO
+and	O
+demyelination	B-DISO
+.	O
+
+Treatment	O
+with	O
+FTY720	B-CHED
+did	O
+not	O
+affect	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+,	O
+expression	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+or	O
+cytolytic	O
+activity	O
+.	O
+
+Steady	O
+-	O
+state	O
+kinetic	O
+analyses	O
+of	O
+purified	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+PLpros	O
+uncovered	O
+significant	O
+differences	O
+in	O
+their	O
+rates	O
+of	O
+hydrolysis	O
+of	O
+5	O
+-	O
+aminomethyl	O
+coumarin	B-CHED
+(	O
+AMC	B-DISO
+)	O
+from	O
+C	O
+-	O
+terminally	O
+labeled	O
+peptide	B-CHED
+,	O
+ubiquitin	B-PROC
+,	O
+and	O
+ISG15	B-PRGE
+substrates	O
+,	O
+as	O
+well	O
+as	O
+in	O
+their	O
+rates	O
+of	O
+isopeptide	O
+bond	O
+cleavage	B-PROC
+of	O
+K48	B-PRGE
+-	I-PRGE
+and	I-PRGE
+K63	I-PRGE
+-	I-PRGE
+linked	I-PRGE
+polyubiquitin	I-PRGE
+chains	I-PRGE
+.	O
+
+MERS	O
+-	O
+CoV	O
+PLpro	O
+was	O
+found	O
+to	O
+have	O
+8	O
+-	O
+fold	O
+and	O
+3	O
+,	O
+500	O
+-	O
+fold	O
+higher	O
+catalytic	O
+efficiencies	O
+for	O
+hydrolysis	O
+of	O
+ISG15	B-PRGE
+-	I-PRGE
+AMC	I-PRGE
+than	O
+for	O
+hydrolysis	O
+of	O
+the	O
+Ub	O
+-	O
+AMC	B-DISO
+and	O
+Z	O
+-	O
+RLRGG	O
+-	O
+AMC	B-DISO
+substrates	O
+,	O
+respectively	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+PLpro	O
+was	O
+found	O
+to	O
+process	O
+K48	O
+-	O
+and	O
+K63	O
+-	O
+linked	O
+polyubiquitin	B-PRGE
+chains	I-PRGE
+at	O
+similar	O
+rates	O
+and	O
+with	O
+similar	O
+debranching	O
+patterns	O
+,	O
+producing	O
+monoubiquitin	O
+species	B-SPEC
+.	O
+
+However	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+PLpro	O
+much	O
+preferred	O
+K48	O
+-	O
+linked	O
+polyubiquitin	B-PRGE
+chains	I-PRGE
+to	O
+K63	O
+-	O
+linked	O
+chains	O
+,	O
+and	O
+it	O
+rapidly	O
+produced	O
+di	O
+-	O
+ubiquitin	B-PROC
+molecules	O
+from	O
+K48	O
+-	O
+linked	O
+chains	O
+.	O
+
+Under	O
+prolonged	O
+and	O
+irremediable	O
+ER	O
+stress	O
+,	O
+however	O
+,	O
+the	O
+UPR	O
+can	O
+also	O
+trigger	O
+apoptosis	B-PATH
+.	O
+
+Knockdown	O
+and	O
+overexpression	B-PROC
+experiments	O
+demonstrated	O
+that	O
+IRE1α	O
+protects	O
+infected	O
+cells	B-COMP
+from	O
+IBV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+,	O
+which	O
+required	O
+both	O
+its	O
+kinase	O
+and	O
+RNase	B-PRGE
+activities	O
+.	O
+
+Modeling	O
+of	O
+the	O
+interaction	O
+between	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+and	O
+its	O
+receptor	O
+dipeptidyl	O
+peptidase	B-PRGE
+4	I-PRGE
+predicted	O
+comparable	O
+interaction	O
+energies	O
+in	O
+common	B-SPEC
+marmosets	I-SPEC
+and	O
+humans	B-SPEC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+description	O
+of	O
+a	O
+severe	O
+,	O
+partially	O
+lethal	O
+,	O
+disease	O
+model	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+as	O
+such	O
+will	O
+have	O
+a	O
+major	O
+impact	O
+on	O
+the	O
+ability	O
+to	O
+assess	O
+the	O
+efficacy	O
+of	O
+vaccines	O
+and	O
+treatment	O
+strategies	O
+as	O
+well	O
+as	O
+allowing	O
+more	O
+detailed	O
+pathogenesis	B-DISO
+studies	O
+.	O
+
+We	O
+prospectively	O
+recruited	O
+patients	O
+consecutively	O
+admitted	O
+for	O
+ARF	B-DISO
+to	O
+the	O
+ICU	O
+of	O
+a	O
+university	O
+teaching	O
+hospital	O
+over	O
+a	O
+12	O
+-	O
+month	O
+period	O
+.	O
+
+This	O
+study	O
+demonstrated	O
+for	O
+the	O
+first	O
+time	O
+to	O
+our	O
+knowledge	O
+a	O
+significantly	O
+better	O
+performance	O
+of	O
+TUS	O
+than	O
+LUS	O
+in	O
+the	O
+diagnosis	O
+of	O
+ARF	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+effects	O
+of	O
+prone	O
+position	O
+ventilation	O
+combined	O
+with	O
+recruitment	B-DISO
+maneuvers	O
+on	O
+outcomes	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+].	O
+
+The	O
+plateau	O
+pressure	O
+and	O
+static	O
+compliance	O
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+were	O
+similar	O
+in	O
+the	O
+two	O
+groups	O
+.	O
+
+In	O
+Mecp2	B-PRGE
+mutant	B-DISO
+mice	B-SPEC
+,	O
+BDNF	O
+deficits	O
+have	O
+been	O
+associated	O
+with	O
+breathing	B-DISO
+abnormalities	I-DISO
+,	O
+a	O
+core	O
+feature	O
+of	O
+RTT	B-DISO
+,	O
+as	O
+well	O
+as	O
+with	O
+synaptic	O
+hyperexcitability	B-PROC
+within	O
+the	O
+brainstem	B-ANAT
+respiratory	O
+network	O
+.	O
+
+In	O
+vivo	O
+,	O
+acute	O
+treatment	O
+of	O
+Mecp2	B-PRGE
+-	O
+null	O
+and	O
+-	O
+heterozygous	O
+mutants	O
+with	O
+LM22A	O
+-	O
+4	O
+completely	O
+eliminated	O
+spontaneous	O
+apneas	B-DISO
+in	O
+resting	B-ANAT
+animals	B-SPEC
+,	O
+without	O
+sedation	B-DISO
+.	O
+
+Together	O
+,	O
+these	O
+data	O
+support	O
+the	O
+hypothesis	O
+that	O
+reduced	O
+BDNF	B-PRGE
+signaling	B-PROC
+and	O
+respiratory	B-DISO
+dysfunction	I-DISO
+in	O
+RTT	B-DISO
+are	O
+linked	O
+,	O
+and	O
+establish	O
+the	O
+proof	O
+-	O
+of	O
+-	O
+concept	O
+that	O
+treatment	O
+with	O
+a	O
+small	O
+-	O
+molecule	O
+structural	O
+mimetic	O
+of	O
+a	O
+BDNF	O
+loop	O
+domain	O
+and	O
+a	O
+TrkB	B-PRGE
+partial	O
+agonist	B-CHED
+can	O
+acutely	O
+reverse	O
+abnormal	B-DISO
+breathing	I-DISO
+at	O
+rest	B-FUNC
+and	O
+in	O
+response	O
+to	O
+behavioral	B-PROC
+arousal	O
+in	O
+symptomatic	O
+RTT	B-DISO
+mice	B-SPEC
+.	O
+
+The	O
+index	O
+case	O
+-	O
+patient	O
+'	O
+s	O
+respiratory	B-ANAT
+tract	I-ANAT
+samples	O
+were	O
+negative	O
+for	O
+MERS	O
+-	O
+CoV	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+,	O
+but	O
+diagnosis	O
+was	O
+retrospectively	O
+confirmed	O
+by	O
+PCR	O
+of	O
+serum	B-COMP
+.	O
+
+TITLE	O
+:	O
+Enhanced	O
+MERS	O
+coronavirus	B-SPEC
+surveillance	O
+of	O
+travelers	O
+from	O
+the	O
+Middle	O
+East	O
+to	O
+England	O
+.	O
+
+Traditional	O
+management	O
+of	O
+aHUS	O
+includes	O
+plasma	B-ANAT
+infusion	O
+/	O
+exchange	O
+,	O
+but	O
+in	O
+small	O
+or	O
+unstable	O
+infants	O
+,	O
+plasma	B-ANAT
+exchange	O
+can	O
+be	O
+challenging	O
+because	O
+of	O
+high	O
+extracorporeal	O
+volume	O
+and	O
+difficulty	O
+to	O
+obtain	O
+an	O
+adequate	O
+venous	B-ANAT
+access	O
+.	O
+
+Part	O
+16	O
+:	O
+Structure	O
+-	O
+based	O
+bioisosterism	O
+design	O
+,	O
+synthesis	B-PROC
+and	O
+biological	O
+evaluation	O
+of	O
+novel	O
+pyrimidinylthioacetanilides	O
+as	O
+potent	O
+HIV	O
+-	O
+1	O
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Mutations	O
+of	O
+3c	O
+and	O
+spike	O
+protein	B-CHED
+genes	O
+correlate	O
+with	O
+the	O
+occurrence	O
+of	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Evolution	B-PROC
+of	O
+polymerase	O
+chain	O
+reaction	O
+testing	O
+for	O
+infectious	O
+pathogens	O
+has	O
+occurred	O
+concurrent	O
+with	O
+a	O
+focus	O
+on	O
+value	O
+-	O
+based	O
+medicine	B-CHED
+.	O
+
+After	O
+RRP	O
+implementation	O
+,	O
+the	O
+mean	O
+time	O
+to	O
+the	O
+test	O
+result	O
+was	O
+shorter	O
+(	O
+383	O
+minutes	O
+versus	O
+1119	O
+minutes	O
+,	O
+P	O
+<	O
+.	O
+001	O
+),	O
+and	O
+the	O
+percentage	O
+of	O
+patients	O
+with	O
+a	O
+result	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+was	O
+greater	O
+(	O
+51	O
+.	O
+6	O
+%	O
+versus	O
+13	O
+.	O
+4	O
+%,	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+In	O
+addition	O
+to	O
+the	O
+two	O
+known	O
+serotypes	O
+of	O
+CCoV	O
+,	O
+novel	O
+recombinant	O
+variants	O
+of	O
+CCoV	O
+have	O
+been	O
+found	O
+containing	O
+spike	O
+protein	B-CHED
+N	O
+-	O
+terminal	O
+domains	O
+(	O
+NTDs	O
+)	O
+that	O
+are	O
+closely	O
+related	O
+to	O
+those	O
+of	O
+feline	B-SPEC
+and	O
+porcine	B-SPEC
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+ability	O
+of	O
+small	O
+interfering	O
+RNAs	O
+(	O
+siRNAs	O
+)	O
+to	O
+inhibit	O
+in	O
+vitro	O
+viral	B-PROC
+replication	I-PROC
+and	O
+gene	B-PROC
+expression	I-PROC
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+).	O
+
+If	O
+iNO	O
+was	O
+initiated	O
+for	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+a	O
+detailed	O
+evaluation	O
+by	O
+the	O
+ECMO	O
+team	O
+determined	O
+if	O
+ECMO	O
+was	O
+indicated	O
+.	O
+
+A	O
+lack	O
+of	O
+serologic	O
+tools	O
+has	O
+hindered	O
+targeted	B-PROC
+studies	O
+of	O
+transmission	O
+.	O
+
+Of	O
+these	O
+cases	O
+,	O
+7	O
+were	O
+identified	O
+by	O
+means	O
+of	O
+RT	O
+-	O
+PCR	O
+,	O
+all	O
+in	O
+samples	O
+obtained	O
+within	O
+14	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+in	O
+index	O
+patients	O
+,	O
+and	O
+5	O
+were	O
+identified	O
+by	O
+means	O
+of	O
+serologic	O
+analysis	O
+,	O
+all	O
+in	O
+samples	O
+obtained	O
+13	O
+days	O
+or	O
+more	O
+after	O
+symptom	B-DISO
+onset	O
+in	O
+index	O
+patients	O
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+61	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+past	O
+medical	O
+history	O
+of	O
+chronic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+emphysema	B-DISO
+,	O
+and	O
+a	O
+known	O
+multiple	B-DISO
+myeloma	I-DISO
+(	O
+Durie	O
+and	O
+Salmon	B-PRGE
+stage	I-PRGE
+III	I-PRGE
+B	I-PRGE
+and	O
+t	O
+(	O
+4	O
+;	O
+14	O
+)	O
+translocation	B-DISO
+).	O
+
+Six	O
+months	O
+after	O
+diagnosis	O
+and	O
+first	O
+line	O
+of	O
+treatment	O
+,	O
+he	O
+presented	O
+acute	B-DISO
+dyspnea	I-DISO
+with	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+.	O
+
+Therefore	O
+,	O
+major	O
+objectives	O
+for	O
+anesthesiologists	O
+and	O
+surgeons	O
+are	O
+first	O
+to	O
+prevent	O
+the	O
+occurrence	O
+of	O
+postoperative	B-DISO
+complications	I-DISO
+and	O
+second	O
+if	O
+ARF	O
+occurs	O
+is	O
+to	O
+ensure	O
+oxygen	B-CHED
+administration	O
+and	O
+carbon	B-CHED
+dioxide	I-CHED
+CO2	B-CHED
+removal	O
+while	O
+avoiding	O
+intubation	O
+.	O
+
+For	O
+effective	O
+control	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+quick	O
+and	O
+specific	O
+diagnosis	O
+is	O
+of	O
+utmost	O
+importance	O
+.	O
+
+A	O
+linear	O
+correlation	O
+was	O
+obtained	O
+between	O
+predicted	O
+antibody	B-COMP
+titres	O
+at	O
+a	O
+single	O
+working	O
+dilution	O
+of	O
+1	O
+:	O
+100	O
+and	O
+the	O
+corresponding	O
+serum	O
+titres	O
+observed	O
+as	O
+determined	O
+by	O
+the	O
+standard	O
+serial	O
+dilution	O
+method	O
+.	O
+
+The	O
+developed	O
+equation	O
+was	O
+then	O
+used	O
+to	O
+extrapolate	O
+predicated	O
+ELISA	O
+antibody	B-COMP
+titer	O
+from	O
+corrected	O
+absorbance	O
+readings	O
+of	O
+the	O
+single	O
+working	O
+dilution	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+has	O
+been	O
+reported	O
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+but	O
+phenotypic	O
+characterisation	O
+of	O
+such	O
+viruses	B-SPEC
+is	O
+limited	O
+.	O
+
+Controversy	O
+remains	O
+as	O
+to	O
+at	O
+what	O
+point	O
+in	O
+the	O
+clinical	O
+pathway	B-PROC
+ECMO	O
+should	O
+be	O
+employed	O
+;	O
+as	O
+a	O
+rescue	O
+therapy	O
+or	O
+more	O
+pro	B-CHED
+-	O
+actively	O
+to	O
+enable	O
+and	O
+ensure	O
+high	O
+-	O
+quality	O
+lung	B-ANAT
+protective	O
+mechanical	O
+ventilation	O
+.	O
+
+Consecutive	O
+adult	O
+patients	O
+with	O
+CAP	B-DISO
+between	O
+April	O
+and	O
+December	O
+,	O
+2009	O
+were	O
+prospectively	O
+enrolled	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Respiratory	O
+virus	B-SPEC
+was	O
+not	O
+a	O
+bystander	O
+,	O
+but	O
+pathogenic	O
+in	O
+pneumonia	B-DISO
+and	O
+was	O
+a	O
+common	O
+cause	O
+of	O
+CAP	B-DISO
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+:	O
+transmission	O
+and	O
+phylogenetic	O
+evolution	B-PROC
+.	O
+
+Among	O
+them	O
+,	O
+twenty	O
+-	O
+three	O
+compounds	O
+showed	O
+much	O
+better	O
+anti	O
+-	O
+HBV	B-DISO
+activity	O
+than	O
+caudatin	O
+,	O
+and	O
+eleven	O
+compounds	O
+significantly	O
+inhibited	O
+the	O
+HBV	B-DISO
+DNA	B-PATH
+replication	I-PATH
+with	O
+IC50	O
+values	O
+<	O
+10	O
+μM	O
+.	O
+Interestingly	O
+,	O
+three	O
+compounds	O
+(	O
+22	O
+,	O
+28	O
+,	O
+29	O
+)	O
+exhibited	O
+excellent	O
+activity	O
+against	O
+the	O
+secretion	B-PROC
+of	O
+HBsAg	O
+(	O
+IC50	O
+=	O
+63	O
+.	O
+02	O
+μM	O
+,	O
+52	O
+.	O
+81	O
+μM	O
+,	O
+56	O
+.	O
+08	O
+μM	O
+),	O
+HBeAg	O
+(	O
+IC50	O
+=	O
+204	O
+.	O
+80	O
+μM	O
+,	O
+173	O
+.	O
+51	O
+μM	O
+,	O
+70	O
+.	O
+39	O
+μM	O
+),	O
+along	O
+with	O
+HBV	B-DISO
+DNA	B-PATH
+replication	I-PATH
+(	O
+IC50	O
+=	O
+24	O
+.	O
+55	O
+μM	O
+,	O
+5	O
+.	O
+69	O
+μM	O
+,	O
+8	O
+.	O
+23	O
+μM	O
+)	O
+with	O
+lower	O
+cytotoxicity	B-DISO
+.	O
+
+The	O
+present	O
+study	O
+demonstrates	O
+that	O
+the	O
+both	O
+BCoV	O
+and	O
+GARV	O
+are	O
+involved	O
+in	O
+the	O
+neonatal	O
+calves	O
+'	O
+diarrhea	B-DISO
+,	O
+where	O
+the	O
+frequency	O
+of	O
+BCoV	O
+is	O
+clearly	O
+higher	O
+than	O
+that	O
+of	O
+GARV	O
+.	O
+
+Furthermore	O
+,	O
+within	O
+the	O
+CD8	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+population	O
+short	O
+-	O
+lived	O
+effector	B-CHED
+cells	B-COMP
+were	O
+increased	O
+and	O
+memory	B-PROC
+precursor	O
+effector	B-CHED
+cells	B-COMP
+were	O
+significantly	O
+decreased	O
+,	O
+consistent	O
+with	O
+higher	O
+T	O
+-	O
+cell	O
+turnover	O
+.	O
+
+However	O
+,	O
+memory	B-PROC
+CD8	B-PRGE
+T	B-ANAT
+cells	I-ANAT
+primed	O
+without	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+and	O
+transferred	O
+into	O
+infected	O
+CD4	B-PRGE
+-	O
+sufficient	O
+recipients	O
+expanded	O
+less	O
+efficiently	O
+and	O
+were	O
+not	O
+sustained	O
+in	O
+the	O
+CNS	B-CHED
+,	O
+contrasting	O
+with	O
+their	O
+helped	O
+counterparts	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+utilizes	O
+heparan	B-CHED
+sulfate	I-CHED
+proteoglycans	B-CHED
+for	O
+attachment	O
+to	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Design	O
+of	O
+an	O
+epitope	B-CHED
+-	O
+based	O
+peptide	B-CHED
+vaccine	O
+against	O
+spike	O
+protein	B-CHED
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+:	O
+an	O
+in	O
+silico	O
+approach	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronavirus	O
+(	O
+HCoV	O
+),	O
+a	O
+member	O
+of	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+,	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+""""	O
+atypical	B-DISO
+pneumonia	I-DISO
+"""."	O
+
+The	O
+frequency	O
+of	O
+cases	O
+and	O
+deaths	B-PROC
+was	O
+calculated	O
+and	O
+adjusted	O
+by	O
+month	O
+,	O
+sex	O
+,	O
+age	O
+group	O
+,	O
+and	O
+region	O
+.	O
+
+Further	O
+analytical	O
+studies	O
+are	O
+required	O
+to	O
+determine	O
+the	O
+source	O
+and	O
+mode	O
+of	O
+infection	B-DISO
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+impact	O
+of	O
+anesthetic	O
+equipment	O
+on	O
+clinical	O
+practice	O
+parameters	O
+associated	O
+with	O
+development	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+has	O
+not	O
+been	O
+extensively	O
+studied	O
+.	O
+
+Existing	O
+anesthesia	B-DISO
+machines	O
+(	O
+Narkomed	O
+IIb	O
+,	O
+Drager	O
+)	O
+were	O
+exchanged	O
+for	O
+new	O
+equipment	O
+(	O
+Aisys	O
+,	O
+General	O
+Electric	O
+).	O
+
+In	O
+response	O
+,	O
+various	O
+surveillance	O
+systems	O
+have	O
+been	O
+developed	O
+to	O
+monitor	O
+the	O
+emergence	O
+of	O
+respiratory	O
+-	O
+tract	O
+infections	B-DISO
+.	O
+
+A	O
+united	O
+and	O
+coordinated	O
+global	O
+response	O
+is	O
+needed	O
+to	O
+tackle	O
+emerging	O
+viruses	B-SPEC
+that	O
+can	O
+cause	O
+fatal	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+to	O
+fill	O
+major	O
+gaps	O
+in	O
+the	O
+understanding	O
+of	O
+the	O
+epidemiology	O
+and	O
+transmission	O
+dynamics	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+New	O
+viral	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+with	O
+epidemic	O
+potential	O
+,	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+swine	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+,	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+require	O
+development	B-PROC
+of	O
+new	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+The	O
+high	O
+cost	O
+of	O
+life	O
+-	O
+long	O
+HAART	O
+and	O
+the	O
+emergence	O
+of	O
+drug	B-PROC
+resistance	I-PROC
+among	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+-	O
+infected	O
+individuals	O
+have	O
+brought	O
+renewed	O
+pressure	O
+for	O
+the	O
+discovery	O
+of	O
+novel	O
+antivirals	B-CHED
+and	O
+alternative	O
+medicines	O
+.	O
+
+ABSTRACT	O
+:	O
+Celiac	O
+and	O
+splanchnic	O
+plexus	B-ANAT
+blocks	O
+are	O
+considered	O
+as	O
+terminal	O
+approaches	O
+for	O
+pain	O
+control	O
+in	O
+end	O
+stage	B-DISO
+pancreatic	I-DISO
+cancer	B-SPEC
+.	O
+
+It	O
+may	O
+be	O
+done	O
+temporarily	O
+(	O
+using	O
+local	B-CHED
+anesthetics	I-CHED
+)	O
+or	O
+as	O
+a	O
+permanent	O
+act	O
+(	O
+using	O
+alcohol	O
+and	O
+/	O
+or	O
+phenol	B-CHED
+).	O
+
+Among	O
+viruses	O
+,	O
+coronavirus	B-SPEC
+was	O
+the	O
+most	O
+commonly	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+characteristics	O
+and	O
+changes	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+strain	O
+CK	O
+/	O
+CH	O
+/	O
+LDL	B-CHED
+/	O
+97I	O
+after	O
+serial	O
+passages	O
+in	O
+chicken	O
+embryos	B-ANAT
+.	O
+
+To	O
+further	O
+characterize	O
+the	O
+catalytic	O
+system	O
+of	O
+CoV	O
+main	O
+proteases	O
+and	O
+to	O
+obtain	O
+information	O
+about	O
+improved	O
+inhibitors	B-CHED
+,	O
+we	O
+performed	O
+comprehensive	O
+simulations	O
+of	O
+the	O
+proton	B-CHED
+-	O
+transfer	O
+reactions	O
+in	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+M	O
+(	O
+pro	B-CHED
+)	O
+active	O
+site	O
+that	O
+lead	O
+to	O
+the	O
+Cys	B-CHED
+(-)/	O
+His	O
+(+)	O
+zwitterionic	O
+state	O
+required	O
+for	O
+efficient	O
+proteolytic	B-PROC
+activity	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+nsp12	O
+,	O
+the	O
+canonical	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+),	O
+exhibits	O
+poorly	O
+processive	O
+RNA	B-PROC
+synthesis	I-PROC
+in	O
+vitro	O
+,	O
+at	O
+odds	O
+with	O
+the	O
+efficient	O
+replication	O
+of	O
+a	O
+very	O
+large	O
+RNA	O
+genome	O
+in	O
+vivo	O
+.	O
+
+Without	O
+a	O
+loss	O
+of	O
+processivity	O
+,	O
+the	O
+nsp7	O
+/	O
+nsp8	O
+/	O
+nsp12	O
+complex	O
+can	O
+associate	O
+with	O
+nsp14	O
+,	O
+a	O
+bifunctional	O
+enzyme	O
+bearing	O
+3	O
+'-	O
+5	O
+'	O
+exoribonuclease	O
+and	O
+RNA	B-PRGE
+cap	I-PRGE
+N7	I-PRGE
+-	I-PRGE
+guanine	B-CHED
+methyltransferase	I-PRGE
+activities	O
+involved	O
+in	O
+replication	O
+fidelity	O
+and	O
+5	O
+'-	O
+RNA	B-PROC
+capping	I-PROC
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Canine	O
+distemper	O
+virus	O
+(	O
+CDV	B-CHED
+)	O
+has	O
+been	O
+associated	O
+with	O
+outbreaks	O
+of	O
+canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+in	O
+shelters	O
+and	O
+boarding	O
+kennel	O
+environments	O
+.	O
+
+CDV	B-CHED
+RT	O
+-	O
+iiPCR	O
+demonstrated	O
+excellent	O
+sensitivity	O
+(	O
+100	O
+%)	O
+and	O
+specificity	O
+(	O
+100	O
+%),	O
+compared	O
+to	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Activation	O
+of	O
+the	O
+complement	O
+system	O
+correlates	O
+with	O
+the	O
+development	B-PROC
+of	O
+FH	O
+.	O
+
+Wild	O
+type	O
+mice	B-SPEC
+were	O
+treated	O
+with	O
+or	O
+without	O
+antagonists	B-CHED
+of	O
+C5aR	B-PRGE
+or	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+and	O
+mice	B-SPEC
+deficient	O
+for	O
+C5aR	B-PRGE
+(	O
+C5aR	B-PRGE
+(-/-)),	O
+Fgl2	B-PRGE
+(	O
+Fgl2	B-PRGE
+(-/-)),	O
+and	O
+Tnfα	O
+(	O
+Tnfα	O
+(-/-))	O
+mice	B-SPEC
+were	O
+not	O
+treated	O
+with	O
+the	O
+antagonists	B-CHED
+.	O
+
+We	O
+observed	O
+that	O
+complement	B-PROC
+activation	I-PROC
+,	O
+coagulation	B-PROC
+and	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokine	B-PROC
+production	I-PROC
+were	O
+upregulated	O
+in	O
+the	O
+HBV	B-DISO
+(+)	O
+patients	O
+with	O
+FH	O
+.	O
+
+Complement	B-PROC
+activation	I-PROC
+and	O
+coagulation	B-PROC
+were	O
+significantly	O
+reduced	O
+in	O
+MHV	B-SPEC
+-	O
+3	O
+infected	O
+mice	B-SPEC
+in	O
+the	O
+absence	O
+of	O
+C5aR	B-PRGE
+,	O
+Tnfα	O
+or	O
+Fgl2	B-PRGE
+.	O
+
+Clinically	O
+,	O
+they	O
+manifest	O
+as	O
+limb	B-ANAT
+and	O
+respiratory	B-ANAT
+muscle	I-ANAT
+weakness	O
+.	O
+
+Substantial	O
+progress	O
+has	O
+been	O
+made	O
+lately	O
+in	O
+the	O
+understanding	O
+of	O
+the	O
+pathophysiology	O
+of	O
+critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+and	O
+myopathy	B-DISO
+.	O
+
+The	O
+present	O
+review	O
+is	O
+aimed	O
+at	O
+providing	O
+the	O
+latest	O
+knowledge	O
+concerning	O
+the	O
+pathophysiology	O
+of	O
+critical	O
+illness	O
+polyneuropathy	O
+/	O
+myopathy	B-DISO
+along	O
+with	O
+relevant	O
+clinical	O
+,	O
+diagnostic	O
+,	O
+differentiating	O
+,	O
+and	O
+treatment	O
+information	O
+for	O
+this	O
+debilitating	O
+neurological	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+non	B-PROC
+-	I-PROC
+nucleoside	I-PROC
+reverse	B-CHED
+transcriptase	I-CHED
+inhibitors	I-CHED
+derived	O
+from	O
+indole	B-CHED
+-	O
+based	O
+α	O
+-	O
+amino	B-CHED
+acids	I-CHED
+were	O
+designed	O
+and	O
+synthesized	O
+.	O
+
+From	O
+the	O
+screened	O
+compounds	O
+,	O
+the	O
+novel	O
+inhibitors	B-CHED
+19	O
+and	O
+29	O
+were	O
+identified	O
+to	O
+be	O
+highly	O
+potent	O
+candidates	O
+with	O
+EC50	O
+values	O
+of	O
+0	O
+.	O
+060	O
+μM	O
+and	O
+0	O
+.	O
+045	O
+μM	O
+respectively	O
+(	O
+CC50	O
+values	O
+of	O
+109	O
+.	O
+545	O
+μM	O
+and	O
+49	O
+.	O
+295	O
+μM	O
+and	O
+SI	O
+values	O
+of	O
+1825	O
+.	O
+8	O
+and	O
+1095	O
+.	O
+4	O
+).	O
+
+The	O
+results	O
+also	O
+indicate	O
+that	O
+the	O
+indole	B-CHED
+-	O
+based	O
+α	O
+-	O
+amino	B-CHED
+acids	I-CHED
+as	O
+efficient	O
+NNRTIs	O
+displayed	O
+comparable	O
+anti	O
+-	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+activities	O
+to	O
+the	O
+reference	O
+drug	O
+NVP	O
+.	O
+
+Immunoglobulin	B-PROC
+neutralize	O
+virus	B-SPEC
+invasion	B-DISO
+and	O
+suppress	O
+viremia	B-DISO
+,	O
+acting	O
+synergistically	O
+with	O
+acyclovir	B-CHED
+.	O
+
+TITLE	O
+:	O
+Current	O
+perspectives	O
+in	O
+transfusion	O
+-	O
+transmitted	B-DISO
+infectious	B-DISO
+diseases	I-DISO
+:	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+infections	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+August	O
+2009	O
+,	O
+a	O
+group	O
+from	O
+the	O
+AABB	O
+(	O
+Stramer	O
+et	O
+al	O
+.,	O
+Transfusion	O
+2009	O
+;	O
+99	O
+:	O
+1S	O
+-	O
+29S	O
+,	O
+Emerging	B-DISO
+Infectious	I-DISO
+Disease	I-DISO
+Agents	O
+and	O
+their	O
+Potential	O
+Threat	O
+to	O
+Transfusion	O
+Safety	O
+;	O
+http	O
+://	O
+www	O
+.	O
+aabb	O
+.	O
+org	O
+/	O
+resources	O
+/	O
+bct	O
+/	O
+eid	O
+/	O
+Pages	O
+/	O
+default	O
+.	O
+aspx	O
+)	O
+published	O
+a	O
+Supplement	O
+to	O
+Transfusion	O
+that	O
+reviewed	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+(	O
+EID	O
+)	O
+agents	O
+that	O
+pose	O
+a	O
+real	O
+or	O
+theoretical	O
+threat	O
+to	O
+transfusion	O
+safety	O
+,	O
+but	O
+for	O
+which	O
+an	O
+existing	O
+effective	O
+intervention	O
+is	O
+lacking	O
+.	O
+
+Agents	O
+given	O
+the	O
+highest	O
+priority	O
+due	O
+to	O
+a	O
+known	O
+transfusion	O
+-	O
+transmission	O
+threat	O
+and	O
+severe	O
+/	O
+fatal	O
+disease	O
+in	O
+recipients	O
+were	O
+the	O
+vCJD	B-DISO
+prion	O
+,	O
+dengue	B-SPEC
+viruses	I-SPEC
+and	O
+the	O
+obligate	O
+red	O
+-	O
+cell	B-COMP
+parasite	O
+that	O
+causes	O
+babesiosis	B-DISO
+(	O
+Since	O
+the	O
+publication	O
+of	O
+the	O
+Supplement	O
+,	O
+six	O
+new	O
+FSs	B-DISO
+(	O
+yellow	B-SPEC
+fever	I-SPEC
+viruses	I-SPEC
+-	O
+including	O
+vaccine	O
+breakthrough	O
+infections	B-DISO
+,	O
+miscellaneous	O
+arboviruses	O
+,	O
+XMRV	O
+,	O
+human	B-SPEC
+parvoviruses	B-SPEC
+/	O
+bocaviruses	B-SPEC
+other	O
+than	O
+B19	O
+,	O
+and	O
+most	O
+recently	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+MERS	O
+-	O
+CoV	O
+)	O
+were	O
+added	O
+and	O
+14	O
+existing	O
+FSs	B-DISO
+updated	O
+(	O
+Anaplasma	B-SPEC
+,	O
+Babesia	B-SPEC
+,	O
+Bartonella	B-SPEC
+,	O
+Erhlichia	O
+,	O
+chronic	B-DISO
+wasting	I-DISO
+disease	I-DISO
+-	O
+CWD	O
+,	O
+human	B-SPEC
+prions	O
+other	O
+than	O
+vCJD	B-DISO
+,	O
+vCJD	B-DISO
+,	O
+The	O
+process	O
+and	O
+final	O
+product	O
+(	O
+toolkit	O
+)	O
+including	O
+methods	O
+to	O
+monitor	O
+EID	O
+agent	O
+emergence	O
+,	O
+identification	O
+/	O
+recognition	O
+of	O
+a	O
+transfusion	O
+-	O
+transmission	O
+threat	O
+,	O
+methods	O
+for	O
+quantitative	O
+risk	O
+assessments	O
+,	O
+and	O
+the	O
+appropriate	O
+management	O
+of	O
+such	O
+threats	O
+should	O
+be	O
+considered	O
+for	O
+implementation	O
+by	O
+all	O
+blood	B-ANAT
+systems	O
+.	O
+
+ABSTRACT	O
+:	O
+Chloroplast	B-COMP
+-	O
+based	O
+expression	B-PROC
+system	O
+is	O
+promising	O
+for	O
+the	O
+hyper	O
+-	O
+expression	B-PROC
+of	O
+plant	B-SPEC
+-	O
+derived	O
+recombinant	O
+therapeutic	O
+proteins	B-CHED
+and	O
+vaccines	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+results	O
+demonstrate	O
+the	O
+feasibility	O
+of	O
+highly	O
+expressing	O
+SARS	B-DISO
+subunit	O
+vaccine	O
+RBD	O
+,	O
+indicating	O
+its	O
+potential	O
+in	O
+subsequent	O
+development	B-PROC
+of	O
+a	O
+plant	B-SPEC
+-	O
+derived	O
+recombinant	O
+subunit	O
+vaccine	O
+and	O
+reagents	B-CHED
+production	O
+for	O
+antibody	B-COMP
+detection	O
+in	O
+SARS	B-DISO
+serological	O
+tests	O
+.	O
+
+An	O
+increasing	O
+body	B-ANAT
+of	O
+evidence	O
+suggests	O
+that	O
+STING	O
+also	O
+modulates	O
+responses	O
+to	O
+RNA	O
+viruses	B-SPEC
+,	O
+though	O
+the	O
+mechanisms	O
+remain	O
+less	O
+clear	O
+.	O
+
+Finally	O
+,	O
+we	O
+discuss	O
+STING	O
+antagonism	O
+in	O
+the	O
+coronaviruses	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+,	O
+which	O
+disrupt	O
+K63	O
+-	O
+linked	O
+polyubiquitination	B-PROC
+and	O
+dimerisation	O
+of	O
+STING	O
+(	O
+both	O
+of	O
+which	O
+are	O
+required	O
+for	O
+STING	O
+-	O
+mediated	O
+activation	O
+of	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+)	O
+via	O
+their	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+.	O
+
+A	O
+meta	B-SPEC
+-	O
+analysis	O
+was	O
+conducted	O
+,	O
+using	O
+published	O
+randomized	O
+and	O
+nonrandomized	O
+controlled	O
+clinical	O
+studies	O
+that	O
+compared	O
+the	O
+treatment	O
+effects	O
+of	O
+integrative	O
+TCM	O
+/	O
+WM	O
+with	O
+WM	O
+alone	O
+from	O
+2002	O
+to	O
+2006	O
+.	O
+
+A	O
+total	O
+of	O
+63	O
+patients	O
+were	O
+divided	O
+into	O
+a	O
+severe	O
+pulmonary	B-ANAT
+contusion	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+group	O
+and	O
+a	O
+non	O
+-	O
+ARDS	O
+group	O
+,	O
+or	O
+a	O
+survivor	O
+group	O
+and	O
+a	O
+non	O
+-	O
+survivor	O
+group	O
+,	O
+or	O
+an	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+<	O
+20	O
+group	O
+and	O
+an	O
+ISS	B-DISO
+≥	O
+20	O
+group	O
+.	O
+
+The	O
+concentration	O
+of	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+showed	O
+a	O
+similar	O
+expression	B-PROC
+pattern	O
+in	O
+both	O
+groups	O
+,	O
+but	O
+the	O
+expression	B-PROC
+increased	O
+more	O
+significantly	O
+in	O
+the	O
+ARDS	B-DISO
+group	O
+than	O
+in	O
+the	O
+non	O
+-	O
+ARDS	B-DISO
+group	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+level	O
+of	O
+plasma	B-ANAT
+vWF	B-PRGE
+was	O
+higher	O
+in	O
+the	O
+ISS	O
+≥	O
+20	O
+group	O
+than	O
+in	O
+the	O
+ISS	B-DISO
+<	O
+20	O
+group	O
+.	O
+
+HVHF	O
+combined	O
+with	O
+fluid	O
+resuscitation	O
+can	O
+improve	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+-	O
+oxygen	B-CHED
+exchange	O
+,	O
+decrease	O
+the	O
+APACHE	O
+II	O
+score	O
+in	O
+patients	O
+with	O
+refractory	O
+septic	B-DISO
+shock	I-DISO
+,	O
+and	O
+thus	O
+it	O
+increases	O
+the	O
+survival	O
+rate	O
+of	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+culture	O
+isolation	O
+and	O
+sequence	O
+analysis	O
+of	O
+genetically	O
+diverse	O
+US	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+strains	O
+including	O
+a	O
+novel	O
+strain	O
+with	O
+a	O
+large	O
+deletion	O
+in	O
+the	O
+spike	O
+gene	O
+.	O
+
+Currently	O
+there	O
+are	O
+no	O
+efficacious	O
+preventive	O
+measures	O
+or	O
+therapeutic	O
+tools	O
+to	O
+control	O
+PEDV	B-SPEC
+in	O
+the	O
+US	O
+.	O
+
+Representative	O
+strains	O
+of	O
+these	O
+three	O
+genetic	O
+groups	O
+were	O
+passaged	O
+serially	O
+and	O
+grew	O
+to	O
+titers	O
+of	O
+∼	O
+5	O
+-	O
+6log10	O
+plaque	B-DISO
+forming	O
+units	O
+/	O
+mL	O
+.	O
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+the	O
+isolation	O
+in	O
+cell	B-COMP
+culture	O
+of	O
+an	O
+S	O
+INDEL	B-PROC
+PEDV	B-SPEC
+strain	O
+and	O
+a	O
+PEDV	B-SPEC
+strain	O
+with	O
+a	O
+large	O
+(	O
+197aa	O
+)	O
+deletion	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+global	O
+condition	B-DISO
+of	O
+epidemics	O
+:	O
+Panoramas	O
+in	O
+A	O
+(	O
+H1N1	O
+)	O
+influenza	B-DISO
+and	O
+their	O
+consequences	O
+for	O
+One	O
+World	O
+One	O
+Health	O
+programme	O
+.	O
+
+Using	O
+a	O
+qualitative	O
+approach	O
+,	O
+I	O
+conducted	O
+individual	O
+semi	O
+-	O
+structured	O
+interviews	O
+with	O
+35	O
+SARS	O
+survivors	O
+,	O
+who	O
+were	O
+purposively	O
+sampled	O
+from	O
+a	O
+tai	O
+chi	B-CHED
+class	B-SPEC
+of	O
+a	O
+SARS	B-DISO
+-	O
+patient	O
+self	O
+-	O
+help	O
+group	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+RESULTS	O
+:	O
+Health	O
+concerns	O
+and	O
+social	O
+experiences	O
+motivated	O
+the	O
+participants	O
+to	O
+practise	O
+tai	B-PRGE
+chi	I-PRGE
+in	O
+post	O
+-	O
+SARS	B-DISO
+Hong	O
+Kong	O
+.	O
+
+Experiencing	O
+health	O
+deterioration	O
+in	O
+relation	O
+to	O
+SARS	B-DISO
+-	O
+associated	O
+sequelae	O
+,	O
+coping	O
+with	O
+unpleasant	O
+experiences	O
+during	O
+follow	O
+-	O
+up	O
+biomedical	O
+treatments	O
+,	O
+a	O
+desire	O
+to	O
+regain	O
+an	O
+active	O
+role	O
+in	O
+recovery	O
+and	O
+rehabilitation	O
+,	O
+overcoming	O
+SARS	B-DISO
+-	O
+associated	O
+stigmas	O
+by	O
+establishing	O
+a	O
+new	O
+social	O
+network	O
+and	O
+preparing	O
+for	O
+potential	O
+future	O
+stigmatization	O
+and	O
+discrimination	O
+were	O
+the	O
+key	O
+motivators	O
+for	O
+them	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+participants	O
+practised	O
+tai	B-PRGE
+chi	I-PRGE
+not	O
+only	O
+because	O
+they	O
+sought	O
+to	O
+improve	O
+their	O
+health	O
+but	O
+also	O
+because	O
+it	O
+provided	O
+a	O
+crucial	O
+social	O
+function	O
+and	O
+meaning	O
+to	O
+them	O
+.	O
+
+Even	O
+if	O
+such	O
+responses	O
+are	O
+initiated	O
+,	O
+the	O
+maturation	O
+pathways	B-PROC
+are	O
+so	O
+extraordinarily	O
+complex	O
+that	O
+prolonged	O
+periods	B-PROC
+of	O
+time	O
+may	O
+be	O
+required	O
+for	O
+elicitation	O
+of	O
+bnAbs	O
+with	O
+defined	O
+unique	O
+sequences	O
+.	O
+
+Here	O
+,	O
+we	O
+discuss	O
+studies	O
+exploring	O
+the	O
+antibody	B-COMP
+germline	O
+/	O
+maturation	B-PROC
+hypothesis	O
+as	O
+related	O
+to	O
+elicitation	O
+of	O
+bnAbs	O
+against	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+and	O
+present	O
+our	O
+recent	O
+data	O
+demonstrating	O
+the	O
+existence	O
+of	O
+germline	O
+-	O
+like	O
+precursors	O
+of	O
+VRC01	O
+antibodies	B-COMP
+in	O
+a	O
+human	B-SPEC
+cord	B-ANAT
+blood	I-ANAT
+IgM	O
+library	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+;	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+)	O
+causes	O
+acute	O
+respiratory	O
+and	O
+reproductive	B-PROC
+and	O
+urogenital	B-DISO
+diseases	I-DISO
+in	O
+chickens	B-SPEC
+.	O
+
+The	O
+present	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+various	O
+combined	O
+non	O
+-	O
+biological	O
+artificial	O
+liver	B-ANAT
+treatments	O
+for	O
+patients	O
+with	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+(	O
+ALF	O
+)	O
+complicated	O
+by	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+).	O
+
+TBIL	O
+and	O
+ALT	B-FUNC
+decreased	O
+more	O
+significantly	O
+after	O
+treatment	O
+in	O
+the	O
+PE	O
++	O
+CVVHDF	O
+and	O
+PE	O
++	O
+HP	O
++	O
+CVVHDF	O
+groups	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Prothrombin	B-PRGE
+time	I-PRGE
+(	O
+PT	O
+)	O
+and	O
+albumin	B-PRGE
+were	O
+significantly	O
+improved	O
+only	O
+in	O
+the	O
+PE	O
++	O
+CVVHDF	O
+and	O
+PE	O
++	O
+HP	O
++	O
+CVVHDF	O
+groups	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Bone	B-ANAT
+marrow	I-ANAT
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+protect	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+from	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+apoptosis	O
+partially	O
+by	O
+inhibiting	O
+the	O
+Wnt	B-PRGE
+/	O
+β	B-PRGE
+-	I-PRGE
+catenin	I-PRGE
+pathway	B-PROC
+.	O
+
+However	O
+,	O
+RBD	O
+-	O
+directed	O
+nAbs	O
+may	O
+be	O
+useful	O
+for	O
+providing	O
+broad	O
+neutralization	O
+and	O
+prevention	O
+of	O
+escape	O
+variants	O
+when	O
+combined	O
+with	O
+other	O
+nAbs	O
+that	O
+target	O
+a	O
+second	O
+conserved	O
+epitope	B-CHED
+with	O
+less	O
+plasticity	O
+and	O
+more	O
+structural	O
+constraint	O
+.	O
+
+Broadly	O
+neutralizing	O
+antibodies	B-COMP
+(	O
+nAbs	O
+)	O
+that	O
+prevent	O
+infection	B-DISO
+of	O
+related	O
+viruses	B-SPEC
+represent	O
+an	O
+important	O
+immunostrategy	O
+for	O
+combating	O
+coronavirus	B-DISO
+infections	I-DISO
+;	O
+however	O
+,	O
+for	O
+this	O
+strategy	O
+to	O
+succeed	O
+,	O
+it	O
+is	O
+essential	O
+to	O
+uncover	O
+nAb	O
+-	O
+mediated	O
+escape	O
+pathways	B-PROC
+and	O
+to	O
+pioneer	O
+strategies	O
+that	O
+prevent	O
+escape	O
+.	O
+
+Here	O
+,	O
+we	O
+used	O
+SARS	B-DISO
+-	O
+CoV	O
+as	O
+a	O
+research	O
+model	O
+and	O
+examined	O
+the	O
+escape	O
+pathways	B-PROC
+of	O
+broad	O
+nAbs	O
+that	O
+target	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Limitations	O
+on	O
+routine	O
+clinical	O
+applicability	O
+of	O
+the	O
+World	O
+Health	O
+Organization	O
+'	O
+s	O
+(	O
+WHO	O
+)	O
+guidelines	O
+for	O
+determination	O
+of	O
+severity	O
+in	O
+malaria	B-PATH
+does	O
+result	O
+in	O
+underestimation	O
+of	O
+the	O
+true	O
+burden	O
+of	O
+clinicians	O
+'	O
+perceived	O
+severity	O
+in	O
+malaria	B-PATH
+.	O
+
+Leucocytosis	B-DISO
+and	O
+severe	O
+thrombocytopaenia	O
+should	O
+be	O
+identified	O
+as	O
+severity	O
+determinant	O
+in	O
+malaria	B-PATH
+.	O
+
+Comparing	O
+to	O
+the	O
+typical	O
+reference	O
+CCV	B-DISO
+strains	O
+(	O
+type	O
+II	O
+),	O
+the	O
+nucleotide	B-CHED
+sequence	O
+of	O
+Korean	O
+strains	O
+had	O
+homology	O
+ranged	O
+from	O
+86	O
+.	O
+3	O
+%	O
+to	O
+98	O
+.	O
+3	O
+%	O
+(	O
+89	O
+.	O
+1	O
+%	O
+to	O
+99	O
+.	O
+2	O
+%	O
+for	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+)	O
+and	O
+87	O
+.	O
+7	O
+%	O
+to	O
+97	O
+.	O
+8	O
+%	O
+(	O
+92	O
+.	O
+4	O
+%	O
+to	O
+100	O
+%	O
+for	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+)	O
+when	O
+compared	O
+to	O
+FCoV	B-PRGE
+-	I-PRGE
+like	I-PRGE
+CCV	I-PRGE
+strains	O
+(	O
+type	O
+I	O
+).	O
+
+The	O
+relative	O
+synonymous	O
+codon	O
+usage	O
+value	O
+of	O
+each	O
+codon	O
+revealed	O
+that	O
+codon	O
+usage	O
+bias	B-SPEC
+exists	O
+and	O
+that	O
+PEDV	B-SPEC
+tends	O
+to	O
+use	O
+codons	O
+that	O
+end	O
+in	O
+T	O
+.	O
+The	O
+mean	O
+ENC	O
+value	O
+of	O
+47	O
+.	O
+91	O
+indicates	O
+that	O
+the	O
+codon	O
+usage	O
+bias	B-SPEC
+is	O
+low	O
+.	O
+
+TITLE	O
+:	O
+Predicting	O
+support	O
+for	O
+non	O
+-	O
+pharmaceutical	B-CHED
+interventions	O
+during	O
+infectious	B-DISO
+outbreaks	O
+:	O
+a	O
+four	O
+region	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+identified	O
+in	O
+patients	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+ABSTRACT	O
+:	O
+WHEN	O
+AN	O
+ANTIVIRAL	O
+IMMUNE	B-PROC
+RESPONSE	I-PROC
+IS	O
+GENERATED	O
+,	O
+A	O
+BALANCE	B-PROC
+MUST	O
+BE	O
+REACHED	O
+BETWEEN	O
+TWO	O
+OPPOSING	O
+PATHWAYS	B-PROC
+:	O
+the	O
+production	O
+of	O
+proinflammatory	O
+and	O
+cytotoxic	O
+effectors	O
+that	O
+drive	O
+a	O
+robust	O
+antiviral	B-CHED
+immune	B-PROC
+response	I-PROC
+to	O
+control	O
+the	O
+infection	B-DISO
+and	O
+regulators	O
+that	O
+function	O
+to	O
+limit	O
+or	O
+blunt	O
+an	O
+excessive	O
+immune	B-PROC
+response	I-PROC
+to	O
+minimize	O
+immune	O
+-	O
+mediated	O
+pathology	B-DISO
+and	O
+repair	B-PROC
+tissue	I-PROC
+damage	O
+.	O
+
+Nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+production	O
+by	O
+iNOS	O
+is	O
+an	O
+important	O
+proinflammatory	O
+mediator	O
+,	O
+whereas	O
+Arg1	B-PRGE
+-	O
+expressing	O
+macrophages	B-ANAT
+contribute	O
+to	O
+the	O
+resolution	O
+of	O
+inflammation	B-DISO
+and	O
+wound	B-PROC
+repair	I-PROC
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+will	O
+discuss	O
+a	O
+variety	O
+of	O
+viral	B-DISO
+infections	I-DISO
+,	O
+including	O
+HIV	B-DISO
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+LCMV	B-SPEC
+,	O
+HCV	B-SPEC
+,	O
+RSV	B-SPEC
+,	O
+and	O
+others	O
+,	O
+where	O
+myeloid	B-ANAT
+cells	I-ANAT
+influence	O
+the	O
+control	O
+and	O
+clearance	O
+of	O
+the	O
+virus	B-SPEC
+from	O
+the	O
+host	B-COMP
+,	O
+as	O
+well	O
+as	O
+the	O
+severity	O
+and	O
+resolution	O
+of	O
+tissue	B-ANAT
+damage	O
+,	O
+via	O
+the	O
+activities	O
+of	O
+iNOS	O
+and	O
+/	O
+or	O
+Arg1	B-PRGE
+.	O
+
+Plasma	B-ANAT
+samples	O
+of	O
+77	O
+patients	O
+with	O
+severe	O
+multiple	O
+trauma	O
+as	O
+defined	O
+by	O
+an	O
+Injury	O
+Severity	O
+Score	O
+(	O
+ISS	B-DISO
+)	O
+16	O
+or	O
+greater	O
+were	O
+obtained	O
+from	O
+a	O
+local	O
+repository	O
+and	O
+levels	O
+of	O
+soluble	O
+RAGE	B-PRGE
+,	O
+endogenous	B-PRGE
+secretory	B-PROC
+RAGE	I-PRGE
+,	I-PRGE
+cytokeratin	I-PRGE
+18	I-PRGE
+,	O
+cleaved	B-ANAT
+cytokeratin	B-PRGE
+18	I-PRGE
+,	O
+and	O
+interleukin	B-PRGE
+6	I-PRGE
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Moreover	O
+,	O
+soluble	O
+RAGE	O
+concentrations	O
+in	O
+patients	O
+with	O
+thoracic	B-DISO
+injuries	O
+were	O
+higher	O
+compared	O
+with	O
+patients	O
+without	O
+injury	O
+,	O
+and	O
+both	O
+isoforms	O
+of	O
+RAGE	O
+discriminated	O
+between	O
+patients	O
+with	O
+most	O
+severe	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+patients	O
+with	O
+milder	O
+forms	O
+.	O
+
+RESULTS	O
+:	O
+Both	O
+RAGE	O
+isoforms	O
+were	O
+transiently	O
+increased	O
+in	O
+plasma	B-ANAT
+within	O
+24	O
+hours	O
+after	O
+trauma	O
+,	O
+while	O
+cytokeratin	B-PRGE
+18	I-PRGE
+levels	O
+were	O
+unchanged	O
+.	O
+
+RAGE	O
+and	O
+cytokeratin	O
+18	O
+isoforms	O
+correlated	O
+significantly	O
+but	O
+to	O
+a	O
+low	O
+extent	O
+with	O
+interleukin	B-PRGE
+6	I-PRGE
+,	O
+while	O
+the	O
+isoforms	O
+of	O
+both	O
+parameters	O
+correlated	O
+to	O
+a	O
+high	O
+extent	O
+with	O
+one	O
+another	O
+.	O
+
+All	O
+patients	O
+were	O
+manually	O
+reviewed	O
+using	O
+a	O
+structured	O
+protocol	O
+in	O
+order	B-SPEC
+to	O
+identify	O
+the	O
+presence	O
+of	O
+infection	B-DISO
+.	O
+
+Incidence	O
+rate	O
+of	O
+sepsis	B-DISO
+of	O
+any	O
+severity	O
+.	O
+
+The	O
+validation	O
+of	O
+the	O
+results	O
+of	O
+swabs	O
+taken	O
+from	O
+the	O
+nose	B-ANAT
+and	O
+throat	B-ANAT
+were	O
+carried	O
+out	O
+in	O
+the	O
+Department	O
+of	O
+Influenza	B-DISO
+Research	O
+,	O
+National	O
+Influenza	B-DISO
+Center	O
+in	O
+Warsaw	O
+.	O
+
+Sal	B-CHED
+CURB	O
+®	O
+(	O
+Kemin	O
+Industries	O
+,	O
+Des	B-DISO
+Moines	O
+,	O
+IA	O
+,	O
+USA	O
+)	O
+is	O
+a	O
+FDA	O
+-	O
+approved	O
+liquid	O
+antimicrobial	B-CHED
+used	O
+to	O
+control	O
+Salmonella	B-DISO
+contamination	O
+in	O
+poultry	O
+and	O
+swine	B-SPEC
+diets	O
+.	O
+
+Clinical	O
+signs	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+(	O
+vomiting	B-DISO
+and	O
+diarrhea	B-DISO
+)	O
+and	O
+viral	B-DISO
+shedding	I-DISO
+in	O
+feces	B-ANAT
+were	O
+observed	O
+in	O
+the	O
+positive	O
+control	O
+group	O
+2	O
+-	O
+3	O
+days	O
+post	O
+-	O
+consumption	O
+of	O
+non	O
+-	O
+treated	O
+feed	O
+.	O
+
+In	O
+contrast	O
+,	O
+no	O
+evidence	O
+of	O
+infection	B-DISO
+was	O
+observed	O
+in	O
+pigs	B-SPEC
+fed	O
+Sal	B-CHED
+CURB	O
+®-	O
+treated	O
+feed	O
+or	O
+in	O
+the	O
+negative	O
+controls	O
+throughout	O
+the	O
+14	O
+-	O
+day	O
+study	O
+period	O
+.	O
+
+RESULTS	O
+:	O
+Sal	B-CHED
+CURB	O
+®	O
+(	O
+Kemin	O
+Industries	O
+,	O
+Des	B-DISO
+Moines	O
+,	O
+IA	O
+,	O
+USA	O
+)	O
+is	O
+a	O
+FDA	O
+-	O
+approved	O
+liquid	O
+antimicrobial	B-CHED
+used	O
+to	O
+control	O
+Salmonella	B-DISO
+contamination	O
+in	O
+poultry	O
+and	O
+swine	B-SPEC
+diets	O
+.	O
+
+In	O
+particular	O
+,	O
+how	O
+TRIM56	B-PRGE
+impacts	O
+human	B-SPEC
+-	O
+pathogenic	O
+viruses	B-SPEC
+is	O
+unknown	O
+.	O
+
+However	O
+,	O
+the	O
+impact	O
+of	O
+TRIM56	B-PRGE
+on	O
+human	B-SPEC
+-	O
+pathogenic	O
+RNA	O
+viruses	B-SPEC
+is	O
+unknown	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+correlate	O
+the	O
+clinicopathological	O
+findings	O
+and	O
+viral	O
+antigen	B-CHED
+distribution	O
+with	O
+the	O
+genotypic	O
+characteristics	O
+of	O
+CCoV	O
+in	O
+11	O
+puppies	O
+from	O
+nine	O
+premises	O
+in	O
+five	O
+states	O
+that	O
+were	O
+submitted	O
+for	O
+diagnostic	O
+investigation	O
+at	O
+Cornell	O
+University	O
+between	O
+2008	O
+and	O
+2013	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+complexity	O
+of	O
+multiple	O
+-	O
+item	O
+criteria	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+often	O
+causes	O
+inconvenience	O
+for	O
+physicians	O
+in	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+).	O
+
+The	O
+sensitivity	O
+,	O
+specificity	O
+,	O
+positive	O
+predictive	O
+value	O
+,	O
+negative	O
+predictive	O
+value	O
+,	O
+and	O
+accuracy	O
+of	O
+SP	O
+-	O
+A	O
+in	O
+the	O
+diagnosis	O
+of	O
+SAP	B-PRGE
+-	O
+induced	O
+ARDS	B-DISO
+were	O
+100	O
+.	O
+0	O
+%,	O
+81	O
+.	O
+8	O
+%,	O
+71	O
+.	O
+4	O
+%,	O
+100	O
+.	O
+0	O
+%,	O
+and	O
+87	O
+.	O
+5	O
+%,	O
+respectively	O
+.	O
+
+The	O
+sensitivity	O
+,	O
+specificity	O
+,	O
+positive	O
+predictive	O
+value	O
+,	O
+negative	O
+predictive	O
+value	O
+,	O
+and	O
+accuracy	O
+of	O
+SP	O
+-	O
+A	O
+in	O
+the	O
+diagnosis	O
+of	O
+SAP	B-PRGE
+-	O
+induced	O
+ARDS	B-DISO
+were	O
+100	O
+.	O
+0	O
+%,	O
+81	O
+.	O
+8	O
+%,	O
+71	O
+.	O
+4	O
+%,	O
+100	O
+.	O
+0	O
+%,	O
+and	O
+87	O
+.	O
+5	O
+%,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Ca2	B-ANAT
++	I-ANAT
+influx	O
+and	O
+ATP	B-CHED
+release	B-PATH
+mediated	O
+by	O
+mechanical	O
+stretch	O
+in	O
+human	B-SPEC
+lung	B-ANAT
+fibroblasts	B-ANAT
+.	O
+
+Hypotonic	B-DISO
+stress	O
+,	O
+which	O
+causes	O
+plasma	B-COMP
+membrane	I-COMP
+stretching	O
+,	O
+also	O
+transiently	O
+increased	O
+the	O
+[	O
+Ca	O
+(	O
+2	O
++)]	O
+i	O
+.	O
+
+This	O
+article	O
+offers	O
+clinicians	O
+a	O
+brief	O
+update	O
+on	O
+the	O
+general	O
+management	O
+guidelines	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+in	O
+pediatric	O
+patients	O
+.	O
+
+Specific	O
+treatment	O
+depends	O
+on	O
+the	O
+exact	O
+cause	O
+,	O
+however	O
+croup	B-DISO
+and	O
+acute	B-DISO
+severe	I-DISO
+asthma	I-DISO
+have	O
+been	O
+discussed	O
+in	O
+this	O
+article	O
+.	O
+
+Modern	O
+extracorporeal	O
+lung	B-ANAT
+support	O
+devices	O
+allow	O
+an	O
+effective	O
+extracorporeal	O
+gas	B-ENZY
+exchange	O
+and	O
+have	O
+become	O
+an	O
+inherent	O
+component	O
+of	O
+intensive	O
+care	O
+treatment	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Six	O
+patients	O
+underwent	O
+HSCT	O
+at	O
+non	O
+-	O
+remission	B-DISO
+status	O
+.	O
+
+Six	O
+patients	O
+experienced	O
+complications	O
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+.	O
+
+TITLE	O
+:	O
+The	O
+influence	O
+of	O
+age	O
+and	O
+genetics	O
+on	O
+natural	O
+resistance	B-PROC
+to	O
+experimentally	O
+induced	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+The	O
+present	O
+study	O
+followed	O
+111	O
+random	O
+-	O
+bred	O
+specific	O
+pathogen	O
+free	O
+(	O
+SPF	O
+)	O
+cats	B-SPEC
+that	O
+were	O
+obtained	O
+from	O
+a	O
+single	O
+research	O
+breeding	B-PROC
+colony	O
+and	O
+experimentally	O
+infected	O
+with	O
+FIPV	O
+.	O
+
+The	O
+cats	B-SPEC
+were	O
+from	O
+several	O
+studies	O
+conducted	O
+over	O
+the	O
+past	O
+5	O
+years	O
+,	O
+and	O
+as	O
+a	O
+result	O
+,	O
+some	O
+of	O
+them	O
+had	O
+prior	O
+exposure	O
+to	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+)	O
+or	O
+avirulent	O
+FIPVs	O
+.	O
+
+Arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+was	O
+conducted	O
+and	O
+serum	B-COMP
+cytokine	O
+levels	O
+,	O
+including	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+),	O
+interleukin	B-PRGE
+4	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+)	O
+and	O
+interleukin	B-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+),	O
+as	O
+well	O
+as	O
+C	B-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+)	O
+were	O
+evaluated	O
+respectively	O
+both	O
+before	O
+and	O
+6h	O
+,	O
+12h	O
+,	O
+and	O
+24h	O
+after	O
+CRRT	O
+therapy	O
+.	O
+
+We	O
+also	O
+showed	O
+that	O
+overexpression	B-PROC
+of	O
+PDK1	B-FUNC
+(	O
+3	O
+-	O
+phosphoinositide	B-CHED
+-	O
+dependent	O
+protein	B-ENZY
+kinase	I-ENZY
+1	O
+),	O
+the	O
+immediate	B-PRGE
+upstream	I-PRGE
+kinase	I-PRGE
+of	O
+PKB	B-PRGE
+/	O
+Akt	B-PRGE
+,	O
+suppressed	O
+M	O
+-	O
+induced	O
+apoptosis	B-PATH
+.	O
+
+Our	O
+work	O
+highlights	O
+that	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+protein	B-CHED
+is	O
+highly	O
+pro	B-CHED
+-	O
+apoptotic	O
+and	O
+is	O
+capable	O
+of	O
+simultaneously	O
+inducing	O
+apoptosis	B-PATH
+via	O
+initiating	O
+caspases	O
+8	O
+and	O
+9	O
+.	O
+
+CK	O
+/	O
+CH	O
+/	O
+SD09	O
+/	O
+005	O
+showed	O
+66	O
+%	O
+-	O
+69	O
+%	O
+and	O
+72	O
+%	O
+-	O
+81	O
+%	O
+nucleotide	B-CHED
+identities	O
+with	O
+the	O
+IBV	B-SPEC
+strains	O
+of	O
+other	O
+six	O
+clades	O
+in	O
+the	O
+S1	O
+and	O
+S2	O
+subunits	O
+,	O
+respectively	O
+.	O
+
+Multiple	O
+genetic	O
+mechanisms	O
+,	O
+including	O
+recombinations	B-PROC
+,	O
+mutations	O
+,	O
+insertions	O
+and	O
+deletions	O
+,	O
+are	O
+likely	O
+to	O
+have	O
+contributed	O
+to	O
+the	O
+emergence	O
+of	O
+this	O
+IBV	B-SPEC
+strain	O
+.	O
+
+The	O
+established	O
+method	O
+had	O
+a	O
+good	O
+linear	O
+correlation	O
+from	O
+7	O
+.	O
+77	O
+x	O
+10	O
+(	O
+8	O
+)	O
+to	O
+10	O
+(	O
+0	O
+)	O
+copies	O
+/	O
+microL	O
+.	O
+SPF	B-PRGE
+chickens	I-PRGE
+developed	O
+typical	O
+clinical	O
+signs	O
+of	O
+IBV	B-SPEC
+at	O
+the	O
+4th	O
+dpi	O
+,	O
+and	O
+the	O
+IBV	B-SPEC
+viral	O
+concentration	O
+of	O
+tissues	B-ANAT
+and	O
+organs	B-ANAT
+gradually	O
+increased	O
+with	O
+a	O
+peak	O
+of	O
+up	O
+to	O
+7	O
+.	O
+13	O
+x	O
+10	O
+(	O
+4	O
+)	O
+copies	O
+/	O
+microL	O
+.	O
+The	O
+viral	O
+concentration	O
+of	O
+most	O
+organs	B-ANAT
+decreased	O
+by	O
+the	O
+10th	O
+dpi	O
+,	O
+but	O
+those	O
+of	O
+the	O
+kidney	B-ANAT
+,	O
+trachea	B-DISO
+and	O
+lung	B-ANAT
+remained	O
+positive	O
+for	O
+IBV	B-SPEC
+at	O
+28	O
+dpi	O
+and	O
+the	O
+heart	O
+was	O
+still	O
+positive	O
+for	O
+IBV	B-SPEC
+at	O
+>	O
+35	O
+dpi	O
+.	O
+
+Throat	B-ANAT
+swab	I-ANAT
+specimens	O
+were	O
+collected	O
+from	O
+483	O
+cases	O
+of	O
+ILI	O
+who	O
+were	O
+outpatients	O
+in	O
+the	O
+influenza	B-DISO
+surveillance	O
+sentinel	O
+hospitals	O
+in	O
+Shijiazhuang	O
+between	O
+January	O
+and	O
+December	O
+2011	O
+.	O
+
+Twenty	O
+-	O
+six	O
+(	O
+5	O
+.	O
+38	O
+%)	O
+of	O
+all	O
+cases	O
+were	O
+co	O
+-	O
+infected	O
+with	O
+two	O
+or	O
+more	O
+viruses	B-SPEC
+,	O
+most	O
+commonly	O
+HEV	B-SPEC
+/	O
+HRV	O
+with	O
+other	O
+viruses	B-SPEC
+.	O
+
+All	O
+cases	O
+of	O
+RSV	B-PRGE
+were	O
+identified	O
+to	O
+be	O
+subtype	O
+A	O
+.	O
+PIV	O
+infection	B-DISO
+was	O
+mainly	O
+caused	O
+by	O
+PIV	O
+-	O
+3	O
+.	O
+
+Both	O
+,	O
+the	O
+One	O
+Health	O
+and	O
+the	O
+ecohealth	O
+approaches	O
+reflect	O
+the	O
+need	O
+for	O
+such	O
+a	O
+holistic	O
+systems	O
+perspective	O
+,	O
+however	O
+the	O
+current	O
+implementation	O
+of	O
+risk	O
+analysis	O
+frameworks	O
+for	O
+animal	B-SPEC
+health	O
+and	O
+food	O
+safety	O
+is	O
+still	O
+dominated	O
+by	O
+a	O
+natural	O
+or	O
+biomedical	O
+perspective	O
+of	O
+science	O
+as	O
+is	O
+the	O
+implementation	O
+of	O
+control	O
+and	O
+prevention	O
+policies	O
+.	O
+
+Mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+(	O
+MAPK	B-FUNC
+)	O
+pathways	B-PROC
+are	O
+involved	O
+in	O
+cytokine	B-PROC
+production	I-PROC
+,	O
+but	O
+the	O
+mechanisms	O
+that	O
+regulate	O
+these	O
+pathways	B-PROC
+remain	O
+poorly	O
+characterized	O
+.	O
+
+After	O
+LPS	B-DISO
+-	O
+injection	O
+,	O
+the	O
+lungs	B-ANAT
+were	O
+harvested	O
+to	O
+assess	O
+leukocyte	B-ANAT
+infiltration	B-DISO
+,	O
+cytokine	O
+and	O
+chemokine	B-PROC
+production	I-PROC
+,	O
+ERK	B-FUNC
+-	O
+MAPK	B-PROC
+activation	I-PROC
+and	O
+immunopathology	B-DISO
+.	O
+
+U0126	B-CHED
+,	O
+a	O
+selective	O
+MEK	B-PRGE
+/	O
+ERK	B-FUNC
+inhibitor	B-CHED
+,	O
+reduced	O
+the	O
+augmented	O
+LPS	B-DISO
+-	O
+induced	O
+inflammation	B-DISO
+in	O
+Spred	O
+-	O
+2	O
+(-/-)	O
+mice	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+LPS	B-DISO
+-	O
+induced	O
+acute	O
+lung	B-DISO
+inflammation	I-DISO
+was	O
+significantly	O
+exacerbated	O
+in	O
+Spred	O
+-	O
+2	O
+(-/-)	O
+mice	B-SPEC
+compared	O
+with	O
+WT	O
+mice	B-SPEC
+,	O
+as	O
+indicated	O
+by	O
+the	O
+numbers	O
+of	O
+infiltrating	B-DISO
+leukocytes	B-ANAT
+,	O
+levels	O
+of	O
+alveolar	B-PRGE
+TNF	I-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+CXCL2	B-PRGE
+and	O
+CCL2	B-PRGE
+in	O
+a	O
+later	O
+phase	O
+,	O
+and	O
+lung	B-ANAT
+pathology	B-DISO
+.	O
+
+A	O
+Cox	O
+proportional	O
+hazards	O
+model	O
+adjusted	O
+for	O
+age	O
+,	O
+sex	O
+and	O
+frailty	O
+,	O
+determined	O
+the	O
+relationship	O
+between	O
+immune	O
+phenotypes	O
+and	O
+time	O
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+uncultivable	O
+bat	B-ENZY
+influenza	B-SPEC
+virus	I-SPEC
+using	O
+a	O
+replicative	O
+synthetic	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+alfa	I-PRGE
+-	I-PRGE
+2a	I-PRGE
+for	O
+severe	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+:	O
+a	O
+retrospective	O
+cohort	O
+study	O
+.	O
+
+This	O
+report	O
+describes	O
+timing	O
+of	O
+antibody	B-COMP
+generation	O
+and	O
+disease	B-DISO
+progression	I-DISO
+following	O
+infection	B-DISO
+with	O
+a	O
+US	O
+PEDV	B-SPEC
+isolate	O
+by	O
+assessing	O
+fecal	B-ANAT
+viral	B-DISO
+shedding	I-DISO
+,	O
+morphometric	O
+analysis	O
+of	O
+intestinal	B-ANAT
+lesions	O
+,	O
+and	O
+magnitude	O
+of	O
+immunohistochemical	O
+staining	O
+.	O
+
+Multivariable	O
+prevalence	O
+ratios	O
+(	O
+mPRs	O
+)	O
+were	O
+used	O
+to	O
+assess	O
+the	O
+association	O
+between	O
+alcohol	O
+intake	O
+and	O
+HPV	O
+infections	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Prevalent	O
+infections	B-DISO
+were	O
+significantly	O
+higher	O
+among	O
+men	O
+in	O
+the	O
+highest	O
+quartile	O
+of	O
+alcohol	O
+intake	O
+and	O
+multivariable	O
+models	O
+revealed	O
+that	O
+the	O
+highest	O
+quartile	O
+of	O
+alcohol	O
+intake	O
+was	O
+associated	O
+with	O
+significantly	O
+increased	O
+risks	O
+for	O
+any	O
+(	O
+mPR	O
+=	O
+1	O
+.	O
+13	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+00	O
+to	O
+1	O
+.	O
+27	O
+)	O
+HPV	O
+types	O
+and	O
+oncogenic	O
+(	O
+mPR	O
+=	O
+1	O
+.	O
+35	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+08	O
+to	O
+1	O
+.	O
+68	O
+)	O
+HPV	O
+types	O
+.	O
+
+These	O
+S	O
+INDEL	B-PROC
+strains	O
+share	O
+99	O
+.	O
+8	O
+%-	O
+100	O
+%	O
+nt	O
+identity	O
+with	O
+each	O
+other	O
+and	O
+96	O
+.	O
+2	O
+%-	O
+96	O
+.	O
+7	O
+%	O
+nt	O
+identity	O
+with	O
+the	O
+initial	O
+US	O
+strains	O
+.	O
+
+The	O
+lung	B-ANAT
+is	O
+constantly	O
+exposed	O
+to	O
+the	O
+environment	O
+and	O
+is	O
+susceptible	O
+to	O
+infectious	B-DISO
+complications	O
+caused	O
+by	O
+bacterial	O
+,	O
+viral	O
+,	O
+fungal	O
+,	O
+and	O
+parasitic	O
+pathogens	O
+.	O
+
+The	O
+findings	O
+of	O
+this	O
+investigation	O
+,	O
+as	O
+well	O
+as	O
+associated	O
+ancillary	O
+studies	O
+,	O
+will	O
+be	O
+disseminated	O
+in	O
+the	O
+form	O
+of	O
+oral	B-ANAT
+and	O
+abstract	O
+presentations	O
+at	O
+major	O
+national	O
+and	O
+international	O
+medical	O
+specialty	O
+meetings	O
+.	O
+
+Immunoglobulin	B-PRGE
+G	I-PRGE
+(	O
+IgG	B-PRGE
+)	O
+titres	O
+peaked	O
+3	O
+weeks	O
+after	O
+the	O
+onset	O
+of	O
+illness	O
+,	O
+whilst	O
+IgM	B-PRGE
+levels	O
+remained	O
+constantly	O
+elevated	O
+during	O
+the	O
+follow	O
+-	O
+up	O
+period	O
+(	O
+second	O
+to	O
+fifth	O
+week	O
+of	O
+illness	O
+).	O
+
+MERS	O
+-	O
+CoV	O
+pseudovirion	O
+infection	O
+was	O
+shown	O
+to	O
+be	O
+enhanced	O
+by	O
+elevated	O
+levels	O
+of	O
+furin	B-PRGE
+expression	B-PROC
+,	O
+and	O
+entry	O
+could	O
+be	O
+decreased	O
+by	O
+furin	B-PRGE
+siRNA	I-PRGE
+silencing	O
+.	O
+
+Overall	O
+,	O
+we	O
+show	O
+that	O
+MERS	O
+-	O
+CoV	O
+has	O
+evolved	O
+an	O
+unusual	O
+two	O
+-	O
+step	O
+furin	B-PRGE
+activation	O
+for	O
+fusion	O
+,	O
+suggestive	O
+of	O
+a	O
+role	O
+during	O
+the	O
+process	O
+of	O
+emergence	O
+into	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+Zoonotic	O
+transmission	O
+of	O
+CoVs	O
+such	O
+as	O
+the	O
+recently	O
+identified	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)-	O
+CoV	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+,	O
+on	O
+the	O
+other	O
+hand	O
+,	O
+may	O
+be	O
+associated	O
+with	O
+severe	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+This	O
+article	O
+reviews	O
+the	O
+clinical	O
+and	O
+pathological	O
+data	O
+available	O
+on	O
+MERS	O
+and	O
+compares	O
+it	O
+to	O
+SARS	B-DISO
+.	O
+
+Most	O
+importantly	O
+,	O
+chest	B-ANAT
+radiographs	O
+and	O
+imaging	O
+results	O
+of	O
+patients	O
+with	O
+MERS	O
+show	O
+features	O
+that	O
+resemble	O
+the	O
+findings	O
+of	O
+organizing	B-DISO
+pneumonia	I-DISO
+,	O
+different	O
+from	O
+the	O
+lesions	O
+in	O
+SARS	B-DISO
+patients	O
+,	O
+which	O
+show	O
+fibrocellular	O
+intra	O
+-	O
+alveolar	B-ANAT
+organization	O
+with	O
+a	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+organizing	I-DISO
+pneumonia	I-DISO
+-	O
+like	O
+pattern	O
+.	O
+
+Analyzing	O
+only	O
+patients	O
+with	O
+severe	O
+hypoxemia	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+a	O
+ratio	O
+of	O
+partial	O
+oxygen	B-CHED
+pressure	O
+in	O
+the	O
+blood	B-ANAT
+to	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+<	O
+100	O
+mmHg	O
+),	O
+the	O
+increased	O
+cost	O
+was	O
+R	O
+$=-	O
+5	O
+,	O
+714	O
+.	O
+00	O
+/	O
+272	O
+.	O
+00	O
+,	O
+with	O
+a	O
+cost	O
+per	O
+six	O
+-	O
+month	O
+quality	O
+-	O
+adjusted	O
+life	O
+-	O
+year	O
+gained	O
+of	O
+R	O
+$=-	O
+9	O
+,	O
+521	O
+.	O
+00	O
+/	O
+293	O
+.	O
+00	O
+and	O
+a	O
+cost	O
+of	O
+R	O
+$=-	O
+280	O
+.	O
+00	O
+/	O
+7	O
+.	O
+00	O
+per	O
+quality	O
+-	O
+adjusted	O
+life	O
+-	O
+year	O
+gained	O
+.	O
+
+TITLE	O
+:	O
+Nucleocapsid	B-ANAT
+phosphorylation	B-PROC
+and	O
+RNA	B-PRGE
+helicase	I-PRGE
+DDX1	I-PRGE
+recruitment	B-DISO
+enables	O
+coronavirus	B-SPEC
+transition	B-DISO
+from	O
+discontinuous	O
+to	O
+continuous	O
+transcription	B-PROC
+.	O
+
+DDX1	B-PRGE
+knockdown	O
+or	O
+loss	O
+of	O
+helicase	B-FUNC
+activity	I-FUNC
+markedly	O
+reduces	O
+the	O
+levels	O
+of	O
+longer	O
+sgmRNAs	O
+.	O
+
+The	O
+polysaccharide	B-CHED
+exhibited	O
+potent	O
+antiviral	B-CHED
+activity	O
+against	O
+PEDV	B-SPEC
+reducing	O
+the	O
+formation	B-PROC
+of	O
+a	O
+visible	O
+CPE	O
+[	O
+a	O
+50	O
+%	O
+inhibitory	O
+concentration	O
+(	O
+IC50	O
+)=	O
+1	O
+.	O
+7	O
+±	O
+1	O
+.	O
+3μg	O
+/	O
+mL	O
+],	O
+compared	O
+to	O
+positive	O
+control	O
+,	O
+ribavirin	B-CHED
+and	O
+it	O
+did	O
+not	O
+show	O
+cytotoxicity	B-DISO
+at	O
+100μg	O
+/	O
+mL	O
+[	O
+a	O
+50	O
+%	O
+cytotoxicity	B-DISO
+concentration	O
+(	O
+CC50	O
+)=	O
+100μg	O
+/	O
+mL	O
+].	O
+
+Therefore	O
+,	O
+polysaccharide	B-CHED
+possessing	O
+effective	O
+inhibitory	O
+effect	O
+on	O
+viral	O
+attachment	O
+and	O
+entry	O
+steps	O
+of	O
+PEDV	B-SPEC
+life	O
+cycle	O
+is	O
+a	O
+good	O
+candidate	O
+for	O
+development	B-PROC
+of	O
+antivirals	B-CHED
+.	O
+
+Among	O
+independently	O
+significant	O
+variables	O
+,	O
+shock	O
+,	O
+severe	O
+anaemia	B-DISO
+,	O
+bradycardia	B-DISO
+,	O
+Glasgow	O
+coma	B-DISO
+scale	O
+(	O
+GCS	O
+)	O
+of	O
+less	O
+than	O
+eight	O
+and	O
+refractory	O
+seizures	B-DISO
+were	O
+found	O
+to	O
+be	O
+significant	O
+and	O
+other	O
+variables	O
+like	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+multiorgan	O
+dysfunction	O
+syndrome	B-DISO
+and	O
+abnormal	O
+coagulation	B-PROC
+profile	O
+were	O
+found	O
+insignificant	O
+on	O
+full	O
+model	O
+of	O
+multivariate	O
+regression	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+and	O
+characteristics	O
+of	O
+infants	O
+with	O
+acute	B-DISO
+viral	I-DISO
+bronchiolitis	I-DISO
+submitted	O
+to	O
+mechanical	O
+ventilation	O
+in	O
+a	O
+Brazilian	O
+pediatric	O
+intensive	O
+care	O
+.	O
+
+We	O
+performed	O
+a	O
+retrospective	O
+study	O
+enrolling	O
+all	O
+infants	O
+(	O
+less	O
+than	O
+12	O
+months	O
+old	O
+)	O
+admitted	O
+with	O
+the	O
+diagnosis	O
+of	O
+acute	B-DISO
+viral	I-DISO
+bronchiolitis	I-DISO
+and	O
+submitted	O
+to	O
+mechanical	O
+ventilation	O
+in	O
+an	O
+university	O
+affiliated	O
+Brazilian	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+between	O
+March	O
+,	O
+2004	O
+and	O
+September	O
+,	O
+2006	O
+(	O
+3	O
+consecutives	O
+winters	O
+).	O
+
+The	O
+declining	O
+mortality	O
+in	O
+acute	B-DISO
+viral	I-DISO
+bronchiolitis	I-DISO
+is	O
+observed	O
+even	O
+in	O
+non	O
+developed	O
+regions	O
+,	O
+involving	O
+children	O
+with	O
+high	O
+rates	O
+of	O
+anemia	B-DISO
+and	O
+premature	B-DISO
+labor	I-DISO
+.	O
+
+Concomitant	O
+infections	B-DISO
+and	O
+low	O
+albumin	B-PRGE
+were	O
+found	O
+to	O
+be	O
+predictors	O
+of	O
+severe	O
+infection	B-DISO
+,	O
+while	O
+age	O
+≥	O
+65	O
+years	O
+was	O
+the	O
+only	O
+predictor	O
+of	O
+increased	O
+mortality	O
+.	O
+
+In	O
+cells	B-COMP
+under	O
+prolonged	O
+and	O
+irremediable	O
+ER	O
+stress	O
+,	O
+UPR	O
+can	O
+also	O
+trigger	O
+apoptotic	B-PROC
+cell	I-PROC
+death	I-PROC
+.	O
+
+Therefore	O
+,	O
+studies	O
+on	O
+the	O
+UPR	O
+are	O
+pivotal	O
+in	O
+elucidating	O
+the	O
+complicated	O
+issue	O
+of	O
+coronavirus	B-SPEC
+-	O
+host	B-COMP
+interaction	O
+.	O
+
+Patients	O
+who	O
+did	O
+not	O
+tolerate	O
+the	O
+protocol	O
+were	O
+usually	O
+in	O
+more	O
+severe	O
+condition	B-DISO
+,	O
+though	O
+a	O
+larger	O
+sample	O
+would	O
+be	O
+needed	O
+to	O
+detect	O
+specific	O
+characteristics	O
+of	O
+this	O
+group	O
+.	O
+
+For	O
+these	O
+patients	O
+there	O
+were	O
+no	O
+changes	O
+in	O
+oxygenation	B-PROC
+,	O
+with	O
+a	O
+PaO2	O
+/	O
+FiO2	O
+of	O
+216mmHg	O
+(	O
+IQR	O
+137	O
+,	O
+260	O
+)	O
+at	O
+the	O
+beginning	O
+versus	O
+205mmHg	O
+(	O
+IQR	O
+99	O
+,	O
+257	O
+)	O
+at	O
+the	O
+end	O
+of	O
+the	O
+study	O
+(	O
+p	O
+=	O
+0	O
+.	O
+08	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Three	O
+out	O
+of	O
+four	O
+hypoxic	B-DISO
+patients	O
+with	O
+elevated	O
+EVLWI	O
+tolerated	O
+the	O
+NFB	O
+protocol	O
+.	O
+
+This	O
+national	O
+and	O
+international	O
+'	O
+s	O
+scientific	O
+literature	O
+review	O
+was	O
+developed	O
+according	O
+to	O
+criteria	O
+established	O
+for	O
+documentary	O
+research	O
+in	O
+the	O
+MedLine	O
+,	O
+LILACS	B-SPEC
+,	O
+SciElo	O
+,	O
+PubMed	O
+and	O
+Cochrane	O
+,	O
+databases	O
+using	O
+the	O
+key	O
+words	O
+:	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+and	O
+noninvasive	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Differential	O
+response	O
+of	O
+porcine	B-SPEC
+immature	B-ANAT
+monocyte	I-ANAT
+-	O
+derived	O
+dendritic	B-ANAT
+cells	B-COMP
+to	O
+virulent	O
+and	O
+inactivated	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Exposure	O
+of	O
+piglets	O
+less	O
+than	O
+2	O
+weeks	O
+of	O
+age	O
+to	O
+virulent	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+gives	O
+rise	O
+to	O
+mortality	O
+as	O
+high	O
+as	O
+100	O
+%,	O
+and	O
+adult	O
+pigs	B-SPEC
+recovering	O
+from	O
+its	O
+infection	B-DISO
+often	O
+become	O
+TGEV	B-SPEC
+carriers	O
+.	O
+
+These	O
+facts	O
+suggest	O
+an	O
+evasion	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+by	O
+virulent	O
+TGEV	B-SPEC
+.	O
+
+The	O
+aim	O
+was	O
+to	O
+compare	O
+the	O
+results	O
+of	O
+IFAT	O
+,	O
+ELISA	O
+and	O
+PCR	O
+and	O
+to	O
+investigate	O
+the	O
+possible	O
+associations	O
+between	O
+seropositivity	O
+to	O
+Leishmania	B-SPEC
+spp	B-ENZY
+and	O
+signalment	O
+,	O
+living	O
+conditions	O
+,	O
+season	O
+of	O
+sampling	O
+,	O
+health	O
+status	O
+of	O
+the	O
+cats	B-SPEC
+,	O
+and	O
+seropositivity	O
+to	O
+other	O
+infectious	B-DISO
+agents	O
+.	O
+
+It	O
+causes	O
+two	O
+syndromes	B-DISO
+:	O
+hemorrhagic	B-DISO
+fever	I-DISO
+with	I-DISO
+renal	B-ANAT
+syndrome	I-DISO
+(	O
+HFRS	B-DISO
+),	O
+endemic	O
+in	O
+Asia	O
+and	O
+Europe	O
+and	O
+the	O
+Hantavirus	B-DISO
+pulmonary	B-ANAT
+syndrome	I-DISO
+(	O
+HPS	B-DISO
+),	O
+found	O
+in	O
+the	O
+American	O
+continent	O
+,	O
+including	O
+Brazil	O
+,	O
+with	O
+high	O
+mortality	O
+rates	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+is	O
+to	O
+report	O
+a	O
+case	O
+of	O
+HPS	B-DISO
+with	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+managed	O
+with	O
+early	O
+goal	O
+-	O
+directed	O
+therapy	O
+guided	O
+by	O
+flow	O
+and	O
+tissue	B-ANAT
+perfusion	O
+parameters	O
+.	O
+
+A	O
+36	O
+year	O
+-	O
+old	O
+male	O
+had	O
+fever	B-PROC
+with	O
+progressive	O
+dispnea	O
+,	O
+severe	O
+hypoxia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Several	O
+""""	O
+negative	O
+""""	O
+randomized	O
+controlled	O
+trials	O
+of	O
+high	O
+-	O
+dose	O
+of	O
+glucocorticoids	B-CHED
+given	O
+for	O
+a	O
+short	O
+period	O
+of	O
+time	O
+in	O
+the	O
+early	O
+course	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+raised	O
+serious	O
+doubts	O
+on	O
+the	O
+benefit	O
+of	O
+this	O
+treatment	O
+.	O
+
+During	O
+sepsis	B-DISO
+,	O
+hemodynamic	B-DISO
+instability	I-DISO
+and	O
+perpetuation	O
+of	O
+inflammatory	O
+state	O
+may	O
+result	O
+from	O
+adrenal	B-DISO
+insufficiency	I-DISO
+(	O
+AI	O
+).	O
+
+Nerve	B-ANAT
+-	O
+evoked	O
+EFS	B-CHED
+contractions	B-DISO
+(	O
+tetrodotoxin	B-CHED
+-	O
+sensitive	O
+)	O
+were	O
+blocked	O
+by	O
+a	O
+combination	O
+of	O
+atropine	B-CHED
+(	O
+cholinergic	B-CHED
+antagonist	I-CHED
+)	O
+and	O
+α	O
+,	O
+β	O
+-	O
+methylene	B-CHED
+ATP	B-PRGE
+(	O
+an	O
+ATP	B-CHED
+analog	O
+that	O
+desensitizes	O
+purinergic	O
+receptors	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+for	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+This	O
+review	O
+was	O
+organized	O
+as	O
+follows	O
+:	O
+introduction	O
+;	O
+metabolism	B-PROC
+and	O
+biological	O
+effects	O
+;	O
+clinical	O
+applications	O
+;	O
+dosage	O
+,	O
+gas	B-ENZY
+administration	O
+and	O
+weaning	B-PROC
+process	O
+;	O
+warnings	O
+and	O
+side	O
+-	O
+effects	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Varicella	B-DISO
+pneumonia	I-DISO
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+two	O
+cases	O
+report	O
+].	O
+
+We	O
+report	O
+two	O
+cases	O
+of	O
+ARDS	B-DISO
+secondary	O
+to	O
+varicella	B-SPEC
+-	I-SPEC
+zoster	B-DISO
+virus	I-SPEC
+pneumonia	B-DISO
+.	O
+
+We	O
+report	O
+two	O
+cases	O
+of	O
+ARDS	B-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+)	O
+secondary	O
+to	O
+varicella	B-SPEC
+-	I-SPEC
+zoster	B-DISO
+virus	I-SPEC
+pneumonia	B-DISO
+.	O
+
+Lab	B-PRGE
+tests	O
+made	O
+upon	O
+his	O
+admission	O
+showed	O
+hyperbilirubinemia	B-DISO
+at	O
+a	O
+level	O
+of	O
+50	O
+mg	O
+/	O
+dL	O
+,	O
+severe	O
+metabolic	B-DISO
+acidosis	I-DISO
+,	O
+thrombocytopenia	O
+,	O
+creatinine	B-CHED
+levels	O
+of	O
+5	O
+.	O
+6	O
+mg	O
+/	O
+dL	O
+and	O
+leukocytosis	B-DISO
+with	O
+deviation	O
+through	O
+metamyelocytes	B-ANAT
+.	O
+
+The	O
+APACHE	O
+II	O
+score	O
+was	O
+37	O
+,	O
+with	O
+death	B-PROC
+estimated	O
+risk	O
+of	O
+88	O
+%.	O
+
+The	O
+presence	O
+of	O
+rotavirus	B-SPEC
+was	O
+correlated	O
+with	O
+diarrheic	O
+feces	B-ANAT
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+rather	O
+than	O
+feces	B-ANAT
+with	O
+normal	O
+consistency	O
+.	O
+
+ABSTRACT	O
+:	O
+Autophagy	B-PROC
+plays	O
+important	O
+roles	O
+in	O
+modulating	O
+viral	B-PROC
+replication	I-PROC
+and	O
+antiviral	B-CHED
+immune	B-PROC
+response	I-PROC
+.	O
+
+Coronavirus	B-DISO
+infection	I-DISO
+is	O
+associated	O
+with	O
+the	O
+autophagic	O
+process	O
+,	O
+however	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+mechanisms	O
+of	O
+autophagy	B-PROC
+induction	O
+and	O
+its	O
+contribution	O
+to	O
+coronavirus	B-SPEC
+regulation	B-PROC
+of	O
+host	B-COMP
+innate	O
+responses	O
+.	O
+
+In	O
+addition	O
+,	O
+H9N2	O
+viral	B-DISO
+infection	I-DISO
+resulted	O
+in	O
+severe	O
+progressive	O
+hypoxemia	O
+,	O
+lymphopenia	B-DISO
+,	O
+and	O
+a	O
+significant	O
+increase	O
+in	O
+interleukin	B-PRGE
+1	I-PRGE
+,	O
+interleukin	B-PRGE
+6	I-PRGE
+,	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+,	O
+and	O
+interferon	B-PRGE
+in	O
+BALF	O
+and	O
+serum	B-COMP
+.	O
+
+Our	O
+data	O
+may	O
+facilitate	O
+the	O
+future	O
+studies	O
+of	O
+potential	O
+avian	B-SPEC
+H9N2	O
+disease	O
+in	O
+humans	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+H9N2	O
+-	O
+AIV	O
+-	O
+infected	O
+mice	B-SPEC
+exhibited	O
+severe	O
+respiratory	O
+syndrome	B-DISO
+,	O
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+50	O
+%.	O
+
+A	O
+mailed	O
+survey	O
+sent	O
+after	O
+the	O
+H1N1	O
+outbreak	O
+compared	O
+with	O
+the	O
+results	O
+of	O
+similar	O
+survey	O
+completed	O
+after	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+frequencies	O
+for	O
+a	O
+large	O
+range	O
+of	O
+respiratory	O
+viruses	B-SPEC
+using	O
+a	O
+sensitive	O
+molecular	O
+detection	O
+technique	O
+in	O
+specimens	O
+from	O
+outpatients	O
+of	O
+all	O
+ages	O
+with	O
+ARIs	O
+.	O
+
+Among	O
+79	O
+,	O
+341	O
+screened	O
+patients	O
+,	O
+1	O
+,	O
+032	O
+met	B-CHED
+inclusion	O
+criteria	O
+.	O
+
+A	O
+model	O
+using	O
+comorbid	O
+conditions	O
+and	O
+physiologic	O
+variables	O
+on	O
+the	O
+day	O
+of	O
+developing	O
+severe	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+can	O
+predict	O
+hospital	O
+mortality	O
+.	O
+
+Hyperammonemia	B-DISO
+could	O
+contribute	O
+to	O
+signs	O
+of	O
+encephalopathic	O
+disease	O
+,	O
+and	O
+the	O
+fecal	B-ANAT
+viral	O
+load	O
+might	O
+be	O
+of	O
+prognostic	O
+value	O
+in	O
+affected	O
+horses	B-SPEC
+.	O
+
+MERS	O
+-	O
+CoV	O
+replication	O
+depends	O
+in	O
+part	O
+on	O
+a	O
+virus	B-SPEC
+-	O
+encoded	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PL	O
+(	O
+pro	B-CHED
+))	O
+that	O
+cleaves	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+polyproteins	I-PRGE
+at	I-PRGE
+three	I-PRGE
+sites	I-PRGE
+releasing	I-PRGE
+non	I-PRGE
+-	I-PRGE
+structural	I-PRGE
+protein	I-PRGE
+1	I-PRGE
+(	O
+nsp1	B-PRGE
+),	O
+nsp2	B-PRGE
+,	O
+and	O
+nsp3	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Laboratory	O
+capability	O
+and	O
+surveillance	O
+testing	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+in	O
+the	O
+WHO	O
+European	O
+Region	O
+,	O
+June	O
+2013	O
+.	O
+
+TITLE	O
+:	O
+Chronic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+due	O
+to	O
+toxic	O
+epidermal	B-DISO
+necrosis	B-PROC
+in	O
+a	O
+10	O
+year	O
+old	O
+girl	O
+.	O
+
+Close	O
+monitoring	O
+of	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+the	O
+course	O
+of	O
+toxic	O
+epidermal	B-DISO
+necrosis	B-PROC
+,	O
+intense	O
+treatment	O
+as	O
+soon	O
+as	O
+they	O
+appear	O
+and	O
+a	O
+long	O
+-	O
+term	O
+follow	O
+-	O
+up	O
+are	O
+essential	O
+to	O
+postpone	O
+chronic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+After	O
+abdominal	B-ANAT
+decompression	O
+,	O
+the	O
+multiorgan	B-DISO
+failure	I-DISO
+was	O
+reversed	O
+.	O
+
+TITLE	O
+:	O
+Challenging	O
+rescue	O
+of	O
+a	O
+4	O
+years	O
+old	O
+boy	O
+with	O
+H1N1	O
+infection	B-DISO
+by	O
+extracorporeal	O
+membrane	B-COMP
+oxygenator	O
+:	O
+A	O
+case	O
+report	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenator	O
+(	O
+ECMO	O
+)	O
+therapy	O
+for	O
+patients	O
+with	O
+H1N1	O
+related	O
+ARDS	B-DISO
+has	O
+been	O
+described	O
+once	O
+all	O
+other	O
+therapeutic	O
+options	O
+have	O
+been	O
+exhausted	B-DISO
+.	O
+
+TITLE	O
+:	O
+G	O
+-	O
+quadruplexes	O
+in	O
+viruses	B-SPEC
+:	O
+function	O
+and	O
+potential	O
+therapeutic	O
+applications	O
+.	O
+
+Complete	O
+sequencing	O
+of	O
+the	O
+human	B-SPEC
+genome	O
+highlighted	O
+the	O
+presence	O
+of	O
+∼	O
+300	O
+,	O
+000	O
+sequences	O
+that	O
+can	O
+potentially	O
+form	O
+G4s	O
+.	O
+
+Moreover	O
+,	O
+a	O
+role	O
+for	O
+G4s	B-PRGE
+has	O
+been	O
+proposed	O
+in	O
+cellular	B-COMP
+and	O
+viral	B-PROC
+replication	I-PROC
+,	O
+recombination	B-PROC
+and	O
+gene	B-PROC
+expression	I-PROC
+control	O
+.	O
+
+Gene	O
+ontology	O
+analysis	O
+of	O
+the	O
+altered	O
+proteins	B-CHED
+showed	O
+enrichment	O
+in	O
+multiple	O
+biological	B-PROC
+processes	I-PROC
+,	O
+including	O
+cell	B-PROC
+adhesion	B-DISO
+,	O
+response	B-PROC
+to	I-PROC
+stress	I-PROC
+,	O
+generation	B-PROC
+of	I-PROC
+precursor	I-PROC
+metabolites	I-PROC
+and	I-PROC
+energy	I-PROC
+,	O
+cell	B-PROC
+motility	B-PROC
+,	O
+protein	B-PROC
+complex	I-PROC
+assembly	I-PROC
+,	O
+growth	B-PROC
+,	O
+developmental	B-PROC
+maturation	I-PROC
+,	O
+immune	B-PROC
+system	I-PROC
+process	I-PROC
+,	O
+extracellular	B-PROC
+matrix	I-PROC
+organization	I-PROC
+,	O
+locomotion	O
+,	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+signaling	I-PROC
+,	O
+neurological	B-PROC
+system	I-PROC
+process	I-PROC
+,	O
+and	O
+cell	B-PROC
+junction	I-PROC
+organization	I-PROC
+.	O
+
+However	O
+,	O
+sometimes	O
+the	O
+other	O
+reasons	O
+for	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+and	O
+heart	B-DISO
+failure	I-DISO
+are	O
+found	O
+.	O
+
+One	O
+of	O
+such	O
+reasons	O
+is	O
+hypereosinophilia	B-DISO
+which	O
+can	O
+be	O
+recognized	O
+if	O
+number	O
+of	O
+blood	B-ANAT
+eosinophils	I-ANAT
+exceeds	O
+1500	O
+/	O
+mm3	O
+.	O
+
+The	O
+most	O
+dangerous	O
+for	O
+patients	O
+is	O
+involvement	O
+of	O
+the	O
+nervous	B-DISO
+and	O
+cardiovascular	B-ANAT
+systems	I-ANAT
+.	O
+
+None	O
+of	O
+the	O
+participants	O
+were	O
+positive	O
+for	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+in	O
+the	O
+liver	B-ANAT
+of	O
+infected	O
+chickens	B-SPEC
+,	O
+the	O
+MBL	B-PRGE
+expression	B-PROC
+was	O
+upregulated	O
+at	O
+day	O
+7	O
+p	O
+.	O
+i	O
+.,	O
+despite	O
+the	O
+fact	O
+that	O
+the	O
+MBL	O
+serum	B-COMP
+concentrations	O
+were	O
+decreased	O
+below	O
+baseline	O
+at	O
+that	O
+time	O
+point	O
+.	O
+
+Furthermore	O
+,	O
+at	O
+week	O
+3	O
+p	O
+.	O
+i	O
+.,	O
+the	O
+number	O
+of	O
+monocytes	B-ANAT
+was	O
+higher	O
+in	O
+infected	O
+and	O
+noninfected	O
+L10H	O
+chickens	B-SPEC
+than	O
+in	O
+the	O
+infected	O
+and	O
+noninfected	O
+L10L	O
+chickens	B-SPEC
+.	O
+
+SARS	B-DISO
+is	O
+a	O
+threat	O
+which	O
+is	O
+similar	O
+to	O
+MERS	O
+virus	B-SPEC
+,	O
+but	O
+the	O
+comorbidity	O
+is	O
+the	O
+key	O
+aspect	O
+to	O
+underline	O
+their	O
+different	O
+impacts	O
+.	O
+
+Moreover	O
+,	O
+SARS	B-DISO
+and	O
+HIV	B-DISO
+infections	I-DISO
+dysregulate	O
+4	O
+genes	O
+(	O
+ANXA3	B-PRGE
+,	O
+GNS	B-PRGE
+,	O
+HIST1H1C	B-PRGE
+,	O
+RASA3	B-PRGE
+)	O
+and	O
+3	O
+genes	O
+(	O
+HBA1	B-PRGE
+,	O
+TFRC	B-PRGE
+,	O
+GHITM	B-PRGE
+)	O
+respectively	O
+that	O
+affect	O
+the	O
+ageing	B-PROC
+process	O
+.	O
+
+It	O
+can	O
+be	O
+defined	O
+as	O
+adverse	O
+physiologic	O
+consequences	O
+that	O
+occur	O
+as	O
+a	O
+result	O
+of	O
+an	O
+acute	O
+increase	O
+in	O
+the	O
+intra	O
+-	O
+abdominal	B-ANAT
+pressure	O
+.	O
+
+The	O
+most	O
+common	O
+causes	O
+are	O
+retroperitoneal	B-ANAT
+haemorrhage	B-DISO
+,	O
+pancreatitis	B-DISO
+,	O
+bowel	B-DISO
+obstruction	I-DISO
+,	O
+tense	B-DISO
+ascites	O
+,	O
+peritonitis	B-DISO
+and	O
+serious	O
+visceral	B-DISO
+edema	I-DISO
+due	O
+to	O
+massive	O
+fluid	O
+resuscitation	O
+.	O
+
+The	O
+diagnostic	O
+method	O
+is	O
+the	O
+intra	O
+-	O
+abdominal	B-ANAT
+pressure	O
+monitoring	O
+.	O
+
+In	O
+our	O
+study	O
+,	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+stimulated	O
+with	O
+LPS	B-DISO
+to	O
+induce	O
+ALI	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Conditions	O
+for	O
+the	O
+transmission	O
+of	O
+Hantavirus	B-SPEC
+in	O
+Rio	O
+Negro	O
+,	O
+Argentina	B-SPEC
+].	O
+
+In	O
+Patagonia	O
+the	O
+disease	O
+is	O
+caused	O
+by	O
+the	O
+Andes	B-SPEC
+Virus	I-SPEC
+(	O
+AND	O
+)	O
+and	O
+transmitted	B-DISO
+by	O
+the	O
+rodent	B-SPEC
+Oligoryzomys	B-SPEC
+longicaudatus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+-	O
+resident	O
+glucosidases	O
+impairs	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+-	O
+mediated	O
+entry	O
+by	O
+altering	O
+the	O
+glycan	B-CHED
+processing	O
+of	O
+angiotensin	B-PRGE
+I	I-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+.	O
+
+Hence	O
+,	O
+in	O
+addition	O
+to	O
+reducing	O
+the	O
+production	O
+of	O
+infectious	B-DISO
+virions	B-COMP
+,	O
+inhibition	B-PROC
+of	O
+ER	O
+glucosidases	O
+also	O
+impairs	O
+the	O
+entry	O
+of	O
+selected	O
+viruses	B-SPEC
+via	O
+a	O
+post	O
+-	O
+receptor	O
+-	O
+binding	B-FUNC
+mechanism	O
+.	O
+
+RecV	O
+was	O
+determined	O
+as	O
+the	O
+time	O
+-	O
+dependent	O
+increase	O
+in	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+volume	O
+following	O
+the	O
+first	O
+expiration	B-PROC
+to	O
+the	O
+new	O
+PEEP	B-CHED
+level	O
+(	O
+ΔTDV	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+findings	O
+suggest	O
+that	O
+RecV	O
+predominately	O
+measures	O
+a	O
+slow	O
+fraction	O
+of	O
+inflation	O
+of	O
+already	O
+aerated	O
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+not	O
+recruitment	B-DISO
+of	O
+collapsed	O
+alveoli	B-ANAT
+.	O
+
+Hemoglobin	B-PRGE
+concentrations	O
+were	O
+kept	O
+between	O
+7	O
+and	O
+9	O
+g	O
+/	O
+dL	O
+with	O
+a	O
+transfusion	O
+trigger	O
+at	O
+7	O
+g	O
+/	O
+dL	O
+or	O
+when	O
+physiological	O
+transfusion	O
+triggers	O
+were	O
+apparent	O
+.	O
+
+Chinese	O
+Clinical	O
+Trial	O
+Registry	O
+(	O
+ChiCTR	O
+-	O
+OCH	B-CHED
+-	O
+14005076	O
+).	O
+
+Treatment	O
+with	O
+S	O
+-	O
+1226	O
+for	O
+2	O
+minutes	O
+following	O
+HDM	O
+challenge	O
+resulted	O
+in	O
+a	O
+more	O
+rapid	O
+,	O
+more	O
+profound	O
+and	O
+more	O
+prolonged	O
+decline	O
+in	O
+lung	B-ANAT
+resistance	B-PROC
+compared	O
+with	O
+the	O
+other	O
+treatment	O
+interventions	O
+.	O
+
+Video	O
+bronchoscopy	O
+showed	O
+an	O
+immediate	O
+and	O
+complete	O
+(	O
+within	O
+5	O
+seconds	O
+)	O
+re	O
+-	O
+opening	O
+of	O
+MCh	B-FUNC
+-	O
+constricted	O
+airways	O
+following	O
+treatment	O
+with	O
+S	O
+-	O
+1226	O
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+detection	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+mild	O
+and	O
+severe	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+Catalonia	O
+,	O
+northeastern	O
+Spain	O
+.	O
+
+ABSTRACT	O
+:	O
+Our	O
+ability	O
+to	O
+respond	O
+appropriately	O
+to	O
+infectious	B-DISO
+diseases	I-DISO
+is	O
+enhanced	O
+by	O
+identifying	O
+differences	O
+in	O
+the	O
+potential	O
+for	O
+transmitting	O
+infection	B-DISO
+between	O
+individuals	O
+.	O
+
+Our	O
+approach	O
+provides	O
+insight	O
+into	O
+a	O
+variety	O
+of	O
+scenarios	O
+,	O
+including	O
+the	O
+transmission	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+the	O
+Arabian	O
+peninsula	O
+,	O
+measles	B-PATH
+in	O
+North	O
+America	O
+,	O
+pre	O
+-	O
+eradication	O
+smallpox	B-DISO
+in	O
+Europe	O
+,	O
+and	O
+human	B-DISO
+monkeypox	I-DISO
+in	O
+the	O
+Democratic	O
+Republic	O
+of	O
+the	O
+Congo	O
+.	O
+
+Meanwhile	O
+,	O
+chain	O
+size	O
+data	O
+for	O
+measles	O
+in	O
+the	O
+United	O
+States	O
+and	O
+Canada	O
+reveal	O
+statistically	O
+significant	O
+geographic	O
+variation	O
+in	O
+R	O
+eff	O
+,	O
+suggesting	O
+that	O
+the	O
+timing	O
+and	O
+coverage	O
+of	O
+national	O
+vaccination	O
+programs	O
+,	O
+as	O
+well	O
+as	O
+contact	O
+tracing	O
+procedures	O
+,	O
+may	O
+shape	O
+the	O
+size	O
+distribution	O
+of	O
+observed	O
+infection	B-DISO
+clusters	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+liquid	O
+chromatography	O
+-	O
+tandem	O
+mass	O
+spectrometry	O
+coupled	O
+to	O
+isobaric	O
+tags	O
+for	O
+relative	O
+and	O
+absolute	O
+quantification	O
+labeling	O
+was	O
+used	O
+to	O
+quantitatively	O
+identify	O
+differentially	O
+expressed	B-PROC
+cellular	B-COMP
+proteins	B-CHED
+after	O
+TGEV	B-SPEC
+infection	B-DISO
+in	O
+PK	O
+-	O
+15	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Mouse	B-SPEC
+hepatitis	I-DISO
+virus	B-DISO
+infection	I-DISO
+upregulates	O
+genes	O
+involved	O
+in	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+RSA59	O
+induced	O
+neuropathology	B-DISO
+is	O
+partially	O
+caused	O
+by	O
+activation	O
+of	O
+CNS	B-CHED
+resident	O
+microglia	B-ANAT
+,	O
+as	O
+demonstrated	O
+by	O
+changes	O
+in	O
+cellular	B-COMP
+morphology	O
+and	O
+increased	O
+expression	B-PROC
+of	O
+a	O
+microglia	B-ANAT
+/	O
+macrophage	B-ANAT
+specific	O
+calcium	B-FUNC
+ion	I-FUNC
+binding	I-FUNC
+factor	O
+,	O
+Iba1	B-PRGE
+.	O
+
+The	O
+most	O
+common	O
+symptoms	O
+at	O
+the	O
+onset	O
+of	O
+illness	O
+were	O
+high	O
+fever	O
+and	O
+cough	B-DISO
+.	O
+
+Treatment	O
+with	O
+antiviral	B-CHED
+drugs	I-CHED
+was	O
+initiated	O
+in	O
+all	O
+the	O
+patients	O
+at	O
+a	O
+median	O
+of	O
+8	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+illness	O
+.	O
+
+The	O
+reviews	O
+assembled	O
+here	O
+focus	O
+on	O
+the	O
+interface	O
+between	O
+virology	O
+and	O
+pathology	B-DISO
+and	O
+encompass	O
+aspects	O
+of	O
+both	O
+the	O
+clinical	O
+pathology	B-DISO
+of	O
+viral	B-DISO
+disease	I-DISO
+and	O
+the	O
+underlying	O
+disease	O
+mechanisms	O
+.	O
+
+The	O
+authors	O
+found	O
+that	O
+:	O
+(	O
+1	O
+)	O
+UP	O
+-	O
+MVcontr	O
+reduced	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+score	O
+in	O
+dorsal	O
+lung	B-ANAT
+zones	O
+(	O
+median	O
+[	O
+interquartile	O
+])	O
+(	O
+12	O
+.	O
+0	O
+[	O
+7	O
+.	O
+0	O
+to	O
+16	O
+.	O
+8	O
+]	O
+vs	O
+.	O
+22	O
+.	O
+5	O
+[	O
+13	O
+.	O
+8	O
+to	O
+40	O
+.	O
+8	O
+]),	O
+but	O
+worsened	O
+oxygenation	B-PROC
+and	O
+intrapulmonary	O
+shunt	O
+,	O
+compared	O
+to	O
+P	O
+-	O
+MVcontr	O
+;	O
+(	O
+2	O
+)	O
+UP	O
+-	O
+MVspont	O
+and	O
+UP	O
+-	O
+MVPS	O
+improved	O
+oxygenation	B-PROC
+and	O
+intrapulmonary	O
+shunt	O
+,	O
+and	O
+redistributed	O
+ventilation	O
+towards	O
+dorsal	O
+areas	O
+,	O
+as	O
+compared	O
+to	O
+UP	O
+-	O
+MVcontr	O
+;	O
+(	O
+3	O
+)	O
+compared	O
+to	O
+P	O
+-	O
+MVcontr	O
+,	O
+UP	O
+-	O
+MVcontr	O
+and	O
+UP	O
+-	O
+MVspont	O
+,	O
+UP	O
+-	O
+MVPS	O
+yielded	O
+higher	O
+levels	O
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+(	O
+6	O
+.	O
+9	O
+[	O
+6	O
+.	O
+5	O
+to	O
+10	O
+.	O
+1	O
+]	O
+vs	O
+.	O
+2	O
+.	O
+8	O
+[	O
+2	O
+.	O
+2	O
+to	O
+3	O
+.	O
+0	O
+],	O
+3	O
+.	O
+6	O
+[	O
+3	O
+.	O
+0	O
+to	O
+4	O
+.	O
+7	O
+]	O
+and	O
+4	O
+.	O
+0	O
+[	O
+2	O
+.	O
+8	O
+to	O
+4	O
+.	O
+4	O
+]	O
+pg	O
+/	O
+mg	O
+,	O
+respectively	O
+)	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+(	O
+216	O
+.	O
+8	O
+[	O
+113	O
+.	O
+5	O
+to	O
+343	O
+.	O
+5	O
+]	O
+vs	O
+.	O
+59	O
+.	O
+8	O
+[	O
+45	O
+.	O
+3	O
+to	O
+66	O
+.	O
+7	O
+],	O
+37	O
+.	O
+6	O
+[	O
+18	O
+.	O
+8	O
+to	O
+52	O
+.	O
+0	O
+],	O
+and	O
+59	O
+.	O
+5	O
+[	O
+36	O
+.	O
+1	O
+to	O
+79	O
+.	O
+7	O
+]	O
+pg	O
+/	O
+mg	O
+,	O
+respectively	O
+)	O
+in	O
+dorsal	O
+lung	B-ANAT
+zones	O
+.	O
+
+During	O
+UP	O
+-	O
+MV	O
+,	O
+pressure	O
+supported	O
+SB	O
+increased	O
+lung	B-DISO
+inflammation	I-DISO
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+High	O
+-	O
+Flow	O
+Nasal	B-ANAT
+Cannula	B-SPEC
+Oxygen	B-CHED
+Therapy	O
+in	O
+Subjects	O
+With	O
+ARDS	B-DISO
+:	O
+A	O
+1	O
+-	O
+Year	O
+Observational	O
+Study	O
+.	O
+
+HFNC	O
+indications	O
+were	O
+reviewed	O
+,	O
+and	O
+demographics	O
+,	O
+clinical	O
+characteristics	O
+,	O
+and	O
+course	O
+of	O
+subjects	O
+with	O
+ARDS	B-DISO
+according	O
+to	O
+intubation	O
+need	O
+were	O
+compared	O
+.	O
+
+Higher	O
+SAPS	B-PRGE
+II	I-PRGE
+scores	O
+were	O
+associated	O
+with	O
+HFNC	O
+failure	O
+in	O
+multivariate	O
+analysis	O
+.	O
+
+A	O
+30	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+complicated	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+presented	O
+with	O
+pain	O
+,	O
+fever	B-PROC
+,	O
+and	O
+hypoxia	B-DISO
+.	O
+
+The	O
+potential	O
+for	O
+complications	O
+from	O
+vancomycin	B-CHED
+infusion	O
+during	O
+acute	O
+sickle	O
+crisis	O
+should	O
+be	O
+considered	O
+,	O
+although	O
+further	O
+study	O
+is	O
+warranted	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+30	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+complicated	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+presented	O
+with	O
+pain	O
+,	O
+fever	B-PROC
+,	O
+and	O
+hypoxia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+virus	B-SPEC
+that	O
+manifests	O
+itself	O
+in	O
+viral	B-DISO
+infection	I-DISO
+with	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+,	O
+renal	B-DISO
+failure	I-DISO
+and	O
+severe	O
+acute	B-DISO
+pneumonia	I-DISO
+,	O
+which	O
+often	O
+result	O
+in	O
+a	O
+fatal	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Enveloped	O
+viruses	O
+need	O
+to	O
+fuse	O
+with	O
+a	O
+host	B-COMP
+cell	I-COMP
+membrane	I-COMP
+in	O
+order	B-SPEC
+to	O
+deliver	O
+their	O
+genome	O
+into	O
+the	O
+host	B-COMP
+cell	I-COMP
+.	O
+
+While	O
+some	O
+viruses	B-SPEC
+fuse	O
+with	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+,	O
+many	O
+viruses	B-SPEC
+are	O
+endocytosed	O
+prior	O
+to	O
+fusion	O
+.	O
+
+Using	O
+siRNA	B-PRGE
+gene	I-PRGE
+silencing	O
+,	O
+we	O
+found	O
+that	O
+proteins	B-CHED
+known	O
+to	O
+be	O
+important	O
+for	O
+late	O
+endosomal	O
+maturation	B-PROC
+and	O
+endosome	B-COMP
+-	O
+lysosome	B-COMP
+fusion	O
+profoundly	O
+promote	O
+infection	B-DISO
+of	O
+cells	B-COMP
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+Compositional	O
+analysis	O
+revealed	O
+,	O
+reductions	O
+in	O
+fractional	O
+compositions	O
+of	O
+saturated	O
+PC	O
+species	B-SPEC
+with	O
+elevated	O
+levels	O
+of	O
+longer	O
+acyl	O
+chain	O
+unsaturated	O
+PC	O
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Activation	O
+of	O
+the	O
+chicken	B-PRGE
+type	I-PRGE
+I	I-PRGE
+interferon	I-PRGE
+response	O
+by	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+from	O
+both	O
+the	O
+Alphacoronavirus	O
+and	O
+Betacoronavirus	B-SPEC
+genera	O
+interfere	O
+with	O
+the	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+response	O
+in	O
+various	O
+ways	O
+,	O
+ensuring	O
+the	O
+limited	O
+activation	O
+of	O
+the	O
+IFN	B-PRGE
+response	O
+in	O
+most	O
+cell	B-COMP
+types	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+avian	B-SPEC
+coronavirus	I-SPEC
+in	O
+wild	O
+aquatic	O
+birds	B-SPEC
+of	O
+the	O
+central	O
+and	O
+eastern	O
+USA	O
+.	O
+
+We	O
+tested	O
+133	O
+pooled	O
+samples	O
+representing	O
+700	O
+first	O
+-	O
+passage	O
+(	O
+in	O
+eggs	O
+)	O
+and	O
+303	O
+direct	O
+cloacal	B-ANAT
+swab	O
+transport	B-PROC
+media	B-ANAT
+samples	O
+from	O
+wild	O
+aquatic	O
+birds	B-SPEC
+in	O
+the	O
+US	O
+that	O
+were	O
+avian	B-DISO
+influenza	I-DISO
+-	O
+negative	O
+.	O
+
+The	O
+methyl	B-CHED
+-	O
+β	O
+-	O
+cyclodextrin	B-CHED
+(	O
+MβCD	O
+)	O
+was	O
+employed	O
+to	O
+remove	O
+cholesterol	B-CHED
+and	O
+to	O
+disrupt	O
+the	O
+lipid	B-COMP
+rafts	I-COMP
+.	O
+
+Via	B-PRGE
+transmission	O
+electron	O
+microscopy	O
+,	O
+these	O
+cells	B-COMP
+were	O
+classified	O
+as	O
+atypical	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+and	O
+some	O
+of	O
+them	O
+showed	O
+cytoplasmic	B-COMP
+vesicles	B-COMP
+and	O
+inclusions	O
+.	O
+
+This	O
+case	O
+report	O
+documents	O
+a	O
+case	O
+in	O
+which	O
+tapentadol	O
+was	O
+identified	O
+as	O
+the	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+For	O
+each	O
+syndrome	B-DISO
+17	O
+-	O
+27	O
+%	O
+of	O
+participants	O
+had	O
+etiologic	O
+diagnoses	O
+that	O
+would	O
+be	O
+non	O
+-	O
+responsive	O
+to	O
+ceftriaxone	B-CHED
+,	O
+but	O
+responsive	O
+to	O
+other	O
+available	O
+antimicrobial	B-CHED
+regimens	O
+including	O
+amphotericin	O
+for	O
+cryptococcosis	B-DISO
+and	O
+histoplasmosis	B-DISO
+;	O
+anti	O
+-	O
+tuberculosis	B-PATH
+therapy	O
+for	O
+bacteremic	O
+disseminated	B-DISO
+tuberculosis	I-DISO
+;	O
+or	O
+tetracycline	B-CHED
+therapy	O
+for	O
+rickettsioses	O
+and	O
+Q	B-DISO
+fever	I-DISO
+.	O
+
+The	O
+recent	O
+emergence	O
+of	O
+virulent	O
+enteric	O
+coronaviruses	O
+[	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)]	O
+in	O
+North	O
+America	O
+and	O
+Asia	O
+,	O
+for	O
+which	O
+no	O
+vaccines	O
+are	O
+available	O
+,	O
+remains	O
+a	O
+challenge	O
+for	O
+the	O
+global	O
+swine	B-SPEC
+industry	O
+.	O
+
+ABSTRACT	O
+:	O
+Study	O
+of	O
+the	O
+clinical	O
+evolution	O
+of	O
+a	O
+primary	O
+ear	B-ANAT
+,	O
+nose	B-ANAT
+,	O
+and	O
+throat	B-DISO
+infection	I-DISO
+complicated	O
+by	O
+septic	B-DISO
+thrombophlebitis	I-DISO
+of	O
+the	O
+internal	B-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+.	O
+
+From	O
+1998	O
+to	O
+2010	O
+,	O
+23	O
+patients	O
+at	O
+our	O
+institution	O
+were	O
+diagnosed	O
+with	O
+a	O
+septic	O
+thrombosis	B-DISO
+of	O
+the	O
+internal	B-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+.	O
+
+To	O
+date	O
+,	O
+no	O
+effective	O
+drugs	O
+that	O
+improve	O
+the	O
+clinical	O
+outcome	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+-	O
+infected	O
+patients	O
+have	O
+been	O
+identified	O
+.	O
+
+Angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+(	O
+ACE	B-PRGE
+)	O
+and	O
+ACE2	B-PRGE
+are	O
+involved	O
+in	O
+several	O
+pathologies	O
+such	O
+as	O
+cardiovascular	B-ANAT
+functions	O
+,	O
+renal	B-DISO
+disease	I-DISO
+,	O
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Moreover	O
+,	O
+ACE2	B-PRGE
+deficiency	O
+worsened	O
+the	O
+disease	O
+pathogenesis	B-DISO
+markedly	O
+,	O
+mainly	O
+by	O
+targeting	B-PROC
+the	O
+angiotensin	B-CHED
+II	I-CHED
+type	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+(	O
+AT1	O
+).	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+by	O
+pathogenic	O
+viruses	O
+results	O
+in	O
+rapid	O
+epithelial	O
+damage	O
+and	O
+significantly	O
+impacts	O
+on	O
+the	O
+condition	B-DISO
+of	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+thus	O
+the	O
+effects	O
+of	O
+viral	B-DISO
+infection	I-DISO
+may	O
+induce	O
+changes	O
+in	O
+microbiota	B-SPEC
+.	O
+
+The	O
+genome	O
+of	O
+M	B-SPEC
+.	I-SPEC
+nonliquefaciens	I-SPEC
+was	O
+found	O
+to	O
+encode	O
+various	O
+proteins	B-CHED
+that	O
+may	O
+play	B-DISO
+roles	I-DISO
+in	O
+pathogenesis	B-DISO
+.	O
+
+No	O
+virus	B-SPEC
+-	O
+specific	O
+bacterial	O
+profile	O
+was	O
+discovered	O
+,	O
+but	O
+comparative	O
+analysis	O
+of	O
+healthy	O
+adults	O
+and	O
+patients	O
+identified	O
+a	O
+bacterium	B-SPEC
+specific	O
+to	O
+young	O
+patients	O
+,	O
+M	B-SPEC
+.	I-SPEC
+nonliquefaciens	I-SPEC
+.	O
+
+RESULTS	O
+:	O
+The	O
+healthy	O
+subjects	O
+harbored	O
+primarily	O
+Streptococcus	B-SPEC
+,	O
+whereas	O
+the	O
+patients	O
+showed	O
+an	O
+enrichment	O
+of	O
+Haemophilus	B-SPEC
+or	O
+Moraxella	B-SPEC
+.	O
+
+The	O
+genome	O
+of	O
+M	B-SPEC
+.	I-SPEC
+nonliquefaciens	I-SPEC
+was	O
+found	O
+to	O
+encode	O
+various	O
+proteins	B-CHED
+that	O
+may	O
+play	B-DISO
+roles	I-DISO
+in	O
+pathogenesis	B-DISO
+.	O
+
+For	O
+many	O
+emerging	O
+bat	B-ENZY
+viruses	B-SPEC
+,	O
+spillover	O
+also	O
+requires	O
+viral	B-DISO
+shedding	I-DISO
+from	O
+bats	B-SPEC
+,	O
+and	O
+survival	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+environment	O
+.	O
+
+Interventions	O
+to	O
+decrease	O
+the	O
+probability	O
+of	O
+virus	B-SPEC
+spillover	O
+can	O
+be	O
+implemented	O
+at	O
+multiple	O
+levels	O
+from	O
+targeting	B-PROC
+the	O
+reservoir	O
+host	B-COMP
+to	O
+managing	O
+recipient	O
+host	B-COMP
+exposure	O
+and	O
+susceptibility	O
+.	O
+
+Potential	O
+of	O
+mean	O
+force	O
+(	O
+PMF	O
+)	O
+profiles	O
+for	O
+mono	B-DISO
+(	O
+Na	O
+(+)	O
+,	O
+K	O
+(+)	O
+,	O
+Cl	O
+(-)	O
+)	O
+and	O
+divalent	O
+(	O
+Ca	O
+(	O
+2	O
++)	O
+)	O
+ions	B-CHED
+along	O
+the	O
+pore	B-COMP
+are	O
+calculated	O
+.	O
+
+Calculations	O
+on	O
+8a	O
+are	O
+compared	O
+to	O
+data	O
+derived	O
+for	O
+a	O
+pentameric	O
+bundle	O
+consisting	O
+of	O
+the	O
+M2	O
+helices	B-SPEC
+of	O
+the	O
+bacterial	O
+pentameric	O
+ligand	O
+gated	O
+ion	O
+channel	O
+GLIC	O
+(	O
+3EHZ	O
+).	O
+
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+had	O
+previously	O
+caused	O
+multiple	O
+health	O
+-	O
+care	O
+-	O
+associated	O
+outbreaks	O
+and	O
+resulted	O
+in	O
+transmission	O
+of	O
+the	O
+virus	B-SPEC
+within	O
+families	O
+.	O
+
+The	O
+control	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+relies	O
+on	O
+prompt	O
+identification	O
+of	O
+cases	O
+within	O
+health	O
+care	O
+facilities	O
+,	O
+with	O
+institutions	O
+applying	O
+appropriate	O
+infection	B-DISO
+control	O
+measures	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+an	O
+infectious	B-DISO
+,	O
+highly	O
+contagious	O
+virus	B-SPEC
+,	O
+and	O
+is	O
+an	O
+etiological	O
+agent	O
+of	O
+acute	O
+entero	O
+-	O
+pathogenic	O
+diarrhea	B-DISO
+in	O
+swine	B-SPEC
+.	O
+
+Antibody	B-COMP
+titers	O
+in	O
+sow	O
+and	O
+piglet	O
+serum	B-COMP
+one	O
+week	O
+after	O
+farrowing	O
+and	O
+that	O
+in	O
+colostrum	B-ANAT
+were	O
+compared	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+and	O
+serum	B-COMP
+neutralization	O
+test	O
+.	O
+
+This	O
+study	O
+clearly	O
+confirms	O
+that	O
+killed	O
+vaccine	O
+has	O
+induced	O
+higher	O
+antibody	B-COMP
+levels	O
+and	O
+may	O
+contribute	O
+to	O
+the	O
+design	O
+of	O
+future	O
+research	O
+and	O
+vaccine	O
+programs	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+15	O
+respiratory	O
+viruses	B-SPEC
+in	O
+children	O
+with	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ARTIs	O
+)	O
+using	O
+multiplex	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+and	O
+to	O
+analyze	O
+the	O
+clinical	O
+and	O
+epidemiological	O
+features	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+A	O
+single	O
+viral	O
+pathogen	O
+was	O
+detected	O
+in	O
+76	O
+patients	O
+,	O
+viral	O
+coinfections	B-DISO
+in	O
+9	O
+,	O
+and	O
+mixed	O
+viral	O
+and	O
+bacterial	O
+pathogens	O
+in	O
+15	O
+.	O
+
+Of	O
+significance	O
+is	O
+the	O
+potential	O
+use	O
+of	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+to	O
+provide	O
+epidemiological	O
+and	O
+virological	O
+data	O
+for	O
+early	O
+detection	O
+of	O
+the	O
+emergence	O
+of	O
+novel	O
+respiratory	O
+viruses	B-SPEC
+in	O
+the	O
+era	B-CHED
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+conference	O
+covered	O
+emerging	O
+and	O
+potentially	O
+pandemic	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+discussed	O
+novel	O
+/	O
+pre	O
+-	O
+licensure	O
+therapeutics	O
+and	O
+currently	O
+approved	O
+antivirals	B-CHED
+and	O
+vaccines	O
+for	O
+the	O
+control	O
+of	O
+influenza	B-DISO
+.	O
+
+The	O
+patients	O
+from	O
+five	O
+ICUs	O
+of	O
+grade	O
+A	O
+tertiary	O
+hospitals	O
+in	O
+Beijing	O
+from	O
+July	O
+2009	O
+to	O
+March	O
+2014	O
+,	O
+including	O
+sepsis	B-DISO
+,	O
+septic	B-DISO
+shock	I-DISO
+,	O
+trauma	O
+,	O
+pneumonia	B-DISO
+,	I-DISO
+aspiration	I-DISO
+,	O
+massive	O
+blood	B-ANAT
+transfusion	O
+,	O
+bacteremia	B-DISO
+and	O
+pulmonary	B-ANAT
+contusion	O
+,	O
+were	O
+enrolled	O
+.	O
+
+According	O
+to	O
+the	O
+admission	O
+diagnosis	O
+in	O
+ICU	O
+,	O
+these	O
+patients	O
+were	O
+divided	O
+into	O
+ARDS	B-DISO
+group	O
+and	O
+other	O
+severe	O
+disease	O
+control	O
+group	O
+.	O
+
+The	O
+risk	O
+factors	O
+of	O
+occurence	O
+and	O
+prognosis	O
+of	O
+ARDS	B-DISO
+were	O
+analyzed	O
+by	O
+univariate	O
+analysis	O
+,	O
+multivariate	O
+logistic	O
+regression	O
+and	O
+multivariate	O
+COX	O
+regression	O
+analysis	O
+.	O
+
+The	O
+28	O
+-	O
+day	O
+mortality	O
+of	O
+ARDS	B-DISO
+group	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+of	O
+severe	O
+control	O
+group	O
+[	O
+30	O
+.	O
+43	O
+%	O
+(	O
+49	O
+/	O
+161	O
+)	O
+vs	O
+.	O
+18	O
+.	O
+99	O
+%	O
+(	O
+34	O
+/	O
+179	O
+),	O
+χ²	O
+=	O
+6	O
+.	O
+013	O
+,	O
+P	O
+=	O
+0	O
+.	O
+014	O
+].	O
+
+Multivariate	O
+logistic	O
+analysis	O
+showed	O
+that	O
+aspiration	B-DISO
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+=	O
+6	O
+.	O
+390	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+=	O
+2	O
+.	O
+046	O
+-	O
+19	O
+.	O
+953	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+],	O
+history	O
+of	O
+alcohol	O
+(	O
+OR	O
+=	O
+4	O
+.	O
+854	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+730	O
+-	O
+13	O
+.	O
+617	O
+,	O
+P	O
+=	O
+0	O
+.	O
+003	O
+),	O
+sepsis	B-DISO
+(	O
+OR	O
+=	O
+2	O
+.	O
+859	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+507	O
+-	O
+5	O
+.	O
+425	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+),	O
+pneumonia	B-DISO
+(	O
+OR	O
+=	O
+2	O
+.	O
+822	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+640	O
+-	O
+4	O
+.	O
+855	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHEII	O
+)	O
+score	O
+(	O
+OR	O
+=	O
+1	O
+.	O
+050	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+007	O
+-	O
+1	O
+.	O
+094	O
+,	O
+P	O
+=	O
+0	O
+.	O
+022	O
+)	O
+were	O
+significantly	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+ARDS	B-DISO
+occurence	O
+.	O
+
+For	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+who	O
+need	O
+the	O
+support	O
+of	O
+ECMO	O
+,	O
+ECMO	O
+-	O
+assisted	O
+transfer	O
+is	O
+safer	O
+than	O
+conventional	O
+ventilation	O
+,	O
+but	O
+transfer	O
+should	O
+be	O
+implemented	O
+by	O
+experienced	O
+team	O
+.	O
+
+Meanwhile	O
+,	O
+ARDS	B-DISO
+patients	O
+were	O
+further	O
+divided	O
+into	O
+survival	O
+group	O
+(	O
+n	O
+=	O
+29	O
+)	O
+and	O
+non	O
+-	O
+survival	O
+group	O
+(	O
+n	O
+=	O
+24	O
+)	O
+according	O
+to	O
+28	O
+-	O
+day	O
+outcomes	O
+.	O
+
+The	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHEII	O
+)	O
+score	O
+,	O
+sequential	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+(	O
+SOFA	O
+)	O
+score	O
+,	O
+oxygenation	O
+index	O
+(	O
+PaO₂	B-PRGE
+/	O
+FiO₂	O
+),	O
+lung	B-ANAT
+injury	O
+score	O
+(	O
+LIS	B-FUNC
+)	O
+were	O
+recorded	O
+within	O
+24	O
+hours	O
+after	O
+admission	O
+.	O
+
+It	O
+was	O
+shown	O
+by	O
+correlation	O
+analysis	O
+that	O
+the	O
+plasma	B-ANAT
+levels	O
+of	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+was	O
+significantly	O
+positive	O
+correlated	O
+with	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+(	O
+r	O
+=	O
+0	O
+.	O
+468	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+CRP	B-PRGE
+(	O
+r	O
+=	O
+0	O
+.	O
+492	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+APACHEII	O
+score	O
+(	O
+r	O
+=	O
+0	O
+.	O
+560	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+SOFA	O
+score	O
+(	O
+r	O
+=	O
+0	O
+.	O
+508	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+)	O
+and	O
+LIS	B-FUNC
+score	O
+(	O
+r	O
+=	O
+0	O
+.	O
+588	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+significantly	O
+negatively	O
+correlated	O
+with	O
+PaO2	O
+/	O
+FiO2	O
+(	O
+r	O
+=-	O
+0	O
+.	O
+685	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+).	O
+
+Factors	O
+,	O
+APACHEII	O
+score	O
+,	O
+LIS	B-FUNC
+score	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+,	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+founded	O
+statistical	O
+significance	O
+in	O
+univariate	O
+analysis	O
+were	O
+analyzed	O
+using	O
+multivariable	O
+logistic	O
+regression	O
+.	O
+
+The	O
+area	O
+under	O
+the	O
+ROC	O
+curve	O
+of	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+was	O
+0	O
+.	O
+964	O
+,	O
+the	O
+optimal	O
+critical	O
+value	O
+of	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+was	O
+1	O
+.	O
+79	O
+μg	O
+/	O
+L	O
+,	O
+the	O
+specificity	O
+was	O
+90	O
+.	O
+0	O
+%,	O
+and	O
+sensitivity	O
+was	O
+92	O
+.	O
+5	O
+%.	O
+
+The	O
+plasma	B-ANAT
+level	O
+of	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+was	O
+correlated	O
+with	O
+the	O
+severity	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+had	O
+important	O
+prognosis	O
+evaluation	O
+.	O
+
+TITLE	O
+:	O
+ATF3	B-PRGE
+protects	O
+pulmonary	B-ANAT
+resident	O
+cells	B-COMP
+from	O
+acute	O
+and	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+by	O
+preventing	O
+Nrf2	O
+degradation	O
+.	O
+
+ABSTRACT	O
+:	O
+Ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+(	O
+VILI	O
+)	O
+contributes	O
+to	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+the	O
+most	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+Knockdown	O
+of	O
+ATF3	B-PRGE
+in	O
+resident	O
+cells	B-COMP
+resulted	O
+in	O
+decreased	O
+junctional	O
+protein	B-PROC
+expression	B-PROC
+and	O
+increased	O
+paracellular	O
+leak	O
+.	O
+
+TITLE	O
+:	O
+Tailoring	O
+subunit	O
+vaccine	O
+immunity	B-PROC
+with	O
+adjuvant	B-CHED
+combinations	O
+and	O
+delivery	O
+routes	O
+using	O
+the	O
+Middle	O
+East	O
+respiratory	O
+coronavirus	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+as	O
+an	O
+antigen	B-CHED
+.	O
+
+Different	O
+vaccination	O
+regimens	O
+were	O
+compared	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+immunized	O
+3	O
+times	O
+intramuscularly	O
+(	O
+i	O
+.	O
+m	O
+.)	O
+with	O
+a	O
+vaccine	O
+containing	O
+10	O
+µg	O
+of	O
+recombinant	O
+MERS	O
+-	O
+CoV	O
+RBD	O
+in	O
+combination	O
+with	O
+either	O
+aluminium	O
+hydroxide	O
+(	O
+alum	O
+)	O
+alone	O
+,	O
+alum	O
+and	O
+polyriboinosinic	O
+acid	O
+(	O
+poly	O
+I	O
+:	O
+C	O
+)	O
+or	O
+alum	O
+and	O
+cysteine	B-CHED
+-	O
+phosphate	B-CHED
+-	O
+guanine	B-CHED
+(	O
+CpG	O
+)	O
+oligodeoxynucleotides	O
+(	O
+ODN	O
+).	O
+
+Interestingly	O
+,	O
+robust	O
+RBD	O
+-	O
+specific	O
+antibody	B-COMP
+and	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+were	O
+induced	O
+in	O
+mice	B-SPEC
+immunized	O
+with	O
+the	O
+rRBD	B-PRGE
+protein	I-PRGE
+in	O
+combination	O
+with	O
+IFA	O
+and	O
+CpG	O
+ODN	O
+,	O
+but	O
+low	O
+level	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+were	O
+elicited	O
+.	O
+
+are	O
+fastidious	O
+,	O
+Gram	O
+-	O
+negative	O
+bacilli	B-SPEC
+that	O
+cause	O
+a	O
+wide	O
+spectrum	O
+of	O
+diseases	O
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+CD26	B-PRGE
+/	O
+DPP4	B-PRGE
+cell	B-COMP
+-	O
+surface	O
+expression	B-PROC
+in	O
+bat	B-ENZY
+cells	B-COMP
+correlates	O
+with	O
+bat	B-PRGE
+cell	B-COMP
+susceptibility	I-PRGE
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+and	O
+evolution	B-PROC
+of	O
+persistent	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+recently	O
+isolated	O
+betacoronavirus	B-SPEC
+identified	O
+as	O
+the	O
+etiologic	O
+agent	O
+of	O
+a	O
+frequently	O
+fatal	O
+disease	O
+in	O
+Western	O
+Asia	O
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+.	O
+
+We	O
+found	O
+that	O
+the	O
+susceptibility	O
+or	O
+resistance	B-PROC
+of	O
+these	O
+bat	B-ENZY
+cell	B-ANAT
+lines	I-ANAT
+directly	O
+correlates	O
+with	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+cell	O
+surface	O
+-	O
+expressed	B-PROC
+CD26	B-PRGE
+/	O
+DPP4	B-PRGE
+,	O
+the	O
+functional	O
+human	B-SPEC
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+Human	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+CD26	I-PRGE
+/	O
+DPP4	B-PRGE
+antibodies	B-COMP
+inhibited	O
+infection	B-DISO
+of	O
+susceptible	O
+bat	B-ENZY
+cells	B-COMP
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+ABSTRACT	O
+:	O
+Acquisition	O
+of	O
+new	O
+proteins	B-CHED
+by	O
+viruses	B-SPEC
+usually	O
+occurs	O
+through	O
+horizontal	B-PROC
+gene	I-PROC
+transfer	I-PROC
+or	O
+through	O
+gene	B-DISO
+duplication	I-DISO
+,	O
+but	O
+another	O
+,	O
+less	O
+common	O
+mechanism	O
+is	O
+the	O
+usage	O
+of	O
+completely	O
+or	O
+partially	O
+overlapping	O
+reading	O
+frames	O
+.	O
+
+Our	O
+findings	O
+indicate	O
+that	O
+the	O
+orf9b	B-PRGE
+gene	I-PRGE
+features	O
+a	O
+discordant	O
+codon	O
+-	O
+usage	O
+pattern	O
+.	O
+
+Carrageenan	B-CHED
+nasal	B-ANAT
+spray	O
+showed	O
+significant	O
+antiviral	B-CHED
+efficacy	O
+in	O
+all	O
+three	O
+virus	B-SPEC
+subgroups	O
+,	O
+the	O
+highest	O
+effectiveness	O
+was	O
+observed	O
+in	O
+human	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+-	O
+infected	O
+patients	O
+.	O
+
+For	O
+this	O
+report	O
+,	O
+medical	O
+masks	O
+(	O
+also	O
+known	O
+as	O
+surgical	O
+masks	O
+or	O
+surgical	O
+face	B-DISO
+masks	O
+)	O
+are	O
+defined	O
+as	O
+unfitted	O
+devices	O
+worn	O
+by	O
+the	O
+healthcare	O
+worker	O
+(	O
+HCW	O
+)	O
+“	O
+to	O
+reduce	O
+transfer	O
+of	O
+potentially	O
+infectious	B-DISO
+bodily	O
+fluids	B-ANAT
+between	O
+individuals	O
+”.	O
+
+Masks	O
+are	O
+designed	O
+prevent	O
+droplets	O
+from	O
+an	O
+infectious	B-DISO
+patient	O
+from	O
+coming	O
+in	O
+contact	O
+with	O
+the	O
+mucous	B-ANAT
+membranes	I-ANAT
+in	O
+the	O
+nose	B-ANAT
+and	O
+mouth	B-ANAT
+of	O
+the	O
+person	O
+wearing	O
+the	O
+mask	O
+.	O
+
+Therefore	O
+,	O
+we	O
+prospectively	O
+investigated	O
+the	O
+incidence	O
+and	O
+clinical	O
+impacts	O
+of	O
+viral	B-DISO
+infection	I-DISO
+in	O
+adults	O
+with	O
+bronchiectasis	B-DISO
+exacerbations	O
+.	O
+
+Virus	B-SPEC
+-	O
+positive	O
+exacerbations	O
+were	O
+associated	O
+with	O
+a	O
+greater	O
+increase	O
+in	O
+markers	O
+of	O
+systemic	O
+and	O
+airway	B-ANAT
+inflammation	B-DISO
+(	O
+serum	B-COMP
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+;	O
+sputum	B-ANAT
+IL	O
+-	O
+1β	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+)	O
+compared	O
+with	O
+virus	B-SPEC
+-	O
+negative	O
+exacerbations	O
+,	O
+but	O
+the	O
+differences	O
+in	O
+spirometric	O
+indexes	O
+,	O
+quality	O
+of	O
+life	O
+,	O
+and	O
+bacterial	O
+density	O
+were	O
+unremarkable	O
+.	O
+
+Furthermore	O
+,	O
+a	O
+greater	O
+proportion	O
+of	O
+patients	O
+with	O
+virus	B-SPEC
+-	O
+positive	O
+exacerbations	O
+received	O
+IV	O
+antibiotics	B-CHED
+.	O
+
+Saffold	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+outpatient	O
+but	O
+not	O
+in	O
+hospitalized	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+respiratory	B-DISO
+infections	I-DISO
+among	O
+Hajj	O
+pilgrims	O
+in	O
+2013	O
+.	O
+
+Infection	B-DISO
+control	O
+and	O
+appropriate	O
+vaccination	O
+are	O
+necessary	O
+to	O
+prevent	O
+transmission	O
+of	O
+respiratory	O
+viruses	B-SPEC
+at	O
+Hajj	O
+and	O
+other	O
+mass	O
+gatherings	O
+.	O
+
+Clinical	O
+signs	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+were	O
+benign	O
+,	O
+but	O
+each	O
+of	O
+the	O
+camels	B-SPEC
+shed	O
+large	O
+quantities	O
+of	O
+virus	B-SPEC
+from	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+potential	O
+transmission	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+to	O
+health	O
+care	O
+workers	O
+in	O
+a	O
+hospital	O
+,	O
+we	O
+serologically	O
+tested	O
+hospital	O
+contacts	O
+of	O
+the	O
+index	O
+case	O
+-	O
+patient	O
+in	O
+Saudi	O
+Arabia	O
+,	O
+4	O
+months	O
+after	O
+his	O
+death	B-PROC
+.	O
+
+Since	O
+liver	B-DISO
+abscess	I-DISO
+is	O
+potentially	O
+lethal	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+on	O
+admission	O
+is	O
+an	O
+additional	O
+risk	O
+factor	O
+of	O
+mortality	O
+,	O
+V	O
+-	O
+V	O
+ECMO	O
+may	O
+serve	O
+as	O
+an	O
+adjunctive	O
+choice	O
+of	O
+artificial	O
+organ	B-ANAT
+support	O
+for	O
+cases	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+caused	O
+by	O
+liver	B-DISO
+abscess	I-DISO
+.	O
+
+Freedom	O
+from	O
+mechanical	O
+ventilation	O
+took	O
+longer	O
+in	O
+the	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+whose	O
+donors	O
+had	O
+Heavy	B-DISO
+Alcohol	I-DISO
+Use	I-DISO
+,	O
+compared	O
+with	O
+those	O
+whose	O
+donors	O
+had	O
+No	O
+Alcohol	O
+Use	O
+or	O
+Moderate	O
+Alcohol	O
+Use	O
+(	O
+p	O
+=	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+increase	O
+in	O
+PGD	B-CHED
+resulted	O
+in	O
+poorer	O
+gas	B-ENZY
+exchange	O
+in	O
+the	O
+recipients	O
+of	O
+donor	B-CHED
+lungs	B-ANAT
+from	O
+heavy	O
+alcohol	O
+users	O
+,	O
+and	O
+these	O
+recipients	O
+subsequently	O
+required	O
+mechanical	O
+ventilation	O
+for	O
+a	O
+longer	O
+time	O
+following	O
+transplant	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Prolonged	O
+VV	O
+ECMO	O
+(	O
+265	O
+Days	O
+)	O
+for	O
+ARDS	B-DISO
+without	O
+technical	O
+complications	O
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+of	O
+zoonotic	O
+origin	O
+are	O
+shaping	O
+today	O
+'	O
+s	O
+infectious	O
+disease	O
+field	O
+more	O
+than	O
+ever	O
+.	O
+
+Nipah	B-SPEC
+virus	I-SPEC
+emerged	O
+a	O
+few	O
+years	O
+later	O
+,	O
+causing	O
+respiratory	B-DISO
+infections	I-DISO
+and	O
+encephalitis	B-DISO
+in	O
+Southeast	O
+Asia	O
+,	O
+with	O
+case	O
+fatality	O
+rates	O
+ranging	O
+from	O
+40	O
+%	O
+to	O
+more	O
+than	O
+90	O
+%.	O
+
+This	O
+prospective	O
+study	O
+was	O
+designed	O
+to	O
+compare	O
+EL	O
+assessed	O
+by	O
+lung	B-ANAT
+barometry	O
+(	O
+ELLB	O
+)	O
+versus	O
+esophageal	B-PROC
+pressure	I-PROC
+(	O
+ELPeso	O
+).	O
+
+EL	O
+and	O
+the	O
+ratio	O
+between	O
+EL	O
+and	O
+respiratory	B-ANAT
+system	I-ANAT
+elastance	O
+(	O
+ERS	B-DISO
+)	O
+calculated	O
+with	O
+the	O
+two	O
+methods	O
+were	O
+compared	O
+.	O
+
+There	O
+were	O
+no	O
+linear	O
+correlation	O
+between	O
+ELLB	O
+/	O
+ERS	B-DISO
+and	O
+ELPeso	O
+/	O
+ERS	B-DISO
+during	O
+the	O
+increase	O
+and	O
+the	O
+decrease	O
+of	O
+PEEP	B-CHED
+(	O
+R²	O
+=	O
+0	O
+.	O
+00	O
+;	O
+R²	O
+=	O
+0	O
+.	O
+00	O
+,	O
+respectively	O
+).	O
+
+We	O
+conducted	O
+a	O
+large	O
+-	O
+scale	O
+investigation	O
+of	O
+the	O
+incidence	O
+of	O
+PEDV	B-SPEC
+in	O
+pigs	B-SPEC
+with	O
+diarrhea	B-DISO
+in	O
+South	O
+Korea	O
+and	O
+consequently	O
+identified	O
+and	O
+characterized	O
+a	O
+novel	O
+PEDV	B-SPEC
+variant	O
+with	O
+a	O
+large	O
+genomic	O
+deletion	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+known	O
+case	O
+of	O
+a	O
+patient	O
+who	O
+survived	O
+Aspergillus	B-SPEC
+sepsis	B-DISO
+after	O
+being	O
+treated	O
+early	O
+with	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+(	O
+ECMO	O
+)	O
+and	O
+antifungal	B-CHED
+therapy	O
+.	O
+
+After	O
+7	O
+days	O
+of	O
+antifungal	O
+treatment	O
+,	O
+Aspergillus	B-SPEC
+antibodies	B-COMP
+were	O
+undetectable	O
+.	O
+
+TITLE	O
+:	O
+Enteric	O
+disease	O
+in	O
+postweaned	O
+beef	O
+calves	O
+associated	O
+with	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+clade	O
+2	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	O
+coronavirus	B-SPEC
+(	O
+BoCV	O
+;	O
+Betacoronavirus	B-SPEC
+1	I-SPEC
+)	O
+infections	B-DISO
+are	O
+associated	O
+with	O
+varied	O
+clinical	O
+presentations	O
+including	O
+neonatal	B-DISO
+diarrhea	I-DISO
+,	O
+winter	B-DISO
+dysentery	I-DISO
+in	O
+dairy	O
+cattle	B-SPEC
+,	O
+and	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+various	O
+ages	O
+of	O
+cattle	B-SPEC
+.	O
+
+Further	O
+investigations	O
+on	O
+the	O
+ecology	O
+of	O
+BoCV	O
+in	O
+cattle	B-SPEC
+are	O
+important	O
+,	O
+as	O
+BoCV	O
+may	O
+be	O
+an	O
+emerging	O
+disease	O
+beyond	O
+the	O
+initial	O
+descriptions	O
+.	O
+
+Tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	B-PRGE
+)	O
+and	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+signaling	B-PROC
+were	O
+not	O
+required	O
+for	O
+effective	O
+host	B-COMP
+control	O
+of	O
+mutant	B-DISO
+virus	B-SPEC
+as	O
+all	O
+N1347A	O
+virus	B-SPEC
+-	O
+infected	O
+mice	B-SPEC
+survived	O
+the	O
+infection	B-DISO
+.	O
+
+For	O
+example	O
+,	O
+highly	O
+similar	O
+coronavirus	B-SPEC
+S1	O
+-	O
+CTDs	O
+within	O
+the	O
+same	O
+genus	B-SPEC
+can	O
+recognize	O
+different	O
+receptors	O
+,	O
+whereas	O
+very	O
+different	O
+coronavirus	B-SPEC
+S1	O
+-	O
+CTDs	O
+from	O
+different	O
+genera	O
+can	O
+recognize	O
+the	O
+same	O
+receptor	O
+.	O
+
+Structural	O
+studies	O
+in	O
+the	O
+past	O
+decade	O
+have	O
+elucidated	O
+many	O
+of	O
+the	O
+puzzles	O
+associated	O
+with	O
+coronavirus	B-SPEC
+-	O
+receptor	B-PROC
+interactions	I-PROC
+.	O
+
+Clinical	O
+data	O
+of	O
+15	O
+severely	O
+burned	O
+patients	O
+with	O
+ARDS	B-DISO
+admitted	O
+to	O
+our	O
+burn	O
+ICU	O
+from	O
+September	O
+2011	O
+to	O
+September	O
+2013	O
+and	O
+conforming	O
+to	O
+the	O
+study	O
+criteria	O
+were	O
+analyzed	O
+.	O
+
+When	O
+OI	O
+was	O
+above	O
+200	O
+mmHg	O
+,	O
+lung	B-ANAT
+recruitment	B-DISO
+maneuver	O
+was	O
+stopped	O
+and	O
+ventilation	O
+with	O
+lung	B-ANAT
+protective	O
+ventilation	O
+strategy	O
+was	O
+continued	O
+.	O
+
+Clinical	O
+histories	O
+,	O
+physical	O
+examination	O
+,	O
+blood	B-ANAT
+and	O
+radiological	O
+tests	O
+were	O
+done	O
+.	O
+
+This	O
+may	O
+be	O
+related	O
+to	O
+focus	O
+on	O
+and	O
+treatment	O
+of	O
+asthma	B-PATH
+in	O
+this	O
+study	O
+,	O
+and	O
+will	O
+be	O
+analysed	O
+in	O
+a	O
+later	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Neonatal	B-DISO
+calf	I-DISO
+diarrhoea	I-DISO
+remains	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+preweaned	O
+dairy	O
+calves	O
+worldwide	O
+.	O
+
+This	O
+review	O
+deals	O
+with	O
+prevention	O
+and	O
+treatment	O
+of	O
+neonatal	O
+dairy	O
+calf	B-ANAT
+diarrhoea	B-DISO
+focusing	O
+on	O
+the	O
+importance	O
+of	O
+a	O
+good	O
+colostrum	B-ANAT
+management	O
+and	O
+a	O
+correct	O
+fluid	O
+therapy	O
+.	O
+
+Phylogenetic	O
+analyses	O
+produced	O
+a	O
+well	O
+-	O
+resolved	O
+phylogeny	O
+,	O
+supporting	O
+the	O
+familial	O
+status	O
+of	O
+Hipposideridae	B-SPEC
+and	O
+demonstrated	O
+the	O
+paraphyly	O
+of	O
+the	O
+largest	O
+genus	B-SPEC
+,	O
+Hipposideros	B-SPEC
+.	O
+
+A	O
+fossil	O
+-	O
+calibrated	O
+timetree	O
+and	O
+biogeographical	O
+analyses	O
+estimated	O
+that	O
+Rhinolophidae	O
+and	O
+Hipposideridae	B-SPEC
+diverged	O
+in	O
+Africa	O
+during	O
+the	O
+Eocene	O
+approximately	O
+42	O
+Ma	O
+.	O
+
+TITLE	O
+:	O
+Mobile	O
+ECMO	O
+team	O
+for	O
+inter	O
+-	O
+hospital	O
+transportation	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+:	O
+a	O
+retrospective	O
+case	O
+series	O
+.	O
+
+The	O
+average	O
+transport	B-PROC
+distance	O
+was	O
+121	O
+.	O
+69	O
+km	O
+(±	O
+183	O
+.	O
+08	O
+)	O
+with	O
+a	O
+range	O
+between	O
+9	O
+km	O
+and	O
+1044	O
+Km	O
+.	O
+
+According	O
+to	O
+our	O
+data	O
+,	O
+we	O
+conclude	O
+that	O
+a	O
+dedicated	O
+mobile	O
+team	O
+allowed	O
+safe	O
+ground	O
+transportation	O
+of	O
+patients	O
+with	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+to	O
+our	O
+tertiary	O
+care	O
+institution	O
+.	O
+
+After	O
+treatment	O
+of	O
+an	O
+anaphylactic	O
+episode	O
+,	O
+follow	O
+-	O
+up	O
+with	O
+a	O
+physician	O
+,	O
+preferably	O
+an	O
+allergy	B-DISO
+/	O
+immunology	O
+specialist	O
+,	O
+is	O
+important	O
+for	O
+confirmation	O
+of	O
+anaphylaxis	B-DISO
+triggers	O
+and	O
+prevention	O
+of	O
+recurrences	B-DISO
+through	O
+avoidance	O
+of	O
+confirmed	O
+specific	O
+triggers	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+can	O
+be	O
+used	O
+as	O
+a	O
+salvage	O
+therapy	O
+,	O
+but	O
+the	O
+effectiveness	O
+is	O
+controversial	O
+.	O
+
+Before	O
+ECMO	O
+,	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+,	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+,	O
+and	O
+Multiple	O
+Organ	B-ANAT
+Dysfunction	O
+scores	O
+were	O
+significantly	O
+lower	O
+for	O
+survivors	O
+than	O
+for	O
+nonsurvivors	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+records	O
+of	O
+65	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+who	O
+received	O
+venovenous	O
+ECMO	O
+were	O
+analyzed	O
+.	O
+
+The	O
+detection	O
+limit	O
+was	O
+10	O
+pg	O
+of	O
+ribonucleic	B-CHED
+acid	I-CHED
+,	O
+consistent	O
+with	O
+RT	O
+-	O
+PCR	O
+,	O
+RT	O
+-	O
+LAMP	O
+detected	O
+products	O
+on	O
+agarose	O
+gels	O
+and	O
+by	O
+direct	O
+calcein	B-CHED
+fluorescence	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+histopathologic	O
+abnormalities	O
+and	O
+predictor	O
+variables	O
+in	O
+autopsies	O
+of	O
+burned	O
+pediatric	O
+patients	O
+.	O
+
+Three	O
+scientists	O
+with	O
+pathology	B-DISO
+training	O
+in	O
+pediatric	O
+burn	O
+care	O
+reviewed	O
+masked	O
+autopsy	O
+slides	O
+of	O
+burned	O
+children	O
+who	O
+died	B-PROC
+after	O
+admission	O
+to	O
+a	O
+burn	O
+center	O
+from	O
+2002	O
+to	O
+2012	O
+(	O
+n	O
+=	O
+43	O
+).	O
+
+Type	O
+II	O
+epithelial	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+was	O
+significantly	O
+more	O
+common	O
+in	O
+cases	O
+with	O
+a	O
+longer	O
+time	O
+between	O
+burn	O
+and	O
+admission	O
+(	O
+p	O
+<	O
+0	O
+.	O
+02	O
+).	O
+
+It	O
+also	O
+summarizes	O
+currently	O
+available	O
+animal	B-SPEC
+models	O
+for	O
+MERS	O
+-	O
+CoV	O
+and	O
+proposes	O
+a	O
+future	O
+direction	O
+for	O
+MERS	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+a	O
+large	O
+group	O
+of	O
+enveloped	O
+,	O
+single	O
+-	O
+stranded	O
+positive	O
+-	O
+sense	O
+RNA	O
+viruses	B-SPEC
+that	O
+infect	O
+a	O
+wide	O
+range	O
+of	O
+avian	B-SPEC
+and	O
+mammalian	B-SPEC
+species	B-SPEC
+,	O
+including	O
+humans	B-SPEC
+.	O
+
+Coronaviruses	O
+have	O
+evolved	O
+multiple	O
+strategies	O
+for	O
+proteolytic	B-PROC
+activation	O
+of	O
+spike	O
+,	O
+and	O
+a	O
+large	O
+number	O
+of	O
+host	B-COMP
+proteases	O
+have	O
+been	O
+shown	O
+to	O
+proteolytically	O
+process	O
+the	O
+spike	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Noninvasive	O
+mechanical	O
+ventilation	O
+in	O
+high	O
+-	O
+risk	O
+pulmonary	B-DISO
+infections	I-DISO
+:	O
+a	O
+clinical	O
+review	O
+.	O
+
+NIV	O
+,	O
+when	O
+applied	O
+early	O
+in	O
+selected	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+H1N1	O
+and	O
+acute	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+infections	B-DISO
+,	O
+can	O
+reverse	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+a	O
+period	O
+of	O
+almost	O
+two	O
+years	O
+,	O
+broilers	O
+chickens	O
+on	O
+several	O
+hundred	O
+Italian	O
+farms	O
+,	O
+were	O
+monitored	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+absence	O
+of	O
+secondary	O
+cases	O
+among	O
+contacts	O
+of	O
+the	O
+reported	O
+cases	O
+can	O
+be	O
+seen	O
+as	O
+evidence	O
+of	O
+the	O
+effectiveness	O
+of	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+precautions	O
+as	O
+an	O
+important	O
+pillar	O
+of	O
+the	O
+national	O
+preparedness	O
+and	O
+response	O
+plan	O
+applied	O
+in	O
+the	O
+health	O
+care	O
+institutions	O
+in	O
+Oman	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+first	O
+description	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+it	O
+has	O
+not	O
+been	O
+known	O
+how	O
+long	O
+patients	O
+shed	O
+the	O
+virus	B-SPEC
+in	O
+respiratory	O
+secretions	B-ANAT
+.	O
+
+This	O
+review	O
+will	O
+give	O
+an	O
+overview	O
+of	O
+the	O
+literature	O
+on	O
+avian	B-SPEC
+coronavirus	I-SPEC
+spike	O
+proteins	B-CHED
+with	O
+particular	O
+focus	O
+on	O
+our	O
+recent	O
+studies	O
+on	O
+binding	B-FUNC
+of	O
+recombinant	B-PRGE
+soluble	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+to	O
+chicken	B-SPEC
+tissues	B-ANAT
+.	O
+
+To	O
+penetrate	O
+host	B-COMP
+cells	B-COMP
+,	O
+the	O
+CoV	O
+can	O
+use	O
+various	O
+cell	B-COMP
+surface	I-COMP
+molecules	O
+,	O
+although	O
+they	O
+preferentially	O
+bind	B-FUNC
+to	O
+ectoenzymes	O
+.	O
+
+Here	O
+we	O
+discuss	O
+the	O
+most	O
+recent	O
+studies	O
+on	O
+the	O
+structure	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+and	O
+its	O
+role	O
+in	O
+virus	B-SPEC
+binding	B-FUNC
+and	O
+entry	O
+,	O
+and	O
+the	O
+development	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+entry	O
+/	O
+fusion	O
+inhibitors	B-CHED
+targeting	B-PROC
+the	O
+S1	B-PRGE
+subunit	I-PRGE
+,	O
+particularly	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+),	O
+and	O
+the	O
+S2	O
+subunit	O
+,	O
+especially	O
+the	O
+HR1	O
+region	O
+,	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+.	O
+
+Deep	O
+sequencing	O
+of	O
+the	O
+viral	O
+structural	O
+genes	O
+at	O
+days	O
+11	O
+and	O
+21	O
+identified	O
+seven	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+in	O
+both	O
+normal	O
+and	O
+SCID	B-DISO
+pigs	B-SPEC
+.	O
+
+The	O
+most	O
+significant	O
+change	O
+was	O
+a	O
+W99R	O
+substitution	O
+in	O
+GP2	B-PRGE
+,	O
+which	O
+was	O
+present	O
+in	O
+the	O
+inoculum	O
+at	O
+a	O
+frequency	O
+of	O
+35	O
+%,	O
+but	O
+eventually	O
+disappeared	O
+from	O
+all	O
+pigs	B-SPEC
+regardless	O
+of	O
+immune	B-PROC
+status	I-PROC
+.	O
+
+Additional	O
+validation	O
+studies	O
+with	O
+the	O
+top	B-PRGE
+3	I-PRGE
+inhibitors	B-CHED
+(	O
+hexachlorophene	O
+,	O
+nitazoxanide	O
+and	O
+homoharringtonine	B-CHED
+)	O
+demonstrated	O
+robust	O
+anti	O
+-	O
+coronavirus	B-SPEC
+activities	O
+(	O
+a	O
+reduction	O
+of	O
+6	O
+to	O
+8log10	O
+in	O
+virus	B-SPEC
+titer	O
+)	O
+with	O
+an	O
+IC50	O
+ranging	O
+from	O
+11nM	O
+to	O
+1	O
+.	O
+2μM	O
+.	O
+Furthermore	O
+,	O
+homoharringtonine	O
+and	O
+hexachlorophene	O
+exhibited	O
+broad	O
+antiviral	B-CHED
+activity	O
+against	O
+diverse	O
+species	B-SPEC
+of	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Société	O
+de	O
+pneumologie	O
+de	O
+langue	O
+française	O
+defines	O
+acute	O
+exacerbation	O
+of	O
+chronic	O
+obstructive	O
+pulmonary	O
+disease	O
+(	O
+AE	O
+COPD	B-DISO
+)	O
+as	O
+an	O
+increase	O
+in	O
+daily	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+basically	O
+duration	O
+≥	O
+48h	O
+or	O
+need	O
+for	O
+treatment	O
+adjustment	O
+.	O
+
+Presences	O
+of	O
+signs	O
+of	O
+severity	O
+impose	O
+hospitalization	O
+:	O
+signs	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+shock	O
+,	O
+acute	O
+confusion	B-DISO
+but	O
+also	O
+fragile	O
+patients	O
+,	O
+insufficient	O
+home	O
+support	O
+or	O
+absence	O
+of	O
+response	O
+to	O
+initial	O
+treatment	O
+.	O
+
+SHFV	O
+infection	B-DISO
+induced	I-DISO
+the	O
+production	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+,	O
+including	O
+IL	O
+-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+/	O
+23	O
+(	O
+p40	B-COMP
+),	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+MIP	B-PRGE
+-	I-PRGE
+1α	I-PRGE
+,	O
+in	O
+macaque	B-SPEC
+cells	B-COMP
+but	O
+not	O
+baboon	B-SPEC
+cells	B-COMP
+.	O
+
+The	O
+patient	O
+met	B-CHED
+the	O
+criteria	O
+for	O
+ARDS	B-DISO
+with	O
+a	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+of	O
+94mmHg	O
+.	O
+
+HbS	B-PRGE
+fraction	O
+failed	O
+from	O
+69	O
+%	O
+to	O
+30	O
+%.	O
+
+Steroids	B-CHED
+were	O
+given	O
+for	O
+48h	O
+and	O
+the	O
+patient	O
+was	O
+successfully	O
+extubated	O
+on	O
+day	O
+7	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+residues	O
+on	O
+human	B-PRGE
+receptor	I-PRGE
+DPP4	I-PRGE
+critical	O
+for	O
+MERS	O
+-	O
+CoV	O
+binding	B-FUNC
+and	O
+entry	O
+.	O
+
+Many	O
+of	O
+these	O
+viral	O
+families	O
+were	O
+previously	O
+unknown	O
+to	O
+dromedaries	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+SHAPE	O
+technology	O
+was	O
+used	O
+to	O
+analyze	O
+RNA	O
+secondary	O
+structure	O
+of	O
+the	O
+5	O
+'	O
+most	O
+474	O
+nts	B-ANAT
+of	O
+the	O
+MHV	B-SPEC
+-	O
+A59	O
+genome	O
+encompassing	O
+the	O
+minimal	O
+5	O
+'	O
+cis	B-DISO
+-	O
+acting	O
+region	O
+required	O
+for	O
+defective	O
+interfering	O
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+Additional	O
+recombination	B-PROC
+events	O
+were	O
+identified	O
+in	O
+LRLV	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+initial	O
+study	O
+sample	O
+was	O
+positive	O
+in	O
+15	O
+patients	O
+with	O
+the	O
+following	O
+respiratory	O
+viruses	B-SPEC
+:	O
+rhinovirus	B-SPEC
+(	O
+6	O
+),	O
+metapneumovirus	B-SPEC
+(	O
+1	O
+),	O
+coronavirus	B-SPEC
+(	O
+2	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+2	O
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+2	O
+),	O
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+2	O
+).	O
+
+Over	O
+the	O
+years	O
+,	O
+it	O
+has	O
+been	O
+proposed	O
+that	O
+HCoVs	O
+play	O
+a	O
+possible	O
+role	O
+in	O
+gastrointestinal	B-DISO
+infections	I-DISO
+.	O
+
+HCoVs	O
+were	O
+present	O
+in	O
+the	O
+stools	B-ANAT
+of	O
+eight	O
+(	O
+4	O
+.	O
+7	O
+%)	O
+of	O
+the	O
+172	O
+children	O
+with	O
+AGE	O
+;	O
+in	O
+six	O
+of	O
+these	O
+cases	O
+,	O
+the	O
+nasal	B-ANAT
+swab	O
+sample	O
+was	O
+also	O
+positive	O
+for	O
+the	O
+respective	O
+HCoV	O
+.	O
+Additionally	O
+,	O
+in	O
+six	O
+of	O
+the	O
+eight	O
+cases	O
+,	O
+the	O
+stool	B-ANAT
+sample	I-ANAT
+contained	O
+either	O
+rotavirus	B-SPEC
+or	O
+calicivirus	O
+.	O
+
+Three	O
+compounds	O
+,	O
+chloroquine	B-CHED
+,	O
+mefloquine	B-CHED
+,	O
+and	O
+hexamethylene	B-CHED
+amiloride	B-CHED
+demonstrated	O
+marked	O
+inhibition	B-PROC
+of	O
+virus	B-SPEC
+induced	O
+CPE	O
+at	O
+low	O
+micromolar	O
+concentrations	O
+.	O
+
+Selectivity	O
+indices	O
+calculated	O
+based	O
+on	O
+in	O
+vitro	O
+cytotoxicity	B-DISO
+screening	O
+and	O
+reductions	O
+in	O
+extracellular	B-COMP
+viral	O
+titre	O
+were	O
+217	O
+,	O
+24	O
+,	O
+and	O
+20	O
+for	O
+chloroquine	B-CHED
+,	O
+mefloquine	B-CHED
+,	O
+and	O
+hexamethylene	B-CHED
+amiloride	B-CHED
+respectively	O
+.	O
+
+Vaccines	O
+and	O
+antiviral	B-CHED
+agents	I-CHED
+are	O
+urgently	O
+needed	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Respiratory	O
+pathogens	O
+were	O
+detected	O
+in	O
+the	O
+air	B-CHED
+and	O
+on	O
+surfaces	O
+in	O
+the	O
+KAAI	O
+Airport	O
+in	O
+Pilgrims	O
+City	O
+.	O
+
+Also	O
+,	O
+survivability	O
+of	O
+PEDV	B-SPEC
+inoculated	O
+on	O
+spray	B-PRGE
+dried	I-PRGE
+bovine	B-SPEC
+plasma	B-ANAT
+(	O
+SDBP	O
+)	O
+and	O
+stored	O
+at	O
+4	O
+,	O
+12	O
+or	O
+22	O
+°	O
+C	O
+was	O
+determined	O
+for	O
+7	O
+,	O
+14	O
+and	O
+21	O
+days	O
+.	O
+
+Commercial	O
+SDBP	O
+powder	O
+was	O
+inoculated	O
+with	O
+PEDV	B-SPEC
+to	O
+an	O
+average	O
+final	O
+titer	O
+of	O
+2	O
+.	O
+8	O
+log10	O
+TCID50	O
+/	O
+g	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+its	O
+milder	O
+form	O
+acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+may	O
+result	O
+from	O
+various	O
+diseases	O
+and	O
+situations	O
+including	O
+sepsis	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+trauma	O
+,	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+aspiration	B-DISO
+of	O
+gastric	B-ANAT
+contents	I-ANAT
+,	O
+near	O
+-	O
+drowning	O
+etc	O
+.	O
+
+Patience	O
+thus	O
+has	O
+the	O
+genomic	O
+profile	O
+of	O
+a	O
+virus	B-SPEC
+that	O
+evolved	O
+primarily	O
+in	O
+one	O
+type	O
+of	O
+host	B-COMP
+genetic	O
+landscape	O
+(	O
+moderate	O
+-	O
+GC	O
+bacteria	B-SPEC
+)	O
+but	O
+has	O
+found	O
+its	O
+way	O
+into	O
+a	O
+distinctly	O
+different	O
+high	O
+-	O
+GC	O
+environment	O
+.	O
+
+We	O
+conducted	O
+a	O
+seroprevalence	O
+study	O
+of	O
+banked	O
+human	B-SPEC
+serum	B-COMP
+samples	O
+collected	O
+in	O
+2012	O
+from	O
+Southern	O
+Saudi	O
+Arabia	O
+.	O
+
+Sera	B-COMP
+from	O
+300	O
+animal	B-SPEC
+workers	O
+(	O
+17	O
+%	O
+with	O
+daily	O
+camel	B-SPEC
+exposure	O
+)	O
+and	O
+50	O
+non	O
+-	O
+animal	B-SPEC
+-	O
+exposed	O
+controls	O
+were	O
+examined	O
+for	O
+serological	O
+evidence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+by	O
+a	O
+pseudoparticle	O
+MERS	O
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+neutralization	O
+assay	O
+.	O
+
+Two	O
+of	O
+the	O
+meta	B-SPEC
+-	O
+analyses	O
+indicated	O
+a	O
+significantly	O
+shorter	O
+hospital	O
+stay	O
+(	O
+5	O
+.	O
+17	O
+-	O
+9	O
+.	O
+49	O
+days	O
+),	O
+and	O
+one	O
+meta	B-SPEC
+-	O
+analysis	O
+found	O
+a	O
+significant	O
+reduction	O
+in	O
+ICU	O
+days	O
+(	O
+1	O
+.	O
+92	O
+).	O
+
+Coronaviruses	O
+encode	O
+16	O
+nonstructural	O
+proteins	B-CHED
+(	O
+nsps	O
+),	O
+three	O
+of	O
+which	O
+,	O
+nsp3	B-PRGE
+,	O
+nsp4	B-PRGE
+,	O
+and	O
+nsp6	O
+,	O
+are	O
+necessary	O
+and	O
+sufficient	O
+for	O
+DMV	O
+formation	B-PROC
+.	O
+
+Thus	O
+,	O
+defining	O
+the	O
+mechanisms	O
+of	O
+virus	B-SPEC
+-	O
+induced	O
+membrane	B-COMP
+modifications	O
+is	O
+essential	O
+for	O
+both	O
+understanding	O
+virus	B-PROC
+replication	I-PROC
+and	O
+development	B-PROC
+of	O
+novel	O
+approaches	O
+to	O
+virus	B-SPEC
+inhibition	B-PROC
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+a	O
+protocol	O
+to	O
+reduce	O
+the	O
+incidence	O
+of	O
+neonatal	B-DISO
+calf	I-DISO
+diarrhoea	I-DISO
+on	O
+dairy	O
+herds	O
+.	O
+
+To	O
+guide	O
+fluid	O
+management	O
+,	O
+the	O
+cardiac	B-ANAT
+index	O
+(	O
+CI	O
+)	O
+was	O
+measured	O
+to	O
+assess	O
+cardiac	B-PROC
+function	I-PROC
+,	O
+the	O
+global	O
+end	O
+-	O
+diastolic	O
+volume	O
+index	O
+(	O
+GEDVI	O
+)	O
+was	O
+used	O
+to	O
+evaluate	O
+cardiac	B-ANAT
+preload	O
+,	O
+and	O
+the	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+index	O
+(	O
+EVLWI	O
+)	O
+was	O
+used	O
+to	O
+evaluate	O
+the	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+We	O
+increased	O
+cardiac	B-ANAT
+output	O
+to	O
+increase	O
+tissue	B-ANAT
+perfusion	O
+and	O
+dehydration	B-DISO
+speed	O
+of	O
+CVVHDF	O
+was	O
+set	O
+at	O
+70	O
+ml	O
+/	O
+h	O
+.	O
+
+CONCLUSIONS	O
+:	O
+PiCCO	O
+monitoring	O
+can	O
+provide	O
+real	O
+-	O
+time	O
+surveillance	O
+of	O
+cardiac	B-PROC
+function	I-PROC
+,	O
+cardiac	B-ANAT
+preload	O
+and	O
+afterload	O
+,	O
+and	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+in	O
+pediatric	O
+patients	O
+with	O
+SAP	O
+combined	O
+with	O
+ARDS	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+rate	O
+of	O
+diffuse	O
+alveolar	O
+damage	O
+(	O
+DAD	O
+)	O
+on	O
+open	O
+lung	B-ANAT
+biopsy	O
+(	O
+OLB	O
+)	O
+performed	O
+in	O
+the	O
+ICU	O
+for	O
+nonresolving	O
+ARDS	B-DISO
+.	O
+
+A	O
+single	O
+-	O
+center	O
+retrospective	O
+study	O
+of	O
+patients	O
+meeting	O
+the	O
+Berlin	O
+definition	O
+criteria	O
+for	O
+ARDS	B-DISO
+who	O
+had	O
+undergone	O
+OLB	O
+for	O
+nonresolving	O
+ARDS	B-DISO
+.	O
+
+The	O
+secondary	O
+endpoint	O
+was	O
+the	O
+ability	O
+of	O
+DAD	O
+to	O
+predict	O
+ARDS	B-DISO
+among	O
+all	O
+the	O
+patients	O
+who	O
+had	O
+OLB	O
+.	O
+
+From	O
+January	O
+1998	O
+to	O
+August	O
+2013	O
+,	O
+113	O
+patients	O
+underwent	O
+OLB	O
+for	O
+acute	O
+hypoxemic	O
+respiratory	O
+failure	O
+,	O
+83	O
+of	O
+whom	O
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+for	O
+ARDS	B-DISO
+.	O
+
+DAD	B-PRGE
+is	O
+present	O
+in	O
+the	O
+majority	O
+of	O
+patients	O
+with	O
+nonresolving	O
+ARDs	B-DISO
+and	O
+its	O
+frequency	O
+is	O
+no	O
+different	O
+across	O
+the	O
+three	O
+ARDS	B-DISO
+stages	O
+.	O
+
+When	O
+P34	O
+and	O
+EAV	B-SPEC
+were	O
+incubated	O
+for	O
+6	O
+h	O
+at	O
+37	O
+°	O
+C	O
+the	O
+viral	O
+titer	O
+reduced	O
+from	O
+10	O
+(	O
+4	O
+.	O
+5	O
+)	O
+TCID50	O
+to	O
+10	O
+(	O
+2	O
+.	O
+75	O
+)	O
+TCID50	O
+,	O
+showing	O
+a	O
+percent	O
+of	O
+inhibition	B-PROC
+of	O
+98	O
+.	O
+6	O
+%.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+caused	O
+209	O
+deaths	B-PROC
+and	O
+699	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+as	O
+of	O
+June	O
+11	O
+,	O
+2014	O
+.	O
+
+Here	O
+we	O
+synthesize	O
+epidemiological	O
+data	O
+and	O
+transmission	O
+models	O
+for	O
+the	O
+MERS	O
+-	O
+CoV	O
+outbreak	O
+during	O
+April	O
+-	O
+October	O
+2013	O
+to	O
+resolve	O
+uncertainties	O
+in	O
+epidemic	O
+risk	O
+,	O
+while	O
+considering	O
+the	O
+impact	O
+of	O
+observation	O
+bias	B-SPEC
+.	O
+
+Alternatively	O
+,	O
+if	O
+these	O
+epidemiological	O
+observations	O
+are	O
+taken	O
+at	O
+face	B-DISO
+value	O
+,	O
+index	O
+cases	O
+are	O
+estimated	O
+to	O
+transmit	O
+substantially	O
+more	O
+effectively	O
+than	O
+secondary	O
+cases	O
+,	O
+(	O
+Ri	O
+=	O
+0	O
+.	O
+84	O
+(	O
+0	O
+.	O
+58	O
+-	O
+1	O
+.	O
+20	O
+)	O
+vs	O
+R	O
+(	O
+s	O
+)	O
+=	O
+0	O
+.	O
+36	O
+(	O
+0	O
+.	O
+24	O
+-	O
+0	O
+.	O
+51	O
+)).	O
+
+Here	O
+we	O
+show	O
+that	O
+PLpro	O
+also	O
+inhibits	O
+IRF3	O
+activation	O
+at	O
+a	O
+step	O
+after	O
+phosphorylation	B-PROC
+and	O
+that	O
+this	O
+inhibition	B-PROC
+is	O
+dependent	O
+on	O
+the	O
+de	O
+-	O
+ubiquitination	B-PROC
+(	O
+DUB	O
+)	O
+activity	O
+of	O
+PLpro	O
+.	O
+
+We	O
+found	O
+that	O
+PLpro	O
+is	O
+able	O
+to	O
+block	O
+the	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+induction	O
+of	O
+a	O
+constitutively	O
+active	O
+IRF3	B-PRGE
+,	O
+but	O
+does	O
+not	O
+inhibit	O
+IRF3	B-PRGE
+dimerization	O
+,	O
+nuclear	O
+localization	B-PROC
+or	O
+DNA	B-FUNC
+binding	I-FUNC
+.	O
+
+Although	O
+diarrhea	B-DISO
+is	O
+a	O
+symptom	B-DISO
+of	O
+infection	B-DISO
+with	O
+various	O
+pathogens	O
+,	O
+investigations	O
+to	O
+detect	O
+the	O
+types	O
+of	O
+pathogens	O
+have	O
+never	O
+been	O
+performed	O
+in	O
+Japan	O
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+prevalence	O
+of	O
+four	O
+major	O
+diarrhea	B-DISO
+-	O
+causing	O
+pathogens	O
+in	O
+calves	O
+:	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+,	O
+rotavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+and	O
+enterotoxigenic	O
+Escherichia	B-SPEC
+coli	I-SPEC
+(	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+K99	O
+).	O
+
+The	O
+frequencies	O
+of	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+,	O
+rotavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+and	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+(	O
+K99	O
+)	O
+in	O
+Okinawa	O
+were	O
+50	O
+%,	O
+28	O
+%,	O
+2	O
+.	O
+3	O
+%,	O
+and	O
+4	O
+.	O
+7	O
+%,	O
+respectively	O
+.	O
+
+In	O
+oocyst	O
+calculations	O
+for	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+,	O
+no	O
+significant	O
+difference	O
+was	O
+observed	O
+between	O
+the	O
+single	O
+-	O
+infection	B-DISO
+cases	O
+and	O
+the	O
+mixed	O
+-	O
+infection	B-DISO
+cases	O
+with	O
+rotavirus	B-SPEC
+.	O
+
+All	O
+recombinant	O
+FCoVs	O
+and	O
+the	O
+reference	O
+strain	O
+isolates	O
+were	O
+found	O
+to	O
+establish	O
+productive	O
+infections	B-DISO
+in	O
+cats	B-SPEC
+.	O
+
+While	O
+none	O
+of	O
+the	O
+type	B-PRGE
+I	I-PRGE
+FCoVs	I-PRGE
+and	O
+chimeric	O
+FCoVs	O
+induced	O
+FIP	B-DISO
+,	O
+the	O
+recombinant	B-PRGE
+type	I-PRGE
+II	I-PRGE
+FCoV	I-PRGE
+strain	O
+79	O
+-	O
+1146	O
+was	O
+as	O
+pathogenic	O
+as	O
+the	O
+parental	O
+isolate	O
+.	O
+
+We	O
+have	O
+begun	O
+to	O
+extend	O
+this	O
+work	O
+using	O
+recombinant	O
+IBVs	O
+,	O
+which	O
+are	O
+chimera	O
+of	O
+different	O
+virus	B-SPEC
+strains	O
+to	O
+study	O
+the	O
+role	O
+of	O
+viral	O
+proteins	B-CHED
+in	O
+the	O
+induction	O
+of	O
+membrane	B-COMP
+rearrangements	O
+.	O
+
+The	O
+timing	O
+of	O
+oral	B-ANAT
+-	O
+sample	O
+collection	O
+is	O
+crucial	O
+to	O
+correctly	O
+interpret	O
+the	O
+negative	O
+results	O
+for	O
+mumps	B-SPEC
+virus	I-SPEC
+RNA	O
+,	O
+especially	O
+when	O
+suspected	O
+cases	O
+occur	O
+in	O
+vaccinated	O
+persons	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+mainly	O
+infects	O
+neonatal	O
+pigs	B-SPEC
+,	O
+resulting	O
+in	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+The	O
+PEDV	B-SPEC
+genome	O
+encodes	O
+two	O
+polyprotein	O
+precursors	O
+required	O
+for	O
+genome	O
+replication	O
+and	O
+transcription	B-PROC
+.	O
+
+In	O
+postoperative	O
+ARF	O
+,	O
+both	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+and	O
+NIV	O
+are	O
+effective	O
+to	O
+improve	O
+clinical	O
+outcomes	O
+,	O
+particularly	O
+in	O
+those	O
+with	O
+abdominal	B-ANAT
+,	O
+cardiac	B-ANAT
+,	O
+and	O
+thoracic	B-DISO
+surgery	O
+.	O
+
+bioinformatics	O
+analysis	O
+of	O
+our	O
+kinome	O
+data	O
+,	O
+including	O
+pathway	B-PROC
+overrepresentation	O
+analysis	O
+(	O
+ORA	O
+)	O
+and	O
+functional	O
+network	O
+analysis	O
+,	O
+suggested	O
+that	O
+extracellular	B-ENZY
+signal	I-ENZY
+-	I-ENZY
+regulated	I-ENZY
+kinase	I-ENZY
+(	O
+ERK	B-FUNC
+)/	O
+mitogen	B-CHED
+-	I-ENZY
+activated	I-ENZY
+protein	B-CHED
+kinase	I-ENZY
+(	O
+MAPK	O
+)	O
+and	O
+phosphoinositol	O
+3	O
+-	O
+kinase	O
+(	O
+PI3K	B-FUNC
+)/	O
+serine	B-PRGE
+-	I-PRGE
+threonine	B-CHED
+kinase	I-PRGE
+(	O
+AKT	B-PRGE
+)/	O
+mammalian	B-SPEC
+target	O
+of	O
+rapamycin	B-CHED
+(	O
+mTOR	B-PRGE
+)	O
+signaling	B-PROC
+responses	O
+were	O
+specifically	O
+modulated	O
+in	O
+response	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+vitro	O
+throughout	O
+the	O
+course	O
+of	O
+infection	B-DISO
+.	O
+
+Incisions	O
+included	O
+anterolateral	O
+thoracotomy	O
+in	O
+69	O
+%	O
+and	O
+sternotomy	O
+in	O
+25	O
+%;	O
+73	O
+%	O
+required	O
+pulmonary	B-ANAT
+resection	O
+,	O
+20	O
+%	O
+required	O
+cardiorraphy	O
+,	O
+and	O
+9	O
+%	O
+had	O
+major	O
+vascular	B-ANAT
+injuries	O
+;	O
+multiple	O
+procedures	O
+were	O
+common	O
+.	O
+
+Forty	O
+-	O
+two	O
+patients	O
+(	O
+95	O
+%)	O
+had	O
+thoracic	B-DISO
+packing	O
+with	O
+vacuum	O
+-	O
+assisted	O
+closure	O
+.	O
+
+All	O
+survivors	O
+were	O
+neurologically	O
+intact	O
+and	O
+dialysis	B-SPEC
+free	O
+.	O
+
+This	O
+was	O
+a	O
+retrospective	O
+study	O
+of	O
+adults	O
+receiving	O
+ECMO	O
+for	O
+ARDS	B-DISO
+after	O
+initiation	O
+of	O
+a	O
+blood	B-ANAT
+conservation	O
+protocol	O
+that	O
+included	O
+a	O
+transfusion	O
+trigger	O
+of	O
+hemoglobin	B-PRGE
+of	O
+less	O
+than	O
+7	O
+.	O
+0	O
+g	O
+/	O
+dL	O
+,	O
+use	O
+of	O
+low	O
+-	O
+dose	O
+anticoagulation	B-PROC
+targeting	B-PROC
+an	O
+activated	O
+partial	O
+thromboplastin	B-PRGE
+time	O
+of	O
+40	O
+to	O
+60	O
+seconds	O
+,	O
+and	O
+autotransfusion	O
+of	O
+circuit	O
+blood	B-ANAT
+during	O
+decannulation	O
+.	O
+
+Twenty	O
+-	O
+eight	O
+patients	O
+(	O
+73	O
+.	O
+7	O
+%)	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Permissive	O
+hypercapnia	B-DISO
+:	O
+what	O
+to	O
+remember	O
+.	O
+
+TITLE	O
+:	O
+EMS	O
+patients	O
+and	O
+walk	O
+-	O
+in	O
+patients	O
+presenting	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+:	O
+differences	O
+in	O
+management	O
+and	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Infection	O
+by	O
+human	B-SPEC
+coronaviruses	O
+is	O
+usually	O
+characterized	O
+by	O
+rampant	O
+viral	B-PROC
+replication	I-PROC
+and	O
+severe	O
+immunopathology	B-DISO
+in	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+By	O
+promoting	O
+p53	B-PRGE
+degradation	O
+,	O
+PLP2	B-PRGE
+inhibits	O
+the	O
+p53	B-PRGE
+-	O
+mediated	O
+antiviral	B-PROC
+response	I-PROC
+and	O
+apoptosis	B-PATH
+to	O
+ensure	O
+viral	O
+growth	B-PROC
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+Thus	O
+,	O
+our	O
+study	O
+reveals	O
+that	O
+coronavirus	O
+engages	O
+PLPs	O
+to	O
+escape	O
+from	O
+the	O
+innate	O
+antiviral	B-PROC
+response	I-PROC
+of	O
+the	O
+host	B-COMP
+by	O
+inhibiting	O
+p53	B-PRGE
+-	O
+IRF7	B-PRGE
+-	O
+IFNβ	O
+signaling	B-PROC
+.	O
+
+TITLE	O
+:	O
+Knowledge	O
+and	O
+attitude	O
+of	O
+healthcare	O
+workers	O
+about	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+in	O
+multispecialty	O
+hospitals	O
+of	O
+Qassim	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+caused	O
+by	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+infection	B-DISO
+,	O
+is	O
+a	O
+highly	O
+lethal	O
+disease	O
+without	O
+effective	O
+therapy	O
+and	O
+prevention	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+the	O
+assessment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+severity	O
+at	O
+standardized	O
+low	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+may	O
+improve	O
+the	O
+association	O
+between	O
+the	O
+underlying	O
+lung	B-ANAT
+injury	O
+,	O
+as	O
+detected	O
+by	O
+CT	O
+,	O
+and	O
+PaO2	O
+/	O
+FIO2	O
+-	O
+derived	O
+severity	O
+.	O
+
+At	O
+clinical	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+11	O
+±	O
+3	O
+cm	O
+H2O	B-CHED
+),	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+had	O
+a	O
+greater	O
+lung	B-ANAT
+tissue	I-ANAT
+weight	O
+and	O
+recruitability	O
+than	O
+patients	O
+with	O
+mild	O
+or	O
+moderate	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+When	O
+patients	O
+were	O
+classified	O
+at	O
+5	O
+cm	O
+H2O	B-CHED
+,	O
+but	O
+not	O
+at	O
+clinical	O
+or	O
+15	O
+cm	O
+H2O	B-CHED
+,	O
+lung	B-ANAT
+recruitability	O
+linearly	O
+increases	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+severity	O
+(	O
+5	O
+%	O
+[	O
+2	O
+-	O
+12	O
+%]	O
+vs	O
+12	O
+%	O
+[	O
+7	O
+-	O
+18	O
+%]	O
+vs	O
+23	O
+%	O
+[	O
+12	O
+-	O
+30	O
+%],	O
+respectively	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Molecular	O
+survey	O
+of	O
+RNA	O
+viruses	B-SPEC
+in	O
+Hungarian	O
+bats	B-SPEC
+:	O
+discovering	O
+novel	O
+astroviruses	O
+,	O
+coronaviruses	O
+,	O
+and	O
+caliciviruses	O
+.	O
+
+The	O
+Hungarian	O
+BtCalV	O
+did	O
+not	O
+cluster	O
+with	O
+any	O
+of	O
+the	O
+calcivirus	O
+genera	O
+identified	O
+in	O
+the	O
+family	B-SPEC
+so	O
+far	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+have	O
+described	O
+new	O
+bat	B-ENZY
+species	B-SPEC
+harboring	O
+BtAstVs	O
+in	O
+Europe	O
+and	O
+found	O
+new	O
+species	B-SPEC
+of	O
+CalVs	O
+.	O
+
+ASA	B-CHED
+desensitization	B-PROC
+helps	O
+improve	O
+symptoms	O
+in	O
+patients	O
+with	O
+AERD	O
+.	O
+
+In	O
+the	O
+less	O
+severe	O
+patients	O
+(	O
+mild	O
+ARDS	B-DISO
+),	O
+however	O
+,	O
+a	O
+few	O
+studies	O
+have	O
+demonstrated	O
+the	O
+benefits	O
+of	O
+preserving	O
+spontaneous	O
+breathing	B-PROC
+with	O
+an	O
+improvement	O
+in	O
+oxygenation	B-PROC
+and	O
+a	O
+decrease	O
+in	O
+the	O
+length	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+life	O
+support	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Advances	O
+in	O
+cannulation	O
+,	O
+circuit	O
+design	O
+,	O
+and	O
+patient	O
+selection	O
+have	O
+made	O
+it	O
+a	O
+safer	O
+therapeutic	O
+option	O
+in	O
+severe	O
+ARDS	B-DISO
+,	O
+and	O
+its	O
+use	O
+has	O
+become	O
+more	O
+widespread	O
+for	O
+nonconventional	O
+indications	O
+.	O
+
+We	O
+found	O
+the	O
+universal	O
+IBV	B-SPEC
+primers	O
+and	O
+probe	O
+set	O
+to	O
+be	O
+comparable	O
+to	O
+challenge	O
+-	O
+virus	B-SPEC
+detection	O
+in	O
+embryonated	O
+eggs	O
+.	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+host	B-COMP
+tropism	B-PROC
+of	O
+Middle	O
+East	B-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+with	O
+the	O
+amino	B-CHED
+acid	I-CHED
+structure	O
+of	O
+host	O
+cell	O
+receptor	O
+dipeptidyl	O
+peptidase	O
+4	O
+.	O
+
+We	O
+found	O
+out	O
+that	O
+,	O
+in	O
+the	O
+binding	B-FUNC
+of	O
+MERS	O
+-	O
+CoV	O
+to	O
+cells	B-COMP
+the	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+in	O
+lancets	O
+4	O
+and	O
+5	O
+of	O
+DPP4	B-PRGE
+receptor	I-PRGE
+,	O
+namely	O
+K267	O
+,	O
+Q286	O
+,	O
+T288	O
+,	O
+R317	O
+,	O
+R336	O
+,	O
+Q344	O
+A291	O
+,	O
+L294	O
+,	O
+and	O
+I295	O
+are	O
+involved	O
+.	O
+
+Coronaviruses	O
+such	O
+as	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+cause	O
+high	O
+case	O
+fatality	O
+rates	O
+and	O
+remain	O
+major	O
+human	B-SPEC
+public	O
+health	O
+threats	O
+,	O
+creating	O
+a	O
+need	O
+for	O
+effective	O
+vaccines	O
+.	O
+
+Thus	O
+,	O
+delta	O
+inulin	B-CHED
+adjuvants	B-CHED
+may	O
+offer	O
+a	O
+unique	O
+ability	O
+to	O
+develop	O
+safer	O
+and	O
+more	O
+effective	O
+coronavirus	B-SPEC
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Mass	O
+Thermography	O
+Screening	O
+for	O
+Infection	B-DISO
+and	O
+Prevention	O
+:	O
+A	O
+Review	O
+of	O
+the	O
+Clinical	O
+Effectiveness	O
+ABSTRACT	O
+:	O
+Thermography	O
+involves	O
+the	O
+quantification	O
+of	O
+emitted	O
+radiation	O
+to	O
+measure	O
+temperature	O
+,	O
+and	O
+provides	O
+a	O
+quick	O
+non	O
+-	O
+invasive	O
+means	O
+to	O
+measure	O
+body	O
+temperature	O
+.	O
+
+Recently	O
+,	O
+the	O
+2014	O
+Ebola	O
+epidemic	O
+in	O
+West	O
+Africa	O
+has	O
+renewed	O
+concerns	O
+of	O
+disease	B-DISO
+transmission	I-DISO
+across	O
+borders	O
+and	O
+increased	O
+vigilance	O
+to	O
+identify	O
+individuals	O
+entering	O
+the	O
+country	O
+who	O
+may	O
+harbour	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+objective	O
+of	O
+the	O
+Scandinavian	O
+Society	O
+of	O
+Anaesthesiology	O
+and	O
+Intensive	O
+Care	O
+Medicine	B-CHED
+(	O
+SSAI	O
+)	O
+task	O
+force	O
+on	O
+mechanical	O
+ventilation	O
+in	O
+adults	O
+with	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+to	O
+formulate	O
+treatment	O
+recommendations	O
+based	O
+on	O
+available	O
+evidence	O
+from	O
+systematic	O
+reviews	O
+and	O
+randomised	O
+trials	O
+.	O
+
+Also	O
+,	O
+we	O
+suggest	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+>	O
+5	O
+cm	O
+H2O	B-CHED
+in	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+and	O
+prone	O
+ventilation	O
+16	O
+/	O
+24	O
+h	O
+for	O
+the	O
+first	O
+week	O
+in	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+(	O
+weak	O
+recommendation	O
+,	O
+low	O
+quality	O
+evidence	O
+).	O
+
+Between	O
+2010	O
+and	O
+2012	O
+,	O
+nasal	B-ANAT
+swabs	O
+were	O
+collected	O
+from	O
+1	O
+,	O
+484	O
+apparently	O
+healthy	O
+cattle	B-SPEC
+destined	O
+for	O
+export	O
+to	O
+the	O
+Middle	O
+East	O
+and	O
+Russian	O
+Federation	O
+.	O
+
+TITLE	O
+:	O
+Genotype	O
+shift	O
+in	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+and	O
+emergence	O
+of	O
+a	O
+novel	O
+genotype	O
+by	O
+natural	O
+recombination	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+(	O
+HCoV	B-SPEC
+)	O
+OC43	O
+is	O
+the	O
+most	O
+prevalent	O
+HCoV	B-SPEC
+in	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+Sixty	O
+of	O
+these	O
+65	O
+samples	O
+belong	O
+to	O
+genotypes	O
+B	O
+,	O
+C	O
+and	O
+D	O
+.	O
+The	O
+remaining	O
+five	O
+strains	O
+had	O
+incongruent	O
+positions	O
+in	O
+the	O
+phylogenetic	O
+trees	O
+of	O
+the	O
+S	O
+,	O
+RdRp	B-FUNC
+and	O
+N	O
+genes	O
+,	O
+suggesting	O
+a	O
+novel	O
+genotype	O
+emerging	O
+,	O
+designated	O
+as	O
+genotype	O
+E	O
+.	O
+Whole	O
+genome	O
+sequencing	O
+and	O
+bootscan	O
+analysis	O
+indicated	O
+that	O
+genotype	O
+E	O
+is	O
+generated	O
+by	O
+recombination	O
+between	O
+genotypes	O
+B	O
+,	O
+C	O
+and	O
+D	O
+.	O
+Temporal	O
+analysis	O
+revealed	O
+a	O
+sequential	O
+genotype	O
+replacement	O
+of	O
+C	O
+,	O
+B	O
+,	O
+D	O
+and	O
+E	O
+over	O
+the	O
+study	O
+period	O
+with	O
+genotype	O
+D	O
+being	O
+the	O
+dominant	O
+genotype	O
+since	O
+2007	O
+.	O
+
+Replicating	O
+virus	B-SPEC
+was	O
+strongly	O
+associated	O
+with	O
+macrophages	B-ANAT
+by	O
+immunohistochemistry	O
+.	O
+
+Virus	B-SPEC
+was	O
+usually	O
+detected	O
+at	O
+relatively	O
+low	O
+levels	O
+in	O
+feces	B-ANAT
+and	O
+there	O
+was	O
+no	O
+evidence	O
+of	O
+enterocyte	B-ANAT
+infection	B-DISO
+.	O
+
+In	O
+addition	O
+to	O
+its	O
+function	O
+as	O
+a	O
+structural	O
+protein	B-CHED
+,	O
+N	B-PRGE
+protein	I-PRGE
+is	O
+involved	O
+in	O
+cell	B-COMP
+apoptosis	B-PATH
+or	O
+cell	B-PROC
+-	I-PROC
+cycle	I-PROC
+regulation	I-PROC
+.	O
+
+Here	O
+,	O
+we	O
+computationally	O
+analyzed	O
+gene	B-PROC
+expression	I-PROC
+changes	O
+in	O
+a	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+line	O
+infected	O
+with	O
+two	O
+genetically	O
+distinct	O
+MERS	O
+-	O
+CoV	O
+strains	O
+obtained	O
+from	O
+human	B-SPEC
+patients	O
+,	O
+MERS	O
+-	O
+CoV	O
+SA	O
+1	O
+and	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Eng	I-PRGE
+1	I-PRGE
+.	O
+
+Predicted	O
+activation	O
+for	O
+STAT3	B-PRGE
+mediating	O
+gene	B-PROC
+expression	I-PROC
+relevant	O
+for	O
+epithelial	B-ANAT
+cell	I-ANAT
+-	O
+to	O
+-	O
+cell	B-COMP
+adherens	O
+and	O
+junction	O
+signaling	B-PROC
+in	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Eng	I-PRGE
+1	I-PRGE
+infection	B-DISO
+suggest	O
+that	O
+these	O
+transcriptional	B-PROC
+differences	O
+may	O
+be	O
+the	O
+result	O
+of	O
+amino	B-CHED
+acid	I-CHED
+differences	O
+in	O
+viral	O
+proteins	B-CHED
+known	O
+to	O
+modulate	O
+innate	B-PROC
+immunity	I-PROC
+during	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+A	O
+total	O
+of	O
+152	O
+patients	O
+(	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+[	O
+39	O
+.	O
+5	O
+%],	O
+health	O
+care	O
+-	O
+associated	O
+pneumonia	B-DISO
+[	O
+40	O
+.	O
+8	O
+%],	O
+and	O
+hospital	O
+-	O
+acquired	O
+pneumonia	O
+[	O
+19	O
+.	O
+7	O
+%])	O
+were	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+A	O
+retrospective	O
+investigation	O
+of	O
+the	O
+clinical	O
+manifestation	O
+,	O
+laboratory	O
+test	O
+,	O
+imagelogy	O
+,	O
+clinical	O
+course	O
+and	O
+outcome	O
+of	O
+3	O
+cases	O
+with	O
+MP	O
+-	O
+HLH	B-DISO
+seen	O
+between	O
+June	O
+2013	O
+and	O
+July	O
+2013	O
+in	O
+Shenzhen	O
+Children	O
+'	O
+s	O
+Hospital	O
+,	O
+and	O
+review	O
+of	O
+relevant	O
+literature	O
+were	O
+conducted	O
+.	O
+
+Diagnosis	O
+of	O
+refractory	O
+Mycoplasma	B-DISO
+pneumoniae	I-DISO
+pneumonia	I-DISO
+was	O
+made	O
+,	O
+which	O
+was	O
+accompanied	O
+by	O
+decreased	O
+neutrophils	B-ANAT
+[(	O
+0	O
+.	O
+08	O
+-	O
+0	O
+.	O
+68	O
+)×	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+],	O
+hemoglobin	B-PRGE
+[(	O
+79	O
+-	O
+103	O
+)	O
+g	O
+/	O
+L	O
+],	O
+platelet	B-ANAT
+[(	O
+64	O
+-	O
+157	O
+)×	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+],	O
+plasma	B-PRGE
+fibrinogen	B-COMP
+[(	O
+1	O
+.	O
+3	O
+-	O
+1	O
+.	O
+5	O
+)	O
+g	O
+/	O
+L	O
+],	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+[(	O
+1	O
+,	O
+170	O
+-	O
+1	O
+,	O
+285	O
+)	O
+U	O
+/	O
+L	O
+]	O
+and	O
+increased	O
+serum	B-ANAT
+ferritin	B-PRGE
+[(	O
+936	O
+.	O
+7	O
+-	O
+39	O
+789	O
+.	O
+0	O
+)	O
+µg	O
+/	O
+L	O
+]	O
+in	O
+the	O
+third	O
+week	O
+of	O
+course	O
+.	O
+
+CT	O
+scan	O
+was	O
+performed	O
+for	O
+all	O
+the	O
+cases	O
+and	O
+consolidation	O
+with	O
+pleural	B-DISO
+effusion	I-DISO
+were	O
+shown	O
+.	O
+
+Too	O
+late	O
+a	O
+diagnosis	O
+or	O
+development	B-PROC
+of	O
+serious	O
+complications	O
+may	O
+lead	O
+to	O
+death	B-PROC
+.	O
+
+DRG	O
+International	O
+Classification	O
+of	O
+Diseases	O
+--	O
+9th	O
+Rev	O
+.	O
+codes	O
+were	O
+crosswalked	O
+to	O
+Abbreviated	O
+Injury	O
+Scale	O
+(	O
+AIS	B-DISO
+)	O
+2005	O
+codes	O
+.	O
+
+We	O
+searched	O
+PubMed	O
+and	O
+EMBASE	O
+between	O
+inception	O
+and	O
+January	O
+2014	O
+,	O
+including	O
+all	O
+studies	O
+reporting	O
+seasonal	O
+incidence	O
+of	O
+GBS	B-DISO
+.	O
+
+Across	O
+all	O
+studies	O
+,	O
+there	O
+was	O
+greater	O
+seasonal	O
+variation	O
+with	O
+respiratory	O
+prodrome	O
+(	O
+IRR	O
+=	O
+3	O
+.	O
+06	O
+,	O
+1	O
+.	O
+84	O
+-	O
+5	O
+.	O
+11	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+than	O
+diarrhoeal	O
+prodrome	B-DISO
+(	O
+IRR	O
+=	O
+1	O
+.	O
+10	O
+,	O
+0	O
+.	O
+60	O
+-	O
+2	O
+.	O
+00	O
+,	O
+p	O
+=	O
+0	O
+.	O
+76	O
+)	O
+and	O
+a	O
+greater	O
+incidence	O
+in	O
+winter	O
+in	O
+Western	O
+countries	O
+(	O
+IRR	O
+=	O
+1	O
+.	O
+28	O
+),	O
+the	O
+Far	O
+East	O
+(	O
+IRR	O
+=	O
+1	O
+.	O
+20	O
+)	O
+and	O
+Middle	O
+East	O
+(	O
+IRR	O
+=	O
+1	O
+.	O
+12	O
+),	O
+with	O
+a	O
+lower	O
+incidence	O
+in	O
+the	O
+Indian	O
+subcontinent	O
+(	O
+IRR	O
+=	O
+0	O
+.	O
+86	O
+)	O
+and	O
+Latin	O
+America	O
+(	O
+IRR	O
+=	O
+0	O
+.	O
+75	O
+).	O
+
+Blood	B-ANAT
+MxA	B-PRGE
+protein	I-PRGE
+levels	O
+were	O
+measured	O
+by	O
+an	O
+enzyme	O
+immunoassay	O
+and	O
+PCR	O
+methods	O
+were	O
+used	O
+for	O
+the	O
+detection	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+nasal	B-ANAT
+swabs	O
+.	O
+
+Rhinovirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+infections	B-DISO
+were	O
+associated	O
+with	O
+elevated	O
+MxA	O
+responses	O
+.	O
+
+Asymptomatic	O
+virus	B-SPEC
+-	O
+negative	O
+children	O
+vaccinated	O
+with	O
+a	O
+live	O
+virus	B-SPEC
+vaccine	O
+had	O
+elevated	O
+MxA	B-PRGE
+protein	I-PRGE
+levels	O
+(	O
+240	O
+[	O
+120	O
+-	O
+540	O
+]	O
+μg	O
+/	O
+L	O
+),	O
+but	O
+significantly	O
+lower	O
+than	O
+children	O
+with	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+,	O
+who	O
+had	O
+not	O
+received	O
+vaccinations	O
+(	O
+740	O
+[	O
+350	O
+-	O
+1425	O
+]	O
+μg	O
+/	O
+L	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+cases	O
+without	O
+documented	O
+contact	O
+with	O
+another	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+case	O
+make	O
+up	O
+61	O
+%	O
+(	O
+517	O
+/	O
+853	O
+)	O
+of	O
+all	O
+reported	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+compare	O
+the	O
+positive	O
+end	O
+-	O
+expiratory	O
+pressure	O
+selection	O
+aiming	O
+either	O
+to	O
+oxygenation	B-PROC
+or	O
+to	O
+the	O
+full	O
+lung	B-ANAT
+opening	O
+.	O
+
+Increasing	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+in	O
+patients	O
+with	O
+severe	O
+hypoxemia	O
+is	O
+associated	O
+with	O
+better	O
+outcome	O
+if	O
+the	O
+oxygenation	B-PROC
+response	O
+is	O
+greater	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+tests	O
+may	O
+be	O
+performed	O
+in	O
+a	O
+few	O
+minutes	O
+.	O
+
+If	O
+,	O
+after	O
+recruitment	B-DISO
+maneuver	O
+,	O
+the	O
+recruitment	B-DISO
+is	O
+not	O
+sustained	O
+by	O
+sufficient	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+the	O
+lung	B-ANAT
+will	O
+unavoidably	O
+collapse	B-DISO
+.	O
+
+Recent	O
+investigations	O
+suggest	O
+the	O
+possible	O
+role	O
+of	O
+NLRP3	B-PRGE
+inflammasomes	I-PRGE
+,	O
+which	O
+regulate	O
+IL	O
+-	O
+1β	O
+production	O
+and	O
+lead	O
+to	O
+inflammatory	B-DISO
+responses	I-DISO
+,	O
+in	O
+the	O
+pathophysiology	O
+of	O
+HALI	O
+;	O
+however	O
+,	O
+their	O
+role	O
+is	O
+not	O
+fully	O
+understood	O
+.	O
+
+ABSTRACT	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+INO	O
+)	O
+improves	O
+ventilation	O
+-	O
+perfusion	O
+matching	O
+and	O
+alleviates	O
+pulmonary	B-DISO
+hypertension	I-DISO
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+better	O
+understanding	O
+of	O
+the	O
+mechanisms	O
+by	O
+which	O
+INO	O
+acts	O
+may	O
+guide	O
+in	O
+improving	O
+treatment	O
+with	O
+INO	O
+in	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+This	O
+might	O
+augment	O
+the	O
+vasoconstriction	B-DISO
+in	O
+atelectatic	O
+lung	B-ANAT
+regions	O
+,	O
+enhancing	O
+the	O
+redistribution	O
+of	O
+pulmonary	B-ANAT
+blood	B-PROC
+flow	I-PROC
+to	O
+ventilated	O
+lung	B-ANAT
+regions	O
+which	O
+are	O
+reached	O
+by	O
+INO	O
+.	O
+
+The	O
+vast	O
+majority	O
+of	O
+patients	O
+presented	O
+a	O
+clinical	O
+picture	O
+compatible	O
+with	O
+acute	O
+cerebellar	B-DISO
+dysfunction	I-DISO
+,	O
+beginning	O
+minutes	O
+and	O
+lasting	O
+up	O
+to	O
+2	O
+days	O
+after	O
+the	O
+accident	O
+.	O
+
+Besides	O
+,	O
+some	O
+patients	O
+presented	O
+myoclonus	B-DISO
+and	O
+fasciculation	B-DISO
+which	O
+can	O
+also	O
+be	O
+attributed	O
+to	O
+cerebellar	O
+dysfunction	O
+or	O
+maybe	O
+the	O
+result	O
+of	O
+direct	O
+action	O
+on	O
+skeletal	B-ANAT
+muscle	I-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+collect	O
+and	O
+interpret	O
+the	O
+recent	O
+experimental	O
+evidence	O
+about	O
+the	O
+role	O
+and	O
+importance	O
+of	O
+membrane	B-COMP
+-	O
+bound	O
+organelles	B-COMP
+in	O
+coronavirus	B-SPEC
+replication	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+development	B-PROC
+of	O
+a	O
+transgenic	O
+mouse	B-SPEC
+model	O
+expressing	O
+porcine	B-SPEC
+APN	O
+which	O
+is	O
+susceptible	O
+to	O
+porcine	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+During	O
+2002	O
+-	O
+2003	O
+,	O
+SARS	B-DISO
+in	O
+-	O
+out	O
+flow	O
+played	O
+an	O
+important	O
+role	O
+in	O
+countrywide	O
+transmission	O
+of	O
+the	O
+disease	O
+in	O
+Mainland	O
+China	O
+.	O
+
+Additional	O
+experiments	O
+revealed	O
+,	O
+unexpectedly	O
+,	O
+that	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+S	O
+-	O
+mediated	O
+entry	O
+also	O
+begins	O
+only	O
+after	O
+a	O
+30	O
+-	O
+min	O
+lag	O
+.	O
+
+Ebola	B-SPEC
+virus	I-SPEC
+is	O
+a	O
+hemorrhagic	B-DISO
+fever	I-DISO
+virus	B-SPEC
+that	O
+causes	O
+high	O
+fatality	O
+rates	O
+when	O
+it	O
+spreads	O
+from	O
+zoonotic	O
+vectors	O
+into	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+No	O
+effective	O
+vaccine	O
+or	O
+treatment	O
+has	O
+yet	O
+been	O
+approved	O
+for	O
+either	O
+virus	B-SPEC
+.	O
+
+This	O
+unexpected	O
+similarity	O
+suggests	O
+an	O
+unexplored	O
+vulnerability	O
+,	O
+trafficking	B-PROC
+to	O
+NPC1	B-DISO
+(+)	O
+LE	O
+/	O
+Lys	B-CHED
+,	O
+as	O
+a	O
+therapeutic	O
+target	O
+for	O
+SARS	B-DISO
+and	O
+EBOV	O
+.	O
+
+Its	O
+unique	O
+putative	O
+cleavage	B-PROC
+sites	O
+between	O
+nonstructural	O
+proteins	B-CHED
+1	O
+and	O
+2	O
+and	O
+in	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+and	O
+low	O
+sequence	O
+identities	O
+to	O
+other	O
+lineage	O
+A	O
+betacoronaviruses	O
+(	O
+βCoVs	O
+)	O
+in	O
+conserved	O
+replicase	B-PRGE
+domains	O
+support	O
+ChRCoV	O
+HKU24	O
+as	O
+a	O
+separate	O
+species	B-SPEC
+.	O
+
+Molecular	O
+clock	O
+analysis	O
+dated	O
+the	O
+time	O
+of	O
+the	O
+most	O
+recent	O
+common	O
+ancestor	O
+of	O
+ChRCoV	O
+HKU24	O
+,	O
+Betacoronavirus	B-SPEC
+1	I-SPEC
+,	O
+and	O
+rabbit	B-PRGE
+coronavirus	B-SPEC
+HKU14	I-PRGE
+to	O
+about	O
+the	O
+year	O
+1400	O
+.	O
+
+We	O
+discovered	O
+a	O
+novel	O
+lineage	O
+A	O
+βCoV	O
+,	O
+China	O
+Rattus	B-SPEC
+coronavirus	B-SPEC
+HKU24	O
+(	O
+ChRCoV	O
+HKU24	O
+),	O
+from	O
+Norway	B-SPEC
+rats	I-SPEC
+in	O
+China	O
+with	O
+a	O
+high	O
+seroprevalence	O
+.	O
+
+The	O
+observation	O
+endpoint	O
+was	O
+set	O
+as	O
+the	O
+time	O
+when	O
+the	O
+lung	B-ANAT
+lesions	O
+were	O
+basically	O
+absorbed	O
+or	O
+12	O
+months	O
+after	O
+withdrawal	B-DISO
+.	O
+
+Lung	B-ANAT
+HRCT	O
+of	O
+severe	O
+ARDS	B-DISO
+survivors	O
+after	O
+ECMO	O
+treatment	O
+showed	O
+various	O
+degrees	O
+of	O
+morphological	O
+changes	O
+in	O
+the	O
+lung	B-ANAT
+parenchyma	I-ANAT
+.	O
+
+One	O
+additional	O
+patient	O
+was	O
+36	O
+days	O
+postpartum	O
+and	O
+required	O
+intensive	O
+care	O
+unit	O
+admission	O
+and	O
+mechanical	O
+ventilation	O
+for	O
+influenza	B-DISO
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+During	O
+the	O
+influenza	B-DISO
+season	O
+,	O
+pregnant	O
+women	O
+with	O
+suspected	O
+influenza	B-DISO
+should	O
+receive	O
+prompt	O
+empiric	O
+antiviral	B-CHED
+therapy	O
+,	O
+regardless	O
+of	O
+rapid	O
+influenza	B-DISO
+diagnostic	O
+test	O
+results	O
+or	O
+vaccination	O
+status	O
+.	O
+
+Recent	O
+annual	O
+applications	O
+for	O
+this	O
+elective	O
+have	O
+been	O
+as	O
+high	O
+as	O
+44	O
+out	O
+of	O
+a	O
+class	B-SPEC
+of	O
+200	O
+students	O
+.	O
+
+Students	O
+undergo	O
+extensive	O
+preparation	O
+prior	O
+to	O
+their	O
+travel	O
+overseas	O
+,	O
+including	O
+a	O
+review	O
+of	O
+individual	O
+health	O
+and	O
+safety	O
+issues	O
+,	O
+travel	O
+and	O
+lodging	O
+,	O
+and	O
+the	O
+nature	O
+of	O
+the	O
+host	B-COMP
+country	O
+culture	O
+,	O
+health	O
+care	O
+system	O
+and	O
+assignment	O
+site	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+mechanical	O
+ventilation	O
+settings	O
+in	O
+adult	O
+patients	O
+treated	O
+for	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+assess	O
+the	O
+potential	O
+impact	O
+of	O
+mechanical	O
+ventilation	O
+settings	O
+on	O
+ICU	O
+mortality	O
+.	O
+
+Lower	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+levels	O
+(	O
+until	O
+day	O
+7	O
+)	O
+and	O
+lower	O
+delivered	O
+tidal	O
+volume	O
+after	O
+3	O
+days	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+were	O
+associated	O
+with	O
+significantly	O
+higher	O
+mortality	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+In	O
+multivariate	O
+analysis	O
+,	O
+higher	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+levels	O
+during	O
+the	O
+first	O
+3	O
+days	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+were	O
+associated	O
+with	O
+lower	O
+mortality	O
+(	O
+odds	O
+ratio	O
+,	O
+0	O
+.	O
+75	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+64	O
+-	O
+0	O
+.	O
+88	O
+;	O
+p	O
+=	O
+0	O
+.	O
+0006	O
+).	O
+
+This	O
+has	O
+been	O
+because	O
+the	O
+concept	O
+of	O
+lung	B-ANAT
+protective	O
+ventilation	O
+strategy	O
+had	O
+not	O
+yet	O
+known	O
+.	O
+
+With	O
+the	O
+accumulating	O
+evidences	O
+of	O
+survival	O
+benefit	O
+,	O
+the	O
+long	O
+-	O
+term	O
+outcome	O
+such	O
+as	O
+pulmonary	B-PROC
+function	I-PROC
+and	O
+quality	O
+of	O
+life	O
+are	O
+in	O
+concern	O
+.	O
+
+This	O
+suggests	O
+that	O
+such	O
+strategies	O
+are	O
+still	O
+sub	O
+-	O
+optimal	O
+for	O
+some	O
+ARDS	B-DISO
+patients	O
+.	O
+
+These	O
+compounds	O
+were	O
+evaluated	O
+for	O
+their	O
+antiviral	B-CHED
+activity	O
+against	O
+PEDV	B-SPEC
+replication	O
+,	O
+and	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+were	O
+discussed	O
+.	O
+
+Women	O
+with	O
+HELLP	B-DISO
+syndrome	I-DISO
+without	O
+clear	O
+Plt	B-PRGE
+and	O
+AST	B-PRGE
+improvement	O
+in	O
+the	O
+first	O
+48	O
+hours	O
+and	O
+with	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+neurological	O
+impairment	B-DISO
+,	O
+or	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+are	O
+at	O
+risk	O
+of	O
+progressing	O
+to	O
+PTMS	O
+.	O
+
+Survival	O
+of	O
+MHV	O
+-	O
+infected	O
+animals	B-SPEC
+treated	O
+with	O
+MT	O
+was	O
+severely	O
+reduced	O
+compared	O
+with	O
+that	O
+of	O
+MHV	B-SPEC
+-	O
+infected	O
+mice	B-SPEC
+or	O
+controls	O
+only	O
+treated	O
+with	O
+MT	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+sociability	O
+offers	O
+many	O
+advantages	O
+,	O
+a	O
+major	O
+drawback	O
+is	O
+the	O
+increased	O
+risk	O
+of	O
+exposure	O
+to	O
+contagious	O
+pathogens	O
+,	O
+like	O
+parasites	O
+,	O
+viruses	O
+,	O
+or	O
+bacteria	B-SPEC
+.	O
+
+In	O
+rodents	B-SPEC
+,	O
+sick	O
+conspecific	O
+avoidance	O
+can	O
+be	O
+induced	O
+by	O
+olfactory	B-PROC
+cues	O
+emitted	O
+by	O
+parasitized	O
+or	O
+infected	O
+conspecifics	O
+.	O
+
+We	O
+found	O
+that	O
+these	O
+chemical	O
+signals	O
+trigger	O
+neural	O
+activity	O
+in	O
+the	O
+vomeronasal	B-ANAT
+system	I-ANAT
+,	O
+an	O
+olfactory	B-PROC
+subsystem	O
+controlling	O
+various	O
+innate	O
+behaviors	B-PROC
+.	O
+
+There	O
+was	O
+no	O
+difference	O
+in	O
+prevalence	O
+of	O
+or	O
+incidence	O
+risk	O
+for	O
+BRSV	B-SPEC
+or	O
+BoCV	O
+between	O
+Swedish	O
+OM	O
+and	O
+CM	O
+herds	O
+.	O
+
+ABSTRACT	O
+:	O
+Newcastle	B-DISO
+disease	I-DISO
+(	O
+ND	O
+)	O
+and	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+(	O
+IB	O
+)	O
+are	O
+contagious	B-DISO
+diseases	I-DISO
+of	O
+chickens	B-SPEC
+.	O
+
+This	O
+determined	O
+six	O
+single	O
+-	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+(	O
+SNPs	O
+)	O
+that	O
+were	O
+associated	O
+with	O
+antibody	B-COMP
+levels	O
+against	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+):	O
+rsZ2494661	O
+,	O
+rsZ2494710	O
+,	O
+rs1211307701	O
+,	O
+rs1211307711	O
+,	O
+rs1218289310	O
+and	O
+rs420701988	O
+.	O
+
+IB	O
+had	O
+two	O
+SNPs	O
+associated	O
+with	O
+antibody	O
+levels	O
+:	O
+rs149988433	O
+and	O
+rs16170823	O
+;	O
+both	O
+reached	O
+chromosome	B-COMP
+-	O
+wide	O
+significance	O
+levels	O
+and	O
+they	O
+were	O
+near	O
+the	O
+USP7	B-PRGE
+and	O
+TRIM27	B-PRGE
+genes	I-PRGE
+,	O
+respectively	O
+.	O
+
+This	O
+study	O
+provides	O
+a	O
+promising	O
+new	O
+template	O
+with	O
+potential	O
+antiviral	B-CHED
+activity	O
+.	O
+
+Consistent	O
+with	O
+the	O
+reported	O
+genetic	O
+differences	O
+,	O
+the	O
+results	O
+of	O
+CCIF	O
+and	O
+VN	O
+assays	O
+also	O
+revealed	O
+higher	O
+antigenic	B-PROC
+variation	I-PROC
+between	O
+PEDV	B-SPEC
+CV777	O
+and	O
+U	O
+.	O
+S	O
+.	O
+strains	O
+.	O
+
+The	O
+K194R	O
+polymorphism	B-PROC
+has	O
+no	O
+effect	O
+on	O
+in	O
+vitro	O
+replication	O
+but	O
+influences	O
+hepatotropism	O
+,	O
+and	O
+introduction	O
+of	O
+R194K	O
+into	O
+JHM	O
+.	O
+SD	O
+promotes	O
+replication	O
+in	O
+the	O
+liver	B-ANAT
+.	O
+
+This	O
+new	O
+and	O
+unique	O
+transgenic	O
+mouse	B-SPEC
+model	O
+will	O
+be	O
+useful	O
+for	O
+furthering	O
+MERS	O
+research	O
+.	O
+
+TITLE	O
+:	O
+The	O
+seasonality	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+patients	O
+with	O
+chronic	B-DISO
+rhinosinusitis	I-DISO
+.	O
+
+The	O
+pattern	O
+of	O
+respiratory	O
+virus	B-SPEC
+seasonality	O
+found	O
+in	O
+nasal	B-ANAT
+mucosa	I-ANAT
+,	O
+polyps	B-DISO
+,	O
+and	O
+paranasal	B-ANAT
+sinus	I-ANAT
+samples	O
+in	O
+patients	O
+with	O
+CRS	B-DISO
+reinforces	O
+the	O
+possibility	O
+of	O
+asymptomatic	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+clinical	O
+and	O
+epidemiological	O
+features	O
+of	O
+sarcoidosis	B-DISO
+patients	O
+in	O
+a	O
+referral	O
+clinic	O
+of	O
+pulmonary	B-DISO
+disease	I-DISO
+in	O
+city	O
+of	O
+Rasht	O
+(	O
+Guilan	O
+-	O
+Iran	O
+).	O
+
+The	O
+most	O
+common	O
+abnormal	O
+finding	O
+in	O
+spirometry	O
+was	O
+small	B-DISO
+airway	I-DISO
+disease	I-DISO
+(	O
+20	O
+.	O
+3	O
+%).	O
+The	O
+follow	O
+-	O
+up	O
+data	O
+showed	O
+that	O
+178	O
+patients	O
+(	O
+45	O
+.	O
+2	O
+%)	O
+had	O
+significant	O
+improvement	O
+clinically	O
+,	O
+radiologically	O
+or	O
+both	O
+.	O
+
+AEP	B-PRGE
+also	O
+presents	O
+with	O
+severe	O
+hypoxia	B-DISO
+but	O
+rapidly	O
+improves	O
+on	O
+treatment	O
+with	O
+corticosteroids	B-CHED
+alone	O
+,	O
+without	O
+subsequent	O
+fibrosis	B-DISO
+.	O
+
+Here	O
+we	O
+investigated	O
+the	O
+histopathology	O
+of	O
+AEP	O
+in	O
+2	O
+surgical	O
+lung	B-ANAT
+biopsy	O
+and	O
+14	O
+transbronchial	O
+lung	B-ANAT
+biopsy	O
+cases	O
+.	O
+
+Here	O
+,	O
+we	O
+develop	O
+a	O
+model	O
+that	O
+explains	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+epidemic	O
+that	O
+occurred	O
+in	O
+Hong	O
+Kong	O
+in	O
+2003	O
+.	O
+
+The	O
+frequency	O
+of	O
+CD8	B-PRGE
+(+)	O
+and	O
+TCRγδ	O
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+expression	B-PROC
+was	O
+examined	O
+by	O
+immunohistochemistry	O
+,	O
+followed	O
+by	O
+image	O
+analysis	O
+.	O
+
+This	O
+article	O
+describes	O
+the	O
+study	O
+design	O
+and	O
+challenges	O
+encountered	O
+during	O
+the	O
+implementation	O
+and	O
+phase	O
+1	O
+component	O
+of	O
+the	O
+START	O
+(	O
+STem	B-ANAT
+cells	I-ANAT
+for	O
+ARDS	B-DISO
+Treatment	O
+)	O
+trial	O
+,	O
+a	O
+phase	O
+1	O
+/	O
+2	O
+trial	O
+of	O
+bone	B-ANAT
+marrow	I-ANAT
+-	O
+derived	O
+human	B-SPEC
+MSCs	B-FUNC
+for	O
+moderate	O
+-	O
+severe	O
+ARDS	B-DISO
+.	O
+
+This	O
+report	O
+describes	O
+study	O
+design	O
+features	O
+that	O
+are	O
+unique	O
+to	O
+a	O
+phase	O
+1	O
+trial	O
+in	O
+critically	O
+ill	O
+subjects	O
+and	O
+the	O
+specific	O
+challenges	O
+of	O
+implementation	O
+of	O
+a	O
+cell	B-COMP
+-	O
+based	O
+therapy	O
+trial	O
+in	O
+the	O
+ICU	O
+.	O
+
+TITLE	O
+:	O
+Combination	O
+siRNA	O
+therapy	O
+against	O
+feline	B-SPEC
+coronavirus	B-SPEC
+can	O
+delay	O
+the	O
+emergence	O
+of	O
+antiviral	B-CHED
+resistance	B-PROC
+in	O
+vitro	O
+.	O
+
+Combined	O
+,	O
+these	O
+data	O
+inform	O
+the	O
+potential	O
+therapeutic	O
+application	O
+of	O
+antiviral	B-CHED
+RNAi	B-PROC
+against	O
+FIPV	O
+.	O
+
+Adverse	B-DISO
+effects	I-DISO
+associated	O
+with	O
+pronation	B-PROC
+were	O
+the	O
+development	B-PROC
+of	O
+pressure	B-DISO
+ulcers	I-DISO
+and	O
+endotracheal	O
+tube	O
+obstruction	B-DISO
+.	O
+
+It	O
+should	O
+be	O
+started	O
+early	O
+,	O
+for	O
+prolonged	O
+periods	B-PROC
+,	O
+and	O
+should	O
+be	O
+associated	O
+to	O
+a	O
+protective	O
+ventilation	O
+strategy	O
+.	O
+
+Data	O
+was	O
+retrospectively	O
+collected	O
+from	O
+three	O
+patients	O
+admitted	O
+with	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+to	O
+Intensive	O
+Care	O
+unit	O
+(	O
+ICU	O
+)	O
+at	O
+King	O
+Abdulaziz	O
+Medical	O
+City	O
+,	O
+Riyadh	O
+.	O
+
+The	O
+mast	B-ANAT
+cells	I-ANAT
+seem	O
+to	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+development	B-PROC
+of	O
+lung	B-ANAT
+injury	O
+and	O
+the	O
+increase	O
+of	O
+vascular	B-PROC
+permeability	I-PROC
+in	O
+mice	B-SPEC
+following	O
+the	O
+subcutaneous	O
+administration	O
+of	O
+Aah	O
+scorpion	B-SPEC
+venom	O
+through	O
+the	O
+NK1	B-PRGE
+receptor	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDv	B-SPEC
+)	O
+infected	O
+approximately	O
+50	O
+%	O
+of	O
+the	O
+US	O
+swine	B-SPEC
+breeding	B-PROC
+herds	O
+from	O
+July	O
+2013	O
+to	O
+July	O
+2014	O
+as	O
+estimated	O
+by	O
+the	O
+Swine	B-SPEC
+Health	O
+Monitoring	O
+Project	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+substrate	O
+specificities	O
+of	O
+IBV	B-SPEC
+PLpro	O
+are	O
+different	O
+from	O
+other	O
+PLpros	O
+and	O
+that	O
+IBV	B-SPEC
+PLpro	O
+might	O
+target	O
+different	O
+ubiquitinated	O
+host	B-COMP
+factors	O
+to	O
+aid	O
+the	O
+propagation	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+The	O
+high	O
+virulence	B-PROC
+and	O
+mortality	O
+rate	O
+prompted	O
+us	O
+to	O
+analyze	O
+aspects	O
+of	O
+MERS	O
+-	O
+CoV	O
+pathogenesis	B-DISO
+,	O
+especially	O
+its	O
+interaction	O
+with	O
+innate	O
+immune	O
+cells	B-COMP
+such	O
+as	O
+antigen	B-ANAT
+-	I-ANAT
+presenting	I-ANAT
+cells	B-COMP
+(	O
+APCs	B-DISO
+).	O
+
+In	O
+parallel	O
+,	O
+human	B-SPEC
+pDCs	O
+are	O
+potent	O
+IFN	O
+-	O
+producing	O
+cells	B-COMP
+upon	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+MERS	O
+-	O
+CoV	O
+causes	O
+a	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+high	O
+fatality	O
+rates	O
+in	O
+human	B-SPEC
+patients	O
+.	O
+
+Human	B-SPEC
+coronaviruses	O
+are	O
+important	O
+zoonotic	O
+pathogens	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+small	O
+deletions	O
+and	O
+modifications	O
+within	O
+the	O
+E	O
+protein	B-CHED
+led	O
+to	O
+virus	B-SPEC
+attenuation	O
+,	O
+manifested	O
+by	O
+minimal	O
+lung	B-ANAT
+injury	O
+,	O
+limited	O
+neutrophil	B-ANAT
+influx	O
+to	O
+the	O
+lungs	B-ANAT
+,	O
+reduced	O
+expression	B-PROC
+of	O
+proinflammatory	O
+cytokines	O
+,	O
+increased	O
+anti	O
+-	O
+inflammatory	O
+cytokine	O
+levels	O
+,	O
+and	O
+enhanced	O
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+counts	O
+in	O
+vivo	O
+,	O
+suggesting	O
+that	O
+these	O
+phenomena	O
+contribute	O
+to	O
+virus	B-SPEC
+attenuation	O
+.	O
+
+TITLE	O
+:	O
+Fused	O
+-	O
+ring	O
+structure	O
+of	O
+decahydroisoquinolin	O
+as	O
+a	O
+novel	O
+scaffold	O
+for	O
+SARS	B-PRGE
+3CL	I-PRGE
+protease	B-CHED
+inhibitors	I-CHED
+.	O
+
+Starting	O
+from	O
+a	O
+cyclohexene	B-CHED
+enantiomer	O
+obtained	O
+by	O
+salt	B-CHED
+resolution	O
+,	O
+trans	O
+-	O
+decahydroisoquinolin	O
+derivatives	O
+were	O
+synthesized	O
+.	O
+
+Patients	O
+were	O
+assigned	O
+to	O
+group	O
+1	O
+if	O
+they	O
+died	B-PROC
+(	O
+n	O
+=	O
+9	O
+)	O
+and	O
+to	O
+group	O
+2	O
+if	O
+they	O
+made	O
+a	O
+full	O
+recovery	O
+(	O
+n	O
+=	O
+6	O
+).	O
+
+All	O
+nine	O
+group	O
+1	O
+patients	O
+and	O
+three	O
+of	O
+six	O
+group	O
+2	O
+patients	O
+had	O
+pleural	B-DISO
+effusion	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+52	O
+).	O
+
+TITLE	O
+:	O
+Exchange	O
+transfusion	O
+in	O
+patients	O
+with	O
+Down	B-DISO
+syndrome	I-DISO
+and	O
+severe	O
+transient	O
+leukemia	B-DISO
+.	O
+
+An	O
+observational	O
+retrospective	O
+study	O
+was	O
+carried	O
+out	O
+at	O
+a	O
+single	O
+center	O
+of	O
+all	O
+five	O
+DS	O
+neonates	O
+with	O
+TL	O
+,	O
+GATA1	B-PRGE
+mutations	O
+,	O
+and	O
+hyperleukocytosis	O
+,	O
+born	O
+at	O
+a	O
+median	O
+gestational	O
+age	O
+of	O
+34	O
+weeks	O
+(	O
+range	O
+,	O
+30	O
+-	O
+38	O
+weeks	O
+)	O
+with	O
+birthweight	O
+2556	O
+g	O
+(	O
+range	O
+,	O
+1756	O
+-	O
+3268	O
+g	O
+)	O
+during	O
+a	O
+24	O
+month	O
+study	O
+period	O
+between	O
+September	O
+2011	O
+and	O
+August	O
+2013	O
+.	O
+
+Two	O
+of	O
+the	O
+three	O
+surviving	O
+neonates	O
+developed	O
+acute	B-DISO
+megakaryocytic	I-DISO
+leukemia	I-DISO
+at	O
+age	O
+90	O
+days	O
+and	O
+222	O
+days	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+patients	O
+required	O
+respiratory	O
+support	O
+before	O
+ExT	B-DISO
+.	O
+After	O
+ExT	B-DISO
+,	O
+respiration	B-PROC
+status	O
+improved	O
+in	O
+all	O
+five	O
+patients	O
+:	O
+WBC	B-ANAT
+count	O
+(	O
+mean	O
+)	O
+decreased	O
+by	O
+85	O
+%	O
+from	O
+143	O
+×	O
+10	O
+(	O
+9	O
+)	O
+/	O
+L	O
+to	O
+21	O
+×	O
+10	O
+(	O
+9	O
+)	O
+/	O
+L	O
+.	O
+
+CONCLUSIONS	O
+:	O
+ExT	B-DISO
+was	O
+very	O
+effective	O
+in	O
+improving	O
+hyperleukocytosis	O
+and	O
+may	O
+have	O
+had	O
+favorable	O
+effects	O
+on	O
+respiration	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+of	O
+the	O
+viral	O
+pathogens	O
+that	O
+cause	O
+infectious	O
+diseases	O
+in	O
+humans	B-SPEC
+have	O
+a	O
+highly	O
+restricted	O
+species	B-SPEC
+tropism	B-PROC
+,	O
+making	O
+the	O
+study	O
+of	O
+their	O
+pathogenesis	B-DISO
+and	O
+the	O
+development	B-PROC
+of	O
+clinical	O
+therapies	O
+difficult	O
+.	O
+
+The	O
+improvement	O
+of	O
+humanized	O
+mouse	B-SPEC
+models	O
+over	O
+the	O
+past	O
+30	O
+years	O
+has	O
+greatly	O
+facilitated	O
+researchers	O
+'	O
+abilities	O
+to	O
+study	O
+host	B-COMP
+responses	O
+to	O
+viral	B-DISO
+infections	I-DISO
+in	O
+a	O
+cost	O
+effective	O
+and	O
+ethical	O
+manner	O
+.	O
+
+To	O
+identify	O
+the	O
+main	O
+respiratory	O
+pathogens	O
+isolated	O
+from	O
+calves	O
+in	O
+Québec	O
+dairy	O
+herds	O
+with	O
+a	O
+high	O
+incidence	O
+of	O
+BRD	O
+,	O
+and	O
+to	O
+determine	O
+if	O
+there	O
+is	O
+an	O
+association	O
+between	O
+the	O
+presence	O
+of	O
+these	O
+pathogens	O
+and	O
+clinical	O
+signs	O
+of	O
+pneumonia	B-DISO
+,	O
+lung	B-DISO
+consolidation	I-DISO
+,	O
+or	O
+average	O
+daily	O
+gain	O
+.	O
+
+TITLE	O
+:	O
+Application	O
+of	O
+""""	O
+hydrogen	B-CHED
+bonding	O
+interaction	O
+""""	O
+in	O
+new	O
+drug	O
+development	B-PROC
+:	O
+design	O
+,	O
+synthesis	B-PROC
+,	O
+antiviral	B-CHED
+activity	O
+,	O
+and	O
+SARs	B-DISO
+of	O
+thiourea	B-CHED
+derivatives	O
+.	O
+
+Most	O
+of	O
+them	O
+exhibited	O
+significantly	O
+higher	O
+anti	O
+-	O
+TMV	B-SPEC
+activity	O
+than	O
+commercial	O
+plant	B-SPEC
+virucides	O
+ribavirin	B-CHED
+,	O
+harmine	B-CHED
+,	O
+and	O
+lead	O
+compound	O
+.	O
+
+The	O
+hydrogen	B-CHED
+bond	O
+was	O
+found	O
+to	O
+be	O
+important	O
+but	O
+not	O
+the	O
+more	O
+the	O
+better	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+here	O
+a	O
+rapid	O
+immunochromatographic	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+antigen	B-CHED
+in	O
+the	O
+nasal	B-ANAT
+swabs	O
+of	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+embolism	I-DISO
+after	O
+arterial	B-ANAT
+chemoembolization	O
+for	O
+hepatocellular	B-DISO
+carcinoma	I-DISO
+:	O
+an	O
+autopsy	O
+case	O
+report	O
+.	O
+
+A	O
+subsequent	O
+autopsy	O
+revealed	O
+that	O
+the	O
+cause	O
+of	O
+death	B-PROC
+was	O
+ARDS	B-DISO
+due	O
+to	O
+pulmonary	B-ANAT
+lipiodol	O
+embolism	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Prone	O
+position	O
+mechanical	O
+ventilation	O
+in	O
+the	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+syndrome	I-DISO
+:	O
+theoretical	O
+and	O
+practical	O
+considerations	O
+].	O
+
+ABSTRACT	O
+:	O
+Currently	O
+the	O
+only	O
+captive	O
+population	O
+of	O
+beira	O
+antelope	B-SPEC
+(	O
+Dorcatragus	B-SPEC
+megalotis	O
+)	O
+is	O
+held	O
+at	O
+the	O
+Al	O
+Wabra	O
+Wildlife	O
+Preservation	O
+,	O
+Qatar	O
+.	O
+
+Reactive	O
+systemic	O
+inflammatory	O
+(	O
+AA	O
+)	O
+amyloidosis	B-DISO
+was	O
+noted	O
+as	O
+a	O
+chronic	O
+manifestation	O
+of	O
+the	O
+disease	O
+.	O
+
+CAdV	O
+-	O
+1	O
+was	O
+confirmed	O
+by	O
+virus	B-SPEC
+isolation	O
+and	O
+nucleotide	B-CHED
+sequencing	O
+.	O
+
+User	O
+-	O
+friendly	O
+,	O
+sensitive	O
+,	O
+rapid	O
+diagnostic	O
+tests	O
+that	O
+utilize	O
+low	O
+-	O
+cost	O
+field	O
+-	O
+deployable	O
+instruments	O
+for	O
+CSF	B-ANAT
+diagnosis	O
+can	O
+be	O
+useful	O
+for	O
+disease	O
+surveillance	O
+and	O
+outbreak	O
+monitoring	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+describe	O
+validation	O
+of	O
+a	O
+new	O
+probe	O
+-	O
+based	O
+insulated	O
+isothermal	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+PCR	O
+(	O
+iiRT	O
+-	O
+PCR	O
+)	O
+assay	O
+for	O
+rapid	O
+detection	O
+of	O
+classical	B-SPEC
+swine	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+(	O
+CSFV	O
+)	O
+on	O
+a	O
+compact	O
+,	O
+user	O
+-	O
+friendly	O
+device	O
+(	O
+POCKIT	O
+(™)	O
+Nucleic	B-CHED
+Acid	I-CHED
+Analyzer	O
+)	O
+that	O
+does	O
+not	O
+need	O
+data	O
+interpretation	O
+by	O
+the	O
+user	O
+.	O
+
+The	O
+assay	O
+has	O
+a	O
+sample	O
+to	O
+answer	O
+turnaround	O
+time	O
+of	O
+less	O
+than	O
+an	O
+hour	O
+using	O
+extracted	O
+RNA	O
+or	O
+diluted	O
+or	O
+low	O
+volume	O
+of	O
+neat	O
+serum	B-COMP
+.	O
+
+To	O
+determine	O
+the	O
+effectiveness	O
+and	O
+safety	O
+of	O
+transfusing	O
+patients	O
+with	O
+severe	O
+trauma	O
+and	O
+major	O
+bleeding	B-DISO
+using	O
+plasma	B-ANAT
+,	O
+platelets	B-ANAT
+,	O
+and	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+in	O
+a	O
+1	O
+:	O
+1	O
+:	O
+1	O
+ratio	O
+compared	O
+with	O
+a	O
+1	O
+:	O
+1	O
+:	O
+2	O
+ratio	O
+.	O
+
+Even	O
+though	O
+there	O
+was	O
+an	O
+increased	O
+use	O
+of	O
+plasma	B-ANAT
+and	O
+platelets	B-ANAT
+transfused	O
+in	O
+the	O
+1	O
+:	O
+1	O
+:	O
+1	O
+group	O
+,	O
+no	O
+other	O
+safety	O
+differences	O
+were	O
+identified	O
+between	O
+the	O
+2	O
+groups	O
+.	O
+
+The	O
+other	O
+horse	B-SPEC
+(	O
+case	O
+No	O
+.	O
+2	O
+)	O
+had	O
+hyperammonemic	O
+encephalopathy	B-DISO
+with	O
+Alzheimer	O
+type	O
+II	O
+astrocytosis	B-DISO
+throughout	O
+the	O
+cerebral	B-ANAT
+cortex	I-ANAT
+.	O
+
+ECoV	O
+was	O
+detected	O
+by	O
+quantitative	O
+polymerase	O
+chain	O
+reaction	O
+in	O
+small	O
+intestinal	O
+tissue	B-ANAT
+,	O
+contents	O
+,	O
+and	O
+/	O
+or	O
+feces	B-ANAT
+,	O
+and	O
+coronavirus	B-SPEC
+antigen	B-CHED
+was	O
+detected	O
+by	O
+immunohistochemistry	O
+in	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+in	O
+all	O
+cases	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+partial	O
+sequences	O
+obtained	O
+from	O
+UAE	O
+camels	B-SPEC
+were	O
+clustering	O
+with	O
+human	B-SPEC
+-	O
+and	O
+camel	B-SPEC
+-	O
+derived	O
+MERS	O
+-	O
+CoV	O
+sequences	O
+in	O
+the	O
+same	O
+geographic	O
+area	O
+.	O
+
+Calf	B-ANAT
+-	O
+and	O
+farm	O
+-	O
+level	O
+data	O
+were	O
+collected	O
+by	O
+means	O
+of	O
+a	O
+questionnaire	O
+and	O
+the	O
+odds	O
+of	O
+liquid	O
+faeces	B-ANAT
+calculated	O
+using	O
+mixed	O
+effects	O
+logistic	O
+regression	O
+models	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+addition	O
+to	O
+transporting	O
+ions	O
+,	O
+the	O
+multisubunit	O
+Na	O
+(+),	O
+K	O
+(+)-	O
+ATPase	B-PRGE
+also	O
+functions	O
+by	O
+relaying	O
+cardiotonic	O
+steroid	B-CHED
+(	O
+CTS	B-DISO
+)-	O
+binding	B-FUNC
+-	O
+induced	O
+signals	O
+into	O
+cells	B-COMP
+.	O
+
+In	O
+agreement	O
+with	O
+an	O
+early	O
+block	O
+in	O
+infection	B-DISO
+,	O
+the	O
+inhibition	B-PROC
+of	O
+VSV	O
+by	O
+CTSs	O
+could	O
+be	O
+bypassed	O
+by	O
+low	O
+-	O
+pH	O
+shock	O
+.	O
+
+TITLE	O
+:	O
+Qualitative	O
+and	O
+quantitative	O
+analysis	O
+of	O
+the	O
+major	O
+constituents	O
+in	O
+Chinese	O
+medical	O
+preparation	O
+Lianhua	O
+-	O
+Qingwen	O
+capsule	B-COMP
+by	O
+UPLC	O
+-	O
+DAD	O
+-	O
+QTOF	O
+-	O
+MS	O
+.	O
+
+Most	O
+strikingly	O
+,	O
+the	O
+high	O
+U	O
+and	O
+low	O
+C	O
+proportions	O
+are	O
+quite	O
+variable	O
+and	O
+act	O
+like	O
+communicating	O
+vessels	B-ANAT
+,	O
+C	O
+goes	B-SPEC
+down	O
+when	O
+U	O
+goes	B-SPEC
+up	O
+and	O
+vice	O
+versa	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+an	O
+antigen	B-CHED
+capture	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+for	O
+virus	B-SPEC
+detection	O
+based	O
+on	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+monoclonal	O
+antibodies	B-COMP
+.	O
+
+In	O
+addition	O
+,	O
+ventilator	O
+parameters	O
+(	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+(	O
+PaO2	O
+):	O
+inspiratory	B-PROC
+oxygen	B-CHED
+fraction	O
+(	O
+FiO2	O
+)	O
+ratio	O
+,	O
+arterial	B-ANAT
+carbon	B-PROC
+dioxide	I-PROC
+tension	B-DISO
+(	O
+PaCO2	O
+),	O
+tidal	O
+volume	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+))	O
+of	O
+ARDS	B-DISO
+patients	O
+and	O
+ventilated	O
+controls	O
+were	O
+also	O
+recorded	O
+.	O
+
+Possible	O
+correlation	O
+between	O
+plasma	B-ANAT
+sRAGE	O
+levels	O
+and	O
+clinical	O
+parameters	O
+were	O
+explored	O
+using	O
+a	O
+simple	O
+linear	O
+model	O
+.	O
+
+TITLE	O
+:	O
+Phylodynamic	O
+analysis	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+South	O
+America	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+report	O
+the	O
+complete	O
+coding	O
+genome	O
+sequences	O
+of	O
+six	O
+FCoVs	O
+:	O
+three	O
+from	O
+faecal	B-ANAT
+samples	O
+from	O
+healthy	O
+cats	B-SPEC
+and	O
+three	O
+from	O
+tissue	B-ANAT
+lesion	O
+samples	O
+from	O
+cats	B-SPEC
+with	O
+confirmed	O
+FIP	B-DISO
+.	O
+
+To	O
+delineate	O
+the	O
+roles	O
+of	O
+Trp	B-ENZY
+residues	O
+of	O
+MPER	O
+in	O
+forming	O
+these	O
+quaternary	O
+structures	O
+and	O
+interacting	O
+with	O
+membranes	B-ANAT
+,	O
+we	O
+employed	O
+a	O
+panel	O
+of	O
+synthetic	O
+peptides	O
+:	O
+MPER	O
+peptide	B-CHED
+(	O
+M	O
+-	O
+wt	O
+)	O
+and	O
+its	O
+alanine	B-CHED
+(	O
+Ala	B-CHED
+)	O
+and	O
+phenylalanine	B-CHED
+(	O
+Phe	B-CHED
+)	O
+analogues	O
+.	O
+
+Ala	B-CHED
+substitutions	O
+of	O
+Trp	B-ENZY
+inhibited	O
+its	O
+association	O
+with	O
+cellular	B-COMP
+membranes	B-ANAT
+.	O
+
+Triple	O
+-	O
+Ala	B-CHED
+substitutions	O
+of	O
+Trp	B-ENZY
+in	O
+M	O
+-	O
+wt	O
+,	O
+but	O
+not	O
+the	O
+corresponding	O
+triple	O
+-	O
+Phe	B-CHED
+analogue	O
+,	O
+disrupted	O
+oligomerization	O
+of	O
+M	O
+-	O
+wt	O
+and	O
+hetero	O
+-	O
+oligomerization	O
+of	O
+M	O
+-	O
+wt	O
+with	O
+IFP23	O
+.	O
+
+We	O
+developed	O
+ALI	O
+/	O
+ARDS	B-DISO
+models	O
+in	O
+piglets	O
+by	O
+intraperitoneal	O
+injection	O
+of	O
+paraquat	B-CHED
+(	O
+PQ	O
+).	O
+
+The	O
+piglets	O
+were	O
+randomly	O
+divided	O
+into	O
+three	O
+groups	O
+:	O
+small	O
+VT	O
+group	O
+(	O
+VT	O
+=	O
+6	O
+ml	O
+/	O
+kg	O
+,	O
+n	O
+=	O
+6	O
+),	O
+middle	O
+VT	O
+group	O
+(	O
+VT	O
+=	O
+10	O
+ml	O
+/	O
+kg	O
+,	O
+n	O
+=	O
+6	O
+),	O
+and	O
+large	O
+VT	O
+group	O
+(	O
+VT	O
+=	O
+15	O
+ml	O
+/	O
+kg	O
+,	O
+n	O
+=	O
+6	O
+),	O
+with	O
+the	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+set	O
+as	O
+10	O
+cmH2O	O
+.	O
+
+The	O
+hemodynamics	B-PROC
+were	O
+monitored	O
+by	O
+pulse	B-PROC
+-	O
+indicated	O
+continuous	O
+cardiac	B-ANAT
+output	O
+(	O
+PiCCO	O
+)	O
+and	O
+the	O
+airway	B-ANAT
+pressure	O
+changes	O
+and	O
+blood	B-PROC
+gas	B-ENZY
+analysis	O
+indexes	O
+were	O
+recorded	O
+at	O
+different	O
+time	O
+points	O
+.	O
+
+PH	O
+,	O
+PaO2	O
+and	O
+oxygenation	B-PROC
+indexes	O
+in	O
+the	O
+three	O
+groups	O
+all	O
+decreased	O
+after	O
+modeling	O
+success	O
+compared	O
+with	O
+baseline	O
+,	O
+and	O
+PaCO2	O
+increased	O
+significantly	O
+.	O
+
+Small	O
+tidal	O
+volume	O
+ventilation	O
+combined	O
+with	O
+PEEP	B-CHED
+could	O
+alleviate	O
+the	O
+acute	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+paraquat	B-CHED
+and	O
+improve	O
+oxygenation	B-PROC
+.	O
+
+RESULTS	O
+:	O
+In	O
+this	O
+intention	O
+-	O
+to	O
+-	O
+treat	O
+population	O
+,	O
+no	O
+significant	O
+differences	O
+between	O
+the	O
+control	O
+and	O
+study	O
+groups	O
+were	O
+found	O
+for	O
+the	O
+PF	O
+ratio	O
+at	O
+day	O
+4	O
+(	O
+213	O
+.	O
+7	O
+±	O
+85	O
+.	O
+6	O
+vs	O
+.	O
+227	O
+.	O
+2	O
+±	O
+67	O
+.	O
+7	O
+,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+24	O
+)	O
+and	O
+day	O
+8	O
+(	O
+187	O
+.	O
+8	O
+±	O
+65	O
+.	O
+2	O
+vs	O
+.	O
+188	O
+.	O
+9	O
+±	O
+56	O
+.	O
+0	O
+,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+82	O
+),	O
+the	O
+incidence	O
+of	O
+ARDS	B-DISO
+/	O
+ALI	O
+(	O
+24	O
+.	O
+1	O
+vs	O
+.	O
+29	O
+.	O
+0	O
+%,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+68	O
+),	O
+length	O
+of	O
+ventilation	O
+time	O
+(	O
+13	O
+.	O
+6	O
+±	O
+10	O
+.	O
+7	O
+vs	O
+.	O
+17	O
+.	O
+0	O
+±	O
+15	O
+.	O
+1	O
+days	O
+,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+15	O
+),	O
+duration	O
+of	O
+ICU	O
+stay	O
+(	O
+16	O
+.	O
+4	O
+±	O
+11	O
+.	O
+3	O
+vs	O
+.	O
+19	O
+.	O
+5	O
+±	O
+15	O
+.	O
+3	O
+days	O
+,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+21	O
+)	O
+and	O
+28	O
+-	O
+day	O
+mortality	O
+(	O
+8	O
+.	O
+6	O
+vs	O
+.	O
+12	O
+.	O
+9	O
+%,	O
+respectively	O
+P	O
+=	O
+0	O
+.	O
+56	O
+).	O
+
+New	O
+studies	O
+have	O
+suggested	O
+strategies	O
+to	O
+identify	O
+patients	O
+at	O
+risk	O
+for	O
+resistant	O
+pathogen	O
+infection	O
+and	O
+therapies	O
+that	O
+optimize	O
+efficacy	O
+,	O
+without	O
+the	O
+overuse	O
+of	O
+broad	O
+-	O
+spectrum	O
+therapy	O
+in	O
+patients	O
+with	O
+healthcare	O
+-	O
+associated	O
+pneumonia	B-DISO
+.	O
+
+Eleven	O
+of	O
+the	O
+15	O
+field	O
+isolates	O
+in	O
+this	O
+study	O
+belonged	O
+to	O
+genogroup	O
+3	O
+and	O
+were	O
+95	O
+.	O
+8	O
+%	O
+to	O
+100	O
+%	O
+identical	O
+in	O
+nucleotide	B-CHED
+sequence	O
+or	O
+95	O
+.	O
+6	O
+%	O
+to	O
+100	O
+%	O
+in	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+to	O
+each	O
+other	O
+.	O
+
+ABSTRACT	O
+:	O
+Gut	B-PRGE
+health	O
+is	O
+very	O
+important	O
+to	O
+get	O
+maximum	O
+returns	O
+in	O
+terms	O
+of	O
+weight	O
+gain	O
+and	O
+egg	O
+production	O
+.	O
+
+Previously	O
+,	O
+electron	O
+microscopy	O
+was	O
+used	O
+to	O
+detect	O
+the	O
+presence	O
+of	O
+enteric	O
+viruses	B-SPEC
+,	O
+which	O
+were	O
+identified	O
+solely	O
+on	O
+the	O
+basis	O
+of	O
+their	O
+morphology	O
+.	O
+
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	I-PRGE
+STAT	I-PRGE
+-	I-PRGE
+1	I-PRGE
+were	O
+both	O
+highly	O
+expressed	B-PROC
+in	O
+bat	B-ENZY
+spleen	B-ANAT
+.	O
+
+ECoV	O
+was	O
+detected	O
+in	O
+59	O
+samples	O
+using	O
+the	O
+RT	B-PRGE
+-	I-PRGE
+LAMP	I-PRGE
+assay	O
+,	O
+and	O
+in	O
+30	O
+and	O
+65	O
+samples	O
+using	O
+RT	O
+-	O
+PCR	O
+or	O
+qRT	O
+-	O
+PCR	O
+assays	O
+,	O
+respectively	O
+.	O
+
+52	O
+%	O
+of	O
+cases	O
+were	O
+identified	O
+as	O
+primary	O
+,	O
+with	O
+the	O
+rest	B-FUNC
+being	O
+secondary	O
+.	O
+
+Overall	O
+case	O
+-	O
+fatality	O
+was	O
+40	O
+%;	O
+depending	O
+on	O
+the	O
+timing	O
+of	O
+171	O
+deaths	B-PROC
+unlinked	O
+to	O
+case	O
+data	O
+,	O
+outbreak	O
+CFR	O
+could	O
+be	O
+higher	O
+,	O
+lower	O
+,	O
+or	O
+equivalent	O
+to	O
+pre	O
+-	O
+outbreak	O
+CFR	O
+.	O
+
+The	O
+results	O
+indicate	O
+the	O
+division	O
+of	O
+isolates	O
+into	O
+two	O
+different	O
+genotypes	O
+of	O
+IBV	B-SPEC
+within	O
+the	O
+province	O
+,	O
+Massachusetts	O
+(	O
+Mass	O
+)-	O
+like	O
+and	O
+QX	O
+-	O
+like	O
+.	O
+
+Zoonotic	O
+infections	B-DISO
+,	O
+such	O
+as	O
+influenza	B-PATH
+A	I-PATH
+,	O
+and	O
+novel	B-SPEC
+coronavirus	I-SPEC
+infections	O
+also	O
+are	O
+of	O
+increasing	O
+concern	O
+because	O
+of	O
+population	O
+mobility	O
+.	O
+
+Administration	O
+of	O
+methylene	B-CHED
+blue	I-CHED
+allowed	O
+for	O
+cessation	O
+of	O
+epinephrine	B-CHED
+infusion	O
+within	O
+2	O
+hours	O
+of	O
+administration	O
+,	O
+and	O
+reduction	O
+in	O
+excessive	O
+fluid	O
+resuscitation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+presence	O
+of	O
+antibodies	B-COMP
+to	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+and	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+),	O
+together	O
+with	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+(	O
+FeLV	O
+)	O
+antigen	B-CHED
+was	O
+investigated	O
+in	O
+169	O
+ill	B-DISO
+household	O
+and	O
+stray	O
+cats	B-SPEC
+attending	O
+a	O
+veterinary	O
+surgery	O
+in	O
+Istanbul	O
+in	O
+2009	O
+-	O
+14	O
+.	O
+
+TITLE	O
+:	O
+High	O
+prevalence	O
+of	O
+common	O
+respiratory	O
+viruses	B-SPEC
+and	O
+no	O
+evidence	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+Hajj	O
+pilgrims	O
+returning	O
+to	O
+Ghana	O
+,	O
+2013	O
+.	O
+
+The	O
+prevalence	O
+of	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+among	O
+Hajj	O
+pilgrims	O
+in	O
+both	O
+symptomatic	O
+and	O
+asymptomatic	O
+subjects	O
+was	O
+high	O
+.	O
+
+,	O
+it	O
+should	O
+be	O
+that	O
+the	O
+2005	O
+International	O
+Health	O
+Regulations	O
+(	O
+IHR	O
+)	O
+Treaty	O
+,	O
+which	O
+gave	O
+unprecedented	O
+authority	O
+to	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+to	O
+provide	O
+global	O
+public	O
+health	O
+security	O
+during	O
+public	O
+health	O
+emergencies	B-DISO
+of	O
+international	O
+concern	O
+,	O
+has	O
+fallen	O
+severely	O
+short	O
+of	O
+its	O
+original	O
+goal	O
+.	O
+
+They	O
+have	O
+been	O
+conducted	O
+through	O
+the	O
+process	O
+known	O
+as	O
+SELEX	O
+(	O
+Systematic	O
+Evolution	B-PROC
+of	O
+Ligands	O
+by	O
+Exponential	O
+Enrichment	O
+).	O
+
+This	O
+review	O
+presents	O
+current	O
+developments	O
+of	O
+using	O
+aptamers	O
+in	O
+the	O
+diagnostics	O
+and	O
+treatment	O
+of	O
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+and	O
+epidemiological	O
+characteristics	O
+provide	O
+new	O
+insights	O
+into	O
+the	O
+phylogeographical	O
+and	O
+spatiotemporal	O
+spread	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+Asia	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+11	O
+complete	O
+genomes	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+field	O
+isolates	O
+from	O
+China	O
+were	O
+determined	O
+and	O
+analyzed	O
+.	O
+
+Many	O
+subgroups	O
+have	O
+formed	O
+,	O
+with	O
+a	O
+wide	O
+array	O
+of	O
+mutations	O
+in	O
+different	O
+countries	O
+,	O
+leading	O
+to	O
+the	O
+outbreak	O
+of	O
+PEDV	B-SPEC
+in	O
+Asia	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+and	O
+virulent	O
+,	O
+systemic	O
+calicivirus	B-DISO
+infection	I-DISO
+are	O
+caused	O
+by	O
+certain	O
+types	O
+of	O
+feline	B-SPEC
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+and	O
+feline	B-SPEC
+caliciviruses	O
+(	O
+FCVs	O
+),	O
+respectively	O
+,	O
+and	O
+are	O
+important	O
+infectious	B-DISO
+diseases	I-DISO
+with	O
+high	O
+fatality	O
+rates	O
+in	O
+members	O
+of	O
+the	O
+Felidae	B-SPEC
+family	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+derivatives	O
+of	O
+peptidyl	O
+compounds	O
+targeting	O
+3CLpro	O
+were	O
+synthesized	O
+and	O
+evaluated	O
+for	O
+their	O
+activities	O
+against	O
+FCoV	O
+and	O
+FCV	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+explored	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+of	O
+the	O
+derivatives	O
+of	O
+3CLpro	O
+inhibitors	B-CHED
+and	O
+identified	O
+inhibitors	B-CHED
+with	O
+potent	O
+dual	O
+activities	O
+against	O
+these	O
+viruses	B-SPEC
+.	O
+
+Overall	O
+,	O
+our	O
+study	O
+provides	O
+the	O
+first	O
+insight	O
+into	O
+a	O
+structural	O
+platform	O
+for	O
+anti	O
+-	O
+FIPV	O
+and	O
+anti	O
+-	O
+FCV	B-CHED
+drug	O
+development	B-PROC
+.	O
+
+We	O
+asked	O
+if	O
+changes	O
+in	O
+the	O
+Ubl	B-PRGE
+domain	I-PRGE
+,	O
+a	O
+conserved	O
+domain	O
+adjacent	O
+to	O
+the	O
+coronavirus	B-SPEC
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+,	O
+altered	O
+the	O
+viral	B-PRGE
+protease	I-PRGE
+activity	O
+or	O
+affected	O
+viral	B-PROC
+replication	I-PROC
+or	O
+pathogenesis	B-DISO
+.	O
+
+Six	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+hypercapnia	B-DISO
+were	O
+studied	O
+.	O
+
+One	O
+hour	O
+after	O
+adjustment	O
+of	O
+PEEP	B-CHED
+and	O
+inspiratory	B-PROC
+driving	O
+pressure	O
+guided	O
+by	O
+transpulmonary	O
+pressure	O
+,	O
+PaCO2	O
+decreased	O
+to	O
+64	O
+.	O
+5	O
+±	O
+16	O
+.	O
+89	O
+mmHg	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Adjustment	O
+of	O
+PEEP	B-CHED
+and	O
+inspiratory	B-PROC
+driving	O
+pressures	O
+did	O
+not	O
+worsen	O
+oxygenation	B-PROC
+and	O
+did	O
+not	O
+affect	O
+cardiac	B-ANAT
+output	O
+significantly	O
+.	O
+
+RESULTS	O
+:	O
+Six	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+hypercapnia	B-DISO
+were	O
+studied	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+viruses	B-SPEC
+from	O
+Germany	O
+and	O
+the	O
+United	O
+States	O
+,	O
+2014	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+variants	O
+of	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+Analysis	O
+from	O
+several	O
+large	O
+trials	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+/	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+have	O
+shown	O
+independent	O
+links	O
+between	O
+volumes	O
+of	O
+fluid	O
+administered	O
+and	O
+outcome	O
+;	O
+conservative	O
+fluid	O
+strategies	O
+have	O
+also	O
+been	O
+associated	O
+with	O
+lower	O
+mortality	O
+in	O
+trauma	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+The	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Every	O
+year	O
+,	O
+more	O
+than	O
+10	O
+million	O
+pilgrims	O
+arrive	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+for	O
+the	O
+Hajj	O
+or	O
+Umrah	O
+.	O
+
+Our	O
+results	O
+strongly	O
+suggest	O
+that	O
+,	O
+given	O
+the	O
+particularly	O
+crowded	O
+conditions	O
+during	O
+the	O
+rituals	B-DISO
+,	O
+an	O
+international	O
+mass	O
+gathering	O
+such	O
+as	O
+the	O
+Hajj	O
+may	O
+contribute	O
+to	O
+the	O
+globalization	O
+of	O
+respiratory	O
+pathogens	O
+after	O
+the	O
+cross	O
+-	O
+contamination	O
+of	O
+pilgrims	O
+harbouring	O
+pathogens	O
+that	O
+easily	O
+spread	O
+among	O
+participants	O
+.	O
+
+Influenza	B-DISO
+and	O
+pneumococcal	O
+vaccination	O
+,	O
+face	B-DISO
+mask	O
+use	O
+and	O
+hand	O
+hygiene	O
+should	O
+be	O
+considered	O
+in	O
+the	O
+context	O
+of	O
+the	O
+Hajj	O
+.	O
+
+We	O
+examined	O
+the	O
+effect	O
+of	O
+HMA	O
+and	O
+other	O
+viroporin	O
+inhibitors	B-CHED
+(	O
+DIDS	B-CHED
+[	O
+4	O
+,	O
+4	O
+'-	O
+disothiocyano	O
+-	O
+2	O
+,	O
+2	O
+'-	O
+stilbenedisulphonic	O
+acid	O
+]	O
+and	O
+amantadine	B-CHED
+)	O
+on	O
+infection	B-DISO
+by	O
+FIPV	O
+serotypes	O
+I	O
+and	O
+II	O
+.	O
+
+We	O
+investigated	O
+whether	O
+there	O
+is	O
+a	O
+difference	O
+in	O
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+of	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+between	O
+viral	O
+serotypes	O
+using	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+cells	B-COMP
+expressing	O
+the	O
+E	O
+protein	B-CHED
+of	O
+FIPV	O
+serotypes	O
+I	O
+and	O
+II	O
+.	O
+
+This	O
+study	O
+attempted	O
+to	O
+identify	O
+viruses	B-SPEC
+from	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+in	O
+adults	O
+visiting	O
+emergency	B-DISO
+departments	O
+for	O
+clinically	O
+suspected	O
+CAP	B-DISO
+.	O
+
+Adults	O
+with	O
+suspected	O
+CAP	B-DISO
+enrolled	O
+in	O
+the	O
+ESCAPED	O
+study	O
+(	O
+impact	O
+of	O
+computed	O
+tomography	O
+on	O
+CAP	B-DISO
+diagnosis	O
+)	O
+had	O
+prospective	O
+nasopharyngeal	B-ANAT
+(	O
+NP	O
+)	O
+samples	O
+studied	O
+by	O
+multiplex	O
+PCR	O
+(	O
+targeting	B-PROC
+15	O
+viruses	B-SPEC
+and	O
+four	O
+intracellular	B-COMP
+bacteria	B-SPEC
+).	O
+
+Viruses	B-SPEC
+seem	O
+common	O
+in	O
+adults	O
+attending	O
+emergency	B-DISO
+departments	O
+with	O
+suspected	O
+CAP	B-DISO
+.	O
+
+Arbekacin	B-CHED
+,	O
+a	O
+relatively	O
+new	O
+aminoglycoside	B-CHED
+,	O
+is	O
+effective	O
+against	O
+Pseudomonas	B-PRGE
+spp	B-ENZY
+.	O
+
+Spontaneous	O
+circulation	B-PROC
+had	O
+earlier	O
+resumed	O
+after	O
+brief	O
+application	O
+of	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+.	O
+
+GEDI	O
+should	O
+be	O
+used	O
+as	O
+a	O
+cardiac	B-ANAT
+preload	O
+parameter	O
+with	O
+awareness	O
+of	O
+its	O
+limitations	O
+.	O
+
+ABSTRACT	O
+:	O
+Here	O
+,	O
+we	O
+measured	O
+presepsins	O
+(	O
+PSPs	O
+)	O
+in	O
+four	O
+patients	O
+with	O
+acute	O
+kidney	O
+injury	O
+(	O
+AKI	O
+)	O
+or	O
+chronic	B-DISO
+kidney	I-DISO
+disease	I-DISO
+(	O
+CKD	O
+)	O
+and	O
+discuss	O
+the	O
+relationship	O
+between	O
+PSP	B-DISO
+and	O
+kidney	B-DISO
+dysfunction	I-DISO
+.	O
+
+Case	O
+4	O
+:	O
+a	O
+62	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+CKD	O
+was	O
+admitted	O
+to	O
+the	O
+ICU	O
+to	O
+control	O
+gastrointestinal	B-DISO
+bleeding	I-DISO
+.	O
+
+Patients	O
+'	O
+clinical	O
+prognoses	O
+were	O
+good	O
+,	O
+with	O
+low	O
+or	O
+moderate	O
+SIRS	B-DISO
+and	O
+APACHE	O
+II	O
+scores	O
+.	O
+
+Therefore	O
+,	O
+evaluation	O
+of	O
+PSP	B-DISO
+in	O
+kidney	B-DISO
+dysfunction	I-DISO
+patients	O
+will	O
+be	O
+difficult	O
+.	O
+
+Further	O
+investigation	O
+is	O
+needed	O
+to	O
+clarify	O
+the	O
+relationship	O
+between	O
+PSP	B-DISO
+and	O
+kidney	B-DISO
+dysfunction	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+ability	O
+to	O
+identify	O
+the	O
+functional	O
+correlates	O
+of	O
+structural	O
+and	O
+sequence	O
+variation	O
+in	O
+proteins	B-CHED
+is	O
+a	O
+critical	O
+capability	O
+.	O
+
+By	O
+superposing	O
+these	O
+spatially	O
+conserved	O
+atoms	B-CHED
+,	O
+we	O
+aligned	O
+the	O
+structures	O
+and	O
+associated	O
+molecules	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+cathepsin	B-PRGE
+and	O
+furin	B-PRGE
+proteolytic	B-PROC
+enzymes	O
+involved	O
+in	O
+viral	B-PRGE
+fusion	I-PRGE
+protein	B-CHED
+activation	O
+in	O
+cells	O
+of	O
+the	O
+bat	B-ENZY
+reservoir	O
+host	B-COMP
+.	O
+
+These	O
+viruses	B-SPEC
+require	O
+proteolytic	B-PROC
+activation	O
+of	O
+surface	B-PRGE
+envelope	I-PRGE
+glycoproteins	B-CHED
+needed	O
+for	O
+entry	O
+,	O
+and	O
+cellular	B-COMP
+cathepsins	O
+have	O
+been	O
+shown	O
+to	O
+be	O
+involved	O
+in	O
+proteolysis	B-PROC
+of	O
+glycoproteins	B-CHED
+from	O
+these	O
+distinct	O
+virus	B-SPEC
+families	O
+.	O
+
+However	O
+,	O
+kinetic	O
+analysis	O
+suggests	O
+that	O
+differences	O
+may	O
+exist	O
+in	O
+the	O
+cellular	B-PROC
+localization	I-PROC
+of	O
+furin	B-PRGE
+between	O
+different	O
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Diagnostic	O
+performance	O
+of	O
+a	O
+rapid	O
+in	O
+-	O
+clinic	O
+test	O
+for	O
+the	O
+detection	O
+of	O
+Canine	O
+Parvovirus	B-DISO
+under	O
+different	O
+storage	O
+conditions	O
+and	O
+vaccination	O
+status	O
+.	O
+
+ABSTRACT	O
+:	O
+Canine	O
+parvovirus	B-DISO
+(	O
+CPV	B-SPEC
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+common	O
+causes	O
+of	O
+acute	O
+haemorrhagic	B-DISO
+enteritis	I-DISO
+in	O
+young	O
+dogs	B-SPEC
+,	O
+while	O
+clinical	O
+diagnosis	O
+is	O
+often	O
+indecisive	O
+.	O
+
+A	O
+total	O
+of	O
+78	O
+duplicated	O
+faecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+diarrhoeic	O
+dogs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+association	O
+of	O
+bovine	O
+respiratory	B-DISO
+disease	I-DISO
+(	O
+BRD	O
+)	O
+or	O
+vaccination	O
+with	O
+serologic	O
+response	O
+in	O
+calves	O
+.	O
+
+Antibody	B-COMP
+rates	O
+of	O
+decay	B-DISO
+were	O
+calculated	O
+.	O
+
+The	O
+use	O
+of	O
+these	O
+devices	O
+has	O
+been	O
+well	O
+established	O
+in	O
+paediatric	O
+and	O
+post	O
+-	O
+heart	B-ANAT
+and	I-ANAT
+lung	I-ANAT
+transplantation	O
+patients	O
+;	O
+however	O
+,	O
+its	O
+use	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+has	O
+gained	O
+acceptance	O
+as	O
+standard	O
+clinical	O
+practice	O
+over	O
+the	O
+past	O
+decade	O
+.	O
+
+Of	O
+255	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+93	O
+died	B-PROC
+(	O
+case	O
+fatality	O
+rate	O
+,	O
+36	O
+.	O
+5	O
+%).	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+CoV	O
+)	O
+infection	B-DISO
+has	O
+recently	O
+emerged	O
+as	O
+a	O
+cause	O
+of	O
+severe	O
+potentially	O
+fatal	O
+pneumonia	B-DISO
+.	O
+
+Based	O
+on	O
+the	O
+incidence	O
+in	O
+Saudi	O
+Arabia	O
+since	O
+June	O
+2012	O
+,	O
+the	O
+most	O
+likely	O
+scenario	O
+given	O
+recent	O
+pilgrim	O
+numbers	O
+is	O
+estimated	O
+to	O
+be	O
+one	O
+case	O
+per	O
+Hajj	O
+,	O
+and	O
+three	O
+Umrah	O
+pilgrims	O
+per	O
+year	O
+,	O
+but	O
+which	O
+could	O
+plausibly	O
+reach	B-PROC
+seven	O
+and	O
+ten	O
+pilgrims	O
+respectively	O
+.	O
+
+The	O
+specific	O
+detection	O
+of	O
+anti	O
+-	O
+FCoV	O
+antibodies	B-COMP
+was	O
+possible	O
+in	O
+all	O
+heparin	B-CHED
+-	O
+anticoagulated	O
+plasma	B-ANAT
+,	O
+serum	B-COMP
+,	O
+whole	B-ANAT
+blood	I-ANAT
+,	O
+and	O
+ascitic	B-ANAT
+fluid	I-ANAT
+samples	O
+from	O
+anti	O
+-	O
+FCoV	O
+antibody	B-COMP
+positive	O
+cats	B-SPEC
+,	O
+and	O
+nonspecific	O
+reaction	O
+was	O
+not	O
+noted	O
+in	O
+samples	O
+from	O
+anti	O
+-	O
+FCoV	O
+antibody	B-COMP
+negative	O
+cats	B-SPEC
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+protocol	O
+to	O
+estimate	O
+selection	O
+pressures	O
+for	O
+the	O
+spike	O
+gene	O
+and	O
+evolutionary	O
+dynamics	O
+of	O
+bovine	B-SPEC
+coronaviruses	O
+.	O
+
+A	O
+simple	O
+technique	O
+for	O
+the	O
+preparation	O
+of	O
+chicken	B-SPEC
+tracheal	O
+organ	B-ANAT
+cultures	O
+in	O
+glass	O
+test	O
+tubes	O
+,	O
+in	O
+which	O
+virus	B-SPEC
+growth	B-PROC
+and	O
+ciliostasis	O
+can	O
+be	O
+readily	O
+observed	O
+,	O
+is	O
+described	O
+.	O
+
+TITLE	O
+:	O
+The	O
+preparation	O
+of	O
+chicken	B-SPEC
+kidney	B-ANAT
+cell	I-ANAT
+cultures	O
+for	O
+virus	B-SPEC
+propagation	O
+.	O
+
+A	O
+technique	O
+for	O
+the	O
+preparation	O
+of	O
+such	O
+cell	B-COMP
+cultures	O
+,	O
+using	O
+a	O
+combination	O
+of	O
+manual	O
+and	O
+trypsin	B-PRGE
+disaggregation	O
+of	O
+kidneys	B-ANAT
+dissected	O
+from	O
+2	O
+-	O
+to	O
+3	O
+-	O
+week	O
+-	O
+old	O
+birds	B-SPEC
+is	O
+described	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+large	O
+size	O
+of	O
+the	O
+coronavirus	O
+(	O
+CoV	B-SPEC
+)	O
+genome	O
+(	O
+around	O
+30	O
+kb	O
+)	O
+and	O
+the	O
+instability	O
+in	O
+bacteria	B-SPEC
+of	O
+plasmids	O
+carrying	O
+CoV	B-PRGE
+replicase	I-PRGE
+sequences	I-PRGE
+represent	O
+serious	O
+restrictions	O
+for	O
+the	O
+development	B-PROC
+of	O
+CoV	B-SPEC
+infectious	B-DISO
+clones	O
+using	O
+reverse	O
+genetic	O
+systems	O
+similar	O
+to	O
+those	O
+used	O
+for	O
+smaller	O
+positive	O
+sense	B-PROC
+RNA	O
+viruses	B-SPEC
+.	O
+
+Receptors	O
+can	O
+be	O
+major	O
+determinants	O
+of	O
+tropism	B-PROC
+,	O
+host	B-COMP
+range	O
+,	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Quantification	O
+of	O
+interferon	B-PATH
+signaling	B-PROC
+in	O
+avian	B-SPEC
+cells	B-COMP
+.	O
+
+The	O
+approaches	O
+described	O
+are	O
+not	O
+limited	O
+to	O
+CoV	O
+-	O
+infected	O
+cells	O
+;	O
+they	O
+can	O
+also	O
+be	O
+applied	O
+to	O
+other	O
+virus	B-SPEC
+-	O
+infected	O
+or	O
+non	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+To	O
+prepare	O
+these	O
+samples	O
+for	O
+imaging	O
+in	O
+the	O
+TEM	B-COMP
+therefore	O
+requires	O
+extensive	O
+processing	O
+which	O
+can	O
+alter	O
+the	O
+ultrastructure	O
+of	O
+the	O
+material	O
+.	O
+
+This	O
+study	O
+suggests	O
+the	O
+potential	O
+role	O
+of	O
+the	O
+TM	O
+domain	O
+in	O
+nsp6	O
+,	O
+the	O
+integrity	O
+of	O
+the	O
+S2	B-PRGE
+protein	I-PRGE
+and	O
+the	O
+B	O
+-	O
+TRS	B-DISO
+3	O
+,	O
+and	O
+the	O
+putative	O
+accessory	O
+protein	B-CHED
+4b	O
+,	O
+as	O
+well	O
+as	O
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+,	O
+in	O
+the	O
+virulence	B-PROC
+and	O
+replication	O
+of	O
+IBV	B-SPEC
+and	O
+has	O
+provided	O
+a	O
+better	O
+understanding	O
+of	O
+relationships	O
+between	O
+the	O
+Australian	O
+vaccine	O
+strain	O
+of	O
+IBV	B-SPEC
+and	O
+those	O
+used	O
+elsewhere	O
+.	O
+
+Patients	O
+with	O
+severe	O
+traumatic	B-DISO
+lung	I-DISO
+injury	O
+that	O
+met	B-CHED
+the	O
+following	O
+criteria	O
+were	O
+candidates	O
+for	O
+ECMO	O
+:	O
+(	O
+1	O
+)	O
+severe	O
+hypoxemia	O
+,	O
+Pao2	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+1	O
+.	O
+0	O
+)	O
+less	O
+than	O
+60	O
+,	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+greater	O
+than	O
+10	O
+cm	O
+H2O	B-CHED
+in	O
+spite	O
+of	O
+vigorous	O
+ventilation	O
+strategy	O
+;	O
+(	O
+2	O
+)	O
+irreversible	O
+CO2	B-DISO
+retention	B-PROC
+with	O
+unstable	O
+hemodynamics	B-PROC
+;	O
+and	O
+(	O
+3	O
+)	O
+an	O
+initial	O
+arterial	B-ANAT
+Pao2	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+1	O
+.	O
+0	O
+)	O
+less	O
+than	O
+60	O
+,	O
+where	O
+the	O
+pulmonary	B-ANAT
+condition	B-DISO
+and	O
+hemodynamics	B-PROC
+rapidly	O
+deteriorated	O
+despite	O
+vigorous	O
+mechanical	O
+ventilation	O
+strategy	O
+.	O
+
+ABSTRACT	O
+:	O
+Gene	O
+encoding	O
+22	O
+-	O
+380	O
+aa	O
+of	O
+spike	O
+protein	B-CHED
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+isolate	O
+in	O
+China	O
+was	O
+cloned	O
+and	O
+expressed	B-PROC
+as	O
+a	O
+recombinant	O
+protein	B-CHED
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+BL21	B-ANAT
+(	O
+DE3	O
+).	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+characterization	O
+of	O
+neutralizing	O
+monoclonal	O
+antibodies	B-COMP
+against	O
+the	O
+S1	B-PRGE
+subunit	I-PRGE
+protein	B-CHED
+of	O
+QX	O
+-	O
+like	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+strain	O
+Sczy3	O
+.	O
+
+The	O
+high	O
+antigenicity	O
+region	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+an	O
+QX	O
+-	O
+like	O
+IBV	B-SPEC
+strain	O
+Sczy3	O
+was	O
+amplified	O
+and	O
+ligated	O
+into	O
+the	O
+prokaryotic	O
+expression	B-PROC
+vector	O
+pET	O
+-	O
+32a	O
+(+),	O
+and	O
+the	O
+recombinant	B-PRGE
+His	I-PRGE
+-	I-PRGE
+S1	I-PRGE
+fusion	I-PRGE
+proteins	I-PRGE
+were	O
+expressed	B-PROC
+and	O
+purified	O
+.	O
+
+The	O
+anti	O
+-	O
+S1	O
+MAbs	O
+produced	O
+in	O
+the	O
+present	O
+work	O
+may	O
+be	O
+valuable	O
+in	O
+developing	O
+an	O
+antigen	B-CHED
+-	O
+capture	O
+ELISA	O
+test	O
+for	O
+antigen	B-CHED
+detection	O
+or	O
+a	O
+competitive	O
+ELISA	O
+test	O
+for	O
+antibody	B-COMP
+detection	O
+or	O
+therapeutic	O
+medicine	B-CHED
+for	O
+IB	O
+in	O
+poultry	O
+.	O
+
+TITLE	O
+:	O
+Monoclonal	O
+antibody	B-COMP
+to	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+envelope	B-COMP
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+protein	B-CHED
+remains	O
+at	O
+the	O
+site	O
+of	O
+assembly	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+assemble	O
+at	O
+endoplasmic	O
+reticulum	O
+Golgi	B-COMP
+intermediate	O
+compartment	B-ANAT
+(	O
+ERGIC	B-COMP
+)	O
+membranes	B-ANAT
+and	O
+egress	O
+from	O
+cells	B-COMP
+in	O
+cargo	O
+vesicles	B-COMP
+.	O
+
+The	O
+role	O
+of	O
+E	O
+in	O
+morphogenesis	B-PROC
+is	O
+not	O
+fully	O
+understood	O
+.	O
+
+To	O
+evaluate	O
+the	O
+effectiveness	O
+and	O
+safety	O
+of	O
+iNO	O
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+hypoxemia	O
+before	O
+and	O
+during	O
+transport	B-PROC
+to	O
+a	O
+tertiary	O
+care	O
+center	O
+.	O
+
+In	O
+35	O
+nonresponders	O
+,	O
+iNO	B-PRGE
+was	O
+discontinued	O
+,	O
+and	O
+15	O
+patients	O
+could	O
+not	O
+be	O
+transferred	O
+owing	O
+to	O
+life	O
+-	O
+threatening	O
+hypoxemia	O
+;	O
+2	O
+were	O
+later	O
+transferred	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Use	O
+of	O
+iNO	O
+significantly	O
+improves	O
+oxygenation	B-PROC
+of	O
+patients	O
+with	O
+severe	O
+hypoxemia	O
+and	O
+allows	O
+safe	O
+transfer	O
+to	O
+a	O
+tertiary	O
+care	O
+center	O
+.	O
+
+RESULTS	O
+:	O
+Patients	O
+treated	O
+with	O
+iNO	O
+had	O
+significant	O
+improvement	O
+in	O
+oxygenation	B-PROC
+:	O
+mean	O
+(	O
+SD	O
+)	O
+for	O
+PaO2	O
+increased	O
+from	O
+60	O
+.	O
+7	O
+(	O
+20	O
+.	O
+2	O
+)	O
+to	O
+72	O
+.	O
+3	O
+(	O
+40	O
+.	O
+6	O
+)	O
+mm	O
+Hg	O
+(	O
+P	O
+=.	O
+008	O
+),	O
+and	O
+mean	O
+(	O
+SD	O
+)	O
+for	O
+ratio	O
+of	O
+PaO2	O
+to	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+P	O
+:	O
+F	O
+)	O
+increased	O
+from	O
+62	O
+.	O
+4	O
+(	O
+26	O
+.	O
+1	O
+)	O
+to	O
+73	O
+.	O
+1	O
+(	O
+42	O
+.	O
+6	O
+)	O
+(	O
+P	O
+=	O
+.	O
+03	O
+).	O
+
+Amikacin	B-CHED
+,	O
+with	O
+four	O
+first	O
+-	O
+line	O
+anti	O
+-	O
+tuberculous	B-DISO
+drugs	O
+,	O
+was	O
+started	O
+in	O
+the	O
+case	O
+of	O
+a	O
+resistant	O
+strain	O
+and	O
+seriousness	O
+of	O
+the	O
+illness	O
+.	O
+
+TITLE	O
+:	O
+(	O
+3Z	O
+)-	O
+3	O
+-(	O
+2	O
+-[	O
+4	O
+-(	O
+aryl	O
+)-	O
+1	O
+,	O
+3	O
+-	O
+thiazol	O
+-	O
+2	O
+-	O
+yl	O
+]	O
+hydrazin	B-CHED
+-	O
+1	O
+-	O
+ylidene	O
+)-	O
+2	O
+,	O
+3	O
+-	O
+dihydro	O
+-	O
+1H	O
+-	O
+indol	B-CHED
+-	I-CHED
+2	I-CHED
+-	I-CHED
+one	I-CHED
+derivatives	O
+as	O
+dual	O
+inhibitors	O
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PRGE
+transcriptase	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+Reverse	B-PRGE
+Transcriptase	I-PRGE
+(	O
+RT	O
+)	O
+is	O
+a	O
+validated	O
+and	O
+deeply	O
+explored	O
+biological	O
+target	O
+for	O
+the	O
+treatment	O
+of	O
+AIDS	O
+.	O
+
+In	O
+samples	O
+from	O
+symptomatic	O
+children	O
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+coronavirus	B-SPEC
+OC43	O
+were	O
+detected	O
+in	O
+addition	O
+to	O
+those	O
+mentioned	O
+above	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+an	O
+emerging	O
+pathogen	O
+that	O
+causes	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+occurs	O
+sporadically	O
+.	O
+
+A	O
+reverse	O
+-	O
+transcription	B-PROC
+PCR	O
+assay	O
+for	O
+MERS	O
+-	O
+CoV	O
+targeting	B-PROC
+a	O
+615	O
+bp	O
+spike	O
+fragment	O
+provides	O
+a	O
+phylogenetic	O
+clustering	O
+of	O
+MERS	O
+-	O
+CoV	O
+variants	O
+comparable	O
+to	O
+that	O
+of	O
+full	O
+-	O
+length	O
+genomes	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aim	O
+was	O
+to	O
+investigate	O
+an	O
+outbreak	O
+of	O
+human	O
+cases	O
+of	O
+unexplained	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+and	O
+fatal	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+(	O
+ARI	B-CHED
+),	O
+with	O
+simultaneous	O
+poultry	O
+illness	O
+and	O
+high	O
+mortality	O
+raising	O
+concerns	O
+of	O
+possible	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+),	O
+virus	B-SPEC
+in	O
+Cote	O
+d	O
+'	O
+Ivoire	O
+in	O
+February	O
+and	O
+March	O
+2007	O
+.	O
+
+Persons	O
+meeting	O
+the	O
+case	O
+definition	O
+were	O
+asked	O
+to	O
+provide	O
+nasopharyngeal	B-ANAT
+specimens	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+clinical	O
+and	O
+epidemiological	O
+information	O
+,	O
+specimens	O
+were	O
+tested	O
+using	O
+conventional	O
+RT	O
+-	O
+PCR	O
+for	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+hemagglutinin	O
+H5	O
+of	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+),	O
+virus	B-SPEC
+;	O
+negative	O
+samples	O
+were	O
+tested	O
+for	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Between	O
+October	O
+2006	O
+,	O
+and	O
+February	O
+2007	O
+,	O
+104	O
+suspected	O
+cases	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Disease	I-DISO
+that	O
+included	O
+;	O
+31	O
+deaths	B-PROC
+recorded	O
+.	O
+
+We	O
+collected	O
+and	O
+tested	O
+73	O
+nasopharyngeal	B-ANAT
+specimens	O
+;	O
+of	O
+which	O
+,	O
+2	O
+,	O
+were	O
+positive	O
+for	O
+human	B-PRGE
+Coronavirus	I-PRGE
+OC43	I-PRGE
+and	O
+1	O
+for	O
+influenza	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+.	O
+
+No	O
+pathogens	O
+were	O
+identified	O
+in	O
+animal	B-SPEC
+specimens	O
+.	O
+
+No	O
+pathogens	O
+were	O
+identified	O
+in	O
+animal	B-SPEC
+specimens	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+identified	O
+several	O
+potential	O
+cellular	B-COMP
+nsp16	O
+-	O
+interacting	O
+proteins	B-CHED
+from	O
+a	O
+human	B-SPEC
+thymus	B-SPEC
+cDNA	O
+library	O
+by	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+screening	O
+.	O
+
+TITLE	O
+:	O
+The	O
+costs	O
+of	O
+inadequate	O
+breastfeeding	B-PROC
+of	O
+infants	O
+in	O
+Mexico	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+total	O
+annual	O
+costs	O
+of	O
+inadequate	O
+breastfeeding	B-PROC
+in	O
+Mexico	O
+for	O
+the	O
+studied	O
+cohort	O
+ranged	O
+from	O
+$	O
+745	O
+.	O
+6	O
+million	O
+to	O
+$	O
+2416	O
+.	O
+5	O
+million	O
+,	O
+where	O
+the	O
+costs	O
+of	O
+infant	O
+formula	O
+accounted	O
+for	O
+11	O
+-	O
+38	O
+%	O
+of	O
+total	O
+costs	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+reports	O
+of	O
+Plasmodium	O
+vivax	O
+associated	O
+with	O
+severe	O
+syndromes	B-DISO
+and	O
+mortality	O
+from	O
+malaria	B-PATH
+endemic	O
+areas	O
+questions	O
+the	O
+""""	O
+benign	O
+""""	O
+course	O
+of	O
+non	O
+-	O
+falciparum	O
+malarias	B-DISO
+.	O
+
+Among	O
+all	O
+cases	O
+,	O
+.	O
+9	O
+%	O
+of	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+cases	O
+resulted	O
+in	O
+death	B-PROC
+and	O
+9	O
+.	O
+3	O
+%	O
+were	O
+classified	O
+as	O
+severe	O
+,	O
+whereas	O
+.	O
+09	O
+%	O
+of	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+cases	O
+resulted	O
+in	O
+death	B-PROC
+and	O
+1	O
+.	O
+3	O
+%	O
+were	O
+classified	O
+as	O
+severe	O
+.	O
+
+In	O
+Argentina	B-SPEC
+,	O
+national	O
+surveillance	O
+programs	O
+for	O
+the	O
+detection	O
+of	O
+respiratory	O
+viruses	B-SPEC
+are	O
+usually	O
+performed	O
+by	O
+using	O
+immunofluorescence	O
+(	O
+IF	O
+)	O
+assays	O
+,	O
+although	O
+it	O
+is	O
+well	O
+known	O
+that	O
+molecular	O
+methods	O
+are	O
+more	O
+sensitive	O
+.	O
+
+ABSTRACT	O
+:	O
+Protective	O
+lung	O
+ventilation	O
+is	O
+recommended	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+to	O
+minimize	O
+additional	O
+injuries	O
+to	O
+the	O
+lung	B-ANAT
+.	O
+
+ARDS	B-DISO
+was	O
+obtained	O
+by	O
+repeated	O
+bronchoalveolar	O
+lavage	O
+.	O
+
+Pulmonary	B-ANAT
+artery	I-ANAT
+pressure	O
+significantly	O
+decreased	O
+to	O
+31	O
+.	O
+6	O
+±	O
+3	O
+.	O
+2	O
+mmHg	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+RV	O
+-	O
+arterial	B-ANAT
+coupling	O
+significantly	O
+improved	O
+(	O
+RV	O
+-	O
+arterial	B-ANAT
+coupling	O
+index	O
+=	O
+1	O
+.	O
+03	O
+±	O
+0	O
+.	O
+33	O
+vs	O
+.	O
+0	O
+.	O
+55	O
+±	O
+0	O
+.	O
+41	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Veno	O
+-	O
+venous	B-ANAT
+CO2	B-CHED
+removal	O
+therapy	O
+enabled	O
+protective	O
+ventilation	O
+while	O
+maintaining	O
+normocarbia	O
+during	O
+ARDS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+ARDS	B-DISO
+induced	O
+severe	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+structure	O
+and	O
+functions	O
+of	O
+coronavirus	B-SPEC
+genomic	O
+3	O
+'	O
+and	O
+5	O
+'	O
+ends	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+an	O
+important	O
+cause	O
+of	O
+illness	O
+in	O
+humans	O
+and	O
+animals	B-SPEC
+.	O
+
+Most	O
+human	B-SPEC
+coronaviruses	O
+commonly	O
+cause	O
+relatively	O
+mild	O
+respiratory	O
+illnesses	O
+;	O
+however	O
+two	O
+zoonotic	O
+coronaviruses	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+,	O
+can	O
+cause	O
+severe	O
+illness	O
+and	O
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+of	O
+erythrocentaurin	O
+derivatives	O
+as	O
+a	O
+new	O
+class	B-SPEC
+of	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+inhibitors	B-CHED
+.	O
+
+Eight	O
+compounds	O
+1	O
+,	O
+2	O
+,	O
+5	O
+,	O
+8	O
+,	O
+9	O
+,	O
+1e	O
+,	O
+1k	O
+,	O
+and	O
+1m	O
+increased	O
+activity	O
+against	O
+HBV	B-DISO
+DNA	B-PATH
+replication	I-PATH
+with	O
+the	O
+SI	O
+values	O
+higher	O
+than	O
+11	O
+.	O
+
+In	O
+particular	O
+,	O
+derivatives	O
+1e	O
+and	O
+1k	O
+exhibited	O
+the	O
+most	O
+potent	O
+inhibition	B-PROC
+on	O
+HBV	B-DISO
+DNA	B-PATH
+replication	I-PATH
+with	O
+the	O
+IC50	O
+values	O
+of	O
+0	O
+.	O
+026	O
+mM	O
+(	O
+SI	O
+>	O
+70	O
+.	O
+8	O
+)	O
+and	O
+0	O
+.	O
+045	O
+mM	O
+(	O
+SI	O
+>	O
+36	O
+.	O
+0	O
+),	O
+respectively	O
+.	O
+
+A	O
+37	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+complaining	O
+of	O
+persisting	O
+cough	B-DISO
+was	O
+referred	O
+to	O
+our	O
+hospital	O
+.	O
+
+Medicinal	O
+plants	B-SPEC
+are	O
+a	O
+rich	O
+source	O
+of	O
+chemical	O
+diversity	O
+and	O
+can	O
+be	O
+used	O
+to	O
+identify	O
+novel	O
+scaffolds	O
+to	O
+be	O
+further	O
+developed	O
+by	O
+chemical	O
+modifications	O
+.	O
+
+We	O
+investigated	O
+the	O
+ability	O
+of	O
+the	O
+main	O
+lignans	B-CHED
+from	O
+Schisandra	B-SPEC
+chinensis	I-SPEC
+(	O
+Turcz	O
+.)	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+characterization	O
+of	O
+porcine	B-SPEC
+deltacoronavirus	O
+from	O
+pigs	B-SPEC
+with	O
+diarrhea	B-DISO
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Patients	O
+with	O
+severe	O
+ILD	O
+and	O
+>	O
+12	O
+months	O
+follow	O
+-	O
+up	O
+post	O
+-	O
+Rtx	O
+were	O
+identified	O
+from	O
+the	O
+Oslo	O
+University	O
+Hospital	O
+ASS	B-SPEC
+cohort	O
+(	O
+n	O
+=	O
+112	O
+).	O
+
+This	O
+study	O
+,	O
+which	O
+included	O
+24	O
+Rtx	O
+-	O
+treated	O
+ASS	B-SPEC
+patients	O
+with	O
+severe	O
+ILD	O
+,	O
+reports	O
+improved	O
+PFTs	O
+after	O
+a	O
+median	O
+52	O
+months	O
+follow	O
+-	O
+up	O
+post	O
+-	O
+Rtx	O
+.	O
+
+Recovery	O
+was	O
+longer	O
+with	O
+acute	O
+gastrointestinal	B-DISO
+infection	I-DISO
+and	O
+acute	O
+motor	O
+axonal	B-DISO
+neuropathy	I-DISO
+.	O
+
+We	O
+present	O
+3	O
+cases	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+severe	O
+pulmonary	B-DISO
+disease	I-DISO
+managed	O
+with	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+,	O
+among	O
+other	O
+ventilatory	O
+modes	O
+,	O
+with	O
+improved	O
+ventilation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+may	O
+be	O
+an	O
+important	O
+option	O
+as	O
+a	O
+ventilatory	O
+mode	O
+for	O
+management	O
+of	O
+maternal	O
+respiratory	B-DISO
+failure	I-DISO
+during	O
+pregnancy	O
+.	O
+
+The	O
+optimum	O
+conditions	O
+for	O
+differentiation	B-PROC
+between	O
+anti	O
+-	O
+TCoV	O
+hyperimmune	O
+serum	B-ANAT
+and	O
+normal	O
+turkey	B-SPEC
+serum	B-COMP
+were	O
+recombinant	B-PRGE
+TCoV	I-PRGE
+N	I-PRGE
+protein	I-PRGE
+concentration	O
+at	O
+20	O
+μg	O
+/	O
+ml	O
+,	O
+serum	B-COMP
+dilution	O
+at	O
+1	O
+:	O
+800	O
+,	O
+and	O
+conjugate	O
+dilution	O
+at	O
+1	O
+:	O
+10	O
+,	O
+000	O
+.	O
+
+Reactivity	O
+of	O
+anti	O
+-	O
+rotavirus	B-SPEC
+,	O
+anti	O
+-	O
+reovirus	B-SPEC
+,	O
+anti	O
+-	O
+adenovirus	B-DISO
+,	O
+or	O
+anti	O
+-	O
+enterovirus	B-SPEC
+antibodies	B-COMP
+with	O
+the	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+coated	O
+on	O
+the	O
+ELISA	O
+plates	O
+was	O
+not	O
+detected	O
+.	O
+
+Structure	O
+and	O
+sequence	O
+alignments	O
+revealed	O
+that	O
+two	O
+residues	O
+,	O
+Y269	O
+and	O
+Q270	O
+,	O
+responsible	O
+for	O
+inhibitor	B-CHED
+binding	B-FUNC
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+,	O
+were	O
+replaced	O
+by	O
+T274	O
+and	O
+A275	O
+in	O
+MERS	O
+-	O
+CoV	O
+PLpro	O
+,	O
+making	O
+critical	O
+binding	B-FUNC
+interactions	O
+difficult	O
+to	O
+form	O
+for	O
+similar	O
+types	O
+of	O
+inhibitors	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+PET	O
+with	O
+[	O
+18F	O
+]	O
+fluoro	B-CHED
+-	O
+2	B-CHED
+-	I-CHED
+deoxy	I-CHED
+-	I-CHED
+D	I-CHED
+-	I-CHED
+glucose	I-CHED
+can	O
+be	O
+used	O
+to	O
+image	O
+cellular	B-PROC
+metabolism	I-PROC
+,	O
+which	O
+during	O
+lung	B-DISO
+inflammation	I-DISO
+mainly	O
+reflects	O
+neutrophil	B-ANAT
+activity	O
+,	O
+allowing	O
+the	O
+study	O
+of	O
+regional	O
+lung	B-DISO
+inflammation	I-DISO
+in	O
+vivo	O
+.	O
+
+[	O
+18F	O
+]	O
+fluoro	B-CHED
+-	O
+2	B-CHED
+-	I-CHED
+deoxy	I-CHED
+-	I-CHED
+D	I-CHED
+-	I-CHED
+glucose	I-CHED
+uptake	O
+rate	O
+was	O
+computed	O
+for	O
+the	O
+total	O
+lung	B-ANAT
+,	O
+four	O
+horizontal	O
+regions	O
+from	O
+top	O
+to	O
+bottom	O
+(	O
+nondependent	O
+to	O
+dependent	O
+regions	O
+)	O
+and	O
+for	O
+voxels	O
+grouped	O
+by	O
+similar	O
+density	O
+using	O
+standard	O
+Hounsfield	O
+units	O
+classification	O
+.	O
+
+The	O
+global	O
+lung	B-ANAT
+uptake	O
+was	O
+elevated	O
+at	O
+3	O
+and	O
+27	O
+hours	O
+,	O
+suggesting	O
+persisting	O
+inflammation	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+comparison	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+outcomes	O
+between	O
+military	O
+and	O
+civilian	O
+burn	O
+patients	O
+.	O
+
+In	O
+a	O
+retrospective	O
+cohort	O
+study	O
+,	O
+burned	O
+military	O
+patients	O
+on	O
+mechanical	O
+ventilation	O
+had	O
+a	O
+significantly	O
+lower	O
+overall	O
+and	O
+ARDS	B-DISO
+mortality	O
+despite	O
+larger	O
+burns	O
+and	O
+more	O
+severe	O
+injury	O
+when	O
+compared	O
+to	O
+civilian	O
+burn	O
+patients	O
+.	O
+
+This	O
+review	O
+will	O
+detail	O
+the	O
+most	O
+current	O
+clinical	O
+and	O
+epidemiological	O
+findings	O
+to	O
+all	O
+respiratory	O
+viruses	B-SPEC
+discovered	O
+since	O
+2001	O
+.	O
+
+Recombinant	B-PRGE
+human	I-PRGE
+interferon	I-PRGE
+alpha	I-PRGE
+2b	I-PRGE
+in	O
+vitro	O
+has	O
+broad	O
+spectrum	O
+antiviral	B-CHED
+activities	O
+,	O
+low	O
+toxicity	O
+and	O
+high	O
+therapeutic	O
+index	O
+.	O
+
+In	O
+addition	O
+to	O
+extensive	O
+intestinal	B-ANAT
+lesions	O
+,	O
+PdCV	O
+caused	O
+significant	O
+lesions	O
+in	O
+the	O
+stomach	B-ANAT
+and	O
+mild	O
+pulmonary	B-ANAT
+lesions	O
+that	O
+have	O
+not	O
+been	O
+reported	O
+for	O
+TGEV	B-SPEC
+and	O
+PEDV	B-SPEC
+.	O
+
+The	O
+GAIT	O
+element	O
+is	O
+involved	O
+in	O
+the	O
+translation	B-PROC
+silencing	O
+of	O
+these	O
+mRNAs	O
+through	O
+its	O
+interaction	O
+with	O
+the	O
+GAIT	B-COMP
+complex	I-COMP
+(	O
+EPRS	B-PRGE
+,	O
+heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoprotein	I-PRGE
+Q	I-PRGE
+,	O
+ribosomal	B-PRGE
+protein	B-CHED
+L13a	I-PRGE
+,	O
+and	O
+glyceraldehyde	B-PRGE
+3	I-PRGE
+-	I-PRGE
+phosphate	I-PRGE
+dehydrogenase	I-PRGE
+)	O
+to	O
+favor	O
+the	O
+resolution	O
+of	O
+inflammation	B-DISO
+.	O
+
+Auxiliary	O
+partial	O
+orthotopic	O
+living	O
+donor	B-CHED
+liver	B-ANAT
+transplantion	O
+(	O
+APOLDLT	O
+)	O
+was	O
+performed	O
+.	O
+
+When	O
+administered	O
+by	O
+CED	B-DISO
+into	O
+the	O
+rat	B-SPEC
+striatum	B-ANAT
+,	O
+highly	O
+PEGylated	O
+DNA	O
+NP	O
+distribute	O
+throughout	O
+and	O
+provide	O
+broad	O
+transgene	O
+expression	B-PROC
+without	O
+vector	O
+-	O
+induced	O
+toxicity	O
+.	O
+
+The	O
+use	O
+of	O
+these	O
+brain	B-ANAT
+-	O
+penetrating	O
+gene	O
+vectors	O
+,	O
+in	O
+conjunction	O
+with	O
+CED	B-DISO
+,	O
+offers	O
+an	O
+avenue	O
+to	O
+improve	O
+gene	O
+therapy	O
+for	O
+CNS	B-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+guided	O
+design	O
+and	O
+optimization	O
+of	O
+dipeptidyl	O
+inhibitors	B-CHED
+of	O
+norovirus	B-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+.	O
+
+He	O
+lost	B-CHED
+consciousness	O
+and	O
+convulsed	B-DISO
+.	O
+
+He	O
+finally	O
+died	B-PROC
+of	O
+pulmonary	B-DISO
+oedema	I-DISO
+,	O
+major	O
+metabolic	B-DISO
+acidosis	I-DISO
+and	O
+acute	O
+multi	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+following	O
+day	O
+,	O
+the	O
+captain	O
+issued	O
+a	O
+rescue	O
+call	O
+from	O
+the	O
+same	O
+vessel	B-ANAT
+for	O
+a	O
+41	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+also	O
+with	O
+abdominal	B-DISO
+pain	I-DISO
+,	O
+vomiting	B-DISO
+and	O
+dizziness	B-DISO
+.	O
+
+Comparisons	O
+between	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+are	O
+briefly	O
+described	O
+.	O
+
+Epidemiological	O
+and	O
+genetic	O
+studies	O
+point	O
+at	O
+zoonotic	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+from	O
+camels	B-SPEC
+and	O
+possibly	O
+bats	B-SPEC
+.	O
+
+Health	O
+-	O
+care	O
+workers	O
+should	O
+always	O
+apply	O
+standard	O
+precautions	O
+consistently	O
+with	O
+all	O
+patients	O
+,	O
+regardless	O
+of	O
+their	O
+diagnosis	O
+due	O
+to	O
+non	O
+-	O
+specific	O
+symptoms	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+the	O
+early	O
+stage	O
+of	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+article	O
+reviews	O
+the	O
+clinical	O
+and	O
+treatment	O
+aspects	O
+of	O
+avian	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+ABSTRACT	O
+:	O
+Ubiquitin	B-PROC
+(	O
+Ub	B-PROC
+)	O
+and	O
+the	O
+Ub	B-PRGE
+-	I-PRGE
+like	I-PRGE
+(	O
+Ubl	B-PRGE
+)	O
+modifier	O
+interferon	B-PRGE
+-	I-PRGE
+stimulated	I-PRGE
+gene	I-PRGE
+15	I-PRGE
+(	O
+ISG15	B-PRGE
+)	O
+participate	O
+in	O
+the	O
+host	B-PROC
+defence	I-PROC
+of	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+compare	O
+substrate	O
+specificities	O
+of	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLpro	O
+)	O
+from	O
+the	O
+recently	O
+emerged	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+hCoV	O
+to	O
+the	O
+related	O
+protease	O
+from	O
+SARS	B-DISO
+,	O
+SARS	B-DISO
+PLpro	O
+.	O
+
+Several	O
+classes	O
+of	O
+nucleoside	B-CHED
+and	O
+non	O
+-	O
+nucleoside	B-CHED
+inhibitors	B-CHED
+,	O
+targeting	B-PROC
+the	O
+different	O
+allosteric	O
+sites	O
+,	O
+have	O
+demonstrated	O
+efficacy	O
+in	O
+clinical	O
+trials	O
+.	O
+
+Compared	O
+to	O
+other	O
+allosteric	O
+sites	O
+,	O
+thumb	B-ANAT
+site	O
+I	O
+is	O
+a	O
+more	O
+compelling	O
+allosteric	O
+target	O
+with	O
+a	O
+significant	O
+number	O
+of	O
+inhibitors	B-CHED
+in	O
+clinical	O
+trials	O
+.	O
+
+We	O
+would	O
+not	O
+start	O
+CRRT	O
+for	O
+the	O
+complexity	O
+of	O
+operation	O
+and	O
+additional	O
+loss	O
+of	O
+blood	B-ANAT
+.	O
+
+The	O
+CDV	B-CHED
+-	O
+H	O
+RT	O
+-	O
+LAMP	O
+assay	O
+rapidly	O
+amplified	O
+the	O
+target	O
+gene	O
+,	O
+within	O
+60	O
+min	O
+,	O
+using	O
+a	O
+water	B-CHED
+bath	O
+held	O
+at	O
+a	O
+constant	O
+temperature	O
+of	O
+65	O
+°	O
+C	O
+.	O
+
+The	O
+system	O
+showed	O
+a	O
+preference	O
+for	O
+wild	O
+-	O
+type	O
+CDV	O
+,	O
+and	O
+exhibited	O
+less	O
+sensitivity	O
+to	O
+canine	O
+parvovirus	B-DISO
+,	O
+canine	B-SPEC
+adenovirus	I-SPEC
+type	O
+1	O
+and	O
+type	O
+2	O
+,	O
+canine	O
+coronavirus	B-SPEC
+,	O
+and	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+in	O
+-	O
+depth	O
+phylogenetic	O
+and	O
+Bayesian	O
+phylogeographic	O
+studies	O
+were	O
+conducted	O
+to	O
+investigate	O
+the	O
+evolutionary	O
+dynamics	O
+of	O
+AvCoVs	O
+detected	O
+in	O
+wild	O
+and	O
+synanthropic	O
+birds	B-SPEC
+.	O
+
+Such	O
+zoonotic	O
+hepatitis	B-DISO
+E	I-DISO
+infection	B-DISO
+has	O
+particular	O
+relevance	O
+to	O
+the	O
+increasing	O
+population	O
+living	O
+with	O
+immunosuppression	B-PROC
+,	O
+due	O
+to	O
+the	O
+risk	O
+of	O
+chronic	B-DISO
+hepatitis	I-DISO
+E	I-DISO
+in	O
+these	O
+patients	O
+.	O
+
+Here	O
+we	O
+examine	O
+how	O
+virulence	B-PROC
+varies	O
+across	O
+host	B-COMP
+species	B-SPEC
+by	O
+carrying	O
+out	O
+a	O
+large	O
+cross	B-DISO
+infection	I-DISO
+experiment	O
+using	O
+48	O
+species	B-SPEC
+of	O
+Drosophilidae	B-SPEC
+and	O
+an	O
+RNA	O
+virus	B-SPEC
+.	O
+
+Host	B-COMP
+shifts	O
+resulted	O
+in	O
+dramatic	O
+variation	O
+in	O
+virulence	B-PROC
+,	O
+with	O
+benign	O
+infections	B-DISO
+in	O
+some	O
+species	B-SPEC
+and	O
+rapid	O
+death	B-PROC
+in	O
+others	O
+.	O
+
+The	O
+change	O
+in	O
+virulence	B-PROC
+was	O
+highly	O
+predictable	O
+from	O
+the	O
+host	B-COMP
+phylogeny	O
+,	O
+with	O
+hosts	B-COMP
+clustering	O
+together	O
+in	O
+distinct	O
+clades	O
+displaying	O
+high	O
+or	O
+low	O
+virulence	B-PROC
+.	O
+
+We	O
+summarize	O
+recent	O
+findings	O
+regarding	O
+the	O
+epidemiology	O
+of	O
+CAP	B-DISO
+in	O
+adults	O
+,	O
+efficacy	O
+of	O
+vaccines	O
+against	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+,	O
+diagnostics	O
+,	O
+and	O
+discuss	O
+the	O
+current	O
+controversy	O
+between	O
+CAP	B-DISO
+and	O
+healthcare	O
+-	O
+associated	O
+pneumonia	B-DISO
+(	O
+HCAP	O
+).	O
+
+TITLE	O
+:	O
+Viral	B-DISO
+gastroenteritis	I-DISO
+in	O
+children	O
+in	O
+Colorado	O
+2006	O
+-	O
+2009	O
+.	O
+
+RT	O
+-	O
+PCR	O
+detected	O
+99	O
+of	O
+111	O
+(	O
+89	O
+%)	O
+adenovirus	B-DISO
+-	O
+positive	O
+samples	O
+versus	O
+12	O
+(	O
+11	O
+%)	O
+by	O
+EM	O
+,	O
+and	O
+186	O
+of	O
+192	O
+(	O
+97	O
+%)	O
+sapovirus	B-SPEC
+/	O
+astrovirus	O
+/	O
+norovirus	B-SPEC
+-	O
+positive	O
+samples	O
+versus	O
+21	O
+(	O
+11	O
+%)	O
+by	O
+EM	O
+.	O
+
+Noroviruses	B-SPEC
+and	O
+adenoviruses	B-SPEC
+are	O
+common	O
+causes	O
+of	O
+gastroenteritis	B-DISO
+in	O
+children	O
+.	O
+
+However	O
+,	O
+the	O
+blockade	O
+of	O
+apoptosis	B-PATH
+in	O
+the	O
+lungs	B-ANAT
+may	O
+also	O
+have	O
+deleterious	O
+effects	O
+by	O
+hampering	O
+viral	O
+clearance	O
+,	O
+and	O
+importantly	O
+,	O
+by	O
+enhancing	O
+or	O
+prolonging	O
+local	O
+proinflammatory	O
+responses	O
+.	O
+
+59	O
+unique	O
+miRNAs	O
+displayed	O
+significant	O
+differentially	O
+expression	B-PROC
+between	O
+the	O
+normal	O
+and	O
+TGEV	B-SPEC
+-	O
+infected	O
+ST	O
+cell	B-COMP
+samples	O
+:	O
+15	O
+miRNAs	O
+were	O
+significantly	O
+up	O
+-	O
+regulated	O
+and	O
+44	O
+were	O
+significantly	O
+down	O
+-	O
+regulated	O
+.	O
+
+The	O
+results	O
+presented	O
+here	O
+will	O
+aid	O
+research	O
+on	O
+the	O
+prevention	O
+and	O
+treatment	O
+of	O
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+We	O
+analyzed	O
+the	O
+differential	O
+protein	B-CHED
+profile	O
+of	O
+PEDV	B-SPEC
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+using	O
+mass	O
+spectrometry	O
+and	O
+an	O
+isobaric	O
+tag	B-DISO
+for	O
+relative	O
+and	O
+absolute	O
+quantification	O
+.	O
+
+In	O
+addition	O
+,	O
+articles	O
+were	O
+searched	O
+on	O
+the	O
+websites	O
+of	O
+the	O
+World	O
+Health	O
+Organization	O
+and	O
+the	O
+U	O
+.	O
+S	O
+.	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+using	O
+the	O
+terms	O
+""""	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+""""	O
+and	O
+""""	O
+novel	B-SPEC
+coronavirus	I-SPEC
+in	O
+Middle	O
+East	O
+.	O
+
+Meta	B-SPEC
+-	O
+analysis	O
+was	O
+performed	O
+using	O
+both	O
+a	O
+fixed	B-ANAT
+-	O
+effect	O
+and	O
+a	O
+random	O
+-	O
+effects	O
+model	O
+.	O
+
+Meta	B-SPEC
+-	O
+analysis	O
+comparing	O
+HFOV	O
+with	O
+CV	O
+revealed	O
+no	O
+evidence	O
+of	O
+effect	O
+on	O
+mortality	O
+at	O
+28	O
+to	O
+30	O
+days	O
+of	O
+age	O
+or	O
+at	O
+approximately	O
+term	O
+equivalent	O
+age	O
+.	O
+
+The	O
+risk	O
+of	O
+CLD	B-DISO
+in	O
+survivors	O
+at	O
+term	O
+equivalent	O
+gestational	O
+age	O
+was	O
+significantly	O
+reduced	O
+with	O
+the	O
+use	O
+of	O
+HFOV	O
+but	O
+this	O
+effect	O
+was	O
+inconsistent	O
+across	O
+studies	O
+,	O
+even	O
+after	O
+the	O
+meta	B-SPEC
+-	O
+analysis	O
+was	O
+restricted	O
+to	O
+studies	O
+that	O
+applied	O
+a	O
+high	O
+lung	B-PROC
+volume	I-PROC
+strategy	O
+with	O
+HFOV	O
+.	O
+
+Specifically	O
+,	O
+use	O
+of	O
+these	O
+building	O
+blocks	O
+to	O
+investigate	O
+protein	B-PROC
+folding	I-PROC
+and	O
+misfolding	O
+has	O
+been	O
+of	O
+particular	O
+value	O
+since	O
+it	O
+can	O
+provide	O
+tremendous	O
+insights	O
+into	O
+peptide	B-CHED
+aggregation	O
+related	O
+to	O
+a	O
+variety	O
+of	O
+protein	B-DISO
+misfolding	I-DISO
+diseases	I-DISO
+,	O
+or	O
+amyloid	B-DISO
+diseases	I-DISO
+(	O
+e	O
+.	O
+g	O
+.,	O
+Alzheimer	B-PATH
+'	I-PATH
+s	I-PATH
+disease	I-PATH
+,	O
+Parkinson	B-PATH
+'	I-PATH
+s	I-PATH
+disease	I-PATH
+,	O
+type	O
+-	O
+II	O
+diabetes	B-DISO
+).	O
+
+Herein	O
+,	O
+the	O
+self	O
+-	O
+assembly	O
+of	O
+TK9	O
+,	O
+a	O
+nine	O
+-	O
+residue	O
+peptide	B-CHED
+of	O
+the	O
+extra	O
+membrane	B-COMP
+C	O
+-	O
+terminal	O
+tail	O
+of	O
+the	O
+SARS	B-PRGE
+corona	B-CHED
+virus	B-SPEC
+envelope	B-COMP
+,	O
+and	O
+its	O
+variants	O
+were	O
+characterized	O
+through	O
+biophysical	O
+,	O
+spectroscopic	O
+,	O
+and	O
+simulated	O
+studies	O
+,	O
+and	O
+it	O
+was	O
+confirmed	O
+that	O
+the	O
+structure	O
+of	O
+these	O
+peptides	O
+influences	O
+their	O
+aggregation	O
+propensity	O
+,	O
+hence	O
+,	O
+mimicking	O
+amyloid	B-DISO
+proteins	B-CHED
+.	O
+
+TK9	O
+,	O
+which	O
+forms	O
+a	O
+beta	O
+-	O
+sheet	O
+rich	O
+fibril	B-COMP
+,	O
+contains	O
+a	O
+key	O
+sequence	O
+motif	O
+that	O
+may	O
+be	O
+critical	O
+for	O
+beta	O
+-	O
+sheet	O
+formation	B-PROC
+,	O
+thus	O
+making	O
+it	O
+an	O
+interesting	O
+system	O
+to	O
+study	O
+amyloid	B-DISO
+fibrillation	B-DISO
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+TK9	O
+inhibits	O
+the	O
+fibrillation	B-DISO
+of	O
+hIAPP	O
+,	O
+a	O
+37	O
+amino	B-CHED
+acid	I-CHED
+peptide	B-CHED
+implicated	O
+in	O
+the	O
+pathology	B-DISO
+of	O
+type	O
+-	O
+II	O
+diabetes	B-DISO
+.	O
+
+Thus	O
+,	O
+biophysical	O
+and	O
+NMR	O
+experimental	O
+results	O
+have	O
+revealed	O
+a	O
+molecular	O
+level	O
+understanding	O
+of	O
+peptide	B-CHED
+folding	O
+events	O
+,	O
+as	O
+well	O
+as	O
+the	O
+inhibition	B-PROC
+of	O
+amyloid	B-PRGE
+-	I-PRGE
+protein	B-CHED
+aggregation	O
+are	O
+reported	O
+.	O
+
+These	O
+results	O
+support	O
+the	O
+idea	B-SPEC
+of	O
+bats	B-SPEC
+as	O
+an	O
+evolutionary	O
+origin	O
+for	O
+PEDV	B-SPEC
+,	O
+implicate	O
+PEDV	B-SPEC
+as	O
+a	O
+potential	O
+threat	O
+to	O
+other	O
+species	B-SPEC
+,	O
+and	O
+suggest	O
+antiviral	B-CHED
+strategies	O
+to	O
+control	O
+its	O
+spread	O
+.	O
+
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+,	O
+caused	O
+by	O
+a	O
+coronavirus	B-SPEC
+,	O
+is	O
+highly	O
+lethal	O
+,	O
+with	O
+a	O
+case	O
+fatality	O
+rate	O
+of	O
+35	O
+to	O
+40	O
+%.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+viruses	B-SPEC
+associated	O
+with	O
+outbreaks	O
+of	O
+severe	O
+diarrhea	O
+in	O
+piglets	O
+in	O
+Jiangxi	O
+,	O
+China	O
+2013	O
+.	O
+
+Unlike	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+that	O
+resolved	O
+within	O
+a	O
+year	O
+,	O
+continued	O
+introductions	O
+of	O
+MERS	O
+-	O
+CoV	O
+present	O
+an	O
+on	O
+-	O
+going	O
+public	O
+health	O
+threat	O
+.	O
+
+We	O
+intended	O
+to	O
+demonstrate	O
+the	O
+incidence	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+detected	O
+by	O
+PCR	O
+and	O
+real	O
+-	O
+time	O
+PCR	O
+in	O
+adult	O
+patients	O
+with	O
+CAP	B-DISO
+.	O
+
+Incidences	O
+ranged	O
+from	O
+8	O
+.	O
+6	O
+to	O
+56	O
+.	O
+2	O
+%	O
+for	O
+overall	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Quarantine	O
+has	O
+been	O
+used	O
+for	O
+centuries	O
+in	O
+an	O
+effort	O
+to	O
+prevent	O
+the	O
+introduction	O
+,	O
+transmission	O
+,	O
+and	O
+spread	O
+of	O
+communicable	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	O
+)	O
+caused	O
+by	O
+novel	O
+Corona	B-CHED
+virus	B-SPEC
+hit	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+(	O
+KSA	O
+)	O
+and	O
+resulted	O
+in	O
+hundreds	O
+of	O
+mortality	O
+and	O
+morbidity	O
+,	O
+fears	O
+and	O
+psychosocial	O
+stress	O
+among	O
+population	O
+,	O
+economic	O
+loss	O
+and	O
+major	O
+political	O
+change	O
+at	O
+Ministry	O
+of	O
+Health	O
+(	O
+MoH	O
+).	O
+
+In	O
+2003	O
+,	O
+similar	O
+virus	B-SPEC
+(	O
+SARS	B-DISO
+)	O
+hit	O
+Canada	O
+and	O
+resulted	O
+in	O
+a	O
+reform	O
+of	O
+Canada	O
+'	O
+s	O
+public	O
+health	O
+system	O
+and	O
+creation	O
+of	O
+a	O
+Canadian	O
+Agency	O
+for	O
+Public	O
+Health	O
+,	O
+similar	O
+to	O
+the	O
+US	O
+Centers	O
+for	O
+Disease	O
+Control	O
+(	O
+CDC	O
+).	O
+
+We	O
+describe	O
+the	O
+discovery	O
+of	O
+a	O
+novel	O
+picornavirus	B-SPEC
+,	O
+dromedary	B-SPEC
+camel	B-SPEC
+enterovirus	B-SPEC
+(	O
+DcEV	O
+),	O
+from	O
+dromedaries	B-SPEC
+in	O
+Dubai	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+DcEV	O
+is	O
+a	O
+novel	O
+species	B-SPEC
+of	O
+the	O
+genus	B-SPEC
+Enterovirus	I-SPEC
+in	O
+the	O
+family	B-SPEC
+Picornaviridae	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+:	O
+another	O
+zoonotic	O
+betacoronavirus	B-SPEC
+causing	O
+SARS	B-DISO
+-	O
+like	O
+disease	O
+.	O
+
+Infectious	B-DISO
+virus	B-SPEC
+,	O
+however	O
+,	O
+was	O
+excreted	O
+from	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+indicating	O
+a	O
+potential	O
+route	O
+of	O
+MERS	O
+-	O
+CoV	O
+transmission	O
+in	O
+some	O
+animal	B-SPEC
+species	B-SPEC
+.	O
+
+Among	O
+these	O
+,	O
+nsp3	B-PRGE
+is	O
+the	O
+largest	O
+and	O
+the	O
+first	O
+to	O
+be	O
+inserted	O
+into	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+.	O
+
+In	O
+the	O
+first	O
+strategy	O
+,	O
+a	O
+mutant	B-DISO
+was	O
+created	O
+in	O
+which	O
+replicase	B-PRGE
+polyprotein	O
+translation	B-PROC
+initiated	O
+with	O
+nsp3	B-PRGE
+,	O
+thereby	O
+establishing	O
+that	O
+complete	O
+elimination	B-PROC
+of	O
+nsp1	B-PRGE
+and	O
+nsp2	B-PRGE
+does	O
+not	O
+abolish	O
+MHV	B-SPEC
+viability	O
+.	O
+
+ABSTRACT	O
+:	O
+Leptospirosis	B-DISO
+is	O
+a	O
+zoonosis	B-DISO
+caused	O
+by	O
+a	O
+pathogenic	O
+spirochete	B-SPEC
+""""	O
+leptospira	B-SPEC
+interrogans	I-SPEC
+.	O
+
+Severe	O
+form	O
+of	O
+leprospira	O
+infection	B-DISO
+is	O
+usually	O
+associated	O
+with	O
+jaundice	B-DISO
+and	O
+renal	B-ANAT
+involvement	O
+,	O
+leading	O
+to	O
+major	O
+hemorrhagic	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+Pathogenicity	O
+of	O
+2	O
+porcine	B-SPEC
+deltacoronavirus	O
+strains	O
+in	O
+gnotobiotic	O
+pigs	B-SPEC
+.	O
+
+These	O
+findings	O
+confirm	O
+that	O
+these	O
+2	O
+strains	O
+are	O
+enteropathogenic	O
+in	O
+pigs	B-SPEC
+.	O
+
+A	O
+few	O
+strategies	O
+to	O
+address	O
+the	O
+situation	O
+are	O
+:	O
+(	O
+i	O
+)	O
+improving	O
+preparedness	O
+with	O
+enhanced	O
+surveillance	O
+in	O
+particular	O
+regions	O
+;	O
+(	O
+ii	O
+)	O
+targeting	B-PROC
+certain	O
+sentinel	O
+groups	O
+for	O
+surveillance	O
+in	O
+hot	B-DISO
+spots	I-DISO
+;	O
+and	O
+(	O
+iii	O
+)	O
+limited	O
+use	O
+of	O
+serosurveillance	O
+.	O
+
+Examined	O
+strains	O
+had	O
+a	O
+hemagglutinin	O
+polymorphism	B-PROC
+associated	O
+with	O
+enhanced	O
+binding	B-FUNC
+to	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+receptors	O
+.	O
+
+The	O
+proportion	O
+of	O
+RVs	O
+in	O
+CAP	B-DISO
+is	O
+higher	O
+than	O
+previously	O
+reported	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+induces	O
+NF	O
+-	O
+κB	O
+activation	O
+through	O
+the	O
+TLR2	B-PRGE
+,	O
+TLR3	B-PRGE
+and	O
+TLR9	O
+pathways	B-PROC
+in	O
+porcine	B-SPEC
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+coronavirus	B-SPEC
+that	O
+induces	O
+persistent	O
+diarrhoea	B-DISO
+in	O
+swine	B-SPEC
+,	O
+resulting	O
+in	O
+severe	O
+economic	O
+losses	O
+in	O
+swine	B-SPEC
+-	O
+producing	O
+countries	O
+.	O
+
+Here	O
+,	O
+we	O
+elucidated	O
+for	O
+the	O
+first	O
+time	O
+to	O
+our	O
+knowledge	O
+the	O
+potential	O
+mechanism	O
+of	O
+PEDV	B-SPEC
+-	O
+mediated	O
+NF	O
+-	O
+κB	O
+activation	O
+in	O
+porcine	B-SPEC
+small	B-ANAT
+intestinal	I-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+IECs	O
+).	O
+
+Aerosol	O
+transmission	O
+is	O
+biologically	O
+plausible	O
+when	O
+infectious	B-DISO
+aerosols	O
+are	O
+generated	O
+by	O
+or	O
+from	O
+an	O
+infectious	B-DISO
+person	O
+,	O
+the	O
+pathogen	O
+remains	O
+viable	O
+in	O
+the	O
+environment	O
+for	O
+some	O
+period	O
+of	O
+time	O
+,	O
+and	O
+the	O
+target	O
+tissues	B-ANAT
+in	O
+which	O
+the	O
+pathogen	O
+initiates	O
+infection	B-DISO
+are	O
+accessible	O
+to	O
+the	O
+aerosol	O
+.	O
+
+RESULTS	O
+:	O
+An	O
+infectious	B-DISO
+aerosol	O
+is	O
+a	O
+collection	O
+of	O
+pathogen	O
+-	O
+laden	O
+particles	O
+in	O
+air	B-CHED
+.	O
+
+The	O
+pathogenesis	B-DISO
+of	O
+BP	O
+in	O
+dogs	B-SPEC
+is	O
+complex	O
+and	O
+the	O
+role	O
+of	O
+canine	O
+respiratory	O
+viruses	B-SPEC
+has	O
+not	O
+been	O
+fully	O
+evaluated	O
+.	O
+
+Canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+(	O
+CPIV	O
+),	O
+canine	B-SPEC
+adenovirus	I-SPEC
+,	O
+canine	O
+herpes	B-SPEC
+virus	I-SPEC
+,	O
+canine	O
+influenzavirus	O
+,	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+)	O
+and	O
+canine	O
+pneumovirus	B-SPEC
+,	O
+as	O
+well	O
+as	O
+B	O
+.	O
+bronchiseptica	O
+and	O
+Mycoplasma	B-PRGE
+spp	B-ENZY
+.	O
+were	O
+analyzed	O
+in	O
+respiratory	B-ANAT
+samples	I-ANAT
+using	O
+PCR	O
+assays	O
+.	O
+
+CPIV	O
+was	O
+detected	O
+in	O
+7	O
+/	O
+20	O
+and	O
+CRCoV	O
+in	O
+1	O
+/	O
+20	O
+dogs	B-SPEC
+with	O
+BP	O
+.	O
+
+Respiratory	O
+viruses	B-SPEC
+were	O
+not	O
+detected	O
+in	O
+dogs	B-SPEC
+with	O
+BBTB	O
+.	O
+
+Respiratory	O
+viruses	B-SPEC
+were	O
+found	O
+frequently	O
+in	O
+dogs	B-SPEC
+with	O
+BP	O
+and	O
+may	O
+therefore	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+etiology	O
+and	O
+pathogenesis	B-DISO
+of	O
+BP	O
+.	O
+
+Additionally	O
+,	O
+no	O
+association	O
+was	O
+observed	O
+between	O
+the	O
+polymorphisms	B-PROC
+and	O
+severity	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Resistance	B-PROC
+to	O
+rocuronium	B-CHED
+and	O
+cisatracurium	O
+in	O
+a	O
+patient	O
+with	O
+a	O
+spinal	O
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+case	O
+of	O
+resistance	B-PROC
+to	O
+rocuronium	B-CHED
+and	O
+cisatracurium	O
+in	O
+a	O
+patient	O
+with	O
+a	O
+spinal	O
+injury	O
+who	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+reported	O
+.	O
+
+As	O
+a	O
+last	O
+attempt	O
+to	O
+improve	O
+oxygenation	B-PROC
+,	O
+the	O
+patient	O
+received	O
+nitric	B-CHED
+oxide	I-CHED
+and	O
+sedation	B-DISO
+with	O
+propofol	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+Inadequate	O
+paralysis	O
+was	O
+achieved	O
+with	O
+rocuronium	B-CHED
+and	O
+cisatracurium	O
+in	O
+a	O
+patient	O
+who	O
+sustained	O
+a	O
+significant	O
+trauma	O
+resulting	O
+in	O
+quadriplegia	B-DISO
+.	O
+
+The	O
+effects	O
+of	O
+recruitment	B-DISO
+maneuvers	O
+on	O
+clinical	O
+outcomes	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+in	O
+patients	O
+with	O
+healthy	O
+lungs	B-ANAT
+undergoing	O
+major	O
+surgery	O
+were	O
+recently	O
+assessed	O
+.	O
+
+In	O
+addition	O
+,	O
+although	O
+recruitment	B-DISO
+maneuvers	O
+are	O
+being	O
+increasingly	O
+used	O
+,	O
+there	O
+remains	O
+a	O
+great	O
+deal	O
+of	O
+uncertainty	O
+regarding	O
+the	O
+precise	O
+way	O
+to	O
+evaluate	O
+the	O
+effect	O
+of	O
+recruitment	B-DISO
+.	O
+
+A	O
+multimodal	O
+and	O
+multiparametric	O
+approach	O
+could	O
+be	O
+a	O
+valuable	O
+option	O
+for	O
+bedside	O
+monitoring	O
+of	O
+recruitment	B-DISO
+maneuvers	O
+both	O
+in	O
+the	O
+ICU	O
+and	O
+in	O
+the	O
+operative	O
+room	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+Eastern	O
+Respiratory	O
+Syndrome	B-DISO
+Corona	B-CHED
+Virus	B-SPEC
+(	O
+MERS	O
+CoV	O
+):	O
+case	O
+reports	O
+from	O
+a	O
+tertiary	O
+care	O
+hospital	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+The	O
+diagnosis	O
+and	O
+treatment	O
+was	O
+delayed	O
+by	O
+an	O
+average	O
+of	O
+15	O
+days	O
+in	O
+those	O
+patients	O
+who	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Safety	O
+and	O
+efficacy	O
+of	O
+bronchoalveolar	O
+lavage	O
+using	O
+a	O
+laryngeal	B-ANAT
+mask	O
+airway	B-ANAT
+in	O
+cases	O
+of	O
+acute	O
+hypoxaemic	O
+respiratory	O
+failure	O
+with	O
+diffuse	O
+lung	B-ANAT
+infiltrates	B-DISO
+.	O
+
+The	O
+application	O
+of	O
+FOB	O
+-	O
+BAL	B-ENZY
+using	O
+a	O
+laryngeal	B-ANAT
+mask	O
+airway	B-ANAT
+(	O
+LMA	O
+)	O
+in	O
+combination	O
+with	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+CPAP	O
+)	O
+may	O
+minimize	O
+the	O
+incidence	O
+of	O
+hypoxaemia	O
+;	O
+however	O
+,	O
+the	O
+safety	O
+and	O
+efficacy	O
+of	O
+this	O
+procedure	O
+have	O
+not	O
+been	O
+investigated	O
+.	O
+
+Several	O
+proteases	O
+cluster	O
+into	O
+tetraspanin	B-PRGE
+-	O
+enriched	O
+microdomains	O
+(	O
+TEMs	O
+),	O
+suggesting	O
+that	O
+TEMs	O
+are	O
+preferred	O
+virus	B-SPEC
+entry	O
+portals	O
+.	O
+
+Thirteen	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+in	O
+the	O
+order	B-PRGE
+5	I-PRGE
+'-	I-PRGE
+UTR	I-PRGE
+-	I-PRGE
+1a	I-PRGE
+-	I-PRGE
+1ab	I-PRGE
+-	I-PRGE
+S	I-PRGE
+-	I-PRGE
+3a	I-PRGE
+-	I-PRGE
+3b	I-PRGE
+-	I-PRGE
+E	I-PRGE
+-	I-PRGE
+M	I-PRGE
+-	I-PRGE
+4b	I-PRGE
+-	I-PRGE
+4c	I-PRGE
+-	I-PRGE
+5a	I-PRGE
+-	I-PRGE
+5b	I-PRGE
+-	I-PRGE
+N	I-PRGE
+-	I-PRGE
+6b	I-PRGE
+-	I-PRGE
+3	I-PRGE
+'	I-PRGE
+UTR	I-PRGE
+were	O
+predicted	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+,	O
+designated	O
+as	O
+ck	O
+/	O
+CH	O
+/	O
+LHLJ	O
+/	O
+140906	O
+,	O
+was	O
+isolated	O
+from	O
+an	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strain	O
+H120	O
+-	O
+vaccinated	O
+chicken	B-SPEC
+flock	O
+,	O
+which	O
+presented	O
+with	O
+a	O
+suspected	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+infection	B-DISO
+.	O
+
+A	O
+phylogenetic	O
+analysis	O
+based	O
+on	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+clustered	O
+ck	O
+/	O
+CH	O
+/	O
+LHLJ	O
+/	O
+140906	O
+with	O
+the	O
+793	O
+/	O
+B	O
+group	O
+;	O
+however	O
+,	O
+a	O
+pairwise	O
+comparison	O
+showed	O
+that	O
+the	O
+5	O
+'	O
+terminal	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+(	O
+containing	O
+hypervariable	O
+regions	O
+I	O
+and	O
+II	O
+)	O
+had	O
+high	O
+sequence	O
+identity	O
+with	O
+the	O
+H120	O
+strain	O
+,	O
+while	O
+the	O
+3	O
+'	O
+terminal	O
+sequence	O
+was	O
+very	O
+similar	O
+to	O
+that	O
+of	O
+IBV	B-SPEC
+4	O
+/	O
+91	O
+strain	O
+.	O
+
+Although	O
+the	O
+isolate	O
+ck	O
+/	O
+CH	O
+/	O
+LHLJ	O
+/	O
+140906	O
+had	O
+slightly	O
+higher	O
+S1	O
+amino	O
+acid	O
+sequence	O
+identity	O
+to	O
+strain	O
+4	O
+/	O
+91	O
+(	O
+88	O
+.	O
+2	O
+%)	O
+than	O
+to	O
+strain	O
+H120	O
+(	O
+86	O
+%),	O
+the	O
+serotype	O
+of	O
+the	O
+virus	B-SPEC
+was	O
+more	O
+closely	O
+related	O
+to	O
+that	O
+of	O
+the	O
+H120	O
+strain	O
+(	O
+32	O
+%	O
+antigenic	O
+relatedness	O
+)	O
+than	O
+to	O
+the	O
+4	O
+/	O
+91	O
+strain	O
+(	O
+15	O
+%	O
+antigenic	O
+relatedness	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+ΔWBC	O
+(	O
+the	O
+ratio	O
+between	O
+DIFF	O
+and	O
+BASO	O
+counts	O
+of	O
+the	O
+Sysmex	O
+XT	O
+-	O
+2000iV	O
+),	O
+hereafter	O
+defined	O
+as	O
+ΔTNC	O
+(	O
+total	O
+nucleated	O
+cells	B-COMP
+),	O
+is	O
+high	O
+in	O
+effusions	B-DISO
+due	O
+to	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+as	O
+cells	B-COMP
+are	O
+entrapped	O
+in	O
+fibrin	O
+clots	B-DISO
+formed	O
+in	O
+the	O
+BASO	O
+reagent	B-CHED
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+diagnostic	O
+accuracy	O
+for	O
+FIP	B-DISO
+and	O
+the	O
+optimal	O
+cutoff	O
+of	O
+ΔTNC	O
+.	O
+
+The	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+phenylpropanoid	B-CHED
+derivatives	O
+had	O
+been	O
+discussed	O
+,	O
+which	O
+were	O
+useful	O
+for	O
+phenylpropanoid	B-CHED
+derivatives	O
+to	O
+be	O
+explored	O
+and	O
+developed	O
+as	O
+novel	O
+anti	B-CHED
+-	I-CHED
+HBV	I-CHED
+agents	I-CHED
+.	O
+
+Pre	O
+-	O
+HCT	O
+and	O
+weekly	O
+post	O
+-	O
+HCT	O
+nasal	B-ANAT
+washes	O
+were	O
+collected	O
+through	O
+day	O
+100	O
+from	O
+patients	O
+with	O
+and	O
+without	O
+symptoms	O
+.	O
+
+These	O
+data	O
+support	O
+routine	O
+testing	O
+for	O
+respiratory	O
+viruses	B-SPEC
+among	O
+symptomatic	O
+patients	O
+before	O
+HCT	O
+,	O
+and	O
+delay	O
+of	O
+transplant	B-ANAT
+with	O
+virus	B-SPEC
+detection	O
+when	O
+feasible	O
+,	O
+even	O
+for	O
+detection	O
+of	O
+rhinovirus	B-SPEC
+alone	O
+.	O
+
+We	O
+conducted	O
+a	O
+retrospective	O
+analysis	O
+of	O
+a	O
+cluster	O
+of	O
+patients	O
+diagnosed	O
+with	O
+or	O
+suspected	O
+of	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+infection	B-DISO
+in	O
+the	O
+period	O
+from	O
+December	O
+2010	O
+to	O
+March	O
+2011	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+blastomycosis	B-DISO
+-	O
+related	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+case	O
+series	O
+.	O
+
+Many	O
+patients	O
+with	O
+sepsis	B-DISO
+are	O
+unable	O
+to	O
+provide	O
+nutrition	B-PROC
+for	O
+themselves	O
+,	O
+and	O
+therefore	O
+initiating	O
+artificial	O
+nutrition	B-PROC
+has	O
+become	O
+part	O
+of	O
+routine	O
+care	O
+for	O
+these	O
+patients	O
+.	O
+
+The	O
+best	O
+recommendations	O
+have	O
+to	O
+be	O
+extrapolated	O
+from	O
+studies	O
+in	O
+heterogeneous	O
+populations	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+or	O
+in	O
+those	O
+with	O
+syndromes	B-DISO
+such	O
+as	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+where	O
+sepsis	B-DISO
+is	O
+a	O
+common	O
+predisposing	O
+etiology	O
+.	O
+
+Thus	O
+,	O
+the	O
+efficient	O
+incorporation	O
+of	O
+viral	B-PRGE
+envelope	I-PRGE
+proteins	B-CHED
+into	O
+CoV	O
+virions	B-COMP
+depends	O
+on	O
+protein	B-PROC
+trafficking	B-PROC
+and	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+near	O
+the	O
+ERGIC	B-COMP
+.	O
+
+The	O
+goal	O
+of	O
+this	O
+review	O
+is	O
+to	O
+summarize	O
+recent	O
+findings	O
+on	O
+the	O
+mechanism	O
+of	O
+incorporation	O
+of	O
+the	O
+M	B-PRGE
+and	I-PRGE
+S	I-PRGE
+glycoproteins	I-PRGE
+into	O
+the	O
+CoV	O
+virion	B-COMP
+,	O
+focusing	O
+on	O
+protein	B-PROC
+trafficking	B-PROC
+and	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+.	O
+
+However	O
+,	O
+decreased	O
+fidelity	O
+is	O
+detrimental	O
+to	O
+CoV	O
+replication	O
+and	O
+virulence	B-PROC
+;	O
+mutant	B-DISO
+CoVs	O
+with	O
+decreased	O
+replication	O
+fidelity	O
+are	O
+attenuated	O
+and	O
+more	O
+sensitive	O
+to	O
+inhibition	B-PROC
+by	O
+RNA	O
+mutagens	B-CHED
+.	O
+
+In	O
+light	O
+of	O
+the	O
+recent	O
+surge	O
+in	O
+reported	O
+infections	B-DISO
+we	O
+have	O
+developed	O
+asymmetric	O
+five	O
+-	O
+primer	O
+reverse	B-PROC
+transcription	I-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+assays	O
+for	O
+detection	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Isothermal	O
+amplification	B-DISO
+assays	O
+will	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+portable	O
+point	O
+-	O
+of	O
+-	O
+care	O
+diagnostics	O
+that	O
+are	O
+crucial	O
+for	O
+management	O
+of	O
+emerging	O
+infections	B-DISO
+.	O
+
+The	O
+following	O
+criteria	O
+were	O
+used	O
+to	O
+establish	O
+a	O
+diagnosis	O
+of	O
+SIADH	B-DISO
+:	O
+urine	B-ANAT
+sodium	O
+level	O
+of	O
+40	O
+mmol	O
+/	O
+L	O
+or	O
+greater	O
+,	O
+urine	B-ANAT
+osmolarity	O
+above	O
+500	O
+mosm	O
+/	O
+Kg	O
+,	O
+and	O
+urine	B-ANAT
+density	O
+of	O
+1020	O
+g	O
+/	O
+L	O
+or	O
+greater	O
+.	O
+
+A	O
+comparison	O
+was	O
+made	O
+between	O
+those	O
+patients	O
+that	O
+met	B-CHED
+urine	B-ANAT
+SIADH	B-DISO
+criteria	O
+and	O
+those	O
+who	O
+did	O
+not	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+126	O
+children	O
+were	O
+included	O
+,	O
+and	O
+23	O
+(	O
+18	O
+.	O
+6	O
+%)	O
+of	O
+them	O
+had	O
+urine	B-ANAT
+SIADH	B-DISO
+criteria	O
+.	O
+
+Prevalence	O
+of	O
+septic	B-DISO
+shock	I-DISO
+was	O
+higher	O
+in	O
+the	O
+group	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+large	O
+TPBT	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+retrospective	O
+cohort	O
+study	O
+was	O
+preformed	O
+aiming	O
+to	O
+verify	O
+the	O
+presence	O
+of	O
+transient	O
+dysfunction	O
+of	O
+gas	O
+exchange	O
+in	O
+the	O
+postoperative	O
+period	O
+of	O
+cardiac	B-ANAT
+surgery	O
+and	O
+determine	O
+if	O
+this	O
+disorder	O
+is	O
+linked	O
+to	O
+cardiorespiratory	O
+events	O
+.	O
+
+Severe	O
+transient	O
+dysfunction	O
+of	O
+gas	B-ENZY
+exchange	O
+was	O
+associated	O
+with	O
+patients	O
+who	O
+had	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0005	O
+),	O
+hemotherapy	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0001	O
+),	O
+enteral	O
+nutrition	B-PROC
+(	O
+P	O
+=	O
+0	O
+.	O
+0012	O
+),	O
+or	O
+cardiac	B-DISO
+arrhythmia	I-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+0451	O
+).	O
+
+ABSTRACT	O
+:	O
+Tracheal	O
+injury	O
+is	O
+a	O
+rare	O
+but	O
+highly	O
+morbid	O
+complication	B-DISO
+of	O
+endotracheal	O
+intubation	O
+.	O
+
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+carries	O
+a	O
+high	O
+mortality	O
+rate	O
+in	O
+patients	O
+who	O
+require	O
+ICU	O
+admission	O
+,	O
+with	O
+a	O
+significant	O
+number	O
+of	O
+patients	O
+developing	O
+MOSF	O
+.	O
+
+In	O
+the	O
+cross	O
+-	O
+sectional	O
+serosurvey	O
+,	O
+we	O
+tested	O
+human	B-SPEC
+serum	B-COMP
+samples	O
+obtained	O
+from	O
+healthy	O
+individuals	O
+older	O
+than	O
+15	O
+years	O
+who	O
+attended	O
+primary	O
+health	O
+-	O
+care	O
+centres	O
+or	O
+participated	O
+in	O
+a	O
+national	O
+burden	O
+-	O
+of	O
+-	O
+disease	O
+study	O
+in	O
+all	O
+13	O
+provinces	O
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+Samples	O
+were	O
+screened	O
+by	O
+recombinant	O
+ELISA	O
+and	O
+MERS	O
+-	O
+CoV	O
+seropositivity	O
+was	O
+confirmed	O
+by	O
+recombinant	O
+immunofluorescence	O
+and	O
+plaque	B-DISO
+reduction	O
+neutralisation	O
+tests	O
+.	O
+
+The	O
+mean	O
+age	O
+of	O
+seropositive	O
+individuals	O
+was	O
+significantly	O
+younger	O
+than	O
+that	O
+of	O
+patients	O
+with	O
+reported	O
+,	O
+laboratory	O
+-	O
+confirmed	O
+,	O
+primary	O
+Middle	O
+Eastern	O
+respiratory	O
+syndrome	B-DISO
+(	O
+43	O
+·	O
+5	O
+years	O
+[	O
+SD	O
+17	O
+·	O
+3	O
+]	O
+vs	O
+53	O
+·	O
+8	O
+years	O
+[	O
+17	O
+·	O
+5	O
+];	O
+p	O
+=	O
+0	O
+·	O
+008	O
+).	O
+
+Seroprevalence	O
+of	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+was	O
+significantly	O
+higher	O
+in	O
+camel	B-SPEC
+-	O
+exposed	O
+individuals	O
+than	O
+in	O
+the	O
+general	O
+population	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+and	O
+dehydration	B-DISO
+in	O
+suckling	O
+pigs	B-SPEC
+and	O
+has	O
+caused	O
+high	O
+rates	O
+of	O
+death	B-PROC
+among	O
+piglets	O
+and	O
+substantial	O
+economic	O
+loss	O
+in	O
+Vietnam	O
+since	O
+2009	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+emergence	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	O
+)	O
+highlights	O
+the	O
+need	O
+to	O
+engineer	O
+new	O
+methods	O
+for	O
+expediting	O
+vaccine	O
+development	B-PROC
+against	O
+emerging	O
+diseases	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Rescue	O
+of	O
+the	O
+recombinant	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+with	O
+the	O
+ectodomain	O
+region	O
+of	O
+H120	B-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+].	O
+
+A	O
+syncytium	B-ANAT
+was	O
+not	O
+observed	O
+until	O
+the	O
+recombinant	O
+virus	B-SPEC
+had	O
+passed	O
+through	O
+four	O
+passages	O
+.	O
+
+Western	O
+blot	O
+analysis	O
+of	O
+rBeau	O
+-	O
+H120	O
+(	O
+S1	O
+)-	O
+infected	O
+Vero	O
+cell	O
+lysates	O
+demonstrated	O
+that	O
+the	O
+nucleocapsid	B-PRGE
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+was	O
+expressed	B-PROC
+,	O
+which	O
+implied	O
+that	O
+rBeau	O
+-	O
+H120	O
+(	O
+S1	O
+)	O
+could	O
+propagate	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+TCIDs0	O
+and	O
+EIDs0	O
+data	O
+demonstrated	O
+that	O
+the	O
+titer	O
+levels	O
+of	O
+rBeau	O
+-	O
+H120	O
+(	O
+S1	O
+)	O
+reached	O
+10	O
+(	O
+590	O
++/-	O
+0	O
+.	O
+22	O
+)	O
+TCID50	O
+/	O
+mL	O
+and	O
+10	O
+(	O
+6	O
+.	O
+13	O
++/-	O
+0	O
+.	O
+23	O
+)	O
+EID50	O
+/	O
+mL	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+and	O
+9	O
+-	O
+day	O
+-	O
+old	O
+SPF	B-PRGE
+chicken	I-PRGE
+embryos	B-ANAT
+,	O
+respectively	O
+.	O
+
+Inoculation	O
+provided	O
+an	O
+85	O
+%	O
+rate	O
+of	O
+immune	O
+protection	O
+against	O
+a	O
+challenge	O
+of	O
+the	O
+virulent	O
+IBV	B-SPEC
+M41	O
+strain	O
+(	O
+103EID50	O
+/	O
+chicken	B-SPEC
+).	O
+
+Here	O
+we	O
+optimized	O
+the	O
+doses	O
+of	O
+S377	O
+-	O
+588	O
+-	O
+Fc	O
+using	O
+MF59	O
+as	O
+an	O
+adjuvant	B-CHED
+in	O
+order	B-SPEC
+to	O
+elicit	O
+strong	O
+immune	B-PROC
+responses	I-PROC
+with	O
+minimal	O
+amount	O
+of	O
+antigen	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+of	O
+serious	O
+respiratory	B-DISO
+complications	I-DISO
+in	O
+PICU	B-SPEC
+in	O
+children	O
+with	O
+measles	B-PATH
+].	O
+
+Laryngitis	B-DISO
+needed	O
+long	O
+time	O
+to	O
+cure	O
+and	O
+had	O
+weaning	B-PROC
+difficulties	O
+,	O
+and	O
+the	O
+case	O
+associated	O
+with	O
+pleural	B-DISO
+effusion	I-DISO
+or	O
+bronchopleural	B-DISO
+fistula	I-DISO
+must	O
+be	O
+treated	O
+with	O
+surgery	O
+,	O
+and	O
+the	O
+patients	O
+easily	O
+develop	O
+secondary	O
+bacterial	B-DISO
+infection	I-DISO
+.	O
+
+To	O
+evaluate	O
+clinical	O
+features	O
+,	O
+lab	O
+values	O
+,	O
+and	O
+outcome	O
+in	O
+patients	O
+with	O
+scrub	B-DISO
+typhus	I-DISO
+and	O
+comparison	O
+in	O
+patients	O
+with	O
+or	O
+without	O
+ARDS	B-DISO
+.	O
+
+Among	O
+24	O
+Scrub	B-DISO
+typhus	I-DISO
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+22	O
+patients	O
+recovered	O
+,	O
+and	O
+2	O
+patients	O
+died	B-PROC
+.	O
+
+Early	O
+diagnosis	O
+and	O
+treatment	O
+with	O
+doxycycline	B-CHED
+can	O
+prevent	O
+the	O
+occurrence	O
+of	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Guillain	B-DISO
+-	I-DISO
+Barre	I-DISO
+syndrome	I-DISO
+(	O
+GBS	B-DISO
+)	O
+is	O
+a	O
+common	O
+cause	O
+of	O
+acute	O
+flaccid	B-DISO
+paralysis	I-DISO
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Diffuse	O
+parenchymal	O
+lung	B-DISO
+disease	I-DISO
+as	O
+first	O
+clinical	O
+manifestation	O
+of	O
+GATA	B-PRGE
+-	I-PRGE
+2	I-PRGE
+deficiency	O
+in	O
+childhood	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+a	O
+17	O
+-	O
+year	O
+-	O
+old	O
+previously	O
+healthy	O
+Caucasian	O
+male	O
+who	O
+was	O
+admitted	O
+to	O
+the	O
+hospital	O
+with	O
+fever	B-PROC
+,	O
+malaise	B-DISO
+,	O
+headache	B-DISO
+,	I-DISO
+cough	I-DISO
+and	O
+dyspnea	B-DISO
+.	O
+
+Lung	B-ANAT
+tissue	I-ANAT
+biopsy	O
+revealed	O
+chronic	O
+reparative	O
+and	O
+resorptive	O
+reaction	O
+with	O
+organizing	O
+vasculitis	B-DISO
+.	O
+
+Within	O
+a	O
+short	O
+time	O
+period	O
+,	O
+confirmed	O
+disease	O
+was	O
+present	O
+on	O
+multiple	O
+sites	O
+within	O
+and	O
+across	O
+breeding	B-PROC
+and	O
+post	O
+weaning	B-PROC
+production	O
+flows	O
+of	O
+the	O
+operation	O
+and	O
+mortality	O
+approached	O
+100	O
+%	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+a	O
+highly	O
+pathogenic	O
+and	O
+transmissible	O
+virus	B-SPEC
+in	O
+swine	B-SPEC
+,	O
+was	O
+first	O
+detected	O
+in	O
+the	O
+U	O
+.	O
+S	O
+.	O
+in	O
+May	O
+,	O
+2013	O
+,	O
+and	O
+has	O
+caused	O
+tremendous	O
+losses	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+Inactivated	O
+adjuvanted	O
+monovalent	O
+vaccines	O
+were	O
+administered	O
+intramuscularly	O
+to	O
+five	O
+week	O
+old	O
+pigs	B-SPEC
+in	O
+a	O
+dose	O
+titration	O
+experimental	O
+design	O
+,	O
+ranging	O
+from	O
+6	O
+.	O
+0	O
+-	O
+8	O
+.	O
+0	O
+log10	O
+tissue	B-ANAT
+culture	O
+infective	O
+dose	O
+(	O
+TCID50	O
+/	O
+mL	O
+),	O
+to	O
+evaluate	O
+immunogenicity	O
+using	O
+a	O
+fluorescent	O
+foci	O
+neutralization	O
+assay	O
+(	O
+FFN	O
+),	O
+fluorescent	O
+microsphere	O
+immunoassay	O
+(	O
+FMIA	O
+),	O
+and	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+on	O
+sera	B-COMP
+.	O
+
+Various	O
+types	O
+of	O
+RMs	O
+such	O
+as	O
+sustained	O
+inflation	O
+at	O
+high	O
+pressure	O
+,	O
+intermittent	O
+sighs	B-DISO
+and	O
+stepwise	O
+increases	O
+of	O
+PEEP	B-CHED
+and	O
+/	O
+or	O
+airway	B-ANAT
+plateau	O
+inspiratory	B-PROC
+pressure	O
+have	O
+been	O
+proposed	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+standardized	O
+trauma	O
+-	O
+related	O
+lung	B-ANAT
+injury	O
+model	O
+.	O
+
+Given	O
+the	O
+invasiveness	O
+and	O
+the	O
+ease	O
+of	O
+the	O
+procedure	O
+,	O
+introduction	O
+of	O
+dual	O
+-	O
+lumen	B-ANAT
+catheters	O
+adequately	O
+sized	O
+for	O
+pediatric	O
+patients	O
+in	O
+Japan	O
+is	O
+required	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+(	O
+ACP	B-DISO
+)	O
+and	O
+patent	B-DISO
+foramen	I-DISO
+ovale	I-DISO
+(	O
+PFO	B-CHED
+)	O
+remain	O
+common	O
+in	O
+patients	O
+under	O
+protective	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+In	O
+this	O
+32	O
+-	O
+month	O
+prospective	O
+multicenter	O
+study	O
+,	O
+195	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+were	O
+assessed	O
+using	O
+echocardiography	O
+during	O
+the	O
+first	O
+48	O
+h	O
+of	O
+admission	O
+(	O
+age	O
+:	O
+56	O
+(	O
+SD	O
+:	O
+15	O
+)	O
+years	O
+;	O
+Simplified	O
+Acute	O
+Physiology	O
+Score	O
+:	O
+46	O
+(	O
+17	O
+);	O
+PaO2	O
+/	O
+FiO2	O
+:	O
+115	O
+(	O
+39	O
+);	O
+VT	O
+:	O
+6	O
+.	O
+5	O
+(	O
+1	O
+.	O
+7	O
+)	O
+mL	O
+/	O
+kg	O
+;	O
+PEEP	B-CHED
+:	O
+11	O
+(	O
+3	O
+)	O
+cmH2O	O
+;	O
+driving	O
+pressure	O
+:	O
+15	O
+(	O
+5	O
+)	O
+cmH2O	O
+).	O
+
+ACP	B-DISO
+was	O
+defined	O
+by	O
+the	O
+association	O
+of	O
+right	O
+ventricular	B-ANAT
+(	O
+RV	O
+)	O
+dilatation	B-DISO
+and	O
+systolic	O
+paradoxical	O
+ventricular	B-ANAT
+septal	O
+motion	O
+.	O
+
+Despite	O
+elevated	O
+sPAP	O
+,	O
+PFO	B-CHED
+shunting	O
+was	O
+associated	O
+with	O
+preserved	O
+RV	O
+systolic	O
+function	O
+.	O
+
+Within	O
+24	O
+hours	O
+after	O
+the	O
+onset	O
+of	O
+ARDS	B-DISO
+,	O
+the	O
+changes	O
+of	O
+peripheral	O
+circulating	O
+Th17	O
+and	O
+Treg	B-ANAT
+cell	I-ANAT
+frequencies	O
+gradually	O
+increased	O
+from	O
+mild	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+At	O
+baseline	O
+,	O
+48	O
+patients	O
+had	O
+mild	O
+to	O
+severe	O
+ARDS	B-DISO
+according	O
+to	O
+Berlin	O
+and	O
+87	O
+according	O
+to	O
+LIS	B-FUNC
+(	O
+Rs	O
+=	O
+0	O
+.	O
+54	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+day	O
+-	O
+by	O
+-	O
+day	O
+Berlin	O
+and	O
+LIS	B-FUNC
+categories	O
+were	O
+inversely	O
+associated	O
+with	O
+albumin	B-PRGE
+levels	O
+(	O
+P	O
+=	O
+0	O
+.	O
+01	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+directly	O
+with	O
+CRP	B-PRGE
+levels	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+,	O
+respectively	O
+).	O
+
+Low	O
+albumin	B-PRGE
+levels	O
+had	O
+monitoring	O
+value	O
+for	O
+ARDS	B-DISO
+severity	O
+on	O
+all	O
+study	O
+days	O
+(	O
+area	O
+under	O
+the	O
+receiver	O
+operating	O
+characteristic	O
+curve	O
+,	O
+AUROC	O
+,	O
+0	O
+.	O
+62	O
+-	O
+0	O
+.	O
+82	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+-	O
+0	O
+.	O
+03	O
+),	O
+whereas	O
+supranormal	O
+CRP	B-PRGE
+levels	O
+performed	O
+less	O
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+that	O
+the	O
+Malagasy	O
+strains	O
+belong	O
+to	O
+the	O
+genus	B-SPEC
+Betacoronavirus	B-SPEC
+but	O
+form	O
+three	O
+distinct	O
+clusters	B-CHED
+,	O
+which	O
+seem	O
+to	O
+represent	O
+previously	O
+undescribed	O
+genetic	O
+lineages	O
+.	O
+
+Our	O
+nsp14	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+typing	O
+(	O
+nsp14	O
+aa	O
+ST	O
+)	O
+showed	O
+that	O
+the	O
+FCoV	O
+clone	O
+with	O
+sequence	O
+type	O
+(	O
+ST	O
+)	O
+42	O
+,	O
+which	O
+was	O
+the	O
+most	O
+predominant	O
+genotype	O
+of	O
+WGS	O
+strains	O
+,	O
+was	O
+prevalent	O
+in	O
+domestic	B-SPEC
+cats	I-SPEC
+in	O
+Japan	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+active	O
+compound	O
+c26	O
+dose	O
+-	O
+dependently	O
+inhibited	O
+ERK	B-FUNC
+phosphorylation	B-PROC
+.	O
+
+Meanwhile	O
+,	O
+compound	O
+c26	O
+reduced	O
+the	O
+LPS	B-DISO
+-	O
+induced	O
+inflammatory	O
+gene	B-PROC
+expression	I-PROC
+in	O
+human	B-SPEC
+pulmonary	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+)	O
+A43	O
+predominated	O
+.	O
+
+No	O
+mixed	O
+respiratory	B-DISO
+virus	I-DISO
+infection	I-DISO
+was	O
+found	O
+.	O
+
+RESULTS	O
+:	O
+Respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+61	O
+.	O
+3	O
+%	O
+of	O
+the	O
+subjects	O
+,	O
+most	O
+of	O
+whom	O
+had	O
+ARI	B-CHED
+(	O
+90	O
+.	O
+8	O
+%,	O
+OR	O
+=	O
+11	O
+.	O
+39	O
+),	O
+were	O
+hospitalized	O
+(	O
+96	O
+.	O
+9	O
+%,	O
+OR	O
+=	O
+22	O
+.	O
+31	O
+),	O
+had	O
+asthma	B-PATH
+exacerbation	O
+(	O
+90	O
+.	O
+9	O
+%,	O
+OR	O
+=	O
+8	O
+.	O
+67	O
+),	O
+and	O
+/	O
+or	O
+had	O
+pneumonia	B-DISO
+(	O
+80	O
+%,	O
+OR	O
+=	O
+4	O
+.	O
+0	O
+).	O
+
+The	O
+primary	O
+goal	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+the	O
+incidence	O
+and	O
+extent	O
+of	O
+hypoxemia	O
+in	O
+intubated	O
+trauma	O
+patients	O
+who	O
+develop	O
+early	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+(	O
+VAP	O
+)	O
+secondary	O
+to	O
+HSB	O
+.	O
+
+Collected	O
+variables	O
+included	O
+day	O
+of	O
+HSBP	O
+diagnosis	O
+;	O
+PaO2	O
+to	O
+FIO2	O
+ratio	O
+(	O
+P	O
+:	O
+F	O
+)	O
+at	O
+HSBP	B-PRGE
+diagnosis	O
+as	O
+well	O
+as	O
+HSBP	B-PRGE
+day	O
+three	O
+and	O
+HSBP	O
+day	O
+seven	O
+;	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+and	O
+its	O
+component	O
+parts	O
+;	O
+admission	O
+Glasgow	O
+Coma	O
+Scale	O
+(	O
+GCS	O
+)	O
+score	O
+;	O
+and	O
+mortality	O
+.	O
+
+Forty	O
+-	O
+three	O
+percent	O
+of	O
+patients	O
+had	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+on	O
+HSBP	B-PRGE
+day	I-PRGE
+1	I-PRGE
+;	O
+this	O
+decreased	O
+to	O
+26	O
+%	O
+on	O
+day	O
+three	O
+and	O
+to	O
+30	O
+%	O
+on	O
+day	O
+seven	O
+.	O
+
+Patients	O
+with	O
+hypoxemia	O
+were	O
+significantly	O
+less	O
+likely	O
+to	O
+have	O
+a	O
+severe	O
+head	B-ANAT
+injury	O
+(	O
+GCS	O
+<	O
+9	O
+),	O
+p	O
+<	O
+0	O
+.	O
+05	O
+.	O
+
+In	O
+summary	O
+,	O
+our	O
+studies	O
+revealed	O
+that	O
+heparan	B-CHED
+sulfate	I-CHED
+acts	O
+as	O
+the	O
+attachment	O
+factor	O
+of	O
+PEDV	B-SPEC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+IFN	B-PRGE
+-	I-PRGE
+α2a	I-PRGE
+or	O
+IFN	B-PRGE
+-	I-PRGE
+β1a	I-PRGE
+in	O
+combination	O
+with	O
+ribavirin	B-CHED
+to	O
+treat	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+pneumonia	B-DISO
+:	O
+a	O
+retrospective	O
+study	O
+.	O
+
+We	O
+retrospectively	O
+analysed	O
+32	O
+patients	O
+with	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+admitted	O
+between	O
+April	O
+2014	O
+and	O
+June	O
+2014	O
+,	O
+by	O
+positive	O
+respiratory	B-ANAT
+sample	I-ANAT
+RT	O
+-	O
+PCR	O
+.	O
+
+Older	O
+age	O
+and	O
+comorbid	O
+conditions	O
+may	O
+have	O
+contributed	O
+to	O
+the	O
+lack	O
+of	O
+efficacy	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+α2a	I-PRGE
+or	O
+IFN	B-PRGE
+-	I-PRGE
+β1a	I-PRGE
+with	O
+ribavirin	B-CHED
+in	O
+treating	O
+MERS	O
+-	O
+CoV	O
+.	O
+Absence	O
+of	O
+fever	B-PROC
+should	O
+not	O
+exclude	O
+MERS	O
+-	O
+CoV	O
+.	O
+RESULTS	O
+:	O
+The	O
+overall	O
+mortality	O
+rate	O
+was	O
+69	O
+%	O
+(	O
+22	O
+/	O
+32	O
+).	O
+
+Forty	O
+1	O
+-	O
+day	O
+-	O
+old	O
+boiler	O
+chicks	O
+were	O
+weighed	O
+and	O
+randomly	O
+divided	O
+into	O
+four	O
+groups	O
+,	O
+10	O
+birds	B-SPEC
+in	O
+each	O
+group	O
+:	O
+(	O
+i	O
+)	O
+control	O
+group	O
+fed	O
+with	O
+basal	O
+diet	O
+;	O
+(	O
+ii	O
+)	O
+DON	O
+group	O
+fed	O
+with	O
+basal	O
+diet	O
+artificially	O
+contaminated	O
+with	O
+10	O
+mg	O
+DON	O
+/	O
+kg	O
+feed	O
+;	O
+(	O
+iii	O
+)	O
+DON	O
++	O
+MFA	O
+group	O
+fed	O
+with	O
+basal	O
+diet	O
+contaminated	O
+with	O
+10	O
+mg	O
+DON	O
+/	O
+kg	O
+feed	O
+and	O
+supplemented	O
+with	O
+2	O
+.	O
+5	O
+kg	O
+of	O
+MFA	O
+/	O
+ton	O
+feed	O
+;	O
+and	O
+(	O
+iv	O
+)	O
+MFA	O
+group	O
+fed	O
+with	O
+basal	O
+diet	O
+supplemented	O
+with	O
+2	O
+.	O
+5	O
+kg	O
+of	O
+MFA	O
+/	O
+ton	O
+feed	O
+.	O
+
+At	O
+35	O
+days	O
+of	O
+age	O
+,	O
+birds	B-SPEC
+were	O
+slaughtered	O
+and	O
+blood	B-ANAT
+was	O
+collected	O
+for	O
+investigating	O
+the	O
+antibody	B-COMP
+titre	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+clinical	O
+chemical	O
+parameters	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+DON	O
+reduced	O
+(	O
+p	O
+=	O
+0	O
+.	O
+032	O
+)	O
+the	O
+titre	O
+against	O
+IBV	O
+,	O
+decreased	O
+(	O
+p	O
+=	O
+0	O
+.	O
+005	O
+)	O
+the	O
+level	O
+of	O
+alanine	B-PRGE
+transaminase	I-PRGE
+(	O
+ALT	B-FUNC
+)	O
+(	O
+4	O
+.	O
+2	O
+±	O
+0	O
+.	O
+5	O
+U	O
+/	O
+l	O
+)	O
+compared	O
+with	O
+control	O
+birds	B-SPEC
+(	O
+6	O
+.	O
+4	O
+±	O
+0	O
+.	O
+5	O
+U	O
+/	O
+l	O
+),	O
+increased	O
+(	O
+p	O
+=	O
+0	O
+.	O
+002	O
+)	O
+the	O
+serum	B-COMP
+cholesterol	B-CHED
+concentration	O
+(	O
+144	O
+±	O
+6	O
+mg	O
+/	O
+dl	O
+)	O
+compared	O
+with	O
+their	O
+control	O
+counterparts	O
+(	O
+123	O
+±	O
+5	O
+mg	O
+/	O
+dl	O
+)	O
+and	O
+increased	O
+(	O
+p	O
+=	O
+0	O
+.	O
+074	O
+)	O
+the	O
+amount	O
+of	O
+circulating	O
+triglycerides	B-CHED
+(	O
+62	O
+.	O
+25	O
+±	O
+7	O
+.	O
+50	O
+mg	O
+/	O
+dl	O
+)	O
+compared	O
+with	O
+controls	O
+(	O
+39	O
+.	O
+55	O
+±	O
+4	O
+.	O
+74	O
+).	O
+
+Following	O
+National	O
+Institute	O
+for	O
+Health	O
+Research	O
+'	O
+s	O
+Research	O
+Centre	O
+(	O
+London	O
+,	O
+United	O
+Kingdom	B-SPEC
+)	O
+approval	O
+,	O
+the	O
+authors	O
+of	O
+this	O
+study	O
+conducted	O
+a	O
+survey	O
+of	O
+specialist	O
+registrars	O
+'	O
+knowledge	O
+of	O
+the	O
+respiratory	O
+and	O
+skin	B-ANAT
+protection	O
+requirements	O
+needed	O
+during	O
+a	O
+resuscitation	O
+scenario	O
+with	O
+Advanced	O
+Life	O
+Support	O
+.	O
+
+The	O
+best	O
+knowledge	O
+of	O
+PPE	B-CHED
+requirements	O
+(	O
+76	O
+%)	O
+was	O
+found	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+with	O
+less	O
+knowledge	O
+about	O
+PPE	B-CHED
+requirements	O
+for	O
+anthrax	B-DISO
+,	O
+plague	B-DISO
+,	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+(	O
+EVD	O
+),	O
+and	O
+smallpox	B-DISO
+(	O
+60	O
+%).	O
+
+The	O
+information	O
+settings	O
+all	O
+took	O
+place	O
+within	O
+the	O
+College	O
+of	O
+Nursing	B-PROC
+,	O
+Princess	O
+Nourah	O
+University	O
+,	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+P6	O
+can	O
+promote	O
+the	O
+ubiquitin	B-PROC
+-	O
+dependent	O
+proteosomal	O
+degradation	O
+of	O
+Nmi	B-PRGE
+.	O
+
+The	O
+antiviral	B-CHED
+activity	O
+was	O
+confirmed	O
+through	O
+a	O
+plaque	B-DISO
+assay	O
+where	O
+viral	O
+titer	O
+reduction	O
+was	O
+observed	O
+in	O
+the	O
+presence	O
+of	O
+selected	O
+compounds	O
+.	O
+
+The	O
+delayed	O
+and	O
+/	O
+or	O
+lower	O
+antibody	B-PROC
+response	I-PROC
+combined	O
+with	O
+lower	O
+IgG	B-PRGE
+avidity	O
+indices	O
+coincided	O
+with	O
+increased	O
+tracheal	B-DISO
+inflammation	I-DISO
+and	O
+depletion	O
+of	O
+tracheal	O
+epithelia	O
+cells	B-COMP
+and	O
+goblet	B-ANAT
+cells	I-ANAT
+upon	O
+IBV	B-SPEC
+field	O
+strain	O
+challenge	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+ECMO	O
+in	O
+the	O
+Management	O
+of	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+:	O
+A	O
+Survey	O
+of	O
+Academic	O
+Medical	O
+Centers	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+ABSTRACT	O
+:	O
+Tumor	B-DISO
+lysis	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+serious	O
+and	O
+dangerous	O
+complication	B-DISO
+usually	O
+associated	O
+with	O
+antiblastic	O
+treatment	O
+in	O
+some	O
+malignancies	B-DISO
+characterized	O
+by	O
+high	O
+cell	B-COMP
+turn	O
+-	O
+over	O
+.	O
+
+Renal	B-ANAT
+damage	O
+can	O
+be	O
+followed	O
+by	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+weight	O
+gain	O
+,	O
+progressive	O
+liver	B-ANAT
+impairment	B-DISO
+,	O
+overproduction	O
+of	O
+cytokines	O
+,	O
+and	O
+subsequent	O
+maintenance	O
+of	O
+multi	O
+-	O
+organ	B-ANAT
+damage	O
+.	O
+
+TITLE	O
+:	O
+Pyogranulomatous	O
+panophthalmitis	B-DISO
+with	O
+systemic	O
+coronavirus	B-SPEC
+disease	O
+in	O
+a	O
+domestic	B-SPEC
+ferret	I-SPEC
+(	O
+Mustela	B-SPEC
+putorius	I-SPEC
+furo	I-SPEC
+).	O
+
+Most	O
+studies	O
+showed	O
+that	O
+,	O
+in	O
+response	O
+to	O
+a	O
+pulmonary	B-ANAT
+insult	O
+,	O
+increasing	O
+age	O
+is	O
+associated	O
+with	O
+more	O
+pulmonary	B-DISO
+inflammation	I-DISO
+,	O
+edema	B-DISO
+,	O
+alveolar	B-ANAT
+damage	O
+,	O
+and	O
+higher	O
+mortality	O
+.	O
+
+Therefore	O
+,	O
+we	O
+analyzed	O
+coagulation	B-PROC
+-	O
+related	O
+parameters	O
+,	O
+need	O
+for	O
+transfusion	O
+,	O
+and	O
+management	O
+of	O
+anticoagulation	B-PROC
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+during	O
+treatment	O
+with	O
+either	O
+pumpless	O
+interventional	O
+lung	B-ANAT
+assist	O
+(	O
+iLA	O
+)	O
+or	O
+veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+(	O
+vv	O
+-	O
+ECMO	O
+).	O
+
+Platelet	B-ANAT
+counts	O
+in	O
+ECMO	O
+-	O
+treated	O
+patients	O
+,	O
+but	O
+not	O
+in	O
+those	O
+treated	O
+with	O
+iLA	B-PRGE
+,	O
+dropped	O
+significantly	O
+during	O
+extracorporeal	O
+support	O
+.	O
+
+A	O
+more	O
+intense	O
+systemic	O
+anticoagulation	B-PROC
+with	O
+a	O
+mean	O
+activated	B-PRGE
+partial	I-PRGE
+thromboplastin	I-PRGE
+time	I-PRGE
+(	O
+aPTT	O
+)	O
+>	O
+53	O
+s	O
+led	O
+to	O
+a	O
+higher	O
+need	O
+for	O
+transfusions	O
+compared	O
+with	O
+the	O
+group	O
+with	O
+a	O
+mean	O
+aPTT	O
+<	O
+53	O
+s	O
+,	O
+whereas	O
+the	O
+average	O
+durability	O
+of	O
+membrane	B-COMP
+oxygenators	O
+was	O
+not	O
+affected	O
+.	O
+
+Data	O
+obtained	O
+from	O
+questionnaires	O
+,	O
+diaries	O
+and	O
+laboratory	O
+tests	O
+will	O
+be	O
+analysed	O
+to	O
+examine	O
+whether	O
+mask	O
+use	O
+significantly	O
+reduces	O
+the	O
+frequency	O
+of	O
+laboratory	O
+-	O
+confirmed	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+and	O
+syndromic	O
+RTI	B-DISO
+as	O
+primary	O
+outcomes	O
+.	O
+
+The	O
+SOFA	O
+showed	O
+the	O
+highest	O
+sensitivity	O
+and	O
+area	O
+under	O
+the	O
+curve	O
+(	O
+AUC	O
+)	O
+for	O
+predicting	O
+the	O
+prognosis	O
+of	O
+patients	O
+with	O
+MODS	B-DISO
+induced	O
+by	O
+acute	O
+exacerbation	O
+of	O
+COPD	B-DISO
+.	O
+
+The	O
+SOFA	O
+score	O
+,	O
+determined	O
+at	O
+the	O
+onset	O
+of	O
+MODS	B-DISO
+in	O
+elderly	O
+patients	O
+with	O
+COPD	B-DISO
+,	O
+was	O
+a	O
+reliable	O
+predictor	O
+of	O
+the	O
+prognosis	O
+.	O
+
+We	O
+evaluated	O
+effects	O
+of	O
+prone	O
+position	O
+duration	O
+and	O
+protective	O
+lung	B-ANAT
+strategies	O
+on	O
+mortality	O
+rates	O
+in	O
+ARDS	B-DISO
+.	O
+
+Prone	O
+positioning	O
+for	O
+ARDS	B-DISO
+patients	O
+should	O
+be	O
+prioritized	O
+over	O
+other	O
+invasive	O
+procedures	O
+because	O
+related	O
+life	O
+-	O
+threatening	O
+complications	O
+are	O
+rare	O
+.	O
+
+In	O
+a	O
+subgroup	O
+analysis	O
+,	O
+the	O
+mortality	O
+rates	O
+for	O
+lung	B-ANAT
+protective	O
+ventilation	O
+(	O
+RR	O
+0	O
+.	O
+73	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+62	O
+-	O
+0	O
+.	O
+86	O
+,	O
+P	O
+=	O
+0	O
+.	O
+0002	O
+)	O
+and	O
+duration	O
+of	O
+prone	O
+positioning	O
+>	O
+12	O
+h	O
+(	O
+RR	O
+0	O
+.	O
+75	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+65	O
+-	O
+0	O
+.	O
+87	O
+,	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+were	O
+reduced	O
+in	O
+the	O
+prone	O
+position	O
+.	O
+
+Hospitals	O
+have	O
+implemented	O
+measures	O
+related	O
+to	O
+healthcare	O
+-	O
+associated	O
+infections	B-DISO
+.	O
+
+A	O
+strong	O
+evidence	O
+-	O
+based	O
+policy	O
+framework	O
+is	O
+required	O
+to	O
+address	O
+healthcare	O
+-	O
+associated	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+One	O
+such	O
+approach	O
+(	O
+the	O
+Buxco	O
+platform	O
+)	O
+performs	O
+unrestrained	O
+whole	B-ANAT
+body	I-ANAT
+plethysmography	O
+on	O
+mice	B-SPEC
+which	O
+infers	O
+thoracic	B-DISO
+movements	B-PROC
+from	O
+pressure	O
+differences	O
+from	O
+the	O
+act	O
+of	O
+inhalation	B-PROC
+and	O
+exhalation	B-PROC
+.	O
+
+We	O
+provide	O
+a	O
+demonstration	O
+of	O
+the	O
+features	O
+of	O
+plethy	O
+using	O
+a	O
+dataset	O
+assessing	O
+the	O
+respiratory	O
+effects	O
+over	O
+time	O
+of	O
+SARS	B-DISO
+and	O
+Influenza	B-PATH
+infection	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+The	O
+patient	O
+remained	O
+in	O
+a	O
+comatose	B-DISO
+state	O
+with	O
+no	O
+signs	O
+of	O
+neurologic	O
+recovery	O
+until	O
+he	O
+died	B-PROC
+few	O
+weeks	O
+later	O
+following	O
+an	O
+increase	O
+in	O
+the	O
+brain	B-DISO
+edema	I-DISO
+and	O
+herniation	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+(	O
+PHEV	O
+)	O
+may	O
+mediate	O
+infection	B-DISO
+by	O
+binding	B-FUNC
+to	O
+a	O
+cellular	B-COMP
+neural	B-ANAT
+cell	I-ANAT
+adhesion	O
+molecule	O
+(	O
+NCAM	O
+).	O
+
+The	O
+distribution	O
+of	O
+respiratory	O
+viruses	B-SPEC
+was	O
+hMPV	B-SPEC
+:	O
+15	O
+(	O
+5	O
+.	O
+3	O
+%),	O
+Boca	B-DISO
+:	O
+14	O
+(	O
+4	O
+.	O
+9	O
+%),	O
+WUV	O
+:	O
+10	O
+(	O
+3	O
+.	O
+5	O
+%)	O
+and	O
+KIV	O
+:	O
+4	O
+(	O
+1	O
+.	O
+4	O
+%).	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+735	O
+patients	O
+,	O
+285	O
+(	O
+38	O
+.	O
+8	O
+%)	O
+were	O
+diagnosed	O
+with	O
+viral	O
+RTI	B-DISO
+.	O
+
+Flocks	O
+were	O
+classified	O
+into	O
+four	O
+groups	O
+according	O
+to	O
+their	O
+IBV	B-SPEC
+vaccination	O
+programme	O
+.	O
+
+Groups	O
+3	O
+and	O
+4	O
+birds	B-SPEC
+received	O
+one	O
+or	O
+two	O
+booster	O
+vaccination	O
+(	O
+s	O
+),	O
+respectively	O
+,	O
+mostly	O
+using	O
+the	O
+H120	O
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+(	O
+hCoV	O
+)	O
+HKU1	O
+is	O
+one	O
+of	O
+six	O
+hCoVs	O
+identified	O
+to	O
+date	O
+and	O
+the	O
+only	O
+one	O
+with	O
+an	O
+unidentified	O
+cellular	B-COMP
+receptor	O
+.	O
+
+hCoV	O
+-	O
+HKU1	O
+encodes	O
+a	O
+hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+(	O
+HE	O
+)	O
+protein	B-CHED
+that	O
+is	O
+unique	O
+to	O
+the	O
+group	O
+a	O
+betacoronaviruses	O
+(	O
+group	O
+2a	O
+).	O
+
+Pretreatment	O
+of	O
+RD	O
+cells	B-COMP
+with	O
+neuraminidase	B-PRGE
+(	O
+NA	O
+)	O
+and	O
+trypsin	B-PRGE
+greatly	O
+reduced	O
+the	O
+binding	B-FUNC
+,	O
+suggesting	O
+that	O
+the	O
+binding	B-FUNC
+was	O
+mediated	O
+by	O
+sialic	B-CHED
+acids	I-CHED
+on	O
+glycoproteins	B-CHED
+.	O
+
+However	O
+,	O
+unlike	O
+other	O
+group	O
+2a	O
+CoVs	O
+,	O
+e	O
+.	O
+g	O
+.,	O
+hCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+for	O
+which	O
+9	O
+-	O
+O	B-CHED
+-	I-CHED
+acetylated	I-CHED
+sialic	I-CHED
+acid	I-CHED
+(	O
+9	O
+-	O
+O	O
+-	O
+Ac	O
+-	O
+Sia	B-SPEC
+)	O
+serves	O
+as	O
+a	O
+receptor	O
+determinant	O
+,	O
+HKU1	O
+-	O
+S1	O
+bound	O
+with	O
+neither	O
+9	O
+-	O
+O	O
+-	O
+Ac	O
+-	O
+Sia	O
+-	O
+containing	O
+glycoprotein	B-CHED
+(	O
+s	O
+)	O
+nor	O
+rat	B-SPEC
+and	O
+mouse	B-SPEC
+erythrocytes	B-ANAT
+.	O
+
+Using	O
+primary	O
+human	B-SPEC
+ciliated	O
+airway	B-ANAT
+epithelial	O
+(	O
+HAE	O
+)	O
+cell	B-COMP
+cultures	O
+,	O
+the	O
+only	O
+in	O
+vitro	O
+replication	O
+model	O
+for	O
+hCoV	O
+-	O
+HKU1	O
+infection	B-DISO
+,	O
+we	O
+confirmed	O
+that	O
+pretreatment	O
+of	O
+HAE	O
+cells	B-COMP
+with	O
+HE	O
+but	O
+not	O
+the	O
+enzymatically	O
+inactive	O
+mutant	B-DISO
+blocked	O
+hCoV	O
+-	O
+HKU1	O
+infection	B-DISO
+.	O
+
+Among	O
+the	O
+six	O
+hCoVs	O
+identified	O
+to	O
+date	O
+,	O
+only	O
+hCoV	O
+-	O
+HKU1	O
+has	O
+no	O
+defined	O
+cellular	B-COMP
+receptor	O
+.	O
+
+Interestingly	O
+,	O
+the	O
+virus	B-SPEC
+seems	O
+to	O
+employ	O
+a	O
+type	O
+of	O
+sialic	B-CHED
+acid	I-CHED
+different	O
+from	O
+those	O
+employed	O
+by	O
+other	O
+group	O
+2a	O
+CoVs	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+determined	O
+that	O
+the	O
+HKU1	B-PRGE
+-	I-PRGE
+HE	I-PRGE
+protein	I-PRGE
+is	O
+an	O
+O	O
+-	O
+acetylesterase	B-ENZY
+and	O
+acts	O
+as	O
+a	O
+receptor	O
+-	O
+destroying	O
+enzyme	O
+(	O
+RDE	O
+)	O
+for	O
+hCoV	O
+-	O
+HKU1	O
+.	O
+
+Identification	O
+of	O
+EBOV	O
+VP35	O
+inhibitors	B-CHED
+requires	O
+a	O
+cellular	B-COMP
+system	O
+able	O
+to	O
+assess	O
+the	O
+VP35	O
+-	O
+based	O
+inhibitory	O
+functions	O
+of	O
+viral	O
+double	O
+-	O
+stranded	O
+RNA	O
+(	O
+dsRNA	B-CHED
+)	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+induction	O
+.	O
+
+This	O
+assay	O
+can	O
+be	O
+used	O
+to	O
+screen	O
+for	O
+EBOV	O
+VP35	O
+inhibitors	B-CHED
+.	O
+
+The	O
+high	O
+degree	O
+of	O
+homology	O
+within	O
+the	O
+protease	O
+'	O
+s	O
+active	O
+site	O
+and	O
+substrate	O
+conservation	O
+supports	O
+the	O
+identification	O
+of	O
+broad	O
+spectrum	O
+lead	B-CHED
+compounds	I-CHED
+.	O
+
+Molecular	O
+dynamics	O
+further	O
+confirmed	O
+ligand	B-PROC
+stability	O
+and	O
+hydrogen	B-CHED
+bonding	O
+networks	O
+.	O
+
+Further	O
+studies	O
+reproduced	O
+the	O
+binding	B-FUNC
+pose	O
+of	O
+16R	O
+within	O
+the	O
+active	O
+site	O
+of	O
+the	O
+generated	O
+model	O
+,	O
+where	O
+its	O
+free	O
+energy	O
+of	O
+binding	B-FUNC
+was	O
+shown	O
+to	O
+equal	O
+that	O
+of	O
+the	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+a	O
+receptor	O
+it	O
+is	O
+experimentally	O
+proven	O
+to	O
+inhibit	O
+.	O
+
+The	O
+lead	O
+compound	O
+16R	O
+may	O
+represent	O
+a	O
+broad	O
+-	O
+spectrum	O
+inhibitor	B-CHED
+of	O
+the	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+of	O
+OC43	O
+and	O
+potentially	O
+other	O
+coronaviruses	O
+.	O
+
+At	O
+present	O
+it	O
+is	O
+unknown	O
+whether	O
+the	O
+risk	O
+for	O
+respiratory	O
+disease	O
+(	O
+BRD	O
+)	O
+or	O
+neonatal	B-DISO
+calf	I-DISO
+diarrhea	I-DISO
+(	O
+NCD	O
+)	O
+in	O
+the	O
+veal	O
+herd	O
+is	O
+associated	O
+with	O
+total	O
+immunoglobulin	B-PROC
+(	O
+Ig	O
+)	O
+and	O
+/	O
+or	O
+on	O
+the	O
+serostatus	O
+for	O
+respiratory	O
+pathogens	O
+measured	O
+at	O
+arrival	O
+.	O
+
+Therefore	O
+,	O
+the	O
+first	O
+objective	O
+of	O
+this	O
+prospective	O
+longitudinal	O
+cohort	O
+study	O
+was	O
+to	O
+determine	O
+associations	O
+between	O
+serum	B-COMP
+protein	B-CHED
+fractions	O
+as	O
+determined	O
+by	O
+routine	O
+electrophoresis	O
+(	O
+total	O
+protein	B-CHED
+,	O
+albumin	B-PRGE
+,	O
+alpha	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	I-PRGE
+-	I-PRGE
+2	I-PRGE
+globulins	I-PRGE
+,	O
+beta	B-PRGE
+-	I-PRGE
+globulins	I-PRGE
+and	O
+Ig	O
+'	O
+s	O
+)	O
+at	O
+arrival	O
+and	O
+BRD	O
+and	O
+NCD	O
+in	O
+the	O
+first	O
+3	O
+weeks	O
+of	O
+the	O
+production	O
+cycle	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+pathogenesis	B-DISO
+of	O
+US	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+strain	O
+PC21A	O
+in	O
+conventional	O
+9	O
+-	O
+day	O
+-	O
+old	O
+nursing	O
+piglets	O
+vs	O
+.	O
+26	O
+-	O
+day	O
+-	O
+old	O
+weaned	B-PROC
+pigs	B-SPEC
+.	O
+
+Pigs	B-SPEC
+were	O
+monitored	O
+for	O
+clinical	O
+signs	O
+and	O
+PEDV	B-SPEC
+RNA	O
+titers	O
+in	O
+feces	B-ANAT
+and	O
+serum	B-COMP
+.	O
+
+Biologic	O
+mediators	O
+that	O
+promote	O
+crypt	B-ANAT
+stem	B-ANAT
+cell	I-ANAT
+regeneration	B-PROC
+would	O
+be	O
+targets	O
+to	O
+improve	O
+the	O
+intestinal	B-ANAT
+epithelium	I-ANAT
+renewal	O
+during	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Pigs	B-SPEC
+S1	O
+and	O
+S2	O
+were	O
+PEDV	B-SPEC
+-	O
+positive	O
+within	O
+24	O
+hours	O
+of	O
+commingling	O
+.	O
+
+All	O
+N	O
+/	O
+C	O
+pigs	B-SPEC
+were	O
+PEDV	B-SPEC
+PCR	O
+-	O
+positive	O
+by	O
+D52	O
+with	O
+detection	O
+out	O
+to	O
+D62	O
+in	O
+3	O
+/	O
+5	O
+N	O
+/	O
+C	O
+pigs	B-SPEC
+.	O
+
+Homologous	O
+re	O
+-	O
+challenge	O
+49	O
+days	O
+post	O
+initial	O
+PEDV	B-SPEC
+exposure	O
+did	O
+not	O
+result	O
+in	O
+re	O
+-	O
+infection	B-DISO
+of	O
+the	O
+pigs	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Outbreak	O
+of	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+in	O
+a	O
+Kidney	B-ANAT
+Transplant	I-ANAT
+Unit	O
+-	O
+Protective	O
+Effect	O
+of	O
+Vaccination	O
+.	O
+
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+had	O
+a	O
+high	O
+mortality	O
+in	O
+our	O
+cohort	O
+of	O
+nonvaccinated	O
+immunosuppressed	O
+patients	O
+early	O
+after	O
+kidney	B-ANAT
+transplantation	O
+.	O
+
+To	O
+accelerate	O
+the	O
+development	B-PROC
+of	O
+3	O
+CL	O
+(	O
+pro	B-CHED
+)	O
+inhibitors	B-CHED
+,	O
+three	O
+crystal	B-ANAT
+structures	O
+of	O
+a	O
+catalytically	O
+inactive	O
+variant	O
+(	O
+C148A	O
+)	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3	I-PRGE
+CL	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+enzyme	I-PRGE
+were	O
+determined	O
+.	O
+
+Viral	O
+RNA	O
+,	O
+histopathological	O
+changes	O
+,	O
+and	O
+viral	O
+nucleoprotein	O
+were	O
+observed	O
+in	O
+the	O
+lung	B-ANAT
+,	O
+trachea	B-DISO
+and	O
+sinus	B-DISO
+of	O
+all	O
+inoculated	O
+mice	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+full	O
+-	O
+length	O
+genome	O
+sequence	O
+of	O
+the	O
+prototype	O
+strain	O
+CB	O
+/	O
+05	O
+,	O
+which	O
+showed	O
+that	O
+this	O
+virus	B-SPEC
+is	O
+genetically	O
+similar	O
+to	O
+CCoV	O
+-	O
+IIa	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Differential	O
+Effects	O
+of	O
+Endotracheal	O
+Suctioning	O
+on	O
+Gas	B-ENZY
+Exchanges	O
+in	O
+Patients	O
+with	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+under	O
+Pressure	O
+-	O
+Controlled	O
+and	O
+Volume	O
+-	O
+Controlled	O
+Ventilation	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+inactivated	O
+vaccines	O
+induce	O
+a	O
+weaker	O
+immune	B-PROC
+response	I-PROC
+and	O
+may	O
+require	O
+multiple	O
+dosing	O
+and	O
+/	O
+or	O
+the	O
+use	O
+of	O
+adjuvants	B-CHED
+that	O
+probably	O
+have	O
+potential	O
+safety	O
+risks	O
+and	O
+increased	O
+economic	O
+burdens	O
+.	O
+
+The	O
+authors	O
+conducted	O
+a	O
+study	O
+to	O
+examine	O
+this	O
+phenomenon	O
+in	O
+patients	O
+with	O
+early	O
+phase	O
+of	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Hypertonic	O
+Saline	O
+(	O
+NaCl	B-CHED
+7	O
+.	O
+5	O
+%)	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+the	O
+most	O
+severe	O
+lung	B-ANAT
+inflammatory	O
+manifestation	O
+and	O
+has	O
+no	O
+effective	O
+therapy	O
+nowadays	O
+.	O
+
+Sepsis	B-DISO
+is	O
+one	O
+of	O
+the	O
+main	O
+illnesses	O
+among	O
+ARDS	B-DISO
+causes	O
+.	O
+
+Thus	O
+,	O
+we	O
+evaluated	O
+the	O
+effect	O
+of	O
+hypertonic	O
+saline	O
+in	O
+the	O
+treatment	O
+of	O
+LPS	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+The	O
+patient	O
+eventually	O
+recovered	O
+,	O
+and	O
+he	O
+was	O
+discharged	O
+after	O
+receiving	O
+antibiotics	B-CHED
+and	O
+other	O
+treatments	O
+to	O
+enhance	O
+immunity	B-PROC
+.	O
+
+TITLE	O
+:	O
+Muscle	B-ANAT
+pain	I-DISO
+,	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+and	O
+progressive	O
+dyspnea	B-DISO
+in	O
+a	O
+woman	O
+with	O
+eosinophilic	B-DISO
+pneumonia	I-DISO
+.	O
+
+A	O
+roundworm	B-DISO
+identified	O
+in	O
+the	O
+patient	O
+'	O
+s	O
+stool	B-ANAT
+confirmed	O
+the	O
+precise	O
+diagnosis	O
+to	O
+be	O
+parasitic	O
+EP	O
+.	O
+
+TITLE	O
+:	O
+Psychological	B-DISO
+autopsy	O
+and	O
+necropsy	O
+of	O
+an	O
+unusual	O
+case	O
+of	O
+suicide	O
+by	O
+intravenous	O
+toluene	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Toluene	O
+(	O
+methylbenzene	B-CHED
+;	O
+volatile	O
+hydrocarbon	B-CHED
+)	O
+is	O
+an	O
+industrial	O
+solvent	B-CHED
+that	O
+causes	O
+major	O
+injury	O
+to	O
+the	O
+lungs	B-ANAT
+;	O
+the	O
+organ	B-ANAT
+being	O
+the	O
+first	O
+capillary	B-ANAT
+bed	I-ANAT
+encountered	O
+.	O
+
+Psychological	B-DISO
+autopsy	O
+revealed	O
+severe	O
+depressive	B-DISO
+disorder	I-DISO
+and	O
+solvent	B-CHED
+(	O
+inhalant	O
+)	O
+abuse	B-DISO
+,	O
+with	O
+marital	O
+disharmony	O
+as	O
+the	O
+precipitating	O
+stressor	O
+for	O
+suicide	O
+.	O
+
+Relevant	O
+literature	O
+of	O
+toluene	B-CHED
+poisoning	O
+was	O
+identified	O
+via	O
+PubMed	O
+,	O
+PubChem	O
+,	O
+ToxNet	O
+,	O
+Hazardous	O
+Substances	O
+Data	O
+Bank	O
+(	O
+HSDB	B-DISO
+),	O
+Embase	O
+,	O
+and	O
+PsycINFO	O
+.	O
+
+TITLE	O
+:	O
+Polytetrafluoroethylene	B-CHED
+fume	O
+-	O
+induced	O
+pulmonary	B-DISO
+edema	I-DISO
+:	O
+a	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+.	O
+
+He	O
+had	O
+left	O
+a	O
+polytetrafluoroethylene	B-CHED
+-	O
+coated	O
+pan	B-COMP
+on	O
+a	O
+gas	B-ENZY
+-	O
+burning	B-DISO
+stove	O
+for	O
+10	O
+hours	O
+while	O
+unconscious	O
+.	O
+
+Pathophysiological	O
+and	O
+radiological	O
+features	O
+were	O
+consistent	O
+with	O
+the	O
+exudative	O
+phase	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+method	O
+for	O
+the	O
+rapid	O
+detection	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+is	O
+to	O
+develop	O
+a	O
+rapid	O
+,	O
+sensitive	O
+,	O
+and	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+method	O
+for	O
+the	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+in	O
+less	O
+equipped	O
+laboratories	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+optimal	O
+reaction	O
+condition	B-DISO
+of	O
+the	O
+current	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+LAMP	O
+for	O
+PEDV	B-SPEC
+was	O
+62	O
+°	O
+C	O
+for	O
+45	O
+min	O
+.	O
+
+TITLE	O
+:	O
+Transcriptome	O
+Profiling	O
+of	O
+the	O
+Virus	B-SPEC
+-	O
+Induced	O
+Innate	B-DISO
+Immune	I-DISO
+Response	I-DISO
+in	O
+Pteropus	B-SPEC
+vampyrus	I-SPEC
+and	O
+Its	O
+Attenuation	O
+by	O
+Nipah	O
+Virus	O
+Interferon	O
+Antagonist	B-PROC
+Functions	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+important	O
+reservoirs	O
+for	O
+several	O
+viruses	B-SPEC
+,	O
+many	O
+of	O
+which	O
+cause	O
+lethal	O
+infections	B-DISO
+in	O
+humans	B-SPEC
+but	O
+have	O
+reduced	O
+pathogenicity	O
+in	O
+bats	B-SPEC
+.	O
+
+As	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+is	O
+critical	O
+for	O
+controlling	O
+viruses	B-SPEC
+,	O
+the	O
+nature	O
+of	O
+this	O
+response	O
+in	O
+bats	B-SPEC
+and	O
+how	O
+it	O
+may	O
+differ	O
+from	O
+that	O
+in	O
+other	O
+mammals	B-SPEC
+are	O
+of	O
+great	O
+interest	O
+.	O
+
+NDV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+also	O
+upregulated	O
+several	O
+genes	O
+not	O
+previously	O
+characterized	O
+to	O
+be	O
+antiviral	B-CHED
+,	O
+such	O
+as	O
+RND1	B-PRGE
+,	O
+SERTAD1	B-PRGE
+,	O
+CHAC1	B-PRGE
+,	O
+and	O
+MORC3	B-PRGE
+.	O
+
+In	O
+fact	O
+,	O
+we	O
+show	O
+that	O
+MORC3	B-PRGE
+is	O
+induced	O
+by	O
+both	O
+IFN	B-PRGE
+and	O
+NDV	B-SPEC
+infection	B-DISO
+in	O
+PVK	B-CHED
+cells	B-COMP
+but	O
+is	O
+not	O
+induced	O
+by	O
+either	O
+stimulus	O
+in	O
+human	B-SPEC
+A549	O
+cells	B-COMP
+.	O
+
+Despite	O
+their	O
+ecological	O
+importance	O
+to	O
+viral	O
+maintenance	O
+,	O
+research	O
+into	O
+their	O
+immune	B-ANAT
+system	I-ANAT
+and	O
+mechanisms	O
+for	O
+viral	O
+control	O
+has	O
+only	O
+recently	O
+begun	O
+.	O
+
+TITLE	O
+:	O
+Combined	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+and	O
+emphysema	B-DISO
+(	O
+CPFE	O
+):	O
+an	O
+entity	O
+different	O
+from	O
+emphysema	B-DISO
+or	O
+pulmonary	B-ANAT
+fibrosis	I-DISO
+alone	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+an	O
+increasing	O
+recognition	O
+of	O
+the	O
+coexistence	O
+of	O
+emphysema	B-DISO
+and	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+in	O
+individuals	O
+.	O
+
+The	O
+association	O
+was	O
+first	O
+described	O
+as	O
+a	O
+syndrome	B-DISO
+by	O
+Cottin	O
+in	O
+2005	O
+,	O
+named	O
+""""	O
+combined	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+and	O
+emphysema	B-DISO
+(	O
+CPFE	O
+")"","	O
+which	O
+is	O
+characterized	O
+by	O
+exertional	B-DISO
+dyspnea	I-DISO
+,	O
+upper	O
+-	O
+lobe	B-ANAT
+emphysema	B-DISO
+and	O
+lower	O
+-	O
+lobe	B-ANAT
+fibrosis	B-DISO
+,	O
+preserved	O
+lung	B-PROC
+volume	I-PROC
+and	O
+severely	O
+diminished	O
+capacity	O
+of	O
+gas	B-ENZY
+exchange	O
+.	O
+
+Although	O
+several	O
+vaccines	O
+against	O
+these	O
+viruses	B-SPEC
+are	O
+commercially	O
+available	O
+there	O
+is	O
+room	O
+for	O
+improvement	O
+,	O
+especially	O
+in	O
+the	O
+case	O
+of	O
+PRRSV	B-SPEC
+.	O
+
+Primary	O
+assay	O
+results	O
+are	O
+archived	O
+at	O
+the	O
+GEO	O
+and	O
+PeptideAtlas	O
+public	O
+repositories	O
+,	O
+while	O
+processed	O
+statistical	O
+results	O
+together	O
+with	O
+standardized	O
+metadata	O
+are	O
+publically	O
+available	O
+at	O
+the	O
+Influenza	O
+Research	O
+Database	O
+(	O
+www	O
+.	O
+fludb	O
+.	O
+org	O
+)	O
+and	O
+the	O
+Virus	B-SPEC
+Pathogen	O
+Resource	O
+(	O
+www	O
+.	O
+viprbrc	O
+.	O
+org	O
+).	O
+
+When	O
+a	O
+functional	O
+ORF3	O
+gene	O
+was	O
+restored	O
+,	O
+the	O
+recombinant	O
+virus	B-SPEC
+could	O
+not	O
+be	O
+rescued	O
+,	O
+suggesting	O
+that	O
+ORF3	O
+could	O
+suppress	O
+PEDV	B-SPEC
+replication	O
+in	O
+vitro	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+1838	O
+patients	O
+with	O
+ARDS	B-DISO
+were	O
+identified	O
+and	O
+open	O
+lung	B-ANAT
+biopsies	O
+were	O
+performed	O
+on	O
+101	O
+patients	O
+(	O
+5	O
+.	O
+5	O
+%)	O
+during	O
+the	O
+study	O
+period	O
+.	O
+
+We	O
+investigated	O
+the	O
+S1	B-PRGE
+glycoprotein	I-PRGE
+of	O
+24	O
+recent	O
+IBV	B-SPEC
+isolates	O
+from	O
+chickens	B-SPEC
+and	O
+demonstrated	O
+that	O
+two	O
+predominant	O
+genetic	O
+groups	O
+were	O
+circulating	O
+in	O
+southern	O
+Thailand	O
+between	O
+2008	O
+and	O
+2013	O
+.	O
+
+Furthermore	O
+,	O
+native	O
+chickens	B-SPEC
+may	O
+contribute	O
+to	O
+the	O
+epidemiology	O
+of	O
+IB	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+concentrated	O
+phenol	B-CHED
+dermal	O
+burns	O
+:	O
+Complications	O
+and	O
+management	O
+.	O
+
+Patient	O
+also	O
+developed	O
+pleural	B-DISO
+effusion	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+but	O
+these	O
+were	O
+successfully	O
+managed	O
+by	O
+intercostal	O
+drain	O
+tube	O
+insertion	O
+and	O
+noninvasive	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Mixed	O
+viral	B-DISO
+infections	I-DISO
+circulating	O
+in	O
+hospitalized	O
+patients	O
+with	O
+respiratory	B-ANAT
+tract	I-ANAT
+infections	I-DISO
+in	O
+kuwait	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+and	O
+the	O
+role	O
+of	O
+histones	O
+.	O
+
+It	O
+is	O
+possible	O
+that	O
+extracellular	B-COMP
+histones	O
+were	O
+derived	O
+from	O
+formation	B-PROC
+of	O
+neutrophil	B-ANAT
+extracellular	B-COMP
+traps	B-DISO
+(	O
+NETs	O
+)	O
+in	O
+lung	B-ANAT
+after	O
+PMN	B-PROC
+contact	O
+with	O
+C5a	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Coyotes	O
+(	O
+Canis	B-SPEC
+latrans	I-SPEC
+)	O
+have	O
+expanded	O
+recently	O
+into	O
+the	O
+eastern	O
+US	O
+and	O
+can	O
+serve	O
+as	O
+a	O
+source	O
+of	O
+pathogens	O
+to	O
+domestic	O
+dogs	B-SPEC
+(	O
+Canis	B-SPEC
+lupus	I-SPEC
+familiaris	I-SPEC
+),	O
+livestock	O
+,	O
+and	O
+humans	B-SPEC
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+coyotes	B-SPEC
+harbor	O
+many	O
+common	O
+pathogens	O
+that	O
+present	O
+health	O
+risks	O
+to	O
+humans	O
+and	O
+domestic	O
+animals	B-SPEC
+and	O
+suggest	O
+that	O
+continued	O
+monitoring	O
+of	O
+the	O
+coyote	B-SPEC
+'	O
+s	O
+role	O
+in	O
+pathogen	B-DISO
+transmission	I-DISO
+is	O
+warranted	O
+.	O
+
+A	O
+significant	O
+rise	O
+in	O
+syphilis	B-DISO
+cases	O
+has	O
+prompted	O
+recommendations	O
+for	O
+increased	O
+prenatal	O
+screening	O
+.	O
+
+ABSTRACT	O
+:	O
+Virus	O
+-	O
+host	B-COMP
+cell	I-COMP
+interactions	O
+are	O
+most	O
+commonly	O
+analyzed	O
+in	O
+cells	B-COMP
+maintained	O
+in	O
+vitro	O
+as	O
+two	O
+-	O
+dimensional	O
+tissue	B-ANAT
+cultures	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+Treatment	O
+for	O
+Salicylate	B-CHED
+Poisoning	O
+:	O
+Systematic	O
+Review	O
+and	O
+Recommendations	O
+From	O
+the	O
+EXTRIP	O
+Workgroup	O
+.	O
+
+Extracorporeal	O
+treatment	O
+is	O
+also	O
+suggested	O
+for	O
+patients	O
+with	O
+severe	O
+acidemia	B-DISO
+(	O
+pH	O
+≤	O
+7	O
+.	O
+20	O
+in	O
+the	O
+absence	O
+of	O
+other	O
+indications	O
+)	O
+(	O
+2D	O
+).	O
+
+TITLE	O
+:	O
+Bleb	B-ANAT
+point	O
+:	O
+mimicker	O
+of	O
+pneumothorax	B-DISO
+in	O
+bullous	B-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Camels	O
+carry	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+but	O
+little	O
+is	O
+known	O
+about	O
+infection	B-DISO
+age	O
+or	O
+prevalence	O
+.	O
+
+With	O
+fatality	O
+rates	O
+of	O
+nearly	O
+50	O
+%-	O
+90	O
+%,	O
+it	O
+has	O
+claimed	O
+,	O
+as	O
+of	O
+11	O
+April	O
+2015	O
+,	O
+10	O
+,	O
+619	O
+human	B-SPEC
+lives	O
+out	O
+of	O
+a	O
+total	O
+of	O
+25	O
+,	O
+626	O
+cases	O
+reported	O
+worldwide	O
+.	O
+
+This	O
+review	O
+describes	O
+the	O
+salient	O
+properties	O
+of	O
+EBOV	O
+and	O
+the	O
+development	B-PROC
+of	O
+novel	O
+diagnostics	O
+,	O
+vaccines	O
+,	O
+and	O
+control	O
+strategies	O
+for	O
+this	O
+emerging	O
+disease	O
+of	O
+high	O
+public	O
+health	O
+concern	O
+and	O
+international	O
+emergency	B-DISO
+.	O
+
+In	O
+total	O
+,	O
+64	O
+United	O
+Kingdom	B-SPEC
+(	O
+UK	O
+)	O
+residents	O
+were	O
+successfully	O
+contacted	O
+,	O
+14	O
+of	O
+whom	O
+were	O
+sat	O
+in	O
+the	O
+priority	O
+area	O
+two	O
+seats	O
+all	O
+around	O
+the	O
+case	O
+(	O
+s	O
+).	O
+
+ABSTRACT	O
+:	O
+Viral	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+infections	I-DISO
+(	O
+LRTIs	O
+)	O
+are	O
+an	O
+underappreciated	O
+cause	O
+of	O
+critical	B-DISO
+illness	I-DISO
+in	O
+adults	O
+.	O
+
+Recent	O
+advances	O
+in	O
+viral	O
+detection	O
+techniques	O
+over	O
+the	O
+past	O
+decade	O
+have	O
+demonstrated	O
+viral	O
+LRTIs	O
+are	O
+associated	O
+with	O
+rates	O
+of	O
+morbidity	O
+,	O
+mortality	O
+,	O
+and	O
+health	O
+care	O
+utilization	O
+comparable	O
+to	O
+those	O
+of	O
+seen	O
+with	O
+bacterial	O
+community	O
+acquired	O
+and	O
+nosocomial	B-DISO
+pneumonias	I-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+describe	O
+the	O
+relationship	O
+between	O
+viral	O
+LRTIs	O
+and	O
+critical	B-DISO
+illness	I-DISO
+,	O
+as	O
+well	O
+as	O
+discuss	O
+relevant	O
+clinical	O
+features	O
+and	O
+management	O
+strategies	O
+for	O
+the	O
+more	O
+prevalent	O
+respiratory	O
+viral	O
+pathogens	O
+.	O
+
+Several	O
+MRV3	O
+isolates	O
+were	O
+obtained	O
+from	O
+chloroform	O
+-	O
+extracted	O
+pig	B-SPEC
+feces	B-ANAT
+or	O
+blood	B-ANAT
+meal	O
+in	O
+cell	B-COMP
+cultures	O
+or	O
+developing	O
+chicken	B-SPEC
+embryos	B-ANAT
+.	O
+
+Within	O
+two	O
+weeks	O
+,	O
+she	O
+had	O
+near	O
+-	O
+complete	O
+bilateral	O
+wrist	B-ANAT
+and	O
+foot	B-DISO
+drop	I-DISO
+.	O
+
+Magnetic	O
+resonance	O
+imaging	O
+of	O
+lumbosacral	O
+and	O
+cervical	O
+spine	O
+showed	O
+tumor	B-DISO
+-	O
+like	O
+masses	O
+mistaken	O
+for	O
+neurofibromatosis	B-DISO
+(	O
+axial	O
+diameter	O
+,	O
+7	O
+.	O
+5	O
+-	O
+10	O
+mm	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	O
+adenovirus	O
+infection	O
+in	O
+children	O
+can	O
+manifest	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+leading	O
+to	O
+the	O
+need	O
+for	O
+prolonged	O
+mechanical	O
+support	O
+in	O
+the	O
+form	O
+of	O
+either	O
+mechanical	O
+ventilation	O
+or	O
+extracorporeal	O
+life	O
+support	O
+.	O
+
+Early	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+intervention	O
+for	O
+children	O
+with	O
+ARDS	B-DISO
+should	O
+be	O
+considered	O
+if	O
+selection	O
+criteria	O
+fulfill	O
+.	O
+
+Real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+tests	O
+of	O
+sputum	B-ANAT
+and	O
+pleural	B-DISO
+effusion	I-DISO
+samples	O
+confirmed	O
+adenovirus	B-DISO
+serotype	O
+7	O
+.	O
+
+Because	O
+conventional	O
+ARDS	B-DISO
+therapies	O
+failed	O
+,	O
+we	O
+initiated	O
+ECMO	O
+with	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+for	O
+9	O
+days	O
+.	O
+
+Chest	B-ANAT
+x	O
+-	O
+rays	B-SPEC
+showed	O
+gradual	O
+improvements	O
+in	O
+lung	B-ANAT
+expansion	O
+.	O
+
+The	O
+unique	O
+lung	B-ANAT
+recruitment	B-DISO
+by	O
+HFOV	O
+can	O
+be	O
+a	O
+useful	O
+therapeutic	O
+option	O
+for	O
+severe	O
+ARDS	B-DISO
+patients	O
+when	O
+combined	O
+with	O
+sufficient	O
+lung	B-ANAT
+rest	B-FUNC
+provided	O
+by	O
+ECMO	O
+.	O
+
+TITLE	O
+:	O
+Bats	B-SPEC
+as	O
+reservoirs	O
+of	O
+severe	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+Now	O
+we	O
+know	O
+that	O
+many	O
+of	O
+these	O
+terrible	O
+diseases	O
+are	O
+caused	O
+by	O
+viruses	B-SPEC
+originated	O
+from	O
+bats	B-SPEC
+(	O
+Table	O
+1	O
+),	O
+such	O
+as	O
+Ebola	O
+virus	B-SPEC
+,	I-SPEC
+Marburg	I-SPEC
+,	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+Nipah	B-SPEC
+virus	I-SPEC
+(	O
+NiV	O
+)	O
+and	O
+Hendra	B-SPEC
+virus	I-SPEC
+(	O
+HeV	B-SPEC
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+present	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+effect	O
+of	O
+supplemental	O
+genistein	O
+(	O
+an	O
+isoflavonoid	B-CHED
+)	O
+on	O
+performance	O
+,	O
+lymphoid	B-ANAT
+organs	I-ANAT
+'	O
+development	B-PROC
+,	O
+and	O
+cellular	B-COMP
+and	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+broiler	O
+chicks	O
+.	O
+
+The	O
+best	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+feed	O
+conversion	O
+ratio	O
+assigned	O
+to	O
+the	O
+birds	B-SPEC
+fed	O
+on	O
+diets	O
+containing	O
+antibiotics	B-CHED
+and	O
+moderate	O
+levels	O
+(	O
+40	O
+to	O
+80	O
+mg	O
+/	O
+kg	O
+)	O
+of	O
+genistein	B-CHED
+.	O
+
+Epidural	B-ANAT
+analgesia	B-DISO
+is	O
+standard	O
+of	O
+care	O
+for	O
+patients	O
+undergoing	O
+thoracotomy	O
+.	O
+
+The	O
+infusion	O
+was	O
+started	O
+thereafter	O
+,	O
+which	O
+provided	O
+excellent	O
+analgesia	B-DISO
+and	O
+facilitated	O
+an	O
+uneventful	O
+recovery	O
+.	O
+
+Our	O
+study	O
+identified	O
+some	O
+prenatal	O
+,	O
+perinatal	O
+and	O
+postnatal	O
+conditions	O
+proving	O
+to	O
+be	O
+relevant	O
+and	O
+independent	O
+risk	O
+factors	O
+for	O
+hospitalization	O
+for	O
+bronchiolitis	B-DISO
+during	O
+the	O
+first	O
+year	O
+of	O
+life	O
+.	O
+
+TITLE	O
+:	O
+Phage	O
+display	O
+for	O
+identifying	O
+peptides	B-CHED
+that	O
+bind	B-FUNC
+the	O
+spike	O
+protein	B-CHED
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+possess	B-DISO
+diagnostic	O
+potential	O
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+we	O
+used	O
+the	O
+rS	O
+-	O
+AD	O
+as	O
+an	O
+immobilized	O
+target	O
+to	O
+identify	O
+peptides	B-CHED
+from	O
+a	O
+phage	O
+-	O
+display	O
+library	O
+with	O
+application	O
+for	O
+diagnosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+(	O
+TLRs	O
+)	O
+are	O
+sensors	O
+that	O
+recognize	O
+molecular	O
+patterns	O
+from	O
+viruses	B-SPEC
+,	O
+bacteria	B-SPEC
+,	O
+and	O
+fungi	B-SPEC
+to	O
+initiate	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+to	O
+invading	O
+pathogens	O
+.	O
+
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+are	O
+a	O
+family	B-SPEC
+of	O
+sensor	O
+proteins	B-CHED
+that	O
+enable	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+to	O
+differentiate	O
+between	O
+""""	O
+self	O
+""""	O
+and	O
+""""	O
+non	O
+-	O
+self	O
+.	O
+
+These	O
+data	O
+should	O
+inform	O
+the	O
+design	O
+and	O
+use	O
+of	O
+TLR	O
+agonists	B-CHED
+and	O
+antagonists	B-CHED
+in	O
+coronavirus	B-SPEC
+-	O
+specific	O
+vaccine	O
+and	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+Septic	B-DISO
+encephalopathy	I-DISO
+(	O
+SE	B-DISO
+)	O
+is	O
+the	O
+most	O
+common	O
+acute	B-DISO
+encephalopathy	I-DISO
+in	O
+ICU	O
+;	O
+however	O
+,	O
+little	O
+attention	O
+has	O
+been	O
+focused	O
+on	O
+risk	O
+of	O
+SE	B-DISO
+in	O
+the	O
+course	O
+of	O
+acute	B-DISO
+stroke	I-DISO
+.	O
+
+Of	O
+94	O
+stroke	B-DISO
+patients	O
+with	O
+NC	O
+,	O
+46	O
+(	O
+49	O
+%)	O
+had	O
+NC	O
+with	O
+SE	O
+and	O
+48	O
+(	O
+51	O
+%)	O
+had	O
+NC	O
+without	O
+SE	O
+.	O
+
+There	O
+was	O
+a	O
+significant	O
+difference	O
+in	O
+body	B-ANAT
+temperature	O
+,	O
+heart	B-ANAT
+rate	O
+,	O
+respiratory	O
+rate	O
+,	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+(	O
+WBC	B-ANAT
+),	O
+systolic	O
+blood	B-PROC
+pressure	I-PROC
+(	O
+SBP	O
+),	O
+diastolic	O
+blood	B-PROC
+pressure	I-PROC
+(	O
+DBP	B-CHED
+),	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+),	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+septic	B-DISO
+shock	I-DISO
+,	O
+hypernatremia	B-DISO
+,	O
+and	O
+sequential	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+(	O
+SOFA	O
+)	O
+score	O
+between	O
+the	O
+SE	O
+and	O
+non	O
+-	O
+SE	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+Of	O
+94	O
+stroke	B-DISO
+patients	O
+with	O
+NC	O
+,	O
+46	O
+(	O
+49	O
+%)	O
+had	O
+NC	O
+with	O
+SE	O
+and	O
+48	O
+(	O
+51	O
+%)	O
+had	O
+NC	O
+without	O
+SE	O
+.	O
+
+In	O
+February	O
+-	O
+March	O
+2013	O
+the	O
+number	O
+of	O
+children	O
+protected	O
+by	O
+antibodies	B-COMP
+against	O
+influenza	B-DISO
+decreased	O
+,	O
+and	O
+circulation	O
+of	O
+influenza	B-SPEC
+viruses	I-SPEC
+A	O
+/	O
+H3N2	B-CHED
+and	O
+A	O
+/	O
+H1N1	O
+/	O
+pdm09	O
+was	O
+detected	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+fraction	O
+of	O
+viruses	B-SPEC
+in	O
+etiologic	O
+structure	O
+ofARI	O
+in	O
+children	O
+varies	O
+depending	O
+on	O
+immune	O
+layer	B-ANAT
+,	O
+season	O
+and	O
+age	O
+of	O
+children	O
+.	O
+
+We	O
+tested	O
+a	O
+recombinant	O
+modified	O
+vaccinia	B-SPEC
+virus	I-SPEC
+Ankara	O
+(	O
+MVA	B-CHED
+)	O
+vaccine	O
+expressing	O
+full	O
+-	O
+length	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+by	O
+immunizing	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+with	O
+either	O
+intramuscular	O
+or	O
+subcutaneous	O
+regimens	O
+.	O
+
+Supine	O
+and	O
+upright	O
+vital	B-PROC
+capacities	I-PROC
+were	O
+not	O
+different	O
+(	O
+P	O
+=	O
+0	O
+.	O
+76	O
+),	O
+suggesting	O
+absence	O
+of	O
+diaphragmatic	B-ANAT
+dysfunction	O
+.	O
+
+Compared	O
+to	O
+controls	O
+,	O
+patients	O
+with	O
+respiratory	B-DISO
+dysfunction	I-DISO
+had	O
+higher	O
+values	O
+for	O
+the	O
+Walton	O
+and	O
+Gardner	O
+-	O
+Medwin	O
+score	O
+(	O
+6	O
+.	O
+1	O
+±	O
+1	O
+.	O
+9	O
+vs	O
+.	O
+3	O
+.	O
+2	O
+±	O
+1	O
+.	O
+2	O
+;	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+body	B-ANAT
+mass	O
+index	O
+(	O
+26	O
+.	O
+9	O
+±	O
+6	O
+.	O
+0	O
+vs	O
+.	O
+22	O
+.	O
+9	O
+±	O
+4	O
+.	O
+0	O
+kg	O
+/	O
+m	O
+(	O
+2	O
+);	O
+P	O
+=	O
+0	O
+.	O
+003	O
+)	O
+and	O
+a	O
+smaller	O
+number	O
+of	O
+D4Z4	O
+allele	O
+repeats	O
+(	O
+4	O
+.	O
+8	O
+±	O
+1	O
+.	O
+6	O
+vs	O
+.	O
+5	O
+.	O
+7	O
+±	O
+1	O
+.	O
+8	O
+;	O
+P	O
+=	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+Tissue	B-PRGE
+factor	I-PRGE
+(	O
+TF	O
+)	O
+and	O
+tissue	B-PRGE
+factor	I-PRGE
+pathway	B-PROC
+inhibitor	B-CHED
+(	O
+TFPI	B-PRGE
+)	O
+play	O
+a	O
+central	O
+role	O
+in	O
+the	O
+endothelial	B-ANAT
+permeability	O
+regulation	B-PROC
+and	O
+dysfunction	O
+,	O
+which	O
+is	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+sepsis	B-DISO
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+).	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+complete	O
+genomes	O
+of	O
+three	O
+Vietnamese	O
+PEDV	B-SPEC
+isolates	O
+were	O
+characterized	O
+.	O
+
+These	O
+three	O
+isolates	O
+were	O
+isolated	O
+from	O
+3	O
+-	O
+day	O
+-	O
+old	O
+pigs	B-SPEC
+experiencing	O
+diarrhea	B-DISO
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+Vietnamese	O
+PEDV	B-SPEC
+isolates	O
+are	O
+new	O
+variants	O
+,	O
+as	O
+evidenced	O
+by	O
+their	O
+genetic	O
+composition	O
+of	O
+insertions	O
+and	O
+a	O
+deletion	O
+in	O
+the	O
+spike	O
+gene	O
+,	O
+and	O
+they	O
+might	O
+have	O
+originated	O
+from	O
+the	O
+same	O
+ancestor	O
+as	O
+the	O
+Chinese	O
+PEDV	B-SPEC
+strain	O
+.	O
+
+The	O
+effects	O
+of	O
+SHED	O
+-	O
+CM	O
+on	O
+macrophage	B-PROC
+differentiation	I-PROC
+in	O
+vitro	O
+were	O
+also	O
+assessed	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+statin	B-PRGE
+therapy	O
+on	O
+mortality	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+depends	O
+on	O
+ARDS	B-DISO
+severity	O
+:	O
+a	O
+prospective	O
+observational	O
+cohort	O
+study	O
+.	O
+
+The	O
+distribution	O
+of	O
+the	O
+ARDS	B-DISO
+subgroups	O
+was	O
+13	O
+%,	O
+59	O
+%,	O
+and	O
+28	O
+%	O
+for	O
+mild	O
+,	O
+moderate	O
+,	O
+and	O
+severe	O
+disease	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+effectiveness	O
+of	O
+a	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+surveillance	O
+protocol	O
+in	O
+the	O
+Emergency	B-DISO
+Department	O
+(	O
+ED	O
+)	O
+at	O
+Hamad	O
+General	O
+Hospital	O
+.	O
+
+Once	O
+identified	O
+,	O
+patients	O
+were	O
+isolated	O
+,	O
+had	O
+a	O
+chest	B-ANAT
+roentgenogram	O
+[	O
+chest	B-ANAT
+radiography	O
+(	O
+CXR	O
+)]	O
+taken	O
+,	O
+and	O
+a	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+for	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+was	O
+sent	O
+with	O
+sputum	O
+samples	O
+for	O
+testing	O
+.	O
+
+The	O
+protocol	O
+also	O
+increased	O
+the	O
+efficiency	O
+of	O
+ED	O
+and	O
+cut	O
+the	O
+turnaround	O
+time	O
+for	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+and	O
+sputum	B-ANAT
+results	O
+from	O
+3	O
+days	O
+to	O
+1	O
+day	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+protocol	O
+successfully	O
+reduced	O
+the	O
+number	O
+of	O
+patients	O
+who	O
+needed	O
+to	O
+be	O
+tested	O
+for	O
+MERS	O
+-	O
+CoV	O
+from	O
+12	O
+,	O
+563	O
+to	O
+514	O
+,	O
+identified	O
+seven	O
+positive	O
+cases	O
+,	O
+and	O
+did	O
+not	O
+lead	O
+to	O
+apparent	O
+cross	O
+infectivity	O
+that	O
+resulted	O
+in	O
+serious	O
+illness	O
+or	O
+death	B-PROC
+.	O
+
+The	O
+protocol	O
+also	O
+increased	O
+the	O
+efficiency	O
+of	O
+ED	O
+and	O
+cut	O
+the	O
+turnaround	O
+time	O
+for	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+and	O
+sputum	B-ANAT
+results	O
+from	O
+3	O
+days	O
+to	O
+1	O
+day	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+widespread	O
+use	O
+of	O
+noninvasive	O
+ventilation	O
+in	O
+children	O
+and	O
+in	O
+children	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+there	O
+are	O
+few	O
+scientific	O
+data	O
+on	O
+the	O
+utility	O
+of	O
+this	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+Ventilatory	O
+support	O
+in	O
+children	O
+with	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+proceedings	O
+from	O
+the	O
+Pediatric	O
+Acute	O
+Lung	O
+Injury	O
+Consensus	O
+Conference	O
+.	O
+
+The	O
+Pediatric	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Consensus	O
+Conference	O
+experts	O
+developed	O
+and	O
+voted	O
+on	O
+a	O
+total	O
+of	O
+27	O
+recommendations	O
+focused	O
+on	O
+the	O
+optimal	O
+mechanical	O
+ventilation	O
+approach	O
+of	O
+the	O
+patient	O
+with	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+If	O
+clinical	O
+pediatric	O
+data	O
+were	O
+sparse	O
+or	O
+unavailable	O
+,	O
+the	O
+findings	O
+from	O
+studies	O
+of	O
+adult	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+animal	B-SPEC
+models	O
+that	O
+might	O
+be	O
+relevant	O
+to	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+were	O
+examined	O
+.	O
+
+Tissue	B-ANAT
+binding	B-FUNC
+profiles	O
+of	O
+avian	B-SPEC
+viral	O
+attachment	O
+proteins	B-CHED
+were	O
+studied	O
+by	O
+performing	O
+histochemistry	O
+on	O
+multi	O
+-	O
+species	B-SPEC
+TMA	B-CHED
+,	O
+comprising	O
+of	O
+selected	O
+tissues	B-ANAT
+from	O
+ten	O
+avian	B-SPEC
+species	B-SPEC
+,	O
+and	O
+single	O
+-	O
+species	B-SPEC
+TMAs	O
+,	O
+grouping	O
+organ	B-ANAT
+systems	I-ANAT
+of	O
+each	O
+species	B-SPEC
+together	O
+.	O
+
+By	O
+applying	O
+this	O
+method	O
+to	O
+MERS	O
+-	O
+CoV	O
+,	O
+the	O
+11	O
+canonical	O
+cleavage	B-PROC
+sites	O
+were	O
+readily	O
+identified	O
+and	O
+verified	O
+by	O
+the	O
+biochemical	O
+assays	O
+.	O
+
+Although	O
+the	O
+epidemic	O
+was	O
+eventually	O
+controlled	O
+through	O
+the	O
+implementation	O
+of	O
+strict	O
+quarantine	O
+measures	O
+,	O
+there	O
+continues	O
+a	O
+need	O
+to	O
+investigate	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+develop	O
+interventions	O
+should	O
+it	O
+re	O
+-	O
+emerge	O
+.	O
+
+In	O
+contrast	O
+,	O
+there	O
+is	O
+little	O
+data	O
+on	O
+the	O
+kinetics	O
+of	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+during	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+little	O
+is	O
+known	O
+about	O
+their	O
+role	O
+in	O
+the	O
+recovery	O
+process	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+host	B-COMP
+factors	O
+relevant	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+replication	O
+,	O
+we	O
+performed	O
+a	O
+small	O
+interfering	O
+RNA	O
+(	O
+siRNA	O
+)	O
+library	O
+screen	O
+targeting	B-PROC
+the	O
+human	B-SPEC
+kinome	O
+.	O
+
+Therefore	O
+,	O
+as	O
+a	O
+proof	O
+of	O
+principle	O
+,	O
+the	O
+current	O
+results	O
+indicate	O
+that	O
+coronavirus	B-SPEC
+2	O
+'-	O
+O	O
+-	O
+MTase	B-PRGE
+activity	O
+can	O
+be	O
+targeted	B-PROC
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+.	O
+
+Our	O
+further	O
+analysis	O
+established	O
+that	O
+this	O
+subunit	O
+is	O
+essential	O
+for	O
+replication	O
+of	O
+this	O
+prototypic	O
+arterivirus	B-SPEC
+.	O
+
+Trimodality	O
+therapy	O
+utilizing	O
+concurrent	O
+carboplatin	B-CHED
+/	O
+paclitaxel	B-CHED
+with	O
+North	O
+American	O
+radiotherapy	O
+doses	O
+appeared	O
+to	O
+have	O
+similar	O
+pathologic	O
+complete	O
+response	O
+rates	O
+compared	O
+with	O
+the	O
+CROSS	O
+trial	O
+,	O
+but	O
+may	O
+be	O
+associated	O
+with	O
+higher	O
+toxicity	O
+.	O
+
+Following	O
+the	O
+detection	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+transfected	O
+MDCK	B-ANAT
+cells	I-ANAT
+after	O
+PEDV	B-SPEC
+challenge	O
+,	O
+we	O
+clearly	O
+demonstrated	O
+that	O
+the	O
+SPC	O
+subdomain	O
+plays	O
+a	O
+key	O
+role	O
+in	O
+cell	B-COMP
+entry	O
+of	O
+PEDV	B-SPEC
+and	O
+its	O
+expression	B-PROC
+permits	B-SPEC
+PEDV	B-SPEC
+growth	B-PROC
+in	O
+transfected	O
+MDCK	B-ANAT
+cells	I-ANAT
+,	O
+while	O
+virus	B-SPEC
+propagation	O
+can	O
+be	O
+inhibited	O
+by	O
+anti	O
+-	O
+SPC	O
+serum	O
+,	O
+indicating	O
+that	O
+the	O
+SPC	O
+subdomain	O
+appears	O
+to	O
+be	O
+a	O
+crucial	O
+functional	O
+domain	O
+in	O
+contributing	O
+to	O
+efficient	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Computed	O
+tomography	O
+(	O
+CT	O
+)	O
+of	O
+the	O
+brain	B-ANAT
+revealed	O
+a	O
+well	O
+-	O
+defined	O
+contrast	O
+-	O
+enhancing	O
+lesion	O
+on	O
+the	O
+rostral	O
+forebrain	B-ANAT
+that	O
+appeared	O
+extraparenchymal	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+case	O
+of	O
+coronavirus	B-SPEC
+granuloma	B-DISO
+described	O
+on	O
+CT	O
+-	O
+scan	O
+in	O
+the	O
+central	O
+nervous	O
+system	O
+of	O
+a	O
+ferret	B-SPEC
+.	O
+
+In	O
+the	O
+case	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+the	O
+activity	O
+was	O
+highly	O
+promising	O
+with	O
+an	O
+EC50	O
+<	O
+10	O
+μM	O
+and	O
+a	O
+CC50	O
+>	O
+100	O
+μM	O
+.	O
+As	O
+such	O
+,	O
+these	O
+doubly	O
+flexible	O
+nucleoside	B-CHED
+analogues	I-CHED
+are	O
+viewed	O
+as	O
+a	O
+novel	O
+new	O
+class	B-SPEC
+of	O
+drug	O
+candidates	O
+with	O
+potential	O
+for	O
+potent	O
+inhibition	B-PROC
+of	O
+coronaviruses	O
+.	O
+
+However	O
+,	O
+the	O
+virus	B-SPEC
+could	O
+mutate	B-PROC
+to	O
+have	O
+increased	O
+interhuman	O
+transmissibility	O
+,	O
+increasing	O
+its	O
+pandemic	O
+potential	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Sweet	B-PROC
+Spot	B-SPEC
+for	O
+Molecular	O
+Diagnostics	O
+:	O
+Coupling	O
+Isothermal	O
+Amplification	B-DISO
+and	O
+Strand	O
+Exchange	O
+Circuits	O
+to	O
+Glucometers	O
+.	O
+
+The	O
+most	O
+prevalent	O
+bacteria	B-SPEC
+were	O
+MRSA	B-DISO
+and	O
+Klebsiella	B-DISO
+pneumonia	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genetic	O
+diversity	O
+,	O
+evolution	O
+,	O
+distribution	O
+,	O
+and	O
+taxonomy	O
+of	O
+some	O
+coronaviruses	O
+dominant	O
+in	O
+birds	B-SPEC
+other	O
+than	O
+chickens	B-SPEC
+remain	O
+enigmatic	O
+.	O
+
+The	O
+viral	B-COMP
+genome	I-COMP
+harbors	O
+a	O
+tandem	O
+repeat	O
+which	O
+is	O
+rare	O
+in	O
+vertebrate	B-SPEC
+RNA	O
+viruses	B-SPEC
+.	O
+
+The	O
+channel	B-FUNC
+activity	I-FUNC
+and	O
+structure	O
+of	O
+some	O
+representative	O
+members	O
+of	O
+these	O
+viroporins	O
+have	O
+been	O
+recently	O
+characterized	O
+in	O
+some	O
+detail	O
+.	O
+
+Herein	O
+,	O
+we	O
+review	O
+the	O
+literature	O
+that	O
+links	O
+C5a	B-PRGE
+and	O
+ALI	O
+,	O
+and	O
+review	O
+our	O
+understanding	O
+of	O
+the	O
+mechanisms	O
+by	O
+which	O
+C5a	O
+affects	O
+ALI	O
+during	O
+highly	O
+pathogenic	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+In	O
+particular	O
+,	O
+we	O
+discuss	O
+the	O
+potential	O
+of	O
+the	O
+blockade	O
+of	O
+C5a	B-PRGE
+signaling	B-PROC
+to	O
+treat	O
+ALI	O
+induced	O
+by	O
+highly	O
+pathogenic	O
+viruses	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+tougher	O
+regulations	O
+on	O
+close	O
+contacts	O
+of	O
+confirmed	O
+patients	O
+and	O
+suspected	O
+cases	O
+are	O
+introduced	O
+in	O
+this	O
+new	O
+Plan	B-DISO
+.	O
+
+Avian	B-SPEC
+coronaviruses	O
+are	O
+economically	O
+important	O
+viruses	B-SPEC
+for	O
+the	O
+poultry	O
+industry	O
+.	O
+
+While	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+a	O
+respiratory	O
+pathogen	O
+of	O
+chickens	B-SPEC
+,	O
+is	O
+rather	O
+well	O
+known	O
+,	O
+other	O
+viruses	B-SPEC
+of	O
+the	O
+genus	B-SPEC
+Gammacoronavirus	B-SPEC
+,	O
+including	O
+those	O
+causing	O
+enteric	O
+disease	O
+,	O
+are	O
+hardly	O
+studied	O
+.	O
+
+Further	O
+comparative	O
+pathology	B-DISO
+study	O
+indicated	O
+that	O
+the	O
+FL2013	O
+strain	O
+had	O
+reduced	O
+virulence	B-PROC
+to	O
+newborn	O
+piglets	O
+.	O
+
+Other	O
+viruses	B-SPEC
+were	O
+also	O
+investigated	O
+in	O
+this	O
+study	O
+with	O
+the	O
+first	O
+report	O
+of	O
+PCV	B-CHED
+,	O
+PAdV	O
+and	O
+lineage	O
+I	O
+G5	O
+RVA	O
+in	O
+Ireland	O
+.	O
+
+Some	O
+specimens	O
+contained	O
+>	O
+1	O
+virus	B-SPEC
+,	O
+with	O
+statistical	O
+analysis	O
+indicating	O
+a	O
+strong	O
+correlation	O
+for	O
+mixed	B-DISO
+infections	I-DISO
+of	O
+PBoV	O
+and	O
+PAdV	O
+on	O
+this	O
+farm	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Investigating	O
+the	O
+diversity	O
+of	O
+circulating	O
+enteric	O
+viruses	B-SPEC
+on	O
+Irish	O
+porcine	B-SPEC
+farms	O
+is	O
+important	O
+to	O
+improve	O
+the	O
+prophylactic	O
+tools	O
+available	O
+and	O
+to	O
+facilitate	O
+the	O
+early	O
+detection	O
+of	O
+changes	O
+in	O
+circulating	O
+viruses	B-SPEC
+.	O
+
+The	O
+median	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+was	O
+12	O
+.	O
+0	O
+(	O
+8	O
+.	O
+8	O
+-	O
+15	O
+.	O
+0	O
+),	O
+and	O
+the	O
+median	O
+lung	B-ANAT
+injury	O
+score	O
+was	O
+3	O
+.	O
+3	O
+(	O
+3	O
+.	O
+3	O
+-	O
+3	O
+.	O
+7	O
+).	O
+
+Furthermore	O
+,	O
+the	O
+multivariate	O
+logistic	O
+regression	O
+analysis	O
+suggests	O
+that	O
+the	O
+necessity	O
+of	O
+renal	B-ANAT
+replacement	O
+therapy	O
+prior	O
+to	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+insertion	O
+was	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+mortality	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+77	O
+-	O
+0	O
+.	O
+88	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+However	O
+,	O
+the	O
+necessity	O
+of	O
+renal	B-ANAT
+replacement	O
+therapy	O
+during	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+was	O
+not	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+mortality	O
+in	O
+these	O
+patients	O
+(	O
+p	O
+=	O
+0	O
+.	O
+37	O
+).	O
+
+Such	O
+a	O
+model	O
+could	O
+be	O
+utilized	O
+in	O
+evaluating	O
+and	O
+developing	O
+better	O
+treatment	O
+for	O
+ALI	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+as	O
+other	O
+available	O
+rodent	B-SPEC
+models	O
+do	O
+not	O
+consistently	O
+produce	O
+the	O
+endothelial	B-ANAT
+permeability	O
+that	O
+is	O
+a	O
+major	O
+component	O
+of	O
+ARDS	B-DISO
+.	O
+
+Recently	O
+,	O
+we	O
+showed	O
+that	O
+LeTx	O
+inactivation	B-DISO
+of	O
+p38	B-PRGE
+MAP	B-ENZY
+kinase	I-ENZY
+signaling	B-PROC
+via	O
+degradation	O
+of	O
+MKK3	O
+in	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+endothelial	I-ANAT
+cells	I-ANAT
+can	O
+be	O
+linked	O
+to	O
+compromise	O
+of	O
+the	O
+endothelial	B-ANAT
+permeability	O
+barrier	O
+.	O
+
+We	O
+have	O
+now	O
+designed	O
+a	O
+peptide	B-CHED
+that	O
+directly	O
+and	O
+specifically	O
+activates	O
+MK2	B-PRGE
+,	O
+causing	O
+HSP27	B-PRGE
+phosphorylation	B-PROC
+in	O
+cells	B-COMP
+and	O
+in	O
+vivo	O
+.	O
+
+MVs	O
+derived	O
+from	O
+human	B-SPEC
+MSCs	B-FUNC
+were	O
+as	O
+effective	O
+as	O
+the	O
+parent	O
+stem	B-ANAT
+cells	I-ANAT
+in	O
+severe	O
+bacterial	B-DISO
+pneumonia	I-DISO
+.	O
+
+We	O
+conducted	O
+a	O
+retrospective	O
+review	O
+of	O
+all	O
+cases	O
+of	O
+CoV	O
+infection	B-DISO
+documented	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+,	O
+(	O
+PCR	O
+)-	O
+based	O
+testing	O
+on	O
+nasopharyngeal	B-ANAT
+and	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+samples	O
+between	O
+June	O
+2010	O
+and	O
+2013	O
+.	O
+
+No	O
+infectious	B-DISO
+PEDV	B-SPEC
+was	O
+recovered	O
+after	O
+treatment	O
+with	O
+evaluated	O
+disinfectants	B-CHED
+.	O
+
+Critical	B-DISO
+illness	I-DISO
+causes	O
+long	O
+-	O
+term	O
+psychological	B-DISO
+and	O
+function	O
+sequelae	O
+:	O
+the	O
+risk	O
+of	O
+a	O
+new	O
+psychiatric	B-DISO
+diagnosis	I-DISO
+and	O
+severe	O
+physical	B-DISO
+impairment	I-DISO
+is	O
+significantly	O
+increased	O
+in	O
+the	O
+months	O
+after	O
+discharge	B-ANAT
+from	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Daily	O
+sedation	B-DISO
+discontinuation	O
+enhances	O
+the	O
+validity	O
+of	O
+routine	O
+delirium	B-DISO
+assessment	O
+.	O
+
+Integrating	O
+""""	O
+big	O
+data	O
+""""	O
+approaches	O
+into	O
+treatment	O
+decisions	O
+and	O
+trial	O
+designs	O
+offers	O
+a	O
+potential	O
+means	O
+of	O
+individualizing	O
+care	O
+to	O
+enhance	O
+outcomes	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+whether	O
+common	O
+variants	O
+across	O
+the	O
+nuclear	B-PRGE
+factor	I-PRGE
+erythroid	I-PRGE
+2	O
+-	O
+like	O
+2	O
+(	O
+NFE2L2	B-PRGE
+)	O
+gene	O
+contribute	O
+to	O
+the	O
+development	B-PROC
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+One	O
+of	O
+those	O
+SNPs	O
+(	O
+rs672961	O
+)	O
+was	O
+previously	O
+associated	O
+with	O
+trauma	O
+-	O
+induced	O
+ARDS	B-DISO
+and	O
+modified	O
+the	O
+promoter	O
+activity	O
+of	O
+the	O
+NFE2L2	B-PRGE
+gene	I-PRGE
+,	O
+showing	O
+an	O
+odds	O
+ratio	O
+of	O
+1	O
+.	O
+93	O
+per	O
+T	O
+allele	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+17	O
+-	O
+3	O
+.	O
+18	O
+;	O
+p	O
+=	O
+0	O
+.	O
+0089	O
+).	O
+
+Cases	O
+were	O
+children	O
+aged	O
+≤	O
+5	O
+years	O
+with	O
+radiological	O
+CAP	B-DISO
+.	O
+
+A	O
+total	O
+of	O
+121	O
+cases	O
+,	O
+of	O
+which	O
+93	O
+cases	O
+met	O
+the	O
+WHO	O
+criteria	O
+for	O
+radiological	O
+pneumonia	B-DISO
+,	O
+and	O
+240	O
+controls	O
+were	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+TITLE	O
+:	O
+Public	O
+health	O
+in	O
+Canada	O
+:	O
+Evolution	B-PROC
+,	O
+meaning	O
+and	O
+a	O
+new	O
+paradigm	O
+for	O
+respiratory	O
+therapy	O
+.	O
+
+Of	O
+these	O
+patients	O
+,	O
+22	O
+(	O
+31	O
+.	O
+9	O
+%)	O
+had	O
+undergone	O
+cardiothoracic	O
+surgery	O
+,	O
+32	O
+(	O
+46	O
+.	O
+4	O
+%)	O
+had	O
+undergone	O
+liver	B-ANAT
+transplantation	O
+,	O
+and	O
+15	O
+(	O
+21	O
+.	O
+7	O
+%)	O
+had	O
+undergone	O
+other	O
+procedures	O
+.	O
+
+TITLE	O
+:	O
+MERS	O
+-	O
+CoV	O
+in	O
+Upper	B-ANAT
+Respiratory	I-ANAT
+Tract	I-ANAT
+and	O
+Lungs	B-ANAT
+of	O
+Dromedary	B-SPEC
+Camels	B-SPEC
+,	O
+Saudi	O
+Arabia	O
+,	O
+2013	O
+-	O
+2014	O
+.	O
+
+ABSTRACT	O
+:	O
+Sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+,	O
+the	O
+most	O
+common	O
+inherited	O
+hemoglobinopathy	O
+in	O
+the	O
+United	O
+States	O
+,	O
+is	O
+a	O
+group	O
+of	O
+autosomal	B-COMP
+recessive	O
+red	B-ANAT
+cell	I-ANAT
+disorders	O
+resulting	O
+from	O
+hemoglobin	B-PRGE
+S	I-PRGE
+.	O
+Hemoglobin	B-PRGE
+S	O
+forms	O
+rigid	B-DISO
+polymers	B-CHED
+when	O
+deoxygenated	O
+that	O
+give	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+their	O
+sickle	O
+crescent	O
+shape	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Advances	O
+in	O
+the	O
+researches	O
+of	O
+genomic	O
+characterization	O
+and	O
+molecular	O
+detection	O
+of	O
+Middel	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+].	O
+
+ABSTRACT	O
+:	O
+Middle	O
+east	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+recently	O
+identified	O
+as	O
+a	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+known	O
+to	O
+infect	O
+human	B-SPEC
+with	O
+high	O
+mortality	O
+.	O
+
+There	O
+are	O
+also	O
+serious	O
+infectious	B-DISO
+diseases	I-DISO
+classically	O
+considered	O
+zoonotic	O
+,	O
+such	O
+as	O
+influenza	B-DISO
+,	O
+rabies	B-DISO
+,	O
+bubonic	B-DISO
+plague	I-DISO
+,	O
+brucellosis	B-DISO
+,	O
+and	O
+leptospirosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+the	O
+Receptor	O
+-	O
+Binding	B-FUNC
+Domain	O
+of	O
+the	O
+Spike	O
+Glycoprotein	B-CHED
+of	O
+Human	B-SPEC
+Betacoronavirus	B-SPEC
+HKU1	I-PRGE
+.	O
+
+To	O
+identify	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+in	O
+the	O
+spike	O
+of	O
+human	B-PRGE
+β	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+HKU1	I-PRGE
+in	O
+group	O
+A	O
+,	O
+we	O
+generated	O
+and	O
+mapped	O
+a	O
+panel	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+to	O
+the	O
+ectodomain	O
+of	O
+HKU1	B-PRGE
+spike	I-PRGE
+protein	I-PRGE
+.	O
+
+Preincubation	O
+of	O
+HTBE	O
+cells	B-COMP
+with	O
+a	O
+truncated	O
+HKU1	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+that	O
+includes	O
+the	O
+C	O
+domain	O
+blocked	O
+infection	B-DISO
+with	O
+HKU1	O
+virus	B-SPEC
+,	O
+but	O
+preincubation	O
+of	O
+cells	B-COMP
+with	O
+truncated	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+containing	O
+only	O
+the	O
+NTD	O
+did	O
+not	O
+block	O
+infection	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+showed	O
+that	O
+for	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+HKU1	O
+,	O
+the	O
+purified	O
+C	O
+domain	O
+,	O
+downstream	O
+of	O
+the	O
+NTD	O
+,	O
+could	O
+block	O
+HKU1	O
+virus	B-DISO
+infection	I-DISO
+of	O
+human	B-SPEC
+respiratory	O
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+that	O
+several	O
+monoclonal	O
+antibodies	B-COMP
+that	O
+mapped	O
+to	O
+the	O
+C	O
+domain	O
+neutralized	O
+virus	B-SPEC
+infectivity	O
+.	O
+
+Surprisingly	O
+,	O
+two	O
+β	O
+-	O
+CoVs	O
+in	O
+group	O
+A	O
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+and	O
+HKU1	O
+,	O
+have	O
+evolved	O
+to	O
+use	O
+different	O
+regions	O
+of	O
+their	O
+spike	O
+glycoproteins	B-CHED
+to	O
+recognize	O
+their	O
+respective	O
+receptors	O
+.	O
+
+Mutational	O
+analysis	O
+of	O
+N	O
+protein	B-CHED
+allowed	O
+us	O
+to	O
+find	O
+out	O
+the	O
+critical	O
+residues	O
+for	O
+the	O
+VSR	O
+activity	O
+.	O
+
+Using	O
+the	O
+MHV	B-SPEC
+-	O
+A59	O
+as	O
+the	O
+coronavirus	B-SPEC
+replication	O
+model	O
+,	O
+we	O
+showed	O
+that	O
+ectopic	B-PROC
+expression	I-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+could	O
+promote	O
+MHV	B-SPEC
+replication	O
+in	O
+RNAi	B-PROC
+-	O
+active	O
+cells	B-COMP
+but	O
+not	O
+in	O
+RNAi	B-PROC
+-	O
+depleted	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+Infections	I-DISO
+in	O
+the	O
+U	O
+.	O
+S	O
+.	O
+Military	O
+:	O
+Recent	O
+Experience	O
+and	O
+Control	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+comprehensive	O
+review	O
+outlines	O
+the	O
+impact	O
+of	O
+military	O
+-	O
+relevant	O
+respiratory	O
+infections	O
+,	O
+with	O
+special	O
+attention	O
+to	O
+recruit	O
+training	O
+environments	O
+,	O
+influenza	B-DISO
+pandemics	O
+in	O
+1918	O
+to	O
+1919	O
+and	O
+2009	O
+to	O
+2010	O
+,	O
+and	O
+peacetime	O
+operations	O
+and	O
+conflicts	O
+in	O
+the	O
+past	O
+25	O
+years	O
+.	O
+
+Outbreaks	O
+and	O
+epidemiologic	O
+investigations	O
+of	O
+viral	O
+and	O
+bacterial	B-DISO
+infections	I-DISO
+among	O
+high	O
+-	O
+risk	O
+groups	O
+are	O
+presented	O
+,	O
+including	O
+(	O
+i	O
+)	O
+experience	O
+by	O
+recruits	O
+at	O
+training	O
+centers	O
+,	O
+(	O
+ii	O
+)	O
+impact	O
+on	O
+advanced	O
+trainees	O
+in	O
+special	O
+settings	O
+,	O
+(	O
+iii	O
+)	O
+morbidity	O
+sustained	O
+by	O
+shipboard	O
+personnel	O
+at	O
+sea	O
+,	O
+and	O
+(	O
+iv	O
+)	O
+experience	O
+of	O
+deployed	O
+personnel	O
+.	O
+
+We	O
+also	O
+outline	O
+military	O
+-	O
+specific	O
+initiatives	O
+in	O
+(	O
+i	O
+)	O
+surveillance	O
+,	O
+(	O
+ii	O
+)	O
+vaccine	O
+development	O
+and	O
+policy	O
+,	O
+(	O
+iii	O
+)	O
+novel	O
+influenza	B-DISO
+and	O
+coronavirus	B-SPEC
+diagnostic	O
+test	O
+development	B-PROC
+and	O
+surveillance	O
+methods	O
+,	O
+(	O
+iv	O
+)	O
+influenza	B-SPEC
+virus	I-SPEC
+transmission	O
+and	O
+severity	O
+prediction	O
+modeling	O
+efforts	O
+,	O
+and	O
+(	O
+v	O
+)	O
+evaluation	O
+and	O
+implementation	O
+of	O
+nonvaccine	O
+,	O
+nonpharmacologic	O
+interventions	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+no	O
+information	O
+about	O
+whether	O
+the	O
+severity	O
+of	O
+acute	O
+-	O
+HCA	O
+or	O
+intra	O
+-	O
+amniotic	B-ANAT
+inflammation	B-DISO
+(	O
+IAI	O
+)	O
+is	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+RDS	O
+.	O
+
+We	O
+then	O
+examined	O
+the	O
+effects	O
+of	O
+these	O
+inhibitors	O
+on	O
+the	O
+activation	O
+of	O
+collagen	B-PRGE
+I	I-PRGE
+and	O
+α	B-PRGE
+-	I-PRGE
+smooth	I-PRGE
+muscle	I-PRGE
+actin	I-PRGE
+(	O
+α	B-PRGE
+-	I-PRGE
+SMA	I-PRGE
+)	O
+induced	O
+by	O
+PDGF	B-FUNC
+or	O
+TGFβ1	O
+stimulation	O
+.	O
+
+To	O
+profile	O
+the	O
+viruses	B-SPEC
+causing	O
+ARI	B-CHED
+in	O
+children	O
+admitted	O
+to	O
+a	O
+community	O
+-	O
+based	O
+hospital	O
+in	O
+central	O
+Taiwan	O
+,	O
+a	O
+cross	O
+-	O
+sectional	O
+study	O
+was	O
+conducted	O
+on	O
+children	O
+under	O
+14	O
+years	O
+of	O
+age	O
+that	O
+were	O
+hospitalized	O
+with	O
+febrile	B-PROC
+ARI	B-CHED
+.	O
+
+In	O
+conclusion	O
+,	O
+Rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+adenovirus	B-DISO
+were	O
+prevalent	O
+in	O
+this	O
+study	O
+by	O
+adopting	O
+RVP	O
+assay	O
+.	O
+
+Both	O
+cases	O
+were	O
+similar	O
+in	O
+terms	O
+of	O
+starting	O
+symptoms	O
+,	O
+the	O
+rapid	O
+progression	O
+to	O
+ARDS	B-DISO
+,	O
+and	O
+the	O
+treatment	O
+strategy	O
+,	O
+direct	O
+hemoperfusion	O
+with	O
+a	O
+polymyxin	B-CHED
+-	O
+B	O
+-	O
+immobilized	O
+fiber	B-ANAT
+column	B-ANAT
+(	O
+PMX	O
+-	O
+DHP	O
+)	O
+and	O
+oseltamivir	B-CHED
+.	O
+
+He	O
+died	B-PROC
+of	O
+respiratory	B-DISO
+failure	I-DISO
+on	O
+day	O
+129	O
+.	O
+
+Pathology	B-DISO
+findings	O
+of	O
+the	O
+lungs	B-ANAT
+during	O
+autopsy	O
+showed	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Rodent	B-SPEC
+-	O
+borne	O
+hantaviruses	B-SPEC
+(	O
+family	B-SPEC
+Bunyaviridae	I-SPEC
+,	O
+genus	B-SPEC
+Hantavirus	I-SPEC
+)	O
+cause	O
+hantavirus	B-DISO
+pulmonary	B-ANAT
+syndrome	I-DISO
+in	O
+the	O
+Americas	O
+and	O
+hemorrhagic	B-DISO
+fever	I-DISO
+with	I-DISO
+renal	B-ANAT
+syndrome	I-DISO
+in	O
+Europe	O
+and	O
+Asia	O
+.	O
+
+TITLE	O
+:	O
+Genetic	B-PROC
+drift	I-PROC
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+spike	I-PRGE
+gene	I-PRGE
+during	O
+adaptive	O
+evolution	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+As	O
+a	O
+single	O
+biological	B-CHED
+marker	I-CHED
+,	O
+the	O
+prognostic	O
+value	O
+for	O
+death	B-PROC
+of	O
+plasma	B-PRGE
+suPAR	I-PRGE
+in	O
+ARDS	B-DISO
+patients	O
+is	O
+low	O
+.	O
+
+PEDV	B-SPEC
+outbreaks	O
+have	O
+occurred	O
+continuously	O
+in	O
+most	O
+swine	B-SPEC
+-	O
+producing	O
+Asian	O
+countries	O
+and	O
+have	O
+recently	O
+emerged	O
+in	O
+the	O
+United	O
+States	O
+,	O
+leading	O
+to	O
+large	O
+economic	O
+losses	O
+for	O
+both	O
+the	O
+Asian	O
+and	O
+US	O
+pig	B-SPEC
+industries	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+produced	O
+an	O
+IgY	O
+against	O
+the	O
+PEDV	B-PRGE
+S1	I-PRGE
+protein	B-CHED
+and	O
+investigated	O
+its	O
+immunoprophylactic	O
+effect	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+We	O
+next	O
+tested	O
+the	O
+ability	O
+of	O
+oral	B-ANAT
+passive	O
+immunization	O
+with	O
+anti	O
+-	O
+PEDV	B-SPEC
+S1	O
+IgY	O
+to	O
+protect	O
+piglets	O
+against	O
+PEDV	B-SPEC
+.	O
+
+Specific	O
+chicken	B-SPEC
+IgY	O
+against	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+was	O
+orally	B-ANAT
+administered	O
+to	O
+neonatal	O
+piglets	O
+,	O
+and	O
+their	O
+responses	O
+subsequent	O
+to	O
+a	O
+virulent	O
+PEDV	B-SPEC
+challenge	O
+were	O
+monitored	O
+.	O
+
+In	O
+preclinical	O
+models	O
+,	O
+p38	B-FUNC
+inhibitors	B-CHED
+reduce	O
+lung	B-ANAT
+injury	O
+following	O
+pancreatitis	B-DISO
+and	O
+burn	O
+injury	O
+.	O
+
+Pharmacokinetic	O
+models	O
+indicated	O
+that	O
+the	O
+higher	O
+dose	O
+of	O
+10	O
+mg	O
+given	O
+as	O
+continuous	O
+infusion	O
+over	O
+24	O
+hours	O
+had	O
+the	O
+most	O
+favorable	O
+plasma	B-ANAT
+concentration	O
+profile	O
+.	O
+
+Chest	B-ANAT
+radiographic	O
+scores	O
+were	O
+estimated	O
+after	O
+dividing	O
+each	O
+lung	B-ANAT
+into	O
+three	O
+zones	O
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+analysis	O
+,	O
+Kaplan	O
+-	O
+Meier	O
+survival	O
+curve	O
+analysis	O
+,	O
+and	O
+the	O
+Mann	O
+-	O
+Whitney	O
+U	O
+test	O
+were	O
+used	O
+to	O
+compare	O
+data	O
+of	O
+deceased	B-PROC
+patients	O
+with	O
+those	O
+of	O
+individuals	O
+who	O
+recovered	O
+to	O
+identify	O
+prognostic	O
+radiographic	O
+features	O
+.	O
+
+Univariate	O
+and	O
+logistic	O
+regression	O
+analyses	O
+identified	O
+the	O
+chest	B-ANAT
+radiographic	O
+score	O
+as	O
+an	O
+independent	O
+predictor	O
+of	O
+mortality	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+1	O
+.	O
+38	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+07	O
+-	O
+1	O
+.	O
+77	O
+;	O
+p	O
+=	O
+0	O
+.	O
+01	O
+).	O
+
+According	O
+to	O
+the	O
+results	O
+of	O
+high	O
+-	O
+resolution	O
+two	O
+-	O
+dimensional	O
+gel	O
+electrophoresis	O
+,	O
+a	O
+total	O
+of	O
+43	O
+protein	B-CHED
+spots	B-DISO
+were	O
+initially	O
+found	O
+to	O
+be	O
+differentially	O
+expressed	B-PROC
+in	O
+PK	O
+-	O
+PDCoV	O
+-	O
+N	O
+cells	B-COMP
+in	O
+comparison	O
+with	O
+control	O
+PK	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Attracting	O
+global	O
+attention	O
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+continues	O
+to	O
+cause	O
+sporadic	O
+cases	O
+and	O
+a	O
+potential	O
+risk	O
+of	O
+healthcare	O
+-	O
+associated	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+Four	O
+Commercial	O
+Multiplex	O
+Molecular	O
+Tests	O
+for	O
+the	O
+Diagnosis	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Infections	I-DISO
+.	O
+
+For	O
+these	O
+techniques	O
+,	O
+the	O
+highest	O
+Youden	O
+'	O
+s	O
+index	O
+(	O
+YI	O
+),	O
+positive	O
+predictive	O
+(	O
+PPV	O
+)	O
+and	O
+specificity	O
+(	O
+Sp	O
+)	O
+values	O
+were	O
+observed	O
+for	O
+Core	O
+tests	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+influenza	B-PATH
+A	I-PATH
+[	O
+YI	O
+:	O
+0	O
+.	O
+86	O
+-	O
+1	O
+.	O
+00	O
+;	O
+PPV	B-CHED
+:	O
+78	O
+.	O
+95	O
+-	O
+100	O
+.	O
+00	O
+;	O
+Sp	O
+:	O
+97	O
+.	O
+32	O
+-	O
+100	O
+.	O
+00	O
+]	O
+&	O
+B	O
+[	O
+YI	O
+:	O
+0	O
+.	O
+44	O
+-	O
+1	O
+.	O
+00	O
+;	O
+PPV	B-CHED
+:	O
+100	O
+.	O
+00	O
+;	O
+Sp	O
+:	O
+100	O
+.	O
+00	O
+],	O
+hRSV	B-SPEC
+[	O
+YI	O
+:	O
+0	O
+.	O
+50	O
+-	O
+0	O
+.	O
+99	O
+;	O
+PPV	B-CHED
+:	O
+85	O
+.	O
+71	O
+-	O
+100	O
+.	O
+00	O
+;	O
+Sp	O
+:	O
+99	O
+.	O
+38	O
+-	O
+100	O
+.	O
+00	O
+],	O
+hMPV	B-SPEC
+[	O
+YI	O
+:	O
+0	O
+.	O
+71	O
+-	O
+1	O
+.	O
+00	O
+;	O
+PPV	B-CHED
+:	O
+83	O
+.	O
+33	O
+-	O
+100	O
+.	O
+00	O
+;	O
+Sp	O
+:	O
+99	O
+.	O
+37	O
+-	O
+100	O
+.	O
+00	O
+],	O
+EV	O
+/	O
+hRV	O
+[	O
+YI	O
+:	O
+0	O
+.	O
+62	O
+-	O
+0	O
+.	O
+82	O
+;	O
+PPV	B-CHED
+:	O
+93	O
+.	O
+33	O
+-	O
+100	O
+.	O
+00	O
+;	O
+Sp	O
+:	O
+94	O
+.	O
+48	O
+-	O
+100	O
+.	O
+00	O
+],	O
+AdV	O
+[	O
+YI	O
+:	O
+1	O
+.	O
+00	O
+;	O
+PPV	B-CHED
+:	O
+100	O
+.	O
+00	O
+;	O
+Sp	O
+:	O
+100	O
+.	O
+00	O
+]	O
+and	O
+hBoV	O
+[	O
+YI	O
+:	O
+0	O
+.	O
+20	O
+-	O
+0	O
+.	O
+80	O
+;	O
+PPV	B-CHED
+:	O
+57	O
+.	O
+14	O
+-	O
+100	O
+.	O
+00	O
+;	O
+Sp	O
+:	O
+98	O
+.	O
+14	O
+-	O
+100	O
+.	O
+00	O
+]).	O
+
+In	O
+a	O
+small	O
+-	O
+molecule	O
+screen	O
+to	O
+identify	O
+host	B-COMP
+mediators	O
+of	O
+reovirus	B-DISO
+infection	I-DISO
+,	O
+we	O
+found	O
+that	O
+treatment	O
+of	O
+cells	B-COMP
+with	O
+5	B-CHED
+-	I-CHED
+nonyloxytryptamine	I-CHED
+(	O
+5	O
+-	O
+NT	O
+),	O
+a	O
+prototype	O
+serotonin	B-PRGE
+receptor	I-PRGE
+agonist	B-CHED
+,	O
+diminished	O
+reovirus	B-SPEC
+cytotoxicity	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+Pattern	O
+of	O
+Brain	B-ANAT
+Microhemorrhages	O
+After	O
+Severe	O
+Lung	B-ANAT
+Failure	O
+Resembles	O
+the	O
+One	O
+Seen	O
+in	O
+High	O
+-	O
+Altitude	O
+Cerebral	O
+Edema	O
+.	O
+
+ABSTRACT	O
+:	O
+At	O
+the	O
+end	O
+of	O
+May	O
+2015	O
+,	O
+an	O
+imported	O
+case	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+was	O
+confirmed	O
+in	O
+China	O
+.	O
+
+From	O
+April	O
+2010	O
+to	O
+May	O
+2011	O
+,	O
+1082	O
+nasopharyngeal	B-ANAT
+swabs	O
+were	O
+screened	O
+for	O
+respiratory	O
+viruses	B-SPEC
+by	O
+PCR	O
+.	O
+
+Children	O
+with	O
+single	O
+HRV	O
+infections	B-DISO
+presented	O
+with	O
+significantly	O
+higher	O
+rate	O
+of	O
+hypoxia	B-DISO
+than	O
+those	O
+infected	O
+with	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+or	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	B-SPEC
+)-	O
+3	O
+(	O
+12	O
+·	O
+4	O
+%	O
+vs	O
+.	O
+3	O
+·	O
+8	O
+%	O
+and	O
+0	O
+%,	O
+respectively	O
+,	O
+P	O
+<	O
+0	O
+·	O
+05	O
+),	O
+higher	O
+rate	O
+of	O
+chest	B-ANAT
+retraction	O
+than	O
+PIV	B-SPEC
+-	O
+1	O
+(	O
+57	O
+·	O
+3	O
+%	O
+vs	O
+.	O
+34	O
+·	O
+5	O
+%,	O
+P	O
+=	O
+0	O
+·	O
+028	O
+),	O
+higher	O
+rate	O
+of	O
+wheezing	O
+than	O
+influenza	B-PATH
+A	I-PATH
+(	O
+63	O
+·	O
+2	O
+%	O
+vs	O
+.	O
+42	O
+·	O
+3	O
+%,	O
+P	O
+=	O
+0	O
+·	O
+038	O
+).	O
+
+Recombinant	O
+S1	O
+was	O
+expressed	B-PROC
+as	O
+a	O
+secreted	B-PROC
+protein	B-CHED
+fused	O
+with	O
+a	O
+trimerization	O
+motif	O
+peptide	B-CHED
+,	O
+then	O
+purified	O
+using	O
+Ni	O
+Sepharose	B-CHED
+.	O
+
+Six	O
+weeks	O
+after	O
+immunization	O
+,	O
+anti	O
+-	O
+IBV	B-SPEC
+neutralizing	O
+titer	O
+and	O
+anti	O
+-	O
+S1	O
+ELISA	O
+titer	O
+were	O
+determined	O
+;	O
+immunized	O
+chickens	B-SPEC
+then	O
+were	O
+inoculated	O
+with	O
+IBV	B-SPEC
+via	O
+the	O
+trachea	B-DISO
+and	O
+ciliary	O
+activity	O
+was	O
+observed	O
+.	O
+
+Results	O
+showed	O
+that	O
+the	O
+recombinant	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+was	O
+highly	O
+glycosylated	O
+,	O
+and	O
+the	O
+neutralizing	O
+antigenicity	O
+of	O
+recombinant	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+was	O
+lower	O
+than	O
+that	O
+of	O
+inactivated	O
+virus	B-SPEC
+.	O
+
+One	O
+piglet	O
+had	O
+a	O
+positive	O
+real	O
+-	O
+time	O
+quantitative	O
+polymerase	O
+chain	O
+reaction	O
+test	O
+on	O
+rectal	O
+swab	O
+at	O
+12	O
+hpi	B-DISO
+,	O
+and	O
+all	O
+remaining	O
+piglets	O
+were	O
+positive	O
+thereafter	O
+,	O
+with	O
+highest	O
+viral	O
+quantities	O
+detected	O
+at	O
+24	O
+and	O
+36	O
+hpi	B-DISO
+.	O
+
+Viremia	B-DISO
+was	O
+confirmed	O
+in	O
+18	O
+of	O
+20	O
+pigs	B-SPEC
+at	O
+euthanasia	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+highly	O
+enteropathogenic	O
+coronavirus	B-SPEC
+of	O
+swine	B-SPEC
+that	O
+causes	O
+acute	O
+enteritis	B-DISO
+with	O
+high	O
+mortality	O
+in	O
+nursery	O
+piglets	O
+.	O
+
+Inhibition	B-PROC
+of	O
+ERK	B-FUNC
+activation	O
+also	O
+diminished	O
+viral	O
+protein	B-CHED
+expression	B-PROC
+and	O
+genomic	O
+and	O
+subgenomic	O
+RNA	O
+transcription	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viral	B-DISO
+infections	I-DISO
+(	O
+RVI	O
+)	O
+are	O
+important	O
+in	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantations	O
+(	O
+HSCT	O
+)	O
+and	O
+knowledge	O
+regarding	O
+incidence	O
+,	O
+morbidity	O
+,	O
+mortality	O
+,	O
+and	O
+long	O
+-	O
+term	O
+pulmonary	B-DISO
+complications	I-DISO
+is	O
+limited	O
+.	O
+
+The	O
+results	O
+indicated	O
+that	O
+NIBV	O
+infection	B-DISO
+could	O
+cause	O
+the	O
+increases	O
+of	O
+renal	B-PRGE
+XOD	I-PRGE
+gene	B-PROC
+transcription	I-PROC
+and	O
+serum	B-COMP
+XOD	O
+activity	O
+,	O
+leading	O
+to	O
+hyperuricemia	B-DISO
+and	O
+reduction	O
+of	O
+antioxidants	B-CHED
+in	O
+the	O
+body	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Overwintering	O
+Is	O
+Associated	O
+with	O
+Reduced	O
+Expression	B-PROC
+of	O
+Immune	O
+Genes	O
+and	O
+Higher	O
+Susceptibility	O
+to	O
+Virus	O
+Infection	O
+in	O
+Honey	B-SPEC
+Bees	I-SPEC
+.	O
+
+We	O
+tested	O
+this	O
+hypothesis	O
+by	O
+comparing	O
+the	O
+expression	B-PROC
+of	O
+eight	O
+immune	O
+genes	O
+and	O
+naturally	O
+occurring	O
+infection	B-DISO
+levels	O
+of	O
+deformed	B-SPEC
+wing	I-SPEC
+virus	I-SPEC
+(	O
+DWV	B-SPEC
+),	O
+one	O
+of	O
+the	O
+most	O
+widespread	O
+viruses	B-SPEC
+in	O
+A	B-SPEC
+.	I-SPEC
+mellifera	I-SPEC
+populations	O
+,	O
+between	O
+summer	O
+and	O
+winter	O
+bees	B-SPEC
+.	O
+
+Our	O
+data	O
+show	O
+that	O
+high	O
+DWV	B-SPEC
+loads	O
+in	O
+winter	O
+bees	B-SPEC
+correlate	O
+with	O
+reduced	O
+expression	B-PROC
+of	O
+genes	O
+involved	O
+in	O
+the	O
+cellular	B-PROC
+immune	I-PROC
+response	I-PROC
+and	O
+physiological	O
+activity	O
+and	O
+high	O
+expression	B-PROC
+of	O
+humoral	O
+immune	O
+genes	O
+involved	O
+in	O
+antibacterial	O
+defense	O
+compared	O
+with	O
+summer	O
+bees	B-SPEC
+.	O
+
+This	O
+expression	B-PROC
+pattern	O
+could	O
+reflect	O
+evolutionary	O
+adaptations	B-PROC
+to	O
+resist	O
+bacterial	O
+pathogens	O
+and	O
+economize	O
+energy	O
+during	O
+the	O
+winter	O
+under	O
+a	O
+pathogen	O
+landscape	O
+with	O
+reduced	O
+risk	O
+of	O
+pathogenic	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+outbreak	O
+of	O
+Varroa	B-SPEC
+destructor	I-SPEC
+infestation	B-DISO
+could	O
+have	O
+overcome	O
+these	O
+adaptations	B-PROC
+by	O
+promoting	O
+the	O
+transmission	O
+of	O
+viruses	B-SPEC
+.	O
+
+Infections	B-DISO
+in	O
+North	O
+America	O
+occur	O
+most	O
+frequently	O
+during	O
+the	O
+spring	O
+and	O
+summer	O
+months	O
+in	O
+the	O
+Northeastern	O
+and	O
+Midwestern	O
+United	O
+States	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+are	O
+some	O
+patients	O
+with	O
+severe	O
+respiratory	O
+disturbances	O
+like	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+suspicion	O
+of	O
+brain	B-DISO
+death	B-PROC
+,	O
+for	O
+whom	O
+typical	O
+performance	O
+of	O
+the	O
+apneic	B-DISO
+test	O
+is	O
+difficult	O
+to	O
+complete	O
+because	O
+of	O
+quick	O
+desaturation	O
+and	O
+rapid	O
+deterioration	O
+without	O
+effective	O
+ventilation	O
+.	O
+
+To	O
+avoid	O
+failure	O
+of	O
+brain	B-DISO
+death	B-PROC
+confirmation	O
+and	O
+possible	O
+loss	O
+of	O
+organ	B-ANAT
+donation	O
+another	O
+approach	O
+to	O
+apneic	B-DISO
+test	O
+is	O
+needed	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+provide	O
+a	O
+useful	O
+reference	O
+for	O
+CEK	O
+-	O
+adapted	O
+IBV	B-SPEC
+field	O
+strains	O
+and	O
+the	O
+production	O
+of	O
+CEK	O
+-	O
+attenuated	O
+IBV	B-SPEC
+vaccine	O
+.	O
+
+We	O
+present	O
+an	O
+adult	O
+SCD	B-DISO
+patient	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+AChS	B-DISO
+,	O
+successfully	O
+treated	O
+with	O
+VV	O
+-	O
+ECMO	O
+.	O
+
+After	O
+NPPV	O
+treatment	O
+,	O
+systolic	O
+pressure	O
+,	O
+heart	B-ANAT
+rate	O
+,	O
+respiratory	O
+rate	O
+,	O
+and	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+decreased	O
+,	O
+whereas	O
+oxygen	B-CHED
+saturation	O
+increased	O
+significantly	O
+in	O
+the	O
+NPPV	O
+success	O
+group	O
+compared	O
+with	O
+the	O
+failed	O
+group	O
+.	O
+
+The	O
+median	O
+incubation	O
+period	O
+was	O
+six	O
+days	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+4	O
+–	O
+7	O
+days	O
+)	O
+and	O
+the	O
+duration	O
+between	O
+suspected	O
+symptom	B-DISO
+onset	O
+and	O
+laboratory	O
+confirmation	O
+was	O
+6	O
+.	O
+5	O
+days	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+4	O
+–	O
+9	O
+).	O
+
+ABSTRACT	O
+:	O
+South	O
+Korea	O
+is	O
+experiencing	O
+the	O
+largest	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infections	I-DISO
+outside	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+with	O
+166	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+,	O
+including	O
+24	O
+deaths	B-PROC
+up	O
+to	O
+19	O
+June	O
+2015	O
+.	O
+
+The	O
+initial	O
+areas	O
+of	O
+demyelination	B-DISO
+increase	O
+only	O
+slightly	O
+after	O
+the	O
+control	O
+of	O
+infection	B-DISO
+.	O
+
+Expanding	O
+lesions	O
+in	O
+the	O
+absence	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+are	O
+characterized	O
+by	O
+sustained	O
+microglial	O
+activation	O
+and	O
+partial	O
+loss	O
+of	O
+macrophage	B-ANAT
+/	O
+microglia	B-ANAT
+exhibiting	O
+an	O
+acquired	O
+deactivation	O
+phenotype	O
+.	O
+
+The	O
+clinical	O
+characteristics	O
+and	O
+mechanisms	O
+underlying	O
+late	O
+-	O
+phase	O
+muscle	B-ANAT
+dysfunction	O
+do	O
+not	O
+involve	O
+the	O
+massive	O
+protein	B-PROC
+degradation	I-PROC
+and	O
+atrophy	B-DISO
+of	O
+the	O
+early	O
+phase	O
+and	O
+may	O
+reflect	O
+a	O
+failure	O
+of	O
+the	O
+musculoskeletal	B-ANAT
+system	I-ANAT
+to	O
+regain	O
+homeostatic	B-PROC
+balance	B-PROC
+.	O
+
+Movement	B-PROC
+toward	O
+American	O
+Burn	O
+Association	O
+-	O
+supported	O
+,	O
+multicenter	O
+studies	O
+to	O
+determine	O
+best	O
+practices	O
+and	O
+guidelines	O
+for	O
+ventilator	O
+management	O
+in	O
+burn	O
+patients	O
+is	O
+prudent	O
+in	O
+light	O
+of	O
+these	O
+findings	O
+.	O
+
+In	O
+all	O
+three	O
+cases	O
+,	O
+PEDV	O
+was	O
+confirmed	O
+in	O
+feces	B-ANAT
+and	O
+small	B-ANAT
+intestines	I-ANAT
+by	O
+RT	O
+-	O
+qPCR	O
+.	O
+
+Phylogenetic	O
+analyses	O
+based	O
+on	O
+full	O
+-	O
+length	O
+PEDV	B-SPEC
+genomes	O
+revealed	O
+high	O
+identity	O
+among	O
+strains	O
+from	O
+all	O
+three	O
+herds	O
+.	O
+
+Moreover	O
+,	O
+the	O
+present	O
+case	O
+report	O
+indicates	O
+that	O
+variant	O
+strains	O
+of	O
+PEDV	B-SPEC
+,	O
+containing	O
+insertions	O
+and	O
+deletions	O
+in	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+,	O
+which	O
+were	O
+reported	O
+to	O
+be	O
+of	O
+lower	O
+virulence	B-PROC
+,	O
+might	O
+be	O
+able	O
+to	O
+cause	O
+high	O
+mortality	O
+in	O
+suckling	O
+piglets	O
+.	O
+
+Understanding	O
+the	O
+mechanism	O
+of	O
+this	O
+disruption	O
+could	O
+lead	O
+to	O
+the	O
+identification	O
+of	O
+novel	O
+antiviral	B-CHED
+therapeutics	O
+.	O
+
+ABSTRACT	O
+:	O
+Myd88	B-PRGE
+signaling	B-PROC
+is	O
+critical	O
+to	O
+the	O
+control	O
+of	O
+numerous	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+infections	B-DISO
+by	O
+promoting	O
+both	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+Nevertheless	O
+,	O
+the	O
+extent	O
+to	O
+which	O
+Myd88	B-PRGE
+regulates	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+versus	O
+proinflammatory	O
+factors	O
+and	O
+T	B-ANAT
+cell	I-ANAT
+function	O
+,	O
+as	O
+well	O
+as	O
+the	O
+anatomical	B-ANAT
+site	I-ANAT
+of	O
+action	O
+,	O
+varies	O
+extensively	O
+with	O
+the	O
+pathogen	O
+.	O
+
+Infected	O
+Myd88	O
+(-/-)	O
+mice	B-SPEC
+failed	O
+to	O
+control	O
+virus	B-SPEC
+,	O
+exhibited	O
+enhanced	O
+clinical	O
+disease	O
+coincident	O
+with	O
+increased	O
+demyelination	B-DISO
+,	O
+and	O
+succumbed	O
+to	O
+infection	B-DISO
+within	O
+3	O
+weeks	O
+.	O
+
+The	O
+induction	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+,	O
+as	O
+well	O
+as	O
+of	O
+proinflammatory	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+was	O
+impaired	O
+early	O
+during	O
+infection	B-DISO
+.	O
+
+Moreover	O
+,	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+but	O
+not	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+were	O
+impaired	B-DISO
+in	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+production	O
+.	O
+
+During	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+infections	B-DISO
+,	O
+signaling	B-PROC
+through	O
+the	O
+adaptor	O
+protein	B-CHED
+Myd88	B-PRGE
+promotes	O
+both	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+By	O
+controlling	O
+both	O
+early	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+and	O
+CD4	B-PRGE
+T	I-PRGE
+cell	O
+-	O
+mediated	O
+antiviral	B-CHED
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+,	O
+Myd88	B-PRGE
+signaling	B-PROC
+limits	O
+the	O
+initial	O
+viral	O
+dissemination	O
+and	O
+is	O
+vital	O
+for	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+control	O
+of	O
+viral	O
+loads	O
+.	O
+
+Severe	O
+infusion	O
+-	O
+associated	O
+reactions	O
+are	O
+consistent	O
+with	O
+CRS	B-DISO
+and	O
+can	O
+cause	O
+serious	O
+cardiac	B-ANAT
+or	O
+respiratory	B-DISO
+problems	I-DISO
+,	O
+or	O
+in	O
+certain	O
+cases	O
+,	O
+mortality	O
+.	O
+
+CRS	B-DISO
+is	O
+a	O
+form	O
+of	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+).	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+the	O
+successful	O
+use	O
+of	O
+MB	O
+as	O
+a	O
+rescue	O
+therapy	O
+for	O
+CRS	B-DISO
+in	O
+a	O
+patient	O
+receiving	O
+rATG	O
+following	O
+a	O
+renal	B-ANAT
+transplant	B-ANAT
+was	O
+reported	O
+.	O
+
+After	O
+the	O
+initial	O
+interspecies	O
+transmission	O
+per	O
+se	O
+,	O
+the	O
+viruses	B-SPEC
+can	O
+disseminate	O
+into	O
+the	O
+human	B-SPEC
+population	O
+through	O
+various	O
+and	O
+distinct	O
+mechanisms	O
+.	O
+
+These	O
+populations	O
+are	O
+living	O
+nearby	O
+the	O
+habitats	O
+of	O
+several	O
+monkeys	B-SPEC
+and	O
+apes	B-SPEC
+,	O
+often	O
+naturally	O
+infected	O
+by	O
+different	O
+retroviruses	B-SPEC
+including	O
+SIV	B-DISO
+,	O
+STLV	O
+and	O
+simianfoamy	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+An	O
+analysis	O
+of	O
+prognostic	O
+factors	O
+in	O
+patients	O
+suffering	B-DISO
+from	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+complicated	O
+with	O
+Yangming	O
+Fushi	O
+syndrome	B-DISO
+:	O
+a	O
+report	O
+of	O
+206	O
+cases	O
+from	O
+multiple	O
+centers	O
+].	O
+
+AUC	O
+of	O
+LIPS	B-ANAT
+was	O
+0	O
+.	O
+725	O
+,	O
+the	O
+cut	O
+-	O
+off	O
+value	O
+was	O
+7	O
+,	O
+when	O
+LIPS	O
+≥	O
+7	O
+,	O
+the	O
+sensitivity	O
+was	O
+71	O
+.	O
+0	O
+%,	O
+specificity	O
+was	O
+75	O
+.	O
+6	O
+%.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+value	O
+of	O
+lung	B-ANAT
+ultrasound	O
+score	O
+(	O
+LUS	O
+)	O
+on	O
+assessing	O
+the	O
+severity	O
+and	O
+prognosis	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+to	O
+investigate	O
+its	O
+correlation	O
+with	O
+oxygenation	B-PROC
+index	O
+,	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluationII	O
+(	O
+APACHEII	O
+)	O
+score	O
+,	O
+sequential	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+(	O
+SOFA	O
+)	O
+score	O
+,	O
+and	O
+clinical	O
+pulmonary	B-DISO
+infection	I-DISO
+score	O
+(	O
+CPIS	O
+),	O
+and	O
+other	O
+traditional	O
+parameters	O
+.	O
+
+RESULTS	O
+:	O
+LUS	O
+had	O
+a	O
+negative	O
+correlation	O
+with	O
+oxygenation	B-PROC
+index	O
+(	O
+r	O
+=-	O
+0	O
+.	O
+755	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+a	O
+good	O
+positive	O
+correlation	O
+with	O
+APACHEII	O
+(	O
+r	O
+=	O
+0	O
+.	O
+504	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+SOFA	O
+(	O
+r	O
+=	O
+0	O
+.	O
+461	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+CPIS	O
+(	O
+r	O
+=	O
+0	O
+.	O
+571	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+was	O
+found	O
+.	O
+
+Area	O
+under	O
+ROC	O
+curve	O
+(	O
+AUC	O
+)	O
+was	O
+calculated	O
+,	O
+and	O
+the	O
+patients	O
+with	O
+LUS	O
+>	O
+19	O
+.	O
+0	O
+had	O
+a	O
+high	O
+mortality	O
+,	O
+sensitivity	O
+for	O
+predicting	O
+death	B-PROC
+was	O
+84	O
+.	O
+0	O
+%,	O
+and	O
+specificity	O
+of	O
+89	O
+.	O
+0	O
+%.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+efficacy	O
+of	O
+bundle	O
+treatment	O
+on	O
+patients	O
+with	O
+moderate	O
+or	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Compared	O
+with	O
+control	O
+group	O
+,	O
+oxygenation	B-PROC
+index	O
+in	O
+bundle	O
+treatment	O
+group	O
+was	O
+significantly	O
+improved	O
+[	O
+mmHg	O
+(	O
+1	O
+mmHg	O
+=	O
+0	O
+.	O
+133	O
+kPa	O
+):	O
+135	O
+.	O
+4	O
+±	O
+34	O
+.	O
+5	O
+vs	O
+.	O
+117	O
+.	O
+1	O
+±	O
+34	O
+.	O
+2	O
+,	O
+t	O
+=-	O
+2	O
+.	O
+273	O
+,	O
+P	O
+=	O
+0	O
+.	O
+026	O
+),	O
+the	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+was	O
+obviously	O
+reduced	O
+(	O
+days	O
+:	O
+8	O
+.	O
+70	O
+±	O
+2	O
+.	O
+50	O
+vs	O
+.	O
+10	O
+.	O
+10	O
+±	O
+2	O
+.	O
+67	O
+,	O
+t	O
+=	O
+2	O
+.	O
+308	O
+,	O
+P	O
+=	O
+0	O
+.	O
+024	O
+),	O
+incidence	O
+of	O
+VAP	O
+was	O
+significantly	O
+lower	O
+[	O
+18	O
+.	O
+2	O
+%	O
+(	O
+6	O
+/	O
+33	O
+)	O
+vs	O
+.	O
+32	O
+.	O
+5	O
+%	O
+(	O
+13	O
+/	O
+40	O
+),	O
+χ2	O
+=	O
+5	O
+.	O
+027	O
+,	O
+P	O
+=	O
+0	O
+.	O
+025	O
+],	O
+and	O
+28	O
+-	O
+day	O
+mortality	O
+rate	O
+was	O
+obviously	O
+lowered	O
+[	O
+24	O
+.	O
+2	O
+%	O
+(	O
+8	O
+/	O
+33	O
+)	O
+vs	O
+.	O
+37	O
+.	O
+5	O
+%	O
+(	O
+15	O
+/	O
+40	O
+),	O
+χ2	O
+=	O
+4	O
+.	O
+372	O
+,	O
+P	O
+=	O
+0	O
+.	O
+037	O
+],	O
+the	O
+length	O
+of	O
+ICU	O
+stay	O
+shown	O
+no	O
+statistical	O
+difference	O
+(	O
+days	O
+:	O
+10	O
+.	O
+40	O
+±	O
+1	O
+.	O
+94	O
+vs	O
+.	O
+11	O
+.	O
+30	O
+±	O
+2	O
+.	O
+34	O
+,	O
+t	O
+=	O
+1	O
+.	O
+620	O
+,	O
+P	O
+=	O
+0	O
+.	O
+110	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+constructed	O
+a	O
+series	O
+of	O
+cytoplasmic	B-COMP
+deletion	O
+mutants	O
+of	O
+MERS	O
+-	O
+CoV	O
+S	O
+and	O
+compared	O
+the	O
+efficiency	O
+with	O
+which	O
+they	O
+formed	O
+pseudotypes	O
+with	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+.	O
+
+Of	O
+282	O
+patients	O
+(	O
+mean	O
+age	O
+,	O
+51	O
+.	O
+6	O
+years	O
+;	O
+45	O
+%	O
+women	O
+;	O
+77	O
+%	O
+white	O
+)	O
+enrolled	O
+in	O
+Albuterol	O
+for	O
+Treatment	O
+of	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+,	O
+28	O
+(	O
+10	O
+%)	O
+developed	O
+new	O
+-	O
+onset	O
+AF	O
+during	O
+the	O
+study	O
+.	O
+
+New	O
+-	O
+onset	O
+AF	O
+during	O
+ARDS	B-DISO
+is	O
+associated	O
+with	O
+increased	O
+mortality	O
+;	O
+however	O
+,	O
+its	O
+mechanisms	O
+require	O
+further	O
+study	O
+.	O
+
+Expression	B-PROC
+of	O
+avian	B-PRGE
+β	I-PRGE
+-	I-PRGE
+defensins	B-PATH
+(	O
+AvBDs	O
+)	O
+and	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+(	O
+TLRs	O
+)	O
+in	O
+16	O
+tissues	B-ANAT
+of	O
+chicken	B-SPEC
+were	O
+compared	O
+at	O
+7	O
+days	O
+PI	O
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+the	O
+application	O
+of	O
+a	O
+reverse	O
+genetic	O
+approach	O
+to	O
+assess	O
+the	O
+importance	O
+of	O
+these	O
+macrodomains	O
+for	O
+the	O
+activity	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+RTC	O
+.	O
+
+The	O
+present	O
+study	O
+was	O
+undertaken	O
+to	O
+show	O
+that	O
+PQ	O
+causes	O
+alveolar	B-ANAT
+type	O
+II	O
+(	O
+A549	O
+)	O
+cell	B-PROC
+death	I-PROC
+and	O
+to	O
+evaluate	O
+whether	O
+chloroquine	B-CHED
+(	O
+CQ	O
+)	O
+can	O
+protect	O
+A549	O
+cells	B-COMP
+against	O
+PQ	O
+-	O
+induced	O
+cell	B-PROC
+death	I-PROC
+.	O
+
+More	O
+importantly	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+CQ	O
+was	O
+found	O
+to	O
+improve	O
+cell	B-PROC
+viability	I-PROC
+of	O
+PQ	O
+treated	O
+A549	O
+cells	B-COMP
+.	O
+
+Moreover	O
+,	O
+our	O
+data	O
+demonstrated	O
+that	O
+CQ	O
+increased	O
+lysosome	B-COMP
+-	O
+associated	O
+membrane	B-COMP
+protein	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+lysosome	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+membrane	B-COMP
+protein	B-CHED
+-	I-PRGE
+2	I-PRGE
+and	O
+light	O
+chain	O
+-	O
+3	O
+expressions	O
+,	O
+suggesting	O
+that	O
+the	O
+mechanism	O
+by	O
+which	O
+CQ	O
+rescues	O
+PQ	O
+-	O
+induced	O
+cytotoxicity	B-DISO
+may	O
+be	O
+through	O
+protection	O
+of	O
+the	O
+lysosomal	O
+membrane	O
+or	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+autophagy	O
+.	O
+
+TITLE	O
+:	O
+Determining	O
+the	O
+Provincial	O
+and	O
+National	O
+Burden	O
+of	O
+Influenza	B-DISO
+-	O
+Associated	O
+Severe	O
+Acute	O
+Respiratory	O
+Illness	O
+in	O
+South	O
+Africa	O
+Using	O
+a	O
+Rapid	O
+Assessment	O
+Methodology	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+combined	O
+immunodeficiency	O
+(	O
+SCID	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+the	O
+absence	O
+of	O
+functional	O
+T	B-ANAT
+lymphocytes	I-ANAT
+and	O
+impairment	B-DISO
+of	O
+adaptive	O
+immunity	B-PROC
+.	O
+
+In	O
+baboons	B-SPEC
+,	O
+OAS1	B-PRGE
+harbors	O
+a	O
+very	O
+low	O
+level	O
+of	O
+variation	O
+.	O
+
+This	O
+represents	O
+an	O
+unusual	O
+case	O
+of	O
+convergent	O
+polymorphism	B-PROC
+.	O
+
+Accumulating	O
+data	O
+show	O
+that	O
+miRNAs	O
+are	O
+involved	O
+in	O
+the	O
+process	O
+of	O
+coronavirus	B-DISO
+infection	I-DISO
+such	O
+as	O
+replication	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+However	O
+,	O
+the	O
+link	O
+between	O
+miRNAs	O
+and	O
+TGEV	B-SPEC
+infection	B-DISO
+is	O
+unknown	O
+.	O
+
+The	O
+results	O
+showed	O
+TGEV	B-SPEC
+infection	B-DISO
+caused	O
+the	O
+change	O
+of	O
+miRNAs	O
+profile	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+and	O
+functional	O
+analysis	O
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+nsp14	I-PRGE
+-	I-PRGE
+nsp10	I-PRGE
+complex	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Nonstructural	O
+protein	O
+14	O
+(	O
+nsp14	O
+)	O
+of	O
+coronaviruses	O
+(	O
+CoV	O
+)	O
+is	O
+important	O
+for	O
+viral	B-PROC
+replication	I-PROC
+and	O
+transcription	B-PROC
+.	O
+
+The	O
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+domain	I-PRGE
+exhibits	O
+a	O
+noncanonical	O
+MTase	B-PRGE
+fold	O
+with	O
+a	O
+rare	O
+β	O
+-	O
+sheet	O
+insertion	O
+and	O
+a	O
+peripheral	O
+zinc	B-CHED
+finger	B-ANAT
+.	O
+
+A	O
+common	O
+approach	O
+for	O
+selecting	O
+a	O
+clock	O
+model	O
+for	O
+a	O
+data	O
+set	O
+of	O
+interest	O
+is	O
+to	O
+examine	O
+a	O
+set	O
+of	O
+candidates	O
+and	O
+to	O
+select	O
+the	O
+model	O
+that	O
+provides	O
+the	O
+best	O
+statistical	O
+fit	B-DISO
+.	O
+
+Clinical	O
+background	O
+,	O
+sedatives	B-CHED
+,	O
+failure	O
+rate	O
+of	O
+sedation	B-DISO
+,	O
+and	O
+complications	O
+were	O
+evaluated	O
+by	O
+1	O
+)	O
+sedative	B-CHED
+methods	O
+(	O
+intermittent	O
+only	O
+,	O
+switched	O
+to	O
+continuous	O
+,	O
+or	O
+initially	O
+continuous	O
+)	O
+and	O
+2	O
+)	O
+code	O
+status	O
+(	O
+do	O
+-	O
+not	O
+-	O
+intubate	O
+[	O
+DNI	O
+]	O
+or	O
+non	O
+-	O
+DNI	O
+).	O
+
+Delivery	O
+route	O
+was	O
+categorized	O
+as	O
+classic	O
+cesarean	O
+delivery	O
+(	O
+CCD	B-DISO
+),	O
+low	O
+transverse	O
+cesarean	O
+delivery	O
+(	O
+LTCD	O
+),	O
+low	O
+vertical	O
+cesarean	O
+delivery	O
+(	O
+LVCD	O
+),	O
+and	O
+vaginal	B-ANAT
+delivery	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+2659	O
+women	O
+who	O
+met	B-CHED
+criteria	O
+for	O
+inclusion	O
+in	O
+this	O
+analysis	O
+,	O
+8	O
+.	O
+6	O
+%	O
+of	O
+women	O
+experienced	O
+serious	O
+maternal	O
+complications	O
+.	O
+
+Interestingly	O
+,	O
+IP	O
+-	O
+10	O
+has	O
+already	O
+been	O
+described	O
+as	O
+a	O
+marker	O
+for	O
+severe	O
+respiratory	B-DISO
+infections	I-DISO
+e	O
+.	O
+g	O
+.	O
+by	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+H5N1	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pulmonar	O
+recruitment	B-DISO
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+However	O
+,	O
+these	O
+strategies	O
+can	O
+promote	O
+lung	B-ANAT
+de	O
+-	O
+recruitment	B-DISO
+,	O
+leading	O
+to	O
+the	O
+cyclic	O
+closing	O
+and	O
+reopening	O
+of	O
+collapsed	O
+alveoli	B-ANAT
+and	O
+small	O
+airways	O
+.	O
+
+Recruitment	B-DISO
+maneuvers	O
+(	O
+RM	O
+)	O
+can	O
+be	O
+used	O
+to	O
+augment	O
+other	O
+methods	O
+,	O
+like	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+and	O
+positioning	O
+,	O
+to	O
+improve	O
+aerated	O
+lung	B-PROC
+volume	I-PROC
+.	O
+
+This	O
+review	O
+aims	O
+to	O
+discuss	O
+recent	O
+findings	O
+about	O
+the	O
+available	O
+types	O
+of	O
+RM	O
+,	O
+and	O
+compare	O
+the	O
+effectiveness	O
+,	O
+indications	O
+and	O
+adverse	B-DISO
+effects	I-DISO
+among	O
+them	O
+,	O
+as	O
+well	O
+as	O
+their	O
+impact	O
+on	O
+morbidity	O
+and	O
+mortality	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+-	I-PRGE
+Bat	B-ENZY
+Interactions	O
+in	O
+Rural	O
+West	O
+Africa	O
+.	O
+
+The	O
+correlation	O
+of	O
+the	O
+aeration	O
+score	O
+variation	O
+(	O
+ASV	O
+)	O
+and	O
+the	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+indexes	O
+(	O
+pH	O
+,	O
+PaO	B-PROC
+(	O
+2	O
+),	O
+PaCO	O
+(	O
+2	O
+),	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+))	O
+were	O
+recorded	O
+also	O
+.	O
+
+The	O
+adverse	O
+reactions	O
+,	O
+ventilator	O
+situation	O
+and	O
+oxygen	B-CHED
+fraction	O
+after	O
+7	O
+days	O
+,	O
+28	O
+-	O
+day	O
+mortality	O
+were	O
+monitored	O
+.	O
+
+Comparisons	O
+of	O
+EVLWI	O
+,	O
+PVPI	O
+and	O
+OI	O
+were	O
+made	O
+for	O
+three	O
+groups	O
+at	O
+different	O
+timepoints	O
+:	O
+As	O
+the	O
+severity	O
+of	O
+ARDS	B-DISO
+aggravated	O
+,	O
+EVLWI	O
+and	O
+PVPI	O
+of	O
+three	O
+groups	O
+increased	O
+significantly	O
+at	O
+any	O
+timepoint	O
+while	O
+OI	O
+decreased	O
+sharply	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Global	O
+warming	O
+also	O
+increases	O
+the	O
+range	O
+of	O
+movement	B-PROC
+of	O
+vectors	O
+such	O
+as	O
+mosquitoes	B-SPEC
+.	O
+
+This	O
+study	O
+offers	O
+a	O
+brief	O
+update	O
+of	O
+the	O
+most	O
+salient	O
+new	O
+aspects	O
+of	O
+the	O
+important	O
+viral	B-DISO
+infections	I-DISO
+,	O
+especially	O
+those	O
+with	O
+known	O
+orofacial	O
+manifestations	O
+or	O
+other	O
+implications	O
+for	O
+oral	B-ANAT
+health	O
+care	O
+.	O
+
+A	O
+sepsis	B-DISO
+mortality	O
+prediction	O
+formula	O
+(	O
+AIIMS	O
+Sepsis	B-DISO
+Score	O
+)	O
+based	O
+on	O
+SAPS	B-PRGE
+II	I-PRGE
+,	O
+SAPS	B-PRGE
+III	I-PRGE
+,	O
+and	O
+SOFA	O
+scores	O
+and	O
+hemoglobin	B-PRGE
+has	O
+greater	O
+predictive	O
+power	O
+than	O
+these	O
+scoring	O
+methods	O
+individually	O
+.	O
+
+TITLE	O
+:	O
+Increased	O
+level	O
+of	O
+protection	O
+of	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+kidney	B-ANAT
+by	O
+combining	O
+different	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccines	O
+against	O
+challenge	O
+with	O
+nephropathogenic	O
+Brazilian	O
+genotype	O
+subcluster	O
+4	O
+strains	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+and	O
+laboratory	O
+features	O
+of	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+--	O
+a	O
+retrospective	O
+study	O
+of	O
+231	O
+confirmed	O
+cases	O
+(	O
+2000	O
+-	O
+2010	O
+).	O
+
+Nearly	O
+85	O
+.	O
+0	O
+%	O
+of	O
+cats	B-SPEC
+had	O
+an	O
+albumin	B-PRGE
+-	I-PRGE
+to	I-PRGE
+-	I-PRGE
+globulin	I-PRGE
+(	O
+A	O
+:	O
+G	O
+)	O
+ratio	O
+<	O
+0	O
+.	O
+8	O
+,	O
+while	O
+67	O
+.	O
+8	O
+%	O
+had	O
+an	O
+A	O
+:	O
+G	O
+ratio	O
+<	O
+0	O
+.	O
+6	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+Mucormycosis	I-DISO
+in	O
+a	O
+Patient	O
+with	O
+Systemic	B-PATH
+Lupus	I-PATH
+Erythematosus	I-PATH
+:	O
+
+ABSTRACT	O
+:	O
+Pulmonary	O
+mucormycosis	O
+is	O
+commonly	O
+encountered	O
+in	O
+patients	O
+with	O
+diabetic	B-DISO
+ketoacidosis	I-DISO
+,	O
+hematologic	B-DISO
+malignancies	I-DISO
+,	O
+neutropenia	O
+,	O
+organ	B-ANAT
+or	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+,	O
+and	O
+malignancy	B-DISO
+,	O
+but	O
+it	O
+rarely	O
+occurs	O
+in	O
+high	O
+-	O
+risk	O
+patients	O
+with	O
+systemic	B-PATH
+lupus	I-PATH
+erythematosus	I-PATH
+(	O
+SLE	B-DISO
+).	O
+
+However	O
+,	O
+with	O
+early	O
+diagnosis	O
+and	O
+antifungal	B-CHED
+therapy	O
+with	O
+lipid	B-CHED
+formulation	O
+-	O
+liposomal	B-CHED
+amphotericin	I-CHED
+B	I-CHED
+and	O
+surgical	O
+removal	O
+of	O
+the	O
+infected	O
+area	O
+,	O
+the	O
+outcome	O
+can	O
+be	O
+improved	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+molecular	O
+characterization	O
+of	O
+caliciviruses	O
+(	O
+vesivirus	B-SPEC
+and	O
+norovirus	B-SPEC
+)	O
+in	O
+an	O
+outbreak	O
+of	O
+acute	O
+diarrhea	O
+in	O
+kittens	O
+from	O
+Brazil	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+bat	B-PRGE
+coronavirus	I-PRGE
+HKU4	I-PRGE
+belongs	O
+to	O
+the	O
+same	O
+2c	O
+lineage	O
+as	O
+that	O
+of	O
+the	O
+deadly	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+shows	O
+high	O
+sequence	O
+similarity	O
+,	O
+therefore	O
+potentiating	O
+a	O
+threat	O
+to	O
+the	O
+human	B-SPEC
+population	O
+through	O
+a	O
+zoonotic	O
+shift	O
+or	O
+'	O
+spill	O
+over	O
+'	O
+event	O
+.	O
+
+An	O
+attractive	O
+target	O
+for	O
+the	O
+development	B-PROC
+of	O
+anti	O
+-	O
+coronaviral	O
+therapeutics	O
+is	O
+the	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+(	O
+pro	B-CHED
+)),	O
+which	O
+is	O
+essential	O
+for	O
+the	O
+progression	O
+of	O
+the	O
+coronaviral	O
+life	O
+cycle	O
+.	O
+
+ABSTRACT	O
+:	O
+Sepsis	O
+,	O
+also	O
+known	O
+as	O
+septicemia	B-DISO
+,	O
+is	O
+one	O
+of	O
+the	O
+10	O
+leading	O
+causes	O
+of	O
+death	B-PROC
+worldwide	O
+.	O
+
+Physiologic	O
+'	O
+extinguishers	O
+'	O
+(	O
+e	O
+.	O
+g	O
+.	O
+suppressor	O
+of	O
+cytokine	B-PROC
+signaling	I-PROC
+3	O
+)	O
+can	O
+be	O
+replenished	O
+through	O
+intracellular	B-COMP
+protein	B-CHED
+therapy	O
+.	O
+
+We	O
+found	O
+that	O
+Trizol	O
+,	O
+AVL	O
+buffer	B-CHED
+and	O
+gamma	O
+irradiation	O
+were	O
+effective	O
+at	O
+inactivating	O
+MERS	O
+-	O
+CoV	O
+,	O
+that	O
+formaldehyde	B-CHED
+-	O
+based	O
+solutions	O
+required	O
+at	O
+least	O
+30	O
+min	O
+of	O
+contact	O
+time	O
+in	O
+a	O
+cell	B-COMP
+culture	O
+system	O
+while	O
+a	O
+mixture	B-CHED
+of	O
+methanol	B-CHED
+and	O
+acetone	B-CHED
+required	O
+60	O
+min	O
+to	O
+inactivate	O
+MERS	O
+-	O
+CoV	O
+.	O
+Together	O
+,	O
+these	O
+data	O
+provide	O
+a	O
+foundation	O
+for	O
+safely	O
+inactivating	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+potentially	O
+other	O
+coronaviruses	O
+,	O
+prior	O
+to	O
+removal	O
+from	O
+biocontainment	O
+facilities	O
+.	O
+
+We	O
+assume	O
+that	O
+knowledge	O
+about	O
+the	O
+number	O
+of	O
+infected	O
+,	O
+recovered	O
+and	O
+vaccinated	O
+individuals	O
+has	O
+an	O
+effect	O
+in	O
+the	O
+contact	O
+rate	O
+between	O
+susceptible	O
+and	O
+infectious	B-DISO
+individuals	O
+.	O
+
+Rhesus	B-SPEC
+macaques	I-SPEC
+develop	O
+a	O
+mild	O
+to	O
+moderate	O
+respiratory	B-DISO
+disease	I-DISO
+upon	O
+inoculation	O
+,	O
+reminiscent	O
+of	O
+milder	O
+MERS	O
+cases	O
+,	O
+whereas	O
+marmosets	B-SPEC
+develop	O
+a	O
+moderate	O
+to	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+,	O
+recapitulating	O
+the	O
+severe	O
+disease	O
+observed	O
+in	O
+some	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Damage	O
+control	O
+resuscitation	O
+of	O
+severe	O
+multiple	O
+trauma	O
+in	O
+the	O
+pelvic	B-ANAT
+fractures	O
+].	O
+
+All	O
+cases	O
+were	O
+treated	O
+with	O
+damage	O
+contral	O
+orthopaedics	O
+and	O
+DCR	O
+strategy	O
+,	O
+namely	O
+that	O
+used	O
+immediately	O
+with	O
+small	O
+capacity	O
+of	O
+balanced	O
+salt	B-CHED
+solution	O
+on	O
+admission	O
+so	O
+as	O
+to	O
+maintain	O
+the	O
+blood	B-PROC
+pressure	I-PROC
+between	O
+80	O
+to	O
+90	O
+mmHg	O
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+emergency	B-DISO
+phase	O
+I	O
+simple	O
+debridement	O
+plus	O
+external	O
+fixator	O
+or	O
+bundled	O
+with	O
+fixed	B-ANAT
+pelvic	B-ANAT
+was	O
+done	O
+,	O
+and	O
+the	O
+chest	B-ANAT
+or	O
+abdomen	B-ANAT
+combined	O
+injury	O
+was	O
+treated	O
+at	O
+first	O
+.	O
+
+Five	O
+cases	O
+were	O
+died	B-PROC
+after	O
+4	O
+to	O
+15	O
+hours	O
+into	O
+hospital	O
+(	O
+3	O
+cases	O
+died	B-PROC
+for	O
+severe	O
+trauma	O
+-	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+2	O
+cases	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+).	O
+
+Dosage	O
+of	O
+balanced	O
+salt	B-CHED
+solution	O
+was	O
+(	O
+3	O
+,	O
+798	O
+±	O
+340	O
+)	O
+ml	O
+and	O
+red	B-ANAT
+cell	I-ANAT
+suspension	O
+was	O
+14	O
+to	O
+18	O
+U	O
+,	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+(	O
+FFP	B-ANAT
+)	O
+was	O
+(	O
+1	O
+,	O
+267	O
+±	O
+58	O
+)	O
+ml	O
+(	O
+1U	O
+FFP	O
+=	O
+100	O
+ml	O
+),	O
+blood	B-ANAT
+platelet	I-ANAT
+was	O
+8	O
+to	O
+12	O
+U	O
+for	O
+9	O
+patients	O
+.	O
+
+The	O
+success	O
+rat	B-SPEC
+of	O
+recovery	O
+was	O
+82	O
+.	O
+2	O
+%	O
+(	O
+23	O
+/	O
+28	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	O
+outbreaks	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+have	O
+re	O
+-	O
+emerged	O
+in	O
+Korea	O
+and	O
+rapidly	O
+swept	O
+across	O
+the	O
+country	O
+,	O
+causing	O
+tremendous	O
+economic	O
+losses	O
+to	O
+producers	O
+and	O
+customers	O
+.	O
+
+Therefore	O
+,	O
+PEDV	B-SPEC
+isolation	O
+in	O
+cell	B-COMP
+culture	O
+is	O
+urgently	O
+needed	O
+to	O
+develop	O
+efficacious	O
+vaccines	O
+and	O
+diagnostic	O
+assays	O
+and	O
+to	O
+conduct	B-PROC
+further	O
+studies	O
+on	O
+the	O
+virus	B-SPEC
+biology	O
+.	O
+
+Our	O
+genomic	O
+analyses	O
+indicated	O
+that	O
+the	O
+Korean	O
+isolate	O
+KNU	O
+-	O
+141112	O
+is	O
+genetically	O
+stable	O
+during	O
+the	O
+first	O
+30	O
+passages	O
+in	O
+cell	B-COMP
+culture	O
+and	O
+is	O
+grouped	O
+within	O
+subgroup	O
+G2b	O
+together	O
+with	O
+the	O
+recent	O
+re	O
+-	O
+emergent	O
+Korean	O
+strains	O
+.	O
+
+We	O
+assessed	O
+3	O
+repurposed	O
+drugs	O
+with	O
+potent	O
+in	O
+vitro	O
+anti	O
+-	O
+MERS	O
+-	O
+CoV	O
+activity	O
+(	O
+mycophenolate	B-CHED
+mofetil	I-CHED
+[	O
+MMF	B-CHED
+],	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+,	O
+and	O
+interferon	B-PRGE
+-	I-PRGE
+β1b	I-PRGE
+)	O
+in	O
+common	B-SPEC
+marmosets	I-SPEC
+with	O
+severe	O
+disease	O
+resembling	O
+MERS	O
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+-	O
+treated	O
+and	O
+interferon	B-PRGE
+-	I-PRGE
+β1b	I-PRGE
+-	O
+treated	O
+animals	B-SPEC
+had	O
+better	O
+outcome	O
+than	O
+the	O
+untreated	O
+animals	B-SPEC
+,	O
+with	O
+improved	O
+clinical	O
+(	O
+mean	O
+clinical	O
+scores	O
+↓	O
+50	O
+.	O
+9	O
+%-	O
+95	O
+.	O
+0	O
+%	O
+and	O
+↓	O
+weight	O
+loss	O
+than	O
+the	O
+untreated	O
+animals	O
+),	O
+radiological	O
+(	O
+minimal	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+),	O
+and	O
+pathological	O
+(	O
+mild	O
+bronchointerstitial	O
+pneumonia	B-DISO
+)	O
+findings	O
+,	O
+and	O
+lower	O
+mean	O
+viral	O
+loads	O
+in	O
+necropsied	O
+lung	B-ANAT
+(↓	O
+0	O
+.	O
+59	O
+-	O
+1	O
+.	O
+06	O
+log10	O
+copies	O
+/	O
+glyceraldehyde	B-PRGE
+3	I-PRGE
+-	I-PRGE
+phosphate	I-PRGE
+dehydrogenase	I-PRGE
+[	O
+GAPDH	B-PRGE
+];	O
+P	O
+<	O
+.	O
+050	O
+)	O
+and	O
+extrapulmonary	O
+(↓	O
+0	O
+.	O
+11	O
+-	O
+1	O
+.	O
+29	O
+log10	O
+copies	O
+/	O
+GAPDH	B-PRGE
+;	O
+P	O
+<	O
+.	O
+050	O
+in	O
+kidney	B-ANAT
+)	O
+tissues	B-ANAT
+.	O
+
+The	O
+mortality	O
+rate	O
+at	O
+36	O
+hours	O
+postinoculation	O
+was	O
+67	O
+%	O
+(	O
+untreated	O
+and	O
+MMF	B-CHED
+-	O
+treated	O
+)	O
+versus	O
+0	O
+-	O
+33	O
+%	O
+(	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+-	O
+treated	O
+and	O
+interferon	B-PRGE
+-	I-PRGE
+β1b	I-PRGE
+-	O
+treated	O
+).	O
+
+TITLE	O
+:	O
+Stress	O
+index	O
+for	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+titration	O
+in	O
+prone	O
+position	O
+:	O
+a	O
+piglet	O
+study	O
+.	O
+
+Respiratory	B-ANAT
+system	I-ANAT
+elastance	O
+and	O
+lung	B-ANAT
+elastance	O
+were	O
+improved	O
+in	O
+the	O
+prone	O
+position	O
+but	O
+the	O
+ratio	O
+of	O
+chest	B-ANAT
+wall	I-ANAT
+elastance	O
+and	O
+respiratory	B-ANAT
+system	I-ANAT
+elastance	O
+was	O
+higher	O
+in	O
+the	O
+prone	O
+position	O
+.	O
+
+This	O
+study	O
+determined	O
+that	O
+a	O
+high	O
+percentage	O
+of	O
+asymptomatic	O
+shelter	O
+dogs	B-SPEC
+harbor	O
+CIRD	O
+pathogens	O
+,	O
+including	O
+the	O
+newly	O
+emerging	O
+pathogen	O
+M	B-SPEC
+.	I-SPEC
+cynos	I-SPEC
+and	O
+the	O
+historically	O
+prevalent	O
+pathogen	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+240	O
+(	O
+47	O
+.	O
+7	O
+%)	O
+asymptomatic	O
+dogs	B-SPEC
+were	O
+PCR	O
+-	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+CIRD	O
+pathogen	O
+.	O
+
+Mycoplasma	B-SPEC
+cynos	I-SPEC
+(	O
+29	O
+.	O
+2	O
+%),	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+(	O
+19	O
+.	O
+5	O
+%),	O
+CAV	B-SPEC
+-	O
+2	O
+(	O
+12	O
+.	O
+5	O
+%),	O
+CDV	B-CHED
+(	O
+7	O
+.	O
+4	O
+%)	O
+and	O
+CPIV	O
+(	O
+3	O
+.	O
+2	O
+%)	O
+were	O
+the	O
+most	O
+commonly	O
+detected	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Silencing	O
+of	O
+Tumor	B-PRGE
+Necrosis	I-PRGE
+Factor	I-PRGE
+Receptor	I-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+Human	B-SPEC
+Lung	B-ANAT
+Microvascular	O
+Endothelial	B-ANAT
+Cells	I-ANAT
+Using	O
+Particle	O
+Platforms	O
+for	O
+siRNA	O
+Delivery	O
+.	O
+
+Overall	O
+,	O
+our	O
+results	O
+suggested	O
+that	O
+the	O
+unusual	O
+capacity	O
+of	O
+MERS	O
+-	O
+CoV	O
+to	O
+infect	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+induce	O
+apoptosis	B-PATH
+might	O
+partly	O
+contribute	O
+to	O
+the	O
+high	O
+pathogenicity	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+The	O
+clinical	O
+evolution	B-PROC
+is	O
+gradual	O
+:	O
+from	O
+mild	O
+non	O
+-	O
+specific	O
+manifestations	O
+of	O
+acute	B-DISO
+tracheobronchitis	I-DISO
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+insufficiency	I-DISO
+determined	O
+by	O
+a	O
+bronchial	B-ANAT
+obstruction	B-DISO
+syndrome	B-DISO
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+activity	O
+relationship	O
+studies	O
+on	O
+quinoxalin	O
+-	O
+2	O
+(	O
+1H	O
+)-	O
+one	O
+derivatives	O
+containing	O
+thiazol	O
+-	O
+2	O
+-	O
+amine	B-CHED
+against	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+leading	O
+to	O
+the	O
+discovery	O
+of	O
+BH6870	O
+.	O
+
+Outline	O
+of	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+revealed	O
+that	O
+compound	O
+BH6870	O
+(	O
+36	O
+)	O
+showed	O
+high	O
+anti	O
+-	O
+HCV	B-SPEC
+potency	O
+([	O
+Formula	O
+:	O
+see	O
+text	O
+])	O
+and	O
+a	O
+good	O
+cell	B-COMP
+safety	O
+index	O
+(	O
+SI	O
+[	O
+Formula	O
+:	O
+see	O
+text	O
+]).	O
+
+ABSTRACT	O
+:	O
+Both	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+are	O
+zoonotic	O
+pathogens	O
+that	O
+crossed	O
+the	O
+species	B-SPEC
+barriers	O
+to	O
+infect	O
+humans	B-SPEC
+.	O
+
+Although	O
+it	O
+has	O
+been	O
+assumed	O
+that	O
+longer	O
+DNA	O
+targets	O
+are	O
+susceptible	O
+to	O
+breakdown	B-PROC
+under	O
+compromised	O
+states	O
+,	O
+scientific	O
+evidence	O
+for	O
+this	O
+hypothesis	O
+has	O
+been	O
+rarely	O
+documented	O
+.	O
+
+We	O
+confirmed	O
+feline	B-SPEC
+-	O
+specificity	O
+by	O
+cross	O
+-	O
+challenging	O
+the	O
+primers	O
+against	O
+10	O
+different	O
+species	B-SPEC
+of	O
+terrestrial	O
+,	O
+aquatic	O
+and	O
+plant	B-SPEC
+origins	O
+in	O
+the	O
+presence	O
+of	O
+a	O
+141	O
+-	O
+bp	O
+site	O
+of	O
+an	O
+18S	B-PRGE
+rRNA	I-PRGE
+gene	I-PRGE
+as	O
+a	O
+universal	O
+eukaryotic	O
+control	O
+.	O
+
+In	O
+China	O
+,	O
+sleep	B-PROC
+medicine	B-CHED
+started	O
+in	O
+late	O
+of	O
+1980	O
+'	O
+s	O
+,	O
+in	O
+recent	O
+years	O
+,	O
+with	O
+the	O
+development	B-PROC
+of	O
+economy	O
+and	O
+the	O
+improvement	O
+of	O
+recognization	O
+,	O
+the	O
+application	O
+of	O
+NPPV	O
+in	O
+Chinese	O
+market	O
+has	O
+become	O
+one	O
+of	O
+the	O
+fastest	O
+growing	O
+in	O
+the	O
+world	O
+.	O
+
+ABSTRACT	O
+:	O
+Hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+)	O
+enters	O
+human	B-SPEC
+hepatocytes	B-ANAT
+through	O
+a	O
+multistep	O
+mechanism	O
+involving	O
+,	O
+among	O
+other	O
+host	B-COMP
+proteins	B-CHED
+,	O
+the	O
+virus	B-PRGE
+receptor	I-PRGE
+CD81	I-PRGE
+.	O
+
+We	O
+further	O
+characterized	O
+serum	B-PRGE
+response	I-PRGE
+factor	I-PRGE
+binding	B-FUNC
+protein	B-CHED
+1	I-PRGE
+(	O
+SRFBP1	B-PRGE
+),	O
+which	O
+is	O
+recruited	O
+to	O
+CD81	B-PRGE
+during	O
+HCV	B-SPEC
+uptake	O
+and	O
+supports	O
+HCV	B-SPEC
+infection	B-DISO
+in	O
+hepatoma	B-DISO
+cells	B-COMP
+and	O
+primary	O
+human	B-SPEC
+hepatocytes	B-ANAT
+.	O
+
+Taking	O
+this	O
+as	O
+an	O
+opportunity	O
+,	O
+the	O
+Korean	O
+government	O
+should	O
+carefully	O
+assess	O
+the	O
+fundamental	O
+problems	O
+of	O
+the	O
+vulnerability	O
+to	O
+hospital	B-DISO
+infection	I-DISO
+and	O
+make	O
+short	O
+-	O
+as	O
+well	O
+as	O
+long	O
+-	O
+term	O
+plans	O
+for	O
+countermeasures	O
+.	O
+
+Lung	B-ANAT
+elastance	O
+decreased	O
+(	O
+20	O
+.	O
+5	O
+±	O
+1	O
+.	O
+8	O
+vs	O
+15	O
+.	O
+5	O
+±	O
+1	O
+.	O
+6	O
+cmH2O	O
+/	O
+l	O
+,	O
+supine	O
+vs	O
+prone	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+increased	O
+(	O
+380	O
+±	O
+82	O
+vs	O
+459	O
+±	O
+60	O
+ml	O
+,	O
+supine	O
+vs	O
+prone	O
+,	O
+p	O
+=	O
+0	O
+.	O
+025	O
+)	O
+in	O
+prone	O
+position	O
+;	O
+specific	O
+lung	B-ANAT
+elastance	O
+did	O
+not	O
+change	O
+(	O
+7	O
+.	O
+0	O
+±	O
+0	O
+.	O
+5	O
+vs	O
+6	O
+.	O
+5	O
+±	O
+0	O
+.	O
+5	O
+cmH2O	O
+,	O
+supine	O
+vs	O
+prone	O
+,	O
+p	O
+=	O
+0	O
+.	O
+24	O
+).	O
+
+There	O
+is	O
+no	O
+licensed	O
+vaccine	O
+or	O
+antiviral	B-CHED
+for	O
+MERS	O
+,	O
+therefore	O
+new	O
+prophylactic	O
+and	O
+therapeutic	O
+strategies	O
+to	O
+combat	B-CHED
+human	B-SPEC
+infections	B-DISO
+are	O
+needed	O
+.	O
+
+The	O
+antibody	B-COMP
+,	O
+named	O
+LCA60	O
+,	O
+binds	B-FUNC
+to	O
+a	O
+novel	O
+site	O
+on	O
+the	O
+spike	O
+protein	B-CHED
+and	O
+potently	O
+neutralizes	O
+infection	B-DISO
+of	O
+multiple	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+by	O
+interfering	O
+with	O
+the	O
+binding	B-FUNC
+to	O
+the	O
+cellular	B-COMP
+receptor	O
+CD26	B-PRGE
+.	O
+
+Importantly	O
+,	O
+using	O
+mice	B-SPEC
+transduced	O
+with	O
+adenovirus	B-DISO
+expressing	O
+human	B-SPEC
+CD26	O
+and	O
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+,	O
+we	O
+show	O
+that	O
+LCA60	O
+can	O
+effectively	O
+protect	O
+in	O
+both	O
+prophylactic	O
+and	O
+postexposure	O
+settings	O
+.	O
+
+The	O
+present	O
+review	O
+aimed	O
+to	O
+update	O
+the	O
+clinical	O
+information	O
+on	O
+pharmacodynamics	O
+,	O
+pharmacokinetics	B-PROC
+,	O
+adverse	B-DISO
+effects	I-DISO
+and	O
+drug	B-PROC
+interactions	I-PROC
+,	O
+and	O
+to	O
+discuss	O
+the	O
+future	O
+directions	O
+of	O
+alogliptin	O
+.	O
+
+The	O
+most	O
+common	O
+risk	O
+factor	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+is	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Full	O
+-	O
+length	O
+genome	O
+analysis	O
+of	O
+canine	O
+coronavirus	B-SPEC
+type	O
+I	O
+.	O
+ABSTRACT	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+types	O
+I	O
+(	O
+CCoV	O
+-	O
+I	O
+)	O
+and	O
+II	O
+(	O
+CCoV	O
+-	O
+II	O
+)	O
+are	O
+usually	O
+responsible	O
+for	O
+mild	O
+enteritis	O
+in	O
+dogs	B-SPEC
+.	O
+
+Thus	O
+,	O
+this	O
+method	O
+may	O
+provide	O
+an	O
+insight	O
+for	O
+the	O
+chemical	O
+synthesis	B-PROC
+of	O
+antiviral	B-PRGE
+RNA	I-PRGE
+molecule	I-PRGE
+for	O
+the	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+at	O
+genomic	O
+level	O
+.	O
+
+All	O
+cases	O
+are	O
+epidemiologically	O
+linked	O
+to	O
+the	O
+Arabian	O
+Penninsula	O
+with	O
+most	O
+cases	O
+reported	O
+from	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+has	O
+three	O
+patterns	O
+of	O
+presentation	O
+:	O
+sporadic	O
+isolated	O
+cases	O
+,	O
+small	O
+clusters	B-CHED
+of	O
+intra	O
+-	O
+familial	O
+transmission	O
+and	O
+large	O
+healthcare	O
+-	O
+associated	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Genotypes	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+circulating	O
+in	O
+the	O
+Middle	O
+East	O
+between	O
+2009	O
+and	O
+2014	O
+.	O
+
+Tissue	B-ANAT
+samples	O
+on	O
+FTA	O
+cards	O
+were	O
+received	O
+over	O
+the	O
+six	O
+-	O
+year	O
+period	O
+.	O
+
+Viral	O
+RNA	O
+was	O
+extracted	O
+using	O
+phenol	B-CHED
+chloroform	B-CHED
+and	O
+subjected	O
+to	O
+nested	O
+RT	O
+-	O
+PCR	O
+targeting	B-PROC
+a	O
+393	O
+bp	O
+region	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+before	O
+being	O
+followed	O
+by	O
+sequencing	O
+.	O
+
+Included	O
+studies	O
+must	O
+have	O
+characterized	O
+the	O
+clinical	O
+outcomes	O
+of	O
+a	O
+cohort	O
+of	O
+patients	O
+treated	O
+with	O
+oral	B-ANAT
+ribavirin	B-CHED
+for	O
+symptomatic	O
+NIRVIs	O
+.	O
+
+Newly	O
+developed	O
+mAbs	O
+to	O
+the	O
+PEDV	B-SPEC
+-	O
+NP	O
+were	O
+used	O
+in	O
+the	O
+bELISA	O
+and	O
+for	O
+expediting	O
+FFN	O
+testing	O
+in	O
+the	O
+detection	O
+and	O
+quantitation	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+Genetic	O
+predisposition	O
+and	O
+Pediatric	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+:	O
+New	O
+tools	O
+for	O
+genetic	O
+study	O
+].	O
+
+Recent	O
+experimental	O
+data	O
+and	O
+clinical	O
+studies	O
+suggest	O
+that	O
+variations	O
+of	O
+genes	O
+involved	O
+in	O
+key	O
+processes	O
+of	O
+tissue	B-ANAT
+,	O
+cellular	B-COMP
+and	O
+molecular	O
+lung	B-ANAT
+damage	O
+may	O
+influence	O
+susceptibility	O
+and	O
+prognosis	O
+of	O
+ARDS	B-DISO
+.	O
+
+All	O
+efforts	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+liver	B-ANAT
+injuries	O
+should	O
+be	O
+directed	O
+to	O
+the	O
+rapid	O
+and	O
+effective	O
+control	O
+of	O
+bleeding	B-DISO
+,	O
+because	O
+uncontrollable	O
+hemorrhage	B-DISO
+is	O
+the	O
+cause	O
+of	O
+early	O
+death	B-PROC
+and	O
+it	O
+requires	O
+massive	O
+blood	B-ANAT
+transfusion	O
+,	O
+all	O
+of	O
+which	O
+contributes	O
+to	O
+the	O
+late	O
+fatal	O
+complication	B-DISO
+.	O
+
+TITLE	O
+:	O
+Minocycline	B-CHED
+-	O
+induced	O
+acute	B-DISO
+eosinophilic	I-DISO
+pneumonia	I-DISO
+:	O
+A	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+.	O
+
+Early	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+is	O
+critical	O
+in	O
+distinguishing	O
+the	O
+diagnosis	O
+to	O
+initiate	O
+proper	O
+management	O
+.	O
+
+RESULTS	O
+:	O
+More	O
+than	O
+half	O
+of	O
+the	O
+dental	O
+students	O
+(	O
+54	O
+%)	O
+interviewed	O
+had	O
+good	O
+knowledge	O
+about	O
+the	O
+etiology	O
+,	O
+symptoms	O
+,	O
+and	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Measurements	O
+for	O
+infection	B-DISO
+control	O
+and	O
+protection	O
+were	O
+also	O
+known	O
+(	O
+79	O
+%).	O
+
+The	O
+sources	O
+of	O
+information	O
+for	O
+the	O
+students	O
+were	O
+:	O
+college	O
+(	O
+27	O
+%),	O
+MOH	O
+(	O
+25	O
+%),	O
+media	B-ANAT
+(	O
+24	O
+%),	O
+and	O
+social	O
+community	O
+(	O
+23	O
+%),	O
+while	O
+17	O
+%	O
+of	O
+the	O
+students	O
+interviewed	O
+had	O
+no	O
+idea	B-SPEC
+about	O
+it	O
+.	O
+
+Amino	B-CHED
+acid	I-CHED
+sequence	O
+comparison	O
+and	O
+phylogenetic	O
+analysis	O
+indicated	O
+the	O
+emergence	O
+of	O
+a	O
+new	O
+Moroccan	O
+genotype	O
+,	O
+clustering	O
+with	O
+regionally	O
+related	O
+isolates	O
+from	O
+Spain	O
+(	O
+Spain	O
+/	O
+05	O
+/	O
+866	O
+)	O
+and	O
+belonging	O
+to	O
+a	O
+new	O
+sub	O
+-	O
+genotype	O
+.	O
+
+These	O
+results	O
+justify	O
+permanent	O
+monitoring	O
+of	O
+circulating	O
+strains	O
+in	O
+order	B-SPEC
+to	O
+rationally	O
+modify	O
+vaccination	O
+strategies	O
+to	O
+make	O
+them	O
+appropriate	O
+to	O
+the	O
+evolving	O
+field	O
+situation	O
+.	O
+
+Amino	B-CHED
+acid	I-CHED
+sequence	O
+comparison	O
+and	O
+phylogenetic	O
+analysis	O
+indicated	O
+the	O
+emergence	O
+of	O
+a	O
+new	O
+Moroccan	O
+genotype	O
+,	O
+clustering	O
+with	O
+regionally	O
+related	O
+isolates	O
+from	O
+Spain	O
+(	O
+Spain	O
+/	O
+05	O
+/	O
+866	O
+)	O
+and	O
+belonging	O
+to	O
+a	O
+new	O
+sub	O
+-	O
+genotype	O
+.	O
+
+TITLE	O
+:	O
+Anti	O
+-	O
+infective	O
+immunoadhesins	O
+from	O
+plants	B-SPEC
+.	O
+
+As	O
+decoy	O
+receptors	O
+,	O
+immunoadhesins	O
+have	O
+potential	O
+advantages	O
+over	O
+pathogen	O
+-	O
+targeted	B-PROC
+monoclonal	O
+antibodies	B-COMP
+.	O
+
+MERS	O
+-	O
+CoV	O
+NP	O
+-	O
+NTD	O
+was	O
+crystallized	O
+at	O
+293	O
+K	O
+using	O
+PEG	B-CHED
+3350	O
+as	O
+a	O
+precipitant	O
+and	O
+a	O
+94	O
+.	O
+5	O
+%	O
+complete	O
+native	O
+data	O
+set	O
+was	O
+collected	O
+from	O
+a	O
+cooled	O
+crystal	B-ANAT
+at	O
+77	O
+K	O
+to	O
+2	O
+.	O
+63	O
+Å	O
+resolution	O
+with	O
+an	O
+overall	O
+Rmerge	O
+of	O
+9	O
+.	O
+6	O
+%.	O
+
+TITLE	O
+:	O
+Newly	O
+Emerged	O
+Porcine	B-SPEC
+Deltacoronavirus	O
+Associated	O
+With	O
+Diarrhoea	B-DISO
+in	O
+Swine	B-SPEC
+in	O
+China	O
+:	O
+Identification	O
+,	O
+Prevalence	O
+and	O
+Full	O
+-	O
+Length	O
+Genome	O
+Sequence	O
+Analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+and	O
+characterize	O
+aetiologic	O
+agent	O
+(	O
+s	O
+)	O
+associated	O
+with	O
+an	O
+outbreak	O
+of	O
+a	O
+severe	O
+diarrhoea	O
+in	O
+piglets	O
+in	O
+Jiangxi	O
+,	O
+China	O
+,	O
+in	O
+March	O
+2015	O
+,	O
+a	O
+nested	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+for	O
+the	O
+detection	O
+of	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+was	O
+developed	O
+.	O
+
+A	O
+survey	O
+based	O
+on	O
+the	O
+nested	O
+RT	O
+-	O
+PCR	O
+established	O
+indicated	O
+that	O
+the	O
+monoinfection	O
+of	O
+PDCoV	O
+(	O
+33	O
+.	O
+71	O
+%)	O
+and	O
+coinfection	B-DISO
+of	O
+PDCoV	O
+(	O
+19	O
+.	O
+66	O
+%)	O
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+were	O
+common	O
+in	O
+diarrhoeal	O
+pigs	B-SPEC
+in	O
+Jiangxi	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+dramatic	O
+increase	O
+in	O
+reported	O
+cases	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+in	O
+pig	B-SPEC
+farms	O
+is	O
+a	O
+potential	O
+threat	O
+to	O
+the	O
+global	O
+swine	B-SPEC
+industry	O
+.	O
+
+To	O
+detect	O
+PEDV	B-SPEC
+antibodies	B-COMP
+in	O
+eight	O
+herds	O
+,	O
+382	O
+serum	B-COMP
+samples	O
+were	O
+collected	O
+from	O
+sows	O
+that	O
+had	O
+been	O
+immunized	O
+with	O
+a	O
+PED	O
+vaccine	O
+,	O
+and	O
+screened	O
+using	O
+the	O
+developed	O
+ELISA	O
+in	O
+parallel	O
+with	O
+a	O
+serum	B-COMP
+neutralization	O
+(	O
+SN	O
+)	O
+assay	O
+.	O
+
+TITLE	O
+:	O
+Genotyping	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+field	O
+isolates	O
+from	O
+various	O
+geographic	O
+locations	O
+in	O
+the	O
+Unites	O
+States	O
+based	O
+on	O
+the	O
+spike	O
+gene	O
+.	O
+
+Twenty	O
+-	O
+four	O
+field	O
+isolates	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+)	O
+from	O
+multiple	O
+states	O
+in	O
+the	O
+United	O
+States	O
+were	O
+recovered	O
+from	O
+1994	O
+to	O
+2010	O
+to	O
+determine	O
+the	O
+genetic	O
+relationships	O
+among	O
+them	O
+.	O
+
+The	O
+findings	O
+of	O
+the	O
+present	O
+study	O
+suggest	O
+endemic	O
+circulation	B-PROC
+of	O
+distinct	O
+TCoV	O
+genotypes	O
+in	O
+different	O
+geographic	O
+locations	O
+.	O
+
+(	O
+1	O
+)	O
+A	O
+43	O
+years	O
+old	O
+male	O
+of	O
+South	O
+Korean	O
+nationality	O
+was	O
+admitted	O
+with	O
+the	O
+complaint	O
+of	O
+back	B-DISO
+ache	I-DISO
+for	O
+7	O
+days	O
+and	O
+fever	B-PROC
+2	O
+days	O
+with	O
+the	O
+following	O
+characteristics	O
+:	O
+back	B-DISO
+ache	I-DISO
+7	O
+days	O
+ago	O
+,	O
+without	O
+fever	B-PROC
+or	O
+cough	B-DISO
+or	O
+expectoration	B-ANAT
+.	O
+
+On	O
+admission	O
+,	O
+the	O
+patient	O
+'	O
+s	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+showed	O
+that	O
+a	O
+small	O
+amount	O
+of	O
+infiltration	B-DISO
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+It	O
+was	O
+changed	O
+to	O
+a	O
+low	O
+flow	O
+oxygen	B-CHED
+inhalation	B-PROC
+nasal	B-ANAT
+cannula	B-SPEC
+on	O
+the	O
+20th	O
+day	O
+,	O
+and	O
+oxygen	B-CHED
+treatment	O
+was	O
+stopped	O
+on	O
+the	O
+24th	O
+day	O
+.	O
+
+There	O
+was	O
+no	O
+sputum	B-ANAT
+at	O
+first	O
+,	O
+then	O
+a	O
+small	O
+amount	O
+of	O
+sputum	B-ANAT
+with	O
+a	O
+little	O
+blood	B-ANAT
+appeared	O
+after	O
+the	O
+admission	O
+.	O
+
+Virus	B-SPEC
+in	O
+sputum	B-ANAT
+disappeared	O
+after	O
+treatment	O
+,	O
+but	O
+pleural	B-DISO
+effusion	I-DISO
+was	O
+not	O
+completely	O
+absorbed	O
+.	O
+
+Pleural	B-DISO
+effusion	I-DISO
+was	O
+rapidly	O
+increased	O
+during	O
+the	O
+first	O
+week	O
+as	O
+shown	O
+by	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+films	O
+,	O
+and	O
+it	O
+began	O
+to	O
+be	O
+absorbed	O
+gradually	O
+in	O
+the	O
+second	O
+week	O
+,	O
+but	O
+it	O
+was	O
+not	O
+completely	O
+absorbed	O
+until	O
+discharge	B-ANAT
+.	O
+
+This	O
+study	O
+provides	O
+evidence	O
+that	O
+CaKVs	O
+circulate	O
+in	O
+diarrhoetic	O
+dogs	O
+in	O
+China	O
+and	O
+that	O
+they	O
+exhibit	O
+substantial	O
+genetic	O
+diversity	O
+and	O
+high	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+rates	O
+with	O
+other	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+The	O
+virus	B-SPEC
+has	O
+been	O
+repeatedly	O
+detected	O
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+(	O
+Camelus	B-SPEC
+dromedarius	I-SPEC
+).	O
+
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+isolated	O
+from	O
+dromedaries	B-SPEC
+is	O
+genetically	O
+and	O
+phenotypically	O
+similar	O
+to	O
+viruses	B-SPEC
+from	O
+humans	B-SPEC
+.	O
+
+Remarkably	O
+,	O
+the	O
+NS2B	O
+cofactor	B-CHED
+plays	O
+a	O
+central	O
+role	O
+in	O
+maintaining	O
+the	O
+correlated	O
+motion	O
+network	O
+required	O
+for	O
+the	O
+catalysis	O
+as	O
+we	O
+previously	O
+decoded	O
+for	O
+the	O
+SARS	B-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Study	O
+of	O
+antimicrobial	O
+activity	O
+of	O
+a	O
+polymer	B-CHED
+compound	O
+--	O
+polyazolidinammonium	O
+,	O
+modified	O
+with	O
+hydrate	B-CHED
+-	O
+ions	B-CHED
+of	O
+iodine	B-CHED
+.	O
+
+High	O
+antibacterial	O
+activity	O
+of	O
+the	O
+studied	O
+compound	O
+was	O
+established	O
+,	O
+especially	O
+against	O
+Gram	B-SPEC
+positive	I-SPEC
+bacteria	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Total	O
+ginsenosides	O
+synergize	O
+with	O
+ulinastatin	O
+against	O
+septic	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+Novel	O
+Noonan	B-DISO
+Syndrome	I-DISO
+RAF1	O
+Mutation	O
+:	O
+Lethal	O
+Course	O
+in	O
+a	O
+Preterm	O
+Infant	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+Noonan	B-DISO
+syndrome	I-DISO
+in	O
+a	O
+preterm	O
+infant	O
+with	O
+hypertrophic	B-DISO
+cardiomyopathy	I-DISO
+and	O
+lethal	O
+outcome	O
+associated	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+Adenovirus	B-DISO
+pneumonia	B-DISO
+.	O
+
+It	O
+causes	O
+severe	O
+malarial	O
+disease	O
+similar	O
+to	O
+those	O
+as	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+including	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+severe	O
+anaemia	B-DISO
+,	O
+severe	O
+thrombocytopenia	O
+,	O
+hepatic	B-DISO
+dysfunction	I-DISO
+,	O
+shock	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+and	O
+pulmonary	B-DISO
+oedema	I-DISO
+.	O
+
+Endoscopic	O
+treatments	O
+(	O
+dilation	B-DISO
+,	O
+laser	B-SPEC
+,	O
+corticosteroid	B-CHED
+injection	O
+,	O
+etc	O
+.)	O
+had	O
+only	O
+transient	O
+efficacy	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+explore	O
+if	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+delivered	O
+by	O
+a	O
+conventional	O
+ICU	O
+ventilator	O
+at	O
+a	O
+moderately	O
+high	O
+frequency	O
+(	O
+HFPPV	O
+)	O
+allows	O
+a	O
+safe	O
+reduction	O
+of	O
+tidal	O
+volume	O
+(	O
+V	O
+T	O
+)	O
+below	O
+6	O
+mL	O
+/	O
+kg	O
+in	O
+a	O
+porcine	B-SPEC
+model	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+at	O
+a	O
+lower	O
+mean	O
+airway	B-ANAT
+pressure	O
+than	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+).	O
+
+In	O
+eight	O
+pigs	B-SPEC
+(	O
+median	O
+weight	O
+34	O
+[	O
+29	O
+,	O
+36	O
+]	O
+kg	O
+),	O
+ARDS	B-DISO
+was	O
+induced	O
+by	O
+pulmonary	B-ANAT
+lavage	O
+and	O
+injurious	O
+ventilation	O
+.	O
+
+Positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+was	O
+14	O
+[	O
+10	O
+,	O
+17	O
+]	O
+cmH2O	O
+.	O
+
+Mean	O
+airway	B-ANAT
+pressure	O
+was	O
+maintained	O
+constant	O
+and	O
+was	O
+increased	O
+only	O
+during	O
+HFOV	O
+.	O
+
+This	O
+article	O
+shows	O
+the	O
+therapeutic	O
+management	O
+and	O
+the	O
+selection	O
+criteria	O
+for	O
+ECMO	O
+in	O
+neonates	O
+and	O
+children	O
+based	O
+on	O
+the	O
+clinical	O
+signs	O
+of	O
+acquired	O
+and	O
+congenital	B-DISO
+diseases	I-DISO
+that	O
+can	O
+lead	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Although	O
+studied	O
+separately	O
+,	O
+their	O
+joint	B-ANAT
+occurrence	O
+and	O
+the	O
+molecular	O
+diversity	O
+in	O
+cattle	B-SPEC
+in	O
+Croatia	O
+have	O
+not	O
+been	O
+investigated	O
+.	O
+
+BCoV	O
+was	O
+detected	O
+in	O
+78	O
+.	O
+8	O
+%	O
+of	O
+fecal	B-ANAT
+samples	O
+from	O
+symptomatic	O
+cattle	B-SPEC
+and	O
+three	O
+nasal	B-ANAT
+and	O
+paired	O
+fecal	B-ANAT
+samples	O
+from	O
+calves	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+BToV	O
+was	O
+detected	O
+in	O
+43	O
+.	O
+2	O
+%	O
+of	O
+fecal	B-ANAT
+samples	O
+from	O
+symptomatic	O
+cattle	B-SPEC
+and	O
+a	O
+fecal	B-ANAT
+sample	O
+from	O
+calves	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Molecular	O
+characterisation	O
+of	O
+those	O
+viruses	B-SPEC
+revealed	O
+some	O
+nucleotide	B-CHED
+and	O
+aminoacid	O
+differences	O
+in	O
+relation	O
+to	O
+reference	O
+strains	O
+.	O
+
+BToV	O
+should	O
+be	O
+regarded	O
+as	O
+a	O
+relevant	O
+pathogen	O
+for	O
+cattle	B-SPEC
+that	O
+plays	O
+a	O
+synergistic	O
+role	O
+in	O
+mixed	O
+enteric	O
+infections	B-DISO
+.	O
+
+Although	O
+two	O
+SARS	B-DISO
+-	O
+related	O
+Rhinolophus	B-SPEC
+sinicus	I-SPEC
+bat	B-ENZY
+CoVs	O
+(	O
+SARSr	O
+-	O
+Rs	O
+-	O
+BatCoVs	O
+)	O
+previously	O
+detected	O
+in	O
+Chinese	O
+horseshoe	B-SPEC
+bats	I-SPEC
+(	O
+Rhinolophus	B-SPEC
+sinicus	I-SPEC
+)	O
+in	O
+Yunnan	O
+,	O
+RsSHC014	O
+and	O
+Rs3367	O
+,	O
+possessed	B-DISO
+95	O
+%	O
+genome	O
+identities	O
+to	O
+human	B-SPEC
+and	O
+civet	B-SPEC
+SARSr	O
+-	O
+CoVs	O
+,	O
+their	O
+ORF8	O
+protein	B-CHED
+exhibited	O
+only	O
+32	O
+.	O
+2	O
+to	O
+33	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identities	O
+to	O
+that	O
+of	O
+human	B-SPEC
+/	O
+civet	B-SPEC
+SARSr	O
+-	O
+CoVs	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genome	O
+analysis	O
+of	O
+equine	B-SPEC
+coronavirus	B-SPEC
+isolated	O
+in	O
+Japan	O
+.	O
+
+All	O
+three	O
+isolates	O
+were	O
+genetically	O
+similar	O
+to	O
+NC99	O
+(	O
+98	O
+.	O
+2	O
+-	O
+98	O
+.	O
+7	O
+%),	O
+but	O
+deletions	O
+and	O
+insertions	O
+were	O
+observed	O
+in	O
+the	O
+genes	O
+nsp3	B-PRGE
+of	O
+ORF1a	O
+,	O
+NS2	B-DISO
+and	O
+p4	O
+.	O
+7	O
+.	O
+
+In	O
+class	B-SPEC
+1	O
+,	O
+coronavirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+and	O
+rhinovirus	B-SPEC
+were	O
+the	O
+most	O
+commonly	O
+identified	O
+respiratory	O
+pathogens	O
+;	O
+only	O
+one	O
+influenza	B-DISO
+PCR	O
+-	O
+positive	O
+infection	B-DISO
+was	O
+detected	O
+in	O
+all	O
+four	O
+classes	O
+.	O
+
+Bed	B-DISO
+locations	O
+of	O
+URI	B-PRGE
+/	O
+ILI	O
+cases	O
+in	O
+class	B-SPEC
+1	O
+tended	O
+to	O
+be	O
+in	O
+closer	O
+proximity	O
+to	O
+each	O
+other	O
+.	O
+
+ABSTRACT	O
+:	O
+Hemodynamic	B-PROC
+monitoring	O
+is	O
+frequently	O
+needed	O
+in	O
+ventilated	O
+patients	O
+with	O
+unstable	O
+hemodynamics	B-PROC
+after	O
+open	O
+-	O
+heart	B-ANAT
+surgery	O
+.	O
+
+The	O
+novel	O
+hemodynamic	B-PROC
+monitoring	O
+device	O
+described	O
+here	O
+appears	O
+valuable	O
+to	O
+help	O
+identifying	O
+severe	O
+post	O
+-	O
+operative	O
+complications	O
+and	O
+guide	O
+acute	O
+care	O
+.	O
+
+We	O
+propose	O
+a	O
+highly	O
+efficient	O
+hydrophilic	O
+system	O
+to	O
+disperse	O
+the	O
+C60	B-CHED
+fullerene	I-CHED
+based	O
+on	O
+the	O
+accurate	O
+atomistic	O
+-	O
+resolution	O
+computer	O
+simulations	O
+.	O
+
+The	O
+introduced	O
+system	O
+is	O
+based	O
+on	O
+1	B-CHED
+-	I-CHED
+butyl	I-CHED
+-	I-CHED
+3	I-CHED
+-	I-CHED
+methylimidazolium	I-CHED
+tetrafluoroborate	B-CHED
+,	O
+[	O
+C4C1IM	O
+][	O
+BF4	B-CHED
+]-	O
+water	B-CHED
+mixtures	O
+.	O
+
+A	O
+specially	O
+designed	O
+ECMO	O
+transport	B-PROC
+system	O
+allows	O
+for	O
+safe	O
+transport	B-PROC
+of	O
+patients	O
+over	O
+long	O
+distances	O
+.	O
+
+Transport	B-PROC
+was	O
+uneventful	O
+,	O
+and	O
+the	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+remained	O
+stable	O
+.	O
+
+The	O
+present	O
+study	O
+aimed	O
+to	O
+estimate	O
+the	O
+case	O
+fatality	O
+ratio	O
+(	O
+CFR	O
+)	O
+by	O
+appropriately	O
+taking	O
+into	O
+account	O
+the	O
+time	O
+delay	O
+from	O
+illness	O
+onset	O
+to	O
+death	B-PROC
+.	O
+
+Crude	O
+ratio	O
+of	O
+cumulative	O
+deaths	B-PROC
+to	O
+cases	O
+underestimates	O
+the	O
+actual	O
+risk	O
+of	O
+MERS	O
+death	B-PROC
+because	O
+of	O
+time	O
+delay	O
+from	O
+illness	O
+onset	O
+to	O
+death	B-PROC
+.	O
+
+During	O
+the	O
+course	O
+of	O
+the	O
+outbreak	O
+,	O
+estimate	O
+of	O
+the	O
+CFR	B-PRGE
+in	O
+real	O
+time	O
+appeared	O
+to	O
+have	O
+decreased	O
+and	O
+become	O
+significantly	O
+lower	O
+than	O
+40	O
+%.	O
+
+Strain	O
+YN	O
+-	O
+inoculated	O
+birds	B-SPEC
+had	O
+clinical	O
+signs	O
+of	O
+varying	O
+severity	O
+with	O
+30	O
+%	O
+mortality	O
+,	O
+while	O
+the	O
+attenuated	O
+group	O
+appeared	O
+healthy	O
+,	O
+with	O
+less	O
+tissue	B-ANAT
+damage	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+Isotope	O
+-	O
+Edited	O
+FTIR	O
+to	O
+Derive	O
+a	O
+Backbone	B-ANAT
+Structure	O
+of	O
+a	O
+Transmembrane	B-COMP
+Protein	B-CHED
+.	O
+
+Herein	O
+,	O
+we	O
+use	O
+noninvasive	O
+isotope	O
+-	O
+edited	O
+FTIR	O
+spectroscopy	O
+to	O
+derive	O
+a	O
+structural	O
+model	O
+for	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+E	I-PRGE
+protein	B-CHED
+transmembrane	B-COMP
+domain	I-PRGE
+in	O
+lipid	B-ANAT
+bilayers	I-ANAT
+.	O
+
+Taken	O
+together	O
+,	O
+we	O
+show	O
+that	O
+isotope	O
+-	O
+edited	O
+FTIR	O
+is	O
+a	O
+powerful	O
+tool	O
+to	O
+analyze	O
+small	O
+membrane	O
+proteins	B-CHED
+in	O
+their	O
+native	O
+environment	O
+,	O
+enabling	O
+us	O
+to	O
+relate	O
+the	O
+unusual	O
+structure	O
+of	O
+the	O
+SARS	B-PRGE
+E	I-PRGE
+protein	B-CHED
+to	O
+its	O
+function	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+rhinoviruses	O
+and	O
+coronaviruses	O
+are	O
+the	O
+most	O
+common	O
+causative	O
+agents	O
+of	O
+the	O
+acute	B-DISO
+upper	I-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Hence	O
+,	O
+acyclic	O
+methodology	O
+in	O
+antiviral	B-CHED
+drug	I-CHED
+design	O
+did	O
+not	O
+take	O
+off	O
+until	O
+the	O
+discovery	O
+and	O
+subsequent	O
+FDA	O
+approval	O
+of	O
+such	O
+analogues	O
+as	O
+Acyclovir	B-CHED
+and	O
+Tenofovir	B-CHED
+.	O
+
+More	O
+recently	O
+,	O
+the	O
+observation	O
+that	O
+flexible	O
+nucleosides	B-CHED
+could	O
+overcome	O
+drug	B-PROC
+resistance	I-PROC
+spawned	O
+a	O
+renewed	O
+interest	O
+in	O
+the	O
+field	O
+of	O
+nucleoside	B-CHED
+drug	O
+design	O
+.	O
+
+Nonetheless	O
+,	O
+the	O
+target	B-ANAT
+cells	I-ANAT
+of	O
+PEDV	B-SPEC
+in	O
+vivo	O
+are	O
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+during	O
+infection	B-DISO
+,	O
+intestinal	B-ANAT
+epithelia	O
+would	O
+be	O
+damaged	O
+and	O
+resulted	O
+in	O
+digestive	B-DISO
+disorders	I-DISO
+.	O
+
+PEDV	B-SPEC
+not	O
+only	O
+failed	O
+to	O
+induce	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+expression	B-PROC
+,	O
+but	O
+also	O
+inhibited	O
+dsRNA	B-CHED
+-	O
+mediated	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+in	O
+IECs	O
+.	O
+
+This	O
+article	O
+describes	O
+the	O
+cases	O
+of	O
+two	O
+patients	O
+with	O
+severe	O
+refractory	O
+adult	B-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+who	O
+failed	O
+to	O
+improve	O
+after	O
+both	O
+standard	O
+life	O
+support	O
+measures	O
+,	O
+including	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+additional	O
+measures	O
+,	O
+including	O
+extracorporeal	O
+ventilation	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+in	O
+a	O
+heart	B-ANAT
+-	O
+lung	B-ANAT
+machine	O
+).	O
+
+ABSTRACT	O
+:	O
+Positive	O
+-	O
+strand	O
+RNA	O
+(+	O
+RNA	O
+)	O
+viruses	O
+are	O
+an	O
+important	O
+group	O
+of	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+pathogens	O
+that	O
+have	O
+significant	O
+global	O
+health	O
+and	O
+economic	O
+impacts	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+characterized	O
+the	O
+concentration	O
+and	O
+size	O
+distribution	O
+of	O
+inhalable	O
+particles	O
+that	O
+transport	B-PROC
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+IAV	O
+),	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+),	O
+and	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+generated	O
+by	O
+acutely	O
+infected	O
+pigs	B-SPEC
+and	O
+assessed	O
+virus	B-SPEC
+viability	O
+for	O
+each	O
+particle	O
+size	O
+range	O
+.	O
+
+Infectious	B-DISO
+status	O
+was	O
+demonstrated	O
+for	O
+the	O
+3	O
+viruses	B-SPEC
+,	O
+and	O
+in	O
+the	O
+case	O
+of	O
+IAV	O
+and	O
+PRRSV	B-SPEC
+,	O
+viruses	B-SPEC
+were	O
+isolated	O
+from	O
+particles	O
+larger	O
+than	O
+2	O
+.	O
+1	O
+μm	O
+.	O
+
+In	O
+summary	O
+,	O
+our	O
+results	O
+indicated	O
+that	O
+airborne	O
+PEDV	B-SPEC
+,	O
+IAV	O
+and	O
+PRRSV	B-SPEC
+can	O
+be	O
+found	O
+in	O
+a	O
+wide	O
+range	O
+of	O
+particle	O
+sizes	O
+.	O
+
+Collected	O
+data	O
+included	O
+history	O
+,	O
+and	O
+pre	O
+-	O
+and	O
+post	O
+-	O
+naloxone	B-CHED
+data	O
+,	O
+including	O
+respiratory	O
+rate	O
+(	O
+RR	O
+),	O
+pulse	B-PROC
+oximetry	O
+(	O
+pulse	B-PROC
+ox	O
+),	O
+end	O
+-	O
+tidal	O
+CO2	B-CHED
+level	O
+(	O
+ET	O
+-	O
+CO2	B-CHED
+),	O
+and	O
+Richmond	O
+Agitation	B-DISO
+Sedation	B-DISO
+Scale	O
+(	O
+RASS	O
+).	O
+
+TITLE	O
+:	O
+A	O
+synthetic	O
+consensus	O
+anti	O
+-	O
+spike	O
+protein	B-CHED
+DNA	O
+vaccine	O
+induces	O
+protective	O
+immunity	B-PROC
+against	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+in	O
+nonhuman	O
+primates	B-SPEC
+.	O
+
+Vaccinated	O
+rhesus	B-SPEC
+macaques	I-SPEC
+seroconverted	O
+rapidly	O
+and	O
+exhibited	O
+high	O
+levels	O
+of	O
+virus	B-SPEC
+-	O
+neutralizing	O
+activity	O
+.	O
+
+These	O
+studies	O
+demonstrate	O
+that	O
+a	O
+consensus	O
+MERS	O
+spike	O
+protein	B-CHED
+synthetic	O
+DNA	O
+vaccine	O
+can	O
+induce	O
+protective	O
+responses	O
+against	O
+viral	O
+challenge	O
+,	O
+indicating	O
+that	O
+this	O
+strategy	O
+may	O
+have	O
+value	O
+as	O
+a	O
+possible	O
+vaccine	O
+modality	O
+against	O
+this	O
+emerging	O
+pathogen	O
+.	O
+
+TITLE	O
+:	O
+Awareness	O
+,	O
+Attitudes	O
+,	O
+and	O
+Practices	O
+Related	O
+to	O
+Coronavirus	B-SPEC
+Pandemic	O
+Among	O
+Public	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+TITLE	O
+:	O
+Laboratory	O
+Testing	O
+for	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+,	O
+California	B-SPEC
+,	O
+USA	O
+,	O
+2013	O
+-	O
+2014	O
+.	O
+
+To	O
+determine	O
+if	O
+mechanical	O
+damage	O
+following	O
+spray	O
+application	O
+plays	O
+a	O
+role	O
+in	O
+failure	O
+of	O
+the	O
+Ark	B-PRGE
+-	O
+DPI	O
+vaccine	O
+,	O
+we	O
+examined	O
+the	O
+morphology	O
+of	O
+three	O
+Ark	B-PRGE
+-	O
+DPI	O
+vaccines	O
+from	O
+different	O
+manufacturers	O
+using	O
+an	O
+electron	O
+microscope	O
+and	O
+included	O
+a	O
+Massachusetts	O
+(	O
+Mass	O
+)	O
+vaccine	O
+as	O
+control	O
+.	O
+
+No	O
+obvious	O
+differences	O
+were	O
+observed	O
+in	O
+virus	B-SPEC
+morphology	O
+and	O
+no	O
+consistent	O
+trend	O
+in	O
+the	O
+number	O
+of	O
+spikes	O
+per	O
+virion	B-COMP
+was	O
+found	O
+in	O
+before	O
+-	O
+and	O
+after	O
+-	O
+spray	O
+samples	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+pathogen	O
+of	O
+swine	B-SPEC
+that	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+and	O
+dehydration	B-DISO
+resulting	O
+in	O
+substantial	O
+morbidity	O
+and	O
+mortality	O
+in	O
+newborn	O
+piglets	O
+.	O
+
+Phage	O
+display	O
+is	O
+a	O
+technique	O
+with	O
+wide	O
+application	O
+,	O
+in	O
+particular	O
+,	O
+the	O
+identification	O
+of	O
+key	O
+antigen	B-CHED
+epitopes	O
+for	O
+the	O
+development	B-PROC
+of	O
+therapeutic	O
+and	O
+diagnostic	O
+reagents	B-CHED
+and	O
+vaccines	O
+.	O
+
+After	O
+multiple	O
+rounds	O
+of	O
+biopanning	O
+and	O
+stringent	O
+washing	O
+,	O
+three	O
+phage	O
+-	O
+displayed	O
+peptides	B-CHED
+,	O
+designated	O
+L	O
+,	O
+W	O
+and	O
+H	O
+,	O
+were	O
+identified	O
+that	O
+recognize	O
+MAb	O
+-	O
+5E12	O
+.	O
+
+In	O
+contrast	O
+to	O
+peptide	B-CHED
+M	O
+,	O
+a	O
+consensus	O
+motif	O
+'	O
+PxxY	O
+'	O
+was	O
+identified	O
+on	O
+both	O
+peptides	B-CHED
+L	O
+and	O
+W	O
+,	O
+and	O
+on	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+,	O
+but	O
+not	O
+on	O
+peptide	B-CHED
+H	O
+.	O
+Peptide	B-CHED
+M	O
+and	O
+the	O
+MAb	O
+-	O
+5E12	O
+-	O
+recognizing	O
+peptides	B-CHED
+L	O
+and	O
+W	O
+significantly	O
+inhibited	O
+the	O
+adsorption	O
+of	O
+PEDV	B-SPEC
+on	O
+the	O
+cell	B-COMP
+surface	I-COMP
+as	O
+monitored	O
+through	O
+plaque	B-DISO
+-	O
+reduction	O
+assays	O
+.	O
+
+iNO	B-PRGE
+and	O
+iEPO	O
+have	O
+shown	O
+similar	O
+efficacy	O
+profiles	O
+;	O
+however	O
+,	O
+they	O
+differ	O
+with	O
+respect	O
+to	O
+cost	O
+and	O
+ease	O
+of	O
+therapeutic	O
+administration	O
+.	O
+
+The	O
+most	O
+beneficial	O
+effects	O
+of	O
+iEPO	O
+have	O
+been	O
+seen	O
+in	O
+adult	O
+patients	O
+with	O
+secondary	O
+ARDS	B-DISO
+as	O
+compared	O
+with	O
+primary	O
+ARDS	B-DISO
+,	O
+most	O
+likely	O
+due	O
+to	O
+the	O
+difference	O
+in	O
+etiology	O
+of	O
+the	O
+two	O
+disease	O
+states	O
+,	O
+and	O
+in	O
+patients	O
+suffering	B-DISO
+from	O
+baseline	O
+right	O
+ventricular	B-ANAT
+heart	B-DISO
+failure	I-DISO
+.	O
+
+One	O
+patient	O
+died	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+treatment	O
+with	O
+ethanolamine	B-CHED
+oleate	B-CHED
+.	O
+
+The	O
+total	O
+sclerosant	O
+volume	O
+was	O
+significantly	O
+lower	O
+for	O
+3	O
+%	O
+polidocanol	B-CHED
+foam	O
+(	O
+13	O
+.	O
+5	O
+±	O
+6	O
+.	O
+8	O
+mL	O
+)	O
+than	O
+for	O
+5	O
+%	O
+ethanolamine	B-CHED
+oleate	B-CHED
+(	O
+30	O
+.	O
+6	O
+±	O
+15	O
+.	O
+6	O
+mL	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Polidocanol	B-CHED
+foam	O
+can	O
+achieve	O
+obliteration	O
+of	O
+gastric	B-DISO
+varices	I-DISO
+comparable	O
+to	O
+that	O
+of	O
+ethanolamine	B-CHED
+oleate	B-CHED
+but	O
+with	O
+a	O
+significantly	O
+lower	O
+sclerosant	O
+dose	O
+and	O
+reduced	O
+risk	O
+of	O
+hemolysis	B-DISO
+-	O
+induced	O
+complications	O
+and	O
+harmful	O
+reactions	O
+,	O
+including	O
+pain	O
+and	O
+fever	B-PROC
+.	O
+
+The	O
+existence	O
+of	O
+astroviruses	O
+(	O
+AstVs	O
+)	O
+in	O
+dromedaries	B-SPEC
+was	O
+previously	O
+unknown	O
+.	O
+
+Recombination	B-PROC
+analysis	O
+revealed	O
+a	O
+possible	O
+recombination	B-PROC
+event	O
+in	O
+ORF2	O
+of	O
+strain	O
+DcAstV	O
+-	O
+274	O
+.	O
+
+The	O
+low	O
+Ka	O
+/	O
+Ks	O
+ratios	O
+(	O
+number	O
+of	O
+non	O
+-	O
+synonymous	O
+substitutions	O
+per	O
+non	O
+-	O
+synonymous	O
+site	O
+to	O
+number	O
+of	O
+synonymous	O
+substitutions	O
+per	O
+synonymous	O
+site	O
+)	O
+of	O
+the	O
+four	O
+ORFs	O
+in	O
+the	O
+DcAstV	O
+genomes	O
+supported	O
+the	O
+suggestion	O
+that	O
+dromedaries	B-SPEC
+are	O
+the	O
+natural	O
+reservoir	O
+where	O
+AstV	O
+is	O
+stably	O
+evolving	O
+.	O
+
+In	O
+humans	B-SPEC
+,	O
+ARDS	B-DISO
+is	O
+very	O
+well	O
+defined	O
+by	O
+a	O
+list	O
+of	O
+clinical	O
+parameters	O
+.	O
+
+Murine	B-SPEC
+ARDS	B-DISO
+models	O
+typically	O
+are	O
+defined	O
+by	O
+such	O
+features	O
+as	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+leukocyte	B-ANAT
+infiltration	B-DISO
+in	O
+cytological	O
+preparations	O
+of	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+and	O
+/	O
+or	O
+lung	B-ANAT
+sections	O
+.	O
+
+ABSTRACT	O
+:	O
+Murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+has	O
+long	O
+served	O
+as	O
+a	O
+model	O
+system	O
+for	O
+the	O
+study	O
+of	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Nucleic	B-CHED
+acid	I-CHED
+(	O
+NA	O
+)-	O
+targeted	B-PROC
+tests	O
+detect	O
+and	O
+quantify	O
+viral	O
+DNA	O
+and	O
+RNA	O
+(	O
+collectively	O
+xNA	O
+)	O
+to	O
+support	O
+epidemiological	O
+surveillance	O
+and	O
+,	O
+in	O
+individual	O
+patients	O
+,	O
+to	O
+guide	O
+therapy	O
+.	O
+
+Therefore	O
+,	O
+ECMO	O
+might	O
+be	O
+considered	O
+as	O
+a	O
+bridge	O
+therapy	O
+for	O
+patients	O
+with	O
+intractable	O
+cardiorespiratory	B-DISO
+failure	I-DISO
+caused	O
+by	O
+AlP	B-CHED
+poisoning	O
+who	O
+are	O
+not	O
+responding	O
+to	O
+conventional	O
+treatment	O
+.	O
+
+In	O
+view	O
+of	O
+recent	O
+reports	O
+of	O
+emergent	O
+IBV	B-SPEC
+variants	O
+in	O
+many	O
+countries	O
+,	O
+there	O
+is	O
+renewed	O
+interest	O
+in	O
+a	O
+more	O
+complete	O
+understanding	O
+of	O
+poultry	O
+immune	B-PROC
+responses	I-PROC
+to	O
+both	O
+virulent	O
+and	O
+vaccine	O
+strains	O
+of	O
+IBVs	O
+.	O
+
+Furthermore	O
+,	O
+significant	O
+downregulation	B-PROC
+was	O
+observed	O
+as	O
+early	O
+as	O
+10	O
+min	O
+after	O
+trauma	O
+for	O
+cytokines	B-PRGE
+and	I-PRGE
+complement	I-PRGE
+factors	I-PRGE
+(	O
+LCR	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+C4	O
+)	O
+as	O
+well	O
+as	O
+for	O
+intracellular	B-COMP
+signaling	B-CHED
+molecules	I-CHED
+(	O
+inhibitory	O
+protein	B-CHED
+phosphatase	B-FUNC
+)	O
+and	O
+ion	O
+-	O
+channels	O
+(	O
+voltage	B-CHED
+-	O
+dependent	O
+Ca	O
+(	O
+2	O
++)	O
+channel	O
+).	O
+
+We	O
+used	O
+recombinant	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+9	O
+of	O
+the	O
+arterivirus	B-SPEC
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+(	O
+EAV	B-SPEC
+)	O
+and	O
+different	O
+biochemical	O
+assays	O
+,	O
+including	O
+irreversible	O
+labeling	O
+with	O
+a	O
+GTP	B-CHED
+analog	O
+followed	O
+by	O
+a	O
+proteomics	O
+analysis	O
+,	O
+to	O
+demonstrate	O
+the	O
+manganese	B-CHED
+-	O
+dependent	O
+covalent	B-PROC
+binding	B-FUNC
+of	O
+guanosine	B-CHED
+and	O
+uridine	B-CHED
+phosphates	I-CHED
+to	O
+a	O
+lysine	B-CHED
+/	O
+histidine	B-CHED
+residue	I-CHED
+.	O
+
+Furthermore	O
+,	O
+this	O
+mutation	O
+crippled	O
+EAV	B-SPEC
+and	O
+prevented	O
+the	O
+replication	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+cell	B-COMP
+culture	O
+,	O
+indicating	O
+that	O
+NiRAN	O
+is	O
+essential	O
+for	O
+nidoviruses	B-SPEC
+.	O
+
+Potential	O
+functions	O
+supported	O
+by	O
+NiRAN	O
+may	O
+include	O
+nucleic	B-CHED
+acid	I-CHED
+ligation	O
+,	O
+mRNA	B-PROC
+capping	B-PROC
+and	O
+protein	B-CHED
+-	O
+primed	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+possibilities	O
+that	O
+remain	O
+to	O
+be	O
+explored	O
+in	O
+future	O
+studies	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+is	O
+a	O
+highly	O
+contagious	O
+,	O
+enteric	O
+disease	O
+of	O
+swine	B-SPEC
+caused	O
+by	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Genome	O
+-	O
+Wide	O
+Screen	O
+Reveals	O
+Valosin	O
+-	O
+Containing	O
+Protein	B-CHED
+Requirement	O
+for	O
+Coronavirus	B-SPEC
+Exit	O
+from	O
+Endosomes	O
+.	O
+
+Thirty	O
+of	O
+these	O
+hits	O
+can	O
+be	O
+placed	O
+in	O
+a	O
+network	O
+of	O
+interactions	O
+with	O
+viral	O
+proteins	B-CHED
+and	O
+are	O
+involved	O
+in	O
+RNA	B-PROC
+splicing	I-PROC
+,	O
+membrane	B-COMP
+trafficking	B-PROC
+,	O
+and	O
+ubiquitin	B-PROC
+conjugation	B-PROC
+.	O
+
+The	O
+several	O
+host	B-COMP
+factors	O
+identified	O
+in	O
+this	O
+study	O
+may	O
+provide	O
+directions	O
+for	O
+future	O
+research	O
+on	O
+targeted	B-PROC
+therapeutics	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+nsp1	B-PRGE
+Inhibits	O
+Host	B-COMP
+Gene	B-PROC
+Expression	I-PROC
+by	O
+Selectively	O
+Targeting	O
+mRNAs	O
+Transcribed	O
+in	O
+the	O
+Nucleus	B-COMP
+while	O
+Sparing	O
+mRNAs	O
+of	O
+Cytoplasmic	B-COMP
+Origin	O
+.	O
+
+Furthermore	O
+,	O
+like	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp1	I-PRGE
+,	O
+the	O
+mRNA	B-PROC
+degradation	I-PROC
+activity	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp1	I-PRGE
+,	O
+most	O
+probably	O
+triggered	O
+by	O
+its	O
+ability	O
+to	O
+induce	O
+an	O
+endonucleolytic	O
+RNA	O
+cleavage	B-PROC
+,	O
+was	O
+separable	O
+from	O
+its	O
+translation	B-PROC
+inhibitory	O
+function	O
+.	O
+
+Interestingly	O
+,	O
+consistent	O
+with	O
+this	O
+notion	O
+,	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp1	I-PRGE
+selectively	O
+targeted	B-PROC
+mRNAs	O
+,	O
+which	O
+are	O
+transcribed	O
+in	O
+the	O
+nucleus	B-COMP
+and	O
+transported	O
+to	O
+the	O
+cytoplasm	B-COMP
+,	O
+for	O
+translation	B-PROC
+inhibition	B-PROC
+and	O
+mRNA	B-PROC
+degradation	I-PROC
+but	O
+spared	O
+exogenous	O
+mRNAs	O
+introduced	O
+directly	O
+into	O
+the	O
+cytoplasm	B-COMP
+or	O
+virus	B-SPEC
+-	O
+like	O
+mRNAs	O
+that	O
+originate	O
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+Injured	O
+lungs	B-ANAT
+can	O
+be	O
+partially	O
+protected	O
+by	O
+optimal	O
+settings	O
+and	O
+ventilation	O
+modes	O
+,	O
+using	O
+low	O
+tidal	O
+volume	O
+(	O
+VT	O
+)	O
+values	O
+and	O
+high	O
+positive	O
+-	O
+end	O
+expiratory	B-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+).	O
+
+For	O
+the	O
+amplification	B-DISO
+of	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+and	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+genes	O
+,	O
+hemi	O
+-	O
+nested	O
+PCR	O
+(	O
+Invitrogen	O
+,	O
+ABD	B-ANAT
+)	O
+was	O
+conducted	O
+,	O
+followed	O
+by	O
+sequence	O
+analysis	O
+of	O
+204	O
+nucleotide	B-CHED
+part	O
+of	O
+N	B-PRGE
+gene	I-PRGE
+.	O
+
+There	O
+was	O
+no	O
+nucleotide	B-CHED
+or	O
+aminoacid	O
+change	O
+in	O
+our	O
+isolate	O
+,	O
+namely	O
+ANK	O
+/	O
+1079	O
+/	O
+2014	O
+when	O
+compared	O
+with	O
+human	B-SPEC
+Betacoronavirus	B-SPEC
+2c	O
+EMC	B-COMP
+/	O
+2012	O
+reference	O
+strain	O
+found	O
+in	O
+Genbank	O
+database	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+high	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+and	O
+multiorgan	O
+dysfunction	O
+that	O
+may	O
+eventually	O
+lead	O
+to	O
+the	O
+death	B-PROC
+of	O
+the	O
+infected	O
+individuals	O
+.	O
+
+The	O
+occurrence	O
+of	O
+the	O
+virus	B-SPEC
+was	O
+first	O
+reported	O
+in	O
+the	O
+Middle	O
+East	O
+and	O
+it	O
+subsequently	O
+spread	O
+to	O
+several	O
+parts	O
+of	O
+the	O
+world	O
+.	O
+
+Currently	O
+,	O
+no	O
+drug	O
+has	O
+been	O
+clinically	O
+approved	O
+to	O
+control	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Two	O
+novel	O
+neutralizing	O
+antigenic	O
+epitopes	O
+of	O
+the	O
+s1	O
+subunit	O
+protein	B-CHED
+of	O
+a	O
+QX	O
+-	O
+like	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	O
+strain	O
+Sczy3	O
+as	O
+revealed	O
+using	O
+a	O
+phage	O
+display	O
+peptide	B-CHED
+library	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+plays	O
+a	O
+central	O
+role	O
+in	O
+the	O
+pathogenicity	O
+,	O
+the	O
+immune	O
+antibody	B-PROC
+production	I-PROC
+,	O
+serotype	O
+and	O
+the	O
+tissue	B-PROC
+tropism	B-PROC
+.	O
+
+Acute	O
+compartment	B-DISO
+syndrome	I-DISO
+is	O
+a	O
+potentially	O
+devastating	O
+sequela	O
+of	O
+soft	O
+-	O
+tissue	B-ANAT
+injury	O
+that	O
+complicates	O
+high	O
+-	O
+energy	O
+injuries	O
+such	O
+as	O
+proximal	O
+tibia	O
+fractures	O
+.	O
+
+Prone	O
+position	O
+ventilation	O
+(	O
+PPV	B-CHED
+)	O
+has	O
+been	O
+shown	O
+to	O
+improve	O
+the	O
+prognosis	O
+of	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+This	O
+study	O
+explored	O
+the	O
+effects	O
+of	O
+PPV	B-CHED
+on	O
+the	O
+respiratory	O
+and	O
+circulatory	B-PROC
+mechanics	O
+of	O
+H7N9	O
+-	O
+infected	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Individuals	O
+admitted	O
+to	O
+four	O
+hospitals	O
+designated	O
+for	O
+H7N9	O
+patients	O
+in	O
+Guangdong	O
+province	O
+were	O
+treated	O
+with	O
+PPV	B-CHED
+,	O
+and	O
+their	O
+clinical	O
+data	O
+were	O
+recorded	O
+before	O
+and	O
+after	O
+receiving	O
+PPV	B-CHED
+.	O
+
+RESULTS	O
+:	O
+Six	O
+of	O
+20	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+in	O
+the	O
+ICU	O
+received	O
+PPV	B-CHED
+.	O
+
+Additionally	O
+,	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+the	O
+mean	O
+values	O
+for	O
+arterial	B-PROC
+pressure	I-PROC
+(	O
+MAP	O
+),	O
+cardiac	B-ANAT
+index	O
+(	O
+CI	O
+),	O
+central	O
+venous	B-PROC
+pressure	I-PROC
+(	O
+CVP	O
+),	O
+heart	B-ANAT
+rate	O
+(	O
+HR	O
+),	O
+lactic	B-CHED
+acid	I-CHED
+(	O
+LAC	B-CHED
+)	O
+levels	O
+or	O
+the	O
+doses	O
+of	O
+norepinephrine	B-CHED
+(	O
+NE	O
+)	O
+administered	O
+when	O
+compared	O
+pre	O
+-	O
+PPV	B-CHED
+,	O
+post	O
+-	O
+PPV	B-CHED
+,	O
+and	O
+post	O
+-	O
+SPV	O
+.	O
+
+TITLE	O
+:	O
+The	O
+dilemma	O
+of	O
+rare	O
+events	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+North	O
+America	O
+.	O
+
+TITLE	O
+:	O
+Glomerulonephritis	B-DISO
+in	O
+a	O
+ferret	B-SPEC
+with	O
+feline	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+In	O
+affected	O
+glomeruli	O
+,	O
+glomerular	B-ANAT
+capillary	I-ANAT
+walls	O
+and	O
+mesangial	O
+areas	O
+were	O
+positive	O
+for	O
+anti	B-PRGE
+-	I-PRGE
+ferret	I-PRGE
+immunoglobulin	B-PROC
+G	O
+.	O
+By	O
+electron	O
+microscopy	O
+,	O
+subepithelial	O
+and	O
+mesangial	O
+electron	O
+-	O
+dense	O
+deposits	O
+were	O
+observed	O
+consistent	O
+with	O
+immune	O
+complex	O
+deposition	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+is	O
+a	O
+devastating	O
+disease	O
+in	O
+livestock	O
+industry	O
+.	O
+
+The	O
+overexpression	B-PROC
+of	O
+NPIPB3	O
+restored	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+responses	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORF6	I-PRGE
+expressing	O
+cells	B-COMP
+,	O
+indicating	O
+that	O
+the	O
+interaction	O
+of	O
+SARS	B-PRGE
+CoV	I-PRGE
+ORF6	I-PRGE
+and	O
+NPIPB3	O
+reduced	O
+Type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+antagonism	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORF6	I-PRGE
+.	O
+
+The	O
+coimmunoprecipitation	O
+assay	O
+demonstrated	O
+the	O
+direct	O
+binding	B-FUNC
+of	O
+ORF6	O
+to	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+of	O
+NPIPB3	O
+in	O
+vitro	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+overexpression	B-PROC
+of	O
+NPIPB3	O
+restored	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+responses	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORF6	I-PRGE
+expressing	O
+cells	B-COMP
+,	O
+indicating	O
+that	O
+the	O
+interaction	O
+of	O
+SARS	B-PRGE
+CoV	I-PRGE
+ORF6	I-PRGE
+and	O
+NPIPB3	O
+reduced	O
+Type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+antagonism	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORF6	I-PRGE
+.	O
+
+This	O
+case	O
+report	O
+highlights	O
+the	O
+complication	B-DISO
+of	O
+ARDS	B-DISO
+during	O
+the	O
+course	O
+of	O
+Pv	O
+infection	B-DISO
+in	O
+a	O
+60	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+.	O
+
+The	O
+data	O
+indicated	O
+the	O
+presence	O
+of	O
+mono	B-DISO
+-	O
+Pv	O
+infection	B-DISO
+in	O
+the	O
+patient	O
+'	O
+s	O
+blood	B-ANAT
+,	O
+and	O
+Pf	O
+infection	B-DISO
+was	O
+specifically	O
+ruled	O
+out	O
+.	O
+
+The	O
+patient	O
+was	O
+discharged	O
+after	O
+intensive	O
+supportive	O
+care	O
+and	O
+antimalarial	B-CHED
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+Dysregulation	O
+of	O
+the	O
+innate	O
+immune	O
+system	O
+drives	O
+lung	B-ANAT
+injury	O
+and	O
+its	O
+systemic	O
+sequelae	O
+due	O
+to	O
+breakdown	B-DISO
+of	O
+vascular	B-ANAT
+barrier	O
+function	O
+,	O
+harmful	O
+hyperinflammation	O
+and	O
+microcirculatory	O
+failure	O
+,	O
+which	O
+contribute	O
+to	O
+the	O
+unfavourable	O
+outcome	O
+of	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+ultrasound	O
+and	O
+pulse	B-PROC
+oximetry	O
+versus	O
+chest	B-ANAT
+radiography	O
+and	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+for	O
+the	O
+diagnosis	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+:	O
+a	O
+pilot	O
+study	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Bats	B-SPEC
+and	O
+Viruses	B-SPEC
+:	O
+complex	O
+relationships	O
+].	O
+
+ABSTRACT	O
+:	O
+With	O
+more	O
+than	O
+1	O
+200	O
+species	B-SPEC
+,	O
+bats	B-SPEC
+and	O
+flying	O
+foxes	O
+(	O
+Order	B-SPEC
+Chiroptera	I-SPEC
+)	O
+constitute	O
+the	O
+most	O
+important	O
+and	O
+diverse	O
+order	B-SPEC
+of	O
+Mammals	B-SPEC
+after	O
+Rodents	B-SPEC
+.	O
+
+Many	O
+species	B-SPEC
+of	O
+bats	B-SPEC
+are	O
+insectivorous	O
+while	O
+others	O
+are	O
+frugivorous	O
+and	O
+few	O
+of	O
+them	O
+are	O
+hematophagous	O
+.	O
+
+Some	O
+of	O
+these	O
+animals	B-SPEC
+fly	B-SPEC
+during	O
+the	O
+night	O
+,	O
+others	O
+are	O
+crepuscular	O
+or	O
+diurnal	O
+.	O
+
+Some	O
+fly	B-SPEC
+long	O
+distances	O
+during	O
+seasonal	O
+migrations	O
+.	O
+
+More	O
+than	O
+sixty	O
+viruses	B-SPEC
+have	O
+been	O
+detected	O
+or	O
+isolated	O
+in	O
+bats	B-SPEC
+;	O
+these	O
+animals	B-SPEC
+are	O
+therefore	O
+involved	O
+in	O
+the	O
+natural	O
+cycles	O
+of	O
+many	O
+of	O
+them	O
+.	O
+
+This	O
+is	O
+the	O
+case	O
+,	O
+for	O
+instance	O
+,	O
+of	O
+rabies	B-SPEC
+virus	I-SPEC
+and	O
+other	O
+Lyssavirus	B-SPEC
+(	O
+Family	B-SPEC
+Rhabdoviridae	I-SPEC
+),	O
+Nipah	O
+and	O
+Hendra	O
+viruses	B-SPEC
+(	O
+Paramyxoviridae	B-SPEC
+),	O
+Ebola	O
+and	O
+Marburg	B-SPEC
+viruses	I-SPEC
+(	O
+Filoviridae	B-SPEC
+),	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+(	O
+Coronaviridae	B-SPEC
+).	O
+
+Some	O
+of	O
+these	O
+bat	B-ENZY
+-	O
+borne	O
+viruses	B-SPEC
+cause	O
+highly	O
+pathogenic	O
+diseases	O
+while	O
+others	O
+are	O
+of	O
+potential	O
+significance	O
+for	O
+humans	B-SPEC
+and	O
+domestic	O
+or	O
+wild	O
+animals	B-SPEC
+;	O
+so	O
+,	O
+bats	B-SPEC
+are	O
+an	O
+important	O
+risk	O
+in	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+public	O
+health	O
+.	O
+
+It	O
+is	O
+also	O
+necessary	O
+to	O
+get	O
+a	O
+better	O
+knowledge	O
+of	O
+the	O
+interactions	O
+between	O
+bats	B-SPEC
+and	O
+ecologic	O
+changes	O
+induced	O
+by	O
+man	B-CHED
+and	O
+to	O
+attentively	O
+follow	O
+bat	B-ENZY
+populations	O
+and	O
+their	O
+viruses	B-SPEC
+through	O
+surveillance	O
+networks	O
+involving	O
+human	B-SPEC
+and	O
+veterinary	O
+physicians	O
+,	O
+specialists	O
+of	O
+wild	O
+fauna	O
+,	O
+ecologists	O
+,	O
+etc	O
+.	O
+
+Calcium	B-PROC
+transport	I-PROC
+through	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+IC	I-PRGE
+was	O
+the	O
+main	O
+trigger	O
+of	O
+this	O
+process	O
+.	O
+
+Murine	B-SPEC
+sialic	B-CHED
+acid	I-CHED
+-	O
+binding	B-FUNC
+immunoglobulin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+lectin	I-PRGE
+-	I-PRGE
+E	I-PRGE
+(	O
+Siglec	B-PRGE
+-	I-PRGE
+E	I-PRGE
+)	O
+and	O
+its	O
+human	B-SPEC
+orthologs	O
+Siglec	O
+-	O
+7	O
+and	O
+Siglec	O
+-	O
+9	O
+are	O
+immunomodulatory	O
+receptors	O
+found	O
+predominantly	O
+on	O
+hematopoietic	O
+cells	B-COMP
+.	O
+
+These	O
+receptors	O
+are	O
+important	O
+negative	O
+regulators	O
+of	O
+acute	O
+inflammatory	B-DISO
+responses	I-DISO
+and	O
+are	O
+potential	O
+targets	O
+for	O
+the	O
+treatment	O
+of	O
+sepsis	B-DISO
+and	O
+ARDS	B-DISO
+.	O
+
+We	O
+also	O
+established	O
+that	O
+interleukin	B-PRGE
+-	I-PRGE
+10	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+)	O
+induced	O
+Siglec	B-PRGE
+-	I-PRGE
+E	I-PRGE
+expression	B-PROC
+and	O
+α2	O
+,	O
+8	O
+NANA	O
+-	O
+NP	O
+further	O
+augmented	O
+the	O
+expression	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+6	O
+duplex	O
+real	O
+-	O
+time	O
+PCR	O
+assays	O
+,	O
+using	O
+EvaGreen	O
+intercalating	O
+dye	B-CHED
+,	O
+were	O
+developed	O
+to	O
+detect	O
+12	O
+major	O
+viruses	B-SPEC
+responsible	O
+for	O
+respiratory	B-DISO
+diseases	I-DISO
+:	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+viruses	B-SPEC
+,	O
+enteroviruses	B-SPEC
+(	O
+including	O
+enterovirus	B-SPEC
+spp	B-ENZY
+,	O
+and	O
+rhinovirus	B-SPEC
+spp	B-ENZY
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+coronaviruses	O
+group	O
+I	O
+(	O
+of	O
+which	O
+CoV	O
+229E	O
+and	O
+CoV	O
+NL63	O
+are	O
+part	O
+)	O
+and	O
+II	O
+(	O
+including	O
+CoV	O
+OC43	O
+and	O
+CoV	O
+HKU1	O
+),	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+type	O
+1	O
+,	O
+2	O
+,	O
+3	O
+and	O
+4	O
+,	O
+human	B-SPEC
+adenoviruses	B-SPEC
+and	O
+human	B-SPEC
+bocaviruses	B-SPEC
+.	O
+
+In	O
+contrast	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+in	O
+children	O
+,	O
+followed	O
+by	O
+enteroviruses	B-SPEC
+,	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+and	O
+coronavirus	B-SPEC
+NL63	O
+.	O
+
+Here	O
+we	O
+provide	O
+a	O
+head	B-ANAT
+-	O
+to	O
+-	O
+head	B-ANAT
+comparison	O
+of	O
+exposure	O
+patterns	O
+and	O
+transmission	O
+dynamics	O
+of	O
+large	O
+hospital	O
+clusters	B-CHED
+of	O
+MERS	O
+and	O
+SARS	B-DISO
+,	O
+including	O
+the	O
+most	O
+recent	O
+South	O
+Korean	O
+outbreak	O
+of	O
+MERS	O
+in	O
+2015	O
+.	O
+
+To	O
+assess	O
+the	O
+unexpected	O
+nature	O
+of	O
+the	O
+recent	O
+South	O
+Korean	O
+nosocomial	O
+outbreak	O
+of	O
+MERS	O
+and	O
+estimate	O
+the	O
+probability	O
+of	O
+future	O
+large	O
+hospital	O
+clusters	B-CHED
+,	O
+we	O
+compared	O
+exposure	O
+and	O
+transmission	O
+patterns	O
+for	O
+previously	O
+reported	O
+hospital	O
+clusters	B-CHED
+of	O
+MERS	O
+and	O
+SARS	B-DISO
+,	O
+based	O
+on	O
+individual	O
+-	O
+level	O
+data	O
+and	O
+transmission	O
+tree	O
+information	O
+.	O
+
+There	O
+was	O
+a	O
+systematic	O
+difference	O
+in	O
+the	O
+exposure	O
+patterns	O
+of	O
+MERS	O
+and	O
+SARS	B-DISO
+:	O
+a	O
+majority	O
+of	O
+MERS	O
+cases	O
+occurred	O
+among	O
+patients	O
+who	O
+sought	O
+care	O
+in	O
+the	O
+same	O
+facilities	O
+as	O
+the	O
+index	O
+case	O
+,	O
+whereas	O
+there	O
+was	O
+a	O
+greater	O
+concentration	O
+of	O
+SARS	B-DISO
+cases	O
+among	O
+healthcare	O
+workers	O
+throughout	O
+the	O
+outbreak	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+present	O
+the	O
+case	O
+of	O
+a	O
+55	O
+-	O
+year	O
+-	O
+old	O
+male	O
+who	O
+died	B-PROC
+of	O
+a	O
+severe	O
+febrile	B-DISO
+neutropenia	I-DISO
+during	O
+adjuvant	B-CHED
+chemotherapy	O
+.	O
+
+We	O
+have	O
+shown	O
+that	O
+experimental	O
+sepsis	B-DISO
+in	O
+baboons	B-SPEC
+recapitulates	O
+ARDS	B-DISO
+progression	O
+in	O
+humans	B-SPEC
+,	O
+including	O
+chronic	B-DISO
+inflammation	I-DISO
+and	O
+long	O
+-	O
+lasting	O
+fibrosis	B-DISO
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+We	O
+identified	O
+the	O
+important	O
+functions	O
+of	O
+the	O
+ns12	O
+.	O
+9	O
+viroporin	O
+in	O
+virion	B-COMP
+morphogenesis	B-PROC
+during	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+defined	O
+as	O
+the	O
+acute	O
+onset	O
+of	O
+noncardiogenic	O
+edema	B-DISO
+and	O
+subsequent	O
+gas	B-ENZY
+-	O
+exchange	O
+impairment	B-DISO
+due	O
+to	O
+a	O
+severe	O
+inflammatory	O
+process	O
+.	O
+
+Therefore	O
+,	O
+the	O
+routine	O
+use	O
+of	O
+ω	O
+-	O
+3	O
+fatty	B-CHED
+acid	I-CHED
+-	O
+enriched	O
+nutrition	O
+cannot	O
+be	O
+recommended	O
+and	O
+further	O
+large	O
+,	O
+homogeneous	O
+,	O
+and	O
+high	O
+-	O
+quality	O
+clinical	O
+trials	O
+need	O
+to	O
+be	O
+conducted	O
+to	O
+clarify	O
+the	O
+effectiveness	O
+of	O
+ω	O
+-	O
+3	O
+polyunsaturated	B-CHED
+fatty	I-CHED
+acids	I-CHED
+.	O
+
+We	O
+conducted	O
+two	O
+prospective	O
+cohort	O
+studies	O
+at	O
+an	O
+urban	O
+,	O
+academic	O
+,	O
+level	O
+I	O
+trauma	O
+center	O
+and	O
+tertiary	O
+referral	O
+center	O
+;	O
+497	O
+patients	O
+with	O
+trauma	O
+admitted	O
+to	O
+the	O
+surgical	O
+intensive	O
+care	O
+unit	O
+between	O
+2005	O
+and	O
+2010	O
+with	O
+an	O
+injury	O
+severity	O
+score	O
+>	O
+15	O
+and	O
+759	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+admitted	O
+to	O
+the	O
+medical	O
+intensive	O
+care	O
+unit	O
+between	O
+2008	O
+and	O
+2013	O
+were	O
+followed	O
+for	O
+6	O
+days	O
+for	O
+the	O
+development	B-PROC
+of	O
+incident	O
+AKI	O
+.	O
+
+Based	O
+on	O
+CT	O
+data	O
+,	O
+clinical	O
+data	O
+,	O
+and	O
+virological	O
+data	O
+,	O
+MERS	O
+-	O
+CoV	O
+inoculation	O
+of	O
+common	B-SPEC
+marmosets	I-SPEC
+results	O
+in	O
+mild	O
+to	O
+moderate	O
+clinical	O
+signs	O
+of	O
+disease	O
+that	O
+are	O
+likely	O
+due	O
+to	O
+manipulations	O
+of	O
+the	O
+marmoset	B-SPEC
+rather	O
+than	O
+as	O
+a	O
+result	O
+of	O
+robust	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+an	O
+emerging	O
+highly	O
+pathogenic	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+Indirect	O
+immunofluorescence	O
+assay	O
+(	O
+FOCUS	O
+Diagnostics	O
+Inc	O
+.)	O
+was	O
+performed	O
+to	O
+detect	O
+IgM	B-PRGE
+and	O
+IgG	B-PRGE
+antibodies	I-PRGE
+to	O
+Rickettsia	B-SPEC
+conorii	I-SPEC
+.	O
+
+During	O
+this	O
+time	O
+,	O
+CDC	O
+'	O
+s	O
+response	O
+integrated	O
+multiple	O
+disciplines	O
+and	O
+was	O
+divided	O
+into	O
+three	O
+distinct	O
+phases	O
+:	O
+before	O
+,	O
+during	O
+,	O
+and	O
+after	O
+the	O
+initial	O
+activation	O
+of	O
+its	O
+Emergency	B-DISO
+Operations	O
+Center	O
+.	O
+
+CDC	O
+'	O
+s	O
+response	O
+to	O
+MERS	O
+-	O
+CoV	O
+required	O
+a	O
+large	O
+effort	B-PROC
+,	O
+deploying	O
+at	O
+least	O
+353	O
+staff	O
+members	O
+who	O
+worked	O
+in	O
+the	O
+areas	O
+of	O
+surveillance	O
+,	O
+laboratory	O
+capacity	O
+,	O
+infection	B-DISO
+control	O
+guidance	O
+,	O
+and	O
+travelers	O
+'	O
+health	O
+.	O
+
+TITLE	O
+:	O
+Suppression	B-PROC
+subtractive	O
+hybridization	B-PROC
+method	O
+for	O
+the	O
+identification	O
+of	O
+a	O
+new	O
+strain	O
+of	O
+murine	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+from	O
+xenografted	O
+SCID	B-DISO
+mice	B-SPEC
+.	O
+
+Analysis	O
+at	O
+the	O
+protein	B-CHED
+level	O
+showed	O
+that	O
+the	O
+virus	B-SPEC
+was	O
+closely	O
+related	O
+to	O
+the	O
+highly	O
+virulent	O
+MHV	B-SPEC
+-	O
+JHM	O
+strain	O
+.	O
+
+Immunized	O
+dogs	B-SPEC
+accounted	O
+for	O
+48	O
+.	O
+42	O
+%	O
+of	O
+95	O
+CPV	B-SPEC
+-	O
+2	O
+-	O
+positive	O
+samples	O
+.	O
+
+The	O
+pretravel	O
+medical	O
+consultation	O
+includes	O
+immunizations	O
+,	O
+malaria	B-PATH
+chemoprophylaxis	O
+,	O
+self	O
+-	O
+treatment	O
+for	O
+traveler	B-DISO
+'	I-DISO
+s	I-DISO
+diarrhea	I-DISO
+,	O
+and	O
+advice	O
+on	O
+the	O
+prevention	O
+of	O
+a	O
+myriad	O
+of	O
+other	O
+infectious	B-DISO
+causes	O
+including	O
+dengue	B-DISO
+,	O
+chikungunya	B-DISO
+,	O
+rickettsiosis	B-DISO
+,	O
+leptospirosis	B-DISO
+,	O
+schistosomiasis	B-DISO
+,	O
+and	O
+strongyloidiasis	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+Highly	O
+Immunogenic	O
+and	O
+Protective	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Vaccine	O
+Based	O
+on	O
+a	O
+Recombinant	O
+Measles	O
+Virus	O
+Vaccine	O
+Platform	O
+.	O
+
+The	O
+main	O
+areas	O
+during	O
+mechanical	O
+ventilation	O
+of	O
+lungs	B-ANAT
+in	O
+patients	O
+with	O
+a	O
+sharp	O
+decline	O
+in	O
+restrictive	O
+lung	B-PROC
+function	I-PROC
+(	O
+ARDS	B-DISO
+,	O
+pneumonia	B-DISO
+),	O
+regardless	O
+of	O
+the	O
+reason	O
+it	O
+was	O
+summoned	O
+,	O
+optimal	O
+value	O
+is	O
+the	O
+observance	O
+of	O
+the	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+the	O
+ratio	O
+of	O
+inhale	B-PROC
+/	O
+exhale	O
+(	O
+depending	O
+on	O
+the	O
+degree	O
+of	O
+hypoxemia	O
+),	O
+to	O
+maintain	O
+sufficient	O
+blood	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+and	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+the	O
+blood	B-ANAT
+plasma	I-ANAT
+.	O
+
+As	O
+this	O
+complication	B-DISO
+may	O
+appear	O
+after	O
+a	O
+free	O
+interval	O
+of	O
+24	O
+-	O
+48	O
+h	O
+,	O
+detection	O
+of	O
+patients	O
+at	O
+risk	O
+is	O
+essential	O
+.	O
+
+A	O
+TTS	O
+score	O
+of	O
+13	O
+-	O
+25	O
+was	O
+found	O
+to	O
+be	O
+independent	O
+risk	O
+factors	O
+of	O
+ARDS	B-DISO
+(	O
+OR	O
+25	O
+.	O
+8	O
+[	O
+95	O
+%	O
+CI	O
+6	O
+.	O
+7	O
+-	O
+99	O
+.	O
+6	O
+]	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+clinical	O
+value	O
+of	O
+B	O
+-	O
+type	O
+natriuretic	O
+peptide	B-CHED
+(	O
+BNP	O
+)	O
+in	O
+the	O
+assessment	O
+of	O
+severity	O
+and	O
+prognosis	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+).	O
+
+Plasma	B-ANAT
+BNP	O
+level	O
+,	O
+arterial	B-ANAT
+blood	I-ANAT
+gases	O
+,	O
+serum	B-PRGE
+C	I-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	B-CHED
+level	O
+,	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+difference	O
+and	O
+oxygenation	B-PROC
+index	O
+were	O
+measured	O
+in	O
+patients	O
+with	O
+and	O
+without	O
+ALI	O
+/	O
+ARDS	B-DISO
+within	O
+24	O
+h	O
+of	O
+admission	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+.	O
+
+When	O
+divided	O
+according	O
+to	O
+outcome	O
+,	O
+the	O
+BNP	B-PRGE
+level	O
+in	O
+the	O
+death	B-PROC
+group	O
+(	O
+267	O
+.	O
+07	O
+±	O
+45	O
+.	O
+06	O
+pg	O
+/	O
+ml	O
+)	O
+was	O
+significantly	O
+higher	O
+than	O
+in	O
+the	O
+survival	O
+group	O
+(	O
+128	O
+.	O
+99	O
+±	O
+45	O
+.	O
+42	O
+pg	O
+/	O
+ml	O
+).	O
+
+Ingenuity	O
+Pathway	B-PROC
+Analysis	O
+was	O
+employed	O
+to	O
+investigate	O
+the	O
+canonical	O
+pathways	B-PROC
+and	O
+functional	O
+networks	O
+involved	O
+in	O
+both	O
+PEDV	O
+infections	B-DISO
+.	O
+
+Compounds	O
+1	O
+-	O
+3	O
+,	O
+and	O
+6	O
+were	O
+evaluated	O
+for	O
+their	O
+antiviral	B-CHED
+activity	O
+against	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+Serial	O
+lactate	B-CHED
+monitoring	O
+is	O
+a	O
+useful	O
+tool	O
+to	O
+gauge	O
+global	O
+tissue	B-ANAT
+hypoxia	B-DISO
+in	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+patients	O
+with	O
+sepsis	B-DISO
+.	O
+
+We	O
+hypothesized	O
+that	O
+patients	O
+undergoing	O
+serial	O
+lactate	B-CHED
+monitoring	O
+(	O
+SL	O
+)	O
+would	O
+demonstrate	O
+a	O
+decreased	O
+incidence	O
+of	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+243	O
+patients	O
+were	O
+assigned	O
+to	O
+SL	O
+(	O
+n	O
+=	O
+132	O
+)	O
+or	O
+no	O
+serial	O
+lactate	B-CHED
+monitoring	O
+(	O
+NL	O
+;	O
+n	O
+=	O
+111	O
+).	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+incidence	O
+is	O
+also	O
+influenced	O
+by	O
+ED	O
+-	O
+based	O
+mechanical	O
+ventilation	O
+.	O
+
+In	O
+the	O
+a	O
+priori	O
+subgroup	O
+of	O
+patients	O
+mechanically	O
+ventilated	O
+in	O
+the	O
+ED	O
+(	O
+n	O
+=	O
+97	O
+),	O
+those	O
+who	O
+developed	O
+ARDS	B-DISO
+received	O
+higher	O
+tidal	O
+volumes	O
+compared	O
+to	O
+patients	O
+who	O
+did	O
+not	O
+develop	O
+ARDS	B-DISO
+(	O
+8	O
+.	O
+7	O
+mL	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+[	O
+interquartile	O
+range	O
+,	O
+7	O
+.	O
+6	O
+-	O
+9	O
+.	O
+5	O
+]	O
+vs	O
+7	O
+.	O
+6	O
+[	O
+interquartile	O
+range	O
+,	O
+6	O
+.	O
+8	O
+-	O
+9	O
+.	O
+0	O
+];	O
+P	O
+<.	O
+01	O
+).	O
+
+The	O
+primers	O
+and	O
+probes	O
+for	O
+these	O
+assays	O
+were	O
+evaluated	O
+and	O
+found	O
+to	O
+have	O
+a	O
+limit	O
+of	O
+detection	O
+(	O
+LOD	B-FUNC
+)	O
+of	O
+0	O
+.	O
+005	O
+plaque	B-DISO
+-	O
+forming	O
+units	O
+/	O
+PCR	O
+(	O
+pfu	B-CHED
+/	O
+PCR	O
+).	O
+
+TITLE	O
+:	O
+Host	B-COMP
+-	O
+directed	O
+therapies	O
+for	O
+improving	O
+poor	O
+treatment	O
+outcomes	O
+associated	O
+with	O
+the	O
+middle	O
+east	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+We	O
+discuss	O
+the	O
+rationale	O
+and	O
+potential	O
+of	O
+using	O
+Host	B-COMP
+-	O
+Directed	O
+Therapies	O
+for	O
+improving	O
+the	O
+poor	O
+treatment	O
+outcomes	O
+associated	O
+with	O
+MERS	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+-	O
+ascertained	O
+study	O
+of	O
+household	O
+transmission	O
+of	O
+seasonal	O
+influenza	B-DISO
+-	O
+South	O
+Africa	O
+,	O
+2013	O
+.	O
+
+The	O
+virus	B-SPEC
+has	O
+caused	O
+several	O
+healthcare	O
+-	O
+related	O
+outbreaks	O
+,	O
+so	O
+prompt	O
+recognition	O
+and	O
+patient	O
+isolation	O
+are	O
+critical	O
+to	O
+containing	O
+the	O
+spread	O
+of	O
+infection	B-DISO
+.	O
+
+Further	O
+experiments	O
+show	O
+that	O
+mice	B-SPEC
+deficient	O
+of	O
+p47phox	B-PRGE
+,	O
+a	O
+nicotinamide	B-CHED
+adenine	I-CHED
+dinucleotide	I-CHED
+phosphate	I-CHED
+(	O
+NADPH	B-PRGE
+)	O
+oxidase	B-PRGE
+subunit	O
+that	O
+controls	O
+acute	O
+ROS	B-CHED
+production	O
+,	O
+present	O
+with	O
+reductions	O
+in	O
+NLRP3	B-PRGE
+inflammasome	I-PRGE
+activation	I-PRGE
+and	I-PRGE
+subsequent	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+1β	I-PRGE
+secretion	B-PROC
+during	O
+viral	B-DISO
+infection	I-DISO
+,	O
+which	O
+appears	O
+to	O
+be	O
+responsible	O
+for	O
+acquiring	O
+resilience	O
+to	O
+viral	O
+FH	O
+.	O
+
+Our	O
+results	O
+demonstrate	O
+that	O
+the	O
+ROS	B-PRGE
+/	O
+NLRP3	B-PRGE
+/	O
+IL	O
+-	O
+1β	O
+axis	B-SPEC
+institutes	O
+an	O
+essential	O
+signaling	B-PROC
+pathway	I-PROC
+,	O
+which	O
+is	O
+over	O
+activated	O
+and	O
+directly	O
+causes	O
+the	O
+severe	O
+liver	B-DISO
+disease	I-DISO
+during	O
+viral	B-DISO
+infection	I-DISO
+,	O
+which	O
+sheds	O
+light	O
+on	O
+development	B-PROC
+of	O
+efficient	O
+treatments	O
+for	O
+human	B-SPEC
+viral	O
+FH	O
+and	O
+other	O
+severe	O
+inflammatory	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+interaction	O
+in	O
+which	O
+outbreaks	O
+of	O
+influenza	B-DISO
+and	O
+other	O
+common	O
+respiratory	O
+viruses	B-SPEC
+might	O
+affect	O
+each	O
+other	O
+has	O
+been	O
+postulated	O
+by	O
+several	O
+short	O
+studies	O
+.	O
+
+We	O
+investigated	O
+time	O
+trends	O
+of	O
+and	O
+the	O
+correlation	O
+between	O
+positive	O
+laboratory	O
+diagnoses	O
+of	O
+eight	O
+common	O
+viruses	B-SPEC
+in	O
+the	O
+Netherlands	O
+over	O
+a	O
+10	O
+-	O
+year	O
+time	O
+period	O
+(	O
+2003	O
+-	O
+2012	O
+):	O
+influenza	B-SPEC
+viruses	I-SPEC
+types	O
+A	O
+and	O
+B	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+rhinovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+norovirus	B-SPEC
+,	O
+enterovirus	B-SPEC
+,	O
+and	O
+rotavirus	B-SPEC
+.	O
+
+We	O
+compared	O
+trends	O
+in	O
+viruses	B-SPEC
+between	O
+early	O
+and	O
+late	O
+influenza	B-DISO
+seasons	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+report	O
+the	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+activity	O
+of	O
+GO	O
+against	O
+pseudorabies	B-SPEC
+virus	I-SPEC
+(	O
+PRV	B-DISO
+,	O
+a	O
+DNA	O
+virus	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+,	O
+an	O
+RNA	O
+virus	B-SPEC
+).	O
+
+Furthermore	O
+,	O
+GO	O
+inactivated	O
+both	O
+viruses	B-SPEC
+by	O
+structural	O
+destruction	O
+prior	O
+to	O
+viral	O
+entry	O
+.	O
+
+Our	O
+results	O
+also	O
+have	O
+important	O
+implications	O
+for	O
+development	B-PROC
+of	O
+vaccine	O
+immunogens	O
+based	O
+on	O
+the	O
+newly	O
+identified	O
+m336	O
+epitope	O
+as	O
+well	O
+as	O
+for	O
+elucidation	O
+of	O
+mechanisms	O
+of	O
+neutralization	O
+by	O
+m336	B-PRGE
+-	I-PRGE
+like	I-PRGE
+antibodies	I-PRGE
+and	O
+their	O
+elicitation	O
+in	O
+vivo	O
+.	O
+
+Fortunately	O
+,	O
+the	O
+condition	B-DISO
+of	O
+this	O
+woman	O
+was	O
+stabilized	O
+and	O
+she	O
+achieved	O
+complete	O
+physical	O
+recovery	O
+,	O
+despite	O
+minor	O
+neurological	O
+deficit	O
+in	O
+the	O
+fingers	B-ANAT
+of	O
+her	O
+right	B-ANAT
+hand	I-ANAT
+.	O
+
+In	O
+adenovirus	B-DISO
+infections	I-DISO
+mean	O
+C	O
+-	O
+reactive	O
+protein	B-CHED
+value	O
+was	O
+72	O
+.	O
+4	O
+mg	O
+/	O
+L	O
+and	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+19	O
+.	O
+000	O
+/	O
+µl	O
+,	O
+both	O
+significantly	O
+higher	O
+than	O
+in	O
+other	O
+viruses	B-SPEC
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+nsp3	B-PRGE
+gene	I-PRGE
+sequences	I-PRGE
+from	O
+three	O
+clinical	O
+samples	O
+of	O
+swine	B-SPEC
+with	O
+PEDV	B-SPEC
+infections	B-DISO
+were	O
+aligned	O
+with	O
+other	O
+strains	O
+available	O
+from	O
+GenBank	O
+and	O
+the	O
+results	O
+suggested	O
+that	O
+the	O
+virus	B-SPEC
+responsible	O
+for	O
+the	O
+2014	O
+PEDV	B-SPEC
+outbreak	O
+in	O
+Taiwan	O
+clustered	O
+together	O
+with	O
+Clade	O
+I	O
+from	O
+the	O
+US	O
+within	O
+Genogroup	O
+2	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+ORF7a	O
+Inhibits	O
+Bone	B-ANAT
+Marrow	I-ANAT
+Stromal	O
+Antigen	B-CHED
+2	O
+Virion	B-ANAT
+Tethering	O
+through	O
+a	O
+Novel	O
+Mechanism	O
+of	O
+Glycosylation	B-PROC
+Interference	O
+.	O
+
+Bone	B-PRGE
+marrow	I-PRGE
+stromal	I-PRGE
+antigen	B-CHED
+2	I-PRGE
+(	O
+BST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+;	O
+also	O
+known	O
+as	O
+CD317	B-PRGE
+or	O
+tetherin	O
+)	O
+was	O
+initially	O
+identified	O
+to	O
+be	O
+a	O
+pre	B-ANAT
+-	I-ANAT
+B	I-ANAT
+-	I-ANAT
+cell	B-COMP
+growth	O
+promoter	O
+,	O
+but	O
+it	O
+also	O
+inhibits	O
+the	O
+release	B-PATH
+of	O
+virions	B-COMP
+of	O
+the	O
+retrovirus	B-SPEC
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+)	O
+by	O
+tethering	O
+budding	B-PATH
+virions	B-COMP
+to	O
+the	O
+host	B-COMP
+cell	I-COMP
+membrane	I-COMP
+.	O
+
+Further	O
+work	O
+has	O
+shown	O
+that	O
+BST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+restricts	O
+the	O
+release	B-PATH
+of	O
+many	O
+other	O
+viruses	B-SPEC
+,	O
+including	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+hCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+),	O
+and	O
+the	O
+genomes	O
+of	O
+many	O
+of	O
+these	O
+viruses	B-SPEC
+encode	O
+BST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+antagonists	B-CHED
+to	O
+overcome	O
+BST	O
+-	O
+2	O
+restriction	O
+.	O
+
+We	O
+further	O
+characterized	O
+the	O
+mechanism	O
+of	O
+BST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+inhibition	B-PROC
+by	O
+ORF7a	O
+and	O
+found	O
+that	O
+ORF7a	O
+localization	B-PROC
+changes	O
+when	O
+BST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+is	O
+overexpressed	O
+and	O
+ORF7a	O
+binds	B-FUNC
+directly	O
+to	O
+BST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+previously	O
+showed	O
+that	O
+close	O
+relatives	O
+of	O
+human	O
+coronavirus	O
+229E	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+exist	O
+in	O
+African	O
+bats	B-SPEC
+.	O
+
+To	O
+compare	O
+the	O
+genetic	O
+diversity	O
+of	O
+bat	B-ENZY
+viruses	B-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+we	O
+tested	O
+historical	O
+isolates	O
+and	O
+diagnostic	O
+specimens	O
+sampled	O
+globally	O
+over	O
+10	O
+years	O
+.	O
+
+A	O
+recently	O
+described	O
+229E	O
+-	O
+related	O
+alpaca	B-SPEC
+virus	B-SPEC
+occupied	O
+an	O
+intermediate	O
+phylogenetic	O
+position	O
+between	O
+bat	O
+and	O
+human	B-SPEC
+viruses	B-SPEC
+.	O
+
+According	O
+to	O
+taxonomic	O
+criteria	O
+,	O
+human	B-SPEC
+,	O
+alpaca	B-SPEC
+,	O
+and	O
+bat	B-ENZY
+viruses	B-SPEC
+form	O
+a	O
+single	O
+CoV	O
+species	B-SPEC
+showing	O
+evidence	O
+for	O
+multiple	O
+recombination	B-PROC
+events	O
+.	O
+
+ORF8	O
+also	O
+existed	O
+in	O
+the	O
+229E	O
+-	O
+related	O
+alpaca	B-SPEC
+virus	B-SPEC
+.	O
+
+Reanalysis	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+sequences	O
+showed	O
+a	O
+conserved	O
+transcription	B-PROC
+regulatory	O
+sequence	O
+preceding	O
+remnants	O
+of	O
+this	O
+ORF	O
+,	O
+suggesting	O
+its	O
+loss	O
+after	O
+acquisition	O
+of	O
+a	O
+229E	O
+-	O
+related	O
+CoV	O
+by	O
+humans	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+provide	O
+conclusive	O
+genetic	O
+evidence	O
+for	O
+an	O
+evolutionary	O
+origin	O
+of	O
+the	O
+common	B-DISO
+cold	I-DISO
+virus	B-SPEC
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+in	O
+hipposiderid	O
+bats	B-SPEC
+by	O
+analyzing	O
+a	O
+large	O
+sample	O
+of	O
+African	O
+bats	B-SPEC
+and	O
+characterizing	O
+several	O
+bat	B-ENZY
+viruses	B-SPEC
+on	O
+a	O
+full	O
+-	O
+genome	O
+level	O
+.	O
+
+Maternal	O
+antibodies	B-COMP
+began	O
+to	O
+decrease	O
+in	O
+the	O
+2nd	O
+month	O
+for	O
+BRSV	B-SPEC
+,	O
+BHV	O
+-	O
+1	O
+and	O
+BAV	B-DISO
+-	O
+3	O
+(	O
+97	O
+.	O
+8	O
+%,	O
+25	O
+.	O
+5	O
+%	O
+and	O
+91	O
+.	O
+4	O
+%)	O
+and	O
+in	O
+the	O
+3rd	O
+month	O
+for	O
+PI	O
+-	O
+3	O
+,	O
+BVDV	B-SPEC
+and	O
+BCoV	O
+(	O
+85	O
+.	O
+1	O
+%,	O
+67	O
+%	O
+and	O
+93	O
+.	O
+6	O
+%).	O
+
+TITLE	O
+:	O
+Right	O
+over	O
+left	O
+ventricular	B-ANAT
+end	O
+-	O
+diastolic	O
+area	O
+relevance	O
+to	O
+predict	O
+hemodynamic	B-PROC
+intolerance	B-PROC
+of	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	O
+.	O
+
+Although	O
+HFOV	O
+did	O
+not	O
+significantly	O
+decrease	O
+the	O
+arterial	B-PROC
+pressure	I-PROC
+(	O
+systolic	O
+,	O
+diastolic	O
+,	O
+mean	O
+and	O
+pulse	B-PROC
+pressure	I-PROC
+),	O
+it	O
+significantly	O
+decreased	O
+the	O
+cardiac	B-ANAT
+index	O
+(	O
+CI	O
+)	O
+by	O
+13	O
+±	O
+18	O
+%	O
+and	O
+significantly	O
+increased	O
+the	O
+RVEDA	O
+/	O
+LVEDA	O
+ratio	O
+by	O
+14	O
+±	O
+11	O
+%.	O
+
+A	O
+high	O
+ratio	O
+under	O
+CMV	B-SPEC
+raises	O
+questions	O
+about	O
+the	O
+use	O
+of	O
+HFOV	O
+in	O
+such	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Dynamics	O
+of	O
+end	O
+expiratory	B-PROC
+lung	B-PROC
+volume	I-PROC
+after	O
+changing	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Lung	B-ANAT
+recruitment	B-DISO
+maneuvers	O
+followed	O
+by	O
+an	O
+individually	O
+titrated	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+are	O
+the	O
+key	O
+components	O
+of	O
+the	O
+open	O
+lung	B-ANAT
+ventilation	O
+strategy	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+staircase	O
+recruitment	B-DISO
+maneuver	O
+is	O
+a	O
+step	O
+-	O
+by	O
+-	O
+step	O
+increase	O
+in	O
+PEEP	B-CHED
+followed	O
+by	O
+a	O
+decremental	O
+PEEP	B-CHED
+trial	O
+.	O
+
+PEEP	B-CHED
+was	O
+progressively	O
+increased	O
+from	O
+5	O
+to	O
+40	O
+cmH2O	O
+and	O
+then	O
+decreased	O
+from	O
+40	O
+to	O
+5	O
+cmH2O	O
+in	O
+steps	O
+of	O
+5	O
+cmH2O	O
+every	O
+2	O
+.	O
+5	O
+minutes	O
+.	O
+
+Data	O
+are	O
+expressed	B-PROC
+as	O
+median	O
+[	O
+25th	O
+-	O
+75th	O
+quartiles	O
+].	O
+
+The	O
+pressure	O
+catecholamine	B-CHED
+index	O
+[	O
+CAIP	O
+=	O
+catecholamine	B-CHED
+index	O
+/	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+;	O
+catecholamine	B-CHED
+index	O
+=	O
+dopamine	B-CHED
++	O
+dobutamine	B-CHED
++	O
+(	O
+adrenaline	B-CHED
++	O
+noradrenaline	B-CHED
+)	O
+×	O
+100	O
+μg	O
+/	O
+kg	O
+per	O
+min	O
+],	O
+as	O
+an	O
+indicator	B-SPEC
+of	O
+hemodynamics	B-PROC
+,	O
+improved	O
+significantly	O
+in	O
+the	O
+survival	O
+group	O
+in	O
+the	O
+period	O
+between	O
+the	O
+start	O
+and	O
+24	O
+h	O
+after	O
+the	O
+end	O
+of	O
+PMX	B-PRGE
+-	I-PRGE
+DHP	I-PRGE
+therapy	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+and	O
+between	O
+2	O
+h	O
+after	O
+the	O
+start	O
+of	O
+and	O
+the	O
+end	O
+of	O
+this	O
+therapy	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Flow	O
+cytometry	O
+was	O
+used	O
+to	O
+determine	O
+mode	O
+of	O
+cell	B-PROC
+death	I-PROC
+in	O
+first	O
+42	O
+h	O
+post	O
+infection	B-DISO
+(	O
+hpi	B-DISO
+).	O
+
+Then	O
+,	O
+next	O
+generation	O
+sequencing	O
+was	O
+performed	O
+on	O
+9	O
+hpi	B-DISO
+and	O
+control	O
+uninfected	O
+cells	B-COMP
+by	O
+Illumina	O
+analyzer	O
+.	O
+
+131	O
+genes	O
+from	O
+apoptosis	B-PATH
+cluster	O
+(	O
+80	O
+down	O
+-	O
+regulated	O
+and	O
+51	O
+up	O
+-	O
+regulated	O
+)	O
+along	O
+with	O
+increase	O
+of	O
+apoptosis	O
+,	O
+p53	B-PRGE
+,	O
+p38	B-FUNC
+MAPK	B-FUNC
+,	O
+VEGF	B-PRGE
+and	O
+chemokines	O
+/	O
+cytokines	O
+signaling	B-PROC
+pathways	B-PROC
+were	O
+probably	O
+involved	O
+in	O
+apoptosis	B-PATH
+process	O
+.	O
+
+Up	O
+-	O
+regulations	O
+of	O
+both	O
+pro	B-CHED
+-	O
+apoptotic	O
+(	O
+i	O
+.	O
+e	O
+.	O
+PDCD5	O
+)	O
+and	O
+anti	O
+-	O
+apoptotic	O
+(	O
+i	O
+.	O
+e	O
+.	O
+TRAF2	B-PRGE
+)	O
+were	O
+detected	O
+from	O
+first	O
+hpi	B-DISO
+and	O
+continuing	O
+to	O
+deregulate	O
+during	O
+apoptosis	B-PATH
+process	O
+in	O
+the	O
+infected	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Heiner	O
+syndrome	B-DISO
+is	O
+a	O
+food	O
+-	O
+induced	O
+pulmonary	O
+hypersensitivity	B-DISO
+disease	O
+that	O
+predominantly	O
+affects	O
+infants	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+signs	O
+of	O
+leukostases	B-DISO
+were	O
+detected	O
+in	O
+more	O
+than	O
+half	O
+of	O
+the	O
+18	O
+patients	O
+with	O
+higher	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+counts	O
+:	O
+13	O
+(	O
+72	O
+%)	O
+with	O
+lung	B-ANAT
+injury	O
+,	O
+including	O
+5	O
+of	O
+them	O
+with	O
+signs	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+6	O
+(	O
+27	O
+.	O
+8	O
+%)	O
+with	O
+neurological	O
+symptomatology	O
+,	O
+7	O
+(	O
+38	O
+.	O
+9	O
+%)	O
+with	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+syndrome	B-DISO
+,	O
+including	O
+1	O
+with	O
+intracranial	B-DISO
+hemorrhage	I-DISO
+.	O
+
+50	O
+%	O
+(	O
+9	O
+/	O
+18	O
+)	O
+achieved	O
+remission	B-DISO
+after	O
+the	O
+first	O
+7	O
++	O
+3	O
+cycle	O
+and	O
+7	O
+more	O
+examinees	O
+did	O
+after	O
+the	O
+second	O
+cycle	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Adequate	O
+cytoreductive	O
+and	O
+accompanying	O
+therapies	O
+for	O
+AML	B-DISO
+with	O
+HL	O
+can	O
+virtually	O
+completely	O
+prevent	O
+massive	O
+tumor	B-DISO
+cytolysis	B-PROC
+syndrome	B-DISO
+and	O
+early	O
+mortality	O
+during	O
+the	O
+first	O
+days	O
+of	O
+induction	O
+chemotherapy	O
+.	O
+
+The	O
+structure	O
+showed	O
+that	O
+4C2	O
+recognizes	O
+an	O
+epitope	B-CHED
+that	O
+partially	O
+overlaps	O
+the	O
+receptor	O
+-	O
+binding	O
+footprint	O
+in	O
+MERS	O
+-	O
+RBD	O
+,	O
+thereby	O
+interfering	O
+with	O
+the	O
+virus	B-SPEC
+/	O
+receptor	B-PROC
+interactions	I-PROC
+by	O
+both	O
+steric	O
+hindrance	O
+and	O
+interface	O
+-	O
+residue	O
+competition	O
+.	O
+
+The	O
+humanized	O
+4C2	O
+(	O
+4C2h	O
+)	O
+antibody	B-COMP
+sustained	O
+similar	O
+neutralizing	O
+activity	O
+and	O
+biochemical	O
+characteristics	O
+to	O
+the	O
+parental	O
+mouse	B-SPEC
+antibody	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Equine	O
+coronavirus	B-SPEC
+(	O
+ECoV	O
+)	O
+is	O
+considered	O
+to	O
+be	O
+a	O
+diarrheic	O
+pathogen	O
+in	O
+foals	O
+.	O
+
+The	O
+majority	O
+of	O
+respondents	O
+had	O
+satisfactory	O
+hand	O
+hygiene	O
+practices	O
+and	O
+avoided	O
+touching	O
+avian	B-SPEC
+species	B-SPEC
+but	O
+did	O
+not	O
+employ	O
+other	O
+preventive	O
+measures	O
+.	O
+
+Self	O
+-	O
+reported	O
+face	B-DISO
+masks	O
+wearing	O
+when	O
+having	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+in	O
+general	O
+population	O
+dropped	O
+from	O
+92	O
+.	O
+4	O
+%	O
+during	O
+H5N1	B-DISO
+period	O
+in	O
+2007	O
+to	O
+39	O
+.	O
+0	O
+%	O
+in	O
+this	O
+study	O
+.	O
+
+Educational	O
+campaigns	O
+and	O
+framing	O
+the	O
+issue	O
+to	O
+increase	O
+public	O
+and	O
+media	B-ANAT
+awareness	O
+are	O
+crucial	O
+in	O
+preventing	O
+the	O
+current	O
+public	O
+fatigue	B-DISO
+towards	O
+outbreaks	O
+.	O
+
+In	O
+the	O
+present	O
+work	O
+,	O
+we	O
+describe	O
+the	O
+resistance	B-PROC
+of	O
+IBV	B-SPEC
+to	O
+IFN	B-PRGE
+and	O
+the	O
+potential	O
+role	O
+of	O
+accessory	O
+proteins	B-CHED
+herein	O
+.	O
+
+We	O
+show	O
+that	O
+IBV	B-SPEC
+is	O
+fairly	O
+resistant	O
+to	O
+the	O
+antiviral	B-CHED
+state	O
+induced	O
+by	O
+IFN	B-PRGE
+and	O
+identify	O
+that	O
+viral	B-PRGE
+accessory	I-PRGE
+protein	I-PRGE
+3a	I-PRGE
+is	O
+involved	O
+in	O
+resistance	B-PROC
+to	O
+IFN	B-PRGE
+,	O
+as	O
+its	O
+absence	O
+renders	O
+IBV	B-SPEC
+less	O
+resistant	O
+to	O
+IFN	B-PRGE
+treatment	O
+.	O
+
+This	O
+study	O
+demonstrates	O
+that	O
+the	O
+gammacoronavirus	B-SPEC
+IBV	B-SPEC
+,	O
+similar	O
+to	O
+its	O
+mammalian	B-SPEC
+counterparts	O
+,	O
+has	O
+evolved	O
+multiple	O
+strategies	O
+to	O
+efficiently	O
+counteract	O
+the	O
+IFN	B-PRGE
+response	O
+of	O
+its	O
+avian	B-SPEC
+host	B-COMP
+,	O
+and	O
+it	O
+identifies	O
+accessory	B-PRGE
+protein	I-PRGE
+3a	I-PRGE
+as	O
+multifaceted	O
+antagonist	B-PROC
+of	O
+the	O
+avian	B-PRGE
+IFN	I-PRGE
+system	O
+.	O
+
+Stochastic	O
+simulations	O
+of	O
+dynamics	O
+on	O
+networks	O
+are	O
+performed	O
+and	O
+compared	O
+to	O
+output	O
+of	O
+pairwise	O
+models	O
+for	O
+several	O
+realistic	O
+examples	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+to	O
+illustrate	O
+the	O
+role	O
+played	O
+by	O
+the	O
+number	O
+of	O
+stages	O
+in	O
+the	O
+disease	O
+dynamics	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+originated	O
+in	O
+bats	B-SPEC
+and	O
+spread	O
+to	O
+humans	B-SPEC
+via	O
+zoonotic	O
+transmission	O
+from	O
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+SPR	O
+biosensor	O
+for	O
+simultaneous	O
+detection	O
+of	O
+multiplex	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+pathogens	O
+with	O
+the	O
+4	O
+highest	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+rates	O
+(	O
+CIRs	O
+)	O
+were	O
+as	O
+follows	O
+:	O
+HCoV	O
+>	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBoV	O
+)	O
+>	O
+enterovirus	B-SPEC
+(	O
+EV	O
+)	O
+>	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+).	O
+
+The	O
+disease	O
+is	O
+transmitted	B-DISO
+through	O
+contact	O
+with	O
+someone	O
+who	O
+has	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+occupational	O
+health	O
+nurse	O
+must	O
+be	O
+cognizant	O
+of	O
+and	O
+educate	O
+the	O
+workforce	O
+about	O
+MERS	O
+-	O
+CoV	O
+transmission	O
+,	O
+prevention	O
+,	O
+and	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+avian	B-DISO
+influenza	I-DISO
+negative	O
+birds	O
+from	O
+live	O
+bird	B-SPEC
+markets	O
+and	O
+backyard	O
+and	O
+commercial	O
+farms	O
+in	O
+Ivory	O
+-	O
+Coast	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreaks	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+previously	O
+in	O
+Middle	O
+East	O
+and	O
+recently	O
+in	O
+South	O
+Korea	O
+have	O
+raised	O
+serious	O
+concerns	O
+worldwide	O
+,	O
+reinforcing	O
+the	O
+importance	O
+of	O
+developing	O
+effective	O
+and	O
+safe	O
+vaccines	O
+against	O
+MERS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+).	O
+
+We	O
+have	O
+devised	O
+a	O
+novel	O
+statistical	O
+model	O
+that	O
+identifies	O
+the	O
+risk	O
+of	O
+MERS	O
+death	B-PROC
+during	O
+the	O
+outbreak	O
+in	O
+real	O
+time	O
+.	O
+
+ABSTRACT	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+(	O
+GBS	O
+)	O
+is	O
+a	O
+fulminant	O
+polyradiculoneuropathy	B-DISO
+that	O
+is	O
+acute	O
+,	O
+frequently	O
+severe	O
+and	O
+autoimmune	B-DISO
+in	O
+nature	O
+.	O
+
+Most	O
+patients	O
+in	O
+plasma	B-ANAT
+exchange	O
+group	O
+belonged	O
+to	O
+the	O
+lower	O
+socio	O
+-	O
+economic	O
+status	O
+.	O
+
+Conduction	B-PROC
+block	O
+determined	O
+indirectly	O
+by	O
+absent	O
+H	B-PROC
+-	I-PROC
+reflex	I-PROC
+was	O
+noted	O
+in	O
+891	O
+(	O
+90	O
+.	O
+64	O
+%)	O
+patients	O
+.	O
+
+This	O
+sensitive	O
+and	O
+specific	O
+antigen	B-CHED
+capture	O
+ELISA	O
+should	O
+be	O
+useful	O
+for	O
+detection	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+human	B-SPEC
+and	O
+dromedaries	B-SPEC
+and	O
+in	O
+field	O
+studies	O
+.	O
+
+Optimal	O
+strategies	O
+for	O
+mechanical	O
+ventilation	O
+also	O
+differ	O
+between	O
+these	O
+two	O
+conditions	O
+;	O
+while	O
+myasthenic	B-DISO
+crisis	I-DISO
+is	O
+ideally	O
+managed	O
+with	O
+noninvasive	O
+bilevel	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+BiPAP	O
+)	O
+ventilation	O
+,	O
+GBS	B-DISO
+demands	O
+early	O
+intubation	O
+.	O
+
+Prompt	O
+recognition	O
+of	O
+neuromuscular	O
+respiratory	B-DISO
+failure	I-DISO
+can	O
+be	O
+lifesaving	O
+,	O
+and	O
+identification	O
+of	O
+its	O
+cause	O
+has	O
+substantial	O
+prognostic	O
+implications	O
+.	O
+
+We	O
+downloaded	O
+proteome	O
+data	O
+(	O
+BTO	O
+:	O
+0000762	O
+)	O
+from	O
+the	O
+Proteomics	O
+Identifications	O
+database	O
+and	O
+identified	O
+the	O
+DEPs	O
+in	O
+the	O
+IAV	O
+-	O
+infected	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+.	O
+
+STAT1	B-PRGE
+,	O
+NS2	B-DISO
+,	O
+CD5	B-PRGE
+,	O
+NCKX6	B-PRGE
+and	O
+PDGFB	B-PRGE
+were	O
+significant	O
+DEPs	O
+in	O
+these	O
+GO	O
+terms	O
+.	O
+
+TITLE	O
+:	O
+Conservation	O
+of	O
+nucleotide	B-CHED
+sequences	O
+for	O
+molecular	O
+diagnosis	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+2015	O
+.	O
+
+The	O
+immunogenicity	O
+of	O
+the	O
+H7	O
+VLP	B-COMP
+vaccine	O
+was	O
+assessed	O
+in	O
+mice	B-SPEC
+and	O
+ferrets	B-SPEC
+after	O
+one	O
+or	O
+two	O
+intramuscular	O
+dose	O
+(	O
+s	O
+)	O
+with	O
+and	O
+without	O
+adjuvant	B-CHED
+(	O
+alum	O
+or	O
+GLA	B-PRGE
+-	I-PRGE
+SE	I-PRGE
+™).	I-PRGE
+
+In	O
+ferrets	B-SPEC
+,	O
+we	O
+also	O
+measured	O
+H7	O
+-	O
+specific	O
+cell	B-PROC
+-	I-PROC
+mediated	I-PROC
+immunity	I-PROC
+.	O
+
+Compared	O
+to	O
+animals	B-SPEC
+injected	O
+with	O
+placebo	O
+,	O
+ferrets	B-SPEC
+vaccinated	O
+with	O
+alum	O
+-	O
+adjuvanted	O
+vaccine	O
+displayed	O
+no	O
+weight	O
+loss	O
+during	O
+the	O
+challenge	O
+.	O
+
+Moreover	O
+,	O
+the	O
+vaccination	O
+significantly	O
+reduced	O
+the	O
+viral	O
+load	O
+in	O
+lungs	B-ANAT
+and	O
+nasal	B-ANAT
+washes	O
+3	O
+days	O
+after	O
+the	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+ORF8	O
+-	O
+Related	O
+Genetic	O
+Evidence	O
+for	O
+Chinese	O
+Horseshoe	B-SPEC
+Bats	I-SPEC
+as	O
+the	O
+Source	O
+of	O
+Human	B-SPEC
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+.	O
+
+These	O
+viruses	B-SPEC
+are	O
+characterized	O
+by	O
+a	O
+set	O
+of	O
+unique	O
+accessory	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+that	O
+are	O
+located	O
+between	O
+the	O
+M	O
+and	O
+N	O
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+is	O
+an	O
+enteric	O
+coronaviral	O
+infection	B-DISO
+that	O
+causes	O
+severe	O
+morbidity	O
+and	O
+mortality	O
+in	O
+suckling	O
+pigs	B-SPEC
+,	O
+but	O
+less	O
+severe	O
+disease	O
+in	O
+older	O
+pigs	B-SPEC
+.	O
+
+Weaned	B-PROC
+26	O
+-	O
+day	O
+-	O
+old	O
+pigs	B-SPEC
+(	O
+n	O
+=	O
+20	O
+)	O
+and	O
+9	O
+-	O
+day	O
+-	O
+old	O
+nursing	B-PROC
+pigs	B-SPEC
+(	O
+n	O
+=	O
+20	O
+)	O
+were	O
+assigned	O
+to	O
+PEDV	B-SPEC
+inoculated	O
+or	O
+uninoculated	O
+control	O
+groups	O
+.	O
+
+The	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cell	O
+frequencies	O
+,	O
+NK	B-ANAT
+cell	I-ANAT
+activities	O
+(	O
+lysis	B-DISO
+of	O
+target	O
+K562	B-ANAT
+tumor	B-ANAT
+cells	B-COMP
+in	O
+vitro	O
+),	O
+CD3	B-PRGE
++	I-PRGE
+CD4	I-PRGE
++	I-PRGE
+T	I-PRGE
+cell	I-PRGE
+and	O
+CD3	B-PRGE
++	I-PRGE
+CD8	I-PRGE
++	I-PRGE
+T	B-ANAT
+cell	I-ANAT
+frequencies	O
+were	O
+measured	O
+in	O
+blood	B-ANAT
+and	O
+ileum	B-ANAT
+at	O
+PIDs	O
+1	O
+and	O
+5	O
+.	O
+
+This	O
+study	O
+provides	O
+novel	O
+findings	O
+in	O
+the	O
+function	O
+of	O
+M	O
+proteins	B-CHED
+of	O
+PEDV	B-SPEC
+.	O
+
+We	O
+examined	O
+the	O
+effect	O
+of	O
+FTY720	B-CHED
+treatment	O
+on	O
+the	O
+biology	O
+of	O
+mouse	B-SPEC
+neural	O
+progenitor	B-ANAT
+cells	I-ANAT
+(	O
+NPCs	O
+)	O
+after	O
+transplantation	O
+in	O
+a	O
+viral	O
+model	O
+of	O
+demyelination	B-DISO
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+molecular	O
+characterization	O
+of	O
+nephropathic	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolates	O
+of	O
+Gujarat	O
+state	O
+,	O
+India	O
+.	O
+
+Five	O
+pooled	O
+tissue	B-ANAT
+suspensions	O
+of	O
+50	O
+layer	B-ANAT
+birds	B-SPEC
+and	O
+one	O
+reference	O
+Massachusetts	O
+vaccine	O
+strain	O
+were	O
+inoculated	O
+into	O
+specific	O
+pathogen	O
+free	O
+(	O
+SPF	O
+)	O
+chicken	B-SPEC
+egg	B-ANAT
+for	O
+isolation	O
+of	O
+IBV	B-SPEC
+.	O
+
+First	O
+,	O
+the	O
+six	O
+exons	O
+encoding	O
+the	O
+ST3GAL1	B-PRGE
+gene	I-PRGE
+were	O
+sequenced	O
+in	O
+68	O
+patients	O
+infected	O
+with	O
+strain	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+.	O
+
+In	O
+a	O
+second	O
+phase	O
+of	O
+the	O
+study	O
+,	O
+the	O
+rs113350588	O
+and	O
+rs1048479	O
+polymorphisms	B-PROC
+identified	O
+in	O
+this	O
+sample	O
+were	O
+genotyped	O
+in	O
+a	O
+sample	O
+of	O
+356	O
+subjects	O
+from	O
+the	O
+northern	O
+and	O
+northeastern	O
+regions	O
+of	O
+Brazil	O
+with	O
+a	O
+diagnosis	O
+of	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2012	O
+,	O
+a	O
+nephrologist	O
+reported	O
+the	O
+development	B-PROC
+of	O
+a	O
+multiorgan	O
+thrombotic	O
+syndromic	O
+complex	O
+resembling	O
+thrombotic	B-DISO
+thrombocytopenic	I-DISO
+purpura	I-DISO
+(	O
+TTP	B-DISO
+)	O
+in	O
+patients	O
+who	O
+were	O
+abusing	O
+long	O
+acting	O
+oxymorphone	O
+hydrochloride	B-CHED
+;	O
+all	O
+patients	O
+had	O
+hemolytic	B-DISO
+anemia	I-DISO
+and	O
+thrombocytopenia	O
+.	O
+
+Herein	O
+,	O
+we	O
+report	O
+another	O
+case	O
+involving	O
+a	O
+31	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+who	O
+self	O
+intravenously	O
+administered	O
+dissolved	O
+oral	B-ANAT
+oxymorphone	O
+resulting	O
+in	O
+thrombotic	O
+sequelae	O
+resembling	O
+Degos	B-DISO
+disease	I-DISO
+.	O
+
+Formalin	B-CHED
+-	O
+fixed	B-ANAT
+and	O
+paraffin	O
+embedded	O
+skin	B-ANAT
+biopsies	O
+were	O
+prepared	O
+according	O
+to	O
+standard	O
+protocols	O
+for	O
+H	O
+&	O
+E	O
+and	O
+immunohistochemistry	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+was	O
+identified	O
+in	O
+the	O
+United	O
+States	O
+(	O
+U	O
+.	O
+S	O
+.)	O
+swine	B-SPEC
+population	O
+for	O
+the	O
+first	O
+time	O
+in	O
+April	O
+2013	O
+and	O
+rapidly	O
+spread	O
+nationwide	O
+.	O
+
+This	O
+information	O
+should	O
+be	O
+taken	O
+into	O
+consideration	O
+when	O
+interpreting	O
+clinical	O
+relevance	O
+of	O
+PEDV	B-SPEC
+PCR	O
+results	O
+and	O
+when	O
+designing	O
+a	O
+PEDV	B-SPEC
+bioassay	O
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lower	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+(	O
+ALRI	B-DISO
+)	O
+remains	O
+a	O
+major	O
+cause	O
+of	O
+childhood	O
+hospitalization	O
+and	O
+mortality	O
+in	O
+young	O
+children	O
+and	O
+the	O
+causal	O
+attribution	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+the	O
+aetiology	O
+of	O
+ALRI	B-DISO
+is	O
+unclear	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+and	O
+Demonstration	O
+of	O
+the	O
+Value	O
+of	O
+a	O
+Lethal	O
+Mouse	B-SPEC
+Model	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-DISO
+Infection	I-DISO
+and	O
+Disease	O
+.	O
+
+Among	O
+HIV	O
++	O
+participants	O
+,	O
+greater	O
+WMH	O
+and	O
+lower	O
+anterior	O
+corona	B-ANAT
+radiata	I-ANAT
+FA	O
+were	O
+associated	O
+with	O
+active	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	B-DISO
+infection	I-DISO
+,	O
+a	O
+history	O
+of	O
+AIDS	O
+,	O
+and	O
+higher	O
+current	O
+CD4	B-ANAT
+cell	B-COMP
+count	O
+.	O
+
+We	O
+experienced	O
+a	O
+patient	O
+with	O
+acute	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+during	O
+high	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+for	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Prone	O
+positioning	O
+was	O
+beneficial	O
+for	O
+unloading	O
+the	O
+right	B-ANAT
+ventricle	I-ANAT
+for	O
+treatment	O
+of	O
+acute	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+.	O
+
+Cold	B-DISO
+medicine	B-CHED
+-	O
+related	O
+SJS	B-DISO
+/	O
+TEN	B-PRGE
+(	O
+CM	B-PRGE
+-	I-PRGE
+SJS	I-PRGE
+/	I-PRGE
+TEN	I-PRGE
+)	O
+with	O
+SOCs	O
+is	O
+associated	O
+with	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+02	I-PRGE
+:	O
+06	O
+in	O
+Japanese	O
+and	O
+Koreans	O
+and	O
+HLA	B-PRGE
+-	I-PRGE
+B	I-PRGE
+*	I-PRGE
+44	I-PRGE
+:	O
+03	O
+in	O
+Japanese	O
+,	O
+Indians	O
+,	O
+and	O
+Brazilian	O
+whites	B-SPEC
+.	O
+
+Cold	B-DISO
+medicines	O
+and	O
+infectious	B-DISO
+agents	O
+such	O
+as	O
+viruses	B-SPEC
+or	O
+other	O
+microbes	O
+are	O
+both	O
+important	O
+in	O
+triggering	O
+the	O
+onset	O
+of	O
+SJS	B-DISO
+/	O
+TEN	B-PRGE
+with	O
+SOCs	O
+.	O
+
+The	O
+study	O
+represents	O
+a	O
+comprehensive	O
+analysis	O
+of	O
+IBV	B-PRGE
+S	I-PRGE
+gene	I-PRGE
+codon	O
+usage	O
+patterns	O
+and	O
+provides	O
+a	O
+basic	O
+understanding	O
+of	O
+the	O
+codon	O
+usage	O
+bias	B-SPEC
+.	O
+
+Using	O
+genetically	O
+diverse	O
+animals	B-SPEC
+from	O
+incipient	O
+lines	O
+of	O
+the	O
+Collaborative	O
+Cross	O
+mouse	B-SPEC
+panel	O
+,	O
+we	O
+demonstrate	O
+a	O
+greatly	O
+expanded	O
+range	O
+of	O
+phenotypes	O
+relative	O
+to	O
+classical	O
+mouse	B-SPEC
+models	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+including	O
+lung	B-ANAT
+pathology	B-DISO
+,	O
+weight	O
+loss	O
+and	O
+viral	O
+titer	O
+.	O
+
+The	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+was	O
+evaluated	O
+over	O
+these	O
+3	O
+days	O
+and	O
+differences	O
+between	O
+the	O
+susceptible	O
+and	O
+resistant	O
+lines	O
+examined	O
+.	O
+
+Potential	O
+candidate	O
+genes	O
+for	O
+resistance	B-PROC
+to	O
+IBV	B-SPEC
+are	O
+highlighted	O
+.	O
+
+The	O
+nucleotide	B-CHED
+sequences	O
+were	O
+compared	O
+by	O
+phylogenetic	O
+analysis	O
+.	O
+
+The	O
+HAdV	O
+infections	B-DISO
+circulated	O
+year	O
+-	O
+round	O
+.	O
+
+HAdV	O
+B7	O
+is	O
+strongly	O
+related	O
+to	O
+severe	O
+infections	B-DISO
+and	O
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Pseudallescheria	B-SPEC
+boydii	I-SPEC
+is	O
+a	O
+fungal	O
+organism	O
+known	O
+to	O
+affect	O
+immunocompromised	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+The	O
+use	O
+of	O
+convalescent	O
+plasma	B-ANAT
+to	O
+treat	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+:	O
+focus	O
+on	O
+Ebola	B-SPEC
+virus	I-SPEC
+disease	I-DISO
+.	O
+
+Even	O
+more	O
+recently	O
+,	O
+convalescent	O
+plasma	B-ANAT
+has	O
+been	O
+used	O
+for	O
+treatment	O
+of	O
+individuals	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+Although	O
+the	O
+first	O
+reports	O
+of	O
+successful	O
+treatment	O
+with	O
+passive	O
+immune	O
+therapy	O
+date	O
+back	B-ANAT
+to	O
+the	O
+early	O
+1900s	O
+,	O
+convalescent	O
+plasma	B-ANAT
+has	O
+materialized	O
+as	O
+a	O
+possible	O
+therapy	O
+for	O
+patients	O
+who	O
+develop	O
+infection	B-DISO
+from	O
+one	O
+of	O
+the	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+such	O
+as	O
+EVD	O
+or	O
+MERS	O
+-	O
+CoV	O
+,	O
+although	O
+the	O
+efficacy	O
+of	O
+such	O
+therapy	O
+has	O
+yet	O
+to	O
+be	O
+proven	O
+in	O
+clinical	O
+trials	O
+.	O
+
+We	O
+searched	O
+the	O
+Scopus	B-SPEC
+database	O
+for	O
+all	O
+literature	O
+on	O
+economic	O
+evaluation	O
+of	O
+mask	O
+or	O
+respirator	O
+use	O
+to	O
+control	O
+respiratory	O
+infection	B-DISO
+transmission	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assemble	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)-	O
+like	O
+particles	O
+bearing	O
+the	O
+recombinant	O
+spike	O
+protein	B-CHED
+and	O
+investigate	O
+the	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+chickens	B-SPEC
+.	O
+
+The	O
+results	O
+demonstrated	O
+that	O
+the	O
+efficiency	O
+of	O
+the	O
+newly	O
+generated	O
+VLPs	B-ANAT
+was	O
+comparable	O
+to	O
+that	O
+of	O
+the	O
+inactivated	O
+M41	O
+viruses	B-SPEC
+in	O
+eliciting	O
+IBV	B-SPEC
+-	O
+specific	O
+antibodies	B-COMP
+and	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+chickens	B-SPEC
+via	O
+subcutaneous	O
+inoculation	O
+.	O
+
+Studies	O
+were	O
+included	O
+if	O
+they	O
+examined	O
+both	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+prone	O
+positioning	O
+simultaneously	O
+for	O
+the	O
+treatment	O
+of	O
+respiratory	O
+failure	O
+in	O
+the	O
+adult	O
+population	O
+.	O
+
+Bleeding	B-DISO
+from	O
+the	O
+chest	B-ANAT
+tube	O
+site	O
+was	O
+reported	O
+in	O
+13	O
+.	O
+5	O
+%	O
+of	O
+prone	O
+positioning	O
+maneuvers	O
+in	O
+1	O
+study	O
+,	O
+and	O
+the	O
+rest	B-FUNC
+of	O
+the	O
+studies	O
+reported	O
+no	O
+evidence	O
+of	O
+chest	B-ANAT
+tube	O
+site	O
+bleeding	B-DISO
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+isolated	O
+from	O
+broiler	O
+chicken	B-SPEC
+farms	O
+in	O
+Iran	O
+,	O
+2014	O
+-	O
+2015	O
+.	O
+
+Three	O
+SYBR	O
+Green	O
+multiplex	O
+real	O
+-	O
+time	O
+PCR	O
+assays	O
+were	O
+developed	O
+for	O
+simultaneous	O
+detection	O
+of	O
+12	O
+respiratory	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+Potential	O
+Role	O
+of	O
+Social	O
+Media	B-ANAT
+Platforms	O
+in	O
+Community	O
+Awareness	O
+of	O
+Antibiotic	B-CHED
+Use	O
+in	O
+the	O
+Gulf	O
+Cooperation	O
+Council	O
+States	O
+:	O
+Luxury	O
+or	O
+Necessity	O
+?	O
+
+This	O
+paper	O
+discusses	O
+the	O
+potential	O
+for	O
+using	O
+social	O
+media	B-ANAT
+tools	O
+as	O
+cost	O
+-	O
+efficient	O
+and	O
+mass	O
+education	O
+platforms	O
+to	O
+raise	O
+awareness	O
+of	O
+appropriate	O
+antibiotic	B-CHED
+use	O
+in	O
+the	O
+general	O
+public	O
+and	O
+in	O
+the	O
+medical	O
+communities	O
+of	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+Older	O
+age	O
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+=	O
+4	O
+.	O
+86	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+)	O
+1	O
+.	O
+90	O
+-	O
+12	O
+.	O
+45	O
+]	O
+and	O
+underlying	O
+respiratory	B-DISO
+disease	I-DISO
+(	O
+OR	O
+=	O
+4	O
+.	O
+90	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+64	O
+-	O
+14	O
+.	O
+65	O
+)	O
+were	O
+significantly	O
+associated	O
+with	O
+mortality	O
+.	O
+
+The	O
+susceptibility	O
+of	O
+2	O
+-,	O
+7	O
+-,	O
+12	O
+-,	O
+30	O
+-,	O
+and	O
+52	O
+-	O
+wk	O
+-	O
+old	O
+turkeys	B-SPEC
+to	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	B-SPEC
+)	O
+and	O
+turkey	B-SPEC
+astrovirus	I-SPEC
+(	O
+TAstV	O
+)	O
+was	O
+evaluated	O
+,	O
+as	O
+well	O
+as	O
+the	O
+effect	O
+of	O
+combined	O
+infection	B-DISO
+of	O
+TAstV	O
+and	O
+TCoV	B-SPEC
+in	O
+2	O
+-	O
+wk	O
+-	O
+old	O
+poults	O
+and	O
+turkey	B-SPEC
+hens	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+recently	O
+identified	O
+virus	B-SPEC
+causing	O
+severe	O
+viral	O
+respiratory	O
+illness	O
+in	O
+people	O
+.	O
+
+Little	O
+is	O
+known	O
+about	O
+the	O
+reservoir	O
+in	O
+the	O
+Horn	B-ANAT
+of	O
+Africa	O
+.	O
+
+ABSTRACT	O
+:	O
+Objectives	O
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+determine	O
+whether	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	B-SPEC
+)	O
+RNA	O
+in	O
+effusion	B-DISO
+samples	O
+can	O
+be	O
+used	O
+as	O
+a	O
+diagnostic	O
+marker	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+);	O
+and	O
+in	O
+FCoV	B-SPEC
+RNA	O
+-	O
+positive	O
+samples	O
+to	O
+examine	O
+amino	B-CHED
+acid	I-CHED
+codons	O
+in	O
+the	O
+FCoV	B-PRGE
+spike	I-PRGE
+protein	B-CHED
+at	O
+positions	O
+1058	O
+and	O
+1060	O
+where	O
+leucine	B-CHED
+and	O
+alanine	B-CHED
+,	O
+respectively	O
+,	O
+have	O
+been	O
+associated	O
+with	O
+systemic	O
+or	O
+virulent	O
+(	O
+FIP	B-DISO
+)	O
+FCoV	B-SPEC
+infection	B-DISO
+.	O
+
+Conclusions	O
+and	O
+relevance	O
+A	O
+positive	O
+FCoV	O
+qRT	O
+-	O
+PCR	O
+result	O
+on	O
+effusions	B-DISO
+appears	O
+specific	O
+for	O
+FIP	B-DISO
+and	O
+may	O
+be	O
+a	O
+useful	O
+diagnostic	O
+marker	O
+for	O
+FIP	B-DISO
+in	O
+cats	B-SPEC
+with	O
+effusions	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+October	O
+2013	O
+,	O
+approximately	O
+1000	O
+outbreaks	O
+of	O
+porcine	O
+epidemic	B-DISO
+diarrhoea	I-DISO
+(	O
+PED	O
+)	O
+have	O
+occurred	O
+,	O
+spanning	O
+almost	O
+all	O
+prefectures	O
+of	O
+Japan	O
+,	O
+after	O
+a	O
+period	O
+of	O
+seven	O
+years	O
+without	O
+a	O
+reported	O
+case	O
+.	O
+
+Moreover	O
+,	O
+the	O
+phylogenetic	O
+dendrogram	O
+of	O
+the	O
+complete	O
+genomes	O
+also	O
+indicated	O
+that	O
+the	O
+38	O
+Japanese	O
+PEDV	B-SPEC
+strains	O
+,	O
+including	O
+the	O
+two	O
+novel	O
+PEDV	B-SPEC
+variants	O
+discovered	O
+in	O
+this	O
+study	O
+,	O
+are	O
+closely	O
+related	O
+to	O
+the	O
+PEDV	B-SPEC
+strains	O
+that	O
+were	O
+widespread	O
+in	O
+the	O
+United	O
+States	O
+and	O
+Korea	O
+in	O
+2013	O
+-	O
+2014	O
+.	O
+
+In	O
+a	O
+second	O
+experiment	O
+,	O
+we	O
+challenged	O
+fully	O
+protected	O
+,	O
+partially	O
+protected	O
+,	O
+and	O
+fully	O
+susceptible	O
+birds	B-SPEC
+with	O
+IBV	B-SPEC
+,	O
+and	O
+then	O
+at	O
+5	O
+days	O
+postchallenge	O
+we	O
+gave	O
+the	O
+birds	B-SPEC
+an	O
+opportunistic	O
+bacterium	O
+intranasally	O
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+,	O
+cytotoxicity	B-DISO
+and	O
+antiviral	B-CHED
+evaluation	O
+of	O
+new	O
+series	O
+of	O
+imidazo	O
+[	O
+4	O
+,	O
+5	O
+-	O
+g	O
+]	O
+quinoline	B-CHED
+and	O
+pyrido	O
+[	O
+2	O
+,	O
+3	O
+-	O
+g	O
+]	O
+quinoxalinone	O
+derivatives	O
+.	O
+
+Lead	B-CHED
+compounds	I-CHED
+1	O
+-	O
+4	O
+were	O
+further	O
+modified	O
+to	O
+enhance	O
+their	O
+antiviral	B-CHED
+activity	O
+and	O
+reduce	O
+their	O
+cytotoxicity	B-DISO
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+and	O
+antigenic	O
+characteristics	O
+of	O
+Massachusetts	O
+genotype	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+in	O
+China	O
+.	O
+
+The	O
+virus	B-SPEC
+cross	O
+-	O
+neutralization	O
+test	O
+found	O
+that	O
+the	O
+antigenicity	O
+of	O
+ck	O
+/	O
+CH	O
+/	O
+LHB	B-PRGE
+/	O
+111172	O
+,	O
+ck	O
+/	O
+CH	O
+/	O
+LSD	B-CHED
+/	O
+111219	O
+,	O
+and	O
+ck	O
+/	O
+CH	O
+/	O
+LHB	B-PRGE
+/	O
+130598	O
+was	O
+similar	O
+to	O
+that	O
+of	O
+H120	O
+.	O
+
+Therefore	O
+,	O
+IBV	B-SPEC
+surveillance	O
+of	O
+chicken	B-SPEC
+flocks	O
+vaccinated	O
+with	O
+IBV	B-SPEC
+live	O
+vaccines	O
+,	O
+as	O
+well	O
+as	O
+the	O
+consideration	O
+of	O
+new	O
+strategies	O
+to	O
+effectively	O
+control	O
+IBV	B-SPEC
+infection	B-DISO
+using	O
+inactivated	O
+or	O
+/	O
+and	O
+genetically	O
+engineered	O
+vaccines	O
+,	O
+is	O
+of	O
+great	O
+importance	O
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+vascular	B-ANAT
+dysfunction	O
+has	O
+been	O
+described	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+We	O
+hypothesized	O
+that	O
+severe	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+dysfunction	O
+and	O
+cor	B-DISO
+pulmonale	I-DISO
+identified	O
+by	O
+echocardiography	O
+before	O
+cannulation	O
+in	O
+these	O
+patients	O
+were	O
+associated	O
+with	O
+worse	O
+survival	O
+.	O
+
+Survival	O
+was	O
+compared	O
+for	O
+those	O
+with	O
+and	O
+without	O
+cor	B-DISO
+pulmonale	I-DISO
+.	O
+
+Acute	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+was	O
+detectable	O
+in	O
+2	O
+patients	O
+(	O
+9	O
+.	O
+5	O
+%),	O
+while	O
+the	O
+remaining	O
+19	O
+patients	O
+showed	O
+moderate	O
+pulmonary	B-ANAT
+dysfunction	O
+.	O
+
+Survivors	O
+had	O
+a	O
+higher	O
+pre	O
+-	O
+cannulation	O
+LV	O
+ejection	O
+fraction	O
+(	O
+EF	O
+)	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+)	O
+and	O
+tricuspid	O
+annular	O
+plane	O
+excursion	O
+(	O
+P	O
+=	O
+0	O
+.	O
+04	O
+),	O
+and	O
+lower	O
+peak	B-PROC
+systolic	I-PROC
+pulmonary	B-ANAT
+artery	I-ANAT
+pressures	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+TITLE	O
+:	O
+Genetic	B-PROC
+polymorphisms	I-PROC
+of	O
+IL28b	B-PRGE
+gene	I-PRGE
+as	O
+predictors	O
+of	O
+response	O
+to	O
+dual	O
+therapy	O
+in	O
+genotypes	O
+1	O
+and	O
+4	O
+-	O
+HCV	O
+and	O
+HIV	B-DISO
+/	O
+HCV	B-SPEC
+-	O
+infected	O
+patients	O
+.	O
+
+Their	O
+antiviral	B-CHED
+and	O
+antifungal	B-CHED
+activities	O
+were	O
+evaluated	O
+.	O
+
+However	O
+,	O
+the	O
+antifungal	B-CHED
+activity	O
+of	O
+(	O
+R	O
+,	O
+R	O
+)-	O
+17	B-CHED
+·	I-CHED
+HCl	I-CHED
+against	O
+Puccinia	B-SPEC
+sorghi	I-SPEC
+is	O
+slightly	O
+lower	O
+than	O
+that	O
+of	O
+(	O
+R	O
+,	O
+R	O
+)-	O
+17	O
+.	O
+
+Learning	B-PROC
+from	O
+the	O
+trends	O
+in	O
+sources	O
+used	O
+in	O
+previous	O
+outbreaks	O
+will	O
+enable	O
+improvements	O
+in	O
+information	O
+access	O
+in	O
+future	O
+outbreaks	O
+.	O
+
+The	O
+use	O
+of	O
+five	O
+or	O
+more	O
+information	O
+sources	O
+increased	O
+by	O
+almost	O
+60	O
+%	O
+between	O
+the	O
+SARS	B-DISO
+and	O
+H1N1	O
+surveys	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+lungs	B-ANAT
+revealed	O
+mononuclear	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+,	O
+alveolar	B-DISO
+edema	I-DISO
+,	O
+and	O
+microvascular	O
+thrombosis	B-DISO
+,	O
+with	O
+airways	O
+generally	O
+unaffected	O
+.	O
+
+Brain	B-DISO
+disease	I-DISO
+was	O
+observed	O
+,	O
+with	O
+the	O
+greatest	O
+involvement	O
+noted	O
+in	O
+the	O
+thalamus	B-ANAT
+and	O
+brain	B-ANAT
+stem	I-ANAT
+.	O
+
+The	O
+infection	B-DISO
+of	O
+target	B-ANAT
+cells	I-ANAT
+by	O
+the	O
+SARS	B-PRGE
+CoV	I-PRGE
+is	O
+mediated	O
+through	O
+the	O
+interaction	O
+of	O
+the	O
+viral	O
+Spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+(	O
+1255	O
+amino	B-CHED
+acids	I-CHED
+)	O
+and	O
+its	O
+cellular	B-COMP
+receptor	O
+,	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+).	O
+
+In	O
+addition	O
+,	O
+the	O
+RBM	O
+is	O
+a	O
+major	O
+antigenic	B-CHED
+determinant	I-CHED
+,	O
+able	O
+to	O
+elicit	O
+production	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+40	O
+amino	B-CHED
+acids	I-CHED
+)	O
+that	O
+can	O
+bind	B-FUNC
+both	O
+the	O
+ACE2	B-PRGE
+receptor	I-PRGE
+and	O
+the	O
+neutralizing	O
+mAb	O
+80R	O
+.	O
+
+Among	O
+102	O
+patients	O
+,	O
+median	O
+Ct	O
+of	O
+31	O
+.	O
+0	O
+for	O
+the	O
+upstream	O
+of	O
+the	O
+E	B-PRGE
+gene	I-PRGE
+target	O
+for	O
+41	O
+(	O
+40	O
+%)	O
+patients	O
+who	O
+died	B-PROC
+was	O
+significantly	O
+lower	O
+than	O
+the	O
+median	O
+of	O
+33	O
+.	O
+0	O
+for	O
+61	O
+survivors	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0087	O
+).	O
+
+In	O
+multivariable	O
+regression	O
+analyses	O
+,	O
+risk	O
+factors	O
+for	O
+death	B-PROC
+were	O
+age	O
+>	O
+60	O
+years	O
+),	O
+underlying	O
+illness	O
+,	O
+and	O
+decreasing	O
+Ct	O
+for	O
+each	O
+1	O
+-	O
+point	O
+decrease	O
+in	O
+Ct	O
+).	O
+
+Patients	O
+were	O
+a	O
+man	B-CHED
+who	O
+had	O
+visited	O
+the	O
+Middle	O
+East	O
+,	O
+his	O
+wife	O
+,	O
+and	O
+a	O
+man	B-CHED
+who	O
+shared	O
+a	O
+hospital	O
+room	O
+with	O
+the	O
+index	O
+patient	O
+.	O
+
+A	O
+strong	O
+candidate	O
+is	O
+a	O
+group	O
+of	O
+unique	O
+compounds	O
+found	O
+in	O
+Camellia	B-SPEC
+sinensis	I-SPEC
+(	O
+tea	B-CHED
+plant	B-SPEC
+):	O
+the	O
+green	O
+tea	B-CHED
+polyphenols	B-CHED
+,	O
+in	O
+particular	O
+epigallocatechin	O
+-	O
+3	O
+-	O
+gallate	B-CHED
+(	O
+EGCG	B-CHED
+)	O
+and	O
+its	O
+lipophilic	O
+derivatives	O
+.	O
+
+Recently	O
+,	O
+a	O
+new	O
+definition	O
+for	O
+ARDS	B-DISO
+was	O
+proposed	O
+,	O
+the	O
+Berlin	O
+definition	O
+.	O
+
+TITLE	O
+:	O
+Prokaryotic	O
+Expression	B-PROC
+of	O
+Truncated	B-PRGE
+S1	I-PRGE
+Protein	I-PRGE
+of	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+and	O
+Production	O
+of	O
+Monoclonal	O
+Antibodies	O
+to	O
+Recombinant	B-PRGE
+Protein	I-PRGE
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+the	O
+truncated	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+,	O
+encoding	O
+the	O
+exterior	O
+of	O
+the	O
+viral	O
+spike	O
+protein	B-CHED
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+was	O
+subcloned	O
+into	O
+prokaryotic	O
+expression	B-PROC
+vector	O
+pET32a	O
+(+)	O
+and	O
+expressed	B-PROC
+as	O
+a	O
+recombinant	O
+protein	B-CHED
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+BL21	B-ANAT
+(	O
+DE3	O
+).	O
+
+Moreover	O
+,	O
+the	O
+larger	O
+tissue	B-ANAT
+mass	O
+suspended	O
+from	O
+a	O
+wider	O
+dorsal	O
+chest	B-ANAT
+wall	I-ANAT
+effects	O
+a	O
+more	O
+homogeneous	O
+distribution	O
+of	O
+pleural	O
+pressures	O
+throughout	O
+the	O
+lung	B-ANAT
+that	O
+reduces	O
+abnormal	O
+strain	O
+and	O
+stress	O
+development	B-PROC
+.	O
+
+Efforts	O
+should	O
+be	O
+made	O
+to	O
+establish	O
+a	O
+methodology	O
+for	O
+rapid	O
+tracking	O
+of	O
+all	O
+possible	O
+contacts	O
+and	O
+elimination	B-PROC
+-	O
+based	O
+identification	O
+of	O
+the	O
+precise	O
+modes	O
+of	O
+transmission	O
+.	O
+
+Sequence	O
+analysis	O
+showed	O
+that	O
+these	O
+isolates	O
+were	O
+divided	O
+into	O
+five	O
+sub	O
+-	O
+clusters	B-CHED
+:	O
+A2	O
+-	O
+like	O
+,	O
+CKCHLDL08I	O
+-	O
+like	O
+,	O
+SAIBK	O
+-	O
+like	O
+,	O
+KM91	B-PRGE
+-	I-PRGE
+like	I-PRGE
+and	I-PRGE
+TW97	I-PRGE
+/	I-PRGE
+4	I-PRGE
+-	I-PRGE
+like	I-PRGE
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+highly	O
+variable	O
+sites	O
+range	O
+from	O
+sub	O
+-	O
+clusters	B-CHED
+,	O
+the	O
+N	O
+-	O
+terminal	O
+sequences	O
+of	O
+4	O
+/	O
+91	O
+-	O
+like	O
+,	O
+TW97	B-PRGE
+/	I-PRGE
+4	I-PRGE
+-	I-PRGE
+like	I-PRGE
+and	O
+Arkansas	O
+-	O
+like	O
+are	O
+more	O
+variable	O
+than	O
+other	O
+sub	O
+-	O
+clusters	B-CHED
+.	O
+
+MRSA	B-DISO
+most	O
+closely	O
+resembled	O
+a	O
+Type	O
+I	O
+pathogen	O
+.	O
+
+Six	O
+patients	O
+who	O
+had	O
+severe	O
+ARDS	B-DISO
+showed	O
+a	O
+diffuse	O
+comet	O
+tail	O
+sign	O
+or	O
+a	O
+consolidation	O
+score	O
+≥	O
+7	O
+and	O
+a	O
+lung	B-ANAT
+ultrasound	O
+score	O
+≥	O
+20	O
+points	O
+.	O
+
+One	O
+patient	O
+showed	O
+a	O
+diffuse	O
+comet	B-SPEC
+tail	O
+sign	O
+or	O
+consolidation	O
+area	O
+in	O
+four	O
+lung	B-ANAT
+areas	O
+,	O
+with	O
+an	O
+ultrasound	O
+score	O
+of	O
+14	O
+.	O
+
+Our	O
+data	O
+corroborate	O
+previous	O
+data	O
+indicating	O
+a	O
+strong	O
+relationship	O
+between	O
+CG	O
+symptoms	O
+and	O
+severe	O
+cardiac	B-ANAT
+problems	O
+.	O
+
+ABSTRACT	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+(	O
+GBS	B-DISO
+)	O
+has	O
+a	O
+cosmopolitan	O
+distribution	O
+.	O
+
+History	O
+of	O
+intestinal	B-DISO
+infection	I-DISO
+was	O
+present	O
+in	O
+40	O
+%	O
+of	O
+patients	O
+,	O
+and	O
+respiratory	B-DISO
+infection	I-DISO
+in	O
+24	O
+.	O
+4	O
+%.	O
+
+Pulmonary	B-ANAT
+intensive	O
+care	O
+may	O
+involve	O
+thoracentesis	O
+,	O
+oxygen	B-CHED
+supplementation	O
+and	O
+in	O
+more	O
+severe	O
+cases	O
+assisted	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Blunt	O
+Hepatic	B-ANAT
+Trauma	O
+in	O
+Polytrauma	O
+Patient	O
+-	O
+Management	O
+and	O
+Outcome	O
+.	O
+
+TITLE	O
+:	O
+Application	O
+of	O
+RT	O
+-	O
+Bst	O
+to	O
+enhance	O
+detection	O
+of	O
+pathogenic	O
+viruses	B-SPEC
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+RT	B-PRGE
+-	I-PRGE
+Bst	I-PRGE
+and	O
+RT	O
+-	O
+Bst	B-PRGE
+PCR	O
+can	O
+be	O
+used	O
+as	O
+alternative	O
+approaches	O
+to	O
+reverse	B-PROC
+transcription	I-PROC
+and	O
+one	O
+-	O
+step	O
+RT	O
+-	O
+PCR	O
+,	O
+respectively	O
+,	O
+for	O
+sequence	O
+-	O
+independent	O
+amplification	B-DISO
+of	O
+RNA	O
+virus	B-SPEC
+sequences	O
+and	O
+a	O
+larger	O
+scale	O
+analysis	O
+of	O
+this	O
+new	O
+diagnostic	O
+approach	O
+is	O
+warranted	O
+.	O
+
+ABSTRACT	O
+:	O
+Detection	O
+of	O
+specific	O
+respiratory	O
+viruses	O
+is	O
+important	O
+for	O
+surveillance	O
+programs	O
+,	O
+where	O
+nasopharyngeal	B-ANAT
+or	O
+nasal	B-ANAT
+swabs	O
+have	O
+traditionally	O
+been	O
+used	O
+.	O
+
+Among	O
+83	O
+university	O
+students	O
+with	O
+acute	B-DISO
+pharyngitis	I-DISO
+,	O
+we	O
+detected	O
+respiratory	O
+viruses	B-SPEC
+with	O
+molecular	O
+assays	O
+on	O
+two	O
+samples	O
+collected	O
+per	O
+student	O
+:	O
+with	O
+a	O
+flocked	O
+nasal	B-ANAT
+mid	O
+-	O
+turbinate	B-ANAT
+swab	O
+and	O
+a	O
+rayon	O
+throat	B-ANAT
+swab	I-ANAT
+.	O
+
+The	O
+flocked	O
+nasal	B-ANAT
+swab	O
+samples	O
+respiratory	O
+viruses	B-SPEC
+well	O
+,	O
+even	O
+among	O
+patients	O
+whose	O
+primary	O
+complaint	O
+is	O
+a	O
+sore	B-DISO
+throat	I-DISO
+.	O
+
+The	O
+pig	B-SPEC
+study	O
+showed	O
+that	O
+the	O
+early	O
+termination	O
+in	O
+ORF3	O
+was	O
+more	O
+important	O
+for	O
+virus	B-SPEC
+cell	B-COMP
+adaptation	B-PROC
+than	O
+virus	B-SPEC
+attenuation	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+SARS	O
+-	O
+CoV	O
+lacking	O
+the	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+E	I-PRGE
+gene	I-PRGE
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-∆	I-PRGE
+E	I-PRGE
+)	O
+was	O
+attenuated	O
+and	O
+an	O
+effective	O
+vaccine	O
+.	O
+
+In	O
+contrast	O
+,	O
+during	O
+SARS	B-DISO
+-	O
+CoV	O
+-∆	O
+E	O
+passage	O
+in	O
+mice	B-SPEC
+,	O
+the	O
+virus	B-SPEC
+incorporated	O
+a	O
+mutated	O
+variant	O
+of	O
+8a	O
+protein	B-CHED
+,	O
+resulting	O
+in	O
+reversion	O
+to	O
+a	O
+virulent	O
+phenotype	O
+.	O
+
+Deletions	O
+in	O
+the	O
+carboxy	B-CHED
+-	O
+terminal	O
+region	O
+of	O
+nsp1	B-PRGE
+protein	I-PRGE
+led	O
+to	O
+higher	O
+host	B-COMP
+interferon	O
+responses	O
+and	O
+virus	B-SPEC
+attenuation	O
+.	O
+
+When	O
+cells	B-COMP
+were	O
+treated	O
+methyl	B-CHED
+-	O
+β	O
+-	O
+cyclodextrin	B-CHED
+(	O
+MβCD	O
+)	O
+and	O
+inoculated	O
+with	O
+type	B-PRGE
+I	I-PRGE
+FCoV	I-PRGE
+,	O
+the	O
+infection	B-DISO
+rate	O
+decreased	O
+significantly	O
+,	O
+and	O
+the	O
+addition	O
+of	O
+exogenous	O
+cholesterol	B-CHED
+to	O
+MβCD	O
+-	O
+treated	O
+cells	B-COMP
+resulted	O
+in	O
+the	O
+recovery	O
+of	O
+the	O
+infectivity	O
+of	O
+type	B-PRGE
+I	I-PRGE
+FCoV	I-PRGE
+.	O
+Furthermore	O
+,	O
+exogenous	O
+cholesterol	B-CHED
+increased	O
+the	O
+infectivity	O
+of	O
+type	B-PRGE
+I	I-PRGE
+FCoV	I-PRGE
+.	O
+In	O
+contrast	O
+,	O
+the	O
+addition	O
+of	O
+MβCD	O
+and	O
+exogenous	O
+cholesterol	B-CHED
+had	O
+little	O
+effect	O
+on	O
+the	O
+efficiency	O
+of	O
+type	O
+II	O
+FCoV	O
+infection	B-DISO
+.	O
+
+These	O
+results	O
+strongly	O
+suggest	O
+that	O
+the	O
+dependence	B-DISO
+of	O
+infection	B-DISO
+by	O
+types	O
+I	O
+and	O
+II	O
+FCoV	O
+on	O
+cholesterol	B-CHED
+differs	O
+.	O
+
+The	O
+study	O
+group	O
+comprised	O
+58	O
+infants	O
+with	O
+severe	O
+measles	B-DISO
+pneumonia	I-DISO
+who	O
+were	O
+admitted	O
+to	O
+the	O
+Second	O
+Pediatric	O
+Intensive	O
+Care	O
+Unit	O
+,	O
+Shengjing	O
+Hospital	O
+of	O
+China	O
+Medical	O
+University	O
+,	O
+from	O
+December	O
+2013	O
+through	O
+May	O
+2014	O
+.	O
+
+The	O
+58	O
+infants	O
+experienced	O
+the	O
+following	O
+:	O
+hypoxemia	O
+,	O
+100	O
+%;	O
+ARDS	O
+,	O
+21	O
+%;	O
+sepsis	B-DISO
+,	O
+34	O
+%;	O
+pneumothorax	B-DISO
+,	O
+14	O
+%;	O
+MODS	B-DISO
+,	O
+16	O
+%;	O
+and	O
+intracranial	B-ANAT
+infection	B-DISO
+,	O
+9	O
+%.	O
+
+If	O
+a	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+changes	O
+abruptly	O
+,	O
+it	O
+is	O
+crucial	O
+to	O
+promptly	O
+respond	O
+to	O
+the	O
+change	O
+and	O
+to	O
+administer	O
+mechanical	O
+ventilation	O
+and	O
+appropriate	O
+antibiotics	B-CHED
+.	O
+
+Respiratory	B-PROC
+mechanics	I-PROC
+,	O
+blood	B-PROC
+gases	I-PROC
+,	O
+hemodynamic	B-PROC
+data	O
+,	O
+and	O
+whole	O
+-	O
+lung	B-ANAT
+computed	O
+tomography	O
+scans	O
+were	O
+recorded	O
+at	O
+each	O
+PEEP	B-CHED
+level	O
+.	O
+
+RESULTS	O
+:	O
+OL	O
+-	O
+PEEP	B-CHED
+was	O
+higher	O
+than	O
+Pes	B-ANAT
+-	O
+PEEP	B-CHED
+,	O
+which	O
+induced	O
+a	O
+higher	O
+PL	O
+-	O
+exp	O
+at	O
+OL	O
+-	O
+PEEP	B-CHED
+than	O
+at	O
+Pes	B-ANAT
+-	O
+PEEP	B-CHED
+(	O
+4	O
+.	O
+6	O
+[	O
+1	O
+.	O
+6	O
+]	O
+cm	O
+H2O	B-CHED
+vs	O
+.	O
+1	O
+.	O
+2	O
+[	O
+0	O
+.	O
+6	O
+]	O
+cm	O
+H2O	B-CHED
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+with	O
+concomitant	O
+impairment	B-DISO
+of	O
+oxygenation	B-PROC
+and	O
+decarboxylation	O
+represents	O
+a	O
+complex	O
+problem	O
+in	O
+patients	O
+with	O
+increased	B-DISO
+intracranial	I-DISO
+pressure	I-DISO
+(	O
+ICP	B-DISO
+).	O
+
+The	O
+medical	O
+records	O
+of	O
+ten	O
+patients	O
+(	O
+eight	O
+male	O
+,	O
+two	O
+female	O
+)	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+severe	O
+TBI	O
+concurrently	O
+managed	O
+with	O
+external	O
+ventricular	B-ANAT
+drainage	B-ANAT
+in	O
+the	O
+neurointensive	O
+care	O
+unit	O
+(	O
+NICU	O
+)	O
+were	O
+retrospectively	O
+analyzed	O
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+potentially	O
+detrimental	O
+hypercapnia	B-DISO
+that	O
+may	O
+increase	O
+ICP	B-DISO
+is	O
+avoided	O
+.	O
+
+RESULTS	O
+:	O
+During	O
+the	O
+study	O
+period	O
+,	O
+88	O
+ESKAPE	O
+pathogens	O
+obtained	O
+from	O
+respiratory	B-ANAT
+tract	I-ANAT
+specimens	O
+of	O
+54	O
+ARDS	B-DISO
+renal	B-ANAT
+recipients	O
+were	O
+documented	O
+including	O
+33	O
+A	O
+.	O
+baumannii	O
+,	O
+24	O
+P	O
+.	O
+aeruginosa	O
+,	O
+17	O
+S	O
+.	O
+aureus	O
+,	O
+6	O
+K	O
+.	O
+pneumoniae	O
+,	O
+8	O
+Enterobacter	B-SPEC
+species	I-SPEC
+,	O
+and	O
+0	O
+E	O
+.	O
+Faecium	O
+.	O
+
+Expanding	O
+migratory	O
+patterns	O
+observed	O
+among	O
+bats	B-SPEC
+and	O
+the	O
+mutation	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+seek	O
+and	O
+successfully	O
+infect	O
+new	O
+hosts	B-COMP
+is	O
+a	O
+significant	O
+departure	O
+from	O
+the	O
+generalized	O
+epidemiological	O
+trend	O
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+1	O
+.	O
+71	O
+%	O
+(	O
+92	O
+/	O
+5365	O
+)	O
+of	O
+the	O
+samples	O
+corresponding	O
+to	O
+5	O
+.	O
+95	O
+%	O
+(	O
+63	O
+/	O
+1058	O
+)	O
+of	O
+the	O
+diarrhea	B-DISO
+cases	O
+in	O
+239	O
+beef	O
+and	O
+324	O
+dairy	O
+farms	O
+.	O
+
+ABSTRACT	O
+:	O
+Modern	O
+human	B-SPEC
+activity	O
+fueled	O
+by	O
+economic	O
+development	O
+is	O
+profoundly	O
+altering	O
+our	O
+relationship	O
+with	O
+microorganisms	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Sequencing	O
+and	O
+Phylogenetic	O
+Analyses	O
+of	O
+Structural	O
+and	O
+Accessory	O
+Proteins	B-CHED
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+from	O
+the	O
+First	O
+Imported	O
+Case	O
+in	O
+China	O
+,	O
+2015	O
+].	O
+
+All	O
+coding	O
+gene	O
+of	O
+structural	O
+(	O
+S	O
+,	O
+E	O
+,	O
+M	O
+,	O
+E	O
+)	O
+and	O
+accessory	O
+(	O
+ORF3	O
+,	O
+ORF4a	O
+,	O
+ORF4b	O
+,	O
+ORF5	O
+,	O
+ORF8b	O
+)	O
+proteins	B-CHED
+were	O
+sequenced	O
+and	O
+analyzed	O
+.	O
+
+In	O
+conclusion	O
+,	O
+genome	O
+of	O
+MERS	O
+-	O
+CoV_	O
+China	O
+GD01	O
+was	O
+general	O
+conserved	O
+although	O
+several	O
+genetic	O
+variations	O
+were	O
+found	O
+among	O
+structural	O
+and	O
+accessory	B-PRGE
+protein	I-PRGE
+coding	I-PRGE
+genes	I-PRGE
+.	O
+
+Future	O
+studies	O
+must	O
+build	O
+upon	O
+larger	O
+-	O
+scale	O
+collaborations	O
+,	O
+but	O
+also	O
+strictly	O
+adhere	O
+to	O
+the	O
+highest	O
+evidence	O
+-	O
+based	O
+principles	O
+in	O
+study	O
+design	O
+,	O
+in	O
+order	B-SPEC
+to	O
+reduce	O
+research	O
+waste	O
+and	O
+provide	O
+clinically	O
+translatable	O
+evidence	O
+.	O
+
+TITLE	O
+:	O
+Non	O
+-	O
+Invasive	O
+Detection	O
+of	O
+Lung	B-DISO
+Inflammation	I-DISO
+by	O
+Near	O
+-	O
+Infrared	O
+Fluorescence	O
+Imaging	O
+Using	O
+Bimodal	O
+Liposomes	O
+.	O
+
+Critical	O
+characteristics	O
+of	O
+ALI	O
+are	O
+alveolar	B-DISO
+edema	I-DISO
+,	O
+infiltration	B-DISO
+of	O
+leukocytes	B-ANAT
+(	O
+neutrophils	B-ANAT
+and	O
+monocytes	B-ANAT
+),	O
+release	B-PATH
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+and	O
+chemokines	O
+into	O
+broncho	O
+-	O
+alveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+and	O
+activation	O
+of	O
+integrin	B-PRGE
+receptors	I-PRGE
+.	O
+
+In	O
+vitro	O
+studies	O
+demonstrated	O
+integrin	B-PRGE
+receptor	I-PRGE
+specificity	O
+of	O
+targeted	B-PROC
+liposomes	O
+.	O
+
+These	O
+targeted	B-PROC
+liposomes	O
+showed	O
+binding	B-FUNC
+to	O
+alphavbeta5	B-PRGE
+integrin	I-PRGE
+receptors	I-PRGE
+expressed	B-PROC
+on	O
+alveolar	B-ANAT
+cells	B-COMP
+.	O
+
+In	O
+this	O
+particular	O
+case	O
+,	O
+the	O
+cardiac	B-ANAT
+electrical	O
+instability	O
+was	O
+definitely	O
+maintained	O
+by	O
+several	O
+causes	O
+,	O
+including	O
+severe	O
+hypokalemia	O
+,	O
+which	O
+has	O
+not	O
+been	O
+previously	O
+reported	O
+as	O
+related	O
+to	O
+Taxus	B-SPEC
+poisoning	O
+.	O
+
+Community	O
+-	O
+acquired	O
+ARDS	B-DISO
+,	O
+hospital	O
+-	O
+acquired	O
+ARDS	B-DISO
+and	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)-	O
+acquired	O
+ARDS	B-DISO
+were	O
+defined	O
+as	O
+ARDS	B-DISO
+occurring	O
+within	O
+48	O
+hours	O
+of	O
+hospital	O
+or	O
+ICU	O
+admission	O
+,	O
+more	O
+than	O
+48	O
+hours	O
+after	O
+hospital	O
+admission	O
+and	O
+ICU	O
+admission	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+ORF3	O
+gene	O
+prolongs	O
+S	B-PROC
+-	I-PROC
+phase	I-PROC
+,	O
+facilitates	O
+formation	B-PROC
+of	O
+vesicles	B-ANAT
+and	O
+promotes	O
+the	O
+proliferation	B-DISO
+of	O
+attenuated	O
+PEDV	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+ORF3	O
+-	O
+expressing	O
+Vero	B-ANAT
+cells	I-ANAT
+had	O
+more	O
+vesicles	B-COMP
+than	O
+the	O
+host	B-COMP
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Sequence	O
+and	O
+phylogenetic	O
+analyses	O
+of	O
+the	O
+M	O
+and	O
+N	O
+genes	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+strains	O
+in	O
+Anhui	O
+Province	O
+,	O
+China	O
+.	O
+
+The	O
+results	O
+revealed	O
+that	O
+the	O
+M	O
+and	O
+N	O
+genes	O
+of	O
+PEDV	B-SPEC
+were	O
+681	O
+and	O
+1326	O
+bp	O
+long	O
+,	O
+respectively	O
+.	O
+
+Compared	O
+with	O
+the	O
+PEDV	O
+reference	O
+strains	O
+,	O
+the	O
+Anhui	O
+PEDV	B-SPEC
+field	O
+strains	O
+had	O
+96	O
+.	O
+9	O
+-	O
+100	O
+%	O
+nucleotide	B-CHED
+sequence	O
+homology	O
+in	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+and	O
+96	O
+.	O
+5	O
+-	O
+99	O
+.	O
+6	O
+%	O
+amino	B-CHED
+acid	I-CHED
+homology	O
+in	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+.	O
+
+Several	O
+studies	O
+confirmed	O
+dromedary	B-SPEC
+camels	B-SPEC
+to	O
+be	O
+a	O
+potential	O
+reservoir	O
+and	O
+a	O
+source	O
+for	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+Epidemiological	O
+information	O
+revealed	O
+that	O
+all	O
+seropositive	O
+camels	B-SPEC
+had	O
+been	O
+imported	O
+from	O
+Africa	O
+20	O
+or	O
+more	O
+years	O
+prior	O
+.	O
+
+Starting	O
+from	O
+the	O
+end	O
+of	O
+2010	O
+,	O
+a	O
+PED	O
+outbreak	O
+occurred	O
+in	O
+several	O
+pig	B-SPEC
+-	O
+producing	O
+provinces	O
+in	O
+southern	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Superspreading	O
+Event	O
+Involving	O
+81	O
+Persons	O
+,	O
+Korea	O
+2015	O
+.	O
+
+As	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreaks	O
+,	O
+superspreading	O
+events	O
+can	O
+cause	O
+a	O
+large	O
+outbreak	O
+of	O
+MERS	O
+in	O
+healthcare	O
+facilities	O
+with	O
+severe	O
+consequences	O
+.	O
+
+ABSTRACT	O
+:	O
+Neurogenic	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+(	O
+NPE	O
+)	O
+is	O
+a	O
+clinical	O
+syndrome	B-DISO
+usually	O
+defined	O
+as	O
+an	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+occurring	O
+shortly	O
+after	O
+a	O
+central	O
+neurologic	O
+insult	O
+.	O
+
+SM	O
+is	O
+a	O
+reversible	O
+cardiomyopathy	B-DISO
+resulting	O
+in	O
+transient	O
+left	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+which	O
+has	O
+been	O
+described	O
+to	O
+occur	O
+in	O
+the	O
+setting	O
+of	O
+catecholamine	B-CHED
+release	B-PATH
+during	O
+situations	O
+of	O
+physiologic	O
+stress	O
+.	O
+
+However	O
+,	O
+there	O
+are	O
+no	O
+methods	O
+available	O
+to	O
+detect	O
+DNA	O
+and	O
+RNA	O
+viruses	B-SPEC
+in	O
+the	O
+same	O
+reaction	O
+system	O
+in	O
+preclinical	O
+level	O
+.	O
+
+In	O
+an	O
+attempt	O
+to	O
+study	O
+the	O
+role	O
+of	O
+this	O
+protein	B-CHED
+in	O
+virus	B-SPEC
+spread	O
+within	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+and	O
+neurovirulence	O
+,	O
+as	O
+well	O
+as	O
+to	O
+identify	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+important	O
+for	O
+such	O
+functions	O
+,	O
+we	O
+compared	O
+the	O
+sequence	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+found	O
+in	O
+the	O
+laboratory	O
+reference	O
+strain	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+ATCC	O
+VR	O
+-	O
+759	O
+to	O
+S	O
+sequences	O
+of	O
+viruses	B-SPEC
+detected	O
+in	O
+clinical	O
+isolates	O
+from	O
+the	O
+human	B-SPEC
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+The	O
+alstotides	O
+(	O
+As1	B-PRGE
+-	I-PRGE
+As4	B-CHED
+)	O
+were	O
+characterized	O
+by	O
+both	O
+proteomic	O
+and	O
+genomic	O
+methods	O
+.	O
+
+In	O
+recent	O
+years	O
+,	O
+some	O
+studies	O
+have	O
+tried	O
+to	O
+clarify	O
+the	O
+pathophysiological	O
+characteristics	O
+underlying	O
+chronic	O
+critical	B-DISO
+illness	I-DISO
+(	O
+CCI	O
+),	O
+a	O
+disease	O
+that	O
+is	O
+also	O
+characterized	O
+by	O
+severe	O
+endocrine	B-CHED
+and	O
+inflammatory	O
+impairments	O
+,	O
+partly	O
+accounting	O
+for	O
+the	O
+almost	O
+constant	O
+set	O
+of	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+Emergence	O
+of	O
+novel	O
+nephropathogenic	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+currently	O
+circulating	O
+in	O
+Chinese	O
+chicken	O
+flocks	O
+.	O
+
+Pathogenicity	O
+experiments	O
+in	O
+chickens	B-SPEC
+using	O
+three	O
+of	O
+the	O
+eight	O
+virus	B-SPEC
+isolates	O
+revealed	O
+that	O
+they	O
+were	O
+nephropathogenic	O
+and	O
+had	O
+similar	O
+pathogenicity	O
+to	O
+the	O
+parental	O
+viruses	B-SPEC
+.	O
+
+MERS	O
+-	O
+CoV	O
+may	O
+be	O
+considered	O
+a	O
+zoonotic	O
+virus	B-SPEC
+that	O
+has	O
+crossed	O
+the	O
+species	B-SPEC
+barrier	O
+to	O
+humans	B-SPEC
+,	O
+but	O
+the	O
+pathogenesis	B-DISO
+and	O
+the	O
+routes	O
+of	O
+transmission	O
+are	O
+not	O
+completely	O
+understood	O
+.	O
+
+Human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+though	O
+was	O
+observed	O
+on	O
+some	O
+occasions	O
+in	O
+Korea	O
+,	O
+it	O
+is	O
+documented	O
+as	O
+non	O
+-	O
+sustainable	O
+event	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+Coronavirus	I-SPEC
+229E	I-SPEC
+Remains	O
+Infectious	B-DISO
+on	O
+Common	O
+Touch	B-PROC
+Surface	O
+Materials	O
+.	O
+
+Exposure	O
+to	O
+copper	B-CHED
+destroyed	O
+the	O
+viral	O
+genomes	O
+and	O
+irreversibly	O
+affected	O
+virus	B-SPEC
+morphology	O
+,	O
+including	O
+disintegration	B-DISO
+of	O
+envelope	B-COMP
+and	O
+dispersal	O
+of	O
+surface	O
+spikes	O
+.	O
+
+We	O
+show	O
+here	O
+that	O
+a	O
+closely	O
+related	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+229E	O
+,	O
+which	O
+causes	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+healthy	O
+individuals	O
+and	O
+serious	O
+disease	O
+in	O
+patients	O
+with	O
+comorbidities	O
+,	O
+remained	O
+infectious	B-DISO
+on	O
+surface	O
+materials	O
+common	O
+to	O
+public	O
+and	O
+domestic	O
+areas	O
+for	O
+several	O
+days	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+examine	O
+complications	O
+associated	O
+with	O
+the	O
+use	O
+of	O
+therapeutic	O
+temperature	O
+modulation	O
+(	O
+mild	O
+hypothermia	O
+and	O
+normothermia	O
+)	O
+in	O
+patients	O
+with	O
+severe	O
+traumatic	O
+brain	B-ANAT
+injury	O
+(	O
+TBI	O
+).	O
+
+The	O
+control	O
+group	O
+received	O
+standard	O
+treatment	O
+with	O
+intermittent	O
+acetaminophen	B-CHED
+for	O
+fever	B-PROC
+.	O
+
+Within	O
+the	O
+TTM	B-DISO
+group	O
+eight	O
+patients	O
+were	O
+treated	O
+with	O
+normothermia	O
+after	O
+TBI	O
+and	O
+35	O
+patients	O
+were	O
+treated	O
+with	O
+hypothermia	O
+.	O
+
+Exposure	O
+to	O
+TTM	B-DISO
+is	O
+associated	O
+with	O
+an	O
+increase	O
+in	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+These	O
+findings	O
+support	O
+more	O
+attention	O
+to	O
+these	O
+complications	O
+in	O
+studies	O
+of	O
+TTM	B-DISO
+in	O
+TBI	O
+patients	O
+.	O
+
+We	O
+aimed	O
+to	O
+describe	O
+the	O
+consequences	O
+of	O
+bronchoscopy	O
+during	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+in	O
+a	O
+bench	O
+study	O
+,	O
+and	O
+thereby	O
+to	O
+determine	O
+the	O
+optimal	O
+diameter	O
+of	O
+the	O
+bronchoscope	O
+for	O
+avoiding	O
+disruption	O
+of	O
+the	O
+protective	O
+-	O
+ventilation	O
+strategy	O
+during	O
+the	O
+procedure	O
+.	O
+
+Inclusion	O
+criteria	O
+were	O
+cats	B-SPEC
+that	O
+had	O
+complete	O
+diagnostic	O
+workups	O
+,	O
+including	O
+clinical	O
+,	O
+clinicopathological	O
+,	O
+serological	O
+,	O
+and	O
+histopathological	O
+data	O
+,	O
+as	O
+well	O
+as	O
+imaging	O
+modalities	O
+.	O
+
+The	O
+conditions	O
+promoting	O
+or	O
+stemming	O
+self	O
+-	O
+reactive	O
+(	O
+SR	O
+)	O
+T	B-ANAT
+cells	I-ANAT
+following	O
+viral	O
+-	O
+induced	O
+tissue	B-ANAT
+damage	O
+thus	O
+need	O
+to	O
+be	O
+better	O
+defined	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+data	O
+demonstrate	O
+the	O
+presence	O
+of	O
+APC	B-COMP
+capable	O
+of	O
+activating	O
+SR	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+both	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+and	O
+the	O
+CNS	B-CHED
+temporally	O
+correlating	O
+with	O
+overt	O
+demyelination	B-DISO
+.	O
+
+Without	O
+these	O
+diagnostic	O
+tools	O
+,	O
+the	O
+geographical	O
+spread	O
+of	O
+new	O
+infections	B-DISO
+,	O
+follow	O
+-	O
+up	O
+of	O
+the	O
+disease	O
+outbreak	O
+and	O
+analysis	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+disease	O
+are	O
+not	O
+possible	O
+.	O
+
+TITLE	O
+:	O
+Prone	O
+position	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+adults	O
+.	O
+
+Ventilation	O
+in	O
+the	O
+prone	O
+position	O
+may	O
+improve	O
+lung	B-ANAT
+mechanics	O
+and	O
+gas	B-ENZY
+exchange	O
+and	O
+could	O
+improve	O
+outcomes	O
+.	O
+
+The	O
+quality	O
+of	O
+the	O
+evidence	O
+for	O
+both	O
+outcomes	O
+was	O
+rated	O
+as	O
+low	O
+as	O
+a	O
+result	O
+of	O
+important	O
+potential	O
+bias	B-SPEC
+and	O
+serious	O
+inconsistency	O
+.	O
+
+Extrapulmonary	O
+loci	O
+of	O
+virus	B-PROC
+replication	I-PROC
+seem	O
+possible	O
+.	O
+
+RESULTS	O
+:	O
+One	O
+hundred	O
+ninety	O
+-	O
+nine	O
+LRT	B-ANAT
+samples	O
+collected	O
+during	O
+the	O
+3	O
+weeks	O
+following	O
+diagnosis	O
+yielded	O
+virus	B-SPEC
+RNA	O
+in	O
+93	O
+%	O
+of	O
+tests	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+Recruitment	B-DISO
+on	O
+Static	O
+and	O
+Dynamic	O
+Lung	B-ANAT
+Strain	O
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+However	O
+,	O
+changes	O
+in	O
+lung	B-PROC
+volumes	I-PROC
+in	O
+response	O
+to	O
+pressures	O
+may	O
+occur	O
+in	O
+injured	O
+lungs	B-ANAT
+and	O
+modify	O
+strain	O
+values	O
+.	O
+
+Lung	B-PROC
+volumes	I-PROC
+were	O
+measured	O
+by	O
+helium	B-CHED
+dilution	O
+and	O
+inductance	O
+plethysmography	O
+.	O
+
+From	O
+both	O
+series	O
+,	O
+recruited	O
+volume	O
+and	O
+lung	B-ANAT
+strain	O
+(	O
+total	O
+,	O
+dynamic	O
+,	O
+and	O
+static	O
+)	O
+were	O
+computed	O
+.	O
+
+An	O
+analysis	O
+restricted	O
+to	O
+the	O
+changes	O
+in	O
+normally	O
+aerated	O
+lung	B-ANAT
+yielded	O
+similar	O
+results	O
+.	O
+
+The	O
+method	O
+of	O
+virus	B-SPEC
+inactivation	B-DISO
+using	O
+a	O
+psoralen	B-CHED
+molecule	O
+appears	O
+to	O
+have	O
+broad	O
+applicability	O
+to	O
+RNA	O
+viruses	B-SPEC
+and	O
+to	O
+leave	O
+both	O
+the	O
+particle	O
+and	O
+RNA	O
+of	O
+the	O
+treated	O
+virus	B-SPEC
+intact	O
+,	O
+while	O
+rendering	O
+the	O
+virus	B-SPEC
+non	O
+-	O
+infectious	B-DISO
+.	O
+
+Systemic	O
+examination	O
+revealed	O
+pyogenic	B-DISO
+liver	I-DISO
+abscess	I-DISO
+and	O
+percutaneous	O
+drainage	B-ANAT
+of	O
+abscess	B-DISO
+disclosed	O
+Klebsiella	B-SPEC
+pneumoniae	I-SPEC
+,	O
+which	O
+was	O
+also	O
+isolated	O
+from	O
+conjunctival	B-DISO
+discharge	I-DISO
+.	O
+
+(	O
+18	O
+)	O
+F	O
+-	O
+Fluorodeoxyglucose	O
+([(	O
+18	O
+)	O
+F	O
+]-	O
+FDG	O
+)-	O
+positron	B-CHED
+emission	B-ANAT
+tomography	O
+/	O
+computed	O
+tomography	O
+(	O
+PET	O
+/	O
+CT	O
+)	O
+as	O
+a	O
+longitudinal	O
+noninvasive	O
+approach	O
+can	O
+be	O
+beneficial	O
+in	O
+providing	O
+biomarkers	O
+for	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+.	O
+
+[(	O
+18	O
+)	O
+F	O
+]-	O
+FDG	O
+-	O
+PET	O
+is	O
+able	O
+to	O
+detect	O
+subtle	O
+changes	O
+in	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+to	O
+contain	O
+a	O
+subclinical	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+However	O
+,	O
+very	O
+little	O
+is	O
+known	O
+about	O
+the	O
+interactions	O
+among	O
+these	O
+accessory	O
+proteins	B-CHED
+.	O
+
+Twenty	O
+-	O
+four	O
+bed	B-DISO
+university	O
+medical	O
+ICU	O
+.	O
+
+Hence	O
+,	O
+sepsis	B-DISO
+patients	O
+with	O
+macrophage	B-DISO
+activation	I-DISO
+syndrome	I-DISO
+features	O
+may	O
+benefit	O
+from	O
+interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+blockade	O
+.	O
+
+Sepsis	B-DISO
+patients	O
+with	O
+multiorgan	O
+dysfunction	O
+syndrome	B-DISO
+and	O
+/	O
+or	O
+shock	O
+(	O
+original	O
+study	O
+)	O
+were	O
+regrouped	O
+based	O
+on	O
+the	O
+presence	O
+or	O
+the	O
+absence	O
+of	O
+concurrent	O
+hepatobiliary	B-ANAT
+dysfunction	O
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+as	O
+features	O
+of	O
+macrophage	B-DISO
+activation	I-DISO
+syndrome	I-DISO
+.	O
+
+To	O
+better	O
+understand	O
+these	O
+processes	O
+,	O
+it	O
+is	O
+important	O
+to	O
+compare	O
+the	O
+phylogenetic	O
+relationships	O
+between	O
+different	O
+agents	O
+to	O
+that	O
+of	O
+their	O
+respective	O
+hosts	B-COMP
+.	O
+
+Interestingly	O
+,	O
+the	O
+sequence	O
+similarities	O
+in	O
+samples	O
+collected	O
+from	O
+the	O
+same	O
+bat	B-ENZY
+species	B-SPEC
+in	O
+different	O
+geographical	O
+areas	O
+were	O
+distinctly	O
+larger	O
+than	O
+the	O
+sequence	O
+similarities	O
+between	O
+samples	O
+from	O
+different	O
+species	B-SPEC
+sampled	O
+at	O
+the	O
+same	O
+location	O
+.	O
+
+Following	O
+an	O
+assessment	O
+of	O
+epidemiologic	O
+risk	O
+factors	O
+,	O
+including	O
+travel	O
+to	O
+countries	O
+with	O
+current	O
+MERS	O
+transmission	O
+and	O
+contact	O
+with	O
+patients	O
+with	O
+confirmed	O
+MERS	O
+within	O
+14	O
+days	O
+,	O
+patients	O
+are	O
+risk	O
+stratified	O
+by	O
+type	O
+of	O
+exposure	O
+coupled	O
+with	O
+symptoms	O
+of	O
+fever	B-PROC
+and	O
+respiratory	O
+illness	O
+.	O
+
+If	O
+criteria	O
+are	O
+met	B-CHED
+,	O
+patients	O
+must	O
+be	O
+immediately	O
+placed	O
+into	O
+airborne	O
+infection	B-DISO
+isolation	O
+(	O
+or	O
+a	O
+private	O
+room	O
+until	O
+this	O
+type	O
+of	O
+isolation	O
+is	O
+available	O
+)	O
+and	O
+the	O
+emergency	B-DISO
+practitioner	O
+must	O
+alert	O
+the	O
+hospital	B-DISO
+infection	I-DISO
+prevention	O
+and	O
+control	O
+team	O
+and	O
+the	O
+local	O
+public	O
+health	O
+department	O
+.	O
+
+ABSTRACT	O
+:	O
+Proton	B-CHED
+transfer	O
+reactions	O
+are	O
+of	O
+crucial	O
+interest	O
+for	O
+the	O
+investigation	O
+of	O
+proteins	B-CHED
+.	O
+
+We	O
+have	O
+investigated	O
+the	O
+accuracy	O
+of	O
+commonly	O
+used	O
+quantum	O
+chemical	O
+methods	O
+for	O
+the	O
+description	O
+of	O
+proton	B-CHED
+transfer	O
+reactions	O
+in	O
+different	O
+environments	O
+(	O
+gas	B-ENZY
+phase	O
+,	O
+COSMO	B-SPEC
+,	O
+QM	O
+/	O
+MM	O
+)	O
+using	O
+the	O
+proton	B-CHED
+transfer	O
+between	O
+the	O
+catalytic	O
+dyad	O
+residues	O
+cysteine	B-CHED
+145	O
+and	O
+histidine	B-CHED
+41	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+main	O
+protease	O
+as	O
+a	O
+case	O
+study	O
+.	O
+
+In	O
+contrast	O
+for	O
+semiempirical	O
+methods	O
+,	O
+the	O
+errors	O
+strongly	O
+diversify	O
+if	O
+one	O
+goes	B-SPEC
+from	O
+gas	B-ENZY
+phase	O
+to	O
+COSMO	B-SPEC
+or	O
+QM	O
+/	O
+MM	O
+.	O
+
+Particular	O
+problems	O
+are	O
+observed	O
+for	O
+the	O
+recent	O
+semiempirical	O
+methods	O
+PM6	O
+and	O
+RM1	O
+,	O
+which	O
+show	O
+the	O
+best	O
+performance	O
+for	O
+gas	B-ENZY
+phase	O
+calculations	O
+but	O
+possess	B-DISO
+larger	O
+errors	O
+in	O
+conjunction	O
+with	O
+COSMO	B-SPEC
+.	O
+
+However	O
+,	O
+the	O
+severity	O
+of	O
+clinical	O
+signs	O
+,	O
+mortality	O
+(	O
+0	O
+-	O
+75	O
+%)	O
+and	O
+fecal	B-ANAT
+PEDV	B-SPEC
+RNA	O
+shedding	O
+titers	O
+varied	O
+among	O
+the	O
+four	O
+S	O
+-	O
+INDEL	O
+Iowa106	O
+-	O
+inoculated	O
+litters	O
+.	O
+
+Prior	O
+infection	B-DISO
+by	O
+S	O
+-	O
+INDEL	B-PROC
+Iowa106	O
+provided	O
+partial	O
+cross	O
+-	O
+protection	O
+to	O
+piglets	O
+against	O
+the	O
+original	O
+PC21A	O
+challenge	O
+at	O
+21	O
+-	O
+29	O
+dpi	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Binational	O
+Border	O
+Infectious	B-DISO
+Disease	I-DISO
+Surveillance	O
+program	O
+began	O
+surveillance	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+SARI	O
+)	O
+on	O
+the	O
+US	O
+-	O
+Mexico	O
+border	B-ANAT
+in	O
+2009	O
+.	O
+
+The	O
+air	O
+emitted	O
+by	O
+15	O
+participants	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+was	O
+sampled	O
+.	O
+
+Of	O
+the	O
+patients	O
+infected	O
+with	O
+influenza	B-PATH
+A	I-PATH
+,	O
+viral	O
+RNA	O
+was	O
+recovered	O
+from	O
+the	O
+air	B-CHED
+emitted	O
+by	O
+9	O
+/	O
+12	O
+patients	O
+using	O
+the	O
+low	O
+-	O
+volume	O
+sampler	O
+;	O
+no	O
+viral	O
+RNA	O
+was	O
+detected	O
+from	O
+air	B-CHED
+emitted	O
+by	O
+patients	O
+with	O
+influenza	B-DISO
+B	O
+(	O
+n	O
+=	O
+3	O
+).	O
+
+The	O
+article	O
+presents	O
+requirements	O
+for	O
+personal	O
+protective	O
+equipment	O
+(	O
+PPE	B-CHED
+)	O
+in	O
+microbiological	O
+laboratories	O
+and	O
+examples	O
+of	O
+selection	O
+and	O
+application	O
+of	O
+disposable	O
+PPE	B-CHED
+.	O
+
+We	O
+determined	O
+the	O
+first	O
+X	O
+-	O
+ray	B-SPEC
+crystal	B-ANAT
+structure	O
+of	O
+FIPV	O
+-	O
+3CL	O
+(	O
+pro	B-PRGE
+)	O
+in	O
+complex	O
+with	O
+the	O
+best	O
+inhibitor	B-CHED
+identified	O
+,	O
+compound	O
+6	O
+,	O
+to	O
+a	O
+resolution	O
+of	O
+2	O
+.	O
+10	O
+Å	O
+to	O
+better	O
+understand	O
+the	O
+structural	O
+basis	O
+for	O
+inhibitor	O
+specificity	O
+.	O
+
+Bronchoscopy	O
+was	O
+performed	O
+on	O
+all	O
+subjects	O
+at	O
+burn	O
+center	O
+admission	O
+and	O
+grading	O
+of	O
+severity	O
+was	O
+documented	O
+using	O
+the	O
+grades	O
+0	O
+to	O
+4	O
+abbreviated	O
+injury	O
+score	O
+(	O
+AIS	B-DISO
+).	O
+
+The	O
+individual	O
+grades	O
+of	O
+the	O
+0	O
+to	O
+4	O
+AIS	B-DISO
+INH	O
+severity	O
+grading	O
+scale	O
+were	O
+not	O
+particularly	O
+robust	O
+in	O
+the	O
+prediction	O
+of	O
+various	O
+outcomes	O
+among	O
+a	O
+population	O
+of	O
+adult	O
+burn	O
+patients	O
+.	O
+
+Investigations	O
+over	O
+the	O
+last	O
+two	O
+decades	O
+have	O
+revolved	O
+around	O
+the	O
+development	B-PROC
+of	O
+rescue	O
+therapies	O
+that	O
+can	O
+be	O
+used	O
+for	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+refractory	O
+hypoxemia	O
+.	O
+
+Finally	O
+,	O
+recent	O
+studies	O
+have	O
+found	O
+that	O
+the	O
+routine	O
+use	O
+of	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+in	O
+severe	O
+ARDS	B-DISO
+does	O
+not	O
+result	O
+in	O
+decreased	O
+mortality	O
+,	O
+although	O
+the	O
+technique	O
+has	O
+not	O
+been	O
+specifically	O
+investigated	O
+as	O
+rescue	O
+therapy	O
+for	O
+severe	O
+refractory	O
+hypoxemia	O
+.	O
+
+This	O
+is	O
+a	O
+retrospective	O
+study	O
+describing	O
+the	O
+radiological	O
+findings	O
+and	O
+evolution	B-PROC
+in	O
+seven	O
+children	O
+with	O
+febrile	B-DISO
+infection	I-DISO
+-	O
+related	O
+epilepsy	B-DISO
+syndrome	B-DISO
+who	O
+presented	O
+from	O
+2009	O
+to	O
+2013	O
+.	O
+
+After	O
+six	O
+to	O
+twelve	O
+months	O
+,	O
+most	O
+of	O
+the	O
+patients	O
+showed	O
+moderate	O
+to	O
+severe	O
+cerebral	B-DISO
+atrophy	I-DISO
+and	O
+by	O
+one	O
+year	O
+,	O
+cerebellar	B-DISO
+atrophy	I-DISO
+was	O
+also	O
+appreciated	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+can	O
+survive	O
+on	O
+surfaces	O
+for	O
+extended	O
+periods	B-PROC
+,	O
+sometimes	O
+up	O
+to	O
+months	O
+.	O
+
+We	O
+investigated	O
+the	O
+spatial	O
+and	O
+cellular	B-PROC
+localization	I-PROC
+of	O
+DPP4	B-PRGE
+to	O
+evaluate	O
+an	O
+association	O
+MERS	O
+clinical	O
+disease	O
+.	O
+
+In	O
+the	O
+parenchyma	B-ANAT
+,	O
+DPP4	B-PRGE
+was	O
+found	O
+principally	O
+in	O
+type	O
+I	O
+and	O
+II	O
+cells	B-COMP
+and	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+and	O
+was	O
+also	O
+detected	O
+in	O
+vascular	B-ANAT
+endothelium	I-ANAT
+(	O
+eg	O
+,	O
+lymphatics	B-ANAT
+)	O
+and	O
+pleural	O
+mesothelia	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+following	O
+cardiovascular	B-ANAT
+surgery	O
+:	O
+current	O
+concepts	O
+and	O
+novel	O
+therapeutic	O
+approaches	O
+.	O
+
+ABSTRACT	O
+:	O
+Silicone	B-CHED
+injections	O
+,	O
+in	O
+particular	O
+illegal	O
+injections	O
+,	O
+carried	O
+out	O
+in	O
+an	O
+aesthetic	O
+purpose	O
+,	O
+can	O
+cause	O
+serious	O
+complications	O
+,	O
+like	O
+silicone	B-CHED
+embolism	B-DISO
+syndrome	B-DISO
+.	O
+
+It	O
+was	O
+the	O
+complications	O
+of	O
+silicone	B-CHED
+injections	O
+which	O
+revealed	O
+a	O
+severe	O
+personality	B-DISO
+disorder	I-DISO
+.	O
+
+A	O
+serious	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+in	O
+a	O
+young	O
+patient	O
+should	O
+raise	O
+suspicion	O
+of	O
+silicone	B-CHED
+embolism	B-DISO
+syndrome	B-DISO
+,	O
+especially	O
+if	O
+there	O
+are	O
+cutaneous	O
+lesions	O
+compatible	O
+with	O
+injections	O
+.	O
+
+Adequate	O
+biosafety	O
+measures	O
+should	O
+be	O
+in	O
+place	O
+at	O
+all	O
+levels	O
+of	O
+the	O
+swine	B-SPEC
+production	O
+chain	O
+,	O
+including	O
+feed	O
+and	O
+feed	O
+ingredients	O
+.	O
+
+This	O
+was	O
+the	O
+second	O
+novel	O
+swine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+detected	O
+in	O
+the	O
+US	O
+since	O
+May	O
+2013	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+conducted	O
+retrospective	O
+testing	O
+of	O
+samples	O
+submitted	O
+to	O
+three	O
+veterinary	O
+diagnostic	O
+laboratories	O
+where	O
+qualifying	O
+biological	O
+samples	O
+were	O
+derived	O
+from	O
+previously	O
+submitted	O
+diagnostic	O
+case	O
+submissions	O
+from	O
+US	O
+commercial	O
+swine	B-SPEC
+farms	O
+with	O
+a	O
+clinical	O
+history	O
+of	O
+enteric	O
+disease	O
+or	O
+from	O
+cases	O
+that	O
+had	O
+been	O
+previously	O
+tested	O
+for	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+,	O
+PEDV	B-SPEC
+,	O
+or	O
+rotavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Intensive	O
+care	O
+unit	O
+surveillance	O
+of	O
+influenza	B-PATH
+infection	B-DISO
+in	O
+France	O
+:	O
+the	O
+2009	O
+/	O
+10	O
+pandemic	O
+and	O
+the	O
+three	O
+subsequent	O
+seasons	O
+.	O
+
+All	O
+severe	O
+influenza	B-DISO
+cases	O
+admitted	O
+to	O
+intensive	O
+care	O
+units	O
+(	O
+ICU	O
+)	O
+were	O
+reported	O
+to	O
+the	O
+Institut	O
+de	O
+Veille	O
+Sanitaire	O
+using	O
+a	O
+standardised	O
+form	O
+:	O
+data	O
+on	O
+demographics	O
+,	O
+immunisation	O
+and	O
+virological	O
+status	O
+,	O
+risk	O
+factors	O
+,	O
+severity	O
+(	O
+e	O
+.	O
+g	O
+.	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+onset	O
+,	O
+mechanical	O
+ventilation	O
+,	O
+extracorporeal	O
+life	O
+support	O
+)	O
+and	O
+outcome	O
+.	O
+
+Most	O
+ICU	O
+patients	O
+were	O
+infected	O
+with	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+,	O
+except	O
+during	O
+the	O
+2011	O
+/	O
+12	O
+winter	O
+season	O
+when	O
+A	O
+(	O
+H3N2	B-CHED
+)-	O
+related	O
+infections	B-DISO
+predominated	O
+.	O
+
+Unfortunately	O
+,	O
+early	O
+investigations	O
+that	O
+used	O
+recycled	O
+""""	O
+pedigree	O
+""""	O
+virus	B-SPEC
+strains	O
+seem	O
+to	O
+have	O
+led	O
+microbiologists	O
+to	O
+dismiss	O
+the	O
+common	O
+folk	O
+belief	O
+that	O
+vARIs	O
+often	O
+follow	O
+chilling	B-DISO
+.	O
+
+Epidemiological	O
+anomalies	O
+such	O
+as	O
+the	O
+repeated	O
+simultaneous	O
+arrival	O
+of	O
+vARIs	O
+over	O
+wide	O
+geographical	O
+areas	O
+,	O
+the	O
+rapid	O
+cessation	O
+of	O
+influenza	B-DISO
+epidemics	O
+,	O
+and	O
+the	O
+low	O
+attack	O
+rate	O
+of	O
+influenza	B-DISO
+within	O
+families	O
+are	O
+compatible	O
+with	O
+M4	O
+,	O
+but	O
+not	O
+M3	O
+(	O
+in	O
+its	O
+simple	O
+form	O
+).	O
+
+Here	O
+,	O
+we	O
+review	O
+researches	O
+related	O
+to	O
+the	O
+pathological	O
+role	O
+of	O
+histone	B-PRGE
+in	O
+context	O
+of	O
+sepsis	B-DISO
+and	O
+ARDS	B-DISO
+and	O
+evaluate	O
+the	O
+potential	O
+value	O
+of	O
+histones	O
+as	O
+biomarkers	O
+and	O
+therapeutic	O
+targets	O
+of	O
+these	O
+diseases	O
+.	O
+
+TITLE	O
+:	O
+Attenuation	O
+mechanism	O
+of	O
+virulent	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strain	O
+with	O
+QX	O
+genotype	O
+by	O
+continuous	O
+passage	O
+in	O
+chicken	O
+embryos	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+virulent	O
+isolate	O
+SDZB0808	O
+of	O
+QX	O
+-	O
+type	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+was	O
+continuously	O
+passaged	O
+in	O
+chicken	B-SPEC
+embryos	B-ANAT
+for	O
+110	O
+generations	O
+.	O
+
+Results	O
+showed	O
+that	O
+with	O
+the	O
+passage	O
+in	O
+chicken	B-SPEC
+embryos	B-ANAT
+,	O
+the	O
+proportion	O
+of	O
+the	O
+viruses	B-SPEC
+with	O
+30bp	O
+deletion	O
+gradually	O
+increased	O
+.	O
+
+Almost	O
+100	O
+%	O
+of	O
+the	O
+viruses	B-SPEC
+in	O
+the	O
+P110	O
+had	O
+30bp	O
+deletion	O
+in	O
+the	O
+replicase	B-PRGE
+1a	I-PRGE
+sequence	I-PRGE
+.	O
+
+This	O
+work	O
+confirmed	O
+the	O
+high	O
+safety	O
+and	O
+immune	O
+efficacy	O
+of	O
+P110	O
+in	O
+SPF	B-PRGE
+chickens	I-PRGE
+.	O
+
+To	O
+determine	O
+whether	O
+these	O
+mutations	O
+lead	O
+to	O
+changes	O
+in	O
+antigenicity	O
+,	O
+as	O
+suggested	O
+by	O
+the	O
+failure	O
+of	O
+PEDV	B-SPEC
+vaccines	O
+in	O
+China	O
+,	O
+we	O
+first	O
+optimized	O
+the	O
+codons	O
+of	O
+typical	O
+S	O
+genes	O
+of	O
+the	O
+CV777	O
+vaccine	O
+strain	O
+(	O
+G1	O
+subtype	O
+)	O
+and	O
+LNCT2	O
+strain	O
+(	O
+G2	O
+subtype	O
+)	O
+and	O
+expressed	B-PROC
+the	O
+recombinant	O
+full	O
+-	O
+length	O
+sequence	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+a	O
+eukaryotic	O
+expression	B-PROC
+system	O
+.	O
+
+The	O
+IgG	B-COMP
+antibody	I-COMP
+levels	O
+of	O
+serum	B-COMP
+from	O
+mice	B-SPEC
+immunized	O
+with	O
+purified	O
+S	B-PRGE
+protein	I-PRGE
+were	O
+markedly	O
+high	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+is	O
+a	O
+viral	O
+respiratory	B-DISO
+disease	I-DISO
+of	O
+serious	O
+consequences	O
+caused	O
+by	O
+MERS	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+A	O
+general	O
+strategy	O
+to	O
+inhibiting	O
+viral	O
+-	O
+1	O
+frameshifting	O
+based	O
+on	O
+upstream	O
+attenuation	O
+duplex	O
+formation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+-	O
+1	O
+programmed	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+(	O
+PRF	B-PROC
+)	O
+as	O
+a	O
+potential	O
+antiviral	B-CHED
+target	O
+has	O
+attracted	O
+interest	O
+because	O
+many	O
+human	B-SPEC
+viral	O
+pathogens	O
+,	O
+including	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+and	O
+coronaviruses	O
+,	O
+rely	O
+on	O
+-	O
+1	O
+PRF	B-PROC
+for	O
+optimal	O
+propagation	O
+.	O
+
+Changes	O
+in	O
+various	O
+hemodynamic	B-PROC
+parameters	O
+after	O
+SAH	B-CHED
+were	O
+analyzed	O
+statistically	O
+.	O
+
+Measurement	O
+of	O
+the	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+index	O
+,	O
+cardiac	B-ANAT
+index	O
+,	O
+and	O
+PVPI	O
+by	O
+PiCCO	O
+-	O
+plus	O
+monitoring	O
+is	O
+useful	O
+for	O
+identifying	O
+pulmonary	B-DISO
+edema	I-DISO
+in	O
+patients	O
+with	O
+SAH	B-CHED
+.	O
+
+The	O
+observed	O
+clinical	O
+improvement	O
+may	O
+partially	O
+be	O
+due	O
+to	O
+the	O
+anti	O
+-	O
+inflammatory	O
+effects	O
+of	O
+PBMC	O
+/	O
+EPO	B-PRGE
+to	O
+promote	O
+tissue	B-PROC
+regeneration	I-PROC
+.	O
+
+However	O
+,	O
+a	O
+complete	O
+genomic	O
+sequence	O
+analysis	O
+showed	O
+that	O
+ck	O
+/	O
+CH	O
+/	O
+LGX	O
+/	O
+130530	O
+was	O
+more	O
+closely	O
+related	O
+to	O
+a	O
+Massachusetts	O
+type	O
+strain	O
+(	O
+95	O
+%	O
+similarity	O
+to	O
+strain	O
+H120	O
+)	O
+than	O
+to	O
+the	O
+tl	O
+/	O
+CH	O
+/	O
+LDT3	O
+/	O
+03	O
+strain	O
+(	O
+86	O
+%),	O
+suggesting	O
+that	O
+recombination	B-PROC
+might	O
+have	O
+occurred	O
+during	O
+the	O
+origin	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+generation	O
+of	O
+computational	O
+models	O
+is	O
+an	O
+alternative	O
+route	O
+to	O
+obtain	O
+reliable	O
+structures	O
+for	O
+the	O
+oligomeric	O
+state	O
+of	O
+membrane	O
+proteins	B-CHED
+.	O
+
+In	O
+the	O
+CP	O
+collection	O
+phase	O
+,	O
+potential	O
+donors	O
+will	O
+be	O
+tested	O
+by	O
+the	O
+enzyme	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+and	O
+the	O
+indirect	O
+fluorescent	O
+antibody	B-COMP
+(	O
+IFA	O
+)	O
+techniques	O
+for	O
+the	O
+presence	O
+of	O
+anti	O
+-	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+.	O
+
+Subjects	O
+with	O
+anti	O
+-	O
+MERS	O
+-	O
+CoV	O
+IFA	O
+titer	O
+of	O
+≥	O
+1	O
+:	O
+160	O
+and	O
+no	O
+clinical	O
+or	O
+laboratory	O
+evidence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+will	O
+be	O
+screened	O
+for	O
+eligibility	O
+for	O
+plasma	B-ANAT
+donation	O
+according	O
+to	O
+standard	O
+donation	O
+criteria	O
+.	O
+
+Post	O
+enrollment	O
+,	O
+patients	O
+will	O
+be	O
+followed	O
+for	O
+clinical	O
+and	O
+laboratory	O
+outcomes	O
+that	O
+include	O
+anti	O
+-	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+and	O
+viral	O
+load	O
+.	O
+
+We	O
+found	O
+that	O
+intravenous	O
+LPS	B-DISO
+induced	O
+a	O
+significant	O
+increase	O
+in	O
+the	O
+activity	O
+of	O
+lung	O
+xanthine	B-PRGE
+oxidoreductase	I-PRGE
+(	O
+XOR	B-PRGE
+),	O
+an	O
+enzyme	O
+which	O
+is	O
+a	O
+major	O
+source	O
+of	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+and	O
+implicated	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+These	O
+results	O
+support	O
+the	O
+testing	O
+of	O
+imatinib	B-CHED
+as	O
+a	O
+novel	O
+pharmacologic	O
+agent	O
+in	O
+the	O
+treatment	O
+of	O
+Gram	O
+-	O
+negative	O
+sepsis	B-DISO
+and	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Altered	O
+Lipid	B-CHED
+Composition	O
+of	O
+Surfactant	B-CHED
+and	O
+Lung	B-ANAT
+Tissue	I-ANAT
+in	O
+Murine	B-SPEC
+Experimental	O
+Malaria	B-PATH
+-	O
+Associated	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+.	O
+
+However	O
+,	O
+little	O
+is	O
+known	O
+about	O
+their	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+high	O
+levels	O
+of	O
+polyunsaturated	B-CHED
+fatty	I-CHED
+acids	I-CHED
+and	O
+the	O
+linoleic	O
+/	O
+oleic	O
+fatty	B-CHED
+acid	I-CHED
+ratio	O
+of	O
+the	O
+latter	O
+reflect	O
+the	O
+fatty	B-CHED
+acid	I-CHED
+composition	O
+of	O
+plasma	B-ANAT
+cholesterol	B-CHED
+esters	I-CHED
+.	O
+
+In	O
+spite	O
+of	O
+the	O
+increased	O
+total	O
+polyunsaturated	B-CHED
+fatty	I-CHED
+acid	I-CHED
+pool	O
+,	O
+which	O
+augments	O
+the	O
+relative	O
+oxidability	O
+of	O
+the	O
+lung	B-ANAT
+membranes	B-ANAT
+,	O
+and	O
+the	O
+presence	O
+of	O
+hemozoin	O
+,	O
+a	O
+known	O
+pro	B-CHED
+-	O
+oxidant	B-CHED
+,	O
+no	O
+excess	O
+oxidative	B-DISO
+stress	I-DISO
+was	O
+detected	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+Plasmodium	B-SPEC
+berghei	I-SPEC
+NK65	O
+infected	O
+mice	B-SPEC
+.	O
+
+Recruitment	B-DISO
+manoeuvres	O
+were	O
+repeated	O
+every	O
+two	O
+hours	O
+for	O
+all	O
+three	O
+groups	O
+.	O
+
+Compared	O
+with	O
+those	O
+in	O
+pre	O
+-	O
+RM	O
+,	O
+pulmonary	B-ANAT
+compliance	O
+,	O
+oxygenation	B-PROC
+index	O
+(	O
+ratio	O
+of	O
+partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+to	O
+fraction	O
+of	O
+inspired	O
+oxygen	B-CHED
+[	O
+PaO2	O
+/	O
+FiO2	O
+])	O
+and	O
+EVLWI	O
+remarkably	O
+improved	O
+in	O
+RM1	O
+,	O
+RM2	O
+,	O
+RM3	O
+and	O
+4	O
+hours	O
+post	O
+-	O
+RRM	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Repeated	O
+recruitment	B-DISO
+manoeuvres	O
+during	O
+lung	B-ANAT
+-	O
+protected	O
+ventilation	O
+can	O
+improve	O
+pulmonary	B-ANAT
+compliance	O
+and	O
+oxygenation	B-PROC
+and	O
+significantly	O
+decrease	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	B-SPEC
+virus	I-SPEC
+(	O
+IFV	B-SPEC
+)	O
+infection	B-DISO
+is	O
+a	O
+common	O
+cause	O
+of	O
+severe	O
+viral	B-DISO
+pneumonia	I-DISO
+associated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+is	O
+difficult	O
+to	O
+control	O
+with	O
+general	O
+immunosuppressive	O
+therapy	O
+including	O
+corticosteroids	B-CHED
+due	O
+to	O
+the	O
+unfavorable	O
+effect	O
+on	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Studies	O
+have	O
+suggested	O
+that	O
+the	O
+excessive	O
+activation	O
+of	O
+the	O
+innate	B-PROC
+immunity	I-PROC
+by	O
+IFV	B-SPEC
+is	O
+responsible	O
+for	O
+severe	O
+pathologies	O
+.	O
+
+ABSTRACT	O
+:	O
+Development	B-PROC
+an	O
+effective	O
+vaccine	O
+against	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+urgent	O
+and	O
+limited	O
+information	O
+is	O
+available	O
+on	O
+vaccination	O
+in	O
+nonhuman	O
+primate	B-SPEC
+(	O
+NHP	O
+)	O
+model	O
+.	O
+
+Monkeys	B-SPEC
+were	O
+euthanized	O
+3	O
+days	O
+after	O
+challenge	O
+and	O
+multiple	O
+specimens	O
+from	O
+tissues	O
+were	O
+collected	O
+for	O
+pathological	O
+,	O
+virological	O
+and	O
+immunological	O
+tests	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+rRBD	O
+vaccine	O
+decreased	O
+viral	O
+load	O
+of	O
+lung	B-ANAT
+,	O
+trachea	B-DISO
+and	O
+oropharyngeal	B-ANAT
+swabs	O
+of	O
+monkeys	B-SPEC
+.	O
+
+Spike	B-PRGE
+protein	I-PRGE
+1	I-PRGE
+(	O
+S1	O
+)	O
+amino	B-CHED
+acid	I-CHED
+identities	O
+between	O
+IBV	B-SPEC
+vaccine	O
+and	O
+challenge	O
+strains	O
+varied	O
+from	O
+76	O
+.	O
+0	O
+%	O
+to	O
+77	O
+.	O
+3	O
+%.	O
+
+TITLE	O
+:	O
+Dynamics	O
+of	O
+avian	B-SPEC
+coronavirus	I-SPEC
+circulation	B-PROC
+in	O
+commercial	O
+and	O
+non	O
+-	O
+commercial	O
+birds	B-SPEC
+in	O
+Asia	O
+--	O
+a	O
+review	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+novel	O
+and	O
+highly	O
+pathogenic	O
+human	B-SPEC
+coronavirus	I-SPEC
+and	O
+has	O
+quickly	O
+spread	O
+to	O
+other	O
+countries	O
+in	O
+the	O
+Middle	O
+East	O
+,	O
+Europe	O
+,	O
+North	O
+Africa	O
+and	O
+Asia	O
+since	O
+2012	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+ORF4b	O
+inhibits	O
+the	O
+production	O
+of	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+through	O
+a	O
+direct	O
+interaction	O
+with	O
+IKKε	O
+/	O
+TBK1	B-FUNC
+in	O
+the	O
+cytoplasm	B-COMP
+,	O
+and	O
+also	O
+in	O
+the	O
+nucleus	B-COMP
+with	O
+unknown	O
+mechanism	O
+.	O
+
+Plants	B-SPEC
+have	O
+the	O
+potential	O
+to	O
+mass	O
+-	O
+produce	O
+pharmaceutical	B-CHED
+products	O
+with	O
+less	O
+cost	O
+than	O
+traditional	O
+methods	O
+.	O
+
+Topics	O
+addressed	O
+include	O
+;	O
+transformation	B-DISO
+and	O
+expression	B-PROC
+systems	O
+,	O
+plant	B-SPEC
+bioreactors	O
+,	O
+safety	O
+concerns	O
+,	O
+and	O
+various	O
+opportunities	O
+to	O
+produce	O
+topical	O
+applications	O
+and	O
+health	O
+supplements	O
+.	O
+
+ABSTRACT	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+nCoV	O
+)	O
+belongs	O
+to	O
+the	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+,	O
+which	O
+includes	O
+the	O
+virus	B-SPEC
+that	O
+causes	O
+SARS	B-DISO
+,	O
+or	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+a	O
+New	O
+Miniaturized	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+System	O
+With	O
+Integrated	O
+Rotary	O
+Blood	O
+Pump	O
+to	O
+a	O
+Standard	O
+System	O
+in	O
+a	O
+Porcine	B-SPEC
+Model	O
+of	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+.	O
+
+Pigs	B-SPEC
+were	O
+assigned	O
+to	O
+the	O
+following	O
+three	O
+groups	O
+:	O
+group	O
+1	O
+(	O
+n	O
+=	O
+4	O
+):	O
+control	O
+group	O
+with	O
+conventional	O
+ventilation	O
+;	O
+group	O
+2	O
+(	O
+n	O
+=	O
+5	O
+):	O
+standard	O
+vv	O
+-	O
+ECMO	O
+;	O
+group	O
+3	O
+(	O
+n	O
+=	O
+5	O
+):	O
+vv	O
+-	O
+ILIAS	O
+.	O
+
+Mean	O
+carbon	B-CHED
+dioxide	I-CHED
+transfer	O
+was	O
+comparable	O
+between	O
+the	O
+conventional	O
+ECMO	O
+and	O
+ILIAS	O
+(	O
+211	O
+.	O
+36	O
+±	O
+78	O
+.	O
+39	O
+mL	O
+/	O
+min	O
+vs	O
+.	O
+219	O
+.	O
+99	O
+±	O
+76	O
+.	O
+72	O
+mL	O
+/	O
+min	O
+,	O
+P	O
+=	O
+n	O
+.	O
+s	O
+.).	O
+
+Coronavirus	B-SPEC
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+detected	O
+.	O
+
+TITLE	O
+:	O
+Costly	O
+Lessons	O
+From	O
+the	O
+2015	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Outbreak	O
+in	O
+Korea	O
+.	O
+
+With	O
+this	O
+number	O
+,	O
+Korea	O
+becomes	O
+second	O
+only	O
+to	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+in	O
+the	O
+ranking	O
+of	O
+cumulative	O
+MERS	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+A	O
+New	O
+Measure	O
+for	O
+Assessing	O
+the	O
+Public	O
+Health	O
+Response	O
+to	O
+a	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	O
+Outbreak	O
+.	O
+
+PEDV	B-SPEC
+had	O
+differing	O
+impacts	O
+for	O
+subsectors	O
+of	O
+the	O
+pork	O
+industry	O
+.	O
+
+This	O
+article	O
+also	O
+identifies	O
+future	O
+considerations	O
+motivated	O
+by	O
+the	O
+appearance	O
+of	O
+PEDV	B-SPEC
+in	O
+the	O
+United	O
+States	O
+,	O
+such	O
+as	O
+discussions	O
+of	O
+industry	O
+-	O
+wide	O
+efficiency	O
+and	O
+competitive	O
+advantage	O
+,	O
+the	O
+future	O
+role	O
+of	O
+PEDV	B-SPEC
+vaccines	O
+,	O
+enhancement	O
+in	O
+biosecurity	O
+measures	O
+,	O
+and	O
+consumer	O
+perceptions	O
+of	O
+food	O
+safety	O
+and	O
+insecurity	O
+.	O
+
+Additionally	O
+,	O
+a	O
+total	O
+of	O
+71	O
+peptides	B-CHED
+with	O
+9	O
+-	O
+mer	O
+core	O
+sequence	O
+were	O
+identified	O
+as	O
+helper	B-ANAT
+T	I-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+,	O
+and	O
+34	O
+peptides	B-CHED
+were	O
+identified	O
+as	O
+CTL	B-ANAT
+epitopes	O
+.	O
+
+In	O
+this	O
+prospective	O
+observational	O
+study	O
+,	O
+we	O
+included	O
+all	O
+consecutive	O
+adults	O
+,	O
+over	O
+a	O
+3	O
+-	O
+year	O
+period	O
+,	O
+who	O
+fulfilled	O
+criteria	O
+for	O
+ARDS	B-DISO
+by	O
+the	O
+Berlin	O
+definition	O
+.	O
+
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+score	O
+,	O
+shock	O
+,	O
+low	O
+PaO2	O
+/	O
+FIO2	O
+,	O
+and	O
+ARDS	B-DISO
+severity	O
+are	O
+associated	O
+with	O
+increased	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+extracorporeal	O
+CO2	B-CHED
+removal	O
+on	O
+right	O
+ventricular	B-ANAT
+and	O
+hemodynamic	B-PROC
+parameters	O
+in	O
+a	O
+patient	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+High	O
+ventilatory	O
+pressures	O
+were	O
+needed	O
+because	O
+of	O
+hypoxia	B-DISO
+and	O
+severe	O
+hypercapnia	B-DISO
+with	O
+respiratory	B-DISO
+acidosis	I-DISO
+,	O
+resulting	O
+in	O
+right	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+with	O
+impaired	B-DISO
+haemodynamic	O
+stability	O
+.	O
+
+Besides	O
+providing	O
+adequate	O
+gas	B-ENZY
+exchange	O
+,	O
+extracorporeal	O
+assist	O
+devices	O
+may	O
+be	O
+helpful	O
+in	O
+ameliorating	O
+right	O
+ventricular	O
+dysfunction	O
+during	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Current	O
+incidence	O
+and	O
+outcome	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Also	O
+,	O
+we	O
+have	O
+reviewed	O
+the	O
+data	O
+on	O
+survival	O
+reported	O
+in	O
+observational	O
+and	O
+randomized	O
+controlled	O
+trials	O
+,	O
+discussed	O
+how	O
+the	O
+current	O
+ARDS	B-DISO
+definition	O
+modifies	O
+the	O
+true	O
+incidence	O
+of	O
+ARDS	B-DISO
+,	O
+and	O
+briefly	O
+mentioned	O
+recent	O
+approaches	O
+that	O
+appear	O
+to	O
+improve	O
+ARDS	B-DISO
+outcome	O
+.	O
+
+Here	O
+we	O
+show	O
+in	O
+Chinese	O
+macaques	B-SPEC
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+traversed	O
+the	O
+mucosa	B-ANAT
+through	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+within	O
+2	O
+days	O
+,	O
+resulting	O
+in	O
+extensive	O
+mucosal	B-ANAT
+infiltration	B-DISO
+by	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+MAC387	O
+(+),	O
+and	O
+CD163	B-PRGE
+(+)	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+followed	O
+by	O
+limited	O
+viral	B-PROC
+replication	I-PROC
+in	O
+the	O
+lung	B-ANAT
+but	O
+persistent	O
+viral	B-DISO
+shedding	I-DISO
+into	O
+the	O
+upper	O
+airway	B-ANAT
+.	O
+
+Besides	O
+,	O
+quite	O
+a	O
+few	O
+nucleoside	B-CHED
+anti	O
+-	O
+HCV	B-SPEC
+agents	O
+are	O
+being	O
+evaluated	O
+in	O
+clinical	O
+trials	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+during	O
+protective	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+prevalence	O
+,	O
+predictors	O
+,	O
+and	O
+clinical	O
+impact	O
+.	O
+
+Independent	O
+risk	O
+factors	O
+for	O
+hospital	O
+mortality	O
+included	O
+severe	O
+ACP	B-DISO
+along	O
+with	O
+male	O
+gender	O
+,	O
+age	O
+,	O
+SAPS	B-PRGE
+II	I-PRGE
+,	O
+shock	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+,	O
+respiratory	O
+rate	O
+,	O
+and	O
+driving	O
+pressure	O
+,	O
+while	O
+prone	O
+position	O
+was	O
+protective	O
+.	O
+
+We	O
+propose	O
+a	O
+simple	O
+clinical	O
+risk	O
+score	O
+for	O
+early	O
+identification	O
+of	O
+ACP	B-DISO
+that	O
+could	O
+trigger	O
+specific	O
+therapeutic	O
+strategies	O
+to	O
+reduce	O
+RV	O
+afterload	O
+.	O
+
+TITLE	O
+:	O
+Crystal	B-ANAT
+Structure	O
+of	O
+Feline	B-DISO
+Infectious	I-DISO
+Peritonitis	I-DISO
+Virus	B-SPEC
+Main	O
+Protease	O
+in	O
+Complex	O
+with	O
+Synergetic	O
+Dual	O
+Inhibitors	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+an	O
+enteropathogenic	O
+coronavirus	B-SPEC
+causing	O
+lethal	O
+watery	B-DISO
+diarrhea	I-DISO
+in	O
+piglets	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+PEDV	B-PRGE
+-	I-PRGE
+encoded	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+,	O
+nsp5	B-PRGE
+,	O
+is	O
+an	O
+IFN	B-PRGE
+antagonist	B-PROC
+that	O
+proteolytically	O
+cleaves	O
+the	O
+nuclear	B-PRGE
+transcription	I-PRGE
+factor	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+)	O
+essential	O
+modulator	O
+(	O
+NEMO	O
+),	O
+an	O
+essential	O
+adaptor	O
+bridging	O
+interferon	B-PRGE
+-	I-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+and	O
+NF	O
+-	O
+κB	O
+activation	O
+.	O
+
+These	O
+data	O
+show	O
+that	O
+PEDV	B-PRGE
+nsp5	I-PRGE
+disrupts	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+signaling	B-PROC
+by	O
+cleaving	O
+NEMO	O
+.	O
+
+During	O
+coevolution	O
+with	O
+its	O
+hosts	B-COMP
+,	O
+PEDV	B-SPEC
+has	O
+acquired	O
+mechanisms	O
+to	O
+subvert	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+for	O
+its	O
+survival	O
+advantage	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+due	O
+to	O
+Inhalation	B-PROC
+of	O
+Baby	O
+Powder	O
+and	O
+Successfully	O
+Treated	O
+with	O
+Venous	O
+-	O
+Venous	B-ANAT
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+.	O
+
+The	O
+crystal	B-ANAT
+structure	O
+of	O
+MERS	O
+-	O
+CoV	O
+Mpro	O
+indicates	O
+that	O
+it	O
+shares	O
+a	O
+similar	O
+scaffold	O
+to	O
+that	O
+of	O
+other	O
+coronaviral	O
+Mpro	O
+and	O
+consists	O
+of	O
+chymotrypsin	B-PRGE
+-	O
+like	O
+domains	O
+I	O
+and	O
+II	O
+and	O
+a	O
+helical	O
+domain	O
+III	O
+of	O
+five	O
+helices	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+is	O
+a	O
+key	O
+mediator	O
+of	O
+pulmonary	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+.	O
+
+HCT	O
+patients	O
+with	O
+a	O
+rising	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+had	O
+70	O
+%	O
+mortality	O
+compared	O
+with	O
+13	O
+%	O
+mortality	O
+for	O
+those	O
+without	O
+(	O
+OR	O
+16	O
+.	O
+3	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+3	O
+-	O
+197	O
+.	O
+8	O
+,	O
+P	O
+=	O
+0	O
+.	O
+028	O
+).	O
+
+TITLE	O
+:	O
+Computational	O
+simulation	O
+indicates	O
+that	O
+moderately	O
+high	O
+-	O
+frequency	O
+ventilation	O
+can	O
+allow	O
+safe	O
+reduction	O
+of	O
+tidal	O
+volumes	O
+and	O
+airway	B-ANAT
+pressures	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severity	O
+of	O
+exacerbation	O
+in	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+due	O
+to	O
+the	O
+overlap	O
+of	O
+obstructive	B-DISO
+sleep	I-DISO
+apnea	I-DISO
+syndrome	I-DISO
+(	O
+OSAS	B-DISO
+)	O
+is	O
+not	O
+known	O
+.	O
+
+They	O
+were	O
+evaluated	O
+for	O
+OSAS	B-DISO
+with	O
+full	O
+polysomnography	O
+after	O
+the	O
+exacerbation	O
+subsided	O
+and	O
+analysed	O
+depending	O
+on	O
+presence	O
+or	O
+absence	O
+of	O
+overlap	O
+syndrome	O
+.	O
+
+Of	O
+51	O
+patients	O
+,	O
+13	O
+had	O
+OSAS	B-DISO
+i	O
+.	O
+e	O
+.	O
+the	O
+prevalence	O
+of	O
+overlap	O
+in	O
+AECOPD	O
+was	O
+25	O
+.	O
+5	O
+%.	O
+
+AECOPD	O
+have	O
+a	O
+high	O
+prevalence	O
+of	O
+OSAS	B-DISO
+.	O
+
+The	O
+report	O
+highlights	O
+the	O
+importance	O
+of	O
+early	O
+diagnosis	O
+and	O
+aggressive	B-DISO
+therapy	O
+in	O
+the	O
+management	O
+of	O
+ARDS	B-DISO
+,	O
+and	O
+summarizes	O
+the	O
+published	O
+literature	O
+on	O
+this	O
+rarely	O
+reported	O
+complication	B-DISO
+of	O
+pediatric	O
+DKA	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+humoral	O
+immune	B-PROC
+status	I-PROC
+in	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+infected	O
+sows	O
+under	O
+field	O
+conditions	O
+.	O
+
+Currently	O
+,	O
+available	O
+vaccines	O
+are	O
+not	O
+completely	O
+effective	O
+and	O
+feedback	O
+methods	O
+utilizing	O
+PEDV	B-SPEC
+infected	O
+material	O
+has	O
+variable	O
+success	O
+in	O
+preventing	O
+reinfection	O
+.	O
+
+TITLE	O
+:	O
+HEALTH	O
+-	O
+SCREENING	O
+PROTOCOLS	O
+FOR	O
+VINACEOUS	O
+AMAZONS	O
+(	O
+AMAZONA	B-SPEC
+VINACEA	I-SPEC
+)	O
+IN	O
+A	O
+REINTRODUCTION	O
+PROJECT	O
+.	O
+
+The	O
+majority	O
+of	O
+samples	O
+returned	O
+negative	O
+results	O
+,	O
+with	O
+the	O
+exception	O
+of	O
+two	O
+individuals	O
+that	O
+tested	O
+positive	O
+for	O
+C	O
+.	O
+psittaci	O
+in	O
+the	O
+first	O
+sampling	O
+and	O
+for	O
+Ascaridia	B-SPEC
+spp	B-ENZY
+.	O
+
+TITLE	O
+:	O
+Contact	O
+tracing	O
+the	O
+first	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+case	O
+in	O
+the	O
+Philippines	O
+,	O
+February	O
+2015	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+causes	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+which	O
+is	O
+a	O
+fatal	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+there	O
+are	O
+no	O
+effective	O
+therapeutic	O
+medicines	O
+or	O
+vaccines	O
+.	O
+
+Here	O
+we	O
+demonstrated	O
+that	O
+genetic	O
+silencing	O
+or	O
+knockout	O
+of	O
+Pin1	B-PRGE
+resulted	O
+in	O
+decreased	O
+FCoV	O
+replication	O
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Vitamin	B-CHED
+D	I-CHED
+/	O
+VDR	B-PRGE
+signaling	B-PROC
+attenuates	O
+lipopolysaccharide	O
+‑	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+by	O
+maintaining	O
+the	O
+integrity	O
+of	O
+the	O
+pulmonary	O
+epithelial	O
+barrier	O
+.	O
+
+This	O
+was	O
+investigated	O
+by	O
+exposing	O
+wild	O
+‑	O
+type	O
+(	O
+WT	O
+)	O
+and	O
+VDR	B-PRGE
+knockout	O
+C57BL	O
+/	O
+6J	O
+mice	B-SPEC
+to	O
+LPS	B-DISO
+,	O
+then	O
+comparing	O
+the	O
+healthy	O
+and	O
+LPS	O
+‑	O
+treated	O
+mice	B-SPEC
+lungs	B-ANAT
+and	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+).	O
+
+More	O
+specifically	O
+,	O
+lung	B-ANAT
+histology	O
+,	O
+mRNA	B-CHED
+levels	O
+of	O
+proinflammatory	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+and	O
+protein	B-PROC
+expression	B-PROC
+levels	O
+of	O
+tight	B-COMP
+junction	I-COMP
+proteins	B-CHED
+were	O
+determined	O
+.	O
+
+Phylogenetic	O
+analyses	O
+demonstrate	O
+that	O
+the	O
+viruses	B-SPEC
+in	O
+Nigeria	O
+are	O
+genetically	O
+distinct	O
+from	O
+those	O
+reported	O
+in	O
+the	O
+Arabian	O
+peninsula	O
+.	O
+
+GJs	O
+play	O
+a	O
+major	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+infection	B-DISO
+-	O
+associated	O
+inflammation	B-DISO
+.	O
+
+Mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infection	B-DISO
+-	O
+induced	O
+demyelination	B-DISO
+is	O
+one	O
+of	O
+the	O
+best	O
+-	O
+studied	O
+experimental	O
+animal	B-SPEC
+models	O
+for	O
+MS	O
+.	O
+
+After	O
+infection	B-DISO
+,	O
+a	O
+significant	O
+amount	O
+of	O
+Cx43	B-PRGE
+was	O
+retained	O
+in	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+/	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+Golgi	B-COMP
+intermediate	O
+complex	O
+(	O
+ER	O
+/	O
+ERGIC	B-COMP
+)	O
+and	O
+GJ	O
+plaque	B-DISO
+formation	B-PROC
+was	O
+impaired	B-DISO
+at	O
+the	O
+cell	B-COMP
+surface	I-COMP
+,	O
+as	O
+evidenced	O
+by	O
+a	O
+reduction	O
+of	O
+the	O
+Triton	B-CHED
+X	I-CHED
+-	I-CHED
+100	I-CHED
+insoluble	B-ANAT
+fraction	I-ANAT
+of	O
+Cx43	B-PRGE
+.	O
+
+In	O
+addition	O
+,	O
+results	O
+show	O
+that	O
+MHV	B-SPEC
+infection	B-DISO
+impairs	O
+Cx43	O
+expression	B-PROC
+in	O
+addition	O
+to	O
+gap	B-COMP
+junction	I-COMP
+communication	O
+in	O
+primary	O
+astrocytes	B-ANAT
+.	O
+
+After	O
+infection	B-DISO
+,	O
+Cx43	O
+did	O
+not	O
+traffic	O
+normally	O
+to	O
+the	O
+membrane	B-COMP
+to	O
+form	O
+gap	B-COMP
+junction	I-COMP
+plaques	B-DISO
+,	O
+and	O
+that	O
+could	O
+be	O
+the	O
+basis	O
+of	O
+reduced	O
+functional	O
+gap	B-COMP
+junction	I-COMP
+coupling	O
+between	O
+astrocytes	B-ANAT
+.	O
+
+This	O
+may	O
+provide	O
+a	O
+basis	O
+for	O
+understanding	O
+how	O
+structural	O
+alterations	O
+of	O
+astrocytic	B-ANAT
+gap	B-COMP
+junctions	I-COMP
+can	O
+disrupt	O
+gap	B-COMP
+junction	I-COMP
+communication	O
+between	O
+other	O
+CNS	B-CHED
+cells	B-COMP
+in	O
+altered	O
+CNS	B-CHED
+environments	O
+due	O
+to	O
+infection	B-DISO
+and	O
+inflammation	B-DISO
+.	O
+
+More	O
+specifically	O
+,	O
+alteration	O
+of	O
+Cx43	B-PRGE
+may	O
+be	O
+the	O
+basis	O
+of	O
+the	O
+destabilization	O
+of	O
+Cx47	B-PRGE
+in	O
+oligodendrocytes	B-ANAT
+seen	O
+in	O
+and	O
+around	O
+inflammatory	O
+demyelinating	O
+plaques	B-DISO
+in	O
+MS	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+An	O
+orthopoxvirus	B-SPEC
+-	O
+based	O
+vaccine	O
+reduces	O
+virus	B-SPEC
+excretion	B-PROC
+after	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+dromedary	B-SPEC
+camels	O
+.	O
+
+The	O
+viral	O
+yields	O
+in	O
+(+)-	O
+catechin	B-CHED
+-	O
+treated	O
+cultures	O
+were	O
+reduced	O
+by	O
+almost	O
+three	O
+log10	O
+units	O
+.	O
+
+Quantitative	O
+real	O
+-	O
+time	O
+PCR	O
+analysis	O
+of	O
+the	O
+TGEV	B-SPEC
+genome	O
+revealed	O
+that	O
+TGEV	B-SPEC
+RNA	B-PROC
+replication	I-PROC
+was	O
+restricted	O
+after	O
+(+)-	O
+catechin	B-CHED
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Biodegradable	O
+DNA	O
+Nanoparticles	B-CHED
+that	O
+Provide	O
+Widespread	O
+Gene	B-PROC
+Delivery	I-PROC
+in	O
+the	O
+Brain	B-ANAT
+.	O
+
+We	O
+report	O
+the	O
+phylogenetic	O
+relationship	O
+of	O
+swine	B-SPEC
+enteric	O
+coronaviruses	O
+collected	O
+in	O
+Italy	O
+during	O
+2007	O
+-	O
+2014	O
+and	O
+identify	O
+a	O
+drastic	O
+shift	O
+in	O
+PEDV	B-SPEC
+strain	O
+variability	O
+and	O
+a	O
+new	O
+swine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+generated	O
+by	O
+recombination	B-PROC
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+PEDV	B-SPEC
+.	O
+
+The	O
+coronavirus	B-SPEC
+referred	O
+to	O
+as	O
+PED	O
+virus	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+was	O
+determined	O
+to	O
+be	O
+the	O
+etiologic	O
+agent	O
+of	O
+this	O
+disease	O
+in	O
+the	O
+late	O
+1970s	O
+.	O
+
+It	O
+is	O
+hoped	O
+that	O
+this	O
+review	O
+will	O
+stimulate	O
+further	O
+basic	O
+and	O
+applied	O
+studies	O
+and	O
+encourage	O
+collaboration	O
+among	O
+producers	O
+,	O
+researchers	O
+,	O
+and	O
+swine	B-SPEC
+veterinarians	O
+to	O
+provide	O
+answers	O
+that	O
+improve	O
+our	O
+understanding	O
+of	O
+PEDV	B-SPEC
+and	O
+PED	O
+in	O
+an	O
+effort	B-PROC
+to	O
+eliminate	O
+this	O
+economically	O
+significant	O
+viral	B-DISO
+disease	I-DISO
+,	O
+which	O
+emerged	O
+or	O
+re	O
+-	O
+emerged	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Bat	B-SPEC
+origin	O
+of	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+Various	O
+species	B-SPEC
+of	O
+horseshoe	B-SPEC
+bats	I-SPEC
+in	O
+China	O
+have	O
+been	O
+found	O
+to	O
+harbor	O
+genetically	O
+diverse	O
+SARS	B-DISO
+-	O
+like	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Coronaviruses	O
+:	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+pathogens	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+:	O
+virus	B-SPEC
+-	O
+host	B-COMP
+cell	I-COMP
+interactions	O
+and	O
+implications	O
+on	O
+pathogenesis	O
+.	O
+
+Currently	O
+,	O
+the	O
+pathogenesis	B-DISO
+of	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+remains	O
+poorly	O
+understood	O
+.	O
+
+Human	B-SPEC
+respiratory	O
+epithelial	B-ANAT
+cells	I-ANAT
+are	O
+highly	O
+susceptible	O
+to	O
+MERS	O
+-	O
+CoV	O
+and	O
+can	O
+support	O
+productive	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+CDC42	B-PRGE
+Use	I-PRGE
+in	O
+Viral	O
+Cell	B-COMP
+Entry	O
+Processes	O
+by	O
+RNA	O
+Viruses	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+the	O
+current	O
+literature	O
+on	O
+the	O
+role	O
+of	O
+Cdc42	B-PRGE
+in	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)-	O
+1	O
+cell	B-COMP
+entry	O
+,	O
+which	O
+represents	O
+the	O
+most	O
+investigated	O
+instance	O
+of	O
+Cdc42	B-PRGE
+function	O
+in	O
+viral	O
+cell	B-COMP
+entry	O
+processes	O
+,	O
+and	O
+also	O
+review	O
+evidence	O
+of	O
+Cdc42	B-PRGE
+use	O
+in	O
+other	O
+RNA	O
+virus	B-SPEC
+cell	B-COMP
+entries	O
+,	O
+demonstrating	O
+prime	O
+areas	O
+for	O
+more	O
+extensive	O
+research	O
+using	O
+similar	O
+techniques	O
+.	O
+
+The	O
+numerical	O
+analysis	O
+shows	O
+that	O
+the	O
+reasons	O
+of	O
+the	O
+outbreak	O
+spread	O
+quickly	O
+are	O
+lack	O
+of	O
+self	O
+-	O
+protection	O
+sense	B-PROC
+and	O
+targeted	B-PROC
+control	O
+measures	O
+.	O
+
+Crystalline	O
+lattices	O
+of	O
+polyomavirus	B-SPEC
+-	O
+like	O
+particles	O
+were	O
+observed	O
+in	O
+the	O
+patient	O
+'	O
+s	O
+lung	B-ANAT
+by	O
+electron	O
+microscopy	O
+.	O
+
+WUPyV	O
+was	O
+detected	O
+in	O
+the	O
+lung	B-ANAT
+and	O
+other	O
+tissues	B-ANAT
+by	O
+real	O
+-	O
+time	O
+quantitative	O
+PCR	O
+and	O
+identified	O
+in	O
+the	O
+lung	B-ANAT
+and	O
+trachea	B-DISO
+by	O
+immunohistochemistry	O
+.	O
+
+We	O
+will	O
+also	O
+present	O
+our	O
+latest	O
+results	O
+on	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	I-PRGE
+and	O
+its	O
+potential	O
+as	O
+an	O
+antiviral	B-CHED
+drug	I-CHED
+target	O
+.	O
+
+TITLE	O
+:	O
+A	O
+multicenter	O
+retrospective	O
+survey	O
+of	O
+poisoning	O
+after	O
+ingestion	O
+of	O
+herbicides	B-CHED
+containing	O
+glyphosate	B-CHED
+potassium	B-CHED
+salt	I-CHED
+or	O
+other	O
+glyphosate	B-CHED
+salts	B-CHED
+in	O
+Japan	O
+.	O
+
+Viral	O
+RNA	O
+was	O
+amplified	O
+from	O
+acute	O
+-	O
+phase	O
+serum	B-COMP
+specimens	O
+of	O
+15	O
+patients	O
+,	O
+and	O
+full	O
+spike	O
+gene	O
+-	O
+coding	O
+sequencing	O
+was	O
+obtained	O
+from	O
+10	O
+patients	O
+who	O
+formed	O
+a	O
+discrete	O
+cluster	O
+;	O
+sequences	O
+from	O
+specimens	O
+of	O
+9	O
+patients	O
+were	O
+closely	O
+related	O
+.	O
+
+Similar	O
+gene	O
+sequences	O
+among	O
+patients	O
+unlinked	O
+by	O
+time	O
+or	O
+location	O
+suggest	O
+unrecognized	O
+viral	B-PROC
+transmission	I-PROC
+.	O
+
+TITLE	O
+:	O
+Potential	O
+Broad	O
+Spectrum	O
+Inhibitors	B-CHED
+of	O
+the	O
+Coronavirus	B-SPEC
+3CLpro	O
+:	O
+A	O
+Virtual	O
+Screening	O
+and	O
+Structure	O
+-	O
+Based	O
+Drug	O
+Design	O
+Study	O
+.	O
+
+Treatment	O
+of	O
+G6PD	B-ENZY
+-	O
+knockdown	O
+cells	B-COMP
+with	O
+siRNA	O
+against	O
+HSCARG	B-PRGE
+enhanced	O
+the	O
+DNA	O
+binding	O
+activity	O
+of	O
+NF	O
+-	O
+κB	O
+and	O
+the	O
+expression	B-PROC
+of	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+MX1	B-PRGE
+,	O
+but	O
+suppressed	O
+the	O
+expression	B-PROC
+of	O
+viral	O
+genes	O
+;	O
+however	O
+,	O
+the	O
+overexpression	B-PROC
+of	O
+HSCARG	B-PRGE
+inhibited	O
+the	O
+antiviral	B-PROC
+response	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+first	O
+known	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	O
+),	O
+associated	O
+with	O
+infection	B-DISO
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	O
+),	O
+occurred	O
+in	O
+2012	O
+in	O
+Jordan	O
+but	O
+were	O
+reported	O
+retrospectively	O
+.	O
+
+Most	O
+human	B-SPEC
+cases	O
+of	O
+MERS	O
+have	O
+been	O
+linked	O
+to	O
+lapses	O
+in	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+(	O
+IPC	B-CHED
+)	O
+in	O
+healthcare	O
+settings	O
+,	O
+with	O
+approximately	O
+20	O
+%	O
+of	O
+all	O
+virus	B-SPEC
+detections	O
+reported	O
+among	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+and	O
+higher	O
+exposures	O
+in	O
+those	O
+with	O
+occupations	O
+that	O
+bring	O
+them	O
+into	O
+close	O
+contact	O
+with	O
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+Indolosesquiterpenoid	O
+Xiamycins	O
+C	O
+-	O
+E	O
+from	O
+a	O
+Halophilic	O
+Actinomycete	B-SPEC
+.	O
+
+The	O
+antiviral	O
+activity	O
+of	O
+xiamycin	O
+D	O
+(	O
+2	O
+)	O
+was	O
+also	O
+supported	O
+by	O
+both	O
+Western	O
+blotting	O
+of	O
+the	O
+GP2	B-PRGE
+spike	I-PRGE
+and	O
+GP6	B-PRGE
+nucleocapsid	I-PRGE
+protein	B-PROC
+synthesis	I-PROC
+of	O
+PEDV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+April	O
+2013	O
+,	O
+a	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+epidemic	O
+began	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Our	O
+study	O
+demonstrated	O
+that	O
+RT	O
+-	O
+PCR	O
+assays	O
+functioned	O
+well	O
+to	O
+detect	O
+PEDV	B-SPEC
+and	O
+that	O
+the	O
+gN	O
+assay	O
+was	O
+slightly	O
+better	O
+.	O
+
+TITLE	O
+:	O
+Multi	O
+-	O
+Organ	B-ANAT
+Damage	O
+in	O
+Human	B-PRGE
+Dipeptidyl	I-PRGE
+Peptidase	I-PRGE
+4	I-PRGE
+Transgenic	B-SPEC
+Mice	I-SPEC
+Infected	O
+with	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+-	O
+Coronavirus	B-SPEC
+.	O
+
+Importantly	O
+,	O
+the	O
+mice	B-SPEC
+exhibited	O
+symptoms	O
+of	O
+paralysis	O
+with	O
+high	O
+viral	O
+burden	O
+and	O
+viral	O
+positive	O
+neurons	B-ANAT
+on	O
+day	O
+9	O
+.	O
+
+Fourteen	O
+subjects	O
+,	O
+including	O
+3	O
+health	O
+-	O
+care	O
+workers	O
+,	O
+met	B-CHED
+study	O
+criteria	O
+.	O
+
+Declining	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+levels	O
+correlated	O
+with	O
+clinical	O
+improvement	O
+despite	O
+continued	O
+positive	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+results	O
+.	O
+
+Those	O
+who	O
+survived	O
+the	O
+acute	B-DISO
+infection	I-DISO
+and	O
+its	O
+complications	O
+remained	O
+well	O
+after	O
+1	O
+y	O
+in	O
+our	O
+study	O
+.	O
+
+The	O
+role	O
+of	O
+ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+warrants	O
+urgent	O
+further	O
+evaluation	O
+.	O
+
+Eleven	O
+subjects	O
+received	O
+ribavirin	B-CHED
+and	O
+peginterferon	O
+α	O
+-	O
+2a	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+feline	B-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+gene	B-PROC
+mutations	I-PROC
+as	O
+a	O
+tool	O
+to	O
+diagnose	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+Results	O
+Specificity	O
+of	O
+RT	O
+-	O
+nPCR	B-PRGE
+was	O
+100	O
+%	O
+in	O
+all	O
+materials	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+in	O
+serum	B-COMP
+/	O
+plasma	B-ANAT
+83	O
+.	O
+9	O
+-	O
+100	O
+.	O
+0	O
+;	O
+95	O
+%	O
+CI	O
+in	O
+effusion	B-DISO
+93	O
+.	O
+0	O
+-	O
+100	O
+.	O
+0	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+lung	O
+function	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+10	O
+years	O
+after	O
+recovery	O
+and	O
+the	O
+influencing	O
+factors	O
+.	O
+
+Total	O
+lung	B-PROC
+volume	I-PROC
+,	O
+residual	O
+capacity	O
+,	O
+vital	B-PROC
+capacity	I-PROC
+,	I-PROC
+forced	I-PROC
+vital	O
+capacity	O
+(	O
+FVC	B-PROC
+),	O
+FEV1	O
+,	O
+FEV1	O
+/	O
+FVC	B-PROC
+and	O
+lung	B-ANAT
+carbon	B-CHED
+monoxide	I-CHED
+diffusion	O
+(	O
+DLCO	O
+)	O
+were	O
+measured	O
+,	O
+and	O
+compared	O
+with	O
+the	O
+values	O
+obtained	O
+immediately	O
+after	O
+recovery	O
+in	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+performed	O
+this	O
+study	O
+to	O
+quantify	O
+resources	O
+required	O
+by	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+hypoxemia	O
+after	O
+critical	O
+care	O
+transport	B-PROC
+(	O
+CCT	B-DISO
+)	O
+and	O
+to	O
+assess	O
+short	O
+-	O
+term	O
+clinical	O
+outcomes	O
+.	O
+
+Upregulation	B-PROC
+of	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+resulted	O
+in	O
+increased	O
+severity	O
+of	O
+ALI	O
+as	O
+evidenced	O
+by	O
+decreased	O
+body	B-ANAT
+weight	O
+and	O
+survival	O
+rate	O
+,	O
+elevated	O
+level	O
+of	O
+total	O
+protein	B-CHED
+and	O
+albumin	B-PRGE
+in	O
+BAL	B-ENZY
+fluid	O
+,	O
+as	O
+well	O
+as	O
+more	O
+apparent	O
+histopathology	O
+changes	O
+of	O
+lung	B-ANAT
+.	O
+
+Of	O
+note	O
+,	O
+blockade	O
+of	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+effectively	O
+inhibited	O
+the	O
+lung	O
+inflammation	O
+and	O
+alleviated	O
+ALI	O
+severity	O
+.	O
+
+Laboratory	O
+biosafety	O
+preparedness	O
+included	O
+class	B-SPEC
+II	O
+biosafety	O
+cabinets	O
+(	O
+100	O
+%);	O
+separated	O
+pre	O
+-	O
+PCR	O
+,	O
+PCR	O
+,	O
+and	O
+post	O
+-	O
+PCR	O
+rooms	O
+(	O
+88	O
+.	O
+6	O
+%);	O
+negative	O
+pressure	O
+pretreatment	O
+rooms	O
+(	O
+48	O
+.	O
+6	O
+%);	O
+and	O
+negative	O
+pressure	O
+sputum	B-ANAT
+collection	O
+rooms	O
+(	O
+20	O
+.	O
+0	O
+%).	O
+
+Spatial	O
+analysis	O
+showed	O
+that	O
+PEDv	B-SPEC
+was	O
+clustered	O
+rather	O
+than	O
+randomly	O
+distributed	O
+,	O
+which	O
+suggested	O
+that	O
+sites	O
+near	O
+a	O
+positive	O
+site	O
+had	O
+increased	O
+risk	O
+of	O
+acquiring	O
+PEDv	B-SPEC
+infection	B-DISO
+.	O
+
+Meteorological	O
+data	O
+were	O
+used	O
+to	O
+investigate	O
+the	O
+hypothesis	O
+that	O
+PEDv	B-SPEC
+was	O
+spread	O
+by	O
+air	B-CHED
+.	O
+
+Similar	O
+comparative	O
+assays	O
+were	O
+done	O
+on	O
+LLC	B-COMP
+-	O
+PK	O
+and	O
+ST	O
+cells	B-COMP
+inoculated	O
+with	O
+the	O
+cell	B-COMP
+-	O
+adapted	O
+PDCoV	O
+strain	O
+OH	O
+-	O
+FD22	O
+-	O
+P44	O
+(	O
+passage	O
+44	O
+)	O
+in	O
+cell	B-COMP
+culture	O
+medium	O
+with	O
+2	O
+.	O
+5	O
+-	O
+10	O
+μg	O
+/	O
+ml	O
+of	O
+trypsin	B-PRGE
+and	O
+1	O
+%	O
+pancreatin	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+introduction	O
+into	O
+the	O
+United	O
+States	O
+:	O
+Root	B-ANAT
+cause	O
+investigation	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+was	O
+identified	O
+in	O
+the	O
+United	O
+States	O
+in	O
+the	O
+spring	O
+of	O
+2013	O
+,	O
+and	O
+professionals	O
+from	O
+many	O
+parts	O
+of	O
+the	O
+U	O
+.	O
+S	O
+.	O
+swine	B-SPEC
+industry	O
+responded	O
+rapidly	O
+to	O
+understand	O
+and	O
+control	O
+the	O
+newly	O
+emerging	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+detection	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+in	O
+a	O
+diarrhea	B-DISO
+outbreak	O
+in	O
+pasture	O
+-	O
+feeding	O
+Nellore	O
+steers	O
+in	O
+southern	O
+Brazil	O
+.	O
+
+This	O
+study	O
+describes	O
+the	O
+molecular	O
+detection	O
+of	O
+BCoV	O
+in	O
+a	O
+diarrhea	B-DISO
+outbreak	O
+in	O
+beef	O
+cattle	B-SPEC
+steers	O
+(	O
+Nellore	O
+)	O
+raised	O
+on	O
+pasture	O
+in	O
+Parana	O
+,	O
+southern	O
+Brazil	O
+.	O
+
+The	O
+BCoV	B-PRGE
+N	I-PRGE
+gene	I-PRGE
+was	O
+identified	O
+in	O
+42	O
+.	O
+9	O
+%	O
+(	O
+6	O
+/	O
+14	O
+)	O
+of	O
+the	O
+diarrheic	O
+fecal	B-ANAT
+samples	O
+evaluated	O
+by	O
+semi	O
+-	O
+nested	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+SN	O
+-	O
+PCR	O
+)	O
+technique	O
+.	O
+
+TITLE	O
+:	O
+Renal	B-ANAT
+Complications	O
+and	O
+Their	O
+Prognosis	O
+in	O
+Korean	O
+Patients	O
+with	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+Coronavirus	B-SPEC
+from	O
+the	O
+Central	O
+MERS	O
+-	O
+CoV	O
+Designated	O
+Hospital	O
+.	O
+
+ABSTRACT	O
+:	O
+Some	O
+cases	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+presented	O
+renal	B-PROC
+function	I-PROC
+impairment	B-DISO
+after	O
+the	O
+first	O
+MERS	O
+-	O
+CoV	O
+patient	O
+died	B-PROC
+of	O
+progressive	O
+respiratory	O
+and	O
+renal	B-DISO
+failure	I-DISO
+.	O
+
+Thus	O
+,	O
+MERS	O
+-	O
+CoV	O
+may	O
+include	O
+kidney	B-ANAT
+tropism	B-PROC
+.	O
+
+This	O
+case	O
+report	O
+describes	O
+the	O
+first	O
+detection	O
+of	O
+PEDV	B-SPEC
+in	O
+Austria	O
+.	O
+
+Reduced	O
+feed	O
+uptake	O
+and	O
+occasional	O
+diarrhea	B-DISO
+were	O
+observed	O
+in	O
+December	O
+2014	O
+in	O
+a	O
+group	O
+of	O
+fattening	O
+pigs	O
+,	O
+kept	O
+on	O
+an	O
+Austrian	O
+swine	B-SPEC
+farm	O
+.	O
+
+RESULTS	O
+:	O
+Between	O
+May	O
+20	O
+and	O
+July	O
+13	O
+,	O
+2015	O
+,	O
+a	O
+total	O
+of	O
+186	O
+confirmed	O
+MERS	O
+cases	O
+(	O
+1	O
+index	O
+case	O
+,	O
+29	O
+secondary	O
+cases	O
+,	O
+125	O
+third	O
+generation	O
+cases	O
+,	O
+25	O
+fourth	O
+generation	O
+cases	O
+and	O
+6	O
+cases	O
+without	O
+clear	O
+generation	O
+data	O
+),	O
+including	O
+36	O
+deaths	B-PROC
+(	O
+case	O
+fatality	O
+rate	O
+:	O
+19	O
+%),	O
+were	O
+reported	O
+in	O
+Korea	O
+.	O
+
+These	O
+results	O
+serve	O
+as	O
+an	O
+exhibition	O
+for	O
+the	O
+existing	O
+pipelines	O
+and	O
+web	B-DISO
+-	O
+based	O
+interface	O
+of	O
+Pathosphere	O
+as	O
+well	O
+as	O
+the	O
+plug	O
+-	O
+in	O
+adaptability	O
+that	O
+allows	O
+for	O
+integration	B-PROC
+of	O
+newer	O
+NGS	O
+analytical	O
+software	O
+as	O
+it	O
+becomes	O
+available	O
+.	O
+
+Meanwhile	O
+,	O
+the	O
+patient	O
+group	O
+showed	O
+decreased	O
+FA	O
+in	O
+the	O
+genu	B-ANAT
+of	O
+capsule	B-COMP
+callosum	O
+,	O
+body	B-ANAT
+of	O
+capsule	B-COMP
+callosum	O
+,	O
+and	O
+bilateral	O
+anterior	O
+corona	B-CHED
+radiate	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+,	O
+family	B-SPEC
+wise	O
+error	O
+[	O
+FEW	O
+]-	O
+corrected	O
+).	O
+
+ABSTRACT	O
+:	O
+Asthma	O
+is	O
+associated	O
+with	O
+poorer	O
+outcomes	O
+in	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+(	O
+SCD	B-DISO
+).	O
+
+Twenty	O
+-	O
+nine	O
+of	O
+forty	O
+children	O
+(	O
+72	O
+.	O
+5	O
+%)	O
+had	O
+a	O
+positive	O
+MCT	B-ENZY
+.	O
+
+Inflammatory	O
+markers	O
+did	O
+not	O
+correlate	O
+with	O
+AHR	B-PRGE
+.	O
+
+There	O
+are	O
+no	O
+reports	O
+on	O
+molecular	O
+characterization	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+in	O
+Ireland	O
+,	O
+and	O
+little	O
+data	O
+exists	O
+apart	O
+from	O
+serological	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+Failure	I-DISO
+in	O
+a	O
+Child	O
+Due	O
+to	O
+Type	O
+2	O
+Postobstructive	O
+Pulmonary	B-DISO
+Edema	I-DISO
+.	O
+
+The	O
+roles	O
+of	O
+diuretics	B-CHED
+and	O
+steroids	B-CHED
+are	O
+controversial	O
+.	O
+
+With	O
+the	O
+rise	O
+of	O
+ambulatory	O
+surgery	O
+,	O
+pediatric	O
+emergency	B-DISO
+physicians	O
+must	O
+be	O
+attuned	O
+to	O
+both	O
+the	O
+surgical	O
+and	O
+anesthetic	O
+complications	O
+that	O
+occur	O
+in	O
+the	O
+early	O
+postoperative	O
+period	O
+.	O
+
+To	O
+elucidate	O
+the	O
+pathogenesis	B-DISO
+of	O
+this	O
+virus	B-SPEC
+and	O
+investigate	O
+mechanisms	O
+underlying	O
+disease	O
+severity	O
+variation	O
+in	O
+the	O
+absence	O
+of	O
+autopsy	O
+data	O
+,	O
+a	O
+rhesus	B-SPEC
+macaque	I-SPEC
+and	O
+common	B-SPEC
+marmoset	I-SPEC
+model	O
+of	O
+MERS	O
+-	O
+CoV	O
+disease	O
+were	O
+analyzed	O
+.	O
+
+Both	O
+nonhuman	O
+primate	B-SPEC
+species	B-SPEC
+exhibited	O
+respiratory	O
+clinical	O
+signs	O
+after	O
+inoculation	O
+,	O
+which	O
+were	O
+more	O
+severe	O
+and	O
+of	O
+longer	O
+duration	O
+in	O
+the	O
+marmosets	B-SPEC
+,	O
+and	O
+developed	O
+bronchointerstitial	O
+pneumonia	B-DISO
+.	O
+
+In	O
+marmosets	B-SPEC
+,	O
+the	O
+pneumonia	B-DISO
+was	O
+more	O
+extensive	O
+,	O
+with	O
+development	B-PROC
+of	O
+severe	O
+airway	O
+lesions	O
+.	O
+
+TITLE	O
+:	O
+Value	O
+of	O
+Autopsy	O
+Emphasized	O
+in	O
+the	O
+Case	O
+Report	O
+of	O
+a	O
+Single	O
+Patient	O
+with	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+.	O
+
+The	O
+best	O
+method	O
+of	O
+preventing	O
+future	O
+outbreaks	O
+is	O
+to	O
+overcome	O
+the	O
+vulnerabilities	O
+observed	O
+in	O
+this	O
+outbreak	O
+,	O
+such	O
+as	O
+ward	O
+crowding	O
+,	O
+patient	O
+migration	B-PROC
+without	O
+appropriate	O
+data	O
+sharing	O
+,	O
+and	O
+the	O
+lack	O
+of	O
+an	O
+initial	O
+broad	O
+quarantine	O
+.	O
+
+The	O
+other	O
+atypical	O
+manifestations	O
+present	O
+were	O
+portal	B-DISO
+hypertension	I-DISO
+,	O
+acalculous	B-DISO
+cholecystitis	I-DISO
+,	O
+appendicitis	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+myocarditis	B-DISO
+,	O
+pericardial	B-DISO
+effusion	I-DISO
+,	O
+paroxysmal	B-DISO
+supraventricular	I-DISO
+tachycardia	I-DISO
+(	O
+PSVT	B-DISO
+),	O
+myositis	B-DISO
+,	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+),	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+and	O
+disseminated	O
+intravascular	O
+coagulopathy	B-DISO
+(	O
+DIC	B-DISO
+).	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+examined	O
+the	O
+potential	O
+immunomodulatory	O
+effects	O
+of	O
+two	O
+indirubin	O
+derivatives	O
+,	O
+indirubin	O
+-	O
+3	O
+'-(	O
+2	O
+,	O
+3	O
+-	O
+dihydroxypropyl	O
+)-	O
+oximether	O
+(	O
+E804	O
+)	O
+and	O
+indirubin	O
+-	O
+3	O
+'-	O
+oxime	B-CHED
+(	O
+E231	O
+),	O
+on	O
+IAV	O
+(	O
+H9N2	O
+)	O
+infected	O
+-	O
+human	B-SPEC
+pulmonary	B-ANAT
+microvascular	O
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+HPMECs	O
+).	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+severe	O
+cases	O
+of	O
+human	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+Such	O
+an	O
+introduction	O
+through	O
+travelling	O
+led	O
+to	O
+the	O
+emergence	O
+of	O
+a	O
+MERS	O
+-	O
+CoV	O
+outbreak	O
+in	O
+Korea	O
+in	O
+May	O
+2015	O
+,	O
+which	O
+caused	O
+more	O
+than	O
+140	O
+confirmed	O
+human	B-SPEC
+cases	O
+in	O
+less	O
+than	O
+a	O
+month	O
+.	O
+
+The	O
+conjugation	B-PROC
+of	O
+double	O
+strand	O
+probes	O
+onto	O
+polymeric	O
+microgels	O
+allows	O
+for	O
+a	O
+sensitive	O
+detection	O
+of	O
+DNA	O
+sequences	O
+from	O
+HIV	B-DISO
+,	O
+HCV	B-SPEC
+and	O
+SARS	B-DISO
+corona	B-CHED
+viruses	B-SPEC
+with	O
+a	O
+LOD	B-PRGE
+of	I-PRGE
+1	I-PRGE
+.	I-PRGE
+4	I-PRGE
+fM	I-PRGE
+,	I-PRGE
+3	I-PRGE
+.	I-PRGE
+7	I-PRGE
+fM	I-PRGE
+and	I-PRGE
+1	I-PRGE
+.	I-PRGE
+4	I-PRGE
+fM	I-PRGE
+,	O
+respectively	O
+,	O
+and	O
+with	O
+a	O
+dynamic	O
+range	O
+of	O
+10	O
+(-	O
+9	O
+)-	O
+10	O
+(-	O
+15	O
+)	O
+M	O
+.	O
+Such	O
+combination	O
+enhances	O
+the	O
+sensitivity	O
+of	O
+the	O
+detection	O
+of	O
+almost	O
+five	O
+orders	O
+of	O
+magnitude	O
+when	O
+compared	O
+to	O
+the	O
+only	O
+probe	O
+.	O
+
+PDE	B-DISO
+activity	O
+is	O
+required	O
+for	O
+robust	O
+replication	O
+in	O
+myeloid	B-ANAT
+cells	I-ANAT
+,	O
+as	O
+a	O
+mutant	B-DISO
+of	O
+MHV	B-SPEC
+(	O
+ns2	B-DISO
+(	O
+H126R	O
+))	O
+encoding	O
+an	O
+inactive	O
+PDE	B-DISO
+fails	O
+to	O
+antagonize	O
+RNase	B-PRGE
+L	I-PRGE
+activation	O
+and	O
+replicates	O
+poorly	O
+in	O
+bone	B-ANAT
+marrow	I-ANAT
+-	I-ANAT
+derived	I-ANAT
+macrophages	I-ANAT
+(	O
+BMM	B-ANAT
+),	O
+while	O
+ns2	B-DISO
+(	O
+H126R	O
+)	O
+replicates	O
+to	O
+high	O
+titer	O
+in	O
+several	O
+types	O
+of	O
+nonmyeloid	O
+cells	B-COMP
+,	O
+as	O
+well	O
+as	O
+in	O
+IFN	B-PRGE
+receptor	I-PRGE
+-	O
+deficient	O
+(	O
+Ifnar1	O
+(-/-))	O
+BMM	B-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+investigated	O
+the	O
+contributions	O
+of	O
+Oas	B-PRGE
+gene	B-PROC
+expression	I-PROC
+,	O
+basal	O
+IFN	B-PRGE
+signaling	B-PROC
+,	O
+and	O
+virus	B-SPEC
+-	O
+induced	O
+IFN	B-PRGE
+to	O
+RNase	B-PRGE
+L	I-PRGE
+activation	O
+.	O
+
+Our	O
+data	O
+further	O
+suggest	O
+that	O
+myeloid	B-ANAT
+cells	I-ANAT
+may	O
+serve	O
+as	O
+sentinels	O
+to	O
+restrict	O
+viral	B-PROC
+replication	I-PROC
+,	O
+thus	O
+protecting	O
+other	O
+cell	B-COMP
+types	O
+from	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+rhinovirus	B-SPEC
+pneumonia	B-DISO
+in	O
+a	O
+young	O
+woman	O
+taking	O
+performance	O
+-	O
+enhancing	O
+drugs	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+22	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+presented	O
+to	O
+the	O
+emergency	O
+room	O
+of	O
+a	O
+local	O
+hospital	O
+with	O
+pleuritic	B-DISO
+chest	I-DISO
+pain	I-DISO
+.	O
+
+Clinical	B-DISO
+findings	I-DISO
+and	O
+further	O
+diagnostic	O
+work	O
+up	O
+revealed	O
+a	O
+diagnosis	O
+of	O
+perimyocarditis	O
+,	O
+and	O
+adequate	O
+therapy	O
+was	O
+initiated	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+newly	O
+emerging	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+encodes	O
+the	O
+conserved	O
+macro	O
+domain	O
+within	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+3	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+macro	O
+domain	O
+was	O
+determined	O
+at	O
+1	O
+.	O
+43	O
+-	O
+Å	O
+resolution	O
+in	O
+complex	O
+with	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+.	O
+
+Furthermore	O
+,	O
+81	O
+%	O
+of	O
+case	O
+dogs	B-SPEC
+tested	O
+positive	O
+for	O
+Mycoplasma	B-SPEC
+cynos	I-SPEC
+,	O
+compared	O
+with	O
+73	O
+%	O
+of	O
+control	O
+dogs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+was	O
+first	O
+diagnosed	O
+in	O
+Ontario	O
+in	O
+January	O
+of	O
+2014	O
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+detected	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+may	O
+be	O
+the	O
+cause	O
+of	O
+illness	O
+or	O
+asymptomatic	O
+shedding	O
+.	O
+
+Influenza	B-DISO
+,	O
+RSV	B-SPEC
+and	O
+hMPV	B-SPEC
+can	O
+be	O
+considered	O
+pathogens	O
+if	O
+detected	O
+in	O
+ILI	O
+and	O
+SARI	O
+while	O
+rhinovirus	B-SPEC
+and	O
+adenovirus	B-DISO
+were	O
+commonly	O
+identified	O
+in	O
+controls	O
+suggesting	O
+that	O
+they	O
+may	O
+cause	O
+only	O
+a	O
+proportion	O
+of	O
+clinical	O
+disease	O
+observed	O
+in	O
+positive	O
+patients	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+enrolled	O
+1959	O
+SARI	O
+,	O
+3784	O
+ILI	O
+and	O
+1793	O
+controls	O
+with	O
+a	O
+HIV	B-DISO
+sero	O
+-	O
+prevalence	O
+of	O
+26	O
+%,	O
+30	O
+%	O
+and	O
+43	O
+%,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Korea	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+confirmed	O
+on	O
+May	O
+20	O
+,	O
+2015	O
+,	O
+with	O
+a	O
+subsequent	O
+outbreak	O
+in	O
+South	O
+Korea	O
+.	O
+
+All	O
+the	O
+patients	O
+had	O
+fever	B-PROC
+,	O
+myalgia	B-DISO
+,	O
+leucopenia	B-DISO
+,	O
+normal	O
+procalcitonin	O
+level	O
+,	O
+and	O
+pneumonia	B-DISO
+.	O
+
+Therefore	O
+,	O
+in	O
+cases	O
+of	O
+lower	O
+-	O
+lobe	B-ANAT
+pneumonia	B-DISO
+that	O
+occur	O
+during	O
+an	O
+MERS	O
+-	O
+CoV	O
+outbreak	O
+and	O
+are	O
+unesponsive	O
+to	O
+antibiotics	B-CHED
+,	O
+clinicians	O
+should	O
+consider	O
+the	O
+possibility	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+We	O
+also	O
+demonstrated	O
+translocation	B-DISO
+of	O
+a	O
+protein	B-CHED
+from	O
+the	O
+airspaces	O
+into	O
+plasma	B-ANAT
+(	O
+RAGE	B-PRGE
+-	I-PRGE
+receptor	I-PRGE
+for	O
+advanced	O
+glycation	O
+end	O
+products	O
+).	O
+
+ABSTRACT	O
+:	O
+Groups	O
+of	O
+one	O
+-	O
+day	O
+-	O
+old	O
+broiler	O
+chicks	O
+were	O
+vaccinated	O
+via	O
+the	O
+oculo	O
+-	O
+nasal	B-ANAT
+route	O
+with	O
+different	O
+live	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccines	O
+:	O
+Massachusetts	O
+(	O
+Mass	O
+),	O
+793B	O
+,	O
+D274	O
+or	O
+Arkansas	O
+(	O
+Ark	O
+).	O
+
+Five	O
+chicks	O
+from	O
+each	O
+group	O
+were	O
+humanely	O
+killed	O
+at	O
+intervals	O
+and	O
+their	O
+tracheas	B-ANAT
+collected	O
+for	O
+ciliary	O
+activity	O
+assessment	O
+and	O
+for	O
+the	O
+detection	O
+of	O
+CD4	B-PRGE
++,	I-PRGE
+CD8	B-PRGE
++	I-PRGE
+and	O
+IgA	B-PRGE
+-	I-PRGE
+bearing	I-PRGE
+B	I-PRGE
+cells	O
+by	O
+immunohistochemistry	O
+(	O
+IHC	O
+).	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+collected	O
+at	O
+intervals	O
+for	O
+the	O
+detection	O
+of	O
+anti	O
+-	O
+IBV	B-SPEC
+antibodies	B-COMP
+.	O
+
+It	O
+was	O
+identified	O
+as	O
+a	O
+recombinant	O
+strain	O
+using	O
+phylogenetic	O
+analysis	O
+and	O
+recombination	B-PROC
+detection	O
+program	O
+.	O
+
+Our	O
+findings	O
+provide	O
+valuable	O
+information	O
+on	O
+PEDV	B-SPEC
+evolution	B-PROC
+and	O
+underscore	O
+the	O
+need	O
+for	O
+ongoing	O
+surveillance	O
+of	O
+this	O
+economically	O
+important	O
+swine	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+test	O
+the	O
+hypothesis	O
+that	O
+abdominal	B-ANAT
+muscle	I-ANAT
+activity	O
+during	O
+mechanically	O
+ventilation	O
+increases	O
+lung	B-ANAT
+injury	O
+in	O
+severe	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Mortality	O
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+decreasing	O
+,	O
+although	O
+its	O
+prognosis	O
+after	O
+hospital	O
+discharge	B-ANAT
+and	O
+the	O
+prognostic	O
+accuracy	O
+of	O
+Berlin	O
+'	O
+s	O
+new	O
+ARDS	B-DISO
+stratification	O
+are	O
+uncertain	O
+.	O
+
+ARDS	B-DISO
+was	O
+defined	O
+by	O
+PaO2	O
+/	O
+FiO2	O
+lower	O
+than	O
+200	O
+mmHg	O
+under	O
+ventilation	O
+with	O
+at	O
+least	O
+10	O
+cm	O
+H2O	B-CHED
+of	O
+PEEP	B-CHED
+and	O
+a	O
+FiO2	O
+higher	O
+or	O
+equal	O
+than	O
+0	O
+.	O
+5	O
+.	O
+
+There	O
+was	O
+no	O
+increase	O
+in	O
+mortality	O
+after	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+this	O
+cohort	O
+,	O
+including	O
+patients	O
+with	O
+severe	O
+hypoxemia	O
+and	O
+high	O
+percentage	O
+of	O
+mayor	O
+co	O
+-	O
+morbidities	O
+,	O
+ARDS	B-DISO
+associated	O
+mortality	O
+was	O
+lower	O
+than	O
+some	O
+previous	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+among	O
+hospitalized	O
+patients	O
+with	O
+pneumonia	B-DISO
+in	O
+Taiwan	O
+.	O
+
+RESULTS	O
+:	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+was	O
+identified	O
+in	O
+8	O
+.	O
+4	O
+%	O
+(	O
+9	O
+/	O
+107	O
+)	O
+of	O
+hospitalized	O
+patients	O
+with	O
+pneumonia	B-DISO
+,	O
+but	O
+not	O
+found	O
+in	O
+outpatients	O
+with	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+.	O
+
+These	O
+data	O
+are	O
+valuable	O
+for	O
+veterinarians	O
+in	O
+advising	O
+clients	O
+on	O
+the	O
+anticipated	O
+impact	O
+and	O
+time	O
+to	O
+re	O
+-	O
+achieve	O
+a	O
+stable	O
+state	O
+with	O
+regards	O
+to	O
+PEDV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Adult	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+:	O
+Current	O
+status	O
+and	O
+future	O
+perspectives	O
+.	O
+
+TITLE	O
+:	O
+Incidence	O
+,	O
+risk	O
+factors	O
+and	O
+outcome	O
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+in	O
+critically	B-DISO
+ill	I-DISO
+children	O
+-	O
+a	O
+developing	O
+country	O
+perspective	O
+.	O
+
+The	O
+RIFLE	O
+criterion	O
+is	O
+an	O
+effective	O
+tool	O
+which	O
+can	O
+be	O
+used	O
+not	O
+only	O
+for	O
+predicting	O
+the	O
+outcomes	O
+,	O
+but	O
+may	O
+help	O
+in	O
+the	O
+early	O
+identification	O
+of	O
+patients	O
+at	O
+risk	O
+for	O
+AKI	B-PRGE
+.	O
+
+CONCLUSIONS	O
+:	O
+A	O
+high	O
+incidence	O
+of	O
+AKI	B-PRGE
+was	O
+noted	O
+in	O
+the	O
+PICU	B-SPEC
+that	O
+was	O
+associated	O
+with	O
+high	O
+mortality	O
+.	O
+
+Thus	O
+,	O
+the	O
+indiscriminate	O
+use	O
+of	O
+antibiotic	B-CHED
+and	O
+anthelminthic	B-CHED
+medication	O
+should	O
+be	O
+re	O
+-	O
+evaluated	O
+.	O
+
+Systematic	O
+measurements	O
+with	O
+the	O
+THP	B-CHED
+-	O
+1	O
+cell	B-ANAT
+line	I-ANAT
+allowed	O
+for	O
+the	O
+establishment	O
+of	O
+a	O
+strong	O
+correlation	O
+between	O
+stiffening	O
+and	O
+the	O
+severity	O
+of	O
+respiratory	O
+status	O
+(	O
+mean	O
+ET	O
+0	O
+.	O
+82	O
+±	O
+0	O
+.	O
+08	O
+seconds	O
+for	O
+healthy	O
+subjects	O
+,	O
+1	O
+.	O
+6	O
+±	O
+1	O
+.	O
+0	O
+seconds	O
+for	O
+ACPE	O
+groups	O
+,	O
+10	O
+.	O
+5	O
+±	O
+6	O
+.	O
+1	O
+seconds	O
+for	O
+mild	O
+ARDS	B-DISO
+,	O
+and	O
+20	O
+.	O
+0	O
+±	O
+8	O
+.	O
+1	O
+seconds	O
+for	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+;	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+leukocyte	B-ANAT
+stiffening	O
+induced	O
+by	O
+cytokines	O
+in	O
+the	O
+sera	B-COMP
+of	O
+patients	O
+might	O
+play	O
+a	O
+role	O
+in	O
+the	O
+sequestration	O
+of	O
+leukocytes	B-ANAT
+in	O
+the	O
+lung	B-ANAT
+capillary	B-ANAT
+beds	O
+during	O
+early	O
+ARDS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Rapid	O
+and	O
+strong	O
+stiffening	O
+of	O
+primary	O
+neutrophils	B-ANAT
+and	O
+monocytes	B-ANAT
+was	O
+induced	O
+within	O
+30	O
+minutes	O
+(	O
+mean	O
+ET	O
+>	O
+50	O
+seconds	O
+)	O
+by	O
+sera	B-COMP
+from	O
+the	O
+ARDS	B-DISO
+group	O
+compared	O
+with	O
+both	O
+the	O
+healthy	O
+subjects	O
+and	O
+the	O
+ACPE	O
+groups	O
+(	O
+mean	O
+ET	O
+<	O
+1	O
+second	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+These	O
+findings	O
+provide	O
+insight	O
+into	O
+the	O
+structural	O
+basis	O
+for	O
+2	O
+-	O
+5A	O
+binding	O
+of	O
+MHV	B-PRGE
+ns2	B-DISO
+.	O
+
+(	O
+4	O
+)	O
+Positive	O
+rates	O
+of	O
+HCoVs	O
+infection	B-DISO
+in	O
+<	O
+1	O
+year	O
+group	O
+,	O
+1	O
+-	O
+3	O
+years	O
+group	O
+,	O
+3	O
+-	O
+6	O
+years	O
+group	O
+and	O
+≥	O
+6	O
+years	O
+group	O
+were	O
+4	O
+.	O
+13	O
+%,	O
+5	O
+.	O
+08	O
+%,	O
+2	O
+.	O
+71	O
+%	O
+and	O
+1	O
+.	O
+23	O
+%,	O
+respectively	O
+.	O
+
+The	O
+clinical	O
+manifestations	O
+and	O
+severity	O
+of	O
+ALRTI	O
+caused	O
+by	O
+single	O
+HCoVs	O
+was	O
+comparable	O
+to	O
+that	O
+of	O
+ALRTI	O
+with	O
+single	O
+RSV	B-DISO
+infection	I-DISO
+in	O
+children	O
+.	O
+
+In	O
+rare	O
+situations	O
+,	O
+severe	O
+pulmonary	B-ANAT
+injury	O
+can	O
+develop	O
+.	O
+
+The	O
+risk	O
+factors	O
+for	O
+severe	O
+disease	O
+were	O
+age	O
+<	O
+2	O
+years	O
+,	O
+underlying	O
+bronchial	B-DISO
+asthma	B-PATH
+and	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+The	O
+three	O
+patients	O
+who	O
+died	B-PROC
+had	O
+a	O
+comorbid	O
+medical	O
+condition	B-DISO
+.	O
+
+The	O
+57	O
+CCoV	O
+strains	O
+exhibited	O
+high	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+rates	O
+with	O
+canine	O
+kobuvirus	O
+(	O
+CaKV	O
+)	O
+(	O
+33	O
+.	O
+33	O
+%)	O
+and	O
+canine	O
+parvovirus	B-DISO
+-	O
+2	O
+(	O
+CPV	B-SPEC
+-	O
+2	O
+)	O
+(	O
+31	O
+.	O
+58	O
+%).	O
+
+ABSTRACT	O
+:	O
+The	O
+truncated	O
+spike	O
+protein	B-CHED
+(	O
+S1	O
+,	O
+390	O
+-	O
+789aa	O
+)	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+was	O
+expressed	B-PROC
+as	O
+a	O
+recombinant	O
+protein	B-CHED
+in	O
+Baculorvirus	O
+expression	B-PROC
+system	O
+.	O
+
+Inducible	O
+expression	B-PROC
+of	O
+CNS	B-PRGE
+-	I-PRGE
+derived	I-PRGE
+CXCL1	I-PRGE
+resulted	O
+in	O
+increased	O
+levels	O
+of	O
+CXCL1	B-PRGE
+protein	I-PRGE
+within	O
+the	O
+serum	B-COMP
+,	O
+brain	B-ANAT
+,	O
+and	O
+spinal	B-ANAT
+cord	I-ANAT
+that	O
+correlated	O
+with	O
+increased	O
+frequency	O
+of	O
+Ly6G	B-PRGE
+(+)	I-PRGE
+CD11b	I-PRGE
+(+)	I-PRGE
+neutrophils	B-ANAT
+present	O
+within	O
+the	O
+CNS	B-CHED
+.	O
+
+Elevated	O
+levels	O
+of	O
+CXCL1	B-PRGE
+did	O
+not	O
+influence	O
+the	O
+generation	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+there	O
+was	O
+no	O
+difference	O
+in	O
+control	O
+of	O
+JHMV	O
+replication	O
+compared	O
+with	O
+control	O
+mice	O
+,	O
+indicating	O
+that	O
+T	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+into	O
+the	O
+CNS	B-CHED
+is	O
+CXCL1	O
+-	O
+independent	O
+.	O
+
+Sustained	O
+CXCL1	B-PRGE
+expression	B-PROC
+within	O
+the	O
+CNS	B-CHED
+resulted	O
+in	O
+increased	O
+mortality	O
+that	O
+correlated	O
+with	O
+elevated	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+,	O
+diminished	O
+numbers	O
+of	O
+mature	O
+oligodendrocytes	B-ANAT
+,	O
+and	O
+an	O
+increase	O
+in	O
+the	O
+severity	O
+of	O
+demyelination	B-DISO
+.	O
+
+Naso	B-SPEC
+-	O
+and	O
+oropharyngeal	B-ANAT
+swabs	O
+were	O
+collected	O
+and	O
+multiplex	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+was	O
+performed	O
+to	O
+identify	O
+the	O
+respiratory	O
+viruses	B-SPEC
+involved	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+poses	O
+a	O
+potential	O
+threat	O
+to	O
+global	O
+public	O
+health	O
+.	O
+
+Patients	O
+presenting	O
+with	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+or	O
+cardiogenic	B-DISO
+shock	I-DISO
+should	O
+be	O
+excluded	O
+from	O
+this	O
+early	O
+treatment	O
+regimen	O
+.	O
+
+Several	O
+viruses	B-SPEC
+including	O
+influenza	B-DISO
+A	I-PATH
+,	O
+rhinovirus	B-SPEC
+,	O
+and	O
+non	O
+-	O
+MERS	O
+coronaviruses	O
+had	O
+low	O
+carriage	O
+rates	O
+among	O
+arriving	O
+pilgrims	O
+and	O
+a	O
+statistically	O
+significant	O
+increase	O
+in	O
+their	O
+carriage	O
+rate	O
+was	O
+observed	O
+,	O
+following	O
+participation	O
+in	O
+the	O
+Hajj	O
+.	O
+
+Influenza	B-DISO
+outbreaks	O
+aboard	O
+cruise	O
+ships	O
+affect	O
+2	O
+-	O
+7	O
+%	O
+of	O
+passengers	O
+.	O
+
+RESULTS	O
+:	O
+Forty	O
+-	O
+one	O
+studies	O
+met	B-CHED
+the	O
+eligibility	O
+criteria	O
+.	O
+
+ABSTRACT	O
+:	O
+Previously	O
+unidentified	O
+viruses	O
+,	O
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+continue	O
+to	O
+emerge	O
+and	O
+threaten	O
+populations	O
+,	O
+while	O
+powerful	O
+new	O
+techniques	O
+have	O
+identified	O
+many	O
+new	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+viruses	B-SPEC
+.	O
+
+These	O
+viruses	B-SPEC
+often	O
+pose	O
+a	O
+challenge	O
+for	O
+researchers	O
+to	O
+study	O
+due	O
+to	O
+their	O
+highly	O
+pathogenic	O
+nature	O
+.	O
+
+In	O
+this	O
+review	O
+we	O
+will	O
+introduce	O
+various	O
+pseudotyping	O
+systems	O
+for	O
+emerging	O
+viruses	O
+,	O
+including	O
+chikungunya	B-SPEC
+virus	I-SPEC
+,	O
+Ebola	B-SPEC
+virus	I-SPEC
+,	O
+SARS	B-DISO
+and	O
+MERS	O
+coronaviruses	O
+and	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+as	O
+well	O
+as	O
+their	O
+use	O
+in	O
+diverse	O
+studies	O
+including	O
+drug	O
+screening	O
+and	O
+antibody	B-COMP
+neutralization	O
+.	O
+
+We	O
+evaluated	O
+the	O
+effect	O
+of	O
+treatment	O
+with	O
+VIS410	O
+,	O
+a	O
+human	B-SPEC
+monoclonal	O
+antibody	B-COMP
+targeting	B-PROC
+the	O
+HA	O
+stem	B-ANAT
+region	O
+,	O
+on	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+after	O
+infection	B-DISO
+with	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+viruses	B-SPEC
+.	O
+
+A	O
+26	O
+-	O
+month	O
+-	O
+old	O
+girl	O
+received	O
+a	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+3	I-PRGE
+/	I-PRGE
+6	I-PRGE
+-	I-PRGE
+allele	I-PRGE
+-	O
+matched	O
+transplant	B-ANAT
+from	O
+cord	B-ANAT
+blood	I-ANAT
+.	O
+
+Although	O
+HSCT	O
+effects	O
+on	O
+the	O
+clinical	O
+manifestations	O
+were	O
+limited	O
+,	O
+laboratory	O
+data	O
+including	O
+plasma	B-ANAT
+lysosomal	B-PRGE
+enzyme	I-PRGE
+activities	O
+and	O
+serum	B-COMP
+levels	O
+of	O
+immunoglobulin	B-PROC
+showed	O
+improvement	O
+.	O
+
+Although	O
+only	O
+5	O
+mutations	O
+were	O
+detected	O
+in	O
+the	O
+consensus	O
+sequences	O
+,	O
+473	O
+intrahost	O
+single	O
+nucleotide	B-CHED
+variants	O
+were	O
+identified	O
+.	O
+
+TITLE	O
+:	O
+MicroRNA	O
+Regulation	B-PROC
+of	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+and	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+In	O
+recent	O
+years	O
+,	O
+microRNAs	O
+(	O
+miRNAs	O
+),	O
+small	O
+non	O
+-	O
+coding	O
+molecules	O
+have	O
+emerged	O
+as	O
+a	O
+major	O
+area	O
+of	O
+biomedical	O
+research	O
+as	O
+they	O
+post	O
+-	O
+transcriptionally	O
+regulate	O
+gene	B-PROC
+expression	I-PROC
+in	O
+diverse	O
+biological	O
+and	O
+pathological	B-DISO
+processes	I-DISO
+,	O
+including	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Finally	O
+,	O
+the	O
+possible	O
+future	O
+directions	O
+that	O
+might	O
+lead	O
+to	O
+novel	O
+therapeutic	O
+strategies	O
+for	O
+the	O
+treatment	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+are	O
+also	O
+reviewed	O
+.	O
+
+TITLE	O
+:	O
+Extensive	O
+Positive	O
+Selection	O
+Drives	O
+the	O
+Evolution	B-PROC
+of	O
+Nonstructural	O
+Proteins	B-CHED
+in	O
+Lineage	O
+C	O
+Betacoronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Statistical	O
+evaluation	O
+of	O
+the	O
+prognosis	O
+of	O
+burned	O
+patients	O
+based	O
+on	O
+the	O
+analysis	O
+of	O
+prognostic	O
+scores	O
+as	O
+quickly	O
+and	O
+easily	O
+obtainable	O
+that	O
+track	O
+the	O
+evolution	B-PROC
+of	O
+burned	O
+patient	O
+in	O
+ICU	O
+.	O
+
+These	O
+systems	O
+applicable	O
+to	O
+the	O
+burned	O
+patient	O
+scores	O
+,	O
+making	O
+a	O
+cut	O
+-	O
+off	O
+of	O
+each	O
+index	O
+/	O
+mortality	O
+probability	O
+score	O
+,	O
+he	O
+can	O
+manifest	O
+usefulness	O
+in	O
+medical	O
+decision	O
+making	O
+process	O
+and	O
+strategy	O
+to	O
+reduce	O
+the	O
+risk	O
+of	O
+death	B-PROC
+in	O
+patients	O
+with	O
+severe	O
+burns	O
+.	O
+
+In	O
+2	O
+,	O
+305	O
+patients	O
+with	O
+AP	O
+,	O
+there	O
+were	O
+301	O
+cases	O
+(	O
+13	O
+.	O
+1	O
+%)	O
+diagnosed	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+136	O
+cases	O
+(	O
+5	O
+.	O
+9	O
+%)	O
+with	O
+shock	O
+,	O
+105	O
+cases	O
+(	O
+4	O
+.	O
+6	O
+%)	O
+with	O
+acute	O
+renal	O
+failure	O
+,	O
+296	O
+cases	O
+(	O
+12	O
+.	O
+8	O
+%)	O
+with	O
+gastrointestinal	B-DISO
+bleeding	I-DISO
+,	O
+based	O
+on	O
+the	O
+old	O
+Atlanta	B-SPEC
+classification	O
+criteria	O
+.	O
+
+In	O
+SAP	O
+patients	O
+by	O
+new	O
+criteria	O
+,	O
+the	O
+discharge	B-ANAT
+rate	O
+in	O
+critical	O
+condition	B-DISO
+and	O
+mortality	O
+were	O
+not	O
+only	O
+higher	O
+than	O
+those	O
+in	O
+MSAP	O
+patients	O
+(	O
+17	O
+.	O
+0	O
+%	O
+vs	O
+4	O
+.	O
+1	O
+%,	O
+4	O
+.	O
+1	O
+%	O
+vs	O
+1	O
+.	O
+5	O
+%,	O
+respectively	O
+,	O
+all	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+but	O
+also	O
+higher	O
+than	O
+those	O
+in	O
+SAP	O
+patients	O
+by	O
+the	O
+old	O
+classification	O
+(	O
+17	O
+.	O
+0	O
+%	O
+vs	O
+7	O
+.	O
+2	O
+%,	O
+4	O
+.	O
+1	O
+%	O
+vs	O
+2	O
+.	O
+1	O
+%,	O
+all	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+This	O
+study	O
+describes	O
+hypertrophic	B-DISO
+cardiomyopathy	I-DISO
+(	O
+HCM	O
+)	O
+and	O
+myocarditis	B-DISO
+associated	O
+with	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+five	O
+cats	B-SPEC
+aged	O
+between	O
+1	O
+and	O
+4	O
+years	O
+.	O
+
+Clinical	O
+manifestations	O
+included	O
+dyspnoea	B-DISO
+in	O
+four	O
+animals	B-SPEC
+,	O
+one	O
+of	O
+which	O
+also	O
+exhibited	O
+restlessness	B-DISO
+.	O
+
+or	O
+Toxoplasma	B-SPEC
+gondii	I-SPEC
+.	O
+
+Mutagenesis	B-PROC
+studies	O
+showed	O
+that	O
+RT	B-PRGE
+RNase	I-PRGE
+H	I-PRGE
+domain	I-PRGE
+residues	O
+Asn474	O
+and	O
+Tyr501	O
+,	O
+and	O
+in	O
+a	O
+lesser	O
+extent	O
+Ala502	O
+and	O
+Ala508	O
+,	O
+are	O
+critical	O
+for	O
+RMNC6	O
+inhibition	B-PROC
+of	O
+the	O
+endonuclease	B-FUNC
+activity	I-FUNC
+of	O
+the	O
+RT	O
+,	O
+without	O
+affecting	O
+its	O
+DNA	O
+polymerization	O
+activity	O
+.	O
+
+Nasal	B-ANAT
+and	O
+pharyngeal	B-ANAT
+swabs	O
+were	O
+tested	O
+using	O
+the	O
+PCR	O
+method	O
+for	O
+the	O
+following	O
+12	O
+viruses	B-SPEC
+:	O
+influenza	B-PATH
+A	I-PATH
+,	O
+influenza	B-DISO
+B	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+A	O
+(	O
+RSV	B-SPEC
+A	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+B	O
+(	O
+RSV	B-SPEC
+B	O
+),	O
+adenovirus	B-DISO
+,	O
+metapneumovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+229E	O
+/	O
+NL63	O
+(	O
+hCoV229	O
+),	O
+coronavirus	B-SPEC
+OC43	O
+(	O
+hCoVOC43	O
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+1	O
+(	O
+PIV	O
+-	O
+1	O
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+2	O
+(	O
+PIV	O
+-	O
+2	O
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+3	O
+(	O
+PIV	O
+-	O
+3	O
+),	O
+and	O
+rhinovirus	B-SPEC
+A	O
+/	O
+B	O
+.	O
+Coinfections	B-DISO
+were	O
+detected	O
+in	O
+nine	O
+(	O
+8	O
+%)	O
+patients	O
+.	O
+
+However	O
+,	O
+ACE2	B-PRGE
+solely	O
+is	O
+not	O
+sufficient	O
+to	O
+allow	O
+host	B-COMP
+cells	B-COMP
+to	O
+become	O
+susceptible	O
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+and	O
+other	O
+host	B-COMP
+factors	O
+may	O
+be	O
+involved	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+-	I-PRGE
+ACE2	I-PRGE
+complex	I-PRGE
+.	O
+
+Moreover	O
+,	O
+flow	O
+cytometry	O
+data	O
+demonstrated	O
+an	O
+increase	O
+of	O
+the	O
+cell	B-COMP
+surface	I-COMP
+vimentin	B-COMP
+level	O
+by	O
+16	O
+.	O
+5	O
+%	O
+after	O
+SARS	B-DISO
+-	O
+CoV	O
+permissive	O
+Vero	O
+E6	O
+cells	B-COMP
+were	O
+treated	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+).	O
+
+A	O
+direct	O
+interaction	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+and	O
+host	B-COMP
+surface	O
+vimentin	B-COMP
+was	O
+further	O
+confirmed	O
+by	O
+far	O
+-	O
+Western	O
+blotting	O
+.	O
+
+In	O
+addition	O
+,	O
+antibody	B-COMP
+neutralization	O
+assay	O
+and	O
+shRNA	O
+knockdown	O
+experiments	O
+indicated	O
+a	O
+vital	O
+role	O
+of	O
+vimentin	B-COMP
+in	O
+cell	B-COMP
+binding	B-FUNC
+and	O
+uptake	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+VLPs	B-ANAT
+and	O
+the	O
+viral	O
+spike	O
+protein	B-CHED
+.	O
+
+Typically	O
+,	O
+IBV	B-SPEC
+is	O
+titrated	O
+in	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+,	O
+and	O
+the	O
+infectivity	O
+of	O
+the	O
+virus	B-SPEC
+dilutions	O
+is	O
+determined	O
+by	O
+assessing	O
+clinical	O
+signs	O
+in	O
+the	O
+embryos	B-ANAT
+as	O
+evidence	O
+of	O
+viral	O
+propagation	O
+.	O
+
+TITLE	O
+:	O
+New	O
+Atlanta	B-SPEC
+Classification	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+in	O
+intensive	O
+care	O
+unit	O
+:	O
+Complications	O
+and	O
+prognosis	O
+.	O
+
+We	O
+collected	O
+demographic	O
+data	O
+,	O
+admission	O
+criteria	O
+,	O
+pancreatitis	B-DISO
+etiology	O
+,	O
+severity	O
+of	O
+illness	O
+,	O
+presence	O
+of	O
+organ	B-DISO
+failure	I-DISO
+,	O
+local	O
+and	O
+systemic	O
+complications	O
+,	O
+ICU	O
+length	O
+of	O
+stay	O
+,	O
+and	O
+mortality	O
+.	O
+
+The	O
+following	O
+clinical	O
+data	O
+were	O
+significantly	O
+higher	O
+in	O
+the	O
+death	B-PROC
+group	O
+than	O
+those	O
+in	O
+the	O
+survival	O
+group	O
+,	O
+namely	O
+body	B-ANAT
+temperature	O
+(	O
+centigrade	O
+:	O
+38	O
+.	O
+67	O
+±	O
+1	O
+.	O
+18	O
+vs	O
+.	O
+37	O
+.	O
+74	O
+±	O
+1	O
+.	O
+18	O
+,	O
+t	O
+=	O
+-	O
+3	O
+.	O
+627	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+pulse	B-PROC
+(	O
+bpm	O
+:	O
+130	O
+.	O
+65	O
+±	O
+15	O
+.	O
+72	O
+vs	O
+.	O
+107	O
+.	O
+26	O
+±	O
+19	O
+.	O
+61	O
+,	O
+t	O
+'	O
+=	O
+-	O
+6	O
+.	O
+133	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+the	O
+ratio	O
+of	O
+concomitant	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+[	O
+45	O
+.	O
+0	O
+%	O
+(	O
+18	O
+/	O
+40	O
+)	O
+vs	O
+.	O
+13	O
+.	O
+0	O
+%	O
+(	O
+6	O
+/	O
+46	O
+),	O
+χ	O
+(	O
+2	O
+)	O
+=	O
+10	O
+.	O
+860	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+],	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+[	O
+FiO2	O
+:	O
+0	O
+.	O
+495	O
+(	O
+0	O
+.	O
+410	O
+,	O
+0	O
+.	O
+600	O
+)	O
+vs	O
+.	O
+0	O
+.	O
+380	O
+(	O
+0	O
+.	O
+290	O
+,	O
+0	O
+.	O
+500	O
+),	O
+Z	O
+=	O
+-	O
+3	O
+.	O
+265	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+],	O
+APACHE	O
+II	O
+score	O
+(	O
+25	O
+.	O
+80	O
+±	O
+5	O
+.	O
+07	O
+vs	O
+.	O
+16	O
+.	O
+39	O
+±	O
+5	O
+.	O
+12	O
+,	O
+t	O
+=-	O
+8	O
+.	O
+540	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+CURB	B-DISO
+-	O
+65	O
+score	O
+[	O
+3	O
+(	O
+3	O
+,	O
+4	O
+)	O
+vs	O
+.	O
+2	O
+(	O
+1	O
+,	O
+2	O
+),	O
+Z	O
+=	O
+-	O
+5	O
+.	O
+562	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+],	O
+MODS	B-DISO
+score	O
+(	O
+8	O
+.	O
+15	O
+±	O
+2	O
+.	O
+49	O
+vs	O
+.	O
+4	O
+.	O
+35	O
+±	O
+2	O
+.	O
+01	O
+,	O
+t	O
+=	O
+-	O
+7	O
+.	O
+832	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+international	O
+normalized	O
+ratio	O
+[	O
+INR	O
+:	O
+1	O
+.	O
+22	O
+(	O
+1	O
+.	O
+08	O
+,	O
+1	O
+.	O
+31	O
+)	O
+vs	O
+.	O
+1	O
+.	O
+07	O
+(	O
+1	O
+.	O
+00	O
+,	O
+1	O
+.	O
+10	O
+),	O
+Z	O
+=	O
+-	O
+4	O
+.	O
+231	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+],	O
+and	O
+activated	O
+partial	O
+thromboplastin	B-PRGE
+time	O
+[	O
+APTT	O
+(	O
+s	O
+):	O
+33	O
+.	O
+80	O
+(	O
+32	O
+.	O
+13	O
+,	O
+38	O
+.	O
+75	O
+)	O
+vs	O
+.	O
+28	O
+.	O
+50	O
+(	O
+25	O
+.	O
+70	O
+,	O
+36	O
+.	O
+00	O
+),	O
+Z	O
+=	O
+-	O
+3	O
+.	O
+482	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+].	O
+
+ABSTRACT	O
+:	O
+Pulmonary	O
+complications	O
+are	O
+common	O
+following	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+.	O
+
+The	O
+incidence	O
+and	O
+outcomes	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+this	O
+setting	O
+are	O
+poorly	O
+characterized	O
+.	O
+
+In	O
+total	O
+,	O
+133	O
+cases	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+developed	O
+in	O
+2	O
+,	O
+635	O
+patients	O
+undergoing	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+(	O
+5	O
+.	O
+0	O
+%).	O
+
+Most	O
+cases	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+following	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+do	O
+not	O
+meet	O
+criteria	O
+for	O
+a	O
+more	O
+specific	O
+post	O
+-	O
+transplantation	O
+pulmonary	B-ANAT
+syndrome	B-DISO
+.	O
+
+Application	O
+of	O
+motifs	O
+as	O
+a	O
+tool	O
+to	O
+examine	O
+the	O
+whole	O
+genome	O
+sequences	O
+of	O
+causative	O
+agents	O
+will	O
+be	O
+more	O
+objective	O
+and	O
+will	O
+be	O
+an	O
+explicit	O
+indicator	B-CHED
+of	O
+their	O
+relationship	O
+.	O
+
+The	O
+plasma	B-ANAT
+cytokine	O
+and	O
+chemokine	O
+profiles	O
+of	O
+57	O
+H7N9	O
+patients	O
+were	O
+investigated	O
+using	O
+a	O
+multiplex	O
+immunoassay	O
+.	O
+
+Further	O
+,	O
+the	O
+association	O
+between	O
+cytokines	O
+and	O
+CRP	B-PRGE
+in	O
+H7N9	O
+infections	B-DISO
+was	O
+explored	O
+.	O
+
+When	O
+all	O
+the	O
+44	O
+patients	O
+of	O
+three	O
+severities	O
+(	O
+during	O
+the	O
+24	O
+hrs	B-DISO
+period	O
+and	O
+during	O
+the	O
+72	O
+hrs	B-DISO
+period	O
+)	O
+were	O
+compared	O
+,	O
+the	O
+OI	O
+gradually	O
+decreased	O
+with	O
+the	O
+increase	O
+of	O
+severity	O
+of	O
+ARDS	B-DISO
+,	O
+while	O
+EVLWI	O
+and	O
+PVPI	O
+ascended	O
+,	O
+and	O
+differences	O
+between	O
+any	O
+two	O
+groups	O
+were	O
+statistically	O
+significant	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+We	O
+also	O
+limited	O
+tidal	O
+volume	O
+to	O
+keep	O
+Ptp	B-DISO
+at	O
+less	O
+than	O
+25	O
+cm	O
+of	O
+water	B-CHED
+at	O
+end	O
+inspiration	B-PROC
+.	O
+
+Transpulmonary	O
+pressure	O
+-	O
+directed	O
+mechanical	O
+ventilation	O
+in	O
+ARDS	B-DISO
+secondary	O
+to	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+patient	O
+with	O
+intraabdominal	B-DISO
+hypertension	I-DISO
+could	O
+not	O
+only	O
+recruit	O
+the	O
+collapsed	O
+alveoli	B-ANAT
+,	O
+improve	O
+lung	B-PROC
+compliance	I-PROC
+,	O
+increase	O
+oxygenation	B-PROC
+index	O
+and	O
+decrease	O
+dead	B-PROC
+space	O
+ventilation	O
+but	O
+also	O
+monitor	O
+lung	B-ANAT
+stress	O
+to	O
+avoid	O
+alveoli	B-ANAT
+overinflation	O
+,	O
+which	O
+might	O
+be	O
+lung	B-ANAT
+protective	O
+.	O
+
+Compared	O
+with	O
+baseline	O
+,	O
+lung	B-PROC
+compliance	I-PROC
+(	O
+CL	O
+)	O
+(	O
+48	O
+.	O
+1	O
+±	O
+10	O
+.	O
+3	O
+)	O
+cmH2O	O
+vs	O
+(	O
+25	O
+.	O
+7	O
+±	O
+6	O
+.	O
+4	O
+)	O
+cmH2O	O
+and	O
+oxygenation	B-PROC
+index	O
+(	O
+PaO2	O
+/	O
+FiO2	O
+)	O
+(	O
+235	O
+±	O
+48	O
+)	O
+mmHg	O
+vs	O
+(	O
+160	O
+±	O
+35	O
+)	O
+mmHg	O
+improved	O
+obviously	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+dead	B-PROC
+space	O
+fraction	O
+(	O
+VD	O
+/	O
+VT	O
+)	O
+(	O
+0	O
+.	O
+48	O
+±	O
+0	O
+.	O
+07	O
+)	O
+vs	O
+(	O
+0	O
+.	O
+59	O
+±	O
+0	O
+.	O
+06	O
+)	O
+decreased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+but	O
+Ccw	O
+and	O
+respiratory	O
+compliance	O
+(	O
+Cr	O
+)	O
+didn	O
+'	O
+t	O
+improve	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+We	O
+hypothesized	O
+that	O
+patients	O
+with	O
+pulmonary	B-ANAT
+contusions	O
+apparent	O
+on	O
+initial	O
+chest	B-ANAT
+radiographs	O
+have	O
+higher	O
+rates	O
+of	O
+mortality	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+than	O
+patients	O
+who	O
+have	O
+delayed	O
+radiographic	O
+changes	O
+of	O
+pulmonary	B-ANAT
+contusions	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+improve	O
+the	O
+tactics	O
+of	O
+treatment	O
+of	O
+bronchoobstructive	O
+syndrome	B-DISO
+(	O
+BOS	B-DISO
+)	O
+in	O
+associative	O
+course	O
+with	O
+gastroesophageal	B-DISO
+reflux	I-DISO
+disease	I-DISO
+(	O
+GERD	B-DISO
+)	O
+in	O
+children	O
+.	O
+
+Peculiarities	O
+of	O
+pre	O
+-	O
+morbid	O
+background	O
+of	O
+BA	O
+and	O
+GERD	B-DISO
+associative	O
+course	O
+were	O
+exhibited	O
+by	O
+gestosis	B-DISO
+,	O
+threat	O
+of	O
+abortion	O
+,	O
+intrauterine	B-DISO
+hypoxia	I-DISO
+of	O
+the	O
+fetus	B-ANAT
+,	O
+social	O
+troubles	O
+of	O
+the	O
+family	B-SPEC
+.	O
+
+A	O
+number	O
+of	O
+interactions	O
+between	O
+cerebral	B-PROC
+function	I-PROC
+and	O
+respiratory	B-PROC
+function	I-PROC
+should	O
+be	O
+regarded	O
+in	O
+patients	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+To	O
+this	O
+end	O
+,	O
+two	O
+chicken	B-SPEC
+lines	O
+,	O
+selected	O
+for	O
+high	O
+(	O
+L10H	O
+line	O
+)	O
+and	O
+low	O
+(	O
+L10L	O
+line	O
+)	O
+serum	B-COMP
+concentration	O
+of	O
+mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+)	O
+were	O
+studied	O
+.	O
+
+This	O
+review	O
+focuses	O
+on	O
+three	O
+specific	O
+aspects	O
+:	O
+the	O
+evolving	O
+trend	O
+toward	O
+open	O
+lung	O
+ventilation	O
+,	O
+tempered	O
+by	O
+the	O
+recent	O
+cautionary	O
+experience	O
+with	O
+high	O
+-	O
+frequency	O
+oscillation	O
+ventilation	O
+;	O
+the	O
+evolution	B-PROC
+of	O
+prone	O
+positioning	O
+as	O
+a	O
+treatment	O
+for	O
+the	O
+most	O
+hypoxemic	O
+patients	O
+;	O
+and	O
+the	O
+continued	O
+future	O
+promise	O
+of	O
+extracorporeal	O
+support	O
+as	O
+a	O
+true	O
+rescue	O
+therapy	O
+.	O
+
+Modern	O
+ICU	O
+practices	O
+favor	O
+lower	O
+dose	O
+of	O
+corticosteroids	B-CHED
+and	O
+very	O
+short	O
+course	O
+of	O
+short	O
+-	O
+acting	O
+curare	O
+for	O
+the	O
+management	O
+of	O
+sepsis	B-DISO
+or	O
+ARDS	B-DISO
+.	O
+
+Recent	O
+trials	O
+provided	O
+no	O
+evidence	O
+for	O
+increased	O
+risk	O
+of	O
+secondary	B-DISO
+infections	I-DISO
+or	O
+critical	B-DISO
+illness	I-DISO
+neuromyopathy	B-DISO
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+or	O
+ARDS	B-DISO
+with	O
+the	O
+use	O
+of	O
+corticosteroids	B-CHED
+or	O
+neuromuscular	O
+blockers	O
+.	O
+
+Prevalence	O
+in	O
+broiler	O
+flocks	O
+was	O
+39	O
+.	O
+4	O
+%	O
+(	O
+26	O
+/	O
+66	O
+)	O
+and	O
+in	O
+local	O
+chicken	B-SPEC
+flocks	O
+was	O
+11	O
+.	O
+9	O
+%	O
+(	O
+5	O
+/	O
+42	O
+).	O
+
+Dogs	B-SPEC
+from	O
+small	O
+private	O
+reserves	O
+were	O
+more	O
+exposed	O
+to	O
+parvovirus	B-DISO
+and	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+than	O
+those	O
+from	O
+larger	O
+state	O
+parks	O
+.	O
+
+Remarkably	O
+,	O
+factors	O
+linked	O
+to	O
+free	O
+-	O
+ranging	O
+behaviour	B-PROC
+of	O
+dogs	B-SPEC
+were	O
+associated	O
+with	O
+the	O
+exposure	O
+for	O
+all	O
+pathogens	O
+detected	O
+.	O
+
+Since	O
+many	O
+virological	O
+and	O
+immunological	O
+data	O
+on	O
+FECV	B-SPEC
+infections	B-DISO
+are	O
+lacking	O
+,	O
+the	O
+present	O
+study	O
+investigated	O
+these	O
+missing	O
+links	O
+during	O
+experimental	O
+infection	B-DISO
+of	O
+three	O
+SPF	O
+cats	B-SPEC
+with	O
+FECV	B-SPEC
+strain	O
+UCD	O
+.	O
+
+Two	O
+cats	B-SPEC
+showed	O
+mild	O
+clinical	O
+signs	O
+,	O
+faecal	B-ANAT
+shedding	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+from	O
+4	O
+dpi	O
+,	O
+a	O
+cell	B-COMP
+-	O
+associated	O
+viraemia	B-DISO
+at	O
+inconsistent	O
+time	O
+points	O
+from	O
+5	O
+dpi	O
+,	O
+a	O
+highly	O
+neutralising	O
+antibody	B-PROC
+response	I-PROC
+from	O
+9	O
+dpi	O
+,	O
+and	O
+no	O
+major	O
+abnormalities	O
+in	O
+leukocyte	B-ANAT
+numbers	O
+.	O
+
+Neutralising	O
+antibodies	B-COMP
+arose	O
+from	O
+21	O
+dpi	O
+.	O
+
+ECLS	O
+during	O
+pregnancy	O
+is	O
+effective	O
+and	O
+relatively	O
+safe	O
+for	O
+the	O
+mother	B-ANAT
+and	I-ANAT
+fetus	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+identified	O
+in	O
+2012	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+a	O
+severe	O
+,	O
+lethal	O
+respiratory	B-DISO
+disease	I-DISO
+occurring	O
+across	O
+several	O
+countries	O
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+in	O
+Brazil	O
+:	O
+surveillance	O
+pathways	B-PROC
+.	O
+
+The	O
+isolated	O
+viruses	B-SPEC
+were	O
+characterized	O
+by	O
+RT	O
+-	O
+PCR	O
+amplification	B-DISO
+and	O
+sequencing	O
+of	O
+the	O
+partial	O
+polymerase	B-PRGE
+(	O
+pol	B-PRGE
+)	O
+gene	O
+.	O
+
+Phylogenetic	O
+evolutionary	O
+analyses	O
+confirmed	O
+the	O
+identities	O
+of	O
+three	O
+HCoV	O
+-	O
+HKU1	O
+,	O
+five	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+eight	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+three	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+Acute	B-DISO
+pancreatitis	I-DISO
+was	O
+induced	O
+in	O
+rats	B-SPEC
+with	O
+repetitive	O
+injections	O
+of	O
+cerulein	B-CHED
+(	O
+50	O
+µg	O
+/	O
+kg	O
+/	O
+h	O
+)	O
+and	O
+a	O
+shot	O
+of	O
+lipopolysaccharide	B-CHED
+(	O
+7	O
+.	O
+5	O
+mg	O
+/	O
+kg	O
+).	O
+
+When	O
+treated	O
+with	O
+dihydro	O
+-	O
+resveratrol	B-CHED
+,	O
+pulmonary	B-ANAT
+architectural	O
+distortion	O
+,	O
+hemorrhage	B-DISO
+,	O
+interstitial	B-DISO
+edema	I-DISO
+,	O
+and	O
+alveolar	B-ANAT
+thickening	O
+were	O
+significantly	O
+reduced	O
+in	O
+rats	B-SPEC
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+In	O
+vivo	O
+experiments	O
+show	O
+that	O
+siRNA	O
+expression	B-PROC
+inhibits	O
+IBV	B-SPEC
+replication	O
+,	O
+significantly	O
+decreases	O
+mortality	O
+and	O
+increases	O
+weight	O
+gain	O
+.	O
+
+Small	O
+interfering	O
+RNA	B-PROC
+expression	I-PROC
+inhibits	O
+avian	B-SPEC
+IBV	B-SPEC
+replication	O
+and	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+inoculated	O
+orally	B-ANAT
+with	O
+SL7207	O
+(	O
+pVAX	O
+-	O
+M	O
+)	O
+at	O
+different	O
+dosages	O
+to	O
+evaluate	O
+safety	O
+of	O
+the	O
+vaccines	O
+.	O
+
+The	O
+bacterium	B-SPEC
+was	O
+safe	O
+to	O
+mice	B-SPEC
+at	O
+a	O
+dosage	O
+of	O
+2	O
+×	O
+10	O
+(	O
+9	O
+)	O
+CFU	O
+,	O
+almost	O
+eliminated	O
+from	O
+the	O
+spleen	B-ANAT
+and	O
+liver	B-ANAT
+at	O
+week	O
+4	O
+post	O
+-	O
+immunization	O
+and	O
+eventually	O
+cleared	O
+at	O
+week	O
+6	O
+.	O
+
+Spherical	O
+virus	B-COMP
+particles	I-COMP
+were	O
+observed	O
+by	O
+transmission	O
+electron	O
+microscopy	O
+.	O
+
+Positive	O
+attitudes	O
+in	O
+the	O
+workplace	O
+,	O
+clinical	O
+improvement	O
+of	O
+infected	O
+colleagues	O
+,	O
+and	O
+stoppage	O
+of	O
+disease	B-DISO
+transmission	I-DISO
+among	O
+HCWs	O
+after	O
+adopting	O
+strict	O
+protective	O
+measures	O
+alleviated	O
+their	O
+fear	O
+and	O
+drove	O
+them	O
+through	O
+the	O
+epidemic	O
+.	O
+
+A	O
+27	O
+-	O
+year	O
+-	O
+old	O
+male	O
+patient	O
+was	O
+suffering	B-DISO
+from	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+myocarditis	I-DISO
+with	O
+circulatory	B-DISO
+shock	I-DISO
+.	O
+
+After	O
+mechanical	O
+ventilation	O
+for	O
+respiratory	O
+support	O
+,	O
+he	O
+was	O
+in	O
+a	O
+persistently	O
+refractory	B-DISO
+shock	I-DISO
+state	O
+.	O
+
+Two	O
+new	O
+species	B-SPEC
+of	O
+bat	B-PRGE
+CoV	I-PRGE
+,	O
+identified	O
+through	O
+sequence	O
+comparison	O
+and	O
+phylogenetic	O
+analysis	O
+,	O
+are	O
+proposed	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+mechanisms	O
+of	O
+coronavirus	B-SPEC
+RNA	B-PROC
+capping	I-PROC
+and	O
+methylation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+5	O
+'-	O
+cap	B-DISO
+structures	O
+of	O
+eukaryotic	O
+mRNAs	O
+are	O
+important	O
+for	O
+RNA	O
+stability	O
+,	O
+pre	O
+-	O
+mRNA	O
+splicing	O
+,	O
+mRNA	B-PROC
+export	I-PROC
+,	O
+and	O
+protein	B-PROC
+translation	B-PROC
+.	O
+
+Many	O
+viruses	B-SPEC
+have	O
+evolved	O
+mechanisms	O
+for	O
+generating	O
+their	O
+own	O
+cap	B-DISO
+structures	O
+with	O
+methylation	B-PROC
+at	O
+the	O
+N7	O
+position	O
+of	O
+the	O
+capped	O
+guanine	B-CHED
+and	O
+the	O
+ribose	B-CHED
+2	O
+'-	O
+Oposition	O
+of	O
+the	O
+first	O
+nucleotide	B-CHED
+,	O
+which	O
+help	O
+viral	O
+RNAs	O
+escape	O
+recognition	O
+by	O
+the	O
+host	B-COMP
+innate	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Friedreich	O
+'	O
+s	O
+ataxia	O
+is	O
+a	O
+predominantly	O
+neurodegenerative	B-DISO
+disease	I-DISO
+caused	O
+by	O
+recessive	O
+mutations	O
+that	O
+produce	O
+a	O
+deficiency	O
+of	O
+frataxin	B-PRGE
+(	O
+FXN	B-PRGE
+).	O
+
+The	O
+""""	O
+SmartECLA	O
+""""	O
+system	O
+was	O
+tested	O
+in	O
+six	O
+animal	B-SPEC
+experiments	O
+with	O
+increasing	O
+pulmonary	B-ANAT
+hypoventilation	B-DISO
+and	O
+hypoxic	B-DISO
+inspiratory	B-PROC
+gas	B-ENZY
+mixture	B-CHED
+to	O
+simulate	O
+progressive	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+replication	O
+in	O
+macrophages	B-ANAT
+/	O
+monocytes	B-ANAT
+induced	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	B-FUNC
+)-	O
+alpha	O
+production	O
+,	O
+and	O
+that	O
+the	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+produced	O
+was	O
+involved	O
+in	O
+aggravating	O
+the	O
+pathology	B-DISO
+of	O
+FIP	B-DISO
+.	O
+
+All	O
+MR	B-PRGE
+-	I-PRGE
+RTs	I-PRGE
+exhibited	O
+similar	O
+sensitivity	O
+toward	O
+RNase	B-PRGE
+H	I-PRGE
+inhibitors	B-CHED
+belonging	O
+to	O
+different	O
+inhibitor	B-CHED
+classes	O
+,	O
+indicating	O
+the	O
+importance	O
+of	O
+developing	O
+RNase	B-PRGE
+H	I-PRGE
+inhibitors	B-CHED
+further	O
+as	O
+anti	O
+-	O
+HIV	B-DISO
+drugs	O
+.	O
+
+Troponin	B-PRGE
+I	I-PRGE
+was	O
+measured	O
+every	O
+12	O
+hours	O
+in	O
+the	O
+first	O
+72	O
+hours	O
+from	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admission	O
+.	O
+
+Moreover	O
+,	O
+troponin	B-PRGE
+release	B-PATH
+can	O
+be	O
+related	O
+to	O
+right	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+,	O
+thus	O
+highlighting	O
+the	O
+clinical	O
+role	O
+of	O
+echocardiography	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Not	O
+all	O
+persons	O
+infected	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+develop	O
+severe	O
+symptoms	O
+,	O
+which	O
+likely	O
+leads	O
+to	O
+an	O
+underestimation	O
+of	O
+the	O
+number	O
+of	O
+people	O
+infected	O
+and	O
+an	O
+overestimation	O
+of	O
+the	O
+severity	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+in	O
+vitro	O
+activities	O
+of	O
+the	O
+ethyl	B-CHED
+acetate	I-CHED
+(	O
+EA	O
+)	O
+fraction	O
+of	O
+Houttuynia	B-SPEC
+cordata	I-SPEC
+(	O
+H	O
+.	O
+cordata	O
+)	O
+Thunb	O
+.	O
+
+The	O
+EA	O
+fraction	O
+of	O
+H	O
+.	O
+cordata	O
+inhibited	O
+viral	O
+infectivity	O
+up	O
+to	O
+6	O
+d	O
+.	O
+Cinanserin	O
+hydrochloride	B-CHED
+was	O
+able	O
+to	O
+inhibit	O
+MHV	B-SPEC
+for	O
+only	O
+2	O
+d	O
+.	O
+The	O
+50	O
+%	O
+inhibitory	O
+concentrations	O
+(	O
+IC50	O
+)	O
+of	O
+the	O
+EA	O
+fraction	O
+of	O
+H	O
+.	O
+cordata	O
+added	O
+before	O
+the	O
+viral	O
+adsorption	O
+stage	O
+were	O
+0	O
+.	O
+98	O
+μg	O
+/	O
+mL	O
+for	O
+MHV	O
+and	O
+7	O
+.	O
+50	O
+μg	O
+/	O
+mL	O
+for	O
+DENV	O
+-	O
+2	O
+with	O
+absence	O
+of	O
+cytotoxicity	B-DISO
+.	O
+
+Tracheobronchial	O
+HAE	O
+cultures	O
+recapitulate	O
+the	O
+primary	O
+entry	O
+point	O
+of	O
+human	O
+respiratory	O
+viruses	B-SPEC
+while	O
+the	O
+alveolar	B-ANAT
+model	O
+allows	O
+for	O
+elucidation	O
+of	O
+mechanisms	O
+involved	O
+in	O
+viral	B-DISO
+infection	I-DISO
+and	O
+pathogenesis	B-DISO
+in	O
+the	O
+alveoli	B-ANAT
+.	O
+
+These	O
+morphological	O
+airway	B-ANAT
+cultures	O
+are	O
+also	O
+well	O
+suited	O
+for	O
+the	O
+identification	O
+of	O
+antivirals	B-CHED
+,	O
+evaluation	O
+of	O
+compound	O
+toxicity	O
+and	O
+viral	O
+inhibition	B-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+Protein	B-CHED
+Corona	B-CHED
+of	O
+Plant	B-SPEC
+Virus	B-SPEC
+Nanoparticles	B-CHED
+Influences	O
+their	O
+Dispersion	O
+Properties	O
+,	O
+Cellular	B-ANAT
+Interactions	O
+,	O
+and	O
+In	O
+Vivo	O
+Fates	O
+.	O
+
+The	O
+impact	O
+of	O
+the	O
+VNP	B-PRGE
+protein	I-PRGE
+corona	B-CHED
+on	O
+molecular	B-PROC
+recognition	I-PROC
+and	O
+cell	B-COMP
+targeting	B-PROC
+in	O
+the	O
+context	O
+of	O
+cancer	B-DISO
+and	O
+thrombosis	B-DISO
+is	O
+investigated	O
+.	O
+
+The	O
+two	O
+mAbs	O
+were	O
+suitable	O
+to	O
+detect	O
+a	O
+24	O
+-	O
+kDa	O
+protein	O
+,	O
+which	O
+represents	O
+the	O
+nonglycosylated	O
+form	O
+of	O
+7b	O
+in	O
+FCoV	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+After	O
+retrieving	O
+163	O
+,	O
+433	O
+news	O
+records	O
+mentioning	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+H1N1	O
+pandemics	O
+,	O
+a	O
+maximum	O
+entropy	O
+model	O
+for	O
+inductive	O
+machine	O
+learning	B-PROC
+was	O
+used	O
+to	O
+identify	O
+relationships	O
+among	O
+500	O
+randomly	O
+sampled	O
+news	O
+records	O
+that	O
+correlated	O
+with	O
+systematic	O
+human	B-SPEC
+assessments	O
+of	O
+their	O
+scientific	O
+quality	O
+and	O
+sensationalism	O
+.	O
+
+The	O
+model	O
+was	O
+validated	O
+by	O
+randomly	O
+sampling	O
+200	O
+records	O
+and	O
+comparing	O
+human	B-SPEC
+assessments	O
+of	O
+them	O
+to	O
+the	O
+computer	O
+assessments	O
+.	O
+
+Automated	O
+methods	O
+can	O
+evaluate	O
+news	O
+records	O
+faster	O
+,	O
+cheaper	O
+,	O
+and	O
+possibly	O
+better	O
+than	O
+humans	B-SPEC
+.	O
+
+We	O
+here	O
+report	O
+a	O
+case	O
+of	O
+HCoV	O
+infection	B-DISO
+in	O
+a	O
+leukemia	B-DISO
+patient	O
+with	O
+fatal	O
+ARDS	B-DISO
+despite	O
+successful	O
+virus	B-SPEC
+elimination	B-PROC
+by	O
+pegylated	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+PEG	B-PRGE
+-	I-PRGE
+IFN	I-PRGE
+-	I-PRGE
+α	I-PRGE
+).	O
+
+CONCLUSIONS	O
+:	O
+This	O
+report	O
+emphasizes	O
+the	O
+fatal	O
+consequences	O
+of	O
+common	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+Pathogenesis	B-DISO
+following	O
+infection	B-DISO
+with	O
+these	O
+viruses	B-SPEC
+is	O
+characterized	O
+by	O
+a	O
+marked	O
+delay	O
+in	O
+the	O
+induction	O
+of	O
+Type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+I	I-PRGE
+)	O
+and	O
+,	O
+subsequently	O
+,	O
+by	O
+a	O
+poor	O
+adaptive	B-PROC
+immune	I-PROC
+response	I-PROC
+.	O
+
+The	O
+structure	O
+shares	O
+a	O
+common	O
+core	O
+with	O
+paramyxovirus	O
+F	O
+proteins	B-CHED
+,	O
+implicating	O
+mechanistic	O
+similarities	O
+and	O
+an	O
+evolutionary	O
+connection	O
+between	O
+these	O
+viral	O
+fusion	O
+proteins	B-CHED
+.	O
+
+Finally	O
+,	O
+comparison	O
+with	O
+crystal	B-ANAT
+structures	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+S	O
+domains	O
+allows	O
+rationalization	O
+of	O
+the	O
+molecular	O
+basis	O
+for	O
+species	B-SPEC
+specificity	O
+based	O
+on	O
+the	O
+use	O
+of	O
+spatially	O
+contiguous	O
+but	O
+distinct	O
+domains	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Cardiopulmonary	B-ANAT
+interactions	O
+in	O
+the	O
+course	O
+of	O
+mechanical	O
+ventilation	O
+].	O
+
+CONCLUSIONS	O
+:	O
+In	O
+this	O
+review	O
+,	O
+we	O
+will	O
+focus	O
+on	O
+severe	O
+COPD	B-DISO
+exacerbation	I-DISO
+,	O
+acute	B-DISO
+left	I-DISO
+heart	I-DISO
+failure	I-DISO
+and	O
+weaning	B-PROC
+from	O
+ventilation	O
+.	O
+
+No	O
+evidence	O
+of	O
+extrapulmonary	O
+MERS	O
+-	O
+CoV	O
+antigens	B-CHED
+were	O
+detected	O
+,	O
+including	O
+the	O
+kidney	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+list	O
+of	O
+extrapulmonary	O
+manifestations	O
+due	O
+to	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+infection	B-DISO
+can	O
+be	O
+classified	O
+according	O
+to	O
+the	O
+following	O
+three	O
+possible	O
+mechanisms	O
+derived	O
+from	O
+the	O
+established	O
+biological	O
+activity	O
+of	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+;	O
+(	O
+1	O
+)	O
+a	O
+direct	O
+type	O
+in	O
+which	O
+the	O
+bacterium	B-SPEC
+is	O
+present	O
+at	O
+the	O
+site	O
+of	O
+inflammation	B-DISO
+and	O
+local	O
+inflammatory	O
+cytokines	O
+induced	O
+by	O
+the	O
+bacterium	B-SPEC
+play	O
+an	O
+important	O
+role	O
+(	O
+2	O
+)	O
+an	O
+indirect	O
+type	O
+in	O
+which	O
+the	O
+bacterium	B-SPEC
+is	O
+not	O
+present	O
+at	O
+the	O
+site	O
+of	O
+inflammation	B-DISO
+and	O
+immune	O
+modulations	O
+,	O
+such	O
+as	O
+autoimmunity	B-DISO
+or	O
+formation	B-PROC
+of	O
+immune	O
+complexes	O
+,	O
+play	O
+an	O
+important	O
+role	O
+,	O
+and	O
+(	O
+3	O
+)	O
+a	O
+vascular	B-DISO
+occlusion	B-PROC
+type	O
+in	O
+which	O
+obstruction	B-DISO
+of	O
+blood	B-PROC
+flow	I-PROC
+induced	O
+either	O
+directly	O
+or	O
+indirectly	O
+by	O
+the	O
+bacterium	B-SPEC
+plays	O
+an	O
+important	O
+role	O
+.	O
+
+Except	O
+negative	O
+result	O
+of	O
+antibody	B-COMP
+test	O
+in	O
+the	O
+well	O
+-	O
+known	O
+""""	O
+acute	O
+window	O
+phase	O
+""","	O
+in	O
+rare	O
+cases	O
+,	O
+patients	O
+do	O
+not	O
+develop	O
+HIV	B-DISO
+antibodies	B-COMP
+despite	O
+demonstrable	O
+infection	B-DISO
+.	O
+
+Multiple	O
+antibiotics	B-CHED
+and	O
+chemotherapy	O
+were	O
+administrated	O
+with	O
+no	O
+clinical	O
+effect	O
+due	O
+to	O
+advanced	O
+stage	O
+and	O
+the	O
+patient	O
+passed	O
+away	O
+soon	O
+after	O
+diagnosis	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+case	O
+of	O
+seronegative	O
+HIV	B-DISO
+-	I-DISO
+1	I-DISO
+infection	I-DISO
+with	O
+presentation	O
+of	O
+primary	O
+pulmonary	B-ANAT
+KS	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+marked	O
+the	O
+explosion	O
+of	O
+health	O
+information	O
+seeking	O
+online	O
+in	O
+China	O
+and	O
+the	O
+increasing	O
+emergence	O
+of	O
+Chinese	O
+health	O
+websites	O
+.	O
+
+Despite	O
+the	O
+relatively	O
+few	O
+numbers	O
+of	O
+cases	O
+to	O
+date	O
+,	O
+research	O
+and	O
+development	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+therapeutic	O
+candidates	O
+is	O
+advancing	O
+quickly	O
+.	O
+
+In	O
+this	O
+issue	O
+of	O
+Cell	B-COMP
+Host	B-COMP
+&	O
+Microbe	O
+,	O
+Channappanavar	O
+et	O
+al	O
+.	O
+(	O
+2016	O
+)	O
+use	O
+a	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+animal	B-SPEC
+model	O
+to	O
+describe	O
+how	O
+rapid	O
+and	O
+robust	O
+virus	B-PROC
+replication	I-PROC
+with	O
+delayed	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+can	O
+lead	O
+to	O
+lung	B-ANAT
+immunopathology	B-DISO
+,	O
+with	O
+fatal	B-DISO
+outcomes	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+factors	O
+leading	O
+to	O
+lung	B-ANAT
+pathology	B-DISO
+are	O
+not	O
+well	O
+understood	O
+.	O
+
+This	O
+delayed	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+signaling	B-PROC
+promotes	O
+the	O
+accumulation	O
+of	O
+pathogenic	O
+inflammatory	O
+monocyte	B-ANAT
+-	O
+macrophages	B-ANAT
+(	O
+IMMs	O
+),	O
+resulting	O
+in	O
+elevated	O
+lung	B-ANAT
+cytokine	O
+/	O
+chemokine	O
+levels	O
+,	O
+vascular	B-ANAT
+leakage	B-DISO
+,	O
+and	O
+impaired	B-DISO
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+.	O
+
+Viruses	B-SPEC
+were	O
+most	O
+commonly	O
+associated	O
+with	O
+severe	O
+CAP	B-DISO
+among	O
+children	O
+aged	O
+less	O
+than	O
+1	O
+year	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+young	O
+and	O
+preterm	O
+infants	O
+with	O
+CAP	B-DISO
+should	O
+be	O
+monitored	O
+closely	O
+due	O
+to	O
+their	O
+high	O
+risk	O
+for	O
+developing	O
+serious	O
+complications	O
+.	O
+
+By	O
+contrast	O
+,	O
+the	O
+CoVs	O
+responsible	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+),	O
+which	O
+were	O
+discovered	O
+in	O
+Hong	O
+Kong	O
+,	O
+China	O
+,	O
+in	O
+2003	O
+,	O
+and	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+,	O
+respectively	O
+,	O
+have	O
+received	O
+global	O
+attention	O
+over	O
+the	O
+past	O
+12	O
+years	O
+owing	O
+to	O
+their	O
+ability	O
+to	O
+cause	O
+community	O
+and	O
+health	O
+-	O
+care	O
+-	O
+associated	O
+outbreaks	O
+of	O
+severe	O
+infections	B-DISO
+in	O
+human	B-SPEC
+populations	O
+.	O
+
+TITLE	O
+:	O
+Hepatitis	B-DISO
+C	I-DISO
+Virus	I-SPEC
+Resistance	B-PROC
+to	O
+Carbohydrate	B-CHED
+-	O
+Binding	B-FUNC
+Agents	O
+.	O
+
+Surprisingly	O
+,	O
+none	O
+of	O
+these	O
+mutations	O
+,	O
+alone	O
+or	O
+in	O
+combination	O
+,	O
+conferred	O
+resistance	B-PROC
+to	O
+CBAs	O
+.	O
+
+With	O
+the	O
+emerging	O
+development	B-PROC
+of	O
+monoclonal	O
+antibodies	B-COMP
+as	O
+therapeutics	O
+,	O
+the	O
+potential	O
+implications	O
+of	O
+antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+of	O
+disease	O
+were	O
+also	O
+addressed	O
+.	O
+
+Vaccination	O
+with	O
+live	O
+attenuated	O
+strains	O
+of	O
+IBV	B-SPEC
+-	O
+H120	O
+and	O
+NDV	B-SPEC
+-	O
+LaSota	O
+are	O
+important	O
+for	O
+the	O
+control	O
+of	O
+IB	O
+and	O
+ND	O
+.	O
+
+However	O
+,	O
+conventional	O
+live	O
+attenuated	O
+vaccines	O
+are	O
+expensive	O
+and	O
+result	O
+in	O
+the	O
+inability	O
+to	O
+differentiate	O
+between	O
+infected	O
+and	O
+vaccinated	O
+chickens	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Interactive	O
+mechanism	O
+between	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+T	B-ANAT
+cell	I-ANAT
+peptide	B-CHED
+and	O
+avian	B-SPEC
+MHC	B-PROC
+I	I-PRGE
+molecule	I-PRGE
+.	O
+
+Flow	O
+cytometric	O
+results	O
+show	O
+that	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+lymphocytes	I-ANAT
+reproduce	O
+stimulated	O
+by	O
+the	O
+Sp6	B-PRGE
+and	O
+the	O
+nonrelated	O
+peptide	B-CHED
+proliferate	O
+by	O
+34	O
+.	O
+8	O
+%	O
+and	O
+2	O
+.	O
+6	O
+%,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+An	O
+Overview	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+-	O
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+3CL	O
+Protease	B-CHED
+Inhibitors	I-CHED
+:	O
+Peptidomimetics	B-CHED
+and	O
+Small	O
+Molecule	O
+Chemotherapy	O
+.	O
+
+We	O
+describe	O
+here	O
+mainly	O
+peptidomimetic	O
+and	O
+small	O
+molecule	O
+inhibitors	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+).	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+83	O
+-	O
+year	O
+-	O
+old	O
+patient	O
+hospitalized	O
+as	O
+a	O
+matter	O
+of	O
+urgency	O
+in	O
+intensive	O
+care	O
+for	O
+which	O
+C	B-SPEC
+.	I-SPEC
+ulcerans	I-SPEC
+was	O
+isolated	O
+in	O
+pure	B-FUNC
+culture	O
+in	O
+its	O
+bronchial	B-ANAT
+samples	O
+.	O
+
+Molecular	B-PROC
+dynamics	I-PROC
+simulations	O
+revealed	O
+that	O
+the	O
+L141T	O
+mutation	O
+disrupts	O
+the	O
+3	O
+(	O
+10	O
+)-	O
+helix	O
+and	O
+helps	O
+to	O
+stabilize	O
+the	O
+active	O
+conformation	O
+.	O
+
+Structure	O
+activity	O
+relationship	O
+studies	O
+of	O
+the	O
+candidate	O
+compounds	O
+were	O
+given	O
+reasonable	O
+inhibitors	B-CHED
+ent	B-ANAT
+-	O
+3	O
+and	O
+ent	B-ANAT
+-	O
+7k	O
+against	O
+SARS	B-PRGE
+3CL	I-PRGE
+R188I	I-PRGE
+mutant	B-DISO
+protease	I-PRGE
+.	O
+
+Most	O
+non	O
+-	O
+falciparum	B-DISO
+malaria	I-DISO
+cases	O
+are	O
+caused	O
+by	O
+Plasmodium	B-SPEC
+vivax	I-SPEC
+;	O
+a	O
+few	O
+cases	O
+are	O
+caused	O
+by	O
+the	O
+other	O
+species	B-SPEC
+of	O
+plasmodium	B-SPEC
+:	O
+Plasmodium	B-SPEC
+ovale	I-SPEC
+,	O
+Plasmodium	B-SPEC
+malariae	I-SPEC
+or	O
+Plasmodium	B-SPEC
+knowlesi	I-SPEC
+.	O
+
+The	O
+optimum	O
+diagnostic	O
+procedure	O
+is	O
+examination	O
+of	O
+thick	O
+and	O
+thin	O
+blood	B-ANAT
+films	O
+by	O
+an	O
+expert	O
+to	O
+detect	O
+and	O
+speciate	O
+the	O
+malarial	O
+parasites	O
+.	O
+
+Artemether	B-CHED
+-	O
+lumefantrine	B-CHED
+(	O
+Riamet	O
+(®))	O
+is	O
+the	O
+drug	O
+of	O
+choice	O
+(	O
+Grade	O
+2C	O
+)	O
+and	O
+dihydroartemisinin	B-CHED
+-	O
+piperaquine	O
+(	O
+Eurartesim	O
+(®))	O
+is	O
+an	O
+alternative	O
+.	O
+
+Severe	O
+malaria	B-PATH
+is	O
+a	O
+rare	O
+complication	B-DISO
+of	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+or	O
+P	B-SPEC
+.	I-SPEC
+knowlesi	I-SPEC
+infection	B-DISO
+and	O
+also	O
+requires	O
+parenteral	O
+therapy	O
+.	O
+
+Children	O
+with	O
+severe	O
+malaria	B-PATH
+should	O
+also	O
+be	O
+treated	O
+with	O
+empirical	O
+broad	O
+spectrum	O
+antibiotics	B-CHED
+until	O
+bacterial	B-DISO
+infection	I-DISO
+can	O
+be	O
+excluded	O
+(	O
+Grade	O
+1B	O
+).	O
+
+Severe	O
+malaria	B-PATH
+in	O
+any	O
+trimester	O
+of	O
+pregnancy	O
+should	O
+be	O
+treated	O
+as	O
+for	O
+any	O
+other	O
+patient	O
+with	O
+artesunate	B-CHED
+preferred	O
+over	O
+quinine	B-CHED
+(	O
+Grade	O
+1C	O
+).	O
+
+Quinine	B-CHED
+with	O
+doxycycline	B-CHED
+or	O
+clindamycin	B-CHED
+,	O
+or	O
+atovaquone	B-CHED
+-	O
+proguanil	B-CHED
+at	O
+appropriate	O
+doses	O
+for	O
+weight	O
+can	O
+also	O
+be	O
+used	O
+.	O
+
+On	O
+admission	O
+to	O
+the	O
+ICU	O
+,	O
+Gram	O
+-	O
+positive	O
+and	O
+Gram	O
+-	O
+negative	O
+bacteria	B-SPEC
+were	O
+found	O
+in	O
+29	O
+.	O
+6	O
+and	O
+26	O
+.	O
+2	O
+%	O
+of	O
+SARI	O
+patients	O
+but	O
+rarely	O
+atypical	O
+bacteria	B-SPEC
+(	O
+1	O
+.	O
+0	O
+%);	O
+viruses	B-SPEC
+were	O
+present	O
+in	O
+7	O
+.	O
+7	O
+%	O
+of	O
+patients	O
+.	O
+
+We	O
+identified	O
+several	O
+risk	O
+factors	O
+for	O
+in	O
+-	O
+hospital	O
+death	B-PROC
+that	O
+may	O
+be	O
+useful	O
+for	O
+risk	O
+stratification	O
+in	O
+these	O
+patients	O
+.	O
+
+Bone	B-DISO
+marrow	I-DISO
+failure	I-DISO
+,	O
+wrist	B-ANAT
+fracture	O
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+were	O
+reported	O
+as	O
+unrelated	O
+severe	O
+adverse	O
+events	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+common	O
+after	O
+traumatic	O
+brain	B-ANAT
+injury	O
+(	O
+TBI	O
+)	O
+and	O
+is	O
+associated	O
+with	O
+worse	O
+neurologic	O
+outcomes	O
+and	O
+longer	O
+hospitalization	O
+.	O
+
+Regression	O
+analyses	O
+were	O
+used	O
+to	O
+test	O
+the	O
+association	O
+between	O
+predictors	O
+of	O
+interest	O
+and	O
+ARDS	B-DISO
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+had	O
+significantly	O
+worse	O
+clinical	O
+outcomes	O
+measured	O
+at	O
+28	O
+days	O
+,	O
+including	O
+longer	O
+median	O
+intensive	O
+care	O
+unit	O
+and	O
+hospital	O
+stays	O
+(	O
+4	O
+days	O
+vs	O
+.	O
+13	O
+days	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+and	O
+7	O
+.	O
+5	O
+days	O
+vs	O
+.	O
+14	O
+.	O
+5	O
+days	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+respectively	O
+).	O
+
+TITLE	O
+:	O
+S1	B-PRGE
+gene	I-PRGE
+-	O
+based	O
+phylogeny	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+:	O
+An	O
+attempt	O
+to	O
+harmonize	O
+virus	B-SPEC
+classification	O
+.	O
+
+The	O
+adoption	O
+of	O
+an	O
+internationally	O
+accepted	O
+viral	O
+nomenclature	O
+is	O
+crucial	O
+for	O
+future	O
+studies	O
+of	O
+IBV	B-SPEC
+epidemiology	O
+and	O
+evolution	B-PROC
+,	O
+and	O
+the	O
+classification	O
+scheme	O
+presented	O
+here	O
+can	O
+be	O
+updated	O
+and	O
+revised	O
+novel	O
+S1	O
+sequences	O
+should	O
+become	O
+available	O
+.	O
+
+TITLE	O
+:	O
+Gene	O
+control	O
+of	O
+tyrosine	B-PRGE
+kinase	I-PRGE
+TIE2	I-PRGE
+and	O
+vascular	B-ANAT
+manifestations	O
+of	O
+infections	B-DISO
+.	O
+
+Forced	O
+Tie2	B-PRGE
+suppression	B-DISO
+sufficed	O
+to	O
+attenuate	O
+barrier	O
+function	O
+and	O
+sensitize	O
+endothelium	B-ANAT
+to	O
+permeability	O
+mediators	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+of	O
+13	O
+November	O
+2015	O
+,	O
+1618	O
+laboratory	O
+-	O
+confirmed	O
+human	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+,	O
+including	O
+579	O
+deaths	B-PROC
+,	O
+had	O
+been	O
+reported	O
+to	O
+the	O
+World	O
+Health	O
+Organization	O
+.	O
+
+We	O
+were	O
+able	O
+to	O
+obtain	O
+viable	O
+chimeras	O
+containing	O
+the	O
+entire	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+protein	B-CHED
+as	O
+well	O
+as	O
+mutants	O
+with	O
+intramolecular	O
+substitutions	O
+that	O
+partitioned	O
+M	B-PRGE
+protein	I-PRGE
+at	O
+the	O
+boundaries	O
+between	O
+the	O
+ectodomain	O
+,	O
+transmembrane	B-COMP
+domains	O
+,	O
+or	O
+endodomain	O
+.	O
+
+Unlike	O
+its	O
+antiviral	B-CHED
+actions	O
+against	O
+positive	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+,	O
+the	O
+anti	O
+-	O
+influenza	B-SPEC
+virus	I-SPEC
+activity	O
+of	O
+TRIM56	B-PRGE
+was	O
+independent	O
+of	O
+the	O
+E3	B-PRGE
+ligase	I-PRGE
+activity	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+is	O
+used	O
+as	O
+life	O
+support	O
+for	O
+lung	B-ANAT
+impairment	B-DISO
+resulting	O
+from	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+More	O
+PKH26	O
+-	O
+labeled	O
+type	O
+II	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+were	O
+detected	O
+by	O
+fluorescence	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+ALI	O
+-	O
+EC	O
+-	O
+T	O
+than	O
+in	O
+CON	O
+-	O
+EC	O
+-	O
+T	O
+as	O
+further	O
+verified	O
+by	O
+the	O
+expression	B-PROC
+of	O
+messenger	B-CHED
+RNA	I-CHED
+of	O
+sex	O
+-	O
+determining	O
+region	O
+of	O
+Y	B-COMP
+chromosome	I-COMP
+.	O
+
+Electromicroscopically	O
+intact	O
+type	O
+II	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+prominent	O
+lattice	O
+-	O
+like	O
+tubular	O
+myelin	B-COMP
+were	O
+also	O
+found	O
+in	O
+ALI	O
+-	O
+EC	O
+-	O
+T	O
+and	O
+CON	B-PRGE
+-	I-PRGE
+MV	I-PRGE
+but	O
+not	O
+in	O
+ALI	O
+-	O
+EC	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+of	O
+June	O
+19	O
+,	O
+2015	O
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+had	O
+received	O
+1	O
+,	O
+338	O
+notifications	O
+of	O
+laboratory	O
+-	O
+confirmed	O
+infection	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+We	O
+describe	O
+an	O
+acute	O
+,	O
+severe	O
+,	O
+life	O
+-	O
+threatening	O
+,	O
+inflammatory	B-DISO
+reaction	I-DISO
+in	O
+a	O
+child	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+case	O
+highlights	O
+the	O
+importance	O
+of	O
+careful	O
+monitoring	O
+of	O
+children	O
+following	O
+zoledronic	B-CHED
+acid	I-CHED
+therapy	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+the	O
+most	O
+severe	O
+form	O
+within	O
+the	O
+pulmonary	B-DISO
+complications	I-DISO
+of	O
+malaria	B-PATH
+,	O
+with	O
+high	O
+mortality	O
+despite	O
+proper	O
+management	O
+.	O
+
+Here	O
+,	O
+we	O
+investigated	O
+the	O
+role	O
+of	O
+bats	B-SPEC
+as	O
+a	O
+potential	O
+reservoir	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+vitro	O
+,	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+interacted	O
+with	O
+Jamaican	O
+fruit	O
+bat	B-ENZY
+(	O
+Artibeus	B-SPEC
+jamaicensis	I-SPEC
+)	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+)	O
+receptor	O
+and	O
+MERS	O
+-	O
+CoV	O
+replicated	O
+efficiently	O
+in	O
+Jamaican	O
+fruit	O
+bat	B-ENZY
+cells	B-COMP
+,	O
+suggesting	O
+there	O
+is	O
+no	O
+restriction	O
+at	O
+the	O
+receptor	O
+or	O
+cellular	B-COMP
+level	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+To	O
+shed	O
+light	O
+on	O
+the	O
+intrinsic	O
+host	B-COMP
+-	O
+virus	B-SPEC
+relationship	O
+,	O
+we	O
+inoculated	O
+10	O
+Jamaican	O
+fruit	O
+bats	B-SPEC
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+Although	O
+all	O
+bats	B-SPEC
+showed	O
+evidence	O
+of	O
+infection	B-DISO
+,	O
+none	O
+of	O
+the	O
+bats	B-SPEC
+showed	O
+clinical	O
+signs	O
+of	O
+disease	O
+.	O
+
+In	O
+addition	O
+,	O
+effusion	B-DISO
+samples	O
+were	O
+stained	O
+with	O
+haematoxylin	B-CHED
+and	O
+eosin	O
+and	O
+evaluated	O
+cytologically	O
+.	O
+
+ABSTRACT	O
+:	O
+Among	O
+the	O
+fire	O
+victims	O
+,	O
+respiratory	O
+tract	O
+injury	O
+resulted	O
+from	O
+smoke	O
+inhalation	B-PROC
+is	O
+the	O
+major	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+hypercapnic	O
+respiratory	O
+failure	O
+is	O
+mostly	O
+seen	O
+in	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+and	O
+obesity	B-DISO
+hypoventilation	I-DISO
+syndrome	I-DISO
+(	O
+OHS	B-DISO
+).	O
+
+Presentation	O
+of	O
+the	O
+current	O
+knowledge	O
+on	O
+indications	O
+and	O
+management	O
+of	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+use	O
+of	O
+NIV	O
+is	O
+the	O
+predominant	O
+treatment	O
+in	O
+patients	O
+with	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+but	O
+close	O
+monitoring	O
+is	O
+necessary	O
+in	O
+order	B-SPEC
+not	O
+to	O
+miss	O
+the	O
+indications	O
+for	O
+intubation	O
+and	O
+invasive	O
+ventilation	O
+.	O
+
+The	O
+period	O
+prevalence	O
+of	O
+mild	O
+ARDS	B-DISO
+was	O
+30	O
+.	O
+0	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+28	O
+.	O
+2	O
+%-	O
+31	O
+.	O
+9	O
+%);	O
+of	O
+moderate	O
+ARDS	B-DISO
+,	O
+46	O
+.	O
+6	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+44	O
+.	O
+5	O
+%-	O
+48	O
+.	O
+6	O
+%);	O
+and	O
+of	O
+severe	O
+ARDS	B-DISO
+,	O
+23	O
+.	O
+4	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+21	O
+.	O
+7	O
+%-	O
+25	O
+.	O
+2	O
+%).	O
+
+ARDS	B-DISO
+represented	O
+0	O
+.	O
+42	O
+cases	O
+per	O
+ICU	O
+bed	B-DISO
+over	O
+4	O
+weeks	O
+and	O
+represented	O
+10	O
+.	O
+4	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+10	O
+.	O
+0	O
+%-	O
+10	O
+.	O
+7	O
+%)	O
+of	O
+ICU	O
+admissions	O
+and	O
+23	O
+.	O
+4	O
+%	O
+of	O
+patients	O
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+Prone	O
+positioning	O
+was	O
+used	O
+in	O
+16	O
+.	O
+3	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+13	O
+.	O
+7	O
+%-	O
+19	O
+.	O
+2	O
+%)	O
+of	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Hospital	O
+mortality	O
+was	O
+34	O
+.	O
+9	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+31	O
+.	O
+4	O
+%-	O
+38	O
+.	O
+5	O
+%)	O
+for	O
+those	O
+with	O
+mild	O
+,	O
+40	O
+.	O
+3	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+37	O
+.	O
+4	O
+%-	O
+43	O
+.	O
+3	O
+%)	O
+for	O
+those	O
+with	O
+moderate	O
+,	O
+and	O
+46	O
+.	O
+1	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+41	O
+.	O
+9	O
+%-	O
+50	O
+.	O
+4	O
+%)	O
+for	O
+those	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+dangerous	O
+infection	B-DISO
+with	O
+pandemic	O
+potential	O
+.	O
+
+TITLE	O
+:	O
+Awake	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+patients	O
+with	O
+severe	O
+postoperative	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Increased	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+generated	O
+by	O
+neutrophils	B-ANAT
+(	O
+PMNs	O
+)	O
+and	O
+other	O
+inflammatory	B-ANAT
+cells	I-ANAT
+play	O
+an	O
+important	O
+role	O
+in	O
+increasing	O
+endothelial	B-ANAT
+permeability	O
+.	O
+
+As	O
+cornerstones	O
+of	O
+pain	O
+and	O
+wound	B-PROC
+healing	I-PROC
+,	O
+pro	B-CHED
+-	O
+inflammatory	O
+mediators	O
+may	O
+be	O
+utilized	O
+for	O
+insight	O
+into	O
+both	O
+processes	O
+.	O
+
+For	O
+development	B-PROC
+of	O
+analgesics	O
+,	O
+these	O
+aberrations	O
+can	O
+significantly	O
+alter	O
+the	O
+potential	O
+efficacy	O
+and	O
+/	O
+or	O
+adverse	B-DISO
+effects	I-DISO
+of	O
+a	O
+prescribed	O
+analgesic	B-CHED
+following	O
+burn	O
+trauma	O
+.	O
+
+The	O
+prototype	O
+strain	O
+exhibited	O
+weaker	O
+sugar	O
+-	O
+binding	B-PROC
+activity	I-PROC
+compared	O
+with	O
+the	O
+variant	O
+field	O
+isolate	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+lentiviruses	O
+pseudotyped	O
+with	O
+S	O
+proteins	B-CHED
+from	O
+coronaviruses	O
+and	O
+cell	B-COMP
+tropisms	B-PROC
+of	O
+porcine	O
+coronaviruses	O
+.	O
+
+Different	O
+coronaviruses	O
+interact	O
+with	O
+their	O
+specific	O
+receptors	O
+to	O
+enter	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+CCL94	O
+(	O
+cat	B-SPEC
+kidney	B-ANAT
+)	O
+cells	B-COMP
+could	O
+be	O
+infected	O
+efficiently	O
+by	O
+TGEV	B-SPEC
+but	O
+not	O
+PEDV	B-SPEC
+.	O
+
+In	O
+light	O
+of	O
+the	O
+broad	O
+antiviral	B-CHED
+activity	O
+of	O
+β	O
+-	O
+defensins	B-PATH
+,	O
+we	O
+tested	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+11	O
+peptides	B-CHED
+derived	O
+from	O
+mouse	B-PRGE
+β	I-PRGE
+-	I-PRGE
+defensin	I-PRGE
+-	I-PRGE
+4	I-PRGE
+and	O
+found	O
+that	O
+a	O
+short	O
+peptide	B-CHED
+,	O
+P9	O
+,	O
+exhibited	O
+potent	O
+and	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+effects	O
+against	O
+multiple	O
+respiratory	O
+viruses	B-SPEC
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+,	O
+including	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+H1N1	O
+,	O
+H3N2	B-CHED
+,	O
+H5N1	B-DISO
+,	O
+H7N7	O
+,	O
+H7N9	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+antiviral	B-CHED
+activity	O
+of	O
+P9	O
+was	O
+attributed	O
+to	O
+its	O
+high	O
+-	O
+affinity	O
+binding	B-FUNC
+to	O
+viral	O
+glycoproteins	B-CHED
+,	O
+as	O
+well	O
+as	O
+the	O
+abundance	O
+of	O
+basic	O
+amino	B-CHED
+acids	I-CHED
+in	O
+its	O
+composition	O
+.	O
+
+After	O
+24	O
+h	O
+,	O
+the	O
+animals	B-SPEC
+with	O
+PaO2	O
+/	O
+FIO2	O
+between	O
+200	O
+and	O
+300	O
+mmHg	O
+were	O
+randomized	O
+into	O
+2	O
+groups	O
+:	O
+prone	O
+position	O
+(	O
+n	O
+=	O
+6	O
+)	O
+and	O
+supine	O
+position	O
+(	O
+n	O
+=	O
+6	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+safety	O
+and	O
+effectiveness	O
+of	O
+a	O
+novel	O
+therapeutic	O
+regimen	O
+for	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+sydrome	O
+(	O
+BOS	B-DISO
+)	O
+affter	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+(	O
+HSCT	O
+).	O
+
+They	O
+received	O
+weekly	O
+intravenous	O
+injection	O
+of	O
+umbilical	B-ANAT
+cord	I-ANAT
+-	O
+derived	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+(	O
+MSC	O
+)	O
+at	O
+a	O
+dose	O
+of	O
+1	O
+×	O
+10	O
+(	O
+6	O
+)/	O
+kg	O
+for	O
+4	O
+weeks	O
+.	O
+
+Methylprednisolone	B-CHED
+was	O
+given	O
+at	O
+a	O
+dose	O
+of	O
+1	O
+mg	O
+/(	O
+kg	O
+·	O
+d	O
+)	O
+for	O
+2	O
+weeks	O
+when	O
+respiratory	B-DISO
+failure	I-DISO
+occured	O
+.	O
+
+CONCLUSIONS	O
+:	O
+MSC	O
+combined	O
+with	O
+budesonide	B-CHED
+,	O
+almeterol	O
+and	O
+azithromycin	B-CHED
+has	O
+been	O
+confirmed	O
+to	O
+be	O
+generally	O
+safe	O
+and	O
+can	O
+reduce	O
+the	O
+dose	O
+of	O
+glucocorticoid	B-CHED
+in	O
+treatment	O
+of	O
+BOS	B-DISO
+after	O
+HSCT	O
+.	O
+
+After	O
+this	O
+new	O
+definition	O
+of	O
+ARDS	B-DISO
+,	O
+each	O
+treatment	O
+to	O
+the	O
+patients	O
+with	O
+ARDS	B-DISO
+should	O
+be	O
+considered	O
+,	O
+depending	O
+on	O
+the	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+such	O
+as	O
+prone	O
+position	O
+to	O
+the	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+muscle	B-ANAT
+paralysis	O
+to	O
+the	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+The	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+genetic	O
+diversity	O
+,	O
+temporal	O
+distribution	O
+,	O
+population	O
+history	O
+and	O
+clinical	O
+symptoms	O
+of	O
+betacoronavirus	B-SPEC
+infections	B-DISO
+in	O
+Kuala	O
+Lumpur	O
+,	O
+Malaysia	O
+between	O
+2012	O
+and	O
+2013	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+spike	O
+gene	O
+showed	O
+that	O
+the	O
+majority	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+isolates	O
+were	O
+grouped	O
+into	O
+two	O
+previously	O
+undefined	O
+genotypes	O
+,	O
+provisionally	O
+assigned	O
+as	O
+novel	O
+lineage	O
+1	O
+and	O
+novel	O
+lineage	O
+2	O
+.	O
+
+We	O
+report	O
+on	O
+the	O
+homology	O
+modeling	O
+,	O
+molecular	B-PROC
+dynamics	I-PROC
+simulation	O
+,	O
+and	O
+docking	B-PROC
+studies	O
+to	O
+explain	O
+the	O
+structure	O
+-	O
+function	O
+relationship	O
+and	O
+the	O
+interaction	O
+mechanism	O
+.	O
+
+Data	O
+from	O
+the	O
+GO	O
+analysis	O
+indicated	O
+that	O
+the	O
+target	O
+genes	O
+of	O
+ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+-	I-PRGE
+α	I-PRGE
+as	O
+well	O
+as	O
+the	O
+genes	O
+from	O
+the	O
+microarray	O
+were	O
+mainly	O
+enriched	O
+in	O
+10	O
+biological	B-PROC
+processes	I-PROC
+,	O
+including	O
+cellular	B-COMP
+process	B-PROC
+,	I-PROC
+metabolic	I-PROC
+process	B-PROC
+,	I-PROC
+immune	I-PROC
+system	I-PROC
+process	O
+and	O
+biological	B-PROC
+regulation	I-PROC
+,	O
+et	O
+al	O
+.	O
+Data	O
+on	O
+drug	O
+target	O
+genes	O
+,	O
+first	O
+and	O
+second	O
+cluster	O
+of	O
+microarray	O
+would	O
+involve	O
+9	O
+,	O
+3	O
+and	O
+23	O
+signaling	B-PROC
+pathways	B-PROC
+respectively	O
+,	O
+and	O
+only	O
+the	O
+former	O
+two	O
+showed	O
+7	O
+common	O
+pathways	B-PROC
+,	O
+which	O
+were	O
+related	O
+to	O
+pathogen	O
+recognition	O
+,	O
+cytokine	O
+release	B-PATH
+and	O
+autoimmune	B-DISO
+response	I-DISO
+.	O
+
+Thus	O
+,	O
+this	O
+retrospective	O
+approach	O
+yielded	O
+valuable	O
+data	O
+on	O
+the	O
+presence	O
+,	O
+absence	O
+and	O
+prevalence	O
+of	O
+certain	O
+respiratory	O
+pathogens	O
+in	O
+dogs	B-SPEC
+with	O
+pneumonia	B-DISO
+.	O
+
+Further	O
+studies	O
+are	O
+necessary	O
+to	O
+characterize	O
+the	O
+role	O
+and	O
+/	O
+or	O
+clinical	O
+significance	O
+of	O
+sVCAM	O
+-	O
+1	O
+and	O
+other	O
+endothelial	B-ANAT
+activation	O
+markers	O
+present	O
+in	O
+the	O
+alveolar	B-ANAT
+space	O
+in	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+efficient	O
+public	O
+health	O
+preparedness	O
+and	O
+response	O
+plan	B-DISO
+for	O
+infectious	B-DISO
+disease	I-DISO
+management	O
+is	O
+important	O
+in	O
+recent	O
+times	O
+when	O
+emerging	O
+and	O
+exotic	O
+diseases	O
+that	O
+hitherto	O
+were	O
+not	O
+common	O
+have	O
+surfaced	O
+in	O
+countries	O
+with	O
+potential	O
+to	O
+spread	O
+outside	O
+borders	O
+.	O
+
+In	O
+this	O
+paper	O
+we	O
+share	O
+our	O
+experiences	O
+in	O
+recent	O
+infectious	B-DISO
+disease	I-DISO
+outbreak	O
+investigations	O
+as	O
+a	O
+reference	O
+laboratory	O
+within	O
+the	O
+Ministry	O
+of	O
+Health	O
+infectious	O
+disease	O
+surveillance	O
+network	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+carotid	O
+body	O
+(	O
+CB	O
+)	O
+is	O
+the	O
+main	O
+peripheral	O
+chemoreceptor	B-ANAT
+that	O
+senses	B-PROC
+the	O
+arterial	B-ANAT
+PO2	B-PROC
+,	O
+PCO2	O
+and	O
+pH	O
+.	O
+In	O
+response	O
+to	O
+hypoxemia	O
+,	O
+hypercapnia	B-DISO
+and	O
+acidosis	B-DISO
+,	O
+carotid	B-ANAT
+chemosensory	O
+discharge	B-ANAT
+elicits	O
+reflex	B-PROC
+respiratory	O
+,	O
+autonomic	B-ANAT
+and	O
+cardiovascular	B-ANAT
+adjustments	O
+.	O
+
+The	O
+fatal	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+highlights	O
+the	O
+threat	O
+posed	O
+by	O
+this	O
+unique	O
+virus	B-SPEC
+subfamily	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+conducted	O
+a	O
+six	O
+-	O
+year	O
+epidemiological	O
+study	O
+on	O
+human	O
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+circulating	O
+in	O
+Hong	O
+Kong	O
+,	O
+using	O
+8275	O
+nasopharyngeal	B-ANAT
+samples	O
+from	O
+patients	O
+with	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+mainly	O
+occurred	O
+in	O
+winter	O
+and	O
+spring	O
+,	O
+while	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+was	O
+predominant	O
+in	O
+summer	O
+and	O
+autumn	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+mRNAs	O
+encoding	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+(	I-PRGE
+TLR	I-PRGE
+)	I-PRGE
+3	I-PRGE
+and	O
+TLR7	B-PRGE
+were	O
+upregulated	O
+at	O
+3	O
+-	O
+8	O
+dpi	O
+,	O
+and	O
+that	O
+of	O
+TIR	O
+-	O
+domain	O
+-	O
+containing	O
+adapter	O
+-	O
+inducing	O
+interferon	B-PRGE
+(	O
+IFN	O
+)	O
+β	O
+(	O
+TRIF	B-PRGE
+)	O
+was	O
+upregulated	O
+at	O
+21	O
+dpi	O
+in	O
+the	O
+trachea	B-DISO
+and	O
+kidney	B-ANAT
+.	O
+
+Moreover	O
+,	O
+melanoma	B-PATH
+differentiation	B-PROC
+-	O
+associated	O
+protein	B-CHED
+5	O
+(	O
+MDA5	O
+),	O
+laboratory	B-PRGE
+of	I-PRGE
+genetics	I-PRGE
+and	I-PRGE
+physiology	I-PRGE
+2	I-PRGE
+(	O
+LGP2	B-PRGE
+),	O
+stimulator	O
+of	O
+IFN	B-PRGE
+genes	O
+(	O
+STING	B-PRGE
+),	O
+and	O
+mitochondrial	B-COMP
+antiviral	B-CHED
+signaling	B-PROC
+protein	B-CHED
+(	O
+MAVS	O
+),	O
+as	O
+well	O
+as	O
+TANK	B-PRGE
+binding	I-PRGE
+kinase	I-PRGE
+1	I-PRGE
+(	O
+TBK1	B-FUNC
+),	O
+inhibitor	B-PRGE
+of	I-PRGE
+kappaB	B-PRGE
+kinase	I-PRGE
+(	I-PRGE
+IKK	I-PRGE
+)	I-PRGE
+ε	I-PRGE
+,	O
+IKKα	O
+,	O
+IKKβ	O
+,	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+(	I-PRGE
+IRF	I-PRGE
+)	I-PRGE
+7	I-PRGE
+,	O
+nuclear	B-PRGE
+factor	I-PRGE
+of	I-PRGE
+kappaB	I-PRGE
+(	O
+NF	O
+-	O
+ĸB	O
+),	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+,	O
+various	O
+interleukins	B-PRGE
+(	I-PRGE
+ILs	I-PRGE
+),	I-PRGE
+and	I-PRGE
+macrophage	B-ANAT
+inflammatory	I-PRGE
+protein	B-CHED
+-	I-PRGE
+1β	I-PRGE
+(	O
+MIP	B-PRGE
+-	I-PRGE
+1β	I-PRGE
+)	O
+were	O
+significantly	O
+upregulated	O
+in	O
+the	O
+trachea	B-DISO
+and	O
+downregulated	O
+in	O
+the	O
+kidney	B-ANAT
+.	O
+
+A	O
+60	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+presented	O
+with	O
+pneumonia	B-DISO
+and	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+serum	B-COMP
+creatinine	B-CHED
+level	O
+was	O
+found	O
+mildly	O
+elevated	O
+.	O
+
+Sputum	B-ANAT
+sample	I-ANAT
+was	O
+positive	O
+for	O
+MeRS	O
+-	O
+CoV	O
+.	O
+Cardiovascular	B-ANAT
+magnetic	O
+resonance	O
+revealed	O
+evidence	O
+of	O
+acute	B-DISO
+myocarditis	I-DISO
+.	O
+
+Six	O
+hundred	O
+ninety	O
+-	O
+four	O
+non	O
+-	O
+HCWs	O
+were	O
+tested	O
+,	O
+of	O
+these	O
+16	O
+tested	O
+positive	O
+for	O
+MERS	O
+-	O
+CoV	O
+and	O
+their	O
+infection	B-DISO
+was	O
+community	O
+acquired	O
+.	O
+
+In	O
+the	O
+data	O
+-	O
+driven	O
+approach	O
+,	O
+incorporating	O
+the	O
+ARDS	B-DISO
+index	O
+(	O
+a	O
+novel	O
+variable	O
+incorporating	O
+oxygenation	B-PROC
+index	O
+and	O
+estimated	O
+dead	B-PROC
+space	O
+),	O
+aspiration	B-DISO
+,	O
+and	O
+change	O
+of	O
+Pao2	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+into	O
+a	O
+simple	O
+prediction	O
+model	O
+yielded	O
+a	O
+c	O
+-	O
+statistic	O
+(	O
+area	O
+under	O
+the	O
+receiver	O
+operating	O
+characteristic	O
+curve	O
+)	O
+of	O
+0	O
+.	O
+71	O
+in	O
+the	O
+validation	O
+cohort	O
+.	O
+
+Our	O
+results	O
+confirm	O
+that	O
+the	O
+SARS	B-DISO
+input	O
+-	O
+output	O
+flows	O
+presented	O
+significant	O
+geographic	O
+spatial	O
+heterogeneity	O
+and	O
+spatial	O
+effects	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+):	O
+animal	B-SPEC
+to	O
+human	B-SPEC
+interaction	O
+.	O
+
+The	O
+clinical	O
+spectrum	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+humans	B-SPEC
+ranges	O
+from	O
+an	O
+asymptomatic	O
+or	O
+mild	O
+respiratory	O
+illness	O
+to	O
+severe	O
+pneumonia	B-DISO
+and	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+;	O
+overall	O
+mortality	O
+is	O
+around	O
+35	O
+.	O
+7	O
+%.	O
+
+Clusters	B-CHED
+can	O
+be	O
+readily	O
+controlled	O
+with	O
+implementation	O
+of	O
+appropriate	O
+infection	B-DISO
+control	O
+procedures	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+serosurveys	O
+are	O
+needed	O
+to	O
+investigate	O
+possible	O
+unrecognized	O
+human	B-SPEC
+infections	B-DISO
+in	O
+Africa	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+largest	O
+nosocomial	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+occurred	O
+in	O
+South	O
+Korea	O
+in	O
+2015	O
+.	O
+
+The	O
+epidemiological	O
+findings	O
+showed	O
+that	O
+the	O
+mean	O
+age	O
+of	O
+MERS	O
+-	O
+HCP	B-DISO
+and	O
+total	O
+MERS	O
+cases	O
+were	O
+40	O
+(	O
+24	O
+~	O
+74	O
+)	O
+and	O
+49	O
+(	O
+2	O
+~	O
+90	O
+)	O
+years	O
+,	O
+respectively	O
+,	O
+much	O
+older	O
+than	O
+those	O
+in	O
+SARS	B-DISO
+[	O
+SARS	B-DISO
+-	O
+HCP	B-DISO
+:	O
+35	O
+(	O
+21	O
+~	O
+68	O
+)	O
+years	O
+,	O
+p	O
+=	O
+0	O
+.	O
+006	O
+;	O
+total	O
+SARS	B-DISO
+:	O
+42	O
+(	O
+0	O
+~	O
+94	O
+)	O
+years	O
+,	O
+p	O
+=	O
+0	O
+.	O
+0002	O
+].	O
+
+In	O
+terms	O
+of	O
+clinical	O
+period	O
+,	O
+the	O
+days	O
+from	O
+onset	O
+to	O
+death	B-PROC
+[	O
+13	O
+(	O
+4	O
+~	O
+17	O
+)	O
+vs	O
+14	O
+.	O
+5	O
+(	O
+0	O
+~	O
+52	O
+),	O
+p	O
+=	O
+0	O
+.	O
+045	O
+]	O
+and	O
+to	O
+discharge	B-ANAT
+[	O
+11	O
+(	O
+5	O
+~	O
+24	O
+)	O
+vs	O
+24	O
+(	O
+0	O
+~	O
+74	O
+),	O
+p	O
+=	O
+0	O
+.	O
+010	O
+]	O
+and	O
+be	O
+hospitalized	O
+days	O
+[	O
+9	O
+.	O
+5	O
+(	O
+3	O
+~	O
+22	O
+)	O
+vs	O
+22	O
+(	O
+0	O
+~	O
+69	O
+),	O
+p	O
+=	O
+0	O
+.	O
+040	O
+]	O
+were	O
+much	O
+shorter	O
+in	O
+MERS	O
+-	O
+HCP	B-DISO
+than	O
+SARS	B-DISO
+-	O
+HCP	B-DISO
+.	O
+
+Similarly	O
+,	O
+days	O
+from	O
+onset	O
+to	O
+confirmation	O
+were	O
+shorter	O
+in	O
+MERS	O
+-	O
+HCP	B-DISO
+than	O
+MERS	O
+-	O
+non	O
+-	O
+HCP	B-DISO
+[	O
+6	O
+(	O
+1	O
+~	O
+14	O
+)	O
+vs	O
+10	O
+(	O
+1	O
+~	O
+21	O
+),	O
+p	O
+=	O
+0	O
+.	O
+044	O
+].	O
+
+Thus	O
+,	O
+prevention	O
+of	O
+nosocomial	B-DISO
+infections	I-DISO
+involving	O
+both	O
+novel	B-SPEC
+Coronavirus	I-SPEC
+is	O
+crucially	O
+important	O
+to	O
+protect	O
+HCP	B-DISO
+.	O
+
+The	O
+objectives	O
+of	O
+this	O
+study	O
+were	O
+to	O
+describe	O
+healthcare	O
+-	O
+seeking	O
+behaviors	B-PROC
+for	O
+respiratory	O
+illnesses	O
+in	O
+one	O
+rural	O
+and	O
+one	O
+urban	O
+community	O
+in	O
+Western	O
+Java	O
+,	O
+and	O
+to	O
+explore	O
+the	O
+factors	O
+that	O
+affect	O
+care	O
+seeking	O
+.	O
+
+Public	O
+health	O
+programs	O
+targeting	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+this	O
+region	O
+should	O
+account	O
+for	O
+care	O
+at	O
+private	O
+hospitals	O
+and	O
+clinics	O
+,	O
+as	O
+well	O
+as	O
+illnesses	O
+that	O
+are	O
+treated	O
+at	O
+home	O
+,	O
+in	O
+order	B-SPEC
+to	O
+capture	O
+the	O
+true	O
+burden	O
+of	O
+illness	O
+in	O
+these	O
+communities	O
+.	O
+
+We	O
+estimated	O
+the	O
+incidence	O
+of	O
+ARIs	O
+in	O
+each	O
+community	O
+,	O
+tested	O
+for	O
+viruses	B-SPEC
+,	O
+and	O
+determined	O
+the	O
+proportion	O
+of	O
+ARIs	O
+associated	O
+with	O
+healthcare	O
+visits	O
+.	O
+
+We	O
+used	O
+a	O
+rolling	O
+cross	O
+-	O
+sectional	O
+design	O
+to	O
+sample	O
+participants	O
+,	O
+conducted	O
+telephone	O
+interviews	O
+to	O
+assess	O
+ARI	B-CHED
+symptoms	O
+(	O
+defined	O
+as	O
+a	O
+current	O
+illness	O
+with	O
+feverishness	O
+or	O
+cough	B-DISO
+within	O
+the	O
+past	O
+7	O
+days	O
+),	O
+collected	O
+nasal	B-ANAT
+/	O
+throat	B-ANAT
+swabs	O
+to	O
+identify	O
+viruses	B-SPEC
+,	O
+and	O
+extracted	O
+healthcare	O
+utilization	O
+from	O
+outpatient	O
+/	O
+inpatient	O
+records	O
+.	O
+
+A	O
+specific	O
+virus	O
+was	O
+identified	O
+in	O
+39	O
+%	O
+of	O
+specimens	O
+:	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+13	O
+%	O
+of	O
+samples	O
+),	O
+rhinovirus	B-SPEC
+(	O
+12	O
+%),	O
+RSV	B-SPEC
+(	O
+7	O
+%),	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+4	O
+%),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+4	O
+%),	O
+and	O
+adenovirus	B-DISO
+(	O
+1	O
+%).	O
+
+Using	O
+extensive	O
+multiplex	O
+PCR	O
+diagnostic	O
+data	O
+generated	O
+by	O
+the	O
+largest	O
+NHS	B-DISO
+board	O
+in	O
+Scotland	O
+,	O
+we	O
+analysed	O
+44230	O
+patient	O
+episodes	O
+of	O
+respiratory	O
+illness	O
+that	O
+were	O
+simultaneously	O
+tested	O
+for	O
+11	O
+virus	B-SPEC
+groups	O
+between	O
+2005	O
+and	O
+2013	O
+,	O
+spanning	O
+the	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+pandemic	O
+.	O
+
+TITLE	O
+:	O
+Spread	O
+of	O
+Mutant	B-DISO
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+with	O
+Reduced	O
+Affinity	O
+to	O
+Human	B-SPEC
+CD26	I-PRGE
+during	O
+the	O
+South	O
+Korean	O
+Outbreak	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+case	O
+report	O
+reported	O
+in	O
+Europe	O
+that	O
+confirms	O
+the	O
+rare	O
+onset	O
+of	O
+sarcoidosis	B-DISO
+as	O
+ARDS	B-DISO
+.	O
+
+Additionally	O
+,	O
+lipid	B-COMP
+rafts	I-COMP
+act	O
+as	O
+signal	O
+platforms	O
+for	O
+the	O
+EGFR	B-FUNC
+-	O
+associated	O
+signaling	B-PROC
+cascade	I-PROC
+and	O
+correlate	O
+with	O
+the	O
+adhesion	B-DISO
+of	O
+TGEV	B-SPEC
+.	O
+
+As	O
+the	O
+largest	O
+known	O
+class	B-SPEC
+I	O
+fusion	O
+protein	B-CHED
+,	O
+its	O
+size	O
+and	O
+extensive	O
+glycosylation	B-PROC
+have	O
+hindered	O
+structural	O
+studies	O
+of	O
+the	O
+full	O
+ectodomain	O
+,	O
+thus	O
+preventing	O
+a	O
+molecular	O
+understanding	O
+of	O
+its	O
+function	O
+and	O
+limiting	O
+development	B-PROC
+of	O
+effective	O
+interventions	O
+.	O
+
+In	O
+the	O
+pre	O
+-	O
+fusion	O
+conformation	O
+,	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+subunits	O
+,	O
+S1	O
+,	O
+rest	B-FUNC
+above	O
+the	O
+fusion	O
+-	O
+mediating	O
+subunits	O
+,	O
+S2	O
+,	O
+preventing	O
+their	O
+conformational	O
+rearrangement	B-PROC
+.	O
+
+180	O
+-	O
+374	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+but	O
+two	O
+serum	B-COMP
+samples	O
+did	O
+not	O
+a	O
+.	O
+a	O
+.	O
+
+To	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+a	O
+laboratory	O
+-	O
+confirmed	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+in	O
+a	O
+pregnant	O
+woman	O
+.	O
+
+This	O
+study	O
+was	O
+aimed	O
+at	O
+investigating	O
+the	O
+prognostic	O
+factors	O
+for	O
+ECMO	O
+-	O
+treated	O
+ARDS	B-DISO
+in	O
+adult	O
+patients	O
+.	O
+
+The	O
+indication	O
+of	O
+VV	O
+-	O
+ECMO	O
+was	O
+a	O
+severe	O
+hypoxemia	O
+(	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+<	O
+70	O
+mmHg	O
+)	O
+under	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+)	O
+with	O
+a	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+(	O
+PIP	B-CHED
+)	O
+>	O
+35	O
+cmH2O	O
+and	O
+a	O
+FiO2	O
+>	O
+0	O
+.	O
+8	O
+.	O
+
+A	O
+single	O
+Black	B-SPEC
+-	I-SPEC
+headed	I-SPEC
+Gull	I-SPEC
+represented	O
+the	O
+only	O
+positive	O
+sample	O
+from	O
+the	O
+order	B-SPEC
+Charadriiformes	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Hypomagnesaemia	O
+in	O
+suckler	O
+cows	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Hypomagnesaemia	O
+in	O
+housed	O
+and	O
+grazing	O
+suckler	O
+cows	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Prophylaxis	O
+With	O
+a	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)-	O
+Specific	O
+Human	B-SPEC
+Monoclonal	O
+Antibody	O
+Protects	O
+Rabbits	B-SPEC
+From	O
+MERS	O
+-	O
+CoV	O
+Infection	B-DISO
+.	O
+
+We	O
+examined	O
+the	O
+in	O
+vivo	O
+efficacy	O
+of	O
+the	O
+human	B-PRGE
+monoclonal	I-PRGE
+antibody	B-COMP
+m336	I-PRGE
+,	O
+which	O
+has	O
+high	O
+neutralizing	O
+activity	O
+against	O
+MERS	O
+-	O
+CoV	O
+in	O
+vitro	O
+.	O
+
+An	O
+antibody	B-PROC
+response	I-PROC
+against	O
+IBV	B-SPEC
+was	O
+detectable	O
+and	O
+the	O
+ratio	O
+of	O
+CD4	B-PRGE
+(+)/	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+decreased	O
+at	O
+7	O
+days	O
+post	O
+-	O
+vaccination	O
+in	O
+each	O
+vaccinated	O
+group	O
+,	O
+suggesting	O
+that	O
+humoral	O
+and	O
+cellular	B-COMP
+responses	O
+were	O
+elicited	O
+in	O
+each	O
+group	O
+as	O
+early	O
+as	O
+7	O
+days	O
+post	O
+-	O
+immunization	O
+.	O
+
+ABSTRACT	O
+:	O
+Because	O
+HIV	O
+-	O
+1	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+is	O
+an	O
+enzyme	O
+whose	O
+catalytic	B-FUNC
+activity	I-FUNC
+depends	O
+on	O
+its	O
+heterodimeric	O
+structure	O
+,	O
+this	O
+system	O
+could	O
+be	O
+a	O
+target	O
+for	O
+inhibitors	B-CHED
+that	O
+perturb	O
+the	O
+interactions	O
+between	O
+the	O
+protein	B-CHED
+subunits	O
+,	O
+p51	B-PRGE
+and	O
+p66	B-PRGE
+.	O
+
+In	O
+this	O
+study	O
+,	O
+some	O
+analogues	O
+of	O
+MAS0	O
+were	O
+rationally	O
+selected	O
+by	O
+docking	B-PROC
+studies	O
+and	O
+evaluated	O
+in	O
+vitro	O
+for	O
+their	O
+ability	O
+to	O
+disrupt	O
+dimeric	O
+assembly	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2013	O
+,	O
+U	O
+.	O
+S	O
+.	O
+swine	B-SPEC
+producers	O
+were	O
+confronted	O
+with	O
+the	O
+disruptive	O
+emergence	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhoea	I-DISO
+(	O
+PED	O
+).	O
+
+Unfortunately	O
+,	O
+there	O
+are	O
+currently	O
+no	O
+effective	O
+antiviral	B-CHED
+therapy	O
+to	O
+contain	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Guillain	O
+-	O
+Barré	O
+Syndrome	B-DISO
+outbreak	O
+associated	O
+with	O
+Zika	B-SPEC
+virus	I-SPEC
+infection	O
+in	O
+French	O
+Polynesia	O
+:	O
+a	O
+case	O
+-	O
+control	O
+study	O
+.	O
+
+39	O
+(	O
+93	O
+%)	O
+patients	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+had	O
+Zika	B-PRGE
+virus	I-PRGE
+IgM	I-PRGE
+and	O
+37	O
+(	O
+88	O
+%)	O
+had	O
+experienced	O
+a	O
+transient	O
+illness	O
+in	O
+a	O
+median	O
+of	O
+6	O
+days	O
+(	O
+IQR	O
+4	O
+-	O
+10	O
+)	O
+before	O
+the	O
+onset	O
+of	O
+neurological	B-DISO
+symptoms	I-DISO
+,	O
+suggesting	O
+recent	O
+Zika	B-SPEC
+virus	I-SPEC
+infection	O
+.	O
+
+No	O
+patients	O
+died	B-PROC
+.	O
+
+Anti	O
+-	O
+glycolipid	B-CHED
+antibody	B-PROC
+activity	I-PROC
+was	O
+found	O
+in	O
+13	O
+(	O
+31	O
+%)	O
+patients	O
+,	O
+and	O
+notably	O
+against	O
+GA1	B-CHED
+in	O
+eight	O
+(	O
+19	O
+%)	O
+patients	O
+,	O
+by	O
+ELISA	O
+and	O
+19	O
+(	O
+46	O
+%)	O
+of	O
+41	O
+by	O
+glycoarray	O
+at	O
+admission	O
+.	O
+
+Past	O
+dengue	B-SPEC
+virus	I-SPEC
+history	O
+did	O
+not	O
+differ	O
+significantly	O
+between	O
+patients	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+and	O
+those	O
+in	O
+the	O
+two	O
+control	O
+groups	O
+(	O
+95	O
+%,	O
+89	O
+%,	O
+and	O
+83	O
+%,	O
+respectively	O
+).	O
+
+This	O
+is	O
+the	O
+first	O
+study	O
+providing	O
+evidence	O
+for	O
+Zika	B-SPEC
+virus	I-SPEC
+infection	O
+causing	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+.	O
+
+After	O
+establishment	O
+of	O
+mice	B-SPEC
+model	O
+,	O
+we	O
+observed	O
+the	O
+clinical	O
+signs	O
+of	O
+disease	B-DISO
+,	I-DISO
+virus	I-DISO
+replication	O
+,	O
+immunopathogenesis	O
+and	O
+antibody	B-PROC
+response	I-PROC
+.	O
+
+The	O
+results	O
+indicated	O
+that	O
+the	O
+infected	O
+mice	B-SPEC
+showed	O
+typical	O
+pneumonia	B-DISO
+,	O
+virus	B-PROC
+replication	I-PROC
+,	O
+histological	O
+lesions	O
+,	O
+and	O
+neutralizing	O
+antibody	B-PROC
+production	I-PROC
+.	O
+
+TITLE	O
+:	O
+Glycopeptide	B-CHED
+Antibiotics	B-CHED
+Potently	O
+Inhibit	O
+Cathepsin	B-ENZY
+L	I-ENZY
+in	O
+the	O
+Late	B-COMP
+Endosome	I-COMP
+/	O
+Lysosome	B-COMP
+and	O
+Block	O
+the	O
+Entry	O
+of	O
+Ebola	O
+Virus	O
+,	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+and	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+development	B-PROC
+of	O
+additional	O
+effective	O
+anti	O
+-	O
+Ebola	O
+therapeutic	O
+agents	O
+is	O
+therefore	O
+quite	O
+urgent	O
+.	O
+
+Mechanistic	O
+studies	O
+showed	O
+that	O
+teicoplanin	O
+blocks	O
+Ebola	B-SPEC
+virus	I-SPEC
+entry	O
+by	O
+specifically	O
+inhibiting	O
+the	O
+activity	O
+of	O
+cathepsin	B-PRGE
+L	I-PRGE
+,	O
+opening	O
+a	O
+novel	O
+avenue	O
+for	O
+the	O
+development	B-PROC
+of	O
+additional	O
+glycopeptides	B-CHED
+as	O
+potential	O
+inhibitors	B-CHED
+of	O
+cathepsin	B-PRGE
+L	I-PRGE
+-	I-PRGE
+dependent	O
+viruses	B-SPEC
+.	O
+
+Genotype	O
+-	O
+specific	O
+primers	O
+,	O
+combined	O
+with	O
+a	O
+generic	O
+probe	O
+targeted	B-PROC
+to	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+,	O
+originated	O
+Mass	O
+RT	O
+-	O
+qPCR	O
+and	O
+BR	O
+RT	O
+-	O
+qPCR	O
+-	O
+specific	O
+assays	O
+.	O
+
+Analytical	O
+sensitivity	O
+and	O
+linearity	O
+of	O
+these	O
+assays	O
+were	O
+determined	O
+in	O
+comparison	O
+with	O
+an	O
+IBV	B-SPEC
+generic	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+based	O
+on	O
+the	O
+5	O
+'	O
+untranslated	O
+region	O
+(	O
+5	O
+'	O
+UTR	O
+RT	O
+-	O
+qPCR	O
+).	O
+
+In	O
+the	O
+remaining	O
+55	O
+samples	O
+,	O
+25	O
+were	O
+positive	O
+only	O
+for	O
+5	B-PRGE
+'	I-PRGE
+UTR	I-PRGE
+RT	I-PRGE
+-	I-PRGE
+qPCR	I-PRGE
+and	O
+30	O
+were	O
+negative	O
+for	O
+the	O
+three	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+Memory	B-PROC
+T	B-ANAT
+cell	I-ANAT
+responses	O
+targeting	B-PROC
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+persist	O
+up	O
+to	O
+11	O
+years	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+highly	O
+contagious	O
+infectious	B-DISO
+disease	I-DISO
+which	O
+first	O
+emerged	O
+in	O
+late	O
+2002	O
+,	O
+caused	O
+by	O
+a	O
+then	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Furthermore	O
+,	O
+these	O
+responses	O
+were	O
+found	O
+to	O
+persist	O
+up	O
+to	O
+11	O
+years	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+These	O
+patients	O
+were	O
+planned	O
+to	O
+ventilate	O
+in	O
+prone	O
+for	O
+16	O
+h	O
+and	O
+in	O
+supine	O
+for	O
+8	O
+h	O
+daily	O
+until	O
+P	O
+/	O
+F	O
+ratio	O
+>	O
+150	O
+with	O
+FiO2	O
+of	O
+0	O
+.	O
+6	O
+or	O
+less	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+<	O
+10	O
+cm	O
+of	O
+H2	O
+O	O
+.	O
+At	O
+admission	O
+,	O
+among	O
+these	O
+six	O
+patients	O
+the	O
+mean	O
+tidal	O
+volume	O
+generated	O
+was	O
+about	O
+376	O
+.	O
+6	O
+ml	O
+which	O
+was	O
+in	O
+the	O
+range	O
+of	O
+6	O
+-	O
+8	O
+ml	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Early	O
+prone	O
+combined	O
+with	O
+ACPC	O
+-	O
+IRV	B-PROC
+in	O
+H1N1	O
+patients	O
+having	O
+severe	O
+ARDS	B-DISO
+can	O
+be	O
+used	O
+as	O
+a	O
+rescue	O
+therapy	O
+and	O
+it	O
+should	O
+be	O
+confirmed	O
+by	O
+large	O
+observational	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Thinking	O
+Outside	O
+the	O
+Triangle	O
+:	O
+Replication	O
+Fidelity	O
+of	O
+the	O
+Largest	O
+RNA	O
+Viruses	B-SPEC
+.	O
+
+In	O
+this	O
+review	O
+we	O
+compare	O
+the	O
+fidelity	O
+of	O
+small	O
+RNA	O
+viruses	B-SPEC
+with	O
+that	O
+of	O
+the	O
+largest	O
+RNA	O
+viruses	B-SPEC
+,	O
+the	O
+coronaviruses	O
+.	O
+
+The	O
+engagement	O
+of	O
+glycans	B-CHED
+facilitates	O
+attachment	O
+and	O
+entry	O
+and	O
+,	O
+consequently	O
+,	O
+is	O
+often	O
+a	O
+key	O
+determinant	O
+of	O
+the	O
+host	B-COMP
+range	O
+,	O
+tissue	B-PROC
+tropism	B-PROC
+,	O
+pathogenicity	O
+,	O
+and	O
+transmissibility	O
+of	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+Host	B-COMP
+Range	O
+Expansion	O
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Emergence	O
+:	O
+Biochemical	O
+Mechanisms	O
+and	O
+Evolutionary	O
+Perspectives	O
+.	O
+
+We	O
+discuss	O
+biochemical	O
+determinants	O
+mediating	O
+MERS	O
+-	O
+CoV	O
+host	O
+cell	O
+permissivity	O
+,	O
+including	O
+virus	B-SPEC
+spike	O
+interactions	O
+with	O
+the	O
+MERS	O
+-	O
+CoV	O
+cell	B-COMP
+surface	I-COMP
+receptor	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+),	O
+and	O
+evolutionary	O
+mechanisms	O
+that	O
+may	O
+facilitate	O
+host	B-COMP
+range	O
+expansion	O
+,	O
+including	O
+recombination	B-PROC
+,	O
+mutator	O
+alleles	O
+,	O
+and	O
+mutational	O
+robustness	O
+.	O
+
+TITLE	O
+:	O
+Continuous	O
+and	O
+Discontinuous	O
+RNA	B-PROC
+Synthesis	I-PROC
+in	O
+Coronaviruses	O
+.	O
+
+Crude	O
+30	O
+-	O
+day	O
+mortality	O
+was	O
+16	O
+.	O
+1	O
+%	O
+(	O
+N	O
+=	O
+342	O
+,	O
+95	O
+%	O
+CI	O
+14	O
+.	O
+5	O
+-	O
+17	O
+.	O
+7	O
+%);	O
+37	O
+.	O
+5	O
+%	O
+(	O
+N	O
+=	O
+24	O
+,	O
+95	O
+%	O
+CI	O
+25	O
+.	O
+7	O
+-	O
+50	O
+.	O
+5	O
+%)	O
+for	O
+hypothermic	O
+patients	O
+,	O
+18	O
+.	O
+3	O
+%	O
+(	O
+N	O
+=	O
+223	O
+,	O
+95	O
+%	O
+CI	O
+16	O
+.	O
+2	O
+-	O
+20	O
+.	O
+6	O
+%)	O
+for	O
+normothermic	O
+patients	O
+and	O
+11	O
+.	O
+2	O
+%	O
+(	O
+N	O
+=	O
+95	O
+,	O
+95	O
+%	O
+CI	O
+9	O
+.	O
+2	O
+-	O
+13	O
+.	O
+5	O
+%)	O
+for	O
+patients	O
+with	O
+fever	B-PROC
+.	O
+
+Compared	O
+to	O
+normothermic	O
+patients	O
+,	O
+the	O
+adjusted	O
+hazard	O
+ratio	O
+of	O
+30	O
+-	O
+day	O
+mortality	O
+among	O
+hypothermic	O
+patients	O
+was	O
+1	O
+.	O
+62	O
+(	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+06	O
+-	O
+2	O
+.	O
+49	O
+)	O
+and	O
+0	O
+.	O
+74	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+58	O
+-	O
+0	O
+.	O
+94	O
+)	O
+among	O
+patients	O
+with	O
+fever	B-PROC
+.	O
+
+Protecting	O
+the	O
+blood	B-PROC
+supply	I-PROC
+from	O
+emerging	O
+infectious	B-DISO
+threats	O
+remains	O
+a	O
+serious	O
+concern	O
+in	O
+the	O
+transfusion	O
+medicine	B-CHED
+community	O
+.	O
+
+Transfusion	O
+services	O
+can	O
+employ	O
+indirect	O
+measures	O
+such	O
+as	O
+surveillance	O
+,	O
+hemovigilance	O
+,	O
+and	O
+donor	B-CHED
+questioning	O
+(	O
+defense	O
+),	O
+protein	B-CHED
+-,	O
+or	O
+nucleic	B-CHED
+acid	I-CHED
+based	O
+direct	O
+testing	O
+(	O
+detection	O
+),	O
+or	O
+pathogen	O
+inactivation	B-DISO
+of	O
+blood	B-ANAT
+products	O
+(	O
+destruction	O
+)	O
+as	O
+strategies	O
+to	O
+mitigate	O
+the	O
+risk	O
+of	O
+transmission	O
+-	O
+transmitted	B-DISO
+infection	B-DISO
+.	O
+
+We	O
+found	O
+that	O
+MERS	O
+-	O
+CoV	O
+shared	O
+30	O
+%	O
+of	O
+its	O
+S	O
+protein	B-CHED
+antigenic	O
+sites	O
+with	O
+HKU4	O
+and	O
+70	O
+%	O
+with	O
+HKU5	B-PRGE
+bat	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Whereas	O
+100	O
+%	O
+of	O
+its	O
+E	O
+,	O
+M	O
+and	O
+N	O
+protein	B-CHED
+'	O
+s	O
+antigenic	O
+sites	O
+are	O
+found	O
+to	O
+be	O
+conserved	O
+with	O
+those	O
+in	O
+HKU4	O
+and	O
+HKU5	O
+.	O
+
+RESULTS	O
+:	O
+Multiple	O
+sequence	O
+alignment	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+),	O
+enveloped	O
+(	O
+E	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+proteins	B-CHED
+was	O
+employed	O
+to	O
+identify	O
+the	O
+sequence	O
+conservation	O
+among	O
+MERS	O
+and	O
+Bat	B-PRGE
+(	O
+HKU4	O
+,	O
+HKU5	O
+)	O
+coronaviruses	O
+.	O
+
+The	O
+child	O
+presented	O
+with	O
+cough	B-DISO
+,	O
+loose	B-DISO
+stools	I-DISO
+,	O
+breathing	B-DISO
+difficulty	I-DISO
+,	O
+and	O
+listlessness	B-DISO
+.	O
+
+Child	O
+was	O
+diagnosed	O
+as	O
+GBS	B-DISO
+and	O
+treated	O
+with	O
+intravenous	O
+immunoglobulin	B-PROC
+.	O
+
+We	O
+did	O
+a	O
+retrospective	O
+cross	O
+-	O
+sectional	O
+multicenter	O
+study	O
+in	O
+Turkey	B-SPEC
+to	O
+explore	O
+the	O
+range	O
+of	O
+infections	B-DISO
+among	O
+inpatients	O
+who	O
+had	O
+recently	O
+returned	O
+from	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+P	O
+generation	O
+cats	B-SPEC
+produced	O
+57	O
+first	O
+filial	O
+(	O
+F1	O
+)	O
+kittens	O
+,	O
+only	O
+five	O
+of	O
+which	O
+(	O
+9	O
+.	O
+0	O
+%)	O
+demonstrated	O
+a	O
+natural	O
+resistance	O
+to	O
+FIPV	O
+infection	B-DISO
+.	O
+
+One	O
+of	O
+these	O
+five	O
+F1	O
+survivors	O
+was	O
+then	O
+used	O
+to	O
+produce	O
+six	O
+F1	O
+/	O
+P	O
+-	O
+backcrosses	O
+kittens	O
+,	O
+only	O
+one	O
+of	O
+which	O
+proved	O
+resistant	O
+to	O
+FIP	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Community	O
+-	O
+Acquired	O
+Pneumonia	B-DISO
+Caused	O
+by	O
+Human	B-SPEC
+Adenovirus	B-DISO
+in	O
+Immunocompetent	O
+Adults	O
+:	O
+A	O
+Multicenter	O
+Case	O
+Series	O
+.	O
+
+A	O
+total	O
+of	O
+15	O
+consecutive	O
+severe	O
+CAP	B-DISO
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+adenovirus	B-DISO
+infections	I-DISO
+were	O
+included	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+15	O
+consecutive	O
+severe	O
+CAP	B-DISO
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+adenovirus	B-DISO
+infections	I-DISO
+were	O
+included	O
+.	O
+
+Corticosteroids	B-CHED
+were	O
+prescribed	O
+to	O
+14	O
+patients	O
+in	O
+this	O
+report	O
+,	O
+but	O
+the	O
+utilization	O
+rate	O
+between	O
+survivors	O
+and	O
+non	O
+-	O
+survivors	O
+was	O
+not	O
+significant	O
+.	O
+
+Ingredients	O
+imported	O
+to	O
+the	O
+USA	O
+from	O
+China	O
+,	O
+including	O
+organic	O
+&	O
+conventional	O
+soybeans	B-SPEC
+and	O
+meal	O
+,	O
+lysine	B-CHED
+hydrochloride	B-CHED
+,	O
+D	O
+-	O
+L	O
+methionine	B-CHED
+,	O
+tryptophan	B-CHED
+,	O
+Vitamins	B-CHED
+A	O
+,	O
+D	O
+&	O
+E	O
+,	O
+choline	B-CHED
+,	O
+carriers	O
+(	O
+rice	B-SPEC
+hulls	O
+,	O
+corn	B-DISO
+cobs	B-FUNC
+)	O
+and	O
+feed	O
+grade	O
+tetracycline	B-CHED
+,	O
+were	O
+inoculated	O
+with	O
+PEDV	B-SPEC
+.	O
+
+Across	O
+control	O
+(	O
+non	O
+-	O
+treated	O
+)	O
+ingredients	O
+,	O
+viable	O
+PEDV	B-SPEC
+was	O
+detected	O
+in	O
+soybean	B-SPEC
+meal	O
+(	O
+organic	O
+and	O
+conventional	O
+),	O
+Vitamin	B-CHED
+D	I-CHED
+,	O
+lysine	B-CHED
+hydrochloride	B-CHED
+and	O
+choline	B-CHED
+chloride	I-CHED
+.	O
+
+Sub	B-PRGE
+-	I-PRGE
+cluster	I-PRGE
+C3	I-PRGE
+includes	O
+prototype	O
+,	O
+vaccine	O
+,	O
+or	O
+attenuated	O
+BCoV	O
+strains	O
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+investigation	O
+of	O
+the	O
+119th	O
+confirmed	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+case	O
+with	O
+an	O
+indefinite	O
+mode	O
+of	O
+transmission	O
+during	O
+the	O
+Pyeongtaek	O
+outbreak	O
+in	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+first	O
+case	O
+was	O
+diagnosed	O
+on	O
+May	O
+20	O
+,	O
+2015	O
+,	O
+there	O
+were	O
+186	O
+confirmed	O
+cases	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+until	O
+the	O
+end	O
+of	O
+outbreak	O
+in	O
+South	O
+Korea	O
+.	O
+
+An	O
+autopsy	O
+revealed	O
+multiple	O
+foci	O
+of	O
+air	B-CHED
+-	O
+space	O
+pneumonia	B-DISO
+containing	O
+numerous	O
+acid	O
+-	O
+fast	B-FUNC
+bacilli	B-SPEC
+without	O
+granuloma	O
+formation	O
+,	O
+accompanied	O
+by	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+.	O
+
+Also	O
+known	O
+as	O
+metabonomics	O
+,	O
+it	O
+comprises	O
+the	O
+analysis	O
+of	O
+all	O
+small	O
+molecules	O
+or	O
+metabolites	O
+that	O
+are	O
+present	O
+within	O
+an	O
+organism	O
+or	O
+a	O
+specific	O
+compartment	B-ANAT
+of	O
+the	O
+body	B-ANAT
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+review	O
+the	O
+burgeoning	O
+field	O
+of	O
+metabolomics	O
+in	O
+its	O
+application	O
+to	O
+acute	O
+lung	B-ANAT
+diseases	I-DISO
+,	O
+specifically	O
+pneumonia	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+syndrome	B-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+Influenza	B-SPEC
+Viruses	I-SPEC
+,	O
+Inflammation	B-DISO
+,	O
+and	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+Cell	I-ANAT
+Immunity	B-PROC
+.	O
+
+Neutrophils	B-ANAT
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+development	B-PROC
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+associated	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+ARDS	B-DISO
+.	O
+
+The	O
+neutrophils	B-ANAT
+that	O
+infiltrate	B-DISO
+the	O
+lungs	B-ANAT
+and	O
+migrate	O
+into	O
+the	O
+airways	O
+express	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+such	O
+as	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+),	O
+interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+beta	I-PRGE
+(	O
+IL	O
+-	O
+1β	O
+),	O
+and	O
+contribute	O
+to	O
+both	O
+the	O
+endothelial	B-ANAT
+and	O
+epithelial	O
+integrity	O
+disruption	O
+of	O
+the	O
+barriers	O
+.	O
+
+However	O
+,	O
+in	O
+vivo	O
+attenuation	O
+suggests	O
+additional	O
+adaptation	B-PROC
+is	O
+required	O
+for	O
+epidemic	B-DISO
+disease	I-DISO
+.	O
+
+Highly	O
+prevalent	O
+IBV	B-SPEC
+and	O
+AI	O
+-	O
+H9N2	O
+were	O
+isolated	O
+and	O
+were	O
+molecularly	O
+characterized	O
+based	O
+on	O
+S1	B-PRGE
+gene	I-PRGE
+hypervariable	I-PRGE
+region	I-PRGE
+3	I-PRGE
+(	O
+HVR3	O
+:	O
+)	O
+and	O
+hemagglutinin	B-PRGE
+gene	I-PRGE
+(	O
+HA	O
+)	O
+sequences	O
+,	O
+respectively	O
+.	O
+
+Further	O
+investigations	O
+of	O
+the	O
+role	O
+of	O
+AI	O
+,	O
+IBV	B-SPEC
+,	O
+and	O
+ND	O
+viruses	B-SPEC
+'	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+and	O
+interference	O
+in	O
+terms	O
+of	O
+altering	O
+the	O
+severity	O
+of	O
+clinical	O
+signs	O
+and	O
+lesions	O
+and	O
+/	O
+or	O
+generating	O
+novel	O
+reassortants	O
+within	O
+each	O
+virus	B-SPEC
+are	O
+needed	O
+.	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+,	O
+molecular	O
+docking	B-PROC
+studies	O
+and	O
+anti	O
+-	O
+HBV	B-DISO
+activity	O
+of	O
+phenylpropanoid	B-CHED
+derivatives	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+DNA	O
+vaccine	O
+SL7207	O
+(	O
+pVAXD	B-PRGE
+-	I-PRGE
+PS1	I-PRGE
+-	I-PRGE
+TS	I-PRGE
+)	O
+co	O
+-	O
+expressing	O
+S	O
+proteins	B-CHED
+of	O
+TGEV	B-SPEC
+and	O
+PEDV	B-SPEC
+delivered	O
+by	O
+attenuated	O
+Salmonella	B-DISO
+typhimurium	O
+was	O
+constructed	O
+and	O
+its	O
+immunogenicity	O
+in	O
+piglets	O
+was	O
+investigated	O
+.	O
+
+Humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+,	O
+as	O
+reflected	O
+by	O
+virus	B-SPEC
+neutralizing	O
+antibodies	B-COMP
+and	O
+specific	O
+IgG	B-PRGE
+and	O
+sIgA	B-PRGE
+,	O
+and	O
+cellular	B-COMP
+immune	I-PROC
+responses	I-PROC
+,	O
+as	O
+reflected	O
+by	O
+IFN	O
+-	O
+γ	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+,	O
+and	O
+lymphocyte	B-PROC
+proliferation	B-DISO
+,	O
+were	O
+evaluated	O
+.	O
+
+SL7207	O
+(	O
+pVAXD	B-PRGE
+-	I-PRGE
+PS1	I-PRGE
+-	I-PRGE
+TS	I-PRGE
+)	O
+simultaneously	O
+elicited	O
+immune	B-PROC
+responses	I-PROC
+against	O
+TGEV	B-SPEC
+and	O
+PEDV	B-SPEC
+after	O
+oral	B-ANAT
+immunization	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+Middle	O
+Eastern	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+one	O
+of	O
+the	O
+major	O
+events	O
+in	O
+South	O
+Korea	O
+in	O
+2015	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+in	O
+healthcare	O
+settings	O
+spread	O
+predominantly	O
+before	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+was	O
+diagnosed	O
+,	O
+underscoring	O
+the	O
+importance	O
+of	O
+increasing	O
+awareness	O
+and	O
+infection	O
+control	O
+measures	O
+at	O
+first	O
+points	O
+of	O
+entry	O
+to	O
+healthcare	O
+facilities	O
+.	O
+
+The	O
+viruses	B-SPEC
+from	O
+Jordan	O
+were	O
+highly	O
+similar	O
+to	O
+isolates	O
+from	O
+Riyadh	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+except	O
+for	O
+deletions	O
+in	O
+open	O
+reading	O
+frames	O
+4a	O
+and	O
+3	O
+.	O
+
+Analyzing	O
+the	O
+phylogenetic	O
+relatedness	O
+of	O
+this	O
+gene	O
+we	O
+found	O
+that	O
+swine	B-SPEC
+and	O
+human	B-PRGE
+neonatal	I-PRGE
+Fc	I-PRGE
+receptor	I-PRGE
+(	O
+FcRn	B-PRGE
+)	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+are	O
+closer	O
+than	O
+rodents	B-SPEC
+.	O
+
+The	O
+development	B-PROC
+of	O
+a	O
+framework	O
+for	O
+graduate	O
+competencies	O
+in	O
+PH	O
+was	O
+perceived	O
+to	O
+be	O
+a	O
+top	O
+priority	O
+.	O
+
+Other	O
+selected	O
+articles	O
+can	O
+be	O
+found	O
+online	O
+at	O
+http	O
+://	O
+www	O
+.	O
+biomedcentral	O
+.	O
+com	B-CHED
+/	O
+collections	O
+/	O
+annualupdate2016	O
+.	O
+
+Further	O
+information	O
+about	O
+the	O
+Annual	O
+Update	O
+in	O
+Intensive	O
+Care	O
+and	O
+Emergency	B-DISO
+Medicine	B-CHED
+is	O
+available	O
+from	O
+http	O
+://	O
+www	O
+.	O
+springer	O
+.	O
+com	B-CHED
+/	O
+series	O
+/	O
+8901	O
+.	O
+
+Plasma	B-ANAT
+adiponectin	B-PRGE
+was	O
+measured	O
+at	O
+the	O
+time	O
+of	O
+ICU	O
+admission	O
+.	O
+
+This	O
+argues	O
+against	O
+low	O
+levels	O
+of	O
+adiponectin	B-PRGE
+as	O
+a	O
+mechanism	O
+explaining	O
+the	O
+association	O
+of	O
+obesity	B-DISO
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Vaccines	O
+for	O
+the	O
+prevention	O
+against	O
+the	O
+threat	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+First	O
+identified	O
+in	O
+2012	O
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+listed	O
+as	O
+a	O
+new	O
+Category	O
+C	O
+Priority	O
+Pathogen	O
+.	O
+
+The	O
+animals	B-SPEC
+were	O
+then	O
+ventilated	O
+with	O
+either	O
+HFJV	O
+or	O
+CMV	B-SPEC
+for	O
+4	O
+h	O
+.	O
+Ventilatory	O
+pressures	O
+,	O
+blood	B-PROC
+gases	I-PROC
+,	O
+and	O
+indexes	O
+of	O
+gas	B-ENZY
+exchange	O
+were	O
+assessed	O
+.	O
+
+We	O
+conclude	O
+that	O
+,	O
+HFJV	O
+may	O
+be	O
+used	O
+for	O
+ventilation	O
+in	O
+acute	O
+non	O
+-	O
+homogenous	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+(	O
+TGE	B-DISO
+)	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+suckling	O
+piglets	O
+,	O
+results	O
+in	O
+enormous	O
+economic	O
+loss	O
+in	O
+swine	B-SPEC
+-	O
+producing	O
+areas	O
+of	O
+the	O
+world	O
+.	O
+
+ABSTRACT	O
+:	O
+Antimicrobial	O
+-	O
+resistant	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+AMR	O
+-	O
+RTIs	O
+)	O
+are	O
+increasing	O
+,	O
+presenting	O
+important	O
+management	O
+challenges	O
+worldwide	O
+.	O
+
+Cellular	B-COMP
+therapy	O
+by	O
+reinfusing	O
+autologous	B-ANAT
+bone	I-ANAT
+marrow	I-ANAT
+-	O
+derived	O
+MSCs	B-FUNC
+into	O
+MDR	B-FUNC
+/	O
+XDR	B-DISO
+-	I-DISO
+TB	I-DISO
+patients	O
+shows	O
+promise	O
+,	O
+whereas	O
+adjunctive	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+based	O
+therapies	O
+are	O
+considered	O
+.	O
+
+Palivizumab	O
+,	O
+an	O
+anti	B-PRGE
+-	I-PRGE
+RSV	I-PRGE
+monoclonal	I-PRGE
+antibody	B-COMP
+,	O
+effectively	O
+prevents	O
+RSV	B-DISO
+infection	I-DISO
+in	O
+high	O
+-	O
+risk	O
+paediatric	O
+populations	O
+.	O
+
+TITLE	O
+:	O
+Microbiological	O
+characterization	O
+of	O
+a	O
+newly	O
+established	O
+pig	B-SPEC
+breed	B-PROC
+,	O
+Aachen	O
+Minipigs	O
+.	O
+
+As	O
+organs	B-ANAT
+from	O
+conventional	O
+pigs	B-SPEC
+are	O
+usually	O
+too	O
+large	O
+,	O
+those	O
+from	O
+minipigs	O
+may	O
+be	O
+better	O
+suited	O
+.	O
+
+HEV	B-SPEC
+RNA	O
+was	O
+found	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+in	O
+most	O
+,	O
+and	O
+DNA	O
+of	O
+PCMV	O
+,	O
+PLHV	O
+-	O
+2	O
+,	O
+and	O
+PLHV	O
+-	O
+3	O
+was	O
+found	O
+by	O
+PCR	O
+in	O
+some	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+and	O
+evaluation	O
+of	O
+novel	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+NNRTIs	O
+with	O
+dual	O
+structural	O
+conformations	O
+targeting	B-PROC
+the	O
+entrance	O
+channel	O
+of	O
+the	O
+NNRTI	O
+binding	B-FUNC
+pocket	O
+.	O
+
+ABSTRACT	O
+:	O
+On	O
+the	O
+basis	O
+of	O
+structure	O
+-	O
+based	O
+bioisosteric	O
+replacement	O
+and	O
+molecular	O
+hybridization	B-PROC
+strategy	O
+,	O
+a	O
+series	O
+of	O
+novel	O
+dual	O
+structural	O
+-	O
+conformation	O
+inhibitors	B-CHED
+targeting	B-PROC
+the	O
+""""	O
+entrance	O
+channel	O
+""""	O
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+NNRTIs	O
+binding	B-FUNC
+pocket	O
+(	O
+NNIBP	O
+)	O
+were	O
+designed	O
+and	O
+synthesized	O
+.	O
+
+It	O
+was	O
+indicated	O
+that	O
+patients	O
+who	O
+were	O
+male	O
+,	O
+of	O
+IgG	B-PRGE
+type	O
+,	O
+with	O
+a	O
+relapse	B-DISO
+status	O
+and	O
+a	O
+previous	O
+history	O
+of	O
+auto	O
+-	O
+PBSCT	O
+had	O
+a	O
+higher	O
+possibility	O
+of	O
+developing	O
+bortezomib	B-CHED
+-	O
+induced	O
+severe	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+leaves	O
+a	O
+TRAIL	B-PRGE
+to	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+One	O
+of	O
+the	O
+driving	O
+features	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+ARDS	B-DISO
+is	O
+the	O
+accumulation	O
+of	O
+fluid	O
+in	O
+the	O
+alveoli	B-ANAT
+,	O
+which	O
+causes	O
+severe	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+impaired	B-DISO
+oxygen	B-CHED
+uptake	O
+.	O
+
+The	O
+authors	O
+conducted	O
+a	O
+prospective	O
+,	O
+randomized	O
+,	O
+crossover	O
+study	O
+on	O
+eight	O
+spontaneously	O
+breathing	B-PROC
+ARDS	B-DISO
+patients	O
+undergoing	O
+venovenous	O
+ECMO	O
+since	O
+28	O
+±	O
+20	O
+days	O
+.	O
+
+To	O
+modulate	O
+carbon	B-CHED
+dioxide	I-CHED
+extraction	O
+,	O
+ECMO	O
+gas	B-ENZY
+flow	O
+(	O
+GF	O
+)	O
+was	O
+decreased	O
+from	O
+baseline	O
+resting	B-ANAT
+protective	O
+conditions	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+GF100	O
+%,	O
+set	O
+to	O
+obtain	O
+pressure	O
+generated	O
+in	O
+the	O
+first	O
+100	O
+ms	O
+of	O
+inspiration	B-PROC
+against	O
+an	O
+occluded	B-DISO
+airway	B-ANAT
+less	O
+than	O
+2	O
+cm	O
+H2O	B-CHED
+,	O
+respiratory	O
+rate	O
+less	O
+than	O
+or	O
+equal	O
+to	O
+25	O
+bpm	O
+,	O
+tidal	O
+volume	O
+less	O
+than	O
+6	O
+ml	O
+/	O
+kg	O
+,	O
+and	O
+peak	O
+airway	O
+pressure	O
+less	O
+than	O
+25	O
+cm	O
+H2O	B-CHED
+)	O
+to	O
+GF50	O
+%-	O
+GF25	O
+%-	O
+GF0	O
+%	O
+during	O
+both	O
+PSV	O
+and	O
+NAVA	O
+(	O
+random	O
+order	B-SPEC
+for	O
+ventilation	O
+mode	O
+).	O
+
+Finally	O
+,	O
+transpulmonary	O
+pressure	O
+linearly	O
+decreased	O
+when	O
+the	O
+amount	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+extracted	O
+by	O
+ECMO	O
+increased	O
+(	O
+R	O
+=	O
+0	O
+.	O
+823	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+In	O
+this	O
+study	O
+we	O
+examine	O
+the	O
+kinetics	O
+of	O
+endocan	O
+in	O
+the	O
+perioperative	O
+period	O
+in	O
+cardiac	B-ANAT
+surgical	O
+patients	O
+.	O
+
+The	O
+baseline	O
+endocan	O
+concentrations	O
+were	O
+elevated	O
+in	O
+patients	O
+with	O
+hypertension	B-DISO
+and	O
+severe	O
+coronary	B-DISO
+artery	I-DISO
+disease	I-DISO
+.	O
+
+Endocan	O
+concentrations	O
+increased	O
+after	O
+induction	O
+of	O
+anaesthesia	B-DISO
+and	O
+decreased	O
+four	O
+hours	O
+after	O
+separation	B-DISO
+from	O
+CPB	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+had	O
+a	O
+three	O
+-	O
+fold	O
+increased	O
+ability	O
+to	O
+differentiate	O
+into	O
+fibrocytes	B-ANAT
+compared	O
+to	O
+ventilated	O
+controls	O
+or	O
+non	O
+-	O
+ventilated	O
+controls	O
+.	O
+
+The	O
+presence	O
+of	O
+fibrocytes	B-ANAT
+in	O
+the	O
+lung	B-ANAT
+during	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+could	O
+result	O
+in	O
+a	O
+balance	B-PROC
+between	O
+higher	O
+ability	O
+of	O
+monocytes	B-ANAT
+to	O
+differentiate	O
+into	O
+fibrocytes	B-ANAT
+and	O
+the	O
+inhibitory	O
+effect	O
+of	O
+the	O
+alveolar	B-ANAT
+environment	O
+,	O
+mainly	O
+dependent	O
+on	O
+serum	B-PRGE
+amyloid	B-DISO
+P	I-PRGE
+.	O
+
+Patient	O
+records	O
+for	O
+2	O
+intervals	O
+were	O
+reviewed	O
+:	O
+Interval	O
+1	O
+,	O
+which	O
+included	O
+87	O
+intensive	O
+care	O
+unit	O
+patients	O
+admitted	O
+January	O
+2005	O
+through	O
+September	O
+2007	O
+,	O
+for	O
+whom	O
+benzodiazedpine	O
+monotherapy	O
+was	O
+utilized	O
+;	O
+and	O
+Interval	O
+2	O
+,	O
+January	O
+2010	O
+through	O
+December	O
+2010	O
+,	O
+for	O
+whom	O
+54	O
+of	O
+84	O
+(	O
+64	O
+.	O
+3	O
+%)	O
+intensive	O
+care	O
+unit	O
+patients	O
+,	O
+including	O
+all	O
+those	O
+intubated	O
+,	O
+received	O
+adjunctive	O
+agents	O
+,	O
+including	O
+dexmedetomidine	B-CHED
+or	O
+propofol	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+aspiration	I-DISO
+of	O
+gastric	O
+or	O
+esophageal	B-ANAT
+contents	I-ANAT
+is	O
+uncommon	O
+;	O
+however	O
+,	O
+it	O
+is	O
+one	O
+of	O
+the	O
+most	O
+severe	O
+complications	O
+in	O
+the	O
+perioperative	O
+period	O
+.	O
+
+Pulmonary	B-DISO
+aspiration	I-DISO
+should	O
+be	O
+prevented	O
+using	O
+multidisciplinary	O
+techniques	O
+and	O
+considerations	O
+that	O
+have	O
+been	O
+shown	O
+to	O
+improve	O
+effectiveness	O
+of	O
+prophylaxes	O
+.	O
+
+Serious	O
+adverse	O
+events	O
+were	O
+defined	O
+as	O
+dislocation	O
+or	O
+obstruction	O
+of	O
+endotracheal	O
+tube	O
+or	O
+tracheal	O
+cannula	B-SPEC
+,	O
+ECMO	O
+cannulas	O
+and	O
+cardiac	B-DISO
+arrest	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+26	O
+patients	O
+were	O
+treated	O
+with	O
+vvECMO	O
+as	O
+bridge	O
+to	O
+recovery	O
+due	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Patients	O
+were	O
+proned	O
+for	O
+a	O
+median	O
+of	O
+5	O
+(	O
+3	O
+;	O
+7	O
+)	O
+periods	B-PROC
+with	O
+a	O
+median	O
+duration	O
+of	O
+12	O
+h	O
+(	O
+8	O
+;	O
+12	O
+).	O
+
+TITLE	O
+:	O
+Evolution	B-PROC
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+China	O
+over	O
+the	O
+past	O
+two	O
+decades	O
+.	O
+
+We	O
+observed	O
+6	O
+,	O
+452	O
+animals	B-SPEC
+listed	O
+by	O
+Lao	O
+PDR	B-DISO
+as	O
+near	O
+extinct	O
+or	O
+threatened	O
+with	O
+extinction	O
+.	O
+
+The	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+is	O
+the	O
+first	O
+line	O
+of	O
+antiviral	B-CHED
+defense	O
+that	O
+culminates	O
+in	O
+the	O
+synthesis	B-PROC
+of	O
+interferon	B-PRGE
+and	O
+proinflammatory	O
+cytokines	O
+to	O
+control	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+These	O
+observations	O
+allowed	O
+us	O
+to	O
+propose	O
+a	O
+novel	O
+role	O
+for	O
+CoV	O
+nsp14	O
+ExoN	O
+activity	O
+in	O
+counteracting	O
+the	O
+antiviral	B-PROC
+response	I-PROC
+,	O
+which	O
+could	O
+serve	O
+as	O
+a	O
+novel	O
+target	O
+for	O
+the	O
+design	O
+of	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+Early	O
+blood	B-ANAT
+purification	O
+clears	O
+inflammatory	O
+cytokines	O
+and	O
+promotes	O
+immune	B-PROC
+function	I-PROC
+recovery	O
+.	O
+
+32	O
+patients	O
+received	O
+routine	O
+treatment	O
+(	O
+control	O
+group	O
+),	O
+whereas	O
+other	O
+32	O
+patients	O
+received	O
+routine	O
+treatment	O
+and	O
+early	O
+blood	B-ANAT
+purification	O
+therapy	O
+(	O
+study	O
+group	O
+).	O
+
+We	O
+evaluated	O
+respiratory	O
+indexes	O
+(	O
+PaO2	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+,	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-CHED
+difference	O
+,	O
+intrapulmonary	O
+arteriovenous	B-DISO
+shunt	I-DISO
+percentage	O
+,	O
+and	O
+respiratory	O
+rate	O
+),	O
+blood	B-ANAT
+biochemical	O
+(	O
+creatinine	B-CHED
+,	O
+blood	B-ANAT
+urea	B-CHED
+nitrogen	B-CHED
+,	O
+alanine	B-PRGE
+aminotransferase	I-PRGE
+,	O
+and	O
+lactate	B-CHED
+levels	O
+)	O
+and	O
+inflammatory	O
+(	O
+CRP	B-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+/	O
+TNF	B-PRGE
+-	O
+α	O
+ratio	O
+)	O
+markers	O
+,	O
+and	O
+prognostic	O
+outcomes	O
+(	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+[	O
+MODS	B-DISO
+]	O
+and	O
+APACHE	O
+II	O
+scores	O
+)	O
+before	O
+and	O
+72	O
+hours	O
+after	O
+the	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+identification	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+by	O
+RT	O
+-	O
+PCR	O
+in	O
+Iran	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+the	O
+detection	O
+and	O
+identification	O
+of	O
+IBV	B-SPEC
+by	O
+reverse	B-PROC
+transcription	I-PROC
+(	O
+RT	O
+)-	O
+PCR	O
+in	O
+Iran	O
+.	O
+
+Primers	O
+targeting	B-PROC
+the	O
+conserved	O
+region	O
+of	O
+known	O
+IBV	B-SPEC
+serotypes	O
+were	O
+used	O
+in	O
+the	O
+RT	O
+-	O
+PCR	O
+assay	O
+.	O
+
+Digital	O
+surveillance	O
+techniques	O
+have	O
+shown	O
+promise	O
+to	O
+aid	O
+with	O
+the	O
+detection	O
+and	O
+monitoring	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+Prospective	O
+clinic	O
+surveillance	O
+was	O
+conducted	O
+to	O
+identify	O
+hospitalized	O
+children	O
+aged	O
+≤	O
+15	O
+years	O
+presenting	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+≤	O
+5	O
+-	O
+day	O
+duration	O
+.	O
+
+While	O
+hRSV	B-SPEC
+showed	O
+seasonal	O
+patterns	O
+,	O
+hAdV	O
+and	O
+RV	O
+/	O
+EV	O
+were	O
+detected	O
+throughout	O
+the	O
+year	O
+and	O
+no	O
+evident	O
+temporal	O
+patterns	O
+were	O
+observed	O
+for	O
+the	O
+remaining	O
+viruses	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+Respiratory	O
+viruses	B-SPEC
+were	O
+associated	O
+with	O
+a	O
+high	O
+burden	O
+of	O
+hospitalizations	O
+among	O
+children	O
+in	O
+Cameroon	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+were	O
+first	O
+described	O
+in	O
+the	O
+1960s	O
+for	O
+patients	O
+with	O
+the	O
+common	O
+cold	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+Leishmania	B-SPEC
+infantum	I-SPEC
+and	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+in	O
+stray	O
+cats	B-SPEC
+in	O
+northern	O
+Italy	O
+.	O
+
+L	B-DISO
+.	I-DISO
+infantum	I-DISO
+-	O
+infected	O
+stray	O
+cats	B-SPEC
+in	O
+Milan	O
+have	O
+a	O
+high	O
+seropositivity	O
+rate	O
+,	O
+comparable	O
+to	O
+that	O
+of	O
+cats	B-SPEC
+in	O
+areas	O
+endemic	O
+for	O
+leishmaniosis	B-DISO
+.	O
+
+It	O
+is	O
+a	O
+respiratory	B-DISO
+disease	I-DISO
+caused	O
+by	O
+coronavirus	B-SPEC
+.	O
+
+Of	O
+134	O
+(	O
+falciparum	O
+-	O
+81	O
+,	O
+vivax	O
+-	O
+48	O
+and	O
+mixed	O
+falciparum	O
+and	O
+vivax	O
+-	O
+5	O
+)	O
+malaria	B-PATH
+cases	O
+,	O
+hyperbilirubinemia	B-DISO
+occurred	O
+in	O
+41	O
+.	O
+04	O
+%.	O
+
+Malarial	O
+hepatopathy	B-DISO
+had	O
+significant	O
+association	O
+with	O
+duration	O
+of	O
+hospitalization	O
+,	O
+parasite	O
+clearance	O
+time	O
+,	O
+fever	B-PROC
+clearance	O
+time	O
+and	O
+jaundice	B-DISO
+clearance	O
+time	O
+in	O
+overall	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+each	O
+)	O
+and	O
+falciparum	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+each	O
+)	O
+but	O
+not	O
+vivax	B-DISO
+malaria	I-DISO
+cases	O
+(	O
+p	O
+>	O
+0	O
+.	O
+05	O
+each	O
+).	O
+
+Mortality	O
+occurred	O
+in	O
+1	O
+(	O
+20	O
+%)	O
+case	O
+of	O
+falciparum	O
+-	O
+induced	O
+hepatopathy	B-DISO
+with	O
+an	O
+overall	O
+mortality	O
+of	O
+16	O
+.	O
+66	O
+%.	O
+
+Prior	O
+to	O
+APRV	O
+initiation	O
+,	O
+median	O
+Murray	O
+Lung	B-ANAT
+Injury	O
+Score	O
+was	O
+3	O
+.	O
+5	O
+(	O
+interquartile	O
+range	O
+(	O
+IQR	O
+)	O
+2	O
+.	O
+5	O
+-	O
+3	O
+.	O
+9	O
+)	O
+and	O
+PaO2	O
+/	O
+FiO2	O
+was	O
+99mmHg	O
+(	O
+IQR	O
+73	O
+-	O
+137	O
+).	O
+
+TITLE	O
+:	O
+Is	O
+capnometry	O
+helpful	O
+in	O
+children	O
+with	O
+bronchiolitis	B-DISO
+?	O
+
+There	O
+is	O
+still	O
+a	O
+debate	O
+as	O
+to	O
+the	O
+role	O
+of	O
+capnometry	O
+in	O
+assessing	O
+ventilation	O
+in	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+,	O
+and	O
+bronchiolitis	B-DISO
+in	O
+particular	O
+.	O
+
+Our	O
+secondary	O
+outcome	O
+measure	O
+was	O
+the	O
+correlation	O
+of	O
+EtCO2	O
+upon	O
+arrival	O
+to	O
+the	O
+ED	O
+and	O
+clinical	O
+measures	O
+of	O
+bronchiolitis	B-DISO
+severity	O
+.	O
+
+NS4b	O
+proteins	B-CHED
+are	O
+distinct	O
+from	O
+lineage	O
+ABetacoronavirusPDEs	O
+and	O
+rotavirus	B-PRGE
+gene	I-PRGE
+-	I-PRGE
+encoded	I-PRGE
+PDEs	I-PRGE
+,	O
+in	O
+having	O
+an	O
+amino	O
+-	O
+terminal	O
+nuclear	O
+localization	B-PROC
+signal	O
+(	O
+NLS	B-DISO
+)	O
+and	O
+are	O
+localized	O
+mostly	O
+to	O
+the	O
+nucleus	B-COMP
+.	O
+
+Like	O
+murine	B-PRGE
+coronavirus	I-PRGE
+NS2	B-DISO
+,	O
+a	O
+previously	O
+characterized	O
+PDE	B-PRGE
+,	I-PRGE
+MERS	I-PRGE
+NS4b	I-PRGE
+,	O
+can	O
+antagonize	O
+activation	O
+of	O
+the	O
+OAS	B-PRGE
+-	I-PRGE
+RNase	B-ENZY
+L	I-PRGE
+pathway	B-PROC
+,	O
+an	O
+interferon	B-PRGE
+-	O
+induced	O
+potent	O
+antiviral	B-CHED
+activity	O
+.	O
+
+Our	O
+report	O
+may	O
+offer	O
+a	O
+potential	O
+target	O
+for	O
+therapeutic	O
+intervention	O
+if	O
+NS4b	O
+proves	O
+to	O
+be	O
+critical	O
+to	O
+pathogenesis	B-DISO
+inin	O
+vivomodels	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Reversal	O
+of	O
+the	O
+Progression	O
+of	O
+Fatal	O
+Coronavirus	B-DISO
+Infection	I-DISO
+in	O
+Cats	B-SPEC
+by	O
+a	O
+Broad	O
+-	O
+Spectrum	O
+Coronavirus	B-SPEC
+Protease	B-CHED
+Inhibitor	I-CHED
+.	O
+
+Experimental	O
+FIP	B-DISO
+is	O
+100	O
+%	O
+fatal	O
+once	O
+certain	O
+clinical	O
+and	O
+laboratory	O
+signs	O
+become	O
+apparent	O
+.	O
+
+These	O
+findings	O
+may	O
+provide	O
+important	O
+insights	O
+into	O
+devising	O
+therapeutic	O
+strategies	O
+and	O
+selection	O
+of	O
+antiviral	B-CHED
+compounds	O
+for	O
+further	O
+development	B-PROC
+for	O
+important	O
+coronaviruses	O
+in	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+TGEV	B-SPEC
+induces	O
+mitophagy	B-PROC
+to	O
+suppress	O
+oxidative	B-DISO
+stress	I-DISO
+and	O
+apoptosis	B-PATH
+induced	O
+by	O
+viral	B-DISO
+infection	I-DISO
+in	O
+porcine	B-SPEC
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+IPEC	O
+-	O
+J2	O
+).	O
+
+We	O
+report	O
+a	O
+significant	O
+correlation	O
+between	O
+infection	B-DISO
+site	I-DISO
+and	O
+mortality	O
+in	O
+patients	O
+with	O
+ALI	O
+,	O
+but	O
+not	O
+in	O
+those	O
+without	O
+ALI	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+the	O
+functionality	O
+of	O
+hamster	B-SPEC
+DPP4	B-PRGE
+as	O
+a	O
+receptor	O
+is	O
+severely	O
+decreased	O
+if	O
+less	O
+than	O
+4	O
+out	O
+of	O
+5	O
+amino	B-CHED
+acids	I-CHED
+are	O
+changed	O
+.	O
+
+Through	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+analysis	O
+of	O
+S	O
+proteins	B-CHED
+of	O
+representative	O
+CoVs	O
+,	O
+we	O
+identified	O
+a	O
+common	O
+region	O
+as	O
+a	O
+possible	O
+FP	O
+(	O
+pFP	B-CHED
+)	O
+that	O
+shares	O
+the	O
+characteristics	O
+of	O
+FPs	B-FUNC
+of	O
+class	B-PRGE
+I	I-PRGE
+viral	I-PRGE
+fusion	I-PRGE
+proteins	B-CHED
+,	O
+including	O
+high	O
+Ala	B-CHED
+/	O
+Gly	B-CHED
+content	O
+,	O
+intermediate	O
+hydrophobicity	O
+,	O
+and	O
+few	O
+charged	O
+residues	O
+.	O
+
+N475	O
+forms	O
+a	O
+hydrogen	B-CHED
+bond	O
+with	O
+R662	O
+in	O
+the	O
+SAM	B-PRGE
+MTase	I-PRGE
+domain	I-PRGE
+,	O
+and	O
+the	O
+R662A	O
+and	O
+R662K	O
+mutations	O
+both	O
+led	O
+to	O
+16	O
+-	O
+fold	O
+decreases	O
+in	O
+kcat	O
+/	O
+Km	O
+.	O
+
+Virological	O
+analysis	O
+determined	O
+that	O
+the	O
+virus	B-SPEC
+belonged	O
+to	O
+H5	B-PRGE
+clade	I-PRGE
+2	I-PRGE
+.	I-PRGE
+3	I-PRGE
+.	I-PRGE
+4	I-PRGE
+.	I-PRGE
+4	I-PRGE
+and	O
+it	O
+has	O
+obtained	O
+partial	O
+ability	O
+for	O
+mammalian	B-SPEC
+adaptation	B-PROC
+and	O
+amantadine	B-CHED
+resistance	B-PROC
+.	O
+
+Spleen	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+and	O
+intestine	B-ANAT
+tissue	B-ANAT
+along	O
+with	O
+fecal	B-ANAT
+and	O
+intestinal	B-ANAT
+lavage	O
+samples	O
+were	O
+obtained	O
+from	O
+50	O
+one	O
+-	O
+to	O
+five	O
+-	O
+week	O
+-	O
+old	O
+alpacas	B-SPEC
+and	O
+analyzed	O
+for	O
+the	O
+presence	O
+of	O
+parasites	O
+,	O
+bacteria	B-SPEC
+,	O
+and	O
+viruses	B-SPEC
+.	O
+
+The	O
+significance	O
+of	O
+such	O
+infections	B-DISO
+is	O
+not	O
+clear	O
+,	O
+but	O
+it	O
+is	O
+noteworthy	O
+that	O
+the	O
+animals	B-SPEC
+suffering	B-DISO
+from	O
+necrotic	B-PROC
+and	O
+/	O
+or	O
+hemorrhagic	B-DISO
+enteritis	I-DISO
+presented	O
+with	O
+quadruple	O
+infections	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Fifteen	O
+ECMO	O
+patients	O
+managed	O
+from	O
+March	O
+2013	O
+to	O
+November	O
+2014	O
+were	O
+identified	O
+,	O
+as	O
+were	O
+14	O
+CONV	O
+patients	O
+managed	O
+from	O
+March	O
+2012	O
+to	O
+February	O
+2013	O
+who	O
+met	B-CHED
+the	O
+Berlin	O
+definition	O
+of	O
+severe	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Successful	O
+Treatment	O
+of	O
+Seasonal	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H3N2	B-CHED
+)	O
+infection	B-DISO
+-	O
+related	O
+Hemophagocytic	O
+Lymphocytosis	B-DISO
+in	O
+an	O
+Elderly	O
+Man	B-CHED
+].	O
+
+Subsequently	O
+,	O
+blood	B-ANAT
+tests	O
+showed	O
+elevation	O
+of	O
+ferritin	B-PRGE
+and	O
+soluble	B-PRGE
+interleukin	I-PRGE
+2	I-PRGE
+receptor	I-PRGE
+(	O
+sIL2R	O
+);	O
+microscopic	O
+examination	O
+of	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+revealed	O
+hemophagocytosis	B-DISO
+.	O
+
+The	O
+patint	O
+was	O
+saved	O
+with	O
+our	O
+early	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+HLH	B-DISO
+and	O
+was	O
+discharged	O
+on	O
+the	O
+92nd	O
+clinical	O
+day	O
+.	O
+
+Viral	O
+-	O
+induced	O
+HLH	B-DISO
+,	O
+formerly	O
+known	O
+as	O
+virus	B-SPEC
+-	O
+associated	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+(	O
+VAHS	O
+),	O
+leads	O
+to	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+due	O
+to	O
+a	O
+cytokine	B-DISO
+storm	I-DISO
+scattered	O
+by	O
+viral	O
+-	O
+infected	O
+pathogenic	O
+inflammatory	B-ANAT
+cells	I-ANAT
+.	O
+
+Currently	O
+,	O
+not	O
+much	O
+is	O
+known	O
+about	O
+HLH	B-DISO
+due	O
+to	O
+seasonal	O
+flu	B-DISO
+;	O
+particularly	O
+,	O
+IAV	O
+(	O
+H3N2	B-CHED
+)-	O
+related	O
+HLH	B-DISO
+cases	O
+are	O
+rare	O
+and	O
+reported	O
+cases	O
+showed	O
+poor	O
+outcomes	O
+as	O
+well	O
+.	O
+
+TITLE	O
+:	O
+S1	O
+domain	O
+of	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+spike	O
+protein	B-CHED
+as	O
+a	O
+vaccine	O
+antigen	B-CHED
+.	O
+
+However	O
+,	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+diarrhea	B-DISO
+,	O
+body	B-ANAT
+weight	O
+and	O
+virus	B-DISO
+shedding	I-DISO
+.	O
+
+Their	O
+concerted	O
+effort	B-PROC
+is	O
+believed	O
+to	O
+have	O
+been	O
+instrumental	O
+in	O
+ending	O
+the	O
+outbreak	O
+.	O
+
+However	O
+,	O
+the	O
+function	O
+of	O
+soluble	O
+form	O
+of	O
+RAGE	O
+(	O
+sRAGE	O
+),	O
+which	O
+is	O
+composed	O
+of	O
+an	O
+extracellular	B-COMP
+domain	O
+of	O
+RAGE	O
+,	O
+in	O
+ARDS	B-DISO
+remains	O
+elusive	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+alveolar	B-ANAT
+release	B-PATH
+of	O
+sRAGE	O
+may	O
+play	O
+a	O
+protective	O
+role	O
+against	O
+HMGB1	B-PRGE
+as	O
+well	O
+as	O
+exogenous	O
+pathogen	O
+-	O
+associated	O
+molecular	O
+patterns	O
+.	O
+
+Supplementary	O
+therapy	O
+with	O
+sRAGE	O
+may	O
+be	O
+an	O
+effective	O
+therapeutic	O
+strategy	O
+for	O
+ARDS	B-DISO
+.	O
+
+The	O
+donor	B-CHED
+was	O
+a	O
+19	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+.	O
+
+No	O
+infectious	B-DISO
+symptom	B-DISO
+was	O
+reported	O
+during	O
+the	O
+medical	O
+interviews	O
+before	O
+and	O
+after	O
+the	O
+donation	O
+and	O
+no	O
+postdonation	O
+information	O
+was	O
+received	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+donor	B-CHED
+was	O
+a	O
+19	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+and	O
+Predicting	O
+Factor	O
+Following	O
+Severe	O
+Traumatic	O
+Brain	B-ANAT
+Injury	O
+:	O
+A	O
+Retrospective	O
+Cross	O
+-	O
+Sectional	O
+Study	O
+.	O
+
+About	O
+(	O
+37	O
+.	O
+5	O
+%)	O
+of	O
+patients	O
+with	O
+anxiety	O
+and	O
+(	O
+27	O
+.	O
+5	O
+%)	O
+had	O
+a	O
+depression	B-DISO
+.	O
+
+GCS	O
+arrival	O
+a	O
+predicate	O
+factor	O
+for	O
+QOL	O
+and	O
+GOS	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+75	O
+,	O
+1	O
+.	O
+94	O
+respectively	O
+);	O
+length	O
+of	O
+ICU	O
+stay	O
+a	O
+predicate	O
+factor	O
+for	O
+QOL	O
+and	O
+GOS	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+11	O
+,	O
+1	O
+.	O
+28	O
+respectively	O
+);	O
+mechanical	O
+ventilation	O
+a	O
+predicate	O
+factor	O
+for	O
+GOS	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+78	O
+);	O
+ventilation	O
+associated	O
+pneumonia	B-DISO
+(	O
+VAP	O
+)	O
+&	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+pupil	B-ANAT
+reactivity	O
+a	O
+predicate	O
+factor	O
+for	O
+GOS	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+36	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+94	O
+respectively	O
+).	O
+
+The	O
+GCS	O
+arrival	O
+and	O
+ICU	O
+stay	O
+a	O
+predicate	O
+factor	O
+for	O
+HAD	B-PRGE
+-	I-PRGE
+A	I-PRGE
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+73	O
+,	O
+1	O
+.	O
+38	O
+respectively	O
+).	O
+
+TITLE	O
+:	O
+Assessing	O
+the	O
+economic	O
+burden	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+on	O
+poultry	O
+farms	O
+in	O
+Brazil	O
+.	O
+
+A	O
+U	O
+.	O
+S	O
+.	O
+PEDV	B-SPEC
+S	O
+-	O
+INDEL	B-PROC
+-	O
+variant	O
+strain	O
+was	O
+isolated	O
+in	O
+cell	B-COMP
+culture	O
+in	O
+this	O
+study	O
+.	O
+
+The	O
+positive	O
+antisera	O
+against	O
+the	O
+prototype	O
+strain	O
+reacted	O
+to	O
+and	O
+neutralized	O
+both	O
+prototype	O
+and	O
+S	O
+-	O
+INDEL	B-PROC
+-	O
+variant	O
+viruses	B-SPEC
+,	O
+and	O
+the	O
+positive	O
+antisera	O
+against	O
+the	O
+S	O
+-	O
+INDEL	B-PROC
+-	O
+variant	O
+strain	O
+also	O
+reacted	O
+to	O
+and	O
+neutralized	O
+both	O
+prototype	O
+and	O
+S	O
+-	O
+INDEL	B-PROC
+-	O
+variant	O
+viruses	B-SPEC
+,	O
+as	O
+examined	O
+by	O
+IFA	O
+antibody	B-COMP
+assays	O
+and	O
+VN	O
+tests	O
+.	O
+
+The	O
+current	O
+serological	O
+assays	O
+based	O
+on	O
+U	O
+.	O
+S	O
+.	O
+PEDV	B-SPEC
+prototype	O
+strain	O
+can	O
+detect	O
+antibodies	B-COMP
+against	O
+both	O
+U	O
+.	O
+S	O
+.	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+In	O
+patients	O
+receiving	O
+ECLS	O
+therapy	O
+,	O
+hemodynamic	B-PROC
+monitoring	O
+is	O
+often	O
+required	O
+.	O
+
+During	O
+the	O
+first	O
+3	O
+days	O
+of	O
+ECLS	O
+therapy	O
+,	O
+repeated	O
+hemodynamic	B-PROC
+measurements	O
+at	O
+different	O
+ECLS	O
+flow	O
+rates	O
+were	O
+performed	O
+.	O
+
+Our	O
+findings	O
+support	O
+the	O
+virus	B-SPEC
+-	O
+host	B-COMP
+co	O
+-	O
+evolution	B-PROC
+hypothesis	O
+,	O
+with	O
+the	O
+detection	O
+of	O
+Miniopterus	B-PRGE
+bat	I-PRGE
+coronavirus	I-PRGE
+HKU8	I-PRGE
+(	O
+previously	O
+reported	O
+in	O
+Miniopterus	B-SPEC
+species	B-SPEC
+in	O
+China	O
+,	O
+Hong	O
+Kong	O
+and	O
+Bulgaria	B-SPEC
+)	O
+in	O
+Australian	O
+Miniopterus	B-SPEC
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+How	O
+ARDS	B-DISO
+should	O
+be	O
+treated	O
+.	O
+
+In	O
+an	O
+inhomogeneous	O
+lung	B-ANAT
+,	O
+stress	O
+risers	O
+locally	O
+increase	O
+the	O
+applied	O
+mechanical	O
+power	O
+.	O
+
+Electron	O
+microscopy	O
+and	O
+immunoelectron	O
+microscopy	O
+results	O
+demonstrate	O
+that	O
+MERS	O
+-	O
+CoV	O
+VLPs	B-ANAT
+are	O
+structurally	O
+similar	O
+to	O
+the	O
+native	O
+virus	B-SPEC
+.	O
+
+Specifically	O
+,	O
+antibody	B-COMP
+-	O
+positive	O
+groups	O
+returned	O
+to	O
+normal	O
+body	B-ANAT
+temperature	O
+faster	O
+and	O
+demonstrated	O
+a	O
+higher	O
+rate	O
+of	O
+survivability	O
+than	O
+piglets	O
+without	O
+PEDV	B-SPEC
+antibody	B-COMP
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+samples	O
+obtained	O
+from	O
+farms	O
+in	O
+Gansu	O
+,	O
+China	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+48	O
+fecal	B-ANAT
+specimens	O
+were	O
+collected	O
+from	O
+piglets	O
+from	O
+four	O
+intensive	O
+swine	B-SPEC
+farms	O
+located	O
+in	O
+the	O
+Gansu	O
+Province	O
+of	O
+China	O
+.	O
+
+The	O
+molecular	O
+diversity	O
+and	O
+phylogenetic	O
+relationships	O
+between	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+viruses	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+prevalent	O
+in	O
+Gansu	O
+were	O
+probed	O
+,	O
+and	O
+the	O
+resultant	O
+proteins	B-CHED
+were	O
+characterized	O
+.	O
+
+Urinary	O
+protein	B-CHED
+excretion	B-PROC
+steadily	O
+increased	O
+for	O
+a	O
+microalbumin	O
+to	O
+creatinine	B-CHED
+ratio	O
+of	O
+538	O
+.	O
+4	O
+mg	O
+/	O
+g	O
+Cr	O
+and	O
+a	O
+protein	B-CHED
+to	O
+creatinine	B-CHED
+ratio	O
+of	O
+3	O
+,	O
+025	O
+.	O
+8	O
+mg	O
+/	O
+g	O
+Cr	O
+.	O
+
+Acute	B-DISO
+tubular	I-DISO
+necrosis	I-DISO
+was	O
+the	O
+main	O
+finding	O
+,	O
+and	O
+proteinaceous	O
+cast	B-ANAT
+formation	B-PROC
+and	O
+acute	B-DISO
+tubulointerstitial	I-DISO
+nephritis	I-DISO
+were	O
+found	O
+.	O
+
+We	O
+could	O
+not	O
+verify	O
+the	O
+virus	B-SPEC
+itself	O
+by	O
+in	O
+situ	O
+hybridization	B-PROC
+and	O
+confocal	O
+microscopy	O
+(	O
+MERS	O
+-	O
+CoV	O
+co	O
+-	O
+stained	O
+with	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+).	O
+
+The	O
+viremic	O
+status	O
+,	O
+urinary	O
+virus	B-SPEC
+excretion	B-PROC
+,	O
+and	O
+timely	O
+kidney	B-ANAT
+biopsy	O
+results	O
+should	O
+be	O
+investigated	O
+with	O
+thorough	O
+precautions	O
+to	O
+reveal	O
+the	O
+direct	O
+effects	O
+of	O
+MERS	O
+-	O
+CoV	O
+with	O
+respect	O
+to	O
+renal	B-ANAT
+complications	O
+.	O
+
+Authors	O
+recently	O
+focused	O
+on	O
+the	O
+mean	O
+systemic	O
+filling	O
+pressure	O
+which	O
+is	O
+one	O
+of	O
+the	O
+determinants	O
+of	O
+venous	B-ANAT
+return	O
+.	O
+
+ABSTRACT	O
+:	O
+Patient	O
+-	O
+ventilator	O
+asynchrony	O
+is	O
+a	O
+major	O
+cause	O
+of	O
+difficult	O
+weaning	B-PROC
+from	O
+mechanical	O
+ventilation	O
+.	O
+
+Electromyographic	O
+analysis	O
+of	O
+the	O
+diaphragm	B-ANAT
+clearly	O
+showed	O
+improved	O
+triggering	O
+of	O
+both	O
+the	O
+start	O
+and	O
+the	O
+end	O
+of	O
+spontaneous	O
+inspiration	B-PROC
+.	O
+
+Moreover	O
+,	O
+the	O
+area	O
+under	O
+receiver	O
+-	O
+operating	O
+curve	O
+for	O
+mortality	O
+prediction	O
+using	O
+PaO2	O
+/	O
+FiO2	O
+on	O
+Day	O
+1	O
+was	O
+significant	O
+higher	O
+than	O
+that	O
+on	O
+Day	O
+0	O
+(	O
+P	O
+=	O
+0	O
+.	O
+016	O
+).	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+on	O
+Day	O
+1	O
+after	O
+applying	O
+mechanical	O
+ventilator	O
+is	O
+a	O
+better	O
+predictor	O
+of	O
+outcomes	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+than	O
+those	O
+on	O
+Day	O
+0	O
+.	O
+
+TITLE	O
+:	O
+Alcohol	B-DISO
+Intoxication	I-DISO
+Reduces	O
+Systemic	O
+Interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+Levels	O
+and	O
+Leukocyte	B-ANAT
+Counts	O
+After	O
+Severe	O
+TBI	O
+Compared	O
+With	O
+Not	O
+Intoxicated	O
+TBI	O
+Patients	O
+.	O
+
+Injury	O
+severity	O
+,	O
+vital	O
+signs	O
+,	O
+complications	O
+,	O
+mortality	O
+,	O
+and	O
+systemic	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+levels	O
+were	O
+prospectively	O
+determined	O
+,	O
+and	O
+BAC	O
+was	O
+quantified	O
+.	O
+
+Inhospital	O
+complications	O
+,	O
+including	O
+single	O
+/	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+,	O
+sepsis	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+showed	O
+no	O
+significant	O
+differences	O
+.	O
+
+ISS	B-DISO
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+no	O
+BAC	O
+group	O
+.	O
+
+However	O
+,	O
+information	O
+on	O
+the	O
+viruses	B-SPEC
+harbored	O
+by	O
+these	O
+bats	B-SPEC
+is	O
+scarce	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+was	O
+first	O
+recognized	O
+in	O
+pigs	B-SPEC
+in	O
+the	O
+United	O
+States	O
+(	O
+US	O
+)	O
+in	O
+May	O
+2013	O
+.	O
+
+In	O
+the	O
+multivariate	O
+analysis	O
+,	O
+age	O
+≥	O
+65	O
+years	O
+,	O
+CAP	B-DISO
+resulting	O
+from	O
+P	O
+aeruginosa	O
+,	O
+chronic	B-DISO
+liver	I-DISO
+disease	I-DISO
+,	O
+neurologic	O
+disease	O
+,	O
+nursing	B-PROC
+home	O
+,	O
+criteria	O
+of	O
+ARDS	B-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+ICU	O
+admission	O
+,	O
+and	O
+inappropriate	O
+empiric	O
+treatment	O
+were	O
+the	O
+factors	O
+associated	O
+with	O
+30	O
+-	O
+day	O
+mortality	O
+.	O
+
+The	O
+risk	O
+factors	O
+described	O
+can	O
+help	O
+clinicians	O
+to	O
+suspect	O
+P	O
+aeruginosa	O
+and	O
+MDR	B-PRGE
+P	I-PRGE
+aeruginosa	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Suspected	O
+drug	O
+-	O
+induced	O
+infiltrative	O
+lung	B-DISO
+disease	I-DISO
+culminating	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+a	O
+dog	O
+treated	O
+with	O
+cytarabine	B-CHED
+and	O
+prednisone	B-CHED
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+vaccines	O
+.	O
+
+Platelets	B-ANAT
+are	O
+dispensable	O
+for	O
+the	O
+initiation	O
+and	O
+development	B-PROC
+of	O
+TRALI	B-DISO
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+impact	O
+of	O
+PRRS	B-DISO
+virus	B-SPEC
+and	O
+PED	O
+virus	B-SPEC
+,	O
+alone	O
+or	O
+in	O
+combination	O
+,	O
+on	O
+growth	B-PROC
+performance	O
+,	O
+feed	O
+efficiency	O
+,	O
+and	O
+digestibility	O
+in	O
+grower	O
+pigs	B-SPEC
+.	O
+
+Forty	O
+-	O
+two	O
+gilts	O
+(	O
+16	O
+±	O
+0	O
+.	O
+98	O
+kg	O
+BW	O
+)	O
+naïve	O
+for	O
+PRRS	B-DISO
+and	O
+PED	O
+were	O
+selected	O
+and	O
+allocated	O
+to	O
+1	O
+of	O
+4	O
+treatments	O
+.	O
+
+Pigs	B-SPEC
+in	O
+treatments	O
+2	O
+and	O
+4	O
+were	O
+inoculated	O
+with	O
+a	O
+live	O
+field	O
+strain	O
+of	O
+PRRS	B-DISO
+virus	B-SPEC
+via	O
+intramuscular	O
+and	O
+intranasal	O
+routes	O
+at	O
+0	O
+d	O
+after	O
+inoculation	O
+(	O
+dpi	O
+).	O
+
+Control	O
+pigs	B-SPEC
+remained	O
+PRRS	B-DISO
+and	O
+PED	O
+virus	B-SPEC
+negative	O
+throughout	O
+the	O
+study	O
+.	O
+
+Compared	O
+with	O
+control	O
+pigs	B-SPEC
+,	O
+PRRS	B-DISO
+infection	B-DISO
+did	O
+not	O
+reduce	O
+apparent	O
+total	O
+tract	O
+digestibility	O
+(	O
+ATTD	O
+)	O
+of	O
+nutrients	B-CHED
+and	O
+energy	O
+.	O
+
+TITLE	O
+:	O
+The	O
+effect	O
+of	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+and	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+challenge	O
+on	O
+growing	O
+pigs	B-SPEC
+II	O
+:	O
+Intestinal	B-ANAT
+integrity	O
+and	O
+function	O
+.	O
+
+Treatments	O
+2	O
+and	O
+4	O
+were	O
+inoculated	O
+with	O
+a	O
+live	O
+field	O
+strain	O
+of	O
+PRRS	B-DISO
+virus	B-SPEC
+on	O
+d	O
+0	O
+after	O
+inoculation	O
+.	O
+
+Interestingly	O
+,	O
+digestive	B-PROC
+machinery	O
+during	O
+PED	O
+challenge	O
+remained	O
+intact	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+is	O
+characterized	O
+by	O
+an	O
+excessive	O
+inflammatory	B-DISO
+response	I-DISO
+to	O
+infectious	B-DISO
+pathogens	O
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+and	O
+basic	O
+experimental	O
+approaches	O
+to	O
+pediatric	O
+acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+),	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+have	O
+historically	O
+focused	O
+on	O
+acute	O
+care	O
+and	O
+management	O
+of	O
+the	O
+patient	O
+.	O
+
+Pediatric	O
+ALI	O
+/	O
+ARDS	B-DISO
+remains	O
+one	O
+of	O
+the	O
+leading	O
+causes	O
+of	O
+infant	O
+and	O
+childhood	O
+morbidity	O
+and	O
+mortality	O
+,	O
+particularly	O
+in	O
+the	O
+developing	O
+world	O
+.	O
+
+In	O
+this	O
+chapter	O
+,	O
+the	O
+long	O
+-	O
+term	O
+effectiveness	O
+of	O
+current	O
+treatments	O
+will	O
+be	O
+examined	O
+,	O
+as	O
+will	O
+the	O
+potential	O
+efficacy	O
+of	O
+novel	O
+,	O
+acute	O
+,	O
+and	O
+long	O
+-	O
+term	O
+therapies	O
+that	O
+support	O
+repair	B-PROC
+and	O
+delay	O
+or	O
+even	O
+impede	O
+the	O
+onset	O
+of	O
+secondary	O
+events	O
+,	O
+including	O
+fibrosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Nosocomial	B-DISO
+infection	I-DISO
+control	O
+in	O
+healthcare	O
+settings	O
+:	O
+Protection	O
+against	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+Strict	O
+infection	B-DISO
+control	O
+measures	O
+were	O
+taken	O
+in	O
+the	O
+hospital	O
+where	O
+an	O
+imported	O
+case	O
+with	O
+MERS	O
+was	O
+treated	O
+in	O
+southern	O
+China	O
+and	O
+53	O
+health	O
+care	O
+workers	O
+were	O
+confirmed	O
+to	O
+be	O
+MERS	O
+-	O
+CoV	O
+negative	O
+.	O
+
+The	O
+mortality	O
+of	O
+the	O
+22	O
+subjects	O
+meeting	O
+the	O
+AECC	O
+,	O
+but	O
+not	O
+the	O
+Berlin	O
+definition	O
+was	O
+not	O
+different	O
+from	O
+patients	O
+without	O
+ARDS	B-DISO
+(	O
+P	O
+=	O
+.	O
+91	O
+).	O
+
+Zoonotic	O
+spillover	O
+from	O
+camels	B-SPEC
+appears	O
+to	O
+play	O
+a	O
+major	O
+role	O
+in	O
+transmission	O
+.	O
+
+Experimentally	O
+infected	O
+animals	B-SPEC
+were	O
+protected	O
+against	O
+reinfection	O
+,	O
+and	O
+those	O
+infected	O
+by	O
+contact	O
+were	O
+partially	O
+protected	O
+.	O
+
+Necropsy	O
+specimens	O
+from	O
+immunologically	O
+naive	O
+animals	B-SPEC
+(	O
+n	O
+=	O
+3	O
+)	O
+obtained	O
+on	O
+day	O
+5	O
+postinfection	O
+showed	O
+virus	B-SPEC
+in	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+TITLE	O
+:	O
+MERS	O
+-	O
+CoV	O
+Antibodies	B-COMP
+in	O
+Humans	B-SPEC
+,	O
+Africa	O
+,	O
+2013	O
+-	O
+2014	O
+.	O
+
+To	O
+search	O
+for	O
+evidence	O
+of	O
+autochthonous	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+humans	B-SPEC
+,	O
+we	O
+tested	O
+archived	O
+serum	B-COMP
+from	O
+livestock	O
+handlers	O
+in	O
+Kenya	O
+for	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+All	O
+eukaryotic	O
+positive	O
+-	O
+stranded	O
+RNA	O
+(+	O
+RNA	O
+)	O
+viruses	O
+appropriate	O
+host	O
+cell	B-COMP
+membranes	I-COMP
+and	O
+transform	O
+them	O
+into	O
+replication	O
+organelles	B-COMP
+,	O
+specialized	O
+micro	O
+-	O
+environments	O
+that	O
+are	O
+thought	O
+to	O
+support	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+In	O
+the	O
+last	O
+years	O
+,	O
+electron	O
+tomography	O
+has	O
+revealed	O
+substantial	O
+differences	O
+between	O
+the	O
+structures	O
+induced	O
+by	O
+these	O
+different	O
+virus	B-SPEC
+groups	O
+.	O
+
+Arterivirus	B-SPEC
+-	O
+induced	O
+DMVs	O
+appear	O
+to	O
+be	O
+closed	O
+compartments	B-ANAT
+that	O
+are	O
+continuous	O
+with	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+membranes	B-ANAT
+,	O
+thus	O
+forming	O
+an	O
+extensive	O
+reticulovesicular	O
+network	O
+(	O
+RVN	O
+)	O
+of	O
+intriguing	O
+complexity	O
+.	O
+
+Using	O
+the	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+(	O
+EAV	B-SPEC
+)	O
+model	O
+system	O
+and	O
+electron	O
+tomography	O
+,	O
+we	O
+present	O
+new	O
+data	O
+regarding	O
+the	O
+biogenesis	B-PROC
+of	O
+arterivirus	B-SPEC
+-	O
+induced	O
+DMVs	O
+and	O
+uncover	O
+numerous	O
+putative	O
+intermediates	O
+in	O
+DMV	O
+formation	B-PROC
+.	O
+
+Initial	O
+vital	O
+signs	O
+demonstrated	O
+a	O
+median	O
+oxygen	B-CHED
+saturation	O
+of	O
+94	O
+%	O
+(	O
+range	O
+90	O
+-	O
+97	O
+%)	O
+supported	O
+with	O
+a	O
+FiO2	O
+of	O
+100	O
+%	O
+for	O
+all	O
+patients	O
+with	O
+a	O
+median	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+of	O
+16	O
+(	O
+range	O
+14	O
+-	O
+20	O
+).	O
+
+There	O
+were	O
+no	O
+deaths	B-PROC
+or	O
+major	O
+incidents	O
+(	O
+tube	O
+dislodgement	O
+or	O
+line	O
+displacement	O
+)	O
+during	O
+patient	O
+transport	B-PROC
+.	O
+
+This	O
+chapter	O
+describes	O
+the	O
+use	O
+of	O
+an	O
+insect	B-SPEC
+cell	B-COMP
+expression	B-PROC
+system	O
+for	O
+rapid	O
+production	O
+of	O
+a	O
+recombinant	O
+vaccine	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+).	O
+
+Three	O
+patients	O
+in	O
+CV	O
+with	O
+LVRM	O
+group	O
+failed	O
+to	O
+wean	B-PROC
+oxygen	B-CHED
+requirement	O
+and	O
+were	O
+cross	O
+-	O
+over	O
+to	O
+HFOV	O
+group	O
+.	O
+
+HFOV	O
+combined	O
+with	O
+LVRM	O
+in	O
+severe	O
+pediatric	O
+ARDS	B-DISO
+had	O
+superior	O
+oxygenation	B-PROC
+and	O
+tended	O
+to	O
+have	O
+better	O
+clinical	O
+effect	O
+over	O
+CV	O
+.	O
+
+We	O
+represent	O
+a	O
+5	O
+-	O
+year	O
+-	O
+old	O
+CD	O
+patient	O
+with	O
+previous	O
+bronchiolitis	B-DISO
+episodes	O
+that	O
+might	O
+have	O
+resulted	O
+from	O
+CD	O
+-	O
+associated	O
+pulmonary	O
+involvement	O
+;	O
+whom	O
+later	O
+developed	O
+severe	O
+pneumonia	B-DISO
+resulting	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+bronchiectasia	O
+following	O
+a	O
+colectomy	O
+operation	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+defined	O
+severe	O
+esophageal	B-DISO
+dysfunction	I-DISO
+using	O
+esophageal	O
+manometry	O
+and	O
+esophageal	O
+morphometry	O
+criteria	O
+on	O
+the	O
+basis	O
+of	O
+chest	B-ANAT
+computed	O
+tomography	O
+images	O
+.	O
+
+The	O
+remaining	O
+post	O
+-	O
+lung	B-ANAT
+transplant	B-ANAT
+outcomes	O
+evaluated	O
+were	O
+also	O
+similar	O
+between	O
+SSc	O
+and	O
+the	O
+other	O
+groups	O
+.	O
+
+Importantly	O
+,	O
+esophageal	B-DISO
+dysfunction	I-DISO
+was	O
+the	O
+sole	B-ANAT
+reason	O
+for	O
+lung	B-ANAT
+transplant	B-ANAT
+denial	B-DISO
+in	O
+a	O
+single	O
+case	O
+.	O
+
+Together	O
+,	O
+our	O
+results	O
+provide	O
+powerful	O
+evidence	O
+that	O
+RA	O
+can	O
+assist	O
+whole	O
+inactivated	O
+TGEV	B-SPEC
+(	O
+WI	O
+-	O
+TGEV	B-SPEC
+)	O
+via	O
+subcutaneous	O
+(	O
+s	O
+.	O
+c	O
+.	O
+
+immunization	O
+to	O
+generate	O
+intestinal	B-ANAT
+immunity	B-PROC
+,	O
+and	O
+offer	O
+new	O
+vaccination	O
+strategies	O
+against	O
+TGEV	B-SPEC
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+RAS	B-PRGE
+has	O
+been	O
+implicated	O
+as	O
+advances	O
+in	O
+the	O
+understanding	O
+of	O
+the	O
+multifunctionality	O
+of	O
+individual	O
+components	O
+of	O
+the	O
+system	O
+have	O
+been	O
+made	O
+,	O
+and	O
+by	O
+the	O
+fact	O
+that	O
+the	O
+RAS	B-PRGE
+acts	O
+not	O
+only	O
+systemically	O
+,	O
+but	O
+also	O
+locally	O
+in	O
+a	O
+variety	O
+of	O
+tissues	B-ANAT
+,	O
+including	O
+the	O
+lung	B-ANAT
+.	O
+
+The	O
+result	O
+was	O
+positive	O
+in	O
+66	O
+.	O
+5	O
+%	O
+of	O
+cases	O
+,	O
+RSV	B-SPEC
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+(	O
+40	O
+.	O
+2	O
+%).	O
+
+Possible	O
+related	O
+risk	O
+factors	O
+for	O
+RSV	B-DISO
+infection	I-DISO
+were	O
+low	O
+age	O
+upon	O
+entry	O
+,	O
+attendance	O
+of	O
+daycare	O
+,	O
+low	O
+gestational	O
+age	O
+,	O
+and	O
+low	O
+educational	O
+level	O
+of	O
+the	O
+father	O
+.	O
+
+TITLE	O
+:	O
+MERS	O
+-	O
+CoV	O
+vaccine	O
+candidates	O
+in	O
+development	B-PROC
+:	O
+The	O
+current	O
+landscape	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+of	O
+growing	O
+global	O
+importance	O
+,	O
+has	O
+caused	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+in	O
+more	O
+than	O
+1600	O
+people	O
+,	O
+resulting	O
+in	O
+more	O
+than	O
+600	O
+deaths	B-PROC
+.	O
+
+Despite	O
+the	O
+relatively	O
+few	O
+number	O
+of	O
+cases	O
+to	O
+-	O
+date	O
+,	O
+research	O
+and	O
+development	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+vaccine	O
+candidates	O
+is	O
+advancing	O
+quickly	O
+.	O
+
+TITLE	O
+:	O
+Tuning	O
+in	O
+and	O
+catching	B-DISO
+on	O
+?	O
+
+The	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+that	O
+was	O
+followed	O
+closely	O
+by	O
+major	O
+media	B-ANAT
+outlets	O
+in	O
+the	O
+USA	O
+provides	O
+an	O
+opportunity	O
+to	O
+examine	O
+the	O
+relationship	O
+between	O
+exposure	O
+to	O
+public	O
+communication	O
+about	O
+epidemics	O
+and	O
+public	O
+awareness	O
+and	O
+knowledge	O
+about	O
+new	O
+risks	O
+.	O
+
+When	O
+organ	B-ANAT
+dysfunction	O
+occurs	O
+,	O
+the	O
+primary	O
+clinical	O
+management	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+is	O
+based	O
+on	O
+support	O
+/	O
+replacement	O
+of	O
+organ	B-ANAT
+function	O
+until	O
+recovery	O
+.	O
+
+To	O
+limit	O
+the	O
+deleterious	O
+effects	O
+of	O
+mechanical	O
+ventilation	O
+and	O
+avoid	O
+excessive	O
+carbon	B-CHED
+dioxide	I-CHED
+accumulation	O
+,	O
+devices	O
+for	O
+extracorporeal	O
+CO2	B-CHED
+removal	O
+(	O
+ECCO2R	O
+),	O
+have	O
+been	O
+developed	O
+.	O
+
+PDCoV	O
+diarrhea	B-DISO
+was	O
+first	O
+reported	O
+in	O
+the	O
+US	O
+in	O
+early	O
+2014	O
+,	O
+concurrently	O
+with	O
+co	O
+-	O
+circulation	B-PROC
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+(	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+,	O
+genus	B-SPEC
+Alphacoronavirus	B-SPEC
+).	O
+
+TC	O
+-	O
+PDCoV	O
+strains	O
+will	O
+be	O
+useful	O
+to	O
+develop	O
+serologic	O
+assays	O
+and	O
+to	O
+evaluate	O
+if	O
+serial	O
+cell	B-COMP
+-	O
+culture	O
+passage	O
+attenuates	O
+TC	O
+-	O
+PDCoV	O
+as	O
+a	O
+potential	O
+vaccine	O
+candidate	O
+strain	O
+.	O
+
+Infection	B-DISO
+control	O
+deficiencies	O
+included	O
+limited	O
+separation	B-DISO
+of	O
+suspected	O
+MERS	O
+patients	O
+,	O
+patient	O
+crowding	B-DISO
+,	O
+and	O
+inconsistent	O
+use	O
+of	O
+infection	B-DISO
+control	O
+precautions	O
+;	O
+aggressive	B-DISO
+improvements	O
+in	O
+these	O
+deficiencies	O
+preceded	O
+a	O
+decline	O
+in	O
+cases	O
+.	O
+
+Detection	O
+of	O
+amplification	B-DISO
+products	O
+based	O
+on	O
+labeled	O
+probe	O
+primers	O
+was	O
+conducted	O
+with	O
+strip	O
+binding	B-FUNC
+antibody	B-COMP
+of	O
+labeled	O
+markers	O
+.	O
+
+The	O
+presence	O
+of	O
+MERS	O
+-	O
+CoV	O
+was	O
+confirmed	O
+by	O
+RT	O
+-	O
+PCR	O
+of	O
+viral	O
+cultures	O
+of	O
+4	O
+of	O
+7	O
+air	B-CHED
+samples	O
+from	O
+2	O
+patients	O
+'	O
+rooms	O
+,	O
+1	O
+patient	O
+'	O
+s	O
+restroom	O
+,	O
+and	O
+1	O
+common	O
+corridor	O
+.	O
+
+IFA	O
+on	O
+the	O
+cultures	O
+of	O
+the	O
+air	B-CHED
+and	O
+swab	O
+samples	O
+revealed	O
+the	O
+presence	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+EM	O
+images	O
+also	O
+revealed	O
+intact	O
+particles	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+viral	O
+cultures	O
+of	O
+the	O
+air	B-CHED
+and	O
+swab	O
+samples	O
+.	O
+
+It	O
+is	O
+unclear	O
+which	O
+type	O
+of	O
+PPE	B-CHED
+protects	O
+best	O
+,	O
+what	O
+is	O
+the	O
+best	O
+way	O
+to	O
+remove	O
+PPE	B-CHED
+,	O
+and	O
+how	O
+to	O
+make	O
+sure	O
+HCWs	O
+use	O
+PPE	B-CHED
+as	O
+instructed	O
+.	O
+
+This	O
+included	O
+studies	O
+that	O
+simulated	O
+contamination	O
+with	O
+fluorescent	O
+markers	O
+or	O
+a	O
+non	O
+-	O
+pathogenic	O
+virus	B-SPEC
+.	O
+
+We	O
+also	O
+found	O
+very	O
+low	O
+quality	O
+evidence	O
+that	O
+double	O
+gloving	O
+and	O
+CDC	O
+doffing	O
+guidance	O
+appear	O
+to	O
+decrease	O
+the	O
+risk	O
+of	O
+contamination	O
+and	O
+that	O
+more	O
+active	O
+training	O
+in	O
+PPE	B-CHED
+use	O
+may	O
+reduce	O
+PPE	B-CHED
+and	O
+doffing	O
+errors	O
+more	O
+than	O
+passive	O
+training	O
+.	O
+
+HCWs	O
+exposed	O
+to	O
+highly	O
+infectious	B-DISO
+diseases	I-DISO
+should	O
+have	O
+their	O
+use	O
+of	O
+PPE	B-CHED
+registered	O
+and	O
+should	O
+be	O
+prospectively	O
+followed	O
+for	O
+their	O
+risk	O
+of	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+has	O
+claimed	O
+hundreds	O
+of	O
+lives	O
+and	O
+has	O
+become	O
+a	O
+global	O
+threat	O
+since	O
+its	O
+emergence	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+.	O
+
+Using	O
+chimeric	O
+and	O
+truncation	B-DISO
+mutants	O
+,	O
+the	O
+N	O
+-	O
+terminal	O
+transmembrane	B-COMP
+domains	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+protein	I-PRGE
+were	O
+found	O
+to	O
+be	O
+sufficient	O
+for	O
+its	O
+inhibitory	O
+effect	O
+on	O
+IFN	B-PRGE
+expression	B-PROC
+,	O
+whereas	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+was	O
+unable	O
+to	O
+induce	O
+this	O
+suppression	B-DISO
+.	O
+
+The	O
+incidence	O
+of	O
+AHF	O
+was	O
+44	O
+%	O
+and	O
+incidence	O
+of	O
+ARDS	B-DISO
+was	O
+23	O
+%.	O
+
+However	O
+,	O
+23	O
+patients	O
+with	O
+pre	O
+-	O
+operative	O
+normal	O
+lung	B-ANAT
+status	O
+developed	O
+AHF	O
+/	O
+ARDS	B-DISO
+in	O
+relation	O
+to	O
+the	O
+surgical	O
+procedure	O
+,	O
+whereas	O
+12	O
+patients	O
+with	O
+AHF	O
+/	O
+ARDS	B-DISO
+normalized	O
+their	O
+lung	B-ANAT
+condition	B-DISO
+.	O
+
+We	O
+found	O
+that	O
+the	O
+incidence	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+ICU	O
+treated	O
+patients	O
+with	O
+pelvis	B-ANAT
+fractures	O
+was	O
+high	O
+,	O
+that	O
+the	O
+procedure	O
+around	O
+surgical	O
+stabilization	O
+seems	O
+to	O
+be	O
+associated	O
+with	O
+a	O
+worsening	O
+in	O
+the	O
+respiratory	B-PROC
+function	I-PROC
+in	O
+patients	O
+with	O
+lung	B-ANAT
+contusion	O
+,	O
+and	O
+that	O
+mortality	O
+was	O
+low	O
+and	O
+was	O
+probably	O
+not	O
+related	O
+to	O
+the	O
+respiratory	O
+condition	B-DISO
+.	O
+
+Plasma	B-ANAT
+was	O
+sampled	O
+from	O
+the	O
+healthy	O
+as	O
+controls	O
+or	O
+patients	O
+with	O
+SP	O
+infected	O
+with	O
+bacteria	B-SPEC
+or	O
+infection	B-DISO
+-	O
+associated	O
+SP	O
+-	O
+ARDS	B-DISO
+on	O
+the	O
+day	O
+of	O
+admission	O
+,	O
+day	O
+3	O
+,	O
+and	O
+day	O
+7	O
+.	O
+
+ARDS	B-DISO
+patients	O
+with	O
+overexpressed	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+CXCL16	B-PRGE
+,	O
+or	O
+IGFBP	B-PRGE
+-	I-PRGE
+4	I-PRGE
+had	O
+significantly	O
+longer	O
+hospital	O
+stay	O
+and	O
+higher	O
+incidence	O
+of	O
+secondary	B-DISO
+infection	I-DISO
+.	O
+
+Our	O
+preliminary	O
+study	O
+suggested	O
+that	O
+integration	B-PROC
+of	O
+proteomic	O
+profiles	O
+with	O
+clinical	O
+informatics	O
+as	O
+part	O
+of	O
+clinical	O
+bioinformatics	O
+is	O
+important	O
+to	O
+validate	O
+and	O
+optimize	O
+disease	O
+-	O
+specific	O
+and	O
+disease	O
+-	O
+staged	O
+biomarkers	O
+.	O
+
+In	O
+nonclinical	O
+studies	O
+involving	O
+lethal	O
+infections	B-DISO
+with	O
+Ebola	O
+virus	B-SPEC
+,	I-SPEC
+Marburg	I-SPEC
+virus	B-SPEC
+,	O
+Rift	B-SPEC
+Valley	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+Yellow	B-SPEC
+Fever	I-SPEC
+virus	I-SPEC
+,	O
+BCX4430	O
+has	O
+demonstrated	O
+pronounced	O
+efficacy	O
+.	O
+
+ICC	B-DISO
+staining	O
+of	O
+CSF	B-ANAT
+macrophages	B-ANAT
+was	O
+performed	O
+in	O
+all	O
+cats	B-SPEC
+.	O
+
+Conclusions	O
+and	O
+relevance	O
+CSF	B-ANAT
+ICC	B-DISO
+is	O
+a	O
+highly	O
+sensitive	O
+test	O
+for	O
+ante	O
+-	O
+mortem	O
+diagnosis	O
+of	O
+FIP	B-DISO
+manifesting	O
+in	O
+the	O
+CNS	B-CHED
+.	O
+
+It	O
+was	O
+hypothesized	O
+that	O
+Mmp3	B-PRGE
+deficient	O
+(	O
+Mmp3	B-PRGE
+(-/-))	O
+mice	B-SPEC
+would	O
+be	O
+protected	O
+against	O
+lung	B-ANAT
+dysfunction	O
+associated	O
+with	O
+ARDS	B-DISO
+and	O
+maintain	O
+a	O
+functional	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+system	O
+.	O
+
+Enterovirus	B-SPEC
+/	O
+rhinovirus	B-SPEC
+was	O
+detected	O
+in	O
+51	O
+.	O
+7	O
+%	O
+patients	O
+,	O
+followed	O
+by	O
+parainfluenza	B-DISO
+virus	B-SPEC
+type	O
+III	O
+(	O
+8	O
+.	O
+3	O
+%),	O
+and	O
+RSV	B-SPEC
+(	O
+5	O
+.	O
+7	O
+%).	O
+
+This	O
+study	O
+extends	O
+current	O
+knowledge	O
+on	O
+the	O
+diversity	O
+and	O
+epidemiology	O
+of	O
+PEDV	B-SPEC
+.	O
+
+G6PD	B-PRGE
+-	O
+deficient	O
+cells	B-COMP
+experience	O
+a	O
+high	O
+level	O
+of	O
+oxidative	B-DISO
+stress	I-DISO
+and	O
+an	O
+increased	O
+susceptibility	O
+to	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Prone	O
+positioning	O
+is	O
+recommended	O
+as	O
+a	O
+rescue	O
+therapy	O
+to	O
+improve	O
+arterial	O
+oxygenation	B-PROC
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Across	O
+a	O
+highly	O
+conserved	O
+region	O
+of	O
+the	O
+viral	B-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+,	O
+the	O
+new	O
+members	O
+of	O
+this	O
+clade	O
+were	O
+up	O
+to	O
+22	O
+%	O
+dissimilar	O
+at	O
+the	O
+nucleotide	B-CHED
+level	O
+to	O
+the	O
+previously	O
+described	O
+Lucheng	O
+virus	B-SPEC
+.	O
+
+As	O
+such	O
+they	O
+might	O
+represent	O
+distinct	O
+species	B-SPEC
+of	O
+alphacoronaviruses	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+describe	O
+a	O
+method	O
+for	O
+the	O
+swift	B-SPEC
+generation	O
+of	O
+a	O
+human	B-PRGE
+-	I-PRGE
+derived	I-PRGE
+monoclonal	I-PRGE
+antibody	B-COMP
+,	O
+known	O
+as	O
+LCA60	O
+,	O
+as	O
+a	O
+treatment	O
+for	O
+MERS	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+the	O
+main	O
+causative	O
+agent	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+).	O
+
+The	O
+amino	B-CHED
+acid	I-CHED
+(	O
+AA	B-CHED
+)	O
+sequence	O
+of	O
+S	B-PRGE
+gene	I-PRGE
+of	O
+YC2014	O
+shared	O
+only	O
+92	O
+.	O
+8	O
+%	O
+~	O
+93	O
+.	O
+4	O
+%	O
+identities	O
+with	O
+classical	O
+CV777	O
+,	O
+DR13	O
+and	O
+JS2008	O
+strains	O
+,	O
+with	O
+5	O
+AA	B-CHED
+insertion	O
+in	O
+two	O
+sites	O
+and	O
+1	O
+AA	B-CHED
+deletion	O
+in	O
+one	O
+site	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+discovery	O
+of	O
+novel	O
+antiviral	B-CHED
+materials	O
+is	O
+important	O
+because	O
+many	O
+infectious	B-DISO
+diseases	I-DISO
+are	O
+caused	O
+by	O
+viruses	B-SPEC
+.	O
+
+Since	O
+domain	O
+N3	O
+is	O
+also	O
+the	O
+region	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+that	O
+interacts	O
+with	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+,	O
+this	O
+finding	O
+suggests	O
+a	O
+mechanism	O
+by	O
+which	O
+selective	O
+genome	O
+packaging	O
+is	O
+accomplished	O
+,	O
+through	O
+the	O
+coupling	O
+of	O
+genome	O
+encapsidation	O
+to	O
+virion	O
+assembly	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+Infection	I-DISO
+in	O
+Ferrets	B-SPEC
+:	O
+Antigen	B-CHED
+Distribution	O
+and	O
+Inflammatory	B-DISO
+Response	I-DISO
+.	O
+
+Nasal	B-ANAT
+swabs	O
+were	O
+collected	O
+from	O
+114	O
+cattle	B-SPEC
+on	O
+initial	O
+BRD	O
+treatment	O
+.	O
+
+Swabs	O
+and	O
+tissue	B-ANAT
+homogenates	O
+were	O
+tested	O
+by	O
+gel	O
+based	O
+PCR	O
+(	O
+G	O
+-	O
+PCR	O
+),	O
+quantitative	O
+-	O
+PCR	O
+(	O
+qPCR	O
+)	O
+and	O
+quantitative	O
+real	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+PCR	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+and	O
+viral	O
+culture	O
+.	O
+
+There	O
+were	O
+87	O
+/	O
+114	O
+(	O
+76	O
+.	O
+3	O
+%)	O
+swabs	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+virus	B-SPEC
+by	O
+at	O
+least	O
+one	O
+test	O
+.	O
+
+However	O
+based	O
+on	O
+sequencing	O
+and	O
+analysis	O
+,	O
+field	O
+and	O
+vaccine	O
+strains	O
+of	O
+culture	O
+positive	O
+BoHV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+BoCV	O
+,	O
+BVDV	B-SPEC
+,	O
+and	O
+PI3V	O
+,	O
+11	O
+/	O
+18	O
+(	O
+61	O
+.	O
+1	O
+%)	O
+of	O
+BoHV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+isolates	O
+,	O
+6	O
+/	O
+17	O
+(	O
+35	O
+.	O
+3	O
+%)	O
+BVDV	B-SPEC
+isolates	O
+,	O
+and	O
+1	O
+/	O
+10	O
+(	O
+10	O
+.	O
+0	O
+%)	O
+PI3V	O
+identified	O
+as	O
+vaccine	O
+.	O
+
+BRSV	B-SPEC
+was	O
+only	O
+identified	O
+by	O
+PCR	O
+testing	O
+.	O
+
+Interpretation	O
+of	O
+laboratory	O
+tests	O
+is	O
+appropriate	O
+as	O
+molecular	O
+based	O
+tests	O
+and	O
+virus	B-SPEC
+isolation	O
+cannot	O
+separate	O
+field	O
+from	O
+vaccine	O
+strains	O
+.	O
+
+SAIBK2	O
+causes	O
+severe	O
+kidney	B-ANAT
+lesions	O
+and	O
+results	O
+in	O
+50	O
+%	O
+mortality	O
+in	O
+30	O
+-	O
+day	O
+-	O
+old	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+(	O
+with	O
+a	O
+dose	O
+of	O
+10	O
+(	O
+5	O
+)	O
+EID50	O
+/	O
+0	O
+.	O
+1	O
+mL	O
+SAIBK2	O
+per	O
+chicken	B-SPEC
+).	O
+
+1	O
+.	O
+0	O
+ml	O
+/	O
+cm	O
+H2O	B-CHED
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+))	O
+moreover	O
+,	O
+there	O
+was	O
+a	O
+concurrent	O
+increase	O
+in	O
+PaO2	O
+:	O
+FiO2	O
+(+	O
+113	O
++/-	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+traumatic	O
+brain	O
+injury	O
+(	O
+TBI	O
+),	O
+optimizing	O
+sedation	B-DISO
+is	O
+challenging	O
+because	O
+maintaining	O
+a	O
+clinical	O
+examination	O
+is	O
+important	O
+in	O
+being	O
+able	O
+to	O
+detect	O
+neurological	O
+deterioration	O
+.	O
+
+Propofol	B-CHED
+(	O
+PROP	B-CHED
+)	O
+is	O
+frequently	O
+used	O
+as	O
+a	O
+sedative	B-CHED
+in	O
+TBI	O
+since	O
+it	O
+has	O
+been	O
+shown	O
+to	O
+reduce	O
+the	O
+cerebral	B-ANAT
+metabolic	B-PROC
+rate	I-PROC
+,	O
+but	O
+it	O
+may	O
+lead	O
+to	O
+PROP	B-CHED
+-	O
+related	O
+infusion	O
+syndrome	B-DISO
+and	O
+hemodynamic	B-PROC
+compromise	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+whether	O
+sedation	B-DISO
+with	O
+DEX	O
+would	O
+be	O
+safe	O
+in	O
+patients	O
+with	O
+severe	O
+TBI	O
+.	O
+
+The	O
+clinical	O
+data	O
+of	O
+58	O
+adult	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+which	O
+met	B-CHED
+the	O
+criteria	O
+for	O
+ECMO	O
+and	O
+treated	O
+in	O
+comprehensive	O
+intensive	O
+care	O
+unit	O
+of	O
+the	O
+Second	O
+Affiliated	O
+Hospital	O
+of	O
+Zhengzhou	O
+University	O
+from	O
+August	O
+2012	O
+to	O
+June	O
+2015	O
+,	O
+were	O
+retrospectively	O
+collected	O
+and	O
+analyzed	O
+.	O
+
+After	O
+ECMO	O
+running	O
+3	O
+days	O
+,	O
+most	O
+factors	O
+of	O
+the	O
+ECMO	O
+survival	O
+group	O
+were	O
+better	O
+than	O
+those	O
+of	O
+the	O
+control	O
+group	O
+(	O
+all	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+except	O
+MAP	B-PRGE
+,	O
+but	O
+most	O
+factors	O
+between	O
+the	O
+ECMO	O
+non	O
+-	O
+survival	O
+group	O
+and	O
+the	O
+control	O
+group	O
+were	O
+not	O
+significantly	O
+different	O
+(	O
+all	O
+P	O
+>	O
+0	O
+.	O
+05	O
+),	O
+while	O
+the	O
+serum	B-COMP
+lactate	B-CHED
+level	O
+was	O
+higher	O
+(	O
+t	O
+=-	O
+3	O
+.	O
+156	O
+,	O
+P	O
+=	O
+0	O
+.	O
+003	O
+)	O
+and	O
+the	O
+MAP	O
+lower	O
+(	O
+t	O
+=	O
+3	O
+.	O
+578	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+Public	O
+Health	O
+England	O
+Birmingham	O
+Laboratory	O
+(	O
+PHEBL	O
+)	O
+is	O
+one	O
+of	O
+a	O
+few	O
+selected	O
+UK	O
+public	O
+health	O
+laboratories	O
+responsible	O
+for	O
+MERS	O
+-	O
+CoV	O
+screening	O
+in	O
+travellers	O
+returning	O
+to	O
+the	O
+UK	O
+from	O
+the	O
+Middle	O
+East	O
+who	O
+present	O
+to	O
+hospital	O
+with	O
+severe	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+A	O
+viral	O
+aetiology	O
+was	O
+detected	O
+in	O
+half	O
+(	O
+50	O
+.	O
+3	O
+%)	O
+of	O
+the	O
+cases	O
+,	O
+with	O
+rhinoviruses	B-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+and	O
+H3N2	B-CHED
+),	O
+and	O
+influenza	B-DISO
+B	O
+being	O
+most	O
+frequent	O
+.	O
+
+Peak	O
+testing	O
+occurred	O
+following	O
+the	O
+annual	O
+Hajj	O
+season	O
+and	O
+in	O
+other	O
+periods	B-PROC
+of	O
+raised	O
+national	O
+awareness	O
+.	O
+
+TITLE	O
+:	O
+Formation	B-PROC
+of	O
+fibroblastic	O
+reticular	O
+network	O
+in	O
+the	O
+brain	B-ANAT
+after	O
+infection	B-DISO
+with	O
+neurovirulent	O
+murine	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+However	O
+,	O
+during	O
+the	O
+initial	O
+phase	O
+of	O
+infection	B-DISO
+between	O
+12	O
+and	O
+24	O
+h	O
+post	O
+-	O
+inoculation	O
+(	O
+hpi	B-DISO
+),	O
+the	O
+viral	O
+antigens	B-CHED
+are	O
+detected	O
+only	O
+in	O
+the	O
+meninges	B-ANAT
+,	O
+followed	O
+by	O
+viral	O
+spread	O
+into	O
+the	O
+ventricular	B-ANAT
+wall	I-ANAT
+before	O
+invasion	B-DISO
+into	O
+the	O
+brain	B-ANAT
+parenchyma	B-ANAT
+,	O
+indicating	O
+that	O
+the	O
+viruses	B-SPEC
+employ	O
+a	O
+passage	O
+between	O
+the	O
+meninges	B-ANAT
+and	O
+ventricular	B-ANAT
+wall	I-ANAT
+as	O
+an	O
+entry	O
+route	O
+into	O
+the	O
+brain	B-ANAT
+parenchyma	B-ANAT
+.	O
+
+At	O
+48	O
+hpi	B-DISO
+,	O
+the	O
+passage	O
+was	O
+found	O
+to	O
+be	O
+constructed	O
+by	O
+ER	B-PRGE
+-	I-PRGE
+TR7	I-PRGE
+antigen	I-PRGE
+(	O
+ERag	O
+)-	O
+positive	O
+fibers	O
+(	O
+ERfibs	O
+)	O
+associated	O
+with	O
+laminin	B-PRGE
+and	O
+collagen	B-PRGE
+III	I-PRGE
+between	O
+the	O
+fourth	B-ANAT
+ventricle	I-ANAT
+and	O
+meninges	B-ANAT
+at	O
+the	O
+cerebellopontine	B-ANAT
+angle	I-ANAT
+.	O
+
+In	O
+the	O
+brain	B-ANAT
+parenchyma	B-ANAT
+,	O
+mature	O
+ERfibs	O
+associated	O
+with	O
+laminin	B-PRGE
+were	O
+found	O
+around	O
+blood	B-ANAT
+vessels	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Early	O
+Percutaneous	O
+Heparin	B-CHED
+-	O
+Free	O
+Veno	O
+-	O
+Venous	B-ANAT
+Extra	O
+Corporeal	O
+Life	O
+Support	O
+(	O
+ECLS	O
+)	O
+is	O
+a	O
+Safe	O
+and	O
+Effective	O
+Means	O
+of	O
+Salvaging	O
+Hypoxemic	O
+Patients	O
+with	O
+Complicated	O
+Chest	O
+Trauma	O
+.	O
+
+MicroRNAs	O
+(	O
+miRNAs	O
+),	O
+a	O
+type	O
+of	O
+non	O
+-	O
+coding	O
+RNA	O
+molecule	O
+that	O
+regulate	O
+gene	B-PROC
+expression	I-PROC
+at	O
+the	O
+post	O
+-	O
+transcriptional	B-PROC
+level	O
+,	O
+have	O
+emerged	O
+as	O
+a	O
+novel	O
+class	B-SPEC
+of	O
+gene	O
+regulators	O
+,	O
+which	O
+have	O
+critical	O
+roles	O
+in	O
+a	O
+wide	O
+range	O
+of	O
+human	B-SPEC
+disorders	O
+and	O
+diseases	O
+,	O
+including	O
+ALI	O
+.	O
+
+The	O
+regulation	B-PROC
+of	O
+miRNA	O
+can	O
+relieve	O
+injury	O
+response	O
+and	O
+promote	O
+the	O
+recovery	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+Rotavirus	B-SPEC
+and	O
+Bovine	B-SPEC
+Coronavirus	B-SPEC
+are	O
+the	O
+most	O
+important	O
+causes	O
+of	O
+diarrhea	B-DISO
+in	O
+newborn	O
+calves	O
+and	O
+in	O
+some	O
+other	O
+species	B-SPEC
+such	O
+as	O
+pigs	B-SPEC
+and	O
+sheep	B-SPEC
+.	O
+
+Spike	O
+glycoprotein	B-CHED
+of	O
+coronavirus	B-SPEC
+is	O
+responsible	O
+for	O
+induction	O
+of	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+.	O
+
+Finally	O
+,	O
+a	O
+chimeric	O
+antigen	B-CHED
+was	O
+designed	O
+using	O
+computational	O
+techniques	O
+.	O
+
+The	O
+chimeric	O
+VP8	O
+-	O
+S2	O
+antigen	B-CHED
+was	O
+constructed	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+Genome	O
+Sequence	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Isolated	O
+from	O
+a	O
+Dromedary	B-SPEC
+Camel	B-SPEC
+in	O
+Egypt	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+a	O
+member	O
+of	O
+the	O
+genus	B-SPEC
+Alphacoronavirus	B-SPEC
+,	O
+has	O
+caused	O
+significant	O
+damage	O
+to	O
+the	O
+Asian	O
+and	O
+American	O
+pork	O
+industries	O
+.	O
+
+Results	O
+of	O
+additional	O
+tests	O
+finally	O
+excluded	O
+pulmonary	B-DISO
+thromboembolism	I-DISO
+and	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+diagnosis	O
+of	O
+inverted	O
+stress	O
+-	O
+induced	O
+cardiomyopathy	B-DISO
+was	O
+set	O
+upon	O
+the	O
+overall	O
+clinical	O
+data	O
+.	O
+
+An	O
+adjusted	O
+multivariable	O
+linear	O
+regression	O
+model	O
+using	O
+the	O
+natural	O
+logarithmic	O
+value	O
+of	O
+the	O
+maximum	O
+sedative	B-CHED
+exposure	O
+in	O
+a	O
+6	O
+-	O
+hour	O
+period	O
+revealed	O
+that	O
+patient	O
+age	O
+(	O
+p	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+administration	O
+of	O
+high	O
+-	O
+dose	O
+fentanyl	B-CHED
+in	O
+the	O
+24	O
+hours	O
+prior	O
+to	O
+the	O
+6	O
+-	O
+hour	O
+period	O
+of	O
+maximum	O
+sedative	B-CHED
+use	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+were	O
+each	O
+independently	O
+associated	O
+with	O
+the	O
+maximum	O
+6	O
+-	O
+hour	O
+sedative	B-CHED
+requirement	O
+reached	O
+,	O
+but	O
+the	O
+use	O
+of	O
+ECMO	O
+was	O
+not	O
+(	O
+p	O
+=	O
+0	O
+.	O
+52	O
+).	O
+
+Compared	O
+with	O
+non	O
+-	O
+ILD	O
+group	O
+,	O
+though	O
+the	O
+compliance	O
+of	O
+respiratory	B-ANAT
+system	I-ANAT
+in	O
+ILD	O
+group	O
+is	O
+increased	O
+during	O
+PPV	B-CHED
+,	O
+long	O
+-	O
+term	O
+effect	O
+is	O
+better	O
+in	O
+non	O
+-	O
+ILD	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+value	O
+of	O
+high	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+(	O
+HFNC	O
+)	O
+in	O
+treating	O
+a	O
+patient	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+The	O
+patient	O
+was	O
+admitted	O
+to	O
+Department	O
+of	O
+Critical	O
+Care	O
+Medicine	B-CHED
+of	O
+Huizhou	O
+Municipal	O
+Central	O
+Hospital	O
+on	O
+May	O
+28th	O
+,	O
+2015	O
+,	O
+and	O
+the	O
+changes	O
+in	O
+various	O
+clinical	O
+parameters	O
+and	O
+their	O
+significance	O
+were	O
+analyzed	O
+.	O
+
+However	O
+,	O
+after	O
+2	O
+-	O
+week	O
+anti	O
+-	O
+virus	B-SPEC
+therapy	O
+,	O
+the	O
+virus	B-SPEC
+test	O
+was	O
+positive	O
+.	O
+
+According	O
+to	O
+his	O
+past	O
+history	O
+,	O
+methimazole	B-CHED
+had	O
+been	O
+given	O
+continuously	O
+for	O
+hyperthyroidism	B-DISO
+and	O
+other	O
+symptomatic	O
+treatment	O
+.	O
+
+Activities	O
+on	O
+bed	B-DISO
+were	O
+gradually	O
+increased	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+43	O
+-	O
+year	O
+old	O
+male	O
+was	O
+admitted	O
+to	O
+negative	O
+pressure	O
+isolation	O
+intensive	O
+care	O
+unit	O
+with	O
+the	O
+complaint	O
+of	O
+back	B-DISO
+ache	I-DISO
+for	O
+7	O
+days	O
+and	O
+fever	B-PROC
+for	O
+2	O
+days	O
+.	O
+
+Risk	O
+factors	O
+of	O
+severe	O
+trauma	O
+patients	O
+were	O
+sorted	B-PROC
+,	O
+from	O
+which	O
+the	O
+meaningful	O
+indicators	O
+were	O
+included	O
+to	O
+calculate	O
+the	O
+warning	O
+score	O
+of	O
+death	B-PROC
+.	O
+
+51	O
+.	O
+50	O
+±	O
+18	O
+.	O
+31	O
+vs	O
+.	O
+45	O
+.	O
+54	O
+±	O
+14	O
+.	O
+70	O
+,	O
+t	O
+=	O
+-	O
+2	O
+.	O
+456	O
+,	O
+P	O
+=	O
+0	O
+.	O
+016	O
+);	O
+SCr	O
+was	O
+increased	O
+(	O
+µmol	O
+/	O
+L	O
+:	O
+94	O
+.	O
+18	O
+±	O
+65	O
+.	O
+51	O
+vs	O
+.	O
+72	O
+.	O
+42	O
+±	O
+28	O
+.	O
+22	O
+,	O
+t	O
+=	O
+-	O
+2	O
+.	O
+611	O
+,	O
+P	O
+=	O
+0	O
+.	O
+011	O
+);	O
+APACHE	O
+II	O
+score	O
+(	O
+24	O
+.	O
+30	O
+±	O
+6	O
+.	O
+23	O
+vs	O
+.	O
+16	O
+.	O
+38	O
+±	O
+6	O
+.	O
+19	O
+,	O
+t	O
+=	O
+-	O
+9	O
+.	O
+353	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+SOFA	O
+score	O
+were	O
+higher	O
+(	O
+7	O
+.	O
+84	O
+±	O
+3	O
+.	O
+68	O
+vs	O
+.	O
+4	O
+.	O
+43	O
+±	O
+2	O
+.	O
+75	O
+,	O
+t	O
+=	O
+-	O
+7	O
+.	O
+049	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+);	O
+and	O
+the	O
+incidence	O
+of	O
+emergency	B-DISO
+intubation	O
+[	O
+79	O
+.	O
+7	O
+%	O
+(	O
+51	O
+/	O
+64	O
+)	O
+vs	O
+.	O
+42	O
+.	O
+7	O
+%	O
+(	O
+141	O
+/	O
+330	O
+),	O
+χ²	O
+=	O
+29	O
+.	O
+309	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+]	O
+and	O
+sepsis	B-DISO
+was	O
+also	O
+higher	O
+[	O
+48	O
+.	O
+4	O
+%	O
+(	O
+31	O
+/	O
+64	O
+)	O
+vs	O
+.	O
+30	O
+.	O
+3	O
+%	O
+(	O
+100	O
+/	O
+330	O
+),	O
+χ²	O
+=	O
+18	O
+.	O
+512	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+],	O
+but	O
+PLT	O
+count	O
+(	O
+X	O
+10⁹	O
+/	O
+L	O
+:	O
+112	O
+.	O
+75	O
+±	O
+59	O
+.	O
+85	O
+vs	O
+.	O
+144	O
+.	O
+12	O
+±	O
+68	O
+.	O
+28	O
+,	O
+t	O
+=	O
+3	O
+.	O
+428	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+GCS	O
+score	O
+(	O
+6	O
+.	O
+44	O
+±	O
+4	O
+.	O
+20	O
+vs	O
+.	O
+11	O
+.	O
+02	O
+±	O
+3	O
+.	O
+93	O
+,	O
+t	O
+=	O
+8	O
+.	O
+449	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+significantly	O
+lower	O
+.	O
+
+The	O
+indicators	O
+with	O
+statistically	O
+significant	O
+difference	O
+from	O
+the	O
+univariate	O
+analysis	O
+were	O
+further	O
+analyzed	O
+by	O
+multivariate	O
+logistic	O
+regression	O
+,	O
+and	O
+the	O
+indices	O
+included	O
+in	O
+the	O
+regression	O
+model	O
+were	O
+age	O
+≥	O
+65	O
+years	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+=	O
+0	O
+.	O
+176	O
+-	O
+1	O
+.	O
+974	O
+,	O
+P	O
+=	O
+0	O
+.	O
+019	O
+],	O
+APACHE	O
+II	O
+score	O
+≥	O
+21	O
+(	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+121	O
+-	O
+2	O
+.	O
+725	O
+,	O
+P	O
+=	O
+0	O
+.	O
+032	O
+),	O
+GCS	O
+<	O
+6	O
+(	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+201	O
+-	O
+3	O
+.	O
+221	O
+,	O
+P	O
+=	O
+0	O
+.	O
+026	O
+),	O
+severe	B-DISO
+sepsis	I-DISO
+(	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+421	O
+-	O
+2	O
+.	O
+735	O
+,	O
+P	O
+=	O
+0	O
+.	O
+008	O
+)	O
+or	O
+septic	B-DISO
+shock	I-DISO
+(	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+430	O
+-	O
+3	O
+.	O
+636	O
+,	O
+P	O
+=	O
+0	O
+.	O
+013	O
+),	O
+with	O
+assigning	O
+scores	O
+of	O
+1	O
+.	O
+0	O
+,	O
+1	O
+.	O
+5	O
+,	O
+1	O
+.	O
+5	O
+,	O
+1	O
+.	O
+5	O
+,	O
+2	O
+.	O
+0	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Improvement	O
+effect	O
+of	O
+early	O
+goal	O
+-	O
+directed	O
+therapy	O
+on	O
+the	O
+prognosis	O
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+].	O
+
+Complete	O
+clinical	O
+data	O
+of	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+admitted	O
+to	O
+emergency	B-DISO
+intensive	O
+care	O
+unit	O
+(	O
+EICU	O
+)	O
+of	O
+Sichuan	O
+Provincial	O
+People	O
+'	O
+s	O
+Hospital	O
+from	O
+May	O
+1994	O
+to	O
+December	O
+2014	O
+were	O
+recorded	O
+and	O
+analyzed	O
+.	O
+
+The	O
+relationship	O
+of	O
+EGDT	O
+compliance	O
+standard	O
+time	O
+and	O
+tissue	B-ANAT
+perfusion	O
+index	O
+recovery	O
+time	O
+between	O
+the	O
+two	O
+groups	O
+of	O
+patients	O
+was	O
+observed	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+presents	O
+as	O
+hypoxia	O
+and	O
+bilateral	B-DISO
+pulmonary	I-DISO
+infiltrates	I-DISO
+on	O
+chest	B-ANAT
+imaging	O
+in	O
+the	O
+absence	O
+of	O
+heart	B-DISO
+failure	I-DISO
+sufficient	O
+to	O
+account	O
+for	O
+this	O
+clinical	O
+state	O
+.	O
+
+Management	O
+is	O
+largely	O
+supportive	O
+,	O
+and	O
+is	O
+focused	O
+on	O
+protective	O
+mechanical	O
+ventilation	O
+and	O
+the	O
+avoidance	O
+of	O
+fluid	B-DISO
+overload	I-DISO
+.	O
+
+The	O
+assays	O
+did	O
+not	O
+amplify	O
+the	O
+porcine	B-SPEC
+deltacoronavirus	O
+OH	O
+-	O
+FD22	O
+strain	O
+or	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+Miller	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+Management	O
+of	O
+infections	B-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+returning	O
+travellers	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+-	O
+I	O
+:	O
+considerations	O
+on	O
+infection	O
+control	O
+and	O
+transmission	O
+of	O
+resistance	B-PROC
+.	O
+
+However	O
+,	O
+malaria	B-PATH
+remains	O
+by	O
+far	O
+the	O
+most	O
+important	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+We	O
+defined	O
+lung	B-ANAT
+protective	O
+ventilation	O
+as	O
+a	O
+tidal	O
+volume	O
+of	O
+less	O
+than	O
+or	O
+equal	O
+to	O
+8	O
+mL	O
+/	O
+kg	O
+of	O
+predicted	O
+body	B-ANAT
+weight	O
+and	O
+compared	O
+outcomes	O
+for	O
+patients	O
+ventilated	O
+with	O
+lung	B-ANAT
+protective	O
+vs	O
+non	O
+-	O
+lung	B-ANAT
+protective	O
+ventilation	O
+,	O
+including	O
+inhospital	O
+mortality	O
+,	O
+ventilator	O
+days	O
+,	O
+intensive	O
+care	O
+unit	O
+length	O
+of	O
+stay	O
+,	O
+and	O
+hospital	O
+length	O
+of	O
+stay	O
+.	O
+
+Our	O
+analyses	O
+show	O
+:	O
+1	O
+)	O
+28	O
+potential	O
+recombinant	O
+sequences	O
+were	O
+detected	O
+and	O
+they	O
+can	O
+be	O
+classified	O
+into	O
+seven	O
+potential	O
+recombinant	O
+types	O
+;	O
+2	O
+)	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+was	O
+under	O
+strong	O
+positive	O
+selection	O
+when	O
+MERS	O
+-	O
+CoV	O
+transmitted	B-DISO
+from	O
+their	O
+natural	O
+host	B-COMP
+to	O
+human	B-SPEC
+;	O
+3	O
+)	O
+Six	O
+out	O
+of	O
+nine	O
+positive	O
+selection	O
+sites	O
+detected	O
+in	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+are	O
+located	O
+in	O
+its	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+which	O
+is	O
+in	O
+direct	O
+contact	O
+with	O
+host	B-COMP
+cells	B-COMP
+;	O
+4	O
+)	O
+MERS	O
+-	O
+CoV	O
+frequently	O
+transmitted	B-DISO
+back	B-ANAT
+and	O
+forth	O
+between	O
+human	B-SPEC
+and	O
+camel	B-SPEC
+after	O
+it	O
+had	O
+acquired	O
+the	O
+human	O
+-	O
+camel	B-SPEC
+infection	B-DISO
+capability	O
+.	O
+
+However	O
+,	O
+the	O
+expression	B-PROC
+of	O
+these	O
+recombinant	B-PRGE
+protein	I-PRGE
+antigens	B-CHED
+using	O
+a	O
+variety	O
+of	O
+expression	B-PROC
+vectors	O
+,	O
+strains	O
+,	O
+and	O
+induction	O
+conditions	O
+invariably	O
+resulted	O
+in	O
+inclusion	B-COMP
+bodies	I-COMP
+.	O
+
+In	O
+an	O
+indirect	O
+ELISA	O
+,	O
+purified	O
+proteins	B-CHED
+showed	O
+immune	O
+reactivity	O
+with	O
+pig	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+PEDV	B-SPEC
+immune	O
+sera	B-COMP
+.	O
+
+TITLE	O
+:	O
+The	O
+world	O
+first	O
+two	O
+cases	O
+of	O
+severe	O
+fever	B-PROC
+with	O
+thrombocytopenia	O
+syndrome	B-DISO
+:	O
+An	O
+epidemiological	O
+study	O
+in	O
+Nagasaki	O
+,	O
+Japan	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+fever	O
+with	O
+thrombocytopenia	O
+syndrome	B-DISO
+(	O
+SFTS	B-DISO
+)	O
+caused	O
+by	O
+the	O
+SFTS	B-DISO
+virus	B-SPEC
+(	O
+SFTSV	O
+),	O
+a	O
+novel	O
+phlebovirus	B-SPEC
+belonging	O
+to	O
+the	O
+family	B-SPEC
+Bunyaviridae	I-SPEC
+,	O
+was	O
+reported	O
+in	O
+China	O
+for	O
+the	O
+first	O
+time	O
+in	O
+2009	O
+.	O
+
+The	O
+farmer	O
+died	B-PROC
+and	O
+the	O
+hunter	O
+survived	O
+.	O
+
+Three	O
+hundred	O
+and	O
+twenty	O
+six	O
+volunteers	O
+in	O
+Nagasaki	O
+prefecture	O
+were	O
+examined	O
+and	O
+none	O
+of	O
+these	O
+tested	O
+positive	O
+for	O
+the	O
+SFTSV	O
+antibody	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Influenza	B-DISO
+virus	I-SPEC
+is	O
+a	O
+leading	O
+cause	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+the	O
+United	O
+States	O
+each	O
+year	O
+.	O
+
+Thus	O
+,	O
+the	O
+precise	O
+role	O
+of	O
+the	O
+ERRS	O
+in	O
+virus	B-PROC
+assembly	I-PROC
+remains	O
+unclear	O
+.	O
+
+Here	O
+,	O
+the	O
+roles	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+ERRS	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+intracellular	B-COMP
+trafficking	B-PROC
+and	O
+S	O
+incorporation	O
+into	O
+virus	B-SPEC
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	O
+)	O
+are	O
+described	O
+.	O
+
+In	O
+contrast	O
+,	O
+mutant	B-PRGE
+S	I-PRGE
+protein	B-CHED
+lacking	O
+the	O
+ERRS	O
+was	O
+distributed	O
+throughout	O
+the	O
+ER	O
+and	O
+only	O
+partially	O
+co	O
+-	O
+localized	O
+with	O
+M	B-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Qualitative	O
+study	O
+on	O
+the	O
+shifting	O
+sociocultural	O
+meanings	O
+of	O
+the	O
+facemask	O
+in	O
+Hong	O
+Kong	O
+since	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+:	O
+implications	O
+for	O
+infection	B-DISO
+control	O
+in	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+era	B-CHED
+.	O
+
+These	O
+findings	O
+have	O
+critical	O
+implications	O
+for	O
+designing	O
+a	O
+culturally	O
+responsive	O
+infection	B-DISO
+prevention	O
+and	O
+facemask	O
+usage	O
+policy	O
+in	O
+the	O
+future	O
+.	O
+
+Because	O
+it	O
+represents	O
+a	O
+violation	O
+of	O
+societal	O
+ideologies	O
+and	O
+traditional	O
+Chinese	O
+cultural	O
+beliefs	O
+,	O
+the	O
+meanings	O
+of	O
+the	O
+facemask	O
+that	O
+had	O
+developed	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+failed	O
+to	O
+be	O
+sustained	O
+in	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+era	B-CHED
+.	O
+
+Comparative	O
+and	O
+kinetic	O
+analyses	O
+revealed	O
+that	O
+high	O
+viral	O
+loads	O
+,	O
+weak	O
+antibody	B-PROC
+responses	I-PROC
+,	O
+and	O
+lymphopenia	B-DISO
+accompanying	O
+thrombocytopenia	O
+were	O
+associated	O
+with	O
+disease	O
+mortality	O
+,	O
+whereas	O
+persistent	O
+and	O
+gradual	O
+increases	O
+in	O
+lymphocyte	B-ANAT
+responses	O
+might	O
+be	O
+required	O
+for	O
+effective	O
+immunity	B-PROC
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+After	O
+determining	O
+the	O
+optimal	O
+combinations	O
+of	O
+these	O
+mAbs	O
+,	O
+we	O
+developed	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+and	O
+a	O
+rapid	O
+immunochromatographic	O
+antigen	B-CHED
+detection	O
+test	O
+that	O
+can	O
+be	O
+reliably	O
+used	O
+for	O
+laboratory	O
+diagnosis	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Thus	O
+,	O
+this	O
+study	O
+provides	O
+strong	O
+evidence	O
+that	O
+the	O
+wheat	B-SPEC
+germ	O
+cell	B-ANAT
+-	I-ANAT
+free	I-ANAT
+system	I-ANAT
+is	O
+useful	O
+for	O
+the	O
+production	O
+of	O
+diagnostic	O
+mAbs	O
+against	O
+emerging	O
+pathogens	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+bone	B-ANAT
+marrow	I-ANAT
+stromal	I-ANAT
+cell	I-ANAT
+antigen	B-CHED
+2	I-PRGE
+(	O
+BST	O
+-	O
+2	O
+)	O
+protein	B-CHED
+was	O
+identified	O
+as	O
+a	O
+novel	O
+virus	B-SPEC
+restriction	O
+factor	O
+that	O
+potently	O
+restricts	O
+the	O
+replication	O
+and	O
+egress	O
+of	O
+enveloped	O
+viruses	B-SPEC
+.	O
+
+Then	O
+,	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+immunized	O
+with	O
+the	O
+purified	O
+rpBST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+protein	I-PRGE
+to	O
+prepare	O
+MAbs	O
+of	O
+BST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+The	O
+specific	O
+MAb	O
+of	O
+porcine	B-PRGE
+BST	I-PRGE
+-	I-PRGE
+2	I-PRGE
+provides	O
+a	O
+valuable	O
+tool	O
+for	O
+further	O
+studies	O
+of	O
+BST	B-PRGE
+-	I-PRGE
+2	I-PRGE
+to	O
+restrict	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+an	O
+uncommon	O
+,	O
+highly	O
+fatal	O
+,	O
+and	O
+poorly	O
+understood	O
+manifestation	O
+of	O
+blastomycosis	B-DISO
+.	O
+
+Appreciable	O
+changes	O
+in	O
+cell	B-COMP
+'	O
+s	O
+morphology	O
+were	O
+detected	O
+with	O
+optimal	O
+trypsin	B-PRGE
+concentration	O
+of	O
+15	O
+-	O
+20	O
+μg	O
+trypsin	B-PRGE
+/	O
+inoculums	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+Africa	O
+:	O
+a	O
+review	O
+.	O
+
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+is	O
+well	O
+studied	O
+in	O
+European	O
+countries	O
+with	O
+identification	O
+of	O
+a	O
+large	O
+number	O
+of	O
+IBV	B-SPEC
+variants	O
+,	O
+whereas	O
+in	O
+African	O
+countries	O
+epidemiological	O
+and	O
+scientific	O
+data	O
+are	O
+poor	O
+and	O
+not	O
+updated	O
+.	O
+
+For	O
+CDV	B-CHED
+SN	O
+titers	O
+,	O
+the	O
+only	O
+statistically	O
+significant	O
+(	O
+P	O
+=	O
+0	O
+.	O
+01	O
+)	O
+difference	O
+was	O
+that	O
+the	O
+control	O
+dogs	B-SPEC
+had	O
+higher	O
+SN	O
+titers	O
+than	O
+the	O
+lean	O
+geriatric	O
+dogs	B-SPEC
+.	O
+
+This	O
+pathophysiology	O
+-	O
+based	O
+review	O
+and	O
+recent	O
+clinical	O
+evidence	O
+strongly	O
+support	O
+the	O
+use	O
+of	O
+prone	O
+positioning	O
+in	O
+the	O
+early	O
+management	O
+of	O
+severe	O
+ARDS	B-DISO
+systematically	O
+and	O
+not	O
+as	O
+a	O
+rescue	O
+maneuver	O
+or	O
+a	O
+last	O
+-	O
+ditch	O
+effort	B-PROC
+.	O
+
+Detailed	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+studies	O
+on	O
+the	O
+aglycone	O
+of	O
+compound	O
+1	O
+indicated	O
+that	O
+the	O
+subtle	O
+modification	O
+of	O
+oleanolic	B-CHED
+acid	I-CHED
+as	O
+an	O
+aglycon	O
+has	O
+key	O
+influences	O
+on	O
+the	O
+antiviral	B-CHED
+activity	O
+.	O
+
+These	O
+results	O
+suggested	O
+that	O
+either	O
+the	O
+introduction	O
+of	O
+a	O
+disubstituted	O
+amide	B-CHED
+structure	O
+at	O
+the	O
+17	O
+-	O
+COOH	O
+of	O
+OA	O
+or	O
+alteration	O
+of	O
+the	O
+C	O
+-	O
+3	O
+configuration	O
+of	O
+OA	O
+from	O
+3β	O
+-	O
+to	O
+3α	O
+-	O
+forms	O
+can	O
+significantly	O
+improve	O
+the	O
+selective	O
+index	O
+while	O
+maintaining	O
+their	O
+antiviral	B-CHED
+activities	O
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Presentation	O
+and	O
+outcome	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+in	O
+Saudi	O
+intensive	O
+care	O
+unit	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-DISO
+infection	I-DISO
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+rates	O
+but	O
+limited	O
+clinical	O
+data	O
+have	O
+been	O
+reported	O
+.	O
+
+After	O
+adjustment	O
+for	O
+the	O
+severity	O
+of	O
+illness	O
+and	O
+the	O
+degree	O
+of	O
+organ	B-ANAT
+dysfunction	O
+,	O
+the	O
+need	O
+for	O
+vasopressors	O
+was	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+death	B-PROC
+in	O
+the	O
+ICU	O
+(	O
+odds	O
+ratio	O
+=	O
+18	O
+.	O
+33	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+:	O
+1	O
+.	O
+11	O
+-	O
+302	O
+.	O
+1	O
+,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+Our	O
+Achilles	B-ANAT
+heel	B-ANAT
+remains	O
+compliance	O
+with	O
+the	O
+best	O
+infection	B-DISO
+prevention	O
+practices	O
+and	O
+their	O
+harmonization	O
+with	O
+patient	O
+flow	O
+.	O
+
+We	O
+initially	O
+developed	O
+a	O
+three	O
+-	O
+dimensional	O
+common	O
+-	O
+feature	O
+pharmacophore	O
+model	O
+according	O
+to	O
+which	O
+two	O
+hydrogen	B-CHED
+bond	O
+acceptors	O
+and	O
+one	O
+hydrophobic	O
+aromatic	O
+feature	O
+are	O
+shared	O
+by	O
+all	O
+molecular	O
+series	O
+in	O
+binding	B-FUNC
+the	O
+viral	B-PRGE
+polymerase	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Outbreaks	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhoea	I-DISO
+(	O
+PED	O
+)	O
+were	O
+reported	O
+across	O
+Europe	O
+during	O
+the	O
+1980s	O
+and	O
+1990s	O
+,	O
+but	O
+only	O
+sporadic	O
+outbreaks	O
+occurred	O
+in	O
+recent	O
+years	O
+.	O
+
+No	O
+evidence	O
+for	O
+infection	B-DISO
+resulted	O
+from	O
+inoculation	O
+of	O
+pigs	B-SPEC
+with	O
+the	O
+German	O
+sample	O
+that	O
+contained	O
+high	O
+levels	O
+of	O
+PEDV	O
+RNA	O
+;	O
+there	O
+were	O
+no	O
+clinical	O
+signs	O
+,	O
+excretion	B-PROC
+of	O
+viral	O
+RNA	O
+or	O
+anti	O
+-	O
+PEDV	B-SPEC
+antibody	B-PROC
+production	I-PROC
+.	O
+
+PEDV	B-SPEC
+RNA	O
+was	O
+detected	O
+throughout	O
+the	O
+intestine	B-ANAT
+in	O
+euthanized	O
+animals	B-SPEC
+at	O
+4	O
+days	O
+post	O
+-	O
+inoculation	O
+.	O
+
+Shell	B-ANAT
+reflectivity	O
+,	O
+L	O
+*	O
+and	O
+PP	O
+IX	O
+were	O
+not	O
+significantly	O
+different	O
+for	O
+eggshells	O
+from	O
+unvaccinated	O
+and	O
+vaccinated	O
+laying	O
+hens	O
+in	O
+the	O
+intact	O
+eggshell	O
+,	O
+but	O
+were	O
+significantly	O
+different	O
+in	O
+shells	B-ANAT
+from	O
+which	O
+cuticle	O
+had	O
+been	O
+removed	O
+.	O
+
+TITLE	O
+:	O
+Ten	O
+years	O
+of	O
+a	O
+hantavirus	B-SPEC
+disease	O
+emergency	B-DISO
+in	O
+the	O
+Federal	O
+District	O
+,	O
+Brazil	O
+.	O
+
+RT	O
+-	O
+PCR	O
+also	O
+confirmed	O
+the	O
+presence	O
+of	O
+the	O
+expected	O
+fragment	O
+sizes	O
+of	O
+the	O
+S1	B-PRGE
+subunit	I-PRGE
+and	O
+M	O
+genes	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Meanwhile	O
+,	O
+homologies	O
+in	O
+the	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+of	O
+IBV	B-SPEC
+ZZ2004	O
+were	O
+86	O
+.	O
+9	O
+-	O
+92	O
+.	O
+0	O
+%	O
+and	O
+91	O
+.	O
+1	O
+-	O
+93	O
+.	O
+9	O
+%,	O
+respectively	O
+,	O
+compared	O
+with	O
+35	O
+other	O
+IBV	B-SPEC
+reference	O
+strains	O
+derived	O
+from	O
+different	O
+regions	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+66	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+,	O
+an	O
+asthmatic	B-DISO
+,	O
+presented	O
+with	O
+symptoms	O
+suggestive	O
+of	O
+an	O
+acute	O
+exacerbation	O
+of	O
+asthma	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Development	B-PROC
+of	O
+peptidic	O
+MERS	O
+-	O
+CoV	O
+entry	O
+inhibitors	B-CHED
+].	O
+
+This	O
+review	O
+focuses	O
+on	O
+the	O
+recent	O
+advance	O
+in	O
+the	O
+development	B-PROC
+of	O
+peptidic	O
+entry	O
+inhibitors	B-CHED
+targeting	B-PROC
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S2	I-PRGE
+subunit	I-PRGE
+.	O
+
+There	O
+is	O
+better	O
+chance	O
+for	O
+those	O
+candidates	O
+to	O
+gain	O
+a	O
+quick	O
+development	B-PROC
+.	O
+
+In	O
+this	O
+observational	O
+study	O
+,	O
+we	O
+measured	O
+EELV	O
+for	O
+up	O
+to	O
+seven	O
+consecutive	O
+days	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+at	O
+different	O
+PEEP	B-CHED
+levels	O
+.	O
+
+Fever	B-PROC
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+were	O
+the	O
+most	O
+common	O
+symptoms	O
+,	O
+and	O
+2	O
+patients	O
+had	O
+watery	B-DISO
+diarrhea	I-DISO
+.	O
+
+The	O
+objective	O
+was	O
+to	O
+investigate	O
+porcine	O
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+outbreak	O
+that	O
+occurred	O
+in	O
+2014	O
+in	O
+Japan	O
+and	O
+its	O
+effects	O
+on	O
+herd	O
+-	O
+level	O
+productivity	O
+using	O
+a	O
+data	O
+recording	O
+system	O
+(	O
+PigINFO	O
+).	O
+
+From	O
+1	O
+April	O
+to	O
+30	O
+June	O
+2014	O
+(	O
+PED	O
+epidemic	O
+),	O
+any	O
+herds	O
+with	O
+clinical	O
+signs	O
+of	O
+PED	O
+and	O
+feces	B-ANAT
+positive	O
+for	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+on	O
+polymerase	O
+chain	O
+reaction	O
+analysis	O
+and	O
+/	O
+or	O
+immunohistochemical	O
+staining	O
+were	O
+defined	O
+as	O
+PED	O
+-	O
+positive	O
+(	O
+n	O
+=	O
+38	O
+).	O
+
+Herds	O
+with	O
+no	O
+clinical	O
+signs	O
+of	O
+PED	B-PRGE
+were	O
+classified	O
+as	O
+PED	B-PRGE
+-	O
+negative	O
+(	O
+n	O
+=	O
+61	O
+).	O
+
+The	O
+PED	O
+outbreak	O
+increased	O
+mortality	O
+and	O
+consequently	O
+reduced	O
+the	O
+numbers	O
+of	O
+marketed	O
+pigs	B-SPEC
+.	O
+
+However	O
+,	O
+despite	O
+the	O
+fact	O
+that	O
+a	O
+large	O
+number	O
+of	O
+genetically	O
+diverse	O
+SL	O
+-	O
+CoV	O
+sequences	O
+have	O
+been	O
+detected	O
+in	O
+bats	B-SPEC
+,	O
+only	O
+two	O
+strains	O
+(	O
+named	O
+WIV1	O
+and	O
+WIV16	O
+)	O
+have	O
+been	O
+successfully	O
+cultured	O
+in	O
+vitro	O
+These	O
+two	O
+strains	O
+differ	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+only	O
+in	O
+containing	O
+an	O
+extra	O
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+(	O
+named	O
+ORFX	O
+),	O
+between	O
+ORF6	O
+and	O
+ORF7	O
+,	O
+which	O
+has	O
+no	O
+homology	O
+to	O
+any	O
+known	O
+protein	B-CHED
+sequences	O
+.	O
+
+Moreover	O
+,	O
+the	O
+reverse	O
+genetics	O
+system	O
+we	O
+constructed	O
+will	O
+be	O
+helpful	O
+for	O
+study	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+this	O
+group	O
+of	O
+viruses	B-SPEC
+and	O
+to	O
+develop	O
+therapeutics	O
+for	O
+future	O
+control	O
+of	O
+emerging	O
+SARS	B-DISO
+-	O
+like	O
+infections	B-DISO
+.	O
+
+These	O
+results	O
+extend	O
+our	O
+understanding	O
+of	O
+nidovirus	B-SPEC
+RNA	B-PROC
+capping	I-PROC
+and	O
+methylation	B-PROC
+beyond	O
+coronaviruses	O
+and	O
+also	O
+strengthen	O
+the	O
+evolutionary	O
+and	O
+functional	O
+links	O
+between	O
+roniviruses	O
+and	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+are	O
+associated	O
+with	O
+a	O
+variety	O
+of	O
+clinical	O
+presentations	O
+in	O
+children	O
+,	O
+but	O
+their	O
+role	O
+in	O
+disease	O
+remains	O
+uncertain	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+-	O
+on	O
+-	O
+Chronic	B-DISO
+Liver	I-DISO
+Failure	I-DISO
+:	O
+Definition	O
+,	O
+Diagnosis	O
+,	O
+and	O
+Clinical	O
+Characteristics	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+-	O
+on	O
+-	O
+chronic	O
+liver	O
+failure	O
+(	O
+ACLF	O
+)	O
+is	O
+a	O
+recently	O
+recognized	O
+syndrome	B-DISO
+in	O
+cirrhosis	B-DISO
+characterized	O
+by	O
+acute	O
+decompensation	O
+(	O
+AD	O
+),	O
+organ	B-DISO
+failure	I-DISO
+(	O
+s	O
+),	O
+and	O
+high	O
+short	O
+-	O
+term	O
+mortality	O
+.	O
+
+A	O
+total	O
+of	O
+13	O
+calves	O
+were	O
+infected	O
+with	O
+rotavirus	B-SPEC
+or	O
+coronavirus	B-SPEC
+(	O
+group	O
+V	O
+),	O
+12	O
+calves	O
+with	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+F5	O
+(	O
+group	B-DISO
+B	I-DISO
+)	O
+and	O
+15	O
+calves	O
+with	O
+Eimeria	B-SPEC
+species	B-SPEC
+(	O
+group	O
+P	O
+).	O
+
+Serum	B-COMP
+SAA	O
+,	O
+Hp	O
+,	O
+IgA	B-PRGE
+and	O
+IgG	B-PRGE
+levels	O
+could	O
+be	O
+useful	O
+for	O
+the	O
+diagnosis	O
+and	O
+differential	O
+diagnosis	O
+of	O
+diarrhea	B-DISO
+caused	O
+by	O
+rotavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+F5	O
+and	O
+Eimeria	B-SPEC
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Andrographolide	B-CHED
+sulfonate	B-CHED
+ameliorates	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+by	O
+down	O
+-	O
+regulating	O
+MAPK	O
+and	O
+NF	O
+-	O
+κB	O
+pathways	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+,	O
+life	O
+-	O
+threatening	O
+medical	O
+condition	B-DISO
+characterized	O
+by	O
+widespread	O
+inflammation	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+,	O
+and	O
+is	O
+a	O
+significant	O
+source	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+the	O
+patient	O
+population	O
+.	O
+
+Our	O
+study	O
+shows	O
+that	O
+water	B-CHED
+-	O
+soluble	O
+andrographolide	B-CHED
+sulfonate	B-CHED
+may	O
+represent	O
+a	O
+new	O
+therapeutic	O
+approach	O
+for	O
+treating	O
+inflammatory	O
+lung	B-DISO
+disorders	I-DISO
+.	O
+
+TITLE	O
+:	O
+Qingfei	O
+Xiaoyan	O
+Wan	O
+,	O
+a	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+formula	O
+,	O
+ameliorates	O
+Pseudomonas	B-SPEC
+aeruginosa	I-SPEC
+-	O
+induced	O
+acute	O
+lung	B-DISO
+inflammation	I-DISO
+by	O
+regulation	B-PROC
+of	O
+PI3K	B-FUNC
+/	O
+AKT	B-PRGE
+and	O
+Ras	B-PRGE
+/	O
+MAPK	B-FUNC
+pathways	B-PROC
+.	O
+
+He	O
+was	O
+suffering	B-DISO
+from	O
+fever	B-PROC
+,	O
+headache	B-DISO
+,	O
+shivering	O
+and	O
+unable	O
+to	O
+maintain	O
+his	O
+balance	B-PROC
+.	O
+
+Third	O
+case	O
+was	O
+a	O
+46	O
+years	O
+old	O
+,	O
+male	O
+patient	O
+who	O
+had	O
+been	O
+working	O
+in	O
+Uganda	O
+,	O
+and	O
+returned	O
+to	O
+Turkey	B-SPEC
+two	O
+weeks	O
+ago	O
+.	O
+
+He	O
+had	O
+sudden	O
+onset	O
+of	O
+fever	B-PROC
+,	O
+headache	B-DISO
+,	O
+nausea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+and	O
+impaired	B-DISO
+consciousness	I-DISO
+.	O
+
+Arthemeter	O
+plus	O
+lumefantrine	B-CHED
+therapy	O
+was	O
+started	O
+,	O
+however	O
+,	O
+he	O
+developed	O
+severe	O
+thrombocytopenia	O
+and	O
+jaundice	B-DISO
+under	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+the	O
+Severe	B-SPEC
+Acute	I-SPEC
+Respiratory	I-SPEC
+Syndrome	I-SPEC
+-	I-SPEC
+Related	I-SPEC
+Coronavirus	I-SPEC
+and	O
+Alphacoronavirus	B-SPEC
+in	O
+the	O
+Bat	O
+Population	O
+of	O
+Taiwan	O
+.	O
+
+A	O
+total	O
+of	O
+405	O
+Chinese	O
+PEDV	B-SPEC
+strains	O
+were	O
+subjected	O
+to	O
+phylogenetic	O
+and	O
+phylogeographic	O
+analysis	O
+.	O
+
+The	O
+N	O
+-	O
+terminal	O
+of	O
+S	B-PRGE
+gene	I-PRGE
+(	O
+1	O
+-	O
+750bp	O
+),	O
+to	O
+some	O
+extent	O
+,	O
+could	O
+represent	O
+S1	O
+or	O
+full	B-PRGE
+length	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+for	O
+phylogenetic	O
+,	O
+similarity	O
+,	O
+antigen	B-CHED
+index	O
+,	O
+hydrophilicity	O
+plot	O
+,	O
+and	O
+differentiation	B-PROC
+analyses	O
+.	O
+
+While	O
+there	O
+is	O
+no	O
+specific	O
+therapy	O
+,	O
+we	O
+decided	O
+to	O
+support	O
+the	O
+patient	O
+with	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+V	O
+-	O
+V	O
+ECMO	O
+)	O
+to	O
+allow	O
+the	O
+ARDS	B-DISO
+to	O
+resolve	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+peer	O
+-	O
+reviewed	O
+journal	O
+Infectious	B-DISO
+Diseases	I-DISO
+of	O
+Poverty	O
+provides	O
+a	O
+new	O
+platform	O
+to	O
+engage	O
+with	O
+,	O
+and	O
+disseminate	O
+in	O
+an	O
+open	O
+-	O
+access	O
+format	O
+,	O
+science	O
+outside	O
+traditional	O
+disciplinary	O
+boundaries	O
+.	O
+
+Overall	O
+,	O
+22	O
+contributions	O
+covering	O
+a	O
+broad	O
+array	O
+of	O
+diseases	O
+are	O
+featured	O
+-	O
+i	O
+.	O
+e	O
+.	O
+clonorchiasis	B-DISO
+,	O
+dengue	B-DISO
+,	O
+hepatitis	B-DISO
+,	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+/	O
+acquired	B-DISO
+immune	I-DISO
+deficiency	I-DISO
+syndrome	I-DISO
+(	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+),	O
+H7N9	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+lymphatic	B-DISO
+filariasis	I-DISO
+,	O
+malaria	B-PATH
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+),	O
+rabies	B-DISO
+,	O
+schistosomiasis	B-DISO
+and	O
+tuberculosis	B-PATH
+(	O
+TB	O
+).	O
+
+The	O
+remaining	O
+13	O
+articles	O
+are	O
+original	O
+contributions	O
+mainly	O
+covering	O
+(	O
+i	O
+)	O
+drug	O
+resistance	O
+;	O
+(	O
+ii	O
+)	O
+innovation	O
+and	O
+validation	O
+in	O
+the	O
+field	O
+of	O
+mathematical	O
+modelling	O
+;	O
+(	O
+iii	O
+)	O
+elimination	B-PROC
+of	O
+infectious	B-DISO
+diseases	I-DISO
+;	O
+and	O
+(	O
+iv	O
+)	O
+social	O
+media	B-ANAT
+reports	O
+on	O
+disease	O
+outbreak	O
+notifications	O
+released	O
+by	O
+national	O
+health	O
+authorities	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+Gammacoronavirus	B-SPEC
+,	O
+Coronaviridae	B-SPEC
+)	O
+is	O
+a	O
+genetically	O
+variable	O
+RNA	O
+virus	B-SPEC
+(	O
+27	O
+.	O
+6kb	O
+)	O
+that	O
+causes	O
+one	O
+of	O
+the	O
+most	O
+persistent	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+poultry	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+Antigen	B-PROC
+Processing	I-PROC
+Machinery	O
+and	O
+Endogenous	O
+Peptide	B-CHED
+Presentation	O
+of	O
+a	O
+Bat	O
+MHC	B-PROC
+Class	B-SPEC
+I	O
+Molecule	O
+.	O
+
+Although	O
+highly	O
+pathogenic	O
+to	O
+their	O
+spillover	O
+hosts	B-COMP
+,	O
+bats	B-SPEC
+harbor	O
+these	O
+viruses	B-SPEC
+,	O
+and	O
+a	O
+large	O
+number	O
+of	O
+other	O
+viruses	B-SPEC
+,	O
+with	O
+little	O
+or	O
+no	O
+clinical	O
+signs	O
+of	O
+disease	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+an	O
+affinity	O
+purification	O
+/	O
+mass	O
+spectrometry	O
+approach	O
+to	O
+demonstrate	O
+that	O
+a	O
+bat	B-PRGE
+MHC	B-PROC
+class	B-SPEC
+I	I-PRGE
+molecule	I-PRGE
+,	O
+Ptal	B-ENZY
+-	O
+N	O
+*	O
+01	O
+:	O
+01	O
+,	O
+binds	B-FUNC
+antigenic	O
+peptides	B-CHED
+and	O
+associates	O
+with	O
+peptide	B-CHED
+-	O
+loading	O
+complex	O
+components	O
+.	O
+
+TITLE	O
+:	O
+Moving	B-PROC
+towards	O
+a	O
+new	O
+vision	B-PROC
+:	O
+implementation	O
+of	O
+a	O
+public	O
+health	O
+policy	O
+intervention	O
+.	O
+
+In	O
+a	O
+previous	O
+study	O
+,	O
+we	O
+isolated	O
+and	O
+serially	O
+cultivated	O
+a	O
+Korean	O
+PEDV	B-SPEC
+epidemic	O
+strain	O
+,	O
+KOR	O
+/	O
+KNU	O
+-	O
+141112	O
+/	O
+2014	O
+,	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+Eleven	O
+(	O
+11	O
+.	O
+7	O
+%)	O
+patients	O
+had	O
+mild	O
+,	O
+47	O
+(	O
+50	O
+.	O
+0	O
+%)	O
+moderate	O
+,	O
+and	O
+36	O
+(	O
+38	O
+.	O
+3	O
+%)	O
+severe	O
+ARDS	B-DISO
+;	O
+mortality	O
+was	O
+27	O
+.	O
+3	O
+,	O
+27	O
+.	O
+7	O
+,	O
+and	O
+63	O
+.	O
+9	O
+%,	O
+respectively	O
+.	O
+
+Most	O
+HEs	B-DISO
+(	O
+type	O
+I	O
+)	O
+target	O
+9	O
+-	O
+O	O
+-	O
+acetylated	O
+sialic	B-CHED
+acids	I-CHED
+(	O
+9	O
+-	O
+O	O
+-	O
+Ac	O
+-	O
+Sias	O
+),	O
+but	O
+one	O
+group	O
+of	O
+coronaviruses	O
+switched	O
+to	O
+using	O
+4	O
+-	O
+O	O
+-	O
+Ac	O
+-	O
+Sias	O
+instead	O
+(	O
+type	O
+II	O
+).	O
+
+Our	O
+findings	O
+provide	O
+fundamental	O
+insights	O
+into	O
+how	O
+proteins	B-CHED
+""""	O
+see	O
+""""	O
+sugars	O
+and	O
+how	O
+this	O
+affects	O
+protein	B-CHED
+and	O
+virus	B-SPEC
+evolution	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+an	O
+acute	O
+,	O
+highly	O
+contagious	O
+,	O
+and	O
+severe	O
+enteric	O
+disease	O
+that	O
+leads	O
+to	O
+high	O
+mortality	O
+rates	O
+in	O
+suckling	O
+piglets	O
+.	O
+
+Many	O
+diagnostic	O
+tests	O
+have	O
+been	O
+recently	O
+developed	O
+and	O
+are	O
+currently	O
+available	O
+for	O
+the	O
+detection	O
+of	O
+PEDV	B-SPEC
+,	O
+its	O
+proteins	B-CHED
+or	O
+nucleic	B-CHED
+acid	I-CHED
+,	O
+including	O
+virus	B-SPEC
+isolation	O
+,	O
+immunofluorescence	O
+(	O
+IF	O
+)	O
+or	O
+immunohistochemistry	O
+(	O
+IHC	O
+),	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+and	O
+isothermal	O
+amplification	B-DISO
+assays	O
+.	O
+
+The	O
+results	O
+show	O
+that	O
+79	O
+%	O
+of	O
+total	O
+101	O
+flocks	O
+tested	O
+were	O
+infected	O
+with	O
+one	O
+or	O
+more	O
+of	O
+the	O
+above	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+Random	O
+Blood	B-ANAT
+Sugar	O
+(	O
+RBS	B-DISO
+)	O
+level	O
+on	O
+admission	O
+was	O
+recorded	O
+.	O
+
+RBS	B-DISO
+is	O
+a	O
+predicate	O
+factor	O
+for	O
+ISS	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+36	O
+),	O
+GCS	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+69	O
+),	O
+mechanical	O
+ventilation	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+27	O
+),	O
+VAP	O
+&	O
+ARDS	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+68	O
+),	O
+length	O
+of	O
+ICU	O
+stay	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+87	O
+)	O
+and	O
+length	O
+of	O
+hospital	O
+stay	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+,	O
+OR	O
+:	O
+1	O
+.	O
+24	O
+).	O
+
+Management	O
+of	O
+hyperglycaemia	B-DISO
+with	O
+insulin	B-PRGE
+protocol	O
+in	O
+cases	O
+with	O
+value	O
+>	O
+200mg	O
+/	O
+dl	O
+,	O
+is	O
+critical	O
+in	O
+improving	O
+the	O
+outcome	O
+of	O
+patients	O
+with	O
+TBI	O
+.	O
+
+Prevalence	O
+of	O
+CCV	B-DISO
+antibodies	B-COMP
+suggested	O
+a	O
+seasonal	O
+pattern	O
+with	O
+higher	O
+prevalence	O
+during	O
+spring	O
+(	O
+43	O
+%)	O
+than	O
+in	O
+fall	O
+(	O
+11	O
+%).	O
+
+It	O
+has	O
+Krebs	B-PROC
+cycle	I-PROC
+metabolism	B-PROC
+,	O
+rapid	O
+clearance	O
+,	O
+relative	O
+hydrophilicity	O
+,	O
+and	O
+unique	O
+drug	B-PROC
+interactions	I-PROC
+.	O
+
+People	O
+drugged	B-DISO
+before	O
+assault	O
+also	O
+need	O
+to	O
+promptly	O
+notify	O
+authorities	O
+because	O
+the	O
+period	O
+to	O
+detect	O
+the	O
+drug	O
+in	O
+the	O
+urine	B-ANAT
+or	O
+blood	B-ANAT
+is	O
+brief	O
+and	O
+the	O
+ultimate	O
+metabolites	B-CHED
+are	O
+carbon	B-CHED
+dioxide	I-CHED
+and	O
+water	B-CHED
+.	O
+
+We	O
+show	O
+that	O
+specificity	O
+for	O
+polyUb	O
+(	O
+Lys48	O
+)	O
+chains	O
+is	O
+predicated	O
+on	O
+contacts	O
+in	O
+the	O
+S2	O
+site	O
+and	O
+enhanced	O
+by	O
+an	O
+S1	O
+-	O
+S1	O
+'	O
+preference	O
+for	O
+a	O
+Lys48	O
+linkage	B-PROC
+across	O
+the	O
+active	O
+site	O
+.	O
+
+In	O
+contrast	O
+,	O
+ISG15	B-PRGE
+specificity	O
+is	O
+dominated	O
+by	O
+contacts	O
+in	O
+the	O
+S1	O
+site	O
+.	O
+
+Aerosolised	O
+bronchodilators	O
+are	O
+useful	O
+in	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+asthma	B-PATH
+and	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+,	O
+but	O
+are	O
+not	O
+recommended	O
+for	O
+those	O
+with	O
+ARDS	B-DISO
+.	O
+
+All	O
+SCD	B-DISO
+patients	O
+presenting	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+as	O
+a	O
+consequence	O
+of	O
+ACS	B-FUNC
+experienced	O
+PVD	B-DISO
+and	O
+more	O
+than	O
+80	O
+%	O
+of	O
+them	O
+exhibited	O
+ACP	B-DISO
+.	O
+
+TITLE	O
+:	O
+Deciphering	O
+the	O
+biology	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+the	O
+era	B-CHED
+of	O
+reverse	O
+genetics	O
+.	O
+
+ABSTRACT	O
+:	O
+Bat	B-ENZY
+species	B-SPEC
+around	O
+the	O
+world	O
+have	O
+recently	O
+been	O
+recognized	O
+as	O
+major	O
+reservoirs	O
+of	O
+several	O
+zoonotic	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+Nipah	B-SPEC
+virus	I-SPEC
+and	O
+Hendra	B-SPEC
+virus	I-SPEC
+.	O
+
+SV	O
+-	O
+A	O
+was	O
+isolated	O
+in	O
+cell	B-COMP
+culture	O
+from	O
+piglet	O
+samples	O
+.	O
+
+Veterinarians	O
+and	O
+animal	B-SPEC
+caretakers	O
+must	O
+remain	O
+vigilant	O
+for	O
+vesicular	O
+foreign	O
+animal	B-DISO
+diseases	I-DISO
+and	O
+report	O
+suspicious	O
+clinical	O
+signs	O
+and	O
+lesions	O
+to	O
+state	O
+animal	B-SPEC
+health	O
+authorities	O
+for	O
+diagnostic	O
+testing	O
+and	O
+further	O
+investigation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+(	O
+MAPK	B-FUNC
+)	O
+pathways	B-PROC
+,	O
+which	O
+are	O
+central	O
+building	O
+blocks	O
+in	O
+the	O
+intracellular	B-COMP
+signaling	B-PROC
+network	O
+,	O
+are	O
+often	O
+manipulated	O
+by	O
+viruses	B-SPEC
+of	O
+diverse	O
+families	O
+to	O
+favor	O
+their	O
+replication	O
+.	O
+
+Among	O
+the	O
+MAPK	B-PRGE
+family	B-SPEC
+,	O
+the	O
+extracellular	B-ENZY
+signal	I-ENZY
+-	I-ENZY
+regulated	I-ENZY
+kinase	I-ENZY
+(	O
+ERK	B-FUNC
+)	O
+pathway	B-PROC
+is	O
+known	O
+to	O
+be	O
+modulated	O
+during	O
+the	O
+infection	B-DISO
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+);	O
+however	O
+,	O
+involvement	O
+of	O
+stress	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	I-PRGE
+kinases	I-PRGE
+(	O
+SAPKs	O
+)	O
+comprising	O
+p38	B-FUNC
+MAPK	B-FUNC
+and	O
+c	B-PRGE
+-	I-PRGE
+Jun	I-PRGE
+NH2	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+kinase	I-PRGE
+(	O
+JNK	B-FUNC
+)	O
+remains	O
+to	O
+be	O
+determined	O
+.	O
+
+ABSTRACT	O
+:	O
+Equine	B-SPEC
+coronavirus	B-SPEC
+(	O
+EqCoV	O
+)	O
+infection	B-DISO
+has	O
+been	O
+documented	O
+in	O
+most	O
+reports	O
+through	O
+quantitative	O
+qPCR	O
+analysis	O
+of	O
+feces	B-ANAT
+and	O
+viral	B-COMP
+genome	I-COMP
+sequencing	O
+.	O
+
+Although	O
+qPCR	O
+is	O
+used	O
+to	O
+detect	O
+antigen	B-CHED
+during	O
+the	O
+acute	B-DISO
+disease	I-DISO
+phase	O
+,	O
+there	O
+is	O
+no	O
+equine	B-SPEC
+-	O
+specific	O
+antibody	B-COMP
+test	O
+available	O
+to	O
+study	O
+EqCoV	O
+seroprevalence	O
+in	O
+various	O
+horse	B-SPEC
+populations	O
+.	O
+
+TITLE	O
+:	O
+Factors	O
+influencing	O
+emergency	B-DISO
+nurses	O
+'	O
+ethical	O
+problems	O
+during	O
+the	O
+outbreak	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+Whenever	O
+there	O
+has	O
+been	O
+a	O
+worldwide	O
+contagious	O
+disease	O
+outbreak	O
+,	O
+there	O
+have	O
+been	O
+reports	O
+of	O
+infection	B-DISO
+and	O
+death	B-PROC
+of	O
+healthcare	O
+workers	O
+.	O
+
+Through	O
+this	O
+study	O
+,	O
+we	O
+obtained	O
+information	O
+on	O
+emergency	B-DISO
+nurses	O
+'	O
+ethical	O
+problems	O
+during	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+coronavirus	B-SPEC
+outbreak	O
+and	O
+identified	O
+the	O
+factors	O
+that	O
+influence	O
+them	O
+.	O
+
+Unlike	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+,	O
+which	O
+rapidly	O
+disappeared	O
+in	O
+less	O
+than	O
+one	O
+year	O
+,	O
+MERS	O
+has	O
+persisted	O
+for	O
+over	O
+three	O
+years	O
+.	O
+
+A	O
+descriptive	O
+study	O
+was	O
+conducted	O
+among	O
+HCWs	O
+who	O
+worked	O
+with	O
+a	O
+MERS	O
+patient	O
+in	O
+Bamrasnaradura	O
+Infectious	B-DISO
+Diseases	I-DISO
+Institute	O
+,	O
+Thailand	O
+,	O
+between	O
+18	O
+June	O
+and	O
+3	O
+July	O
+2015	O
+.	O
+
+Paired	O
+sera	B-COMP
+were	O
+tested	O
+for	O
+detection	O
+of	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+by	O
+using	O
+an	O
+indirect	O
+ELISA	O
+.	O
+
+Although	O
+several	O
+PEDV	B-SPEC
+studies	O
+have	O
+been	O
+conducted	O
+in	O
+Japan	O
+,	O
+more	O
+PEDV	B-SPEC
+isolates	O
+and	O
+sequence	O
+information	O
+are	O
+needed	O
+to	O
+understand	O
+the	O
+molecular	O
+biology	O
+and	O
+epidemiology	O
+of	O
+PEDV	B-SPEC
+.	O
+
+Our	O
+isolates	O
+and	O
+findings	O
+will	O
+be	O
+useful	O
+for	O
+future	O
+investigations	O
+aimed	O
+at	O
+understanding	O
+,	O
+controlling	O
+,	O
+and	O
+preventing	O
+PED	B-PRGE
+.	O
+
+Therefore	O
+,	O
+our	O
+data	O
+suggest	O
+that	O
+the	O
+OKN	O
+-	O
+1	O
+/	O
+JPN	O
+/	O
+2013	O
+PEDV	O
+isolate	O
+is	O
+virulent	O
+,	O
+whereas	O
+the	O
+TTR	B-PRGE
+-	I-PRGE
+2	I-PRGE
+/	O
+JPN	O
+/	O
+2014	O
+PEDV	B-SPEC
+isolate	O
+is	O
+avirulent	O
+.	O
+
+TITLE	O
+:	O
+Hajj	O
+-	O
+associated	O
+infections	B-DISO
+.	O
+
+Pyoderma	B-DISO
+and	O
+furuncles	B-DISO
+are	O
+also	O
+frequently	O
+observed	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+is	O
+a	O
+serious	O
+infection	B-DISO
+in	O
+neonatal	O
+piglets	O
+.	O
+
+Interactions	O
+between	O
+Mo	B-PRGE
+-	I-PRGE
+DCs	I-PRGE
+and	O
+UV	O
+-	O
+PEDV	B-SPEC
+significantly	O
+stimulate	O
+T	B-PROC
+-	I-PROC
+cell	I-PROC
+proliferation	B-DISO
+in	O
+vitro	O
+.	O
+
+Consistent	O
+with	O
+these	O
+results	O
+,	O
+there	O
+is	O
+an	O
+enhancement	O
+in	O
+the	O
+ability	O
+of	O
+porcine	O
+intestinal	B-ANAT
+DCs	B-DISO
+to	O
+activate	O
+T	B-PROC
+-	I-PROC
+cell	I-PROC
+proliferation	B-DISO
+in	O
+vivo	O
+.	O
+
+The	O
+clinical	O
+course	O
+of	O
+the	O
+disease	O
+ranges	O
+from	O
+asymptomatic	B-DISO
+infection	I-DISO
+to	O
+severe	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illness	O
+with	O
+multiorgan	O
+involvement	O
+and	O
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+Sentinel	O
+surveillance	O
+for	O
+influenza	B-DISO
+among	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+and	O
+acute	O
+febrile	B-PROC
+illness	I-DISO
+inpatients	O
+at	O
+three	O
+hospitals	O
+in	O
+Ghana	O
+.	O
+
+To	O
+compare	O
+influenza	B-DISO
+-	O
+related	O
+epidemiologic	O
+data	O
+,	O
+from	O
+October	O
+2010	O
+through	O
+March	O
+2013	O
+,	O
+we	O
+enrolled	O
+hospitalized	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+(	O
+SARI	O
+;	O
+fever	B-PROC
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+)	O
+and	O
+acute	O
+febrile	B-DISO
+illness	I-DISO
+(	O
+AFI	O
+;	O
+fever	B-PROC
+without	O
+respiratory	O
+or	O
+other	O
+localizing	O
+symptoms	O
+)	O
+patients	O
+from	O
+three	O
+referral	O
+hospitals	O
+in	O
+Ghana	O
+.	O
+
+Interestingly	O
+,	O
+3f	O
+,	O
+3g	O
+and	O
+3m	O
+could	O
+inhibit	O
+both	O
+NA	B-PRGE
+and	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+and	O
+serve	O
+as	O
+a	O
+starting	O
+point	O
+to	O
+develop	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+report	O
+is	O
+to	O
+share	O
+SKKUSOM	O
+'	O
+s	O
+experience	O
+against	O
+the	O
+MERS	O
+outbreak	O
+and	O
+provide	O
+suggestions	O
+for	O
+medical	O
+schools	O
+to	O
+consider	O
+in	O
+the	O
+face	B-DISO
+of	O
+similar	O
+challenges	O
+.	O
+
+Five	O
+suggestions	O
+are	O
+extracted	O
+for	O
+medical	O
+schools	O
+to	O
+consider	O
+in	O
+infection	B-DISO
+outbreaks	O
+:	O
+instant	O
+cessation	O
+of	O
+clinical	O
+clerkships	O
+;	O
+rational	O
+decision	O
+making	O
+on	O
+a	O
+school	O
+closure	O
+;	O
+use	O
+of	O
+information	O
+technology	O
+;	O
+constant	O
+communication	O
+with	O
+hospitals	O
+;	O
+and	O
+open	O
+communication	O
+with	O
+faculty	O
+,	O
+staff	O
+,	O
+and	O
+students	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+virus	O
+(	O
+FIPV	O
+)	O
+is	O
+highly	O
+virulent	O
+and	O
+responsible	O
+for	O
+the	O
+highly	O
+fatal	O
+disease	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+whereas	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+)	O
+is	O
+widespread	O
+among	O
+the	O
+feline	B-SPEC
+population	O
+and	O
+typically	O
+causes	O
+asymptomatic	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+primary	O
+outcome	O
+of	O
+this	O
+prospective	O
+observational	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+feasibility	O
+,	O
+safety	O
+and	O
+contribution	O
+in	O
+diagnosis	O
+and	O
+/	O
+or	O
+modification	O
+of	O
+the	O
+ongoing	O
+treatment	O
+of	O
+fiberoptic	O
+bronchoscopy	O
+(	O
+FOB	O
+)	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+treated	O
+with	O
+NIV	O
+.	O
+
+FOB	O
+under	O
+NIV	O
+could	O
+be	O
+considered	O
+as	O
+a	O
+feasible	O
+tool	O
+for	O
+diagnosis	O
+and	O
+guide	O
+for	O
+treatment	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+treated	O
+via	O
+NIV	O
+in	O
+intensive	O
+care	O
+units	O
+.	O
+
+The	O
+enzyme	O
+appears	O
+not	O
+to	O
+be	O
+optimized	O
+for	O
+catalytic	O
+efficiency	O
+;	O
+thus	O
+,	O
+replacement	O
+of	O
+Phe269	O
+by	O
+Tyr	B-CHED
+leads	O
+to	O
+increased	O
+peptidolytic	O
+and	O
+deubiquitinating	B-PROC
+activities	O
+.	O
+
+Ubiquitin	B-FUNC
+binding	I-FUNC
+by	O
+MERS	O
+-	O
+CoV	O
+PL	O
+(	O
+pro	B-PRGE
+)	O
+involves	O
+remarkable	O
+differences	O
+compared	O
+to	O
+the	O
+corresponding	O
+complex	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PL	I-PRGE
+(	O
+pro	B-PRGE
+).	O
+
+The	O
+structure	O
+and	O
+the	O
+mutational	O
+study	O
+help	O
+understand	O
+common	O
+and	O
+unique	O
+features	O
+of	O
+the	O
+deubiquitinating	B-PROC
+activity	O
+of	O
+MERS	O
+-	O
+CoV	O
+PL	O
+(	O
+pro	B-PRGE
+).	O
+
+The	O
+Predicting	O
+Death	B-PROC
+for	O
+Severe	O
+ARDS	B-DISO
+on	O
+V	O
+-	O
+V	O
+ECMO	O
+(	O
+PRESERVE	O
+)	O
+score	O
+showed	O
+good	O
+discrimination	O
+of	O
+mortality	O
+prediction	O
+for	O
+patients	O
+on	O
+ECMO	O
+with	O
+AUC	O
+of	O
+0	O
+.	O
+80	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+66	O
+-	O
+0	O
+.	O
+90	O
+).	O
+
+TITLE	O
+:	O
+HTCC	O
+:	O
+Broad	O
+Range	O
+Inhibitor	B-CHED
+of	O
+Coronavirus	B-SPEC
+Entry	O
+.	O
+
+Importantly	O
+,	O
+no	O
+drugs	O
+against	O
+human	B-SPEC
+coronaviruses	O
+exist	O
+,	O
+and	O
+only	O
+supportive	O
+therapy	O
+is	O
+available	O
+.	O
+
+TITLE	O
+:	O
+Echocardiographic	O
+parameters	O
+of	O
+right	B-PROC
+ventricular	I-PROC
+function	I-PROC
+predict	O
+mortality	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+pilot	O
+study	O
+.	O
+
+In	O
+multivariate	O
+logistic	O
+regression	O
+models	O
+,	O
+TAPSE	O
+maintained	O
+a	O
+significant	O
+association	O
+with	O
+mortality	O
+independent	O
+of	O
+age	O
+,	O
+pH	O
+,	O
+PaO2	O
+∶	O
+FiO2	O
+ratios	O
+,	O
+positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+,	O
+PCO2	O
+,	O
+serum	B-COMP
+bicarbonate	B-CHED
+,	O
+plateau	O
+pressures	O
+,	O
+driving	O
+pressures	O
+,	O
+APACHE	O
+II	O
+,	O
+SAPS	O
+II	O
+,	O
+and	O
+SOFA	O
+scores	O
+.	O
+
+In	O
+conclusion	O
+,	O
+TAPSE	O
+and	O
+other	O
+TTE	O
+parameters	O
+should	O
+be	O
+used	O
+as	O
+novel	O
+predictive	O
+indicators	O
+for	O
+RV	O
+dysfunction	O
+in	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Positive	O
+-	O
+strand	O
+RNA	O
+(+	O
+RNA	O
+)	O
+viruses	O
+rearrange	O
+cellular	B-COMP
+membranes	B-ANAT
+during	O
+replication	O
+,	O
+possibly	O
+in	O
+order	B-SPEC
+to	O
+concentrate	O
+and	O
+arrange	O
+viral	B-PROC
+replication	I-PROC
+machinery	O
+for	O
+efficient	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+Here	O
+we	O
+compared	O
+structures	O
+induced	O
+by	O
+Beau	O
+-	O
+R	O
+with	O
+the	O
+pathogenic	O
+lab	O
+strain	O
+M41	O
+to	O
+determine	O
+whether	O
+membrane	B-COMP
+rearrangements	O
+are	O
+strain	O
+dependent	O
+.	O
+
+We	O
+then	O
+compared	O
+a	O
+panel	O
+of	O
+pathogenic	O
+,	O
+mild	O
+and	O
+attenuated	O
+IBV	B-SPEC
+strains	O
+in	O
+ex	O
+vivo	O
+tracheal	O
+organ	B-ANAT
+culture	O
+(	O
+TOC	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+a	O
+noncardiogenic	O
+pulmonary	B-DISO
+edema	I-DISO
+with	O
+bilateral	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+opacities	B-DISO
+and	O
+reduction	O
+in	O
+lung	B-PROC
+compliance	I-PROC
+,	O
+and	O
+the	O
+hallmark	O
+of	O
+the	O
+syndrome	B-DISO
+is	O
+hypoxemia	O
+refractory	O
+to	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+We	O
+performed	O
+an	O
+up	O
+-	O
+to	O
+-	O
+date	O
+clinical	O
+review	O
+of	O
+the	O
+possible	O
+available	O
+strategies	O
+for	O
+ARDS	B-DISO
+patients	O
+with	O
+severe	O
+hypoxemia	O
+.	O
+
+Severe	O
+ARDS	B-DISO
+patients	O
+should	O
+receive	O
+a	O
+holistic	O
+framework	O
+of	O
+respiratory	O
+and	O
+hemodynamic	B-PROC
+support	O
+aimed	O
+to	O
+ensure	O
+adequate	O
+gas	B-ENZY
+exchange	O
+while	O
+minimizing	O
+the	O
+risk	O
+of	O
+VILI	O
+,	O
+by	O
+promoting	O
+lung	B-ANAT
+recruitment	B-DISO
+and	O
+setting	O
+protective	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+The	O
+proteome	O
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+Beau	O
+-	O
+R	O
+virion	B-COMP
+.	O
+
+Some	O
+of	O
+these	O
+proteins	B-CHED
+were	O
+unique	O
+to	O
+this	O
+study	O
+,	O
+while	O
+others	O
+were	O
+found	O
+to	O
+be	O
+orthologous	O
+to	O
+proteins	O
+identified	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+virions	B-COMP
+and	O
+also	O
+virions	B-COMP
+from	O
+a	O
+number	O
+of	O
+other	O
+RNA	O
+and	O
+DNA	O
+viruses	B-SPEC
+.	O
+
+Our	O
+findings	O
+show	O
+a	O
+higher	O
+level	O
+of	O
+spatial	O
+heterogeneity	O
+in	O
+zoonotic	O
+transmission	O
+compared	O
+to	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+,	O
+highlighting	O
+the	O
+strong	O
+environmental	O
+component	O
+of	O
+the	O
+epidemic	O
+.	O
+
+Lung	B-ANAT
+mononuclear	O
+infiltrates	B-DISO
+occurred	O
+in	O
+all	O
+groups	O
+after	O
+virus	B-SPEC
+challenge	O
+but	O
+with	O
+increased	O
+infiltrates	B-DISO
+that	O
+contained	O
+eosinophils	B-ANAT
+and	O
+increases	O
+in	O
+the	O
+eosinophil	B-ANAT
+promoting	O
+IL	B-FUNC
+-	I-FUNC
+5	I-FUNC
+and	O
+IL	B-PRGE
+-	I-PRGE
+13	I-PRGE
+cytokines	I-PRGE
+only	O
+in	O
+the	O
+vaccine	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+:	O
+Overview	O
+of	O
+infection	B-DISO
+dynamics	O
+,	O
+diagnostic	O
+methods	O
+,	O
+prevalence	O
+and	O
+genetic	O
+evolution	O
+.	O
+
+This	O
+study	O
+was	O
+performed	O
+at	O
+Mayo	B-SPEC
+Clinic	O
+,	O
+Rochester	O
+,	O
+MN	O
+,	O
+in	O
+years	O
+2007	O
+-	O
+2009	O
+.	O
+
+This	O
+study	O
+included	O
+a	O
+total	O
+of	O
+181	O
+consecutive	O
+adult	O
+patients	O
+admitted	O
+to	O
+the	O
+medical	O
+intensive	O
+care	O
+unit	O
+meeting	O
+criteria	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+within	O
+24	O
+h	O
+of	O
+admission	O
+and	O
+transported	O
+from	O
+an	O
+acute	O
+care	O
+facility	O
+by	O
+a	O
+helicopter	O
+or	O
+ground	O
+ambulance	O
+.	O
+
+The	O
+primary	O
+predictive	O
+variable	O
+was	O
+the	O
+mode	O
+of	O
+transport	B-PROC
+.	O
+
+TITLE	O
+:	O
+Low	O
+Blood	B-ANAT
+Arterial	I-ANAT
+Oxygenation	B-PROC
+During	O
+Venovenous	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+:	O
+Proposal	O
+for	O
+a	O
+Rational	O
+Algorithm	O
+-	O
+Based	O
+Management	O
+.	O
+
+Observational	O
+trial	O
+over	O
+a	O
+3	O
+-	O
+year	O
+period	O
+on	O
+outcome	O
+in	O
+trauma	O
+patients	O
+(	O
+Injury	O
+Severity	O
+Score	O
+,	O
+ISS	B-DISO
+≥	O
+16	O
+)	O
+with	O
+severe	O
+thoracic	B-DISO
+injury	O
+(	O
+Abbreviated	O
+Injury	O
+Scale	O
+,	O
+AIS	B-DISO
+Over	O
+the	O
+3	O
+-	O
+year	O
+period	O
+76	O
+patients	O
+with	O
+ISS	B-DISO
+≥	O
+16	O
+/	O
+AIS	B-DISO
+CLRT	O
+remains	O
+a	O
+therapeutic	O
+option	O
+to	O
+reduce	O
+pulmonary	B-DISO
+complications	I-DISO
+after	O
+severe	O
+chest	B-ANAT
+trauma	O
+in	O
+our	O
+center	O
+.	O
+
+To	O
+address	O
+this	O
+,	O
+C57BL	O
+/	O
+6	O
+(	O
+wild	O
+-	O
+type	O
+;	O
+WT	O
+)	O
+and	O
+TLR2	B-PRGE
+knockout	O
+(	O
+KO	O
+)	O
+groups	O
+of	O
+mice	B-SPEC
+were	O
+intraperitoneally	O
+infected	O
+with	O
+MHV3	O
+or	O
+MHV	B-SPEC
+-	O
+A59	O
+.	O
+
+MHV3	O
+infection	B-DISO
+provoked	O
+a	O
+fulminant	B-DISO
+hepatitis	I-DISO
+in	O
+WT	O
+mice	B-SPEC
+,	O
+characterized	O
+by	O
+early	O
+mortality	O
+and	O
+high	O
+alanine	B-CHED
+and	O
+aspartate	B-PRGE
+transaminase	I-PRGE
+levels	O
+,	O
+histopathological	O
+lesions	O
+and	O
+viral	B-PROC
+replication	I-PROC
+whereas	O
+infection	B-DISO
+of	O
+TLR2	B-PRGE
+KO	I-PRGE
+mice	B-SPEC
+was	O
+markedly	O
+less	O
+severe	O
+.	O
+
+We	O
+present	O
+the	O
+clinical	O
+course	O
+and	O
+the	O
+emergency	B-DISO
+C	O
+-	O
+sec	B-CHED
+in	O
+a	O
+pregnant	O
+woman	O
+with	O
+MERS	O
+.	O
+
+TITLE	O
+:	O
+First	O
+genome	O
+sequences	O
+of	O
+buffalo	O
+coronavirus	B-SPEC
+from	O
+water	B-CHED
+buffaloes	O
+in	O
+Bangladesh	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+complete	O
+genome	O
+sequences	O
+of	O
+a	O
+buffalo	O
+coronavirus	O
+(	O
+BufCoV	O
+HKU26	O
+)	O
+detected	O
+from	O
+the	O
+faecal	B-ANAT
+samples	O
+of	O
+two	O
+domestic	O
+water	B-CHED
+buffaloes	O
+(	O
+Bubalus	B-SPEC
+bubalis	I-SPEC
+)	O
+in	O
+Bangladesh	O
+.	O
+
+Whether	O
+noninvasive	O
+positive	O
+pressure	O
+ventilation	O
+(	O
+NIPPV	O
+)	O
+should	O
+be	O
+attempted	O
+in	O
+patients	O
+with	O
+H1N1	O
+pneumonia	B-DISO
+is	O
+still	O
+a	O
+matter	O
+of	O
+debate	O
+.	O
+
+Since	O
+PDCoV	O
+was	O
+just	O
+recently	O
+linked	O
+with	O
+clinical	O
+disease	O
+,	O
+few	O
+specific	O
+antibody	B-COMP
+-	O
+based	O
+reagents	B-CHED
+were	O
+available	O
+to	O
+assist	O
+in	O
+diagnosis	O
+of	O
+PDCoV	O
+and	O
+limited	O
+serological	O
+capabilities	O
+were	O
+available	O
+to	O
+detect	O
+an	O
+antibody	B-PROC
+response	I-PROC
+to	O
+this	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Fecal	B-ANAT
+calprotectin	O
+and	O
+immunoglobulin	B-PRGE
+A	I-PRGE
+(	O
+IgA	B-PRGE
+)	O
+are	O
+markers	O
+of	O
+intestinal	B-ANAT
+inflammation	B-DISO
+and	O
+immunity	B-PROC
+in	O
+adult	O
+dogs	B-SPEC
+.	O
+
+Fecal	B-ANAT
+calprotectin	O
+and	O
+IgA	B-PRGE
+are	O
+of	O
+no	O
+diagnostic	O
+value	O
+to	O
+detect	O
+presence	O
+of	O
+enteropathogens	O
+in	O
+clinically	O
+healthy	O
+puppies	O
+or	O
+puppies	O
+with	O
+abnormal	O
+feces	B-ANAT
+,	O
+but	O
+could	O
+help	O
+to	O
+better	O
+understand	O
+the	O
+maturation	B-PROC
+of	O
+digestive	B-ANAT
+tract	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Homology	O
+-	O
+Based	O
+Identification	O
+of	O
+a	O
+Mutation	O
+in	O
+the	O
+Coronavirus	B-SPEC
+RNA	O
+-	O
+Dependent	O
+RNA	B-PATH
+Polymerase	I-PATH
+
+We	O
+modeled	O
+the	O
+CoV	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+nsp12	O
+-	O
+RdRp	B-FUNC
+structure	O
+and	O
+superimposed	O
+it	O
+on	O
+solved	O
+picornaviral	O
+RdRp	B-FUNC
+structures	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+nsp12	O
+-	O
+RdRp	B-FUNC
+likely	O
+functions	O
+in	O
+fidelity	O
+regulation	B-PROC
+and	O
+that	O
+,	O
+despite	O
+low	O
+sequence	O
+conservation	O
+,	O
+some	O
+determinants	O
+of	O
+RdRp	B-FUNC
+nucleotide	B-CHED
+selectivity	O
+are	O
+conserved	O
+across	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+The	O
+conserved	O
+epitope	B-CHED
+was	O
+also	O
+recognized	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+and	O
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+DR2	I-PRGE
+and	O
+DR3	O
+transgenic	B-SPEC
+mice	I-SPEC
+,	O
+indicating	O
+potential	O
+relevance	O
+in	O
+human	B-SPEC
+populations	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+can	O
+cause	O
+serious	O
+disease	O
+and	O
+even	O
+death	B-PROC
+in	O
+neonatal	O
+piglets	O
+,	O
+resulting	O
+in	O
+serious	O
+damage	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+worldwide	O
+.	O
+
+Site	O
+One	O
+was	O
+PEDV	B-SPEC
+positive	O
+;	O
+Site	O
+Two	O
+was	O
+PEDV	B-SPEC
+negative	O
+.	O
+
+On	O
+Site	O
+One	O
+,	O
+pen	O
+samples	O
+(	O
+feces	B-ANAT
+and	O
+oral	B-ANAT
+fluids	B-ANAT
+)	O
+and	O
+pig	B-SPEC
+samples	O
+(	O
+rectal	O
+swabs	O
+and	O
+sera	B-COMP
+)	O
+were	O
+collected	O
+both	O
+before	O
+and	O
+after	O
+the	O
+population	O
+was	O
+exposed	O
+to	O
+PEDV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+anti	O
+-	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+neutralizing	O
+activity	O
+in	O
+mammary	B-ANAT
+secretions	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+a	O
+severe	O
+clinical	O
+enteric	O
+disease	O
+in	O
+suckling	O
+neonates	O
+with	O
+up	O
+to	O
+100	O
+%	O
+mortality	O
+,	O
+resulting	O
+in	O
+devastating	O
+economic	O
+losses	O
+to	O
+the	O
+pork	O
+industry	O
+in	O
+recent	O
+years	O
+.	O
+
+Alternatively	O
+,	O
+infiltration	B-DISO
+of	O
+activated	O
+cells	B-COMP
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+may	O
+be	O
+detrimental	O
+,	O
+as	O
+these	O
+cells	B-COMP
+can	O
+contribute	O
+to	O
+neuropathology	B-DISO
+that	O
+may	O
+result	O
+in	O
+long	O
+-	O
+term	O
+cellular	B-COMP
+damage	O
+or	O
+death	B-PROC
+.	O
+
+This	O
+review	O
+highlights	O
+recent	O
+studies	O
+using	O
+coronavirus	O
+-	O
+induced	O
+neurologic	O
+disease	O
+as	O
+a	O
+model	O
+to	O
+determine	O
+how	O
+neutrophils	B-ANAT
+affect	O
+effective	O
+control	O
+of	O
+viral	B-PROC
+replication	I-PROC
+as	O
+well	O
+as	O
+demyelination	B-DISO
+.	O
+
+TITLE	O
+:	O
+Phylogenetic	O
+and	O
+antigenic	O
+characterization	O
+of	O
+newly	O
+isolated	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+viruses	B-SPEC
+in	O
+Japan	O
+.	O
+
+TITLE	O
+:	O
+Salmonella	B-SPEC
+Typhi	O
+-	O
+Induced	O
+Septic	B-DISO
+Shock	I-DISO
+and	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+a	O
+Previously	O
+Healthy	O
+Teenage	O
+Patient	O
+Treated	O
+With	O
+High	O
+-	O
+Dose	O
+Dexamethasone	O
+.	O
+
+Sensitivity	O
+was	O
+evaluated	O
+by	O
+serial	O
+dilution	O
+of	O
+HCoV	B-PRGE
+-	I-PRGE
+NL63	I-PRGE
+RNA	I-PRGE
+from	O
+1	O
+.	O
+6	O
+x	O
+10	O
+(	O
+9	O
+)	O
+to	O
+1	O
+.	O
+6	O
+x	O
+10	O
+(	O
+1	O
+)	O
+per	O
+reaction	O
+.	O
+
+A	O
+live	O
+animal	B-SPEC
+experiment	O
+was	O
+conducted	O
+,	O
+with	O
+direct	O
+contact	O
+between	O
+animal	B-SPEC
+groups	O
+for	O
+24	O
+h	O
+as	O
+challenge	O
+procedure	O
+.	O
+
+Nasal	B-ANAT
+shedding	O
+preceded	O
+fecal	B-ANAT
+shedding	O
+,	O
+and	O
+the	O
+calves	O
+had	O
+detectable	O
+amounts	O
+of	O
+viral	O
+RNA	O
+intermittently	O
+in	O
+feces	B-ANAT
+through	O
+day	O
+35	O
+and	O
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+through	O
+day	O
+28	O
+,	O
+however	O
+virus	B-SPEC
+isolation	O
+was	O
+unsuccessful	O
+from	O
+day	O
+six	O
+and	O
+day	O
+18	O
+from	O
+the	O
+two	O
+calves	O
+investigated	O
+.	O
+
+Although	O
+the	O
+calves	O
+were	O
+shedding	O
+BCoV	O
+RNA	O
+21	O
+days	O
+after	O
+infection	B-DISO
+the	O
+sentinel	O
+animals	B-SPEC
+were	O
+not	O
+infected	O
+.	O
+
+Although	O
+the	O
+calves	O
+were	O
+shedding	O
+BCoV	O
+RNA	O
+21	O
+days	O
+after	O
+infection	B-DISO
+the	O
+sentinel	O
+animals	B-SPEC
+were	O
+not	O
+infected	O
+.	O
+
+Over	O
+85	O
+natural	O
+dibenzylbutyrolactone	O
+lignans	B-CHED
+known	O
+to	O
+date	O
+and	O
+their	O
+corresponding	O
+plant	B-SPEC
+sources	O
+are	O
+summarized	O
+herein	O
+for	O
+the	O
+first	O
+time	O
+,	O
+highlighting	O
+a	O
+taxon	O
+-	O
+and	O
+organ	B-ANAT
+-	O
+specific	O
+accumulation	O
+of	O
+these	O
+compounds	O
+.	O
+
+In	O
+the	O
+present	O
+article	O
+we	O
+have	O
+reviewed	O
+the	O
+literature	O
+on	O
+the	O
+several	O
+facets	B-ANAT
+like	O
+transmission	O
+,	O
+precautions	O
+and	O
+effectiveness	O
+of	O
+treatments	O
+used	O
+in	O
+patients	O
+with	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-DISO
+infections	B-DISO
+.	O
+
+Our	O
+observation	O
+suggests	O
+that	O
+AEC2	O
+attenuates	O
+LPS	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+via	O
+the	O
+Ang	O
+-(	O
+1	O
+-	O
+7	O
+)/	O
+Mas	B-COMP
+pathway	B-PROC
+by	O
+inhibiting	O
+ERK	B-FUNC
+/	O
+NF	O
+-	O
+κB	O
+activation	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+Al	O
+-	O
+Madinah	O
+City	O
+,	O
+Saudi	O
+Arabia	O
+:	O
+Demographic	O
+,	O
+clinical	O
+and	O
+survival	O
+data	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+is	O
+an	O
+emerging	O
+virus	B-SPEC
+respiratory	B-DISO
+infection	I-DISO
+.	O
+
+Associated	O
+comorbidities	O
+were	O
+diabetes	B-DISO
+mellitus	I-DISO
+in	O
+nine	O
+(	O
+31	O
+%)	O
+patients	O
+and	O
+chronic	B-DISO
+kidney	I-DISO
+disease	I-DISO
+(	O
+CKD	O
+)	O
+in	O
+eight	O
+(	O
+27	O
+%)	O
+patients	O
+.	O
+
+The	O
+frequency	O
+of	O
+cases	O
+and	O
+deaths	B-PROC
+is	O
+higher	O
+among	O
+men	O
+than	O
+women	O
+and	O
+among	O
+patients	O
+with	O
+comorbidities	O
+.	O
+
+Strategies	O
+to	O
+identify	O
+antiviral	B-CHED
+compounds	O
+as	O
+inhibitors	B-CHED
+of	O
+ncRNA	B-DISO
+are	O
+increasingly	O
+emphasizing	O
+consideration	O
+of	O
+drug	O
+-	O
+like	O
+properties	O
+of	O
+candidate	O
+molecules	O
+emerging	O
+from	O
+screening	O
+and	O
+ligand	B-PROC
+design	O
+.	O
+
+Therefore	O
+,	O
+many	O
+different	O
+antigenic	O
+forms	O
+,	O
+serotypes	O
+,	O
+or	O
+variant	O
+strains	O
+of	O
+avian	B-PRGE
+coronaviruses	I-PRGE
+(	O
+AvCoV	O
+)	O
+exist	O
+worldwide	O
+.	O
+
+The	O
+result	O
+of	O
+this	O
+variability	O
+is	O
+an	O
+inconsistent	O
+nomenclature	O
+and	O
+classification	O
+of	O
+virus	B-SPEC
+strains	O
+.	O
+
+At	O
+necropsy	O
+,	O
+the	O
+small	B-ANAT
+intestines	I-ANAT
+were	O
+pale	B-DISO
+and	O
+distended	O
+with	O
+watery	O
+contents	O
+.	O
+
+Using	O
+immunohistochemistry	O
+(	O
+IHC	O
+),	O
+IBV	B-PRGE
+antigen	B-CHED
+was	O
+detected	O
+in	O
+the	O
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+as	O
+well	O
+as	O
+in	O
+the	O
+proventriculus	B-ANAT
+and	O
+pancreas	B-ANAT
+.	O
+
+In	O
+contrast	O
+to	O
+the	O
+field	O
+infection	B-DISO
+,	O
+birds	B-SPEC
+in	O
+the	O
+experimental	O
+group	O
+showed	O
+clear	O
+respiratory	O
+signs	O
+and	O
+lesions	O
+in	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+The	O
+frequency	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+this	O
+group	O
+of	O
+patients	O
+suggests	O
+an	O
+etiologic	O
+role	O
+in	O
+febrile	B-DISO
+neutropenia	I-DISO
+.	O
+
+RESULTS	O
+:	O
+At	O
+least	O
+one	O
+respiratory	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+samples	O
+from	O
+39	O
+of	O
+87	O
+episodes	O
+of	O
+febrile	B-DISO
+neutropenia	I-DISO
+(	O
+45	O
+%),	O
+with	O
+rhinoviruses	B-SPEC
+the	O
+most	O
+frequently	O
+detected	O
+.	O
+
+For	O
+the	O
+current	O
+study	O
+,	O
+we	O
+utilized	O
+hNPCs	O
+differentiated	O
+from	O
+a	O
+human	B-SPEC
+induced	O
+pluripotent	O
+cell	B-ANAT
+line	I-ANAT
+via	O
+an	O
+embryoid	B-ANAT
+body	I-ANAT
+intermediate	O
+stage	O
+(	O
+EB	O
+-	O
+NPCs	O
+).	O
+
+Dampened	O
+neuroinflammation	O
+and	O
+remyelination	B-PROC
+was	O
+correlated	O
+with	O
+a	O
+transient	B-PRGE
+increase	I-PRGE
+in	I-PRGE
+CD4	I-PRGE
++	I-PRGE
+FOXP3	I-PRGE
++	I-PRGE
+regulatory	I-PRGE
+T	I-PRGE
+cells	I-PRGE
+(	O
+Tregs	O
+)	O
+concentrated	O
+within	O
+the	O
+peripheral	O
+lymphatics	B-ANAT
+.	O
+
+APE	B-SPEC
+symptoms	O
+which	O
+caused	O
+an	O
+arousal	O
+from	O
+sleep	B-PROC
+or	O
+occurred	O
+within	O
+the	O
+first	O
+hour	O
+after	O
+wake	B-PROC
+-	O
+up	O
+were	O
+considered	O
+to	O
+be	O
+sleep	B-PROC
+-	O
+related	O
+.	O
+
+OSA	B-DISO
+might	O
+trigger	O
+APE	B-SPEC
+,	O
+possibly	O
+reflecting	O
+a	O
+pathophysiological	O
+relationship	O
+between	O
+these	O
+two	O
+conditions	O
+.	O
+
+Currently	O
+,	O
+there	O
+are	O
+no	O
+effective	O
+treatments	O
+for	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+and	O
+ironically	O
+,	O
+therapies	O
+intended	O
+to	O
+aid	O
+patients	O
+(	O
+specifically	O
+mechanical	O
+ventilation	O
+,	O
+MV	O
+)	O
+may	O
+aggravate	O
+the	O
+symptoms	O
+.	O
+
+Numerous	O
+studies	O
+have	O
+demonstrated	O
+the	O
+importance	O
+of	O
+Nrf2	B-PRGE
+activation	O
+in	O
+the	O
+protection	O
+against	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+as	O
+pharmacological	O
+activation	O
+of	O
+Nrf2	B-PRGE
+prevents	O
+the	O
+occurrence	O
+or	O
+mitigates	O
+the	O
+severity	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+The	O
+ethanolic	O
+flower	O
+extract	O
+was	O
+the	O
+most	O
+potent	O
+inhibitor	B-CHED
+of	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+RT	I-PRGE
+DNA	I-PRGE
+polymerase	I-PRGE
+RNA	O
+-	O
+dependent	O
+and	O
+Ribonuclease	B-PRGE
+H	I-PRGE
+with	O
+IC50	O
+values	O
+of	O
+0	O
+.	O
+26	O
+and	O
+0	O
+.	O
+33	O
+μg	O
+/	O
+mL	O
+,	O
+respectively	O
+.	O
+
+Using	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+,	O
+we	O
+tested	O
+respiratory	B-ANAT
+tract	I-ANAT
+samples	O
+for	O
+MERS	O
+-	O
+CoV	O
+and	O
+identified	O
+65	O
+case	O
+-	O
+patients	O
+.	O
+
+The	O
+S	B-PRGE
+protein	I-PRGE
+has	O
+a	O
+multidomain	O
+architecture	O
+and	O
+has	O
+been	O
+reported	O
+to	O
+bind	B-FUNC
+to	O
+carbohydrate	B-CHED
+(	O
+sialic	B-CHED
+acid	I-CHED
+)	O
+and	O
+proteinaceous	O
+(	O
+aminopeptidase	B-PRGE
+N	I-PRGE
+)	O
+cell	B-COMP
+surface	I-COMP
+molecules	O
+.	O
+
+While	O
+,	O
+at	O
+first	O
+,	O
+it	O
+appeared	O
+as	O
+a	O
+disease	O
+affecting	O
+feeder	O
+pigs	B-SPEC
+,	O
+fattening	O
+-	O
+and	O
+adult	O
+swine	B-SPEC
+,	O
+it	O
+later	O
+also	O
+became	O
+pathogenic	O
+for	O
+neonatal	O
+and	O
+suckling	O
+pigs	B-SPEC
+hereby	O
+drastically	O
+increasing	O
+its	O
+economic	O
+impact	O
+.	O
+
+Pathogenesis	B-DISO
+studies	O
+with	O
+the	O
+prototype	O
+strain	O
+CV777	O
+showed	O
+severe	O
+villous	O
+atrophy	B-DISO
+in	O
+neonatal	O
+pigs	B-SPEC
+and	O
+the	O
+virus	B-SPEC
+-	O
+animal	B-SPEC
+interactions	O
+showed	O
+many	O
+similarities	O
+with	O
+transmissible	O
+gastro	B-ANAT
+-	O
+enteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+another	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+the	O
+pulmonary	B-ANAT
+dead	B-PROC
+-	O
+space	O
+fraction	O
+derived	O
+from	O
+ventilator	O
+volumetric	O
+capnography	O
+and	O
+a	O
+validated	O
+equation	O
+in	O
+the	O
+survival	O
+prediction	O
+of	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+Regional	O
+changes	O
+in	O
+lung	B-ANAT
+aeration	O
+can	O
+be	O
+assessed	O
+by	O
+lung	B-ANAT
+ultrasound	O
+(	O
+LUS	O
+).	O
+
+High	O
+seroprevalences	O
+of	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+and	O
+the	O
+high	O
+virus	B-SPEC
+prevalence	O
+in	O
+Saudi	O
+Arabian	O
+dromedary	B-SPEC
+camels	B-SPEC
+indicate	O
+an	O
+endemicity	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+which	O
+predates	O
+the	O
+2012	O
+human	B-SPEC
+MERS	O
+index	O
+case	O
+.	O
+
+Target	O
+attainment	O
+(	O
+area	O
+under	O
+the	O
+concentration	O
+-	O
+time	O
+curve	O
+over	O
+12	O
+h	O
+[	O
+AUC12	O
+]/	O
+MIC	B-CHED
+ratio	O
+of	O
+>	O
+50	O
+;	O
+MIC	B-CHED
+=	O
+2	O
+mg	O
+/	O
+liter	O
+)	O
+was	O
+calculated	O
+for	O
+both	O
+the	O
+study	O
+patients	O
+and	O
+a	O
+simulated	O
+independent	O
+patient	O
+group	O
+(	O
+n	O
+=	O
+67	O
+,	O
+000	O
+).	O
+
+Analysis	O
+of	O
+state	O
+responses	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+using	O
+international	O
+relations	O
+theories	O
+must	O
+consider	O
+domestic	O
+political	O
+factors	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Analysis	O
+of	O
+state	O
+responses	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+using	O
+international	O
+relations	O
+theories	O
+must	O
+consider	O
+domestic	O
+political	O
+factors	O
+.	O
+
+The	O
+challenge	O
+is	O
+how	O
+to	O
+take	O
+this	O
+academic	O
+virology	O
+knowledge	O
+into	O
+a	O
+drug	O
+discovery	O
+and	O
+development	B-PROC
+domain	O
+.	O
+
+TITLE	O
+:	O
+Dialysis	B-SPEC
+disequilibrium	I-DISO
+syndrome	I-DISO
+:	O
+A	O
+preventable	O
+fatal	O
+acute	O
+complication	B-DISO
+.	O
+
+We	O
+described	O
+a	O
+case	O
+of	O
+DDS	B-DISO
+resulting	O
+in	O
+irreversible	O
+brain	B-ANAT
+injury	O
+and	O
+death	B-PROC
+following	O
+acute	O
+haemodialysis	O
+.	O
+
+A	O
+13	O
+-	O
+year	O
+-	O
+old	O
+male	O
+with	O
+no	O
+past	O
+medical	O
+history	O
+and	O
+weighing	O
+30kg	O
+,	O
+presented	O
+to	O
+hospital	O
+with	O
+severe	O
+urosepsis	B-DISO
+complicated	O
+by	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+Creatinine	B-CHED
+1422mmol	O
+/	O
+L	O
+;	O
+Urea	B-CHED
+74	O
+.	O
+2mmol	O
+/	O
+L	O
+,	O
+Potassium	B-CHED
+6	O
+.	O
+3mmol	O
+/	O
+L	O
+,	O
+Sodium	O
+137mmol	O
+/	O
+L	O
+)	O
+and	O
+severe	O
+metabolic	B-DISO
+acidosis	I-DISO
+(	O
+pH	O
+6	O
+.	O
+99	O
+,	O
+HC03	O
+1	O
+.	O
+7mmol	O
+/	O
+L	O
+).	O
+
+CT	O
+Brain	B-ANAT
+showed	O
+generalised	O
+cerebral	B-DISO
+oedema	I-DISO
+consistent	O
+with	O
+global	O
+hypoxic	O
+changes	O
+involving	O
+the	O
+brainstem	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Maternal	O
+-	O
+fetal	B-ANAT
+prognosis	O
+in	O
+HELLP	B-DISO
+syndrome	I-DISO
+in	O
+a	O
+level	O
+3	O
+maternal	O
+-	O
+fetal	B-ANAT
+care	O
+centre	O
+.	O
+
+The	O
+leading	O
+maternal	O
+complications	O
+associated	O
+with	O
+HELLP	B-DISO
+syndrome	I-DISO
+were	O
+the	O
+following	O
+:	O
+severe	B-DISO
+preeclampsia	I-DISO
+,	O
+eclampsia	B-DISO
+,	O
+placental	B-DISO
+abruption	I-DISO
+,	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+,	O
+acute	B-DISO
+kidney	I-DISO
+failure	I-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+syndrome	B-DISO
+,	O
+and	O
+immediate	O
+maternal	B-PROC
+death	I-PROC
+.	O
+
+The	O
+management	O
+and	O
+delivery	O
+of	O
+the	O
+patients	O
+with	O
+HELLP	O
+syndrome	O
+must	O
+take	O
+place	O
+in	O
+a	O
+tertiary	O
+referral	O
+maternal	O
+and	O
+fetal	B-ANAT
+care	O
+centre	O
+.	O
+
+After	O
+an	O
+incubation	O
+period	O
+of	O
+2	O
+-	O
+7	O
+days	O
+,	O
+symptomatic	O
+patients	O
+develop	O
+rapid	O
+onset	O
+fever	O
+,	O
+maculopapular	O
+rash	B-DISO
+,	O
+arthralgia	B-DISO
+,	O
+and	O
+conjunctivitis	B-DISO
+,	O
+often	O
+associated	O
+with	O
+headache	B-DISO
+and	O
+myalgias	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+efficacy	O
+and	O
+therapeutic	O
+mechanisms	O
+of	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+CRRT	O
+)	O
+for	O
+improvement	O
+of	O
+oxygenation	B-PROC
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+remain	O
+controversial	O
+.	O
+
+Improvement	O
+in	O
+oxygenation	B-PROC
+is	O
+likely	O
+related	O
+to	O
+both	O
+restoration	O
+of	O
+fluid	B-PROC
+balance	I-PROC
+and	O
+clearance	O
+of	O
+inflammatory	O
+mediators	O
+.	O
+
+Epidemiological	O
+and	O
+other	O
+data	O
+suggest	O
+that	O
+the	O
+source	O
+of	O
+most	O
+primary	O
+cases	O
+is	O
+exposure	O
+to	O
+camels	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Data	O
+on	O
+prolonged	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+usage	O
+in	O
+influenza	B-DISO
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+are	O
+lacking	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+on	O
+inanimate	O
+surfaces	O
+:	O
+A	O
+risk	O
+for	O
+health	O
+care	O
+transmission	O
+.	O
+
+Sonography	O
+,	O
+however	O
+,	O
+revealed	O
+a	O
+retrochorial	O
+hematoma	B-DISO
+;	O
+the	O
+patient	O
+was	O
+diagnosed	O
+with	O
+abortus	B-ANAT
+imminens	O
+and	O
+successfully	O
+treated	O
+with	O
+magnesium	B-CHED
+substitution	O
+and	O
+bed	B-DISO
+rest	B-FUNC
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+diarrhea	B-DISO
+,	O
+vomiting	B-DISO
+,	O
+and	O
+high	O
+mortality	O
+in	O
+suckling	O
+pigs	B-SPEC
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+thermal	O
+and	O
+electron	O
+beam	O
+processing	O
+,	O
+and	O
+the	O
+inclusion	O
+of	O
+feed	O
+additives	O
+on	O
+the	O
+inactivation	B-DISO
+of	O
+PEDV	B-SPEC
+in	O
+feed	O
+.	O
+
+Three	O
+hundred	O
+five	O
+enteric	O
+contents	O
+of	O
+29	O
+bat	B-ENZY
+species	B-SPEC
+were	O
+tested	O
+using	O
+a	O
+panCoV	O
+nested	O
+RT	O
+-	O
+PCR	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+obesity	B-DISO
+-	O
+associated	O
+hyperleptinemia	O
+,	O
+and	O
+not	O
+body	B-ANAT
+mass	O
+per	O
+se	O
+,	O
+drives	O
+attenuation	O
+of	O
+the	O
+pulmonary	B-ANAT
+inflammatory	B-DISO
+response	I-DISO
+and	O
+that	O
+this	O
+e_ect	O
+could	O
+also	O
+impair	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Acute	B-DISO
+Infection	I-DISO
+Due	O
+to	O
+Serratia	B-SPEC
+marcescens	I-SPEC
+Causing	O
+Respiratory	B-DISO
+Distress	I-DISO
+in	O
+An	O
+Immunocompetent	O
+Adult	O
+.	O
+
+It	O
+often	O
+causes	O
+nosocomial	O
+device	O
+-	O
+associated	O
+outbreaks	O
+and	O
+rarely	O
+serious	O
+invasive	O
+community	B-DISO
+acquired	I-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+comorbidities	O
+in	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+):	O
+a	O
+systematic	O
+review	O
+and	O
+meta	O
+-	O
+analysis	O
+.	O
+
+Leukopenia	B-DISO
+and	O
+subsequent	O
+bacterial	B-DISO
+infection	I-DISO
+occurred	O
+,	O
+but	O
+the	O
+patient	O
+recovered	O
+completely	O
+and	O
+was	O
+discharged	O
+from	O
+the	O
+hospital	O
+after	O
+54days	O
+.	O
+
+Nasal	B-ANAT
+swabs	O
+from	O
+1113	O
+dromedary	B-SPEC
+camels	B-SPEC
+(	O
+39	O
+farms	O
+)	O
+and	O
+34	O
+sheep	B-SPEC
+(	O
+1	O
+farm	O
+)	O
+and	O
+sputum	B-ANAT
+samples	O
+from	O
+2	O
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+camel	B-SPEC
+farm	O
+owners	O
+and	O
+1	O
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+sheep	B-SPEC
+farm	O
+owner	O
+were	O
+collected	O
+.	O
+
+Samples	O
+from	O
+camels	B-SPEC
+and	O
+humans	B-SPEC
+underwent	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+quantitative	O
+PCR	O
+screening	O
+to	O
+detect	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+addition	O
+,	O
+sequencing	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+partially	O
+characterized	O
+MERS	O
+-	O
+CoV	O
+genome	O
+fragments	O
+obtained	O
+from	O
+camels	B-SPEC
+were	O
+performed	O
+.	O
+
+The	O
+maximum	O
+duration	O
+of	O
+viral	B-DISO
+shedding	I-DISO
+from	O
+infected	O
+camels	B-SPEC
+was	O
+2	O
+weeks	O
+after	O
+the	O
+first	O
+positive	O
+test	O
+result	O
+as	O
+detected	O
+in	O
+nasal	B-ANAT
+swabs	O
+and	O
+in	O
+rectal	O
+swabs	O
+obtained	O
+from	O
+infected	O
+calves	O
+.	O
+
+Data	O
+provided	O
+further	O
+evidence	O
+of	O
+the	O
+zoonotic	O
+potential	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+strongly	O
+suggested	O
+that	O
+camels	B-SPEC
+may	O
+have	O
+a	O
+role	O
+in	O
+the	O
+transmission	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+characterization	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+associated	O
+with	O
+the	O
+2014	O
+disease	O
+outbreak	O
+in	O
+Mexico	O
+:	O
+case	O
+report	O
+.	O
+
+The	O
+presence	O
+of	O
+the	O
+PEDV	B-SPEC
+in	O
+cultures	O
+and	O
+clinical	O
+samples	O
+was	O
+confirmed	O
+by	O
+RT	O
+-	O
+PCR	O
+amplification	B-DISO
+and	O
+sequencing	O
+of	O
+a	O
+651	O
+-	O
+bp	O
+segment	O
+of	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+gene	O
+,	O
+as	O
+well	O
+as	O
+a	O
+681	B-PRGE
+-	I-PRGE
+bp	I-PRGE
+matrix	I-PRGE
+protein	I-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+nucleotide	B-CHED
+sequence	O
+analysis	O
+of	O
+the	O
+Mexican	O
+isolates	O
+showed	O
+marked	O
+homology	O
+to	O
+viruses	B-SPEC
+that	O
+circulated	O
+in	O
+2013	O
+in	O
+Colorado	O
+,	O
+USA	O
+.	O
+
+Retinal	B-DISO
+vasculitis	I-DISO
+was	O
+seen	O
+in	O
+13	O
+.	O
+7	O
+%	O
+(	O
+36	O
+/	O
+262	O
+),	O
+and	O
+the	O
+risk	O
+appeared	O
+higher	O
+in	O
+females	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+an	O
+epidemiological	O
+study	O
+of	O
+ferret	O
+coronaviruses	O
+(	O
+FRCoVs	O
+),	O
+novel	O
+FRCoV	O
+strains	O
+(	O
+Saitama	O
+-	O
+1	O
+and	O
+Aichi	O
+-	O
+1	O
+)	O
+were	O
+detected	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+and	O
+nucleotide	B-CHED
+sequence	O
+analysis	O
+of	O
+partial	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+genes	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+results	O
+of	O
+SimPlot	O
+analysis	O
+indicated	O
+that	O
+FRCoV	O
+(	O
+MSU	B-PRGE
+-	I-PRGE
+2	I-PRGE
+strain	O
+)	O
+emerged	O
+via	O
+a	O
+recombination	B-PROC
+event	O
+of	O
+S	O
+protein	B-CHED
+between	O
+the	O
+MSU	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+Saitama	O
+-	O
+1	O
+strains	O
+.	O
+
+Limits	O
+of	O
+detection	O
+(	O
+LOD	B-FUNC
+)	O
+with	O
+95	O
+%	O
+probability	O
+values	O
+were	O
+estimated	O
+by	O
+testing	O
+16	O
+replicates	O
+of	O
+upstream	B-PRGE
+of	I-PRGE
+the	I-PRGE
+envelope	I-PRGE
+gene	I-PRGE
+(	O
+upE	O
+)	O
+and	O
+open	O
+reading	O
+frame	O
+1a	O
+(	O
+ORF1a	O
+)	O
+RNA	O
+transcripts	O
+.	O
+
+Specificity	O
+was	O
+estimated	O
+by	O
+using	O
+28	O
+nasopharyngeal	B-ANAT
+swabs	O
+that	O
+were	O
+positive	O
+for	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+overall	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+all	O
+six	O
+assay	O
+systems	O
+were	O
+sufficient	O
+for	O
+diagnosing	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+all	O
+eight	O
+strains	O
+were	O
+genetically	O
+and	O
+serotypically	O
+different	O
+from	O
+the	O
+strain	O
+ck	O
+/	O
+CH	O
+/	O
+LDL	B-CHED
+/	O
+140520	O
+.	O
+
+The	O
+new	O
+CPV	B-SPEC
+-	O
+2a	O
+variant	O
+was	O
+more	O
+prevalent	O
+than	O
+the	O
+new	O
+CPV	B-SPEC
+-	O
+2b	O
+variant	O
+in	O
+Henan	O
+province	O
+.	O
+
+The	O
+epidemiology	O
+of	O
+CPV	B-SPEC
+infection	B-DISO
+and	O
+identification	O
+of	O
+the	O
+circulating	O
+genotypes	O
+in	O
+Henan	O
+province	O
+,	O
+China	O
+from	O
+2009	O
+to	O
+2014	O
+determined	O
+that	O
+the	O
+new	O
+CPV	B-SPEC
+-	O
+2a	O
+variant	O
+was	O
+more	O
+prevalent	O
+.	O
+
+It	O
+is	O
+now	O
+defined	O
+as	O
+an	O
+abnormal	O
+host	B-PROC
+response	I-PROC
+to	O
+infection	B-DISO
+,	O
+resulting	O
+in	O
+life	O
+-	O
+threatening	O
+dysfunction	O
+of	O
+organs	B-ANAT
+.	O
+
+Corticosteroids	B-CHED
+may	O
+also	O
+shorten	O
+the	O
+duration	O
+of	O
+stay	O
+in	O
+the	O
+ICU	O
+.	O
+
+Except	O
+for	O
+increased	O
+blood	B-ANAT
+glucose	B-CHED
+and	O
+sodium	O
+levels	O
+,	O
+treatment	O
+with	O
+corticosteroids	B-CHED
+was	O
+rather	O
+well	O
+tolerated	O
+in	O
+the	O
+context	O
+of	O
+clinical	O
+trials	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Three	O
+-	O
+phase	O
+Approach	O
+for	O
+the	O
+Early	O
+Identification	O
+of	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Induced	O
+by	O
+Severe	B-DISO
+Sepsis	B-SPEC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+prevent	O
+ALI	O
+/	O
+ARDS	B-DISO
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+,	O
+countermeasures	O
+for	O
+NET	O
+and	O
+platelet	B-PROC
+aggregation	I-PROC
+should	O
+be	O
+pre	O
+-	O
+emptively	O
+employed	O
+and	O
+confirmed	O
+by	O
+several	O
+trials	O
+.	O
+
+Factor	O
+analysis	O
+provided	O
+a	O
+questionnaire	O
+of	O
+23	O
+items	O
+on	O
+5	O
+dimensions	O
+of	O
+sleep	B-DISO
+disturbance	I-DISO
+in	O
+coronary	B-ANAT
+patients	O
+:	O
+""""	O
+sleep	B-PROC
+onset	I-PROC
+and	O
+continuity	O
+disorder	O
+","""	O
+""""	O
+disorder	O
+in	O
+daytime	O
+functioning	O
+","""	O
+""""	O
+sleep	B-DISO
+disturbance	I-DISO
+caused	O
+by	O
+environmental	O
+factors	O
+","""	O
+""""	O
+sleep	O
+disturbance	O
+as	O
+a	O
+result	O
+of	O
+cardiac	B-DISO
+diseases	I-DISO
+","""	O
+and	O
+""""	O
+respiratory	B-DISO
+disorders	I-DISO
+during	O
+sleep	B-PROC
+.	O
+
+Sleep	B-DISO
+disturbance	I-DISO
+questionnaire	O
+for	O
+patients	O
+with	O
+ACS	B-FUNC
+hospitalized	O
+in	O
+coronary	B-ANAT
+care	O
+unit	O
+(	O
+CCU	O
+)	O
+was	O
+identified	O
+in	O
+5	O
+dimensions	O
+and	O
+assessed	O
+for	O
+validity	O
+and	O
+reliability	O
+.	O
+
+In	O
+the	O
+first	O
+group	O
+(	O
+APRV	O
+)	O
+the	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+was	O
+used	O
+;	O
+the	O
+second	O
+group	O
+(	O
+SIMV	O
+)	O
+was	O
+ventilated	O
+using	O
+synchronized	O
+intermittent	O
+mandatory	O
+ventilation	O
+mode	O
+and	O
+positive	O
+end	O
+expiratory	O
+pressure	O
+(	O
+PEEP	B-CHED
+).	O
+
+In	O
+APRV	O
+group	O
+ventilation	O
+central	O
+venous	O
+pressure	O
+(	O
+CVP	O
+)	O
+and	O
+systemic	O
+circulation	B-PROC
+resistance	B-PROC
+index	O
+(	O
+SVRI	O
+)	O
+were	O
+reduced	O
+,	O
+but	O
+cardiac	B-ANAT
+index	O
+(	O
+CI	O
+)	O
+increased	O
+,	O
+and	O
+at	O
+the	O
+same	O
+time	O
+lac	B-CHED
+and	O
+oxygen	B-CHED
+saturation	O
+of	O
+central	O
+venous	B-ANAT
+blood	I-ANAT
+(	O
+ScvO2	O
+)	O
+were	O
+improved	O
+.	O
+
+TITLE	O
+:	O
+Regulation	B-PROC
+of	O
+Stress	O
+Responses	O
+and	O
+Translational	B-PROC
+Control	O
+by	O
+Coronavirus	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+review	O
+the	O
+strategies	O
+exploited	O
+by	O
+coronavirus	B-SPEC
+to	O
+modulate	O
+cellular	B-DISO
+stress	B-PATH
+response	I-PATH
+pathways	B-PROC
+.	O
+
+During	O
+virus	B-DISO
+infection	I-DISO
+,	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+is	O
+a	O
+key	O
+mediator	O
+of	O
+innate	O
+antiviral	B-CHED
+responses	O
+.	O
+
+Our	O
+findings	O
+reveal	O
+a	O
+new	O
+mechanism	O
+evolved	O
+by	O
+PEDV	B-SPEC
+to	O
+circumvent	O
+the	O
+host	B-COMP
+antiviral	B-PROC
+response	I-PROC
+.	O
+
+All	O
+-	O
+trans	O
+retinoic	B-CHED
+acid	I-CHED
+(	O
+ATRA	O
+),	O
+oral	B-ANAT
+administration	O
+,	O
+was	O
+initiated	O
+.	O
+
+On	O
+day	O
+25	O
+,	O
+he	O
+developed	O
+fever	B-PROC
+and	O
+respiratory	B-DISO
+distress	I-DISO
+with	O
+bilateral	B-DISO
+pulmonary	I-DISO
+infiltrates	I-DISO
+,	O
+suggesting	O
+differentiation	B-PROC
+syndrome	B-DISO
+(	O
+DS	O
+)	O
+caused	O
+by	O
+ATRA	O
+.	O
+
+Pathological	O
+examination	O
+of	O
+the	O
+resected	O
+ileocecal	O
+intestines	O
+revealed	O
+multiple	B-DISO
+ulcers	I-DISO
+and	O
+perforations	O
+.	O
+
+No	O
+leukemic	B-ANAT
+cell	I-ANAT
+infiltration	B-DISO
+was	O
+observed	O
+.	O
+
+In	O
+this	O
+case	O
+,	O
+only	O
+ATRA	O
+was	O
+administered	O
+for	O
+APL	B-DISO
+treatment	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+fire	O
+-	O
+eater	O
+'	O
+s	O
+pneumonia	B-DISO
+in	O
+a	O
+28	O
+-	O
+year	O
+-	O
+old	O
+white	O
+man	B-CHED
+with	O
+severe	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+This	O
+study	O
+was	O
+conducted	O
+to	O
+evaluate	O
+the	O
+diagnostic	O
+and	O
+prognostic	O
+value	O
+of	O
+Presepsin	O
+in	O
+ICU	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+(	O
+SS	O
+),	O
+septic	B-DISO
+shock	I-DISO
+(	O
+SSh	O
+)	O
+and	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+(	O
+sCAP	O
+).	O
+
+In	O
+the	O
+72	O
+/	O
+144	O
+patients	O
+admitted	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+the	O
+capability	O
+of	O
+Presepsin	O
+to	O
+diagnose	O
+sCAP	O
+was	O
+significantly	O
+better	O
+than	O
+PCT	B-DISO
+.	O
+
+Presepsin	O
+levels	O
+were	O
+also	O
+predictive	O
+of	O
+ICU	O
+mortality	O
+in	O
+sepsis	B-DISO
+and	O
+in	O
+sCAP	O
+patients	O
+.	O
+
+In	O
+view	O
+of	O
+the	O
+rapid	O
+onset	O
+and	O
+extent	O
+of	O
+hemorrhage	O
+which	O
+may	O
+culminate	O
+quickly	O
+into	O
+asphyxiation	B-DISO
+and	O
+death	B-PROC
+,	O
+HFOV	O
+may	O
+indeed	O
+be	O
+lifesaving	O
+in	O
+severe	O
+LPHS	O
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+Infection	I-PROC
+and	O
+Titration	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+Mouse	B-ANAT
+Lung	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Preventing	O
+Facial	B-ANAT
+Pressure	B-DISO
+Ulcers	I-DISO
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+acute	O
+lung	O
+injury	O
+and	O
+/	O
+or	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+prone	O
+positioning	O
+is	O
+a	O
+therapeutic	O
+intervention	O
+to	O
+improve	O
+oxygenation	B-PROC
+.	O
+
+Neurotropic	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+mice	B-SPEC
+provides	O
+a	O
+useful	O
+tool	O
+for	O
+studying	O
+mechanisms	O
+of	O
+demyelination	B-DISO
+in	O
+a	O
+virus	B-SPEC
+-	O
+induced	O
+experimental	O
+model	O
+of	O
+MS	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+enteric	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+cause	O
+severe	O
+disease	O
+in	O
+the	O
+porcine	O
+herds	O
+worldwide	O
+,	O
+leading	O
+to	O
+important	O
+economic	O
+losses	O
+.	O
+
+This	O
+review	O
+is	O
+focused	O
+in	O
+the	O
+host	B-COMP
+cell	I-COMP
+responses	O
+to	O
+enteric	O
+porcine	B-SPEC
+CoV	O
+infection	B-DISO
+and	O
+the	O
+viral	O
+proteins	B-CHED
+involved	O
+in	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+most	O
+serious	O
+side	B-DISO
+effect	I-DISO
+of	O
+HA	O
+is	O
+aspiration	B-DISO
+pneumonia	I-DISO
+.	O
+
+We	O
+identified	O
+all	O
+patients	O
+and	O
+health	O
+-	O
+care	O
+workers	O
+who	O
+had	O
+been	O
+in	O
+the	O
+emergency	B-DISO
+room	O
+with	O
+the	O
+index	O
+case	O
+between	O
+May	O
+27	O
+and	O
+May	O
+29	O
+,	O
+2015	O
+.	O
+
+The	O
+first	O
+portion	O
+of	O
+this	O
+review	O
+outlines	O
+the	O
+diagnostic	O
+role	O
+of	O
+bedside	O
+ultrasound	O
+in	O
+the	O
+medically	O
+critically	B-DISO
+ill	I-DISO
+patient	O
+population	O
+for	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+,	O
+and	O
+severe	O
+hypoxemia	O
+.	O
+
+Patients	O
+with	O
+hemodynamic	B-DISO
+instability	I-DISO
+,	O
+coma	B-DISO
+and	O
+uncooperative	O
+patients	O
+were	O
+excluded	O
+from	O
+study	O
+.	O
+
+Present	O
+ongoing	O
+epidemic	O
+of	O
+this	O
+deadly	O
+virus	B-SPEC
+in	O
+poultry	O
+livestock	O
+and	O
+humans	B-SPEC
+has	O
+had	O
+major	O
+economic	O
+and	O
+health	O
+repercussions	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+causes	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+which	O
+is	O
+associated	O
+with	O
+severe	O
+inflammation	B-DISO
+and	O
+lung	B-ANAT
+damage	O
+and	O
+has	O
+a	O
+high	O
+mortality	O
+and	O
+for	O
+which	O
+there	O
+is	O
+no	O
+therapy	O
+.	O
+
+MSCs	B-FUNC
+reduce	O
+the	O
+pro	B-CHED
+-	O
+inflammatory	B-DISO
+response	I-DISO
+to	O
+injury	O
+while	O
+augmenting	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+bacterial	B-DISO
+infection	I-DISO
+.	O
+
+Strategies	O
+to	O
+further	O
+enhance	O
+the	O
+efficacy	O
+of	O
+MSCs	B-FUNC
+,	O
+such	O
+as	O
+by	O
+overexpressing	O
+anti	B-PRGE
+-	I-PRGE
+inflammatory	I-PRGE
+or	I-PRGE
+pro	I-PRGE
+-	I-PRGE
+repair	B-PROC
+molecules	I-PRGE
+,	O
+are	O
+also	O
+being	O
+investigated	O
+.	O
+
+Although	O
+considerable	O
+translational	B-PROC
+challenges	O
+,	O
+such	O
+as	O
+concerns	O
+regarding	O
+cell	B-COMP
+manufacture	O
+scale	O
+-	O
+up	O
+and	O
+issues	O
+regarding	O
+cell	B-COMP
+potency	O
+and	O
+batch	O
+variability	O
+,	O
+must	O
+be	O
+overcome	O
+,	O
+MSCs	B-FUNC
+constitute	O
+a	O
+highly	O
+promising	O
+potential	O
+therapy	O
+for	O
+ARDS	B-DISO
+.	O
+
+Initiation	O
+of	O
+ECMO	O
+for	O
+adult	O
+ARDS	B-DISO
+should	O
+be	O
+considered	O
+when	O
+conventional	O
+therapy	O
+cannot	O
+maintain	O
+adequate	O
+oxygenation	B-PROC
+.	O
+
+ECMO	O
+is	O
+not	O
+a	O
+treatment	O
+for	O
+the	O
+underlying	O
+cause	O
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+severe	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+treated	O
+with	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+:	O
+A	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+.	O
+
+The	O
+optimal	O
+cutoff	O
+values	O
+were	O
+risk	O
+class	B-SPEC
+3	O
+.	O
+5	O
+for	O
+RESP	O
+and	O
+35	O
+.	O
+5	O
+for	O
+APACHE	O
+II	O
+score	O
+,	O
+and	O
+both	O
+showed	O
+70	O
+.	O
+0	O
+%	O
+sensitivity	O
+and	O
+84	O
+.	O
+6	O
+%	O
+specificity	O
+.	O
+
+Development	B-PROC
+of	O
+a	O
+scoring	O
+system	O
+with	O
+national	O
+characteristics	O
+might	O
+be	O
+warranted	O
+.	O
+
+TITLE	O
+:	O
+Productive	O
+replication	O
+of	O
+nephropathogenic	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+monocytic	B-ANAT
+cells	B-COMP
+,	O
+a	O
+strategy	O
+for	O
+viral	O
+dissemination	O
+and	O
+kidney	B-DISO
+infection	I-DISO
+in	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+present	O
+study	O
+,	O
+the	O
+replication	O
+kinetics	O
+of	O
+nephropathogenic	O
+(	O
+B1648	O
+)	O
+and	O
+respiratory	O
+(	O
+Massachusetts	O
+-	O
+M41	O
+)	O
+IBV	B-SPEC
+strains	O
+were	O
+compared	O
+in	O
+vitro	O
+in	O
+respiratory	O
+mucosa	B-ANAT
+explants	O
+and	O
+blood	B-ANAT
+monocytes	I-ANAT
+(	O
+KUL01	O
+(+)	O
+cells	B-COMP
+),	O
+and	O
+in	O
+vivo	O
+in	O
+chickens	B-SPEC
+to	O
+understand	O
+why	O
+some	O
+IBV	B-SPEC
+strains	O
+have	O
+a	O
+kidney	B-ANAT
+tropism	B-PROC
+.	O
+
+In	O
+B1648	O
+inoculated	O
+animals	B-SPEC
+,	O
+10	O
+(	O
+2	O
+.	O
+7	O
+-	O
+6	O
+.	O
+8	O
+)	O
+viral	O
+RNA	O
+copies	O
+/	O
+100	O
+mg	O
+were	O
+detected	O
+in	O
+tracheal	O
+secretions	B-ANAT
+at	O
+2	O
+,	O
+4	O
+,	O
+6	O
+,	O
+8	O
+,	O
+10	O
+and	O
+12	O
+days	O
+post	O
+inoculation	O
+(	O
+dpi	O
+),	O
+10	O
+(	O
+2	O
+.	O
+4	O
+-	O
+4	O
+.	O
+5	O
+)	O
+viral	O
+RNA	O
+copies	O
+/	O
+mL	O
+in	O
+plasma	B-ANAT
+at	O
+2	O
+,	O
+4	O
+,	O
+6	O
+,	O
+8	O
+,	O
+10	O
+and	O
+12	O
+dpi	O
+and	O
+10	O
+(	O
+1	O
+.	O
+8	O
+-	O
+4	O
+.	O
+4	O
+)	O
+viral	O
+RNA	O
+copies	O
+/	O
+10	O
+(	O
+6	O
+)	O
+mononuclear	O
+cells	O
+in	O
+blood	B-ANAT
+at	O
+2	O
+,	O
+4	O
+,	O
+6	O
+and	O
+8	O
+dpi	O
+.	O
+
+The	O
+nutrition	B-PROC
+indicators	O
+before	O
+and	O
+after	O
+EN	O
+therapy	O
+were	O
+compared	O
+by	O
+paired	O
+t	O
+-	O
+test	O
+.	O
+
+EN	O
+is	O
+suitable	O
+for	O
+a	O
+variety	O
+of	O
+children	O
+'	O
+s	O
+digestive	B-DISO
+diseases	I-DISO
+,	O
+which	O
+can	O
+improve	O
+the	O
+nutritional	O
+status	O
+of	O
+the	O
+patients	O
+and	O
+was	O
+safe	O
+for	O
+clinical	O
+application	O
+.	O
+
+The	O
+extent	O
+of	O
+pulmonary	O
+infiltration	O
+observed	O
+on	O
+the	O
+first	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+and	O
+the	O
+diagnosis	O
+of	O
+invasive	O
+fungal	B-DISO
+infection	I-DISO
+were	O
+the	O
+most	O
+relevant	O
+early	O
+predictive	O
+factors	O
+of	O
+the	O
+severity	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Since	O
+the	O
+therapeutic	O
+strategies	O
+for	O
+IPS	O
+are	O
+clearly	O
+different	O
+from	O
+those	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+and	O
+therapeutic	O
+delay	O
+causes	O
+a	O
+poor	O
+prognosis	O
+,	O
+radiologists	O
+should	O
+be	O
+aware	O
+of	O
+some	O
+characteristic	O
+HRCT	O
+findings	O
+of	O
+IPS	B-DISO
+,	O
+which	O
+includes	O
+a	O
+wide	O
+spectrum	O
+of	O
+entities	O
+.	O
+
+AEGIS	O
+adds	O
+nucleotides	B-CHED
+to	O
+the	O
+four	O
+found	O
+in	O
+standard	O
+DNA	O
+and	O
+RNA	O
+(	O
+xNA	O
+);	O
+AEGIS	O
+nucleotides	B-CHED
+pair	O
+orthogonally	O
+to	O
+the	O
+A	O
+:	O
+T	O
+and	O
+G	O
+:	O
+C	O
+pairs	O
+.	O
+
+Placing	O
+AEGIS	O
+components	O
+in	O
+the	O
+stems	B-ANAT
+of	O
+molecular	O
+beacons	O
+is	O
+shown	O
+to	O
+lower	O
+noise	O
+by	O
+preventing	O
+unwanted	O
+stem	B-ANAT
+invasion	B-DISO
+by	O
+adventitious	O
+natural	O
+xNA	O
+.	O
+
+ABSTRACT	O
+:	O
+Highly	O
+pathogenic	O
+human	O
+coronaviruses	O
+associated	O
+with	O
+a	O
+severe	O
+respiratory	O
+syndrome	B-DISO
+,	O
+including	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+have	O
+recently	O
+emerged	O
+.	O
+
+We	O
+tested	O
+the	O
+antiviral	B-CHED
+effect	O
+of	O
+griffithsin	O
+(	O
+GRFT	O
+),	O
+a	O
+lectin	B-PRGE
+isolated	O
+from	O
+the	O
+red	O
+marine	O
+alga	O
+Griffithsia	B-SPEC
+sp	O
+.	O
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+The	O
+trauma	O
+integration	B-PROC
+treatment	O
+system	O
+can	O
+improve	O
+the	O
+treatment	O
+quality	O
+of	O
+patients	O
+with	O
+severe	O
+trauma	O
+.	O
+
+More	O
+than	O
+half	O
+(	O
+54	O
+%)	O
+of	O
+infections	B-DISO
+were	O
+believed	O
+to	O
+be	O
+caught	O
+at	O
+the	O
+emergency	B-DISO
+department	O
+.	O
+
+Four	O
+children	O
+from	O
+two	O
+unrelated	O
+kindreds	O
+died	B-PROC
+of	O
+severe	O
+pulmonary	B-DISO
+disease	I-DISO
+during	O
+infancy	O
+following	O
+viral	B-DISO
+pneumonia	I-DISO
+with	O
+evidence	O
+of	O
+combined	O
+T	O
+and	O
+B	B-ANAT
+cell	I-ANAT
+immunodeficiency	B-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+among	O
+children	O
+in	O
+MERS	O
+-	O
+endemic	O
+Riyadh	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+2012	O
+-	O
+2013	O
+.	O
+
+Sudden	O
+and	O
+unexpected	O
+deaths	B-PROC
+have	O
+been	O
+reported	O
+in	O
+SPS	B-DISO
+,	O
+and	O
+all	O
+described	O
+cases	O
+have	O
+been	O
+associated	O
+with	O
+apnea	B-DISO
+.	O
+
+Angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+IL	B-PRGE
+-	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+antagonist	B-PROC
+concentrations	O
+did	O
+not	O
+differ	O
+between	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+for	O
+the	O
+Treatment	O
+of	O
+Influenza	B-DISO
+-	O
+Induced	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+Immunocompromised	O
+Adults	O
+.	O
+
+Cats	B-SPEC
+without	O
+FIP	B-DISO
+were	O
+further	O
+subdivided	O
+into	O
+three	O
+subgroups	O
+:	O
+cardiac	B-DISO
+disease	I-DISO
+,	O
+neoplasia	B-DISO
+and	O
+other	O
+diseases	O
+.	O
+
+This	O
+situation	O
+led	O
+to	O
+a	O
+nationwide	O
+chaos	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Epidemiologic	O
+parameters	O
+are	O
+important	O
+in	O
+planning	O
+infection	O
+control	O
+policies	O
+during	O
+the	O
+outbreak	O
+of	O
+emerging	O
+infections	B-DISO
+.	O
+
+We	O
+estimated	O
+the	O
+incubation	O
+periods	B-PROC
+of	O
+162	O
+cases	O
+whose	O
+sources	O
+of	O
+exposure	O
+were	O
+identified	O
+and	O
+the	O
+temporal	O
+trend	O
+was	O
+evaluated	O
+.	O
+
+Despite	O
+the	O
+initial	O
+delay	O
+,	O
+the	O
+stringent	O
+countermeasures	O
+targeted	B-PROC
+towards	O
+second	O
+generation	O
+cases	O
+appeared	O
+to	O
+effectively	O
+contain	O
+the	O
+MERS	O
+outbreak	O
+in	O
+Korea	O
+as	O
+suggested	O
+by	O
+the	O
+decline	O
+of	O
+R	O
+(	O
+c	O
+)	O
+shortly	O
+after	O
+implementation	O
+.	O
+
+Further	O
+research	O
+should	O
+be	O
+focused	O
+on	O
+characterizing	O
+superspreaders	O
+in	O
+comparison	O
+to	O
+non	O
+-	O
+transmitting	O
+cases	O
+with	O
+regard	O
+to	O
+environmental	O
+,	O
+behavioral	B-PROC
+,	O
+and	O
+virologic	O
+and	O
+host	B-COMP
+genetic	O
+factors	O
+in	O
+order	B-SPEC
+to	O
+better	O
+prepare	O
+for	O
+future	O
+outbreaks	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+RESULTS	O
+:	O
+The	O
+estimated	O
+median	O
+incubation	O
+period	O
+was	O
+7	O
+.	O
+4	O
+days	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+6	O
+.	O
+9	O
+-	O
+8	O
+.	O
+0	O
+).	O
+
+A	O
+total	O
+of	O
+186	O
+patients	O
+,	O
+including	O
+36	O
+deaths	B-PROC
+,	O
+had	O
+been	O
+diagnosed	O
+with	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+as	O
+of	O
+September	O
+30th	O
+,	O
+2015	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+was	O
+diagnosed	O
+using	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+assay	O
+.	O
+
+In	O
+septic	O
+patients	O
+with	O
+ARDS	B-DISO
+complement	B-PROC
+activation	I-PROC
+products	O
+were	O
+found	O
+to	O
+be	O
+elevated	O
+in	O
+the	O
+plasma	B-ANAT
+.	O
+
+In	O
+single	O
+models	O
+like	O
+LPS	B-PRGE
+or	I-PRGE
+trauma	I-PRGE
+complement	I-PRGE
+has	O
+been	O
+studied	O
+to	O
+some	O
+degree	O
+,	O
+however	O
+in	O
+clinically	O
+highly	O
+relevant	O
+double	O
+hit	O
+models	O
+such	O
+as	O
+the	O
+one	O
+used	O
+here	O
+little	O
+data	O
+is	O
+available	O
+.	O
+
+12	O
+hrs	B-DISO
+after	O
+DH	O
+in	O
+mice	B-SPEC
+the	O
+local	O
+and	O
+systemic	O
+cytokines	O
+and	O
+chemokines	O
+were	O
+quantified	O
+by	O
+multiplex	O
+bead	O
+array	O
+or	O
+ELISA	O
+,	O
+activated	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+by	O
+western	O
+blot	O
+.	O
+
+In	O
+lung	B-ANAT
+tissue	I-ANAT
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+,	O
+monocyte	B-PRGE
+chemo	I-PRGE
+attractant	B-PROC
+protein	B-CHED
+-	I-PRGE
+1	I-PRGE
+(	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+and	O
+granulocyte	B-PRGE
+-	I-PRGE
+colony	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+was	O
+elevated	O
+in	O
+both	O
+C5	O
+-/-	O
+mice	B-SPEC
+and	O
+wildtype	O
+littermates	O
+(	O
+wt	O
+),	O
+whereas	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+was	O
+reduced	O
+in	O
+lungs	B-ANAT
+after	O
+DH	O
+in	O
+C5	O
+-/-	O
+mice	B-SPEC
+.	O
+
+Dromedary	O
+camels	B-SPEC
+should	O
+be	O
+considered	O
+for	O
+the	O
+development	B-PROC
+of	O
+veterinary	O
+vaccines	O
+.	O
+
+Several	O
+vaccine	O
+technology	O
+platforms	O
+targeting	B-PROC
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+were	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Alternative	O
+autophagy	B-PROC
+,	O
+brefeldin	B-CHED
+A	I-CHED
+and	O
+viral	O
+trafficking	B-PROC
+pathways	B-PROC
+.	O
+
+We	O
+suggest	O
+that	O
+noncanonical	O
+autophagy	B-PROC
+,	O
+which	O
+is	O
+sensitive	O
+to	O
+treatment	O
+with	O
+brefeldin	B-CHED
+A	I-CHED
+,	O
+may	O
+converge	O
+with	O
+the	O
+infectious	B-DISO
+cycles	O
+of	O
+certain	O
+DNA	O
+and	O
+RNA	O
+viruses	B-SPEC
+that	O
+utilize	O
+membrane	B-COMP
+from	O
+the	O
+ER	O
+and	O
+cis	B-DISO
+-	O
+Golgi	B-COMP
+.	O
+
+TITLE	O
+:	O
+The	O
+impact	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+on	O
+outcome	O
+after	O
+oesophagectomy	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+the	O
+macro	O
+domain	O
+from	O
+hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+(	O
+HEV	B-SPEC
+)	O
+serves	O
+as	O
+an	O
+ADP	B-PRGE
+-	I-PRGE
+ribose	B-CHED
+-	I-PRGE
+protein	B-CHED
+hydrolase	I-PRGE
+for	O
+mono	B-DISO
+-	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+(	O
+MAR	B-DISO
+)	O
+and	O
+poly	O
+(	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+)	O
+(	O
+PAR	O
+)	O
+chain	O
+removal	O
+(	O
+de	O
+-	O
+MARylation	O
+and	O
+de	O
+-	O
+PARylation	O
+,	O
+respectively	O
+)	O
+from	O
+mono	B-DISO
+-	O
+and	O
+poly	O
+(	O
+ADP	B-CHED
+)-	O
+ribosylated	O
+proteins	B-CHED
+,	O
+respectively	O
+.	O
+
+Although	O
+the	O
+APACHE	O
+II	O
+score	O
+(	O
+p	O
+=	O
+0	O
+.	O
+01	O
+),	O
+presence	O
+of	O
+liver	B-DISO
+failure	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+08	O
+),	O
+and	O
+platelet	B-ANAT
+transfusion	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0009	O
+)	O
+were	O
+different	O
+between	O
+the	O
+severe	O
+T	O
+(	O
+18	O
+/	O
+85	O
+[	O
+21	O
+%])	O
+and	O
+non	O
+-	O
+severe	O
+T	O
+groups	O
+(	O
+67	O
+/	O
+85	O
+[	O
+79	O
+%]),	O
+the	O
+incidence	O
+of	O
+septic	O
+shock	O
+(	O
+p	O
+=	O
+0	O
+.	O
+64	O
+),	O
+heparin	B-CHED
+infusion	O
+use	O
+(	O
+p	O
+=	O
+0	O
+.	O
+41	O
+),	O
+exposure	O
+to	O
+non	O
+-	O
+heparin	B-CHED
+T	O
+-	O
+causing	O
+medications	O
+(	O
+p	O
+=	O
+0	O
+.	O
+77	O
+)	O
+and	O
+ECMO	O
+use	O
+(	O
+p	O
+=	O
+0	O
+.	O
+5	O
+)	O
+were	O
+not	O
+.	O
+
+TITLE	O
+:	O
+Relationship	O
+between	O
+elevated	O
+soluble	O
+CD74	B-PRGE
+and	O
+severity	O
+of	O
+experimental	O
+and	O
+clinical	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+The	O
+elevated	O
+levels	O
+of	O
+sCD74	O
+in	O
+BALF	O
+positively	O
+correlated	O
+with	O
+lung	B-ANAT
+permeability	O
+and	O
+inflammation	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+clinical	O
+effects	O
+of	O
+microinvasive	B-DISO
+video	O
+-	O
+assisted	O
+thoracoscopic	O
+surgery	O
+(	O
+VATS	O
+)	O
+combined	O
+with	O
+mechanical	O
+ventilation	O
+in	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+secondary	O
+to	O
+severe	O
+chest	B-ANAT
+trauma	O
+.	O
+
+We	O
+postulated	O
+that	O
+adjunctive	O
+treatment	O
+of	O
+persistent	O
+ARDS	B-DISO
+with	O
+intravenous	O
+dexamethasone	B-CHED
+might	O
+change	O
+the	O
+pulmonary	B-ANAT
+and	O
+systemic	O
+inflammatory	B-DISO
+response	I-DISO
+and	O
+thereby	O
+reduce	O
+morbidity	O
+,	O
+leading	O
+to	O
+a	O
+decrease	O
+in	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+and	O
+a	O
+decrease	O
+in	O
+mortality	O
+.	O
+
+Persistent	O
+ARDS	B-DISO
+is	O
+defined	O
+as	O
+maintaining	O
+a	O
+PaO2	O
+/	O
+FiO2	O
+≤	O
+200	O
+mmHg	O
+on	O
+PEEP	B-CHED
+≥	O
+10	O
+cmH2O	O
+and	O
+FiO2	O
+≥	O
+0	O
+.	O
+5	O
+after	O
+24	O
+hours	O
+of	O
+routine	O
+intensive	O
+care	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+explored	O
+whether	O
+pAPN	O
+functions	O
+as	O
+a	O
+receptor	O
+for	O
+PEDV	B-SPEC
+.	O
+
+Human	B-SPEC
+HeLa	B-ANAT
+cells	I-ANAT
+expressing	O
+pAPN	O
+and	O
+pAPN	O
+-	O
+positive	O
+porcine	B-PRGE
+CPK	I-PRGE
+cells	B-COMP
+failed	O
+to	O
+support	O
+PEDV	B-SPEC
+infection	B-DISO
+,	O
+but	O
+were	O
+susceptible	O
+to	O
+infection	B-DISO
+by	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+which	O
+utilizes	O
+pAPN	O
+as	O
+a	O
+functional	O
+receptor	O
+.	O
+
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+Infection	B-DISO
+in	O
+the	O
+United	O
+States	O
+,	O
+2014	O
+.	O
+
+RESULTS	O
+:	O
+Applying	O
+the	O
+same	O
+process	O
+used	O
+to	O
+trace	O
+and	O
+notify	O
+travelers	O
+during	O
+routine	O
+investigations	O
+,	O
+such	O
+as	O
+those	O
+for	O
+tuberculosis	B-PATH
+or	O
+measles	B-PATH
+,	O
+CDC	O
+was	O
+able	O
+to	O
+notify	O
+most	O
+travelers	O
+of	O
+their	O
+potential	O
+exposure	O
+to	O
+MERS	O
+-	O
+CoV	O
+during	O
+the	O
+first	O
+few	O
+days	O
+of	O
+each	O
+investigation	O
+.	O
+
+We	O
+estimate	O
+that	O
+12	O
+%	O
+[	O
+95	O
+%	O
+credible	O
+interval	O
+(	O
+CI	O
+):	O
+9	O
+%,	O
+15	O
+%]	O
+of	O
+cases	O
+were	O
+infected	O
+from	O
+the	O
+reservoir	O
+,	O
+the	O
+rest	B-FUNC
+via	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+in	O
+clusters	B-CHED
+(	O
+60	O
+%;	O
+CI	O
+:	O
+57	O
+%,	O
+63	O
+%),	O
+within	O
+(	O
+23	O
+%;	O
+CI	O
+:	O
+20	O
+%,	O
+27	O
+%),	O
+or	O
+between	O
+(	O
+5	O
+%;	O
+CI	O
+:	O
+2	O
+%,	O
+8	O
+%)	O
+regions	O
+.	O
+
+The	O
+approach	O
+we	O
+present	O
+allows	O
+the	O
+study	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+transmission	I-DISO
+when	O
+data	O
+linking	O
+cases	O
+to	O
+each	O
+other	O
+remain	O
+limited	O
+and	O
+uncertain	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Case	O
+of	O
+Scrub	B-DISO
+Typhus	I-DISO
+Complicated	O
+by	O
+Adult	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+and	O
+Successful	O
+Management	O
+with	O
+Extracorporeal	O
+Membrane	O
+Oxygenation	B-PROC
+.	O
+
+Two	O
+factors	O
+that	O
+affect	O
+the	O
+difficulty	O
+of	O
+infectious	B-DISO
+clone	O
+construction	O
+are	O
+genome	O
+length	O
+and	O
+genome	O
+complexity	O
+.	O
+
+The	O
+second	O
+EIA	B-DISO
+uses	O
+RSV	B-PRGE
+F	I-PRGE
+or	O
+G	B-PRGE
+gene	I-PRGE
+-	I-PRGE
+expressed	I-PRGE
+antigen	B-CHED
+in	O
+HEp	B-PRGE
+-	I-PRGE
+2	I-PRGE
+cells	B-COMP
+.	O
+
+We	O
+specifically	O
+identified	O
+the	O
+imatinib	B-CHED
+target	O
+,	O
+Abelson	B-PRGE
+tyrosine	B-CHED
+-	O
+protein	B-ENZY
+kinase	I-ENZY
+2	O
+(	O
+Abl2	B-PRGE
+),	O
+as	O
+required	O
+for	O
+efficient	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+replication	O
+in	O
+vitro	O
+These	O
+data	O
+demonstrate	O
+that	O
+specific	O
+approved	O
+drugs	O
+can	O
+be	O
+characterized	O
+in	O
+vitro	O
+for	O
+their	O
+anticoronavirus	O
+activity	O
+and	O
+used	O
+to	O
+identify	O
+host	B-COMP
+proteins	B-CHED
+required	O
+for	O
+coronavirus	B-SPEC
+replication	O
+.	O
+
+Treatment	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+is	O
+limited	O
+to	O
+providing	O
+supportive	O
+therapy	O
+consistent	O
+with	O
+any	O
+serious	O
+lung	B-DISO
+disease	I-DISO
+,	O
+as	O
+no	O
+specific	O
+drugs	O
+have	O
+been	O
+approved	O
+as	O
+therapeutics	O
+.	O
+
+TITLE	O
+:	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+:	O
+Targets	O
+for	O
+vaccines	O
+and	O
+therapeutics	O
+.	O
+
+The	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+is	O
+an	O
+important	O
+viral	O
+antigen	B-CHED
+known	O
+to	O
+mediate	O
+host	B-COMP
+-	O
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+virus	B-SPEC
+entry	O
+,	O
+as	O
+well	O
+as	O
+induce	O
+robust	O
+humoral	O
+and	O
+cell	B-COMP
+-	O
+mediated	O
+responses	O
+in	O
+humans	B-SPEC
+during	O
+infection	B-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+highlight	O
+the	O
+importance	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+the	O
+MERS	O
+-	O
+CoV	O
+life	O
+cycle	O
+,	O
+summarize	O
+recent	O
+advances	O
+in	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+and	O
+therapeutics	O
+based	O
+on	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+and	O
+discuss	O
+strategies	O
+that	O
+can	O
+be	O
+explored	O
+to	O
+develop	O
+new	O
+medical	O
+countermeasures	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Short	O
+communication	O
+:	O
+antiviral	B-CHED
+activity	O
+of	O
+porcine	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+λ3	I-PRGE
+against	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+in	O
+vitro	O
+.	O
+
+The	O
+full	O
+-	O
+length	O
+poIFN	B-PRGE
+-	I-PRGE
+λ3	I-PRGE
+cDNA	I-PRGE
+sequence	I-PRGE
+encoded	O
+196	O
+amino	B-CHED
+acids	I-CHED
+with	O
+a	O
+23	O
+amino	B-CHED
+acid	I-CHED
+signal	O
+peptide	B-CHED
+.	O
+
+The	O
+highest	O
+inhibition	B-PROC
+of	O
+PEDV	B-SPEC
+was	O
+observed	O
+in	O
+Vero	O
+E6	O
+cell	B-COMP
+cultures	O
+pretreated	O
+with	O
+poIFN	O
+-	O
+λ3	O
+(	O
+prior	O
+to	O
+PEDV	B-SPEC
+infection	B-DISO
+).	O
+
+TITLE	O
+:	O
+Parenchymal	O
+lung	B-ANAT
+involvement	O
+in	O
+adult	B-DISO
+-	I-DISO
+onset	I-DISO
+Still	I-DISO
+disease	I-DISO
+:	O
+A	O
+STROBE	O
+-	O
+compliant	O
+case	O
+series	O
+and	O
+literature	O
+review	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	O
+are	O
+notorious	O
+reservoirs	O
+of	O
+genetically	O
+-	O
+diverse	O
+and	O
+high	O
+-	O
+profile	O
+pathogens	O
+,	O
+and	O
+are	O
+playing	O
+crucial	O
+roles	O
+in	O
+the	O
+emergence	O
+and	O
+re	O
+-	O
+emergence	O
+of	O
+viruses	B-SPEC
+,	O
+both	O
+in	O
+human	B-SPEC
+and	O
+in	O
+animals	B-SPEC
+.	O
+
+These	O
+results	O
+highlight	O
+the	O
+virus	B-SPEC
+richness	O
+of	O
+bats	B-SPEC
+and	O
+their	O
+possible	O
+roles	O
+in	O
+the	O
+public	O
+health	O
+.	O
+
+We	O
+performed	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+to	O
+screen	O
+for	O
+the	O
+presence	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+and	O
+an	O
+indirect	O
+immunofluorescence	O
+test	O
+(	O
+IIFT	O
+)	O
+to	O
+confirm	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+.	O
+We	O
+used	O
+a	O
+questionnaire	O
+to	O
+collect	O
+information	O
+regarding	O
+the	O
+exposure	O
+.	O
+
+Health	O
+workers	O
+collected	O
+nose	B-ANAT
+and	O
+throat	B-ANAT
+swabs	O
+for	O
+virus	B-SPEC
+detection	O
+by	O
+multiplex	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+271	O
+(	O
+62	O
+.	O
+3	O
+%)	O
+of	O
+435	O
+nose	B-ANAT
+/	O
+throat	B-ANAT
+swabs	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+of	O
+the	O
+15	O
+viruses	B-SPEC
+tested	O
+.	O
+
+There	O
+was	O
+no	O
+clear	O
+seasonality	O
+,	O
+but	O
+78	O
+%	O
+of	O
+episodes	O
+occurred	O
+in	O
+Winter	O
+/	O
+Spring	O
+for	O
+Influenza	B-DISO
+compared	O
+to	O
+32	O
+%	O
+for	O
+Rhinovirus	B-SPEC
+.	O
+
+These	O
+data	O
+demonstrate	O
+that	O
+interaction	O
+of	O
+Alphacoronavirus	O
+spike	O
+proteins	B-CHED
+with	O
+tubulin	B-PRGE
+supports	I-PRGE
+S	I-PRGE
+protein	B-PROC
+transport	B-PROC
+and	O
+incorporation	O
+into	O
+virus	B-COMP
+particles	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+evaluated	O
+the	O
+diagnostic	O
+and	O
+clinical	O
+usefulness	O
+of	O
+blood	B-ANAT
+specimens	O
+to	O
+detect	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+21	O
+patients	O
+from	O
+the	O
+2015	O
+outbreak	O
+in	O
+South	O
+Korea	O
+.	O
+
+Viral	O
+RNA	O
+was	O
+detected	O
+in	O
+blood	B-ANAT
+from	O
+33	O
+%	O
+of	O
+patients	O
+at	O
+initial	O
+diagnosis	O
+,	O
+and	O
+the	O
+detection	O
+preceded	O
+a	O
+worse	O
+clinical	O
+course	O
+.	O
+
+Patients	O
+had	O
+history	O
+&	O
+physical	O
+,	O
+CRP	B-PRGE
+,	O
+hemogram	O
+and	O
+nasopharyngeal	B-ANAT
+swabs	O
+for	O
+rhinovirus	B-SPEC
+A	O
+/	O
+B	O
+,	O
+influenza	B-PATH
+A	I-PATH
+/	O
+B	O
+,	O
+adenovirus	B-DISO
+A	O
+/	O
+B	O
+/	O
+C	O
+/	O
+D	O
+/	O
+E	O
+,	O
+coronavirus	B-SPEC
+229E	O
+/	O
+NL63	O
+and	O
+OC43	O
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+1	O
+/	O
+2	O
+/	O
+3	O
+,	O
+respiratory	O
+syncytial	O
+virusA	O
+/	O
+B	O
+,	O
+metapneumovirus	B-SPEC
+and	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+,	O
+Legionella	B-SPEC
+pneumophila	I-SPEC
+and	O
+Bordetella	B-SPEC
+pertussis	I-SPEC
+by	O
+PCR	O
+and	O
+for	O
+ABHS	B-DISO
+culture	O
+.	O
+
+Influenza	B-SPEC
+virus	I-SPEC
+predominated	O
+in	O
+January	O
+(	O
+51	O
+%).	O
+
+TITLE	O
+:	O
+Spike	O
+gene	B-DISO
+deletion	I-DISO
+quasispecies	O
+in	O
+serum	B-COMP
+of	O
+patient	O
+with	O
+acute	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+During	O
+investigation	O
+of	O
+a	O
+multi	O
+-	O
+facility	O
+outbreak	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+Taif	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+we	O
+identified	O
+a	O
+mixed	O
+population	O
+of	O
+wild	O
+-	O
+type	O
+and	O
+variant	O
+sequences	O
+with	O
+a	O
+large	O
+530	O
+nucleotide	B-CHED
+deletion	O
+in	O
+the	O
+spike	O
+gene	O
+from	O
+the	O
+serum	B-COMP
+of	O
+one	O
+patient	O
+.	O
+
+The	O
+out	B-PROC
+of	I-PROC
+frame	I-PROC
+deletion	I-PROC
+predicted	O
+loss	O
+of	O
+most	O
+of	O
+the	O
+S2	O
+subunit	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+leaving	O
+the	O
+S1	B-PRGE
+subunit	I-PRGE
+with	O
+an	O
+intact	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+)	O
+and	O
+coronavirus	O
+(	O
+HCoV	O
+)	O
+infections	B-DISO
+are	O
+associated	O
+with	O
+both	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illness	O
+"("""	O
+the	O
+common	B-DISO
+cold	I-DISO
+""")"	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illness	O
+(	O
+pneumonia	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+enveloped	O
+RNA	O
+viruses	O
+that	O
+infect	O
+birds	B-SPEC
+,	O
+mammals	B-SPEC
+,	O
+and	O
+humans	B-SPEC
+.	O
+
+Although	O
+bats	B-SPEC
+might	O
+serve	O
+as	O
+a	O
+reservoir	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+it	O
+is	O
+unlikely	O
+that	O
+they	O
+are	O
+the	O
+direct	O
+source	O
+for	O
+most	O
+human	B-SPEC
+cases	O
+.	O
+
+The	O
+combination	O
+regimen	O
+of	O
+type	O
+1	O
+interferon	O
++	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+is	O
+considered	O
+as	O
+the	O
+first	O
+-	O
+line	O
+therapy	O
+for	O
+MERS	O
+.	O
+
+Thereafter	O
+,	O
+the	O
+development	B-PROC
+of	O
+cost	O
+-	O
+effective	O
+,	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+agents	I-CHED
+is	O
+the	O
+urgent	O
+mission	O
+of	O
+both	O
+virologists	O
+and	O
+pharmacologists	O
+.	O
+
+However	O
+,	O
+post	O
+-	O
+admission	O
+decreases	O
+in	O
+the	O
+serum	B-COMP
+levels	O
+of	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+17	O
+,	O
+IL	B-PRGE
+-	I-PRGE
+7	I-PRGE
+,	I-PRGE
+and	I-PRGE
+monocyte	B-ANAT
+chemoattractant	I-PRGE
+protein	B-CHED
+-	I-PRGE
+1	I-PRGE
+were	O
+significantly	O
+greater	O
+in	O
+the	O
+SLEDf	O
+group	O
+.	O
+
+However	O
+,	O
+upon	O
+viral	B-DISO
+infection	I-DISO
+or	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+2	I-PRGE
+(	O
+TLR2	B-PRGE
+)	O
+activation	O
+,	O
+LSECs	O
+can	O
+achieve	O
+proinflammatory	O
+functions	O
+,	O
+but	O
+their	O
+role	O
+in	O
+hepatic	B-ANAT
+inflammation	B-DISO
+during	O
+acute	B-DISO
+viral	I-DISO
+hepatitis	I-DISO
+is	O
+unknown	O
+.	O
+
+Viral	B-DISO
+hepatitis	I-DISO
+B	I-DISO
+and	O
+C	O
+infections	B-DISO
+are	O
+serious	O
+health	O
+problems	O
+affecting	O
+over	O
+350	O
+million	O
+and	O
+170	O
+million	O
+people	O
+worldwide	O
+,	O
+respectively	O
+.	O
+
+More	O
+importantly	O
+,	O
+the	O
+entry	O
+of	O
+MERS	O
+-	O
+CoV	O
+was	O
+increased	O
+when	O
+CEACAM5	O
+was	O
+overexpressed	O
+in	O
+permissive	O
+cells	B-COMP
+,	O
+which	O
+suggested	O
+that	O
+CEACAM5	B-PRGE
+could	O
+facilitate	O
+MERS	O
+-	O
+CoV	O
+entry	O
+in	O
+conjunction	O
+with	O
+DPP4	B-PRGE
+despite	O
+not	O
+being	O
+able	O
+to	O
+support	O
+MERS	O
+-	O
+CoV	O
+entry	O
+independently	O
+.	O
+
+Taken	O
+together	O
+,	O
+the	O
+results	O
+of	O
+our	O
+study	O
+identified	O
+CEACAM5	O
+as	O
+a	O
+novel	O
+cell	B-FUNC
+surface	I-FUNC
+binding	I-FUNC
+target	O
+of	O
+MERS	O
+-	O
+CoV	O
+that	O
+facilitates	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+by	O
+augmenting	O
+the	O
+attachment	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+the	O
+host	B-COMP
+cell	I-COMP
+surface	I-COMP
+.	O
+
+Infection	B-DISO
+with	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+associated	O
+with	O
+the	O
+highest	O
+mortality	O
+rate	O
+among	O
+all	O
+known	O
+human	B-SPEC
+-	O
+pathogenic	O
+coronaviruses	O
+.	O
+
+Currently	O
+,	O
+there	O
+are	O
+no	O
+approved	O
+vaccines	O
+or	O
+therapeutics	O
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+was	O
+used	O
+to	O
+detect	O
+H5N6	B-PRGE
+virus	I-PRGE
+RNA	I-PRGE
+in	O
+clinical	O
+and	O
+environment	O
+samples	O
+.	O
+
+The	O
+patient	O
+initially	O
+developed	O
+sore	B-DISO
+throat	I-DISO
+and	O
+coughs	B-DISO
+on	O
+27	O
+January	O
+2015	O
+.	O
+
+A	O
+total	O
+of	O
+1408	O
+patients	O
+were	O
+included	O
+;	O
+69	O
+.	O
+5	O
+%	O
+were	O
+male	O
+,	O
+78	O
+%	O
+had	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+22	O
+%	O
+had	O
+stable	O
+CAD	B-DISO
+.	O
+
+69	O
+.	O
+5	O
+%	O
+were	O
+male	O
+,	O
+78	O
+%	O
+had	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+22	O
+%	O
+had	O
+stable	O
+CAD	B-DISO
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+identified	O
+age	O
+,	O
+sex	O
+,	O
+body	B-ANAT
+mass	O
+index	O
+,	O
+and	O
+CABG	O
+as	O
+independent	O
+risk	O
+factors	O
+for	O
+severe	O
+SDB	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+Characterization	O
+of	O
+the	O
+ORF3	O
+and	O
+S1	O
+Genes	O
+of	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+Non	O
+S	O
+-	O
+INDEL	O
+Strains	O
+in	O
+Seven	O
+Regions	O
+of	O
+China	O
+,	O
+2015	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+an	O
+effort	B-PROC
+to	O
+trace	O
+the	O
+evolution	B-PROC
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+S1	B-PRGE
+and	I-PRGE
+ORF3	I-PRGE
+genes	I-PRGE
+of	O
+viruses	B-SPEC
+identified	O
+in	O
+41	O
+pig	B-SPEC
+farms	O
+from	O
+seven	O
+regions	O
+(	O
+North	O
+,	O
+Northeast	O
+,	O
+Northwest	O
+,	O
+Central	O
+,	O
+East	O
+,	O
+South	O
+West	O
+,	O
+and	O
+South	O
+,	O
+respectively	O
+)	O
+of	O
+China	O
+in	O
+2015	O
+were	O
+sequenced	O
+and	O
+analyzed	O
+.	O
+
+Neutrophil	B-PROC
+chemotaxis	I-PROC
+to	O
+ARDS	B-DISO
+BAL	B-ENZY
+fluid	O
+was	O
+evaluated	O
+and	O
+the	O
+contribution	O
+of	O
+each	O
+was	O
+assessed	O
+and	O
+compared	O
+with	O
+chemokine	O
+(	O
+C	O
+-	O
+X	O
+-	O
+C	O
+motif	O
+)	O
+ligand	B-PROC
+8	O
+(	O
+CXCL8	O
+).	O
+
+Furthermore	O
+,	O
+neutrophils	B-ANAT
+isolated	O
+from	O
+the	O
+blood	B-ANAT
+or	O
+BAL	B-ENZY
+fluid	O
+differentially	O
+regulated	O
+the	O
+cell	B-COMP
+surface	I-COMP
+expression	B-PROC
+of	O
+chemokine	B-PRGE
+(	I-PRGE
+C	I-PRGE
+-	I-PRGE
+X	I-PRGE
+-	I-PRGE
+C	I-PRGE
+motif	I-PRGE
+)	I-PRGE
+receptor	I-PRGE
+1	I-PRGE
+and	O
+C	B-PRGE
+-	I-PRGE
+C	I-PRGE
+chemokine	I-PRGE
+receptor	I-PRGE
+type	I-PRGE
+2	I-PRGE
+during	O
+ARDS	B-DISO
+.	O
+
+Furthermore	O
+,	O
+neutrophils	B-ANAT
+isolated	O
+from	O
+the	O
+blood	B-ANAT
+or	O
+BAL	B-ENZY
+fluid	O
+differentially	O
+regulated	O
+the	O
+cell	B-COMP
+surface	I-COMP
+expression	B-PROC
+of	O
+chemokine	B-PRGE
+(	I-PRGE
+C	I-PRGE
+-	I-PRGE
+X	I-PRGE
+-	I-PRGE
+C	I-PRGE
+motif	I-PRGE
+)	I-PRGE
+receptor	I-PRGE
+1	I-PRGE
+and	O
+C	B-PRGE
+-	I-PRGE
+C	I-PRGE
+chemokine	I-PRGE
+receptor	I-PRGE
+type	I-PRGE
+2	I-PRGE
+during	O
+ARDS	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+generated	O
+fused	O
+S1	O
+proteins	B-CHED
+with	O
+HA2	B-PRGE
+protein	B-CHED
+(	O
+rS1	B-PRGE
+-	I-PRGE
+HA2	I-PRGE
+)	O
+or	O
+transmembrane	B-COMP
+domain	O
+and	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+(	O
+rS1	O
+-	O
+H3	O
+(	O
+TM	O
+))	O
+from	O
+hemagglutinin	O
+of	O
+H3N2	B-CHED
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+The	O
+protection	O
+rates	O
+of	O
+groups	O
+immunized	O
+with	O
+rS1	O
+-	O
+HA2	O
+(	O
+87	O
+%)	O
+were	O
+significantly	O
+higher	O
+than	O
+the	O
+groups	O
+inoculated	O
+with	O
+rS1	B-PRGE
+(	O
+47	O
+%)	O
+and	O
+inactivated	O
+M41	O
+vaccine	O
+(	O
+53	O
+%).	O
+
+TITLE	O
+:	O
+Thin	O
+-	O
+Section	O
+Computed	O
+Tomography	O
+Manifestations	O
+During	O
+Convalescence	O
+and	O
+Long	O
+-	O
+Term	O
+Follow	O
+-	O
+Up	O
+of	O
+Patients	O
+with	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Therapeutic	O
+potential	O
+of	O
+recombinant	O
+thrombomodulin	B-PRGE
+for	O
+lung	B-ANAT
+injury	O
+after	O
+pneumonectomy	O
+via	O
+inhibition	B-PROC
+of	O
+high	B-PRGE
+-	I-PRGE
+mobility	I-PRGE
+group	I-PRGE
+box	I-PRGE
+1	I-PRGE
+in	O
+mice	B-SPEC
+.	O
+
+On	O
+histologic	O
+analysis	O
+,	O
+left	O
+pneumonectomy	O
+followed	O
+by	O
+LPS	O
+administration	O
+induced	O
+both	O
+severe	O
+inflammatory	O
+cellular	B-PROC
+infiltration	B-DISO
+and	O
+alveolar	B-ANAT
+wall	I-ANAT
+congestion	B-DISO
+with	O
+hemorrhage	B-DISO
+.	O
+
+Also	O
+,	O
+LPS	B-DISO
+alone	O
+showed	O
+no	O
+statistical	O
+differences	O
+in	O
+HMGB1	B-PRGE
+or	O
+proinflammatory	O
+cytokine	O
+level	O
+compared	O
+with	O
+pneumonectomy	O
+(	O
+PNX	O
+)	O
+group	O
+.	O
+
+RESULTS	O
+:	O
+On	O
+histologic	O
+analysis	O
+,	O
+left	O
+pneumonectomy	O
+followed	O
+by	O
+LPS	B-DISO
+administration	O
+induced	O
+both	O
+severe	O
+inflammatory	O
+cellular	B-PROC
+infiltration	B-DISO
+and	O
+alveolar	B-ANAT
+wall	I-ANAT
+congestion	B-DISO
+with	O
+hemorrhage	B-DISO
+.	O
+
+Broad	O
+-	O
+spectrum	O
+antibiotics	B-CHED
+were	O
+administered	O
+,	O
+including	O
+doxycycline	B-CHED
+,	O
+due	O
+to	O
+a	O
+high	O
+suspicion	O
+of	O
+leptospirosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Assessment	O
+of	O
+the	O
+risk	O
+posed	O
+to	O
+Singapore	O
+by	O
+the	O
+2015	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+outbreak	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+.	O
+
+Nonetheless	O
+,	O
+the	O
+risk	O
+of	O
+a	O
+serious	O
+public	O
+health	O
+impact	O
+to	O
+Singapore	O
+in	O
+the	O
+event	O
+of	O
+an	O
+imported	O
+case	O
+of	O
+MERS	O
+would	O
+be	O
+mitigated	O
+by	O
+its	O
+strong	O
+health	O
+-	O
+care	O
+system	O
+and	O
+established	O
+infection	B-DISO
+control	O
+practices	O
+.	O
+
+The	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+induced	O
+by	O
+LPS	B-DISO
+can	O
+cause	O
+extensive	O
+damage	O
+to	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+the	O
+severe	O
+stage	O
+of	O
+which	O
+is	O
+termed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+when	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+may	O
+appear	O
+.	O
+
+This	O
+evaluation	O
+demonstrates	O
+that	O
+the	O
+use	O
+of	O
+TOF	O
+monitoring	O
+for	O
+neuromuscular	B-DISO
+blockade	I-DISO
+does	O
+not	O
+correlate	O
+with	O
+gas	B-ENZY
+exchange	O
+markers	O
+in	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+378	O
+patients	O
+were	O
+screened	O
+for	O
+inclusion	O
+,	O
+with	O
+107	O
+evaluable	B-DISO
+patients	O
+meeting	O
+criteria	O
+at	O
+baseline	O
+.	O
+
+TITLE	O
+:	O
+Inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+thrombosis	I-DISO
+as	O
+a	O
+cause	O
+of	O
+haemolysis	B-DISO
+in	O
+a	O
+patient	O
+on	O
+ECMO	O
+.	O
+
+This	O
+case	O
+report	O
+outlines	O
+an	O
+unusual	O
+case	O
+of	O
+haemolysis	B-DISO
+,	O
+thought	O
+secondary	O
+to	O
+a	O
+large	O
+mobile	O
+thrombus	B-DISO
+in	O
+the	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+is	O
+a	O
+disease	O
+of	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+is	O
+characterized	O
+by	O
+high	O
+mortality	O
+.	O
+
+It	O
+is	O
+caused	O
+by	O
+a	O
+beta	O
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+)	O
+referred	O
+to	O
+as	O
+MERS	O
+-	O
+CoV	B-SPEC
+.	O
+Majority	O
+of	O
+MERS	O
+-	O
+CoV	O
+cases	O
+have	O
+been	O
+reported	O
+from	O
+Saudi	O
+Arabia	O
+.	O
+
+A	O
+total	O
+of	O
+23	O
+Saudi	O
+patients	O
+with	O
+severe	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+were	O
+typed	O
+for	O
+HLA	B-PRGE
+class	B-SPEC
+II	O
+,	O
+results	O
+were	O
+compared	O
+with	O
+those	O
+of	O
+161	O
+healthy	O
+controls	O
+.	O
+
+Peripheral	B-ANAT
+blood	I-ANAT
+eosinophilia	B-DISO
+is	O
+common	O
+but	O
+may	O
+be	O
+absent	O
+at	O
+presentation	O
+in	O
+idiopathic	O
+acute	B-DISO
+eosinophilic	I-DISO
+pneumonia	I-DISO
+,	O
+which	O
+may	O
+be	O
+misdiagnosed	O
+as	O
+severe	O
+infectious	B-DISO
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+RNA	O
+Helicases	O
+of	O
+ssRNA	O
+(+)	O
+Virus	B-SPEC
+Belonging	O
+to	O
+Flaviviridae	B-SPEC
+,	O
+Coronaviridae	B-SPEC
+and	O
+Picornaviridae	B-SPEC
+Families	O
+.	O
+
+RESULTS	O
+:	O
+Based	O
+on	O
+our	O
+results	O
+,	O
+in	O
+the	O
+second	O
+group	O
+,	O
+IBV	B-SPEC
+vaccine	O
+strain	O
+(	O
+4	O
+/	O
+91	O
+)	O
+at	O
+all	O
+titration	O
+and	O
+M41	O
+in	O
+10	O
+(-	O
+2	O
+)	O
+and	O
+10	O
+(-	O
+3	O
+)	O
+titration	O
+and	O
+in	O
+the	O
+third	O
+group	O
+both	O
+variants	O
+of	O
+virus	B-SPEC
+the	O
+embryonic	B-ANAT
+Index	O
+(	O
+EI	O
+)	O
+was	O
+significantly	O
+increased	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+garlic	B-SPEC
+extract	O
+had	O
+inhibitory	O
+effects	O
+on	O
+IBV	B-SPEC
+in	O
+the	O
+chickens	B-SPEC
+embryo	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+the	O
+biased	O
+nucleotide	B-CHED
+composition	O
+of	O
+viral	O
+RNA	O
+genomes	O
+on	O
+RNA	O
+structure	O
+and	O
+codon	O
+usage	O
+.	O
+
+Without	O
+exception	O
+,	O
+the	O
+virus	B-SPEC
+-	O
+specific	O
+nucleotide	B-CHED
+bias	B-SPEC
+was	O
+enriched	O
+in	O
+the	O
+unpaired	O
+,	O
+single	O
+-	O
+stranded	O
+regions	O
+of	O
+the	O
+RNA	O
+genome	O
+,	O
+thus	O
+creating	O
+an	O
+even	O
+more	O
+striking	O
+virus	B-SPEC
+-	O
+specific	O
+signature	O
+.	O
+
+TITLE	O
+:	O
+Predictive	O
+factors	O
+for	O
+pneumonia	B-DISO
+development	B-PROC
+and	O
+progression	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+MERS	O
+-	O
+CoV	O
+infected	O
+patients	O
+.	O
+
+For	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+the	O
+indicators	O
+included	O
+male	O
+,	O
+hypertension	B-DISO
+,	O
+low	O
+albumin	B-PRGE
+concentration	O
+,	O
+thrombocytopenia	O
+,	O
+lymphopenia	B-DISO
+,	O
+and	O
+CRP	B-PRGE
+≥	O
+4	O
+mg	O
+/	O
+dL	O
+(	O
+all	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+With	O
+≥	O
+two	O
+predictive	O
+factors	O
+for	O
+pneumonia	B-DISO
+development	B-PROC
+,	O
+100	O
+%	O
+of	O
+patients	O
+developed	O
+pneumonia	B-DISO
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+had	O
+larger	O
+%	O
+TBSA	O
+burns	O
+[	O
+30	O
+.	O
+5	O
+(	O
+23	O
+.	O
+1	O
+-	O
+47	O
+.	O
+0	O
+)	O
+vs	O
+.	O
+24	O
+.	O
+8	O
+(	O
+17	O
+.	O
+1	O
+-	O
+35	O
+),	O
+p	O
+=	O
+0	O
+.	O
+007	O
+],	O
+larger	O
+FT	O
+burns	O
+[	O
+20	O
+.	O
+5	O
+(	O
+5	O
+.	O
+4	O
+-	O
+35	O
+.	O
+5	O
+)	O
+vs	O
+.	O
+7	O
+(	O
+0	O
+-	O
+22	O
+.	O
+1	O
+),	O
+p	O
+=	O
+0	O
+.	O
+001	O
+],	O
+but	O
+had	O
+no	O
+significant	O
+difference	O
+in	O
+the	O
+incidence	O
+of	O
+inhalation	B-PROC
+injury	O
+(	O
+p	O
+=	O
+0	O
+.	O
+216	O
+),	O
+compared	O
+to	O
+those	O
+without	O
+ARDS	B-DISO
+.	O
+
+ARDS	B-DISO
+is	O
+common	O
+among	O
+mechanically	O
+ventilated	O
+civilian	O
+burn	O
+patients	O
+,	O
+and	O
+develops	O
+early	O
+after	O
+burn	O
+.	O
+
+We	O
+addressed	O
+this	O
+problem	O
+by	O
+using	O
+the	O
+-	O
+1	O
+PRF	O
+stimulation	O
+pseudoknot	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+SARS	B-PRGE
+-	I-PRGE
+PK	I-PRGE
+)	O
+to	O
+build	O
+a	O
+ligand	B-PROC
+-	O
+dependent	O
+-	O
+1	O
+PRF	O
+stimulator	O
+.	O
+
+Conformational	O
+and	O
+functional	O
+analyses	O
+indicate	O
+that	O
+the	O
+engineered	O
+theophylline	B-CHED
+-	O
+responsive	O
+RNA	O
+functions	O
+as	O
+a	O
+mammalian	B-SPEC
+riboswitch	O
+with	O
+robust	O
+theophylline	B-CHED
+-	O
+dependent	O
+-	O
+1	O
+PRF	O
+stimulation	O
+activity	O
+in	O
+a	O
+stable	O
+human	B-SPEC
+293T	O
+cell	B-COMP
+-	O
+line	O
+.	O
+
+TITLE	O
+:	O
+Critical	O
+care	O
+ultrasonography	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+A	O
+pragmatic	O
+strategy	O
+based	O
+on	O
+the	O
+serial	O
+use	O
+of	O
+CCUS	O
+for	O
+the	O
+management	O
+of	O
+patients	O
+presenting	O
+with	O
+ARF	B-DISO
+of	O
+various	O
+origins	O
+is	O
+detailed	O
+in	O
+the	O
+present	O
+manuscript	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+surveillance	O
+of	O
+traditional	O
+and	O
+emerging	O
+pathogens	O
+associated	O
+with	O
+canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+(	O
+CPIV	O
+)	O
+was	O
+the	O
+most	O
+commonly	O
+detected	O
+CIRD	O
+pathogen	O
+,	O
+followed	O
+by	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+),	O
+Bordetella	B-SPEC
+bronchiseptica	I-SPEC
+,	O
+Mycoplasma	B-SPEC
+cynos	I-SPEC
+,	O
+Mycoplasma	B-SPEC
+canis	I-SPEC
+and	O
+canine	O
+pneumovirus	B-SPEC
+(	O
+CnPnV	O
+).	O
+
+Our	O
+results	O
+indicated	O
+that	O
+PEDV	B-SPEC
+is	O
+circulating	O
+in	O
+the	O
+wild	B-SPEC
+boar	I-SPEC
+and	O
+provided	O
+a	O
+novel	O
+knowledge	O
+into	O
+epidemiology	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+decipher	O
+the	O
+molecular	O
+epidemiological	O
+and	O
+antigenic	O
+characteristics	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+strains	O
+(	O
+IBVs	O
+)	O
+isolated	O
+in	O
+recent	O
+years	O
+in	O
+southwestern	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Prolonged	O
+Glucocorticoid	B-CHED
+Treatment	O
+in	O
+ARDS	B-DISO
+:	O
+
+In	O
+addition	O
+,	O
+NF	O
+-	O
+κB	O
+-	O
+mediated	O
+signaling	B-PROC
+plays	O
+a	O
+significant	O
+role	O
+in	O
+mechanical	O
+ventilation	O
+-	O
+induced	O
+diaphragmatic	B-ANAT
+atrophy	B-DISO
+and	O
+contractile	B-PROC
+dysfunction	O
+.	O
+
+Extrapolating	O
+data	O
+from	O
+the	O
+adult	O
+population	O
+to	O
+the	O
+pediatric	O
+population	O
+is	O
+complicated	O
+as	O
+we	O
+know	O
+that	O
+physiology	O
+and	O
+the	O
+body	B-ANAT
+'	O
+s	O
+response	O
+to	O
+disease	O
+can	O
+be	O
+different	O
+between	O
+adult	O
+and	O
+pediatric	O
+patients	O
+.	O
+
+There	O
+are	O
+physiologic	O
+studies	O
+that	O
+suggest	O
+alternative	O
+mechanisms	O
+for	O
+explaining	O
+the	O
+positive	O
+effects	O
+of	O
+iNO	O
+,	O
+such	O
+as	O
+platelet	B-PROC
+aggregation	I-PROC
+inhibition	B-PROC
+and	O
+reduction	O
+in	O
+systemic	O
+inflammation	B-DISO
+.	O
+
+Undertaking	O
+clinical	O
+trials	O
+of	O
+convalescent	O
+plasma	B-ANAT
+for	O
+passive	O
+immunotherapy	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+may	O
+be	O
+feasible	O
+,	O
+but	O
+such	O
+trials	O
+would	O
+be	O
+challenging	O
+because	O
+of	O
+the	O
+small	O
+pool	O
+of	O
+potential	O
+donors	O
+with	O
+sufficiently	O
+high	O
+antibody	B-COMP
+titers	O
+.	O
+
+Alternative	O
+strategies	O
+to	O
+identify	O
+convalescent	O
+plasma	O
+donors	O
+with	O
+adequate	O
+antibody	B-COMP
+titers	O
+should	O
+be	O
+explored	O
+,	O
+including	O
+the	O
+sampling	O
+of	O
+serum	B-COMP
+from	O
+patients	O
+with	O
+more	O
+severe	O
+disease	O
+and	O
+sampling	O
+at	O
+earlier	O
+points	O
+during	O
+illness	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+repeatedly	O
+caused	O
+outbreaks	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+Therefore	O
+,	O
+the	O
+present	O
+work	O
+focused	O
+on	O
+the	O
+expression	B-PROC
+of	O
+the	O
+EC	O
+adhesion	B-DISO
+molecules	O
+and	O
+possible	O
+triggers	O
+of	O
+EC	O
+activation	O
+during	O
+the	O
+development	B-PROC
+of	O
+FIP	B-DISO
+.	O
+
+A	O
+multiple	O
+logistic	O
+regression	O
+model	O
+identified	O
+9	O
+independent	O
+parameters	O
+that	O
+were	O
+used	O
+to	O
+construct	O
+the	O
+MSTFI	O
+:	O
+anemia	B-DISO
+,	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+,	O
+coagulopathy	B-DISO
+,	O
+electrolyte	O
+abnormalities	O
+,	O
+pulmonary	B-PROC
+circulation	B-PROC
+disorders	O
+,	O
+renal	B-DISO
+failure	I-DISO
+,	O
+malnutrition	B-DISO
+,	O
+emergent	O
+/	O
+urgent	O
+admission	O
+,	O
+and	O
+anterior	O
+/	O
+combined	O
+surgical	O
+approach	O
+.	O
+
+In	O
+surgically	O
+treated	O
+patients	O
+with	O
+spinal	O
+metastasis	B-DISO
+,	O
+certain	O
+perioperative	O
+parameters	O
+may	O
+significantly	O
+predict	O
+the	O
+risk	O
+of	O
+major	O
+in	O
+-	O
+hospital	O
+complications	O
+and	O
+mortality	O
+.	O
+
+This	O
+manuscript	O
+reviews	O
+the	O
+status	O
+of	O
+PEDV	B-SPEC
+vaccines	O
+available	O
+in	O
+the	O
+United	O
+States	O
+and	O
+Canada	O
+,	O
+and	O
+describes	O
+an	O
+experiment	O
+evaluating	O
+the	O
+potential	O
+use	O
+of	O
+young	O
+pigs	O
+as	O
+a	O
+surrogate	O
+model	O
+to	O
+evaluate	O
+potential	O
+sow	O
+vaccines	O
+.	O
+
+RESULTS	O
+:	O
+Syndecan	B-PRGE
+-	I-PRGE
+1	I-PRGE
+was	O
+measured	O
+in	O
+175	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+Nafamostat	O
+as	O
+a	O
+Potent	O
+Inhibitor	B-CHED
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+S	O
+Protein	B-CHED
+-	O
+Mediated	O
+Membrane	B-PROC
+Fusion	I-PROC
+Using	O
+the	O
+Split	O
+-	O
+Protein	B-CHED
+-	O
+Based	O
+Cell	B-PROC
+-	I-PROC
+Cell	B-COMP
+Fusion	I-PROC
+Assay	O
+.	O
+
+Here	O
+,	O
+we	O
+developed	O
+a	O
+cell	B-COMP
+-	O
+based	O
+fusion	O
+assay	O
+for	O
+S	O
+in	O
+a	O
+TMPRSS2	O
+-	O
+dependent	O
+manner	O
+using	O
+cell	O
+lines	O
+expressing	O
+Renilla	B-SPEC
+luciferase	B-ENZY
+(	O
+RL	O
+)-	O
+based	O
+split	O
+reporter	O
+proteins	B-CHED
+.	O
+
+Nafamostat	O
+also	O
+blocked	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+vitro	O
+Our	O
+assay	O
+has	O
+the	O
+potential	O
+to	O
+facilitate	O
+the	O
+discovery	O
+of	O
+new	O
+inhibitors	B-CHED
+of	O
+membrane	B-PROC
+fusion	I-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+as	O
+well	O
+as	O
+other	O
+viruses	B-SPEC
+that	O
+rely	O
+on	O
+the	O
+activity	O
+of	O
+TMPRSS2	O
+.	O
+
+Transmissible	O
+gastroenteritis	B-DISO
+is	O
+an	O
+acute	O
+enteric	O
+disease	O
+of	O
+swine	B-SPEC
+that	O
+is	O
+caused	O
+by	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+The	O
+establishment	O
+and	O
+characteristics	O
+of	O
+cell	B-COMP
+-	O
+adapted	O
+IBV	B-SPEC
+strain	O
+H120	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	O
+is	O
+an	O
+important	O
+pathogen	O
+in	O
+poultry	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Antagonism	O
+of	O
+RNase	B-PRGE
+L	I-PRGE
+Is	O
+Required	O
+for	O
+Murine	B-SPEC
+Coronavirus	I-SPEC
+Replication	O
+in	O
+Kupffer	B-ANAT
+Cells	I-ANAT
+and	O
+Liver	B-ANAT
+Sinusoidal	O
+Endothelial	B-ANAT
+Cells	I-ANAT
+but	O
+Not	O
+in	O
+Hepatocytes	B-ANAT
+.	O
+
+Three	O
+intramuscular	O
+(	O
+IM	O
+)	O
+immunizations	O
+with	O
+the	O
+recombinant	O
+ORFV	O
+-	O
+PEDV	B-SPEC
+-	O
+S	O
+in	O
+3	O
+-	O
+week	O
+-	O
+old	O
+pigs	B-SPEC
+elicited	O
+robust	O
+serum	B-COMP
+IgG	B-PRGE
+,	O
+IgA	B-PRGE
+and	O
+neutralizing	O
+antibody	B-PROC
+responses	I-PROC
+against	O
+PEDV	B-SPEC
+.	O
+
+Inhibiting	O
+GSK	B-PRGE
+-	I-PRGE
+3α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+,	O
+one	O
+of	O
+the	O
+downstream	O
+effectors	O
+of	O
+PI3K	B-FUNC
+/	O
+Akt	B-PRGE
+pathway	B-PROC
+and	O
+regulated	O
+by	O
+Akt	B-PRGE
+during	O
+PEDV	B-SPEC
+infected	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+also	O
+enhanced	O
+PEDV	B-SPEC
+replication	O
+.	O
+
+Not	O
+all	O
+suspicious	O
+cases	O
+of	O
+influenza	B-DISO
+are	O
+confirmed	O
+;	O
+however	O
+,	O
+all	O
+patients	O
+need	O
+treatment	O
+and	O
+generate	O
+additional	O
+costs	O
+to	O
+the	O
+institutions	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+continuing	O
+circulation	B-PROC
+of	O
+MERS	O
+in	O
+the	O
+Middle	O
+East	O
+makes	O
+the	O
+international	O
+dissemination	O
+of	O
+the	O
+disease	O
+a	O
+permanent	O
+threat	O
+.	O
+
+We	O
+modelled	O
+importations	O
+in	O
+time	O
+based	O
+on	O
+air	B-CHED
+travel	O
+combined	O
+with	O
+incidence	O
+in	O
+Middle	O
+East	O
+.	O
+
+Countries	O
+at	O
+risk	O
+of	O
+importation	O
+should	O
+focus	O
+their	O
+resources	O
+on	O
+strict	O
+infection	B-DISO
+control	O
+measures	O
+for	O
+the	O
+management	O
+of	O
+potential	O
+cases	O
+in	O
+healthcare	O
+settings	O
+and	O
+on	O
+prompt	O
+MERS	O
+cases	O
+identification	O
+.	O
+
+From	O
+September	O
+to	O
+December	O
+2014	O
+,	O
+NHs	B-DISO
+in	O
+Corsica	O
+were	O
+invited	O
+to	O
+participate	O
+in	O
+an	O
+ongoing	O
+daily	O
+epidemiological	O
+and	O
+microbiological	O
+surveillance	O
+for	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+among	O
+residents	O
+and	O
+health	O
+care	O
+workers	O
+(	O
+HCWs	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+study	O
+involved	O
+12	O
+NHs	B-DISO
+.	O
+
+Although	O
+antivirals	B-CHED
+were	O
+available	O
+,	O
+prophylaxis	O
+was	O
+not	O
+used	O
+.	O
+
+TITLE	O
+:	O
+Trend	O
+and	O
+manifestations	O
+of	O
+falciparum	B-DISO
+malaria	I-DISO
+in	O
+a	O
+tertiary	O
+care	O
+hospital	O
+of	O
+India	O
+.	O
+
+The	O
+data	O
+were	O
+collected	O
+on	O
+demographic	O
+and	O
+time	O
+characteristics	O
+,	O
+clinical	O
+and	O
+laboratory	O
+findings	O
+,	O
+the	O
+outcome	O
+of	O
+disease	O
+and	O
+expressed	B-PROC
+in	O
+proportion	O
+or	O
+percentages	O
+.	O
+
+Manifestations	O
+of	O
+severe	O
+falciparum	B-DISO
+malaria	I-DISO
+included	O
+hepatopathy	B-DISO
+(	O
+38	O
+%),	O
+renal	B-DISO
+failure	I-DISO
+(	O
+28	O
+%),	O
+shock	O
+(	O
+9	O
+%),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+7	O
+%),	O
+hypoglycemia	B-DISO
+(	O
+3	O
+%),	O
+and	O
+severe	B-DISO
+anemia	I-DISO
+(	O
+1	O
+%).	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+and	O
+morbidity	O
+.	O
+
+Here	O
+,	O
+we	O
+employed	O
+isobaric	O
+tags	O
+for	O
+relative	O
+and	O
+absolute	O
+quantitation	O
+(	O
+iTRAQ	O
+)	O
+technology	O
+to	O
+identify	O
+potential	O
+biomarkers	O
+for	O
+early	O
+ARDS	B-DISO
+diagnosis	O
+and	O
+predict	O
+the	O
+risk	O
+for	O
+increased	O
+disease	O
+severity	O
+induced	O
+by	O
+pneumonia	B-DISO
+.	O
+
+Our	O
+results	O
+indicate	O
+that	O
+DMBT1	B-PRGE
+can	O
+potentially	O
+serve	O
+as	O
+a	O
+biomarker	B-CHED
+for	O
+early	O
+ARDS	B-DISO
+diagnosis	O
+and	O
+disease	O
+severity	O
+assessment	O
+.	O
+
+It	O
+indicated	O
+that	O
+the	O
+CK	O
+/	O
+CH	O
+/	O
+XDC	O
+-	O
+2	O
+/	O
+2013	O
+isolate	O
+has	O
+robust	O
+kidney	B-ANAT
+tissue	B-PROC
+tropism	B-PROC
+,	O
+and	O
+new	O
+nephropathogenic	O
+IBV	B-SPEC
+strains	O
+are	O
+continuously	O
+evolving	O
+in	O
+China	O
+.	O
+
+To	O
+successfully	O
+decrease	O
+mortality	O
+for	O
+severe	O
+CAP	B-DISO
+,	O
+early	O
+and	O
+close	O
+collaboration	O
+between	O
+emergency	B-DISO
+medicine	B-CHED
+and	O
+respiratory	O
+and	O
+critical	O
+care	O
+medicine	B-CHED
+teams	O
+is	O
+required	O
+.	O
+
+MERS	O
+is	O
+often	O
+complicated	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+(	O
+1	O
+,	O
+2	O
+).	O
+
+The	O
+high	O
+incidence	O
+of	O
+renal	B-DISO
+failure	I-DISO
+in	O
+MERS	O
+is	O
+a	O
+unique	O
+clinical	O
+feature	O
+not	O
+often	O
+found	O
+in	O
+other	O
+human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+(	O
+3	O
+,	O
+4	O
+).	O
+
+Here	O
+,	O
+we	O
+demonstrated	O
+renal	B-DISO
+infection	I-DISO
+and	O
+apoptotic	O
+induction	O
+by	O
+MERS	O
+-	O
+CoV	O
+in	O
+human	B-SPEC
+ex	O
+vivo	O
+organ	B-ANAT
+culture	O
+and	O
+a	O
+nonhuman	O
+primate	B-SPEC
+model	O
+.	O
+
+RESULTS	O
+:	O
+Ten	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+were	O
+included	O
+.	O
+
+The	O
+transition	B-DISO
+from	O
+prefusion	O
+to	O
+postfusion	O
+conformation	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+must	O
+be	O
+triggered	O
+,	O
+leading	O
+to	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+Mild	O
+to	O
+severe	O
+atrophic	B-DISO
+enteritis	B-DISO
+with	O
+PDCoV	B-PRGE
+antigen	I-PRGE
+staining	O
+was	O
+observed	O
+in	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+of	O
+affected	O
+piglets	O
+from	O
+2	O
+to	O
+8	O
+dpi	O
+.	O
+
+There	O
+was	O
+a	O
+difference	O
+in	O
+the	O
+worry	O
+and	O
+fear	O
+scale	O
+of	O
+contracting	O
+the	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+between	O
+participants	O
+who	O
+worked	O
+in	O
+areas	O
+likely	O
+to	O
+admit	O
+and	O
+have	O
+MERS	O
+-	O
+CoV	O
+suspected	O
+or	O
+positive	O
+cases	O
+.	O
+
+However	O
+,	O
+they	O
+soon	O
+relapsed	O
+,	O
+which	O
+eventually	O
+led	O
+to	O
+complete	O
+tetraplegia	B-DISO
+and	O
+the	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+.	O
+
+She	O
+frequently	O
+developed	O
+sepsis	B-DISO
+;	O
+therefore	O
+,	O
+we	O
+could	O
+no	O
+longer	O
+continue	O
+any	O
+immunosupressive	O
+therapies	O
+,	O
+but	O
+monthly	O
+IVIg	O
+administrations	O
+were	O
+given	O
+.	O
+
+Eighteen	O
+months	O
+after	O
+admission	O
+,	O
+her	O
+muscle	B-PROC
+strength	I-PROC
+corresponded	O
+to	O
+2	O
+on	O
+manual	O
+muscle	B-ANAT
+testing	O
+,	O
+and	O
+wheelchair	O
+transfer	O
+became	O
+possible	O
+.	O
+
+TITLE	O
+:	O
+Synbiotics	O
+suppress	O
+the	O
+release	B-PATH
+of	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+,	O
+promote	O
+non	B-PROC
+-	I-PROC
+specific	I-PROC
+immunity	I-PROC
+and	O
+integrity	O
+of	O
+jejunum	O
+mucosa	O
+in	O
+piglets	O
+.	O
+
+The	O
+impact	O
+of	O
+such	O
+additives	O
+on	O
+the	O
+release	B-PATH
+of	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+;	O
+spectroscopic	O
+and	O
+electrophoretic	O
+assay	O
+),	O
+alteration	O
+of	O
+immunity	B-PROC
+(	O
+index	O
+of	O
+metabolic	B-PROC
+activity	O
+),	O
+jejunum	B-ANAT
+histology	O
+(	O
+light	O
+microscopy	O
+),	O
+and	O
+health	O
+of	O
+conventional	O
+piglets	O
+from	O
+a	O
+problematic	O
+breed	O
+(	O
+monitoring	O
+of	O
+hematology	O
+,	O
+consistency	O
+and	O
+moisture	O
+of	O
+feces	B-ANAT
+and	O
+body	B-ANAT
+temperature	O
+)	O
+were	O
+examined	O
+.	O
+
+We	O
+found	O
+significant	O
+decrease	O
+in	O
+LDH	B-PRGE
+leakage	B-DISO
+in	O
+the	O
+blood	B-COMP
+serum	I-COMP
+and	O
+tissue	B-ANAT
+extracts	O
+,	O
+indicating	O
+better	O
+cell	B-COMP
+membrane	I-COMP
+integrity	O
+in	O
+the	O
+individual	O
+organs	B-ANAT
+of	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+review	O
+of	O
+treatment	O
+modalities	O
+for	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+.	O
+
+Corticosteroids	B-CHED
+,	O
+ribavirin	B-CHED
+monotherapy	O
+and	O
+mycophenolic	B-CHED
+acid	I-CHED
+likely	O
+have	O
+toxicities	O
+that	O
+exceed	O
+potential	O
+benefits	O
+.	O
+
+TITLE	O
+:	O
+Critically	B-DISO
+ill	I-DISO
+obstetric	O
+patients	O
+requiring	O
+mechanical	O
+ventilation	O
+in	O
+rural	O
+western	O
+India	O
+:	O
+A	O
+retrospective	O
+analysis	O
+.	O
+
+We	O
+analysed	O
+factors	O
+that	O
+influence	O
+seeking	O
+of	O
+antenatal	O
+care	O
+,	O
+pregnancy	O
+and	O
+its	O
+complications	O
+,	O
+severity	O
+assessment	O
+score	O
+,	O
+indications	O
+and	O
+initiation	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+multiorgan	B-DISO
+failure	I-DISO
+and	O
+their	O
+correlation	O
+with	O
+maternal	O
+mortality	O
+.	O
+
+Of	O
+the	O
+6708	O
+obstetric	O
+admissions	O
+studied	O
+,	O
+1112	O
+were	O
+of	O
+critically	B-DISO
+ill	I-DISO
+(	O
+16	O
+.	O
+5	O
+%)	O
+patients	O
+and	O
+200	O
+(	O
+17	O
+%)	O
+of	O
+these	O
+required	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+common	O
+indications	O
+for	O
+mechanical	O
+ventilation	O
+were	O
+pulmonary	B-DISO
+oedema	I-DISO
+,	O
+ARDS	B-DISO
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Distribution	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strains	O
+in	O
+different	O
+organs	B-ANAT
+and	O
+evidence	O
+of	O
+vertical	B-DISO
+transmission	I-DISO
+in	O
+natural	O
+infection	B-DISO
+.	O
+
+Additionally	O
+,	O
+a	O
+fragment	O
+of	O
+viral	O
+RNA	O
+with	O
+that	O
+was	O
+completely	O
+identical	O
+to	O
+the	O
+corresponding	O
+region	O
+of	O
+the	O
+Ma5	O
+vaccine	O
+was	O
+detected	O
+in	O
+the	O
+allantoic	B-ANAT
+fluid	I-ANAT
+of	O
+viable	O
+embryos	B-ANAT
+from	O
+the	O
+hens	O
+under	O
+study	O
+after	O
+18	O
+days	O
+of	O
+incubation	O
+.	O
+
+Samples	O
+were	O
+pre	O
+-	O
+screened	O
+,	O
+using	O
+a	O
+quantitative	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	O
+chain	O
+reaction	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+multiprobe	O
+for	O
+coronavirus	B-SPEC
+,	O
+and	O
+subjected	O
+to	O
+confirmatory	O
+pancoronavirus	O
+and	O
+/	O
+or	O
+strain	O
+-	O
+specific	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+)-	O
+PCR	O
+followed	O
+by	O
+sequence	O
+analysis	O
+.	O
+
+The	O
+most	O
+frequent	O
+strain	O
+detected	O
+was	O
+HCoV	B-PRGE
+-	I-PRGE
+OC43	I-PRGE
+-	I-PRGE
+like	I-PRGE
+followed	O
+by	O
+NL63	O
+-	O
+like	O
+;	O
+only	O
+one	O
+sample	O
+was	O
+positive	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+one	O
+for	O
+HCoV	O
+-	O
+HKU1	O
+.	O
+
+These	O
+droplets	O
+or	O
+droplet	O
+nuclei	B-CHED
+are	O
+transported	O
+by	O
+expired	O
+airflows	O
+,	O
+which	O
+are	O
+sometimes	O
+affected	O
+by	O
+the	O
+human	B-ANAT
+body	I-ANAT
+plume	O
+and	O
+use	O
+of	O
+a	O
+face	B-DISO
+mask	O
+,	O
+as	O
+well	O
+as	O
+room	O
+airflow	B-PROC
+.	O
+
+We	O
+have	O
+shown	O
+the	O
+opportunities	O
+for	O
+infection	B-DISO
+control	O
+at	O
+different	O
+stages	O
+of	O
+the	O
+spread	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+collected	O
+through	O
+brachial	B-ANAT
+vein	I-ANAT
+at	O
+the	O
+end	O
+of	O
+wk	O
+16	O
+.	O
+
+Interaction	O
+of	O
+SN	O
+with	O
+FR	O
+revealed	O
+maximum	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+cholesterol	B-CHED
+whereas	O
+interaction	O
+of	O
+PW	O
+with	O
+SI	O
+indicated	O
+maximum	O
+antibody	B-COMP
+titer	O
+against	O
+NDV	B-SPEC
+.	O
+
+Birds	B-SPEC
+of	O
+PW	O
+variety	O
+indicated	O
+higher	O
+glucose	B-CHED
+,	O
+total	O
+protein	B-CHED
+,	O
+albumin	B-PRGE
+,	O
+uric	B-CHED
+acid	I-CHED
+,	O
+and	O
+creatinine	B-CHED
+,	O
+the	O
+lowest	O
+cholesterol	B-CHED
+under	O
+FR	O
+and	O
+the	O
+enhanced	O
+antibody	B-COMP
+titer	O
+against	O
+NDV	B-SPEC
+and	O
+IBV	B-SPEC
+.	O
+
+ECMO	O
+oxygenation	B-PROC
+did	O
+not	O
+explain	O
+PF	O
+ratio	O
+variation	O
+that	O
+remained	O
+stable	O
+in	O
+PF	O
+-	O
+d	O
+and	O
+decreased	O
+in	O
+PF	O
+-	O
+i	O
+(	O
+198	O
+±	O
+12	O
+.	O
+7	O
+mL	O
+/	O
+min	O
+versus	O
+171	O
+±	O
+8	O
+.	O
+8	O
+mL	O
+/	O
+min	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+observe	O
+the	O
+occurrence	O
+rate	O
+of	O
+elevated	O
+serum	B-PRGE
+amylase	I-PRGE
+and	O
+lipase	B-PRGE
+in	O
+critically	B-DISO
+ill	I-DISO
+children	O
+,	O
+to	O
+explore	O
+the	O
+relationship	O
+between	O
+elevated	O
+pancreatic	B-ANAT
+enzymes	O
+and	O
+pancreatic	B-ANAT
+injury	O
+,	O
+and	O
+the	O
+effect	O
+of	O
+elevated	O
+pancreatic	B-ANAT
+enzymes	O
+on	O
+state	O
+of	O
+illness	O
+and	O
+the	O
+prognosis	O
+.	O
+
+The	O
+cases	O
+were	O
+divided	O
+into	O
+three	O
+groups	O
+:	O
+the	O
+control	O
+group	O
+(	O
+amylase	B-PRGE
+or	O
+lipase	B-PRGE
+were	O
+normal	O
+),	O
+mildly	O
+elevated	O
+group	O
+(	O
+1	O
+time	O
+<	O
+increase	O
+of	O
+serum	B-COMP
+amylase	B-PRGE
+or	O
+<	O
+3	O
+times	O
+increase	O
+of	O
+lipase	B-PRGE
+),	O
+highly	O
+elevated	O
+group	O
+(	O
+serum	B-PRGE
+amylase	I-PRGE
+or	O
+lipase	B-PRGE
+increased	O
+>	O
+3	O
+times	O
+).	O
+
+The	O
+risk	O
+factors	O
+of	O
+elevated	O
+amylase	B-PRGE
+or	O
+lipase	B-PRGE
+were	O
+analyzed	O
+by	O
+Logistic	O
+regression	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Complex	O
+control	O
+of	O
+the	O
+source	O
+of	O
+infection	B-DISO
+in	O
+sepsis	B-DISO
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+as	O
+a	O
+bridging	O
+concept	O
+for	O
+tracheal	O
+fistula	O
+repair	B-PROC
+in	O
+sepsis	B-DISO
+-	O
+associated	O
+ARDS	B-DISO
+].	O
+
+Using	O
+detailed	O
+mainland	O
+China	O
+epidemiological	O
+data	O
+,	O
+we	O
+study	O
+spatiotemporal	O
+aspects	O
+of	O
+this	O
+person	O
+-	O
+to	O
+-	O
+person	O
+contagious	B-DISO
+disease	I-DISO
+and	O
+simulate	O
+its	O
+spatiotemporal	O
+transmission	O
+dynamics	O
+via	O
+the	O
+Bayesian	O
+Maximum	O
+Entropy	O
+(	O
+BME	O
+)	O
+method	O
+.	O
+
+Nineteen	O
+mechanically	O
+ventilated	O
+patients	O
+underwent	O
+six	O
+consecutive	O
+ventilatory	O
+conditions	O
+:	O
+three	O
+on	O
+volume	O
+assist	O
+-	O
+control	O
+(	O
+VC	O
+)	O
+mode	O
+,	O
+each	O
+with	O
+set	O
+Vt	O
+of	O
+6	O
+,	O
+7	O
+.	O
+5	O
+,	O
+and	O
+9	O
+ml	O
+/	O
+kg	O
+,	O
+and	O
+three	O
+on	O
+adaptive	O
+pressure	O
+-	O
+control	O
+(	O
+APC	B-COMP
+)	O
+mode	O
+,	O
+with	O
+those	O
+same	O
+set	O
+Vts	O
+and	O
+matching	O
+inspiratory	B-PROC
+times	O
+.	O
+
+Under	O
+APC	B-COMP
+mode	O
+,	O
+compared	O
+with	O
+VC	O
+,	O
+DIs	O
+were	O
+lower	O
+at	O
+set	O
+Vt	O
+of	O
+6	O
+and	O
+7	O
+.	O
+5	O
+ml	O
+/	O
+kg	O
+(	O
+P	O
+=	O
+0	O
+.	O
+004	O
+for	O
+both	O
+).	O
+
+Lower	O
+Vts	O
+during	O
+VC	O
+ventilation	O
+result	O
+in	O
+higher	O
+patient	O
+-	O
+ventilator	O
+dyssynchrony	O
+in	O
+most	O
+patients	O
+with	O
+or	O
+at	O
+risk	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Induced	O
+High	O
+Levels	O
+of	O
+IgA	O
+Response	O
+in	O
+Mice	B-SPEC
+and	O
+Piglets	O
+.	O
+
+In	O
+our	O
+study	O
+,	O
+stool	B-ANAT
+samples	O
+from	O
+203	O
+wild	B-SPEC
+boars	I-SPEC
+culled	O
+during	O
+hunting	O
+season	O
+2014	O
+-	O
+2015	O
+(	O
+from	O
+October	O
+to	O
+January	O
+)	O
+were	O
+examined	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Our	O
+study	O
+provides	O
+the	O
+first	O
+evidence	O
+of	O
+RVC	O
+prevalence	O
+in	O
+wild	B-SPEC
+boars	I-SPEC
+and	O
+indicates	O
+that	O
+wild	B-SPEC
+boars	I-SPEC
+might	O
+contribute	O
+to	O
+the	O
+genetic	O
+variability	O
+of	O
+RVA	O
+and	O
+also	O
+serve	O
+as	O
+an	O
+important	O
+reservoir	O
+of	O
+other	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+This	O
+study	O
+provides	O
+detailed	O
+information	O
+on	O
+the	O
+pathological	O
+changes	O
+in	O
+the	O
+hen	O
+ovary	B-ANAT
+and	O
+oviduct	B-ANAT
+after	O
+challenge	O
+with	O
+IBV	O
+strain	O
+YN	O
+,	O
+which	O
+could	O
+provide	O
+a	O
+better	O
+understanding	O
+about	O
+the	O
+pathogenicity	O
+of	O
+IBV	B-SPEC
+.	O
+
+(	O
+2	O
+)	O
+The	O
+areas	O
+under	O
+the	O
+ROC	O
+curve	O
+of	O
+APACHE	O
+Ⅳ	O
+score	O
+for	O
+predicting	O
+death	B-PROC
+were	O
+largest	O
+(	O
+0	O
+.	O
+792	O
+±	O
+0	O
+.	O
+076	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+643	O
+-	O
+0	O
+.	O
+940	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Risk	O
+of	O
+global	O
+spread	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+via	O
+the	O
+air	B-CHED
+transport	O
+network	O
+.	O
+
+Sputum	B-ANAT
+specimens	O
+were	O
+collected	O
+from	O
+participants	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+productive	B-DISO
+cough	I-DISO
+at	O
+the	O
+time	O
+of	O
+their	O
+interview	O
+.	O
+
+The	O
+2015	O
+MERS	O
+-	O
+CoV	O
+outbreak	O
+in	O
+South	O
+Korea	O
+,	O
+in	O
+which	O
+184	O
+MERS	O
+cases	O
+including	O
+33	O
+deaths	B-PROC
+occurred	O
+in	O
+2	O
+months	O
+,	O
+that	O
+was	O
+imported	O
+from	O
+the	O
+Middle	O
+East	O
+by	O
+a	O
+South	O
+Korean	O
+businessman	O
+was	O
+a	O
+wake	O
+-	O
+up	O
+call	O
+for	O
+the	O
+global	O
+community	O
+to	O
+refocus	O
+attention	O
+on	O
+MERS	O
+-	O
+CoV	O
+and	O
+other	O
+emerging	O
+and	O
+re	B-DISO
+-	I-DISO
+emerging	I-DISO
+infectious	I-DISO
+diseases	I-DISO
+with	O
+epidemic	O
+potential	O
+.	O
+
+The	O
+international	O
+donor	B-CHED
+community	O
+and	O
+Middle	O
+Eastern	O
+countries	O
+should	O
+make	O
+available	O
+resources	O
+for	O
+,	O
+and	O
+make	O
+a	O
+serious	O
+commitment	O
+to	O
+,	O
+taking	O
+forward	O
+a	O
+""""	O
+One	O
+Health	O
+""""	O
+global	O
+network	O
+for	O
+proactive	O
+surveillance	O
+,	O
+rapid	O
+detection	O
+,	O
+and	O
+prevention	O
+of	O
+MERS	O
+-	O
+CoV	O
+and	O
+other	O
+epidemic	O
+infectious	B-DISO
+diseases	I-DISO
+threats	O
+.	O
+
+The	O
+Egyptian	O
+variant	O
+IBVs	O
+also	O
+contained	O
+additional	O
+N	O
+-	O
+glycosylation	B-PROC
+sites	O
+compared	O
+to	O
+the	O
+classical	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+MicroRNA	O
+-	O
+155	O
+enhances	O
+T	B-ANAT
+cell	I-ANAT
+trafficking	B-PROC
+and	O
+antiviral	B-CHED
+effector	B-CHED
+function	O
+in	O
+a	O
+model	O
+of	O
+coronavirus	B-SPEC
+-	O
+induced	O
+neurologic	O
+disease	O
+.	O
+
+To	O
+determine	O
+the	O
+impact	O
+of	O
+miR	O
+-	O
+155	O
+on	O
+trafficking	B-PROC
+,	O
+T	B-ANAT
+cells	I-ANAT
+from	O
+infected	O
+WT	O
+or	O
+miR	O
+-	O
+155	O
+(-/-)	O
+mice	B-SPEC
+were	O
+adoptively	O
+transferred	O
+into	O
+RAG1	O
+(-/-)	O
+mice	B-SPEC
+,	O
+and	O
+T	B-ANAT
+cell	I-ANAT
+accumulation	O
+into	O
+the	O
+CNS	B-CHED
+was	O
+assessed	O
+using	O
+flow	O
+cytometry	O
+.	O
+
+Compared	O
+to	O
+WT	O
+mice	B-SPEC
+,	O
+JHMV	O
+-	O
+infected	O
+miR	O
+-	O
+155	O
+(-/-)	O
+mice	B-SPEC
+developed	O
+exacerbated	O
+disease	O
+concomitant	O
+with	O
+increased	O
+morbidity	O
+/	O
+mortality	O
+and	O
+an	O
+inability	O
+to	O
+control	O
+viral	B-PROC
+replication	I-PROC
+within	O
+the	O
+CNS	B-CHED
+.	O
+
+We	O
+estimated	O
+the	O
+relative	O
+risks	O
+of	O
+death	B-PROC
+and	O
+severe	O
+disease	O
+among	O
+MERS	O
+-	O
+CoV	O
+patients	O
+in	O
+the	O
+Middle	O
+East	O
+between	O
+2012	O
+and	O
+2015	O
+for	O
+several	O
+risk	O
+factors	O
+,	O
+using	O
+Poisson	O
+regression	O
+with	O
+robust	O
+variance	O
+and	O
+a	O
+bootstrap	O
+-	O
+based	O
+expectation	O
+maximization	O
+algorithm	O
+to	O
+handle	O
+extensive	O
+missing	O
+data	O
+.	O
+
+Increased	O
+age	O
+and	O
+underlying	O
+comorbidity	O
+were	O
+risk	O
+factors	O
+for	O
+both	O
+death	B-PROC
+and	O
+severe	O
+disease	O
+,	O
+while	O
+cases	O
+arising	O
+in	O
+Saudi	O
+Arabia	O
+were	O
+more	O
+likely	O
+to	O
+be	O
+severe	O
+.	O
+
+TITLE	O
+:	O
+In	O
+the	O
+era	B-CHED
+of	O
+corona	B-CHED
+virus	B-SPEC
+:	O
+health	O
+care	O
+professionals	O
+'	O
+knowledge	O
+,	O
+attitudes	O
+,	O
+and	O
+practice	O
+of	O
+hand	O
+hygiene	O
+in	O
+Saudi	O
+primary	O
+care	O
+centers	O
+:	O
+a	O
+cross	O
+-	O
+sectional	O
+study	O
+.	O
+
+Data	O
+were	O
+analyzed	O
+using	O
+IBM	B-DISO
+SPSS	O
+software	O
+.	O
+
+2299	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+We	O
+found	O
+that	O
+for	O
+patients	O
+with	O
+PaO2	O
+/	O
+FiO2	O
+below	O
+150	O
+mm	O
+Hg	O
+,	O
+but	O
+above	O
+100	O
+mm	O
+Hg	O
+or	O
+an	O
+oxygenation	B-PROC
+index	O
+above	O
+12	O
+(	O
+moderate	O
+ARDS	B-DISO
+),	O
+higher	O
+PEEP	B-CHED
+reduces	O
+hospital	O
+mortality	O
+,	O
+but	O
+the	O
+beneficial	O
+effect	O
+appears	O
+to	O
+level	O
+off	O
+for	O
+patients	O
+with	O
+very	O
+severe	O
+ARDS	B-DISO
+.	O
+
+On	O
+Day	O
+2	O
+,	O
+Pa	O
+In	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+use	O
+of	O
+inhaled	B-PROC
+sevoflurane	B-CHED
+improved	O
+oxygenation	B-PROC
+and	O
+decreased	O
+levels	O
+of	O
+a	O
+marker	O
+of	O
+epithelial	O
+injury	O
+and	O
+of	O
+some	O
+inflammatory	O
+markers	O
+,	O
+compared	O
+with	O
+midazolam	O
+.	O
+
+ABSTRACT	O
+:	O
+Haemoglobinuria	B-DISO
+is	O
+an	O
+uncommon	O
+complication	B-DISO
+of	O
+severe	O
+malaria	B-PATH
+,	O
+reflecting	O
+acute	O
+intravascular	B-DISO
+haemolysis	I-DISO
+and	O
+potentially	O
+leading	O
+to	O
+acute	O
+kidney	B-ANAT
+injury	O
+.	O
+
+It	O
+can	O
+occur	O
+early	O
+in	O
+the	O
+course	O
+of	O
+infection	B-DISO
+as	O
+a	O
+consequence	O
+of	O
+a	O
+high	O
+parasite	O
+burden	O
+,	O
+or	O
+may	O
+occur	O
+following	O
+commencement	O
+of	O
+anti	O
+-	O
+malarial	O
+treatment	O
+.	O
+
+Treatment	O
+with	O
+quinine	B-CHED
+has	O
+been	O
+described	O
+as	O
+a	O
+risk	O
+factor	O
+;	O
+however	O
+the	O
+syndrome	B-DISO
+may	O
+also	O
+occur	O
+following	O
+treatment	O
+with	O
+intravenous	O
+artesunate	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Bat	O
+-	O
+borne	O
+viral	B-DISO
+diseases	I-DISO
+are	O
+a	O
+major	O
+public	O
+health	O
+concern	O
+among	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+which	O
+includes	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+Nipah	O
+,	O
+Marburg	O
+and	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+.	O
+
+During	O
+the	O
+survey	O
+for	O
+Nipah	B-SPEC
+virus	I-SPEC
+among	O
+bats	B-SPEC
+at	O
+North	O
+-	O
+East	O
+region	O
+of	O
+India	O
+;	O
+Tioman	B-SPEC
+virus	I-SPEC
+(	O
+TioV	O
+),	O
+a	O
+new	O
+member	O
+of	O
+the	O
+Paramyxoviridae	B-SPEC
+family	B-SPEC
+was	O
+isolated	O
+from	O
+tissues	B-ANAT
+of	O
+Pteropus	B-SPEC
+giganteus	I-SPEC
+bats	B-SPEC
+for	O
+the	O
+first	O
+time	O
+in	O
+India	O
+.	O
+
+However	O
+,	O
+further	O
+analyses	O
+,	O
+using	O
+other	O
+TGEV	B-SPEC
+-	O
+and	O
+PEDV	B-SPEC
+-	O
+specific	O
+RT	O
+-	O
+qPCR	O
+assays	O
+,	O
+provided	O
+results	O
+inconsistent	O
+with	O
+infection	B-DISO
+by	O
+either	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+Specific	O
+detection	O
+of	O
+the	O
+chimeric	O
+SeCoVs	O
+either	O
+requires	O
+development	B-PROC
+of	O
+a	O
+new	O
+diagnostic	O
+RT	O
+-	O
+qPCR	O
+assay	O
+or	O
+the	O
+combined	O
+use	O
+of	O
+assays	O
+targeting	B-PROC
+the	O
+PEDV	B-PRGE
+S	I-PRGE
+-	I-PRGE
+gene	I-PRGE
+and	O
+another	O
+part	O
+of	O
+the	O
+TGEV	B-SPEC
+genome	O
+.	O
+
+We	O
+have	O
+isolated	O
+and	O
+passaged	O
+the	O
+PDCoV	O
+strain	O
+OH	O
+-	O
+FD22	O
+in	O
+an	O
+LLC	B-COMP
+porcine	B-SPEC
+kidney	B-ANAT
+(	O
+LLC	B-COMP
+-	O
+PK	O
+)	O
+cell	B-ANAT
+line	I-ANAT
+.	O
+
+Histologic	O
+lesions	O
+were	O
+limited	O
+to	O
+the	O
+villous	O
+epithelium	O
+of	O
+the	O
+jejunum	B-ANAT
+and	O
+ileum	B-ANAT
+at	O
+PID	B-DISO
+3	O
+.	O
+
+An	O
+analysis	O
+of	O
+full	O
+-	O
+length	O
+S	O
+and	O
+N	O
+genes	O
+of	O
+TC	O
+-	O
+and	O
+Gn	O
+-	O
+pig	B-SPEC
+-	O
+passaged	O
+OH	O
+-	O
+FD22	O
+revealed	O
+a	O
+high	O
+genetic	O
+stability	O
+in	O
+cell	B-COMP
+culture	O
+and	O
+pigs	B-SPEC
+.	O
+
+Epidemiological	O
+and	O
+clinical	O
+data	O
+on	O
+maternal	O
+and	O
+neonatal	O
+infections	B-DISO
+were	O
+collected	O
+prospectively	O
+and	O
+analyzed	O
+.	O
+
+Leukocytosis	B-DISO
+with	O
+neutrophilia	O
+and	O
+normal	O
+or	O
+increased	B-DISO
+platelets	I-DISO
+was	O
+a	O
+common	O
+finding	O
+,	O
+and	O
+in	O
+those	O
+with	O
+signs	O
+of	O
+meningeal	O
+involvement	O
+,	O
+moderate	O
+lymphocytic	O
+pleocytosis	O
+with	O
+normal	O
+glucose	B-CHED
+and	O
+protein	B-CHED
+levels	O
+was	O
+typical	O
+.	O
+
+ABSTRACT	O
+:	O
+Sequencing	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+spike	O
+genes	O
+re	O
+-	O
+isolated	O
+from	O
+vaccinated	O
+chicks	O
+revealed	O
+that	O
+many	O
+sequence	O
+changes	O
+are	O
+found	O
+on	O
+the	O
+S1	B-PRGE
+spike	I-PRGE
+gene	I-PRGE
+.	O
+
+These	O
+findings	O
+are	O
+important	O
+because	O
+they	O
+propose	O
+that	O
+specific	O
+changes	O
+in	O
+S1	O
+enhances	O
+virus	O
+fitness	O
+by	O
+more	O
+effective	O
+binding	B-FUNC
+to	O
+host	B-COMP
+tissues	B-ANAT
+(	O
+Y43H	O
+)	O
+and	O
+by	O
+evading	O
+a	O
+vaccine	O
+-	O
+induced	O
+antibody	B-PROC
+response	I-PROC
+(∆	O
+344	O
+).	O
+
+The	O
+most	O
+common	O
+clinical	O
+manifestations	O
+were	O
+fever	B-PROC
+(	O
+94	O
+.	O
+6	O
+%),	O
+conjunctival	B-DISO
+congestion	I-DISO
+(	O
+89	O
+.	O
+6	O
+%),	O
+myalgia	B-DISO
+(	O
+81	O
+.	O
+9	O
+%),	O
+coryza	B-DISO
+(	O
+79	O
+.	O
+7	O
+%),	O
+headache	B-DISO
+(	O
+75	O
+.	O
+1	O
+%),	O
+palmar	B-ANAT
+erythema	B-DISO
+(	O
+62	O
+.	O
+8	O
+%),	O
+and	O
+retro	B-DISO
+-	I-DISO
+orbital	I-DISO
+pain	I-DISO
+(	O
+51	O
+.	O
+3	O
+%).	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+261	O
+confirmed	O
+cases	O
+of	O
+dengue	B-DISO
+fever	I-DISO
+non	O
+-	O
+severe	O
+and	O
+severe	O
+dengue	B-DISO
+infection	B-DISO
+was	O
+seen	O
+in	O
+60	O
+.	O
+9	O
+%	O
+and	O
+39	O
+.	O
+1	O
+%,	O
+respectively	O
+.	O
+
+CONCLUSIONS	O
+:	O
+There	O
+has	O
+been	O
+a	O
+resurgence	O
+of	O
+dengue	B-DISO
+fever	I-DISO
+with	O
+a	O
+change	O
+in	O
+the	O
+pattern	O
+of	O
+presentation	O
+during	O
+the	O
+recent	O
+epidemics	O
+.	O
+
+A	O
+56	O
+-	O
+year	O
+-	O
+old	O
+Japanese	O
+woman	O
+who	O
+presented	O
+with	O
+severe	O
+pneumonia	B-DISO
+secondary	O
+to	O
+scleroderma	B-DISO
+was	O
+treated	O
+under	O
+ventilator	O
+support	O
+because	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Selection	O
+of	O
+reference	O
+genes	O
+for	O
+gene	B-PROC
+expression	I-PROC
+analysis	O
+by	O
+real	O
+-	O
+time	O
+qPCR	O
+in	O
+avian	B-SPEC
+cells	B-COMP
+infected	O
+with	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+This	O
+is	O
+most	O
+notable	O
+when	O
+measuring	O
+the	O
+transcription	B-PROC
+of	O
+AKT1	B-PRGE
+,	O
+where	O
+changes	O
+are	O
+minimal	O
+during	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+Importance	O
+of	O
+Ground	O
+Critical	O
+Care	O
+Transport	B-PROC
+.	O
+
+We	O
+report	O
+4	O
+cases	O
+of	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+from	O
+influenza	B-DISO
+in	O
+need	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+evaluation	O
+at	O
+a	O
+tertiary	O
+care	O
+center	O
+,	O
+transported	O
+by	O
+ground	O
+.	O
+
+In	O
+3	O
+cases	O
+,	O
+they	O
+stopped	O
+bicarbonate	O
+drips	O
+being	O
+used	O
+to	O
+treat	O
+mixed	O
+metabolic	B-PROC
+and	O
+respiratory	B-DISO
+acidosis	I-DISO
+,	O
+and	O
+in	O
+1	O
+case	O
+,	O
+they	O
+administered	O
+furosemide	B-CHED
+.	O
+
+In	O
+1	O
+case	O
+,	O
+they	O
+started	O
+cisatracurium	O
+,	O
+and	O
+in	O
+3	O
+others	O
+,	O
+they	O
+initiated	O
+inhaled	B-PROC
+epoprostenol	B-CHED
+.	O
+
+A	O
+subacute	O
+cardiac	B-ANAT
+catheterization	O
+showed	O
+no	O
+signs	O
+of	O
+significant	O
+coronary	B-DISO
+stenosis	B-SPEC
+.	O
+
+In	O
+rhesus	B-SPEC
+macaques	I-SPEC
+,	O
+the	O
+spike	O
+glycoprotein	B-CHED
+peptides	B-CHED
+S471	O
+-	O
+503	O
+,	O
+S604	O
+-	O
+625	O
+,	O
+and	O
+S1164	O
+-	O
+1191	O
+elicited	O
+antibodies	B-COMP
+that	O
+efficiently	O
+prevented	O
+infection	B-DISO
+in	O
+non	O
+-	O
+human	B-SPEC
+primates	B-SPEC
+.	O
+
+To	O
+allow	O
+diagnosis	O
+,	O
+two	O
+conventional	O
+multiplex	O
+polymerase	O
+chain	O
+reactions	O
+(	O
+PCR	O
+)	O
+were	O
+developed	O
+to	O
+simultaneously	O
+identify	O
+four	O
+RNA	O
+and	O
+two	O
+DNA	O
+viruses	B-SPEC
+associated	O
+with	O
+CIRDC	O
+.	O
+
+Plasma	B-ANAT
+markers	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+are	O
+associated	O
+with	O
+ARDS	B-DISO
+in	O
+patients	O
+with	O
+severe	O
+TBI	O
+.	O
+
+Moreover	O
+,	O
+the	O
+Km	O
+of	O
+ATP	B-CHED
+for	O
+M	O
+-	O
+nsp13	O
+is	O
+inversely	O
+proportional	O
+to	O
+the	O
+length	O
+of	O
+the	O
+5	O
+'	O
+loading	O
+strand	O
+of	O
+the	O
+partially	O
+duplex	O
+RNA	O
+substrates	O
+.	O
+
+Cytokine	B-DISO
+release	I-DISO
+syndrome	I-DISO
+,	O
+the	O
+most	O
+severe	O
+toxicity	O
+,	O
+presents	O
+a	O
+novel	O
+critical	B-DISO
+illness	I-DISO
+syndrome	B-DISO
+with	O
+limited	O
+data	O
+regarding	O
+diagnosis	O
+,	O
+prognosis	O
+,	O
+and	O
+therapy	O
+.	O
+
+Thirteen	O
+subjects	O
+with	O
+cardiovascular	B-ANAT
+dysfunction	O
+were	O
+treated	O
+with	O
+the	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+receptor	I-PRGE
+antibody	I-PRGE
+tocilizumab	O
+.	O
+
+Eighteen	O
+subjects	O
+(	O
+46	O
+%)	O
+developed	O
+grade	O
+3	O
+-	O
+4	O
+cytokine	B-DISO
+release	I-DISO
+syndrome	I-DISO
+,	O
+with	O
+prolonged	O
+fever	B-PROC
+(	O
+median	O
+,	O
+6	O
+.	O
+5	O
+d	O
+),	O
+hyperferritinemia	O
+(	O
+median	O
+peak	O
+ferritin	B-PRGE
+,	O
+60	O
+,	O
+214	O
+ng	O
+/	O
+mL	O
+),	O
+and	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Subjects	O
+had	O
+a	O
+median	O
+of	O
+15	O
+organ	B-ANAT
+dysfunction	O
+days	O
+(	O
+interquartile	O
+range	O
+,	O
+8	O
+-	O
+20	O
+).	O
+
+Clinicians	O
+should	O
+be	O
+aware	O
+of	O
+expanding	O
+use	O
+of	O
+this	O
+breakthrough	O
+therapy	O
+and	O
+implications	O
+for	O
+critical	O
+care	O
+units	O
+in	O
+cancer	B-DISO
+centers	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+a	O
+diverse	O
+group	O
+of	O
+viruses	B-SPEC
+that	O
+infect	O
+mammals	B-SPEC
+and	O
+birds	B-SPEC
+.	O
+
+Calibration	O
+was	O
+moderate	O
+using	O
+the	O
+original	O
+cutoff	O
+values	O
+(	O
+Hosmer	O
+-	O
+Lemeshow	O
+goodness	O
+of	O
+fit	B-DISO
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+recalibration	O
+was	O
+performed	O
+for	O
+the	O
+cutoff	O
+value	O
+for	O
+age	O
+and	O
+plateau	O
+pressure	O
+.	O
+
+The	O
+novel	O
+virus	B-SPEC
+belongs	O
+to	O
+the	O
+coronaviruses	O
+family	B-SPEC
+,	O
+which	O
+is	O
+responsible	O
+for	O
+causing	O
+mild	O
+to	O
+moderate	O
+colds	B-DISO
+.	O
+
+The	O
+control	O
+and	O
+command	O
+center	O
+of	O
+Saudi	O
+Ministry	O
+of	O
+Health	O
+issues	O
+a	O
+daily	O
+report	O
+on	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+cases	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+build	O
+our	O
+prediction	O
+models	O
+,	O
+we	O
+split	O
+the	O
+dataset	O
+into	O
+two	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+first	O
+emerged	O
+in	O
+2003	O
+,	O
+causing	O
+the	O
+SARS	B-DISO
+epidemic	O
+which	O
+resulted	O
+in	O
+a	O
+10	O
+%	O
+fatality	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Emerging	O
+infectious	B-DISO
+agents	O
+].	O
+
+The	O
+establishment	O
+of	O
+the	O
+African	O
+Regional	O
+polio	B-DISO
+laboratory	O
+for	O
+the	O
+Polio	B-DISO
+Eradication	O
+Initiative	O
+(	O
+PEI	B-CHED
+)	O
+has	O
+contributed	O
+in	O
+supporting	O
+countries	O
+in	O
+their	O
+efforts	O
+to	O
+strengthen	O
+laboratory	O
+capacity	O
+.	O
+
+Through	O
+laboratory	O
+technical	O
+staff	O
+training	O
+supported	O
+by	O
+the	O
+PEI	B-CHED
+,	O
+skills	O
+and	O
+knowledge	O
+were	O
+gained	O
+to	O
+reinforce	O
+laboratories	O
+capacity	O
+and	O
+performance	O
+in	O
+quality	O
+laboratory	O
+functioning	O
+,	O
+processes	O
+and	O
+techniques	O
+such	O
+as	O
+cell	B-COMP
+culture	O
+.	O
+
+General	O
+laboratory	O
+quality	O
+standards	O
+,	O
+including	O
+the	O
+entire	O
+laboratory	O
+key	O
+elements	O
+was	O
+improved	O
+through	O
+the	O
+PEI	B-CHED
+accreditation	O
+process	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+Polio	B-DISO
+Eradication	O
+Initiative	O
+(	O
+PEI	B-CHED
+)	O
+is	O
+a	O
+good	O
+example	O
+of	O
+contribution	O
+in	O
+strengthening	O
+public	O
+health	O
+laboratories	O
+systems	O
+in	O
+the	O
+African	O
+region	O
+.	O
+
+Studies	O
+were	O
+included	O
+and	O
+analyzed	O
+if	O
+they	O
+met	B-CHED
+all	O
+of	O
+the	O
+following	O
+criteria	O
+:	O
+""""	O
+probable	O
+or	O
+confirmed	O
+infant	O
+microcephaly	B-DISO
+""""	O
+and	O
+""""	O
+probable	O
+or	O
+confirmed	O
+ZIKV	O
+infection	B-DISO
+among	O
+mothers	O
+or	O
+infants	O
+"""."	O
+
+The	O
+chance	O
+of	O
+catch	B-DISO
+-	O
+up	O
+growth	B-PROC
+may	O
+decrease	O
+the	O
+number	O
+of	O
+pervious	O
+""""	O
+diagnosed	O
+""""	O
+microcephaly	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+within	O
+the	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+show	O
+variations	O
+within	O
+their	O
+genome	O
+sequences	O
+,	O
+especially	O
+within	O
+the	O
+major	O
+structural	O
+protein	B-CHED
+the	O
+Spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+gene	I-PRGE
+.	O
+
+From	O
+time	O
+to	O
+time	O
+,	O
+antigenic	O
+virus	B-SPEC
+variants	O
+appear	O
+,	O
+which	O
+differ	O
+significantly	O
+from	O
+known	O
+serotypes	O
+.	O
+
+TITLE	O
+:	O
+Mood	B-DISO
+disorders	I-DISO
+and	O
+non	B-DISO
+-	I-DISO
+celiac	I-DISO
+gluten	I-DISO
+sensitivity	I-DISO
+.	O
+
+Bipolar	B-DISO
+disorder	I-DISO
+patients	O
+show	O
+an	O
+increase	O
+of	O
+blood	B-ANAT
+anti	O
+gliadin	O
+deamidated	O
+antibodies	B-COMP
+(	O
+IgG	B-PRGE
+).	O
+
+The	O
+patterns	O
+of	O
+parenchymal	O
+lesions	O
+,	O
+involved	O
+segments	O
+and	O
+presence	O
+of	O
+cavity	B-DISO
+,	O
+bronchiectasis	B-DISO
+and	O
+bronchogenic	O
+spread	O
+of	O
+the	O
+lesions	O
+with	O
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+and	O
+chest	B-ANAT
+/	O
+X	O
+-	O
+ray	B-SPEC
+(	O
+CXR	O
+)	O
+were	O
+recorded	O
+and	O
+analyzed	O
+.	O
+
+A	O
+total	O
+of	O
+250	O
+swabs	O
+were	O
+randomly	O
+selected	O
+and	O
+analyzed	O
+by	O
+multiplex	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+including	O
+research	O
+of	O
+18	O
+viruses	B-SPEC
+and	O
+4	O
+bacteria	B-SPEC
+.	O
+
+We	O
+observed	O
+important	O
+seasonal	O
+differences	O
+,	O
+with	O
+circulation	O
+of	O
+Human	B-SPEC
+Metapneumoviruses	B-SPEC
+,	O
+RSV	B-SPEC
+A	O
+and	O
+B	O
+and	O
+coronavirus	B-SPEC
+only	O
+during	O
+summer	O
+;	O
+whereas	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+were	O
+identified	O
+only	O
+during	O
+winter	O
+.	O
+
+In	O
+conclusion	O
+,	O
+this	O
+study	O
+highlights	O
+a	O
+substantial	O
+circulation	B-PROC
+of	O
+multiple	O
+respiratory	O
+pathogens	O
+in	O
+Réunion	O
+Island	O
+throughout	O
+the	O
+year	O
+.	O
+
+Secondary	O
+analysis	O
+of	O
+data	O
+from	O
+the	O
+Randomized	O
+Evaluation	O
+of	O
+Sedation	B-DISO
+Titration	O
+for	O
+Respiratory	B-DISO
+Failure	I-DISO
+clinical	O
+trial	O
+.	O
+
+TITLE	O
+:	O
+Activated	O
+GL7	O
+ABSTRACT	O
+:	O
+Central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+inflammation	B-DISO
+associated	O
+with	O
+viral	B-PROC
+infection	I-PROC
+and	O
+autoimmune	B-DISO
+disease	I-DISO
+results	O
+in	O
+the	O
+accumulation	O
+of	O
+B	B-ANAT
+cells	I-ANAT
+in	O
+various	O
+differentiation	B-PROC
+stages	O
+.	O
+
+Pyrrolyl	O
+diketo	O
+acid	O
+(	O
+DKA	O
+)	O
+derivatives	O
+inhibit	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+replication	O
+by	O
+interacting	O
+with	O
+the	O
+Mg	O
+
+We	O
+also	O
+screened	O
+these	O
+samples	O
+for	O
+Bartonella	B-SPEC
+spp	B-ENZY
+.	O
+and	O
+found	O
+that	O
+38	O
+%	O
+of	O
+individuals	O
+tested	O
+positive	O
+.	O
+
+Accessory	O
+proteins	B-CHED
+are	O
+genus	B-SPEC
+-	O
+specific	O
+for	O
+coronavirus	B-SPEC
+,	O
+and	O
+two	O
+putative	O
+accessory	O
+proteins	B-CHED
+,	O
+NS6	B-DISO
+and	O
+NS7	B-DISO
+,	O
+are	O
+predicted	O
+to	O
+be	O
+encoded	O
+by	O
+PDCoV	O
+;	O
+however	O
+,	O
+this	O
+remains	O
+to	O
+be	O
+confirmed	O
+experimentally	O
+.	O
+
+Though	O
+we	O
+have	O
+reported	O
+the	O
+utility	O
+of	O
+this	O
+approach	O
+in	O
+bacterial	O
+and	O
+cell	B-COMP
+culture	O
+studies	O
+previously	O
+,	O
+this	O
+is	O
+the	O
+first	O
+comprehensive	O
+study	O
+to	O
+confirm	O
+that	O
+network	O
+topology	O
+can	O
+be	O
+used	O
+to	O
+predict	O
+phenotypes	O
+in	O
+mice	B-SPEC
+with	O
+experimental	O
+validation	O
+.	O
+
+The	O
+safe	O
+and	O
+effective	O
+vaccine	O
+to	O
+control	O
+IBV	B-SPEC
+spread	O
+is	O
+imperative	O
+.	O
+
+Despite	O
+their	O
+biomedical	O
+importance	O
+,	O
+coronavirus	B-SPEC
+S	O
+glycoproteins	B-CHED
+have	O
+proven	O
+difficult	O
+targets	O
+for	O
+structural	O
+characterization	O
+,	O
+precluding	O
+high	O
+-	O
+resolution	O
+studies	O
+of	O
+the	O
+biologically	O
+relevant	O
+trimer	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+the	O
+minimum	O
+infectious	B-DISO
+dose	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+virus	B-SPEC
+-	O
+inoculated	O
+feed	O
+.	O
+
+ABSTRACT	O
+:	O
+OBJECTIVE	O
+To	O
+determine	O
+the	O
+minimum	O
+infectious	O
+dose	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+in	O
+virus	B-SPEC
+-	O
+inoculated	O
+feed	O
+.	O
+
+RESULTS	O
+The	O
+PCR	O
+cycle	O
+threshold	O
+(	O
+Ct	O
+)	O
+decreased	O
+by	O
+approximately	O
+10	O
+when	O
+PEDV	B-SPEC
+was	O
+added	O
+to	O
+feed	O
+,	O
+compared	O
+with	O
+results	O
+for	O
+equivalent	O
+PEDV	O
+diluted	O
+in	O
+tissue	B-ANAT
+culture	O
+medium	O
+.	O
+
+by	O
+molecular	O
+testing	O
+;	O
+however	O
+,	O
+all	O
+lions	B-SPEC
+were	O
+positive	O
+for	O
+Babesia	B-SPEC
+spp	B-ENZY
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+extreme	O
+variability	O
+and	O
+rapid	O
+evolution	O
+of	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+has	O
+always	O
+represented	O
+the	O
+key	O
+challenge	O
+for	O
+its	O
+control	O
+because	O
+of	O
+the	O
+limited	O
+cross	O
+-	O
+protection	O
+among	O
+different	O
+strains	O
+.	O
+
+Diagnoses	O
+were	O
+status	B-DISO
+asthmaticus	I-DISO
+(	O
+2	O
+),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+septic	B-DISO
+shock	I-DISO
+(	O
+1	O
+),	O
+aspergillus	B-DISO
+pneumonia	I-DISO
+(	O
+1	O
+),	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+parainfluenza	B-DISO
+(	O
+1	O
+).	O
+
+TITLE	O
+:	O
+Predictors	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+:	O
+A	O
+large	O
+case	O
+control	O
+study	O
+of	O
+patients	O
+presenting	O
+with	O
+ILI	O
+at	O
+a	O
+MERS	O
+-	O
+CoV	O
+referral	O
+hospital	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+None	O
+of	O
+the	O
+presenting	O
+symptoms	O
+are	O
+specific	O
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Phylogenetic	O
+analysis	O
+clearly	O
+proved	O
+that	O
+the	O
+wild	O
+strain	O
+clustered	O
+into	O
+a	O
+subclass	B-SPEC
+with	O
+a	O
+HEV	B-SPEC
+-	O
+JT06	O
+strain	O
+.	O
+
+All	O
+patients	O
+admitted	O
+between	O
+March	O
+2009	O
+and	O
+April	O
+2013	O
+who	O
+met	B-CHED
+inclusion	O
+criteria	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+All	O
+patients	O
+who	O
+met	B-CHED
+American	O
+European	O
+Consensus	O
+Conference	O
+criteria	O
+and	O
+141	O
+(	O
+98	O
+.	O
+6	O
+%)	O
+patients	O
+who	O
+met	B-CHED
+Berlin	O
+criteria	O
+also	O
+met	B-CHED
+Pediatric	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Consensus	O
+Conference	O
+criteria	O
+.	O
+
+Applying	O
+the	O
+Pediatric	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Consensus	O
+Conference	O
+definition	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+has	O
+the	O
+potential	O
+to	O
+significantly	O
+increase	O
+the	O
+number	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+identified	O
+,	O
+with	O
+a	O
+lower	O
+overall	O
+mortality	O
+rate	O
+.	O
+
+However	O
+,	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+associated	O
+with	O
+extremely	O
+high	O
+mortality	O
+,	O
+particularly	O
+if	O
+present	O
+at	O
+24	O
+hours	O
+after	O
+initial	O
+diagnosis	O
+.	O
+
+Fecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+25	O
+diarrheic	O
+calves	O
+.	O
+
+The	O
+mAbs	O
+5E8	O
+and	O
+3D7	O
+reacted	O
+with	O
+native	O
+N	B-PRGE
+protein	I-PRGE
+in	O
+western	O
+blotting	O
+and	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+).	O
+
+Two	O
+linear	O
+epitopes	O
+,	O
+189SVEQAVLAALKKLG202	O
+and	O
+246VTRFYGARSSSA257	O
+,	O
+located	O
+in	O
+the	O
+LKR	O
+and	O
+CTD	O
+of	O
+TGEV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+,	O
+respectively	O
+,	O
+were	O
+identified	O
+after	O
+truncating	O
+the	O
+protein	B-CHED
+and	O
+applying	O
+a	O
+peptide	B-CHED
+scanning	O
+technique	O
+.	O
+
+Symptom	B-DISO
+data	O
+on	O
+158	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+with	O
+a	O
+laboratory	O
+-	O
+confirmed	O
+respiratory	B-DISO
+virus	I-DISO
+infection	I-DISO
+were	O
+collected	O
+using	O
+standardized	O
+data	O
+collection	O
+forms	O
+from	O
+three	O
+separate	O
+studies	O
+.	O
+
+Rates	O
+varied	O
+by	O
+virus	B-SPEC
+:	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+25	O
+·	O
+3	O
+%,	O
+19	O
+/	O
+75	O
+),	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+30	O
+%,	O
+3	O
+/	O
+10	O
+),	O
+coronavirus	B-SPEC
+(	O
+28	O
+·	O
+6	O
+%,	O
+2	O
+/	O
+7	O
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+28	O
+·	O
+6	O
+%,	O
+2	O
+/	O
+7	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+14	O
+·	O
+3	O
+%,	O
+4	O
+/	O
+28	O
+)	O
+and	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+8	O
+·	O
+3	O
+%,	O
+1	O
+/	O
+12	O
+).	O
+
+Pathway	B-PROC
+analysis	O
+identified	O
+significant	O
+differences	O
+in	O
+multiple	O
+signaling	B-PROC
+pathways	B-PROC
+that	O
+may	O
+explain	O
+the	O
+differences	O
+in	O
+epithelial	O
+repair	B-PROC
+.	O
+
+TITLE	O
+:	O
+Putative	O
+Receptor	B-FUNC
+Binding	I-FUNC
+Domain	O
+of	O
+Bat	B-PRGE
+-	I-PRGE
+Derived	I-PRGE
+Coronavirus	B-SPEC
+HKU9	I-PRGE
+Spike	I-PRGE
+Protein	B-CHED
+:	O
+Evolution	B-PROC
+of	O
+Betacoronavirus	O
+Receptor	B-FUNC
+Binding	I-FUNC
+Motifs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+suggested	O
+bat	B-ENZY
+origin	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+revitalized	O
+the	O
+studies	O
+of	O
+other	O
+bat	B-ENZY
+-	O
+derived	O
+coronaviruses	O
+with	O
+respect	O
+to	O
+interspecies	O
+transmission	O
+potential	O
+.	O
+
+The	O
+core	O
+subdomain	O
+fold	O
+resembles	O
+those	O
+of	O
+other	O
+betaCoV	O
+RBDs	O
+,	O
+whereas	O
+the	O
+external	O
+subdomain	O
+is	O
+structurally	O
+unique	O
+with	O
+a	O
+single	O
+helix	O
+,	O
+explaining	O
+the	O
+inability	O
+of	O
+HKU9	O
+-	O
+RBD	O
+to	O
+react	O
+with	O
+either	O
+ACE2	B-PRGE
+or	O
+CD26	B-PRGE
+.	O
+
+The	O
+detected	O
+virus	B-SPEC
+did	O
+not	O
+influence	O
+clinical	O
+features	O
+of	O
+febrile	B-DISO
+seizure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Tissue	B-ANAT
+localization	B-PROC
+,	O
+shedding	B-DISO
+,	I-DISO
+virus	I-DISO
+carriage	O
+,	O
+antibody	B-PROC
+response	I-PROC
+,	O
+and	O
+aerosol	O
+transmission	O
+of	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+following	O
+inoculation	O
+of	O
+4	O
+-	O
+week	O
+-	O
+old	O
+feeder	O
+pigs	B-SPEC
+.	O
+
+Real	O
+-	O
+time	O
+PCR	O
+detected	O
+PEDV	B-SPEC
+in	O
+fecal	B-ANAT
+and	O
+nasal	B-ANAT
+swabs	O
+,	O
+oral	B-ANAT
+fluids	B-ANAT
+,	O
+serum	B-COMP
+,	O
+and	O
+gastrointestinal	O
+and	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+July	O
+-	O
+August	O
+2015	O
+,	O
+the	O
+number	O
+of	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+reported	O
+from	O
+Saudi	O
+Arabia	O
+increased	O
+dramatically	O
+.	O
+
+Oxygen	B-PROC
+content	I-PROC
+was	O
+significantly	O
+different	O
+between	O
+PFC	O
+post	O
+-	O
+OA	O
+and	O
+the	O
+control	O
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+virion	B-COMP
+provides	O
+the	O
+means	O
+to	O
+deliver	O
+the	O
+viral	B-COMP
+genome	I-COMP
+across	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+of	O
+a	O
+host	B-COMP
+cell	I-COMP
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+cis	B-DISO
+-	O
+Acting	O
+RNA	O
+Elements	O
+.	O
+
+The	O
+protein	B-COMP
+complex	I-COMP
+is	O
+thought	O
+to	O
+bind	B-FUNC
+specific	O
+cis	B-DISO
+-	O
+acting	O
+RNA	O
+elements	O
+primarily	O
+located	O
+in	O
+the	O
+5	O
+'-	O
+and	O
+3	O
+'-	O
+terminal	O
+genome	O
+regions	O
+and	O
+upstream	O
+of	O
+the	O
+open	O
+reading	O
+frames	O
+located	O
+in	O
+the	O
+3	O
+'-	O
+proximal	O
+one	O
+-	O
+third	O
+of	O
+the	O
+genome	O
+.	O
+
+The	O
+5	O
+'-	O
+terminal	O
+two	O
+-	O
+thirds	O
+of	O
+the	O
+genome	O
+contain	O
+two	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+),	O
+1a	O
+and	O
+1b	O
+,	O
+that	O
+together	O
+make	O
+up	O
+the	O
+viral	O
+replicase	O
+gene	O
+and	O
+encode	O
+two	O
+large	O
+polyproteins	O
+that	O
+are	O
+processed	O
+by	O
+viral	O
+proteases	O
+into	O
+15	O
+-	O
+16	O
+nonstructural	O
+proteins	B-CHED
+,	O
+most	O
+of	O
+them	O
+being	O
+involved	O
+in	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+The	O
+review	O
+summarizes	O
+our	O
+current	O
+knowledge	O
+of	O
+the	O
+genome	O
+and	O
+proteome	O
+of	O
+feline	B-SPEC
+coronaviruses	O
+(	O
+FCoVs	O
+),	O
+focusing	O
+on	O
+the	O
+viral	O
+surface	O
+(	O
+spike	O
+)	O
+protein	B-CHED
+S	O
+and	O
+the	O
+five	O
+accessory	O
+proteins	B-CHED
+.	O
+
+We	O
+discuss	O
+the	O
+recent	O
+progress	O
+in	O
+the	O
+development	B-PROC
+of	O
+FCoV	O
+reverse	O
+genetics	O
+systems	O
+suitable	O
+to	O
+generate	O
+recombinant	O
+field	O
+viruses	B-SPEC
+containing	O
+appropriate	O
+mutations	O
+for	O
+in	O
+vivo	O
+studies	O
+.	O
+
+To	O
+meet	O
+these	O
+requirements	O
+,	O
+vaccine	O
+studies	O
+need	O
+to	O
+provide	O
+a	O
+comprehensive	O
+understanding	O
+of	O
+(	O
+i	O
+)	O
+the	O
+protective	O
+roles	O
+of	O
+antiviral	B-CHED
+B	O
+and	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+immune	B-PROC
+responses	I-PROC
+,	O
+(	O
+ii	O
+)	O
+the	O
+complexity	O
+and	O
+plasticity	O
+of	O
+major	O
+viral	O
+antigens	B-CHED
+,	O
+and	O
+(	O
+iii	O
+)	O
+virus	B-SPEC
+molecular	O
+biology	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+primary	O
+determinant	O
+of	O
+CoV	O
+tropism	B-PROC
+is	O
+the	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+entry	O
+protein	B-CHED
+.	O
+
+A	O
+thorough	O
+understanding	O
+of	O
+the	O
+key	O
+role	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+CoV	O
+entry	O
+is	O
+critical	O
+to	O
+further	O
+our	O
+understanding	O
+of	O
+virus	B-SPEC
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+and	O
+pathogenesis	B-DISO
+and	O
+for	O
+development	B-PROC
+of	O
+intervention	O
+strategies	O
+.	O
+
+The	O
+primary	O
+functions	O
+that	O
+direct	O
+coronavirus	B-SPEC
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+processing	O
+reside	O
+in	O
+nonstructural	O
+protein	B-CHED
+(	O
+nsp	O
+)	O
+7	O
+to	O
+nsp16	O
+,	O
+which	O
+are	O
+cleavage	B-PROC
+products	O
+of	O
+two	O
+large	B-PRGE
+replicase	I-PRGE
+polyproteins	I-PRGE
+translated	O
+from	O
+the	O
+coronavirus	B-SPEC
+genome	O
+.	O
+
+Understanding	O
+the	O
+structure	O
+,	O
+function	O
+,	O
+and	O
+interactions	O
+of	O
+the	O
+RNA	O
+-	O
+synthesizing	O
+machinery	O
+of	O
+coronaviruses	O
+will	O
+be	O
+key	O
+to	O
+rationalizing	O
+their	O
+evolutionary	O
+success	O
+and	O
+the	O
+development	B-PROC
+of	O
+improved	O
+control	O
+strategies	O
+.	O
+
+TITLE	O
+:	O
+An	O
+outbreak	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+due	O
+to	O
+coronavirus	B-SPEC
+in	O
+Al	O
+-	O
+Ahssa	O
+Region	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+2015	O
+.	O
+
+The	O
+first	O
+seven	O
+cases	O
+occurred	O
+in	O
+one	O
+family	B-SPEC
+;	O
+these	O
+were	O
+followed	O
+by	O
+45	O
+cases	O
+in	O
+three	O
+public	O
+hospitals	O
+.	O
+
+This	O
+literature	O
+review	O
+was	O
+therefore	O
+conducted	O
+to	O
+describe	O
+the	O
+burden	O
+of	O
+epidemicand	O
+pandemic	O
+-	O
+prone	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+ARI	B-CHED
+)	O
+in	O
+the	O
+Region	O
+which	O
+may	O
+help	O
+in	O
+the	O
+development	B-PROC
+of	O
+evidence	O
+-	O
+based	O
+disease	O
+prevention	O
+and	O
+control	O
+policies	O
+.	O
+
+Fifteen	O
+patients	O
+(	O
+60	O
+.	O
+0	O
+%)	O
+developed	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+14	O
+(	O
+56	O
+%)	O
+died	B-PROC
+of	O
+the	O
+ARDS	B-DISO
+or	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+Early	O
+oseltamivir	B-CHED
+treatment	O
+was	O
+associated	O
+with	O
+a	O
+reduced	O
+risk	O
+of	O
+developing	O
+ARDS	B-DISO
+.	O
+
+The	O
+histopathology	O
+of	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+remodeling	O
+in	O
+survivors	O
+was	O
+similar	O
+in	O
+Ctsl	O
+-/-	O
+and	O
+Ctsl	O
++/+	O
+mice	B-SPEC
+,	O
+although	O
+Ctsl	O
++/+	O
+mice	B-SPEC
+cleared	O
+immunoreactive	O
+virus	B-SPEC
+sooner	O
+.	O
+
+ABSTRACT	O
+:	O
+Ovarian	B-DISO
+hyperstimulation	I-DISO
+syndrome	I-DISO
+(	O
+OHSS	B-DISO
+)	O
+was	O
+first	O
+described	O
+in	O
+1960	O
+.	O
+
+It	O
+may	O
+occur	O
+as	O
+a	O
+complication	B-DISO
+of	O
+gonadotropin	O
+hormone	B-CHED
+therapy	O
+during	O
+assisted	O
+pregnancy	O
+or	O
+for	O
+primary	B-DISO
+infertility	I-DISO
+.	O
+
+She	O
+was	O
+found	O
+to	O
+have	O
+edema	B-DISO
+,	O
+ascites	O
+,	O
+effusion	B-DISO
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+).	O
+
+TITLE	O
+:	O
+Prevalence	O
+and	O
+Risk	O
+Factors	O
+of	O
+Respiratory	O
+Viral	B-DISO
+Infections	I-DISO
+in	O
+Exacerbations	O
+of	O
+Chronic	B-DISO
+Obstructive	I-DISO
+Pulmonary	I-DISO
+Disease	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+278	O
+episodes	O
+of	O
+COPD	B-DISO
+exacerbations	O
+were	O
+recorded	O
+in	O
+213	O
+patients	O
+with	O
+COPD	B-DISO
+(	O
+number	O
+of	O
+females	O
+=	O
+73	O
+).	O
+
+The	O
+most	O
+common	O
+virus	B-SPEC
+was	O
+rhinovirus	B-SPEC
+(	O
+38	O
+.	O
+8	O
+%),	O
+followed	O
+by	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+,	O
+parainfluenza	B-DISO
+,	O
+adenovirus	B-DISO
+and	O
+metapneumovirus	B-SPEC
+.	O
+
+The	O
+severity	O
+of	O
+COPD	B-DISO
+exacerbations	O
+were	O
+not	O
+different	O
+between	O
+positive	O
+and	O
+negative	O
+viral	O
+detections	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+novel	O
+zoonotic	O
+pathogen	O
+.	O
+
+In	O
+2012	O
+,	O
+the	O
+infectious	B-DISO
+outbreak	O
+caused	O
+by	O
+MERS	O
+-	O
+CoV	O
+in	O
+Saudi	O
+Arabia	O
+has	O
+spread	O
+to	O
+more	O
+than	O
+1600	O
+patients	O
+in	O
+26	O
+countries	O
+,	O
+resulting	O
+in	O
+over	O
+600	O
+deaths	B-PROC
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+summarize	O
+the	O
+recent	O
+findings	O
+in	O
+the	O
+field	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+especially	O
+its	O
+molecular	O
+virology	O
+,	O
+interspecies	O
+mechanisms	O
+,	O
+clinical	O
+features	O
+,	O
+antiviral	B-CHED
+therapies	O
+,	O
+and	O
+the	O
+further	O
+investigation	O
+into	O
+this	O
+disease	O
+.	O
+
+Laboratory	O
+testing	O
+is	O
+required	O
+for	O
+a	O
+reliable	O
+diagnosis	O
+of	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+,	O
+as	O
+a	O
+clinical	O
+diagnosis	O
+can	O
+be	O
+difficult	O
+since	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+are	O
+often	O
+overlapping	O
+and	O
+not	O
+specific	O
+for	O
+any	O
+one	O
+virus	B-SPEC
+.	O
+
+Adenovirus	B-DISO
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+detected	O
+at	O
+71	O
+.	O
+1	O
+%.	O
+
+We	O
+found	O
+that	O
+the	O
+PEDV	B-SPEC
+spike	O
+is	O
+activated	O
+by	O
+lysosomal	B-PRGE
+cysteine	B-CHED
+proteases	I-PRGE
+but	I-PRGE
+not	I-PRGE
+proprotein	I-PRGE
+convertases	I-PRGE
+or	I-PRGE
+cell	B-COMP
+surface	I-COMP
+serine	B-CHED
+proteases	I-PRGE
+.	O
+
+To	O
+gain	O
+insights	O
+into	O
+mechanisms	O
+of	O
+PEDV	B-SPEC
+-	O
+pAPN	O
+interactions	O
+,	O
+the	O
+present	O
+study	O
+aimed	O
+at	O
+identifying	O
+the	O
+domain	O
+that	O
+is	O
+critical	O
+for	O
+PEDV	B-SPEC
+binding	B-FUNC
+.	O
+
+The	O
+mutants	O
+were	O
+;	O
+domain	O
+VII	O
+deletion	O
+mutant	B-DISO
+and	O
+domains	O
+IV	O
+-	O
+VI	O
+deletion	O
+mutant	B-DISO
+.	O
+
+These	O
+findings	O
+are	O
+important	O
+for	O
+therapeutic	O
+development	B-PROC
+as	O
+well	O
+as	O
+creating	O
+a	O
+platform	O
+for	O
+future	O
+studies	O
+on	O
+PEDV	B-SPEC
+.	O
+
+After	O
+20	O
+passages	O
+in	O
+HeLa	B-ANAT
+cells	I-ANAT
+,	O
+the	O
+ability	O
+of	O
+the	O
+isolate	O
+to	O
+use	O
+cathepsin	B-PRGE
+increased	O
+so	O
+that	O
+it	O
+was	O
+equal	O
+to	O
+that	O
+of	O
+the	O
+laboratory	O
+strain	O
+;	O
+this	O
+increase	O
+was	O
+caused	O
+by	O
+an	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+(	O
+I577S	O
+)	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+passaged	O
+virus	B-SPEC
+showed	O
+a	O
+reduced	O
+ability	O
+to	O
+replicate	O
+in	O
+differentiated	B-PROC
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+cultured	O
+at	O
+an	O
+air	B-CHED
+-	O
+liquid	O
+interface	O
+.	O
+
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+utilizes	O
+endosomal	O
+cathepsin	B-PRGE
+L	I-PRGE
+to	O
+activate	O
+the	O
+spike	O
+protein	B-CHED
+after	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+Microproteinuria	B-DISO
+has	O
+been	O
+associated	O
+with	O
+the	O
+presence	O
+of	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+as	O
+well	O
+as	O
+trauma	O
+,	O
+although	O
+its	O
+association	O
+with	O
+AP	O
+is	O
+not	O
+well	O
+understood	O
+.	O
+
+Urine	B-ANAT
+samples	O
+were	O
+collected	O
+upon	O
+admission	O
+,	O
+12	O
+-	O
+24	O
+h	O
+after	O
+admission	O
+,	O
+and	O
+3	O
+months	O
+post	O
+-	O
+discharge	B-ANAT
+for	O
+calculation	O
+of	O
+urine	B-ANAT
+α1	O
+-	O
+microglobulin	O
+-,	O
+albumin	B-PRGE
+-,	O
+IgG	B-PRGE
+-,	O
+and	O
+IgM	B-PRGE
+/	O
+creatinine	B-CHED
+ratios	O
+.	O
+
+The	O
+α1	O
+-	O
+microglobulin	O
+-,	O
+albumin	B-PRGE
+-,	O
+and	O
+IgG	B-PRGE
+/	O
+creatinine	B-CHED
+ratios	O
+correlated	O
+with	O
+high	O
+-	O
+sensitivity	O
+C	O
+-	O
+reactive	O
+protein	B-CHED
+48	O
+h	O
+after	O
+admission	O
+(	O
+r	O
+=	O
+0	O
+.	O
+47	O
+-	O
+0	O
+.	O
+61	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+for	O
+all	O
+).	O
+
+The	O
+α1	O
+-	O
+microglobulin	O
+/	O
+creatinine	B-CHED
+ratio	O
+upon	O
+admission	O
+predicted	O
+organ	B-DISO
+failure	I-DISO
+[	O
+adjusted	O
+odds	O
+ratio	O
+1	O
+.	O
+286	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+)	O
+1	O
+.	O
+024	O
+-	O
+1	O
+.	O
+614	O
+]	O
+with	O
+similar	O
+accuracy	O
+(	O
+AUROC	O
+0	O
+.	O
+81	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+69	O
+-	O
+0	O
+.	O
+94	O
+)	O
+as	O
+the	O
+more	O
+complex	O
+APACHE	O
+II	O
+score	O
+(	O
+AUROC	O
+0	O
+.	O
+86	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+70	O
+-	O
+1	O
+.	O
+00	O
+).	O
+
+The	O
+α1	O
+-	O
+microglobulin	O
+/	O
+creatinine	B-CHED
+ratio	O
+upon	O
+presentation	O
+with	O
+AP	O
+is	O
+related	O
+to	O
+inflammation	B-DISO
+and	O
+predicts	O
+development	B-PROC
+of	O
+organ	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Gastroenteritis	O
+represents	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+the	O
+most	O
+common	O
+infectious	B-DISO
+disease	I-DISO
+syndrome	B-DISO
+of	O
+humans	B-SPEC
+in	O
+developing	O
+countries	O
+.	O
+
+With	O
+this	O
+manuscript	O
+,	O
+we	O
+want	O
+to	O
+explore	O
+and	O
+emphasize	O
+the	O
+critical	O
+aspect	O
+of	O
+acute	B-DISO
+gastroenteritis	I-DISO
+in	O
+Middle	O
+-	O
+East	O
+Countries	O
+and	O
+its	O
+correlation	O
+with	O
+the	O
+clinical	O
+aspect	O
+of	O
+gut	B-ANAT
+microbiota	B-SPEC
+modification	O
+and	O
+intestinal	B-ANAT
+homeostasis	B-PROC
+.	O
+
+Approximately	O
+1	O
+of	O
+50	O
+children	O
+born	O
+each	O
+year	O
+in	O
+developed	O
+nations	O
+is	O
+hospitalized	O
+for	O
+acute	B-DISO
+gastroenteritis	I-DISO
+sometime	O
+during	O
+childhood	O
+.	O
+
+In	O
+this	O
+scenario	O
+,	O
+one	O
+of	O
+the	O
+most	O
+interesting	O
+aspects	O
+is	O
+that	O
+probiotics	O
+and	O
+gut	B-ANAT
+microbiota	B-SPEC
+modulation	O
+could	O
+deeply	O
+improve	O
+the	O
+prevention	O
+and	O
+treatment	O
+of	O
+this	O
+devastating	O
+GI	O
+pathology	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Approximately	O
+1	O
+of	O
+50	O
+children	O
+born	O
+each	O
+year	O
+in	O
+developed	O
+nations	O
+is	O
+hospitalized	O
+for	O
+acute	B-DISO
+gastroenteritis	I-DISO
+sometime	O
+during	O
+childhood	O
+.	O
+
+A	O
+total	O
+of	O
+95	O
+pythons	B-SPEC
+,	O
+84	O
+boas	B-SPEC
+and	O
+22	O
+snakes	B-SPEC
+of	O
+unknown	O
+species	B-SPEC
+were	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+Nidoviruses	B-SPEC
+are	O
+believed	O
+to	O
+be	O
+an	O
+important	O
+cause	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+pythons	B-SPEC
+,	O
+but	O
+can	O
+also	O
+infect	O
+boas	B-SPEC
+.	O
+
+Detection	O
+of	O
+these	O
+viruses	B-SPEC
+in	O
+live	O
+animals	B-SPEC
+is	O
+now	O
+possible	O
+and	O
+can	O
+be	O
+of	O
+interest	O
+both	O
+in	O
+diseased	O
+animals	B-SPEC
+as	O
+well	O
+as	O
+in	O
+quarantine	O
+situations	O
+.	O
+
+The	O
+objective	O
+of	O
+our	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+hydrocortisone	B-CHED
+treatment	O
+in	O
+sepsis	B-DISO
+-	O
+associated	O
+ARDS	B-DISO
+.	O
+
+The	O
+treatment	O
+group	O
+had	O
+significant	O
+improvement	O
+in	O
+the	O
+ratio	O
+of	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+to	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+and	O
+lung	B-ANAT
+injury	O
+score	O
+(	O
+p	O
+=	O
+0	O
+.	O
+01	O
+),	O
+and	O
+similar	O
+timing	O
+to	O
+removal	O
+of	O
+vital	O
+organ	B-ANAT
+support	O
+(	O
+HR	O
+0	O
+.	O
+74	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+51	O
+-	O
+1	O
+.	O
+07	O
+;	O
+p	O
+=	O
+0	O
+.	O
+107	O
+).	O
+
+In	O
+this	O
+review	O
+we	O
+summarize	O
+recent	O
+findings	O
+on	O
+the	O
+molecular	O
+evolution	B-PROC
+of	O
+HCoV	O
+genomes	O
+,	O
+with	O
+special	O
+attention	O
+to	O
+recombination	B-PROC
+and	O
+adaptive	O
+events	O
+that	O
+generated	O
+new	O
+viral	O
+species	B-SPEC
+and	O
+contributed	O
+to	O
+host	B-COMP
+shifts	O
+and	O
+to	O
+HCoV	O
+emergence	O
+.	O
+
+AIV	O
+infection	B-DISO
+of	O
+macrophages	B-ANAT
+was	O
+required	O
+to	O
+activate	O
+T	B-ANAT
+lymphocytes	I-ANAT
+and	O
+prior	O
+in	O
+vivo	O
+exposure	O
+of	O
+chickens	B-SPEC
+to	O
+NP	O
+AIV	O
+plasmid	O
+enhanced	O
+responses	O
+to	O
+infected	O
+macrophages	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+is	O
+commonly	O
+used	O
+to	O
+prevent	O
+endotracheal	O
+intubation	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+).	O
+
+Patients	O
+with	O
+hypoxemic	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+who	O
+fail	O
+an	O
+NIV	O
+trial	O
+carry	O
+a	O
+worse	O
+prognosis	O
+as	O
+compared	O
+to	O
+those	O
+who	O
+succeed	O
+.	O
+
+There	O
+is	O
+therefore	O
+an	O
+ongoing	O
+debate	O
+as	O
+to	O
+whether	O
+and	O
+which	O
+ARDS	B-DISO
+patients	O
+are	O
+good	O
+candidates	O
+to	O
+an	O
+NIV	O
+trial	O
+.	O
+
+The	O
+F	B-PRGE
+protein	I-PRGE
+of	O
+RSV	B-SPEC
+was	O
+detected	O
+in	O
+the	O
+renal	B-ANAT
+tissue	I-ANAT
+by	O
+indirect	O
+immunofluorescence	O
+.	O
+
+At	O
+a	O
+higher	O
+infection	B-DISO
+dose	O
+,	O
+6	O
+×	O
+10	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+trimeric	O
+protein	B-CHED
+,	O
+RBD	O
+-	O
+Fd	O
+,	O
+was	O
+generated	O
+by	O
+fusing	O
+RBD	O
+with	O
+foldon	O
+trimerization	O
+motif	O
+.	O
+
+ABSTRACT	O
+:	O
+Noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+is	O
+increasingly	O
+used	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Etiology	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Infections	I-DISO
+in	O
+Infants	O
+:	O
+A	O
+Prospective	O
+Birth	B-PROC
+Cohort	O
+Study	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+this	O
+cohort	O
+of	O
+infants	O
+,	O
+ARI	B-CHED
+incidence	O
+was	O
+1	O
+.	O
+8	O
+episodes	O
+per	O
+year	O
+per	O
+infant	O
+;	O
+95	O
+%	O
+were	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+The	O
+results	O
+of	O
+our	O
+study	O
+are	O
+consistent	O
+with	O
+available	O
+,	O
+yet	O
+very	O
+limited	O
+,	O
+published	O
+data	O
+regarding	O
+the	O
+potential	O
+pathways	B-PROC
+of	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+at	O
+the	O
+animal	B-SPEC
+-	O
+human	B-SPEC
+interface	O
+.	O
+
+TITLE	O
+:	O
+Chest	B-ANAT
+radiographic	O
+manifestations	O
+of	O
+scrub	B-DISO
+typhus	I-DISO
+.	O
+
+Details	O
+and	O
+radiographic	O
+findings	O
+were	O
+noted	O
+and	O
+factors	O
+associated	O
+with	O
+abnormal	O
+X	O
+-	O
+rays	B-SPEC
+were	O
+analyzed	O
+.	O
+
+Common	O
+presenting	O
+complaints	O
+included	O
+fever	B-PROC
+(	O
+100	O
+%),	O
+generalized	O
+myalgia	B-DISO
+(	O
+83	O
+%),	O
+headache	B-DISO
+(	O
+65	O
+%),	O
+dyspnea	B-DISO
+(	O
+54	O
+%),	O
+cough	B-DISO
+(	O
+24	O
+.	O
+3	O
+%),	O
+and	O
+altered	O
+sensorium	O
+(	O
+14	O
+%).	O
+
+Patients	O
+with	O
+an	O
+abnormal	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+had	O
+a	O
+higher	O
+requirement	O
+of	O
+noninvasive	O
+ventilation	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]:	O
+13	O
+.	O
+98	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+CI	O
+:	O
+5	O
+.	O
+89	O
+-	O
+33	O
+.	O
+16	O
+),	O
+invasive	O
+ventilation	O
+(	O
+OR	O
+:	O
+18	O
+.	O
+07	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+6	O
+.	O
+42	O
+-	O
+50	O
+.	O
+88	O
+),	O
+inotropes	O
+(	O
+OR	O
+:	O
+8	O
+.	O
+76	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+4	O
+.	O
+35	O
+-	O
+17	O
+.	O
+62	O
+),	O
+higher	O
+involvement	O
+of	O
+other	O
+organ	B-ANAT
+systems	I-ANAT
+,	O
+longer	O
+duration	O
+of	O
+hospital	O
+stay	O
+(	O
+3	O
+.	O
+18	O
+±	O
+3	O
+vs	O
+.	O
+7	O
+.	O
+27	O
+±	O
+5	O
+.	O
+58	O
+days	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+higher	O
+mortality	O
+(	O
+OR	O
+:	O
+4	O
+.	O
+63	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+54	O
+-	O
+13	O
+.	O
+85	O
+).	O
+
+TITLE	O
+:	O
+Outcomes	O
+in	O
+Critically	B-DISO
+Ill	I-DISO
+Patients	O
+with	O
+Cancer	B-DISO
+-	O
+Related	O
+Complications	O
+.	O
+
+Compared	O
+to	O
+those	O
+without	O
+cancer	B-DISO
+-	O
+related	O
+complications	O
+,	O
+they	O
+more	O
+frequently	O
+had	O
+worse	O
+performance	O
+status	O
+(	O
+PS	O
+)	O
+(	O
+57	O
+%	O
+vs	O
+36	O
+%	O
+with	O
+PS	O
+≥	O
+2	O
+),	O
+active	O
+malignancy	B-DISO
+(	O
+95	O
+%	O
+vs	O
+58	O
+%),	O
+need	O
+for	O
+vasopressors	O
+(	O
+45	O
+%	O
+vs	O
+34	O
+%),	O
+mechanical	O
+ventilation	O
+(	O
+70	O
+%	O
+vs	O
+51	O
+%)	O
+and	O
+dialysis	B-SPEC
+(	O
+12	O
+%	O
+vs	O
+8	O
+%)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+for	O
+all	O
+analyses	O
+).	O
+
+Chemo	O
+/	O
+radiation	O
+therapy	O
+-	O
+induced	O
+toxicity	O
+(	O
+6	O
+%),	O
+venous	B-DISO
+thromboembolism	I-DISO
+(	O
+5	O
+%),	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+4	O
+%),	O
+gastrointestinal	O
+involvement	O
+(	O
+3	O
+%)	O
+and	O
+vena	B-DISO
+cava	I-DISO
+syndrome	I-DISO
+(	O
+VCS	O
+)	O
+(	O
+2	O
+%)	O
+were	O
+the	O
+most	O
+frequent	O
+cancer	B-DISO
+-	O
+related	O
+complications	O
+.	O
+
+The	O
+prognostic	O
+impact	O
+of	O
+cancer	B-DISO
+-	O
+related	O
+complications	O
+was	O
+variable	O
+.	O
+
+R	B-SPEC
+.	I-SPEC
+palmatum	I-SPEC
+L	O
+.	O
+and	O
+R	B-SPEC
+.	I-SPEC
+officinale	I-SPEC
+Baill	O
+.	O
+
+Viral	O
+DNA	O
+production	O
+and	O
+time	O
+of	O
+addition	O
+studies	O
+showed	O
+that	O
+Sennoside	O
+A	O
+targets	O
+the	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PROC
+transcription	I-PROC
+process	I-PROC
+.	O
+
+TITLE	O
+:	O
+Nur77	B-PRGE
+attenuates	O
+endothelin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expression	B-PROC
+via	O
+downregulation	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+and	O
+p38	B-FUNC
+MAPK	B-FUNC
+in	O
+A549	O
+cells	B-ANAT
+and	O
+in	O
+an	O
+ARDS	B-DISO
+rat	B-SPEC
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+inflammatory	O
+injury	O
+to	O
+the	O
+alveolar	B-ANAT
+and	O
+capillary	B-ANAT
+barriers	O
+that	O
+results	O
+in	O
+impaired	B-DISO
+gas	I-DISO
+exchange	I-DISO
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+LPS	B-DISO
+-	O
+induced	O
+phosphorylation	B-PROC
+and	O
+nuclear	B-PROC
+translocation	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+and	O
+p38	B-FUNC
+MAPK	B-FUNC
+were	O
+blocked	O
+by	O
+Nur77	B-PRGE
+overexpression	B-PROC
+and	O
+augmented	O
+by	O
+Nur77	B-PRGE
+knockdown	O
+in	O
+A549	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Healthcare	O
+settings	O
+can	O
+amplify	O
+transmission	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+but	O
+knowledge	O
+gaps	O
+about	O
+the	O
+epidemiology	O
+of	O
+transmission	O
+remain	O
+.	O
+
+TITLE	O
+:	O
+Hemolytic	B-DISO
+uremic	I-DISO
+syndrome	I-DISO
+in	O
+children	O
+.	O
+
+Typical	O
+management	O
+of	O
+STEC	O
+-	O
+HUS	O
+patients	O
+relies	O
+on	O
+supportive	O
+care	O
+of	O
+electrolyte	O
+and	O
+water	B-CHED
+imbalance	B-DISO
+,	O
+anemia	B-DISO
+,	O
+hypertension	B-DISO
+and	O
+renal	B-DISO
+failure	I-DISO
+.	O
+
+Only	O
+CPV	B-SPEC
+and	O
+CCoV	O
+were	O
+significantly	O
+associated	O
+with	O
+diarrhoea	B-DISO
+,	O
+hEC	O
+with	O
+a	O
+subset	O
+of	O
+puppies	O
+that	O
+had	O
+diarrhoea	B-DISO
+and	O
+severe	O
+clinical	O
+signs	O
+.	O
+
+Puppies	O
+from	O
+high	O
+-	O
+volume	O
+dog	B-SPEC
+breeders	O
+were	O
+significantly	O
+at	O
+increased	O
+risk	O
+for	O
+CPV	B-SPEC
+(	O
+OR	O
+4	O
+.	O
+20	O
+),	O
+CCoV	O
+(	O
+OR	O
+4	O
+.	O
+50	O
+)	O
+and	O
+Cystoisospora	B-SPEC
+spp	B-ENZY
+.	O
+
+One	O
+of	O
+the	O
+more	O
+serious	O
+adverse	B-DISO
+effects	I-DISO
+includes	O
+amiodarone	B-CHED
+pulmonary	B-DISO
+toxicity	I-DISO
+(	O
+APT	O
+).	O
+
+Physical	O
+exam	O
+found	O
+bilateral	O
+rhonchi	B-DISO
+with	O
+bibasilar	O
+crackles	B-DISO
+and	O
+subcutaneous	B-DISO
+emphysema	I-DISO
+along	O
+the	O
+left	O
+anterior	B-ANAT
+chest	I-ANAT
+wall	I-ANAT
+.	O
+
+A	O
+chest	B-ANAT
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+on	O
+post	O
+-	O
+operative	O
+day	O
+3	O
+showed	O
+extensive	O
+and	O
+severe	O
+bilateral	O
+ground	O
+glass	O
+opacities	B-DISO
+.	O
+
+APT	B-PRGE
+occurs	O
+via	O
+cytotoxic	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+and	O
+indirectly	O
+by	O
+immunological	O
+reaction	O
+.	O
+
+Some	O
+elements	O
+require	O
+consideration	O
+:	O
+a	O
+baseline	O
+pulmonary	B-PROC
+function	I-PROC
+test	O
+(	O
+PFT	B-CHED
+)	O
+did	O
+not	O
+exist	O
+prior	O
+.	O
+
+Therefore	O
+,	O
+not	O
+every	O
+type	O
+of	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+could	O
+be	O
+ruled	O
+out	O
+.	O
+
+Key	O
+features	O
+support	O
+a	O
+clinical	O
+diagnosis	O
+:	O
+(	O
+1	O
+)	O
+new	O
+dyspnea	B-DISO
+,	O
+(	O
+2	O
+)	O
+exclusion	O
+of	O
+lung	B-DISO
+infection	I-DISO
+,	O
+(	O
+3	O
+)	O
+exclusion	O
+of	O
+heart	B-DISO
+failure	I-DISO
+,	O
+(	O
+4	O
+)	O
+new	O
+radiographic	O
+features	O
+,	O
+(	O
+5	O
+)	O
+improvement	O
+with	O
+withdrawal	B-DISO
+of	O
+amiodarone	B-CHED
+.	O
+
+Thus	O
+,	O
+an	O
+early	O
+evaluation	O
+of	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+can	O
+mitigate	O
+unforeseen	O
+outcomes	O
+within	O
+a	O
+series	O
+of	O
+multiple	O
+compounds	O
+,	O
+although	O
+there	O
+have	O
+been	O
+very	O
+few	O
+examples	O
+to	O
+follow	O
+such	O
+a	O
+policy	O
+.	O
+
+In	O
+this	O
+letter	O
+,	O
+a	O
+novel	O
+""""	O
+head	B-ANAT
+-	O
+to	O
+-	O
+tail	O
+""""	O
+approach	O
+to	O
+discover	O
+a	O
+diverse	O
+set	O
+of	O
+PI4KIIIα	O
+inhibitors	B-CHED
+is	O
+reported	O
+.	O
+
+In	O
+addition	O
+,	O
+when	O
+dealing	O
+with	O
+organisms	O
+that	O
+are	O
+not	O
+obligately	O
+sexually	O
+reproducing	O
+,	O
+recombination	B-PROC
+gives	O
+insight	O
+into	O
+the	O
+rate	O
+at	O
+which	O
+distinct	O
+genetic	O
+lineages	O
+come	O
+into	O
+contact	O
+.	O
+
+Recombination	B-PROC
+in	O
+MERS	O
+-	O
+CoV	O
+implies	O
+frequent	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+distinct	O
+lineages	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+probably	O
+in	O
+camels	B-SPEC
+given	O
+the	O
+current	O
+understanding	O
+of	O
+MERS	O
+-	O
+CoV	O
+epidemiology	O
+.	O
+
+We	O
+examined	O
+the	O
+incubation	O
+period	O
+distribution	O
+of	O
+MERS	O
+coronavirus	B-DISO
+infection	I-DISO
+for	O
+cases	O
+in	O
+South	O
+Korea	O
+and	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Mycobacterial	O
+liquid	O
+culture	O
+and	O
+Xpert	O
+MTB	B-COMP
+/	O
+RIF	O
+was	O
+performed	O
+on	O
+2	O
+induced	O
+sputa	O
+obtained	O
+from	O
+each	O
+participant	O
+.	O
+
+Using	O
+quadratic	O
+discriminant	O
+analysis	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+C	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+,	O
+coronavirus	B-SPEC
+043	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+C	O
+virus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+and	O
+cytomegalovirus	B-SPEC
+best	O
+discriminated	O
+children	O
+with	O
+definite	O
+-	O
+TB	O
+from	O
+the	O
+other	O
+groups	O
+of	O
+children	O
+.	O
+
+Ventilation	O
+with	O
+low	O
+tidal	O
+volumes	O
+and	O
+pressure	O
+limitation	O
+at	O
+30cmH	O
+Demographic	O
+data	O
+,	O
+risk	O
+factors	O
+and	O
+severity	O
+of	O
+ARDS	B-DISO
+,	O
+APACHE	O
+II	O
+and	O
+SOFA	O
+scores	O
+,	O
+daily	O
+Lung	B-ANAT
+Injury	O
+Score	O
+,	O
+ventilatory	O
+measurements	O
+,	O
+ICU	O
+and	O
+hospital	O
+stay	O
+,	O
+organ	B-DISO
+failure	I-DISO
+and	O
+mortality	O
+at	O
+day	O
+28	O
+and	O
+90	O
+after	O
+inclusion	O
+.	O
+
+Infection	B-DISO
+prevention	O
+practices	O
+were	O
+intensified	O
+.	O
+
+ABSTRACT	O
+:	O
+Venovenous	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+vv	O
+-	O
+ECMO	O
+)	O
+is	O
+an	O
+established	O
+salvage	O
+therapy	O
+for	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+and	O
+may	O
+provide	O
+an	O
+alternative	O
+form	O
+of	O
+treatment	O
+for	O
+trauma	O
+-	O
+induced	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+when	O
+conventional	O
+treatments	O
+have	O
+failed	O
+.	O
+
+Two	O
+patients	O
+treated	O
+with	O
+heparin	B-CHED
+-	O
+free	O
+ECMO	O
+developed	O
+thromboembolic	O
+complications	O
+.	O
+
+For	O
+patients	O
+with	O
+a	O
+moderate	O
+risk	O
+of	O
+bleeding	B-DISO
+,	O
+use	O
+of	O
+a	O
+heparin	B-CHED
+infusion	O
+keeping	O
+an	O
+ACT	O
+target	O
+shorter	O
+than	O
+150	O
+seconds	O
+can	O
+be	O
+appropriate	O
+.	O
+
+Performance	O
+of	O
+an	O
+emergent	O
+thoracotomy	O
+,	O
+blunt	O
+mechanism	O
+,	O
+and	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+administration	O
+were	O
+independently	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+early	O
+ARDS	B-DISO
+.	O
+
+The	O
+median	O
+lung	B-ANAT
+injury	O
+score	O
+was	O
+9	O
+(	O
+8	O
+-	O
+10	O
+).	O
+
+The	O
+overall	O
+median	O
+CoV	O
+and	O
+regional	O
+lung	B-ANAT
+filling	O
+characteristics	O
+were	O
+not	O
+affected	O
+by	O
+NMB	O
+,	O
+indicating	O
+no	O
+ventilation	O
+shift	O
+toward	O
+the	O
+non	O
+-	O
+dependent	O
+lung	B-ANAT
+zones	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	B-PRGE
+Respiratory	I-PRGE
+Coronavirus	I-PRGE
+Accessory	I-PRGE
+Protein	B-CHED
+4a	I-PRGE
+Inhibits	O
+PKR	B-PRGE
+-	O
+Mediated	O
+Antiviral	B-CHED
+Stress	O
+Responses	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+cellular	O
+infection	B-DISO
+with	O
+MERS	O
+-	O
+CoV	O
+does	O
+not	O
+lead	O
+to	O
+the	O
+formation	B-PROC
+of	O
+SGs	B-DISO
+.	O
+
+By	O
+inserting	O
+p4a	O
+in	O
+a	O
+picornavirus	B-SPEC
+lacking	O
+its	O
+natural	O
+PKR	B-PRGE
+antagonist	B-PROC
+,	O
+we	O
+showed	O
+that	O
+p4a	O
+exerts	B-PROC
+PKR	B-PRGE
+antagonistic	O
+activity	O
+also	O
+under	O
+infection	B-DISO
+conditions	O
+.	O
+
+PEDV	B-SPEC
+vaccines	O
+are	O
+available	O
+in	O
+Asia	O
+and	O
+Europe	O
+,	O
+and	O
+conditionally	O
+-	O
+licensed	O
+vaccines	O
+recently	O
+became	O
+available	O
+in	O
+the	O
+United	O
+States	O
+but	O
+the	O
+efficacies	O
+of	O
+these	O
+vaccines	O
+in	O
+eliminating	O
+PEDV	B-SPEC
+from	O
+swine	B-SPEC
+populations	O
+are	O
+questionable	O
+.	O
+
+The	O
+viral	B-DISO
+infections	I-DISO
+have	O
+been	O
+reported	O
+in	O
+more	O
+than	O
+1700	O
+humans	B-SPEC
+,	O
+ranging	O
+from	O
+asymptomatic	O
+or	O
+mild	O
+cases	O
+to	O
+severe	O
+pneumonia	B-DISO
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+40	O
+%.	O
+
+It	O
+is	O
+well	O
+documented	O
+now	O
+that	O
+dromedary	B-SPEC
+camels	B-SPEC
+contract	O
+the	O
+infection	B-DISO
+and	O
+shed	O
+the	O
+virus	B-SPEC
+without	O
+notable	O
+symptoms	O
+,	O
+and	O
+such	O
+animals	B-SPEC
+had	O
+been	O
+infected	O
+by	O
+at	O
+least	O
+the	O
+early	O
+1980s	O
+.	O
+
+The	O
+mechanism	O
+of	O
+camel	B-SPEC
+to	O
+human	B-SPEC
+transmission	O
+is	O
+still	O
+not	O
+clear	O
+,	O
+but	O
+several	O
+primary	O
+cases	O
+have	O
+been	O
+associated	O
+with	O
+camel	B-SPEC
+contact	O
+.	O
+
+Bacteria	B-SPEC
+were	O
+associated	O
+with	O
+almost	O
+half	O
+of	O
+community	O
+-	O
+acquired	O
+acute	B-DISO
+bronchitis	I-DISO
+cases	O
+.	O
+
+TITLE	O
+:	O
+Proteolytic	B-PROC
+processing	I-PROC
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+spikes	O
+expands	O
+virus	B-SPEC
+tropism	B-PROC
+.	O
+
+Consistent	O
+with	O
+these	O
+findings	O
+,	O
+precleaved	O
+MERS	O
+viruses	B-SPEC
+used	O
+receptor	O
+-	O
+proximal	O
+,	O
+cell	B-COMP
+-	O
+surface	O
+proteases	O
+to	O
+effect	O
+the	O
+second	O
+fusion	O
+-	O
+activating	O
+cleavages	O
+during	O
+cell	B-COMP
+entry	O
+,	O
+whereas	O
+the	O
+more	O
+rigid	B-DISO
+uncleaved	O
+MERS	O
+viruses	B-SPEC
+trafficked	B-PROC
+past	O
+these	O
+cell	B-COMP
+-	O
+surface	O
+proteases	O
+and	O
+into	O
+endosomes	O
+.	O
+
+Nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+is	O
+the	O
+RNA	O
+-	O
+binding	B-FUNC
+protein	B-CHED
+of	O
+PEDV	B-SPEC
+,	O
+which	O
+plays	O
+an	O
+important	O
+role	O
+for	O
+virus	B-SPEC
+life	O
+cycle	O
+.	O
+
+There	O
+were	O
+1	O
+,	O
+286	O
+compounds	O
+of	O
+FDA	O
+-	O
+approved	O
+drug	O
+database	O
+that	O
+could	O
+virtually	O
+bind	B-FUNC
+to	O
+the	O
+RNA	O
+-	O
+binding	B-FUNC
+region	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+Arterivirus	B-SPEC
+nonstructural	O
+protein	B-CHED
+11	O
+(	O
+nsp11	O
+)	O
+was	O
+shown	O
+to	O
+have	O
+NendoU	O
+activity	O
+and	O
+play	O
+essential	O
+roles	O
+in	O
+the	O
+viral	B-PROC
+life	I-PROC
+cycle	I-PROC
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+three	O
+crystal	B-ANAT
+structures	O
+of	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+)	O
+and	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+(	O
+EAV	B-SPEC
+)	O
+nsp11	O
+mutants	O
+.	O
+
+Although	O
+the	O
+NTD	O
+is	O
+nearly	O
+identical	O
+,	O
+the	O
+catalytic	O
+region	O
+of	O
+the	O
+arterivirus	B-PRGE
+nsp11	I-PRGE
+family	B-SPEC
+proteins	B-CHED
+is	O
+remarkably	O
+flexible	O
+,	O
+and	O
+the	O
+oligomerization	O
+may	O
+be	O
+concentration	O
+dependent	O
+.	O
+
+Due	O
+to	O
+the	O
+lack	O
+of	O
+a	O
+suitable	O
+vaccine	O
+or	O
+effective	O
+drug	O
+treatment	O
+and	O
+the	O
+quick	O
+spread	O
+of	O
+these	O
+viruses	B-SPEC
+,	O
+infected	O
+animals	B-SPEC
+either	O
+die	O
+quickly	O
+or	O
+must	O
+be	O
+culled	O
+.	O
+
+The	O
+hydrophobic	O
+groove	B-ANAT
+of	O
+the	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+)	O
+gp41	O
+NHR	O
+trimer	O
+has	O
+been	O
+known	O
+as	O
+the	O
+classic	O
+drug	O
+target	O
+to	O
+develop	O
+fusion	O
+inhibitors	B-CHED
+derived	O
+from	O
+the	O
+gp41	O
+CHR	B-DISO
+.	O
+
+We	O
+identified	O
+a	O
+shallow	O
+pocket	O
+adjacent	O
+to	O
+the	O
+groove	B-ANAT
+in	O
+the	O
+NHR	O
+trimer	O
+and	O
+added	O
+a	O
+short	O
+artificial	O
+peptide	B-CHED
+consisting	O
+of	O
+three	O
+amino	B-CHED
+acids	I-CHED
+(	O
+IDL	O
+)	O
+to	O
+the	O
+C	O
+terminus	O
+of	O
+a	O
+fusion	O
+inhibitor	B-CHED
+to	O
+fit	B-DISO
+this	O
+new	O
+target	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+harboring	O
+two	O
+point	B-PROC
+mutations	I-PROC
+in	O
+the	O
+spike	O
+glycoprotein	B-CHED
+(	O
+rOC	O
+/	O
+U	O
+Because	O
+they	O
+are	O
+naturally	O
+neuroinvasive	O
+and	O
+neurotropic	O
+,	O
+human	B-SPEC
+coronaviruses	O
+are	O
+suspected	O
+to	O
+participate	O
+in	O
+the	O
+development	B-PROC
+of	O
+neurological	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+binds	B-FUNC
+to	O
+cellular	B-COMP
+receptor	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+)	O
+via	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+).	O
+
+MERS	O
+-	O
+CoV	O
+was	O
+first	O
+identified	O
+in	O
+June	O
+2012	O
+and	O
+has	O
+since	O
+spread	O
+in	O
+humans	B-SPEC
+and	O
+camels	B-SPEC
+.	O
+
+We	O
+have	O
+previously	O
+described	O
+a	O
+mouse	B-SPEC
+model	O
+in	O
+which	O
+mDPP4	O
+was	O
+replaced	O
+with	O
+hDPP4	O
+such	O
+that	O
+hDPP4	O
+is	O
+expressed	B-PROC
+under	O
+the	O
+endogenous	O
+mDPP4	O
+promoter	O
+.	O
+
+Porcine	B-SPEC
+circovirus	I-SPEC
+2	I-SPEC
+(	O
+PCV2	O
+)	O
+is	O
+an	O
+essential	O
+component	O
+of	O
+PCVAD	O
+,	O
+although	O
+an	O
+etiologic	O
+role	O
+in	O
+PDNS	O
+is	O
+not	O
+well	O
+established	O
+.	O
+
+Here	O
+,	O
+a	O
+novel	O
+circovirus	B-SPEC
+,	O
+designated	O
+porcine	B-SPEC
+circovirus	I-SPEC
+3	O
+(	O
+PCV3	O
+),	O
+was	O
+identified	O
+in	O
+sows	O
+that	O
+died	B-PROC
+acutely	O
+with	O
+PDNS	O
+-	O
+like	O
+clinical	O
+signs	O
+.	O
+
+Aborted	B-ANAT
+fetuses	I-ANAT
+from	O
+sows	O
+with	O
+PDNS	O
+contained	O
+high	O
+levels	O
+of	O
+PCV3	O
+(	O
+7	O
+.	O
+57	O
+×	O
+10	O
+While	O
+porcine	B-SPEC
+circovirus	I-SPEC
+2	I-SPEC
+(	O
+PCV2	B-SPEC
+)	O
+was	O
+first	O
+identified	O
+in	O
+sporadic	O
+cases	O
+of	O
+postweaning	O
+multisystemic	O
+wasting	B-DISO
+syndrome	I-DISO
+in	O
+Canada	O
+in	O
+the	O
+early	O
+1990s	O
+,	O
+an	O
+epidemic	O
+of	O
+severe	O
+systemic	O
+disease	O
+due	O
+to	O
+PCV2	B-SPEC
+spread	O
+worldwide	O
+in	O
+the	O
+ensuing	O
+decade	O
+.	O
+
+TITLE	O
+:	O
+Health	O
+evaluation	O
+of	O
+African	O
+penguins	B-SPEC
+(<	O
+i	O
+>	O
+Spheniscus	B-SPEC
+demersus	I-SPEC
+</	O
+i	O
+>)	O
+in	O
+southern	O
+Africa	O
+.	O
+
+Avoiding	O
+regions	O
+symptomatic	O
+of	O
+conformational	O
+flexibility	O
+such	O
+as	O
+disordered	O
+sites	O
+and	O
+sites	O
+with	O
+nonconserved	O
+secondary	O
+structure	O
+to	O
+identify	O
+potential	O
+broad	O
+-	O
+specificity	O
+antiviral	B-CHED
+targets	O
+,	O
+only	O
+one	O
+sequence	O
+motif	O
+(	O
+five	O
+residues	O
+or	O
+longer	O
+)	O
+remains	O
+from	O
+the	O
+>	O
+10	O
+,	O
+000	O
+starting	O
+sites	O
+across	O
+all	O
+coronaviruses	O
+in	O
+this	O
+study	O
+.	O
+
+We	O
+found	O
+here	O
+that	O
+production	O
+of	O
+the	O
+cytokine	B-PRGE
+IL	I-PRGE
+-	I-PRGE
+15	I-PRGE
+by	O
+FRCs	B-PROC
+was	O
+essential	O
+for	O
+the	O
+maintenance	O
+of	O
+group	O
+1	O
+innate	O
+lymphoid	B-ANAT
+cells	I-ANAT
+(	O
+ILCs	O
+)	O
+in	O
+Peyer	B-ANAT
+'	I-ANAT
+s	I-ANAT
+patches	I-ANAT
+and	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+
+TITLE	O
+:	O
+Isolation	O
+of	O
+Coronavirus	B-SPEC
+NL63	O
+from	O
+Blood	B-ANAT
+from	O
+Children	O
+in	O
+Rural	O
+Haiti	O
+:	O
+Phylogenetic	O
+Similarities	O
+with	O
+Recent	O
+Isolates	O
+from	O
+Malaysia	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronavirus	O
+(	O
+HCoV	O
+)	O
+NL63	O
+is	O
+recognized	O
+as	O
+a	O
+common	O
+cause	O
+of	O
+upper	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+and	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+.	O
+
+Our	O
+data	O
+highlight	O
+the	O
+variety	O
+of	O
+presentations	O
+that	O
+may	O
+be	O
+seen	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+and	O
+underscore	O
+the	O
+apparent	O
+ease	O
+with	O
+which	O
+CoV	O
+strains	O
+move	O
+among	O
+countries	O
+,	O
+with	O
+our	O
+data	O
+consistent	O
+with	O
+recurrent	O
+introduction	O
+of	O
+strains	O
+into	O
+the	O
+Caribbean	O
+(	O
+Haiti	O
+and	O
+Florida	O
+)	O
+from	O
+Asia	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+is	O
+an	O
+effective	O
+treatment	O
+for	O
+severe	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+refractory	O
+hypoxemia	O
+.	O
+
+However	O
+,	O
+the	O
+rescue	O
+effects	O
+of	O
+HFOV	O
+on	O
+severe	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PARDS	O
+)	O
+with	O
+hypoxemia	O
+refractory	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+)	O
+remain	O
+unclear	O
+.	O
+
+Two	O
+were	O
+phylogenetically	O
+similar	O
+to	O
+the	O
+Circovirus	B-SPEC
+genus	B-SPEC
+,	O
+whereas	O
+the	O
+other	O
+four	O
+nucleotide	B-CHED
+fragments	O
+showed	O
+no	O
+similarity	O
+to	O
+any	O
+of	O
+the	O
+known	O
+genera	O
+within	O
+the	O
+family	O
+Circoviridae	O
+.	O
+
+The	O
+Mirasol	O
+Pathogen	O
+Reduction	O
+Technology	O
+System	O
+uses	O
+riboflavin	B-CHED
+and	O
+ultraviolet	O
+(	O
+UV	O
+)	O
+light	O
+to	O
+render	O
+blood	B-ANAT
+-	O
+borne	O
+pathogens	O
+noninfectious	O
+while	O
+maintaining	O
+blood	B-ANAT
+product	O
+quality	O
+.	O
+
+The	O
+infectious	B-DISO
+titers	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+the	O
+samples	O
+before	O
+and	O
+after	O
+treatment	O
+were	O
+determined	O
+by	O
+plaque	B-DISO
+assay	O
+on	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+mean	O
+log	O
+reductions	O
+in	O
+the	O
+viral	O
+titers	O
+were	O
+≥	O
+4	O
+.	O
+07	O
+and	O
+≥	O
+4	O
+.	O
+42	O
+for	O
+the	O
+pooled	O
+and	O
+individual	O
+donor	B-CHED
+plasma	B-ANAT
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Septic	O
+porcine	B-SPEC
+blood	B-ANAT
+does	O
+not	O
+further	O
+activate	O
+coagulation	B-PROC
+during	O
+in	O
+vitro	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+For	O
+patients	O
+with	O
+a	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+represents	O
+a	O
+life	O
+-	O
+saving	O
+measure	O
+.	O
+
+Frequently	O
+,	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+also	O
+show	O
+signs	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+In	O
+this	O
+pilot	O
+study	O
+,	O
+we	O
+show	O
+for	O
+the	O
+first	O
+time	O
+that	O
+blood	B-ANAT
+neutrophils	I-ANAT
+from	O
+patients	O
+with	O
+ARDS	B-DISO
+can	O
+express	O
+GILZ	O
+,	O
+in	O
+keeping	O
+with	O
+an	O
+anti	O
+-	O
+inflammatory	O
+and	O
+regulatory	O
+endogenous	O
+role	O
+of	O
+GILZ	O
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+the	O
+clinical	O
+features	O
+and	O
+risk	O
+factors	O
+for	O
+adverse	O
+outcome	O
+in	O
+patients	O
+with	O
+RT	O
+-	O
+PCR	O
+confirmed	O
+MERS	O
+and	O
+in	O
+those	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+who	O
+were	O
+MERS	O
+-	O
+CoV	O
+negative	O
+,	O
+presenting	O
+to	O
+the	O
+King	O
+Fahad	O
+Medical	O
+City	O
+(	O
+KFMC	O
+)	O
+in	O
+Riyadh	O
+between	O
+October	O
+2012	O
+and	O
+May	O
+2014	O
+.	O
+
+The	O
+demographics	O
+,	O
+clinical	O
+and	O
+laboratory	O
+characteristics	O
+and	O
+clinical	O
+outcomes	O
+of	O
+patients	O
+with	O
+RT	O
+-	O
+PCR	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+was	O
+compared	O
+with	O
+those	O
+testing	O
+negative	O
+MERS	O
+-	O
+CoV	O
+PCR	O
+.	O
+
+This	O
+article	O
+focuses	O
+on	O
+the	O
+epidemiology	O
+,	O
+transmission	O
+,	O
+and	O
+control	O
+of	O
+health	O
+care	O
+-	O
+associated	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+A	O
+subset	O
+of	O
+calves	O
+was	O
+systematically	O
+selected	O
+for	O
+fecal	B-ANAT
+sampling	O
+at	O
+3	O
+time	O
+points	O
+between	O
+7	O
+and	O
+27d	O
+of	O
+age	O
+.	O
+
+Postweaning	O
+body	B-ANAT
+weight	O
+and	O
+carcass	O
+grading	O
+information	O
+was	O
+collected	O
+from	O
+the	O
+veal	O
+calves	O
+at	O
+slaughter	O
+once	O
+a	O
+live	O
+weight	O
+between	O
+300	O
+and	O
+350kg	O
+had	O
+been	O
+achieved	O
+.	O
+
+TITLE	O
+:	O
+A	O
+comprehensive	O
+systematic	O
+review	O
+of	O
+healthcare	O
+workers	O
+'	O
+perceptions	O
+of	O
+risk	O
+from	O
+exposure	O
+to	O
+emerging	O
+acute	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+the	O
+perceived	O
+effectiveness	O
+of	O
+strategies	O
+used	O
+to	O
+facilitate	O
+healthy	O
+coping	O
+in	O
+acute	O
+hospital	O
+and	O
+community	O
+healthcare	O
+settings	O
+.	O
+
+Organizational	O
+implementation	O
+of	O
+infection	B-DISO
+control	O
+measures	O
+;	O
+avoidance	O
+of	O
+patients	O
+;	O
+and	O
+complying	O
+with	O
+personal	O
+protective	O
+equipment	O
+were	O
+identified	O
+as	O
+risk	O
+-	O
+mitigating	O
+strategies	O
+.	O
+
+PACUs	B-SPEC
+were	O
+excluded	O
+because	O
+there	O
+are	O
+aspects	O
+of	O
+the	O
+presence	O
+of	O
+visitors	O
+to	O
+these	O
+units	O
+that	O
+are	O
+very	O
+specific	O
+,	O
+and	O
+differ	O
+from	O
+the	O
+general	O
+visits	O
+to	O
+patients	O
+who	O
+are	O
+not	O
+in	O
+the	O
+immediate	O
+post	O
+-	O
+operative	O
+stage	O
+.	O
+
+Due	O
+to	O
+type	O
+of	O
+designs	O
+and	O
+quality	O
+of	O
+available	O
+studies	O
+,	O
+it	O
+was	O
+not	O
+possible	O
+to	O
+pool	O
+quantitative	O
+research	O
+study	O
+results	O
+in	O
+a	O
+statistical	O
+meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+No	O
+connection	O
+was	O
+found	O
+between	O
+liberal	O
+visiting	O
+hours	O
+and	O
+increased	O
+infection	B-DISO
+rates	O
+.	O
+
+The	O
+metabolite	B-CHED
+,	O
+protein	B-CHED
+,	O
+and	O
+lipid	B-CHED
+extraction	O
+(	O
+MPLEx	O
+)	O
+protocol	O
+proved	O
+to	O
+be	O
+robust	O
+and	O
+applicable	O
+to	O
+a	O
+diverse	O
+set	O
+of	O
+sample	O
+types	O
+,	O
+including	O
+cell	B-COMP
+cultures	O
+,	O
+microbial	O
+communities	O
+,	O
+and	O
+tissues	B-ANAT
+.	O
+
+Moreover	O
+,	O
+many	O
+of	O
+these	O
+viruses	B-SPEC
+are	O
+select	O
+agents	O
+(	O
+SAs	O
+),	O
+and	O
+their	O
+genomes	O
+are	O
+also	O
+considered	O
+SAs	O
+.	O
+
+For	O
+this	O
+reason	O
+,	O
+cDNAs	O
+and	O
+/	O
+or	O
+their	O
+derivatives	O
+must	O
+be	O
+tested	O
+to	O
+ensure	O
+the	O
+absence	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+and	O
+/	O
+or	O
+viral	O
+RNA	O
+before	O
+transfer	O
+out	O
+of	O
+the	O
+BSL	O
+-	O
+3	O
+/	O
+4	O
+and	O
+/	O
+or	O
+SA	O
+laboratory	O
+.	O
+
+Here	O
+,	O
+we	O
+present	O
+a	O
+sequence	O
+-	O
+independent	O
+method	O
+to	O
+rapidly	O
+amplify	O
+viral	O
+genomic	O
+RNA	O
+while	O
+simultaneously	O
+abolishing	O
+both	O
+viral	O
+and	O
+genomic	O
+RNA	O
+infectivity	O
+across	O
+multiple	O
+single	O
+-	O
+stranded	O
+positive	O
+-	O
+sense	B-PROC
+RNA	O
+(	O
+ssRNA	O
++)	O
+virus	B-SPEC
+families	O
+.	O
+
+Our	O
+barcoding	O
+approach	O
+allows	O
+for	O
+up	O
+to	O
+288	O
+barcoded	O
+samples	O
+to	O
+be	O
+pooled	O
+into	O
+a	O
+single	O
+library	O
+and	O
+run	O
+across	O
+various	O
+NGS	O
+platforms	O
+without	O
+potential	O
+reconstitution	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+Cytoplasmic	B-COMP
+GLTSCR2	O
+was	O
+able	O
+to	O
+interact	O
+with	O
+retinoic	B-CHED
+acid	I-CHED
+-	O
+inducible	O
+gene	B-PRGE
+I	I-PRGE
+(	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+and	O
+the	O
+ubiquitin	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+protease	I-PRGE
+15	I-PRGE
+(	O
+USP15	B-PRGE
+),	O
+and	O
+the	O
+triple	O
+interaction	O
+induced	O
+USP15	B-PRGE
+activity	O
+to	O
+remove	O
+K63	O
+-	O
+linked	O
+ubiquitination	B-PROC
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+,	O
+leading	O
+to	O
+attenuation	O
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+.	O
+
+GLTSCR2	O
+-	O
+mediated	O
+attenuation	O
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+led	O
+to	O
+alleviation	O
+of	O
+host	B-COMP
+cell	I-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Two	O
+-	O
+tailed	B-ANAT
+
+TITLE	O
+:	O
+Manipulating	O
+the	O
+air	B-CHED
+-	O
+filled	O
+zebrafish	B-SPEC
+swim	O
+bladder	B-ANAT
+as	O
+a	O
+neutrophilic	B-PROC
+inflammation	B-DISO
+model	O
+for	O
+acute	O
+lung	O
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+more	O
+severe	O
+form	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+are	O
+life	O
+-	O
+threatening	O
+diseases	O
+that	O
+are	O
+associated	O
+with	O
+high	O
+mortality	O
+rates	O
+due	O
+to	O
+treatment	O
+limitations	O
+.	O
+
+We	O
+performed	O
+a	O
+retrospective	O
+observational	O
+study	O
+of	O
+adults	O
+hospitalized	O
+during	O
+the	O
+2014	O
+season	O
+with	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+or	O
+A	O
+(	O
+H3N2	B-CHED
+).	O
+
+A	O
+(	O
+H1N1	O
+)	O
+patients	O
+were	O
+younger	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+),	O
+developed	O
+more	O
+pneumonia	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+),	O
+respiratory	B-DISO
+complications	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+015	O
+),	O
+ARDS	B-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+047	O
+),	O
+and	O
+septic	B-DISO
+shock	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+049	O
+),	O
+were	O
+more	O
+frequently	O
+admitted	O
+to	O
+the	O
+ICU	O
+(	O
+p	O
+=	O
+0	O
+.	O
+022	O
+),	O
+required	O
+IMV	O
+(	O
+p	O
+=	O
+0	O
+.	O
+049	O
+),	O
+and	O
+were	O
+less	O
+frequently	O
+vaccinated	O
+(	O
+p	O
+=	O
+0	O
+.	O
+008	O
+).	O
+
+The	O
+genome	O
+is	O
+closely	O
+related	O
+to	O
+the	O
+other	O
+OC43	O
+genome	O
+sequences	O
+available	O
+,	O
+ranging	O
+from	O
+99	O
+.	O
+8	O
+%	O
+to	O
+98	O
+.	O
+2	O
+%	O
+nucleotide	B-CHED
+sequence	O
+identity	O
+.	O
+
+Mechanisms	O
+for	O
+its	O
+development	B-PROC
+have	O
+focused	O
+on	O
+immune	O
+mediated	O
+causes	O
+,	O
+aspects	O
+of	O
+our	O
+understanding	O
+are	O
+not	O
+complete	O
+,	O
+and	O
+we	O
+lack	O
+biomarkers	O
+.	O
+
+Samples	O
+were	O
+then	O
+collected	O
+on	O
+the	O
+third	O
+day	O
+after	O
+the	O
+animals	B-SPEC
+were	O
+euthanized	O
+.	O
+
+While	O
+postponing	O
+the	O
+response	O
+to	O
+treatment	O
+,	O
+to	O
+limit	O
+mechanical	O
+ventilation	O
+side	O
+effects	O
+,	O
+extracorporeal	O
+membrane	B-COMP
+oxygene	B-CHED
+can	O
+be	O
+proposed	O
+.	O
+
+ECCO	O
+This	O
+observation	O
+presents	O
+the	O
+diagnostic	O
+and	O
+therapeutic	O
+difficulties	O
+of	O
+the	O
+lung	B-ANAT
+parenchymental	O
+disease	O
+in	O
+intensive	O
+care	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+canine	O
+coronavirus	B-SPEC
+spread	O
+among	O
+domestic	O
+dogs	B-SPEC
+in	O
+Vietnam	O
+.	O
+
+To	O
+detect	O
+genes	O
+of	O
+CCoV	O
+,	O
+fecal	B-ANAT
+samples	O
+collected	O
+from	O
+30	O
+diarrheic	O
+and	O
+50	O
+healthy	O
+dogs	B-SPEC
+were	O
+examinated	O
+by	O
+RT	O
+-	O
+PCR	O
+,	O
+confirming	O
+that	O
+2	O
+diarrheic	O
+dogs	B-SPEC
+and	O
+5	O
+healthy	O
+dogs	B-SPEC
+were	O
+positive	O
+for	O
+CCoV	O
+.	O
+Nucleotide	B-CHED
+sequences	O
+of	O
+N	O
+-	O
+terminal	O
+region	O
+of	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+indicated	O
+that	O
+CCoV	O
+strains	O
+were	O
+divided	O
+into	O
+two	O
+subgenotypes	O
+,	O
+CCoV	B-PRGE
+-	I-PRGE
+IIa	I-PRGE
+and	O
+-	O
+IIb	O
+,	O
+respectively	O
+.	O
+
+Extracorporeal	O
+gas	B-ENZY
+exchange	O
+is	O
+an	O
+accepted	O
+rescue	O
+therapy	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+select	O
+patients	O
+.	O
+
+The	O
+non	O
+-	O
+ARDS	B-DISO
+patient	O
+population	O
+is	O
+much	O
+larger	O
+,	O
+so	O
+the	O
+potential	O
+for	O
+rapid	O
+growth	B-PROC
+is	O
+high	O
+.	O
+
+A	O
+67	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+a	O
+normal	O
+platelet	B-ANAT
+count	O
+(	O
+220	O
+K	O
+/	O
+uL	O
+)	O
+developed	O
+atrial	B-DISO
+fibrillation	I-DISO
+,	O
+left	B-DISO
+bundle	I-DISO
+branch	I-DISO
+block	I-DISO
+,	O
+and	O
+respiratory	B-DISO
+insufficiency	I-DISO
+consistent	O
+with	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+two	O
+days	O
+after	O
+colectomy	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+meta	O
+-	O
+analysis	O
+synthesized	O
+current	O
+evidence	O
+from	O
+10	O
+trials	O
+to	O
+evaluate	O
+the	O
+association	O
+between	O
+steroid	B-CHED
+therapy	O
+and	O
+osteonecrosis	B-DISO
+incidence	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+celastrol	B-CHED
+exhibits	O
+antiviral	B-CHED
+activity	O
+against	O
+HIV	B-DISO
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+To	O
+date	O
+,	O
+no	O
+investigations	O
+of	O
+the	O
+anti	O
+-	O
+DENV	O
+activity	O
+of	O
+celastrol	B-CHED
+have	O
+been	O
+reported	O
+.	O
+
+A	O
+four	O
+-	O
+serotype	O
+DENV	O
+infection	B-DISO
+system	O
+was	O
+performed	O
+to	O
+determine	O
+the	O
+anti	O
+-	O
+DENV	O
+effect	O
+of	O
+celastrol	B-CHED
+by	O
+detecting	O
+DENV	O
+RNA	B-PROC
+replication	I-PROC
+and	O
+protein	B-PROC
+synthesis	I-PROC
+.	O
+
+RESULTS	O
+:	O
+Celastrol	B-CHED
+inhibited	O
+DENV	O
+-	O
+1	O
+,	O
+-	O
+2	O
+,	O
+-	O
+3	O
+,	O
+and	O
+-	O
+4	O
+RNA	B-PROC
+replication	I-PROC
+with	O
+EC	O
+CONCLUSIONS	O
+:	O
+Celastrol	B-CHED
+represents	O
+a	O
+potential	O
+anti	O
+-	O
+DENV	O
+agent	O
+that	O
+induces	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+expression	B-PROC
+and	O
+stimulates	O
+a	O
+downstream	O
+antiviral	B-PROC
+response	I-PROC
+,	O
+making	O
+the	O
+therapy	O
+a	O
+promising	O
+drug	O
+or	O
+dietary	B-CHED
+supplement	I-CHED
+for	O
+the	O
+treatment	O
+of	O
+DENV	O
+-	O
+infected	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+is	O
+the	O
+most	O
+abundant	O
+component	O
+of	O
+the	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+particle	O
+.	O
+
+To	O
+exploit	O
+the	O
+possibility	O
+of	O
+using	O
+RNA	B-PROC
+interference	I-PROC
+(	O
+RNAi	B-PROC
+)	O
+as	O
+a	O
+strategy	O
+against	O
+TGEV	B-SPEC
+infection	B-DISO
+,	O
+three	O
+plasmids	O
+(	O
+pRNAT	O
+-	O
+1	O
+,	O
+pRNAT	O
+-	O
+2	O
+,	O
+and	O
+pRNAT	O
+-	O
+3	O
+)	O
+expressing	O
+short	O
+hairpin	O
+RNAs	O
+were	O
+designed	O
+to	O
+target	O
+three	O
+different	O
+coding	O
+regions	O
+of	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+of	O
+TGEV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Lung	B-ANAT
+protective	O
+ventilation	O
+has	O
+not	O
+been	O
+evaluated	O
+in	O
+patients	O
+with	O
+brain	B-ANAT
+injury	O
+.	O
+
+For	O
+every	O
+centimeter	O
+H	O
+Our	O
+results	O
+suggest	O
+that	O
+PEEP	B-CHED
+can	O
+be	O
+applied	O
+safely	O
+in	O
+patients	O
+with	O
+acute	O
+brain	B-ANAT
+injury	O
+as	O
+it	O
+does	O
+not	O
+have	O
+a	O
+clinically	O
+significant	O
+effect	O
+on	O
+ICP	B-DISO
+or	O
+CPP	O
+.	O
+
+METHODS	O
+:	O
+Retrospective	O
+data	O
+were	O
+collected	O
+from	O
+341	O
+patients	O
+with	O
+severe	O
+acute	O
+brain	B-ANAT
+injury	O
+admitted	O
+to	O
+the	O
+ICU	O
+between	O
+2008	O
+and	O
+2015	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+adjusted	O
+analysis	O
+,	O
+a	O
+statistically	O
+significant	O
+relationship	O
+between	O
+PEEP	B-CHED
+and	O
+ICP	B-DISO
+and	O
+PEEP	B-CHED
+and	O
+CPP	O
+was	O
+found	O
+only	O
+among	O
+observations	O
+occurring	O
+during	O
+periods	B-PROC
+of	O
+severe	O
+lung	B-ANAT
+injury	O
+.	O
+
+For	O
+every	O
+centimeter	O
+H	O
+CONCLUSIONS	O
+:	O
+Our	O
+results	O
+suggest	O
+that	O
+PEEP	B-CHED
+can	O
+be	O
+applied	O
+safely	O
+in	O
+patients	O
+with	O
+acute	O
+brain	B-ANAT
+injury	O
+as	O
+it	O
+does	O
+not	O
+have	O
+a	O
+clinically	O
+significant	O
+effect	O
+on	O
+ICP	B-DISO
+or	O
+CPP	O
+.	O
+
+Swallowing	B-DISO
+disorders	I-DISO
+and	O
+respiratory	O
+muscular	B-DISO
+weakness	I-DISO
+quickly	O
+required	O
+invasive	O
+ventilation	O
+.	O
+
+There	O
+has	O
+been	O
+no	O
+evidence	O
+of	O
+viral	B-PROC
+transmission	I-PROC
+following	O
+the	O
+implantation	B-PROC
+of	O
+these	O
+same	O
+encapsulated	O
+and	O
+functional	O
+porcine	B-SPEC
+islets	O
+into	O
+non	O
+-	O
+immunosuppressed	O
+diabetic	O
+cynomolgus	O
+macaques	B-SPEC
+for	O
+up	O
+to	O
+4	O
+years	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+1207	O
+monthly	O
+samples	O
+taken	O
+from	O
+random	O
+animals	B-SPEC
+over	O
+a	O
+2	O
+-	O
+year	O
+period	O
+,	O
+only	O
+a	O
+single	O
+positive	O
+result	O
+for	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+was	O
+observed	O
+,	O
+demonstrating	O
+the	O
+high	O
+level	O
+of	O
+biosecurity	O
+maintained	O
+in	O
+the	O
+source	O
+herd	O
+.	O
+
+Some	O
+outbreaks	O
+of	O
+which	O
+(	O
+eg	O
+,	O
+SARS	B-DISO
+and	O
+MERS	O
+CoVs	O
+)	O
+caused	O
+the	O
+mortality	O
+of	O
+hundreds	O
+of	O
+people	O
+worldwide	O
+.	O
+
+Both	O
+QSAR	O
+and	O
+molecular	O
+docking	B-PROC
+showed	O
+that	O
+IDX	O
+-	O
+184	O
+is	O
+superior	O
+compared	O
+to	O
+Ribavirin	B-CHED
+against	O
+MERS	O
+CoV	O
+,	O
+a	O
+result	O
+that	O
+was	O
+also	O
+reported	O
+for	O
+HCV	B-SPEC
+.	O
+
+Chest	B-ANAT
+radiographs	O
+showed	O
+newly	O
+developed	O
+consolidative	O
+opacity	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+accounted	O
+for	O
+half	O
+the	O
+isolated	O
+viruses	B-SPEC
+,	O
+especially	O
+subtype	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+among	O
+patients	O
+aged	O
+20	O
+-	O
+59	O
+years	O
+old	O
+,	O
+and	O
+subtype	O
+A	O
+(	O
+H3N2	B-CHED
+)	O
+in	O
+those	O
+aged	O
+60	O
+or	O
+over	O
+;	O
+the	O
+most	O
+frequently	O
+identified	O
+respiratory	O
+virus	B-SPEC
+among	O
+children	O
+under	O
+five	O
+years	O
+old	O
+was	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+65	O
+.	O
+6	O
+%),	O
+followed	O
+by	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+21	O
+.	O
+2	O
+%);	O
+influenza	B-SPEC
+virus	I-SPEC
+circulated	O
+in	O
+all	O
+seasons	O
+of	O
+the	O
+year	O
+and	O
+its	O
+periods	B-PROC
+of	O
+greatest	O
+incidence	O
+were	O
+interspersed	O
+with	O
+those	O
+of	O
+higher	O
+Respiratory	B-SPEC
+Syncytial	I-SPEC
+Virus	I-SPEC
+activity	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Pancreatitis	I-DISO
+Complicated	O
+with	O
+Diabetic	B-DISO
+Ketoacidosis	I-DISO
+in	O
+a	O
+Young	O
+Adult	O
+without	O
+Hypertriglyceridemia	O
+:	O
+A	O
+Case	O
+Report	O
+.	O
+
+Finally	O
+,	O
+the	O
+patient	O
+was	O
+diagnosed	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+complicated	O
+with	O
+diabetic	B-DISO
+ketoacidosis	I-DISO
+unrelated	O
+to	O
+hypertriglyceridemia	O
+.	O
+
+Following	O
+primary	O
+or	O
+secondary	O
+inoculation	O
+,	O
+3	O
+-	O
+10	O
+pigs	B-SPEC
+were	O
+euthanized	O
+at	O
+days	O
+post	O
+-	O
+inoculation	O
+(	O
+dpi	O
+)	O
+1	O
+,	O
+2	O
+,	O
+3	O
+,	O
+7	O
+or	O
+14	O
+.	O
+
+Typical	O
+severe	O
+atrophic	B-DISO
+enteritis	B-DISO
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+was	O
+observed	O
+at	O
+dpi	O
+3	O
+in	O
+both	O
+age	O
+groups	O
+,	O
+and	O
+at	O
+dpi	O
+4	O
+and	O
+14	O
+fecal	B-ANAT
+shedding	O
+patterns	O
+were	O
+also	O
+similar	O
+.	O
+
+The	O
+most	O
+common	O
+source	O
+of	O
+infection	B-DISO
+was	O
+household	O
+contact	O
+(	O
+10	O
+of	O
+15	O
+with	O
+reported	O
+source	O
+)	O
+and	O
+5	O
+patients	O
+acquired	O
+infection	B-DISO
+within	O
+a	O
+health	O
+care	O
+facility	O
+.	O
+
+Using	O
+real	O
+time	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+of	O
+pediatric	O
+patients	O
+revealed	O
+that	O
+9	O
+out	O
+of	O
+552	O
+(	O
+1	O
+.	O
+6	O
+%)	O
+was	O
+positive	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+The	O
+PaO	B-PROC
+This	O
+study	O
+investigated	O
+the	O
+usefulness	O
+of	O
+the	O
+PiCCO	O
+system	O
+in	O
+improving	O
+outcomes	O
+for	O
+patient	O
+with	O
+severe	O
+thoracic	B-DISO
+trauma	O
+and	O
+ARDS	B-DISO
+and	O
+provided	O
+new	O
+evidence	O
+for	O
+fluid	O
+management	O
+in	O
+critical	O
+care	O
+settings	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+Coronavirus	I-SPEC
+in	O
+the	O
+2014	O
+Winter	O
+Season	O
+as	O
+a	O
+Cause	O
+of	O
+Lower	B-DISO
+Respiratory	I-DISO
+Tract	I-DISO
+Infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Introduction	O
+of	O
+neutralizing	O
+immunogenicity	O
+index	O
+to	O
+the	O
+rational	O
+design	O
+of	O
+MERS	O
+coronavirus	B-SPEC
+subunit	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+subunit	O
+vaccines	O
+often	O
+contain	O
+immunodominant	O
+non	O
+-	O
+neutralizing	O
+epitopes	O
+that	O
+divert	O
+host	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+To	O
+determine	O
+the	O
+NII	O
+,	O
+we	O
+mask	O
+the	O
+epitope	B-CHED
+with	O
+a	O
+glycan	B-CHED
+probe	O
+and	O
+then	O
+assess	O
+the	O
+epitope	B-CHED
+'	O
+s	O
+contribution	O
+to	O
+the	O
+vaccine	O
+'	O
+s	O
+overall	O
+neutralizing	O
+immunogenicity	O
+.	O
+
+ABSTRACT	O
+:	O
+CHARGE	O
+(	O
+coloboma	O
+,	O
+heart	B-DISO
+defect	I-DISO
+,	O
+atresia	B-DISO
+choanae	B-ANAT
+,	O
+retarded	B-DISO
+growth	I-DISO
+and	O
+development	B-PROC
+,	O
+genital	B-ANAT
+hypoplasia	B-DISO
+,	O
+and	O
+ear	B-DISO
+anomalies	I-DISO
+/	O
+deafness	B-DISO
+)	O
+syndrome	B-DISO
+is	O
+a	O
+rare	O
+genetic	B-DISO
+disorder	I-DISO
+caused	O
+by	O
+CHD7	B-PRGE
+mutation	I-PRGE
+and	O
+is	O
+related	O
+to	O
+immunodeficiency	B-DISO
+.	O
+
+Disseminated	B-DISO
+BCG	I-DISO
+infection	B-DISO
+did	O
+not	O
+resolve	O
+despite	O
+administration	O
+of	O
+anti	O
+-	O
+tuberculosis	B-PATH
+drugs	O
+and	O
+intravenous	O
+immune	O
+globulins	O
+,	O
+and	O
+she	O
+subsequently	O
+died	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Successful	O
+VV	O
+-	O
+ECMO	O
+treatment	O
+in	O
+patients	O
+with	O
+extremely	O
+severe	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+positive	O
+results	O
+of	O
+the	O
+CESAR	O
+trial	O
+have	O
+led	O
+to	O
+an	O
+exponential	O
+use	O
+of	O
+the	O
+technology	O
+in	O
+recent	O
+years	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+an	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+strain	O
+exhibiting	O
+a	O
+classical	O
+genotype	O
+but	O
+altered	O
+antigenicity	O
+,	O
+pathogenicity	O
+,	O
+and	O
+innate	O
+immunity	O
+profile	O
+.	O
+
+Sequence	O
+analyses	O
+revealed	O
+that	O
+3575	O
+/	O
+08	O
+and	O
+2575	O
+/	O
+98	O
+shared	O
+high	O
+homology	O
+in	O
+their	O
+structural	O
+genes	O
+,	O
+but	O
+not	O
+in	O
+non	O
+-	O
+structural	O
+accessory	O
+proteins	B-CHED
+such	O
+as	O
+3a	O
+,	O
+3b	O
+and	O
+5b	O
+.	O
+
+Animal	B-SPEC
+challenge	O
+experiments	O
+exhibited	O
+strong	O
+respiratory	O
+and	O
+renal	O
+pathogenicity	O
+for	O
+3575	O
+/	O
+08	O
+.	O
+
+We	O
+conclude	O
+that	O
+AEN	O
+should	O
+be	O
+suspected	O
+in	O
+any	O
+patient	O
+with	O
+haematemesis	B-DISO
+and	O
+substance	B-DISO
+abuse	I-DISO
+,	O
+and	O
+discovery	O
+of	O
+AEN	O
+should	O
+prompt	O
+a	O
+thorough	O
+evaluation	O
+for	O
+potentially	O
+lethal	O
+comorbid	O
+conditions	O
+.	O
+
+Conversely	O
+,	O
+exposure	O
+to	O
+CIH	O
+in	O
+early	O
+life	O
+,	O
+results	O
+in	O
+upper	O
+airway	B-ANAT
+muscle	B-DISO
+weakness	I-DISO
+equivalent	O
+between	O
+the	O
+two	O
+sexes	O
+at	O
+3	O
+and	O
+6	O
+weeks	O
+of	O
+age	O
+.	O
+
+Ovariectomy	O
+exacerbates	O
+the	O
+deleterious	O
+effects	O
+of	O
+exposure	O
+to	O
+CIH	O
+in	O
+adult	O
+female	O
+upper	O
+airway	B-ANAT
+muscle	B-ANAT
+,	O
+an	O
+effect	O
+partially	O
+restored	O
+by	O
+oestrogen	B-CHED
+replacement	O
+therapy	O
+.	O
+
+Intriguingly	O
+,	O
+female	O
+advantage	O
+intrinsic	O
+to	O
+upper	O
+airway	B-ANAT
+muscle	B-ANAT
+exists	O
+with	O
+evidence	O
+of	O
+substantially	O
+greater	O
+loss	O
+of	O
+performance	O
+in	O
+male	O
+muscle	B-ANAT
+during	O
+acute	O
+exposure	O
+to	O
+severe	O
+hypoxic	B-DISO
+stress	O
+.	O
+
+Influenza	B-DISO
+B	O
+infections	B-DISO
+accounted	O
+for	O
+the	O
+greatest	O
+burden	O
+of	O
+absenteeism	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Melting	O
+Curve	O
+-	O
+Based	O
+Multiplex	O
+RT	O
+-	O
+qPCR	O
+Assay	O
+for	O
+Simultaneous	O
+Detection	O
+of	O
+Four	O
+Human	B-SPEC
+Coronaviruses	O
+.	O
+
+The	O
+detection	O
+sensitivity	O
+of	O
+the	O
+assay	O
+was	O
+3	O
+×	O
+10²	O
+copies	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+and	O
+3	O
+×	O
+10¹	O
+copies	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	O
+-	O
+HKU1	O
+per	O
+30	O
+μL	O
+reaction	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+central	O
+China	O
+based	O
+on	O
+the	O
+ORF3	O
+gene	O
+and	O
+the	O
+S1	O
+gene	O
+.	O
+
+To	O
+investigate	O
+further	O
+the	O
+infectivity	O
+,	O
+genetic	O
+diversity	O
+and	O
+molecular	O
+epidemiology	O
+of	O
+its	O
+causative	O
+agent	O
+,	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+we	O
+assessed	O
+129	O
+clinical	O
+samples	O
+,	O
+which	O
+were	O
+the	O
+intestinal	B-ANAT
+tissue	B-ANAT
+of	O
+piglets	O
+with	O
+severe	B-DISO
+diarrhea	I-DISO
+,	O
+from	O
+17	O
+cities	O
+in	O
+central	O
+China	O
+.	O
+
+Both	O
+the	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+(	O
+S1	O
+,	O
+1	O
+-	O
+789	O
+amino	B-CHED
+acids	I-CHED
+(	O
+aa	O
+))	O
+and	O
+the	O
+full	O
+-	O
+length	O
+ORF3	O
+gene	O
+of	O
+21	O
+representative	O
+field	O
+strains	O
+from	O
+21	O
+farms	O
+in	O
+11	O
+cities	O
+were	O
+sequenced	O
+and	O
+analysed	O
+.	O
+
+Effects	O
+of	O
+adiposity	B-DISO
+on	O
+acute	B-DISO
+asthma	I-DISO
+remain	O
+uncertain	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	B-ANAT
+membrane	B-PROC
+fusion	I-PROC
+is	O
+an	O
+orchestrated	O
+process	O
+triggered	O
+by	O
+membrane	B-COMP
+-	O
+anchored	O
+viral	O
+fusion	O
+glycoproteins	B-CHED
+.	O
+
+The	O
+S2	O
+subunit	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+contains	O
+internal	O
+domains	O
+called	O
+fusion	O
+peptides	B-CHED
+(	O
+FP	O
+)	O
+that	O
+play	O
+essential	O
+roles	O
+in	O
+virus	B-SPEC
+entry	O
+.	O
+
+Here	O
+we	O
+employed	O
+differential	O
+scanning	O
+calorimetry	O
+(	O
+DSC	O
+)	O
+and	O
+electron	O
+spin	O
+resonance	O
+(	O
+ESR	O
+)	O
+to	O
+gather	O
+information	O
+on	O
+the	O
+membrane	B-PROC
+fusion	I-PROC
+mechanism	O
+promoted	O
+by	O
+two	O
+putative	O
+SARS	B-DISO
+FPs	B-FUNC
+.	O
+
+Although	O
+myriads	O
+of	O
+diagnostic	O
+methods	O
+based	O
+on	O
+RNA	O
+amplification	B-DISO
+have	O
+been	O
+developed	O
+in	O
+the	O
+last	O
+decades	O
+,	O
+they	O
+continue	O
+to	O
+lack	O
+speed	O
+,	O
+sensitivity	O
+,	O
+and	O
+specificity	O
+for	O
+clinical	O
+use	O
+.	O
+
+In	O
+this	O
+prospective	O
+study	O
+,	O
+45	O
+patients	O
+with	O
+ARDS	B-DISO
+were	O
+included	O
+for	O
+the	O
+assessment	O
+of	O
+PPP	B-DISO
+.	O
+
+Monthly	O
+incidence	O
+in	O
+TW	O
+was	O
+respectively	O
+27	O
+.	O
+9	O
+%	O
+(	O
+EHV	O
+-	O
+5	O
+),	O
+24	O
+.	O
+8	O
+%	O
+(	O
+EHV	B-SPEC
+-	I-SPEC
+2	I-SPEC
+),	O
+7	O
+.	O
+1	O
+%	O
+(	O
+ERBV	O
+),	O
+3	O
+.	O
+8	O
+%	O
+(	O
+EHV	B-SPEC
+-	I-SPEC
+4	I-SPEC
+),	O
+1	O
+.	O
+9	O
+%	O
+(	O
+EAdV1	O
+)	O
+and	O
+0	O
+.	O
+2	O
+%	O
+(	O
+EHV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+;	O
+ERAV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+The	O
+recombinant	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+spike	O
+proteins	B-CHED
+is	O
+a	O
+potential	O
+vaccine	O
+against	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+Additionally	O
+,	O
+according	O
+to	O
+the	O
+enzyme	O
+-	O
+linked	O
+immunospot	O
+,	O
+intracellular	B-COMP
+cytokine	O
+staining	O
+,	O
+and	O
+cytometric	O
+bead	O
+array	O
+assays	O
+,	O
+significant	O
+and	O
+functional	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+immunity	B-PROC
+was	O
+induced	O
+by	O
+10μg	O
+of	O
+the	O
+rNTD	O
+vaccination	O
+with	O
+aluminum	B-CHED
+and	O
+CpG	O
+adjuvant	B-CHED
+.	O
+
+These	O
+data	O
+show	O
+that	O
+rNTD	O
+induced	O
+potent	O
+cellular	B-PROC
+immunity	I-PROC
+and	O
+antigen	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+in	O
+mice	B-SPEC
+and	O
+that	O
+it	O
+demonstrated	O
+protective	O
+capacity	O
+against	O
+a	O
+viral	O
+challenge	O
+,	O
+indicating	O
+that	O
+rNTD	O
+is	O
+a	O
+vaccine	O
+candidate	O
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+Variation	O
+Resource	O
+-	O
+improved	O
+response	O
+to	O
+emergent	O
+viral	O
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Virus	B-SPEC
+Variation	O
+Resource	O
+is	O
+a	O
+value	O
+-	O
+added	O
+viral	O
+sequence	O
+data	O
+resource	O
+hosted	O
+by	O
+the	O
+National	O
+Center	O
+for	O
+Biotechnology	O
+Information	O
+.	O
+
+These	O
+processes	O
+in	O
+turn	O
+support	O
+a	O
+purpose	O
+-	O
+built	O
+search	O
+interface	O
+where	O
+users	O
+can	O
+select	O
+sequences	O
+based	O
+on	O
+standardized	O
+gene	O
+,	O
+protein	B-CHED
+and	O
+metadata	O
+terms	O
+.	O
+
+Deep	O
+-	O
+sequencing	O
+analysis	O
+of	O
+MERS	O
+-	O
+CoV	O
+genomes	O
+performed	O
+on	O
+specimens	O
+from	O
+eight	O
+patients	O
+revealed	O
+significant	O
+intrapatient	O
+variation	O
+;	O
+therefore	O
+,	O
+sequence	O
+heterogeneity	O
+was	O
+further	O
+analyzed	O
+using	O
+targeted	B-PROC
+deep	O
+sequencing	O
+.	O
+
+To	O
+determine	O
+whether	O
+other	O
+animals	B-SPEC
+are	O
+potential	O
+reservoirs	O
+,	O
+we	O
+inoculated	O
+MERS	O
+-	O
+CoV	O
+into	O
+llamas	B-SPEC
+,	O
+pigs	B-SPEC
+,	O
+sheep	B-SPEC
+,	O
+and	O
+horses	B-SPEC
+and	O
+collected	O
+nasal	B-ANAT
+and	O
+rectal	B-ANAT
+swab	I-ANAT
+samples	O
+at	O
+various	O
+times	O
+.	O
+
+The	O
+presence	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+the	O
+nose	B-ANAT
+of	O
+pigs	B-SPEC
+and	O
+llamas	B-SPEC
+was	O
+confirmed	O
+by	O
+PCR	O
+,	O
+titration	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+,	O
+immunohistochemistry	O
+,	O
+and	O
+in	O
+situ	O
+hybridization	B-PROC
+;	O
+seroconversion	O
+was	O
+detected	O
+in	O
+animals	B-SPEC
+of	O
+both	O
+species	B-SPEC
+.	O
+
+Conversely	O
+,	O
+in	O
+sheep	B-SPEC
+and	O
+horses	B-SPEC
+,	O
+virus	B-SPEC
+-	O
+specific	O
+antibodies	B-COMP
+did	O
+not	O
+develop	O
+and	O
+no	O
+evidence	O
+of	O
+viral	B-PROC
+replication	I-PROC
+in	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+was	O
+found	O
+.	O
+
+The	O
+influence	O
+of	O
+the	O
+increased	O
+SNP	O
+and	O
+hydrophobic	O
+properties	O
+of	O
+the	O
+translated	O
+proteins	O
+on	O
+the	O
+vaccine	O
+viruses	B-SPEC
+'	O
+virulence	B-PROC
+is	O
+unknown	O
+.	O
+
+Retrospective	O
+review	O
+of	O
+all	O
+patients	O
+with	O
+acute	O
+or	O
+acute	B-DISO
+-	I-DISO
+on	I-DISO
+-	I-DISO
+chronic	I-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+due	O
+to	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+[	O
+COPD	B-DISO
+]	O
+with	O
+severe	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+when	O
+non	O
+-	O
+invasive	O
+ventilation	O
+failed	O
+;	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+COPD	B-DISO
+;	O
+or	O
+asthma	B-PATH
+when	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+was	O
+not	O
+feasible	O
+due	O
+to	O
+hypercapnia	B-DISO
+)	O
+for	O
+whom	O
+the	O
+Hemolung	O
+was	O
+used	O
+.	O
+
+In	O
+the	O
+remaining	O
+10	O
+patients	O
+,	O
+the	O
+strategy	O
+of	O
+instituting	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+was	O
+successful	O
+.	O
+
+The	O
+pH	O
+and	O
+PCO	B-DISO
+CONCLUSIONS	O
+:	O
+Our	O
+data	O
+shows	O
+that	O
+ECCOR	O
+was	O
+safe	O
+and	O
+effective	O
+in	O
+this	O
+cohort	O
+.	O
+
+TITLE	O
+:	O
+Protective	O
+T	B-ANAT
+Cell	I-ANAT
+Responses	O
+Featured	O
+by	O
+Concordant	O
+Recognition	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+-	O
+Derived	O
+CD8	B-PRGE
++	I-PRGE
+T	I-PRGE
+Cell	I-PRGE
+Epitopes	I-PRGE
+and	I-PRGE
+Host	B-COMP
+MHC	B-PROC
+.	O
+
+We	O
+experienced	O
+3	O
+cases	O
+of	O
+adenoviral	B-DISO
+pneumonia	I-DISO
+associated	O
+with	O
+ARDS	B-DISO
+and	O
+treated	O
+with	O
+cidofovir	B-CHED
+and	O
+respiratory	O
+support	O
+,	O
+including	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+The	O
+Himalayan	O
+regions	O
+possess	B-DISO
+variety	O
+of	O
+ethnomedicinal	O
+plants	B-SPEC
+used	O
+against	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+but	O
+still	O
+there	O
+are	O
+only	O
+few	O
+studies	O
+related	O
+with	O
+their	O
+in	O
+-	O
+vitro	O
+validation	O
+.	O
+
+We	O
+find	O
+that	O
+assuming	O
+the	O
+relative	O
+vulnerability	O
+in	O
+the	O
+existing	O
+labor	B-PROC
+market	O
+shows	O
+a	O
+U	O
+shape	O
+with	O
+age	O
+increase	O
+,	O
+the	O
+U	O
+-	O
+shaped	O
+curve	O
+became	O
+J	O
+-	O
+shaped	O
+after	O
+the	O
+outbreak	O
+.	O
+
+Early	O
+initiation	O
+of	O
+appropriate	O
+antimicrobial	B-CHED
+therapy	O
+is	O
+a	O
+crucial	O
+step	O
+in	O
+the	O
+prevention	O
+of	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+The	O
+majority	O
+of	O
+patients	O
+had	O
+met	B-CHED
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+criteria	O
+with	O
+fever	B-PROC
+>	O
+38	O
+°	O
+C	O
+(	O
+71	O
+%),	O
+heart	B-ANAT
+rate	O
+>	O
+90	O
+beats	O
+per	O
+minute	O
+(	O
+71	O
+%),	O
+and	O
+respiratory	O
+rate	O
+>	O
+20	O
+breaths	O
+per	O
+minute	O
+(	O
+86	O
+%).	O
+
+ABSTRACT	O
+:	O
+After	O
+prompt	O
+diagnosis	O
+,	O
+severe	O
+myasthenia	B-DISO
+gravis	I-DISO
+and	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+(	O
+GBS	B-DISO
+)	O
+usually	O
+require	O
+management	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Noninvasive	O
+ventilation	O
+can	O
+be	O
+attempted	O
+prior	O
+to	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+in	O
+the	O
+setting	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Differential	O
+Cell	B-COMP
+Count	O
+and	O
+CRP	B-PRGE
+Level	O
+in	O
+Blood	B-ANAT
+as	O
+Predictors	O
+for	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-DISO
+Infection	I-DISO
+in	O
+Acute	O
+Febrile	B-PROC
+Patients	O
+during	O
+Nosocomial	O
+Outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+epidemiological	O
+features	O
+,	O
+clinical	O
+characteristics	O
+,	O
+and	O
+outcomes	O
+of	O
+human	O
+rhinovirus	O
+(	O
+HRV	O
+)	O
+infections	B-DISO
+in	O
+comparison	O
+with	O
+other	O
+community	O
+acquired	O
+respiratory	O
+virus	B-SPEC
+(	O
+CRV	B-DISO
+)	O
+infections	B-DISO
+in	O
+patients	O
+hospitalized	O
+for	O
+two	O
+consecutive	O
+years	O
+.	O
+
+Bioinformatics	O
+analysis	O
+revealed	O
+that	O
+these	O
+proteins	O
+were	O
+involved	O
+in	O
+stress	O
+responses	O
+,	O
+signal	B-PROC
+transduction	I-PROC
+,	O
+and	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+Following	O
+vaccination	O
+,	O
+swabs	O
+and	O
+tissues	B-ANAT
+collected	O
+at	O
+intervals	O
+were	O
+pooled	O
+and	O
+RNA	O
+was	O
+extracted	O
+for	O
+detection	O
+of	O
+IBV	B-SPEC
+by	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Emerging	O
+zoonotic	O
+pathogens	O
+,	O
+for	O
+example	O
+,	O
+MERS	O
+coronavirus	B-SPEC
+,	O
+avian	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+Coxiella	B-SPEC
+,	O
+and	O
+Francisella	B-SPEC
+,	O
+would	O
+have	O
+pandemic	O
+potential	O
+were	O
+they	O
+to	O
+acquire	O
+efficient	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmissibility	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+has	O
+known	O
+a	O
+growing	O
+interest	O
+over	O
+the	O
+last	O
+decades	O
+with	O
+promising	O
+results	O
+during	O
+the	O
+2009	O
+A	O
+(	O
+H1N1	O
+)	O
+influenza	B-DISO
+epidemic	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Inflammatory	O
+lung	B-ANAT
+diseases	I-DISO
+like	O
+asthma	B-PATH
+bronchiale	O
+,	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+and	O
+allergic	O
+airway	B-ANAT
+inflammation	B-DISO
+are	O
+widespread	O
+public	O
+diseases	O
+that	O
+constitute	O
+an	O
+enormous	O
+burden	O
+to	O
+the	O
+health	O
+systems	O
+.	O
+
+Inflammatory	O
+lung	B-DISO
+diseases	I-DISO
+predispose	O
+patients	O
+to	O
+severe	O
+lung	B-ANAT
+failures	O
+like	O
+alveolar	B-DISO
+oedema	I-DISO
+,	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Prehospital	O
+professionals	O
+face	B-DISO
+the	O
+risk	O
+of	O
+infection	B-DISO
+as	O
+they	O
+work	O
+to	O
+save	O
+lives	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+has	O
+tools	O
+to	O
+counteract	O
+the	O
+formation	B-PROC
+of	O
+these	O
+virus	B-SPEC
+-	O
+induced	O
+replication	O
+organelles	B-COMP
+in	O
+order	B-SPEC
+to	O
+inhibit	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+using	O
+an	O
+expression	B-PROC
+system	O
+that	O
+closely	O
+mimics	O
+the	O
+formation	B-PROC
+of	O
+arterivirus	B-SPEC
+replication	O
+structures	O
+,	O
+we	O
+show	O
+for	O
+the	O
+first	O
+time	O
+that	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+treatment	O
+clearly	O
+reduces	O
+the	O
+amount	O
+of	O
+induced	O
+membrane	B-COMP
+structures	O
+.	O
+
+Mycoplasma	B-SPEC
+gallisepticum	I-SPEC
+was	O
+also	O
+found	O
+to	O
+be	O
+present	O
+;	O
+however	O
+,	O
+infectious	B-SPEC
+laryngotracheitis	B-DISO
+virus	I-SPEC
+was	O
+not	O
+detected	O
+by	O
+PCR	O
+.	O
+
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+)	O
+was	O
+not	O
+detected	O
+by	O
+PCR	O
+,	O
+but	O
+variable	O
+levels	O
+of	O
+anti	O
+-	O
+NDV	B-SPEC
+HI	O
+antibody	B-COMP
+titres	O
+shows	O
+possible	O
+exposure	O
+to	O
+virulent	O
+strains	O
+or	O
+poor	O
+vaccine	O
+take	O
+,	O
+or	O
+both	O
+.	O
+
+TITLE	O
+:	O
+Adenosine	B-CHED
+-	O
+dependent	O
+phrenic	O
+motor	O
+facilitation	B-PROC
+is	O
+inflammation	B-DISO
+resistant	O
+.	O
+
+ABSTRACT	O
+:	O
+Phrenic	O
+motor	O
+facilitation	O
+(	O
+pMF	O
+),	O
+a	O
+form	O
+of	O
+respiratory	O
+plasticity	O
+,	O
+can	O
+be	O
+elicited	O
+by	O
+acute	O
+intermittent	O
+hypoxia	B-DISO
+(	O
+i	O
+.	O
+e	O
+.,	O
+phrenic	O
+long	O
+-	O
+term	O
+facilitation	B-PROC
+,	O
+pLTF	O
+)	O
+or	O
+direct	O
+application	O
+of	O
+drugs	O
+to	O
+the	O
+cervical	B-ANAT
+spinal	I-ANAT
+cord	I-ANAT
+.	O
+
+The	O
+identification	O
+of	O
+astroviruses	O
+in	O
+a	O
+wide	O
+range	O
+of	O
+animals	B-SPEC
+highlights	O
+the	O
+zoonotic	O
+importance	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+As	O
+some	O
+RNA	O
+viruses	B-SPEC
+can	O
+be	O
+directly	O
+transmitted	B-DISO
+from	O
+bats	B-SPEC
+to	O
+humans	B-SPEC
+,	O
+it	O
+is	O
+crucial	O
+to	O
+collect	O
+data	O
+about	O
+their	O
+frequency	O
+,	O
+genetic	O
+diversity	O
+and	O
+phylogenetic	O
+characterization	O
+.	O
+
+IB	O
+virus	B-SPEC
+primarily	O
+affects	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+but	O
+strains	O
+differ	O
+in	O
+their	O
+tropism	B-PROC
+for	O
+such	O
+other	O
+target	O
+organs	B-ANAT
+as	O
+kidneys	B-ANAT
+and	O
+alimentary	B-ANAT
+tract	I-ANAT
+.	O
+
+Most	O
+outpatients	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+do	O
+not	O
+require	O
+microbiologic	O
+testing	O
+of	O
+sputum	B-ANAT
+or	O
+blood	B-ANAT
+and	O
+can	O
+be	O
+treated	O
+empirically	O
+with	O
+a	O
+macrolide	B-CHED
+,	O
+doxycycline	B-CHED
+,	O
+or	O
+a	O
+respiratory	O
+fluoroquinolone	O
+.	O
+
+In	O
+Europe	O
+and	O
+North	O
+America	O
+most	O
+victims	O
+are	O
+breeders	O
+,	O
+with	O
+a	O
+few	O
+snakebites	O
+from	O
+wild	O
+native	O
+American	O
+rattlesnakes	B-SPEC
+.	O
+
+This	O
+review	O
+article	O
+summarizes	O
+the	O
+clinical	O
+syndromes	B-DISO
+caused	O
+by	O
+severe	O
+envenoming	O
+and	O
+the	O
+therapeutic	O
+options	O
+available	O
+in	O
+the	O
+intensive	O
+care	O
+setting	O
+.	O
+
+He	O
+developed	O
+severe	O
+neuromuscular	O
+dysfunction	O
+after	O
+sepsis	B-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+93	O
+samples	O
+(	O
+4	O
+.	O
+7	O
+%)	O
+from	O
+17	O
+genera	O
+of	O
+bats	B-SPEC
+tested	O
+positive	O
+.	O
+
+Sequence	O
+analysis	O
+revealed	O
+the	O
+presence	O
+of	O
+potentially	O
+37	O
+and	O
+56	O
+coronavirus	B-SPEC
+belonging	O
+to	O
+alpha	B-PRGE
+-	I-PRGE
+coronavirus	I-PRGE
+(	I-PRGE
+αCoV	I-PRGE
+)	I-PRGE
+and	I-PRGE
+beta	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+βCoV	O
+),	O
+respectively	O
+.	O
+
+This	O
+study	O
+extends	O
+our	O
+understanding	O
+of	O
+the	O
+genetic	O
+diversity	O
+of	O
+rotaviruses	B-SPEC
+in	O
+bats	B-SPEC
+.	O
+
+After	O
+recording	O
+clinical	O
+and	O
+demographic	O
+data	O
+,	O
+twin	O
+swabs	O
+(	O
+nasopharyngeal	B-ANAT
+and	O
+throat	B-ANAT
+)	O
+were	O
+collected	O
+from	O
+each	O
+participant	O
+,	O
+pooled	O
+in	O
+viral	O
+transport	B-PROC
+media	B-ANAT
+and	O
+tested	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+PCR	O
+for	O
+MERS	O
+-	O
+CoV	O
+and	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+viruses	O
+and	O
+their	O
+subtypes	O
+.	O
+
+Despite	O
+a	O
+proven	O
+survival	O
+benefit	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+studies	O
+have	O
+also	O
+shown	O
+underutilization	O
+of	O
+prone	O
+positioning	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+October	O
+2016	O
+,	O
+a	O
+severe	O
+infection	B-DISO
+with	O
+swine	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+of	O
+the	O
+Eurasian	O
+avian	B-SPEC
+lineage	O
+occurred	O
+in	O
+a	O
+child	O
+with	O
+a	O
+previous	O
+history	O
+of	O
+eczema	B-DISO
+in	O
+the	O
+Netherlands	O
+,	O
+following	O
+contact	O
+to	O
+pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+carry	O
+and	O
+shed	O
+many	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+agents	O
+including	O
+Ebola	B-SPEC
+virus	I-SPEC
+and	O
+SARS	B-DISO
+-	O
+like	O
+Coronaviruses	O
+,	O
+yet	O
+they	O
+rarely	O
+display	O
+clinical	O
+symptoms	O
+of	O
+infection	B-DISO
+.	O
+
+Therefore	O
+,	O
+preclinical	O
+identification	O
+of	O
+PEDV	B-SPEC
+is	O
+of	O
+great	O
+significance	O
+for	O
+preventing	O
+the	O
+outbreak	O
+and	O
+spread	O
+of	O
+this	O
+disease	O
+.	O
+
+Then	O
+,	O
+oligonucleotides	O
+specific	O
+for	O
+PEDV	B-SPEC
+coated	O
+on	O
+AuNPs	O
+were	O
+eluted	O
+from	O
+the	O
+complex	O
+and	O
+were	O
+further	O
+amplified	O
+and	O
+characterized	O
+by	O
+PCR	O
+.	O
+
+In	O
+a	O
+word	O
+,	O
+this	O
+study	O
+provided	O
+a	O
+RNA	O
+extraction	O
+and	O
+transcription	B-PROC
+free	O
+,	O
+rapid	O
+and	O
+economical	O
+method	O
+for	O
+preclinical	O
+PEDV	B-SPEC
+infection	B-DISO
+,	O
+which	O
+showed	O
+higher	O
+sensitivity	O
+,	O
+specificity	O
+and	O
+reproducibility	O
+,	O
+and	O
+exhibited	O
+application	O
+potency	O
+for	O
+evaluating	O
+viral	O
+loads	O
+of	O
+preclinical	O
+samples	O
+.	O
+
+TITLE	O
+:	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+:	O
+a	O
+key	O
+target	O
+for	O
+antivirals	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+continual	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	B-DISO
+)	O
+threat	O
+highlights	O
+the	O
+importance	O
+of	O
+developing	O
+effective	O
+antiviral	B-CHED
+therapeutics	O
+to	O
+prevent	O
+and	O
+treat	O
+MERS	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+However	O
+,	O
+emergence	O
+of	O
+escape	O
+mutant	B-DISO
+viruses	B-SPEC
+and	O
+mAb	O
+'	O
+s	O
+limitations	O
+make	O
+it	O
+necessary	O
+for	O
+combining	O
+neutralizing	O
+mAbs	O
+recognizing	O
+different	O
+neutralizing	O
+epitopes	O
+and	O
+engineering	O
+them	O
+with	O
+improved	O
+efficacy	O
+and	O
+reduced	O
+cost	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+caused	O
+extensive	O
+economic	O
+losses	O
+to	O
+pig	B-SPEC
+producers	O
+in	O
+many	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+Full	O
+genome	O
+analysis	O
+of	O
+Australian	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+suggests	O
+frequent	O
+recombination	B-PROC
+events	O
+between	O
+vaccine	O
+strains	O
+and	O
+multiple	O
+phylogenetically	O
+distant	O
+avian	B-SPEC
+coronaviruses	O
+of	O
+unknown	O
+origin	O
+.	O
+
+Piglets	O
+were	O
+monitored	O
+daily	O
+for	O
+clinical	O
+signs	O
+,	O
+body	B-ANAT
+weight	O
+,	O
+and	O
+body	B-ANAT
+temperature	O
+through	O
+day	O
+post	O
+-	O
+inoculation	O
+(	O
+DPI	O
+)	O
+12	O
+(	O
+Groups	O
+2	O
+and	O
+3	O
+)	O
+or	O
+14	O
+(	O
+Group	O
+1	O
+).	O
+
+TITLE	O
+:	O
+Isolation	O
+,	O
+genomic	O
+characterization	O
+,	O
+and	O
+pathogenicity	O
+of	O
+a	O
+Chinese	O
+porcine	B-SPEC
+deltacoronavirus	O
+strain	O
+CHN	O
+-	O
+HN	O
+-	O
+2014	O
+.	O
+
+Both	O
+kinds	O
+of	O
+piglets	O
+developed	O
+clear	O
+clinical	O
+symptoms	O
+,	O
+including	O
+vomiting	B-DISO
+,	O
+anorexia	B-DISO
+,	O
+lethargy	B-DISO
+,	O
+and	O
+severe	B-DISO
+diarrhea	I-DISO
+,	O
+by	O
+2days	O
+postinoculation	O
+(	O
+DPI	O
+),	O
+and	O
+diarrhea	B-DISO
+persisted	O
+for	O
+about	O
+5	O
+-	O
+6	O
+days	O
+.	O
+
+Influenza	B-DISO
+was	O
+the	O
+predominant	O
+virus	B-SPEC
+(	O
+14	O
+.	O
+17	O
+%,	O
+137	O
+/	O
+967	O
+),	O
+detected	O
+from	O
+21	O
+.	O
+35	O
+%	O
+(	O
+76	O
+/	O
+356	O
+)	O
+of	O
+the	O
+outpatients	O
+and	O
+9	O
+.	O
+98	O
+%	O
+(	O
+61	O
+/	O
+611	O
+)	O
+of	O
+the	O
+inpatients	O
+.	O
+
+Since	O
+the	O
+1970s	O
+,	O
+PED	O
+outbreaks	O
+have	O
+become	O
+a	O
+source	O
+of	O
+problems	O
+in	O
+pig	B-SPEC
+producing	O
+countries	O
+all	O
+over	O
+the	O
+world	O
+,	O
+causing	O
+large	O
+economic	O
+losses	O
+for	O
+pig	B-SPEC
+producers	O
+.	O
+
+As	O
+diagnostic	O
+tools	O
+have	O
+increased	O
+in	O
+sensitivity	O
+,	O
+our	O
+understanding	O
+of	O
+the	O
+etiology	O
+of	O
+CAP	B-DISO
+has	O
+begun	O
+to	O
+change	O
+with	O
+a	O
+significant	O
+increase	O
+in	O
+confirmed	O
+viral	B-DISO
+infections	I-DISO
+and	O
+the	O
+recognition	O
+that	O
+multiple	O
+pathogens	O
+are	O
+frequently	O
+present	O
+.	O
+
+ABSTRACT	O
+:	O
+Coagulation	O
+and	O
+fibrinolysis	B-PROC
+remain	O
+sparsely	O
+addressed	O
+with	O
+regards	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+RESULTS	O
+:	O
+Of	O
+24	O
+patients	O
+at	O
+risk	O
+,	O
+6	O
+developed	O
+mild	O
+ARDS	B-DISO
+and	O
+4	O
+of	O
+each	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+,	O
+respectively	O
+,	O
+3	O
+±	O
+2	O
+(	O
+mean	O
+±	O
+SD	O
+)	O
+days	O
+after	O
+inclusion	O
+.	O
+
+(	O
+2	O
+)	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+new	O
+corona	B-CHED
+virus	B-SPEC
+isolated	O
+for	O
+the	O
+first	O
+time	O
+in	O
+a	O
+patients	O
+who	O
+died	B-PROC
+of	O
+severe	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+Jeddah	O
+(	O
+Saudi	O
+Arabia	O
+)	O
+in	O
+June	O
+2012	O
+(	O
+Zaki	O
+et	O
+al	O
+.	O
+2012	O
+).	O
+
+The	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+have	O
+held	O
+nine	O
+meetings	O
+of	O
+the	O
+Emergency	B-DISO
+Committee	O
+(	O
+EC	O
+)	O
+convened	O
+by	O
+the	O
+Director	O
+-	O
+General	O
+under	O
+the	O
+International	O
+Health	O
+Regulations	O
+(	O
+IHR	O
+2005	O
+)	O
+regarding	O
+MERS	O
+-	O
+CoV	O
+(	O
+WHO	O
+2015c	O
+).	O
+
+There	O
+is	O
+wishful	O
+anticipation	O
+in	O
+the	O
+political	O
+and	O
+scientific	O
+communities	O
+that	O
+MERS	O
+-	O
+CoV	O
+like	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+will	O
+disappear	O
+with	O
+time	O
+.	O
+
+There	O
+is	O
+a	O
+large	O
+MERS	O
+-	O
+CoV	O
+camel	B-SPEC
+reservoir	O
+,	O
+and	O
+there	O
+is	O
+no	O
+specific	O
+treatment	O
+or	O
+vaccine	O
+(	O
+Zumla	O
+et	O
+al	O
+.	O
+2015a	O
+).	O
+
+Two	O
+linear	O
+epitopes	O
+,	O
+243YSTEART249	O
+(	O
+1C3	O
+)	O
+and	O
+243YSTEARTDNLSEQEKLLHMV262	O
+(	O
+4C7	O
+),	O
+were	O
+identified	O
+in	O
+the	O
+endodomain	O
+of	O
+the	O
+TGEV	B-PRGE
+M	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+1C3	O
+mAb	O
+can	O
+be	O
+used	O
+for	O
+the	O
+detection	O
+of	O
+the	O
+TGEV	B-PRGE
+M	I-PRGE
+protein	B-CHED
+in	O
+different	O
+assays	O
+.	O
+
+The	O
+two	O
+groups	O
+were	O
+compared	O
+in	O
+terms	O
+of	O
+the	O
+time	O
+to	O
+improvements	O
+of	O
+symptoms	O
+after	O
+treatment	O
+,	O
+serum	B-COMP
+levels	O
+of	O
+inflammatory	O
+factors	O
+,	O
+proportion	O
+of	O
+children	O
+undergoing	O
+invasive	O
+ventilation	O
+,	O
+treatment	O
+response	O
+rate	O
+,	O
+and	O
+adverse	O
+events	O
+.	O
+
+After	O
+5	O
+days	O
+of	O
+treatment	O
+,	O
+the	O
+low	O
+-	O
+and	O
+high	O
+-	O
+dose	O
+groups	O
+had	O
+significant	O
+reductions	O
+in	O
+serum	O
+levels	O
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+,	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+and	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+the	O
+reductions	O
+of	O
+these	O
+markers	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+Early	O
+v	O
+-	O
+v	O
+ECMO	O
+implantation	B-PROC
+could	O
+be	O
+considered	O
+to	O
+support	O
+and	O
+to	O
+conduct	B-PROC
+weaning	B-PROC
+both	O
+from	O
+sedation	B-DISO
+and	O
+from	O
+invasive	O
+mechanical	O
+ventilation	O
+,	O
+with	O
+the	O
+goal	O
+to	O
+perform	O
+physiokinesitherapy	O
+during	O
+awake	O
+ECMO	O
+.	O
+
+We	O
+describe	O
+a	O
+case	O
+of	O
+HEV	B-SPEC
+infection	B-DISO
+in	O
+a	O
+previously	O
+healthy	O
+male	O
+trauma	O
+patient	O
+in	O
+France	O
+who	O
+received	O
+massive	O
+transfusions	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	I-PRGE
+nsp5	I-PRGE
+inhibits	O
+interferon	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+through	O
+the	O
+cleavage	B-PROC
+of	O
+NEMO	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrate	O
+that	O
+nonstructural	O
+protein	B-CHED
+5	O
+(	O
+nsp5	O
+)	O
+of	O
+PDCoV	O
+,	O
+the	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+,	O
+significantly	O
+inhibits	O
+Sendai	B-SPEC
+virus	I-SPEC
+(	O
+SEV	O
+)-	O
+induced	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+by	O
+targeting	B-PROC
+the	O
+NF	O
+-	O
+κB	O
+essential	O
+modulator	O
+(	O
+NEMO	B-PRGE
+),	O
+confirmed	O
+by	O
+the	O
+diminished	O
+function	O
+of	O
+NEMO	O
+cleaved	B-ANAT
+by	O
+PDCoV	O
+.	O
+The	O
+PDCoV	O
+nsp5	B-PRGE
+cleavage	B-PROC
+site	O
+in	O
+the	O
+NEMO	B-PRGE
+protein	I-PRGE
+was	O
+identified	O
+as	O
+glutamine	B-CHED
+231	O
+,	O
+and	O
+was	O
+identical	O
+to	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+nsp5	B-PRGE
+cleavage	B-PROC
+site	O
+,	O
+revealing	O
+the	O
+likelihood	O
+of	O
+a	O
+common	O
+target	O
+in	O
+NEMO	O
+for	O
+coronaviruses	O
+.	O
+
+Furthermore	O
+,	O
+this	O
+cleavage	B-PROC
+impaired	B-DISO
+the	O
+ability	O
+of	O
+NEMO	B-PRGE
+to	O
+activate	O
+the	O
+IFN	B-PRGE
+response	O
+and	O
+downstream	O
+signaling	B-PROC
+.	O
+
+In	O
+the	O
+period	O
+from	O
+December	O
+2014	O
+to	O
+December	O
+2015	O
+,	O
+sufficient	O
+data	O
+of	O
+Peking	O
+University	O
+First	O
+Hospital	O
+Respiratory	O
+and	O
+Critical	O
+Care	O
+Medicine	B-CHED
+Department	O
+for	O
+analysis	O
+were	O
+identified	O
+in	O
+218	O
+subjects	O
+.	O
+
+In	O
+the	O
+malignant	O
+group	O
+,	O
+the	O
+patient	O
+-	O
+related	O
+independent	O
+clinical	O
+risk	O
+factor	O
+for	O
+the	O
+early	B-DISO
+complication	I-DISO
+rate	O
+was	O
+current	O
+smoking	O
+status	O
+(	O
+B	O
+=	O
+2	O
+.	O
+953	O
+,	O
+P	O
+=	O
+0	O
+.	O
+006	O
+,	O
+OR	O
+=	O
+19	O
+.	O
+161	O
+,	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+360	O
+-	O
+155	O
+.	O
+572	O
+).	O
+
+Here	O
+,	O
+two	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+specific	O
+to	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+a	O
+PEDV	B-SPEC
+strain	O
+,	O
+FJzz1	O
+/	O
+2011	O
+,	O
+were	O
+generated	O
+and	O
+screened	O
+against	O
+a	O
+partially	O
+overlapping	O
+library	O
+of	O
+24	O
+GST	B-PRGE
+-	O
+fusion	O
+N	O
+protein	B-CHED
+-	O
+truncated	O
+constructs	O
+.	O
+
+However	O
+,	O
+the	O
+lack	O
+of	O
+a	O
+vaccine	O
+,	O
+together	O
+with	O
+the	O
+increasing	O
+resistance	B-PROC
+to	O
+the	O
+highly	O
+active	O
+anti	O
+-	O
+retroviral	B-SPEC
+therapy	O
+(	O
+HAART	O
+),	O
+make	O
+HIV	B-DISO
+-	I-DISO
+1	I-DISO
+infection	I-DISO
+still	O
+a	O
+serious	O
+global	O
+emergency	B-DISO
+.	O
+
+Here	O
+we	O
+present	O
+a	O
+work	O
+in	O
+which	O
+we	O
+suggest	O
+that	O
+kuwanon	O
+-	O
+L	O
+,	O
+a	O
+natural	B-CHED
+product	I-CHED
+active	O
+as	O
+an	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+integrase	B-PRGE
+(	O
+IN	O
+)	O
+inhibitor	B-CHED
+,	O
+might	O
+exert	B-PROC
+its	O
+overall	O
+antiviral	B-CHED
+activity	O
+through	O
+binding	B-FUNC
+to	O
+multiple	O
+viral	O
+targets	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+unintentional	O
+sewing	O
+machine	O
+lubricant	O
+ingestion	O
+:	O
+A	O
+case	O
+report	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Hypoxemia	O
+in	O
+a	O
+Healthy	O
+Donor	B-CHED
+for	O
+Allogeneic	O
+Hematopoietic	B-ANAT
+Stem	I-ANAT
+Cell	I-ANAT
+Transplantation	O
+after	O
+Only	O
+the	O
+First	O
+Administration	O
+of	O
+Granulocyte	O
+-	O
+Colony	O
+Stimulating	O
+Factor	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+clinical	O
+syndrome	B-DISO
+with	O
+mortality	O
+rate	O
+as	O
+high	O
+as	O
+30	O
+-	O
+40	O
+%.	O
+
+When	O
+it	O
+was	O
+used	O
+in	O
+combination	O
+with	O
+S1P	B-PRGE
+,	O
+the	O
+expression	B-PROC
+regulation	B-PROC
+result	O
+of	O
+related	O
+genes	O
+was	O
+not	O
+simply	O
+the	O
+superposition	O
+of	O
+each	O
+other	O
+,	O
+but	O
+more	O
+significant	O
+outcome	O
+was	O
+obtained	O
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+of	O
+a	O
+novel	O
+accessory	O
+protein	B-CHED
+NS7a	O
+encoded	O
+by	O
+porcine	B-SPEC
+deltacoronavirus	O
+.	O
+
+Imbalance	B-DISO
+between	O
+coagulation	B-PROC
+and	O
+inflammation	B-DISO
+is	O
+a	O
+predominant	O
+characteristic	O
+of	O
+ARDS	B-DISO
+,	O
+leading	O
+to	O
+extreme	O
+inflammatory	B-DISO
+response	I-DISO
+and	O
+diffuse	O
+fibrin	B-DISO
+deposition	I-DISO
+in	O
+vascular	B-ANAT
+capillary	B-ANAT
+bed	I-ANAT
+and	O
+alveoli	B-ANAT
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+review	O
+how	O
+aptamers	O
+working	O
+against	O
+viral	O
+proteins	B-CHED
+are	O
+discovered	O
+,	O
+with	O
+a	O
+focus	O
+on	O
+recent	O
+advances	O
+that	O
+improve	O
+the	O
+aptamers	O
+'	O
+properties	O
+as	O
+a	O
+real	O
+tool	O
+for	O
+viral	B-DISO
+infection	I-DISO
+detection	O
+and	O
+treatment	O
+.	O
+
+Strain	O
+D998	O
+/	O
+15	O
+had	O
+a	O
+distinct	O
+phylogenetic	O
+position	O
+within	O
+clade	O
+A	O
+,	O
+being	O
+more	O
+closely	O
+related	O
+to	O
+the	O
+dromedary	B-SPEC
+isolate	O
+NRCE	O
+-	O
+HKU205	O
+from	O
+Egypt	O
+than	O
+to	O
+the	O
+human	B-SPEC
+isolates	O
+EMC	B-COMP
+/	O
+2012	O
+and	O
+Jordan	O
+-	O
+N3	O
+/	O
+2012	O
+.	O
+
+Two	O
+B3	O
+strains	O
+,	O
+D1271	O
+/	O
+15	O
+and	O
+D1189	O
+.	O
+1	O
+/	O
+15	O
+,	O
+showed	O
+evidence	O
+of	O
+recombination	B-PROC
+between	O
+lineages	O
+B4	O
+and	O
+B5	O
+in	O
+ORF1ab	O
+.	O
+
+TITLE	O
+:	O
+A	O
+camel	B-SPEC
+-	O
+derived	O
+MERS	O
+-	O
+CoV	O
+with	O
+a	O
+variant	O
+spike	O
+protein	B-PROC
+cleavage	I-PROC
+site	O
+and	O
+distinct	O
+fusion	O
+activation	O
+properties	O
+.	O
+
+The	O
+present	O
+review	O
+gives	O
+an	O
+overview	O
+of	O
+common	O
+bacterial	O
+lung	B-ANAT
+infections	B-DISO
+,	O
+such	O
+as	O
+pneumococcal	B-DISO
+infection	I-DISO
+and	O
+of	O
+widely	O
+neglected	O
+pathogens	O
+modeled	O
+in	O
+ex	O
+vivo	O
+infected	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+This	O
+overview	O
+summarizes	O
+several	O
+salient	O
+points	O
+,	O
+namely	O
+:	O
+a	O
+)	O
+ARDS	B-DISO
+is	O
+an	O
+oxygenation	B-PROC
+defect	O
+:	O
+consolidation	O
+/	O
+difuse	O
+alveolar	B-ANAT
+damage	O
+is	O
+reversed	O
+by	O
+PEEP	B-CHED
+and	O
+/	O
+or	O
+prone	O
+positioning	O
+,	O
+at	O
+least	O
+during	O
+the	O
+early	O
+phase	O
+of	O
+ARDS	B-DISO
+b	O
+)	O
+ARDS	B-DISO
+is	O
+a	O
+dynamic	O
+disease	O
+and	O
+partially	O
+iatrogenic	O
+.	O
+
+Indeed	O
+,	O
+a	O
+high	O
+PEEP	B-CHED
+(	O
+10	O
+-	O
+24	O
+cm	O
+H₂O	O
+)	O
+appears	O
+to	O
+be	O
+a	O
+life	O
+-	O
+saver	O
+in	O
+the	O
+context	O
+of	O
+early	O
+severe	O
+diffuse	O
+ARDS	O
+;	O
+c	O
+)	O
+tidal	O
+volume	O
+and	O
+plateau	O
+pressure	O
+cannot	O
+be	O
+identical	O
+for	O
+all	O
+patients	O
+;	O
+d	O
+)	O
+the	O
+only	O
+remaining	O
+rationale	O
+for	O
+CMV	B-SPEC
+and	O
+muscle	B-DISO
+relaxation	I-DISO
+is	O
+to	O
+suppress	O
+patient	O
+-	O
+ventilator	O
+asynchrony	O
+and	O
+to	O
+lower	O
+VO2	B-CHED
+,	O
+during	O
+the	O
+acute	O
+cardio	O
+-	O
+ventilatory	O
+distress	O
+.	O
+
+In	O
+this	O
+context	O
+,	O
+a	O
+deeper	O
+understanding	O
+of	O
+how	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+in	O
+the	O
+elderly	O
+functions	O
+in	O
+relation	O
+to	O
+ZIKV	O
+infection	B-DISO
+is	O
+necessary	O
+,	O
+as	O
+well	O
+as	O
+an	O
+understanding	O
+of	O
+what	O
+kind	O
+of	O
+alterations	O
+of	O
+the	O
+nervous	B-ANAT
+system	I-ANAT
+such	O
+an	O
+infection	B-DISO
+triggers	O
+in	O
+the	O
+elderly	O
+,	O
+beyond	O
+GBS	B-DISO
+.	O
+
+Recent	O
+outbreaks	O
+have	O
+stressed	O
+the	O
+urgency	O
+of	O
+effective	O
+research	O
+on	O
+the	O
+dynamics	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+spread	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+difficult	O
+to	O
+predict	O
+when	O
+and	O
+where	O
+outbreaks	O
+may	O
+emerge	O
+and	O
+how	O
+infectious	B-DISO
+diseases	I-DISO
+spread	O
+because	O
+many	O
+factors	O
+affect	O
+their	O
+transmission	O
+,	O
+and	O
+some	O
+of	O
+them	O
+may	O
+be	O
+unknown	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Potential	O
+of	O
+Social	O
+Media	B-ANAT
+and	O
+Internet	O
+-	O
+Based	O
+Data	O
+in	O
+Preventing	O
+and	O
+Fighting	O
+Infectious	B-DISO
+Diseases	I-DISO
+:	O
+From	O
+Internet	O
+to	O
+Twitter	O
+.	O
+
+More	O
+importantly	O
+,	O
+at	O
+the	O
+moment	O
+,	O
+the	O
+prevention	O
+and	O
+control	O
+of	O
+viral	O
+infectious	B-DISO
+diseases	I-DISO
+is	O
+difficult	O
+due	O
+to	O
+a	O
+lack	O
+of	O
+effective	O
+vaccines	O
+.	O
+
+RESULTS	O
+:	O
+Following	O
+intravenous	O
+dosing	O
+,	O
+dilmapimod	O
+was	O
+quickly	O
+distributed	O
+to	O
+peripheral	O
+compartments	B-ANAT
+and	O
+then	O
+slowly	O
+eliminated	O
+.	O
+
+The	O
+variation	O
+analyses	O
+demonstrated	O
+that	O
+six	O
+regions	O
+(	O
+nt	O
+1317	O
+-	O
+1436	O
+,	O
+2997	O
+-	O
+3096	O
+,	O
+19	O
+,	O
+737	O
+-	O
+19	O
+,	O
+836	O
+,	O
+20	O
+,	O
+277	O
+-	O
+20	O
+,	O
+376	O
+,	O
+21	O
+,	O
+177	O
+-	O
+21	O
+,	O
+276	O
+,	O
+and	O
+22	O
+,	O
+371	O
+-	O
+22	O
+,	O
+416	O
+)	O
+in	O
+ORF1a	B-PRGE
+/	I-PRGE
+b	I-PRGE
+and	I-PRGE
+spike	I-PRGE
+genes	I-PRGE
+exhibit	O
+high	O
+sequence	O
+variation	O
+between	O
+Thai	O
+and	O
+other	O
+PDCoV	O
+.	O
+The	O
+analyses	O
+of	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+suggested	O
+that	O
+they	O
+could	O
+potentially	O
+be	O
+from	O
+different	O
+lineages	O
+.	O
+
+The	O
+apnea	B-DISO
+-	O
+hypopnea	O
+index	O
+(	O
+AHI	O
+)	O
+correlated	O
+significantly	O
+with	O
+the	O
+number	O
+of	O
+severe	O
+asthma	B-PATH
+exacerbations	O
+(	O
+r	O
+=	O
+0	O
+.	O
+507	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+0	O
+.	O
+357	O
+-	O
+0	O
+.	O
+637	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+binding	B-FUNC
+of	O
+the	O
+""""	O
+down	O
+""""	O
+CTD1s	O
+to	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+ACE2	I-PRGE
+is	O
+not	O
+possible	O
+due	O
+to	O
+steric	O
+clashes	O
+,	O
+suggesting	O
+that	O
+the	O
+conformation	O
+1	O
+represents	O
+a	O
+receptor	O
+-	O
+binding	B-FUNC
+inactive	O
+state	O
+.	O
+
+The	O
+""""	O
+up	O
+""""	O
+CTD1	O
+exposes	O
+the	O
+receptor	O
+-	O
+binding	O
+site	O
+for	O
+ACE2	B-PRGE
+engagement	O
+,	O
+suggesting	O
+that	O
+the	O
+conformations	O
+2	O
+-	O
+4	O
+represent	O
+a	O
+receptor	O
+-	O
+binding	B-FUNC
+active	O
+state	O
+.	O
+
+This	O
+conformational	B-PROC
+change	I-PROC
+is	O
+also	O
+required	O
+for	O
+the	O
+binding	B-FUNC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+targeting	B-PROC
+the	O
+CTD1	O
+.	O
+
+High	O
+flows	O
+through	O
+nasal	B-ANAT
+cannulae	O
+(	O
+HFNC	O
+)	O
+is	O
+a	O
+system	O
+which	O
+allows	O
+increased	O
+CO2	B-CHED
+wash	O
+-	O
+out	O
+of	O
+anatomical	O
+dead	B-PROC
+space	O
+,	O
+positive	O
+nasopharyngeal	B-ANAT
+pressure	O
+,	O
+a	O
+relatively	O
+constant	O
+FiO2	O
+,	O
+and	O
+an	O
+improvement	O
+of	O
+mucociliary	O
+function	O
+.	O
+
+Virus	B-DISO
+shedding	I-DISO
+was	O
+only	O
+detected	O
+in	O
+swabs	O
+obtained	O
+from	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+primarily	O
+observed	O
+in	O
+camels	B-SPEC
+younger	O
+than	O
+3	O
+years	O
+.	O
+
+The	O
+sequence	O
+was	O
+analysed	O
+for	O
+the	O
+presence	O
+of	O
+coding	O
+and	O
+non	O
+-	O
+coding	O
+features	O
+,	O
+its	O
+similarity	O
+with	O
+reported	O
+isolates	O
+and	O
+epitope	B-CHED
+analysis	O
+of	O
+capsid	B-PRGE
+structural	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+capsid	B-PRGE
+structural	I-PRGE
+protein	B-CHED
+of	O
+CAstV	O
+/	O
+INDIA	O
+/	O
+ANAND	O
+/	O
+2016	O
+showed	O
+84	O
+.	O
+67	O
+%	O
+similarity	O
+with	O
+chicken	B-SPEC
+astrovirus	I-SPEC
+isolate	O
+CAstV	O
+/	O
+GA2011	O
+,	O
+81	O
+.	O
+06	O
+%	O
+with	O
+CAstV	O
+/	O
+4175	O
+and	O
+41	O
+.	O
+18	O
+%	O
+with	O
+CAstV	O
+/	O
+Poland	O
+/	O
+G059	O
+/	O
+2014	O
+isolates	O
+.	O
+
+TITLE	O
+:	O
+Perceived	O
+safety	O
+and	O
+efficacy	O
+of	O
+neuromuscular	O
+blockers	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+among	O
+medical	O
+intensive	O
+care	O
+unit	O
+practitioners	O
+:	O
+A	O
+multicenter	O
+survey	O
+.	O
+
+More	O
+NP	O
+/	O
+PAs	B-COMP
+identified	O
+the	O
+association	O
+of	O
+consciousness	O
+with	O
+the	O
+use	O
+of	O
+NMBAs	O
+than	O
+physicians	O
+(	O
+P	O
+=.	O
+047	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+whether	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+(	O
+NMBA	O
+)	O
+exert	B-PROC
+beneficial	O
+effects	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+by	O
+reason	O
+of	O
+their	O
+action	O
+on	O
+respiratory	B-PROC
+mechanics	I-PROC
+,	O
+particularly	O
+transpulmonary	O
+pressures	O
+(	O
+P	O
+A	O
+prospective	O
+randomised	O
+controlled	O
+study	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+within	O
+48	O
+h	O
+of	O
+the	O
+onset	O
+of	O
+ARDS	B-DISO
+.	O
+
+Severe	O
+ARDS	B-DISO
+patients	O
+did	O
+not	O
+undergo	O
+randomisation	O
+and	O
+all	O
+received	O
+cisatracurium	B-CHED
+besylate	I-CHED
+per	O
+protocol	O
+.	O
+
+The	O
+changes	O
+during	O
+the	O
+48	O
+-	O
+h	O
+study	O
+period	O
+in	O
+oxygenation	B-PROC
+and	O
+in	O
+respiratory	B-PROC
+mechanics	I-PROC
+,	O
+including	O
+inspiratory	B-PROC
+and	O
+expiratory	B-PROC
+P	O
+Thirty	O
+patients	O
+were	O
+included	O
+,	O
+24	O
+with	O
+moderate	O
+ARDS	O
+and	O
+6	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+Leukemia	I-SPEC
+Virus	I-SPEC
+(	O
+MLV	O
+)-	O
+based	O
+Coronavirus	B-SPEC
+Spike	O
+-	O
+pseudotyped	O
+Particle	O
+Production	O
+and	O
+Infection	B-DISO
+.	O
+
+The	O
+basis	O
+for	O
+their	O
+generation	O
+lies	O
+in	O
+the	O
+capacity	O
+of	O
+some	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+murine	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+(	O
+MLV	O
+),	O
+to	O
+incorporate	O
+envelope	B-COMP
+glycoproteins	B-CHED
+of	O
+other	O
+viruses	B-SPEC
+into	O
+a	O
+pseudotyped	O
+virus	B-COMP
+particle	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+exacerbation	O
+(	O
+AE	O
+)	O
+is	O
+a	O
+severe	O
+complication	B-DISO
+of	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+(	O
+IPF	O
+),	O
+which	O
+shares	O
+some	O
+common	O
+pathological	O
+features	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+STBI	O
+is	O
+frequently	O
+followed	O
+by	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+which	O
+is	O
+not	O
+usually	O
+treated	O
+with	O
+CS	O
+.	O
+
+The	O
+study	O
+involved	O
+an	O
+analysis	O
+of	O
+the	O
+treatment	O
+results	O
+in	O
+267	O
+patients	O
+with	O
+STBI	O
+followed	O
+by	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+ARDS	B-DISO
+,	O
+who	O
+were	O
+treated	O
+with	O
+and	O
+without	O
+CS	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Extracorporeal	O
+Life	O
+Support	O
+Organisation	B-PROC
+accepts	O
+permissive	O
+hypoxaemia	O
+in	O
+adult	O
+patients	O
+during	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+Blood	B-ANAT
+lactate	B-CHED
+concentrations	O
+were	O
+used	O
+as	O
+a	O
+surrogate	O
+for	O
+tissue	O
+oxygenation	B-PROC
+.	O
+
+Permissive	O
+hypoxaemia	O
+during	O
+ECMO	O
+might	O
+not	O
+negatively	O
+affect	O
+long	O
+-	O
+term	O
+cognitive	O
+outcome	O
+if	O
+adequate	O
+organ	B-ANAT
+perfusion	O
+is	O
+maintained	O
+.	O
+
+To	O
+do	O
+so	O
+,	O
+lung	B-ANAT
+recruitability	O
+should	O
+be	O
+considered	O
+,	O
+as	O
+well	O
+as	O
+the	O
+avoidance	O
+of	O
+lung	B-ANAT
+overstress	O
+by	O
+monitoring	O
+transpulmonary	O
+pressure	O
+or	O
+airway	B-ANAT
+driving	O
+pressure	O
+.	O
+
+We	O
+report	O
+here	O
+the	O
+efficacy	O
+of	O
+a	O
+vaccine	O
+consisting	O
+of	O
+chimeric	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLP	B-COMP
+)	O
+expressing	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+this	O
+study	O
+,	O
+a	O
+fusion	O
+of	O
+the	O
+canine	O
+parvovirus	B-DISO
+(	O
+CPV	B-SPEC
+)	O
+VP2	B-PRGE
+structural	O
+protein	B-CHED
+gene	O
+with	O
+the	O
+RBD	O
+of	O
+MERS	O
+-	O
+CoV	O
+can	O
+self	O
+-	O
+assemble	O
+into	O
+chimeric	O
+,	O
+spherical	O
+VLP	B-COMP
+(	O
+sVLP	O
+).	O
+
+However	O
+,	O
+the	O
+inability	O
+to	O
+cryopreserve	O
+embryos	B-ANAT
+significantly	O
+reduces	O
+its	O
+broader	O
+application	O
+,	O
+and	O
+as	O
+such	O
+limits	O
+the	O
+capacity	O
+to	O
+utilize	O
+elite	O
+genetic	O
+resources	O
+internationally	O
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+the	O
+results	O
+of	O
+a	O
+recent	O
+dromedary	B-SPEC
+camel	B-SPEC
+embryo	B-ANAT
+transfer	O
+study	O
+which	O
+produced	O
+a	O
+high	O
+morphologic	O
+integrity	O
+and	O
+survival	O
+rate	O
+of	O
+Open	O
+Pulled	O
+Straw	O
+-	O
+vitrified	O
+embryos	B-ANAT
+are	O
+also	O
+discussed	O
+.	O
+
+219	O
+CS	O
+patients	O
+were	O
+categorized	O
+by	O
+the	O
+maximum	O
+intensity	O
+of	O
+ventilatory	O
+support	O
+they	O
+needed	O
+during	O
+the	O
+first	O
+24h	O
+into	O
+MV	O
+(	O
+n	O
+=	O
+137	O
+;	O
+63	O
+%)	O
+,	O
+NIV	O
+(	O
+n	O
+=	O
+26	O
+;	O
+12	O
+%),	O
+and	O
+supplementary	O
+oxygen	B-CHED
+(	O
+n	O
+=	O
+56	O
+;	O
+26	O
+%)	O
+groups	O
+.	O
+
+Health	O
+-	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+are	O
+at	O
+risk	O
+of	O
+acquiring	O
+and	O
+transmitting	O
+this	O
+virus	B-SPEC
+,	O
+so	O
+the	O
+concerns	O
+of	O
+HCWs	O
+in	O
+Saudi	O
+Arabia	O
+regarding	O
+MERS	O
+were	O
+evaluated	O
+.	O
+
+Since	O
+then	O
+,	O
+several	O
+concurrent	O
+infections	B-DISO
+have	O
+been	O
+reported	O
+between	O
+the	O
+dengue	B-SPEC
+virus	I-SPEC
+(	O
+DENV	O
+)	O
+and	O
+the	O
+malaria	B-PATH
+protozoans	O
+,	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+and	O
+Plasmodium	B-SPEC
+vivax	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+evolutionary	O
+dynamics	O
+of	O
+two	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+genotypes	O
+associated	O
+with	O
+acute	O
+respiratory	O
+infections	O
+:	O
+phylogenetic	O
+,	O
+spatiotemporal	O
+and	O
+transmission	O
+network	O
+analyses	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+is	O
+commonly	O
+associated	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+humans	B-SPEC
+,	O
+with	O
+five	O
+genetically	O
+distinct	O
+genotypes	O
+(	O
+A	O
+to	O
+E	O
+)	O
+described	O
+so	O
+far	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+obtained	O
+the	O
+full	O
+-	O
+length	O
+genomes	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+strains	O
+from	O
+two	O
+previously	O
+unrecognized	O
+lineages	O
+identified	O
+among	O
+patients	O
+presenting	O
+with	O
+severe	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+symptoms	O
+in	O
+a	O
+cross	O
+-	O
+sectional	O
+molecular	O
+surveillance	O
+study	O
+in	O
+Kuala	O
+Lumpur	O
+,	O
+Malaysia	O
+,	O
+between	O
+2012	O
+and	O
+2013	O
+.	O
+
+The	O
+dynamics	O
+of	O
+natural	O
+infection	B-DISO
+in	O
+camels	B-SPEC
+are	O
+not	O
+well	O
+understood	O
+.	O
+
+Through	O
+systematic	O
+surveillance	O
+in	O
+Egypt	O
+,	O
+nasal	B-ANAT
+,	O
+rectal	O
+,	O
+milk	O
+,	O
+urine	B-ANAT
+and	O
+serum	B-COMP
+samples	O
+were	O
+collected	O
+from	O
+camels	B-SPEC
+between	O
+June	O
+2014	O
+and	O
+February	O
+2016	O
+.	O
+
+An	O
+outbreak	O
+in	O
+a	O
+breeding	B-PROC
+herd	O
+,	O
+showed	O
+that	O
+antibodies	B-COMP
+rapidly	O
+wane	O
+,	O
+that	O
+camels	B-SPEC
+become	O
+re	O
+-	O
+infected	O
+,	O
+and	O
+that	O
+outbreaks	O
+in	O
+a	O
+herd	O
+are	O
+sustained	O
+for	O
+an	O
+extended	O
+time	O
+.	O
+
+Our	O
+results	O
+support	O
+the	O
+hypothesis	O
+that	O
+camels	B-SPEC
+are	O
+a	O
+reservoir	O
+for	O
+MERS	O
+-	O
+CoV	O
+and	O
+that	O
+camel	B-SPEC
+trade	O
+is	O
+an	O
+important	O
+route	O
+of	O
+introducing	O
+the	O
+virus	B-SPEC
+into	O
+importing	O
+countries	O
+.	O
+
+This	O
+paper	O
+focuses	O
+on	O
+the	O
+mechanisms	O
+of	O
+the	O
+military	O
+-	O
+cooperative	O
+emergency	B-DISO
+response	O
+to	O
+infectious	B-DISO
+diseases	I-DISO
+--	O
+the	O
+joint	B-ANAT
+working	O
+mechanism	O
+,	O
+the	O
+information	O
+-	O
+sharing	O
+mechanism	O
+,	O
+the	O
+research	O
+collaboration	O
+mechanism	O
+,	O
+and	O
+the	O
+joint	B-ANAT
+disposal	O
+mechanism	O
+--	O
+and	O
+presents	O
+a	O
+sorted	B-PROC
+summary	O
+of	O
+the	O
+practices	O
+and	O
+experiences	O
+of	O
+cooperative	O
+emergency	O
+responses	O
+to	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Infections	B-DISO
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+can	O
+lead	O
+to	O
+severe	O
+complications	O
+,	O
+such	O
+as	O
+empyema	O
+,	O
+lung	B-DISO
+abscesses	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Although	O
+a	O
+definite	O
+diagnosis	O
+is	O
+sometimes	O
+difficult	O
+or	O
+even	O
+impossible	O
+to	O
+establish	O
+using	O
+chest	O
+X	B-SPEC
+‑	I-SPEC
+ray	I-SPEC
+or	O
+CT	O
+,	O
+there	O
+are	O
+several	O
+findings	O
+indicative	O
+of	O
+intrapulmonary	O
+or	O
+extrapulmonary	O
+complications	O
+of	O
+pneumonia	B-DISO
+.	O
+
+Clinicians	O
+should	O
+re	O
+-	O
+evaluate	O
+asthma	B-PATH
+management	O
+and	O
+be	O
+aware	O
+of	O
+the	O
+complications	O
+associated	O
+with	O
+asthma	B-DISO
+attacks	I-DISO
+such	O
+as	O
+stress	O
+-	O
+induced	O
+cardiomyopathy	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Recognizing	O
+apical	B-DISO
+ballooning	I-DISO
+syndrome	I-DISO
+is	O
+challenging	O
+in	O
+patients	O
+with	O
+a	O
+history	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+because	O
+the	O
+symptoms	O
+of	O
+the	O
+last	O
+entity	O
+may	O
+complicate	O
+the	O
+diagnostic	O
+approach	O
+.	O
+
+Risk	O
+factors	O
+for	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+in	O
+humans	B-SPEC
+are	O
+incompletely	O
+understood	O
+.	O
+
+TITLE	O
+:	O
+Understanding	O
+the	O
+early	O
+dynamics	O
+of	O
+the	O
+2014	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+outbreak	O
+in	O
+Ontario	O
+using	O
+the	O
+incidence	O
+decay	O
+and	O
+exponential	O
+adjustment	O
+(	O
+IDEA	B-SPEC
+)	O
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+Safety	O
+tested	O
+Modified	O
+Vaccinia	B-SPEC
+virus	I-SPEC
+Ankara	O
+(	O
+MVA	B-CHED
+)	O
+is	O
+licensed	O
+as	O
+third	O
+-	O
+generation	O
+vaccine	O
+against	O
+smallpox	B-DISO
+and	O
+serves	O
+as	O
+a	O
+potent	O
+vector	O
+system	O
+for	O
+development	B-PROC
+of	O
+new	O
+candidate	O
+vaccines	O
+against	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+cancer	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+nurses	O
+suffer	B-DISO
+from	O
+persistent	O
+stress	O
+after	O
+experiencing	O
+the	O
+traumatic	O
+event	O
+of	O
+exposure	O
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+which	O
+can	O
+subsequently	O
+lead	O
+to	O
+burnout	O
+.	O
+
+ck	O
+/	O
+CH	O
+/	O
+LGX	O
+/	O
+111119	O
+is	O
+a	O
+nephropathogenic	O
+strain	O
+,	O
+although	O
+it	O
+had	O
+broader	O
+tissue	B-PROC
+tropism	B-PROC
+(	O
+respiratory	O
+,	O
+digestive	B-PROC
+,	O
+urinary	O
+,	O
+and	O
+reproductive	B-PROC
+tracts	B-ANAT
+)	O
+among	O
+chickens	B-SPEC
+challenged	O
+at	O
+one	O
+day	O
+old	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+infections	B-DISO
+with	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+virus	B-SPEC
+are	O
+frequently	O
+fatal	O
+but	O
+the	O
+mechanisms	O
+of	O
+disease	O
+remain	O
+ill	B-DISO
+-	O
+defined	O
+.	O
+
+Conventional	O
+intratracheal	O
+inoculation	O
+of	O
+a	O
+liquid	O
+suspension	O
+of	O
+H5N1	B-DISO
+influenza	I-DISO
+virus	O
+in	O
+nonhuman	O
+primates	B-SPEC
+likely	O
+results	O
+in	O
+efficient	O
+clearance	O
+of	O
+virus	B-SPEC
+within	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+rarely	O
+produces	O
+severe	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Roles	O
+of	O
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+in	O
+virus	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+Also	O
+,	O
+these	O
+infections	B-DISO
+may	O
+be	O
+more	O
+severe	O
+in	O
+immunocompromised	O
+patients	O
+than	O
+in	O
+the	O
+general	O
+population	O
+.	O
+
+Early	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+viral	B-DISO
+infections	I-DISO
+continue	O
+to	O
+be	O
+of	O
+paramount	O
+importance	O
+in	O
+immunocompromised	O
+patients	O
+;	O
+because	O
+once	O
+viral	B-PROC
+replication	I-PROC
+and	O
+invasive	O
+infections	B-DISO
+are	O
+evident	O
+,	O
+prognosis	O
+can	O
+be	O
+grave	O
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+exposure	O
+to	O
+the	O
+plant	B-SPEC
+toxin	O
+ricin	B-FUNC
+leads	O
+to	O
+respiratory	B-DISO
+insufficiency	I-DISO
+and	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	O
+respiratory	O
+disease	O
+complex	O
+(	O
+BRDC	O
+)	O
+is	O
+frequently	O
+found	O
+in	O
+cattle	B-SPEC
+worldwide	O
+.	O
+
+The	O
+etiology	O
+of	O
+BRDC	O
+is	O
+complicated	O
+by	O
+infections	B-DISO
+with	O
+multiple	O
+pathogens	O
+,	O
+making	O
+identification	O
+of	O
+the	O
+causal	O
+pathogen	O
+difficult	O
+.	O
+
+TMV	B-SPEC
+-	O
+wt	O
+was	O
+paired	O
+with	O
+a	O
+genetically	O
+engineered	O
+TMV	B-SPEC
+-	O
+lys	B-CHED
+variant	O
+that	O
+displays	O
+a	O
+corona	B-CHED
+of	O
+lysine	B-CHED
+side	O
+chains	O
+on	O
+its	O
+solvent	B-CHED
+-	O
+exposed	O
+surface	O
+.	O
+
+Since	O
+the	O
+resulting	O
+morphology	O
+closely	O
+resembles	O
+the	O
+3	O
+-	O
+dimensional	O
+fibrous	O
+network	O
+of	O
+an	O
+extracellular	O
+matrix	O
+(	O
+ECM	B-COMP
+),	O
+the	O
+capability	O
+of	O
+the	O
+TMV	B-SPEC
+assemblies	O
+to	O
+support	O
+the	O
+adhesion	B-DISO
+of	O
+NIH	O
+-	O
+3T3	O
+fibroblast	B-ANAT
+cells	B-COMP
+was	O
+investigated	O
+,	O
+demonstrating	O
+potential	O
+utility	O
+in	O
+regenerative	O
+medicine	B-CHED
+.	O
+
+Clinical	O
+protocols	O
+or	O
+checklists	O
+for	O
+mechanically	O
+ventilated	O
+patients	O
+were	O
+available	O
+in	O
+128	O
+of	O
+133	O
+(	O
+96	O
+%)	O
+ICUs	O
+,	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+54	O
+of	O
+132	O
+(	O
+41	O
+%)	O
+ICUs	O
+,	O
+prone	O
+positioning	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+37	O
+of	O
+134	O
+(	O
+28	O
+%)	O
+ICUs	O
+,	O
+and	O
+family	B-SPEC
+meetings	O
+in	O
+19	O
+of	O
+134	O
+(	O
+14	O
+%)	O
+ICUs	O
+.	O
+
+Variable	O
+numbers	O
+use	O
+clinical	O
+protocols	O
+for	O
+life	O
+-	O
+saving	O
+therapies	O
+,	O
+and	O
+few	O
+use	O
+structured	O
+family	B-SPEC
+engagement	O
+strategies	O
+.	O
+
+In	O
+single	O
+viral	B-DISO
+infections	I-DISO
+,	O
+some	O
+statistically	O
+significant	O
+differences	O
+in	O
+demographics	O
+,	O
+clinical	B-DISO
+findings	I-DISO
+,	O
+disease	O
+severity	O
+and	O
+outcome	O
+were	O
+found	O
+between	O
+children	O
+with	O
+different	O
+viral	O
+etiologies	O
+.	O
+
+TITLE	O
+:	O
+X	O
+-	O
+ray	B-SPEC
+Structure	O
+and	O
+Enzymatic	B-PROC
+Activity	I-PROC
+Profile	O
+of	O
+a	O
+Core	O
+Papain	B-ENZY
+-	O
+like	O
+Protease	O
+of	O
+MERS	O
+Coronavirus	B-SPEC
+with	O
+utility	O
+for	O
+structure	O
+-	O
+based	O
+drug	O
+design	O
+.	O
+
+Moreover	O
+,	O
+PLpro	O
+-∆	O
+Ubl2	B-PRGE
+catalysis	O
+against	O
+different	O
+substrates	O
+and	O
+a	O
+purported	O
+inhibitor	B-CHED
+revealed	O
+no	O
+differences	O
+in	O
+catalytic	O
+efficiency	O
+,	O
+substrate	O
+specificity	O
+,	O
+and	O
+inhibition	B-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+First	O
+Infant	O
+Death	B-PROC
+Associated	O
+With	O
+Human	B-PRGE
+Coronavirus	I-PRGE
+NL63	I-PRGE
+Infection	B-DISO
+.	O
+
+However	O
+,	O
+the	O
+drug	O
+-	O
+mediated	O
+depletion	O
+of	O
+lipid	O
+rafts	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+before	O
+IBV	B-SPEC
+attachment	O
+significantly	O
+reduced	O
+the	O
+expression	B-PROC
+of	O
+viral	O
+structural	O
+proteins	B-CHED
+,	O
+suggesting	O
+that	O
+drug	O
+treatment	O
+impaired	B-DISO
+the	O
+attachment	O
+of	O
+IBV	B-SPEC
+to	O
+the	O
+cell	B-COMP
+surface	I-COMP
+.	O
+
+Even	O
+though	O
+the	O
+poultry	O
+industry	O
+extensively	O
+vaccinates	O
+against	O
+IBV	B-SPEC
+,	O
+emergence	O
+of	O
+new	O
+serotypes	O
+and	O
+variants	O
+continually	O
+occur	O
+,	O
+making	O
+control	O
+of	O
+the	O
+disease	O
+difficult	O
+.	O
+
+Data	O
+from	O
+the	O
+Saudi	O
+Ministry	O
+of	O
+Health	O
+of	O
+confirmed	O
+outbreak	O
+and	O
+non	O
+-	O
+outbreak	O
+cases	O
+of	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infections	B-DISO
+from	O
+September	O
+2012	O
+through	O
+October	O
+2015	O
+were	O
+abstracted	O
+and	O
+analysed	O
+.	O
+
+It	O
+was	O
+relieved	O
+by	O
+sitting	O
+up	O
+straight	O
+and	O
+did	O
+not	O
+radiate	O
+to	O
+her	O
+left	B-ANAT
+arm	I-ANAT
+or	O
+jaw	B-ANAT
+.	O
+
+CT	O
+angiography	O
+of	O
+the	O
+chest	B-ANAT
+with	O
+axial	O
+contrast	O
+showed	O
+mild	O
+left	O
+pleural	B-ANAT
+effusion	I-ANAT
+as	O
+well	O
+as	O
+a	O
+small	O
+pericardial	B-DISO
+effusion	I-DISO
+with	O
+bilateral	O
+lower	O
+lobe	B-ANAT
+interstitial	B-ANAT
+infiltrates	B-DISO
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+Diabetes	B-DISO
+in	O
+the	O
+2009	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+and	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+:	O
+A	O
+Systematic	O
+Review	O
+and	O
+Meta	B-SPEC
+-	O
+Analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+the	O
+past	O
+two	O
+decades	O
+a	O
+number	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+outbreaks	O
+such	O
+as	O
+the	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+and	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+have	O
+emerged	O
+and	O
+presented	O
+a	O
+considerable	O
+global	O
+public	O
+health	O
+threat	O
+.	O
+
+TITLE	O
+:	O
+Super	O
+-	O
+oxidized	O
+water	B-CHED
+inactivates	O
+major	O
+viruses	B-SPEC
+circulating	O
+in	O
+swine	B-SPEC
+farms	O
+.	O
+
+The	O
+drug	O
+was	O
+sprayed	B-DISO
+intra	O
+-	O
+orally	B-ANAT
+(	O
+3	O
+×	O
+daily	O
+)	O
+for	O
+75	O
+days	O
+.	O
+
+Of	O
+the	O
+94	O
+individuals	O
+who	O
+completed	O
+the	O
+study	O
+(	O
+placebo	O
+:	O
+n	O
+=	O
+44	O
+,	O
+ARMS	B-DISO
+-	O
+I	O
+:	O
+n	O
+=	O
+50	O
+),	O
+six	O
+presented	O
+with	O
+confirmed	O
+URI	O
+(	O
+placebo	O
+:	O
+4	O
+,	O
+ARMS	B-DISO
+-	O
+I	O
+:	O
+2	O
+),	O
+representing	O
+a	O
+55	O
+%	O
+relative	O
+reduction	O
+,	O
+albeit	O
+this	O
+was	O
+statistically	O
+not	O
+significant	O
+).	O
+
+TITLE	O
+:	O
+Propofol	B-CHED
+as	O
+a	O
+Risk	O
+Factor	O
+for	O
+ICU	O
+-	O
+Acquired	O
+Weakness	B-DISO
+in	O
+Septic	O
+Patients	O
+with	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+(	O
+CIN	B-DISO
+)	O
+and	O
+critical	B-DISO
+illness	I-DISO
+myopathy	I-DISO
+(	O
+CIM	O
+),	O
+together	O
+""""	O
+ICU	O
+-	O
+Acquired	O
+weakness	B-DISO
+(	O
+ICUAW	O
+"),"""	O
+occur	O
+frequently	O
+in	O
+septic	O
+patients	O
+.	O
+
+An	O
+interaction	O
+through	O
+sodium	O
+channel	O
+inactivation	B-DISO
+is	O
+hypothesized	O
+.	O
+
+TITLE	O
+:	O
+MPLEx	O
+:	O
+a	O
+method	O
+for	O
+simultaneous	O
+pathogen	O
+inactivation	B-DISO
+and	O
+extraction	O
+of	O
+samples	O
+for	O
+multi	O
+-	O
+omics	O
+profiling	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+continued	O
+emergence	O
+and	O
+spread	O
+of	O
+infectious	O
+agents	O
+is	O
+of	O
+great	O
+concern	O
+,	O
+and	O
+systems	O
+biology	O
+approaches	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+research	O
+can	O
+advance	O
+our	O
+understanding	O
+of	O
+host	B-COMP
+-	O
+pathogen	O
+relationships	O
+and	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+new	O
+therapies	O
+and	O
+vaccines	O
+.	O
+
+Molecular	O
+characterization	O
+of	O
+infectious	B-DISO
+samples	O
+outside	O
+of	O
+appropriate	O
+biosafety	O
+containment	O
+can	O
+take	O
+place	O
+only	O
+subsequent	O
+to	O
+pathogen	O
+inactivation	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+report	O
+the	O
+emergence	O
+,	O
+mixed	B-DISO
+infection	I-DISO
+,	O
+and	O
+genetic	O
+characterization	O
+of	O
+15	O
+novel	O
+field	O
+PEDV	B-SPEC
+variants	O
+with	O
+large	O
+genomic	O
+deletions	O
+.	O
+
+Among	O
+17	O
+PEDV	B-SPEC
+samples	O
+isolated	O
+from	O
+individual	O
+pigs	B-SPEC
+,	O
+all	O
+of	O
+them	O
+contained	O
+at	O
+least	O
+two	O
+distinct	O
+genotypes	O
+with	O
+large	O
+genomic	O
+deletions	O
+,	O
+and	O
+94	O
+.	O
+1	O
+%	O
+of	O
+them	O
+were	O
+found	O
+to	O
+consist	O
+of	O
+strains	O
+with	O
+an	O
+intact	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+mixed	B-DISO
+infections	I-DISO
+caused	O
+by	O
+various	O
+genotypes	O
+of	O
+PEDV	B-SPEC
+and	O
+would	O
+be	O
+important	O
+for	O
+the	O
+studies	O
+of	O
+viral	O
+isolation	O
+,	O
+pathogenesis	B-DISO
+,	O
+and	O
+molecular	O
+epidemiology	O
+of	O
+the	O
+disease	O
+.	O
+
+Serum	B-COMP
+pretreatment	O
+of	O
+the	O
+nitrocellulose	B-CHED
+also	O
+eliminated	O
+false	O
+positives	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+clinical	O
+observation	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+relationship	O
+between	O
+the	O
+serum	O
+levels	O
+of	O
+vascular	B-PROC
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PROC
+(	O
+VEGF	B-PRGE
+)	O
+and	O
+its	O
+soluble	O
+receptors	O
+with	O
+the	O
+severity	O
+and	O
+the	O
+occurrence	O
+of	O
+late	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+early	O
+trauma	O
+.	O
+
+sVEGFR1	O
+in	O
+the	O
+ARDS	O
+group	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+in	O
+the	O
+non	O
+-	O
+ARDS	B-DISO
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+and	O
+sVEGFR2	O
+in	O
+the	O
+ARDS	B-DISO
+group	O
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+in	O
+the	O
+non	O
+-	O
+ARDS	B-DISO
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+sVEGFR1	O
+in	O
+the	O
+ARDS	B-DISO
+group	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+in	O
+the	O
+non	O
+-	O
+ARDS	B-DISO
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+and	O
+sVEGFR2	O
+in	O
+the	O
+ARDS	B-DISO
+group	O
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+in	O
+the	O
+non	O
+-	O
+ARDS	B-DISO
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+ABSTRACT	O
+:	O
+BACKGROUND	O
+Pulmonary	B-DISO
+infections	I-DISO
+are	O
+a	O
+major	O
+cause	O
+of	O
+mortality	O
+and	O
+morbidity	O
+in	O
+patients	O
+infected	O
+with	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+and	O
+can	O
+progress	O
+rapidly	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+death	B-PROC
+without	O
+appropriate	O
+therapy	O
+.	O
+
+CASE	O
+REPORT	O
+A	O
+47	O
+-	O
+year	O
+-	O
+old	O
+nonsmoking	O
+Hispanic	O
+man	B-CHED
+with	O
+advanced	O
+HIV	B-PATH
+infection	I-PATH
+presented	O
+with	O
+severe	O
+acute	O
+necrotizing	B-DISO
+pneumonia	I-DISO
+secondary	O
+to	O
+R	B-SPEC
+.	I-SPEC
+equi	I-SPEC
+.	O
+
+Cytokine	O
+analysis	O
+revealed	O
+that	O
+the	O
+level	O
+of	O
+serum	B-PRGE
+granulocyte	B-FUNC
+colony	I-FUNC
+-	I-FUNC
+stimulating	I-FUNC
+factor	I-FUNC
+(	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+was	O
+significantly	O
+higher	O
+in	O
+both	O
+CoV	O
+-	O
+CNS	B-CHED
+and	O
+CoV	O
+-	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+compared	O
+with	O
+healthy	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+Genetic	O
+and	O
+environmental	O
+factors	O
+,	O
+i	O
+.	O
+e	O
+.	O
+infections	B-DISO
+,	O
+have	O
+been	O
+proposed	O
+to	O
+contribute	O
+to	O
+disease	O
+induction	O
+and	O
+relapsing	O
+events	O
+in	O
+multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+),	O
+an	O
+autoimmune	B-DISO
+demyelinating	B-DISO
+disease	I-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+).	O
+
+The	O
+results	O
+showed	O
+that	O
+plasma	B-ANAT
+potassium	B-CHED
+,	O
+sodium	O
+,	O
+chlorine	B-CHED
+,	O
+magnesium	B-CHED
+,	O
+calcium	B-CHED
+,	O
+and	O
+phosphorus	B-CHED
+levels	O
+were	O
+increased	O
+.	O
+
+The	O
+relationship	O
+between	O
+maximum	O
+PaCO	O
+Severe	O
+hypercapnia	B-DISO
+appears	O
+to	O
+be	O
+independently	O
+associated	O
+with	O
+higher	O
+ICU	O
+mortality	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+rpIFN	O
+-	O
+L1	O
+exhibited	O
+greater	O
+antiviral	O
+activity	O
+against	O
+PEDV	B-SPEC
+infection	B-DISO
+of	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+than	O
+that	O
+of	O
+porcine	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+showed	O
+that	O
+CK	O
+/	O
+CH	O
+/	O
+2010	O
+/	O
+JT	O
+-	O
+1	O
+and	O
+31	O
+other	O
+isolates	O
+could	O
+be	O
+grouped	O
+as	O
+a	O
+new	O
+genotypic	O
+cluster	O
+.	O
+
+Whole	O
+-	O
+genome	O
+sequence	O
+analysis	O
+showed	O
+that	O
+CK	O
+/	O
+CH	O
+/	O
+2010	O
+/	O
+JT	O
+-	O
+1	O
+originated	O
+from	O
+multiple	O
+template	O
+switches	O
+among	O
+QX	O
+-	O
+like	O
+,	O
+CK	O
+/	O
+CH	O
+/	O
+LSC	B-PRGE
+/	O
+99I	O
+-,	O
+tl	O
+/	O
+CH	O
+/	O
+LDT3	O
+/	O
+03	O
+-	O
+and	O
+4	O
+/	O
+91	O
+-	O
+type	O
+IBVs	O
+.	O
+
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+an	O
+Alphacoronavirus	B-SPEC
+genera	O
+virus	B-SPEC
+,	O
+is	O
+an	O
+important	O
+pathogen	O
+that	O
+mainly	O
+infects	O
+piglet	O
+,	O
+but	O
+little	O
+is	O
+known	O
+about	O
+the	O
+activation	O
+of	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+.	O
+
+Finally	O
+,	O
+the	O
+activation	O
+of	O
+IFN	B-PRGE
+responses	O
+induced	O
+by	O
+TGEV	B-SPEC
+infection	B-DISO
+cannot	O
+inhibit	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Methods	O
+Samples	O
+from	O
+sick	O
+(	O
+n	O
+=	O
+96	O
+)	O
+and	O
+dead	B-PROC
+(	O
+n	O
+=	O
+15	O
+)	O
+cats	B-SPEC
+were	O
+analysed	O
+using	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+.	O
+
+Tubular	O
+parenchymal	O
+cells	B-ANAT
+,	I-ANAT
+lymphoid	I-ANAT
+and	O
+plasma	B-ANAT
+cells	I-ANAT
+in	O
+kidney	B-ANAT
+and	O
+hepatocytes	B-ANAT
+,	O
+lymphoid	O
+and	O
+plasma	B-ANAT
+cells	I-ANAT
+in	O
+liver	B-ANAT
+from	O
+dead	B-PROC
+cats	B-SPEC
+were	O
+also	O
+positive	O
+by	O
+immunohistochemistry	O
+for	O
+the	O
+viral	O
+N	O
+protein	B-CHED
+.	O
+
+FmoPV	O
+RNA	O
+-	O
+positive	O
+cats	B-SPEC
+had	O
+lower	O
+median	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+,	O
+haemoglobin	B-CHED
+,	O
+albumin	B-PRGE
+,	O
+albumin	B-PRGE
+/	O
+globulin	O
+and	O
+urobilinogen	B-CHED
+and	O
+higher	B-PRGE
+alanine	I-PRGE
+transaminase	I-PRGE
+,	O
+alkaline	B-PRGE
+phosphatase	I-PRGE
+and	O
+bilirubin	B-CHED
+compared	O
+with	O
+non	O
+-	O
+infected	O
+cats	B-SPEC
+.	O
+
+Widespread	O
+lymphoid	B-ANAT
+cell	I-ANAT
+infiltrates	B-DISO
+were	O
+detected	O
+in	O
+the	O
+renal	B-ANAT
+cortex	I-ANAT
+and	O
+medullary	B-ANAT
+regions	O
+of	O
+the	O
+kidneys	B-ANAT
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+ruminal	O
+,	O
+abomasal	O
+,	O
+or	O
+umbilical	B-ANAT
+cord	I-ANAT
+tissue	I-ANAT
+inflammation	B-DISO
+,	O
+or	O
+pathogen	O
+test	O
+-	O
+positive	O
+status	O
+between	O
+cases	O
+and	O
+controls	O
+.	O
+
+The	O
+early	O
+and	O
+NC1	O
+viruses	B-SPEC
+had	O
+KM91	B-PRGE
+-	I-PRGE
+like	I-PRGE
+backgrounds	O
+,	O
+but	O
+the	O
+recurrent	O
+viruses	B-SPEC
+had	O
+QX	O
+-	O
+like	O
+genomic	O
+backgrounds	O
+.	O
+
+The	O
+absence	O
+of	O
+pure	B-FUNC
+QX	O
+-	O
+like	O
+viruses	B-SPEC
+before	O
+the	O
+appearance	O
+of	O
+the	O
+early	O
+viruses	B-SPEC
+suggests	O
+that	O
+the	O
+viruses	B-SPEC
+were	O
+introduced	O
+from	O
+other	O
+countries	O
+after	O
+recombination	B-PROC
+,	O
+but	O
+the	O
+NC1	O
+viruses	B-SPEC
+originated	O
+in	O
+Korea	O
+.	O
+
+The	O
+recent	O
+prevalence	O
+of	O
+recurrent	O
+viruses	B-SPEC
+with	O
+different	O
+genomic	O
+backgrounds	O
+and	O
+spike	O
+genes	O
+from	O
+the	O
+early	O
+and	O
+the	O
+NC1	O
+viruses	B-SPEC
+may	O
+indicate	O
+the	O
+repeated	O
+introduction	O
+of	O
+different	O
+infectious	O
+bronchitis	B-DISO
+viruses	B-SPEC
+from	O
+other	O
+countries	O
+and	O
+their	O
+successful	O
+evasion	O
+of	O
+vaccine	O
+immunity	B-PROC
+in	O
+the	O
+field	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+which	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+in	O
+China	O
+and	O
+other	O
+countries	O
+,	O
+is	O
+responsible	O
+for	O
+serious	O
+economic	O
+losses	O
+in	O
+the	O
+pork	O
+industry	O
+.	O
+
+TITLE	O
+:	O
+Update	O
+on	O
+low	O
+-	O
+dose	O
+corticosteroids	B-CHED
+.	O
+
+Retrospective	O
+propensity	O
+-	O
+score	O
+analyses	O
+also	O
+suggest	O
+that	O
+LDC	B-PRGE
+administered	O
+in	O
+severe	O
+septic	B-DISO
+shock	I-DISO
+or	O
+in	O
+septic	B-DISO
+shock	I-DISO
+due	O
+to	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+or	O
+intestinal	B-DISO
+perforation	I-DISO
+may	O
+improve	O
+survival	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Corona	B-CHED
+Virus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+transmitted	B-DISO
+via	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+causes	O
+severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+by	O
+infecting	O
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+macrophages	B-ANAT
+.	O
+
+These	O
+findings	O
+support	O
+a	O
+DPP4	B-PRGE
+-	O
+mediated	O
+suppressive	O
+action	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+macrophages	B-ANAT
+and	O
+suggest	O
+a	O
+potential	O
+target	O
+for	O
+effective	O
+elimination	B-PROC
+of	O
+its	O
+pathogenicity	O
+.	O
+
+We	O
+developed	O
+an	O
+efficient	O
+and	O
+rapid	O
+method	O
+with	O
+high	O
+specificity	O
+for	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+based	O
+on	O
+one	O
+-	O
+pot	B-DISO
+reverse	B-PROC
+transcription	I-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+one	O
+-	O
+pot	B-DISO
+RT	B-PRGE
+-	I-PRGE
+LAMP	I-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+survival	O
+predictors	O
+and	O
+optimal	O
+mechanical	O
+ventilator	O
+settings	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+undergoing	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+are	O
+uncertain	O
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	O
+pathogenic	O
+viruses	O
+such	O
+as	O
+Ebola	O
+and	O
+Middle	O
+Eastern	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+can	O
+cause	O
+acute	B-DISO
+infections	I-DISO
+through	O
+the	O
+evasion	O
+of	O
+the	O
+host	B-COMP
+'	O
+s	O
+antiviral	B-CHED
+immune	B-PROC
+responses	I-PROC
+and	O
+by	O
+inducing	O
+the	O
+upregulation	B-PROC
+of	O
+inflammatory	O
+cytokines	O
+.	O
+
+Human	B-SPEC
+rhinovirus	I-SPEC
+is	O
+the	O
+most	O
+commonly	O
+encountered	O
+respiratory	O
+viral	O
+pathogen	O
+in	O
+CF	O
+although	O
+adenovirus	B-DISO
+,	O
+bocavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+influenza	B-DISO
+,	O
+parainfluenza	B-DISO
+,	O
+metapneumovirus	B-SPEC
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+are	O
+all	O
+also	O
+responsible	O
+for	O
+infections	B-DISO
+in	O
+this	O
+population	O
+.	O
+
+TITLE	O
+:	O
+Spontaneous	O
+intracranial	B-DISO
+hemorrhage	I-DISO
+in	O
+a	O
+patient	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+corona	B-SPEC
+virus	B-SPEC
+.	O
+
+She	O
+never	O
+had	O
+uncontrolled	B-DISO
+hypertension	I-DISO
+,	O
+or	O
+coagulopathy	B-DISO
+,	O
+nor	O
+she	O
+received	O
+antiplatelets	O
+.	O
+
+Paramedics	O
+are	O
+at	O
+greater	O
+risk	O
+of	O
+acquiring	O
+these	O
+infectious	B-DISO
+diseases	I-DISO
+compared	O
+to	O
+the	O
+general	O
+public	O
+.	O
+
+The	O
+majority	O
+of	O
+patients	O
+were	O
+admitted	O
+with	O
+acute	B-DISO
+leukemia	I-DISO
+(	O
+n	O
+=	O
+60	O
+,	O
+76	O
+%),	O
+8	O
+(	O
+10	O
+%)	O
+with	O
+lymphoma	B-DISO
+,	O
+and	O
+11	O
+(	O
+14	O
+%)	O
+with	O
+chronic	B-DISO
+leukemia	I-DISO
+,	O
+multiple	B-DISO
+myeloma	I-DISO
+,	O
+or	O
+myelodysplastic	B-DISO
+syndrome	I-DISO
+.	O
+
+nsp15	O
+localizes	O
+to	O
+sites	O
+of	O
+RNA	B-PROC
+replication	I-PROC
+,	O
+but	O
+whether	O
+it	O
+acts	O
+independently	O
+or	O
+requires	O
+additional	O
+interactions	O
+for	O
+its	O
+function	O
+remains	O
+unknown	O
+.	O
+
+To	O
+begin	O
+to	O
+address	O
+these	O
+questions	O
+,	O
+we	O
+created	O
+an	O
+in	O
+situ	O
+tagged	O
+form	O
+of	O
+nsp15	O
+using	O
+the	O
+prototypic	O
+CoV	O
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+there	O
+were	O
+101	O
+ARDS	B-DISO
+subjects	O
+during	O
+10	O
+months	O
+of	O
+study	O
+.	O
+
+RESULTS	O
+:	O
+there	O
+were	O
+101	O
+ARDS	B-DISO
+subjects	O
+during	O
+10	O
+months	O
+of	O
+study	O
+.	O
+
+CONCLUSIONS	O
+:	O
+the	O
+short	O
+-	O
+term	O
+survival	O
+rate	O
+of	O
+ARDS	B-DISO
+in	O
+developing	O
+countries	O
+including	O
+Indonesia	O
+is	O
+still	O
+low	O
+and	O
+early	O
+management	O
+with	O
+optimal	O
+treatment	O
+provided	O
+within	O
+the	O
+first	O
+week	O
+may	O
+improve	O
+the	O
+survival	O
+rate	O
+.	O
+
+Antiviral	B-CHED
+therapy	O
+was	O
+instituted	O
+in	O
+influenza	B-DISO
+-	O
+positive	O
+patients	O
+.	O
+
+Appropriate	O
+preventive	O
+strategies	O
+like	O
+influenza	B-DISO
+vaccination	O
+also	O
+need	O
+to	O
+be	O
+employed	O
+routinely	O
+.	O
+
+Laboratory	O
+findings	O
+included	O
+severe	O
+hypoxemia	O
+and	O
+inflammatory	O
+syndrome	B-DISO
+.	O
+
+Psychological	B-DISO
+sequelae	O
+are	O
+also	O
+frequent	O
+following	O
+the	O
+trauma	O
+of	O
+widespread	O
+epidermal	B-DISO
+necrolysis	I-DISO
+.	O
+
+Type	B-PROC
+I	I-PROC
+IFN	I-PROC
+production	I-PROC
+induced	O
+by	O
+poly	O
+I	O
+·	O
+C	O
+or	O
+Sendai	B-SPEC
+virus	I-SPEC
+(	O
+SeV	O
+)	O
+was	O
+suppressed	O
+by	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+These	O
+findings	O
+provide	O
+an	O
+insightful	O
+interpretation	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	O
+mediated	O
+host	B-COMP
+innate	O
+immune	B-DISO
+suppression	I-DISO
+caused	O
+by	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+outbreak	O
+in	O
+South	O
+Korea	O
+,	O
+2015	O
+:	O
+epidemiology	O
+,	O
+characteristics	O
+and	O
+public	O
+health	O
+implications	O
+.	O
+
+The	O
+main	O
+underlying	O
+diseases	O
+were	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+cancer	B-DISO
+and	O
+hypertension	B-DISO
+.	O
+
+The	O
+evaluation	O
+of	O
+the	O
+effect	O
+of	O
+sesquiterpenoids	B-CHED
+on	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+replication	O
+showed	O
+that	O
+compounds	O
+1	O
+-	O
+5	O
+,	O
+12	O
+,	O
+14	O
+,	O
+16	O
+,	O
+17	O
+,	O
+19	O
+,	O
+and	O
+21	O
+increased	O
+cell	B-PROC
+viability	I-PROC
+against	O
+cell	B-PROC
+death	I-PROC
+in	O
+PEDV	B-SPEC
+-	O
+injected	O
+cells	B-COMP
+.	O
+
+Accordingly	O
+,	O
+EndoU	O
+-	O
+deficient	O
+viruses	B-SPEC
+can	O
+retain	O
+replication	O
+only	O
+in	O
+cells	B-COMP
+that	O
+are	O
+deficient	O
+in	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+expression	B-PROC
+or	O
+sensing	O
+,	O
+and	O
+in	O
+cells	B-COMP
+lacking	O
+both	O
+RNase	B-PRGE
+L	I-PRGE
+and	O
+PKR	B-PRGE
+.	O
+
+Supportive	O
+care	O
+for	O
+adults	O
+with	O
+ARDS	B-DISO
+caused	O
+by	O
+respiratory	O
+viruses	B-SPEC
+is	O
+similar	O
+to	O
+the	O
+care	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+from	O
+other	O
+causes	O
+.	O
+
+ABSTRACT	O
+:	O
+Polymerase	O
+chain	O
+reaction	O
+-	O
+based	O
+diagnosis	O
+has	O
+become	O
+the	O
+standard	O
+for	O
+viral	O
+pneumonia	O
+and	O
+other	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+the	O
+natural	O
+reservoirs	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+like	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+and	O
+likely	O
+the	O
+reservoir	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)-	O
+CoV	O
+.	O
+The	O
+clinical	O
+features	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+are	O
+similar	O
+but	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+progresses	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+more	O
+rapidly	O
+.	O
+
+TITLE	O
+:	O
+Goblet	B-ANAT
+cell	I-ANAT
+depletion	O
+in	O
+small	B-ANAT
+intestinal	I-ANAT
+villous	O
+and	O
+crypt	B-ANAT
+epithelium	I-ANAT
+of	O
+conventional	O
+nursing	B-PROC
+and	O
+weaned	B-PROC
+pigs	B-SPEC
+infected	O
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+Conventional	O
+9	O
+-	O
+day	O
+-	O
+old	O
+nursing	B-PROC
+pigs	B-SPEC
+[	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+(	O
+n	O
+=	O
+9	O
+);	O
+Mock	O
+(	O
+n	O
+=	O
+11	O
+)]	O
+and	O
+26	O
+-	O
+day	O
+-	O
+old	O
+weaned	B-PROC
+[	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+(	O
+n	O
+=	O
+11	O
+);	O
+Mock	O
+(	O
+n	O
+=	O
+9	O
+)]	O
+were	O
+inoculated	O
+orally	B-ANAT
+[	O
+8	O
+.	O
+9	O
+log	O
+
+So	O
+far	O
+,	O
+specific	O
+immunohistochemical	O
+markers	O
+for	O
+camelid	O
+immune	O
+cells	B-COMP
+are	O
+rarely	O
+commercially	O
+available	O
+,	O
+and	O
+cross	O
+-	O
+reactivity	O
+studies	O
+are	O
+restricted	O
+to	O
+the	O
+use	O
+of	O
+frozen	O
+dromedary	B-SPEC
+tissues	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+VV	O
+-	O
+ECMO	O
+was	O
+indicated	O
+in	O
+8	O
+ppARDS	O
+patients	O
+for	O
+refractory	O
+hypoxemia	O
+(	O
+median	O
+partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+:	O
+68	O
+[	O
+range	O
+,	O
+60	O
+to	O
+75	O
+]	O
+mm	O
+Hg	O
+).	O
+
+Nidoviruses	B-SPEC
+are	O
+characterized	O
+by	O
+their	O
+polycistronic	O
+plus	O
+-	O
+stranded	O
+RNA	O
+genome	O
+,	O
+the	O
+production	O
+of	O
+subgenomic	O
+mRNAs	O
+and	O
+the	O
+conservation	O
+of	O
+a	O
+specific	O
+array	O
+of	O
+replicase	B-PRGE
+domains	O
+,	O
+including	O
+key	O
+RNA	O
+-	O
+synthesizing	O
+enzymes	O
+.	O
+
+TITLE	O
+:	O
+Glycyrrhizin	B-CHED
+inhibits	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+and	O
+attenuates	O
+the	O
+proinflammatory	O
+responses	O
+by	O
+inhibition	O
+of	O
+high	B-PRGE
+mobility	I-PRGE
+group	I-PRGE
+box	I-PRGE
+-	I-PRGE
+1	I-PRGE
+protein	I-PRGE
+.	O
+
+In	O
+summary	O
+,	O
+our	O
+studies	O
+provide	O
+a	O
+molecular	O
+basis	O
+for	O
+developing	O
+novel	O
+therapeutic	O
+methods	O
+to	O
+control	O
+PEDV	O
+infection	B-DISO
+,	O
+based	O
+on	O
+glycyrrhizin	B-CHED
+and	O
+its	O
+derivatives	O
+.	O
+
+Pigs	B-SPEC
+were	O
+allotted	O
+based	O
+on	O
+BW	O
+and	O
+sex	O
+,	O
+stratified	O
+across	O
+3	O
+treatments	O
+with	O
+8	O
+pens	O
+per	O
+treatment	O
+.	O
+
+Overall	O
+,	O
+Control	O
+and	O
+PDCoV	O
+pigs	B-SPEC
+did	O
+not	O
+differ	O
+in	O
+ADG	O
+,	O
+ADFI	O
+or	O
+G	O
+:	O
+F	O
+(	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+During	O
+the	O
+first	O
+week	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+patients	O
+were	O
+categorized	O
+as	O
+:	O
+no	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+or	O
+mild	O
+,	O
+moderate	O
+,	O
+or	O
+severe	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+based	O
+on	O
+oxygenation	B-PROC
+index	O
+or	O
+oxygen	B-CHED
+saturation	O
+index	O
+.	O
+
+Nonsurvivors	O
+had	O
+a	O
+higher	O
+median	O
+maximum	O
+oxygenation	B-PROC
+index	O
+than	O
+survivors	O
+at	O
+28	O
+.	O
+6	O
+(	O
+interquartile	O
+range	O
+,	O
+15	O
+.	O
+5	O
+-	O
+49	O
+.	O
+9	O
+)	O
+versus	O
+15	O
+.	O
+0	O
+(	O
+interquartile	O
+range	O
+,	O
+8	O
+.	O
+4	O
+-	O
+29	O
+.	O
+6	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+ABSTRACT	O
+:	O
+Healthcare	O
+personnel	O
+often	O
+use	O
+incorrect	O
+technique	O
+for	O
+donning	O
+and	O
+doffing	O
+of	O
+personal	O
+protective	O
+equipment	O
+(	O
+PPE	B-CHED
+).	O
+
+We	O
+tested	O
+the	O
+hypothesis	O
+that	O
+medical	O
+students	O
+receive	O
+insufficient	O
+training	O
+on	O
+correct	O
+methods	O
+for	O
+donning	O
+and	O
+doffing	O
+PPE	B-CHED
+.	O
+
+To	O
+obtain	O
+additional	O
+information	O
+on	O
+PPE	B-CHED
+training	O
+during	O
+medical	O
+education	O
+,	O
+residents	O
+,	O
+fellows	O
+,	O
+and	O
+attending	O
+physicians	O
+completed	O
+written	O
+questionnaires	O
+on	O
+PPE	B-CHED
+training	O
+received	O
+during	O
+medical	O
+school	O
+and	O
+on	O
+knowledge	O
+of	O
+PPE	B-CHED
+protocols	O
+recommended	O
+by	O
+the	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+.	O
+
+ABSTRACT	O
+:	O
+One	O
+of	O
+the	O
+most	O
+commonly	O
+applied	O
+protectotype	O
+vaccination	O
+protocol	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+in	O
+broiler	O
+chickens	B-SPEC
+in	O
+the	O
+EU	O
+is	O
+simultaneous	O
+or	O
+alternate	O
+use	O
+of	O
+Ma5	O
+and	O
+4	O
+/	O
+91	O
+vaccine	O
+strains	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+'	O
+ve	O
+investigated	O
+the	O
+development	B-PROC
+of	O
+URT	O
+and	O
+systemic	O
+,	O
+cell	B-COMP
+-	O
+mediated	O
+and	O
+humoral	B-PROC
+immunity	I-PROC
+in	O
+commercial	O
+broiler	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+Ma5	B-PRGE
+and	O
+/	O
+or	O
+4	O
+/	O
+91	O
+strains	O
+at	O
+hatch	B-PROC
+day	O
+.	O
+
+The	O
+maximal	O
+recruitment	B-DISO
+strategy	O
+(	O
+MRS	B-DISO
+)	O
+maneuver	O
+,	O
+which	O
+implements	O
+gradual	O
+increments	O
+of	O
+positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+followed	O
+by	O
+PEEP	B-CHED
+titration	O
+,	O
+produced	O
+improvements	O
+in	O
+PF	O
+ratio	O
+,	O
+carbon	O
+dioxide	O
+elimination	B-PROC
+and	O
+dynamic	O
+strain	O
+in	O
+all	O
+23	O
+in	O
+-	O
+silico	O
+patients	O
+considered	O
+.	O
+
+Reduced	O
+cardiac	B-ANAT
+output	O
+in	O
+the	O
+moderate	O
+and	O
+mild	O
+in	O
+silico	O
+ARDS	B-DISO
+patients	O
+produced	O
+significant	O
+drops	O
+in	O
+oxygen	B-CHED
+delivery	O
+during	O
+the	O
+RM	O
+(	O
+average	O
+decrease	O
+of	O
+423	O
+ml	O
+min	O
+Our	O
+results	O
+support	O
+the	O
+hypothesis	O
+that	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+significant	O
+numbers	O
+of	O
+alveolar	B-ANAT
+units	O
+available	O
+for	O
+recruitment	B-DISO
+may	O
+benefit	O
+more	O
+from	O
+RMs	O
+.	O
+
+ABSTRACT	O
+:	O
+Scopus	B-SPEC
+database	O
+was	O
+searched	O
+for	O
+the	O
+following	O
+pathogens	O
+/	O
+infectious	B-DISO
+diseases	I-DISO
+:	O
+Ebola	O
+,	O
+Marburg	O
+,	O
+Lassa	O
+,	O
+Rift	O
+valley	O
+,	O
+Crimean	O
+-	O
+Congo	O
+,	O
+Nipah	O
+,	O
+Middle	O
+Eastern	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+),	O
+and	O
+Severe	O
+Respiratory	O
+Acute	O
+Syndrome	B-DISO
+(	O
+SARS	B-DISO
+).	O
+
+METHODS	O
+:	O
+Scopus	B-SPEC
+database	O
+was	O
+searched	O
+for	O
+the	O
+following	O
+pathogens	O
+/	O
+infectious	B-DISO
+diseases	I-DISO
+:	O
+Ebola	O
+,	O
+Marburg	O
+,	O
+Lassa	O
+,	O
+Rift	O
+valley	O
+,	O
+Crimean	O
+-	O
+Congo	O
+,	O
+Nipah	O
+,	O
+Middle	O
+Eastern	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+),	O
+and	O
+Severe	O
+Respiratory	O
+Acute	O
+Syndrome	B-DISO
+(	O
+SARS	B-DISO
+).	O
+
+RESULTS	O
+Hemodynamics	B-PROC
+and	O
+oxygenation	B-PROC
+parameters	O
+were	O
+significantly	O
+improved	O
+after	O
+ECMO	O
+initiation	O
+.	O
+
+While	O
+79	O
+%	O
+were	O
+aware	O
+that	O
+the	O
+disease	O
+can	O
+transmit	O
+through	O
+droplet	O
+from	O
+infected	O
+person	O
+,	O
+only	O
+12	O
+%	O
+stated	O
+that	O
+MERS	O
+-	O
+CoV	O
+transmits	O
+via	O
+camels	B-SPEC
+;	O
+people	O
+in	O
+Saudi	O
+Arabia	O
+were	O
+better	O
+aware	O
+of	O
+the	O
+transmission	O
+.	O
+
+The	O
+WHO	O
+report	O
+conjectured	O
+that	O
+the	O
+sanitary	O
+plumbing	O
+system	O
+was	O
+one	O
+transmission	O
+route	O
+for	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Inflammation	B-DISO
+-	O
+induced	O
+caveolin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+BMPRII	B-PRGE
+depletion	O
+promotes	O
+endothelial	B-DISO
+dysfunction	I-DISO
+and	O
+TGF	O
+-	O
+β	O
+-	O
+driven	O
+pulmonary	O
+vascular	B-ANAT
+remodeling	O
+.	O
+
+ABSTRACT	O
+:	O
+Endothelial	B-ANAT
+cell	I-ANAT
+(	O
+EC	O
+)	O
+activation	O
+and	O
+vascular	B-ANAT
+injury	O
+are	O
+hallmark	O
+features	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+To	O
+better	O
+understand	O
+the	O
+prevalence	O
+situation	O
+,	O
+we	O
+conducted	O
+molecular	O
+epidemiological	O
+analyses	O
+of	O
+38	O
+PEDV	B-SPEC
+strains	O
+isolated	O
+from	O
+13	O
+cities	O
+in	O
+Shandong	O
+Province	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+and	O
+evaluation	O
+of	O
+conventional	O
+RT	B-PRGE
+-	I-PRGE
+PCR	I-PRGE
+,	O
+SYBR	B-CHED
+green	I-CHED
+I	I-CHED
+and	O
+TaqMan	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+.	O
+
+We	O
+ascertained	O
+the	O
+epidemiologic	O
+link	O
+between	O
+patients	O
+and	O
+calculated	O
+the	O
+secondary	O
+attack	O
+rate	O
+per	O
+10	O
+,	O
+000	O
+patients	O
+visiting	O
+the	O
+ER	O
+(	O
+SAR	B-PRGE
+/	O
+10	O
+,	O
+000	O
+)	O
+in	O
+3	O
+phases	O
+of	O
+the	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+and	O
+dromedaries	B-SPEC
+.	O
+
+MERS	O
+-	O
+CoV	O
+is	O
+mainly	O
+acquired	O
+in	O
+dromedaries	B-SPEC
+when	O
+they	O
+are	O
+less	O
+than	O
+1	O
+year	O
+of	O
+age	O
+,	O
+and	O
+the	O
+proportion	O
+of	O
+seropositivity	O
+increases	O
+with	O
+age	O
+to	O
+a	O
+seroprevalence	O
+of	O
+100	O
+%	O
+in	O
+adult	O
+dromedaries	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Seroprevalence	O
+and	O
+risk	O
+factors	O
+for	O
+infection	B-DISO
+with	O
+equine	B-SPEC
+coronavirus	B-SPEC
+in	O
+healthy	O
+horses	B-SPEC
+in	O
+the	O
+USA	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+addition	O
+to	O
+severe	O
+hypoxia	B-DISO
+and	O
+hypercapnia	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+can	O
+present	O
+with	O
+substantial	O
+hemodynamic	B-PROC
+compromise	O
+,	O
+requiring	O
+inotropic	O
+or	O
+vasopressor	O
+support	O
+or	O
+both	O
+.	O
+
+Either	O
+venovenous	O
+(	O
+VV	O
+)	O
+or	O
+venoarterial	O
+(	O
+VA	O
+)	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+can	O
+be	O
+offered	O
+in	O
+this	O
+situation	O
+.	O
+
+VV	O
+ECMO	O
+was	O
+associated	O
+with	O
+less	O
+gastrointestinal	B-DISO
+bleeding	I-DISO
+and	O
+hemolysis	B-DISO
+,	O
+but	O
+overall	O
+rates	O
+of	O
+bleeding	B-DISO
+,	O
+stroke	B-DISO
+,	O
+and	O
+renal	B-DISO
+failure	I-DISO
+were	O
+similar	O
+.	O
+
+Multivariable	O
+regression	O
+analysis	O
+revealed	O
+VV	O
+ECMO	O
+to	O
+be	O
+an	O
+independent	O
+predictor	O
+of	O
+survival	O
+to	O
+discharge	B-ANAT
+relative	O
+to	O
+VA	O
+ECMO	O
+.	O
+
+This	O
+study	O
+showed	O
+that	O
+the	O
+developed	O
+rRT	O
+-	O
+PCR	O
+assays	O
+are	O
+rapid	O
+,	O
+reliable	O
+,	O
+reproducible	O
+,	O
+specific	O
+,	O
+sensitive	O
+,	O
+and	O
+simple	O
+tools	O
+for	O
+detection	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Finally	O
+,	O
+a	O
+kit	B-FUNC
+consisting	O
+of	O
+two	O
+assay	O
+signatures	O
+and	O
+controls	O
+was	O
+assembled	O
+,	O
+which	O
+can	O
+be	O
+distributed	O
+to	O
+public	O
+health	O
+laboratories	O
+in	O
+Iran	O
+to	O
+support	O
+international	O
+MERS	O
+-	O
+CoV	O
+surveillance	O
+and	O
+public	O
+health	O
+response	O
+.	O
+
+TITLE	O
+:	O
+Scrotal	B-ANAT
+Abscess	I-DISO
+:	O
+A	O
+Rare	O
+Presentation	O
+of	O
+Complicated	O
+Necrotizing	B-DISO
+Pancreatitis	I-DISO
+.	O
+
+It	O
+seems	O
+that	O
+the	O
+scrotal	B-DISO
+abscess	I-DISO
+is	O
+a	O
+very	O
+rare	O
+complication	B-DISO
+of	O
+necrotizing	B-DISO
+pancreatitis	I-DISO
+.	O
+
+We	O
+performed	O
+MTT	B-CHED
+and	O
+neutral	O
+red	O
+uptake	O
+assays	O
+to	O
+assess	O
+the	O
+survival	O
+rates	O
+of	O
+MERS	O
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+By	O
+consecutive	O
+administration	O
+of	O
+resveratrol	B-CHED
+,	O
+we	O
+were	O
+able	O
+to	O
+reduce	O
+the	O
+concentration	O
+of	O
+resveratrol	B-CHED
+while	O
+achieving	O
+inhibitory	O
+effectiveness	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+this	O
+study	O
+,	O
+we	O
+first	O
+demonstrated	O
+that	O
+resveratrol	B-CHED
+is	O
+a	O
+potent	O
+anti	O
+-	O
+MERS	O
+agent	O
+in	O
+vitro	O
+.	O
+
+We	O
+perceive	O
+that	O
+resveratrol	B-CHED
+can	O
+be	O
+a	O
+potential	O
+antiviral	B-CHED
+agent	I-CHED
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+the	O
+near	O
+future	O
+.	O
+
+Risk	O
+factors	O
+for	O
+experiencing	O
+anxiety	O
+symptoms	O
+and	O
+anger	O
+at	O
+four	O
+to	O
+six	O
+months	O
+after	O
+release	B-PATH
+included	O
+symptoms	O
+related	O
+to	O
+MERS	O
+during	O
+isolation	O
+,	O
+inadequate	O
+supplies	O
+(	O
+food	O
+,	O
+clothes	O
+,	O
+accommodation	O
+),	O
+social	O
+networking	O
+activities	O
+(	O
+email	O
+,	O
+text	O
+,	O
+Internet	O
+),	O
+history	O
+of	O
+psychiatric	O
+illnesses	O
+,	O
+and	O
+financial	O
+loss	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	B-PROC
+)	O
+is	O
+performed	O
+as	O
+an	O
+acceptable	O
+life	O
+-	O
+saving	O
+bridging	O
+procedure	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+To	O
+patients	O
+with	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)-	O
+associated	O
+ARDS	B-DISO
+,	O
+ECMO	B-PROC
+could	O
+be	O
+adopted	O
+as	O
+a	O
+feasible	O
+therapeutic	O
+solution	O
+.	O
+
+Bleeding	B-DISO
+and	O
+infection	B-DISO
+almost	O
+killed	O
+the	O
+patient	O
+'	O
+s	O
+life	O
+.	O
+
+TITLE	O
+:	O
+Polymerase	O
+cross	O
+-	O
+linking	O
+spiral	O
+reaction	O
+(	O
+PCLSR	O
+)	O
+for	O
+detection	O
+of	O
+African	B-SPEC
+swine	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+(	O
+ASFV	O
+)	O
+in	O
+pigs	B-SPEC
+and	O
+wild	B-SPEC
+boars	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Mitochondrial	B-ANAT
+DNA	I-ANAT
+-	O
+Induced	O
+Inflammatory	B-DISO
+Responses	I-DISO
+and	O
+Lung	B-ANAT
+Injury	O
+in	O
+Thermal	O
+Injury	O
+Rat	B-SPEC
+Model	O
+:	O
+Protective	O
+Effect	O
+of	O
+Epigallocatechin	O
+Gallate	O
+.	O
+
+ABSTRACT	O
+:	O
+Lungs	B-ANAT
+are	O
+easily	O
+damaged	O
+by	O
+the	O
+inflammatory	B-DISO
+responses	I-DISO
+induced	O
+after	O
+extensive	O
+burns	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+mtDNA	B-COMP
+is	O
+important	O
+for	O
+thermal	O
+injury	O
+-	O
+induced	O
+inflammation	B-DISO
+and	O
+associated	O
+ARDS	B-DISO
+.	O
+
+However	O
+,	O
+the	O
+association	O
+between	O
+the	O
+local	O
+immune	B-PROC
+responses	I-PROC
+induced	O
+by	O
+IBV	B-SPEC
+and	O
+the	O
+mechanisms	O
+of	O
+pathogenesis	B-DISO
+has	O
+not	O
+yet	O
+been	O
+completely	O
+elucidated	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Risk	O
+factors	O
+for	O
+poor	O
+prognosis	O
+in	O
+children	O
+with	O
+severe	O
+adenovirus	B-DISO
+pneumonia	B-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+risk	O
+factors	O
+for	O
+poor	O
+prognosis	O
+of	O
+severe	O
+adenovirus	O
+pneumonia	B-DISO
+(	O
+SAP	O
+)	O
+in	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+development	B-PROC
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+antibody	B-COMP
+-	O
+based	O
+assays	O
+is	O
+important	O
+for	O
+detecting	O
+infected	O
+animals	B-SPEC
+,	O
+confirming	O
+previous	O
+virus	B-SPEC
+exposure	O
+,	O
+and	O
+monitoring	O
+sow	O
+herd	B-PROC
+immunity	I-PROC
+.	O
+
+However	O
+,	O
+the	O
+effects	O
+of	O
+DOX	O
+,	O
+which	O
+is	O
+widely	O
+used	O
+in	O
+porcine	B-SPEC
+husbandry	O
+by	O
+feed	O
+,	O
+on	O
+the	O
+porcine	B-SPEC
+intestinal	B-ANAT
+epithelium	I-ANAT
+are	O
+unclear	O
+.	O
+
+Patients	O
+were	O
+stratified	O
+according	O
+to	O
+the	O
+antibiotic	B-CHED
+strategy	O
+administered	O
+:	O
+(	O
+i	O
+)	O
+fluoroquinolone	O
+-	O
+based	O
+versus	O
+non	O
+-	O
+fluoroquinolone	O
+-	O
+based	O
+therapy	O
+;	O
+and	O
+(	O
+ii	O
+)	O
+monotherapy	O
+versus	O
+combination	O
+therapy	O
+.	O
+
+We	O
+evaluated	O
+whether	O
+supernatants	O
+from	O
+effusions	B-DISO
+retain	O
+the	O
+ability	O
+to	O
+induce	O
+cell	B-COMP
+clumping	O
+and	O
+assessed	O
+the	O
+diagnostic	O
+accuracy	O
+of	O
+this	O
+modified	O
+ΔTNC	O
+method	O
+.	O
+
+ΔTNC	O
+was	O
+measured	O
+on	O
+fresh	B-ANAT
+samples	O
+and	O
+on	O
+frozen	O
+-	O
+thawed	O
+supernatants	O
+after	O
+the	O
+addition	O
+of	O
+feline	B-SPEC
+blood	B-ANAT
+at	O
+1	O
+:	O
+10	O
+dilution	O
+.	O
+
+Diagnostic	O
+accuracy	O
+was	O
+assessed	O
+at	O
+the	O
+cutoffs	O
+of	O
+suggestive	O
+of	O
+FIP	B-DISO
+(	O
+ΔTNC	O
+=	O
+1	O
+.	O
+7	O
+)	O
+and	O
+consistent	O
+with	O
+FIP	B-DISO
+(	O
+ΔTNC	O
+=	O
+3	O
+.	O
+4	O
+).	O
+
+Most	O
+patients	O
+(	O
+93	O
+%)	O
+with	O
+indirect	O
+lung	B-ANAT
+injury	O
+from	O
+sepsis	B-DISO
+presented	O
+with	O
+concurrent	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+,	O
+whereas	O
+patients	O
+with	O
+direct	O
+lung	B-ANAT
+injury	O
+had	O
+both	O
+concurrent	O
+(	O
+56	O
+%)	O
+and	O
+new	O
+(	O
+12	O
+%)	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Epigenetic	O
+Landscape	O
+during	O
+Coronavirus	B-DISO
+Infection	I-DISO
+.	O
+
+Epigenetics	B-PROC
+research	O
+investigates	O
+the	O
+genetic	O
+and	O
+non	O
+-	O
+genetic	O
+factors	O
+that	O
+regulate	O
+phenotypic	O
+variation	O
+,	O
+usually	O
+caused	O
+by	O
+external	O
+and	O
+environmental	O
+factors	O
+that	O
+alter	O
+host	B-COMP
+expression	B-PROC
+patterns	O
+and	O
+performance	O
+without	O
+any	O
+change	O
+in	O
+the	O
+underlying	O
+genotype	O
+.	O
+
+Genomic	O
+sequence	O
+analysis	O
+revealed	O
+open	O
+reading	O
+frames	O
+encoding	O
+polyproteins	O
+of	O
+2	O
+,	O
+331	O
+(	O
+HuN1	O
+,	O
+2	O
+and	O
+3	O
+)	O
+and	O
+2	O
+,	O
+332	O
+(	O
+HuN4	O
+)	O
+amino	B-CHED
+acids	I-CHED
+.	O
+
+In	O
+addition	O
+,	O
+recombination	B-PROC
+analysis	O
+among	O
+PSVs	B-DISO
+indicates	O
+that	O
+a	O
+recombinant	O
+(	O
+HuN2	O
+strain	O
+)	O
+exist	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Zoonotic	O
+transmission	O
+of	O
+novel	O
+viruses	O
+represents	O
+a	O
+significant	O
+threat	O
+to	O
+global	O
+public	O
+health	O
+and	O
+is	O
+fueled	O
+by	O
+globalization	O
+,	O
+the	O
+loss	O
+of	O
+natural	O
+habitats	O
+,	O
+and	O
+exposure	O
+to	O
+new	O
+hosts	B-COMP
+.	O
+
+This	O
+study	O
+was	O
+designed	O
+to	O
+assess	O
+attitudes	O
+to	O
+,	O
+and	O
+awareness	O
+of	O
+,	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+policies	O
+and	O
+guidelines	O
+among	O
+healthcare	O
+workers	O
+of	O
+different	O
+professions	O
+and	O
+institution	O
+types	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Carelessness	O
+of	O
+healthcare	O
+workers	O
+was	O
+the	O
+top	O
+-	O
+cited	O
+factor	O
+contributing	O
+to	O
+causes	O
+of	O
+outbreaks	O
+(	O
+65	O
+.	O
+07	O
+%	O
+of	O
+total	O
+group	O
+),	O
+and	O
+hospital	O
+infrastructure	O
+and	O
+design	O
+was	O
+the	O
+top	O
+-	O
+cited	O
+factor	O
+contributing	O
+to	O
+spread	O
+of	O
+infection	B-DISO
+in	O
+the	O
+hospital	O
+(	O
+54	O
+.	O
+20	O
+%),	O
+followed	O
+closely	O
+by	O
+lack	O
+and	O
+shortage	O
+of	O
+staff	O
+(	O
+53	O
+.	O
+71	O
+%)	O
+and	O
+no	O
+infection	B-DISO
+control	O
+training	O
+program	O
+(	O
+51	O
+.	O
+73	O
+%).	O
+
+We	O
+have	O
+identified	O
+areas	O
+of	O
+concern	O
+among	O
+healthcare	O
+workers	O
+in	O
+Saudi	O
+Arabia	O
+on	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+which	O
+vary	O
+between	O
+institutions	O
+and	O
+among	O
+different	O
+professions	O
+.	O
+
+Recent	O
+outbreaks	O
+,	O
+including	O
+those	O
+caused	O
+by	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+,	O
+have	O
+highlighted	O
+the	O
+importance	O
+of	O
+infection	B-DISO
+control	O
+.	O
+
+Moreover	O
+,	O
+HAIs	O
+,	O
+especially	O
+those	O
+caused	O
+by	O
+multidrug	O
+-	O
+resistant	O
+Gram	O
+-	O
+negative	O
+rods	B-ANAT
+,	O
+have	O
+become	O
+a	O
+top	O
+global	O
+priority	O
+.	O
+
+While	O
+evidence	O
+-	O
+based	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+(	O
+IPC	O
+)	O
+principles	O
+and	O
+practices	O
+are	O
+universal	O
+,	O
+studies	O
+are	O
+needed	O
+to	O
+evaluate	O
+simplified	O
+approaches	O
+that	O
+can	O
+be	O
+better	O
+adapted	O
+to	O
+LMIC	O
+needs	O
+,	O
+in	O
+order	B-SPEC
+to	O
+guide	O
+IPC	B-CHED
+in	O
+practice	O
+.	O
+
+A	O
+group	O
+of	O
+experts	O
+from	O
+around	O
+the	O
+world	O
+attended	O
+a	O
+workshop	O
+held	O
+at	O
+the	O
+17th	O
+International	O
+Congress	O
+on	O
+Infectious	B-DISO
+Diseases	I-DISO
+in	O
+Hyderabad	O
+,	O
+India	O
+in	O
+March	O
+2016	O
+,	O
+to	O
+discuss	O
+the	O
+existing	O
+IPC	B-CHED
+practices	O
+in	O
+LMICs	O
+,	O
+and	O
+how	O
+best	O
+these	O
+can	O
+be	O
+improved	O
+within	O
+the	O
+local	O
+context	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+evaluation	O
+of	O
+potent	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+3CL	O
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+with	O
+fever	B-PROC
+,	O
+cough	B-DISO
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+.	O
+
+Community	O
+-	O
+ARI	B-CHED
+and	O
+inpatient	O
+-	O
+ARI	B-CHED
+was	O
+also	O
+combined	O
+with	O
+mild	O
+and	O
+severe	O
+cases	O
+of	O
+influenza	B-DISO
+from	O
+a	O
+historical	O
+prospective	O
+study	O
+as	O
+mild	O
+-	O
+ARI	B-CHED
+and	O
+severe	O
+-	O
+ARI	B-CHED
+respectively	O
+to	O
+evaluate	O
+the	O
+performance	O
+of	O
+clinical	O
+case	O
+definitions	O
+.	O
+
+Therefore	O
+,	O
+the	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+develop	O
+a	O
+duplex	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+(	O
+RT	O
+)-	O
+PCR	O
+method	O
+for	O
+the	O
+simultaneous	O
+detection	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Dromedary	O
+camels	B-SPEC
+from	O
+Africa	O
+and	O
+Arabia	O
+are	O
+an	O
+established	O
+source	O
+for	O
+zoonotic	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+among	O
+humans	B-SPEC
+.	O
+
+Using	O
+an	O
+indirect	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+)	O
+and	O
+a	O
+commercial	O
+ELISA	O
+kit	B-FUNC
+as	O
+reference	O
+,	O
+we	O
+optimized	O
+the	O
+nsp5	B-PRGE
+-	I-PRGE
+ELISA	I-PRGE
+and	O
+determined	O
+its	O
+cut	O
+-	O
+off	O
+as	O
+0	O
+.	O
+12	O
+.	O
+
+The	O
+diagnostic	O
+sensitivity	O
+(	O
+DSN	B-DISO
+),	O
+specificity	O
+(	O
+DSP	O
+)	O
+and	O
+accuracy	O
+of	O
+the	O
+nsp5	B-PRGE
+-	I-PRGE
+ELISA	I-PRGE
+were	O
+93	O
+.	O
+11	O
+%,	O
+95	O
+.	O
+38	O
+%	O
+and	O
+93	O
+.	O
+33	O
+%,	O
+respectively	O
+,	O
+compared	O
+with	O
+IFA	O
+in	O
+660	O
+field	O
+serum	B-COMP
+samples	O
+,	O
+and	O
+were	O
+98	O
+.	O
+11	O
+%,	O
+95	O
+.	O
+00	O
+%	O
+and	O
+97	O
+.	O
+62	O
+%,	O
+respectively	O
+,	O
+compared	O
+with	O
+the	O
+commercial	O
+IBV	O
+ELISA	O
+kit	B-FUNC
+(	O
+IDEXX	O
+)	O
+in	O
+126	O
+field	O
+sera	B-COMP
+samples	O
+.	O
+
+The	O
+host	B-COMP
+factors	O
+associated	O
+with	O
+high	O
+CFR	O
+were	O
+pre	O
+-	O
+existing	O
+pneumonia	B-DISO
+,	O
+smoking	O
+history	O
+,	O
+an	O
+incubation	O
+period	O
+of	O
+less	O
+than	O
+5	O
+days	O
+,	O
+leukocytosis	B-DISO
+,	O
+abnormal	B-DISO
+renal	I-DISO
+function	I-DISO
+at	O
+diagnosis	O
+,	O
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+such	O
+as	O
+sputum	B-ANAT
+and	O
+dyspnea	B-DISO
+.	O
+
+During	O
+a	O
+return	O
+flight	B-PROC
+to	O
+the	O
+United	O
+States	O
+,	O
+she	O
+developed	O
+increasing	O
+dyspnea	B-DISO
+and	O
+hypoxemia	O
+that	O
+rapidly	O
+developed	O
+into	O
+acute	O
+lung	B-ANAT
+injury	O
+that	O
+led	O
+to	O
+ARDS	B-DISO
+.	O
+
+First	O
+,	O
+we	O
+expressed	B-PROC
+the	O
+S1	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+explore	O
+the	O
+effects	O
+of	O
+continuous	O
+blood	B-ANAT
+purification	O
+(	O
+CBP	B-PRGE
+)	O
+treatment	O
+in	O
+pigs	B-SPEC
+affected	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+In	O
+the	O
+group	O
+of	O
+dogs	B-SPEC
+with	O
+diarrhoea	B-DISO
+the	O
+prevalence	O
+of	O
+DogCV	O
+was	O
+20	O
+.	O
+1	O
+%	O
+(	O
+37	O
+/	O
+184	O
+),	O
+in	O
+the	O
+healthy	O
+control	O
+group	O
+it	O
+was	O
+7	O
+.	O
+3	O
+%	O
+(	O
+6	O
+/	O
+82	O
+).	O
+
+Therefore	O
+,	O
+the	O
+virus	B-SPEC
+could	O
+be	O
+detected	O
+significantly	O
+more	O
+frequently	O
+in	O
+dogs	B-SPEC
+with	O
+diarrhoea	B-DISO
+.	O
+
+In	O
+approximately	O
+50	O
+%	O
+of	O
+the	O
+DogCV	O
+-	O
+positive	O
+dogs	B-SPEC
+,	O
+infections	B-DISO
+with	O
+other	O
+enteropathogenic	O
+organisms	O
+were	O
+diagnosed	O
+.	O
+
+The	O
+role	O
+of	O
+co	O
+-	O
+infection	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+disease	O
+remains	O
+unclear	O
+,	O
+but	O
+there	O
+appears	O
+to	O
+be	O
+an	O
+association	O
+between	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+and	O
+disease	O
+severity	O
+.	O
+
+Evidence	O
+of	O
+DogCV	O
+in	O
+clinically	O
+healthy	O
+dogs	B-SPEC
+appears	O
+important	O
+for	O
+the	O
+epidemiology	O
+and	O
+raises	O
+questions	O
+about	O
+its	O
+pathogenicity	O
+.	O
+
+TITLE	O
+:	O
+The	O
+pathogens	O
+profile	O
+in	O
+children	O
+with	O
+otitis	B-DISO
+media	I-DISO
+with	I-DISO
+effusion	B-ANAT
+and	O
+adenoid	B-DISO
+hypertrophy	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+presence	O
+of	O
+viruses	O
+and	O
+bacteria	B-SPEC
+in	O
+middle	B-ANAT
+ear	I-ANAT
+and	O
+adenoids	B-ANAT
+of	O
+patients	O
+with	O
+and	O
+without	O
+otitis	B-DISO
+media	I-DISO
+with	I-DISO
+effusion	B-ANAT
+(	O
+OME	O
+).	O
+
+Adenoid	B-ANAT
+samples	O
+and	O
+middle	B-ANAT
+ear	I-ANAT
+washes	O
+(	O
+MEW	O
+)	O
+were	O
+obtained	O
+from	O
+children	O
+with	O
+OME	O
+associated	O
+with	O
+adenoid	B-DISO
+hypertrophy	I-DISO
+undergoing	O
+adenoidectomy	O
+and	O
+tympanostomy	O
+,	O
+and	O
+compared	O
+to	O
+those	O
+obtained	O
+from	O
+patients	O
+undergoing	O
+cochlear	B-ANAT
+implant	O
+surgery	O
+,	O
+as	O
+a	O
+control	O
+group	O
+.	O
+
+These	O
+findings	O
+could	O
+suggest	O
+that	O
+these	O
+pathogens	O
+could	O
+contribute	O
+to	O
+the	O
+fluid	O
+persistence	O
+in	O
+the	O
+middle	B-ANAT
+ear	I-ANAT
+.	O
+
+It	O
+causes	O
+severe	O
+viral	B-DISO
+pneumonia	I-DISO
+and	O
+is	O
+associated	O
+with	O
+a	O
+high	O
+fatality	O
+rate	O
+.	O
+
+The	O
+characteristic	O
+inflammatory	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+lungs	B-ANAT
+of	O
+rhesus	B-SPEC
+macaques	I-SPEC
+and	O
+common	B-SPEC
+marmosets	I-SPEC
+were	O
+eosinophils	B-ANAT
+and	O
+neutrophils	B-ANAT
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Evolutionary	O
+and	O
+epidemiological	O
+analyses	O
+based	O
+on	O
+spike	O
+genes	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+circulating	O
+in	O
+Thailand	O
+in	O
+2008	O
+-	O
+2015	O
+.	O
+
+In	O
+the	O
+study	O
+,	O
+117	O
+complete	O
+spike	O
+gene	O
+sequences	O
+of	O
+Thai	O
+PED	O
+virus	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+collected	O
+from	O
+2008	O
+to	O
+2015	O
+were	O
+clustered	O
+along	O
+with	O
+95	O
+references	O
+of	O
+PEDV	B-SPEC
+spike	O
+sequences	O
+,	O
+and	O
+analyzed	O
+with	O
+the	O
+US	O
+sequences	O
+dataset	O
+(	O
+n	O
+=	O
+99	O
+).	O
+
+Uncertainties	O
+remain	O
+as	O
+to	O
+whether	O
+or	O
+not	O
+ARDS	B-DISO
+patients	O
+in	O
+the	O
+postoperative	O
+period	O
+of	O
+abdominal	B-ANAT
+surgery	O
+should	O
+be	O
+turned	O
+prone	O
+because	O
+of	O
+the	O
+risk	O
+of	O
+abdominal	B-ANAT
+complications	O
+.	O
+
+The	O
+first	O
+prone	O
+session	O
+significantly	O
+increased	O
+PaO	B-PROC
+Prone	O
+position	O
+of	O
+ARDS	B-DISO
+patients	O
+after	O
+abdominal	B-ANAT
+surgery	O
+was	O
+not	O
+associated	O
+with	O
+an	O
+increased	O
+rate	O
+of	O
+surgical	O
+complication	B-DISO
+.	O
+
+It	O
+has	O
+been	O
+suggested	O
+that	O
+administration	O
+of	O
+buprenorphine	B-CHED
+,	O
+a	O
+partial	O
+μ	O
+-	O
+opioid	B-CHED
+receptor	I-CHED
+agonist	I-CHED
+,	O
+to	O
+an	O
+opioid	O
+-	O
+intoxicated	O
+patient	O
+may	O
+result	O
+in	O
+reversal	O
+of	O
+respiratory	B-DISO
+depression	I-DISO
+with	O
+less	O
+severe	O
+withdrawal	B-DISO
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+characteristics	O
+of	O
+influenza	B-DISO
+in	O
+Southeast	O
+of	O
+China	O
+haven	O
+'	O
+t	O
+been	O
+fully	O
+studied	O
+.	O
+
+To	O
+induce	O
+VRC	O
+formation	B-PROC
+,	O
+these	O
+viruses	B-SPEC
+extensively	O
+rewire	O
+lipid	B-PROC
+metabolism	I-PROC
+.	O
+
+Dynamic	O
+gene	B-PROC
+expression	I-PROC
+analysis	O
+revealed	O
+key	O
+genes	O
+that	O
+performed	O
+important	O
+functions	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Findings	O
+demonstrated	O
+that	O
+the	O
+tool	O
+was	O
+easy	O
+to	O
+use	O
+,	O
+effective	O
+in	O
+supporting	O
+discussion	O
+and	O
+in	O
+assisting	O
+participants	O
+in	O
+reaching	B-PROC
+consensus	O
+on	O
+rating	O
+a	O
+large	O
+number	O
+of	O
+JHSC	O
+characteristics	O
+.	O
+
+TITLE	O
+:	O
+Severity	O
+of	O
+Hypoxemia	O
+and	O
+Effect	O
+of	O
+High	O
+-	O
+Frequency	O
+Oscillatory	O
+Ventilation	O
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+individual	O
+patient	O
+data	O
+meta	B-SPEC
+-	O
+analysis	O
+was	O
+to	O
+identify	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+patient	O
+subgroups	O
+with	O
+differential	O
+outcomes	O
+from	O
+HFOV	O
+.	O
+
+We	O
+enrolled	O
+patients	O
+from	O
+five	O
+academic	O
+PICUs	B-SPEC
+between	O
+2008	O
+and	O
+2015	O
+.	O
+
+We	O
+measured	O
+biomarker	B-CHED
+levels	O
+in	O
+194	O
+patients	O
+,	O
+including	O
+38	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+nonsurvivors	O
+.	O
+
+In	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+pro	B-CHED
+-	O
+and	O
+anti	O
+-	O
+inflammatory	O
+cytokines	O
+are	O
+strongly	O
+associated	O
+with	O
+mortality	O
+,	O
+ICU	O
+morbidity	O
+,	O
+and	O
+biochemical	O
+evidence	O
+of	O
+endothelial	B-ANAT
+injury	O
+.	O
+
+STAT2	B-PRGE
+cleavage	B-PROC
+was	O
+dependent	O
+on	O
+the	O
+protease	B-PROC
+activity	I-PROC
+of	O
+nsp5	B-PRGE
+.	O
+
+The	O
+results	O
+of	O
+our	O
+study	O
+demonstrate	O
+that	O
+PDCoV	B-PRGE
+nsp5	I-PRGE
+antagonizes	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+signaling	B-PROC
+by	O
+cleaving	O
+STAT2	B-PRGE
+and	O
+provides	O
+structural	O
+insights	O
+for	O
+comprehending	O
+the	O
+cleavage	B-PROC
+mechanism	O
+of	O
+PDCoV	B-PRGE
+nsp5	I-PRGE
+,	O
+revealing	O
+a	O
+potential	O
+new	O
+function	O
+for	O
+PDCoV	B-PRGE
+nsp5	I-PRGE
+in	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+signaling	B-PROC
+.	O
+
+Monitoring	O
+of	O
+the	O
+status	O
+of	O
+such	O
+proteins	B-CHED
+will	O
+be	O
+important	O
+to	O
+track	O
+viral	O
+pathogenicity	O
+.	O
+
+There	O
+were	O
+marked	O
+changes	O
+in	O
+the	O
+root	B-ANAT
+-	O
+mean	O
+-	O
+square	O
+deviation	O
+(	O
+RMSD	O
+)	O
+in	O
+the	O
+ubiquitin	B-PRGE
+like	I-PRGE
+domain	I-PRGE
+(	O
+Ubl	B-PRGE
+)	O
+and	O
+the	O
+fingers	B-ANAT
+subdomain	O
+of	O
+the	O
+catalytic	O
+domain	O
+of	O
+Plpro	O
+.	O
+
+We	O
+report	O
+here	O
+several	O
+crystal	B-ANAT
+structures	O
+of	O
+RNA	O
+-	O
+bound	O
+human	B-PRGE
+IFIT1	I-PRGE
+,	O
+including	O
+a	O
+1	O
+.	O
+6	O
+-	O
+Å	O
+complex	O
+with	O
+capped	O
+RNA	O
+.	O
+
+Tidal	O
+volume	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+had	O
+no	O
+impact	O
+on	O
+mortality	O
+.	O
+
+Plateau	O
+pressure	O
+was	O
+slightly	O
+better	O
+than	O
+driving	O
+pressure	O
+in	O
+predicting	O
+hospital	O
+death	B-PROC
+in	O
+patients	O
+managed	O
+with	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+evaluated	O
+on	O
+standardized	O
+ventilator	O
+settings	O
+24	O
+hours	O
+after	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+onset	O
+.	O
+
+TITLE	O
+:	O
+Natural	B-CHED
+product	I-CHED
+-	O
+inspired	B-PROC
+esters	B-CHED
+and	O
+amides	B-CHED
+of	O
+ferulic	O
+and	O
+caffeic	B-CHED
+acid	I-CHED
+as	O
+dual	O
+inhibitors	B-CHED
+of	O
+HIV	O
+-	O
+1	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+.	O
+
+All	O
+pre	O
+-	O
+BD	O
+quantitative	O
+sagittal	B-ANAT
+features	O
+measuring	O
+diaphragm	B-ANAT
+flattening	O
+and	O
+hyperinflation	B-DISO
+were	O
+not	O
+significantly	O
+different	O
+between	O
+patients	O
+with	O
+COPD	O
+and	O
+patients	O
+with	O
+ACOS	O
+(	O
+P	O
+values	O
+all	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+relation	O
+between	O
+viral	O
+load	O
+and	O
+disease	O
+severity	O
+in	O
+childhood	O
+acute	O
+respiratory	O
+tract	O
+infections	O
+(	O
+ARI	B-CHED
+)	O
+is	O
+not	O
+fully	O
+understood	O
+.	O
+
+As	O
+the	O
+tonsils	B-ANAT
+of	O
+healthy	O
+individuals	O
+are	O
+already	O
+heavily	O
+and	O
+diversely	O
+colonized	O
+,	O
+the	O
+identification	O
+of	O
+significant	O
+pathogens	O
+is	O
+challenging	O
+.	O
+
+To	O
+explore	O
+the	O
+microbiology	O
+of	O
+PTA	B-DISO
+with	O
+a	O
+special	O
+attention	O
+to	O
+Fusobacterium	B-SPEC
+necrophorum	I-SPEC
+(	O
+FN	O
+).	O
+
+To	O
+characterize	O
+patients	O
+with	O
+PPA	B-DISO
+,	O
+explore	O
+the	O
+relationship	O
+between	O
+PPA	B-DISO
+and	O
+PTA	B-DISO
+,	O
+identify	O
+the	O
+pathogens	O
+associated	O
+with	O
+PPA	B-DISO
+,	O
+and	O
+review	O
+our	O
+management	O
+of	O
+PPA	B-DISO
+.	O
+
+We	O
+also	O
+analysed	O
+sera	B-COMP
+taken	O
+acutely	O
+and	O
+at	O
+least	O
+two	O
+weeks	O
+after	O
+surgery	O
+for	O
+the	O
+presence	O
+of	O
+anti	O
+-	O
+FN	O
+antibodies	B-COMP
+.	O
+
+Using	O
+PCR	O
+analysis	O
+for	O
+the	O
+presence	O
+of	O
+herpes	B-DISO
+simplex	I-DISO
+1	I-DISO
+and	O
+2	O
+,	O
+adenovirus	B-DISO
+,	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+(	O
+EBV	O
+),	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+A	O
+and	O
+B	O
+,	O
+we	O
+explored	O
+a	O
+possible	O
+role	O
+of	O
+viruses	B-SPEC
+in	O
+PTA	B-DISO
+.	O
+
+We	O
+found	O
+that	O
+smoking	O
+was	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+PTA	B-DISO
+for	O
+both	O
+genders	O
+and	O
+across	O
+all	O
+age	O
+groups	O
+.	O
+
+Conclusions	O
+on	O
+causality	O
+cannot	O
+be	O
+drawn	O
+from	O
+this	O
+retrospective	O
+study	O
+,	O
+but	O
+the	O
+pathophysiology	O
+behind	O
+the	O
+increased	O
+risk	O
+of	O
+PTA	B-DISO
+in	O
+smokers	O
+may	O
+be	O
+related	O
+to	O
+,	O
+previously	O
+shown	O
+,	O
+alterations	O
+in	O
+the	O
+tonsillar	B-ANAT
+,	O
+bacterial	O
+flora	O
+or	O
+the	O
+local	O
+and	O
+systemical	O
+inflammatory	O
+and	O
+immunological	O
+milieu	O
+.	O
+
+We	O
+therefore	O
+suggest	O
+that	O
+combined	O
+tonsillectomy	O
+and	O
+intrapharyngeal	O
+incision	B-ANAT
+in	O
+cases	O
+where	O
+PTA	B-DISO
+is	O
+present	O
+or	O
+suspected	O
+.	O
+
+The	O
+results	O
+of	O
+our	O
+routine	O
+cultures	O
+could	O
+not	O
+support	O
+a	O
+frequent	O
+role	O
+of	O
+FN	O
+in	O
+PPA	B-DISO
+.	O
+
+Bacteremia	B-DISO
+during	O
+abscess	B-DISO
+tonsillectomy	O
+is	O
+no	O
+more	O
+prevalent	O
+than	O
+during	O
+elective	O
+tonsillectomy	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+fatal	O
+disease	O
+with	O
+no	O
+clinically	O
+effective	O
+treatment	O
+.	O
+
+The	O
+survival	O
+times	O
+in	O
+our	O
+study	O
+were	O
+significantly	O
+longer	O
+in	O
+cats	B-SPEC
+who	O
+were	O
+not	O
+treated	O
+with	O
+corticosteroids	B-CHED
+concurrently	O
+with	O
+PI	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+article	O
+reviews	O
+the	O
+current	O
+epidemiology	O
+and	O
+clinical	O
+presentation	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+and	O
+describes	O
+the	O
+preparedness	O
+plan	B-DISO
+of	O
+several	O
+countries	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+is	O
+a	O
+relatively	O
+new	O
+virus	O
+,	O
+and	O
+this	O
+work	O
+is	O
+intended	O
+to	O
+add	B-DISO
+to	O
+the	O
+still	O
+-	O
+sparse	O
+data	O
+on	O
+its	O
+epidemiology	O
+,	O
+modes	O
+of	O
+transmission	O
+,	O
+natural	O
+history	O
+,	O
+and	O
+clinical	O
+features	O
+as	O
+well	O
+as	O
+to	O
+describe	O
+the	O
+preparedness	O
+plan	B-DISO
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+several	O
+countries	O
+.	O
+
+Neuropathological	O
+findings	O
+consisted	O
+of	O
+granulomatous	B-DISO
+meningoencephalitis	I-DISO
+and	O
+larvae	O
+and	O
+adult	O
+females	O
+of	O
+Halicephalobus	B-SPEC
+gingivalis	I-SPEC
+were	O
+isolated	O
+and	O
+identified	O
+from	O
+the	O
+digested	B-PROC
+brain	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Immune	B-PROC
+response	I-PROC
+of	O
+gilts	O
+to	O
+single	O
+and	O
+double	O
+infection	B-DISO
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+In	O
+summary	O
+,	O
+a	O
+single	O
+infection	B-DISO
+at	O
+gilt	O
+acclimatization	B-PROC
+resulted	O
+in	O
+slightly	O
+increased	O
+serum	B-COMP
+antibody	B-COMP
+titers	O
+as	O
+determined	O
+by	O
+VN	O
+assay	O
+and	O
+IgG	B-PRGE
+ELISA	O
+,	O
+but	O
+not	O
+by	O
+IgA	B-PRGE
+ELISA	O
+.	O
+
+We	O
+describe	O
+a	O
+fatal	O
+case	O
+of	O
+rhabdomyolysis	B-DISO
+with	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+complicated	O
+by	O
+SFTS	O
+.	O
+
+This	O
+study	O
+measured	O
+the	O
+overall	O
+level	O
+of	O
+disease	O
+-	O
+related	O
+worry	O
+during	O
+the	O
+MERS	O
+outbreak	O
+period	O
+in	O
+Korea	O
+and	O
+the	O
+influencing	O
+factors	O
+and	O
+levels	O
+of	O
+disease	O
+-	O
+related	O
+worry	O
+during	O
+key	O
+outbreak	O
+periods	B-PROC
+.	O
+
+However	O
+,	O
+the	O
+macropinocytosis	B-PROC
+inhibitors	B-CHED
+could	O
+not	O
+impede	O
+virus	B-PROC
+replication	I-PROC
+once	O
+the	O
+virus	B-SPEC
+had	O
+entered	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Comparative	O
+analysis	O
+of	O
+the	O
+amino	B-CHED
+acids	I-CHED
+encoded	O
+by	O
+the	O
+S	O
+genes	O
+revealed	O
+the	O
+N	O
+-	O
+terminal	O
+of	O
+the	O
+deduced	O
+JSCZ1601	O
+S	O
+protein	O
+had	O
+a	O
+novel	O
+two	O
+-	O
+amino	O
+-	O
+acid	O
+deletion	O
+(	O
+N58	O
+and	O
+S59	O
+)	O
+compared	O
+with	O
+all	O
+identified	O
+genogroups	O
+.	O
+
+The	O
+animal	B-SPEC
+experiment	O
+revealed	O
+that	O
+this	O
+strain	O
+was	O
+high	O
+pathogenic	O
+to	O
+neonatal	O
+pigs	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Betacoronavirus	B-SPEC
+Adaptation	B-PROC
+to	O
+Humans	B-SPEC
+Involved	O
+Progressive	O
+Loss	O
+of	O
+Hemagglutinin	B-PRGE
+-	I-PRGE
+Esterase	I-PRGE
+Lectin	B-PROC
+Activity	I-PROC
+.	O
+
+The	O
+findings	O
+suggest	O
+that	O
+the	O
+dynamics	O
+of	O
+virion	B-COMP
+-	O
+glycan	B-CHED
+interactions	O
+contribute	O
+to	O
+host	B-COMP
+tropism	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Up	O
+to	O
+80	O
+%	O
+of	O
+sore	B-DISO
+throats	I-DISO
+are	O
+caused	O
+by	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+BACKGROUND	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+(	O
+GBS	B-DISO
+)	O
+is	O
+an	O
+acute	B-DISO
+inflammatory	I-DISO
+demyelinating	I-DISO
+polyneuropathy	I-DISO
+that	O
+is	O
+usually	O
+associated	O
+with	O
+preceding	O
+respiratory	O
+or	O
+gastrointestinal	B-DISO
+infection	I-DISO
+and	O
+has	O
+the	O
+hallmark	O
+manifestation	O
+of	O
+ascending	O
+flaccid	B-DISO
+paralysis	I-DISO
+.	O
+
+Head	B-ANAT
+and	O
+chest	B-ANAT
+imaging	O
+was	O
+unrevealing	O
+.	O
+
+Thirty	O
+-	O
+three	O
+ARDS	B-DISO
+patients	O
+(	O
+5	O
+mild	O
+,	O
+10	O
+moderate	O
+,	O
+9	O
+severe	O
+without	O
+extracorporeal	O
+support	O
+,	O
+ECMO	O
+,	O
+and	O
+9	O
+severe	O
+with	O
+it	O
+)	O
+underwent	O
+two	O
+low	O
+-	O
+dose	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+CT	O
+scans	O
+at	O
+PEEP	B-CHED
+5	O
+and	O
+15	O
+cmH	B-DISO
+The	O
+lung	B-ANAT
+tissue	I-ANAT
+which	O
+is	O
+opened	O
+between	O
+30	O
+and	O
+45	O
+cmH	B-DISO
+Data	O
+show	O
+that	O
+the	O
+prerequisites	O
+of	O
+the	O
+open	O
+lung	B-ANAT
+strategy	O
+are	O
+not	O
+satisfied	O
+using	O
+PEEP	B-CHED
+up	O
+to	O
+15	O
+cmH	B-DISO
+Clinicaltrials	O
+.	O
+gov	O
+identifier	O
+:	O
+NCT01670747	O
+(	O
+www	O
+.	O
+clinicaltrials	O
+.	O
+gov	O
+).	O
+
+This	O
+article	O
+reviews	O
+these	O
+options	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Compared	O
+with	O
+P120	O
+,	O
+P160	O
+replicated	O
+less	O
+efficiently	O
+in	O
+the	O
+intestine	O
+of	O
+pigs	B-SPEC
+and	O
+induced	O
+a	O
+lower	O
+rate	O
+of	O
+protection	O
+after	O
+challenge	O
+.	O
+
+However	O
+,	O
+the	O
+overall	O
+pattern	O
+of	O
+attenuation	O
+-	O
+related	O
+genetic	O
+changes	O
+in	O
+PC22A	O
+differed	O
+from	O
+those	O
+of	O
+the	O
+other	O
+four	O
+pairs	O
+of	O
+PEDV	B-SPEC
+wild	O
+type	O
+strains	O
+and	O
+their	O
+attenuated	O
+derivatives	O
+.	O
+
+ABSTRACT	O
+:	O
+Group	B-SPEC
+A	I-SPEC
+rotaviruses	I-SPEC
+(	O
+RVA	O
+)	O
+are	O
+regarded	O
+as	O
+major	O
+enteric	O
+pathogens	O
+of	O
+large	O
+ruminants	B-SPEC
+,	O
+including	O
+cattle	B-SPEC
+.	O
+
+Rotavirus	B-SPEC
+antigen	B-CHED
+was	O
+detected	O
+by	O
+enzyme	O
+-	O
+immunoassay	O
+in	O
+the	O
+intestinal	B-ANAT
+content	I-ANAT
+or	O
+the	O
+fecal	B-ANAT
+samples	O
+of	O
+all	O
+examined	O
+animals	B-SPEC
+.	O
+
+Besides	O
+RVA	O
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+bovine	B-SPEC
+enteric	I-SPEC
+calicivirus	I-SPEC
+were	O
+detected	O
+in	O
+some	O
+samples	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+early	O
+administration	O
+of	O
+acetazolamide	B-CHED
+on	O
+the	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+chronic	O
+obstructive	O
+pulmonary	O
+disease	O
+or	O
+obesity	B-DISO
+-	I-DISO
+hypoventilation	I-DISO
+syndrome	I-DISO
+with	O
+metabolic	B-DISO
+alkalosis	I-DISO
+.	O
+
+Test	O
+-	O
+treatment	O
+,	O
+ACTZ	O
+500	O
+mg	O
+or	O
+placebo	O
+,	O
+was	O
+daily	O
+administered	O
+if	O
+pH	O
+>	O
+7	O
+.	O
+35	O
+and	O
+bicarbonate	B-CHED
+>	O
+26	O
+mmol	O
+/	O
+L	O
+.	O
+Clinical	O
+,	O
+respiratory	O
+and	O
+laboratory	O
+parameters	O
+were	O
+recorded	O
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+between	O
+groups	O
+in	O
+comorbidities	O
+,	O
+baseline	O
+characteristics	O
+or	O
+arterial	B-ANAT
+blood	I-ANAT
+gases	O
+at	O
+inclusion	O
+.	O
+
+Between	O
+-	O
+group	O
+comparison	O
+of	O
+estimated	O
+marginal	O
+means	O
+(	O
+CI	O
+95	O
+%)	O
+during	O
+MV	O
+were	O
+,	O
+respectively	O
+:	O
+PaCO	O
+Among	O
+patients	O
+with	O
+MA	O
+and	O
+COPD	O
+or	O
+OHS	B-DISO
+,	O
+early	O
+treatment	O
+with	O
+ACTZ	O
+did	O
+not	O
+shorten	O
+significantly	O
+the	O
+duration	O
+of	O
+MV	O
+compared	O
+with	O
+placebo	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+median	O
+(	O
+interquartile	O
+range	O
+)	O
+time	O
+from	O
+site	O
+receipt	O
+of	O
+the	O
+protocol	O
+to	O
+REB	B-PRGE
+submission	O
+was	O
+73	O
+(	O
+30	O
+-	O
+126	O
+)	O
+days	O
+;	O
+to	O
+REB	O
+approval	O
+,	O
+158	O
+(	O
+42	O
+-	O
+188	O
+)	O
+days	O
+;	O
+to	O
+DSA	O
+completion	O
+,	O
+276	O
+(	O
+186	O
+-	O
+312	O
+)	O
+days	O
+;	O
+and	O
+to	O
+study	O
+screening	O
+initiation	O
+,	O
+293	O
+(	O
+269	O
+-	O
+391	O
+)	O
+days	O
+.	O
+
+TITLE	O
+:	O
+Resection	O
+and	O
+Primary	O
+Closure	O
+of	O
+Edematous	B-DISO
+Glossoepiglottic	O
+Mucosa	B-ANAT
+in	O
+a	O
+Dog	B-SPEC
+Causing	O
+Laryngeal	B-ANAT
+Obstruction	I-DISO
+.	O
+
+The	O
+causes	O
+of	O
+death	B-PROC
+were	O
+multi	O
+-	O
+system	B-ANAT
+organ	I-ANAT
+failure	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Autophagy	B-PROC
+also	O
+plays	O
+an	O
+important	O
+part	O
+in	O
+virus	B-DISO
+infection	I-DISO
+and	O
+propagation	O
+.	O
+
+PHEV	O
+triggered	O
+autophagy	B-PROC
+in	O
+Neuro	O
+-	O
+2a	O
+cells	B-COMP
+is	O
+dependent	O
+on	O
+the	O
+presence	O
+of	O
+bulk	O
+double	O
+-	O
+or	O
+single	O
+-	O
+membrane	B-COMP
+vacuoles	B-COMP
+,	O
+the	O
+accumulation	O
+of	O
+GFP	O
+-	O
+LC3	O
+fluorescent	O
+dots	O
+,	O
+and	O
+the	O
+LC3	O
+lipidation	O
+.	O
+
+We	O
+also	O
+investigated	O
+the	O
+change	O
+in	O
+viral	B-PROC
+replication	I-PROC
+by	O
+pharmacological	O
+experiments	O
+with	O
+the	O
+autophagy	B-PROC
+inducer	O
+rapamycin	B-CHED
+or	O
+the	O
+autophagy	B-PRGE
+inhibitor	B-CHED
+3	I-PRGE
+-	I-PRGE
+MA	I-PRGE
+,	O
+and	O
+the	O
+lysosomal	B-ANAT
+inhibitor	B-CHED
+chloroquine	B-CHED
+(	O
+CQ	O
+).	O
+
+To	O
+evaluate	O
+agreement	O
+among	O
+TTW	O
+and	O
+NS	O
+,	O
+NPS	B-DISO
+,	O
+or	O
+BAL	B-ENZY
+for	O
+identification	O
+of	O
+viral	O
+and	O
+bacterial	O
+pathogens	O
+in	O
+dairy	O
+calves	O
+with	O
+BRD	O
+.	O
+
+Agreement	O
+among	O
+TTW	O
+and	O
+NS	O
+,	O
+NPS	B-DISO
+,	O
+or	O
+BAL	B-ENZY
+was	O
+evaluated	O
+by	O
+calculating	O
+the	O
+kappa	O
+statistic	O
+and	O
+percent	O
+positive	O
+agreement	O
+.	O
+
+RESULTS	O
+:	O
+Agreement	O
+among	O
+TTW	O
+and	O
+NS	O
+,	O
+TTW	O
+and	O
+NPS	B-DISO
+,	O
+and	O
+TTW	O
+and	O
+BAL	B-ENZY
+,	O
+was	O
+very	O
+good	O
+for	O
+identification	O
+of	O
+P	B-SPEC
+.	I-SPEC
+multocida	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+,	O
+and	O
+M	B-SPEC
+.	I-SPEC
+bovis	I-SPEC
+.	O
+
+Pneumonia	B-DISO
+occurred	O
+in	O
+63	O
+.	O
+64	O
+%,	O
+42	O
+.	O
+31	O
+%,	O
+and	O
+32	O
+.	O
+42	O
+%	O
+of	O
+adenovirus	B-DISO
+,	O
+influenza	B-DISO
+,	O
+and	O
+RSV	B-PRGE
+RVI	I-PRGE
+episodes	O
+,	O
+respectively	O
+,	O
+but	O
+was	O
+also	O
+non	O
+-	O
+negligible	O
+in	O
+the	O
+more	O
+benign	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+coronavirus	B-SPEC
+(	O
+31	O
+.	O
+58	O
+%)	O
+and	O
+rhinovirus	B-SPEC
+(	O
+23	O
+.	O
+68	O
+%).	O
+
+Serological	O
+data	O
+suggest	O
+that	O
+lineage	O
+A	O
+betacoronavirus	B-SPEC
+infections	B-DISO
+are	O
+commonly	O
+infecting	O
+horses	B-SPEC
+in	O
+Saudi	O
+Arabia	O
+and	O
+Oman	O
+but	O
+antibody	B-COMP
+cross	O
+-	O
+reactivities	O
+between	O
+these	O
+viruses	B-SPEC
+do	O
+not	O
+permit	B-SPEC
+us	O
+to	O
+use	O
+serological	O
+data	O
+alone	O
+to	O
+identify	O
+which	O
+coronaviruses	O
+are	O
+causing	O
+these	O
+infections	B-DISO
+.	O
+
+Instead	O
+,	O
+the	O
+compound	O
+could	O
+depress	O
+the	O
+activity	O
+of	O
+IMPDH	B-PRGE
+type	I-PRGE
+II	I-PRGE
+.	O
+
+Based	O
+on	O
+these	O
+findings	O
+,	O
+we	O
+further	O
+confirmed	O
+that	O
+N30	O
+provided	O
+a	O
+strong	O
+inhibition	O
+on	O
+the	O
+replication	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+enterovirus	B-SPEC
+71	O
+and	O
+a	O
+diverse	O
+strains	O
+of	O
+coxsackie	O
+B	B-SPEC
+virus	I-SPEC
+.	O
+
+RESULTS	O
+:	O
+The	O
+results	O
+demonstrated	O
+that	O
+N30	O
+inhibited	O
+the	O
+replication	O
+of	O
+H1N1	O
+,	O
+H3N2	B-CHED
+,	O
+influenza	B-DISO
+B	O
+viruses	B-SPEC
+,	O
+including	O
+oseltamivir	B-CHED
+and	O
+amantadine	B-CHED
+resistant	O
+strains	O
+in	O
+vitro	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+the	O
+miR	B-PRGE
+-	I-PRGE
+21a	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+is	O
+notably	O
+up	O
+-	O
+regulated	O
+in	O
+the	O
+brains	B-ANAT
+of	O
+mice	B-SPEC
+and	O
+N2a	O
+cells	B-COMP
+infected	O
+with	O
+PHEV	O
+,	O
+and	O
+it	O
+down	O
+-	O
+regulated	O
+the	O
+expression	B-PROC
+of	O
+CASK	B-PRGE
+-	I-PRGE
+interactive	I-PRGE
+protein1	I-PRGE
+(	O
+Caskin1	B-PRGE
+)	O
+by	O
+directly	O
+targeting	B-PROC
+the	O
+3	O
+'-	O
+UTR	O
+of	O
+Caskin1	O
+using	O
+a	O
+Dual	O
+-	O
+Luciferase	B-ENZY
+reporter	O
+assay	O
+.	O
+
+TITLE	O
+:	O
+ORF3a	O
+deletion	O
+in	O
+field	O
+strains	O
+of	O
+porcine	B-SPEC
+-	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+in	O
+China	O
+:	O
+A	O
+hint	O
+of	O
+association	O
+with	O
+porcine	O
+respiratory	O
+coronavirus	B-SPEC
+.	O
+
+Phylogenetic	O
+tree	O
+analysis	O
+of	O
+ORF3	O
+showed	O
+that	O
+the	O
+eight	O
+TGEV	B-SPEC
+ORF3	O
+genes	O
+all	O
+belonged	O
+to	O
+the	O
+Miller	O
+cluster	O
+.	O
+
+For	O
+this	O
+study	O
+,	O
+we	O
+aimed	O
+to	O
+determine	O
+the	O
+minimum	O
+infectious	B-DISO
+dose	O
+for	O
+the	O
+spray	O
+-	O
+administered	O
+ArkDPI	O
+vaccine	O
+,	O
+which	O
+we	O
+designate	O
+as	O
+the	O
+dose	O
+that	O
+achieves	O
+the	O
+same	O
+level	O
+of	O
+infection	B-DISO
+and	O
+replication	O
+as	O
+the	O
+eye	B-ANAT
+drop	O
+-	O
+administered	O
+ArkDPI	O
+vaccine	O
+.	O
+
+This	O
+study	O
+also	O
+represents	O
+the	O
+first	O
+description	O
+of	O
+a	O
+DNA	O
+-	O
+launched	O
+reverse	O
+genetics	O
+system	O
+for	O
+the	O
+highly	O
+virulent	O
+PEDV	B-SPEC
+.	O
+
+By	O
+concentrating	O
+drugs	O
+in	O
+inflamed	O
+alveoli	B-ANAT
+,	O
+PELs	B-CHED
+solve	O
+pharmacological	O
+challenge	O
+(	O
+1	O
+)	O
+above	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+DNA	O
+viruses	B-SPEC
+are	O
+undetectable	O
+in	O
+nasopharyngeal	B-ANAT
+secretions	B-ANAT
+from	O
+adenotonsillectomized	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+is	O
+an	O
+emerging	O
+pathogen	O
+that	O
+continues	O
+to	O
+cause	O
+outbreaks	O
+in	O
+the	O
+Arabian	O
+peninsula	O
+and	O
+in	O
+travelers	O
+from	O
+this	O
+region	O
+,	O
+raising	O
+the	O
+concern	O
+that	O
+a	O
+global	O
+pandemic	O
+could	O
+occur	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+a	O
+DNA	O
+vaccine	O
+encoding	O
+the	O
+first	O
+725	O
+amino	B-CHED
+acids	I-CHED
+(	O
+S1	O
+)	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+induces	O
+antigen	B-CHED
+-	O
+specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+mice	B-SPEC
+.	O
+
+Overall	O
+,	O
+these	O
+results	O
+demonstrate	O
+that	O
+the	O
+IBV	B-SPEC
+-	O
+encoded	O
+PLP	B-PRGE
+-	I-PRGE
+TM	I-PRGE
+functions	O
+as	O
+a	O
+DUB	B-PRGE
+enzyme	I-PRGE
+and	O
+suggest	O
+that	O
+IBV	B-SPEC
+may	O
+interfere	O
+with	O
+the	O
+activation	O
+of	O
+host	B-COMP
+antiviral	B-CHED
+signaling	B-PROC
+pathway	I-PROC
+by	O
+degrading	O
+polyubiquitin	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+proteins	B-CHED
+.	O
+
+The	O
+producibility	O
+of	O
+these	O
+extracellular	B-COMP
+matrices	I-COMP
+(	O
+ECMs	O
+)	O
+by	O
+astrocytes	B-ANAT
+was	O
+further	O
+confirmed	O
+by	O
+primary	O
+brain	B-ANAT
+cultures	O
+,	O
+which	O
+disclosed	O
+the	O
+dissociation	B-DISO
+of	O
+laminin	B-PRGE
+and	O
+ERag	O
+production	O
+,	O
+and	O
+the	O
+close	O
+association	O
+of	O
+ERag	O
+production	O
+with	O
+that	O
+of	O
+collagen	B-COMP
+,	O
+forming	O
+a	O
+fibrous	O
+structure	O
+.	O
+
+TITLE	O
+:	O
+Domestic	B-SPEC
+Pig	I-SPEC
+Unlikely	O
+Reservoir	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+We	O
+tested	O
+the	O
+suitability	O
+of	O
+the	O
+domestic	B-SPEC
+pig	I-SPEC
+as	O
+a	O
+model	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+NT	O
+-	O
+proBNP	O
+was	O
+associated	O
+with	O
+poor	O
+outcomes	O
+for	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+and	O
+its	O
+level	O
+predicted	O
+mortality	O
+.	O
+
+During	O
+April	O
+2015	O
+-	O
+February	O
+2016	O
+,	O
+Saudi	O
+Arabia	O
+identified	O
+and	O
+tested	O
+57	O
+,	O
+363	O
+persons	O
+(	O
+18	O
+.	O
+4	O
+/	O
+10	O
+,	O
+000	O
+residents	O
+)	O
+with	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+;	O
+384	O
+(	O
+0	O
+.	O
+7	O
+%)	O
+tested	O
+positive	O
+.	O
+
+TITLE	O
+:	O
+Venovenous	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+as	O
+a	O
+Treatment	O
+for	O
+Obesity	B-DISO
+Hypoventilation	I-DISO
+Syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+Significance	O
+of	O
+Human	B-SPEC
+Coronavirus	I-SPEC
+in	O
+Bronchoalveolar	O
+Lavage	O
+Samples	O
+From	O
+Hematopoietic	B-ANAT
+Cell	I-ANAT
+Transplant	B-ANAT
+Recipients	O
+and	O
+Patients	O
+With	O
+Hematologic	B-DISO
+Malignancies	I-DISO
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+and	O
+Management	O
+of	O
+Refractory	O
+Respiratory	B-DISO
+Failure	I-DISO
+With	O
+Timely	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	O
+:	O
+Single	O
+-	O
+Center	O
+Experience	O
+With	O
+Legionella	B-DISO
+Pneumonia	I-DISO
+.	O
+
+The	O
+structure	O
+of	O
+the	O
+CTD	O
+reveals	O
+the	O
+mode	O
+of	O
+N	O
+protein	B-CHED
+dimerization	O
+.	O
+
+Dexamethasone	B-CHED
+is	O
+also	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+a	O
+severe	O
+complication	B-DISO
+of	O
+influenza	B-DISO
+;	O
+however	O
+,	O
+its	O
+influence	O
+on	O
+the	O
+pharmacokinetics	B-PROC
+(	O
+PK	O
+)	O
+of	O
+oseltamivir	B-CHED
+is	O
+controversial	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+coadministering	O
+oseltamivir	B-CHED
+and	O
+dexamethasone	B-CHED
+on	O
+the	O
+PK	O
+of	O
+oseltamivir	B-CHED
+in	O
+healthy	O
+volunteers	O
+.	O
+
+This	O
+result	O
+suggests	O
+that	O
+CES1	B-PRGE
+is	O
+inhibited	O
+by	O
+dexamethasone	B-CHED
+in	O
+humans	B-SPEC
+.	O
+
+Fifty	O
+-	O
+three	O
+animals	B-SPEC
+presented	O
+for	O
+slaughter	O
+were	O
+sampled	O
+.	O
+
+Of	O
+1	O
+,	O
+078	O
+camels	B-SPEC
+,	O
+41	O
+(	O
+3	O
+.	O
+8	O
+%)	O
+were	O
+positive	O
+for	O
+MERS	O
+-	O
+CoV	O
+genetic	O
+material	O
+.	O
+
+Additionally	O
+,	O
+endemic	O
+zoonoses	B-DISO
+,	O
+such	O
+as	O
+rabies	B-DISO
+,	O
+burden	O
+countries	O
+year	O
+after	O
+year	O
+,	O
+placing	O
+demands	O
+on	O
+limited	O
+finances	O
+and	O
+personnel	O
+.	O
+
+For	O
+emerging	O
+zoonoses	B-DISO
+,	O
+28	O
+ministries	O
+performed	O
+formal	B-CHED
+prioritization	O
+exercises	O
+.	O
+
+This	O
+study	O
+investigated	O
+serum	B-COMP
+concentrations	O
+of	O
+IP	O
+-	O
+10	O
+in	O
+healthy	O
+individuals	O
+who	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+(	O
+ARI	B-CHED
+).	O
+
+Data	O
+come	O
+from	O
+a	O
+randomized	O
+controlled	O
+trial	O
+measuring	O
+the	O
+effects	O
+of	O
+mindfulness	O
+meditation	O
+or	O
+exercise	O
+on	O
+ARI	B-CHED
+(	O
+Clinical	O
+Trials	O
+ID	O
+:	O
+NCT01654289	O
+).	O
+
+ARI	O
+severity	O
+was	O
+measured	O
+using	O
+the	O
+validated	O
+Wisconsin	O
+Upper	B-DISO
+Respiratory	I-DISO
+Symptom	I-DISO
+Survey	O
+(	O
+WURSS	O
+-	O
+24	O
+)	O
+until	O
+the	O
+ARI	B-CHED
+episode	O
+resolved	O
+.	O
+
+A	O
+sensitive	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+targeting	B-PROC
+the	O
+IBV	B-PRGE
+nucleocapsid	B-COMP
+gene	I-PRGE
+(	O
+N	O
+)	O
+was	O
+developed	O
+to	O
+screen	O
+clinical	O
+samples	O
+for	O
+presence	O
+of	O
+IBV	B-SPEC
+.	O
+
+Corticosteroid	B-CHED
+treatment	O
+was	O
+safe	O
+and	O
+well	O
+tolerated	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recombinant	O
+LaSota	O
+strain	O
+expressing	O
+a	O
+chimeric	O
+IBV	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+(	O
+rLaSota	O
+-	O
+S1	O
+)	O
+was	O
+constructed	O
+with	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+LX4	B-PRGE
+type	I-PRGE
+IBV	I-PRGE
+ck	I-PRGE
+/	O
+CH	O
+/	O
+LDL	B-CHED
+/	O
+091022	O
+.	O
+
+In	O
+addition	O
+,	O
+vaccination	O
+with	O
+the	O
+rLaSota	O
+-	O
+S1	O
+strain	O
+induced	O
+IBV	B-SPEC
+-	O
+specific	O
+IgG	B-PRGE
+antibodies	I-PRGE
+and	O
+cellular	B-PROC
+immunity	I-PROC
+;	O
+however	O
+,	O
+a	O
+single	O
+vaccination	O
+provided	O
+partial	O
+protection	O
+with	O
+reduced	O
+virus	B-DISO
+shedding	I-DISO
+.	O
+
+We	O
+present	O
+2	O
+cases	O
+of	O
+ARDS	B-DISO
+secondary	O
+to	O
+H1N1	B-DISO
+influenza	I-DISO
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+.	O
+
+RESULTS	O
+:	O
+We	O
+present	O
+2	O
+cases	O
+of	O
+ARDS	B-DISO
+secondary	O
+to	O
+H1N1	B-DISO
+influenza	I-DISO
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+.	O
+
+We	O
+did	O
+a	O
+review	O
+of	O
+the	O
+literature	O
+summarizing	O
+38	O
+patients	O
+in	O
+10	O
+publications	O
+where	O
+TH	O
+was	O
+successfully	O
+utilized	O
+in	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Therapeutic	O
+hypothermia	O
+may	O
+be	O
+a	O
+viable	O
+salvage	O
+therapy	O
+for	O
+ARDS	B-DISO
+refractory	O
+to	O
+the	O
+current	O
+evidence	O
+-	O
+based	O
+therapy	O
+but	O
+needs	O
+further	O
+evaluation	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+newly	O
+discovered	O
+coronavirus	B-SPEC
+that	O
+causes	O
+diarrhoea	B-DISO
+,	O
+vomiting	B-DISO
+and	O
+dehydration	B-DISO
+in	O
+sucking	B-PROC
+and	O
+nursing	B-PROC
+piglets	O
+.	O
+
+In	O
+our	O
+study	O
+,	O
+252	O
+faecal	B-ANAT
+and	O
+intestinal	B-ANAT
+samples	O
+from	O
+sucking	B-PROC
+piglets	O
+and	O
+sows	O
+with	O
+diarrhoea	B-DISO
+were	O
+surveyed	O
+for	O
+common	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+We	O
+found	O
+a	O
+prevalence	O
+of	O
+PDCoV	O
+(	O
+21	O
+.	O
+8	O
+%),	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+65	O
+.	O
+5	O
+%),	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+0	O
+%),	O
+rotavirus	B-SPEC
+group	I-SPEC
+A	I-SPEC
+(	O
+25	O
+.	O
+0	O
+%)	O
+and	O
+porcine	B-SPEC
+kobuvirus	B-SPEC
+(	O
+68	O
+.	O
+7	O
+%).	O
+
+This	O
+suggested	O
+a	O
+possible	O
+recombination	B-PROC
+event	O
+between	O
+the	O
+Thai	O
+and	O
+the	O
+newly	O
+described	O
+Chinese	O
+strain	O
+.	O
+
+We	O
+undertook	O
+enhanced	O
+surveillance	O
+of	O
+those	O
+presenting	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+at	O
+five	O
+healthcare	O
+centers	O
+by	O
+testing	O
+all	O
+symptomatic	O
+outpatients	O
+between	O
+November	O
+2013	O
+and	O
+January	O
+2014	O
+(	O
+winter	O
+time	O
+).	O
+
+Human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+hRV	O
+)	O
+was	O
+the	O
+most	O
+detected	O
+pathogen	O
+(	O
+40	O
+.	O
+9	O
+%)	O
+followed	O
+by	O
+non	O
+-	O
+MERS	O
+-	O
+CoV	O
+human	B-SPEC
+coronaviruses	O
+(	O
+19	O
+.	O
+3	O
+%),	O
+influenza	B-DISO
+(	O
+Flu	B-DISO
+)	O
+viruses	B-SPEC
+(	O
+15	O
+.	O
+9	O
+%),	O
+and	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+hRSV	B-SPEC
+)	O
+(	O
+13	O
+.	O
+6	O
+%).	O
+
+We	O
+show	O
+that	O
+the	O
+comparative	O
+effectiveness	O
+of	O
+symptom	B-DISO
+monitoring	O
+and	O
+quarantine	O
+depends	O
+critically	O
+on	O
+the	O
+natural	O
+history	O
+of	O
+the	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+its	O
+inherent	O
+transmissibility	O
+,	O
+and	O
+the	O
+intervention	O
+feasibility	O
+in	O
+the	O
+particular	O
+healthcare	O
+setting	O
+.	O
+
+Seven	O
+CoVs	O
+belonging	O
+to	O
+distinct	O
+groups	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+like	O
+CoVs	O
+and	O
+α	O
+-	O
+CoVs	O
+were	O
+detected	O
+in	O
+samples	O
+from	O
+least	B-SPEC
+horseshoe	I-SPEC
+bats	I-SPEC
+.	O
+
+Whole	O
+-	O
+genome	O
+sequencing	O
+of	O
+a	O
+new	O
+isolate	O
+(	O
+F46	O
+)	O
+from	O
+a	O
+rectal	B-ANAT
+swab	I-ANAT
+from	O
+a	O
+least	B-SPEC
+horseshoe	I-SPEC
+bat	I-SPEC
+showed	O
+that	O
+it	O
+contained	O
+29	O
+699	O
+nucleotides	B-CHED
+,	O
+excluding	O
+the	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+,	O
+with	O
+13	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+).	O
+
+To	O
+obtain	O
+more	O
+insight	O
+into	O
+the	O
+signals	O
+and	O
+molecular	O
+events	O
+that	O
+coordinate	O
+global	O
+host	B-COMP
+responses	O
+in	O
+the	O
+nucleus	B-COMP
+of	O
+coronavirus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+,	O
+first	O
+,	O
+transcriptome	O
+dynamics	O
+was	O
+studied	O
+in	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)-	O
+infected	O
+A549	O
+and	O
+HuH7	O
+cells	B-COMP
+,	O
+respectively	O
+,	O
+revealing	O
+a	O
+core	O
+signature	O
+of	O
+upregulated	O
+genes	O
+in	O
+these	O
+cells	B-COMP
+.	O
+
+The	O
+data	O
+revealed	O
+that	O
+,	O
+in	O
+HCoV	O
+-	O
+infected	O
+(	O
+but	O
+not	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+-	O
+treated	O
+)	O
+cells	B-COMP
+,	O
+an	O
+extensive	O
+set	O
+of	O
+genes	O
+was	O
+activated	O
+without	O
+inducible	O
+p65	B-PRGE
+NF	O
+-	O
+κB	O
+being	O
+recruited	O
+.	O
+
+Thirty	O
+-	O
+six	O
+percent	O
+of	O
+patients	O
+reported	O
+significant	O
+psychiatric	B-DISO
+symptoms	I-DISO
+on	O
+at	O
+least	O
+one	O
+scale	O
+.	O
+
+In	O
+multiple	O
+regression	O
+analyses	O
+,	O
+younger	O
+age	O
+,	O
+female	O
+sex	O
+,	O
+higher	O
+severity	O
+of	O
+illness	O
+,	O
+fewer	O
+steroid	B-CHED
+treatment	O
+days	O
+,	O
+and	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+treatment	O
+were	O
+all	O
+independently	O
+associated	O
+with	O
+more	O
+severe	O
+psychiatric	B-DISO
+symptoms	I-DISO
+on	O
+at	O
+least	O
+one	O
+scale	O
+.	O
+
+Our	O
+studies	O
+revealed	O
+that	O
+the	O
+ISR	O
+signaling	B-PROC
+pathway	I-PROC
+is	O
+a	O
+key	O
+modulator	O
+of	O
+epithelial	O
+permeability	O
+.	O
+
+Chemical	O
+inhibition	B-PROC
+of	O
+protein	B-ENZY
+kinase	I-ENZY
+RNA	O
+-	O
+like	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+kinase	O
+,	O
+an	O
+upstream	O
+regulator	O
+of	O
+the	O
+pathway	B-PROC
+,	O
+resulted	O
+in	O
+decreased	O
+injury	O
+signaling	B-PROC
+and	O
+improved	O
+barrier	O
+function	O
+after	O
+prolonged	O
+cyclic	O
+stretch	O
+and	O
+injurious	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+reliability	O
+of	O
+methods	O
+for	O
+quantifying	O
+particle	O
+-	O
+associated	O
+viruses	B-SPEC
+as	O
+well	O
+as	O
+the	O
+size	O
+distribution	O
+of	O
+aerosolized	O
+particles	O
+bearing	O
+these	O
+viruses	B-SPEC
+under	O
+field	O
+conditions	O
+are	O
+not	O
+well	O
+documented	O
+.	O
+
+Interaction	O
+of	O
+the	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+surface	O
+glycoprotein	B-CHED
+-	O
+through	O
+its	O
+S1	O
+subunit	O
+-	O
+with	O
+the	O
+host	B-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+is	O
+the	O
+first	O
+step	O
+in	O
+infection	B-DISO
+and	O
+the	O
+main	O
+determinant	O
+for	O
+virus	B-SPEC
+tropism	B-PROC
+.	O
+
+Consistently	O
+,	O
+unlike	O
+TGEV	B-SPEC
+-	O
+S1	O
+,	O
+PEDV	B-SPEC
+-	O
+S1	O
+exhibited	O
+no	O
+binding	B-FUNC
+to	O
+cell	B-COMP
+-	O
+surface	O
+expressed	O
+APN	B-PRGE
+or	O
+to	O
+a	O
+soluble	O
+version	O
+of	O
+APN	O
+.	O
+
+In	O
+this	O
+volume	O
+we	O
+explored	O
+special	O
+aspects	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+including	O
+:	O
+the	O
+application	O
+of	O
+the	O
+theory	O
+of	O
+focality	O
+of	O
+diseases	O
+to	O
+infective	O
+syndrome	B-DISO
+;	O
+the	O
+human	B-SPEC
+-	O
+animal	B-SPEC
+inter	O
+-	O
+face	B-DISO
+focusing	O
+on	O
+influenza	B-DISO
+;	O
+the	O
+role	O
+of	O
+bats	B-SPEC
+as	O
+main	O
+reservoir	O
+of	O
+emerging	O
+and	O
+novel	O
+human	B-SPEC
+pathogens	O
+;	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+epidemiology	O
+and	O
+clinical	O
+presentation	O
+;	O
+immediate	O
+impact	O
+on	O
+human	B-SPEC
+health	O
+of	O
+the	O
+last	O
+Zika	B-SPEC
+virus	I-SPEC
+outbreak	O
+occurred	O
+in	O
+Pacific	O
+Ocean	O
+and	O
+the	O
+Americas	O
+;	O
+the	O
+role	O
+and	O
+potential	O
+application	O
+of	O
+animal	B-SPEC
+models	O
+for	O
+the	O
+study	O
+of	O
+emerging	O
+infections	B-DISO
+,	O
+to	O
+improve	O
+disease	O
+knowledge	O
+and	O
+for	O
+developing	O
+therapeutic	O
+drugs	O
+during	O
+ongoing	O
+outbreak	O
+.	O
+
+Endobronchial	O
+valves	B-ANAT
+(	O
+EBV	O
+)	O
+are	O
+frequently	O
+deployed	O
+after	O
+pulmonary	B-ANAT
+resection	O
+in	O
+noncritically	O
+ill	B-DISO
+patients	O
+to	O
+reduce	O
+and	O
+eliminate	O
+bronchopleural	O
+fistulas	B-DISO
+(	O
+BPFs	O
+)	O
+with	O
+persistent	B-DISO
+air	I-DISO
+leak	I-DISO
+(	O
+PAL	B-FUNC
+).	O
+
+However	O
+,	O
+this	O
+approach	O
+might	O
+increase	O
+the	O
+risk	O
+of	O
+novel	O
+development	B-PROC
+of	O
+lung	B-ANAT
+allograft	O
+cancer	B-DISO
+,	O
+a	O
+potential	O
+fatal	O
+complication	B-DISO
+that	O
+must	O
+be	O
+considered	O
+during	O
+follow	O
+-	O
+up	O
+of	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+.	O
+
+Throat	B-ANAT
+swabs	O
+and	O
+tracheal	O
+aspirates	B-ANAT
+were	O
+collected	O
+from	O
+SARI	O
+patients	O
+according	O
+to	O
+WHO	O
+guidelines	O
+.	O
+
+More	O
+than	O
+30	O
+%	O
+(	O
+32	O
+.	O
+1	O
+%,	O
+313	O
+samples	O
+)	O
+of	O
+the	O
+samples	O
+showed	O
+evidence	O
+of	O
+infection	B-DISO
+with	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+including	O
+A	O
+/	O
+H3N2	B-CHED
+(	O
+48	O
+samples	O
+),	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+(	O
+221	O
+samples	O
+),	O
+influenza	B-DISO
+B	O
+(	O
+42	O
+samples	O
+),	O
+and	O
+co	O
+-	O
+infection	O
+of	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+or	O
+A	O
+/	O
+H3N2	B-CHED
+and	O
+influenza	B-DISO
+B	O
+(	O
+2	O
+samples	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+develop	O
+nanoparticle	O
+drug	O
+carriers	O
+that	O
+interact	O
+with	O
+cells	B-COMP
+specifically	O
+in	O
+the	O
+mildly	O
+acidic	O
+tumor	B-DISO
+microenvironment	O
+,	O
+we	O
+produced	O
+polymeric	O
+nanoparticles	B-CHED
+modified	O
+with	O
+amidated	O
+TAT	B-ENZY
+peptide	B-CHED
+via	O
+a	O
+simple	O
+surface	O
+modification	O
+method	O
+.	O
+
+Comparison	O
+of	O
+particle	O
+stability	O
+and	O
+protein	B-CHED
+corona	B-CHED
+formation	B-PROC
+in	O
+media	B-ANAT
+containing	O
+sera	B-COMP
+from	O
+different	O
+species	B-SPEC
+suggests	O
+that	O
+NPpT	O
+-	O
+CA	O
+has	O
+been	O
+activated	O
+and	O
+opsonized	O
+in	O
+mouse	B-ANAT
+blood	I-ANAT
+to	O
+a	O
+greater	O
+extent	O
+than	O
+those	O
+in	O
+bovine	B-SPEC
+serum	B-COMP
+-	O
+containing	O
+medium	O
+,	O
+thus	O
+losing	O
+the	O
+benefits	O
+of	O
+pH	O
+-	O
+sensitivity	O
+expected	O
+from	O
+in	O
+vitro	O
+experiments	O
+.	O
+
+Clinical	O
+microbiological	O
+,	O
+ventilation	O
+and	O
+other	O
+pertinent	O
+PICU	B-SPEC
+data	O
+were	O
+collected	O
+.	O
+
+Severe	O
+pediatric	O
+pneumonia	B-DISO
+accounts	O
+for	O
+a	O
+significant	O
+number	O
+of	O
+PICU	B-SPEC
+admissions	O
+and	O
+is	O
+associated	O
+with	O
+significant	O
+mortality	O
+risk	O
+.	O
+
+After	O
+adjusting	O
+for	O
+severity	O
+of	O
+illness	O
+,	O
+risk	O
+factors	O
+for	O
+mortality	O
+were	O
+:	O
+hospital	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+(	O
+HAP	O
+)	O
+(	O
+aOR	B-FUNC
+:	O
+2	O
+.	O
+92	O
+[	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+15	O
+,	O
+7	O
+.	O
+40	O
+];	O
+P	O
+=	O
+0	O
+.	O
+024	O
+)	O
+and	O
+bacteremia	B-DISO
+(	O
+aOR	B-FUNC
+:	O
+5	O
+.	O
+03	O
+[	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+77	O
+,	O
+14	O
+.	O
+35	O
+];	O
+P	O
+=	O
+0	O
+.	O
+003	O
+).	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+identified	O
+the	O
+cardiomyopathy	B-DISO
+-	O
+susceptibility	O
+gene	O
+vinculin	B-PRGE
+(	O
+In	O
+8	O
+of	O
+120	O
+SUNDS	B-DISO
+cases	O
+,	O
+we	O
+detected	B-PRGE
+an	I-PRGE
+East	I-PRGE
+Asian	I-PRGE
+common	I-PRGE
+VCL	I-PRGE
+variant	I-PRGE
+p	O
+.	O
+
+To	O
+investigate	O
+these	O
+differences	O
+,	O
+we	O
+infected	O
+male	O
+and	O
+female	O
+mice	B-SPEC
+of	O
+different	O
+age	O
+groups	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+analyzed	O
+their	O
+susceptibility	O
+to	O
+the	O
+infection	B-DISO
+.	O
+
+Enhanced	O
+susceptibility	O
+of	O
+male	O
+mice	B-SPEC
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+associated	O
+with	O
+elevated	O
+virus	B-SPEC
+titers	O
+,	O
+enhanced	O
+vascular	O
+leakage	B-DISO
+,	O
+and	O
+alveolar	B-DISO
+edema	I-DISO
+.	O
+
+TITLE	O
+:	O
+Calves	O
+are	O
+susceptible	O
+to	O
+infection	B-DISO
+with	O
+the	O
+newly	O
+emerged	O
+porcine	B-SPEC
+deltacoronavirus	O
+,	O
+but	O
+not	O
+with	O
+the	O
+swine	O
+enteric	O
+alphacoronavirus	B-SPEC
+,	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Patient	O
+safety	O
+has	O
+become	O
+a	O
+worldwide	O
+concern	O
+in	O
+relation	O
+to	O
+infectious	B-DISO
+diseases	I-DISO
+(	O
+Ebola	O
+/	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+/	O
+flu	B-DISO
+).	O
+
+These	O
+themes	O
+fit	B-DISO
+within	O
+safety	O
+cultures	O
+described	O
+by	O
+participants	O
+:	O
+individual	O
+culture	O
+,	O
+blame	O
+culture	O
+,	O
+and	O
+collaborative	O
+culture	O
+.	O
+
+ABSTRACT	O
+:	O
+Nosocomial	O
+transmission	O
+is	O
+an	O
+important	O
+characteristic	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+During	O
+the	O
+Korean	O
+outbreak	O
+in	O
+2015	O
+,	O
+186	O
+patients	O
+had	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Consistently	O
+,	O
+initial	O
+CYFRA21	O
+-	O
+1	O
+levels	O
+were	O
+identified	O
+as	O
+the	O
+most	O
+promising	O
+predictor	O
+of	O
+ARDS	B-DISO
+,	O
+whereas	O
+day	O
+-	O
+2	O
+CC16	O
+levels	O
+have	O
+to	O
+be	O
+considered	O
+as	O
+most	O
+appropriate	O
+for	O
+predicting	O
+pneumonia	B-DISO
+.	O
+
+Two	O
+thermal	O
+processing	O
+experiments	O
+were	O
+designed	O
+to	O
+determine	O
+if	O
+different	O
+pellet	O
+mill	O
+conditioner	O
+retention	B-PROC
+times	O
+and	O
+temperatures	O
+would	O
+impact	O
+PEDV	B-SPEC
+quantity	O
+and	O
+infectivity	O
+by	O
+analysis	O
+of	O
+quantitative	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+and	O
+bioassay	O
+.	O
+
+Regardless	O
+of	O
+time	O
+or	O
+temperature	O
+,	O
+pelleting	O
+reduced	O
+(	O
+<	O
+0	O
+.	O
+05	O
+)	O
+the	O
+quantity	O
+of	O
+detectable	O
+viral	O
+PEDV	B-SPEC
+RNA	O
+compared	O
+with	O
+the	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+unprocessed	O
+mash	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+biosecurity	O
+measures	O
+to	O
+prevent	O
+indirect	O
+transmission	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+indirect	O
+PEDV	B-SPEC
+transmission	O
+through	O
+contaminated	O
+PPE	B-CHED
+occurs	O
+rapidly	O
+(	O
+within	O
+24	O
+h	O
+)	O
+under	O
+modeled	O
+conditions	O
+.	O
+
+RESULTS	O
+:	O
+PEDV	B-SPEC
+RNA	O
+was	O
+detected	O
+from	O
+rectal	O
+swabs	O
+of	O
+experimentally	O
+infected	O
+(	O
+INF	O
+)	O
+and	O
+sentinel	O
+pigs	B-SPEC
+by	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+rRT	O
+-	O
+PCR	O
+).	O
+
+TITLE	O
+:	O
+Group	B-SPEC
+A	I-SPEC
+Rotaviruses	I-SPEC
+in	O
+Chinese	O
+Bats	B-SPEC
+:	O
+Genetic	O
+Composition	O
+,	O
+Serology	O
+,	O
+and	O
+Evidence	O
+for	O
+Bat	B-ENZY
+-	O
+to	O
+-	O
+Human	B-SPEC
+Transmission	O
+and	O
+Reassortment	O
+.	O
+
+Strain	O
+GLRL1	O
+possessed	B-DISO
+a	O
+completely	O
+novel	O
+genotype	O
+constellation	O
+,	O
+whereas	O
+the	O
+other	O
+three	O
+possessed	B-DISO
+a	O
+constellation	O
+consistent	O
+with	O
+the	O
+MSLH14	B-PRGE
+-	I-PRGE
+like	I-PRGE
+genotype	I-PRGE
+,	O
+a	O
+newly	O
+characterized	O
+group	O
+of	O
+viruses	B-SPEC
+widely	O
+prevalent	O
+in	O
+Chinese	O
+insectivorous	O
+bats	B-SPEC
+.	O
+
+Bats	B-SPEC
+in	O
+Guangxi	O
+and	O
+Yunnan	O
+had	O
+a	O
+higher	O
+RVA	O
+-	O
+specific	O
+antibody	B-COMP
+prevalence	O
+than	O
+those	O
+from	O
+Fujian	O
+and	O
+Zhejiang	O
+provinces	O
+.	O
+
+The	O
+epitopes	O
+of	O
+potent	O
+neutralizing	O
+antibodies	B-COMP
+segregated	O
+into	O
+two	O
+epitope	B-CHED
+classes	O
+and	O
+mapped	O
+within	O
+the	O
+N	O
+-	O
+terminal	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+domain	O
+and	O
+in	O
+the	O
+more	O
+C	O
+-	O
+terminal	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+.	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+for	O
+MERS	O
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+in	O
+Burkina	O
+Faso	O
+,	O
+Ethiopia	O
+,	O
+and	O
+Morocco	O
+,	O
+2015	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+help	O
+reveal	O
+the	O
+diversity	O
+and	O
+evolution	O
+of	O
+bat	B-ENZY
+coronaviruses	O
+we	O
+collected	O
+1067	O
+bats	B-SPEC
+from	O
+21	O
+species	B-SPEC
+in	O
+China	O
+.	O
+
+A	O
+total	O
+of	O
+73	O
+coronaviruses	O
+(	O
+32	O
+alphacoronaviruses	O
+and	O
+41	O
+betacoronaviruses	O
+)	O
+were	O
+identified	O
+in	O
+these	O
+bats	B-SPEC
+,	O
+with	O
+an	O
+overall	O
+prevalence	O
+of	O
+6	O
+.	O
+84	O
+%.	O
+
+TITLE	O
+:	O
+Risk	O
+Factors	O
+for	O
+Primary	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-DISO
+Infection	I-DISO
+in	O
+Camel	B-SPEC
+Workers	O
+in	O
+Qatar	O
+During	O
+2013	O
+-	O
+2014	O
+:	O
+A	O
+Case	O
+-	O
+Control	O
+Study	O
+.	O
+
+We	O
+used	O
+the	O
+World	O
+Health	O
+Organization	O
+questionnaire	O
+for	O
+MERS	O
+-	O
+CoV	O
+case	O
+-	O
+control	O
+studies	O
+to	O
+assess	O
+risk	O
+factors	O
+for	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+seropositivity	O
+at	O
+a	O
+farm	O
+complex	O
+in	O
+Qatar	O
+.	O
+
+This	O
+study	O
+provides	O
+an	O
+insight	O
+on	O
+the	O
+various	O
+immune	O
+mediators	O
+detected	O
+in	O
+FCoV	O
+-	O
+positive	O
+cats	B-SPEC
+which	O
+may	O
+be	O
+responsible	O
+for	O
+the	O
+development	B-PROC
+of	O
+FIP	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+continue	O
+to	O
+be	O
+identified	O
+and	O
+with	O
+a	O
+lack	O
+of	O
+effective	O
+clinical	O
+treatment	O
+and	O
+no	O
+preventative	O
+strategies	O
+,	O
+treatment	O
+using	O
+convalescent	O
+plasma	B-ANAT
+or	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+)	O
+is	O
+a	O
+potential	O
+quick	O
+route	O
+to	O
+an	O
+intervention	O
+.	O
+
+Passive	O
+immunotherapy	O
+via	O
+either	O
+convalescent	O
+plasma	B-ANAT
+or	O
+mAbs	O
+has	O
+proven	O
+to	O
+be	O
+effective	O
+for	O
+other	O
+infectious	B-DISO
+agents	O
+.	O
+
+A	O
+decrease	O
+in	O
+gross	O
+pathology	B-DISO
+was	O
+found	O
+only	O
+in	O
+the	O
+mAb	O
+-	O
+treated	O
+group	O
+,	O
+but	O
+no	O
+histological	O
+differences	O
+were	O
+observed	O
+between	O
+treated	O
+and	O
+control	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Lithium	B-CHED
+chloride	I-CHED
+inhibits	O
+early	O
+stages	O
+of	O
+foot	B-SPEC
+-	I-SPEC
+and	I-SPEC
+-	I-SPEC
+mouth	B-ANAT
+disease	I-SPEC
+virus	I-SPEC
+(	O
+FMDV	B-SPEC
+)	O
+replication	O
+in	O
+vitro	O
+.	O
+
+Autopsies	O
+of	O
+patients	O
+that	O
+died	B-PROC
+from	O
+SARS	B-DISO
+also	O
+showed	O
+fibrosis	B-DISO
+to	O
+varying	O
+extents	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+is	O
+the	O
+first	O
+country	O
+-	O
+wide	O
+surveillance	O
+of	O
+bat	B-ENZY
+-	O
+borne	O
+viruses	B-SPEC
+in	O
+Kenya	O
+spanning	O
+from	O
+2012	O
+-	O
+2015	O
+covering	O
+sites	O
+perceived	O
+to	O
+have	O
+medium	O
+to	O
+high	O
+level	O
+bat	B-ENZY
+-	O
+human	B-SPEC
+interaction	O
+.	O
+
+We	O
+captured	O
+two	O
+states	O
+of	O
+the	O
+RBD	O
+with	O
+receptor	B-FUNC
+binding	I-FUNC
+region	O
+either	O
+buried	O
+(	O
+lying	O
+state	O
+)	O
+or	O
+exposed	O
+(	O
+standing	B-PROC
+state	O
+),	O
+demonstrating	O
+an	O
+inherently	O
+flexible	O
+RBD	O
+readily	O
+recognized	O
+by	O
+the	O
+receptor	O
+.	O
+
+Further	O
+sequence	O
+conservation	O
+analysis	O
+of	O
+six	O
+human	B-SPEC
+-	O
+infecting	O
+coronaviruses	O
+revealed	O
+that	O
+the	O
+fusion	O
+peptide	B-CHED
+,	O
+HR1	O
+region	O
+and	O
+the	O
+central	O
+helix	O
+are	O
+potential	O
+targets	O
+for	O
+eliciting	O
+broadly	O
+neutralizing	O
+antibodies	O
+.	O
+
+Coronavirus	B-PRGE
+envelope	B-COMP
+proteins	B-CHED
+specifically	O
+recognized	O
+the	O
+open	O
+APN	O
+form	O
+,	O
+prevented	O
+ectodomain	O
+progression	O
+to	O
+the	O
+closed	O
+form	O
+and	O
+substrate	O
+hydrolysis	O
+.	O
+
+Blocking	B-DISO
+APN	B-PRGE
+dynamics	I-PRGE
+can	O
+thus	O
+be	O
+a	O
+valuable	O
+approach	O
+to	O
+development	B-PROC
+of	O
+drugs	O
+that	O
+target	O
+this	O
+ectoenzyme	O
+.	O
+
+Given	O
+the	O
+on	O
+-	O
+going	O
+risk	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+outbreaks	O
+in	O
+an	O
+era	B-CHED
+of	O
+unprecedented	O
+population	O
+density	O
+,	O
+international	O
+travel	O
+and	O
+human	B-SPEC
+impact	O
+on	O
+the	O
+environment	O
+it	O
+is	O
+pertinent	O
+to	O
+focus	O
+on	O
+improving	O
+the	O
+research	O
+and	O
+development	B-PROC
+landscape	O
+for	O
+treatments	O
+of	O
+emerging	O
+and	O
+epidemic	O
+-	O
+prone	O
+infections	B-DISO
+.	O
+
+This	O
+review	O
+discusses	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+children	O
+and	O
+healthcare	O
+workers	O
+,	O
+especially	O
+pediatric	O
+dentists	O
+,	O
+and	O
+considerations	O
+pertaining	O
+to	O
+pediatric	O
+dentistry	O
+.	O
+
+Included	O
+in	O
+this	O
+retrospective	O
+cohort	O
+study	O
+were	O
+all	O
+polytraumatized	O
+patients	O
+over	O
+18	O
+years	O
+of	O
+age	O
+,	O
+with	O
+an	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+of	O
+at	O
+least	O
+16	O
+,	O
+who	O
+were	O
+admitted	O
+to	O
+our	O
+level	O
+I	O
+trauma	O
+center	O
+over	O
+a	O
+three	O
+-	O
+year	O
+time	O
+period	O
+.	O
+
+In	O
+general	O
+,	O
+ARDS	B-DISO
+was	O
+diagnosed	O
+prior	O
+to	O
+pneumonia	B-DISO
+and	O
+was	O
+therefore	O
+identified	O
+as	O
+its	O
+risk	O
+factor	O
+(	O
+OR	O
+=	O
+11	O
+.	O
+033	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+4	O
+.	O
+812	O
+-	O
+25	O
+.	O
+299	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+RESULTS	O
+:	O
+Two	O
+hundred	O
+and	O
+eighty	O
+-	O
+eight	O
+patients	O
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+.	O
+
+Finally	O
+,	O
+an	O
+overall	O
+mortality	O
+rate	O
+of	O
+21	O
+.	O
+2	O
+%	O
+was	O
+observed	O
+,	O
+which	O
+was	O
+neither	O
+affected	O
+by	O
+thoracic	B-DISO
+trauma	O
+nor	O
+ARDS	B-DISO
+.	O
+
+Any	O
+surviving	O
+virus	B-SPEC
+was	O
+eluted	O
+in	O
+a	O
+buffer	B-CHED
+solution	O
+and	O
+then	O
+titrated	O
+in	O
+swine	B-SPEC
+testicular	O
+cells	B-COMP
+.	O
+
+Both	O
+Weibull	O
+and	O
+log	O
+-	O
+linear	O
+kinetic	O
+models	O
+were	O
+used	O
+to	O
+analyze	O
+virus	B-SPEC
+survival	O
+curves	O
+.	O
+
+At	O
+recommended	O
+concentrations	O
+,	O
+delta	O
+values	O
+(	O
+days	O
+to	O
+decrease	O
+virus	B-SPEC
+concentration	O
+by	O
+1	O
+log	O
+)	O
+ranged	O
+from	O
+0	O
+.	O
+62	O
+-	O
+1	O
+.	O
+72	O
+days	O
+,	O
+but	O
+there	O
+were	O
+no	O
+differences	O
+on	O
+virus	B-SPEC
+survival	O
+among	O
+feed	O
+samples	O
+with	O
+or	O
+without	O
+additives	O
+at	O
+the	O
+manufacturers	O
+recommended	O
+concentrations	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+severe	O
+impairment	B-DISO
+of	O
+gas	B-ENZY
+exchange	O
+.	O
+
+TITLE	O
+:	O
+Pilot	O
+Feasibility	O
+Study	O
+of	O
+Therapeutic	O
+Hypothermia	O
+for	O
+Moderate	O
+to	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Prospective	O
+hypothermia	O
+treatment	O
+in	O
+eight	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+with	O
+PaO2	O
+/	O
+FIO2	O
+less	O
+than	O
+150	O
+receiving	O
+neuromuscular	B-DISO
+blockade	I-DISO
+.	O
+
+Average	O
+patient	O
+core	O
+temperature	O
+was	O
+36	O
+.	O
+7	O
+°	O
+C	O
+(	O
+36	O
+-	O
+37	O
+.	O
+3	O
+°	O
+C	O
+),	O
+and	O
+fever	B-PROC
+occurred	O
+during	O
+neuromuscular	B-DISO
+blockade	I-DISO
+in	O
+30	O
+of	O
+58	O
+retrospective	O
+patients	O
+.	O
+
+Patients	O
+completed	O
+the	O
+Nijmegen	O
+score	O
+and	O
+underwent	O
+a	O
+hyperventilation	O
+provocation	O
+test	O
+(	O
+HVPT	O
+)	O
+and	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+and	O
+cardiopulmonary	B-ANAT
+tests	O
+.	O
+
+Patients	O
+with	O
+HVS	B-FUNC
+were	O
+asked	O
+to	O
+complete	O
+the	O
+Sinonasal	O
+Outcome	O
+Test	O
+(	O
+SNOT	O
+)-	O
+16	O
+questionnaire	O
+before	O
+and	O
+after	O
+a	O
+specific	O
+eight	O
+-	O
+session	O
+respiratory	O
+rehabilitation	O
+program	O
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+and	O
+Outcome	O
+of	O
+Patients	O
+After	O
+Allogeneic	O
+Hematopoietic	B-ANAT
+Stem	I-ANAT
+Cell	I-ANAT
+Transplantation	O
+Treated	O
+With	O
+Extracorporeal	O
+Membrane	O
+Oxygenation	B-PROC
+for	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+The	O
+main	O
+reason	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+was	O
+pneumonia	B-DISO
+in	O
+81	O
+%	O
+of	O
+patients	O
+.	O
+
+Only	O
+one	O
+of	O
+24	O
+patients	O
+(	O
+4	O
+%)	O
+initiated	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+within	O
+240	O
+days	O
+after	O
+allogeneic	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+survived	O
+compared	O
+to	O
+six	O
+of	O
+13	O
+(	O
+46	O
+%)	O
+of	O
+those	O
+treated	O
+thereafter	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Apart	O
+from	O
+such	O
+microbiological	O
+agents	O
+associated	O
+with	O
+enteritis	O
+as	O
+bacteria	B-SPEC
+and	O
+parasites	O
+,	O
+a	O
+lot	O
+of	O
+research	O
+has	O
+been	O
+recently	O
+conducted	O
+on	O
+viral	O
+origin	O
+of	O
+enteric	O
+diseases	O
+.	O
+
+The	O
+present	O
+study	O
+aimed	O
+at	O
+determination	O
+of	O
+the	O
+prevalence	O
+of	O
+four	O
+enteric	O
+viruses	B-SPEC
+,	O
+namely	O
+astrovirus	O
+,	O
+coronavirus	B-SPEC
+,	O
+parvovirus	B-DISO
+and	O
+rotavirus	B-SPEC
+in	O
+meat	O
+-	O
+type	O
+turkey	B-SPEC
+flocks	O
+in	O
+Poland	O
+as	O
+well	O
+as	O
+at	O
+statistical	O
+evaluation	O
+of	O
+the	O
+occurrence	O
+of	O
+the	O
+studied	O
+viruses	B-SPEC
+and	O
+their	O
+relationships	O
+with	O
+the	O
+health	O
+status	O
+and	O
+the	O
+age	O
+of	O
+birds	B-SPEC
+.	O
+
+Different	O
+statistical	O
+methods	O
+(	O
+i	O
+.	O
+e	O
+.	O
+the	O
+independence	O
+chi	B-CHED
+-	O
+square	O
+test	O
+,	O
+the	O
+correspondence	O
+analysis	O
+and	O
+the	O
+logistic	O
+regression	O
+model	O
+)	O
+were	O
+used	O
+to	O
+establish	O
+any	O
+relationships	O
+between	O
+the	O
+analyzed	O
+data	O
+.	O
+
+Overall	O
+,	O
+137	O
+(	O
+66	O
+.	O
+2	O
+%,	O
+95	O
+%	O
+CI	O
+:	O
+59	O
+.	O
+3	O
+-	O
+72	O
+.	O
+6	O
+)	O
+of	O
+the	O
+207	O
+turkey	B-SPEC
+flocks	O
+sampled	O
+were	O
+infected	O
+with	O
+one	O
+or	O
+more	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+No	O
+flock	O
+was	O
+simultaneously	O
+infected	O
+with	O
+all	O
+four	O
+viruses	B-SPEC
+studied	O
+.	O
+
+Young	O
+turkeys	B-SPEC
+aged	O
+1	O
+-	O
+4	O
+weeks	O
+old	O
+had	O
+the	O
+highest	O
+(	O
+82	O
+.	O
+1	O
+%,	O
+95	O
+%	O
+CI	O
+:	O
+71	O
+.	O
+7	O
+-	O
+89	O
+.	O
+8	O
+)	O
+prevalence	O
+of	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+presented	O
+results	O
+provide	O
+valuable	O
+feedback	O
+which	O
+could	O
+help	O
+to	O
+evaluate	O
+the	O
+role	O
+of	O
+some	O
+enteric	O
+viruses	B-SPEC
+in	O
+the	O
+etiology	O
+of	O
+enteritis	B-DISO
+in	O
+turkey	B-SPEC
+.	O
+
+Both	O
+PRESERVE	O
+and	O
+RESP	O
+scores	O
+are	O
+useful	O
+for	O
+predicting	O
+survival	O
+in	O
+Asian	O
+ARDS	O
+patients	O
+,	O
+and	O
+both	O
+scores	O
+had	O
+similar	O
+prognostic	O
+accuracies	O
+in	O
+our	O
+Korean	O
+ARDS	B-DISO
+cohort	O
+.	O
+
+Specific	O
+inhibitors	B-CHED
+for	O
+TGF	O
+-	O
+βRI	O
+,	O
+p38	B-FUNC
+MAPK	B-FUNC
+,	O
+MEK	B-PRGE
+,	O
+and	O
+STAT3	B-PRGE
+proved	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+induced	O
+TGF	O
+-	O
+β1	O
+-	O
+dependent	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+Type	B-PRGE
+I	I-PRGE
+collagen	I-PRGE
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+.	O
+
+To	O
+address	O
+this	O
+paucity	O
+of	O
+data	O
+,	O
+we	O
+sampled	O
+three	O
+bat	B-ENZY
+farms	O
+and	O
+three	O
+wet	O
+markets	O
+trading	O
+in	O
+rat	B-SPEC
+meat	O
+in	O
+the	O
+Mekong	O
+Delta	O
+region	O
+of	O
+southern	O
+Viet	O
+Nam	O
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+that	O
+the	O
+bat	B-ENZY
+paramyxoviruses	O
+and	O
+bat	B-ENZY
+and	O
+rat	B-SPEC
+coronaviruses	O
+were	O
+related	O
+to	O
+viruses	B-SPEC
+circulating	O
+in	O
+bat	B-ENZY
+and	O
+rodent	B-SPEC
+populations	O
+globally	O
+,	O
+but	O
+showed	O
+no	O
+cross	O
+-	O
+species	B-SPEC
+mixing	O
+of	O
+viruses	B-SPEC
+between	O
+bat	B-ENZY
+and	O
+rat	B-SPEC
+populations	O
+within	O
+Viet	O
+Nam	O
+.	O
+
+This	O
+article	O
+describes	O
+the	O
+risk	O
+communication	O
+framework	O
+in	O
+Taiwan	O
+,	O
+which	O
+has	O
+been	O
+used	O
+to	O
+respond	O
+to	O
+the	O
+2009	O
+-	O
+2016	O
+influenza	B-DISO
+epidemics	O
+,	O
+Ebola	O
+in	O
+West	O
+Africa	O
+(	O
+2014	O
+-	O
+16	O
+),	O
+and	O
+MERS	O
+-	O
+CoV	O
+in	O
+South	O
+Korea	O
+(	O
+2015	O
+)	O
+during	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+era	B-CHED
+.	O
+
+Failure	O
+to	O
+prepare	O
+has	O
+deep	O
+costs	O
+in	O
+human	B-SPEC
+lives	O
+and	O
+economic	O
+productivity	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+test	O
+DE	O
+as	O
+adjuvant	B-CHED
+in	O
+an	O
+Ark	B-PRGE
+-	O
+DPI	O
+live	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccine	O
+after	O
+ocular	B-PROC
+or	O
+spray	O
+application	O
+.	O
+
+These	O
+proteases	O
+share	O
+in	O
+processing	O
+MERS	O
+CoV	O
+polyproteins	O
+at	O
+different	O
+sites	O
+to	O
+yield	O
+16	O
+nonstructural	O
+proteins	B-CHED
+.	O
+
+In	O
+this	O
+work	O
+,	O
+we	O
+provide	O
+evidence	O
+that	O
+MERS	O
+CoV	O
+3CLpro	O
+and	O
+PLpro	O
+are	O
+subject	O
+to	O
+different	O
+genetic	O
+and	O
+evolutionary	O
+influences	O
+that	O
+shape	O
+the	O
+protein	B-CHED
+sequence	O
+,	O
+codon	O
+usage	O
+pattern	O
+,	O
+and	O
+codon	O
+usage	O
+bias	B-SPEC
+.	O
+
+TITLE	O
+:	O
+C	B-PRGE
+-	I-PRGE
+C	I-PRGE
+Motif	I-PRGE
+Chemokine	I-PRGE
+Ligand	I-PRGE
+2	I-PRGE
+(	O
+CCL2	B-PRGE
+)	O
+Mediates	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Induced	O
+by	O
+Lethal	O
+Influenza	B-DISO
+H7N9	O
+Virus	O
+.	O
+
+Most	O
+H7N9	O
+infections	B-DISO
+resulted	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+is	O
+a	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+that	O
+contributes	O
+to	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+findings	O
+demonstrate	O
+that	O
+CCL2	B-PRGE
+is	O
+essential	O
+for	O
+H7N9	O
+virus	B-DISO
+infection	I-DISO
+and	O
+thus	O
+that	O
+it	O
+is	O
+a	O
+potential	O
+therapeutic	O
+target	O
+for	O
+influenza	B-DISO
+.	O
+
+TITLE	O
+:	O
+Two	O
+deletion	O
+variants	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+found	O
+in	O
+a	O
+patient	O
+with	O
+characteristic	O
+symptoms	O
+.	O
+
+We	O
+used	O
+adult	O
+C57Bl6	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+knock	O
+-	O
+out	O
+(	O
+IL	O
+-	O
+6KO	O
+)	O
+mice	B-SPEC
+.	O
+
+The	O
+animals	B-SPEC
+received	O
+intravenous	O
+recombinant	B-PRGE
+human	I-PRGE
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+(	O
+rHuIL	O
+-	O
+6	O
+)	O
+or	O
+vehicle	O
+followed	O
+by	O
+intratracheal	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)	O
+or	O
+saline	O
+before	O
+undergoing	O
+low	O
+tidal	O
+volume	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+)	O
+for	O
+5	O
+h	O
+.	O
+Before	O
+sacrifice	O
+,	O
+right	O
+ventricular	B-ANAT
+systolic	O
+pressure	O
+and	O
+cardiac	B-ANAT
+output	O
+were	O
+measured	O
+and	O
+total	O
+pulmonary	B-ANAT
+resistance	B-PROC
+was	O
+calculated	O
+.	O
+
+TITLE	O
+:	O
+A	O
+metagenomics	O
+study	O
+for	O
+the	O
+identification	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+mixed	O
+clinical	O
+specimens	O
+:	O
+an	O
+application	O
+of	O
+the	O
+iterative	O
+mapping	O
+approach	O
+.	O
+
+We	O
+analyzed	O
+40	O
+clinical	O
+specimens	O
+from	O
+hospitalized	O
+children	O
+diagnosed	O
+with	O
+acute	B-DISO
+bronchiolitis	I-DISO
+,	O
+croup	B-DISO
+,	O
+or	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+which	O
+virus	B-SPEC
+identification	O
+by	O
+viral	O
+culture	O
+or	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+was	O
+unsuccessful	O
+.	O
+
+Neither	O
+seven	O
+of	O
+the	O
+nine	O
+viremic	O
+cats	B-SPEC
+with	O
+follow	O
+-	O
+up	O
+nor	O
+the	O
+single	O
+cat	B-SPEC
+with	O
+replicating	O
+FCoV	O
+with	O
+positive	O
+qRT	O
+-	O
+PCR	O
+results	O
+developed	O
+signs	O
+compatible	O
+with	O
+FIP	B-DISO
+within	O
+6	O
+months	O
+of	O
+sample	O
+collection	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+typically	O
+manifested	O
+by	O
+refractory	O
+hypoxemia	O
+with	O
+high	O
+mortality	O
+.	O
+
+Lastly	O
+,	O
+prevention	O
+of	O
+aspiration	B-DISO
+,	O
+stress	B-DISO
+ulcers	I-DISO
+,	O
+deep	B-DISO
+vein	I-DISO
+thrombosis	I-DISO
+,	O
+catheter	B-DISO
+-	I-DISO
+related	I-DISO
+infection	I-DISO
+,	O
+overhydration	B-DISO
+,	O
+and	O
+heavy	O
+sedation	B-DISO
+is	O
+essential	O
+to	O
+achieve	O
+better	O
+outcomes	O
+in	O
+ARDS	B-DISO
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+this	O
+finding	O
+,	O
+a	O
+series	O
+of	O
+novel	O
+1	O
+,	O
+4	O
+-	O
+pentadien	O
+-	O
+3	O
+-	O
+one	O
+derivatives	O
+containing	O
+a	O
+1	B-CHED
+,	I-CHED
+3	I-CHED
+,	I-CHED
+4	I-CHED
+-	I-CHED
+thiadiazole	I-CHED
+moiety	O
+were	O
+designed	O
+and	O
+synthesized	O
+,	O
+and	O
+their	O
+structures	O
+confirmed	O
+by	O
+IR	O
+,	O
+¹H	O
+-	O
+NMR	O
+,	O
+and	O
+
+ABSTRACT	O
+:	O
+There	O
+are	O
+a	O
+large	O
+number	O
+of	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+systems	O
+and	O
+configurations	O
+.	O
+
+However	O
+,	O
+two	O
+deletions	O
+in	O
+two	O
+respective	O
+loops	O
+located	O
+in	O
+HKU5	B-PRGE
+-	I-PRGE
+CTD	I-PRGE
+result	O
+in	O
+conformational	O
+variations	O
+in	O
+CD26	O
+-	O
+binding	B-FUNC
+interface	O
+and	O
+are	O
+responsible	O
+for	O
+the	O
+non	O
+-	O
+binding	B-FUNC
+of	O
+HKU5	O
+-	O
+CTD	O
+to	O
+CD26	B-PRGE
+.	O
+
+This	O
+study	O
+concluded	O
+that	O
+the	O
+CFS	B-DISO
+of	O
+all	O
+tested	O
+lactobacilli	O
+,	O
+and	O
+live	O
+Lact	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+4	O
+hours	O
+of	O
+normothermic	O
+EVLP	O
+would	O
+improve	O
+compliance	O
+and	O
+oxygenation	B-PROC
+in	O
+a	O
+porcine	B-SPEC
+model	O
+of	O
+sepsis	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+latter	O
+function	O
+involves	O
+reversing	O
+the	O
+post	B-PROC
+-	I-PROC
+translational	I-PROC
+modification	I-PROC
+of	O
+cellular	B-COMP
+proteins	B-CHED
+conjugated	O
+with	O
+either	O
+ubiquitin	B-PROC
+(	O
+Ub	B-PROC
+)	O
+or	O
+Ub	B-PROC
+-	O
+like	O
+interferon	B-PRGE
+-	I-PRGE
+stimulated	I-PRGE
+gene	I-PRGE
+product	I-PRGE
+15	I-PRGE
+(	O
+ISG15	B-PRGE
+).	O
+
+It	O
+has	O
+been	O
+described	O
+in	O
+several	O
+diseases	O
+like	O
+asthma	B-PATH
+,	O
+cystic	B-DISO
+fibrosis	I-DISO
+,	I-DISO
+pulmonary	I-DISO
+infection	B-DISO
+,	O
+cyanotic	B-DISO
+congenital	I-DISO
+heart	I-DISO
+disease	I-DISO
+and	O
+in	O
+few	O
+young	O
+children	O
+with	O
+homozygous	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+Realization	O
+of	O
+fiberoptic	O
+bronchoscopy	O
+to	O
+diagnose	O
+endobronchial	O
+injury	O
+and	O
+preventive	O
+measures	O
+such	O
+as	O
+fluidification	O
+of	O
+sputum	B-ANAT
+at	O
+the	O
+early	O
+stage	O
+of	O
+thoracic	B-DISO
+vaso	O
+-	O
+occlusive	O
+crisis	O
+are	O
+essential	O
+.	O
+
+Sepsis	B-DISO
+is	O
+one	O
+of	O
+the	O
+most	O
+prevalent	O
+causes	O
+of	O
+this	O
+condition	B-DISO
+(	O
+30	O
+-	O
+50	O
+%).	O
+
+Despite	O
+these	O
+complications	O
+,	O
+some	O
+studies	O
+have	O
+shown	O
+a	O
+decrease	O
+in	O
+the	O
+rates	O
+of	O
+orotracheal	O
+intubation	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+low	O
+severity	O
+scores	O
+,	O
+hemodynamic	B-PROC
+stability	O
+,	O
+and	O
+the	O
+absence	O
+of	O
+other	O
+organ	B-ANAT
+dysfunctions	O
+.	O
+
+Lymphocytosis	B-DISO
+was	O
+not	O
+a	O
+feature	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+RESULTS	O
+:	O
+During	O
+the	O
+21	O
+days	O
+of	O
+observation	O
+,	O
+there	O
+was	O
+no	O
+significant	O
+change	O
+in	O
+the	O
+hepatic	B-ANAT
+panel	O
+or	O
+creatinine	B-CHED
+tests	O
+.	O
+
+TITLE	O
+:	O
+Plasminogen	B-PRGE
+Activator	O
+Inhibitor	B-PRGE
+-	I-PRGE
+1	I-PRGE
+Is	O
+Critical	O
+in	O
+Alcohol	O
+-	O
+Enhanced	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+in	O
+Mice	B-SPEC
+.	O
+
+Apart	O
+from	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+insectivorous	O
+bats	B-SPEC
+are	O
+suggested	O
+as	O
+another	O
+natural	O
+reservoir	O
+for	O
+MERS	O
+-	O
+like	O
+-	O
+CoVs	O
+.	O
+
+In	O
+the	O
+insectivorous	O
+bats	B-SPEC
+,	O
+however	O
+,	O
+DPP4	B-PRGE
+expression	B-PROC
+in	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+was	O
+almost	O
+absent	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+is	O
+a	O
+porcine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+which	O
+causes	O
+lethal	O
+severe	O
+watery	B-DISO
+diarrhea	I-DISO
+in	O
+piglets	O
+.	O
+
+RESULTS	O
+:	O
+Median	O
+age	O
+of	O
+ARDS	B-DISO
+patients	O
+was	O
+58	O
+years	O
+,	O
+69	O
+%	O
+were	O
+male	O
+.	O
+
+This	O
+study	O
+evaluated	O
+the	O
+efficacy	O
+of	O
+aerosolized	O
+tobramycin	B-CHED
+for	O
+P	O
+.	O
+aeruginosa	O
+VAP	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Virucidal	O
+Activity	O
+of	O
+World	O
+Health	O
+Organization	O
+-	O
+Recommended	O
+Formulations	O
+Against	O
+Enveloped	O
+Viruses	B-SPEC
+,	O
+Including	O
+Zika	O
+,	O
+Ebola	O
+,	O
+and	O
+Emerging	O
+Coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Synthesis	B-PROC
+and	O
+evaluation	O
+of	O
+new	O
+scaffold	O
+phenylisoserine	O
+derivatives	O
+connected	O
+with	O
+the	O
+essential	O
+functional	O
+groups	O
+against	O
+SARS	B-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+are	O
+described	O
+.	O
+
+When	O
+adjuvanted	O
+with	O
+aluminum	B-CHED
+hydroxide	I-CHED
+,	O
+this	O
+protein	B-CHED
+elicited	O
+high	O
+neutralizing	O
+antibody	B-COMP
+titers	O
+and	O
+high	O
+RBD	O
+-	O
+specific	O
+antibody	B-COMP
+titers	O
+.	O
+
+HFNC	O
+can	O
+provide	O
+well	O
+heated	O
+and	O
+humidified	O
+high	O
+flow	O
+gas	B-ENZY
+with	O
+a	O
+high	O
+concentration	O
+of	O
+oxygen	B-CHED
+,	O
+which	O
+can	O
+improve	O
+the	O
+oxygenation	B-PROC
+and	O
+degree	O
+of	O
+comfort	O
+of	O
+patients	O
+after	O
+extubation	O
+.	O
+
+If	O
+it	O
+is	O
+not	O
+treated	O
+in	O
+time	O
+,	O
+it	O
+will	O
+progress	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+will	O
+be	O
+a	O
+serious	O
+threat	O
+to	O
+the	O
+lives	O
+of	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Use	O
+of	O
+GMP	B-CHED
+-	O
+Produced	O
+Bone	B-ANAT
+Marrow	I-ANAT
+-	O
+Derived	O
+Stem	B-ANAT
+Cells	I-ANAT
+in	O
+Combination	O
+with	O
+Extracorporeal	O
+Membrane	B-ANAT
+Oxygenation	B-PROC
+in	O
+ARDS	B-DISO
+:	O
+An	O
+Animal	B-SPEC
+Model	O
+.	O
+
+A	O
+total	O
+of	O
+11	O
+sheep	B-SPEC
+were	O
+used	O
+.	O
+
+The	O
+respiratory	O
+parameters	O
+by	O
+means	O
+of	O
+blood	B-PROC
+gas	B-ENZY
+results	O
+,	O
+measurements	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+inflammatory	B-DISO
+responses	I-DISO
+,	O
+and	O
+integrity	O
+of	O
+the	O
+alveolar	B-ANAT
+capillary	B-ANAT
+barrier	O
+after	O
+the	O
+infusion	O
+of	O
+these	O
+cells	B-COMP
+were	O
+analyzed	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+still	O
+unclear	O
+whether	O
+EGFR	B-FUNC
+inhibition	B-PROC
+can	O
+prevent	O
+ALI	O
+.	O
+
+TITLE	O
+:	O
+Anticoagulation	B-PROC
+and	O
+Transfusions	O
+Management	O
+in	O
+Veno	O
+-	O
+Venous	B-ANAT
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+for	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+:	O
+Assessment	O
+of	O
+Factors	O
+Associated	O
+With	O
+Transfusion	O
+Requirements	O
+and	O
+Mortality	O
+.	O
+
+We	O
+targeted	B-PROC
+an	O
+activated	O
+partial	O
+thromboplastin	B-PRGE
+time	O
+of	O
+40	O
+to	O
+50	O
+seconds	O
+and	O
+a	O
+hematocrit	O
+of	O
+24	O
+%	O
+to	O
+30	O
+%.	O
+
+Additionally	O
+,	O
+ileum	B-ANAT
+gas	B-ENZY
+was	O
+detected	O
+for	O
+ten	O
+of	O
+the	O
+sixteen	O
+cases	O
+in	O
+the	O
+upper	B-ANAT
+abdomen	I-ANAT
+during	O
+assessment	O
+with	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+.	O
+
+In	O
+summary	O
+,	O
+our	O
+study	O
+described	O
+HS	O
+/	O
+DS	O
+cases	O
+with	O
+pulmonary	B-ANAT
+manifestations	O
+including	O
+,	O
+ARDS	B-DISO
+,	O
+bacterial	B-DISO
+pneumonia	I-DISO
+and	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Bivariate	O
+logistic	O
+analysis	O
+showed	O
+that	O
+mortality	O
+and	O
+worse	O
+outcomes	O
+were	O
+correlated	O
+with	O
+FFP	O
+transfusion	O
+and	O
+Glasgow	O
+Coma	B-DISO
+Scale	O
+score	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+hCoVs	O
+)	O
+can	O
+be	O
+divided	O
+into	O
+low	O
+pathogenic	O
+and	O
+highly	O
+pathogenic	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+The	O
+ICM	B-COMP
+research	O
+agenda	O
+on	O
+extracorporeal	O
+life	O
+support	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+concisely	O
+describe	O
+the	O
+current	O
+standards	O
+of	O
+care	O
+,	O
+major	O
+recent	O
+advances	O
+,	O
+common	O
+beliefs	O
+that	O
+have	O
+been	O
+contradicted	O
+by	O
+recent	O
+trials	O
+,	O
+areas	O
+of	O
+uncertainty	O
+,	O
+and	O
+clinical	O
+studies	O
+that	O
+need	O
+to	O
+be	O
+performed	O
+over	O
+the	O
+next	O
+decade	O
+and	O
+their	O
+expected	O
+outcomes	O
+with	O
+regard	O
+to	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+In	O
+patients	O
+with	O
+cardiogenic	B-DISO
+shock	I-DISO
+,	O
+short	O
+-	O
+term	O
+veno	O
+-	O
+arterial	B-ANAT
+ECMO	O
+(	O
+VA	O
+-	O
+ECMO	O
+)	O
+provides	O
+both	O
+pulmonary	B-ANAT
+and	O
+circulatory	B-PROC
+support	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+a	O
+causative	O
+agent	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+,	O
+causes	O
+economic	O
+loss	O
+in	O
+the	O
+global	O
+swine	B-SPEC
+industry	O
+.	O
+
+Vero	B-ANAT
+cell	I-ANAT
+,	O
+an	O
+African	B-SPEC
+green	I-SPEC
+monkey	I-SPEC
+kidney	B-ANAT
+cell	I-ANAT
+line	O
+,	O
+has	O
+been	O
+commonly	O
+used	O
+to	O
+isolate	O
+and	O
+propagate	O
+PEDV	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+observed	O
+that	O
+human	B-SPEC
+embryonic	B-ANAT
+kidney	B-ANAT
+293	O
+(	O
+HEK293	O
+)	O
+cells	B-COMP
+were	O
+susceptible	O
+to	O
+infection	B-DISO
+with	O
+PEDV	B-SPEC
+vaccine	O
+strain	O
+CV777	O
+(	O
+G1	O
+subtype	O
+)	O
+and	O
+field	O
+isolate	O
+LNCT2	O
+(	O
+G2	O
+subtype	O
+).	O
+
+Taken	O
+together	O
+,	O
+our	O
+findings	O
+suggest	O
+that	O
+HEK293	O
+cells	O
+can	O
+be	O
+efficiently	O
+infected	O
+by	O
+PEDV	B-SPEC
+,	O
+which	O
+might	O
+provide	O
+a	O
+useful	O
+tool	O
+for	O
+understanding	O
+the	O
+fundamental	O
+mechanisms	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+vitro	O
+.	O
+
+The	O
+article	O
+examines	O
+two	O
+recent	O
+cases	O
+:	O
+the	O
+first	O
+detection	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+outbreak	O
+in	O
+Saudi	O
+Arabia	O
+,	O
+and	O
+the	O
+first	O
+months	O
+of	O
+the	O
+Ebola	O
+outbreak	O
+in	O
+Guinea	B-SPEC
+.	O
+
+The	O
+article	O
+argues	O
+that	O
+to	O
+realize	O
+the	O
+full	O
+potential	O
+of	O
+a	O
+transparent	O
+disease	O
+outbreak	O
+reporting	O
+process	O
+,	O
+there	O
+is	O
+a	O
+need	O
+for	O
+a	O
+human	B-SPEC
+rights	O
+framework	O
+that	O
+expressly	O
+articulates	O
+its	O
+right	O
+to	O
+receive	O
+reports	O
+and	O
+outlines	O
+appropriate	O
+behaviour	B-PROC
+for	O
+the	O
+WHO	O
+,	O
+states	O
+,	O
+and	O
+non	O
+-	O
+state	O
+actors	O
+.	O
+
+Multiplex	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+was	O
+done	O
+to	O
+identify	O
+the	O
+viruses	B-SPEC
+in	O
+the	O
+samples	O
+.	O
+
+Human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+)	O
+was	O
+the	O
+predominant	O
+virus	B-SPEC
+detected	O
+in	O
+25	O
+.	O
+7	O
+per	O
+cent	O
+children	O
+followed	O
+by	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+,	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+)	O
+and	O
+human	B-SPEC
+adenovirus	B-DISO
+(	O
+HAdV	O
+)	O
+in	O
+19	O
+.	O
+9	O
+,	O
+11	O
+.	O
+0	O
+and	O
+8	O
+.	O
+8	O
+per	O
+cent	O
+children	O
+,	O
+respectively	O
+.	O
+
+The	O
+HMPV	B-SPEC
+was	O
+at	O
+its	O
+peak	O
+in	O
+February	O
+2013	O
+,	O
+HAdV	O
+showed	O
+two	O
+peaks	O
+in	O
+March	O
+-	O
+April	O
+,	O
+2012	O
+and	O
+November	O
+2012	O
+-	O
+March	O
+2013	O
+while	O
+HRV	O
+was	O
+detected	O
+throughout	O
+the	O
+year	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+overall	O
+positivity	O
+for	O
+viruses	B-SPEC
+in	O
+the	O
+study	O
+was	O
+found	O
+to	O
+be	O
+72	O
+.	O
+9	O
+per	O
+cent	O
+with	O
+a	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+rate	O
+of	O
+19	O
+.	O
+5	O
+per	O
+cent	O
+.	O
+
+A	O
+number	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+outbreaks	O
+have	O
+been	O
+linked	O
+to	O
+healthcare	O
+facilities	O
+.	O
+
+Information	O
+technology	O
+,	O
+laboratory	O
+preparedness	O
+,	O
+clinical	O
+and	O
+public	O
+health	O
+management	O
+,	O
+and	O
+infection	B-DISO
+control	O
+preparedness	O
+provide	O
+a	O
+comprehensive	O
+and	O
+generalizable	O
+preparedness	O
+plan	B-DISO
+for	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+Serological	O
+evidence	O
+of	O
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+native	O
+hamadryas	B-SPEC
+baboons	I-SPEC
+(	O
+Papio	B-SPEC
+hamadryas	I-SPEC
+hamadryas	I-SPEC
+)	O
+of	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+There	O
+are	O
+no	O
+peer	O
+-	O
+reviewed	O
+publications	O
+on	O
+viral	B-DISO
+infections	I-DISO
+of	O
+the	O
+baboons	B-SPEC
+of	O
+KSA	O
+.	O
+
+One	O
+of	O
+these	O
+may	O
+be	O
+the	O
+fibromyalgia	B-DISO
+syndrome	I-DISO
+,	O
+a	O
+chronic	O
+painful	B-DISO
+disorder	O
+for	O
+which	O
+no	O
+satisfactory	O
+treatment	O
+exists	O
+.	O
+
+Should	O
+fibromyalgia	O
+and	O
+acute	B-DISO
+mountain	I-DISO
+sickness	I-DISO
+have	O
+a	O
+common	O
+etiology	O
+,	O
+may	O
+they	O
+also	O
+share	O
+a	O
+common	O
+form	O
+of	O
+treatment	O
+?	O
+
+In	O
+LPS	B-DISO
+-	O
+treated	O
+Raw264	O
+.	O
+7	O
+macrophages	B-ANAT
+,	O
+miR	O
+-	O
+19	O
+mimics	O
+blocking	B-DISO
+the	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+LPS	B-DISO
+-	O
+induced	O
+p47phox	B-PRGE
+expression	B-PROC
+,	O
+the	O
+accumulation	O
+of	O
+ROS	B-CHED
+,	O
+and	O
+the	O
+release	B-PATH
+of	O
+inflammatory	O
+cytokines	O
+.	O
+
+We	O
+found	O
+that	O
+the	O
+accumulation	O
+of	O
+ROS	B-CHED
+inhibited	O
+the	O
+LPS	B-DISO
+-	O
+induced	O
+release	B-PATH
+of	O
+inflammatory	O
+cytokines	O
+,	O
+the	O
+upregulation	B-PROC
+of	O
+miR	B-PRGE
+-	I-PRGE
+19	I-PRGE
+and	O
+the	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+LPS	B-DISO
+-	O
+induced	O
+p47phox	B-PRGE
+expression	B-PROC
+.	O
+
+Finally	O
+,	O
+we	O
+constructed	O
+a	O
+p47phox	B-PRGE
+3	I-PRGE
+'	I-PRGE
+UTR	I-PRGE
+luciferase	I-PRGE
+reporter	O
+plasmid	O
+to	O
+provide	O
+direct	O
+confirmation	O
+that	O
+miR	B-PRGE
+-	I-PRGE
+19	I-PRGE
+targets	O
+p47phox	B-PRGE
+expression	B-PROC
+.	O
+
+Age	O
+<	O
+2	O
+years	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+=	O
+5	O
+.	O
+0	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+9	O
+-	O
+13	O
+.	O
+1	O
+)	O
+and	O
+cardiovascular	B-ANAT
+(	O
+OR	O
+=	O
+3	O
+.	O
+9	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+6	O
+-	O
+9	O
+.	O
+5	O
+),	O
+genetic	O
+/	O
+congenital	O
+(	O
+OR	O
+=	O
+2	O
+.	O
+8	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+1	O
+-	O
+7	O
+.	O
+0	O
+),	O
+and	O
+respiratory	O
+chronic	O
+complex	O
+conditions	O
+([	O
+CCCs	B-CHED
+]	O
+OR	O
+=	O
+4	O
+.	O
+5	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+7	O
+-	O
+12	O
+.	O
+0	O
+)	O
+were	O
+associated	O
+with	O
+receiving	O
+respiratory	O
+support	O
+.	O
+
+A	O
+57	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+rapidly	O
+had	O
+severe	O
+vomiting	B-DISO
+and	O
+diarrhea	B-DISO
+2	O
+h	O
+after	O
+a	O
+meal	O
+.	O
+
+Brain	B-ANAT
+magnetic	O
+resonance	O
+imaging	O
+(	O
+MRI	O
+)	O
+showed	O
+a	O
+heart	B-ANAT
+-	O
+shaped	O
+region	O
+of	O
+diffusion	O
+abnormality	O
+,	O
+characteristic	O
+of	O
+BMP	B-PRGE
+infarction	B-DISO
+.	O
+
+After	O
+admission	O
+,	O
+she	O
+had	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+required	O
+intubation	O
+.	O
+
+Lumbar	B-ANAT
+puncture	O
+was	O
+evaluated	O
+for	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+,	O
+but	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+protein	B-CHED
+concentration	O
+was	O
+normal	O
+.	O
+
+Severe	O
+ARDS	B-DISO
+survivors	O
+admitted	O
+to	O
+two	O
+ICUs	O
+in	O
+China	O
+between	O
+January	O
+2012	O
+and	O
+January	O
+2014	O
+were	O
+enrolled	O
+.	O
+
+Two	O
+hours	O
+following	O
+the	O
+injury	O
+,	O
+decreased	O
+mean	O
+arterial	B-ANAT
+blood	I-ANAT
+pressure	O
+(	O
+60	O
+-	O
+70	O
+mmHg	O
+)	O
+and	O
+cardiac	B-ANAT
+index	O
+(<	O
+2	O
+L	O
+.	O
+min	O
+-	O
+1	O
+.	O
+m	O
+-	O
+2	O
+)	O
+were	O
+observed	O
+in	O
+the	O
+animals	B-SPEC
+in	O
+the	O
+SS	O
+group	O
+,	O
+while	O
+systemic	B-PROC
+vascular	I-PROC
+resistance	I-PROC
+index	O
+was	O
+increased	O
+.	O
+
+Severe	O
+lung	B-ANAT
+injury	O
+in	O
+the	O
+SS	O
+group	O
+was	O
+confirmed	O
+by	O
+the	O
+histopathology	O
+evaluations	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+novel	O
+porcine	B-SPEC
+model	O
+of	O
+septic	B-DISO
+shock	I-DISO
+induced	O
+by	O
+ARDS	B-DISO
+due	O
+to	O
+severe	O
+MRSA	B-DISO
+pneumonia	I-DISO
+with	O
+characteristic	O
+hyperdynamic	O
+and	O
+hypodynamic	O
+phases	O
+in	O
+24	O
+h	O
+,	O
+which	O
+mimicked	O
+the	O
+hemodynamic	B-PROC
+changing	O
+of	O
+septic	B-DISO
+shock	I-DISO
+in	O
+human	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+Predictive	O
+Value	O
+of	O
+Coefficient	O
+of	O
+PCT	B-DISO
+×	O
+BG	O
+for	O
+Anastomotic	B-DISO
+Leak	I-DISO
+in	O
+Esophageal	B-DISO
+Carcinoma	I-DISO
+Patients	O
+With	O
+ARDS	O
+After	O
+Esophagectomy	O
+.	O
+
+Clinical	O
+data	O
+were	O
+collected	O
+from	O
+the	O
+patients	O
+'	O
+electronic	O
+medical	O
+records	O
+,	O
+including	O
+their	O
+clinically	O
+hematological	O
+examination	O
+,	O
+drainage	O
+fluid	O
+cultures	O
+,	O
+and	O
+sputum	B-ANAT
+culture	O
+.	O
+
+Inflammatory	O
+markers	O
+,	O
+such	O
+as	O
+CRP	B-PRGE
+,	O
+PCT	B-DISO
+,	O
+and	O
+the	O
+coefficient	O
+of	O
+BG	O
+and	O
+PCT	B-DISO
+,	O
+were	O
+significantly	O
+different	O
+between	O
+the	O
+2	O
+groups	O
+.	O
+
+Enrichment	O
+blood	B-ANAT
+culture	O
+/	O
+PCR	O
+using	O
+We	O
+conclude	O
+that	O
+microbiological	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+
+Moreover	O
+,	O
+this	O
+new	O
+assay	O
+enables	O
+the	O
+assessment	O
+of	O
+viral	O
+load	O
+measurement	O
+which	O
+might	O
+be	O
+useful	O
+for	O
+epidemiology	O
+and	O
+pathogenesis	B-DISO
+studies	O
+.	O
+
+ICC	B-DISO
+was	O
+carried	O
+out	O
+as	O
+avidin	O
+-	O
+biotin	B-CHED
+complex	O
+method	O
+.	O
+
+ABSTRACT	O
+:	O
+Fulminant	B-DISO
+hepatitis	I-DISO
+(	O
+FH	O
+)	O
+is	O
+characterized	O
+by	O
+rapid	O
+liver	B-DISO
+failure	I-DISO
+and	O
+high	O
+mortality	O
+.	O
+
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+is	O
+a	O
+member	O
+of	O
+the	O
+IL	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+related	I-PRGE
+cytokines	I-PRGE
+,	O
+considered	O
+to	O
+be	O
+an	O
+""""	O
+alarmin	O
+""""	O
+that	O
+participates	O
+in	O
+various	O
+diseases	O
+,	O
+but	O
+its	O
+precise	O
+role	O
+in	O
+the	O
+coagulation	B-PROC
+of	O
+FH	O
+is	O
+not	O
+very	O
+clear	O
+.	O
+
+Our	O
+studies	O
+showed	O
+that	O
+IL	O
+-	O
+33	O
+administration	O
+in	O
+a	O
+MHV	B-SPEC
+-	O
+3	O
+infection	B-DISO
+promoted	O
+survival	O
+during	O
+FH	O
+,	O
+with	O
+a	O
+significant	O
+reduction	O
+in	O
+FGL2	B-PRGE
+expression	B-PROC
+and	O
+liver	B-ANAT
+inflammation	B-DISO
+.	O
+
+The	O
+current	O
+study	O
+indicates	O
+that	O
+considerable	O
+differences	O
+in	O
+immunocompetence	B-PROC
+may	O
+exist	O
+between	O
+commercial	O
+layer	B-ANAT
+lines	O
+used	O
+in	O
+organic	O
+production	O
+.	O
+
+ABSTRACT	O
+:	O
+CNS	B-CHED
+inflammation	B-DISO
+resulting	O
+from	O
+infection	B-DISO
+,	O
+injury	O
+,	O
+or	O
+neurodegeneration	B-DISO
+leads	O
+to	O
+accumulation	O
+of	O
+diverse	O
+B	B-ANAT
+cell	I-ANAT
+subsets	O
+.	O
+
+Although	O
+antibody	B-ANAT
+secreting	B-PROC
+cells	B-COMP
+(	O
+ASC	O
+)	O
+within	O
+the	O
+inflamed	O
+CNS	B-CHED
+have	O
+been	O
+extensively	O
+examined	O
+,	O
+memory	B-ANAT
+B	I-ANAT
+cell	B-COMP
+(	O
+Bmem	O
+)	O
+characterization	O
+has	O
+been	O
+limited	O
+as	O
+they	O
+do	O
+not	O
+secrete	B-PROC
+antibody	B-COMP
+without	O
+stimulation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Simultaneous	O
+enumeration	O
+of	O
+antigen	B-CHED
+-	O
+specific	O
+Bmem	O
+and	O
+ASC	O
+using	O
+the	O
+Bmem	O
+assay	O
+optimized	O
+for	O
+CNS	B-CHED
+-	O
+derived	O
+cells	B-COMP
+enables	O
+characterization	O
+of	O
+temporal	O
+changes	O
+during	O
+microbial	O
+or	O
+auto	O
+-	O
+antigen	B-CHED
+induced	O
+neuroinflammation	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+highly	O
+prevalent	O
+in	O
+chicken	B-SPEC
+populations	O
+and	O
+is	O
+responsible	O
+for	O
+severe	O
+economic	O
+losses	O
+to	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+The	O
+genome	O
+of	O
+strain	O
+CU	O
+/	O
+1	O
+/	O
+2014	O
+is	O
+closely	O
+related	O
+to	O
+vaccine	O
+strain	O
+H120	O
+but	O
+showed	O
+genome	O
+-	O
+wide	O
+point	O
+mutations	O
+that	O
+lead	O
+to	O
+27	O
+,	O
+14	O
+,	O
+11	O
+,	O
+1	O
+,	O
+1	O
+,	O
+2	O
+,	O
+2	O
+,	O
+and	O
+2	O
+amino	B-CHED
+acid	I-CHED
+differences	O
+between	O
+the	O
+two	O
+strains	O
+in	O
+1a	O
+,	O
+1b	O
+,	O
+S	O
+,	O
+3a	O
+,	O
+M	O
+,	O
+4b	O
+,	O
+4c	O
+,	O
+and	O
+N	O
+proteins	B-CHED
+,	O
+respectively	O
+,	O
+suggesting	O
+that	O
+strain	O
+CU	O
+/	O
+1	O
+/	O
+2014	O
+is	O
+probably	O
+a	O
+revertant	O
+of	O
+the	O
+vaccine	O
+strain	O
+H120	O
+and	O
+evolved	O
+by	O
+accumulation	O
+of	O
+point	B-PROC
+mutations	I-PROC
+.	O
+
+Recombination	B-PROC
+analysis	O
+of	O
+strain	O
+CU	O
+/	O
+4	O
+/	O
+2014	O
+showed	O
+evidence	O
+for	O
+recombination	B-PROC
+from	O
+at	O
+least	O
+three	O
+different	O
+IBV	B-SPEC
+strains	O
+,	O
+namely	O
+,	O
+the	O
+Italian	O
+strain	O
+90254	O
+/	O
+2005	O
+(	O
+QX	O
+-	O
+like	O
+strain	O
+),	O
+4	O
+/	O
+91	O
+,	O
+and	O
+H120	O
+.	O
+
+In	O
+addition	O
+to	O
+lung	B-ANAT
+protection	O
+ventilator	O
+strategies	O
+and	O
+bronchoscopy	O
+,	O
+intrapulmonary	O
+percussive	O
+ventilation	O
+was	O
+initiated	O
+to	O
+facilitate	O
+lung	B-ANAT
+recruitment	B-DISO
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+as	O
+a	O
+treatment	O
+strategy	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+the	O
+low	O
+tidal	O
+volume	O
+era	B-CHED
+:	O
+A	O
+systematic	O
+review	O
+.	O
+
+Electronic	O
+databases	O
+were	O
+searched	O
+for	O
+studies	O
+of	O
+at	O
+least	O
+10	O
+adult	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+comparing	O
+the	O
+use	O
+of	O
+ECMO	O
+with	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+to	O
+mechanical	O
+ventilation	O
+with	O
+a	O
+low	O
+tidal	O
+volume	O
+alone	O
+.	O
+
+Future	O
+studies	O
+on	O
+the	O
+use	O
+of	O
+ECMO	O
+for	O
+severe	O
+ARDS	B-DISO
+are	O
+needed	O
+to	O
+clarify	O
+the	O
+role	O
+of	O
+ECMO	O
+in	O
+this	O
+disease	O
+.	O
+
+In	O
+contrast	O
+to	O
+our	O
+hypothesis	O
+,	O
+anthropogenic	O
+habitat	O
+disturbance	O
+was	O
+not	O
+associated	O
+with	O
+corona	B-CHED
+-	O
+and	O
+astrovirus	O
+detection	O
+rates	O
+in	O
+fecal	B-ANAT
+samples	O
+.	O
+
+Since	O
+it	O
+was	O
+first	O
+identified	O
+in	O
+a	O
+patient	O
+who	O
+died	B-PROC
+in	O
+a	O
+Jeddah	O
+hospital	O
+in	O
+2012	O
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+has	O
+been	O
+notified	O
+of	O
+1735	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+from	O
+27	O
+countries	O
+,	O
+including	O
+628	O
+deaths	B-PROC
+.	O
+
+The	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+nitazoxanide	O
+has	O
+been	O
+shown	O
+to	O
+have	O
+in	O
+vitro	O
+activity	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+Synthetic	O
+peptides	B-CHED
+and	O
+candidate	O
+vaccines	O
+based	O
+on	O
+regions	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+have	O
+shown	O
+promise	O
+in	O
+rodent	B-SPEC
+and	O
+non	O
+-	O
+human	B-SPEC
+primate	B-SPEC
+models	O
+.	O
+
+We	O
+performed	O
+a	O
+systematic	O
+review	O
+and	O
+meta	B-SPEC
+-	O
+analysis	O
+of	O
+the	O
+most	O
+recent	O
+literature	O
+to	O
+analyse	O
+complications	O
+and	O
+hospital	O
+mortality	O
+associated	O
+with	O
+this	O
+technique	O
+.	O
+
+The	O
+objectives	O
+of	O
+this	O
+review	O
+are	O
+to	O
+describe	O
+the	O
+rationale	O
+of	O
+ECLS	O
+techniques	O
+,	O
+to	O
+review	O
+the	O
+pulmonary	B-DISO
+diseases	I-DISO
+potentially	O
+treated	O
+by	O
+ECLS	O
+,	O
+and	O
+finally	O
+to	O
+demonstrate	O
+the	O
+efficacy	O
+of	O
+ECLS	O
+,	O
+using	O
+recently	O
+published	O
+data	O
+from	O
+the	O
+literature	O
+,	O
+in	O
+order	B-SPEC
+to	O
+practice	O
+evidence	O
+based	O
+medicine	B-CHED
+.	O
+
+In	O
+the	O
+field	O
+of	O
+lung	B-ANAT
+transplantation	O
+,	O
+ECLS	O
+may	O
+be	O
+used	O
+successfully	O
+as	O
+a	O
+bridge	O
+to	O
+transplantation	O
+,	O
+as	O
+intraoperative	O
+cardiorespiratory	O
+support	O
+or	O
+as	O
+a	O
+bridge	O
+to	O
+recovery	O
+in	O
+cases	O
+of	O
+severe	O
+primary	B-DISO
+graft	I-DISO
+dysfunction	I-DISO
+.	O
+
+In	O
+general	O
+thoracic	B-DISO
+surgery	O
+,	O
+ECLS	O
+technology	O
+seems	O
+to	O
+be	O
+safe	O
+and	O
+efficient	O
+as	O
+intraoperative	O
+respiratory	O
+support	O
+for	O
+tracheobronchial	O
+surgery	O
+or	O
+for	O
+severe	O
+respiratory	O
+insufficiency	O
+,	O
+without	O
+significant	O
+increase	O
+in	O
+perioperative	O
+risk	O
+.	O
+
+In	O
+most	O
+cases	O
+,	O
+making	O
+an	O
+early	O
+diagnosis	O
+is	O
+challenging	O
+due	O
+to	O
+the	O
+treatments	O
+that	O
+consist	O
+in	O
+the	O
+rapid	O
+administration	O
+of	O
+intravenous	O
+immunoglobulin	B-PROC
+or	O
+plasma	B-ANAT
+exchange	O
+.	O
+
+This	O
+strategy	O
+leads	O
+to	O
+a	O
+novel	O
+sensing	O
+platform	O
+with	O
+good	O
+extendibility	O
+for	O
+DNA	O
+analysis	O
+,	O
+and	O
+provides	O
+a	O
+powerful	O
+protocol	O
+for	O
+facilitating	O
+the	O
+cognition	B-PROC
+of	O
+DNA	O
+conformation	O
+on	O
+metal	B-CHED
+surfaces	O
+.	O
+
+Phylogenetic	O
+analysis	O
+based	O
+on	O
+complete	O
+genome	O
+of	O
+all	O
+available	O
+coronaviruses	O
+consistently	O
+show	O
+that	O
+CRCoV	O
+BJ232	O
+is	O
+most	O
+closely	O
+related	O
+to	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+and	O
+BCoV	O
+,	O
+forming	O
+a	O
+separate	O
+clade	O
+that	O
+split	O
+off	O
+early	O
+from	O
+other	O
+Betacoronavirus	B-SPEC
+1	I-SPEC
+.	O
+
+However	O
+orf1ab	O
+,	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+genes	O
+were	O
+more	O
+related	O
+to	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+than	O
+CRCoV	O
+-	O
+B232	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+pulmonary	B-ANAT
+diseases	I-DISO
+such	O
+as	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+progressive	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+is	O
+caused	O
+by	O
+dysregulated	O
+wound	B-PROC
+healing	I-PROC
+via	O
+activation	O
+of	O
+fibroblasts	B-ANAT
+after	O
+lung	B-DISO
+inflammation	I-DISO
+or	O
+severe	O
+damage	O
+.	O
+
+We	O
+evaluated	O
+the	O
+effects	O
+of	O
+substrate	O
+stiffness	B-DISO
+on	O
+the	O
+morphology	O
+,	O
+
+TITLE	O
+:	O
+Efficient	O
+Reverse	O
+Genetic	O
+Systems	O
+for	O
+Rapid	O
+Genetic	O
+Manipulation	O
+of	O
+Emergent	O
+and	O
+Preemergent	O
+Infectious	B-DISO
+Coronaviruses	O
+.	O
+
+In	O
+this	O
+protocol	O
+we	O
+describe	O
+a	O
+well	O
+-	O
+developed	O
+reverse	O
+genetic	O
+platform	O
+strategy	O
+for	O
+CoVs	O
+that	O
+is	O
+comprised	O
+of	O
+partitioning	O
+the	O
+viral	B-COMP
+genome	I-COMP
+into	O
+5	O
+-	O
+7	O
+independent	O
+DNA	O
+fragments	O
+(	O
+depending	O
+on	O
+the	O
+CoV	O
+genome	O
+),	O
+each	O
+subcloned	O
+into	O
+a	O
+plasmid	O
+for	O
+increased	O
+stability	O
+and	O
+ease	O
+of	O
+genetic	O
+manipulation	O
+and	O
+amplification	O
+.	O
+
+Secretory	B-PROC
+phospholipase	B-ENZY
+A2	I-ENZY
+plays	O
+an	O
+important	O
+role	O
+in	O
+inflammation	B-DISO
+and	O
+possible	O
+dysfunction	O
+of	O
+surfactants	B-CHED
+in	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+Prevalence	O
+of	O
+Penile	B-DISO
+Pearly	I-DISO
+Papules	I-DISO
+among	O
+Young	O
+Men	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+prevalence	O
+of	O
+pearly	O
+penile	O
+papules	O
+(	O
+PPP	B-DISO
+)	O
+among	O
+young	O
+men	O
+in	O
+Eskisehir	O
+,	O
+Turkey	B-SPEC
+.	O
+
+All	O
+medical	O
+practitioners	O
+should	O
+be	O
+familiar	O
+with	O
+PPP	B-DISO
+.	O
+
+Their	O
+similarity	O
+to	O
+genital	B-DISO
+warts	I-DISO
+may	O
+generate	O
+a	O
+false	O
+apprehension	O
+of	O
+venereal	B-DISO
+disease	I-DISO
+and	O
+may	O
+lead	O
+to	O
+unwanted	O
+and	O
+hazardous	O
+treatments	O
+.	O
+
+During	O
+the	O
+winter	O
+season	O
+,	O
+viral	O
+respiratory	O
+pathogens	O
+,	O
+mainly	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+were	O
+clinically	O
+underdiagnosed	O
+in	O
+70	O
+%	O
+of	O
+patients	O
+positive	O
+by	O
+the	O
+multiplex	O
+PCR	O
+assay	O
+.	O
+
+The	O
+hazard	O
+ratio	O
+(	O
+HR	O
+)	O
+comparing	O
+plasma	B-ANAT
+plus	O
+standard	O
+care	O
+with	O
+standard	O
+care	O
+alone	O
+was	O
+1	O
+·	O
+71	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+·	O
+96	O
+-	O
+3	O
+·	O
+06	O
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+bacterial	B-DISO
+pneumonia	I-DISO
+,	O
+lung	B-ANAT
+damage	O
+resulting	O
+from	O
+epithelial	B-ANAT
+cell	I-ANAT
+injury	O
+is	O
+a	O
+major	O
+contributor	O
+to	O
+the	O
+severity	O
+of	O
+disease	O
+and	O
+,	O
+in	O
+some	O
+cases	O
+,	O
+can	O
+lead	O
+to	O
+long	O
+-	O
+term	O
+sequelae	O
+,	O
+especially	O
+in	O
+the	O
+setting	O
+of	O
+severe	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Leukemia	B-PROC
+inhibitory	I-PROC
+factor	I-PROC
+(	O
+LIF	B-PROC
+),	O
+a	O
+member	O
+of	O
+the	O
+IL	B-PRGE
+-	I-PRGE
+6	I-PRGE
+cytokine	I-PRGE
+family	B-SPEC
+,	O
+is	O
+a	O
+critical	O
+determinant	O
+of	O
+lung	B-ANAT
+tissue	I-ANAT
+protection	O
+during	O
+pneumonia	B-DISO
+,	O
+but	O
+the	O
+cellular	B-COMP
+sources	O
+of	O
+LIF	B-PROC
+and	O
+the	O
+signaling	B-PROC
+pathways	B-PROC
+leading	O
+to	O
+its	O
+production	O
+in	O
+the	O
+infected	O
+lung	B-ANAT
+are	O
+not	O
+known	O
+.	O
+
+Overall	O
+,	O
+our	O
+data	O
+suggest	O
+a	O
+signaling	B-PROC
+axis	B-SPEC
+whereby	O
+activation	O
+of	O
+NF	B-PRGE
+-	I-PRGE
+κB	I-PRGE
+RelA	I-PRGE
+in	O
+myeloid	B-ANAT
+cells	I-ANAT
+promotes	O
+epithelial	O
+LIF	B-PRGE
+induction	O
+during	O
+lung	B-ANAT
+infections	B-DISO
+,	O
+representing	O
+a	O
+means	O
+through	O
+which	O
+these	O
+two	O
+cell	B-COMP
+types	O
+collaborate	O
+to	O
+improve	O
+tissue	B-ANAT
+resilience	O
+during	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Combination	O
+of	O
+H120	O
+and	O
+1	O
+/	O
+96	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+vaccine	O
+strains	O
+protect	O
+chickens	B-SPEC
+against	O
+challenge	O
+with	O
+IS	O
+/	O
+1494	O
+/	O
+06	O
+(	O
+variant	O
+2	O
+)-	O
+like	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+SPF	B-PRGE
+chickens	I-PRGE
+were	O
+divided	O
+into	O
+four	O
+groups	O
+(	O
+n	O
+=	O
+20	O
+).	O
+
+The	O
+trachea	B-DISO
+pathological	O
+scores	O
+and	O
+histopathological	O
+findings	O
+in	O
+the	O
+lungs	B-ANAT
+and	O
+kidneys	B-ANAT
+also	O
+confirmed	O
+better	O
+protective	O
+efficacy	O
+of	O
+vaccinated	O
+groups	O
+.	O
+
+It	O
+is	O
+a	O
+causative	O
+agent	O
+of	O
+enteric	O
+and	O
+respiratory	B-DISO
+diseases	I-DISO
+of	O
+cattle	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Type	B-PRGE
+II	I-PRGE
+transmembrane	I-PRGE
+serine	B-CHED
+proteases	I-PRGE
+(	O
+TTSPs	O
+)	O
+facilitate	O
+the	O
+spread	O
+and	O
+replication	O
+of	O
+viruses	B-SPEC
+such	O
+as	O
+influenza	B-DISO
+and	O
+human	B-SPEC
+coronaviruses	O
+,	O
+although	O
+it	O
+remains	O
+unclear	O
+whether	O
+TTSPs	O
+play	O
+a	O
+role	O
+in	O
+the	O
+progression	O
+of	O
+animal	B-SPEC
+coronavirus	B-DISO
+infections	I-DISO
+,	O
+such	O
+as	O
+that	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+Our	O
+results	O
+showed	O
+that	O
+TMPRSS2	O
+and	O
+MSPL	O
+played	O
+significant	O
+roles	O
+in	O
+the	O
+stages	O
+of	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+and	O
+virus	B-SPEC
+-	O
+cell	B-PROC
+fusion	I-PROC
+,	O
+whereas	O
+HAT	B-PRGE
+and	O
+DESC1	B-PRGE
+exhibited	O
+weaker	O
+effects	O
+.	O
+
+This	O
+activation	O
+may	O
+be	O
+involved	O
+in	O
+the	O
+interaction	O
+between	O
+TTSPs	O
+and	O
+the	O
+PEDV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+,	O
+as	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+extensively	O
+co	O
+-	O
+localized	O
+with	O
+TMPRSS2	B-PRGE
+and	O
+MSPL	B-PRGE
+and	O
+could	O
+be	O
+cleaved	B-ANAT
+by	O
+co	O
+-	O
+expression	B-PROC
+with	O
+TMPRSS2	O
+or	O
+MSPL	O
+.	O
+
+TITLE	O
+:	O
+Is	O
+There	O
+a	O
+Preinterventional	O
+Mechanical	O
+Ventilation	O
+Time	O
+Limit	O
+for	O
+Candidates	O
+of	O
+Adult	O
+Respiratory	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+.	O
+
+This	O
+retrospective	O
+study	O
+included	O
+129	O
+adult	O
+patients	O
+receiving	O
+VV	O
+-	O
+ECMO	O
+for	O
+ARDS	B-DISO
+in	O
+a	O
+single	O
+institution	O
+from	O
+2007	O
+to	O
+2016	O
+.	O
+
+KGF	B-PRGE
+did	O
+not	O
+improve	O
+physiological	O
+or	O
+clinical	O
+outcomes	O
+in	O
+ARDS	B-DISO
+and	O
+might	O
+be	O
+harmful	O
+to	O
+patient	O
+health	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+and	O
+high	O
+fatality	O
+of	O
+piglets	O
+,	O
+influencing	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+Compounds	O
+1	O
+-	O
+7	O
+had	O
+no	O
+cytotoxicity	B-DISO
+at	O
+20μM	O
+on	O
+VERO	O
+cells	O
+,	O
+while	O
+compounds	O
+8	O
+-	O
+10	O
+showed	O
+strong	O
+cytotoxicity	B-DISO
+at	O
+similar	O
+concentrations	O
+on	O
+PEDV	B-SPEC
+.	O
+
+Information	O
+on	O
+71	O
+patients	O
+at	O
+>	O
+25	O
+weeks	O
+gestation	B-PROC
+in	O
+the	O
+ICU	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+was	O
+recorded	O
+between	O
+2009	O
+and	O
+2013	O
+.	O
+
+Maintenance	O
+of	O
+coronavirus	B-SPEC
+within	O
+the	O
+study	O
+population	O
+was	O
+more	O
+likely	O
+in	O
+an	O
+epidemic	O
+model	O
+that	O
+included	O
+both	O
+persistently	O
+and	O
+transiently	O
+infectious	O
+bats	B-SPEC
+,	O
+compared	O
+with	O
+the	O
+epidemic	O
+model	O
+with	O
+non	O
+-	O
+grouping	O
+of	O
+bats	B-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+molecular	O
+survey	O
+for	O
+selected	O
+viral	O
+enteropathogens	O
+revealed	O
+a	O
+limited	O
+role	O
+of	O
+Canine	O
+circovirus	B-SPEC
+in	O
+the	O
+development	B-PROC
+of	O
+canine	O
+acute	B-DISO
+gastroenteritis	I-DISO
+.	O
+
+A	O
+high	O
+prevalence	O
+of	O
+viral	B-DISO
+infections	I-DISO
+was	O
+detected	O
+in	O
+dogs	B-SPEC
+with	O
+gastroenteritis	B-DISO
+(	O
+77	O
+.	O
+16	O
+%),	O
+with	O
+CPV	B-SPEC
+representing	O
+the	O
+most	O
+frequently	O
+detected	O
+enteropathogen	O
+,	O
+followed	O
+by	O
+CanineCV	O
+and	O
+CCoV	O
+.	O
+While	O
+CPV	O
+and	O
+CCoV	O
+infections	B-DISO
+displayed	O
+a	O
+strong	O
+association	O
+with	O
+occurrence	O
+of	O
+acute	B-DISO
+gastroenteritis	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+00001	O
+),	O
+detection	O
+of	O
+CanineCV	O
+in	O
+control	O
+dogs	B-SPEC
+(	O
+28	O
+.	O
+35	O
+%)	O
+occurred	O
+with	O
+prevalence	O
+comparable	O
+to	O
+that	O
+of	O
+clinical	O
+cases	O
+(	O
+32	O
+.	O
+42	O
+%),	O
+so	O
+that	O
+its	O
+correlation	O
+with	O
+gastrointestinal	B-DISO
+disease	I-DISO
+was	O
+not	O
+statistically	O
+supported	O
+(	O
+p	O
+=	O
+0	O
+.	O
+530988	O
+).	O
+
+This	O
+study	O
+supports	O
+the	O
+role	O
+of	O
+CanineCV	O
+as	O
+a	O
+co	O
+-	O
+pathogen	O
+in	O
+the	O
+development	B-PROC
+of	O
+gastrointestinal	B-DISO
+disease	I-DISO
+,	O
+mainly	O
+acting	O
+in	O
+synergism	B-PROC
+with	O
+other	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+Here	O
+we	O
+present	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+HKU1	B-PRGE
+CTD	I-PRGE
+at	O
+1	O
+.	O
+9	O
+Å	O
+resolution	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+and	O
+Comparison	O
+of	O
+the	O
+Pathogenicity	O
+and	O
+Host	B-COMP
+Immune	B-PROC
+Responses	I-PROC
+Induced	O
+by	O
+a	O
+G2b	O
+Taiwan	O
+Porcine	O
+Epidemic	O
+Diarrhea	O
+Virus	O
+(	O
+Strain	O
+Pintung	O
+52	O
+)	O
+and	O
+Its	O
+Highly	O
+Cell	B-COMP
+-	O
+Culture	O
+Passaged	O
+Strain	O
+in	O
+Conventional	O
+5	O
+-	O
+Week	O
+-	O
+Old	O
+Pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+caused	O
+fatal	O
+infections	B-DISO
+,	O
+some	O
+through	O
+hospital	O
+-	O
+acquired	O
+transmission	O
+,	O
+in	O
+affected	O
+regions	O
+since	O
+its	O
+emergence	O
+in	O
+2012	O
+.	O
+
+Coagulation	B-DISO
+defect	I-DISO
+was	O
+seen	O
+in	O
+89	O
+%	O
+patients	O
+.	O
+
+RESULTS	O
+:	O
+One	O
+hundred	O
+and	O
+twenty	O
+-	O
+one	O
+patients	O
+were	O
+diagnosed	O
+with	O
+snake	B-SPEC
+bite	B-PROC
+-	O
+induced	O
+AKI	O
+.	O
+
+TITLE	O
+:	O
+Uvaria	B-SPEC
+angolensis	I-SPEC
+as	O
+a	O
+promising	O
+source	O
+of	O
+inhibitors	B-CHED
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	I-PRGE
+-	I-PRGE
+associated	I-PRGE
+RNA	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+DNA	I-PRGE
+polymerase	I-PRGE
+and	O
+RNase	O
+H	O
+functions	O
+.	O
+
+In	O
+the	O
+present	O
+work	O
+,	O
+we	O
+investigated	O
+the	O
+effect	O
+of	O
+Uvaria	B-SPEC
+angolensis	I-SPEC
+extracts	O
+on	O
+the	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	I-PRGE
+associated	I-PRGE
+DNA	I-PRGE
+polymerase	I-PRGE
+and	O
+ribonuclease	B-PRGE
+H	I-PRGE
+activities	O
+.	O
+
+In	O
+addition	O
+to	O
+this	O
+,	O
+moisture	O
+and	O
+ether	B-CHED
+content	O
+appear	O
+to	O
+be	O
+an	O
+important	O
+determinant	O
+of	O
+virus	B-SPEC
+survival	O
+in	O
+feed	O
+ingredients	O
+.	O
+
+They	O
+bind	B-FUNC
+and	O
+remove	O
+ubiquitin	B-PROC
+(	O
+Ub	O
+)	O
+and	O
+interferon	B-PRGE
+stimulated	I-PRGE
+gene	I-PRGE
+15	I-PRGE
+(	O
+ISG15	B-PRGE
+)	O
+from	O
+cellular	B-COMP
+proteins	B-CHED
+to	O
+suppress	O
+host	B-COMP
+antiviral	B-CHED
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+Together	O
+,	O
+this	O
+makes	O
+vDUBs	O
+highly	O
+attractive	O
+antiviral	B-CHED
+drug	I-CHED
+targets	O
+.	O
+
+UbVs	O
+bound	O
+the	O
+vDUBs	O
+with	O
+high	O
+affinity	O
+and	O
+specificity	O
+to	O
+inhibit	O
+deubiquitination	B-PROC
+,	O
+deISGylation	O
+and	O
+in	O
+the	O
+case	O
+of	O
+MERS	O
+-	O
+CoV	O
+also	O
+viral	O
+replicative	O
+polyprotein	O
+processing	O
+.	O
+
+It	O
+enters	O
+the	O
+body	B-ANAT
+via	O
+skin	B-ANAT
+,	O
+respiratory	O
+and	O
+gastrointestinal	B-ANAT
+tracts	I-ANAT
+.	O
+
+Zinc	B-CHED
+phosphide	B-CHED
+is	O
+hydrolyzed	O
+by	O
+the	O
+gastric	B-ANAT
+acid	I-ANAT
+and	O
+is	O
+transformed	O
+into	O
+phosphine	B-CHED
+gas	B-ENZY
+.	O
+
+The	O
+late	O
+deaths	B-PROC
+(	O
+beyond	O
+24	O
+h	O
+)	O
+had	O
+been	O
+commonly	O
+due	O
+to	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+liver	B-ANAT
+and	O
+renal	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+critical	O
+condition	B-DISO
+characterized	O
+by	O
+bilateral	B-DISO
+pulmonary	I-DISO
+infiltrates	I-DISO
+and	O
+severe	O
+hypoxemia	O
+.	O
+
+The	O
+correlation	O
+between	O
+serum	B-COMP
+CC16	O
+levels	O
+and	O
+the	O
+severity	O
+of	O
+ARDS	B-DISO
+as	O
+quantified	O
+by	O
+PaO	B-PROC
+The	O
+serum	B-COMP
+CC16	O
+levels	O
+in	O
+ARDS	B-DISO
+patients	O
+were	O
+significantly	O
+higher	O
+than	O
+that	O
+in	O
+non	O
+-	O
+ARDS	O
+patients	O
+(	O
+54	O
+.	O
+44	O
+±	O
+19	O
+.	O
+62	O
+vs	O
+24	O
+.	O
+13	O
+±	O
+12	O
+.	O
+32	O
+ng	O
+/	O
+mL	O
+,	O
+P	O
+=.	O
+001	O
+).	O
+
+Emergency	B-DISO
+departments	O
+and	O
+ICUs	O
+at	O
+two	O
+academic	O
+children	O
+'	O
+s	O
+hospitals	O
+.	O
+
+The	O
+most	O
+common	O
+cause	O
+of	O
+death	B-PROC
+was	O
+refractory	B-DISO
+shock	I-DISO
+(	O
+34	O
+%),	O
+then	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+after	O
+shock	O
+recovery	O
+(	O
+27	O
+%),	O
+neurologic	O
+injury	O
+(	O
+19	O
+%),	O
+single	O
+-	O
+organ	B-ANAT
+respiratory	B-DISO
+failure	I-DISO
+(	O
+9	O
+%),	O
+and	O
+nonseptic	O
+comorbidity	O
+(	O
+6	O
+%).	O
+
+Comparing	O
+the	O
+normal	O
+transcription	B-PROC
+regulatory	O
+sequence	O
+(	O
+TRS	B-DISO
+),	O
+3	O
+variant	O
+TRS	B-DISO
+sequences	O
+upstream	O
+the	O
+spike	O
+(	O
+S	O
+),	O
+ORF3	O
+,	O
+and	O
+ORF8	O
+genes	O
+were	O
+found	O
+in	O
+the	O
+genome	O
+of	O
+AcCoV	O
+-	O
+JC34	O
+.	O
+
+Both	O
+alphacoronaviruses	O
+and	O
+betacoronaviruses	O
+were	O
+detected	O
+in	O
+Apodemus	B-SPEC
+chevrieri	I-SPEC
+in	O
+the	O
+Yunnan	O
+Province	O
+of	O
+China	O
+,	O
+indicating	O
+that	O
+Apodemus	B-SPEC
+chevrieri	I-SPEC
+is	O
+an	O
+important	O
+host	B-COMP
+for	O
+coronavirus	B-SPEC
+.	O
+
+Influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+IAV	O
+)	O
+infection	B-DISO
+is	O
+the	O
+cause	O
+of	O
+a	O
+respiratory	B-DISO
+disease	I-DISO
+that	O
+poses	O
+a	O
+significant	O
+global	O
+public	O
+health	O
+concern	O
+.	O
+
+For	O
+severity	O
+of	O
+ARDS	B-DISO
+,	O
+subjects	O
+were	O
+stratified	O
+according	O
+to	O
+P	O
+A	O
+total	O
+of	O
+2	O
+,	O
+914	O
+subjects	O
+were	O
+included	O
+in	O
+these	O
+trials	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+prone	O
+posture	O
+is	O
+known	O
+to	O
+have	O
+numerous	O
+effects	O
+on	O
+gas	B-ENZY
+exchange	O
+,	O
+both	O
+under	O
+normal	O
+conditions	O
+and	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+MERS	O
+-	O
+CoV	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PL	O
+
+During	O
+delivery	O
+she	O
+developed	O
+coma	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+septic	B-DISO
+shock	I-DISO
+in	O
+a	O
+cat	B-SPEC
+with	O
+disseminated	B-DISO
+toxoplasmosis	I-DISO
+.	O
+
+Despite	O
+initial	O
+treatment	O
+with	O
+oxygen	B-CHED
+supplementation	O
+and	O
+intravenous	O
+clindamycin	B-CHED
+,	O
+the	O
+cat	B-SPEC
+developed	O
+refractory	O
+hypoxemia	O
+and	O
+hypotension	O
+requiring	O
+mechanical	O
+ventilation	O
+and	O
+vasopressor	O
+support	O
+within	O
+24	O
+hours	O
+of	O
+hospital	O
+admission	O
+.	O
+
+GJ	O
+proteins	B-CHED
+,	O
+connexin	B-PROC
+43	O
+(	O
+Cx43	B-PRGE
+)	O
+and	O
+connexin	B-PRGE
+47	I-PRGE
+(	O
+Cx47	B-PRGE
+),	O
+play	O
+a	O
+crucial	O
+role	O
+in	O
+production	O
+and	O
+maintenance	O
+of	O
+CNS	B-CHED
+myelin	B-COMP
+.	O
+
+The	O
+sequence	O
+alignment	O
+using	O
+Clustal	O
+W	O
+shows	O
+that	O
+the	O
+signal	O
+sequence	O
+present	O
+at	O
+the	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+plays	O
+an	O
+important	O
+role	O
+in	O
+spike	O
+protein	B-PROC
+localization	I-PROC
+.	O
+
+This	O
+study	O
+sheds	O
+some	O
+light	O
+on	O
+the	O
+role	O
+of	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+of	O
+spike	O
+protein	B-CHED
+in	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-PROC
+fusion	I-PROC
+,	O
+coronavirus	B-SPEC
+host	B-COMP
+cell	I-COMP
+fusion	O
+and	O
+subsequent	O
+pathogenicity	O
+.	O
+
+Seventeen	O
+patients	O
+had	O
+abbreviated	O
+injury	O
+score	O
+(	O
+AIS	B-DISO
+)	O
+0	O
+,	O
+81	O
+patients	O
+had	O
+low	O
+-	O
+grade	O
+injury	O
+(	O
+AIS	B-DISO
+1	O
+and	O
+2	O
+),	O
+and	O
+63	O
+patients	O
+had	O
+high	O
+-	O
+grade	O
+injury	O
+(	O
+AIS	B-DISO
+3	O
+and	O
+4	O
+).	O
+
+Patients	O
+with	O
+high	O
+-	O
+grade	O
+INH	O
+had	O
+worse	O
+pulmonary	B-ANAT
+dysfunction	O
+,	O
+worse	O
+oxygenation	B-PROC
+indices	O
+(	O
+P	O
+=	O
+0	O
+.	O
+01	O
+)	O
+and	O
+plasma	B-ANAT
+carboxyhemoglobin	O
+(	O
+COHgb	O
+;	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+on	O
+admission	O
+,	O
+increased	O
+fluid	O
+requirements	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+at	O
+24	O
+hours	O
+;	O
+P	O
+=	O
+0	O
+.	O
+04	O
+at	O
+48	O
+hours	O
+),	O
+MODS	O
+(	O
+P	O
+=	O
+0	O
+.	O
+04	O
+),	O
+pneumonia	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+01	O
+at	O
+48	O
+hours	O
+),	O
+fewer	O
+28	O
+-	O
+day	O
+ventilator	O
+-	O
+free	O
+days	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+greater	O
+ventilator	O
+dependence	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+03	O
+),	O
+and	O
+longer	O
+length	O
+of	O
+stay	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+HFRS	B-DISO
+is	O
+endemic	O
+in	O
+Europe	O
+and	O
+Russia	O
+,	O
+where	O
+the	O
+mild	O
+form	O
+of	O
+the	O
+disease	O
+is	O
+prevalent	O
+in	O
+the	O
+Tatarstan	O
+region	O
+.	O
+
+HFRS	B-DISO
+and	O
+HPS	B-DISO
+are	O
+usually	O
+acquired	O
+via	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+by	O
+inhalation	B-PROC
+of	O
+virus	B-SPEC
+-	O
+contaminated	O
+aerosol	O
+.	O
+
+Overall	O
+,	O
+serum	B-COMP
+cytokine	O
+profiles	O
+associated	O
+with	O
+HPS	B-DISO
+revealed	O
+a	O
+more	O
+pro	B-CHED
+-	O
+inflammatory	O
+milieu	O
+as	O
+compared	O
+to	O
+HFRS	B-DISO
+.	O
+
+To	O
+predict	O
+the	O
+potential	O
+B	B-ANAT
+cell	I-ANAT
+epitopes	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+,	O
+three	O
+most	O
+effective	O
+online	O
+epitope	B-CHED
+prediction	O
+programs	O
+,	O
+the	O
+ABCpred	O
+,	O
+Bepipred	O
+,	O
+and	O
+Protean	O
+programs	O
+from	O
+the	O
+LaserGene	O
+software	O
+were	O
+used	O
+.	O
+
+The	O
+2C10	O
+mAb	O
+was	O
+transiently	O
+expressed	B-PROC
+in	O
+
+TITLE	O
+:	O
+Recurrent	O
+elevated	O
+liver	B-ANAT
+transaminases	O
+and	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+in	O
+two	O
+siblings	O
+with	O
+novel	O
+bi	O
+-	O
+allelic	O
+mutations	O
+of	O
+NBAS	O
+.	O
+
+This	O
+structure	O
+provides	O
+strong	O
+experimental	O
+support	O
+for	O
+the	O
+recent	O
+proposal	O
+advanced	O
+by	O
+us	O
+and	O
+others	O
+that	O
+the	O
+""""	O
+SARS	B-DISO
+-	O
+unique	O
+""""	O
+region	O
+is	O
+not	O
+unique	O
+to	O
+the	O
+human	O
+SARS	B-DISO
+virus	B-SPEC
+,	O
+but	O
+is	O
+conserved	O
+among	O
+several	O
+different	O
+phylogenetic	O
+groups	O
+of	O
+coronaviruses	O
+and	O
+provides	O
+essential	O
+functions	O
+.	O
+
+TITLE	O
+:	O
+MERS	O
+-	O
+CoV	O
+Antibody	B-PROC
+Responses	I-PROC
+1	O
+Year	O
+after	O
+Symptom	B-DISO
+Onset	O
+,	O
+South	O
+Korea	O
+,	O
+2015	O
+.	O
+
+Antibody	B-COMP
+titers	O
+in	O
+4	O
+of	O
+6	O
+patients	O
+who	O
+had	O
+mild	O
+illness	O
+were	O
+undetectable	O
+even	O
+though	O
+most	O
+had	O
+evidence	O
+of	O
+pneumonia	B-DISO
+.	O
+
+Obtaining	O
+convalescent	O
+-	O
+phase	O
+plasma	B-ANAT
+with	O
+high	O
+antibody	B-COMP
+titers	O
+to	O
+treat	O
+MERS	O
+will	O
+be	O
+challenging	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genome	O
+sequence	O
+of	O
+a	O
+novel	O
+S	O
+-	O
+insertion	O
+variant	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+from	O
+South	O
+Korea	O
+.	O
+
+The	O
+genome	O
+of	O
+the	O
+PEDV	B-SPEC
+strain	O
+KOR	O
+/	O
+KNU	O
+-	O
+1601	O
+/	O
+2016	O
+was	O
+sequenced	O
+and	O
+analyzed	O
+to	O
+characterize	O
+the	O
+S	O
+-	O
+insertion	O
+variant	O
+circulating	O
+on	O
+Jeju	O
+Island	O
+.	O
+
+Time	O
+since	O
+respiratory	B-DISO
+symptom	I-DISO
+onset	O
+was	O
+2	O
+(	O
+1	O
+-	O
+3	O
+)	O
+days	O
+.	O
+
+Samples	O
+from	O
+different	O
+age	O
+groups	O
+and	O
+the	O
+carcass	O
+of	O
+a	O
+piglet	O
+were	O
+examined	O
+by	O
+various	O
+methods	O
+including	O
+pathology	B-DISO
+,	O
+bacteriology	O
+and	O
+molecular	O
+biology	O
+.	O
+
+TITLE	O
+:	O
+A	O
+reverse	O
+genetics	O
+system	O
+for	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+based	O
+on	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+respiratory	O
+pathogen	O
+of	O
+chickens	B-SPEC
+that	O
+causes	O
+severe	O
+economic	O
+losses	O
+in	O
+the	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+Herein	O
+,	O
+the	O
+genomic	O
+part	O
+coding	O
+for	O
+the	O
+spike	O
+glycoprotein	B-CHED
+ectodomain	O
+was	O
+replaced	O
+by	O
+that	O
+of	O
+the	O
+coronavirus	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+allowing	O
+for	O
+the	O
+selection	O
+and	O
+propagation	O
+of	O
+recombinant	O
+mIBV	O
+in	O
+murine	B-SPEC
+cells	B-COMP
+.	O
+
+Targeted	B-PROC
+RNA	O
+recombination	B-PROC
+allowed	O
+for	O
+the	O
+modification	O
+of	O
+the	O
+3	O
+'-	O
+end	O
+of	O
+the	O
+IBV	B-SPEC
+genome	O
+,	O
+encoding	O
+all	O
+structural	O
+and	O
+accessory	O
+genes	O
+.	O
+
+Overall	O
+,	O
+low	O
+-	O
+quality	O
+evidence	O
+indicates	O
+that	O
+blood	O
+purification	O
+with	O
+CVVH	O
+might	O
+be	O
+associated	O
+with	O
+a	O
+significant	O
+reduction	O
+in	O
+mortality	O
+when	O
+performed	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+or	O
+ARDS	B-DISO
+.	O
+
+There	O
+was	O
+no	O
+intervention	O
+to	O
+control	O
+the	O
+infection	B-DISO
+in	O
+the	O
+early	O
+phase	O
+of	O
+the	O
+outbreak	O
+,	O
+thus	O
+the	O
+data	O
+used	O
+here	O
+provide	O
+the	O
+best	O
+conditions	O
+to	O
+evaluate	O
+the	O
+epidemic	O
+characteristics	O
+of	O
+MERS	O
+,	O
+such	O
+as	O
+the	O
+basic	O
+reproduction	B-PROC
+number	O
+.	O
+
+An	O
+evaluation	O
+of	O
+basic	O
+reproduction	B-PROC
+number	O
+using	O
+epidemic	O
+data	O
+could	O
+be	O
+problematic	O
+if	O
+there	O
+are	O
+stochastic	O
+fluctuations	B-DISO
+in	O
+the	O
+early	O
+phase	O
+of	O
+the	O
+outbreak	O
+,	O
+or	O
+if	O
+the	O
+report	O
+is	O
+not	O
+accurate	O
+and	O
+there	O
+is	O
+bias	B-SPEC
+in	O
+the	O
+data	O
+.	O
+
+For	O
+all	O
+18	O
+DBoV2	O
+genomes	O
+,	O
+an	O
+AT	O
+-	O
+rich	O
+region	O
+of	O
+variable	O
+length	O
+and	O
+composition	O
+was	O
+present	O
+downstream	O
+to	O
+NP1	B-PRGE
+.	O
+
+Though	O
+typically	O
+self	O
+-	O
+limited	O
+,	O
+more	O
+severe	O
+exposure	O
+may	O
+lead	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+even	O
+death	B-PROC
+.	O
+
+ARDS	B-DISO
+is	O
+defined	O
+as	O
+an	O
+acute	B-DISO
+disorder	I-DISO
+that	O
+starts	O
+within	O
+7	O
+days	O
+of	O
+the	O
+inciting	O
+event	O
+and	O
+is	O
+characterized	O
+by	O
+bilateral	O
+lung	B-ANAT
+infiltrates	B-DISO
+and	O
+severe	O
+progressive	O
+hypoxemia	O
+in	O
+the	O
+absence	O
+of	O
+any	O
+evidence	O
+of	O
+cardiogenic	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+.	O
+
+Once	O
+ARDS	B-DISO
+develops	O
+,	O
+patients	O
+usually	O
+have	O
+varying	O
+degrees	O
+of	O
+pulmonary	B-ANAT
+artery	I-ANAT
+vasoconstriction	B-DISO
+and	O
+,	O
+subsequently	O
+,	O
+may	O
+develop	O
+pulmonary	B-DISO
+hypertension	I-DISO
+.	O
+
+ARDS	B-DISO
+carries	O
+a	O
+high	O
+mortality	O
+,	O
+and	O
+few	O
+effective	O
+therapeutic	O
+modalities	O
+exist	O
+to	O
+combat	B-CHED
+this	O
+condition	B-DISO
+.[	O
+1	O
+][	O
+2	O
+]	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+patients	O
+experienced	O
+more	O
+clinically	O
+significant	O
+iatrogenic	O
+withdrawal	B-DISO
+than	O
+moderate	O
+/	O
+severe	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+managed	O
+without	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Compared	O
+to	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+patients	O
+managed	O
+per	O
+Randomized	O
+Evaluation	O
+of	O
+Sedation	B-DISO
+Titration	O
+for	O
+Respiratory	B-DISO
+Failure	I-DISO
+protocol	O
+,	O
+usual	O
+care	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+patients	O
+received	O
+more	O
+opioids	O
+during	O
+the	O
+study	O
+period	O
+(	O
+mean	O
+cumulative	O
+dose	O
+of	O
+183	O
+.	O
+0	O
+vs	O
+89	O
+.	O
+8	O
+mg	O
+/	O
+kg	O
+;	O
+p	O
+=	O
+0	O
+.	O
+02	O
+),	O
+over	O
+6	O
+.	O
+5	O
+greater	O
+exposure	O
+days	O
+(	O
+p	O
+=	O
+0	O
+.	O
+002	O
+)	O
+with	O
+no	O
+differences	O
+in	O
+wakefulness	O
+or	O
+agitation	B-DISO
+.	O
+
+To	O
+assess	O
+potential	O
+drug	B-DISO
+-	I-DISO
+induced	I-DISO
+liver	I-DISO
+injury	I-DISO
+,	O
+we	O
+also	O
+analyzed	O
+biomarkers	O
+of	O
+liver	B-ANAT
+cell	I-ANAT
+integrity	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+Coronavirus	I-SPEC
+-	I-PRGE
+HKU1	I-PRGE
+Infection	B-DISO
+Among	O
+Adults	O
+in	O
+Cleveland	O
+,	O
+Ohio	O
+.	O
+
+Coronavirus	B-SPEC
+-	O
+HKU1	O
+has	O
+been	O
+described	O
+predominantly	O
+among	O
+children	O
+less	O
+than	O
+5	O
+years	O
+of	O
+age	O
+in	O
+the	O
+United	O
+States	O
+with	O
+few	O
+studies	O
+characterizing	O
+the	O
+disease	O
+spectrum	O
+among	O
+adults	O
+.	O
+
+Seven	O
+(	O
+54	O
+%)	O
+required	O
+hospitalization	O
+,	O
+5	O
+(	O
+71	O
+%)	O
+of	O
+these	O
+needed	O
+supplemental	O
+oxygen	B-CHED
+,	O
+and	O
+2	O
+(	O
+29	O
+%)	O
+were	O
+admitted	O
+to	O
+intensive	O
+care	O
+.	O
+
+TITLE	O
+:	O
+This	O
+could	O
+be	O
+the	O
+start	O
+of	O
+something	O
+big	O
+-	O
+20	O
+years	O
+since	O
+the	O
+identification	O
+of	O
+bats	B-SPEC
+as	O
+the	O
+natural	O
+host	O
+of	O
+Hendra	B-SPEC
+virus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Hendra	B-SPEC
+virus	I-SPEC
+was	O
+first	O
+described	O
+in	O
+1994	O
+in	O
+Australia	O
+,	O
+causally	O
+associated	O
+with	O
+a	O
+cluster	O
+of	O
+fatal	O
+equine	B-SPEC
+and	O
+human	B-SPEC
+cases	O
+at	O
+a	O
+thoroughbred	O
+racing	O
+stable	O
+in	O
+the	O
+Brisbane	O
+suburb	O
+of	O
+Hendra	O
+.	O
+
+TITLE	O
+:	O
+Absence	O
+of	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+in	O
+feral	O
+camels	B-SPEC
+in	O
+Australia	O
+:	O
+Implications	O
+for	O
+the	O
+pathogen	O
+'	O
+s	O
+origin	O
+and	O
+spread	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+continue	O
+to	O
+be	O
+a	O
+serious	O
+emerging	O
+disease	O
+problem	O
+internationally	O
+with	O
+well	O
+over	O
+1000	O
+cases	O
+and	O
+a	O
+major	O
+outbreak	O
+outside	O
+of	O
+the	O
+Middle	O
+East	O
+region	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+still	O
+causes	O
+outbreaks	O
+despite	O
+public	O
+awareness	O
+and	O
+implementation	O
+of	O
+health	O
+care	O
+measures	O
+,	O
+such	O
+as	O
+rapid	O
+viral	O
+diagnosis	O
+and	O
+patient	O
+quarantine	O
+.	O
+
+Coronaviruses	O
+are	O
+also	O
+a	O
+threat	O
+for	O
+humans	B-SPEC
+,	O
+as	O
+evidenced	O
+in	O
+2002	O
+/	O
+2003	O
+with	O
+infection	B-DISO
+by	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+which	O
+caused	O
+more	O
+than	O
+8000	O
+human	B-SPEC
+infections	B-DISO
+with	O
+10	O
+%	O
+fatality	O
+rate	O
+in	O
+37	O
+countries	O
+.	O
+
+Finally	O
+,	O
+the	O
+relevance	O
+of	O
+potential	O
+new	O
+target	O
+species	B-SPEC
+is	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Co	B-DISO
+-	I-DISO
+infection	I-DISO
+of	O
+H9N2	O
+subtype	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+decreases	O
+SP	O
+-	O
+A	O
+expression	B-PROC
+level	O
+in	O
+chickens	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+the	O
+detection	O
+and	O
+characterization	O
+of	O
+cSP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+in	O
+co	O
+-	O
+infected	O
+chickens	B-SPEC
+.	O
+
+For	O
+this	O
+purpose	O
+,	O
+four	O
+-	O
+week	O
+-	O
+old	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+chickens	B-SPEC
+were	O
+divided	O
+into	O
+five	O
+groups	O
+and	O
+inoculated	O
+intranasally	O
+with	O
+H9N2	O
+subtype	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AIV	O
+),	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+or	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+).	O
+
+The	O
+remaining	O
+seven	O
+IBV	B-SPEC
+isolates	O
+were	O
+shown	O
+to	O
+have	O
+originated	O
+from	O
+recombination	B-PROC
+events	O
+between	O
+a	O
+4	O
+/	O
+91	O
+-	O
+like	O
+vaccine	O
+strain	O
+and	O
+a	O
+GX	O
+-	O
+LY9	O
+-	O
+like	O
+virus	B-SPEC
+,	O
+which	O
+were	O
+responsible	O
+for	O
+the	O
+emergence	O
+of	O
+a	O
+novel	O
+serotype	O
+.	O
+
+Peripheral	O
+smear	O
+revealed	O
+multilobulated	O
+neutrophils	B-ANAT
+with	O
+schistocytes	B-ANAT
+,	O
+poikilocytes	B-ANAT
+and	O
+anisocytes	B-ANAT
+.	O
+
+Lactic	B-CHED
+acid	I-CHED
+normalized	O
+,	O
+acute	O
+kidney	B-ANAT
+injury	O
+resolved	O
+and	O
+mentation	O
+improved	O
+after	O
+transfusion	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Pernicious	B-DISO
+anemia	I-DISO
+is	O
+a	O
+chronic	B-DISO
+disease	I-DISO
+with	O
+subtle	O
+presentation	O
+but	O
+may	O
+present	O
+as	O
+life	O
+-	O
+threatening	O
+complications	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+past	O
+20	O
+years	O
+,	O
+our	O
+understanding	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+management	O
+has	O
+improved	O
+,	O
+but	O
+the	O
+worldwide	O
+incidence	O
+and	O
+current	O
+outcomes	O
+are	O
+unclear	O
+.	O
+
+ABSTRACT	O
+:	O
+TGEV	B-SPEC
+is	O
+a	O
+coronavirus	B-SPEC
+that	O
+is	O
+still	O
+widely	O
+spread	O
+in	O
+pig	B-SPEC
+farming	O
+.	O
+
+Finally	O
+,	O
+TGEV	O
+GFP	O
+is	O
+a	O
+recombinant	O
+strain	O
+that	O
+obtained	O
+its	O
+main	O
+body	B-ANAT
+from	O
+TGEV	B-SPEC
+PUR	O
+46	O
+-	O
+MAD	B-PROC
+,	O
+but	O
+its	O
+spike	O
+protein	B-CHED
+from	O
+TGEV	B-SPEC
+PUR	O
+-	O
+C11	O
+that	O
+showed	O
+high	O
+mortality	O
+in	O
+piglets	O
+in	O
+vivo	O
+.	O
+
+TGEV	B-SPEC
+Miller	O
+mildly	O
+and	O
+TGEV	B-SPEC
+GFP	O
+extensively	O
+infected	O
+the	O
+cells	B-COMP
+in	O
+the	O
+jejunum	B-ANAT
+based	O
+on	O
+the	O
+amount	O
+of	O
+positive	O
+stained	O
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Down	O
+-	O
+regulating	O
+heat	B-PRGE
+shock	I-PRGE
+protein	B-CHED
+27	I-PRGE
+is	O
+involved	O
+in	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+escaping	O
+from	O
+host	O
+antiviral	B-CHED
+mechanism	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+is	O
+the	O
+etiological	O
+agent	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PED	O
+),	O
+causes	O
+high	O
+mortality	O
+with	O
+severe	O
+vomiting	B-DISO
+,	O
+diarrhea	B-DISO
+,	O
+and	O
+dehydration	B-DISO
+in	O
+swine	B-SPEC
+farms	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+PEDV	B-SPEC
+strain	O
+85	O
+-	O
+7	O
+could	O
+be	O
+proliferated	O
+effectively	O
+in	O
+MARC	O
+-	O
+145	O
+cells	B-COMP
+,	O
+and	O
+caused	O
+a	O
+distinct	O
+inhibition	B-PROC
+of	O
+the	O
+expression	B-PROC
+of	O
+interferon	B-PRGE
+-	I-PRGE
+β	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+,	O
+encoded	O
+by	O
+IFNB1	B-PRGE
+),	O
+which	O
+suggested	O
+that	O
+a	O
+full	O
+understanding	O
+how	O
+this	O
+virus	B-SPEC
+manipulates	O
+the	O
+host	B-COMP
+immune	B-PROC
+responses	I-PROC
+is	O
+critical	O
+in	O
+the	O
+fight	O
+against	O
+the	O
+spread	O
+of	O
+PEDV	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+described	O
+the	O
+isolation	O
+of	O
+a	O
+PEDV	B-SPEC
+-	O
+neutralizing	O
+antibody	B-COMP
+from	O
+the	O
+B	B-ANAT
+cell	I-ANAT
+of	O
+a	O
+vaccinated	O
+pig	B-SPEC
+.	O
+
+Significant	O
+differences	O
+of	O
+codon	O
+preferences	O
+in	O
+BCoV	O
+genes	O
+in	O
+relation	O
+to	O
+codon	O
+usage	O
+of	O
+Bos	B-PRGE
+taurus	I-PRGE
+host	B-COMP
+genes	I-PRGE
+were	O
+found	O
+.	O
+
+Testing	O
+ruled	O
+out	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+and	O
+identified	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+as	O
+the	O
+cause	O
+of	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+in	O
+the	O
+affected	O
+swine	B-SPEC
+.	O
+
+Despite	O
+this	O
+,	O
+only	O
+6	O
+%	O
+of	O
+all	O
+CoV	O
+sequences	O
+in	O
+GenBank	O
+are	O
+from	O
+bats	B-SPEC
+.	O
+
+We	O
+identified	O
+sequences	O
+representing	O
+100	O
+discrete	O
+phylogenetic	O
+clusters	B-CHED
+,	O
+ninety	O
+-	O
+one	O
+of	O
+which	O
+were	O
+found	O
+in	O
+bats	B-SPEC
+,	O
+and	O
+used	O
+ecological	O
+and	O
+epidemiologic	O
+analyses	O
+to	O
+show	O
+that	O
+patterns	O
+of	O
+CoV	O
+diversity	O
+correlate	O
+with	O
+those	O
+of	O
+bat	O
+diversity	O
+.	O
+
+Co	O
+-	O
+phylogenetic	O
+reconciliation	O
+analysis	O
+was	O
+also	O
+used	O
+to	O
+show	O
+that	O
+host	B-COMP
+switching	O
+has	O
+contributed	O
+to	O
+CoV	O
+evolution	B-PROC
+,	O
+and	O
+a	O
+preliminary	O
+analysis	O
+suggests	O
+that	O
+regional	O
+variation	O
+exists	O
+in	O
+the	O
+dynamics	O
+of	O
+this	O
+process	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Eight	O
+percent	O
+of	O
+ARDS	B-DISO
+patients	O
+have	O
+no	O
+identified	O
+risk	O
+factor	O
+,	O
+80	O
+%	O
+of	O
+whom	O
+have	O
+no	O
+etiological	O
+diagnosis	O
+made	O
+.	O
+
+ABSTRACT	O
+:	O
+Controlled	O
+hypoventilation	O
+while	O
+accepting	O
+hypercapnia	B-DISO
+has	O
+been	O
+advocated	O
+to	O
+reduce	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Out	O
+of	O
+150	O
+episodes	O
+of	O
+admission	O
+to	O
+the	O
+PICU	B-SPEC
+88	O
+children	O
+underwent	O
+invasive	O
+mechanical	O
+ventilation	O
+for	O
+>	O
+24h	O
+(	O
+overall	O
+survival	O
+75	O
+%).	O
+
+Fifteen	O
+children	O
+survived	O
+and	O
+were	O
+discharged	O
+from	O
+the	O
+PICU	B-SPEC
+.	O
+
+After	O
+that	O
+,	O
+groups	O
+2	O
+and	O
+4	O
+were	O
+orally	B-ANAT
+administered	O
+tea	B-CHED
+saponins	O
+in	O
+drinking	B-PROC
+water	B-CHED
+for	O
+7	O
+d	O
+.	O
+Then	O
+,	O
+groups	O
+1	O
+to	O
+4	O
+were	O
+immunized	O
+with	O
+a	O
+live	O
+,	O
+bivalent	O
+vaccine	O
+of	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+However	O
+,	O
+parental	O
+asthma	B-PATH
+,	O
+ever	O
+wheezing	B-DISO
+and	O
+environmental	O
+tobacco	B-SPEC
+smoke	O
+exposure	O
+are	O
+risk	O
+factors	O
+for	O
+severe	O
+viral	B-DISO
+pneumonia	I-DISO
+in	O
+children	O
+.	O
+
+To	O
+develop	O
+a	O
+radiological	O
+metric	O
+of	O
+injurious	O
+inflation	O
+derived	O
+from	O
+matched	O
+inspiratory	B-PROC
+and	O
+expiratory	B-PROC
+CT	O
+scans	O
+,	O
+calibrate	O
+it	O
+in	O
+a	O
+model	O
+of	O
+experimental	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+test	O
+it	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+clinical	O
+characteristics	O
+of	O
+patients	O
+presenting	O
+with	O
+influenza	B-DISO
+like	I-DISO
+illness	I-DISO
+or	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+with	O
+development	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Each	O
+patient	O
+was	O
+assessed	O
+for	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+,	O
+clinical	O
+features	O
+,	O
+treatment	O
+,	O
+complications	O
+and	O
+outcome	O
+of	O
+ILI	O
+and	O
+SARI	O
+.	O
+
+We	O
+found	O
+that	O
+SARS	B-DISO
+S	O
+residue	O
+R667	O
+,	O
+a	O
+previously	O
+identified	O
+trypsin	B-PRGE
+cleavage	B-PROC
+site	O
+,	O
+is	O
+also	O
+required	O
+for	O
+S	B-PRGE
+protein	I-PRGE
+cleavage	O
+by	O
+TMPRSS2	O
+.	O
+
+The	O
+cleavage	B-PROC
+fragments	O
+produced	O
+by	O
+trypsin	B-PRGE
+and	O
+TMPRSS2	B-PRGE
+differed	O
+in	O
+their	O
+decoration	O
+with	O
+N	B-CHED
+-	I-CHED
+glycans	I-CHED
+,	O
+suggesting	O
+that	O
+these	O
+proteases	O
+cleave	O
+different	O
+SARS	B-DISO
+S	O
+glycoforms	O
+.	O
+
+Conversely	O
+,	O
+residue	O
+R797	O
+,	O
+previously	O
+reported	O
+to	O
+be	O
+required	O
+for	O
+SARS	B-PRGE
+S	I-PRGE
+activation	O
+by	O
+trypsin	B-PRGE
+,	O
+was	O
+dispensable	O
+for	O
+S	B-PRGE
+protein	I-PRGE
+cleavage	O
+but	O
+required	O
+for	O
+S	B-PRGE
+protein	I-PRGE
+activation	O
+by	O
+TMPRSS2	O
+.	O
+
+We	O
+then	O
+performed	O
+combination	O
+studies	O
+of	O
+Lupeol	B-CHED
+and	O
+the	O
+active	O
+site	O
+RNase	B-PRGE
+H	I-PRGE
+inhibitor	B-CHED
+RDS1759	O
+,	O
+and	O
+blind	B-DISO
+docking	B-PROC
+calculations	O
+,	O
+demonstrating	O
+that	O
+Lupeol	B-CHED
+binds	B-FUNC
+to	O
+an	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+allosteric	O
+pocket	O
+.	O
+
+Results	O
+supported	O
+the	O
+potential	O
+of	O
+this	O
+plant	B-SPEC
+as	O
+a	O
+valuable	O
+multitarget	O
+active	O
+drug	O
+source	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+shrews	O
+are	O
+one	O
+of	O
+the	O
+largest	O
+groups	O
+of	O
+mammals	B-SPEC
+,	O
+little	O
+is	O
+known	O
+about	O
+their	O
+role	O
+in	O
+the	O
+evolution	B-PROC
+and	O
+transmission	O
+of	O
+viral	O
+pathogens	O
+,	O
+including	O
+coronaviruses	O
+(	O
+CoVs	O
+).	O
+
+ABSTRACT	O
+:	O
+Patients	O
+receiving	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+are	O
+at	O
+risk	O
+of	O
+circuit	O
+thrombosis	B-DISO
+due	O
+to	O
+constant	O
+contact	O
+between	O
+blood	B-ANAT
+and	O
+the	O
+extracorporeal	O
+components	O
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+27	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+who	O
+developed	O
+HIT	O
+while	O
+on	O
+venovenous	O
+ECMO	O
+with	O
+continuous	O
+venovenous	O
+hemofiltration	O
+.	O
+
+Seasonal	O
+variation	O
+in	O
+the	O
+occurrence	O
+of	O
+these	O
+viruses	B-SPEC
+was	O
+also	O
+noted	O
+.	O
+
+NF	O
+-	O
+κB	O
+activation	O
+is	O
+a	O
+common	O
+pro	B-CHED
+-	O
+inflammatory	B-DISO
+response	I-DISO
+of	O
+host	B-COMP
+cells	B-COMP
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Compared	O
+to	O
+other	O
++	O
+RNA	O
+viruses	B-SPEC
+,	O
+coronaviruses	O
+have	O
+an	O
+exceptionally	O
+large	O
+genome	O
+and	O
+employ	O
+a	O
+complex	O
+genome	O
+expression	B-PROC
+strategy	O
+.	O
+
+For	O
+example	O
+,	O
+by	O
+interacting	O
+with	O
+the	O
+host	B-COMP
+cell	I-COMP
+to	O
+create	O
+an	O
+optimal	O
+environment	O
+for	O
+coronavirus	B-SPEC
+replication	O
+,	O
+by	O
+altering	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+or	O
+by	O
+counteracting	O
+the	O
+host	B-COMP
+'	O
+s	O
+antiviral	B-CHED
+defenses	O
+.	O
+
+Veno	O
+-	O
+Venous	B-ANAT
+ECMO	O
+(	O
+V	O
+-	O
+V	O
+ECMO	O
+)	O
+is	O
+a	O
+lifesaving	O
+treatment	O
+of	O
+patients	O
+in	O
+whom	O
+severe	O
+ARDS	B-DISO
+makes	O
+artificial	O
+lung	B-ANAT
+ventilation	O
+unlikely	O
+to	O
+provide	O
+satisfactory	O
+blood	B-ANAT
+oxygenation	B-PROC
+for	O
+preventing	O
+further	O
+vital	O
+organs	B-ANAT
+damage	O
+and	O
+progression	O
+to	O
+death	B-PROC
+.	O
+
+Putative	O
+factors	O
+related	O
+to	O
+increased	O
+survival	O
+include	O
+patients	O
+retrieval	O
+after	O
+connecting	O
+them	O
+to	O
+ECMO	O
+,	O
+and	O
+less	O
+intensive	O
+anticoagulation	B-PROC
+protocols	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+the	O
+Luminex	O
+xTAG	O
+Respiratory	O
+Viral	O
+Panel	O
+Fast	B-FUNC
+v2	O
+Assay	O
+With	O
+Anyplex	O
+II	O
+RV16	O
+Detection	O
+Kit	O
+and	O
+AdvanSure	O
+RV	O
+Real	O
+-	O
+Time	O
+RT	O
+-	O
+PCR	O
+Assay	O
+for	O
+the	O
+Detection	O
+of	O
+Respiratory	O
+Viruses	B-SPEC
+.	O
+
+The	O
+agreement	O
+levels	O
+were	O
+relatively	O
+low	O
+(	O
+94	O
+.	O
+1	O
+-	O
+97	O
+.	O
+6	O
+%)	O
+for	O
+specimens	O
+of	O
+adenovirus	B-DISO
+,	O
+coronavirus	B-SPEC
+NL63	O
+,	O
+and	O
+parainfluenza	B-DISO
+type	O
+3	O
+.	O
+
+The	O
+xTAG	B-PRGE
+RVP	I-PRGE
+Fast	I-PRGE
+v2	I-PRGE
+assay	O
+showed	O
+comparable	O
+capabilities	O
+compared	O
+with	O
+the	O
+other	O
+assays	O
+;	O
+it	O
+will	O
+be	O
+useful	O
+for	O
+identifying	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+patients	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Clinicians	O
+should	O
+be	O
+aware	O
+of	O
+the	O
+characteristics	O
+of	O
+the	O
+assays	O
+they	O
+use	O
+,	O
+since	O
+different	O
+assays	O
+show	O
+different	O
+detectability	O
+for	O
+each	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+August	O
+2015	O
+,	O
+the	O
+Corona	B-CHED
+outbreak	O
+caused	O
+by	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+the	O
+9th	O
+episode	O
+since	O
+June	O
+2012	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Almost	O
+all	O
+participants	O
+heard	O
+about	O
+the	O
+corona	B-CHED
+disease	O
+and	O
+causative	O
+agent	O
+.	O
+
+Notably	O
+,	O
+epitope	B-CHED
+mapping	O
+by	O
+peptide	B-CHED
+ELISAs	O
+revealed	O
+that	O
+nine	O
+of	O
+these	O
+mAbs	O
+recognized	O
+linear	O
+neutralizing	O
+epitopes	O
+located	O
+in	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+the	O
+S2	O
+glycoprotein	B-CHED
+subunit	O
+(	O
+amino	B-CHED
+acids	I-CHED
+[	O
+aa	O
+]	O
+744	O
+-	O
+759	O
+,	O
+747	O
+-	O
+774	O
+and	O
+/	O
+or	O
+756	O
+-	O
+771	O
+).	O
+
+PHTR	O
+effectively	O
+prevent	O
+exposure	O
+during	O
+commercial	O
+air	O
+travel	O
+to	O
+persons	O
+with	O
+potentially	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+We	O
+report	O
+here	O
+the	O
+first	O
+structure	O
+of	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+coronavirus	I-PRGE
+helicase	I-PRGE
+,	O
+MERS	O
+-	O
+CoV	O
+nsp13	O
+.	O
+
+TITLE	O
+:	O
+Potent	O
+Inhibition	B-PROC
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+Replication	O
+in	O
+Resting	B-ANAT
+CD4	B-PRGE
+T	I-PRGE
+Cells	O
+by	O
+Resveratrol	B-CHED
+and	O
+Pterostilbene	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Microscopic	O
+polyangiitis	O
+(	O
+MPA	O
+)	O
+is	O
+part	O
+of	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+neutrophil	I-PRGE
+cytoplasmic	B-COMP
+antibodies	B-COMP
+(	O
+ANCA	B-PRGE
+)-	O
+related	O
+vasculitis	B-DISO
+,	O
+which	O
+usually	O
+presents	O
+as	O
+renal	B-DISO
+pulmonary	B-ANAT
+syndrome	I-DISO
+.	O
+
+The	O
+natural	O
+history	O
+of	O
+AS	O
+begins	O
+with	O
+a	O
+prolonged	O
+asymptomatic	O
+period	O
+,	O
+but	O
+when	O
+symptomatic	O
+,	O
+respiratory	B-DISO
+failure	I-DISO
+is	O
+one	O
+of	O
+its	O
+main	O
+clinical	O
+presentations	O
+.	O
+
+The	O
+incidence	O
+of	O
+this	O
+condition	B-DISO
+is	O
+estimated	O
+at	O
+1	O
+/	O
+1000	O
+per	O
+year	O
+.	O
+
+In	O
+a	O
+rare	O
+variant	O
+of	O
+the	O
+syndrome	B-DISO
+,	O
+involvement	O
+of	O
+both	O
+phrenic	B-ANAT
+nerves	I-ANAT
+can	O
+occur	O
+,	O
+leading	O
+to	O
+diaphragmatic	B-ANAT
+paralysis	O
+and	O
+severe	O
+orthopnoea	B-DISO
+.	O
+
+Imaging	O
+studies	O
+showed	O
+bilateral	O
+diaphragmatic	B-ANAT
+paralysis	O
+,	O
+and	O
+electromyography	O
+(	O
+EMG	O
+)	O
+confirmed	O
+neuropathy	B-DISO
+of	O
+both	O
+phrenic	B-ANAT
+nerves	I-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+Isolated	O
+phrenic	O
+nerve	O
+neuropathy	B-DISO
+is	O
+a	O
+rare	O
+variant	O
+of	O
+neuralgic	B-DISO
+amyotrophy	I-DISO
+,	O
+leading	O
+to	O
+orthopnoea	B-DISO
+.	O
+
+We	O
+show	O
+that	O
+a	O
+nucleotide	B-CHED
+prodrug	B-CHED
+,	O
+GS	O
+-	O
+5734	O
+,	O
+currently	O
+in	O
+clinical	O
+development	B-PROC
+for	O
+treatment	O
+of	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+,	O
+can	O
+inhibit	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+replication	O
+in	O
+multiple	O
+in	O
+vitro	O
+systems	O
+,	O
+including	O
+primary	O
+human	O
+airway	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+cultures	O
+with	O
+submicromolar	O
+IC	O
+
+The	O
+combination	O
+of	O
+broad	O
+live	O
+priming	O
+using	O
+Mass	O
+and	O
+793B	O
+vaccines	O
+and	O
+boosting	O
+with	O
+multiple	O
+inactivated	O
+IBV	B-SPEC
+antigens	B-CHED
+induced	O
+the	O
+highest	O
+level	O
+of	O
+VNA	O
+against	O
+Q1	O
+strains	O
+,	O
+which	O
+might	O
+be	O
+indicative	O
+for	O
+higher	O
+levels	O
+of	O
+protection	O
+against	O
+Q1	O
+challenge	O
+in	O
+laying	O
+birds	B-SPEC
+.	O
+
+The	O
+massive	O
+inflammatory	B-DISO
+reaction	I-DISO
+that	O
+follows	O
+deep	O
+burn	O
+injury	O
+,	O
+compounded	O
+by	O
+episodes	O
+of	O
+sepsis	B-DISO
+and	O
+organ	B-ANAT
+dysfunction	O
+,	O
+predisposes	O
+patients	O
+to	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+.	O
+
+A	O
+rapidly	O
+deteriorating	O
+clinical	O
+course	O
+in	O
+a	O
+patient	O
+with	O
+SCD	B-DISO
+presenting	O
+with	O
+ACS	B-FUNC
+or	O
+severe	O
+vaso	O
+-	O
+occlusive	O
+crisis	O
+should	O
+trigger	O
+a	O
+high	O
+index	O
+of	O
+suspicion	O
+for	O
+FES	O
+.	O
+
+Young	O
+children	O
+living	O
+in	O
+a	O
+group	O
+context	O
+have	O
+a	O
+high	O
+risk	O
+of	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+,	O
+especially	O
+rhinovirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Lateral	O
+medullary	B-ANAT
+infarction	B-DISO
+rarely	O
+leads	O
+to	O
+central	O
+hypoventilation	B-DISO
+syndrome	I-DISO
+(	O
+CHS	B-DISO
+).	O
+
+CHS	B-DISO
+after	O
+unilateral	O
+medullary	B-ANAT
+infarction	B-DISO
+involving	O
+respiratory	B-ANAT
+centers	I-ANAT
+tends	O
+to	O
+occur	O
+in	O
+the	O
+acute	O
+and	O
+subacute	O
+phase	O
+and	O
+may	O
+be	O
+lethal	O
+without	O
+careful	O
+respiratory	O
+management	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+previously	O
+demonstrated	O
+that	O
+adaptation	O
+of	O
+an	O
+embryo	B-ANAT
+-	O
+attenuated	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+Arkansas	O
+(	O
+Ark	O
+)	O
+Delmarva	O
+Poultry	O
+Industry	O
+(	O
+DPI	O
+)-	O
+derived	O
+vaccine	O
+to	O
+chicken	B-SPEC
+embryo	B-ANAT
+kidney	B-ANAT
+(	O
+CEK	O
+)	O
+cells	B-COMP
+(	O
+CEKp7	O
+)	O
+shifted	O
+the	O
+virus	B-SPEC
+population	O
+towards	O
+homogeneity	O
+in	O
+spike	O
+(	O
+S	O
+)	O
+and	O
+nonstructural	O
+protein	B-CHED
+genes	O
+.	O
+
+Moreover	O
+,	O
+the	O
+typical	O
+Ark	O
+vaccine	O
+subpopulations	O
+emerging	O
+in	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+commercial	O
+Ark	O
+vaccines	O
+were	O
+not	O
+detected	O
+in	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+CEKp7	O
+,	O
+indicating	O
+that	O
+kidney	B-ANAT
+-	O
+cell	B-COMP
+adaptation	B-PROC
+drastically	O
+increased	O
+the	O
+stability	O
+of	O
+the	O
+vaccine	O
+virus	B-SPEC
+population	O
+in	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Syndromic	O
+surveillance	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+SARI	O
+)	O
+is	O
+important	O
+to	O
+assess	O
+seriousness	O
+of	O
+disease	O
+as	O
+recommended	O
+by	O
+WHO	O
+for	O
+influenza	B-DISO
+.	O
+
+The	O
+SCD	B-DISO
+comprised	O
+2	O
+.	O
+2	O
+times	O
+patients	O
+as	O
+the	O
+BCD	B-DISO
+,	O
+and	O
+3	O
+.	O
+6	O
+times	O
+as	O
+many	O
+as	O
+the	O
+TCD	B-DISO
+.	O
+
+Our	O
+ICD	B-DISO
+-	O
+10	O
+-	O
+based	O
+approach	O
+proved	O
+to	O
+be	O
+useful	O
+for	O
+fulfilling	O
+requirements	O
+for	O
+SARI	O
+surveillance	O
+.	O
+
+TITLE	O
+:	O
+A	O
+case	O
+of	O
+severe	O
+empyema	B-DISO
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+Slackia	B-SPEC
+exigua	I-SPEC
+requiring	O
+veno	O
+-	O
+venous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+The	O
+patient	O
+was	O
+treated	O
+with	O
+amoxicillin	B-CHED
+-	O
+clavulanic	B-CHED
+acid	I-CHED
+according	O
+to	O
+sensitivity	O
+and	O
+made	O
+significant	O
+recovery	O
+.	O
+
+Using	O
+biomass	O
+for	O
+cooking	O
+,	O
+daycare	O
+attendance	O
+,	O
+absence	O
+of	O
+breastfeeding	B-PROC
+,	O
+and	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+were	O
+found	O
+to	O
+be	O
+statistically	O
+significant	O
+risk	O
+factors	O
+for	O
+the	O
+presence	O
+of	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+Retrospective	O
+cohort	O
+study	O
+in	O
+a	O
+24	O
+-	O
+bed	B-DISO
+neuroscience	O
+critical	O
+care	O
+unit	O
+(	O
+NCCU	O
+)	O
+at	O
+a	O
+tertiary	O
+care	O
+hospital	O
+.	O
+
+TITLE	O
+:	O
+Determination	O
+of	O
+the	O
+cell	B-COMP
+tropism	B-PROC
+of	O
+serotype	O
+1	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+using	O
+the	O
+spike	O
+affinity	O
+histochemistry	O
+in	O
+paraffin	O
+-	O
+embedded	O
+tissues	O
+.	O
+
+Survivors	O
+still	O
+suffered	B-DISO
+as	O
+a	O
+result	O
+of	O
+their	O
+traumatic	O
+experiences	O
+,	O
+which	O
+might	O
+negatively	O
+influence	O
+their	O
+performance	O
+.	O
+
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+spread	O
+first	O
+in	O
+southern	O
+China	O
+in	O
+2003	O
+with	O
+about	O
+8000	O
+infected	O
+cases	O
+in	O
+few	O
+months	O
+.	O
+
+This	O
+is	O
+especially	O
+true	O
+as	O
+no	O
+vaccine	O
+nor	O
+specific	O
+therapeutic	O
+are	O
+available	O
+against	O
+either	O
+SARS	B-DISO
+-	O
+or	O
+MERS	O
+-	O
+CoV	O
+.	O
+Therefore	O
+,	O
+new	O
+drugs	O
+need	O
+to	O
+be	O
+identified	O
+in	O
+order	B-SPEC
+to	O
+develop	O
+antiviral	B-CHED
+treatments	O
+limiting	O
+CoV	O
+replication	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+focus	O
+on	O
+the	O
+nsp14	B-PRGE
+protein	I-PRGE
+,	O
+which	O
+plays	O
+a	O
+key	O
+role	O
+in	O
+virus	B-PROC
+replication	I-PROC
+as	O
+it	O
+methylates	O
+the	O
+RNA	O
+cap	B-DISO
+structure	O
+at	O
+the	O
+N7	O
+position	O
+of	O
+the	O
+guanine	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Comparisons	O
+of	O
+the	O
+characteristics	O
+of	O
+chronic	O
+obstructive	O
+pulmonary	O
+disease	O
+(	O
+COPD	B-DISO
+)	O
+and	O
+asthma	B-PATH
+-	O
+COPD	B-DISO
+overlap	B-DISO
+syndrome	I-DISO
+(	O
+ACOS	O
+)	O
+have	O
+been	O
+the	O
+focus	O
+of	O
+several	O
+studies	O
+since	O
+the	O
+diseases	O
+were	O
+defined	O
+by	O
+the	O
+Global	O
+Initiative	O
+for	O
+Asthma	B-PATH
+and	O
+Global	O
+Initiative	O
+for	O
+Chronic	B-DISO
+Obstructive	I-DISO
+Lung	I-DISO
+Disease	I-DISO
+guidelines	O
+.	O
+
+The	O
+occurrence	O
+of	O
+ACO	O
+was	O
+defined	O
+as	O
+a	O
+positive	O
+response	O
+to	O
+a	O
+bronchodilator	B-CHED
+(	O
+an	O
+increase	O
+in	O
+forced	B-PROC
+expiratory	I-PROC
+volume	I-PROC
+in	O
+1	O
+second	O
+[	O
+FEV1	O
+]	O
+of	O
+12	O
+%	O
+and	O
+200	O
+mL	O
+).	O
+
+TITLE	O
+:	O
+Molecular	O
+detection	O
+of	O
+viral	O
+agents	O
+in	O
+free	O
+-	O
+ranging	O
+and	O
+captive	O
+neotropical	O
+felids	B-SPEC
+in	O
+Brazil	O
+.	O
+
+Our	O
+data	O
+document	O
+the	O
+circulation	B-PROC
+of	O
+FHV	O
+-	O
+1	O
+,	O
+CPPV	O
+-	O
+1	O
+,	O
+and	O
+FIV	B-SPEC
+in	O
+neotropical	O
+felids	B-SPEC
+in	O
+Brazil	O
+.	O
+
+Moreover	O
+,	O
+in	O
+a	O
+bleomycin	B-CHED
+-	O
+based	O
+model	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+megalin	O
+
+The	O
+median	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+was	O
+13	O
+(	O
+interquartile	O
+range	O
+[	O
+IQR	O
+]	O
+9	O
+-	O
+22	O
+).	O
+
+In	O
+this	O
+large	O
+cohort	O
+study	O
+of	O
+216	O
+trauma	O
+centers	O
+,	O
+significant	O
+practice	O
+variability	O
+was	O
+observed	O
+in	O
+delayed	O
+fixation	O
+of	O
+femoral	B-ANAT
+shaft	I-ANAT
+fractures	O
+,	O
+which	O
+could	O
+not	O
+be	O
+explained	O
+by	O
+differences	O
+in	O
+patient	O
+case	O
+mix	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+effect	O
+of	O
+PED	B-PRGE
+on	O
+individual	O
+sow	O
+productivity	O
+differed	O
+with	O
+the	O
+production	O
+stage	O
+in	O
+which	O
+sows	O
+were	O
+exposed	O
+to	O
+PED	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+Epidemic	B-DISO
+Diarrhea	I-DISO
+in	O
+Europe	O
+:	O
+In	O
+-	O
+Detail	O
+Analyses	O
+of	O
+Disease	O
+Dynamics	O
+and	O
+Molecular	O
+Epidemiology	O
+.	O
+
+Despite	O
+all	O
+efforts	O
+,	O
+therapy	O
+remains	O
+limited	O
+,	O
+and	O
+ARDS	B-DISO
+is	O
+still	O
+associated	O
+with	O
+high	O
+mortality	O
+and	O
+morbidity	O
+.	O
+
+We	O
+found	O
+that	O
+α	O
+-	O
+bis	B-FUNC
+-	O
+LNCs	O
+(	O
+30	O
+,	O
+50	O
+,	O
+and	O
+100	O
+mg	O
+kg	O
+
+TITLE	O
+:	O
+Chicken	B-SPEC
+mannose	B-PROC
+binding	I-PROC
+lectin	I-PROC
+has	O
+antiviral	B-CHED
+activity	O
+towards	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+rcMBL	O
+inhibited	O
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+the	O
+infection	B-DISO
+of	O
+BHK	O
+-	O
+21	O
+cells	B-COMP
+by	O
+IBV	B-SPEC
+-	O
+Beaudette	O
+,	O
+as	O
+detected	O
+by	O
+immunofluorescence	O
+staining	O
+of	O
+viral	O
+proteins	B-CHED
+and	O
+qPCR	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+demonstrated	O
+that	O
+MBL	B-PRGE
+bound	O
+specifically	O
+to	O
+the	O
+spike	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+of	O
+IBV	B-SPEC
+which	O
+mediates	O
+viral	O
+attachment	O
+.	O
+
+This	O
+subsequently	O
+blocked	O
+the	O
+attachment	O
+of	O
+S1	O
+to	O
+IBV	B-SPEC
+-	O
+susceptible	O
+cells	B-COMP
+in	O
+chicken	B-SPEC
+tracheal	O
+tissues	B-ANAT
+as	O
+shown	O
+in	O
+protein	O
+histochemistry	O
+.	O
+
+Taken	O
+together	O
+,	O
+rcMBL	O
+exhibits	O
+antiviral	B-CHED
+activity	O
+against	O
+IBV	B-SPEC
+,	O
+based	O
+on	O
+a	O
+direct	O
+interaction	O
+with	O
+IBV	B-SPEC
+virions	B-COMP
+.	O
+
+TITLE	O
+:	O
+Co	O
+-	O
+circulation	B-PROC
+of	O
+three	O
+clusters	B-CHED
+of	O
+793	O
+/	O
+B	O
+-	O
+like	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+genotypes	O
+in	O
+Iranian	O
+chicken	O
+flocks	O
+.	O
+
+Results	O
+showed	O
+that	O
+the	O
+Iranian	O
+793	O
+/	O
+B	O
+-	O
+like	O
+IBV	B-SPEC
+isolates	O
+could	O
+be	O
+divided	O
+in	O
+to	O
+three	O
+clusters	B-CHED
+:	O
+4	O
+/	O
+91	O
+-	O
+like	O
+(	O
+50	O
+%),	O
+1	O
+/	O
+96	O
+-	O
+like	O
+(	O
+40	O
+%),	O
+and	O
+IB88	O
+-	O
+like	O
+(	O
+10	O
+%).	O
+
+TITLE	O
+:	O
+miRNA	O
+-	O
+200c	O
+-	O
+3p	O
+is	O
+crucial	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Downregulation	B-PROC
+of	O
+ACE2	B-PRGE
+is	O
+always	O
+associated	O
+with	O
+the	O
+ALI	O
+or	O
+ARDS	B-DISO
+induced	O
+by	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+sepsis	B-DISO
+.	O
+
+Kidney	B-ANAT
+ureate	O
+deposition	O
+was	O
+only	O
+observed	O
+in	O
+variant	O
+IBV	B-SPEC
+challenge	O
+group	O
+.	O
+
+Also	O
+,	O
+IBV	B-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+increased	O
+the	O
+shedding	O
+of	O
+AIV	O
+-	O
+H9N2	O
+in	O
+experimentally	O
+infected	O
+birds	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+characterization	O
+of	O
+a	O
+new	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+variant	O
+that	O
+occurred	O
+in	O
+Korea	O
+in	O
+2014	O
+.	O
+
+Isolating	O
+and	O
+culturing	O
+PED	O
+virus	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+allow	O
+investigations	O
+into	O
+its	O
+pathogenesis	B-DISO
+and	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+and	O
+diagnostic	O
+assays	O
+.	O
+
+28	O
+/	O
+53	O
+infants	O
+had	O
+B	O
+.	O
+pertussis	O
+alone	O
+and	O
+25	O
+viral	O
+coinfection	B-DISO
+:	O
+10	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+9	O
+alone	O
+and	O
+1	O
+in	O
+coinfection	B-DISO
+with	O
+parainfluenza	B-DISO
+virus	B-SPEC
+),	O
+3	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+2	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+Infants	O
+with	O
+B	B-SPEC
+.	I-SPEC
+pertussis	I-SPEC
+alone	O
+were	O
+younger	O
+than	O
+infants	O
+with	O
+coinfections	B-DISO
+,	O
+and	O
+less	O
+often	O
+breastfeed	B-PROC
+at	O
+admission	O
+.	O
+
+Multiple	O
+virus	B-SPEC
+infections	B-DISO
+,	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+bacteria	B-SPEC
+/	O
+fungus	B-SPEC
+,	O
+and	O
+bacteremia	B-DISO
+/	O
+fungemia	B-DISO
+were	O
+observed	O
+in	O
+60	O
+%,	O
+49	O
+%,	O
+and	O
+32	O
+%	O
+of	O
+children	O
+,	O
+respectively	O
+.	O
+
+Learning	B-PROC
+from	O
+past	O
+outbreaks	O
+is	O
+important	O
+for	O
+future	O
+preparation	O
+.	O
+
+To	O
+consider	O
+ID	O
+,	O
+SGA	O
+had	O
+to	O
+be	O
+isolated	O
+in	O
+sterile	B-DISO
+samples	O
+;	O
+in	O
+patients	O
+with	O
+fascitis	B-DISO
+necroticans	O
+in	O
+skin	B-ANAT
+samples	O
+or	O
+in	O
+any	O
+sample	O
+in	O
+patients	O
+with	O
+the	O
+diagnostic	O
+of	O
+Streptococcal	B-DISO
+Toxic	I-DISO
+Shock	I-DISO
+Syndrome	I-DISO
+(	O
+STSS	O
+).	O
+
+The	O
+SSTS	O
+was	O
+defined	O
+as	O
+hypotension	O
+and	O
+at	O
+least	O
+2	O
+of	O
+these	O
+criteria	O
+:	O
+renal	B-DISO
+failure	I-DISO
+,	O
+hepatic	B-ANAT
+failure	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+,	O
+tissue	B-ANAT
+necrosis	B-PROC
+or	O
+desquamative	O
+erythematous	O
+rash	B-DISO
+.	O
+
+Skin	B-ANAT
+and	O
+soft	B-DISO
+tissue	I-DISO
+infections	I-DISO
+,	O
+and	O
+pleuroneumonia	O
+were	O
+the	O
+most	O
+common	O
+forms	O
+of	O
+ID	O
+.	O
+
+These	O
+recombinant	O
+virus	B-SPEC
+have	O
+been	O
+extraordinary	O
+successful	O
+,	O
+persisting	O
+in	O
+the	O
+continent	O
+for	O
+several	O
+years	O
+with	O
+a	O
+notorious	O
+wide	O
+geographic	O
+distribution	O
+.	O
+
+Newly	O
+Discovered	O
+Nycteribiid	O
+Bat	B-SPEC
+Flies	I-SPEC
+Infesting	O
+Previously	O
+Unknown	O
+Pteropodid	O
+Bats	O
+in	O
+Uganda	O
+.	O
+
+The	O
+coding	O
+-	O
+complete	O
+genome	O
+of	O
+the	O
+new	O
+virus	O
+,	O
+named	O
+Kanyawara	O
+virus	B-SPEC
+(	O
+KYAV	O
+),	O
+is	O
+only	O
+distantly	O
+related	O
+to	O
+that	O
+of	O
+its	O
+closest	O
+known	O
+relative	O
+,	O
+Mount	B-SPEC
+Elgon	I-SPEC
+bat	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+was	O
+found	O
+at	O
+high	O
+titers	O
+in	O
+bat	B-SPEC
+flies	I-SPEC
+but	O
+not	O
+in	O
+blood	B-ANAT
+or	O
+on	O
+mucosal	B-ANAT
+surfaces	O
+of	O
+host	B-COMP
+bats	B-SPEC
+.	O
+
+Before	O
+diagnosis	O
+,	O
+he	O
+visited	O
+4	O
+hospitals	O
+,	O
+potentially	O
+resulting	O
+in	O
+secondary	B-DISO
+transmission	I-DISO
+to	O
+28	O
+patients	O
+.	O
+
+On	O
+admission	O
+to	O
+the	O
+National	O
+Medical	O
+Center	O
+(	O
+day	O
+9	O
+,	O
+post	O
+-	O
+onset	O
+of	O
+clinical	O
+illness	O
+),	O
+he	O
+presented	O
+with	O
+drowsiness	O
+,	O
+hypoxia	B-DISO
+,	O
+and	O
+multiple	O
+patchy	O
+infiltrations	O
+on	O
+the	O
+chest	B-ANAT
+radiograph	O
+.	O
+
+He	O
+was	O
+intubated	O
+(	O
+day	O
+12	O
+)	O
+because	O
+of	O
+progressive	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+INF	B-PRGE
+-	I-PRGE
+α2a	I-PRGE
+and	O
+ribavirin	B-CHED
+treatment	O
+was	O
+commenced	O
+.	O
+
+TITLE	O
+:	O
+Novel	O
+Alphacoronaviruses	O
+and	O
+Paramyxoviruses	O
+Cocirculate	O
+with	O
+Type	O
+1	O
+and	O
+Severe	O
+Acute	O
+Respiratory	B-ANAT
+System	I-ANAT
+(	O
+SARS	B-DISO
+)-	O
+Related	O
+Betacoronaviruses	O
+in	O
+Synanthropic	O
+Bats	B-SPEC
+of	O
+Luxembourg	O
+.	O
+
+From	O
+160	O
+-	O
+220days	O
+of	O
+age	O
+,	O
+gilts	O
+were	O
+exposed	O
+daily	O
+to	O
+vasectomized	O
+boars	B-SPEC
+and	O
+observed	O
+for	O
+behavioral	B-PROC
+estrus	B-PROC
+.	O
+
+Gilts	O
+fed	O
+the	O
+low	O
+lysine	B-CHED
+diet	O
+had	O
+lower	O
+average	O
+daily	O
+gain	O
+and	O
+BW	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+but	O
+not	O
+fat	O
+depth	O
+:	O
+LD	O
+ratio	O
+.	O
+
+The	O
+rate	O
+of	O
+puberty	B-PROC
+attainment	O
+may	O
+have	O
+been	O
+less	O
+because	O
+all	O
+gilts	O
+contracted	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PEDv	B-SPEC
+)	O
+just	O
+as	O
+boar	B-SPEC
+exposure	O
+was	O
+to	O
+begin	O
+for	O
+the	O
+first	O
+group	O
+of	O
+gilts	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Corona	B-CHED
+Virus	B-SPEC
+Alert	O
+Verification	O
+In	O
+Mirpur	O
+,	O
+Azad	O
+Kashmir	O
+.	O
+
+Arrived	O
+on	O
+16th	O
+December	O
+2012	O
+,	O
+mostly	O
+stayed	O
+at	O
+daughter	O
+'	O
+s	O
+house	O
+,	O
+visited	O
+by	O
+relatives	O
+,	O
+on	O
+19th	O
+January	O
+,	O
+left	O
+for	O
+KSA	O
+accompanied	O
+by	O
+daughter	O
+,	O
+developed	O
+fever	B-DISO
+with	I-DISO
+chills	I-DISO
+and	O
+body	B-ANAT
+aches	B-DISO
+on	O
+23rd	O
+January	O
+.	O
+
+Daughter	O
+developed	O
+mild	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+confirmed	O
+as	O
+MERS	O
+-	O
+CoV	O
+on	O
+16th	O
+Feb	O
+and	O
+recovered	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+a	O
+severe	O
+disease	O
+associated	O
+with	O
+an	O
+~	O
+40	O
+%	O
+mortality	O
+rate	O
+and	O
+as	O
+many	O
+as	O
+200	O
+,	O
+000	O
+new	O
+cases	O
+annually	O
+.	O
+
+The	O
+miRNA	O
+expression	B-PROC
+profile	O
+of	O
+the	O
+GSE57223	O
+dataset	O
+was	O
+downloaded	O
+from	O
+the	O
+Gene	B-PROC
+Expression	I-PROC
+Omnibus	O
+database	O
+.	O
+
+Following	O
+data	O
+normalization	O
+,	O
+differentially	O
+expressed	B-PROC
+miRNAs	O
+were	O
+identified	O
+using	O
+the	O
+t	O
+‑	O
+test	O
+method	O
+.	O
+
+The	O
+four	O
+downregulated	O
+rno	O
+‑	O
+let	O
+‑	O
+7	O
+miRNAs	O
+may	O
+be	O
+involved	O
+in	O
+the	O
+inflammatory	O
+process	O
+in	O
+the	O
+pathogenesis	B-DISO
+and	O
+progression	O
+of	O
+ARDS	B-DISO
+,	O
+via	O
+the	O
+synergistic	O
+regulation	B-PROC
+of	O
+their	O
+target	O
+genes	O
+,	O
+such	O
+as	O
+IL	O
+‑	O
+6	O
+.	O
+
+We	O
+found	O
+that	O
+7	O
+%	O
+of	O
+samples	O
+were	O
+seropositive	O
+for	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+),	O
+10	O
+%	O
+for	O
+canine	O
+parvovirus	B-DISO
+type	O
+2	O
+,	O
+2	O
+%	O
+for	O
+canine	B-SPEC
+adenovirus	I-SPEC
+type	O
+1	O
+,	O
+6	O
+%	O
+for	O
+canine	B-SPEC
+adenovirus	I-SPEC
+type	O
+2	O
+,	O
+and	O
+7	O
+%	O
+for	O
+canine	O
+coronavirus	B-SPEC
+.	O
+
+Because	O
+raccoons	B-SPEC
+belong	O
+to	O
+the	O
+suborder	B-SPEC
+Caniformia	I-SPEC
+,	O
+similar	O
+to	O
+dogs	B-SPEC
+(	O
+Canis	B-SPEC
+lupus	I-SPEC
+familiaris	I-SPEC
+),	O
+our	O
+results	O
+suggest	O
+that	O
+they	O
+can	O
+act	O
+as	O
+reservoirs	O
+for	O
+some	O
+of	O
+these	O
+important	O
+canine	O
+viruses	B-SPEC
+and	O
+might	O
+be	O
+involved	O
+in	O
+viral	B-PROC
+transmission	I-PROC
+.	O
+
+The	O
+objective	O
+was	O
+to	O
+assess	O
+the	O
+impact	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+outbreak	O
+on	O
+the	O
+use	O
+of	O
+emergency	B-DISO
+resources	O
+.	O
+
+CONCLUSIONS	O
+:	O
+MERS	O
+outbreak	O
+appears	O
+to	O
+have	O
+had	O
+a	O
+significant	O
+effects	O
+on	O
+ED	O
+use	O
+by	O
+febrile	B-PROC
+patients	O
+.	O
+
+The	O
+diagnosis	O
+of	O
+asthma	B-PATH
+requires	O
+these	O
+symptoms	O
+and	O
+demonstration	O
+of	O
+reversible	O
+airway	B-DISO
+obstruction	I-DISO
+using	O
+spirometry	O
+.	O
+
+Using	O
+in	O
+vitro	O
+pull	O
+-	O
+down	O
+experiments	O
+and	O
+density	O
+glycerol	B-CHED
+gradients	O
+,	O
+we	O
+found	O
+that	O
+at	O
+least	O
+3	O
+regions	O
+distributed	O
+over	O
+its	O
+entire	O
+length	O
+mediate	O
+the	O
+self	O
+-	O
+interaction	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+N	O
+protein	B-CHED
+.	O
+
+However	O
+,	O
+a	O
+month	O
+later	O
+,	O
+she	O
+returned	O
+to	O
+the	O
+ER	O
+,	O
+complaining	O
+of	O
+nausea	B-DISO
+,	O
+vomiting	B-DISO
+,	O
+diarrhea	B-DISO
+,	O
+dizziness	B-DISO
+,	O
+chills	B-DISO
+,	O
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+over	O
+the	O
+past	O
+two	O
+days	O
+.	O
+
+Expert	O
+commentary	O
+:	O
+Use	O
+of	O
+this	O
+platform	O
+can	O
+substantially	O
+accelerate	O
+process	O
+development	B-PROC
+and	O
+facilitate	O
+licensure	O
+because	O
+of	O
+the	O
+substantial	O
+existing	O
+data	O
+set	O
+available	O
+for	O
+the	O
+cell	B-COMP
+matrix	I-COMP
+.	O
+
+However	O
+,	O
+little	O
+research	O
+has	O
+been	O
+conducted	O
+on	O
+bat	B-ENZY
+coronaviruses	O
+in	O
+South	O
+Korea	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+bat	B-ENZY
+samples	O
+(	O
+332	O
+oral	B-ANAT
+swabs	O
+,	O
+245	O
+fecal	B-ANAT
+samples	O
+,	O
+38	O
+urine	B-ANAT
+samples	O
+,	O
+and	O
+57	O
+bat	B-ENZY
+carcasses	O
+)	O
+were	O
+collected	O
+at	O
+33	O
+natural	O
+bat	B-ENZY
+habitat	O
+sites	O
+in	O
+South	O
+Korea	O
+.	O
+
+Four	O
+nucleotide	B-CHED
+sequences	O
+displayed	O
+the	O
+highest	O
+identity	O
+(	O
+94	O
+.	O
+1	O
+-	O
+95	O
+.	O
+1	O
+%)	O
+with	O
+Bat	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+HKU5	I-PRGE
+from	O
+Hong	O
+Kong	O
+.	O
+
+Studies	O
+on	O
+the	O
+modes	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+are	O
+limited	O
+though	O
+a	O
+number	O
+of	O
+outbreak	O
+studies	O
+have	O
+revealed	O
+the	O
+possible	O
+airborne	O
+route	O
+.	O
+
+TITLE	O
+:	O
+Diagnostic	O
+delays	O
+in	O
+537	O
+symptomatic	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+The	O
+median	O
+time	O
+interval	O
+between	O
+symptom	B-DISO
+onset	O
+and	O
+confirmation	O
+of	O
+the	O
+MERS	O
+diagnosis	O
+was	O
+4	O
+days	O
+(	O
+interquartile	O
+range	O
+2	O
+-	O
+7	O
+days	O
+),	O
+ranging	O
+from	O
+0	O
+to	O
+36	O
+days	O
+.	O
+
+According	O
+to	O
+the	O
+negative	O
+binomial	O
+model	O
+,	O
+the	O
+unadjusted	O
+rate	O
+ratio	O
+(	O
+RR	O
+)	O
+of	O
+delays	O
+in	O
+the	O
+diagnosis	O
+was	O
+significantly	O
+higher	O
+in	O
+older	O
+patients	O
+(>	O
+65	O
+years	O
+)	O
+(	O
+RR	O
+1	O
+.	O
+42	O
+),	O
+non	O
+-	O
+healthcare	O
+workers	O
+(	O
+RR	O
+1	O
+.	O
+74	O
+),	O
+patients	O
+with	O
+severe	O
+illness	O
+(	O
+RR	O
+1	O
+.	O
+22	O
+),	O
+those	O
+with	O
+an	O
+unknown	O
+source	O
+of	O
+infection	B-DISO
+(	O
+RR	O
+1	O
+.	O
+84	O
+),	O
+and	O
+those	O
+who	O
+had	O
+been	O
+in	O
+close	O
+contact	O
+with	O
+camels	B-SPEC
+(	O
+RR	O
+1	O
+.	O
+74	O
+).	O
+
+The	O
+time	O
+interval	O
+from	O
+symptom	B-DISO
+onset	O
+to	O
+diagnosis	O
+was	O
+greater	O
+in	O
+older	O
+patients	O
+,	O
+non	O
+-	O
+healthcare	O
+workers	O
+,	O
+patients	O
+with	O
+severe	O
+illness	O
+,	O
+patients	O
+with	O
+an	O
+unknown	O
+source	O
+of	O
+infection	B-DISO
+,	O
+and	O
+patients	O
+who	O
+had	O
+been	O
+in	O
+close	O
+contact	O
+with	O
+camels	B-SPEC
+.	O
+
+The	O
+findings	O
+warrant	O
+educational	O
+interventions	O
+to	O
+raise	O
+general	O
+public	O
+awareness	O
+of	O
+the	O
+importance	O
+of	O
+early	O
+symptom	B-DISO
+notification	O
+.	O
+
+Moreover	O
+,	O
+mRNA	B-CHED
+levels	O
+of	O
+inflammatory	O
+cytokines	O
+(	O
+TNF	O
+-	O
+α	O
+,	O
+IL	O
+-	O
+1β	O
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+)	O
+significantly	O
+increased	O
+with	O
+ADE	B-CHED
+of	O
+FIPV	O
+79	O
+-	O
+1146	O
+infection	B-DISO
+in	O
+primary	O
+feline	B-SPEC
+monocytes	B-ANAT
+,	O
+but	O
+FECV	B-SPEC
+79	O
+-	O
+1683	O
+did	O
+not	O
+demonstrate	O
+an	O
+increase	O
+in	O
+these	O
+levels	O
+.	O
+
+TITLE	O
+:	O
+Awareness	O
+among	O
+a	O
+Saudi	O
+Arabian	O
+university	O
+community	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+following	O
+an	O
+outbreak	O
+.	O
+
+Moreover	O
+,	O
+an	O
+in	O
+vitro	O
+analysis	O
+demonstrated	O
+that	O
+interleukin	B-PRGE
+-	I-PRGE
+13	I-PRGE
+and	O
+-	O
+31	O
+and	O
+hemozoin	O
+induced	O
+pneumocytic	O
+cell	B-DISO
+injury	I-DISO
+and	O
+apoptosis	B-PATH
+,	O
+as	O
+assessed	O
+by	O
+EB	O
+/	O
+AO	O
+staining	O
+,	O
+electron	O
+microscopy	O
+and	O
+the	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+CARD	B-PRGE
+-	I-PRGE
+9	I-PRGE
+mRNA	I-PRGE
+(	O
+caspase	B-PRGE
+recruitment	B-DISO
+domain	O
+-	O
+9	O
+messenger	O
+-	O
+ribonucleic	B-CHED
+acid	I-CHED
+).	O
+
+The	O
+dysregulation	O
+of	O
+EPCR	O
+and	O
+TM	O
+in	O
+the	O
+lung	B-ANAT
+,	O
+especially	O
+in	O
+those	O
+with	O
+increased	O
+levels	O
+of	O
+hemozoin	O
+,	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+malaria	B-PATH
+-	O
+associated	O
+ARDS	B-DISO
+through	O
+an	O
+apoptotic	O
+pathway	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+is	O
+a	O
+case	O
+of	O
+a	O
+19	O
+-	O
+year	O
+-	O
+old	O
+male	O
+who	O
+presented	O
+to	O
+the	O
+medical	O
+tent	O
+at	O
+an	O
+outdoor	O
+electronic	O
+dance	O
+music	O
+festival	O
+(	O
+EDMF	O
+)	O
+due	O
+to	O
+an	O
+altered	O
+mental	O
+state	O
+in	O
+the	O
+setting	O
+of	O
+acute	O
+3	O
+,	O
+4	O
+-	O
+methylenedioxymethamphetamine	O
+(	O
+MDMA	B-CHED
+)	O
+intoxication	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+being	O
+used	O
+more	O
+often	O
+as	O
+a	O
+bridge	O
+to	O
+transplantation	O
+(	O
+BTT	O
+)	O
+in	O
+patients	O
+with	O
+acutely	O
+decompensated	O
+end	O
+-	O
+stage	O
+lung	B-DISO
+disease	I-DISO
+in	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+analysis	O
+of	O
+cardiac	O
+injury	O
+markers	O
+in	O
+patients	O
+with	O
+OSA	B-DISO
+who	O
+sustain	O
+an	O
+episode	O
+of	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-DISO
+)	O
+may	O
+contribute	O
+to	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+interactions	O
+and	O
+impact	O
+of	O
+OSA	B-DISO
+in	O
+subjects	O
+with	O
+ACS	B-DISO
+.	O
+
+We	O
+compared	O
+peak	O
+cardiac	B-PRGE
+troponin	I-PRGE
+I	I-PRGE
+(	O
+cTnI	B-PRGE
+)	O
+levels	O
+in	O
+patients	O
+with	O
+OSA	B-DISO
+and	O
+patients	O
+without	O
+OSA	B-DISO
+who	O
+were	O
+admitted	O
+for	O
+ACS	B-FUNC
+.	O
+
+The	O
+multivariable	O
+linear	O
+regression	O
+analysis	O
+of	O
+the	O
+relationship	O
+between	O
+peak	O
+cTnI	O
+value	O
+and	O
+patient	O
+group	O
+,	O
+age	O
+,	O
+sex	O
+,	O
+and	O
+type	O
+of	O
+ACS	O
+showed	O
+that	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+OSA	B-DISO
+significantly	O
+contributed	O
+to	O
+the	O
+peak	O
+cTnI	B-PRGE
+level	O
+,	O
+which	O
+was	O
+54	O
+%	O
+lower	O
+in	O
+patients	O
+with	O
+OSA	B-DISO
+than	O
+in	O
+those	O
+without	O
+OSA	B-DISO
+.	O
+
+The	O
+multivariable	O
+linear	O
+regression	O
+analysis	O
+of	O
+the	O
+relationship	O
+between	O
+peak	O
+cTnI	O
+value	O
+and	O
+patient	O
+group	O
+,	O
+age	O
+,	O
+sex	O
+,	O
+and	O
+type	O
+of	O
+ACS	B-FUNC
+showed	O
+that	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+OSA	B-DISO
+significantly	O
+contributed	O
+to	O
+the	O
+peak	O
+cTnI	B-PRGE
+level	O
+,	O
+which	O
+was	O
+54	O
+%	O
+lower	O
+in	O
+patients	O
+with	O
+OSA	B-DISO
+than	O
+in	O
+those	O
+without	O
+OSA	B-DISO
+.	O
+
+We	O
+demonstrated	O
+that	O
+binding	B-FUNC
+of	O
+nsp4	B-PRGE
+with	O
+nsp3	B-PRGE
+is	O
+essential	O
+for	O
+membrane	B-COMP
+rearrangement	B-PROC
+and	O
+identified	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+in	O
+nsp4	B-PRGE
+responsible	O
+for	O
+the	O
+interaction	O
+with	O
+nsp3	B-PRGE
+.	O
+
+Finally	O
+,	O
+we	O
+showed	O
+that	O
+loss	O
+of	O
+the	O
+nsp3	B-PRGE
+-	O
+nsp4	B-PRGE
+interaction	O
+eliminated	O
+viral	B-PROC
+replication	I-PROC
+by	O
+using	O
+an	O
+infectious	B-DISO
+cDNA	O
+clone	O
+and	O
+replicon	O
+system	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+These	O
+findings	O
+provide	O
+clues	O
+to	O
+the	O
+mechanism	O
+of	O
+the	O
+replication	O
+/	O
+transcription	O
+complex	O
+assembly	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+could	O
+reveal	O
+an	O
+antiviral	B-CHED
+target	O
+for	O
+the	O
+treatment	O
+of	O
+betacoronavirus	B-SPEC
+infection	B-DISO
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+as	O
+the	O
+major	O
+immunity	B-PROC
+-	O
+eliciting	O
+antigen	B-CHED
+,	O
+has	O
+previously	O
+been	O
+used	O
+for	O
+serological	O
+testing	O
+and	O
+has	O
+been	O
+found	O
+to	O
+correlate	O
+significantly	O
+with	O
+the	O
+results	O
+of	O
+the	O
+serum	B-COMP
+neutralization	O
+(	O
+SN	O
+)	O
+test	O
+.	O
+
+Previous	O
+work	O
+revealed	O
+that	O
+glycosylation	B-PROC
+of	O
+mouse	B-SPEC
+DPP4	B-PRGE
+plays	O
+a	O
+role	O
+in	O
+blocking	B-DISO
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+tested	O
+whether	O
+glycosylation	B-PROC
+also	O
+acts	O
+as	O
+a	O
+determinant	O
+of	O
+permissivity	O
+for	O
+ferret	B-SPEC
+,	O
+hamster	B-SPEC
+,	O
+and	O
+guinea	B-PRGE
+pig	I-PRGE
+DPP4	I-PRGE
+.	O
+
+We	O
+evaluated	O
+four	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infections	B-DISO
+who	O
+showed	O
+neurological	O
+complications	O
+during	O
+MERS	O
+treatment	O
+.	O
+
+Ten	O
+multidisciplinary	O
+PICUs	B-SPEC
+in	O
+Asia	O
+.	O
+
+Besides	O
+the	O
+biological	O
+interest	O
+behind	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+non	I-PRGE
+-	I-PRGE
+structural	I-PRGE
+protein	B-CHED
+1	I-PRGE
+(	O
+nsp1	B-PRGE
+,	O
+117	O
+amino	B-CHED
+acids	I-CHED
+),	O
+this	O
+study	O
+model	O
+has	O
+two	O
+structural	O
+features	O
+that	O
+motivated	O
+its	O
+use	O
+in	O
+this	O
+work	O
+:	O
+1	O
+-	O
+its	O
+recombinant	O
+production	O
+is	O
+dependent	O
+on	O
+the	O
+temperature	O
+,	O
+with	O
+greater	O
+solubility	O
+when	O
+expressed	B-PROC
+at	O
+low	O
+temperatures	O
+.	O
+
+We	O
+identified	O
+the	O
+presence	O
+of	O
+regular	O
+secondary	O
+structure	O
+after	O
+the	O
+fourth	O
+native	O
+β	O
+-	O
+strand	O
+is	O
+present	O
+(	O
+89	O
+amino	B-CHED
+acids	I-CHED
+),	O
+in	O
+parallel	O
+to	O
+the	O
+collapse	B-DISO
+to	O
+a	O
+non	O
+-	O
+native	O
+3D	O
+structure	O
+.	O
+
+TITLE	O
+:	O
+Comprehensive	O
+,	O
+technology	O
+-	O
+based	O
+,	O
+team	O
+approach	O
+for	O
+a	O
+patient	O
+with	O
+locked	B-DISO
+-	I-DISO
+in	I-DISO
+syndrome	I-DISO
+:	O
+A	O
+case	O
+report	O
+of	O
+improved	O
+function	O
+&	O
+quality	O
+of	O
+life	O
+.	O
+
+Patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+induced	O
+by	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+)	O
+were	O
+randomly	O
+divided	O
+into	O
+three	O
+groups	O
+based	O
+on	O
+the	O
+treatment	O
+:	O
+conventional	O
+therapy	O
+alone	O
+(	O
+group	O
+A	O
+),	O
+electroacupuncture	O
+of	O
+nonacupoints	O
+with	O
+conventional	O
+therapy	O
+(	O
+group	B-DISO
+B	I-DISO
+),	O
+and	O
+electroacupuncture	O
+at	O
+the	O
+Lieque	O
+(	O
+LU7	B-ANAT
+),	O
+Chize	O
+(	O
+LU5	B-ANAT
+),	O
+and	O
+Zusanli	O
+(	O
+ST36	B-ANAT
+)	O
+points	O
+(	O
+group	O
+C	O
+)	O
+once	O
+a	O
+day	O
+for	O
+5	O
+days	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Comprehensive	O
+Review	O
+of	O
+Common	O
+Bacterial	O
+,	O
+Parasitic	O
+and	O
+Viral	O
+Zoonoses	B-DISO
+at	O
+the	O
+Human	B-SPEC
+-	O
+Animal	B-SPEC
+Interface	O
+in	O
+Egypt	O
+.	O
+
+Some	O
+zoonotic	O
+agents	O
+are	O
+""""	O
+exotic	O
+""""	O
+for	O
+Egypt	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+MERS	O
+-	O
+CoV	O
+and	O
+Crimean	B-SPEC
+-	I-SPEC
+Congo	I-SPEC
+hemorrhagic	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+),	O
+others	O
+are	O
+endemic	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+Brucellosis	B-DISO
+,	O
+Schistosomiasis	B-DISO
+and	O
+Avian	B-DISO
+influenza	I-DISO
+).	O
+
+We	O
+further	O
+characterized	O
+the	O
+complete	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+genes	O
+from	O
+the	O
+positive	O
+samples	O
+and	O
+found	O
+21	O
+different	O
+S	O
+genes	O
+with	O
+amino	B-CHED
+acid	I-CHED
+mutations	O
+.	O
+
+The	O
+PEDV	B-SPEC
+isolates	O
+here	O
+presented	O
+most	O
+of	O
+the	O
+genotypes	O
+which	O
+were	O
+found	O
+previously	O
+in	O
+field	O
+isolates	O
+in	O
+East	O
+and	O
+South	O
+-	O
+East	O
+Asia	O
+,	O
+North	O
+America	O
+,	O
+and	O
+Europe	O
+.	O
+
+This	O
+work	O
+highlighted	O
+the	O
+complexity	O
+of	O
+the	O
+epidemiology	O
+of	O
+PEDV	B-SPEC
+and	O
+emphasized	O
+the	O
+need	O
+for	O
+reassessing	O
+the	O
+efficacy	O
+of	O
+classic	O
+PEDV	B-SPEC
+vaccines	O
+against	O
+emerging	O
+variant	O
+strains	O
+and	O
+developing	O
+new	O
+vaccines	O
+to	O
+facilitate	O
+the	O
+prevention	O
+and	O
+control	O
+of	O
+PEDV	B-SPEC
+in	O
+fields	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+has	O
+been	O
+reported	O
+to	O
+improve	O
+outcomes	O
+in	O
+patients	O
+with	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+share	O
+our	O
+successful	O
+experience	O
+of	O
+ECMO	O
+treatment	O
+in	O
+the	O
+casualties	O
+of	O
+the	O
+Formosa	B-SPEC
+Water	B-CHED
+Park	B-DISO
+Dust	O
+Explosion	O
+Disaster	O
+.	O
+
+ECMO	O
+may	O
+be	O
+a	O
+lifesaving	O
+modality	O
+for	O
+burn	O
+patients	O
+with	O
+severe	O
+lung	B-ANAT
+injury	O
+who	O
+are	O
+nonresponsive	O
+to	O
+maximal	O
+medical	O
+management	O
+,	O
+especially	O
+for	O
+young	O
+patients	O
+with	O
+early	O
+ECMO	O
+intervention	O
+.	O
+
+Animal	B-SPEC
+inoculation	O
+studies	O
+revealed	O
+that	O
+the	O
+virulence	B-PROC
+of	O
+both	O
+S	O
+DEL2	O
+/	O
+ORF3	B-PRGE
+and	O
+S	O
+DEL5	O
+/	O
+ORF3	O
+viruses	B-SPEC
+with	O
+a	O
+large	O
+46	O
+-	O
+nt	O
+deletion	O
+in	O
+the	O
+intergenic	O
+portion	O
+of	O
+S	O
+and	O
+ORF3	O
+was	O
+remarkably	O
+diminished	O
+,	O
+indicating	O
+viral	O
+attenuation	O
+in	O
+the	O
+natural	O
+host	O
+.	O
+
+The	O
+sequence	O
+analysis	O
+revealed	O
+that	O
+the	O
+S	O
+genes	O
+of	O
+Vietnamese	O
+PEDVs	O
+were	O
+heterogeneous	O
+and	O
+classified	O
+into	O
+four	O
+genotypes	O
+,	O
+namely	O
+North	O
+America	O
+and	O
+Asian	O
+non	O
+-	O
+S	O
+INDEL	B-PROC
+,	O
+Asian	O
+non	O
+-	O
+S	O
+INDEL	B-PROC
+,	O
+new	O
+S	O
+INDEL	B-PROC
+and	O
+classical	O
+S	O
+INDEL	B-PROC
+.	O
+
+The	O
+study	O
+revealed	O
+that	O
+7b	O
+is	O
+N	O
+-	O
+terminally	O
+processed	O
+by	O
+a	O
+cellular	B-COMP
+signalase	O
+.	O
+
+This	O
+study	O
+is	O
+based	O
+on	O
+a	O
+retrospective	O
+analysis	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+outbreak	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+between	O
+June	O
+2012	O
+and	O
+July	O
+2015	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+causes	O
+respiratory	B-DISO
+disease	I-DISO
+leading	O
+to	O
+loss	O
+of	O
+egg	B-ANAT
+and	O
+meat	O
+production	O
+in	O
+chickens	B-SPEC
+.	O
+
+Further	O
+,	O
+IBV	B-SPEC
+productive	O
+infection	B-DISO
+in	O
+macrophages	B-ANAT
+was	O
+confirmed	O
+by	O
+demonstrating	O
+corona	B-CHED
+viral	B-COMP
+particles	I-COMP
+in	O
+macrophages	B-ANAT
+and	O
+IBV	B-SPEC
+ribonucleic	B-CHED
+acid	I-CHED
+(	O
+RNA	O
+)	O
+in	O
+culture	O
+supernatants	O
+.	O
+
+Insights	O
+for	O
+Managing	O
+Medical	O
+Complexity	O
+after	O
+Critical	B-DISO
+Illness	I-DISO
+.	O
+
+TITLE	O
+:	O
+Sensitivity	O
+and	O
+specificity	O
+of	O
+a	O
+real	O
+-	O
+time	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+detecting	O
+feline	O
+coronavirus	B-SPEC
+mutations	O
+in	O
+effusion	B-DISO
+and	O
+serum	B-COMP
+/	O
+plasma	B-ANAT
+of	O
+cats	B-SPEC
+to	O
+diagnose	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+It	O
+was	O
+hypothesized	O
+that	O
+this	O
+test	O
+would	O
+correctly	O
+discriminate	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+and	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+).	O
+
+Twenty	O
+-	O
+five	O
+control	O
+cats	B-SPEC
+were	O
+definitively	O
+diagnosed	O
+with	O
+a	O
+disease	O
+other	O
+than	O
+FIP	B-DISO
+.	O
+
+No	O
+serum	B-COMP
+/	O
+plasma	B-ANAT
+samples	O
+were	O
+positive	O
+for	O
+FIPV	O
+.	O
+
+Although	O
+specificity	O
+of	O
+the	O
+test	O
+in	O
+effusions	B-DISO
+was	O
+high	O
+,	O
+one	O
+false	O
+positive	O
+result	O
+occurred	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+Genomic	O
+Analysis	O
+MERS	O
+CoV	O
+Isolated	O
+from	O
+Humans	B-SPEC
+and	O
+Camels	B-SPEC
+with	O
+Special	O
+Reference	O
+to	O
+Virus	O
+Encoded	O
+Helicase	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+CoV	O
+)	O
+is	O
+a	O
+new	O
+emerging	O
+viral	B-DISO
+disease	I-DISO
+characterized	O
+by	O
+high	O
+fatality	O
+rate	O
+.	O
+
+MERS	O
+CoV	O
+genome	O
+shaping	O
+seems	O
+to	O
+be	O
+under	O
+compositional	O
+and	O
+mutational	O
+bias	B-SPEC
+,	O
+as	O
+revealed	O
+by	O
+preference	O
+of	O
+A	O
+/	O
+T	O
+over	O
+G	O
+/	O
+C	O
+nucleotides	B-CHED
+,	O
+preferred	O
+codons	O
+,	O
+nucleotides	B-CHED
+at	O
+the	O
+third	O
+position	O
+of	O
+codons	O
+(	O
+NT3s	O
+),	O
+relative	O
+synonymous	O
+codon	O
+usage	O
+,	O
+hydropathicity	O
+(	O
+Gravy	O
+),	O
+and	O
+aromaticity	O
+(	O
+Aromo	O
+)	O
+indices	O
+.	O
+
+Additionally	O
+,	O
+virtual	O
+screening	O
+and	O
+binding	B-FUNC
+experiments	O
+were	O
+able	O
+to	O
+identify	O
+three	O
+new	O
+virus	B-PRGE
+-	I-PRGE
+encoded	I-PRGE
+helicase	I-PRGE
+binding	B-FUNC
+compounds	O
+.	O
+
+These	O
+compounds	O
+can	O
+be	O
+used	O
+for	O
+further	O
+optimization	O
+of	O
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Evolution	B-PROC
+and	O
+Emergence	O
+of	O
+Pathogenic	O
+Viruses	B-SPEC
+:	O
+Past	O
+,	O
+Present	O
+,	O
+and	O
+Future	O
+.	O
+
+The	O
+intricate	O
+""""	O
+host	B-COMP
+-	O
+pathogen	O
+-	O
+environment	O
+""""	O
+relationship	O
+remains	O
+the	O
+key	O
+to	O
+understanding	O
+the	O
+emergence	O
+/	O
+re	O
+-	O
+emergence	O
+of	O
+pathogenic	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Airway	B-ANAT
+and	O
+parenchyma	B-ANAT
+immune	O
+cells	B-COMP
+in	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+viral	O
+and	O
+non	O
+-	O
+viral	O
+diffuse	B-DISO
+alveolar	B-ANAT
+damage	I-DISO
+.	O
+
+Retrospective	O
+analysis	O
+of	O
+all	O
+microbiologically	O
+documented	O
+bloodstream	B-PROC
+infections	B-DISO
+caused	O
+by	O
+VGS	O
+during	O
+the	O
+9	O
+-	O
+year	O
+time	O
+period	O
+(	O
+from	O
+January	O
+2006	O
+until	O
+December	O
+2014	O
+)	O
+was	O
+carried	O
+out	O
+.	O
+
+88	O
+.	O
+2	O
+%	O
+(	O
+45	O
+/	O
+51	O
+)	O
+of	O
+patients	O
+were	O
+on	O
+recommended	O
+ciprofloxacin	B-CHED
+prophylaxis	O
+.	O
+
+Twenty	O
+-	O
+four	O
+(	O
+47	O
+.	O
+0	O
+%)	O
+patients	O
+presented	O
+with	O
+bilateral	O
+lung	B-ANAT
+infiltrated	B-DISO
+upon	O
+chest	B-ANAT
+imaging	O
+,	O
+and	O
+two	O
+(	O
+4	O
+.	O
+0	O
+%)	O
+patients	O
+had	O
+unilateral	O
+lung	B-ANAT
+infiltrates	B-DISO
+.	O
+
+Three	O
+patients	O
+(	O
+5	O
+.	O
+9	O
+%)	O
+died	B-PROC
+due	O
+to	O
+VGS	O
+BSI	B-CHED
+until	O
+day	O
+28	O
+of	O
+observation	O
+.	O
+
+TITLE	O
+:	O
+TMPRSS2	O
+:	O
+A	O
+potential	O
+target	O
+for	O
+treatment	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+a	O
+highly	O
+lethal	O
+pneumonia	B-DISO
+.	O
+
+We	O
+obtained	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+and	O
+/	O
+or	O
+sera	B-COMP
+from	O
+21	O
+MERS	O
+survivors	O
+.	O
+
+Using	O
+Gene	O
+Ontology	O
+(	O
+GO	O
+)	O
+enrichment	O
+prediction	O
+,	O
+the	O
+DE	O
+miRNAs	O
+were	O
+shown	O
+to	O
+be	O
+mostly	O
+associated	O
+with	O
+metabolic	B-PROC
+processes	I-PROC
+,	O
+catalytic	O
+activities	O
+,	O
+gene	O
+expression	O
+,	O
+binding	B-FUNC
+activities	O
+and	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+demonstration	O
+that	O
+infection	B-DISO
+with	O
+different	O
+virulent	O
+IBVs	O
+elicits	O
+different	O
+expression	B-PROC
+of	O
+miRNAs	O
+in	O
+chicken	B-SPEC
+kidneys	B-ANAT
+;	O
+this	O
+expression	B-PROC
+also	O
+seems	O
+to	O
+be	O
+associated	O
+with	O
+the	O
+virulence	B-PROC
+of	O
+IBV	B-SPEC
+.	O
+
+These	O
+results	O
+are	O
+significant	O
+for	O
+the	O
+study	O
+of	O
+immune	B-PROC
+responses	I-PROC
+to	O
+infection	B-DISO
+with	O
+different	O
+virulent	O
+IBVs	O
+mediated	O
+by	O
+miRNAs	O
+as	O
+well	O
+as	O
+the	O
+interaction	O
+between	O
+the	O
+chicken	B-SPEC
+host	B-COMP
+and	O
+IBV	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+Thoracoscopic	O
+approach	O
+to	O
+esophagectomy	O
+significantly	O
+reduced	O
+PPC	O
+frequency	O
+with	O
+minimal	O
+additional	O
+effect	O
+from	O
+laparoscopic	O
+gastric	B-ANAT
+mobilization	O
+.	O
+
+Three	O
+hundred	O
+and	O
+twenty	O
+-	O
+four	O
+samples	O
+which	O
+were	O
+found	O
+to	O
+be	O
+negative	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+after	O
+screening	O
+with	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+and	O
+cell	B-COMP
+-	O
+based	O
+culture	O
+techniques	O
+demonstrated	O
+the	O
+potential	O
+for	O
+viral	B-DISO
+infection	I-DISO
+with	O
+evident	O
+cytopathic	B-DISO
+effect	I-DISO
+(	O
+CPE	O
+)	O
+in	O
+several	O
+cell	O
+lines	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+mono	B-DISO
+-	O
+and	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+by	O
+swine	B-DISO
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+and	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+in	O
+porcine	B-SPEC
+precision	O
+-	O
+cut	O
+lung	B-ANAT
+slices	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+as	O
+well	O
+as	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+are	O
+widely	O
+spread	O
+in	O
+pig	B-SPEC
+fattening	O
+and	O
+can	O
+cause	O
+high	O
+economical	O
+loss	O
+.	O
+
+Again	O
+lower	O
+titers	O
+in	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+groups	O
+indicated	O
+an	O
+interference	O
+of	O
+the	O
+two	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+This	O
+is	O
+in	O
+accordance	O
+with	O
+in	O
+vivo	O
+experiments	O
+,	O
+revealing	O
+cell	B-COMP
+innate	O
+immune	O
+answers	O
+to	O
+both	O
+PRCoV	O
+and	O
+SIV	B-DISO
+that	O
+are	O
+able	O
+to	O
+restrict	O
+the	O
+virulence	B-PROC
+and	O
+pathogenicity	O
+of	O
+the	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+cholesterol	B-PROC
+transport	B-PROC
+inhibitor	B-CHED
+U18666A	O
+inhibits	O
+type	O
+I	O
+feline	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+HDACi	B-CHED
+has	O
+been	O
+reported	O
+to	O
+revert	O
+U18666A	O
+-	O
+induced	O
+dysfunction	O
+of	O
+Niemann	B-PRGE
+-	I-PRGE
+Pick	I-PRGE
+C1	I-PRGE
+(	O
+NPC1	B-DISO
+).	O
+
+U18666A	O
+or	O
+other	O
+cholesterol	B-PROC
+transport	B-PROC
+inhibitor	B-CHED
+may	O
+be	O
+considered	O
+as	O
+the	O
+antiviral	B-CHED
+drug	I-CHED
+for	O
+the	O
+treatment	O
+of	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+Currently	O
+,	O
+the	O
+recovery	O
+goal	O
+in	O
+sow	O
+units	O
+infected	O
+with	O
+PEDV	B-SPEC
+is	O
+to	O
+become	O
+fully	O
+naive	O
+again	O
+or	O
+use	O
+natural	O
+virus	B-DISO
+infection	I-DISO
+to	O
+develop	O
+immune	O
+gilts	O
+through	O
+a	O
+feedback	O
+program	O
+before	O
+introduction	O
+into	O
+the	O
+sow	O
+herd	O
+.	O
+
+The	O
+results	O
+illustrate	O
+that	O
+intramuscular	O
+vaccination	O
+increased	O
+neutralizing	O
+antibody	O
+titers	O
+,	O
+and	O
+anti	B-PRGE
+-	I-PRGE
+PEDV	I-PRGE
+IgA	I-PRGE
+and	O
+IgG	B-PRGE
+in	O
+milk	O
+and	O
+colostrum	B-ANAT
+of	O
+sows	O
+that	O
+were	O
+previously	O
+infected	O
+.	O
+
+TITLE	O
+:	O
+Periurban	O
+outbreaks	O
+of	O
+bovine	B-SPEC
+calf	B-ANAT
+scours	O
+in	O
+Northern	O
+India	O
+caused	O
+by	O
+Cryptosporidium	B-SPEC
+in	O
+association	O
+with	O
+other	O
+enteropathogens	O
+.	O
+
+The	O
+detection	O
+rate	O
+of	O
+the	O
+other	O
+enteropathogens	O
+associated	O
+with	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+was	O
+45	O
+·	O
+71	O
+%	O
+for	O
+C	B-SPEC
+.	I-SPEC
+perfringens	I-SPEC
+followed	O
+by	O
+Salmonella	B-DISO
+spp	B-ENZY
+(	O
+40	O
+·	O
+0	O
+%),	O
+rotavirus	B-SPEC
+(	O
+36	O
+·	O
+0	O
+%),	O
+coronavirus	B-SPEC
+(	O
+16	O
+·	O
+0	O
+%),	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+(	O
+12	O
+·	O
+0	O
+%)	O
+and	O
+Eimeria	B-SPEC
+spp	B-ENZY
+(	O
+4	O
+·	O
+0	O
+%)	O
+The	O
+sensitivity	O
+for	O
+detection	O
+of	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+by	O
+ELISA	O
+and	O
+mZN	O
+staining	O
+in	O
+comparison	O
+to	O
+PCR	O
+was	O
+97	O
+·	O
+14	O
+%	O
+and	O
+72	O
+·	O
+72	O
+%,	O
+respectively	O
+.	O
+
+The	O
+results	O
+of	O
+the	O
+Real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+showed	O
+that	O
+52	O
+.	O
+16	O
+%	O
+of	O
+flocks	O
+were	O
+IBV	B-SPEC
+positive	O
+.	O
+
+Proper	O
+control	O
+strategies	O
+are	O
+essential	O
+to	O
+overcoming	O
+the	O
+high	O
+frequency	O
+of	O
+occurrence	O
+of	O
+IS	O
+-	O
+1494	O
+-	O
+like	O
+IBV	B-SPEC
+.	O
+
+Further	O
+studies	O
+are	O
+needed	O
+and	O
+should	O
+include	O
+the	O
+isolation	O
+and	O
+full	O
+-	O
+length	O
+molecular	O
+characterization	O
+of	O
+IBV	B-SPEC
+in	O
+Iran	O
+.	O
+
+TITLE	O
+:	O
+Persistent	O
+Transmissible	O
+Gastroenteritis	B-DISO
+Virus	B-DISO
+Infection	I-DISO
+Enhances	O
+Enterotoxigenic	O
+Escherichia	B-SPEC
+coli	I-SPEC
+K88	O
+Adhesion	B-DISO
+by	O
+Promoting	O
+Epithelial	B-PROC
+-	I-PROC
+Mesenchymal	I-PROC
+Transition	I-PROC
+in	O
+Intestinal	B-ANAT
+Epithelial	B-ANAT
+Cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+is	O
+a	O
+coronavirus	B-SPEC
+characterized	O
+by	O
+diarrhea	B-DISO
+and	O
+high	O
+morbidity	O
+rates	O
+,	O
+and	O
+the	O
+mortality	O
+rate	O
+is	O
+100	O
+%	O
+in	O
+piglets	O
+less	O
+than	O
+2	O
+weeks	O
+old	O
+.	O
+
+Pigs	B-SPEC
+infected	O
+with	O
+TGEV	B-SPEC
+often	O
+suffer	B-DISO
+secondary	B-DISO
+infection	I-DISO
+by	O
+other	O
+pathogens	O
+,	O
+which	O
+aggravates	O
+the	O
+severity	O
+of	O
+diarrhea	B-DISO
+,	O
+but	O
+the	O
+mechanisms	O
+remain	O
+unknown	O
+.	O
+
+A	O
+computer	O
+tomography	O
+-(	O
+CT	O
+)-	O
+scan	O
+presented	O
+bilateral	O
+interstitial	B-ANAT
+and	O
+alveolar	B-ANAT
+infiltrations	O
+.	O
+
+One	O
+should	O
+consider	O
+APT	O
+when	O
+signs	O
+of	O
+pulmonary	B-DISO
+failure	I-DISO
+occur	O
+during	O
+brief	O
+periods	B-PROC
+of	O
+amiodarone	B-CHED
+therapy	O
+especially	O
+after	O
+thoracic	B-DISO
+surgery	O
+.	O
+
+Spread	O
+of	O
+the	O
+infection	B-DISO
+occurred	O
+worldwide	O
+;	O
+however	O
+,	O
+most	O
+cases	O
+of	O
+mortality	O
+have	O
+occurred	O
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+TITLE	O
+:	O
+Benign	O
+Acute	O
+Childhood	O
+Myositis	B-DISO
+During	O
+Influenza	B-DISO
+B	O
+Outbreak	O
+.	O
+
+Laboratory	O
+results	O
+show	O
+increased	O
+serum	B-PRGE
+creatinine	B-CHED
+kinase	I-PRGE
+and	O
+AST	B-PRGE
+.	O
+
+Little	O
+is	O
+known	O
+about	O
+the	O
+course	O
+of	O
+this	O
+infection	B-DISO
+in	O
+pregnancy	O
+.	O
+
+The	O
+patient	O
+'	O
+s	O
+respiratory	O
+status	O
+continued	O
+to	O
+decline	O
+postpartum	O
+,	O
+and	O
+she	O
+ultimately	O
+required	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Tissues	B-ANAT
+were	O
+infected	O
+with	O
+RV	O
+-	O
+A55	O
+,	O
+RV	O
+-	O
+A49	O
+,	O
+RV	O
+-	O
+B48	O
+,	O
+RV	O
+-	O
+C8	O
+,	O
+and	O
+RV	O
+-	O
+C15	O
+;	O
+respiratory	O
+EV	O
+-	O
+D68	O
+;	O
+influenza	B-SPEC
+virus	I-SPEC
+H3N2	B-CHED
+;	O
+RSV	B-PRGE
+-	I-PRGE
+B	I-PRGE
+;	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)-	O
+OC43	O
+.	O
+
+H3N2	B-CHED
+was	O
+also	O
+detected	O
+in	O
+rare	O
+goblet	O
+and	O
+basal	B-ANAT
+cells	I-ANAT
+.	O
+
+All	O
+viruses	B-SPEC
+,	O
+except	O
+RV	O
+-	O
+B48	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+altered	O
+cilia	B-COMP
+beating	O
+and	O
+mucociliary	O
+clearance	O
+.	O
+
+Our	O
+results	O
+highlight	O
+the	O
+differential	O
+in	O
+vitro	O
+pathogenesis	B-DISO
+of	O
+respiratory	O
+viruses	B-SPEC
+during	O
+the	O
+acute	B-DISO
+infection	I-DISO
+phase	O
+and	O
+their	O
+ability	O
+to	O
+persist	O
+under	O
+immune	B-DISO
+tolerance	I-DISO
+.	O
+
+A	O
+PEDV	B-SPEC
+strain	O
+was	O
+isolated	O
+from	O
+the	O
+intestinal	B-ANAT
+tract	I-ANAT
+of	O
+diarrheic	O
+piglets	O
+from	O
+a	O
+pig	B-SPEC
+farm	O
+in	O
+Jiangsu	O
+Province	O
+in	O
+March	O
+2016	O
+,	O
+termed	O
+the	O
+JS201603	O
+isolate	O
+.	O
+
+After	O
+identifying	O
+the	O
+causing	O
+factor	O
+(	O
+Pneumocyctis	O
+jiroveci	O
+),	O
+EIT	O
+monitoring	O
+was	O
+maintained	O
+to	O
+assess	O
+the	O
+effectiveness	O
+of	O
+targeted	B-PROC
+microbial	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+an	O
+HIV	B-DISO
+-	O
+positive	O
+man	B-CHED
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+secondary	O
+to	O
+pneumocystis	B-DISO
+and	O
+cytomegalovirus	B-DISO
+pneumonia	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+management	O
+of	O
+critically	B-DISO
+ill	I-DISO
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)-	O
+positive	O
+patients	O
+is	O
+challenging	O
+;	O
+however	O
+,	O
+intensive	O
+care	O
+unit	O
+-	O
+related	O
+mortality	O
+has	O
+declined	O
+significantly	O
+in	O
+recent	O
+years	O
+.	O
+
+There	O
+are	O
+10	O
+case	O
+reports	O
+in	O
+the	O
+literature	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+use	O
+in	O
+HIV	B-DISO
+-	O
+positive	O
+patients	O
+,	O
+of	O
+whom	O
+seven	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+We	O
+describe	O
+a	O
+33	O
+-	O
+year	O
+-	O
+old	O
+Brazilian	O
+man	B-CHED
+who	O
+presented	O
+with	O
+Pneumocystis	B-SPEC
+jirovecii	I-SPEC
+pneumonia	B-DISO
+and	O
+severe	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Despite	O
+poor	O
+evidence	O
+surrounding	O
+the	O
+use	O
+of	O
+ECMO	O
+in	O
+immunocompromised	O
+patients	O
+,	O
+it	O
+is	O
+evident	O
+that	O
+ECMO	O
+could	O
+represent	O
+an	O
+important	O
+rescue	O
+therapy	O
+in	O
+HIV	O
+-	O
+positive	O
+patients	O
+with	O
+refractory	O
+ARDS	B-DISO
+.	O
+
+The	O
+animals	B-SPEC
+showed	O
+clinical	O
+signs	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+with	O
+frothy	O
+nasal	B-DISO
+discharge	B-ANAT
+(	O
+1	O
+-	O
+2	O
+days	O
+)	O
+and	O
+mortality	O
+of	O
+twenty	O
+animals	B-SPEC
+(	O
+80	O
+%)	O
+within	O
+48	O
+hr	O
+.	O
+
+There	O
+was	O
+no	O
+characteristic	O
+lesion	O
+in	O
+the	O
+intestine	B-ANAT
+.	O
+
+The	O
+present	O
+information	O
+of	O
+PPR	B-DISO
+in	O
+Chowsingha	O
+is	O
+the	O
+first	O
+report	O
+of	O
+PPRV	O
+lineage	O
+IV	O
+causing	O
+cross	O
+-	O
+species	B-SPEC
+fatal	O
+disease	O
+in	O
+subfamily	B-SPEC
+bovinae	I-SPEC
+and	O
+family	B-SPEC
+Bovidae	I-SPEC
+.	O
+
+The	O
+acute	O
+manifestation	O
+of	O
+the	O
+disease	O
+indicates	O
+high	O
+susceptibility	O
+of	O
+this	O
+vulnerable	O
+wild	O
+bovid	B-SPEC
+species	B-SPEC
+to	O
+PPR	B-DISO
+lineage	O
+IV	O
+.	O
+
+The	O
+lateral	O
+cephalogram	O
+is	O
+a	O
+useful	O
+tool	O
+in	O
+the	O
+differentiation	B-PROC
+of	O
+UARS	O
+from	O
+other	O
+OSA	B-DISO
+phenotypes	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+characterisation	O
+and	O
+analysis	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolated	O
+from	O
+Brazilian	O
+flocks	O
+between	O
+2010	O
+and	O
+2015	O
+.	O
+
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+variants	O
+in	O
+Brazil	O
+were	O
+isolated	O
+during	O
+2010	O
+-	O
+2015	O
+for	O
+epidemiological	O
+and	O
+molecular	O
+analysis	O
+to	O
+characterise	O
+the	O
+different	O
+variants	O
+and	O
+perform	O
+a	O
+bioinformatic	O
+analysis	O
+to	O
+compare	O
+with	O
+sequences	O
+of	O
+variants	O
+collected	O
+over	O
+the	O
+previous	O
+40	O
+years	O
+.	O
+
+Brazilian	O
+IBV	B-SPEC
+genotype	O
+BR	O
+-	O
+I	O
+is	O
+currently	O
+the	O
+predominant	O
+genotype	O
+circulating	O
+in	O
+Brazil	O
+and	O
+South	O
+America	O
+.	O
+
+TITLE	O
+:	O
+What	O
+We	O
+Are	O
+Watching	O
+-	O
+Top	O
+Global	O
+Infectious	B-DISO
+Disease	I-DISO
+Threats	O
+,	O
+2013	O
+-	O
+2016	O
+:	O
+An	O
+Update	O
+from	O
+CDC	O
+'	O
+s	O
+Global	O
+Disease	O
+Detection	O
+Operations	O
+Center	O
+.	O
+
+The	O
+ORF1a	O
+and	O
+upE	O
+MERS	O
+-	O
+CoV	O
+RT	O
+-	O
+iiPCR	O
+assays	O
+coupled	O
+with	O
+a	O
+field	O
+-	O
+deployable	O
+system	O
+provide	O
+a	O
+platform	O
+for	O
+a	O
+highly	O
+sensitive	O
+and	O
+specific	O
+on	O
+-	O
+site	O
+tool	O
+for	O
+diagnosis	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+lineage	O
+C	O
+betacoronavirus	B-SPEC
+that	O
+since	O
+its	O
+emergence	O
+in	O
+2012	O
+has	O
+caused	O
+outbreaks	O
+in	O
+human	B-SPEC
+populations	O
+with	O
+case	O
+-	O
+fatality	O
+rates	O
+of	O
+∼	O
+36	O
+%.	O
+
+Recombinase	B-PRGE
+polymerase	I-PRGE
+amplification	I-PRGE
+(	O
+RPA	B-COMP
+),	O
+as	O
+an	O
+isothermal	O
+gene	B-DISO
+amplification	I-DISO
+technique	O
+,	O
+has	O
+been	O
+explored	O
+for	O
+the	O
+molecular	O
+detection	O
+of	O
+diverse	O
+pathogens	O
+.	O
+
+A	O
+series	O
+of	O
+other	O
+viruses	B-SPEC
+were	O
+tested	O
+by	O
+the	O
+RT	B-PRGE
+-	I-PRGE
+RPA	I-PRGE
+.	O
+Thirty	O
+-	O
+two	O
+field	O
+samples	O
+were	O
+further	O
+tested	O
+by	O
+RT	B-PRGE
+-	I-PRGE
+RPA	I-PRGE
+,	O
+and	O
+the	O
+resuts	O
+were	O
+compared	O
+with	O
+those	O
+obtained	O
+by	O
+the	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+we	O
+discovered	O
+a	O
+plausible	O
+explanation	O
+for	O
+the	O
+public	O
+overreaction	O
+to	O
+MERS	O
+in	O
+terms	O
+of	O
+the	O
+interplay	O
+between	O
+the	O
+disease	O
+,	O
+mass	O
+media	B-ANAT
+,	O
+and	O
+public	O
+emotions	O
+.	O
+
+ABSTRACT	O
+:	O
+Zinc	B-CHED
+chloride	I-CHED
+smoke	O
+bomb	O
+exposure	O
+is	O
+frequently	O
+seen	O
+in	O
+military	O
+drills	B-SPEC
+,	O
+combat	B-CHED
+exercises	O
+,	O
+metal	B-CHED
+industry	O
+works	O
+,	O
+and	O
+disaster	O
+simulations	O
+.	O
+
+We	O
+suggest	O
+that	O
+an	O
+extended	O
+course	O
+of	O
+high	O
+dose	O
+corticosteroids	B-CHED
+should	O
+be	O
+considered	O
+for	O
+the	O
+treatment	O
+of	O
+smoke	O
+inhalation	B-PROC
+related	O
+ARDS	B-DISO
+and	O
+should	O
+be	O
+introduced	O
+as	O
+early	O
+as	O
+possible	O
+to	O
+minimize	O
+the	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Cardiorespiratory	O
+pathogenesis	B-DISO
+of	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+in	O
+a	O
+mouse	B-SPEC
+model	O
+.	O
+
+At	O
+postnatal	O
+day	O
+3	O
+,	O
+43	O
+%	O
+of	O
+SAD	B-DISO
+mice	B-SPEC
+showed	O
+marked	O
+apneas	B-DISO
+,	O
+anemia	B-DISO
+,	O
+and	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+congestion	B-DISO
+typical	O
+of	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+;	O
+none	O
+of	O
+these	O
+mice	B-SPEC
+survived	O
+to	O
+maturity	O
+.	O
+
+Diagnosis	O
+leading	O
+to	O
+ARDS	B-DISO
+was	O
+pneumonia	B-DISO
+in	O
+63	O
+.	O
+1	O
+%	O
+of	O
+the	O
+patients	O
+.	O
+
+Twenty	O
+-	O
+eight	O
+patients	O
+(	O
+60	O
+.	O
+9	O
+%)	O
+were	O
+successfully	O
+weaned	B-PROC
+from	O
+ECMO	O
+and	O
+22	O
+patients	O
+survived	O
+(	O
+47	O
+.	O
+8	O
+%).	O
+
+Areas	O
+covered	O
+:	O
+This	O
+review	O
+presents	O
+an	O
+overview	O
+of	O
+MERS	O
+-	O
+CoV	O
+within	O
+the	O
+last	O
+five	O
+years	O
+,	O
+with	O
+a	O
+particular	O
+emphasis	O
+on	O
+the	O
+key	O
+areas	O
+of	O
+transmission	B-DISO
+,	I-DISO
+infection	I-DISO
+control	O
+and	O
+prevention	O
+,	O
+and	O
+therapies	O
+and	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+burdened	O
+with	O
+significant	O
+mortality	O
+,	O
+mainly	O
+in	O
+connection	O
+with	O
+circulatory	B-DISO
+failure	I-DISO
+.	O
+
+Driving	O
+pressure	O
+≥	O
+18	O
+cmH	B-DISO
+
+TITLE	O
+:	O
+Altered	O
+Lipid	B-PROC
+Metabolism	I-PROC
+in	O
+Recovered	O
+SARS	B-DISO
+Patients	O
+Twelve	O
+Years	O
+after	O
+Infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+is	O
+an	O
+infective	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+that	O
+causes	O
+diarrhea	B-DISO
+-	O
+related	O
+morbidity	O
+and	O
+mortality	O
+in	O
+piglets	O
+.	O
+
+For	O
+the	O
+first	O
+time	O
+,	O
+a	O
+natural	O
+recombination	B-PROC
+strain	O
+of	O
+a	O
+TGEV	B-SPEC
+Anhui	O
+Hefei	O
+(	O
+AHHF	O
+)	O
+virus	B-SPEC
+between	O
+the	O
+Purdue	O
+and	O
+the	O
+Miller	O
+clusters	B-CHED
+was	O
+isolated	O
+from	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+content	O
+of	O
+piglets	O
+in	O
+China	O
+.	O
+
+Such	O
+viruses	B-SPEC
+have	O
+become	O
+a	O
+more	O
+common	O
+cause	O
+of	O
+severe	O
+respiratory	O
+-	O
+tract	O
+infections	B-DISO
+,	O
+especially	O
+in	O
+children	O
+with	O
+underlying	O
+lung	B-DISO
+disease	I-DISO
+such	O
+as	O
+asthma	B-PATH
+.	O
+
+TITLE	O
+:	O
+Clinicopathologic	O
+Features	O
+and	O
+Magnetic	O
+Resonance	O
+Imaging	O
+Findings	O
+in	O
+24	O
+Cats	B-SPEC
+With	O
+Histopathologically	O
+Confirmed	O
+Neurologic	O
+Feline	O
+Infectious	O
+Peritonitis	O
+.	O
+
+Information	O
+regarding	O
+the	O
+magnetic	O
+resonance	O
+imaging	O
+(	O
+MRI	O
+)	O
+findings	O
+of	O
+neurologic	O
+FIP	B-DISO
+currently	O
+is	O
+limited	O
+,	O
+resulting	O
+in	O
+the	O
+need	O
+for	O
+better	O
+descriptions	O
+to	O
+optimize	O
+its	O
+use	O
+as	O
+a	O
+diagnostic	O
+tool	O
+.	O
+
+To	O
+describe	O
+the	O
+clinicopathologic	O
+features	O
+and	O
+MRI	O
+findings	O
+in	O
+cases	O
+of	O
+confirmed	O
+neurologic	O
+FIP	B-DISO
+.	O
+
+Twenty	O
+-	O
+four	O
+client	O
+-	O
+owned	O
+cats	B-SPEC
+with	O
+histopathologic	O
+confirmation	O
+of	O
+neurologic	O
+FIP	B-DISO
+.	O
+
+All	O
+24	O
+cats	B-SPEC
+were	O
+euthanized	O
+with	O
+a	O
+median	O
+survival	O
+time	O
+of	O
+14	O
+days	O
+(	O
+range	O
+,	O
+2	O
+-	O
+115	O
+)	O
+from	O
+onset	O
+of	O
+clinical	O
+signs	O
+.	O
+
+An	O
+83	O
+-	O
+year	O
+-	O
+old	O
+Japanese	O
+man	B-CHED
+developed	O
+acute	O
+anterior	O
+hypopituitarism	B-DISO
+;	O
+he	O
+showed	O
+anorexia	B-DISO
+,	O
+fatigue	B-DISO
+,	O
+lethargy	B-DISO
+,	O
+severe	O
+bilateral	O
+periorbital	B-DISO
+edema	I-DISO
+,	O
+and	O
+mild	O
+cardiac	B-ANAT
+dysfunction	O
+in	O
+the	O
+absence	O
+of	O
+headache	B-DISO
+,	O
+visual	B-DISO
+disturbance	I-DISO
+,	O
+altered	B-DISO
+mental	I-DISO
+status	I-DISO
+,	O
+and	O
+cranial	B-ANAT
+nerve	I-ANAT
+palsy	I-DISO
+.	O
+
+Magnetic	O
+resonance	O
+imaging	O
+showed	O
+a	O
+2	O
+.	O
+5	O
+-	O
+cm	O
+pituitary	B-DISO
+tumor	I-DISO
+containing	O
+a	O
+mixed	O
+pattern	O
+of	O
+solid	O
+and	O
+liquid	O
+components	O
+indicating	O
+pituitary	B-DISO
+tumor	I-DISO
+apoplexy	B-DISO
+due	O
+to	O
+hemorrhage	B-DISO
+in	O
+a	O
+preexisting	O
+pituitary	B-DISO
+adenoma	I-DISO
+.	O
+
+In	O
+the	O
+present	O
+case	O
+,	O
+the	O
+patient	O
+'	O
+s	O
+acute	O
+central	B-DISO
+hypothyroidism	I-DISO
+was	O
+probably	O
+involved	O
+in	O
+the	O
+development	B-PROC
+of	O
+both	O
+periorbital	B-DISO
+edema	I-DISO
+and	O
+cardiac	B-ANAT
+dysfunction	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+some	O
+cells	O
+were	O
+able	O
+to	O
+survive	O
+the	O
+infection	B-DISO
+,	O
+as	O
+demonstrated	O
+by	O
+continued	O
+tdTomato	O
+expression	B-PROC
+after	O
+virus	B-SPEC
+antigen	B-CHED
+could	O
+no	O
+longer	O
+be	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+outcomes	O
+of	O
+isolated	O
+renal	B-DISO
+failure	I-DISO
+compared	O
+to	O
+other	O
+forms	O
+of	O
+organ	B-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+pancreatitis	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+differences	O
+in	O
+clinical	O
+outcomes	O
+of	O
+isolated	O
+renal	B-DISO
+failure	I-DISO
+(	O
+RF	O
+)	O
+compared	O
+to	O
+other	O
+forms	O
+of	O
+organ	B-DISO
+failure	I-DISO
+(	O
+OF	O
+)	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+).	O
+
+Differences	O
+in	O
+clinical	O
+outcomes	O
+after	O
+development	B-PROC
+of	O
+isolated	O
+RF	O
+in	O
+comparison	O
+to	O
+other	O
+forms	O
+of	O
+OF	O
+were	O
+determined	O
+using	O
+independent	O
+t	O
+and	O
+Mann	O
+-	O
+Whitney	O
+Among	O
+500	O
+patients	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+111	O
+patients	O
+developed	O
+persistent	O
+OF	O
+:	O
+mean	O
+age	O
+was	O
+54	O
+years	O
+,	O
+and	O
+75	O
+(	O
+67	O
+.	O
+6	O
+%)	O
+were	O
+male	O
+.	O
+
+To	O
+this	O
+end	O
+,	O
+the	O
+GLs	O
+should	O
+include	O
+appropriate	O
+recruitment	B-DISO
+protocols	O
+and	O
+questionnaire	O
+-	O
+based	O
+risk	O
+profiles	O
+to	O
+identify	O
+suitable	O
+donors	O
+.	O
+
+This	O
+study	O
+examines	O
+the	O
+profiles	O
+of	O
+upregulation	B-PROC
+and	O
+downregulation	B-PROC
+of	O
+various	O
+cytokines	O
+and	O
+chemokines	O
+in	O
+relation	O
+to	O
+asthmatic	B-DISO
+control	O
+status	O
+.	O
+
+IL	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+was	O
+significantly	O
+upregulated	O
+in	O
+patients	O
+with	O
+the	O
+uncontrolled	O
+and	O
+refractory	O
+status	O
+.	O
+
+Therefore	O
+,	O
+IL	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+may	O
+play	O
+important	O
+roles	O
+in	O
+asthmatic	B-DISO
+exacerbation	O
+,	O
+and	O
+its	O
+high	O
+level	O
+,	O
+in	O
+combination	O
+with	O
+upregulated	O
+Th2	O
+and	O
+other	O
+cytokines	O
+,	O
+may	O
+indicate	O
+the	O
+refractory	O
+endotype	O
+of	O
+asthma	B-PATH
+.	O
+
+In	O
+contrast	O
+,	O
+viral	O
+RNA	O
+circumvents	O
+the	O
+nsp1	B-PRGE
+-	O
+mediated	O
+translational	B-PROC
+shutoff	O
+for	O
+an	O
+efficient	O
+propagation	O
+.	O
+
+The	O
+challenges	O
+in	O
+vaccine	O
+development	B-PROC
+and	O
+the	O
+approach	O
+to	O
+clinical	O
+trial	O
+design	O
+to	O
+test	O
+vaccine	O
+candidates	O
+for	O
+disease	O
+entities	O
+with	O
+a	O
+changing	O
+epidemiology	O
+are	O
+discussed	O
+.	O
+
+During	O
+2015	O
+-	O
+2016	O
+,	O
+a	O
+total	O
+of	O
+104	O
+diarrheic	O
+fecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+puppies	O
+and	O
+adult	O
+dogs	B-SPEC
+,	O
+with	O
+or	O
+without	O
+hemorrhagic	B-DISO
+gastroenteritis	I-DISO
+,	O
+on	O
+the	O
+Caribbean	O
+island	O
+of	O
+St	O
+.	O
+Kitts	O
+(	O
+KNA	O
+).	O
+
+The	O
+method	O
+was	O
+performed	O
+using	O
+a	O
+MassARRAY	O
+matrix	O
+-	O
+assisted	O
+laser	B-SPEC
+desorption	O
+/	O
+ionization	O
+time	O
+-	O
+of	O
+-	O
+flight	B-PROC
+mass	O
+spectrometry	O
+(	O
+MALDI	O
+-	O
+TOF	B-DISO
+MS	O
+)	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+an	O
+enteropathogenic	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+of	O
+porcine	B-SPEC
+,	O
+causes	O
+lethal	O
+watery	B-DISO
+diarrhea	I-DISO
+and	O
+severe	B-DISO
+dehydration	I-DISO
+in	O
+piglets	O
+and	O
+leads	O
+to	O
+severe	O
+economic	O
+losses	O
+in	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+M2	O
+,	O
+especially	O
+M2c	O
+,	O
+induced	O
+Tregs	O
+without	O
+any	O
+influence	O
+on	O
+Tregs	O
+immunosuppression	B-PROC
+function	O
+.	O
+
+The	O
+survival	O
+analysis	O
+revealed	O
+a	O
+higher	O
+90	O
+-	O
+day	O
+mortality	O
+risk	O
+among	O
+T	O
+homozygotes	O
+than	O
+among	O
+C	O
+-	O
+allele	O
+carriers	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0144	O
+)	O
+exclusively	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	O
+due	O
+to	O
+pneumonia	B-DISO
+.	O
+
+A	O
+total	O
+of	O
+254	O
+small	B-ANAT
+intestinal	I-ANAT
+or	O
+fecal	B-ANAT
+samples	O
+collected	O
+from	O
+10	O
+provinces	O
+including	O
+Henan	O
+,	O
+Hunan	O
+,	O
+Zhejiang	O
+,	O
+Jiangxi	O
+,	O
+Anhui	O
+,	O
+Hebei	O
+,	O
+Heilongjiang	O
+,	O
+Jiangsu	O
+,	O
+Shandong	O
+and	O
+Shanghai	O
+between	O
+2014	O
+and	O
+2015	O
+,	O
+were	O
+screened	O
+by	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+targeting	B-PROC
+the	O
+viral	B-PRGE
+M	I-PRGE
+gene	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Entry	O
+of	O
+the	O
+α	O
+-	O
+coronavirus	B-SPEC
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+requires	O
+specific	O
+proteases	O
+to	O
+activate	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+for	O
+the	O
+membrane	B-PROC
+fusion	I-PROC
+of	O
+the	O
+virion	B-COMP
+to	O
+the	O
+host	B-COMP
+cell	I-COMP
+following	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+Otherwise	O
+,	O
+a	O
+novel	O
+variation	O
+(	O
+16	O
+-	O
+20	O
+aa	O
+deletion	O
+and	O
+an	O
+L25P	O
+mutation	O
+)	O
+in	O
+the	O
+transmembrane	B-COMP
+domain	O
+of	O
+the	O
+E	O
+protein	B-CHED
+affected	O
+multiple	O
+infection	B-DISO
+processes	O
+,	O
+including	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+the	O
+production	O
+of	O
+the	O
+ER	O
+stress	O
+indicator	B-CHED
+GRP78	B-PRGE
+,	O
+improving	O
+the	O
+expression	B-PROC
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	B-PRGE
+IL	I-PRGE
+-	I-PRGE
+6	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+promoting	O
+apoptosis	B-PATH
+.	O
+
+The	O
+current	O
+therapies	O
+have	O
+mainly	O
+been	O
+adapted	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+treatments	O
+,	O
+including	O
+broad	O
+-	O
+spectrum	O
+antibiotics	B-CHED
+,	O
+corticosteroids	B-CHED
+,	O
+interferons	O
+,	O
+ribavirin	B-CHED
+,	O
+lopinavir	O
+-	O
+ritonavir	B-CHED
+or	O
+mycophenolate	B-CHED
+mofetil	I-CHED
+,	O
+and	O
+have	O
+not	O
+been	O
+subject	O
+to	O
+well	O
+-	O
+organized	O
+clinical	O
+trials	O
+.	O
+
+There	O
+are	O
+many	O
+options	O
+for	O
+the	O
+development	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+-	O
+specific	O
+therapies	O
+.	O
+
+Tissue	B-ANAT
+needle	O
+biopsies	O
+were	O
+obtained	O
+from	O
+brain	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+lung	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+kidney	B-ANAT
+and	O
+skeletal	B-ANAT
+muscle	I-ANAT
+.	O
+
+We	O
+identified	O
+the	O
+pyrazolecarbothioamide	O
+derivative	O
+A15	O
+,	O
+able	O
+to	O
+inhibit	O
+viral	B-PROC
+replication	I-PROC
+and	O
+both	O
+RNase	B-PRGE
+H	I-PRGE
+and	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+DNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RDDP	O
+)	O
+RT	O
+-	O
+associated	O
+activities	O
+in	O
+the	O
+low	O
+micromolar	O
+range	O
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+PDCoV	I-PRGE
+IgG	I-PRGE
+antibodies	I-PRGE
+were	O
+detected	O
+in	O
+11	O
+%	O
+(	O
+96	O
+/	O
+871	O
+)	O
+of	O
+the	O
+samples	O
+and	O
+in	O
+25	O
+%	O
+(	O
+10	O
+/	O
+40	O
+)	O
+of	O
+the	O
+investigated	O
+farms	O
+.	O
+
+TITLE	O
+:	O
+Protective	O
+ventilation	O
+reduces	O
+Pseudomonas	B-SPEC
+aeruginosa	I-SPEC
+growth	B-PROC
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+in	O
+a	O
+porcine	B-SPEC
+pneumonia	B-DISO
+model	O
+.	O
+
+The	O
+protective	B-CHED
+group	I-CHED
+(	O
+n	O
+=	O
+10	O
+)	O
+had	O
+an	O
+end	O
+expiratory	B-PROC
+pressure	O
+of	O
+10	O
+cm	O
+H	O
+The	O
+protective	B-CHED
+group	I-CHED
+displayed	O
+lower	O
+numbers	O
+of	O
+Pseudomonas	B-SPEC
+aeruginosa	I-SPEC
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+and	O
+a	O
+lower	O
+wet	O
+-	O
+to	O
+-	O
+dry	O
+ratio	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+than	O
+the	O
+control	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+characterize	O
+sedation	B-DISO
+,	O
+analgesia	B-DISO
+,	O
+delirium	B-DISO
+,	O
+and	O
+mobilization	O
+practices	O
+in	O
+patients	O
+supported	O
+with	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Following	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+initiation	O
+,	O
+97	O
+%	O
+respondents	O
+administer	O
+sedative	B-CHED
+/	O
+analgesic	B-CHED
+infusions	O
+,	O
+and	O
+the	O
+sedation	B-DISO
+target	O
+was	O
+""""	O
+sedated	O
+""""	O
+or	O
+""""	O
+very	O
+sedated	O
+""""	O
+for	O
+59	O
+%,	O
+""""	O
+calm	O
+and	O
+cooperative	O
+""""	O
+for	O
+25	O
+%,	O
+and	O
+""""	O
+unarousable	O
+""""	O
+for	O
+16	O
+%.	O
+
+The	O
+majority	O
+of	O
+respondents	O
+reported	O
+targeting	B-PROC
+moderate	O
+to	O
+deep	O
+sedation	B-DISO
+following	O
+cannulation	O
+,	O
+with	O
+the	O
+use	O
+of	O
+sedative	B-CHED
+and	O
+opioid	O
+infusions	O
+.	O
+
+There	O
+is	O
+considerable	O
+variability	O
+surrounding	O
+early	O
+physical	O
+therapy	O
+and	O
+mobilization	O
+goals	O
+for	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+supported	O
+by	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Ethyl	B-CHED
+pyruvate	B-CHED
+(	O
+EP	O
+)	O
+has	O
+multiple	O
+immunoregulation	B-PROC
+functions	O
+in	O
+several	O
+serious	O
+illnesses	O
+,	O
+such	O
+as	O
+burn	O
+injury	O
+,	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+acute	O
+respiratory	O
+syndrome	B-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+summarize	O
+our	O
+understanding	O
+of	O
+the	O
+molecular	O
+and	O
+biological	O
+events	O
+of	O
+compounds	O
+acting	O
+as	O
+MERS	O
+-	O
+CoV	O
+inhibitors	B-CHED
+,	O
+the	O
+outcomes	O
+of	O
+existing	O
+therapeutic	O
+options	O
+and	O
+the	O
+various	O
+drugs	O
+undergoing	O
+clinical	O
+trials	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+propose	O
+the	O
+feasibility	O
+of	O
+developing	O
+effective	O
+agents	O
+by	O
+repurposing	O
+the	O
+existing	O
+and	O
+clinically	O
+approved	O
+anti	O
+-	O
+coronavirus	B-SPEC
+and	O
+anti	O
+-	O
+viral	O
+peptide	B-CHED
+drugs	O
+.	O
+
+A	O
+24	O
+-	O
+year	O
+-	O
+old	O
+male	O
+patient	O
+who	O
+developed	O
+septic	O
+-	O
+induced	O
+cardiomyopathy	B-DISO
+secondary	I-DISO
+to	O
+pulmonary	B-DISO
+TB	I-DISO
+was	O
+administered	O
+veno	O
+-	O
+arterial	B-ANAT
+(	O
+VA	O
+)	O
+ECMO	O
+for	O
+cardiac	B-ANAT
+support	O
+.	O
+
+Especially	O
+,	O
+compound	O
+g18	O
+showed	O
+excellent	O
+curative	O
+and	O
+protective	O
+activities	O
+against	O
+CMV	B-SPEC
+,	O
+with	O
+half	O
+-	O
+maximal	O
+effective	O
+concentration	O
+(	O
+EC	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+resulted	O
+in	O
+multiple	O
+healthcare	O
+associated	O
+outbreaks	O
+.	O
+
+A	O
+formal	B-CHED
+educational	O
+program	O
+was	O
+implemented	O
+to	O
+ensure	O
+a	O
+standardized	O
+approach	O
+to	O
+care	O
+planning	O
+and	O
+delivery	O
+.	O
+
+The	O
+emergence	O
+of	O
+drug	O
+-	O
+resistant	O
+strains	O
+further	O
+necessitates	O
+the	O
+development	B-PROC
+of	O
+novel	O
+antivirals	B-CHED
+that	O
+target	O
+the	O
+host	B-COMP
+factors	O
+crucial	O
+for	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Area	O
+covered	O
+:	O
+This	O
+review	O
+summarizes	O
+the	O
+current	O
+understanding	O
+of	O
+the	O
+structural	O
+and	O
+functional	O
+properties	O
+of	O
+type	B-PRGE
+II	I-PRGE
+transmembrane	I-PRGE
+serine	B-CHED
+proteases	I-PRGE
+(	O
+TTSPs	O
+)	O
+as	O
+a	O
+proteolytic	B-PROC
+activator	O
+of	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+and	O
+discusses	O
+their	O
+potential	O
+as	O
+antiviral	B-CHED
+targets	O
+.	O
+
+It	O
+also	O
+explores	O
+the	O
+experimental	O
+evidence	O
+accumulated	O
+for	O
+inhibitors	B-CHED
+of	O
+TTSPs	O
+as	O
+novel	O
+,	O
+broad	O
+-	O
+spectrum	O
+antivirals	B-CHED
+against	O
+various	O
+influenza	B-SPEC
+virus	I-SPEC
+subtypes	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+
+We	O
+enrolled	O
+174	O
+patients	O
+:	O
+113	O
+had	O
+respiratory	B-DISO
+symptoms	I-DISO
+/	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+31	O
+had	O
+confirmed	O
+influenza	B-PATH
+A	I-PATH
+or	O
+B	O
+infection	B-DISO
+,	O
+23	O
+had	O
+a	O
+recent	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+and	O
+7	O
+had	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+1	O
+year	O
+before	O
+.	O
+
+TITLE	O
+:	O
+Think	O
+globally	O
+,	O
+act	O
+locally	O
+:	O
+Phylodynamic	O
+reconstruction	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+QX	O
+genotype	O
+(	O
+GI	O
+-	O
+19	O
+lineage	O
+)	O
+reveals	O
+different	O
+population	O
+dynamics	O
+and	O
+spreading	O
+patterns	O
+when	O
+evaluated	O
+on	O
+different	O
+epidemiological	O
+scales	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+represents	O
+one	O
+of	O
+the	O
+poultry	O
+industry	O
+major	O
+threats	O
+,	O
+particularly	O
+in	O
+high	O
+density	O
+producing	O
+countries	O
+.	O
+
+The	O
+emergence	O
+and	O
+spread	O
+of	O
+new	O
+IBV	B-SPEC
+genotypes	O
+have	O
+frustrated	O
+the	O
+various	O
+disease	O
+control	O
+efforts	O
+implemented	O
+over	O
+time	O
+.	O
+
+Despite	O
+that	O
+,	O
+few	O
+comprehensive	O
+and	O
+large	O
+scale	O
+studies	O
+have	O
+been	O
+performed	O
+to	O
+understand	O
+the	O
+international	O
+and	O
+local	O
+spreading	O
+dynamics	O
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+The	O
+presence	O
+of	O
+several	O
+well	O
+supported	O
+epidemiological	O
+links	O
+among	O
+distantly	O
+related	O
+Italian	O
+regions	O
+testifies	O
+that	O
+animal	B-SPEC
+transportation	O
+and	O
+indirect	O
+transmission	O
+routes	O
+rather	O
+than	O
+local	O
+airborne	O
+diffusion	O
+contribute	O
+to	O
+the	O
+QX	O
+success	O
+and	O
+persistence	O
+at	O
+local	O
+scale	O
+.	O
+
+Piglets	O
+without	O
+MDA	B-CHED
+showed	O
+a	O
+morbidity	O
+of	O
+100	O
+%	O
+and	O
+low	O
+lethality	O
+,	O
+while	O
+almost	O
+all	O
+MDA	O
+-	O
+positive	O
+piglets	O
+stayed	O
+clinically	O
+healthy	O
+and	O
+showed	O
+considerably	O
+lower	O
+virus	B-DISO
+shedding	I-DISO
+.	O
+
+Nevertheless	O
+,	O
+a	O
+major	O
+research	O
+area	O
+,	O
+notably	O
+their	O
+impact	O
+on	O
+viruses	B-SPEC
+,	O
+has	O
+so	O
+far	O
+been	O
+neglected	O
+.	O
+
+All	O
+structure	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+were	O
+tested	O
+on	O
+the	O
+human	B-SPEC
+norovirus	B-SPEC
+surrogate	O
+phage	O
+MS2	O
+and	O
+phage	O
+P100	O
+representing	O
+non	O
+-	O
+enveloped	O
+DNA	O
+viruses	B-SPEC
+.	O
+
+Overall	O
+,	O
+four	O
+ILs	B-DISO
+,	O
+covering	O
+different	O
+structural	O
+elements	O
+,	O
+were	O
+found	O
+to	O
+reduce	O
+phage	O
+P100	O
+infectivity	O
+by	O
+≥	O
+4	O
+log	O
+
+Although	O
+cholesterol	B-CHED
+is	O
+known	O
+to	O
+affect	O
+the	O
+replication	O
+of	O
+a	O
+broad	O
+range	O
+of	O
+viruses	B-SPEC
+in	O
+vitro	O
+,	O
+its	O
+significance	O
+and	O
+role	O
+in	O
+porcine	B-SPEC
+nidovirus	B-SPEC
+infection	B-DISO
+remains	O
+to	O
+be	O
+elucidated	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+depletion	O
+of	O
+cellular	B-COMP
+cholesterol	B-CHED
+by	O
+treating	O
+cells	B-COMP
+with	O
+methyl	B-CHED
+-	O
+β	O
+-	O
+cyclodextrin	B-CHED
+(	O
+MβCD	O
+)	O
+dose	O
+-	O
+dependently	O
+suppressed	O
+the	O
+replication	O
+of	O
+both	O
+nidoviruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+Pearls	O
+in	O
+Venovenous	O
+Extracorporeal	O
+Life	O
+Support	O
+for	O
+Adult	O
+Respiratory	B-DISO
+Failure	I-DISO
+.	O
+
+However	O
+,	O
+its	O
+uptake	O
+in	O
+the	O
+case	O
+of	O
+adult	O
+respiratory	B-DISO
+failure	I-DISO
+has	O
+been	O
+slow	O
+because	O
+of	O
+a	O
+paucity	O
+of	O
+quality	O
+evidence	O
+and	O
+a	O
+sluggish	O
+tempo	B-CHED
+of	O
+ECLS	O
+-	O
+related	O
+technological	O
+advances	O
+.	O
+
+HPeV	O
+was	O
+a	O
+probable	O
+cause	O
+of	O
+the	O
+disease	O
+in	O
+47	O
+.	O
+7	O
+%	O
+(	O
+42	O
+/	O
+88	O
+),	O
+mostly	O
+self	O
+-	O
+limiting	O
+including	O
+acute	B-DISO
+gastroenteritis	I-DISO
+,	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+and	O
+maculopapular	O
+rash	B-DISO
+.	O
+
+A	O
+high	O
+proportion	O
+(	O
+60	O
+.	O
+0	O
+%)	O
+of	O
+children	O
+coinfected	O
+with	O
+HPeV	O
+and	O
+other	O
+respiratory	O
+virus	B-SPEC
+(	O
+es	O
+)	O
+had	O
+acute	B-DISO
+bronchiolitis	I-DISO
+or	O
+pneumonia	B-DISO
+.	O
+
+Most	O
+rash	B-DISO
+illnesses	O
+exhibited	O
+a	O
+generalized	O
+maculopapular	O
+pattern	O
+involving	O
+the	O
+trunk	B-ANAT
+and	O
+limbs	B-ANAT
+,	O
+and	O
+were	O
+more	O
+likely	O
+associated	O
+with	O
+HPeV4	O
+compared	O
+to	O
+other	O
+syndrome	B-DISO
+groups	O
+(	O
+36	O
+.	O
+4	O
+%	O
+vs	O
+.	O
+3	O
+.	O
+1	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+011	O
+).	O
+
+TITLE	O
+:	O
+Transcatheter	O
+Aortic	B-ANAT
+Valve	I-ANAT
+Implantation	B-PROC
+Versus	O
+Surgical	O
+Aortic	B-ANAT
+Valve	I-ANAT
+Replacement	O
+in	O
+Lower	O
+-	O
+Surgical	O
+-	O
+Risk	O
+Patients	O
+With	O
+Chronic	O
+Obstructive	O
+Pulmonary	O
+Disease	O
+.	O
+
+Transfemoral	O
+TAVI	O
+without	O
+general	B-PROC
+anesthesia	I-PROC
+(	O
+28	O
+patients	O
+)	O
+was	O
+associated	O
+with	O
+the	O
+lowest	O
+rate	O
+of	O
+respiratory	B-DISO
+complications	I-DISO
+(	O
+3	O
+.	O
+6	O
+%).	O
+
+Among	O
+patients	O
+with	O
+moderate	O
+or	O
+severe	O
+COPD	B-DISO
+at	O
+low	O
+-	O
+to	O
+-	O
+intermediate	O
+surgical	O
+risk	O
+,	O
+TAVI	O
+patients	O
+had	O
+a	O
+similar	O
+rate	O
+of	O
+30	O
+-	O
+day	O
+major	O
+pulmonary	B-DISO
+complications	I-DISO
+compared	O
+with	O
+SAVR	O
+patients	O
+despite	O
+a	O
+higher	O
+baseline	O
+risk	O
+profile	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-ANAT
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+support	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+has	O
+been	O
+increasing	O
+.	O
+
+Limited	O
+knowledge	O
+is	O
+currently	O
+available	O
+regarding	O
+the	O
+role	O
+of	O
+dendritic	B-ANAT
+cells	B-COMP
+in	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Surprisingly	O
+,	O
+we	O
+did	O
+not	O
+detect	O
+any	O
+interferon	B-PRGE
+-	I-PRGE
+β	I-PRGE
+in	O
+the	O
+supernatants	O
+of	O
+infected	O
+cells	B-COMP
+.	O
+
+We	O
+also	O
+observed	O
+a	O
+markedly	O
+increased	O
+transcription	B-PROC
+of	O
+interferon	B-PRGE
+inducible	O
+protein	B-PRGE
+-	I-PRGE
+10	I-PRGE
+(	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+).	O
+
+Overall	O
+,	O
+PEDV	B-SPEC
+does	O
+not	O
+replicate	O
+in	O
+porcine	B-SPEC
+Mo	O
+-	O
+DC	O
+,	O
+but	O
+activates	O
+the	O
+transcription	B-PROC
+of	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+and	O
+chemokine	O
+IP	O
+-	O
+10	O
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+biomarkers	O
+in	O
+acute	O
+traumatic	B-DISO
+lung	I-DISO
+injury	O
+.	O
+
+We	O
+describe	O
+a	O
+10	O
+-	O
+year	O
+-	O
+old	O
+boy	O
+who	O
+was	O
+presented	O
+with	O
+high	O
+grade	O
+fever	B-PROC
+,	O
+dysphagia	B-DISO
+and	O
+tender	O
+swelling	B-DISO
+over	O
+left	B-ANAT
+side	I-ANAT
+of	I-ANAT
+neck	I-ANAT
+.	O
+
+The	O
+findings	O
+can	O
+serve	O
+as	O
+a	O
+guide	O
+for	O
+healthcare	O
+practitioners	O
+by	O
+appropriately	O
+identifying	O
+and	O
+managing	O
+potential	O
+patients	O
+at	O
+high	O
+risk	O
+of	O
+death	B-PROC
+.	O
+
+Multivariate	O
+predictors	O
+of	O
+30	O
+-	O
+day	O
+mortality	O
+were	O
+elderly	O
+,	O
+non	O
+-	O
+healthcare	O
+workers	O
+,	O
+pre	O
+-	O
+existing	O
+illness	O
+,	O
+severity	O
+of	O
+illness	O
+,	O
+and	O
+hospital	O
+-	O
+acquired	O
+infections	B-DISO
+(	O
+aHR	O
+=	O
+1	O
+.	O
+7	O
+;	O
+19	O
+.	O
+2	O
+;	O
+2	O
+.	O
+1	O
+;	O
+3	O
+.	O
+7	O
+;	O
+and	O
+2	O
+.	O
+9	O
+,	O
+respectively	O
+).	O
+
+TITLE	O
+:	O
+Epidemiological	O
+and	O
+clinical	O
+assessment	O
+of	O
+a	O
+shared	O
+territorial	O
+malaria	B-PATH
+guideline	O
+in	O
+the	O
+10	O
+years	O
+of	O
+its	O
+implementation	O
+(	O
+Barcelona	O
+,	O
+North	O
+Metropolitan	O
+Area	O
+,	O
+Catalonia	O
+,	O
+Spain	O
+,	O
+2007	O
+-	O
+2016	O
+).	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+is	O
+to	O
+assess	O
+the	O
+evolution	B-PROC
+of	O
+malaria	B-PATH
+cases	O
+in	O
+the	O
+area	O
+as	O
+well	O
+as	O
+its	O
+clinical	O
+management	O
+over	O
+the	O
+10	O
+years	O
+of	O
+its	O
+implementation	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+190	O
+malaria	B-PATH
+cases	O
+,	O
+all	O
+them	O
+imported	O
+,	O
+have	O
+been	O
+recorded	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	O
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+is	O
+a	O
+viral	O
+enteric	O
+pathogen	O
+associated	O
+with	O
+calf	B-ANAT
+diarrhea	B-DISO
+worldwide	O
+being	O
+,	O
+in	O
+Argentina	B-SPEC
+,	O
+mostly	O
+detected	O
+in	O
+dairy	O
+husbandry	O
+systems	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+,	O
+a	O
+newly	O
+identified	O
+pathogen	O
+,	O
+causes	O
+severe	O
+pneumonia	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+recently	O
+defined	O
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+,	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+),	O
+is	O
+generally	O
+expressed	B-PROC
+in	O
+endothelial	B-ANAT
+and	O
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+present	O
+on	O
+cultured	O
+human	B-SPEC
+nonciliated	O
+bronchiolar	B-ANAT
+epithelium	B-ANAT
+cells	B-COMP
+.	O
+
+Mice	B-SPEC
+lacking	O
+all	O
+inflammasome	O
+signaling	B-PROC
+due	O
+to	O
+the	O
+absence	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+-	O
+11	O
+were	O
+more	O
+vulnerable	O
+to	O
+infection	B-DISO
+,	O
+with	O
+poor	O
+survival	O
+and	O
+elevated	O
+viral	B-PROC
+replication	I-PROC
+compared	O
+to	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+.	O
+
+The	O
+results	O
+reveal	O
+that	O
+the	O
+three	O
+IBV	B-SPEC
+isolates	O
+mainly	O
+exhibited	O
+mutations	O
+in	O
+the	O
+hypervariable	O
+regions	O
+(	O
+HVRs	O
+)	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+and	O
+protein	B-CHED
+,	O
+but	O
+were	O
+phylogenetically	O
+and	O
+serologically	O
+closely	O
+related	O
+,	O
+belonging	O
+to	O
+lineage	O
+11	O
+of	O
+the	O
+GI	O
+genotype	O
+,	O
+the	O
+former	O
+BR	O
+genotype	O
+I	O
+.	O
+All	O
+three	O
+isolates	O
+caused	O
+persistent	O
+infection	O
+in	O
+broiler	O
+breeders	O
+reared	O
+in	O
+the	O
+field	O
+,	O
+despite	O
+high	O
+systemic	O
+anti	O
+-	O
+IBV	B-SPEC
+antibody	B-COMP
+titres	O
+,	O
+and	O
+exhibited	O
+tropism	B-PROC
+and	O
+pathogenicity	O
+for	O
+the	O
+trachea	B-DISO
+and	O
+kidney	B-ANAT
+after	O
+experimental	O
+infection	B-DISO
+in	O
+SPF	B-PRGE
+chickens	I-PRGE
+and	O
+contact	O
+birds	B-SPEC
+.	O
+
+Therefore	O
+,	O
+we	O
+immunized	O
+chickens	B-SPEC
+with	O
+recombinant	B-PRGE
+trimeric	I-PRGE
+soluble	I-PRGE
+IBV	I-PRGE
+Ark	I-PRGE
+-	I-PRGE
+type	I-PRGE
+S1	I-PRGE
+or	O
+S	B-PRGE
+-	I-PRGE
+ectodomain	I-PRGE
+protein	I-PRGE
+produced	O
+from	O
+codon	O
+-	O
+optimized	O
+constructs	O
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+.	O
+
+Notably	O
+,	O
+the	O
+incremental	O
+change	O
+of	O
+daily	O
+death	B-PROC
+rate	O
+was	O
+most	O
+prominent	O
+during	O
+the	O
+first	O
+week	O
+since	O
+disease	O
+onset	O
+with	O
+an	O
+average	O
+increase	O
+of	O
+13	O
+%,	O
+but	O
+then	O
+stabilized	O
+in	O
+the	O
+remaining	O
+two	O
+weeks	O
+when	O
+it	O
+only	O
+increased	O
+3	O
+%	O
+on	O
+average	O
+.	O
+
+TITLE	O
+:	O
+Efficacy	O
+of	O
+a	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+inhibitor	O
+in	O
+treating	O
+various	O
+forms	O
+of	O
+acquired	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+The	O
+seventh	O
+was	O
+a	O
+6	O
+.	O
+8	O
+-	O
+year	O
+-	O
+old	O
+cat	B-SPEC
+with	O
+only	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+node	I-ANAT
+involvement	O
+that	O
+went	O
+into	O
+remission	B-DISO
+after	O
+three	O
+relapses	O
+that	O
+required	O
+progressively	O
+longer	O
+repeat	O
+treatments	O
+over	O
+a	O
+10	O
+month	O
+period	O
+.	O
+
+ABSTRACT	O
+:	O
+Camels	O
+are	O
+known	O
+carriers	O
+for	O
+many	O
+viral	O
+pathogens	O
+,	O
+including	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+performed	O
+metagenomic	O
+sequencing	O
+analysis	O
+on	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+samples	O
+from	O
+108	O
+MERS	O
+-	O
+CoV	O
+-	O
+positive	O
+dromedary	B-SPEC
+camels	B-SPEC
+from	O
+a	O
+live	O
+animal	B-SPEC
+market	O
+in	O
+Abu	B-CHED
+Dhabi	O
+,	O
+United	O
+Arab	O
+Emirates	O
+.	O
+
+Some	O
+viral	O
+sequences	O
+belong	O
+to	O
+known	O
+camel	B-SPEC
+or	O
+human	B-SPEC
+viruses	B-SPEC
+and	O
+others	O
+are	O
+from	O
+potentially	O
+novel	O
+camel	B-SPEC
+viruses	B-SPEC
+with	O
+only	O
+limited	O
+sequence	O
+similarity	O
+to	O
+virus	B-SPEC
+sequences	O
+in	O
+GenBank	O
+.	O
+
+Co	B-DISO
+-	I-DISO
+infection	I-DISO
+of	O
+at	O
+least	O
+two	O
+recently	O
+identified	O
+camel	B-SPEC
+coronaviruses	O
+was	O
+detected	O
+in	O
+92	O
+.	O
+6	O
+%	O
+of	O
+the	O
+camels	B-SPEC
+in	O
+the	O
+study	O
+.	O
+
+Thus	O
+,	O
+the	O
+diagnosis	O
+of	O
+EV	O
+-	O
+HRV	O
+pneumonia	B-DISO
+complicated	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+was	O
+established	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+251	O
+clinically	O
+significant	O
+bacteria	B-SPEC
+were	O
+identified	O
+in	O
+233	O
+patients	O
+with	O
+post	O
+-	O
+viral	O
+bacterial	B-DISO
+pneumonia	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+rationally	O
+designed	O
+a	O
+novel	O
+fusion	O
+inhibitor	B-CHED
+named	O
+MERS	O
+-	O
+five	O
+-	O
+helix	O
+bundle	O
+(	O
+MERS	O
+-	O
+5HB	O
+)	O
+derived	O
+from	O
+the	O
+six	O
+-	O
+helix	O
+bundle	O
+(	O
+MERS	O
+-	O
+6HB	O
+)	O
+which	O
+was	O
+formed	O
+by	O
+the	O
+process	O
+of	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+TITLE	O
+:	O
+Management	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+and	O
+Refractory	O
+Hypoxemia	O
+.	O
+
+To	O
+describe	O
+mechanical	O
+ventilation	O
+strategies	O
+and	O
+treatment	O
+adjuncts	O
+for	O
+adults	O
+with	O
+ARDS	B-DISO
+,	O
+including	O
+refractory	O
+hypoxemia	O
+.	O
+
+On	O
+Study	O
+Day	O
+1	O
+,	O
+mean	O
+Vt	O
+was	O
+7	O
+.	O
+5	O
+(	O
+SD	O
+=	O
+2	O
+.	O
+1	O
+)	O
+ml	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+(	O
+n	O
+=	O
+625	O
+);	O
+80	O
+%	O
+(	O
+n	O
+=	O
+501	O
+)	O
+received	O
+Vt	O
+greater	O
+than	O
+6	O
+ml	O
+/	O
+kg	O
+.	O
+
+Mean	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+was	O
+10	O
+.	O
+5	O
+(	O
+3	O
+.	O
+7	O
+)	O
+cm	O
+H	O
+
+ABSTRACT	O
+:	O
+Recent	O
+outbreaks	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+have	O
+revealed	O
+significant	O
+health	O
+care	O
+system	O
+vulnerabilities	O
+and	O
+highlighted	O
+the	O
+importance	O
+of	O
+rapid	O
+recognition	O
+and	O
+isolation	O
+of	O
+patients	O
+with	O
+potentially	O
+severe	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Evaluators	O
+captured	O
+key	O
+infection	B-DISO
+control	O
+performance	O
+measures	O
+,	O
+including	O
+time	O
+to	O
+patient	O
+masking	O
+and	O
+isolation	O
+.	O
+
+Ninety	O
+-	O
+five	O
+drills	B-SPEC
+(	O
+53	O
+measles	B-PATH
+and	O
+42	O
+MERS	O
+)	O
+were	O
+conducted	O
+in	O
+49	O
+EDs	B-DISO
+with	O
+patients	O
+masked	O
+and	O
+isolated	O
+in	O
+78	O
+%	O
+of	O
+drills	O
+.	O
+
+Our	O
+previous	O
+study	O
+found	O
+that	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+17A	O
+production	O
+by	O
+humans	B-SPEC
+or	O
+mice	B-SPEC
+infected	O
+with	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+substantially	O
+contributes	O
+to	O
+ALI	O
+and	O
+subsequent	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+severe	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+infection	B-DISO
+was	O
+established	O
+.	O
+
+TITLE	O
+:	O
+The	O
+influence	O
+of	O
+the	O
+method	O
+of	O
+initial	O
+stabilization	O
+of	O
+traumatic	O
+femoral	B-ANAT
+shaft	I-ANAT
+fractures	O
+on	O
+postoperative	O
+morbidity	O
+and	O
+mortality	O
+-	O
+a	O
+retrospective	O
+study	O
+.	O
+
+Although	O
+not	O
+statistically	O
+significant	O
+,	O
+MODS	B-DISO
+and	O
+ARDS	B-DISO
+incidences	O
+were	O
+higher	O
+in	O
+the	O
+DCO	B-DISO
+shock	O
+group	O
+:	O
+MODS	B-DISO
+(	O
+41	O
+.	O
+7	O
+%	O
+versus	O
+22	O
+.	O
+6	O
+%	O
+and	O
+20	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+08	O
+/	O
+0	O
+.	O
+17	O
+),	O
+ARDS	B-DISO
+(	O
+29	O
+.	O
+2	O
+%	O
+versus	O
+17	O
+%	O
+and	O
+20	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+22	O
+/	O
+0	O
+.	O
+53	O
+).	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+Bovine	B-SPEC
+Coronavirus	B-SPEC
+in	O
+Healthy	O
+and	O
+Diarrheic	O
+Dairy	O
+Calves	O
+.	O
+
+A	O
+specific	O
+BCoV	O
+-	O
+RT	O
+-	O
+PCR	O
+assay	O
+was	O
+used	O
+to	O
+detect	O
+BCoV	O
+in	O
+fecal	B-ANAT
+samples	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+respiratory	O
+support	O
+,	O
+also	O
+known	O
+as	O
+extracorporeal	O
+gas	B-ENZY
+exchange	O
+,	O
+may	O
+be	O
+used	O
+to	O
+rescue	O
+the	O
+most	O
+severe	O
+forms	O
+of	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+high	O
+blood	B-PROC
+flow	I-PROC
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Alternatively	O
+,	O
+lower	O
+flow	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+might	O
+be	O
+applied	O
+to	O
+reduce	O
+the	O
+intensity	O
+of	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+less	O
+severe	O
+forms	O
+of	O
+the	O
+disease	O
+.	O
+
+However	O
+,	O
+in	O
+patients	O
+with	O
+syndromic	O
+CIDs	O
+,	O
+autosomal	B-COMP
+recessive	O
+mutations	O
+in	O
+ataxia	B-DISO
+-	I-DISO
+telangiectasia	I-DISO
+mutated	O
+(	O
+ATM	B-PATH
+),	O
+autosomal	B-COMP
+dominant	O
+mutations	O
+in	O
+signal	B-PRGE
+transducer	I-PRGE
+and	I-PRGE
+activator	I-PRGE
+of	I-PRGE
+transcription	I-PRGE
+3	I-PRGE
+(	O
+STAT3	B-PRGE
+),	O
+and	O
+microdeletions	O
+in	O
+22q11	O
+.	O
+21	O
+were	O
+the	O
+most	O
+commonly	O
+affected	O
+genomic	O
+loci	O
+.	O
+
+Vaccination	O
+of	O
+swine	B-SPEC
+with	O
+rSPV	O
+-	O
+St	O
+elicited	O
+a	O
+robust	O
+antibody	B-PROC
+response	I-PROC
+specific	O
+for	O
+the	O
+homologous	O
+PEDV	B-SPEC
+SQ2014	O
+.	O
+
+Sixteen	O
+substitutions	O
+resulted	O
+in	O
+amino	B-CHED
+acid	I-CHED
+coding	O
+changes	O
+of	O
+which	O
+half	O
+were	O
+in	O
+spike	O
+.	O
+
+To	O
+Determine	O
+the	O
+Active	O
+Status	O
+and	O
+Duration	O
+of	O
+Acute	O
+Viral	B-DISO
+Infection	I-DISO
+.	O
+
+Serology	O
+testing	O
+for	O
+the	O
+presence	O
+of	O
+virus	B-SPEC
+-	O
+elicited	O
+antibodies	B-COMP
+in	O
+blood	B-ANAT
+is	O
+one	O
+of	O
+the	O
+methods	O
+used	O
+commonly	O
+for	O
+clinical	O
+diagnosis	O
+of	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Interstitial	O
+pneumonia	O
+with	O
+autoimmune	B-DISO
+features	O
+(	O
+IPAF	O
+)	O
+identifies	O
+a	O
+recently	O
+recognized	O
+autoimmune	B-DISO
+syndrome	B-DISO
+characterized	O
+by	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+and	O
+autoantibodies	O
+positivity	O
+,	O
+but	O
+absence	O
+of	O
+a	O
+specific	O
+connective	B-DISO
+tissue	I-DISO
+disease	I-DISO
+diagnosis	O
+or	O
+alternative	O
+etiology	O
+.	O
+
+We	O
+compared	O
+baseline	O
+characteristics	O
+and	O
+clinical	O
+outcome	O
+of	O
+IPAF	O
+patients	O
+with	O
+those	O
+of	O
+the	O
+population	O
+of	O
+ARDS	B-DISO
+patients	O
+admitted	O
+in	O
+the	O
+same	O
+period	O
+.	O
+
+All	O
+patients	O
+required	O
+prolonged	O
+mechanical	O
+ventilation	O
+(	O
+median	O
+duration	O
+49	O
+days	O
+,	O
+range	O
+10	O
+-	O
+88	O
+);	O
+four	O
+received	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+one	O
+received	O
+low	O
+-	O
+flow	O
+extracorporeal	O
+CO	O
+This	O
+is	O
+the	O
+first	O
+description	O
+of	O
+a	O
+cohort	O
+of	O
+critical	O
+patients	O
+meeting	O
+the	O
+diagnostic	O
+criteria	O
+for	O
+IPAF	O
+presenting	O
+with	O
+ARDS	B-DISO
+.	O
+
+As	O
+part	O
+of	O
+a	O
+bigger	O
+study	O
+investigating	O
+pathogens	O
+in	O
+African	O
+bats	B-SPEC
+we	O
+screened	O
+animals	B-SPEC
+for	O
+the	O
+presence	O
+of	O
+known	O
+and	O
+unknown	O
+viruses	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+study	O
+shows	O
+the	O
+presence	O
+of	O
+a	O
+coltivirus	B-SPEC
+-	O
+related	O
+virus	B-SPEC
+in	O
+bats	B-SPEC
+from	O
+Sub	O
+-	O
+Sahara	O
+Africa	O
+.	O
+
+Most	O
+patients	O
+received	O
+NAIs	B-SPEC
+and	O
+85	O
+.	O
+9	O
+%	O
+received	O
+antibiotics	B-CHED
+.	O
+
+Recombination	B-PROC
+analyses	O
+with	O
+other	O
+gammacoronaviruses	O
+revealed	O
+that	O
+Polish	O
+GI	O
+-	O
+23	O
+strain	O
+may	O
+originate	O
+from	O
+recombination	O
+events	O
+and	O
+potential	O
+donors	O
+of	O
+build	O
+-	O
+in	O
+sequences	O
+are	O
+IBV	B-SPEC
+of	O
+GI	O
+-	O
+1	O
+,	O
+GI	O
+-	O
+13	O
+and	O
+G	O
+-	O
+19	O
+lineages	O
+(	O
+Mass	O
+-,	O
+793B	O
+-	O
+and	O
+QX	O
+-	O
+like	O
+strains	O
+,	O
+respectively	O
+).	O
+
+Leader	O
+alterations	O
+such	O
+as	O
+deletion	O
+and	O
+nucleotide	B-CHED
+substitution	O
+were	O
+observed	O
+in	O
+MHVs	O
+,	O
+while	O
+a	O
+dynamic	O
+one	O
+-	O
+orientation	O
+'	O
+sequential	O
+deletion	O
+'	O
+was	O
+found	O
+among	O
+the	O
+leaders	O
+of	O
+76	O
+SARS	O
+-	O
+CoV	O
+isolates	O
+.	O
+
+As	O
+part	O
+of	O
+its	O
+viral	B-COMP
+genome	I-COMP
+,	O
+MERS	O
+-	O
+CoV	O
+encodes	O
+a	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLpro	O
+)	O
+that	O
+has	O
+been	O
+observed	O
+to	O
+act	O
+as	O
+a	O
+deubiquitinase	B-PROC
+and	O
+deISGylase	O
+to	O
+antagonize	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+immune	O
+pathways	B-PROC
+.	O
+
+UV	O
+-	O
+inactivated	O
+IBV	B-SPEC
+also	O
+lost	B-CHED
+the	O
+ability	O
+of	O
+apoptosis	B-PROC
+induction	I-PROC
+.	O
+
+RESULTS	O
+:	O
+In	O
+this	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+single	O
+-	O
+tube	O
+one	O
+-	O
+step	O
+reverse	O
+transcription	O
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+assay	O
+specific	O
+for	O
+nucleocapsid	B-PRGE
+gene	I-PRGE
+to	O
+diagnose	O
+and	O
+monitor	O
+PDCoV	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Avoidance	O
+of	O
+excessive	O
+sedation	O
+and	O
+subsequent	O
+prolonged	O
+mechanical	O
+ventilation	O
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+)	O
+is	O
+recommended	O
+,	O
+but	O
+no	O
+data	O
+are	O
+available	O
+for	O
+critically	B-DISO
+ill	I-DISO
+postoperative	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Maternal	O
+hemorrhage	B-DISO
+,	O
+defined	O
+as	O
+a	O
+cumulative	O
+blood	O
+loss	O
+of	O
+greater	O
+than	O
+or	O
+equal	O
+to	O
+1	O
+,	O
+000	O
+mL	O
+or	O
+blood	B-DISO
+loss	I-DISO
+accompanied	O
+by	O
+signs	O
+or	O
+symptoms	O
+of	O
+hypovolemia	O
+within	O
+24	O
+hours	O
+after	O
+the	O
+birth	B-PROC
+process	O
+,	O
+remains	O
+the	O
+leading	O
+cause	O
+of	O
+maternal	O
+mortality	O
+worldwide	O
+(	O
+1	O
+).	O
+
+Numerous	O
+studies	O
+on	O
+the	O
+molecular	O
+and	O
+pathogenic	O
+characterization	O
+of	O
+IBV	B-SPEC
+variants	O
+have	O
+been	O
+performed	O
+between	O
+2007	O
+and	O
+2017	O
+,	O
+which	O
+we	O
+have	O
+reviewed	O
+herein	O
+.	O
+
+A	O
+multispecialty	O
+task	O
+force	O
+of	O
+16	O
+international	O
+experts	O
+in	O
+critical	O
+care	O
+medicine	B-CHED
+,	O
+endocrinology	O
+,	O
+and	O
+guideline	O
+methods	O
+,	O
+all	O
+of	O
+them	O
+members	O
+of	O
+the	O
+Society	O
+of	O
+Critical	O
+Care	O
+Medicine	B-CHED
+and	O
+/	O
+or	O
+the	O
+European	O
+Society	O
+of	O
+Intensive	O
+Care	O
+Medicine	B-CHED
+.	O
+
+For	O
+treatment	O
+of	O
+specific	O
+conditions	O
+,	O
+we	O
+suggest	O
+using	O
+IV	O
+hydrocortisone	B-CHED
+<	O
+400	O
+mg	O
+/	O
+day	O
+for	O
+≥	O
+3	O
+days	O
+at	O
+full	O
+dose	O
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+that	O
+is	O
+not	O
+responsive	O
+to	O
+fluid	O
+and	O
+moderate	O
+-	O
+to	O
+high	O
+-	O
+dose	O
+vasopressor	O
+therapy	O
+(	O
+conditional	O
+,	O
+low	O
+quality	O
+of	O
+evidence	O
+).	O
+
+We	O
+suggest	O
+the	O
+use	O
+of	O
+IV	O
+methylprednisolone	B-CHED
+1	O
+mg	O
+/	O
+kg	O
+/	O
+day	O
+in	O
+patients	O
+with	O
+early	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PaO	B-PROC
+
+We	O
+describe	O
+an	O
+unusual	O
+case	O
+of	O
+fulminant	O
+herpes	B-DISO
+zoster	I-DISO
+(	O
+HZ	O
+)	O
+in	O
+a	O
+healthy	O
+,	O
+immunocompetent	O
+37	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+.	O
+
+Results	O
+from	O
+reverse	B-PROC
+transcription	O
+‑	O
+quantitative	O
+polymerase	O
+chain	O
+reaction	O
+,	O
+western	O
+blotting	O
+and	O
+ELISA	O
+analysis	O
+demonstrated	O
+that	O
+calcitriol	O
+also	O
+modulated	O
+the	O
+expression	B-PROC
+of	O
+members	O
+of	O
+the	O
+renin	B-PRGE
+‑	I-PRGE
+angiotensin	I-PRGE
+system	I-PRGE
+(	O
+RAS	B-PRGE
+),	O
+including	O
+angiotensin	B-CHED
+(	O
+Ang	O
+)	O
+I	O
+‑	O
+converting	O
+enzymes	O
+(	O
+ACE	B-PRGE
+and	O
+ACE2	B-PRGE
+),	O
+renin	B-PRGE
+and	O
+Ang	B-PRGE
+II	I-PRGE
+,	O
+which	O
+indicates	O
+that	O
+calcitriol	B-CHED
+may	O
+exert	B-PROC
+protective	O
+effects	O
+on	O
+LPS	O
+‑	O
+induced	O
+lung	B-ANAT
+injury	O
+,	O
+at	O
+least	O
+partially	O
+,	O
+by	O
+regulating	O
+the	O
+balance	B-PROC
+between	O
+the	O
+expression	B-PROC
+of	O
+members	O
+of	O
+the	O
+RAS	B-CHED
+.	O
+
+To	O
+develop	O
+an	O
+effective	O
+bivalent	O
+oral	B-ANAT
+vaccine	O
+against	O
+TGEV	B-SPEC
+and	O
+PEDV	B-SPEC
+infection	B-DISO
+,	O
+the	O
+D	O
+antigenic	O
+site	O
+of	O
+the	O
+TGEV	B-SPEC
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+and	O
+the	O
+major	O
+antigen	B-CHED
+site	O
+(	O
+core	O
+neutralizing	O
+epitope	B-CHED
+-	O
+COE	O
+)	O
+of	O
+the	O
+PEDV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+were	O
+used	O
+as	O
+immunogens	O
+,	O
+and	O
+the	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+eGFP	O
+)	O
+gene	O
+was	O
+used	O
+as	O
+a	O
+reporter	O
+to	O
+construct	O
+genetically	O
+engineered	O
+
+After	O
+immunizing	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+intramuscularly	O
+,	O
+rH7HA	O
+proteins	B-CHED
+formulated	O
+in	O
+this	O
+adjuvant	B-CHED
+instead	O
+of	O
+an	O
+alum	O
+adjuvant	B-CHED
+elicited	O
+higher	O
+IgG	B-PRGE
+,	O
+hemagglutination	B-PROC
+-	O
+inhibition	B-PROC
+,	O
+and	O
+virus	B-SPEC
+neutralizing	O
+antibodies	B-COMP
+in	O
+sera	B-COMP
+;	O
+induced	O
+higher	O
+numbers	O
+of	O
+H7HA	O
+-	O
+specific	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+-	O
+secreting	B-PROC
+T	B-ANAT
+cells	I-ANAT
+and	O
+antibody	B-ANAT
+secreting	B-PROC
+cells	B-COMP
+in	O
+spleen	B-ANAT
+;	O
+and	O
+provided	O
+improved	O
+protection	O
+against	O
+live	O
+virus	B-SPEC
+challenges	O
+.	O
+
+During	O
+the	O
+up	O
+-	O
+to	O
+-	O
+date	O
+investigation	O
+of	O
+PEDV	B-SPEC
+prevalence	O
+in	O
+Fujian	O
+China	O
+2016	O
+,	O
+PEDV	B-SPEC
+was	O
+identified	O
+in	O
+vaccinated	O
+pig	B-SPEC
+farms	O
+suffering	B-DISO
+severe	B-DISO
+diarrhea	I-DISO
+while	O
+other	O
+common	O
+diarrhea	B-DISO
+-	O
+associated	O
+pathogens	O
+were	O
+not	O
+detected	O
+.	O
+
+Remarkably	O
+,	O
+the	O
+natural	O
+recombinant	O
+HNQX	O
+-	O
+3	O
+isolate	O
+serves	O
+as	O
+a	O
+parental	O
+virus	B-SPEC
+for	O
+both	O
+natural	O
+recombinants	O
+identified	O
+in	O
+this	O
+study	O
+.	O
+
+TITLE	O
+:	O
+Prognostic	O
+value	O
+of	O
+serum	B-COMP
+zinc	B-CHED
+levels	O
+in	O
+patients	O
+with	O
+acute	O
+HC	O
+/	O
+zinc	B-CHED
+chloride	I-CHED
+smoke	O
+inhalation	B-PROC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+is	O
+to	O
+investigate	O
+the	O
+correlation	O
+between	O
+the	O
+serum	B-COMP
+zinc	B-CHED
+in	O
+patients	O
+with	O
+HC	O
+/	O
+ZnCl	O
+smoke	O
+inhalation	B-PROC
+lung	B-ANAT
+injury	O
+and	O
+disease	O
+severity	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+serum	O
+zinc	B-CHED
+level	O
+correlated	O
+well	O
+with	O
+the	O
+TLC	O
+,	O
+FVC	B-PROC
+,	O
+and	O
+FEV1	O
+(	O
+r	O
+=	O
+-	O
+0	O
+.	O
+587	O
+,	O
+-	O
+0	O
+.	O
+626	O
+,	O
+-	O
+0	O
+.	O
+617	O
+,	O
+respectively	O
+;	O
+P	O
+=	O
+.	O
+027	O
+,	O
+.	O
+017	O
+,	O
+.	O
+019	O
+,	O
+respectively	O
+).	O
+
+Chest	B-ANAT
+CT	O
+scan	O
+showed	O
+diffuse	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+that	O
+were	O
+suggestive	O
+of	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+.	O
+
+Recently	O
+,	O
+reverse	O
+genetics	O
+techniques	O
+including	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+,	O
+bacteria	B-SPEC
+artificial	O
+chromosome	B-COMP
+system	O
+and	O
+in	O
+vitro	O
+ligation	O
+have	O
+been	O
+successfully	O
+used	O
+to	O
+manipulate	O
+the	O
+genome	O
+of	O
+PEDV	B-SPEC
+,	O
+which	O
+providing	O
+new	O
+strategies	O
+for	O
+the	O
+clear	O
+delineation	O
+of	O
+the	O
+functions	O
+of	O
+the	O
+viral	O
+proteins	B-CHED
+,	O
+the	O
+mechanisms	O
+behind	O
+PEDV	B-SPEC
+pathogenesis	B-DISO
+and	O
+the	O
+design	O
+of	O
+novel	O
+vaccines	O
+against	O
+PEDV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+previously	O
+demonstrated	O
+that	O
+chickens	B-SPEC
+primed	O
+with	O
+a	O
+recombinant	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+LaSota	O
+(	O
+rLS	B-DISO
+)	O
+expressing	O
+the	O
+S2	B-PRGE
+gene	I-PRGE
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+boosted	O
+with	O
+an	O
+attenuated	O
+IBV	B-SPEC
+Massachusetts	O
+(	O
+Mass	O
+)-	O
+type	O
+vaccine	O
+were	O
+protected	O
+against	O
+IBV	B-SPEC
+Arkansas	O
+(	O
+Ark	O
+)-	O
+type	O
+virulent	O
+challenge	O
+.	O
+
+TITLE	O
+:	O
+High	O
+reproduction	B-PROC
+number	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+nosocomial	O
+outbreaks	O
+:	O
+mathematical	O
+modelling	O
+in	O
+Saudi	O
+Arabia	O
+and	O
+South	O
+Korea	O
+.	O
+
+Lnc	B-PRGE
+-	I-PRGE
+IL7R	I-PRGE
+plays	O
+a	O
+considerable	O
+role	O
+in	O
+the	O
+regulation	B-PROC
+of	O
+inflammation	B-DISO
+,	O
+but	O
+its	O
+prognostic	O
+potential	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+has	O
+not	O
+been	O
+fully	O
+explained	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+role	O
+of	O
+lnc	B-PRGE
+-	I-PRGE
+IL7R	I-PRGE
+as	O
+a	O
+potential	O
+biomarker	B-CHED
+in	O
+ARDS	B-DISO
+was	O
+examined	O
+.	O
+
+The	O
+area	O
+under	O
+the	O
+curve	O
+(	O
+AUC	O
+)	O
+of	O
+lnc	B-PRGE
+-	I-PRGE
+IL7R	I-PRGE
+for	O
+ARDS	B-DISO
+diagnosis	O
+was	O
+0	O
+.	O
+87	O
+(	O
+sensitivity	O
+75	O
+.	O
+3	O
+%,	O
+specificity	O
+93	O
+.	O
+9	O
+%).	O
+
+Lnc	B-PRGE
+-	I-PRGE
+IL7R	I-PRGE
+is	O
+a	O
+novel	O
+biomarker	B-CHED
+for	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+and	O
+predicts	O
+the	O
+severity	O
+of	O
+ARDS	B-DISO
+and	O
+28	O
+-	O
+day	O
+mortality	O
+in	O
+this	O
+patients	O
+cohort	O
+.	O
+
+survivors	O
+showed	O
+higher	O
+lnc	B-PRGE
+-	I-PRGE
+IL7R	I-PRGE
+level	O
+and	O
+lower	O
+APACHE	O
+II	O
+score	O
+,	O
+SOFA	O
+score	O
+and	O
+length	O
+of	O
+mechanical	O
+ventilation	O
+than	O
+in	O
+the	O
+non	O
+-	O
+survivors	O
+(	O
+P	O
+=	O
+.	O
+0109	O
+,	O
+P	O
+<	O
+.	O
+001	O
+,	O
+P	O
+<	O
+.	O
+001	O
+and	O
+P	O
+=	O
+.	O
+017	O
+,	O
+respectively	O
+).	O
+
+The	O
+first	O
+two	O
+steps	O
+consisted	O
+of	O
+a	O
+randomized	O
+order	B-SPEC
+of	O
+inspiratory	B-PROC
+pauses	O
+of	O
+10	O
+and	O
+30	O
+%	O
+of	O
+inspiratory	B-PROC
+time	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-PROC
+mechanics	I-PROC
+to	O
+understand	O
+ARDS	B-DISO
+and	O
+guide	O
+mechanical	O
+ventilation	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+respiratory	B-PROC
+mechanics	I-PROC
+might	O
+guide	O
+protective	O
+mechanical	O
+ventilation	O
+settings	O
+.	O
+
+TITLE	O
+:	O
+Host	B-COMP
+-	O
+Feeding	O
+Patterns	O
+of	O
+Culex	B-SPEC
+stigmatosoma	O
+(	O
+Diptera	B-SPEC
+:	O
+Culicidae	B-SPEC
+)	O
+in	O
+Southern	O
+California	B-SPEC
+.	O
+
+Early	O
+diagnosis	O
+and	O
+management	O
+of	O
+preeclampsia	B-DISO
+,	O
+eclampsia	B-DISO
+and	O
+HELLP	B-DISO
+syndrome	I-DISO
+are	O
+critical	O
+with	O
+involvement	O
+of	O
+a	O
+multidisciplinary	O
+team	O
+that	O
+includes	O
+Obstetrics	O
+,	O
+Maternal	O
+Fetal	O
+Medicine	B-CHED
+and	O
+Critical	O
+Care	O
+.	O
+
+The	O
+data	O
+of	O
+this	O
+survey	O
+also	O
+provided	O
+valuable	O
+information	O
+about	O
+the	O
+replication	O
+of	O
+IBD	B-DISO
+vaccines	O
+and	O
+subsequent	O
+infectious	B-SPEC
+bursal	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+IBDV	B-SPEC
+)	O
+antibody	B-PROC
+responses	I-PROC
+under	O
+field	O
+conditions	O
+.	O
+
+The	O
+Intraoperative	O
+Norepinephrine	B-CHED
+to	O
+Control	O
+Arterial	B-PROC
+Pressure	I-PROC
+(	O
+INPRESS	O
+)	O
+study	O
+was	O
+a	O
+multicenter	O
+,	O
+randomized	O
+,	O
+parallel	O
+-	O
+group	O
+clinical	O
+trial	O
+conducted	O
+in	O
+9	O
+French	O
+university	O
+and	O
+nonuniversity	O
+hospitals	O
+.	O
+
+Among	O
+patients	O
+predominantly	O
+undergoing	O
+abdominal	B-ANAT
+surgery	O
+who	O
+were	O
+at	O
+increased	O
+postoperative	O
+risk	O
+,	O
+management	O
+targeting	B-PROC
+an	O
+individualized	O
+systolic	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+compared	O
+with	O
+standard	O
+management	O
+,	O
+reduced	O
+the	O
+risk	O
+of	O
+postoperative	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+Lung	B-ANAT
+Recruitment	B-DISO
+and	O
+Titrated	O
+Positive	O
+End	B-PROC
+-	I-PROC
+Expiratory	I-PROC
+Pressure	O
+(	O
+PEEP	B-CHED
+)	O
+vs	O
+Low	O
+PEEP	B-CHED
+on	O
+Mortality	O
+in	O
+Patients	O
+With	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+:	O
+A	O
+Randomized	O
+Clinical	O
+Trial	O
+.	O
+
+To	O
+determine	O
+if	O
+lung	B-ANAT
+recruitment	B-DISO
+associated	O
+with	O
+PEEP	B-CHED
+titration	O
+according	O
+to	O
+the	O
+best	O
+respiratory	O
+-	O
+system	O
+compliance	O
+decreases	O
+28	O
+-	O
+day	O
+mortality	O
+of	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+compared	O
+with	O
+a	O
+conventional	O
+low	O
+-	O
+PEEP	B-CHED
+strategy	O
+.	O
+
+An	O
+experimental	O
+strategy	O
+with	O
+a	O
+lung	B-ANAT
+recruitment	B-DISO
+maneuver	O
+and	O
+PEEP	B-CHED
+titration	O
+according	O
+to	O
+the	O
+best	O
+respiratory	O
+-	O
+system	O
+compliance	O
+(	O
+n	O
+=	O
+501	O
+;	O
+experimental	O
+group	O
+)	O
+or	O
+a	O
+control	O
+strategy	O
+of	O
+low	O
+PEEP	O
+(	O
+n	O
+=	O
+509	O
+).	O
+
+Alternatively	O
+,	O
+a	O
+3D	O
+structure	O
+can	O
+be	O
+defined	O
+by	O
+incorporating	O
+a	O
+multivalent	O
+cross	O
+-	O
+linking	O
+agent	O
+,	O
+and	O
+this	O
+approach	O
+has	O
+been	O
+successfully	O
+developed	O
+for	O
+the	O
+selection	O
+of	O
+bicyclic	O
+peptides	B-CHED
+from	O
+large	O
+random	O
+-	O
+sequence	O
+libraries	O
+.	O
+
+The	O
+designed	O
+CovCore	O
+proteins	B-CHED
+were	O
+prepared	O
+by	O
+chemical	O
+synthesis	B-PROC
+,	O
+and	O
+their	O
+structures	O
+were	O
+determined	O
+by	O
+solution	O
+NMR	O
+or	O
+X	O
+-	O
+ray	O
+crystallography	O
+.	O
+
+A	O
+qualitative	O
+comparative	O
+case	O
+study	O
+approach	O
+was	O
+employed	O
+in	O
+the	O
+present	O
+study	O
+,	O
+using	O
+a	O
+set	O
+of	O
+8	O
+risk	O
+communication	O
+principles	O
+selected	O
+from	O
+international	O
+literature	O
+to	O
+suit	O
+the	O
+Chinese	O
+context	O
+for	O
+the	O
+comparative	O
+analysis	O
+of	O
+emergency	B-DISO
+responses	O
+of	O
+SARS	B-DISO
+and	O
+H7N9	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+report	O
+aimed	O
+to	O
+describe	O
+the	O
+outcomes	O
+of	O
+the	O
+patients	O
+with	O
+severe	O
+H1N1	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+who	O
+were	O
+treated	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+therapy	O
+.	O
+
+Seven	O
+patients	O
+were	O
+transferred	O
+to	O
+our	O
+center	O
+for	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+consideration	O
+(	O
+all	O
+within	O
+72	O
+hours	O
+of	O
+initiating	O
+mechanical	O
+ventilation	O
+).	O
+
+Neuroprotective	O
+ventilation	O
+was	O
+impossible	O
+without	O
+supramaximal	O
+tidal	O
+volumes	O
+due	O
+to	O
+a	O
+combination	O
+of	O
+chest	B-ANAT
+trauma	O
+and	O
+severe	O
+bronchospasm	B-DISO
+.	O
+
+The	O
+resulting	O
+reporter	O
+virus	B-SPEC
+achieved	O
+titres	O
+nearly	O
+identical	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+48	O
+h	O
+after	O
+infection	B-DISO
+of	O
+Vero	B-ANAT
+cells	I-ANAT
+at	O
+m	O
+.	O
+o	O
+.	O
+i	O
+.	O
+
+No	O
+pigs	B-SPEC
+in	O
+the	O
+PC21A	O
+-	O
+group	O
+developed	O
+diarrhea	B-DISO
+,	O
+whereas	O
+81	O
+and	O
+100	O
+%	O
+of	O
+pigs	B-SPEC
+in	O
+the	O
+S	O
+-	O
+INDEL	B-PROC
+and	O
+mock	O
+-	O
+groups	O
+had	O
+diarrhea	B-DISO
+post	O
+challenge	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Disruption	O
+of	O
+the	O
+endothelial	B-ANAT
+glycocalyx	B-COMP
+contributes	O
+to	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+experimental	O
+sepsis	B-DISO
+but	O
+has	O
+not	O
+been	O
+well	O
+studied	O
+in	O
+humans	B-SPEC
+.	O
+
+A	O
+self	O
+-	O
+administered	O
+questionnaire	O
+was	O
+designed	O
+based	O
+on	O
+modifications	O
+of	O
+related	O
+questionnaires	O
+,	O
+and	O
+used	O
+to	O
+assess	O
+levels	O
+of	O
+stress	O
+,	O
+professionalism	O
+,	O
+and	O
+nursing	B-PROC
+intention	O
+according	O
+to	O
+participants	O
+'	O
+experiences	O
+during	O
+the	O
+outbreak	O
+.	O
+
+Bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	B-SPEC
+)	O
+is	O
+antigenically	O
+related	O
+to	O
+ECoV	O
+;	O
+it	O
+is	O
+therefore	O
+possible	O
+that	O
+BCoV	B-SPEC
+vaccine	O
+will	O
+induce	O
+antibodies	B-COMP
+against	O
+ECoV	O
+in	O
+horses	B-SPEC
+.	O
+
+The	O
+latter	O
+situation	O
+may	O
+lead	O
+to	O
+1	O
+)	O
+diagnostic	O
+problems	O
+during	O
+the	O
+nonepidemic	O
+season	O
+or	O
+in	O
+places	O
+where	O
+diagnostic	O
+techniques	O
+are	O
+lacking	O
+and	O
+2	O
+)	O
+therapeutic	O
+difficulties	O
+resulting	O
+from	O
+the	O
+unavailability	O
+of	O
+techniques	O
+for	O
+the	O
+management	O
+of	O
+severe	O
+influenza	B-PATH
+infection	B-DISO
+in	O
+tourist	O
+areas	O
+.	O
+
+TITLE	O
+:	O
+Increased	O
+Mortality	O
+in	O
+Seasonal	O
+H3N2	B-CHED
+Patients	O
+Compared	O
+with	O
+those	O
+with	O
+Pandemic	O
+2009	O
+H1N1	O
+in	O
+Taiwan	O
+,	O
+2009	O
+-	O
+2010	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+conducted	O
+a	O
+retrospective	O
+study	O
+to	O
+compare	O
+clinical	O
+and	O
+laboratory	O
+findings	O
+between	O
+1	O
+)	O
+severe	O
+influenza	O
+A	O
+and	O
+mild	O
+influenza	B-PATH
+A	I-PATH
+and	O
+2	O
+)	O
+pandemic	O
+2009	O
+H1N1	O
+(	O
+pdm09	O
+A	O
+/	O
+H1	O
+)	O
+and	O
+seasonal	O
+H3N2	B-CHED
+(	O
+A	O
+/	O
+H3	O
+)	O
+from	O
+2009	O
+to	O
+2010	O
+.	O
+
+The	O
+SIRS	B-DISO
+response	O
+in	O
+polytraumatized	O
+children	O
+is	O
+poorly	O
+understood	O
+.	O
+
+Experimental	O
+results	O
+show	O
+that	O
+diphyllin	O
+dose	O
+-	O
+dependently	O
+inhibits	O
+endosomal	O
+acidification	B-PROC
+in	O
+fcwf	O
+-	O
+4	O
+cells	B-COMP
+,	O
+alters	O
+the	O
+cellular	B-COMP
+susceptibility	O
+to	O
+FIPV	O
+,	O
+and	O
+inhibits	O
+the	O
+downstream	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Quaternized	O
+chitosan	B-CHED
+nanoparticles	B-CHED
+loaded	O
+with	O
+the	O
+combined	O
+attenuated	O
+live	O
+vaccine	O
+against	O
+Newcastle	B-DISO
+disease	I-DISO
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+elicit	O
+immune	B-PROC
+response	I-PROC
+in	O
+chicken	B-SPEC
+after	O
+intranasal	O
+administration	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+study	O
+in	O
+the	O
+field	O
+of	O
+animal	B-SPEC
+vaccines	O
+demonstrating	O
+that	O
+intranasal	O
+administration	O
+of	O
+chickens	B-SPEC
+with	O
+antigens	B-CHED
+(	O
+NDV	B-SPEC
+and	O
+IBV	B-SPEC
+)	O
+encapsulated	O
+with	O
+chitosan	B-CHED
+derivative	O
+could	O
+induce	O
+humoral	O
+,	O
+cellular	B-COMP
+,	O
+and	O
+mucosal	B-PROC
+immune	I-PROC
+responses	I-PROC
+,	O
+which	O
+protected	O
+chickens	B-SPEC
+from	O
+the	O
+infection	B-DISO
+of	O
+highly	O
+virulent	O
+NDV	B-SPEC
+and	O
+IBV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Much	O
+concern	O
+has	O
+arisen	O
+regarding	O
+serious	O
+epidemics	O
+due	O
+to	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+.	O
+
+During	O
+2013	O
+-	O
+2016	O
+,	O
+a	O
+total	O
+of	O
+42351	O
+throat	B-ANAT
+swabs	O
+were	O
+examined	O
+for	O
+presence	O
+of	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+MERS	O
+-	O
+CoV	O
+in	O
+Iranian	O
+general	O
+population	O
+and	O
+pilgrims	O
+returning	O
+from	O
+Mecca	O
+and	O
+Karbala	O
+with	O
+SARI	O
+by	O
+using	O
+one	O
+step	O
+RT	O
+-	O
+PCR	O
+kit	B-FUNC
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+showed	O
+the	O
+prevalence	O
+of	O
+influenza	B-DISO
+infections	B-DISO
+among	O
+Iranian	O
+pilgrims	O
+and	O
+general	O
+population	O
+and	O
+suggests	O
+continuing	O
+surveillance	O
+,	O
+infection	B-DISO
+control	O
+and	O
+appropriate	O
+vaccination	O
+especially	O
+nowadays	O
+that	O
+the	O
+risk	O
+of	O
+influenza	B-DISO
+pandemic	O
+threatens	O
+the	O
+world	O
+,	O
+meanwhile	O
+accurate	O
+screening	O
+for	O
+MERS	O
+-	O
+CoV	O
+is	O
+also	O
+recommended	O
+.	O
+
+Thus	O
+,	O
+admitted	O
+patients	O
+are	O
+potentially	O
+manageable	O
+with	O
+Oseltamivir	B-CHED
+or	O
+Zanamivir	B-CHED
+therapy	O
+.	O
+
+Patients	O
+develop	O
+pulmonary	B-DISO
+edema	I-DISO
+with	O
+hemorrhages	B-DISO
+and	O
+leukocyte	B-ANAT
+extravasation	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+Lung	B-ANAT
+Microbiota	B-SPEC
+Is	O
+Related	O
+to	O
+Smoking	O
+Status	O
+and	O
+to	O
+Development	B-PROC
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+Critically	B-DISO
+Ill	I-DISO
+Trauma	O
+Patients	O
+.	O
+
+To	O
+determine	O
+whether	O
+cigarette	O
+smoking	O
+contributes	O
+to	O
+ARDS	B-DISO
+development	B-PROC
+after	O
+trauma	O
+by	O
+altering	O
+community	O
+composition	O
+of	O
+the	O
+lung	B-ANAT
+microbiota	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+on	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+is	O
+the	O
+main	O
+determinant	O
+of	O
+infectivity	O
+.	O
+
+Among	O
+these	O
+sites	O
+,	O
+8	O
+sites	O
+were	O
+confirmed	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+extracted	O
+from	O
+partially	O
+purified	O
+virus	B-COMP
+particles	I-COMP
+by	O
+proteomics	O
+approaches	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+non	O
+-	O
+structural	O
+proteins	B-CHED
+8	O
+and	O
+12	O
+form	O
+stable	O
+complex	O
+independent	O
+of	O
+the	O
+non	O
+-	O
+translated	O
+regions	O
+of	O
+viral	O
+RNA	O
+and	O
+other	O
+viral	O
+proteins	O
+.	O
+
+Influenza	B-DISO
+vaccine	O
+utilizing	O
+the	O
+2016	O
+(	O
+Southern	O
+Hemisphere	O
+vaccine	O
+to	O
+all	O
+pilgrims	O
+)	O
+was	O
+recommended	O
+but	O
+was	O
+not	O
+obligatory	O
+for	O
+pilgrims	O
+.	O
+
+One	O
+or	O
+more	O
+respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+172	O
+(	O
+46	O
+.	O
+6	O
+%)	O
+cases	O
+and	O
+their	O
+prevalence	O
+were	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+19	O
+.	O
+2	O
+%),	O
+adenovirus	B-DISO
+(	O
+8	O
+.	O
+7	O
+%),	O
+human	B-SPEC
+rhinovirus	I-SPEC
+A	I-SPEC
+(	O
+7	O
+.	O
+9	O
+%),	O
+coronavirus	B-SPEC
+OC43	O
+(	O
+4	O
+.	O
+3	O
+%),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+1	O
+(	O
+2	O
+.	O
+7	O
+%),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+3	O
+(	O
+2	O
+.	O
+7	O
+%),	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+2	O
+.	O
+2	O
+%),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+B	O
+(	O
+2	O
+.	O
+2	O
+%),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+1	O
+.	O
+4	O
+%),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+A	O
+(	O
+1	O
+.	O
+1	O
+%),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+2	O
+(	O
+0	O
+.	O
+5	O
+%)	O
+and	O
+coronavirus	B-SPEC
+229E	O
+(	O
+0	O
+.	O
+5	O
+%).	O
+
+These	O
+results	O
+are	O
+useful	O
+in	O
+order	B-SPEC
+to	O
+guide	O
+future	O
+surveillance	O
+and	O
+case	O
+management	O
+strategies	O
+involving	O
+respiratory	O
+illnesses	O
+in	O
+Uganda	O
+.	O
+
+Increased	O
+probability	O
+of	O
+direct	O
+,	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+due	O
+to	O
+clinical	O
+manifestations	O
+associated	O
+with	O
+death	O
+,	O
+as	O
+well	O
+as	O
+indirect	O
+transmission	O
+via	O
+environmental	O
+contamination	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+fomites	O
+and	O
+indoor	O
+ventilation	O
+systems	O
+),	O
+may	O
+serve	O
+as	O
+mechanistic	O
+explanations	O
+for	O
+nosocomial	O
+amplification	B-DISO
+of	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+in	O
+South	O
+Korea	O
+.	O
+
+Medications	O
+administered	O
+(	O
+sedative	B-CHED
+,	O
+analgesic	B-CHED
+,	O
+paralytic	O
+,	O
+and	O
+antipsychotic	O
+),	O
+sedation	B-DISO
+depth	O
+(	O
+Sedation	B-DISO
+Agitation	B-DISO
+Scale	O
+[	O
+SAS	O
+]	O
+score	O
+)	O
+delirium	B-DISO
+assessments	O
+,	O
+and	O
+mobilization	O
+were	O
+recorded	O
+daily	O
+.	O
+
+These	O
+processes	O
+all	O
+have	O
+a	O
+redox	B-PROC
+component	O
+,	O
+and	O
+this	O
+chapter	O
+focuses	O
+on	O
+the	O
+role	O
+played	O
+by	O
+ROS	B-CHED
+during	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-DISO
+-	O
+CoV	O
+Fusion	O
+Peptide	B-CHED
+Forms	O
+an	O
+Extended	O
+Bipartite	O
+Fusion	O
+Platform	O
+that	O
+Perturbs	O
+Membrane	B-ANAT
+Order	B-SPEC
+in	O
+a	O
+Calcium	B-CHED
+-	O
+Dependent	O
+Manner	O
+.	O
+
+However	O
+,	O
+S	O
+proteins	B-CHED
+have	O
+two	O
+distinct	O
+cleavage	B-PROC
+sites	O
+that	O
+can	O
+be	O
+activated	O
+by	O
+a	O
+much	O
+wider	O
+range	O
+of	O
+proteases	O
+.	O
+
+Recently	O
+,	O
+RVD	B-PROC
+has	O
+been	O
+suggested	O
+to	O
+play	O
+a	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+runting	O
+and	O
+stunting	O
+syndrome	B-DISO
+(	O
+RSS	B-DISO
+),	O
+alongside	O
+other	O
+viruses	B-SPEC
+such	O
+as	O
+reovirus	B-SPEC
+,	O
+astrovirus	O
+,	O
+coronavirus	B-SPEC
+,	O
+and	O
+others	O
+,	O
+all	O
+of	O
+which	O
+cause	O
+colossal	O
+economic	O
+losses	O
+to	O
+the	O
+poultry	O
+industry	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+the	O
+HA7	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+antibody	B-COMP
+was	O
+generated	O
+earlier	O
+than	O
+the	O
+neutralizing	O
+antibody	B-COMP
+.	O
+
+A	O
+Systematic	O
+Review	O
+and	O
+Meta	B-SPEC
+-	O
+Analysis	O
+.	O
+
+Determining	O
+a	O
+correlation	O
+between	O
+the	O
+viruses	B-SPEC
+and	O
+IPF	O
+is	O
+not	O
+an	O
+easy	O
+task	O
+,	O
+and	O
+therefore	O
+,	O
+this	O
+will	O
+require	O
+more	O
+research	O
+.	O
+
+ABSTRACT	O
+:	O
+Bilateral	O
+acute	O
+iris	B-SPEC
+transillumination	O
+(	O
+BAIT	O
+)	O
+is	O
+a	O
+poorly	O
+-	O
+understood	O
+ocular	B-PROC
+syndrome	B-DISO
+in	O
+which	O
+patients	O
+present	O
+with	O
+acute	B-DISO
+iridocyclitis	I-DISO
+and	O
+pigmentary	O
+dispersion	O
+with	O
+or	O
+without	O
+ocular	B-DISO
+hypertension	I-DISO
+.	O
+
+The	O
+etiology	O
+of	O
+the	O
+disease	O
+remains	O
+unknown	O
+,	O
+though	O
+recent	O
+reports	O
+suggest	O
+an	O
+antecedent	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+or	O
+systemic	O
+antibiotic	B-CHED
+administration	O
+may	O
+trigger	O
+the	O
+clinical	O
+syndrome	B-DISO
+.	O
+
+Ophthalmologists	O
+should	O
+remain	O
+aware	O
+of	O
+the	O
+association	O
+between	O
+systemic	O
+fluoroquinolones	O
+and	O
+acute	O
+pigmentary	O
+dispersion	O
+that	O
+can	O
+progress	O
+to	O
+glaucoma	B-DISO
+.	O
+
+The	O
+Trabectome	O
+remains	O
+a	O
+viable	O
+option	O
+for	O
+management	O
+of	O
+pigmentary	O
+and	O
+uveitic	B-DISO
+glaucoma	I-DISO
+resistant	O
+to	O
+medical	O
+treatment	O
+.	O
+
+PdCoV	O
+spike	O
+possesses	B-DISO
+several	O
+structural	O
+features	O
+that	O
+may	O
+facilitate	O
+immune	B-PROC
+evasion	I-PROC
+by	O
+the	O
+virus	B-SPEC
+,	O
+such	O
+as	O
+its	O
+compact	O
+structure	O
+,	O
+concealed	O
+receptor	O
+-	O
+binding	B-FUNC
+sites	O
+,	O
+and	O
+shielded	O
+critical	O
+epitopes	O
+.	O
+
+Overall	O
+,	O
+this	O
+study	O
+reveals	O
+that	O
+deltacoronavirus	O
+spikes	O
+are	O
+structurally	O
+and	O
+evolutionally	O
+more	O
+closely	O
+related	O
+to	O
+alphacoronavirus	B-SPEC
+spikes	O
+than	O
+to	O
+betacoronavirus	B-SPEC
+spikes	O
+;	O
+it	O
+also	O
+has	O
+implications	O
+for	O
+the	O
+receptor	O
+recognition	O
+,	O
+membrane	B-PROC
+fusion	I-PROC
+,	O
+and	O
+immune	B-PROC
+evasion	I-PROC
+by	O
+deltacoronaviruses	O
+as	O
+well	O
+as	O
+coronaviruses	O
+in	O
+general	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+atomic	O
+structure	O
+of	O
+a	O
+spike	O
+protein	B-CHED
+from	O
+the	O
+deltacoronavirus	O
+genus	B-SPEC
+,	O
+which	O
+is	O
+divergent	O
+in	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+from	O
+the	O
+well	O
+-	O
+studied	O
+alpha	O
+-	O
+and	O
+betacoronavirus	B-SPEC
+spike	O
+proteins	B-CHED
+.	O
+
+Based	O
+on	O
+the	O
+structures	O
+and	O
+functions	O
+of	O
+these	O
+structural	O
+elements	O
+,	O
+we	O
+discussed	O
+the	O
+evolution	B-PROC
+of	O
+PdCoV	B-PRGE
+spike	I-PRGE
+protein	I-PRGE
+in	O
+relation	O
+to	O
+the	O
+spike	O
+proteins	B-CHED
+from	O
+other	O
+coronavirus	B-SPEC
+genera	O
+.	O
+
+We	O
+also	O
+biochemically	O
+characterized	O
+the	O
+molecular	O
+events	O
+associated	O
+with	O
+refolding	O
+of	O
+the	O
+metastable	O
+prefusion	O
+S	O
+glycoprotein	B-CHED
+to	O
+the	O
+postfusion	O
+conformation	O
+using	O
+limited	O
+proteolysis	B-PROC
+,	O
+mass	O
+spectrometry	O
+,	O
+and	O
+single	O
+-	O
+particle	O
+EM	O
+.	O
+
+We	O
+aimed	O
+to	O
+identify	O
+characteristics	O
+associated	O
+with	O
+severe	O
+renal	B-DISO
+failure	I-DISO
+(	O
+Kidney	B-DISO
+Disease	I-DISO
+Improving	O
+Global	O
+Outcome	O
+(	O
+KDIGO	O
+)	O
+3	O
+)	O
+and	O
+its	O
+impact	O
+on	O
+3	O
+-	O
+month	O
+outcome	O
+.	O
+
+CONCLUSIONS	O
+:	O
+KDIGO	O
+3	O
+AKI	O
+occurrence	O
+is	O
+correlated	O
+with	O
+the	O
+severity	O
+of	O
+patients	O
+'	O
+clinical	O
+condition	B-DISO
+prior	O
+to	O
+ECMO	O
+insertion	O
+and	O
+is	O
+negatively	O
+associated	O
+with	O
+90	O
+-	O
+day	O
+survival	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+strains	O
+from	O
+the	O
+G1b	O
+cluster	O
+are	O
+considered	O
+less	O
+pathogenic	O
+compared	O
+to	O
+the	O
+G2b	O
+cluster	O
+.	O
+
+The	O
+oral	B-ANAT
+,	O
+but	O
+not	O
+the	O
+intramuscular	O
+,	O
+experimental	O
+G1b	O
+-	O
+based	O
+live	O
+virus	B-SPEC
+exposure	O
+induced	O
+a	O
+high	O
+anti	B-PRGE
+-	I-PRGE
+PEDV	I-PRGE
+IgA	I-PRGE
+response	O
+prior	O
+to	O
+challenge	O
+,	O
+which	O
+apparently	O
+did	O
+not	O
+impact	O
+PEDV	B-SPEC
+shedding	O
+compared	O
+to	O
+POS	O
+-	O
+CONTROL	O
+pigs	B-SPEC
+.	O
+
+Sepsis	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+patients	O
+have	O
+significantly	O
+lower	O
+PaO2	O
+/	O
+FiO2	O
+ratios	O
+than	O
+patients	O
+with	O
+non	O
+-	O
+sepsis	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+.	O
+
+Clinical	O
+outcomes	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+are	O
+also	O
+worse	O
+,	O
+associated	O
+with	O
+significantly	O
+higher	O
+28	O
+-	O
+day	O
+and	O
+60	O
+-	O
+day	O
+mortality	O
+rates	O
+(	O
+31	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+16	O
+.	O
+3	O
+%	O
+and	O
+38	O
+.	O
+2	O
+%	O
+vs	O
+.	O
+22	O
+.	O
+6	O
+%,	O
+respectively	O
+).	O
+
+It	O
+is	O
+extremely	O
+important	O
+to	O
+optimally	O
+adjust	O
+ventilator	O
+setting	O
+to	O
+current	O
+condition	B-DISO
+of	O
+lungs	B-ANAT
+,	O
+while	O
+providing	O
+all	O
+other	O
+therapeutic	O
+measures	O
+in	O
+the	O
+treatment	O
+of	O
+sepsis	B-DISO
+,	I-DISO
+severe	I-DISO
+sepsis	B-DISO
+and	O
+septic	O
+shock	O
+.	O
+
+Ventilator	O
+modes	O
+and	O
+adequate	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+settings	O
+play	O
+a	O
+major	O
+role	O
+in	O
+these	O
+strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+great	O
+economic	O
+burden	O
+both	O
+for	O
+productive	O
+losses	O
+and	O
+costs	O
+of	O
+the	O
+control	O
+strategies	O
+.	O
+
+TITLE	O
+:	O
+Reference	O
+gene	O
+selection	O
+for	O
+gene	B-PROC
+expression	I-PROC
+study	O
+in	O
+shell	B-ANAT
+gland	I-ANAT
+and	O
+spleen	B-ANAT
+of	O
+laying	O
+hens	O
+challenged	O
+with	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+Validation	O
+studies	O
+showed	O
+that	O
+the	O
+use	O
+of	O
+the	O
+two	O
+most	O
+stable	O
+reference	O
+genes	O
+produced	O
+accurate	O
+and	O
+more	O
+robust	O
+gene	B-PROC
+expression	I-PROC
+data	O
+.	O
+
+ChAd	O
+vectors	O
+are	O
+safe	O
+and	O
+induce	O
+antigen	B-CHED
+-	O
+specific	O
+cellular	B-COMP
+and	O
+humoral	B-PROC
+immunity	I-PROC
+in	O
+all	O
+age	O
+groups	O
+,	O
+as	O
+well	O
+as	O
+circumventing	O
+the	O
+problem	O
+of	O
+pre	O
+-	O
+existing	O
+immunity	B-PROC
+encountered	O
+with	O
+human	B-SPEC
+Ad	O
+vectors	O
+.	O
+
+Significant	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+elimination	B-PROC
+,	O
+averaging	O
+between	O
+5	O
+and	O
+18	O
+%	O
+per	O
+blood	B-ANAT
+pass	O
+throughout	O
+the	O
+entire	O
+treatment	O
+period	O
+was	O
+recorded	O
+.	O
+
+The	O
+proportion	O
+of	O
+patients	O
+receiving	O
+renal	B-ANAT
+replacement	O
+therapy	O
+at	O
+the	O
+time	O
+of	O
+enrollment	O
+was	O
+higher	O
+in	O
+the	O
+treatment	O
+group	O
+(	O
+31	O
+.	O
+9	O
+%)	O
+when	O
+compared	O
+to	O
+the	O
+control	O
+group	O
+(	O
+16	O
+.	O
+3	O
+%).	O
+
+ABSTRACT	O
+:	O
+Attachment	O
+to	O
+cellular	O
+surfaces	O
+is	O
+a	O
+major	O
+attribute	O
+among	O
+infectious	B-DISO
+pathogens	O
+for	O
+initiating	O
+disease	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+resulting	O
+nanoparticles	B-CHED
+possess	B-DISO
+a	O
+distinctive	O
+membrane	B-COMP
+corona	B-CHED
+,	O
+a	O
+sialylated	O
+surface	O
+,	O
+and	O
+form	O
+colloidally	O
+stable	O
+clusters	O
+with	O
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Follow	O
+-	O
+up	O
+chest	B-ANAT
+radiographic	O
+findings	O
+in	O
+patients	O
+with	O
+MERS	O
+-	O
+CoV	O
+after	O
+recovery	O
+.	O
+
+Among	O
+the	O
+patients	O
+with	O
+abnormal	O
+chest	B-ANAT
+radiographs	O
+(	O
+13	O
+/	O
+36	O
+,	O
+36	O
+%),	O
+the	O
+following	O
+were	O
+found	O
+:	O
+lung	B-DISO
+fibrosis	I-DISO
+in	O
+12	O
+(	O
+33	O
+%)	O
+patients	O
+GGO	O
+in	O
+2	O
+(	O
+5	O
+.	O
+5	O
+%)	O
+patients	O
+,	O
+and	O
+pleural	B-DISO
+thickening	I-DISO
+in	O
+2	O
+(	O
+5	O
+.	O
+5	O
+%)	O
+patients	O
+.	O
+
+The	O
+retrospective	O
+study	O
+was	O
+performed	O
+including	O
+a	O
+total	O
+of	O
+37	O
+post	O
+-	O
+SARS	B-DISO
+ONFH	O
+patients	O
+(	O
+66	O
+hip	B-ANAT
+joints	I-ANAT
+)	O
+in	O
+the	O
+Department	O
+of	O
+Orthopedics	O
+of	O
+the	O
+General	O
+Hospital	O
+of	O
+Tianjin	O
+Medical	O
+University	O
+between	O
+November	O
+2003	O
+and	O
+November	O
+2015	O
+,	O
+consisting	O
+of	O
+6	O
+males	O
+(	O
+11	O
+hip	B-ANAT
+joints	I-ANAT
+)	O
+and	O
+31	O
+females	O
+(	O
+55	O
+hip	B-ANAT
+joints	I-ANAT
+),	O
+with	O
+age	O
+between	O
+19	O
+and	O
+47	O
+years	O
+(	O
+average	O
+29	O
+.	O
+9	O
+years	O
+).	O
+
+Flushing	B-DISO
+animal	B-SPEC
+food	O
+-	O
+contact	O
+surfaces	O
+with	O
+low	O
+-	O
+risk	O
+feed	O
+is	O
+commonly	O
+used	O
+to	O
+reduce	O
+cross	O
+-	O
+contamination	O
+in	O
+animal	B-SPEC
+feed	O
+manufacturing	O
+.	O
+
+A	O
+bioassay	O
+to	O
+test	O
+infectivity	O
+of	O
+dust	O
+from	O
+animal	B-SPEC
+food	O
+-	O
+contact	O
+surfaces	O
+failed	O
+to	O
+produce	O
+infectivity	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+advancements	O
+in	O
+ventilator	O
+technologies	O
+,	O
+lung	O
+supportive	O
+and	O
+rescue	O
+therapies	O
+,	O
+the	O
+outcome	O
+and	O
+prognostication	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+incremental	O
+and	O
+ambiguous	O
+.	O
+
+In	O
+our	O
+study	O
+patients	O
+diagnosed	O
+with	O
+mild	O
+and	O
+moderate	O
+/	O
+severe	O
+ARDS	B-DISO
+clinically	O
+governed	O
+by	O
+hypoxemic	O
+P	O
+/	O
+F	O
+ratio	O
+between	O
+100	O
+-	O
+300	O
+but	O
+with	O
+indistinct	O
+molecular	O
+phenotype	O
+were	O
+discriminated	O
+employing	O
+nuclear	O
+magnetic	O
+resonance	O
+(	O
+NMR	O
+)	O
+based	O
+metabolomics	O
+of	O
+mini	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+mBALF	O
+).	O
+
+Resulting	O
+biomarker	B-CHED
+prototype	O
+comprising	O
+six	O
+metabolites	B-CHED
+was	O
+substantiated	O
+highlighting	O
+ARDS	B-DISO
+susceptibility	O
+/	O
+recovery	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+successfully	O
+isolated	O
+and	O
+attenuated	O
+the	O
+PEDV	B-SPEC
+epidemic	O
+strain	O
+Zhejiang08	O
+,	O
+which	O
+was	O
+characterized	O
+by	O
+good	O
+cell	B-COMP
+adaptation	B-PROC
+and	O
+high	O
+-	O
+titer	O
+production	O
+48	O
+h	O
+post	O
+infection	B-DISO
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Outbreaks	O
+of	O
+diarrhea	O
+in	O
+newborn	O
+piglets	O
+without	O
+detection	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+),	O
+have	O
+been	O
+recorded	O
+in	O
+a	O
+pig	B-SPEC
+farm	O
+in	O
+southern	O
+China	O
+since	O
+February	O
+2017	O
+.	O
+
+Complete	O
+genomic	O
+sequencing	O
+and	O
+analyses	O
+of	O
+SeACoV	O
+indicated	O
+that	O
+the	O
+extreme	O
+amino	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+SeACoV	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	O
+structurally	O
+similar	O
+to	O
+the	O
+domain	O
+0	O
+of	O
+the	O
+alphacoronavirus	B-SPEC
+NL63	O
+,	O
+whereas	O
+the	O
+rest	B-FUNC
+part	O
+of	O
+S	O
+structurally	O
+resembles	O
+domains	O
+B	O
+to	O
+D	O
+of	O
+the	O
+betacoronavirus	B-SPEC
+.	O
+
+These	O
+results	O
+confirmed	O
+that	O
+it	O
+is	O
+a	O
+novel	O
+swine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+representing	O
+the	O
+fifth	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+on	O
+nursery	O
+pig	B-SPEC
+intestinal	B-ANAT
+function	O
+and	O
+barrier	O
+integrity	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pig	O
+intestinal	B-ANAT
+epithelium	I-ANAT
+can	O
+be	O
+compromised	O
+by	O
+pathogens	O
+leading	O
+to	O
+reduced	O
+integrity	O
+and	O
+function	O
+.	O
+
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+recently	O
+detected	O
+in	O
+North	O
+America	O
+,	O
+exemplifies	O
+intestinal	B-ANAT
+epithelial	O
+insult	O
+.	O
+
+Fifty	O
+recently	O
+-	O
+weaned	B-PROC
+,	O
+5	O
+-	O
+week	O
+-	O
+old	O
+barrows	O
+and	O
+gilts	O
+(	O
+BW	O
+=	O
+9	O
+.	O
+92	O
+±	O
+0	O
+.	O
+49kg	O
+)	O
+were	O
+sorted	B-PROC
+based	O
+on	O
+body	B-ANAT
+weight	O
+(	O
+BW	O
+)	O
+and	O
+sex	O
+into	O
+two	O
+treatments	O
+:	O
+1	O
+)	O
+Control	O
+or	O
+2	O
+)	O
+PEDV	B-SPEC
+inoculated	O
+.	O
+
+At	O
+2	O
+,	O
+5	O
+,	O
+7	O
+,	O
+and	O
+14days	O
+post	O
+inoculation	O
+(	O
+dpi	O
+),	O
+4	O
+pigs	B-SPEC
+per	O
+treatment	O
+were	O
+euthanized	O
+and	O
+jejunum	B-ANAT
+sections	O
+collected	O
+.	O
+
+PEDV	B-PRGE
+antigen	B-CHED
+was	O
+detected	O
+in	O
+inoculated	O
+pigs	B-SPEC
+by	O
+immunohistochemistry	O
+in	O
+50	O
+%	O
+(	O
+2	O
+/	O
+4	O
+)	O
+at	O
+dpi	O
+2	O
+,	O
+100	O
+%	O
+(	O
+4	O
+/	O
+4	O
+)	O
+at	O
+dpi	O
+5	O
+,	O
+and	O
+none	O
+at	O
+later	O
+time	O
+points	O
+.	O
+
+Collectively	O
+,	O
+these	O
+data	O
+reveal	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+results	O
+in	O
+time	O
+-	O
+dependent	O
+changes	O
+not	O
+only	O
+in	O
+intestinal	B-ANAT
+morphology	O
+but	O
+also	O
+barrier	O
+integrity	O
+and	O
+function	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+and	O
+biological	O
+characterization	O
+of	O
+a	O
+Porcine	B-DISO
+Reproductive	I-DISO
+and	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Virus	I-SPEC
+2	O
+(	O
+PRRSV	O
+-	O
+2	O
+)	O
+causing	O
+significant	O
+clinical	O
+disease	O
+in	O
+the	O
+field	O
+.	O
+
+Due	O
+to	O
+the	O
+clinical	O
+observations	O
+of	O
+reproductive	B-PROC
+failure	O
+in	O
+sows	O
+and	O
+high	O
+mortality	O
+in	O
+piglets	O
+,	O
+it	O
+was	O
+speculated	O
+that	O
+a	O
+new	O
+,	O
+more	O
+pathogenic	O
+or	O
+vaccine	O
+evading	O
+PRRSV	B-SPEC
+strain	O
+had	O
+emerged	O
+in	O
+Denmark	O
+.	O
+
+Complete	O
+genome	O
+sequencing	O
+of	O
+isolates	O
+from	O
+this	O
+herd	O
+revealed	O
+that	O
+although	O
+the	O
+case	O
+strain	O
+had	O
+some	O
+unique	O
+genetic	O
+features	O
+including	O
+a	O
+deduced	O
+3	O
+amino	O
+acid	O
+deletion	O
+,	O
+it	O
+was	O
+in	O
+overall	O
+very	O
+similar	O
+to	O
+the	O
+other	O
+PRRS	B-DISO
+-	O
+2	O
+viruses	B-SPEC
+circulating	O
+in	O
+Denmark	O
+.	O
+
+Fibrinous	O
+bronchopneumonia	B-DISO
+was	O
+diagnosed	O
+in	O
+one	O
+steer	O
+that	O
+died	B-PROC
+;	O
+samples	O
+were	O
+positive	O
+for	O
+H	B-SPEC
+.	I-SPEC
+somni	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+by	O
+PCR	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+major	O
+internal	O
+component	O
+of	O
+the	O
+HIV	B-DISO
+virion	B-COMP
+core	O
+is	O
+the	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+7	I-PRGE
+(	O
+NCp7	O
+),	O
+a	O
+small	O
+,	O
+highly	O
+basic	O
+protein	B-CHED
+that	O
+is	O
+essential	O
+for	O
+multiple	O
+stages	O
+of	O
+the	O
+viral	O
+replicative	O
+cycle	O
+,	O
+and	O
+whose	O
+structure	O
+is	O
+preserved	O
+in	O
+all	O
+viral	O
+strains	O
+,	O
+including	O
+clinical	O
+isolates	O
+from	O
+therapy	O
+-	O
+experienced	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Exacerbation	O
+of	O
+macrophage	O
+-	O
+mediated	O
+inflammation	B-DISO
+contributes	O
+to	O
+pathogenesis	B-DISO
+of	O
+various	O
+inflammatory	O
+diseases	O
+,	O
+but	O
+the	O
+immunometabolic	O
+programs	O
+underlying	O
+regulation	B-PROC
+of	I-PROC
+macrophage	I-PROC
+activation	I-PROC
+are	O
+unclear	O
+.	O
+
+ABSTRACT	O
+:	O
+Intra	O
+-	O
+vitam	O
+diagnosis	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+challenge	O
+for	O
+veterinary	O
+diagnosticians	O
+,	O
+since	O
+there	O
+are	O
+no	O
+highly	O
+specific	O
+and	O
+sensitive	O
+assays	O
+currently	O
+available	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+RNA	O
+genome	O
+is	O
+the	O
+largest	O
+among	O
+the	O
+single	O
+-	O
+stranded	O
+positive	O
+-	O
+sense	B-PROC
+RNA	O
+viruses	B-SPEC
+.	O
+
+We	O
+constructed	O
+a	O
+recombinant	O
+adenovirus	B-DISO
+that	O
+simultaneously	O
+expresses	O
+the	O
+S1	B-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+of	O
+IBV	B-SPEC
+and	O
+the	O
+TM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+protein	I-PRGE
+of	O
+MG	O
+(	O
+pBH	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+-	I-PRGE
+TM	I-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+EGFP	I-PRGE
+).	O
+
+Groups	O
+of	O
+seven	O
+-	O
+day	O
+-	O
+old	O
+specific	O
+pathogen	O
+free	O
+chicks	O
+were	O
+immunized	O
+twice	O
+,	O
+two	O
+weeks	O
+apart	O
+,	O
+via	O
+the	O
+oculonasal	O
+route	O
+with	O
+the	O
+pBH	O
+-	O
+S1	O
+-	O
+TM	O
+-	O
+1	O
+-	O
+EGFP	O
+,	O
+pBH	O
+-	O
+S1	O
+-	O
+EGFP	O
+,	O
+or	O
+pBH	B-PRGE
+-	I-PRGE
+TM	I-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+EGFP	O
+vaccine	O
+candidates	O
+or	O
+the	O
+commercial	O
+attenuated	O
+infectious	B-DISO
+bronchitis	B-DISO
+vaccine	O
+strain	O
+H52	O
+and	O
+MG	O
+vaccine	O
+strain	O
+F	O
+-	O
+36	O
+(	O
+positive	O
+controls	O
+),	O
+and	O
+challenged	O
+with	O
+virulent	O
+IBV	B-SPEC
+or	O
+MG	O
+two	O
+weeks	O
+later	O
+.	O
+
+Using	O
+peripheral	B-ANAT
+blood	I-ANAT
+obtained	O
+from	O
+mature	O
+infants	O
+with	O
+and	O
+without	O
+NRDS	O
+,	O
+in	O
+tandem	O
+with	O
+mRNA	B-CHED
+sequencing	O
+(	O
+mRNA	O
+‑	O
+seq	O
+)	O
+analysis	O
+,	O
+the	O
+present	O
+study	O
+identified	O
+that	O
+,	O
+while	O
+cell	B-PROC
+cycle	I-PROC
+regulation	I-PROC
+and	O
+alveolar	B-ANAT
+surfactants	B-CHED
+serve	O
+a	O
+role	O
+in	O
+deterring	O
+the	O
+further	O
+onset	O
+of	O
+NRDS	O
+,	O
+innate	O
+and	O
+pathogen	O
+‑	O
+induced	O
+responses	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+are	O
+among	O
+the	O
+most	O
+important	O
+factors	O
+in	O
+the	O
+pathology	O
+.	O
+
+The	O
+overall	O
+prevalence	O
+of	O
+porcine	B-SPEC
+astrovirus	I-SPEC
+(	O
+PAstV	O
+)	O
+was	O
+75	O
+%	O
+with	O
+69	O
+.	O
+8	O
+%	O
+of	O
+the	O
+PAstV	O
+positive	O
+pigs	B-SPEC
+infected	O
+with	O
+PAstV	O
+type	O
+3	O
+.	O
+
+Using	O
+Next	O
+Generation	O
+de	O
+novo	O
+sequencing	O
+(	O
+de	O
+novo	O
+NGS	O
+)	O
+on	O
+pools	O
+of	O
+samples	O
+from	O
+case	O
+animals	B-SPEC
+within	O
+all	O
+herds	O
+,	O
+PKV	O
+-	O
+1	O
+was	O
+detected	O
+in	O
+four	O
+herds	O
+and	O
+rotavirus	B-SPEC
+A	I-SPEC
+,	O
+rotavirus	B-SPEC
+C	I-SPEC
+and	O
+PTV	B-SPEC
+were	O
+detected	O
+in	O
+one	O
+herd	O
+each	O
+.	O
+
+Using	O
+Next	O
+Generation	O
+de	O
+novo	O
+sequencing	O
+(	O
+de	O
+novo	O
+NGS	O
+)	O
+on	O
+pools	O
+of	O
+samples	O
+from	O
+case	O
+animals	B-SPEC
+within	O
+all	O
+herds	O
+,	O
+PKV	O
+-	O
+1	O
+was	O
+detected	O
+in	O
+four	O
+herds	O
+and	O
+rotavirus	B-SPEC
+A	I-SPEC
+,	O
+rotavirus	B-SPEC
+C	I-SPEC
+and	O
+PTV	B-SPEC
+were	O
+detected	O
+in	O
+one	O
+herd	O
+each	O
+.	O
+
+We	O
+identified	O
+sequences	O
+from	O
+market	O
+camels	B-SPEC
+nearly	O
+identical	O
+to	O
+the	O
+previously	O
+reported	O
+2015	O
+German	O
+case	O
+who	O
+visited	O
+the	O
+market	O
+during	O
+his	O
+incubation	O
+period	O
+.	O
+
+We	O
+described	O
+10	O
+recombination	B-PROC
+events	O
+in	O
+the	O
+camel	B-SPEC
+samples	O
+.	O
+
+TITLE	O
+:	O
+Design	O
+and	O
+Delivery	O
+of	O
+Therapeutic	O
+siRNAs	O
+:	O
+Application	O
+to	O
+MERS	O
+-	O
+Coronavirus	B-SPEC
+.	O
+
+The	O
+replication	O
+of	O
+MERS	O
+-	O
+CoV	O
+is	O
+mediated	O
+by	O
+ORF	B-PRGE
+1ab	I-PRGE
+and	O
+viral	O
+gene	O
+activity	O
+can	O
+be	O
+modulated	O
+by	O
+RNAi	B-PROC
+approach	O
+.	O
+
+The	O
+efficient	O
+delivery	O
+of	O
+siRNAs	O
+into	O
+targeted	B-PROC
+cells	B-COMP
+faces	B-ANAT
+many	O
+challenges	O
+like	O
+enzymatic	O
+degradation	O
+and	O
+quick	O
+clearance	O
+through	O
+renal	B-ANAT
+system	O
+.	O
+
+This	O
+innovative	O
+technology	O
+has	O
+attracted	O
+researchers	O
+,	O
+academia	O
+and	O
+pharmaceuticals	B-CHED
+industries	O
+towards	O
+designing	O
+and	O
+development	B-PROC
+of	O
+highly	O
+effective	O
+and	O
+targeted	B-PROC
+disease	O
+therapy	O
+.	O
+
+In	O
+most	O
+of	O
+the	O
+cases	O
+analyzed	O
+over	O
+the	O
+period	O
+2010	O
+-	O
+2012	O
+,	O
+anesthesia	B-DISO
+and	O
+resuscitation	O
+have	O
+been	O
+involved	O
+in	O
+the	O
+occurrence	O
+of	O
+maternal	B-PROC
+deaths	I-PROC
+,	O
+mainly	O
+through	O
+strategic	O
+errors	O
+in	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+severe	O
+pathology	B-DISO
+before	O
+delivery	O
+,	O
+as	O
+well	O
+as	O
+through	O
+insufficient	O
+cardiac	B-ANAT
+resuscitation	O
+duration	O
+after	O
+cardiac	B-DISO
+arrest	I-DISO
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+characteristics	O
+and	O
+prognosis	O
+of	O
+drug	O
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+compared	O
+with	O
+non	O
+-	O
+drug	O
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+single	O
+-	O
+centre	O
+retrospective	O
+study	O
+in	O
+Japan	O
+.	O
+
+She	O
+presented	O
+with	O
+grand	B-DISO
+mal	I-DISO
+seizures	I-DISO
+and	O
+vomiting	B-DISO
+on	O
+admission	O
+to	O
+our	O
+Emergency	B-DISO
+Center	O
+,	O
+with	O
+a	O
+fluvoxamine	B-CHED
+serum	B-COMP
+concentration	O
+of	O
+4	O
+.	O
+58	O
+μg	O
+/	O
+mL	O
+.	O
+The	O
+patient	O
+was	O
+diagnosed	O
+with	O
+status	B-DISO
+epilepticus	I-DISO
+,	O
+which	O
+could	O
+not	O
+be	O
+fully	O
+suppressed	O
+with	O
+the	O
+maximum	O
+dosage	O
+of	O
+benzodiazepines	B-CHED
+.	O
+
+The	O
+patient	O
+also	O
+developed	O
+circulatory	B-DISO
+collapse	I-DISO
+after	O
+resuscitation	O
+for	O
+sudden	B-DISO
+cardiac	I-DISO
+arrest	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+believed	O
+to	O
+be	O
+secondary	O
+to	O
+aspiration	B-DISO
+.	O
+
+TITLE	O
+:	O
+Nsp3	B-PRGE
+of	O
+coronaviruses	O
+:	O
+Structures	O
+and	O
+functions	O
+of	O
+a	O
+large	O
+multi	O
+-	O
+domain	O
+protein	B-CHED
+.	O
+
+Secondary	O
+nucleotide	B-CHED
+peaks	O
+identified	O
+in	O
+the	O
+chromatogram	O
+for	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+sequence	O
+revealed	O
+that	O
+all	O
+original	O
+vaccines	O
+(	O
+H120	O
+and	O
+Ma5	O
+)	O
+were	O
+composed	O
+by	O
+different	O
+subpopulations	O
+of	O
+IBV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+outbreak	O
+of	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+(	O
+MERS	B-DISO
+)	O
+in	O
+Korea	O
+in	O
+2015	O
+,	O
+the	O
+Korea	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+(	O
+KCDC	O
+)	O
+confirmed	O
+a	O
+case	O
+of	O
+MERS	B-DISO
+in	O
+a	O
+healthcare	O
+worker	O
+in	O
+Daejeon	O
+,	O
+South	O
+Korea	O
+.	O
+
+The	O
+healthcare	O
+worker	O
+,	O
+a	O
+nurse	O
+,	O
+was	O
+infected	O
+while	O
+performing	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+(	O
+CPR	B-ENZY
+)	O
+for	O
+a	O
+MERS	O
+patient	O
+in	O
+an	O
+isolation	O
+room	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+Virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+,	O
+which	O
+is	O
+a	O
+devastating	O
+viral	B-DISO
+disease	I-DISO
+and	O
+causes	O
+severe	O
+economic	O
+loss	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+However	O
+,	O
+the	O
+absence	O
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+in	I-PRGE
+chickens	I-PRGE
+raises	O
+the	O
+question	O
+of	O
+whether	O
+this	O
+protein	B-CHED
+influences	O
+the	O
+antiviral	B-CHED
+immune	B-PROC
+response	I-PROC
+against	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+We	O
+also	O
+found	O
+that	O
+IBV	B-SPEC
+can	O
+cleave	O
+MAVS	O
+,	O
+an	O
+adaptor	O
+protein	B-CHED
+downstream	O
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+MDA5	B-PRGE
+that	O
+acts	O
+as	O
+a	O
+platform	O
+for	O
+antiviral	B-CHED
+innate	B-PROC
+immunity	B-PROC
+at	O
+an	O
+early	O
+stage	O
+of	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+the	O
+efficacy	O
+and	O
+safety	O
+of	O
+FP	O
+-	O
+1201	O
+-	O
+lyo	O
+(	O
+intravenously	O
+administered	O
+recombinant	B-PRGE
+human	I-PRGE
+interferon	I-PRGE
+beta	I-PRGE
+-	I-PRGE
+1a	I-PRGE
+)	O
+and	O
+placebo	O
+in	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+moderate	O
+or	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+study	O
+protocol	O
+for	O
+a	O
+randomized	O
+controlled	O
+trial	O
+.	O
+
+There	O
+are	O
+no	O
+effective	O
+specific	O
+treatments	O
+for	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+mortality	O
+rates	O
+remain	O
+high	O
+.	O
+
+The	O
+results	O
+from	O
+this	O
+study	O
+will	O
+provide	O
+evidence	O
+regarding	O
+the	O
+efficacy	O
+of	O
+a	O
+potential	O
+new	O
+therapeutic	O
+agent	O
+,	O
+FP	O
+-	O
+1201	O
+-	O
+lyo	O
+,	O
+in	O
+improving	O
+the	O
+clinical	O
+course	O
+and	O
+outcome	O
+for	O
+patients	O
+with	O
+moderate	O
+/	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Blood	B-ANAT
+transfusions	O
+may	O
+be	O
+required	O
+and	O
+treatment	O
+of	O
+seizures	B-DISO
+and	O
+raised	B-DISO
+intracranial	I-DISO
+pressure	I-DISO
+is	O
+important	O
+in	O
+cerebral	B-DISO
+malaria	B-PATH
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Traumatic	O
+Fractures	O
+of	O
+the	O
+Cervical	B-ANAT
+Spine	I-ANAT
+:	O
+Analysis	O
+of	O
+Changes	O
+in	O
+Incidence	O
+,	O
+Cause	O
+,	O
+Concurrent	O
+Injuries	O
+,	O
+and	O
+Complications	O
+Among	O
+488	O
+,	O
+262	O
+Patients	O
+from	O
+2005	O
+to	O
+2013	O
+.	O
+
+Common	O
+concurrent	O
+injuries	O
+included	O
+fractures	O
+to	O
+the	O
+rib	B-CHED
+/	O
+sternum	B-ANAT
+/	O
+larynx	B-DISO
+/	O
+trachea	B-DISO
+(	O
+19	O
+.	O
+6	O
+%).	O
+
+For	O
+the	O
+second	O
+phase	O
+,	O
+""""	O
+One	O
+Health	O
+""""	O
+was	O
+searched	O
+as	O
+a	O
+Medical	O
+subject	O
+heading	O
+(	O
+MeSH	O
+)	O
+term	O
+,	O
+which	O
+is	O
+the	O
+National	O
+Library	O
+of	O
+Medicine	B-CHED
+controlled	O
+vocabulary	O
+thesaurus	O
+used	O
+for	O
+indexing	O
+articles	O
+.	O
+
+Meta	B-SPEC
+-	O
+analysis	O
+of	O
+randomized	O
+controlled	O
+trials	O
+(	O
+RCTs	O
+)	O
+indicated	O
+a	O
+protective	O
+effect	O
+of	O
+masks	O
+and	O
+respirators	O
+against	O
+clinical	O
+respiratory	O
+illness	O
+(	O
+CRI	O
+)	O
+(	O
+risk	O
+ratio	O
+[	O
+RR	O
+]	O
+=	O
+0	O
+.	O
+59	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]:	O
+0	O
+.	O
+46	O
+-	O
+0	O
+.	O
+77	O
+)	O
+and	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+(	O
+RR	O
+=	O
+0	O
+.	O
+34	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+14	O
+-	O
+0	O
+.	O
+82	O
+).	O
+
+Multicentre	O
+RCTs	O
+with	O
+standardized	O
+protocols	O
+conducted	O
+outside	O
+epidemic	O
+periods	B-PROC
+would	O
+help	O
+to	O
+clarify	O
+the	O
+circumstances	O
+under	O
+which	O
+the	O
+use	O
+of	O
+masks	O
+or	O
+respirators	O
+is	O
+most	O
+warranted	O
+.	O
+
+However	O
+,	O
+at	O
+24	O
+hours	O
+,	O
+cigarette	O
+smoke	O
+exposure	O
+was	O
+associated	O
+with	O
+increased	O
+impairment	B-DISO
+in	O
+platelet	B-PROC
+aggregation	I-PROC
+,	O
+reflecting	O
+a	O
+statistically	O
+significant	O
+decline	O
+in	O
+platelet	B-PROC
+aggregation	I-PROC
+over	O
+the	O
+initial	O
+24	O
+hours	O
+after	O
+trauma	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+first	O
+steps	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+)	O
+infection	B-DISO
+were	O
+previously	O
+described	O
+.	O
+
+ABSTRACT	O
+:	O
+No	O
+specific	O
+antivirals	O
+are	O
+currently	O
+available	O
+for	O
+two	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+This	O
+review	O
+presents	O
+current	O
+knowledge	O
+on	O
+the	O
+epidemiology	O
+,	O
+pathogenesis	B-DISO
+and	O
+clinical	O
+features	O
+of	O
+the	O
+SARS	B-DISO
+and	O
+MERS	O
+coronaviruses	O
+.	O
+
+The	O
+drugs	O
+we	O
+discuss	O
+belong	O
+to	O
+a	O
+wide	O
+range	O
+of	O
+different	O
+drug	O
+classes	O
+,	O
+such	O
+as	O
+cancer	B-DISO
+therapeutics	O
+,	O
+antipsychotics	B-CHED
+,	O
+and	O
+antimalarials	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+MicroRNA	O
+(	O
+miRNA	O
+)	O
+mediates	O
+RNA	B-PROC
+interference	I-PROC
+to	O
+regulate	O
+a	O
+variety	O
+of	O
+innate	O
+immune	O
+processes	O
+,	O
+but	O
+how	O
+miRNAs	O
+coordinate	O
+the	O
+mechanisms	O
+underlying	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+)	O
+in	O
+patients	O
+with	O
+pulmonary	B-ANAT
+inflammatory	O
+injury	O
+is	O
+still	O
+unknown	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+being	O
+increasingly	O
+used	O
+for	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+refractory	O
+to	O
+otherwise	O
+conventional	O
+management	O
+.	O
+
+A	O
+29year	O
+old	O
+male	O
+arrived	O
+with	O
+Emergency	B-DISO
+Medical	O
+Services	O
+(	O
+EMS	O
+)	O
+status	O
+post	O
+presumed	O
+heroin	B-CHED
+overdose	O
+.	O
+
+The	O
+patient	O
+arrived	O
+in	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+with	O
+a	O
+pulse	B-PROC
+oximetry	O
+level	O
+of	O
+50	O
+%	O
+and	O
+was	O
+immediately	O
+intubated	O
+.	O
+
+In	O
+the	O
+Coronary	B-ANAT
+REvascularisation	O
+Demonstrating	O
+Outcome	O
+Study	O
+in	O
+Kyoto	O
+PCI	O
+/	O
+coronary	B-ANAT
+artery	I-ANAT
+bypass	O
+grafting	B-ANAT
+registry	O
+cohort	O
+-	O
+2	O
+,	O
+there	O
+were	O
+2018	O
+patients	O
+who	O
+underwent	O
+elective	O
+multivessel	O
+PCI	O
+.	O
+
+Related	O
+to	O
+their	O
+frequency	O
+of	O
+detection	O
+,	O
+RSV	B-PRGE
+A	I-PRGE
+/	I-PRGE
+B	I-PRGE
+was	O
+the	O
+most	O
+associated	O
+pathogen	O
+with	O
+patient	O
+'	O
+s	O
+demographic	O
+situation	O
+and	O
+clinical	O
+manifestations	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Adenovirus	B-DISO
+was	O
+statistically	O
+associated	O
+to	O
+the	O
+manifestation	O
+of	O
+gastroenteritis	B-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+004	O
+).	O
+
+After	O
+the	O
+intravenous	O
+administration	O
+of	O
+second	O
+steroid	B-CHED
+,	O
+immediate	O
+anaphylaxis	B-DISO
+was	O
+recorded	O
+and	O
+treatment	O
+was	O
+stopped	O
+.	O
+
+Patients	O
+who	O
+have	O
+food	B-DISO
+allergies	I-DISO
+need	O
+to	O
+pay	O
+particular	O
+attention	O
+to	O
+the	O
+prescription	O
+of	O
+drugs	O
+and	O
+their	O
+formulation	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Research	O
+progress	O
+of	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+in	O
+the	O
+treatment	O
+of	O
+ALI	O
+].	O
+
+Its	O
+severe	O
+stage	O
+is	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+characterized	O
+by	O
+rapid	O
+onset	O
+and	O
+high	O
+mortality	O
+.	O
+
+Based	O
+on	O
+many	O
+preclinical	O
+studies	O
+,	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+(	O
+MSCs	B-COMP
+)	O
+have	O
+great	O
+potential	O
+as	O
+a	O
+therapeutic	O
+strategy	O
+for	O
+ALI	O
+,	O
+clinical	O
+trials	O
+are	O
+underway	O
+,	O
+and	O
+studies	O
+on	O
+the	O
+therapeutic	O
+effects	O
+of	O
+MSCs	B-COMP
+progressively	O
+deep	O
+into	O
+the	O
+molecular	O
+mechanism	O
+and	O
+continue	O
+to	O
+make	O
+new	O
+progress	O
+.	O
+
+However	O
+,	O
+the	O
+use	O
+of	O
+MSCs	B-FUNC
+,	O
+their	O
+specific	O
+methods	O
+and	O
+risks	O
+,	O
+especially	O
+on	O
+the	O
+risk	O
+of	O
+iatrogenic	O
+tumor	B-DISO
+formation	B-PROC
+remains	O
+unresolved	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+after	O
+Laparoscopic	O
+Appendectomy	O
+in	O
+a	O
+Young	O
+Adult	O
+.	O
+
+However	O
+,	O
+the	O
+mode	O
+of	O
+virus	B-SPEC
+transmission	O
+is	O
+not	O
+well	O
+understood	O
+.	O
+
+We	O
+also	O
+identified	O
+the	O
+evidence	O
+of	O
+enteric	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+the	O
+stool	B-ANAT
+specimen	I-ANAT
+of	O
+a	O
+clinical	O
+patient	O
+.	O
+
+With	O
+the	O
+progression	O
+of	O
+the	O
+enteric	O
+infection	B-DISO
+,	O
+inflammation	B-DISO
+,	O
+virus	B-SPEC
+-	O
+positive	O
+cells	B-COMP
+,	O
+and	O
+live	O
+viruses	B-SPEC
+emerged	O
+in	O
+the	O
+lung	B-ANAT
+tissues	I-ANAT
+,	O
+indicating	O
+the	O
+development	B-PROC
+of	O
+sequential	O
+respiratory	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Nonstructural	O
+Protein	B-CHED
+16	O
+Is	O
+Necessary	O
+for	O
+Interferon	O
+Resistance	O
+and	O
+Viral	B-DISO
+Pathogenesis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Does	O
+a	O
+Mobile	O
+ECLS	O
+Program	O
+Reduce	O
+Mortality	O
+for	O
+Patients	O
+Transported	O
+for	O
+ECLS	O
+Therapy	O
+for	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+?	O
+
+A	O
+MERS	O
+screening	O
+clinic	O
+(	O
+MSC	O
+)	O
+for	O
+HCP	B-DISO
+was	O
+setup	O
+in	O
+the	O
+National	O
+Medical	O
+Center	O
+during	O
+the	O
+MERS	O
+outbreak	O
+in	O
+2015	O
+.	O
+
+In	O
+the	O
+context	O
+of	O
+permanently	O
+wheelchair	O
+bound	O
+and	O
+on	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+)	O
+patients	O
+,	O
+the	O
+clinical	O
+presentation	O
+of	O
+acute	B-DISO
+heart	I-DISO
+failure	I-DISO
+(	O
+AHF	O
+)	O
+syndrome	B-DISO
+may	O
+be	O
+atypical	O
+.	O
+
+We	O
+included	O
+genetically	O
+proven	O
+DMD	B-DISO
+and	O
+BMD	B-DISO
+patients	O
+on	O
+HMV	O
+admitted	O
+for	O
+AHF	O
+.	O
+
+At	O
+admission	O
+,	O
+dyspnoea	B-DISO
+was	O
+present	O
+in	O
+46	O
+%,	O
+lipothymia	O
+in	O
+23	O
+%,	O
+and	O
+abdominal	B-DISO
+discomfort	I-DISO
+in	O
+38	O
+.	O
+4	O
+%	O
+of	O
+patients	O
+.	O
+
+In	O
+patients	O
+with	O
+cardiogenic	B-DISO
+shock	I-DISO
+,	O
+intra	O
+-	O
+hospital	O
+mortality	O
+rate	O
+was	O
+66	O
+.	O
+6	O
+%,	O
+reaching	B-PROC
+83	O
+.	O
+3	O
+%	O
+after	O
+1	O
+year	O
+.	O
+
+RESULTS	O
+:	O
+Our	O
+results	O
+showed	O
+that	O
+Msr1	B-PRGE
+
+We	O
+conducted	O
+a	O
+prospective	O
+longitudinal	O
+study	O
+on	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+(	O
+RVIs	O
+)	O
+in	O
+allo	O
+-	O
+HSCT	O
+recipients	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+from	O
+December	O
+2013	O
+until	O
+June	O
+2016	O
+.	O
+
+Respiratory	O
+virus	B-SPEC
+in	O
+upper	O
+and	O
+/	O
+or	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+(	O
+URT	O
+and	O
+LRT	B-ANAT
+)	O
+specimens	O
+were	O
+tested	O
+using	O
+Luminex	B-PRGE
+xTAG	I-PRGE
+RVP	I-PRGE
+Fast	I-PRGE
+v1	I-PRGE
+assay	O
+.	O
+
+There	O
+were	O
+160	O
+persons	O
+placed	O
+on	O
+PHTRs	O
+:	O
+142	O
+(	O
+89	O
+%)	O
+involved	O
+exposure	O
+to	O
+Ebola	B-SPEC
+virus	I-SPEC
+,	O
+16	O
+(	O
+10	O
+%)	O
+to	O
+Lassa	B-DISO
+fever	I-DISO
+virus	B-SPEC
+,	O
+and	O
+2	O
+(	O
+1	O
+%)	O
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+most	O
+common	O
+precipitant	O
+is	O
+community	O
+-	O
+acquired	O
+bacterial	B-DISO
+pneumonia	I-DISO
+,	O
+but	O
+other	O
+putative	O
+pathogens	O
+include	O
+viruses	B-SPEC
+and	O
+fungi	B-SPEC
+.	O
+
+Consequently	O
+,	O
+an	O
+increasing	O
+number	O
+of	O
+mAbs	O
+,	O
+which	O
+exhibit	O
+high	O
+potency	O
+against	O
+emerging	O
+viruses	B-SPEC
+in	O
+vitro	O
+and	O
+in	O
+animal	B-SPEC
+models	O
+of	O
+infection	B-DISO
+,	O
+have	O
+been	O
+developed	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+paper	O
+,	O
+an	O
+SIR	O
+patch	O
+model	O
+with	O
+vaccination	O
+is	O
+formulated	O
+to	O
+investigate	O
+the	O
+effect	O
+of	O
+vaccination	O
+coverage	O
+and	O
+the	O
+impact	O
+of	O
+human	B-SPEC
+mobility	O
+on	O
+the	O
+spread	O
+of	O
+diseases	O
+among	O
+patches	O
+.	O
+
+These	O
+are	O
+transformed	O
+into	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+(	O
+DMVs	O
+)	O
+containing	O
+viral	O
+double	O
+-	O
+stranded	O
+RNA	O
+and	O
+into	O
+other	O
+membranous	B-ANAT
+elements	O
+such	O
+as	O
+convoluted	O
+membranes	B-ANAT
+,	O
+together	O
+forming	O
+a	O
+reticulovesicular	O
+network	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+develop	O
+rapid	O
+molecular	O
+assays	O
+for	O
+differentiating	O
+vaccine	O
+strains	O
+Ma5	O
+and	O
+4	O
+/	O
+91	O
+of	O
+the	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+We	O
+therefore	O
+evaluated	O
+clinical	O
+and	O
+microbiological	O
+factors	O
+associated	O
+with	O
+the	O
+presence	O
+of	O
+GI	O
+symptoms	O
+in	O
+patients	O
+consulting	O
+a	O
+general	O
+practitioner	O
+(	O
+GP	O
+)	O
+for	O
+ARI	B-PRGE
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+,	O
+stool	B-ANAT
+specimens	O
+and	O
+clinical	O
+data	O
+from	O
+patients	O
+presenting	O
+to	O
+GPs	B-DISO
+with	O
+an	O
+ARI	B-CHED
+were	O
+prospectively	O
+collected	O
+during	O
+two	O
+winter	O
+seasons	O
+(	O
+2014	O
+-	O
+2016	O
+).	O
+
+Consumption	O
+of	O
+antipyretic	B-CHED
+medication	O
+before	O
+the	O
+consultation	O
+seemed	O
+to	O
+reduce	O
+the	O
+risk	O
+of	O
+developing	O
+GI	O
+symptoms	O
+for	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+influenza	B-DISO
+(	O
+aOR	B-FUNC
+=	O
+0	O
+.	O
+3	O
+;	O
+[	O
+0	O
+.	O
+1	O
+-	O
+0	O
+.	O
+6	O
+];	O
+p	O
+=	O
+0	O
+.	O
+002	O
+).	O
+
+Moreover	O
+,	O
+several	O
+novel	O
+mutations	O
+including	O
+nucleotides	B-CHED
+substitution	O
+and	O
+the	O
+insertion	O
+of	O
+spike	O
+of	O
+the	O
+glycoprotein	B-CHED
+on	O
+the	O
+viral	O
+surface	O
+were	O
+discovered	O
+.	O
+
+Moreover	O
+,	O
+several	O
+novel	O
+mutations	O
+including	O
+nucleotides	B-CHED
+substitution	O
+and	O
+the	O
+insertion	O
+of	O
+spike	O
+of	O
+the	O
+glycoprotein	B-CHED
+on	O
+the	O
+viral	O
+surface	O
+were	O
+discovered	O
+.	O
+
+A	O
+multidisciplinary	O
+group	O
+of	O
+heads	B-ANAT
+of	O
+infectious	B-DISO
+disease	I-DISO
+departments	O
+from	O
+reference	O
+hospitals	O
+was	O
+created	O
+to	O
+build	O
+a	O
+network	O
+of	O
+clinical	O
+expertise	O
+for	O
+care	O
+,	O
+training	O
+,	O
+and	O
+research	O
+in	O
+the	O
+field	O
+of	O
+epidemic	O
+and	O
+biological	O
+risk	O
+(	O
+EBR	O
+).	O
+
+TITLE	O
+:	O
+Astragalus	B-ANAT
+polysaccharides	B-CHED
+inhibit	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-DISO
+infection	I-DISO
+by	O
+regulating	O
+viral	O
+replication	O
+.	O
+
+Therefore	O
+,	O
+development	B-PROC
+of	O
+novel	O
+antiviral	B-CHED
+treatment	O
+strategies	O
+is	O
+urgently	O
+required	O
+.	O
+
+We	O
+also	O
+discuss	O
+some	O
+general	O
+strategies	O
+for	O
+developing	O
+small	B-PRGE
+-	I-PRGE
+molecule	I-PRGE
+viral	O
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Life	O
+-	O
+threatening	O
+idiopathic	O
+reaction	O
+to	O
+hydrochlorothiazide	O
+treated	O
+with	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+.	O
+
+The	O
+clustering	O
+of	O
+gene	B-PROC
+expression	I-PROC
+profile	O
+among	O
+the	O
+three	O
+virus	B-SPEC
+inoculated	O
+groups	O
+indicated	O
+that	O
+the	O
+majority	O
+of	O
+up	O
+-	O
+regulated	O
+DE	O
+genes	O
+on	O
+apoptosis	B-PATH
+in	O
+very	O
+virulent	O
+SCDY2	O
+group	O
+were	O
+up	O
+-	O
+regulated	O
+more	O
+or	O
+less	O
+in	O
+virulent	O
+SCK2	B-PRGE
+group	O
+and	O
+those	O
+down	O
+-	O
+regulated	O
+on	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+in	O
+SCDY2	O
+group	O
+were	O
+also	O
+down	O
+-	O
+regulated	O
+differently	O
+in	O
+SCK2	B-PRGE
+group	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+number	O
+of	O
+apoptotic	O
+cells	B-COMP
+detected	O
+experimentally	O
+in	O
+kidney	B-ANAT
+tissue	B-ANAT
+were	O
+very	O
+different	O
+among	O
+the	O
+three	O
+virus	B-SPEC
+inoculated	O
+groups	O
+and	O
+were	O
+positively	O
+accordant	O
+with	O
+the	O
+viral	O
+titer	O
+,	O
+kidney	B-ANAT
+lesions	O
+and	O
+viral	O
+virulence	B-PROC
+of	O
+each	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+Lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+(	O
+LPV	O
+)	O
+has	O
+become	O
+the	O
+cornerstone	O
+of	O
+management	O
+in	O
+patients	O
+with	O
+ARDS	O
+.	O
+
+However	O
+,	O
+inflammation	B-DISO
+-	O
+directed	O
+therapies	O
+have	O
+yet	O
+failed	O
+to	O
+improve	O
+the	O
+outcome	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+One	O
+of	O
+the	O
+reasons	O
+may	O
+be	O
+the	O
+underestimated	O
+complexity	O
+of	O
+inflammation	B-DISO
+.	O
+
+We	O
+suggest	O
+to	O
+consider	O
+inflammation	B-DISO
+in	O
+ARDS	B-DISO
+as	O
+a	O
+system	O
+controlled	O
+by	O
+scale	O
+-	O
+free	O
+networks	O
+of	O
+genome	O
+-	O
+wide	O
+molecular	B-FUNC
+interaction	I-FUNC
+with	O
+hubs	O
+(	O
+e	O
+.	O
+g	O
+.	O
+NFκB	O
+,	O
+C	O
+/	O
+EBPβ	O
+,	O
+ATF3	B-PRGE
+),	O
+exhibiting	O
+nonlinear	O
+emergence	O
+and	O
+the	O
+ability	O
+to	O
+adapt	O
+,	O
+meaning	O
+for	O
+instance	O
+that	O
+mild	O
+and	O
+life	O
+-	O
+threatening	O
+inflammation	O
+in	O
+ARDS	B-DISO
+are	O
+distinct	O
+processes	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+aerosol	O
+infection	O
+through	O
+cough	B-DISO
+generates	O
+large	O
+amounts	O
+of	O
+viral	O
+aerosol	O
+and	O
+can	O
+result	O
+in	O
+many	O
+adverse	O
+health	O
+effects	O
+such	O
+as	O
+influenza	B-DISO
+flu	B-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Current	O
+condensation	B-DISO
+growth	B-PROC
+methods	O
+only	O
+have	O
+good	O
+physical	O
+collection	O
+efficiency	O
+and	O
+viral	O
+preservation	O
+at	O
+low	O
+flow	O
+rate	O
+(<	O
+10	O
+LPM	O
+).	O
+
+The	O
+aims	O
+of	O
+this	O
+study	O
+were	O
+to	O
+develop	O
+an	O
+effective	O
+M	B-ANAT
+cell	I-ANAT
+-	O
+targeting	B-PROC
+oral	B-ANAT
+vaccine	O
+,	O
+involving	O
+Lactobacillus	B-SPEC
+casei	I-SPEC
+to	O
+deliver	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+core	O
+neutralizing	O
+epitope	B-CHED
+(	O
+COE	O
+)	O
+antigen	B-CHED
+conjugated	O
+with	O
+M	B-ANAT
+cell	I-ANAT
+-	O
+targeting	B-PROC
+peptide	B-CHED
+Co1	O
+as	O
+an	O
+adjuvant	B-CHED
+,	O
+against	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Currently	O
+two	O
+conditionally	O
+approved	O
+vaccines	O
+exist	O
+in	O
+the	O
+US	O
+,	O
+but	O
+there	O
+is	O
+no	O
+live	O
+attenuated	O
+vaccine	O
+,	O
+which	O
+is	O
+considered	O
+the	O
+best	O
+option	O
+in	O
+controlling	O
+PEDV	B-SPEC
+by	O
+inducing	O
+transferrable	O
+mucosal	B-PROC
+immunity	I-PROC
+to	O
+susceptible	O
+neonatal	O
+piglets	O
+.	O
+
+There	O
+was	O
+no	O
+difference	O
+in	O
+the	O
+BAL	B-PRGE
+E	I-PRGE
+coli	I-PRGE
+colony	I-PRGE
+-	I-PRGE
+forming	I-PRGE
+units	I-PRGE
+,	O
+macrophage	B-ANAT
+,	O
+or	O
+neutrophil	B-ANAT
+numbers	O
+at	O
+any	O
+time	O
+point	O
+.	O
+
+TITLE	O
+:	O
+Methods	O
+Using	O
+Social	O
+Media	B-ANAT
+and	O
+Search	O
+Queries	O
+to	O
+Predict	O
+Infectious	B-DISO
+Disease	I-DISO
+Outbreaks	O
+.	O
+
+Here	O
+,	O
+we	O
+introduce	O
+an	O
+approach	O
+to	O
+develop	O
+such	O
+a	O
+digital	B-ANAT
+surveillance	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Livestock	B-PRGE
+Emergency	I-PRGE
+Response	I-PRGE
+Plan	B-DISO
+(	O
+LERP	O
+)	O
+was	O
+published	O
+in	O
+2014	O
+as	O
+a	O
+toolkit	O
+to	O
+assist	O
+state	O
+agricultural	O
+emergency	B-DISO
+planners	O
+in	O
+writing	O
+or	O
+modifying	O
+state	O
+foreign	O
+animal	B-DISO
+disease	I-DISO
+/	O
+high	O
+-	O
+consequence	O
+disease	O
+(	O
+FAD	B-CHED
+/	O
+HCD	B-DISO
+)	O
+plans	O
+.	O
+
+In	O
+1998	O
+the	O
+European	O
+Network	O
+for	O
+Diagnostics	O
+of	O
+""""	O
+Imported	O
+""""	O
+Viral	B-DISO
+Diseases	I-DISO
+(	O
+ENIVD	O
+)	O
+was	O
+established	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+Alpha	O
+and	O
+Beta	O
+Coronavirus	B-SPEC
+in	O
+Wildlife	O
+Species	B-SPEC
+in	O
+France	O
+:	O
+Bats	B-SPEC
+,	O
+Rodents	B-SPEC
+,	O
+Rabbits	B-SPEC
+,	O
+and	O
+Hedgehogs	B-SPEC
+.	O
+
+This	O
+study	O
+explored	O
+the	O
+presence	O
+of	O
+coronaviruses	O
+in	O
+four	O
+wild	O
+mammal	B-SPEC
+orders	O
+in	O
+France	O
+:	O
+Bats	B-SPEC
+,	O
+rodents	B-SPEC
+,	O
+lagomorphs	B-SPEC
+,	O
+and	O
+hedgehogs	B-SPEC
+.	O
+
+Results	O
+showed	O
+that	O
+transaminase	O
+levels	O
+markedly	O
+decreased	O
+in	O
+MHV	B-SPEC
+-	O
+A59	O
+-	O
+infected	O
+mice	B-SPEC
+treated	O
+with	O
+MAb	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+17A	I-PRGE
+whereas	O
+plasmatic	O
+Ig	O
+concentration	O
+sharply	O
+increased	O
+.	O
+
+ABSTRACT	O
+:	O
+Type	O
+III	O
+interferons	O
+(	O
+IFNs	O
+)	O
+play	O
+a	O
+vital	O
+role	O
+in	O
+maintaining	O
+the	O
+antiviral	B-CHED
+state	O
+of	O
+the	O
+mucosal	B-ANAT
+epithelial	O
+surface	O
+in	O
+the	O
+gut	B-ANAT
+,	O
+and	O
+in	O
+turn	O
+,	O
+enteric	O
+viruses	B-SPEC
+may	O
+have	O
+evolved	O
+to	O
+evade	O
+the	O
+type	B-PRGE
+III	I-PRGE
+IFN	I-PRGE
+responses	O
+during	O
+infection	B-DISO
+.	O
+
+Fourteen	O
+patients	O
+were	O
+listed	O
+for	O
+LTPL	O
+due	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Cell	B-COMP
+entry	O
+studies	O
+demonstrated	O
+that	O
+three	O
+newly	O
+identified	O
+SARSr	O
+-	O
+CoVs	O
+with	O
+different	O
+S	O
+protein	B-CHED
+sequences	O
+are	O
+all	O
+able	O
+to	O
+use	O
+human	B-PRGE
+ACE2	I-PRGE
+as	O
+the	O
+receptor	O
+,	O
+further	O
+exhibiting	O
+the	O
+close	O
+relationship	O
+between	O
+strains	O
+in	O
+this	O
+cave	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+This	O
+work	O
+provides	O
+new	O
+insights	O
+into	O
+the	O
+origin	O
+and	O
+evolution	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+highlights	O
+the	O
+necessity	O
+of	O
+preparedness	O
+for	O
+future	O
+emergence	O
+of	O
+SARS	B-DISO
+-	O
+like	O
+diseases	O
+.	O
+
+One	O
+15	O
+.	O
+24	O
+X	O
+15	O
+.	O
+24	O
+X	O
+2	O
+.	O
+54	O
+cm	O
+aluminum	B-CHED
+coupon	O
+,	O
+contaminated	O
+with	O
+swine	B-SPEC
+feces	B-ANAT
+,	O
+and	O
+randomly	O
+matched	O
+to	O
+one	O
+pig	B-SPEC
+was	O
+the	O
+experimental	O
+unit	O
+.	O
+
+This	O
+study	O
+also	O
+suggests	O
+that	O
+a	O
+positive	O
+RT	O
+-	O
+qPCR	O
+result	O
+for	O
+PEDV	B-SPEC
+on	O
+an	O
+environmental	O
+sample	O
+should	O
+be	O
+expected	O
+when	O
+the	O
+AHP	B-DISO
+disinfectant	B-CHED
+is	O
+applied	O
+under	O
+freezing	O
+conditions	O
+,	O
+but	O
+does	O
+not	O
+necessarily	O
+indicate	O
+that	O
+an	O
+infectious	B-DISO
+dose	O
+of	O
+PEDV	B-SPEC
+remains	O
+after	O
+disinfection	O
+.	O
+
+A	O
+retrospective	O
+observational	O
+study	O
+with	O
+prospective	O
+QoL	O
+assessment	O
+through	O
+administration	O
+of	O
+the	O
+questionnaire	O
+EuroQol	O
+-	O
+5	O
+Dimension	O
+was	O
+conducted	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+who	O
+h	O
+ad	O
+ECMO	O
+as	O
+a	O
+rescue	O
+therapy	O
+for	O
+reversible	O
+refractory	O
+hypoxemia	O
+from	O
+January	O
+2013	O
+until	O
+December	O
+2015	O
+in	O
+an	O
+Italian	O
+referral	O
+ECMO	O
+center	O
+.	O
+
+Our	O
+aim	O
+was	O
+to	O
+combine	O
+epidemiological	O
+data	O
+from	O
+literature	O
+with	O
+genetic	O
+information	O
+from	O
+viruses	B-SPEC
+sequenced	O
+around	O
+the	O
+world	O
+to	O
+present	O
+a	O
+phylodynamic	O
+picture	O
+of	O
+MERS	O
+spread	O
+molecular	O
+level	O
+to	O
+global	O
+scale	O
+.	O
+
+Among	O
+influenza	B-DISO
+-	O
+positive	O
+ILI	O
+patients	O
+,	O
+1431	O
+(	O
+63	O
+%)	O
+were	O
+influenza	B-PATH
+A	I-PATH
+[	O
+820	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+,	O
+611	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H3N2	B-CHED
+)]	O
+and	O
+847	O
+(	O
+37	O
+%)	O
+were	O
+influenza	B-DISO
+B	O
+.	O
+A	O
+majority	O
+of	O
+SARI	O
+and	O
+ILI	O
+case	O
+-	O
+patients	O
+who	O
+tested	O
+positive	O
+for	O
+influenza	B-DISO
+(	O
+72	O
+%	O
+SARI	O
+and	O
+59	O
+%	O
+ILI	O
+)	O
+were	O
+children	O
+aged	O
+0	O
+-	O
+4	O
+years	O
+,	O
+as	O
+were	O
+a	O
+majority	O
+of	O
+those	O
+enrolled	O
+in	O
+surveillance	O
+.	O
+
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+was	O
+predicted	O
+to	O
+have	O
+HR	O
+regions	O
+(	O
+HR1	O
+and	O
+HR2	O
+)	O
+in	O
+the	O
+spike	O
+glycoprotein	B-CHED
+S2	O
+subunit	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+human	B-SPEC
+coronaviruses	O
+(	O
+CoV	O
+)	O
+include	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+and	O
+HCoV	O
+-	O
+HKU1	O
+,	O
+some	O
+of	O
+which	O
+have	O
+been	O
+known	O
+for	O
+decades	O
+.	O
+
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+CoV	O
+briefly	O
+emerged	O
+into	O
+the	O
+human	B-SPEC
+population	O
+but	O
+was	O
+controlled	O
+.	O
+
+Targeted	B-PROC
+research	O
+remains	O
+key	O
+to	O
+developing	O
+control	O
+strategies	O
+for	O
+MERS	O
+-	O
+CoV	O
+,	O
+a	O
+cause	O
+of	O
+mild	O
+illness	O
+in	O
+its	O
+camel	B-SPEC
+reservoir	O
+.	O
+
+An	O
+AHT	O
+animal	B-SPEC
+model	O
+was	O
+developed	O
+on	O
+12	O
+-	O
+day	O
+-	O
+old	O
+mice	B-SPEC
+subjected	O
+to	O
+90	O
+°	O
+head	B-ANAT
+extension	O
+-	O
+flexion	B-PROC
+sagittal	B-ANAT
+shaking	B-DISO
+repeated	O
+30	O
+,	O
+60	O
+,	O
+80	O
+and	O
+100	O
+times	O
+.	O
+
+Acute	O
+oxygen	B-CHED
+desaturation	O
+was	O
+observed	O
+by	O
+pulse	B-PROC
+oximetry	O
+during	O
+respiratory	O
+and	O
+cardiac	B-ANAT
+suppression	B-DISO
+.	O
+
+The	O
+resultant	O
+hypoxia	B-DISO
+/	O
+ischemia	B-DISO
+suggests	O
+a	O
+potential	O
+mechanism	O
+underlying	O
+the	O
+secondary	O
+rotational	O
+acceleration	O
+-	O
+deceleration	O
+-	O
+induced	O
+brain	B-ANAT
+injury	O
+in	O
+developing	O
+mice	B-SPEC
+.	O
+
+Parainfluenza	B-DISO
+virus	B-SPEC
+4	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+B	O
+and	O
+enterovirus	B-SPEC
+were	O
+the	O
+most	O
+common	O
+viruses	B-SPEC
+in	O
+the	O
+clinical	O
+sample	O
+;	O
+present	O
+in	O
+93	O
+.	O
+8	O
+%	O
+(	O
+15	O
+/	O
+16	O
+)	O
+of	O
+clinical	O
+subjects	O
+,	O
+and	O
+6	O
+.	O
+7	O
+%	O
+(	O
+5	O
+/	O
+75	O
+)	O
+of	O
+community	O
+subjects	O
+(	O
+significant	O
+difference	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Coronavirus	B-SPEC
+OC43	O
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+detected	O
+in	O
+community	O
+members	O
+(	O
+13	O
+.	O
+3	O
+%,	O
+10	O
+/	O
+75	O
+).	O
+
+However	O
+,	O
+it	O
+remains	O
+unclear	O
+how	O
+SIVcpz	O
+has	O
+evolved	O
+into	O
+pandemic	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+in	O
+humans	B-SPEC
+.	O
+
+Humanized	O
+mice	B-SPEC
+infected	O
+with	O
+SIVcpz	O
+strain	O
+MB897	O
+,	O
+a	O
+virus	B-SPEC
+phylogenetically	O
+similar	O
+to	O
+pandemic	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+exhibited	O
+a	O
+peak	O
+viral	O
+load	O
+comparable	O
+to	O
+that	O
+of	O
+mice	B-SPEC
+infected	O
+with	O
+pandemic	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+while	O
+peak	O
+viral	O
+loads	O
+of	O
+mice	B-SPEC
+infected	O
+with	O
+SIVcpz	O
+strain	O
+EK505	O
+or	O
+MT145	O
+as	O
+well	O
+as	O
+nonpandemic	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+strains	O
+were	O
+significantly	O
+lower	O
+.	O
+
+TITLE	O
+:	O
+Wild	O
+-	O
+type	O
+human	B-SPEC
+coronaviruses	O
+prefer	O
+cell	B-COMP
+-	O
+surface	O
+TMPRSS2	B-PRGE
+to	O
+endosomal	O
+cathepsins	O
+for	O
+cell	B-COMP
+entry	O
+.	O
+
+To	O
+explore	O
+the	O
+potential	O
+role	O
+of	O
+miR	O
+-	O
+4331	O
+in	O
+mitochondrial	B-DISO
+damage	I-DISO
+,	O
+we	O
+adopted	O
+a	O
+strategy	O
+consisting	O
+of	O
+quantitative	O
+proteomic	O
+analysis	O
+of	O
+porcine	B-SPEC
+kidney	B-ANAT
+(	O
+PK	O
+-	O
+15	O
+)	O
+cells	B-COMP
+in	O
+response	O
+to	O
+miR	O
+-	O
+4331	O
+and	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+Eventually	O
+,	O
+69	O
+differentially	O
+expressed	B-PROC
+proteins	B-CHED
+were	O
+gained	O
+.	O
+
+ABSTRACT	O
+:	O
+While	O
+prone	O
+positioning	O
+(	O
+PP	O
+)	O
+has	O
+been	O
+shown	O
+to	O
+improve	O
+patient	O
+survival	O
+in	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+,	O
+the	O
+rate	O
+of	O
+application	O
+of	O
+PP	O
+in	O
+clinical	O
+practice	O
+still	O
+appears	O
+low	O
+.	O
+
+ABSTRACT	O
+:	O
+Venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+is	O
+a	O
+valuable	O
+life	O
+support	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+adult	O
+patients	O
+.	O
+
+We	O
+recruited	O
+246	O
+consecutive	O
+adult	O
+ischemic	B-DISO
+stroke	I-DISO
+patients	O
+.	O
+
+Sleep	B-DISO
+apnea	I-DISO
+was	O
+present	O
+in	O
+the	O
+vast	O
+majority	O
+of	O
+ischemic	B-DISO
+stroke	I-DISO
+patients	O
+.	O
+
+Sleep	B-DISO
+apnea	I-DISO
+was	O
+more	O
+severe	O
+among	O
+those	O
+receiving	O
+thrombolysis	O
+as	O
+compared	O
+to	O
+those	O
+who	O
+were	O
+not	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+younger	O
+sibling	O
+presented	O
+with	O
+an	O
+acute	O
+episode	O
+of	O
+neurological	O
+impairment	B-DISO
+in	O
+his	O
+third	O
+year	O
+of	O
+life	O
+,	O
+from	O
+which	O
+he	O
+recovered	O
+without	O
+sequelae	O
+within	O
+a	O
+few	O
+weeks	O
+.	O
+
+TITLE	O
+:	O
+The	O
+significance	O
+of	O
+changes	O
+in	O
+platelet	B-ANAT
+concentration	O
+during	O
+the	O
+early	O
+phase	O
+after	O
+severe	O
+burn	O
+injury	O
+in	O
+a	O
+Chinese	O
+mass	O
+casualty	O
+.	O
+
+We	O
+analyzed	O
+the	O
+platelet	O
+concentration	O
+of	O
+the	O
+two	O
+groups	O
+using	O
+The	O
+group	O
+with	O
+successful	O
+resuscitation	O
+had	O
+higher	O
+platelet	B-ANAT
+concentration	O
+than	O
+the	O
+failure	O
+group	O
+on	O
+day	O
+3	O
+and	O
+day	O
+5	O
+.	O
+
+The	O
+patients	O
+who	O
+suffered	B-DISO
+from	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+and	O
+septic	B-DISO
+shock	I-DISO
+had	O
+a	O
+lower	O
+platelet	B-ANAT
+concentration	O
+than	O
+non	O
+-	O
+sufferers	O
+on	O
+day	O
+3	O
+and	O
+day	O
+5	O
+.	O
+
+The	O
+platelet	B-ANAT
+concentration	O
+of	O
+burn	O
+patients	O
+can	O
+dynamically	O
+reflect	O
+the	O
+pathophysiological	O
+changes	O
+of	O
+the	O
+body	B-ANAT
+.	O
+
+Detection	O
+data	O
+from	O
+clinical	O
+specimens	O
+showed	O
+that	O
+the	O
+rMLA	O
+had	O
+diagnostic	O
+sensitivities	O
+of	O
+97	O
+.	O
+10	O
+%	O
+for	O
+FluA	O
+,	O
+94	O
+.	O
+59	O
+%	O
+for	O
+FluB	O
+,	O
+98	O
+.	O
+68	O
+%	O
+for	O
+PIV	O
+-	O
+3	O
+,	O
+94	O
+.	O
+87	O
+%	O
+for	O
+RSV	B-SPEC
+and	O
+95	O
+.	O
+92	O
+%	O
+for	O
+MPV	B-SPEC
+(	O
+No	O
+Data	O
+for	O
+MERS	O
+-	O
+CoV	O
+due	O
+to	O
+the	O
+lack	O
+of	O
+positive	O
+specimens	O
+).	O
+
+The	O
+results	O
+indicated	O
+that	O
+the	O
+rMLA	B-PRGE
+is	O
+a	O
+sensitive	O
+,	O
+specific	O
+detection	O
+tool	O
+and	O
+comparable	O
+to	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+,	O
+especially	O
+suitable	O
+for	O
+high	O
+-	O
+throughput	O
+detection	O
+of	O
+respiratory	O
+specimens	O
+.	O
+
+TITLE	O
+:	O
+Estradiol	B-CHED
+mediates	O
+the	O
+long	O
+-	O
+lasting	O
+lung	B-DISO
+inflammation	I-DISO
+induced	O
+by	O
+intestinal	B-DISO
+ischemia	I-DISO
+and	O
+reperfusion	O
+.	O
+
+ABSTRACT	O
+:	O
+Lung	O
+inflammation	O
+is	O
+one	O
+of	O
+the	O
+main	O
+consequences	O
+of	O
+intestinal	B-DISO
+ischemia	I-DISO
+reperfusion	O
+(	O
+intestinal	B-ANAT
+IR	O
+)	O
+and	O
+,	O
+in	O
+severe	O
+cases	O
+,	O
+can	O
+lead	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+death	B-PROC
+.	O
+
+Furthermore	O
+,	O
+our	O
+data	O
+confirm	O
+that	O
+the	O
+inflammatory	B-DISO
+responses	I-DISO
+caused	O
+by	O
+intestinal	B-ANAT
+IR	O
+are	O
+estradiol	B-CHED
+mediated	O
+.	O
+
+ATII	O
+cells	B-COMP
+regulate	O
+the	O
+immune	B-PROC
+response	I-PROC
+by	O
+synthesizing	O
+surfactant	B-CHED
+and	O
+other	O
+anti	O
+-	O
+inflammatory	O
+proteins	B-CHED
+and	O
+lipids	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+evaluated	O
+the	O
+microbiological	O
+diagnosis	O
+in	O
+14	O
+patients	O
+with	O
+epidemiological	O
+and	O
+clinical	O
+suspicion	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+attended	O
+in	O
+a	O
+non	O
+-	O
+endemic	O
+area	O
+between	O
+June	O
+2015	O
+and	O
+January	O
+2017	O
+.	O
+
+While	O
+no	O
+MERS	O
+-	O
+CoV	O
+was	O
+detected	O
+,	O
+other	O
+respiratory	O
+viruses	B-SPEC
+were	O
+identified	O
+in	O
+12	O
+cases	O
+and	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+in	O
+1	O
+case	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+devastating	O
+cause	O
+of	O
+diarrhea	B-DISO
+in	O
+pigs	B-SPEC
+worldwide	O
+.	O
+
+Here	O
+,	O
+using	O
+the	O
+Illumina	O
+MiSeq	O
+platform	O
+,	O
+we	O
+examined	O
+and	O
+compared	O
+the	O
+impact	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+on	O
+the	O
+GM	O
+of	O
+sows	O
+and	O
+their	O
+piglets	O
+less	O
+than	O
+10	O
+days	O
+old	O
+.	O
+
+TITLE	O
+:	O
+Activation	O
+of	O
+the	O
+c	B-PRGE
+-	I-PRGE
+Jun	I-PRGE
+NH	O
+ABSTRACT	O
+:	O
+Mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinases	I-PRGE
+(	O
+MAPKs	O
+)	O
+are	O
+conserved	O
+protein	O
+kinases	O
+that	O
+regulate	O
+a	O
+variety	O
+of	O
+important	O
+cellular	B-COMP
+signaling	B-PROC
+pathways	B-PROC
+.	O
+
+Previously	O
+,	O
+activation	O
+of	O
+the	O
+JNK	B-PROC
+pathway	I-PROC
+has	O
+been	O
+detected	O
+in	O
+cells	B-COMP
+infected	O
+with	O
+several	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+emergence	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+2012	O
+,	O
+there	O
+have	O
+been	O
+a	O
+number	O
+of	O
+clusters	B-CHED
+of	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+sequenced	O
+whole	O
+MERS	O
+-	O
+CoV	O
+genomes	O
+directly	O
+from	O
+respiratory	B-ANAT
+samples	I-ANAT
+collected	O
+from	O
+23	O
+confirmed	O
+MERS	O
+cases	O
+in	O
+the	O
+United	O
+Arab	O
+Emirates	O
+(	O
+UAE	O
+).	O
+
+Using	O
+a	O
+nationally	O
+representative	O
+database	O
+,	O
+patients	O
+who	O
+were	O
+admitted	O
+to	O
+the	O
+ICU	O
+with	O
+a	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+or	O
+an	O
+ARDS	B-DISO
+risk	O
+factor	O
+,	O
+received	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+were	O
+treated	O
+with	O
+a	O
+continuous	O
+infusion	O
+of	O
+neuromuscular	O
+blocking	B-DISO
+agent	O
+for	O
+at	O
+least	O
+2	O
+days	O
+within	O
+2	O
+days	O
+of	O
+hospital	O
+admission	O
+were	O
+included	O
+.	O
+
+To	O
+identify	O
+the	O
+molecular	O
+characteristics	O
+of	O
+the	O
+PEDV	B-PRGE
+Spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+gene	I-PRGE
+in	O
+Mexico	O
+,	O
+116	O
+samples	O
+of	O
+the	O
+intestine	B-ANAT
+and	O
+diarrhea	B-DISO
+of	O
+piglets	O
+with	O
+clinical	O
+signs	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+were	O
+obtained	O
+.	O
+
+After	O
+amplification	B-DISO
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+,	O
+the	O
+obtained	O
+products	O
+were	O
+sequenced	O
+and	O
+assembled	O
+.	O
+
+A	O
+phylogenetic	O
+analysis	O
+determined	O
+the	O
+circulation	O
+of	O
+G2b	O
+and	O
+INDEL	B-PROC
+strains	O
+in	O
+Mexico	O
+.	O
+
+For	O
+norovirus	O
+,	O
+the	O
+simulation	O
+results	O
+suggested	O
+that	O
+the	O
+fomite	O
+route	O
+played	O
+the	O
+dominant	O
+role	O
+(	O
+contributes	O
+85	O
+%,	O
+95	O
+%	O
+CI	O
+:	O
+83	O
+%-	O
+87	O
+%)	O
+in	O
+most	O
+cases	O
+;	O
+as	O
+a	O
+result	O
+,	O
+passengers	O
+in	O
+aisle	O
+seats	O
+had	O
+a	O
+significantly	O
+higher	O
+infection	B-DISO
+risk	O
+than	O
+others	O
+(	O
+RR	O
+:	O
+9	O
+.	O
+5	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+2	O
+-	O
+77	O
+.	O
+4	O
+,	O
+P	O
+=	O
+.	O
+022	O
+).	O
+
+ABSTRACT	O
+:	O
+Mobile	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	B-PROC
+)	O
+retrieval	O
+teams	O
+(	O
+MERTs	O
+)	O
+assure	O
+ECMO	B-PROC
+implantation	B-PROC
+and	O
+under	O
+-	O
+ECMO	B-PROC
+retrieval	O
+of	O
+patients	O
+with	O
+most	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+to	O
+experienced	O
+ECMO	B-PROC
+centers	O
+.	O
+
+RNA	O
+viruses	B-SPEC
+,	O
+including	O
+PEDV	B-SPEC
+,	O
+can	O
+interact	O
+with	O
+a	O
+large	O
+number	O
+of	O
+pattern	O
+recognition	O
+receptors	O
+(	O
+PRRs	B-DISO
+)	O
+in	O
+the	O
+intestinal	B-ANAT
+mucosa	I-ANAT
+,	O
+including	O
+toll	O
+-	O
+like	O
+receptors	O
+(	O
+TLRs	O
+)	O
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+(	O
+RLRs	O
+).	O
+
+We	O
+investigated	O
+the	O
+differential	O
+gene	O
+modulation	O
+of	O
+TLRs	O
+,	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+,	O
+and	O
+downstream	O
+mediators	O
+on	O
+the	O
+intestinal	B-ANAT
+mucosa	I-ANAT
+of	O
+neonatal	O
+pigs	B-SPEC
+infected	O
+with	O
+PEDV	B-SPEC
+S	O
+-	O
+INDEL	B-PROC
+and	O
+non	O
+-	O
+S	O
+-	O
+INDEL	B-PROC
+strains	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Systematic	O
+,	O
+Thematic	O
+Review	O
+of	O
+Social	O
+and	O
+Occupational	O
+Factors	O
+Associated	O
+With	O
+Psychological	B-DISO
+Outcomes	O
+in	O
+Healthcare	O
+Employees	O
+During	O
+an	O
+Infectious	B-DISO
+Disease	I-DISO
+Outbreak	O
+.	O
+
+It	O
+provides	O
+a	O
+description	O
+of	O
+key	O
+epidemiologic	O
+events	O
+and	O
+news	O
+released	O
+from	O
+a	O
+prime	O
+daily	O
+newspaper	O
+and	O
+main	O
+Emergency	O
+Risk	O
+Communication	O
+(	O
+ERC	B-COMP
+)	O
+actions	O
+that	O
+were	O
+undertaken	O
+by	O
+public	O
+health	O
+authorities	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+usually	O
+causes	O
+self	O
+-	O
+limiting	O
+upper	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+and	O
+occasionally	O
+causes	O
+pneumonia	B-DISO
+in	O
+immunocompromised	O
+hosts	B-COMP
+.	O
+
+Here	O
+,	O
+we	O
+analyzed	O
+the	O
+effects	O
+of	O
+the	O
+plant	B-SPEC
+compound	O
+silvestrol	B-CHED
+,	O
+a	O
+specific	O
+inhibitor	B-CHED
+of	O
+the	O
+DEAD	B-PRGE
+-	I-PRGE
+box	I-PRGE
+RNA	I-PRGE
+helicase	I-PRGE
+eIF4A	I-PRGE
+,	O
+on	O
+viral	O
+translation	B-PROC
+using	O
+a	O
+dual	O
+luciferase	B-ENZY
+assay	O
+and	O
+virus	B-SPEC
+-	O
+infected	O
+primary	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+a	O
+case	O
+of	O
+bilateral	O
+central	B-DISO
+retinal	I-DISO
+artery	I-DISO
+occlusion	B-PROC
+with	O
+both	O
+anterior	O
+and	O
+posterior	B-DISO
+ischemic	I-DISO
+optic	I-DISO
+neuropathy	I-DISO
+.	O
+
+A	O
+65	O
+-	O
+year	O
+-	O
+old	O
+Caucasian	O
+woman	O
+presented	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+Of	O
+234	O
+patients	O
+with	O
+ARDS	B-DISO
+(	O
+age	O
+62	O
+.	O
+3	O
+±	O
+14	O
+.	O
+3	O
+years	O
+;	O
+88	O
+/	O
+37	O
+.	O
+6	O
+%	O
+female	O
+;	O
+APACHE	O
+II	O
+26	O
+.	O
+8	O
+±	O
+8	O
+.	O
+3	O
+;	O
+26	O
+.	O
+5	O
+%	O
+ICU	O
+mortality	O
+;	O
+32	O
+.	O
+1	O
+%	O
+hospital	O
+mortality	O
+),	O
+94	O
+(	O
+40	O
+.	O
+2	O
+%)	O
+had	O
+at	O
+least	O
+one	O
+major	O
+BCCE	O
+-	O
+detected	O
+abnormality	O
+.	O
+
+BCCE	O
+abnormalities	O
+were	O
+common	O
+,	O
+but	O
+only	O
+severe	O
+ACP	B-DISO
+had	O
+prognostic	O
+significance	O
+in	O
+ARDS	B-DISO
+,	O
+identifying	O
+patients	O
+who	O
+are	O
+at	O
+increased	O
+risk	O
+of	O
+ICU	O
+and	O
+hospital	O
+mortality	O
+.	O
+
+A	O
+cross	O
+-	O
+sectional	O
+survey	O
+(	O
+N	O
+=	O
+533	O
+)	O
+among	O
+residents	O
+of	O
+Hong	O
+Kong	O
+was	O
+conducted	O
+to	O
+assess	O
+the	O
+relationships	O
+between	O
+the	O
+effects	O
+of	O
+outbreak	O
+-	O
+related	O
+mass	O
+media	B-ANAT
+coverage	O
+,	O
+interpersonal	O
+communication	O
+,	O
+the	O
+perceived	O
+level	O
+of	O
+concern	O
+in	O
+one	O
+'	O
+s	O
+close	O
+environment	O
+,	O
+and	O
+the	O
+uptake	O
+of	O
+preventive	O
+measures	O
+.	O
+
+Ten	O
+clinical	O
+trials	O
+conducted	O
+at	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Network	O
+hospitals	O
+between	O
+1996	O
+and	O
+2013	O
+.	O
+
+Among	O
+2	O
+,	O
+994	O
+participants	O
+(	O
+mean	O
+age	O
+,	O
+51	O
+.	O
+3	O
+yr	O
+;	O
+54	O
+%	O
+male	O
+)	O
+with	O
+a	O
+study	O
+-	O
+entry	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+that	O
+met	B-CHED
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+criteria	O
+,	O
+average	O
+cumulative	O
+above	O
+goal	O
+oxygen	B-CHED
+exposure	O
+was	O
+0	O
+.	O
+24	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+-	O
+days	O
+(	O
+interquartile	O
+range	O
+,	O
+0	O
+-	O
+0	O
+.	O
+38	O
+).	O
+
+Participants	O
+with	O
+above	O
+goal	O
+oxygen	B-CHED
+exposure	O
+were	O
+more	O
+likely	O
+to	O
+die	O
+(	O
+adjusted	O
+interquartile	O
+range	O
+odds	O
+ratio	O
+,	O
+1	O
+.	O
+20	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+11	O
+-	O
+1	O
+.	O
+31	O
+)	O
+and	O
+have	O
+lower	O
+ventilator	O
+-	O
+free	O
+days	O
+(	O
+adjusted	O
+interquartile	O
+range	O
+mean	O
+difference	O
+of	O
+-	O
+0	O
+.	O
+83	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+1	O
+.	O
+18	O
+to	O
+-	O
+0	O
+.	O
+48	O
+)	O
+and	O
+lower	O
+hospital	O
+-	O
+free	O
+days	O
+(	O
+adjusted	O
+interquartile	O
+range	O
+mean	O
+difference	O
+of	O
+-	O
+1	O
+.	O
+38	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+2	O
+.	O
+09	O
+to	O
+-	O
+0	O
+.	O
+68	O
+).	O
+
+We	O
+observed	O
+a	O
+dose	O
+-	O
+response	O
+relationship	O
+between	O
+the	O
+cumulative	O
+above	O
+goal	O
+oxygen	B-CHED
+exposure	O
+and	O
+worsened	O
+clinical	O
+outcomes	O
+for	O
+participants	O
+with	O
+mild	O
+,	O
+moderate	O
+,	O
+or	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+suggesting	O
+that	O
+the	O
+observed	O
+relationship	O
+is	O
+not	O
+primarily	O
+influenced	O
+by	O
+severity	O
+of	O
+illness	O
+.	O
+
+Oxygen	B-CHED
+exposure	O
+resulting	O
+in	O
+arterial	B-ANAT
+oxygen	B-CHED
+tensions	B-DISO
+above	O
+the	O
+protocol	O
+goal	O
+occurred	O
+frequently	O
+and	O
+was	O
+associated	O
+with	O
+worse	O
+clinical	O
+outcomes	O
+at	O
+all	O
+levels	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+severity	O
+.	O
+
+We	O
+conditionally	O
+deleted	O
+the	O
+Abca3	B-PRGE
+gene	I-PRGE
+in	O
+AT2	B-CHED
+cells	B-COMP
+in	O
+the	O
+mature	O
+mouse	B-ANAT
+lung	I-ANAT
+.	O
+
+mNGS	O
+revealed	O
+a	O
+548	O
+-	O
+nucleotide	B-CHED
+deletion	O
+,	O
+which	O
+comprised	O
+the	O
+near	O
+entirety	O
+of	O
+the	O
+ORF4	B-PRGE
+gene	I-PRGE
+,	O
+and	O
+no	O
+minor	O
+allele	O
+variants	O
+were	O
+detected	O
+to	O
+suggest	O
+a	O
+mixed	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+pathological	O
+condition	B-DISO
+that	O
+involves	O
+diffuse	O
+lung	B-ANAT
+injury	O
+and	O
+severe	O
+hypoxemia	O
+caused	O
+by	O
+pulmonary	B-ANAT
+and	O
+systemic	O
+diseases	O
+.	O
+
+In	O
+α	O
+-	O
+GalCer	O
+/	O
+LPS	B-DISO
+-	O
+treated	O
+mice	B-SPEC
+,	O
+the	O
+number	O
+of	O
+CD4	B-PRGE
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+past	O
+twenty	O
+years	O
+,	O
+numerous	O
+novel	O
+zoonotic	O
+viral	O
+agents	O
+with	O
+pandemic	O
+potential	O
+have	O
+emerged	O
+in	O
+China	O
+,	O
+such	O
+as	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+and	O
+,	O
+more	O
+recently	O
+,	O
+the	O
+avian	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H7N9	O
+virus	B-SPEC
+,	O
+which	O
+have	O
+caused	O
+outbreaks	O
+among	O
+humans	B-SPEC
+with	O
+high	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+In	O
+addition	O
+,	O
+several	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+viral	O
+pathogens	O
+have	O
+also	O
+been	O
+imported	O
+into	O
+China	O
+from	O
+travelers	O
+,	O
+e	O
+.	O
+g	O
+.	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+and	O
+Zika	B-SPEC
+virus	I-SPEC
+(	O
+ZIKV	O
+).	O
+
+The	O
+compact	O
+cluster	O
+of	O
+beta	O
+-	O
+CoVs	O
+from	O
+R	B-SPEC
+.	I-SPEC
+ferrumequinum	I-SPEC
+roosts	O
+expands	O
+the	O
+current	O
+viral	O
+sequence	O
+database	O
+,	O
+specifically	O
+for	O
+this	O
+species	B-SPEC
+in	O
+Europe	O
+.	O
+
+Our	O
+aim	O
+was	O
+to	O
+determine	O
+if	O
+serum	B-COMP
+MBL	O
+levels	O
+correlate	O
+with	O
+the	O
+risk	O
+of	O
+mortality	O
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICU	O
+)	O
+patients	O
+with	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+infection	B-DISO
+.	O
+
+Prospective	O
+observational	O
+study	O
+was	O
+performed	O
+in	O
+ICU	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+virus	B-SPEC
+.	O
+
+Kaplan	O
+-	O
+Meier	O
+analysis	O
+demonstrated	O
+a	O
+strong	O
+association	O
+between	O
+MBL	B-PRGE
+levels	O
+and	O
+mortality	O
+(	O
+log	O
+-	O
+rank	O
+7	O
+.	O
+8	O
+,	O
+p	O
+=	O
+0	O
+.	O
+005	O
+).	O
+
+This	O
+study	O
+shows	O
+that	O
+baseline	O
+MBL	O
+>	O
+1870	O
+ng	O
+/	O
+ml	O
+is	O
+associated	O
+with	O
+higher	O
+mortality	O
+in	O
+ICU	O
+patients	O
+with	O
+severe	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Correction	O
+to	O
+:	O
+Simultaneous	O
+detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+,	O
+and	O
+related	O
+bat	B-ENZY
+coronaviruses	O
+by	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+.	O
+
+Coronavirus	B-SPEC
+entry	O
+is	O
+unusual	O
+in	O
+that	O
+it	O
+is	O
+often	O
+biphasic	O
+in	O
+nature	O
+,	O
+and	O
+can	O
+occur	O
+at	O
+or	O
+near	O
+the	O
+cell	B-COMP
+surface	I-COMP
+or	O
+in	O
+late	O
+endosomes	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+electrical	B-PROC
+activity	I-PROC
+of	O
+the	O
+diaphragm	B-ANAT
+(	O
+EAdi	O
+)	O
+shows	O
+global	O
+diaphragmatic	B-ANAT
+activation	O
+and	O
+power	O
+output	O
+from	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+.	O
+
+Turning	O
+off	O
+the	O
+sweep	O
+gas	B-ENZY
+flow	O
+immediately	O
+led	O
+to	O
+EAdi	O
+elevation	O
+,	O
+followed	O
+by	O
+hypoxia	B-DISO
+.	O
+
+Severe	B-DISO
+sepsis	I-DISO
+is	O
+also	O
+associated	O
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+cardiomyopathy	B-DISO
+,	O
+a	O
+reversible	O
+myocardial	B-DISO
+depression	I-DISO
+.	O
+
+Viruses	B-SPEC
+associated	O
+to	O
+synanthropic	O
+bat	B-ENZY
+genera	O
+,	O
+such	O
+as	O
+Myotis	B-SPEC
+or	O
+Scotophilus	B-SPEC
+were	O
+associated	O
+to	O
+highly	O
+transformed	O
+habitats	O
+with	O
+human	B-SPEC
+presence	O
+while	O
+viruses	B-SPEC
+associated	O
+to	O
+fruit	O
+bat	B-ENZY
+genera	O
+were	O
+correlated	O
+with	O
+natural	O
+environments	O
+with	O
+dense	O
+forest	O
+,	O
+grassland	O
+areas	O
+and	O
+regions	O
+of	O
+high	O
+elevation	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+Frequency	O
+Oscillatory	O
+Ventilation	O
+Use	O
+and	O
+Severe	O
+Pediatric	O
+ARDS	B-DISO
+in	O
+the	O
+Pediatric	O
+Hematopoietic	B-ANAT
+Cell	I-ANAT
+Transplant	B-ANAT
+Recipient	O
+.	O
+
+We	O
+sought	O
+to	O
+identify	O
+current	O
+practice	O
+patterns	O
+of	O
+HFOV	O
+,	O
+investigate	O
+parameters	O
+during	O
+HFOV	O
+and	O
+their	O
+association	O
+with	O
+mortality	O
+,	O
+and	O
+compare	O
+the	O
+use	O
+of	O
+HFOV	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+in	O
+severe	O
+pediatric	O
+ARDS	B-DISO
+.	O
+
+ExoN	O
+excises	O
+nucleotide	B-CHED
+mismatches	O
+at	O
+the	O
+RNA	O
+3	O
+'-	O
+end	O
+in	O
+vitro	O
+,	O
+and	O
+its	O
+inactivation	B-DISO
+in	O
+vivo	O
+jeopardizes	O
+viral	O
+genetic	O
+stability	O
+.	O
+
+Infection	B-DISO
+is	O
+a	O
+common	O
+cause	O
+in	O
+children	O
+,	O
+whereas	O
+adults	O
+usually	O
+present	O
+with	O
+pain	O
+crises	O
+.	O
+
+A	O
+plethora	O
+of	O
+pathogens	O
+can	O
+cause	O
+these	O
+diseases	O
+,	O
+with	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+enterotoxigenic	O
+Escherichia	B-SPEC
+coli	I-SPEC
+K88	O
+(	O
+ETEC	O
+)	O
+being	O
+two	O
+of	O
+the	O
+most	O
+salient	O
+.	O
+
+Lipoproteins	B-CHED
+'	O
+main	O
+constituents	O
+are	O
+phospholipids	B-CHED
+and	O
+apolipoproteins	B-CHED
+,	O
+forming	O
+a	O
+corona	B-CHED
+that	O
+encloses	O
+a	O
+hydrophobic	O
+core	O
+of	O
+triglycerides	B-CHED
+and	O
+cholesterol	B-CHED
+esters	I-CHED
+.	O
+
+The	O
+use	O
+of	O
+comprehensive	O
+fever	B-PROC
+syndromic	O
+surveillance	O
+,	O
+with	O
+enhanced	O
+clinical	O
+microbiology	O
+,	O
+advanced	O
+diagnostics	O
+and	O
+more	O
+robust	O
+epidemiologic	O
+investigation	O
+,	O
+could	O
+enable	O
+healthcare	O
+providers	O
+to	O
+offer	O
+a	O
+differential	O
+diagnosis	O
+of	O
+fever	B-PROC
+syndrome	B-DISO
+and	O
+more	O
+appropriate	O
+care	O
+and	O
+treatment	O
+.	O
+
+Blood	B-ANAT
+and	O
+naso	B-SPEC
+-	O
+pharyngeal	B-ANAT
+/	O
+oral	B-ANAT
+-	O
+pharyngeal	B-ANAT
+(	O
+NP	O
+/	O
+OP	O
+)	O
+specimens	O
+were	O
+collected	O
+and	O
+analyzed	O
+,	O
+respectively	O
+,	O
+using	O
+AFI	O
+and	O
+respiratory	O
+TaqMan	O
+Array	O
+Cards	O
+(	O
+TAC	B-CHED
+)	O
+for	O
+multi	O
+-	O
+pathogen	O
+detection	O
+of	O
+57	O
+potential	O
+causative	O
+agents	O
+.	O
+
+Of	O
+the	O
+57	O
+agents	O
+surveyed	O
+,	O
+Plasmodium	B-SPEC
+was	O
+the	O
+most	O
+common	O
+agent	O
+detected	O
+.	O
+
+Furthermore	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+of	O
+human	B-SPEC
+epithelial	O
+and	O
+neuronal	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+of	O
+mixed	O
+murine	B-SPEC
+primary	O
+cultures	O
+from	O
+the	O
+central	O
+nervous	O
+system	O
+and	O
+of	O
+mouse	B-ANAT
+central	I-ANAT
+nervous	B-DISO
+system	I-ANAT
+showed	O
+that	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+is	O
+critical	O
+for	O
+efficient	O
+and	O
+optimal	O
+virus	B-PROC
+replication	I-PROC
+and	O
+propagation	O
+,	O
+and	O
+thereby	O
+for	O
+neurovirulence	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+described	O
+the	O
+development	B-PROC
+of	O
+lateral	O
+-	O
+flow	O
+dipstick	O
+isothermal	O
+recombinase	B-PRGE
+polymerase	I-PRGE
+amplification	B-DISO
+(	O
+LFD	B-PRGE
+-	I-PRGE
+RPA	I-PRGE
+)	O
+assays	O
+for	O
+detection	O
+of	O
+BEFV	O
+.	O
+
+RPA	B-COMP
+primers	O
+and	O
+LF	O
+probes	O
+were	O
+designed	O
+by	O
+targeting	B-PROC
+the	O
+specific	O
+G	B-PRGE
+gene	I-PRGE
+,	O
+and	O
+the	O
+amplification	B-DISO
+product	O
+can	O
+be	O
+visualized	O
+on	O
+a	O
+simple	O
+lateral	O
+flow	O
+dipstick	O
+with	O
+the	O
+naked	O
+eyes	B-ANAT
+.	O
+
+The	O
+RPA	B-COMP
+combined	O
+with	O
+LFD	O
+assay	O
+probably	O
+provides	O
+a	O
+rapid	O
+and	O
+sensitive	O
+alternative	O
+for	O
+diagnosis	O
+of	O
+BEFV	O
+infections	B-DISO
+outbreak	O
+.	O
+
+This	O
+suggests	O
+that	O
+CPK	B-PRGE
+alone	O
+may	O
+not	O
+be	O
+a	O
+sensitive	O
+marker	O
+for	O
+rhabdomyolysis	B-DISO
+-	O
+induced	O
+AKI	O
+in	O
+some	O
+cases	O
+.	O
+
+As	O
+of	O
+November	O
+2017	O
+,	O
+MERS	O
+-	O
+CoV	O
+had	O
+infected	O
+at	O
+least	O
+2102	O
+people	O
+with	O
+a	O
+fatality	O
+rate	O
+of	O
+about	O
+35	O
+%	O
+globally	O
+,	O
+and	O
+hence	O
+there	O
+is	O
+an	O
+urgent	O
+need	O
+to	O
+identify	O
+antiviral	B-CHED
+drugs	I-CHED
+that	O
+are	O
+active	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+Here	O
+we	O
+show	O
+that	O
+a	O
+clinically	O
+available	O
+alcohol	O
+-	O
+aversive	O
+drug	O
+,	O
+disulfiram	B-CHED
+,	O
+can	O
+inhibit	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+(	O
+PL	O
+
+First	O
+,	O
+we	O
+evaluated	O
+the	O
+inhibitory	O
+effects	O
+of	O
+compounds	O
+2	O
+and	O
+3	O
+on	O
+PRRSV	B-SPEC
+3CLSP	B-ENZY
+activity	O
+.	O
+
+Fifteen	O
+CRRT	O
+patients	O
+required	O
+transition	B-DISO
+to	O
+intermittent	O
+hemodialysis	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+immunity	B-PROC
+against	O
+the	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+an	O
+inefficient	O
+inducer	O
+of	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+response	O
+.	O
+
+It	O
+expresses	O
+various	O
+proteins	B-CHED
+that	O
+effectively	O
+circumvent	O
+IFN	B-PRGE
+production	O
+at	O
+different	O
+levels	O
+via	O
+distinct	O
+mechanisms	O
+.	O
+
+We	O
+also	O
+found	O
+that	O
+proteins	B-CHED
+8b	O
+and	O
+8ab	O
+could	O
+physically	O
+interact	O
+with	O
+IRF3	B-PRGE
+.	O
+
+Although	O
+this	O
+is	O
+possible	O
+in	O
+theory	O
+,	O
+it	O
+does	O
+not	O
+explain	O
+the	O
+occurrence	O
+of	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+(	O
+VILI	O
+)	O
+in	O
+lungs	B-ANAT
+ventilated	O
+with	O
+much	O
+lower	O
+tidal	O
+volumes	O
+.	O
+
+In	O
+the	O
+end	O
+,	O
+decreasing	O
+mechanical	O
+power	O
+,	O
+increasing	O
+lung	B-ANAT
+homogeneity	O
+,	O
+and	O
+avoiding	O
+reaching	B-PROC
+the	O
+anatomical	O
+limits	O
+of	O
+the	O
+'	O
+baby	O
+lung	B-ANAT
+'	O
+should	O
+be	O
+the	O
+goals	O
+for	O
+safe	O
+ventilation	O
+in	O
+ARDS	B-DISO
+.	O
+
+Recently	O
+diagnosed	O
+immunodeficiency	B-DISO
+is	O
+associated	O
+with	O
+a	O
+much	O
+better	O
+prognosis	O
+in	O
+ECMO	O
+-	O
+treated	O
+severe	O
+ARDS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Recently	O
+diagnosed	O
+immunodeficiency	B-DISO
+is	O
+associated	O
+with	O
+a	O
+much	O
+better	O
+prognosis	O
+in	O
+ECMO	O
+-	O
+treated	O
+severe	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+which	O
+first	O
+broken	O
+out	O
+in	O
+Jeddah	O
+in	O
+2012	O
+,	O
+causes	O
+a	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+through	O
+a	O
+two	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+of	O
+a	O
+special	O
+bat	B-ENZY
+population	O
+in	O
+one	O
+specific	O
+cave	O
+of	O
+south	O
+China	O
+,	O
+we	O
+illustrate	O
+that	O
+Ro	O
+-	O
+BatCoV	O
+GCCDC1	O
+persistently	O
+circulates	O
+among	O
+bats	B-SPEC
+.	O
+
+Commercial	O
+vaccines	O
+against	O
+PEDV	B-SPEC
+are	O
+available	O
+but	O
+their	O
+efficacies	O
+are	O
+inadequate	O
+.	O
+
+Therefore	O
+,	O
+vaccines	O
+with	O
+improved	O
+efficacy	O
+are	O
+needed	O
+to	O
+effectively	O
+control	O
+PEDV	B-SPEC
+infections	B-DISO
+.	O
+
+The	O
+vaccine	O
+also	O
+reduced	O
+the	O
+amount	O
+of	O
+PEDV	B-PRGE
+antigen	B-CHED
+in	O
+intestinal	B-ANAT
+tissues	B-ANAT
+presented	O
+with	O
+intestinal	B-ANAT
+villi	I-ANAT
+regrowth	O
+.	O
+
+The	O
+suckling	O
+piglets	O
+in	O
+the	O
+DC	O
+-	O
+targeted	B-PROC
+vaccine	O
+group	O
+showed	O
+increased	O
+gross	O
+pathological	O
+lesions	O
+in	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Free	O
+-	O
+Form	O
+Deformation	O
+Approach	O
+for	O
+Registration	O
+of	O
+Visible	O
+and	O
+Infrared	O
+Facial	B-ANAT
+Images	O
+in	O
+Fever	B-PROC
+Screening	O
+.	O
+
+When	O
+comparing	O
+radial	O
+versus	O
+femoral	B-ANAT
+,	O
+there	O
+was	O
+no	O
+significant	O
+interaction	O
+for	O
+MACCE	O
+and	O
+NACE	O
+stratified	O
+by	O
+sex	O
+(	O
+p	O
+Women	O
+showed	O
+a	O
+higher	O
+risk	O
+of	O
+severe	O
+bleeding	B-DISO
+and	O
+access	O
+site	O
+complications	O
+,	O
+and	O
+radial	O
+access	O
+was	O
+an	O
+effective	O
+method	O
+to	O
+reduce	O
+these	O
+complications	O
+as	O
+well	O
+as	O
+composite	O
+ischemic	O
+and	O
+ischemic	O
+or	O
+bleeding	B-DISO
+endpoints	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ALRIs	O
+)	O
+caused	O
+by	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+are	O
+a	O
+leading	O
+cause	O
+of	O
+hospitalization	O
+in	O
+infants	O
+.	O
+
+Meta	B-SPEC
+-	O
+analyses	O
+were	O
+performed	O
+on	O
+extracted	O
+data	O
+using	O
+STATA	O
+statistical	O
+software	O
+,	O
+and	O
+hospitalisation	O
+rates	O
+for	O
+children	O
+with	O
+and	O
+without	O
+DS	O
+under	O
+the	O
+age	O
+of	O
+2	O
+were	O
+calculated	O
+.	O
+
+In	O
+summary	O
+,	O
+IBV	B-SPEC
+M41	O
+replication	O
+in	O
+infected	O
+HD11	O
+macrophages	B-ANAT
+seems	O
+to	O
+induce	O
+mitochondrial	B-COMP
+bioenergy	O
+failure	O
+,	O
+acting	O
+as	O
+a	O
+respiratory	B-COMP
+chain	I-COMP
+uncoupler	O
+,	O
+without	O
+compromising	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+gender	O
+,	O
+age	O
+,	O
+onset	O
+to	O
+diagnosis	O
+time	O
+,	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+)	O
+score	O
+,	O
+oxygenation	B-PROC
+index	O
+(	O
+PaO	B-PROC
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+gender	O
+,	O
+age	O
+,	O
+onset	O
+to	O
+diagnosis	O
+time	O
+,	O
+APACHE	O
+II	O
+score	O
+,	O
+PaO	B-PROC
+Early	O
+bundle	O
+therapy	O
+has	O
+a	O
+significant	O
+effect	O
+on	O
+severe	O
+human	B-SPEC
+infection	B-DISO
+by	O
+avian	B-DISO
+influenza	I-DISO
+H7N9	O
+,	O
+which	O
+can	O
+improve	O
+the	O
+prognosis	O
+and	O
+reduce	O
+the	O
+mortality	O
+of	O
+patients	O
+.	O
+
+The	O
+clinical	O
+data	O
+of	O
+patients	O
+,	O
+including	O
+gender	O
+,	O
+age	O
+,	O
+heart	B-ANAT
+rate	O
+(	O
+HR	O
+)	O
+and	O
+blood	B-PROC
+pressure	I-PROC
+within	O
+24	O
+hours	O
+after	O
+admission	O
+to	O
+the	O
+hospital	O
+,	O
+indicators	O
+of	O
+blood	B-ANAT
+routine	O
+and	O
+blood	O
+biochemistry	O
+,	O
+severity	O
+of	O
+disease	O
+,	O
+severity	O
+of	O
+trauma	O
+,	O
+whether	O
+received	O
+the	O
+emergency	B-DISO
+intubation	O
+or	O
+surgery	O
+within	O
+24	O
+hours	O
+or	O
+not	O
+,	O
+whether	O
+developed	O
+sepsis	B-DISO
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+during	O
+hospitalization	O
+,	O
+were	O
+recorded	O
+,	O
+and	O
+univariate	O
+analysis	O
+was	O
+conducted	O
+.	O
+
+Compared	O
+with	O
+non	O
+-	O
+MODS	B-DISO
+group	O
+,	O
+HR	O
+,	O
+Na	O
+MODS	B-DISO
+warning	O
+score	O
+is	O
+composed	O
+of	O
+five	O
+factors	O
+,	O
+including	O
+the	O
+number	O
+of	O
+injured	O
+places	O
+,	O
+shock	O
+at	O
+admission	O
+,	O
+APACHE	O
+II	O
+score	O
+,	O
+SOFA	O
+score	O
+and	O
+APTT	O
+,	O
+which	O
+could	O
+be	O
+regarded	O
+as	O
+early	O
+warning	O
+score	O
+system	O
+for	O
+predicting	O
+MODS	B-DISO
+in	O
+patients	O
+with	O
+severe	O
+trauma	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+characterized	O
+by	O
+acute	O
+hypoxic	B-DISO
+respiratory	B-DISO
+dysfunction	I-DISO
+or	O
+failure	O
+,	O
+is	O
+a	O
+manifestation	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+(	O
+MOF	B-DISO
+)	O
+in	O
+the	O
+lung	B-ANAT
+,	O
+which	O
+often	O
+caused	O
+by	O
+various	O
+non	O
+-	O
+cardiac	B-ANAT
+reasons	O
+,	O
+included	O
+severe	O
+trauma	O
+,	O
+infection	B-DISO
+,	O
+shock	O
+;	O
+and	O
+the	O
+most	O
+common	O
+risk	O
+factor	O
+is	O
+sepsis	B-DISO
+which	O
+would	O
+cause	O
+uncontrolled	O
+host	B-PROC
+response	I-PROC
+to	O
+infecting	O
+factors	O
+.	O
+
+Therefore	O
+,	O
+to	O
+explore	O
+the	O
+signal	B-PROC
+transduction	I-PROC
+pathway	I-PROC
+of	O
+α	O
+-	O
+AR	O
+,	O
+during	O
+sepsis	B-DISO
+,	O
+is	O
+important	O
+for	O
+revealing	O
+the	O
+mechanism	O
+of	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+the	O
+clinico	O
+pathological	O
+presentation	O
+of	O
+20	O
+cases	O
+of	O
+tenofovir	B-CHED
+-	O
+induced	O
+tubulopathy	O
+,	O
+and	O
+investigated	O
+the	O
+renal	B-ANAT
+expression	B-PROC
+of	O
+the	O
+megalin	B-PRGE
+and	O
+cubilin	B-PRGE
+proteins	I-PRGE
+,	O
+as	O
+well	O
+as	O
+the	O
+mitochondrial	B-COMP
+respiratory	I-COMP
+chain	I-COMP
+activity	O
+.	O
+
+Data	O
+from	O
+36	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+treated	O
+with	O
+VV	O
+-	O
+ECMO	O
+at	O
+a	O
+University	O
+Hospital	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+were	O
+analyzed	O
+retrospectively	O
+.	O
+
+Patients	O
+suffering	B-DISO
+from	O
+severe	O
+hemorrhage	B-DISO
+had	O
+a	O
+lower	O
+survival	O
+rate	O
+on	O
+VV	O
+-	O
+ECMO	O
+(	O
+43	O
+%	O
+Severe	O
+hemorrhage	B-DISO
+under	O
+VV	O
+-	O
+ECMO	O
+is	O
+associated	O
+with	O
+higher	O
+mortality	O
+.	O
+
+This	O
+study	O
+demonstrates	O
+that	O
+in	O
+C57BL	O
+/	O
+6J	O
+mice	B-SPEC
+,	O
+depending	O
+on	O
+the	O
+parasite	O
+species	B-SPEC
+,	O
+malaria	B-PATH
+-	O
+induced	O
+liver	B-ANAT
+pathology	B-DISO
+results	O
+in	O
+different	O
+manifestations	O
+,	O
+which	O
+may	O
+contribute	O
+to	O
+the	O
+different	O
+outcomes	O
+.	O
+
+On	O
+the	O
+contrary	O
+,	O
+in	O
+P	B-SPEC
+.	I-SPEC
+chabaudi	I-SPEC
+AS	O
+infected	O
+mice	B-SPEC
+the	O
+antioxidant	B-CHED
+enzymes	O
+and	O
+the	O
+lipid	B-CHED
+content	O
+and	O
+composition	O
+were	O
+normal	O
+or	O
+even	O
+lower	O
+than	O
+uninfected	O
+controls	O
+.	O
+
+Hypothermic	O
+patients	O
+were	O
+more	O
+severely	O
+injured	O
+(	O
+ISS	B-DISO
+35	O
+.	O
+6	O
+±	O
+11	O
+.	O
+1	O
+vs	O
+.	O
+31	O
+.	O
+2	O
+±	O
+10	O
+.	O
+1	O
+,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+;	O
+APACHE	O
+II	O
+18	O
+.	O
+1	O
+±	O
+7	O
+.	O
+4	O
+vs	O
+.	O
+16	O
+.	O
+2	O
+±	O
+7	O
+.	O
+3	O
+,	O
+p	O
+=	O
+0	O
+.	O
+045	O
+)	O
+and	O
+had	O
+a	O
+higher	O
+transfusion	O
+requirement	O
+.	O
+
+Accidental	O
+hypothermia	O
+seems	O
+to	O
+have	O
+a	O
+negative	O
+impact	O
+on	O
+neurological	O
+recovery	O
+in	O
+older	O
+patients	O
+with	O
+multiple	O
+injuries	O
+including	O
+traumatic	O
+brain	B-ANAT
+injury	O
+which	O
+outweighs	O
+potential	O
+benefits	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+for	O
+Refractory	O
+Severe	O
+Respiratory	B-DISO
+Failure	I-DISO
+in	O
+Acute	B-DISO
+Interstitial	B-ANAT
+Pneumonia	I-DISO
+.	O
+
+ECMO	O
+allowed	O
+AIP	B-DISO
+diagnosis	O
+and	O
+treatment	O
+in	O
+the	O
+presence	O
+of	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+therefore	O
+reducing	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+and	O
+bridging	O
+lung	B-ANAT
+recovery	O
+in	O
+two	O
+patients	O
+.	O
+
+Established	O
+models	O
+of	O
+severe	O
+ARDS	B-DISO
+(	O
+rabbit	B-SPEC
+,	O
+pig	B-SPEC
+)	O
+were	O
+used	O
+.	O
+
+Although	O
+injury	O
+during	O
+muscle	B-ANAT
+paralysis	O
+was	O
+predominantly	O
+in	O
+nondependent	O
+and	O
+middle	O
+lung	B-ANAT
+regions	O
+at	O
+low	O
+(	O
+vs	O
+.	O
+high	O
+)	O
+PEEP	B-CHED
+,	O
+strong	O
+inspiratory	B-PROC
+effort	B-PROC
+increased	O
+injury	O
+(	O
+indicated	O
+by	O
+positron	B-CHED
+emission	B-ANAT
+tomography	O
+and	O
+histology	O
+)	O
+in	O
+dependent	O
+lung	B-ANAT
+.	O
+
+Strong	O
+effort	B-PROC
+increased	O
+dependent	O
+lung	B-ANAT
+injury	O
+,	O
+where	O
+higher	O
+local	O
+lung	B-ANAT
+stress	O
+and	O
+stretch	O
+was	O
+generated	O
+;	O
+effort	B-PROC
+-	O
+dependent	O
+lung	B-ANAT
+injury	O
+was	O
+minimized	O
+by	O
+high	O
+PEEP	B-CHED
+in	O
+severe	O
+ARDS	B-DISO
+,	O
+which	O
+may	O
+offset	O
+need	O
+for	O
+paralysis	O
+.	O
+
+Clinical	O
+relevance	O
+between	O
+CFs	O
+and	O
+ALI	O
+/	O
+ARDS	B-DISO
+was	O
+investigated	O
+.	O
+
+The	O
+greater	O
+number	O
+of	O
+CFs	B-DISO
+in	O
+the	O
+ALI	O
+/	O
+ARDS	B-DISO
+group	O
+implied	O
+higher	O
+degree	O
+of	O
+lung	B-ANAT
+injury	O
+and	O
+more	O
+severe	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Harmful	O
+effects	O
+of	O
+spontaneous	O
+breathing	B-PROC
+have	O
+been	O
+shown	O
+in	O
+experimental	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Thirty	O
+-	O
+five	O
+Wistar	B-SPEC
+rats	I-SPEC
+(	O
+weight	O
+±	O
+SD	O
+,	O
+310	O
+±	O
+19	O
+)	O
+g	O
+received	O
+Escherichia	B-SPEC
+coli	I-SPEC
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)	O
+intratracheally	O
+.	O
+
+After	O
+24	O
+h	O
+,	O
+the	O
+animals	B-SPEC
+were	O
+anaesthetised	O
+and	O
+randomly	O
+allocated	O
+to	O
+either	O
+PCV	B-CHED
+(	O
+n	O
+=	O
+14	O
+)	O
+or	O
+PSV	O
+(	O
+n	O
+=	O
+14	O
+)	O
+groups	O
+.	O
+
+Peak	O
+transpulmonary	O
+pressure	O
+correlated	O
+positively	O
+with	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+[	O
+Spearman	O
+'	O
+s	O
+rho	O
+(	O
+ρ	O
+)	O
+=	O
+0	O
+.	O
+62	O
+,	O
+P	O
+=	O
+0	O
+.	O
+0007	O
+]	O
+and	O
+CINC	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expressions	O
+(	O
+ρ	O
+=	O
+0	O
+.	O
+50	O
+,	O
+P	O
+=	O
+0	O
+.	O
+01	O
+)	O
+and	O
+negatively	O
+with	O
+E	B-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+expression	B-PROC
+(	O
+ρ	O
+=	O
+-	O
+0	O
+.	O
+67	O
+,	O
+P	O
+=	O
+0	O
+.	O
+0002	O
+).	O
+
+TITLE	O
+:	O
+Ulinastatin	B-PRGE
+Protects	O
+Against	O
+LPS	B-DISO
+-	O
+Induced	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+By	O
+Attenuating	O
+TLR4	B-PRGE
+/	O
+NF	O
+-	O
+κB	O
+Pathway	B-PROC
+Activation	O
+and	O
+Reducing	O
+Inflammatory	O
+Mediators	O
+.	O
+
+Neutrophil	B-ANAT
+extracellular	B-COMP
+traps	B-DISO
+(	O
+NETs	O
+)	O
+can	O
+be	O
+induced	O
+by	O
+pathogens	O
+and	O
+are	O
+responsible	O
+for	O
+immune	O
+tissue	B-ANAT
+damage	O
+.	O
+
+Here	O
+,	O
+we	O
+sought	O
+to	O
+determine	O
+the	O
+prevalence	O
+of	O
+different	O
+respiratory	O
+viruses	B-SPEC
+during	O
+asthma	B-PATH
+exacerbations	O
+.	O
+
+TITLE	O
+:	O
+Correction	O
+to	O
+:	O
+Detection	O
+and	O
+full	O
+genome	O
+characterization	O
+of	O
+two	O
+beta	O
+CoV	O
+viruses	B-SPEC
+related	O
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+from	O
+bats	B-SPEC
+in	O
+Italy	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+:	O
+Insights	O
+into	O
+viral	B-DISO
+pathogenesis	I-DISO
+based	O
+on	O
+the	O
+spike	O
+protein	B-CHED
+structure	O
+and	O
+function	O
+.	O
+
+We	O
+describe	O
+the	O
+specific	O
+structural	O
+characteristics	O
+of	O
+the	O
+FCoV	O
+S	O
+,	O
+in	O
+comparison	O
+with	O
+other	O
+coronavirus	B-SPEC
+spikes	O
+.	O
+
+A	O
+total	O
+of	O
+749	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+patients	O
+presenting	O
+at	O
+Johns	O
+Hopkins	O
+Aramco	O
+Healthcare	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+each	O
+submitted	O
+a	O
+clinical	O
+sample	O
+for	O
+influenza	B-PATH
+A	I-PATH
+reflex	B-PROC
+testing	O
+using	O
+the	O
+on	O
+-	O
+site	O
+Cepheid	B-PRGE
+®	I-PRGE
+Xpert	I-PRGE
+Flu	I-PRGE
+assay	O
+and	O
+at	O
+the	O
+Ministry	O
+of	O
+Health	O
+laboratory	O
+by	O
+the	O
+Roche	O
+PCR	O
+assay	O
+.	O
+
+Specificity	O
+of	O
+the	O
+Cepheid	B-PRGE
+®	I-PRGE
+Xpert	I-PRGE
+Flu	I-PRGE
+was	O
+95	O
+.	O
+8	O
+%	O
+for	O
+H1N1	O
+and	O
+94	O
+.	O
+4	O
+%	O
+for	O
+total	O
+influenza	B-PATH
+A	I-PATH
+.	O
+Cepheid	O
+®	O
+Xpert	O
+Flu	B-DISO
+sensitivity	O
+for	O
+influenza	B-PATH
+A	I-PATH
+was	O
+100	O
+%	O
+for	O
+younger	O
+patients	O
+(	O
+0	O
+-	O
+19	O
+-	O
+year	O
+age	O
+group	O
+)	O
+but	O
+significantly	O
+lower	O
+both	O
+for	O
+older	O
+patients	O
+(	O
+68	O
+.	O
+2	O
+%	O
+for	O
+60	O
+-	O
+79	O
+-	O
+year	O
+and	O
+50	O
+%	O
+for	O
+≥	O
+80	O
+-	O
+year	O
+age	O
+groups	O
+)	O
+and	O
+overall	O
+for	O
+males	O
+compared	O
+to	O
+females	O
+(	O
+72	O
+.	O
+6	O
+%	O
+and	O
+94	O
+.	O
+0	O
+%,	O
+respectively	O
+).	O
+
+Specificity	O
+of	O
+the	O
+Cepheid	O
+®	O
+Xpert	O
+Flu	B-DISO
+test	O
+was	O
+high	O
+;	O
+however	O
+,	O
+sensitivity	O
+for	O
+total	O
+influenza	B-DISO
+A	I-PATH
+was	O
+lower	O
+particularly	O
+in	O
+males	O
+and	O
+older	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Safety	O
+and	O
+tolerability	O
+of	O
+a	O
+novel	O
+,	O
+polyclonal	O
+human	B-SPEC
+anti	O
+-	O
+MERS	O
+coronavirus	B-SPEC
+antibody	B-COMP
+produced	O
+from	O
+transchromosomic	O
+cattle	O
+:	O
+a	O
+phase	O
+1	O
+randomised	O
+,	O
+double	O
+-	O
+blind	B-DISO
+,	O
+single	O
+-	O
+dose	O
+-	O
+escalation	O
+study	O
+.	O
+
+The	O
+results	O
+suggest	O
+differential	O
+expression	B-PROC
+of	O
+chicken	B-SPEC
+interferon	B-PRGE
+,	O
+among	O
+them	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+elaborate	O
+a	O
+major	O
+role	O
+in	O
+fighting	O
+off	O
+virus	B-SPEC
+.	O
+
+This	O
+study	O
+provides	O
+the	O
+first	O
+comprehensive	O
+analysis	O
+of	O
+host	O
+-	O
+virus	B-SPEC
+interactions	O
+of	O
+IBV	B-SPEC
+with	O
+chicken	B-SPEC
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+mediated	O
+by	O
+interferon	B-PRGE
+in	O
+various	O
+groups	O
+.	O
+
+Commercial	O
+-	O
+inactivated	O
+vaccines	O
+against	O
+avian	B-DISO
+influenza	I-DISO
+(	O
+AI	O
+)	O
+and	O
+Newcastle	B-DISO
+disease	I-DISO
+(	O
+ND	O
+)	O
+viruses	B-SPEC
+,	O
+and	O
+living	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccine	O
+were	O
+administered	O
+by	O
+spray	O
+method	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+collected	O
+from	O
+birds	B-SPEC
+1	O
+week	O
+after	O
+each	O
+vaccination	O
+to	O
+determine	O
+antibody	B-COMP
+titers	O
+.	O
+
+We	O
+amplified	O
+partial	O
+RNA	O
+-	O
+dependent	O
+RNA	B-PRGE
+polymerase	I-PRGE
+genes	I-PRGE
+of	O
+Alpha	O
+and	O
+Betacoronavirus	B-SPEC
+together	O
+with	O
+the	O
+partial	B-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+of	O
+Paramyxovirus	O
+.	O
+
+Identified	O
+coronaviruses	O
+were	O
+related	O
+to	O
+pathogenic	O
+human	O
+strains	O
+and	O
+the	O
+paramyxovirus	O
+belonged	O
+to	O
+the	O
+recently	O
+described	O
+Jeilongvirus	O
+genus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+zoonotic	O
+virus	B-SPEC
+from	O
+camels	B-SPEC
+causing	O
+significant	O
+mortality	O
+and	O
+morbidity	O
+in	O
+humans	B-SPEC
+in	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+The	O
+epidemiology	O
+of	O
+the	O
+virus	B-SPEC
+remains	O
+poorly	O
+understood	O
+,	O
+and	O
+while	O
+case	O
+-	O
+based	O
+and	O
+seroepidemiological	O
+studies	O
+have	O
+been	O
+employed	O
+extensively	O
+throughout	O
+the	O
+epidemic	O
+,	O
+viral	O
+sequence	O
+data	O
+have	O
+not	O
+been	O
+utilised	O
+to	O
+their	O
+full	O
+potential	O
+.	O
+
+Without	O
+heretofore	O
+unseen	O
+evolution	O
+of	O
+host	B-COMP
+tropism	B-PROC
+,	O
+MERS	O
+-	O
+CoV	O
+is	O
+unlikely	O
+to	O
+become	O
+endemic	O
+in	O
+humans	B-SPEC
+.	O
+
+However	O
+,	O
+the	O
+prevalence	O
+of	O
+IBV	B-SPEC
+strains	O
+in	O
+Malaysia	O
+is	O
+poorly	O
+characterized	O
+.	O
+
+Group	O
+1	O
+(	O
+IBS124	O
+/	O
+2015	O
+,	O
+IBS125	O
+/	O
+2015	O
+,	O
+IBS126	O
+/	O
+2015	O
+,	O
+IBS130	O
+/	O
+2015	O
+,	O
+IBS131	O
+/	O
+2015	O
+,	O
+IBS138	O
+/	O
+2015	O
+,	O
+and	O
+IBS142	O
+/	O
+2015	O
+)	O
+shared	O
+90	O
+%-	O
+95	O
+%	O
+nucleotide	B-CHED
+and	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+similarities	O
+to	O
+the	O
+QX	O
+-	O
+like	O
+strain	O
+.	O
+
+Meanwhile	O
+,	O
+IBV	O
+isolates	O
+in	O
+Group	O
+2	O
+(	O
+IBS037A	O
+/	O
+2015	O
+,	O
+IBS037B	O
+/	O
+2015	O
+,	O
+IBS051	O
+/	O
+2015	O
+,	O
+and	O
+IBS180	O
+/	O
+2015	O
+)	O
+were	O
+91	O
+.	O
+62	O
+%	O
+and	O
+89	O
+.	O
+09	O
+%	O
+identical	O
+to	O
+Malaysian	O
+variant	O
+strain	O
+MH5365	O
+/	O
+95	O
+(	O
+EU086600	O
+)	O
+at	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+levels	O
+,	O
+respectively	O
+.	O
+
+A	O
+focal	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+therapy	O
+were	O
+more	O
+frequent	O
+in	O
+patients	O
+with	O
+a	O
+positive	O
+response	O
+to	O
+almitrine	B-CHED
+.	O
+
+Importantly	O
+,	O
+epigenetic	O
+analysis	O
+suggested	O
+that	O
+DNA	B-PROC
+methylation	I-PROC
+,	O
+rather	O
+than	O
+histone	B-PROC
+modification	I-PROC
+,	O
+plays	O
+a	O
+crucial	O
+role	O
+in	O
+MERS	O
+-	O
+CoV	O
+-	O
+mediated	O
+antagonism	O
+of	O
+antigen	B-CHED
+-	O
+presentation	O
+gene	B-PROC
+expression	I-PROC
+;	O
+in	O
+contrast	O
+,	O
+H5N1	B-DISO
+-	O
+VN1203	O
+likely	O
+utilizes	O
+a	O
+combination	O
+of	O
+epigenetic	O
+mechanisms	O
+to	O
+target	O
+antigen	B-PROC
+presentation	I-PROC
+.	O
+
+A	O
+higher	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+(	O
+P	O
+=	O
+0	O
+.	O
+05	O
+)	O
+and	O
+the	O
+complications	O
+of	O
+ARDS	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+004	O
+)	O
+and	O
+encephalopathy	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+004	O
+)	O
+were	O
+associated	O
+with	O
+mortality	O
+.	O
+
+Kidney	B-ANAT
+biopsy	O
+was	O
+done	O
+in	O
+13	O
+patients	O
+.	O
+
+On	O
+renal	B-ANAT
+histology	O
+,	O
+ATN	B-DISO
+and	O
+AIN	O
+are	O
+common	O
+.	O
+
+Data	O
+on	O
+the	O
+treatment	O
+of	O
+and	O
+the	O
+outcomes	O
+of	O
+ARDS	B-DISO
+were	O
+collected	O
+to	O
+determine	O
+the	O
+clinical	O
+characteristics	O
+associated	O
+with	O
+ICU	O
+mortality	O
+.	O
+
+RESULTS	O
+:	O
+During	O
+the	O
+8	O
+-	O
+year	O
+study	O
+period	O
+,	O
+among	O
+a	O
+total	O
+of	O
+821	O
+patients	O
+with	O
+ARDS	B-DISO
+admitted	O
+to	O
+the	O
+ICU	O
+,	O
+all	O
+185	O
+patients	O
+with	O
+hematological	B-DISO
+malignancies	I-DISO
+were	O
+included	O
+in	O
+the	O
+analysis	O
+.	O
+
+SPC	B-PRGE
+-	I-PRGE
+TK	I-PRGE
+mice	B-SPEC
+express	O
+the	O
+inducible	O
+suicide	B-PRGE
+gene	I-PRGE
+thymidine	I-PRGE
+kinase	I-PRGE
+from	O
+by	O
+the	O
+SPC	B-PRGE
+promoter	I-PRGE
+,	O
+which	O
+targets	O
+alveolar	B-ANAT
+type	O
+2	O
+(	O
+AT2	B-CHED
+)	O
+cells	B-COMP
+for	O
+depletion	O
+in	O
+response	O
+to	O
+ganciclovir	B-CHED
+(	O
+GCV	O
+).	O
+
+SPC	B-PRGE
+-	O
+TK	O
+/	O
+SPC	B-PRGE
+-	O
+KO	O
+mice	B-SPEC
+had	O
+highly	O
+elevated	O
+inflammatory	O
+cytokines	O
+and	O
+granulocyte	B-ANAT
+infiltration	B-DISO
+in	O
+the	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluid	O
+.	O
+
+The	O
+level	O
+of	O
+suppressor	O
+of	O
+cytokine	B-PROC
+signaling	I-PROC
+3	O
+,	O
+an	O
+anti	O
+-	O
+inflammatory	O
+mediator	O
+that	O
+decreases	O
+pSTAT3	O
+signaling	B-PROC
+,	O
+was	O
+significantly	O
+decreased	O
+in	O
+the	O
+BAL	B-ENZY
+fluid	O
+of	O
+SPC	B-PRGE
+-	O
+TK	O
+/	O
+SPC	B-PRGE
+-	O
+KO	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+optimal	O
+strategy	O
+for	O
+initiation	O
+of	O
+renal	O
+replacement	O
+therapy	O
+(	O
+RRT	O
+)	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+kidney	B-ANAT
+injury	O
+in	O
+the	O
+context	O
+of	O
+septic	B-DISO
+shock	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+unknown	O
+.	O
+
+A	O
+delayed	O
+RRT	O
+initiation	O
+strategy	O
+allowed	O
+45	O
+%	O
+of	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+and	O
+46	O
+%	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+to	O
+escape	O
+RRT	O
+.	O
+
+Renal	B-PROC
+function	B-DISO
+recovery	I-DISO
+occurred	O
+earlier	O
+with	O
+the	O
+delayed	O
+RRT	O
+strategy	O
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+or	O
+ARDS	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+and	O
+P	O
+=	O
+0	O
+.	O
+003	O
+,	O
+respectively	O
+).	O
+
+Early	O
+RRT	O
+initiation	O
+strategy	O
+was	O
+not	O
+associated	O
+with	O
+any	O
+improvement	O
+of	O
+60	O
+-	O
+day	O
+mortality	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+kidney	B-ANAT
+injury	O
+and	O
+septic	B-DISO
+shock	I-DISO
+or	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+2015	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+outbreak	O
+in	O
+Korea	O
+caused	O
+major	O
+economic	O
+and	O
+social	O
+problems	O
+.	O
+
+TITLE	O
+:	O
+Interplay	O
+between	O
+co	O
+-	O
+divergence	O
+and	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+in	O
+the	O
+evolutionary	O
+history	O
+of	O
+bat	O
+coronaviruses	O
+.	O
+
+In	O
+sum	O
+,	O
+it	O
+is	O
+time	O
+to	O
+think	O
+about	O
+the	O
+realistic	O
+potential	O
+of	O
+Omics	O
+biotechnologies	O
+beyond	O
+clinical	O
+practice	O
+and	O
+precision	O
+medicine	B-CHED
+so	O
+as	O
+to	O
+harness	O
+the	O
+opportunities	O
+and	O
+address	O
+the	O
+uncertainties	O
+associated	O
+not	O
+only	O
+with	O
+GCBRs	O
+but	O
+also	O
+with	O
+other	O
+emerging	O
+Omics	O
+applications	O
+in	O
+health	O
+and	O
+society	O
+.	O
+
+TITLE	O
+:	O
+GBT1118	O
+,	O
+a	O
+compound	O
+that	O
+increases	O
+the	O
+oxygen	B-PROC
+affinity	I-PROC
+of	O
+hemoglobin	B-PRGE
+,	O
+improves	O
+survival	O
+in	O
+murine	B-SPEC
+hypoxic	B-DISO
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+leading	O
+to	O
+arterial	B-ANAT
+hypoxemia	O
+and	O
+death	B-PROC
+if	O
+the	O
+hypoxemia	O
+is	O
+severe	O
+.	O
+
+The	O
+therapeutic	O
+effect	O
+of	O
+two	O
+different	O
+doses	O
+of	O
+GBT1118	O
+,	O
+a	O
+compound	O
+that	O
+increases	O
+the	O
+oxygen	B-PROC
+affinity	I-PROC
+of	O
+hemoglobin	B-PRGE
+,	O
+was	O
+evaluated	O
+in	O
+a	O
+murine	B-SPEC
+model	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+intratracheal	O
+LPS	B-DISO
+instillation	O
+24	O
+h	O
+before	O
+exposure	O
+to	O
+5	O
+%	O
+or	O
+10	O
+%	O
+hypoxia	B-DISO
+(	O
+n	O
+=	O
+8	O
+-	O
+15	O
+per	O
+group	O
+).	O
+
+TITLE	O
+:	O
+Temporary	O
+carriage	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+by	O
+fomites	O
+and	O
+human	O
+nasal	B-ANAT
+mucosa	I-ANAT
+after	O
+exposure	O
+to	O
+infected	O
+calves	O
+.	O
+
+Infective	O
+virions	B-COMP
+were	O
+not	O
+detected	O
+in	O
+mucosal	B-ANAT
+swabs	O
+(	O
+n	O
+=	O
+2	O
+).	O
+
+A	O
+high	O
+viral	O
+RNA	O
+load	O
+was	O
+detected	O
+on	O
+97	O
+%	O
+(	O
+n	O
+=	O
+44	O
+)	O
+of	O
+the	O
+fomites	O
+24	O
+h	O
+after	O
+exposure	O
+,	O
+and	O
+infective	O
+virions	B-COMP
+were	O
+detected	O
+in	O
+two	O
+of	O
+three	O
+swabs	O
+.	O
+
+Of	O
+the	O
+fomites	O
+,	O
+89	O
+%	O
+(	O
+n	O
+=	O
+38	O
+)	O
+were	O
+positive	O
+for	O
+BRSV	B-SPEC
+RNA	O
+24	O
+h	O
+after	O
+exposure	O
+,	O
+but	O
+all	O
+were	O
+negative	O
+for	O
+infective	O
+viruses	B-SPEC
+.	O
+
+Survival	O
+outcomes	O
+remain	O
+unclear	O
+in	O
+those	O
+who	O
+develop	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+requiring	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+CRRT	O
+)	O
+during	O
+VV	O
+ECMO	O
+for	O
+isolated	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+adult	O
+populations	O
+.	O
+
+Patients	O
+supported	O
+by	O
+veno	O
+-	O
+arterial	B-ANAT
+ECMO	O
+were	O
+excluded	O
+.	O
+
+However	O
+,	O
+PDCoV	O
+strains	O
+from	O
+Tibetan	O
+pigs	B-SPEC
+formed	O
+different	O
+branches	O
+within	O
+the	O
+same	O
+cluster	O
+,	O
+implying	O
+continuous	O
+evolution	B-PROC
+in	O
+the	O
+field	O
+.	O
+
+Compared	O
+with	O
+infected	O
+WT	O
+mice	B-SPEC
+,	O
+infected	O
+Gal	B-CHED
+-	O
+3KO	O
+mice	B-SPEC
+exhibited	O
+less	O
+inflammation	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+and	O
+reduced	O
+IL	O
+-	O
+1β	O
+levels	O
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+.	O
+
+An	O
+association	O
+was	O
+also	O
+observed	O
+between	O
+galectin	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+NLRP3	B-PRGE
+/	O
+apoptosis	B-PATH
+-	O
+associated	O
+speck	O
+-	O
+like	O
+proteins	B-CHED
+containing	O
+caspase	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+recruitment	I-PRGE
+domain	I-PRGE
+complex	I-PRGE
+.	O
+
+To	O
+this	O
+end	O
+,	O
+we	O
+deleted	O
+the	O
+nonessential	O
+group	O
+-	O
+specific	O
+accessory	O
+genes	O
+3	O
+and	O
+/	O
+or	O
+5	O
+in	O
+the	O
+IBV	B-SPEC
+genome	O
+by	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+and	O
+selected	O
+the	O
+recombinant	O
+viruses	B-SPEC
+in	O
+embryonated	O
+eggs	O
+.	O
+
+After	O
+homologous	O
+challenge	O
+with	O
+the	O
+virulent	O
+IBV	B-SPEC
+strain	O
+M41	O
+,	O
+all	O
+vaccinated	O
+chickens	B-SPEC
+were	O
+protected	O
+against	O
+disease	O
+based	O
+on	O
+reduced	O
+loss	O
+of	O
+ciliary	O
+movement	B-PROC
+in	O
+the	O
+trachea	B-DISO
+compared	O
+to	O
+the	O
+non	O
+-	O
+vaccinated	O
+but	O
+challenged	O
+controls	O
+.	O
+
+Taken	O
+together	O
+,	O
+deletion	O
+of	O
+accessory	O
+genes	O
+3ab	O
+and	O
+/	O
+or	O
+5ab	O
+in	O
+IBV	B-SPEC
+resulted	O
+in	O
+mutant	B-DISO
+viruses	B-SPEC
+with	O
+an	O
+attenuated	O
+phenotype	O
+and	O
+the	O
+ability	O
+to	O
+induce	O
+protection	O
+in	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+review	O
+discusses	O
+the	O
+clinical	O
+challenges	O
+associated	O
+with	O
+ventilatory	O
+support	O
+and	O
+pharmacological	O
+interventions	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+determine	O
+if	O
+PEDV	B-SPEC
+could	O
+be	O
+detected	O
+in	O
+semen	B-ANAT
+from	O
+infected	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+boars	B-SPEC
+inoculated	O
+with	O
+a	O
+PEDV	B-SPEC
+US	O
+non	O
+-	O
+InDel	B-PROC
+strain	O
+suggesting	O
+venereal	O
+transmission	O
+may	O
+occur	O
+.	O
+
+Two	O
+boars	B-SPEC
+orally	B-ANAT
+inoculated	O
+with	O
+PEDV	B-SPEC
+showed	O
+clinical	O
+signs	O
+and	O
+virus	B-DISO
+shedding	I-DISO
+in	O
+feces	B-ANAT
+.	O
+
+Transient	O
+presence	O
+of	O
+the	O
+PEDV	B-SPEC
+genome	O
+was	O
+detected	O
+by	O
+RT	O
+-	O
+qPCR	O
+in	O
+the	O
+seminal	O
+(	O
+5	O
+.	O
+06	O
+×	O
+10	O
+
+Interestingly	O
+,	O
+we	O
+also	O
+found	O
+that	O
+both	O
+in	O
+isolation	O
+and	O
+during	O
+infection	B-DISO
+,	O
+4b	O
+interacted	O
+with	O
+α	B-PRGE
+-	I-PRGE
+karyopherin	I-PRGE
+proteins	I-PRGE
+in	O
+an	O
+NLS	B-DISO
+-	O
+dependent	O
+manner	O
+.	O
+
+The	O
+NGS	O
+-	O
+based	O
+CNV	B-SPEC
+detection	O
+method	O
+is	O
+useful	O
+for	O
+comprehensive	O
+screening	O
+of	O
+CNVs	O
+,	O
+and	O
+our	O
+results	O
+revealed	O
+that	O
+,	O
+for	O
+a	O
+certain	O
+proportion	O
+of	O
+cases	O
+,	O
+CNV	B-SPEC
+analysis	O
+is	O
+necessary	O
+for	O
+accurate	O
+genetic	O
+diagnosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Group	B-SPEC
+A	I-SPEC
+Streptococcus	I-SPEC
+(	O
+GAS	B-ENZY
+)	O
+are	O
+pathogenic	O
+bacteria	B-SPEC
+of	O
+the	O
+genus	B-SPEC
+Streptococcus	I-SPEC
+and	O
+cause	O
+severe	O
+invasive	O
+infections	B-DISO
+that	O
+comprise	O
+a	O
+wide	O
+range	O
+of	O
+diverse	O
+diseases	O
+,	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+renal	B-DISO
+failure	I-DISO
+,	O
+toxic	B-DISO
+shock	I-DISO
+-	O
+like	O
+syndrome	B-DISO
+,	I-DISO
+sepsis	I-DISO
+,	O
+cellulitis	B-DISO
+and	O
+necrotizing	B-DISO
+fasciitis	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+pathogenic	O
+mechanisms	O
+underlying	O
+influenza	B-SPEC
+virus	I-SPEC
+-	O
+GAS	B-PRGE
+superinfection	B-DISO
+are	O
+not	O
+yet	O
+fully	O
+understood	O
+.	O
+
+The	O
+present	O
+review	O
+describes	O
+the	O
+current	O
+knowledge	O
+about	O
+invasive	O
+GAS	O
+infections	B-DISO
+by	O
+superinfection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Hepatitis	B-DISO
+E	I-DISO
+virus	I-SPEC
+seroprevalence	O
+,	O
+seroincidence	O
+and	O
+seroreversion	O
+in	O
+the	O
+German	O
+adult	O
+population	O
+.	O
+
+We	O
+measured	O
+anti	B-PRGE
+-	I-PRGE
+HEV	I-PRGE
+IgG	I-PRGE
+prevalence	O
+in	O
+10	O
+407	O
+adults	O
+participating	O
+in	O
+two	O
+linked	O
+,	O
+population	O
+-	O
+representative	O
+serosurveys	O
+(	O
+total	O
+n	O
+=	O
+12	O
+971	O
+)	O
+conducted	O
+in	O
+1998	O
+and	O
+2010	O
+.	O
+
+On	O
+day	O
+post	O
+-	O
+inoculation	O
+(	O
+dpi	O
+)	O
+0	O
+,	O
+PEDV	B-SPEC
+pigs	B-SPEC
+were	O
+inoculated	O
+via	O
+intragastric	O
+gavage	O
+with	O
+PEDV	B-SPEC
+isolate	O
+(	O
+USA	O
+/	O
+Iowa	O
+/	O
+18984	O
+/	O
+2013	O
+).	O
+
+Markers	O
+of	O
+muscle	B-ANAT
+proteolysis	B-PROC
+were	O
+not	O
+different	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+)	O
+between	O
+treatments	O
+within	O
+dpi	O
+;	O
+however	O
+,	O
+at	O
+dpi	B-PRGE
+5	I-PRGE
+,	O
+20S	B-COMP
+proteasome	I-COMP
+activity	O
+was	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+longissimus	B-ANAT
+dorsi	O
+of	O
+PEDV	B-SPEC
+pigs	B-SPEC
+compared	O
+with	O
+Control	O
+pigs	B-SPEC
+.	O
+
+This	O
+study	O
+provides	O
+insight	O
+into	O
+the	O
+effects	O
+of	O
+an	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+on	O
+postabsorptive	O
+metabolism	B-PROC
+in	O
+nursery	O
+pigs	B-SPEC
+.	O
+
+The	O
+sequence	O
+from	O
+the	O
+PED	O
+-	O
+outbreak	O
+in	O
+Ecuador	O
+was	O
+grouped	O
+into	O
+the	O
+clade	O
+II	O
+of	O
+PEDV	B-SPEC
+genogroup	O
+2a	O
+together	O
+with	O
+other	O
+sequences	O
+of	O
+isolates	O
+from	O
+Mexico	O
+,	O
+Canada	O
+,	O
+and	O
+United	O
+States	O
+.	O
+
+A	O
+phage	O
+display	O
+library	O
+of	O
+specific	O
+nano	O
+-	O
+antibodies	B-COMP
+against	O
+the	O
+MERS	O
+-	O
+CoV	O
+were	O
+obtained	O
+and	O
+used	O
+to	O
+screen	O
+and	O
+characterize	O
+the	O
+nano	O
+-	O
+antibodies	B-COMP
+.	O
+
+The	O
+majority	O
+of	O
+cases	O
+occurred	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+and	O
+the	O
+disease	O
+carries	O
+a	O
+high	O
+case	O
+fatality	O
+rate	O
+.	O
+
+Two	O
+patients	O
+received	O
+ribavirin	B-CHED
+and	O
+IFN	B-PRGE
+-	I-PRGE
+a2b	I-PRGE
+in	O
+addition	O
+to	O
+supportive	O
+management	O
+.	O
+
+To	O
+establish	O
+productive	O
+infection	B-DISO
+,	O
+viruses	B-SPEC
+must	O
+first	O
+circumvent	O
+the	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+stimulated	O
+epidermal	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+receptor	I-PRGE
+(	O
+EGFR	B-FUNC
+)	O
+activation	O
+,	O
+which	O
+has	O
+been	O
+linked	O
+to	O
+not	O
+only	O
+anticancer	O
+therapeutics	O
+,	O
+but	O
+also	O
+antiviral	B-CHED
+signaling	B-PROC
+.	O
+
+One	O
+reported	O
+case	O
+of	O
+severe	O
+invasive	O
+pneumococcal	O
+disease	O
+in	O
+a	O
+68	O
+year	O
+old	O
+female	O
+,	O
+that	O
+presented	O
+with	O
+Austrian	O
+'	O
+s	O
+triad	B-COMP
+of	O
+meningitis	B-DISO
+,	O
+pneumonia	B-DISO
+and	O
+endocarditis	B-DISO
+,	O
+and	O
+progressed	O
+to	O
+develop	O
+Guillain	B-DISO
+Barre	I-DISO
+syndrome	I-DISO
+,	O
+an	O
+association	O
+never	O
+been	O
+documented	O
+before	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+13	O
+year	O
+old	O
+male	O
+,	O
+presented	O
+with	O
+hypoactivity	B-DISO
+and	O
+inability	O
+to	O
+bare	O
+his	O
+own	O
+weight	O
+,	O
+developed	O
+septic	B-DISO
+shock	I-DISO
+due	O
+to	O
+pneumococcus	O
+with	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+,	O
+and	O
+was	O
+found	O
+to	O
+have	O
+neurological	O
+findings	O
+of	O
+Guillain	B-DISO
+-	I-DISO
+Barre	I-DISO
+Syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+a	O
+case	O
+of	O
+hemophagocytic	O
+lymphohistiocytosis	O
+(	O
+HLH	B-DISO
+)	O
+with	O
+severe	O
+pulmonary	B-DISO
+complication	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+hospitalized	O
+in	O
+our	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+in	O
+2014	O
+;	O
+distinctive	O
+trait	O
+of	O
+this	O
+case	O
+has	O
+been	O
+the	O
+challenging	O
+diagnosis	O
+,	O
+with	O
+a	O
+bone	B-ANAT
+marrow	I-ANAT
+biopsy	O
+always	O
+negative	O
+,	O
+the	O
+severe	O
+pulmonary	B-DISO
+complication	I-DISO
+with	O
+ARDS	B-DISO
+and	O
+severe	O
+pulmonary	B-DISO
+hypertension	I-DISO
+,	O
+and	O
+the	O
+ferritin	B-PRGE
+temporal	O
+kinetics	O
+that	O
+precisely	O
+followed	O
+the	O
+clinical	O
+course	O
+of	O
+disease	O
+.	O
+
+A	O
+32	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+from	O
+the	O
+Philippines	O
+first	O
+diagnosed	O
+with	O
+upper	O
+airway	B-ANAT
+infection	B-DISO
+,	O
+was	O
+subsequently	O
+hospitalized	O
+in	O
+infectious	B-DISO
+disease	I-DISO
+department	O
+and	O
+treated	O
+for	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+.	O
+
+Severe	O
+infections	B-DISO
+were	O
+reported	O
+in	O
+19	O
+patients	O
+,	O
+11	O
+of	O
+which	O
+were	O
+fatal	O
+,	O
+Legionela	O
+pneumophila	O
+,	O
+rhinovirus	B-SPEC
+,	O
+HMPV	B-SPEC
+and	O
+RSV	B-SPEC
+associated	O
+with	O
+these	O
+fatalities	O
+.	O
+
+These	O
+data	O
+provides	O
+information	O
+about	O
+the	O
+circulating	O
+viruses	B-SPEC
+in	O
+ECC	O
+and	O
+highlights	O
+the	O
+importance	O
+of	O
+searching	O
+both	O
+viruses	B-SPEC
+and	O
+atypical	O
+bacteria	B-SPEC
+in	O
+severe	O
+ARI	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Swine	B-SPEC
+enteric	O
+coronaviruses	O
+,	O
+including	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+),	O
+have	O
+emerged	O
+and	O
+spread	O
+throughout	O
+the	O
+North	O
+American	O
+swine	B-SPEC
+industry	O
+over	O
+the	O
+last	O
+four	O
+years	O
+.	O
+
+Similar	O
+to	O
+other	O
+enteric	O
+coronaviruses	O
+,	O
+such	O
+as	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+these	O
+emerging	O
+swine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+diseases	O
+(	O
+SECD	O
+)	O
+are	O
+age	O
+-	O
+dependent	O
+,	O
+with	O
+high	O
+morbidity	O
+and	O
+mortality	O
+in	O
+neonatal	O
+pigs	B-SPEC
+.	O
+
+Since	O
+the	O
+introduction	O
+of	O
+SECD	O
+,	O
+research	O
+has	O
+focused	O
+on	O
+investigating	O
+viral	B-DISO
+pathogenesis	I-DISO
+through	O
+experimental	O
+inoculation	O
+,	O
+increasing	O
+maternal	O
+antibody	B-COMP
+for	O
+neonatal	O
+protection	O
+,	O
+understanding	O
+transmission	O
+risks	O
+through	O
+feed	O
+and	O
+transportation	O
+,	O
+and	O
+outlining	O
+the	O
+importance	O
+of	O
+biosecurity	O
+in	O
+preventing	O
+SECD	O
+introduction	O
+and	O
+spread	O
+.	O
+
+This	O
+review	O
+serves	O
+to	O
+describe	O
+the	O
+current	O
+knowledge	O
+of	O
+SECD	O
+and	O
+the	O
+characteristics	O
+of	O
+these	O
+viruses	B-SPEC
+which	O
+provide	O
+both	O
+opportunities	O
+and	O
+challenges	O
+for	O
+long	O
+-	O
+term	O
+disease	O
+control	O
+and	O
+potential	O
+eradication	O
+from	O
+the	O
+US	O
+swine	B-SPEC
+population	O
+.	O
+
+Since	O
+the	O
+late	O
+1990	O
+'	O
+s	O
+,	O
+live	O
+vaccines	O
+based	O
+on	O
+genogroup	O
+1	O
+virus	B-SPEC
+have	O
+been	O
+used	O
+in	O
+Japan	O
+,	O
+and	O
+a	O
+significant	O
+amount	O
+of	O
+the	O
+vaccine	O
+has	O
+been	O
+used	O
+even	O
+after	O
+new	O
+genogroups	O
+invaded	O
+in	O
+2013	O
+.	O
+
+The	O
+challenged	O
+piglets	O
+exhibited	O
+watery	B-DISO
+diarrhea	I-DISO
+with	O
+or	O
+without	O
+vaccination	O
+.	O
+
+BAIT	O
+syndrome	B-DISO
+is	O
+a	O
+new	O
+clinical	O
+condition	B-DISO
+characterised	O
+by	O
+severe	O
+transillumination	O
+of	O
+the	O
+iris	B-SPEC
+,	O
+acute	O
+onset	O
+of	O
+pigment	O
+dispersion	O
+in	O
+the	O
+anterior	B-ANAT
+chamber	I-ANAT
+,	O
+and	O
+a	O
+medial	O
+mydriatic	B-DISO
+pupil	I-DISO
+that	O
+is	O
+unresponsive	O
+or	O
+poorly	O
+responsive	O
+to	O
+light	O
+,	O
+due	O
+to	O
+a	O
+sphincter	B-ANAT
+paralysis	O
+.	O
+
+The	O
+case	O
+is	O
+presented	O
+of	O
+a	O
+53	O
+year	O
+-	O
+old	O
+woman	O
+,	O
+who	O
+,	O
+after	O
+being	O
+treated	O
+with	O
+moxifloxacin	B-CHED
+for	O
+an	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+developed	O
+a	O
+BAIT	O
+syndrome	B-DISO
+,	O
+which	O
+was	O
+initially	O
+diagnosed	O
+as	O
+acute	B-DISO
+anterior	I-DISO
+uveitis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+profile	O
+and	O
+promoter	O
+analysis	O
+of	O
+HEPIS	O
+.	O
+
+Approximately	O
+one	O
+third	O
+of	O
+severe	O
+pancreatitis	B-DISO
+patients	O
+develop	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+that	O
+account	O
+for	O
+60	O
+%	O
+of	O
+all	O
+deaths	B-PROC
+within	O
+the	O
+first	O
+week	O
+.	O
+
+The	O
+major	O
+causes	O
+of	O
+ALI	O
+and	O
+ARDS	B-DISO
+are	O
+sepsis	B-DISO
+,	O
+trauma	O
+,	O
+aspiration	B-DISO
+,	O
+multiple	O
+blood	B-ANAT
+transfusion	O
+,	O
+and	O
+most	O
+importantly	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+This	O
+study	O
+tested	O
+the	O
+hypothesis	O
+that	O
+treatment	O
+with	O
+simvastatin	B-CHED
+would	O
+improve	O
+clinical	O
+outcomes	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+study	O
+was	O
+completed	O
+when	O
+540	O
+patients	O
+were	O
+recruited	O
+with	O
+259	O
+patients	O
+allocated	O
+to	O
+simvastatin	B-CHED
+and	O
+281	O
+patients	O
+to	O
+placebo	O
+,	O
+with	O
+258	O
+patients	O
+in	O
+the	O
+simvastatin	B-CHED
+group	O
+and	O
+279	O
+patients	O
+in	O
+the	O
+placebo	O
+group	O
+included	O
+in	O
+the	O
+analysis	O
+of	O
+the	O
+primary	O
+outcome	O
+.	O
+
+The	O
+heterogenous	O
+cohort	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+was	O
+an	O
+attempt	O
+to	O
+ensure	O
+that	O
+our	O
+findings	O
+would	O
+be	O
+generalisable	O
+;	O
+however	O
+,	O
+it	O
+may	O
+be	O
+more	O
+appropriate	O
+to	O
+target	O
+potential	O
+therapies	O
+based	O
+on	O
+their	O
+proposed	O
+biological	O
+mechanism	O
+for	O
+a	O
+specific	O
+population	O
+of	O
+patients	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+Health	O
+and	O
+Social	O
+Care	O
+Research	O
+and	O
+Development	B-PROC
+division	O
+of	O
+the	O
+Public	O
+Health	O
+Agency	O
+in	O
+Northern	O
+Ireland	O
+,	O
+the	O
+Intensive	O
+Care	O
+Society	O
+of	O
+Ireland	O
+and	O
+REVIVE	O
+provided	O
+additional	O
+funding	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+recent	O
+years	O
+,	O
+there	O
+have	O
+been	O
+increasing	O
+numbers	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+that	O
+spread	O
+rapidly	O
+to	O
+population	O
+centers	O
+resulting	O
+from	O
+global	O
+travel	O
+,	O
+population	O
+vulnerabilities	O
+,	O
+environmental	O
+factors	O
+,	O
+and	O
+ecological	O
+disasters	O
+such	O
+as	O
+floods	O
+and	O
+earthquakes	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+OC43	O
+infection	B-DISO
+causes	O
+severe	O
+pneumonia	B-DISO
+in	O
+patients	O
+presenting	O
+with	O
+comorbidities	O
+,	O
+but	O
+clinical	O
+signs	O
+alone	O
+do	O
+not	O
+allow	O
+for	O
+viral	O
+identification	O
+.	O
+
+To	O
+analyze	O
+acute	O
+manifestations	O
+of	O
+Coronavirus	B-SPEC
+OC43	O
+infections	B-DISO
+and	O
+outcomes	O
+of	O
+patients	O
+admitted	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+).	O
+
+was	O
+42	O
+[	O
+28	O
+;	O
+53	O
+],	O
+pneumonia	B-DISO
+severity	O
+index	O
+159	O
+[	O
+139	O
+;	O
+182	O
+]	O
+vs	O
+73	O
+[	O
+40	O
+.	O
+5	O
+;	O
+107	O
+]	O
+for	O
+patients	O
+in	O
+medical	O
+wards	O
+,	O
+and	O
+43	O
+%	O
+required	O
+mechanical	O
+ventilation	O
+.	O
+
+As	O
+for	O
+MERS	O
+Co	O
+-	O
+V	O
+infections	B-DISO
+,	O
+underlying	O
+comorbidities	O
+impacted	O
+the	O
+clinical	O
+outcomes	O
+of	O
+OC43	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Epidemiological	O
+studies	O
+on	O
+obstructive	O
+sleep	O
+apnoea	O
+syndrome	O
+(	O
+OSAS	B-DISO
+)	O
+in	O
+Asia	O
+,	O
+South	O
+East	O
+Asia	O
+in	O
+particular	O
+,	O
+are	O
+few	O
+.	O
+
+Anonymized	O
+datasets	O
+from	O
+all	O
+pig	B-SPEC
+farms	O
+were	O
+provided	O
+by	O
+Kagoshima	O
+(	O
+709	O
+farms	O
+)	O
+and	O
+Miyazaki	O
+Prefectures	O
+(	O
+506	O
+farms	O
+).	O
+
+TITLE	O
+:	O
+Investigation	O
+of	O
+three	O
+outbreaks	O
+of	O
+Porcine	B-SPEC
+Epidemic	B-DISO
+Diarrhea	I-DISO
+in	O
+Germany	O
+in	O
+2016	O
+demonstrates	O
+age	O
+dependent	O
+differences	O
+in	O
+the	O
+development	O
+of	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+.	O
+
+Antibodies	B-COMP
+were	O
+detectable	O
+in	O
+all	O
+fattening	O
+pigs	B-SPEC
+(	O
+100	O
+%)	O
+within	O
+10	O
+days	O
+after	O
+the	O
+occurrence	O
+of	O
+first	O
+clinical	O
+signs	O
+and	O
+remained	O
+detectable	O
+for	O
+about	O
+two	O
+months	O
+at	O
+least	O
+in	O
+20	O
+.	O
+6	O
+%	O
+(	O
+farm	O
+1	O
+)	O
+and	O
+45	O
+.	O
+7	O
+%	O
+(	O
+farm	O
+2	O
+)	O
+of	O
+the	O
+animals	B-SPEC
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+Respiratory	O
+Viruses	B-SPEC
+in	O
+Children	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+an	O
+enveloped	O
+RNA	O
+virus	B-SPEC
+that	O
+causes	O
+deformities	B-DISO
+in	O
+eggshells	O
+.	O
+
+Then	O
+,	O
+the	O
+effects	O
+of	O
+PGE2	B-CHED
+on	O
+the	O
+expression	B-PROC
+of	O
+innate	O
+antiviral	B-CHED
+factors	O
+in	O
+cultured	O
+uterine	B-ANAT
+mucosal	B-ANAT
+cells	B-COMP
+were	O
+examined	O
+.	O
+
+The	O
+number	O
+of	O
+AvBD2	O
+-	O
+positive	O
+cells	B-COMP
+in	O
+the	O
+mucosa	B-ANAT
+also	O
+increased	O
+in	O
+response	O
+to	O
+aIBV	O
+.	O
+
+Both	O
+the	O
+1	O
+:	O
+100	O
+and	O
+1	O
+:	O
+600	O
+dilutions	O
+of	O
+peroxygen	O
+-	O
+based	O
+disinfectant	B-CHED
+successfully	O
+inactivated	O
+PEDV	B-SPEC
+under	O
+the	O
+conditions	O
+of	O
+this	O
+study	O
+.	O
+
+Genome	O
+-	O
+wide	O
+analysis	O
+of	O
+differentially	O
+expressed	B-PROC
+genes	O
+(	O
+DEGs	O
+)	O
+was	O
+performed	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+post	O
+-	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Although	O
+most	O
+of	O
+the	O
+IFN	B-PRGE
+-	O
+regulatory	O
+and	O
+-	O
+related	O
+genes	O
+evaluated	O
+in	O
+this	O
+study	O
+were	O
+either	O
+down	O
+-	O
+regulated	O
+or	O
+remained	O
+unchanged	O
+,	O
+IL11	B-PRGE
+behaved	O
+significantly	O
+up	O
+-	O
+regulated	O
+,	O
+with	O
+the	O
+peak	O
+at	O
+16	O
+hpi	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+disease	I-DISO
+epidemics	O
+match	O
+wars	O
+and	O
+natural	O
+disasters	O
+in	O
+their	O
+capacity	O
+to	O
+threaten	O
+lives	O
+and	O
+damage	O
+economies	O
+.	O
+
+In	O
+addition	O
+to	O
+causing	O
+immense	O
+human	B-SPEC
+suffering	B-DISO
+,	O
+these	O
+epidemics	O
+particularly	O
+affect	O
+low	O
+-	O
+and	O
+middle	O
+-	O
+income	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+A	O
+retrospective	O
+study	O
+of	O
+the	O
+neuropathology	B-DISO
+and	O
+diagnosis	O
+of	O
+naturally	O
+occurring	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+Fresh	B-ANAT
+tissue	I-ANAT
+samples	O
+were	O
+submitted	O
+for	O
+fluorescent	O
+antibody	B-COMP
+testing	O
+(	O
+FAT	O
+)	O
+after	O
+autopsy	O
+in	O
+17	O
+cases	O
+,	O
+and	O
+positive	O
+results	O
+were	O
+found	O
+in	O
+only	O
+7	O
+cases	O
+.	O
+
+To	O
+determine	O
+the	O
+prevalence	O
+and	O
+the	O
+molecular	O
+characteristics	O
+of	O
+common	O
+PEDV	B-SPEC
+strains	O
+in	O
+China	O
+,	O
+1272	O
+faeces	B-ANAT
+and	O
+small	B-ANAT
+intestine	I-ANAT
+samples	O
+in	O
+pigs	B-SPEC
+were	O
+collected	O
+from	O
+17	O
+provinces	O
+and	O
+inspected	O
+for	O
+PEDV	B-SPEC
+;	O
+the	O
+full	O
+-	O
+length	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+of	O
+18	O
+detected	O
+PEDV	B-SPEC
+strains	O
+collected	O
+from	O
+five	O
+eastern	O
+provinces	O
+were	O
+sequenced	O
+and	O
+analysed	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+an	O
+epidemic	O
+of	O
+a	O
+novel	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+many	O
+healthcare	O
+workers	O
+suffer	B-DISO
+from	O
+mental	O
+health	O
+problems	O
+.	O
+
+Studies	O
+in	O
+animal	B-SPEC
+models	O
+suggest	O
+that	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+induces	O
+a	O
+strong	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+which	O
+may	O
+be	O
+related	O
+to	O
+the	O
+severity	O
+of	O
+disease	O
+.	O
+
+Data	O
+showing	O
+the	O
+cytokine	O
+profiles	O
+in	O
+humans	B-SPEC
+during	O
+the	O
+acute	O
+phase	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+are	O
+limited	O
+.	O
+
+Neutrophil	B-ANAT
+extracellular	B-COMP
+traps	B-DISO
+(	O
+NETs	B-DISO
+)	O
+have	O
+been	O
+proposed	O
+as	O
+an	O
+innate	O
+defense	O
+mechanism	O
+responsible	O
+for	O
+pathogen	O
+clearance	O
+,	O
+but	O
+there	O
+are	O
+concerns	O
+that	O
+NETs	B-DISO
+may	O
+induce	O
+collateral	B-ANAT
+damage	O
+to	O
+host	B-COMP
+tissues	B-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+detected	O
+NETs	O
+in	O
+abundance	O
+in	O
+mouse	B-SPEC
+models	O
+of	O
+severe	O
+bacterial	B-DISO
+pneumonia	I-DISO
+/	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+in	O
+human	B-SPEC
+subjects	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+from	O
+pneumonia	B-DISO
+or	O
+sepsis	B-DISO
+.	O
+
+After	O
+immunization	O
+,	O
+significantly	O
+higher	O
+levels	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+PEDV	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+antibodies	B-COMP
+with	O
+PEDV	B-SPEC
+neutralizing	O
+activity	O
+in	O
+the	O
+sera	B-COMP
+and	O
+mucosal	B-ANAT
+sIgA	B-PRGE
+antibodies	B-COMP
+in	O
+the	O
+tractus	O
+genitalis	O
+,	O
+intestinal	B-ANAT
+mucus	B-ANAT
+,	O
+and	O
+stools	B-ANAT
+were	O
+detected	O
+in	O
+mice	B-SPEC
+orally	B-ANAT
+administered	O
+with	O
+the	O
+recombinant	O
+strain	O
+pPG	O
+-	O
+COE	O
+-	O
+Col	B-PRGE
+-	O
+DCpep	O
+/	O
+L393	O
+,	O
+which	O
+expressed	B-PROC
+DCpep	O
+and	O
+Col	O
+targeting	B-PROC
+ligands	O
+fused	O
+with	O
+the	O
+PEDV	B-PRGE
+COE	I-PRGE
+antigen	B-CHED
+,	O
+compared	O
+to	O
+mice	B-SPEC
+orally	B-ANAT
+immunized	O
+with	O
+the	O
+recombinant	O
+strain	O
+pPG	B-CHED
+-	O
+COE	O
+/	O
+L393	O
+without	O
+the	O
+DCpep	O
+and	O
+Col	O
+targeting	B-PROC
+ligands	O
+.	O
+
+RESULTS	O
+:	O
+After	O
+immunization	O
+,	O
+significantly	O
+higher	O
+levels	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+PEDV	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+antibodies	B-COMP
+with	O
+PEDV	B-SPEC
+neutralizing	O
+activity	O
+in	O
+the	O
+sera	B-COMP
+and	O
+mucosal	B-ANAT
+sIgA	B-PRGE
+antibodies	B-COMP
+in	O
+the	O
+tractus	O
+genitalis	O
+,	O
+intestinal	B-ANAT
+mucus	B-ANAT
+,	O
+and	O
+stools	B-ANAT
+were	O
+detected	O
+in	O
+mice	B-SPEC
+orally	B-ANAT
+administered	O
+with	O
+the	O
+recombinant	O
+strain	O
+pPG	B-CHED
+-	O
+COE	O
+-	O
+Col	B-PRGE
+-	O
+DCpep	O
+/	O
+L393	O
+,	O
+which	O
+expressed	B-PROC
+DCpep	O
+and	O
+Col	O
+targeting	B-PROC
+ligands	O
+fused	O
+with	O
+the	O
+PEDV	B-PRGE
+COE	I-PRGE
+antigen	B-CHED
+,	O
+compared	O
+to	O
+mice	B-SPEC
+orally	B-ANAT
+immunized	O
+with	O
+the	O
+recombinant	O
+strain	O
+pPG	B-CHED
+-	O
+COE	O
+/	O
+L393	O
+without	O
+the	O
+DCpep	O
+and	O
+Col	O
+targeting	B-PROC
+ligands	O
+.	O
+
+Moreover	O
+,	O
+in	O
+response	O
+to	O
+restimulation	O
+with	O
+the	O
+PEDV	B-PRGE
+COE	I-PRGE
+antigen	B-CHED
+in	O
+vitro	O
+,	O
+a	O
+significant	O
+difference	O
+in	O
+splenocyte	B-ANAT
+proliferation	B-DISO
+response	O
+and	O
+Th2	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+cytokine	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+4	I-PRGE
+level	O
+was	O
+observed	O
+in	O
+the	O
+group	O
+of	O
+mice	B-SPEC
+orally	B-ANAT
+immunized	O
+with	O
+pPG	B-PRGE
+-	I-PRGE
+COE	I-PRGE
+-	I-PRGE
+Col	I-PRGE
+-	I-PRGE
+DCpep	I-PRGE
+/	O
+L393	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+compared	O
+to	O
+the	O
+groups	O
+of	O
+mice	B-SPEC
+that	O
+received	O
+pPG	B-PRGE
+-	I-PRGE
+COE	I-PRGE
+-	I-PRGE
+Col	I-PRGE
+/	O
+L393	O
+and	O
+pPG	B-PRGE
+-	I-PRGE
+COE	I-PRGE
+-	I-PRGE
+DCpep	I-PRGE
+/	I-PRGE
+L393	I-PRGE
+,	O
+respectively	O
+.	O
+
+As	O
+one	O
+of	O
+the	O
+key	O
+component	O
+of	O
+the	O
+avian	B-SPEC
+immune	B-ANAT
+system	I-ANAT
+,	O
+the	O
+innate	O
+immune	B-ANAT
+system	I-ANAT
+has	O
+a	O
+crucial	O
+role	O
+in	O
+limiting	O
+virus	B-PROC
+replication	I-PROC
+at	O
+the	O
+initial	O
+stage	O
+of	O
+the	O
+infection	B-DISO
+.	O
+
+However	O
+,	O
+only	O
+the	O
+recruitment	B-DISO
+of	O
+macrophages	B-ANAT
+in	O
+the	O
+lung	B-ANAT
+correlated	O
+with	O
+IBV	B-SPEC
+genome	O
+loads	O
+in	O
+this	O
+tissue	B-ANAT
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+present	O
+study	O
+demonstrates	O
+that	O
+recruitment	B-DISO
+of	O
+macrophages	B-ANAT
+and	O
+the	O
+production	O
+of	O
+IL	O
+-	O
+1β	O
+originating	O
+from	O
+macrophages	B-ANAT
+,	O
+as	O
+well	O
+as	O
+other	O
+sources	O
+,	O
+occur	O
+following	O
+IBV	B-SPEC
+infection	B-DISO
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+suggesting	O
+potential	O
+roles	O
+of	O
+these	O
+mediators	O
+in	O
+the	O
+host	B-COMP
+responses	O
+to	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+However	O
+,	O
+further	O
+studies	O
+are	O
+warranted	O
+to	O
+elucidate	O
+whether	O
+macrophages	B-ANAT
+and	O
+IL	O
+-	O
+1β	O
+are	O
+the	O
+causes	O
+of	O
+reduced	O
+IBV	B-SPEC
+genome	O
+loads	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+also	O
+to	O
+investigate	O
+whether	O
+immune	O
+mediators	O
+that	O
+were	O
+not	O
+measured	O
+in	O
+the	O
+current	O
+study	O
+were	O
+involved	O
+in	O
+reducing	O
+IBV	B-SPEC
+genome	O
+load	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+towards	O
+the	O
+end	O
+of	O
+the	O
+study	O
+.	O
+
+HCoVs	O
+are	O
+globally	O
+distributed	O
+and	O
+the	O
+predominant	O
+species	B-SPEC
+may	O
+vary	O
+by	O
+region	O
+or	O
+year	O
+.	O
+
+For	O
+a	O
+subset	O
+of	O
+HCoV	O
+positive	O
+submissions	O
+with	O
+age	O
+and	O
+sex	O
+of	O
+the	O
+patient	O
+available	O
+,	O
+we	O
+tested	O
+for	O
+differences	O
+in	O
+age	O
+and	O
+sex	O
+across	O
+the	O
+four	O
+HCoV	O
+species	O
+using	O
+Chi	B-CHED
+Square	O
+and	O
+Kruskal	O
+Wallace	O
+tests	O
+.	O
+
+This	O
+enteric	O
+virus	B-SPEC
+is	O
+transmitted	B-DISO
+via	O
+the	O
+feco	O
+-	O
+oral	B-ANAT
+route	O
+and	O
+horses	B-SPEC
+become	O
+infected	O
+by	O
+ingesting	O
+fecally	O
+contaminated	O
+feed	O
+and	O
+water	B-CHED
+.	O
+
+The	O
+severe	O
+pathophysiological	O
+changes	O
+in	O
+lung	B-ANAT
+parenchyma	I-ANAT
+and	O
+pulmonary	B-PROC
+circulation	B-PROC
+together	O
+with	O
+the	O
+effects	O
+of	O
+positive	O
+pressure	O
+ventilation	O
+profoundly	O
+affect	O
+heart	B-ANAT
+lung	I-ANAT
+interactions	O
+in	O
+ARDS	B-DISO
+.	O
+
+When	O
+severe	O
+,	O
+PVD	B-DISO
+can	O
+lead	O
+to	O
+RV	O
+failure	O
+which	O
+is	O
+associated	O
+to	O
+an	O
+increased	O
+mortality	O
+.	O
+
+In	O
+this	O
+review	O
+we	O
+will	O
+describe	O
+some	O
+pathophysiological	O
+aspects	O
+of	O
+heart	B-ANAT
+-	O
+lung	B-ANAT
+interactions	O
+during	O
+the	O
+ventilatory	O
+support	O
+of	O
+ARDS	B-DISO
+,	O
+its	O
+clinical	O
+assessment	O
+and	O
+discuss	O
+therapeutic	O
+interventions	O
+to	O
+prevent	O
+the	O
+occurrence	O
+and	O
+progression	O
+of	O
+PVD	B-DISO
+and	O
+RV	O
+failure	O
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+of	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+newly	O
+diagnosed	O
+acute	B-DISO
+myeloid	I-DISO
+leukemia	I-DISO
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+280	O
+patients	O
+with	O
+newly	O
+diagnosed	O
+AML	B-DISO
+in	O
+order	B-SPEC
+to	O
+describe	O
+the	O
+incidence	O
+,	O
+risk	O
+factors	O
+and	O
+early	O
+mortality	O
+associated	O
+with	O
+ARDS	B-DISO
+within	O
+15	O
+d	O
+.	O
+Univariate	O
+and	O
+then	O
+multivariate	O
+analysis	O
+were	O
+performed	O
+.	O
+
+TITLE	O
+:	O
+An	O
+Exploratory	O
+Reanalysis	O
+of	O
+the	O
+Randomized	O
+Trial	O
+on	O
+Efficacy	O
+of	O
+Corticosteroids	B-CHED
+as	O
+Rescue	O
+Therapy	O
+for	O
+the	O
+Late	O
+Phase	O
+of	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+.	O
+
+To	O
+explore	O
+this	O
+possibility	O
+,	O
+we	O
+investigated	O
+the	O
+timing	O
+that	O
+events	O
+occurred	O
+in	O
+each	O
+treatment	O
+arm	B-ANAT
+during	O
+active	O
+treatment	O
+intervention	O
+(	O
+efficacy	O
+)	O
+and	O
+after	O
+stopping	O
+therapy	O
+.	O
+
+Participants	O
+returning	O
+to	O
+mechanical	O
+ventilation	O
+without	O
+reinstitution	O
+of	O
+methylprednisolone	B-CHED
+had	O
+increased	O
+risk	O
+of	O
+ventilator	O
+dependence	B-DISO
+and	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+provides	O
+rescue	O
+treatment	O
+for	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+when	O
+conventional	O
+management	O
+fails	O
+.	O
+
+The	O
+injured	O
+lungs	B-ANAT
+may	O
+recover	B-PROC
+completely	O
+with	O
+effective	O
+ECMO	O
+therapy	O
+.	O
+
+He	O
+had	O
+skeletal	B-DISO
+dysplasia	I-DISO
+with	O
+metabolic	B-DISO
+bone	B-ANAT
+disease	I-DISO
+and	O
+episodes	O
+of	O
+hyperthermia	B-PROC
+with	O
+lactic	B-DISO
+acidosis	I-DISO
+.	O
+
+For	O
+the	O
+purpose	O
+of	O
+this	O
+study	O
+,	O
+only	O
+non	O
+-	O
+sleepy	O
+patients	O
+with	O
+moderate	O
+or	O
+severe	O
+OSA	B-DISO
+and	O
+randomized	O
+to	O
+receive	O
+CPAP	O
+treatment	O
+were	O
+analysed	O
+(	O
+n	O
+=	O
+357	O
+).	O
+
+According	O
+to	O
+the	O
+unadjusted	O
+analysis	O
+,	O
+higher	O
+apnoea	O
+-	O
+hypopnea	O
+index	O
+(	O
+AHI	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+oxygen	B-CHED
+desaturation	O
+index	O
+(	O
+ODI	O
+)	O
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+)	O
+were	O
+associated	O
+with	O
+a	O
+lower	O
+risk	O
+of	O
+non	O
+-	O
+compliance	O
+.	O
+
+It	O
+also	O
+showed	O
+a	O
+significant	O
+interaction	O
+between	O
+ACS	B-FUNC
+history	O
+and	O
+age	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0131	O
+),	O
+such	O
+that	O
+young	O
+patients	O
+with	O
+their	O
+first	O
+ACS	B-FUNC
+showed	O
+significantly	O
+lower	O
+odds	O
+of	O
+CPAP	O
+non	O
+-	O
+compliance	O
+than	O
+patients	O
+with	O
+recurrent	O
+ACS	B-FUNC
+and	O
+significantly	O
+lower	O
+odds	O
+of	O
+CPAP	O
+non	O
+-	O
+compliance	O
+were	O
+associated	O
+with	O
+ageing	B-PROC
+only	O
+in	O
+patients	O
+with	O
+recurrent	O
+ACS	B-FUNC
+.	O
+
+TITLE	O
+:	O
+Differences	O
+in	O
+the	O
+intestinal	B-ANAT
+microbiota	B-SPEC
+between	O
+uninfected	O
+piglets	O
+and	O
+piglets	O
+infected	O
+with	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+.	O
+
+Additionally	O
+,	O
+the	O
+composition	O
+of	O
+the	O
+small	B-ANAT
+intestinal	I-ANAT
+microbiota	B-SPEC
+of	O
+sucking	B-PROC
+piglets	O
+infected	O
+with	O
+PEDV	B-SPEC
+showed	O
+marked	O
+differences	O
+from	O
+that	O
+of	O
+the	O
+uninfected	O
+piglets	O
+.	O
+
+The	O
+presence	O
+of	O
+a	O
+copathogen	O
+and	O
+host	B-COMP
+factors	O
+,	O
+including	O
+an	O
+immunocompromised	O
+state	O
+,	O
+were	O
+associated	O
+with	O
+increased	O
+risk	O
+for	O
+severe	O
+LRTD	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+median	O
+ages	O
+of	O
+85	O
+immunocompromised	O
+and	O
+1152	O
+nonimmunocompromised	O
+children	O
+with	O
+HCoV	O
+infection	B-DISO
+were	O
+6	O
+.	O
+3	O
+and	O
+1	O
+.	O
+6	O
+years	O
+,	O
+respectively	O
+.	O
+
+Due	O
+to	O
+his	O
+ineligibility	O
+for	O
+evacuation	O
+and	O
+worsening	O
+ARDS	B-DISO
+,	O
+despite	O
+5	O
+d	O
+of	O
+conventional	O
+ventilation	O
+strategies	O
+,	O
+he	O
+was	O
+started	O
+on	O
+VV	O
+-	O
+ECMO	O
+.	O
+
+CONCLUSIONS	O
+:	O
+As	O
+future	O
+advancements	O
+are	O
+sought	O
+,	O
+VV	O
+-	O
+ECMO	O
+may	O
+become	O
+a	O
+consideration	O
+for	O
+casualties	O
+with	O
+severe	O
+ARDS	B-DISO
+at	O
+the	O
+point	O
+of	O
+injury	O
+and	O
+at	O
+lower	O
+echelons	O
+of	O
+military	O
+care	O
+.	O
+
+In	O
+vitro	O
+,	O
+pneumolysin	O
+enhanced	O
+endothelial	B-ANAT
+angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+release	I-PRGE
+,	O
+angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+increased	O
+endothelial	B-ANAT
+permeability	O
+,	O
+and	O
+angiopoietin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+reduced	O
+pneumolysin	O
+-	O
+evoked	O
+endothelial	B-ANAT
+permeability	O
+.	O
+
+Ventilated	O
+and	O
+perfused	O
+lungs	B-ANAT
+of	O
+mice	B-SPEC
+with	O
+angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+knockdown	O
+showed	O
+reduced	O
+permeability	O
+on	O
+pneumolysin	O
+stimulation	O
+.	O
+
+These	O
+new	O
+findings	O
+support	O
+a	O
+restrictive	O
+approach	O
+to	O
+antibiotic	B-CHED
+prescribing	O
+for	O
+LRTI	B-DISO
+and	O
+the	O
+use	O
+of	O
+first	O
+-	O
+line	O
+,	O
+narrow	O
+-	O
+spectrum	O
+agents	O
+in	O
+primary	O
+care	O
+.	O
+
+Both	O
+vaccines	O
+showed	O
+similar	O
+ability	O
+to	O
+protect	O
+infected	O
+chickens	B-SPEC
+from	O
+clinical	O
+signs	O
+,	O
+although	O
+ts	O
+-	O
+11	O
+performed	O
+slightly	O
+better	O
+.	O
+
+Despite	O
+the	O
+lower	O
+protection	O
+against	O
+clinical	O
+disease	O
+,	O
+6	O
+/	O
+85	O
+-	O
+vaccinated	O
+birds	B-SPEC
+had	O
+significantly	O
+(	O
+P	O
+≤	O
+0	O
+.	O
+05	O
+)	O
+lower	O
+tracheal	O
+lesion	O
+scores	O
+and	O
+mucosal	B-ANAT
+thickness	O
+at	O
+day	O
+28	O
+post	O
+-	O
+vaccination	O
+(	O
+7	O
+days	O
+post	O
+-	O
+challenge	O
+[	O
+dpc	B-CHED
+]	O
+with	O
+MG	O
+,	O
+2	O
+dpc	B-CHED
+IBV	B-SPEC
+)	O
+and	O
+day	O
+31	O
+post	O
+-	O
+vaccination	O
+(	O
+10	O
+dpc	B-CHED
+MG	O
+challenge	O
+,	O
+5	O
+dpc	B-CHED
+IBV	B-SPEC
+)	O
+compared	O
+to	O
+ts	O
+-	O
+11	O
+vaccinated	O
+birds	B-SPEC
+,	O
+but	O
+these	O
+difference	O
+was	O
+not	O
+significant	O
+at	O
+day	O
+33	O
+(	O
+12	O
+dpc	O
+MG	O
+,	O
+7	O
+dpc	B-CHED
+IBV	B-SPEC
+).	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+natural	O
+reservoirs	O
+for	O
+a	O
+variety	O
+of	O
+emerging	O
+viruses	O
+that	O
+cause	O
+significant	O
+disease	O
+in	O
+humans	B-SPEC
+and	O
+domestic	O
+animals	B-SPEC
+yet	O
+rarely	O
+cause	O
+clinical	O
+disease	O
+in	O
+bats	B-SPEC
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+highlight	O
+the	O
+current	O
+progress	O
+in	O
+understanding	O
+bat	B-ENZY
+-	O
+virus	B-SPEC
+interactions	O
+in	O
+bat	B-ENZY
+cell	B-ANAT
+line	I-ANAT
+systems	O
+and	O
+some	O
+of	O
+the	O
+challenges	O
+and	O
+limitations	O
+associated	O
+with	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+To	O
+determine	O
+the	O
+association	O
+between	O
+ARDS	B-DISO
+and	O
+increased	O
+CPP	O
+after	O
+TBI	O
+.	O
+
+Patients	O
+who	O
+developed	O
+ARDS	B-DISO
+had	O
+a	O
+higher	O
+ΔP	O
+(	O
+15	O
+mmHg	O
+[	O
+5	O
+]	O
+vs	O
+.	O
+12	O
+mmHg	O
+[	O
+4	O
+],	O
+p	O
+=	O
+0	O
+.	O
+016	O
+)	O
+and	O
+lower	O
+lung	B-PROC
+compliance	I-PROC
+(	O
+35	O
+ml	O
+/	O
+cmH2O	O
+[	O
+10	O
+]	O
+vs	O
+.	O
+49	O
+ml	O
+/	O
+cmH2O	O
+[	O
+18	O
+],	O
+p	O
+=	O
+0	O
+.	O
+024	O
+)	O
+versus	O
+those	O
+who	O
+did	O
+not	O
+.	O
+
+We	O
+did	O
+not	O
+observe	O
+an	O
+association	O
+between	O
+increased	O
+CPP	O
+and	O
+ARDS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+did	O
+not	O
+observe	O
+an	O
+association	O
+between	O
+increased	O
+CPP	O
+and	O
+ARDS	B-DISO
+.	O
+
+Interestingly	O
+,	O
+all	O
+MAstV5	O
+-	O
+positive	O
+samples	O
+derived	O
+from	O
+dogs	B-SPEC
+displaying	O
+clinical	O
+signs	O
+suggestive	O
+of	O
+gastroenteritis	B-DISO
+,	O
+other	O
+enteric	O
+viruses	B-SPEC
+were	O
+simultaneously	O
+detected	O
+(	O
+canine	O
+parvovirus	B-DISO
+,	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+canine	O
+coronavirus	B-SPEC
+,	O
+canine	B-SPEC
+adenovirus	I-SPEC
+and	O
+canine	O
+rotavirus	B-SPEC
+).	O
+
+He	O
+began	O
+to	O
+cry	O
+,	O
+with	O
+an	O
+increased	B-DISO
+respiratory	I-DISO
+rate	I-DISO
+of	O
+over	O
+40	O
+breaths	O
+per	O
+minute	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+HRs	B-DISO
+sequences	O
+were	O
+designed	O
+and	O
+connected	O
+with	O
+a	O
+flexible	O
+linker	O
+.	O
+
+Fourteen	O
+hydrophobic	O
+and	O
+three	O
+polar	O
+residues	O
+from	O
+each	O
+HR1	O
+peptide	B-CHED
+are	O
+packed	O
+in	O
+layers	B-ANAT
+at	O
+the	O
+coiled	O
+-	O
+coil	O
+interface	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+an	O
+inflammatory	O
+disease	O
+characterized	O
+by	O
+dysfunction	O
+of	O
+pulmonary	B-ANAT
+epithelial	O
+and	O
+capillary	B-ANAT
+endothelial	I-ANAT
+cells	I-ANAT
+,	O
+infiltration	B-DISO
+of	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+and	O
+neutrophils	B-ANAT
+,	O
+cell	B-COMP
+apoptosis	B-PATH
+,	O
+necroptosis	B-DISO
+,	O
+NETosis	O
+,	O
+and	O
+fibrosis	B-DISO
+.	O
+
+No	O
+gender	O
+difference	O
+related	O
+to	O
+infection	B-DISO
+was	O
+found	O
+at	O
+the	O
+sites	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+variant	O
+with	O
+a	O
+large	O
+spike	O
+gene	B-DISO
+deletion	I-DISO
+from	O
+a	O
+clinical	O
+swine	O
+sample	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Complete	O
+genome	O
+sequence	O
+analyses	O
+indicated	O
+this	O
+PEDV	B-SPEC
+variant	O
+was	O
+genetically	O
+similar	O
+to	O
+US	O
+non	O
+-	O
+S	O
+INDEL	B-PROC
+strain	O
+but	O
+had	O
+a	O
+continuous	O
+600	O
+-	O
+nt	O
+(	O
+200	O
+-	O
+aa	O
+)	O
+deletion	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+spike	O
+gene	O
+compared	O
+to	O
+non	O
+-	O
+S	O
+INDEL	B-PROC
+PEDVs	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+detecting	O
+PEDV	B-SPEC
+bearing	O
+large	O
+spike	O
+gene	B-DISO
+deletion	I-DISO
+in	O
+clinical	O
+swine	B-SPEC
+samples	O
+in	O
+the	O
+USA	O
+.	O
+
+A	O
+25	O
+-	O
+year	O
+-	O
+old	O
+pregnant	O
+woman	O
+was	O
+initiated	O
+with	O
+ECMO	O
+due	O
+to	O
+severe	O
+ARDS	B-DISO
+caused	O
+by	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Department	O
+of	O
+Health	O
+and	O
+Human	B-SPEC
+Services	O
+Framework	O
+for	O
+Guiding	O
+Funding	O
+Decisions	O
+about	O
+Proposed	O
+Research	O
+Involving	O
+Enhanced	O
+Potential	O
+Pandemic	O
+Pathogens	O
+(	O
+PPPs	O
+)	O
+contains	O
+a	O
+series	O
+of	O
+principles	O
+for	O
+governing	O
+the	O
+funding	O
+and	O
+conduct	B-PROC
+of	O
+gain	O
+-	O
+of	O
+-	O
+function	O
+(	O
+GOF	O
+)	O
+research	O
+resulting	O
+in	O
+the	O
+creation	O
+of	O
+PPPs	O
+.	O
+
+I	O
+then	O
+address	O
+some	O
+objections	O
+to	O
+this	O
+claim	O
+,	O
+and	O
+provide	O
+policy	O
+recommendations	O
+moving	B-PROC
+forward	O
+.	O
+
+TITLE	O
+:	O
+Duration	O
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Data	O
+from	O
+clinical	O
+,	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+suggest	O
+that	O
+virus	B-SPEC
+-	O
+induced	O
+cytokine	O
+dysregulation	O
+could	O
+be	O
+a	O
+contributory	O
+factor	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+human	B-SPEC
+H5N1	B-DISO
+disease	O
+.	O
+
+Our	O
+data	O
+reveals	O
+that	O
+two	O
+macrophage	B-ANAT
+populations	O
+corresponding	O
+to	O
+M1	O
+(	O
+classically	O
+activated	O
+)	O
+and	O
+M2	O
+(	O
+alternatively	O
+activated	O
+)	O
+macrophage	B-ANAT
+subtypes	O
+respond	O
+distinctly	O
+to	O
+H5N1	B-DISO
+virus	B-DISO
+infection	I-DISO
+when	O
+compared	O
+to	O
+H1N1	O
+virus	B-SPEC
+or	O
+mock	O
+infection	B-DISO
+,	O
+a	O
+distinction	O
+that	O
+could	O
+not	O
+be	O
+made	O
+from	O
+previous	O
+microarray	O
+studies	O
+.	O
+
+In	O
+particular	O
+,	O
+interferons	O
+,	O
+and	O
+interferon	B-PRGE
+-	O
+stimulated	O
+genes	O
+are	O
+broadly	O
+affected	O
+.	O
+
+Elevated	O
+levels	O
+of	O
+these	O
+suppressors	O
+could	O
+lead	O
+to	O
+the	O
+eventual	O
+suppression	B-DISO
+of	O
+cellular	B-COMP
+antiviral	B-CHED
+genes	O
+,	O
+contributing	O
+to	O
+pathophysiology	O
+of	O
+H5N1	B-DISO
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Some	O
+but	O
+not	O
+all	O
+of	O
+the	O
+Nidovirus	B-SPEC
+sg	O
+mRNAs	O
+also	O
+have	O
+a	O
+common	O
+5	O
+'	O
+leader	O
+sequence	O
+that	O
+is	O
+acquired	O
+by	O
+a	O
+discontinuous	O
+RNA	B-PROC
+synthesis	I-PROC
+mechanism	O
+regulated	O
+by	O
+multiple	O
+3	O
+'	O
+body	B-ANAT
+transcription	B-PROC
+regulating	O
+sequences	O
+(	O
+TRSs	O
+)	O
+and	O
+the	O
+5	O
+'	O
+leader	O
+TRS	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+Conserved	O
+Distal	O
+Lung	B-ANAT
+Regenerative	O
+Pathway	B-PROC
+in	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+.	O
+
+In	O
+addition	O
+,	O
+mirroring	O
+data	O
+from	O
+murine	B-SPEC
+models	O
+of	O
+lung	B-ANAT
+injury	O
+/	O
+regeneration	B-PROC
+,	O
+peribronchiolar	O
+basaloid	O
+pods	O
+(	O
+previously	O
+described	O
+as	O
+squamous	B-DISO
+metaplasia	I-DISO
+)	O
+and	O
+ciliated	O
+bronchiolarization	O
+were	O
+identified	O
+in	O
+these	O
+patients	O
+and	O
+in	O
+39	O
+%	O
+of	O
+57	O
+historical	O
+cases	O
+with	O
+diffuse	O
+alveolar	O
+damage	O
+.	O
+
+ABSTRACT	O
+:	O
+Practical	O
+relevance	O
+:	O
+Feline	O
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+infection	B-DISO
+is	O
+very	O
+common	O
+in	O
+cats	B-SPEC
+,	O
+usually	O
+causing	O
+only	O
+mild	O
+intestinal	B-ANAT
+signs	O
+such	O
+as	O
+diarrhoea	B-DISO
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+identify	O
+risk	O
+factors	O
+associated	O
+with	O
+exposure	O
+to	O
+BRD	O
+pathogens	O
+during	O
+the	O
+peri	O
+-	O
+weaning	B-PROC
+period	O
+(	O
+day	O
+(	O
+d	O
+)-	O
+14	O
+to	O
+d	O
+14	O
+relative	O
+to	O
+weaning	B-PROC
+at	O
+0	O
+)	O
+in	O
+dairy	O
+bull	O
+calves	O
+using	O
+serological	O
+responses	O
+to	O
+these	O
+pathogens	O
+as	O
+surrogate	O
+markers	O
+of	O
+exposure	O
+.	O
+
+Animals	B-SPEC
+with	O
+a	O
+high	O
+maximum	O
+respiratory	O
+score	O
+(≥	O
+8	O
+)	O
+recorded	O
+significant	O
+increases	O
+in	O
+H	B-SPEC
+.	I-SPEC
+somni	I-SPEC
+S	O
+/	O
+P	O
+during	O
+the	O
+peri	O
+-	O
+weaning	B-PROC
+period	O
+when	O
+compared	O
+to	O
+those	O
+with	O
+respiratory	O
+scores	O
+of	O
+≤	O
+3	O
+.	O
+
+Haptoglobin	B-PRGE
+levels	O
+of	O
+between	O
+1	O
+.	O
+32	O
+and	O
+1	O
+.	O
+60	O
+mg	O
+/	O
+ml	O
+at	O
+d	O
+-	O
+14	O
+were	O
+significantly	O
+associated	O
+with	O
+decreases	O
+in	O
+BHV	O
+-	O
+1	O
+S	O
+/	O
+N	O
+during	O
+the	O
+peri	O
+-	O
+weaning	B-PROC
+period	O
+.	O
+
+The	O
+significant	O
+associations	O
+between	O
+the	O
+pre	O
+-	O
+weaning	B-PROC
+levels	O
+of	O
+antibodies	B-COMP
+to	O
+certain	O
+BRD	O
+pathogens	O
+and	O
+changes	O
+in	O
+the	O
+levels	O
+of	O
+antibodies	B-COMP
+to	O
+the	O
+various	O
+pathogens	O
+during	O
+the	O
+peri	O
+-	O
+weaning	B-PROC
+period	O
+may	O
+reflect	O
+a	O
+cohort	O
+of	O
+possibly	O
+genetically	O
+linked	O
+'	O
+better	O
+responders	O
+'	O
+among	O
+the	O
+study	O
+population	O
+.	O
+
+Upper	B-ANAT
+arm	I-ANAT
+anthropometrics	O
+can	O
+provide	O
+a	O
+quick	O
+,	O
+non	O
+-	O
+invasive	O
+estimate	O
+of	O
+muscle	B-ANAT
+status	O
+,	O
+but	O
+its	O
+accuracy	O
+is	O
+unknown	O
+.	O
+
+Alternate	O
+screening	O
+measures	O
+should	O
+be	O
+evaluated	O
+in	O
+ARDS	B-DISO
+survivors	O
+.	O
+
+TITLE	O
+:	O
+Predictors	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+:	O
+a	O
+systematic	O
+review	O
+and	O
+meta	O
+-	O
+analysis	O
+.	O
+
+We	O
+searched	O
+the	O
+PubMed	O
+and	O
+Ovid	O
+MEDLINE	O
+databases	O
+with	O
+the	O
+search	O
+terms	O
+""""	O
+guillain	B-DISO
+barre	I-DISO
+syndrome	I-DISO
+""""	O
+OR	O
+""""	O
+acute	B-DISO
+inflammatory	I-DISO
+demyelinating	I-DISO
+polyneuropathy	I-DISO
+""""	O
+OR	O
+""""	O
+acute	O
+motor	O
+axonal	B-DISO
+neuropathy	I-DISO
+""""	O
+OR	O
+""""	O
+acute	O
+motor	O
+sensory	O
+axonal	B-DISO
+neuropathy	I-DISO
+""""	O
+AND	O
+""""	O
+respiratory	B-DISO
+failure	I-DISO
+""""	O
+OR	O
+""""	O
+mechanical	O
+ventilation	O
+"""."	O
+
+Facial	B-DISO
+weakness	I-DISO
+(	O
+OR	O
+,	O
+3	O
+.	O
+74	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+2	O
+.	O
+05	O
+-	O
+6	O
+.	O
+81	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+autonomic	B-DISO
+instability	I-DISO
+(	O
+OR	O
+,	O
+6	O
+.	O
+40	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+2	O
+.	O
+83	O
+-	O
+14	O
+.	O
+5	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+significantly	O
+more	O
+frequent	O
+in	O
+patients	O
+requiring	O
+intubation	O
+in	O
+our	O
+meta	B-SPEC
+-	O
+analyses	O
+;	O
+however	O
+,	O
+the	O
+differences	O
+were	O
+not	O
+statistically	O
+significant	O
+in	O
+individual	O
+multivariable	O
+analysis	O
+studies	O
+.	O
+
+Understanding	O
+the	O
+Latest	O
+Human	B-SPEC
+Coronavirus	I-SPEC
+Threat	O
+.	O
+
+In	O
+2012	O
+,	O
+a	O
+sixth	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+hCoV	O
+)	O
+was	O
+isolated	O
+from	O
+a	O
+patient	O
+presenting	O
+with	O
+severe	O
+respiratory	O
+illness	O
+.	O
+
+This	O
+review	O
+summarises	O
+the	O
+current	O
+understanding	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+with	O
+special	O
+reference	O
+to	O
+the	O
+(	O
+i	O
+)	O
+genome	O
+structure	O
+;	O
+(	O
+ii	O
+)	O
+clinical	O
+features	O
+;	O
+(	O
+iii	O
+)	O
+diagnosis	O
+of	O
+infection	B-DISO
+;	O
+and	O
+(	O
+iv	O
+)	O
+treatment	O
+and	O
+vaccine	O
+development	O
+.	O
+
+Since	O
+no	O
+drugs	O
+target	O
+VP24	O
+,	O
+the	O
+identification	O
+of	O
+molecules	O
+able	O
+to	O
+inhibit	O
+VP24	O
+,	O
+restoring	O
+and	O
+possibly	O
+enhancing	O
+the	O
+IFN	B-PRGE
+response	O
+,	O
+is	O
+a	O
+goal	O
+of	O
+concern	O
+.	O
+
+Cotransfection	O
+of	O
+cells	B-COMP
+with	O
+a	O
+plasmid	O
+expressing	O
+VP24	O
+cloned	O
+from	O
+a	O
+virus	B-SPEC
+isolated	O
+during	O
+the	O
+last	O
+2014	O
+outbreak	O
+led	O
+to	O
+the	O
+inhibition	B-PROC
+of	O
+ISRE	O
+transcription	B-PROC
+,	O
+quantified	O
+by	O
+a	O
+luminescent	O
+signal	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	O
+infectious	O
+bronchitis	O
+(	O
+IB	O
+)	O
+is	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+which	O
+is	O
+a	O
+considerable	O
+economic	O
+threat	O
+to	O
+the	O
+poultry	O
+industry	O
+.	O
+
+Additionally	O
+,	O
+an	O
+excellent	O
+protective	O
+effect	O
+of	O
+SZ130	O
+vaccination	O
+was	O
+observed	O
+when	O
+vaccinated	O
+birds	B-SPEC
+were	O
+challenged	O
+with	O
+SD	O
+,	O
+with	O
+no	O
+clinical	O
+signs	O
+or	O
+gross	O
+lesions	O
+,	O
+decreased	O
+target	O
+tissue	O
+replication	O
+rates	O
+,	O
+and	O
+lower	O
+ciliostasis	O
+scores	O
+in	O
+all	O
+immunized	O
+groups	O
+.	O
+
+To	O
+prepare	O
+for	O
+the	O
+manufacture	O
+and	O
+first	O
+-	O
+in	O
+-	O
+human	B-SPEC
+testing	O
+of	O
+the	O
+vaccine	O
+,	O
+we	O
+have	O
+developed	O
+a	O
+process	O
+to	O
+stably	O
+produce	O
+the	O
+recombinant	O
+MERS	O
+S377	O
+-	O
+588	O
+protein	B-CHED
+in	O
+Chinese	B-SPEC
+hamster	I-SPEC
+ovary	B-ANAT
+(	O
+CHO	B-FUNC
+)	O
+cells	B-COMP
+.	O
+
+We	O
+then	O
+demonstrated	O
+the	O
+interleukin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+signal	O
+peptide	B-CHED
+-	O
+directed	O
+secretion	B-PROC
+of	O
+the	O
+recombinant	O
+protein	B-CHED
+into	O
+extracellular	B-COMP
+milieu	O
+.	O
+
+The	O
+adCHO	O
+-	O
+expressed	B-PROC
+S377	O
+-	O
+588	O
+-	O
+Fc	O
+recombinant	O
+protein	B-CHED
+demonstrated	O
+functionality	O
+and	O
+binding	B-FUNC
+specificity	O
+identical	O
+to	O
+those	O
+of	O
+the	O
+protein	B-CHED
+from	O
+transiently	O
+transfected	O
+HEK293T	O
+cells	B-COMP
+.	O
+
+This	O
+report	O
+describes	O
+the	O
+detection	O
+of	O
+coronavirus	B-SPEC
+RNA	O
+in	O
+P	O
+.	O
+medius	O
+bat	B-ENZY
+guano	O
+collected	O
+in	O
+Peradeniya	O
+,	O
+Sri	O
+Lanka	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+critical	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+pathogens	O
+because	O
+of	O
+their	O
+potential	O
+to	O
+cause	O
+severe	O
+epidemics	O
+of	O
+respiratory	O
+or	O
+enteric	O
+diseases	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+designed	O
+a	O
+new	O
+primer	O
+set	O
+to	O
+amplify	O
+a	O
+668	O
+bp	O
+-	O
+region	O
+within	O
+the	O
+RNA	O
+-	O
+dependent	O
+RNA	O
+polymerase	O
+(	O
+RdRP	B-FUNC
+)	O
+gene	O
+that	O
+encodes	O
+the	O
+most	O
+conserved	O
+protein	B-CHED
+domain	O
+of	O
+α	O
+-,	O
+β	O
+-,	O
+γ	O
+-,	O
+and	O
+δ	O
+-	O
+CoVs	O
+.	O
+
+Critically	B-DISO
+ill	I-DISO
+patients	O
+over	O
+18	O
+years	O
+of	O
+age	O
+,	O
+undergoing	O
+invasive	O
+mechanical	O
+ventilation	O
+,	O
+diagnosed	O
+with	O
+ARDS	B-DISO
+of	O
+unknown	O
+etiology	O
+,	O
+and	O
+with	O
+OLB	O
+performed	O
+at	O
+the	O
+bedside	O
+.	O
+
+TITLE	O
+:	O
+A	O
+nano	O
+silicon	B-CHED
+adjuvant	B-CHED
+enhances	O
+inactivated	O
+transmissible	O
+gastroenteritis	B-DISO
+vaccine	O
+through	O
+activation	O
+the	O
+Toll	O
+-	O
+like	O
+receptors	O
+and	O
+promotes	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Inactivated	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+vaccines	O
+are	O
+widely	O
+used	O
+in	O
+swine	B-SPEC
+herds	O
+in	O
+China	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+70	O
+-	O
+nm	O
+nano	O
+silicon	B-CHED
+particle	O
+was	O
+applied	O
+with	O
+inactivated	O
+TGEV	B-SPEC
+vaccine	O
+in	O
+mice	B-SPEC
+,	O
+and	O
+its	O
+immune	O
+-	O
+enhancing	O
+effects	O
+and	O
+mechanism	B-PROC
+of	I-PROC
+action	I-PROC
+investigated	O
+.	O
+
+RESULTS	O
+:	O
+Nurses	O
+'	O
+experiences	O
+of	O
+care	O
+for	O
+patients	O
+with	O
+MERS	O
+-	O
+CoV	O
+were	O
+categorized	O
+as	O
+follows	O
+:	O
+""""	O
+Going	O
+into	O
+a	O
+dangerous	O
+field	O
+","""	O
+""""	O
+Strong	O
+pressure	O
+because	O
+of	O
+MERS	O
+-	O
+CoV	O
+","""	O
+""""	O
+The	O
+strength	O
+that	O
+make	O
+me	O
+endure	O
+","""	O
+""""	O
+Growth	B-PROC
+as	O
+a	O
+nurse	O
+","""	O
+and	O
+""""	O
+Remaining	O
+task	O
+.	O
+
+This	O
+outbreak	O
+provides	O
+a	O
+unique	O
+opportunity	O
+to	O
+fill	O
+the	O
+gap	O
+in	O
+our	O
+knowledge	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Viruses	B-SPEC
+from	O
+Africa	O
+(	O
+clade	O
+C	O
+)	O
+are	O
+phylogenetically	O
+distinct	O
+from	O
+contemporary	O
+viruses	B-SPEC
+from	O
+the	O
+Arabian	O
+Peninsula	O
+(	O
+clades	O
+A	O
+and	O
+B	O
+)	O
+but	O
+remain	O
+antigenically	O
+similar	O
+in	O
+microneutralization	O
+tests	O
+.	O
+
+Viruses	B-SPEC
+from	O
+West	O
+(	O
+Nigeria	O
+,	O
+Burkina	O
+Faso	O
+)	O
+and	O
+North	O
+(	O
+Morocco	O
+)	O
+Africa	O
+form	O
+a	O
+subclade	O
+,	O
+C1	O
+,	O
+that	O
+shares	O
+clade	O
+-	O
+defining	O
+genetic	O
+signatures	O
+including	O
+deletions	O
+in	O
+the	O
+accessory	O
+gene	O
+
+The	O
+incidence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+very	O
+low	O
+but	O
+10	O
+-	O
+30	O
+%	O
+of	O
+anesthesia	B-DISO
+-	O
+related	O
+deaths	B-PROC
+are	O
+caused	O
+by	O
+the	O
+consequences	O
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+in	O
+nasal	B-ANAT
+swab	O
+of	O
+non	O
+-	O
+captive	O
+wild	O
+water	B-CHED
+deer	B-SPEC
+,	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	O
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+is	O
+a	O
+causative	O
+agent	O
+of	O
+respiratory	O
+and	O
+enteric	O
+diseases	O
+in	O
+cattle	B-SPEC
+and	O
+calves	O
+.	O
+
+Recently	O
+,	O
+water	B-CHED
+deer	B-SPEC
+are	O
+recognized	O
+as	O
+the	O
+most	O
+common	O
+wildlife	O
+to	O
+approach	O
+farmhouses	O
+and	O
+livestock	O
+barns	O
+in	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+detection	O
+of	O
+MERS	O
+coronavirus	B-SPEC
+-	O
+like	O
+viruses	B-SPEC
+in	O
+bats	B-SPEC
+:	O
+pote1ntial	O
+for	O
+tracking	O
+MERS	O
+coronavirus	B-SPEC
+transmission	O
+and	O
+animal	B-SPEC
+origin	O
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+we	O
+developed	O
+a	O
+monoclonal	O
+antibody	B-COMP
+-	O
+based	O
+rapid	O
+nucleocapsid	B-COMP
+protein	B-CHED
+detection	O
+assay	O
+for	O
+diagnosis	O
+of	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+humans	B-SPEC
+and	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+metapneumovirus	I-SPEC
+in	O
+Southern	O
+Brazil	O
+.	O
+
+Human	B-SPEC
+metapneumovirus	I-SPEC
+was	O
+detected	O
+by	O
+direct	O
+immunofluorescence	O
+and	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+analysis	O
+of	O
+Mouse	B-SPEC
+Inoculation	O
+Test	O
+and	O
+Virus	B-SPEC
+Isolation	O
+in	O
+Cell	B-COMP
+Culture	O
+for	O
+rabies	B-DISO
+diagnosis	O
+in	O
+animals	B-SPEC
+of	O
+Parana	O
+,	O
+Brazil	O
+.	O
+
+ABSTRACT	O
+:	O
+Rabies	B-DISO
+is	O
+an	O
+acute	O
+zoonotic	O
+disease	O
+,	O
+caused	O
+by	O
+a	O
+rhabdovirus	B-SPEC
+that	O
+can	O
+affect	O
+all	O
+mammals	B-SPEC
+,	O
+and	O
+is	O
+commonly	O
+transmitted	B-DISO
+by	O
+the	O
+bite	B-PROC
+of	O
+a	O
+rabid	O
+animal	B-SPEC
+.	O
+
+These	O
+protocols	O
+should	O
+continue	O
+to	O
+be	O
+checked	O
+and	O
+tested	O
+by	O
+desk	O
+-	O
+top	O
+exercises	O
+to	O
+ensure	O
+that	O
+all	O
+staff	O
+concerned	O
+are	O
+familiar	O
+with	O
+them	O
+,	O
+especially	O
+in	O
+the	O
+context	O
+of	O
+staff	O
+turn	O
+-	O
+over	O
+.	O
+o	O
+The	O
+roles	O
+and	O
+responsibilities	O
+of	O
+the	O
+various	O
+agencies	O
+must	O
+be	O
+clear	O
+to	O
+avoid	O
+role	O
+confusion	B-DISO
+.	O
+o	O
+Equipment	O
+and	O
+infrastructure	O
+capacities	O
+must	O
+be	O
+considered	O
+and	O
+in	O
+place	O
+in	O
+advance	O
+of	O
+an	O
+actual	O
+incident	O
+or	O
+test	O
+,	O
+for	O
+example	O
+whether	O
+or	O
+not	O
+cell	B-COMP
+phone	O
+signals	O
+require	O
+boosting	O
+during	O
+a	O
+major	O
+event	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+isolated	O
+from	O
+a	O
+pigeon	B-SPEC
+sample	O
+induced	O
+clinical	O
+disease	B-DISO
+,	I-DISO
+tracheal	I-DISO
+ciliostasis	O
+,	O
+and	O
+a	O
+high	O
+humoral	O
+response	O
+in	O
+day	O
+-	O
+old	O
+chicks	O
+.	O
+
+Eyes	B-ANAT
+were	O
+obtained	O
+from	O
+49	O
+cats	B-SPEC
+diagnosed	O
+with	O
+chronic	O
+idiopathic	O
+lymphoplasmacytic	O
+anterior	B-DISO
+uveitis	I-DISO
+,	O
+7	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+and	O
+9	O
+cats	B-SPEC
+euthanized	O
+for	O
+nonocular	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Effect	O
+of	O
+lateral	O
+position	O
+ventilation	O
+combined	O
+with	O
+vibration	O
+sputum	B-ANAT
+drainage	B-ANAT
+on	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+:	O
+a	O
+prospective	O
+randomized	O
+controlled	O
+trial	O
+].	O
+
+The	O
+patients	O
+in	O
+both	O
+groups	O
+received	O
+etiological	O
+treatment	O
+,	O
+protective	O
+ventilation	O
+strategy	O
+,	O
+sensitive	O
+antibiotics	B-CHED
+for	O
+anti	O
+-	O
+infection	B-DISO
+,	O
+and	O
+calefacient	O
+and	O
+humidifying	O
+treatment	O
+.	O
+
+Compared	O
+with	O
+the	O
+simple	O
+ventilation	O
+group	O
+,	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+(	O
+WBC	B-ANAT
+),	O
+procalcitonin	O
+(	O
+PCT	B-DISO
+),	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+)	O
+at	O
+24	O
+hours	O
+of	O
+treatment	O
+in	O
+the	O
+combined	O
+treatment	O
+group	O
+were	O
+significantly	O
+decreased	O
+[	O
+WBC	B-ANAT
+(×	O
+10	O
+Compared	O
+with	O
+lateral	O
+position	O
+ventilation	O
+alone	O
+,	O
+the	O
+treatment	O
+of	O
+combined	O
+with	O
+vibration	O
+sputum	B-ANAT
+drainage	B-ANAT
+is	O
+more	O
+effective	O
+for	O
+improving	O
+the	O
+respiratory	B-PROC
+function	I-PROC
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+reducing	O
+infection	B-DISO
+action	O
+,	O
+shortening	O
+the	O
+duration	O
+of	O
+MV	O
+and	O
+the	O
+length	O
+of	O
+ICU	O
+stay	O
+,	O
+and	O
+improve	O
+the	O
+recovery	O
+,	O
+promote	O
+the	O
+rehabitation	O
+of	O
+patients	O
+.	O
+
+This	O
+paper	O
+summarized	O
+the	O
+basic	O
+and	O
+clinical	O
+results	O
+obtained	O
+in	O
+application	O
+of	O
+MSC	O
+in	O
+treatment	O
+of	O
+ARDS	B-DISO
+,	O
+and	O
+discussed	O
+the	O
+problems	O
+needed	O
+to	O
+be	O
+resolved	O
+in	O
+the	O
+further	O
+studies	O
+in	O
+order	B-SPEC
+to	O
+provide	O
+new	O
+ideas	O
+for	O
+clinical	O
+treatment	O
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+24	O
+-	O
+Year	O
+-	O
+Old	O
+Woman	O
+With	O
+Precipitous	O
+Respiratory	B-DISO
+Failure	I-DISO
+After	O
+Lung	B-ANAT
+Transplantation	O
+.	O
+
+In	O
+addition	O
+,	O
+PR40	O
+infection	B-DISO
+showed	O
+an	O
+early	O
+depletion	O
+of	O
+activated	O
+CD4	B-PRGE
++	I-PRGE
+CD25	I-PRGE
++	I-PRGE
+T	B-ANAT
+lymphocytes	I-ANAT
+and	O
+Tregs	O
+together	O
+with	O
+an	O
+intense	O
+and	O
+lasting	O
+depletion	O
+of	O
+CD21	B-PRGE
++	I-PRGE
+B	I-PRGE
+lymphocytes	O
+.	O
+
+However	O
+,	O
+the	O
+subcellular	O
+localization	B-PROC
+and	O
+other	O
+functions	O
+of	O
+the	O
+TGEV	B-PRGE
+nsp7	I-PRGE
+protein	B-CHED
+are	O
+still	O
+unclear	O
+.	O
+
+That	O
+Is	O
+the	O
+Question	O
+-	O
+Predictability	O
+of	O
+Ionic	B-CHED
+Liquid	I-CHED
+'	O
+s	O
+Virucidal	O
+Potential	O
+in	O
+Biological	O
+Test	O
+Systems	O
+.	O
+
+This	O
+probably	O
+reflects	O
+the	O
+paucity	O
+of	O
+understanding	O
+virus	B-SPEC
+inactivation	B-DISO
+.	O
+
+TITLE	O
+:	O
+Transfusion	O
+-	O
+transmitted	B-DISO
+malaria	B-PATH
+masquerading	O
+as	O
+sickle	B-DISO
+cell	I-DISO
+crisis	I-DISO
+with	O
+multisystem	B-DISO
+organ	B-ANAT
+failure	I-DISO
+.	O
+
+A	O
+source	O
+of	O
+infection	B-DISO
+was	O
+not	O
+readily	O
+identified	O
+,	O
+but	O
+treatment	O
+was	O
+initiated	O
+with	O
+continuous	O
+intravenous	O
+fluids	B-ANAT
+and	O
+empiric	O
+antibiotics	B-CHED
+.	O
+
+A	O
+manual	O
+peripheral	O
+blood	O
+smear	O
+revealed	O
+intraerythrocytic	O
+inclusions	O
+suggestive	O
+of	O
+Plasmodium	B-SPEC
+,	O
+and	O
+molecular	O
+studies	O
+confirmed	O
+Plasmodium	B-DISO
+falciparum	I-DISO
+infection	I-DISO
+.	O
+
+Only	O
+18	O
+.	O
+3	O
+%	O
+(	O
+n	O
+=	O
+62	O
+)	O
+of	O
+respondents	O
+identified	O
+PCR	O
+as	O
+the	O
+proper	O
+diagnostic	O
+confirmatory	O
+test	O
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Regarding	O
+MERS	O
+-	O
+CoV	O
+clinical	O
+features	O
+,	O
+76	O
+.	O
+4	O
+%	O
+(	O
+n	O
+=	O
+259	O
+)	O
+recognized	O
+the	O
+presence	O
+of	O
+sub	O
+-	O
+clinical	B-DISO
+infection	I-DISO
+,	O
+64	O
+.	O
+7	O
+%	O
+(	O
+n	O
+=	O
+218	O
+)	O
+indicated	O
+that	O
+cases	O
+should	O
+be	O
+immediately	O
+isolated	O
+,	O
+and	O
+46	O
+.	O
+9	O
+%	O
+(	O
+n	O
+=	O
+159	O
+)	O
+identified	O
+the	O
+main	O
+cause	O
+of	O
+mortality	O
+as	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Although	O
+CAM	B-PRGE
+use	I-PRGE
+can	O
+be	O
+beneficial	O
+,	O
+some	O
+can	O
+be	O
+very	O
+harmful	O
+,	O
+especially	O
+for	O
+cancer	B-DISO
+patients	O
+.	O
+
+Thirty	O
+percent	O
+of	O
+CAM	B-DISO
+users	O
+had	O
+discussed	O
+the	O
+issue	O
+with	O
+their	O
+doctors	O
+;	O
+only	O
+7	O
+.	O
+7	O
+%	O
+had	O
+done	O
+so	O
+with	O
+their	O
+nurses	O
+.	O
+
+TITLE	O
+:	O
+The	O
+relationship	O
+between	O
+physical	O
+ill	B-DISO
+-	O
+health	O
+and	O
+mental	O
+ill	B-DISO
+-	O
+health	O
+in	O
+adults	O
+with	O
+intellectual	B-DISO
+disabilities	I-DISO
+.	O
+
+Physical	O
+-	O
+mental	O
+comorbidity	O
+has	O
+been	O
+shown	O
+to	O
+result	O
+in	O
+poorer	O
+outcomes	O
+in	O
+the	O
+general	O
+population	O
+,	O
+but	O
+little	O
+is	O
+known	O
+about	O
+this	O
+relationship	O
+in	O
+adults	O
+with	O
+intellectual	B-DISO
+disabilities	I-DISO
+.	O
+
+To	O
+identify	O
+whether	O
+physical	O
+ill	B-DISO
+-	O
+health	O
+is	O
+associated	O
+with	O
+mental	O
+ill	B-DISO
+-	O
+health	O
+in	O
+adults	O
+with	O
+intellectual	B-DISO
+disabilities	I-DISO
+and	O
+whether	O
+the	O
+extent	O
+of	O
+physical	O
+multi	O
+-	O
+morbidity	O
+can	O
+predict	O
+the	O
+likelihood	O
+of	O
+mental	O
+ill	B-DISO
+-	O
+health	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+extent	O
+of	O
+physical	O
+multi	O
+-	O
+morbidity	O
+was	O
+not	O
+associated	O
+with	O
+mental	O
+ill	B-DISO
+-	O
+health	O
+in	O
+adults	O
+with	O
+intellectual	B-DISO
+disabilities	I-DISO
+as	O
+only	O
+0	O
+.	O
+8	O
+%	O
+of	O
+the	O
+sample	O
+had	O
+no	O
+physical	O
+conditions	O
+.	O
+
+Co	O
+-	O
+immunoprecipitation	O
+(	O
+CO	O
+-	O
+IP	O
+)	O
+results	O
+clearly	O
+demonstrated	O
+that	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+could	O
+bind	B-FUNC
+to	O
+human	B-PRGE
+hnRNP	B-ANAT
+A1	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Addressing	O
+the	O
+selectivity	O
+and	O
+toxicity	O
+of	O
+antiviral	B-CHED
+nucleosides	B-CHED
+.	O
+
+Charts	O
+were	O
+reviewed	O
+for	O
+RVI	O
+events	O
+associated	O
+with	O
+hospitalization	O
+within	O
+1	O
+year	O
+after	O
+the	O
+transplant	B-ANAT
+.	O
+
+The	O
+incidence	O
+of	O
+RVI	O
+was	O
+calculated	O
+,	O
+and	O
+the	O
+association	O
+of	O
+baseline	O
+SOT	O
+factors	O
+with	O
+subsequent	O
+pulmonary	B-ANAT
+complications	I-DISO
+and	O
+death	O
+was	O
+assessed	O
+.	O
+
+RVI	O
+was	O
+associated	O
+with	O
+younger	O
+median	O
+age	O
+at	O
+transplant	B-ANAT
+(	O
+1	O
+.	O
+72	O
+vs	O
+7	O
+.	O
+89	O
+years	O
+;	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+among	O
+liver	B-ANAT
+or	O
+kidney	B-ANAT
+transplant	I-ANAT
+recipients	O
+with	O
+the	O
+receipt	O
+of	O
+a	O
+deceased	B-PROC
+-	O
+donor	B-CHED
+graft	B-ANAT
+compared	O
+to	O
+a	O
+living	O
+donor	B-CHED
+(	O
+P	O
+=	O
+.	O
+01	O
+).	O
+
+Multivariable	O
+logistic	O
+regression	O
+models	O
+revealed	O
+that	O
+age	O
+was	O
+independently	O
+associated	O
+with	O
+increased	O
+risk	O
+for	O
+a	O
+pulmonary	B-DISO
+complication	I-DISO
+(	O
+odds	O
+ratio	O
+,	O
+1	O
+.	O
+24	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+02	O
+-	O
+1	O
+.	O
+51	O
+])	O
+and	O
+that	O
+receipt	O
+of	O
+an	O
+intestine	B-ANAT
+/	O
+multivisceral	O
+transplant	B-ANAT
+was	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+all	O
+-	O
+cause	O
+death	B-PROC
+(	O
+odds	O
+ratio	O
+,	O
+24	O
+.	O
+54	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+69	O
+-	O
+327	O
+.	O
+96	O
+]).	O
+
+Here	O
+,	O
+we	O
+reported	O
+the	O
+case	O
+of	O
+a	O
+woman	O
+co	O
+-	O
+infected	O
+by	O
+influenza	B-PATH
+A	I-PATH
+H7N9	O
+and	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+whose	O
+treatment	O
+process	O
+was	O
+a	O
+little	O
+bit	B-CHED
+longer	O
+and	O
+a	O
+little	O
+bit	B-CHED
+complicated	O
+as	O
+well	O
+.	O
+
+She	O
+was	O
+diagnosed	O
+as	O
+having	O
+severe	O
+influenza	B-PATH
+A	I-PATH
+H7N9	O
+and	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+,	O
+and	O
+was	O
+admitted	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Oseltamivir	B-CHED
+was	O
+discontinued	O
+because	O
+of	O
+three	O
+consecutive	O
+negative	O
+results	O
+of	O
+nucleic	B-CHED
+acid	I-CHED
+for	O
+influenza	B-PATH
+A	I-PATH
+H7N9	O
+,	O
+but	O
+anti	O
+-	O
+Mycoplasma	B-DISO
+treatment	O
+was	O
+continued	O
+.	O
+
+Although	O
+her	O
+symptoms	O
+and	O
+abnormal	O
+changes	O
+on	O
+computed	O
+tomography	O
+scan	O
+slowly	O
+went	O
+away	O
+,	O
+she	O
+finally	O
+recovered	O
+from	O
+the	O
+mixed	B-DISO
+infection	I-DISO
+after	O
+a	O
+total	O
+of	O
+33	O
+days	O
+of	O
+management	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+fatal	O
+disease	O
+in	O
+cats	B-SPEC
+worldwide	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+test	O
+two	O
+commercially	O
+available	O
+reaction	O
+mixtures	O
+in	O
+a	O
+reverse	B-PROC
+transcription	I-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+assay	O
+to	O
+detect	O
+feline	B-SPEC
+Coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+in	O
+body	B-ANAT
+cavity	I-ANAT
+effusions	B-DISO
+of	O
+cats	B-SPEC
+with	O
+and	O
+without	O
+FIP	B-DISO
+,	O
+in	O
+order	B-SPEC
+to	O
+minimize	O
+the	O
+time	O
+from	O
+sampling	O
+to	O
+obtaining	O
+results	O
+.	O
+
+Further	O
+modifications	O
+of	O
+primers	O
+might	O
+lead	O
+to	O
+a	O
+suitable	O
+in	O
+-	O
+house	O
+test	O
+and	O
+accelerate	O
+the	O
+diagnosis	O
+of	O
+FIP	B-DISO
+.	O
+
+In	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+24	O
+/	O
+34	O
+tested	O
+positive	O
+for	O
+FIPV	O
+.	O
+
+This	O
+study	O
+assessed	O
+the	O
+efficacy	O
+and	O
+safety	O
+of	O
+bivalirudin	B-CHED
+compared	O
+with	O
+UFH	O
+with	O
+or	O
+without	O
+GPIs	B-CHED
+in	O
+patients	O
+with	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+)	O
+who	O
+underwent	O
+invasive	O
+management	O
+.	O
+
+Based	O
+on	O
+the	O
+baseline	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+/	O
+inspiratory	B-PROC
+oxygen	B-CHED
+fraction	O
+ratio	O
+,	O
+60	O
+(	O
+48	O
+%),	O
+49	O
+(	O
+40	O
+%)	O
+and	O
+15	O
+(	O
+12	O
+%)	O
+patients	O
+had	O
+mild	O
+,	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Future	O
+Research	O
+Directions	O
+in	O
+Pneumonia	B-DISO
+.	O
+
+Severe	O
+outbreaks	O
+of	O
+PEDV	B-SPEC
+variants	O
+have	O
+re	O
+-	O
+emerged	O
+in	O
+Asia	O
+and	O
+North	O
+America	O
+since	O
+2010	O
+,	O
+causing	O
+tremendous	O
+economic	O
+losses	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+antiviral	B-CHED
+effect	O
+of	O
+LiCl	B-CHED
+on	O
+PEDV	B-SPEC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+was	O
+evaluated	O
+.	O
+
+Real	O
+-	O
+time	O
+quantitative	O
+PCR	O
+and	O
+indirect	O
+immunofluorescence	O
+assay	O
+indicated	O
+that	O
+LiCl	B-CHED
+effectively	O
+inhibited	O
+the	O
+entry	O
+and	O
+replication	O
+of	O
+PEDV	B-SPEC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+Moreover	O
+,	O
+addition	O
+of	O
+LiCl	B-CHED
+inhibited	O
+both	O
+early	O
+and	O
+late	O
+cell	O
+apoptosis	B-PATH
+induced	O
+by	O
+PEDV	B-SPEC
+.	O
+
+Identification	O
+of	O
+new	O
+types	O
+of	O
+PEDV	B-SPEC
+strains	O
+would	O
+stimulate	O
+the	O
+development	B-PROC
+of	O
+effective	O
+vaccines	O
+for	O
+the	O
+prevention	O
+and	O
+control	O
+of	O
+PED	B-PRGE
+in	O
+a	O
+more	O
+precise	O
+manner	O
+.	O
+
+TITLE	O
+:	O
+Mapping	O
+Potential	O
+Amplification	B-DISO
+and	O
+Transmission	O
+Hotspots	O
+for	O
+MERS	O
+-	O
+CoV	O
+,	O
+Kenya	O
+.	O
+
+ABSTRACT	O
+:	O
+Dromedary	B-SPEC
+camels	B-SPEC
+have	O
+been	O
+implicated	O
+consistently	O
+as	O
+the	O
+source	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+human	B-SPEC
+infections	B-DISO
+and	O
+attention	O
+to	O
+prevent	O
+and	O
+control	O
+it	O
+has	O
+focused	O
+on	O
+camels	B-SPEC
+.	O
+
+Primary	O
+and	O
+secondary	O
+MERS	O
+-	O
+CoV	O
+seroprevalence	O
+data	O
+from	O
+specific	O
+sites	O
+were	O
+analyzed	O
+,	O
+and	O
+location	O
+-	O
+based	O
+prevalence	O
+matching	O
+with	O
+camel	B-SPEC
+densities	O
+was	O
+conducted	O
+.	O
+
+Although	O
+Kenyan	O
+camels	B-SPEC
+are	O
+predisposed	O
+to	O
+MERS	O
+-	O
+CoV	O
+,	O
+no	O
+shedding	O
+is	O
+documented	O
+to	O
+date	O
+.	O
+
+In	O
+this	O
+chapter	O
+,	O
+we	O
+discuss	O
+a	O
+powerful	O
+combinatorial	O
+technology	O
+in	O
+association	O
+with	O
+animal	B-SPEC
+immunisation	O
+that	O
+is	O
+capable	O
+of	O
+generating	O
+biologic	O
+drugs	O
+with	O
+high	O
+affinity	O
+,	O
+efficacy	O
+and	O
+limited	O
+off	O
+-	O
+site	O
+toxicity	O
+,	O
+and	O
+diagnostic	O
+tools	O
+with	O
+great	O
+precision	O
+.	O
+
+ABSTRACT	O
+:	O
+Disseminated	O
+intravascular	O
+coagulations	O
+(	O
+DIC	B-DISO
+),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+are	O
+major	O
+organ	B-ANAT
+dysfunctions	O
+that	O
+occur	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+detection	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+in	O
+swine	B-SPEC
+small	B-ANAT
+intestine	I-ANAT
+samples	O
+using	O
+real	O
+-	O
+time	O
+reverse	O
+transcription	O
+recombinase	O
+polymerase	O
+amplification	B-DISO
+.	O
+
+Further	O
+validation	O
+of	O
+the	O
+prediction	O
+model	O
+on	O
+a	O
+large	O
+prospective	O
+cohort	O
+of	O
+representative	O
+patients	O
+with	O
+pneumonia	B-DISO
+is	O
+necessary	O
+.	O
+
+This	O
+will	O
+provide	O
+an	O
+insight	O
+into	O
+possible	O
+therapeutic	O
+targets	O
+to	O
+treat	O
+infections	B-DISO
+by	O
+current	O
+as	O
+well	O
+as	O
+newly	O
+emerging	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Hemolytic	O
+uremic	O
+syndrome	O
+(	O
+HUS	O
+)	O
+is	O
+a	O
+clinical	O
+syndrome	B-DISO
+characterized	O
+by	O
+hemolytic	B-DISO
+anemia	I-DISO
+,	O
+thrombocytopenia	O
+,	O
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+.	O
+
+After	O
+treatment	O
+,	O
+the	O
+homocysteine	B-CHED
+and	O
+methylmalonic	B-CHED
+acid	I-CHED
+levels	O
+were	O
+normalized	O
+but	O
+hemolysis	B-DISO
+and	O
+acute	B-DISO
+kidney	I-DISO
+failure	I-DISO
+persisted	O
+.	O
+
+After	O
+eculizumab	O
+treatment	O
+,	O
+the	O
+renal	B-ANAT
+and	O
+hematologic	O
+indices	O
+improved	O
+and	O
+he	O
+was	O
+free	O
+of	O
+dialysis	B-SPEC
+.	O
+
+TITLE	O
+:	O
+When	O
+Information	O
+from	O
+Public	O
+Health	O
+Officials	O
+is	O
+Untrustworthy	O
+:	O
+The	O
+Use	O
+of	O
+Online	O
+News	O
+,	O
+Interpersonal	O
+Networks	O
+,	O
+and	O
+Social	O
+Media	B-ANAT
+during	O
+the	O
+MERS	O
+Outbreak	O
+in	O
+South	O
+Korea	O
+.	O
+
+Calves	O
+that	O
+suffered	B-DISO
+from	O
+diarrhea	B-DISO
+or	O
+died	B-PROC
+within	O
+the	O
+first	O
+month	O
+of	O
+life	O
+had	O
+lower	O
+serum	B-COMP
+Ig	O
+concentrations	O
+than	O
+those	O
+that	O
+remained	O
+healthy	O
+or	O
+survived	O
+(	O
+P	O
+<	O
+.	O
+05	O
+).	O
+
+Encouragingly	O
+,	O
+all	O
+the	O
+tested	O
+compounds	O
+showed	O
+good	O
+activities	O
+against	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+(	O
+IIIB	O
+)	O
+with	O
+EC	O
+
+Patients	O
+with	O
+H7N9	O
+had	O
+higher	O
+rates	O
+of	O
+invasive	O
+mechanical	O
+ventilation	O
+;	O
+serious	O
+complications	O
+,	O
+including	O
+alimentary	O
+tract	O
+hemorrhage	B-DISO
+,	O
+pneumothorax	B-DISO
+or	O
+septum	B-COMP
+emphysema	B-DISO
+,	O
+hospital	O
+-	O
+acquired	O
+pneumonia	B-DISO
+(	O
+HAP	O
+)	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+);	O
+and	O
+hospital	O
+mortality	O
+(	O
+P	O
+<	O
+.	O
+05	O
+).	O
+
+Induction	O
+of	O
+autophagic	O
+signals	O
+promotes	O
+EV	O
+-	O
+D68	O
+replication	O
+,	O
+but	O
+the	O
+virus	B-SPEC
+inhibits	O
+the	O
+downstream	O
+degradative	O
+steps	O
+of	O
+autophagy	B-PROC
+in	O
+multiple	O
+ways	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+describe	O
+the	O
+current	O
+medical	O
+need	O
+resulting	O
+from	O
+respiratory	B-DISO
+infections	I-DISO
+caused	O
+by	O
+RNA	O
+viruses	B-SPEC
+,	O
+which	O
+justifies	O
+drug	O
+discovery	O
+efforts	O
+to	O
+identify	O
+new	O
+therapeutic	O
+agents	O
+.	O
+
+This	O
+includes	O
+molecules	O
+with	O
+very	O
+broad	O
+antiviral	B-CHED
+spectrum	O
+such	O
+as	O
+ribavirin	B-CHED
+and	O
+T	O
+-	O
+705	O
+(	O
+favipiravir	O
+),	O
+and	O
+others	O
+targeting	B-PROC
+more	O
+specifically	O
+one	O
+or	O
+a	O
+few	O
+virus	B-SPEC
+families	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+'	O
+Therapeutics	O
+discovery	O
+:	O
+From	O
+bench	O
+to	O
+first	O
+in	O
+-	O
+human	O
+trials	O
+'	O
+conference	O
+,	O
+held	O
+at	O
+the	O
+King	O
+Abdullah	O
+International	O
+Medical	O
+Research	O
+Center	O
+(	O
+KAIMRC	O
+),	O
+Ministry	O
+of	O
+National	O
+Guard	O
+Health	O
+Affairs	O
+(	O
+MNGHA	O
+),	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+(	O
+KSA	O
+)	O
+from	O
+October	O
+10	O
+-	O
+12	O
+,	O
+2017	O
+,	O
+provided	O
+a	O
+unique	O
+opportunity	O
+for	O
+experts	O
+worldwide	O
+to	O
+discuss	O
+advances	O
+in	O
+drug	O
+discovery	O
+and	O
+development	B-PROC
+,	O
+focusing	O
+on	O
+phase	O
+I	O
+clinical	O
+trials	O
+.	O
+
+Unlike	O
+in	O
+established	O
+cells	B-COMP
+,	O
+toremifene	B-CHED
+had	O
+marginal	O
+activity	O
+when	O
+tested	O
+in	O
+antigen	B-ANAT
+presenting	I-ANAT
+cells	B-COMP
+,	O
+with	O
+high	O
+apparent	O
+cytotoxicity	B-DISO
+,	O
+also	O
+limiting	O
+its	O
+potential	O
+as	O
+a	O
+therapeutic	O
+option	O
+.	O
+
+AE	O
+-	O
+IPF	O
+shares	O
+several	O
+pathophysiological	O
+features	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+a	O
+very	O
+severe	O
+condition	B-DISO
+commonly	O
+treated	O
+in	O
+this	O
+setting	O
+.	O
+
+A	O
+review	O
+of	O
+the	O
+literature	O
+has	O
+been	O
+conducted	O
+to	O
+underline	O
+similarities	O
+and	O
+differences	O
+in	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+AE	O
+-	O
+IPF	O
+and	O
+ARDS	B-DISO
+.	O
+During	O
+AE	O
+-	O
+IPF	O
+,	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+and	O
+massive	O
+loss	O
+of	O
+aeration	O
+occurs	O
+,	O
+similar	O
+to	O
+what	O
+is	O
+observed	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Complete	O
+Genome	O
+Sequence	O
+of	O
+Human	B-PRGE
+Coronavirus	I-PRGE
+NL63	I-PRGE
+CN0601	O
+/	O
+14	O
+,	O
+First	O
+Isolated	O
+in	O
+South	O
+Korea	O
+.	O
+
+Babesia	B-SPEC
+microti	I-SPEC
+is	O
+the	O
+main	O
+pathogen	O
+causing	O
+human	B-SPEC
+disease	O
+and	O
+is	O
+endemic	O
+in	O
+the	O
+northeastern	O
+and	O
+upper	O
+midwestern	O
+parts	O
+of	O
+the	O
+USA	O
+.	O
+
+However	O
+,	O
+she	O
+was	O
+re	O
+-	O
+admitted	O
+on	O
+postoperative	O
+day	O
+10	O
+for	O
+febrile	B-PROC
+hemolytic	B-DISO
+anemia	I-DISO
+.	O
+
+Further	O
+exposure	O
+history	O
+was	O
+obtained	O
+and	O
+was	O
+significant	O
+for	O
+multiple	O
+tick	B-SPEC
+bites	O
+8	O
+weeks	O
+preceding	O
+the	O
+index	O
+hospitalization	O
+.	O
+
+In	O
+contrast	O
+to	O
+other	O
+complications	O
+of	O
+babesiosis	B-DISO
+,	O
+SR	O
+is	O
+not	O
+correlated	O
+with	O
+parasite	O
+burden	O
+or	O
+immune	B-PROC
+status	I-PROC
+of	O
+the	O
+affected	O
+host	B-COMP
+.	O
+
+Babesiosis	B-DISO
+should	O
+be	O
+considered	O
+as	O
+part	O
+of	O
+the	O
+differential	O
+diagnosis	O
+in	O
+patients	O
+from	O
+endemic	O
+areas	O
+presenting	O
+with	O
+atraumatic	O
+splenic	B-ANAT
+rupture	O
+.	O
+
+The	O
+spike	O
+protein	B-CHED
+(	O
+S1	O
+subunit	O
+)	O
+is	O
+responsible	O
+for	O
+the	O
+molecular	O
+diversity	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+many	O
+sero	O
+/	O
+genotypes	O
+are	O
+described	O
+around	O
+the	O
+world	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+diversity	O
+in	O
+practice	O
+in	O
+non	O
+-	O
+invasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+in	O
+European	O
+pediatric	O
+intensive	O
+care	O
+units	O
+(	O
+PICUs	B-SPEC
+).	O
+
+Regarding	O
+respiratory	B-DISO
+failure	I-DISO
+cause	O
+,	O
+NIV	O
+was	O
+delivered	O
+in	O
+pneumonia	B-DISO
+(	O
+97	O
+.	O
+3	O
+%),	O
+bronchiolitis	B-DISO
+(	O
+94	O
+.	O
+6	O
+%),	O
+bronchospasm	B-DISO
+(	O
+75	O
+.	O
+2	O
+%),	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+(	O
+84	O
+.	O
+1	O
+%),	O
+upper	B-DISO
+airway	I-DISO
+obstruction	I-DISO
+(	O
+76	O
+.	O
+1	O
+%),	O
+and	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+91	O
+%	O
+if	O
+mild	O
+,	O
+53	O
+.	O
+1	O
+%	O
+if	O
+moderate	O
+,	O
+and	O
+5	O
+.	O
+3	O
+%	O
+if	O
+severe	O
+).	O
+
+Areas	O
+covered	O
+:	O
+Several	O
+mechanisms	O
+of	O
+VILI	O
+have	O
+been	O
+described	O
+,	O
+such	O
+as	O
+:	O
+inspiratory	B-PROC
+and	O
+/	O
+or	O
+expiratory	B-PROC
+stress	O
+inducing	O
+overdistension	O
+(	O
+volutrauma	O
+);	O
+interfaces	O
+between	O
+collapsed	O
+or	O
+edema	B-DISO
+-	O
+filled	O
+alveoli	B-ANAT
+with	O
+surrounding	O
+open	O
+alveoli	B-ANAT
+,	O
+acting	O
+as	O
+stress	O
+raisers	O
+;	O
+alveoli	B-ANAT
+that	O
+repetitively	O
+open	O
+and	O
+close	O
+during	O
+tidal	O
+breathing	B-PROC
+(	O
+atelectrauma	O
+);	O
+and	O
+peripheral	O
+airway	B-ANAT
+dynamics	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+discuss	O
+:	O
+the	O
+definition	O
+and	O
+classification	O
+of	O
+ARDS	B-DISO
+;	O
+ventilatory	O
+parameters	O
+that	O
+act	O
+as	O
+VILI	O
+determinants	O
+(	O
+tidal	O
+volume	O
+,	O
+respiratory	O
+rate	O
+,	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+peak	O
+,	O
+plateau	O
+,	O
+driving	O
+and	O
+transpulmonary	O
+pressures	O
+,	O
+energy	O
+,	O
+mechanical	O
+power	O
+,	O
+and	O
+intensity	O
+);	O
+and	O
+the	O
+roles	O
+of	O
+prone	O
+positioning	O
+and	O
+muscle	O
+paralysis	O
+.	O
+
+Expert	O
+commentary	O
+:	O
+To	O
+prevent	O
+VILI	O
+,	O
+mechanical	O
+ventilation	O
+strategies	O
+should	O
+minimize	O
+inspiratory	B-PROC
+/	O
+expiratory	B-PROC
+stress	O
+,	O
+dynamic	O
+/	O
+static	O
+strain	O
+,	O
+energy	O
+,	O
+mechanical	O
+power	O
+,	O
+and	O
+intensity	O
+,	O
+as	O
+well	O
+as	O
+mitigate	O
+the	O
+hemodynamic	B-PROC
+consequences	O
+of	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+goal	O
+-	O
+directed	O
+haemodynamic	O
+therapy	O
+on	O
+postoperative	B-DISO
+complications	I-DISO
+in	O
+low	O
+-	O
+moderate	O
+risk	O
+surgical	O
+patients	O
+:	O
+a	O
+multicentre	O
+randomised	O
+controlled	O
+trial	O
+(	O
+FEDORA	O
+trial	O
+).	O
+
+In	O
+the	O
+GDHT	O
+group	O
+,	O
+the	O
+intraoperative	O
+goals	O
+were	O
+to	O
+maintain	O
+a	O
+maximal	O
+stroke	B-DISO
+volume	O
+,	O
+with	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+>	O
+70	O
+mm	O
+Hg	O
+,	O
+and	O
+cardiac	B-ANAT
+index	O
+≥	O
+2	O
+.	O
+5	O
+litres	O
+min	O
+In	O
+total	O
+,	O
+450	O
+patients	O
+were	O
+randomized	O
+to	O
+the	O
+GDHT	O
+group	O
+(	O
+n	O
+=	O
+224	O
+)	O
+or	O
+control	O
+group	O
+(	O
+n	O
+=	O
+226	O
+).	O
+
+We	O
+found	O
+that	O
+vaccination	O
+at	O
+early	O
+stages	O
+of	O
+pregnancy	O
+induces	O
+similar	O
+levels	O
+of	O
+serum	B-COMP
+and	O
+colostrum	B-ANAT
+antibodies	B-COMP
+with	O
+those	O
+at	O
+late	O
+stages	O
+of	O
+pregnancy	O
+.	O
+
+Sepsis	B-DISO
+syndrome	I-DISO
+is	O
+developed	O
+when	O
+the	O
+balance	B-PROC
+between	O
+the	O
+substances	O
+that	O
+contribute	O
+to	O
+the	O
+inflammation	B-DISO
+and	O
+anti	O
+-	O
+inflammatory	O
+substances	O
+is	O
+violated	O
+.	O
+
+By	O
+the	O
+mentioned	O
+case	O
+there	O
+is	O
+sepsis	B-DISO
+-	O
+induced	O
+polyorganic	O
+insufficiency	O
+with	O
+underlying	O
+severe	O
+somatic	O
+pathological	O
+condition	B-DISO
+,	O
+with	O
+violation	O
+of	O
+hemodynamics	B-PROC
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+ascertain	O
+the	O
+gastrointestinal	O
+virome	O
+of	O
+these	O
+bats	B-SPEC
+,	O
+as	O
+viruses	B-SPEC
+excreted	O
+in	O
+fecal	B-ANAT
+material	O
+or	O
+which	O
+may	O
+be	O
+replicating	O
+in	O
+rectal	O
+or	O
+intestinal	B-ANAT
+tissues	B-ANAT
+have	O
+the	O
+greatest	O
+opportunities	O
+of	O
+coming	O
+into	O
+contact	O
+with	O
+other	O
+hosts	B-COMP
+.	O
+
+With	O
+the	O
+exception	O
+of	O
+the	O
+coronaviruses	O
+,	O
+the	O
+study	O
+represents	O
+the	O
+first	O
+report	O
+of	O
+sequence	O
+data	O
+from	O
+several	O
+viral	O
+families	O
+within	O
+a	O
+Southern	O
+African	O
+insectivorous	O
+bat	B-ENZY
+genus	B-SPEC
+;	O
+highlighting	O
+the	O
+need	O
+for	O
+continued	O
+investigations	O
+in	O
+this	O
+regard	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+infection	I-DISO
+retards	O
+the	O
+development	B-PROC
+of	O
+the	O
+cortico	O
+-	O
+medullary	B-ANAT
+capillary	B-ANAT
+network	I-ANAT
+in	O
+the	O
+bursa	O
+of	O
+Fabricius	O
+of	O
+chicken	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+Zika	B-SPEC
+Virus	I-SPEC
+Replication	O
+by	O
+Silvestrol	B-CHED
+.	O
+
+Very	O
+recently	O
+,	O
+the	O
+natural	O
+compound	O
+silvestrol	B-CHED
+isolated	O
+from	O
+the	O
+plant	B-SPEC
+
+The	O
+concentration	O
+of	O
+sDPP4	O
+in	O
+the	O
+plasma	B-ANAT
+of	O
+MERS	O
+patients	O
+(	O
+474	O
+.	O
+76	O
+±	O
+108	O
+.	O
+06	O
+ng	O
+/	O
+ml	O
+)	O
+was	O
+significantly	O
+lower	O
+than	O
+those	O
+of	O
+healthy	O
+controls	O
+(	O
+703	O
+.	O
+42	O
+±	O
+169	O
+.	O
+96	O
+ng	O
+/	O
+ml	O
+),	O
+but	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+among	O
+the	O
+patient	O
+groups	O
+.	O
+
+Therefore	O
+,	O
+sDPP4	O
+levels	O
+in	O
+the	O
+plasma	O
+of	O
+MERS	O
+patients	O
+are	O
+significantly	O
+reduced	O
+below	O
+the	O
+threshold	O
+needed	O
+to	O
+exert	B-PROC
+an	O
+antiviral	B-CHED
+effect	O
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+severe	O
+form	O
+,	O
+known	O
+as	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+are	O
+caused	O
+by	O
+direct	O
+pulmonary	B-ANAT
+insults	O
+and	O
+indirect	O
+systemic	O
+inflammatory	B-DISO
+responses	I-DISO
+that	O
+result	O
+from	O
+conditions	O
+such	O
+as	O
+sepsis	B-DISO
+,	O
+trauma	O
+,	O
+and	O
+major	O
+surgery	O
+.	O
+
+Emerging	O
+evidence	O
+has	O
+revealed	O
+that	O
+alveolar	B-ANAT
+macrophage	I-ANAT
+(	O
+AM	O
+)	O
+death	B-PROC
+plays	O
+important	O
+roles	O
+in	O
+the	O
+progression	O
+of	O
+lung	B-DISO
+inflammation	I-DISO
+through	O
+its	O
+influence	O
+on	O
+other	O
+immune	O
+cell	B-COMP
+populations	O
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+A	O
+total	O
+of	O
+404	O
+critically	O
+ill	O
+ARDS	B-DISO
+patients	O
+were	O
+analyzed	O
+.	O
+
+A	O
+cutoff	O
+level	O
+of	O
+220	O
+NRBC	O
+/	O
+µl	O
+was	O
+associated	O
+with	O
+a	O
+more	O
+than	O
+tripled	O
+risk	O
+of	O
+ICU	O
+death	B-PROC
+(	O
+OR	O
+3	O
+.	O
+2	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+93	O
+-	O
+5	O
+.	O
+35	O
+;	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+NRBCs	O
+may	O
+predict	O
+mortality	O
+in	O
+ARDS	B-DISO
+with	O
+high	O
+prognostic	O
+power	O
+.	O
+
+Because	O
+some	O
+auto	O
+-	O
+antibodies	B-COMP
+associated	O
+with	O
+acute	O
+/	O
+subacute	O
+onset	O
+IP	O
+have	O
+recently	O
+become	O
+available	O
+in	O
+clinic	O
+,	O
+we	O
+examined	O
+those	O
+including	O
+anti	B-PRGE
+-	I-PRGE
+aminoacyl	I-PRGE
+tRNA	I-PRGE
+synthetase	I-PRGE
+(	O
+ARS	O
+)	O
+antibodies	B-COMP
+,	O
+and	O
+found	O
+that	O
+she	O
+was	O
+positive	O
+for	O
+anti	O
+-	O
+PL	O
+-	O
+7	O
+antibody	B-COMP
+.	O
+
+We	O
+diagnosed	O
+her	O
+anti	B-PRGE
+-	I-PRGE
+synthetase	I-PRGE
+syndrome	B-DISO
+(	O
+ASS	B-DISO
+)	O
+without	O
+symptom	B-DISO
+of	O
+myositis	B-DISO
+,	O
+and	O
+her	O
+IP	O
+was	O
+considered	O
+to	O
+be	O
+ASS	B-DISO
+-	O
+related	O
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+the	O
+psychiatric	O
+complications	O
+or	O
+risk	O
+factors	O
+for	O
+depression	O
+in	O
+suspected	O
+or	O
+confirmed	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+patients	O
+quarantined	O
+in	O
+hospital	O
+.	O
+
+27	O
+suspected	O
+or	O
+confirmed	O
+MERS	O
+patients	O
+(	O
+age	O
+41	O
+.	O
+15	O
+±	O
+18	O
+.	O
+64	O
+,	O
+male	O
+37	O
+.	O
+0	O
+%)	O
+completed	O
+psychological	B-DISO
+assessments	O
+.	O
+
+TITLE	O
+:	O
+Combined	O
+pharmacotherapy	O
+for	O
+osteonecrosis	B-DISO
+of	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+after	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+interstitial	B-DISO
+pneumonia	I-DISO
+:	O
+two	O
+and	O
+a	O
+half	O
+to	O
+fourteen	O
+year	O
+follow	O
+-	O
+up	O
+.	O
+
+From	O
+August	O
+2003	O
+to	O
+June	O
+2015	O
+,	O
+five	O
+patients	O
+(	O
+ten	O
+hips	B-ANAT
+)	O
+of	O
+ONFH	O
+in	O
+ARCO	B-SPEC
+stage	O
+I	O
+,	O
+after	O
+SARS	B-DISO
+and	O
+Interstitial	B-DISO
+pneumonia	I-DISO
+,	O
+were	O
+treated	O
+by	O
+combined	O
+pharmacotherapy	O
+.	O
+
+Radiologic	O
+findings	O
+show	O
+no	O
+signs	O
+of	O
+collapse	B-DISO
+,	O
+necrotic	B-PROC
+focus	O
+was	O
+repaired	O
+,	O
+and	O
+ARCO	B-SPEC
+stages	O
+were	O
+changed	O
+from	O
+I	O
+This	O
+combined	O
+pharmacotherapy	O
+has	O
+promising	O
+treatment	O
+results	O
+for	O
+delaying	O
+or	O
+preventing	O
+collapse	B-DISO
+of	O
+ONFH	O
+in	O
+ARCO	B-SPEC
+stage	O
+I	O
+.	O
+METHODS	O
+:	O
+From	O
+August	O
+2003	O
+to	O
+June	O
+2015	O
+,	O
+five	O
+patients	O
+(	O
+ten	O
+hips	B-ANAT
+)	O
+of	O
+ONFH	O
+in	O
+ARCO	B-SPEC
+stage	O
+I	O
+,	O
+after	O
+SARS	B-DISO
+and	O
+Interstitial	O
+pneumonia	O
+,	O
+were	O
+treated	O
+by	O
+combined	O
+pharmacotherapy	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+devastating	O
+clinical	O
+syndrome	B-DISO
+whose	O
+diagnosis	O
+and	O
+therapy	O
+are	O
+still	O
+in	O
+question	O
+.	O
+
+Lung	B-ANAT
+protective	O
+strategies	O
+with	O
+low	O
+tidal	O
+volume	O
+(	O
+VT	O
+)	O
+and	O
+lung	B-ANAT
+recruitment	B-DISO
+should	O
+consider	O
+the	O
+physiology	O
+of	O
+ARDS	B-DISO
+because	O
+ARDS	B-DISO
+presents	O
+lung	B-ANAT
+inhomogeneity	O
+;	O
+the	O
+same	O
+low	O
+VT	O
+might	O
+increase	O
+local	O
+stress	O
+and	O
+strain	O
+in	O
+some	O
+patients	O
+with	O
+low	O
+compliance	O
+,	O
+and	O
+lung	B-ANAT
+recruitment	B-DISO
+could	O
+injure	O
+lungs	B-ANAT
+in	O
+ARDS	B-DISO
+patients	O
+with	O
+low	O
+recruitability	O
+and	O
+hemodynamic	B-DISO
+instability	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Life	O
+threatening	O
+manifestations	O
+of	O
+lupus	B-DISO
+and	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+in	O
+internal	O
+medicine	B-CHED
+].	O
+
+The	O
+two	O
+-	O
+hit	O
+lung	B-ANAT
+injury	O
+models	O
+described	O
+,	O
+resulting	O
+in	O
+additive	O
+but	O
+differential	O
+acute	O
+lung	B-ANAT
+injury	O
+recaptures	O
+the	O
+clinical	O
+relevant	O
+multifactorial	O
+etiology	O
+of	O
+ALI	O
+and	O
+could	O
+be	O
+a	O
+valuable	O
+tool	O
+in	O
+translational	B-PROC
+research	O
+.	O
+
+Among	O
+them	O
+,	O
+the	O
+3	O
+-(	O
+13	O
+-	O
+hydroxygeranyl	O
+)-	O
+1	O
+-(	O
+2	O
+'-	O
+methylbutanoyl	O
+)	O
+phloroglucinol	B-CHED
+was	O
+reported	O
+here	O
+for	O
+the	O
+first	O
+time	O
+.	O
+
+TITLE	O
+:	O
+Therapeutic	O
+potentials	O
+of	O
+Houttuynia	B-SPEC
+cordata	I-SPEC
+Thunb	O
+.	O
+
+against	O
+inflammation	B-DISO
+and	O
+oxidative	B-DISO
+stress	I-DISO
+:	O
+A	O
+review	O
+.	O
+
+Traditionally	O
+the	O
+plant	B-SPEC
+is	O
+used	O
+for	O
+its	O
+various	O
+beneficial	O
+properties	O
+against	O
+inflammation	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+muscular	B-ANAT
+sprain	O
+,	O
+stomach	B-DISO
+ulcer	I-DISO
+etc	O
+.	O
+
+This	O
+review	O
+aims	O
+to	O
+provide	O
+up	O
+-	O
+to	O
+-	O
+date	O
+and	O
+comprehensive	O
+information	O
+on	O
+the	O
+efficacy	O
+of	O
+H	B-SPEC
+.	I-SPEC
+cordata	I-SPEC
+extracts	O
+as	O
+well	O
+as	O
+its	O
+bioactive	O
+compounds	O
+both	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+,	O
+against	O
+oxidative	O
+stress	O
+and	O
+inflammation	B-DISO
+MATERIALS	O
+AND	O
+METHODS	O
+:	O
+Relevant	O
+information	O
+on	O
+H	B-SPEC
+.	I-SPEC
+cordata	I-SPEC
+against	O
+oxidative	B-DISO
+stress	I-DISO
+and	O
+inflammation	B-DISO
+were	O
+collected	O
+from	O
+the	O
+established	O
+scientific	O
+databases	O
+such	O
+as	O
+NCBI	O
+,	O
+Web	B-DISO
+of	O
+Science	O
+,	O
+ScienceDirect	O
+,	O
+Elsevier	O
+,	O
+and	O
+Springer	O
+.	O
+
+As	O
+both	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+studies	O
+were	O
+shown	O
+that	O
+H	B-SPEC
+.	I-SPEC
+cordata	I-SPEC
+did	O
+not	O
+have	O
+any	O
+toxicity	O
+on	O
+the	O
+various	O
+model	O
+systems	O
+used	O
+,	O
+future	O
+clinical	O
+studies	O
+will	O
+hopefully	O
+make	O
+an	O
+impact	O
+on	O
+the	O
+future	O
+direction	O
+of	O
+treating	O
+inflammation	B-DISO
+-	O
+related	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+were	O
+first	O
+identified	O
+in	O
+Canada	O
+in	O
+2014	O
+.	O
+
+TITLE	O
+:	O
+Extravascular	O
+lung	B-ANAT
+water	B-CHED
+measurements	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+why	O
+,	O
+how	O
+,	O
+and	O
+when	O
+?	O
+
+Currently	O
+,	O
+EVLW	O
+and	O
+pulmonary	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+index	O
+(	O
+PVPI	O
+)	O
+can	O
+be	O
+quantitatively	O
+measured	O
+using	O
+the	O
+transpulmonary	O
+thermodilution	O
+(	O
+TPTD	O
+)	O
+technique	O
+.	O
+
+Two	O
+days	O
+after	O
+initiation	O
+of	O
+oral	B-ANAT
+chloroquine	B-CHED
+treatment	O
+,	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+was	O
+diagnosed	O
+through	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+and	O
+chest	B-ANAT
+CT	O
+scan	O
+with	O
+intravenous	O
+contrast	O
+.	O
+
+Intravenous	O
+artesunate	B-CHED
+and	O
+oral	B-ANAT
+doxycycline	B-CHED
+were	O
+started	O
+and	O
+he	O
+made	O
+a	O
+full	O
+recovery	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Ovale	B-DISO
+malaria	I-DISO
+is	O
+usually	O
+considered	O
+a	O
+tropical	B-DISO
+infectious	I-DISO
+disease	I-DISO
+associated	O
+with	O
+low	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Both	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+were	O
+shown	O
+to	O
+express	O
+proteins	B-CHED
+with	O
+the	O
+potential	O
+to	O
+evade	O
+early	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+The	O
+potential	O
+role	O
+of	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+structural	O
+(	O
+M	O
+and	O
+N	O
+)	O
+and	O
+accessory	O
+proteins	B-CHED
+(	O
+ns2a	O
+and	O
+ns5a	O
+)	O
+in	O
+the	O
+alteration	O
+of	O
+antiviral	B-CHED
+gene	B-PROC
+expression	I-PROC
+was	O
+investigated	O
+in	O
+this	O
+study	O
+.	O
+
+HCoV	O
+-	O
+OC43M	O
+,	O
+N	O
+,	O
+ns2a	O
+and	O
+ns5a	O
+proteins	B-CHED
+were	O
+expressed	B-PROC
+in	O
+human	B-SPEC
+embryonic	B-ANAT
+kidney	B-ANAT
+293	O
+(	O
+HEK	O
+-	O
+293	O
+)	O
+cells	B-COMP
+before	O
+challenge	O
+with	O
+Sendai	B-SPEC
+virus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strains	O
+,	O
+designated	O
+as	O
+γCoV	O
+/	O
+ck	O
+/	O
+China	O
+/	O
+I0712	O
+/	O
+11	O
+(	O
+I0712	O
+/	O
+11	O
+)	O
+and	O
+γCoV	O
+/	O
+ck	O
+/	O
+China	O
+/	O
+I0108	O
+/	O
+17	O
+(	O
+I0108	O
+/	O
+17	O
+),	O
+were	O
+isolated	O
+from	O
+diseased	O
+chicken	B-SPEC
+flocks	O
+in	O
+different	O
+provinces	O
+in	O
+China	O
+and	O
+genotyped	O
+as	O
+Arkansas	O
+(	O
+Ark	B-PRGE
+)-	O
+type	O
+viruses	B-SPEC
+with	O
+three	O
+other	O
+Chinese	O
+Ark	B-PRGE
+field	O
+strains	O
+,	O
+the	O
+Jilin	O
+vaccine	O
+strain	O
+,	O
+and	O
+the	O
+American	O
+Ark	B-PRGE
+-	O
+and	O
+Ark	B-PRGE
+DPI	O
+-	O
+like	O
+viruses	B-SPEC
+.	O
+
+On	O
+postmortem	O
+examination	O
+,	O
+one	O
+bird	B-SPEC
+each	O
+in	O
+the	O
+MGC	B-DISO
++	O
+IBV	B-SPEC
+and	O
+IBV	B-SPEC
+groups	O
+developed	O
+peritonitis	B-DISO
+or	O
+airsacculitis	B-DISO
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+and	O
+Pathologic	O
+Characterization	O
+of	O
+a	O
+Novel	O
+Recombinant	O
+TC07	O
+-	O
+2	O
+-	O
+Type	O
+Avian	B-SPEC
+Infectious	I-DISO
+Bronchitis	I-DISO
+Virus	O
+.	O
+
+When	O
+7	O
+-	O
+day	O
+-	O
+old	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+were	O
+inoculated	O
+with	O
+the	O
+KrD1515	O
+virus	B-SPEC
+,	O
+they	O
+developed	O
+severe	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+tracheal	O
+lesions	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+one	O
+of	O
+the	O
+foremost	O
+causes	O
+of	O
+a	O
+persistent	O
+economic	O
+burden	O
+to	O
+poultry	O
+industries	O
+worldwide	O
+.	O
+
+The	O
+PDCoV	O
+-	O
+inoculated	O
+piglets	O
+showed	O
+acute	O
+,	O
+watery	B-DISO
+diarrhoea	I-DISO
+,	O
+but	O
+all	O
+recovered	O
+and	O
+survived	O
+.	O
+
+The	O
+outcome	O
+of	O
+interest	O
+was	O
+5	O
+-	O
+year	O
+mortality	O
+following	O
+infection	B-DISO
+.	O
+
+Variables	O
+of	O
+patient	O
+background	O
+and	O
+infectious	B-DISO
+episode	O
+were	O
+studied	O
+in	O
+association	O
+with	O
+the	O
+main	O
+outcome	O
+through	O
+multiple	O
+logistic	O
+regression	O
+.	O
+
+Age	O
+,	O
+previous	O
+comorbidities	O
+,	O
+and	O
+functional	O
+status	O
+and	O
+infection	B-DISO
+by	O
+an	O
+ESKAPE	O
+pathogen	O
+were	O
+consistently	O
+associated	O
+with	O
+long	O
+-	O
+term	O
+prognosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+coccidioidal	O
+pneumonia	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+.	O
+
+RESULTS	O
+:	O
+Three	O
+cases	O
+of	O
+severe	O
+coccidioidal	O
+ARDS	B-DISO
+survived	O
+after	O
+treatment	O
+with	O
+ECMO	O
+.	O
+
+TITLE	O
+:	O
+Infection	B-DISO
+,	O
+genetic	O
+and	O
+virulence	B-PROC
+characteristics	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+northwest	O
+China	O
+.	O
+
+Typical	O
+clinical	O
+symptoms	O
+of	O
+the	O
+disease	O
+included	O
+severe	B-DISO
+diarrhea	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+dehydration	B-DISO
+and	O
+death	B-PROC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+identify	O
+the	O
+pathogen	O
+,	O
+27	O
+intestinal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+dead	B-PROC
+piglets	O
+in	O
+Shaanxi	O
+,	O
+Gansu	O
+and	O
+Qinghai	O
+provinces	O
+and	O
+from	O
+Ningxia	O
+Hui	O
+Autonomous	O
+Region	O
+.	O
+
+Six	O
+strains	O
+were	O
+successfully	O
+isolated	O
+from	O
+positive	O
+samples	O
+and	O
+were	O
+serially	O
+passaged	O
+40	O
+times	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+with	O
+obvious	O
+cytopathic	O
+effects	O
+observed	O
+after	O
+24	O
+h	O
+post	O
+inoculation	O
+(	O
+hpi	B-DISO
+)	O
+and	O
+virus	B-SPEC
+titers	O
+reaching	B-PROC
+1	O
+.	O
+0	O
+×	O
+10	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+frequency	O
+of	O
+different	O
+pathogens	O
+involved	O
+in	O
+cases	O
+of	O
+recurrent	O
+neonatal	B-DISO
+diarrhoea	I-DISO
+in	O
+Spain	O
+.	O
+
+A	O
+total	O
+of	O
+327	O
+litters	O
+from	O
+109	O
+sow	O
+farms	O
+located	O
+in	O
+Spain	O
+with	O
+neonatal	O
+recurrent	O
+diarrhoea	B-DISO
+were	O
+sampled	O
+to	O
+establish	O
+a	O
+differential	O
+diagnosis	O
+against	O
+the	O
+main	O
+enteric	O
+pathogens	O
+in	O
+piglets	O
+.	O
+
+We	O
+investigated	O
+the	O
+in	O
+vitro	O
+bactericidal	O
+and	O
+virucidal	O
+efficacy	O
+of	O
+povidone	B-CHED
+-	O
+iodine	B-CHED
+(	O
+PVP	B-CHED
+-	O
+I	O
+)	O
+7	O
+%	O
+gargle	O
+/	O
+mouthwash	O
+at	O
+defined	O
+dilution	O
+against	O
+oral	B-ANAT
+and	O
+respiratory	B-ANAT
+tract	I-ANAT
+pathogens	O
+.	O
+
+PVP	B-CHED
+-	O
+I	O
+was	O
+tested	O
+against	O
+Klebsiella	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+according	O
+to	O
+bactericidal	O
+quantitative	O
+suspension	O
+test	O
+EN13727	O
+and	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronaviruses	O
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+),	O
+rotavirus	B-SPEC
+strain	O
+Wa	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+subtype	O
+H1N1	O
+according	O
+to	O
+virucidal	O
+quantitative	O
+suspension	O
+test	O
+EN14476	O
+.	O
+
+A	O
+≥	O
+5	O
+log	O
+PVP	B-CHED
+-	O
+I	O
+gargle	O
+/	O
+mouthwash	O
+diluted	O
+1	O
+:	O
+30	O
+(	O
+equivalent	O
+to	O
+a	O
+concentration	O
+of	O
+0	O
+.	O
+23	O
+%	O
+PVP	B-CHED
+-	O
+I	O
+)	O
+showed	O
+effective	O
+bactericidal	B-PROC
+activity	I-PROC
+against	O
+Klebsiella	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+and	O
+rapidly	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+(	O
+H1N1	O
+)	O
+and	O
+rotavirus	B-SPEC
+after	O
+15	O
+s	O
+of	O
+exposure	O
+.	O
+
+Veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+can	O
+be	O
+utilized	O
+for	O
+severe	O
+ACS	B-FUNC
+in	O
+adult	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+Prompt	O
+initiation	O
+of	O
+this	O
+modality	O
+may	O
+improve	O
+outcomes	O
+in	O
+adult	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+complicated	O
+by	O
+life	O
+threatening	O
+ACS	B-FUNC
+.	O
+
+TITLE	O
+:	O
+Resiquimod	B-CHED
+enhances	O
+mucosal	B-ANAT
+and	O
+systemic	O
+immunity	B-PROC
+against	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+vaccine	O
+in	O
+the	O
+chicken	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+effect	O
+of	O
+R	B-CHED
+-	I-CHED
+848	I-CHED
+when	O
+adjuvanted	O
+with	O
+live	O
+or	O
+inactivated	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccines	O
+with	O
+special	O
+emphasis	O
+on	O
+mucosal	B-PROC
+immunity	I-PROC
+.	O
+
+Groups	O
+that	O
+received	O
+either	O
+PBS	B-DISO
+or	O
+R	B-CHED
+-	I-CHED
+848	I-CHED
+served	O
+as	O
+control	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+many	O
+factors	O
+including	O
+inhalation	B-PROC
+of	O
+toxicants	O
+,	O
+acute	O
+barotrauma	O
+,	O
+acid	O
+aspiration	B-DISO
+,	O
+and	O
+burns	O
+.	O
+
+Glycerolipids	B-CHED
+,	O
+particularly	O
+those	O
+containing	O
+polyunsaturated	B-CHED
+fatty	I-CHED
+acid	I-CHED
+side	O
+-	O
+chains	O
+,	O
+represented	O
+many	O
+of	O
+the	O
+lipids	B-CHED
+with	O
+higher	O
+concentrations	O
+in	O
+survivors	O
+.	O
+
+These	O
+findings	O
+support	O
+future	O
+research	O
+aimed	O
+at	O
+integrating	O
+lipidomics	O
+into	O
+critical	O
+care	O
+medicine	B-CHED
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+that	O
+PDCoV	B-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+was	O
+close	O
+to	O
+the	O
+cluster	O
+containing	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+which	O
+utilizes	O
+porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+pAPN	O
+)	O
+as	O
+a	O
+functional	O
+receptor	O
+.	O
+
+This	O
+close	O
+proximity	O
+between	O
+human	B-SPEC
+and	O
+bats	B-SPEC
+provides	O
+ample	O
+opportunity	O
+for	O
+zoonotic	O
+events	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+determine	O
+during	O
+human	B-SPEC
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+the	O
+alveolar	B-ANAT
+macrophage	I-ANAT
+polarization	O
+,	O
+the	O
+effect	O
+of	O
+alveolar	B-ANAT
+environment	O
+on	O
+macrophage	B-ANAT
+polarization	O
+,	O
+and	O
+the	O
+role	O
+of	O
+polarized	O
+macrophages	B-ANAT
+on	O
+epithelial	O
+repair	B-PROC
+.	O
+
+Ex	O
+vivo	O
+,	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+from	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+exhibited	O
+anti	O
+-	O
+inflammatory	O
+characteristics	O
+with	O
+high	O
+CD163	B-PRGE
+expression	B-PROC
+and	O
+interleukin	B-PROC
+-	I-PROC
+10	I-PROC
+production	I-PROC
+.	O
+
+Early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+alveolar	B-ANAT
+environment	O
+drives	O
+an	O
+anti	O
+-	O
+inflammatory	O
+macrophage	B-ANAT
+polarization	O
+favoring	O
+epithelial	O
+repair	B-PROC
+through	O
+activation	O
+of	O
+the	O
+hepatocyte	B-PROC
+growth	B-PROC
+factor	I-PROC
+pathway	B-PROC
+.	O
+
+The	O
+risk	O
+of	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+to	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+was	O
+assessed	O
+in	O
+an	O
+outbreak	O
+in	O
+Riyadh	O
+.	O
+
+In	O
+an	O
+effort	B-PROC
+to	O
+overcome	O
+the	O
+PK	O
+shortcomings	O
+,	O
+modifications	O
+to	O
+the	O
+P3	O
+-	O
+P4	O
+junction	O
+were	O
+made	O
+.	O
+
+IBV	B-SPEC
+-	O
+CS	O
+vaccine	O
+administered	O
+alone	O
+resulted	O
+in	O
+markedly	O
+mucosal	B-PROC
+immune	I-PROC
+responses	I-PROC
+,	O
+characterized	O
+by	O
+high	O
+levels	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+IBV	I-PRGE
+IgA	I-PRGE
+isotype	I-PRGE
+antibodies	B-COMP
+and	O
+IFNγ	B-PRGE
+gene	I-PRGE
+expression	O
+at	O
+1dpi	O
+.	O
+
+TITLE	O
+:	O
+Is	O
+ambient	O
+air	B-CHED
+pollution	O
+associated	O
+with	O
+onset	O
+of	O
+sudden	B-DISO
+infant	I-DISO
+death	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+case	O
+-	O
+crossover	O
+study	O
+in	O
+the	O
+UK	O
+.	O
+
+For	O
+an	O
+IQR	O
+increase	O
+in	O
+previous	O
+day	O
+pollutant	O
+concentration	O
+,	O
+the	O
+percentage	O
+increases	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+in	O
+SIDS	B-DISO
+were	O
+16	O
+(	O
+6	O
+to	O
+27	O
+)	O
+for	O
+PM	O
+The	O
+results	O
+indicated	O
+ambient	O
+air	O
+pollutants	O
+,	O
+particularly	O
+PM	O
+RESULTS	O
+:	O
+For	O
+an	O
+IQR	O
+increase	O
+in	O
+previous	O
+day	O
+pollutant	O
+concentration	O
+,	O
+the	O
+percentage	O
+increases	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+in	O
+SIDS	B-DISO
+were	O
+16	O
+(	O
+6	O
+to	O
+27	O
+)	O
+for	O
+PM	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+characterisation	O
+of	O
+coronaviruses	O
+in	O
+migratory	O
+and	O
+non	O
+-	O
+migratory	O
+Australian	O
+wild	O
+birds	B-SPEC
+.	O
+
+Given	O
+that	O
+Australian	O
+duck	B-SPEC
+gammacoronaviruses	O
+are	O
+highly	O
+similar	O
+to	O
+those	O
+found	O
+in	O
+other	O
+regions	O
+,	O
+and	O
+Australian	O
+ducks	B-SPEC
+rarely	O
+come	O
+into	O
+contact	O
+with	O
+migratory	O
+Palearctic	O
+duck	B-SPEC
+species	B-SPEC
+,	O
+we	O
+hypothesise	O
+that	O
+migratory	O
+shorebirds	B-SPEC
+are	O
+the	O
+important	O
+vector	O
+for	O
+moving	B-PROC
+wild	O
+bird	B-SPEC
+coronaviruses	O
+into	O
+and	O
+out	O
+of	O
+Australia	O
+.	O
+
+Mitochondrial	B-COMP
+function	O
+analysis	O
+in	O
+cultured	O
+patient	O
+fibroblasts	B-ANAT
+was	O
+undertaken	O
+to	O
+confirm	O
+the	O
+pathogenicity	O
+of	O
+candidate	O
+variants	O
+.	O
+
+The	O
+patient	O
+presented	O
+at	O
+18	O
+months	O
+with	O
+acute	O
+hemiplegia	B-DISO
+and	O
+cognitive	O
+regression	O
+without	O
+obvious	O
+trigger	O
+.	O
+
+Previously	O
+reported	O
+cases	O
+of	O
+multiple	B-DISO
+mitochondrial	I-DISO
+dysfunctions	I-DISO
+syndrome	I-DISO
+2	I-DISO
+(	O
+MMDS2	B-DISO
+)	O
+with	O
+hyperglycinaemia	B-DISO
+caused	O
+by	O
+BOLA3	O
+mutations	O
+have	O
+leukodystrophy	B-DISO
+with	O
+severe	O
+,	O
+progressive	O
+neurological	O
+and	O
+multisystem	O
+disease	O
+.	O
+
+We	O
+have	O
+identified	O
+a	O
+novel	O
+disease	O
+-	O
+causing	O
+variant	O
+in	O
+BOLA3	B-PRGE
+validated	O
+by	O
+functional	O
+cellular	B-COMP
+studies	O
+.	O
+
+Our	O
+patient	O
+'	O
+s	O
+clinical	O
+course	O
+broadens	O
+the	O
+phenotypic	O
+spectrum	O
+of	O
+MMDS2	B-DISO
+and	O
+highlights	O
+the	O
+potential	O
+for	O
+some	O
+genetic	O
+leukoencephalopathies	B-DISO
+to	O
+spontaneously	O
+improve	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+patient	O
+presented	O
+at	O
+18	O
+months	O
+with	O
+acute	O
+hemiplegia	B-DISO
+and	O
+cognitive	O
+regression	O
+without	O
+obvious	O
+trigger	O
+.	O
+
+A	O
+serologic	O
+study	O
+was	O
+conducted	O
+to	O
+determine	O
+the	O
+asymptomatic	O
+MERS	O
+infection	B-DISO
+rate	O
+in	O
+healthcare	O
+workers	O
+and	O
+non	O
+-	O
+healthcare	O
+workers	O
+by	O
+exposure	O
+status	O
+.	O
+
+The	O
+case	O
+was	O
+quarantined	O
+at	O
+home	O
+for	O
+2	O
+weeks	O
+after	O
+discharge	O
+,	O
+and	O
+had	O
+underlying	O
+diseases	O
+,	O
+including	O
+hypertension	B-DISO
+,	O
+angina	B-DISO
+,	O
+and	O
+degenerative	B-DISO
+arthritis	I-DISO
+.	O
+
+A	O
+national	O
+,	O
+multicenter	O
+,	O
+point	O
+-	O
+prevalence	O
+study	O
+was	O
+conducted	O
+to	O
+determine	O
+the	O
+prevalence	O
+,	O
+causative	O
+microorganisms	O
+,	O
+and	O
+outcome	O
+of	O
+sepsis	B-DISO
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+)	O
+in	O
+Turkey	B-SPEC
+.	O
+
+The	O
+presence	O
+of	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+),	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+and	O
+septic	B-DISO
+shock	I-DISO
+were	O
+assessed	O
+and	O
+documented	O
+based	O
+on	O
+the	O
+consensus	O
+criteria	O
+of	O
+the	O
+American	O
+College	O
+of	O
+Chest	B-ANAT
+Physicians	O
+and	O
+Society	O
+of	O
+Critical	O
+Care	O
+Medicine	B-CHED
+(	O
+SEPSIS	B-DISO
+-	O
+I	O
+)	O
+in	O
+infected	O
+patients	O
+.	O
+
+According	O
+to	O
+SEPSIS	B-DISO
+-	O
+III	O
+,	O
+104	O
+(	O
+6	O
+.	O
+9	O
+%)	O
+patients	O
+had	O
+septic	B-DISO
+shock	I-DISO
+(	O
+mortality	O
+rate	O
+,	O
+75	O
+.	O
+9	O
+%).	O
+
+Approximately	O
+,	O
+74	O
+.	O
+9	O
+%,	O
+39	O
+.	O
+1	O
+%,	O
+and	O
+26	O
+.	O
+5	O
+%	O
+of	O
+Acinetobacter	B-SPEC
+,	O
+Klebsiella	B-SPEC
+,	O
+and	O
+Pseudomonas	B-SPEC
+spp	B-ENZY
+.	O
+
+Although	O
+the	O
+prevalence	O
+of	O
+carbapenem	B-CHED
+resistance	B-PROC
+was	O
+high	O
+in	O
+Turkish	O
+ICUs	O
+,	O
+it	O
+was	O
+not	O
+associated	O
+with	O
+a	O
+higher	O
+risk	O
+for	O
+mortality	O
+.	O
+
+infection	B-DISO
+,	O
+renal	B-ANAT
+replacement	O
+treatment	O
+,	O
+and	O
+a	O
+nurse	O
+-	O
+to	O
+-	O
+patient	O
+ratio	O
+of	O
+1	O
+:	O
+4	O
+(	O
+compared	O
+with	O
+a	O
+nurse	O
+-	O
+to	O
+-	O
+patient	O
+ratio	O
+of	O
+1	O
+:	O
+2	O
+)	O
+were	O
+independent	O
+predictors	O
+of	O
+mortality	O
+in	O
+infected	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Varicella	O
+pneumonia	O
+is	O
+a	O
+rare	O
+but	O
+a	O
+serious	O
+complication	B-DISO
+of	O
+chickenpox	B-DISO
+in	O
+adults	O
+.	O
+
+Fisher	B-SPEC
+'	O
+s	O
+Z	O
+-	O
+test	O
+of	O
+proportions	O
+and	O
+analysis	O
+of	O
+variance	O
+were	O
+applied	O
+.	O
+
+The	O
+mortality	O
+was	O
+higher	O
+among	O
+patients	O
+with	O
+qSOFA	O
+>	O
+3	O
+,	O
+mean	O
+arterial	B-ANAT
+blood	I-ANAT
+pressure	O
+<	O
+60	O
+mmHg	O
+,	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+at	O
+presentation	O
+.	O
+
+Patients	O
+with	O
+severe	O
+varicella	B-DISO
+pneumonia	I-DISO
+are	O
+at	O
+an	O
+increased	O
+risk	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+microvascular	O
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+ECs	O
+)	O
+are	O
+integral	O
+to	O
+the	O
+alveoli	B-ANAT
+-	O
+capillary	B-ANAT
+barrier	O
+of	O
+the	O
+lung	B-ANAT
+.	O
+
+Of	O
+the	O
+33	O
+APIP	O
+patients	O
+,	O
+26	O
+(	O
+79	O
+%)	O
+developed	O
+APIP	O
+in	O
+the	O
+late	B-DISO
+pregnancy	I-DISO
+.	O
+
+Among	O
+the	O
+31	O
+neonates	O
+born	O
+alive	O
+(	O
+two	O
+of	O
+them	O
+were	O
+twins	O
+),	O
+1	O
+(	O
+3	O
+%)	O
+died	B-PROC
+,	O
+12	O
+(	O
+39	O
+%)	O
+experienced	O
+neonatal	B-DISO
+hyperbilirubinemia	I-DISO
+,	O
+8	O
+(	O
+26	O
+%)	O
+had	O
+neonatal	B-DISO
+hypoglycemia	I-DISO
+,	O
+6	O
+(	O
+19	O
+%)	O
+had	O
+neonatal	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+5	O
+(	O
+16	O
+%)	O
+experienced	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+and	O
+2	O
+(	O
+6	O
+%)	O
+experienced	O
+intracranial	B-DISO
+hemorrhage	I-DISO
+.	O
+
+The	O
+study	O
+indicated	O
+three	O
+statistically	O
+significant	O
+risk	O
+factors	O
+of	O
+influenza	B-DISO
+severity	O
+,	O
+including	O
+presence	O
+of	O
+chronic	O
+underlying	O
+illness	O
+/	O
+condition	B-DISO
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+of	O
+15	O
+.	O
+2	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+)	O
+of	O
+1	O
+.	O
+8	O
+–	O
+125	O
+.	O
+4	O
+,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+),	O
+age	O
+≥	O
+15	O
+years	O
+(	O
+OR	O
+9	O
+.	O
+2	O
+,	O
+95	O
+%	O
+CI	O
+3	O
+.	O
+5	O
+–	O
+24	O
+.	O
+1	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+delay	O
+in	O
+medical	O
+care	O
+of	O
+more	O
+than	O
+two	O
+days	O
+after	O
+the	O
+symptoms	O
+onset	O
+(	O
+OR	O
+3	O
+.	O
+2	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+6	O
+–	O
+6	O
+.	O
+4	O
+,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+prevalence	O
+,	O
+symptom	O
+course	O
+,	O
+and	O
+shedding	O
+in	O
+persons	O
+infected	O
+with	O
+the	O
+4	O
+most	O
+common	O
+human	B-SPEC
+coronaviruses	O
+(	O
+HCoV	O
+)-	O
+229E	O
+,	O
+HKU1	O
+,	O
+NL63	O
+,	O
+and	O
+OC43	O
+are	O
+poorly	O
+described	O
+.	O
+
+We	O
+estimate	O
+their	O
+prevalence	O
+and	O
+associated	B-DISO
+symptoms	I-DISO
+among	O
+college	O
+students	O
+identified	O
+via	O
+a	O
+social	O
+network	O
+study	O
+design	O
+.	O
+
+Whereas	O
+RV	O
+outbreaks	O
+were	O
+coincident	O
+between	O
+the	O
+KCDC	O
+and	O
+the	O
+adult	O
+graph	O
+with	O
+respect	O
+to	O
+influenza	O
+virus	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+the	O
+same	O
+was	O
+not	O
+true	O
+for	O
+human	B-SPEC
+bocavirus	I-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+and	O
+adenovirus	B-DISO
+.	O
+
+A	O
+national	O
+RV	O
+surveillance	O
+dataset	O
+may	O
+be	O
+useful	O
+in	O
+identifying	O
+RV	O
+outbreaks	O
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+ARI	B-CHED
+.	O
+
+The	O
+mean	O
+of	O
+survival	O
+days	O
+from	O
+onset	O
+of	O
+illness	O
+to	O
+death	O
+was	O
+46	O
+.	O
+6	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+30	O
+.	O
+5	O
+-	O
+62	O
+.	O
+6	O
+)	O
+for	O
+the	O
+IFN	B-PRGE
+group	I-PRGE
+compared	O
+with	O
+18	O
+.	O
+8	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+10	O
+.	O
+3	O
+-	O
+27	O
+.	O
+4	O
+)	O
+for	O
+the	O
+supportive	O
+-	O
+only	O
+group	O
+(	O
+P	O
+=	O
+.	O
+001	O
+).	O
+
+Thus	O
+,	O
+the	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+fecal	B-ANAT
+S100A12	O
+concentrations	O
+in	O
+a	O
+cohort	O
+of	O
+puppies	O
+with	O
+intestinal	B-DISO
+parasites	I-DISO
+(	O
+Cystoisospora	B-SPEC
+spp	B-ENZY
+.,	O
+Toxocara	B-SPEC
+canis	I-SPEC
+,	O
+Giardia	B-DISO
+sp	O
+.)	O
+and	O
+viral	O
+agents	O
+that	O
+are	O
+frequently	O
+encountered	O
+and	O
+known	O
+to	O
+cause	O
+gastrointestinal	O
+signs	O
+in	O
+dogs	B-SPEC
+(	O
+coronavirus	B-SPEC
+,	O
+parvovirus	B-DISO
+)	O
+as	O
+a	O
+comparative	O
+model	O
+.	O
+
+(	O
+C	B-SPEC
+.	I-SPEC
+canis	I-SPEC
+and	O
+C	B-SPEC
+.	I-SPEC
+ohioensis	I-SPEC
+),	O
+Toxocara	B-SPEC
+canis	I-SPEC
+,	O
+Giardia	B-DISO
+sp	O
+.,	O
+as	O
+well	O
+as	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCV	B-DISO
+)	O
+and	O
+parvovirus	B-DISO
+(	O
+CPV	B-SPEC
+).	O
+
+Of	O
+16928	O
+NPSs	O
+tested	O
+for	O
+the	O
+common	O
+viruses	B-SPEC
+,	O
+4259	O
+(	O
+25	O
+.	O
+2	O
+%)	O
+were	O
+positive	O
+for	O
+≥	O
+1	O
+target	O
+;	O
+596	O
+(	O
+13	O
+.	O
+8	O
+%)	O
+had	O
+coinfections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Burden	O
+and	O
+Risk	O
+Factors	O
+for	O
+Coronavirus	B-DISO
+Infections	I-DISO
+in	O
+Infants	O
+in	O
+Rural	O
+Nepal	O
+.	O
+
+ABSTRACT	O
+:	O
+Knowledge	O
+of	O
+risk	O
+factors	O
+for	O
+symptomatic	O
+human	O
+coronavirus	O
+(	O
+HCoV	O
+)	O
+infections	B-DISO
+in	O
+children	O
+in	O
+community	O
+settings	O
+is	O
+limited	O
+.	O
+
+There	O
+is	O
+an	O
+increased	O
+risk	O
+of	O
+HCoV	O
+infection	B-DISO
+beyond	O
+the	O
+first	O
+month	O
+of	O
+life	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+represented	O
+a	O
+human	B-SPEC
+health	O
+threat	O
+since	O
+2012	O
+.	O
+
+International	O
+health	O
+community	O
+'	O
+s	O
+attention	O
+goes	B-SPEC
+towards	O
+this	O
+mass	O
+gathering	O
+and	O
+the	O
+possibility	O
+of	O
+the	O
+development	B-PROC
+of	O
+any	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+due	O
+to	O
+the	O
+high	O
+risk	O
+of	O
+acquisition	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+We	O
+searched	O
+MEDLINE	O
+/	O
+PubMed	O
+and	O
+Scopus	B-SPEC
+databases	O
+for	O
+relevant	O
+papers	O
+describing	O
+the	O
+prevalence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+among	O
+Hajj	O
+pilgrims	O
+.	O
+
+Post	O
+-	O
+Hajj	O
+cohort	O
+studies	O
+would	O
+further	O
+evaluate	O
+the	O
+impact	O
+of	O
+the	O
+Hajj	O
+on	O
+the	O
+acquisition	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Data	O
+of	O
+spirometry	O
+,	O
+total	O
+lung	B-PROC
+capacity	I-PROC
+(	O
+TLC	O
+),	O
+diffusing	O
+capacity	O
+of	O
+carbon	B-CHED
+monoxide	I-CHED
+(	O
+DL	O
+Nine	O
+survivors	O
+of	O
+H1N1	O
+-	O
+ARDS	B-DISO
+in	O
+the	O
+study	O
+period	O
+were	O
+included	O
+.	O
+
+ABSTRACT	O
+:	O
+Infections	B-DISO
+with	O
+bat	B-ENZY
+-	O
+origin	O
+coronaviruses	O
+have	O
+caused	O
+severe	O
+illness	O
+in	O
+humans	O
+by	O
+'	B-COMP
+host	I-COMP
+jump	O
+'.	O
+
+Recently	O
+,	O
+novel	O
+bat	B-ENZY
+-	O
+origin	O
+coronaviruses	O
+were	O
+found	O
+in	O
+pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+lethal	O
+zoonosis	B-DISO
+that	O
+causes	O
+death	B-PROC
+in	O
+35	O
+·	O
+7	O
+%	O
+of	O
+cases	O
+.	O
+
+The	O
+clinical	O
+features	O
+associated	O
+with	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+are	O
+not	O
+MERS	O
+-	O
+specific	O
+and	O
+are	O
+similar	O
+to	O
+other	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+cell	B-COMP
+-	O
+invading	O
+molecular	O
+machinery	O
+,	O
+coronavirus	B-SPEC
+spike	O
+proteins	B-CHED
+pose	O
+an	O
+evolutionary	O
+conundrum	O
+due	O
+to	O
+their	O
+high	O
+divergence	O
+.	O
+
+Based	O
+on	O
+the	O
+above	O
+structural	O
+and	O
+functional	O
+comparisons	O
+,	O
+we	O
+propose	O
+that	O
+the	O
+evolutionary	O
+spectrum	O
+of	O
+coronavirus	B-SPEC
+spikes	O
+follows	O
+the	O
+order	B-SPEC
+of	O
+α	O
+-,	O
+δ	O
+-,	O
+γ	O
+-,	O
+and	O
+β	O
+-	O
+genus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+hypervariable	O
+regions	O
+in	O
+spike	O
+protein	B-CHED
+on	O
+pathogenicity	O
+,	O
+tropism	B-PROC
+,	O
+and	O
+serotypes	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+All	O
+seven	O
+recombinant	O
+IBVs	O
+proliferated	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+but	O
+the	O
+heterogenous	O
+HVRs	O
+could	O
+reduce	O
+their	O
+capacity	O
+for	O
+adsorption	O
+during	O
+in	O
+vitro	O
+infection	B-DISO
+.	O
+
+Distal	O
+embolization	O
+was	O
+noted	O
+in	O
+four	O
+patients	O
+(	O
+6	O
+%),	O
+of	O
+whom	O
+two	O
+had	O
+AMI	B-DISO
+.	O
+
+All	O
+large	O
+emboli	O
+were	O
+retrieved	O
+using	O
+catheter	O
+aspiration	B-DISO
+devices	O
+,	O
+but	O
+one	O
+small	O
+distal	O
+embolus	O
+was	O
+left	O
+untreated	O
+with	O
+no	O
+clinical	O
+consequences	O
+.	O
+
+Despite	O
+the	O
+use	O
+of	O
+EPD	B-DISO
+,	O
+distal	O
+embolization	O
+occurred	O
+in	O
+6	O
+%	O
+of	O
+patients	O
+and	O
+was	O
+successfully	O
+treated	O
+using	O
+catheter	O
+aspiration	B-DISO
+devices	O
+.	O
+
+All	O
+samples	O
+were	O
+collected	O
+on	O
+the	O
+day	O
+of	O
+weaning	O
+and	O
+14	O
+days	O
+after	O
+weaning	B-PROC
+.	O
+
+More	O
+emphasis	O
+should	O
+be	O
+placed	O
+on	O
+educating	O
+the	O
+student	O
+participants	O
+about	O
+preventive	O
+measures	O
+such	O
+as	O
+using	O
+tissues	B-ANAT
+when	O
+sneezing	O
+and	O
+coughing	B-DISO
+and	O
+proper	O
+tissue	B-ANAT
+disposal	O
+.	O
+
+TITLE	O
+:	O
+Factors	O
+among	O
+patients	O
+receiving	O
+prone	O
+positioning	O
+for	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+found	O
+useful	O
+for	O
+predicting	O
+mortality	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Therefore	O
+,	O
+the	O
+combined	O
+induction	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+CD8	B-PRGE
+T	B-ANAT
+cells	I-ANAT
+and	O
+antibodies	B-COMP
+may	O
+provide	O
+optimal	O
+protective	O
+immunity	B-PROC
+.	O
+
+We	O
+screened	O
+case	O
+records	O
+of	O
+all	O
+children	O
+aged	O
+1	O
+month	O
+to	O
+17	O
+years	O
+of	O
+age	O
+admitted	O
+to	O
+the	O
+Pediatric	O
+Intensive	O
+Care	O
+Unit	O
+(	O
+PICU	B-SPEC
+)	O
+over	O
+a	O
+3	O
+-	O
+year	O
+period	O
+(	O
+2015	O
+-	O
+2017	O
+)	O
+for	O
+presence	O
+of	O
+any	O
+respiratory	B-DISO
+difficulty	I-DISO
+at	O
+admission	O
+or	O
+during	O
+PICU	B-SPEC
+stay	O
+.	O
+
+A	O
+total	O
+of	O
+61	O
+children	O
+(	O
+prevalence	O
+9	O
+.	O
+9	O
+%;	O
+95	O
+%	O
+CI	O
+:	O
+7	O
+.	O
+8	O
+-	O
+12	O
+.	O
+4	O
+)	O
+fulfilled	O
+the	O
+definition	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+with	O
+either	O
+of	O
+the	O
+two	O
+criteria	O
+.	O
+
+Among	O
+the	O
+recently	O
+emerged	O
+respiratory	O
+pathogens	O
+are	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+coronaviruses	O
+,	O
+enteroviruses	B-SPEC
+,	O
+and	O
+adenoviruses	B-SPEC
+.	O
+
+As	O
+the	O
+genesis	O
+of	O
+these	O
+emerging	O
+viruses	B-SPEC
+is	O
+not	O
+well	O
+understood	O
+and	O
+their	O
+detection	O
+normally	O
+occurs	O
+after	O
+they	O
+have	O
+crossed	O
+over	O
+and	O
+adapted	O
+to	O
+man	B-CHED
+,	O
+ideally	O
+,	O
+strategies	O
+for	O
+such	O
+novel	O
+virus	O
+detection	O
+should	O
+include	O
+intensive	O
+surveillance	O
+at	O
+the	O
+human	B-SPEC
+-	O
+animal	B-SPEC
+interface	O
+,	O
+particularly	O
+if	O
+one	O
+believes	O
+the	O
+paradigm	O
+that	O
+many	O
+novel	O
+emerging	O
+zoonotic	O
+viruses	B-SPEC
+first	O
+circulate	O
+in	O
+animal	B-SPEC
+populations	O
+and	O
+occasionally	O
+infect	O
+man	B-CHED
+before	O
+they	O
+fully	O
+adapt	O
+to	O
+man	B-CHED
+;	O
+early	O
+detection	O
+at	O
+the	O
+human	B-SPEC
+-	O
+animal	B-SPEC
+interface	O
+will	O
+provide	O
+earlier	O
+warning	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+is	O
+one	O
+of	O
+the	O
+main	O
+aetiological	O
+agents	O
+of	O
+gastroenteritis	O
+in	O
+calves	O
+,	O
+causing	O
+significant	O
+economic	O
+damage	O
+to	O
+livestock	O
+.	O
+
+A	O
+total	O
+of	O
+114	O
+faecal	B-ANAT
+samples	O
+from	O
+beef	O
+and	O
+dairy	O
+calves	O
+with	O
+or	O
+without	O
+clinical	O
+symptoms	O
+of	O
+diarrhoea	B-DISO
+from	O
+five	O
+Brazilian	O
+states	O
+(	O
+São	O
+Paulo	O
+,	O
+Minas	O
+Gerais	O
+,	O
+Santa	O
+Catarina	O
+,	O
+Mato	O
+Grosso	O
+and	O
+Bahia	B-SPEC
+)	O
+were	O
+evaluated	O
+between	O
+2008	O
+and	O
+2015	O
+by	O
+technique	O
+of	O
+Semi	O
+-	O
+nested	O
+RT	O
+-	O
+PCR	O
+for	O
+gene	O
+N	O
+and	O
+genealogical	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recently	O
+emerged	O
+highly	O
+virulent	O
+variants	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+have	O
+caused	O
+colossal	O
+economic	O
+losses	O
+to	O
+the	O
+worldwide	O
+swine	B-SPEC
+industry	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+Marburg	B-SPEC
+virus	I-SPEC
+(	O
+MARV	O
+)	O
+are	O
+among	O
+the	O
+World	O
+Health	O
+Organization	O
+'	O
+s	O
+top	O
+8	O
+emerging	O
+pathogens	O
+.	O
+
+For	O
+both	O
+MERS	O
+-	O
+CoV	O
+(	O
+pseudovirus	O
+)	O
+as	O
+well	O
+as	O
+MARV	O
+(	O
+GPs	B-DISO
+),	O
+4	O
+LAP	B-DISO
+devices	O
+(	O
+Mini	O
+Hemopurifiers	O
+,	O
+Aethlon	O
+Medical	O
+,	O
+San	O
+Diego	O
+,	O
+CA	O
+,	O
+USA	O
+)	O
+and	O
+4	O
+negative	O
+controls	O
+were	O
+tested	O
+.	O
+
+Considering	O
+the	O
+high	O
+lethality	O
+and	O
+missing	O
+established	O
+treatment	O
+options	O
+,	O
+LAP	B-DISO
+should	O
+be	O
+evaluated	O
+in	O
+vivo	O
+.	O
+
+The	O
+algorithm	O
+was	O
+proposed	O
+for	O
+respiratory	O
+treatment	O
+by	O
+veno	O
+-	O
+venous	O
+(	O
+VV	O
+)	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+The	O
+scenario	O
+includes	O
+all	O
+critical	O
+stages	O
+:	O
+hospital	O
+identification	O
+(	O
+Regional	O
+Department	O
+of	O
+Intensive	O
+Care	O
+)	O
+-	O
+inclusion	O
+and	O
+exclusion	O
+criteria	O
+matching	O
+using	O
+an	O
+authorship	O
+protocol	O
+;	O
+ECMO	O
+team	O
+transport	B-PROC
+;	O
+therapy	O
+confirmation	O
+;	O
+veno	O
+-	O
+venous	B-ANAT
+cannulation	O
+of	O
+mannequin	O
+'	O
+s	O
+artificial	O
+vessels	B-ANAT
+and	O
+implementation	O
+of	O
+perfusion	O
+therapy	O
+and	O
+transport	B-PROC
+with	O
+ECMO	O
+to	O
+another	O
+hospital	O
+in	O
+a	O
+provincial	O
+city	O
+(	O
+Clinical	O
+Department	O
+of	O
+Intensive	O
+Care	O
+),	O
+where	O
+the	O
+VV	O
+ECMO	O
+therapy	O
+was	O
+performed	O
+in	O
+the	O
+next	O
+48	O
+h	O
+,	O
+as	O
+training	O
+platform	O
+.	O
+
+It	O
+was	O
+found	O
+that	O
+four	O
+miRNAs	O
+(	O
+miR	B-PRGE
+-	I-PRGE
+1454	I-PRGE
+,	O
+miR	B-PRGE
+-	I-PRGE
+3538	I-PRGE
+,	O
+miR	B-PRGE
+-	I-PRGE
+146a	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+and	O
+miR	B-PRGE
+-	I-PRGE
+215	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+)	O
+were	O
+related	O
+to	O
+the	O
+infection	B-DISO
+of	O
+virulent	O
+nephropathogenic	O
+IBV	B-SPEC
+with	O
+transcript	O
+per	O
+million	O
+(	O
+TPM	B-CHED
+)	O
+>	O
+500	O
+and	O
+more	O
+than	O
+a	O
+2	O
+-	O
+fold	O
+alteration	O
+.	O
+
+In	O
+vitro	O
+,	O
+we	O
+found	O
+that	O
+high	O
+levels	O
+of	O
+miR	B-PRGE
+-	I-PRGE
+146a	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+could	O
+enhance	O
+the	O
+replication	O
+of	O
+IBV	B-SPEC
+at	O
+the	O
+early	O
+stage	O
+of	O
+infection	B-DISO
+,	O
+and	O
+its	O
+down	O
+regulated	O
+level	O
+could	O
+slow	O
+down	O
+the	O
+replication	O
+of	O
+IBV	B-SPEC
+.	O
+
+Finally	O
+,	O
+high	O
+levels	O
+of	O
+exogenous	O
+miR	B-PRGE
+-	I-PRGE
+146a	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+in	O
+HD11	O
+cells	B-COMP
+led	O
+to	O
+down	B-PROC
+regulation	I-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+receptor	I-PRGE
+associated	I-PRGE
+kinase	I-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+IRAK2	O
+)	O
+and	O
+Tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+receptor	I-PRGE
+superfamily	B-SPEC
+member	I-PRGE
+18	I-PRGE
+(	O
+TNFRSF18	O
+)	O
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+are	O
+limited	O
+data	O
+on	O
+the	O
+epidemiology	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+necessitating	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+chronic	I-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+).	O
+
+A	O
+retrospective	O
+study	O
+of	O
+patients	O
+admitted	O
+to	O
+a	O
+quaternary	O
+referral	O
+medical	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+between	O
+January	O
+2008	O
+and	O
+December	O
+2012	O
+with	O
+a	O
+diagnosis	O
+of	O
+severe	O
+COPD	B-DISO
+and	O
+requiring	O
+invasive	O
+mechanical	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+ICU	O
+mortality	O
+(	O
+9	O
+%	O
+vs	O
+27	O
+%;	O
+P	O
+<	O
+.	O
+001	O
+),	O
+and	O
+the	O
+hospital	O
+mortality	O
+(	O
+17	O
+%	O
+vs	O
+32	O
+%;	O
+P	O
+=	O
+.	O
+004	O
+)	O
+for	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+an	O
+acute	O
+exacerbation	O
+of	O
+severe	O
+COPD	B-DISO
+were	O
+lower	O
+than	O
+those	O
+with	O
+other	O
+etiologies	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Following	O
+serial	O
+dilutions	O
+of	O
+AF	O
+,	O
+detection	O
+limits	O
+of	O
+the	O
+partial	O
+assay	O
+were	O
+higher	O
+than	O
+those	O
+of	O
+the	O
+full	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+associated	O
+with	O
+a	O
+severe	O
+pro	B-CHED
+-	O
+inflammatory	B-DISO
+response	I-DISO
+;	O
+although	O
+decreased	O
+plasma	B-ANAT
+cholesterol	B-CHED
+concentration	O
+has	O
+been	O
+linked	O
+to	O
+systemic	O
+inflammation	B-DISO
+,	O
+any	O
+association	O
+of	O
+phospholipid	B-CHED
+metabolic	B-PATH
+pathways	B-PROC
+with	O
+ARDS	B-DISO
+has	O
+not	O
+been	O
+characterized	O
+.	O
+
+A	O
+high	O
+level	O
+of	O
+vigilance	O
+and	O
+proper	O
+disposition	O
+will	O
+enable	O
+the	O
+emergency	B-DISO
+clinician	O
+to	O
+effectively	O
+diagnose	O
+,	O
+manage	O
+,	O
+and	O
+contain	O
+these	O
+diseases	O
+.	O
+
+PEDV	B-SPEC
+NA	O
+,	O
+IgG	B-PRGE
+and	O
+IgA	B-PRGE
+were	O
+detected	O
+in	O
+the	O
+serum	B-COMP
+of	O
+piglets	O
+born	O
+to	O
+immunized	O
+gilts	O
+,	O
+demonstrating	O
+the	O
+transfer	O
+of	O
+antibodies	B-COMP
+through	O
+colostrum	B-ANAT
+and	O
+milk	O
+.	O
+
+TITLE	O
+:	O
+Right	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+during	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+.	O
+
+Emergency	B-DISO
+Health	O
+Services	O
+Life	O
+Flight	B-PROC
+,	O
+the	O
+primary	O
+critical	O
+care	O
+transport	B-PROC
+program	O
+in	O
+Eastern	O
+Canada	O
+,	O
+developed	O
+a	O
+prone	O
+position	O
+protocol	O
+to	O
+meet	O
+this	O
+clinical	O
+need	O
+.	O
+
+TITLE	O
+:	O
+Temporal	O
+relationship	O
+between	O
+antibiotic	B-CHED
+use	O
+and	O
+respiratory	O
+virus	B-SPEC
+activities	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+:	O
+a	O
+time	O
+-	O
+series	O
+analysis	O
+.	O
+
+The	O
+monthly	O
+detection	O
+rates	O
+of	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+adenovirus	B-DISO
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+and	O
+human	B-SPEC
+rhinovirus	I-SPEC
+,	O
+were	O
+collected	O
+from	O
+Korea	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+.	O
+
+Cross	O
+-	O
+correlation	O
+analysis	O
+was	O
+conducted	O
+to	O
+quantify	O
+the	O
+temporal	O
+relationship	O
+between	O
+antibiotic	O
+use	O
+and	O
+respiratory	O
+virus	B-SPEC
+activities	O
+as	O
+well	O
+as	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+primary	O
+clinics	O
+.	O
+
+We	O
+described	O
+the	O
+incidence	O
+of	O
+ARDS	B-DISO
+within	O
+1	O
+week	O
+following	O
+the	O
+detection	O
+of	O
+HMP	B-PRGE
+or	O
+RSV	B-SPEC
+using	O
+recently	O
+developed	O
+Pediatric	O
+ARDS	B-DISO
+(	O
+PARDS	O
+)	O
+criteria	O
+.	O
+
+Children	O
+with	O
+either	O
+virus	B-SPEC
+and	O
+a	O
+neurologic	O
+comorbidity	O
+or	O
+an	O
+increased	O
+PIM	B-CHED
+3	O
+probability	O
+of	O
+mortality	O
+were	O
+at	O
+increased	O
+risk	O
+for	O
+PARDS	O
+.	O
+
+TITLE	O
+:	O
+Heterologous	O
+prime	O
+-	O
+boost	O
+vaccination	O
+with	O
+adenoviral	B-SPEC
+vector	O
+and	O
+protein	B-CHED
+nanoparticles	B-CHED
+induces	O
+both	O
+Th1	O
+and	O
+Th2	O
+responses	O
+against	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+highly	O
+pathogenic	O
+and	O
+zoonotic	O
+virus	B-SPEC
+with	O
+a	O
+fatality	O
+rate	O
+in	O
+humans	B-SPEC
+of	O
+over	O
+35	O
+%.	O
+
+Our	O
+results	O
+demonstrate	O
+that	O
+heterologous	O
+immunization	O
+by	O
+priming	O
+with	O
+Ad5	B-DISO
+/	O
+MERS	O
+and	O
+boosting	O
+with	O
+spike	O
+protein	B-CHED
+nanoparticles	B-CHED
+could	O
+be	O
+an	O
+efficient	O
+prophylactic	O
+strategy	O
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Early	O
+events	O
+during	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+entry	O
+to	O
+the	O
+cell	B-COMP
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+how	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+enters	O
+the	O
+susceptible	O
+cell	B-COMP
+.	O
+
+With	O
+our	O
+research	O
+we	O
+strove	O
+to	O
+broaden	O
+the	O
+understanding	O
+of	O
+the	O
+infection	B-DISO
+process	O
+,	O
+which	O
+in	O
+future	O
+may	O
+be	O
+beneficial	O
+for	O
+the	O
+development	B-PROC
+of	O
+a	O
+potential	O
+therapeutics	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+was	O
+detected	O
+in	O
+1	O
+.	O
+3	O
+%	O
+(	O
+75	O
+/	O
+5573	O
+)	O
+of	O
+child	O
+pneumonia	B-DISO
+admissions	O
+.	O
+
+TITLE	O
+:	O
+Sevoflurane	B-CHED
+improves	O
+respiratory	B-PROC
+mechanics	I-PROC
+and	O
+gas	B-ENZY
+exchange	O
+in	O
+a	O
+case	O
+series	O
+of	O
+infants	O
+with	O
+severe	O
+bronchiolitis	O
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+More	O
+than	O
+one	O
+virus	B-SPEC
+positivity	O
+occurred	O
+in	O
+13	O
+FN	O
+episodes	O
+.	O
+
+Whole	O
+-	O
+brain	B-ANAT
+analysis	O
+of	O
+DTI	O
+metrics	O
+between	O
+groups	O
+was	O
+conducted	O
+by	O
+employing	O
+tract	O
+-	O
+based	O
+spatial	O
+statistics	O
+(	O
+TBSS	O
+),	O
+including	O
+fractional	O
+anisotropy	O
+(	O
+FA	O
+),	O
+mean	O
+diffusivity	O
+(	O
+MD	O
+),	O
+axial	O
+diffusivity	O
+(	O
+AD	O
+)	O
+and	O
+radial	O
+diffusivity	O
+(	O
+RD	O
+).	O
+
+DTI	O
+-	O
+TBSS	O
+is	O
+helpful	O
+to	O
+explore	O
+the	O
+WM	O
+microstructure	O
+abnormalities	O
+and	O
+provide	O
+a	O
+new	O
+perspective	O
+for	O
+the	O
+investigation	O
+of	O
+the	O
+pathomechanism	O
+of	O
+HIV	B-DISO
+-	O
+associated	O
+WM	O
+injury	O
+.	O
+
+The	O
+impairments	O
+in	O
+the	O
+corona	B-ANAT
+radiata	I-ANAT
+had	O
+significant	O
+correlations	O
+with	O
+the	O
+current	O
+CD4	B-PRGE
+
+TITLE	O
+:	O
+Differential	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+induced	O
+by	O
+classical	O
+and	O
+variant	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+in	O
+specific	O
+pathogen	O
+free	O
+chicks	O
+.	O
+
+Upper	O
+and	O
+lower	O
+respiratory	B-ANAT
+samples	I-ANAT
+were	O
+obtained	O
+from	O
+17	O
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+patients	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+sub	O
+-	O
+genomic	O
+mRNA	B-CHED
+was	O
+detected	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+and	O
+MERS	O
+-	O
+CoV	O
+genomic	O
+RNA	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+In	O
+oropharyngeal	B-ANAT
+and	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+specimens	O
+,	O
+the	O
+detection	O
+of	O
+sub	O
+-	O
+genomic	O
+mRNA	B-CHED
+and	O
+genomic	O
+RNA	O
+did	O
+not	O
+correlate	O
+.	O
+
+Although	O
+not	O
+all	O
+cases	O
+manifest	O
+with	O
+typical	O
+patterns	O
+,	O
+most	O
+typical	O
+imaging	O
+patterns	O
+of	O
+viral	B-DISO
+pneumonia	I-DISO
+can	O
+be	O
+classified	O
+according	O
+to	O
+viral	O
+families	O
+.	O
+
+Although	O
+a	O
+definite	O
+diagnosis	O
+cannot	O
+be	O
+achieved	O
+on	O
+the	O
+basis	O
+of	O
+imaging	O
+features	O
+alone	O
+,	O
+recognition	O
+of	O
+viral	B-DISO
+pneumonia	I-DISO
+patterns	O
+may	O
+aid	O
+in	O
+differentiating	O
+viral	O
+pathogens	O
+,	O
+thus	O
+reducing	O
+the	O
+use	O
+of	O
+antibiotics	B-CHED
+.	O
+
+Previously	O
+,	O
+we	O
+developed	O
+a	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+MERS	O
+-	O
+CoV	O
+[	O
+Virol	O
+J	O
+.	O
+2014	O
+.	O
+
+With	O
+very	O
+intensive	O
+care	O
+for	O
+oxygenation	B-PROC
+,	O
+respiration	B-PROC
+and	O
+consciousness	O
+,	O
+and	O
+monitoring	O
+,	O
+she	O
+was	O
+successfully	O
+cured	O
+by	O
+comprehensive	O
+managements	O
+,	O
+among	O
+which	O
+noninvasive	O
+mechanical	O
+ventilation	O
+(	O
+NIV	O
+)	O
+was	O
+the	O
+major	O
+respiratory	O
+support	O
+method	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+a	O
+panel	O
+of	O
+plasma	B-ANAT
+biomarkers	O
+could	O
+be	O
+used	O
+to	O
+diagnose	O
+ARDS	B-DISO
+in	O
+severe	O
+trauma	O
+.	O
+
+To	O
+test	O
+this	O
+hypothesis	O
+,	O
+we	O
+derived	O
+and	O
+validated	O
+a	O
+biomarker	B-CHED
+panel	O
+in	O
+three	O
+independent	O
+cohorts	O
+and	O
+compared	O
+the	O
+diagnostic	O
+performance	O
+to	O
+clinician	O
+recognition	O
+of	O
+ARDS	B-DISO
+.	O
+
+Eleven	O
+plasma	B-ANAT
+biomarkers	O
+of	O
+inflammation	B-DISO
+,	I-DISO
+lung	I-DISO
+epithelial	O
+and	O
+endothelial	B-ANAT
+injury	O
+were	O
+measured	O
+in	O
+a	O
+derivation	O
+cohort	O
+of	O
+439	O
+severe	O
+trauma	O
+patients	O
+.	O
+
+A	O
+two	O
+-	O
+biomarker	B-CHED
+panel	O
+consisting	O
+of	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+RAGE	O
+performed	O
+well	O
+across	O
+multiple	O
+patient	O
+cohorts	O
+and	O
+outperformed	O
+clinical	O
+providers	O
+for	O
+diagnosing	O
+ARDS	B-DISO
+in	O
+severe	O
+trauma	O
+.	O
+
+TITLE	O
+:	O
+Securitizing	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+:	O
+a	O
+game	O
+changer	O
+in	O
+state	O
+-	O
+societal	O
+relations	O
+in	O
+China	O
+?	O
+
+Face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+interviews	O
+for	O
+this	O
+research	O
+were	O
+conducted	O
+between	O
+January	O
+and	O
+May	O
+in	O
+2011	O
+,	O
+and	O
+between	O
+December	O
+2016	O
+and	O
+January	O
+2017	O
+,	O
+in	O
+China	O
+.	O
+
+An	O
+internal	O
+and	O
+external	O
+factor	O
+was	O
+identified	O
+to	O
+verify	O
+the	O
+argument	O
+,	O
+namely	O
+(	O
+1	O
+)	O
+the	O
+reduction	O
+of	O
+international	O
+financial	O
+commitments	O
+,	O
+as	O
+well	O
+as	O
+(	O
+2	O
+)	O
+the	O
+fragmentation	B-DISO
+of	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+-	O
+focused	O
+NGO	O
+community	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Pneumoperitoneum	O
+in	O
+preterm	O
+infants	O
+is	O
+a	O
+surgical	O
+emergency	B-DISO
+as	O
+it	O
+is	O
+usually	O
+indicative	O
+of	O
+intestinal	B-DISO
+perforation	I-DISO
+.	O
+
+Rare	O
+cases	O
+of	O
+idiopathic	O
+pneumoperitoneum	B-DISO
+have	O
+been	O
+described	O
+in	O
+the	O
+literature	O
+,	O
+the	O
+underlying	O
+causes	O
+and	O
+pathophysiology	O
+of	O
+which	O
+remain	O
+uncertain	O
+.	O
+
+Despite	O
+the	O
+insertion	O
+of	O
+two	O
+surgical	O
+drains	O
+and	O
+two	O
+exploratory	O
+laparotomies	O
+in	O
+which	O
+no	O
+obvious	O
+intestinal	B-DISO
+perforation	I-DISO
+was	O
+noted	O
+,	O
+the	O
+free	O
+air	B-CHED
+in	O
+the	O
+abdomen	B-ANAT
+reaccumulated	O
+.	O
+
+She	O
+was	O
+successfully	O
+extubated	O
+on	O
+the	O
+fourth	O
+week	O
+of	O
+life	O
+and	O
+the	O
+pneumoperitoneum	B-DISO
+resolved	O
+spontaneously	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrated	O
+that	O
+infection	B-DISO
+with	O
+the	O
+alphacoronavirus	B-SPEC
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+induced	O
+ER	O
+stress	O
+and	O
+triggered	O
+the	O
+unfolded	O
+protein	B-CHED
+response	O
+(	O
+UPR	O
+)	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+has	O
+recently	O
+emerged	O
+as	O
+an	O
+enteric	O
+pathogen	O
+that	O
+can	O
+cause	O
+serious	O
+vomiting	B-DISO
+and	O
+diarrhea	B-DISO
+in	O
+suckling	O
+piglets	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+results	O
+demonstrate	O
+that	O
+ectopic	B-PROC
+expression	I-PROC
+of	O
+NS6	B-DISO
+antagonizes	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+by	O
+interfering	O
+with	O
+the	O
+binding	B-FUNC
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+/	O
+MDA5	B-PRGE
+to	O
+double	O
+-	O
+stranded	O
+RNA	O
+,	O
+revealing	O
+a	O
+new	O
+strategy	O
+employed	O
+by	O
+PDCoV	O
+accessory	O
+proteins	B-CHED
+to	O
+counteract	O
+the	O
+host	B-COMP
+innate	O
+antiviral	B-CHED
+immune	B-PROC
+response	I-PROC
+.	O
+
+Complete	O
+genome	O
+sequencing	O
+showed	O
+that	O
+FalCoV	O
+UAE	O
+-	O
+HKU27	O
+,	O
+HouCoV	O
+UAE	O
+-	O
+HKU28	O
+,	O
+and	O
+PiCoV	O
+UAE	O
+-	O
+HKU29	O
+belong	O
+to	O
+the	O
+same	O
+CoV	O
+species	B-SPEC
+,	O
+suggesting	O
+recent	O
+interspecies	O
+transmission	O
+between	O
+falcons	B-SPEC
+and	O
+their	O
+prey	O
+,	O
+houbara	O
+bustards	O
+and	O
+pigeons	B-SPEC
+,	O
+possibly	O
+along	O
+the	O
+food	O
+chain	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+FCoVs	O
+were	O
+analyzed	O
+for	O
+the	O
+frequency	O
+and	O
+location	O
+of	O
+mutations	O
+in	O
+the	O
+S	O
+and	O
+3c	O
+genes	O
+from	O
+faecal	B-ANAT
+samples	O
+of	O
+cats	B-SPEC
+in	O
+an	O
+animal	B-SPEC
+shelter	O
+and	O
+the	O
+faeces	B-ANAT
+,	O
+effusions	B-DISO
+,	O
+and	O
+tissues	B-ANAT
+of	O
+cats	B-SPEC
+that	O
+were	O
+referred	O
+to	O
+veterinary	O
+hospitals	O
+.	O
+
+The	O
+GPHIN	O
+identified	O
+the	O
+early	O
+SARS	B-DISO
+outbreak	O
+in	O
+China	O
+,	O
+was	O
+credited	O
+with	O
+the	O
+first	O
+alert	O
+on	O
+MERS	O
+-	O
+CoV	O
+and	O
+has	O
+played	O
+a	O
+significant	O
+role	O
+in	O
+the	O
+monitoring	O
+of	O
+the	O
+Ebola	O
+outbreak	O
+in	O
+West	O
+Africa	O
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+(	O
+EIDs	B-DISO
+),	O
+including	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Lyme	B-DISO
+disease	I-DISO
+,	O
+have	O
+had	O
+a	O
+direct	O
+effect	O
+within	O
+Canada	O
+,	O
+while	O
+many	O
+more	O
+EIDs	B-DISO
+such	O
+as	O
+Zika	O
+,	O
+chikungunya	B-DISO
+and	O
+Ebola	O
+are	O
+a	O
+threat	O
+to	O
+Canadians	O
+while	O
+travelling	O
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+and	O
+antigenic	O
+characterization	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+strains	O
+isolated	O
+from	O
+South	O
+Korea	O
+,	O
+2017	O
+.	O
+
+The	O
+median	O
+cost	O
+per	O
+mild	O
+influenza	B-DISO
+-	O
+associated	O
+ARI	B-CHED
+episode	O
+was	O
+$	O
+22	O
+among	O
+healthy	O
+and	O
+$	O
+25	O
+among	O
+high	O
+-	O
+risk	O
+children	O
+(	O
+3	O
+-	O
+4	O
+%	O
+of	O
+monthly	O
+household	O
+income	O
+;	O
+difference	O
+in	O
+medians	O
+:	O
+-$	O
+1	O
+;	O
+95	O
+%	O
+CI	O
+for	O
+difference	O
+in	O
+medians	O
+:	O
+-$	O
+9	O
+to	O
+$	O
+6	O
+).	O
+
+Compared	O
+to	O
+high	O
+-	O
+risk	O
+children	O
+,	O
+healthy	O
+children	O
+had	O
+higher	O
+incidence	O
+of	O
+mild	O
+influenza	B-DISO
+-	O
+associated	O
+ARI	B-PRGE
+but	O
+not	O
+severe	O
+influenza	B-DISO
+-	O
+associated	O
+ARI	B-PRGE
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+role	O
+for	O
+CD26	B-PRGE
+/	I-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+IV	O
+as	O
+a	O
+therapeutic	O
+target	O
+.	O
+
+TITLE	O
+:	O
+Pancreatitis	B-DISO
+and	O
+Systemic	O
+Coronavirus	B-DISO
+Infection	I-DISO
+in	O
+a	O
+Ferret	B-SPEC
+(	O
+ABSTRACT	O
+:	O
+A	O
+1	O
+-	O
+y	O
+-	O
+old	O
+spayed	O
+female	O
+ferret	O
+(	O
+Mustela	B-SPEC
+putorius	I-SPEC
+furo	I-SPEC
+)	O
+was	O
+referred	O
+for	O
+additional	O
+diagnostic	O
+evaluation	O
+after	O
+physical	O
+examination	O
+by	O
+the	O
+referring	O
+veterinarian	O
+revealed	O
+a	O
+cranial	B-ANAT
+abdominal	B-ANAT
+mass	O
+.	O
+
+Abdominal	B-ANAT
+ultrasonography	O
+confirmed	O
+the	O
+presence	O
+of	O
+a	O
+soft	O
+-	O
+tissue	B-ANAT
+structure	O
+,	O
+with	O
+a	O
+moderate	O
+blood	B-PROC
+supply	I-PROC
+and	O
+mesenteric	B-DISO
+lymphadenopathy	I-DISO
+.	O
+
+Positive	O
+immunohistochemistry	O
+for	O
+feline	B-SPEC
+coronavirus	B-SPEC
+confirmed	O
+a	O
+diagnosis	O
+of	O
+ferret	B-SPEC
+systemic	I-SPEC
+coronavirus	I-SPEC
+disease	O
+(	O
+FSCD	O
+).	O
+
+TITLE	O
+:	O
+The	O
+nucleoside	B-CHED
+analog	O
+GS	O
+-	O
+441524	O
+strongly	O
+inhibits	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+virus	B-SPEC
+in	O
+tissue	O
+culture	O
+and	O
+experimental	O
+cat	B-SPEC
+infection	B-DISO
+studies	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+primary	O
+objective	O
+of	O
+this	O
+randomized	O
+controlled	O
+trial	O
+was	O
+to	O
+determine	O
+whether	O
+anti	O
+-	O
+IL	O
+-	O
+10	O
+egg	B-ANAT
+yolk	B-COMP
+antibodies	B-COMP
+fed	O
+upon	O
+arrival	O
+to	O
+a	O
+calf	B-ANAT
+ranch	O
+would	O
+lower	O
+the	O
+prevalence	O
+of	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+shedding	O
+in	O
+naturally	O
+challenged	O
+preweaned	O
+dairy	O
+calves	O
+.	O
+
+Packed	O
+cell	B-COMP
+volume	O
+and	O
+serum	O
+total	O
+protein	B-CHED
+concentration	O
+were	O
+measured	O
+at	O
+enrollment	O
+and	O
+on	O
+d	O
+7	O
+and	O
+14	O
+.	O
+
+Fecal	B-ANAT
+pathogen	O
+shedding	O
+at	O
+d	O
+14	O
+,	O
+respiratory	B-DISO
+disease	I-DISO
+at	O
+d	O
+56	O
+,	O
+and	O
+antibiotic	B-CHED
+usage	O
+were	O
+compared	O
+using	O
+relative	O
+risk	O
+(	O
+RR	O
+)	O
+and	O
+chi	B-CHED
+-	O
+squared	O
+test	O
+.	O
+
+After	O
+multivariable	O
+analyses	O
+,	O
+hipometer	O
+weights	O
+(	O
+least	O
+squares	O
+means	O
+±	O
+standard	O
+error	O
+)	O
+were	O
+1	O
+.	O
+7	O
+±	O
+0	O
+.	O
+8	O
+kg	O
+greater	O
+on	O
+d	O
+56	O
+in	O
+MAB	O
+compared	O
+with	O
+MEP	B-CHED
+;	O
+however	O
+,	O
+ADG	O
+was	O
+0	O
+.	O
+04	O
+±	O
+0	O
+.	O
+02	O
+kg	O
+/	O
+d	O
+lower	O
+in	O
+MAB	O
+calves	O
+.	O
+
+The	O
+mouse	O
+macrophage	O
+cell	B-ANAT
+line	I-ANAT
+(	O
+J774	O
+A	O
+.	O
+1	O
+)	O
+was	O
+incubated	O
+with	O
+LPS	B-DISO
+and	O
+ATP	B-CHED
+,	O
+with	O
+or	O
+without	O
+PFD	B-DISO
+pre	O
+-	O
+treatment	O
+.	O
+
+In	O
+vitro	O
+,	O
+the	O
+experiments	O
+revealed	O
+that	O
+PFD	B-DISO
+significantly	O
+suppressed	O
+LPS	B-DISO
+/	O
+ATP	B-CHED
+-	O
+induced	O
+production	O
+of	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+and	O
+decreased	O
+caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+activation	O
+and	O
+the	O
+level	O
+of	O
+IL	O
+-	O
+1β	O
+in	O
+J774	O
+A	O
+.	O
+1	O
+cells	B-COMP
+.	O
+
+These	O
+findings	O
+indicated	O
+that	O
+PFD	B-DISO
+can	O
+down	O
+-	O
+regulate	O
+NLRP3	B-PROC
+inflammasome	I-PROC
+activation	I-PROC
+and	O
+that	O
+it	O
+may	O
+offer	O
+a	O
+promising	O
+therapeutic	O
+approach	O
+for	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Nevertheless	O
+,	O
+co	O
+-	O
+occurring	O
+post	O
+-	O
+intensive	O
+care	O
+syndrome	B-DISO
+problems	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+in	O
+two	O
+or	O
+more	O
+domains	O
+)	O
+were	O
+present	O
+in	O
+25	O
+%	O
+at	O
+3	O
+months	O
+and	O
+21	O
+%	O
+at	O
+12	O
+months	O
+.	O
+
+In	O
+this	O
+multicenter	O
+cohort	O
+study	O
+,	O
+one	O
+or	O
+more	O
+post	O
+-	O
+intensive	O
+care	O
+syndrome	B-DISO
+problems	O
+were	O
+present	O
+in	O
+the	O
+majority	O
+of	O
+survivors	O
+,	O
+but	O
+co	O
+-	O
+occurring	O
+problems	O
+were	O
+present	O
+in	O
+only	O
+one	O
+out	O
+of	O
+four	O
+.	O
+
+Echocardiography	O
+plays	O
+a	O
+key	O
+role	O
+throughout	O
+the	O
+ECLS	O
+care	O
+,	O
+including	O
+patient	O
+selection	O
+,	O
+adequate	O
+placement	O
+of	O
+cannulas	O
+,	O
+monitoring	O
+,	O
+weaning	B-PROC
+and	O
+follow	O
+-	O
+up	O
+after	O
+decannulation	O
+.	O
+
+In	O
+the	O
+current	O
+editorial	O
+,	O
+we	O
+discuss	O
+the	O
+mechanisms	O
+of	O
+action	O
+of	O
+acetylcholine	B-PRGE
+receptor	I-PRGE
+antagonists	B-CHED
+beyond	O
+neuromuscular	B-DISO
+blockade	I-DISO
+.	O
+
+Additionally	O
+,	O
+proteins	B-CHED
+3a	O
+and	O
+E	O
+have	O
+a	O
+PDZ	O
+-	O
+binding	B-FUNC
+motif	O
+(	O
+PBM	O
+),	O
+which	O
+can	O
+potentially	O
+bind	B-FUNC
+over	O
+400	O
+cellular	B-COMP
+proteins	B-CHED
+which	O
+contain	O
+a	O
+PDZ	B-PRGE
+domain	I-PRGE
+,	O
+making	O
+them	O
+potentially	O
+important	O
+for	O
+the	O
+control	O
+of	O
+cell	B-PROC
+function	I-PROC
+.	O
+
+In	O
+the	O
+present	O
+work	O
+,	O
+a	O
+comparative	O
+study	O
+of	O
+the	O
+functional	O
+motifs	O
+included	O
+within	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+viroporins	O
+was	O
+performed	O
+,	O
+mostly	O
+focusing	O
+on	O
+the	O
+roles	O
+of	O
+the	O
+IC	O
+and	O
+PBM	O
+of	O
+E	O
+and	O
+3a	O
+proteins	B-CHED
+.	O
+
+A	O
+virus	O
+missing	O
+both	O
+the	O
+E	O
+and	O
+3a	O
+proteins	B-CHED
+was	O
+not	O
+viable	O
+,	O
+whereas	O
+the	O
+presence	O
+of	O
+either	O
+protein	B-CHED
+with	O
+a	O
+functional	O
+PBM	O
+restored	O
+virus	B-SPEC
+viability	O
+.	O
+
+Therefore	O
+,	O
+dominance	O
+of	O
+the	O
+IC	O
+and	O
+PBM	O
+of	O
+protein	B-CHED
+E	O
+over	O
+those	O
+of	O
+protein	B-CHED
+3a	O
+was	O
+demonstrated	O
+in	O
+the	O
+induction	O
+of	O
+pathogenesis	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+The	O
+cyclopropylquinoline	O
+derivative	O
+IV	O
+displayed	O
+high	O
+potency	O
+towards	O
+Rift	B-SPEC
+Valley	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+(	O
+RVFV	B-SPEC
+)	O
+and	O
+Tacaribe	B-SPEC
+virus	I-SPEC
+(	O
+TCRV	O
+)	O
+towards	O
+Rift	B-SPEC
+Valley	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+(	O
+RVFV	B-SPEC
+).	O
+
+The	O
+cyclopropylquinoline	O
+derivative	O
+IV	O
+is	O
+nearly	O
+28	O
+times	O
+more	O
+potent	O
+in	O
+our	O
+initial	O
+in	O
+vitro	O
+visual	O
+assay	O
+(	O
+EC50	O
+:	O
+0	O
+.	O
+39	O
+µg	O
+/	O
+ml	O
+)	O
+and	O
+nearly	O
+17	O
+times	O
+more	O
+potent	O
+in	O
+neutral	O
+red	O
+assay	O
+(	O
+EC50	O
+:	O
+0	O
+.	O
+71	O
+μg	O
+/	O
+ml	O
+)	O
+compared	O
+to	O
+the	O
+standard	O
+drug	O
+Ribavirin	B-CHED
+(	O
+EC50	O
+:	O
+11	O
+µg	O
+/	O
+ml	O
+;	O
+visual	O
+assay	O
+and	O
+EC50	O
+:	O
+12	O
+µg	O
+/	O
+ml	O
+;	O
+neutral	O
+red	O
+assay	O
+).	O
+
+It	O
+is	O
+nearly	O
+12	O
+times	O
+more	O
+potent	O
+in	O
+our	O
+initial	O
+in	O
+vitro	O
+visual	O
+assay	O
+(	O
+EC50	O
+:	O
+>	O
+1	O
+µg	O
+/	O
+ml	O
+)	O
+and	O
+nearly	O
+8	O
+times	O
+more	O
+potent	O
+in	O
+neutral	O
+red	O
+assay	O
+(	O
+EC50	O
+:	O
+>	O
+1	O
+.	O
+3	O
+µg	O
+/	O
+ml	O
+)	O
+compared	O
+to	O
+the	O
+standard	O
+drug	O
+Ribavirin	B-CHED
+(	O
+EC50	O
+:	O
+12	O
+µg	O
+/	O
+ml	O
+;	O
+visual	O
+assay	O
+and	O
+EC50	O
+:	O
+9	O
+.	O
+9	O
+µg	O
+/	O
+ml	O
+;	O
+neutral	O
+red	O
+assay	O
+)	O
+towards	O
+Tacaribe	B-SPEC
+virus	I-SPEC
+(	O
+TCRV	O
+).	O
+
+METHODS	O
+:	O
+A	O
+focused	O
+set	O
+of	O
+thienyl	B-CHED
+chalcone	B-CHED
+derivaties	O
+II	O
+-	O
+VI	O
+was	O
+screened	O
+for	O
+selected	O
+viruses	B-SPEC
+Hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+HBV	B-DISO
+),	O
+Herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+1	I-SPEC
+(	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+),	O
+Human	B-PRGE
+cytomegalovirus	I-PRGE
+(	O
+HCMV	O
+),	O
+Dengue	B-SPEC
+virus	I-SPEC
+2	O
+(	O
+DENV2	O
+),	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+,	O
+MERS	O
+coronavirus	B-SPEC
+,	O
+Poliovirus	B-SPEC
+1	O
+(	O
+PV	O
+1	O
+),	O
+Rift	B-DISO
+Valley	I-DISO
+fever	I-DISO
+(	O
+RVF	B-DISO
+),	O
+Tacaribe	B-SPEC
+virus	I-SPEC
+(	O
+TCRV	O
+),	O
+Venezuelan	B-SPEC
+equine	I-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+(	O
+VEE	O
+)	O
+and	O
+Zika	B-SPEC
+virus	I-SPEC
+(	O
+ZIKV	O
+)	O
+using	O
+the	O
+National	O
+Institute	O
+of	O
+Allergy	B-DISO
+and	O
+Infectious	B-DISO
+Diseases	I-DISO
+(	O
+NIAID	O
+)'	O
+s	O
+Division	O
+of	O
+Microbiology	O
+and	O
+Infectious	B-DISO
+Diseases	I-DISO
+(	O
+DMID	O
+)	O
+antiviral	B-CHED
+screening	O
+program	O
+.	O
+
+Additionally	O
+,	O
+cyclopropylquinoline	O
+derivative	O
+IV	O
+has	O
+shown	O
+strong	O
+growth	B-PROC
+inhibitory	O
+activity	O
+towards	O
+three	O
+major	O
+cancers	B-DISO
+(	O
+colon	B-ANAT
+,	O
+breast	B-ANAT
+,	O
+and	O
+leukemia	B-DISO
+)	O
+cell	B-ANAT
+lines	I-ANAT
+and	O
+moderate	O
+growth	B-PROC
+inhibition	B-PROC
+shown	O
+towards	O
+other	O
+cancer	B-ANAT
+cell	B-COMP
+lines	O
+screened	O
+.	O
+
+The	O
+assembly	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+into	O
+virus	B-COMP
+particles	I-COMP
+involves	O
+viral	O
+structural	O
+proteins	B-CHED
+and	O
+is	O
+believed	O
+to	O
+be	O
+mediated	O
+through	O
+recognition	O
+of	O
+specific	O
+sequences	O
+and	O
+RNA	O
+structures	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+Using	O
+the	O
+VLP	B-COMP
+system	O
+,	O
+a	O
+258	O
+-	O
+nucleotide	B-CHED
+RNA	O
+fragment	O
+,	O
+which	O
+spans	O
+nucleotides	B-CHED
+19	O
+,	O
+712	O
+to	O
+19	O
+,	O
+969	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+genome	O
+(	O
+designated	O
+PS258	O
+(	O
+19712	O
+-	O
+19969	O
+)	O
+A	O
+MERS	O
+-	O
+oV	O
+RNA	O
+packaging	O
+signal	O
+was	O
+identified	O
+by	O
+the	O
+detection	O
+of	O
+GFP	O
+expression	B-PROC
+following	O
+an	O
+incubation	O
+of	O
+MERS	O
+VLPs	B-ANAT
+carrying	O
+the	O
+heterologous	O
+mRNA	O
+GFP	O
+-	O
+PS258	O
+(	O
+19712	O
+-	O
+19969	O
+)	O
+
+TITLE	O
+:	O
+Saracatinib	O
+Inhibits	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+Coronavirus	B-SPEC
+Replication	O
+In	O
+Vitro	O
+.	O
+
+Since	O
+its	O
+emergence	O
+,	O
+MERS	O
+-	O
+CoV	O
+continues	O
+to	O
+spread	O
+to	O
+countries	O
+outside	O
+of	O
+the	O
+Arabian	O
+Peninsula	O
+and	O
+gives	O
+rise	O
+to	O
+sporadic	O
+human	B-SPEC
+infections	B-DISO
+following	O
+the	O
+entry	O
+of	O
+infected	O
+individuals	O
+to	O
+other	O
+countries	O
+,	O
+which	O
+can	O
+precipitate	O
+outbreaks	O
+similar	O
+to	O
+the	O
+one	O
+that	O
+occurred	O
+in	O
+South	O
+Korea	O
+in	O
+2015	O
+.	O
+
+Current	O
+therapeutics	O
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+have	O
+primarily	O
+been	O
+adapted	O
+from	O
+previous	O
+drugs	O
+used	O
+for	O
+the	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Complete	O
+Genome	O
+Sequences	O
+of	O
+Four	O
+Novel	O
+Human	B-PRGE
+Coronavirus	I-PRGE
+OC43	I-PRGE
+Isolates	O
+Associated	O
+with	O
+Severe	O
+Acute	O
+Respiratory	O
+Infection	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+data	O
+characterizing	O
+spontaneous	O
+infections	O
+of	O
+Old	B-SPEC
+World	I-SPEC
+monkeys	I-SPEC
+:	O
+measles	B-PATH
+,	O
+poliomyelitis	B-DISO
+,	O
+hepatitis	B-DISO
+A	I-DISO
+(	O
+HPA	B-CHED
+),	O
+encephalomyocarditis	O
+,	O
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+simian	B-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+(	O
+SHF	O
+),	O
+are	O
+presented	O
+.	O
+
+On	O
+these	O
+models	O
+,	O
+pathogenesis	B-DISO
+and	O
+epidemiology	O
+of	O
+these	O
+diseases	O
+were	O
+studied	O
+.	O
+
+Several	O
+important	O
+pathogenic	O
+mechanisms	O
+common	O
+for	O
+various	O
+hemorrhagic	B-DISO
+fevers	I-DISO
+were	O
+studied	O
+on	O
+experimental	O
+SHF	O
+of	O
+macaques	B-SPEC
+.	O
+
+Among	O
+6218	O
+patients	O
+with	O
+nonmissing	O
+outcome	O
+status	O
+in	O
+the	O
+combined	O
+cohort	O
+,	O
+643	O
+(	O
+10	O
+%)	O
+died	B-PROC
+.	O
+
+These	O
+self	O
+-	O
+binding	B-FUNC
+sequences	O
+represent	O
+opportunities	O
+for	O
+the	O
+development	B-PROC
+of	O
+biochemical	O
+tools	O
+and	O
+/	O
+or	O
+therapeutics	O
+.	O
+
+The	O
+Cluster	O
+I	O
+consensus	O
+octapeptide	O
+sequence	O
+GINITNFR	O
+was	O
+predicted	O
+by	O
+the	O
+Eisenberg	O
+'	O
+s	O
+3D	O
+profile	O
+method	O
+to	O
+have	O
+high	O
+amyloid	O
+-	O
+like	O
+fibrillation	B-DISO
+potential	O
+through	O
+steric	O
+β	O
+-	O
+zipper	O
+formation	B-PROC
+.	O
+
+Meanwhile	O
+,	O
+the	O
+coiled	O
+-	O
+coil	O
+-	O
+forming	O
+Leu	B-CHED
+/	O
+Ile	B-CHED
+heptad	O
+repeat	O
+sequences	O
+within	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+were	O
+under	O
+-	O
+represented	O
+during	O
+peptide	B-CHED
+array	O
+scanning	O
+,	O
+in	O
+agreement	O
+with	O
+that	O
+long	O
+peptide	B-CHED
+lengths	O
+were	O
+required	O
+to	O
+attain	O
+high	O
+helix	O
+-	O
+mediated	O
+interaction	O
+avidity	O
+.	O
+
+A	O
+Kraken	O
+algorithm	O
+-	O
+based	O
+bioinformatics	O
+analysis	O
+revealed	O
+the	O
+presence	O
+of	O
+up	O
+to	O
+9	O
+different	O
+RNA	O
+genera	O
+besides	O
+PEDV	B-SPEC
+(	O
+Alphacoronavirus	B-SPEC
+genus	B-SPEC
+),	O
+including	O
+Mamastrovirus	B-SPEC
+(	O
+52	O
+%,	O
+113	O
+/	O
+217	O
+),	O
+Enterovirus	B-SPEC
+(	O
+39	O
+%,	O
+85	O
+/	O
+217	O
+),	O
+Sapelovirus	B-SPEC
+(	O
+31	O
+%,	O
+67	O
+/	O
+217	O
+),	O
+Posavirus	O
+(	O
+30	O
+%,	O
+66	O
+/	O
+217	O
+),	O
+Kobuvirus	B-SPEC
+(	O
+23	O
+%,	O
+49	O
+/	O
+217	O
+),	O
+Sapovirus	B-SPEC
+(	O
+13	O
+%,	O
+28	O
+/	O
+217	O
+),	O
+Teschovirus	B-SPEC
+(	O
+10	O
+%,	O
+22	O
+/	O
+217	O
+),	O
+Pasivirus	B-SPEC
+(	O
+9	O
+%,	O
+20	O
+/	O
+217	O
+),	O
+and	O
+Deltacoronavirus	O
+(	O
+3	O
+%,	O
+6	O
+/	O
+217	O
+).	O
+
+These	O
+findings	O
+demonstrated	O
+that	O
+PEDV	B-SPEC
+infected	O
+diarrheic	O
+pigs	B-SPEC
+had	O
+an	O
+extensive	O
+RNA	O
+viral	O
+flora	O
+consisting	O
+of	O
+four	O
+different	O
+families	O
+:	O
+Astroviridae	B-SPEC
+,	O
+Picornaviridae	B-SPEC
+,	O
+Caliciviridae	B-SPEC
+,	O
+and	O
+Coronaviridae	B-SPEC
+.	O
+
+Interestingly	O
+,	O
+some	O
+recent	O
+studies	O
+have	O
+indicated	O
+that	O
+pAPN	O
+is	O
+not	O
+a	O
+functional	O
+receptor	O
+for	O
+PEDV	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+prepared	O
+pAPN	O
+ectodomain	O
+and	O
+the	O
+truncated	O
+variants	O
+of	O
+PEDV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+in	O
+Drosophila	B-SPEC
+S2	O
+cells	B-COMP
+.	O
+
+We	O
+then	O
+assayed	O
+the	O
+purified	O
+target	O
+proteins	B-CHED
+through	O
+immunogenicity	O
+tests	O
+,	O
+PEDV	B-SPEC
+binding	B-FUNC
+interference	O
+assays	O
+,	O
+circular	O
+dichroism	O
+(	O
+CD	O
+)	O
+measurements	O
+,	O
+pAPN	O
+activity	O
+assay	O
+and	O
+structural	O
+determination	O
+,	O
+demonstrating	O
+that	O
+they	O
+were	O
+biologically	O
+functional	O
+.	O
+
+We	O
+investigated	O
+its	O
+interactions	O
+with	O
+3	O
+chlorine	B-CHED
+disinfectants	B-CHED
+to	O
+determine	O
+if	O
+the	O
+additive	O
+would	O
+adversely	O
+affect	O
+the	O
+disinfectants	B-CHED
+'	O
+antimicrobial	B-CHED
+efficacy	O
+or	O
+skin	B-ANAT
+safety	O
+.	O
+
+In	O
+contrast	O
+to	O
+S2	O
+trimer	O
+,	O
+S2	O
+monomer	O
+was	O
+unstable	O
+,	O
+having	O
+high	O
+RMSDs	O
+with	O
+major	O
+drifts	O
+above	O
+8	O
+Å	O
+.	O
+Fluctuation	B-DISO
+of	O
+HR	O
+residue	O
+positions	O
+revealed	O
+major	O
+changes	O
+in	O
+the	O
+C	O
+-	O
+terminal	O
+of	O
+HR2	O
+and	O
+the	O
+linker	O
+coil	O
+between	O
+HR1	O
+and	O
+HR2	O
+in	O
+both	O
+monomer	O
+and	O
+trimer	O
+.	O
+
+Analysis	O
+of	O
+HR1	O
+-	O
+HR2	O
+inter	O
+-	O
+residue	O
+contacts	O
+and	O
+interaction	O
+energy	O
+revealed	O
+three	O
+energy	O
+scales	B-ANAT
+along	O
+HR	O
+helices	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+pooled	O
+testing	O
+system	O
+for	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhoea	I-DISO
+using	O
+real	O
+-	O
+time	O
+fluorescent	O
+reverse	O
+-	O
+transcription	O
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+assay	O
+.	O
+
+We	O
+recommended	O
+including	O
+dromedary	B-SPEC
+camels	B-SPEC
+in	O
+animal	B-SPEC
+surveillance	O
+and	O
+control	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+Saudi	O
+Arabia	O
+which	O
+could	O
+help	O
+reduce	O
+their	O
+sporadic	O
+introductions	O
+to	O
+humans	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+canine	O
+astrovirus	O
+(	O
+CaAstV	O
+)	O
+infection	B-DISO
+in	O
+southwest	O
+China	O
+.	O
+
+Interestingly	O
+,	O
+putative	O
+recombination	B-PROC
+events	O
+were	O
+observed	O
+among	O
+four	O
+of	O
+the	O
+five	O
+complete	O
+ORF2	O
+sequences	O
+cloned	O
+in	O
+this	O
+study	O
+,	O
+and	O
+three	O
+of	O
+the	O
+five	O
+complete	O
+ORF2	O
+sequences	O
+formed	O
+a	O
+single	O
+unique	O
+group	O
+,	O
+suggesting	O
+that	O
+these	O
+strains	O
+could	O
+be	O
+a	O
+novel	O
+genotype	O
+.	O
+
+TITLE	O
+:	O
+Ultrapotent	O
+Human	B-PRGE
+Neutralizing	I-PRGE
+Antibody	B-COMP
+Repertoires	O
+Against	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	O
+From	O
+a	O
+Recovered	O
+Patient	O
+.	O
+
+We	O
+describe	O
+the	O
+germline	O
+diversity	O
+and	O
+neutralizing	O
+activity	O
+of	O
+13	O
+potent	O
+human	B-SPEC
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+)	O
+that	O
+target	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+.	O
+
+Our	O
+study	O
+suggests	O
+that	O
+WHO	O
+guidelines	O
+produced	O
+in	O
+the	O
+context	O
+of	O
+a	O
+public	O
+health	O
+emergency	B-DISO
+can	O
+be	O
+improved	O
+upon	O
+,	O
+helping	O
+to	O
+assure	O
+the	O
+trustworthiness	O
+and	O
+utility	O
+of	O
+WHO	O
+information	O
+products	O
+in	O
+future	O
+emergencies	B-DISO
+.	O
+
+We	O
+have	O
+performed	O
+thoracoscopic	O
+surgery	O
+for	O
+esophageal	B-DISO
+disease	I-DISO
+at	O
+our	O
+department	O
+since	O
+1994	O
+.	O
+
+It	O
+is	O
+linked	O
+to	O
+common	O
+cold	B-DISO
+symptoms	I-DISO
+in	O
+healthy	O
+adults	O
+.	O
+
+Younger	O
+children	O
+and	O
+the	O
+elderly	O
+are	O
+considered	O
+vulnerable	O
+to	O
+developing	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+LRTIs	O
+).	O
+
+In	O
+particular	O
+,	O
+immunocompromised	O
+patients	O
+have	O
+been	O
+reported	O
+with	O
+severe	O
+and	O
+life	O
+-	O
+threatening	O
+LRTIs	O
+attributed	O
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+Since	O
+the	O
+first	O
+case	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+was	O
+reported	O
+on	O
+May	O
+20	O
+,	O
+2015	O
+in	O
+South	O
+Korea	O
+,	O
+186	O
+people	O
+,	O
+including	O
+health	O
+care	O
+workers	O
+,	O
+were	O
+infected	O
+,	O
+and	O
+36	O
+died	B-PROC
+.	O
+
+This	O
+study	O
+showed	O
+that	O
+creating	O
+a	O
+supportive	O
+and	O
+safe	O
+work	O
+environment	O
+is	O
+essential	O
+by	O
+ensuring	O
+adequate	O
+nurse	O
+staffing	O
+,	O
+supplying	O
+best	O
+-	O
+quality	O
+personal	O
+protective	O
+equipment	O
+,	O
+and	O
+improving	O
+communication	O
+to	O
+provide	O
+the	O
+quality	O
+of	O
+care	O
+during	O
+infection	B-DISO
+outbreak	O
+.	O
+
+Genome	O
+comparison	O
+with	O
+extant	O
+global	O
+PEDV	B-SPEC
+strains	O
+revealed	O
+a	O
+high	O
+nucleotide	B-CHED
+identity	O
+with	O
+recently	O
+reported	O
+European	O
+and	O
+American	O
+S	O
+-	O
+INDEL	B-PROC
+PEDVs	O
+.	O
+
+is	O
+an	O
+FDA	O
+certified	O
+multiplex	O
+PCR	O
+that	O
+can	O
+detect	O
+17	O
+viruses	B-SPEC
+and	O
+3	O
+bacteria	B-SPEC
+responsible	O
+for	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+thus	O
+it	O
+is	O
+potentially	O
+useful	O
+to	O
+the	O
+assessment	O
+of	O
+the	O
+age	O
+-	O
+related	O
+prevalence	O
+of	O
+these	O
+pathogens	O
+.	O
+
+Among	O
+656	O
+respiratory	B-ANAT
+samples	I-ANAT
+tested	O
+,	O
+362	O
+(	O
+55	O
+%)	O
+were	O
+from	O
+male	O
+and	O
+294	O
+(	O
+45	O
+%)	O
+from	O
+female	O
+patients	O
+,	O
+while	O
+356	O
+(	O
+54	O
+.	O
+3	O
+%)	O
+were	O
+positive	O
+and	O
+300	O
+(	O
+45	O
+.	O
+7	O
+%)	O
+negative	O
+.	O
+
+In	O
+the	O
+age	O
+-	O
+group	O
+(≥	O
+5	O
+,	O
+<	O
+10	O
+),	O
+HRV	O
+was	O
+identified	O
+in	O
+25	O
+/	O
+80	O
+samples	O
+(	O
+31	O
+.	O
+3	O
+%),	O
+Adv	O
+in	O
+18	O
+(	O
+22	O
+.	O
+5	O
+%),	O
+influenza	B-DISO
+in	O
+11	O
+(	O
+13	O
+.	O
+8	O
+%),	O
+and	O
+Hmpv	B-SPEC
+in	O
+6	O
+(	O
+7	O
+.	O
+5	O
+%).	O
+
+Influenza	B-DISO
+predominated	O
+in	O
+the	O
+age	O
+-	O
+group	O
+(≥	O
+10	O
+,	O
+<	O
+18	O
+),	O
+with	O
+4	O
+/	O
+22	O
+samples	O
+(	O
+18	O
+.	O
+2	O
+%),	O
+while	O
+in	O
+the	O
+remaining	O
+age	O
+-	O
+groups	O
+(≥	O
+18	O
+),	O
+HRV	O
+was	O
+the	O
+commonest	O
+isolated	O
+pathogen	O
+,	O
+33	O
+/	O
+286	O
+(	O
+11	O
+.	O
+5	O
+%),	O
+followed	O
+by	O
+influenza	B-DISO
+with	O
+20	O
+(	O
+7	O
+%)	O
+(	O
+influenza	B-PATH
+A	I-PATH
+H1	O
+-	O
+2009	O
+,	O
+11	O
+/	O
+20	O
+).	O
+In	O
+our	O
+patient	O
+series	O
+,	O
+HRV	O
+seemed	O
+to	O
+prevail	O
+in	O
+most	O
+age	O
+-	O
+groups	O
+,	O
+followed	O
+by	O
+Adv	O
+,	O
+although	O
+Influenza	B-DISO
+was	O
+the	O
+second	O
+most	O
+frequent	O
+pathogen	O
+isolated	O
+in	O
+the	O
+age	O
+-	O
+groups	O
+(≥	O
+18	O
+).	O
+
+Multiple	O
+studies	O
+suggest	O
+that	O
+dromedary	B-SPEC
+camels	B-SPEC
+are	O
+a	O
+source	O
+for	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+To	O
+date	O
+,	O
+MERS	O
+-	O
+CoV	O
+-	O
+related	O
+illness	O
+has	O
+not	O
+been	O
+reported	O
+and	O
+the	O
+burden	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+the	O
+Israeli	O
+population	O
+is	O
+unknown	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+prevalence	O
+of	O
+MERS	O
+-	O
+CoV	O
+seropositivity	O
+in	O
+dromedary	O
+camels	B-SPEC
+in	O
+Israel	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+(	O
+IB	O
+)	O
+is	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+,	O
+and	O
+hazardous	O
+to	O
+the	O
+poultry	O
+industry	O
+.	O
+
+TITLE	O
+:	O
+Efficacy	O
+of	O
+statin	B-CHED
+therapy	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+/	O
+acute	O
+lung	B-ANAT
+injury	O
+:	O
+a	O
+systematic	O
+review	O
+and	O
+meta	O
+-	O
+analysis	O
+.	O
+
+RESULTS	O
+:	O
+Baseline	O
+characteristics	O
+indicated	O
+that	O
+APACHE	O
+-	O
+III	O
+score	O
+to	O
+be	O
+lower	O
+in	O
+statin	B-CHED
+users	O
+,	O
+suggesting	O
+some	O
+beneficial	O
+effects	O
+.	O
+
+Laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+cases	O
+may	O
+be	O
+asymptomatic	O
+,	O
+have	O
+mild	O
+disease	O
+,	O
+or	O
+have	O
+a	O
+life	O
+-	O
+threatening	O
+infection	B-DISO
+with	O
+a	O
+high	O
+case	O
+fatality	O
+rate	O
+.	O
+
+At	O
+the	O
+present	O
+,	O
+there	O
+exists	O
+no	O
+specific	O
+therapy	O
+for	O
+HEV	B-SPEC
+.	O
+
+These	O
+data	O
+further	O
+characterize	O
+the	O
+complex	O
+antiviral	B-CHED
+activity	O
+of	O
+silvestrol	B-CHED
+and	O
+show	O
+silvestrol	B-CHED
+'	O
+s	O
+broad	O
+spectrum	O
+of	O
+function	O
+,	O
+since	O
+HEV	B-SPEC
+is	O
+a	O
+virus	B-SPEC
+without	O
+complex	O
+secondary	O
+structures	O
+in	O
+its	O
+genome	O
+,	O
+but	O
+it	O
+is	O
+still	O
+affected	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+)	O
+is	O
+one	O
+of	O
+the	O
+main	O
+clinical	O
+complications	O
+of	O
+severe	O
+malaria	B-PATH
+;	O
+it	O
+is	O
+characterized	O
+by	O
+a	O
+high	O
+mortality	O
+rate	O
+and	O
+can	O
+even	O
+occur	O
+after	O
+antimalarial	B-CHED
+treatment	O
+when	O
+parasitemia	B-DISO
+is	O
+not	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+Plant	O
+viral	O
+nanoparticles	B-CHED
+(	O
+VNPs	O
+)	O
+are	O
+currently	O
+being	O
+developed	O
+as	O
+novel	O
+vessels	B-ANAT
+for	O
+delivery	O
+of	O
+diagnostic	O
+and	O
+therapeutic	O
+cargos	O
+to	O
+sites	O
+of	O
+disease	O
+.	O
+
+Here	O
+we	O
+describe	O
+a	O
+few	O
+general	O
+methods	O
+to	O
+isolate	O
+and	O
+study	O
+the	O
+VNP	O
+-	O
+protein	B-CHED
+corona	B-CHED
+complexes	O
+,	O
+in	O
+order	B-SPEC
+to	O
+evaluate	O
+the	O
+impact	O
+of	O
+protein	B-CHED
+corona	B-CHED
+on	O
+molecular	B-PROC
+recognition	I-PROC
+of	O
+VNPs	O
+by	O
+target	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+clearance	O
+by	O
+phagocytes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+detection	O
+and	O
+monitoring	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+increasingly	O
+recognized	O
+as	O
+important	O
+respiratory	O
+pathogens	O
+associated	O
+with	O
+a	O
+broad	O
+range	O
+of	O
+clinical	O
+diseases	O
+.	O
+
+We	O
+report	O
+that	O
+Unc51	B-PRGE
+-	I-PRGE
+like	I-PRGE
+kinase	I-PRGE
+1	I-PRGE
+(	O
+Ulk1	B-PRGE
+/	O
+Unc51	B-PRGE
+.	I-PRGE
+1	I-PRGE
+)	O
+is	O
+a	O
+pivotal	O
+regulator	O
+of	O
+PHEV	O
+-	O
+induced	O
+neurological	B-DISO
+disorders	I-DISO
+and	O
+functions	O
+to	O
+selectively	O
+control	O
+the	O
+initiation	O
+of	O
+nerve	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+(	O
+NGF	B-PRGE
+)/	O
+TrkA	B-PRGE
+endosome	B-COMP
+trafficking	B-PROC
+.	O
+
+We	O
+then	O
+showed	O
+that	O
+Ulk1	B-PRGE
+forms	O
+a	O
+multiprotein	O
+complex	O
+with	O
+TrkA	B-PRGE
+and	O
+the	O
+early	B-COMP
+endosome	I-COMP
+marker	O
+Rab5	B-PRGE
+and	O
+that	O
+Ulk1	B-PRGE
+defects	O
+lead	O
+to	O
+either	O
+blocking	B-DISO
+of	O
+NGF	B-PRGE
+/	O
+TrkA	B-PRGE
+endocytosis	B-PATH
+or	O
+premature	O
+degradation	O
+of	O
+pTrkA	O
+via	O
+constitutive	O
+activation	O
+of	O
+the	O
+Rab5	B-PRGE
+GTPase	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Nasal	B-ANAT
+priming	O
+by	O
+a	O
+murine	B-SPEC
+coronavirus	I-SPEC
+provides	O
+protective	O
+immunity	B-PROC
+against	O
+lethal	O
+heterologous	O
+virus	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+the	O
+use	O
+of	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+on	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+outcomes	O
+:	O
+A	O
+systematic	O
+review	O
+.	O
+
+With	O
+limitations	O
+applied	O
+,	O
+three	O
+original	O
+randomized	O
+controlled	O
+trials	O
+investigating	O
+the	O
+use	O
+of	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+(	O
+NMBAs	O
+)	O
+in	O
+severe	O
+ARDS	B-DISO
+were	O
+identified	O
+and	O
+reviewed	O
+.	O
+
+The	O
+results	O
+of	O
+phylogenetic	O
+and	O
+recombination	B-PROC
+analyses	O
+showed	O
+that	O
+GDS10	O
+strain	O
+shared	O
+a	O
+common	O
+ancestor	O
+with	O
+CO13	O
+strain	O
+,	O
+which	O
+was	O
+obtained	O
+from	O
+a	O
+piglet	O
+with	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+USA	O
+.	O
+
+TITLE	O
+:	O
+Epidermal	B-ANAT
+growth	B-PROC
+factor	I-FUNC
+receptor	I-PRGE
+is	O
+a	O
+co	O
+-	O
+factor	O
+for	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+entry	O
+.	O
+
+It	O
+is	O
+well	O
+established	O
+that	O
+porcine	B-SPEC
+intestinal	B-ANAT
+epithelium	I-ANAT
+is	O
+the	O
+target	O
+of	O
+the	O
+TGEV	B-SPEC
+infection	B-DISO
+,	O
+however	O
+the	O
+mechanism	O
+that	O
+TGEV	B-SPEC
+invades	O
+the	O
+host	B-COMP
+epithelium	B-ANAT
+remains	O
+largely	O
+unknown	O
+.	O
+
+We	O
+aim	O
+to	O
+study	O
+AKI	O
+in	O
+the	O
+pediatric	O
+ARF	B-DISO
+population	O
+.	O
+
+Patients	O
+with	O
+AKI	O
+had	O
+significantly	O
+higher	O
+serum	B-COMP
+creatinine	B-CHED
+(	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+lower	O
+estimated	O
+creatinine	B-CHED
+clearance	O
+(	O
+P	O
+<	O
+.	O
+001	O
+)	O
+compared	O
+with	O
+those	O
+without	O
+AKI	B-PRGE
+.	O
+
+Patients	O
+with	O
+AKI	O
+had	O
+significantly	O
+lower	O
+PaO	B-PROC
+
+However	O
+,	O
+therapeutic	O
+treatment	O
+on	O
+day	O
+one	O
+after	O
+challenge	O
+was	O
+less	O
+efficacious	O
+as	O
+it	O
+did	O
+not	O
+prevent	O
+the	O
+development	O
+of	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+all	O
+treated	O
+animals	B-SPEC
+developed	O
+bronchointerstitial	O
+pneumonia	B-DISO
+of	O
+similar	O
+severity	O
+as	O
+the	O
+control	O
+animals	B-SPEC
+.	O
+
+The	O
+mean	O
+abbreviated	O
+burn	O
+severity	O
+index	O
+(	O
+ABSI	O
+)	O
+was	O
+10	O
+.	O
+6	O
+±	O
+1	O
+.	O
+5	O
+in	O
+the	O
+ARDS	B-DISO
+group	O
+and	O
+6	O
+.	O
+6	O
+±	O
+2	O
+.	O
+3	O
+in	O
+the	O
+non	O
+-	O
+ARDS	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+group	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+the	O
+ABSI	O
+is	O
+effective	O
+for	O
+predicting	O
+ARDS	B-DISO
+in	O
+young	O
+individuals	O
+with	O
+severe	O
+starch	B-CHED
+-	O
+based	O
+powder	O
+burn	O
+.	O
+
+The	O
+results	O
+revealed	O
+contributions	O
+of	O
+risk	O
+factors	O
+such	O
+as	O
+camel	B-SPEC
+contact	O
+,	O
+male	O
+,	O
+old	O
+age	O
+and	O
+being	O
+from	O
+Saudi	O
+Arabia	O
+and	O
+Middle	O
+East	O
+regions	O
+to	O
+the	O
+overall	O
+reported	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+trend	O
+component	O
+and	O
+several	O
+risk	O
+factors	O
+for	O
+global	O
+MERS	O
+-	O
+CoV	O
+cases	O
+,	O
+including	O
+camel	B-SPEC
+contact	O
+,	O
+male	O
+,	O
+age	O
+and	O
+geography	O
+/	O
+region	O
+significantly	O
+affected	O
+the	O
+series	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+identified	O
+membrane	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+78	I-PRGE
+-	I-PRGE
+kDa	I-PRGE
+glucose	B-CHED
+-	I-PRGE
+regulated	I-PRGE
+protein	B-CHED
+(	O
+GRP78	B-PRGE
+)	O
+as	O
+an	O
+additional	O
+binding	B-FUNC
+target	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+spike	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viral	B-DISO
+infections	I-DISO
+cause	O
+mild	O
+to	O
+severe	O
+diseases	O
+,	O
+such	O
+as	O
+common	B-DISO
+cold	I-DISO
+,	O
+bronchiolitis	B-DISO
+and	O
+pneumonia	B-DISO
+and	O
+are	O
+associated	O
+with	O
+substantial	O
+burden	O
+for	O
+society	O
+.	O
+
+ACGs	O
+reduced	O
+the	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+microvascular	B-PROC
+permeability	I-PROC
+,	O
+demonstrating	O
+a	O
+dose	O
+-	O
+dependent	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+LPS	B-DISO
+-	O
+induced	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	O
+-	O
+1β	O
+expression	B-PROC
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+along	O
+with	O
+reduced	O
+apoptosis	B-PATH
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+sandwich	O
+Enzyme	O
+-	O
+Linked	O
+Immunosorbent	O
+Assay	O
+for	O
+the	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+in	O
+fecal	B-ANAT
+samples	O
+.	O
+
+Of	O
+2813	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+584	O
+(	O
+20	O
+.	O
+8	O
+%)	O
+were	O
+immunocompromised	O
+,	O
+38	O
+.	O
+9	O
+%	O
+of	O
+whom	O
+had	O
+an	O
+unspecified	O
+cause	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+2813	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+584	O
+(	O
+20	O
+.	O
+8	O
+%)	O
+were	O
+immunocompromised	O
+,	O
+38	O
+.	O
+9	O
+%	O
+of	O
+whom	O
+had	O
+an	O
+unspecified	O
+cause	O
+.	O
+
+Hospital	O
+mortality	O
+was	O
+higher	O
+in	O
+immunocompromised	O
+than	O
+in	O
+immunocompetent	O
+patients	O
+(	O
+52	O
+.	O
+4	O
+%	O
+vs	O
+36	O
+.	O
+2	O
+%;	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+despite	O
+similar	O
+severity	O
+of	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+established	O
+a	O
+nucleic	B-CHED
+acid	I-CHED
+visualization	O
+technique	O
+that	O
+combines	O
+the	O
+reverse	B-PROC
+transcription	I-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+technique	O
+and	O
+a	O
+vertical	O
+flow	O
+visualization	O
+strip	O
+(	O
+RT	O
+-	O
+LAMP	O
+-	O
+VF	O
+)	O
+to	O
+detect	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+RT	O
+-	O
+LAMP	O
+-	O
+VF	O
+assay	O
+was	O
+performed	O
+in	O
+a	O
+constant	O
+temperature	O
+water	B-CHED
+bath	O
+for	O
+30	O
+min	O
+,	O
+and	O
+the	O
+result	O
+was	O
+visible	O
+by	O
+the	O
+naked	O
+eye	B-ANAT
+within	O
+5	O
+min	O
+.	O
+
+Tropical	B-DISO
+diseases	I-DISO
+in	O
+present	O
+study	O
+constituted	O
+66	O
+(	O
+56	O
+.	O
+89	O
+%)	O
+cases	O
+of	O
+which	O
+31	O
+(	O
+47	O
+%)	O
+died	B-PROC
+.	O
+
+ECMO	O
+should	O
+be	O
+considered	O
+as	O
+an	O
+adjunctive	O
+strategy	O
+in	O
+burn	O
+patients	O
+without	O
+inhalation	B-PROC
+injury	O
+to	O
+minimize	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+when	O
+high	O
+levels	O
+of	O
+support	O
+are	O
+needed	O
+to	O
+achieve	O
+adequate	O
+ventilation	O
+in	O
+patients	O
+with	O
+ARDS	O
+.	O
+
+TITLE	O
+:	O
+Live	O
+-	O
+attenuated	O
+bivalent	O
+measles	B-SPEC
+virus	I-SPEC
+-	O
+derived	O
+vaccines	O
+targeting	B-PROC
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+induce	O
+robust	O
+and	O
+multifunctional	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+against	O
+both	O
+viruses	B-SPEC
+in	O
+an	O
+appropriate	O
+mouse	B-SPEC
+model	O
+.	O
+
+We	O
+report	O
+our	O
+recent	O
+experience	O
+treating	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+with	O
+ECMO	O
+in	O
+a	O
+burn	O
+intensive	O
+care	O
+unit	O
+.	O
+
+The	O
+average	O
+total	B-ANAT
+body	I-ANAT
+surface	I-ANAT
+area	O
+burned	O
+in	O
+the	O
+11	O
+patients	O
+with	O
+burn	O
+injury	O
+was	O
+27	O
+%	O
+(	O
+range	O
+0	O
+.	O
+25	O
+-	O
+76	O
+%).	O
+
+A	O
+lower	O
+-	O
+limbs	B-ANAT
+ultrasonography	O
+confirmed	O
+the	O
+presence	O
+of	O
+extensive	O
+DVT	B-DISO
+extending	O
+to	O
+the	O
+lower	O
+segment	O
+of	O
+the	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+.	O
+
+Likewise	O
+,	O
+underlying	O
+causing	O
+factors	O
+such	O
+as	O
+venous	B-DISO
+congestion	I-DISO
+due	O
+to	O
+OCCP	O
+-	O
+related	O
+DVT	B-DISO
+should	O
+be	O
+considered	O
+in	O
+the	O
+diagnosis	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+13	O
+of	O
+24	O
+(	O
+54	O
+%)	O
+case	O
+patients	O
+with	O
+available	O
+sera	B-COMP
+,	O
+including	O
+1	O
+severely	O
+symptomatic	O
+,	O
+9	O
+mildly	O
+symptomatic	O
+,	O
+and	O
+3	O
+asymptomatic	O
+case	O
+patients	O
+.	O
+
+We	O
+conducted	O
+a	O
+review	O
+of	O
+the	O
+indications	O
+of	O
+the	O
+main	O
+drug	O
+agencies	O
+(	O
+Spanish	O
+,	O
+European	O
+and	O
+American	O
+)	O
+and	O
+other	O
+possible	O
+indications	O
+,	O
+mainly	O
+haemorrhagic	O
+fevers	B-PROC
+and	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+most	O
+frequent	O
+combination	O
+comprised	O
+rhinovirus	B-SPEC
+plus	O
+adenovirus	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Viruses	B-SPEC
+were	O
+detected	O
+in	O
+708	O
+(	O
+91	O
+.	O
+5	O
+%;	O
+95	O
+%	O
+CI	O
+:	O
+89	O
+.	O
+3	O
+-	O
+93	O
+.	O
+3	O
+)	O
+cases	O
+,	O
+out	O
+of	O
+which	O
+491	O
+(	O
+69	O
+.	O
+4	O
+%;	O
+95	O
+%	O
+CI	O
+:	O
+65	O
+.	O
+9	O
+-	O
+72	O
+.	O
+7	O
+)	O
+harbored	O
+multiple	O
+viruses	B-SPEC
+.	O
+
+To	O
+be	O
+specific	O
+,	O
+in	O
+IEC	O
+,	O
+TGEV	B-SPEC
+N	O
+protein	B-CHED
+induces	O
+cell	B-PATH
+cycle	I-PATH
+prolongation	O
+at	O
+the	O
+S	B-PROC
+-	I-PROC
+phase	I-PROC
+,	O
+ER	O
+stress	O
+and	O
+up	O
+-	O
+regulates	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+expression	B-PROC
+.	O
+
+We	O
+studied	O
+one	O
+mechanism	O
+by	O
+which	O
+vomiting	B-DISO
+is	O
+induced	O
+in	O
+pigs	B-SPEC
+infected	O
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+by	O
+characterization	O
+of	O
+swine	B-SPEC
+EC	O
+cells	B-COMP
+by	O
+immunohistochemistry	O
+.	O
+
+Conventional	O
+or	O
+gnotobiotic	O
+(	O
+Gn	O
+)	O
+9	O
+-	O
+day	O
+-	O
+old	O
+pigs	B-SPEC
+[	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+(	O
+n	O
+=	O
+12	O
+);	O
+Mock	O
+(	O
+n	O
+=	O
+14	O
+)]	O
+were	O
+inoculated	O
+orally	B-ANAT
+(	O
+8	O
+.	O
+9	O
+-	O
+9	O
+.	O
+2	O
+log	O
+
+In	O
+addition	O
+,	O
+nasal	B-ANAT
+swabs	O
+of	O
+661	O
+camels	B-SPEC
+,	O
+alpacas	B-SPEC
+and	O
+lamas	B-SPEC
+,	O
+obtained	O
+from	O
+January	O
+2015	O
+to	O
+December	O
+2017	O
+,	O
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+Respiratory	O
+Viruses	B-SPEC
+in	O
+Deceased	B-PROC
+Persons	O
+,	O
+Spain	O
+,	O
+2017	O
+.	O
+
+Only	O
+7	O
+%	O
+of	O
+participants	O
+had	O
+received	O
+a	O
+diagnosis	O
+of	O
+infection	B-DISO
+with	O
+the	O
+detected	O
+virus	B-SPEC
+before	O
+death	B-PROC
+.	O
+
+Here	O
+,	O
+a	O
+feline	B-SPEC
+HS	O
+cell	B-ANAT
+line	I-ANAT
+,	O
+FHS	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+was	O
+established	O
+from	O
+a	O
+case	O
+of	O
+feline	B-SPEC
+HS	O
+and	O
+characterized	O
+.	O
+
+This	O
+report	O
+details	O
+several	O
+design	O
+changes	O
+made	O
+to	O
+a	O
+Hepatitis	B-PRGE
+B	I-PRGE
+virus	I-PRGE
+core	I-PRGE
+antigen	B-CHED
+(	O
+HBcAg	O
+)-	O
+based	O
+recombinant	O
+vaccine	O
+strategy	O
+,	O
+and	O
+their	O
+effect	O
+in	O
+vivo	O
+.	O
+
+In	O
+most	O
+areas	O
+of	O
+Africa	O
+,	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+infection	B-DISO
+is	O
+essentially	O
+absent	O
+because	O
+of	O
+the	O
+inherited	O
+lack	O
+of	O
+Duffy	B-PRGE
+antigen	I-PRGE
+receptor	I-PRGE
+for	O
+chemokines	O
+on	O
+the	O
+surface	O
+of	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+that	O
+is	O
+involved	O
+in	O
+the	O
+parasite	O
+invasion	B-DISO
+of	O
+erythrocytes	B-ANAT
+.	O
+
+Although	O
+,	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+infection	B-DISO
+has	O
+long	O
+been	O
+considered	O
+to	O
+be	O
+benign	O
+,	O
+recent	O
+studies	O
+have	O
+reported	O
+life	O
+-	O
+threatening	O
+consequences	O
+,	O
+including	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+,	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+dyserythropoiesis	B-DISO
+and	O
+anaemia	B-DISO
+.	O
+
+Another	O
+characteristic	O
+feature	O
+of	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+infection	B-DISO
+,	O
+compared	O
+to	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+infection	B-DISO
+,	O
+is	O
+persistence	O
+of	O
+the	O
+parasite	O
+as	O
+dormant	O
+liver	B-ANAT
+-	O
+stage	O
+hypnozoites	O
+,	O
+causing	O
+recurrent	O
+episodes	O
+of	O
+malaria	B-PATH
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characteristic	O
+and	O
+pathogenicity	O
+analysis	O
+of	O
+a	O
+virulent	O
+recombinant	O
+avain	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolated	O
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+incidences	O
+of	O
+organ	B-ANAT
+dysfunction	O
+in	O
+the	O
+early	O
+resuscitation	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+patients	O
+:	O
+a	O
+retrospective	O
+analysis	O
+].	O
+
+The	O
+incidence	O
+of	O
+ARDS	B-DISO
+,	O
+AKI	O
+,	O
+and	O
+cardiac	B-DISO
+insufficiency	I-DISO
+was	O
+80	O
+.	O
+9	O
+％	O
+(	O
+414	O
+/	O
+512	O
+),	O
+71	O
+.	O
+3	O
+％	O
+(	O
+365	O
+/	O
+512	O
+),	O
+and	O
+61	O
+.	O
+9	O
+％	O
+(	O
+317	O
+/	O
+512	O
+)	O
+respectively	O
+.	O
+
+There	O
+were	O
+205	O
+senior	O
+patients	O
+and	O
+307	O
+younger	O
+,	O
+as	O
+well	O
+as	O
+154in	O
+high	O
+-	O
+PCT	B-DISO
+group	O
+and	O
+358	O
+in	O
+control	O
+group	O
+.	O
+
+In	O
+the	O
+senior	O
+postoperative	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+,	O
+the	O
+incidence	O
+of	O
+ARDS	B-DISO
+and	O
+cardiac	B-DISO
+insufficiency	I-DISO
+,	O
+and	O
+the	O
+mortality	O
+were	O
+increased	O
+.	O
+
+Therefore	O
+,	O
+the	O
+patient	O
+was	O
+brought	O
+to	O
+interventional	O
+radiology	O
+and	O
+bronchography	O
+was	O
+performed	O
+for	O
+selective	O
+fistula	B-DISO
+mapping	O
+.	O
+
+We	O
+found	O
+that	O
+GBF1	B-PRGE
+is	O
+involved	O
+in	O
+the	O
+replication	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+effects	O
+of	O
+convalescent	O
+plasma	O
+(	O
+CP	O
+)	O
+infusion	O
+,	O
+one	O
+of	O
+the	O
+treatment	O
+options	O
+for	O
+severe	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+,	O
+have	O
+not	O
+yet	O
+been	O
+evaluated	O
+.	O
+
+TITLE	O
+:	O
+High	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+oxygen	B-CHED
+versus	O
+noninvasive	O
+ventilation	O
+in	O
+adult	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+:	O
+a	O
+systematic	O
+review	O
+of	O
+randomized	O
+-	O
+controlled	O
+trials	O
+.	O
+
+Patients	O
+had	O
+hypoxaemic	O
+ARF	B-DISO
+(	O
+PaO2	O
+/	O
+FiO2	O
+≤	O
+300	O
+mmHg	O
+).	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+role	O
+of	O
+TCs	B-DISO
+in	O
+VILI	O
+in	O
+mice	B-SPEC
+and	O
+the	O
+associated	O
+mechanisms	O
+.	O
+
+zooepidemicus	O
+,	O
+and	O
+Mycoplasma	B-SPEC
+cynos	I-SPEC
+nucleic	B-CHED
+acids	I-CHED
+by	O
+quantitative	O
+PCR	O
+(	O
+qPCR	O
+).	O
+
+RESULTS	O
+The	O
+mean	O
+age	O
+of	O
+diseased	O
+dogs	O
+(	O
+2	O
+.	O
+7	O
+,	O
+min	O
+<	O
+0	O
+.	O
+5	O
+,	O
+max	O
+8	O
+.	O
+5	O
+years	O
+)	O
+was	O
+lower	O
+than	O
+the	O
+mean	O
+age	O
+of	O
+healthy	O
+dogs	B-SPEC
+(	O
+5	O
+.	O
+3	O
+,	O
+min	O
+<	O
+0	O
+.	O
+5	O
+,	O
+max	O
+17	O
+years	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Diseased	O
+dogs	B-SPEC
+were	O
+most	O
+commonly	O
+positive	O
+for	O
+M	B-SPEC
+.	I-SPEC
+cynos	I-SPEC
+(	O
+8	O
+/	O
+47	O
+,	O
+17	O
+%),	O
+followed	O
+by	O
+CPIV	O
+(	O
+3	O
+/	O
+47	O
+,	O
+6	O
+%)	O
+and	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+(	O
+3	O
+/	O
+47	O
+,	O
+6	O
+%),	O
+while	O
+healthy	O
+dogs	B-SPEC
+were	O
+most	O
+commonly	O
+positive	O
+for	O
+CAdV	O
+-	O
+2	O
+(	O
+6	O
+/	O
+47	O
+,	O
+13	O
+%),	O
+followed	O
+by	O
+M	B-SPEC
+.	I-SPEC
+cynos	I-SPEC
+(	O
+2	O
+/	O
+47	O
+,	O
+4	O
+%).	O
+
+All	O
+samples	O
+were	O
+negative	O
+for	O
+CIV	B-SPEC
+,	O
+CRCoV	O
+,	O
+CDV	B-CHED
+and	O
+S	O
+.	O
+equi	O
+subsp	O
+.	O
+
+Samples	O
+from	O
+diseased	O
+dogs	B-SPEC
+were	O
+more	O
+frequently	O
+seropositive	O
+for	O
+CRCoV	O
+,	O
+with	O
+higher	O
+POI	O
+,	O
+than	O
+samples	O
+from	O
+healthy	O
+dogs	B-SPEC
+.	O
+
+CONCLUSIONS	O
+AND	O
+CLINICAL	O
+RELEVANCE	O
+We	O
+showed	O
+that	O
+CAdV	O
+-	O
+2	O
+,	O
+CPIV	O
+,	O
+CHV	O
+,	O
+CRCoV	O
+,	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+cynos	I-SPEC
+circulated	O
+among	O
+sampled	O
+dogs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+are	O
+recognized	O
+respiratory	O
+pathogens	O
+for	O
+which	O
+accumulating	O
+evidence	O
+indicates	O
+that	O
+in	O
+vulnerable	O
+patients	O
+the	O
+infection	B-DISO
+can	O
+cause	O
+more	O
+severe	O
+pathologies	O
+.	O
+
+HCoVs	O
+are	O
+not	O
+always	O
+confined	O
+to	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+can	O
+invade	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+under	O
+still	O
+unclear	O
+circumstances	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+the	O
+diverse	O
+dimerization	O
+forms	O
+of	O
+coronavirus	B-SPEC
+nsp9	O
+proteins	B-CHED
+enhance	O
+their	O
+nucleic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+affinity	O
+.	O
+
+H7N9	O
+-	O
+specific	O
+antibody	B-COMP
+concentrations	O
+declined	O
+over	O
+time	O
+,	O
+and	O
+protective	O
+antibodies	B-COMP
+persisted	O
+longer	O
+in	O
+severely	O
+ill	B-DISO
+patients	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+and	O
+patients	O
+presenting	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+than	O
+in	O
+patients	O
+with	O
+mild	O
+disease	O
+.	O
+
+During	O
+a	O
+recurrence	B-DISO
+of	O
+fever	B-PROC
+on	O
+day	O
+11	O
+,	O
+blood	B-ANAT
+cultures	O
+were	O
+found	O
+to	O
+be	O
+positive	O
+for	O
+a	O
+yeast	B-SPEC
+-	O
+like	O
+organism	O
+,	O
+which	O
+was	O
+later	O
+confirmed	O
+by	O
+mass	O
+spectrometry	O
+to	O
+be	O
+G	B-SPEC
+.	I-SPEC
+capitatum	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Ecology	O
+and	O
+diversity	O
+in	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+microbial	O
+population	O
+structures	O
+from	O
+a	O
+cross	O
+-	O
+sectional	O
+community	O
+swabbing	O
+study	O
+.	O
+
+TITLE	O
+:	O
+Poliovirus	B-SPEC
+induces	O
+autophagic	O
+signaling	B-PROC
+independent	O
+of	O
+the	O
+ULK1	B-PRGE
+complex	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Differential	O
+susceptibility	O
+of	O
+macrophages	B-ANAT
+to	O
+serotype	O
+II	O
+feline	B-SPEC
+coronaviruses	O
+correlates	O
+with	O
+differences	O
+in	O
+the	O
+viral	O
+spike	O
+protein	O
+.	O
+
+The	O
+sample	O
+types	O
+included	O
+nasopharyngeal	B-ANAT
+swabs	O
+(	O
+n	O
+=	O
+677	O
+),	O
+expectorated	O
+deep	O
+cough	B-ANAT
+sputum	I-ANAT
+(	O
+n	O
+=	O
+32	O
+),	O
+induced	B-ANAT
+sputum	I-ANAT
+(	O
+n	O
+=	O
+17	O
+),	O
+and	O
+tracheal	O
+aspirates	B-ANAT
+(	O
+n	O
+=	O
+23	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+incidence	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+was	O
+higher	O
+among	O
+younger	O
+patients	O
+;	O
+27	O
+.	O
+94	O
+%	O
+of	O
+patients	O
+in	O
+the	O
+0	O
+-	O
+19	O
+-	O
+year	O
+age	O
+group	O
+tested	O
+positive	O
+compared	O
+to	O
+only	O
+3	O
+.	O
+51	O
+%	O
+of	O
+patients	O
+in	O
+the	O
+≥	O
+80	O
+-	O
+year	O
+age	O
+group	O
+.	O
+
+As	O
+a	O
+first	O
+step	O
+toward	O
+understanding	O
+the	O
+effect	O
+of	O
+PDCoV	O
+on	O
+host	B-COMP
+cells	B-COMP
+,	O
+we	O
+elucidated	O
+mechanisms	O
+underlying	O
+the	O
+process	O
+of	O
+apoptotic	B-PROC
+cell	I-PROC
+death	I-PROC
+after	O
+PDCoV	O
+infection	B-DISO
+.	O
+
+Furthermore	O
+,	O
+PDCoV	O
+infection	B-DISO
+necessitated	O
+the	O
+activation	O
+of	O
+the	O
+initiator	O
+caspase	B-ENZY
+-	I-ENZY
+9	I-ENZY
+responsible	O
+for	O
+the	O
+intrinsic	O
+mitochondrial	B-COMP
+apoptosis	B-PROC
+pathway	B-PROC
+.	O
+
+Replication	O
+interference	O
+between	O
+these	O
+two	O
+viruses	B-SPEC
+was	O
+described	O
+using	O
+cell	B-COMP
+cultures	O
+(	O
+CC	O
+)	O
+and	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+(	O
+ECE	O
+).	O
+
+Real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+was	O
+developed	O
+to	O
+specifically	O
+quantify	O
+both	O
+AIV	O
+and	O
+IBV	B-SPEC
+genomes	O
+as	O
+well	O
+as	O
+viral	O
+gene	O
+copy	O
+numbers	O
+during	O
+mixed	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+amount	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+1	I-PRGE
+beta	I-PRGE
+,	O
+in	O
+supernatants	O
+of	O
+co	O
+-	O
+infected	O
+cell	B-COMP
+cultures	O
+,	O
+was	O
+determined	O
+using	O
+an	O
+ELISA	O
+assay	O
+.	O
+
+It	O
+appears	O
+that	O
+either	O
+AIV	O
+or	O
+IBV	B-SPEC
+has	O
+a	O
+negative	O
+impact	O
+on	O
+the	O
+other	O
+virus	B-SPEC
+growth	B-PROC
+when	O
+they	O
+are	O
+inoculated	O
+simultaneously	O
+or	O
+sequentially	O
+.	O
+
+The	O
+ELISA	O
+results	O
+showed	O
+that	O
+higher	O
+level	O
+of	O
+secreted	B-PROC
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+varies	O
+,	O
+depending	O
+on	O
+the	O
+viral	O
+interference	O
+conditions	O
+between	O
+both	O
+viruses	B-SPEC
+,	O
+during	O
+mixed	B-DISO
+infections	I-DISO
+.	O
+
+As	O
+demyelination	B-DISO
+is	O
+caused	O
+by	O
+multifactorial	O
+insults	O
+,	O
+our	O
+results	O
+highlight	O
+the	O
+plasticity	O
+of	O
+microglia	B-ANAT
+in	O
+responding	O
+to	O
+distinct	O
+inflammatory	O
+settings	O
+,	O
+which	O
+may	O
+be	O
+relevant	O
+for	O
+MS	O
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Tonsillar	B-ANAT
+cytokine	O
+expression	B-PROC
+between	O
+patients	O
+with	O
+tonsillar	B-DISO
+hypertrophy	I-DISO
+and	O
+recurrent	O
+tonsillitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Tonsils	B-ANAT
+provide	O
+an	O
+innovative	O
+in	O
+vivo	O
+model	O
+for	O
+investigating	O
+immune	B-PROC
+response	I-PROC
+to	O
+infections	B-DISO
+and	O
+allergens	O
+.	O
+
+Tonsils	B-ANAT
+of	O
+89	O
+surgical	O
+patients	O
+with	O
+tonsillar	B-DISO
+hypertrophy	I-DISO
+(	O
+n	O
+=	O
+47	O
+)	O
+or	O
+recurrent	O
+tonsillitis	B-DISO
+(	O
+n	O
+=	O
+42	O
+)	O
+were	O
+analysed	O
+.	O
+
+Quantitative	O
+real	O
+-	O
+time	O
+PCR	O
+was	O
+used	O
+to	O
+analyse	O
+intratonsillar	O
+gene	B-PROC
+expressions	I-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+IL	B-PRGE
+-	I-PRGE
+13	I-PRGE
+,	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+,	O
+IL	B-FUNC
+-	I-FUNC
+28	I-FUNC
+,	O
+IL	B-PRGE
+-	I-PRGE
+29	I-PRGE
+,	O
+IL	O
+-	O
+37	O
+,	O
+TGF	O
+-	O
+β	O
+,	O
+FOXP3	B-PRGE
+,	O
+GATA3	B-PRGE
+,	O
+RORC2	O
+and	O
+Tbet	B-PRGE
+.	O
+
+Patients	O
+with	O
+tonsillar	B-DISO
+hypertrophy	I-DISO
+were	O
+younger	O
+,	O
+smoked	O
+less	O
+often	O
+,	O
+had	O
+less	O
+pollen	B-DISO
+allergy	I-DISO
+and	O
+had	O
+more	O
+adenovirus	B-DISO
+,	O
+bocavirus	B-SPEC
+-	O
+1	O
+,	O
+coronavirus	B-SPEC
+and	O
+rhinovirus	B-SPEC
+in	O
+nasopharynx	B-ANAT
+(	O
+all	O
+Intratonsillar	O
+T	B-ANAT
+cell	I-ANAT
+and	O
+interferon	B-PRGE
+gene	I-PRGE
+expressions	O
+appeared	O
+to	O
+be	O
+relatively	O
+stable	O
+for	O
+both	O
+tonsillar	B-DISO
+hypertrophy	I-DISO
+and	O
+recurrent	O
+tonsillitis	B-DISO
+.	O
+
+Included	O
+were	O
+children	O
+between	O
+2	O
+and	O
+59	O
+months	O
+of	O
+age	O
+hospitalized	O
+with	O
+WHO	O
+-	O
+defined	O
+severe	O
+CAP	B-DISO
+with	O
+consistent	O
+radiological	O
+abnormalities	O
+.	O
+
+From	O
+2014	O
+to	O
+2016	O
+,	O
+of	O
+420	O
+screened	O
+cases	O
+,	O
+350	O
+were	O
+eligible	O
+and	O
+included	O
+,	O
+of	O
+which	O
+132	O
+(	O
+37	O
+.	O
+7	O
+%)	O
+had	O
+no	O
+complication	B-DISO
+and	O
+218	O
+(	O
+62	O
+.	O
+3	O
+%)	O
+had	O
+AO	O
+,	O
+which	O
+included	O
+complications	O
+like	O
+empyema	B-DISO
+,	O
+pyopneumothorax	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+septic	B-DISO
+shock	I-DISO
+of	O
+these	O
+24	O
+(	O
+6	O
+.	O
+9	O
+%)	O
+expired	O
+.	O
+
+Serum	B-PRGE
+IL1RA	I-PRGE
+(	O
+ng	O
+/	O
+mL	O
+)	O
+was	O
+statistically	O
+significantly	O
+elevated	O
+in	O
+CAP	B-DISO
+with	O
+AO	O
+(	O
+2	O
+.	O
+55	O
+±	O
+1	O
+.	O
+44	O
+)	O
+versus	O
+uncomplicated	O
+(	O
+0	O
+.	O
+87	O
+±	O
+0	O
+.	O
+52	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Serum	B-PRGE
+IL1RA	I-PRGE
+(	O
+ng	O
+/	O
+mL	O
+)	O
+was	O
+statistically	O
+significantly	O
+elevated	O
+in	O
+CAP	B-DISO
+with	O
+AO	O
+(	O
+2	O
+.	O
+55	O
+±	O
+1	O
+.	O
+44	O
+)	O
+versus	O
+uncomplicated	O
+(	O
+0	O
+.	O
+87	O
+±	O
+0	O
+.	O
+52	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Epitope	B-CHED
+mapping	O
+analysis	O
+using	O
+synthesized	O
+peptides	B-CHED
+revealed	O
+that	O
+IBV	B-SPEC
+TM86	O
+spike	O
+669	O
+-	O
+685	O
+(	O
+SNFSTGAFNISLLLTPP	O
+),	O
+686	O
+-	O
+697	O
+(	O
+SNPRGRSFIEDL	O
+),	O
+and	O
+692	O
+-	O
+703	O
+(	O
+SFIEDLLFTSVE	O
+)	O
+residues	O
+were	O
+major	O
+linear	O
+epitopes	O
+;	O
+two	O
+identified	O
+epitopes	O
+(	O
+686	O
+-	O
+697	O
+and	O
+692	O
+-	O
+703	O
+)	O
+were	O
+covered	O
+by	O
+the	O
+fusion	O
+peptide	O
+,	O
+and	O
+the	O
+other	O
+epitope	B-CHED
+(	O
+669	O
+-	O
+685	O
+)	O
+was	O
+adjacent	O
+to	O
+the	O
+fusion	O
+peptide	B-CHED
+.	O
+
+TITLE	O
+:	O
+Global	O
+seasonal	O
+occurrence	O
+of	O
+middle	O
+east	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+We	O
+aimed	O
+at	O
+investigating	O
+the	O
+global	O
+seasonal	O
+occurrence	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+outbreaks	O
+.	O
+
+Tissues	B-ANAT
+were	O
+analyzed	O
+by	O
+histology	O
+,	O
+immunohistochemistry	O
+,	O
+immunofluorescence	O
+,	O
+and	O
+scanning	O
+electron	O
+microscopy	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+mock	O
+-	O
+vaccinated	O
+dromedaries	B-SPEC
+revealed	O
+high	O
+numbers	O
+of	O
+MERS	O
+-	O
+CoV	O
+-	O
+nucleocapsid	O
+positive	O
+cells	B-COMP
+,	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+macrophages	B-ANAT
+within	O
+nasal	B-ANAT
+turbinates	I-ANAT
+and	O
+trachea	B-DISO
+at	O
+day	O
+four	O
+post	O
+infection	B-DISO
+.	O
+
+Double	O
+immunolabeling	O
+demonstrated	O
+cytokeratin	B-PRGE
+(	O
+CK	O
+)	O
+18	O
+expressing	O
+epithelial	B-ANAT
+cells	I-ANAT
+to	O
+be	O
+the	O
+prevailing	O
+target	B-ANAT
+cell	I-ANAT
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+while	O
+CK5	B-PRGE
+/	I-PRGE
+6	I-PRGE
+and	O
+CK14	B-PRGE
+expressing	O
+cells	B-COMP
+did	O
+not	O
+co	O
+-	O
+localize	O
+with	O
+virus	B-SPEC
+.	O
+
+The	O
+present	O
+study	O
+underlines	O
+significant	O
+species	B-SPEC
+-	O
+specific	O
+manifestations	O
+of	O
+MERS	O
+and	O
+highlights	O
+ciliary	O
+loss	O
+as	O
+an	O
+important	O
+finding	O
+in	O
+dromedaries	B-SPEC
+.	O
+
+IAP	B-PRGE
+was	O
+measured	O
+in	O
+301	O
+patients	O
+(	O
+80	O
+·	O
+5	O
+per	O
+cent	O
+),	O
+of	O
+whom	O
+274	O
+(	O
+91	O
+·	O
+0	O
+per	O
+cent	O
+)	O
+had	O
+IAH	O
+and	O
+103	O
+(	O
+34	O
+·	O
+2	O
+per	O
+cent	O
+)	O
+acute	O
+compartment	B-DISO
+syndrome	I-DISO
+.	O
+
+0	O
+·	O
+73	O
+to	O
+0	O
+·	O
+84	O
+),	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+AUC	O
+0	O
+·	O
+82	O
+,	O
+0	O
+·	O
+77	O
+to	O
+0	O
+·	O
+87	O
+),	O
+renal	B-DISO
+failure	I-DISO
+(	O
+AUC	O
+0	O
+·	O
+93	O
+,	O
+0	O
+·	O
+89	O
+to	O
+0	O
+·	O
+96	O
+)	O
+and	O
+mortality	O
+(	O
+AUC	O
+0	O
+·	O
+89	O
+,	O
+0	O
+·	O
+86	O
+to	O
+0	O
+·	O
+93	O
+).	O
+
+Neither	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+any	O
+of	O
+the	O
+samples	O
+,	O
+indicating	O
+that	O
+waterfowl	B-SPEC
+likely	O
+did	O
+not	O
+contribute	O
+to	O
+the	O
+rapid	O
+spread	O
+of	O
+these	O
+viruses	B-SPEC
+within	O
+central	O
+US	O
+.	O
+
+A	O
+wood	O
+bison	B-SPEC
+population	O
+in	O
+southwestern	O
+Yukon	O
+,	O
+Canada	O
+was	O
+reintroduced	O
+into	O
+the	O
+wild	O
+in	O
+1988	O
+,	O
+but	O
+no	O
+health	O
+assessment	O
+has	O
+been	O
+done	O
+since	O
+then	O
+.	O
+
+To	O
+provide	O
+an	O
+initial	O
+assessment	O
+of	O
+the	O
+health	O
+status	O
+and	O
+,	O
+hence	O
+,	O
+the	O
+conservation	O
+value	O
+of	O
+this	O
+population	O
+,	O
+we	O
+serologically	O
+tested	O
+31	O
+wood	O
+bison	B-SPEC
+(	O
+approximately	O
+3	O
+%	O
+of	O
+the	O
+population	O
+)	O
+for	O
+pathogens	O
+of	O
+interest	O
+and	O
+obtained	O
+histopathology	O
+results	O
+for	O
+select	O
+tissues	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Display	O
+of	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+Spike	O
+Protein	B-CHED
+on	O
+Baculovirus	B-SPEC
+to	O
+Improve	O
+Immunogenicity	O
+and	O
+Protective	O
+Efficacy	O
+.	O
+
+Our	O
+results	O
+also	O
+showed	O
+that	O
+piglets	O
+in	O
+the	O
+S	O
+-	O
+Bac	O
+group	O
+elicited	O
+superior	O
+PEDV	B-SPEC
+-	O
+specific	O
+neutralizing	O
+antibodies	B-COMP
+than	O
+those	O
+of	O
+the	O
+S1	O
+-	O
+Bac	O
+and	O
+control	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+,	O
+which	O
+results	O
+in	O
+considerable	O
+economic	O
+losses	O
+.	O
+
+We	O
+seek	O
+to	O
+provide	O
+a	O
+further	O
+understanding	O
+of	O
+this	O
+process	O
+,	O
+with	O
+the	O
+report	O
+of	O
+a	O
+case	O
+of	O
+splenic	B-ANAT
+rupture	O
+followed	O
+by	O
+a	O
+systematic	O
+review	O
+of	O
+the	O
+current	O
+literature	O
+.	O
+
+It	O
+has	O
+been	O
+proposed	O
+that	O
+in	O
+these	O
+conditions	O
+,	O
+bacteria	B-SPEC
+from	O
+the	O
+gut	B-ANAT
+might	O
+enter	O
+the	O
+lungs	B-ANAT
+via	O
+translocation	B-DISO
+,	O
+a	O
+process	O
+facilitated	O
+by	O
+increased	O
+gut	B-ANAT
+and	O
+alveolo	O
+-	O
+capillary	B-PROC
+permeability	I-PROC
+.	O
+
+With	O
+further	O
+insights	O
+,	O
+this	O
+area	O
+of	O
+investigation	O
+could	O
+lead	O
+to	O
+the	O
+development	B-PROC
+of	O
+novel	O
+,	O
+microbiome	O
+-	O
+targeted	B-PROC
+,	O
+and	O
+immunomodulation	B-PROC
+strategies	O
+with	O
+the	O
+potential	O
+to	O
+improve	O
+outcomes	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+sepsis	B-DISO
+,	O
+trauma	O
+,	O
+and	O
+ARDS	B-DISO
+.	O
+
+All	O
+the	O
+compounds	O
+are	O
+not	O
+a	O
+substrate	O
+of	O
+P	B-PROC
+-	I-PROC
+glycoprotein	I-PROC
+.	O
+
+Their	O
+clinical	O
+phenotypes	O
+including	O
+laboratory	O
+test	O
+results	O
+,	O
+high	O
+-	O
+resolution	O
+lung	O
+computed	O
+tomography	O
+data	O
+,	O
+response	O
+to	O
+therapy	O
+,	O
+and	O
+prognosis	O
+were	O
+compared	O
+between	O
+those	O
+who	O
+were	O
+positive	O
+and	O
+negative	O
+for	O
+MAAs	O
+,	O
+such	O
+as	O
+antinuclear	O
+antibody	B-COMP
+(	O
+ANA	O
+),	O
+anti	O
+-	O
+cyclic	O
+citrullinated	O
+peptide	B-CHED
+(	O
+CCP	B-DISO
+),	O
+anti	B-PRGE
+-	I-PRGE
+SSA	I-PRGE
+,	O
+and	O
+anti	B-PRGE
+-	I-PRGE
+SSB	I-PRGE
+antibodies	B-COMP
+.	O
+
+Coexistent	O
+MAAs	O
+could	O
+be	O
+biomarkers	O
+for	O
+a	O
+favorable	O
+prognosis	O
+in	O
+anti	B-PRGE
+-	I-PRGE
+MDA5	I-PRGE
+-	O
+positive	O
+patients	O
+with	O
+CADM	O
+.	O
+
+TITLE	O
+:	O
+Low	O
+endocan	O
+levels	O
+are	O
+predictive	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	O
+shock	O
+.	O
+
+Patients	O
+admitted	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+in	O
+the	O
+ICU	O
+of	O
+a	O
+French	O
+University	O
+Hospital	O
+were	O
+included	O
+in	O
+a	O
+prospective	O
+single	O
+-	O
+center	O
+observational	O
+study	O
+between	O
+October	O
+2014	O
+and	O
+March	O
+2016	O
+.	O
+
+For	O
+endocan	O
+blood	B-ANAT
+values	O
+>	O
+5	O
+.	O
+36	O
+ng	O
+/	O
+mL	O
+,	O
+the	O
+adjusted	O
+OR	O
+for	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+at	O
+72	O
+h	O
+was	O
+of	O
+0	O
+.	O
+001	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+-	O
+0	O
+.	O
+215	O
+;	O
+p	O
+=	O
+0	O
+.	O
+011	O
+).	O
+
+Samples	O
+were	O
+tested	O
+for	O
+PEDV	B-SPEC
+antibodies	B-COMP
+utilising	O
+three	O
+different	O
+serological	O
+methods	O
+:	O
+commercially	O
+-	O
+available	O
+indirect	O
+ELISA	O
+,	O
+in	O
+-	O
+house	O
+blocking	B-DISO
+ELISA	O
+test	O
+and	O
+Immunoperoxidase	O
+Monolayer	O
+Assay	O
+(	O
+IPMA	O
+)	O
+test	O
+.	O
+
+TITLE	O
+:	O
+Efficacy	O
+of	O
+heat	O
+-	O
+labile	O
+enterotoxin	O
+B	O
+subunit	O
+-	O
+adjuvanted	O
+parenteral	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+trimeric	O
+spike	O
+subunit	O
+vaccine	O
+in	O
+piglets	O
+.	O
+
+To	O
+induce	O
+systemic	O
+and	O
+mucosal	B-PROC
+immunity	I-PROC
+,	O
+conventional	O
+5	O
+-	O
+week	O
+-	O
+old	O
+piglets	O
+were	O
+immunized	O
+with	O
+the	O
+trimeric	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+combined	O
+with	O
+the	O
+B	O
+subunit	O
+of	O
+Escherichia	B-SPEC
+coli	I-SPEC
+heat	O
+-	O
+labile	O
+enterotoxin	O
+(	O
+LTB	O
+)	O
+by	O
+the	O
+intramuscular	O
+(	O
+IM	O
+)	O
+route	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Advances	O
+in	O
+the	O
+Animal	B-SPEC
+Models	O
+of	O
+MERS	O
+-	O
+CoV	O
+].	O
+
+RESULTS	O
+87	O
+(	O
+22	O
+.	O
+9	O
+%)	O
+cats	B-SPEC
+died	B-PROC
+or	O
+were	O
+euthanized	O
+before	O
+discharge	B-ANAT
+from	O
+the	O
+hospital	O
+.	O
+
+The	O
+patient	O
+was	O
+diagnosed	O
+with	O
+bilateral	B-DISO
+pneumonia	I-DISO
+,	O
+pulmonary	B-DISO
+sepsis	B-SPEC
+and	O
+underwent	O
+invasive	O
+mechanical	O
+ventilation	O
+.	O
+
+Clinical	O
+improvement	O
+cannot	O
+always	O
+be	O
+expected	O
+in	O
+spite	O
+of	O
+targeted	B-PROC
+antibiotic	B-CHED
+therapy	O
+.	O
+
+This	O
+pathogen	O
+should	O
+be	O
+considered	O
+responsible	O
+for	O
+infections	B-DISO
+that	O
+usually	O
+develop	O
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+He	O
+rapidly	O
+developed	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+required	O
+treatment	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+which	O
+included	O
+mechanical	O
+ventilation	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+This	O
+is	O
+a	O
+unique	O
+case	O
+report	O
+of	O
+a	O
+patient	O
+suffering	B-DISO
+a	O
+grade	O
+4	O
+adverse	O
+event	O
+under	O
+nivolumab	O
+who	O
+survived	O
+having	O
+been	O
+treated	O
+with	O
+ECMO	O
+.	O
+
+A	O
+subsequent	O
+improvement	O
+in	O
+the	O
+respiratory	O
+parameters	O
+and	O
+vital	O
+functions	O
+resulted	O
+in	O
+weaning	B-PROC
+from	O
+ventilator	O
+8	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+the	O
+ARDS	O
+and	O
+transfer	O
+to	O
+the	O
+surgery	O
+ward	O
+14	O
+days	O
+after	O
+pneumonectomy	O
+.	O
+
+All	O
+infected	O
+pigs	B-SPEC
+shed	O
+virus	B-SPEC
+in	O
+faeces	B-ANAT
+regardless	O
+of	O
+PEDV	B-SPEC
+strain	O
+with	O
+9	O
+of	O
+30	O
+pigs	B-SPEC
+showing	O
+intermittent	O
+faecal	B-ANAT
+shedding	O
+.	O
+
+For	O
+coronavirus	B-SPEC
+,	O
+we	O
+used	O
+the	O
+spike	O
+gene	O
+sequences	O
+,	O
+while	O
+for	O
+rabies	B-DISO
+and	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+,	O
+we	O
+used	O
+the	O
+more	O
+conserved	O
+nucleoprotein	O
+gene	O
+sequences	O
+.	O
+
+The	O
+virus	B-SPEC
+is	O
+a	O
+betacoronavirus	B-SPEC
+and	O
+a	O
+close	O
+relative	O
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Medicinal	O
+mushrooms	B-SPEC
+contain	O
+biologically	O
+active	O
+substances	O
+that	O
+can	O
+be	O
+used	O
+as	O
+an	O
+immune	O
+-	O
+modulating	O
+agent	O
+in	O
+poultry	O
+.	O
+
+The	O
+newly	O
+discovered	O
+type	B-PRGE
+III	I-PRGE
+IFN	I-PRGE
+,	O
+which	O
+plays	O
+a	O
+crucial	O
+role	O
+in	O
+antiviral	B-CHED
+immunity	B-PROC
+,	O
+has	O
+strong	O
+antiviral	B-CHED
+activity	O
+against	O
+PEDV	B-SPEC
+proliferation	B-DISO
+in	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+aimed	O
+to	O
+investigate	O
+the	O
+effect	O
+of	O
+PEDV	B-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+on	O
+type	B-PRGE
+III	I-PRGE
+IFN	I-PRGE
+-	I-PRGE
+λ	I-PRGE
+.	O
+
+Subsequently	O
+,	O
+we	O
+demonstrated	O
+that	O
+the	O
+inhibition	B-PROC
+of	O
+poly	O
+(	O
+I	O
+:	O
+C	O
+)-	O
+induced	O
+IFN	B-PRGE
+-	I-PRGE
+λ3	I-PRGE
+production	O
+by	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+was	O
+dependent	O
+on	O
+the	O
+blocking	B-DISO
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+κB	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+)	O
+nuclear	B-PROC
+translocation	I-PROC
+.	O
+
+Data	O
+regarding	O
+the	O
+incidence	O
+,	O
+clinical	O
+features	O
+and	O
+microbiological	O
+characteristics	O
+related	O
+to	O
+hvKp	O
+infections	B-DISO
+in	O
+the	O
+Western	O
+world	O
+are	O
+scarce	O
+.	O
+
+The	O
+concept	O
+of	O
+a	O
+""""	O
+genomic	O
+storm	O
+","""	O
+caused	O
+by	O
+microbes	O
+triggering	O
+florid	O
+production	O
+of	O
+inflammatory	O
+mediators	O
+,	O
+is	O
+based	O
+on	O
+septic	O
+reprogramming	O
+of	O
+the	O
+human	B-SPEC
+genome	O
+.	O
+
+The	O
+result	O
+is	O
+a	O
+700	O
+-	O
+fold	O
+reduction	O
+in	O
+the	O
+bacterial	O
+burden	O
+of	O
+the	O
+lungs	B-ANAT
+and	O
+improvement	O
+of	O
+sepsis	B-DISO
+-	O
+associated	O
+thrombocytopaenia	O
+and	O
+blood	B-ANAT
+markers	O
+of	O
+endothelial	B-ANAT
+injury	O
+.	O
+
+The	O
+nature	O
+and	O
+extent	O
+of	O
+inter	O
+-	O
+sectoral	O
+collaboration	O
+varied	O
+according	O
+to	O
+the	O
+sectors	O
+involved	O
+,	O
+with	O
+those	O
+sectors	O
+that	O
+have	O
+traditionally	O
+had	O
+good	O
+collaboration	O
+(	O
+e	O
+.	O
+g	O
+.	O
+animal	B-SPEC
+health	O
+and	O
+food	O
+safety	O
+),	O
+as	O
+well	O
+as	O
+those	O
+that	O
+have	O
+a	O
+financial	O
+incentive	O
+for	O
+controlling	O
+infectious	B-DISO
+diseases	I-DISO
+(	O
+e	O
+.	O
+g	O
+.	O
+agriculture	O
+,	O
+tourism	O
+,	O
+and	O
+air	B-CHED
+travel	O
+)	O
+seen	O
+as	O
+most	O
+likely	O
+to	O
+have	O
+integrated	O
+public	O
+health	O
+preparedness	O
+and	O
+response	O
+plans	O
+.	O
+
+Although	O
+cases	O
+of	O
+smallpox	B-DISO
+still	O
+occurred	O
+,	O
+they	O
+were	O
+far	O
+fewer	O
+than	O
+expected	O
+,	O
+and	O
+it	O
+is	O
+believed	O
+that	O
+the	O
+vaccination	O
+program	O
+contributed	O
+to	O
+victory	O
+in	O
+the	O
+War	O
+of	O
+Independence	O
+.	O
+
+Effective	O
+military	O
+force	O
+requires	O
+personnel	O
+who	O
+are	O
+healthy	O
+and	O
+combat	B-CHED
+ready	O
+for	O
+worldwide	O
+deployment	O
+.	O
+
+With	O
+US	O
+military	O
+personnel	O
+present	O
+in	O
+every	O
+region	O
+of	O
+the	O
+globe	B-ANAT
+,	O
+one	O
+of	O
+the	O
+most	O
+cost	O
+-	O
+effective	O
+ways	O
+to	O
+maintain	O
+military	O
+effectiveness	O
+is	O
+to	O
+develop	O
+vaccines	O
+against	O
+prioritized	O
+threats	O
+to	O
+military	O
+members	O
+'	O
+health	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Codon	O
+Bias	B-SPEC
+Analysis	O
+in	O
+the	O
+Coding	O
+Genes	O
+of	O
+Structural	O
+and	O
+Accessory	O
+Proteins	B-CHED
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+].	O
+
+It	O
+is	O
+found	O
+that	O
+codon	O
+usage	O
+frequency	O
+of	O
+MERS	O
+-	O
+Co	O
+V	O
+is	O
+more	O
+close	O
+to	O
+yeast	B-SPEC
+,	O
+compared	O
+with	O
+other	O
+three	O
+kinds	O
+of	O
+biological	O
+codon	O
+usage	O
+frequency	O
+.	O
+
+In	O
+total	O
+,	O
+838	O
+blood	B-ANAT
+samples	I-ANAT
+from	O
+sows	O
+from	O
+267	O
+farms	O
+and	O
+101	O
+samples	O
+from	O
+wild	B-SPEC
+boars	I-SPEC
+were	O
+collected	O
+from	O
+May	O
+till	O
+November	O
+2014	O
+and	O
+tested	O
+for	O
+antibodies	B-COMP
+against	O
+PEDV	B-SPEC
+by	O
+ELISA	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+vaccine	O
+evaluation	O
+using	O
+a	O
+newly	O
+isolated	O
+strain	O
+from	O
+Korea	O
+.	O
+
+We	O
+conducted	O
+quantification	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+or	O
+viral	O
+RNA	O
+,	O
+immunofluorescent	O
+(	O
+IF	O
+)	O
+staining	O
+for	O
+the	O
+detection	O
+of	O
+PDCoV	O
+antigens	B-CHED
+,	O
+and	O
+TUNEL	O
+assay	O
+in	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+inoculated	O
+with	O
+the	O
+strain	O
+OH	O
+-	O
+FD22	O
+-	O
+P8	O
+grown	O
+in	O
+LLC	B-COMP
+-	O
+PK	O
+cells	B-COMP
+,	O
+and	O
+supplemented	O
+with	O
+10	O
+μg	O
+/	O
+ml	O
+of	O
+trypsin	B-PRGE
+in	O
+the	O
+cell	B-COMP
+culture	O
+medium	O
+.	O
+
+There	O
+was	O
+increased	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+in	O
+PDCoV	O
+-	O
+infected	O
+IPEC	O
+-	O
+J2	O
+cell	B-COMP
+culture	O
+supernatants	O
+at	O
+post	O
+-	O
+inoculation	O
+hour	O
+(	O
+PIH	O
+)	O
+48	O
+-	O
+96	O
+,	O
+as	O
+evaluated	O
+by	O
+ELISA	O
+,	O
+concurrent	O
+with	O
+increased	O
+titers	O
+of	O
+PDCoV	O
+at	O
+PIH	O
+24	O
+-	O
+72	O
+.	O
+
+Examination	O
+of	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+demonstrated	O
+yeast	B-SPEC
+cells	B-COMP
+with	O
+broad	O
+-	O
+based	O
+budding	B-PATH
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+life	O
+threatening	O
+condition	B-DISO
+characterized	O
+by	O
+severe	O
+hypoxemia	O
+due	O
+to	O
+pulmonary	B-PROC
+gas	B-ENZY
+exchange	I-PROC
+failure	O
+and	O
+was	O
+first	O
+recognized	O
+in	O
+1960s	O
+.	O
+
+We	O
+conclude	O
+that	O
+the	O
+recombinant	O
+baculovirus	B-SPEC
+expressed	B-PROC
+IBV	B-SPEC
+N	O
+protein	B-CHED
+could	O
+serve	O
+as	O
+a	O
+useful	O
+diagnostic	O
+antigen	B-CHED
+for	O
+detection	O
+of	O
+IBV	B-SPEC
+infections	B-DISO
+in	O
+chickens	B-SPEC
+by	O
+ELISA	O
+.	O
+
+These	O
+include	O
+an	O
+infectious	B-DISO
+model	O
+of	O
+ARDS	B-DISO
+driven	O
+by	O
+direct	O
+administration	O
+of	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+and	O
+a	O
+sterile	B-DISO
+inflammatory	O
+model	O
+mediated	O
+by	O
+intratracheal	O
+administration	O
+of	O
+lipopolysaccharide	B-CHED
+.	O
+
+Assessment	O
+of	O
+gut	B-ANAT
+microbial	O
+composition	O
+may	O
+help	O
+in	O
+TRALI	B-DISO
+risk	O
+assessment	O
+before	O
+transfusion	O
+.	O
+
+Nonetheless	O
+,	O
+these	O
+factors	O
+are	O
+common	O
+to	O
+both	O
+studies	O
+and	O
+trials	O
+,	O
+and	O
+fail	O
+to	O
+explain	O
+the	O
+higher	O
+mortality	O
+rate	O
+of	O
+ARDS	B-DISO
+observational	O
+studies	O
+.	O
+
+Then	O
+,	O
+we	O
+obtained	O
+the	O
+miRNAs	O
+by	O
+using	O
+solexa	O
+sequencing	O
+technology	O
+and	O
+analyzed	O
+these	O
+differentially	O
+expressed	B-PROC
+miRNAs	O
+.	O
+
+Heatmap	O
+cluster	O
+analysis	O
+showed	O
+that	O
+the	O
+vast	O
+majority	O
+of	O
+the	O
+viral	O
+groups	O
+were	O
+differentially	O
+expressed	B-PROC
+in	O
+miRNA	O
+compared	O
+with	O
+the	O
+control	O
+group	O
+,	O
+Go	O
+analysis	O
+showed	O
+that	O
+miRNAs	O
+are	O
+widely	O
+involved	O
+in	O
+combination	O
+,	O
+binding	B-FUNC
+protein	B-CHED
+,	O
+protein	B-FUNC
+kinase	I-FUNC
+activity	I-FUNC
+,	O
+transfer	O
+enzyme	B-FUNC
+activity	I-FUNC
+,	O
+phosphorus	B-CHED
+containing	O
+radicals	B-CHED
+transfer	O
+,	O
+phosphotransferase	O
+enzyme	B-FUNC
+activity	I-FUNC
+and	O
+other	O
+biological	O
+effects	O
+.	O
+
+The	O
+expression	B-PROC
+trends	O
+of	O
+RT	O
+-	O
+qPCR	O
+verified	O
+by	O
+miRNA	O
+were	O
+consistent	O
+with	O
+the	O
+high	O
+throughput	O
+sequencing	O
+results	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+unique	O
+epitope	B-CHED
+and	O
+unusual	O
+neutralizing	O
+mechanism	O
+of	O
+the	O
+isolated	O
+human	B-SPEC
+antibody	B-COMP
+MERS	O
+-	O
+4	O
+.	O
+
+Structurally	O
+,	O
+MERS	O
+-	O
+4	O
+approached	O
+the	O
+RBD	O
+from	O
+the	O
+outside	O
+of	O
+the	O
+RBD	O
+-	O
+DPP4	B-PRGE
+binding	B-FUNC
+interface	O
+.	O
+
+Such	O
+binding	B-FUNC
+resulted	O
+in	O
+the	O
+folding	O
+of	O
+the	O
+β5	O
+-	O
+β6	O
+loop	O
+toward	O
+a	O
+shallow	O
+groove	B-ANAT
+on	O
+the	O
+RBD	O
+interface	O
+critical	O
+for	O
+accommodating	O
+DPP4	B-PRGE
+.	O
+
+The	O
+key	O
+residues	O
+for	O
+binding	B-FUNC
+are	O
+identified	O
+through	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+.	O
+
+Structural	O
+modeling	O
+revealed	O
+that	O
+MERS	O
+-	O
+4	O
+binds	B-FUNC
+to	O
+RBD	O
+only	O
+in	O
+the	O
+""""	O
+up	O
+""""	O
+position	O
+in	O
+the	O
+S	O
+trimer	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+,	O
+demographics	O
+,	O
+and	O
+survey	O
+information	O
+on	O
+symptoms	O
+,	O
+medical	O
+history	O
+,	O
+and	O
+recent	O
+travel	O
+were	O
+obtained	O
+from	O
+2	O
+,	O
+685	O
+adults	O
+over	O
+two	O
+seasonal	O
+arms	B-DISO
+.	O
+
+Depending	O
+on	O
+the	O
+definition	O
+of	O
+symptomatic	O
+infection	B-DISO
+,	O
+65	O
+%	O
+to	O
+97	O
+%	O
+of	O
+infections	B-DISO
+were	O
+classified	O
+as	O
+asymptomatic	O
+.	O
+
+Two	O
+clinical	O
+pig	B-SPEC
+diarrhea	B-DISO
+samples	O
+were	O
+amplified	O
+and	O
+sequencing	O
+results	O
+confirmed	O
+that	O
+the	O
+fragments	O
+amplified	O
+were	O
+M	O
+gene	O
+.	O
+
+An	O
+MCC	B-COMP
+tree	O
+based	O
+on	O
+relative	O
+synonymous	O
+codon	O
+usage	O
+(	O
+RSCU	O
+)	O
+data	O
+integrating	O
+data	O
+from	O
+both	O
+viruses	O
+and	O
+hosts	B-COMP
+into	O
+a	O
+same	O
+analysis	O
+indicated	O
+three	O
+putative	O
+host	B-COMP
+/	O
+virus	B-SPEC
+contact	O
+dates	O
+ranging	O
+from	O
+1	O
+.	O
+54E8	O
+to	O
+2	O
+.	O
+44E5	O
+years	O
+ago	O
+,	O
+suggesting	O
+that	O
+an	O
+ancestor	O
+coronavirus	B-SPEC
+might	O
+have	O
+followed	O
+human	B-SPEC
+evolution	B-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Current	O
+Status	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Vaccines	O
+].	O
+
+The	O
+wide	O
+spectrum	O
+of	O
+microbial	O
+agents	O
+underlying	O
+the	O
+pathology	B-DISO
+renders	O
+the	O
+diagnosis	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+challenging	O
+.	O
+
+Lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+samples	O
+had	O
+comparable	O
+final	O
+-	O
+run	O
+success	O
+-	O
+rates	O
+and	O
+discordant	O
+-	O
+rates	O
+as	O
+compared	O
+to	O
+UTM	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+outcome	O
+for	O
+influenza	B-DISO
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+Japan	O
+between	O
+2009	O
+and	O
+2016	O
+.	O
+
+The	O
+outcome	O
+of	O
+ECMO	O
+use	O
+had	O
+improved	O
+in	O
+2016	O
+compared	O
+with	O
+the	O
+outcome	O
+in	O
+2009	O
+in	O
+patients	O
+with	O
+influenza	B-DISO
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Routine	O
+treatment	O
+of	O
+ARDS	B-DISO
+in	O
+both	O
+groups	O
+was	O
+the	O
+same	O
+.	O
+
+As	O
+time	O
+went	O
+on	O
+,	O
+PaO	B-PROC
+
+TITLE	O
+:	O
+Associations	O
+Between	O
+Hand	O
+Hygiene	O
+Education	O
+and	O
+Self	O
+-	O
+Reported	O
+Hand	O
+-	O
+Washing	O
+Behaviors	B-PROC
+Among	O
+Korean	O
+Adults	O
+During	O
+MERS	O
+-	O
+CoV	O
+Outbreak	O
+.	O
+
+Infectious	B-DISO
+disease	I-DISO
+outbreak	O
+may	O
+also	O
+affect	O
+individuals	O
+'	O
+awareness	O
+.	O
+
+However	O
+,	O
+MERS	O
+-	O
+CoV	O
+-	O
+induced	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+is	O
+associated	O
+with	O
+high	O
+viral	O
+loads	O
+in	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+which	O
+may	O
+be	O
+difficult	O
+to	O
+achieve	O
+in	O
+nonhuman	O
+primate	B-SPEC
+models	O
+.	O
+
+Therefore	O
+,	O
+it	O
+is	O
+used	O
+as	O
+the	O
+active	O
+component	O
+in	O
+the	O
+antiviral	B-CHED
+nasal	B-ANAT
+spray	O
+Coldamaris	O
+prophylactic	O
+(	O
+1	O
+.	O
+2	O
+mg	O
+/	O
+mL	O
+iota	B-CHED
+-	I-CHED
+carrageenan	I-CHED
+in	O
+0	O
+.	O
+5	O
+%	O
+NaCl	B-CHED
+)	O
+and	O
+other	O
+medical	O
+device	O
+nasal	B-ANAT
+sprays	B-DISO
+that	O
+are	O
+approved	O
+and	O
+marketed	O
+in	O
+the	O
+EU	O
+.	O
+
+ABSTRACT	O
+:	O
+Sepsis	O
+leads	O
+to	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+)	O
+that	O
+is	O
+associated	O
+with	O
+enhanced	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+stress	O
+.	O
+
+Cyclophilins	O
+have	O
+been	O
+reported	O
+to	O
+play	O
+an	O
+essential	O
+role	O
+in	O
+the	O
+replication	O
+of	O
+several	O
+other	O
+RNA	O
+viruses	B-SPEC
+,	O
+including	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+-	O
+1	O
+,	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+.	O
+
+Further	O
+PTP	B-DISO
+and	O
+enhanced	O
+links	O
+with	O
+expert	O
+laboratories	O
+globally	O
+may	O
+improve	O
+the	O
+laboratory	O
+performance	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+prognostic	O
+factors	O
+of	O
+patients	O
+admitted	O
+to	O
+a	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+(	O
+PICU	B-SPEC
+)	O
+after	O
+drowning	O
+.	O
+
+In	O
+this	O
+group	O
+,	O
+there	O
+was	O
+also	O
+a	O
+higher	O
+incidence	O
+of	O
+seizures	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+hemodynamic	B-PROC
+compromise	O
+,	O
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+StatPearls	O
+ABSTRACT	O
+:	O
+Hypersensitivity	B-DISO
+reactions	I-DISO
+(	O
+HR	O
+)	O
+are	O
+immune	B-PROC
+responses	I-PROC
+that	O
+are	O
+exaggerated	O
+or	O
+inappropriate	O
+against	O
+an	O
+antigen	O
+or	O
+allergen	B-CHED
+.	O
+
+Antibodies	B-COMP
+including	O
+IgE	B-DISO
+,	O
+IgM	B-PRGE
+,	O
+and	O
+IgG	B-PRGE
+mediate	O
+them	O
+.[	O
+1	O
+]	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+reexamined	O
+furin	B-ENZY
+usage	O
+by	O
+MERS	O
+-	O
+CoV	O
+using	O
+a	O
+real	O
+-	O
+time	O
+PCR	O
+-	O
+based	O
+virus	B-SPEC
+cell	B-COMP
+entry	O
+assay	O
+after	O
+inhibition	B-PROC
+of	O
+cellular	B-COMP
+proteases	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+severe	O
+threats	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+TITLE	O
+:	O
+Elevated	O
+plasma	B-ANAT
+levels	O
+of	O
+TIMP	B-PRGE
+-	I-PRGE
+3	I-PRGE
+are	O
+associated	O
+with	O
+a	O
+higher	O
+risk	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+death	B-PROC
+following	O
+severe	O
+isolated	O
+traumatic	O
+brain	B-ANAT
+injury	O
+.	O
+
+TIMP	B-PRGE
+-	O
+3	O
+was	O
+significantly	O
+higher	O
+among	O
+subjects	O
+who	O
+developed	O
+ARDS	O
+compared	O
+with	O
+those	O
+who	O
+did	O
+not	O
+(	O
+median	O
+2810	O
+pg	O
+/	O
+mL	O
+vs	O
+.	O
+2260	O
+pg	O
+/	O
+mL	O
+,	O
+p	O
+=	O
+0	O
+.	O
+008	O
+),	O
+and	O
+significantly	O
+higher	O
+among	O
+subjects	O
+who	O
+died	B-PROC
+than	O
+among	O
+those	O
+who	O
+survived	O
+to	O
+discharge	B-ANAT
+(	O
+median	O
+2960	O
+pg	O
+/	O
+mL	O
+vs	O
+.	O
+2080	O
+pg	O
+/	O
+mL	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Our	O
+findings	O
+reveal	O
+a	O
+comprehensive	O
+CD81	B-PRGE
+network	I-PRGE
+in	O
+human	B-SPEC
+liver	B-ANAT
+cells	I-ANAT
+and	O
+show	O
+that	O
+HCV	B-SPEC
+and	O
+Plasmodium	B-SPEC
+highjack	O
+selective	O
+CD81	B-PRGE
+interactions	O
+,	O
+including	O
+CAPN5	B-PRGE
+and	O
+CBLB	B-PRGE
+for	O
+HCV	B-SPEC
+,	O
+to	O
+invade	O
+cells	B-COMP
+.	O
+
+However	O
+,	O
+they	O
+have	O
+not	O
+been	O
+previously	O
+tested	O
+as	O
+ARDS	B-DISO
+therapeutics	O
+alone	O
+or	O
+in	O
+combination	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+used	O
+a	O
+fatal	O
+ARDS	B-DISO
+mouse	B-SPEC
+model	O
+induced	O
+via	O
+administration	O
+of	O
+α	O
+-	O
+galactosylceramide	B-CHED
+and	O
+lipopolysaccharide	B-CHED
+,	O
+which	O
+resulted	O
+in	O
+the	O
+development	B-PROC
+of	O
+severe	O
+lung	B-ANAT
+injury	O
+with	O
+hypercytokinemia	O
+and	O
+hemophagocytosis	O
+,	O
+all	O
+of	O
+which	O
+were	O
+observed	O
+in	O
+ARDS	B-DISO
+patients	O
+infected	O
+with	O
+highly	O
+pathogenic	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Yeşilbaş	O
+O	O
+,	O
+Şevketoğlu	O
+E	O
+,	O
+Kıhtır	O
+HS	O
+,	O
+Hatipoğlu	O
+N	O
+,	O
+Yıldırım	O
+HM	O
+,	O
+Akyol	O
+MB	O
+,	O
+Aktay	O
+-	O
+Ayaz	O
+N	O
+,	O
+Gökçe	O
+İ	O
+.	O
+Leptospirosis	O
+in	O
+a	O
+child	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Plasmapheresis	O
+and	O
+hemofiltration	O
+should	O
+be	O
+considered	O
+in	O
+cases	O
+of	O
+severe	O
+leptospirosis	B-DISO
+with	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Aim	B-PRGE
+of	O
+our	O
+study	O
+was	O
+assessment	O
+of	O
+developmental	O
+outcome	O
+of	O
+neonates	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+evaluation	O
+of	O
+the	O
+impact	O
+of	O
+RDS	O
+on	O
+child	O
+'	O
+s	O
+health	O
+,	O
+growth	B-PROC
+and	O
+neurodevelopment	B-PROC
+at	O
+2	O
+years	O
+of	O
+age	O
+.	O
+
+We	O
+assessed	O
+the	O
+health	O
+status	O
+,	O
+physical	B-PROC
+growth	I-PROC
+and	O
+development	O
+of	O
+children	O
+at	O
+mean	O
+age	O
+(	O
+corrected	O
+age	O
+)	O
+of	O
+24	O
++	O
+4	O
+months	O
+.	O
+
+Growth	B-PROC
+assessment	O
+does	O
+not	O
+show	O
+significant	O
+difference	O
+in	O
+child	O
+'	O
+s	O
+height	O
+and	O
+head	B-ANAT
+circumference	O
+,	O
+while	O
+the	O
+percentage	O
+of	O
+children	O
+with	O
+underweight	O
+according	O
+corrected	O
+age	O
+was	O
+more	O
+evident	O
+in	O
+I	O
+and	O
+II	O
+group	O
+than	O
+in	O
+control	O
+(	O
+p	O
+=	O
+0	O
+,	O
+0401	O
+).	O
+
+We	O
+found	O
+that	O
+premature	O
+children	O
+at	O
+2	O
+years	O
+of	O
+age	O
+despite	O
+RDS	O
+have	O
+lower	O
+scores	O
+comparing	O
+to	O
+term	O
+newborns	O
+in	O
+fine	O
+motor	O
+and	O
+language	O
+development	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+molecular	O
+mechanisms	O
+underlying	O
+the	O
+pathogenesis	B-DISO
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+infection	B-DISO
+are	O
+poorly	O
+understood	O
+.	O
+
+TITLE	O
+:	O
+Pediatric	O
+trauma	O
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+Incidence	O
+,	O
+risk	O
+factors	O
+,	O
+and	O
+outcomes	O
+.	O
+
+PT	O
+-	O
+ARDS	B-DISO
+was	O
+identified	O
+in	O
+0	O
+.	O
+5	O
+%	O
+(	O
+2660	O
+/	O
+488	O
+,	O
+381	O
+)	O
+of	O
+the	O
+analysis	O
+cohort	O
+,	O
+with	O
+an	O
+associated	O
+mortality	O
+of	O
+18	O
+.	O
+6	O
+%	O
+(	O
+494	O
+/	O
+2660	O
+).	O
+
+Timely	O
+recognition	O
+of	O
+ARDS	B-DISO
+with	O
+strict	O
+adherence	O
+to	O
+protective	O
+ventilation	O
+strategy	O
+of	O
+lowering	O
+V	O
+
+TITLE	O
+:	O
+The	O
+Antiviral	B-CHED
+Effects	O
+of	O
+Na	O
+,	O
+K	B-PRGE
+-	I-PRGE
+ATPase	I-PRGE
+Inhibition	B-PROC
+:	O
+A	O
+Minireview	O
+.	O
+
+TITLE	O
+:	O
+New	O
+Approaches	O
+to	O
+Respiratory	O
+Assist	O
+:	O
+Bioengineering	O
+an	O
+Ambulatory	O
+,	O
+Miniaturized	O
+Bioartificial	O
+Lung	B-ANAT
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+discuss	O
+some	O
+of	O
+the	O
+novel	O
+concepts	O
+and	O
+critical	O
+prerequisites	O
+for	O
+such	O
+respiratory	O
+lung	B-ANAT
+assist	O
+devices	O
+that	O
+can	O
+be	O
+used	O
+with	O
+an	O
+adequate	O
+safety	O
+profile	O
+,	O
+in	O
+the	O
+intensive	O
+care	O
+setting	O
+,	O
+as	O
+well	O
+as	O
+for	O
+long	O
+-	O
+term	O
+domiciliary	O
+therapy	O
+in	O
+patients	O
+with	O
+chronic	O
+ventilatory	O
+failure	O
+.	O
+
+The	O
+patient	O
+was	O
+diagnosed	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+chlorine	B-CHED
+gas	B-ENZY
+exposure	O
+.	O
+
+HVHF	O
+is	O
+a	O
+potential	O
+method	O
+for	O
+improvement	O
+of	O
+chlorine	B-CHED
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+worsening	O
+hypoxemia	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+experimental	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+random	O
+variation	O
+of	O
+tidal	O
+volumes	O
+(	O
+
+To	O
+provide	O
+the	O
+results	O
+of	O
+an	O
+analysis	O
+of	O
+impacts	O
+of	O
+SARS	B-DISO
+and	O
+H7N9	O
+based	O
+on	O
+feedback	O
+from	O
+documents	O
+,	O
+informants	O
+,	O
+and	O
+focus	O
+groups	O
+on	O
+events	O
+during	O
+the	O
+SARS	B-DISO
+and	O
+H7N9	O
+outbreaks	O
+.	O
+
+All	O
+patients	O
+with	O
+influenza	B-DISO
+>	O
+18	O
+-	O
+years	O
+-	O
+old	O
+hospitalized	O
+to	O
+the	O
+ICU	O
+department	O
+of	O
+Tunisian	O
+University	O
+hospital	O
+of	O
+Sousse	O
+,	O
+between	O
+December	O
+1	O
+,	O
+2009	O
+and	O
+March	O
+31	O
+,	O
+2016	O
+,	O
+with	O
+a	O
+positive	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+/	O
+09	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+from	O
+a	O
+nasopharyngeal	B-ANAT
+specimen	O
+were	O
+included	O
+,	O
+were	O
+included	O
+.	O
+
+The	O
+rRT	O
+-	O
+PCR	O
+results	O
+were	O
+positive	O
+for	O
+PDCoV	O
+(	O
+29	O
+/	O
+172	O
+,	O
+16	O
+.	O
+9	O
+%),	O
+PEDV	B-SPEC
+(	O
+36	O
+/	O
+172	O
+,	O
+20	O
+.	O
+9	O
+%),	O
+TGEV	B-SPEC
+(	O
+2	O
+/	O
+172	O
+,	O
+1	O
+.	O
+2	O
+%),	O
+and	O
+coinfections	B-DISO
+(	O
+16	O
+/	O
+172	O
+,	O
+9	O
+.	O
+3	O
+%).	O
+
+Our	O
+results	O
+showed	O
+that	O
+depletion	O
+of	O
+cholesterol	B-CHED
+from	O
+cells	B-COMP
+or	O
+virions	B-COMP
+by	O
+treating	O
+them	O
+with	O
+methyl	B-CHED
+-	O
+β	O
+-	O
+cyclodextrin	B-CHED
+(	O
+MβCD	O
+)	O
+diminished	O
+PDCoV	O
+infection	B-DISO
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+A	O
+/	O
+H1N1pdm09	O
+viruses	B-SPEC
+analyzed	O
+by	O
+gene	O
+sequencing	O
+fell	O
+into	O
+genetic	O
+groups	O
+6B	O
+and	O
+6B	O
+.	O
+1	O
+;	O
+A	O
+/	O
+H3N2	B-CHED
+viruses	B-SPEC
+belonged	O
+to	O
+genetic	O
+subclades	O
+3C	O
+.	O
+3b	O
+,	O
+3C	O
+.	O
+3a	O
+,	O
+3C	O
+.	O
+2a	O
+and	O
+3C	O
+.	O
+2a1	O
+;	O
+B	O
+/	O
+Yamagata	O
+lineage	O
+viruses	B-SPEC
+were	O
+of	O
+clade	O
+3	O
+and	O
+B	O
+/	O
+Victoria	B-SPEC
+lineage	O
+viruses	B-SPEC
+fell	O
+in	O
+clade1A	O
+.	O
+
+RESULTS	O
+:	O
+32	O
+%	O
+(	O
+397	O
+/	O
+1248	O
+)	O
+of	O
+ILI	O
+and	O
+29	O
+%	O
+(	O
+581	O
+/	O
+1997	O
+)	O
+of	O
+SARI	O
+patients	O
+tested	O
+were	O
+positive	O
+for	O
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+An	O
+84	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+underwent	O
+reperfusion	O
+therapy	O
+for	O
+acute	O
+left	B-ANAT
+internal	I-ANAT
+carotid	I-ANAT
+artery	I-ANAT
+occlusion	O
+;	O
+complete	O
+reperfusion	O
+was	O
+achieved	O
+.	O
+
+TITLE	O
+:	O
+Immune	B-PROC
+response	I-PROC
+characterization	O
+of	O
+mice	B-SPEC
+immunized	O
+with	O
+Lactobacillus	B-SPEC
+plantarum	I-SPEC
+expressing	O
+spike	O
+antigen	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+.	O
+
+Although	O
+MERS	O
+-	O
+CoV	O
+has	O
+had	O
+a	O
+consistently	O
+high	O
+mortality	O
+rate	O
+in	O
+humans	B-SPEC
+,	O
+no	O
+vaccines	O
+have	O
+been	O
+approved	O
+to	O
+prevent	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+a	O
+bafinivirus	B-SPEC
+exoribonuclease	B-FUNC
+activity	I-FUNC
+.	O
+
+The	O
+374	O
+-	O
+residue	O
+protein	B-CHED
+displayed	O
+robust	O
+3	O
+'-	O
+to	O
+-	O
+5	O
+'	O
+exoribonuclease	B-FUNC
+activity	I-FUNC
+in	O
+the	O
+presence	O
+of	O
+Mg	O
+
+ABSTRACT	O
+:	O
+Postpneumonectomy	O
+acute	O
+respiratory	O
+failure	O
+leading	O
+to	O
+invasive	O
+mechanical	O
+ventilation	O
+carries	O
+a	O
+severe	O
+prognosis	O
+,	O
+especially	O
+when	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+develops	O
+.	O
+
+Among	O
+the	O
+543	O
+patients	O
+undergoing	O
+pneumonectomy	O
+,	O
+89	O
+(	O
+16	O
+.	O
+4	O
+%)	O
+needed	O
+reintubation	O
+within	O
+the	O
+30th	O
+postoperative	O
+day	O
+,	O
+including	O
+60	O
+(	O
+11	O
+%)	O
+who	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Operative	O
+mortality	O
+was	O
+8	O
+.	O
+1	O
+%	O
+for	O
+all	O
+pneumonectomies	O
+,	O
+43	O
+.	O
+8	O
+%	O
+(	O
+n	O
+=	O
+39	O
+/	O
+89	O
+)	O
+in	O
+intubated	O
+patients	O
+,	O
+and	O
+56	O
+.	O
+7	O
+%	O
+(	O
+34	O
+/	O
+60	O
+)	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Luxembourg	O
+has	O
+a	O
+high	O
+degree	O
+of	O
+habitat	O
+fragmentation	B-DISO
+,	O
+and	O
+hybridisation	B-PROC
+rates	O
+between	O
+domestic	B-SPEC
+cats	I-SPEC
+and	O
+wildcats	O
+are	O
+high	O
+.	O
+
+TITLE	O
+:	O
+Preparation	O
+and	O
+characterization	O
+of	O
+an	O
+attenuated	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+strain	O
+by	O
+serial	O
+passaging	O
+.	O
+
+Piglets	O
+orally	B-ANAT
+fed	O
+with	O
+JS	O
+-	O
+2	O
+/	O
+2014	O
+G90	O
+showed	O
+no	O
+clinical	O
+symptoms	O
+,	O
+and	O
+no	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+the	O
+feces	B-ANAT
+and	O
+nasal	B-ANAT
+fluid	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+national	O
+control	O
+program	O
+against	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+)	O
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+was	O
+launched	O
+in	O
+Norway	O
+in	O
+2016	O
+.	O
+
+FIPVs	O
+are	O
+suggested	O
+to	O
+emerge	O
+from	O
+feline	B-SPEC
+enteric	O
+coronaviruses	O
+(	O
+FECVs	O
+)	O
+by	O
+acquiring	O
+mutations	O
+in	O
+specific	O
+genes	O
+in	O
+the	O
+course	O
+of	O
+persistent	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Deletion	O
+of	O
+accessory	O
+genes	O
+3a	O
+,	O
+3b	O
+,	O
+5a	O
+or	O
+5b	O
+from	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+induces	O
+an	O
+attenuated	O
+phenotype	O
+both	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+.	O
+
+In	O
+vitro	O
+inoculation	O
+of	O
+chicken	B-SPEC
+embryo	B-ANAT
+kidney	B-ANAT
+cells	B-COMP
+with	O
+recombinant	O
+and	O
+wild	O
+-	O
+type	O
+viruses	B-SPEC
+demonstrated	O
+that	O
+the	O
+accessory	B-PRGE
+protein	I-PRGE
+5b	I-PRGE
+is	O
+involved	O
+in	O
+the	O
+delayed	O
+activation	O
+of	O
+the	O
+interferon	B-PRGE
+response	O
+of	O
+the	O
+host	B-COMP
+after	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+for	O
+all	O
+viruses	B-SPEC
+,	O
+while	O
+growing	O
+to	O
+the	O
+same	O
+titre	O
+as	O
+wild	O
+-	O
+type	O
+rIBV	O
+at	O
+48	O
+h	O
+p	O
+.	O
+i	O
+.	O
+
+TITLE	O
+:	O
+Promoting	O
+remyelination	B-PROC
+through	O
+cell	B-COMP
+transplantation	O
+therapies	O
+in	O
+a	O
+model	O
+of	O
+viral	O
+-	O
+induced	O
+neurodegenerative	B-DISO
+disease	I-DISO
+.	O
+
+Infiltration	B-DISO
+of	O
+activated	O
+lymphocytes	B-ANAT
+and	O
+myeloid	B-ANAT
+cells	I-ANAT
+are	O
+thought	O
+to	O
+be	O
+primarily	O
+responsible	O
+for	O
+white	B-ANAT
+matter	I-ANAT
+damage	O
+and	O
+axonopathy	O
+.	O
+
+In	O
+recent	O
+years	O
+,	O
+there	O
+has	O
+been	O
+increasing	O
+evidence	O
+that	O
+some	O
+kinds	O
+of	O
+stem	B-ANAT
+cells	I-ANAT
+and	O
+their	O
+derivatives	O
+seem	O
+to	O
+be	O
+able	O
+to	O
+mute	O
+neuroinflammation	O
+as	O
+well	O
+as	O
+promote	O
+remyelination	B-PROC
+and	O
+axonal	O
+integrity	O
+.	O
+
+JHMV	O
+-	O
+infected	O
+mice	B-SPEC
+receiving	O
+these	O
+cells	B-COMP
+display	O
+extensive	O
+remyelination	B-PROC
+associated	O
+with	O
+axonal	O
+sparing	O
+.	O
+
+The	O
+impact	O
+of	O
+SG	O
+formation	B-PROC
+on	O
+virus	B-PROC
+replication	I-PROC
+varies	O
+among	O
+different	O
+viruses	B-SPEC
+,	O
+and	O
+the	O
+significance	O
+of	O
+SGs	B-DISO
+in	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+replication	O
+is	O
+largely	O
+unknown	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+first	O
+case	O
+of	O
+human	B-SPEC
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	B-PATH
+)	O
+virus	B-DISO
+infection	I-DISO
+in	O
+2013	O
+,	O
+five	O
+H7N9	B-PATH
+epidemics	O
+have	O
+occurred	O
+in	O
+China	O
+,	O
+all	O
+of	O
+which	O
+caused	O
+severe	O
+diseases	O
+,	O
+including	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+the	O
+fatality	O
+rates	O
+of	O
+these	O
+epidemics	O
+were	O
+as	O
+high	O
+as	O
+30	O
+-	O
+40	O
+%.	O
+
+However	O
+,	O
+when	O
+we	O
+immunized	O
+the	O
+mice	B-SPEC
+with	O
+two	O
+doses	O
+of	O
+both	O
+vaccines	O
+separately	O
+,	O
+the	O
+nasal	B-ANAT
+spray	O
+H7N9	O
+vaccine	O
+induced	O
+higher	O
+titers	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+HA	I-PRGE
+IgG	I-PRGE
+(	O
+19	O
+.	O
+26	O
+±	O
+0	O
+.	O
+67	O
+vs	O
+.	O
+17	O
+.	O
+56	O
+±	O
+0	O
+.	O
+57	O
+,	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+anti	B-PRGE
+-	I-PRGE
+HA	I-PRGE
+sIgA	I-PRGE
+(	O
+7	O
+.	O
+13	O
+±	O
+2	O
+.	O
+54	O
+vs	O
+.	O
+4	O
+.	O
+02	O
+±	O
+0	O
+.	O
+33	O
+,	O
+P	O
+=	O
+0	O
+.	O
+0026	O
+)	O
+than	O
+did	O
+the	O
+intramuscular	O
+H7N9	O
+vaccine	O
+,	O
+and	O
+there	O
+was	O
+no	O
+difference	O
+in	O
+HI	O
+titer	O
+between	O
+the	O
+two	O
+groups	O
+(	O
+P	O
+=	O
+0	O
+.	O
+3745	O
+).	O
+
+ABSTRACT	O
+:	O
+Conceptions	B-PROC
+of	O
+acute	O
+public	O
+health	O
+events	O
+typically	O
+assume	O
+that	O
+they	O
+are	O
+tackled	O
+exclusively	O
+or	O
+principally	O
+through	O
+technical	O
+and	O
+medical	O
+solutions	O
+.	O
+
+Three	O
+diverse	O
+case	O
+studies	O
+are	O
+interpreted	O
+from	O
+a	O
+disaster	O
+diplomacy	O
+perspective	O
+:	O
+Cuba	O
+'	O
+s	O
+medical	O
+diplomacy	O
+,	O
+China	O
+and	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+),	O
+and	O
+polio	B-DISO
+vaccination	O
+.	O
+
+TITLE	O
+:	O
+Successful	O
+treatment	O
+of	O
+canine	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+secondary	O
+to	O
+inhalant	O
+toxin	O
+exposure	O
+.	O
+
+TITLE	O
+:	O
+A	O
+mathematical	O
+model	O
+of	O
+CO	O
+ABSTRACT	O
+:	O
+Venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+vv	O
+-	O
+ECMO	O
+)	O
+is	O
+an	O
+effective	O
+treatment	O
+for	O
+severe	O
+respiratory	O
+failure	O
+.	O
+
+In	O
+2014	O
+,	O
+PEDV	B-SPEC
+re	O
+-	O
+emerged	O
+in	O
+many	O
+European	O
+countries	O
+,	O
+but	O
+most	O
+countries	O
+only	O
+reported	O
+a	O
+few	O
+sporadic	O
+cases	O
+.	O
+
+We	O
+describe	O
+our	O
+experience	O
+with	O
+three	O
+consecutive	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+supported	O
+with	O
+right	O
+jugular	O
+-	O
+femoral	B-ANAT
+configuration	O
+of	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+without	O
+therapeutic	O
+anticoagulation	B-PROC
+as	O
+an	O
+alternative	O
+to	O
+lung	B-ANAT
+-	O
+protective	O
+mechanical	O
+ventilation	O
+.	O
+
+During	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+,	O
+all	O
+patients	O
+were	O
+able	O
+to	O
+maintain	O
+a	O
+normal	O
+respiratory	O
+rate	O
+and	O
+experienced	O
+steady	O
+improvements	O
+in	O
+vital	B-PROC
+capacities	I-PROC
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+can	O
+provide	O
+a	O
+safe	O
+and	O
+effective	O
+alternative	O
+to	O
+lung	B-ANAT
+-	O
+protective	O
+mechanical	O
+ventilation	O
+in	O
+carefully	O
+selected	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+causes	O
+a	O
+highly	O
+contagious	O
+respiratory	O
+,	O
+reproductive	B-PROC
+and	O
+urogenital	B-ANAT
+tract	I-ANAT
+disease	O
+in	O
+chickens	B-SPEC
+worldwide	O
+,	O
+resulting	O
+in	O
+substantial	O
+economic	O
+losses	O
+for	O
+the	O
+poultry	O
+industry	O
+.	O
+
+Retrospective	O
+chart	O
+review	O
+of	O
+all	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+who	O
+were	O
+admitted	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+to	O
+the	O
+MICU	O
+from	O
+January	O
+2009	O
+-	O
+August	O
+2016	O
+was	O
+completed	O
+.	O
+
+Out	O
+of	O
+14	O
+compounds	O
+,	O
+4	O
+showed	O
+potent	O
+inhibition	B-PROC
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+activity	O
+at	O
+significantly	O
+low	O
+concentration	O
+.	O
+
+Next	O
+,	O
+a	O
+pathogenic	O
+PEDV	B-SPEC
+isolate	O
+was	O
+used	O
+to	O
+inoculate	O
+49	O
+.	O
+5	O
+kg	O
+of	O
+PEDV	B-SPEC
+-	O
+free	O
+feed	O
+to	O
+form	O
+the	O
+positive	O
+control	O
+.	O
+
+Bioassay	O
+was	O
+conducted	O
+using	O
+66	O
+mixed	O
+sex	O
+10	O
+-	O
+d	O
+-	O
+old	O
+pigs	B-SPEC
+confirmed	O
+negative	O
+for	O
+PEDV	B-SPEC
+allocated	O
+to	O
+22	O
+different	O
+rooms	O
+.	O
+
+One	O
+replicate	O
+of	O
+pigs	B-SPEC
+from	O
+mixer	O
+sequence	O
+1	O
+was	O
+rRT	O
+-	O
+PCR	O
+positive	O
+(	O
+3	O
+/	O
+3	O
+)	O
+by	O
+7	O
+dpi	O
+.	O
+
+Therefore	O
+,	O
+a	O
+sequencing	O
+protocol	O
+can	O
+reduce	O
+but	O
+not	O
+eliminate	O
+the	O
+risk	O
+of	O
+producing	O
+infectious	B-DISO
+PEDV	B-SPEC
+carryover	O
+from	O
+the	O
+first	O
+sequenced	O
+batch	O
+of	O
+feed	O
+.	O
+
+The	O
+selected	O
+VHHs	O
+bind	B-FUNC
+with	O
+exceptionally	O
+high	O
+affinity	O
+to	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+of	O
+the	O
+viral	O
+spike	O
+protein	B-CHED
+.	O
+
+Among	O
+these	O
+seven	O
+synthesized	O
+compounds	O
+,	O
+linear	O
+reniochalistatin	O
+B	O
+was	O
+found	O
+to	O
+have	O
+potent	O
+activity	O
+against	O
+several	O
+cancer	B-ANAT
+cell	B-COMP
+lines	O
+not	O
+shown	O
+by	O
+the	O
+cyclic	O
+reniochalistatin	O
+B	O
+counterpart	O
+.	O
+
+39	O
+patients	O
+died	B-PROC
+,	O
+with	O
+a	O
+75	O
+%	O
+case	O
+-	O
+fatality	O
+rate	O
+.	O
+
+The	O
+complex	O
+structure	O
+shows	O
+that	O
+only	O
+one	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+the	O
+trimeric	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+binds	B-FUNC
+ACE2	B-PRGE
+and	O
+adopts	O
+a	O
+protruding	B-DISO
+""""	O
+up	O
+""""	O
+conformation	O
+.	O
+
+Structural	O
+comparisons	O
+suggested	O
+that	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+retains	O
+a	O
+prefusion	O
+architecture	O
+after	O
+trypsin	B-PRGE
+cleavage	B-PROC
+into	O
+the	O
+S1	O
+and	O
+S2	O
+subunits	O
+and	O
+acidic	O
+pH	O
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+),	O
+which	O
+re	O
+-	O
+emerged	O
+in	O
+China	O
+in	O
+October	O
+2010	O
+,	O
+has	O
+spread	O
+rapidly	O
+worldwide	O
+.	O
+
+Detailed	O
+analyses	O
+of	O
+the	O
+complete	O
+genomes	O
+of	O
+different	O
+PEDV	B-SPEC
+strains	O
+are	O
+essential	O
+to	O
+understand	O
+the	O
+relationships	O
+among	O
+re	O
+-	O
+emerging	O
+and	O
+historic	O
+strains	O
+worldwide	O
+.	O
+
+This	O
+study	O
+has	O
+significant	O
+implications	O
+for	O
+understanding	O
+ongoing	O
+global	O
+PEDV	B-SPEC
+outbreaks	O
+and	O
+will	O
+guide	O
+future	O
+efforts	O
+to	O
+develop	O
+effective	O
+preventative	O
+measures	O
+against	O
+PEDV	B-SPEC
+.	O
+
+The	O
+BRDC	O
+and	O
+BED	B-DISO
+multiplex	O
+PCR	O
+-	O
+microarray	O
+-	O
+assays	O
+developed	O
+in	O
+this	O
+study	O
+,	O
+with	O
+further	O
+clinical	O
+validation	O
+,	O
+could	O
+be	O
+used	O
+in	O
+veterinary	O
+diagnostic	O
+laboratories	O
+for	O
+the	O
+rapid	O
+and	O
+simultaneous	O
+identification	O
+of	O
+pathogens	O
+to	O
+facilitate	O
+quick	O
+and	O
+accurate	O
+decision	O
+making	O
+for	O
+the	O
+control	O
+and	O
+treatment	O
+of	O
+these	O
+two	O
+economically	O
+important	O
+disease	O
+complexes	O
+.	O
+
+TITLE	O
+:	O
+Cerebral	B-ANAT
+toxoplasmosis	B-PATH
+in	O
+a	O
+cat	B-SPEC
+with	O
+feline	B-DISO
+leukemia	I-DISO
+and	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+viral	B-PROC
+infections	I-PROC
+.	O
+
+Hypoxemia	O
+was	O
+defined	O
+as	O
+a	O
+PaO	B-PROC
+Of	O
+1604	O
+patients	O
+included	O
+,	O
+859	O
+(	O
+54	O
+%,	O
+95	O
+%	O
+CI	O
+51	O
+-	O
+56	O
+%)	O
+were	O
+hypoxemic	O
+,	O
+51	O
+%	O
+with	O
+mild	O
+(	O
+n	O
+=	O
+440	O
+),	O
+40	O
+%	O
+with	O
+moderate	O
+(	O
+n	O
+=	O
+345	O
+),	O
+and	O
+9	O
+%	O
+(	O
+n	O
+=	O
+74	O
+)	O
+with	O
+severe	O
+hypoxemia	O
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+serological	O
+evidence	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+virus	B-SPEC
+exposed	O
+camel	B-SPEC
+abattoir	O
+workers	O
+in	O
+Nigeria	O
+,	O
+2016	O
+.	O
+
+Passaging	O
+virus	B-SPEC
+on	O
+cells	B-COMP
+expressing	O
+this	O
+DPP4	B-PRGE
+variant	O
+led	O
+to	O
+accumulation	O
+of	O
+mutations	O
+in	O
+the	O
+viral	O
+spike	O
+which	O
+increased	O
+replication	O
+.	O
+
+Parallel	O
+passages	O
+revealed	O
+distinct	O
+paths	O
+of	O
+viral	O
+adaptation	B-PROC
+to	O
+the	O
+same	O
+DPP4	B-PRGE
+variant	O
+.	O
+
+Structural	O
+analysis	O
+and	O
+functional	O
+assays	O
+showed	O
+that	O
+these	O
+mutations	O
+enhanced	O
+viral	O
+entry	O
+with	O
+suboptimal	O
+DPP4	B-PRGE
+by	O
+altering	O
+the	O
+surface	O
+charge	O
+of	O
+spike	O
+.	O
+
+This	O
+article	O
+presents	O
+a	O
+clinical	O
+case	O
+of	O
+antisynthetase	B-DISO
+syndrome	I-DISO
+with	O
+severe	O
+ARDS	B-DISO
+successfully	O
+treated	O
+with	O
+immunosuppressive	B-CHED
+agents	I-CHED
+and	O
+ECMO	O
+.	O
+
+Discouraging	O
+survival	O
+rates	O
+in	O
+patients	O
+treated	O
+after	O
+allo	O
+-	O
+SCT	B-DISO
+do	O
+not	O
+support	O
+the	O
+use	O
+of	O
+ECMO	O
+for	O
+ARDS	B-DISO
+in	O
+this	O
+patient	O
+subgroup	O
+.	O
+
+ABSTRACT	O
+:	O
+Peyer	B-ANAT
+'	I-ANAT
+s	I-ANAT
+patches	I-ANAT
+(	O
+PPs	B-DISO
+)	O
+can	O
+be	O
+considered	O
+as	O
+the	O
+immune	O
+site	O
+of	O
+the	O
+intestine	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Ventilation	O
+control	O
+for	O
+airborne	O
+transmission	O
+of	O
+human	B-SPEC
+exhaled	B-PROC
+bio	O
+-	O
+aerosols	O
+in	O
+buildings	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+aim	O
+was	O
+to	O
+establish	O
+two	O
+ELISA	O
+systems	O
+for	O
+detecting	O
+antigens	B-CHED
+and	O
+antibodies	B-COMP
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+Using	O
+a	O
+recombinant	O
+full	O
+-	O
+length	O
+S	O
+protein	B-CHED
+,	O
+an	O
+indirect	O
+ELISA	O
+was	O
+developed	O
+and	O
+found	O
+to	O
+detect	O
+MERS	O
+-	O
+CoV	O
+-	O
+specific	O
+antibodies	B-COMP
+in	O
+animal	B-SPEC
+sera	B-COMP
+and	O
+sera	B-COMP
+of	O
+patient	O
+with	O
+MERS	O
+.	O
+
+Injury	O
+characteristics	O
+included	O
+firearm	O
+injuries	O
+(	O
+relative	O
+risk	O
+1	O
+.	O
+93	O
+;	O
+1	O
+.	O
+50	O
+-	O
+2	O
+.	O
+48	O
+)	O
+and	O
+motor	O
+vehicle	O
+crashes	O
+(	O
+relative	O
+risk	O
+,	O
+1	O
+.	O
+91	O
+;	O
+1	O
+.	O
+57	O
+-	O
+2	O
+.	O
+31	O
+)	O
+relative	O
+to	O
+falls	O
+;	O
+spine	O
+(	O
+relative	O
+risk	O
+,	O
+1	O
+.	O
+39	O
+;	O
+1	O
+.	O
+20	O
+-	O
+1	O
+.	O
+60	O
+),	O
+chest	B-ANAT
+(	O
+relative	O
+risk	O
+,	O
+1	O
+.	O
+36	O
+;	O
+1	O
+.	O
+22	O
+-	O
+1	O
+.	O
+52	O
+),	O
+or	O
+lower	B-ANAT
+extremity	I-ANAT
+injuries	O
+(	O
+relative	O
+risk	O
+,	O
+1	O
+.	O
+26	O
+;	O
+1	O
+.	O
+10	O
+-	O
+1	O
+.	O
+44	O
+);	O
+amputations	O
+(	O
+relative	O
+risk	O
+,	O
+2	O
+.	O
+10	O
+;	O
+1	O
+.	O
+51	O
+-	O
+2	O
+.	O
+91	O
+);	O
+and	O
+more	O
+severe	O
+injury	O
+(	O
+relative	O
+risk	O
+,	O
+3	O
+.	O
+69	O
+for	O
+Injury	O
+Severity	O
+Score	O
+40	O
+-	O
+75	O
+vs	O
+1	O
+-	O
+8	O
+;	O
+2	O
+.	O
+50	O
+-	O
+5	O
+.	O
+44	O
+).	O
+
+We	O
+provide	O
+the	O
+first	O
+description	O
+of	O
+the	O
+incidence	O
+of	O
+and	O
+risk	O
+factors	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+among	O
+pediatric	O
+trauma	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Interhospital	O
+transport	B-PROC
+of	O
+ARDS	B-DISO
+patients	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Transporting	O
+ARDS	B-DISO
+patients	O
+to	O
+ECMO	O
+centers	O
+for	O
+treatment	O
+can	O
+be	O
+dangerous	O
+because	O
+of	O
+the	O
+risk	O
+of	O
+hypoxemia	O
+during	O
+transport	B-PROC
+.	O
+
+This	O
+raises	O
+the	O
+question	O
+if	O
+ECMO	O
+should	O
+not	O
+be	O
+already	O
+initiated	O
+in	O
+the	O
+transferring	O
+hospital	O
+before	O
+transport	B-PROC
+.	O
+
+No	O
+patient	O
+died	O
+during	O
+transport	B-PROC
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+whole	O
+genome	O
+sequence	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+624I	O
+genotype	O
+confirms	O
+the	O
+close	O
+relationship	O
+with	O
+Q1	O
+genotype	O
+.	O
+
+During	O
+2015	O
+⁻	O
+2016	O
+,	O
+a	O
+total	O
+of	O
+27	O
+egg	B-ANAT
+layer	B-ANAT
+flocks	O
+were	O
+screened	O
+in	O
+AB	O
+(	O
+
+The	O
+model	O
+of	O
+FVH	O
+was	O
+established	O
+by	O
+intraperitoneal	O
+injection	O
+of	O
+MHV	B-SPEC
+-	O
+3	O
+into	O
+Balb	O
+/	O
+cJ	O
+mice	B-SPEC
+.	O
+
+Antemortem	O
+evaluation	O
+revealed	O
+severe	O
+neurologic	B-DISO
+signs	I-DISO
+,	O
+including	O
+disorientation	B-DISO
+,	O
+torticollis	B-DISO
+,	O
+and	O
+opisthotonos	B-DISO
+.	O
+
+Based	O
+on	O
+sequencing	O
+analysis	O
+,	O
+the	O
+IBV	B-SPEC
+appeared	O
+99	O
+%	O
+homologous	O
+to	O
+strain	O
+CA1737	O
+.	O
+
+ER	O
+stress	O
+signal	O
+responses	O
+to	O
+mechanical	O
+stretch	O
+were	O
+studied	O
+in	O
+ex	O
+-	O
+vivo	O
+ventilated	O
+pig	O
+lungs	B-ANAT
+.	O
+
+The	O
+Nsp7	O
+/	O
+Nsp8	O
+complex	O
+displays	O
+a	O
+higher	O
+binding	B-FUNC
+affinity	O
+for	O
+Nsp15	O
+.	O
+
+While	O
+the	O
+two	O
+proteins	B-CHED
+display	O
+strong	O
+structural	O
+conservation	O
+and	O
+the	O
+mechanisms	O
+underlying	O
+membrane	B-PROC
+fusion	I-PROC
+are	O
+similar	O
+,	O
+they	O
+share	O
+no	O
+sequence	O
+similarity	O
+.	O
+
+Treatment	O
+with	O
+endocytosis	B-PATH
+inhibitors	B-CHED
+did	O
+not	O
+affect	O
+syncytium	B-PROC
+formation	I-PROC
+by	O
+infected	O
+cells	B-COMP
+.	O
+
+It	O
+can	O
+cause	O
+extreme	O
+dehydration	B-DISO
+and	O
+death	B-PROC
+in	O
+neonatal	O
+piglets	O
+.	O
+
+In	O
+Asia	O
+,	O
+modified	O
+live	O
+attenuated	O
+vaccines	O
+have	O
+been	O
+used	O
+to	O
+control	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+recent	O
+years	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+pregnancy	O
+,	O
+infection	B-DISO
+with	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+may	O
+produce	O
+symptoms	O
+similar	O
+to	O
+infection	B-DISO
+with	O
+seasonal	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+Patients	O
+may	O
+rarely	O
+come	O
+with	O
+a	O
+clinical	O
+condition	B-DISO
+causing	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+Parainfluenzaviruses	O
+(	O
+PIVs	O
+)	O
+account	O
+for	O
+a	O
+significant	O
+proportion	O
+of	O
+viral	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+ARIs	O
+)	O
+in	O
+children	O
+,	O
+and	O
+are	O
+also	O
+associated	O
+with	O
+morbidity	O
+and	O
+mortality	O
+in	O
+adults	O
+,	O
+including	O
+nosocomial	B-DISO
+infections	I-DISO
+.	O
+
+Between	O
+December	O
+2016	O
+and	O
+December	O
+2017	O
+,	O
+6121	O
+samples	O
+were	O
+collected	O
+,	O
+and	O
+submitted	O
+to	O
+viral	O
+culture	O
+and	O
+genomic	O
+quantification	O
+,	O
+specifically	O
+Parainfluenza	B-DISO
+1	O
+-	O
+4	O
+(	O
+PIV1	O
+-	O
+4	O
+),	O
+Influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+Respiratory	B-SPEC
+Syncytial	I-SPEC
+Virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+A	O
+and	O
+B	O
+,	O
+Adenovirus	B-DISO
+,	O
+Metapneumovirus	B-SPEC
+,	O
+Coronavirus	B-SPEC
+,	O
+Rhinovirus	B-SPEC
+,	O
+and	O
+Enterovirus	B-SPEC
+.	O
+
+MERS	O
+was	O
+caused	O
+by	O
+a	O
+virus	B-SPEC
+that	O
+was	O
+originally	O
+called	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+Erasmus	O
+Medical	O
+Center	O
+/	O
+2012	O
+but	O
+was	O
+later	O
+renamed	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+MERS	O
+-	O
+CoV	O
+causes	O
+high	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+and	O
+multiorgan	O
+dysfunction	O
+that	O
+may	O
+eventually	O
+lead	O
+to	O
+the	O
+death	B-PROC
+of	O
+the	O
+infected	O
+individuals	O
+.	O
+
+Recent	O
+studies	O
+on	O
+Middle	O
+Eastern	O
+respiratory	O
+continue	O
+to	O
+highlight	O
+the	O
+need	O
+for	O
+further	O
+understanding	O
+the	O
+virus	O
+-	O
+host	B-COMP
+interactions	O
+that	O
+govern	O
+disease	O
+severity	O
+and	O
+infection	B-DISO
+outcome	O
+.	O
+
+Quantitative	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+rRT	O
+-	O
+PCR	O
+)	O
+was	O
+applied	O
+on	O
+the	O
+collected	O
+tracheal	O
+swabs	O
+for	O
+detecting	O
+RNA	O
+copies	O
+of	O
+H9N2	B-PRGE
+AIV	I-PRGE
+.	O
+
+It	O
+has	O
+been	O
+utilised	O
+as	O
+a	O
+viral	O
+vector	O
+to	O
+develop	O
+many	O
+vaccines	O
+against	O
+cancer	B-DISO
+and	O
+infectious	B-DISO
+diseases	I-DISO
+such	O
+as	O
+malaria	B-PATH
+,	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+,	O
+influenza	B-DISO
+,	O
+and	O
+tuberculosis	B-PATH
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+Ebola	B-DISO
+virus	I-DISO
+infection	I-DISO
+.	O
+
+There	O
+is	O
+accumulating	O
+data	O
+from	O
+many	O
+preclinical	O
+and	O
+clinical	O
+studies	O
+that	O
+highlights	O
+the	O
+excellent	O
+safety	O
+and	O
+immunogenicity	O
+of	O
+MVA	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+global	O
+community	O
+continues	O
+to	O
+incur	O
+the	O
+high	O
+costs	O
+of	O
+crisis	O
+mitigation	O
+and	O
+emergency	B-DISO
+response	O
+to	O
+outbreaks	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+those	O
+caused	O
+by	O
+the	O
+H5N1	B-DISO
+highly	O
+pathogenic	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+Ebola	B-SPEC
+virus	I-SPEC
+,	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+Zika	B-SPEC
+virus	I-SPEC
+or	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+These	O
+signals	O
+include	O
+trade	O
+bans	O
+,	O
+market	O
+closures	O
+,	O
+civil	O
+unrest	B-DISO
+,	O
+heavy	O
+rains	O
+and	O
+droughts	O
+associated	O
+with	O
+climate	O
+change	O
+,	O
+and	O
+livestock	O
+intensification	O
+or	O
+changes	O
+in	O
+consumer	O
+behaviour	B-PROC
+.	O
+
+The	O
+goal	O
+of	O
+the	O
+Food	O
+and	O
+Agriculture	O
+Organization	O
+of	O
+the	O
+United	O
+Nations	O
+(	O
+FAO	O
+)	O
+is	O
+to	O
+end	O
+hunger	B-DISO
+and	O
+poverty	O
+,	O
+which	O
+is	O
+a	O
+challenging	O
+and	O
+complex	O
+task	O
+.	O
+
+ABSTRACT	O
+:	O
+Tracheal	O
+swabs	O
+and	O
+different	O
+organs	O
+are	O
+collected	O
+from	O
+17	O
+chicken	B-SPEC
+farms	O
+showing	O
+respiratory	O
+signs	O
+and	O
+variable	O
+mortalities	O
+in	O
+different	O
+governorates	O
+.	O
+
+However	O
+,	O
+IBV	B-SPEC
+S78	O
+and	O
+IBV	B-SPEC
+S82	O
+are	O
+related	O
+to	O
+Egyptian	O
+variant	O
+2	O
+IBV	B-SPEC
+strains	O
+Ck	O
+/	O
+Eg	O
+/	O
+BSU	O
+-	O
+2	O
+/	O
+2011	O
+and	O
+Ck	O
+/	O
+Eg	O
+/	O
+BSU	O
+-	O
+3	O
+/	O
+201	O
+1	O
+.	O
+These	O
+results	O
+indicate	O
+the	O
+continuous	O
+evolution	B-PROC
+of	O
+Egyptian	O
+IBV	B-SPEC
+circulating	O
+in	O
+chickens	B-SPEC
+despite	O
+vaccination	O
+using	O
+H120	O
+live	O
+attenuated	O
+vaccine	O
+.	O
+
+The	O
+2017	O
+literature	O
+concerning	O
+public	O
+health	O
+and	O
+epidemiology	O
+informatics	O
+was	O
+searched	O
+in	O
+PubMed	O
+and	O
+Web	B-DISO
+of	O
+Science	O
+,	O
+and	O
+the	O
+returned	O
+references	O
+were	O
+reviewed	O
+by	O
+the	O
+two	O
+section	O
+editors	O
+to	O
+select	O
+14	O
+candidate	O
+best	O
+papers	O
+.	O
+
+RESULTS	O
+:	O
+Nucleic	B-CHED
+acid	I-CHED
+of	O
+at	O
+least	O
+one	O
+respiratory	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+9	O
+out	O
+of	O
+90	O
+(	O
+10	O
+%)	O
+surface	O
+samples	O
+,	O
+including	O
+:	O
+a	O
+plastic	O
+toy	O
+dog	B-SPEC
+in	O
+the	O
+children	O
+'	O
+s	O
+playground	O
+(	O
+2	O
+/	O
+3	O
+swabs	O
+,	O
+67	O
+%);	O
+hand	O
+-	O
+carried	O
+luggage	O
+trays	O
+at	O
+the	O
+security	O
+check	O
+area	O
+(	O
+4	O
+/	O
+8	O
+,	O
+50	O
+%);	O
+the	O
+buttons	O
+of	O
+the	O
+payment	O
+terminal	O
+at	O
+the	O
+pharmacy	O
+(	O
+1	O
+/	O
+2	O
+,	O
+50	O
+%);	O
+the	O
+handrails	O
+of	O
+stairs	O
+(	O
+1	O
+/	O
+7	O
+,	O
+14	O
+%);	O
+and	O
+the	O
+passenger	O
+side	O
+desk	O
+and	O
+divider	O
+glass	O
+at	O
+a	O
+passport	O
+control	O
+point	O
+(	O
+1	O
+/	O
+3	O
+,	O
+33	O
+%).	O
+
+TITLE	O
+:	O
+Screening	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+among	O
+febrile	B-PROC
+Indonesian	O
+Hajj	O
+pilgrims	O
+:	O
+A	O
+study	O
+on	O
+28	O
+,	O
+197	O
+returning	O
+pilgrims	O
+.	O
+
+Fifteen	O
+pilgrims	O
+had	O
+fever	B-PROC
+(>	O
+38	O
+°	O
+C	O
+)	O
+accompanied	O
+by	O
+respiratory	B-DISO
+symptoms	I-DISO
+;	O
+of	O
+these	O
+,	O
+12	O
+patients	O
+were	O
+diagnosed	O
+with	O
+upper	O
+and	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+three	O
+patients	O
+with	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+Rare	O
+Axonal	O
+Variant	O
+of	O
+Guillain	O
+-	O
+Barré	O
+Syndrome	B-DISO
+following	O
+Elective	O
+Spinal	O
+Surgery	O
+.	O
+
+Although	O
+rare	O
+,	O
+GBS	B-DISO
+has	O
+been	O
+reported	O
+as	O
+a	O
+complication	B-DISO
+of	O
+surgery	O
+.	O
+
+Because	O
+of	O
+its	O
+risk	O
+of	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+,	O
+as	O
+well	O
+as	O
+similar	O
+presentation	O
+to	O
+more	O
+common	O
+spinal	O
+postoperative	O
+complications	O
+,	O
+GBS	B-DISO
+should	O
+always	O
+be	O
+included	O
+in	O
+the	O
+differential	O
+diagnosis	O
+whenever	O
+motor	O
+or	O
+sensory	O
+weakness	B-DISO
+is	O
+observed	O
+after	O
+spinal	O
+surgery	O
+.	O
+
+TITLE	O
+:	O
+Management	O
+of	O
+Acute	O
+Complications	O
+of	O
+Targeted	B-PROC
+Therapy	O
+in	O
+Patients	O
+With	O
+Cancer	B-DISO
+:	O
+A	O
+Review	O
+of	O
+Cases	O
+Managed	O
+in	O
+ICU	O
+.	O
+
+The	O
+main	O
+gastrointestinal	O
+side	O
+effects	O
+are	O
+fulminant	B-DISO
+hepatitis	I-DISO
+that	O
+may	O
+be	O
+fatal	O
+,	O
+colitis	B-DISO
+that	O
+may	O
+be	O
+complicated	O
+by	O
+hemorrhage	B-DISO
+,	O
+and	O
+perforation	O
+.	O
+
+Remarkably	O
+,	O
+4	O
+mAbs	O
+(	O
+designed	O
+2G8	O
+,	O
+2B11	O
+,	O
+3D9	O
+,	O
+1E3	O
+)	O
+neutralized	O
+virus	B-DISO
+infection	I-DISO
+potently	O
+,	O
+of	O
+which	O
+2B11	O
+and	O
+1E3	O
+targeted	B-PROC
+the	O
+conformational	O
+epitope	B-CHED
+of	O
+the	O
+PEDV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+RESULTS	O
+:	O
+We	O
+identified	O
+10	O
+monoclonal	O
+antibodies	B-COMP
+using	O
+hybridoma	B-ANAT
+technology	O
+.	O
+
+The	O
+new	O
+teicoplanin	O
+pseudoaglycon	O
+-	O
+derived	O
+lipoglycopeptides	O
+were	O
+prepared	O
+by	O
+coupling	O
+one	O
+or	O
+two	O
+side	O
+chains	O
+to	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+the	O
+glycopeptide	B-CHED
+core	O
+,	O
+using	O
+various	O
+conjugation	B-PROC
+methods	O
+.	O
+
+This	O
+study	O
+is	O
+the	O
+first	O
+retrospective	O
+investigation	O
+for	O
+SADS	O
+-	O
+CoV	O
+and	O
+provides	O
+the	O
+epidemiological	O
+information	O
+of	O
+this	O
+new	O
+virus	B-SPEC
+in	O
+China	O
+,	O
+which	O
+highlights	O
+the	O
+urgency	O
+to	O
+develop	O
+effective	O
+measures	O
+to	O
+control	O
+SADS	O
+-	O
+CoV	O
+.	O
+
+We	O
+present	O
+a	O
+new	O
+case	O
+of	O
+this	O
+syndrome	B-DISO
+,	O
+caused	O
+by	O
+a	O
+mutation	O
+not	O
+previously	O
+described	O
+.	O
+
+A	O
+full	O
+term	O
+infant	O
+presented	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+generalized	B-DISO
+weakness	I-DISO
+.	O
+
+The	O
+genetic	O
+analysis	O
+revealed	O
+the	O
+patient	O
+to	O
+be	O
+compound	O
+heterozygous	O
+for	O
+a	O
+new	B-DISO
+mutation	I-DISO
+of	O
+the	O
+SCL5A7	B-PRGE
+gene	I-PRGE
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+investigate	O
+HPV	O
+infection	B-DISO
+of	O
+the	O
+external	B-ANAT
+genitalia	I-ANAT
+in	O
+men	O
+whose	O
+female	O
+partners	O
+have	O
+cervical	B-ANAT
+HPV	O
+infection	B-DISO
+.	O
+
+We	O
+obtained	O
+samples	O
+with	O
+nylon	O
+swabs	O
+from	O
+the	O
+glans	B-ANAT
+penis	I-ANAT
+,	O
+corona	B-CHED
+,	O
+inner	O
+layer	B-ANAT
+of	O
+the	O
+prepuce	B-ANAT
+and	O
+penile	B-ANAT
+body	I-ANAT
+and	O
+detected	O
+different	O
+types	O
+of	O
+HPV	O
+infection	B-DISO
+using	O
+the	O
+Hybribio	O
+HPV	O
+typing	O
+kit	B-FUNC
+,	O
+PCR	O
+and	O
+membrane	B-COMP
+hybridization	B-PROC
+.	O
+
+A	O
+descriptive	O
+study	O
+was	O
+carried	O
+out	O
+on	O
+159	O
+adult	O
+burn	O
+patients	O
+with	O
+burn	O
+extent	O
+≥	O
+20	O
+%	O
+total	B-ANAT
+body	I-ANAT
+surface	I-ANAT
+area	O
+,	O
+treated	O
+at	O
+the	O
+Burn	O
+Intensive	O
+Care	O
+Unit	O
+,	O
+National	O
+Institute	O
+of	O
+Burns	O
+.	O
+
+Risk	O
+factors	O
+for	O
+developing	O
+ARDS	B-DISO
+and	O
+outcome	O
+were	O
+recorded	O
+and	O
+analyzed	O
+.	O
+
+Results	O
+showed	O
+that	O
+45	O
+patients	O
+developed	O
+ARDS	B-DISO
+(	O
+28	O
+.	O
+3	O
+%).	O
+
+This	O
+assay	O
+will	O
+be	O
+a	O
+useful	O
+tool	O
+for	O
+quality	O
+control	O
+and	O
+environmental	O
+monitoring	O
+for	O
+dogs	B-SPEC
+used	O
+as	O
+laboratory	O
+animals	B-SPEC
+,	O
+may	O
+even	O
+be	O
+applied	O
+in	O
+laboratory	O
+epidemiological	O
+investigations	O
+.	O
+
+Viral	O
+CAP	B-DISO
+and	O
+mixed	O
+CAP	B-DISO
+were	O
+not	O
+independent	O
+factors	O
+for	O
+death	B-PROC
+.	O
+
+Nowadays	O
+,	O
+they	O
+are	O
+easily	O
+transmitted	B-DISO
+among	O
+the	O
+continents	O
+via	O
+vehicles	O
+,	O
+equipment	O
+,	O
+and	O
+cargo	O
+.	O
+
+Patients	O
+were	O
+followed	O
+up	O
+for	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+within	O
+7	O
+days	O
+(	O
+primary	O
+outcome	O
+).	O
+
+ABSTRACT	O
+:	O
+Virus	B-SPEC
+like	O
+particles	O
+(	O
+VLPs	B-ANAT
+)	O
+produced	O
+by	O
+the	O
+expression	B-PROC
+of	O
+viral	O
+structural	O
+proteins	B-CHED
+can	O
+serve	O
+as	O
+versatile	O
+nanovectors	O
+or	O
+potential	O
+vaccine	O
+candidates	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+describe	O
+for	O
+the	O
+first	O
+time	O
+the	O
+generation	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+VLPs	B-ANAT
+using	O
+baculovirus	B-SPEC
+system	O
+.	O
+
+Production	O
+of	O
+a	O
+specific	O
+delivery	O
+vector	O
+is	O
+a	O
+major	O
+challenge	O
+for	O
+research	O
+concerning	O
+targeting	B-PROC
+molecules	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+and	O
+Epidemiologic	O
+Patterns	O
+of	O
+Chikungunya	B-DISO
+Virus	I-DISO
+Infection	I-DISO
+and	O
+Coincident	O
+Arboviral	B-DISO
+Disease	I-DISO
+in	O
+a	O
+School	O
+Cohort	O
+in	O
+Haiti	O
+,	O
+2014	O
+-	O
+2015	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+host	B-COMP
+innate	B-PROC
+immunity	I-PROC
+,	O
+type	B-PRGE
+I	I-PRGE
+interferons	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+are	O
+major	O
+antiviral	B-CHED
+molecules	O
+,	O
+and	O
+coronaviruses	O
+have	O
+evolved	O
+diverse	O
+strategies	O
+to	O
+counter	B-CHED
+the	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+response	O
+during	O
+infection	B-DISO
+.	O
+
+While	O
+previously	O
+implicated	O
+in	O
+a	O
+non	O
+-	O
+inflammatory	O
+apoptotic	B-PROC
+cell	I-PROC
+death	I-PROC
+pathway	B-PROC
+,	O
+here	O
+we	O
+extend	O
+the	O
+range	O
+of	O
+SARS	B-DISO
+3a	O
+pathophysiologic	O
+targets	O
+by	O
+examining	O
+its	O
+effects	O
+on	O
+necrotic	B-PROC
+cell	I-PROC
+death	I-PROC
+pathways	B-PROC
+.	O
+
+Consequently	O
+,	O
+Transcription	B-PRGE
+Factor	I-PRGE
+EB	I-PRGE
+(	O
+TFEB	B-PRGE
+)	O
+translocates	O
+to	O
+the	O
+nucleus	B-COMP
+increasing	O
+the	O
+transcription	B-PROC
+of	O
+autophagy	B-PROC
+-	O
+and	O
+lysosome	B-COMP
+-	O
+related	O
+genes	O
+.	O
+
+In	O
+summary	O
+,	O
+Rip3	B-PRGE
+-	O
+mediated	O
+oligomerization	O
+of	O
+SARS	B-PRGE
+3a	I-PRGE
+causes	O
+necrotic	B-PROC
+cell	I-PROC
+death	I-PROC
+,	O
+lysosomal	B-ANAT
+damage	O
+,	O
+and	O
+caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+activation	O
+-	O
+all	O
+likely	O
+contributing	O
+to	O
+the	O
+clinical	O
+manifestations	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Researchers	O
+can	O
+use	O
+cpsRNAs	O
+to	O
+study	O
+the	O
+infection	B-DISO
+or	O
+pathogenesis	B-DISO
+of	O
+pathogenic	O
+viruses	B-SPEC
+when	O
+these	O
+viruses	B-SPEC
+are	O
+not	O
+available	O
+.	O
+
+The	O
+discovery	O
+of	O
+psRNAs	O
+and	O
+cpsRNAs	O
+,	O
+as	O
+a	O
+novel	O
+class	B-SPEC
+of	O
+small	O
+RNAs	O
+,	O
+also	O
+inspire	O
+researchers	O
+to	O
+investigate	O
+DNA	O
+palindromes	O
+and	O
+DNA	O
+complemented	O
+palindromes	O
+with	O
+lengths	O
+of	O
+psRNAs	O
+and	O
+cpsRNAs	O
+in	O
+viral	O
+genomes	O
+.	O
+
+He	O
+developed	O
+a	O
+fever	B-PROC
+of	O
+39	O
+°	O
+C	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+was	O
+transported	O
+by	O
+ambulance	O
+to	O
+his	O
+usual	O
+doctor	O
+.	O
+
+Chest	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+on	O
+arrival	O
+showed	O
+ground	O
+glass	O
+opacity	B-DISO
+(	O
+GGO	O
+)	O
+in	O
+the	O
+bilateral	O
+lungs	B-ANAT
+with	O
+emphysematous	O
+change	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+is	O
+a	O
+highly	O
+lethal	O
+disease	O
+caused	O
+by	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+,	O
+leading	O
+to	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Inhibition	B-PROC
+of	O
+coiled	O
+coil	O
+-	O
+mediated	O
+interactions	O
+using	O
+bioactive	O
+peptides	B-CHED
+that	O
+replicate	O
+an	O
+α	O
+-	O
+helical	O
+chain	O
+from	O
+the	O
+viral	O
+fusion	O
+machinery	O
+has	O
+significant	O
+antiviral	B-CHED
+potential	O
+.	O
+
+Here	O
+,	O
+we	O
+present	O
+the	O
+construction	O
+of	O
+a	O
+series	O
+of	O
+lipopeptides	B-CHED
+composed	O
+of	O
+a	O
+de	O
+novo	O
+heptad	O
+repeat	O
+sequence	O
+-	O
+based	O
+α	O
+-	O
+helical	O
+peptide	B-CHED
+plus	O
+a	O
+hydrocarbon	B-CHED
+tail	O
+.	O
+
+Together	O
+,	O
+these	O
+findings	O
+reveal	O
+a	O
+new	O
+strategy	O
+for	O
+relatively	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+drug	I-CHED
+discovery	O
+by	O
+relying	O
+on	O
+the	O
+tunability	O
+of	O
+the	O
+α	O
+-	O
+helical	O
+coiled	O
+-	O
+coil	O
+domains	O
+present	O
+in	O
+all	O
+class	O
+I	O
+fusion	O
+proteins	B-CHED
+and	O
+the	O
+amphiphilic	O
+nature	O
+of	O
+the	O
+individual	O
+helices	B-SPEC
+from	O
+this	O
+multihelix	O
+motif	O
+.	O
+
+The	O
+full	O
+-	O
+length	O
+genomes	O
+of	O
+viruses	B-SPEC
+from	O
+egg	B-ANAT
+passages	O
+1	O
+,	O
+20	O
+,	O
+40	O
+,	O
+and	O
+60	O
+were	O
+sequenced	O
+using	O
+the	O
+Illumina	O
+platform	O
+and	O
+the	O
+data	O
+showed	O
+single	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+(	O
+SNPs	O
+)	O
+had	O
+accumulated	O
+in	O
+regions	O
+of	O
+the	O
+genome	O
+associated	O
+with	O
+viral	B-PROC
+replication	I-PROC
+,	O
+pathogenicity	O
+,	O
+and	O
+cell	B-COMP
+tropism	B-PROC
+.	O
+
+The	O
+aim	O
+of	O
+our	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+lung	B-ANAT
+ultrasound	O
+in	O
+out	O
+-	O
+of	O
+-	O
+hospital	O
+non	O
+-	O
+traumatic	O
+respiratory	B-DISO
+insufficiency	I-DISO
+.	O
+
+Here	O
+,	O
+the	O
+complete	O
+fusion	O
+-	O
+core	O
+structure	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+has	O
+been	O
+determined	O
+at	O
+1	O
+.	O
+86	O
+Å	O
+resolution	O
+,	O
+representing	O
+the	O
+most	O
+complete	O
+post	O
+-	O
+fusion	O
+conformation	O
+thus	O
+far	O
+among	O
+published	O
+human	B-SPEC
+alphacoronavirus	B-SPEC
+(	O
+α	O
+-	O
+HCoV	O
+)	O
+fusion	O
+-	O
+core	O
+structures	O
+.	O
+
+Side	O
+-	O
+by	O
+-	O
+side	O
+electrostatic	O
+surface	O
+comparisons	O
+reveal	O
+that	O
+the	O
+electrostatic	O
+surface	O
+potentials	O
+are	O
+opposite	O
+in	O
+α	O
+-	O
+HCoVs	O
+and	O
+β	O
+-	O
+HCoVs	O
+at	O
+certain	O
+positions	O
+and	O
+that	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+surface	O
+also	O
+appears	O
+to	O
+be	O
+the	O
+most	O
+hydrophobic	O
+among	O
+the	O
+various	O
+HCoVs	O
+.	O
+
+The	O
+most	O
+recent	O
+common	O
+ancestor	O
+of	O
+HBV	B-DISO
+/	O
+C	O
+was	O
+traced	O
+back	B-ANAT
+to	O
+the	O
+early	O
+1900s	O
+in	O
+China	O
+,	O
+where	O
+it	O
+eventually	O
+diverged	O
+into	O
+two	O
+major	O
+lineages	O
+during	O
+the	O
+1930s	O
+-	O
+1960s	O
+that	O
+gave	O
+rise	O
+to	O
+distinct	O
+epidemic	O
+waves	O
+spreading	O
+exponentially	O
+to	O
+other	O
+East	O
+Asian	O
+countries	O
+and	O
+the	O
+USA	O
+.	O
+
+We	O
+report	O
+two	O
+potential	O
+nidovirus	B-SPEC
+genomes	O
+,	O
+a	O
+highly	O
+divergent	O
+35	O
+.	O
+9	O
+kb	O
+likely	O
+complete	O
+genome	O
+from	O
+the	O
+California	B-SPEC
+sea	I-SPEC
+hare	I-SPEC
+Aplysia	B-SPEC
+californica	I-SPEC
+,	O
+which	O
+we	O
+assign	O
+to	O
+a	O
+nidovirus	B-SPEC
+named	O
+Aplysia	B-PRGE
+abyssovirus	I-PRGE
+1	I-PRGE
+(	O
+AAbV	O
+),	O
+and	O
+a	O
+coronavirus	B-SPEC
+-	O
+like	O
+22	O
+.	O
+3	O
+kb	O
+partial	O
+genome	O
+from	O
+the	O
+ornamented	O
+pygmy	B-DISO
+frog	B-SPEC
+Microhyla	B-SPEC
+fissipes	I-SPEC
+,	O
+which	O
+we	O
+assign	O
+to	O
+a	O
+nidovirus	B-SPEC
+named	O
+Microhyla	B-SPEC
+alphaletovirus	O
+1	O
+(	O
+MLeV	O
+).	O
+
+AAbV	O
+was	O
+shown	O
+to	O
+encode	O
+a	O
+functional	O
+main	O
+proteinase	B-PROC
+,	O
+and	O
+a	O
+translational	B-PROC
+readthrough	I-PROC
+signal	O
+.	O
+
+ABSTRACT	O
+:	O
+Base	B-PRGE
+on	O
+the	O
+sequence	O
+of	O
+
+ABSTRACT	O
+:	O
+Acute	O
+Respiratory	O
+Infections	O
+(	O
+ARI	B-CHED
+)	O
+are	O
+common	O
+causes	O
+of	O
+febrile	B-PROC
+illnesses	O
+in	O
+many	O
+settings	O
+in	O
+Senegal	O
+.	O
+
+In	O
+addition	O
+,	O
+there	O
+are	O
+limited	O
+data	O
+on	O
+the	O
+spectrum	O
+of	O
+pathogens	O
+commonly	O
+responsible	O
+for	O
+these	O
+ARI	B-CHED
+.	O
+
+Although	O
+fatalities	O
+from	O
+septicemia	B-DISO
+after	O
+uterine	B-ANAT
+artery	I-ANAT
+embolization	O
+have	O
+been	O
+reported	O
+,	O
+aseptic	O
+inflammatory	B-DISO
+responses	I-DISO
+to	O
+uterine	B-ANAT
+degeneration	B-DISO
+can	O
+also	O
+lead	O
+to	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Investigating	O
+type	O
+I	O
+feline	B-SPEC
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+in	O
+tissue	B-ANAT
+culture	O
+is	O
+critical	O
+for	O
+understanding	O
+the	O
+basic	O
+virology	O
+,	O
+pathogenesis	B-DISO
+,	O
+and	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactome	O
+of	O
+these	O
+important	O
+veterinary	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+in	O
+non	O
+-	O
+myeloid	B-ANAT
+cells	I-ANAT
+is	O
+augmented	O
+by	O
+chloride	B-CHED
+ions	B-CHED
+via	O
+an	O
+increase	O
+in	O
+intracellular	O
+hypochlorous	B-CHED
+acid	I-CHED
+levels	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+case	O
+study	O
+report	O
+describes	O
+a	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+infection	B-DISO
+presented	O
+in	O
+a	O
+commercial	O
+pig	B-SPEC
+herd	O
+.	O
+
+In	O
+conclusion	O
+,	O
+this	O
+case	O
+study	O
+reported	O
+an	O
+epidemic	O
+TGEV	B-SPEC
+infection	B-DISO
+in	O
+piglets	O
+,	O
+characterized	O
+by	O
+low	O
+mortality	O
+and	O
+medium	O
+morbidity	O
+rates	O
+accompanied	O
+by	O
+typical	O
+histopathological	O
+lesions	O
+in	O
+small	B-ANAT
+intestine	I-ANAT
+,	O
+as	O
+well	O
+as	O
+by	O
+coexisting	O
+brain	B-DISO
+lesions	I-DISO
+,	O
+that	O
+are	O
+described	O
+for	O
+the	O
+first	O
+time	O
+.	O
+
+Consequently	O
+,	O
+on	O
+challenge	O
+with	O
+the	O
+virulent	O
+IBV	B-SPEC
+strain	O
+at	O
+28	O
+
+TITLE	O
+:	O
+Recombinant	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Viruses	B-SPEC
+Expressing	O
+Chimeric	O
+Spike	O
+Glycoproteins	B-CHED
+Induce	O
+Partial	O
+Protective	O
+Immunity	O
+against	O
+Homologous	O
+Challenge	O
+despite	O
+Limited	O
+Replication	O
+ABSTRACT	O
+:	O
+Vaccination	O
+regimes	O
+against	O
+
+To	O
+further	O
+understand	O
+the	O
+evolutionary	O
+relationship	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+its	O
+reservoirs	O
+,	O
+334	O
+bats	B-SPEC
+were	O
+collected	O
+from	O
+Zhoushan	O
+city	O
+,	O
+Zhejiang	O
+province	O
+,	O
+China	O
+,	O
+between	O
+2015	O
+and	O
+2017	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+usually	O
+require	O
+ventilatory	O
+support	O
+treatment	O
+.	O
+
+ECMO	O
+support	O
+showed	O
+many	O
+advantages	O
+in	O
+treating	O
+severe	O
+ARDS	B-DISO
+,	O
+such	O
+as	O
+reducing	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+and	O
+correcting	O
+hypoxemia	O
+.	O
+
+This	O
+paper	O
+reviews	O
+the	O
+applications	O
+of	O
+ECMO	O
+for	O
+the	O
+treatment	O
+of	O
+ARDS	B-DISO
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Advances	O
+in	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+TITLE	O
+:	O
+Major	O
+Infectious	B-DISO
+Diseases	I-DISO
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+diseases	I-DISO
+were	O
+responsible	O
+for	O
+the	O
+largest	O
+global	O
+burden	O
+of	O
+premature	O
+death	O
+and	O
+disability	O
+until	O
+the	O
+end	O
+of	O
+the	O
+twentieth	O
+century	O
+,	O
+when	O
+that	O
+distinction	O
+passed	O
+to	O
+noncommunicable	O
+diseases	O
+.	O
+
+At	O
+least	O
+as	O
+early	O
+as	O
+the	O
+late	O
+1800s	O
+,	O
+improved	O
+living	O
+conditions	O
+(	O
+such	O
+as	O
+better	O
+sanitation	O
+and	O
+piped	O
+water	B-CHED
+supplies	O
+),	O
+particularly	O
+in	O
+high	O
+-	O
+income	O
+countries	O
+(	O
+HICs	O
+),	O
+began	O
+to	O
+drive	O
+down	O
+the	O
+infectious	B-DISO
+disease	I-DISO
+burden	O
+.	O
+
+However	O
+,	O
+table	O
+1	O
+.	O
+1	O
+shows	O
+also	O
+that	O
+if	O
+the	O
+death	B-PROC
+rates	O
+of	O
+2010	O
+remain	O
+static	O
+,	O
+about	O
+5	O
+.	O
+1	O
+million	O
+people	O
+will	O
+still	O
+die	O
+in	O
+2030	O
+from	O
+these	O
+three	O
+conditions	O
+and	O
+from	O
+other	O
+communicable	B-DISO
+diseases	I-DISO
+,	O
+many	O
+of	O
+which	O
+are	O
+concentrated	O
+in	O
+LMICs	O
+.	O
+
+Left	O
+untreated	O
+,	O
+the	O
+condition	B-DISO
+may	O
+rapidly	O
+progress	O
+to	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+death	B-PROC
+.	O
+
+MDMA	B-CHED
+is	O
+a	O
+stimulant	O
+and	O
+psychedelic	O
+with	O
+a	O
+chemical	O
+structure	O
+similar	O
+to	O
+serotonin	O
+.	O
+
+Psychosocial	O
+intervention	O
+is	O
+the	O
+main	O
+form	O
+of	O
+treatment	O
+for	O
+addiction	B-DISO
+to	O
+these	O
+substances	O
+.	O
+
+TITLE	O
+:	O
+MOLECULAR	O
+IDENTIFICATION	O
+OF	O
+AVIAN	B-SPEC
+VIRUSES	B-SPEC
+IN	O
+NEOTROPIC	O
+CORMORANTS	B-SPEC
+(	O
+PHALACROCORAX	B-SPEC
+BRASILIANUS	I-SPEC
+)	O
+IN	O
+CHILE	O
+.	O
+
+TITLE	O
+:	O
+A	O
+self	O
+-	O
+adjuvanted	O
+nanoparticle	B-CHED
+based	O
+vaccine	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+In	O
+this	O
+vaccine	O
+,	O
+B	B-ANAT
+cell	I-ANAT
+epitopes	O
+derived	O
+from	O
+the	O
+second	O
+heptad	O
+repeat	O
+(	O
+HR2	O
+)	O
+region	O
+of	O
+IBV	B-SPEC
+spike	O
+proteins	B-CHED
+were	O
+repetitively	O
+presented	O
+in	O
+its	O
+native	O
+trimeric	O
+conformation	O
+.	O
+
+Three	O
+groups	O
+of	O
+chickens	B-SPEC
+were	O
+immunized	O
+at	O
+four	O
+weeks	O
+of	O
+age	O
+with	O
+the	O
+vaccine	O
+prototype	O
+,	O
+IBV	B-SPEC
+-	O
+Flagellin	O
+-	O
+SAPN	O
+,	O
+a	O
+negative	O
+-	O
+control	O
+construct	O
+Flagellin	O
+-	O
+SAPN	O
+or	O
+a	O
+buffer	B-CHED
+control	O
+.	O
+
+In	O
+ex	O
+vivo	O
+proliferation	B-DISO
+tests	O
+,	O
+peripheral	O
+mononuclear	B-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+)	O
+derived	O
+from	O
+IBV	B-SPEC
+-	O
+Flagellin	O
+-	O
+SAPN	O
+immunized	O
+chickens	B-SPEC
+had	O
+a	O
+significantly	O
+higher	O
+stimulation	O
+index	O
+than	O
+that	O
+of	O
+PBMCs	O
+from	O
+chickens	B-SPEC
+receiving	O
+Flagellin	O
+-	O
+SAPN	O
+.	O
+
+The	O
+global	O
+networks	O
+of	O
+Dengue	B-DISO
+and	O
+Zika	O
+proteases	O
+are	O
+coordinated	O
+by	O
+their	O
+NS2B	O
+-	O
+cofactors	B-CHED
+.	O
+
+Therefore	O
+,	O
+by	O
+introducing	O
+extra	O
+domains	O
+/	O
+cofactors	B-CHED
+,	O
+nature	O
+develops	O
+diverse	O
+strategies	O
+to	O
+regulate	O
+the	O
+catalytic	O
+machinery	O
+embedded	O
+on	O
+the	O
+chymotrypsin	B-PRGE
+fold	O
+through	O
+folding	O
+,	O
+structurally	O
+-	O
+and	O
+dynamically	O
+-	O
+driven	O
+allostery	O
+,	O
+all	O
+of	O
+which	O
+might	O
+be	O
+exploited	O
+to	O
+develop	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+Adult	O
+patients	O
+with	O
+acute	O
+severe	O
+poisoning	O
+in	O
+the	O
+emergency	B-DISO
+intensive	O
+care	O
+unit	O
+(	O
+EICU	O
+)	O
+of	O
+Nanjing	O
+Drum	O
+Tower	O
+Hospital	O
+from	O
+January	O
+2008	O
+to	O
+December	O
+2017	O
+were	O
+enrolled	O
+.	O
+
+There	O
+were	O
+28	O
+patients	O
+died	B-PROC
+(	O
+31	O
+.	O
+46	O
+%)	O
+in	O
+the	O
+elderly	O
+group	O
+and	O
+the	O
+cause	O
+of	O
+death	B-PROC
+were	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+53	O
+.	O
+57	O
+%),	O
+circulatory	B-DISO
+failure	I-DISO
+(	O
+32	O
+.	O
+14	O
+%)	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+,	O
+14	O
+.	O
+29	O
+%).	O
+
+There	O
+were	O
+67	O
+patients	O
+died	B-PROC
+(	O
+26	O
+.	O
+38	O
+%)	O
+in	O
+the	O
+youth	O
+group	O
+and	O
+the	O
+cause	O
+of	O
+death	B-PROC
+were	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+59	O
+.	O
+70	O
+%),	O
+MODS	B-DISO
+(	O
+20	O
+.	O
+90	O
+%)	O
+and	O
+circulatory	B-DISO
+failure	I-DISO
+(	O
+19	O
+.	O
+40	O
+%).	O
+
+Logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+AKI	B-PRGE
+was	O
+the	O
+independent	O
+risk	O
+factor	O
+for	O
+death	B-PROC
+in	O
+elderly	O
+patients	O
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+=	O
+8	O
+.	O
+449	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+=	O
+2	O
+.	O
+347	O
+-	O
+30	O
+.	O
+410	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+prognosis	O
+of	O
+hematologic	B-DISO
+malignancies	I-DISO
+has	O
+improved	O
+over	O
+the	O
+past	O
+three	O
+decades	O
+.	O
+
+Initial	O
+reports	O
+regarding	O
+the	O
+utility	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+hematologic	B-DISO
+malignancies	I-DISO
+have	O
+been	O
+controversial	O
+,	O
+with	O
+limited	O
+evaluations	O
+of	O
+acute	B-DISO
+leukemia	I-DISO
+patients	O
+supported	O
+by	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Overall	O
+,	O
+75	O
+%	O
+(	O
+three	O
+of	O
+four	O
+)	O
+survived	O
+to	O
+decannulation	O
+with	O
+a	O
+1	O
+-	O
+year	O
+survival	O
+rate	O
+following	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+of	O
+50	O
+%	O
+(	O
+two	O
+of	O
+four	O
+).	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+optimal	O
+drainage	B-ANAT
+cannula	B-SPEC
+position	O
+.	O
+
+No	O
+cross	B-PROC
+-	I-PROC
+reaction	I-PROC
+was	O
+detected	O
+with	O
+antibodies	B-COMP
+against	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+subtypes	O
+(	O
+H5	O
+,	O
+H7	O
+,	O
+and	O
+H9	O
+),	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+,	O
+Marek	B-SPEC
+'	I-SPEC
+s	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+,	O
+infectious	B-SPEC
+bursal	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+chicken	B-SPEC
+anemia	I-SPEC
+virus	I-SPEC
+.	O
+
+Furthermore	O
+,	O
+the	O
+RDT	B-DISO
+,	O
+which	O
+was	O
+visible	O
+to	O
+the	O
+naked	O
+eye	B-ANAT
+,	O
+could	O
+be	O
+completed	O
+within	O
+15	O
+min	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+visual	O
+triage	O
+for	O
+screening	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+patients	O
+.	O
+
+In	O
+2017	O
+the	O
+Saudi	O
+Ministry	O
+of	O
+Health	O
+released	O
+a	O
+visual	O
+triage	O
+system	O
+with	O
+scoring	O
+to	O
+alert	O
+healthcare	O
+workers	O
+in	O
+emergency	B-DISO
+departments	O
+(	O
+EDs	B-DISO
+)	O
+and	O
+haemodialysis	O
+units	O
+for	O
+the	O
+possibility	O
+of	O
+occurrence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+and	O
+assess	O
+the	O
+potential	O
+public	O
+health	O
+risks	O
+of	O
+emergency	O
+events	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+in	O
+the	O
+surrounding	O
+areas	O
+of	O
+Hangzhou	O
+during	O
+the	O
+11th	O
+G20	O
+summit	O
+,	O
+and	O
+to	O
+assess	O
+their	O
+impacts	O
+on	O
+the	O
+G20	O
+summit	O
+.	O
+
+Here	O
+we	O
+explored	O
+the	O
+functions	O
+of	O
+CVC1303	O
+on	O
+the	O
+humoral	O
+,	O
+cellular	B-COMP
+and	O
+mucosal	B-PROC
+immune	I-PROC
+response	I-PROC
+to	O
+PEDV	B-SPEC
+vaccine	O
+in	O
+mice	B-SPEC
+immunization	O
+.	O
+
+To	O
+determine	O
+how	O
+coinfection	B-DISO
+by	O
+these	O
+two	O
+unrelated	O
+respiratory	O
+viruses	B-SPEC
+affects	O
+pathogenesis	B-DISO
+,	O
+we	O
+established	O
+a	O
+mouse	B-SPEC
+model	O
+using	O
+a	O
+minor	O
+serogroup	O
+rhinovirus	B-SPEC
+(	O
+rhinovirus	B-SPEC
+strain	O
+1B	O
+[	O
+RV1B	O
+])	O
+and	O
+mouse	B-SPEC
+-	O
+adapted	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+A	O
+/	O
+Puerto	O
+Rico	O
+/	O
+8	O
+/	O
+1934	O
+[	O
+PR8	O
+]).	O
+
+TITLE	O
+:	O
+An	O
+alternative	O
+pathway	B-PROC
+of	O
+enteric	O
+PEDV	B-SPEC
+dissemination	O
+from	O
+nasal	B-ANAT
+cavity	I-ANAT
+to	O
+intestinal	B-ANAT
+mucosa	I-ANAT
+in	O
+swine	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+catastrophic	O
+impacts	O
+on	O
+the	O
+global	O
+pig	B-SPEC
+industry	O
+.	O
+
+Although	O
+the	O
+fecal	B-ANAT
+-	O
+oral	B-ANAT
+route	O
+is	O
+generally	O
+accepted	O
+,	O
+an	O
+increased	O
+number	O
+of	O
+reports	O
+indicate	O
+that	O
+airborne	O
+transmission	O
+may	O
+contribute	O
+to	O
+PEDV	B-SPEC
+outbreak	O
+.	O
+
+Firstly	O
+,	O
+PEDV	B-SPEC
+can	O
+develop	O
+a	O
+transient	O
+nasal	B-ANAT
+epithelium	I-ANAT
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+pARDS	O
+)	O
+is	O
+a	O
+rare	O
+but	O
+very	O
+severe	O
+condition	B-DISO
+.	O
+
+To	O
+perform	O
+a	O
+descriptive	O
+assessment	O
+of	O
+pARDS	O
+based	O
+on	O
+the	O
+modified	O
+Berlin	O
+Definition	O
+by	O
+using	O
+the	O
+SpO	B-PRGE
+The	O
+data	O
+of	O
+all	O
+children	O
+on	O
+mechanical	O
+ventilation	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+admitted	O
+between	O
+2005	O
+and	O
+2012	O
+were	O
+reviewed	O
+retrospectively	O
+for	O
+this	O
+study	O
+.	O
+
+Thus	O
+,	O
+we	O
+examined	O
+whether	O
+intranasal	O
+inoculation	O
+with	O
+MHV	B-SPEC
+at	O
+doses	O
+equivalent	O
+to	O
+those	O
+given	O
+intracranially	O
+could	O
+induce	O
+optic	O
+neuritis	O
+-	O
+inflammation	B-DISO
+,	O
+demyelination	B-DISO
+and	O
+loss	O
+of	O
+retinal	B-ANAT
+ganglion	B-DISO
+cells	B-COMP
+(	O
+RGCs	O
+)	O
+in	O
+the	O
+optic	B-ANAT
+nerve	I-ANAT
+with	O
+or	O
+without	O
+inducing	O
+spinal	B-ANAT
+cord	I-ANAT
+demyelination	B-DISO
+.	O
+
+The	O
+most	O
+frequently	O
+detected	O
+virus	B-SPEC
+was	O
+adenovirus	B-DISO
+,	O
+followed	O
+by	O
+influenza	B-PATH
+A	I-PATH
+and	O
+influenza	B-DISO
+B	O
+.	O
+Detection	O
+of	O
+more	O
+than	O
+one	O
+virus	B-SPEC
+was	O
+present	O
+in	O
+58	O
+.	O
+3	O
+%	O
+of	O
+the	O
+children	O
+with	O
+FS	O
+,	O
+and	O
+the	O
+most	O
+common	O
+co	O
+-	O
+existence	O
+was	O
+the	O
+presence	O
+of	O
+adenovirus	B-DISO
+and	O
+influenza	B-DISO
+B	O
+.	O
+In	O
+children	O
+younger	O
+than	O
+12	O
+months	O
+,	O
+Coronavirus	B-SPEC
+OC43	O
+was	O
+the	O
+most	O
+common	O
+,	O
+while	O
+influenza	B-PATH
+A	I-PATH
+was	O
+most	O
+frequently	O
+observed	O
+in	O
+children	O
+older	O
+than	O
+48	O
+months	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Human	B-SPEC
+bocavirus	I-SPEC
+was	O
+common	O
+in	O
+children	O
+who	O
+experienced	O
+complex	O
+FS	O
+,	O
+while	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+A	O
+was	O
+more	O
+common	O
+in	O
+children	O
+who	O
+experienced	O
+simple	O
+FS	O
+.	O
+
+Influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+identified	O
+in	O
+children	O
+who	O
+were	O
+experiencing	O
+their	O
+first	O
+incidence	O
+of	O
+FS	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Widespread	O
+use	O
+of	O
+the	O
+existing	O
+quadrivalent	O
+influenza	B-DISO
+vaccine	O
+might	O
+be	O
+useful	O
+for	O
+the	O
+prevention	O
+of	O
+FS	O
+related	O
+to	O
+the	O
+flu	B-DISO
+.	O
+
+Further	O
+vaccine	O
+candidates	O
+for	O
+potential	O
+respiratory	O
+pathogens	O
+,	O
+including	O
+RSV	B-PRGE
+,	O
+might	O
+be	O
+helpful	O
+for	O
+the	O
+prevention	O
+of	O
+FS	O
+.	O
+
+Its	O
+use	O
+in	O
+patients	O
+with	O
+obstructive	B-DISO
+pulmonary	I-DISO
+diseases	I-DISO
+has	O
+been	O
+rare	O
+since	O
+obstructions	B-DISO
+could	O
+not	O
+be	O
+monitored	O
+on	O
+a	O
+regional	O
+level	O
+at	O
+the	O
+bedside	O
+.	O
+
+In	O
+addition	O
+,	O
+exemplarily	O
+in	O
+patients	O
+with	O
+moderate	O
+-	O
+severe	O
+ARDS	B-DISO
+or	O
+COPD	B-DISO
+exacerbation	I-DISO
+,	O
+different	O
+PEEP	B-CHED
+levels	O
+were	O
+shown	O
+to	O
+have	O
+an	O
+influence	O
+on	O
+the	O
+distribution	O
+pattern	O
+of	O
+regional	O
+time	O
+constants	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+is	O
+a	O
+coronavirus	B-SPEC
+that	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+suckling	O
+piglets	O
+.	O
+
+Since	O
+the	O
+2017	O
+meeting	O
+,	O
+progress	O
+has	O
+been	O
+made	O
+on	O
+several	O
+key	O
+actions	O
+in	O
+animal	B-SPEC
+populations	O
+,	O
+at	O
+the	O
+animal	B-SPEC
+/	O
+human	B-SPEC
+interface	O
+and	O
+in	O
+human	B-SPEC
+populations	O
+.	O
+
+ABSTRACT	O
+:	O
+Low	O
+baseline	O
+plasma	O
+25	O
+-	O
+hydroxyvitamin	O
+D	O
+(	O
+25	O
+(	O
+OH	O
+)	O
+D	O
+)	O
+is	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+,	O
+but	O
+its	O
+association	O
+with	O
+long	O
+-	O
+term	O
+risk	O
+of	O
+sepsis	B-DISO
+remains	O
+unclear	O
+.	O
+
+Isolate	O
+LDL	B-CHED
+/	O
+150434	O
+-	O
+I	O
+was	O
+a	O
+re	O
+-	O
+isolation	O
+of	O
+H120	O
+vaccine	O
+strain	O
+that	O
+was	O
+introduced	O
+into	O
+the	O
+chicken	B-SPEC
+flock	O
+by	O
+vaccination	O
+,	O
+transmitted	B-DISO
+between	O
+chickens	B-SPEC
+,	O
+and	O
+later	O
+accumulated	O
+several	O
+genomic	O
+mutations	O
+.	O
+
+Isolate	O
+LDL	B-CHED
+/	O
+150434	O
+-	O
+II	O
+was	O
+a	O
+novel	O
+variant	O
+that	O
+originated	O
+from	O
+recombination	B-PROC
+events	O
+between	O
+H120	O
+and	O
+ck	O
+/	O
+CH	O
+/	O
+LDT3	O
+/	O
+03	O
+-	O
+like	O
+viruses	B-SPEC
+.	O
+
+The	O
+three	O
+IBV	B-SPEC
+isolates	O
+were	O
+avirulent	O
+when	O
+they	O
+infected	O
+SPF	B-PRGE
+chickens	I-PRGE
+.	O
+
+The	O
+results	O
+provide	O
+insights	O
+into	O
+the	O
+evolution	B-PROC
+of	O
+the	O
+viruses	B-SPEC
+and	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+of	O
+chickens	B-SPEC
+with	O
+different	O
+virus	B-SPEC
+serotypes	O
+.	O
+
+The	O
+safety	O
+of	O
+the	O
+PEP	B-CHED
+regimen	O
+was	O
+assessed	O
+.	O
+
+A	O
+total	O
+of	O
+90	O
+chicken	B-SPEC
+serum	B-COMP
+samples	O
+from	O
+a	O
+chicken	B-SPEC
+farm	O
+were	O
+tested	O
+by	O
+xMAP	O
+and	O
+ELISA	O
+assays	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+coincidence	O
+rates	O
+were	O
+84	O
+.	O
+44	O
+and	O
+100	O
+%	O
+for	O
+ILTV	B-SPEC
+and	O
+IBV	B-SPEC
+detection	O
+,	O
+respectively	O
+.	O
+
+Then	O
+,	O
+MERS	O
+-	O
+N	O
+was	O
+stably	O
+overexpressed	O
+in	O
+A549	O
+cells	B-COMP
+,	O
+and	O
+a	O
+PCR	O
+array	O
+containing	O
+84	O
+genes	O
+was	O
+used	O
+to	O
+screen	O
+for	O
+genes	O
+transcriptionally	O
+regulated	O
+by	O
+it	O
+.	O
+
+Lipopolysaccharide	B-CHED
+was	O
+intratracheally	O
+administered	O
+to	O
+rats	B-SPEC
+to	O
+establish	O
+experimental	O
+ARDS	B-DISO
+.	O
+
+Lung	B-ANAT
+histological	O
+damage	O
+was	O
+severe	O
+in	O
+the	O
+dorsal	O
+dependent	O
+area	O
+in	O
+both	O
+groups	O
+,	O
+but	O
+was	O
+attenuated	O
+by	O
+OLA	O
+.	O
+
+Further	O
+studies	O
+revealed	O
+that	O
+TA	O
+-	O
+dampened	O
+inflammatory	O
+responses	O
+by	O
+downregulating	O
+the	O
+LPS	B-DISO
+-	O
+induced	O
+toll	O
+-	O
+like	O
+receptor	B-PRGE
+4	I-PRGE
+(	O
+TLR4	B-PRGE
+)	O
+expression	B-PROC
+and	O
+inhibiting	O
+extracellular	B-PRGE
+-	I-PRGE
+signal	I-PRGE
+-	I-PRGE
+regulated	I-PRGE
+kinase	I-PRGE
+(	I-PRGE
+ERK	B-FUNC
+)	I-PRGE
+1	I-PRGE
+/	I-PRGE
+2	I-PRGE
+and	O
+p38	B-FUNC
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+(	O
+MAPK	B-FUNC
+)	O
+activation	O
+.	O
+
+TITLE	O
+:	O
+Beyond	O
+Low	O
+Tidal	O
+Volume	O
+Ventilation	O
+:	O
+Treatment	O
+Adjuncts	O
+for	O
+Severe	O
+Respiratory	B-DISO
+Failure	I-DISO
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+may	O
+be	O
+life	O
+-	O
+saving	O
+in	O
+selected	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+but	O
+should	O
+be	O
+used	O
+only	O
+when	O
+other	O
+alternatives	O
+have	O
+been	O
+applied	O
+.	O
+
+In	O
+addition	O
+,	O
+fecal	B-ANAT
+samples	O
+and	O
+pen	O
+bedding	O
+environmental	B-SPEC
+samples	I-SPEC
+were	O
+processed	O
+and	O
+analyzed	O
+for	O
+diagnosis	O
+of	O
+intestinal	O
+parasite	O
+eggs	O
+under	O
+a	O
+compound	O
+light	O
+microscope	O
+.	O
+
+This	O
+study	O
+produced	O
+evidence	O
+that	O
+exposure	O
+to	O
+IBDV	B-SPEC
+,	O
+IBV	B-SPEC
+,	O
+and	O
+intestinal	B-DISO
+parasites	I-DISO
+in	O
+broilers	O
+on	O
+Santa	O
+Cruz	O
+Island	O
+and	O
+San	O
+Cristobal	O
+Island	O
+is	O
+important	O
+.	O
+
+The	O
+clinical	O
+diagnosis	O
+of	O
+TGEV	B-SPEC
+infections	B-DISO
+in	O
+endemic	O
+regions	O
+is	O
+challenging	O
+due	O
+to	O
+the	O
+epidemiological	O
+distribution	O
+and	O
+coinfection	B-DISO
+with	O
+other	O
+enteric	O
+pathogens	O
+that	O
+mask	O
+the	O
+clinical	O
+presentation	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+previously	O
+demonstrated	O
+that	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+could	O
+induce	O
+apoptosis	B-PATH
+through	O
+caspase	B-PRGE
+signaling	B-PROC
+.	O
+
+However	O
+,	O
+apoptosis	B-PATH
+was	O
+not	O
+completely	O
+prevented	O
+by	O
+caspases	O
+inhibitors	B-CHED
+,	O
+suggesting	O
+that	O
+there	O
+may	O
+be	O
+a	O
+caspase	B-PRGE
+-	O
+independent	O
+pathway	B-PROC
+involved	O
+in	O
+TGEV	B-SPEC
+-	O
+induced	O
+cell	B-COMP
+apoptosis	B-PATH
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+results	O
+suggest	O
+that	O
+the	O
+p53	B-PRGE
+-	O
+and	O
+ROS	B-CHED
+-	O
+mediated	O
+AIF	B-PROC
+pathway	I-PROC
+and	O
+caspase	B-PRGE
+-	O
+dependent	O
+pathway	B-PROC
+were	O
+involved	O
+in	O
+TGEV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+.	O
+
+TITLE	O
+:	O
+Viral	B-DISO
+Respiratory	I-DISO
+Tract	I-DISO
+Infection	I-DISO
+
+Viral	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+VRTI	O
+)	O
+has	O
+been	O
+previously	O
+associated	O
+with	O
+CLAD	O
+development	B-PROC
+.	O
+
+Data	O
+regarding	O
+clinical	O
+characteristics	O
+and	O
+infectious	B-DISO
+events	O
+were	O
+recorded	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+Newcastle	B-DISO
+Disease	I-DISO
+,	O
+H9N2	O
+Avian	B-DISO
+Influenza	I-DISO
+,	O
+and	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Viruses	B-SPEC
+in	O
+Respiratory	B-DISO
+Diseases	I-DISO
+in	O
+Backyard	O
+Chickens	B-SPEC
+in	O
+Ahvaz	O
+,	O
+Iran	O
+,	O
+in	O
+2014	O
+-	O
+2015	O
+.	O
+
+ABSTRACT	O
+:	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AIV	O
+),	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+are	O
+the	O
+most	O
+prevalent	O
+viral	O
+pathogens	O
+in	O
+the	O
+Iranian	O
+poultry	O
+industry	O
+.	O
+
+In	O
+the	O
+RT	O
+-	O
+PCR	O
+,	O
+95	O
+%	O
+of	O
+the	O
+birds	B-SPEC
+were	O
+positive	O
+for	O
+one	O
+of	O
+the	O
+three	O
+viruses	B-SPEC
+.	O
+
+The	O
+results	O
+demonstrated	O
+that	O
+the	O
+Iranian	O
+backyard	O
+chickens	B-SPEC
+were	O
+infected	O
+with	O
+NDV	B-SPEC
+,	O
+AIV	O
+,	O
+and	O
+IBV	B-SPEC
+.	O
+
+The	O
+cat	B-SPEC
+received	O
+a	O
+blood	B-ANAT
+transfusion	O
+and	O
+supportive	O
+therapy	O
+,	O
+but	O
+the	O
+owner	O
+declined	O
+to	O
+continue	O
+the	O
+treatments	O
+owing	O
+to	O
+poor	O
+response	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+report	O
+describes	O
+the	O
+first	O
+disease	O
+outbreak	O
+caused	O
+by	O
+chimeric	O
+swine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+SeCoV	O
+)	O
+on	O
+two	O
+pig	B-SPEC
+farms	O
+in	O
+Slovakia	O
+in	O
+early	O
+2015	O
+.	O
+
+Subsequently	O
+,	O
+loss	B-DISO
+of	I-DISO
+appetite	I-DISO
+and	O
+diarrhoea	B-DISO
+were	O
+observed	O
+in	O
+both	O
+boars	B-SPEC
+during	O
+the	O
+first	O
+three	O
+days	O
+in	O
+the	O
+isolation	O
+unit	O
+.	O
+
+The	O
+infection	B-DISO
+gradually	O
+spread	O
+to	O
+the	O
+farrowing	B-PROC
+area	O
+and	O
+throughout	O
+the	O
+farm	O
+in	O
+two	O
+weeks	O
+and	O
+later	O
+to	O
+another	O
+nearby	O
+farm	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+an	O
+available	O
+vaccine	O
+,	O
+the	O
+pregnant	O
+sows	O
+were	O
+dosed	O
+by	O
+mouth	B-ANAT
+with	O
+a	O
+10	O
+%	O
+suspension	O
+prepared	O
+from	O
+the	O
+intestine	B-ANAT
+and	O
+faeces	B-ANAT
+of	O
+infected	O
+piglets	O
+in	O
+warm	O
+water	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+enteric	O
+coronaviruses	O
+have	O
+three	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+in	O
+region	O
+3	O
+(	O
+3a	O
+,	O
+3b	O
+,	O
+and	O
+3c	O
+).	O
+
+The	O
+expression	B-PROC
+of	O
+3c	O
+-	O
+eGFP	O
+is	O
+clearly	O
+cell	B-COMP
+type	I-COMP
+dependent	O
+,	O
+it	O
+is	O
+more	O
+stable	O
+in	O
+MARC	O
+145	O
+cells	O
+than	O
+in	O
+Fcwf	O
+-	O
+4	O
+or	O
+CrFK	O
+cells	B-COMP
+,	O
+which	O
+might	O
+reflect	O
+in	O
+vivo	O
+stability	O
+differences	O
+of	O
+3c	O
+in	O
+natural	O
+target	B-ANAT
+cells	I-ANAT
+(	O
+enterocytes	B-ANAT
+vs	O
+.	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+).	O
+
+In	O
+contrast	O
+,	O
+induction	O
+of	O
+IFNβ	O
+by	O
+type	O
+II	O
+FCoV	O
+infection	B-DISO
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+by	O
+type	O
+I	O
+FIPV	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+evolution	B-PROC
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+and	O
+porcine	B-SPEC
+deltacoronavirus	O
+strains	O
+in	O
+Central	O
+China	O
+.	O
+
+However	O
+,	O
+whether	O
+these	O
+changes	O
+affect	O
+the	O
+pathogenicity	O
+and	O
+antigenicity	O
+of	O
+wild	O
+PEDV	B-SPEC
+is	O
+unknown	O
+and	O
+is	O
+worth	O
+for	O
+further	O
+investigation	O
+.	O
+
+It	O
+is	O
+usually	O
+diagnosed	O
+in	O
+chronic	B-DISO
+liver	I-DISO
+disease	I-DISO
+patients	O
+following	O
+pre	O
+-	O
+transplant	B-ANAT
+evaluation	O
+or	O
+mild	O
+dyspnea	B-DISO
+investigation	O
+.	O
+
+Specific	O
+primers	O
+were	O
+designed	O
+to	O
+target	O
+the	O
+highly	O
+-	O
+conserved	O
+region	O
+of	O
+L	B-PRGE
+gene	I-PRGE
+of	O
+SFTSV	O
+.	O
+
+TITLE	O
+:	O
+Sequencing	O
+and	O
+In	O
+Silico	O
+Multi	O
+-	O
+aspect	O
+Analysis	O
+of	O
+S1	O
+Glycoprotein	B-CHED
+in	O
+793	O
+/	O
+B	O
+Serotype	O
+of	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+Isolated	O
+From	O
+Iran	O
+in	O
+2003	O
+and	O
+2011	O
+.	O
+
+The	O
+cut	O
+-	O
+off	O
+titer	O
+was	O
+set	O
+at	O
+titer	O
+of	O
+1	O
+:	O
+2	O
+dilution	O
+and	O
+farms	O
+with	O
+at	O
+least	O
+one	O
+positive	O
+sample	O
+in	O
+duplicate	O
+were	O
+classified	O
+as	O
+PED	B-PRGE
+-	O
+positive	O
+farms	O
+.	O
+
+The	O
+proportion	O
+of	O
+seropositive	O
+animals	B-SPEC
+from	O
+case	O
+farms	O
+was	O
+63	O
+.	O
+7	O
+%,	O
+significantly	O
+different	O
+from	O
+that	O
+of	O
+non	O
+-	O
+case	O
+farms	O
+(	O
+4	O
+.	O
+3	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+New	O
+Vaccine	O
+Technologies	O
+to	O
+Combat	B-CHED
+Outbreak	O
+Situations	O
+.	O
+
+However	O
+,	O
+radical	B-CHED
+changes	O
+in	O
+the	O
+density	O
+,	O
+age	O
+distribution	O
+and	O
+traveling	O
+habits	O
+of	O
+the	O
+population	O
+worldwide	O
+as	O
+well	O
+as	O
+the	O
+changing	O
+climate	O
+favor	O
+the	O
+emergence	O
+of	O
+old	O
+and	O
+new	O
+pathogens	O
+that	O
+bear	B-SPEC
+the	O
+risk	O
+of	O
+becoming	O
+pandemic	O
+threats	O
+.	O
+
+What	O
+is	O
+more	O
+,	O
+the	O
+emergence	O
+of	O
+antibiotic	O
+resistant	O
+bacteria	B-SPEC
+calls	O
+for	O
+new	O
+approaches	O
+to	O
+prevent	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+influence	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+on	O
+pig	B-SPEC
+small	B-ANAT
+intestine	I-ANAT
+mucosal	B-ANAT
+epithelial	B-ANAT
+cell	B-PROC
+function	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+is	O
+a	O
+highly	O
+contagious	O
+,	O
+acute	O
+enteric	O
+tract	O
+infectious	B-DISO
+disease	I-DISO
+of	O
+pigs	B-SPEC
+(	O
+Sus	B-SPEC
+domesticus	I-SPEC
+)	O
+caused	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+PED	O
+is	O
+characterized	O
+by	O
+watery	B-DISO
+diarrhea	I-DISO
+,	O
+dehydration	B-DISO
+,	O
+weight	O
+loss	O
+,	O
+vomiting	B-DISO
+and	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Chlordecone	B-CHED
+is	O
+an	O
+organochlorine	O
+used	O
+in	O
+the	O
+1970	O
+'	O
+s	O
+as	O
+a	O
+pesticide	B-CHED
+in	O
+banana	B-SPEC
+plantations	O
+.	O
+
+Chlordecone	B-CHED
+targets	O
+,	O
+and	O
+mainly	O
+accumulates	O
+in	O
+,	O
+the	O
+liver	B-ANAT
+,	O
+leading	O
+to	O
+hepatomegaly	B-DISO
+and	O
+neurological	O
+signs	O
+in	O
+mammals	B-SPEC
+.	O
+
+To	O
+study	O
+the	O
+attenuation	O
+determinants	O
+of	O
+PEDVPT	O
+-	O
+P96	O
+and	O
+establish	O
+a	O
+PEDVPT	O
+-	O
+P96	O
+-	O
+based	O
+recombinant	O
+vector	O
+as	O
+a	O
+vaccine	O
+platform	O
+for	O
+further	O
+antigenicity	O
+modification	O
+,	O
+iPEDVPT	B-PRGE
+-	I-PRGE
+P96	I-PRGE
+,	O
+a	O
+full	O
+-	O
+length	O
+cDNA	O
+clone	O
+of	O
+PEDVPT	O
+-	O
+P96	O
+,	O
+was	O
+established	O
+.	O
+
+Viral	B-DISO
+diseases	I-DISO
+are	O
+highly	O
+infectious	B-DISO
+and	O
+capable	O
+of	O
+causing	O
+pandemics	O
+as	O
+evidenced	O
+by	O
+outbreaks	O
+of	O
+diseases	O
+like	O
+Ebola	O
+,	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+,	I-DISO
+West	I-DISO
+Nile	O
+,	O
+SARS	B-DISO
+-	O
+Corona	B-CHED
+,	O
+Nipah	O
+,	O
+Hendra	O
+,	O
+Avian	B-DISO
+influenza	I-DISO
+and	O
+Swine	B-DISO
+influenza	I-DISO
+.	O
+
+Diseases	O
+like	O
+Eastern	B-DISO
+equine	I-DISO
+encephalitis	I-DISO
+(	O
+EEE	B-DISO
+),	O
+Western	B-DISO
+equine	I-DISO
+encephalitis	I-DISO
+(	O
+WEE	B-DISO
+),	O
+and	O
+Venezuelan	O
+-	O
+equine	B-DISO
+encephalitis	I-DISO
+(	O
+VEE	O
+)	O
+are	O
+highly	O
+infectious	B-DISO
+and	O
+can	O
+be	O
+disseminated	O
+as	O
+aerosols	O
+.	O
+
+TITLE	O
+:	O
+Serologic	O
+Survey	O
+of	O
+Selected	O
+Viral	O
+Pathogens	O
+in	O
+Free	O
+-	O
+Ranging	O
+Eurasian	O
+Brown	B-SPEC
+Bears	I-SPEC
+(	O
+Ursus	B-SPEC
+arctos	I-SPEC
+arctos	I-SPEC
+)	O
+from	O
+Slovakia	O
+.	O
+
+Evidence	O
+of	O
+exposure	O
+of	O
+free	O
+-	O
+ranging	O
+European	B-SPEC
+brown	I-SPEC
+bears	I-SPEC
+to	O
+CCV	B-DISO
+and	O
+ADV	O
+has	O
+not	O
+been	O
+reported	O
+.	O
+
+One	O
+was	O
+a	O
+69	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+who	O
+had	O
+been	O
+treated	O
+with	O
+combination	O
+fluconazole	B-CHED
+and	O
+liposomal	O
+amphotericin	O
+for	O
+over	O
+6	O
+weeks	O
+,	O
+with	O
+persistent	B-DISO
+fever	I-DISO
+and	O
+pneumonia	B-DISO
+.	O
+
+Rapid	O
+improvement	O
+was	O
+noted	O
+in	O
+both	O
+cases	O
+and	O
+raises	O
+the	O
+possibility	O
+that	O
+the	O
+addition	O
+of	O
+systemic	O
+corticosteroids	B-CHED
+may	O
+hasten	O
+recovery	O
+in	O
+patients	O
+with	O
+severe	O
+coccidioidomycosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Assessment	O
+of	O
+fever	B-PROC
+in	O
+the	O
+returning	O
+traveller	O
+.	O
+
+An	O
+understanding	O
+of	O
+the	O
+incubation	O
+periods	B-PROC
+of	O
+common	O
+imported	O
+infections	B-DISO
+and	O
+a	O
+syndromic	O
+approach	O
+to	O
+patients	O
+'	O
+symptoms	O
+is	O
+helpful	O
+in	O
+order	B-SPEC
+to	O
+narrow	O
+down	O
+the	O
+likely	O
+diagnosis	O
+.	O
+
+Our	O
+study	O
+suggest	O
+that	O
+MERS	O
+patients	O
+with	O
+radiographic	O
+score	O
+>	O
+10	O
+on	O
+day	O
+10	O
+from	O
+viral	O
+exposure	O
+require	O
+aggressive	B-DISO
+therapy	O
+with	O
+careful	O
+surveillance	O
+and	O
+follow	O
+-	O
+up	O
+evaluation	O
+.	O
+
+Best	O
+-	O
+fitting	B-DISO
+ARIMA	O
+model	O
+inferred	O
+statistically	O
+significant	O
+biannual	O
+seasonality	O
+in	O
+Riyadh	O
+region	O
+,	O
+a	O
+region	O
+characterised	O
+by	O
+heavy	O
+seasonal	O
+camel	B-SPEC
+-	O
+related	O
+activities	O
+.	O
+
+Our	O
+study	O
+suggested	O
+new	O
+insights	O
+into	O
+the	O
+epidemiology	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+including	O
+inferences	O
+about	O
+epidemic	O
+progression	O
+and	O
+evidence	O
+for	O
+seasonality	O
+.	O
+
+ABSTRACT	O
+:	O
+Excessive	O
+extravascular	O
+lung	O
+water	B-CHED
+(	O
+EVLW	O
+)	O
+is	O
+associated	O
+with	O
+increased	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+EVLW	O
+index	O
+was	O
+measured	O
+by	O
+the	O
+TPTD	O
+method	O
+,	O
+and	O
+an	O
+index	O
+of	O
+≥	O
+10	O
+mL	O
+/	O
+kg	O
+was	O
+considered	O
+diagnostic	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+Consideration	O
+of	O
+limitations	O
+of	O
+the	O
+latter	O
+protocols	O
+may	O
+prevent	O
+clinicians	O
+from	O
+reaching	B-PROC
+premature	O
+conclusions	O
+regarding	O
+the	O
+prediction	O
+of	O
+EVLW	O
+.	O
+
+Intriguingly	O
+,	O
+these	O
+viruses	B-SPEC
+also	O
+all	O
+originate	O
+from	O
+bat	B-ENZY
+reservoirs	O
+.	O
+
+Not	O
+only	O
+are	O
+they	O
+the	O
+only	O
+mammals	B-SPEC
+capable	O
+of	O
+powered	O
+flight	O
+,	O
+they	O
+have	O
+extraordinarily	O
+long	O
+life	O
+spans	O
+,	O
+with	O
+little	O
+detectable	O
+increases	O
+in	O
+mortality	O
+or	O
+senescence	O
+until	O
+high	O
+ages	O
+.	O
+
+Do	O
+our	O
+life	O
+history	O
+traits	O
+make	O
+us	O
+susceptible	O
+to	O
+generating	O
+damaging	O
+immune	B-PROC
+responses	I-PROC
+to	O
+RNA	O
+viruses	B-SPEC
+or	O
+does	O
+the	O
+physiology	O
+of	O
+bats	B-SPEC
+make	O
+them	O
+particularly	O
+tolerant	O
+or	O
+resistant	O
+?	O
+
+In	O
+early	O
+2016	O
+,	O
+sera	B-COMP
+and	O
+standardized	O
+interviews	O
+were	O
+obtained	O
+from	O
+MERS	O
+-	O
+CoV	O
+cases	O
+and	O
+their	O
+contacts	O
+.	O
+
+Among	O
+16	O
+cases	O
+,	O
+11	O
+(	O
+69	O
+%)	O
+had	O
+health	O
+care	O
+exposure	O
+and	O
+5	O
+(	O
+31	O
+%)	O
+were	O
+relatives	O
+of	O
+a	O
+known	O
+case	O
+;	O
+13	O
+(	O
+81	O
+%)	O
+were	O
+symptomatic	O
+,	O
+and	O
+7	O
+(	O
+44	O
+%)	O
+died	B-PROC
+.	O
+
+We	O
+describe	O
+isolation	O
+of	O
+infectious	B-DISO
+MERS	O
+-	O
+CoV	O
+from	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+of	O
+a	O
+mildly	O
+ill	B-DISO
+27	O
+-	O
+year	O
+-	O
+old	O
+female	O
+in	O
+Saudi	O
+Arabia	O
+15	O
+days	O
+after	O
+illness	O
+onset	O
+.	O
+
+TITLE	O
+:	O
+Interplay	O
+between	O
+coronavirus	B-SPEC
+,	O
+a	O
+cytoplasmic	B-COMP
+RNA	O
+virus	B-SPEC
+,	O
+and	O
+nonsense	B-PROC
+-	I-PROC
+mediated	I-PROC
+mRNA	I-PROC
+decay	B-DISO
+pathway	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+),	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+,	O
+are	O
+enveloped	O
+RNA	O
+viruses	B-SPEC
+that	O
+carry	O
+a	O
+large	O
+positive	O
+-	O
+sense	B-PROC
+single	O
+-	O
+stranded	O
+RNA	O
+genome	O
+and	O
+cause	O
+a	O
+variety	O
+of	O
+diseases	O
+in	O
+humans	B-SPEC
+and	O
+domestic	O
+animals	B-SPEC
+.	O
+
+A	O
+key	O
+contribution	O
+to	O
+the	O
+high	O
+lethality	O
+observed	O
+during	O
+EBOV	O
+outbreaks	O
+comes	O
+from	O
+viral	O
+evasion	O
+of	O
+the	O
+host	B-COMP
+antiviral	B-CHED
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+in	O
+which	O
+viral	B-PRGE
+protein	I-PRGE
+VP35	I-PRGE
+plays	O
+a	O
+crucial	O
+role	O
+,	O
+blocking	B-DISO
+interferon	B-PROC
+type	I-PROC
+I	I-PROC
+production	I-PROC
+,	O
+first	O
+by	O
+masking	O
+the	O
+viral	O
+double	O
+-	O
+stranded	O
+RNA	O
+(	O
+dsRNA	B-CHED
+)	O
+and	O
+preventing	O
+its	O
+detection	O
+by	O
+the	O
+pattern	O
+recognition	O
+receptor	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+.	O
+Aiming	O
+to	O
+identify	O
+inhibitors	B-CHED
+of	O
+the	O
+interaction	O
+of	O
+VP35	O
+with	O
+the	O
+viral	O
+dsRNA	B-CHED
+,	O
+counteracting	O
+the	O
+VP35	O
+viral	O
+innate	O
+immune	B-PROC
+evasion	I-PROC
+,	O
+we	O
+established	O
+a	O
+new	O
+methodology	O
+for	O
+high	O
+-	O
+yield	O
+recombinant	O
+VP35	O
+(	O
+rVP35	O
+)	O
+expression	B-PROC
+and	O
+purification	O
+and	O
+a	O
+novel	O
+and	O
+robust	O
+fluorescence	O
+-	O
+based	O
+rVP35	O
+-	O
+RNA	O
+interaction	O
+assay	O
+(	O
+Z	O
+'	O
+factor	O
+of	O
+0	O
+.	O
+69	O
+).	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Megakaryoblastic	I-DISO
+Leukemia	I-DISO
+With	O
+Diffuse	O
+Periosteal	O
+Reaction	O
+of	O
+Bilateral	O
+Lower	B-ANAT
+Extremities	I-ANAT
+.	O
+
+RESULTS	O
+:	O
+One	O
+hundred	O
+and	O
+eighty	O
+-	O
+one	O
+patients	O
+were	O
+diagnosed	O
+with	O
+AKI	B-PRGE
+caused	O
+by	O
+venomous	O
+creatures	O
+.	O
+
+Snakebite	O
+(	O
+77	O
+.	O
+9	O
+%)	O
+and	O
+wasp	O
+stings	O
+(	O
+19	O
+.	O
+9	O
+%)	O
+were	O
+the	O
+leading	O
+causes	O
+of	O
+AKI	B-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+Modified	O
+David	O
+-	O
+Komeda	O
+Repair	B-PROC
+for	O
+Ventricular	B-DISO
+Septal	I-DISO
+Perforation	I-DISO
+Complicated	O
+with	O
+Severe	O
+Postoperative	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+;	O
+Report	O
+of	O
+a	O
+Case	O
+].	O
+
+Cells	B-COMP
+from	O
+cotton	B-SPEC
+rat	B-SPEC
+,	O
+goat	B-SPEC
+,	O
+and	O
+sheep	B-SPEC
+provided	O
+control	O
+scenarios	O
+that	O
+represent	O
+host	B-COMP
+systems	O
+in	O
+which	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+neither	O
+endemic	O
+nor	O
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+Countrywide	O
+Survey	O
+for	O
+MERS	O
+-	O
+Coronavirus	B-SPEC
+Antibodies	B-COMP
+in	O
+Dromedaries	B-SPEC
+and	O
+Humans	B-SPEC
+in	O
+Pakistan	O
+.	O
+
+An	O
+in	O
+-	O
+house	O
+ELISA	O
+was	O
+developed	O
+to	O
+detect	O
+IgG	B-PRGE
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+A	O
+total	O
+of	O
+794	O
+camels	B-SPEC
+were	O
+found	O
+seropositive	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+Prevalence	O
+increased	O
+with	O
+the	O
+age	O
+and	O
+the	O
+highest	O
+seroprevalence	O
+was	O
+recorded	O
+in	O
+camels	B-SPEC
+aged	O
+>	O
+10	O
+years	O
+(	O
+81	O
+.	O
+37	O
+%)	O
+followed	O
+by	O
+those	O
+aged	O
+3	O
+.	O
+1	O
+-	O
+10	O
+years	O
+(	O
+78	O
+.	O
+65	O
+%)	O
+and	O
+≤	O
+3	O
+years	O
+(	O
+58	O
+.	O
+19	O
+%).	O
+
+Sensitivity	O
+analyses	O
+show	O
+that	O
+the	O
+incremental	O
+cost	O
+-	O
+effectiveness	O
+ratio	O
+is	O
+sensitive	O
+to	O
+the	O
+efficacy	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+therapy	O
+and	O
+costs	O
+.	O
+
+Kyoto	O
+Encyclopedia	O
+of	O
+Genes	O
+and	O
+Genomes	O
+(	O
+KEGG	O
+)	O
+analysis	O
+showed	O
+differentially	O
+expressed	B-PROC
+mRNAs	O
+were	O
+linked	O
+to	O
+inflammation	B-DISO
+-	O
+related	O
+pathways	B-PROC
+,	O
+including	O
+NF	O
+-	O
+κB	O
+,	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+,	O
+NOD	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+,	O
+Jak	B-PROC
+-	O
+STAT	B-PRGE
+,	O
+TNF	B-PRGE
+,	O
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+pathways	B-PROC
+.	O
+
+The	O
+interactions	O
+among	O
+mRNA	B-CHED
+,	O
+miRNA	O
+,	O
+and	O
+circRNA	O
+were	O
+analyzed	O
+.	O
+
+In	O
+contrast	O
+,	O
+inhibition	B-PROC
+of	O
+miR	B-PRGE
+-	I-PRGE
+22	I-PRGE
+had	O
+the	O
+opposite	O
+effects	O
+.	O
+
+Moreover	O
+,	O
+silencing	O
+of	O
+ssc_circ_009380	O
+inhibited	O
+accumulation	O
+of	O
+p65	B-PRGE
+in	O
+nucleus	B-COMP
+and	O
+phosphorylation	B-PROC
+of	O
+IκB	O
+-	O
+α	O
+.	O
+
+Venovenous	O
+ECMO	O
+(	O
+vv	O
+-	O
+ECMO	O
+)	O
+was	O
+initiated	O
+in	O
+the	O
+Emergency	B-DISO
+Department	O
+and	O
+he	O
+was	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+As	O
+subepithelial	O
+myofibroblasts	B-ANAT
+secrete	B-PROC
+extracellular	B-COMP
+matrix	I-COMP
+and	O
+growth	B-PROC
+factors	O
+contributing	O
+to	O
+the	O
+attachment	O
+,	O
+proliferation	B-DISO
+and	O
+differentiation	B-PROC
+of	O
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+co	O
+-	O
+cultures	O
+of	O
+primary	O
+porcine	B-SPEC
+enterocytes	B-ANAT
+(	O
+ileocytes	O
+and	O
+colonocytes	O
+)	O
+with	O
+myofibroblasts	B-ANAT
+were	O
+developed	O
+and	O
+evaluated	O
+for	O
+their	O
+susceptibility	O
+to	O
+enteric	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Resistance	B-PROC
+to	O
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+amino	O
+peptidase	O
+N	O
+-	O
+deficient	O
+pigs	B-SPEC
+.	O
+
+The	O
+biological	O
+relevance	O
+of	O
+amino	B-PRGE
+peptidase	I-PRGE
+N	I-PRGE
+(	O
+ANPEP	B-PRGE
+)	O
+as	O
+a	O
+putative	O
+receptor	O
+for	O
+TGEV	B-SPEC
+and	O
+PEDV	B-SPEC
+in	O
+pigs	B-SPEC
+was	O
+evaluated	O
+by	O
+using	O
+CRISPR	O
+/	O
+Cas9	O
+to	O
+edit	O
+exon	O
+2	O
+of	O
+ANPEP	O
+resulting	O
+in	O
+a	O
+premature	O
+stop	O
+codon	O
+.	O
+
+Fecal	B-ANAT
+swabs	O
+were	O
+collected	O
+daily	O
+from	O
+each	O
+animal	B-SPEC
+beginning	O
+1	O
+day	O
+prior	O
+to	O
+challenge	O
+with	O
+PEDV	B-SPEC
+until	O
+the	O
+termination	O
+of	O
+the	O
+study	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+initiation	O
+of	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+a	O
+mechanically	O
+ventilated	O
+patient	O
+with	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+ABSTRACT	O
+:	O
+Because	O
+the	O
+Berlin	O
+definition	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+has	O
+only	O
+moderate	O
+reliability	O
+,	O
+physicians	O
+disagree	O
+about	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+in	O
+some	O
+patients	O
+.	O
+
+To	O
+characterize	O
+patients	O
+with	O
+diagnostic	O
+disagreement	O
+about	O
+ARDS	B-DISO
+among	O
+critical	O
+-	O
+care	O
+-	O
+trained	O
+physicians	O
+and	O
+compare	O
+them	O
+with	O
+patients	O
+with	O
+a	O
+consensus	O
+that	O
+ARDS	B-DISO
+developed	O
+.	O
+
+Individual	O
+TGEV	O
+protein	B-CHED
+screening	O
+results	O
+demonstrated	O
+that	O
+Nsp2	B-PRGE
+exhibited	O
+a	O
+high	O
+potential	O
+for	O
+activating	O
+NF	O
+-	O
+κB	O
+and	O
+enhancing	O
+the	O
+expression	B-PROC
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+.	O
+
+Oropharyngeal	B-ANAT
+(	O
+OP	O
+)	O
+swabs	O
+were	O
+taken	O
+from	O
+eight	O
+birds	B-SPEC
+per	O
+flock	O
+and	O
+accompanied	O
+with	O
+flock	O
+health	O
+information	O
+.	O
+
+Multi	O
+-	O
+locus	O
+sequence	O
+typing	O
+(	O
+MLST	O
+)	O
+analysis	O
+identified	O
+the	O
+majority	O
+of	O
+positive	O
+Ms	O
+as	O
+ST21	B-ANAT
+,	O
+along	O
+with	O
+ST2	B-PRGE
+(	O
+MS	B-PRGE
+-	I-PRGE
+H	I-PRGE
+-	I-PRGE
+like	I-PRGE
+),	O
+ST6	B-PRGE
+and	O
+ST43	B-ANAT
+.	O
+
+IBV	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+sequencing	O
+identified	O
+strains	O
+as	O
+793B	O
+(	O
+66	O
+.	O
+7	O
+%),	O
+Arkansas	O
+(	O
+23	O
+.	O
+8	O
+%)	O
+and	O
+Massachusetts	O
+(	O
+9	O
+.	O
+5	O
+%).	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+encephalopathy	I-DISO
+with	O
+biphasic	O
+seizures	B-DISO
+and	O
+late	O
+reduced	O
+diffusion	O
+accompanied	O
+by	O
+Takotsubo	B-DISO
+cardiomyopathy	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+encephalopathy	I-DISO
+with	O
+biphasic	O
+seizures	B-DISO
+and	O
+late	O
+reduced	O
+diffusion	O
+(	O
+AESD	O
+)	O
+is	O
+characterized	O
+by	O
+biphasic	O
+seizures	B-DISO
+and	O
+impaired	B-DISO
+consciousness	I-DISO
+.	O
+
+On	O
+the	O
+next	O
+day	O
+,	O
+her	O
+cardiac	B-PROC
+function	I-PROC
+deteriorated	O
+,	O
+and	O
+echocardiography	O
+revealed	O
+systolic	O
+apical	O
+ballooning	O
+of	O
+the	O
+left	B-ANAT
+ventricle	I-ANAT
+accompanied	O
+by	O
+hyperkinesis	O
+of	O
+the	O
+basal	O
+wall	O
+,	O
+which	O
+are	O
+typical	O
+in	O
+patients	O
+with	O
+TTC	O
+.	O
+
+However	O
+,	O
+a	O
+role	O
+for	O
+virus	B-SPEC
+-	O
+specific	O
+memory	B-PROC
+B	B-ANAT
+cells	I-ANAT
+(	O
+Bmem	O
+)	O
+within	O
+the	O
+CNS	B-CHED
+is	O
+poorly	O
+explored	O
+due	O
+to	O
+lack	O
+of	O
+robust	O
+phenotypic	O
+or	O
+functional	O
+identification	O
+in	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+-	O
+mediated	O
+reduction	O
+of	O
+lung	B-ANAT
+epithelial	O
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+leads	O
+to	O
+dysregulated	O
+pulmonary	B-ANAT
+fluid	O
+homeostasis	B-PROC
+.	O
+
+ENaC	B-PRGE
+,	O
+CFTR	B-PRGE
+,	O
+and	O
+Na	B-PRGE
+,	I-PRGE
+K	I-PRGE
+-	I-PRGE
+ATPase	I-PRGE
+activities	O
+and	O
+protein	B-CHED
+levels	O
+were	O
+also	O
+reduced	O
+in	O
+virally	O
+infected	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Pharmacologic	O
+correction	O
+of	O
+CFTR	B-PRGE
+function	O
+ameliorated	O
+IAV	O
+-	O
+induced	O
+physiologic	O
+changes	O
+.	O
+
+TITLE	O
+:	O
+Examination	O
+of	O
+Hospital	O
+Workers	O
+'	O
+Emotional	O
+Responses	O
+to	O
+an	O
+Infectious	B-DISO
+Disease	I-DISO
+Outbreak	O
+:	O
+Lessons	O
+From	O
+the	O
+2015	O
+MERS	O
+Co	O
+-	O
+V	O
+Outbreak	O
+in	O
+South	O
+Korea	O
+.	O
+
+Therefore	O
+,	O
+hospital	O
+crisis	O
+management	O
+should	O
+implement	O
+efforts	O
+to	O
+improve	O
+hospital	O
+workers	O
+'	O
+preparedness	O
+in	O
+responding	O
+to	O
+public	O
+health	O
+emergencies	B-DISO
+caused	O
+by	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+For	O
+fast	B-FUNC
+and	O
+reliable	O
+diagnosis	O
+of	O
+the	O
+causative	O
+agent	O
+associated	O
+with	O
+viral	B-DISO
+diarrhea	I-DISO
+in	O
+pigs	B-SPEC
+,	O
+an	O
+inexpensive	O
+and	O
+easy	O
+to	O
+perform	O
+gel	O
+-	O
+based	O
+multiplex	O
+PCR	O
+assay	O
+was	O
+developed	O
+in	O
+this	O
+study	O
+to	O
+detect	O
+and	O
+differentiate	O
+the	O
+different	O
+viruses	B-SPEC
+by	O
+amplicon	O
+size	O
+.	O
+
+RESULTS	O
+:	O
+7	O
+out	O
+of	O
+13	O
+patients	O
+showed	O
+negative	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+transpulmonary	O
+pressures	O
+(	O
+Ptp	B-DISO
+-)	O
+with	O
+both	O
+strategies	O
+(	O
+PEEP	B-CHED
+
+Here	O
+we	O
+reported	O
+a	O
+case	O
+of	O
+individualized	O
+vancomycin	B-CHED
+dosing	O
+for	O
+a	O
+patient	O
+diagnosed	O
+as	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+treated	O
+with	O
+concurrent	O
+ECMO	O
+and	O
+CVVH	O
+.	O
+
+On	O
+ICU	O
+day	O
+14	O
+,	O
+a	O
+vancomycin	B-CHED
+trough	O
+serum	B-COMP
+concentration	O
+of	O
+17	O
+mg	O
+/	O
+L	O
+was	O
+obtained	O
+.	O
+
+This	O
+vancomycin	B-CHED
+regimen	O
+was	O
+successful	O
+in	O
+providing	O
+a	O
+target	O
+attainment	O
+of	O
+trough	O
+serum	B-COMP
+concentration	O
+ranging	O
+from	O
+10	O
+-	O
+20	O
+mg	O
+/	O
+L	O
+quickly	O
+and	O
+in	O
+controlling	O
+infection	B-DISO
+-	O
+related	O
+symptoms	B-DISO
+and	I-DISO
+signs	I-DISO
+properly	O
+.	O
+
+However	O
+,	O
+numerous	O
+extra	O
+-	O
+cardiac	B-ANAT
+conditions	O
+indirectly	O
+convey	O
+changes	O
+to	O
+the	O
+echocardiographic	O
+appearance	O
+through	O
+alterations	O
+in	O
+the	O
+governing	O
+physiology	O
+.	O
+
+Overwhelming	O
+pulmonary	B-DISO
+inflammation	I-DISO
+and	O
+endothelium	B-ANAT
+disruption	O
+are	O
+commonly	O
+observed	O
+.	O
+
+The	O
+presence	O
+of	O
+PAstV	O
+and	O
+PSaV	O
+was	O
+studied	O
+in	O
+411	O
+rectal	O
+swabs	O
+collected	O
+from	O
+healthy	O
+(	O
+n	O
+=	O
+251	O
+)	O
+and	O
+diarrheic	O
+(	O
+n	O
+=	O
+160	O
+)	O
+pigs	B-SPEC
+of	O
+different	O
+age	O
+categories	O
+:	O
+suckling	O
+(	O
+n	O
+=	O
+143	O
+),	O
+weaned	B-PROC
+(	O
+n	O
+=	O
+147	O
+)	O
+and	O
+fattening	O
+(	O
+n	O
+=	O
+121	O
+)	O
+animals	B-SPEC
+on	O
+farms	O
+in	O
+Slovakia	O
+.	O
+
+PSaV	O
+was	O
+detected	O
+less	O
+often	O
+,	O
+but	O
+also	O
+equally	O
+in	O
+clinically	O
+healthy	O
+(	O
+8	O
+.	O
+4	O
+%)	O
+and	O
+diarrheic	O
+(	O
+10	O
+%)	O
+pigs	B-SPEC
+.	O
+
+Neither	O
+TGEV	B-SPEC
+nor	O
+PEDV	B-SPEC
+was	O
+detected	O
+in	O
+any	O
+diarrheic	O
+sample	O
+.	O
+
+The	O
+phylogenetic	O
+analysis	O
+of	O
+a	O
+part	O
+of	O
+the	O
+RdRp	B-FUNC
+region	O
+revealed	O
+the	O
+presence	O
+of	O
+all	O
+five	O
+lineages	O
+of	O
+PAstV	O
+in	O
+Slovakia	O
+(	O
+PAstV	O
+-	O
+1	O
+-	O
+PAstV	O
+-	O
+5	O
+),	O
+with	O
+the	O
+most	O
+frequent	O
+lineages	O
+being	O
+PAstV	O
+-	O
+2	O
+and	O
+PAstV	O
+-	O
+4	O
+.	O
+
+The	O
+medical	O
+records	O
+of	O
+Prince	O
+Mohamed	O
+Bin	O
+Abdulaziz	O
+Hospital	O
+were	O
+reviewed	O
+between	O
+April	O
+2014	O
+and	O
+December	O
+2015	O
+to	O
+identify	O
+admission	O
+and	O
+discharge	B-ANAT
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+Patient	O
+'	O
+s	O
+characteristics	O
+,	O
+epidemiologic	O
+and	O
+clinical	O
+data	O
+and	O
+laboratory	O
+results	O
+were	O
+extracted	O
+and	O
+described	O
+.	O
+
+Additionally	O
+,	O
+the	O
+intestines	B-ANAT
+of	O
+bats	B-SPEC
+infected	O
+with	O
+fungus	B-SPEC
+exhibited	O
+different	O
+expression	B-PROC
+of	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+pathway	B-PROC
+and	O
+cytokine	O
+related	O
+transcripts	O
+,	O
+irrespective	O
+of	O
+viral	O
+presence	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+a	O
+Chinese	O
+virulent	O
+genotype	O
+GIIb	O
+PEDV	B-SPEC
+strain	O
+,	O
+CH	O
+/	O
+HNPJ	O
+/	O
+2017	O
+,	O
+was	O
+serially	O
+propagated	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+for	O
+up	O
+to	O
+90	O
+passages	O
+.	O
+
+TGEV	B-SPEC
+infection	B-DISO
+increased	O
+in	O
+TGEV	B-SPEC
+-	O
+susceptible	O
+ST	O
+or	O
+IPEC	O
+-	O
+J2	O
+cell	B-ANAT
+lines	I-ANAT
+and	O
+TGEV	B-SPEC
+-	O
+resistant	O
+Caco	O
+-	O
+2	O
+cells	B-COMP
+when	O
+porcine	B-SPEC
+TfR1	O
+was	O
+over	O
+-	O
+expressed	B-PROC
+.	O
+
+Our	O
+results	O
+support	O
+the	O
+hypothesis	O
+that	O
+TfR1	B-PRGE
+is	O
+an	O
+additional	O
+receptor	O
+for	O
+TGEV	B-SPEC
+and	O
+assists	O
+TGEV	B-SPEC
+invasion	B-DISO
+and	O
+replication	O
+.	O
+
+RESULTS	O
+:	O
+Our	O
+study	O
+investigated	O
+the	O
+possibility	O
+that	O
+TfR1	B-PRGE
+can	O
+serve	O
+as	O
+a	O
+receptor	O
+for	O
+TGEV	B-SPEC
+infection	B-DISO
+and	O
+enables	O
+the	O
+invasion	B-DISO
+and	O
+replication	O
+of	O
+TGEV	B-SPEC
+.	O
+
+During	O
+the	O
+initial	O
+stages	O
+of	O
+the	O
+MERS	O
+outbreak	O
+,	O
+healthcare	O
+workers	O
+who	O
+performed	O
+MERS	O
+-	O
+related	O
+tasks	O
+scored	O
+significantly	O
+higher	O
+on	O
+the	O
+total	O
+IES	B-CHED
+-	O
+R	O
+and	O
+its	O
+subscales	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+(	O
+HFNC	O
+)	O
+therapy	O
+is	O
+increasingly	O
+proposed	O
+as	O
+first	O
+-	O
+line	O
+respiratory	O
+support	O
+for	O
+infants	O
+with	O
+acute	B-DISO
+viral	I-DISO
+bronchiolitis	I-DISO
+(	O
+AVB	O
+).	O
+
+This	O
+clinical	O
+trial	O
+was	O
+recorded	O
+on	O
+the	O
+National	O
+Library	O
+of	O
+Medicine	B-CHED
+registry	O
+(	O
+NCT02824744	O
+).	O
+
+TITLE	O
+:	O
+Moderate	O
+Hypertriglyceridemia	O
+Causing	O
+Recurrent	B-DISO
+Pancreatitis	I-DISO
+:	O
+
+After	O
+initial	O
+management	O
+of	O
+HTG	O
+with	O
+insulin	B-PRGE
+infusion	O
+,	O
+oral	B-ANAT
+gemfibrozil	B-CHED
+was	O
+started	O
+for	O
+long	O
+-	O
+term	O
+treatment	O
+of	O
+HTG	O
+.	O
+
+Emerging	O
+literature	O
+implicates	O
+HTG	O
+as	O
+an	O
+independent	O
+indicator	B-CHED
+of	O
+poor	O
+prognosis	O
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+AP	O
+).	O
+
+To	O
+demonstrate	O
+the	O
+potential	O
+utility	O
+of	O
+Bayesian	O
+analyses	O
+by	O
+estimating	O
+the	O
+posterior	O
+probability	O
+,	O
+under	O
+various	O
+assumptions	O
+,	O
+that	O
+early	O
+ECMO	O
+was	O
+associated	O
+with	O
+reduced	O
+mortality	O
+in	O
+patients	O
+with	O
+very	O
+severe	O
+ARDS	B-DISO
+in	O
+a	O
+randomized	O
+clinical	O
+trial	O
+(	O
+RCT	O
+).	O
+
+Post	O
+hoc	O
+Bayesian	O
+analysis	O
+of	O
+data	O
+from	O
+a	O
+randomized	O
+clinical	O
+trial	O
+of	O
+early	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+compared	O
+with	O
+conventional	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+with	O
+the	O
+option	O
+for	O
+rescue	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+among	O
+patients	O
+with	O
+very	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+provides	O
+information	O
+about	O
+the	O
+posterior	O
+probability	O
+of	O
+mortality	O
+benefit	O
+under	O
+a	O
+broad	O
+set	O
+of	O
+assumptions	O
+that	O
+may	O
+help	O
+inform	O
+interpretation	O
+of	O
+the	O
+study	O
+findings	O
+.	O
+
+A	O
+predominance	O
+of	O
+the	O
+rhinovirus	B-DISO
+infection	I-DISO
+was	O
+observed	O
+in	O
+this	O
+study	O
+.	O
+
+Coronavirus	B-SPEC
+subtypes	O
+were	O
+described	O
+for	O
+the	O
+first	O
+time	O
+in	O
+Tunisia	O
+.	O
+
+TITLE	O
+:	O
+Recombinant	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+expressing	O
+heterologous	O
+S1	O
+subunits	O
+:	O
+potential	O
+for	O
+a	O
+new	O
+generation	O
+of	O
+vaccines	O
+that	O
+replicate	O
+in	O
+Vero	O
+cells	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+rIBVs	O
+are	O
+able	O
+to	O
+express	O
+S1	O
+subunits	O
+from	O
+genetically	O
+diverse	O
+strains	O
+of	O
+IBV	B-SPEC
+,	O
+which	O
+will	O
+enable	O
+the	O
+rational	O
+design	O
+of	O
+a	O
+future	O
+generation	O
+of	O
+IBV	B-SPEC
+vaccines	O
+that	O
+may	O
+be	O
+grown	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+selected	O
+two	O
+epitope	B-CHED
+peptide	B-CHED
+sequences	O
+within	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+.	O
+
+We	O
+used	O
+a	O
+complex	O
+consisting	O
+of	O
+the	O
+epitope	B-CHED
+peptide	B-CHED
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+and	O
+CpG	O
+-	O
+DNA	O
+encapsulated	O
+in	O
+liposome	O
+complex	O
+to	O
+immunize	O
+mice	B-SPEC
+,	O
+and	O
+produced	O
+the	O
+monoclonal	O
+antibodies	B-COMP
+506	O
+-	O
+2G10G5	O
+and	O
+492	O
+-	O
+1G10E4E2	O
+.	O
+
+The	O
+western	O
+blotting	O
+data	O
+showed	O
+that	O
+both	O
+monoclonal	O
+antibodies	B-COMP
+detected	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+immunoprecipitated	O
+the	O
+native	O
+form	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+emerged	O
+in	O
+2002	O
+as	O
+a	O
+highly	O
+transmissible	O
+pathogenic	O
+human	B-SPEC
+betacoronavirus	B-SPEC
+.	O
+
+As	O
+SARS	B-DISO
+-	O
+CoV	O
+enters	O
+host	B-COMP
+cells	B-COMP
+,	O
+the	O
+viral	O
+S	O
+is	O
+believed	O
+to	O
+undergo	O
+a	O
+number	O
+of	O
+conformational	O
+transitions	O
+as	O
+it	O
+is	O
+cleaved	B-ANAT
+by	O
+host	B-COMP
+proteases	O
+and	O
+binds	B-FUNC
+to	O
+host	B-COMP
+receptors	O
+.	O
+
+We	O
+recently	O
+developed	O
+stabilizing	O
+mutations	O
+for	O
+coronavirus	B-SPEC
+spikes	O
+that	O
+prevent	O
+the	O
+transition	B-DISO
+from	O
+the	O
+pre	O
+-	O
+fusion	O
+to	O
+post	O
+-	O
+fusion	O
+states	O
+.	O
+
+Neither	O
+binding	B-FUNC
+to	O
+ACE2	B-PRGE
+nor	O
+cleavage	B-PROC
+by	O
+trypsin	O
+at	O
+the	O
+S1	O
+/	O
+S2	O
+cleavage	B-PROC
+site	O
+impart	O
+large	O
+conformational	O
+changes	O
+within	O
+stabilized	O
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+or	O
+expose	O
+the	O
+secondary	O
+cleavage	B-PROC
+site	O
+,	O
+S2	O
+'.	O
+
+Secondary	O
+outcomes	O
+included	O
+length	O
+of	O
+ICU	O
+and	O
+hospital	O
+stay	O
+;	O
+ICU	O
+,	O
+hospital	O
+,	O
+and	O
+28	O
+-	O
+and	O
+90	O
+-	O
+day	O
+mortality	O
+;	O
+and	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+severe	O
+atelectasis	B-DISO
+,	O
+or	O
+pneumothorax	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+performed	O
+qRT	O
+-	O
+PCR	O
+and	O
+viral	O
+metagenomic	O
+analysis	O
+of	O
+the	O
+extraction	O
+efficiency	O
+of	O
+four	O
+commonly	O
+used	O
+Qiagen	O
+extraction	O
+kits	O
+:	O
+QIAamp	O
+Viral	B-PRGE
+RNA	I-PRGE
+Mini	I-PRGE
+Kit	I-PRGE
+(	O
+VRMK	O
+),	O
+QIAamp	O
+MinElute	B-PRGE
+Virus	I-PRGE
+Spin	I-PRGE
+Kit	B-FUNC
+(	O
+MVSK	O
+),	O
+RNeasy	O
+Mini	O
+Kit	B-FUNC
+(	O
+RMK	O
+),	O
+and	O
+RNeasy	B-PRGE
+Plus	I-PRGE
+Micro	I-PRGE
+Kit	I-PRGE
+(	O
+RPMK	O
+),	O
+using	O
+a	O
+mixed	O
+respiratory	O
+clinical	O
+sample	O
+without	O
+any	O
+pre	O
+-	O
+treatment	O
+.	O
+
+Most	O
+importantly	O
+,	O
+compared	O
+to	O
+the	O
+other	O
+three	O
+kits	O
+the	O
+highest	O
+proportion	O
+of	O
+non	O
+-	O
+host	B-COMP
+reads	O
+was	O
+obtained	O
+by	O
+the	O
+RPMK	O
+.	O
+
+The	O
+RPMK	O
+was	O
+most	O
+applicable	O
+for	O
+the	O
+metagenomic	O
+analysis	O
+of	O
+viral	O
+RNA	O
+and	O
+enabled	O
+more	O
+sensitive	O
+identification	O
+of	O
+the	O
+RNA	O
+virus	B-SPEC
+genome	O
+in	O
+respiratory	O
+clinical	O
+samples	O
+.	O
+
+In	O
+addition	O
+,	O
+viral	O
+RNA	O
+extraction	O
+kits	O
+were	O
+also	O
+applicable	O
+for	O
+metagenomic	O
+analysis	O
+of	O
+the	O
+DNA	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+ABO	O
+blood	B-ANAT
+types	O
+and	O
+major	O
+outcomes	O
+in	O
+patients	O
+with	O
+acute	O
+hypoxaemic	O
+respiratory	B-DISO
+failure	I-DISO
+:	O
+A	O
+multicenter	O
+retrospective	O
+cohort	O
+study	O
+.	O
+
+Exclusion	O
+criteria	O
+included	O
+meeting	O
+PARDS	O
+criteria	O
+more	O
+than	O
+24	O
+h	O
+before	O
+screening	O
+,	O
+cyanotic	O
+heart	O
+disease	O
+,	O
+active	O
+perinatal	O
+lung	B-DISO
+disease	I-DISO
+,	O
+and	O
+preparation	O
+or	O
+recovery	O
+from	O
+a	O
+cardiac	B-ANAT
+intervention	O
+.	O
+
+Of	O
+71	O
+samples	O
+,	O
+38	O
+%	O
+tested	O
+positive	O
+for	O
+H1N1	O
+virus	B-SPEC
+.	O
+
+Many	O
+different	O
+genotypes	O
+of	O
+IBV	B-SPEC
+are	O
+recognized	O
+which	O
+cause	O
+different	O
+clinical	O
+manifestations	O
+.	O
+
+According	O
+to	O
+the	O
+antigenic	O
+differences	O
+,	O
+different	O
+serotypes	O
+of	O
+the	O
+virus	B-SPEC
+do	O
+not	O
+cross	O
+-	O
+protect	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+in	O
+an	O
+Italian	O
+wolf	O
+(	O
+Canis	O
+lupus	O
+italicus	O
+)	O
+of	O
+pantropic	O
+canine	O
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+which	O
+has	O
+previously	O
+been	O
+detected	O
+only	O
+in	O
+dogs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	B-DISO
+),	O
+a	O
+highly	O
+lethal	O
+respiratory	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+),	O
+is	O
+an	O
+emerging	O
+disease	O
+with	O
+high	O
+potential	O
+for	O
+epidemic	O
+spread	O
+.	O
+
+Analysis	O
+of	O
+potential	O
+recombination	B-PROC
+sites	O
+showed	O
+that	O
+CHN	B-DISO
+-	O
+HG	O
+-	O
+2017	O
+is	O
+a	O
+possible	O
+recombinant	O
+originating	O
+from	O
+the	O
+strains	O
+CH	O
+/	O
+SXD1	B-PRGE
+/	O
+2015	O
+and	O
+Vietnam	O
+/	O
+HaNoi6	O
+/	O
+2015	O
+.	O
+
+Interestingly	O
+,	O
+high	O
+titers	O
+of	O
+virus	B-SPEC
+-	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+sera	B-COMP
+were	O
+detected	O
+at	O
+21	O
+DPI	O
+.	O
+
+Our	O
+analysis	O
+of	O
+the	O
+full	O
+genome	O
+sequence	O
+of	O
+a	O
+recombinant	O
+PDCoV	O
+and	O
+its	O
+virulence	B-PROC
+in	O
+suckling	O
+piglets	O
+might	O
+provide	O
+new	O
+insights	O
+into	O
+the	O
+pathogenesis	B-DISO
+of	O
+PDCoV	O
+and	O
+facilitate	O
+further	O
+investigation	O
+of	O
+this	O
+newly	O
+emerged	O
+pathogen	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+Newcastle	B-DISO
+disease	I-DISO
+,	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+in	O
+broiler	O
+flocks	O
+infected	O
+with	O
+multifactorial	O
+respiratory	O
+diseases	O
+in	O
+Iran	O
+,	O
+2015	O
+-	O
+2016	O
+.	O
+
+Thus	O
+,	O
+the	O
+permanent	O
+monitoring	O
+of	O
+cases	O
+that	O
+have	O
+occurred	O
+and	O
+the	O
+review	O
+of	O
+vaccination	O
+plans	O
+of	O
+affected	O
+flocks	O
+every	O
+year	O
+are	O
+some	O
+of	O
+the	O
+necessary	O
+measures	O
+needed	O
+for	O
+strategic	O
+control	O
+of	O
+respiratory	O
+syndrome	B-DISO
+in	O
+broilers	O
+.	O
+
+Spontaneous	O
+breathing	B-PROC
+was	O
+associated	O
+with	O
+increased	O
+ventilator	O
+-	O
+free	O
+days	O
+(	O
+13	O
+[	O
+0	O
+-	O
+22	O
+]	O
+vs	O
+8	O
+[	O
+0	O
+-	O
+20	O
+];	O
+p	O
+=	O
+0	O
+.	O
+014	O
+)	O
+and	O
+shorter	O
+duration	O
+of	O
+ICU	O
+stay	O
+(	O
+11	O
+[	O
+6	O
+-	O
+20	O
+]	O
+vs	O
+12	O
+[	O
+7	O
+-	O
+22	O
+];	O
+p	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+Although	O
+these	O
+results	O
+support	O
+the	O
+use	O
+of	O
+spontaneous	O
+breathing	B-PROC
+in	I-PROC
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+independent	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+severity	O
+,	O
+the	O
+use	O
+of	O
+controlled	O
+ventilation	O
+indicates	O
+a	O
+bias	B-SPEC
+toward	O
+use	O
+in	O
+patients	O
+with	O
+higher	O
+disease	O
+severity	O
+.	O
+
+Our	O
+findings	O
+will	O
+aid	O
+the	O
+development	B-PROC
+of	O
+preventive	O
+and	O
+therapeutic	O
+strategies	O
+for	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+validation	O
+of	O
+a	O
+monoclonal	O
+antibody	B-COMP
+-	O
+based	O
+competitive	O
+ELISA	O
+for	O
+detection	O
+of	O
+antibodies	O
+against	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+ABSTRACT	O
+:	O
+Hematopoietic	B-PRGE
+stem	I-PRGE
+cell	I-PRGE
+transplant	B-ANAT
+(	O
+HSCT	O
+)	O
+recipients	O
+are	O
+at	O
+increased	O
+risk	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+and	O
+their	O
+associated	O
+complications	O
+.	O
+
+We	O
+conclude	O
+that	O
+HCoV	O
+is	O
+common	O
+and	O
+clinically	O
+significant	O
+in	O
+HSCT	O
+recipients	O
+,	O
+with	O
+nearly	O
+one	O
+-	O
+third	O
+of	O
+patients	O
+progressing	O
+to	O
+proven	O
+or	O
+probable	O
+LRTI	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+appearance	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+,	O
+widespread	O
+and	O
+continued	O
+outbreaks	O
+of	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+since	O
+2004	O
+,	O
+the	O
+H1N1	O
+pandemic	O
+in	O
+2009	O
+and	O
+emergence	O
+of	O
+MERS	O
+CoV	O
+in	O
+2012	O
+reflect	O
+the	O
+seriousness	O
+of	O
+public	O
+health	O
+challenges	O
+posed	O
+by	O
+influenza	O
+and	O
+emerging	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+In	O
+France	O
+,	O
+the	O
+immune	B-PROC
+status	I-PROC
+of	O
+the	O
+pig	B-SPEC
+population	O
+against	O
+PED	O
+virus	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+was	O
+expected	O
+to	O
+be	O
+low	O
+due	O
+to	O
+the	O
+absence	O
+of	O
+circulation	B-PROC
+of	O
+the	O
+virus	B-SPEC
+since	O
+the	O
+80	O
+'	O
+s	O
+and	O
+a	O
+compulsory	O
+notification	O
+of	O
+PED	O
+was	O
+set	O
+up	O
+in	O
+2014	O
+.	O
+
+Here	O
+,	O
+we	O
+reported	O
+the	O
+first	O
+case	O
+of	O
+a	O
+PED	O
+outbreak	O
+in	O
+December	O
+2014	O
+in	O
+the	O
+North	O
+of	O
+France	O
+after	O
+a	O
+long	O
+absence	O
+of	O
+the	O
+disease	O
+,	O
+the	O
+monitoring	O
+of	O
+the	O
+excretion	B-PROC
+and	O
+the	O
+control	O
+measure	O
+implementation	O
+.	O
+
+An	O
+increase	O
+to	O
+a	O
+pH	O
+12	O
+of	O
+liquid	O
+manure	O
+by	O
+liming	O
+led	O
+to	O
+the	O
+absence	O
+of	O
+PEDV	B-SPEC
+detection	O
+by	O
+RT	O
+-	O
+PCR	O
+after	O
+seven	O
+days	O
+.	O
+
+Supportive	O
+treatment	O
+includes	O
+the	O
+use	O
+of	O
+lung	B-ANAT
+-	O
+protective	O
+ventilatory	O
+strategies	O
+that	O
+decrease	O
+the	O
+work	B-PROC
+of	I-PROC
+breathing	I-PROC
+,	O
+can	O
+improve	O
+oxygenation	B-PROC
+,	O
+and	O
+minimize	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Our	O
+focus	O
+is	O
+on	O
+platelet	B-PRGE
+-	I-PRGE
+endothelial	B-ANAT
+cell	I-ANAT
+adhesion	I-PRGE
+molecule	I-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+which	O
+contributes	O
+to	O
+the	O
+maintenance	O
+and	O
+restoration	O
+of	O
+vascular	B-ANAT
+integrity	O
+following	O
+barrier	O
+disruption	O
+.	O
+
+Fever	B-PROC
+,	O
+above	O
+38	O
+.	O
+5	O
+-	O
+39	O
+.	O
+5	O
+°	O
+C	O
+,	O
+increases	O
+both	O
+the	O
+ventilatory	O
+(	O
+high	O
+respiratory	O
+drive	O
+:	O
+large	O
+tidal	O
+volume	O
+,	O
+high	O
+respiratory	O
+rate	O
+)	O
+and	O
+the	O
+metabolic	B-PROC
+(	O
+increased	O
+O2	O
+consumption	O
+)	O
+demands	O
+,	O
+further	O
+limiting	O
+the	O
+cardio	O
+-	O
+ventilatory	O
+reserve	O
+.	O
+
+Some	O
+data	O
+(	O
+case	O
+reports	O
+,	O
+uncontrolled	O
+trial	O
+,	O
+small	O
+randomized	O
+prospective	O
+trials	O
+)	O
+suggest	O
+that	O
+control	O
+of	O
+elevated	O
+body	B-ANAT
+temperature	O
+"("""	O
+fever	B-PROC
+control	O
+""")"	O
+leading	O
+to	O
+normothermia	O
+(	O
+35	O
+.	O
+5	O
+-	O
+37	O
+°	O
+C	O
+)	O
+will	O
+lower	O
+both	O
+the	O
+ventilatory	O
+and	O
+metabolic	B-PROC
+demands	O
+:	O
+fever	B-PROC
+control	O
+should	O
+simplify	O
+critical	O
+care	O
+management	O
+when	O
+limited	O
+cardio	O
+-	O
+ventilatory	O
+reserve	O
+is	O
+at	O
+stake	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+a	O
+recombination	B-PROC
+-	O
+resistant	O
+coronavirus	B-SPEC
+as	O
+a	O
+broadly	O
+applicable	O
+,	O
+rapidly	O
+implementable	O
+vaccine	O
+platform	O
+.	O
+
+Vaccines	O
+are	O
+key	O
+for	O
+reducing	O
+coronaviral	O
+disease	O
+burden	O
+;	O
+however	O
+,	O
+the	O
+utility	O
+of	O
+live	O
+-	O
+attenuated	O
+vaccines	O
+is	O
+limited	O
+by	O
+risks	O
+of	O
+reversion	O
+or	O
+repair	B-PROC
+.	O
+
+Because	O
+of	O
+their	O
+history	O
+of	O
+emergence	O
+events	O
+due	O
+to	O
+their	O
+prevalence	O
+in	O
+zoonotic	O
+pools	O
+,	O
+designing	O
+live	O
+-	O
+attenuated	O
+coronavirus	B-SPEC
+vaccines	O
+that	O
+can	O
+be	O
+rapidly	O
+and	O
+broadly	O
+implemented	O
+is	O
+essential	O
+for	O
+outbreak	O
+preparedness	O
+.	O
+
+While	O
+a	O
+3	O
+-	O
+nt	O
+rewired	O
+TRN	O
+reverts	O
+via	O
+second	O
+-	O
+site	O
+mutation	O
+upon	O
+serial	O
+passage	O
+,	O
+a	O
+7	O
+-	O
+nt	O
+rewired	O
+TRN	O
+is	O
+more	O
+stable	O
+,	O
+suggesting	O
+that	O
+a	O
+more	O
+extensively	O
+rewired	O
+TRN	O
+might	O
+be	O
+essential	O
+for	O
+avoiding	O
+growth	B-PROC
+selection	O
+.	O
+
+Retrospective	O
+chart	O
+reviews	O
+were	O
+performed	O
+to	O
+identify	O
+all	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+of	O
+MERS	O
+-	O
+COV	O
+infection	B-DISO
+in	O
+Saudi	O
+Arabia	O
+that	O
+were	O
+reported	O
+to	O
+the	O
+Ministry	O
+of	O
+Health	O
+of	O
+Saudi	O
+Arabia	O
+between	O
+23	O
+April	O
+2014	O
+and	O
+7	O
+June	O
+2016	O
+.	O
+
+TITLE	O
+:	O
+Transforming	O
+Growth	B-PROC
+Factor	O
+-	O
+β1	O
+in	O
+predicting	O
+early	O
+lung	B-ANAT
+fibroproliferation	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Pulmonary	B-ANAT
+levels	O
+of	O
+TGF	O
+-	O
+β1	O
+during	O
+the	O
+first	O
+week	O
+of	O
+ARDS	B-DISO
+were	O
+not	O
+associated	O
+nor	O
+with	O
+the	O
+presence	O
+of	O
+fibroproliferation	O
+neither	O
+with	O
+death	B-PROC
+.	O
+
+The	O
+current	O
+available	O
+literature	O
+suggests	O
+that	O
+48	O
+h	O
+of	O
+NMBA	O
+therapy	O
+in	O
+patients	O
+with	O
+early	O
+,	O
+severe	O
+ARDS	B-DISO
+improves	O
+mortality	O
+,	O
+without	O
+resulting	O
+in	O
+additional	O
+patient	O
+harm	O
+.	O
+
+TITLE	O
+:	O
+Prospects	O
+for	O
+the	O
+use	O
+of	O
+spherical	O
+gold	B-CHED
+nanoparticles	B-CHED
+in	O
+immunization	O
+.	O
+
+We	O
+used	O
+spherical	O
+gold	B-CHED
+nanoparticles	B-CHED
+(	O
+average	O
+diameter	O
+,	O
+15	O
+nm	O
+)	O
+as	O
+a	O
+platform	O
+for	O
+the	O
+antigen	B-CHED
+for	O
+swine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+The	O
+increased	O
+concentration	O
+of	O
+IL	O
+-	O
+1β	O
+in	O
+the	O
+immunized	O
+animals	B-SPEC
+directly	O
+correlated	O
+with	O
+the	O
+activity	O
+of	O
+macrophages	B-ANAT
+and	O
+stimulated	O
+B	B-ANAT
+cells	I-ANAT
+,	O
+which	O
+produce	O
+this	O
+cytokine	O
+when	O
+activated	O
+.	O
+
+The	O
+activation	O
+or	O
+cleavage	B-PROC
+of	O
+main	O
+apoptosis	B-PATH
+-	O
+associated	O
+molecular	O
+such	O
+as	O
+AIFM1	B-PRGE
+,	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+,	O
+caspase	B-PRGE
+-	I-PRGE
+8	I-PRGE
+,	O
+caspase	B-PRGE
+-	I-PRGE
+9	I-PRGE
+and	O
+PARP	B-PRGE
+in	O
+PEDV	B-SPEC
+infected	O
+host	B-COMP
+cells	B-COMP
+were	O
+analyzed	O
+by	O
+western	O
+blotting	O
+.	O
+
+The	O
+overexpressing	O
+plasmids	O
+of	O
+16	O
+non	O
+-	O
+structural	O
+proteins	B-CHED
+(	O
+Nsp1	B-PRGE
+-	I-PRGE
+16	I-PRGE
+)	O
+and	O
+6	O
+structural	O
+proteins	B-CHED
+(	O
+M	O
+,	O
+N	O
+,	O
+E	O
+,	O
+ORF3	O
+,	O
+S1	O
+and	O
+S2	O
+)	O
+were	O
+constructed	O
+by	O
+cloning	O
+.	O
+
+CONCLUSIONS	O
+:	O
+S1	B-PRGE
+Spike	I-PRGE
+protein	I-PRGE
+is	O
+one	O
+of	O
+the	O
+most	O
+critical	O
+functional	O
+proteins	B-CHED
+that	O
+contribute	O
+to	O
+cell	B-COMP
+apoptosis	B-PATH
+.	O
+
+Furthermore	O
+,	O
+we	O
+orally	B-ANAT
+inoculated	O
+five	O
+groups	O
+of	O
+5	O
+-	O
+day	O
+-	O
+old	O
+gnotobiotic	O
+piglets	O
+with	O
+the	O
+three	O
+mutants	O
+,	O
+icPC22A	O
+,	O
+or	O
+a	O
+mock	O
+treatment	O
+.	O
+
+The	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+binds	B-FUNC
+to	O
+the	O
+cellular	B-COMP
+protein	B-CHED
+DPP4	B-PRGE
+via	O
+its	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+and	O
+mediates	O
+viral	O
+entry	O
+into	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+All	O
+adult	O
+patients	O
+with	O
+severe	O
+malaria	B-PATH
+were	O
+studied	O
+during	O
+2012	O
+-	O
+2014	O
+.	O
+
+Within	O
+several	O
+days	O
+of	O
+hospitalization	O
+,	O
+patient	O
+developed	O
+acute	O
+worsening	O
+of	O
+his	O
+chronic	B-DISO
+hypercapnic	I-DISO
+respiratory	I-DISO
+failure	I-DISO
+thought	O
+to	O
+be	O
+due	O
+to	O
+worsening	O
+of	O
+pulmonary	B-DISO
+arterial	B-ANAT
+hypertension	I-DISO
+with	O
+right	B-DISO
+heart	I-DISO
+failure	I-DISO
+.	O
+
+Disease	O
+status	O
+of	O
+the	O
+animals	B-SPEC
+was	O
+determined	O
+using	O
+a	O
+combination	O
+of	O
+gross	O
+pathology	B-DISO
+,	O
+histopathology	O
+and	O
+/	O
+or	O
+'	B-PRGE
+FIP	I-PRGE
+profile	I-PRGE
+',	I-PRGE
+consisting	O
+of	O
+serology	O
+,	O
+clinical	O
+pathology	B-DISO
+and	O
+clinical	O
+signs	O
+.	O
+
+Viruses	B-SPEC
+were	O
+detected	O
+in	O
+1254	O
+(	O
+64	O
+.	O
+6	O
+%)	O
+children	O
+at	O
+enrollment	O
+;	O
+HRV	O
+,	O
+RSV	B-PRGE
+,	O
+HAdV	O
+and	O
+hMPV	B-SPEC
+were	O
+detected	O
+in	O
+499	O
+(	O
+25	O
+.	O
+7	O
+%),	O
+439	O
+(	O
+22	O
+.	O
+6	O
+%),	O
+156	O
+(	O
+8	O
+.	O
+0	O
+%)	O
+and	O
+47	O
+(	O
+2	O
+.	O
+4	O
+%)	O
+children	O
+,	O
+respectively	O
+.	O
+
+In	O
+an	O
+effort	B-PROC
+to	O
+improve	O
+knowledge	O
+about	O
+the	O
+practice	O
+of	O
+respiratory	O
+protection	O
+against	O
+respiratory	O
+infectious	B-DISO
+agents	O
+,	O
+a	O
+NIOSH	O
+-	O
+funded	O
+project	O
+that	O
+included	O
+an	O
+educational	O
+program	O
+,	O
+observations	O
+of	O
+HCWs	O
+,	O
+and	O
+focus	O
+groups	O
+was	O
+conducted	O
+.	O
+
+This	O
+study	O
+identified	O
+respiratory	O
+protection	O
+practice	O
+issues	O
+among	O
+HCWs	O
+and	O
+strategies	O
+for	O
+integration	B-PROC
+of	O
+respiratory	O
+protection	O
+standards	O
+and	O
+procedures	O
+into	O
+practice	O
+.	O
+
+A	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+induced	O
+ALI	O
+rat	B-SPEC
+model	O
+was	O
+established	O
+through	O
+intratracheal	O
+instillation	O
+.	O
+
+The	O
+wet	O
+/	O
+dry	O
+ratios	O
+of	O
+lung	B-ANAT
+tissues	I-ANAT
+were	O
+measured	O
+,	O
+and	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+)	O
+was	O
+collected	O
+to	O
+test	O
+protein	B-CHED
+concentrations	O
+,	O
+total	O
+cell	B-COMP
+/	O
+macrophage	B-ANAT
+numbers	O
+,	O
+and	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokine	O
+levels	O
+.	O
+
+LPS	B-DISO
+-	O
+induced	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+autocrine	B-PROC
+upregulated	O
+the	O
+expression	B-PROC
+of	O
+MMP2	B-PRGE
+and	O
+MMP9	B-PRGE
+through	O
+activating	O
+STAT3	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+September	O
+2012	O
+,	O
+a	O
+novel	O
+coronavirus	O
+was	O
+isolated	O
+from	O
+a	O
+patient	O
+who	O
+died	B-PROC
+in	O
+Saudi	O
+Arabia	O
+after	O
+presenting	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+.	O
+
+Analysis	O
+revealed	O
+the	O
+disease	O
+to	O
+be	O
+due	O
+to	O
+a	O
+novel	O
+virus	B-SPEC
+which	O
+was	O
+named	O
+Middle	O
+East	O
+Respiratory	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+In	O
+this	O
+review	O
+we	O
+highlight	O
+epidemiological	O
+,	O
+clinical	O
+,	O
+and	O
+infection	B-DISO
+control	O
+aspects	O
+of	O
+MERS	O
+-	O
+CoV	O
+as	O
+informed	O
+by	O
+the	O
+Saudi	O
+experience	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+cleavage	B-PROC
+at	O
+S2	O
+'	O
+is	O
+carried	O
+out	O
+by	O
+proteases	O
+recognizing	O
+a	O
+single	O
+arginine	B-CHED
+,	O
+most	O
+likely	O
+TMPRSS2	B-PRGE
+and	O
+cathepsin	B-PRGE
+L	I-PRGE
+.	O
+Finally	O
+,	O
+mutation	O
+of	O
+the	O
+proposed	O
+cathepsin	B-PRGE
+L	I-PRGE
+site	I-PRGE
+did	O
+not	O
+impact	O
+viral	O
+entry	O
+and	O
+double	O
+mutation	O
+of	O
+S1	O
+/	O
+S2	O
+and	O
+S2	O
+'	O
+site	O
+was	O
+compatible	O
+with	O
+cathepsin	B-PRGE
+L	I-PRGE
+-	O
+but	O
+not	O
+TMPRSS2	O
+-	O
+dependent	O
+host	B-COMP
+cell	I-COMP
+entry	O
+,	O
+indicating	O
+that	O
+cathepsin	B-PRGE
+L	I-PRGE
+can	O
+process	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+at	O
+auxiliary	O
+sites	O
+.	O
+
+Usually	O
+,	O
+CNS	B-CHED
+pathologies	O
+are	O
+caused	O
+by	O
+known	O
+neurotropic	O
+viruses	B-SPEC
+such	O
+as	O
+measles	B-SPEC
+virus	I-SPEC
+(	O
+MV	O
+),	O
+herpes	B-SPEC
+virus	I-SPEC
+and	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+),	O
+among	O
+others	O
+.	O
+
+However	O
+,	O
+nowadays	O
+respiratory	O
+viruses	B-SPEC
+have	O
+placed	O
+themselves	O
+as	O
+relevant	O
+agents	O
+responsible	O
+for	O
+CNS	B-CHED
+pathologies	O
+.	O
+
+To	O
+evaluate	O
+the	O
+potential	O
+for	O
+improvement	O
+in	O
+management	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+this	O
+study	O
+was	O
+designed	O
+to	O
+describe	O
+the	O
+incidence	O
+and	O
+management	O
+of	O
+ARDS	B-DISO
+in	O
+mainland	O
+China	O
+.	O
+
+ClinicalTrials	O
+.	O
+gov	O
+NCT01666834	O
+;	O
+date	O
+of	O
+registration	O
+release	B-PATH
+:	O
+August	O
+14	O
+
+To	O
+study	O
+the	O
+effects	O
+of	O
+halogenated	O
+agents	O
+on	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+under	O
+""""	O
+physiologic	O
+""""	O
+conditions	O
+,	O
+we	O
+describe	O
+an	O
+easy	O
+system	O
+to	O
+culture	O
+cells	B-COMP
+at	O
+the	O
+air	B-CHED
+-	O
+liquid	O
+interface	O
+and	O
+expose	O
+them	O
+to	O
+halogenated	O
+agents	O
+to	O
+provide	O
+precise	O
+controlled	O
+""""	O
+air	B-CHED
+""""	O
+fractions	O
+and	O
+""""	O
+medium	O
+""""	O
+concentrations	O
+for	O
+these	O
+agents	O
+.	O
+
+RESULTS	O
+:	O
+HCoV	O
+was	O
+present	O
+in	O
+9	O
+.	O
+1	O
+%	O
+(	O
+313	O
+/	O
+3458	O
+)	O
+of	O
+all	O
+RTI	B-DISO
+episodes	O
+:	O
+46	O
+.	O
+6	O
+%	O
+OC43	O
+,	O
+32	O
+.	O
+3	O
+%	O
+NL63	O
+,	O
+16	O
+.	O
+0	O
+%	O
+HKU1	O
+,	O
+and	O
+5	O
+.	O
+8	O
+%	O
+229E	O
+.	O
+
+Pregnant	O
+women	O
+infected	O
+with	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+were	O
+at	O
+increased	O
+risk	O
+of	O
+hospitalization	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+,	O
+while	O
+their	O
+newborns	O
+had	O
+an	O
+increased	O
+risk	O
+of	O
+pre	O
+-	O
+term	B-PROC
+birth	I-PROC
+or	O
+low	O
+birth	B-PROC
+weight	O
+.	O
+
+Pregnant	O
+women	O
+have	O
+a	O
+unique	O
+immunological	O
+profile	O
+modulated	O
+by	O
+the	O
+sex	B-CHED
+hormones	I-CHED
+required	O
+to	O
+maintain	O
+pregnancy	O
+,	O
+namely	O
+progesterone	B-CHED
+and	O
+estrogens	B-CHED
+.	O
+
+Following	O
+this	O
+,	O
+he	O
+was	O
+diagnosed	O
+with	O
+bacterial	B-DISO
+pneumonia	I-DISO
+and	O
+treated	O
+with	O
+tazobactam	O
+/	O
+piperacillin	B-CHED
+;	O
+however	O
+,	O
+he	O
+showed	O
+little	O
+clinical	O
+improvement	O
+with	O
+this	O
+treatment	O
+approach	O
+.	O
+
+Consequently	O
+,	O
+with	O
+this	O
+treatment	O
+,	O
+he	O
+recovered	O
+from	O
+severe	O
+mycoplasma	B-DISO
+pneumonia	I-DISO
+.	O
+
+In	O
+patients	O
+who	O
+present	O
+with	O
+severe	O
+mycoplasma	B-DISO
+pneumonia	I-DISO
+with	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+nasal	B-ANAT
+high	O
+-	O
+flow	O
+oxygen	B-CHED
+therapy	O
+can	O
+help	O
+reduce	O
+the	O
+needs	O
+for	O
+ventilator	O
+management	O
+including	O
+intubation	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+an	O
+emerging	O
+zoonotic	O
+pathogen	O
+discovered	O
+in	O
+2012	O
+.	O
+
+We	O
+summarize	O
+characteristics	O
+of	O
+animal	B-SPEC
+studies	O
+including	O
+study	O
+design	O
+,	O
+study	O
+population	O
+and	O
+outcomes	O
+of	O
+interest	O
+for	O
+future	O
+transmission	O
+modelling	O
+in	O
+the	O
+reservoir	O
+population	O
+.	O
+
+From	O
+2011	O
+to	O
+2014	O
+,	O
+a	O
+birth	B-PROC
+cohort	O
+of	O
+infants	O
+in	O
+rural	O
+Nepal	O
+was	O
+enrolled	O
+and	O
+followed	O
+with	O
+weekly	O
+household	O
+-	O
+based	O
+active	O
+surveillance	O
+for	O
+respiratory	B-DISO
+symptoms	I-DISO
+until	O
+6	O
+months	O
+of	O
+age	O
+.	O
+
+The	O
+risk	O
+of	O
+primary	O
+and	O
+repeated	O
+infections	B-DISO
+with	O
+the	O
+same	O
+virus	B-SPEC
+was	O
+evaluated	O
+using	O
+Poisson	O
+regression	O
+.	O
+
+In	O
+infants	O
+in	O
+rural	O
+Nepal	O
+,	O
+repeated	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+were	O
+frequent	O
+,	O
+and	O
+we	O
+found	O
+no	O
+decrease	O
+in	O
+illness	O
+severity	O
+with	O
+repeated	O
+infections	B-DISO
+and	O
+no	O
+evidence	O
+of	O
+replacement	O
+with	O
+another	O
+virus	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Of	O
+3528	O
+infants	O
+,	O
+1726	O
+(	O
+49	O
+%)	O
+had	O
+a	O
+primary	B-DISO
+infection	I-DISO
+,	O
+and	O
+419	O
+(	O
+12	O
+%)	O
+had	O
+a	O
+repeated	O
+infection	B-DISO
+.	O
+
+Influenza	B-DISO
+has	O
+been	O
+reported	O
+from	O
+Indian	O
+Hajj	O
+and	O
+Umrah	O
+returning	O
+pilgrims	O
+,	O
+but	O
+data	O
+on	O
+other	O
+respiratory	O
+pathogens	O
+are	O
+sparse	O
+in	O
+India	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+detection	O
+of	O
+rhinovirus	B-SPEC
+C	O
+in	O
+a	O
+boy	O
+with	O
+a	O
+clinical	O
+presentation	O
+of	O
+myocarditis	B-DISO
+,	O
+suggesting	O
+a	O
+possible	O
+causative	O
+role	O
+of	O
+this	O
+virus	B-SPEC
+in	O
+this	O
+case	O
+.	O
+
+Further	O
+characterization	O
+of	O
+the	O
+enterovirus	B-SPEC
+group	O
+was	O
+carried	O
+out	O
+using	O
+PCR	O
+with	O
+primers	O
+targeting	B-PROC
+the	O
+VP4	B-PRGE
+/	O
+VP2	B-PRGE
+gene	O
+,	O
+followed	O
+by	O
+sequencing	O
+.	O
+
+TITLE	O
+:	O
+Ehrlichiosis	B-DISO
+presenting	O
+as	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+meningoencephalitis	B-DISO
+in	O
+an	O
+immunocompetent	O
+adult	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+identification	O
+of	O
+Betacoronavirus	B-SPEC
+in	O
+bats	B-SPEC
+from	O
+Sardinia	O
+(	O
+Italy	O
+):	O
+first	O
+detection	O
+and	O
+phylogeny	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+complication	B-DISO
+that	O
+affects	O
+approximately	O
+40	O
+%	O
+of	O
+burn	O
+patients	O
+and	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+rates	O
+.	O
+
+We	O
+identified	O
+8	O
+patients	O
+who	O
+had	O
+ARDS	B-DISO
+secondary	O
+to	O
+burn	O
+who	O
+were	O
+placed	O
+onto	O
+ECMO	O
+during	O
+this	O
+10	O
+-	O
+year	O
+period	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Mortality	O
+in	O
+burn	O
+patients	O
+with	O
+ARDS	B-DISO
+who	O
+are	O
+managed	O
+with	O
+ECMO	O
+is	O
+extremely	O
+low	O
+.	O
+
+This	O
+manuscript	O
+describes	O
+a	O
+readily	O
+available	O
+and	O
+relatively	O
+simple	O
+adjunct	O
+that	O
+can	O
+provide	O
+partial	O
+lung	B-ANAT
+support	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+complicated	O
+by	O
+severe	O
+hypercapnia	B-DISO
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+requiring	O
+dialysis	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+pathophysiology	O
+,	O
+current	O
+clinical	O
+practice	O
+,	O
+and	O
+emerging	O
+therapies	O
+.	O
+
+According	O
+to	O
+the	O
+outcomes	O
+,	O
+the	O
+patients	O
+were	O
+divided	O
+into	O
+ARDS	B-DISO
+group	O
+and	O
+non	O
+-	O
+ARDS	B-DISO
+group	O
+.	O
+
+The	O
+top	O
+four	O
+prevalence	O
+diseases	O
+in	O
+the	O
+emergency	B-DISO
+critical	O
+disease	O
+spectrum	O
+were	O
+cardiovascular	B-DISO
+diseases	I-DISO
+[	O
+41	O
+.	O
+8	O
+%,	O
+716	O
+males	O
+and	O
+610	O
+females	O
+,	O
+age	O
+(	O
+70	O
+.	O
+25	O
+±	O
+15	O
+.	O
+08	O
+)	O
+years	O
+old	O
+],	O
+nervous	B-DISO
+system	I-DISO
+diseases	I-DISO
+[	O
+26	O
+.	O
+7	O
+%,	O
+502	O
+males	O
+and	O
+346	O
+females	O
+,	O
+age	O
+(	O
+60	O
+.	O
+28	O
+±	O
+17	O
+.	O
+57	O
+)	O
+years	O
+old	O
+],	O
+respiratory	B-DISO
+disease	I-DISO
+[	O
+12	O
+.	O
+3	O
+%,	O
+226	O
+males	O
+and	O
+166	O
+females	O
+,	O
+age	O
+(	O
+72	O
+.	O
+96	O
+±	O
+16	O
+.	O
+23	O
+)	O
+years	O
+old	O
+]	O
+and	O
+digestive	B-DISO
+system	I-DISO
+diseases	I-DISO
+[	O
+5	O
+.	O
+6	O
+%,	O
+119	O
+males	O
+and	O
+60	O
+females	O
+,	O
+age	O
+(	O
+65	O
+.	O
+40	O
+±	O
+17	O
+.	O
+96	O
+)	O
+years	O
+old	O
+],	O
+accounting	O
+for	O
+86	O
+.	O
+4	O
+%	O
+of	O
+the	O
+total	O
+.	O
+
+The	O
+high	O
+incidence	O
+of	O
+acute	O
+critical	B-DISO
+illness	I-DISO
+in	O
+the	O
+emergency	B-DISO
+department	O
+occurred	O
+in	O
+winter	O
+(	O
+287	O
+cases	O
+in	O
+December	O
+and	O
+277	O
+cases	O
+in	O
+January	O
+)	O
+and	O
+the	O
+early	O
+stage	O
+of	O
+spring	O
+(	O
+282	O
+cases	O
+in	O
+March	O
+).	O
+
+The	O
+average	O
+treatment	O
+time	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+in	O
+emergency	B-DISO
+room	O
+was	O
+1	O
+.	O
+5	O
+days	O
+(	O
+the	O
+longest	O
+was	O
+23	O
+.	O
+0	O
+days	O
+,	O
+the	O
+shortest	O
+was	O
+6	O
+minutes	O
+),	O
+among	O
+them	O
+,	O
+85	O
+.	O
+6	O
+%	O
+of	O
+the	O
+patients	O
+could	O
+be	O
+discharged	O
+from	O
+the	O
+emergency	B-DISO
+within	O
+3	O
+days	O
+,	O
+and	O
+1	O
+.	O
+9	O
+%	O
+of	O
+the	O
+patients	O
+stayed	O
+in	O
+the	O
+emergency	B-DISO
+for	O
+more	O
+than	O
+7	O
+days	O
+.	O
+
+Patients	O
+with	O
+chronic	B-DISO
+renal	I-DISO
+impairment	I-DISO
+represented	O
+a	O
+particularly	O
+high	O
+-	O
+risk	O
+group	O
+that	O
+should	O
+receive	O
+extra	O
+caution	O
+during	O
+suspected	O
+or	O
+confirmed	O
+MERS	O
+cases	O
+clinical	O
+care	O
+assignment	O
+and	O
+during	O
+outbreaks	O
+.	O
+
+Moreover	O
+,	O
+a	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+18	B-PRGE
+complete	I-PRGE
+VP1	I-PRGE
+sequences	I-PRGE
+from	O
+this	O
+study	O
+revealed	O
+that	O
+14	O
+strains	O
+belonged	O
+to	O
+lineage	O
+1	O
+and	O
+4	O
+strains	O
+belonged	O
+to	O
+lineage	O
+3	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+in	O
+ovo	B-SPEC
+delivery	O
+of	O
+cytosine	B-CHED
+-	O
+guanosine	B-CHED
+(	O
+CpG	O
+)	O
+oligodeoxynucleotides	O
+(	O
+ODNs	O
+)	O
+protects	O
+chickens	B-SPEC
+against	O
+many	O
+bacterial	O
+and	O
+viral	B-DISO
+infections	I-DISO
+,	O
+by	O
+activating	O
+the	O
+toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+(	O
+TLR	O
+)	O
+21	O
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+Although	O
+the	O
+delivery	O
+of	O
+CpG	O
+ODNs	O
+in	O
+ovo	B-SPEC
+at	O
+embryo	B-ANAT
+day	O
+(	O
+ED	O
+)	O
+18	O
+has	O
+been	O
+shown	O
+to	O
+reduce	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+loads	O
+in	O
+embryonic	B-ANAT
+chicken	B-SPEC
+lungs	B-ANAT
+pre	O
+-	O
+hatch	B-PROC
+,	O
+whether	O
+in	O
+ovo	B-SPEC
+delivered	O
+CpG	O
+ODNs	O
+are	O
+capable	O
+of	O
+protecting	O
+chickens	B-SPEC
+against	O
+a	O
+post	O
+-	O
+hatch	B-PROC
+challenge	O
+is	O
+unknown	O
+.	O
+
+TITLE	O
+:	O
+Patients	O
+experiencing	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+have	O
+high	O
+postoperative	O
+mortality	O
+after	O
+pneumonectomy	O
+.	O
+
+Risk	O
+factors	O
+and	O
+outcome	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+were	O
+assessed	O
+in	O
+univariate	O
+and	O
+multivariate	O
+analysis	O
+.	O
+
+The	O
+aim	O
+of	O
+our	O
+study	O
+was	O
+to	O
+review	O
+polygraphic	O
+(	O
+PG	O
+)	O
+findings	O
+and	O
+the	O
+need	O
+for	O
+noninvasive	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+CPAP	O
+)	O
+or	O
+noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+in	O
+children	O
+with	O
+MPS	B-DISO
+IVA	I-DISO
+.	O
+
+Larger	O
+trials	O
+are	O
+needed	O
+to	O
+assess	O
+efficacy	O
+,	O
+and	O
+the	O
+viability	O
+of	O
+MSCs	B-FUNC
+must	O
+be	O
+improved	O
+.	O
+
+TITLE	O
+:	O
+Neuromuscular	O
+blocking	B-DISO
+agents	O
+for	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+A	O
+meta	O
+-	O
+analysis	O
+of	O
+randomized	O
+controlled	O
+trials	O
+.	O
+
+We	O
+included	O
+randomized	O
+controlled	O
+trials	O
+that	O
+evaluated	O
+NMBAs	O
+compared	O
+with	O
+placebo	O
+or	O
+usual	O
+treatment	O
+in	O
+adult	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Protective	O
+ventilation	O
+strategies	O
+based	O
+NMBAs	O
+treatment	O
+reduces	O
+mortality	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Protective	O
+ventilation	O
+strategies	O
+based	O
+NMBAs	O
+treatment	O
+reduces	O
+mortality	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Thus	O
+,	O
+the	O
+establishment	O
+of	O
+BP	O
+-	O
+caKII	O
+and	O
+the	O
+identified	O
+mutations	O
+in	O
+this	O
+study	O
+may	O
+provide	O
+insight	O
+into	O
+the	O
+genetic	O
+background	O
+of	O
+embryo	B-ANAT
+and	O
+cold	B-DISO
+adaptations	B-PROC
+,	O
+and	O
+the	O
+attenuation	O
+of	O
+coronaviruses	O
+.	O
+
+However	O
+,	O
+the	O
+role	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+on	O
+pulmonary	B-ANAT
+dysfunctions	O
+in	O
+immune	O
+-	O
+competent	O
+patients	O
+with	O
+ARDS	B-DISO
+is	O
+only	O
+incompletely	O
+understood	O
+.	O
+
+The	O
+most	O
+common	O
+site	O
+of	O
+infection	B-DISO
+was	O
+the	O
+lung	B-ANAT
+(	O
+31	O
+%).	O
+
+Particularly	O
+,	O
+the	O
+efficacious	O
+suppression	B-DISO
+of	O
+the	O
+IFN	B-PRGE
+cascade	O
+contributes	O
+to	O
+disease	B-DISO
+progression	I-DISO
+and	O
+severity	O
+.	O
+
+Insights	O
+into	O
+the	O
+structural	O
+characteristics	O
+of	O
+VP35	O
+and	O
+VP24	O
+domains	O
+revealed	O
+crucial	O
+pockets	O
+exploitable	O
+for	O
+drug	O
+development	B-PROC
+.	O
+
+S	O
+is	O
+the	O
+primary	O
+target	O
+for	O
+MERS	O
+-	O
+CoV	O
+vaccine	O
+and	O
+antibody	B-COMP
+development	B-PROC
+,	O
+and	O
+it	O
+has	O
+become	O
+increasingly	O
+important	O
+to	O
+understand	O
+MERS	O
+-	O
+CoV	O
+antibody	B-COMP
+binding	B-FUNC
+specificity	O
+and	O
+function	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+endemic	O
+diarrhea	B-DISO
+virus	B-DISO
+infection	I-DISO
+regulates	O
+long	O
+noncoding	O
+RNA	B-PROC
+expression	I-PROC
+.	O
+
+These	O
+findings	O
+provide	O
+the	O
+first	O
+large	O
+-	O
+scale	O
+survey	O
+of	O
+lncRNAs	O
+associated	O
+with	O
+PEDV	O
+infection	B-DISO
+,	O
+specifically	O
+the	O
+lncRNAs	O
+responsible	O
+for	O
+the	O
+activation	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+within	O
+the	O
+ileum	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+neutralization	I-PROC
+study	O
+using	O
+H120	O
+,	O
+H52	O
+,	O
+793	O
+/	O
+B	O
+antisera	O
+against	O
+Iranian	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+genotypes	O
+.	O
+
+Principally	O
+,	O
+the	O
+serotypes	O
+are	O
+identified	O
+by	O
+virus	B-PROC
+neutralization	I-PROC
+(	O
+VN	O
+)	O
+tests	O
+.	O
+
+The	O
+data	O
+are	O
+useful	O
+for	O
+the	O
+development	B-PROC
+of	O
+new	O
+vaccine	O
+strategies	O
+.	O
+
+Keywords	O
+:	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+;	O
+Iran	O
+;	O
+virus	B-PROC
+neutralization	I-PROC
+.	O
+
+Moreover	O
+,	O
+chickens	B-SPEC
+infected	O
+with	O
+the	O
+GD	O
+strain	O
+showed	O
+inefficient	O
+recovery	O
+of	O
+damaged	O
+cilia	B-COMP
+after	O
+infection	B-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+used	O
+low	O
+dose	O
+of	O
+TGEV	B-SPEC
+to	O
+infect	O
+p53	B-PRGE
+wild	I-PRGE
+-	I-PRGE
+type	I-PRGE
+PK	I-PRGE
+-	O
+15	O
+cells	B-COMP
+(	O
+WT	O
+PK	O
+-	O
+15	O
+cells	B-COMP
+)	O
+and	O
+p53	B-PRGE
+deficient	O
+cells	B-COMP
+(	O
+p53	B-PRGE
+-/-	I-PRGE
+PK	I-PRGE
+-	O
+15	O
+cells	B-COMP
+),	O
+to	O
+investigate	O
+the	O
+modulation	O
+of	O
+IFN	B-PRGE
+signaling	B-PROC
+and	O
+virus	B-PROC
+replication	I-PROC
+by	O
+p53	B-PRGE
+.	O
+
+Evidence	O
+-	O
+based	O
+management	O
+includes	O
+early	O
+administration	O
+of	O
+empiric	O
+antibiotics	B-CHED
+against	O
+plausible	O
+bacterial	O
+pathogens	O
+while	O
+awaiting	O
+results	O
+of	O
+microbiologic	O
+cultures	O
+.	O
+
+He	O
+was	O
+started	O
+on	O
+broad	O
+-	O
+spectrum	O
+antibiotics	B-CHED
+and	O
+was	O
+found	O
+to	O
+have	O
+septic	O
+thrombophlebitis	O
+of	O
+the	O
+left	B-ANAT
+internal	I-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+(	O
+Lemierre	B-DISO
+syndrome	I-DISO
+),	O
+with	O
+blood	B-ANAT
+cultures	O
+growing	O
+Fusobacterium	B-SPEC
+necrophorum	I-SPEC
+.	O
+
+He	O
+eventually	O
+developed	O
+bilateral	O
+empyemas	O
+growing	O
+Mycoplasma	B-SPEC
+hominis	I-SPEC
+.	O
+
+A	O
+subgroup	O
+analysis	O
+was	O
+also	O
+done	O
+based	O
+on	O
+the	O
+response	O
+to	O
+passive	O
+leg	B-ANAT
+raise	O
+(	O
+PLR	O
+).	O
+
+Critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+H1N1	O
+ARDS	B-DISO
+have	O
+increased	O
+risk	O
+of	O
+venous	B-ANAT
+thrombotic	O
+complications	O
+,	O
+particularly	O
+pulmonary	B-DISO
+thromboembolism	I-DISO
+.	O
+
+TITLE	O
+:	O
+Twitter	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+,	O
+South	O
+Korea	O
+,	O
+2015	O
+:	O
+A	O
+multi	O
+-	O
+lingual	B-ANAT
+study	O
+.	O
+
+Among	O
+the	O
+top	O
+30	O
+sources	O
+of	O
+retweets	O
+for	O
+each	O
+corpus	B-ANAT
+(	O
+150	O
+in	O
+total	O
+),	O
+70	O
+(	O
+46	O
+.	O
+7	O
+%)	O
+were	O
+media	B-ANAT
+;	O
+29	O
+(	O
+19	O
+.	O
+3	O
+%)	O
+were	O
+K	O
+-	O
+pop	O
+fans	O
+;	O
+7	O
+(	O
+4	O
+.	O
+7	O
+%)	O
+were	O
+political	O
+;	O
+9	O
+(	O
+6	O
+%)	O
+were	O
+medical	O
+;	O
+and	O
+35	O
+(	O
+23	O
+.	O
+3	O
+%)	O
+were	O
+categorized	O
+as	O
+'	O
+Others	O
+'.	O
+
+Furthermore	O
+,	O
+two	O
+recent	O
+clinical	O
+randomized	O
+,	O
+placebo	O
+-	O
+controlled	O
+pilot	O
+studies	O
+demonstrated	O
+that	O
+treatment	O
+of	O
+ARDS	B-DISO
+with	O
+MSCs	B-FUNC
+appears	O
+to	O
+be	O
+safe	O
+and	O
+feasible	O
+.	O
+
+Muse	B-CHED
+cells	B-COMP
+are	O
+stress	O
+-	O
+tolerant	O
+and	O
+non	O
+-	O
+tumorigenic	O
+endogenous	O
+pluripotent	O
+-	O
+like	O
+stem	B-ANAT
+cells	I-ANAT
+.	O
+
+Muse	B-CHED
+cells	B-COMP
+are	O
+known	O
+to	O
+migrate	O
+to	O
+the	O
+damaged	O
+tissue	B-ANAT
+after	O
+local	O
+or	O
+systemic	O
+administration	O
+,	O
+spontaneously	O
+differentiate	O
+into	O
+the	O
+tissue	B-ANAT
+-	O
+compatible	O
+cells	B-COMP
+,	O
+and	O
+also	O
+secrete	B-PROC
+factors	O
+related	O
+to	O
+immunomodulation	B-PROC
+and	O
+tissue	B-PROC
+repair	I-PROC
+.	O
+
+This	O
+study	O
+analyzed	O
+patients	O
+from	O
+the	O
+international	O
+prospective	O
+Large	O
+Observational	O
+Study	O
+to	O
+Understand	O
+the	O
+Global	O
+Impact	O
+of	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+(	O
+LUNG	B-ANAT
+SAFE	O
+)	O
+who	O
+had	O
+initial	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+first	O
+day	O
+of	O
+inclusion	O
+.	O
+
+This	O
+study	O
+defined	O
+three	O
+groups	O
+based	O
+on	O
+the	O
+evolution	B-PROC
+of	O
+severity	O
+in	O
+the	O
+first	O
+week	O
+:	O
+""""	O
+worsening	O
+""""	O
+if	O
+moderate	O
+or	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+criteria	O
+were	O
+met	B-CHED
+,	O
+""""	O
+persisting	O
+""""	O
+if	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+criteria	O
+were	O
+the	O
+most	O
+severe	O
+category	O
+,	O
+and	O
+""""	O
+improving	O
+""""	O
+if	O
+patients	O
+did	O
+not	O
+fulfill	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+criteria	O
+any	O
+more	O
+from	O
+day	O
+2	O
+.	O
+
+Among	O
+580	O
+patients	O
+with	O
+initial	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+18	O
+%	O
+(	O
+103	O
+of	O
+580	O
+)	O
+continuously	O
+improved	O
+,	O
+36	O
+%	O
+(	O
+210	O
+of	O
+580	O
+)	O
+had	O
+persisting	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+46	O
+%	O
+(	O
+267	O
+of	O
+580	O
+)	O
+worsened	O
+in	O
+the	O
+first	O
+week	O
+after	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+onset	O
+.	O
+
+Most	O
+patients	O
+with	O
+initial	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+continue	O
+to	O
+fulfill	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+criteria	O
+in	O
+the	O
+first	O
+week	O
+,	O
+and	O
+nearly	O
+half	O
+worsen	O
+in	O
+severity	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+580	O
+patients	O
+with	O
+initial	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+18	O
+%	O
+(	O
+103	O
+of	O
+580	O
+)	O
+continuously	O
+improved	O
+,	O
+36	O
+%	O
+(	O
+210	O
+of	O
+580	O
+)	O
+had	O
+persisting	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+46	O
+%	O
+(	O
+267	O
+of	O
+580	O
+)	O
+worsened	O
+in	O
+the	O
+first	O
+week	O
+after	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+onset	O
+.	O
+
+Prone	O
+position	O
+ventilation	O
+and	O
+bundle	O
+care	O
+were	O
+conducted	O
+as	O
+lung	B-ANAT
+protection	O
+ventilator	O
+strategy	O
+.	O
+
+Such	O
+outbreaks	O
+increase	O
+economic	O
+and	O
+infection	B-DISO
+control	O
+burdens	O
+.	O
+
+Other	O
+major	O
+threats	O
+to	O
+Singapore	O
+include	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+and	O
+various	O
+avian	B-SPEC
+and	O
+swine	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+The	O
+ability	O
+to	O
+quickly	O
+identify	O
+and	O
+robustly	O
+track	O
+such	O
+threats	O
+to	O
+initiate	O
+an	O
+early	O
+emergency	B-DISO
+response	O
+remains	O
+a	O
+significant	O
+challenge	O
+.	O
+
+Nine	O
+(	O
+10	O
+%)	O
+tested	O
+positive	O
+for	O
+adenovirus	B-DISO
+,	O
+four	O
+(	O
+4	O
+.	O
+5	O
+%)	O
+tested	O
+positive	O
+for	O
+respiratory	O
+syncytial	O
+virus	O
+type	O
+A	O
+,	O
+and	O
+one	O
+(	O
+1	O
+%)	O
+tested	O
+positive	O
+for	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+using	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+/	O
+PCR	O
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+time	O
+molecular	O
+evidence	O
+for	O
+any	O
+infectious	B-DISO
+respiratory	O
+agent	O
+has	O
+been	O
+collected	O
+from	O
+Singapore	O
+'	O
+s	O
+MRT	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+is	O
+the	O
+acute	O
+respiratory	O
+syndrome	B-DISO
+caused	O
+by	O
+betacoronavirus	B-SPEC
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+first	O
+case	O
+of	O
+this	O
+disease	O
+was	O
+reported	O
+from	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+.	O
+
+This	O
+virus	B-SPEC
+is	O
+lethal	O
+and	O
+is	O
+a	O
+close	O
+relative	O
+of	O
+a	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+which	O
+is	O
+responsible	O
+for	O
+more	O
+than	O
+3000	O
+deaths	B-PROC
+in	O
+2002	O
+-	O
+2003	O
+.	O
+
+The	O
+MERS	O
+-	O
+CoV	O
+is	O
+a	O
+RNA	O
+virus	B-SPEC
+with	O
+protein	B-CHED
+envelope	B-COMP
+.	O
+
+Eighty	O
+-	O
+nine	O
+consecutive	O
+patients	O
+affected	O
+with	O
+ARF	B-DISO
+on	O
+VV	O
+-	O
+ECMO	O
+from	O
+2008	O
+to	O
+2016	O
+were	O
+compared	O
+according	O
+to	O
+type	O
+of	O
+cannulation	O
+:	O
+older	O
+percutaneous	O
+cannula	B-SPEC
+(	O
+Standard	O
+group	O
+,	O
+52	O
+patients	O
+)	O
+and	O
+HLS	O
+The	O
+two	O
+study	O
+groups	O
+were	O
+comparable	O
+in	O
+terms	O
+of	O
+baseline	O
+characteristics	O
+[	O
+age	O
+,	O
+body	B-ANAT
+mass	O
+index	O
+(	O
+BMI	O
+),	O
+Simplified	O
+Acute	O
+Physiology	O
+Score	O
+(	O
+SAPS	O
+-	O
+II	O
+),	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+(	O
+SOFA	O
+),	O
+Predicting	O
+Death	O
+For	O
+Severe	O
+ARDS	B-DISO
+on	O
+VV	O
+-	O
+ECMO	O
+(	O
+PRESERVE	O
+)	O
+score	O
+]	O
+and	O
+ECMO	O
+management	O
+[	O
+median	O
+hematocrit	O
+(	O
+Htc	O
+),	O
+platelet	B-ANAT
+nadir	O
+,	O
+antithrombin	B-PRGE
+III	I-PRGE
+(	O
+AT	B-PRGE
+III	I-PRGE
+),	O
+heparin	B-CHED
+,	O
+activated	B-PRGE
+partial	I-PRGE
+thromboplastin	I-PRGE
+time	I-PRGE
+(	O
+APTT	O
+)].	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+characterize	O
+the	O
+influenza	B-DISO
+and	O
+other	O
+respiratory	O
+pathogens	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+assay	O
+.	O
+
+Among	O
+the	O
+influenza	B-PATH
+A	I-PATH
+-	O
+positive	O
+cases	O
+,	O
+25	O
+(	O
+20	O
+.	O
+8	O
+%)	O
+were	O
+A	O
+/	O
+H1N1	O
+pdm09	O
+and	O
+95	O
+(	O
+79	O
+.	O
+2	O
+%)	O
+were	O
+A	O
+/	O
+H3	O
+subtypes	O
+.	O
+
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+been	O
+a	O
+global	O
+public	O
+health	O
+threat	O
+with	O
+a	O
+high	O
+fatality	O
+rate	O
+and	O
+worldwide	O
+distribution	O
+.	O
+
+A	O
+major	O
+problem	O
+with	O
+neutralizing	O
+mAb	O
+therapy	O
+is	O
+mutant	B-DISO
+escape	O
+under	O
+selective	O
+pressure	O
+,	O
+which	O
+can	O
+be	O
+solved	O
+by	O
+combination	O
+of	O
+neutralizing	O
+mAbs	O
+targeting	B-PROC
+different	O
+epitopes	O
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+IBV	B-SPEC
+strain	O
+-	O
+specific	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+broad	O
+spectrum	O
+protection	O
+in	O
+layer	B-ANAT
+pullets	O
+primed	O
+with	O
+IBV	B-SPEC
+Massachusetts	O
+(	O
+Mass	O
+)	O
+and	O
+793B	O
+vaccines	O
+prior	O
+to	O
+injection	O
+of	O
+inactivated	O
+vaccine	O
+containing	O
+Mass	O
+antigen	B-CHED
+.	O
+
+Increased	O
+VN	O
+titres	O
+were	O
+recorded	O
+against	O
+the	O
+five	O
+IBV	B-SPEC
+challenge	O
+strains	O
+,	O
+with	O
+a	O
+significantly	O
+higher	O
+level	O
+of	O
+protection	O
+against	O
+drops	O
+in	O
+egg	B-ANAT
+production	O
+following	O
+challenge	O
+.	O
+
+However	O
+,	O
+recently	O
+,	O
+the	O
+pathologic	O
+features	O
+resembling	O
+human	B-SPEC
+PVOD	B-DISO
+were	O
+retrospectively	O
+described	O
+in	O
+post	O
+-	O
+mortem	O
+lung	B-ANAT
+samples	O
+of	O
+dogs	B-SPEC
+presenting	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+hypertension	I-DISO
+(	O
+PH	B-DISO
+),	O
+which	O
+suggests	O
+that	O
+PVOD	B-DISO
+contributes	O
+to	O
+an	O
+unknown	O
+percentage	O
+of	O
+cases	O
+with	O
+unexplained	O
+PH	B-DISO
+.	O
+
+Histopathology	O
+of	O
+the	O
+lungs	B-ANAT
+showed	O
+venous	B-ANAT
+and	O
+arterial	B-ANAT
+remodelling	O
+,	O
+segmental	O
+congestion	B-DISO
+of	O
+alveolar	B-ANAT
+capillaries	B-ANAT
+and	O
+foci	O
+of	O
+vascular	B-ANAT
+changes	O
+similar	O
+to	O
+human	B-SPEC
+pulmonary	B-DISO
+capillary	I-DISO
+hemangiomatosis	I-DISO
+,	O
+indicating	O
+that	O
+the	O
+dog	B-SPEC
+suffered	B-DISO
+from	O
+PVOD	B-DISO
+.	O
+
+Low	O
+-	O
+dose	O
+inhaled	B-PROC
+carbon	B-CHED
+monoxide	I-CHED
+(	O
+iCO	O
+)	O
+confers	O
+cytoprotection	B-PROC
+in	O
+preclinical	O
+models	O
+of	O
+sepsis	B-DISO
+and	O
+ARDS	B-DISO
+.	O
+
+Circulating	O
+mitochondrial	B-COMP
+DNA	I-COMP
+levels	O
+were	O
+reduced	O
+in	O
+iCO	O
+-	O
+treated	O
+participants	O
+compared	O
+with	O
+placebo	O
+-	O
+treated	O
+subjects	O
+.	O
+
+TITLE	O
+:	O
+Co	O
+-	O
+localization	B-PROC
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+dipeptidyl	O
+peptidase	O
+-	O
+4	O
+in	O
+the	O
+respiratory	O
+tract	O
+and	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+of	O
+pigs	B-SPEC
+and	O
+llamas	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+investigated	O
+the	O
+co	O
+-	O
+localization	B-PROC
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+its	O
+receptor	O
+dipeptidyl	O
+peptidase	B-PRGE
+-	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+)	O
+by	O
+immunohistochemistry	O
+(	O
+IHC	O
+)	O
+across	O
+respiratory	O
+and	O
+lymphoid	B-ANAT
+organs	I-ANAT
+of	O
+experimentally	O
+MERS	O
+-	O
+CoV	O
+infected	O
+pigs	B-SPEC
+and	O
+llamas	B-SPEC
+.	O
+
+Compared	O
+with	O
+neurotypical	O
+subjects	O
+,	O
+subjects	O
+with	O
+cognitive	B-DISO
+impairment	I-DISO
+were	O
+older	O
+(	O
+median	O
+,	O
+years	O
+,	O
+6	O
+.	O
+2	O
+vs	O
+1	O
+.	O
+4	O
+;	O
+P	O
+<	O
+.	O
+001	O
+)	O
+with	O
+more	O
+severe	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+40	O
+%	O
+vs	O
+33	O
+%;	O
+P	O
+=	O
+.	O
+009	O
+).	O
+
+Subjects	O
+with	O
+cognitive	B-DISO
+impairment	I-DISO
+had	O
+more	O
+documented	O
+iatrogenic	O
+withdrawal	B-DISO
+symptoms	I-DISO
+than	O
+neurotypical	O
+subjects	O
+.	O
+
+Additionally	O
+,	O
+our	O
+in	O
+vivo	O
+findings	O
+suggested	O
+that	O
+TRIM8	B-PRGE
+knockdown	O
+effectively	O
+attenuated	O
+LPS	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+nu	O
+decrease	O
+of	O
+lung	B-ANAT
+wet	O
+/	O
+dry	O
+(	O
+W	O
+/	O
+T	O
+)	O
+ratio	O
+,	O
+protein	B-CHED
+concentrations	O
+,	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+,	O
+myeloperoxidase	B-PRGE
+(	O
+MPO	B-FUNC
+)	O
+activity	O
+,	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+production	O
+and	O
+superoxide	B-PRGE
+dismutase	I-PRGE
+(	O
+SOD	B-FUNC
+)	O
+depletion	O
+.	O
+
+Together	O
+,	O
+our	O
+study	O
+firstly	O
+provided	O
+a	O
+support	O
+that	O
+TRIM8	B-PRGE
+knockdown	O
+effectively	O
+protected	O
+LPS	B-DISO
+-	O
+induced	O
+ALI	O
+against	O
+inflammation	B-DISO
+and	O
+oxidative	B-DISO
+stress	I-DISO
+largely	O
+dependent	O
+on	O
+the	O
+promotion	O
+of	O
+AMPKα	O
+pathway	B-PROC
+.	O
+
+TITLE	O
+:	O
+Profile	O
+analysis	O
+of	O
+circRNAs	O
+induced	O
+by	O
+porcine	B-SPEC
+endemic	O
+diarrhea	B-DISO
+virus	B-DISO
+infection	I-DISO
+in	O
+porcine	B-SPEC
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+functional	O
+annotation	O
+analysis	O
+revealed	O
+that	O
+the	O
+parent	O
+genes	O
+of	O
+differentially	O
+expressed	B-PROC
+circRNAs	O
+might	O
+be	O
+associated	O
+with	O
+host	B-PROC
+response	I-PROC
+to	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Serum	B-COMP
+sodium	O
+and	O
+urine	B-DISO
+output	I-DISO
+decreased	I-DISO
+and	O
+urine	B-ANAT
+osmolality	O
+increased	O
+after	O
+subcutaneous	O
+DDAVP	O
+administration	O
+.	O
+
+TITLE	O
+:	O
+Origin	O
+and	O
+evolution	B-PROC
+of	O
+pathogenic	O
+coronaviruses	O
+.	O
+
+Both	O
+viruses	B-SPEC
+likely	O
+originated	O
+in	O
+bats	B-SPEC
+,	O
+and	O
+genetically	O
+diverse	O
+coronaviruses	O
+that	O
+are	O
+related	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+were	O
+discovered	O
+in	O
+bats	B-SPEC
+worldwide	O
+.	O
+
+However	O
+,	O
+intratumoral	O
+activity	O
+was	O
+influenced	O
+by	O
+the	O
+number	O
+of	O
+TAT	B-ENZY
+peptides	B-CHED
+present	O
+.	O
+
+At	O
+200	O
+TAT	B-ENZY
+peptides	B-CHED
+,	O
+the	O
+preparation	O
+appeared	O
+to	O
+be	O
+least	O
+effective	O
+,	O
+which	O
+likely	O
+results	O
+from	O
+augmented	O
+interaction	O
+with	O
+tumor	B-ANAT
+cells	B-COMP
+directly	O
+upon	O
+extravasation	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+fatal	O
+complication	B-DISO
+of	O
+tirofiban	B-CHED
+in	O
+an	O
+octogenarian	O
+:	O
+Diffuse	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+.	O
+
+Ten	O
+minutes	O
+following	O
+tirofiban	B-CHED
+administration	O
+,	O
+the	O
+patient	O
+complained	O
+of	O
+hemoptysis	B-DISO
+and	O
+severe	O
+dyspnea	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+knowledge	O
+and	O
+attitude	O
+of	O
+senior	O
+medical	O
+,	O
+dental	O
+,	O
+nursing	B-PROC
+and	O
+pharmacy	O
+students	O
+toward	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+corona	B-CHED
+virus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+A	O
+portable	O
+oxygen	B-CHED
+concentrator	O
+has	O
+the	O
+advantage	O
+of	O
+operating	O
+solely	O
+from	O
+electrical	O
+power	O
+and	O
+theoretically	O
+is	O
+a	O
+never	O
+-	O
+exhausting	O
+supply	O
+of	O
+oxygen	B-CHED
+.	O
+
+Our	O
+previous	O
+bench	O
+work	O
+demonstrated	O
+that	O
+the	O
+pulsed	O
+dose	O
+setting	O
+of	O
+the	O
+concentrator	O
+can	O
+be	O
+used	O
+in	O
+concert	O
+with	O
+the	O
+ventilator	O
+to	O
+maximize	O
+oxygen	B-CHED
+delivery	O
+.	O
+
+The	O
+ventilator	O
+was	O
+modified	O
+to	O
+allow	O
+closed	O
+loop	O
+control	O
+of	O
+oxygen	O
+based	O
+on	O
+the	O
+oxygen	B-CHED
+saturation	O
+(	O
+SpO2	O
+)	O
+via	O
+the	O
+integral	O
+pulse	B-PROC
+oximetry	O
+sensor	O
+.	O
+
+It	O
+was	O
+a	O
+secondary	O
+analysis	O
+of	O
+data	O
+from	O
+randomized	O
+controlled	O
+trial	O
+that	O
+included	O
+patients	O
+with	O
+moderate	O
+/	O
+severe	O
+ARDS	B-DISO
+with	O
+at	O
+least	O
+one	O
+follow	O
+-	O
+up	O
+visit	O
+performed	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+of	O
+development	B-PROC
+of	O
+multi	O
+-	O
+epitope	B-CHED
+vaccine	O
+against	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+using	O
+in	O
+silico	O
+approach	O
+.	O
+
+The	O
+cDNAs	O
+of	O
+both	O
+MEVs	O
+were	O
+generated	O
+and	O
+analyzed	O
+in	O
+silico	O
+for	O
+their	O
+expression	B-PROC
+in	O
+a	O
+mammalian	B-SPEC
+host	B-COMP
+cell	I-COMP
+line	O
+(	O
+human	B-SPEC
+).	O
+
+The	O
+cDNA	O
+analysis	O
+of	O
+both	O
+the	O
+MEVs	O
+have	O
+shown	O
+high	O
+expression	B-PROC
+tendency	O
+in	O
+mammalian	B-SPEC
+host	B-COMP
+cell	I-COMP
+line	O
+(	O
+human	B-SPEC
+).	O
+
+After	O
+multistage	O
+in	O
+silico	O
+analysis	O
+,	O
+both	O
+the	O
+MEVs	O
+are	O
+predicted	O
+to	O
+elicit	O
+humoral	O
+as	O
+well	O
+as	O
+cell	B-PROC
+mediated	I-PROC
+immune	I-PROC
+response	I-PROC
+.	O
+
+ARDS	B-DISO
+was	O
+detected	O
+in	O
+10	O
+patients	O
+on	O
+enrolment	O
+and	O
+associated	O
+with	O
+90	O
+%	O
+case	O
+fatality	O
+.	O
+
+This	O
+study	O
+demonstrates	O
+the	O
+potential	O
+usefulness	O
+of	O
+point	O
+-	O
+of	O
+-	O
+care	O
+lung	B-ANAT
+ultrasound	O
+to	O
+detect	O
+lung	B-ANAT
+abnormalities	O
+in	O
+patients	O
+with	O
+malaria	B-PATH
+or	O
+sepsis	B-DISO
+in	O
+a	O
+resource	O
+-	O
+constrained	O
+hospital	O
+setting	O
+.	O
+
+TITLE	O
+:	O
+Combined	O
+use	O
+of	O
+ELISA	O
+and	O
+Western	O
+blot	O
+with	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+is	O
+a	O
+powerful	O
+tool	O
+for	O
+the	O
+immunodiagnosis	O
+of	O
+avian	O
+infectious	O
+bronchitis	O
+.	O
+
+WB	O
+confirmed	O
+all	O
+false	O
+negative	O
+sera	B-COMP
+in	O
+ELISA	O
+-	O
+rN	O
+or	O
+IDEXX	O
+test	O
+as	O
+truly	O
+positive	O
+.	O
+
+A	O
+total	O
+of	O
+389	O
+serum	B-COMP
+samples	O
+from	O
+chickens	B-SPEC
+were	O
+used	O
+to	O
+develop	O
+and	O
+evaluate	O
+the	O
+ELISA	O
+-	O
+rN	O
+test	O
+.	O
+
+Positive	O
+and	O
+negative	O
+sera	B-COMP
+for	O
+IBV	B-SPEC
+were	O
+used	O
+as	O
+controls	O
+.	O
+
+Sera	B-COMP
+that	O
+tested	O
+negative	O
+in	O
+the	O
+ELISA	O
+-	O
+rN	O
+and	O
+positive	O
+in	O
+the	O
+commercial	O
+test	O
+also	O
+reacted	O
+with	O
+the	O
+rN	B-PRGE
+protein	I-PRGE
+in	O
+Western	O
+blot	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+expected	O
+cDNA	O
+fragment	O
+of	O
+approximately	O
+1240	O
+bp	O
+was	O
+successfully	O
+amplified	O
+by	O
+PCR	O
+using	O
+primers	O
+designed	O
+to	O
+select	O
+for	O
+the	O
+coding	O
+region	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+Human	B-PRGE
+Sodium	B-CHED
+Iodide	I-CHED
+Symporter	I-PRGE
+as	O
+a	O
+Reporter	O
+Gene	O
+for	O
+Studying	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Pathogenesis	B-DISO
+.	O
+
+The	O
+human	B-PRGE
+sodium	B-CHED
+iodide	I-CHED
+symporter	I-PRGE
+(	O
+hNIS	B-PRGE
+),	O
+a	O
+SPECT	O
+and	O
+positron	B-CHED
+emission	B-ANAT
+tomography	O
+reporter	O
+gene	O
+,	O
+was	O
+inserted	O
+into	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+a	O
+recently	O
+emerged	O
+virus	B-SPEC
+that	O
+can	O
+cause	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+death	B-PROC
+in	O
+afflicted	O
+humans	B-SPEC
+to	O
+obtain	O
+a	O
+quantifiable	O
+and	O
+sensitive	O
+marker	O
+for	O
+viral	B-PROC
+replication	I-PROC
+to	O
+further	O
+MERS	O
+-	O
+CoV	O
+animal	B-SPEC
+model	O
+development	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+beginning	O
+of	O
+the	O
+2000s	O
+,	O
+globalization	O
+has	O
+accelerated	O
+because	O
+of	O
+the	O
+development	B-PROC
+of	O
+transportation	O
+systems	O
+that	O
+allow	O
+for	O
+human	B-SPEC
+and	O
+material	O
+exchanges	O
+throughout	O
+the	O
+world	O
+.	O
+
+However	O
+,	O
+this	O
+globalization	O
+has	O
+brought	O
+with	O
+it	O
+the	O
+rise	O
+of	O
+various	O
+pathogenic	O
+viral	O
+agents	O
+,	O
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+Zika	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+Dengue	B-SPEC
+virus	I-SPEC
+.	O
+
+T3	O
+has	O
+been	O
+reported	O
+in	O
+varied	O
+clinical	O
+settings	O
+to	O
+favorably	O
+affect	O
+cardiac	B-ANAT
+lusitropy	O
+,	O
+inotropy	O
+,	O
+and	O
+chronotropy	O
+without	O
+significant	O
+side	O
+effects	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+infections	I-DISO
+,	O
+especially	O
+those	O
+of	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+remain	O
+a	O
+foremost	O
+cause	O
+of	O
+mortality	O
+and	O
+morbidity	O
+of	O
+children	O
+greater	O
+than	O
+5	O
+years	O
+in	O
+developing	O
+countries	O
+including	O
+Pakistan	O
+.	O
+
+This	O
+paper	O
+aims	O
+to	O
+emphasise	O
+the	O
+need	O
+for	O
+standard	O
+methods	O
+to	O
+record	O
+the	O
+incidence	O
+and	O
+etiology	O
+of	O
+associated	O
+pathogens	O
+in	O
+order	B-SPEC
+to	O
+provide	O
+effective	O
+treatment	O
+against	O
+viral	B-DISO
+infections	I-DISO
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+to	O
+reduce	O
+death	B-PROC
+rates	O
+.	O
+
+TITLE	O
+:	O
+Globalization	O
+and	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+During	O
+2002	O
+-	O
+2003	O
+,	O
+a	O
+new	O
+coronavirus	B-SPEC
+,	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+was	O
+found	O
+to	O
+be	O
+the	O
+cause	O
+of	O
+an	O
+acute	O
+,	O
+severe	O
+frequently	O
+fatal	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+prominent	O
+systemic	O
+symptoms	O
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+).	O
+
+The	O
+outbreak	O
+originated	O
+in	O
+south	O
+-	O
+ern	O
+China	O
+,	O
+probably	O
+following	O
+transmission	O
+from	O
+an	O
+animal	B-SPEC
+in	O
+animal	B-SPEC
+markets	O
+or	O
+bats	B-SPEC
+to	O
+hu	O
+-	O
+mans	B-SPEC
+.	O
+
+The	O
+current	O
+global	O
+spread	O
+of	O
+hu	O
+-	O
+man	O
+infection	B-DISO
+by	O
+this	O
+subtype	O
+started	O
+in	O
+2003	O
+.	O
+
+Following	O
+outbreaks	O
+of	O
+highly	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+the	O
+past	O
+decades	O
+,	O
+hospital	O
+prepared	O
+-	O
+ness	O
+for	O
+travel	O
+-	O
+related	O
+infections	B-DISO
+focuses	O
+on	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+.	O
+
+Emerging	O
+viral	B-DISO
+pneumonias	I-DISO
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+H7N9	O
+are	O
+major	O
+concerns	O
+.	O
+
+TITLE	O
+:	O
+Onset	O
+of	O
+Takotsubo	B-DISO
+Syndrome	I-DISO
+during	O
+the	O
+Clinical	O
+Course	O
+of	O
+Anti	B-PRGE
+-	I-PRGE
+Neutrophil	B-ANAT
+Cytoplasmic	B-COMP
+Antibody	B-FUNC
+-	I-DISO
+Associated	I-DISO
+Vasculitis	I-DISO
+:	O
+A	O
+Case	O
+Report	O
+.	O
+
+A	O
+78	O
+-	O
+year	O
+-	O
+old	O
+Japanese	O
+woman	O
+presented	O
+with	O
+severe	O
+renal	B-ANAT
+dysfunction	O
+,	O
+which	O
+was	O
+diagnosed	O
+as	O
+MPO	B-FUNC
+-	O
+ANCA	B-PRGE
+-	O
+associated	O
+systemic	O
+vasculitis	B-DISO
+.	O
+
+Considering	O
+the	O
+present	O
+case	O
+and	O
+the	O
+previously	O
+reported	O
+coexisting	O
+cases	O
+of	O
+takotsubo	B-DISO
+syndrome	I-DISO
+and	O
+AAV	O
+,	O
+we	O
+propose	O
+that	O
+female	O
+sex	O
+,	O
+initiation	O
+of	O
+glucocorticoid	B-CHED
+therapy	O
+,	O
+and	O
+high	O
+titer	O
+of	O
+MPO	B-FUNC
+-	O
+ANCA	B-PRGE
+are	O
+potential	O
+risk	O
+factors	O
+of	O
+developing	O
+takotsubo	B-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+a	O
+novel	O
+infectious	B-DISO
+agent	O
+causing	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+death	B-PROC
+in	O
+humans	B-SPEC
+,	O
+was	O
+first	O
+described	O
+in	O
+2012	O
+.	O
+
+Antibodies	B-COMP
+directed	O
+against	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+are	O
+thought	O
+to	O
+play	O
+a	O
+major	O
+role	O
+in	O
+controlling	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+in	O
+mediating	O
+vaccine	O
+-	O
+induced	O
+protective	O
+immunity	B-PROC
+.	O
+
+Modified	O
+Vaccinia	B-SPEC
+virus	I-SPEC
+Ankara	O
+(	O
+MVA	B-CHED
+),	O
+a	O
+safety	O
+-	O
+tested	O
+strain	O
+of	O
+vaccinia	B-SPEC
+virus	I-SPEC
+for	O
+preclinical	O
+and	O
+clinical	O
+vaccine	O
+research	O
+,	O
+was	O
+used	O
+for	O
+generating	O
+MVA	B-CHED
+-	O
+MERS	O
+-	O
+N	O
+expressing	O
+recombinant	O
+N	O
+protein	B-CHED
+.	O
+
+In	O
+cases	O
+of	O
+severe	O
+aortic	B-DISO
+stenosis	B-SPEC
+,	O
+however	O
+,	O
+evidence	O
+of	O
+left	B-DISO
+ventricular	I-DISO
+outflow	I-DISO
+tract	I-DISO
+obstruction	I-DISO
+via	O
+both	O
+symptoms	O
+and	O
+echocardiographic	O
+findings	O
+may	O
+be	O
+minimized	O
+due	O
+to	O
+extremely	O
+high	O
+afterload	O
+on	O
+the	O
+left	B-ANAT
+ventricle	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+a	O
+non	O
+-	O
+prime	O
+site	O
+substituent	O
+and	O
+warheads	O
+combined	O
+with	O
+a	O
+decahydroisoquinolin	O
+scaffold	O
+as	O
+a	O
+SARS	B-PRGE
+3CL	I-PRGE
+protease	B-CHED
+inhibitor	I-CHED
+.	O
+
+This	O
+variant	O
+was	O
+located	O
+in	O
+the	O
+C3b	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+site	I-PRGE
+and	O
+functional	O
+tests	O
+revealed	O
+that	O
+it	O
+perturbed	O
+the	O
+regulatory	O
+activity	O
+of	O
+factor	O
+H	O
+.	O
+This	O
+case	O
+suggests	O
+that	O
+pertussis	B-PATH
+is	O
+a	O
+strong	O
+trigger	O
+of	O
+HUS	O
+and	O
+that	O
+complement	O
+investigations	O
+are	O
+necessary	O
+to	O
+guide	O
+treatment	O
+and	O
+understand	O
+the	O
+pathophysiology	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+tracer	B-CHED
+gas	B-ENZY
+was	O
+barely	O
+detected	O
+in	O
+a	O
+maternity	O
+ward	O
+to	O
+the	O
+south	O
+of	O
+room	O
+8104	O
+,	O
+where	O
+there	O
+was	O
+no	O
+secondary	O
+infected	O
+patient	O
+.	O
+
+Between	O
+the	O
+eight	O
+different	O
+influenza	B-DISO
+epidemics	O
+under	O
+study	O
+,	O
+the	O
+value	O
+of	O
+each	O
+of	O
+the	O
+severity	O
+parameters	O
+varied	O
+.	O
+
+Prospective	O
+syndromic	O
+ICU	O
+SARI	O
+surveillance	O
+,	O
+as	O
+proposed	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+,	O
+thereby	O
+would	O
+provide	O
+insight	O
+into	O
+the	O
+severity	O
+of	O
+ongoing	O
+influenza	B-DISO
+epidemics	O
+,	O
+which	O
+differ	O
+from	O
+season	O
+to	O
+season	O
+.	O
+
+ABSTRACT	O
+:	O
+Host	B-COMP
+factors	O
+render	O
+cells	B-ANAT
+susceptible	O
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+To	O
+understand	O
+the	O
+cytokine	O
+milieu	O
+and	O
+immune	B-PROC
+responses	I-PROC
+in	O
+infected	O
+host	B-COMP
+tissues	B-ANAT
+,	O
+non	O
+-	O
+human	B-SPEC
+primate	B-SPEC
+(	O
+NHP	O
+)	O
+models	O
+have	O
+emerged	O
+as	O
+important	O
+tools	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+Evidence	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+Cov	O
+)	O
+and	O
+Widespread	O
+Seroprevalence	O
+among	O
+Camels	O
+in	O
+Kenya	O
+.	O
+
+Further	O
+one	O
+-	O
+health	O
+surveillance	O
+approaches	O
+in	O
+camels	B-SPEC
+,	O
+wildlife	O
+,	O
+and	O
+human	B-SPEC
+populations	O
+are	O
+needed	O
+.	O
+
+We	O
+also	O
+compare	O
+the	O
+outcomes	O
+of	O
+ARDS	B-DISO
+in	O
+pregnant	O
+and	O
+non	O
+-	O
+pregnant	O
+females	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emerging	O
+avian	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+,	O
+a	O
+subtype	O
+of	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+was	O
+first	O
+discovered	O
+in	O
+March	O
+2013	O
+in	O
+China	O
+.	O
+
+A	O
+56	O
+-	O
+year	O
+-	O
+old	O
+female	O
+patient	O
+(	O
+case	O
+1	O
+)	O
+and	O
+a	O
+78	O
+-	O
+year	O
+-	O
+old	O
+female	O
+patient	O
+(	O
+case	O
+2	O
+)	O
+were	O
+admitted	O
+because	O
+of	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+chest	B-DISO
+tightness	I-DISO
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+have	O
+summarized	O
+some	O
+of	O
+the	O
+recent	O
+advancements	O
+made	O
+in	O
+the	O
+area	O
+of	O
+nucleic	B-CHED
+acid	I-CHED
+based	O
+therapeutics	O
+and	O
+highlighted	O
+the	O
+emerging	O
+roles	O
+of	O
+nucleic	B-CHED
+acids	I-CHED
+in	O
+the	O
+management	O
+of	O
+some	O
+of	O
+the	O
+severe	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Our	O
+investigation	O
+also	O
+revealed	O
+that	O
+patients	O
+with	O
+an	O
+HA	O
+-	O
+MERS	O
+infection	B-DISO
+experienced	O
+a	O
+significantly	O
+longer	O
+hospital	O
+stay	O
+and	O
+were	O
+more	O
+likely	O
+to	O
+die	O
+from	O
+the	O
+disease	O
+.	O
+
+The	O
+new	O
+classification	O
+of	O
+ventilator	O
+-	O
+associated	O
+events	O
+(	O
+VAE	O
+)	O
+proposed	O
+by	O
+the	O
+centers	O
+for	O
+disease	O
+control	O
+and	O
+prevention	O
+(	O
+CDC	O
+)	O
+enhance	O
+the	O
+spectra	O
+of	O
+complications	O
+due	O
+to	O
+MV	O
+including	O
+both	O
+infection	B-DISO
+-	O
+related	O
+and	O
+non	O
+-	O
+infectious	B-DISO
+events	O
+.	O
+
+Noninfective	O
+events	O
+explain	O
+up	O
+to	O
+30	O
+%	O
+of	O
+VAEs	O
+,	O
+the	O
+main	O
+causes	O
+being	O
+atelectasis	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+pulmonary	B-DISO
+embolism	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+significant	O
+drug	O
+pharmacokinetic	O
+modifications	O
+by	O
+the	O
+device	O
+may	O
+lead	O
+to	O
+low	O
+plasmatic	O
+antibiotic	B-CHED
+concentration	O
+and	O
+potential	O
+treatment	O
+failure	O
+.	O
+
+Additionally	O
+,	O
+confocal	O
+microscopy	O
+revealed	O
+that	O
+EIF4A2	B-PRGE
+and	O
+M	O
+were	O
+colocalized	O
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+44	O
+-	O
+year	O
+-	O
+old	O
+male	O
+with	O
+ongoing	O
+chest	B-DISO
+pain	I-DISO
+and	O
+left	B-PROC
+ventricular	I-PROC
+ejection	I-PROC
+fraction	O
+<	O
+20	O
+%	O
+was	O
+transferred	O
+from	O
+a	O
+peripheral	O
+hospital	O
+with	O
+intra	O
+-	O
+aortic	B-ANAT
+balloon	O
+pump	O
+placement	O
+following	O
+a	O
+non	O
+-	O
+ST	O
+-	O
+elevation	O
+myocardial	B-DISO
+infarction	I-DISO
+(	O
+STEMI	B-DISO
+).	O
+
+Due	O
+to	O
+clot	B-DISO
+formation	B-PROC
+,	O
+an	O
+oxygenator	O
+change	O
+-	O
+out	O
+was	O
+necessary	O
+shortly	O
+after	O
+initiation	O
+.	O
+
+On	O
+POD	O
+#	O
+24	O
+,	O
+the	O
+decision	O
+was	O
+made	O
+to	O
+implant	O
+a	O
+left	O
+ventricle	O
+assist	O
+device	O
+(	O
+LVAD	O
+)	O
+as	O
+a	O
+bridge	O
+to	O
+heart	B-ANAT
+transplantation	O
+.	O
+
+At	O
+the	O
+time	O
+of	O
+admission	O
+,	O
+headache	B-DISO
+(	O
+28	O
+.	O
+6	O
+%	O
+vs	O
+.	O
+3	O
+.	O
+6	O
+%;	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+10	O
+.	O
+60	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+22	O
+-	O
+92	O
+.	O
+27	O
+),	O
+myalgia	B-DISO
+(	O
+57	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+9	O
+.	O
+1	O
+%;	O
+OR	O
+,	O
+13	O
+.	O
+33	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+2	O
+.	O
+30	O
+-	O
+77	O
+.	O
+24	O
+),	O
+and	O
+diarrhea	B-DISO
+(	O
+57	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+14	O
+.	O
+5	O
+%;	O
+OR	O
+,	O
+7	O
+.	O
+83	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+47	O
+-	O
+41	O
+.	O
+79	O
+)	O
+were	O
+common	O
+among	O
+MERS	O
+-	O
+CoV	O
+-	O
+positive	O
+patients	O
+.	O
+
+Chest	B-ANAT
+radiography	O
+with	O
+diffuse	O
+bronchopneumonia	B-DISO
+was	O
+more	O
+frequent	O
+in	O
+MERS	O
+-	O
+CoV	O
+-	O
+positive	O
+patients	O
+than	O
+in	O
+negative	O
+patients	O
+(	O
+100	O
+%	O
+vs	O
+.	O
+62	O
+.	O
+5	O
+%;	O
+P	O
+=	O
+0	O
+.	O
+491	O
+).	O
+
+CoVs	O
+harboured	O
+by	O
+avian	B-SPEC
+species	B-SPEC
+are	O
+classified	O
+to	O
+the	O
+genera	O
+gamma	O
+-	O
+and	O
+deltacoronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Changing	O
+epidemiological	O
+patterns	O
+of	O
+HIV	B-DISO
+and	O
+AIDS	O
+in	O
+China	O
+in	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+era	B-CHED
+identified	O
+by	O
+the	O
+nationwide	O
+surveillance	O
+system	O
+.	O
+
+But	O
+the	O
+changing	O
+patterns	O
+of	O
+HIV	B-DISO
+and	O
+AIDS	O
+incidence	O
+based	O
+on	O
+the	O
+longitudinal	O
+observation	O
+data	O
+were	O
+rarely	O
+studied	O
+.	O
+
+A	O
+total	O
+of	O
+483	O
+,	O
+010	O
+newly	O
+HIV	B-DISO
+infections	I-DISO
+and	O
+214	O
+,	O
+205	O
+AIDS	O
+cases	O
+were	O
+reported	O
+between	O
+2004	O
+and	O
+2014	O
+nationwide	O
+.	O
+
+The	O
+relative	O
+increase	O
+for	O
+HIV	B-DISO
+and	O
+AIDS	O
+RI	O
+was	O
+higher	O
+in	O
+northwest	O
+provinces	O
+while	O
+lower	O
+in	O
+Henan	O
+,	O
+Xinjiang	O
+,	O
+Guangxi	O
+and	O
+Yunnan	O
+.	O
+
+HIV	B-DISO
+and	O
+AIDS	O
+showed	O
+an	O
+increasing	O
+trend	O
+in	O
+China	O
+from	O
+2004	O
+to	O
+2014	O
+,	O
+respectively	O
+,	O
+but	O
+the	O
+epidemic	O
+tended	O
+to	O
+be	O
+under	O
+control	O
+among	O
+provinces	O
+and	O
+young	O
+people	O
+that	O
+used	O
+to	O
+have	O
+a	O
+high	O
+HIV	B-DISO
+and	O
+AIDS	O
+incidence	O
+.	O
+
+The	O
+overall	O
+relative	O
+changes	O
+for	O
+HIV	B-PATH
+infection	I-PATH
+and	O
+AIDS	O
+incidence	O
+were	O
+1	O
+.	O
+11	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+1	O
+.	O
+10	O
+-	O
+1	O
+.	O
+13	O
+)	O
+and	O
+1	O
+.	O
+28	O
+(	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+23	O
+-	O
+1	O
+.	O
+33	O
+),	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Flail	O
+chest	O
+is	O
+considered	O
+as	O
+one	O
+of	O
+the	O
+most	O
+severe	O
+forms	O
+of	O
+blunt	O
+thoracic	B-DISO
+trauma	O
+.	O
+
+Patients	O
+with	O
+flail	B-DISO
+chest	I-DISO
+more	O
+often	O
+had	O
+lung	B-ANAT
+contusions	O
+(	O
+70	O
+vs	O
+.	O
+50	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+pneumo	O
+-/	O
+hematothorax	O
+(	O
+93	O
+vs	O
+.	O
+71	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+005	O
+).	O
+
+MK2	B-PRGE
+regulates	O
+the	O
+expression	B-PROC
+of	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+human	B-SPEC
+pulmonary	B-ANAT
+microvascular	O
+endothelial	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+mouse	B-SPEC
+lung	B-ANAT
+tissue	I-ANAT
+histopathology	O
+,	O
+wet	O
+/	O
+dry	O
+weight	O
+ratio	O
+(	O
+W	O
+/	O
+D	O
+),	O
+and	O
+the	O
+neutrophil	B-ANAT
+count	O
+were	O
+used	O
+to	O
+measure	O
+the	O
+severity	O
+of	O
+lung	B-ANAT
+inflammation	I-DISO
+in	O
+mice	O
+.	O
+
+The	O
+pulmonary	B-ANAT
+microvascular	O
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+PMVECs	O
+)	O
+of	O
+the	O
+mice	B-SPEC
+were	O
+isolated	O
+.	O
+
+The	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+mouse	B-SPEC
+PMVECs	O
+was	O
+determined	O
+using	O
+RT	O
+-	O
+PCR	O
+,	O
+and	O
+the	O
+protein	B-PROC
+expression	B-PROC
+of	O
+MK2	B-PRGE
+and	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+mouse	B-SPEC
+PMVECs	O
+was	O
+analyzed	O
+using	O
+Western	O
+blotting	O
+and	O
+immunohistochemistry	O
+.	O
+
+ABSTRACT	O
+:	O
+Enterovirus	B-SPEC
+D68	O
+(	O
+EV	O
+-	O
+D68	O
+)	O
+is	O
+a	O
+pathogen	O
+that	O
+causes	O
+outbreaks	O
+of	O
+respiratory	O
+illness	O
+across	O
+the	O
+world	O
+,	O
+mostly	O
+in	O
+children	O
+,	O
+and	O
+can	O
+be	O
+especially	O
+severe	O
+in	O
+those	O
+with	O
+asthma	O
+.	O
+
+TITLE	O
+:	O
+Prediction	O
+and	O
+evaluation	O
+of	O
+the	O
+severity	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+following	O
+severe	O
+acute	O
+pancreatitis	O
+using	O
+an	O
+artificial	O
+neural	B-PROC
+network	I-PROC
+algorithm	O
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+clinical	O
+value	O
+of	O
+immature	O
+granulocytes	B-ANAT
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+for	O
+prediction	O
+of	O
+persistent	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+)	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+AP	O
+).	O
+
+They	O
+replicate	O
+well	O
+in	O
+experimentally	O
+infected	O
+pigs	B-SPEC
+.	O
+
+The	O
+severity	O
+of	O
+diarrhea	O
+and	O
+intestinal	B-ANAT
+atrophy	B-DISO
+were	O
+similar	O
+between	O
+icPC22A	O
+and	O
+the	O
+coinfection	B-DISO
+groups	O
+,	O
+but	O
+were	O
+significantly	O
+higher	O
+than	O
+icPC22A	O
+-	O
+S1Δ197	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+route	O
+of	O
+inoculation	O
+on	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+to	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	B-DISO
+infection	I-DISO
+in	O
+suckling	O
+pigs	B-SPEC
+.	O
+
+Twenty	O
+-	O
+four	O
+conventional	O
+5	O
+-	O
+day	O
+-	O
+old	O
+suckling	O
+piglets	O
+were	O
+randomly	O
+divided	O
+into	O
+four	O
+groups	O
+and	O
+were	O
+inoculated	O
+orally	B-ANAT
+,	O
+intranasally	O
+(	O
+I	O
+.	O
+N	O
+.),	O
+intramuscularly	O
+(	O
+I	O
+.	O
+M	O
+.)	O
+with	O
+PEDV	B-SPEC
+or	O
+DMEM	O
+(	O
+mock	O
+).	O
+
+Serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+levels	O
+followed	O
+a	O
+similar	O
+pattern	O
+while	O
+the	O
+fold	O
+-	O
+change	O
+was	O
+much	O
+lower	O
+.	O
+
+TITLE	O
+:	O
+Spotted	B-DISO
+fever	I-DISO
+rickettsioses	O
+causing	O
+myocarditis	B-DISO
+and	O
+ARDS	B-DISO
+:	O
+a	O
+case	O
+from	O
+Sri	O
+Lanka	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+Rickettsial	O
+infections	B-DISO
+can	O
+present	O
+with	O
+diverse	O
+manifestations	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+a	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+outbreak	O
+event	O
+involving	O
+multiple	O
+healthcare	O
+facilities	O
+in	O
+Riyadh	O
+,	O
+Saudi	O
+Arabia	O
+;	O
+to	O
+characterize	O
+transmission	O
+;	O
+and	O
+to	O
+explore	O
+infection	B-DISO
+control	O
+implications	O
+.	O
+
+The	O
+patient	O
+arrived	O
+there	O
+on	O
+August	O
+16	O
+,	O
+2018	O
+,	O
+developed	O
+watery	B-DISO
+diarrhea	I-DISO
+on	O
+August	O
+28	O
+(	O
+day	O
+0	O
+),	O
+and	O
+came	O
+back	B-ANAT
+to	O
+Korea	O
+on	O
+September	O
+7	O
+(	O
+day	O
+10	O
+)	O
+as	O
+his	O
+condition	B-DISO
+worsened	O
+.	O
+
+Most	O
+pulmonary	B-DISO
+complications	I-DISO
+(	O
+over	O
+50	O
+%)	O
+occurred	O
+in	O
+sepsis	B-DISO
+-	O
+induced	O
+acute	O
+kidney	B-ANAT
+injury	O
+.	O
+
+Regarding	O
+the	O
+clinical	O
+aspects	O
+of	O
+pulmonary	B-DISO
+complications	I-DISO
+,	O
+the	O
+most	O
+frequent	O
+were	O
+ARDS	B-DISO
+,	O
+atelectasisand	O
+bronchopneumopathies	B-DISO
+,	O
+determined	O
+by	O
+the	O
+etiological	O
+factors	O
+that	O
+had	O
+caused	O
+the	O
+acute	O
+kidney	B-ANAT
+injury	O
+in	O
+the	O
+first	O
+place	O
+,	O
+and	O
+by	O
+the	O
+acute	O
+kidney	B-ANAT
+injury	O
+-	O
+induced	O
+physiological	B-PROC
+effects	I-PROC
+.	O
+
+Multivariate	O
+analysis	O
+identified	O
+low	O
+blood	B-ANAT
+pH	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+6	O
+.	O
+580	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+1	O
+.	O
+12	O
+-	O
+38	O
+.	O
+51	O
+),	O
+high	O
+serum	B-COMP
+lactate	B-CHED
+level	O
+(	O
+OR	O
+1	O
+.	O
+041	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+01	O
+-	O
+1	O
+.	O
+07	O
+),	O
+high	O
+ISS	B-DISO
+(	O
+OR	O
+1	O
+.	O
+109	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+06	O
+-	O
+1	O
+.	O
+16	O
+),	O
+high	O
+APACHE	O
+II	O
+score	O
+(	O
+OR	O
+1	O
+.	O
+189	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+07	O
+-	O
+1	O
+.	O
+33	O
+),	O
+traumatic	O
+brain	B-ANAT
+injury	O
+(	O
+TBI	O
+)	O
+(	O
+OR	O
+4	O
+.	O
+358	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+76	O
+-	O
+24	O
+.	O
+86	O
+),	O
+severe	O
+hemorrhage	B-DISO
+(	O
+OR	O
+5	O
+.	O
+314	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+07	O
+-	O
+26	O
+.	O
+49	O
+),	O
+and	O
+coagulopathy	B-DISO
+(	O
+OR	O
+5	O
+.	O
+916	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+17	O
+-	O
+29	O
+.	O
+90	O
+)	O
+as	O
+useful	O
+predictors	O
+of	O
+acute	O
+in	O
+-	O
+hospital	O
+mortality	O
+.	O
+
+High	O
+ISS	O
+(	O
+OR	O
+1	O
+.	O
+047	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+02	O
+-	O
+1	O
+.	O
+08	O
+),	O
+TBI	O
+(	O
+OR	O
+8	O
+.	O
+922	O
+,	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+57	O
+-	O
+31	O
+.	O
+00	O
+),	O
+sepsis	B-DISO
+(	O
+OR	O
+4	O
+.	O
+956	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+99	O
+-	O
+12	O
+.	O
+36	O
+),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+(	O
+OR	O
+8	O
+.	O
+036	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+85	O
+-	O
+34	O
+.	O
+84	O
+),	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+OR	O
+9	O
+.	O
+630	O
+,	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+64	O
+-	O
+35	O
+.	O
+14	O
+),	O
+renal	B-DISO
+failure	I-DISO
+(	O
+OR	O
+74	O
+.	O
+803	O
+,	O
+95	O
+%	O
+CI	O
+11	O
+.	O
+34	O
+-	O
+493	O
+.	O
+43	O
+),	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+[	O
+MOF	B-DISO
+]	O
+(	O
+OR	O
+10	O
+.	O
+415	O
+,	O
+95	O
+%	O
+CI	O
+4	O
+.	O
+48	O
+-	O
+24	O
+.	O
+24	O
+)	O
+were	O
+risk	O
+factors	O
+for	O
+late	O
+in	O
+-	O
+hospital	O
+mortality	O
+.	O
+
+We	O
+observed	O
+a	O
+complete	O
+loss	O
+of	O
+9	O
+-	O
+O	O
+-	O
+acetylation	B-PROC
+of	O
+sialic	B-CHED
+acid	I-CHED
+on	O
+the	O
+surface	O
+of	O
+myeloid	O
+,	O
+erythroid	O
+and	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+in	O
+Casd1	B-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+.	O
+
+Although	O
+9	O
+-	O
+O	O
+-	O
+acetylation	B-PROC
+of	O
+sialic	B-CHED
+acids	I-CHED
+on	O
+multiple	O
+hematopoietic	O
+lineages	O
+was	O
+lost	B-CHED
+,	O
+there	O
+were	O
+no	O
+obvious	O
+defects	O
+in	O
+hematopoiesis	B-PROC
+.	O
+
+Interestingly	O
+,	O
+erythrocytes	B-ANAT
+from	O
+Casd1	B-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+also	O
+lost	B-CHED
+reactivity	O
+to	O
+TER	B-PRGE
+-	I-PRGE
+119	I-PRGE
+,	O
+a	O
+rat	B-SPEC
+monoclonal	O
+antibody	B-COMP
+that	O
+is	O
+widely	O
+used	O
+to	O
+mark	O
+the	O
+murine	B-SPEC
+erythroid	O
+lineage	O
+.	O
+
+The	O
+sialic	B-CHED
+acid	I-CHED
+glyco	O
+-	O
+epitope	B-CHED
+recognized	O
+by	O
+TER	B-COMP
+-	O
+119	O
+on	O
+erythrocytes	B-ANAT
+was	O
+sensitive	O
+to	O
+the	O
+sialic	B-PRGE
+acid	I-PRGE
+O	I-PRGE
+-	I-PRGE
+acetyl	B-CHED
+esterase	B-FUNC
+activity	I-FUNC
+of	O
+the	O
+hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+from	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+but	O
+not	O
+to	O
+the	O
+corresponding	O
+enzyme	O
+from	O
+the	O
+influenza	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+several	O
+reports	O
+suggest	O
+that	O
+the	O
+entry	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+depends	O
+on	O
+lipid	B-COMP
+rafts	I-COMP
+and	O
+low	O
+pH	O
+,	O
+the	O
+endocytic	O
+route	O
+and	O
+intracellular	B-COMP
+trafficking	B-PROC
+are	O
+unclear	O
+.	O
+
+in	O
+late	B-COMP
+endosome	I-COMP
+/	O
+lysosome	B-COMP
+.	O
+
+The	O
+discovery	O
+and	O
+exploitation	O
+of	O
+oil	O
+and	O
+gas	B-ENZY
+led	O
+to	O
+a	O
+5	O
+-	O
+fold	O
+increase	O
+in	O
+Qatar	O
+GDP	B-CHED
+coupled	O
+with	O
+a	O
+7	O
+-	O
+fold	O
+population	O
+growth	B-PROC
+in	O
+the	O
+past	O
+30	O
+years	O
+.	O
+
+Methemoglobinemia	B-DISO
+and	O
+hemolysis	B-DISO
+are	O
+known	O
+side	O
+effects	O
+of	O
+rasburicase	O
+that	O
+result	O
+from	O
+oxidative	B-DISO
+stress	I-DISO
+caused	O
+by	O
+hydrogen	B-CHED
+peroxide	I-CHED
+,	O
+a	O
+byproduct	O
+generated	O
+during	O
+the	O
+breakdown	B-DISO
+of	O
+uric	B-CHED
+acid	I-CHED
+to	O
+allantoin	B-CHED
+.	O
+
+He	O
+also	O
+had	O
+a	O
+discrepancy	O
+of	O
+the	O
+transcutaneous	O
+saturation	O
+(	O
+75	O
+%)	O
+and	O
+the	O
+saturation	O
+in	O
+an	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+value	O
+(	O
+99	O
+%).	O
+
+His	O
+methemoglobin	B-PRGE
+level	O
+was	O
+found	O
+to	O
+be	O
+11	O
+.	O
+9	O
+%.	O
+
+The	O
+most	O
+recent	O
+randomized	O
+clinical	O
+trial	O
+,	O
+Conventional	O
+Ventilation	O
+or	O
+ECMO	O
+for	O
+Severe	O
+Adult	O
+Respiratory	B-DISO
+Failure	I-DISO
+(	O
+CESAR	O
+),	O
+showed	O
+a	O
+significant	O
+mortality	O
+reduction	O
+in	O
+ARDS	B-DISO
+patients	O
+who	O
+were	O
+treated	O
+with	O
+ECMO	O
+[	O
+Peek	B-CHED
+2009	O
+].	O
+
+The	O
+results	O
+of	O
+the	O
+trial	O
+have	O
+led	O
+some	O
+to	O
+believe	O
+that	O
+the	O
+widespread	O
+adoption	O
+of	O
+ECMO	O
+as	O
+a	O
+feasible	O
+treatment	O
+for	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+is	O
+forthcoming	O
+[	O
+MacLaren	O
+2012	O
+;	O
+Del	O
+Sorbo	O
+2014	O
+].	O
+
+ABSTRACT	O
+:	O
+Influenza	B-SPEC
+viruses	I-SPEC
+infect	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+system	I-ANAT
+,	O
+causing	O
+usually	O
+a	O
+self	O
+-	O
+limited	O
+disease	O
+with	O
+mild	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+,	O
+pulmonary	B-ANAT
+microvascular	O
+leakage	B-DISO
+and	O
+cardiovascular	B-DISO
+collapse	I-DISO
+may	O
+occur	O
+in	O
+severe	O
+cases	O
+,	O
+usually	O
+in	O
+the	O
+elderly	O
+or	O
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+However	O
+,	O
+the	O
+main	O
+clinical	O
+devastating	O
+effects	O
+are	O
+caused	O
+by	O
+endothelial	B-DISO
+dysfunction	I-DISO
+,	O
+thought	O
+to	O
+be	O
+the	O
+main	O
+mechanism	O
+leading	O
+to	O
+pulmonary	B-DISO
+oedema	I-DISO
+,	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+cardiovascular	B-DISO
+collapse	I-DISO
+.	O
+
+The	O
+incidence	O
+of	O
+admission	O
+due	O
+to	O
+AMI	B-DISO
+during	O
+an	O
+acute	O
+viral	B-DISO
+infection	I-DISO
+was	O
+six	O
+times	O
+as	O
+high	O
+during	O
+the	O
+7	O
+days	O
+after	O
+laboratory	O
+confirmation	O
+of	O
+influenza	B-DISO
+infection	B-DISO
+as	O
+during	O
+the	O
+control	O
+interval	O
+(	O
+10	O
+-	O
+fold	O
+in	O
+influenza	B-DISO
+B	O
+,	O
+5	O
+-	O
+fold	O
+in	O
+influenza	B-PATH
+A	I-PATH
+,	O
+3	O
+.	O
+5	O
+-	O
+fold	O
+in	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+2	O
+.	O
+7	O
+-	O
+fold	O
+for	O
+all	O
+other	O
+viruses	B-SPEC
+).	O
+
+In	O
+other	O
+words	O
+,	O
+both	O
+T1	O
+PHQ	O
+-	O
+9	O
+and	O
+T2	O
+PHQ	O
+-	O
+9	O
+fully	O
+mediated	O
+the	O
+relationship	O
+between	O
+T1	O
+FSS	B-DISO
+and	O
+T2	O
+IES	B-CHED
+.	O
+
+The	O
+characteristics	O
+of	O
+this	O
+cohort	O
+of	O
+patients	O
+,	O
+including	O
+the	O
+risk	O
+of	O
+bleeding	B-DISO
+and	O
+the	O
+need	O
+for	O
+systemic	O
+anticoagulation	B-PROC
+,	O
+are	O
+generally	O
+considered	O
+as	O
+relative	O
+contraindications	O
+to	O
+ECMO	O
+treatment	O
+.	O
+
+The	O
+recent	O
+findings	O
+suggest	O
+that	O
+venous	B-ANAT
+-	O
+venous	B-ANAT
+ECMO	O
+can	O
+be	O
+feasible	O
+in	O
+the	O
+treatment	O
+of	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+trauma	O
+-	O
+related	O
+.	O
+
+MERS	O
+is	O
+caused	O
+by	O
+a	O
+novel	O
+betacoronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+Interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+acts	O
+as	O
+a	O
+mediator	O
+between	O
+pro	B-CHED
+-	O
+and	O
+anti	O
+-	O
+inflammatory	O
+reactivity	O
+by	O
+initiating	O
+trans	O
+-	O
+and	O
+classical	O
+-	O
+signaling	B-PROC
+,	O
+respectively	O
+.	O
+
+This	O
+ncRNA	B-DISO
+consists	O
+of	O
+563	O
+nucleotides	B-CHED
+excluding	O
+a	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+,	O
+is	O
+mainly	O
+derived	O
+from	O
+the	O
+3	O
+'-	O
+untranslated	O
+region	O
+of	O
+IBV	B-SPEC
+genome	O
+,	O
+and	O
+contains	O
+a	O
+63	O
+-	O
+nt	O
+-	O
+long	O
+of	O
+terminal	O
+leader	O
+sequence	O
+derived	O
+from	O
+the	O
+5	O
+'	O
+end	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+However	O
+,	O
+with	O
+the	O
+exception	O
+of	O
+neuraminidase	B-PROC
+inhibitors	I-PROC
+for	O
+influenza	B-PATH
+infection	B-DISO
+,	O
+there	O
+are	O
+no	O
+accepted	O
+treatments	O
+.	O
+
+Multiple	O
+two	O
+-	O
+mode	O
+networks	O
+with	O
+swine	B-SPEC
+herds	O
+and	O
+service	O
+suppliers	O
+were	O
+constructed	O
+.	O
+
+Network	O
+descriptive	O
+measures	O
+,	O
+as	O
+well	O
+as	O
+the	O
+results	O
+of	O
+the	O
+hypotheses	O
+testing	O
+indicate	O
+little	O
+significance	O
+in	O
+the	O
+roles	O
+of	O
+animal	B-SPEC
+movement	B-PROC
+,	O
+animal	B-SPEC
+transportation	O
+companies	O
+,	O
+and	O
+semen	B-ANAT
+suppliers	O
+during	O
+the	O
+initial	O
+phase	O
+of	O
+the	O
+2014	O
+Canadian	O
+PED	O
+outbreak	O
+.	O
+
+Polymerase	B-PRGE
+δ	I-PRGE
+-	I-PRGE
+interacting	I-PRGE
+protein	I-PRGE
+2	I-PRGE
+(	O
+Poldip2	B-PRGE
+)	O
+is	O
+a	O
+novel	O
+regulator	O
+of	O
+blood	B-PROC
+-	I-PROC
+brain	I-PROC
+barrier	I-PROC
+permeability	O
+;	O
+however	O
+,	O
+its	O
+role	O
+in	O
+regulating	O
+lung	B-ANAT
+permeability	O
+and	O
+vascular	B-DISO
+inflammation	I-DISO
+is	O
+unknown	O
+.	O
+
+Moreover	O
+,	O
+reduced	O
+Poldip2	B-PRGE
+-	O
+suppressed	O
+LP	O
+-	O
+induced	O
+vascular	B-PRGE
+cell	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+(	O
+VCAM	B-PRGE
+)-	O
+1	O
+induction	O
+,	O
+leukocyte	B-ANAT
+recruitment	B-DISO
+,	O
+and	O
+mitochondrial	B-ANAT
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+production	O
+
+TITLE	O
+:	O
+Production	O
+of	O
+porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+pAPN	O
+)	O
+site	O
+-	O
+specific	O
+edited	O
+pigs	B-SPEC
+.	O
+
+We	O
+evaluated	O
+different	O
+thresholds	O
+for	O
+patient	O
+'	O
+s	O
+age	O
+,	O
+PaO2	O
+/	O
+FIO2	O
+,	O
+plateau	O
+pressure	O
+,	O
+and	O
+number	O
+of	O
+extrapulmonary	O
+organ	B-ANAT
+failures	O
+to	O
+predict	O
+ICU	O
+outcome	O
+at	O
+24	O
+hours	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+diagnosis	O
+.	O
+
+Combined	O
+thresholds	O
+for	O
+patient	O
+'	O
+s	O
+age	O
+,	O
+PaO2	O
+/	O
+FIO2	O
+,	O
+plateau	O
+pressure	O
+,	O
+and	O
+extrapulmonary	O
+organ	B-DISO
+failure	I-DISO
+provides	O
+prognostic	O
+enrichment	O
+accuracy	O
+for	O
+stratifying	O
+and	O
+selecting	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+for	O
+randomized	O
+controlled	O
+trials	O
+.	O
+
+Two	O
+patients	O
+suffered	B-DISO
+postpartum	B-DISO
+hemorrhage	I-DISO
+despite	O
+the	O
+management	O
+.	O
+
+Five	O
+out	O
+of	O
+six	O
+newborns	O
+required	O
+hospitalization	O
+,	O
+three	O
+of	O
+them	O
+due	O
+to	O
+neonatal	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Comprehensive	O
+treatment	O
+including	O
+fluids	B-ANAT
+resuscitation	O
+and	O
+uterine	B-ANAT
+inhibition	B-PROC
+in	O
+pregnant	O
+women	O
+with	O
+severe	O
+dengue	B-DISO
+in	O
+preterm	O
+or	O
+term	O
+labor	B-PROC
+could	O
+be	O
+useful	O
+.	O
+
+We	O
+concluded	O
+that	O
+although	O
+tocolysis	O
+is	O
+not	O
+regularly	O
+used	O
+in	O
+patients	O
+with	O
+dengue	B-DISO
+fever	I-DISO
+,	O
+our	O
+results	O
+suggest	O
+that	O
+our	O
+protocol	O
+could	O
+benefit	O
+pregnant	O
+patients	O
+with	O
+thrombocytopenia	O
+due	O
+to	O
+dengue	B-DISO
+;	O
+however	O
+,	O
+prospective	O
+studies	O
+which	O
+determine	O
+the	O
+safety	O
+and	O
+effectiveness	O
+of	O
+our	O
+intervention	O
+are	O
+needed	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Comprehensive	O
+treatment	O
+including	O
+fluids	B-ANAT
+resuscitation	O
+and	O
+uterine	B-ANAT
+inhibition	B-PROC
+in	O
+pregnant	O
+women	O
+with	O
+severe	O
+dengue	B-DISO
+in	O
+preterm	O
+or	O
+term	O
+labor	B-PROC
+could	O
+be	O
+useful	O
+.	O
+
+Several	O
+animal	B-SPEC
+models	O
+have	O
+been	O
+established	O
+to	O
+study	O
+disease	O
+pathogenesis	B-DISO
+and	O
+to	O
+develop	O
+vaccines	O
+and	O
+therapeutic	O
+agents	O
+.	O
+
+On	O
+day	O
+5	O
+or	O
+7	O
+postinoculation	O
+,	O
+lungs	B-ANAT
+of	O
+adult	O
+Tg	O
+mice	B-SPEC
+contained	O
+higher	O
+levels	O
+of	O
+proinflammatory	O
+cytokines	O
+and	O
+chemokines	O
+associated	O
+with	O
+migration	B-PROC
+of	O
+macrophages	B-ANAT
+.	O
+
+A	O
+72	O
+-	O
+year	O
+-	O
+old	O
+male	O
+was	O
+referred	O
+to	O
+the	O
+respiratory	O
+intensive	O
+care	O
+unit	O
+for	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+At	O
+discharge	B-ANAT
+,	O
+major	O
+improvements	O
+were	O
+observed	O
+for	O
+upper	B-ANAT
+limb	I-ANAT
+activities	O
+.	O
+
+Herein	O
+,	O
+we	O
+describe	O
+adjunctive	O
+extended	O
+therapeutic	O
+hypothermia	O
+for	O
+refractory	O
+hypoxemia	O
+despite	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+successful	O
+management	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+secondary	O
+to	O
+Legionella	B-SPEC
+.	O
+
+Horses	B-SPEC
+were	O
+divided	O
+into	O
+3	O
+groups	O
+based	O
+on	O
+fecal	B-ANAT
+diagnostic	O
+test	O
+results	O
+:	O
+ECoV	O
+-	O
+positive	O
+,	O
+Salmonella	B-DISO
+-	O
+positive	O
+,	O
+or	O
+unknown	O
+diagnosis	O
+(	O
+UNK	O
+).	O
+
+ABSTRACT	O
+:	O
+Positive	O
+-	O
+sense	O
+RNA	O
+viruses	B-SPEC
+hijack	O
+intracellular	B-COMP
+membranes	B-ANAT
+that	O
+provide	O
+niches	O
+for	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+a	O
+platform	O
+for	O
+interactions	O
+with	O
+host	B-COMP
+proteins	B-CHED
+.	O
+
+Notably	O
+,	O
+detection	O
+of	O
+translation	B-PROC
+initiation	I-PROC
+factors	O
+at	O
+the	O
+RTC	O
+was	O
+instrumental	O
+to	O
+visualize	O
+and	O
+demonstrate	O
+active	O
+translation	B-PROC
+proximal	O
+to	O
+replication	O
+complexes	O
+of	O
+several	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+speculated	O
+to	O
+be	O
+reservoirs	O
+of	O
+several	O
+emerging	O
+viruses	B-SPEC
+including	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+that	O
+cause	O
+serious	O
+disease	O
+in	O
+humans	B-SPEC
+and	O
+agricultural	O
+animals	B-SPEC
+.	O
+
+We	O
+hope	O
+that	O
+this	O
+review	O
+will	O
+enable	O
+readers	O
+to	O
+identify	O
+gaps	O
+in	O
+knowledge	O
+that	O
+currently	O
+exist	O
+and	O
+initiate	O
+a	O
+dialogue	O
+amongst	O
+bat	B-ENZY
+researchers	O
+to	O
+share	O
+resources	O
+to	O
+overcome	O
+present	O
+limitations	O
+.	O
+
+We	O
+found	O
+that	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+induced	I-DISO
+pyroptosis	B-PROC
+and	O
+over	O
+-	O
+activation	O
+of	O
+complement	O
+in	O
+human	B-SPEC
+macrophages	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+Whole	O
+-	O
+Virus	B-SPEC
+ELISA	O
+for	O
+Serological	O
+Evaluation	O
+of	O
+Domestic	O
+Livestock	O
+as	O
+Possible	O
+Hosts	O
+of	O
+Human	B-PRGE
+Coronavirus	I-PRGE
+NL63	I-PRGE
+.	O
+
+We	O
+developed	O
+a	O
+testing	O
+algorithm	O
+for	O
+high	O
+throughput	O
+screening	O
+of	O
+livestock	O
+sera	B-COMP
+with	O
+ELISA	O
+and	O
+confirmation	O
+with	O
+recombinant	O
+immunofluorescence	O
+assay	O
+testing	O
+for	O
+antibodies	B-COMP
+against	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+in	O
+livestock	O
+.	O
+
+In	O
+the	O
+United	O
+States	O
+,	O
+inactivated	O
+and	O
+subunit	O
+PEDV	B-SPEC
+vaccines	O
+for	O
+pregnant	O
+sows	O
+are	O
+available	O
+,	O
+but	O
+fail	O
+to	O
+induce	O
+sufficient	O
+protection	O
+in	O
+neonatal	O
+piglets	O
+farrowed	O
+from	O
+PEDV	B-SPEC
+naïve	O
+sows	O
+.	O
+
+PEDV	B-SPEC
+PC22A	O
+P100C4	O
+and	O
+P120	B-PRGE
+were	O
+fully	O
+attenuated	O
+in	O
+weaned	B-PROC
+pigs	B-SPEC
+but	O
+failed	O
+to	O
+elicit	O
+protection	O
+against	O
+virulent	O
+P3	O
+challenge	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+were	O
+analyzed	O
+by	O
+multiplex	O
+real	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+,	O
+for	O
+18	O
+viruses	B-SPEC
+and	O
+3	O
+bacteria	B-SPEC
+(	O
+H	B-SPEC
+.	I-SPEC
+influenzae	I-SPEC
+type	O
+b	O
+,	O
+C	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+).	O
+
+Moreover	O
+,	O
+using	O
+time	O
+-	O
+of	O
+-	O
+addition	O
+assays	O
+and	O
+RT	O
+-	O
+qPCR	O
+,	O
+we	O
+found	O
+that	O
+delayed	O
+addition	O
+of	O
+Griffithsin	O
+had	O
+a	O
+weaker	O
+inhibitory	O
+effect	O
+on	O
+PEDV	B-SPEC
+than	O
+earlier	O
+treatment	O
+.	O
+
+Six	O
+adults	O
+had	O
+polyomavirus	B-DISO
+infection	I-DISO
+and	O
+four	O
+(	O
+1	O
+.	O
+6	O
+%)	O
+had	O
+monoinfection	O
+.	O
+
+TITLE	O
+:	O
+Gonadal	B-ANAT
+pathogenicity	O
+of	O
+an	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strain	O
+from	O
+the	O
+Massachusetts	O
+genotype	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+we	O
+observed	O
+ovarian	B-ANAT
+and	O
+testicle	B-ANAT
+lesions	O
+.	O
+
+Consecutive	O
+children	O
+with	O
+Guillain	O
+Barré	O
+syndrome	B-DISO
+were	O
+recruited	O
+to	O
+compare	O
+the	O
+clinical	O
+profile	O
+and	O
+short	O
+term	O
+outcome	O
+among	O
+the	O
+subtypes	O
+.	O
+
+Tidal	O
+volume	O
+was	O
+calculated	O
+based	O
+on	O
+actual	O
+body	B-ANAT
+weight	O
+and	O
+two	O
+different	O
+formulations	O
+of	O
+ideal	O
+body	B-ANAT
+weight	O
+.	O
+
+Tidal	O
+volume	O
+,	O
+based	O
+on	O
+both	O
+actual	O
+body	B-ANAT
+weight	O
+and	O
+ideal	O
+body	B-ANAT
+weight	O
+,	O
+was	O
+not	O
+associated	O
+with	O
+either	O
+increased	O
+mortality	O
+or	O
+decreased	O
+probability	O
+of	O
+extubation	O
+after	O
+adjusting	O
+for	O
+oxygenation	B-PROC
+index	O
+in	O
+the	O
+whole	O
+cohort	O
+,	O
+whereas	O
+associations	O
+between	O
+higher	O
+tidal	O
+volume	O
+and	O
+poor	O
+outcomes	O
+were	O
+seen	O
+in	O
+subgroup	O
+analyses	O
+in	O
+overweight	B-DISO
+children	O
+and	O
+in	O
+severe	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Our	O
+retrospective	O
+analysis	O
+of	O
+a	O
+cohort	O
+of	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+did	O
+not	O
+find	O
+a	O
+consistent	O
+association	O
+between	O
+tidal	O
+volume	O
+adjusted	O
+for	O
+ideal	O
+body	B-ANAT
+weight	O
+and	O
+outcomes	O
+,	O
+although	O
+an	O
+association	O
+may	O
+exist	O
+in	O
+certain	O
+subgroups	O
+.	O
+
+Both	O
+patients	O
+presented	O
+with	O
+a	O
+chief	O
+complaint	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+and	O
+were	O
+previously	O
+diagnosed	O
+with	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+(	O
+IPF	O
+).	O
+
+Since	O
+pertussis	B-PATH
+can	O
+be	O
+prevented	O
+with	O
+vaccination	O
+and	O
+is	O
+expected	O
+to	O
+be	O
+affected	O
+by	O
+antibiotics	B-CHED
+,	O
+consideration	O
+of	O
+pertussis	B-PATH
+infection	B-DISO
+as	O
+a	O
+causative	O
+virulent	O
+factor	O
+of	O
+AE	B-PRGE
+-	I-PRGE
+IPF	I-PRGE
+may	O
+be	O
+important	O
+for	O
+management	O
+of	O
+subjects	O
+with	O
+IPF	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+results	O
+suggest	O
+that	O
+L	B-SPEC
+.	I-SPEC
+acidophilus	I-SPEC
+S	B-COMP
+-	I-COMP
+layer	I-COMP
+protein	B-CHED
+plays	O
+an	O
+inhibitory	O
+role	O
+during	O
+PEDV	B-SPEC
+infection	B-DISO
+of	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+that	O
+the	O
+antagonistic	O
+activity	O
+of	O
+the	O
+protein	B-CHED
+is	O
+not	O
+via	O
+competition	O
+with	O
+PEDV	B-SPEC
+for	O
+binding	B-FUNC
+sites	O
+.	O
+
+However	O
+,	O
+the	O
+efficacy	O
+of	O
+venovenous	O
+ECMO	O
+in	O
+people	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+uncertain	O
+according	O
+to	O
+the	O
+most	O
+recent	O
+data	O
+.	O
+
+In	O
+this	O
+systematic	O
+review	O
+and	O
+meta	B-SPEC
+-	O
+analysis	O
+,	O
+we	O
+searched	O
+MEDLINE	O
+(	O
+including	O
+MEDLINE	O
+In	O
+-	O
+Process	O
+and	O
+Epub	O
+Ahead	O
+of	O
+Print	O
+),	O
+Embase	O
+and	O
+the	O
+Wiley	O
+search	O
+platform	O
+in	O
+the	O
+Cochrane	O
+database	O
+for	O
+randomised	O
+controlled	O
+trials	O
+and	O
+observational	O
+studies	O
+with	O
+matching	O
+of	O
+conventional	O
+mechanical	O
+ventilation	O
+with	O
+and	O
+without	O
+venovenous	O
+ECMO	O
+in	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+order	B-SPEC
+to	O
+contribute	O
+to	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+nucleoprotein	O
+(	O
+N	O
+)	O
+in	O
+charge	O
+of	O
+RNA	O
+genome	O
+encapsidation	O
+,	O
+the	O
+structure	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+of	O
+N	O
+from	O
+MERS	O
+-	O
+CoV	O
+obtained	O
+using	O
+single	O
+-	O
+crystal	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+diffraction	O
+is	O
+reported	O
+here	O
+at	O
+1	O
+.	O
+97	O
+Å	O
+resolution	O
+.	O
+
+Comparison	O
+of	O
+this	O
+ISG15	O
+structure	O
+with	O
+those	O
+from	O
+human	B-SPEC
+and	O
+mouse	B-SPEC
+not	O
+only	O
+underscores	O
+the	O
+structural	O
+impact	O
+of	O
+ISG15	B-PRGE
+species	B-SPEC
+-	O
+species	B-SPEC
+differences	O
+,	O
+but	O
+also	O
+highlights	O
+a	O
+conserved	O
+hydrophobic	O
+motif	O
+formed	O
+between	O
+the	O
+two	O
+domains	O
+of	O
+ISG15	B-PRGE
+.	O
+
+Recently	O
+,	O
+numerous	O
+evolutionary	O
+studies	O
+have	O
+suggested	O
+that	O
+MERS	O
+-	O
+CoV	O
+originated	O
+from	O
+bat	B-ENZY
+coronavirus	B-SPEC
+(	O
+BatCoV	O
+).	O
+
+We	O
+herein	O
+reported	O
+that	O
+three	O
+peptides	B-CHED
+derived	O
+from	O
+the	O
+HR2	O
+region	O
+in	O
+spike	O
+protein	B-CHED
+of	O
+BatCoV	O
+HKU4	O
+,	O
+including	O
+HKU4	O
+-	O
+HR2P1	O
+,	O
+HKU4	O
+-	O
+HR2P2	O
+and	O
+HKU4	O
+-	O
+HR2P3	O
+,	O
+could	O
+bind	B-FUNC
+the	O
+MERS	O
+-	O
+CoV	O
+HR1	O
+-	O
+derived	O
+peptide	B-CHED
+to	O
+form	O
+a	O
+six	O
+-	O
+helix	O
+bundle	O
+(	O
+6	O
+-	O
+HB	O
+)	O
+with	O
+high	O
+stability	O
+.	O
+
+After	O
+four	O
+rounds	O
+of	O
+biopanning	O
+,	O
+scFvs	O
+that	O
+showed	O
+higher	O
+affinity	O
+to	O
+the	O
+PEDV	B-PRGE
+antigen	B-CHED
+were	O
+selected	O
+for	O
+further	O
+study	O
+.	O
+
+These	O
+scFvs	O
+were	O
+shown	O
+to	O
+inhibit	O
+PEDV	B-SPEC
+infectivity	O
+by	O
+the	O
+plaque	B-DISO
+reduction	O
+neutralization	O
+assay	O
+.	O
+
+Piglets	O
+orally	B-ANAT
+administered	O
+scFvs	O
+showed	O
+no	O
+to	O
+mild	O
+clinical	O
+symptoms	O
+,	O
+significantly	O
+less	O
+viral	B-DISO
+shedding	I-DISO
+,	O
+no	O
+mortality	O
+and	O
+no	O
+intestinal	B-ANAT
+lesions	O
+.	O
+
+We	O
+outline	O
+the	O
+research	O
+still	O
+needed	O
+to	O
+fully	O
+elucidate	O
+the	O
+pathogenic	O
+mechanism	O
+of	O
+these	O
+viruses	B-SPEC
+,	O
+to	O
+construct	O
+reproducible	O
+animal	B-SPEC
+models	O
+,	O
+and	O
+ultimately	O
+develop	O
+countermeasures	O
+to	O
+conquer	O
+not	O
+only	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+,	O
+but	O
+also	O
+these	O
+emerging	O
+coronaviral	O
+diseases	O
+.	O
+
+Together	O
+with	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+is	O
+one	O
+of	O
+the	O
+immunodominant	O
+regions	O
+among	O
+coronaviruses	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+two	O
+-	O
+way	O
+antigenic	O
+cross	O
+-	O
+reactivity	O
+between	O
+the	O
+N	O
+proteins	B-CHED
+of	O
+PEDV	B-SPEC
+and	O
+TGEV	B-SPEC
+was	O
+observed	O
+by	O
+indirect	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+)	O
+and	O
+Western	O
+blot	O
+analysis	O
+.	O
+
+The	O
+clinical	O
+signs	O
+and	O
+pathogenesis	B-DISO
+of	O
+the	O
+three	O
+viruses	B-SPEC
+are	O
+similar	O
+.	O
+
+Besides	O
+strict	O
+biosecurity	O
+measures	O
+,	O
+individual	O
+vaccines	O
+are	O
+needed	O
+for	O
+each	O
+virus	B-SPEC
+for	O
+disease	O
+prevention	O
+and	O
+control	O
+.	O
+
+It	O
+has	O
+also	O
+been	O
+associated	O
+with	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+).	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+NRI	B-CHED
+in	O
+the	O
+no	O
+-	O
+ARDS	B-DISO
+group	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+NRI	B-CHED
+in	O
+the	O
+no	O
+-	O
+ARDS	B-DISO
+group	O
+.	O
+
+Our	O
+data	O
+further	O
+suggested	O
+that	O
+lipid	B-PROC
+metabolism	B-PROC
+regulation	I-PROC
+would	O
+be	O
+a	O
+common	O
+and	O
+druggable	O
+target	O
+for	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+study	O
+objective	O
+was	O
+to	O
+compare	O
+titration	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+with	O
+electrical	B-PROC
+impedance	I-PROC
+tomography	O
+(	O
+EIT	O
+)	O
+and	O
+with	O
+ventilator	O
+-	O
+embedded	O
+pressure	O
+-	O
+volume	O
+loop	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Twenty	O
+-	O
+four	O
+severe	O
+ARDS	B-DISO
+patients	O
+(	O
+arterial	B-ANAT
+oxygen	B-PROC
+partial	I-PROC
+pressure	I-PROC
+to	O
+fractional	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+,	O
+PaO	B-PROC
+Patients	O
+in	O
+the	O
+EIT	O
+group	O
+were	O
+younger	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+and	O
+their	O
+mean	O
+plateau	O
+pressure	O
+was	O
+1	O
+.	O
+5	O
+cmH	B-DISO
+In	O
+severe	O
+ARDS	B-DISO
+patients	O
+,	O
+it	O
+was	O
+feasible	O
+and	O
+safe	O
+to	O
+guide	O
+PEEP	B-CHED
+titration	O
+with	O
+EIT	O
+at	O
+the	O
+bedside	O
+.	O
+
+ABSTRACT	O
+:	O
+Paracetamol	O
+is	O
+a	O
+popular	O
+and	O
+easily	O
+available	O
+drug	O
+which	O
+is	O
+used	O
+world	O
+-	O
+wide	O
+as	O
+analgesic	B-CHED
+,	O
+antipyretic	B-CHED
+agent	O
+.	O
+
+The	O
+optimal	O
+mAb	O
+4A11	O
+was	O
+coated	O
+on	O
+NC	O
+membrane	B-COMP
+as	O
+the	O
+capturing	O
+reagent	B-CHED
+and	O
+the	O
+mAb	O
+A11H7	O
+was	O
+coupled	O
+to	O
+gold	B-CHED
+nanoparticles	B-CHED
+(	O
+AuNPs	O
+)	O
+as	O
+detection	O
+reagent	B-CHED
+for	O
+the	O
+new	O
+ICA	B-CHED
+.	O
+
+Results	O
+indicated	O
+that	O
+the	O
+limit	O
+of	O
+detection	O
+(	O
+LOD	O
+)	O
+of	O
+the	O
+new	O
+ICA	B-CHED
+was	O
+0	O
+.	O
+47	O
+μg	O
+/	O
+mL	O
+(	O
+5	O
+.	O
+9	O
+×	O
+10	O
+A	O
+new	O
+ICA	B-CHED
+based	O
+on	O
+mAbs	O
+prepared	O
+by	O
+CSFIA	O
+was	O
+developed	O
+in	O
+this	O
+study	O
+.	O
+
+Results	O
+indicated	O
+that	O
+the	O
+limit	O
+of	O
+detection	O
+(	O
+LOD	B-FUNC
+)	O
+of	O
+the	O
+new	O
+ICA	B-CHED
+was	O
+0	O
+.	O
+47	O
+μg	O
+/	O
+mL	O
+(	O
+5	O
+.	O
+9	O
+×	O
+10	O
+
+Of	O
+228	O
+severe	B-DISO
+sepsis	I-DISO
+patients	O
+included	O
+,	O
+80	O
+(	O
+35	O
+%)	O
+developed	O
+AKI	B-PRGE
+-	I-PRGE
+RRT	I-PRGE
+.	O
+
+Plasma	B-PRGE
+sVE	I-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+levels	O
+by	O
+quartile	O
+were	O
+significantly	O
+higher	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+patients	O
+with	O
+acute	O
+kidney	B-ANAT
+injury	O
+stage	O
+3	O
+(	O
+p	O
+=	O
+0	O
+.	O
+044	O
+)	O
+as	O
+defined	O
+by	O
+Kidney	B-DISO
+Disease	I-DISO
+Improving	O
+Global	O
+Outcomes	O
+(	O
+KDIGO	O
+)	O
+criteria	O
+.	O
+
+In	O
+a	O
+multivariable	O
+analysis	O
+,	O
+plasma	B-PRGE
+sVE	I-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+was	O
+independently	O
+associated	O
+with	O
+AKI	B-PRGE
+-	I-PRGE
+RRT	I-PRGE
+(	O
+odds	O
+ratio	O
+6	O
+.	O
+44	O
+per	O
+log	O
+increase	O
+in	O
+plasma	B-PRGE
+sVE	I-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+126	O
+-	O
+36	O
+.	O
+847	O
+,	O
+p	O
+=	O
+0	O
+.	O
+036	O
+).	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+are	O
+the	O
+causative	O
+agents	O
+of	O
+severe	O
+systemic	B-DISO
+disease	I-DISO
+(	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+:	O
+FIP	B-DISO
+)	O
+in	O
+domestic	O
+and	O
+wild	B-SPEC
+cats	I-SPEC
+.	O
+
+Therefore	O
+,	O
+it	O
+is	O
+necessary	O
+to	O
+provide	O
+antiviral	B-CHED
+agents	I-CHED
+for	O
+type	O
+I	O
+FCoV	O
+infection	B-DISO
+.	O
+
+Sixteen	O
+patients	O
+(	O
+13	O
+.	O
+9	O
+%)	O
+died	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+2012	O
+,	O
+MERS	O
+-	O
+CoV	O
+has	O
+caused	O
+up	O
+to	O
+2220	O
+cases	O
+and	O
+790	O
+deaths	O
+in	O
+27	O
+countries	O
+with	O
+Saudi	O
+Arabia	O
+being	O
+the	O
+most	O
+affected	O
+country	O
+with	O
+~	O
+83	O
+.	O
+1	O
+%	O
+of	O
+the	O
+cases	O
+and	O
+~	O
+38	O
+.	O
+8	O
+%	O
+local	O
+death	B-PROC
+rate	O
+.	O
+
+First	O
+part	O
+of	O
+Kapha	O
+pitta	B-SPEC
+samrushtavata	O
+(	O
+Vatadosha	O
+associated	O
+with	O
+Kapha	O
+and	O
+Pitta	B-SPEC
+dosha	O
+)	O
+and	O
+then	O
+vatahara	O
+chikitsa	O
+were	O
+followed	O
+.	O
+
+Here	O
+we	O
+provide	O
+a	O
+brief	O
+review	O
+of	O
+the	O
+latest	O
+findings	O
+in	O
+bat	B-ENZY
+viruses	B-SPEC
+and	O
+their	O
+potential	O
+risk	O
+of	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+years	O
+have	O
+seen	O
+unprecedented	O
+investment	O
+in	O
+research	O
+and	O
+development	O
+for	O
+countermeasures	O
+for	O
+high	O
+-	O
+threat	O
+pathogens	O
+,	O
+including	O
+specific	O
+and	O
+ambitious	O
+objectives	O
+for	O
+development	B-PROC
+of	O
+diagnostics	O
+,	O
+therapeutics	O
+,	O
+and	O
+vaccines	O
+.	O
+
+The	O
+pipeline	O
+has	O
+been	O
+validated	O
+on	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+,	O
+human	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+1	I-SPEC
+-	O
+4	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+human	B-SPEC
+coronaviruses	O
+(	O
+229E	O
+/	O
+OC43	O
+/	O
+NL63	O
+/	O
+HKU1	O
+/	O
+SARS	B-DISO
+/	O
+MERS	O
+),	O
+human	B-SPEC
+enteroviruses	B-SPEC
+/	O
+rhinoviruses	B-SPEC
+,	O
+measles	B-SPEC
+virus	I-SPEC
+,	O
+mumps	B-SPEC
+virus	I-SPEC
+,	O
+Hepatitis	B-DISO
+A	I-DISO
+-	O
+E	O
+Virus	B-SPEC
+,	O
+Chikungunya	B-SPEC
+virus	I-SPEC
+,	O
+dengue	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+as	O
+well	O
+the	O
+human	B-SPEC
+polyomaviruses	B-SPEC
+BK	O
+/	O
+JC	O
+/	O
+MCV	O
+,	O
+human	B-SPEC
+adenoviruses	B-SPEC
+,	O
+and	O
+human	B-SPEC
+papillomaviruses	O
+.	O
+
+VAPiD	O
+is	O
+programmed	O
+in	O
+Python	B-SPEC
+and	O
+is	O
+compatible	O
+with	O
+Windows	O
+,	O
+Linux	O
+,	O
+and	O
+Mac	B-PRGE
+OS	I-PRGE
+systems	I-PRGE
+.	O
+
+TITLE	O
+:	O
+What	O
+Have	O
+We	O
+Learned	B-PROC
+About	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Emergence	O
+in	O
+Humans	B-SPEC
+?	O
+
+There	O
+have	O
+been	O
+sustained	O
+health	O
+care	O
+-	O
+associated	O
+human	B-SPEC
+outbreaks	O
+in	O
+Saudi	O
+Arabia	O
+and	O
+South	O
+Korea	O
+,	O
+the	O
+latter	O
+originating	O
+from	O
+one	O
+traveler	O
+returning	O
+from	O
+the	O
+Middle	O
+East	O
+.	O
+
+Various	O
+potential	O
+therapeutics	O
+have	O
+been	O
+identified	O
+,	O
+but	O
+not	O
+yet	O
+evaluated	O
+in	O
+human	B-SPEC
+clinical	O
+trials	O
+.	O
+
+ABSTRACT	O
+:	O
+Neutrophil	B-ANAT
+extracellular	B-COMP
+traps	B-DISO
+have	O
+been	O
+associated	O
+with	O
+tissue	B-ANAT
+damage	O
+.	O
+
+Whether	O
+these	O
+are	O
+involved	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+human	B-SPEC
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+could	O
+be	O
+a	O
+potential	O
+therapeutic	O
+target	O
+is	O
+unknown	O
+.	O
+
+The	O
+authors	O
+quantified	O
+bronchoalveolar	O
+and	O
+blood	B-ANAT
+neutrophil	B-ANAT
+extracellular	B-COMP
+traps	B-DISO
+in	O
+patients	O
+with	O
+pneumonia	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+and	O
+assessed	O
+their	O
+relationship	O
+with	O
+ventilator	O
+-	O
+free	O
+days	O
+.	O
+
+Immunocompetent	O
+patients	O
+with	O
+pneumonia	B-DISO
+and	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+(	O
+n	O
+=	O
+35	O
+)	O
+and	O
+controls	O
+(	O
+n	O
+=	O
+4	O
+)	O
+were	O
+included	O
+in	O
+a	O
+prospective	O
+monocentric	O
+study	O
+.	O
+
+Neutrophil	B-ANAT
+extracellular	B-COMP
+trap	O
+concentrations	O
+were	O
+quantified	O
+(	O
+as	O
+DNA	B-PRGE
+-	I-PRGE
+myeloperoxidase	I-PRGE
+complexes	I-PRGE
+)	O
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+and	O
+serum	B-COMP
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+selected	O
+and	O
+analyzed	O
+the	O
+genetic	O
+evolution	B-PROC
+of	O
+15	O
+PEDV	B-SPEC
+representative	O
+strains	O
+that	O
+were	O
+identified	O
+in	O
+fecal	B-ANAT
+samples	O
+of	O
+diarrheic	O
+piglets	O
+in	O
+10	O
+provinces	O
+and	O
+cities	O
+during	O
+2011	O
+-	O
+2017	O
+.	O
+
+Compared	O
+with	O
+oral	B-DISO
+infection	I-DISO
+,	O
+intramuscular	O
+infection	B-DISO
+could	O
+also	O
+cause	O
+typical	O
+clinical	O
+signs	O
+but	O
+with	O
+a	O
+slightly	O
+delayed	O
+onset	O
+,	O
+confirming	O
+that	O
+the	O
+variant	O
+PEDV	B-SPEC
+isolate	O
+FJzz1	O
+was	O
+highly	O
+pathogenic	O
+to	O
+suckling	O
+piglets	O
+.	O
+
+This	O
+study	O
+shows	O
+the	O
+necessity	O
+of	O
+monitoring	O
+the	O
+molecular	O
+epidemiology	O
+and	O
+the	O
+etiological	O
+characteristics	O
+of	O
+the	O
+epidemic	O
+PEDV	B-SPEC
+isolates	O
+,	O
+which	O
+may	O
+help	O
+better	O
+control	O
+the	O
+PED	O
+outbreaks	O
+.	O
+
+Occupational	O
+risk	O
+for	O
+customs	O
+officers	O
+also	O
+includes	O
+noise	O
+-	O
+induced	O
+hearing	B-DISO
+loss	I-DISO
+,	O
+exposure	O
+to	O
+diesel	O
+engine	O
+emission	B-ANAT
+and	O
+stored	O
+tobacco	B-SPEC
+and	O
+occupational	O
+stress	O
+due	O
+to	O
+their	O
+increased	O
+time	O
+-	O
+schedule	O
+and	O
+decision	O
+-	O
+making	O
+duties	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+45	O
+studies	O
+(	O
+including	O
+data	O
+from	O
+15	O
+,	O
+990	O
+pigs	B-SPEC
+)	O
+met	B-CHED
+our	O
+evaluation	O
+criteria	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+findings	O
+suggest	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+is	O
+common	O
+among	O
+pigs	B-SPEC
+in	O
+China	O
+.	O
+
+These	O
+viruses	B-SPEC
+are	O
+well	O
+-	O
+recognized	O
+for	O
+their	O
+ability	O
+to	O
+change	O
+tissue	B-PROC
+tropism	B-PROC
+,	O
+to	O
+hurdle	O
+the	O
+interspecies	O
+barriers	O
+and	O
+to	O
+adapt	O
+ecological	O
+variations	O
+.	O
+
+Although	O
+it	O
+has	O
+long	O
+been	O
+known	O
+as	O
+a	O
+restrictive	O
+cattle	B-SPEC
+pathogen	O
+,	O
+CoVs	O
+that	O
+are	O
+closely	O
+related	O
+to	O
+BCoV	O
+have	O
+been	O
+recognized	O
+in	O
+dogs	O
+,	O
+humans	B-SPEC
+and	O
+in	O
+other	O
+ruminant	B-SPEC
+species	B-SPEC
+.	O
+
+Biologic	O
+,	O
+antigenic	O
+and	O
+genetic	O
+analyses	O
+of	O
+the	O
+so	O
+-	O
+called	O
+'	B-SPEC
+bovine	I-SPEC
+-	O
+like	O
+CoVs	O
+'	O
+proposed	O
+classification	O
+of	O
+these	O
+viruses	B-SPEC
+as	O
+host	B-COMP
+-	O
+range	O
+variants	O
+rather	O
+than	O
+distinct	O
+virus	B-SPEC
+species	B-SPEC
+.	O
+
+However	O
+,	O
+a	O
+primary	O
+peritoneal	B-DISO
+infection	I-DISO
+in	O
+previously	O
+healthy	O
+patients	O
+may	O
+also	O
+ensue	O
+.	O
+
+Although	O
+infected	O
+ascitic	B-ANAT
+fluid	I-ANAT
+is	O
+seen	O
+,	O
+there	O
+is	O
+no	O
+rupture	O
+.	O
+
+Intravenous	O
+administration	O
+of	O
+LCA60	O
+one	O
+day	O
+before	O
+virus	B-SPEC
+challenge	O
+resulted	O
+in	O
+high	O
+levels	O
+of	O
+MERS	O
+-	O
+CoV	O
+-	O
+neutralizing	O
+activity	O
+in	O
+circulating	B-ANAT
+blood	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+distribution	O
+width	O
+is	O
+an	O
+independent	O
+risk	O
+factor	O
+in	O
+the	O
+prediction	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+severe	O
+burns	O
+.	O
+
+A	O
+blood	B-ANAT
+sample	I-ANAT
+was	O
+taken	O
+at	O
+admission	O
+and	O
+CBC	B-COMP
+parameters	O
+were	O
+examined	O
+.	O
+
+Every	O
+1	O
+%	O
+increase	O
+in	O
+RDW	O
+was	O
+associated	O
+with	O
+a	O
+29	O
+%	O
+increase	O
+in	O
+the	O
+risk	O
+to	O
+develop	O
+ARDS	B-DISO
+.	O
+
+Every	O
+1	O
+%	O
+increase	O
+in	O
+RDW	O
+was	O
+associated	O
+with	O
+a	O
+29	O
+%	O
+increase	O
+in	O
+the	O
+risk	O
+to	O
+develop	O
+ARDS	B-DISO
+.	O
+
+The	O
+technique	O
+is	O
+very	O
+flexible	O
+and	O
+can	O
+be	O
+used	O
+to	O
+investigate	O
+the	O
+proteolytic	B-PROC
+activity	O
+of	O
+a	O
+single	O
+protease	O
+on	O
+many	O
+different	O
+substrates	O
+,	O
+and	O
+in	O
+addition	O
+,	O
+it	O
+also	O
+allows	O
+exploration	O
+of	O
+the	O
+activity	O
+of	O
+multiple	O
+proteases	O
+on	O
+one	O
+or	O
+more	O
+peptide	B-CHED
+substrates	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+are	O
+common	O
+causes	O
+of	O
+febrile	B-PROC
+episodes	O
+in	O
+children	O
+.	O
+
+The	O
+first	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+viral	O
+etiology	O
+and	O
+seasonality	O
+of	O
+acute	O
+viral	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+in	O
+pediatric	O
+patients	O
+with	O
+cancer	B-DISO
+in	O
+a	O
+3	O
+-	O
+year	O
+study	O
+.	O
+
+The	O
+mean	O
+duration	O
+of	O
+symptoms	O
+of	O
+viral	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+was	O
+6	O
+.	O
+8	O
+±	O
+4	O
+.	O
+2	O
+(	O
+range	O
+:	O
+2	O
+to	O
+31	O
+)	O
+days	O
+.	O
+
+The	O
+10th	O
+International	O
+GVN	O
+meeting	O
+was	O
+held	O
+from	O
+November	O
+28	O
+-	O
+30	O
+,	O
+2018	O
+in	O
+Veyrier	O
+du	O
+Lac	B-CHED
+,	O
+France	O
+and	O
+was	O
+co	O
+-	O
+hosted	O
+by	O
+the	O
+two	O
+GVN	O
+Centers	O
+of	O
+Excellence	O
+,	O
+the	O
+Mérieux	O
+Foundation	O
+and	O
+the	O
+University	O
+of	O
+Veterinary	O
+Medicine	B-CHED
+Hannover	O
+(	O
+TiHo	O
+).	O
+
+TITLE	O
+:	O
+Macrolides	B-CHED
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+.	O
+
+However	O
+,	O
+patients	O
+who	O
+received	O
+macrolides	B-CHED
+were	O
+more	O
+likely	O
+to	O
+be	O
+admitted	O
+with	O
+community	O
+-	O
+acquired	O
+MERS	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+an	O
+almost	O
+invariably	O
+fatal	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)-	O
+induced	O
+disease	O
+thought	O
+to	O
+arise	O
+from	O
+a	O
+combination	O
+of	O
+viral	O
+mutations	O
+and	O
+an	O
+overexuberant	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+Natural	O
+initial	O
+enteric	O
+FCoV	O
+infection	B-DISO
+may	O
+remain	O
+subclinical	O
+,	O
+or	O
+result	O
+in	O
+mild	O
+enteric	O
+signs	O
+or	O
+the	O
+development	B-PROC
+of	O
+FIP	B-DISO
+;	O
+cats	B-SPEC
+may	O
+also	O
+carry	O
+the	O
+virus	B-SPEC
+systemically	O
+with	O
+no	O
+adverse	B-DISO
+effect	I-DISO
+.	O
+
+ICC	B-DISO
+was	O
+positive	O
+in	O
+17	O
+of	O
+30	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+but	O
+also	O
+in	O
+1	O
+of	O
+11	O
+control	O
+cats	B-SPEC
+that	O
+was	O
+diagnosed	O
+with	O
+lymphoma	B-DISO
+.	O
+
+Focusing	O
+on	O
+the	O
+mechanism	O
+of	O
+transmission	O
+and	O
+infection	B-DISO
+for	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+zoonosis	B-DISO
+,	O
+this	O
+research	O
+will	O
+provide	O
+an	O
+important	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+discovery	O
+of	O
+novel	O
+alphacoronaviruses	O
+(	O
+alpha	O
+-	O
+CoVs	O
+)	O
+in	O
+European	O
+and	O
+Asian	O
+rodents	O
+revealed	O
+that	O
+rodent	B-SPEC
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+sampled	O
+worldwide	O
+formed	O
+a	O
+discrete	O
+phylogenetic	O
+group	O
+within	O
+this	O
+genus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+19	O
+-	O
+week	O
+-	O
+old	O
+neutered	O
+male	O
+domestic	O
+shorthair	O
+cat	O
+was	O
+examined	O
+because	O
+of	O
+multiple	O
+raised	O
+pruritic	O
+skin	B-ANAT
+lesions	O
+along	O
+the	O
+dorsal	O
+head	B-ANAT
+and	O
+back	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+application	O
+of	O
+an	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+using	O
+recombinant	O
+S1	O
+for	O
+serological	O
+testing	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+PEDV	B-SPEC
+recombinant	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+(	O
+rS1	B-PRGE
+)	O
+was	O
+expressed	B-PROC
+with	O
+the	O
+Bac	O
+-	O
+to	O
+-	O
+Bac	O
+system	O
+and	O
+purified	O
+by	O
+nickel	B-CHED
+-	O
+affinity	O
+chromatography	O
+.	O
+
+An	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+based	O
+on	O
+rS1	B-PRGE
+(	O
+rS1	B-PRGE
+-	I-PRGE
+ELISA	I-PRGE
+)	O
+was	O
+then	O
+developed	O
+and	O
+optimized	O
+by	O
+checkerboard	O
+assays	O
+with	O
+serial	O
+dilutions	O
+of	O
+antigen	B-CHED
+and	O
+serum	B-COMP
+.	O
+
+Serum	B-COMP
+samples	O
+from	O
+453	O
+domestic	B-SPEC
+pigs	I-SPEC
+and	O
+42	O
+vaccinated	O
+pigs	B-SPEC
+were	O
+analyzed	O
+by	O
+the	O
+indirect	O
+fluorescent	O
+antibody	B-COMP
+(	O
+IFA	O
+)	O
+test	O
+and	O
+rS1	O
+-	O
+ELISA	O
+.	O
+
+This	O
+rS1	B-PRGE
+-	I-PRGE
+ELISA	I-PRGE
+was	O
+then	O
+applied	O
+to	O
+antibody	B-COMP
+detection	O
+in	O
+inactivated	O
+PEDV	B-SPEC
+vaccinated	O
+pigs	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+the	O
+presence	O
+of	O
+unilateral	O
+or	O
+bilateral	O
+diaphragmatic	B-ANAT
+paralysis	O
+of	O
+undetermined	O
+aetiology	O
+,	O
+it	O
+seems	O
+relevant	O
+to	O
+perform	O
+Lyme	O
+serology	O
+in	O
+the	O
+blood	B-ANAT
+and	O
+,	O
+in	O
+positive	O
+cases	O
+,	O
+to	O
+follow	O
+up	O
+with	O
+a	O
+lumbar	B-ANAT
+puncture	O
+in	O
+order	B-SPEC
+to	O
+detect	O
+intrathecal	B-ANAT
+IgG	B-PRGE
+synthesis	B-PROC
+.	O
+
+Drug	O
+repositioning	O
+has	O
+emerged	O
+as	O
+a	O
+cost	O
+-	O
+effective	O
+and	O
+time	O
+-	O
+efficient	O
+alternative	O
+approach	O
+to	O
+traditional	O
+drug	O
+discovery	O
+and	O
+development	B-PROC
+.	O
+
+This	O
+new	O
+shift	O
+focuses	O
+on	O
+the	O
+repurposing	O
+of	O
+clinically	O
+approved	O
+drugs	O
+and	O
+promising	O
+preclinical	O
+drug	O
+candidates	O
+for	O
+the	O
+therapeutic	O
+development	B-PROC
+of	O
+host	B-COMP
+-	O
+based	O
+antiviral	B-CHED
+agents	I-CHED
+to	O
+control	O
+diseases	O
+caused	O
+by	O
+coronavirus	B-SPEC
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+pneumoperitoneum	B-DISO
+,	O
+after	O
+an	O
+endoscopic	O
+mucosal	B-ANAT
+resection	O
+with	O
+the	O
+development	B-PROC
+of	O
+ACS	B-FUNC
+.	O
+
+Decompressive	O
+laparotomy	O
+is	O
+the	O
+first	O
+treatment	O
+option	O
+for	O
+both	O
+most	O
+forms	O
+of	O
+pneumoperitoneum	B-DISO
+and	O
+ACS	B-FUNC
+;	O
+nevertheless	O
+,	O
+this	O
+issue	O
+is	O
+controversial	O
+.	O
+
+We	O
+found	O
+no	O
+signal	O
+interference	O
+between	O
+monoplex	B-SPEC
+and	O
+multiplex	O
+assay	O
+formats	O
+(	O
+R	O
+
+Disk	B-ANAT
+diffusion	O
+technique	O
+and	O
+PCR	O
+were	O
+used	O
+as	O
+methodologies	O
+.	O
+
+RESULTS	O
+:	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolates	O
+from	O
+calves	O
+with	O
+diarrhea	B-DISO
+were	O
+phylogenetically	O
+classified	O
+as	O
+B1	O
+(	O
+70	O
+%,	O
+21	O
+/	O
+30	O
+),	O
+B2	O
+(	O
+3	O
+.	O
+33	O
+%,	O
+1	O
+/	O
+30	O
+),	O
+C	O
+(	O
+3	O
+.	O
+33	O
+%,	O
+1	O
+/	O
+30	O
+),	O
+D	O
+(	O
+3	O
+.	O
+33	O
+%,	O
+1	O
+/	O
+30	O
+),	O
+E	O
+(	O
+13	O
+.	O
+33	O
+%,	O
+4	O
+/	O
+30	O
+)	O
+and	O
+unknown	O
+(	O
+6	O
+.	O
+7	O
+%;	O
+2	O
+/	O
+30	O
+),	O
+whereas	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolates	O
+from	O
+the	O
+control	O
+group	O
+were	O
+classified	O
+only	O
+as	O
+B1	O
+(	O
+83	O
+.	O
+3	O
+%,	O
+25	O
+/	O
+30	O
+),	O
+E	O
+(	O
+10	O
+%;	O
+3	O
+/	O
+30	O
+)	O
+and	O
+unknown	O
+(	O
+6	O
+,	O
+7	O
+%;	O
+2	O
+/	O
+30	O
+).	O
+
+We	O
+update	O
+and	O
+summarize	O
+the	O
+role	O
+of	O
+spontaneous	O
+breathing	B-PROC
+during	O
+mechanical	O
+ventilation	O
+in	O
+ARDS	B-DISO
+,	O
+which	O
+can	O
+be	O
+beneficial	O
+or	O
+deleterious	O
+,	O
+depending	O
+on	O
+the	O
+strength	O
+of	O
+spontaneous	O
+activity	O
+and	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+Adenovirus	B-DISO
+-	O
+positive	O
+participants	O
+with	O
+FRI	O
+episodes	O
+tended	O
+to	O
+be	O
+protected	O
+against	O
+subsequent	O
+infection	B-DISO
+with	O
+adenovirus	B-DISO
+,	O
+coronavirus	B-SPEC
+,	O
+enterovirus	B-SPEC
+/	O
+rhinovirus	B-SPEC
+,	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+P	O
+=	O
+.	O
+062	O
+-.	O
+093	O
+),	O
+while	O
+men	O
+with	O
+influenza	B-SPEC
+virus	I-SPEC
+-	O
+positive	O
+FRI	O
+episodes	O
+tended	O
+be	O
+protected	O
+against	O
+subsequent	O
+infection	B-DISO
+with	O
+adenovirus	B-DISO
+(	O
+P	O
+=	O
+.	O
+044	O
+)	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+P	O
+=	O
+.	O
+081	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Prior	O
+adenovirus	B-DISO
+or	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+conferred	O
+cross	O
+-	O
+protection	O
+against	O
+subsequent	O
+FRI	O
+episodes	O
+relative	O
+to	O
+prior	O
+infection	B-DISO
+due	O
+to	O
+other	O
+circulating	O
+viruses	B-SPEC
+.	O
+
+The	O
+new	O
+S3	O
+guideline	O
+is	O
+the	O
+first	O
+to	O
+contain	O
+recommendations	O
+for	O
+the	O
+entire	O
+process	O
+of	O
+treatment	O
+in	O
+these	O
+groups	O
+of	O
+patients	O
+(	O
+indications	O
+,	O
+ventilation	O
+modes	O
+/	O
+parameters	O
+,	O
+ac	O
+-	O
+companying	O
+measures	O
+,	O
+treatments	O
+for	O
+refractory	O
+impairment	B-DISO
+of	O
+gas	B-ENZY
+exchange	O
+,	O
+weaning	B-PROC
+,	O
+and	O
+follow	O
+-	O
+up	O
+care	O
+).	O
+
+If	O
+mechanical	O
+ventilation	O
+is	O
+needed	O
+,	O
+ventilation	O
+modes	O
+allowing	O
+spontaneous	O
+breathing	B-PROC
+seem	O
+beneficial	O
+(	O
+quality	O
+of	O
+evidence	O
+[	O
+QoE	O
+]:	O
+very	O
+low	O
+).	O
+
+An	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+(	O
+ABG	O
+)	O
+specifically	O
+tests	O
+blood	B-ANAT
+taken	O
+from	O
+an	O
+artery	B-ANAT
+.	O
+
+When	O
+assessing	O
+the	O
+acid	B-PROC
+-	I-PROC
+base	I-PROC
+balance	I-PROC
+,	O
+most	O
+ABG	O
+analyzers	O
+measure	O
+the	O
+pH	O
+and	O
+PaCo2	O
+directly	O
+and	O
+through	O
+a	O
+derivative	O
+of	O
+the	O
+Hasselbach	O
+equation	O
+calculate	O
+the	O
+serum	B-COMP
+bicarbonate	B-CHED
+(	O
+HCO3	O
+)	O
+and	O
+base	O
+deficit	B-DISO
+or	O
+excess	O
+.	O
+
+The	O
+measured	O
+HCO3	O
+uses	O
+a	O
+strong	O
+alkali	O
+that	O
+liberates	O
+all	O
+CO2	B-CHED
+in	O
+serum	B-COMP
+,	O
+including	O
+dissolved	O
+CO2	B-CHED
+,	O
+carbamino	O
+compounds	O
+,	O
+and	O
+carbonic	B-CHED
+acid	I-CHED
+.	O
+
+In	O
+most	O
+cases	O
+,	O
+when	O
+the	O
+patients	O
+'	O
+vital	O
+signs	O
+have	O
+been	O
+stabilized	O
+,	O
+the	O
+repair	B-PROC
+can	O
+be	O
+performed	O
+.	O
+
+Though	O
+the	O
+patient	O
+was	O
+treated	O
+with	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+),	O
+his	O
+oxygenation	B-PROC
+was	O
+still	O
+not	O
+stable	O
+.	O
+
+Thus	O
+,	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+V	O
+-	O
+V	O
+ECMO	O
+)	O
+was	O
+initiated	O
+;	O
+upon	O
+improvement	O
+of	O
+oxygenation	B-PROC
+,	O
+the	O
+patient	O
+received	O
+an	O
+exploratory	O
+thoracotomy	O
+.	O
+
+Infection	B-DISO
+of	O
+piglets	O
+with	O
+the	O
+parental	O
+Colorado	O
+strain	O
+,	O
+icPEDV	O
+-	O
+wt	O
+,	O
+or	O
+icPEDV	O
+-	O
+EnUmt	O
+revealed	O
+that	O
+all	O
+viruses	B-SPEC
+replicated	O
+in	O
+the	O
+gut	B-ANAT
+and	O
+induced	O
+diarrhea	B-DISO
+;	O
+however	O
+,	O
+there	O
+was	O
+reduced	O
+viral	B-DISO
+shedding	I-DISO
+and	O
+mortality	O
+in	O
+the	O
+icPEDV	O
+-	O
+EnUmt	O
+-	O
+infected	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+More	O
+than	O
+two	O
+million	O
+Muslims	O
+visit	O
+Makkah	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+annually	O
+to	O
+perform	O
+the	O
+religious	O
+rituals	O
+of	O
+Hajj	O
+where	O
+the	O
+risk	O
+of	O
+spreading	O
+respiratory	B-DISO
+infections	I-DISO
+is	O
+very	O
+common	O
+.	O
+
+The	O
+most	O
+common	O
+respiratory	O
+virus	B-SPEC
+was	O
+influenza	B-PATH
+A	I-PATH
+,	O
+followed	O
+by	O
+non	O
+-	O
+MERS	O
+human	B-SPEC
+coronaviruses	O
+,	O
+rhinoviruses	B-SPEC
+,	O
+and	O
+influenza	B-DISO
+B	O
+.	O
+Together	O
+,	O
+we	O
+found	O
+that	O
+it	O
+was	O
+not	O
+MERS	O
+-	O
+CoV	O
+but	O
+other	O
+respiratory	O
+viruses	B-SPEC
+that	O
+caused	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+among	O
+pilgrims	O
+.	O
+
+TITLE	O
+:	O
+Construction	O
+and	O
+characterization	O
+of	O
+porcine	B-SPEC
+single	O
+-	O
+chain	O
+fragment	O
+variable	O
+antibodies	B-COMP
+that	O
+neutralize	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+in	O
+vitro	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+infection	B-DISO
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+piglets	O
+and	O
+imposes	O
+a	O
+significant	O
+economic	O
+burden	O
+on	O
+pig	B-SPEC
+farms	O
+.	O
+
+All	O
+three	O
+scFv	O
+clones	O
+identified	O
+had	O
+neutralizing	O
+activity	O
+against	O
+TGEV	B-SPEC
+.	O
+
+The	O
+computed	O
+tomography	O
+scan	O
+showed	O
+no	O
+obvious	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+2	O
+months	O
+after	O
+poisoning	O
+.	O
+
+ABSTRACT	O
+:	O
+Thrombocytopenia	O
+is	O
+associated	O
+with	O
+worse	O
+outcomes	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+which	O
+is	O
+most	O
+commonly	O
+caused	O
+by	O
+infection	B-DISO
+and	O
+marked	O
+by	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+barrier	O
+disruption	O
+.	O
+
+However	O
+,	O
+the	O
+mechanisms	O
+by	O
+which	O
+platelets	B-ANAT
+protect	O
+the	O
+lung	B-ANAT
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+barrier	O
+during	O
+infectious	B-DISO
+injury	O
+remain	O
+unclear	O
+.	O
+
+TITLE	O
+:	O
+Geographical	O
+structure	O
+of	O
+bat	B-ENZY
+SARS	B-DISO
+-	O
+related	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+generated	O
+by	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+causes	O
+economic	O
+difficulties	O
+for	O
+livestock	O
+farmers	O
+.	O
+
+The	O
+3D8	O
+single	O
+chain	O
+variable	O
+fragment	O
+(	O
+scFv	O
+)	O
+protein	B-CHED
+is	O
+a	O
+recombinant	O
+antibody	B-COMP
+with	O
+nuclease	B-FUNC
+activity	I-FUNC
+that	O
+shows	O
+antiviral	B-CHED
+effects	O
+against	O
+various	O
+DNA	O
+and	O
+RNA	O
+viruses	B-SPEC
+in	O
+mice	B-SPEC
+and	O
+chickens	B-SPEC
+.	O
+
+Granulomas	B-DISO
+manifest	O
+primarily	O
+in	O
+lungs	B-ANAT
+and	O
+lung	B-ANAT
+-	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+(	O
+LLNs	O
+)	O
+but	O
+these	O
+compartments	B-ANAT
+are	O
+less	O
+studied	O
+compared	O
+to	O
+blood	B-ANAT
+and	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+).	O
+
+Sarcoidosis	B-DISO
+can	O
+present	O
+with	O
+an	O
+acute	O
+onset	O
+(	O
+usually	O
+Löfgren	O
+'	O
+s	O
+syndrome	B-DISO
+(	O
+LS	B-DISO
+))	O
+or	O
+a	O
+gradual	O
+onset	O
+(	O
+non	O
+-	O
+LS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Life	O
+-	O
+threatening	O
+complications	O
+among	O
+women	O
+with	O
+severe	O
+ovarian	B-DISO
+hyperstimulation	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	O
+Manifestations	O
+of	O
+Neuromuscular	B-DISO
+Disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+nearly	O
+a	O
+decade	O
+ago	O
+with	O
+worldwide	O
+distribution	O
+,	O
+was	O
+believed	O
+to	O
+be	O
+of	O
+zoonotic	O
+origin	O
+from	O
+bats	B-SPEC
+with	O
+dromedary	B-SPEC
+camels	B-SPEC
+as	O
+intermediate	O
+hosts	B-COMP
+.	O
+
+The	O
+presence	O
+of	O
+coronaviruses	O
+,	O
+closely	O
+related	O
+to	O
+MERS	O
+-	O
+CoV	O
+in	O
+Ghanaian	O
+bats	B-SPEC
+,	O
+presented	O
+the	O
+opportunity	O
+to	O
+test	O
+the	O
+hypothesis	O
+of	O
+transmissibility	O
+of	O
+this	O
+virus	B-SPEC
+through	O
+domestic	O
+livestock	O
+species	B-SPEC
+.	O
+
+The	O
+possible	O
+interactions	O
+between	O
+livestock	O
+and	O
+bats	B-SPEC
+in	O
+31	O
+household	O
+farms	O
+were	O
+accessed	O
+by	O
+observation	O
+and	O
+interviews	O
+with	O
+farmers	O
+.	O
+
+Blood	B-ANAT
+lactate	B-CHED
+levels	O
+and	O
+HRCT	O
+score	O
+might	O
+be	O
+predictive	O
+of	O
+the	O
+outcome	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+The	O
+currently	O
+used	O
+live	O
+-	O
+attenuated	O
+vaccines	O
+have	O
+the	O
+tendency	O
+to	O
+mutate	B-PROC
+and	O
+/	O
+or	O
+recombine	O
+with	O
+circulating	O
+field	O
+strains	O
+resulting	O
+in	O
+the	O
+emergence	O
+of	O
+vaccine	O
+-	O
+derived	O
+variant	O
+viruses	B-SPEC
+.	O
+
+A	O
+wild	O
+type	O
+and	O
+two	O
+modified	O
+versions	O
+of	O
+the	O
+IBV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+were	O
+expressed	B-PROC
+individually	O
+by	O
+rNDV	O
+.	O
+
+TITLE	O
+:	O
+First	O
+Complete	O
+Genome	O
+Sequence	O
+of	O
+Human	B-PRGE
+Coronavirus	I-PRGE
+HKU1	I-PRGE
+from	O
+a	O
+Nonill	O
+Bat	B-ENZY
+Guano	O
+Miner	O
+in	O
+Thailand	O
+.	O
+
+It	O
+is	O
+usually	O
+caused	O
+by	O
+A	O
+young	O
+Romanian	O
+male	O
+presented	O
+with	O
+fever	B-PROC
+and	O
+rigors	B-DISO
+,	O
+mild	O
+tachypnea	B-DISO
+,	O
+hypoxia	B-DISO
+,	O
+sore	B-DISO
+throat	I-DISO
+,	O
+decayed	B-DISO
+teeth	I-DISO
+,	O
+and	O
+tenderness	B-DISO
+of	O
+the	O
+left	B-ANAT
+carotid	I-ANAT
+triangle	I-ANAT
+.	O
+
+Laboratory	O
+examination	O
+indicated	O
+severe	B-DISO
+sepsis	I-DISO
+with	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+while	O
+the	O
+Doppler	O
+ultrasonography	O
+of	O
+the	O
+carotids	B-ANAT
+revealed	O
+left	O
+internal	O
+jugular	O
+venous	B-DISO
+thrombosis	I-DISO
+.	O
+
+Because	O
+of	O
+the	O
+syndrome	B-DISO
+'	O
+s	O
+rarity	O
+and	O
+the	O
+atypical	O
+microorganisms	O
+isolated	O
+in	O
+this	O
+case	O
+,	O
+increased	O
+awareness	O
+is	O
+advised	O
+for	O
+its	O
+diagnosis	O
+and	O
+the	O
+underlying	O
+mechanisms	O
+involved	O
+in	O
+its	O
+genesis	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+S	O
+protein	O
+which	O
+is	O
+responsible	O
+for	O
+membrane	B-PROC
+fusion	I-PROC
+had	O
+an	O
+amino	B-CHED
+acid	I-CHED
+homology	O
+of	O
+96	O
+.	O
+9	O
+%.	O
+
+TITLE	O
+:	O
+PES	B-ANAT
+Pathogens	O
+in	O
+Severe	O
+Community	O
+-	O
+Acquired	O
+Pneumonia	B-DISO
+.	O
+
+Since	O
+most	O
+IBV	B-SPEC
+vaccines	O
+are	O
+type	O
+-	O
+specific	O
+,	O
+there	O
+is	O
+a	O
+need	O
+for	O
+constant	O
+surveillance	O
+of	O
+the	O
+circulating	O
+lineages	O
+and	O
+knowledge	O
+about	O
+their	O
+genetic	O
+and	O
+antigenic	O
+properties	O
+.	O
+
+The	O
+genetic	O
+analysis	O
+was	O
+performed	O
+using	O
+the	O
+S1	O
+complete	O
+coding	O
+sequences	O
+of	O
+all	O
+available	O
+South	O
+American	O
+strains	O
+,	O
+including	O
+newly	O
+obtained	O
+Argentine	B-SPEC
+and	O
+Uruguayan	O
+field	O
+samples	O
+.	O
+
+The	O
+GI	O
+-	O
+16	O
+lineage	O
+emerged	O
+around	O
+1979	O
+,	O
+and	O
+is	O
+currently	O
+circulating	O
+in	O
+most	O
+South	O
+American	O
+territories	O
+(	O
+Argentina	B-SPEC
+,	O
+Chile	O
+,	O
+Uruguay	O
+,	O
+Colombia	O
+and	O
+Peru	O
+).	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+extend	O
+our	O
+knowledge	O
+about	O
+the	O
+present	O
+and	O
+past	O
+IBV	B-SPEC
+variability	O
+in	O
+South	O
+America	O
+and	O
+provide	O
+relevant	O
+elements	O
+to	O
+improve	O
+the	O
+control	O
+programmes	O
+by	O
+considering	O
+the	O
+genetic	O
+and	O
+antigenic	O
+attributes	O
+of	O
+IBV	B-SPEC
+.	O
+
+Real	O
+-	O
+time	O
+PCR	O
+confirmed	O
+viral	B-DISO
+infection	I-DISO
+in	O
+77	O
+swabs	O
+(	O
+86	O
+.	O
+5	O
+%).	O
+
+RESULTS	O
+:	O
+We	O
+obtained	O
+89	O
+nasopharyngeal	B-ANAT
+swabs	O
+from	O
+patients	O
+with	O
+pediatric	B-DISO
+cancer	I-DISO
+(	O
+mean	O
+age	O
+,	O
+5	O
+.	O
+8	O
+±	O
+4	O
+.	O
+2	O
+years	O
+).	O
+
+ABSTRACT	O
+:	O
+Vaccination	O
+programs	O
+are	O
+implemented	O
+in	O
+poultry	O
+farms	O
+to	O
+limit	O
+outbreaks	O
+and	O
+spread	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+which	O
+is	O
+a	O
+substantial	O
+economic	O
+burden	O
+in	O
+the	O
+poultry	O
+industry	O
+.	O
+
+Fourteen	O
+patients	O
+were	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+and	O
+six	O
+patients	O
+died	B-PROC
+(	O
+five	O
+premature	O
+deaths	B-PROC
+).	O
+
+Therefore	O
+,	O
+physiological	O
+variables	O
+need	O
+to	O
+be	O
+identified	O
+by	O
+stratifying	O
+ARDS	B-DISO
+subphenotypes	O
+and	O
+endotype	O
+,	O
+to	O
+target	O
+ARDS	B-DISO
+heterogeneity	O
+.	O
+
+The	O
+interlinked	O
+biological	O
+pathway	B-PROC
+of	O
+these	O
+disease	O
+specific	O
+endotype	O
+further	O
+elucidated	O
+their	O
+role	O
+as	O
+candidate	O
+biomarker	B-CHED
+in	O
+governing	O
+ARDS	B-DISO
+heterogeneous	O
+biology	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+enhanced	O
+inflammatory	O
+cytokine	B-PROC
+production	I-PROC
+in	O
+response	B-PROC
+to	I-PROC
+lipopolysaccharide	I-PROC
+(	O
+LPS	B-DISO
+)	O
+is	O
+due	O
+to	O
+increased	O
+TGF	B-PRGE
+-	I-PRGE
+β	I-PRGE
+-	I-PRGE
+activated	I-PRGE
+kinase	I-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+TAK1	B-PRGE
+)	O
+phosphorylation	B-PROC
+with	O
+subsequent	O
+activation	O
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+κB	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+).	O
+
+Some	O
+viruses	B-SPEC
+circulated	O
+predominantly	O
+during	O
+winter	O
+,	O
+whereas	O
+others	O
+were	O
+found	O
+year	O
+round	O
+.	O
+
+The	O
+observations	O
+identify	O
+children	O
+as	O
+the	O
+principal	O
+source	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+Children	O
+registered	O
+the	O
+highest	O
+positivity	O
+rates	O
+,	O
+and	O
+adults	O
+with	O
+daily	O
+contacts	O
+with	O
+children	O
+experienced	O
+significantly	O
+more	O
+infections	B-DISO
+than	O
+their	O
+counterparts	O
+without	O
+children	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Respiratory	O
+viral	B-DISO
+infections	I-DISO
+are	O
+widespread	O
+among	O
+the	O
+general	O
+population	O
+with	O
+the	O
+majority	O
+of	O
+individuals	O
+presenting	O
+multiple	O
+infections	B-DISO
+per	O
+year	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+Epidemic	O
+Diarrhea	O
+Virus	O
+(	O
+PEDV	B-SPEC
+)	O
+emerged	O
+in	O
+North	O
+America	O
+in	O
+2013	O
+.	O
+
+TITLE	O
+:	O
+Absence	O
+of	O
+neutralizing	O
+activity	O
+in	O
+serum	B-COMP
+1	O
+year	O
+after	O
+successful	O
+treatment	O
+with	O
+antivirals	B-CHED
+and	O
+recovery	O
+from	O
+MERS	O
+in	O
+South	O
+Korea	O
+.	O
+
+The	O
+neutralizing	O
+activity	O
+in	O
+serum	B-COMP
+was	O
+measured	O
+by	O
+pseudovirus	O
+inhibition	B-PROC
+assays	O
+.	O
+
+Two	O
+hundred	O
+mechanically	O
+ventilated	O
+patients	O
+aged	O
+16	O
+years	O
+and	O
+older	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+(	O
+Pao2	O
+:	O
+Fio2	O
+≤	O
+200	O
+mm	O
+Hg	O
+)	O
+were	O
+enrolled	O
+between	O
+October	O
+31	O
+,	O
+2012	O
+,	O
+and	O
+September	O
+14	O
+,	O
+2017	O
+;	O
+long	O
+-	O
+term	O
+follow	O
+-	O
+up	O
+was	O
+completed	O
+July	O
+30	O
+,	O
+2018	O
+.	O
+
+Participants	O
+were	O
+randomized	O
+to	O
+PES	O
+-	O
+guided	O
+PEEP	B-CHED
+(	O
+n	O
+=	O
+102	O
+)	O
+or	O
+empirical	O
+high	O
+PEEP	B-CHED
+-	O
+Fio2	O
+(	O
+n	O
+=	O
+98	O
+).	O
+
+The	O
+primary	O
+outcome	O
+was	O
+a	O
+ranked	O
+composite	O
+score	O
+incorporating	O
+death	B-PROC
+and	O
+days	O
+free	O
+from	O
+mechanical	O
+ventilation	O
+among	O
+survivors	O
+through	O
+day	O
+28	O
+.	O
+
+This	O
+study	O
+determines	O
+the	O
+cost	O
+-	O
+effectiveness	O
+of	O
+interventions	O
+to	O
+increase	O
+utilization	O
+of	O
+proning	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+From	O
+a	O
+hospital	O
+perspective	O
+,	O
+the	O
+intervention	O
+yielded	O
+0	O
+.	O
+072	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+008	O
+-	O
+0	O
+.	O
+147	O
+)	O
+more	O
+survivals	O
+-	O
+to	O
+-	O
+discharge	B-ANAT
+at	O
+a	O
+cost	O
+of	O
+$	O
+5	O
+,	O
+242	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+-$	O
+19	O
+,	O
+035	O
+to	O
+$	O
+41	O
+,	O
+019	O
+)	O
+(	O
+incremental	O
+cost	O
+-	O
+effectiveness	O
+ratio	O
+=	O
+$	O
+44	O
+,	O
+615	O
+per	O
+extra	O
+survival	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+-$	O
+250	O
+,	O
+912	O
+to	O
+$	O
+558	O
+,	O
+222	O
+]).	O
+
+If	O
+hospitals	O
+were	O
+willing	O
+to	O
+pay	O
+$	O
+100	O
+,	O
+000	O
+per	O
+survival	O
+-	O
+to	O
+-	O
+discharge	B-ANAT
+,	O
+any	O
+intervention	O
+costing	O
+less	O
+than	O
+$	O
+5	O
+,	O
+140	O
+per	O
+patient	O
+would	O
+represent	O
+good	O
+value	O
+.	O
+
+A	O
+total	O
+of	O
+222	O
+metabolites	B-CHED
+were	O
+identified	O
+in	O
+our	O
+study	O
+,	O
+of	O
+which	O
+128	O
+were	O
+significantly	O
+altered	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+compared	O
+with	O
+healthy	O
+controls	O
+.	O
+
+Plasma	B-ANAT
+metabolomics	O
+may	O
+improve	O
+our	O
+understanding	O
+of	O
+ARDS	B-DISO
+biology	O
+.	O
+
+We	O
+discovered	O
+92	O
+pathways	B-PROC
+that	O
+were	O
+significantly	O
+different	O
+between	O
+ARDS	B-DISO
+and	O
+control	O
+groups	O
+,	O
+including	O
+57	O
+pathways	B-PROC
+linked	O
+to	O
+metabolism	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+p53	B-PRGE
+is	O
+a	O
+tumor	B-PROC
+suppressor	I-PROC
+gene	O
+that	O
+can	O
+be	O
+activated	O
+in	O
+many	O
+contexts	O
+,	O
+such	O
+as	O
+DNA	B-DISO
+damage	I-DISO
+or	O
+stressful	O
+conditions	O
+.	O
+
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+major	O
+enteric	O
+pathogen	O
+of	O
+the	O
+coronavirus	B-SPEC
+family	B-SPEC
+that	O
+causes	O
+extensive	O
+mortality	O
+among	O
+piglets	O
+.	O
+
+These	O
+findings	O
+demonstrate	O
+that	O
+p53	B-PRGE
+suppresses	O
+PEDV	B-SPEC
+infection	B-DISO
+,	O
+offering	O
+a	O
+novel	O
+therapeutic	O
+strategy	O
+for	O
+combatting	O
+this	O
+deadly	O
+disease	O
+in	O
+piglets	O
+.	O
+
+For	O
+plant	B-SPEC
+pathogenic	O
+fungi	B-SPEC
+,	O
+6	O
+-	O
+26	O
+showed	O
+excellent	O
+activity	O
+at	O
+50	O
+mg	O
+/	O
+L	O
+dosage	O
+.	O
+
+Cloacal	B-ANAT
+/	O
+throat	B-ANAT
+double	O
+swabs	O
+were	O
+collected	O
+from	O
+60	O
+birds	B-SPEC
+at	O
+each	O
+farm	O
+according	O
+to	O
+a	O
+random	O
+sampling	O
+method	O
+.	O
+
+Five	O
+H9N2	O
+and	O
+one	O
+H3N8	O
+avian	O
+influenza	B-SPEC
+viruses	I-SPEC
+were	O
+detected	O
+at	O
+the	O
+farms	O
+and	O
+were	O
+identified	O
+as	O
+low	O
+pathogenic	O
+avian	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+according	O
+to	O
+HA	O
+cleavage	B-PROC
+sites	O
+analysis	O
+.	O
+
+In	O
+addition	O
+to	O
+overall	O
+morbidity	O
+,	O
+non	O
+-	O
+Hispanic	O
+black	O
+women	O
+were	O
+at	O
+significantly	O
+greater	O
+risk	O
+for	O
+eclampsia	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+renal	B-DISO
+failure	I-DISO
+than	O
+other	O
+racial	O
+groups	O
+(	O
+P	O
+<.	O
+05	O
+all	O
+).	O
+
+RESULTS	O
+:	O
+Of	O
+11	O
+.	O
+3	O
+million	O
+births	B-PROC
+,	O
+207	O
+,	O
+730	O
+(	O
+1	O
+.	O
+8	O
+%)	O
+women	O
+admitted	O
+postpartum	O
+from	O
+2012	O
+to	O
+2014	O
+were	O
+analyzed	O
+,	O
+including	O
+96	O
+,	O
+670	O
+white	O
+,	O
+47	O
+,	O
+015	O
+black	O
+,	O
+and	O
+33	O
+,	O
+410	O
+Hispanic	O
+women	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+equine	B-SPEC
+coronavirus	B-SPEC
+fecal	B-ANAT
+shedding	O
+among	O
+hospitalized	O
+horses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Currently	O
+,	O
+diagnosis	O
+of	O
+equine	O
+coronavirus	B-SPEC
+(	O
+ECoV	B-SPEC
+)	O
+relies	O
+on	O
+the	O
+exclusion	O
+of	O
+other	O
+infectious	B-DISO
+causes	O
+of	O
+enteric	O
+disease	O
+along	O
+with	O
+molecular	O
+detection	O
+of	O
+ECoV	B-SPEC
+in	O
+feces	B-ANAT
+or	O
+tissue	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2015	O
+,	O
+a	O
+One	O
+Health	O
+Working	O
+Group	O
+was	O
+established	O
+in	O
+Qatar	O
+to	O
+conduct	B-PROC
+a	O
+survey	O
+in	O
+the	O
+Gulf	O
+Cooperation	O
+Council	O
+countries	O
+,	O
+Egypt	O
+,	O
+and	O
+Jordan	O
+to	O
+monitor	O
+preparedness	O
+of	O
+public	O
+health	O
+and	O
+veterinary	O
+health	O
+authorities	O
+in	O
+response	O
+to	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+epidemic	O
+.	O
+
+All	O
+but	O
+1	O
+country	O
+indicated	O
+they	O
+established	O
+joint	B-ANAT
+One	O
+Health	O
+policy	O
+teams	O
+for	O
+investigation	O
+and	O
+response	O
+.	O
+
+National	O
+and	O
+regional	O
+leaders	O
+,	O
+policy	O
+makers	O
+,	O
+and	O
+stakeholders	O
+should	O
+be	O
+prompted	O
+to	O
+advocate	O
+and	O
+enhance	O
+adoption	O
+of	O
+the	O
+One	O
+Health	O
+framework	O
+to	O
+mitigate	O
+the	O
+risk	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+and	O
+other	O
+emerging	O
+zoonotic	O
+diseases	O
+.	O
+
+Patients	O
+with	O
+hypothermia	O
+were	O
+significantly	O
+older	O
+than	O
+those	O
+with	O
+a	O
+body	B-ANAT
+temperature	O
+of	O
+36	O
+-	O
+38	O
+°	O
+C	O
+or	O
+greater	O
+than	O
+38	O
+°	O
+C	O
+and	O
+had	O
+a	O
+lower	B-ANAT
+body	I-ANAT
+mass	O
+index	O
+and	O
+higher	O
+prevalence	O
+of	O
+septic	B-DISO
+shock	I-DISO
+than	O
+those	O
+with	O
+body	B-ANAT
+temperature	O
+greater	O
+than	O
+38	O
+°	O
+C	O
+.	O
+
+TITLE	O
+:	O
+Enhanced	O
+Ability	O
+of	O
+Oligomeric	O
+Nanobodies	O
+Targeting	B-PROC
+MERS	O
+Coronavirus	B-SPEC
+Receptor	O
+-	O
+Binding	B-FUNC
+Domain	O
+.	O
+
+Therapeutic	O
+antibodies	B-COMP
+are	O
+key	O
+tools	O
+for	O
+preventing	O
+and	O
+treating	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+but	O
+to	O
+date	O
+no	O
+such	O
+agents	O
+have	O
+been	O
+approved	O
+for	O
+treatment	O
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+Overall	O
+,	O
+the	O
+engineered	O
+Nbs	B-DISO
+could	O
+be	O
+developed	O
+into	O
+effective	O
+therapeutic	O
+agents	O
+for	O
+prevention	O
+and	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Global	O
+Epidemiology	O
+of	O
+Bat	B-ENZY
+Coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+a	O
+unique	O
+group	O
+of	O
+mammals	B-SPEC
+of	O
+the	O
+order	O
+
+TITLE	O
+:	O
+Patterns	O
+of	O
+invasive	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+severe	O
+blunt	O
+chest	B-ANAT
+trauma	O
+and	O
+lung	B-ANAT
+contusion	O
+:	O
+A	O
+French	O
+multicentric	O
+evaluation	O
+of	O
+practices	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+severe	O
+economic	O
+loss	O
+in	O
+the	O
+pig	B-SPEC
+industry	O
+each	O
+year	O
+.	O
+
+ABSTRACT	O
+:	O
+Nucleoside	B-CHED
+analogues	I-CHED
+are	O
+well	O
+known	O
+antitumor	O
+,	O
+antiviral	B-CHED
+,	O
+and	O
+chemotherapeutic	O
+agents	O
+.	O
+
+C5	O
+-	O
+arylalkynyl	O
+-	O
+β	O
+-	O
+D	O
+-	O
+ribofuranonucleosides	O
+3	O
+-	O
+6	O
+,	O
+3	O
+΄-	O
+deoxy	O
+12	O
+-	O
+15	O
+,	O
+3	O
+΄-	O
+deoxy	O
+-	O
+3	O
+΄-	O
+C	O
+-	O
+methyl	B-CHED
+-	O
+β	O
+-	O
+D	O
+-	O
+ribofurananucleosides	O
+18	O
+-	O
+21	O
+and	O
+2	O
+΄-	O
+deoxy	O
+-	O
+β	O
+-	O
+D	O
+-	O
+ribofuranonucleosides	O
+23	O
+-	O
+26	O
+of	O
+uracil	B-CHED
+,	O
+were	O
+synthesized	O
+using	O
+a	O
+one	O
+-	O
+step	O
+Sonogashira	O
+reaction	O
+under	O
+microwave	O
+irradiation	O
+and	O
+subsequent	O
+deprotection	O
+.	O
+
+This	O
+report	O
+describes	O
+the	O
+total	O
+and	O
+facile	O
+synthesis	B-PROC
+of	O
+modified	O
+furanononucleosides	O
+of	O
+uracil	B-CHED
+,	O
+with	O
+alterations	O
+on	O
+both	O
+the	O
+sugar	O
+and	O
+the	O
+heterocyclic	O
+portions	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+newly	O
+synthesized	O
+nucleosides	B-CHED
+were	O
+tested	O
+for	O
+their	O
+antitumor	O
+or	O
+antiviral	B-CHED
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+clinical	O
+cytology	O
+,	O
+the	O
+applicability	O
+of	O
+an	O
+ancillary	O
+test	O
+such	O
+as	O
+immunocytochemistry	O
+is	O
+too	O
+often	O
+limited	O
+by	O
+low	O
+sample	O
+volume	O
+,	O
+poor	O
+cell	B-COMP
+representation	O
+,	O
+and	O
+sample	O
+preservation	O
+.	O
+
+Cellular	B-COMP
+antigens	B-CHED
+were	O
+reliably	O
+detected	O
+with	O
+immunocytochemistry	O
+after	O
+smears	O
+were	O
+stained	O
+with	O
+a	O
+Romansky	O
+stain	O
+and	O
+were	O
+coverslipped	O
+early	O
+after	O
+staining	O
+and	O
+stayed	O
+coverslipped	O
+until	O
+immediately	O
+before	O
+immunolabeling	O
+.	O
+
+RESULTS	O
+:	O
+Cellular	B-COMP
+antigens	B-CHED
+were	O
+reliably	O
+detected	O
+with	O
+immunocytochemistry	O
+after	O
+smears	O
+were	O
+stained	O
+with	O
+a	O
+Romansky	O
+stain	O
+and	O
+were	O
+coverslipped	O
+early	O
+after	O
+staining	O
+and	O
+stayed	O
+coverslipped	O
+until	O
+immediately	O
+before	O
+immunolabeling	O
+.	O
+
+Myong	O
+Ji	O
+Hospital	O
+learned	B-PROC
+two	O
+important	O
+lessons	O
+in	O
+responding	O
+to	O
+emerging	O
+infectious	O
+diseases	O
+;	O
+the	O
+first	O
+was	O
+to	O
+prepare	O
+a	O
+form	O
+of	O
+workforce	O
+,	O
+facility	O
+,	O
+manual	O
+and	O
+drills	B-SPEC
+;	O
+the	O
+second	O
+was	O
+to	O
+prepare	O
+proper	O
+communication	O
+methods	O
+.	O
+
+ABSTRACT	O
+:	O
+Evaluation	O
+of	O
+the	O
+thermal	O
+and	O
+physical	O
+conditions	O
+for	O
+inactivation	B-DISO
+of	O
+adenovirus	B-DISO
+(	O
+AdV	O
+),	O
+porcine	B-SPEC
+sapelovirus	I-SPEC
+1	O
+(	O
+PSV1	O
+)	O
+and	O
+the	O
+economically	O
+important	O
+viruses	B-SPEC
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+circovirus	I-SPEC
+2	I-SPEC
+(	O
+PCV2	O
+)	O
+in	O
+the	O
+production	O
+of	O
+spray	O
+-	O
+dried	B-ANAT
+porcine	B-SPEC
+plasma	B-ANAT
+(	O
+SDPP	O
+).	O
+
+Reverse	B-PROC
+transcription	I-PROC
+(	O
+RT	O
+)-	O
+quantitative	O
+PCR	O
+detected	O
+no	O
+notable	O
+reduction	O
+in	O
+viral	O
+genomes	O
+in	O
+treated	O
+plasma	O
+and	O
+SDPP	O
+samples	O
+.	O
+
+No	O
+infectious	B-DISO
+PSV1	O
+was	O
+re	O
+-	O
+isolated	O
+from	O
+plasma	B-ANAT
+and	O
+SDPP	O
+samples	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+Spray	O
+drying	O
+in	O
+combination	O
+with	O
+storage	B-PROC
+for	O
+≥	O
+2	O
+weeks	O
+at	O
+20	O
+°	O
+C	O
+eliminated	O
+infectivity	O
+of	O
+PEDV	B-SPEC
+effectively	O
+.	O
+
+As	O
+the	O
+only	O
+flying	O
+mammal	B-SPEC
+,	O
+bats	B-SPEC
+endure	O
+high	O
+metabolic	B-PROC
+rates	I-PROC
+yet	O
+exhibit	O
+elongated	O
+lifespans	O
+.	O
+
+The	O
+important	O
+inflammasome	O
+sensor	O
+,	O
+NLR	B-PRGE
+family	I-PRGE
+pyrin	I-PRGE
+domain	I-PRGE
+containing	I-PRGE
+3	I-PRGE
+(	O
+NLRP3	B-PRGE
+),	O
+has	O
+been	O
+linked	O
+to	O
+both	O
+viral	O
+-	O
+induced	O
+and	O
+age	O
+-	O
+related	O
+inflammation	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+significantly	O
+dampened	O
+activation	O
+of	O
+the	O
+NLRP3	B-PRGE
+inflammasome	I-PRGE
+in	O
+bat	B-ENZY
+primary	O
+immune	O
+cells	B-COMP
+compared	O
+to	O
+human	B-SPEC
+or	O
+mouse	B-SPEC
+counterparts	O
+.	O
+
+We	O
+identified	O
+dampened	O
+transcriptional	B-PROC
+priming	O
+,	O
+a	O
+novel	O
+splice	O
+variant	O
+and	O
+an	O
+altered	O
+leucine	B-CHED
+-	O
+rich	O
+repeat	O
+domain	O
+of	O
+bat	B-PRGE
+NLRP3	I-PRGE
+as	O
+the	O
+cause	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+use	O
+of	O
+mechanical	O
+ventilation	O
+is	O
+an	O
+invaluable	O
+tool	O
+in	O
+caring	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Expert	O
+opinion	O
+:	O
+As	O
+we	O
+have	O
+advanced	O
+in	O
+our	O
+care	O
+,	O
+we	O
+are	O
+seeing	B-PROC
+children	O
+survive	O
+illnesses	O
+that	O
+would	O
+have	O
+once	O
+claimed	O
+their	O
+lives	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+and	O
+reemergence	O
+of	O
+coronavirus	B-SPEC
+epidemics	O
+sparked	O
+renewed	O
+concerns	O
+from	O
+global	O
+epidemiology	O
+researchers	O
+and	O
+public	O
+health	O
+administrators	O
+.	O
+
+Mathematical	O
+models	O
+that	O
+represented	O
+how	O
+contact	O
+tracing	O
+and	O
+follow	O
+-	O
+up	O
+may	O
+control	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+transmissions	O
+were	O
+developed	O
+for	O
+evaluating	O
+different	O
+infection	B-DISO
+control	O
+interventions	O
+,	O
+estimating	O
+likely	O
+number	O
+of	O
+infections	B-DISO
+as	O
+well	O
+as	O
+facilitating	O
+understanding	O
+of	O
+their	O
+likely	O
+epidemiology	O
+.	O
+
+Persons	O
+in	O
+the	O
+health	O
+field	O
+including	O
+physicians	O
+and	O
+veterinarians	O
+,	O
+pet	O
+owners	O
+,	O
+pet	O
+store	O
+owners	O
+,	O
+exporters	O
+,	O
+border	B-ANAT
+guards	O
+,	O
+and	O
+people	O
+involved	O
+in	O
+businesses	O
+related	O
+to	O
+animal	B-SPEC
+products	O
+have	O
+adopted	O
+various	O
+preventive	O
+strategies	O
+.	O
+
+TITLE	O
+:	O
+An	O
+updated	O
+roadmap	O
+for	O
+MERS	O
+-	O
+CoV	O
+research	O
+and	O
+product	O
+development	B-PROC
+:	O
+focus	O
+on	O
+diagnostics	O
+.	O
+
+In	O
+this	O
+review	O
+we	O
+identified	O
+sources	O
+for	O
+molecular	O
+and	O
+serological	O
+diagnostic	O
+tests	O
+used	O
+in	O
+MERS	O
+-	O
+CoV	O
+detection	O
+,	O
+case	O
+management	O
+and	O
+outbreak	O
+investigations	O
+,	O
+as	O
+well	O
+as	O
+surveillance	O
+for	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+(	O
+camels	B-SPEC
+),	O
+and	O
+summarised	O
+the	O
+performance	O
+of	O
+currently	O
+available	O
+tests	O
+,	O
+diagnostic	O
+needs	O
+,	O
+and	O
+associated	O
+challenges	O
+for	O
+diagnostic	O
+test	O
+development	B-PROC
+and	O
+implementation	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+recent	O
+advances	O
+,	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+a	O
+severe	O
+and	O
+often	O
+fatal	O
+disease	O
+for	O
+which	O
+there	O
+is	O
+no	O
+therapy	O
+able	O
+to	O
+reduce	O
+the	O
+underlying	O
+excessive	O
+lung	B-DISO
+inflammation	I-DISO
+or	O
+enhance	O
+resolution	O
+of	O
+injury	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+inhibiting	O
+glutamine	B-PROC
+metabolism	I-PROC
+reduces	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+promotes	O
+resolution	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+spike	O
+glycoprotein	B-CHED
+from	O
+strain	O
+RSA59	O
+(	O
+PP	O
+)	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+contains	O
+two	O
+central	O
+,	O
+consecutive	O
+prolines	O
+in	O
+the	O
+FP	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+continuation	O
+of	O
+our	O
+efforts	O
+toward	O
+the	O
+discovery	O
+of	O
+potent	O
+non	O
+-	O
+nucleoside	B-CHED
+HBV	B-DISO
+inhibitors	B-CHED
+with	O
+novel	O
+structures	O
+,	O
+we	O
+have	O
+explored	O
+the	O
+solvent	B-CHED
+-	O
+exposed	O
+protein	B-CHED
+region	O
+of	O
+heteroaryldihydropyrimidines	O
+(	O
+HAPs	O
+)	O
+derivatives	O
+.	O
+
+Participants	O
+underwent	O
+bronchoscopy	O
+with	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+and	O
+a	O
+subset	O
+underwent	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+.	O
+
+Rhinovirus	B-SPEC
+was	O
+the	O
+most	O
+prevalent	O
+virus	B-SPEC
+(	O
+66	O
+%),	O
+followed	O
+by	O
+parainfluenza	B-DISO
+(	O
+19	O
+%),	O
+and	O
+coronavirus	B-SPEC
+(	O
+16	O
+%).	O
+
+The	O
+course	O
+of	O
+treatment	O
+of	O
+4	O
+cases	O
+of	O
+ARDS	B-DISO
+caused	O
+by	O
+acute	O
+phosgene	B-CHED
+poisoning	O
+admitted	O
+to	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+of	O
+Jiangxi	O
+Provincial	O
+People	O
+'	O
+s	O
+Hospital	O
+in	O
+April	O
+2018	O
+was	O
+retrospectively	O
+analyzed	O
+.	O
+
+The	O
+main	O
+pathological	O
+features	O
+are	O
+the	O
+diffuse	O
+inflammatory	O
+and	O
+protein	B-CHED
+-	O
+rich	O
+pulmonary	B-DISO
+edema	I-DISO
+caused	O
+by	O
+destruction	O
+of	O
+the	O
+blood	B-ANAT
+-	O
+air	B-CHED
+barrier	O
+.	O
+
+Among	O
+many	O
+systems	O
+producing	O
+ROS	B-CHED
+,	O
+nicotinamide	B-CHED
+-	I-CHED
+adenine	I-CHED
+dinucleotide	I-CHED
+phosphate	I-CHED
+(	O
+NADPH	B-CHED
+)	O
+oxidase	B-PRGE
+-	O
+mediated	O
+ROS	B-CHED
+is	O
+the	O
+main	O
+source	O
+,	O
+and	O
+its	O
+functional	O
+subunit	O
+is	O
+the	O
+transmembrane	B-COMP
+subunit	O
+NOX	O
+family	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Chicken	B-SPEC
+anaemia	I-SPEC
+virus	I-SPEC
+enhances	O
+and	O
+prolongs	O
+subsequent	O
+avian	B-DISO
+influenza	I-DISO
+(	O
+H9N2	O
+)	O
+and	O
+infectious	B-DISO
+bronchitis	O
+viral	O
+infections	O
+.	O
+
+The	O
+results	O
+exhibit	O
+that	O
+chickens	B-SPEC
+previously	O
+infected	O
+with	O
+CAV	B-SPEC
+produceconsiderablyhigher	O
+titresof	O
+LPAI	O
+-	O
+H9N2	O
+or	O
+IB	O
+viruses	B-SPEC
+in	O
+the	O
+oropharyngeal	B-ANAT
+swabs	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+tracheas	B-ANAT
+and	O
+kidneys	B-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+carried	O
+out	O
+detailed	O
+phylogenetic	O
+analysis	O
+and	O
+sequence	O
+comparisons	O
+based	O
+on	O
+74	O
+complete	O
+nucleotide	B-CHED
+sequences	O
+of	O
+the	O
+IBV	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+,	O
+including	O
+strain	O
+I0636	O
+/	O
+16	O
+and	O
+73	O
+representative	O
+sequences	O
+from	O
+each	O
+genotype	O
+and	O
+lineage	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+and	O
+comparison	O
+of	O
+immunogenicity	O
+and	O
+cross	O
+-	O
+protective	O
+efficacy	O
+of	O
+two	O
+inactivated	O
+cell	B-COMP
+culture	O
+-	O
+derived	O
+GIIa	O
+-	O
+and	O
+GIIb	O
+-	O
+genotype	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+vaccines	O
+in	O
+suckling	O
+piglets	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+both	O
+vaccine	O
+candidates	O
+induced	O
+high	O
+levels	O
+of	O
+PEDV	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+antibodies	B-COMP
+and	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+reduced	O
+the	O
+levels	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+at	O
+21	O
+dpv	O
+in	O
+suckling	O
+piglets	O
+.	O
+
+The	O
+GIIa	O
+-	O
+based	O
+inactivated	O
+vaccine	O
+protected	O
+all	O
+piglets	O
+(	O
+8	O
+/	O
+8	O
+)	O
+against	O
+virulent	O
+homologous	O
+and	O
+heterologous	O
+virus	B-SPEC
+challenge	O
+,	O
+while	O
+the	O
+GIIb	O
+strain	O
+-	O
+based	O
+inactivated	O
+vaccine	O
+protected	O
+only	O
+2	O
+/	O
+4	O
+and	O
+1	O
+/	O
+4	O
+piglets	O
+against	O
+virulent	O
+homologous	O
+and	O
+heterologous	O
+virus	O
+challenge	O
+,	O
+respectively	O
+.	O
+
+Taken	O
+together	O
+,	O
+the	O
+data	O
+presented	O
+in	O
+this	O
+study	O
+indicate	O
+that	O
+GIIa	O
+strain	O
+-	O
+based	O
+inactivated	O
+vaccine	O
+candidates	O
+are	O
+more	O
+promising	O
+than	O
+GIIb	O
+-	O
+based	O
+candidates	O
+for	O
+the	O
+development	B-PROC
+of	O
+an	O
+effective	O
+vaccine	O
+against	O
+the	O
+current	O
+highly	O
+virulent	O
+pandemic	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+TITLE	O
+:	O
+Successful	O
+extracorporeal	O
+life	O
+support	O
+in	O
+respiratory	B-DISO
+failure	I-DISO
+after	O
+copper	B-CHED
+sulphate	B-CHED
+ingestion	O
+.	O
+
+This	O
+required	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+management	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+TITLE	O
+:	O
+Anti	B-PRGE
+-	I-PRGE
+spike	I-PRGE
+IgG	I-PRGE
+causes	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+by	O
+skewing	O
+macrophage	B-ANAT
+responses	O
+during	O
+acute	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Newly	O
+emerging	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+Middle	O
+Eastern	O
+respiratory	O
+syndrome	B-DISO
+CoVs	O
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+and	O
+H7N9	O
+,	O
+cause	O
+fatal	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+by	O
+driving	O
+hypercytokinemia	O
+and	O
+aggressive	B-DISO
+inflammation	B-DISO
+through	O
+mechanisms	O
+that	O
+remain	O
+elusive	O
+.	O
+
+Alveolar	B-ANAT
+macrophages	I-ANAT
+underwent	O
+functional	O
+polarization	O
+in	O
+acutely	O
+infected	O
+macaques	B-SPEC
+,	O
+demonstrating	O
+simultaneously	O
+both	O
+proinflammatory	O
+and	O
+wound	O
+-	O
+healing	B-PROC
+characteristics	O
+.	O
+
+Leptospirosis	B-DISO
+can	O
+induce	O
+serious	O
+but	O
+transient	O
+ARDS	B-DISO
+with	O
+a	O
+better	O
+prognosis	O
+than	O
+that	O
+of	O
+other	O
+causes	O
+of	O
+ARDS	B-DISO
+.	O
+
+SARS	B-DISO
+and	O
+MERS	O
+emerged	O
+in	O
+2003	O
+and	O
+2012	O
+,	O
+respectively	O
+,	O
+and	O
+caused	O
+a	O
+worldwide	O
+pandemic	O
+that	O
+claimed	O
+thousands	O
+of	O
+human	B-SPEC
+lives	O
+,	O
+while	O
+SADS	O
+struck	B-DISO
+the	O
+swine	B-SPEC
+industry	O
+in	O
+2017	O
+.	O
+
+Interruption	O
+of	O
+the	O
+zoonotic	O
+transmission	O
+chain	O
+from	O
+camels	B-SPEC
+to	O
+humans	B-SPEC
+,	O
+therefore	O
+,	O
+may	O
+be	O
+an	O
+effective	O
+strategy	O
+to	O
+control	O
+the	O
+ongoing	O
+MERS	O
+-	O
+CoV	O
+outbreak	O
+.	O
+
+Protection	O
+in	O
+alpaca	B-SPEC
+correlates	O
+with	O
+high	O
+serum	B-COMP
+neutralizing	O
+antibody	B-COMP
+titers	O
+.	O
+
+Through	O
+different	O
+inoculation	O
+routes	O
+,	O
+MHV	B-SPEC
+-	O
+A59	O
+can	O
+provide	O
+animal	B-SPEC
+models	O
+for	O
+encephalitis	B-DISO
+,	O
+hepatitis	B-DISO
+and	O
+pneumonia	B-DISO
+to	O
+explore	O
+viral	O
+life	O
+machinery	O
+and	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+.	O
+
+We	O
+restructure	O
+the	O
+original	O
+data	O
+into	O
+run	O
+-	O
+off	O
+triangle	O
+data	O
+,	O
+where	O
+the	O
+cells	B-COMP
+contain	O
+the	O
+numbers	O
+of	O
+cured	O
+patients	O
+,	O
+deceased	B-PROC
+patients	O
+,	O
+and	O
+patients	O
+still	O
+having	O
+the	O
+disease	O
+at	O
+a	O
+given	O
+combination	O
+of	O
+calendar	O
+and	O
+disease	O
+-	O
+duration	O
+times	O
+.	O
+
+Data	O
+from	O
+GIS	O
+and	O
+multiple	O
+potential	O
+infection	B-DISO
+factors	O
+were	O
+used	O
+to	O
+pinpoint	O
+cluster	O
+dissemination	O
+in	O
+areas	O
+with	O
+large	O
+numbers	O
+of	O
+swine	B-SPEC
+farms	O
+in	O
+southern	O
+Taiwan	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+explored	O
+the	O
+ability	O
+of	O
+PEDV	B-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+in	O
+improving	O
+viral	O
+yields	O
+in	O
+cell	B-COMP
+culture	O
+systems	O
+.	O
+
+Interestingly	O
+,	O
+PEDV	O
+N	O
+also	O
+slightly	O
+enhances	O
+replication	O
+of	O
+porcine	B-SPEC
+reproductive	B-PROC
+and	O
+respiratory	O
+virus	B-SPEC
+,	O
+a	O
+PEDV	B-SPEC
+relative	O
+in	O
+the	O
+Nidovirales	B-SPEC
+order	B-SPEC
+.	O
+
+These	O
+results	O
+solidify	O
+the	O
+importance	O
+of	O
+N	O
+in	O
+PEDV	B-SPEC
+recovery	O
+and	O
+propagation	O
+and	O
+suggest	O
+a	O
+potentially	O
+useful	O
+consideration	O
+in	O
+designing	O
+vaccine	O
+production	O
+platforms	O
+for	O
+PEDV	B-SPEC
+or	O
+closely	O
+related	O
+pathogens	O
+.	O
+
+Among	O
+them	O
+,	O
+the	O
+62	O
+who	O
+required	O
+ECMO	O
+for	O
+ARDS	B-DISO
+were	O
+analyzed	O
+.	O
+
+Lower	O
+median	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+and	O
+median	O
+dynamic	O
+driving	O
+pressure	O
+were	O
+observed	O
+in	O
+the	O
+extended	O
+group	O
+24	O
+hours	O
+after	O
+ECMO	O
+support	O
+.	O
+
+Sequencing	O
+revealed	O
+89	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+between	O
+the	O
+viral	B-PRGE
+attachment	I-PRGE
+protein	I-PRGE
+S1	I-PRGE
+of	O
+GfCoV	O
+/	O
+2014	O
+and	O
+that	O
+of	O
+the	O
+previously	O
+identified	O
+GfCoV	O
+/	O
+2011	O
+.	O
+
+It	O
+is	O
+evident	O
+from	O
+both	O
+multiple	O
+alignment	O
+and	O
+phylogenetic	O
+analyses	O
+that	O
+some	O
+genes	O
+of	O
+a	O
+particular	O
+SARSr	O
+-	O
+CoV	O
+from	O
+bats	B-SPEC
+may	O
+possess	B-DISO
+higher	O
+while	O
+other	O
+genes	O
+possess	B-DISO
+much	O
+lower	O
+nucleotide	B-CHED
+identity	O
+to	O
+the	O
+corresponding	O
+genes	O
+of	O
+SARSr	O
+-	O
+CoV	O
+from	O
+human	B-SPEC
+/	O
+civets	B-SPEC
+,	O
+resulting	O
+in	O
+the	O
+shift	O
+of	O
+phylogenetic	O
+position	O
+in	O
+different	O
+phylogenetic	O
+trees	O
+.	O
+
+TITLE	O
+:	O
+An	O
+electrochemical	O
+immunosensor	O
+for	O
+the	O
+corona	B-CHED
+virus	B-SPEC
+associated	O
+with	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+using	O
+an	O
+array	O
+of	O
+gold	B-CHED
+nanoparticle	I-CHED
+-	O
+modified	O
+carbon	B-CHED
+electrodes	O
+.	O
+
+The	O
+biosensor	O
+is	O
+based	O
+on	O
+indirect	O
+competition	O
+between	O
+free	O
+virus	B-SPEC
+in	O
+the	O
+sample	O
+and	O
+immobilized	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	I-PRGE
+for	O
+a	O
+fixed	B-ANAT
+concentration	O
+of	O
+antibody	B-COMP
+added	O
+to	O
+the	O
+sample	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+approaches	O
+that	O
+antagonize	O
+viral	O
+nonstructural	O
+proteins	B-CHED
+,	O
+neutralize	O
+structural	O
+proteins	B-CHED
+,	O
+or	O
+modulate	O
+essential	O
+host	B-COMP
+elements	O
+of	O
+viral	B-DISO
+infection	I-DISO
+with	O
+varying	O
+levels	O
+of	O
+efficacy	O
+in	O
+models	O
+of	O
+highly	O
+pathogenic	O
+coronavirus	O
+disease	O
+are	O
+discussed	O
+.	O
+
+Here	O
+,	O
+we	O
+screened	O
+PEDV	B-SPEC
+RNA	B-PROC
+modification	I-PROC
+enzymes	O
+involved	O
+in	O
+regulating	O
+antiviral	B-PROC
+response	I-PROC
+.	O
+
+Whereas	O
+the	O
+PEDV	B-SPEC
+nsp13	O
+barely	O
+regulates	O
+type	O
+I	O
+IFN	O
+,	O
+inflammatory	O
+cytokines	O
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+a	I-PRGE
+)	O
+and	O
+MHCII	O
+,	O
+nsp16	O
+and	O
+nsp14	O
+(	O
+to	O
+a	O
+lesser	O
+extent	O
+)	O
+down	O
+-	O
+regulate	O
+these	O
+antiviral	B-CHED
+effectors	O
+.	O
+
+TITLE	O
+:	O
+Profiling	O
+DUBs	O
+and	O
+Ubl	B-PRGE
+-	O
+specific	O
+proteases	O
+with	O
+activity	O
+-	O
+based	O
+probes	O
+.	O
+
+Deubiquitinating	B-PROC
+enzymes	O
+(	O
+DUBs	O
+)	O
+reverse	O
+Ub	O
+signaling	B-PROC
+by	O
+disassembly	O
+of	O
+one	O
+or	O
+multiple	O
+poly	O
+-	O
+Ub	O
+chain	O
+types	O
+and	O
+their	O
+malfunction	O
+is	O
+often	O
+associated	O
+with	O
+human	B-SPEC
+disease	O
+.	O
+
+Severe	O
+and	O
+irreversible	O
+morphology	O
+changes	O
+in	O
+lung	B-ANAT
+specimen	O
+,	O
+leading	O
+to	O
+ischemic	O
+damage	O
+of	O
+all	O
+internal	O
+organs	B-ANAT
+and	O
+tissues	B-ANAT
+,	O
+were	O
+observed	O
+during	O
+histological	O
+examination	O
+.	O
+
+ABSTRACT	O
+:	O
+Due	O
+to	O
+the	O
+inconsistent	O
+development	B-PROC
+of	O
+enteric	O
+signs	O
+associated	O
+with	O
+ECoV	O
+infection	B-DISO
+in	O
+adult	O
+horses	B-SPEC
+,	O
+many	O
+practitioners	O
+collect	O
+nasal	B-ANAT
+secretions	B-ANAT
+rather	O
+than	O
+feces	B-ANAT
+for	O
+the	O
+molecular	O
+diagnostic	O
+work	O
+-	O
+up	O
+of	O
+such	O
+horses	B-SPEC
+.	O
+
+Feces	B-ANAT
+were	O
+tested	O
+for	O
+ECoV	O
+and	O
+nasal	B-ANAT
+secretions	B-ANAT
+for	O
+common	O
+respiratory	O
+pathogens	O
+(	O
+equine	B-SPEC
+herpesvirus	B-SPEC
+(	O
+EHV	O
+)-	O
+1	O
+,	O
+EHV	B-SPEC
+-	I-SPEC
+4	I-SPEC
+,	O
+equine	B-DISO
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+EIV	O
+),	O
+equine	B-SPEC
+rhinitis	B-DISO
+viruses	B-SPEC
+(	O
+ERVs	O
+)	O
+and	O
+The	O
+total	O
+number	O
+of	O
+horses	B-SPEC
+testing	O
+qPCR	O
+-	O
+positive	O
+for	O
+ECoV	O
+in	O
+feces	B-ANAT
+was	O
+20	O
+(	O
+7	O
+.	O
+2	O
+%),	O
+4	O
+of	O
+which	O
+also	O
+tested	O
+qPCR	O
+-	O
+positive	O
+for	O
+ECoV	O
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+.	O
+
+In	O
+the	O
+same	O
+population	O
+9	O
+.	O
+0	O
+%	O
+of	O
+horses	B-SPEC
+tested	O
+qPCR	O
+-	O
+positive	O
+for	O
+EHV	O
+-	O
+4	O
+,	O
+6	O
+.	O
+1	O
+%	O
+for	O
+EIV	O
+,	O
+4	O
+.	O
+3	O
+%	O
+for	O
+The	O
+present	O
+study	O
+results	O
+showed	O
+that	O
+7	O
+.	O
+2	O
+%	O
+of	O
+horses	B-SPEC
+with	O
+acute	O
+onset	O
+of	O
+fever	B-PROC
+tested	O
+qPCR	O
+-	O
+positive	O
+for	O
+ECoV	O
+in	O
+feces	B-ANAT
+,	O
+highlighting	O
+the	O
+importance	O
+of	O
+testing	O
+such	O
+horses	B-SPEC
+for	O
+ECoV	O
+in	O
+feces	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Decline	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+its	O
+complex	O
+evolutionary	O
+relationship	O
+with	O
+porcine	O
+respiratory	O
+coronavirus	B-SPEC
+in	O
+the	O
+United	O
+States	O
+.	O
+
+The	O
+""""	O
+variant	O
+""""	O
+genotype	O
+shared	O
+similar	O
+unique	O
+deletions	O
+and	O
+amino	O
+acid	O
+changes	O
+with	O
+the	O
+recent	O
+PRCV	O
+strain	O
+identified	O
+in	O
+this	O
+study	O
+,	O
+suggesting	O
+a	O
+recombination	B-PROC
+event	O
+occurred	O
+between	O
+the	O
+''	O
+variant	O
+''	O
+TGEV	B-SPEC
+and	O
+PRCV	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+is	O
+the	O
+most	O
+abundant	O
+structural	O
+protein	B-CHED
+playing	O
+a	O
+critical	O
+role	O
+in	O
+virion	B-PROC
+assembly	I-PROC
+.	O
+
+Dual	O
+mutations	O
+at	O
+the	O
+two	O
+sites	O
+(	O
+N3D	O
+/	O
+N6D	O
+)	O
+did	O
+not	O
+affect	O
+particle	O
+assembly	B-PROC
+,	I-PROC
+virus	I-PROC
+-	O
+like	O
+particle	O
+formation	B-PROC
+and	O
+viral	B-PROC
+replication	I-PROC
+in	O
+culture	O
+cells	B-COMP
+.	O
+
+Unfortunately	O
+,	O
+we	O
+have	O
+only	O
+started	O
+to	O
+unravel	O
+the	O
+underlying	O
+viral	O
+mechanisms	O
+used	O
+to	O
+manipulate	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+gather	O
+current	O
+knowledge	O
+concerning	O
+the	O
+interplay	O
+between	O
+these	O
+viruses	B-SPEC
+and	O
+components	O
+of	O
+host	B-COMP
+innate	B-PROC
+immunity	I-PROC
+,	O
+focusing	O
+on	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+induction	O
+and	O
+signaling	B-PROC
+in	O
+particular	O
+,	O
+and	O
+the	O
+mechanisms	O
+by	O
+which	O
+virus	B-SPEC
+-	O
+encoded	O
+gene	O
+products	O
+antagonize	O
+and	O
+subvert	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+Finally	O
+,	O
+we	O
+provide	O
+some	O
+perspectives	O
+on	O
+the	O
+advantages	O
+gained	O
+from	O
+a	O
+better	O
+understanding	O
+of	O
+host	B-COMP
+-	O
+pathogen	O
+interactions	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+caused	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+in	O
+newborn	O
+piglets	O
+.	O
+
+In	O
+our	O
+study	O
+,	O
+the	O
+S1	O
+region	O
+of	O
+PEDV	B-SPEC
+strain	O
+CH	O
+/	O
+JLDH	O
+/	O
+2016	B-PRGE
+spike	I-PRGE
+gene	I-PRGE
+was	O
+inserted	O
+into	O
+the	O
+Lactococcus	B-SPEC
+lactis	I-SPEC
+expression	B-PROC
+vector	O
+,	O
+pNZ8149	O
+,	O
+resulting	O
+in	O
+recombinant	O
+plasmid	O
+pNZ8149	O
+-	O
+S1	O
+,	O
+and	O
+the	O
+immunogenicity	O
+of	O
+recombinant	O
+L	B-SPEC
+.	I-SPEC
+lactis	I-SPEC
+pNZ8149	O
+-	O
+S1	O
+/	O
+NZ3900	O
+was	O
+evaluated	O
+in	O
+mice	B-SPEC
+.	O
+
+Lymphocyte	O
+proliferation	B-DISO
+assay	O
+results	O
+showed	O
+that	O
+the	O
+recombinant	O
+L	B-SPEC
+.	I-SPEC
+lactis	I-SPEC
+pNZ8149	O
+-	O
+S1	O
+/	O
+NZ3900	O
+significantly	O
+stimulated	O
+the	O
+proliferation	B-DISO
+of	O
+splenic	B-ANAT
+lymphocytes	B-ANAT
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Thrombosis	B-DISO
+was	O
+classified	O
+as	O
+a	O
+large	O
+thrombosis	B-DISO
+by	O
+vein	B-DISO
+occlusion	B-PROC
+of	O
+greater	O
+than	O
+50	O
+%.	O
+
+Additional	O
+samples	O
+were	O
+obtained	O
+per	O
+-	O
+Hajj	O
+,	O
+at	O
+symptom	B-DISO
+onset	O
+in	O
+ill	B-DISO
+pilgrims	O
+.	O
+
+Viruses	B-SPEC
+were	O
+identified	O
+using	O
+the	O
+BioFire	O
+FilmArray	O
+109	O
+pilgrims	O
+were	O
+included	O
+.	O
+
+Point	O
+of	O
+care	O
+-	O
+rapid	O
+multiplex	O
+PCR	O
+assays	O
+are	O
+valuable	O
+diagnosis	O
+tools	O
+in	O
+this	O
+context	O
+when	O
+used	O
+at	O
+respiratory	B-DISO
+symptom	I-DISO
+onset	O
+or	O
+soon	O
+after	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+secondary	O
+to	O
+antisynthetase	B-DISO
+syndrome	I-DISO
+:	O
+A	O
+case	O
+report	O
+and	O
+review	O
+of	O
+literature	O
+.	O
+
+Sequencing	O
+and	O
+phylogenetic	O
+analysis	O
+showed	O
+that	O
+strain	O
+CH	O
+/	O
+HBXT	O
+/	O
+2018	O
+contained	O
+novel	O
+insertion	O
+and	O
+deletion	B-PROC
+mutations	I-PROC
+in	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+region	O
+relative	O
+to	O
+the	O
+classical	O
+strain	O
+and	O
+belonged	O
+to	O
+the	O
+genotype	O
+GIIa	O
+,	O
+similar	O
+to	O
+other	O
+recently	O
+isolated	O
+PEDV	B-SPEC
+strains	O
+from	O
+China	O
+and	O
+the	O
+United	O
+States	O
+.	O
+
+Pig	B-SPEC
+infection	B-DISO
+studies	O
+indicated	O
+that	O
+the	O
+CH	O
+/	O
+HBXT	O
+/	O
+2018	O
+strain	O
+was	O
+highly	O
+virulent	O
+in	O
+suckling	O
+piglets	O
+,	O
+and	O
+the	O
+median	O
+pig	O
+diarrhea	B-DISO
+dose	O
+(	O
+PDD	B-DISO
+
+A	O
+list	O
+of	O
+TTD	O
+includes	O
+infections	B-DISO
+caused	O
+by	O
+human	B-SPEC
+T	O
+-	O
+lymphotropic	O
+virus	B-SPEC
+1	O
+,	O
+cytomegalovirus	B-SPEC
+and	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+malaria	B-PATH
+,	O
+Chagas	B-DISO
+disease	I-DISO
+,	O
+babesiosis	B-DISO
+,	O
+leishmaniasis	B-PATH
+,	O
+variant	B-DISO
+Creutzfeldt	I-DISO
+-	I-DISO
+Jakob	I-DISO
+disease	I-DISO
+,	O
+Zika	O
+,	O
+Dengue	B-DISO
+,	O
+Chikungunya	B-DISO
+,	O
+and	O
+anaplasmosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Endemic	O
+infection	B-DISO
+can	O
+shape	O
+exposure	O
+to	O
+novel	O
+pathogens	O
+:	O
+Pathogen	O
+co	O
+-	O
+occurrence	O
+networks	O
+in	O
+the	O
+Serengeti	O
+lions	O
+.	O
+
+TITLE	O
+:	O
+ECMO	O
+for	O
+Adults	O
+with	O
+Severe	O
+Respiratory	B-DISO
+Failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+identified	O
+a	O
+strain	O
+of	O
+Alphacoronavirus	O
+1	O
+,	O
+FCoV	O
+-	O
+SB22	O
+,	O
+from	O
+a	O
+pool	O
+of	O
+fecal	B-ANAT
+samples	O
+from	O
+domestic	B-SPEC
+cats	I-SPEC
+from	O
+a	O
+rural	O
+settlement	O
+in	O
+the	O
+municipality	O
+of	O
+Santa	O
+Bárbara	O
+,	O
+Pará	O
+,	O
+Brazil	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+Characteristics	O
+and	O
+Outcome	O
+of	O
+Children	O
+Hospitalized	O
+With	O
+Scrub	B-DISO
+Typhus	I-DISO
+in	O
+an	O
+Area	O
+of	O
+Endemicity	O
+.	O
+
+Patients	O
+with	O
+confirmed	O
+scrub	B-DISO
+typhus	I-DISO
+had	O
+clinical	O
+symptoms	O
+,	O
+including	O
+fever	B-PROC
+(	O
+35	O
+of	O
+35	O
+[	O
+100	O
+%]),	O
+eschar	B-DISO
+(	O
+21	O
+of	O
+35	O
+[	O
+60	O
+%]),	O
+cough	B-DISO
+(	O
+21	O
+of	O
+35	O
+[	O
+60	O
+%]),	O
+tachypnea	B-DISO
+(	O
+16	O
+of	O
+35	O
+[	O
+46	O
+%]),	O
+lymphadenopathy	O
+(	O
+15	O
+of	O
+35	O
+[	O
+43	O
+%]),	O
+and	O
+headache	B-DISO
+(	O
+14	O
+of	O
+35	O
+[	O
+40	O
+%]).	O
+
+We	O
+detected	O
+90	O
+%	O
+PRNT	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+antibody	B-COMP
+in	O
+35	O
+(	O
+55	O
+.	O
+6	O
+%)	O
+of	O
+63	O
+sera	B-COMP
+from	O
+sheep	B-SPEC
+collected	O
+from	O
+Senegal	O
+,	O
+two	O
+sheep	B-SPEC
+(	O
+1	O
+.	O
+8	O
+%)	O
+of	O
+114	O
+in	O
+Tunisia	O
+and	O
+a	O
+goat	O
+(	O
+0	O
+.	O
+9	O
+%)	O
+of	O
+107	O
+in	O
+Egypt	O
+,	O
+with	O
+titres	O
+ranging	O
+from	O
+1	O
+:	O
+80	O
+to	O
+≥	O
+1	O
+:	O
+320	O
+.	O
+
+We	O
+recommend	O
+expanding	O
+current	O
+MERS	O
+-	O
+CoV	O
+surveillance	O
+in	O
+animals	B-SPEC
+to	O
+include	O
+other	O
+livestock	O
+in	O
+close	O
+contact	O
+with	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+The	O
+segregation	O
+of	O
+camels	B-SPEC
+from	O
+other	O
+livestock	O
+in	O
+farms	O
+and	O
+live	O
+animal	B-SPEC
+markets	O
+may	O
+need	O
+to	O
+be	O
+considered	O
+.	O
+
+TITLE	O
+:	O
+Global	O
+status	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+:	O
+a	O
+systematic	O
+review	O
+.	O
+
+This	O
+systematic	O
+review	O
+aims	O
+to	O
+compile	O
+and	O
+analyse	O
+all	O
+published	O
+data	O
+on	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+in	O
+the	O
+global	O
+camel	B-SPEC
+population	O
+to	O
+provide	O
+an	O
+overview	O
+of	O
+current	O
+knowledge	O
+on	O
+the	O
+distribution	O
+,	O
+spread	O
+and	O
+risk	O
+factors	O
+of	O
+infections	B-DISO
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+We	O
+included	O
+original	O
+research	O
+articles	O
+containing	O
+laboratory	O
+evidence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+in	O
+the	O
+field	O
+from	O
+2013	O
+to	O
+April	O
+2018	O
+.	O
+
+In	O
+general	O
+,	O
+camels	B-SPEC
+only	O
+show	O
+minor	O
+clinical	O
+signs	O
+of	O
+disease	O
+after	O
+being	O
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+Serological	O
+evidence	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+camels	B-SPEC
+has	O
+been	O
+found	O
+in	O
+20	O
+countries	O
+,	O
+with	O
+molecular	O
+evidence	O
+for	O
+virus	B-SPEC
+circulation	B-PROC
+in	O
+13	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+Hematological	O
+Effects	O
+of	O
+Non	O
+-	O
+Homogenous	O
+Ionizing	O
+Radiation	O
+Exposure	O
+in	O
+a	O
+Non	O
+-	O
+Human	B-SPEC
+Primate	B-SPEC
+Model	O
+.	O
+
+Animals	B-SPEC
+in	O
+the	O
+bilateral	O
+UHBI	O
+arm	B-ANAT
+presented	O
+with	O
+myelosuppression	B-DISO
+;	O
+however	O
+,	O
+none	O
+of	O
+the	O
+animals	B-SPEC
+developed	O
+severe	O
+neutropenia	O
+or	O
+thrombocytopenia	O
+(	O
+ANC	O
+remained	O
+>	O
+500	O
+/	O
+µl	O
+;	O
+platelets	B-ANAT
+>	O
+50	O
+,	O
+000	O
+/	O
+µl	O
+during	O
+14	O
+-	O
+day	O
+follow	O
+-	O
+up	O
+).	O
+
+The	O
+clinical	O
+presentation	O
+of	O
+MERS	O
+varied	O
+from	O
+asymptomatic	O
+to	O
+severe	O
+bilateral	B-DISO
+pneumonia	I-DISO
+,	O
+depending	O
+on	O
+the	O
+case	O
+definition	O
+and	O
+surveillance	O
+strategies	O
+.	O
+
+Future	O
+directions	O
+include	O
+efforts	O
+to	O
+facilitate	O
+earlier	O
+recognition	O
+of	O
+ARDS	B-DISO
+,	O
+identifying	O
+responsive	O
+subsets	O
+of	O
+patients	O
+and	O
+ongoing	O
+efforts	O
+to	O
+understand	O
+fundamental	O
+mechanisms	O
+of	O
+lung	B-ANAT
+injury	O
+to	O
+design	O
+specific	O
+treatments	O
+.	O
+
+The	O
+presence	O
+of	O
+influenza	B-SPEC
+D	I-SPEC
+virus	I-SPEC
+(	O
+IDV	O
+),	O
+bovine	B-SPEC
+rhinitis	B-DISO
+A	O
+virus	B-SPEC
+(	O
+BRAV	O
+),	O
+bovine	B-SPEC
+rhinitis	I-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+BRBV	O
+),	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+and	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+)	O
+was	O
+associated	O
+with	O
+BRD	O
+.	O
+
+Non	O
+-	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+patients	O
+had	O
+lower	O
+health	O
+-	O
+related	O
+quality	O
+-	O
+of	O
+-	O
+life	O
+scores	O
+and	O
+higher	O
+rates	O
+of	O
+posttraumatic	B-DISO
+stress	I-DISO
+disorder	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+variant	O
+strains	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+severely	O
+threaten	O
+the	O
+pig	B-SPEC
+industry	O
+worldwide	O
+and	O
+cause	O
+up	O
+to	O
+100	O
+%	O
+mortality	O
+in	O
+suckling	O
+piglets	O
+.	O
+
+Assessment	O
+of	O
+faeces	B-ANAT
+by	O
+PCR	O
+revealed	O
+concurrent	O
+infection	B-DISO
+with	O
+FCoV	O
+and	O
+FPV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+characterization	O
+of	O
+a	O
+novel	O
+linear	O
+epitope	B-CHED
+in	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+immunoregulated	O
+agents	O
+,	O
+such	O
+as	O
+asthymosin	O
+α1	O
+,	O
+are	O
+also	O
+of	O
+great	O
+value	O
+in	O
+renal	B-ANAT
+transplant	B-ANAT
+recipients	O
+in	O
+the	O
+setting	O
+of	O
+opportunistic	O
+pathogen	O
+infections	B-DISO
+.	O
+
+Among	O
+case	O
+-	O
+patients	O
+who	O
+died	B-PROC
+,	O
+development	B-PROC
+of	O
+robust	O
+neutralizing	O
+serum	B-COMP
+antibody	B-PROC
+responses	I-PROC
+during	O
+the	O
+second	O
+and	O
+third	O
+week	O
+of	O
+illness	O
+was	O
+not	O
+sufficient	O
+for	O
+patient	O
+recovery	O
+or	O
+virus	B-SPEC
+clearance	O
+.	O
+
+PAP	B-DISO
+was	O
+significantly	O
+higher	O
+in	O
+neonates	O
+with	O
+ALI	O
+/	O
+ADDSp	O
+than	O
+in	O
+neonates	O
+with	O
+ALI	O
+/	O
+ADDSexp	O
+.	O
+
+This	O
+can	O
+be	O
+used	O
+as	O
+a	O
+monitoring	O
+indicator	B-CHED
+for	O
+the	O
+severity	O
+of	O
+illness	O
+.	O
+
+Once	O
+formed	O
+and	O
+released	O
+from	O
+producer	O
+cells	B-COMP
+,	O
+these	O
+pseudovirions	O
+incorporate	O
+a	O
+luciferase	B-PRGE
+reporter	I-PRGE
+gene	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+is	O
+a	O
+rescue	O
+treatment	O
+for	O
+respiratory	O
+or	O
+cardiac	B-DISO
+failure	I-DISO
+.	O
+
+Endovascular	B-ANAT
+aneurysm	B-DISO
+repair	B-PROC
+of	O
+aortic	B-DISO
+dissection	I-DISO
+and	O
+venoarterial	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+were	O
+performed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+battle	O
+against	O
+SARS	B-DISO
+and	O
+MERS	O
+coronaviruses	O
+:	O
+Reservoirs	O
+and	O
+Animal	B-SPEC
+Models	O
+.	O
+
+TITLE	O
+:	O
+Host	B-COMP
+Determinants	O
+of	O
+MERS	O
+-	O
+CoV	O
+Transmission	O
+and	O
+Pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+While	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+infects	O
+and	O
+replicates	O
+in	O
+enterocytes	B-ANAT
+lining	O
+villi	O
+of	O
+neonatal	O
+piglets	O
+with	O
+high	O
+efficiency	O
+,	O
+naturally	O
+isolated	O
+variants	O
+typically	O
+grow	O
+poorly	O
+in	O
+established	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+unless	O
+adapted	O
+by	O
+multiple	O
+passages	O
+.	O
+
+Further	O
+mutational	O
+analyses	O
+revealed	O
+that	O
+a	O
+single	O
+mutation	O
+at	O
+the	O
+amino	O
+acid	O
+residue	O
+position	O
+672	O
+(	O
+V672F	O
+)	O
+could	O
+enable	O
+the	O
+chimeric	O
+S	O
+with	O
+the	O
+entire	O
+RBD	O
+derived	O
+from	O
+the	O
+G2	O
+strain	O
+to	O
+trigger	O
+large	O
+syncytia	B-ANAT
+.	O
+
+Interestingly	O
+,	O
+we	O
+also	O
+demonstrated	O
+that	O
+while	O
+the	O
+V672F	O
+mutation	O
+is	O
+critical	O
+for	O
+the	O
+syncytium	B-PROC
+formation	I-PROC
+in	O
+VeroE6	B-PRGE
+-	I-PRGE
+APN	I-PRGE
+cells	B-COMP
+,	O
+it	O
+exerts	B-PROC
+a	O
+minimal	O
+effect	O
+in	O
+Huh	O
+-	O
+7	O
+cells	B-COMP
+,	O
+thereby	O
+suggesting	O
+the	O
+difference	O
+in	O
+receptor	O
+preference	O
+of	O
+PEDV	B-SPEC
+among	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+PMS	B-DISO
+for	O
+knowledge	O
+was	O
+71	O
+.	O
+1	O
+±	O
+19	O
+.	O
+4	O
+.	O
+
+Both	O
+upper	O
+and	O
+lower	O
+respiratory	O
+specimens	O
+were	O
+collected	O
+for	O
+the	O
+analysis	O
+from	O
+all	O
+the	O
+patients	O
+who	O
+visited	O
+the	O
+Sheikh	O
+Khalifa	O
+Specialty	O
+Hospital	O
+(	O
+SKSH	O
+)	O
+with	O
+ARI	B-CHED
+for	O
+over	O
+2	O
+years	O
+.	O
+
+The	O
+pattern	O
+of	O
+FLU	B-DISO
+in	O
+the	O
+UAE	O
+parallels	O
+to	O
+that	O
+of	O
+temperate	O
+countries	O
+.	O
+
+All	O
+testicles	B-ANAT
+were	O
+negative	O
+at	O
+immunohistochemistry	O
+,	O
+while	O
+six	O
+were	O
+positive	O
+at	O
+nRT	B-PRGE
+-	O
+PCR	O
+for	O
+FCoV	O
+.	O
+Serology	O
+and	O
+blood	B-ANAT
+PCR	O
+results	O
+suggest	O
+that	O
+the	O
+virus	B-SPEC
+was	O
+present	O
+in	O
+the	O
+environment	O
+,	O
+stimulating	O
+transient	O
+seroconversion	O
+.	O
+
+In	O
+the	O
+light	O
+of	O
+these	O
+preliminary	O
+results	O
+,	O
+artificial	O
+insemination	B-PROC
+appears	O
+safer	O
+than	O
+natural	O
+mating	B-PROC
+as	O
+it	O
+eliminates	O
+the	O
+direct	O
+contact	O
+between	O
+animals	B-SPEC
+,	O
+thus	O
+diminishing	O
+the	O
+probability	O
+of	O
+faecal	B-ANAT
+-	O
+oral	B-ANAT
+FCoV	O
+transmission	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+small	O
+interfering	O
+RNA	O
+generation	O
+system	O
+that	O
+expressed	B-PROC
+two	O
+different	O
+short	O
+hairpin	O
+RNAs	O
+(	O
+shRNAs	O
+)	O
+targeting	B-PROC
+the	O
+M	B-PRGE
+gene	I-PRGE
+of	O
+PEDV	B-SPEC
+and	O
+SADS	O
+-	O
+CoV	O
+and	O
+the	O
+N	O
+gene	O
+of	O
+PDCoV	O
+,	O
+respectively	O
+.	O
+
+Our	O
+results	O
+demonstrated	O
+that	O
+simultaneous	O
+expression	B-PROC
+of	O
+these	O
+specific	O
+shRNA	O
+molecules	O
+inhibited	O
+expression	O
+of	O
+PEDV	B-PRGE
+M	I-PRGE
+gene	I-PRGE
+,	O
+SADS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+gene	I-PRGE
+,	O
+and	O
+PDCoV	B-PRGE
+N	I-PRGE
+gene	I-PRGE
+RNA	I-PRGE
+by	O
+99	O
+.	O
+7	O
+%,	O
+99	O
+.	O
+4	O
+%,	O
+and	O
+98	O
+.	O
+8	O
+%,	O
+respectively	O
+,	O
+in	O
+infected	O
+cell	B-COMP
+cultures	O
+.	O
+
+In	O
+addition	O
+,	O
+shRNA	O
+molecules	O
+significantly	O
+restricted	O
+the	O
+expression	B-PROC
+of	O
+M	O
+and	O
+N	O
+protein	B-CHED
+,	O
+and	O
+impaired	B-DISO
+the	O
+replication	O
+of	O
+PEDV	B-SPEC
+,	O
+SADS	O
+-	O
+CoV	O
+,	O
+and	O
+PDCoV	O
+simultaneously	O
+.	O
+
+We	O
+generated	O
+rAd5	B-PRGE
+constructs	O
+expressing	O
+CD40	B-PRGE
+-	O
+targeted	B-PROC
+S1	B-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+(	O
+rAd5	B-PRGE
+-	O
+S1	O
+/	O
+F	O
+/	O
+CD40L	B-PRGE
+),	O
+untargeted	O
+S1	O
+(	O
+rAd5	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+),	O
+and	O
+Green	B-PRGE
+Fluorescent	I-PRGE
+Protein	I-PRGE
+(	O
+rAd5	B-PRGE
+-	I-PRGE
+GFP	I-PRGE
+),	O
+and	O
+evaluated	O
+their	O
+efficacy	O
+and	O
+safety	O
+in	O
+human	B-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+transgenic	I-PRGE
+(	O
+hDPP4	O
+Tg	O
++)	O
+mice	B-SPEC
+.	O
+
+Immunization	O
+of	O
+hDPP4	O
+Tg	O
++	O
+mice	B-SPEC
+with	O
+a	O
+single	O
+dose	O
+of	O
+rAd5	B-PRGE
+-	O
+S1	O
+/	O
+F	O
+/	O
+CD40L	B-PRGE
+elicited	O
+as	O
+robust	O
+and	O
+significant	O
+specific	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+and	I-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+as	O
+those	O
+induced	O
+with	O
+2	O
+doses	O
+of	O
+rAd5	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+.	O
+
+Given	O
+the	O
+high	O
+mortality	O
+associated	O
+with	O
+ARDS	B-DISO
+,	O
+numerous	O
+animal	B-SPEC
+models	O
+have	O
+been	O
+developed	O
+to	O
+support	O
+translational	B-PROC
+research	O
+.	O
+
+Inclusion	O
+criteria	O
+:	O
+animal	B-SPEC
+models	O
+combining	O
+features	O
+of	O
+experimental	O
+ARDS	B-DISO
+with	O
+ECMO	O
+.	O
+
+Seventeen	O
+models	O
+of	O
+ARDS	B-DISO
+and	O
+ECMO	O
+were	O
+identified	O
+.	O
+
+A	O
+limited	O
+number	O
+of	O
+models	O
+combine	O
+the	O
+features	O
+of	O
+experimental	O
+ARDS	B-DISO
+with	O
+ECMO	O
+.	O
+
+These	O
+include	O
+interferon	B-PRGE
+(	O
+IFN	O
+),	O
+oligoadenylate	O
+synthetase	O
+(	O
+OAS	B-DISO
+)-	O
+RNase	B-ENZY
+L	O
+,	O
+and	O
+protein	B-PRGE
+kinase	I-PRGE
+R	I-PRGE
+(	O
+PKR	B-PRGE
+).	O
+
+Coronaviruses	O
+,	O
+including	O
+MERS	O
+-	O
+CoV	O
+,	O
+potently	O
+suppress	O
+the	O
+activation	O
+of	O
+these	O
+pathways	B-PROC
+,	O
+inducing	O
+only	O
+modest	O
+host	B-COMP
+responses	O
+.	O
+
+TITLE	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+with	O
+unilateral	O
+peripheral	O
+facial	B-ANAT
+and	O
+bulbar	B-DISO
+palsy	I-DISO
+in	O
+a	O
+child	O
+:	O
+A	O
+case	O
+report	O
+.	O
+
+Cranial	B-DISO
+nerve	I-DISO
+palsies	I-DISO
+are	O
+frequent	O
+in	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+nonstructural	O
+protein	B-CHED
+8	O
+(	O
+nsp8	O
+)	O
+has	O
+been	O
+suggested	O
+to	O
+have	O
+diverse	O
+activities	O
+,	O
+including	O
+noncanonical	O
+template	O
+-	O
+dependent	O
+polymerase	O
+activities	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+Coronavirus	B-SPEC
+Temperature	O
+-	O
+Sensitive	O
+Mutants	O
+Reveals	O
+an	O
+Interplay	O
+between	O
+the	O
+Macrodomain	O
+and	O
+Papain	O
+-	O
+Like	O
+Protease	O
+Impacting	O
+Replication	O
+and	O
+Pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Analysis	O
+of	O
+temperature	O
+-	O
+sensitive	O
+(	O
+ts	O
+)	O
+mutant	B-DISO
+viruses	B-SPEC
+is	O
+a	O
+classic	O
+method	O
+allowing	O
+researchers	O
+to	O
+identify	O
+genetic	O
+loci	O
+involved	O
+in	O
+viral	B-PROC
+replication	I-PROC
+and	O
+pathogenesis	B-DISO
+.	O
+
+Hemoadsorption	O
+therapy	O
+was	O
+initiated	O
+due	O
+to	O
+prolonged	O
+high	O
+levels	O
+of	O
+conjugated	O
+bilirubin	B-CHED
+.	O
+
+In	O
+our	O
+patient	O
+,	O
+CytoSorb	O
+was	O
+a	O
+useful	O
+therapeutic	O
+option	O
+in	O
+prolonged	O
+cholestasis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Enteric	O
+viral	O
+diseases	O
+of	O
+swine	B-SPEC
+are	O
+one	O
+of	O
+the	O
+most	O
+frequent	O
+disorders	O
+causing	O
+huge	O
+economic	O
+losses	O
+in	O
+pork	O
+production	O
+.	O
+
+A	O
+total	O
+of	O
+384	O
+faecal	B-ANAT
+samples	O
+collected	O
+during	O
+a	O
+twoyear	O
+period	O
+from	O
+diarrhoeic	O
+and	O
+asymptomatic	O
+pigs	B-SPEC
+of	O
+various	O
+ages	O
+in	O
+17	O
+farms	O
+were	O
+screened	O
+by	O
+conventional	O
+and	O
+real	O
+-	O
+time	O
+PCR	O
+methods	O
+.	O
+
+Luminex	O
+multi	O
+-	O
+analyte	O
+-	O
+technology	O
+was	O
+used	O
+for	O
+biomarker	B-CHED
+analysis	O
+.	O
+
+By	O
+analyzing	O
+simulated	O
+outbreaks	O
+under	O
+various	O
+contact	O
+tracing	O
+scenarios	O
+,	O
+we	O
+demonstrate	O
+that	O
+contact	O
+data	O
+significantly	O
+improves	O
+our	O
+ability	O
+to	O
+reconstruct	O
+transmission	O
+trees	O
+,	O
+even	O
+under	O
+realistic	O
+limitations	O
+on	O
+the	O
+coverage	O
+of	O
+the	O
+contact	O
+tracing	O
+effort	B-PROC
+and	O
+the	O
+amount	O
+of	O
+non	O
+-	O
+infectious	B-DISO
+mixing	O
+between	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+3	O
+-	O
+Trifluoromethylpyrazolones	O
+derived	O
+nucleosides	B-CHED
+:	O
+Synthesis	B-PROC
+and	O
+antiviral	B-CHED
+evaluation	O
+.	O
+
+TITLE	O
+:	O
+Pharmacokinetics	B-PROC
+of	O
+Ketamine	B-CHED
+at	O
+Dissociative	O
+Doses	O
+in	O
+an	O
+Adult	O
+Patient	O
+With	O
+Refractory	O
+Status	B-DISO
+Asthmaticus	I-DISO
+Receiving	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+Therapy	O
+.	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+44	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+for	O
+status	B-DISO
+asthmaticus	I-DISO
+requiring	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+plasma	B-ANAT
+concentration	O
+at	O
+steady	O
+state	O
+was	O
+1018	O
+.	O
+7	O
+ng	O
+/	O
+mL	O
+,	O
+with	O
+an	O
+estimated	O
+clearance	O
+of	O
+1	O
+.	O
+96	O
+L	O
+/	O
+kg	O
+/	O
+h	O
+after	O
+up	O
+-	O
+titration	O
+.	O
+
+This	O
+observational	O
+retrospective	O
+study	O
+analyzed	O
+onco	O
+-	O
+hematological	O
+patients	O
+with	O
+ARpF	O
+in	O
+the	O
+Intensive	O
+Care	O
+Unit	O
+(	O
+ICU	O
+)	O
+of	O
+a	O
+cancer	B-DISO
+center	O
+in	O
+southern	O
+Brazil	O
+between	O
+2010	O
+-	O
+2016	O
+,	O
+who	O
+required	O
+mechanical	O
+ventilation	O
+and	O
+were	O
+submitted	O
+to	O
+open	O
+SLB	O
+.	O
+
+In	O
+this	O
+case	O
+study	O
+we	O
+aim	O
+to	O
+describe	O
+the	O
+importance	O
+of	O
+considering	O
+mycoplasma	B-DISO
+pneumonia	I-DISO
+in	O
+high	O
+-	O
+risk	O
+groups	O
+.	O
+
+Mycoplasma	B-DISO
+pneumonia	I-DISO
+is	O
+a	O
+common	O
+type	O
+of	O
+pneumonia	B-DISO
+in	O
+the	O
+community	O
+,	O
+but	O
+only	O
+a	O
+small	O
+percentage	O
+of	O
+patients	O
+require	O
+hospitalization	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+yak	B-SPEC
+(	O
+Bosgrunniens	O
+)	O
+is	O
+a	O
+unique	O
+domestic	O
+bovine	B-SPEC
+species	B-SPEC
+that	O
+plays	O
+an	O
+indispensable	O
+role	O
+for	O
+herdsmen	O
+in	O
+the	O
+Qinghai	O
+-	O
+Tibet	O
+Plateau	O
+.	O
+
+Here	O
+,	O
+336	O
+diarrhoeic	O
+samples	O
+were	O
+collected	O
+from	O
+yaks	B-SPEC
+on	O
+29	O
+farms	O
+in	O
+the	O
+Qinghai	O
+-	O
+Tibet	O
+Plateau	O
+from	O
+2015	O
+to	O
+2017	O
+.	O
+
+Furthermore	O
+,	O
+a	O
+BCoV	O
+strain	O
+(	O
+designated	O
+YAK	B-SPEC
+/	O
+HY24	O
+/	O
+CH	O
+/	O
+2017	O
+)	O
+was	O
+isolated	O
+from	O
+one	O
+diarrhoeic	O
+sample	O
+(	O
+virus	B-SPEC
+titre	O
+:	O
+10	O
+
+The	O
+N	B-PRGE
+-	I-PRGE
+Terminal	I-PRGE
+Domain	I-PRGE
+of	O
+Spike	B-PRGE
+Protein	I-PRGE
+Is	O
+Not	O
+the	O
+Enteric	O
+Tropism	B-PROC
+Determinant	O
+for	O
+Transmissible	O
+Gastroenteritis	O
+Virus	B-SPEC
+in	O
+Piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+Menkes	B-DISO
+disease	I-DISO
+(	O
+MD	O
+)	O
+usually	O
+presents	O
+in	O
+infancy	O
+with	O
+respiratory	O
+and	O
+neurological	O
+complications	O
+.	O
+
+However	O
+,	O
+postmortem	O
+review	O
+of	O
+facial	B-ANAT
+traits	O
+raised	O
+the	O
+suspicion	O
+of	O
+MD	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+,	O
+phylogenetic	O
+and	O
+evolutionary	O
+analysis	O
+of	O
+porcine	B-SPEC
+deltacoronavirus	O
+in	O
+Henan	O
+province	O
+,	O
+China	O
+.	O
+
+His	O
+ECMO	O
+course	O
+was	O
+complicated	O
+by	O
+severe	O
+hemolysis	B-DISO
+and	O
+hyperbilirubinemia	B-DISO
+,	O
+which	O
+precluded	O
+accurate	O
+monitoring	O
+of	O
+heparin	B-CHED
+activity	O
+.	O
+
+In	O
+total	O
+11	O
+patients	O
+(	O
+64	O
+,	O
+7	O
+%)	O
+survived	O
+the	O
+treatment	O
+,	O
+with	O
+10	O
+patients	O
+(	O
+58	O
+,	O
+8	O
+%)	O
+surviving	O
+hospital	O
+discharge	B-ANAT
+,	O
+all	O
+of	O
+who	O
+were	O
+still	O
+alive	O
+at	O
+long	O
+-	O
+term	O
+follow	O
+-	O
+up	O
+,	O
+with	O
+a	O
+median	O
+follow	O
+-	O
+up	O
+time	O
+of	O
+9	O
+years	O
+(	O
+August	O
+15th	O
+,	O
+2017	O
+).	O
+
+These	O
+antibodies	B-COMP
+belong	O
+to	O
+six	O
+distinct	O
+epitope	B-CHED
+groups	O
+and	O
+interfere	O
+with	O
+the	O
+three	O
+critical	O
+entry	O
+functions	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+:	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+,	O
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+Virus	B-SPEC
+Infections	B-DISO
+of	O
+the	O
+Stem	O
+Cell	B-ANAT
+Transplant	I-ANAT
+Recipient	O
+and	O
+the	O
+Hematologic	B-DISO
+Malignancy	I-DISO
+Patient	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+carried	O
+out	O
+the	O
+first	O
+detection	O
+,	O
+sequencing	O
+and	O
+characterization	O
+of	O
+this	O
+virus	B-SPEC
+in	O
+Mexico	O
+.	O
+
+We	O
+found	O
+85	O
+positive	O
+samples	O
+for	O
+porcine	B-SPEC
+deltacoronavirus	O
+,	O
+representing	O
+9	O
+.	O
+6	O
+%	O
+of	O
+the	O
+total	O
+samples	O
+,	O
+and	O
+we	O
+determined	O
+that	O
+the	O
+most	O
+frequent	O
+coinfection	B-DISO
+was	O
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+54	O
+.	O
+1	O
+%).	O
+
+TITLE	O
+:	O
+Using	O
+selective	O
+lung	B-ANAT
+injury	O
+to	O
+improve	O
+murine	B-SPEC
+models	O
+of	O
+spatially	O
+heterogeneous	O
+lung	B-ANAT
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+multiplex	O
+reverse	O
+transcription	O
+polymerase	O
+chain	O
+rection	O
+(	O
+mRT	B-ANAT
+-	O
+PCR	O
+)	O
+was	O
+developed	O
+for	O
+simultaneous	O
+detection	O
+of	O
+four	O
+RNA	O
+viruses	B-SPEC
+in	O
+swine	B-SPEC
+.	O
+
+SI	O
+-	O
+ALI	O
+model	O
+rats	B-SPEC
+had	O
+a	O
+high	O
+mortality	O
+rate	O
+and	O
+severe	O
+lung	B-ANAT
+injury	O
+with	O
+proinflammatory	O
+,	O
+procoagulant	O
+,	O
+and	O
+pro	B-CHED
+-	O
+fibrotic	O
+changes	O
+.	O
+
+Three	O
+and	O
+7	O
+-	O
+day	O
+MP	O
+treatments	O
+significantly	O
+attenuated	O
+this	O
+process	O
+,	O
+which	O
+was	O
+reflected	O
+by	O
+a	O
+reduction	O
+in	O
+pro	B-CHED
+-	O
+fibrotic	O
+chemokine	O
+levels	O
+.	O
+
+Plasma	B-ANAT
+samples	O
+from	O
+the	O
+HD	O
+patients	O
+and	O
+medical	O
+staff	O
+were	O
+collected	O
+at	O
+the	O
+time	O
+of	O
+isolation	O
+(	O
+M0	O
+),	O
+the	O
+following	O
+month	O
+(	O
+M1	O
+),	O
+and	O
+three	O
+months	O
+after	O
+isolation	O
+(	O
+M3	O
+).	O
+
+Parameters	O
+for	O
+stress	O
+included	O
+circulating	O
+cell	B-COMP
+-	O
+free	O
+genomic	O
+DNA	O
+(	O
+ccf	B-DISO
+-	O
+gDNA	O
+),	O
+circulating	O
+cell	B-COMP
+-	O
+free	O
+mitochondria	B-COMP
+DNA	O
+(	O
+ccf	B-DISO
+-	O
+mtDNA	B-COMP
+),	O
+and	O
+pentraxin	B-PRGE
+-	I-PRGE
+3	I-PRGE
+(	O
+PTX	B-PRGE
+-	I-PRGE
+3	I-PRGE
+).	O
+
+Mice	B-SPEC
+were	O
+euthanized	O
+on	O
+Day	O
+7	O
+after	O
+the	O
+second	O
+immunization	O
+.	O
+
+Then	O
+,	O
+retroorbital	B-ANAT
+bleeding	B-DISO
+was	O
+carried	O
+out	O
+and	O
+the	O
+chest	B-ANAT
+was	O
+rapidly	O
+opened	O
+to	O
+collect	O
+the	O
+trachea	B-DISO
+and	O
+tissues	B-ANAT
+from	O
+both	O
+lungs	B-ANAT
+for	O
+testing	O
+.	O
+
+CpG	O
+ODN	O
+significantly	O
+improved	O
+the	O
+pathologic	O
+impairment	O
+in	O
+mice	B-SPEC
+lung	B-ANAT
+,	O
+especially	O
+after	O
+the	O
+intranasal	O
+administration	O
+of	O
+50	O
+μg	O
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+nasal	B-ANAT
+and	O
+rectal	O
+administration	O
+of	O
+CpG	O
+ODN	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+before	O
+LPS	B-DISO
+immunization	O
+did	O
+not	O
+appear	O
+to	O
+exhibit	O
+any	O
+significant	O
+protective	O
+effects	O
+.	O
+
+The	O
+intranasal	O
+administration	O
+of	O
+CpG	B-PRGE
+ODN	I-PRGE
+may	O
+be	O
+a	O
+potential	O
+treatment	O
+approach	O
+to	O
+ARDS	B-DISO
+.	O
+
+At	O
+the	O
+nadir	O
+of	O
+illness	O
+,	O
+the	O
+most	O
+frequent	O
+diagnosis	O
+in	O
+H	B-SPEC
+.	I-SPEC
+influenzae	I-SPEC
+-	O
+related	O
+cases	O
+was	O
+""""	O
+pure	B-FUNC
+FS	O
+""""	O
+without	O
+limb	B-DISO
+weakness	I-DISO
+or	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+involvement	O
+(	O
+71	O
+%),	O
+in	O
+C	B-SPEC
+.	I-SPEC
+jejuni	I-SPEC
+-	O
+related	O
+cases	O
+""""	O
+incomplete	O
+FS	O
+""""	O
+such	O
+as	O
+acute	O
+ophthalmoparesis	B-DISO
+with	O
+or	O
+without	O
+ataxia	B-DISO
+(	O
+60	O
+%),	O
+and	O
+in	O
+CMV	B-SPEC
+-	O
+related	O
+cases	O
+(	O
+50	O
+%)	O
+advanced	O
+conditions	O
+such	O
+as	O
+GBS	B-DISO
+overlap	O
+and	O
+Bickerstaff	B-DISO
+brainstem	I-DISO
+encephalitis	I-DISO
+.	O
+
+Pregnant	O
+sows	O
+were	O
+primed	O
+orally	B-ANAT
+with	O
+an	O
+S	O
+DEL5	O
+/	O
+ORF3	O
+live	O
+vaccine	O
+and	O
+boosted	O
+intramuscularly	O
+twice	O
+with	O
+a	O
+commercial	O
+killed	O
+vaccine	O
+at	O
+2	O
+-	O
+week	O
+intervals	O
+prior	O
+to	O
+parturition	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+despite	O
+a	O
+2	O
+-	O
+3	O
+day	O
+period	O
+of	O
+weight	O
+loss	O
+in	O
+piglets	O
+from	O
+vaccinated	O
+sows	O
+after	O
+challenge	O
+,	O
+their	O
+daily	O
+weight	O
+gain	O
+was	O
+recovered	O
+at	O
+7	O
+days	O
+post	O
+-	O
+challenge	O
+and	O
+became	O
+similar	O
+to	O
+that	O
+of	O
+unchallenged	O
+pigs	B-SPEC
+from	O
+unvaccinated	O
+sows	O
+over	O
+the	O
+course	O
+of	O
+the	O
+experiment	O
+.	O
+
+A	O
+series	O
+of	O
+studies	O
+have	O
+shown	O
+that	O
+25HC	O
+activity	O
+in	O
+hosts	B-COMP
+plays	O
+a	O
+vital	O
+role	O
+in	O
+inhibiting	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+downregulated	O
+the	O
+expression	B-PROC
+of	O
+CH25H	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+CH25H	O
+and	O
+25HC	O
+inhibited	O
+the	O
+replication	O
+of	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+Interestingly	O
+,	O
+careful	O
+literature	O
+analysis	O
+shows	O
+that	O
+viruses	B-SPEC
+indeed	O
+bind	B-FUNC
+to	O
+the	O
+cell	B-COMP
+surface	I-COMP
+via	O
+sialic	B-CHED
+acids	I-CHED
+,	O
+but	O
+there	O
+is	O
+no	O
+solid	O
+data	O
+that	O
+these	O
+moieties	O
+mediate	O
+virus	B-SPEC
+entry	O
+.	O
+
+CRCoV	O
+and	O
+BCoV	O
+appear	O
+to	O
+employ	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+class	B-SPEC
+I	I-PRGE
+(	O
+HLA	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+as	O
+the	O
+entry	O
+receptor	O
+.	O
+
+Summarizing	O
+,	O
+we	O
+delineated	O
+early	O
+events	O
+during	O
+CRCoV	O
+,	O
+BCoV	O
+,	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+entry	O
+and	O
+systematically	O
+studied	O
+the	O
+attachment	O
+and	O
+entry	O
+receptor	O
+utilized	O
+by	O
+these	O
+viruses	B-SPEC
+.	O
+
+However	O
+,	O
+the	O
+presence	O
+of	O
+wild	O
+animals	B-SPEC
+and	O
+daily	O
+dung	B-ANAT
+removal	O
+were	O
+negatively	O
+associated	O
+with	O
+seroprevalence	O
+.	O
+
+The	O
+results	O
+support	O
+previous	O
+findings	O
+that	O
+public	O
+health	O
+emergencies	O
+due	O
+to	O
+traveler	O
+-	O
+associated	O
+outbreaks	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+can	O
+cause	O
+significant	O
+losses	O
+to	O
+the	O
+broader	O
+economies	O
+of	O
+affected	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+StatPearls	O
+ABSTRACT	O
+:	O
+In	O
+Curtis	O
+Lester	O
+Mendelson	O
+’	O
+s	O
+original	O
+1946	O
+description	O
+of	O
+his	O
+namesake	O
+syndrome	B-DISO
+,	O
+a	O
+chemical	B-DISO
+pneumonitis	I-DISO
+was	O
+described	O
+in	O
+young	O
+and	O
+healthy	O
+obstetrical	O
+patients	O
+following	O
+aspiration	B-DISO
+of	O
+gastric	B-ANAT
+acid	I-ANAT
+under	O
+anesthesia	B-DISO
+.[	O
+1	O
+]	O
+In	O
+the	O
+case	O
+series	O
+by	O
+Mendelson	O
+,	O
+66	O
+obstetrical	O
+patients	O
+under	O
+anesthesia	B-DISO
+with	O
+ether	B-CHED
+aspirated	B-DISO
+gastric	B-ANAT
+contents	I-ANAT
+.	O
+
+Pregnant	O
+women	O
+are	O
+treated	O
+as	O
+though	O
+they	O
+have	O
+a	O
+“	O
+full	O
+stomach	O
+”	O
+regardless	O
+of	O
+their	O
+last	O
+meal	O
+,	O
+and	O
+inhalational	O
+anesthesia	B-DISO
+without	O
+intubation	O
+is	O
+strictly	O
+avoided	O
+.	O
+
+Care	O
+has	O
+also	O
+improved	O
+by	O
+advances	O
+in	O
+difficult	O
+airway	B-ANAT
+management	O
+devices	O
+including	O
+video	O
+laryngoscopes	O
+,	O
+endotracheal	O
+tube	O
+introducers	O
+,	O
+optical	O
+stylets	O
+,	O
+and	O
+flexible	O
+endoscopes	O
+.	O
+
+TITLE	O
+:	O
+A	O
+viral	O
+metagenomic	O
+survey	O
+identifies	O
+known	O
+and	O
+novel	O
+mammalian	B-SPEC
+viruses	B-SPEC
+in	O
+bats	B-SPEC
+from	O
+Saudi	O
+Arabia	O
+.	O
+
+However	O
+,	O
+since	O
+it	O
+shared	O
+homology	O
+with	O
+Hepeviridae	B-SPEC
+and	O
+Astroviridae	B-SPEC
+at	O
+ORF1	O
+and	O
+in	O
+ORF2	O
+,	O
+respectively	O
+,	O
+the	O
+newly	O
+discovered	O
+Hepe	O
+-	O
+Astrovirus	O
+may	O
+represent	O
+a	O
+phylogenetic	O
+bridge	O
+between	O
+Hepeviridae	B-SPEC
+and	O
+Astroviridae	B-SPEC
+.	O
+
+Machine	O
+learning	B-PROC
+algorithms	O
+can	O
+be	O
+used	O
+to	O
+generate	O
+dynamic	O
+prediction	O
+after	O
+injury	O
+while	O
+avoiding	O
+the	O
+risk	O
+of	O
+over	O
+-	O
+and	O
+under	O
+-	O
+fitting	B-DISO
+inherent	O
+in	O
+ad	O
+hoc	O
+statistical	O
+approaches	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+long	O
+non	O
+-	O
+coding	O
+RNAs	O
+in	O
+neonatal	O
+piglets	O
+at	O
+different	O
+stages	O
+of	O
+porcine	B-SPEC
+deltacoronavirus	O
+infection	O
+.	O
+
+We	O
+obtained	O
+expression	B-PROC
+data	O
+of	O
+miRNAs	O
+,	O
+lncRNAs	O
+and	O
+mRNAs	O
+during	O
+PDCoV	O
+infection	B-DISO
+and	O
+constructed	O
+and	O
+investigated	O
+an	O
+interaction	O
+network	O
+.	O
+
+This	O
+study	O
+is	O
+the	O
+first	O
+to	O
+examine	O
+differentially	O
+expressed	B-PROC
+lncRNAs	O
+after	O
+PDCoV	O
+infection	B-DISO
+of	O
+piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+coryza	B-DISO
+is	O
+a	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+of	O
+chickens	B-SPEC
+associated	O
+with	O
+large	O
+economic	O
+losses	O
+in	O
+affected	O
+commercial	O
+flocks	O
+.	O
+
+Patients	O
+with	O
+identified	O
+viruses	B-SPEC
+had	O
+significantly	O
+lower	O
+rates	O
+for	O
+ICU	O
+admission	O
+,	O
+hospital	O
+stay	O
+,	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+overall	O
+mortality	O
+than	O
+those	O
+without	O
+identified	O
+viruses	B-SPEC
+.	O
+
+Viral	O
+pathogens	O
+were	O
+encountered	O
+in	O
+one	O
+-	O
+third	O
+of	O
+hospitalized	O
+adult	O
+and	O
+pediatric	O
+Egyptian	O
+patients	O
+with	O
+SARI	O
+,	O
+while	O
+atypical	O
+bacteria	B-SPEC
+had	O
+a	O
+minor	O
+role	O
+.	O
+
+TITLE	O
+:	O
+Delayed	O
+retroperitoneal	B-ANAT
+hemorrhage	B-DISO
+during	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+:	O
+a	O
+case	O
+report	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+are	O
+several	O
+reports	O
+of	O
+retroperitoneal	O
+hemorrhage	B-DISO
+induced	O
+by	O
+percutaneous	O
+femoral	B-ANAT
+cannulation	O
+for	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+It	O
+has	O
+been	O
+associated	O
+with	O
+a	O
+multitude	O
+of	O
+activities	O
+over	O
+time	O
+;	O
+most	O
+recently	O
+recreational	O
+water	B-CHED
+-	O
+based	O
+activities	O
+including	O
+'	O
+mud	O
+-	O
+runs	O
+'	O
+in	O
+endemic	O
+areas	O
+have	O
+been	O
+added	O
+to	O
+the	O
+list	O
+of	O
+routes	O
+of	O
+exposure	O
+.	O
+
+The	O
+important	O
+factors	O
+impelling	O
+the	O
+recovery	O
+are	O
+found	O
+using	O
+machine	O
+learning	B-PROC
+.	O
+
+Recent	O
+studies	O
+suggested	O
+that	O
+there	O
+were	O
+limited	O
+insight	O
+available	O
+on	O
+the	O
+development	B-PROC
+of	O
+novel	O
+therapeutic	O
+strategies	O
+to	O
+induce	O
+immunity	B-PROC
+against	O
+the	O
+virus	B-SPEC
+.	O
+
+Whether	O
+the	O
+global	O
+health	O
+system	O
+as	O
+currently	O
+constituted	O
+can	O
+provide	O
+effective	O
+protection	O
+against	O
+a	O
+dynamic	O
+array	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+threats	O
+has	O
+been	O
+called	O
+into	O
+question	O
+by	O
+recent	O
+outbreaks	O
+of	O
+Ebola	O
+,	O
+Zika	O
+,	O
+dengue	B-DISO
+,	O
+Middle	O
+East	O
+respiratory	B-DISO
+syndrome	I-DISO
+,	I-DISO
+severe	I-DISO
+acute	I-DISO
+respiratory	O
+syndrome	B-DISO
+,	O
+and	O
+influenza	B-DISO
+and	O
+by	O
+the	O
+looming	O
+threat	O
+of	O
+rising	O
+antimicrobial	B-CHED
+resistance	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+hCoV	O
+)	O
+usually	O
+cause	O
+mild	O
+to	O
+moderate	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illnesses	O
+.	O
+
+PHC	O
+physicians	O
+'	O
+knowledge	O
+about	O
+MERS	O
+-	O
+CoV	O
+differed	O
+significantly	O
+according	O
+to	O
+their	O
+nationality	O
+(	O
+There	O
+are	O
+knowledge	O
+gaps	O
+among	O
+PHC	O
+physicians	O
+in	O
+Abha	O
+city	O
+,	O
+and	O
+their	O
+practice	O
+is	O
+suboptimal	O
+regarding	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+These	O
+infections	B-DISO
+with	O
+epidemic	O
+or	O
+pandemic	O
+potential	O
+present	O
+a	O
+persistent	O
+threat	O
+to	O
+public	O
+health	O
+and	O
+a	O
+huge	O
+burden	O
+on	O
+healthcare	O
+services	O
+in	O
+the	O
+Asia	O
+-	O
+Pacific	O
+region	O
+.	O
+
+Survival	O
+in	O
+ALI	O
+patients	O
+appear	O
+to	O
+be	O
+influenced	O
+by	O
+the	O
+stress	O
+generated	O
+by	O
+mechanical	O
+ventilation	O
+and	O
+by	O
+ALI	O
+-	O
+associated	O
+factors	O
+that	O
+initiate	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+Mice	B-SPEC
+were	O
+exposed	O
+intranasally	O
+to	O
+FF	O
+or	O
+UFP	O
+according	O
+to	O
+acute	O
+(	O
+10	O
+,	O
+50	O
+or	O
+100	O
+µg	O
+of	O
+PM	O
+)	O
+and	O
+repeated	O
+(	O
+10	O
+µg	O
+of	O
+PM	O
+3	O
+times	O
+a	O
+week	O
+during	O
+1	O
+or	O
+3	O
+months	O
+)	O
+exposure	O
+protocols	O
+.	O
+
+The	O
+positive	O
+rates	O
+for	O
+65	O
+clinical	O
+samples	O
+using	O
+the	O
+new	O
+RT	B-PRGE
+-	I-PRGE
+PSR	I-PRGE
+assay	O
+and	O
+the	O
+conventional	O
+RT	O
+-	O
+PCR	O
+assay	O
+were	O
+58	O
+.	O
+46	O
+%	O
+(	O
+38	O
+/	O
+65	O
+)	O
+and	O
+53	O
+.	O
+84	O
+%	O
+(	O
+35	O
+/	O
+65	O
+),	O
+respectively	O
+.	O
+
+In	O
+the	O
+RT	O
+-	O
+PSR	O
+assay	O
+,	O
+the	O
+addition	O
+of	O
+a	O
+mixture	B-CHED
+of	O
+dyes	B-PROC
+allowed	O
+a	O
+positive	O
+reaction	O
+to	O
+be	O
+directly	O
+observed	O
+by	O
+the	O
+naked	O
+eye	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+The	O
+RT	B-PRGE
+-	I-PRGE
+PSR	I-PRGE
+was	O
+optimized	O
+,	O
+and	O
+PEDV	B-SPEC
+could	O
+be	O
+detected	O
+after	O
+a	O
+50	O
+min	O
+incubation	O
+at	O
+62	O
+°	O
+C	O
+,	O
+in	O
+addition	O
+to	O
+the	O
+15	O
+min	O
+required	O
+for	O
+reverse	B-PROC
+transcription	I-PROC
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+an	O
+improved	O
+procedure	O
+of	O
+affinity	O
+selection	O
+against	O
+crude	O
+or	O
+non	O
+-	O
+purified	O
+antigen	B-CHED
+by	O
+saturation	O
+of	O
+non	O
+-	O
+binders	O
+with	O
+blocking	B-DISO
+agents	O
+to	O
+promote	O
+positive	O
+binder	O
+enrichment	O
+termed	O
+as	O
+Yin	O
+-	O
+Yang	O
+panning	O
+.	O
+
+TITLE	O
+:	O
+A	O
+pan	B-ANAT
+-	I-PRGE
+coronavirus	B-SPEC
+fusion	I-PRGE
+inhibitor	B-CHED
+targeting	B-PROC
+the	O
+HR1	B-PRGE
+domain	I-PRGE
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+spike	O
+.	O
+
+ABSTRACT	O
+:	O
+Continuously	O
+emerging	O
+highly	O
+pathogenic	O
+human	O
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+remain	O
+a	O
+major	O
+threat	O
+to	O
+human	B-SPEC
+health	O
+,	O
+as	O
+illustrated	O
+in	O
+past	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+outbreaks	O
+.	O
+
+Here	O
+,	O
+we	O
+found	O
+that	O
+peptide	B-CHED
+OC43	O
+-	O
+HR2P	O
+,	O
+derived	O
+from	O
+the	O
+HR2	O
+domain	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+exhibited	O
+broad	O
+fusion	O
+inhibitory	O
+activity	O
+against	O
+multiple	O
+HCoVs	O
+.	O
+
+EK1	B-PRGE
+,	O
+the	O
+optimized	O
+form	O
+of	O
+OC43	O
+-	O
+HR2P	O
+,	O
+showed	O
+substantially	O
+improved	O
+pan	B-COMP
+-	O
+CoV	O
+fusion	O
+inhibitory	O
+activity	O
+and	O
+pharmaceutical	B-CHED
+properties	O
+.	O
+
+Crystal	B-ANAT
+structures	O
+indicated	O
+that	O
+EK1	B-PRGE
+can	O
+form	O
+a	O
+stable	O
+six	O
+-	O
+helix	O
+bundle	O
+structure	O
+with	O
+both	O
+short	O
+α	O
+-	O
+HCoV	O
+and	O
+long	O
+β	O
+-	O
+HCoV	O
+HR1s	O
+,	O
+further	O
+supporting	O
+the	O
+role	O
+of	O
+HR1	O
+region	O
+as	O
+a	O
+viable	O
+pan	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+target	O
+site	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+Microminipig	O
+is	O
+a	O
+good	O
+small	O
+animal	B-SPEC
+model	O
+for	O
+PED	B-PRGE
+,	O
+which	O
+may	O
+contribute	O
+to	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+PEDV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+can	O
+cause	O
+diarrhea	B-DISO
+in	O
+nursing	B-PROC
+piglets	O
+.	O
+
+Therefore	O
+,	O
+it	O
+can	O
+be	O
+preliminarily	O
+concluded	O
+that	O
+PPAR	B-PRGE
+differential	O
+expression	B-PROC
+caused	O
+by	O
+PDCoV	O
+was	O
+mostly	O
+associated	O
+with	O
+weight	O
+loss	O
+and	O
+death	B-PROC
+from	O
+emaciation	B-DISO
+.	O
+
+We	O
+also	O
+examined	O
+the	O
+representation	O
+of	O
+major	O
+etiologies	O
+for	O
+ARDS	B-DISO
+across	O
+the	O
+Berlin	O
+definition	O
+classifications	O
+.	O
+
+Many	O
+of	O
+the	O
+emerging	O
+pathogens	O
+are	O
+zoonoses	B-DISO
+and	O
+,	O
+as	O
+such	O
+,	O
+there	O
+is	O
+scope	O
+for	O
+intervention	O
+at	O
+the	O
+animal	B-SPEC
+/	O
+insect	B-SPEC
+/	O
+environmental	O
+reservoir	O
+.	O
+
+We	O
+report	O
+a	O
+suicide	O
+case	O
+after	O
+inhalation	O
+of	O
+a	O
+pyrethrins	B-CHED
+containing	O
+insecticide	B-CHED
+spray	O
+.	O
+
+Bats	B-SPEC
+are	O
+reservoirs	O
+for	O
+a	O
+high	O
+diversity	O
+of	O
+coronaviruses	O
+,	O
+and	O
+focused	O
+surveillance	O
+detected	O
+several	O
+strains	O
+genetically	O
+similar	O
+to	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+,	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+,	O
+and	O
+the	O
+human	B-SPEC
+coronaviruses	O
+229E	O
+and	O
+NL63	O
+.	O
+
+Monocytes	B-ANAT
+of	O
+QFS	O
+patients	O
+produced	O
+significantly	O
+less	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+(	O
+p	O
+=	O
+0	O
+.	O
+032	O
+),	O
+IL	O
+-	O
+1β	O
+(	O
+0	O
+.	O
+004	O
+,	O
+0	O
+.	O
+024	O
+,	O
+and	O
+0	O
+.	O
+008	O
+),	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+(	O
+0	O
+.	O
+043	O
+),	O
+RANTES	O
+(	O
+0	O
+.	O
+033	O
+),	O
+IP	O
+-	O
+10	O
+(	O
+0	O
+.	O
+049	O
+),	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+0	O
+.	O
+022	O
+),	O
+IL	O
+-	O
+13	O
+(	O
+0	O
+.	O
+029	O
+),	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+(	O
+0	O
+.	O
+026	O
+)	O
+than	O
+healthy	O
+controls	O
+when	O
+stimulated	O
+with	O
+various	O
+ligands	O
+.	O
+
+ABSTRACT	O
+:	O
+Camel	O
+contact	O
+is	O
+a	O
+recognized	O
+risk	O
+factor	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+On	O
+multivariable	O
+analyses	O
+,	O
+working	O
+as	O
+a	O
+camel	B-SPEC
+salesman	O
+,	O
+handling	O
+live	O
+camels	B-SPEC
+or	O
+their	O
+waste	O
+,	O
+and	O
+having	O
+diabetes	B-DISO
+were	O
+associated	O
+with	O
+seropositivity	O
+among	O
+all	O
+workers	O
+,	O
+whereas	O
+handling	O
+live	O
+camels	O
+and	O
+either	O
+administering	O
+medications	O
+or	O
+cleaning	O
+equipment	O
+was	O
+associated	O
+with	O
+seropositivity	O
+among	O
+market	O
+workers	O
+.	O
+
+After	O
+ruling	O
+out	O
+other	O
+causes	O
+,	O
+the	O
+diagnosis	O
+of	O
+gabapentin	B-CHED
+withdrawal	B-DISO
+was	O
+considered	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+diagnostic	O
+delays	O
+remain	O
+a	O
+major	O
+challenge	O
+in	O
+health	O
+systems	O
+,	O
+the	O
+source	O
+of	O
+delays	O
+has	O
+not	O
+been	O
+recognized	O
+in	O
+the	O
+literature	O
+.	O
+
+The	O
+emergency	B-DISO
+management	O
+program	O
+ensures	O
+quality	O
+and	O
+continuous	O
+improvement	O
+through	O
+its	O
+certification	O
+in	O
+International	O
+Organization	O
+for	O
+Standardization	O
+(	O
+ISO	B-SPEC
+)	O
+9001	O
+and	O
+structured	O
+review	O
+processes	O
+.	O
+
+The	O
+patient	O
+was	O
+diagnosed	O
+as	O
+tension	B-DISO
+pneumothorax	I-DISO
+complicated	O
+by	O
+TTS	O
+.	O
+
+However	O
+,	O
+the	O
+patient	O
+further	O
+underwent	O
+ligation	O
+bullectomy	O
+for	O
+persistent	O
+air	B-DISO
+leakage	I-DISO
+2	O
+weeks	O
+later	O
+.	O
+
+The	O
+most	O
+common	O
+viruses	B-SPEC
+detected	O
+were	O
+human	B-SPEC
+rhinovirus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+,	O
+influenzavirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+.	O
+
+Interpretation	O
+of	O
+molecular	O
+diagnostic	O
+assays	O
+for	O
+viruses	B-SPEC
+must	O
+be	O
+informed	O
+by	O
+understanding	O
+of	O
+local	O
+rates	O
+of	O
+asymptomatic	B-DISO
+infection	I-DISO
+by	O
+such	O
+viruses	B-SPEC
+.	O
+
+Our	O
+study	O
+aims	O
+to	O
+explore	O
+the	O
+epidemiology	O
+and	O
+risk	O
+factors	O
+affecting	O
+outcomes	O
+of	O
+ARDS	B-DISO
+patients	O
+and	O
+provide	O
+a	O
+theoretical	O
+basis	O
+for	O
+patients	O
+'	O
+prognosis	O
+.	O
+
+TITLE	O
+:	O
+Protection	O
+conferred	O
+by	O
+a	O
+vaccine	O
+derived	O
+from	O
+an	O
+inactivated	O
+Egyptian	O
+variant	O
+of	O
+infectious	B-DISO
+bronchitis	O
+virus	B-SPEC
+:	O
+a	O
+challenge	O
+experiment	O
+.	O
+
+Canine	B-SPEC
+adenovirus	I-SPEC
+,	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+H3N2	B-CHED
+and	O
+H3N8	O
+),	O
+Bordetella	B-SPEC
+bronchiseptica	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+canis	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+cynos	I-SPEC
+and	O
+Streptococcus	O
+equi	O
+subsp	O
+.	O
+
+Results	O
+showed	O
+low	O
+occurrence	O
+of	O
+classical	O
+CIRD	O
+agents	O
+such	O
+as	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+,	O
+canine	B-SPEC
+adenovirus	I-SPEC
+and	O
+distemper	B-DISO
+virus	B-SPEC
+,	O
+while	O
+highlighting	O
+the	O
+potential	O
+role	O
+of	O
+emerging	O
+bacteria	B-SPEC
+such	O
+as	O
+M	B-SPEC
+.	I-SPEC
+canis	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+cynos	I-SPEC
+.	O
+
+This	O
+study	O
+provides	O
+new	O
+insights	O
+into	O
+the	O
+current	O
+understanding	O
+of	O
+the	O
+prevalence	O
+and	O
+role	O
+of	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+with	O
+selected	O
+viruses	B-SPEC
+and	O
+bacteria	B-SPEC
+in	O
+the	O
+etiology	O
+of	O
+CIRD	O
+,	O
+while	O
+underscoring	O
+the	O
+importance	O
+of	O
+molecular	O
+diagnosis	O
+and	O
+vaccination	O
+against	O
+this	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Transmission	O
+in	O
+Rabbits	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+rabbits	B-SPEC
+to	O
+further	O
+characterize	O
+the	O
+transmission	O
+potential	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+line	O
+with	O
+the	O
+presence	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+in	O
+the	O
+rabbit	B-SPEC
+nasal	B-ANAT
+epithelium	I-ANAT
+,	O
+high	O
+levels	O
+of	O
+viral	O
+RNA	O
+were	O
+shed	O
+from	O
+the	O
+nose	B-ANAT
+following	O
+virus	B-SPEC
+inoculation	O
+.	O
+
+As	O
+a	O
+result	O
+of	O
+VPS36	B-PRGE
+-	I-PRGE
+ORF3	I-PRGE
+interaction	O
+,	O
+PEDV	B-SPEC
+replication	O
+was	O
+substantially	O
+suppressed	O
+in	O
+cells	B-COMP
+overexpressing	O
+VPS36	B-PRGE
+.	O
+
+MERS	O
+-	O
+CoV	O
+causes	O
+an	O
+acute	O
+lower	O
+-	O
+respiratory	B-DISO
+infection	I-DISO
+in	O
+humans	B-SPEC
+,	O
+with	O
+a	O
+fatality	O
+rate	O
+of	O
+~	O
+35	O
+.	O
+5	O
+%.	O
+
+To	O
+develop	O
+a	O
+simple	O
+,	O
+rapid	O
+,	O
+accurate	O
+,	O
+and	O
+high	O
+-	O
+throughput	O
+detection	O
+method	O
+for	O
+diagnosis	O
+and	O
+differential	O
+diagnosis	O
+on	O
+swine	B-SPEC
+enteric	O
+coronaviruses	O
+,	O
+specific	O
+primers	O
+and	O
+probes	O
+were	O
+designed	O
+based	O
+on	O
+the	O
+highly	O
+conserved	O
+regions	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+N	O
+,	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+M	O
+,	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+M	O
+,	O
+and	O
+porcine	B-SPEC
+enteric	O
+alphacoronavirus	B-SPEC
+(	O
+PEAV	O
+)	O
+N	O
+genes	O
+respectively	O
+.	O
+
+Our	O
+previous	O
+study	O
+demonstrated	O
+that	O
+the	O
+vasoactive	B-PRGE
+intestinal	I-PRGE
+peptide	B-PRGE
+(	I-PRGE
+VIP	B-CHED
+)	I-PRGE
+is	O
+mediated	O
+by	O
+lentivirus	B-SPEC
+attenuates	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+induced	O
+ARDS	B-DISO
+in	O
+a	O
+murine	B-SPEC
+model	O
+,	O
+and	O
+VIP	B-PRGE
+inhibits	O
+the	O
+release	B-PATH
+of	O
+interleukin	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+(	O
+IL	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+)	O
+from	O
+activation	O
+macrophages	B-ANAT
+.	O
+
+Furthermore	O
+,	O
+we	O
+found	O
+that	O
+VIP	B-PRGE
+inhibited	O
+the	O
+expression	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+17R	I-FUNC
+in	O
+the	O
+lungs	B-ANAT
+of	O
+mice	B-SPEC
+with	O
+ARDS	B-DISO
+and	O
+NIH3T3	O
+cells	B-COMP
+stimulated	O
+with	O
+LPS	B-DISO
+,	O
+which	O
+was	O
+partly	O
+inhibited	O
+by	O
+antagonists	B-CHED
+of	O
+protein	B-PRGE
+kinase	I-PRGE
+A	I-PRGE
+and	O
+protein	B-PRGE
+kinase	I-PRGE
+C	I-PRGE
+.	O
+Taken	O
+together	O
+,	O
+our	O
+results	O
+demonstrated	O
+that	O
+VIP	B-PRGE
+inhibited	O
+the	O
+activation	O
+of	O
+fibroblast	B-ANAT
+via	O
+downregulation	B-PROC
+of	O
+IL	O
+-	O
+17RC	O
+,	O
+which	O
+may	O
+contribute	O
+to	O
+the	O
+protective	O
+effects	O
+of	O
+VIP	O
+against	O
+ARDS	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+(	O
+Gene	O
+Ontology	O
+)	O
+GO	O
+annotation	O
+and	O
+functional	O
+enrichment	O
+analysis	O
+indicated	O
+that	O
+all	O
+of	O
+the	O
+DEGs	O
+(	O
+differentially	O
+expressed	O
+genes	O
+)	O
+were	O
+annotated	O
+into	O
+biological	B-PROC
+process	I-PROC
+,	O
+cellular	B-COMP
+component	I-COMP
+and	O
+molecular	B-FUNC
+function	I-FUNC
+.	O
+
+Most	O
+of	O
+these	O
+unigenes	O
+are	O
+annotated	O
+were	O
+related	O
+to	O
+immune	B-ANAT
+system	I-ANAT
+response	O
+to	O
+the	O
+infectious	B-DISO
+diseases	I-DISO
+pathways	B-PROC
+.	O
+
+TITLE	O
+:	O
+Veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+life	O
+support	O
+for	O
+blastomycosis	B-DISO
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+two	O
+patients	O
+,	O
+long	O
+-	O
+term	O
+functional	O
+and	O
+neuropsychological	O
+outcomes	O
+showed	O
+similar	O
+limitations	O
+to	O
+what	O
+is	O
+seen	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+who	O
+are	O
+not	O
+supported	O
+with	O
+extracorporeal	O
+life	O
+support	O
+and	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+without	O
+blastomycosis	B-DISO
+,	O
+but	O
+worse	O
+pulmonary	B-PROC
+function	I-PROC
+outcomes	O
+in	O
+the	O
+form	O
+of	O
+obstructive	O
+and	O
+restrictive	O
+changes	O
+that	O
+correlated	O
+with	O
+the	O
+radiological	O
+imaging	O
+.	O
+
+Although	O
+there	O
+has	O
+been	O
+extensive	O
+research	O
+on	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+of	O
+TGEV	B-SPEC
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+intracellular	B-COMP
+role	O
+of	O
+TGEV	B-SPEC
+-	O
+S1	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+also	O
+found	O
+that	O
+p38	B-PRGE
+MAPK	B-FUNC
+and	O
+SAPK	B-FUNC
+/	O
+JNK	B-FUNC
+were	O
+activated	O
+in	O
+PEDV	B-SPEC
+-	O
+infected	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+However	O
+,	O
+some	O
+high	O
+-	O
+risk	O
+patients	O
+with	O
+a	O
+very	O
+advanced	O
+disease	O
+develop	O
+choriocarcinoma	B-DISO
+syndrome	B-DISO
+(	O
+CS	O
+)	O
+connected	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+poor	O
+prognosis	O
+and	O
+high	O
+mortality	O
+rate	O
+shortly	O
+after	O
+beginning	O
+systemic	O
+chemotherapy	O
+.	O
+
+ABSTRACT	O
+:	O
+Synthesis	B-PROC
+of	O
+the	O
+negative	O
+-	O
+strand	O
+((-)-	O
+strand	O
+)	O
+counterpart	O
+is	O
+the	O
+first	O
+step	O
+of	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+replication	O
+;	O
+however	O
+,	O
+the	O
+detailed	O
+mechanism	O
+of	O
+the	O
+early	O
+event	O
+and	O
+the	O
+factors	O
+involved	O
+remain	O
+to	O
+be	O
+determined	O
+.	O
+
+Based	O
+on	O
+dissociation	B-DISO
+constant	O
+(	O
+K	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+capable	O
+of	O
+inducing	O
+a	O
+storm	O
+of	O
+proinflammatory	O
+cytokines	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+its	O
+ORF3a	O
+protein	B-CHED
+were	O
+found	O
+to	O
+be	O
+potent	O
+activators	O
+of	O
+pro	B-PRGE
+-	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+1β	I-PRGE
+gene	B-PROC
+transcription	I-PROC
+and	O
+protein	B-PROC
+maturation	B-PROC
+,	O
+the	O
+2	O
+signals	O
+required	O
+for	O
+activation	O
+of	O
+the	O
+NLRP3	B-PRGE
+inflammasome	I-PRGE
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+findings	O
+reveal	O
+a	O
+new	O
+mechanism	O
+by	O
+which	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORF3a	I-PRGE
+protein	B-CHED
+activates	O
+NF	O
+-	O
+κB	O
+and	O
+the	O
+NLRP3	B-PRGE
+inflammasome	I-PRGE
+by	O
+promoting	O
+TRAF3	B-PRGE
+-	O
+dependent	O
+ubiquitination	B-PROC
+of	O
+p105	B-PRGE
+and	O
+ASC	O
+.-	O
+Siu	O
+,	O
+K	O
+.-	O
+L	O
+.,	O
+Yuen	O
+,	O
+K	O
+.-	O
+S	O
+.,	O
+Castaño	O
+-	O
+Rodriguez	O
+,	O
+C	O
+.,	O
+Ye	O
+,	O
+Z	O
+.-	O
+W	O
+.,	O
+Yeung	O
+,	O
+M	O
+.-	O
+L	O
+.,	O
+Fung	O
+,	O
+S	O
+.-	O
+Y	O
+.,	O
+Yuan	O
+,	O
+S	O
+.,	O
+Chan	O
+,	O
+C	O
+.-	O
+P	O
+.,	O
+Yuen	O
+,	O
+K	O
+.-	O
+Y	O
+.,	O
+Enjuanes	O
+,	O
+L	O
+.,	O
+Jin	O
+,	O
+D	O
+.-	O
+Y	O
+.	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+ORF3a	O
+protein	B-CHED
+activates	O
+the	O
+NLRP3	B-PRGE
+inflammasome	I-PRGE
+by	O
+promoting	O
+TRAF3	B-PRGE
+-	O
+dependent	O
+ubiquitination	B-PROC
+of	O
+ASC	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+frequency	O
+of	O
+infections	O
+caused	O
+by	O
+Influenza	B-SPEC
+viruses	I-SPEC
+,	O
+i	O
+.	O
+e	O
+.	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+,	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H3N2	B-CHED
+)	O
+and	O
+Influenza	B-DISO
+B	O
+in	O
+patients	O
+presenting	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+i	O
+.	O
+e	O
+.	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+and	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+(	O
+SARI	O
+).	O
+
+Multiplex	O
+PCR	O
+was	O
+done	O
+for	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+,	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H3N2	B-CHED
+)	O
+and	O
+Influenza	B-DISO
+B	O
+.	O
+A	O
+total	O
+of	O
+200	O
+(	O
+32	O
+%)	O
+samples	O
+were	O
+found	O
+to	O
+be	O
+positive	O
+for	O
+Influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+Commonest	O
+Influenza	B-DISO
+subtype	O
+in	O
+age	O
+group	O
+-	O
+IV	O
+was	O
+H3N2	B-CHED
+found	O
+in	O
+20	O
+(	O
+32	O
+.	O
+8	O
+%)	O
+patients	O
+,	O
+followed	O
+by	O
+H1N1	O
+in	O
+15	O
+(	O
+12	O
+.	O
+5	O
+%)	O
+patients	O
+.	O
+
+The	O
+level	O
+of	O
+plasma	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+was	O
+greater	O
+in	O
+higher	O
+CCI	O
+score	O
+(≥	O
+4	O
+)	O
+group	O
+compared	O
+with	O
+lower	O
+CCI	O
+score	O
+(<	O
+4	O
+)	O
+group	O
+(	O
+Patients	O
+with	O
+a	O
+higher	O
+CCI	O
+score	O
+had	O
+more	O
+severe	O
+symptoms	O
+,	O
+functional	O
+impairment	B-DISO
+and	O
+higher	O
+level	O
+of	O
+inflammatory	O
+factors	O
+and	O
+high	O
+frequency	O
+of	O
+hospital	O
+admission	O
+due	O
+to	O
+acute	O
+exacerbation	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+top	O
+five	O
+comorbidities	O
+were	O
+hypertension	B-DISO
+,	O
+metabolic	B-DISO
+syndrome	I-DISO
+and	O
+diabetes	B-DISO
+osteoporosis	B-DISO
+,	O
+bronchiectasis	B-DISO
+and	O
+peripheral	B-DISO
+vascular	I-DISO
+diseases	I-DISO
+.	O
+
+Furthermore	O
+,	O
+effective	O
+vaccines	O
+to	O
+prevent	O
+RSV	B-DISO
+infection	I-DISO
+are	O
+currently	O
+unavailable	O
+.	O
+
+All	O
+four	O
+final	O
+egg	B-ANAT
+-	O
+passaged	O
+viruses	B-SPEC
+were	O
+attenuated	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+identify	O
+peptides	B-CHED
+within	O
+the	O
+polyprotein	O
+(	O
+Pp	O
+)	O
+1	O
+ab	O
+that	O
+are	O
+differentially	O
+recognised	O
+by	O
+cats	B-SPEC
+with	O
+either	O
+enteric	O
+or	O
+systemic	B-DISO
+disease	I-DISO
+following	O
+infection	B-DISO
+with	O
+feline	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Peptide	B-CHED
+4934	O
+reacted	O
+equally	O
+with	O
+positive	O
+sera	B-COMP
+from	O
+healthy	O
+cats	B-SPEC
+and	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+while	O
+peptide	B-CHED
+16433	O
+was	O
+recognized	O
+predominantly	O
+by	O
+FIP	B-DISO
+-	O
+affected	O
+cats	B-SPEC
+.	O
+
+Patients	O
+with	O
+high	O
+IAP	B-PRGE
+have	O
+shown	O
+a	O
+higher	O
+mortality	O
+frequency	O
+,	O
+compared	O
+to	O
+others	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Patients	O
+with	O
+high	O
+IAP	B-PRGE
+have	O
+shown	O
+a	O
+higher	O
+mortality	O
+frequency	O
+,	O
+compared	O
+to	O
+others	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+virus	I-SPEC
+RNA	O
+recovered	O
+from	O
+droplets	O
+and	O
+droplet	O
+nuclei	B-CHED
+emitted	O
+by	O
+adults	O
+in	O
+an	O
+acute	O
+care	O
+setting	O
+.	O
+
+In	O
+addition	O
+,	O
+healthcare	O
+worker	O
+participants	O
+providing	O
+care	O
+to	O
+infected	O
+participants	O
+were	O
+recruited	O
+to	O
+wear	O
+a	O
+polytetrafluoroethylene	O
+(	O
+PTFE	B-CHED
+)	O
+filter	O
+cassette	O
+in	O
+their	O
+breathing	B-PROC
+zones	O
+.	O
+
+Viral	O
+RNA	O
+was	O
+recovered	O
+in	O
+droplet	O
+nuclei	B-CHED
+and	O
+beyond	O
+1	O
+m	O
+from	O
+naturally	O
+-	O
+infected	O
+participants	O
+in	O
+the	O
+healthcare	O
+setting	O
+and	O
+from	O
+the	O
+breathing	B-PROC
+zone	O
+of	O
+one	O
+healthcare	O
+worker	O
+.	O
+
+ABSTRACT	O
+:	O
+Introduction	O
+:	O
+The	O
+clinical	O
+course	O
+of	O
+acute	O
+respiratory	O
+viral	O
+infections	O
+was	O
+not	O
+sufficiently	O
+studied	O
+,	O
+specially	O
+the	O
+state	O
+of	O
+oxidative	O
+homeostasis	B-PROC
+in	O
+children	O
+with	O
+influenza	B-DISO
+stomatitis	B-DISO
+.	O
+
+To	O
+analyze	O
+lipid	B-PROC
+peroxidation	I-PROC
+we	O
+used	O
+a	O
+spectrophotometric	O
+determination	O
+of	O
+diene	O
+conjugates	O
+.	O
+
+Results	O
+:	O
+We	O
+found	O
+the	O
+intensification	O
+of	O
+lipid	B-PROC
+peroxidation	I-PROC
+:	O
+a	O
+significant	O
+increase	O
+of	O
+diene	O
+conjugates	O
+in	O
+serum	B-COMP
+up	O
+to	O
+13	O
+.	O
+78	O
+%,	O
+the	O
+level	O
+of	O
+which	O
+depended	O
+on	O
+the	O
+severity	O
+of	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+in	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+(	O
+DIC	B-DISO
+)	O
+associated	O
+with	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+)	O
+plays	O
+pivotal	O
+roles	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+The	O
+2018	O
+Jeju	O
+isolates	O
+shared	O
+96	O
+.	O
+7	O
+%-	O
+98	O
+.	O
+7	O
+%	O
+and	O
+98	O
+.	O
+5	O
+%-	O
+99	O
+.	O
+4	O
+%	O
+identity	O
+at	O
+the	O
+S	O
+gene	O
+and	O
+whole	O
+-	O
+genome	O
+levels	O
+,	O
+respectively	O
+,	O
+compared	O
+to	O
+global	O
+G2b	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+In	O
+vivo	O
+animal	B-SPEC
+studies	O
+showed	O
+that	O
+variant	O
+strain	O
+KNU	O
+-	O
+1807	O
+had	O
+decreased	O
+virulence	B-PROC
+in	O
+suckling	O
+piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+Approximately	O
+half	O
+of	O
+the	O
+reported	O
+laboratory	O
+-	O
+confirmed	O
+infections	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+have	O
+occurred	O
+in	O
+healthcare	O
+settings	O
+,	O
+and	O
+healthcare	O
+workers	O
+constitute	O
+over	O
+one	O
+third	O
+of	O
+all	O
+secondary	B-DISO
+infections	I-DISO
+.	O
+
+Year	O
+of	O
+infection	B-DISO
+(	O
+2013	O
+-	O
+2018	O
+)	O
+and	O
+having	O
+no	O
+comorbidities	O
+were	O
+independent	O
+protective	O
+factors	O
+against	O
+death	B-PROC
+among	O
+secondary	O
+healthcare	O
+workers	O
+cases	O
+.	O
+
+However	O
+,	O
+many	O
+conditions	O
+,	O
+including	O
+cardiomyopathy	B-DISO
+,	O
+pulmonary	B-DISO
+embolism	I-DISO
+,	O
+or	O
+myocarditis	B-DISO
+,	O
+can	O
+cause	O
+an	O
+elevation	O
+in	O
+serum	B-PRGE
+troponin	I-PRGE
+.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+a	O
+patient	O
+who	O
+presented	O
+with	O
+symptoms	O
+consistent	O
+with	O
+viral	B-PATH
+myocarditis	I-PATH
+but	O
+ultimately	O
+was	O
+found	O
+to	O
+have	O
+severe	O
+coronary	B-DISO
+artery	I-DISO
+disease	I-DISO
+(	O
+CAD	B-DISO
+).	O
+
+A	O
+33	O
+-	O
+year	O
+-	O
+old	O
+Caucasian	O
+male	O
+with	O
+no	O
+cardiac	B-ANAT
+risk	O
+factors	O
+other	O
+than	O
+a	O
+five	O
+-	O
+pack	O
+year	O
+smoking	O
+history	O
+,	O
+presented	O
+with	O
+progressively	O
+worsening	O
+upper	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+including	O
+sore	B-DISO
+throat	I-DISO
+and	O
+a	O
+non	B-DISO
+-	I-DISO
+productive	I-DISO
+cough	I-DISO
+that	O
+began	O
+a	O
+few	O
+weeks	O
+ago	O
+.	O
+
+A	O
+transthoracic	O
+echocardiogram	O
+showed	O
+wall	O
+motion	O
+abnormalities	O
+with	O
+low	O
+-	O
+normal	O
+left	B-PROC
+ventricular	I-PROC
+ejection	I-PROC
+fraction	O
+.	O
+
+A	O
+coronary	B-ANAT
+angiogram	O
+showed	O
+severe	O
+CAD	B-DISO
+and	O
+he	O
+underwent	O
+staged	O
+a	O
+percutaneous	O
+coronary	B-ANAT
+intervention	O
+with	O
+the	O
+resolution	O
+of	O
+symptoms	O
+.	O
+
+Noninvasive	O
+ventilation	O
+must	O
+be	O
+used	O
+with	O
+caution	O
+in	O
+ARDS	B-DISO
+as	O
+excessively	O
+high	O
+respiratory	O
+drive	O
+can	O
+further	O
+exacerbate	O
+lung	B-ANAT
+injury	O
+;	O
+newer	O
+modes	O
+of	O
+delivery	O
+offer	O
+promising	O
+approaches	O
+in	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Despite	O
+a	O
+disappointing	O
+lack	O
+of	O
+benefit	O
+(	O
+and	O
+possible	O
+harm	O
+)	O
+in	O
+patients	O
+with	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+,	O
+possibly	O
+due	O
+to	O
+lung	B-ANAT
+hyperdistention	B-DISO
+and	O
+right	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+,	O
+high	O
+-	O
+frequency	O
+oscillation	O
+may	O
+improve	O
+outcome	O
+in	O
+patients	O
+with	O
+very	O
+severe	O
+hypoxemia	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+Strategies	O
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+VV	O
+-	O
+ECLS	O
+can	O
+be	O
+configured	O
+as	O
+a	O
+system	O
+that	O
+uses	O
+higher	O
+blood	B-PROC
+flows	I-PROC
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+or	O
+as	O
+one	O
+that	O
+uses	O
+lower	O
+blood	B-PROC
+flows	I-PROC
+for	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+(	O
+VV	O
+-	O
+ECCO	O
+
+An	O
+EriCoV	O
+-	O
+specific	O
+BRYT	O
+-	O
+Green	O
+®	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+assay	O
+was	O
+used	O
+to	O
+test	O
+351	O
+samples	O
+of	O
+faeces	B-ANAT
+or	O
+distal	O
+large	O
+intestinal	B-ANAT
+tract	I-ANAT
+contents	O
+collected	O
+from	O
+casualty	O
+or	O
+dead	B-PROC
+hedgehogs	B-SPEC
+from	O
+a	O
+wide	O
+area	O
+across	O
+GB	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+causes	O
+considerable	O
+economic	O
+losses	O
+in	O
+the	O
+poultry	O
+industry	O
+worldwide	O
+,	O
+including	O
+Taiwan	O
+.	O
+
+Routine	O
+laboratory	O
+tests	O
+and	O
+cultures	O
+cannot	O
+confirm	O
+many	O
+tropical	O
+infections	B-DISO
+,	O
+and	O
+pathogen	O
+directed	O
+testing	O
+is	O
+typically	O
+required	O
+.	O
+
+Throughout	O
+the	O
+study	O
+period	O
+the	O
+overall	O
+number	O
+of	O
+calls	O
+did	O
+not	O
+vary	O
+,	O
+but	O
+the	O
+percentage	O
+of	O
+ECMO	O
+retrievals	O
+decreased	O
+,	O
+whereas	O
+the	O
+percentage	O
+of	O
+ARF	B-DISO
+patients	O
+from	O
+peripheral	O
+hospital	O
+admitted	O
+to	O
+our	O
+ECMO	O
+center	O
+on	O
+conventional	O
+ventilation	O
+increased	O
+.	O
+
+Data	O
+were	O
+extracted	O
+from	O
+a	O
+secondary	O
+analysis	O
+of	O
+an	O
+international	O
+point	O
+prevalence	O
+study	O
+of	O
+pediatric	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Pediatric	O
+patients	O
+with	O
+postsurgical	O
+sepsis	B-DISO
+had	O
+different	O
+risk	O
+factors	O
+for	O
+mortality	O
+compared	O
+with	O
+medical	O
+sepsis	B-DISO
+.	O
+
+Phylogenetic	O
+analysis	O
+using	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+the	O
+ORF	O
+1ab	O
+and	O
+the	O
+spike	O
+gene	O
+showed	O
+that	O
+the	O
+bat	B-ENZY
+coronavirus	B-SPEC
+strain	O
+16BO133	O
+was	O
+grouped	O
+with	O
+the	O
+Beta	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+lineage	O
+B	O
+and	O
+was	O
+closely	O
+related	O
+to	O
+the	O
+JTMC15	O
+strain	O
+isolated	O
+from	O
+Rhinolophus	B-SPEC
+ferrumequinum	I-SPEC
+in	O
+China	O
+.	O
+
+However	O
+,	O
+16BO133	O
+was	O
+distinctly	O
+located	O
+in	O
+the	O
+phylogenetic	O
+topology	O
+of	O
+the	O
+human	B-PRGE
+SARS	B-DISO
+CoV	I-PRGE
+strain	O
+(	O
+Tor2	O
+).	O
+
+The	O
+spike	O
+region	O
+of	O
+16BO133	O
+showed	O
+84	O
+.	O
+7	O
+%	O
+and	O
+75	O
+.	O
+2	O
+%	O
+amino	O
+acid	O
+identity	O
+with	O
+Rf1	B-PRGE
+(	O
+SARS	B-DISO
+-	O
+like	O
+bat	B-ENZY
+CoV	O
+)	O
+and	O
+Tor2	B-PRGE
+(	O
+human	B-PRGE
+SARS	B-DISO
+CoV	I-PRGE
+),	O
+respectively	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+of	O
+16BO133	O
+was	O
+found	O
+to	O
+contain	O
+the	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+of	O
+two	O
+critical	O
+residues	O
+(	O
+N479S	O
+and	O
+T487	O
+V	O
+)	O
+associated	O
+with	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+conserved	O
+segment	O
+containing	O
+one	O
+SNP	O
+A4408C	O
+of	O
+parvovirus	B-DISO
+was	O
+used	O
+for	O
+real	O
+-	O
+time	O
+PCR	O
+amplification	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	O
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+diarrhoea	B-DISO
+in	O
+newborn	O
+calves	O
+,	O
+winter	B-DISO
+dysentery	I-DISO
+in	O
+adult	O
+cattle	B-SPEC
+and	O
+respiratory	B-ANAT
+tract	I-ANAT
+illnesses	O
+in	O
+cattle	B-SPEC
+across	O
+the	O
+world	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+BCoV	O
+is	O
+widely	O
+circulating	O
+in	O
+dairy	O
+cattle	B-SPEC
+in	O
+China	O
+,	O
+contributing	O
+to	O
+the	O
+diagnosis	O
+and	O
+control	O
+of	O
+dairy	O
+calves	O
+diarrhoea	B-DISO
+.	O
+
+Our	O
+findings	O
+will	O
+enhance	O
+current	O
+understanding	O
+about	O
+the	O
+genetic	O
+evolution	B-PROC
+of	O
+BCoV	O
+.	O
+
+Accumulation	O
+of	O
+mutations	O
+in	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+and	O
+the	O
+accessory	O
+gene	B-PRGE
+5a	I-PRGE
+were	O
+observed	O
+,	O
+suggesting	O
+a	O
+potential	O
+role	O
+in	O
+the	O
+loss	O
+of	O
+viral	O
+pathogenicity	O
+.	O
+
+Embryo	B-ANAT
+mortality	O
+time	O
+/	O
+rate	O
+showed	O
+that	O
+rYN	O
+-	O
+S	O
+-	O
+aYN	O
+and	O
+rYN	O
+-	O
+5a	O
+-	O
+aYN	O
+had	O
+an	O
+attenuated	O
+phenotype	O
+in	O
+ovo	B-SPEC
+.	O
+
+We	O
+present	O
+X	O
+-	O
+ray	B-SPEC
+structures	O
+for	O
+the	O
+CavV	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+
+TITLE	O
+:	O
+A	O
+Co	O
+-	O
+Occurrence	O
+of	O
+Serologically	O
+Proven	O
+Myasthenia	B-DISO
+Gravis	I-DISO
+and	O
+Pharyngeal	B-ANAT
+-	O
+Cervical	B-ANAT
+-	O
+Brachial	O
+Variant	O
+of	O
+Guillain	O
+-	O
+Barré	O
+Syndrome	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+on	O
+a	O
+co	O
+-	O
+occurrence	O
+case	O
+of	O
+ocular	B-DISO
+myasthenia	I-DISO
+gravis	I-DISO
+with	O
+exacerbation	O
+leading	O
+to	O
+myasthenic	B-DISO
+crisis	I-DISO
+in	O
+addition	O
+to	O
+pharyngeal	B-ANAT
+-	O
+cervical	B-ANAT
+-	O
+brachial	O
+variant	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+in	O
+a	O
+patient	O
+with	O
+severe	O
+oropharyngeal	B-DISO
+dysphagia	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+42	O
+male	O
+rats	B-SPEC
+were	O
+divided	O
+to	O
+seven	O
+groups	O
+named	O
+control	O
+,	O
+OA	O
+,	O
+ALA	B-CHED
+,	O
+VITE	O
+,	O
+VITC	O
+,	O
+LDMP	O
+,	O
+and	O
+HDMP	O
+.	O
+
+OA	O
+increased	O
+MDA	O
+level	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IL	B-PRGE
+-	I-PRGE
+1β	I-PRGE
+cytokine	I-PRGE
+levels	O
+in	O
+serum	B-COMP
+.	O
+
+ALA	B-PRGE
+,	O
+VITE	O
+,	O
+VITC	O
+,	O
+and	O
+both	O
+dose	O
+of	O
+MP	O
+significantly	O
+decreased	O
+the	O
+cytokine	O
+levels	O
+.	O
+
+Nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+specimens	O
+or	O
+induced	B-ANAT
+sputum	I-ANAT
+were	O
+tested	O
+for	O
+eight	O
+categories	O
+respiratory	O
+viral	O
+targets	O
+.	O
+
+IFV	B-SPEC
+,	O
+RSV	B-SPEC
+,	O
+HRV	O
+,	O
+and	O
+ADV	O
+accounted	O
+for	O
+more	O
+than	O
+two	O
+-	O
+thirds	O
+of	O
+all	O
+viral	O
+SALRTI	O
+.	O
+
+TITLE	O
+:	O
+Pathogenicity	O
+of	O
+a	O
+GI	O
+-	O
+22	O
+genotype	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolated	O
+in	O
+China	O
+and	O
+protection	O
+against	O
+it	O
+afforded	O
+by	O
+GI	O
+-	O
+19	O
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	O
+infectious	O
+bronchitis	O
+(	O
+IB	O
+)	O
+is	O
+a	O
+globally	O
+circulating	O
+bird	B-DISO
+disease	I-DISO
+caused	O
+by	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+In	O
+China	O
+,	O
+the	O
+most	O
+prevalent	O
+IBV	B-SPEC
+genotype	O
+is	O
+GI	O
+-	O
+19	O
+/	O
+QX	O
+-	O
+like	O
+because	O
+the	O
+protective	O
+efficiency	O
+of	O
+the	O
+classical	O
+IBV	B-SPEC
+vaccine	O
+is	O
+low	O
+,	O
+and	O
+new	O
+GI	O
+-	O
+19	O
+vaccines	O
+are	O
+under	O
+development	B-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+demonstrate	O
+that	O
+autophagosome	B-PROC
+formation	I-PROC
+and	O
+apparent	O
+autophagic	O
+flux	O
+are	O
+induced	O
+in	O
+cells	B-COMP
+infected	O
+with	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+-	O
+a	O
+gammacoronavirus	B-SPEC
+.	O
+
+Notably	O
+,	O
+IBV	B-SPEC
+-	O
+induced	O
+autophagy	B-PROC
+was	O
+dependent	O
+on	O
+autophagy	B-PRGE
+related	I-PRGE
+5	I-PRGE
+(	O
+ATG5	B-PRGE
+)	O
+but	O
+not	O
+beclin1	B-PRGE
+(	O
+BECN1	B-PRGE
+),	O
+although	O
+both	O
+are	O
+essential	O
+proteins	B-CHED
+in	O
+the	O
+canonical	O
+autophagy	B-PROC
+pathway	B-PROC
+.	O
+
+Finally	O
+,	O
+the	O
+anti	O
+-	O
+apoptotic	O
+extracellular	O
+signal	O
+-	O
+regulated	O
+kinase	O
+1	O
+/	O
+2	O
+(	O
+ERK1	B-PRGE
+/	I-PRGE
+2	I-PRGE
+)	O
+also	O
+contributed	O
+to	O
+IBV	B-SPEC
+-	O
+induced	O
+autophagy	B-PROC
+.	O
+
+TITLE	O
+:	O
+Occurrence	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+in	O
+layer	B-ANAT
+birds	B-SPEC
+in	O
+Plateau	O
+state	O
+,	O
+north	O
+central	O
+Nigeria	O
+.	O
+
+In	O
+addition	O
+,	O
+virus	B-SPEC
+isolation	O
+was	O
+attempted	O
+in	O
+9	O
+-	O
+11	O
+day	O
+-	O
+old	O
+embryonating	O
+chicken	B-SPEC
+eggs	O
+(	O
+ECE	O
+).	O
+
+Besides	O
+testing	O
+for	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+samples	O
+were	O
+screened	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AIV	O
+)	O
+by	O
+RT	O
+-	O
+qPCR	O
+as	O
+well	O
+as	O
+by	O
+non	O
+-	O
+directed	O
+cell	B-COMP
+-	O
+culture	O
+approach	O
+on	O
+LMH	O
+-	O
+cells	B-COMP
+.	O
+
+Carbon	B-CHED
+dioxide	I-CHED
+is	O
+easily	O
+removed	O
+,	O
+and	O
+normal	O
+PaCO2	O
+is	O
+easily	O
+reached	O
+.	O
+
+The	O
+normal	O
+range	O
+of	O
+PaCO2	O
+is	O
+easy	O
+to	O
+reach	B-PROC
+.	O
+
+Venous	B-ANAT
+-	O
+venous	B-ANAT
+-	O
+ECMO	O
+support	O
+potentially	O
+relieves	O
+hypoxic	B-DISO
+pulmonary	B-ANAT
+vasoconstriction	B-DISO
+.	O
+
+Sawdust	O
+-	O
+based	O
+cat	B-SPEC
+litters	O
+are	O
+not	O
+useful	O
+in	O
+FCoV	O
+-	O
+endemic	O
+households	O
+because	O
+they	O
+track	O
+badly	O
+and	O
+have	O
+a	O
+poor	O
+effect	O
+on	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+ADP	B-CHED
+-	O
+ribosylation	O
+is	O
+a	O
+ubiquitous	O
+post	O
+-	O
+translational	B-PROC
+addition	O
+of	O
+either	O
+monomers	O
+or	O
+polymers	B-CHED
+of	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+to	O
+target	O
+proteins	B-CHED
+by	O
+ADP	B-PRGE
+-	I-PRGE
+ribosyltransferases	I-PRGE
+,	O
+usually	O
+by	O
+interferon	B-PRGE
+-	O
+inducible	O
+diphtheria	B-PRGE
+toxin	I-PRGE
+-	I-PRGE
+like	I-PRGE
+enzymes	I-PRGE
+known	O
+as	O
+PARPs	B-CHED
+.	O
+
+PARP14	B-PRGE
+was	O
+also	O
+important	O
+for	O
+the	O
+induction	O
+of	O
+interferon	B-PRGE
+in	O
+mouse	B-SPEC
+and	O
+human	B-SPEC
+cells	B-COMP
+,	O
+indicating	O
+a	O
+critical	O
+role	O
+for	O
+this	O
+PARP	B-PRGE
+in	O
+the	O
+regulation	B-PROC
+of	O
+innate	B-PROC
+immunity	I-PROC
+.	O
+
+In	O
+summary	O
+,	O
+these	O
+data	O
+demonstrate	O
+that	O
+the	O
+macrodomain	O
+is	O
+required	O
+to	O
+prevent	O
+PARP	B-PRGE
+-	O
+mediated	O
+inhibition	B-PROC
+of	O
+coronavirus	B-SPEC
+replication	O
+and	O
+enhancement	O
+of	O
+interferon	B-PROC
+production	I-PROC
+.	O
+
+Although	O
+the	O
+patient	O
+died	B-PROC
+of	O
+MOF	B-DISO
+triggered	O
+by	O
+severe	O
+lung	B-DISO
+fibrosis	I-DISO
+at	O
+last	O
+,	O
+the	O
+successful	O
+treatment	O
+of	O
+refractory	O
+pneumothorax	B-DISO
+by	O
+combination	O
+of	O
+ECMO	O
+with	O
+VATS	O
+is	O
+encouraging	O
+.	O
+
+CASE	O
+REPORT	O
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+22	O
+-	O
+year	O
+-	O
+old	O
+gravid	O
+2	O
+Para	B-CHED
+1	O
+woman	O
+who	O
+presented	O
+to	O
+the	O
+Emergency	B-DISO
+Department	O
+with	O
+pyelonephritis	B-DISO
+,	O
+who	O
+subsequently	O
+developed	O
+sepsis	B-DISO
+that	O
+progressed	O
+to	O
+ARDS	B-DISO
+.	O
+
+Analyses	O
+of	O
+nucleotide	B-CHED
+and	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+showed	O
+that	O
+NB1	B-PRGE
+differed	O
+from	O
+18	O
+other	O
+Korean	O
+PEDV	B-SPEC
+mostly	O
+in	O
+4	O
+protein	B-CHED
+coding	O
+genes	O
+:	O
+ORF1a	O
+,	O
+ORF1b	O
+,	O
+S	O
+,	O
+and	O
+N	O
+.	O
+Two	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+(	O
+V635E	O
+and	O
+Y681Q	O
+)	O
+in	O
+the	O
+COE	B-PRGE
+and	I-PRGE
+S1D	I-PRGE
+neutralizing	I-PRGE
+epitopes	I-PRGE
+of	O
+NB1	O
+resulted	O
+in	O
+antigenic	O
+index	O
+alteration	O
+of	O
+the	O
+adjacent	O
+sites	O
+,	O
+one	O
+of	O
+which	O
+contributed	O
+to	O
+a	O
+mutation	O
+that	O
+escaped	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+Currently	O
+,	O
+only	O
+few	O
+antiviral	B-CHED
+agents	I-CHED
+are	O
+available	O
+for	O
+the	O
+treatment	O
+of	O
+MERS	O
+,	O
+but	O
+their	O
+effects	O
+have	O
+been	O
+greatly	O
+impaired	B-DISO
+by	O
+low	O
+antiviral	B-CHED
+activity	O
+,	O
+poor	O
+metabolic	B-PROC
+stability	O
+,	O
+and	O
+serious	O
+adverse	B-DISO
+effects	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+series	O
+of	O
+heptad	O
+repeat	O
+1	O
+(	O
+HR1	O
+)	O
+peptide	B-CHED
+inhibitors	B-CHED
+have	O
+been	O
+developed	O
+to	O
+inhibit	O
+HR1	O
+/	O
+HR2	B-PRGE
+-	O
+mediated	O
+membrane	B-PROC
+fusion	I-PROC
+between	O
+MERS	O
+-	O
+CoV	O
+and	O
+host	B-COMP
+cells	B-COMP
+,	O
+which	O
+is	O
+the	O
+major	O
+pathway	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+-	O
+induced	O
+host	B-COMP
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+FORMATION	B-PROC
+OF	O
+EXCESSIVE	O
+AMOUNT	O
+OF	O
+ENDOGENOUS	O
+CARBON	B-CHED
+MONOXIDE	I-CHED
+AND	O
+INCREASE	O
+OF	O
+CARBOXYLATED	O
+HEMOGLOBIN	B-CHED
+CONTENT	O
+IN	O
+PATIENTS	O
+WITH	O
+POLYTRAUMA	O
+.	O
+
+There	O
+are	O
+serious	O
+conditions	O
+for	O
+increasing	O
+the	O
+production	O
+of	O
+endogenous	O
+carbon	B-CHED
+monoxide	I-CHED
+(	O
+CO	O
+)	O
+in	O
+patients	O
+with	O
+polytrauma	O
+.	O
+
+To	O
+determine	O
+the	O
+relationship	O
+between	O
+the	O
+severity	O
+of	O
+hemolysis	B-DISO
+and	O
+the	O
+intensity	O
+of	O
+production	O
+of	O
+endogenous	O
+CO	O
+in	O
+patients	O
+with	O
+polytrauma	O
+,	O
+40	O
+patients	O
+were	O
+examined	O
+for	O
+the	O
+concentration	O
+of	O
+free	O
+hemoglobin	B-PRGE
+in	O
+the	O
+blood	B-ANAT
+plasma	I-ANAT
+using	O
+the	O
+benzidine	O
+method	O
+.	O
+
+The	O
+maximum	O
+HbCO	O
+%	O
+blood	B-ANAT
+content	O
+in	O
+patients	O
+who	O
+were	O
+in	O
+a	O
+state	O
+of	O
+shock	O
+was	O
+ascertained	O
+during	O
+reperfusion	O
+,	O
+an	O
+hour	O
+after	O
+the	O
+start	O
+of	O
+an	O
+urgent	O
+surgical	O
+intervention	O
+.	O
+
+The	O
+results	O
+from	O
+regression	O
+models	O
+and	O
+sensitivity	O
+analyses	O
+demonstrated	O
+that	O
+areas	O
+with	O
+≥	O
+100	O
+SARS	B-DISO
+cases	O
+and	O
+closer	O
+proximity	O
+to	O
+the	O
+ROK	O
+had	O
+significantly	O
+larger	O
+percentage	O
+decreases	O
+in	O
+traveler	O
+volumes	O
+during	O
+the	O
+outbreak	O
+.	O
+
+Bronchoalveolar	O
+lavage	O
+should	O
+obtain	O
+lower	O
+respiratory	O
+tract	O
+samples	O
+for	O
+galactomannan	B-CHED
+assay	O
+,	O
+direct	O
+microscopy	O
+,	O
+culture	O
+,	O
+and	O
+bacterial	O
+,	O
+fungal	O
+and	O
+viral	O
+PCR	O
+.	O
+
+In	O
+case	O
+of	O
+positive	O
+Aspergillus	B-SPEC
+testing	O
+,	O
+chest	B-ANAT
+CT	O
+is	O
+the	O
+imaging	O
+modality	O
+of	O
+choice	O
+.	O
+
+We	O
+assessed	O
+the	O
+clinical	O
+characteristics	O
+of	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+(	O
+SARI	O
+)	O
+evolving	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+the	O
+factors	O
+related	O
+to	O
+death	B-PROC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+establish	O
+the	O
+basic	O
+,	O
+in	O
+vitro	O
+characteristics	O
+of	O
+the	O
+life	O
+cycle	O
+such	O
+as	O
+replication	O
+kinetics	O
+,	O
+cellular	B-COMP
+ultrastructure	O
+,	O
+virion	B-COMP
+morphology	O
+,	O
+and	O
+induction	O
+of	O
+autophagy	B-PROC
+of	O
+PDCoV	O
+.	O
+Time	O
+-	O
+course	O
+analysis	O
+of	O
+viral	O
+subgenomic	O
+and	O
+genomic	O
+RNA	O
+loads	O
+and	O
+infectious	B-DISO
+titers	O
+indicated	O
+that	O
+one	O
+replication	O
+cycle	O
+of	O
+PDCoV	O
+takes	O
+5	O
+to	O
+6	O
+h	O
+.	O
+Electron	O
+microscopy	O
+showed	O
+that	O
+PDCoV	O
+infection	B-DISO
+induced	I-DISO
+the	O
+membrane	B-COMP
+rearrangements	O
+with	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+and	O
+large	O
+virion	B-COMP
+-	O
+containing	O
+vacuoles	B-COMP
+.	O
+
+Binary	O
+Logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+neutral	O
+red	O
+phagocytosis	B-PROC
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+=	O
+0	O
+.	O
+596	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+=	O
+0	O
+.	O
+212	O
+-	O
+0	O
+.	O
+997	O
+]	O
+and	O
+alkaline	B-FUNC
+phosphatase	I-FUNC
+activity	I-FUNC
+(	O
+OR	O
+=	O
+0	O
+.	O
+573	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+339	O
+-	O
+0	O
+.	O
+968	O
+)	O
+were	O
+the	O
+influencing	O
+factors	O
+of	O
+prognosis	O
+(	O
+both	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+AUC	O
+of	O
+alkaline	B-PRGE
+phosphatase	I-PRGE
+for	O
+the	O
+prognosis	O
+of	O
+ARDS	B-DISO
+patients	O
+caused	O
+by	O
+abdominal	B-DISO
+infection	I-DISO
+was	O
+0	O
+.	O
+813	O
+;	O
+when	O
+the	O
+cut	O
+-	O
+off	O
+value	O
+was	O
+19	O
+.	O
+72	O
+μmol	O
+/	O
+L	O
+,	O
+the	O
+sensitivity	O
+was	O
+75	O
+.	O
+0	O
+%,	O
+and	O
+the	O
+specificity	O
+was	O
+87	O
+.	O
+5	O
+%.	O
+
+Mean	O
+airway	B-ANAT
+pressures	O
+(	O
+Paw	B-ANAT
+),	O
+oxygenation	B-PROC
+index	O
+(	O
+OI	O
+),	O
+arterial	B-ANAT
+oxygen	B-PROC
+partial	I-PROC
+pressure	I-PROC
+(	O
+PaO	B-PROC
+
+A	O
+2	O
+-	O
+year	O
+-	O
+old	O
+child	O
+presented	O
+with	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+progressed	O
+to	O
+develop	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+necessitating	O
+high	O
+-	O
+pressure	O
+mechanical	O
+ventilation	O
+.	O
+
+Diagnosis	O
+of	O
+mercury	B-CHED
+poisoning	O
+was	O
+confirmed	O
+by	O
+blood	B-ANAT
+levels	O
+,	O
+and	O
+despite	O
+treatment	O
+with	O
+dimercaprol	B-CHED
+(	O
+mercury	B-CHED
+chelator	B-CHED
+)	O
+and	O
+high	O
+-	O
+frequency	O
+ventilation	O
+,	O
+the	O
+child	O
+subsequently	O
+succumbed	O
+within	O
+26	O
+hours	O
+.	O
+
+While	O
+in	O
+the	O
+hospital	O
+,	O
+patients	O
+in	O
+the	O
+intervention	O
+group	O
+were	O
+less	O
+physically	O
+active	O
+and	O
+had	O
+more	O
+adverse	O
+cardiovascular	B-ANAT
+events	O
+than	O
+patients	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+presentation	O
+,	O
+diagnostic	B-DISO
+findings	I-DISO
+,	O
+and	O
+outcome	O
+of	O
+adult	O
+horses	B-SPEC
+with	O
+equine	B-SPEC
+coronavirus	B-SPEC
+infection	I-DISO
+at	O
+a	O
+veterinary	O
+teaching	O
+hospital	O
+:	O
+33	O
+cases	O
+(	O
+2012	O
+-	O
+2018	O
+).	O
+
+The	O
+calves	O
+were	O
+monitored	O
+for	O
+BRD	O
+and	O
+those	O
+that	O
+developed	O
+signs	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+were	O
+sampled	O
+for	O
+diagnostic	O
+testing	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+considered	O
+highly	O
+fatal	O
+in	O
+its	O
+naturally	O
+occurring	O
+form	O
+,	O
+although	O
+up	O
+to	O
+36	O
+%	O
+of	O
+cats	B-SPEC
+resist	O
+disease	O
+after	O
+experimental	O
+infection	B-DISO
+,	O
+suggesting	O
+that	O
+cats	B-SPEC
+in	O
+nature	O
+may	O
+also	O
+resist	O
+development	B-PROC
+of	O
+FIP	B-DISO
+in	O
+the	O
+face	B-DISO
+of	O
+infection	B-DISO
+with	O
+FIP	B-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+).	O
+
+Antiviral	B-CHED
+T	B-ANAT
+cell	I-ANAT
+responses	O
+during	O
+early	O
+primary	B-DISO
+infection	I-DISO
+were	O
+also	O
+similar	O
+between	O
+cats	B-SPEC
+that	O
+developed	O
+FIP	B-DISO
+and	O
+cats	B-SPEC
+remaining	O
+healthy	O
+.	O
+
+Cats	B-SPEC
+that	O
+survived	O
+primary	B-DISO
+infection	I-DISO
+were	O
+challenged	O
+a	O
+second	O
+time	O
+to	O
+pathogenic	O
+FIPV	O
+and	O
+tested	O
+for	O
+antiviral	B-CHED
+T	B-ANAT
+cell	I-ANAT
+responses	O
+over	O
+a	O
+four	O
+week	O
+period	O
+.	O
+
+In	O
+summary	O
+,	O
+definitive	O
+adaptive	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+predictive	O
+of	O
+disease	O
+outcome	O
+were	O
+not	O
+detected	O
+during	O
+the	O
+early	O
+phase	O
+of	O
+primary	O
+FIPV	O
+infection	B-DISO
+.	O
+
+This	O
+review	O
+will	O
+discuss	O
+the	O
+role	O
+of	O
+two	O
+cellular	B-COMP
+eukaryotic	O
+processes	O
+that	O
+are	O
+vital	O
+for	O
+maintenance	O
+of	O
+cellular	B-PROC
+homeostasis	I-PROC
+-	O
+1	O
+)	O
+the	O
+nonsense	B-PROC
+-	I-PROC
+mediated	I-PROC
+mRNA	I-PROC
+decay	B-DISO
+(	O
+NMD	B-PROC
+)	O
+pathway	B-PROC
+and	O
+2	O
+)	O
+the	O
+transient	O
+formation	B-PROC
+of	O
+stress	O
+granules	O
+(	O
+SG	O
+)	O
+-	O
+and	O
+explore	O
+the	O
+current	O
+literature	O
+on	O
+their	O
+roles	O
+in	O
+antiviral	B-CHED
+defence	O
+.	O
+
+It	O
+is	O
+the	O
+most	O
+frequent	O
+gastrointestinal	O
+cause	O
+for	O
+hospitalization	O
+and	O
+one	O
+of	O
+the	O
+leading	O
+causes	O
+of	O
+in	O
+-	O
+hospital	O
+deaths	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+first	O
+reported	O
+by	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+,	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+responsible	O
+for	O
+an	O
+acute	O
+human	B-SPEC
+respiratory	O
+syndrome	B-DISO
+.	O
+
+An	O
+articulated	O
+action	O
+plan	B-DISO
+ought	O
+to	O
+be	O
+taken	O
+,	O
+preferably	O
+from	O
+a	O
+One	O
+Health	O
+perspective	O
+,	O
+for	O
+appropriately	O
+advanced	O
+countermeasures	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Exploitation	O
+of	O
+glycosylation	B-PROC
+in	O
+enveloped	O
+virus	B-SPEC
+pathobiology	O
+.	O
+
+As	O
+obligate	O
+parasites	O
+,	O
+viruses	B-SPEC
+exploit	O
+host	B-COMP
+-	O
+cell	B-COMP
+machinery	O
+to	O
+glycosylate	O
+their	O
+own	O
+proteins	B-CHED
+during	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+outbreaks	O
+of	O
+SARS	O
+-	O
+Coronavirus	B-SPEC
+and	O
+MERS	O
+-	O
+Coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+have	O
+heightened	O
+awareness	O
+about	O
+the	O
+lack	O
+of	O
+vaccines	O
+or	O
+antiviral	B-CHED
+compounds	O
+approved	O
+for	O
+prevention	O
+or	O
+treatment	O
+of	O
+human	B-SPEC
+or	O
+potential	O
+zoonotic	O
+CoVs	O
+.	O
+
+Anti	O
+-	O
+CoV	O
+drug	O
+development	B-PROC
+has	O
+long	O
+been	O
+challenged	O
+by	O
+the	O
+activity	O
+of	O
+a	O
+3	O
+'	O
+to	O
+5	O
+'	O
+proofreading	O
+exoribonuclease	O
+unique	O
+to	O
+CoVs	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+nucleotide	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+oligomerization	I-PRGE
+domain	I-PRGE
+containing	I-PRGE
+2	I-PRGE
+(	O
+Nod2	B-PRGE
+),	O
+type	B-PRGE
+I	I-PRGE
+interferons	I-PRGE
+,	O
+(	O
+IFNs	O
+),	O
+and	O
+proinflammatory	O
+mediators	O
+was	O
+enhanced	O
+in	O
+S	O
+RBD	O
+-	O
+HBD	B-DISO
+2	O
+-	O
+treated	O
+THP	B-CHED
+-	O
+1	O
+cells	B-COMP
+.	O
+
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+continues	O
+to	O
+have	O
+a	O
+high	O
+case	O
+fatality	O
+rate	O
+and	O
+a	O
+large	O
+proportion	O
+of	O
+patients	O
+were	O
+HCWs	O
+.	O
+
+Furthermore	O
+,	O
+study	O
+revealed	O
+that	O
+PDCoV	O
+N	O
+protein	B-PRGE
+interacted	O
+with	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+MDA5	B-PRGE
+in	O
+an	O
+in	O
+vitro	O
+overexpression	B-PROC
+system	O
+and	O
+evident	O
+interactions	O
+between	O
+N	B-PRGE
+protein	I-PRGE
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+could	O
+be	O
+detected	O
+in	O
+the	O
+context	O
+of	O
+PDCoV	O
+infection	B-DISO
+,	O
+which	O
+interfered	O
+with	O
+the	O
+binding	B-FUNC
+of	O
+dsRNA	B-PRGE
+and	I-PRGE
+protein	B-CHED
+activator	I-PRGE
+of	I-PRGE
+protein	B-ENZY
+kinase	I-ENZY
+R	I-PRGE
+(	O
+PACT	B-DISO
+)	O
+to	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+.	O
+Together	O
+,	O
+our	O
+results	O
+demonstrate	O
+that	O
+PDCoV	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+is	O
+an	O
+IFN	B-PRGE
+antagonist	B-PROC
+and	O
+utilizes	O
+diverse	O
+strategies	O
+to	O
+attenuate	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+recognition	O
+and	O
+activation	O
+.	O
+
+The	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+envelope	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+serves	O
+as	O
+a	O
+crucial	O
+target	O
+for	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+vaccine	O
+development	B-PROC
+,	O
+as	O
+it	O
+plays	O
+a	O
+critical	O
+role	O
+in	O
+mediating	O
+viral	O
+entry	O
+through	O
+interactions	O
+with	O
+the	O
+cellular	B-COMP
+receptor	O
+,	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+).	O
+
+Analysis	O
+of	O
+sera	B-COMP
+absorption	O
+and	O
+isolated	O
+monoclonal	O
+antibodies	B-COMP
+from	O
+immunized	O
+mice	B-SPEC
+demonstrated	O
+that	O
+the	O
+potent	O
+and	O
+broad	O
+neutralizing	O
+activity	O
+was	O
+largely	O
+attributed	O
+to	O
+antibodies	B-COMP
+targeting	B-PROC
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+In	O
+our	O
+study	O
+,	O
+at	O
+least	O
+one	O
+respiratory	O
+virus	B-SPEC
+was	O
+detected	O
+by	O
+Rt	O
+-	O
+PCR	O
+in	O
+379	O
+(	O
+45	O
+.	O
+4	O
+%)	O
+of	O
+total	O
+834	O
+cases	O
+,	O
+whereas	O
+no	O
+viral	O
+agent	O
+was	O
+identified	O
+in	O
+455	O
+(	O
+54	O
+.	O
+6	O
+%)	O
+of	O
+the	O
+cases	O
+.	O
+
+When	O
+all	O
+cases	O
+were	O
+evaluated	O
+in	O
+terms	O
+of	O
+infection	B-DISO
+,	O
+positive	O
+results	O
+were	O
+detected	O
+in	O
+469	O
+(	O
+56	O
+.	O
+2	O
+%)	O
+cases	O
+.	O
+
+As	O
+a	O
+result	O
+;	O
+postmortem	O
+microbiological	O
+diagnosis	O
+with	O
+autopsy	O
+and	O
+histopathological	O
+detection	O
+of	O
+the	O
+patients	O
+who	O
+are	O
+thought	O
+to	O
+have	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+will	O
+also	O
+determine	O
+the	O
+infectious	B-DISO
+agents	O
+causing	O
+death	B-PROC
+.	O
+
+Of	O
+all	O
+the	O
+potential	O
+drug	O
+targets	O
+,	O
+the	O
+helicase	B-PRGE
+of	O
+CoVs	O
+is	O
+considered	O
+to	O
+be	O
+one	O
+of	O
+the	O
+most	O
+important	O
+.	O
+
+Recent	O
+studies	O
+have	O
+expanded	O
+on	O
+its	O
+structural	O
+motifs	O
+and	O
+topology	O
+,	O
+its	O
+functions	O
+as	O
+an	O
+ion	O
+-	O
+channelling	O
+viroporin	O
+,	O
+and	O
+its	O
+interactions	O
+with	O
+both	O
+other	O
+CoV	O
+proteins	B-CHED
+and	O
+host	B-COMP
+cell	I-COMP
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+Saudi	O
+Arabia	O
+:	O
+toward	O
+a	O
+complete	O
+picture	O
+.	O
+
+The	O
+data	O
+support	O
+the	O
+view	O
+that	O
+continuous	O
+entry	O
+and	O
+exit	O
+of	O
+pilgrims	O
+and	O
+foreign	O
+workers	O
+with	O
+different	O
+ethnicities	O
+and	O
+socioeconomic	O
+backgrounds	O
+in	O
+Saudi	O
+Arabia	O
+is	O
+the	O
+most	O
+likely	O
+vehicle	O
+for	O
+global	O
+dissemination	O
+of	O
+respiratory	O
+viruses	B-SPEC
+and	O
+for	O
+the	O
+emergence	O
+of	O
+new	O
+viruses	B-SPEC
+(	O
+or	O
+virus	B-SPEC
+variants	O
+)	O
+capable	O
+of	O
+greater	O
+dissemination	O
+.	O
+
+This	O
+hypothesis	O
+was	O
+tested	O
+by	O
+using	O
+KO	O
+piglets	O
+that	O
+were	O
+challenged	O
+with	O
+PEDV	B-SPEC
+.	O
+
+III	O
+,	O
+the	O
+animals	B-SPEC
+exhibited	O
+clinical	O
+and	O
+pathological	O
+signs	O
+after	O
+inoculation	O
+similar	O
+to	O
+those	O
+in	O
+exp	O
+.	O
+
+Annually	O
+,	O
+seasonal	O
+influenza	B-DISO
+epidemics	O
+attack	O
+human	B-SPEC
+populations	O
+leading	O
+to	O
+290	O
+-	O
+650	O
+thousand	O
+deaths	B-PROC
+/	O
+year	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+influenza	I-DISO
+H9N2	O
+subtype	O
+in	O
+Ghana	O
+:	O
+virus	B-SPEC
+characterization	O
+and	O
+evidence	O
+of	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+detection	O
+of	O
+a	O
+potentially	O
+zoonotic	O
+subtype	O
+,	O
+such	O
+as	O
+the	O
+H9N2	O
+,	O
+in	O
+a	O
+region	O
+where	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	I-DISO
+H5Nx	O
+is	O
+currently	O
+circulating	O
+highlights	O
+the	O
+urgency	O
+of	O
+implementing	O
+enhanced	O
+monitoring	O
+strategies	O
+and	O
+supporting	O
+improved	O
+investments	O
+in	O
+regional	O
+diagnostic	O
+technologies	O
+.	O
+
+In	O
+further	O
+studies	O
+no	O
+virus	B-SPEC
+plaques	B-DISO
+(	O
+plaque	B-DISO
+reduction	O
+rate	O
+100	O
+%)	O
+or	O
+cytopathogenic	O
+effect	O
+(	O
+decrease	O
+of	O
+TCID	O
+Many	O
+extracts	O
+of	O
+plants	O
+acted	O
+against	O
+IBV	B-SPEC
+prior	O
+to	O
+and	O
+during	O
+infection	B-DISO
+,	O
+but	O
+the	O
+most	O
+effective	O
+were	O
+those	O
+of	O
+M	B-SPEC
+.	I-SPEC
+piperita	I-SPEC
+,	O
+T	B-SPEC
+.	I-SPEC
+vulgaris	I-SPEC
+and	O
+D	O
+.	O
+canadense	O
+.	O
+
+RESULTS	O
+:	O
+Extracts	O
+of	O
+S	B-SPEC
+.	I-SPEC
+montana	I-SPEC
+,	O
+O	B-SPEC
+.	I-SPEC
+vulgare	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+piperita	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+officinalis	I-SPEC
+,	O
+T	B-SPEC
+.	I-SPEC
+vulgaris	I-SPEC
+,	O
+H	B-SPEC
+.	I-SPEC
+officinalis	I-SPEC
+,	O
+S	B-SPEC
+.	I-SPEC
+officinalis	I-SPEC
+and	O
+D	O
+.	O
+canadense	O
+showed	O
+anti	O
+-	O
+IBV	B-SPEC
+activity	O
+prior	O
+to	O
+and	O
+during	O
+infection	B-DISO
+,	O
+while	O
+S	B-SPEC
+.	I-SPEC
+montana	I-SPEC
+showed	O
+activity	O
+prior	O
+to	O
+and	O
+after	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+Yeast	B-SPEC
+Suppressor	O
+Screen	O
+Used	O
+To	O
+Identify	O
+Mammalian	B-SPEC
+SIRT1	O
+as	O
+a	O
+Proviral	O
+Factor	O
+for	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+Replication	O
+.	O
+
+The	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)-	O
+mediated	O
+antiviral	B-PROC
+response	I-PROC
+is	O
+an	O
+important	O
+component	O
+of	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+and	O
+plays	O
+an	O
+essential	O
+role	O
+in	O
+inhibiting	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+However	O
+,	O
+PDCoV	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+restrained	O
+the	O
+pRiplet	B-PRGE
+binding	I-PRGE
+pRIG	I-PRGE
+-	I-PRGE
+I	I-PRGE
+to	O
+inhibit	O
+pRIG	O
+-	O
+I	O
+K63	O
+-	O
+linked	O
+polyubiquitination	B-PROC
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+detected	O
+not	O
+only	O
+in	O
+intestines	B-ANAT
+but	O
+also	O
+in	O
+lungs	B-ANAT
+and	O
+liver	B-ANAT
+.	O
+
+Laboratory	O
+investigation	O
+showed	O
+high	O
+erythrocyte	B-ANAT
+sedimentation	O
+rate	O
+and	O
+C	B-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+leucocytosis	B-DISO
+,	O
+anaemia	B-DISO
+,	O
+mild	O
+thrombocytopaenia	O
+,	O
+renal	B-DISO
+impairment	I-DISO
+,	O
+hyperbilirubinaemia	B-DISO
+and	O
+abnormal	B-DISO
+liver	I-DISO
+function	I-DISO
+tests	O
+;	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+showed	O
+respiratory	B-DISO
+alkalosis	I-DISO
+with	O
+severe	O
+hypoxia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+HLJ	O
+-	O
+073	O
+,	O
+a	O
+recombinant	O
+canine	O
+coronavirus	B-SPEC
+strain	O
+from	O
+China	O
+with	O
+an	O
+ORF3abc	O
+deletion	O
+.	O
+
+Phylogenetic	O
+analysis	O
+based	O
+on	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+showed	O
+that	O
+HLJ	O
+-	O
+073	O
+was	O
+more	O
+closely	O
+related	O
+to	O
+members	O
+of	O
+the	O
+FCoV	O
+II	O
+cluster	O
+than	O
+to	O
+members	O
+of	O
+the	O
+CCoV	O
+I	O
+or	O
+CCoV	O
+II	O
+cluster	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+increase	O
+in	O
+international	O
+travel	O
+,	O
+the	O
+growing	O
+presence	O
+of	O
+arbovirus	O
+vectors	O
+in	O
+our	O
+country	O
+,	O
+and	O
+notifications	O
+of	O
+haemorrhagic	B-DISO
+fever	I-DISO
+such	O
+as	O
+the	O
+current	O
+outbreak	O
+of	O
+Ebola	O
+in	O
+D	O
+.	O
+R	O
+.	O
+Congo	O
+and	O
+the	O
+cases	O
+of	O
+Crimea	O
+-	O
+Congo	B-DISO
+haemorrhagic	I-DISO
+fever	I-DISO
+in	O
+our	O
+country	O
+have	O
+again	O
+cast	B-ANAT
+the	O
+spotlight	O
+on	O
+tropical	B-DISO
+diseases	I-DISO
+Isolating	O
+suspected	O
+cases	O
+of	O
+highly	O
+contagious	O
+and	O
+lethal	O
+diseases	O
+must	O
+be	O
+a	O
+priority	O
+(	O
+Haemorrhagic	B-DISO
+fever	I-DISO
+,	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+Nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+were	O
+collected	O
+from	O
+patients	O
+from	O
+June	O
+1st	O
+,	O
+2008	O
+to	O
+May	O
+31st	O
+,	O
+2009within	O
+the	O
+first	O
+48	O
+hours	O
+of	O
+hospitalization	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+for	O
+human	B-SPEC
+coronavirus	I-SPEC
+attachment	O
+to	O
+sialic	B-PRGE
+acid	I-PRGE
+receptors	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+cause	O
+respiratory	O
+tract	O
+infections	O
+in	O
+humans	B-SPEC
+and	O
+outbreaks	O
+of	O
+deadly	O
+pneumonia	B-DISO
+worldwide	O
+.	O
+
+The	O
+receptor	B-PRGE
+-	I-PRGE
+interacting	I-PRGE
+site	I-PRGE
+is	O
+conserved	O
+in	O
+all	O
+coronavirus	B-SPEC
+S	O
+glycoproteins	B-CHED
+that	O
+engage	O
+9	O
+-	O
+O	O
+-	O
+acetyl	B-CHED
+-	O
+sialogycans	O
+,	O
+with	O
+an	O
+architecture	O
+similar	O
+to	O
+those	O
+of	O
+the	O
+ligand	B-PROC
+-	O
+binding	B-FUNC
+pockets	O
+of	O
+coronavirus	O
+hemagglutinin	O
+esterases	B-FUNC
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+C	O
+/	O
+D	O
+hemagglutinin	O
+-	O
+esterase	B-PRGE
+fusion	O
+glycoproteins	B-CHED
+.	O
+
+Hospitalised	O
+immunocompetent	O
+patients	O
+with	O
+CAP	B-DISO
+were	O
+prospectively	O
+recruited	O
+from	O
+34	O
+hospitals	O
+in	O
+mainland	O
+China	O
+.	O
+
+Respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+by	O
+molecular	O
+methods	O
+.	O
+
+Pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+contributes	O
+to	O
+a	O
+significant	O
+burden	O
+in	O
+the	O
+PICU	B-SPEC
+of	O
+a	O
+developing	O
+country	O
+and	O
+is	O
+associated	O
+with	O
+significantly	O
+higher	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+spread	O
+through	O
+27	O
+countries	O
+and	O
+infected	O
+more	O
+than	O
+2	O
+,	O
+200	O
+people	O
+since	O
+its	O
+first	O
+outbreak	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+.	O
+
+ABSTRACT	O
+:	O
+Buprenorphine	B-CHED
+,	O
+used	O
+for	O
+opioid	O
+use	O
+disorder	O
+(	O
+OUD	O
+)	O
+treatment	O
+during	O
+pregnancy	O
+,	O
+provides	O
+unknown	O
+effects	O
+on	O
+maternal	O
+physiological	O
+activity	O
+.	O
+
+The	O
+primary	O
+aim	O
+of	O
+this	O
+report	O
+is	O
+to	O
+document	O
+acute	O
+effects	O
+of	O
+buprenorphine	B-CHED
+administration	O
+on	O
+indicators	O
+of	O
+maternal	O
+autonomic	B-ANAT
+functioning	O
+.	O
+
+Forty	O
+-	O
+nine	O
+pregnant	O
+,	O
+buprenorphine	B-CHED
+-	O
+maintained	O
+women	O
+yielded	O
+maternal	O
+physiologic	O
+information	O
+(	O
+heart	B-ANAT
+rate	O
+and	O
+variability	O
+,	O
+electrodermal	O
+activity	O
+,	O
+and	O
+respiratory	O
+rate	O
+)	O
+at	O
+24	O
+,	O
+28	O
+,	O
+32	O
+and	O
+36	O
+weeks	O
+gestation	B-PROC
+.	O
+
+Buprenorphine	B-CHED
+administration	O
+accelerated	O
+maternal	O
+heart	B-ANAT
+rate	O
+and	O
+reduced	O
+variability	O
+at	O
+two	O
+gestational	O
+ages	O
+(	O
+24	O
+and	O
+36	O
+weeks	O
+)	O
+and	O
+suppressed	O
+sympathetic	O
+(	O
+electrodermal	O
+)	O
+activation	O
+at	O
+24	O
+,	O
+28	O
+and	O
+32	O
+weeks	O
+at	O
+times	O
+of	O
+peak	O
+maternal	O
+medication	O
+levels	O
+.	O
+
+RESULTS	O
+:	O
+Buprenorphine	B-CHED
+administration	O
+accelerated	O
+maternal	O
+heart	B-ANAT
+rate	O
+and	O
+reduced	O
+variability	O
+at	O
+two	O
+gestational	O
+ages	O
+(	O
+24	O
+and	O
+36	O
+weeks	O
+)	O
+and	O
+suppressed	O
+sympathetic	O
+(	O
+electrodermal	O
+)	O
+activation	O
+at	O
+24	O
+,	O
+28	O
+and	O
+32	O
+weeks	O
+at	O
+times	O
+of	O
+peak	O
+maternal	O
+medication	O
+levels	O
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+we	O
+aimed	O
+to	O
+investigate	O
+the	O
+effect	O
+of	O
+NBP	B-PRGE
+on	O
+ALI	O
+in	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+treated	O
+mice	B-SPEC
+.	O
+
+Moreover	O
+,	O
+the	O
+absence	O
+of	O
+SIRT1	B-PRGE
+notably	O
+inhibited	O
+NBP	B-PRGE
+-	O
+induced	O
+protective	O
+effects	O
+against	O
+LPS	B-DISO
+-	O
+induced	O
+increase	O
+of	O
+W	O
+/	O
+D	O
+ratio	O
+of	O
+lung	B-ANAT
+,	O
+histological	O
+injury	O
+of	O
+lung	B-ANAT
+,	O
+infiltration	B-DISO
+of	O
+inflammatory	B-ANAT
+cells	I-ANAT
+,	O
+release	B-PATH
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+and	O
+oxidative	B-PATH
+damage	I-PATH
+.	O
+
+ABSTRACT	O
+:	O
+Data	O
+are	O
+lacking	O
+on	O
+impact	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+on	O
+health	O
+-	O
+related	O
+quality	O
+of	O
+life	O
+(	O
+HRQoL	O
+)	O
+among	O
+survivors	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+introduction	O
+of	O
+blood	O
+donor	B-CHED
+screening	O
+by	O
+virus	B-SPEC
+nucleic	B-CHED
+acid	I-CHED
+amplification	B-DISO
+technology	O
+(	O
+NAT	B-ENZY
+)	O
+in	O
+the	O
+mid	O
+to	O
+late	O
+1990s	O
+was	O
+driven	O
+by	O
+the	O
+so	O
+-	O
+called	O
+AIDS	O
+and	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+)	O
+epidemic	O
+,	O
+with	O
+thousands	O
+of	O
+recipients	O
+of	O
+infected	O
+blood	B-ANAT
+products	O
+and	O
+components	O
+.	O
+
+Thus	O
+,	O
+antibody	B-COMP
+and	O
+antigen	B-CHED
+testing	O
+may	O
+be	O
+dispensable	O
+in	O
+the	O
+long	O
+run	O
+,	O
+particularly	O
+in	O
+the	O
+combination	O
+of	O
+NAT	B-ENZY
+testing	O
+with	O
+pathogen	O
+reduction	O
+.	O
+
+However	O
+,	O
+each	O
+of	O
+these	O
+has	O
+limitations	O
+,	O
+either	O
+in	O
+throughput	O
+,	O
+costs	O
+,	O
+automation	O
+,	O
+time	O
+to	O
+result	O
+,	O
+specificity	O
+,	O
+or	O
+the	O
+need	O
+for	O
+NAT	B-ENZY
+as	O
+an	O
+integral	O
+part	O
+of	O
+the	O
+technology	O
+.	O
+
+Donor	B-CHED
+screening	O
+NAT	B-ENZY
+also	O
+contributed	O
+significantly	O
+to	O
+our	O
+knowledge	O
+on	O
+how	O
+fast	B-FUNC
+viruses	B-SPEC
+replicate	O
+,	O
+and	O
+on	O
+the	O
+respective	O
+diagnostic	O
+window	O
+.	O
+
+Accordingly	O
+,	O
+new	O
+therapeutic	O
+agents	O
+that	O
+will	O
+attenuate	O
+ongoing	O
+inflammation	B-DISO
+and	O
+,	O
+at	O
+the	O
+same	O
+time	O
+,	O
+promote	O
+regeneration	B-PROC
+of	O
+injured	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+are	O
+urgently	O
+needed	O
+.	O
+
+ABSTRACT	O
+:	O
+Fifteen	O
+recommendations	O
+and	O
+a	O
+therapeutic	O
+algorithm	O
+regarding	O
+the	O
+management	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+at	O
+the	O
+early	O
+phase	O
+in	O
+adults	O
+are	O
+proposed	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Prognostic	O
+value	O
+of	O
+the	O
+dynamic	O
+changes	O
+in	O
+extra	B-ANAT
+vascular	I-ANAT
+lung	I-ANAT
+water	I-ANAT
+index	O
+and	O
+angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+severe	O
+multiple	O
+trauma	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+A	O
+total	O
+of	O
+54	O
+severe	O
+multiple	O
+trauma	O
+patients	O
+with	O
+ARDS	B-DISO
+admitted	O
+to	O
+emergency	B-DISO
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+of	O
+the	O
+Affiliated	O
+Hospital	O
+of	O
+Guizhou	O
+Medical	O
+University	O
+from	O
+June	O
+2014	O
+to	O
+December	O
+2018	O
+were	O
+enrolled	O
+.	O
+
+The	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+),	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+and	O
+oxygenation	B-PROC
+index	O
+(	O
+PaO	B-PROC
+115	O
+patients	O
+were	O
+enrolled	O
+in	O
+the	O
+final	O
+analysis	O
+,	O
+72	O
+survived	O
+in	O
+28	O
+days	O
+,	O
+43	O
+died	B-PROC
+,	O
+and	O
+the	O
+mortality	O
+rate	O
+was	O
+37	O
+.	O
+4	O
+%.	O
+
+RESULTS	O
+:	O
+115	O
+patients	O
+were	O
+enrolled	O
+in	O
+the	O
+final	O
+analysis	O
+,	O
+72	O
+survived	O
+in	O
+28	O
+days	O
+,	O
+43	O
+died	B-PROC
+,	O
+and	O
+the	O
+mortality	O
+rate	O
+was	O
+37	O
+.	O
+4	O
+%.	O
+
+Severe	O
+trauma	O
+can	O
+lead	O
+to	O
+SIRS	B-DISO
+,	O
+which	O
+is	O
+one	O
+of	O
+the	O
+common	O
+risk	O
+factors	O
+of	O
+ARDS	B-DISO
+.	O
+
+Therefore	O
+,	O
+the	O
+research	O
+status	O
+of	O
+spleen	B-ANAT
+-	O
+mediated	O
+inflammatory	B-DISO
+response	I-DISO
+in	O
+traumatic	O
+ARDS	B-DISO
+is	O
+of	O
+great	O
+significance	O
+for	O
+the	O
+prevention	O
+and	O
+treatment	O
+of	O
+traumatic	O
+ARDS	O
+.	O
+
+This	O
+article	O
+reports	O
+the	O
+spleen	B-ANAT
+-	O
+mediated	O
+systemic	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+the	O
+role	O
+of	O
+inflammatory	O
+mediators	O
+in	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+,	O
+and	O
+the	O
+current	O
+state	O
+of	O
+research	O
+on	O
+ARDS	B-DISO
+treatment	O
+to	O
+explore	O
+new	O
+approaches	O
+to	O
+the	O
+prevention	O
+and	O
+treatment	O
+of	O
+traumatic	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Fat	O
+embolism	O
+syndrome	O
+is	O
+a	O
+rare	O
+but	O
+fatal	O
+complication	B-DISO
+seen	O
+commonly	O
+in	O
+patients	O
+with	O
+polytrauma	O
+.	O
+
+He	O
+had	O
+burst	O
+fracture	O
+of	O
+5th	O
+lumbar	B-ANAT
+vertebra	I-ANAT
+with	O
+canal	B-ANAT
+compromise	O
+along	O
+with	O
+other	O
+fractures	O
+.	O
+
+There	O
+was	O
+no	O
+neurological	O
+insult	O
+and	O
+in	O
+the	O
+next	O
+two	O
+days	O
+,	O
+he	O
+was	O
+weaned	B-PROC
+off	O
+from	O
+the	O
+ventilator	O
+.	O
+
+Here	O
+,	O
+the	O
+epidemiology	O
+of	O
+viruses	B-SPEC
+circulating	O
+among	O
+backyard	O
+poultry	O
+in	O
+Vientiane	O
+Province	O
+was	O
+assessed	O
+to	O
+guide	O
+future	O
+control	O
+strategies	O
+.	O
+
+While	O
+CoV	B-PRGE
+RNA	I-PRGE
+was	O
+detected	O
+in	O
+oral	B-ANAT
+/	O
+tracheal	O
+swabs	O
+of	O
+9	O
+.	O
+3	O
+%	O
+of	O
+the	O
+chickens	B-SPEC
+and	O
+2	O
+.	O
+4	O
+%	O
+of	O
+the	O
+ducks	B-SPEC
+,	O
+rates	O
+were	O
+higher	O
+in	O
+faecal	B-ANAT
+swabs	O
+of	O
+both	O
+species	B-SPEC
+(	O
+27	O
+.	O
+3	O
+%	O
+and	O
+48	O
+.	O
+2	O
+%).	O
+
+RNA	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+duck	B-SPEC
+CoV	O
+was	O
+found	O
+in	O
+faecal	B-ANAT
+swabs	O
+of	O
+chickens	B-SPEC
+(	O
+19	O
+.	O
+7	O
+%	O
+and	O
+7	O
+.	O
+1	O
+%)	O
+and	O
+ducks	B-SPEC
+(	O
+4	O
+.	O
+1	O
+%	O
+and	O
+44	O
+.	O
+1	O
+%).	O
+
+Here	O
+we	O
+report	O
+our	O
+new	O
+finding	O
+that	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+,	O
+similar	O
+to	O
+Vpu	O
+,	O
+is	O
+capable	O
+of	O
+antagonizing	O
+the	O
+BST2	O
+tethering	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+and	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+via	O
+BST2	B-PRGE
+downregulation	B-PROC
+.	O
+
+However	O
+,	O
+unlike	O
+Vpu	O
+(	O
+which	O
+downmodulates	O
+BST2	O
+by	O
+means	O
+of	O
+proteasomal	O
+and	O
+lysosomal	B-ANAT
+degradation	O
+pathways	B-PROC
+),	O
+BST2	B-PRGE
+downregulation	B-PROC
+is	O
+apparently	O
+mediated	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+through	O
+the	O
+lysosomal	B-ANAT
+degradation	O
+pathway	B-PROC
+only	O
+.	O
+
+Thiazole	B-CHED
+containing	O
+compounds	O
+(	O
+thiazoles	B-CHED
+)	O
+have	O
+shown	O
+various	O
+biological	O
+activities	O
+like	O
+antioxidant	B-CHED
+,	O
+analgesic	B-CHED
+,	O
+antibacterial	O
+,	O
+anticancer	O
+,	O
+antiallergic	O
+,	O
+antihypertensive	B-CHED
+,	O
+antiinflammatory	O
+,	O
+antimalarial	B-CHED
+,	O
+antifungal	B-CHED
+and	O
+antipsychotic	O
+.	O
+
+And	O
+yet	O
+from	O
+May	O
+2017	O
+to	O
+January	O
+2019	O
+,	O
+there	O
+were	O
+no	O
+new	O
+SADS	O
+cases	O
+arising	O
+in	O
+pig	B-SPEC
+herds	O
+in	O
+Guangdong	O
+.	O
+
+We	O
+analyzed	O
+symptom	B-DISO
+data	O
+and	O
+quantitative	O
+viral	O
+load	O
+to	O
+investigate	O
+the	O
+association	O
+between	O
+viruses	B-SPEC
+,	O
+symptoms	O
+and	O
+viral	O
+quantity	O
+in	O
+qRT	O
+-	O
+PCR	O
+-	O
+positive	O
+PSPs	O
+.	O
+
+CoV	O
+(	O
+OC43	O
+,	O
+HKU1	O
+)	O
+infections	B-DISO
+with	O
+a	O
+higher	O
+viral	O
+load	O
+were	O
+mostly	O
+observed	O
+in	O
+asymptomatic	O
+PSPs	O
+progressing	O
+to	O
+alveolar	B-ANAT
+or	O
+interstitial	B-ANAT
+infiltration	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Sixty	O
+-	O
+nine	O
+children	O
+,	O
+age	O
+0	O
+-	O
+24	O
+months	O
+,	O
+affected	O
+by	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+treated	O
+with	O
+exogenous	O
+porcine	B-SPEC
+surfactant	B-CHED
+were	O
+enrolled	O
+.	O
+
+ADP	B-CHED
+-	O
+ribosylation	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+several	O
+biological	B-PROC
+processes	I-PROC
+such	O
+as	O
+DNA	B-PROC
+repair	I-PROC
+,	O
+transcription	B-PROC
+,	O
+chromatin	B-PROC
+remodelling	I-PROC
+,	O
+host	B-COMP
+-	O
+virus	B-SPEC
+interactions	O
+,	O
+cellular	B-DISO
+stress	B-PATH
+response	I-PATH
+and	O
+many	O
+more	O
+.	O
+
+Using	O
+biochemical	O
+methods	O
+we	O
+identify	O
+RNA	O
+as	O
+a	O
+novel	O
+target	O
+of	O
+reversible	O
+mono	B-DISO
+-	O
+ADP	B-CHED
+-	O
+ribosylation	O
+.	O
+
+We	O
+demonstrate	O
+that	O
+the	O
+human	B-SPEC
+PARPs	B-CHED
+-	O
+PARP10	B-PRGE
+,	O
+PARP11	B-PRGE
+and	O
+PARP15	B-PRGE
+as	O
+well	O
+as	O
+a	O
+highly	O
+diverged	O
+PARP	B-PRGE
+homologue	O
+TRPT1	B-PRGE
+,	O
+ADP	B-CHED
+-	O
+ribosylate	O
+phosphorylated	O
+ends	O
+of	O
+RNA	O
+.	O
+
+Environmental	O
+factors	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+drug	B-DISO
+use	I-DISO
+,	O
+occupational	O
+chemical	O
+exposure	O
+,	O
+infectious	B-DISO
+agents	O
+,	O
+and	O
+irradiation	O
+)	O
+could	O
+account	O
+for	O
+chromosome	B-COMP
+changes	O
+.	O
+
+Previous	O
+evidence	O
+of	O
+differences	O
+in	O
+male	O
+and	O
+female	O
+gametogenesis	B-PROC
+could	O
+suggest	O
+an	O
+environmental	O
+role	O
+in	O
+the	O
+causation	O
+of	O
+the	O
+paternal	O
+15q11	O
+-	O
+q13	O
+deletion	O
+seen	O
+in	O
+PWS	B-DISO
+.	O
+
+Although	O
+early	O
+evidence	O
+supported	O
+birth	B-PROC
+seasonality	O
+differences	O
+in	O
+PWS	B-DISO
+,	O
+a	O
+larger	O
+number	O
+of	O
+individuals	O
+in	O
+our	O
+recent	O
+study	O
+using	O
+advanced	O
+genetic	O
+testing	O
+methods	O
+did	O
+not	O
+find	O
+this	O
+observation	O
+.	O
+
+TITLE	O
+:	O
+Modifications	O
+in	O
+the	O
+branched	B-ANAT
+arms	B-DISO
+of	O
+a	O
+class	B-SPEC
+of	O
+dual	O
+inhibitors	B-CHED
+of	O
+HIV	B-DISO
+and	O
+EV71	O
+replication	O
+expand	O
+their	O
+antiviral	O
+spectrum	O
+.	O
+
+Here	O
+a	O
+novel	O
+series	O
+of	O
+dendrimers	O
+with	O
+divalent	O
+and	O
+tetravalent	O
+branched	B-ANAT
+arms	B-DISO
+,	O
+instead	O
+of	O
+the	O
+trivalent	O
+ones	O
+present	O
+on	O
+the	O
+prototype	O
+,	O
+has	O
+been	O
+synthesized	O
+and	O
+its	O
+activity	O
+against	O
+HIV	B-DISO
+,	O
+EV71	O
+and	O
+a	O
+panel	O
+of	O
+16	O
+different	O
+viruses	B-SPEC
+and	O
+other	O
+pathogens	O
+has	O
+been	O
+determined	O
+.	O
+
+Our	O
+findings	O
+demonstrate	O
+that	O
+only	O
+compounds	O
+with	O
+tetravalent	O
+branched	B-ANAT
+arms	B-DISO
+showed	O
+the	O
+same	O
+anti	O
+-	O
+HIV	B-DISO
+and	O
+anti	O
+-	O
+EV71	O
+activity	O
+of	O
+the	O
+prototype	O
+(	O
+low	O
+micromolar	O
+)	O
+and	O
+even	O
+gain	O
+significant	O
+antiviral	B-CHED
+activity	O
+against	O
+new	O
+pathogens	O
+such	O
+as	O
+HSV	O
+-	O
+2	O
+,	O
+adenovirus	B-DISO
+-	O
+2	O
+,	O
+human	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+being	O
+the	O
+first	O
+members	O
+of	O
+the	O
+Trp	B-PRGE
+dendrimer	B-CHED
+family	B-SPEC
+that	O
+showed	O
+activity	O
+against	O
+those	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Three	O
+different	O
+Hepatozoon	O
+(	O
+Apicomplexa	B-SPEC
+,	O
+Hepatozoidae	B-SPEC
+)	O
+species	B-SPEC
+have	O
+been	O
+described	O
+infecting	O
+domestic	B-SPEC
+cats	I-SPEC
+in	O
+Europe	O
+(	O
+i	O
+.	O
+e	O
+.	O
+H	B-SPEC
+.	I-SPEC
+felis	I-SPEC
+,	O
+H	B-SPEC
+.	I-SPEC
+canis	I-SPEC
+and	O
+H	O
+.	O
+silvestris	O
+),	O
+however	O
+,	O
+reports	O
+on	O
+clinical	O
+hepatozoonosis	B-DISO
+are	O
+uncommon	O
+and	O
+treatment	O
+protocols	O
+are	O
+not	O
+clearly	O
+defined	O
+.	O
+
+Here	O
+,	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+were	O
+screened	O
+by	O
+pediatrics	O
+;	O
+and	O
+a	O
+total	O
+of	O
+150	O
+radiographically	O
+-	O
+confirmed	O
+CAP	B-DISO
+patients	O
+(	O
+aged	O
+3	O
+months	O
+to	O
+10	O
+years	O
+)	O
+from	O
+two	O
+clinical	O
+centers	O
+in	O
+Sao	O
+Luis	O
+,	O
+Brazil	O
+were	O
+recruited	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+outbreak	O
+was	O
+caused	O
+by	O
+a	O
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+)	O
+named	O
+the	O
+SARS	B-DISO
+-	O
+CoV	B-SPEC
+.	O
+SARS	B-DISO
+pathology	B-DISO
+is	O
+propagated	O
+both	O
+by	O
+direct	O
+cytotoxic	O
+effects	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+aberrant	O
+activation	O
+of	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+While	O
+in	O
+those	O
+cells	B-COMP
+lacking	O
+NLRP3	B-PRGE
+accumulating	O
+ORF8b	O
+cytosolic	B-COMP
+aggregates	O
+cause	O
+ER	O
+stress	O
+,	O
+mitochondrial	B-COMP
+dysfunction	O
+,	O
+and	O
+caspase	B-PRGE
+-	O
+independent	O
+cell	B-PROC
+death	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+newly	O
+emerging	O
+enteropathogenic	O
+swine	O
+coronavirus	B-SPEC
+causing	O
+acute	O
+diarrhea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+in	O
+pigs	B-SPEC
+.	O
+
+Compared	O
+with	O
+normal	O
+cells	B-COMP
+,	O
+the	O
+amount	O
+of	O
+cytochrome	B-PROC
+C	I-PROC
+released	O
+from	O
+mitochondria	B-COMP
+to	O
+cytoplasm	B-COMP
+increased	O
+significantly	O
+in	O
+PDCoV	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+and	O
+the	O
+release	B-PATH
+increased	O
+with	O
+the	O
+prolongation	O
+of	O
+infection	O
+,	O
+while	O
+the	O
+apoptosis	B-PATH
+-	O
+inducing	O
+factor	O
+was	O
+always	O
+localized	O
+to	O
+mitochondria	B-COMP
+,	O
+suggesting	O
+that	O
+PDCoV	O
+induced	O
+apoptosis	B-PATH
+was	O
+initiated	O
+through	O
+caspase	B-PRGE
+-	O
+dependent	O
+mitochondrial	B-COMP
+apoptosis	B-PROC
+pathway	B-PROC
+by	O
+promoting	O
+cytochrome	B-PROC
+C	I-PROC
+in	O
+the	O
+mitochondrial	B-COMP
+membrane	I-COMP
+gap	O
+into	O
+the	O
+cytosol	B-COMP
+.	O
+
+TITLE	O
+:	O
+Comparing	O
+the	O
+yield	O
+of	O
+oropharyngeal	B-ANAT
+swabs	O
+and	O
+sputum	B-ANAT
+for	O
+detection	O
+of	O
+11	O
+common	O
+pathogens	O
+in	O
+hospitalized	O
+children	O
+with	O
+lower	O
+respiratory	O
+tract	O
+infection	O
+.	O
+
+In	O
+this	O
+work	O
+,	O
+we	O
+performed	O
+a	O
+head	B-ANAT
+-	O
+to	O
+-	O
+head	B-ANAT
+comparison	O
+to	O
+evaluate	O
+the	O
+multiplex	O
+-	O
+PCR	O
+yields	O
+between	O
+two	O
+samples	O
+,	O
+sputum	B-ANAT
+and	O
+flocked	O
+oropharyngeal	B-ANAT
+swabs	O
+(	O
+OPS	B-DISO
+).	O
+
+Both	O
+types	O
+of	O
+specimens	O
+had	O
+similarly	O
+very	O
+good	O
+kappa	O
+values	O
+for	O
+most	O
+of	O
+pathogens	O
+,	O
+except	O
+for	O
+Mycoplasma	B-DISO
+pneumonia	I-DISO
+(	O
+κ	O
+=	O
+0	O
+.	O
+61	O
+)	O
+and	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+(	O
+κ	O
+=	O
+0	O
+.	O
+24	O
+).	O
+
+There	O
+was	O
+a	O
+trend	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0798	O
+)	O
+for	O
+AAV	O
+-	O
+Pck2	B-PRGE
+overexpression	B-PROC
+to	O
+reduce	O
+TA	O
+muscle	B-ANAT
+weights	O
+,	O
+but	O
+there	O
+was	O
+no	O
+significant	O
+effect	O
+on	O
+muscle	B-COMP
+fibre	I-COMP
+diameters	O
+or	O
+myosin	B-PRGE
+heavy	I-PRGE
+chain	I-PRGE
+isoform	I-PRGE
+(	O
+MyHC	B-PRGE
+)	O
+mRNA	B-PROC
+expression	B-PROC
+.	O
+
+Biological	O
+samples	O
+were	O
+collected	O
+from	O
+13	O
+hospitalized	O
+patients	O
+suspected	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+Prof	O
+.	O
+Dr	O
+.	O
+Sulianti	O
+Saroso	O
+IDH	B-ENZY
+from	O
+July	O
+2015	O
+to	O
+December	O
+2016	O
+.	O
+
+The	O
+sequences	O
+of	O
+nine	O
+viral	O
+agents	O
+under	O
+different	O
+taxa	O
+were	O
+detected	O
+in	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+patients	O
+,	O
+including	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+paramyxovirus	O
+,	O
+coronavirus	B-SPEC
+,	O
+enterovirus	B-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+and	O
+herpesvirus	B-SPEC
+.	O
+
+RSV	B-DISO
+infection	I-DISO
+can	O
+be	O
+associated	O
+as	O
+a	O
+serious	O
+disease	O
+in	O
+newborns	O
+involving	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+and	O
+causing	O
+seizures	B-DISO
+or	O
+acute	B-DISO
+encephalopathy	I-DISO
+.	O
+
+Some	O
+studies	O
+highlight	O
+that	O
+this	O
+virus	B-SPEC
+-	O
+related	O
+encephalopathy	B-DISO
+lead	O
+to	O
+sudden	B-DISO
+infant	I-DISO
+death	I-DISO
+syndrome	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+presence	O
+of	O
+neurological	O
+involvement	O
+during	O
+RSV	B-SPEC
+-	O
+infection	B-DISO
+must	O
+be	O
+taken	O
+in	O
+consideration	O
+to	O
+performing	O
+instrumental	O
+test	O
+to	O
+detect	O
+cerebral	B-DISO
+edema	I-DISO
+.	O
+
+In	O
+reality	O
+,	O
+many	O
+hosts	B-COMP
+form	O
+multi	O
+-	O
+species	B-SPEC
+aggregations	O
+and	O
+may	O
+be	O
+infected	O
+with	O
+an	O
+assemblage	O
+of	O
+pathogens	O
+.	O
+
+Virome	O
+connectivity	O
+was	O
+apparent	O
+in	O
+two	O
+well	O
+described	O
+multi	O
+-	O
+host	O
+virus	B-SPEC
+species	B-SPEC
+-	O
+avian	B-SPEC
+coronavirus	I-SPEC
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+-	O
+and	O
+a	O
+novel	O
+Rotavirus	B-SPEC
+species	B-SPEC
+that	O
+were	O
+shared	O
+among	O
+some	O
+Anseriform	O
+species	B-SPEC
+,	O
+while	O
+virome	O
+heterogeneity	O
+was	O
+reflected	O
+in	O
+the	O
+absence	O
+of	O
+viruses	B-SPEC
+shared	O
+between	O
+Anseriformes	B-SPEC
+and	O
+Charadriiformes	B-SPEC
+,	O
+as	O
+well	O
+as	O
+differences	O
+in	O
+viral	O
+abundance	O
+and	O
+alpha	O
+diversity	O
+among	O
+species	B-SPEC
+.	O
+
+Overall	O
+,	O
+we	O
+demonstrate	O
+complex	O
+virome	O
+structures	O
+across	O
+host	B-COMP
+species	B-SPEC
+that	O
+co	O
+-	O
+exist	O
+in	O
+multi	O
+-	O
+species	B-SPEC
+aggregations	O
+.	O
+
+Triplet	O
+phasing	O
+of	O
+RiboSeq	O
+data	O
+allowed	O
+precise	O
+determination	O
+of	O
+reading	O
+frames	O
+and	O
+revealed	O
+the	O
+translation	B-PROC
+of	O
+two	O
+ORFs	O
+(	O
+ORF4b	O
+and	O
+ORF4c	O
+on	O
+sgmRNA	O
+IR	O
+),	O
+which	O
+are	O
+widely	O
+conserved	O
+across	O
+IBV	B-SPEC
+isolates	O
+.	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+Synthesis	B-PROC
+,	O
+and	O
+Anti	B-PRGE
+-	I-PRGE
+RNA	I-PRGE
+Virus	B-SPEC
+Activity	O
+of	O
+6	O
+'-	O
+Fluorinated	O
+-	O
+Aristeromycin	O
+Analogues	O
+.	O
+
+Diffuse	B-DISO
+alveolar	B-ANAT
+damage	I-DISO
+scoring	O
+was	O
+performed	O
+post	O
+mortem	O
+.	O
+
+Qshunt	O
+correlated	O
+with	O
+PFR	O
+(	O
+r	O
+=	O
+0	O
+.	O
+75	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+,	O
+APRV	O
+and	O
+(	O
+r	O
+=	O
+0	O
+.	O
+65	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+,	O
+CMV	B-SPEC
+).	O
+
+Smoke	O
+inhalation	B-PROC
+injury	O
+leads	O
+to	O
+early	O
+development	B-PROC
+of	O
+shunt	O
+,	O
+V	O
+/	O
+Q	O
+mismatch	O
+,	O
+lung	B-DISO
+consolidation	I-DISO
+,	O
+and	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+.	O
+
+CT	O
+showed	O
+decrease	O
+in	O
+normally	O
+aerated	O
+lung	B-ANAT
+,	O
+while	O
+poorly	O
+and	O
+nonaerated	O
+lung	B-ANAT
+increased	O
+.	O
+
+TITLE	O
+:	O
+Automatic	O
+proximal	O
+airway	B-ANAT
+volume	O
+segmentation	B-PROC
+using	O
+optical	O
+coherence	O
+tomography	O
+for	O
+assessment	O
+of	O
+inhalation	O
+injury	O
+.	O
+
+Measurements	O
+of	O
+PaO2	O
+-	O
+to	O
+-	O
+FiO2	O
+ratio	O
+(	O
+PFR	O
+),	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+(	O
+PIP	B-CHED
+),	O
+dynamic	O
+compliance	O
+,	O
+airway	B-PROC
+resistance	I-PROC
+,	O
+and	O
+OCT	O
+bronchoscopy	O
+were	O
+performed	O
+at	O
+baseline	O
+,	O
+postinjury	O
+,	O
+24	O
+hours	O
+,	O
+48	O
+hours	O
+,	O
+72	O
+hours	O
+after	O
+injury	O
+.	O
+
+PAV	O
+was	O
+significantly	O
+correlated	O
+with	O
+PIP	B-CHED
+(	O
+r	O
+=	O
+0	O
+.	O
+48	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+compliance	O
+(	O
+r	O
+=	O
+0	O
+.	O
+55	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+resistance	B-PROC
+(	O
+r	O
+=	O
+0	O
+.	O
+35	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+),	O
+MT	O
+(	O
+r	O
+=	O
+0	O
+.	O
+60	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+PFR	O
+(	O
+r	O
+=	O
+0	O
+.	O
+34	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+recruitment	B-DISO
+or	O
+expansion	O
+of	O
+cluster	O
+of	O
+differentiation	B-PROC
+(	O
+CD	O
+)	O
+4	O
+
+Pilgrims	O
+had	O
+a	O
+higher	O
+rate	O
+of	O
+correct	O
+responses	O
+on	O
+each	O
+question	O
+at	O
+the	O
+time	O
+they	O
+completed	O
+the	O
+second	O
+questionnaire	O
+,	O
+as	O
+compared	O
+with	O
+the	O
+first	O
+,	O
+with	O
+11	O
+of	O
+13	O
+questions	O
+answered	O
+significantly	O
+better	O
+after	O
+delivery	O
+of	O
+educational	O
+information	O
+about	O
+MERS	O
+-	O
+CoV	O
+.	O
+However	O
+,	O
+although	O
+the	O
+rate	O
+of	O
+correct	O
+answers	O
+to	O
+the	O
+questions	O
+about	O
+routes	O
+of	O
+transmission	O
+,	O
+symptoms	O
+,	O
+preventive	O
+behaviours	O
+to	O
+adopt	O
+in	O
+case	O
+of	O
+fever	B-PROC
+and	O
+time	O
+delay	O
+between	O
+return	O
+and	O
+potential	O
+MERS	O
+-	O
+CoV	O
+occurrence	O
+increased	O
+significantly	O
+after	O
+receiving	O
+the	O
+information	O
+,	O
+the	O
+rates	O
+remained	O
+below	O
+50	O
+%.	O
+
+Pilgrims	O
+had	O
+a	O
+higher	O
+rate	O
+of	O
+correct	O
+responses	O
+on	O
+each	O
+question	O
+at	O
+the	O
+time	O
+they	O
+completed	O
+the	O
+second	O
+questionnaire	O
+,	O
+as	O
+compared	O
+with	O
+the	O
+first	O
+,	O
+with	O
+11	O
+of	O
+13	O
+questions	O
+answered	O
+significantly	O
+better	O
+after	O
+delivery	O
+of	O
+educational	O
+information	O
+about	O
+MERS	O
+-	O
+CoV	O
+.	O
+However	O
+,	O
+although	O
+the	O
+rate	O
+of	O
+correct	O
+answers	O
+to	O
+the	O
+questions	O
+about	O
+routes	O
+of	O
+transmission	O
+,	O
+symptoms	O
+,	O
+preventive	O
+behaviours	O
+to	O
+adopt	O
+in	O
+case	O
+of	O
+fever	B-PROC
+and	O
+time	O
+delay	O
+between	O
+return	O
+and	O
+potential	O
+MERS	O
+-	O
+CoV	O
+occurrence	O
+increased	O
+significantly	O
+after	O
+receiving	O
+the	O
+information	O
+,	O
+the	O
+rates	O
+remained	O
+below	O
+50	O
+%.	O
+
+TITLE	O
+:	O
+NETs	B-PRGE
+promote	O
+ALI	O
+/	O
+ARDS	B-DISO
+inflammation	B-DISO
+by	O
+regulating	O
+alveolar	B-ANAT
+macrophage	I-ANAT
+polarization	O
+.	O
+
+We	O
+determined	O
+that	O
+NET	B-PRGE
+levels	O
+in	O
+ARDS	B-DISO
+patients	O
+were	O
+positively	O
+correlated	O
+with	O
+M1	O
+-	O
+like	O
+macrophage	B-ANAT
+polarization	O
+.	O
+
+Regardless	O
+of	O
+LPS	B-DISO
+pre	O
+-	O
+stimulation	O
+,	O
+significant	O
+secretion	B-PROC
+of	O
+proinflammatory	O
+cytokines	O
+and	O
+upregulated	O
+M1	O
+markers	O
+were	O
+detected	O
+from	O
+bone	B-ANAT
+marrow	I-ANAT
+-	I-ANAT
+derived	I-ANAT
+macrophages	I-ANAT
+(	O
+M0	O
+and	O
+M2	O
+)	O
+cocultured	O
+with	O
+high	O
+concentrations	O
+of	O
+NETs	O
+;	O
+conversely	O
+,	O
+M2	O
+markers	O
+were	O
+downregulated	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+and	O
+Atypical	O
+Bacterial	O
+Respiratory	B-DISO
+Infections	I-DISO
+in	O
+a	O
+University	O
+Teaching	O
+Hospital	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viral	O
+and	O
+atypical	O
+bacterial	O
+agents	O
+lead	O
+to	O
+infections	O
+in	O
+a	O
+large	O
+spectrum	O
+,	O
+from	O
+mild	O
+symptoms	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+The	O
+British	O
+Thoracic	B-DISO
+Society	O
+supports	O
+the	O
+recommendations	O
+in	O
+this	O
+guideline	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+epidemics	O
+of	O
+highly	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+Ebola	B-DISO
+Virus	I-DISO
+Disease	I-DISO
+(	O
+EVD	O
+)	O
+or	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+healthcare	O
+workers	O
+(	O
+HCW	O
+)	O
+are	O
+at	O
+much	O
+greater	O
+risk	O
+of	O
+infection	B-DISO
+than	O
+the	O
+general	O
+population	O
+,	O
+due	O
+to	O
+their	O
+contact	O
+with	O
+patients	O
+'	O
+contaminated	O
+body	B-ANAT
+fluids	I-ANAT
+.	O
+
+Different	O
+types	O
+of	O
+PPEPPE	O
+made	O
+of	O
+more	O
+breathable	O
+material	O
+may	O
+not	O
+lead	O
+to	O
+more	O
+contamination	O
+spots	B-DISO
+on	O
+the	O
+trunk	B-ANAT
+(	O
+Mean	O
+Difference	O
+(	O
+MD	O
+)	O
+1	O
+.	O
+60	O
+(	O
+95	O
+%	O
+Confidence	O
+Interval	O
+(	O
+CI	O
+)	O
+-	O
+0	O
+.	O
+15	O
+to	O
+3	O
+.	O
+35	O
+)	O
+than	O
+more	O
+water	B-CHED
+repellent	O
+material	O
+but	O
+may	O
+have	O
+greater	O
+user	O
+satisfaction	O
+(	O
+MD	O
+-	O
+0	O
+.	O
+46	O
+;	O
+95	O
+%	O
+CI	O
+-	O
+0	O
+.	O
+84	O
+to	O
+-	O
+0	O
+.	O
+08	O
+,	O
+scale	O
+of	O
+1	O
+to	O
+5	O
+).	O
+Gowns	O
+may	O
+protect	O
+better	O
+against	O
+contamination	O
+than	O
+aprons	O
+(	O
+MD	O
+large	O
+patches	O
+-	O
+1	O
+.	O
+36	O
+95	O
+%	O
+CI	O
+-	O
+1	O
+.	O
+78	O
+to	O
+-	O
+0	O
+.	O
+94	O
+).	O
+The	O
+use	O
+of	O
+a	O
+powered	O
+air	B-CHED
+-	O
+purifying	O
+respirator	O
+may	O
+protect	O
+better	O
+than	O
+a	O
+simple	O
+ensemble	O
+of	O
+PPE	B-CHED
+without	O
+such	O
+respirator	O
+(	O
+Relative	O
+Risk	O
+(	O
+RR	O
+)	O
+0	O
+.	O
+27	O
+;	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+17	O
+to	O
+0	O
+.	O
+43	O
+).	O
+Five	O
+different	O
+PPE	B-CHED
+ensembles	O
+(	O
+such	O
+as	O
+gown	O
+vs	O
+.	O
+coverall	O
+,	O
+boots	O
+with	O
+or	O
+without	O
+covers	O
+,	O
+hood	O
+vs	O
+.	O
+cap	B-DISO
+,	O
+length	O
+and	O
+number	O
+of	O
+gloves	O
+)	O
+were	O
+evaluated	O
+in	O
+one	O
+study	O
+,	O
+but	O
+there	O
+were	O
+no	O
+event	O
+data	O
+available	O
+for	O
+compared	O
+groups	O
+.	O
+
+Compound	O
+7b	O
+underwent	O
+cyclization	O
+to	O
+afford	O
+pyridine	B-CHED
+derivative	O
+8	O
+.	O
+
+Arylhydrazono	O
+derivatives	O
+9a	O
+,	O
+b	O
+were	O
+produced	O
+through	O
+the	O
+reaction	O
+of	O
+compound	O
+7a	O
+with	O
+aryldiazonium	O
+chlorides	B-CHED
+.	O
+
+Fused	O
+thiophene	B-CHED
+derivatives	O
+14a	O
+,	O
+b	O
+were	O
+produced	O
+via	O
+reaction	O
+of	O
+compounds	O
+4a	O
+,	O
+b	O
+with	O
+a	O
+mixture	B-CHED
+of	O
+malononitrile	B-CHED
+and	O
+ethylorthoformate	O
+.	O
+
+Of	O
+them	O
+,	O
+10	O
+,	O
+353	O
+patients	O
+were	O
+excluded	O
+due	O
+to	O
+incomplete	O
+data	O
+or	O
+not	O
+meeting	O
+the	O
+consensus	O
+criteria	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+;	O
+245	O
+patients	O
+were	O
+included	O
+with	O
+complete	O
+data	O
+.	O
+
+Eighty	O
+-	O
+six	O
+percent	O
+of	O
+patients	O
+had	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+at	O
+the	O
+point	O
+at	O
+which	O
+severe	B-DISO
+sepsis	I-DISO
+was	O
+recognized	O
+,	O
+and	O
+31	O
+%	O
+had	O
+underlying	O
+conditions	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+influence	O
+of	O
+social	O
+determinants	O
+and	O
+health	O
+communication	O
+on	O
+Public	O
+health	O
+emergency	O
+preparedness	O
+(	O
+PHEP	O
+)	O
+as	O
+well	O
+as	O
+the	O
+mediating	O
+effect	O
+of	O
+health	O
+communication	O
+were	O
+investigated	O
+with	O
+respect	O
+to	O
+the	O
+2015	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+outbreak	O
+in	O
+South	O
+Korea	O
+.	O
+
+Health	O
+communication	O
+such	O
+as	O
+information	O
+seeking	O
+and	O
+processing	O
+mediated	O
+the	O
+effect	O
+of	O
+social	O
+determinants	O
+on	O
+the	O
+behaviors	B-PROC
+and	O
+information	O
+seeking	O
+was	O
+found	O
+to	O
+have	O
+the	O
+most	O
+significant	O
+mediating	O
+effect	O
+on	O
+the	O
+relationship	O
+between	O
+the	O
+practice	O
+of	O
+both	O
+preventive	O
+and	O
+avoidance	O
+behaviors	O
+and	O
+social	O
+determinants	O
+such	O
+as	O
+education	O
+and	O
+age	O
+.	O
+
+A	O
+total	O
+of	O
+445	O
+nasopharyngeal	B-ANAT
+swabs	O
+specimens	O
+from	O
+patients	O
+with	O
+AFRS	O
+were	O
+analyzed	O
+using	O
+the	O
+RespiFinderSmart22kit	O
+(	O
+PathoFinder	O
+BV	O
+,	O
+Netherlands	O
+)	O
+and	O
+the	O
+LightCycler	O
+480	O
+real	O
+-	O
+time	O
+PCR	O
+system	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+found	O
+286	O
+CA	O
+-	O
+RVI	O
+cases	O
+,	O
+including	O
+85	O
+solid	B-ANAT
+organ	I-ANAT
+transplantation	O
+recipients	O
+(	O
+G1	O
+),	O
+61	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+recipients	O
+(	O
+G2	O
+),	O
+and	O
+140	O
+non	O
+-	O
+transplant	B-ANAT
+critically	B-DISO
+ill	I-DISO
+patients	O
+in	O
+ICU	O
+(	O
+G3	O
+),	O
+excluding	O
+those	O
+with	O
+repeated	O
+isolation	O
+within	O
+30	O
+days	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Inhaled	B-PROC
+streptokinase	O
+serves	O
+as	O
+rescue	O
+therapy	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+with	O
+improving	O
+oxygenation	B-PROC
+and	O
+lung	B-ANAT
+mechanics	O
+more	O
+quickly	O
+than	O
+heparin	O
+or	O
+conventional	O
+management	O
+.	O
+
+Different	O
+associations	O
+between	O
+vaccination	O
+protocol	O
+,	O
+production	O
+type	O
+,	O
+animal	B-SPEC
+category	O
+,	O
+birds	B-SPEC
+density	O
+,	O
+age	O
+,	O
+presence	O
+of	O
+clinical	O
+signs	O
+,	O
+and	O
+IBV	O
+and	O
+/	O
+or	O
+aMPV	O
+infection	B-DISO
+were	O
+tested	O
+.	O
+
+When	O
+tested	O
+with	O
+IBV	B-SPEC
+or	O
+NDV	B-SPEC
+single	O
+infected	O
+samples	O
+,	O
+the	O
+mean	O
+detection	O
+rates	O
+were	O
+98	O
+.	O
+65	O
+%	O
+and	O
+97	O
+.	O
+25	O
+%,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+laboratory	O
+and	O
+diagnostic	O
+preparedness	O
+to	O
+accelerate	O
+vaccine	O
+development	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Tight	B-COMP
+junction	I-COMP
+proteins	B-CHED
+are	O
+important	O
+for	O
+the	O
+maintenance	O
+and	O
+repair	B-PROC
+of	O
+the	O
+intestinal	B-ANAT
+mucosal	B-ANAT
+barrier	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+six	O
+tight	B-COMP
+junction	I-COMP
+protein	B-CHED
+genes	O
+was	O
+lower	O
+in	O
+PEDV	B-SPEC
+-	O
+infected	O
+piglets	O
+than	O
+in	O
+the	O
+normal	O
+animals	B-SPEC
+.	O
+
+Therefore	O
+,	O
+we	O
+aimed	O
+to	O
+determine	O
+effects	O
+of	O
+lung	B-ANAT
+recruitment	B-DISO
+maneuver	O
+(	O
+RM	O
+)	O
+and	O
+titrated	O
+PEEP	B-CHED
+Data	O
+sources	O
+and	O
+study	O
+selection	O
+proceeded	O
+as	O
+follows	O
+:	O
+PubMed	O
+,	O
+Ovid	O
+,	O
+EBSCO	O
+,	O
+and	O
+Cochrane	O
+Library	O
+databases	O
+were	O
+searched	O
+from	O
+2003	O
+to	O
+May	O
+2018	O
+.	O
+
+TITLE	O
+:	O
+Incidence	O
+of	O
+post	O
+-	O
+traumatic	O
+pneumonia	B-DISO
+in	O
+poly	O
+-	O
+traumatized	O
+patients	O
+:	O
+identifying	O
+the	O
+role	O
+of	O
+traumatic	O
+brain	O
+injury	O
+and	O
+chest	B-ANAT
+trauma	O
+.	O
+
+Complications	O
+(	O
+i	O
+.	O
+e	O
+.	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+multi	O
+-	O
+organ	B-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+)	O
+and	O
+pneumonia	O
+)	O
+were	O
+documented	O
+by	O
+a	O
+review	O
+of	O
+the	O
+medical	O
+records	O
+.	O
+
+Chest	B-ANAT
+trauma	O
+alone	O
+and	O
+especially	O
+its	O
+combination	O
+with	O
+TBI	O
+represent	O
+high	O
+-	O
+risk	O
+injury	O
+patterns	O
+for	O
+the	O
+development	B-PROC
+of	O
+pneumonia	B-DISO
+,	O
+which	O
+forms	O
+the	O
+strongest	O
+predictor	O
+of	O
+mortality	O
+in	O
+poly	O
+-	O
+traumatized	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+An	O
+Intensive	O
+Care	O
+Unit	O
+Outbreak	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+due	O
+to	O
+Human	B-SPEC
+Metapneumo	O
+Virus	O
+Infection	O
+.	O
+
+We	O
+report	O
+an	O
+outbreak	O
+of	O
+6	O
+cases	O
+of	O
+human	B-SPEC
+metapneumo	O
+virus	B-DISO
+infection	I-DISO
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+of	O
+a	O
+metropolitan	O
+tertiary	O
+care	O
+center	O
+over	O
+6	O
+weeks	O
+,	O
+leading	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+Envelope	B-COMP
+-	O
+Like	O
+Self	O
+-	O
+Assembled	O
+Nanoparticles	B-CHED
+Based	O
+on	O
+ABSTRACT	O
+:	O
+Pathogen	O
+-	O
+sized	O
+particles	O
+exhibit	O
+better	O
+performance	O
+in	O
+inducing	O
+immune	O
+responses	O
+than	O
+soluble	O
+protein	B-CHED
+antigens	B-CHED
+.	O
+
+However	O
+,	O
+the	O
+effects	O
+of	O
+fraxin	O
+on	O
+ARDS	B-DISO
+have	O
+yet	O
+to	O
+be	O
+reported	O
+.	O
+
+ELISA	O
+and	O
+Western	O
+blot	O
+results	O
+revealed	O
+that	O
+fraxin	O
+might	O
+inhibit	O
+the	O
+production	O
+of	O
+inflammatory	O
+factors	O
+,	O
+namely	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+and	O
+IL	O
+-	O
+1β	O
+,	O
+and	O
+the	O
+activation	O
+of	O
+NF	O
+-	O
+κB	O
+and	O
+MAPK	B-FUNC
+signaling	I-PROC
+pathways	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+Fraxin	O
+might	O
+inhibit	O
+the	O
+increase	O
+in	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+and	O
+malondialdehyde	B-CHED
+(	O
+MDA	B-CHED
+),	O
+a	O
+product	O
+of	O
+lipid	B-PROC
+peroxidation	I-PROC
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+.	O
+
+Children	O
+1	O
+month	O
+to	O
+15	O
+years	O
+old	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+admitted	O
+to	O
+the	O
+PICU	B-SPEC
+from	O
+January	O
+2013	O
+to	O
+December	O
+2016	O
+.	O
+
+To	O
+better	O
+understand	O
+the	O
+cause	O
+of	O
+this	O
+difference	O
+,	O
+the	O
+virological	O
+properties	O
+of	O
+African	O
+camel	B-SPEC
+MERS	O
+-	O
+CoV	O
+were	O
+analyzed	O
+based	O
+on	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+in	O
+Ethiopia	O
+.	O
+
+In	O
+neutralizing	O
+assays	O
+,	O
+Amibara	O
+S	O
+recombinants	O
+were	O
+neutralized	O
+by	O
+lower	O
+concentrations	O
+of	O
+sera	B-COMP
+from	O
+both	O
+Ethiopian	O
+dromedaries	B-SPEC
+and	O
+EMC	B-COMP
+isolate	O
+(	O
+wild	O
+-	O
+type	O
+)-	O
+immunized	O
+mouse	B-SPEC
+sera	B-COMP
+,	O
+relative	O
+to	O
+the	O
+EMC	B-PRGE
+S	I-PRGE
+recombinants	I-PRGE
+,	O
+indicating	O
+that	O
+viruses	B-SPEC
+coated	O
+in	O
+the	O
+Amibara	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+were	O
+easier	O
+to	O
+neutralize	O
+than	O
+the	O
+EMC	B-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+A	O
+recent	O
+example	O
+of	O
+these	O
+events	O
+is	O
+the	O
+avian	B-SPEC
+-	O
+origin	O
+H7N9	O
+influenza	B-SPEC
+virus	I-SPEC
+outbreak	O
+currently	O
+undergoing	O
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+A	O
+heterologous	O
+'	O
+prime	O
+-	O
+boost	O
+'	O
+anti	O
+-	O
+PEDV	B-SPEC
+immunization	O
+for	O
+pregnant	O
+sows	O
+protects	O
+neonatal	O
+piglets	O
+through	O
+lactogenic	O
+immunity	O
+against	O
+PEDV	B-SPEC
+.	O
+
+It	O
+causes	O
+enteritis	B-DISO
+in	O
+swine	B-SPEC
+of	O
+all	O
+ages	O
+and	O
+is	O
+often	O
+fatal	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+An	O
+inadequate	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+output	O
+flow	O
+was	O
+observed	O
+,	O
+possibly	O
+because	O
+of	O
+severe	O
+polycythemia	B-DISO
+and	O
+hyperviscosity	O
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+acute	O
+normovolemic	O
+hemodilution	O
+to	O
+improve	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+outflow	O
+.	O
+
+TITLE	O
+:	O
+Plasma	B-ANAT
+Midkine	O
+Is	O
+Associated	O
+With	O
+28	O
+-	O
+Day	O
+Mortality	O
+and	O
+Organ	B-ANAT
+Function	O
+in	O
+Sepsis	B-DISO
+.	O
+
+In	O
+conclusion	O
+,	O
+compared	O
+to	O
+cutaneous	O
+burn	O
+-	O
+induced	O
+ARDS	B-DISO
+,	O
+ARDS	B-DISO
+in	O
+patients	O
+with	O
+inhalation	B-PROC
+injury	O
+has	O
+earlier	O
+onset	O
+,	O
+causes	O
+more	O
+severe	O
+oxygenation	B-PROC
+disorder	O
+and	O
+has	O
+a	O
+higher	O
+mortality	O
+rate	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+influenza	B-DISO
+infections	B-DISO
+are	O
+often	O
+associated	O
+with	O
+the	O
+excessive	O
+induction	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+,	O
+which	O
+is	O
+also	O
+referred	O
+to	O
+as	O
+""""	O
+cytokine	O
+storms	O
+"""."	O
+
+First	O
+,	O
+we	O
+found	O
+that	O
+IBV	B-SPEC
+stimulation	O
+did	O
+not	O
+enhance	O
+the	O
+maturation	B-PROC
+ability	O
+of	O
+avian	B-SPEC
+DCs	B-DISO
+.	O
+
+We	O
+identified	O
+1093	O
+up	O
+-	O
+regulated	O
+and	O
+845	O
+down	O
+-	O
+regulated	O
+mRNAs	O
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+avian	B-SPEC
+DCs	B-DISO
+.	O
+
+Conditions	O
+at	O
+the	O
+time	O
+of	O
+death	B-PROC
+were	O
+sepsis	B-DISO
+(	O
+25	O
+),	O
+pneumonia	B-DISO
+(	O
+16	O
+),	O
+AKI	O
+(	O
+15	O
+),	O
+bleeding	B-DISO
+disorders	I-DISO
+(	O
+11	O
+),	O
+neurological	O
+complications	O
+(	O
+10	O
+),	O
+ARDS	B-DISO
+(	O
+10	O
+),	O
+CKD	O
+(	O
+4	O
+),	O
+AKI	B-PRGE
+in	O
+addition	O
+to	O
+CKD	O
+(	O
+3	O
+).	O
+
+Conditions	O
+at	O
+the	O
+time	O
+of	O
+death	B-PROC
+were	O
+sepsis	B-DISO
+(	O
+25	O
+),	O
+pneumonia	B-DISO
+(	O
+16	O
+),	O
+AKI	O
+(	O
+15	O
+),	O
+bleeding	B-DISO
+disorders	I-DISO
+(	O
+11	O
+),	O
+neurological	O
+complications	O
+(	O
+10	O
+),	O
+ARDS	B-DISO
+(	O
+10	O
+),	O
+CKD	O
+(	O
+4	O
+),	O
+AKI	B-PRGE
+in	O
+addition	O
+to	O
+CKD	O
+(	O
+3	O
+).	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+incidence	O
+is	O
+increased	O
+in	O
+obese	B-DISO
+patients	O
+.	O
+
+Transcriptomic	O
+analysis	O
+of	O
+lung	B-ANAT
+homogenates	O
+identified	O
+Fasn	O
+as	O
+one	O
+of	O
+the	O
+most	O
+significantly	O
+altered	O
+mitochondrial	B-COMP
+associated	O
+genes	O
+in	O
+mice	B-SPEC
+receiving	O
+60	O
+%	O
+compared	O
+to	O
+10	O
+%	O
+fat	O
+diet	O
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+H1N1	O
+infection	B-DISO
+in	O
+immunocompromised	O
+host	B-COMP
+:	O
+A	O
+concise	O
+review	O
+.	O
+
+ZM	O
+-	O
+treated	O
+heifers	O
+had	O
+9	O
+g	O
+decreased	O
+ADG	O
+compared	O
+to	O
+placebo	O
+-	O
+treated	O
+heifers	O
+(	O
+P	O
+=	O
+0	O
+.	O
+037	O
+),	O
+after	O
+adjusting	O
+for	O
+average	O
+birth	B-PROC
+weight	O
+.	O
+
+Endocan	O
+also	O
+acted	O
+as	O
+an	O
+inhibitor	B-CHED
+of	O
+transendothelial	B-PROC
+migration	I-PROC
+of	O
+mouse	B-SPEC
+leukocytes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+Lung	B-ANAT
+Injury	O
+in	O
+Infants	O
+with	O
+Congenital	B-DISO
+Diaphragmatic	I-DISO
+Hernia	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+presence	O
+of	O
+lung	O
+injury	O
+and	O
+the	O
+factors	O
+that	O
+contribute	O
+to	O
+it	O
+in	O
+infants	O
+with	O
+congenital	B-DISO
+diaphragmatic	I-DISO
+hernia	I-DISO
+(	O
+CDH	B-DISO
+)	O
+have	O
+not	O
+been	O
+objectively	O
+measured	O
+during	O
+their	O
+clinical	O
+course	O
+.	O
+
+In	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+higher	O
+serum	B-COMP
+levels	O
+of	O
+surfactant	B-PRGE
+protein	B-CHED
+D	I-PRGE
+(	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+)	O
+are	O
+linked	O
+to	O
+lung	B-ANAT
+injury	O
+and	O
+worse	O
+outcomes	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+serum	B-COMP
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+levels	O
+would	O
+be	O
+elevated	O
+in	O
+CDH	B-DISO
+infants	O
+and	O
+that	O
+the	O
+levels	O
+would	O
+correlate	O
+to	O
+the	O
+amount	O
+of	O
+lung	B-ANAT
+injury	O
+present	O
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+target	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+and	O
+block	O
+its	O
+binding	B-FUNC
+to	O
+the	O
+cellular	B-COMP
+receptor	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+).	O
+
+Variable	O
+Ventilation	O
+Is	O
+Equally	O
+Effective	O
+as	O
+Conventional	O
+Pressure	O
+Control	O
+Ventilation	O
+for	O
+Optimizing	O
+Lung	B-PROC
+Function	I-PROC
+in	O
+a	O
+Rabbit	B-SPEC
+Model	O
+of	O
+ARDS	B-DISO
+.	O
+
+This	O
+outcome	O
+may	O
+be	O
+related	O
+to	O
+the	O
+excessive	O
+increases	O
+in	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+with	O
+the	O
+latter	O
+ventilation	O
+modes	O
+.	O
+
+TITLE	O
+:	O
+Stochastic	O
+and	O
+spatio	O
+-	O
+temporal	O
+analysis	O
+of	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+outbreak	O
+in	O
+South	O
+Korea	O
+,	O
+2015	O
+.	O
+
+The	O
+MERS	O
+outbreak	O
+in	O
+South	O
+Korea	O
+during	O
+2015	O
+was	O
+the	O
+largest	O
+outbreak	O
+of	O
+the	O
+Coronavirus	B-SPEC
+outside	O
+the	O
+Middle	O
+East	O
+.	O
+
+TITLE	O
+:	O
+Interaction	O
+between	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+strategy	O
+and	O
+severity	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+retrospective	O
+cohort	O
+study	O
+.	O
+
+The	O
+benefits	O
+of	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+remain	O
+uncertain	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Nutritional	O
+stress	O
+also	O
+had	O
+long	O
+-	O
+term	O
+colony	O
+effects	O
+,	O
+because	O
+bee	B-SPEC
+population	O
+did	O
+not	O
+recover	B-PROC
+in	O
+spring	O
+,	O
+as	O
+in	O
+supplemented	O
+colonies	O
+did	O
+.	O
+
+In	O
+conclusion	O
+,	O
+nutritional	O
+stress	O
+and	O
+Nosema	B-SPEC
+spp	B-ENZY
+.	O
+
+infection	B-DISO
+had	O
+a	O
+severe	O
+impact	O
+on	O
+colony	O
+strength	O
+with	O
+consequences	O
+in	O
+both	O
+short	O
+and	O
+long	O
+-	O
+term	O
+.	O
+
+Prospectively	O
+,	O
+nasal	B-ANAT
+and	O
+tonsillar	B-ANAT
+swabs	O
+from	O
+214	O
+dogs	B-SPEC
+affected	O
+with	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+,	O
+and	O
+50	O
+healthy	O
+control	O
+dogs	B-SPEC
+were	O
+tested	O
+for	O
+nucleic	B-CHED
+acids	I-CHED
+specific	O
+to	O
+the	O
+various	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Canine	O
+coronavirus	B-SPEC
+-	O
+specific	O
+nucleic	B-CHED
+acid	I-CHED
+was	O
+detected	O
+in	O
+4	O
+.	O
+0	O
+%	O
+of	O
+healthy	O
+dogs	B-SPEC
+.	O
+
+Canine	O
+coronavirus	B-SPEC
+-	O
+specific	O
+nucleic	B-CHED
+acid	I-CHED
+was	O
+detected	O
+in	O
+4	O
+.	O
+0	O
+%	O
+of	O
+healthy	O
+dogs	B-SPEC
+.	O
+
+Hospitalization	O
+months	O
+significantly	O
+differed	O
+for	O
+these	O
+common	O
+pathogens	O
+(	O
+P	O
+≤	O
+0	O
+.	O
+01	O
+),	O
+except	O
+for	O
+coronavirus	B-SPEC
+(	O
+P	O
+=	O
+0	O
+.	O
+30	O
+).	O
+
+ABSTRACT	O
+:	O
+Environmental	O
+disinfection	O
+with	O
+sodium	O
+hypochlorite	B-CHED
+and	O
+hydrogen	B-CHED
+peroxide	I-CHED
+vapor	O
+was	O
+performed	O
+after	O
+a	O
+hospital	O
+-	O
+associated	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Diarrhea	B-DISO
+,	O
+caused	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+is	O
+a	O
+catastrophic	O
+gastrointestinal	B-DISO
+disease	I-DISO
+among	O
+suckling	O
+piglets	O
+,	O
+with	O
+high	O
+infectivity	O
+,	O
+morbidity	O
+,	O
+and	O
+mortality	O
+,	O
+causing	O
+huge	O
+economic	O
+losses	O
+to	O
+the	O
+pig	B-SPEC
+industry	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+different	O
+microbiota	B-SPEC
+from	O
+the	O
+cecal	B-ANAT
+mucosa	I-ANAT
+and	O
+cecal	B-ANAT
+contents	O
+between	O
+healthy	O
+and	O
+PEDV	B-SPEC
+-	O
+infected	O
+piglets	O
+.	O
+
+The	O
+proportion	O
+of	O
+Proteobacteria	O
+in	O
+the	O
+infected	O
+groups	O
+was	O
+relatively	O
+high	O
+(	O
+24	O
+.	O
+67	O
+%	O
+and	O
+22	O
+.	O
+79	O
+%,	O
+respectively	O
+),	O
+whereas	O
+that	O
+in	O
+the	O
+healthy	O
+group	O
+was	O
+13	O
+.	O
+13	O
+%	O
+and	O
+11	O
+.	O
+34	O
+%	O
+in	O
+the	O
+cecal	B-ANAT
+mucosa	I-ANAT
+and	O
+contents	O
+,	O
+respectively	O
+.	O
+
+Prone	O
+positioning	O
+is	O
+known	O
+to	O
+improve	O
+outcome	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Temporal	O
+,	O
+seasonal	O
+,	O
+spatial	O
+and	O
+spatiotemporal	O
+cluster	O
+analyses	O
+were	O
+performed	O
+using	O
+Kulldorff	O
+'	O
+s	O
+spatial	O
+scan	O
+statistics	O
+to	O
+determine	O
+the	O
+time	O
+period	O
+and	O
+geographical	O
+areas	O
+with	O
+the	O
+highest	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+risk	O
+.	O
+
+Most	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+occurred	O
+during	O
+the	O
+spring	O
+season	O
+(	O
+41	O
+.	O
+88	O
+%),	O
+with	O
+April	O
+and	O
+May	O
+showing	O
+significant	O
+seasonal	O
+clusters	O
+.	O
+
+Myocarditis	B-DISO
+and	O
+late	O
+-	O
+onset	O
+cardiovascular	B-ANAT
+complications	O
+are	O
+associated	O
+with	O
+mortality	O
+.	O
+
+Then	O
+the	O
+MP	O
+and	O
+LUS	O
+were	O
+analyzed	O
+by	O
+bivariate	O
+correlation	O
+analysis	O
+,	O
+and	O
+their	O
+correlations	O
+with	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+),	O
+sequential	O
+organ	O
+failure	O
+assessment	O
+(	O
+SOFA	O
+),	O
+oxygenation	B-PROC
+index	O
+(	O
+PaO	B-PROC
+At	O
+the	O
+end	O
+,	O
+83	O
+patients	O
+were	O
+enrolled	O
+,	O
+with	O
+32	O
+died	B-PROC
+and	O
+51	O
+survived	O
+in	O
+28	O
+-	O
+day	O
+.	O
+
+Here	O
+,	O
+we	O
+examined	O
+the	O
+intermediate	O
+conformation	O
+of	O
+the	O
+murine	B-PRGE
+coronavirus	I-PRGE
+fusion	I-PRGE
+protein	B-CHED
+,	O
+called	O
+the	O
+spike	O
+protein	B-CHED
+,	O
+which	O
+must	O
+be	O
+cleaved	B-ANAT
+by	O
+a	O
+cellular	B-COMP
+protease	O
+following	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+Western	O
+blot	O
+analysis	O
+of	O
+protease	O
+digestion	B-PROC
+products	O
+revealed	O
+that	O
+two	O
+subunits	O
+(	O
+67	O
+and	O
+69	O
+kDa	O
+)	O
+are	O
+produced	O
+from	O
+a	O
+single	O
+spike	O
+protein	B-CHED
+(	O
+180	O
+kDa	O
+).	O
+
+Subsequent	O
+proteolysis	B-PROC
+induces	O
+simultaneous	O
+packing	O
+of	O
+the	O
+remaining	O
+unpacked	O
+HRs	B-DISO
+upon	O
+assembly	O
+of	O
+three	O
+HRs	B-DISO
+at	O
+the	O
+central	O
+axis	B-SPEC
+to	O
+generate	O
+a	O
+six	O
+-	O
+helix	O
+bundle	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+mapped	O
+the	O
+M	O
+protein	B-CHED
+site	O
+responsible	O
+for	O
+the	O
+interaction	O
+with	O
+HSPG	B-PRGE
+and	O
+confirmed	O
+its	O
+relevance	O
+using	O
+a	O
+viable	O
+virus	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+with	O
+the	O
+example	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+response	O
+process	O
+,	O
+the	O
+evolutionary	O
+scenarios	O
+that	O
+include	O
+infected	O
+patients	O
+and	O
+diagnostic	O
+processes	O
+are	O
+transformed	O
+into	O
+simulation	O
+processes	O
+.	O
+
+To	O
+meet	O
+the	O
+urgent	O
+requirements	O
+of	O
+emergency	B-DISO
+response	O
+,	O
+the	O
+DES	B-DISO
+-	O
+PSDF	O
+method	O
+introduces	O
+a	O
+new	O
+response	O
+decision	O
+-	O
+making	O
+concept	O
+for	O
+unconventional	O
+public	O
+health	O
+emergencies	B-DISO
+.	O
+
+In	O
+2017	O
+,	O
+a	O
+post	O
+-	O
+outbreak	O
+serology	O
+was	O
+carried	O
+out	O
+in	O
+three	O
+counties	O
+in	O
+Eastern	O
+Croatia	O
+,	O
+revealing	O
+seropositivity	O
+in	O
+pigs	B-SPEC
+bred	O
+on	O
+four	O
+large	O
+industrial	O
+holdings	O
+(	O
+9	O
+.	O
+09	O
+%).	O
+
+ABSTRACT	O
+:	O
+Around	O
+0	O
+.	O
+1	O
+-	O
+0	O
+.	O
+2	O
+%	O
+of	O
+all	O
+pregnancies	O
+are	O
+complicated	O
+by	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Respiratory	B-DISO
+failure	I-DISO
+in	O
+pregnancy	O
+may	O
+have	O
+detrimental	O
+fetal	B-ANAT
+complications	O
+,	O
+therefore	O
+extensive	O
+knowledge	O
+of	O
+the	O
+range	O
+of	O
+therapeutic	O
+options	O
+is	O
+necessary	O
+.	O
+
+A	O
+previously	O
+healthy	O
+30	O
+-	O
+year	O
+-	O
+old	O
+P1G2	O
+at	O
+26	O
+weeks	O
+and	O
+6	O
+days	O
+of	O
+gestation	B-PROC
+was	O
+admitted	O
+to	O
+the	O
+emergency	B-DISO
+department	O
+because	O
+of	O
+a	O
+severe	O
+respiratory	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+identified	O
+an	O
+optimal	O
+spatial	O
+arrangement	O
+of	O
+these	O
+patches	O
+on	O
+certain	O
+dendrimers	O
+that	O
+enabled	O
+their	O
+interaction	O
+with	O
+human	B-SPEC
+adenovirus	B-DISO
+5	O
+(	O
+Ad5	B-DISO
+).	O
+
+Therefore	O
+,	O
+a	O
+novel	O
+method	O
+that	O
+can	O
+distinguish	O
+these	O
+viruses	B-SPEC
+quickly	O
+and	O
+simultaneously	O
+is	O
+urgently	O
+needed	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+an	O
+oligonucleotide	B-CHED
+microarray	O
+system	O
+was	O
+developed	O
+.	O
+
+Three	O
+probes	O
+specific	O
+for	O
+AIV	O
+,	O
+NDV	B-SPEC
+,	O
+and	O
+IBV	B-SPEC
+,	O
+as	O
+well	O
+as	O
+three	O
+other	O
+probes	O
+for	O
+differentiating	O
+H5	O
+,	O
+H7	O
+,	O
+and	O
+H9	O
+of	O
+AIV	O
+,	O
+were	O
+first	O
+designed	O
+and	O
+jet	O
+-	O
+printed	O
+to	O
+predetermined	O
+locations	O
+of	O
+initiator	O
+-	O
+integrated	O
+poly	O
+(	O
+dimethylsiloxane	O
+)	O
+for	O
+the	O
+synchronous	O
+detection	O
+of	O
+the	O
+six	O
+pathogens	O
+.	O
+
+The	O
+marked	O
+multiplex	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+products	O
+were	O
+hybridized	O
+with	O
+the	O
+specific	O
+probes	O
+,	O
+and	O
+the	O
+results	O
+of	O
+hybridization	B-PROC
+were	O
+read	O
+directly	O
+with	O
+the	O
+naked	O
+eyes	B-ANAT
+.	O
+
+The	O
+microarray	O
+is	O
+an	O
+accurate	O
+,	O
+high	O
+-	O
+throughput	O
+,	O
+and	O
+relatively	O
+simple	O
+method	O
+for	O
+the	O
+rapid	O
+detection	O
+of	O
+avian	B-SPEC
+respiratory	O
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+sensitivity	O
+of	O
+the	O
+method	O
+was	O
+at	O
+least	O
+100	O
+times	O
+higher	O
+than	O
+that	O
+of	O
+the	O
+conventional	O
+PCR	O
+,	O
+and	O
+the	O
+detection	O
+limit	O
+of	O
+NDV	B-SPEC
+,	O
+AIV	O
+,	O
+H5	O
+,	O
+H7	O
+,	O
+and	O
+H9	O
+can	O
+reach	B-PROC
+0	O
+.	O
+1	O
+EID	O
+
+Virus	B-SPEC
+transmission	O
+occurs	O
+through	O
+a	O
+susceptible	O
+individual	O
+'	O
+s	O
+contact	O
+with	O
+aerosols	O
+or	O
+respiratory	O
+fomites	O
+from	O
+an	O
+infected	O
+individual	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+evaluate	O
+the	O
+detailed	O
+association	O
+between	O
+these	O
+two	O
+markers	O
+and	O
+clinical	O
+outcomes	O
+in	O
+sepsis	B-DISO
+patients	O
+.	O
+
+The	O
+decreased	O
+levels	O
+of	O
+the	O
+fibrinogen	B-COMP
+and	O
+antithrombin	B-PRGE
+activity	O
+were	O
+significantly	O
+associated	O
+with	O
+an	O
+increase	O
+in	O
+mortality	O
+(	O
+P	O
+=	O
+0	O
+.	O
+011	O
+and	O
+0	O
+.	O
+002	O
+,	O
+respectively	O
+).	O
+
+TITLE	O
+:	O
+Activation	O
+of	O
+pituitary	B-ANAT
+axis	B-SPEC
+according	O
+to	O
+underlying	O
+critical	B-DISO
+illness	I-DISO
+and	O
+its	O
+effect	O
+on	O
+outcome	O
+.	O
+
+Activation	O
+of	O
+the	O
+hypothalamic	B-ANAT
+pituitary	I-ANAT
+adrenal	I-ANAT
+axis	I-ANAT
+was	O
+a	O
+predictor	O
+of	O
+ICU	O
+mortality	O
+independently	O
+from	O
+the	O
+underlying	O
+critical	B-DISO
+illness	I-DISO
+[	O
+OR	O
+3	O
+.	O
+952	O
+(	O
+C	O
+.	O
+I	O
+.	O
+95	O
+%	O
+1	O
+.	O
+129	O
+-	O
+13	O
+.	O
+838	O
+)].	O
+
+RESULTS	O
+:	O
+One	O
+hundred	O
+-	O
+thirteen	O
+critical	O
+ill	B-DISO
+patients	O
+were	O
+studied	O
+.	O
+
+The	O
+samples	O
+'	O
+alpha	O
+-	O
+diversity	O
+curves	O
+did	O
+not	O
+reach	B-PROC
+a	O
+proper	O
+plateau	O
+and	O
+,	O
+for	O
+the	O
+beta	O
+-	O
+diversity	O
+,	O
+the	O
+samples	O
+seemed	O
+not	O
+to	O
+group	O
+perfectly	O
+by	O
+category	O
+,	O
+even	O
+if	O
+the	O
+healthy	O
+FCoV	O
+-	O
+positive	O
+group	O
+showed	O
+a	O
+hybrid	O
+microbial	O
+composition	O
+between	O
+FCoV	O
+-	O
+negative	O
+and	O
+FIP	O
+groups	O
+.	O
+
+We	O
+performed	O
+an	O
+analysis	O
+of	O
+literature	O
+and	O
+a	O
+systematic	O
+review	O
+of	O
+our	O
+post	O
+-	O
+bariatric	O
+patients	O
+who	O
+underwent	O
+body	B-ANAT
+contouring	O
+procedures	O
+which	O
+required	O
+general	O
+anaesthesia	B-DISO
+from	O
+2013	O
+to	O
+2018	O
+and	O
+divided	O
+them	O
+in	O
+two	O
+groups	O
+:	O
+OAGB	O
+-	O
+MGB	O
+group	O
+and	O
+other	O
+bariatric	O
+procedures	O
+in	O
+order	B-SPEC
+to	O
+compare	O
+the	O
+rate	O
+of	O
+aspiration	O
+/	O
+pneumonia	B-DISO
+occurred	O
+in	O
+time	O
+.	O
+
+Literature	O
+confirmed	O
+high	O
+risk	O
+of	O
+biliar	O
+reflux	B-DISO
+after	O
+OAGB	O
+-	O
+MGB	O
+procedure	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+interstitial	I-DISO
+pneumonia	I-DISO
+(	O
+AIP	B-DISO
+)	O
+is	O
+a	O
+rare	O
+and	O
+severe	O
+form	O
+of	O
+diffuse	O
+lung	B-ANAT
+injury	O
+that	O
+affects	O
+previously	O
+healthy	O
+individuals	O
+.	O
+
+It	O
+is	O
+a	O
+subset	O
+of	O
+idiopathic	O
+lung	B-DISO
+disease	I-DISO
+with	O
+a	O
+rapidly	O
+progressive	O
+course	O
+.	O
+
+Based	O
+on	O
+the	O
+reported	O
+imaging	O
+findings	O
+,	O
+we	O
+propose	O
+that	O
+Leigh	B-DISO
+Syndrome	I-DISO
+should	O
+be	O
+added	O
+to	O
+the	O
+differential	O
+diagnosis	O
+of	O
+acute	O
+cerebellitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+incidence	O
+,	O
+outcomes	O
+,	O
+and	O
+risk	O
+factors	O
+of	O
+postoperative	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+patients	O
+undergoing	O
+surgical	O
+repair	B-PROC
+for	O
+acute	O
+type	B-DISO
+A	I-DISO
+aortic	I-DISO
+dissection	I-DISO
+.	O
+
+This	O
+retrospective	O
+study	O
+involved	O
+270	O
+patients	O
+who	O
+underwent	O
+surgical	O
+repair	B-PROC
+for	O
+acute	O
+type	B-DISO
+A	I-DISO
+aortic	I-DISO
+dissection	I-DISO
+between	O
+January	O
+2009	O
+and	O
+December	O
+2015	O
+.	O
+
+Primary	O
+outcome	O
+was	O
+postoperative	O
+ARDS	B-DISO
+,	O
+according	O
+to	O
+the	O
+2012	O
+Berlin	O
+definition	O
+for	O
+ARDS	B-DISO
+and	O
+was	O
+reviewed	O
+by	O
+2	O
+qualified	O
+physicians	O
+with	O
+expertise	O
+in	O
+critical	O
+care	O
+and	O
+cardiac	B-ANAT
+surgery	O
+.	O
+
+Three	O
+,	O
+20	O
+,	O
+and	O
+14	O
+patients	O
+had	O
+mild	O
+,	O
+moderate	O
+,	O
+and	O
+severe	O
+ARDS	B-DISO
+,	O
+respectively	O
+,	O
+according	O
+to	O
+the	O
+Berlin	O
+definition	O
+,	O
+with	O
+no	O
+significant	O
+difference	O
+in	O
+age	O
+,	O
+sex	O
+,	O
+and	O
+underlying	O
+disease	O
+.	O
+
+Their	O
+mechanical	O
+power	O
+was	O
+monitored	O
+and	O
+recorded	O
+,	O
+the	O
+TGF	O
+-	O
+β1	O
+and	O
+CTGF	B-PRGE
+levels	O
+were	O
+detected	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+),	O
+their	O
+relevance	O
+was	O
+analyzed	O
+,	O
+and	O
+the	O
+relationship	O
+between	O
+mechanical	O
+power	O
+and	O
+28	O
+-	O
+day	O
+survival	O
+rate	O
+was	O
+investigated	O
+.	O
+
+The	O
+complete	O
+blood	B-ANAT
+count	O
+is	O
+the	O
+most	O
+ordered	O
+clinical	O
+test	O
+in	O
+the	O
+United	O
+States	O
+serving	O
+as	O
+the	O
+cornerstone	O
+of	O
+clinical	O
+medicine	B-CHED
+and	O
+differential	O
+diagnosis	O
+.	O
+
+We	O
+recently	O
+generated	O
+a	O
+mouse	B-SPEC
+model	O
+for	O
+MERS	O
+-	O
+CoV	O
+pathogenesis	B-DISO
+through	O
+the	O
+humanization	O
+of	O
+the	O
+orthologous	O
+entry	O
+receptor	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+).	O
+
+MERS	O
+-	O
+CoV	O
+lung	B-ANAT
+titer	O
+peaked	O
+2	O
+days	O
+post	O
+infection	B-DISO
+concurrent	O
+with	O
+lymphopenia	B-DISO
+and	O
+neutrophilia	O
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+,	O
+two	O
+phenomena	O
+also	O
+observed	O
+in	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+of	O
+humans	B-SPEC
+.	O
+
+Veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+may	O
+be	O
+an	O
+alternative	O
+option	O
+for	O
+treating	O
+TB	O
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+In	O
+order	B-SPEC
+to	O
+manage	O
+and	O
+maintain	O
+stable	O
+productivity	O
+,	O
+it	O
+is	O
+important	O
+to	O
+establish	O
+policies	O
+for	O
+biosecurity	O
+.	O
+
+Mycoplasmas	B-SPEC
+and	O
+IBV	B-SPEC
+were	O
+detected	O
+on	O
+poultry	O
+farms	O
+in	O
+Myanmar	O
+.	O
+
+Real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+revealed	O
+that	O
+all	O
+17	O
+fecal	B-ANAT
+samples	O
+from	O
+post	O
+-	O
+weaned	B-PROC
+calves	O
+with	O
+diarrhea	B-DISO
+and	O
+one	O
+out	O
+of	O
+15	O
+from	O
+diarrhea	B-DISO
+-	O
+recovered	O
+calves	O
+were	O
+positive	O
+for	O
+BCoV	O
+and	O
+negative	O
+for	O
+Cryptosporidium	B-PRGE
+spp	B-ENZY
+.,	I-PRGE
+Escherichia	B-SPEC
+coli	I-SPEC
+K99	I-PRGE
+,	I-PRGE
+Salmonella	B-DISO
+spp	B-ENZY
+.,	O
+bovine	B-SPEC
+rotavirus	B-SPEC
+,	O
+and	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Demographics	O
+,	O
+management	O
+and	O
+outcome	O
+of	O
+females	O
+and	O
+males	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+LUNG	B-ANAT
+SAFE	O
+prospective	O
+cohort	O
+study	O
+.	O
+
+Females	O
+received	O
+higher	O
+tidal	O
+volumes	O
+(	O
+8	O
+.	O
+2	O
+±	O
+2	O
+.	O
+1	O
+Shorter	O
+females	O
+with	O
+ARDS	B-DISO
+are	O
+less	O
+likely	O
+to	O
+receive	O
+lower	O
+tidal	O
+volume	O
+ventilation	O
+,	O
+while	O
+females	O
+with	O
+severe	O
+confirmed	O
+ARDS	B-DISO
+have	O
+a	O
+higher	O
+mortality	O
+risk	O
+.	O
+
+ABSTRACT	O
+:	O
+Mechanical	O
+ventilation	O
+is	O
+a	O
+life	O
+-	O
+saving	O
+therapy	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+).	O
+
+However	O
+,	O
+mechanical	O
+ventilation	O
+itself	O
+causes	O
+severe	O
+co	O
+-	O
+morbidities	O
+in	O
+that	O
+it	O
+can	O
+trigger	O
+ventilator	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+(	O
+VALI	O
+)	O
+in	O
+humans	B-SPEC
+or	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+(	O
+VILI	O
+)	O
+in	O
+experimental	O
+animal	B-SPEC
+models	O
+.	O
+
+In	O
+this	O
+line	O
+,	O
+we	O
+engineered	O
+an	O
+attenuated	O
+virus	B-SPEC
+based	O
+on	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+genome	O
+,	O
+expressing	O
+a	O
+chimeric	O
+spike	O
+protein	B-CHED
+from	O
+a	O
+virulent	O
+United	O
+States	O
+(	O
+US	O
+)	O
+PEDV	B-SPEC
+strain	O
+.	O
+
+This	O
+virus	B-SPEC
+(	O
+rTGEV	O
+-	O
+RS	O
+-	O
+SPEDV	O
+)	O
+was	O
+attenuated	O
+in	O
+highly	O
+-	O
+sensitive	O
+five	O
+-	O
+day	O
+-	O
+old	O
+piglets	O
+,	O
+as	O
+infected	O
+animals	B-SPEC
+did	O
+not	O
+lose	O
+weight	O
+and	O
+none	O
+of	O
+them	O
+died	B-PROC
+.	O
+
+Altogether	O
+,	O
+the	O
+data	O
+indicated	O
+that	O
+rTGEV	O
+-	O
+RS	O
+-	O
+SPEDV	O
+is	O
+a	O
+promising	O
+vaccine	O
+candidate	O
+against	O
+virulent	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+enveloped	O
+,	O
+single	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+that	O
+are	O
+distributed	O
+worldwide	O
+.	O
+
+They	O
+include	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+and	O
+the	O
+human	B-SPEC
+coronaviruses	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+many	O
+of	O
+which	O
+seriously	O
+endanger	O
+human	B-SPEC
+health	O
+and	O
+well	O
+-	O
+being	O
+.	O
+
+Only	O
+alphacoronaviruses	O
+and	O
+betacoronaviruses	O
+harbor	O
+nonstructural	B-PRGE
+protein	I-PRGE
+1	I-PRGE
+(	O
+nsp1	B-PRGE
+),	O
+which	O
+performs	O
+multiple	O
+functions	O
+in	O
+inhibiting	O
+antiviral	B-CHED
+host	B-COMP
+responses	O
+.	O
+
+In	O
+conclusion	O
+,	O
+mice	B-SPEC
+with	O
+CIE	B-DISO
+developed	O
+three	O
+phenotypes	O
+of	O
+neurologic	O
+impairment	B-DISO
+mimicking	O
+different	O
+types	O
+of	O
+MS	O
+progression	O
+in	O
+humans	B-SPEC
+and	O
+showed	O
+differential	O
+mechanisms	O
+driving	O
+neurogenic	O
+bladder	B-DISO
+dysfunction	I-DISO
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genome	O
+sequences	O
+of	O
+novel	O
+S	O
+-	O
+deletion	O
+variants	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+identified	O
+from	O
+a	O
+recurrent	O
+outbreak	O
+on	O
+Jeju	O
+Island	O
+,	O
+South	O
+Korea	O
+.	O
+
+Their	O
+genomes	O
+were	O
+28	O
+,	O
+023	O
+nucleotides	B-CHED
+in	O
+length	O
+,	O
+15	O
+nucleotides	O
+shorter	O
+than	O
+those	O
+of	O
+the	O
+classical	O
+G2b	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+The	O
+two	O
+S	O
+-	O
+DEL	O
+isolates	O
+had	O
+96	O
+.	O
+4	O
+-	O
+99	O
+.	O
+2	O
+%	O
+and	O
+98	O
+.	O
+3	O
+-	O
+99	O
+.	O
+7	O
+%	O
+identity	O
+at	O
+the	O
+S	B-PRGE
+-	I-PRGE
+gene	I-PRGE
+and	O
+full	O
+-	O
+genome	O
+level	O
+,	O
+respectively	O
+,	O
+to	O
+other	O
+global	O
+G2b	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+To	O
+further	O
+identify	O
+and	O
+characterize	O
+the	O
+PDCoV	B-PRGE
+-	I-PRGE
+encoded	I-PRGE
+IFN	I-PRGE
+antagonists	B-CHED
+will	O
+broaden	O
+our	O
+understanding	O
+of	O
+its	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+most	O
+common	O
+unsolicited	O
+adverse	O
+events	O
+were	O
+infections	B-DISO
+,	O
+occurring	O
+in	O
+27	O
+participants	O
+(	O
+36	O
+%);	O
+six	O
+(	O
+8	O
+%)	O
+were	O
+deemed	O
+possibly	O
+related	O
+to	O
+study	O
+treatment	O
+.	O
+
+There	O
+were	O
+no	O
+laboratory	O
+abnormalities	O
+of	O
+grade	O
+3	O
+or	O
+higher	O
+that	O
+were	O
+related	O
+to	O
+study	O
+treatment	O
+;	O
+laboratory	O
+abnormalities	O
+were	O
+uncommon	O
+,	O
+except	O
+for	O
+15	O
+increases	O
+in	O
+creatine	B-CHED
+phosphokinase	O
+in	O
+14	O
+participants	O
+(	O
+three	O
+participants	O
+in	O
+the	O
+0	O
+·	O
+67	O
+mg	O
+group	O
+,	O
+three	O
+in	O
+the	O
+2	O
+mg	O
+group	O
+,	O
+and	O
+seven	O
+in	O
+the	O
+6	O
+mg	O
+group	O
+).	O
+
+Immune	B-PROC
+responses	I-PROC
+were	O
+dose	O
+-	O
+independent	O
+,	O
+detected	O
+in	O
+more	O
+than	O
+85	O
+%	O
+of	O
+participants	O
+after	O
+two	O
+vaccinations	O
+,	O
+and	O
+durable	O
+through	O
+1	O
+year	O
+of	O
+follow	O
+-	O
+up	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Clinical	O
+Risk	O
+Scoring	O
+System	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+-	O
+Induced	O
+Acute	O
+Kidney	B-ANAT
+Injury	O
+.	O
+
+The	O
+incidences	O
+of	O
+AKI	O
+in	O
+group	O
+A	O
+(	O
+score	O
+0	O
+-	O
+2	O
+,	O
+n	O
+=	O
+9	O
+),	O
+group	B-DISO
+B	I-DISO
+(	O
+score	O
+3	O
+-	O
+4	O
+,	O
+n	O
+=	O
+16	O
+),	O
+group	O
+C	O
+(	O
+score	O
+5	O
+-	O
+6	O
+,	O
+n	O
+=	O
+33	O
+),	O
+and	O
+group	O
+D	O
+(	O
+score	O
+≥	O
+7	O
+,	O
+n	O
+=	O
+72	O
+)	O
+were	O
+10	O
+.	O
+98	O
+%,	O
+16	O
+.	O
+00	O
+%,	O
+31	O
+.	O
+13	O
+%,	O
+and	O
+49	O
+.	O
+66	O
+%,	O
+respectively	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+(	O
+n	O
+=	O
+7	O
+,	O
+32	O
+%)	O
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+(	O
+n	O
+=	O
+6	O
+,	O
+28	O
+%)	O
+were	O
+other	O
+major	O
+organ	B-ANAT
+dysfunctions	O
+.	O
+
+Mean	O
+(	O
+SD	O
+)	O
+duration	O
+of	O
+PICU	B-SPEC
+stay	O
+was	O
+3	O
+.	O
+6	O
+(	O
+1	O
+.	O
+5	O
+)	O
+d	O
+with	O
+13	O
+.	O
+6	O
+%	O
+mortality	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+we	O
+identified	O
+a	O
+list	O
+of	O
+putative	O
+AMPs	O
+which	O
+binds	B-FUNC
+to	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+which	O
+may	O
+be	O
+crucial	O
+in	O
+providing	O
+the	O
+inhibitory	O
+action	O
+.	O
+
+Together	O
+,	O
+these	O
+results	O
+suggest	O
+that	O
+the	O
+relative	O
+timing	O
+of	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+response	O
+and	O
+maximal	O
+virus	B-PROC
+replication	I-PROC
+is	O
+key	O
+in	O
+determining	O
+outcomes	O
+,	O
+at	O
+least	O
+in	O
+infected	O
+mice	B-SPEC
+.	O
+
+Thus	O
+,	O
+virus	B-SPEC
+-	O
+host	B-COMP
+-	O
+interactions	O
+at	O
+the	O
+entry	O
+stage	O
+may	O
+not	O
+limit	O
+spread	O
+of	O
+North	O
+-	O
+and	O
+West	O
+-	O
+African	O
+MERS	O
+-	O
+CoV	O
+in	O
+human	B-SPEC
+cells	B-COMP
+.	O
+
+A	O
+total	O
+of	O
+86	O
+cases	O
+of	O
+SAP	B-PRGE
+complicated	O
+with	O
+ARDS	B-DISO
+were	O
+randomly	O
+divided	O
+into	O
+group	O
+A	O
+and	O
+group	B-DISO
+B	I-DISO
+,	O
+with	O
+43	O
+cases	O
+in	O
+each	O
+group	O
+.	O
+
+Compared	O
+with	O
+continuous	O
+hemofiltration	O
+alone	O
+,	O
+treatment	O
+with	O
+continuous	O
+hemofiltration	O
+plus	O
+octreotide	B-CHED
+is	O
+higher	O
+in	O
+efficiency	O
+,	O
+but	O
+did	O
+not	O
+translate	O
+into	O
+improved	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+A	O
+systematic	O
+risk	O
+-	O
+based	O
+strategy	O
+to	O
+select	O
+personal	O
+protective	O
+equipment	O
+for	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Because	O
+guidance	O
+for	O
+this	O
+process	O
+is	O
+extremely	O
+limited	O
+,	O
+we	O
+proposed	O
+a	O
+systematic	O
+,	O
+risk	O
+-	O
+based	O
+approach	O
+to	O
+the	O
+selection	O
+and	O
+evaluation	O
+of	O
+PPE	B-CHED
+ensembles	O
+to	O
+protect	O
+HCP	B-DISO
+against	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+approach	O
+was	O
+demonstrated	O
+for	O
+the	O
+activity	O
+of	O
+intubation	O
+of	O
+a	O
+patient	O
+with	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+or	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+This	O
+area	O
+of	O
+tension	B-DISO
+includes	O
+other	O
+important	O
+questions	O
+regarding	O
+usefulness	O
+,	O
+quality	O
+,	O
+ethical	O
+compliance	O
+,	O
+scientific	O
+evidence	O
+,	O
+structural	O
+capacities	O
+and	O
+economy	O
+.	O
+
+TITLE	O
+:	O
+Using	O
+routine	O
+testing	O
+data	O
+to	O
+understand	O
+circulation	B-PROC
+patterns	O
+of	O
+influenza	B-PATH
+A	I-PATH
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+other	O
+respiratory	O
+viruses	B-SPEC
+in	O
+Victoria	B-SPEC
+,	O
+Australia	O
+.	O
+
+TITLE	O
+:	O
+Obstructive	B-DISO
+sleep	I-DISO
+apnoea	I-DISO
+in	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+breath	B-ANAT
+analysis	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+diagnostics	O
+using	O
+a	O
+portable	O
+two	O
+-	O
+dimensional	O
+gas	O
+chromatography	O
+device	O
+.	O
+
+Therefore	O
+,	O
+there	O
+is	O
+a	O
+significant	O
+need	O
+for	O
+early	O
+,	O
+rapid	O
+detection	O
+and	O
+diagnosis	O
+as	O
+well	O
+as	O
+clinical	O
+trajectory	O
+monitoring	O
+of	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+becomes	O
+available	O
+utilization	O
+for	O
+pediatric	O
+critically	B-DISO
+ill	I-DISO
+,	O
+but	O
+the	O
+impact	O
+of	O
+mortality	O
+rate	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+remains	O
+no	O
+consistent	O
+conclusion	O
+.	O
+
+Four	O
+PICUs	B-SPEC
+of	O
+tertiary	O
+university	O
+children	O
+'	O
+s	O
+hospital	O
+in	O
+China	O
+.	O
+
+The	O
+consecutive	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+admitted	O
+to	O
+study	O
+PICUs	B-SPEC
+were	O
+enrolled	O
+from	O
+July	O
+2016	O
+to	O
+June	O
+2018	O
+.	O
+
+Continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+with	O
+an	O
+ultrafiltration	O
+rate	O
+of	O
+50	O
+mL	O
+/	O
+kg	O
+/	O
+hr	O
+decreases	O
+hospital	O
+mortality	O
+rate	O
+in	O
+pediatric	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+especially	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Complications	O
+of	O
+AIV	O
+infection	B-DISO
+,	O
+such	O
+as	O
+bacterial	B-DISO
+pneumonia	I-DISO
+are	O
+treatable	O
+,	O
+but	O
+other	O
+severe	O
+complications	O
+such	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+leading	O
+to	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+DAD	O
+)	O
+are	O
+limited	O
+to	O
+supportive	O
+therapy	O
+and	O
+self	O
+-	O
+resolution	O
+.	O
+
+Regardless	O
+of	O
+a	O
+poor	O
+prognosis	O
+,	O
+the	O
+clinical	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+are	O
+congruent	O
+with	O
+imaging	O
+and	O
+attest	O
+to	O
+the	O
+importance	O
+of	O
+vaccination	O
+,	O
+which	O
+protect	O
+against	O
+high	O
+mortality	O
+rates	O
+.	O
+
+Virus	B-SPEC
+propagation	O
+in	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+(	O
+ECEs	O
+),	O
+after	O
+three	O
+successive	O
+passages	O
+,	O
+revealed	O
+typical	O
+IBV	B-SPEC
+lesions	O
+such	O
+as	O
+curling	O
+and	O
+dwarfism	B-DISO
+.	O
+
+The	O
+reported	O
+isolate	O
+was	O
+identified	O
+by	O
+a	O
+real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+PCR	O
+assay	O
+targeting	B-PROC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+gene	O
+and	O
+,	O
+further	O
+characterized	O
+by	O
+full	O
+-	O
+length	O
+spike	O
+(	O
+S1	O
+)	O
+gene	O
+sequencing	O
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+clustering	O
+of	O
+the	O
+isolated	O
+virus	B-SPEC
+within	O
+4	O
+/	O
+91	O
+genotype	O
+of	O
+GI	O
+-	O
+13	O
+lineage	O
+.	O
+
+The	O
+latter	O
+is	O
+a	O
+rare	O
+subtype	O
+of	O
+acute	B-PATH
+myeloid	I-PATH
+leukemia	I-PATH
+and	O
+represents	O
+a	O
+hematological	O
+emergency	B-DISO
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+polymorphisms	B-PROC
+in	O
+inflammatory	O
+mediator	O
+and	O
+cellular	B-PROC
+adhesion	B-DISO
+genes	O
+as	O
+risk	O
+factors	O
+for	O
+feline	O
+infectious	O
+peritonitis	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+high	O
+mortality	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+We	O
+successfully	O
+generated	O
+recombinant	O
+virus	B-SPEC
+(	O
+rC3663	O
+)	O
+from	O
+Fcwf	O
+-	O
+4	O
+cells	B-COMP
+transfected	O
+with	O
+infectious	B-DISO
+cDNA	O
+that	O
+showed	O
+growth	B-PROC
+kinetics	O
+similar	O
+to	O
+those	O
+shown	O
+by	O
+the	O
+parental	O
+virus	B-SPEC
+.	O
+
+Next	O
+,	O
+we	O
+constructed	O
+a	O
+reporter	O
+C3663	O
+virus	B-SPEC
+carrying	O
+the	O
+nanoluciferase	O
+(	O
+Nluc	O
+)	O
+gene	O
+to	O
+measure	O
+viral	B-PROC
+replication	I-PROC
+with	O
+high	O
+sensitivity	O
+.	O
+
+Thus	O
+,	O
+our	O
+reporter	O
+virus	B-SPEC
+is	O
+useful	O
+for	O
+uncovering	O
+the	O
+infectivity	O
+of	O
+type	O
+I	O
+FCoV	O
+in	O
+different	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+including	O
+canine	O
+-	O
+derived	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+strain	O
+of	O
+porcine	O
+epidemic	O
+diarrhoea	O
+virus	O
+(	O
+PEDV	B-SPEC
+),	O
+namely	O
+HLJBY	O
+,	O
+was	O
+isolated	O
+in	O
+Heilongjiang	O
+province	O
+,	O
+China	O
+.	O
+
+To	O
+provide	O
+insight	O
+into	O
+the	O
+understanding	O
+of	O
+the	O
+phylogenetic	O
+and	O
+the	O
+current	O
+epidemiological	O
+status	O
+of	O
+PEDV	B-SPEC
+,	O
+PEDV	B-SPEC
+HLJBY	O
+was	O
+compared	O
+with	O
+CV777	O
+and	O
+other	O
+PEDV	B-SPEC
+strains	O
+deposited	O
+in	O
+the	O
+GenBank	O
+.	O
+
+The	O
+highest	O
+nucleotide	B-CHED
+identity	O
+was	O
+99	O
+.	O
+9	O
+%	O
+compared	O
+with	O
+PEDV	B-SPEC
+-	O
+SX	O
+/	O
+China	O
+/	O
+2017	O
+strain	O
+,	O
+and	O
+the	O
+lowest	O
+nucleotide	O
+identity	O
+was	O
+60	O
+.	O
+0	O
+%	O
+compared	O
+with	O
+PEDV	B-SPEC
+/	O
+Belgorod	O
+/	O
+dom	O
+/	O
+2008	O
+strain	O
+.	O
+
+The	O
+length	O
+of	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+S	O
+proteins	B-CHED
+varied	O
+from	O
+1	O
+,	O
+372	O
+to	O
+1	O
+,	O
+390	O
+amino	B-CHED
+acids	I-CHED
+(	O
+aa	O
+).	O
+
+Previous	O
+studies	O
+have	O
+revealed	O
+that	O
+the	O
+coronaviruses	O
+develop	O
+various	O
+strategies	O
+to	O
+evade	O
+the	O
+host	B-COMP
+innate	B-PROC
+immunity	I-PROC
+through	O
+the	O
+inhibition	B-PROC
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+)	O
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+dual	O
+luciferase	B-ENZY
+reporter	O
+assay	O
+was	O
+used	O
+to	O
+confirm	O
+the	O
+inhibition	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+by	O
+TGEV	B-SPEC
+infection	B-DISO
+and	O
+to	O
+identify	O
+the	O
+major	O
+viral	O
+proteins	B-CHED
+involved	O
+in	O
+the	O
+inhibition	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+.	O
+
+Real	O
+-	O
+time	O
+quantitative	O
+PCR	O
+was	O
+used	O
+to	O
+quantify	O
+the	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+inflammatory	O
+factors	O
+.	O
+
+In	O
+ST	O
+and	O
+IPEC	O
+-	O
+J2	O
+cells	O
+,	O
+TGEV	B-SPEC
+exhibited	O
+a	O
+dose	O
+-	O
+dependent	O
+inhibition	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+activity	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+ST	O
+and	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+,	O
+TGEV	B-SPEC
+exhibited	O
+a	O
+dose	O
+-	O
+dependent	O
+inhibition	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+activity	O
+.	O
+
+CONCLUSIONS	O
+:	O
+TGEV	B-SPEC
+infection	B-DISO
+can	O
+inhibit	O
+the	O
+activation	O
+of	O
+the	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathway	I-PROC
+,	O
+which	O
+is	O
+mainly	O
+mediated	O
+by	O
+Nsp3	B-PRGE
+through	O
+the	O
+canonical	O
+pathway	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+the	O
+causative	O
+agent	O
+of	O
+PED	O
+,	O
+is	O
+an	O
+enveloped	O
+,	O
+positive	O
+-	O
+stranded	O
+RNA	O
+virus	B-SPEC
+in	O
+the	O
+genus	B-SPEC
+Alphacoronavirus	B-SPEC
+,	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+,	O
+order	B-SPEC
+Nidovirales	I-SPEC
+.	O
+
+Our	O
+previous	O
+study	O
+showed	O
+that	O
+PEDV	B-PRGE
+ORF3	I-PRGE
+has	O
+expression	B-PROC
+characteristic	O
+of	O
+aggregation	O
+in	O
+cytoplasm	B-COMP
+,	O
+but	O
+its	O
+biological	B-PROC
+function	I-PROC
+remains	O
+elusive	O
+.	O
+
+Thus	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+plays	O
+a	O
+crucial	O
+role	O
+in	O
+curtailing	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+infection	O
+and	O
+may	O
+serve	O
+as	O
+an	O
+effective	O
+prophylactic	O
+and	O
+/	O
+or	O
+therapeutic	O
+agent	O
+against	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Ultra	O
+-	O
+Protective	O
+Ventilation	O
+Reduces	O
+Biotrauma	O
+in	O
+Patients	O
+on	O
+Venovenous	O
+Extracorporeal	O
+Membrane	B-ANAT
+Oxygenation	B-PROC
+for	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Ventilator	O
+settings	O
+for	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+supported	O
+by	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+are	O
+currently	O
+set	O
+arbitrarily	O
+.	O
+
+After	O
+starting	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+patients	O
+were	O
+switched	O
+to	O
+the	O
+bi	O
+-	O
+level	O
+positive	O
+airway	B-ANAT
+pressure	O
+mode	O
+with	O
+1	O
+second	O
+of	O
+24	O
+cm	O
+H2O	B-CHED
+high	O
+pressure	O
+and	O
+2	O
+seconds	O
+of	O
+12	O
+cm	O
+H2O	B-CHED
+low	O
+pressure	O
+for	O
+24	O
+hours	O
+.	O
+
+Plasma	B-ANAT
+sRAGE	O
+and	O
+cytokines	O
+were	O
+comparable	O
+within	O
+each	O
+on	O
+-	O
+ECMO	O
+experimental	O
+step	O
+,	O
+but	O
+the	O
+lowest	O
+bronchoalveolar	O
+lavage	O
+sRAGE	O
+levels	O
+were	O
+obtained	O
+at	O
+minimal	O
+driving	O
+pressure	O
+.	O
+
+TITLE	O
+:	O
+Time	O
+-	O
+course	O
+of	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+viral	B-DISO
+infection	I-DISO
+and	O
+COPD	B-DISO
+exacerbation	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+respiratory	O
+tract	O
+infections	O
+have	O
+been	O
+implicated	O
+as	O
+the	O
+predominant	O
+risk	O
+factor	O
+for	O
+acute	O
+exacerbations	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+AECOPD	O
+).	O
+
+Swabs	O
+were	O
+taken	O
+during	O
+stable	O
+periods	B-PROC
+(	O
+n	O
+=	O
+1909	O
+),	O
+at	O
+URTI	B-DISO
+onset	O
+(	O
+n	O
+=	O
+391	O
+),	O
+10	O
+days	O
+after	O
+the	O
+URTI	B-DISO
+(	O
+n	O
+=	O
+356	O
+)	O
+and	O
+during	O
+an	O
+AECOPD	O
+(	O
+n	O
+=	O
+177	O
+)	O
+and	O
+tested	O
+using	O
+a	O
+multiplex	O
+nucleic	B-CHED
+acid	I-CHED
+amplification	B-DISO
+test	O
+.	O
+
+Evidence	O
+of	O
+at	O
+least	O
+one	O
+respiratory	O
+virus	B-SPEC
+was	O
+significantly	O
+higher	O
+at	O
+URTI	B-DISO
+onset	O
+(	O
+52	O
+.	O
+7	O
+%),	O
+10	O
+days	O
+after	O
+the	O
+URTI	B-DISO
+(	O
+15	O
+.	O
+2	O
+%)	O
+and	O
+during	O
+an	O
+AECOPD	O
+(	O
+38	O
+.	O
+4	O
+%),	O
+compared	O
+with	O
+the	O
+stable	O
+period	O
+(	O
+5	O
+.	O
+3	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+During	O
+stable	O
+visits	O
+,	O
+rhinovirus	O
+accounted	O
+for	O
+54	O
+.	O
+2	O
+%	O
+of	O
+all	O
+viral	B-DISO
+infections	I-DISO
+,	O
+followed	O
+by	O
+coronavirus	B-SPEC
+(	O
+20	O
+.	O
+5	O
+%).	O
+
+Patients	O
+with	O
+a	O
+viral	B-DISO
+infection	I-DISO
+at	O
+URTI	B-DISO
+onset	O
+did	O
+not	O
+have	O
+a	O
+higher	O
+incidence	O
+of	O
+exacerbation	O
+than	O
+patients	O
+without	O
+viral	B-DISO
+infection	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+993	O
+).	O
+
+Detection	O
+of	O
+parainfluenza	B-DISO
+3	O
+at	O
+URTI	B-DISO
+onset	O
+was	O
+associated	O
+with	O
+a	O
+higher	O
+risk	O
+of	O
+an	O
+AECOPD	O
+(	O
+p	O
+=	O
+0	O
+.	O
+003	O
+).	O
+
+A	O
+total	O
+of	O
+seven	O
+studies	O
+comprising	O
+8010	O
+patients	O
+were	O
+included	O
+in	O
+this	O
+meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+severe	O
+manifestation	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+in	O
+human	B-SPEC
+lung	B-ANAT
+are	O
+induced	O
+by	O
+inflammatory	O
+cytokines	O
+and	O
+endogenous	O
+factors	O
+such	O
+as	O
+miRNAs	O
+.	O
+
+Meanwhile	O
+,	O
+miR	O
+-	O
+150	O
+improved	O
+the	O
+72	O
+h	O
+survival	O
+rate	O
+of	O
+LPS	B-DISO
+-	O
+induced	O
+ALI	O
+mice	B-SPEC
+.	O
+
+Further	O
+,	O
+AKT3	B-PRGE
+was	O
+a	O
+direct	O
+target	O
+of	O
+miR	O
+-	O
+150	O
+.	O
+
+In	O
+addition	O
+,	O
+miR	O
+-	O
+150	O
+or	O
+si	O
+-	O
+AKT3	B-PRGE
+effectively	O
+inhibited	O
+the	O
+phosphorylation	B-PROC
+levels	O
+of	O
+c	B-PRGE
+-	I-PRGE
+Jun	I-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+kinase	I-PRGE
+(	O
+JNK	B-FUNC
+)	O
+and	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+κB	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+)	O
+(	O
+p65	B-PRGE
+and	O
+IκBα	O
+).	O
+
+In	O
+the	O
+control	O
+group	O
+,	O
+patients	O
+received	O
+a	O
+tidal	O
+volume	O
+of	O
+6	O
+mL	O
+/	O
+kg	O
+per	O
+predicted	O
+bodyweight	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+was	O
+selected	O
+according	O
+to	O
+a	O
+low	O
+PEEP	B-CHED
+and	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+table	O
+,	O
+and	O
+early	O
+prone	O
+position	O
+was	O
+encouraged	O
+.	O
+
+In	O
+the	O
+personalised	O
+group	O
+,	O
+the	O
+treatment	O
+approach	O
+was	O
+based	O
+on	O
+lung	B-ANAT
+morphology	O
+;	O
+patients	O
+with	O
+focal	O
+ARDS	B-DISO
+received	O
+a	O
+tidal	O
+volume	O
+of	O
+8	O
+mL	O
+/	O
+kg	O
+,	O
+low	O
+PEEP	B-CHED
+,	O
+and	O
+prone	O
+position	O
+.	O
+
+Personalisation	O
+of	O
+mechanical	O
+ventilation	O
+did	O
+not	O
+decrease	O
+mortality	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+possibly	O
+because	O
+of	O
+the	O
+misclassification	O
+of	O
+21	O
+%	O
+of	O
+patients	O
+.	O
+
+The	O
+results	O
+revealed	O
+that	O
+HY	O
+had	O
+a	O
+good	O
+anti	O
+-	O
+IBV	B-SPEC
+effect	O
+when	O
+HY	O
+directly	O
+treated	O
+the	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+,	O
+and	O
+virus	B-SPEC
+infectivity	O
+decreased	O
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+TITLE	O
+:	O
+Unfolded	O
+Protein	B-CHED
+Response	O
+supports	O
+endothelial	B-ANAT
+barrier	O
+function	O
+.	O
+
+ABSTRACT	O
+:	O
+Ongoing	O
+efforts	O
+are	O
+oriented	O
+towards	O
+the	O
+development	O
+of	O
+novel	O
+therapeutic	O
+agents	O
+to	O
+repress	O
+lung	B-ANAT
+hyperpermeability	O
+responses	O
+due	O
+to	O
+inflammation	B-DISO
+.	O
+
+The	O
+role	O
+of	O
+extracorporeal	O
+life	O
+support	O
+in	O
+the	O
+management	O
+of	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+is	O
+being	O
+redefined	O
+by	O
+advances	O
+in	O
+technology	O
+and	O
+increasing	O
+evidence	O
+of	O
+its	O
+effectiveness	O
+.	O
+
+We	O
+used	O
+a	O
+prospective	O
+nationwide	O
+cohort	O
+targeting	B-PROC
+consecutive	O
+adult	O
+severe	B-DISO
+sepsis	I-DISO
+patients	O
+in	O
+59	O
+intensive	O
+care	O
+units	O
+in	O
+Japan	O
+to	O
+assess	O
+associations	O
+between	O
+anticoagulant	B-CHED
+therapy	O
+and	O
+in	O
+-	O
+hospital	O
+mortality	O
+according	O
+to	O
+DIC	B-DISO
+(	O
+International	O
+Society	O
+on	O
+Thrombosis	B-DISO
+and	O
+Haemostasis	B-PROC
+[	O
+ISTH	O
+]	O
+overt	O
+and	O
+Japanese	O
+Association	O
+for	O
+Acute	O
+Medicine	B-CHED
+DIC	B-DISO
+scores	O
+)	O
+and	O
+disease	O
+severity	O
+(	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+[	O
+APACHE	O
+II	O
+]	O
+and	O
+Sequential	O
+Organ	O
+Failure	O
+Assessment	O
+scores	O
+).	O
+
+Multivariable	O
+Cox	O
+proportional	O
+hazard	O
+regression	O
+analysis	O
+with	O
+nonlinear	O
+restricted	O
+cubic	O
+spline	O
+including	O
+a	O
+two	O
+-	O
+way	O
+interaction	O
+term	O
+(	O
+treatment	O
+×	O
+each	O
+score	O
+)	O
+and	O
+three	O
+-	O
+way	O
+interaction	O
+term	O
+(	O
+treatment	O
+×	O
+ISTH	O
+overt	O
+DIC	B-DISO
+score	O
+×	O
+APACHE	O
+II	O
+score	O
+)	O
+was	O
+performed	O
+.	O
+
+The	O
+regression	O
+model	O
+including	O
+the	O
+two	O
+-	O
+way	O
+interaction	O
+term	O
+showed	O
+significant	O
+interaction	O
+between	O
+intervention	O
+and	O
+disease	O
+severity	O
+as	O
+indicated	O
+by	O
+the	O
+ISTH	O
+overt	O
+DIC	B-DISO
+score	O
+and	O
+APACHE	O
+II	O
+score	O
+(	O
+CONCLUSIONS	O
+:	O
+Anticoagulant	B-CHED
+therapy	O
+was	O
+associated	O
+with	O
+better	O
+outcome	O
+according	O
+to	O
+the	O
+deterioration	O
+of	O
+both	O
+DIC	B-DISO
+and	O
+disease	O
+severity	O
+,	O
+suggesting	O
+that	O
+anticoagulant	B-CHED
+therapy	O
+should	O
+be	O
+restricted	O
+to	O
+patients	O
+having	O
+DIC	B-DISO
+and	O
+high	O
+disease	O
+severity	O
+simultaneously	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+left	O
+ventricular	O
+(	O
+LV	O
+)	O
+systolic	O
+failure	O
+as	O
+a	O
+consequence	O
+of	O
+acute	O
+severe	O
+brain	B-ANAT
+injury	O
+with	O
+status	B-DISO
+epilepticus	I-DISO
+in	O
+a	O
+young	O
+infant	O
+is	O
+not	O
+common	O
+;	O
+managing	O
+such	O
+a	O
+patient	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+),	O
+which	O
+requires	O
+proper	O
+anticoagulation	B-PROC
+adds	O
+further	O
+substrate	O
+to	O
+a	O
+particularly	O
+intriguing	O
+and	O
+novel	O
+case	O
+worthy	O
+of	O
+reporting	O
+.	O
+
+The	O
+average	O
+duration	O
+of	O
+infection	B-DISO
+is	O
+8	O
+days	O
+and	O
+up	O
+to	O
+2	O
+weeks	O
+;	O
+if	O
+the	O
+child	O
+presents	O
+with	O
+3	O
+episodes	O
+of	O
+acute	O
+infections	O
+over	O
+a	O
+period	O
+of	O
+6	O
+months	O
+,	O
+the	O
+respiratory	B-DISO
+infections	I-DISO
+are	O
+then	O
+considered	O
+recurrent	O
+.	O
+
+ABSTRACT	O
+:	O
+Immune	B-DISO
+thrombocytopenic	I-DISO
+purpura	I-DISO
+(	O
+ITP	B-DISO
+)	O
+is	O
+an	O
+autoimmune	B-DISO
+disorder	I-DISO
+that	O
+causes	O
+isolated	O
+thrombocytopenia	O
+.	O
+
+Several	O
+non	O
+-	O
+feline	B-SPEC
+coronaviruses	O
+have	O
+been	O
+reported	O
+to	O
+infect	O
+feline	B-SPEC
+cells	B-COMP
+as	O
+well	O
+as	O
+cats	B-SPEC
+after	O
+experimental	O
+infection	B-DISO
+,	O
+supported	O
+by	O
+their	O
+ability	O
+to	O
+engage	O
+the	O
+feline	B-SPEC
+receptor	O
+ortholog	O
+for	O
+cell	B-COMP
+entry	O
+.	O
+
+To	O
+conclude	O
+,	O
+we	O
+provide	O
+the	O
+first	O
+evidence	O
+of	O
+antigenic	O
+cross	O
+-	O
+reactivity	O
+among	O
+S1	O
+proteins	B-CHED
+of	O
+coronaviruses	O
+,	O
+which	O
+should	O
+be	O
+considered	O
+in	O
+the	O
+development	B-PROC
+of	O
+serological	O
+diagnoses	O
+.	O
+
+To	O
+further	O
+elucidate	O
+specific	O
+interactions	O
+between	O
+human	B-SPEC
+respiratory	O
+viruses	B-SPEC
+and	O
+important	O
+host	B-COMP
+factors	O
+in	O
+the	O
+airway	B-ANAT
+epithelium	B-ANAT
+,	O
+it	O
+is	O
+important	O
+to	O
+make	O
+hAEC	O
+cultures	O
+amenable	O
+to	O
+genetic	O
+modification	O
+.	O
+
+Moreover	O
+,	O
+the	O
+propagation	O
+kinetics	O
+of	O
+both	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+and	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+hRSV	B-SPEC
+)	O
+were	O
+not	O
+affected	O
+.	O
+
+Studies	O
+have	O
+shown	O
+that	O
+hand	O
+washing	O
+with	O
+PVP	B-CHED
+-	O
+I	O
+-	O
+based	O
+antiseptics	O
+is	O
+effective	O
+for	O
+the	O
+decontamination	O
+of	O
+skin	B-ANAT
+,	O
+while	O
+PVP	B-CHED
+-	O
+I	O
+mouthwashes	O
+and	O
+gargles	O
+significantly	O
+reduce	O
+viral	O
+load	O
+in	O
+the	O
+oral	B-ANAT
+cavity	I-ANAT
+and	O
+the	O
+oropharynx	O
+.	O
+
+The	O
+importance	O
+of	O
+PVP	B-CHED
+-	O
+I	O
+has	O
+been	O
+emphasised	O
+by	O
+its	O
+inclusion	O
+in	O
+the	O
+World	O
+Health	O
+Organization	O
+'	O
+s	O
+list	O
+of	O
+essential	O
+medicines	O
+,	O
+and	O
+high	O
+potency	O
+for	O
+virucidal	O
+activity	O
+has	O
+been	O
+observed	O
+against	O
+viruses	B-SPEC
+of	O
+significant	O
+global	O
+concern	O
+,	O
+including	O
+hepatitis	B-DISO
+A	I-DISO
+and	O
+influenza	B-DISO
+,	O
+as	O
+well	O
+as	O
+the	O
+Middle	O
+-	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+and	O
+Sudden	O
+Acute	O
+Respiratory	O
+Syndrome	B-DISO
+coronaviruses	O
+.	O
+
+Forty	O
+-	O
+seven	O
+adults	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+requiring	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Patients	O
+with	O
+potential	O
+for	O
+lung	B-ANAT
+recruitment	B-DISO
+above	O
+the	O
+median	O
+had	O
+significantly	O
+shorter	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+duration	O
+(	O
+8	O
+vs	O
+13	O
+d	O
+;	O
+p	O
+=	O
+0	O
+.	O
+013	O
+)	O
+and	O
+shorter	O
+ICU	O
+stay	O
+(	O
+15	O
+vs	O
+22	O
+d	O
+;	O
+p	O
+=	O
+0	O
+.	O
+028	O
+),	O
+but	O
+mortality	O
+was	O
+not	O
+statistically	O
+different	O
+(	O
+24	O
+%	O
+vs	O
+46	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+159	O
+).	O
+
+The	O
+availability	O
+of	O
+the	O
+SeACoV	O
+infectious	B-DISO
+clone	O
+and	O
+a	O
+panel	O
+of	O
+antibodies	B-COMP
+against	O
+different	O
+viral	O
+proteins	B-CHED
+will	O
+facilitate	O
+further	O
+studies	O
+on	O
+understanding	O
+the	O
+molecular	O
+mechanisms	O
+of	O
+SeACoV	O
+replication	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+Autonomic	B-ANAT
+nerve	I-ANAT
+dysfunctions	O
+,	O
+such	O
+as	O
+blood	B-PROC
+pressure	I-PROC
+fluctuations	B-DISO
+and	O
+arrhythmia	B-DISO
+could	O
+be	O
+caused	O
+in	O
+GBS	B-DISO
+,	O
+of	O
+which	O
+about	O
+3	O
+%-	O
+10	O
+%	O
+of	O
+GBS	B-DISO
+patients	O
+would	O
+die	O
+.	O
+
+The	O
+key	O
+measures	O
+taken	O
+on	O
+lung	B-ANAT
+recruitment	B-DISO
+was	O
+postural	O
+drainage	B-ANAT
+on	O
+this	O
+case	O
+with	O
+a	O
+low	O
+cost	O
+but	O
+a	O
+qualified	O
+effectiveness	O
+.	O
+
+Average	O
+95th	O
+percentile	O
+pressure	O
+was	O
+low	O
+(	O
+9	O
+.	O
+3	O
+±	O
+1	O
+.	O
+7	O
+cmH	B-DISO
+CONCLUSIONS	O
+:	O
+Adherence	O
+to	O
+CPAP	O
+after	O
+acute	O
+,	O
+traumatic	O
+tetraplegia	B-DISO
+is	O
+low	O
+.	O
+
+We	O
+describe	O
+a	O
+collaborative	O
+study	O
+to	O
+investigate	O
+the	O
+comparability	O
+of	O
+serologic	O
+assays	O
+for	O
+MERS	O
+-	O
+CoV	O
+and	O
+assess	O
+any	O
+benefit	O
+associated	O
+with	O
+the	O
+introduction	O
+of	O
+a	O
+standard	O
+reference	O
+reagent	B-CHED
+for	O
+MERS	O
+-	O
+CoV	O
+serology	O
+.	O
+
+We	O
+found	O
+that	O
+a	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+S1	I-PRGE
+protein	I-PRGE
+-	O
+based	O
+ELISA	O
+,	O
+routinely	O
+used	O
+in	O
+surveillance	O
+studies	O
+,	O
+showed	O
+low	O
+sensitivity	O
+in	O
+detecting	O
+infections	B-DISO
+among	O
+PCR	O
+-	O
+confirmed	O
+patients	O
+with	O
+mild	O
+clinical	O
+symptoms	O
+and	O
+cross	O
+-	O
+reactivity	O
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+-	O
+positive	O
+serum	B-COMP
+samples	O
+.	O
+
+Using	O
+in	O
+-	O
+house	O
+S1	O
+ELISA	O
+and	O
+protein	B-CHED
+microarray	O
+,	O
+we	O
+demonstrate	O
+that	O
+most	O
+PCR	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+case	O
+-	O
+patients	O
+with	O
+mild	O
+infections	B-DISO
+seroconverted	O
+;	O
+nonetheless	O
+,	O
+some	O
+of	O
+these	O
+samples	O
+did	O
+not	O
+have	O
+detectable	O
+levels	O
+of	O
+virus	B-SPEC
+-	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+Recent	O
+Advances	O
+in	O
+the	O
+Vaccine	O
+Development	B-PROC
+Against	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+Coronavirus	B-SPEC
+.	O
+
+It	O
+continues	O
+to	O
+be	O
+one	O
+of	O
+the	O
+most	O
+important	O
+preventable	O
+causes	O
+of	O
+blindness	B-DISO
+in	O
+children	O
+.	O
+
+However	O
+,	O
+when	O
+a	O
+multivariate	O
+analysis	O
+was	O
+performed	O
+,	O
+only	O
+low	O
+gestational	O
+age	O
+,	O
+total	O
+days	O
+on	O
+oxygen	B-CHED
+supplement	O
+and	O
+high	O
+bilirubin	B-CHED
+levels	O
+were	O
+significant	O
+regarding	O
+the	O
+development	B-PROC
+of	O
+ROP	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+a	O
+pathogenic	O
+avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+QX	O
+-	O
+type	O
+strain	O
+YN	O
+was	O
+successfully	O
+rescued	O
+by	O
+vaccinia	B-SPEC
+virus	I-SPEC
+based	O
+reverse	O
+genetic	O
+technology	O
+.	O
+
+This	O
+strategy	O
+was	O
+chosen	O
+to	O
+facilitate	O
+the	O
+rescue	O
+procedure	O
+and	O
+to	O
+ensure	O
+that	O
+the	O
+recombinant	O
+rYN	O
+virus	B-SPEC
+will	O
+not	O
+require	O
+any	O
+cell	B-COMP
+culture	O
+adaptations	B-PROC
+.	O
+
+All	O
+patients	O
+with	O
+serology	O
+proven	O
+dengue	B-DISO
+fever	I-DISO
+admitted	O
+to	O
+MICU	O
+between	O
+1st	O
+July	O
+2015	O
+and1st	O
+December	O
+2015	O
+were	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+Survival	O
+to	O
+hospital	O
+discharge	B-ANAT
+was	O
+78	O
+.	O
+9	O
+%.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+and	O
+shock	O
+were	O
+the	O
+clinical	O
+syndromes	B-DISO
+associated	O
+with	O
+mortality	O
+.	O
+
+We	O
+present	O
+an	O
+unusual	O
+case	O
+of	O
+left	B-ANAT
+upper	I-ANAT
+limb	I-ANAT
+acute	O
+arterial	B-DISO
+thrombosis	I-DISO
+with	O
+purpura	B-DISO
+fulminans	I-DISO
+like	O
+skin	B-ANAT
+lesions	O
+precipitated	O
+by	O
+swine	B-DISO
+flu	I-DISO
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+with	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+subsequently	O
+developing	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+retinal	B-CHED
+infarcts	B-DISO
+,	O
+multiple	O
+acute	O
+cerebral	B-DISO
+infarcts	I-DISO
+,	O
+cardiac	B-ANAT
+valvular	O
+vegetations	B-DISO
+and	O
+hemolytic	B-DISO
+anemia	I-DISO
+with	O
+recurrent	O
+bleeding	B-DISO
+episodes	O
+.	O
+
+ABSTRACT	O
+:	O
+Paraquat	B-CHED
+(	O
+1	O
+,	O
+1	O
+'-	O
+dimethyl	B-CHED
+-	O
+4	O
+,	O
+4	O
+'-	O
+dipyridylium	O
+)	O
+is	O
+a	O
+broad	O
+-	O
+spectrum	O
+liquid	O
+herbicide	B-CHED
+associated	O
+with	O
+both	O
+accidental	O
+and	O
+intentional	O
+ingestion	O
+leading	O
+to	O
+severe	O
+and	O
+often	O
+fatal	O
+toxicity	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+report	O
+:	O
+Detection	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+corona	B-CHED
+virus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+of	O
+a	O
+dead	B-PROC
+human	B-SPEC
+.	O
+
+Detection	O
+of	O
+C	O
+.	O
+psittaci	O
+was	O
+achieved	O
+using	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+testing	O
+of	O
+swabs	O
+of	O
+nasal	B-ANAT
+secretions	B-ANAT
+(	O
+4	O
+/	O
+6	O
+)	O
+and	O
+rectal	B-ANAT
+mucosa	I-ANAT
+(	O
+5	O
+/	O
+7	O
+)	O
+from	O
+live	O
+foals	O
+,	O
+lung	B-ANAT
+tissues	I-ANAT
+of	O
+foals	O
+at	O
+necropsy	O
+(	O
+11	O
+/	O
+14	O
+)	O
+and	O
+foetal	O
+membranes	B-ANAT
+(	O
+4	O
+/	O
+5	O
+).	O
+
+It	O
+was	O
+also	O
+deduced	O
+that	O
+some	O
+flavonoid	B-CHED
+derivatives	O
+with	O
+hydrophobic	O
+or	O
+carbohydrate	B-CHED
+attached	O
+to	O
+their	O
+core	O
+structures	O
+have	O
+a	O
+good	O
+inhibitory	O
+effect	O
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+and	O
+Characterization	O
+of	O
+Novel	O
+RNA	O
+Viruses	B-SPEC
+in	O
+Aquatic	O
+North	O
+American	O
+Wild	O
+Birds	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Wild	O
+birds	O
+are	O
+recognized	O
+viral	O
+reservoirs	O
+but	O
+our	O
+understanding	O
+about	O
+avian	B-SPEC
+viral	O
+diversity	O
+is	O
+limited	O
+.	O
+
+We	O
+describe	O
+here	O
+three	O
+novel	O
+RNA	O
+viruses	B-SPEC
+that	O
+we	O
+identified	O
+in	O
+oropharyngeal	B-ANAT
+/	O
+cloacal	B-ANAT
+swabs	O
+collected	O
+from	O
+wild	O
+birds	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Simple	O
+phenomenological	O
+growth	B-PROC
+models	O
+can	O
+be	O
+useful	O
+for	O
+estimating	O
+transmission	O
+parameters	O
+and	O
+forecasting	O
+epidemic	O
+trajectories	O
+.	O
+
+Furthermore	O
+,	O
+our	O
+findings	O
+support	O
+the	O
+view	O
+that	O
+the	O
+national	O
+incidence	O
+curve	O
+of	O
+the	O
+Ebola	O
+epidemic	O
+in	O
+DRC	B-PRGE
+follows	O
+a	O
+stable	O
+incidence	O
+pattern	O
+with	O
+periodic	O
+behavior	O
+that	O
+can	O
+be	O
+decomposed	O
+into	O
+overlapping	O
+sub	O
+-	O
+epidemics	O
+.	O
+
+ABSTRACT	O
+:	O
+Sequence	O
+analyses	O
+of	O
+RNA	O
+virus	O
+genomes	O
+remain	O
+challenging	O
+owing	O
+to	O
+the	O
+exceptional	O
+genetic	O
+plasticity	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+Because	O
+of	O
+high	O
+mutation	O
+and	O
+recombination	B-PROC
+rates	O
+,	O
+genome	O
+replication	O
+by	O
+viral	O
+RNA	O
+-	O
+dependent	O
+RNA	B-PRGE
+polymerases	I-PRGE
+leads	O
+to	O
+populations	O
+of	O
+closely	O
+related	O
+viruses	B-SPEC
+,	O
+so	O
+-	O
+called	O
+""""	O
+quasispecies	O
+.	O
+
+Standard	O
+(	O
+short	O
+-	O
+read	O
+)	O
+sequencing	O
+technologies	O
+are	O
+ill	B-DISO
+-	O
+suited	O
+to	O
+reconstruct	O
+large	O
+numbers	O
+of	O
+full	O
+-	O
+length	O
+haplotypes	O
+of	O
+(	O
+1	O
+)	O
+RNA	O
+virus	B-SPEC
+genomes	O
+and	O
+(	O
+2	O
+)	O
+subgenome	O
+-	O
+length	O
+(	O
+sg	O
+)	O
+RNAs	O
+composed	O
+of	O
+noncontiguous	O
+genome	O
+regions	O
+.	O
+
+A	O
+literature	O
+search	O
+was	O
+conducted	O
+to	O
+identify	O
+studies	O
+related	O
+to	O
+nutrition	B-PROC
+support	O
+and	O
+macronutrient	B-CHED
+ratios	O
+in	O
+burn	O
+patients	O
+.	O
+
+During	O
+a	O
+weaning	B-PROC
+period	O
+on	O
+day	O
+7	O
+,	O
+she	O
+developed	O
+left	O
+tension	B-DISO
+pneumothorax	I-DISO
+requiring	O
+intercostal	O
+drainage	B-ANAT
+and	O
+a	O
+markedly	O
+large	O
+amount	O
+of	O
+pneumoperitoneum	B-DISO
+.	O
+
+A	O
+case	O
+of	O
+tension	B-DISO
+pneumoperitoneum	B-DISO
+probably	O
+caused	O
+by	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+was	O
+reported	O
+.	O
+
+CONCLUSIONS	O
+:	O
+A	O
+case	O
+of	O
+tension	B-DISO
+pneumoperitoneum	B-DISO
+probably	O
+caused	O
+by	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+was	O
+reported	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+the	O
+renal	B-ANAT
+status	O
+and	O
+fluid	B-PROC
+balance	I-PROC
+parameters	O
+between	O
+the	O
+non	O
+-	O
+survivors	O
+and	O
+survivors	O
+in	O
+the	O
+2013	O
+-	O
+2016	O
+cohort	O
+.	O
+
+We	O
+demonstrate	O
+that	O
+emerging	O
+and	O
+clinically	O
+relevant	O
+human	B-SPEC
+pathogens	O
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+Zika	B-SPEC
+virus	I-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+cytomegalovirus	B-SPEC
+replicate	O
+in	O
+vivo	O
+in	O
+these	O
+lung	B-ANAT
+implants	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Coronaviruses	O
+as	O
+the	O
+cause	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+].	O
+
+In	O
+current	O
+clinical	O
+practice	O
+SARS	B-DISO
+-	O
+CoV	O
+has	O
+no	O
+importance	O
+as	O
+it	O
+has	O
+not	O
+been	O
+detected	O
+in	O
+humans	B-SPEC
+for	O
+15	O
+years	O
+;	O
+however	O
+,	O
+a	O
+possible	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+should	O
+be	O
+taken	O
+into	O
+account	O
+in	O
+patients	O
+with	O
+typical	O
+symptoms	O
+and	O
+travel	O
+history	O
+to	O
+endemic	O
+regions	O
+.	O
+
+CONCLUSIONS	O
+:	O
+All	O
+six	O
+human	B-SPEC
+CoVs	O
+can	O
+be	O
+diagnosed	O
+using	O
+RT	O
+-	O
+PCR	O
+on	O
+respiratory	O
+specimens	O
+but	O
+this	O
+is	O
+rarely	O
+necessary	O
+for	O
+the	O
+four	O
+endemic	O
+strains	O
+.	O
+
+Cattle	B-SPEC
+production	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+economic	O
+sectors	O
+in	O
+Uruguay	O
+.	O
+
+The	O
+detection	O
+rate	O
+of	O
+BCoV	O
+in	O
+samples	O
+from	O
+deceased	B-PROC
+and	O
+live	O
+calves	O
+was	O
+10	O
+.	O
+0	O
+%	O
+(	O
+6	O
+/	O
+60	O
+)	O
+and	O
+7	O
+.	O
+6	O
+%	O
+(	O
+58	O
+/	O
+763	O
+),	O
+respectively	O
+.	O
+
+Because	O
+of	O
+their	O
+origin	O
+in	O
+the	O
+bat	B-ENZY
+enteric	O
+system	O
+,	O
+we	O
+wondered	O
+if	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+or	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+also	O
+use	O
+bacterial	O
+components	O
+to	O
+modulate	O
+infectivity	O
+.	O
+
+ARF	B-DISO
+as	O
+a	O
+consequence	O
+of	O
+neurological	O
+complications	O
+were	O
+observed	O
+in	O
+25	O
+(	O
+18	O
+.	O
+1	O
+%)	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+the	O
+year	O
+following	O
+the	O
+initiation	O
+of	O
+the	O
+mPATH	O
+team	O
+,	O
+we	O
+observed	O
+earlier	O
+time	O
+to	O
+occupational	O
+,	O
+physical	O
+,	O
+and	O
+speech	B-PROC
+therapist	O
+evaluation	O
+,	O
+decreased	O
+length	O
+of	O
+stay	O
+,	O
+and	O
+cost	O
+savings	O
+in	O
+severe	O
+traumatic	O
+brain	B-ANAT
+and	I-ANAT
+spinal	I-ANAT
+cord	I-ANAT
+injury	O
+patients	O
+requiring	O
+tracheostomy	O
+compared	O
+with	O
+our	O
+historical	O
+control	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+identify	O
+the	O
+mortality	O
+risk	O
+factors	O
+in	O
+the	O
+patients	O
+with	O
+severe	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+admitted	O
+to	O
+the	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+(	O
+PICU	B-SPEC
+).	O
+Seventy	O
+-	O
+seven	O
+pediatric	O
+patients	O
+with	O
+severe	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+who	O
+were	O
+admitted	O
+in	O
+the	O
+PICU	B-SPEC
+at	O
+Guangzhou	O
+Women	O
+and	O
+Children	O
+'	O
+s	O
+Medical	O
+Center	O
+between	O
+2013	O
+and	O
+2017	O
+were	O
+evaluated	O
+.	O
+
+Haemophilus	O
+influenzae	O
+(	O
+11	O
+.	O
+7	O
+%)	O
+and	O
+adenovirus	B-DISO
+(	O
+9	O
+.	O
+1	O
+%)	O
+were	O
+the	O
+predominant	O
+bacterial	O
+and	O
+viral	O
+pathogens	O
+isolated	O
+,	O
+respectively	O
+.	O
+
+Higher	O
+P	O
+/	O
+F	O
+ratio	O
+was	O
+a	O
+protective	O
+factor	O
+against	O
+death	B-PROC
+in	O
+patients	O
+.	O
+
+This	O
+study	O
+was	O
+aimed	O
+at	O
+evaluating	O
+whether	O
+microRNAs	O
+(	O
+miRNAs	O
+)	O
+in	O
+circulating	O
+exosomes	O
+have	O
+the	O
+predictive	O
+values	O
+for	O
+patients	O
+at	O
+risk	O
+of	O
+developing	O
+ARDS	B-DISO
+due	O
+to	O
+SCAP	B-PRGE
+.	O
+
+Despite	O
+its	O
+utility	O
+in	O
+treating	O
+severe	O
+ARDS	B-DISO
+and	O
+other	O
+pulmonary	B-DISO
+disease	I-DISO
+processes	O
+,	O
+ECMO	O
+has	O
+not	O
+been	O
+universally	O
+embraced	O
+by	O
+the	O
+trauma	O
+community	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Novel	O
+Bacterium	B-SPEC
+-	O
+Like	O
+Particle	O
+Vaccine	O
+Displaying	O
+the	O
+MERS	O
+-	O
+CoV	O
+Receptor	O
+-	O
+Binding	B-FUNC
+Domain	O
+Induces	O
+Specific	O
+Mucosal	O
+and	O
+Systemic	O
+Immune	B-PROC
+Responses	I-PROC
+in	O
+Mice	B-SPEC
+.	O
+
+The	O
+development	B-PROC
+of	O
+prophylactics	O
+and	O
+therapeutics	O
+is	O
+urgently	O
+needed	O
+to	O
+prevent	O
+and	O
+control	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+analyze	O
+the	O
+influence	O
+of	O
+accidental	O
+hypothermia	O
+on	O
+pulmonary	B-DISO
+complications	I-DISO
+in	O
+multiply	O
+injured	O
+patients	O
+with	O
+blunt	O
+chest	B-ANAT
+trauma	O
+.	O
+
+Multiply	O
+injured	O
+patients	O
+[	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+≥	O
+16	O
+]	O
+with	O
+severe	O
+blunt	O
+chest	B-ANAT
+trauma	O
+[	O
+abbreviated	O
+injury	O
+scale	O
+of	O
+the	O
+chest	B-ANAT
+(	O
+AISchest	O
+)	O
+≥	O
+3	O
+]	O
+were	O
+analyzed	O
+.	O
+
+The	O
+recruitment	B-DISO
+maneuver	O
+(	O
+RM	O
+)	O
+is	O
+one	O
+of	O
+the	O
+interventions	O
+used	O
+for	O
+ARDS	B-DISO
+patients	O
+suffering	B-DISO
+from	O
+severe	O
+hypoxemia	O
+.	O
+
+To	O
+assess	O
+the	O
+effects	O
+of	O
+RM	O
+in	O
+ARDS	B-DISO
+,	O
+we	O
+conducted	O
+a	O
+study	O
+using	O
+three	O
+groups	O
+of	O
+pigs	B-SPEC
+(	O
+n	O
+=	O
+6	O
+in	O
+each	O
+group	O
+):	O
+group	O
+I	O
+(	O
+control	O
+),	O
+group	O
+II	O
+(	O
+ARDS	B-DISO
+),	O
+and	O
+group	O
+III	O
+(	O
+ARDS	B-DISO
+with	O
+RM	O
+).	O
+
+All	O
+such	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+were	O
+confirmed	O
+to	O
+originate	O
+from	O
+bats	B-SPEC
+.	O
+
+Neuraminidase	B-PROC
+inhibitors	I-PROC
+are	O
+currently	O
+the	O
+treatment	O
+of	O
+choice	O
+for	O
+IV	O
+infections	B-DISO
+.	O
+
+The	O
+patients	O
+had	O
+3	O
+.	O
+4	O
+±	O
+1	O
+.	O
+7	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+episodes	O
+per	O
+child	O
+per	O
+year	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+peptide	B-CHED
+domains	O
+involved	O
+in	O
+the	O
+subcellular	O
+localization	B-PROC
+of	O
+the	O
+feline	B-SPEC
+coronavirus	B-SPEC
+3b	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Our	O
+pilot	O
+study	O
+suggested	O
+that	O
+noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+reduced	O
+the	O
+need	O
+for	O
+intubation	O
+compared	O
+with	O
+conventional	O
+administration	O
+of	O
+oxygen	B-CHED
+on	O
+patients	O
+with	O
+""""	O
+early	O
+""""	O
+stage	O
+of	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+,	O
+PaO	B-PROC
+To	O
+evaluate	O
+whether	O
+early	O
+NIV	O
+can	O
+reduce	O
+the	O
+need	O
+for	O
+invasive	O
+ventilation	O
+in	O
+patients	O
+with	O
+pneumonia	B-DISO
+-	O
+induced	O
+early	O
+mild	O
+ARDS	B-DISO
+.	O
+
+The	O
+major	O
+bottlenecks	O
+in	O
+implementing	O
+OH	O
+in	O
+Nepal	O
+include	O
+poor	O
+organizational	O
+structure	O
+to	O
+support	O
+OH	O
+,	O
+absence	O
+of	O
+a	O
+legal	O
+framework	O
+to	O
+implement	O
+OH	O
+,	O
+poor	O
+coordination	B-PROC
+among	O
+different	O
+governmental	O
+agencies	O
+,	O
+insufficient	O
+technical	O
+expertise	O
+,	O
+poor	O
+data	O
+sharing	O
+mechanism	O
+across	O
+sectors	O
+,	O
+limited	O
+budget	O
+and	O
+poor	O
+understanding	O
+at	O
+political	O
+level	O
+.	O
+
+TITLE	O
+:	O
+Some	O
+One	O
+Health	O
+based	O
+control	O
+strategies	O
+for	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Infected	O
+camels	B-SPEC
+shed	O
+the	O
+virus	B-SPEC
+in	O
+body	B-ANAT
+secretions	I-ANAT
+,	O
+particularly	O
+nasal	B-ANAT
+discharges	B-ANAT
+.	O
+
+The	O
+use	O
+of	O
+plasmapheresis	O
+is	O
+considered	O
+useful	O
+in	O
+acute	O
+anti	O
+-	O
+glomerular	B-ANAT
+basement	I-ANAT
+membrane	I-ANAT
+(	O
+GBM	B-DISO
+)	O
+disease	O
+(	O
+Goodpasture	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+)	O
+or	O
+catastrophic	O
+antiphospholipid	B-DISO
+antibody	I-DISO
+syndrome	I-DISO
+(	O
+APS	B-DISO
+).	O
+
+In	O
+Henan	O
+province	O
+of	O
+China	O
+,	O
+three	O
+swine	B-SPEC
+farms	O
+broke	O
+out	O
+diarrhea	B-DISO
+in	O
+different	O
+ages	O
+of	O
+pigs	B-SPEC
+during	O
+June	O
+of	O
+2017	O
+,	O
+March	O
+of	O
+2018	O
+and	O
+January	O
+of	O
+2019	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Pediatric	O
+firearm	O
+-	O
+related	O
+traumatic	O
+brain	B-ANAT
+injury	O
+in	O
+United	O
+States	O
+trauma	O
+centers	O
+.	O
+
+Variables	O
+of	O
+interest	O
+included	O
+injury	O
+intent	O
+,	O
+firearm	O
+type	O
+,	O
+site	O
+of	O
+incident	O
+,	O
+age	O
+,	O
+sex	O
+,	O
+race	O
+,	O
+health	O
+insurance	O
+,	O
+geographic	O
+region	O
+,	O
+trauma	O
+center	O
+level	O
+,	O
+isolated	O
+traumatic	O
+brain	B-ANAT
+injury	O
+(	O
+TBI	O
+),	O
+hypotension	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+,	O
+Glasgow	O
+Coma	B-DISO
+Scale	O
+(	O
+GCS	O
+)	O
+score	O
+,	O
+and	O
+Injury	O
+Severity	O
+Score	O
+(	O
+ISS	B-DISO
+).	O
+
+Lower	O
+GCS	O
+scores	O
+,	O
+higher	O
+ISSs	O
+,	O
+and	O
+emergency	B-DISO
+room	O
+hypotension	O
+predicted	O
+poorer	O
+outcomes	O
+.	O
+
+TITLE	O
+:	O
+Peptide	B-CHED
+presentation	O
+by	O
+bat	B-PRGE
+MHC	B-PROC
+class	B-SPEC
+I	O
+provides	O
+new	O
+insight	O
+into	O
+the	O
+antiviral	B-CHED
+immunity	B-PROC
+of	O
+bats	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Myocardial	B-DISO
+calcification	I-DISO
+in	O
+a	O
+patient	O
+with	O
+B	O
+-	O
+lymphoblastic	B-DISO
+leukemia	I-DISO
+accompanied	O
+by	O
+tumor	B-DISO
+lysis	B-PROC
+syndrome	I-DISO
+.	O
+
+Circulatory	B-PROC
+and	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+left	B-DISO
+heart	I-DISO
+failure	I-DISO
+progressed	O
+,	O
+and	O
+he	O
+died	B-PROC
+3	O
+days	O
+after	O
+administration	O
+of	O
+prednisolone	B-CHED
+.	O
+
+The	O
+drastic	O
+increase	O
+in	O
+the	O
+serum	B-COMP
+phosphorus	B-CHED
+level	O
+caused	O
+by	O
+tumor	B-DISO
+lysis	I-DISO
+syndrome	I-DISO
+seemed	O
+to	O
+be	O
+associated	O
+with	O
+myocardial	B-DISO
+calcification	I-DISO
+.	O
+
+High	O
+dose	O
+corticosteroid	B-CHED
+therapy	O
+and	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+strategies	O
+may	O
+help	O
+for	O
+complete	O
+recovery	O
+of	O
+lung	O
+function	O
+.	O
+
+According	O
+to	O
+western	O
+blots	O
+,	O
+serum	O
+antibody	B-PROC
+interactions	I-PROC
+with	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+were	O
+relatively	O
+more	O
+sensitive	O
+and	O
+specific	O
+than	O
+ORF3C	O
+,	O
+E	O
+and	O
+Ac	O
+.	O
+
+We	O
+observed	O
+that	O
+knockdown	O
+of	O
+G3BP1	B-PRGE
+by	O
+silencing	O
+RNA	O
+significantly	O
+increased	O
+PEDV	B-SPEC
+replication	O
+.	O
+
+Site	O
+mutagenesis	B-PROC
+and	O
+peptide	B-CHED
+-	O
+based	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assays	O
+(	O
+ELISAs	O
+)	O
+showed	O
+that	O
+16R	O
+in	O
+S2	B-PRGE
+protein	I-PRGE
+was	O
+a	O
+key	O
+amino	B-CHED
+acid	I-CHED
+mediating	O
+the	O
+antigenicity	O
+of	O
+S2	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+State	O
+University	O
+of	O
+New	O
+York	O
+Upstate	O
+Medical	O
+University	O
+and	O
+the	O
+Trudeau	O
+Institute	O
+convened	O
+a	O
+summit	O
+of	O
+key	O
+opinion	O
+and	O
+thought	O
+leaders	O
+in	O
+the	O
+life	O
+sciences	O
+and	O
+biomedical	O
+research	O
+and	O
+development	B-PROC
+enterprises	O
+to	O
+explore	O
+global	O
+biopreparedness	O
+challenges	O
+,	O
+take	O
+an	O
+inventory	O
+of	O
+existing	O
+capabilities	O
+and	O
+capacities	O
+related	O
+to	O
+preparation	O
+and	O
+response	O
+,	O
+assess	O
+current	O
+""""	O
+gaps	O
+","""	O
+and	O
+prospect	O
+what	O
+could	O
+be	O
+done	O
+to	O
+improve	O
+our	O
+position	O
+.	O
+
+Herein	O
+we	O
+describe	O
+the	O
+summit	O
+proceedings	O
+,	O
+""""	O
+Translational	O
+Immunology	O
+Supporting	O
+Biomedical	O
+Countermeasure	O
+Development	B-PROC
+for	O
+Emerging	O
+Vector	O
+-	O
+borne	O
+Viral	B-DISO
+Diseases	I-DISO
+","""	O
+held	O
+October	O
+2	O
+-	O
+3	O
+,	O
+2018	O
+,	O
+at	O
+the	O
+Trudeau	O
+Institute	O
+in	O
+Saranac	O
+Lake	B-SPEC
+,	O
+NY	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+the	O
+use	O
+of	O
+extra	O
+-	O
+corporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	B-PROC
+)	O
+has	O
+been	O
+rapidly	O
+increasing	O
+,	O
+the	O
+benefit	O
+of	O
+ECMO	B-PROC
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+unclear	O
+.	O
+
+TITLE	O
+:	O
+Influenza	B-PATH
+A	I-PATH
+virus	B-PROC
+infection	I-PROC
+induces	O
+liver	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+occurrence	O
+of	O
+hepatitis	B-DISO
+by	O
+establishing	O
+a	O
+model	O
+for	O
+infected	O
+mice	B-SPEC
+for	O
+three	O
+different	O
+subtypes	O
+of	O
+respiratory	O
+IAVs	O
+(	O
+H1N1	O
+,	O
+H5N1	B-DISO
+,	O
+and	O
+H7N2	O
+).	O
+
+TITLE	O
+:	O
+Multiple	O
+divergent	O
+Human	B-SPEC
+mastadenovirus	B-SPEC
+C	O
+co	O
+-	O
+circulating	O
+in	O
+mainland	O
+of	O
+China	O
+.	O
+
+Using	O
+this	O
+ancient	O
+therapy	O
+as	O
+a	O
+complementary	O
+medicine	O
+,	O
+the	O
+management	O
+of	O
+serious	O
+medical	O
+conditions	O
+,	O
+such	O
+as	O
+SARS	B-DISO
+,	O
+acute	O
+heart	B-DISO
+diseases	I-DISO
+,	O
+and	O
+ischemic	O
+cerebral	B-DISO
+stroke	I-DISO
+,	O
+are	O
+presented	O
+.	O
+
+We	O
+conclude	O
+that	O
+NMB	O
+is	O
+frequently	O
+used	O
+by	O
+academic	O
+intensivists	O
+to	O
+facilitate	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+212	O
+(	O
+24	O
+.	O
+3	O
+%)	O
+of	O
+871	O
+respondents	O
+completed	O
+the	O
+survey	O
+:	O
+94	O
+.	O
+7	O
+%	O
+were	O
+board	O
+-	O
+certified	O
+in	O
+internal	O
+medicine	B-CHED
+,	O
+88	O
+%	O
+in	O
+pulmonary	B-ANAT
+and	O
+critical	O
+care	O
+;	O
+90	O
+.	O
+3	O
+%	O
+practiced	O
+in	O
+academic	O
+medical	O
+centers	O
+,	O
+with	O
+87	O
+%	O
+working	O
+in	O
+medical	O
+ICUs	O
+;	O
+96	O
+.	O
+6	O
+%	O
+of	O
+respondents	O
+who	O
+treat	O
+ARDS	B-DISO
+use	O
+NMB	O
+,	O
+and	O
+39	O
+.	O
+7	O
+%	O
+use	O
+NMB	O
+in	O
+≥	O
+50	O
+%	O
+of	O
+these	O
+patients	O
+.	O
+
+Vaccination	O
+is	O
+an	O
+important	O
+method	O
+to	O
+control	O
+the	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+development	B-PROC
+of	O
+an	O
+innovative	O
+mouse	B-SPEC
+model	O
+of	O
+pneumococcal	B-DISO
+pneumonia	I-DISO
+developed	O
+for	O
+enhanced	O
+clinical	O
+relevance	O
+.	O
+
+We	O
+then	O
+did	O
+a	O
+series	O
+of	O
+experiments	O
+in	O
+mice	B-SPEC
+in	O
+which	O
+we	O
+systematically	O
+varied	O
+the	O
+pneumococcal	O
+inoculum	O
+and	O
+the	O
+timing	O
+of	O
+antibiotics	B-CHED
+while	O
+measuring	O
+systemic	O
+and	O
+lung	B-ANAT
+-	O
+specific	O
+end	O
+points	O
+,	O
+producing	O
+a	O
+range	O
+of	O
+models	O
+that	O
+mirrors	O
+the	O
+spectrum	O
+of	O
+pneumococcal	O
+lung	B-DISO
+disease	I-DISO
+in	O
+patients	O
+,	O
+from	O
+mild	O
+self	O
+-	O
+resolving	O
+infection	B-DISO
+to	O
+severe	O
+pneumonia	B-DISO
+refractory	O
+to	O
+antibiotics	B-CHED
+.	O
+
+Community	O
+-	O
+acquired	O
+respiratory	O
+viruses	B-SPEC
+(	O
+CARVs	O
+)	O
+pose	O
+a	O
+particular	O
+challenge	O
+due	O
+to	O
+the	O
+frequent	O
+exposure	O
+pre	O
+-,	O
+peri	O
+-,	O
+and	O
+posttransplantation	O
+.	O
+
+We	O
+describe	O
+the	O
+management	O
+of	O
+ACS	B-FUNC
+with	O
+VV	O
+-	O
+ECMO	O
+using	O
+two	O
+different	O
+approaches	O
+,	O
+namely	O
+with	O
+and	O
+without	O
+mechanical	O
+ventilation	O
+.	O
+
+This	O
+work	O
+proposes	O
+a	O
+framework	O
+to	O
+guide	O
+the	O
+evaluation	O
+of	O
+PPE	B-CHED
+.	O
+
+Here	O
+,	O
+we	O
+review	O
+our	O
+understanding	O
+of	O
+the	O
+infection	B-DISO
+mechanism	O
+used	O
+by	O
+coronaviruses	O
+derived	O
+from	O
+recent	O
+structural	O
+and	O
+biochemical	O
+studies	O
+.	O
+
+Then	O
+,	O
+purified	O
+Nb2	B-PRGE
+-	O
+Avi	O
+-	O
+tag	B-DISO
+fusion	O
+protein	B-CHED
+was	O
+biotinylated	O
+in	O
+vitro	O
+.	O
+
+One	O
+hundred	O
+and	O
+fifty	O
+clinical	O
+serum	B-COMP
+samples	O
+were	O
+tested	O
+by	O
+both	O
+newly	O
+developed	O
+bELISA	O
+and	O
+commercial	O
+kits	O
+.	O
+
+The	O
+2017	O
+-	O
+2018	O
+influenza	B-DISO
+season	O
+in	O
+Italy	O
+was	O
+of	O
+greater	O
+severity	O
+than	O
+previous	O
+seasons	O
+.	O
+
+The	O
+incidence	O
+of	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+was	O
+analysed	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+collected	O
+from	O
+patients	O
+with	O
+ILI	O
+from	O
+week	O
+46	O
+/	O
+2017	O
+to	O
+week	O
+17	O
+/	O
+2018	O
+were	O
+tested	O
+to	O
+identify	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+(	O
+IAV	O
+)	O
+and	O
+influenza	B-DISO
+B	O
+viruses	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+Among	O
+the	O
+>	O
+64	O
+-	O
+year	O
+age	O
+group	O
+,	O
+18	O
+out	O
+of	O
+26	O
+ICU	O
+-	O
+ARDS	B-DISO
+cases	O
+(	O
+69	O
+.	O
+2	O
+%)	O
+were	O
+caused	O
+by	O
+IBV	B-SPEC
+,	O
+and	O
+14	O
+of	O
+these	O
+(	O
+77	O
+.	O
+8	O
+%)	O
+were	O
+B	O
+/	O
+Yamagata	O
+lineage	O
+.	O
+
+IBV	B-SPEC
+mismatch	O
+between	O
+the	O
+trivalent	O
+vaccine	O
+and	O
+the	O
+circulating	O
+strains	O
+occurred	O
+.	O
+
+Despite	O
+the	O
+importance	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+in	O
+viral	O
+entry	O
+and	O
+host	B-COMP
+immune	B-PROC
+responses	I-PROC
+,	O
+high	O
+-	O
+resolution	O
+structural	O
+information	O
+concerning	O
+this	O
+large	O
+macromolecular	O
+machine	O
+has	O
+been	O
+difficult	O
+to	O
+obtain	O
+.	O
+
+The	O
+pathogenic	O
+mechanisms	O
+that	O
+lead	O
+to	O
+respiratory	B-DISO
+complications	I-DISO
+,	O
+such	O
+as	O
+vascular	B-ANAT
+leakage	B-DISO
+,	O
+remain	O
+unclear	O
+.	O
+
+Here	O
+,	O
+we	O
+confirm	O
+that	O
+depleting	O
+CD8	B-PRGE
+
+Histologic	O
+examination	O
+of	O
+the	O
+tissues	B-ANAT
+with	O
+subsequent	O
+immunohistochemistry	O
+confirmed	O
+FIP	B-DISO
+-	O
+associated	O
+meningoencephalomyelitis	B-DISO
+following	O
+necropsy	O
+.	O
+
+The	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+showed	O
+severe	O
+oxygenation	B-PROC
+impairment	B-DISO
+and	O
+he	O
+was	O
+intubated	O
+for	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+radiographs	O
+showed	O
+bilateral	O
+widespread	O
+interstitial	B-ANAT
+shadowing	O
+.	O
+
+The	O
+echocardiography	O
+showed	O
+normal	O
+heart	B-ANAT
+and	O
+ruled	O
+out	O
+cardiogenic	O
+pulmonary	B-ANAT
+oedemic	O
+.	O
+
+It	O
+can	O
+cause	O
+ARDS	B-DISO
+and	O
+other	O
+respiratory	O
+illnesses	O
+such	O
+as	O
+bronchitis	B-DISO
+,	O
+metal	B-CHED
+fumes	O
+fever	B-PROC
+and	O
+chronic	O
+pneumonitis	B-DISO
+.	O
+
+However	O
+,	O
+the	O
+primary	O
+element	O
+influencing	O
+the	O
+codon	O
+bias	B-SPEC
+of	O
+PDCoVs	O
+was	O
+natural	O
+selection	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+general	O
+,	O
+heterocyclic	B-CHED
+compounds	I-CHED
+are	O
+a	O
+significant	O
+source	O
+of	O
+pharmacologically	O
+active	O
+compounds	O
+.	O
+
+So	O
+far	O
+,	O
+many	O
+natural	O
+and	O
+synthetic	O
+indole	B-CHED
+derivatives	O
+have	O
+been	O
+discovered	O
+as	O
+promising	O
+anti	O
+-	O
+cancer	B-DISO
+agents	O
+used	O
+in	O
+clinic	O
+or	O
+clinical	O
+evaluations	O
+,	O
+suggesting	O
+its	O
+prominent	O
+place	O
+in	O
+anti	O
+-	O
+cancer	B-DISO
+drugs	O
+development	B-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+patient	O
+characteristics	O
+and	O
+physician	O
+behaviors	B-PROC
+were	O
+demonstrated	O
+to	O
+be	O
+associated	O
+with	O
+differences	O
+in	O
+ventilator	O
+management	O
+in	O
+both	O
+ARDS	B-DISO
+and	O
+control	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Generating	O
+and	O
+evaluating	O
+type	O
+I	O
+interferon	B-PRGE
+receptor	I-PRGE
+-	O
+deficient	O
+and	O
+feline	B-SPEC
+TMPRSS2	O
+-	O
+expressing	O
+cells	O
+for	O
+propagating	O
+serotype	O
+I	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+.	O
+
+Before	O
+the	O
+start	O
+of	O
+ECMO	O
+,	O
+RV	B-DISO
+hypertrophy	I-DISO
+was	O
+present	O
+in	O
+28	O
+patients	O
+(	O
+60	O
+.	O
+8	O
+%)	O
+with	O
+no	O
+significant	O
+differences	O
+in	O
+baseline	O
+characteristics	O
+between	O
+the	O
+2	O
+subgroups	O
+.	O
+
+At	O
+ICU	O
+discharge	B-ANAT
+,	O
+all	O
+patients	O
+showed	O
+RV	B-DISO
+hypertrophy	I-DISO
+.	O
+
+TITLE	O
+:	O
+Selection	O
+and	O
+Characterization	O
+of	O
+Monoclonal	O
+Antibodies	B-COMP
+Targeting	B-PROC
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+through	O
+a	O
+Human	B-PRGE
+Synthetic	I-PRGE
+Fab	I-PRGE
+Phage	O
+Display	O
+Library	O
+Panning	O
+.	O
+
+Proteomic	O
+analysis	O
+was	O
+then	O
+conducted	O
+to	O
+assess	O
+the	O
+expression	B-PROC
+dynamics	O
+of	O
+the	O
+host	B-COMP
+proteins	B-CHED
+in	O
+the	O
+PDCoV	B-PRGE
+NS7	I-PRGE
+-	O
+expressing	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Mechanical	O
+ventilation	O
+with	O
+ultra	O
+-	O
+low	O
+tidal	O
+volume	O
+(	O
+VT	O
+)	O
+during	O
+ARDS	B-DISO
+may	O
+reduce	O
+alveolar	B-ANAT
+strain	O
+,	O
+driving	O
+pressure	O
+and	O
+hence	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+,	O
+with	O
+the	O
+main	O
+drawback	O
+of	O
+worsening	O
+respiratory	B-DISO
+acidosis	I-DISO
+.	O
+
+Diabetic	O
+mice	B-SPEC
+had	O
+fewer	O
+inflammatory	O
+monocyte	B-ANAT
+/	O
+macrophages	B-ANAT
+and	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+,	O
+which	O
+correlated	O
+with	O
+lower	O
+levels	O
+of	O
+Ccl2	B-PRGE
+and	O
+Cxcl10	B-PRGE
+expression	B-PROC
+.	O
+
+Among	O
+them	O
+,	O
+α	O
+-	O
+hydroxytropolones	O
+,	O
+N	O
+-	O
+hydroxyisoquinolinediones	O
+and	O
+N	O
+-	O
+hydroxypyridinediones	O
+represent	O
+chemotypes	O
+active	O
+against	O
+both	O
+HIV	B-DISO
+and	O
+HBV	B-DISO
+RNases	O
+H	O
+.	O
+In	O
+this	O
+review	O
+we	O
+summarize	O
+recent	O
+developments	O
+in	O
+the	O
+field	O
+including	O
+the	O
+identification	O
+of	O
+novel	O
+RNase	B-PRGE
+H	I-PRGE
+inhibitors	B-CHED
+,	O
+compounds	O
+with	O
+dual	O
+inhibitory	O
+activity	O
+,	O
+broad	O
+specificity	O
+and	O
+efforts	O
+to	O
+decrease	O
+their	O
+toxicity	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+emerged	O
+into	O
+the	O
+human	B-SPEC
+population	O
+in	O
+2012	O
+and	O
+has	O
+caused	O
+substantial	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+structural	O
+and	O
+functional	O
+characterization	O
+of	O
+G2	O
+,	O
+a	O
+neutralizing	O
+antibody	B-COMP
+targeting	B-PROC
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S1	I-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+domain	I-PRGE
+(	O
+S1	O
+-	O
+NTD	O
+).	O
+
+In	O
+dogs	B-SPEC
+,	O
+Salmonella	B-DISO
+spp	B-ENZY
+.	O
+
+Based	O
+on	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+phylogenetic	O
+tree	O
+,	O
+LX4	O
+-	O
+type	O
+(	O
+GI	O
+-	O
+19	O
+)	O
+was	O
+the	O
+most	O
+dominant	O
+genotype	O
+,	O
+which	O
+was	O
+different	O
+from	O
+that	O
+during	O
+1985	O
+-	O
+2008	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+infection	B-DISO
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+poses	O
+an	O
+ongoing	O
+threat	O
+to	O
+public	O
+health	O
+worldwide	O
+.	O
+
+Of	O
+the	O
+27	O
+trials	O
+reporting	O
+reduced	O
+mortality	O
+,	O
+six	O
+had	O
+assessed	O
+interventions	O
+likely	O
+to	O
+decrease	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+,	O
+including	O
+low	O
+tidal	O
+volume	O
+,	O
+prone	O
+position	O
+,	O
+and	O
+neuromuscular	O
+blockers	O
+,	O
+demonstrating	O
+the	O
+negative	O
+effects	O
+of	O
+mechanical	O
+ventilation	O
+strategies	O
+or	O
+improved	O
+process	O
+of	O
+care	O
+rather	O
+than	O
+positive	O
+effects	O
+of	O
+new	O
+therapies	O
+.	O
+
+We	O
+assessed	O
+the	O
+clinical	O
+phenotype	O
+,	O
+frequency	O
+,	O
+clinical	O
+implications	O
+(	O
+surgery	O
+,	O
+length	O
+of	O
+treatment	O
+in	O
+hospitals	O
+/	O
+intensive	O
+care	O
+units	O
+,	O
+and	O
+antibiotic	B-CHED
+treatments	O
+),	O
+and	O
+potential	O
+preventability	O
+of	O
+severe	O
+PVL	O
+-	O
+SA	O
+infections	B-DISO
+in	O
+children	O
+.	O
+
+PVL	O
+-	O
+SA	O
+causes	O
+severe	O
+to	O
+life	O
+-	O
+threatening	O
+infections	B-DISO
+requiring	O
+lengthy	O
+treatments	O
+in	O
+hospital	O
+in	O
+a	O
+substantial	O
+percentage	O
+of	O
+symptomatic	O
+PVL	O
+-	O
+SA	O
+colonized	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Efficacy	O
+of	O
+blood	B-ANAT
+purification	O
+for	O
+severe	O
+pancreatitis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+will	O
+search	O
+the	O
+following	O
+electronic	O
+databases	O
+of	O
+Ovid	O
+MEDLINE	O
+,	O
+EMBASE	O
+,	O
+Web	B-DISO
+of	O
+Science	O
+,	O
+Cochrane	O
+Library	O
+,	O
+Scopus	B-SPEC
+,	O
+Cumulative	O
+Index	O
+to	O
+Nursing	B-PROC
+and	O
+Allied	O
+Health	O
+Literature	O
+,	O
+the	O
+Allied	O
+and	O
+Complementary	O
+Medicine	B-CHED
+Database	O
+,	O
+Chinese	O
+Biomedical	O
+Literature	O
+Database	O
+,	O
+China	O
+National	O
+Knowledge	O
+Infrastructure	O
+,	O
+and	O
+WANGFANG	O
+from	O
+inception	O
+to	O
+the	O
+present	O
+without	O
+language	O
+restriction	O
+.	O
+
+This	O
+systematic	O
+review	O
+will	O
+evaluate	O
+the	O
+efficacy	O
+and	O
+safety	O
+of	O
+BP	O
+for	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+SP	O
+and	O
+ARDS	B-DISO
+.	O
+
+The	O
+primary	O
+outcome	O
+includes	O
+respiratory	O
+indexes	O
+,	O
+blood	B-ANAT
+biochemical	O
+and	O
+inflammatory	O
+factors	O
+.	O
+
+TITLE	O
+:	O
+Mucosal	B-ANAT
+Immune	I-PROC
+Response	I-PROC
+to	O
+Feline	B-SPEC
+Enteric	B-SPEC
+Coronavirus	I-SPEC
+Infection	O
+.	O
+
+Thirty	O
+-	O
+three	O
+cats	B-SPEC
+were	O
+grouped	O
+according	O
+to	O
+FECV	B-SPEC
+seropositivity	O
+and	O
+fecal	B-ANAT
+virus	B-DISO
+shedding	I-DISO
+into	O
+naïve	O
+/	O
+immunologically	O
+quiescent	O
+,	O
+convalescent	O
+and	O
+actively	O
+infected	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+Novel	O
+tick	B-SPEC
+-	O
+borne	O
+phleboviruses	B-SPEC
+in	O
+the	O
+
+Data	O
+was	O
+collected	O
+by	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+interview	O
+using	O
+standardised	O
+questionnaire	O
+,	O
+and	O
+analyzed	O
+using	O
+SPSS	O
+.	O
+
+Histopathological	O
+examination	O
+revealed	O
+kidney	B-ANAT
+hemorrhages	B-DISO
+,	O
+multifocal	O
+necrosis	B-PROC
+of	O
+the	O
+renal	B-ANAT
+tubules	I-ANAT
+and	O
+trachea	B-DISO
+with	O
+cilia	B-COMP
+loss	O
+,	O
+sloughing	B-ANAT
+of	O
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+edema	B-DISO
+of	O
+the	O
+lamina	B-ANAT
+propria	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+Vitamin	B-CHED
+C	I-CHED
+Infusion	O
+on	O
+Organ	B-DISO
+Failure	I-DISO
+and	O
+Biomarkers	O
+of	O
+Inflammation	B-DISO
+and	O
+Vascular	B-ANAT
+Injury	O
+in	O
+Patients	O
+With	O
+Sepsis	O
+and	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+:	O
+The	O
+CITRIS	O
+-	O
+ALI	O
+Randomized	O
+Clinical	O
+Trial	O
+.	O
+
+ABSTRACT	O
+:	O
+Experimental	O
+data	O
+suggest	O
+that	O
+intravenous	O
+vitamin	B-CHED
+C	I-CHED
+may	O
+attenuate	O
+inflammation	B-DISO
+and	O
+vascular	B-ANAT
+injury	O
+associated	O
+with	O
+sepsis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+To	O
+determine	O
+the	O
+effect	O
+of	O
+intravenous	O
+vitamin	B-CHED
+C	I-CHED
+infusion	O
+on	O
+organ	B-DISO
+failure	I-DISO
+scores	O
+and	O
+biological	O
+markers	O
+of	O
+inflammation	B-DISO
+and	O
+vascular	B-ANAT
+injury	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+and	O
+ARDS	B-DISO
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+between	O
+the	O
+vitamin	B-CHED
+C	I-CHED
+and	O
+placebo	O
+groups	O
+in	O
+the	O
+primary	O
+end	O
+points	O
+of	O
+change	O
+in	O
+mean	O
+modified	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+from	O
+baseline	O
+to	O
+96	O
+hours	O
+(	O
+from	O
+9	O
+.	O
+8	O
+to	O
+6	O
+.	O
+8	O
+in	O
+the	O
+vitamin	B-CHED
+C	I-CHED
+group	O
+[	O
+3	O
+points	O
+]	O
+and	O
+from	O
+10	O
+.	O
+3	O
+to	O
+6	O
+.	O
+8	O
+in	O
+the	O
+placebo	O
+group	O
+[	O
+3	O
+.	O
+5	O
+points	O
+];	O
+difference	O
+,	O
+-	O
+0	O
+.	O
+10	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+1	O
+.	O
+23	O
+to	O
+1	O
+.	O
+03	O
+;	O
+P	O
+=	O
+.	O
+86	O
+)	O
+or	O
+in	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+levels	O
+(	O
+54	O
+.	O
+1	O
+vs	O
+46	O
+.	O
+1	O
+μg	O
+/	O
+mL	O
+;	O
+difference	O
+,	O
+7	O
+.	O
+94	O
+μg	O
+/	O
+mL	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+8	O
+.	O
+2	O
+to	O
+24	O
+.	O
+11	O
+;	O
+P	O
+=	O
+.	O
+33	O
+)	O
+and	O
+thrombomodulin	B-PRGE
+levels	O
+(	O
+14	O
+.	O
+5	O
+vs	O
+13	O
+.	O
+8	O
+ng	O
+/	O
+mL	O
+;	O
+difference	O
+,	O
+0	O
+.	O
+69	O
+ng	O
+/	O
+mL	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+2	O
+.	O
+8	O
+to	O
+4	O
+.	O
+2	O
+;	O
+P	O
+=	O
+.	O
+70	O
+)	O
+at	O
+168	O
+hours	O
+.	O
+
+Gene	O
+Ontology	O
+function	O
+classification	O
+and	O
+Kyoto	O
+Encyclopedia	O
+of	O
+Genes	O
+and	O
+Genomes	O
+signaling	B-PROC
+pathway	I-PROC
+enrichment	O
+analysis	O
+were	O
+performed	O
+based	O
+on	O
+the	O
+DEGs	O
+that	O
+exhibited	O
+the	O
+same	O
+expression	B-PROC
+tendencies	O
+with	O
+most	O
+of	O
+the	O
+innate	O
+immune	O
+-	O
+associated	O
+genes	O
+among	O
+these	O
+PK	O
+-	O
+15	O
+cell	B-COMP
+samples	O
+described	O
+above	O
+.	O
+
+Additionally	O
+,	O
+16	O
+of	O
+the	O
+host	B-COMP
+cell	I-COMP
+endogenous	O
+miRNAs	O
+were	O
+predicted	O
+as	O
+potential	O
+contributors	O
+to	O
+the	O
+modulation	O
+of	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+affected	O
+by	O
+PDCoV	O
+.	O
+Our	O
+research	O
+findings	O
+indicated	O
+that	O
+the	O
+innate	O
+immune	O
+-	O
+associated	O
+genes	O
+and	O
+signaling	B-PROC
+pathways	B-PROC
+in	O
+PK	O
+-	O
+15	O
+cells	B-COMP
+could	O
+be	O
+modified	O
+by	O
+the	O
+infection	B-DISO
+of	O
+PDCoV	O
+,	O
+which	O
+provides	O
+a	O
+fundamental	O
+foundation	O
+for	O
+further	O
+studies	O
+to	O
+better	O
+understand	O
+the	O
+mechanism	O
+of	O
+PDCoV	O
+infections	B-DISO
+,	O
+so	O
+as	O
+to	O
+effectively	O
+control	O
+and	O
+prevent	O
+PDCoV	O
+-	O
+induced	O
+swine	B-SPEC
+diarrheal	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+Furthermore	O
+,	O
+GHRH	B-PRGE
+antagonists	B-CHED
+supported	O
+the	O
+integrity	O
+of	O
+endothelial	B-ANAT
+barrier	O
+,	O
+while	O
+GHRH	B-PRGE
+and	O
+GHRH	B-PRGE
+agonists	B-CHED
+had	O
+the	O
+contrary	O
+effects	O
+,	O
+as	O
+reflected	O
+in	O
+measurements	O
+of	O
+transendothelial	O
+resistance	B-PROC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+on	O
+cell	O
+adaption	B-PROC
+of	O
+a	O
+virulent	O
+SADS	O
+-	O
+CoV	O
+strain	O
+,	O
+which	O
+gives	O
+information	O
+on	O
+the	O
+potential	O
+virulence	B-PROC
+determinants	O
+of	O
+SADS	O
+-	O
+CoV	O
+.	O
+
+The	O
+primary	O
+analysis	O
+was	O
+done	O
+in	O
+the	O
+intention	O
+-	O
+to	O
+-	O
+treat	O
+population	O
+,	O
+excluding	O
+two	O
+participants	O
+who	O
+did	O
+not	O
+receive	O
+plasma	B-ANAT
+.	O
+
+One	O
+participant	O
+from	O
+each	O
+group	O
+did	O
+not	O
+receive	O
+plasma	B-ANAT
+.	O
+
+93	O
+%	O
+of	O
+planned	O
+plasma	B-ANAT
+infusions	O
+were	O
+completed	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+integrin	B-PRGE
+αvβ3	I-PRGE
+enhances	O
+PEDV	B-SPEC
+replication	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+and	O
+IECs	O
+.	O
+
+Modelling	O
+of	O
+3CLpro	O
+carrying	O
+the	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+was	O
+conducted	O
+to	O
+probe	O
+the	O
+structural	O
+basis	O
+for	O
+these	O
+findings	O
+.	O
+
+Moreover	O
+,	O
+Rotavirus	B-SPEC
+A	I-SPEC
+(	O
+RVA	O
+),	O
+Rotavirus	B-SPEC
+B	I-SPEC
+(	O
+RVB	O
+),	O
+Rotavirus	B-SPEC
+C	I-SPEC
+(	O
+RVC	O
+),	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+were	O
+also	O
+determined	O
+by	O
+RT	O
+-	O
+qPCR	O
+.	O
+
+Moreover	O
+,	O
+virus	B-SPEC
+-	O
+specific	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+both	O
+MERS	O
+-	O
+CoV	O
+and	O
+RV	O
+were	O
+induced	O
+in	O
+mice	B-SPEC
+inoculated	O
+intraperitoneally	O
+with	O
+RVΔP	O
+-	O
+MERS	O
+/	O
+S1	O
+.	O
+
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+as	O
+well	O
+as	O
+developing	O
+infection	B-DISO
+by	O
+nematodes	B-SPEC
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+These	O
+data	O
+emphasize	O
+the	O
+plasticity	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+genome	O
+during	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Standard	O
+Expected	O
+Years	O
+of	O
+Life	O
+Lost	B-CHED
+as	O
+a	O
+Neglected	O
+Index	O
+for	O
+Calculating	O
+the	O
+Burden	O
+of	O
+Premature	O
+Mortality	O
+due	O
+to	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+.	O
+
+Coronaviruses	O
+specifically	O
+package	O
+genomic	O
+RNA	O
+into	O
+assembled	O
+virions	B-COMP
+,	O
+and	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+it	O
+is	O
+reported	O
+that	O
+this	O
+process	O
+is	O
+driven	O
+by	O
+an	O
+interaction	O
+between	O
+the	O
+N	O
+-	O
+protein	B-CHED
+and	O
+a	O
+packaging	O
+signal	O
+encoded	O
+within	O
+the	O
+viral	O
+RNA	O
+.	O
+
+While	O
+recent	O
+studies	O
+have	O
+uncovered	O
+the	O
+sequence	O
+of	O
+this	O
+packaging	O
+signal	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+specific	O
+interaction	O
+between	O
+the	O
+N	O
+-	O
+protein	B-CHED
+and	O
+the	O
+packaging	O
+signal	O
+sequence	O
+,	O
+and	O
+the	O
+mechanisms	O
+by	O
+which	O
+this	O
+interaction	O
+drives	O
+viral	B-PROC
+genome	I-PROC
+packaging	I-PROC
+.	O
+
+Our	O
+results	O
+demonstrate	O
+that	O
+the	O
+N	O
+-	O
+protein	O
+specifically	O
+recognizes	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+packaging	O
+signal	O
+with	O
+greater	O
+affinity	O
+compared	O
+to	O
+signals	O
+from	O
+other	O
+coronaviruses	O
+or	O
+non	O
+-	O
+coronavirus	B-SPEC
+species	B-SPEC
+.	O
+
+These	O
+results	O
+describe	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+in	O
+vivo	O
+evidence	O
+for	O
+an	O
+interaction	O
+between	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+-	I-PRGE
+protein	B-CHED
+and	O
+its	O
+packaging	O
+signal	O
+RNA	O
+,	O
+and	O
+demonstrate	O
+the	O
+feasibility	O
+of	O
+using	O
+this	O
+cell	B-COMP
+-	O
+based	O
+assay	O
+to	O
+further	O
+probe	O
+viral	O
+RNA	O
+-	O
+protein	B-CHED
+interactions	O
+in	O
+future	O
+studies	O
+.	O
+
+ABSTRACT	O
+:	O
+Various	O
+objective	O
+scoring	O
+systems	O
+were	O
+developed	O
+to	O
+standardize	O
+the	O
+approach	O
+to	O
+the	O
+designation	O
+of	O
+severity	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	O
+(	O
+CAP	B-DISO
+).	O
+
+The	O
+CURB	B-DISO
+-	O
+65	O
+was	O
+extracted	O
+from	O
+the	O
+available	O
+medical	O
+records	O
+.	O
+
+Here	O
+we	O
+reported	O
+a	O
+novel	O
+role	O
+of	O
+IFI204	B-PRGE
+that	O
+specifically	O
+inhibits	O
+the	O
+IRF7	B-PRGE
+-	O
+mediated	O
+type	O
+I	O
+interferons	O
+response	O
+during	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+IFI204	B-PRGE
+and	O
+other	O
+p200	B-PRGE
+family	I-PRGE
+proteins	B-CHED
+are	O
+highly	O
+expressed	B-PROC
+in	O
+mouse	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+-	O
+infected	O
+bone	B-ANAT
+marrow	I-ANAT
+-	O
+derived	O
+dendritic	B-ANAT
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Mepolizumab	O
+rescue	O
+therapy	O
+for	O
+acute	O
+pneumonitis	B-DISO
+secondary	O
+to	O
+DRESS	O
+.	O
+
+He	O
+was	O
+diagnosed	O
+with	O
+DRESS	B-DISO
+syndrome	I-DISO
+secondary	O
+to	O
+pregabalin	B-CHED
+and	O
+was	O
+treated	O
+with	O
+subcutaneous	O
+mepolizumab	O
+.	O
+
+Additionally	O
+,	O
+the	O
+vaccination	O
+status	O
+of	O
+3349	O
+cases	O
+of	O
+influenza	B-DISO
+were	O
+compared	O
+to	O
+three	O
+different	O
+control	O
+groups	O
+:	O
+all	O
+controls	O
+(	O
+N	O
+=	O
+6120	O
+),	O
+non	O
+-	O
+influenza	B-DISO
+positive	O
+controls	O
+(	O
+N	O
+=	O
+2880	O
+),	O
+and	O
+pan	B-COMP
+-	O
+negative	O
+controls	O
+(	O
+N	O
+=	O
+3240	O
+).	O
+
+Examining	O
+virus	B-SPEC
+interference	O
+by	O
+specific	O
+respiratory	O
+viruses	B-SPEC
+showed	O
+mixed	O
+results	O
+.	O
+
+Vaccine	O
+derived	O
+virus	B-SPEC
+interference	O
+was	O
+significantly	O
+associated	O
+with	O
+coronavirus	B-SPEC
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+;	O
+however	O
+,	O
+significant	O
+protection	O
+with	O
+vaccination	O
+was	O
+associated	O
+not	O
+only	O
+with	O
+most	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+but	O
+also	O
+parainfluenza	B-DISO
+,	O
+RSV	B-SPEC
+,	O
+and	O
+non	O
+-	O
+influenza	B-SPEC
+virus	I-SPEC
+coinfections	B-DISO
+.	O
+
+Diagnosis	O
+is	O
+based	O
+on	O
+the	O
+occurrence	O
+of	O
+acute	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+not	O
+explained	O
+by	O
+cardiac	B-DISO
+insufficiency	I-DISO
+or	O
+volume	B-DISO
+overload	I-DISO
+,	O
+within	O
+7	O
+days	O
+after	O
+a	O
+recognized	O
+risk	O
+factor	O
+,	O
+and	O
+in	O
+the	O
+presence	O
+of	O
+bilateral	O
+pulmonary	B-ANAT
+opacities	B-DISO
+not	O
+fully	O
+explained	O
+by	O
+effusions	B-DISO
+,	O
+atelectasis	B-DISO
+or	O
+nodules	B-DISO
+on	O
+the	O
+chest	B-ANAT
+radiography	O
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+lacking	O
+its	O
+transmembrane	B-COMP
+and	O
+cytoplasmic	B-COMP
+domains	O
+(	O
+SΔTM	O
+)	O
+was	O
+secreted	B-PROC
+into	O
+the	O
+hemolymph	B-ANAT
+of	O
+silkworm	B-SPEC
+larvae	O
+using	O
+a	O
+bombyxin	O
+signal	O
+peptide	B-CHED
+and	O
+purified	O
+using	O
+affinity	O
+chromatography	O
+.	O
+
+The	O
+purified	O
+SΔTM	O
+from	O
+silkworm	B-SPEC
+larvae	O
+and	O
+S	B-PRGE
+protein	I-PRGE
+-	O
+displaying	O
+nanovesicles	O
+from	O
+Bm5	O
+cells	B-COMP
+may	O
+lead	O
+to	O
+the	O
+development	B-PROC
+of	O
+nanoparticle	B-CHED
+-	O
+based	O
+vaccines	O
+against	O
+MERS	O
+-	O
+CoV	O
+and	O
+the	O
+diagnostic	O
+detection	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+identify	O
+which	O
+aerosol	O
+-	O
+generating	O
+medical	O
+procedures	O
+and	O
+emerging	O
+viruses	B-SPEC
+pose	O
+a	O
+high	O
+risk	O
+to	O
+health	O
+-	O
+care	O
+workers	O
+,	O
+we	O
+explore	O
+the	O
+mechanisms	O
+of	O
+aerosol	O
+-	O
+generating	O
+medical	O
+procedures	O
+,	O
+as	O
+well	O
+as	O
+the	O
+transmission	O
+pathways	O
+and	O
+characteristics	O
+of	O
+highly	O
+pathogenic	O
+viruses	B-SPEC
+associated	O
+with	O
+nosocomial	O
+transmission	O
+.	O
+
+Findings	O
+were	O
+validated	O
+in	O
+an	O
+independent	O
+cohort	O
+of	O
+394	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+sepsis	B-DISO
+admitted	O
+to	O
+the	O
+University	O
+of	O
+California	B-SPEC
+San	O
+Francisco	O
+(	O
+UCSF	O
+).	O
+In	O
+the	O
+VUMC	O
+cohort	O
+,	O
+shorter	O
+PBL	O
+-	O
+TL	O
+was	O
+associated	O
+with	O
+worse	O
+90	O
+-	O
+day	O
+survival	O
+(	O
+adjusted	O
+hazard	O
+ratio	O
+(	O
+aHR	O
+)	O
+1	O
+.	O
+3	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+1	O
+-	O
+1	O
+.	O
+6	O
+per	O
+1	O
+kb	O
+TL	O
+decrease	O
+;	O
+p	O
+=	O
+0	O
+.	O
+004	O
+);	O
+in	O
+subgroup	O
+analyses	O
+,	O
+shorter	O
+PBL	O
+-	O
+TL	O
+was	O
+associated	O
+with	O
+worse	O
+90	O
+-	O
+day	O
+survival	O
+for	O
+patients	O
+with	O
+sepsis	B-DISO
+(	O
+aHR	B-PRGE
+1	I-PRGE
+.	O
+5	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+2	O
+-	O
+2	O
+.	O
+0	O
+per	O
+1	O
+kb	O
+TL	O
+decrease	O
+;	O
+p	O
+=	O
+0	O
+.	O
+001	O
+),	O
+but	O
+not	O
+trauma	O
+.	O
+
+The	O
+associations	O
+of	O
+PBL	O
+-	O
+TL	O
+with	O
+survival	O
+(	O
+adjusted	O
+HR	O
+1	O
+.	O
+6	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+2	O
+-	O
+2	O
+.	O
+1	O
+per	O
+1	O
+kb	O
+TL	O
+decrease	O
+;	O
+p	O
+=	O
+0	O
+.	O
+003	O
+)	O
+and	O
+risk	O
+for	O
+developing	O
+severe	O
+ARDS	B-DISO
+(	O
+OR	O
+2	O
+.	O
+5	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+1	O
+-	O
+6	O
+.	O
+3	O
+per	O
+1	O
+kb	O
+TL	O
+decrease	O
+;	O
+p	O
+=	O
+0	O
+.	O
+044	O
+)	O
+were	O
+validated	O
+in	O
+the	O
+UCSF	O
+cohort	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+telomere	B-COMP
+dysfunction	O
+may	O
+contribute	O
+to	O
+outcomes	O
+from	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+After	O
+Severe	O
+Carbon	B-CHED
+Monoxide	I-CHED
+Poisoning	O
+Is	O
+Likely	O
+Due	O
+to	O
+Cytopathic	O
+Hypoxia	O
+:	O
+A	O
+Case	O
+Report	O
+and	O
+Discussion	O
+.	O
+
+Despite	O
+global	O
+efforts	O
+to	O
+prevent	O
+and	O
+treat	O
+virus	B-SPEC
+infections	B-DISO
+to	O
+limit	O
+morbidity	O
+and	O
+mortality	O
+,	O
+the	O
+continued	O
+emergence	O
+and	O
+re	O
+-	O
+emergence	O
+of	O
+new	O
+outbreaks	O
+as	O
+well	O
+as	O
+common	O
+infections	B-DISO
+such	O
+as	O
+influenza	B-DISO
+persist	O
+as	O
+a	O
+health	O
+threat	O
+.	O
+
+We	O
+then	O
+used	O
+comprehensive	O
+preinfection	O
+immunophenotyping	O
+to	O
+identify	O
+global	O
+baseline	O
+immune	O
+correlates	O
+of	O
+protection	O
+from	O
+mortality	O
+to	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+-	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+,	O
+life	O
+-	O
+threatening	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+a	O
+technique	O
+involving	O
+oxygenation	B-PROC
+of	O
+blood	B-ANAT
+and	O
+elimination	B-PROC
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+in	O
+patients	O
+with	O
+life	O
+-	O
+threatening	O
+,	O
+but	O
+potentially	O
+reversible	O
+conditions	O
+.	O
+
+Thanks	O
+to	O
+the	O
+modification	O
+of	O
+extracorporeal	O
+circulation	B-PROC
+used	O
+during	O
+cardiac	B-ANAT
+surgeries	O
+,	O
+this	O
+technique	O
+can	O
+be	O
+used	O
+in	O
+intensive	O
+care	O
+units	O
+.	O
+
+ECMO	O
+does	O
+not	O
+cure	O
+the	O
+heart	B-ANAT
+and	O
+/	O
+or	O
+lungs	B-ANAT
+,	O
+but	O
+it	O
+gives	O
+the	O
+patient	O
+a	O
+chance	O
+to	O
+survive	O
+a	O
+period	O
+when	O
+these	O
+organs	B-ANAT
+are	O
+inefficient	O
+.	O
+
+TITLE	O
+:	O
+Improved	O
+inference	O
+of	O
+time	O
+-	O
+varying	O
+reproduction	B-PROC
+numbers	O
+during	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+""""	O
+Elucidation	O
+of	O
+better	O
+biomarkers	O
+to	O
+determine	O
+the	O
+underlying	O
+pathogenic	O
+phenotype	O
+will	O
+significantly	O
+advance	O
+our	O
+understanding	O
+and	O
+prediction	O
+of	O
+which	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+will	O
+benefit	O
+from	O
+GC	O
+and	O
+who	O
+would	O
+experience	O
+a	O
+deleterious	O
+effect	O
+from	O
+its	O
+use	O
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+high	O
+identity	O
+between	O
+CoV	O
+strains	O
+detected	O
+in	O
+calves	O
+and	O
+alpacas	B-SPEC
+.	O
+
+Automated	O
+web	B-DISO
+-	O
+based	O
+infectious	B-DISO
+disease	I-DISO
+surveillance	O
+technologies	O
+are	O
+available	O
+;	O
+however	O
+,	O
+human	B-SPEC
+input	O
+is	O
+still	O
+needed	O
+to	O
+review	O
+,	O
+validate	O
+,	O
+and	O
+interpret	O
+these	O
+sources	O
+.	O
+
+Owing	O
+to	O
+the	O
+severity	O
+of	O
+the	O
+condition	B-DISO
+,	O
+conventional	O
+methods	O
+of	O
+oxygenation	B-PROC
+are	O
+often	O
+insufficient	O
+.	O
+
+Therefore	O
+,	O
+a	O
+need	O
+exists	O
+for	O
+a	O
+safer	O
+and	O
+more	O
+effective	O
+method	O
+of	O
+oxygenation	B-PROC
+for	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+work	O
+,	O
+the	O
+feasibility	O
+of	O
+using	O
+intraperitoneal	O
+perfusions	O
+of	O
+oxygen	B-CHED
+microbubbles	O
+-	O
+peritoneal	B-ANAT
+microbubble	O
+oxygenation	B-PROC
+(	O
+PMO	O
+)-	O
+to	O
+treat	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+ARDS	B-DISO
+was	O
+explored	O
+with	O
+the	O
+objective	O
+of	O
+showing	O
+restoration	O
+of	O
+normoxic	O
+conditions	O
+after	O
+a	O
+single	O
+bolus	O
+infusion	O
+of	O
+oxygen	B-CHED
+microbubbles	O
+.	O
+
+The	O
+study	O
+included	O
+48	O
+patients	O
+diagnosed	O
+with	O
+primary	B-DISO
+acquired	I-DISO
+nasolacrimal	I-DISO
+duct	I-DISO
+obstruction	I-DISO
+undergoing	O
+dacryocystorhinostomy	O
+surgery	O
+.	O
+
+TITLE	O
+:	O
+GILT	B-PRGE
+restricts	O
+the	O
+cellular	B-COMP
+entry	O
+mediated	O
+by	O
+the	O
+envelope	B-PRGE
+glycoproteins	B-CHED
+of	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+,	O
+Ebola	B-SPEC
+virus	I-SPEC
+and	O
+Lassa	B-DISO
+fever	I-DISO
+virus	B-SPEC
+.	O
+
+We	O
+report	O
+herein	O
+that	O
+gamma	B-PRGE
+-	I-PRGE
+interferon	I-PRGE
+-	O
+inducible	O
+lysosomal	B-PRGE
+thiol	B-CHED
+reductase	I-PRGE
+(	O
+GILT	B-PRGE
+),	O
+a	O
+lysosome	B-COMP
+-	O
+associated	O
+ISG	O
+,	O
+restricts	O
+the	O
+infectious	B-DISO
+entry	O
+of	O
+selected	O
+enveloped	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+mutations	O
+that	O
+impaired	B-DISO
+the	O
+thiol	B-PRGE
+reductase	I-PRGE
+activity	O
+or	O
+disrupted	O
+the	O
+N	O
+-	O
+linked	O
+glycosylation	B-PROC
+,	O
+a	O
+posttranslational	O
+modification	O
+essential	O
+for	O
+its	O
+lysosomal	B-ANAT
+localization	B-PROC
+,	O
+largely	O
+compromised	O
+GILT	O
+restriction	O
+of	O
+viral	O
+entry	O
+.	O
+
+Multiple	O
+case	O
+reports	O
+and	O
+small	O
+series	O
+describing	O
+ECMO	O
+use	O
+as	O
+rescue	O
+for	O
+adults	O
+with	O
+severe	O
+hypoxemia	O
+from	O
+various	O
+lung	B-ANAT
+pathologies	O
+have	O
+appeared	O
+in	O
+the	O
+literature	O
+over	O
+the	O
+past	O
+three	O
+decades	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+review	O
+,	O
+we	O
+discuss	O
+common	O
+difficulties	O
+that	O
+clinicians	O
+may	O
+encounter	O
+while	O
+managing	O
+patients	O
+treated	O
+with	O
+venovenous	O
+(	O
+VV	O
+)	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+Standard	O
+mechanical	O
+ventilation	O
+can	O
+activate	O
+inflammation	B-DISO
+and	O
+worsen	O
+the	O
+pulmonary	B-ANAT
+damage	O
+caused	O
+by	O
+the	O
+underlying	O
+disease	O
+,	O
+leading	O
+to	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+This	O
+is	O
+an	O
+unfortunate	O
+condition	B-DISO
+and	O
+this	O
+report	O
+will	O
+raise	O
+awareness	O
+to	O
+a	O
+potential	O
+complication	B-DISO
+in	O
+the	O
+burn	O
+patient	O
+population	O
+as	O
+well	O
+as	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+in	O
+other	O
+settings	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+well	O
+-	O
+known	O
+immunosuppressive	O
+drug	O
+cyclosporin	B-CHED
+A	I-CHED
+inhibits	O
+replication	O
+of	O
+various	O
+viruses	B-SPEC
+including	O
+coronaviruses	O
+by	O
+binding	B-FUNC
+to	O
+cellular	B-PRGE
+cyclophilins	I-PRGE
+thus	O
+inactivating	O
+their	O
+cis	B-DISO
+-	O
+trans	O
+peptidyl	B-PRGE
+-	I-PRGE
+prolyl	I-PRGE
+isomerase	I-PRGE
+function	O
+.	O
+
+Overall	O
+,	O
+the	O
+long	O
+-	O
+term	O
+prognosis	O
+was	O
+satisfactory	O
+,	O
+suggesting	O
+that	O
+this	O
+procedure	O
+is	O
+less	O
+invasive	O
+and	O
+effective	O
+for	O
+treatment	O
+of	O
+MAS	B-COMP
+due	O
+to	O
+TA	O
+,	O
+in	O
+emergencies	B-DISO
+.	O
+
+While	O
+AIV	O
+and	O
+AAVV	O
+-	O
+1	O
+were	O
+frequently	O
+detected	O
+(	O
+16	O
+to	O
+17	O
+%	O
+of	O
+farms	O
+),	O
+IBV	B-SPEC
+and	O
+aMPV	O
+were	O
+rarely	O
+detected	O
+(	O
+in	O
+3	O
+to	O
+5	O
+%	O
+of	O
+farms	O
+)	O
+and	O
+ILTV	B-SPEC
+was	O
+not	O
+detected	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+trial	O
+registers	O
+to	O
+be	O
+searched	O
+will	O
+include	O
+:	O
+World	O
+Health	O
+Organization	O
+International	O
+Clinical	O
+Trials	O
+Registry	O
+Platform	O
+(	O
+ICTRP	O
+),	O
+United	O
+States	O
+National	O
+Library	O
+of	O
+Medicine	B-CHED
+Drug	O
+Information	O
+Portal	B-ANAT
+and	O
+ClinicalTrials	O
+.	O
+gov	O
+.	O
+
+TITLE	O
+:	O
+Immunohistochemical	O
+and	O
+molecular	O
+detection	O
+of	O
+natural	O
+cases	O
+of	O
+bovine	B-SPEC
+rotavirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+infection	I-DISO
+causing	O
+enteritis	B-DISO
+in	O
+dairy	O
+calves	O
+.	O
+
+Further	O
+RT	O
+-	O
+PCR	O
+positive	O
+cases	O
+were	O
+confirmed	O
+by	O
+immunohistochemistry	O
+(	O
+IHC	O
+)	O
+in	O
+paraffin	O
+-	O
+embedded	O
+intestinal	B-ANAT
+tissue	B-ANAT
+sections	O
+.	O
+
+Bi	O
+-	O
+variate	O
+comparisons	O
+and	O
+multiple	O
+logistic	O
+regressions	B-DISO
+were	O
+the	O
+choice	O
+of	O
+data	O
+analyses	O
+.	O
+
+Patients	O
+who	O
+were	O
+admitted	O
+with	O
+septic	B-DISO
+shock	I-DISO
+and	O
+/	O
+or	O
+organ	B-DISO
+failure	I-DISO
+were	O
+significantly	O
+more	O
+likely	O
+to	O
+die	O
+than	O
+patients	O
+who	O
+were	O
+admitted	O
+with	O
+pneumonia	B-DISO
+and	O
+/	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+OR	O
+=	O
+47	O
+.	O
+9	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+3	O
+.	O
+9	O
+,	O
+585	O
+.	O
+5	O
+,	O
+p	O
+-	O
+value	O
+0	O
+.	O
+002	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Hospital	O
+mortality	O
+was	O
+25	O
+%;	O
+septic	B-DISO
+shock	I-DISO
+/	O
+organ	B-DISO
+failure	I-DISO
+at	O
+admittance	O
+was	O
+a	O
+significant	O
+predictor	O
+of	O
+mortality	O
+.	O
+
+Opioids	O
+also	O
+have	O
+direct	O
+cardiovascular	B-ANAT
+effects	O
+,	O
+decreasing	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+causing	O
+vasodilation	B-DISO
+and	O
+decreasing	O
+cardiac	B-ANAT
+work	O
+.	O
+
+They	O
+can	O
+also	O
+be	O
+informally	O
+classified	O
+based	O
+upon	O
+their	O
+major	O
+use	O
+such	O
+as	O
+anesthesia	B-DISO
+(	O
+fentanyl	B-CHED
+,	O
+alfentanil	B-CHED
+,	O
+remifentanil	B-CHED
+,	O
+sufentanil	B-CHED
+),	O
+severe	B-DISO
+pain	I-DISO
+(	O
+morphine	B-CHED
+,	O
+hydromorphone	B-CHED
+,	O
+levorphanol	O
+,	O
+merperidine	O
+),	O
+moderate	O
+to	O
+severe	O
+acute	O
+or	O
+chronic	B-DISO
+pain	I-DISO
+(	O
+transdermal	O
+or	O
+transbuccal	O
+fentanyl	B-CHED
+,	O
+codeine	B-CHED
+,	O
+oxycodone	B-CHED
+,	O
+hydrocodone	B-CHED
+,	O
+levorphanol	O
+,	O
+methadone	B-CHED
+),	O
+diarrhea	B-DISO
+(	O
+loperamide	B-CHED
+,	O
+diphenoxylate	B-CHED
+),	O
+and	O
+cough	B-DISO
+(	O
+codeine	B-CHED
+,	O
+hydrocodone	B-CHED
+).	O
+
+This	O
+constellation	O
+of	O
+events	O
+is	O
+referred	O
+to	O
+as	O
+inadvertent	O
+or	O
+unintended	O
+acetaminophen	B-CHED
+overdose	O
+or	O
+more	O
+colloquially	O
+as	O
+a	O
+“	O
+therapeutic	O
+misadventure	O
+”.	O
+
+References	O
+to	O
+the	O
+safety	O
+and	O
+hepatotoxic	O
+potential	O
+of	O
+the	O
+various	O
+opiate	B-CHED
+agonists	I-CHED
+are	O
+given	O
+together	O
+at	O
+the	O
+end	O
+of	O
+this	O
+Overview	O
+section	O
+.	O
+
+Loperamide	B-CHED
+.	O
+
+The	O
+aminopenicillins	O
+,	O
+like	O
+the	O
+natural	O
+first	O
+generation	O
+penicillins	B-CHED
+,	O
+bind	B-FUNC
+to	O
+bacterial	O
+proteins	B-CHED
+and	O
+inhibit	O
+synthesis	B-PROC
+of	O
+the	O
+bacterial	O
+cell	B-COMP
+wall	I-COMP
+,	O
+causing	O
+cell	B-COMP
+lysis	B-DISO
+particularly	O
+in	O
+rapidly	O
+growing	O
+organisms	O
+.	O
+
+The	O
+aminopenicillins	O
+are	O
+widely	O
+used	O
+for	O
+therapy	O
+of	O
+mild	O
+-	O
+to	O
+-	O
+severe	O
+urinary	O
+,	O
+respiratory	O
+,	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+,	O
+skin	B-ANAT
+,	O
+bone	B-DISO
+and	I-DISO
+joint	I-DISO
+infections	I-DISO
+.	O
+
+For	O
+these	O
+reasons	O
+,	O
+amoxicillin	B-CHED
+/	O
+clavulanate	B-CHED
+is	O
+discussed	O
+separately	O
+and	O
+references	O
+are	O
+provided	O
+with	O
+that	O
+discussion	O
+.	O
+
+ABSTRACT	O
+:	O
+Dromedary	O
+camels	B-SPEC
+are	O
+important	O
+reservoir	O
+hosts	B-COMP
+of	O
+various	O
+coronaviruses	O
+,	O
+including	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+that	O
+cause	O
+human	B-SPEC
+infections	B-DISO
+.	O
+
+CoV	O
+genomes	O
+regularly	O
+undergo	O
+recombination	B-PROC
+during	O
+infection	B-DISO
+as	O
+observed	O
+in	O
+bat	B-ENZY
+SARS	B-DISO
+-	O
+related	O
+CoVs	O
+.	O
+
+We	O
+failed	O
+to	O
+find	O
+molecular	O
+evidence	O
+of	O
+an	O
+HKU8r	O
+-	O
+CoV	O
+or	O
+a	O
+putative	O
+recombinant	O
+virus	B-SPEC
+.	O
+
+We	O
+had	O
+to	O
+use	O
+'	B-ANAT
+airway	I-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+'	O
+mode	O
+in	O
+view	O
+of	O
+severe	O
+refractory	O
+hypoxemia	O
+.	O
+
+We	O
+suggest	O
+that	O
+'	B-ANAT
+airway	I-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+'	O
+mode	O
+may	O
+be	O
+used	O
+successfully	O
+in	O
+patients	O
+with	O
+'	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+'	O
+complicated	O
+by	O
+pneumothorax	B-DISO
+if	O
+intensive	O
+and	O
+close	O
+monitoring	O
+is	O
+done	O
+.	O
+
+TITLE	O
+:	O
+One	O
+-	O
+step	O
+triplex	O
+reverse	O
+-	O
+transcription	B-PROC
+PCR	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+porcine	B-SPEC
+sapelovirus	I-SPEC
+,	O
+and	O
+porcine	B-SPEC
+sapovirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+Novel	O
+Betacoronavirus	B-SPEC
+(	O
+ABSTRACT	O
+:	O
+While	O
+dromedaries	B-SPEC
+are	O
+the	O
+immediate	O
+animal	B-SPEC
+source	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+epidemic	O
+,	O
+viruses	B-SPEC
+related	O
+to	O
+MERS	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+)	O
+have	O
+also	O
+been	O
+found	O
+in	O
+bats	B-SPEC
+as	O
+well	O
+as	O
+hedgehogs	B-SPEC
+.	O
+
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+related	O
+to	O
+MERS	O
+-	O
+CoV	O
+,	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+caused	O
+enormous	O
+economic	O
+losses	O
+to	O
+the	O
+global	O
+pig	B-SPEC
+industry	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+highly	O
+virulent	O
+epidemic	O
+virus	B-SPEC
+strain	O
+CT	O
+was	O
+serially	O
+passaged	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+for	O
+up	O
+to	O
+120	O
+generations	O
+(	O
+P120	O
+).	O
+
+RESULTS	O
+:	O
+Pathogenicity	O
+experiments	O
+using	O
+P120	O
+in	O
+piglets	O
+revealed	O
+significant	O
+reductions	O
+in	O
+clinical	O
+symptoms	O
+,	O
+histopathological	O
+lesions	O
+,	O
+and	O
+intestinal	B-PRGE
+PEDV	B-SPEC
+antigen	B-CHED
+distribution	O
+;	O
+the	O
+piglet	O
+survival	O
+rate	O
+in	O
+the	O
+P120	O
+group	O
+was	O
+100	O
+%.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+use	O
+of	O
+lung	O
+protective	O
+ventilation	O
+(	O
+LPV	O
+)	O
+strategies	O
+,	O
+a	O
+severe	O
+form	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+unfortunately	O
+associated	O
+with	O
+high	O
+mortality	O
+rates	O
+,	O
+which	O
+sometimes	O
+exceed	O
+60	O
+%.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+focused	O
+on	O
+the	O
+most	O
+important	O
+clinical	O
+trials	O
+aiming	O
+at	O
+a	O
+final	O
+conclusion	O
+about	O
+the	O
+effectiveness	O
+of	O
+ECLS	O
+in	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Of	O
+them	O
+,	O
+976	O
+patients	O
+received	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+and	O
+209	O
+patients	O
+received	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+(	O
+ECCO	O
+
+ABSTRACT	O
+:	O
+The	O
+syndrome	B-DISO
+of	O
+drug	O
+reaction	O
+with	O
+eosinophilia	B-DISO
+and	O
+systemic	O
+symptoms	O
+(	O
+DRESS	O
+)	O
+is	O
+a	O
+rare	O
+,	O
+yet	O
+potentially	O
+fatal	O
+hypersensitivity	B-DISO
+reaction	I-DISO
+,	O
+most	O
+commonly	O
+associated	O
+with	O
+anticonvulsants	B-CHED
+,	O
+sulfonamides	B-CHED
+,	O
+and	O
+allopurinol	B-CHED
+.	O
+
+In	O
+95	O
+%	O
+of	O
+cases	O
+,	O
+another	O
+visceral	O
+organ	B-ANAT
+was	O
+involved	O
+(	O
+most	O
+commonly	O
+liver	B-ANAT
+or	O
+kidneys	B-ANAT
+).	O
+
+Pulmonary	B-ANAT
+manifestations	O
+are	O
+less	O
+common	O
+but	O
+are	O
+typically	O
+seen	O
+in	O
+more	O
+severe	O
+cases	O
+.	O
+
+MERS	O
+were	O
+transmitted	B-DISO
+to	O
+them	O
+indirectly	O
+by	O
+staff	O
+who	O
+cared	O
+for	O
+the	O
+index	O
+patient	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Extensive	O
+HF	O
+burns	O
+combined	O
+with	O
+an	O
+inhalation	B-PROC
+injury	O
+led	O
+to	O
+a	O
+potentially	O
+fatal	O
+electrolyte	B-DISO
+imbalance	I-DISO
+and	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+:	O
+Historical	O
+,	O
+Epidemiologic	O
+,	O
+and	O
+Clinical	O
+Features	O
+.	O
+
+Bats	B-SPEC
+are	O
+likely	O
+an	O
+important	O
+reservoir	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+SARS	B-PRGE
+-	I-PRGE
+like	I-PRGE
+CoVs	I-PRGE
+have	O
+been	O
+detected	O
+in	O
+horseshoe	B-SPEC
+bats	I-SPEC
+and	O
+civet	B-SPEC
+cats	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+is	O
+a	O
+novel	O
+lethal	O
+zoonotic	O
+disease	O
+of	O
+humans	B-SPEC
+caused	O
+by	O
+the	O
+MERS	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+).	O
+
+PSN	O
+treatment	O
+significantly	O
+attenuated	O
+HKMRSA	O
+-	O
+induced	O
+pathological	O
+injury	O
+,	O
+pulmonary	B-ANAT
+neutrophil	B-ANAT
+infiltration	B-DISO
+,	O
+tissue	B-ANAT
+permeability	O
+and	O
+the	O
+production	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IL	O
+-	O
+1β	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+)	O
+in	O
+murine	B-SPEC
+ALI	O
+model	O
+.	O
+
+Furthermore	O
+,	O
+treatment	O
+with	O
+PSN	O
+suppressed	O
+the	O
+activation	O
+of	O
+MAPKs	O
+(	O
+e	O
+.	O
+g	O
+.	O
+p38	B-FUNC
+MAPK	B-FUNC
+,	O
+JNK	B-FUNC
+and	O
+ERK	B-FUNC
+)	O
+and	O
+NF	O
+-	O
+κB	O
+.	O
+Collectively	O
+,	O
+our	O
+results	O
+suggest	O
+that	O
+PSN	O
+ameliorates	O
+gram	B-SPEC
+-	I-SPEC
+positive	I-SPEC
+bacteria	I-SPEC
+-	O
+induced	O
+ALI	O
+in	O
+mice	B-SPEC
+by	O
+inhibition	B-PROC
+of	O
+the	O
+MAPK	B-FUNC
+and	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathways	B-PROC
+,	O
+and	O
+our	O
+studies	O
+suggest	O
+that	O
+PSN	B-PRGE
+might	O
+be	O
+a	O
+novel	O
+candidate	O
+for	O
+treating	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Since	O
+its	O
+launch	O
+in	O
+2017	O
+,	O
+CEPI	O
+has	O
+mobilised	O
+over	O
+US	O
+$	O
+750	O
+million	O
+to	O
+support	O
+its	O
+mission	O
+to	O
+develop	O
+vaccines	O
+against	O
+agents	O
+such	O
+as	O
+Lassa	B-SPEC
+Virus	I-SPEC
+,	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+Nipah	B-SPEC
+Virus	I-SPEC
+,	O
+as	O
+well	O
+as	O
+several	O
+rapid	O
+response	O
+vaccine	O
+platforms	O
+to	O
+accelerate	O
+response	O
+times	O
+to	O
+unexpected	O
+epidemic	O
+threats	O
+.	O
+
+This	O
+commentary	O
+provides	O
+an	O
+overview	O
+of	O
+the	O
+global	O
+health	O
+challenges	O
+CEPI	O
+was	O
+established	O
+to	O
+address	O
+,	O
+its	O
+achievements	O
+to	O
+date	O
+,	O
+and	O
+indicates	O
+priorities	O
+for	O
+funding	O
+and	O
+coordination	B-PROC
+in	O
+the	O
+coming	O
+years	O
+.	O
+
+Retinoic	B-CHED
+acid	I-CHED
+-	O
+inducible	O
+gene	B-PRGE
+-	I-PRGE
+I	I-PRGE
+(	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+and	O
+MDA5	B-PRGE
+both	O
+belong	O
+to	O
+the	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+family	B-SPEC
+,	O
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+is	O
+known	O
+to	O
+be	O
+involved	O
+in	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+DEV	I-PRGE
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+overexpression	B-PROC
+and	O
+knockdown	O
+methods	O
+to	O
+determine	O
+if	O
+MDA5	B-PRGE
+affected	O
+DEV	O
+infection	B-DISO
+in	O
+ducks	B-SPEC
+.	O
+
+We	O
+demonstrated	O
+that	O
+overexpression	B-PROC
+of	O
+duck	B-SPEC
+MDA5	B-PRGE
+significantly	O
+upregulated	O
+expression	B-PROC
+of	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)-	O
+stimulated	O
+genes	O
+,	O
+including	O
+myxovirus	B-PRGE
+resistance	I-PRGE
+protein	B-CHED
+(	O
+Mx	O
+),	O
+IFN	O
+-	O
+induced	O
+oligodenylate	O
+synthetase	O
+-	O
+like	O
+(	O
+OASL	B-PRGE
+),	O
+IFN	B-PRGE
+-	I-PRGE
+induced	I-PRGE
+transmembrane	I-PRGE
+protein	B-CHED
+1	I-PRGE
+(	O
+IFITM1	B-PRGE
+)	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+results	O
+of	O
+base	O
+composition	O
+analysis	O
+showed	O
+A	O
+/	O
+T	O
+rich	O
+and	O
+G	O
+/	O
+C	O
+poor	O
+in	O
+PEDV	B-PRGE
+orf3	I-PRGE
+genes	I-PRGE
+,	O
+and	O
+the	O
+most	O
+abundant	O
+base	O
+was	O
+nucleotide	B-CHED
+T	O
+.	O
+The	O
+relative	O
+synonymous	O
+codon	O
+usage	O
+value	O
+in	O
+each	O
+codon	O
+revealed	O
+that	O
+codon	O
+usage	O
+bias	B-SPEC
+existed	O
+.	O
+
+The	O
+mean	O
+ENC	O
+value	O
+of	O
+each	O
+gene	O
+was	O
+48	O
+.	O
+75	O
+,	O
+indicating	O
+a	O
+low	O
+codon	O
+usage	O
+bias	B-SPEC
+,	O
+as	O
+well	O
+as	O
+a	O
+relatively	O
+instable	O
+change	O
+in	O
+PEDV	B-PRGE
+orf3	I-PRGE
+genes	I-PRGE
+.	O
+
+LRN	O
+-	O
+B	O
+laboratories	O
+tested	O
+1097	O
+specimens	O
+during	O
+the	O
+2014	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+outbreak	O
+,	O
+180	O
+specimens	O
+during	O
+the	O
+2014	O
+-	O
+2015	O
+Ebola	O
+outbreak	O
+,	O
+and	O
+92	O
+686	O
+specimens	O
+during	O
+the	O
+2016	O
+-	O
+2017	O
+Zika	B-SPEC
+virus	I-SPEC
+outbreak	O
+.	O
+
+The	O
+results	O
+were	O
+similar	O
+to	O
+those	O
+obtained	O
+from	O
+the	O
+VN	O
+test	O
+using	O
+live	O
+MERS	O
+-	O
+CoV	O
+and	O
+were	O
+more	O
+sensitive	O
+than	O
+the	O
+ELISA	O
+performed	O
+using	O
+synthetic	O
+MERS	O
+S1	O
+fragment	O
+as	O
+the	O
+antigen	B-CHED
+as	O
+well	O
+as	O
+the	O
+competitive	O
+ELISA	O
+performed	O
+using	O
+a	O
+monoclonal	O
+antibody	B-COMP
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+According	O
+to	O
+the	O
+comprehensive	O
+results	O
+of	O
+the	O
+four	O
+types	O
+of	O
+serodiagnosis	O
+methods	O
+,	O
+positive	O
+antibodies	B-COMP
+were	O
+detected	O
+only	O
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+and	O
+the	O
+remaining	O
+herbivorous	O
+animals	O
+were	O
+not	O
+infected	O
+with	O
+the	O
+virus	B-SPEC
+.	O
+
+The	O
+characteristic	O
+skin	B-ANAT
+lesions	O
+appear	O
+as	O
+ring	O
+-	O
+shaped	O
+hemorrhagic	O
+pustules	O
+that	O
+evolve	O
+into	O
+necrotic	B-PROC
+ulcers	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+recent	O
+years	O
+,	O
+many	O
+studies	O
+have	O
+shown	O
+that	O
+recombinant	O
+adenovirus	B-DISO
+live	O
+vector	O
+-	O
+based	O
+vaccines	O
+are	O
+a	O
+promising	O
+novel	O
+vaccine	O
+candidate	O
+against	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Right	O
+ventricular	B-ANAT
+endomyocardial	O
+biopsy	O
+was	O
+performed	O
+in	O
+dogs	B-SPEC
+with	O
+UMRD	O
+(	O
+dilated	B-PATH
+cardiomyopathy	I-PATH
+[	O
+n	O
+=	O
+25	O
+],	O
+atrioventricular	B-DISO
+block	I-DISO
+[	O
+6	O
+],	O
+and	O
+nonfamilial	O
+ventricular	B-ANAT
+[	O
+4	O
+]	O
+and	O
+supraventricular	B-DISO
+arrhythmias	I-DISO
+[	O
+2	O
+])	O
+or	O
+CHD	O
+(	O
+10	O
+)	O
+that	O
+required	O
+right	O
+ventricular	B-ANAT
+catheterization	O
+.	O
+
+Dogs	B-SPEC
+with	O
+UMRD	O
+were	O
+significantly	O
+more	O
+likely	O
+than	O
+dogs	B-SPEC
+with	O
+CHD	O
+to	O
+have	O
+pathogens	O
+detected	O
+in	O
+biopsy	O
+samples	O
+(	O
+OR	O
+,	O
+11	O
+.	O
+8	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+3	O
+to	O
+103	O
+.	O
+0	O
+).	O
+
+The	O
+most	O
+common	O
+pathogens	O
+in	O
+dogs	B-SPEC
+with	O
+UMRD	O
+were	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+canine	O
+coronavirus	B-SPEC
+,	O
+canine	O
+parvovirus	B-DISO
+2	O
+,	O
+and	O
+
+It	O
+infects	O
+pigs	B-SPEC
+of	O
+all	O
+ages	O
+,	O
+and	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+and	O
+high	O
+mortality	O
+rates	O
+in	O
+newborn	O
+pigs	B-SPEC
+,	O
+leading	O
+to	O
+devastating	O
+economic	O
+losses	O
+in	O
+the	O
+pork	O
+industry	O
+worldwide	O
+.	O
+
+However	O
+,	O
+to	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+there	O
+has	O
+been	O
+no	O
+reported	O
+cases	O
+of	O
+effective	O
+antiviral	B-CHED
+antibody	B-COMP
+-	O
+peptide	B-CHED
+bispecific	O
+fusion	O
+proteins	B-CHED
+.	O
+
+We	O
+previously	O
+developed	O
+potent	O
+fully	O
+human	B-SPEC
+monoclonal	O
+antibodies	B-COMP
+and	O
+inhibitory	O
+peptides	B-CHED
+against	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+causes	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+with	O
+high	O
+mortality	O
+.	O
+
+We	O
+found	O
+that	O
+one	O
+of	O
+these	O
+fusion	O
+proteins	B-CHED
+,	O
+designated	O
+as	O
+m336	O
+diabody	O
+-	O
+pep	B-CHED
+,	O
+exhibited	O
+more	O
+potent	O
+inhibitory	O
+activity	O
+than	O
+the	O
+antibody	B-COMP
+or	O
+the	O
+peptide	B-CHED
+alone	O
+against	O
+pseudotyped	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+-	O
+mediated	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+,	O
+suggesting	O
+its	O
+potential	O
+to	O
+be	O
+developed	O
+as	O
+an	O
+effective	O
+bispecific	O
+immunotherapeutic	O
+for	O
+clinical	O
+use	O
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+status	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+2019	O
+:	O
+an	O
+update	O
+from	O
+January	O
+1	O
+to	O
+March	O
+31	O
+,	O
+2019	O
+.	O
+
+Health	O
+care	O
+workers	O
+had	O
+2	O
+.	O
+4	O
+fold	O
+[	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+2	O
+-	O
+3	O
+.	O
+1	O
+]	O
+greater	O
+odds	O
+of	O
+death	B-PROC
+compared	O
+to	O
+other	O
+people	O
+.	O
+
+Following	O
+the	O
+development	B-PROC
+of	O
+tissue	B-ANAT
+culture	O
+adapted	O
+strains	O
+of	O
+PDCoV	O
+,	O
+it	O
+is	O
+now	O
+possible	O
+to	O
+address	O
+questions	O
+regarding	O
+virus	B-SPEC
+-	O
+host	B-COMP
+cell	I-COMP
+interactions	O
+for	O
+this	O
+genera	O
+of	O
+coronavirus	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+presented	O
+a	O
+detailed	O
+study	O
+of	O
+PDCoV	O
+-	O
+induced	O
+replication	O
+organelles	B-COMP
+.	O
+
+Initial	O
+laboratory	O
+testing	O
+was	O
+significant	O
+for	O
+a	O
+serum	B-COMP
+creatinine	B-CHED
+concentration	O
+of	O
+4	O
+.	O
+1	O
+mg	O
+/	O
+dl	O
+,	O
+a	O
+mixed	O
+metabolic	B-PROC
+and	O
+respiratory	B-DISO
+acidosis	I-DISO
+,	O
+thrombocytopenia	O
+,	O
+abnormal	O
+hepatic	B-ANAT
+transaminases	O
+,	O
+and	O
+coagulation	B-PROC
+tests	O
+.	O
+
+Our	O
+patient	O
+simultaneously	O
+had	O
+kidney	B-DISO
+failure	I-DISO
+,	O
+rhabdomyolysis	B-DISO
+,	O
+and	O
+permanent	O
+hearing	B-DISO
+loss	I-DISO
+following	O
+methadone	B-CHED
+poisoning	O
+.	O
+
+Here	O
+,	O
+we	O
+elucidate	O
+the	O
+determinants	O
+for	O
+kidney	B-ANAT
+tropism	B-PROC
+by	O
+studying	O
+interactions	O
+between	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+viral	O
+attachment	O
+protein	B-CHED
+spike	O
+from	O
+two	O
+IBV	B-SPEC
+strains	O
+with	O
+different	O
+tropisms	B-PROC
+.	O
+
+Recombinantly	O
+produced	O
+RBDs	O
+from	O
+the	O
+nephropathogenic	O
+IBV	B-SPEC
+strain	O
+QX	O
+and	O
+from	O
+the	O
+nonnephropathogenic	O
+strain	O
+M41	O
+bound	O
+to	O
+the	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+trachea	B-DISO
+.	O
+
+While	O
+removal	O
+of	O
+sialic	B-CHED
+acids	I-CHED
+from	O
+tissues	B-ANAT
+prevented	O
+binding	B-FUNC
+of	O
+all	O
+proteins	B-CHED
+to	O
+all	O
+tissues	B-ANAT
+,	O
+binding	B-FUNC
+of	O
+QX	O
+-	O
+RBD	O
+to	O
+trachea	B-DISO
+and	O
+kidney	B-ANAT
+could	O
+not	O
+be	O
+blocked	O
+by	O
+preincubation	O
+with	O
+synthetic	O
+alpha	O
+-	O
+2	O
+,	O
+3	O
+-	O
+linked	O
+sialic	B-CHED
+acids	I-CHED
+.	O
+
+The	O
+lack	O
+of	O
+binding	B-FUNC
+of	O
+QX	O
+-	O
+RBD	O
+to	O
+a	O
+previously	O
+identified	O
+IBV	B-PRGE
+-	I-PRGE
+M41	I-PRGE
+receptor	I-PRGE
+was	O
+confirmed	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+),	O
+demonstrating	O
+that	O
+tissue	B-ANAT
+binding	B-FUNC
+of	O
+QX	O
+-	O
+RBD	O
+is	O
+dependent	O
+on	O
+a	O
+different	O
+sialylated	O
+glycan	B-CHED
+receptor	O
+.	O
+
+Using	O
+chimeric	O
+RBD	O
+proteins	B-CHED
+,	O
+we	O
+discovered	O
+that	O
+the	O
+region	O
+encompassing	O
+amino	B-CHED
+acids	I-CHED
+99	O
+to	O
+159	O
+of	O
+QX	O
+-	O
+RBD	O
+was	O
+required	O
+to	O
+establish	O
+kidney	B-ANAT
+binding	B-FUNC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+aryl	B-PRGE
+hydrocarbon	I-PRGE
+receptor	I-PRGE
+(	O
+AhR	B-PRGE
+)	O
+is	O
+a	O
+cytoplasmic	B-COMP
+receptor	O
+/	O
+transcription	B-PROC
+factor	O
+that	O
+modulates	O
+several	O
+cellular	B-COMP
+and	O
+immunological	O
+processes	O
+following	O
+activation	O
+by	O
+pathogen	O
+-	O
+associated	O
+stimuli	O
+,	O
+though	O
+its	O
+role	O
+during	O
+virus	B-DISO
+infection	I-DISO
+is	O
+largely	O
+unknown	O
+.	O
+
+The	O
+use	O
+and	O
+experience	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+in	O
+burn	O
+patients	O
+developing	O
+ARDS	B-DISO
+are	O
+still	O
+limited	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+Rates	O
+of	O
+Hospitalization	O
+Between	O
+Single	O
+and	O
+Dual	O
+Virus	B-SPEC
+Detection	O
+in	O
+a	O
+Mexican	O
+Cohort	O
+of	O
+Children	O
+and	O
+Adults	O
+With	O
+Influenza	O
+-	O
+Like	O
+Illness	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+assess	O
+the	O
+efficacy	O
+of	O
+the	O
+INTERCEPT	O
+™	O
+Blood	O
+System	O
+[	O
+amotosalen	O
+/	O
+ultraviolet	O
+A	O
+(	O
+UVA	O
+)	O
+light	O
+]	O
+to	O
+reduce	O
+the	O
+risk	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+transmission	O
+by	O
+human	B-SPEC
+platelet	B-ANAT
+concentrates	O
+.	O
+
+Complete	O
+inactivation	B-DISO
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+spiked	O
+platelet	B-ANAT
+units	O
+was	O
+achieved	O
+by	O
+treatment	O
+with	O
+Amotosalen	O
+/	O
+UVA	O
+light	O
+with	O
+a	O
+mean	O
+log	O
+reduction	O
+of	O
+4	O
+·	O
+48	O
+±	O
+0	O
+·	O
+3	O
+.	O
+
+There	O
+were	O
+19	O
+cases	O
+diagnosed	O
+with	O
+ARDS	B-DISO
+and	O
+treated	O
+with	O
+ECMO	O
+and	O
+57	O
+controls	O
+with	O
+ARDS	B-DISO
+.	O
+
+Reopening	O
+the	O
+sternum	B-ANAT
+postoperatively	O
+may	O
+help	O
+maintaining	O
+hemodynamics	B-PROC
+and	O
+respiratory	B-PROC
+function	I-PROC
+.	O
+
+Furthermore	O
+,	O
+docking	B-PROC
+analyses	O
+revealed	O
+that	O
+the	O
+predicted	O
+peptides	B-CHED
+engaged	O
+in	O
+strong	O
+bonding	O
+with	O
+the	O
+HLA	B-PRGE
+-	I-PRGE
+B7	I-PRGE
+allele	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Humoral	O
+Immunogenicity	O
+and	O
+Efficacy	O
+of	O
+a	O
+Single	O
+Dose	O
+of	O
+ChAdOx1	O
+MERS	O
+Vaccine	O
+Candidate	O
+in	O
+Dromedary	B-SPEC
+Camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Non	O
+-	O
+invasive	O
+bioluminescence	B-PROC
+imaging	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+and	O
+therapy	O
+in	O
+the	O
+central	B-ANAT
+nervous	B-DISO
+system	I-ANAT
+of	O
+live	O
+mice	B-SPEC
+.	O
+
+Inflammatory	B-DISO
+responses	I-DISO
+have	O
+a	O
+significant	O
+impact	O
+on	O
+MERS	O
+-	O
+CoV	O
+pathogenesis	B-DISO
+and	O
+disease	O
+outcome	O
+.	O
+
+This	O
+was	O
+undertaken	O
+by	O
+assessing	O
+IBV	B-SPEC
+viral	O
+RNA	O
+sequences	O
+from	O
+the	O
+ORF	O
+encoding	O
+the	O
+S1	O
+portion	O
+of	O
+viral	O
+surface	O
+glycoprotein	B-CHED
+(	O
+S	O
+)	O
+before	O
+and	O
+after	O
+the	O
+introduction	O
+of	O
+a	O
+new	O
+live	O
+vaccine	O
+on	O
+broiler	O
+farms	O
+in	O
+northern	O
+-	O
+Italy	O
+.	O
+
+This	O
+evidence	O
+strongly	O
+supports	O
+the	O
+action	O
+of	O
+vaccine	O
+-	O
+induced	O
+immunity	B-PROC
+in	O
+conditioning	O
+viral	O
+evolution	B-PROC
+,	O
+potentially	O
+leading	O
+to	O
+the	O
+emergence	O
+of	O
+new	O
+vaccine	O
+-	O
+escape	O
+variants	O
+.	O
+
+Reports	O
+also	O
+reveal	O
+high	O
+seroprevalence	O
+,	O
+which	O
+indicates	O
+that	O
+the	O
+disease	O
+burden	O
+of	O
+enterovirus	B-SPEC
+D68	O
+may	O
+be	O
+underestimated	O
+via	O
+viral	O
+culture	O
+or	O
+polymerase	O
+chain	O
+reaction	O
+results	O
+.	O
+
+Although	O
+most	O
+infected	O
+cases	O
+have	O
+mild	O
+respiratory	O
+illness	O
+,	O
+severe	O
+complications	O
+including	O
+acute	O
+flaccid	O
+myelitis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+have	O
+also	O
+been	O
+reported	O
+.	O
+
+In	O
+the	O
+position	O
+of	O
+an	O
+emerging	O
+pathogen	O
+,	O
+enterovirus	B-SPEC
+D68	O
+poses	O
+a	O
+threat	O
+to	O
+public	O
+health	O
+and	O
+may	O
+cause	O
+devastating	O
+diseases	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+due	O
+to	O
+Sai	O
+-	O
+rei	O
+-	O
+to	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+successfully	O
+treated	O
+by	O
+multi	O
+-	O
+modal	O
+therapy	O
+including	O
+immunosuppressive	O
+therapy	O
+,	O
+plasma	O
+exchange	O
+,	O
+and	O
+intravenous	O
+immunoglobulin	B-PROC
+:	O
+A	O
+case	O
+report	O
+.	O
+
+Further	O
+,	O
+tests	O
+for	O
+anti	O
+-	O
+glomerular	B-ANAT
+basement	I-ANAT
+membrane	I-ANAT
+antibody	B-COMP
+,	O
+myeloperoxidase	B-PRGE
+-	I-PRGE
+ANCA	B-CHED
+,	I-PRGE
+and	I-PRGE
+proteinase	B-ENZY
+3	I-ENZY
+-	I-PRGE
+ANCA	B-CHED
+revealed	O
+negative	O
+results	O
+.	O
+
+Children	O
+under	O
+two	O
+years	O
+of	O
+age	O
+and	O
+children	O
+with	O
+malnutrition	B-DISO
+may	O
+have	O
+a	O
+risk	O
+of	O
+prolonged	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.	O
+
+Factors	O
+such	O
+as	O
+developmental	O
+level	O
+of	O
+the	O
+countries	O
+,	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+nutritional	O
+status	O
+,	O
+living	O
+in	O
+crowded	O
+environments	O
+,	O
+contact	O
+with	O
+contaminated	O
+water	B-CHED
+,	O
+close	O
+contact	O
+with	O
+animals	B-SPEC
+,	O
+working	O
+at	O
+a	O
+hospital	O
+and	O
+hot	O
+and	O
+humid	O
+climate	O
+affect	O
+the	O
+incidence	O
+of	O
+Cryptosporidiosis	B-DISO
+.	O
+
+Blocking	B-DISO
+MERS	O
+-	O
+CoV	O
+zoonotic	O
+transmission	O
+from	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+the	O
+animal	B-SPEC
+reservoir	O
+,	O
+could	O
+potentially	O
+reduce	O
+the	O
+number	O
+of	O
+primary	O
+human	B-SPEC
+cases	O
+.	O
+
+Using	O
+CRISPR	O
+/	O
+Cas9	O
+technology	O
+,	O
+a	O
+recombinant	O
+virus	B-SPEC
+rAJ1102	O
+-	O
+ΔORF3	O
+-	O
+EGFP	O
+in	O
+which	O
+the	O
+ORF3	O
+gene	O
+was	O
+replaced	O
+with	O
+an	O
+EGFP	B-PRGE
+gene	I-PRGE
+,	O
+was	O
+successfully	O
+generated	O
+,	O
+and	O
+its	O
+proliferation	B-DISO
+characteristics	O
+were	O
+compared	O
+with	O
+the	O
+parental	O
+rAJ1102	O
+.	O
+
+RESULTS	O
+:	O
+As	O
+compared	O
+with	O
+controls	O
+,	O
+DNA	O
+from	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+was	O
+significantly	O
+more	O
+frequent	O
+in	O
+CSF	B-ANAT
+and	O
+blood	B-ANAT
+from	O
+cases	O
+with	O
+ON	O
+;	O
+VZV	B-SPEC
+and	O
+HSV	B-SPEC
+-	O
+2	O
+were	O
+found	O
+only	O
+in	O
+CSF	B-ANAT
+;	O
+EBV	O
+was	O
+found	O
+only	O
+in	O
+blood	B-ANAT
+samples	I-ANAT
+(	O
+p	O
+<	O
+0	O
+.	O
+006	O
+).	O
+
+The	O
+presence	O
+of	O
+a	O
+BCG	B-CHED
+vaccination	O
+scar	B-DISO
+was	O
+observed	O
+in	O
+2	O
+patients	O
+(	O
+8	O
+%).	O
+
+Radiological	O
+images	O
+with	O
+micronodular	O
+opacities	B-DISO
+were	O
+the	O
+most	O
+common	O
+(	O
+54	O
+%),	O
+followed	O
+by	O
+macronodular	O
+densities	O
+(	O
+33	O
+%),	O
+and	O
+reticulonodular	O
+densities	O
+(	O
+13	O
+%).	O
+
+An	O
+improved	O
+accessibility	O
+to	O
+early	O
+diagnosis	O
+and	O
+treatment	O
+and	O
+prevention	O
+of	O
+TB	O
+infection	B-DISO
+should	O
+reduce	O
+its	O
+prevalence	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+study	O
+demonstrated	O
+that	O
+ΔEVLWI2	O
+is	O
+an	O
+independent	O
+prognostic	O
+factor	O
+for	O
+early	O
+ARDS	B-DISO
+in	O
+severe	O
+burns	O
+.	O
+
+Fifty	O
+patients	O
+(	O
+11	O
+.	O
+85	O
+%)	O
+were	O
+diagnosed	O
+with	O
+sepsis	B-DISO
+.	O
+
+Multivariate	O
+analysis	O
+demonstrated	O
+that	O
+,	O
+in	O
+men	O
+,	O
+high	O
+lactate	B-CHED
+level	O
+and	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+transfusion	O
+within	O
+24	O
+hours	O
+were	O
+risk	O
+factors	O
+for	O
+sepsis	B-DISO
+.	O
+
+Reassessment	O
+of	O
+sepsis	B-DISO
+should	O
+be	O
+considered	O
+at	O
+day	O
+8	O
+of	O
+hospital	O
+stay	O
+or	O
+day	O
+4	O
+postoperatively	O
+.	O
+
+TITLE	O
+:	O
+Oxygenation	B-PROC
+Index	O
+in	O
+the	O
+First	O
+24	O
+Hours	O
+after	O
+the	O
+Diagnosis	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+as	O
+a	O
+Surrogate	O
+Metric	O
+for	O
+Risk	O
+Stratification	O
+in	O
+Children	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+diagnosis	O
+of	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PARDS	O
+)	O
+is	O
+a	O
+pragmatic	O
+decision	O
+based	O
+on	O
+the	O
+degree	O
+of	O
+hypoxia	B-DISO
+at	O
+the	O
+time	O
+of	O
+onset	O
+.	O
+
+Reclassification	O
+based	O
+on	O
+data	O
+measured	O
+24	O
+hours	O
+after	O
+diagnosis	O
+was	O
+compared	O
+with	O
+the	O
+initial	O
+classification	O
+,	O
+and	O
+changes	O
+in	O
+pressure	O
+parameters	O
+and	O
+oxygenation	B-PROC
+were	O
+investigated	O
+for	O
+their	O
+prognostic	O
+value	O
+with	O
+respect	O
+to	O
+mortality	O
+.	O
+
+Therefore	O
+,	O
+researches	O
+targeting	B-PROC
+these	O
+viruses	B-SPEC
+have	O
+been	O
+required	O
+.	O
+
+The	O
+antiviral	B-CHED
+activity	O
+of	O
+some	O
+flavonoids	B-CHED
+against	O
+CoVs	O
+is	O
+presumed	O
+directly	O
+caused	O
+by	O
+inhibiting	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CLpro	O
+).	O
+
+Herbacetin	O
+,	O
+rhoifolin	B-CHED
+and	O
+pectolinarin	O
+were	O
+found	O
+to	O
+efficiently	O
+block	O
+the	O
+enzymatic	B-PROC
+activity	I-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+.	O
+
+The	O
+most	O
+SEYLL	O
+related	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	O
+was	O
+in	O
+the	O
+early	O
+four	O
+years	O
+of	O
+the	O
+onset	O
+of	O
+the	O
+pandemic	O
+(	O
+2012	O
+to	O
+2015	O
+)	O
+and	O
+in	O
+the	O
+last	O
+four	O
+years	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+pandemic	O
+(	O
+216	O
+to	O
+2019	O
+),	O
+a	O
+significant	O
+reduction	O
+was	O
+observed	O
+in	O
+the	O
+SEYLL	O
+related	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+the	O
+MERS	O
+patients	O
+.	O
+
+Maximum	O
+likelihood	O
+phylogenies	O
+showed	O
+that	O
+the	O
+OC43	O
+strains	O
+were	O
+genetically	O
+dissimilar	O
+and	O
+that	O
+the	O
+NL63	O
+strain	O
+was	O
+closely	O
+related	O
+to	O
+NL63	O
+genotype	O
+B	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+emerges	O
+when	O
+feline	B-SPEC
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+mutate	B-PROC
+within	O
+their	O
+host	B-COMP
+to	O
+a	O
+highly	O
+virulent	O
+biotype	O
+and	O
+the	O
+immune	B-PROC
+response	I-PROC
+is	O
+not	O
+able	O
+to	O
+control	O
+the	O
+infection	B-DISO
+.	O
+
+MERS	O
+-	O
+CoV	O
+transmission	O
+in	O
+healthcare	O
+facility	O
+mainly	O
+results	O
+from	O
+laps	O
+in	O
+infection	B-DISO
+control	O
+measures	O
+and	O
+late	O
+isolation	O
+of	O
+suspected	O
+cases	O
+.	O
+
+Thus	O
+,	O
+the	O
+neonatal	O
+piglet	O
+model	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+serves	O
+as	O
+an	O
+excellent	O
+model	O
+to	O
+study	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+is	O
+the	O
+preferred	O
+animal	B-SPEC
+model	O
+for	O
+reasons	O
+of	O
+availability	O
+,	O
+body	B-ANAT
+size	O
+,	O
+similarities	O
+of	O
+porcine	B-SPEC
+and	O
+human	O
+lung	B-ANAT
+,	O
+robustness	O
+,	O
+and	O
+costs	O
+.	O
+
+An	O
+integrated	O
+nostril	B-ANAT
+-	O
+gastric	B-ANAT
+feeding	O
+tube	O
+containing	O
+an	O
+esophageal	O
+electrode	O
+and	O
+balloon	O
+was	O
+placed	O
+in	O
+14	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+prior	O
+to	O
+PPV	B-CHED
+.	O
+
+Monitoring	O
+EMGdi	O
+regularly	O
+during	O
+PPV	B-CHED
+in	O
+ARDS	B-DISO
+patients	O
+is	O
+feasible	O
+and	O
+can	O
+be	O
+used	O
+as	O
+a	O
+reference	O
+for	O
+lung	B-ANAT
+protective	O
+ventilation	O
+strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+high	O
+percentage	O
+of	O
+camel	O
+handlers	O
+in	O
+Saudi	O
+Arabia	O
+are	O
+seropositive	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+use	O
+of	O
+therapeutic	O
+drug	O
+monitoring	O
+for	O
+patients	O
+receiving	O
+antimicrobial	O
+therapy	O
+with	O
+concurrent	O
+ECMO	O
+may	O
+facilitate	O
+appropriate	O
+drug	O
+dosing	O
+to	O
+achieve	O
+adequate	O
+serum	B-COMP
+concentrations	O
+and	O
+optimize	O
+favorable	O
+patient	O
+outcomes	O
+.	O
+
+The	O
+fusion	O
+peptide	B-CHED
+alters	O
+the	O
+membrane	B-PROC
+organization	I-PROC
+and	O
+dynamics	O
+of	O
+the	O
+host	B-COMP
+membrane	B-COMP
+to	O
+facilitate	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+We	O
+have	O
+used	O
+depth	O
+-	O
+dependent	O
+fluorescence	O
+probes	O
+,	O
+1	B-CHED
+,	I-CHED
+6	I-CHED
+-	I-CHED
+diphenyl	I-CHED
+-	I-CHED
+1	I-CHED
+,	I-CHED
+3	I-CHED
+,	I-CHED
+5	I-CHED
+-	I-CHED
+hexatriene	I-CHED
+(	O
+DPH	B-CHED
+)	O
+and	O
+its	O
+trimethylammonium	B-CHED
+derivative	O
+(	O
+TMA	B-CHED
+-	O
+DPH	B-CHED
+),	O
+to	O
+evaluate	O
+the	O
+effect	O
+of	O
+the	O
+peptide	B-FUNC
+binding	I-FUNC
+along	O
+the	O
+bilayer	O
+normal	O
+.	O
+
+We	O
+have	O
+further	O
+evaluated	O
+the	O
+effect	O
+of	O
+membrane	B-COMP
+cholesterol	B-CHED
+on	O
+the	O
+binding	B-FUNC
+and	O
+organization	O
+of	O
+the	O
+peptide	B-CHED
+and	O
+the	O
+impact	O
+of	O
+peptide	B-FUNC
+binding	I-FUNC
+on	O
+the	O
+depth	O
+-	O
+dependent	O
+physical	O
+properties	O
+of	O
+the	O
+membrane	B-COMP
+at	O
+various	O
+cholesterol	B-CHED
+concentrations	O
+.	O
+
+We	O
+report	O
+on	O
+a	O
+case	O
+of	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+secondary	O
+to	O
+inhalation	B-PROC
+of	O
+cannabis	B-DISO
+oil	O
+via	O
+a	O
+vape	O
+pen	O
+,	O
+and	O
+propose	O
+a	O
+new	O
+term	O
+that	O
+describes	O
+lung	B-ANAT
+injury	O
+related	O
+to	O
+vaping	O
+.	O
+
+There	O
+was	O
+a	O
+decreasing	O
+trend	O
+for	O
+in	O
+-	O
+hospital	O
+mortality	O
+for	O
+sepsis	B-DISO
+over	O
+time	O
+in	O
+SOT	O
+patients	O
+and	O
+non	O
+-	O
+SOT	O
+patients	O
+(	O
+P	O
+<	O
+.	O
+05	O
+)	O
+due	O
+to	O
+early	O
+sepsis	B-DISO
+recognition	O
+and	O
+improved	O
+standard	O
+of	O
+care	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+),	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+share	O
+tropism	B-PROC
+for	O
+swine	B-SPEC
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+We	O
+found	O
+that	O
+PDCoV	O
+N	O
+and	O
+TGEV	B-SPEC
+N	O
+can	O
+competitively	O
+interact	O
+with	O
+PEDV	B-SPEC
+N	O
+.	O
+However	O
+,	O
+the	O
+presence	O
+of	O
+PDCoV	O
+or	O
+TGEV	B-SPEC
+N	O
+led	O
+to	O
+very	O
+different	O
+outcomes	O
+on	O
+PEDV	B-SPEC
+replication	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+a	O
+lack	O
+of	O
+early	O
+signs	O
+suggesting	O
+right	O
+ventricular	B-ANAT
+systolic	O
+and	O
+diastolic	B-DISO
+dysfunction	I-DISO
+prior	O
+to	O
+acute	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+development	B-PROC
+.	O
+
+We	O
+conducted	O
+a	O
+retrospective	O
+analytical	O
+cohort	O
+study	O
+of	O
+patients	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+undertaking	O
+an	O
+echocardiography	O
+during	O
+admission	O
+in	O
+the	O
+cardiothoracic	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Hilar	O
+congestion	B-DISO
+was	O
+highlighted	O
+on	O
+chest	B-ANAT
+x	O
+-	O
+ray	B-SPEC
+.	O
+
+Sacubitril	O
+/	O
+valsartan	B-CHED
+should	O
+be	O
+effective	O
+on	O
+pathophysiologic	O
+mechanisms	O
+and	O
+cardiovascular	B-ANAT
+outcomes	O
+of	O
+Marfan	B-DISO
+syndrome	I-DISO
+-	O
+related	O
+cardiovascular	B-ANAT
+complications	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+(	O
+PLPs	O
+or	O
+PLpro	O
+),	O
+such	O
+as	O
+the	O
+one	O
+encoded	O
+in	O
+the	O
+genome	O
+of	O
+the	O
+infectious	B-DISO
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+virus	B-SPEC
+,	O
+have	O
+multiple	O
+enzymatic	O
+activities	O
+that	O
+promote	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Exit	O
+screening	O
+was	O
+part	O
+of	O
+the	O
+World	O
+Health	O
+Organisation	B-PROC
+'	O
+s	O
+(	O
+WHO	O
+)	O
+temporary	O
+recommendations	O
+for	O
+implementation	O
+in	O
+certain	O
+points	O
+of	O
+entry	O
+,	O
+for	O
+specific	O
+time	O
+periods	B-PROC
+.	O
+
+Despite	O
+the	O
+ineffectiveness	O
+of	O
+entry	O
+and	O
+exit	O
+screening	O
+measures	O
+,	O
+authors	O
+reported	O
+several	O
+important	O
+concomitant	O
+positive	O
+effects	O
+that	O
+their	O
+impact	O
+is	O
+difficult	O
+to	O
+assess	O
+,	O
+including	O
+discouraging	O
+travel	O
+of	O
+ill	B-DISO
+persons	O
+,	O
+raising	O
+awareness	O
+,	O
+and	O
+educating	O
+the	O
+traveling	O
+public	O
+and	O
+maintaining	O
+operation	O
+of	O
+flights	O
+from	O
+/	O
+to	O
+the	O
+affected	O
+areas	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+an	O
+original	O
+,	O
+highly	O
+virulent	O
+PEAV	O
+strain	O
+GDS04	O
+was	O
+serially	O
+passaged	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+Compared	O
+with	O
+P15	B-PRGE
+and	O
+P67	B-PRGE
+,	O
+P100	B-PRGE
+resulted	O
+in	O
+only	O
+mild	O
+clinical	O
+signs	O
+and	O
+intestinal	B-ANAT
+lesions	O
+in	O
+piglets	O
+.	O
+
+However	O
+,	O
+viral	O
+distribution	O
+and	O
+viral	O
+shedding	O
+showed	O
+that	O
+the	O
+viral	O
+loads	O
+of	O
+rIBYZ	O
+-	O
+ScAUG3a	O
+were	O
+lower	O
+than	O
+those	O
+of	O
+rIBYZ	O
+in	O
+tissue	B-ANAT
+samples	O
+and	O
+swab	O
+specimens	O
+.	O
+
+Protein	B-PRGE
+3b	I-PRGE
+has	O
+a	O
+greater	O
+effect	O
+on	O
+pathogenicity	O
+than	O
+protein	B-CHED
+3a	O
+.	O
+
+Viruses	B-SPEC
+were	O
+common	O
+causes	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+;	O
+with	O
+≥	O
+1	O
+virus	B-SPEC
+being	O
+detected	O
+in	O
+65	O
+.	O
+2	O
+%	O
+of	O
+patients	O
+.	O
+
+He	O
+was	O
+then	O
+administered	O
+valsartan	B-CHED
+tablets	O
+at	O
+a	O
+dosage	O
+of	O
+80	O
+mg	O
+per	O
+day	O
+and	O
+L	B-CHED
+-	I-CHED
+carnitine	I-CHED
+supplements	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Thus	O
+,	O
+gene	O
+examination	O
+can	O
+help	O
+to	O
+understand	O
+the	O
+etiology	O
+of	O
+repetitive	O
+nontraumatic	O
+rhabdomyolysis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+as	O
+an	O
+Organ	B-ANAT
+Phenotype	O
+of	O
+Vascular	B-ANAT
+Microthrombotic	O
+Disease	O
+:	O
+Based	O
+on	O
+Hemostatic	O
+Theory	O
+and	O
+Endothelial	B-ANAT
+Molecular	O
+Pathogenesis	B-DISO
+.	O
+
+ARDS	B-DISO
+is	O
+one	O
+of	O
+organ	B-ANAT
+phenotypes	O
+among	O
+MODS	B-DISO
+associated	O
+with	O
+TTP	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+.	O
+
+RSV	B-SPEC
+was	O
+the	O
+most	O
+frequently	O
+co	O
+-	O
+detected	O
+virus	B-SPEC
+(	O
+61	O
+.	O
+3	O
+%).	O
+
+When	O
+compared	O
+with	O
+HBoV	O
+detection	O
+alone	O
+,	O
+the	O
+co	O
+-	O
+detection	O
+of	O
+RSV	B-PRGE
+and	O
+HBoV	O
+was	O
+associated	O
+with	O
+male	O
+sex	O
+(	O
+P	O
+=	O
+0	O
+.	O
+013	O
+),	O
+younger	O
+age	O
+(	O
+P	O
+=	O
+0	O
+.	O
+01	O
+),	O
+and	O
+lower	O
+blood	B-ANAT
+neutrophil	B-ANAT
+count	O
+(	O
+P	O
+=	O
+0	O
+.	O
+032	O
+).	O
+
+RESULTS	O
+:	O
+HBoV	O
+was	O
+detected	O
+alone	O
+in	O
+29	O
+(	O
+48	O
+.	O
+3	O
+%)	O
+patients	O
+,	O
+while	O
+in	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+other	O
+viruses	B-SPEC
+in	O
+31	O
+patients	O
+(	O
+51	O
+.	O
+7	O
+%),	O
+with	O
+a	O
+peak	O
+between	O
+December	O
+and	O
+January	O
+.	O
+
+Pregnant	O
+women	O
+and	O
+young	O
+children	O
+,	O
+especially	O
+those	O
+born	O
+prematurely	O
+,	O
+may	O
+develop	O
+serious	O
+complications	O
+if	O
+infected	O
+with	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+We	O
+performed	O
+a	O
+1	O
+:	O
+1	O
+case	O
+-	O
+control	O
+study	O
+enrolling	O
+previously	O
+healthy	O
+full	O
+-	O
+term	O
+infants	O
+(≤	O
+12	O
+months	O
+)	O
+with	O
+bronchiolitis	B-DISO
+admitted	O
+to	O
+the	O
+PICU	B-SPEC
+as	O
+cases	O
+and	O
+those	O
+to	O
+the	O
+general	O
+pediatric	O
+ward	O
+as	O
+controls	O
+from	O
+2015	O
+to	O
+2017	O
+.	O
+
+The	O
+PICU	B-SPEC
+patients	O
+were	O
+younger	O
+(	O
+median	O
+:	O
+2	O
+.	O
+2	O
+months	O
+,	O
+interquartile	O
+range	O
+:	O
+1	O
+.	O
+3	O
+-	O
+4	O
+.	O
+2	O
+)	O
+than	O
+the	O
+general	O
+ward	O
+patients	O
+(	O
+median	O
+:	O
+3	O
+.	O
+2	O
+months	O
+,	O
+interquartile	O
+range	O
+:	O
+1	O
+.	O
+6	O
+-	O
+6	O
+.	O
+4	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Early	O
+FO	O
+≥	O
+5	O
+%	O
+has	O
+been	O
+linked	O
+to	O
+adverse	O
+postoperative	O
+outcomes	O
+in	O
+pediatric	O
+patients	O
+undergoing	O
+repair	B-PROC
+for	O
+ALCAPA	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+a	O
+case	O
+of	O
+a	O
+young	O
+boy	O
+who	O
+sustained	O
+a	O
+traumatic	O
+brain	B-ANAT
+injury	O
+(	O
+TBI	O
+)	O
+complicated	O
+by	O
+intractable	O
+intracranial	B-DISO
+hypertension	I-DISO
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+with	O
+hypercapnia	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+fatal	O
+case	O
+of	O
+APS	B-DISO
+type	I-DISO
+1	I-DISO
+with	O
+hypotension	O
+and	O
+profound	O
+hypoglycemia	B-DISO
+in	O
+a	O
+24	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+who	O
+was	O
+found	O
+unconsciousness	O
+at	O
+home	O
+and	O
+progressively	O
+evolved	O
+into	O
+pulseless	B-DISO
+electrical	I-DISO
+activity	I-DISO
+.	O
+
+Postmortem	O
+examination	O
+revealed	O
+severely	O
+atrophic	B-DISO
+adrenal	B-ANAT
+glands	I-ANAT
+with	O
+lymphocytic	B-DISO
+infiltration	I-DISO
+.	O
+
+Furthermore	O
+,	O
+it	O
+underscores	O
+the	O
+fact	O
+that	O
+Addison	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+can	O
+occur	O
+as	O
+part	O
+of	O
+a	O
+constellation	O
+of	O
+autoimmune	B-DISO
+manifestations	O
+within	O
+the	O
+context	O
+of	O
+an	O
+underlying	O
+polyglandular	O
+syndrome	B-DISO
+,	O
+such	O
+as	O
+APS	B-DISO
+type	I-DISO
+1	I-DISO
+.	O
+
+Whole	O
+-	O
+genome	O
+and	O
+S	O
+gene	O
+sequences	O
+were	O
+obtained	O
+from	O
+nasal	B-ANAT
+swabs	O
+using	O
+next	O
+-	O
+generation	O
+sequencing	O
+and	O
+phylogenetic	O
+trees	O
+were	O
+constructed	O
+.	O
+
+Similar	O
+identity	O
+matrix	O
+and	O
+determination	O
+of	O
+the	O
+most	O
+common	O
+ancestor	O
+were	O
+used	O
+to	O
+compare	O
+clusters	B-CHED
+of	O
+patient	O
+'	O
+s	O
+sequences	O
+.	O
+
+TITLE	O
+:	O
+Prone	O
+Position	O
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Patients	O
+:	O
+A	O
+Retrospective	O
+Analysis	O
+of	O
+Complications	O
+.	O
+
+ABSTRACT	O
+:	O
+Early	O
+application	O
+of	O
+prolonged	O
+prone	O
+positioning	O
+has	O
+been	O
+shown	O
+to	O
+improve	O
+patient	O
+survival	O
+in	O
+moderate	O
+to	O
+severe	O
+adult	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+.	O
+
+Twenty	O
+-	O
+three	O
+patients	O
+developed	O
+pressure	B-DISO
+sores	I-DISO
+after	O
+prone	O
+position	O
+(	O
+14	O
+%).	O
+
+TITLE	O
+:	O
+Combining	O
+Procalcitonin	O
+and	O
+Rapid	O
+Multiplex	O
+Respiratory	O
+Virus	B-SPEC
+Testing	O
+for	O
+Antibiotic	B-CHED
+Stewardship	O
+in	O
+Older	O
+Adult	O
+Patients	O
+With	O
+Severe	O
+Acute	O
+Respiratory	O
+Infection	O
+.	O
+
+More	O
+than	O
+one	O
+-	O
+fourth	O
+(	O
+27	O
+.	O
+9	O
+%)	O
+of	O
+the	O
+patients	O
+in	O
+the	O
+experimental	O
+group	O
+tested	O
+positive	O
+for	O
+virus	B-SPEC
+.	O
+
+Compared	O
+with	O
+controls	O
+,	O
+the	O
+experimental	O
+group	O
+had	O
+a	O
+significantly	O
+higher	O
+proportion	O
+of	O
+antibiotics	B-CHED
+discontinuation	O
+or	O
+de	O
+-	O
+escalation	O
+in	O
+the	O
+ED	O
+(	O
+26	O
+.	O
+0	O
+%	O
+vs	O
+16	O
+.	O
+1	O
+%,	O
+P	O
+=	O
+.	O
+007	O
+),	O
+neuraminidase	B-CHED
+inhibitor	I-CHED
+uses	O
+(	O
+8	O
+.	O
+9	O
+%	O
+vs	O
+0	O
+.	O
+6	O
+%,	O
+P	O
+<	O
+.	O
+001	O
+),	O
+and	O
+shorter	O
+duration	O
+of	O
+intravenous	O
+antibiotics	B-CHED
+(	O
+10	O
+.	O
+0	O
+vs	O
+14	O
+.	O
+5	O
+days	O
+,	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+severe	O
+and	O
+often	O
+lethal	O
+respiratory	O
+illness	O
+in	O
+humans	B-SPEC
+,	O
+and	O
+no	O
+vaccines	O
+or	O
+specific	O
+treatments	O
+are	O
+available	O
+.	O
+
+As	O
+usual	O
+,	O
+cardiopulmonary	B-ANAT
+bypass	O
+circuit	O
+is	O
+required	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+Life	O
+Support	O
+in	O
+Adults	O
+with	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+:	O
+Current	O
+Evidence	O
+-	O
+Based	O
+Practices	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+used	O
+to	O
+rescue	O
+patients	O
+with	O
+severe	O
+hypoxemic	O
+and	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+refractory	O
+to	O
+optimal	O
+therapy	O
+and	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+(	O
+ECCO2R	O
+)	O
+supports	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+allows	O
+very	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+to	O
+minimize	O
+the	O
+risk	O
+of	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Dromedaries	B-SPEC
+are	O
+the	O
+source	O
+of	O
+human	B-SPEC
+zoonotic	B-DISO
+infection	I-DISO
+.	O
+
+MERS	O
+-	O
+CoV	O
+is	O
+enzootic	O
+among	O
+dromedaries	B-SPEC
+on	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+the	O
+Middle	O
+East	O
+and	O
+in	O
+Africa	O
+.	O
+
+ResultsSerum	O
+samples	O
+were	O
+collected	O
+from	O
+camel	B-SPEC
+slaughterhouse	O
+workers	O
+(	O
+n	O
+=	O
+137	O
+),	O
+camel	B-SPEC
+herders	O
+(	O
+n	O
+=	O
+156	O
+)	O
+and	O
+individuals	O
+of	O
+the	O
+general	O
+population	O
+without	O
+occupational	O
+contact	O
+with	O
+camels	B-SPEC
+but	O
+living	O
+in	O
+camel	B-SPEC
+herding	O
+areas	O
+(	O
+n	O
+=	O
+186	O
+).	O
+
+MERS	O
+-	O
+CoV	O
+neutralising	O
+antibodies	B-COMP
+with	O
+≥	O
+90	O
+%	O
+reduction	O
+of	O
+plaque	B-DISO
+numbers	O
+were	O
+detected	O
+in	O
+two	O
+(	O
+1	O
+.	O
+5	O
+%)	O
+slaughterhouse	O
+workers	O
+,	O
+none	O
+of	O
+the	O
+camel	B-SPEC
+herders	O
+and	O
+one	O
+individual	O
+from	O
+the	O
+general	O
+population	O
+(	O
+0	O
+.	O
+5	O
+%).	O
+ConclusionsThis	O
+study	O
+provides	O
+evidence	O
+of	O
+zoonotic	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+Morocco	O
+in	O
+people	O
+who	O
+have	O
+direct	O
+or	O
+indirect	O
+exposure	O
+to	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Utility	O
+of	O
+Point	O
+-	O
+of	O
+-	O
+Care	O
+Lung	B-ANAT
+Ultrasound	O
+for	O
+Initial	O
+Assessment	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Patients	O
+in	O
+the	O
+Emergency	B-DISO
+Department	O
+.	O
+
+In	O
+our	O
+study	O
+,	O
+we	O
+aim	O
+to	O
+assess	O
+the	O
+utility	O
+of	O
+point	O
+-	O
+of	O
+-	O
+care	O
+ultrasound	O
+(	O
+POCUS	O
+)-	O
+LUS	O
+in	O
+the	O
+initial	O
+assessment	O
+of	O
+ARDS	B-DISO
+patients	O
+presenting	O
+to	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+).	O
+
+The	O
+bedside	O
+LUS	O
+was	O
+performed	O
+by	O
+the	O
+trained	O
+emergency	B-DISO
+physician	O
+on	O
+patients	O
+with	O
+undifferentiated	O
+dyspnea	B-DISO
+with	O
+a	O
+clinical	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+according	O
+to	O
+the	O
+Berlin	O
+'	O
+s	O
+criteria	O
+.	O
+
+The	O
+distributions	O
+of	O
+study	O
+individuals	O
+were	O
+as	O
+follows	O
+:	O
+27	O
+%	O
+-	O
+mild	O
+ARDS	B-DISO
+,	O
+37	O
+%	O
+-	O
+moderate	O
+ARDS	B-DISO
+,	O
+and	O
+36	O
+%	O
+-	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Recently	O
+,	O
+several	O
+outbreaks	O
+of	O
+ECoV	O
+infection	B-DISO
+have	O
+also	O
+been	O
+reported	O
+in	O
+adult	O
+horses	B-SPEC
+from	O
+the	O
+USA	O
+,	O
+France	O
+and	O
+Japan	O
+.	O
+
+Overall	O
+,	O
+the	O
+results	O
+demonstrated	O
+that	O
+the	O
+ECoV	O
+S1	O
+-	O
+based	O
+ELISA	O
+has	O
+reliable	O
+diagnostic	O
+performance	O
+compared	O
+to	O
+the	O
+VN	O
+assay	O
+and	O
+is	O
+a	O
+useful	O
+assay	O
+to	O
+support	O
+seroconversion	O
+in	O
+horses	B-SPEC
+involved	O
+with	O
+ECoV	O
+outbreaks	O
+and	O
+to	O
+estimate	O
+ECoV	O
+seroprevalence	O
+in	O
+populations	O
+of	O
+horses	B-SPEC
+.	O
+
+Finally	O
+,	O
+we	O
+found	O
+that	O
+the	O
+addition	O
+of	O
+exogenous	O
+trypsin	B-PRGE
+also	O
+rescues	O
+HKU5	O
+-	O
+CoV	O
+,	O
+a	O
+second	O
+bat	B-PRGE
+group	I-PRGE
+2c	I-PRGE
+CoV	I-PRGE
+.	O
+Together	O
+,	O
+these	O
+results	O
+indicate	O
+that	O
+proteolytic	B-PROC
+cleavage	B-PROC
+of	O
+the	O
+spike	O
+,	O
+not	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+is	O
+the	O
+primary	B-DISO
+infection	I-DISO
+barrier	O
+for	O
+these	O
+two	O
+group	O
+2c	O
+CoVs	O
+.	O
+
+TITLE	O
+:	O
+Attenuation	O
+and	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+in	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+Iranian	O
+793	O
+/	O
+B	O
+serotype	O
+during	O
+serial	O
+passaging	O
+in	O
+embryonated	O
+chicken	O
+eggs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+use	O
+of	O
+live	O
+attenuated	O
+vaccine	O
+(	O
+LAV	O
+)	O
+is	O
+the	O
+main	O
+method	O
+for	O
+controlling	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+).	O
+
+The	O
+results	O
+showed	O
+a	O
+decrease	O
+in	O
+the	O
+virulence	B-PROC
+and	O
+pathogenicity	O
+of	O
+the	O
+isolates	O
+at	O
+passage	O
+90	O
+compared	O
+to	O
+passage	O
+15	O
+,	O
+although	O
+this	O
+decrease	O
+in	O
+pathogenicity	O
+was	O
+very	O
+mild	O
+and	O
+viruses	O
+after	O
+passage	O
+90	O
+were	O
+not	O
+adequately	O
+attenuated	O
+.	O
+
+Keywords	O
+:	O
+infectious	B-DISO
+bronchitis	B-DISO
+;	O
+live	O
+attenuated	O
+vaccine	O
+;	O
+793	O
+/	O
+B	O
+serotype	O
+;	O
+pathogenicity	O
+;	O
+attenuation	O
+;	O
+nucleotide	B-CHED
+sequencing	O
+.	O
+
+TITLE	O
+:	O
+Coronaviruses	O
+Detected	O
+in	O
+Bats	B-SPEC
+in	O
+Close	O
+Contact	O
+with	O
+Humans	B-SPEC
+in	O
+Rwanda	O
+.	O
+
+Mucosal	B-ANAT
+swabs	O
+from	O
+503	O
+bats	B-SPEC
+representing	O
+17	O
+species	B-SPEC
+were	O
+sampled	O
+from	O
+2010	O
+to	O
+2014	O
+and	O
+screened	O
+by	O
+consensus	O
+PCR	O
+for	O
+11	O
+viral	O
+families	O
+.	O
+
+Samples	O
+were	O
+negative	O
+for	O
+all	O
+viral	O
+families	O
+except	O
+coronaviruses	O
+,	O
+which	O
+were	O
+detected	O
+in	O
+27	O
+bats	B-SPEC
+belonging	O
+to	O
+eight	O
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Choking	B-DISO
+agents	O
+and	O
+chlorine	B-CHED
+gas	B-ENZY
+-	O
+History	O
+,	O
+pathophysiology	O
+,	O
+clinical	O
+effects	O
+and	O
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+Choking	O
+agent	O
+exposure	O
+,	O
+among	O
+them	O
+chlorine	B-CHED
+gas	B-ENZY
+,	O
+occurs	O
+in	O
+household	O
+or	O
+industrial	O
+accidents	O
+,	O
+chemical	O
+warfare	O
+and	O
+terrorist	O
+attacks	O
+.	O
+
+Chlorine	B-CHED
+gas	B-ENZY
+has	O
+a	O
+medium	O
+solubility	O
+,	O
+also	O
+causing	O
+delayed	O
+lower	O
+airway	B-ANAT
+symptoms	O
+,	O
+mainly	O
+due	O
+to	O
+its	O
+oxidizing	O
+potential	O
+by	O
+releasing	O
+hypochlorous	O
+and	O
+hydrochloric	B-CHED
+acid	I-CHED
+,	O
+but	O
+also	O
+by	O
+interacting	O
+with	O
+Transient	O
+Receptor	O
+Potential	O
+channels	O
+.	O
+
+Burns	O
+of	O
+the	O
+oronasal	O
+mucosa	B-ANAT
+and	O
+trachea	B-DISO
+can	O
+occur	O
+.	O
+
+Chlorine	B-CHED
+gas	B-ENZY
+can	O
+cause	O
+toxic	B-DISO
+pneumonitis	I-DISO
+,	O
+lung	B-DISO
+edema	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+CONCLUSIONS	O
+:	O
+Treatment	O
+is	O
+mainly	O
+symptom	B-DISO
+oriented	O
+.	O
+
+The	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+is	O
+influenced	O
+by	O
+climate	O
+conditions	O
+with	O
+increasing	O
+incidence	O
+between	O
+April	O
+and	O
+August	O
+.	O
+
+The	O
+effort	B-PROC
+-	O
+dependent	O
+lung	B-ANAT
+injury	O
+has	O
+been	O
+termed	O
+'	O
+patient	O
+self	O
+-	O
+inflicted	O
+lung	B-ANAT
+injury	O
+(	O
+P	O
+-	O
+SILI	O
+)'	O
+in	O
+2017	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+the	O
+immunodominant	O
+neutralizing	O
+regions	O
+in	O
+the	O
+spike	O
+glycoprotein	B-CHED
+of	O
+porcine	B-SPEC
+deltacoronavirus	O
+.	O
+
+Crucial	O
+to	O
+halting	O
+PDCoV	O
+transmission	O
+and	O
+infection	B-DISO
+is	O
+the	O
+development	B-PROC
+of	O
+effective	O
+therapies	O
+and	O
+vaccines	O
+.	O
+
+We	O
+describe	O
+our	O
+experience	O
+with	O
+12	O
+consecutive	O
+severe	O
+ARDS	B-DISO
+patients	O
+(	O
+age	O
+,	O
+39	O
+.	O
+1	O
+±	O
+16	O
+.	O
+4	O
+years	O
+)	O
+supported	O
+with	O
+awake	O
+ECMO	O
+to	O
+wait	O
+for	O
+native	O
+lung	B-ANAT
+recovery	O
+during	O
+prolonged	O
+ECMO	O
+treatment	O
+from	O
+July	O
+2013	O
+to	O
+January	O
+2018	O
+.	O
+
+The	O
+study	O
+involved	O
+a	O
+retrospective	O
+chart	O
+review	O
+of	O
+confirmed	O
+cases	O
+of	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+in	O
+a	O
+tertiary	O
+care	O
+referral	O
+center	O
+in	O
+Riyadh	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+from	O
+January	O
+2015	O
+to	O
+October	O
+2018	O
+.	O
+
+Two	O
+of	O
+the	O
+24	O
+patients	O
+died	B-PROC
+.	O
+
+Nephropathogenic	O
+IBVs	O
+might	O
+reach	B-PROC
+the	O
+kidney	B-ANAT
+also	O
+via	O
+an	O
+ascending	O
+route	O
+from	O
+the	O
+cloaca	B-SPEC
+,	O
+based	O
+on	O
+our	O
+observation	O
+that	O
+viral	O
+RNA	O
+was	O
+detected	O
+in	O
+the	O
+cloaca	B-SPEC
+one	O
+day	O
+before	O
+detection	O
+in	O
+the	O
+kidney	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Recent	O
+Research	O
+on	O
+Occupational	O
+Animal	B-SPEC
+Exposures	O
+and	O
+Health	O
+Risks	O
+:	O
+A	O
+Narrative	O
+Review	O
+.	O
+
+16s	B-CHED
+RNA	O
+amplicon	O
+sequencing	O
+identified	O
+distinct	O
+microbiota	B-SPEC
+compositions	O
+in	O
+households	O
+with	O
+active	O
+animal	B-SPEC
+farmers	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+-	O
+syndrome	B-DISO
+in	O
+the	O
+general	O
+complications	O
+of	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+The	O
+most	O
+frequent	O
+clinical	O
+form	O
+(	O
+15	O
+cases	O
+)	O
+was	O
+ARDS	B-DISO
+of	O
+moderate	O
+severity	O
+(	O
+41	O
+.	O
+5	O
+%).	O
+
+The	O
+total	O
+mortality	O
+due	O
+to	O
+pancreatitis	B-DISO
+-	O
+associated	O
+ARDS	B-DISO
+made	O
+44	O
+.	O
+5	O
+%.	O
+
+All	O
+lethal	O
+outcomes	O
+occurred	O
+due	O
+to	O
+progressing	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+mediates	O
+viral	O
+entry	O
+into	O
+cells	B-COMP
+by	O
+first	O
+binding	B-FUNC
+to	O
+a	O
+receptor	O
+on	O
+the	O
+host	B-COMP
+cell	I-COMP
+surface	I-COMP
+and	O
+then	O
+fusing	O
+viral	O
+and	O
+host	B-COMP
+membranes	B-ANAT
+.	O
+
+Camel	B-SPEC
+and	O
+bats	B-SPEC
+have	O
+been	O
+identified	O
+as	O
+a	O
+potential	O
+source	O
+of	O
+virus	B-SPEC
+for	O
+disease	O
+spread	O
+to	O
+human	B-SPEC
+.	O
+
+The	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+variations	O
+were	O
+observed	O
+in	O
+28	O
+/	O
+35	O
+samples	O
+and	O
+two	O
+unique	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+variations	O
+were	O
+observed	O
+in	O
+all	O
+samples	O
+analyzed	O
+while	O
+total	O
+19	O
+nucleotides	B-CHED
+sequences	O
+variations	O
+were	O
+observed	O
+in	O
+the	O
+Spike	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+minor	O
+recombination	B-PROC
+events	O
+were	O
+identified	O
+in	O
+eight	O
+different	O
+sequences	O
+at	O
+various	O
+hotspots	O
+in	O
+both	O
+human	B-SPEC
+and	O
+camel	B-SPEC
+samples	O
+using	O
+recombination	B-PROC
+detection	O
+programme	O
+.	O
+
+The	O
+results	O
+demonstrated	O
+that	O
+four	O
+compounds	O
+(	O
+6g	O
+,	O
+6l	O
+,	O
+6y	O
+and	O
+8c	O
+)	O
+showed	O
+robust	O
+anti	O
+-	O
+influenza	B-DISO
+potencies	O
+against	O
+H5N1	B-DISO
+,	O
+H5N2	B-CHED
+and	O
+H5N6	O
+strains	O
+in	O
+both	O
+enzymatic	O
+assay	O
+and	O
+cellular	B-COMP
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+fatal	O
+immune	O
+-	O
+mediated	O
+disease	O
+of	O
+cats	B-SPEC
+,	O
+induced	O
+by	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+).	O
+
+A	O
+combination	O
+of	O
+as	O
+yet	O
+poorly	O
+understood	O
+host	B-COMP
+and	O
+viral	O
+factors	O
+combine	O
+to	O
+cause	O
+a	O
+minority	O
+of	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+to	O
+develop	O
+FIP	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+database	O
+of	O
+geopositioned	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+occurrences	O
+.	O
+
+More	O
+broadly	O
+,	O
+it	O
+may	O
+also	O
+provide	O
+useful	O
+data	O
+for	O
+the	O
+development	B-PROC
+of	O
+targeted	B-PROC
+MERS	O
+-	O
+CoV	O
+surveillance	O
+,	O
+which	O
+would	O
+prove	O
+invaluable	O
+in	O
+preventing	O
+future	O
+zoonotic	O
+spillover	O
+.	O
+
+Furthermore	O
+,	O
+ORF8b	O
+was	O
+able	O
+to	O
+inhibit	O
+all	O
+forms	O
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+;	O
+full	O
+-	O
+length	O
+,	O
+RIG	O
+-	O
+I	O
+-	O
+1	O
+-	O
+734	O
+,	O
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+228	O
+,	O
+last	O
+of	O
+which	O
+contains	O
+only	O
+the	O
+CARD	B-PRGE
+domains	I-PRGE
+.	O
+
+Collectively	O
+,	O
+we	O
+suggest	O
+that	O
+this	O
+hDPP4	O
+-	O
+transgenic	O
+mouse	B-SPEC
+is	O
+useful	O
+to	O
+enable	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+for	O
+antiviral	B-CHED
+research	O
+and	O
+vaccine	O
+development	B-PROC
+against	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+reported	O
+on	O
+aristeromycin	O
+(	O
+1	O
+)	O
+and	O
+6	O
+'-	O
+fluorinated	O
+-	O
+aristeromycin	O
+analogues	O
+(	O
+2	O
+),	O
+which	O
+are	O
+active	O
+against	O
+RNA	O
+viruses	B-SPEC
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+Zika	B-SPEC
+virus	I-SPEC
+(	O
+ZIKV	O
+),	O
+and	O
+Chikungunya	B-SPEC
+virus	I-SPEC
+(	O
+CHIKV	O
+).	O
+
+TITLE	O
+:	O
+Enzootic	O
+patterns	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+imported	O
+African	O
+and	O
+local	O
+Arabian	O
+dromedary	O
+camels	B-SPEC
+:	O
+a	O
+prospective	O
+genomic	O
+study	O
+.	O
+
+Reproduction	B-PROC
+number	O
+estimates	O
+informed	O
+by	O
+the	O
+sequences	O
+suggest	O
+sustained	O
+endemicity	O
+of	O
+NRC	B-PRGE
+,	O
+with	O
+a	O
+mean	O
+R	O
+Despite	O
+frequent	O
+imports	O
+of	O
+MERS	O
+-	O
+CoV	O
+with	O
+camels	B-SPEC
+from	O
+Africa	O
+,	O
+African	O
+lineages	O
+of	O
+MERS	O
+-	O
+CoV	O
+do	O
+not	O
+establish	O
+themselves	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Phylogenetic	O
+analysis	O
+indicated	O
+complex	O
+ecological	O
+interactions	O
+including	O
+virus	O
+-	O
+host	B-COMP
+associations	O
+,	O
+cross	O
+-	O
+species	B-SPEC
+infections	B-DISO
+,	O
+and	O
+multiple	O
+viral	O
+strains	O
+circulating	O
+concurrently	O
+within	O
+selected	O
+bat	B-ENZY
+populations	O
+.	O
+
+TITLE	O
+:	O
+SKP2	B-PRGE
+attenuates	O
+autophagy	B-PROC
+through	O
+Beclin1	O
+-	O
+ubiquitination	B-PROC
+and	O
+its	O
+inhibition	B-PROC
+reduces	O
+MERS	O
+-	O
+Coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+Genetic	O
+or	O
+pharmacological	O
+inhibition	B-PROC
+of	O
+SKP2	B-PRGE
+decreases	O
+BECN1	B-PRGE
+ubiquitination	B-PROC
+,	O
+decreases	O
+BECN1	B-PRGE
+degradation	O
+and	O
+enhances	O
+autophagic	O
+flux	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+Ambulance	O
+Dispatch	O
+Calls	O
+for	O
+Surveillance	O
+of	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+manipulation	O
+of	O
+porcine	B-SPEC
+deltacoronavirus	O
+reveals	O
+insights	O
+into	O
+NS6	B-DISO
+and	O
+NS7	B-DISO
+functions	O
+:	O
+a	O
+novel	O
+strategy	O
+for	O
+vaccine	O
+design	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+an	O
+emerging	O
+swine	B-SPEC
+coronavirus	B-SPEC
+that	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+,	O
+resulting	O
+in	O
+high	O
+mortality	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+The	O
+tissue	B-PROC
+tropism	B-PROC
+is	O
+determined	O
+by	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+although	O
+the	O
+molecular	O
+bases	B-CHED
+for	O
+enteric	O
+tropism	B-PROC
+remain	O
+to	O
+be	O
+fully	O
+characterized	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viruses	B-SPEC
+infect	O
+the	O
+human	B-SPEC
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+mostly	O
+causing	O
+mild	O
+diseases	O
+.	O
+
+According	O
+to	O
+the	O
+biological	O
+activity	O
+studies	O
+of	O
+the	O
+compounds	O
+,	O
+5a	O
+-	O
+c	O
+displayed	O
+hope	O
+promising	O
+antitubercular	B-CHED
+activity	O
+,	O
+6d	O
+was	O
+found	O
+as	O
+potent	O
+for	O
+Coxsackie	O
+B4	O
+virus	B-SPEC
+,	O
+5d	O
+was	O
+found	O
+as	O
+effective	O
+against	O
+Feline	B-SPEC
+corona	B-CHED
+and	O
+Feline	B-SPEC
+herpes	B-DISO
+viruses	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+Pregnant	O
+women	O
+with	O
+H1N1	O
+infection	B-DISO
+are	O
+at	O
+higher	O
+risk	O
+of	O
+pneumonia	B-DISO
+and	O
+death	B-PROC
+than	O
+other	O
+women	O
+in	O
+the	O
+reproductive	B-PROC
+period	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+tested	O
+samples	O
+which	O
+were	O
+originally	O
+found	O
+negative	O
+for	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+virus	B-SPEC
+were	O
+also	O
+found	O
+to	O
+be	O
+negative	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+In	O
+this	O
+present	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+detection	O
+system	O
+of	O
+microbes	O
+from	O
+porcine	B-SPEC
+respiratory	O
+by	O
+using	O
+TaqMan	O
+real	O
+-	O
+time	O
+PCR	O
+(	O
+referred	O
+to	O
+as	O
+Dempo	O
+-	O
+PCR	O
+)	O
+to	O
+screen	O
+a	O
+broad	O
+range	O
+of	O
+pathogens	O
+associated	O
+with	O
+porcine	B-SPEC
+respiratory	B-DISO
+diseases	I-DISO
+in	O
+a	O
+single	O
+run	O
+.	O
+
+TITLE	O
+:	O
+Fill	O
+the	O
+gap	O
+between	O
+traditional	O
+and	O
+new	O
+era	B-CHED
+:	O
+The	O
+medical	O
+educational	O
+reform	O
+in	O
+Taiwan	O
+.	O
+
+Now	O
+,	O
+the	O
+first	O
+class	B-SPEC
+of	O
+physicians	O
+will	O
+enter	O
+the	O
+workplace	O
+in	O
+2019	O
+,	O
+subject	O
+to	O
+various	O
+clinical	O
+challenges	O
+.	O
+
+We	O
+found	O
+MALAT1	O
+was	O
+significantly	O
+increased	O
+in	O
+the	O
+ARDS	B-DISO
+patients	O
+'	O
+plasma	B-ANAT
+and	O
+PBMCs	O
+.	O
+
+MALAT1	B-PRGE
+interacted	O
+with	O
+miR	O
+-	O
+425	O
+and	O
+protected	O
+phosphatase	B-PRGE
+and	I-PRGE
+tensin	I-PRGE
+homolog	I-PRGE
+(	O
+PTEN	B-PRGE
+)	O
+expression	B-PROC
+in	O
+A549	O
+and	O
+HFL	O
+-	O
+1	O
+cells	B-COMP
+.	O
+
+However	O
+,	O
+little	O
+is	O
+known	O
+about	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+(	O
+HSV	B-SPEC
+)	O
+and	O
+Cytomegalovirus	B-SPEC
+(	O
+CMV	B-SPEC
+)	O
+reactivation	O
+occurring	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+under	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+We	O
+tried	O
+to	O
+determine	O
+the	O
+frequency	O
+of	O
+Herpesviridae	B-SPEC
+reactivation	O
+and	O
+its	O
+impact	O
+on	O
+patients	O
+'	O
+prognosis	O
+during	O
+ECMO	O
+for	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Disease	O
+involving	O
+all	O
+three	O
+Yang	O
+channels	O
+is	O
+the	O
+core	O
+of	O
+the	O
+pathogenesis	O
+of	O
+Chaige	O
+Jieji	O
+Decoction	O
+syndrome	B-DISO
+,	O
+in	O
+which	O
+headache	B-DISO
+is	O
+the	O
+key	O
+indications	O
+.	O
+
+Chaige	O
+Jieji	O
+Decoction	O
+can	O
+not	O
+only	O
+treat	O
+exogenous	O
+diseases	O
+,	O
+but	O
+also	O
+treat	O
+nosocomial	B-DISO
+infections	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+during	O
+hospitalization	O
+.	O
+
+Blood	B-ANAT
+investigations	O
+revealed	O
+moderate	O
+eosinophilia	B-DISO
+and	O
+elevated	O
+IgE	B-DISO
+levels	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+usually	O
+diagnosed	O
+through	O
+highly	O
+sensitive	O
+and	O
+specific	O
+genetic	O
+tests	O
+such	O
+as	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+METHODS	O
+:	O
+A	O
+series	O
+of	O
+benzo	O
+[	O
+d	O
+][	O
+1	O
+,	O
+2	O
+,	O
+3	O
+]	O
+triazol	O
+-	O
+1	O
+(	O
+2	O
+)-	O
+yl	O
+derivatives	O
+(	O
+here	O
+named	O
+benzotriazol	O
+-	O
+1	O
+(	O
+2	O
+)-	O
+yl	O
+)	O
+(	O
+4a	O
+-	O
+i	O
+,	O
+5a	O
+-	O
+h	O
+,	O
+6a	O
+-	O
+e	O
+,	O
+g	O
+,	O
+i	O
+,	O
+j	O
+and	O
+7a	O
+-	O
+f	O
+,	O
+h	O
+-	O
+j	O
+)	O
+were	O
+designed	O
+,	O
+synthesized	O
+and	O
+in	O
+vitro	O
+evaluated	O
+for	O
+cytotoxicity	B-DISO
+and	O
+antiviral	B-CHED
+activity	O
+against	O
+two	O
+important	O
+human	B-SPEC
+enteroviruses	B-SPEC
+(	O
+HEVs	O
+)	O
+members	O
+of	O
+the	O
+Picornaviridae	B-SPEC
+family	B-SPEC
+[	O
+Coxsackievirus	B-SPEC
+B	O
+5	O
+(	O
+CVB	O
+-	O
+5	O
+)	O
+and	O
+Poliovirus	B-SPEC
+1	O
+(	O
+Sb	O
+-	O
+1	O
+)].	O
+
+ABSTRACT	O
+:	O
+Management	O
+of	O
+H1N1	O
+viral	O
+infection	O
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+has	O
+primarily	O
+been	O
+focused	O
+on	O
+lung	B-ANAT
+protective	O
+ventilation	O
+strategies	O
+,	O
+despite	O
+that	O
+mortality	O
+remains	O
+high	O
+(	O
+up	O
+to	O
+45	O
+%).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+identified	O
+a	O
+newly	O
+emerged	O
+swine	B-SPEC
+acute	B-DISO
+diarrhea	I-DISO
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+SADS	O
+-	O
+CoV	O
+)	O
+in	O
+diarrheal	O
+samples	O
+of	O
+piglets	O
+from	O
+Fujian	O
+province	O
+in	O
+Southern	O
+China	O
+,	O
+and	O
+the	O
+prevalence	O
+rate	O
+of	O
+SADS	O
+-	O
+CoV	O
+was	O
+10	O
+.	O
+29	O
+%	O
+(	O
+7	O
+/	O
+68	O
+).	O
+
+The	O
+most	O
+frequent	O
+mutations	O
+were	O
+present	O
+in	O
+the	O
+collagenase	B-PRGE
+equivalent	I-PRGE
+(	O
+COE	O
+)	O
+and	O
+epitope	B-CHED
+regions	O
+of	O
+the	O
+spike	O
+gene	O
+of	O
+the	O
+PEDVs	O
+currently	O
+circulating	O
+in	O
+the	O
+field	O
+.	O
+
+The	O
+findings	O
+of	O
+this	O
+study	O
+indicated	O
+that	O
+variant	O
+PEDV	B-SPEC
+,	O
+PDCoV	O
+,	O
+and	O
+SADS	O
+-	O
+CoV	O
+were	O
+leading	O
+etiologic	O
+agents	O
+of	O
+porcine	B-SPEC
+diarrhea	B-DISO
+,	O
+and	O
+either	O
+mono	B-DISO
+-	O
+infections	B-DISO
+or	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+of	O
+pathogenic	O
+enteric	O
+CoVs	O
+were	O
+common	O
+in	O
+pigs	B-SPEC
+in	O
+Southern	O
+China	O
+during	O
+2012	O
+-	O
+2018	O
+.	O
+
+Here	O
+we	O
+describe	O
+these	O
+methods	O
+,	O
+highlighting	O
+virus	B-SPEC
+-	O
+cell	B-COMP
+entry	O
+factors	O
+,	O
+entry	O
+inhibitors	B-CHED
+,	O
+and	O
+viral	O
+determinants	O
+that	O
+specify	O
+the	O
+cell	B-COMP
+entry	O
+routes	O
+.	O
+
+TITLE	O
+:	O
+Bacterial	O
+Artificial	O
+Chromosome	B-COMP
+-	O
+Based	O
+Lambda	O
+Red	O
+Recombination	B-PROC
+with	O
+the	O
+I	B-PRGE
+-	I-PRGE
+SceI	I-PRGE
+Homing	I-PRGE
+Endonuclease	I-PRGE
+for	O
+Genetic	B-DISO
+Alteration	I-DISO
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+Over	O
+the	O
+past	O
+two	O
+decades	O
+,	O
+several	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infectious	B-DISO
+clones	O
+have	O
+been	O
+engineered	O
+,	O
+allowing	O
+for	O
+the	O
+manipulation	O
+of	O
+their	O
+large	O
+viral	O
+genomes	O
+(~	O
+30	O
+kb	O
+)	O
+using	O
+unique	O
+reverse	O
+genetic	O
+systems	O
+.	O
+
+Quickly	O
+after	O
+the	O
+identification	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+CoV	O
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+both	O
+in	O
+vitro	O
+ligation	O
+and	O
+BAC	O
+-	O
+based	O
+reverse	O
+genetic	O
+technologies	O
+were	O
+engineered	O
+for	O
+MERS	O
+-	O
+CoV	O
+to	O
+study	O
+its	O
+basic	O
+biological	O
+properties	O
+,	O
+develop	O
+live	O
+-	O
+attenuated	O
+vaccines	O
+,	O
+and	O
+test	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+Coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+has	O
+an	O
+exceptionally	O
+large	O
+RNA	O
+genome	O
+(~	O
+30	O
+kb	O
+)	O
+and	O
+it	O
+encodes	O
+an	O
+essential	O
+replicase	B-PRGE
+,	O
+the	O
+nonstructural	O
+protein	B-CHED
+13	O
+(	O
+nsp13	O
+),	O
+a	O
+member	O
+of	O
+superfamily	B-PRGE
+1	I-PRGE
+helicases	I-PRGE
+.	O
+
+With	O
+these	O
+methods	O
+,	O
+catalytically	O
+active	O
+recombinant	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp13	I-PRGE
+protein	I-PRGE
+can	O
+be	O
+prepared	O
+and	O
+crystallized	O
+and	O
+the	O
+crystal	B-ANAT
+structure	O
+can	O
+be	O
+solved	O
+.	O
+
+TITLE	O
+:	O
+Antigen	B-CHED
+Capture	O
+Enzyme	O
+-	O
+Linked	O
+Immunosorbent	O
+Assay	O
+for	O
+Detecting	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+in	O
+Humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Quantification	O
+of	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+Coronavirus	B-SPEC
+RNA	O
+in	O
+Tissues	B-ANAT
+by	O
+Quantitative	O
+Real	O
+-	O
+Time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+leads	O
+to	O
+a	O
+variety	O
+of	O
+clinical	O
+outcomes	O
+in	O
+humans	B-SPEC
+ranging	O
+from	O
+asymptomatic	O
+and	O
+mild	O
+infection	B-DISO
+to	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+death	B-PROC
+.	O
+
+To	O
+study	O
+the	O
+pathogenesis	B-DISO
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+development	B-PROC
+of	O
+medical	O
+countermeasures	O
+(	O
+MCMs	O
+)	O
+for	O
+MERS	O
+,	O
+a	O
+number	O
+of	O
+genetically	O
+modified	O
+mouse	B-SPEC
+models	O
+have	O
+been	O
+developed	O
+,	O
+including	O
+various	O
+versions	O
+of	O
+transgenic	B-SPEC
+mice	I-SPEC
+expressing	O
+the	O
+human	B-PRGE
+DPP4	I-PRGE
+viral	I-PRGE
+receptor	I-PRGE
+.	O
+
+Tracking	O
+and	O
+quantifying	O
+viral	B-DISO
+infection	I-DISO
+,	O
+among	O
+others	O
+,	O
+in	O
+permissive	O
+hosts	B-COMP
+is	O
+a	O
+key	O
+endpoint	O
+for	O
+studying	O
+MERS	O
+pathogenesis	B-DISO
+and	O
+evaluating	O
+the	O
+efficacy	O
+of	O
+selected	O
+MCMs	O
+developed	O
+for	O
+MERS	O
+.	O
+
+TITLE	O
+:	O
+Generation	O
+of	O
+MERS	O
+-	O
+CoV	O
+Pseudotyped	O
+Viral	B-COMP
+Particles	I-COMP
+for	O
+the	O
+Evaluation	O
+of	O
+Neutralizing	O
+Antibodies	B-COMP
+in	O
+Mammalian	B-SPEC
+Sera	B-COMP
+.	O
+
+This	O
+platform	O
+is	O
+optimized	O
+to	O
+generate	O
+high	O
+titer	O
+of	O
+MERSpp	O
+and	O
+to	O
+test	O
+sera	B-COMP
+from	O
+different	O
+mammalian	B-SPEC
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Qualitative	O
+and	O
+Quantitative	O
+Determination	O
+of	O
+MERS	O
+-	O
+CoV	O
+S1	O
+-	O
+Specific	O
+Antibodies	B-COMP
+Using	O
+ELISA	O
+.	O
+
+The	O
+ongoing	O
+threat	O
+to	O
+global	O
+public	O
+health	O
+and	O
+the	O
+need	O
+for	O
+novel	O
+therapeutic	O
+countermeasures	O
+have	O
+driven	O
+the	O
+development	B-PROC
+of	O
+animal	B-SPEC
+models	O
+that	O
+can	O
+reproducibly	O
+replicate	O
+the	O
+pathology	B-DISO
+associated	O
+with	O
+MERS	O
+-	O
+CoV	O
+in	O
+human	B-SPEC
+infections	B-DISO
+.	O
+
+Identification	O
+of	O
+human	B-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+IV	I-PRGE
+(	O
+hDPP4	O
+)	O
+as	O
+the	O
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+opened	O
+the	O
+door	O
+for	O
+genetic	O
+engineering	O
+of	O
+mice	B-SPEC
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+MPLEx	O
+protocol	O
+,	O
+highlight	O
+the	O
+step	O
+of	O
+inactivation	B-DISO
+,	O
+and	O
+describe	O
+the	O
+details	O
+of	O
+downstream	O
+processing	O
+,	O
+instrumental	O
+analysis	O
+of	O
+the	O
+three	O
+separate	O
+analytes	O
+,	O
+and	O
+their	O
+subsequent	O
+informatics	O
+pipelines	O
+.	O
+
+Consequently	O
+,	O
+the	O
+ability	O
+of	O
+neutrophils	B-ANAT
+and	O
+Inflammatory	O
+Monocyte	B-ANAT
+Macrophages	B-ANAT
+(	O
+IMMs	O
+)	O
+to	O
+secrete	B-PROC
+inflammatory	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+and	O
+its	O
+correlation	O
+with	O
+the	O
+disease	O
+severity	O
+,	O
+is	O
+not	O
+well	O
+defined	O
+.	O
+
+We	O
+also	O
+describe	O
+a	O
+simple	O
+method	O
+to	O
+measure	O
+intracellular	B-COMP
+cytokine	B-PROC
+production	I-PROC
+to	O
+evaluate	O
+the	O
+inflammatory	O
+activity	O
+of	O
+neutrophils	B-ANAT
+and	O
+IMMs	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+infection	O
+.	O
+
+Histopathology	O
+studies	O
+allow	O
+for	O
+identification	O
+of	O
+lesions	O
+and	O
+affected	O
+cell	B-COMP
+types	O
+to	O
+better	O
+understand	O
+viral	B-DISO
+pathogenesis	I-DISO
+and	O
+clarify	O
+effective	O
+therapies	O
+.	O
+
+This	O
+case	O
+report	O
+describes	O
+the	O
+circumstances	O
+surrounding	O
+the	O
+critical	B-DISO
+illness	I-DISO
+of	O
+a	O
+healthy	O
+7	O
+-	O
+year	O
+-	O
+old	O
+child	O
+who	O
+developed	O
+a	O
+massive	O
+air	B-CHED
+leak	O
+syndrome	B-DISO
+secondary	O
+to	O
+influenza	B-DISO
+B	O
+.	O
+She	O
+required	O
+the	O
+emergent	O
+insertion	O
+of	O
+a	O
+chest	B-ANAT
+tube	O
+as	O
+well	O
+as	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+as	O
+a	O
+model	O
+to	O
+explore	O
+potential	O
+evasion	O
+strategies	O
+employed	O
+by	O
+SADS	O
+-	O
+CoV	O
+.	O
+Our	O
+results	O
+showed	O
+that	O
+SADS	O
+-	O
+CoV	O
+infection	B-DISO
+failed	O
+to	O
+induce	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+,	O
+and	O
+inhibited	O
+poly	O
+(	O
+I	O
+:	O
+C	O
+)	O
+and	O
+Sendai	B-SPEC
+virus	I-SPEC
+(	O
+SeV	O
+)-	O
+triggered	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+expression	B-PROC
+.	O
+
+SADS	O
+-	O
+CoV	O
+also	O
+blocked	O
+poly	O
+(	O
+I	O
+:	O
+C	O
+)-	O
+induced	O
+phosphorylation	B-PROC
+and	O
+nuclear	B-PROC
+translocation	I-PROC
+of	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+NF	O
+-	O
+κB	O
+.	O
+Furthermore	O
+,	O
+SADS	O
+-	O
+CoV	O
+did	O
+not	O
+interfere	O
+with	O
+the	O
+activity	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+promoter	I-PRGE
+stimulated	O
+by	O
+IRF3	B-PRGE
+,	O
+TBK1	B-FUNC
+and	O
+IKKε	O
+,	O
+but	O
+counteracted	O
+its	O
+activation	O
+induced	O
+by	O
+IPS	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+.	O
+Collectively	O
+,	O
+this	O
+study	O
+is	O
+the	O
+first	O
+investigation	O
+that	O
+shows	O
+interactions	O
+between	O
+SADS	O
+-	O
+CoV	O
+and	O
+the	O
+host	O
+innate	B-PROC
+immunity	I-PROC
+,	O
+which	O
+provides	O
+information	O
+of	O
+the	O
+molecular	O
+mechanisms	O
+underlying	O
+SASD	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Adenovirus	B-SPEC
+type	O
+7	O
+was	O
+identified	O
+in	O
+bronchoalveolar	O
+lavages	O
+and	O
+plasma	B-ANAT
+samples	O
+of	O
+both	O
+patients	O
+,	O
+each	O
+of	O
+whom	O
+received	O
+cidofovir	B-CHED
+.	O
+
+Although	O
+treatment	O
+is	O
+predominantly	O
+supportive	O
+,	O
+early	O
+use	O
+of	O
+cidofovir	B-CHED
+may	O
+improve	O
+outcomes	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+illness	O
+and	O
+acute	O
+flaccid	O
+myelitis	B-DISO
+in	O
+the	O
+Tokai	O
+district	O
+in	O
+2018	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+increases	O
+in	O
+children	O
+hospitalized	O
+with	O
+severe	O
+respiratory	O
+illnesses	O
+might	O
+be	O
+associated	O
+with	O
+increase	O
+in	O
+acute	O
+flaccid	O
+myelitis	B-DISO
+also	O
+in	O
+autumn	O
+2018	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+is	O
+a	O
+pathogen	O
+causing	O
+a	O
+lethal	O
+infectious	B-DISO
+disease	I-DISO
+in	O
+cats	B-SPEC
+,	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+Her	O
+medical	O
+history	O
+included	O
+bipolar	B-DISO
+disorder	I-DISO
+on	O
+quetiapine	B-CHED
+and	O
+sertraline	B-CHED
+,	O
+as	O
+well	O
+as	O
+a	O
+previous	O
+ICU	O
+admission	O
+,	O
+approximately	O
+2	O
+years	O
+prior	O
+,	O
+for	O
+non	O
+-	O
+cirrhotic	O
+hyperammonaemic	O
+encephalopathy	B-DISO
+that	O
+was	O
+complicated	O
+by	O
+prolonged	O
+post	O
+discharge	B-ANAT
+anxiety	O
+and	O
+post	B-DISO
+-	I-DISO
+traumatic	I-DISO
+stress	I-DISO
+disorder	I-DISO
+-	O
+like	O
+symptoms	O
+,	O
+consistent	O
+with	O
+post	O
+-	O
+intensive	O
+-	O
+care	O
+syndrome	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+present	O
+a	O
+case	O
+,	O
+and	O
+explore	O
+the	O
+outcomes	O
+for	O
+a	O
+patient	O
+who	O
+had	O
+two	O
+separate	O
+admissions	O
+with	O
+life	O
+-	O
+threatening	O
+illnesses	O
+,	O
+but	O
+had	O
+distinct	O
+differences	O
+in	O
+the	O
+psychological	B-DISO
+outcomes	O
+following	O
+each	O
+illness	O
+.	O
+
+TITLE	O
+:	O
+Cryo	O
+-	O
+EM	O
+analysis	O
+of	O
+a	O
+feline	B-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+reveals	O
+a	O
+unique	O
+structure	O
+and	O
+camouflaging	O
+glycans	O
+.	O
+
+The	O
+close	O
+genetic	O
+relationship	O
+,	O
+but	O
+obvious	O
+differences	O
+between	O
+PhCoVs	O
+and	O
+IBVs	O
+suggested	O
+the	O
+IBVs	O
+could	O
+be	O
+the	O
+ancestors	O
+of	O
+PhCoVs	O
+,	O
+and	O
+that	O
+PhCoVs	O
+isolated	O
+from	O
+different	O
+outbreaks	O
+may	O
+have	O
+evolved	O
+independently	O
+from	O
+IBVs	O
+circulating	O
+in	O
+the	O
+specific	O
+region	O
+by	O
+adaption	B-PROC
+in	O
+pheasants	O
+.	O
+
+A	O
+total	O
+of	O
+15	O
+types	O
+of	O
+RNA	O
+viruses	B-SPEC
+and	O
+a	O
+single	O
+type	O
+of	O
+DNA	O
+virus	B-SPEC
+were	O
+detected	O
+.	O
+
+The	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+(	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+)-	O
+mediated	O
+immune	B-PROC
+responses	I-PROC
+provide	O
+host	B-COMP
+protection	O
+from	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Further	O
+investigation	O
+revealed	O
+that	O
+the	O
+cleavage	B-PROC
+products	O
+of	O
+NEMO	O
+lost	B-CHED
+the	O
+ability	O
+to	O
+activate	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+promoter	I-PRGE
+.	O
+
+Some	O
+enzymatic	O
+activities	O
+are	O
+generally	O
+associated	O
+with	O
+RNA	O
+viruses	B-SPEC
+such	O
+as	O
+RNA	O
+-	O
+or	O
+DNA	O
+-	O
+dependent	O
+RNA	B-PRGE
+polymerases	I-PRGE
+,	O
+RNA	B-PRGE
+helicases	I-PRGE
+or	O
+proteases	O
+.	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+Epoprostenol	B-CHED
+to	O
+Facilitate	O
+Safe	O
+Transport	B-PROC
+in	O
+Legionnaires	B-DISO
+'	I-DISO
+Disease	I-DISO
+.	O
+
+A	O
+39	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+who	O
+lives	O
+in	O
+Bangkok	O
+presented	O
+with	O
+fever	B-PROC
+,	O
+severe	O
+myalgia	B-DISO
+and	O
+haemoptysis	B-DISO
+.	O
+
+Prior	O
+to	O
+surgery	O
+,	O
+patients	O
+received	O
+a	O
+125	O
+-	O
+mg	O
+bolus	O
+injection	O
+of	O
+methylprednisolone	B-CHED
+and	O
+continuous	O
+intravenous	O
+infusion	O
+of	O
+sivelestat	O
+sodium	B-CHED
+hydrate	I-CHED
+(	O
+sivelestat	O
+)	O
+for	O
+2	O
+days	O
+.	O
+
+In	O
+this	O
+work	O
+,	O
+we	O
+aimed	O
+to	O
+target	O
+the	O
+liver	B-ANAT
+macrophages	B-ANAT
+with	O
+lipid	B-CHED
+polymer	B-CHED
+hybrid	O
+nanoparticles	B-CHED
+(	O
+LPH	O
+),	O
+combining	O
+the	O
+merit	O
+of	O
+polymeric	O
+nanoparticles	B-CHED
+and	O
+lipid	B-CHED
+vesicles	B-COMP
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+remdesivir	O
+(	O
+RDV	B-SPEC
+)	O
+and	O
+IFNb	B-PRGE
+have	O
+superior	O
+antiviral	B-CHED
+activity	O
+to	O
+LPV	O
+and	O
+RTV	O
+in	O
+vitro	O
+.	O
+
+Of	O
+34	O
+children	O
+with	O
+PARDS	O
+managed	O
+with	O
+HFOV	O
+after	O
+failure	O
+of	O
+conventional	O
+ventilation	O
+to	O
+improve	O
+oxygenation	B-PROC
+,	O
+8	O
+survived	O
+.	O
+
+Although	O
+BCoV	O
+(	O
+P	O
+=	O
+0	O
+.	O
+032	O
+)	O
+and	O
+BoRVA	O
+(	O
+P	O
+=	O
+0	O
+.	O
+007	O
+)	O
+were	O
+significantly	O
+associated	O
+with	O
+diarrhea	B-DISO
+in	O
+pre	O
+-	O
+weaned	B-PROC
+calves	O
+,	O
+BNoV	O
+and	O
+BToV	O
+showed	O
+no	O
+association	O
+.	O
+
+P	O
+[	O
+5	O
+]-	O
+VIII	B-PRGE
+lineage	O
+was	O
+dominant	O
+in	O
+pre	O
+-	O
+weaned	B-PROC
+Korean	O
+native	O
+calves	O
+.	O
+
+Although	O
+neurological	O
+manifestations	O
+are	O
+rare	O
+in	O
+leptospirosis	B-DISO
+,	O
+aseptic	B-DISO
+meningitis	I-DISO
+,	O
+myeloradiculopathy	B-DISO
+,	O
+transverse	B-DISO
+myelitis	I-DISO
+,	O
+and	O
+cerebellar	B-DISO
+syndrome	I-DISO
+are	O
+well	O
+recognised	O
+.	O
+
+TITLE	O
+:	O
+Durability	O
+and	O
+clinical	O
+experience	O
+using	O
+a	O
+bovine	B-SPEC
+pericardial	B-ANAT
+prosthetic	O
+aortic	B-ANAT
+valve	I-ANAT
+.	O
+
+At	O
+hospital	O
+discharge	B-ANAT
+,	O
+68	O
+patients	O
+(	O
+5	O
+.	O
+5	O
+%)	O
+had	O
+moderate	O
+PPM	O
+,	O
+and	O
+no	O
+patients	O
+had	O
+severe	O
+PPM	O
+.	O
+
+Patients	O
+'	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+extracted	O
+.	O
+
+Lnc	O
+-	O
+MALAT1	B-PRGE
+expression	B-PROC
+was	O
+positively	O
+correlated	O
+with	O
+APACHE	O
+II	O
+score	O
+,	O
+SOFA	O
+score	O
+,	O
+and	O
+inflammatory	O
+factors	O
+levels	O
+including	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+procalcitonin	O
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IL	O
+-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+.	O
+
+The	O
+neonatal	O
+Fc	O
+receptor	O
+(	O
+FcRn	B-PRGE
+)	O
+and	O
+polymeric	O
+immunoglobulin	B-PROC
+receptor	O
+(	O
+pIgR	B-PRGE
+)	O
+are	O
+crucial	B-PRGE
+immunoglobulin	I-PRGE
+(	O
+Ig	O
+)	O
+receptors	O
+for	O
+the	O
+transcytosis	B-PROC
+ofimmunoglobulin	O
+G	O
+(	O
+IgG	B-PRGE
+),	O
+IgA	B-PRGE
+,	O
+or	O
+IgM	B-PRGE
+.	O
+Importantly	O
+,	O
+CHN	B-DISO
+-	O
+JS	O
+-	O
+2017	O
+infected	O
+five	O
+-	O
+day	O
+-	O
+old	O
+piglets	O
+could	O
+significantly	O
+down	O
+-	O
+regulate	O
+the	O
+expression	B-PROC
+of	O
+FcRn	B-PRGE
+,	O
+pIgR	B-PRGE
+,	O
+and	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+)	O
+in	O
+the	O
+intestinal	B-ANAT
+mucosa	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Lipopolysaccharides	B-CHED
+increase	O
+Kir2	B-PRGE
+.	I-PRGE
+1	I-PRGE
+expression	B-PROC
+in	O
+lung	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Kir2	B-PRGE
+.	I-PRGE
+1	I-PRGE
+is	O
+an	O
+inwardly	O
+rectifying	O
+K	O
+
+Because	O
+of	O
+the	O
+limited	O
+proofreading	O
+capability	O
+in	O
+the	O
+viral	B-PRGE
+encoded	I-PRGE
+polymerase	I-PRGE
+,	O
+they	O
+emerge	O
+genetically	O
+diverse	O
+.	O
+
+The	O
+results	O
+revealed	O
+that	O
+RVA	O
+was	O
+the	O
+primary	O
+agent	O
+among	O
+the	O
+positive	O
+samples	O
+obtained	O
+from	O
+calves	O
+aged	O
+three	O
+weeks	O
+or	O
+less	O
+,	O
+while	O
+BEV	B-SPEC
+was	O
+the	O
+primary	O
+among	O
+those	O
+from	O
+the	O
+older	O
+than	O
+three	O
+weeks	O
+old	O
+.	O
+
+They	O
+can	O
+be	O
+employed	O
+as	O
+useful	O
+viral	O
+pathogen	O
+indicators	O
+for	O
+soundly	O
+evaluating	O
+biosecurity	O
+at	O
+bovine	B-SPEC
+farms	O
+.	O
+
+hDPP4	O
+transgenic	B-SPEC
+mice	I-SPEC
+were	O
+successfully	O
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+aerosols	O
+via	O
+an	O
+animal	B-SPEC
+nose	B-ANAT
+-	O
+only	O
+exposure	O
+device	O
+,	O
+and	O
+aerosol	O
+-	O
+and	O
+instillation	O
+-	O
+infected	O
+mice	B-SPEC
+simulated	O
+the	O
+clinical	O
+symptoms	O
+of	O
+moderate	O
+diffuse	O
+interstitial	B-DISO
+pneumonia	I-DISO
+.	O
+
+There	O
+is	O
+currently	O
+an	O
+outbreak	O
+of	O
+pneumonia	B-DISO
+of	O
+unknown	O
+aetiology	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+relatively	O
+recent	O
+human	B-SPEC
+disease	O
+reported	O
+initially	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+September	O
+,	O
+2012	O
+.	O
+
+Therefore	O
+,	O
+we	O
+recommend	O
+the	O
+adoption	O
+of	O
+this	O
+newly	O
+established	O
+model	O
+of	O
+MERS	O
+-	O
+CoV	O
+to	O
+short	O
+-	O
+list	O
+corona	B-CHED
+suspected	O
+cases	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-ANAT
+tract	I-ANAT
+viral	B-DISO
+infection	I-DISO
+caused	O
+by	O
+viruses	B-SPEC
+or	O
+bacteria	B-SPEC
+is	O
+one	O
+of	O
+the	O
+most	O
+common	O
+diseases	O
+in	O
+human	B-SPEC
+worldwide	O
+,	O
+while	O
+those	O
+caused	O
+by	O
+emerging	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+that	O
+caused	O
+the	O
+pneumonia	B-DISO
+outbreak	O
+in	O
+Wuhan	O
+,	O
+China	O
+most	O
+recently	O
+,	O
+have	O
+posed	O
+great	O
+threats	O
+to	O
+global	O
+public	O
+health	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+novel	O
+monoclonal	O
+antibodies	B-COMP
+against	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+.	O
+
+Additionally	O
+,	O
+one	O
+mAb	O
+RBD	O
+-	O
+14F8	O
+did	O
+not	O
+show	O
+neutralizing	O
+activity	O
+against	O
+pseudoviruses	O
+with	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+of	O
+L506	O
+F	O
+or	O
+D509	O
+G	O
+(	O
+England1	O
+strain	O
+,	O
+EMC	O
+/	O
+2012	O
+L506	O
+F	O
+,	O
+and	O
+EMC	B-COMP
+/	O
+2012	O
+D509	O
+G	O
+),	O
+and	O
+RBD	O
+-	O
+43E4	O
+mAb	O
+could	O
+not	O
+neutralize	O
+the	O
+pseudotyped	O
+I529	O
+T	O
+mutation	O
+,	O
+while	O
+three	O
+other	O
+neutralizing	O
+mAbs	O
+showed	O
+broad	O
+neutralizing	O
+activity	O
+.	O
+
+Three	O
+intramuscular	O
+or	O
+oral	B-ANAT
+vaccinations	O
+with	O
+rAd	B-PRGE
+-	I-PRGE
+LTB	I-PRGE
+-	I-PRGE
+COE	I-PRGE
+at	O
+two	O
+-	O
+week	O
+intervals	O
+induced	O
+robust	O
+humoral	O
+and	O
+mucosal	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+Fifteen	O
+respiratory	O
+viruses	B-SPEC
+were	O
+included	O
+in	O
+our	O
+investigation	O
+:	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+A	O
+/	O
+B	O
+(	O
+RSV	B-SPEC
+),	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+(	O
+FluA	O
+)	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+B	O
+(	O
+FluB	O
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+MPV	B-SPEC
+),	O
+enterovirus	B-SPEC
+(	O
+EV	O
+),	O
+human	B-SPEC
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+types	O
+1	O
+-	O
+4	O
+,	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+RV	O
+),	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+,	O
+NL63	O
+,	O
+and	O
+229E	O
+,	O
+human	B-SPEC
+adenovirus	B-SPEC
+(	O
+ADV	O
+),	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+Boca	B-DISO
+).	O
+
+Respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+more	O
+frequently	O
+by	O
+PCR	O
+(	O
+357	O
+,	O
+75	O
+.	O
+3	O
+%)	O
+than	O
+they	O
+were	O
+by	O
+traditional	O
+tests	O
+(	O
+229	O
+,	O
+49	O
+.	O
+3	O
+%).	O
+
+In	O
+contrast	O
+,	O
+ARDS	B-DISO
+was	O
+found	O
+more	O
+frequently	O
+in	O
+the	O
+DCO	B-DISO
+-	O
+ST	O
+group	O
+(	O
+81	O
+%	O
+versus	O
+54	O
+%;	O
+P	O
+=	O
+0	O
+.	O
+035	O
+).	O
+
+TITLE	O
+:	O
+Pathogen	O
+-	O
+specific	O
+risk	O
+factors	O
+in	O
+acute	O
+outbreaks	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+calves	O
+.	O
+
+Bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+was	O
+the	O
+most	O
+frequently	O
+isolated	O
+virus	B-SPEC
+(	O
+38	O
+.	O
+4	O
+%),	O
+followed	O
+by	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+bRSV	B-SPEC
+;	O
+29	O
+.	O
+4	O
+%)	O
+and	O
+parainfluenzavirus	O
+type	O
+3	O
+(	O
+PI	O
+-	O
+3	O
+;	O
+8	O
+.	O
+1	O
+%).	O
+
+This	O
+study	O
+identified	O
+pathogen	O
+-	O
+specific	O
+risk	O
+factors	O
+that	O
+might	O
+be	O
+useful	O
+for	O
+the	O
+development	B-PROC
+of	O
+customized	O
+control	O
+and	O
+prevention	O
+and	O
+for	O
+the	O
+design	O
+of	O
+decision	O
+support	O
+tools	O
+to	O
+justify	O
+antimicrobial	B-CHED
+use	O
+by	O
+predicting	O
+the	O
+most	O
+likely	O
+pathogen	O
+before	O
+sampling	O
+results	O
+are	O
+available	O
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+and	O
+SARs	B-DISO
+of	O
+dopamine	B-CHED
+derivatives	O
+as	O
+potential	O
+inhibitors	B-CHED
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+PA	O
+ABSTRACT	O
+:	O
+Currently	O
+,	O
+influenza	O
+PA	O
+
+This	O
+disease	O
+should	O
+be	O
+considered	O
+a	O
+differential	O
+diagnosis	O
+in	O
+felids	B-SPEC
+,	O
+including	O
+exotic	O
+cats	B-SPEC
+,	O
+with	O
+signs	O
+of	O
+neuromuscular	B-DISO
+disease	I-DISO
+of	O
+unknown	O
+etiopathogenesis	O
+.	O
+
+In	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+,	O
+the	O
+administration	O
+of	O
+NMBAs	O
+could	O
+reduce	O
+21	O
+to	O
+28	O
+-	O
+day	O
+mortality	O
+and	O
+barotrauma	O
+,	O
+and	O
+improve	O
+oxygenation	B-PROC
+at	O
+48	O
+hours	O
+,	O
+but	O
+have	O
+no	O
+significant	O
+effects	O
+on	O
+90	O
+-	O
+day	O
+/	O
+ICU	O
+mortality	O
+,	O
+days	O
+free	O
+of	O
+ventilation	O
+at	O
+day	O
+28	O
+and	O
+the	O
+risk	O
+of	O
+ICU	O
+-	O
+acquired	O
+weakness	B-DISO
+.	O
+
+Registration	O
+:	O
+PROSPERO	B-SPEC
+(	O
+ID	O
+:	O
+CRD	B-DISO
+42019139656	O
+).	O
+
+The	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+mediates	O
+viral	O
+entry	O
+into	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Association	O
+between	O
+electromyographical	O
+findings	O
+and	O
+intensive	O
+care	O
+unit	O
+mortality	O
+among	O
+mechanically	O
+ventilated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+under	O
+profound	O
+sedation	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Yellow	O
+fever	O
+(	O
+YF	O
+)	O
+and	O
+leptospirosis	B-DISO
+are	O
+under	O
+-	O
+diagnosed	O
+endemic	O
+zoonoses	B-DISO
+of	O
+the	O
+tropical	O
+regions	O
+of	O
+Africa	O
+and	O
+South	O
+America	O
+.	O
+
+Results	O
+obtained	O
+from	O
+our	O
+analyses	O
+suggest	O
+that	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+may	O
+appear	O
+to	O
+be	O
+a	O
+recombinant	O
+virus	B-SPEC
+between	O
+the	O
+bat	B-ENZY
+coronavirus	B-SPEC
+and	O
+an	O
+origin	O
+-	O
+unknown	O
+coronavirus	B-SPEC
+.	O
+
+However	O
+,	O
+a	O
+recent	O
+study	O
+revealed	O
+that	O
+direct	O
+inoculation	O
+of	O
+Bactrian	B-SPEC
+camels	I-SPEC
+intranasally	O
+with	O
+MERS	O
+-	O
+CoV	O
+can	O
+lead	O
+to	O
+infection	B-DISO
+with	O
+abundant	O
+virus	B-DISO
+shedding	I-DISO
+and	O
+seroconversion	O
+.	O
+
+A	O
+previously	O
+unknown	O
+betacoronavirus	B-SPEC
+was	O
+discovered	O
+through	O
+the	O
+use	O
+of	O
+unbiased	O
+sequencing	O
+in	O
+samples	O
+from	O
+patients	O
+with	O
+pneumonia	B-DISO
+.	O
+
+Different	O
+from	O
+both	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+is	O
+the	O
+seventh	O
+member	O
+of	O
+the	O
+family	B-SPEC
+of	O
+coronaviruses	O
+that	O
+infect	O
+humans	B-SPEC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+study	O
+demonstrating	O
+that	O
+miRNAs	O
+regulate	O
+IBV	O
+replication	O
+by	O
+regulating	O
+the	O
+deubiquitinating	B-PROC
+enzyme	I-PROC
+(	O
+DUBs	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+usefulness	O
+of	O
+intestinal	B-ANAT
+biomarkers	O
+in	O
+determining	O
+the	O
+presence	O
+of	O
+intestinal	B-ANAT
+epithelial	O
+damage	O
+in	O
+neonatal	O
+calves	O
+with	O
+diarrhea	B-DISO
+caused	O
+by	O
+4	O
+etiologic	O
+agents	O
+.	O
+
+40	O
+neonatal	O
+calves	O
+that	O
+were	O
+healthy	O
+(	O
+n	O
+=	O
+10	O
+)	O
+or	O
+had	O
+diarrhea	B-DISO
+(	O
+30	O
+).	O
+
+Results	O
+indicated	O
+that	O
+degree	O
+of	O
+intestinal	B-ANAT
+epithelial	O
+damage	O
+differed	O
+among	O
+calves	O
+grouped	O
+by	O
+the	O
+etiologic	O
+agent	O
+of	O
+diarrhea	B-DISO
+and	O
+that	O
+such	O
+damage	O
+might	O
+have	O
+been	O
+more	O
+severe	O
+in	O
+calves	O
+with	O
+diarrhea	B-DISO
+caused	O
+by	O
+K99	O
+RESULTS	O
+:	O
+Across	O
+the	O
+3	O
+time	O
+points	O
+at	O
+which	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+obtained	O
+and	O
+evaluated	O
+,	O
+the	O
+groups	O
+of	O
+calves	O
+with	O
+diarrhea	B-DISO
+generally	O
+had	O
+markedly	O
+higher	O
+mean	O
+serum	B-COMP
+concentrations	O
+of	O
+L	B-PRGE
+-	I-PRGE
+FABP	I-PRGE
+,	O
+TFF	O
+-	O
+3	O
+,	O
+IAP	B-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+LP	O
+,	O
+compared	O
+with	O
+the	O
+control	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Increased	O
+mobilization	O
+of	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+undergoing	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+pulmonary	B-ANAT
+epithelial	O
+and	O
+endothelial	B-ANAT
+barrier	O
+dysfunction	O
+and	O
+injury	O
+.	O
+
+In	O
+severe	O
+forms	O
+of	O
+ARDS	B-DISO
+,	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+often	O
+the	O
+last	O
+option	O
+for	O
+life	O
+support	O
+.	O
+
+However	O
+,	O
+we	O
+still	O
+lack	O
+sufficient	O
+knowledge	O
+about	O
+how	O
+ECMO	O
+might	O
+affect	O
+EPC	O
+-	O
+and	O
+MSC	O
+-	O
+mediated	O
+regenerative	O
+pathways	B-PROC
+in	O
+ARDS	B-DISO
+.	O
+
+Therefore	O
+,	O
+we	O
+investigated	O
+if	O
+ECMO	O
+impacts	O
+EPC	O
+and	O
+MSC	O
+numbers	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+The	O
+number	O
+and	O
+presence	O
+of	O
+circulating	O
+EPC	B-PRGE
+and	O
+MSC	B-PRGE
+was	O
+detected	O
+by	O
+flow	O
+cytometry	O
+.	O
+
+ECMO	O
+support	O
+in	O
+ARDS	B-DISO
+is	O
+specifically	O
+associated	O
+with	O
+an	O
+increased	O
+number	O
+of	O
+circulating	O
+MSC	B-PRGE
+,	O
+most	O
+likely	O
+due	O
+to	O
+enhanced	O
+mobilization	O
+,	O
+but	O
+not	O
+with	O
+a	O
+higher	O
+numbers	O
+of	O
+EPC	O
+or	O
+serum	B-COMP
+concentrations	O
+of	O
+VEGF	B-PRGE
+and	O
+Ang2	B-PRGE
+.	O
+
+We	O
+defined	O
+persistent	O
+severe	O
+ARDS	B-DISO
+as	O
+a	O
+partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+to	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+(	O
+PaO2	O
+:	O
+FiO2	O
+)	O
+of	O
+equal	O
+to	O
+or	O
+less	O
+than	O
+100	O
+mmHg	O
+on	O
+the	O
+second	O
+study	O
+day	O
+following	O
+enrollment	O
+.	O
+
+Usage	O
+of	O
+vasopressors	O
+was	O
+greater	O
+[	O
+144	O
+/	O
+232	O
+(	O
+62	O
+%)	O
+versus	O
+623	O
+/	O
+1299	O
+(	O
+48	O
+%);	O
+p	O
+<	O
+0	O
+.	O
+001	O
+]	O
+and	O
+baseline	O
+severity	O
+of	O
+illness	O
+was	O
+higher	O
+in	O
+patients	O
+with	O
+versus	O
+without	O
+persistent	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Mortality	O
+at	O
+60	O
+days	O
+[	O
+95	O
+/	O
+232	O
+(	O
+41	O
+%)	O
+versus	O
+233	O
+/	O
+1299	O
+(	O
+18	O
+%);	O
+p	O
+<	O
+0	O
+.	O
+001	O
+]	O
+was	O
+higher	O
+,	O
+and	O
+ventilator	O
+-	O
+free	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+intensive	O
+care	O
+unit	O
+-	O
+free	O
+[	O
+0	O
+(	O
+0	O
+-	O
+14	O
+)	O
+versus	O
+19	O
+(	O
+7	O
+-	O
+23	O
+);	O
+p	O
+<	O
+0	O
+.	O
+001	O
+]	O
+and	O
+non	O
+-	O
+pulmonary	B-ANAT
+organ	B-DISO
+failure	I-DISO
+-	O
+free	O
+[	O
+3	O
+(	O
+0	O
+-	O
+21	O
+)	O
+versus	O
+20	O
+(	O
+1	O
+-	O
+26	O
+);	O
+p	O
+<	O
+0	O
+.	O
+001	O
+]	O
+days	O
+were	O
+fewer	O
+in	O
+patients	O
+with	O
+versus	O
+without	O
+persistent	O
+severe	O
+ARDS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+1531	O
+individuals	O
+with	O
+ARDS	B-DISO
+alive	O
+on	O
+the	O
+second	O
+study	O
+day	O
+after	O
+enrollment	O
+,	O
+232	O
+(	O
+15	O
+%)	O
+had	O
+persistent	O
+severe	O
+ARDS	B-DISO
+.	O
+
+26	O
+(	O
+63	O
+%)	O
+of	O
+41	O
+patients	O
+had	O
+lymphopenia	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+rare	O
+case	O
+of	O
+Reye	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+induced	O
+by	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+with	O
+use	O
+of	O
+ibuprofen	B-CHED
+in	O
+an	O
+adult	O
+.	O
+
+She	O
+had	O
+taken	O
+ibuprofen	B-CHED
+for	O
+headache	B-DISO
+.	O
+
+The	O
+laboratory	O
+findings	O
+revealed	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+with	O
+prothrombin	B-PRGE
+time	O
+-	O
+international	O
+normalized	O
+ratio	O
+of	O
+3	O
+.	O
+16	O
+,	O
+aspartate	O
+aminotransferase	O
+12	O
+,	O
+548	O
+IU	O
+/	O
+L	O
+,	O
+alanine	B-PRGE
+aminotransferase	I-PRGE
+5	O
+,	O
+725	O
+IU	O
+/	O
+L	O
+,	O
+and	O
+blood	B-ANAT
+ammonia	B-CHED
+102	O
+μg	O
+/	O
+dL	O
+.	O
+Head	B-ANAT
+magnetic	O
+resonance	O
+imaging	O
+showed	O
+hyperintense	O
+signals	O
+on	O
+diffusion	O
+-	O
+weighed	O
+images	O
+of	O
+globus	B-ANAT
+pallidus	I-ANAT
+.	O
+
+RESULTS	O
+:	O
+The	O
+workflow	O
+reliably	O
+detects	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+,	O
+and	O
+further	O
+discriminates	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Through	O
+coordination	B-PROC
+between	O
+academic	O
+and	O
+public	O
+laboratories	O
+,	O
+we	O
+confirmed	O
+assay	O
+exclusivity	O
+based	O
+on	O
+297	O
+original	O
+clinical	O
+specimens	O
+containing	O
+a	O
+full	O
+spectrum	O
+of	O
+human	B-SPEC
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+DRC	O
+Ministry	O
+of	O
+Health	O
+(	O
+MoH	O
+),	O
+supported	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+and	O
+a	O
+range	O
+of	O
+regional	O
+and	O
+international	O
+partners	O
+,	O
+are	O
+implementing	O
+EVD	O
+response	O
+plans	O
+in	O
+these	O
+affected	O
+areas	O
+such	O
+as	O
+screening	O
+of	O
+suspect	O
+cases	O
+at	O
+points	O
+of	O
+entry	O
+,	O
+case	O
+detection	O
+,	O
+contact	O
+tracing	O
+,	O
+laboratory	O
+testing	O
+,	O
+case	O
+management	O
+and	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+,	O
+safe	O
+and	O
+dignified	O
+burials	O
+,	O
+ring	O
+vaccination	O
+(	O
+this	O
+involves	O
+vaccination	O
+of	O
+infected	O
+individuals	O
+,	O
+direct	O
+contacts	O
+of	O
+infected	O
+individuals	O
+and	O
+contacts	O
+of	O
+their	O
+contacts	O
+),	O
+and	O
+therapeutics	O
+,	O
+community	O
+mobilization	O
+and	O
+free	O
+access	O
+to	O
+healthcare	O
+services	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+provide	O
+a	O
+preliminary	O
+evolutionary	O
+and	O
+molecular	O
+epidemiological	O
+analysis	O
+of	O
+this	O
+new	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Updated	O
+understanding	O
+of	O
+the	O
+outbreak	O
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+help	O
+health	O
+workers	O
+and	O
+the	O
+public	O
+recognize	O
+and	O
+deal	O
+with	O
+the	O
+2019	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+quickly	O
+,	O
+effectively	O
+,	O
+and	O
+calmly	O
+with	O
+an	O
+updated	O
+understanding	O
+.	O
+
+In	O
+the	O
+early	O
+period	O
+of	O
+exponential	O
+growth	B-PROC
+,	O
+we	O
+estimated	O
+the	O
+epidemic	O
+doubling	O
+time	O
+and	O
+the	O
+basic	O
+reproductive	B-PROC
+number	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+)	O
+is	O
+primarily	O
+associated	O
+with	O
+common	B-DISO
+cold	I-DISO
+in	O
+children	O
+,	O
+elderly	O
+and	O
+immunocompromised	O
+individuals	O
+.	O
+
+Whole	O
+genomes	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+were	O
+obtained	O
+using	O
+next	O
+-	O
+generation	O
+sequencing	O
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+of	O
+Bat	B-ENZY
+Coronaviruses	O
+through	O
+Surveillance	O
+and	O
+Probe	O
+Capture	O
+-	O
+Based	O
+Next	O
+-	O
+Generation	O
+Sequencing	O
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)-	O
+CoV	O
+both	O
+originated	O
+from	O
+bats	B-SPEC
+,	O
+and	O
+it	O
+is	O
+highly	O
+likely	O
+that	O
+bat	B-ENZY
+coronaviruses	O
+will	O
+cause	O
+future	O
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+has	O
+emerged	O
+from	O
+Wuhan	O
+,	O
+China	O
+,	O
+causing	O
+symptoms	O
+in	O
+humans	B-SPEC
+similar	O
+to	O
+those	O
+caused	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Second	O
+,	O
+several	O
+critical	O
+residues	O
+in	O
+2019	O
+-	O
+nCoV	O
+RBM	O
+(	O
+particularly	O
+Gln493	O
+)	O
+provide	O
+favorable	O
+interactions	O
+with	O
+human	B-SPEC
+ACE2	O
+,	O
+consistent	O
+with	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+'	O
+s	O
+capacity	O
+for	O
+human	B-SPEC
+cell	B-COMP
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Potential	O
+of	O
+large	O
+""""	O
+first	O
+generation	O
+""""	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+genetic	O
+diversity	O
+,	O
+time	O
+origin	O
+,	O
+and	O
+evolutionary	O
+history	O
+of	O
+the	O
+2019	O
+-	O
+nCoV	O
+outbreak	O
+in	O
+China	O
+and	O
+Thailand	O
+,	O
+a	O
+total	O
+of	O
+12	O
+genome	O
+sequences	O
+of	O
+the	O
+virus	B-SPEC
+with	O
+known	O
+sampling	O
+date	O
+(	O
+24	O
+December	O
+2019	O
+and	O
+13	O
+January	O
+2020	O
+)	O
+and	O
+geographic	O
+location	O
+(	O
+primarily	O
+Wuhan	O
+city	O
+,	O
+Hubei	O
+Province	O
+,	O
+China	O
+,	O
+but	O
+also	O
+Bangkok	O
+,	O
+Thailand	O
+)	O
+were	O
+analyzed	O
+.	O
+
+There	O
+is	O
+a	O
+paucity	O
+of	O
+studies	O
+on	O
+the	O
+progression	O
+and	O
+outcome	O
+of	O
+Systemic	O
+Inflammatory	O
+Response	O
+Syndrome	O
+(	O
+SIRS	B-DISO
+)	O
+with	O
+its	O
+determinants	O
+.	O
+
+TITLE	O
+:	O
+Atypical	O
+presentation	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+a	O
+Lebanese	O
+patient	O
+returning	O
+from	O
+Saudi	O
+Arabia	O
+.	O
+
+In	O
+the	O
+last	O
+decade	O
+,	O
+there	O
+is	O
+a	O
+growing	O
+body	B-ANAT
+of	O
+evidence	O
+that	O
+veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+is	O
+lifesaving	O
+in	O
+multiple	O
+trauma	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+thanks	O
+to	O
+technical	O
+improvements	O
+in	O
+ECMO	O
+devices	O
+.	O
+
+The	O
+main	O
+causes	O
+of	O
+ARDS	B-DISO
+were	O
+pneumonia	B-DISO
+due	O
+to	O
+influenza	B-DISO
+(	O
+9	O
+cases	O
+,	O
+45	O
+%)	O
+and	O
+other	O
+viruses	B-SPEC
+(	O
+2	O
+cases	O
+,	O
+10	O
+%).	O
+
+RESULTS	O
+:	O
+Between	O
+January	O
+2018	O
+and	O
+April	O
+2019	O
+,	O
+20	O
+ARDS	B-DISO
+patients	O
+were	O
+enrolled	O
+.	O
+
+The	O
+stress	O
+level	O
+(	O
+as	O
+reported	O
+on	O
+1	O
+-	O
+10	O
+scale	O
+)	O
+shows	O
+significant	O
+correlation	O
+with	O
+Generalized	B-DISO
+Anxiety	I-DISO
+Disorder	I-DISO
+(	O
+GAD	B-DISO
+-	O
+7	O
+)	O
+score	O
+.	O
+
+We	O
+collected	O
+clinical	O
+data	O
+and	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+specimens	O
+from	O
+five	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+from	O
+Jin	O
+Yin	O
+-	O
+tan	O
+Hospital	O
+of	O
+Wuhan	O
+,	O
+Hubei	O
+province	O
+,	O
+China	O
+.	O
+
+Five	O
+patients	O
+hospitalized	O
+from	O
+December	O
+18	O
+to	O
+December	O
+29	O
+,	O
+2019	O
+presented	O
+with	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+and	O
+dyspnea	B-DISO
+accompanied	O
+by	O
+complications	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+that	O
+began	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+has	O
+spread	O
+rapidly	O
+,	O
+with	O
+cases	O
+now	O
+confirmed	O
+in	O
+multiple	O
+countries	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+emerged	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+and	O
+caused	O
+an	O
+epidemic	O
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+RESULTS	O
+:	O
+Four	O
+hundred	O
+and	O
+twenty	O
+-	O
+six	O
+(	O
+426	O
+)	O
+samples	O
+from	O
+264	O
+patients	O
+were	O
+tested	O
+for	O
+MERS	O
+Co	O
+-	O
+V	O
+and	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Specifically	O
+,	O
+in	O
+the	O
+5	O
+'-	O
+part	O
+spanning	O
+the	O
+first	O
+11	O
+,	O
+498	O
+nucleotides	B-CHED
+and	O
+the	O
+last	O
+3	O
+'-	O
+part	O
+spanning	O
+24	O
+,	O
+341	O
+-	O
+30	O
+,	O
+696	O
+positions	O
+,	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+and	O
+RaTG13	O
+formed	O
+a	O
+single	O
+cluster	O
+with	O
+Bat_SARS	O
+-	O
+like	O
+coronavirus	B-SPEC
+sequences	O
+,	O
+whereas	O
+in	O
+the	O
+middle	O
+region	O
+spanning	O
+the	O
+3	O
+'-	O
+end	O
+of	O
+ORF1a	O
+,	O
+the	O
+ORF1b	O
+and	O
+almost	O
+half	O
+of	O
+the	O
+spike	O
+regions	O
+,	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+and	O
+RaTG13	O
+grouped	O
+in	O
+a	O
+separate	O
+distant	O
+lineage	O
+within	O
+the	O
+sarbecovirus	O
+branch	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+newly	O
+recognized	O
+zoonotic	O
+coronavirus	B-SPEC
+.	O
+
+Patients	O
+randomised	O
+to	O
+the	O
+intervention	O
+will	O
+have	O
+PEEP	B-CHED
+selected	O
+based	O
+on	O
+a	O
+minimal	O
+elastance	O
+using	O
+a	O
+model	O
+-	O
+based	O
+computerised	O
+method	O
+.	O
+
+The	O
+primary	O
+outcome	O
+is	O
+the	O
+area	O
+under	O
+the	O
+curve	O
+(	O
+AUC	O
+)	O
+ratio	O
+of	O
+arterial	B-ANAT
+blood	I-ANAT
+oxygenation	B-PROC
+to	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+over	O
+time	O
+.	O
+
+CURE	O
+aims	O
+to	O
+demonstrate	O
+the	O
+hypothesized	O
+benefit	O
+of	O
+patient	O
+-	O
+specific	O
+PEEP	B-CHED
+and	O
+attest	O
+to	O
+the	O
+significance	O
+of	O
+real	O
+-	O
+time	O
+monitoring	O
+and	O
+decision	O
+-	O
+support	O
+for	O
+MV	O
+in	O
+the	O
+critical	O
+care	O
+environment	O
+.	O
+
+17	O
+(	O
+17	O
+%)	O
+patients	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+,	O
+among	O
+them	O
+,	O
+11	O
+(	O
+11	O
+%)	O
+patients	O
+worsened	O
+in	O
+a	O
+short	O
+period	O
+of	O
+time	O
+and	O
+died	B-PROC
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+ten	O
+genome	O
+sequences	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+obtained	O
+from	O
+the	O
+nine	O
+patients	O
+were	O
+extremely	O
+similar	O
+,	O
+exhibiting	O
+more	O
+than	O
+99	O
+·	O
+98	O
+%	O
+sequence	O
+identity	O
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+that	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+fell	O
+within	O
+the	O
+subgenus	B-SPEC
+Sarbecovirus	O
+of	O
+the	O
+genus	B-SPEC
+Betacoronavirus	B-SPEC
+,	O
+with	O
+a	O
+relatively	O
+long	O
+branch	B-ANAT
+length	O
+to	O
+its	O
+closest	O
+relatives	O
+bat	B-ENZY
+-	O
+SL	O
+-	O
+CoVZC45	O
+and	O
+bat	B-ENZY
+-	O
+SL	O
+-	O
+CoVZXC21	O
+,	O
+and	O
+was	O
+genetically	O
+distinct	O
+from	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Notably	O
+,	O
+homology	O
+modelling	O
+revealed	O
+that	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+had	O
+a	O
+similar	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+structure	O
+to	O
+that	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+despite	O
+amino	B-CHED
+acid	I-CHED
+variation	O
+at	O
+some	O
+key	O
+residues	O
+.	O
+
+The	O
+future	O
+evolution	B-PROC
+,	O
+adaptation	B-PROC
+,	O
+and	O
+spread	O
+of	O
+this	O
+virus	B-SPEC
+warrant	O
+urgent	O
+investigation	O
+.	O
+
+We	O
+present	O
+estimates	O
+of	O
+the	O
+basic	O
+reproduction	B-PROC
+number	O
+,	O
+R	O
+Accounting	O
+for	O
+the	O
+impact	O
+of	O
+the	O
+variations	O
+in	O
+disease	O
+reporting	O
+rate	O
+,	O
+we	O
+modelled	O
+the	O
+epidemic	O
+curve	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+cases	O
+time	O
+series	O
+,	O
+in	O
+mainland	O
+China	O
+from	O
+January	O
+10	O
+to	O
+January	O
+24	O
+,	O
+2020	O
+,	O
+through	O
+the	O
+exponential	O
+growth	B-PROC
+.	O
+
+With	O
+the	O
+estimated	O
+intrinsic	O
+growth	B-PROC
+rate	O
+(	O
+γ	O
+),	O
+we	O
+estimated	O
+R	O
+The	O
+early	O
+outbreak	O
+data	O
+largely	O
+follows	O
+the	O
+exponential	O
+growth	B-PROC
+.	O
+
+TITLE	O
+:	O
+Reduced	O
+cortical	B-ANAT
+arousability	O
+to	O
+nocturnal	O
+apneic	B-DISO
+episodes	O
+in	O
+patients	O
+with	O
+wake	B-PROC
+-	O
+up	O
+ischemic	B-DISO
+stroke	I-DISO
+.	O
+
+Respiratory	O
+arousals	O
+have	O
+an	O
+important	O
+role	O
+in	O
+responding	O
+to	O
+danger	O
+during	O
+sleep	B-PROC
+,	O
+yet	O
+currently	O
+no	O
+studies	O
+have	O
+investigated	O
+respiratory	O
+arousability	O
+in	O
+WUS	O
+.	O
+
+We	O
+enrolled	O
+119	O
+patients	O
+with	O
+acute	O
+ischemic	B-DISO
+stroke	I-DISO
+and	O
+assigned	O
+them	O
+into	O
+WUS	O
+(	O
+n	O
+=	O
+34	O
+)	O
+and	O
+non	O
+-	O
+WUS	O
+(	O
+n	O
+=	O
+85	O
+)	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+History	O
+is	O
+repeating	O
+itself	O
+:	O
+Probable	O
+zoonotic	O
+spillover	O
+as	O
+the	O
+cause	O
+of	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+Coronavirus	I-SPEC
+Epidemic	O
+ABSTRACT	O
+:	O
+Pathogen	B-DISO
+transmission	I-DISO
+from	O
+a	O
+vertebrate	B-SPEC
+animal	B-SPEC
+to	O
+a	O
+human	B-SPEC
+,	O
+also	O
+known	O
+as	O
+zoonotic	O
+spillover	O
+,	O
+represents	O
+a	O
+global	O
+public	O
+health	O
+burden	O
+,	O
+which	O
+while	O
+associated	O
+with	O
+multiple	O
+outbreaks	O
+,	O
+still	O
+remains	O
+a	O
+poorly	O
+understood	O
+phenomenon	O
+.	O
+
+Coronaviruses	O
+,	O
+like	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+circulate	O
+in	O
+nature	O
+in	O
+various	O
+animal	B-SPEC
+species	B-SPEC
+.	O
+
+An	O
+IB	O
+-	O
+like	O
+avian	O
+coronavirus	O
+was	O
+isolated	O
+from	O
+healthy	O
+Eclectus	B-SPEC
+parrots	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Bats	O
+host	B-COMP
+virulent	O
+zoonotic	O
+viruses	B-SPEC
+without	O
+experiencing	O
+disease	O
+.	O
+
+We	O
+carried	O
+out	O
+virus	B-SPEC
+infectivity	O
+assays	O
+on	O
+bat	B-ENZY
+cell	B-ANAT
+lines	I-ANAT
+expressing	O
+induced	O
+and	O
+constitutive	O
+immune	O
+phenotypes	O
+,	O
+then	O
+developed	O
+a	O
+theoretical	O
+model	O
+of	O
+our	O
+Bats	B-SPEC
+can	O
+carry	O
+viruses	B-SPEC
+that	O
+are	O
+deadly	O
+to	O
+other	O
+mammals	B-SPEC
+without	O
+themselves	O
+showing	O
+serious	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+-	O
+associated	O
+hemophagocytic	B-DISO
+lymphohistiocytosis	I-DISO
+in	O
+a	O
+small	O
+child	O
+:	O
+A	O
+case	O
+report	O
+.	O
+
+ABSTRACT	O
+:	O
+Hemophagocytic	O
+lymphohistiocytosis	O
+(	O
+HLH	B-DISO
+)	O
+is	O
+a	O
+rare	O
+,	O
+potentially	O
+lethal	O
+disorder	O
+,	O
+characterized	O
+by	O
+a	O
+dysregulation	O
+of	O
+the	O
+immune	B-PROC
+response	I-PROC
+,	O
+leading	O
+to	O
+a	O
+severe	O
+inflammatory	O
+syndrome	B-DISO
+.	O
+
+Initial	O
+laboratory	O
+tests	O
+revealed	O
+pancytopenia	B-DISO
+.	O
+
+Plasma	B-PRGE
+hemoglobin	B-CHED
+,	O
+serum	B-COMP
+calcium	B-CHED
+,	O
+and	O
+serum	B-COMP
+albumin	B-PRGE
+levels	O
+and	O
+single	O
+-	O
+pool	O
+Kt	O
+/	O
+V	O
+decreased	O
+during	O
+the	O
+isolation	O
+period	O
+but	O
+normalized	O
+thereafter	O
+.	O
+
+Patients	O
+who	O
+were	O
+subjected	O
+to	O
+self	O
+-	O
+imposed	O
+quarantine	O
+had	O
+higher	O
+systolic	O
+and	O
+diastolic	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+lower	O
+total	O
+cholesterol	B-CHED
+level	O
+,	O
+and	O
+lower	O
+Kt	O
+/	O
+V	O
+than	O
+those	O
+who	O
+underwent	O
+single	O
+-	O
+room	O
+or	O
+cohort	O
+isolation	O
+.	O
+
+Human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+can	O
+induce	O
+not	O
+only	O
+mild	O
+to	O
+severe	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+but	O
+also	O
+inflammation	B-DISO
+,	O
+high	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+and	O
+dysfunction	O
+of	O
+internal	O
+organs	B-ANAT
+that	O
+may	O
+lead	O
+to	O
+death	B-PROC
+.	O
+
+In	O
+our	O
+baseline	O
+scenario	O
+,	O
+we	O
+estimated	O
+that	O
+the	O
+basic	O
+reproductive	B-PROC
+number	O
+for	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+was	O
+2	O
+·	O
+68	O
+(	O
+95	O
+%	O
+CrI	O
+2	O
+·	O
+47	O
+-	O
+2	O
+·	O
+86	O
+)	O
+and	O
+that	O
+75	O
+815	O
+individuals	O
+(	O
+95	O
+%	O
+CrI	O
+37	O
+304	O
+-	O
+130	O
+330	O
+)	O
+have	O
+been	O
+infected	O
+in	O
+Wuhan	O
+as	O
+of	O
+Jan	B-PRGE
+25	I-PRGE
+,	O
+2020	O
+.	O
+
+Recombinant	B-PRGE
+camel	I-PRGE
+IFN	I-PRGE
+-	I-PRGE
+α1	I-PRGE
+induced	O
+the	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+interferon	B-PRGE
+-	O
+stimulated	O
+genes	O
+(	O
+ISGs	O
+)	O
+in	O
+camel	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+A	O
+pneumonia	B-DISO
+outbreak	O
+associated	O
+with	O
+a	O
+new	O
+coronavirus	B-SPEC
+of	O
+probable	O
+bat	B-ENZY
+origin	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+18	O
+years	O
+ago	O
+,	O
+a	O
+large	O
+number	O
+of	O
+SARS	B-DISO
+-	O
+related	O
+coronaviruses	O
+(	O
+SARSr	O
+-	O
+CoVs	O
+)	O
+have	O
+been	O
+discovered	O
+in	O
+their	O
+natural	O
+reservoir	O
+host	B-COMP
+,	O
+bats	B-SPEC
+
+A	O
+search	O
+was	O
+performed	O
+of	O
+the	O
+Pubmed	O
+,	O
+Scopus	B-SPEC
+,	O
+Clinicaltrials	O
+.	O
+gov	O
+,	O
+and	O
+Virtual	O
+Health	O
+Library	O
+databases	O
+for	O
+randomized	O
+controlled	O
+trials	O
+(	O
+RCT	O
+)	O
+evaluating	O
+28	O
+-	O
+day	O
+mortality	O
+in	O
+ARDS	B-DISO
+patients	O
+treated	O
+with	O
+NMBA	O
+within	O
+48	O
+h	O
+.	O
+An	O
+English	O
+language	O
+restriction	O
+was	O
+applied	O
+.	O
+
+He	O
+had	O
+just	O
+returned	O
+home	O
+from	O
+work	O
+as	O
+a	O
+cabinetmaker	O
+,	O
+where	O
+he	O
+experienced	O
+inhalational	O
+exposure	O
+to	O
+hydrocarbons	B-CHED
+and	O
+solvents	B-CHED
+,	O
+and	O
+had	O
+smoked	O
+a	O
+marijuana	B-DISO
+cigarette	O
+.	O
+
+Diffuse	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+from	O
+Goodpasture	B-DISO
+'	I-DISO
+s	I-DISO
+Syndrome	I-DISO
+has	O
+manifested	O
+following	O
+inhalation	B-PROC
+of	O
+hydrocarbons	B-CHED
+and	O
+following	O
+smoking	O
+.	O
+
+EIT	O
+-	O
+based	O
+optimal	O
+PEEP	B-CHED
+was	O
+significantly	O
+lower	O
+in	O
+PP	O
+than	O
+in	O
+supine	O
+position	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+is	O
+a	O
+swine	B-SPEC
+enteropathogenic	O
+coronavirus	B-SPEC
+that	O
+causes	O
+significant	O
+economic	O
+losses	O
+in	O
+swine	B-SPEC
+industry	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+TGEVs	O
+enter	O
+ST	O
+cells	B-COMP
+via	O
+clathrin	B-PRGE
+-	O
+and	O
+caveolae	B-COMP
+-	O
+mediated	O
+endocytic	O
+,	O
+actin	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+,	I-PRGE
+and	I-PRGE
+dynamin	I-PRGE
+2	I-PRGE
+-	O
+dependent	O
+pathways	B-PROC
+.	O
+
+This	O
+prospective	O
+study	O
+over	O
+November	O
+2017	O
+-	O
+October	O
+2019	O
+was	O
+conducted	O
+in	O
+a	O
+single	O
+-	O
+center	O
+multidisciplinary	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+(	O
+PICU	B-SPEC
+)	O
+and	O
+included	O
+patients	O
+<	O
+21years	O
+of	O
+age	O
+with	O
+PARDS	O
+.	O
+
+Despite	O
+fulfilling	O
+criteria	O
+in	O
+6	O
+/	O
+85	O
+(	O
+7	O
+.	O
+1	O
+%),	O
+hypoxemia	O
+contributed	O
+by	O
+bronchospasm	B-DISO
+,	O
+mucus	B-DISO
+plugging	I-DISO
+,	O
+fluid	B-DISO
+overload	I-DISO
+,	O
+and	O
+atelectasis	B-DISO
+was	O
+quickly	O
+reversible	O
+and	O
+PARDS	O
+was	O
+unlikely	O
+in	O
+these	O
+patients	O
+.	O
+
+These	O
+data	O
+demonstrate	O
+that	O
+Nox2	B-PRGE
+/	O
+ROS	B-PRGE
+/	O
+ZO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+axis	B-SPEC
+is	O
+of	O
+great	O
+importance	O
+in	O
+AECs	O
+damage	O
+induced	O
+by	O
+LPS	B-DISO
+,	O
+and	O
+the	O
+utilization	O
+of	O
+VAS2870	O
+to	O
+inhibit	O
+this	O
+pathway	B-PROC
+might	O
+lighten	O
+LPS	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+We	O
+investigated	O
+two	O
+patients	O
+who	O
+developed	O
+acute	O
+respiratory	O
+syndromes	B-DISO
+after	O
+independent	O
+contact	O
+history	O
+with	O
+this	O
+market	O
+.	O
+
+A	O
+maximum	O
+clade	O
+credibility	O
+tree	O
+has	O
+been	O
+built	O
+using	O
+a	O
+dataset	O
+of	O
+54	O
+genome	O
+sequences	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+plus	O
+two	O
+closely	O
+related	O
+bat	B-ENZY
+strains	O
+(	O
+SARS	B-DISO
+-	O
+like	O
+CoV	O
+)	O
+available	O
+in	O
+GenBank	O
+.	O
+
+The	O
+Bayesian	O
+phylogenetic	O
+reconstruction	O
+showed	O
+that	O
+2019	O
+-	O
+2020	O
+nCoV	O
+firstly	O
+introduced	O
+in	O
+Wuhan	O
+on	O
+25	O
+November	O
+2019	O
+,	O
+started	O
+epidemic	O
+transmission	O
+reaching	O
+many	O
+countries	O
+worldwide	O
+,	O
+including	O
+Europe	O
+and	O
+Italy	O
+where	O
+the	O
+two	O
+strains	O
+isolated	O
+dated	O
+back	B-ANAT
+19	O
+January	O
+2020	O
+,	O
+the	O
+same	O
+that	O
+the	O
+Chinese	O
+tourists	O
+arrived	O
+in	O
+Italy	O
+.	O
+
+In	O
+conclusion	O
+,	O
+this	O
+report	O
+suggests	O
+that	O
+further	O
+spread	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+epidemic	O
+was	O
+supported	O
+by	O
+human	B-SPEC
+mobility	O
+and	O
+that	O
+quarantine	O
+of	O
+suspected	O
+or	O
+diagnosed	O
+cases	O
+is	O
+useful	O
+to	O
+prevent	O
+further	O
+transmission	O
+.	O
+
+Viral	B-COMP
+genome	I-COMP
+phylogenetic	O
+analysis	O
+represents	O
+a	O
+useful	O
+tool	O
+for	O
+the	O
+evaluation	O
+of	O
+transmission	O
+dynamics	O
+and	O
+preventive	O
+action	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Suggestions	O
+for	O
+prevention	O
+of	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+infection	I-DISO
+in	O
+otolaryngology	O
+head	B-ANAT
+and	I-ANAT
+neck	I-ANAT
+surgery	O
+medical	O
+staff	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Diagnosis	O
+and	O
+clinical	O
+management	O
+of	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+infection	I-DISO
+:	O
+an	O
+operational	O
+recommendation	O
+of	O
+Peking	O
+Union	O
+Medical	O
+College	O
+Hospital	O
+(	O
+V2	O
+.	O
+0	O
+)].	O
+
+China	O
+rapidly	O
+identified	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+-	O
+related	O
+pneumonia	B-DISO
+a	O
+statutory	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+pneumonia	B-DISO
+caused	O
+by	O
+the	O
+novel	O
+coronavirus	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+in	O
+Wuhan	O
+,	O
+Hubei	O
+province	O
+of	O
+China	O
+,	O
+at	O
+the	O
+end	O
+of	O
+2019	O
+shaped	O
+tremendous	O
+challenges	O
+to	O
+China	O
+'	O
+s	O
+public	O
+health	O
+and	O
+clinical	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+miRNA	O
+repertoire	O
+and	O
+host	B-COMP
+immune	O
+factor	O
+regulation	B-PROC
+upon	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infection	O
+in	O
+eggs	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+study	O
+that	O
+describes	O
+the	O
+modulation	O
+of	O
+miRNAs	O
+and	O
+the	O
+related	O
+host	B-COMP
+immune	O
+factors	O
+by	O
+IBV	B-SPEC
+in	O
+chicken	B-SPEC
+embryos	B-ANAT
+.	O
+
+We	O
+identified	O
+three	O
+phylogenetic	O
+clusters	B-CHED
+using	O
+the	O
+Bayesian	O
+inference	O
+framework	O
+and	O
+three	O
+transmission	O
+clusters	B-CHED
+using	O
+transmission	O
+network	O
+analysis	O
+,	O
+with	O
+only	O
+one	O
+cluster	O
+identified	O
+by	O
+both	O
+methods	O
+using	O
+the	O
+above	O
+genome	O
+sequences	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+strains	O
+.	O
+
+Full	O
+genomic	O
+sequences	O
+have	O
+been	O
+released	O
+by	O
+the	O
+worldwide	O
+scientific	O
+community	O
+in	O
+the	O
+last	O
+few	O
+weeks	O
+to	O
+understand	O
+the	O
+evolutionary	O
+origin	O
+and	O
+molecular	O
+characteristics	O
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+As	O
+of	O
+February	O
+4	O
+,	O
+2020	O
+,	O
+a	O
+total	O
+of	O
+20	O
+,	O
+471	O
+confirmed	O
+cases	O
+,	O
+including	O
+2	O
+,	O
+788	O
+(	O
+13	O
+.	O
+6	O
+%)	O
+with	O
+severe	O
+illness	O
+,*	O
+and	O
+425	O
+deaths	B-PROC
+(	O
+2	O
+.	O
+1	O
+%)	O
+had	O
+been	O
+reported	O
+by	O
+the	O
+National	O
+Health	O
+Commission	O
+of	O
+China	O
+(	O
+2	O
+).	O
+
+On	O
+January	O
+30	O
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+Director	O
+-	O
+General	O
+declared	O
+that	O
+the	O
+2019	O
+-	O
+nCoV	O
+outbreak	O
+constitutes	O
+a	O
+Public	O
+Health	O
+Emergency	B-DISO
+of	O
+International	O
+Concern	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+and	O
+contribution	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+the	O
+community	O
+to	O
+rates	O
+of	O
+emergency	B-DISO
+department	O
+visits	O
+and	O
+hospitalizations	O
+with	O
+respiratory	O
+tract	O
+infections	O
+,	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+and	O
+asthma	B-PATH
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+individual	O
+and	O
+combined	O
+contribution	O
+of	O
+viral	O
+prevalence	O
+in	O
+the	O
+community	O
+to	O
+Emergency	B-DISO
+Department	O
+(	O
+ED	O
+)	O
+visits	O
+and	O
+hospitalizations	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+RTIs	O
+),	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+and	O
+asthma	B-PATH
+is	O
+unclear	O
+.	O
+
+The	O
+percentage	O
+of	O
+positive	O
+tests	O
+to	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+parainfluenza	B-DISO
+and	O
+adenovirus	B-DISO
+prevalence	O
+explained	O
+57	O
+.	O
+4	O
+%	O
+of	O
+ED	O
+visits	O
+and	O
+63	O
+.	O
+8	O
+%	O
+of	O
+hospitalizations	O
+for	O
+RTI	B-DISO
+,	O
+41	O
+.	O
+4	O
+%	O
+of	O
+ED	O
+visits	O
+and	O
+39	O
+.	O
+2	O
+%	O
+of	O
+hospitalizations	O
+with	O
+COPD	B-DISO
+but	O
+only	O
+1	O
+.	O
+5	O
+%	O
+of	O
+ED	O
+visits	O
+and	O
+2	O
+.	O
+7	O
+%	O
+of	O
+hospitalizations	O
+for	O
+asthma	B-PATH
+.	O
+
+In	O
+rare	O
+cases	O
+,	O
+AIHA	O
+is	O
+comorbid	O
+with	O
+other	O
+immunological	O
+disorders	O
+;	O
+for	O
+instance	O
+,	O
+when	O
+AIHA	O
+is	O
+complicated	O
+with	O
+immunologic	O
+thrombocytopenic	B-DISO
+purpura	I-DISO
+(	O
+ITP	B-DISO
+)	O
+it	O
+is	O
+called	O
+Evans	B-DISO
+Syndrome	I-DISO
+(	O
+ES	O
+).	O
+
+His	O
+background	O
+immunological	O
+status	O
+was	O
+complicated	O
+because	O
+AIHA	O
+was	O
+mixed	O
+-	O
+type	O
+(	O
+warm	O
+and	O
+cold	B-DISO
+antibody	B-COMP
+type	O
+).	O
+
+ITP	B-DISO
+and	O
+mixed	O
+-	O
+type	O
+AIHA	O
+.	O
+
+Our	O
+case	O
+suggested	O
+multiple	O
+immunological	O
+background	O
+,	O
+ITP	B-DISO
+,	O
+and	O
+mixed	O
+type	O
+AIHA	O
+,	O
+could	O
+be	O
+associated	O
+to	O
+a	O
+risk	O
+for	O
+thromboembolism	B-DISO
+(	O
+TE	O
+).	O
+
+TITLE	O
+:	O
+A	O
+rapid	O
+advice	O
+guideline	O
+for	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+infected	O
+pneumonia	B-DISO
+(	O
+standard	O
+version	O
+).	O
+
+This	O
+guideline	O
+includes	O
+the	O
+guideline	O
+methodology	O
+,	O
+epidemiological	O
+characteristics	O
+,	O
+disease	O
+screening	O
+and	O
+population	O
+prevention	O
+,	O
+diagnosis	O
+,	O
+treatment	O
+and	O
+control	O
+(	O
+including	O
+traditional	O
+Chinese	O
+Medicine	O
+),	O
+nosocomial	B-DISO
+infection	I-DISO
+prevention	O
+and	O
+control	O
+,	O
+and	O
+disease	O
+nursing	B-PROC
+of	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+Moreover	O
+,	O
+we	O
+also	O
+provide	O
+a	O
+whole	O
+process	O
+of	O
+a	O
+successful	O
+treatment	O
+case	O
+of	O
+the	O
+severe	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+infected	O
+pneumonia	B-DISO
+and	O
+experience	O
+and	O
+lessons	O
+of	O
+hospital	O
+rescue	O
+for	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+infections	B-DISO
+.	O
+
+This	O
+rapid	O
+advice	O
+guideline	O
+is	O
+suitable	O
+for	O
+the	O
+first	O
+frontline	O
+doctors	O
+and	O
+nurses	O
+,	O
+managers	O
+of	O
+hospitals	O
+and	O
+healthcare	O
+sections	O
+,	O
+community	O
+residents	O
+,	O
+public	O
+health	O
+persons	O
+,	O
+relevant	O
+researchers	O
+,	O
+and	O
+all	O
+person	O
+who	O
+are	O
+interested	O
+in	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Associations	O
+between	O
+changes	O
+in	O
+oxygenation	B-PROC
+,	O
+dead	B-PROC
+space	O
+and	O
+driving	O
+pressure	O
+induced	O
+by	O
+the	O
+first	O
+prone	O
+position	O
+session	O
+and	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+The	O
+primary	O
+endpoint	O
+was	O
+the	O
+prognostic	O
+capacity	O
+of	O
+the	O
+PP	O
+-	O
+induced	O
+changes	O
+in	O
+PaO	B-PROC
+Ninety	O
+patients	O
+were	O
+included	O
+;	O
+28	O
+-	O
+day	O
+mortality	O
+was	O
+46	O
+%.	O
+
+TITLE	O
+:	O
+Clinical	O
+Characteristics	O
+of	O
+138	O
+Hospitalized	O
+Patients	O
+With	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+-	O
+Infected	O
+Pneumonia	B-DISO
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+Chest	B-ANAT
+computed	O
+tomographic	O
+scans	O
+showed	O
+bilateral	O
+patchy	O
+shadows	O
+or	O
+ground	O
+glass	O
+opacity	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+of	O
+all	O
+patients	O
+.	O
+
+In	O
+this	O
+single	O
+-	O
+center	O
+case	O
+series	O
+of	O
+138	O
+hospitalized	O
+patients	O
+with	O
+confirmed	O
+NCIP	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+presumed	O
+hospital	O
+-	O
+related	O
+transmission	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+was	O
+suspected	O
+in	O
+41	O
+%	O
+of	O
+patients	O
+,	O
+26	O
+%	O
+of	O
+patients	O
+received	O
+ICU	O
+care	O
+,	O
+and	O
+mortality	O
+was	O
+4	O
+.	O
+3	O
+%.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+coronavirus	O
+of	O
+zoonotic	O
+origin	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+has	O
+recently	O
+been	O
+identified	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+.	O
+
+This	O
+virus	B-SPEC
+is	O
+genetically	O
+similar	O
+to	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+bat	B-ENZY
+SARS	B-DISO
+-	O
+like	O
+coronaviruses	O
+.	O
+
+Molecular	O
+tests	O
+for	O
+rapid	O
+detection	O
+of	O
+this	O
+virus	B-SPEC
+are	O
+urgently	O
+needed	O
+for	O
+early	O
+identification	O
+of	O
+infected	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+An	O
+integrative	O
+review	O
+of	O
+the	O
+limited	O
+evidence	O
+on	O
+international	O
+travel	O
+bans	O
+as	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+disaster	O
+control	O
+measure	O
+.	O
+
+To	O
+increase	O
+awareness	O
+about	O
+its	O
+serious	O
+complications	O
+,	O
+we	O
+report	O
+three	O
+cases	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+complicated	O
+with	O
+hemolytic	B-DISO
+uremic	I-DISO
+syndrome	I-DISO
+,	O
+myocarditis	B-DISO
+and	O
+acute	B-DISO
+necrotizing	I-DISO
+encephalopathy	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+Rate	O
+of	O
+Underascertainment	O
+of	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+Infection	B-DISO
+:	O
+
+Assuming	O
+that	O
+the	O
+mean	O
+detection	O
+window	O
+of	O
+the	O
+virus	B-SPEC
+can	O
+be	O
+informed	O
+by	O
+the	O
+mean	O
+serial	O
+interval	O
+(	O
+estimated	O
+at	O
+7	O
+.	O
+5	O
+days	O
+),	O
+the	O
+ascertainment	O
+rate	O
+of	O
+infection	B-DISO
+was	O
+estimated	O
+at	O
+9	O
+.	O
+2	O
+%	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+:	O
+5	O
+.	O
+0	O
+,	O
+20	O
+.	O
+0	O
+).	O
+
+This	O
+statement	O
+is	O
+based	O
+on	O
+the	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+Infection	O
+Pneumonia	B-DISO
+Diagnosis	O
+and	O
+Treatment	O
+Standards	O
+(	O
+the	O
+fourth	O
+edition	O
+)	O
+(	O
+National	O
+Health	O
+Committee	O
+)	O
+and	O
+other	O
+previous	O
+diagnosis	O
+and	O
+treatment	O
+strategies	O
+for	O
+pediatric	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+We	O
+evaluated	O
+the	O
+effectiveness	O
+of	O
+ProMED	O
+as	O
+a	O
+source	O
+of	O
+epidemiological	O
+data	O
+on	O
+coronavirus	B-SPEC
+.	O
+
+Ruscogenin	O
+(	O
+RUS	O
+)	O
+has	O
+been	O
+found	O
+to	O
+exert	B-PROC
+significant	O
+protective	O
+effect	O
+on	O
+ALI	O
+induced	O
+by	O
+lipopolysaccharides	B-CHED
+(	O
+LPS	B-DISO
+),	O
+but	O
+there	O
+is	O
+little	O
+information	O
+about	O
+its	O
+role	O
+in	O
+LPS	B-DISO
+-	O
+induced	O
+pulmonary	B-ANAT
+endothelial	B-PROC
+cell	I-PROC
+apoptosis	B-PATH
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+RUS	O
+could	O
+attenuate	O
+LPS	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+and	O
+pulmonary	B-ANAT
+endothelial	B-ANAT
+apoptosis	B-PATH
+significantly	O
+.	O
+
+There	O
+is	O
+currently	O
+no	O
+approved	O
+therapeutic	O
+for	O
+human	B-SPEC
+use	O
+against	O
+NiV	O
+infection	B-DISO
+.	O
+
+The	O
+neonatal	O
+Fc	B-PRGE
+receptor	I-PRGE
+(	O
+FcRn	B-PRGE
+)	O
+is	O
+the	O
+only	O
+IgG	B-PRGE
+transport	I-PRGE
+receptor	I-PRGE
+,	O
+its	O
+expression	B-PROC
+on	O
+mucosal	B-ANAT
+surfaces	O
+is	O
+triggered	O
+upon	O
+viral	O
+stimulation	O
+,	O
+which	O
+significantly	O
+enhances	O
+mucosal	B-PROC
+immunity	I-PROC
+.	O
+
+TGEV	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+also	O
+enhanced	O
+FcRn	B-PRGE
+promoter	I-PRGE
+activity	O
+via	O
+the	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathway	I-PROC
+and	O
+its	O
+central	O
+region	O
+(	O
+aa	O
+128	O
+-	O
+252	O
+)	O
+was	O
+essential	O
+for	O
+FcRn	B-PRGE
+activation	O
+.	O
+
+Significant	O
+complications	O
+include	O
+variceal	O
+bleeding	B-DISO
+,	O
+hepatic	B-DISO
+encephalopathy	I-DISO
+,	O
+hepatorenal	B-DISO
+syndrome	I-DISO
+,	O
+and	O
+infection	B-DISO
+.	O
+
+Extrahepatic	O
+complications	O
+often	O
+include	O
+renal	B-ANAT
+,	O
+cardiovascular	B-ANAT
+,	O
+and	O
+respiratory	O
+failures	O
+.	O
+
+Here	O
+,	O
+we	O
+present	O
+a	O
+novel	O
+two	O
+-	O
+stage	O
+procedure	O
+for	O
+the	O
+identification	O
+of	O
+host	B-COMP
+factors	O
+involved	O
+in	O
+the	O
+replication	O
+of	O
+different	O
+viruses	B-SPEC
+using	O
+a	O
+combination	O
+of	O
+random	O
+effects	O
+models	O
+and	O
+Markov	O
+random	O
+walks	O
+on	O
+a	O
+functional	O
+interaction	O
+network	O
+.	O
+
+Evidence	O
+-	O
+based	O
+supportive	O
+care	O
+is	O
+the	O
+mainstay	O
+for	O
+management	O
+of	O
+severe	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+.	O
+
+Furthermore	O
+,	O
+phylogenetic	O
+analysis	O
+of	O
+BCoV	O
+S	O
+genes	O
+including	O
+those	O
+of	O
+European	O
+and	O
+Asian	O
+BCoVs	O
+and	O
+human	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+along	O
+with	O
+the	O
+Japanese	O
+BCoVs	O
+revealed	O
+that	O
+BCoVs	O
+differentiated	B-PROC
+into	O
+two	O
+major	O
+types	O
+(	O
+European	O
+and	O
+American	O
+types	O
+).	O
+
+TITLE	O
+:	O
+Identifying	O
+factors	O
+and	O
+target	O
+preventive	O
+therapies	O
+for	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+sucsibtable	O
+patients	O
+.	O
+
+According	O
+to	O
+a	O
+causal	O
+directed	O
+acyclic	O
+graph	O
+(	O
+DAG	O
+)	O
+that	O
+included	O
+respiratory	B-ANAT
+system	I-ANAT
+compliance	O
+(	O
+C	O
+C	O
+
+The	O
+most	O
+common	O
+adverse	O
+events	O
+were	O
+hyperglycaemia	B-DISO
+in	O
+the	O
+ICU	O
+(	O
+105	O
+[	O
+76	O
+%]	O
+patients	O
+in	O
+the	O
+dexamethasone	B-CHED
+group	O
+vs	O
+97	O
+[	O
+70	O
+%]	O
+patients	O
+in	O
+the	O
+control	O
+group	O
+),	O
+new	O
+infections	B-DISO
+in	O
+the	O
+ICU	O
+(	O
+eg	O
+,	O
+pneumonia	B-DISO
+or	O
+sepsis	B-DISO
+;	O
+33	O
+[	O
+24	O
+%]	O
+vs	O
+35	O
+[	O
+25	O
+%]),	O
+and	O
+barotrauma	O
+(	O
+14	O
+[	O
+10	O
+%]	O
+vs	O
+10	O
+[	O
+7	O
+%]).	O
+
+ABSTRACT	O
+:	O
+Alveolar	O
+flooding	O
+and	O
+airway	B-DISO
+obstruction	I-DISO
+are	O
+present	O
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Six	O
+patients	O
+underwent	O
+lung	B-ANAT
+and	O
+airway	B-ANAT
+imaging	O
+at	O
+four	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+levels	O
+in	O
+a	O
+cohort	O
+trial	O
+.	O
+
+This	O
+technique	O
+offers	O
+3	O
+-	O
+dimensional	O
+visualisation	O
+and	O
+quantification	O
+of	O
+patients	O
+'	O
+airway	B-ANAT
+and	O
+lung	B-ANAT
+geometry	O
+on	O
+a	O
+regional	O
+level	O
+.	O
+
+Clinical	O
+data	O
+from	O
+137	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+-	O
+infected	O
+patients	O
+admitted	O
+to	O
+the	O
+respiratory	O
+departments	O
+of	O
+the	O
+respiratory	O
+departments	O
+of	O
+nine	O
+tertiary	O
+hospitals	O
+in	O
+Hubei	O
+province	O
+from	O
+December	O
+30	O
+,	O
+2019	O
+to	O
+January	O
+24	O
+,	O
+2020	O
+were	O
+retrospectively	O
+collected	O
+,	O
+including	O
+general	O
+status	O
+,	O
+clinical	O
+manifestations	O
+,	O
+laboratory	O
+test	O
+results	O
+,	O
+imaging	O
+characteristics	O
+,	O
+and	O
+treatment	O
+regimens	O
+.	O
+
+TITLE	O
+:	O
+α	O
+-	O
+Ketoamides	O
+as	O
+Broad	O
+-	O
+Spectrum	O
+Inhibitors	B-CHED
+of	O
+Coronavirus	B-SPEC
+and	O
+Enterovirus	B-SPEC
+Replication	O
+:	O
+Structure	O
+-	O
+Based	O
+Design	O
+,	O
+Synthesis	O
+,	O
+and	O
+Activity	O
+Assessment	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+main	O
+protease	O
+of	O
+coronaviruses	O
+and	O
+the	O
+3C	B-PRGE
+protease	I-PRGE
+of	O
+enteroviruses	B-SPEC
+share	O
+a	O
+similar	O
+active	O
+-	O
+site	O
+architecture	O
+and	O
+a	O
+unique	O
+requirement	O
+for	O
+glutamine	B-CHED
+in	O
+the	O
+P1	O
+position	O
+of	O
+the	O
+substrate	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+obtain	O
+near	O
+-	O
+equipotent	O
+,	O
+broad	O
+-	O
+spectrum	O
+antivirals	B-CHED
+against	O
+alphacoronaviruses	O
+,	O
+betacoronaviruses	O
+,	O
+and	O
+enteroviruses	B-SPEC
+,	O
+we	O
+pursued	O
+a	O
+structure	O
+-	O
+based	O
+design	O
+of	O
+peptidomimetic	B-CHED
+α	O
+-	O
+ketoamides	O
+as	O
+inhibitors	B-CHED
+of	O
+main	O
+and	O
+3C	O
+proteases	O
+.	O
+
+The	O
+best	O
+near	O
+-	O
+equipotent	O
+inhibitors	B-CHED
+,	O
+
+As	O
+this	O
+bivalent	O
+binding	B-FUNC
+may	O
+enable	O
+broad	O
+zoonotic	O
+CoV	O
+infection	B-DISO
+,	O
+we	O
+aimed	O
+to	O
+identify	O
+roles	O
+for	O
+each	O
+receptor	O
+in	O
+distinct	O
+infection	B-DISO
+stages	O
+.	O
+
+Overall	O
+,	O
+these	O
+findings	O
+reveal	O
+roles	O
+for	O
+sialic	B-CHED
+acids	I-CHED
+in	O
+virus	B-SPEC
+-	O
+cell	B-COMP
+binding	B-FUNC
+,	O
+viral	O
+spike	O
+protein	B-CHED
+-	O
+directed	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+,	O
+and	O
+resultant	O
+spread	O
+of	O
+CoV	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Consistent	O
+detection	O
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+in	O
+saliva	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Synanthropic	O
+rodents	B-SPEC
+as	O
+virus	B-SPEC
+reservoirs	O
+and	O
+transmitters	O
+.	O
+
+Despite	O
+their	O
+potential	O
+impact	O
+on	O
+human	B-SPEC
+health	O
+,	O
+relatively	O
+few	O
+studies	O
+have	O
+addressed	O
+the	O
+monitoring	O
+of	O
+these	O
+viruses	B-SPEC
+in	O
+rodents	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Some	O
+patients	O
+with	O
+positive	O
+chest	O
+CT	O
+findings	O
+may	O
+present	O
+with	O
+negative	O
+results	O
+of	O
+real	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+-	O
+polymerase	O
+chain	O
+-	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+for	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+).	O
+
+The	O
+disease	O
+is	O
+officially	O
+named	O
+as	O
+the	O
+Severe	O
+Specific	O
+Contagious	O
+Pneumonia	B-DISO
+(	O
+SSCP	O
+)	O
+in	O
+1	O
+/	O
+15	O
+/	O
+2019	O
+and	O
+is	O
+a	O
+notifiable	O
+communicable	B-DISO
+disease	I-DISO
+of	O
+the	O
+5	O
+category	O
+by	O
+the	O
+Taiwan	O
+CDC	O
+,	O
+the	O
+Ministry	O
+of	O
+Health	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+assess	O
+the	O
+potential	O
+of	O
+the	O
+Wuhan	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+to	O
+cause	O
+maternal	O
+,	O
+fetal	B-ANAT
+and	O
+neonatal	O
+morbidity	O
+and	O
+other	O
+poor	O
+obstetrical	O
+outcomes	O
+,	O
+this	O
+communication	O
+reviews	O
+the	O
+published	O
+data	O
+addressing	O
+the	O
+epidemiological	O
+and	O
+clinical	O
+effects	O
+of	O
+SARS	B-DISO
+,	O
+MERS	O
+,	O
+and	O
+other	O
+coronavirus	B-DISO
+infections	I-DISO
+on	O
+pregnant	O
+women	O
+and	O
+their	O
+infants	O
+.	O
+
+TITLE	O
+:	O
+Facilitating	O
+ventilator	O
+weaning	B-PROC
+through	O
+rib	B-CHED
+fixation	O
+combined	O
+with	O
+video	O
+-	O
+assisted	O
+thoracoscopic	O
+surgery	O
+in	O
+severe	O
+blunt	O
+chest	O
+injury	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Some	O
+patients	O
+who	O
+received	O
+rib	B-CHED
+fixation	O
+with	O
+VATS	O
+were	O
+enrolled	O
+as	O
+group	O
+1	O
+,	O
+and	O
+the	O
+others	O
+who	O
+received	O
+only	O
+VATS	O
+were	O
+designated	O
+as	O
+group	O
+2	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Perinatal	O
+and	O
+neonatal	O
+management	O
+plan	B-DISO
+for	O
+prevention	O
+and	O
+control	O
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+infection	I-DISO
+(	O
+1st	O
+Edition	O
+)].	O
+
+In	O
+order	B-SPEC
+to	O
+further	O
+standardize	O
+and	O
+enhance	O
+the	O
+clinical	O
+management	O
+of	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+in	O
+children	O
+,	O
+reduce	O
+the	O
+incidence	O
+,	O
+and	O
+decrease	O
+the	O
+number	O
+of	O
+severe	O
+cases	O
+,	O
+we	O
+have	O
+formulated	O
+this	O
+diagnosis	O
+and	O
+treatment	O
+recommendation	O
+according	O
+to	O
+the	O
+recent	O
+information	O
+at	O
+home	O
+and	O
+abroad	O
+.	O
+
+TITLE	O
+:	O
+Practical	O
+recommendations	O
+for	O
+critical	O
+care	O
+and	O
+anesthesiology	O
+teams	O
+caring	O
+for	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+global	O
+health	O
+emergency	B-DISO
+has	O
+been	O
+declared	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+as	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+outbreak	O
+spreads	O
+across	O
+the	O
+world	O
+,	O
+with	O
+confirmed	O
+patients	O
+in	O
+Canada	O
+.	O
+
+Patients	O
+infected	O
+with	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+are	O
+at	O
+risk	O
+for	O
+developing	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+requiring	O
+admission	O
+to	O
+critical	O
+care	O
+units	O
+.	O
+
+While	O
+providing	O
+optimal	O
+treatment	O
+for	O
+these	O
+patients	O
+,	O
+careful	O
+execution	O
+of	O
+infection	B-DISO
+control	O
+measures	O
+is	O
+necessary	O
+to	O
+prevent	O
+nosocomial	O
+transmission	O
+to	O
+other	O
+patients	O
+and	O
+to	O
+healthcare	O
+workers	O
+providing	O
+care	O
+.	O
+
+Although	O
+the	O
+exact	O
+mechanisms	O
+of	O
+transmission	O
+are	O
+currently	O
+unclear	O
+,	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+can	O
+occur	O
+,	O
+and	O
+the	O
+risk	O
+of	O
+airborne	O
+spread	O
+during	O
+aerosol	O
+-	O
+generating	O
+medical	O
+procedures	O
+remains	O
+a	O
+concern	O
+in	O
+specific	O
+circumstances	O
+.	O
+
+TITLE	O
+:	O
+Potential	O
+interventions	O
+for	O
+novel	B-SPEC
+coronavirus	I-SPEC
+in	O
+China	O
+:	O
+A	O
+systematic	O
+review	O
+.	O
+
+The	O
+total	O
+CT	O
+score	O
+was	O
+the	O
+sum	O
+of	O
+lung	B-ANAT
+involvement	O
+(	O
+5	O
+lobes	B-ANAT
+,	O
+score	O
+1	O
+-	O
+5	O
+for	O
+each	O
+lobe	B-ANAT
+,	O
+range	O
+,	O
+0	O
+none	O
+,	O
+25	O
+maximum	O
+)	O
+was	O
+determined	O
+.	O
+
+Results	O
+Twenty	O
+one	O
+patients	O
+(	O
+6	O
+males	O
+and	O
+15	O
+females	O
+,	O
+age	O
+25	O
+-	O
+63	O
+years	O
+)	O
+with	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+were	O
+evaluated	O
+.	O
+
+We	O
+estimated	O
+the	O
+probability	O
+of	O
+transportation	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+from	O
+Wuhan	O
+to	O
+369	O
+other	O
+cities	O
+in	O
+China	O
+before	O
+the	O
+quarantine	O
+.	O
+
+Expected	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+risk	O
+is	O
+>	O
+50	O
+%	O
+in	O
+130	O
+(	O
+95	O
+%	O
+CI	O
+89	O
+-	O
+190	O
+)	O
+cities	O
+and	O
+>	O
+99	O
+%	O
+in	O
+the	O
+4	O
+largest	O
+metropolitan	O
+areas	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+presence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+the	O
+lower	O
+airways	O
+of	O
+individuals	O
+undergoing	O
+invasive	O
+mechanical	O
+ventilation	O
+,	O
+with	O
+and	O
+without	O
+acute	O
+lower	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+(	O
+respectively	O
+WRI	O
+and	O
+WORI	O
+groups	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+continued	O
+emergence	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+cases	O
+with	O
+a	O
+high	O
+case	O
+fatality	O
+rate	O
+stresses	O
+the	O
+need	O
+for	O
+the	O
+availability	O
+of	O
+effective	O
+antiviral	B-CHED
+treatments	O
+.	O
+
+Remdesivir	O
+(	O
+GS	O
+-	O
+5734	O
+)	O
+effectively	O
+inhibited	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+replication	O
+in	O
+vitro	O
+,	O
+and	O
+showed	O
+efficacy	O
+against	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+.	O
+
+A	O
+narrative	O
+review	O
+from	O
+a	O
+clinical	O
+perspective	O
+of	O
+clinical	O
+features	O
+,	O
+diagnostic	O
+tests	O
+,	O
+treatments	O
+and	O
+outcomes	O
+of	O
+patients	O
+with	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+.	O
+
+Substantial	O
+advances	O
+have	O
+been	O
+made	O
+in	O
+the	O
+care	O
+of	O
+patients	O
+with	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+(	O
+EVD	O
+),	O
+precipitated	O
+by	O
+the	O
+unprecedented	O
+extent	O
+of	O
+the	O
+2014	O
+-	O
+2016	O
+outbreak	O
+.	O
+
+With	O
+specific	O
+anti	O
+-	O
+Ebola	O
+medications	O
+,	O
+most	O
+patients	O
+can	O
+survive	O
+Ebola	B-DISO
+virus	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Initial	O
+CT	O
+findings	O
+and	O
+temporal	O
+changes	O
+in	O
+patients	O
+with	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+):	O
+a	O
+study	O
+of	O
+63	O
+patients	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+The	O
+number	O
+of	O
+affected	O
+lobes	B-ANAT
+,	O
+ground	O
+glass	O
+nodules	B-DISO
+(	O
+GGO	O
+),	O
+patchy	O
+/	O
+punctate	O
+ground	O
+glass	O
+opacities	B-DISO
+,	O
+patchy	O
+consolidation	O
+,	O
+fibrous	O
+stripes	O
+and	O
+irregular	O
+solid	O
+nodules	B-DISO
+in	O
+each	O
+patient	O
+'	O
+s	O
+chest	B-ANAT
+CT	O
+image	O
+were	O
+recorded	O
+.	O
+
+The	O
+mean	O
+number	O
+of	O
+affected	O
+lobes	B-ANAT
+was	O
+3	O
+.	O
+3	O
+±	O
+1	O
+.	O
+8	O
+.	O
+
+•	O
+High	O
+-	O
+resolution	O
+CT	O
+(	O
+HRCT	O
+)	O
+of	O
+the	O
+chest	B-ANAT
+is	O
+critical	O
+for	O
+early	O
+detection	O
+,	O
+evaluation	O
+of	O
+disease	O
+severity	O
+and	O
+follow	O
+-	O
+up	O
+of	O
+patients	O
+with	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+.	O
+
+•	O
+The	O
+manifestations	O
+of	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+are	O
+diverse	O
+and	O
+change	O
+rapidly	O
+.	O
+
+Fifty	O
+-	O
+four	O
+(	O
+85	O
+.	O
+7	O
+%)	O
+patients	O
+progressed	O
+,	O
+including	O
+single	O
+GGO	O
+increased	O
+,	O
+enlarged	O
+and	O
+consolidated	O
+;	O
+fibrous	O
+stripe	O
+enlarged	O
+,	O
+while	O
+solid	O
+nodules	B-DISO
+increased	O
+and	O
+enlarged	O
+.	O
+
+ROC	O
+curve	O
+analysis	O
+showed	O
+that	O
+lateral	O
+,	O
+inferior	O
+,	O
+global	O
+(	O
+average	O
+of	O
+the	O
+3	O
+RV	O
+walls	O
+)	O
+longitudinal	O
+systolic	O
+strain	O
+(	O
+LSS	B-DISO
+)	O
+and	O
+global	O
+strain	O
+rate	O
+demonstrated	O
+significant	O
+diagnostic	O
+values	O
+when	O
+compared	O
+to	O
+several	O
+conventional	O
+indices	O
+(	O
+TAPSE	O
+,	O
+S	O
+',	O
+RV	O
+FAC	B-DISO
+).	O
+
+Patients	O
+were	O
+screened	O
+for	O
+picornavirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+coronavirus	B-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+bocavirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+and	O
+influenza	B-DISO
+,	O
+by	O
+PCR	O
+on	O
+nasopharyngeal	B-ANAT
+samples	O
+.	O
+
+Together	O
+with	O
+the	O
+other	O
+two	O
+highly	O
+pathogenic	O
+coronaviruses	O
+,	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+2019	B-SPEC
+-	I-SPEC
+nCov	I-SPEC
+and	O
+other	O
+yet	O
+to	O
+be	O
+identified	O
+coronaviruses	O
+pose	O
+a	O
+global	O
+threat	O
+to	O
+public	O
+health	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+two	O
+confirmed	O
+cases	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+pneumonia	B-DISO
+with	O
+chest	B-ANAT
+computed	O
+tomography	O
+findings	O
+of	O
+multiple	O
+regions	O
+of	O
+patchy	O
+consolidation	O
+and	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+in	O
+both	O
+lungs	B-ANAT
+.	O
+
+The	O
+54	O
+-	O
+year	O
+old	O
+male	O
+is	O
+the	O
+third	O
+patient	O
+diagnosed	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+in	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+Systemic	O
+BK	B-DISO
+Virus	I-DISO
+Infection	I-DISO
+in	O
+a	O
+Pediatric	O
+Patient	O
+With	O
+Severe	B-DISO
+Combined	I-DISO
+Immunodeficiency	I-DISO
+.	O
+
+However	O
+,	O
+conditions	O
+causing	O
+immunosuppression	B-PROC
+can	O
+lead	O
+to	O
+increased	O
+virus	B-PROC
+replication	I-PROC
+and	O
+tissue	B-ANAT
+damage	O
+.	O
+
+This	O
+prompted	O
+a	O
+search	O
+for	O
+immunodeficiencies	B-DISO
+,	O
+which	O
+revealed	O
+the	O
+presence	O
+of	O
+severe	B-DISO
+combined	I-DISO
+immunodeficiency	I-DISO
+.	O
+
+The	O
+published	O
+cohorts	O
+of	O
+2019	O
+new	O
+Coronavirus	B-SPEC
+(	O
+n	O
+-	O
+Cov	O
+)	O
+are	O
+single	O
+-	O
+center	O
+studies	O
+,	O
+or	O
+retrospective	O
+studies	O
+.	O
+
+It	O
+'	O
+s	O
+more	O
+urgent	O
+to	O
+implement	O
+strict	O
+and	O
+efficient	O
+infection	B-DISO
+control	O
+protocols	O
+.	O
+
+ABSTRACT	O
+:	O
+Through	O
+literature	O
+review	O
+and	O
+group	O
+discussion	O
+,	O
+Special	O
+Expert	O
+Group	O
+for	O
+Control	O
+of	O
+the	O
+Epidemic	O
+of	O
+Novel	O
+Coronavirus	O
+Pneumonia	B-DISO
+of	O
+the	O
+Chinese	O
+Preventive	O
+Medicine	B-CHED
+Association	O
+formulated	O
+an	O
+update	O
+on	O
+the	O
+epidemiological	O
+characteristics	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+(	O
+NCP	B-FUNC
+).	O
+
+The	O
+virus	B-SPEC
+is	O
+believed	O
+transmitted	B-DISO
+mostly	O
+via	O
+droplets	O
+or	O
+contact	O
+.	O
+
+Strategies	O
+for	O
+prevention	O
+and	O
+control	O
+of	O
+NCP	B-FUNC
+include	O
+improving	O
+epidemic	O
+surveillance	O
+,	O
+quarantining	O
+the	O
+source	O
+of	O
+infection	B-DISO
+,	O
+speeding	O
+up	O
+the	O
+diagnosis	O
+of	O
+suspected	O
+cases	O
+,	O
+optimizing	O
+the	O
+management	O
+of	O
+close	O
+contacts	O
+,	O
+tightening	O
+prevention	O
+and	O
+control	O
+of	O
+cluster	O
+outbreaks	O
+and	O
+hospital	B-DISO
+infection	I-DISO
+,	O
+preventing	O
+possible	O
+rebound	O
+of	O
+the	O
+epidemic	O
+after	O
+people	O
+return	O
+to	O
+work	O
+from	O
+the	O
+Chinese	O
+Spring	O
+Festival	O
+holiday	O
+,	O
+and	O
+strengthening	O
+community	O
+prevention	O
+and	O
+control	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Recommendations	O
+for	O
+general	O
+surgery	O
+clinical	O
+practice	O
+in	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+situation	O
+].	O
+
+The	O
+results	O
+of	O
+dwarf	B-DISO
+chicken	B-SPEC
+embryos	B-ANAT
+,	O
+growth	B-PROC
+kinetics	O
+,	O
+and	O
+viral	O
+titration	O
+in	O
+the	O
+embryos	B-ANAT
+demonstrated	O
+that	O
+the	O
+biological	O
+characteristics	O
+of	O
+the	O
+recombinant	O
+virus	B-SPEC
+remained	O
+unchanged	O
+.	O
+
+Compared	O
+to	O
+rH120	O
+vaccination	O
+group	O
+,	O
+when	O
+the	O
+efficacy	O
+of	O
+this	O
+strain	O
+was	O
+evaluated	O
+against	O
+the	O
+QX	B-PRGE
+-	I-PRGE
+like	I-PRGE
+IBV	I-PRGE
+strain	O
+,	O
+better	O
+protection	O
+,	O
+with	O
+100	O
+%	O
+survival	O
+rate	O
+and	O
+no	O
+disease	O
+symptom	B-DISO
+or	O
+gross	O
+lesion	O
+was	O
+observed	O
+in	O
+the	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+rH120	O
+-	O
+S1	O
+/	O
+YZ	O
+.	O
+
+TITLE	O
+:	O
+The	O
+spike	O
+glycoprotein	B-CHED
+of	O
+the	O
+new	O
+coronavirus	B-SPEC
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+contains	O
+a	O
+furin	B-PRGE
+-	O
+like	O
+cleavage	B-PROC
+site	O
+absent	O
+in	O
+CoV	O
+of	O
+the	O
+same	O
+clade	O
+.	O
+
+The	O
+evolution	O
+in	O
+the	O
+basic	O
+reproduction	B-PROC
+number	O
+(	O
+R0	O
+)	O
+warns	O
+that	O
+MERS	O
+-	O
+CoV	O
+may	O
+easily	O
+take	O
+an	O
+epidemic	O
+form	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	O
+coronavirus	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+infected	O
+patients	O
+by	O
+binding	B-FUNC
+human	B-SPEC
+ACE2	O
+,	O
+leading	O
+to	O
+severe	O
+pneumonia	B-DISO
+and	O
+highly	O
+mortality	O
+rate	O
+in	O
+patients	O
+.	O
+
+The	O
+balance	B-PROC
+of	O
+the	O
+RAS	B-CHED
+system	O
+was	O
+broken	O
+,	O
+and	O
+this	O
+would	O
+lead	O
+to	O
+the	O
+exacerbation	O
+of	O
+acute	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+CDV	B-PRGE
+RNA	I-PRGE
+was	O
+mainly	O
+detected	O
+in	O
+the	O
+Canidae	B-SPEC
+family	B-SPEC
+,	O
+with	O
+viral	O
+nucleic	B-CHED
+acid	I-CHED
+recorded	O
+between	O
+2005	O
+and	O
+2008	O
+with	O
+a	O
+peak	O
+prevalence	O
+of	O
+67	O
+%	O
+among	O
+the	O
+wolf	O
+population	O
+,	O
+followed	O
+by	O
+a	O
+sharp	O
+decline	O
+,	O
+suggesting	O
+an	O
+epizootic	O
+behaviour	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+On	O
+December	O
+31	O
+,	O
+2019	O
+,	O
+the	O
+Wuhan	O
+Municipal	O
+Health	O
+Commission	O
+announced	O
+an	O
+outbreak	O
+of	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+),	O
+China	O
+is	O
+now	O
+at	O
+a	O
+critical	O
+period	O
+in	O
+the	O
+control	O
+of	O
+the	O
+epidemic	O
+.	O
+
+Although	O
+China	O
+has	O
+made	O
+great	O
+efforts	O
+to	O
+strengthen	O
+the	O
+ability	O
+to	O
+quickly	O
+respond	O
+to	O
+public	O
+health	O
+emergencies	B-DISO
+since	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+and	O
+it	O
+has	O
+clarified	O
+requirements	O
+for	O
+emergency	O
+supplies	O
+through	O
+legislation	O
+,	O
+the	O
+emergency	B-DISO
+reserve	O
+supplies	O
+program	O
+has	O
+not	O
+been	O
+effectively	O
+implemented	O
+,	O
+and	O
+there	O
+are	O
+also	O
+deficiencies	O
+in	O
+the	O
+types	O
+,	O
+quantity	O
+,	O
+and	O
+availability	O
+of	O
+emergency	B-DISO
+medical	O
+supplies	O
+.	O
+
+Relative	O
+risk	O
+(	O
+RR	O
+)	O
+was	O
+calculated	O
+for	O
+the	O
+incidence	O
+of	O
+barotrauma	O
+and	O
+mortality	O
+using	O
+the	O
+random	O
+-	O
+effect	O
+or	O
+fixed	B-ANAT
+-	O
+effect	O
+model	O
+according	O
+to	O
+heterogeneity	O
+analysis	O
+.	O
+
+Long	O
+non	O
+-	O
+coding	O
+RNAs	O
+(	O
+lncRNAs	O
+)	O
+are	O
+known	O
+to	O
+be	O
+important	O
+regulators	O
+during	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+a	O
+comprehensive	O
+transcriptome	O
+profile	O
+of	O
+lncRNA	O
+in	O
+PDCoV	O
+-	O
+infected	O
+swine	B-SPEC
+testicular	O
+(	O
+ST	O
+)	O
+cells	B-COMP
+.	O
+
+Gene	O
+Ontology	O
+(	O
+GO	O
+)	O
+and	O
+Kyoto	O
+Encyclopedia	O
+of	O
+Genes	O
+and	O
+Genomes	O
+(	O
+KEGG	O
+)	O
+analysis	O
+revealed	O
+that	O
+these	O
+lncRNAs	O
+might	O
+be	O
+involved	O
+in	O
+numerous	O
+biological	B-PROC
+processes	I-PROC
+.	O
+
+Furthermore	O
+,	O
+we	O
+constructed	O
+a	O
+lncRNA	O
+-	O
+protein	B-CHED
+-	O
+coding	O
+gene	O
+co	O
+-	O
+expression	B-PROC
+interaction	O
+network	O
+.	O
+
+In	O
+this	O
+clustering	O
+outbreak	O
+,	O
+4	O
+patients	O
+remained	O
+asymptomatic	O
+,	O
+but	O
+PCR	O
+and	O
+IgM	B-PRGE
+antibodies	B-COMP
+were	O
+positive	O
+,	O
+indicating	O
+that	O
+asymptomatic	O
+patients	O
+may	O
+be	O
+the	O
+key	O
+point	O
+to	O
+control	O
+the	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+December	O
+2019	O
+,	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+epidemic	O
+occurred	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+,	O
+and	O
+spread	O
+rapidly	O
+across	O
+the	O
+country	O
+.	O
+
+TITLE	O
+:	O
+Potent	O
+binding	B-FUNC
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+spike	O
+protein	B-CHED
+by	O
+a	O
+SARS	B-DISO
+coronavirus	B-SPEC
+-	I-PRGE
+specific	I-PRGE
+human	B-SPEC
+monoclonal	I-PRGE
+antibody	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+and	O
+serological	O
+investigation	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+infected	O
+patients	O
+:	O
+implication	O
+of	O
+multiple	O
+shedding	O
+routes	O
+.	O
+
+Likewise	O
+,	O
+patient	O
+will	O
+be	O
+released	O
+upon	O
+two	O
+times	O
+of	O
+negative	O
+detection	O
+from	O
+oral	B-ANAT
+swabs	O
+.	O
+
+We	O
+conducted	O
+investigation	O
+on	O
+patients	O
+in	O
+a	O
+local	O
+hospital	O
+who	O
+were	O
+infected	O
+with	O
+this	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+December	O
+2019	O
+,	O
+an	O
+outbreak	O
+of	O
+corona	O
+virus	B-PROC
+disease	I-PROC
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+occurred	O
+in	O
+Wuhan	O
+,	O
+and	O
+rapidly	O
+spread	O
+to	O
+almost	O
+all	O
+parts	O
+of	O
+China	O
+.	O
+
+There	O
+were	O
+3	O
+studies	O
+using	O
+CM	O
+for	O
+prevention	O
+of	O
+SARS	B-DISO
+and	O
+4	O
+studies	O
+for	O
+H1N1	B-DISO
+influenza	I-DISO
+.	O
+
+None	O
+of	O
+the	O
+participants	O
+who	O
+took	O
+CM	O
+contracted	O
+SARS	B-DISO
+in	O
+the	O
+3	O
+studies	O
+.	O
+
+These	O
+results	O
+do	O
+not	O
+support	O
+the	O
+use	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+-	I-PRGE
+1a	I-PRGE
+in	O
+the	O
+management	O
+of	O
+ARDS	B-DISO
+.	O
+
+iNOS	B-PRGE
+and	O
+OAS	B-DISO
+genes	O
+in	O
+CAM	B-DISO
+.	O
+
+It	O
+may	O
+be	O
+speculated	O
+that	O
+in	O
+ovo	B-SPEC
+administration	O
+of	O
+these	O
+TLR	O
+ligands	O
+may	O
+enhance	O
+resistance	B-PROC
+against	O
+viral	B-DISO
+infection	I-DISO
+in	O
+neonatal	O
+chicken	B-SPEC
+and	O
+may	O
+contribute	O
+towards	O
+the	O
+development	B-PROC
+of	O
+more	O
+effective	O
+and	O
+safer	O
+vaccines	O
+including	O
+in	O
+ovo	B-SPEC
+vaccines	O
+.	O
+
+Rapid	O
+diagnosis	O
+of	O
+concomitant	O
+NCP	B-FUNC
+,	O
+safe	O
+and	O
+effective	O
+transportation	O
+,	O
+implementation	O
+of	O
+the	O
+interventional	O
+procedure	O
+,	O
+protection	O
+of	O
+vascular	B-ANAT
+surgical	O
+team	O
+and	O
+postoperative	O
+management	O
+and	O
+follow	O
+-	O
+up	O
+of	O
+such	O
+patients	O
+have	O
+become	O
+urgent	O
+problems	O
+for	O
+us	O
+.	O
+
+The	O
+results	O
+revealed	O
+that	O
+the	O
+use	O
+of	O
+NMBAs	O
+in	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+could	O
+significantly	O
+decrease	O
+the	O
+mortality	O
+truncated	O
+to	O
+day	O
+28	O
+(	O
+RR	O
+0	O
+.	O
+74	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+56	O
+to	O
+0	O
+.	O
+98	O
+,	O
+P	O
+=	O
+0	O
+.	O
+03	O
+)	O
+and	O
+day	O
+90	O
+(	O
+RR	O
+0	O
+.	O
+77	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+60	O
+to	O
+0	O
+.	O
+99	O
+,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+7	O
+trials	O
+enrolling	O
+1598	O
+patients	O
+were	O
+finally	O
+included	O
+in	O
+this	O
+meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+The	O
+epidemiological	O
+evidence	O
+has	O
+shown	O
+a	O
+potential	O
+transmission	O
+of	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+during	O
+the	O
+incubation	O
+period	O
+.	O
+
+Thirty	O
+-	O
+one	O
+patients	O
+with	O
+ARDS	B-DISO
+on	O
+invasive	O
+mechanical	O
+ventilation	O
+with	O
+driving	O
+pressure	O
+of	O
+13	O
+cmH2O	O
+or	O
+higher	O
+.	O
+
+As	O
+at	O
+12	O
+February	O
+2020	O
+,	O
+two	O
+cases	O
+have	O
+been	O
+discharged	O
+and	O
+the	O
+third	O
+one	O
+remains	O
+symptomatic	O
+with	O
+a	O
+persistent	O
+cough	O
+,	O
+and	O
+no	O
+secondary	B-DISO
+transmission	I-DISO
+has	O
+been	O
+identified	O
+.	O
+
+ABSTRACT	O
+:	O
+Necrosis	B-PROC
+with	O
+inflammation	B-DISO
+plays	O
+a	O
+crucial	O
+role	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+activation	O
+of	O
+RIPK3	B-PRGE
+-	I-PRGE
+MLKL	I-PRGE
+by	O
+tumour	B-DISO
+necrosis	I-DISO
+factor	I-PRGE
+receptor	I-PRGE
+1	I-PRGE
+(	O
+TNFR1	O
+)	O
+and	O
+TNFR1	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+death	I-PRGE
+domain	I-PRGE
+protein	B-CHED
+(	O
+TRADD	B-PRGE
+)	O
+required	O
+catalytically	O
+active	O
+RIPK1	B-PRGE
+and	O
+the	O
+inhibition	B-PROC
+of	O
+Fas	B-DISO
+-	O
+associated	O
+protein	B-CHED
+with	O
+death	B-PRGE
+domain	I-PRGE
+(	O
+FADD	B-PRGE
+)/	O
+caspase	B-ENZY
+-	I-ENZY
+8	I-ENZY
+catalytic	B-FUNC
+activity	I-FUNC
+.	O
+
+KEY	O
+MESSAGES	O
+:	O
+Lung	B-ANAT
+injury	O
+in	O
+high	O
+-	O
+dose	O
+LPS	B-DISO
+-	O
+induced	O
+severe	O
+ARDS	B-DISO
+is	O
+mainly	O
+due	O
+to	O
+RIP3	B-PRGE
+-	O
+MLKL	B-PRGE
+-	O
+mediated	O
+necroptosis	B-DISO
+and	O
+endothelial	B-DISO
+dysfunction	I-DISO
+.	O
+
+HSP90	B-PRGE
+/	O
+p23	B-PRGE
+is	O
+a	O
+novel	O
+RIP3	B-PRGE
+-	O
+and	O
+MLKL	B-PRGE
+-	I-PRGE
+interacting	I-PRGE
+complex	I-PRGE
+in	O
+RIP	B-PRGE
+-	O
+MLKL	B-PRGE
+-	O
+mediated	O
+necroptosis	B-DISO
+,	O
+inflammation	B-DISO
+and	O
+endothelial	B-DISO
+dysfunction	I-DISO
+.	O
+
+Consumption	O
+of	O
+30	O
+g	O
+dry	O
+beef	O
+can	O
+fully	O
+meet	O
+daily	O
+physiological	O
+needs	O
+of	O
+the	O
+healthy	O
+70	O
+-	O
+kg	O
+adult	O
+human	B-SPEC
+for	O
+taurine	O
+and	O
+carnosine	B-CHED
+,	O
+and	O
+can	O
+also	O
+provide	O
+large	O
+amounts	O
+of	O
+creatine	B-CHED
+,	O
+anserine	B-CHED
+and	O
+4	B-CHED
+-	I-CHED
+hydroxyproline	I-CHED
+to	O
+improve	O
+human	B-SPEC
+nutrition	B-PROC
+and	O
+health	O
+,	O
+including	O
+metabolic	B-PROC
+,	O
+retinal	B-CHED
+,	O
+immunological	O
+,	O
+muscular	B-ANAT
+,	O
+cartilage	B-ANAT
+,	O
+neurological	O
+,	O
+and	O
+cardiovascular	B-ANAT
+health	O
+.	O
+
+TITLE	O
+:	O
+2019	B-SPEC
+Novel	I-SPEC
+coronavirus	I-SPEC
+:	O
+where	O
+we	O
+are	O
+and	O
+what	O
+we	O
+know	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+Genetic	O
+Diagnostic	O
+Methods	O
+for	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+2019	O
+(	O
+nCoV	O
+-	O
+2019	O
+)	O
+in	O
+Japan	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Several	O
+suggestion	O
+of	O
+operation	O
+for	O
+colorectal	B-PATH
+cancer	I-PATH
+under	O
+the	O
+outbreak	O
+of	O
+Corona	B-CHED
+Virus	B-SPEC
+Disease	I-PROC
+19	O
+in	O
+China	O
+].	O
+
+Based	O
+onLaparoscopic	O
+colorectal	O
+operation	O
+experiences	O
+,	O
+the	O
+author	O
+suggests	O
+that	O
+the	O
+surgery	O
+strategy	O
+for	O
+colorectal	B-PATH
+cancer	I-PATH
+patients	O
+under	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+situation	O
+.	O
+
+For	O
+colorectal	O
+malignancy	B-DISO
+with	O
+simple	O
+intestinal	B-DISO
+obstruction	I-DISO
+,	O
+stent	O
+placement	O
+can	O
+achieve	O
+a	O
+high	O
+success	O
+rate	O
+,	O
+which	O
+not	O
+only	O
+helps	O
+avoid	O
+emergency	B-DISO
+surgery	O
+,	O
+but	O
+also	O
+creates	O
+a	O
+better	O
+condition	B-DISO
+for	O
+subsequent	O
+surgery	O
+.	O
+
+TITLE	O
+:	O
+Real	O
+-	O
+Time	O
+Estimation	O
+of	O
+the	O
+Risk	O
+of	O
+Death	B-PROC
+from	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+Infection	B-DISO
+:	O
+Inference	O
+Using	O
+Exported	O
+Cases	O
+.	O
+
+Knowledge	O
+of	O
+the	O
+cCFR	O
+is	O
+critical	O
+to	O
+characterize	O
+the	O
+severity	O
+and	O
+understand	O
+the	O
+pandemic	O
+potential	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+the	O
+early	O
+stage	O
+of	O
+the	O
+epidemic	O
+.	O
+
+We	O
+modeled	O
+epidemic	O
+growth	B-PROC
+either	O
+from	O
+a	O
+single	O
+index	O
+case	O
+with	O
+illness	O
+onset	O
+on	O
+8	O
+December	O
+,	O
+2019	O
+(	O
+Scenario	O
+1	O
+),	O
+or	O
+using	O
+the	O
+growth	B-PROC
+rate	O
+fitted	B-DISO
+along	O
+with	O
+the	O
+other	O
+parameters	O
+(	O
+Scenario	O
+2	O
+)	O
+based	O
+on	O
+data	O
+from	O
+20	O
+exported	O
+cases	O
+reported	O
+by	O
+24	O
+January	O
+2020	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+related	O
+liver	B-ANAT
+injury	O
+:	O
+etiological	O
+analysis	O
+and	O
+treatment	O
+strategy	O
+].	O
+
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+chloroquine	B-CHED
+phosphate	B-CHED
+(	O
+chloroquine	B-CHED
+)	O
+had	O
+a	O
+wide	O
+range	O
+of	O
+antiviral	B-CHED
+effects	O
+,	O
+including	O
+anti	O
+-	O
+coronavirus	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+62	O
+patients	O
+studied	O
+(	O
+median	O
+age	O
+41	O
+years	O
+),	O
+only	O
+one	O
+was	O
+admitted	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+,	O
+and	O
+no	O
+patients	O
+died	B-PROC
+during	O
+the	O
+study	O
+.	O
+
+Asthma	B-PATH
+or	O
+other	O
+allergic	O
+diseases	O
+were	O
+not	O
+reported	O
+by	O
+any	O
+of	O
+the	O
+patients	O
+.	O
+
+Detailed	O
+clinical	O
+investigation	O
+of	O
+140	O
+hospitalized	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+suggests	O
+eosinopenia	B-DISO
+together	O
+with	O
+lymphopenia	B-DISO
+may	O
+be	O
+a	O
+potential	O
+indicator	B-CHED
+for	O
+diagnosis	O
+.	O
+
+RESULTS	O
+:	O
+An	O
+approximately	O
+1	O
+:	O
+1	O
+ratio	O
+of	O
+male	O
+(	O
+50	O
+.	O
+7	O
+%)	O
+and	O
+female	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+was	O
+found	O
+,	O
+with	O
+an	O
+overall	O
+median	O
+age	O
+of	O
+57	O
+.	O
+0	O
+years	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Detailed	O
+clinical	O
+investigation	O
+of	O
+140	O
+hospitalized	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+suggests	O
+eosinopenia	B-DISO
+together	O
+with	O
+lymphopenia	B-DISO
+may	O
+be	O
+a	O
+potential	O
+indicator	B-CHED
+for	O
+diagnosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+late	O
+December	O
+2019	O
+,	O
+an	O
+outbreak	O
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+diseases	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+Wuhan	O
+
+Lung	B-DISO
+cancer	B-SPEC
+patients	O
+should	O
+be	O
+the	O
+priority	O
+group	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+prevention	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Strategy	O
+of	O
+nursing	B-PROC
+care	O
+on	O
+the	O
+face	B-ANAT
+skin	I-ANAT
+injuries	O
+caused	O
+by	O
+wearing	O
+medical	O
+-	O
+grade	O
+protective	O
+equipment	O
+].	O
+
+According	O
+to	O
+the	O
+current	O
+status	O
+,	O
+blocking	B-DISO
+transmission	O
+,	O
+isolation	O
+,	O
+protection	O
+,	O
+and	O
+alternative	O
+medication	O
+are	O
+the	O
+urgent	O
+management	O
+strategies	O
+against	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+
+Using	O
+publicly	O
+available	O
+event	O
+-	O
+date	O
+data	O
+from	O
+the	O
+ongoing	O
+epidemic	O
+,	O
+the	O
+present	O
+study	O
+investigated	O
+the	O
+incubation	O
+period	O
+and	O
+other	O
+time	O
+intervals	O
+that	O
+govern	O
+the	O
+epidemiological	O
+dynamics	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+edema	I-DISO
+following	O
+diuretic	B-CHED
+therapy	O
+:	O
+A	O
+case	O
+report	O
+.	O
+
+After	O
+treatments	O
+including	O
+antibiotics	B-CHED
+,	O
+lung	B-ANAT
+protective	O
+ventilation	O
+strategies	O
+,	O
+and	O
+restrictive	O
+fluid	O
+management	O
+,	O
+his	O
+respiratory	B-DISO
+symptoms	I-DISO
+improved	O
+.	O
+
+Following	O
+these	O
+treatment	O
+,	O
+the	O
+patient	O
+'	O
+s	O
+respiratory	B-DISO
+distress	I-DISO
+improved	O
+remarkably	O
+.	O
+
+It	O
+is	O
+likely	O
+that	O
+a	O
+wider	O
+use	O
+of	O
+POCUS	O
+will	O
+help	O
+physicians	O
+to	O
+obtain	O
+a	O
+faster	O
+,	O
+and	O
+more	O
+accurate	O
+,	O
+diagnosis	O
+of	O
+the	O
+etiology	O
+of	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+,	O
+thus	O
+allowing	O
+a	O
+more	O
+appropriate	O
+therapy	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+following	O
+diuretic	B-CHED
+therapy	O
+to	O
+stress	O
+the	O
+need	O
+of	O
+physicians	O
+to	O
+follow	O
+guidelines	O
+of	O
+clinical	O
+practice	O
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+Isolation	O
+from	O
+the	O
+First	O
+Patient	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+is	O
+found	O
+to	O
+cause	O
+a	O
+large	O
+outbreak	O
+started	O
+from	O
+Wuhan	O
+since	O
+December	O
+2019	O
+in	O
+China	O
+and	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infections	B-DISO
+have	O
+been	O
+reported	O
+with	O
+epidemiological	O
+linkage	B-PROC
+to	O
+China	O
+in	O
+25	O
+countries	O
+until	O
+now	O
+.	O
+
+We	O
+isolated	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+from	O
+the	O
+oropharyngeal	B-ANAT
+sample	O
+obtained	O
+from	O
+the	O
+patient	O
+with	O
+the	O
+first	O
+laboratory	O
+-	O
+confirmed	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+in	O
+Korea	O
+.	O
+
+Phylogenetic	O
+analyses	O
+of	O
+whole	O
+genome	O
+sequences	O
+showed	O
+that	O
+it	O
+clustered	O
+with	O
+other	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+reported	O
+from	O
+Wuhan	O
+.	O
+
+Nanjing	O
+Stomatological	O
+Hospital	O
+has	O
+implemented	O
+the	O
+emergency	B-DISO
+management	O
+practices	O
+for	O
+the	O
+prevention	O
+and	O
+control	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+(	O
+NCP	B-FUNC
+),	O
+mainly	O
+focusing	O
+on	O
+the	O
+implementation	O
+of	O
+prevention	O
+and	O
+control	O
+training	O
+programs	O
+for	O
+medical	O
+staffs	O
+and	O
+the	O
+infection	B-DISO
+control	O
+projects	O
+on	O
+the	O
+hospital	O
+environment	O
+.	O
+
+Currently	O
+,	O
+controlling	O
+infection	B-DISO
+to	O
+prevent	O
+the	O
+spread	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+is	O
+the	O
+primary	O
+intervention	O
+being	O
+used	O
+.	O
+
+The	O
+positive	O
+selective	O
+pressure	O
+could	O
+account	O
+for	O
+some	O
+clinical	O
+features	O
+of	O
+this	O
+virus	B-SPEC
+compared	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Bat	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+like	I-PRGE
+CoV	I-PRGE
+.	O
+The	O
+stabilizing	O
+mutation	O
+falling	O
+in	O
+the	O
+endosome	B-COMP
+-	O
+associated	O
+-	O
+protein	B-CHED
+-	O
+like	O
+domain	O
+of	O
+the	O
+nsp2	B-PRGE
+protein	I-PRGE
+could	O
+account	O
+for	O
+COVID	O
+-	O
+2019	O
+high	O
+ability	O
+of	O
+contagious	O
+,	O
+while	O
+the	O
+destabilizing	O
+mutation	O
+in	O
+nsp3	B-PRGE
+proteins	I-PRGE
+could	O
+suggest	O
+a	O
+potential	O
+mechanism	O
+differentiating	O
+COVID	O
+-	O
+2019	O
+from	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+is	O
+the	O
+causative	O
+agent	O
+of	O
+a	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+a	O
+high	O
+case	O
+fatality	O
+rate	O
+.	O
+
+To	O
+date	O
+,	O
+CT	O
+findings	O
+have	O
+been	O
+recommended	O
+as	O
+major	O
+evidence	O
+for	O
+clinical	O
+diagnosis	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Hubei	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+continues	O
+to	O
+cause	O
+frequent	O
+outbreaks	O
+in	O
+hospitals	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Concern	O
+over	O
+transmitting	O
+MERS	O
+-	O
+CoV	O
+to	O
+family	B-SPEC
+members	O
+was	O
+the	O
+most	O
+predictive	O
+factor	O
+for	O
+anxiety	O
+among	O
+non	O
+-	O
+physician	O
+HCWs	O
+.	O
+
+(	O
+2	O
+)	O
+Colonoscopy	O
+examination	O
+may	O
+cause	O
+cross	B-DISO
+infection	I-DISO
+of	O
+NCP	B-FUNC
+to	O
+patients	O
+and	O
+doctors	O
+.	O
+
+Therefore	O
+,	O
+it	O
+is	O
+prior	O
+to	O
+examine	O
+the	O
+emergency	B-DISO
+cases	O
+and	O
+life	O
+-	O
+threatening	O
+patients	O
+(	O
+bleeding	B-DISO
+,	O
+obstruction	B-DISO
+,	O
+gastrointestinal	O
+foreign	O
+bodies	O
+,	O
+etc	O
+.).	O
+
+If	O
+the	O
+emergent	O
+patients	O
+(	O
+intestinal	B-DISO
+obstruction	I-DISO
+)	O
+with	O
+suspected	O
+or	O
+confirmed	O
+NCP	B-FUNC
+,	O
+the	O
+surgeons	O
+must	O
+perform	O
+emergency	B-DISO
+surgery	O
+,	O
+and	O
+intestinal	B-ANAT
+decompressive	O
+tube	O
+through	O
+colonoscopy	O
+is	O
+not	O
+recommended	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Psychological	B-DISO
+intervention	O
+in	O
+oral	B-ANAT
+patients	O
+in	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+outbreak	O
+period	O
+].	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-DISO
+,	O
+MERS	O
+and	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+epidemics	O
+,	O
+the	O
+newest	O
+and	O
+biggest	O
+global	O
+health	O
+threats	O
+:	O
+what	O
+lessons	O
+have	O
+we	O
+learned	O
+?	O
+
+The	O
+availability	O
+of	O
+connecting	O
+flights	O
+,	O
+the	O
+timing	O
+of	O
+the	O
+outbreak	O
+during	O
+the	O
+Chinese	O
+(	O
+Lunar	O
+)	O
+New	O
+Year	O
+,	O
+and	O
+the	O
+massive	O
+rail	B-SPEC
+transit	O
+hub	O
+located	O
+in	O
+Wuhan	O
+has	O
+enabled	O
+the	O
+virus	B-SPEC
+to	O
+perforate	O
+throughout	O
+China	O
+,	O
+and	O
+eventually	O
+,	O
+globally	O
+.	O
+
+The	O
+availability	O
+of	O
+connecting	O
+flights	O
+,	O
+the	O
+timing	O
+of	O
+the	O
+outbreak	O
+during	O
+the	O
+Chinese	O
+(	O
+Lunar	O
+)	O
+New	O
+Year	O
+,	O
+and	O
+the	O
+massive	O
+rail	B-SPEC
+transit	O
+hub	O
+located	O
+in	O
+Wuhan	O
+has	O
+enabled	O
+the	O
+virus	B-SPEC
+to	O
+perforate	O
+throughout	O
+China	O
+,	O
+and	O
+eventually	O
+,	O
+globally	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+keypoints	O
+in	O
+treatment	O
+of	O
+the	O
+critical	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+patient	O
+].	O
+
+The	O
+best	O
+respiratory	O
+support	O
+mode	O
+should	O
+be	O
+selected	O
+,	O
+but	O
+the	O
+timing	O
+of	O
+intubation	O
+and	O
+protection	O
+during	O
+intubation	O
+are	O
+two	O
+difficulties	O
+;	O
+patients	O
+with	O
+high	O
+level	O
+peep	B-CHED
+and	O
+poor	O
+effect	O
+in	O
+prone	O
+position	O
+can	O
+be	O
+given	O
+ECMO	O
+support	O
+.	O
+
+The	O
+management	O
+and	O
+control	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+importations	O
+heavily	O
+rely	O
+on	O
+a	O
+country	O
+'	O
+s	O
+health	O
+capacity	O
+.	O
+
+Here	O
+we	O
+evaluate	O
+the	O
+preparedness	O
+and	O
+vulnerability	O
+of	O
+African	O
+countries	O
+against	O
+their	O
+risk	O
+of	O
+importation	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+We	O
+determined	O
+the	O
+country	O
+'	O
+s	O
+capacity	O
+to	O
+detect	O
+and	O
+respond	O
+to	O
+cases	O
+with	O
+two	O
+indicators	O
+:	O
+preparedness	O
+,	O
+using	O
+the	O
+WHO	O
+International	O
+Health	O
+Regulations	O
+Monitoring	O
+and	O
+Evaluation	O
+Framework	O
+;	O
+and	O
+vulnerability	O
+,	O
+using	O
+the	O
+Infectious	B-DISO
+Disease	I-DISO
+Vulnerability	O
+Index	O
+.	O
+
+Chronic	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+is	O
+the	O
+terminal	O
+stage	O
+of	O
+pulmonary	B-DISO
+hypertension	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Adjunctive	O
+strategies	O
+are	O
+an	O
+important	O
+part	O
+of	O
+the	O
+management	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+We	O
+wished	O
+to	O
+determine	O
+the	O
+frequency	O
+and	O
+patterns	O
+of	O
+use	O
+of	O
+adjunctive	O
+strategies	O
+in	O
+patients	O
+with	O
+moderate	O
+-	O
+severe	O
+ARDS	B-DISO
+(	O
+P	O
+/	O
+F	O
+ratio	O
+<	O
+150	O
+)	O
+enrolled	O
+into	O
+the	O
+Large	O
+observational	O
+study	O
+to	O
+UNderstand	O
+the	O
+Global	O
+impact	O
+of	O
+Severe	O
+Acute	B-DISO
+respiratory	I-DISO
+FailurE	I-DISO
+(	O
+LUNG	B-ANAT
+SAFE	O
+)	O
+study	O
+.	O
+
+Of	O
+1	O
+,	O
+151	O
+invasively	O
+ventilated	O
+patients	O
+with	O
+moderate	O
+-	O
+severe	O
+ARDS	B-DISO
+,	O
+818	O
+pts	O
+(	O
+71	O
+%)	O
+received	O
+no	O
+adjunct	O
+within	O
+48h	O
+of	O
+ARDS	B-DISO
+onset	O
+.	O
+
+TITLE	O
+:	O
+First	O
+respiratory	O
+transmitted	B-DISO
+food	O
+borne	O
+outbreak	O
+?	O
+
+Based	O
+on	O
+the	O
+limited	O
+initial	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+and	O
+timely	O
+clustering	O
+of	O
+cases	O
+in	O
+Huanan	O
+market	O
+among	O
+elderly	O
+men	O
+,	O
+coupled	O
+with	O
+knowledge	O
+that	O
+coronaviruses	O
+are	O
+derived	O
+from	O
+animals	B-SPEC
+and	O
+relationship	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+to	O
+bat	B-ENZY
+coronavirus	B-SPEC
+,	O
+zoonotic	O
+transmission	O
+in	O
+the	O
+first	O
+instance	O
+is	O
+probable	O
+.	O
+
+Domestically	O
+in	O
+China	O
+,	O
+the	O
+virus	B-SPEC
+has	O
+also	O
+been	O
+noted	O
+in	O
+several	O
+cities	O
+and	O
+provinces	O
+with	O
+cases	O
+in	O
+all	O
+but	O
+one	O
+provinence	O
+.	O
+
+While	O
+zoonotic	O
+transmission	O
+appears	O
+to	O
+be	O
+the	O
+original	O
+source	O
+of	O
+infections	O
+,	O
+the	O
+most	O
+alarming	O
+development	B-PROC
+is	O
+that	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+is	O
+now	O
+prevelant	O
+.	O
+
+We	O
+also	O
+present	O
+data	O
+on	O
+the	O
+use	O
+of	O
+in	O
+silico	O
+docking	B-PROC
+in	O
+gaining	O
+insight	O
+into	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+Spike	B-PRGE
+-	I-PRGE
+receptor	I-PRGE
+binding	O
+to	O
+aid	O
+in	O
+therapeutic	O
+development	B-PROC
+.	O
+
+Diagnostic	O
+PCR	O
+protocols	O
+can	O
+be	O
+found	O
+at	O
+https	O
+://	O
+www	O
+.	O
+who	O
+.	O
+int	O
+/	O
+health	O
+-	O
+topics	O
+/	O
+coronavirus	B-SPEC
+/	O
+laboratory	O
+-	O
+diagnostics	O
+-	O
+for	O
+-	O
+novel	O
+-	O
+coronavirus	B-SPEC
+.	O
+
+Lung	B-ANAT
+lesions	O
+were	O
+characterized	O
+by	O
+a	O
+high	O
+Although	O
+RESULTS	O
+:	O
+All	O
+patients	O
+had	O
+peripheral	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+and	O
+/	O
+or	O
+lung	B-ANAT
+consolidations	O
+in	O
+more	O
+than	O
+two	O
+pulmonary	B-ANAT
+lobes	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+newly	O
+emerging	O
+threat	O
+to	O
+the	O
+global	O
+porcine	B-SPEC
+industry	O
+.	O
+
+This	O
+knowledge	O
+can	O
+potentially	O
+contribute	O
+to	O
+improvement	O
+of	O
+virus	B-SPEC
+production	O
+efficiency	O
+in	O
+culture	O
+,	O
+not	O
+only	O
+for	O
+vaccine	O
+preparation	O
+but	O
+also	O
+to	O
+develop	O
+antiviral	B-CHED
+treatments	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+2	O
+-	O
+family	O
+cluster	O
+of	O
+persons	O
+infected	O
+with	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+in	O
+the	O
+city	O
+of	O
+Zhoushan	O
+,	O
+Zhejiang	O
+Province	O
+,	O
+China	O
+,	O
+during	O
+January	O
+2020	O
+.	O
+
+The	O
+infections	B-DISO
+resulted	O
+from	O
+contact	O
+with	O
+an	O
+infected	O
+but	O
+potentially	O
+presymptomatic	O
+traveler	O
+from	O
+the	O
+city	O
+of	O
+Wuhan	O
+in	O
+Hubei	O
+Province	O
+.	O
+
+These	O
+findings	O
+can	O
+support	O
+evidence	O
+-	O
+based	O
+policy	O
+to	O
+combat	B-CHED
+the	O
+spread	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+and	O
+prospective	O
+planning	O
+to	O
+mitigate	O
+future	O
+emerging	O
+pathogens	O
+.	O
+
+With	O
+regards	O
+to	O
+the	O
+clinical	O
+manifestations	O
+,	O
+58	O
+/	O
+80	O
+(	O
+73	O
+%)	O
+of	O
+patients	O
+had	O
+cough	B-DISO
+,	O
+61	O
+/	O
+80	O
+(	O
+76	O
+%)	O
+of	O
+patients	O
+had	O
+high	B-PROC
+temperature	I-PROC
+levels	O
+.	O
+
+Correlation	O
+analysis	O
+showed	O
+that	O
+the	O
+PII	O
+value	O
+was	O
+significantly	O
+correlated	O
+with	O
+the	O
+values	O
+of	O
+lymphocyte	B-ANAT
+count	O
+,	O
+monocyte	B-ANAT
+count	O
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+procalcitonin	O
+,	O
+days	O
+from	O
+illness	O
+onset	O
+and	O
+body	B-ANAT
+temperature	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+CONCLUSIONS	O
+:	O
+The	O
+common	O
+chest	B-ANAT
+CT	O
+findings	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+are	O
+multiple	O
+GGO	O
+,	O
+consolidation	O
+and	O
+interlobular	O
+septal	O
+thickening	O
+in	O
+both	O
+lungs	B-ANAT
+,	O
+which	O
+are	O
+mostly	O
+distributed	O
+under	O
+the	O
+pleura	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+December	O
+2019	O
+,	O
+a	O
+novel	O
+coronavirus	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+pneumonia	B-DISO
+emerged	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+The	O
+World	O
+Health	O
+Organization	O
+declared	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+outbreak	O
+a	O
+global	O
+public	O
+health	O
+emergency	B-DISO
+.	O
+
+TITLE	O
+:	O
+Rigidity	B-DISO
+of	O
+the	O
+Outer	O
+Shell	B-ANAT
+Predicted	O
+by	O
+a	O
+Protein	B-CHED
+Intrinsic	O
+Disorder	O
+Model	O
+Sheds	O
+Light	O
+on	O
+the	O
+COVID	O
+-	O
+19	O
+(	O
+Wuhan	O
+-	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+Infectivity	O
+.	O
+
+Therefore	O
+,	O
+although	O
+SARS	O
+,	O
+MERS	O
+,	O
+and	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+are	O
+all	O
+the	O
+result	O
+of	O
+coronaviral	O
+infections	B-DISO
+,	O
+the	O
+causes	O
+of	O
+the	O
+coronaviruses	O
+differ	O
+dramatically	O
+in	O
+their	O
+transmissibility	O
+.	O
+
+TITLE	O
+:	O
+Risk	O
+Assessment	O
+of	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+Outbreaks	O
+Outside	O
+China	O
+.	O
+
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+was	O
+identified	O
+to	O
+be	O
+accountable	O
+for	O
+this	O
+disease	O
+.	O
+
+Pretreatment	O
+of	O
+HNE	B-CHED
+and	O
+HTE	B-CHED
+cells	B-COMP
+with	O
+glycopyrronium	O
+or	O
+formoterol	B-CHED
+decreased	O
+viral	O
+RNA	O
+levels	O
+and	O
+/	O
+or	O
+titers	O
+,	O
+the	O
+expression	B-PROC
+of	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+receptor	I-PRGE
+CD13	I-PRGE
+,	O
+the	O
+number	O
+and	O
+fluorescence	O
+intensity	O
+of	O
+acidic	O
+endosomes	O
+where	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+RNA	O
+enters	O
+the	O
+cytoplasm	B-COMP
+,	O
+and	O
+the	O
+infection	B-DISO
+-	O
+induced	O
+production	O
+of	O
+cytokines	O
+,	O
+including	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+.	O
+
+Treatment	O
+of	O
+the	O
+cells	B-COMP
+with	O
+the	O
+CD13	B-PRGE
+inhibitor	B-CHED
+2	O
+'	O
+2	O
+'-	O
+dipyridyl	O
+decreased	O
+viral	O
+titers	O
+.	O
+
+Pretreatment	O
+with	O
+formoterol	B-CHED
+increased	O
+cAMP	B-CHED
+levels	O
+and	O
+treatment	O
+with	O
+cAMP	B-CHED
+decreased	O
+viral	O
+titers	O
+,	O
+CD13	B-PRGE
+expression	B-PROC
+,	O
+and	O
+the	O
+fluorescence	O
+intensity	O
+of	O
+acidic	O
+endosomes	O
+.	O
+
+Here	O
+,	O
+we	O
+co	O
+-	O
+expressed	B-PROC
+the	O
+MERS	O
+-	O
+CoV	O
+nonstructural	O
+proteins	B-CHED
+nsp5	B-PRGE
+,	O
+nsp7	O
+,	O
+nsp8	O
+,	O
+and	O
+nsp12	O
+(	O
+RdRp	B-FUNC
+)	O
+in	O
+insect	B-SPEC
+cells	B-COMP
+as	O
+a	O
+part	O
+a	O
+polyprotein	O
+to	O
+study	O
+the	O
+mechanism	O
+of	O
+inhibition	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+RdRp	B-FUNC
+by	O
+RDV	B-SPEC
+.	O
+
+The	O
+triphosphate	B-CHED
+form	O
+of	O
+the	O
+inhibitor	B-CHED
+(	O
+RDV	B-SPEC
+-	O
+TP	O
+)	O
+competes	O
+with	O
+its	O
+natural	O
+counterpart	O
+ATP	O
+.	O
+
+Together	O
+,	O
+these	O
+results	O
+help	O
+to	O
+explain	O
+the	O
+high	O
+potency	O
+of	O
+RDV	B-SPEC
+against	O
+RNA	O
+viruses	B-SPEC
+in	O
+cell	B-COMP
+-	O
+based	O
+assays	O
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+has	O
+been	O
+reported	O
+that	O
+ACE2	O
+is	O
+the	O
+main	O
+host	B-COMP
+cell	I-COMP
+receptor	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+and	O
+plays	O
+a	O
+crucial	O
+role	O
+in	O
+the	O
+entry	O
+of	O
+virus	B-SPEC
+into	O
+the	O
+cell	B-COMP
+to	O
+cause	O
+the	O
+final	O
+infection	B-DISO
+.	O
+
+RNA	O
+-	O
+seq	O
+profiling	O
+data	O
+of	O
+13	O
+organ	B-ANAT
+types	O
+with	O
+para	B-CHED
+-	O
+carcinoma	B-DISO
+normal	O
+tissues	B-ANAT
+from	O
+TCGA	O
+and	O
+14	O
+organ	B-ANAT
+types	O
+with	O
+normal	O
+tissues	B-ANAT
+from	O
+FANTOM5	O
+CAGE	O
+were	O
+analyzed	O
+in	O
+order	B-SPEC
+to	O
+explore	O
+and	O
+validate	O
+the	O
+expression	B-PROC
+of	O
+ACE2	B-PRGE
+on	O
+the	O
+mucosa	B-ANAT
+of	O
+oral	B-ANAT
+cavity	I-ANAT
+.	O
+
+Interestingly	O
+,	O
+this	O
+receptor	O
+was	O
+highly	O
+enriched	O
+in	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+tongue	B-ANAT
+.	O
+
+Preliminarily	O
+,	O
+those	O
+findings	O
+have	O
+explained	O
+the	O
+basic	O
+mechanism	O
+that	O
+the	O
+oral	B-ANAT
+cavity	I-ANAT
+is	O
+a	O
+potentially	O
+high	O
+risk	O
+for	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+infectious	B-DISO
+susceptibility	O
+and	O
+provided	O
+a	O
+piece	O
+of	O
+evidence	O
+for	O
+the	O
+future	O
+prevention	O
+strategy	O
+in	O
+dental	O
+clinical	O
+practice	O
+as	O
+well	O
+as	O
+daily	O
+life	O
+.	O
+
+Since	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+first	O
+identified	O
+in	O
+animal	B-SPEC
+markets	O
+,	O
+global	O
+viromics	O
+projects	O
+have	O
+discovered	O
+thousands	O
+of	O
+coronavirus	B-SPEC
+sequences	O
+in	O
+diverse	O
+animals	B-SPEC
+and	O
+geographic	O
+regions	O
+.	O
+
+Unfortunately	O
+,	O
+there	O
+are	O
+few	O
+tools	O
+available	O
+to	O
+functionally	O
+test	O
+these	O
+viruses	B-SPEC
+for	O
+their	O
+ability	O
+to	O
+infect	O
+humans	B-SPEC
+,	O
+which	O
+has	O
+severely	O
+hampered	O
+efforts	O
+to	O
+predict	O
+the	O
+next	O
+zoonotic	O
+viral	O
+outbreak	O
+.	O
+
+Fifty	O
+-	O
+two	O
+cases	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+admitted	O
+in	O
+the	O
+First	O
+Affiliated	O
+Hospital	O
+of	O
+Zhejiang	O
+University	O
+School	O
+of	O
+Medicine	B-CHED
+.	O
+
+The	O
+obvious	O
+shadows	O
+infiltrating	B-DISO
+the	O
+lungs	B-ANAT
+were	O
+shown	O
+on	O
+CT	O
+images	O
+in	O
+50	O
+cases	O
+,	O
+for	O
+other	O
+2	O
+cases	O
+there	O
+was	O
+no	O
+abnormal	O
+changes	O
+in	O
+the	O
+lungs	B-ANAT
+during	O
+the	O
+first	O
+CT	O
+examination	O
+.	O
+
+During	O
+hospitalization	O
+,	O
+GGO	O
+lesions	O
+in	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+gradually	O
+became	O
+rare	O
+,	O
+the	O
+fibrous	O
+strip	O
+shadows	O
+increased	O
+and	O
+it	O
+became	O
+the	O
+most	O
+common	O
+imaging	O
+manifestation	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Management	O
+of	O
+corona	B-CHED
+virus	B-DISO
+disease	I-DISO
+-	O
+19	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+):	O
+the	O
+Zhejiang	O
+experience	O
+].	O
+
+As	O
+the	O
+National	O
+Clinical	O
+Research	O
+Center	O
+for	O
+Infectious	B-DISO
+Diseases	I-DISO
+,	O
+the	O
+First	O
+Affiliated	O
+Hospital	O
+of	O
+Zhejiang	O
+University	O
+School	O
+of	O
+Medicine	B-CHED
+is	O
+the	O
+primary	O
+medical	O
+care	O
+center	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+inZhejiang	O
+Province	O
+.	O
+
+The	O
+""""	O
+Four	O
+-	O
+Anti	O
+and	O
+Two	O
+-	O
+Balance	B-PROC
+""""	O
+strategyeffectively	O
+increased	O
+cure	O
+rate	O
+and	O
+reduced	O
+mortality	O
+.	O
+
+Moreover	O
+,	O
+it	O
+also	O
+favoredthe	O
+balance	B-PROC
+of	O
+fluid	O
+,	O
+electrolyte	O
+and	O
+acid	O
+-	O
+base	O
+and	O
+thus	O
+improved	O
+treatment	O
+efficacy	O
+in	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+For	O
+cases	O
+of	O
+severe	O
+illness	O
+,	O
+early	O
+and	O
+also	O
+short	O
+periods	B-PROC
+of	O
+moderate	O
+glucocorticoid	B-CHED
+was	O
+supported	O
+.	O
+
+Conservative	O
+oxygen	B-CHED
+therapy	O
+was	O
+preferred	O
+and	O
+noninvasive	O
+ventilation	O
+was	O
+not	O
+recommended	O
+.	O
+
+Patients	O
+with	O
+mechanical	O
+ventilation	O
+should	O
+be	O
+strictly	O
+supervised	O
+with	O
+cluster	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+prevention	O
+strategies	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Surgical	O
+treatment	O
+strategy	O
+for	O
+digestive	B-ANAT
+system	I-ANAT
+malignancies	B-DISO
+during	O
+the	O
+outbreak	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+].	O
+
+ABSTRACT	O
+:	O
+Severe	O
+fever	O
+with	O
+thrombocytopenia	O
+syndrome	B-DISO
+(	O
+SFTS	O
+)	O
+is	O
+an	O
+emerging	O
+zoonosis	B-DISO
+infected	O
+by	O
+virus	B-SPEC
+(	O
+SFTSV	O
+)	O
+in	O
+central	O
+and	O
+eastern	O
+China	O
+,	O
+which	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+.	O
+
+116	O
+patients	O
+with	O
+SFTSV	O
+infection	B-DISO
+were	O
+included	O
+(	O
+mean	O
+age	O
+63	O
+±	O
+9	O
+years	O
+,	O
+59	O
+[	O
+51	O
+.	O
+3	O
+%]	O
+males	O
+).	O
+
+Non	O
+-	O
+survivors	O
+(	O
+43	O
+.	O
+1	O
+%)	O
+were	O
+older	O
+,	O
+and	O
+had	O
+lower	O
+Glasgow	O
+Coma	B-DISO
+Score	O
+(	O
+GCS	O
+),	O
+higher	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+)	O
+and	O
+sequential	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+(	O
+SOFA	O
+)	O
+score	O
+at	O
+ICU	O
+admission	O
+.	O
+
+TITLE	O
+:	O
+Estimation	O
+of	O
+the	O
+reproductive	B-PROC
+number	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+and	O
+the	O
+probable	O
+outbreak	O
+size	O
+on	O
+the	O
+Diamond	O
+Princess	O
+cruise	O
+ship	O
+:	O
+A	O
+data	O
+-	O
+driven	O
+analysis	O
+.	O
+
+We	O
+fitted	B-DISO
+the	O
+reported	O
+serial	O
+interval	O
+(	O
+mean	O
+and	O
+standard	O
+deviation	O
+)	O
+with	O
+a	O
+gamma	O
+distribution	O
+and	O
+applied	O
+""""	O
+earlyR	O
+""""	O
+package	O
+in	O
+R	O
+to	O
+estimate	O
+the	O
+R0	O
+in	O
+the	O
+early	O
+stage	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+Maximum	O
+-	O
+Likelihood	O
+(	O
+ML	O
+)	O
+value	O
+of	O
+R0	O
+was	O
+2	O
+.	O
+28	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+at	O
+the	O
+early	O
+stage	O
+on	O
+the	O
+ship	O
+.	O
+
+AVNP2	O
+also	O
+alleviated	O
+the	O
+decline	O
+of	O
+long	B-PATH
+-	I-PATH
+term	I-PATH
+potentiation	I-PATH
+(	O
+LTP	B-PROC
+)	O
+and	O
+the	O
+decreased	O
+density	O
+of	O
+dendritic	B-COMP
+spines	I-COMP
+in	O
+the	O
+CA1	B-PRGE
+region	I-PRGE
+induced	O
+by	O
+C6	O
+.	O
+
+First	O
+,	O
+division	O
+of	O
+the	O
+cumulative	O
+number	O
+of	O
+deaths	B-PROC
+by	O
+that	O
+of	O
+cases	O
+tends	O
+to	O
+underestimate	O
+the	O
+actual	O
+risk	O
+because	O
+deaths	B-PROC
+that	O
+will	O
+occur	O
+have	O
+not	O
+yet	O
+observed	O
+,	O
+and	O
+so	O
+the	O
+delay	O
+in	O
+time	O
+from	O
+illness	O
+onset	O
+to	O
+death	B-PROC
+must	O
+be	O
+addressed	O
+.	O
+
+The	O
+coronavirus	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+
+TITLE	O
+:	O
+Chest	B-ANAT
+Radiographic	O
+and	O
+CT	O
+Findings	O
+of	O
+the	O
+2019	B-DISO
+Novel	I-DISO
+Coronavirus	I-DISO
+Disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+):	O
+Analysis	O
+of	O
+Nine	O
+Patients	O
+Treated	O
+in	O
+Korea	O
+.	O
+
+As	O
+part	O
+of	O
+a	O
+multi	O
+-	O
+institutional	O
+collaboration	O
+coordinated	O
+by	O
+the	O
+Korean	O
+Society	O
+of	O
+Thoracic	B-DISO
+Radiology	O
+,	O
+we	O
+collected	O
+nine	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infections	B-DISO
+who	O
+had	O
+undergone	O
+chest	B-ANAT
+radiography	O
+and	O
+CT	O
+scans	O
+.	O
+
+Patchy	O
+to	O
+confluent	O
+lesions	O
+were	O
+primarily	O
+distributed	O
+in	O
+the	O
+lower	O
+lobes	B-ANAT
+(	O
+CONCLUSIONS	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+in	O
+Korea	O
+primarily	O
+manifested	O
+as	O
+pure	B-FUNC
+to	O
+mixed	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+with	O
+a	O
+patchy	O
+to	O
+confluent	O
+or	O
+nodular	O
+shape	O
+in	O
+the	O
+bilateral	O
+peripheral	O
+posterior	O
+lungs	B-ANAT
+.	O
+
+CT	O
+showed	O
+rapidly	O
+progressing	O
+peripheral	O
+consolidations	O
+and	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+in	O
+both	O
+lungs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Passengers	O
+'	O
+destinations	O
+from	O
+China	O
+:	O
+low	O
+risk	O
+of	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+transmission	O
+into	O
+Africa	O
+and	O
+South	O
+America	O
+.	O
+
+Twenty	O
+-	O
+one	O
+common	O
+-	O
+type	O
+and	O
+nine	O
+severe	O
+-	O
+type	O
+NCP	B-FUNC
+patients	O
+were	O
+enrolled	O
+.	O
+
+The	O
+breast	B-DISO
+cancer	B-SPEC
+patients	O
+should	O
+synthetically	O
+consider	O
+the	O
+epidemic	O
+prevention	O
+situation	O
+of	O
+inhabitance	O
+,	O
+the	O
+disease	O
+stage	O
+and	O
+previous	O
+therapeutic	O
+schedule	O
+to	O
+decide	O
+the	O
+next	O
+therapeutic	O
+schedule	O
+.	O
+
+For	O
+metastatic	B-DISO
+colorectal	I-DISO
+cancer	I-DISO
+(	O
+CRC	B-DISO
+)	O
+patients	O
+,	O
+maintenance	O
+therapy	O
+is	O
+the	O
+optimal	O
+choice	O
+.	O
+
+60	O
+%	O
+to	O
+93	O
+%	O
+of	O
+cases	O
+had	O
+initial	O
+positive	O
+CT	O
+consistent	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+prior	O
+(	O
+or	O
+parallel	O
+)	O
+to	O
+the	O
+initial	O
+positive	O
+RT	O
+-	O
+PCR	O
+results	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+the	O
+forward	O
+environment	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-DISO
+Disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+),	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+),	O
+is	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+expert	O
+panel	O
+of	O
+airway	B-ANAT
+management	O
+in	O
+Chinese	O
+Society	O
+of	O
+Anaesthesiology	O
+has	O
+deliberated	O
+and	O
+drafted	O
+this	O
+recommendation	O
+,	O
+by	O
+which	O
+we	O
+hope	O
+to	O
+guide	O
+the	O
+performance	O
+of	O
+endotracheal	O
+intubation	O
+by	O
+frontline	O
+anesthesiologists	O
+and	O
+critical	O
+care	O
+physicians	O
+.	O
+
+To	O
+promote	O
+the	O
+data	O
+sharing	O
+and	O
+make	O
+all	O
+relevant	O
+information	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+publicly	O
+available	O
+,	O
+we	O
+construct	O
+the	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+Resource	O
+(	O
+2019nCoVR	O
+,	O
+https	O
+://	O
+bigd	O
+.	O
+big	O
+.	O
+ac	O
+.	O
+cn	O
+/	O
+ncov	O
+).	O
+
+TITLE	O
+:	O
+Negative	O
+Nasopharyngeal	B-ANAT
+and	O
+Oropharyngeal	B-ANAT
+Swab	O
+Does	O
+Not	O
+Rule	O
+Out	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+We	O
+could	O
+learn	B-PROC
+from	O
+SARS	B-DISO
+and	O
+MERS	O
+.	O
+
+TITLE	O
+:	O
+Evolutionary	O
+history	O
+,	O
+potential	O
+intermediate	O
+animal	B-SPEC
+host	B-COMP
+,	O
+and	O
+cross	O
+-	O
+species	B-SPEC
+analyses	O
+of	O
+SARS	B-DISO
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+neuroinvasive	O
+potential	O
+of	O
+SARS	B-DISO
+-	O
+CoV2	O
+may	O
+play	O
+a	O
+role	O
+in	O
+the	O
+respiratory	B-DISO
+failure	I-DISO
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+.	O
+
+Increasing	O
+evidence	O
+shows	O
+that	O
+coronaviruses	O
+are	O
+not	O
+always	O
+confined	O
+to	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+that	O
+they	O
+may	O
+also	O
+invade	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+inducing	O
+neurological	O
+diseases	O
+.	O
+
+The	O
+infection	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+has	O
+been	O
+reported	O
+in	O
+the	O
+brains	B-ANAT
+from	O
+both	O
+patients	O
+and	O
+experimental	O
+animals	B-SPEC
+,	O
+where	O
+the	O
+brainstem	B-ANAT
+was	O
+heavily	O
+infected	O
+.	O
+
+Considering	O
+the	O
+high	O
+similarity	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV2	I-PRGE
+,	O
+it	O
+remains	O
+to	O
+make	O
+clear	O
+whether	O
+the	O
+potential	O
+invasion	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV2	O
+is	O
+partially	O
+responsible	O
+for	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+of	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+TITLE	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+an	O
+overview	O
+for	O
+emergency	B-DISO
+clinicians	O
+ABSTRACT	O
+:	O
+Prior	O
+to	O
+the	O
+global	O
+outbreak	O
+of	O
+SARS	O
+-	O
+CoV	O
+in	O
+2003	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+were	O
+the	O
+only	O
+coronaviruses	O
+known	O
+to	O
+infect	O
+humans	B-SPEC
+.	O
+
+It	O
+has	O
+also	O
+brought	O
+great	O
+challenges	O
+to	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+cancer	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+evidence	O
+suggest	O
+that	O
+dysregulation	O
+of	O
+the	O
+tumor	B-DISO
+suppressor	I-PROC
+P53	I-PRGE
+,	O
+in	O
+combination	O
+with	O
+disharmonious	O
+activities	O
+of	O
+the	O
+small	O
+GTPase	O
+RhoA	O
+,	O
+may	O
+lead	O
+to	O
+irreversible	O
+progression	O
+of	O
+human	B-SPEC
+disease	O
+.	O
+
+The	O
+purpose	O
+of	O
+the	O
+present	O
+study	O
+is	O
+to	O
+communicate	O
+the	O
+most	O
+recent	O
+information	O
+regarding	O
+the	O
+highly	O
+interrelated	O
+P53	B-PRGE
+/	O
+RhoA	B-PRGE
+network	O
+.	O
+
+Of	O
+710	O
+patients	O
+with	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+pneumonia	B-DISO
+,	O
+52	O
+critically	B-DISO
+ill	I-DISO
+adult	O
+patients	O
+were	O
+included	O
+.	O
+
+Thereafter	O
+,	O
+the	O
+prevalence	O
+of	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+continued	O
+to	O
+decrease	O
+(	O
+17	O
+[	O
+57	O
+%]	O
+of	O
+30	O
+patients	O
+in	O
+group	O
+3	O
+,	O
+and	O
+five	O
+[	O
+33	O
+%]	O
+of	O
+15	O
+in	O
+group	O
+4	O
+),	O
+and	O
+consolidation	O
+and	O
+mixed	O
+patterns	O
+became	O
+more	O
+frequent	O
+(	O
+12	O
+[	O
+40	O
+%]	O
+in	O
+group	O
+3	O
+,	O
+eight	O
+[	O
+53	O
+%]	O
+in	O
+group	O
+4	O
+).	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+caused	O
+by	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+began	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+,	O
+China	O
+in	O
+December	O
+2019	O
+,	O
+and	O
+has	O
+spread	O
+throughout	O
+China	O
+and	O
+to	O
+31	O
+other	O
+countries	O
+and	O
+territories	O
+,	O
+including	O
+the	O
+United	O
+States	O
+(	O
+1	O
+).	O
+
+There	O
+have	O
+been	O
+2	O
+,	O
+462	O
+associated	O
+deaths	B-PROC
+worldwide	O
+;	O
+no	O
+deaths	B-PROC
+have	O
+been	O
+reported	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Although	O
+these	O
+measures	O
+might	O
+not	O
+prevent	O
+widespread	O
+transmission	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+United	O
+States	O
+,	O
+they	O
+are	O
+being	O
+implemented	O
+to	O
+1	O
+)	O
+slow	O
+the	O
+spread	O
+of	O
+illness	O
+;	O
+2	O
+)	O
+provide	O
+time	O
+to	O
+better	O
+prepare	O
+state	O
+and	O
+local	O
+health	O
+departments	O
+,	O
+health	O
+care	O
+systems	O
+,	O
+businesses	O
+,	O
+educational	O
+organizations	O
+,	O
+and	O
+the	O
+general	O
+public	O
+in	O
+the	O
+event	O
+that	O
+widespread	O
+transmission	O
+occurs	O
+;	O
+and	O
+3	O
+)	O
+better	O
+characterize	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+to	O
+guide	O
+public	O
+health	O
+recommendations	O
+and	O
+the	O
+development	B-PROC
+and	O
+deployment	O
+of	O
+medical	O
+countermeasures	O
+,	O
+including	O
+diagnostics	O
+,	O
+therapeutics	O
+,	O
+and	O
+vaccines	O
+.	O
+
+As	O
+more	O
+is	O
+learned	B-PROC
+about	O
+this	O
+novel	O
+virus	B-SPEC
+and	O
+this	O
+outbreak	O
+,	O
+CDC	O
+will	O
+rapidly	O
+incorporate	O
+new	O
+knowledge	O
+into	O
+guidance	O
+for	O
+action	O
+by	O
+CDC	O
+,	O
+state	O
+and	O
+local	O
+health	O
+departments	O
+,	O
+health	O
+care	O
+providers	O
+,	O
+and	O
+communities	O
+.	O
+
+TITLE	O
+:	O
+Disposable	O
+DNA	B-PROC
+Amplification	I-PROC
+Chips	O
+with	O
+Integrated	O
+Low	O
+-	O
+Cost	O
+Heaters	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+beginning	O
+of	O
+2020	O
+has	O
+seen	O
+the	O
+emergence	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+Severe	B-SPEC
+Acute	I-SPEC
+Respiratory	I-SPEC
+Syndrome	I-SPEC
+Coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+).	O
+
+There	O
+is	O
+an	O
+imminent	O
+need	O
+to	O
+better	O
+understand	O
+this	O
+new	O
+virus	B-SPEC
+and	O
+to	O
+develop	O
+ways	O
+to	O
+control	O
+its	O
+spread	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+sought	O
+to	O
+gain	O
+insights	O
+for	O
+vaccine	O
+design	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+by	O
+considering	O
+the	O
+high	O
+genetic	O
+similarity	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+which	O
+caused	O
+the	O
+outbreak	O
+in	O
+2003	O
+,	O
+and	O
+leveraging	O
+existing	O
+immunological	O
+studies	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+By	O
+screening	O
+the	O
+experimentally	O
+-	O
+determined	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+derived	O
+B	B-ANAT
+cell	I-ANAT
+and	O
+T	B-ANAT
+cell	I-ANAT
+epitopes	O
+in	O
+the	O
+immunogenic	O
+structural	O
+proteins	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+we	O
+identified	O
+a	O
+set	O
+of	O
+B	B-ANAT
+cell	I-ANAT
+and	O
+T	B-ANAT
+cell	I-ANAT
+epitopes	O
+derived	O
+from	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+proteins	B-CHED
+that	O
+map	O
+identically	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+proteins	B-CHED
+.	O
+
+Two	O
+other	O
+coronavirus	B-DISO
+infections	I-DISO
+-	O
+SARS	B-DISO
+in	O
+2002	O
+-	O
+2003	O
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+in	O
+2012	O
+-	O
+both	O
+caused	O
+severe	O
+respiratory	O
+syndrome	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+detail	O
+current	O
+evidence	O
+and	O
+understanding	O
+of	O
+the	O
+transmission	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+through	O
+blood	B-ANAT
+products	O
+as	O
+of	O
+February	O
+10	O
+,	O
+2020	O
+,	O
+and	O
+also	O
+discuss	O
+pathogen	O
+inactivation	B-DISO
+methods	O
+on	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pneumonia	O
+caused	O
+by	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+also	O
+called	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+recently	O
+break	O
+out	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+and	O
+was	O
+named	O
+as	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Of	O
+all	O
+included	O
+patients	O
+,	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+presented	O
+with	O
+ground	O
+glass	O
+opacities	B-DISO
+in	O
+65	O
+(	O
+72	O
+%),	O
+consolidation	O
+in	O
+12	O
+(	O
+13	O
+%),	O
+crazy	O
+paving	O
+pattern	O
+in	O
+11	O
+(	O
+12	O
+%),	O
+interlobular	O
+thickening	O
+in	O
+33	O
+(	O
+37	O
+%),	O
+adjacent	O
+pleura	B-DISO
+thickening	I-DISO
+in	O
+50	O
+(	O
+56	O
+%),	O
+and	O
+linear	O
+opacities	B-DISO
+combined	O
+in	O
+55	O
+(	O
+61	O
+%).	O
+
+In	O
+addition	O
+,	O
+baseline	O
+chest	B-ANAT
+CT	O
+did	O
+not	O
+show	O
+any	O
+abnormalities	O
+in	O
+21	O
+patients	O
+(	O
+23	O
+%),	O
+but	O
+3	O
+patients	O
+presented	O
+bilateral	O
+ground	O
+glass	O
+opacities	B-DISO
+on	O
+the	O
+second	O
+CT	O
+after	O
+3	O
+-	O
+4	O
+days	O
+.	O
+
+Multiple	O
+patchy	O
+ground	O
+glass	O
+opacities	B-DISO
+in	O
+bilateral	O
+multiple	O
+lobular	O
+with	O
+periphery	O
+distribution	O
+are	O
+typical	O
+chest	B-ANAT
+CT	O
+imaging	O
+features	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+.	O
+
+Between	O
+October	O
+2015	O
+and	O
+March	O
+2016	O
+,	O
+consecutive	O
+ICU	O
+patients	O
+with	O
+virology	O
+-	O
+proven	O
+influenza	B-DISO
+infections	B-DISO
+who	O
+fulfilled	O
+ARDS	B-DISO
+and	O
+received	O
+invasive	O
+mechanical	O
+ventilation	O
+were	O
+enrolled	O
+.	O
+
+Clinicians	O
+should	O
+be	O
+cautious	O
+while	O
+using	O
+corticosteroid	B-CHED
+treatment	O
+in	O
+this	O
+patient	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+characteristics	O
+of	O
+hospitalized	O
+patients	O
+with	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+:	O
+A	O
+single	O
+arm	B-ANAT
+meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+a	O
+novel	O
+coronavirus	O
+(	O
+SARS	B-SPEC
+-	I-SPEC
+COV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+emerged	O
+which	O
+is	O
+responsible	O
+for	O
+the	O
+recent	O
+outbreak	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+Since	O
+its	O
+release	B-PATH
+in	O
+2019	O
+,	O
+we	O
+have	O
+produced	O
+a	O
+number	O
+of	O
+typing	O
+tools	O
+for	O
+emergent	O
+viruses	B-SPEC
+that	O
+have	O
+caused	O
+large	O
+outbreaks	O
+,	O
+such	O
+as	O
+Zika	O
+and	O
+Yellow	B-SPEC
+Fever	I-SPEC
+Virus	I-SPEC
+in	O
+Brazil	O
+.	O
+
+The	O
+tool	O
+also	O
+allows	O
+tracking	O
+of	O
+new	O
+viral	O
+mutations	O
+as	O
+the	O
+outbreak	O
+expands	O
+globally	O
+,	O
+which	O
+may	O
+help	O
+to	O
+accelerate	O
+the	O
+development	B-PROC
+of	O
+novel	O
+diagnostics	O
+,	O
+drugs	O
+and	O
+vaccines	O
+to	O
+stop	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+disease	O
+.	O
+
+https	O
+://	O
+www	O
+.	O
+genomedetective	O
+.	O
+com	B-PRGE
+/	O
+app	B-PRGE
+/	O
+typingtool	O
+/	O
+cov	O
+.	O
+
+Diarrhea	B-DISO
+was	O
+uncommon	O
+(	O
+3	O
+.	O
+8	O
+%).	O
+
+On	O
+admission	O
+,	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+was	O
+the	O
+most	O
+common	O
+radiologic	O
+finding	O
+on	O
+chest	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+(	O
+56	O
+.	O
+4	O
+%).	O
+
+Lymphocytopenia	B-DISO
+was	O
+present	O
+in	O
+83	O
+.	O
+2	O
+%	O
+of	O
+the	O
+patients	O
+on	O
+admission	O
+.	O
+
+By	O
+4	O
+February	O
+,	O
+public	O
+health	O
+measures	O
+such	O
+as	O
+removal	O
+and	O
+isolation	O
+of	O
+ill	B-DISO
+passengers	O
+and	O
+quarantine	O
+of	O
+non	O
+-	O
+ill	B-DISO
+passengers	O
+were	O
+implemented	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+Characteristics	O
+of	O
+Imported	O
+Cases	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Jiangsu	O
+Province	O
+:	O
+A	O
+Multicenter	O
+Descriptive	O
+Study	O
+.	O
+
+We	O
+retrospectively	O
+investigated	O
+the	O
+clinical	O
+,	O
+imaging	O
+,	O
+and	O
+laboratory	O
+characteristics	O
+of	O
+confirmed	O
+cases	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+with	O
+WHO	O
+interim	O
+guidance	O
+in	O
+three	O
+Grade	O
+ⅢA	O
+hospitals	O
+of	O
+Jiangsu	O
+from	O
+Jan	B-PRGE
+22	I-PRGE
+to	O
+Feb	O
+14	O
+,	O
+2020	O
+.	O
+
+The	O
+main	O
+clinical	O
+manifestations	O
+of	O
+the	O
+patients	O
+were	O
+fever	B-PROC
+and	O
+cough	B-DISO
+,	O
+which	O
+accounted	O
+for	O
+63	O
+cases	O
+(	O
+78	O
+.	O
+75	O
+%)	O
+and	O
+51	O
+cases	O
+(-	O
+63	O
+.	O
+75	O
+%)	O
+respectively	O
+.	O
+
+Imaging	O
+examination	O
+showed	O
+that	O
+55	O
+patients	O
+(-	O
+68	O
+.	O
+75	O
+%)	O
+showed	O
+abnormal	O
+,	O
+25	O
+cases	O
+(	O
+31	O
+.	O
+25	O
+%)	O
+had	O
+no	O
+abnormal	O
+density	O
+shadow	O
+in	O
+the	O
+parenchyma	B-ANAT
+of	O
+both	O
+lungs	B-ANAT
+.	O
+
+A	O
+retrospective	O
+analysis	O
+was	O
+performed	O
+on	O
+the	O
+imaging	O
+findings	O
+of	O
+patients	O
+confirmed	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+who	O
+had	O
+chest	B-ANAT
+CT	O
+scanning	O
+and	O
+treatment	O
+after	O
+disease	O
+onset	O
+.	O
+
+The	O
+ongoing	O
+outbreak	O
+presents	O
+a	O
+challenge	O
+for	O
+modelers	O
+,	O
+as	O
+limited	O
+data	O
+are	O
+available	O
+on	O
+the	O
+early	O
+growth	B-PROC
+trajectory	O
+,	O
+and	O
+the	O
+epidemiological	O
+characteristics	O
+of	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+are	O
+yet	O
+to	O
+be	O
+fully	O
+elucidated	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+the	O
+containment	O
+strategies	O
+implemented	O
+in	O
+China	O
+are	O
+successfully	O
+reducing	O
+transmission	O
+and	O
+that	O
+the	O
+epidemic	O
+growth	B-PROC
+has	O
+slowed	O
+in	O
+recent	O
+days	O
+.	O
+
+TITLE	O
+:	O
+Potential	O
+Rapid	O
+Diagnostics	O
+,	O
+Vaccine	O
+and	O
+Therapeutics	O
+for	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+):	O
+
+It	O
+is	O
+timely	O
+to	O
+systematically	O
+review	O
+the	O
+potential	O
+of	O
+these	O
+interventions	O
+,	O
+including	O
+those	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+,	O
+to	O
+guide	O
+policymakers	O
+globally	O
+on	O
+their	O
+prioritization	O
+of	O
+resources	O
+for	O
+research	O
+and	O
+development	B-PROC
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+named	O
+as	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+by	O
+International	O
+Committee	O
+on	O
+Taxonomy	O
+of	O
+Viruses	B-SPEC
+on	O
+11	O
+February	O
+,	O
+2020	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+Bats	B-SPEC
+-	O
+Hosts	B-COMP
+-	O
+Reservoir	O
+-	O
+People	O
+transmission	O
+network	O
+model	O
+for	O
+simulating	O
+the	O
+potential	O
+transmission	O
+from	O
+the	O
+infection	B-DISO
+source	O
+(	O
+probably	O
+be	O
+bats	B-SPEC
+)	O
+to	O
+the	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+reported	O
+two	O
+cases	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	O
+caused	O
+by	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+who	O
+returned	O
+from	O
+Wuhan	O
+,	O
+China	O
+in	O
+January	O
+,	O
+2020	O
+.	O
+
+Therefore	O
+,	O
+we	O
+developed	O
+an	O
+online	O
+follow	O
+-	O
+up	O
+program	O
+for	O
+convenient	O
+monitoring	O
+of	O
+bilirubin	B-CHED
+level	O
+of	O
+newborns	O
+that	O
+is	O
+based	O
+on	O
+our	O
+practical	O
+experiences	O
+.	O
+
+Thus	O
+,	O
+this	O
+study	O
+aimed	O
+to	O
+examine	O
+the	O
+correlation	O
+between	O
+the	O
+spatial	O
+distribution	O
+of	O
+primary	O
+MERS	O
+-	O
+CoV	O
+cases	O
+with	O
+or	O
+without	O
+a	O
+history	O
+of	O
+camel	B-SPEC
+exposure	O
+reported	O
+between	O
+2012	O
+and	O
+2019	O
+and	O
+dromedary	B-SPEC
+camels	B-SPEC
+at	O
+the	O
+provincial	O
+level	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Furthermore	O
+,	O
+spatial	O
+correlations	O
+between	O
+MERS	O
+-	O
+CoV	O
+cases	O
+and	O
+camel	B-SPEC
+sex	O
+,	O
+age	O
+and	O
+dairy	O
+status	O
+were	O
+significant	O
+.	O
+
+Although	O
+oncologists	O
+are	O
+not	O
+fighting	O
+on	O
+the	O
+front	O
+line	O
+to	O
+against	O
+the	O
+epidemic	O
+,	O
+during	O
+this	O
+special	O
+period	O
+,	O
+we	O
+should	O
+not	O
+only	O
+protect	O
+patients	O
+,	O
+their	O
+families	O
+and	O
+medical	O
+staff	O
+from	O
+the	O
+infection	B-DISO
+of	O
+novel	B-SPEC
+Coronavirus	I-SPEC
+,	O
+but	O
+also	O
+minimize	O
+the	O
+impact	O
+of	O
+the	O
+epidemic	O
+on	O
+the	O
+diagnosis	O
+and	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+cancer	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outside	O
+Hubei	O
+.	O
+
+Most	O
+patients	O
+presented	O
+with	O
+a	O
+mild	O
+infection	B-DISO
+in	O
+our	O
+study	O
+.	O
+
+The	O
+imaging	O
+pattern	O
+of	O
+multifocal	O
+peripheral	O
+ground	O
+glass	O
+or	O
+mixed	O
+opacity	B-DISO
+with	O
+predominance	O
+in	O
+the	O
+lower	O
+lung	B-ANAT
+is	O
+highly	O
+suspicious	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+the	O
+first	O
+week	O
+of	O
+disease	O
+onset	O
+.	O
+
+The	O
+follow	O
+-	O
+up	O
+with	O
+chest	B-ANAT
+X	O
+-	O
+Rays	B-SPEC
+and	O
+CT	O
+scans	O
+was	O
+also	O
+included	O
+,	O
+showing	O
+a	O
+progressive	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+RESULTS	O
+:	O
+Moderate	O
+to	O
+severe	O
+progression	O
+of	O
+the	O
+lung	B-ANAT
+infiltrates	B-DISO
+,	O
+with	O
+increasing	O
+percentage	O
+of	O
+high	O
+-	O
+density	O
+infiltrates	B-DISO
+sustained	O
+by	O
+a	O
+bilateral	O
+and	O
+multi	O
+-	O
+segmental	O
+extension	O
+of	O
+lung	B-ANAT
+opacities	B-DISO
+,	O
+were	O
+seen	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+is	O
+caused	O
+by	O
+SARS	B-DISO
+-	O
+COV2	O
+and	O
+represents	O
+the	O
+causative	O
+agent	O
+of	O
+a	O
+potentially	O
+fatal	O
+disease	O
+that	O
+is	O
+of	O
+great	O
+global	O
+public	O
+health	O
+concern	O
+.	O
+
+In	O
+the	O
+second	O
+step	O
+we	O
+searched	O
+Chinese	O
+herbal	O
+databases	O
+to	O
+identify	O
+plants	B-SPEC
+containing	O
+the	O
+selected	O
+compounds	O
+.	O
+
+Plants	B-SPEC
+containing	O
+2	O
+or	O
+more	O
+of	O
+the	O
+compounds	O
+identified	O
+in	O
+our	O
+screen	O
+were	O
+then	O
+checked	O
+against	O
+the	O
+catalogue	O
+for	O
+classic	O
+herbal	O
+usage	O
+.	O
+
+TITLE	O
+:	O
+Corona	B-SPEC
+Virus	B-SPEC
+International	O
+Public	O
+Health	O
+Emergencies	B-DISO
+:	O
+Implications	O
+for	O
+Radiology	O
+Management	O
+.	O
+
+This	O
+article	O
+discusses	O
+how	O
+radiology	O
+departments	O
+can	O
+most	O
+effectively	O
+respond	O
+to	O
+this	O
+public	O
+health	O
+emergency	B-DISO
+.	O
+
+Hyaline	B-DISO
+membranes	B-ANAT
+were	O
+not	O
+prominent	O
+.	O
+
+The	O
+differential	O
+counts	O
+of	O
+white	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+were	O
+analyzed	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Advances	O
+in	O
+the	O
+research	O
+of	O
+cytokine	B-DISO
+storm	I-DISO
+mechanism	O
+induced	O
+by	O
+Corona	B-DISO
+Virus	B-PROC
+Disease	I-PROC
+2019	I-DISO
+and	O
+the	O
+corresponding	O
+immunotherapies	O
+].	O
+
+In	O
+the	O
+later	O
+stage	O
+of	O
+disease	O
+,	O
+some	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+may	O
+develop	O
+into	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+or	O
+even	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+We	O
+analyzed	O
+the	O
+data	O
+of	O
+patients	O
+who	O
+received	O
+corticosteroids	B-CHED
+within	O
+7	O
+days	O
+of	O
+the	O
+onset	O
+of	O
+ARDS	B-DISO
+between	O
+June	O
+2006	O
+and	O
+December	O
+2015	O
+at	O
+a	O
+single	O
+tertiary	O
+teaching	O
+hospital	O
+.	O
+
+The	O
+author	O
+had	O
+the	O
+opportunity	O
+to	O
+examine	O
+the	O
+infectivity	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+during	O
+the	O
+incubation	O
+period	O
+by	O
+conducting	B-PROC
+an	O
+epidemiological	O
+survey	O
+on	O
+a	O
+confirmed	O
+patient	O
+who	O
+had	O
+visited	O
+Jeju	O
+Island	O
+during	O
+the	O
+incubation	O
+period	O
+.	O
+
+The	O
+epidemiological	O
+findings	O
+support	O
+the	O
+claim	O
+that	O
+the	O
+COVID	B-SPEC
+-	I-SPEC
+19	I-SPEC
+virus	I-SPEC
+does	O
+not	O
+have	O
+infectivity	O
+during	O
+the	O
+incubation	O
+period	O
+.	O
+
+The	O
+disease	O
+condition	B-DISO
+of	O
+the	O
+main	O
+children	O
+was	O
+mild	O
+.	O
+
+TITLE	O
+:	O
+Novel	O
+Insights	O
+Into	O
+Immune	B-ANAT
+Systems	I-ANAT
+of	O
+Bats	B-SPEC
+.	O
+
+Mice	B-SPEC
+were	O
+then	O
+placed	O
+on	O
+high	O
+-	O
+volume	O
+MV	O
+(	O
+30	O
+ml	O
+/	O
+kg	O
+with	O
+3	O
+cmH	B-DISO
+
+While	O
+vaccine	O
+research	O
+should	O
+be	O
+pursued	O
+intensely	O
+,	O
+there	O
+exists	O
+today	O
+no	O
+therapy	O
+to	O
+treat	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+upon	O
+infection	B-DISO
+,	O
+despite	O
+an	O
+urgent	O
+need	O
+to	O
+find	O
+options	O
+to	O
+help	O
+these	O
+patients	O
+and	O
+preclude	O
+potential	O
+death	B-PROC
+.	O
+
+I	O
+consider	O
+the	O
+options	O
+of	O
+drug	O
+repurposing	O
+,	O
+developing	O
+neutralizing	O
+monoclonal	O
+antibody	B-COMP
+therapy	O
+,	O
+and	O
+an	O
+oligonucleotide	B-CHED
+strategy	O
+targeting	B-PROC
+the	O
+viral	O
+RNA	O
+genome	O
+,	O
+emphasizing	O
+the	O
+promise	O
+and	O
+pitfalls	O
+of	O
+these	O
+approaches	O
+.	O
+
+ABSTRACT	O
+:	O
+With	O
+the	O
+increasing	O
+number	O
+of	O
+cases	O
+and	O
+widening	O
+geographical	O
+spread	O
+,	O
+the	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+has	O
+been	O
+classified	O
+as	O
+one	O
+of	O
+the	O
+class	B-SPEC
+B	O
+infectious	B-DISO
+diseases	I-DISO
+but	O
+prevented	O
+and	O
+controlled	O
+as	O
+class	B-SPEC
+A	O
+infectious	B-DISO
+disease	I-DISO
+by	O
+the	O
+National	O
+Health	O
+Commission	O
+of	O
+China	O
+.	O
+
+The	O
+chest	B-ANAT
+CT	O
+images	O
+and	O
+clinical	O
+data	O
+of	O
+them	O
+were	O
+reviewed	O
+and	O
+compared	O
+.	O
+
+RESULTS	O
+:	O
+Compared	O
+with	O
+the	O
+ordinary	O
+patients	O
+,	O
+the	O
+severe	O
+/	O
+critical	O
+patients	O
+had	O
+older	O
+ages	O
+,	O
+higher	O
+incidence	O
+of	O
+comorbidities	O
+,	O
+cough	B-DISO
+,	O
+expectoration	B-ANAT
+,	O
+chest	B-DISO
+pain	I-DISO
+and	O
+dyspnea	B-DISO
+.	O
+
+The	O
+persistence	O
+and	O
+clearance	O
+of	O
+viral	O
+RNA	O
+from	O
+different	O
+specimens	O
+of	O
+patients	O
+with	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+remain	O
+unclear	O
+.	O
+
+The	O
+clinical	O
+data	O
+and	O
+laboratory	O
+test	O
+results	O
+of	O
+convalescent	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+who	O
+were	O
+admitted	O
+to	O
+from	O
+January	O
+20	O
+,	O
+2020	O
+to	O
+February	O
+10	O
+,	O
+2020	O
+were	O
+collected	O
+retrospectively	O
+.	O
+
+After	O
+in	O
+-	O
+hospital	O
+treatment	O
+,	O
+patients	O
+'	O
+inflammatory	O
+indicators	O
+decreased	O
+with	O
+improved	O
+clinical	O
+condition	B-DISO
+.	O
+
+In	O
+brief	O
+,	O
+as	O
+the	O
+clearance	O
+of	O
+viral	O
+RNA	O
+in	O
+patients	O
+'	O
+stools	B-ANAT
+was	O
+delayed	O
+compared	O
+to	O
+that	O
+in	O
+oropharyngeal	B-ANAT
+swabs	O
+,	O
+it	O
+is	O
+important	O
+to	O
+identify	O
+viral	O
+RNA	O
+in	O
+feces	B-ANAT
+during	O
+convalescence	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+factors	O
+associated	O
+with	O
+disease	O
+outcomes	O
+in	O
+hospitalized	O
+patients	O
+with	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+disease	I-DISO
+.	O
+
+For	O
+all	O
+the	O
+78	O
+patients	O
+,	O
+fever	B-PROC
+was	O
+the	O
+most	O
+common	O
+initial	O
+symptom	B-DISO
+,	O
+and	O
+the	O
+maximum	O
+body	B-ANAT
+temperature	O
+at	O
+admission	O
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+progression	O
+group	O
+than	O
+in	O
+the	O
+improvement	O
+/	O
+stabilization	O
+group	O
+(	O
+38	O
+.	O
+2	O
+[	O
+37	O
+.	O
+8	O
+,	O
+38	O
+.	O
+6	O
+]	O
+vs	O
+.	O
+37	O
+.	O
+5	O
+[	O
+37	O
+.	O
+0	O
+,	O
+38	O
+.	O
+4	O
+]°	O
+C	O
+,	O
+U	O
+=	O
+2	O
+.	O
+057	O
+,	O
+P	O
+=	O
+0	O
+.	O
+027	O
+).	O
+
+Several	O
+factors	O
+that	O
+led	O
+to	O
+the	O
+progression	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+were	O
+identified	O
+,	O
+including	O
+age	O
+,	O
+history	O
+of	O
+smoking	O
+,	O
+maximum	O
+body	B-ANAT
+temperature	O
+on	O
+admission	O
+,	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+albumin	B-PRGE
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+ongoing	O
+new	O
+coronavirus	O
+pneumonia	B-DISO
+(	O
+Corona	B-DISO
+Virus	B-PROC
+Disease	I-PROC
+2019	I-DISO
+,	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+outbreak	O
+is	O
+spreading	O
+in	O
+China	O
+,	O
+but	O
+it	O
+has	O
+not	O
+yet	O
+reached	O
+its	O
+peak	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+confirmed	O
+and	O
+death	B-PROC
+cases	O
+in	O
+Hubei	O
+province	O
+accounted	O
+for	O
+59	O
+.	O
+91	O
+%	O
+(	O
+5806	O
+/	O
+9692	O
+)	O
+and	O
+95	O
+.	O
+77	O
+%	O
+(	O
+204	O
+/	O
+213	O
+)	O
+of	O
+the	O
+total	O
+cases	O
+in	O
+China	O
+respectively	O
+.	O
+
+However	O
+,	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+is	O
+associated	O
+with	O
+a	O
+coagulopathy	B-DISO
+characterized	O
+by	O
+thromboembolic	O
+and	O
+hemorrhagic	O
+complications	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+characterize	O
+the	O
+pathomechanism	O
+of	O
+the	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+-	O
+associated	O
+coagulopathy	B-DISO
+and	O
+identify	O
+options	O
+to	O
+optimize	O
+its	O
+monitoring	O
+and	O
+therapy	O
+.	O
+
+Fibrinogen	B-COMP
+levels	O
+,	O
+fibrin	O
+polymerization	O
+,	O
+platelet	B-PROC
+activation	I-PROC
+,	O
+and	O
+microparticle	B-PROC
+release	I-PROC
+were	O
+increased	O
+in	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+compared	O
+to	O
+venoarterial	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+patients	O
+.	O
+
+It	O
+is	O
+characterized	O
+by	O
+individual	O
+changes	O
+of	O
+coagulation	B-PROC
+parameters	O
+and	O
+platelets	B-ANAT
+and	O
+is	O
+aggravated	O
+by	O
+anticoagulants	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+presented	O
+a	O
+case	O
+of	O
+a	O
+30	O
+-	O
+week	O
+pregnant	O
+woman	O
+with	O
+COVID	O
+-	O
+19	O
+delivering	O
+a	O
+healthy	O
+baby	O
+with	O
+no	O
+evidence	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+We	O
+used	O
+the	O
+model	O
+to	O
+quantify	O
+the	O
+potential	O
+effectiveness	O
+of	O
+contact	O
+tracing	O
+and	O
+isolation	O
+of	O
+cases	O
+at	O
+controlling	O
+a	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)-	O
+like	O
+pathogen	O
+.	O
+
+TITLE	O
+:	O
+Asymptomatic	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+patient	O
+outside	O
+Wuhan	O
+:	O
+The	O
+value	O
+of	O
+CT	O
+images	O
+in	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+.	O
+
+This	O
+is	O
+being	O
+emphasised	O
+as	O
+the	O
+outbreak	O
+gains	O
+ground	O
+in	O
+other	O
+countries	O
+,	O
+leading	O
+towards	O
+a	O
+global	O
+health	O
+emergency	B-DISO
+,	O
+and	O
+as	O
+global	O
+collaboration	O
+is	O
+sought	O
+in	O
+numerous	O
+quarters	O
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+Identification	O
+of	O
+A	O
+Novel	O
+Pathogen	O
+in	O
+Real	O
+Time	O
+:	O
+Analysis	O
+of	O
+the	O
+Atypical	B-DISO
+Pneumonia	I-DISO
+Outbreak	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+2019	O
+-	O
+2020	O
+.	O
+
+ABSTRACT	O
+:	O
+Virological	O
+tests	O
+have	O
+now	O
+shown	O
+conclusively	O
+that	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+is	O
+causing	O
+the	O
+2019	O
+-	O
+2020	O
+atypical	B-DISO
+pneumonia	I-DISO
+outbreak	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+We	O
+hope	O
+our	O
+initial	O
+experience	O
+in	O
+stepping	B-DISO
+up	O
+infection	B-DISO
+control	O
+measures	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+in	O
+ophthalmology	O
+can	O
+help	O
+ophthalmologists	O
+globally	O
+to	O
+prepare	O
+for	O
+the	O
+potential	O
+community	O
+outbreak	O
+or	O
+pandemic	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+minimise	O
+transmission	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+ophthalmologists	O
+should	O
+work	O
+closely	O
+with	O
+local	O
+infection	B-DISO
+control	O
+teams	O
+to	O
+implement	O
+infection	B-DISO
+control	O
+measures	O
+that	O
+are	O
+appropriate	O
+for	O
+their	O
+own	O
+clinical	O
+settings	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+confirmed	O
+and	O
+suspected	O
+cases	O
+of	O
+the	O
+2019	O
+novel	O
+coronavirus	O
+disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+have	O
+increased	O
+not	O
+only	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+but	O
+also	O
+China	O
+and	O
+the	O
+world	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+is	O
+an	O
+obvious	O
+concern	O
+globally	O
+regarding	O
+the	O
+fact	O
+about	O
+the	O
+emerging	O
+coronavirus	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+as	O
+a	O
+worldwide	O
+public	O
+health	O
+threat	O
+.	O
+
+As	O
+the	O
+outbreak	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+causes	O
+by	O
+the	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+progresses	O
+within	O
+China	O
+and	O
+beyond	O
+,	O
+rapidly	O
+available	O
+epidemiological	O
+data	O
+are	O
+needed	O
+to	O
+guide	O
+strategies	O
+for	O
+situational	O
+awareness	O
+and	O
+intervention	O
+.	O
+
+The	O
+recent	O
+outbreak	O
+of	O
+pneumonia	B-DISO
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+caused	O
+by	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+emphasizes	O
+the	O
+importance	O
+of	O
+analyzing	O
+the	O
+epidemiological	O
+data	O
+of	O
+this	O
+novel	O
+virus	B-SPEC
+and	O
+predicting	O
+their	O
+risks	O
+of	O
+infecting	O
+people	O
+all	O
+around	O
+the	O
+globe	B-ANAT
+.	O
+
+In	O
+response	O
+to	O
+the	O
+above	O
+questions	O
+,	O
+we	O
+put	O
+forward	O
+corresponding	O
+suggestions	O
+and	O
+reflections	O
+from	O
+the	O
+perspective	O
+of	O
+the	O
+infectious	B-DISO
+clinician	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Individualized	O
+treatment	O
+recommendations	O
+for	O
+lung	B-DISO
+cancer	B-SPEC
+patients	O
+at	O
+different	O
+stages	O
+of	O
+treatment	O
+during	O
+the	O
+outbreak	O
+of	O
+2019	O
+novel	O
+coronavirus	O
+disease	O
+epidemic	O
+].	O
+
+Given	O
+the	O
+systemic	O
+immunosuppressive	O
+state	O
+caused	O
+by	O
+malignancy	B-DISO
+and	O
+anticancer	O
+treatments	O
+,	O
+patients	O
+with	O
+advanced	O
+lung	B-DISO
+cancer	B-SPEC
+may	O
+be	O
+at	O
+a	O
+higher	O
+risk	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+.	O
+
+During	O
+epidemic	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+a	O
+guideline	O
+for	O
+the	O
+optimal	O
+management	O
+of	O
+patients	O
+with	O
+advanced	O
+lung	B-DISO
+cancer	B-SPEC
+urgently	O
+needs	O
+to	O
+be	O
+proposed	O
+to	O
+distinguish	O
+the	O
+symptoms	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+the	O
+side	O
+effects	O
+of	O
+antitumor	O
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Community	O
+Transmission	O
+of	O
+Severe	B-SPEC
+Acute	I-SPEC
+Respiratory	I-SPEC
+Syndrome	I-SPEC
+Coronavirus	I-SPEC
+2	I-SPEC
+,	O
+Shenzhen	O
+,	O
+China	O
+,	O
+2020	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+early	O
+January	O
+2020	O
+,	O
+after	O
+the	O
+outbreak	O
+of	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+infection	I-DISO
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+≈	O
+365	O
+confirmed	O
+cases	O
+have	O
+been	O
+reported	O
+in	O
+Shenzhen	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	O
+2	O
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+emerged	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+in	O
+December	O
+2019	O
+and	O
+has	O
+spread	O
+globally	O
+with	O
+sustained	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+outside	O
+China	O
+.	O
+
+Descriptive	O
+case	O
+series	O
+of	O
+the	O
+first	O
+18	O
+patients	O
+diagnosed	O
+with	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)-	O
+confirmed	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+at	O
+4	O
+hospitals	O
+in	O
+Singapore	O
+from	O
+January	O
+23	O
+to	O
+February	O
+3	O
+,	O
+2020	O
+;	O
+final	O
+follow	O
+-	O
+up	O
+date	O
+was	O
+February	O
+25	O
+,	O
+2020	O
+.	O
+
+Clinical	O
+course	O
+was	O
+summarized	O
+,	O
+including	O
+requirement	O
+for	O
+supplemental	O
+oxygen	B-CHED
+and	O
+intensive	O
+care	O
+and	O
+use	O
+of	O
+empirical	O
+treatment	O
+with	O
+lopinavir	O
+-	O
+ritonavir	O
+.	O
+
+Among	O
+the	O
+18	O
+hospitalized	O
+patients	O
+with	O
+PCR	O
+-	O
+confirmed	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+(	O
+median	O
+age	O
+,	O
+47	O
+years	O
+;	O
+9	O
+[	O
+50	O
+%]	O
+women	O
+),	O
+clinical	O
+presentation	O
+was	O
+an	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+12	O
+(	O
+67	O
+%),	O
+and	O
+viral	B-DISO
+shedding	I-DISO
+from	O
+the	O
+nasopharynx	B-ANAT
+was	O
+prolonged	O
+for	O
+7	O
+days	O
+or	O
+longer	O
+among	O
+15	O
+(	O
+83	O
+%).	O
+
+TITLE	O
+:	O
+Understanding	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+-	O
+Mediated	O
+Inflammatory	B-DISO
+Responses	I-DISO
+:	O
+From	O
+Mechanisms	O
+to	O
+Potential	O
+Therapeutic	O
+Tools	O
+.	O
+
+We	O
+performed	O
+a	O
+15	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+on	O
+the	O
+lung	B-ANAT
+and	O
+bone	B-ANAT
+conditions	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Two	O
+patients	O
+died	B-PROC
+of	O
+SARS	B-DISO
+,	O
+and	O
+78	O
+were	O
+enrolled	O
+in	O
+this	O
+study	O
+from	O
+August	O
+2003	O
+to	O
+March	O
+2018	O
+.	O
+
+The	O
+percentage	O
+of	O
+pulmonary	B-ANAT
+lesions	O
+on	O
+CT	O
+scans	O
+diminished	O
+from	O
+2003	O
+(	O
+9	O
+.	O
+40	O
+±	O
+7	O
+.	O
+83	O
+)%	O
+to	O
+2004	O
+(	O
+3	O
+.	O
+20	O
+±	O
+4	O
+.	O
+78	O
+)%	O
+(	O
+
+Developing	O
+vaccines	O
+against	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+virus	B-SPEC
+may	O
+take	O
+many	O
+months	O
+.	O
+
+The	O
+median	O
+number	O
+of	O
+intra	O
+-	O
+host	B-COMP
+variants	O
+was	O
+1	O
+-	O
+4	O
+in	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infected	O
+patients	O
+,	O
+which	O
+ranged	O
+between	O
+0	O
+and	O
+51	O
+in	O
+different	O
+samples	O
+.	O
+
+However	O
+,	O
+very	O
+few	O
+intra	O
+-	O
+host	B-COMP
+variants	O
+were	O
+observed	O
+in	O
+the	O
+population	O
+as	O
+polymorphism	B-PROC
+,	O
+implying	O
+either	O
+a	O
+bottleneck	O
+or	O
+purifying	O
+selection	O
+involved	O
+in	O
+the	O
+transmission	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+or	O
+a	O
+consequence	O
+of	O
+the	O
+limited	O
+diversity	O
+represented	O
+in	O
+the	O
+current	O
+polymorphism	B-PROC
+data	O
+.	O
+
+The	O
+microbiota	B-SPEC
+in	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infected	O
+patients	O
+was	O
+similar	O
+to	O
+those	O
+in	O
+CAP	B-DISO
+,	O
+either	O
+dominated	O
+by	O
+the	O
+pathogens	O
+or	O
+with	O
+elevated	O
+levels	O
+of	O
+oral	B-ANAT
+and	O
+upper	O
+respiratory	O
+commensal	O
+bacteria	B-SPEC
+.	O
+
+Although	O
+how	O
+the	O
+intra	O
+-	O
+host	B-COMP
+variant	O
+spreads	O
+in	O
+the	O
+population	O
+is	O
+still	O
+elusive	O
+,	O
+it	O
+is	O
+necessary	O
+to	O
+strengthen	O
+the	O
+surveillance	O
+of	O
+the	O
+viral	O
+evolution	B-PROC
+in	O
+the	O
+population	O
+and	O
+associated	O
+clinical	O
+changes	O
+.	O
+
+One	O
+of	O
+these	O
+novel	O
+approaches	O
+is	O
+based	O
+on	O
+the	O
+use	O
+of	O
+autologous	O
+or	O
+allogeneic	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cells	B-COMP
+to	O
+treat	O
+cancer	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+further	O
+alterations	O
+in	O
+the	O
+expression	B-PROC
+of	O
+activating	B-PRGE
+and	I-PRGE
+inhibitory	I-PRGE
+receptors	I-PRGE
+are	O
+found	O
+in	O
+NK	B-ANAT
+cells	I-ANAT
+from	O
+cancer	B-DISO
+patients	O
+,	O
+likely	O
+because	O
+of	O
+their	O
+interaction	O
+with	O
+tumour	B-DISO
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+December	O
+2019	O
+,	O
+a	O
+novel	O
+coronavirus	O
+,	O
+called	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+was	O
+discovered	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+and	O
+has	O
+spread	O
+to	O
+different	O
+cities	O
+in	O
+China	O
+as	O
+well	O
+as	O
+to	O
+24	O
+other	O
+countries	O
+.	O
+
+Healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+are	O
+at	O
+high	O
+risk	O
+while	O
+combating	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+at	O
+the	O
+very	O
+frontline	O
+,	O
+and	O
+nosocomial	O
+outbreaks	O
+among	O
+HCWs	O
+are	O
+not	O
+unusual	O
+in	O
+similar	O
+settings	O
+;	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+led	O
+to	O
+over	O
+966	O
+HCW	O
+infections	B-DISO
+with	O
+1	O
+.	O
+4	O
+%	O
+deaths	B-PROC
+in	O
+mainland	O
+China	O
+[	O
+2	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+infection	B-DISO
+control	O
+preparedness	O
+for	O
+Coronavirus	B-SPEC
+Disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+due	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+[	O
+previously	O
+known	O
+as	O
+2019	O
+-	O
+novel	B-SPEC
+coronavirus	I-SPEC
+]	O
+in	O
+the	O
+first	O
+42	O
+days	O
+after	O
+announcement	O
+of	O
+a	O
+cluster	O
+of	O
+pneumonia	B-DISO
+in	O
+China	O
+,	O
+on	O
+31	O
+December	O
+2019	O
+(	O
+day	O
+1	O
+)	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+A	O
+bundle	O
+approach	O
+of	O
+active	O
+and	O
+enhanced	O
+laboratory	O
+surveillance	O
+,	O
+early	O
+airborne	O
+infection	B-DISO
+isolation	O
+,	O
+rapid	O
+molecular	O
+diagnostic	O
+testing	O
+,	O
+and	O
+contact	O
+tracing	O
+for	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+with	O
+unprotected	O
+exposure	O
+in	O
+the	O
+hospitals	O
+was	O
+implemented	O
+.	O
+
+Environmental	O
+surveillance	O
+performed	O
+in	O
+a	O
+patient	O
+with	O
+viral	O
+load	O
+of	O
+3	O
+.	O
+3x106	O
+copies	O
+/	O
+ml	O
+(	O
+pooled	O
+nasopharyngeal	B-ANAT
+/	O
+throat	B-ANAT
+swab	I-ANAT
+)	O
+and	O
+5	O
+.	O
+9x106	O
+copies	O
+/	O
+ml	O
+(	O
+saliva	B-ANAT
+)	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+for	O
+the	O
+recognition	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+by	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+human	I-PRGE
+ACE2	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	O
+-	O
+converting	O
+enzyme	O
+2	O
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+the	O
+cellular	B-COMP
+receptor	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+the	O
+new	O
+coronavirus	B-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+that	O
+is	O
+causing	O
+the	O
+serious	O
+epidemic	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+Effects	O
+of	O
+Social	O
+Support	O
+on	O
+Sleep	B-PROC
+Quality	O
+of	O
+Medical	O
+Staff	O
+Treating	O
+Patients	O
+with	O
+Coronavirus	B-SPEC
+Disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+January	O
+and	O
+February	O
+2020	O
+in	O
+China	O
+.	O
+
+MATERIAL	O
+AND	O
+METHODS	O
+A	O
+one	O
+-	O
+month	O
+cross	O
+-	O
+sectional	O
+observational	O
+study	O
+included	O
+180	O
+medical	O
+staff	O
+who	O
+treated	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+.	O
+
+Levels	O
+of	O
+anxiety	O
+were	O
+significantly	O
+associated	O
+with	O
+the	O
+levels	O
+of	O
+stress	O
+,	O
+which	O
+negatively	O
+impacted	B-DISO
+self	O
+-	O
+efficacy	O
+and	O
+sleep	B-PROC
+quality	O
+.	O
+
+The	O
+intubation	O
+procedure	O
+,	O
+anesthetic	O
+regimen	O
+,	O
+and	O
+complication	B-DISO
+were	O
+collected	O
+and	O
+analyzed	O
+.	O
+
+The	O
+mean	O
+change	O
+in	O
+Pao	B-PROC
+Fixed	B-ANAT
+-	O
+dose	O
+iEPO	O
+was	O
+comparable	O
+to	O
+iNO	B-PRGE
+in	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+for	O
+oxygenation	B-PROC
+and	O
+ventilation	O
+parameters	O
+as	O
+well	O
+as	O
+clinical	O
+outcomes	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+239	O
+patients	O
+were	O
+included	O
+with	O
+139	O
+(	O
+58	O
+.	O
+2	O
+%)	O
+and	O
+100	O
+(	O
+41	O
+.	O
+8	O
+%)	O
+in	O
+the	O
+iEPO	O
+and	O
+iNO	B-PRGE
+groups	O
+,	O
+respectively	O
+.	O
+
+In	O
+this	O
+observational	O
+study	O
+,	O
+airway	B-ANAT
+secretions	B-ANAT
+from	O
+children	O
+(	O
+n	O
+=	O
+104	O
+)	O
+with	O
+CF	O
+presenting	O
+with	O
+pulmonary	B-ANAT
+exacerbations	O
+were	O
+collected	O
+and	O
+tested	O
+for	O
+bacteria	B-SPEC
+,	O
+fungi	B-SPEC
+,	O
+mycobacteria	B-SPEC
+and	O
+viral	O
+pathogens	O
+using	O
+appropriate	O
+laboratory	O
+techniques	O
+.	O
+
+Non	O
+-	O
+tuberculous	B-DISO
+mycobacteria	B-SPEC
+were	O
+not	O
+isolated	O
+,	O
+whereas	O
+infection	B-DISO
+with	O
+Bcc	O
+and	O
+Mycobacterium	B-SPEC
+tuberculosis	I-SPEC
+was	O
+observed	O
+,	O
+which	O
+could	O
+probably	O
+have	O
+a	O
+role	O
+in	O
+CF	O
+morbidity	O
+.	O
+
+RESULTS	O
+:	O
+Thirteen	O
+pediatric	O
+patients	O
+(	O
+13	O
+/	O
+20	O
+,	O
+65	O
+%)	O
+had	O
+an	O
+identified	O
+history	O
+of	O
+close	O
+contact	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+diagnosed	O
+family	B-SPEC
+members	O
+.	O
+
+TITLE	O
+:	O
+Perspectives	O
+on	O
+monoclonal	O
+antibody	B-COMP
+therapy	O
+as	O
+potential	O
+therapeutic	O
+intervention	O
+for	O
+Coronavirus	B-SPEC
+disease	I-DISO
+-	I-DISO
+19	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+).	O
+
+Ironically	O
+,	O
+even	O
+after	O
+a	O
+decade	O
+of	O
+research	O
+on	O
+coronavirus	B-SPEC
+,	O
+still	O
+there	O
+are	O
+no	O
+licensed	O
+vaccines	O
+or	O
+therapeutic	O
+agents	O
+to	O
+treat	O
+coronavirus	B-DISO
+infection	I-DISO
+which	O
+highlights	O
+an	O
+urgent	O
+need	O
+to	O
+develop	O
+effective	O
+vaccines	O
+or	O
+post	O
+-	O
+exposure	O
+prophylaxis	O
+to	O
+prevent	O
+future	O
+epidemics	O
+.	O
+
+Follow	O
+-	O
+up	O
+CT	O
+findings	O
+showed	O
+progressive	O
+opacifications	O
+,	O
+consolidation	O
+,	O
+interstitial	B-ANAT
+thickening	O
+,	O
+fibrous	O
+strips	O
+and	O
+air	B-CHED
+bronchograms	O
+,	O
+compared	O
+to	O
+initial	O
+CT	O
+(	O
+all	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+erythrocyte	B-ANAT
+sedimentation	O
+rate	O
+and	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+showed	O
+significantly	O
+positive	O
+correlation	O
+with	O
+the	O
+severity	O
+of	O
+pneumonia	B-DISO
+assessed	O
+on	O
+initial	O
+CT	O
+(	O
+R	O
+range	O
+0	O
+.	O
+36	O
+-	O
+0	O
+.	O
+75	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Both	O
+epidemics	O
+occurred	O
+in	O
+cold	B-DISO
+dry	O
+winter	O
+seasons	O
+celebrated	O
+with	O
+major	O
+holidays	O
+,	O
+and	O
+started	O
+in	O
+regions	O
+where	O
+dietary	O
+consumption	O
+of	O
+wildlife	O
+is	O
+a	O
+fashion	O
+.	O
+
+These	O
+factors	O
+are	O
+discussed	O
+in	O
+different	O
+scenarios	O
+in	O
+order	B-SPEC
+to	O
+promote	O
+more	O
+research	O
+for	O
+achieving	O
+final	O
+validation	O
+.	O
+
+TITLE	O
+:	O
+The	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+Outbreak	O
+-	O
+A	O
+Global	O
+Threat	O
+.	O
+
+TITLE	O
+:	O
+Influence	O
+of	O
+trust	O
+on	O
+two	O
+different	O
+risk	O
+perceptions	O
+as	O
+an	O
+affective	O
+and	O
+cognitive	O
+dimension	O
+during	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+outbreak	O
+in	O
+South	O
+Korea	O
+:	O
+serial	O
+cross	O
+-	O
+sectional	O
+surveys	O
+.	O
+
+TITLE	O
+:	O
+Author	O
+Correction	O
+:	O
+China	O
+'	O
+s	O
+response	O
+to	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+stands	O
+in	O
+stark	O
+contrast	O
+to	O
+the	O
+2002	O
+SARS	O
+outbreak	O
+response	O
+.	O
+
+However	O
+,	O
+such	O
+sources	O
+of	O
+infection	B-DISO
+cannot	O
+be	O
+effectively	O
+identified	O
+due	O
+to	O
+the	O
+symptoms	O
+absent	O
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+(	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+2019	O
+)	O
+-	O
+recent	O
+trends	O
+.	O
+
+The	O
+COVID	B-SPEC
+-	I-SPEC
+19	I-SPEC
+virus	I-SPEC
+was	O
+known	O
+earlier	O
+as	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+As	O
+of	O
+12	O
+February	O
+2020	O
+,	O
+WHO	O
+reported	O
+45	O
+,	O
+171	O
+cases	O
+and	O
+1115	O
+deaths	B-PROC
+related	O
+to	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+This	O
+study	O
+aimed	O
+at	O
+investigating	O
+the	O
+global	O
+prevalence	O
+,	O
+biological	O
+and	O
+clinical	O
+characteristics	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+Wuhan	O
+China	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+),	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+outbreaks	O
+.	O
+
+The	O
+fatality	O
+rate	O
+of	O
+coronavirus	B-SPEC
+MERS	O
+-	O
+CoV	O
+was	O
+(	O
+34	O
+.	O
+77	O
+%)	O
+higher	O
+than	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+10	O
+.	O
+87	O
+%)	O
+and	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+(	O
+2	O
+.	O
+08	O
+%);	O
+however	O
+,	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+transmitted	B-DISO
+rapidly	O
+in	O
+comparison	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+novel	B-SPEC
+coronavirus	I-SPEC
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+has	O
+diverse	O
+epidemiological	O
+and	O
+biological	O
+characteristics	O
+,	O
+making	O
+it	O
+more	O
+contagious	O
+than	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+.	O
+It	O
+has	O
+affected	O
+more	O
+people	O
+in	O
+a	O
+short	O
+time	O
+period	O
+compared	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+,	O
+although	O
+the	O
+fatality	O
+rate	O
+of	O
+MERS	O
+-	O
+CoV	O
+was	O
+higher	O
+than	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+The	O
+major	O
+clinical	O
+manifestations	O
+in	O
+coronavirus	B-DISO
+infections	I-DISO
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+SARS	B-PRGE
+CoV	I-PRGE
+are	O
+fever	B-PROC
+,	O
+chills	B-DISO
+,	O
+cough	B-DISO
+,	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+,	O
+generalized	O
+myalgia	B-DISO
+,	O
+malaise	B-DISO
+,	O
+drowsy	O
+,	O
+diarrhea	B-DISO
+,	O
+confusion	B-DISO
+,	O
+dyspnea	B-DISO
+,	O
+and	O
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+2019	O
+novel	O
+coronavirus	O
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+),	O
+which	O
+originated	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+has	O
+attracted	O
+the	O
+world	O
+'	O
+s	O
+attention	O
+over	O
+the	O
+last	O
+month	O
+.	O
+
+The	O
+Chinese	O
+government	O
+has	O
+taken	O
+emergency	B-DISO
+measures	O
+to	O
+control	O
+the	O
+outbreak	O
+and	O
+has	O
+undertaken	O
+initial	O
+steps	O
+in	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+infection	I-DISO
+disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+).	O
+
+Unravelling	O
+which	O
+cellular	B-COMP
+factors	O
+are	O
+used	O
+by	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+for	O
+entry	O
+might	O
+provide	O
+insights	O
+into	O
+viral	B-PROC
+transmission	I-PROC
+and	O
+reveal	O
+therapeutic	O
+targets	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrate	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+uses	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+ACE2	I-PRGE
+for	O
+entry	O
+and	O
+the	O
+serine	B-PRGE
+protease	I-PRGE
+TMPRSS2	I-PRGE
+for	O
+S	B-PRGE
+protein	I-PRGE
+priming	O
+.	O
+
+As	O
+of	O
+late	O
+February	O
+2020	O
+,	O
+tens	O
+of	O
+thousands	O
+of	O
+cases	O
+and	O
+several	O
+thousand	O
+deaths	B-PROC
+have	O
+been	O
+reported	O
+in	O
+China	O
+alone	O
+,	O
+in	O
+addition	O
+to	O
+thousands	O
+of	O
+cases	O
+in	O
+other	O
+countries	O
+.	O
+
+The	O
+future	O
+of	O
+human	B-SPEC
+CoV	O
+outbreaks	O
+will	O
+not	O
+only	O
+depend	O
+on	O
+how	O
+the	O
+viruses	B-SPEC
+will	O
+evolve	O
+,	O
+but	O
+will	O
+also	O
+depend	O
+on	O
+how	O
+we	O
+develop	O
+efficient	O
+prevention	O
+and	O
+treatment	O
+strategies	O
+to	O
+deal	O
+with	O
+this	O
+continuous	O
+threat	O
+.	O
+
+This	O
+viral	O
+epidemic	O
+in	O
+China	O
+has	O
+led	O
+to	O
+the	O
+deaths	B-PROC
+of	O
+over	O
+1800	O
+people	O
+,	O
+mostly	O
+elderly	O
+or	O
+those	O
+with	O
+an	O
+underlying	O
+chronic	B-DISO
+disease	I-DISO
+or	O
+immunosuppressed	O
+state	O
+.	O
+
+It	O
+is	O
+currently	O
+believed	O
+that	O
+this	O
+deadly	O
+Coronavirus	B-SPEC
+strain	O
+originated	O
+from	O
+wild	O
+animals	B-SPEC
+at	O
+the	O
+Huanan	O
+market	O
+in	O
+Wuhan	O
+,	O
+a	O
+city	O
+in	O
+Hubei	O
+province	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+clear	O
+that	O
+finding	O
+an	O
+effective	O
+antiviral	B-CHED
+and	O
+developing	O
+a	O
+vaccine	O
+are	O
+still	O
+significant	O
+challenges	O
+.	O
+
+TITLE	O
+:	O
+The	O
+effect	O
+of	O
+travel	O
+restrictions	O
+on	O
+the	O
+spread	O
+of	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Motivated	O
+by	O
+the	O
+rapid	O
+spread	O
+of	O
+COVID	O
+-	O
+19	O
+in	O
+Mainland	O
+China	O
+,	O
+we	O
+use	O
+a	O
+global	O
+metapopulation	O
+disease	B-DISO
+transmission	I-DISO
+model	O
+to	O
+project	O
+the	O
+impact	O
+of	O
+travel	O
+limitations	O
+on	O
+the	O
+national	O
+and	O
+international	O
+spread	O
+of	O
+the	O
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+A	O
+conceptual	O
+model	O
+for	O
+the	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+outbreak	O
+in	O
+Wuhan	O
+,	O
+China	O
+with	O
+individual	O
+reaction	O
+and	O
+governmental	O
+action	O
+.	O
+
+We	O
+propose	O
+conceptual	O
+models	O
+for	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+in	O
+Wuhan	O
+with	O
+the	O
+consideration	O
+of	O
+individual	O
+behavioural	O
+reaction	O
+and	O
+governmental	O
+actions	O
+,	O
+e	O
+.	O
+g	O
+.,	O
+holiday	O
+extension	O
+,	O
+travel	O
+restriction	O
+,	O
+hospitalisation	O
+and	O
+quarantine	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+estimate	O
+the	O
+serial	O
+interval	O
+of	O
+novel	O
+coronavirus	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+from	O
+information	O
+on	O
+28	O
+infector	O
+-	O
+infectee	O
+pairs	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Healing	B-PROC
+the	O
+schism	O
+between	O
+public	O
+health	O
+and	O
+medicine	B-CHED
+,	O
+promoting	O
+the	O
+integration	B-PROC
+of	O
+prevention	O
+and	O
+treatment	O
+].	O
+
+By	O
+interrupting	O
+all	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+,	O
+SARS	B-DISO
+was	O
+effectively	O
+eradicated	O
+.	O
+
+The	O
+data	O
+showed	O
+that	O
+58	O
+.	O
+73	O
+%	O
+of	O
+imported	O
+camels	B-SPEC
+and	O
+25	O
+%	O
+of	O
+traders	O
+had	O
+antibodies	B-COMP
+specific	O
+to	O
+MERS	O
+-	O
+CoV	O
+.	O
+Interestingly	O
+,	O
+like	O
+seroreactive	O
+camels	B-SPEC
+,	O
+all	O
+seropositive	O
+humans	B-SPEC
+were	O
+apparently	O
+healthy	O
+without	O
+any	O
+history	O
+of	O
+developing	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+the	O
+14	O
+days	O
+prior	O
+to	O
+sampling	O
+.	O
+
+Having	O
+specific	O
+antibodies	B-COMP
+among	O
+the	O
+examined	O
+camel	B-SPEC
+sera	B-COMP
+was	O
+significantly	O
+different	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+in	O
+relation	O
+to	O
+various	O
+sampling	O
+localities	O
+,	O
+gender	O
+and	O
+age	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	B-SPEC
+coronavirus	I-SPEC
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+first	O
+appeared	O
+in	O
+December	O
+2019	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+characteristics	O
+of	O
+24	O
+asymptomatic	B-DISO
+infections	I-DISO
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+screened	O
+among	O
+close	O
+contacts	O
+in	O
+Nanjing	O
+,	O
+China	O
+.	O
+
+Twelve	O
+(	O
+50	O
+.	O
+0	O
+%)	O
+cases	O
+showed	O
+typical	O
+CT	O
+images	O
+of	O
+ground	O
+-	O
+glass	O
+chest	B-ANAT
+and	O
+5	O
+(	O
+20	O
+.	O
+8	O
+%)	O
+presented	O
+stripe	O
+shadowing	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+None	O
+of	O
+the	O
+24	O
+cases	O
+developed	O
+severe	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+or	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Of	O
+chloroquine	B-CHED
+and	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+This	O
+case	O
+highlights	O
+the	O
+importance	O
+of	O
+dynamic	O
+surveillance	O
+of	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+RNA	O
+for	O
+infectivity	O
+assessment	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Breakthroughs	O
+in	O
+global	O
+critical	O
+care	O
+medicine	B-CHED
+2019	O
+].	O
+
+In	O
+addition	O
+,	O
+there	O
+are	O
+many	O
+significantly	O
+important	O
+trials	O
+with	O
+positive	O
+results	O
+:	O
+high	O
+dose	O
+vitamin	B-CHED
+C	I-CHED
+for	O
+septic	B-DISO
+shock	I-DISO
+,	O
+weaning	B-PROC
+strategy	O
+with	O
+pressure	O
+support	O
+ventilation	O
+(	O
+PSV	O
+)	O
+mode	O
+,	O
+tranexamic	B-CHED
+acid	I-CHED
+for	O
+patients	O
+with	O
+acute	O
+traumatic	O
+brain	B-ANAT
+injury	O
+,	O
+and	O
+new	O
+monoclonal	O
+antibody	B-COMP
+for	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+.	O
+
+And	O
+there	O
+are	O
+also	O
+negatives	O
+trials	O
+as	O
+following	O
+:	O
+individual	O
+mechanical	O
+ventilation	O
+,	O
+maximal	O
+recruitment	B-DISO
+open	O
+lung	B-ANAT
+ventilation	O
+or	O
+early	O
+neuromuscular	B-DISO
+blockade	I-DISO
+for	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+,	O
+N95	O
+respirators	O
+preventing	O
+influenza	B-DISO
+,	O
+flexible	O
+family	B-SPEC
+visit	O
+program	O
+against	O
+delirium	O
+or	O
+early	O
+sedation	B-DISO
+with	O
+dexmedetomidine	B-CHED
+to	O
+mechanically	O
+ventilated	O
+patients	O
+,	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+diary	O
+or	O
+nurse	O
+-	O
+led	O
+preventive	O
+psychological	B-DISO
+intervention	O
+against	O
+posttraumatic	B-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+)	O
+in	O
+patients	O
+with	O
+mechanical	O
+ventilation	O
+,	O
+recombinant	B-PRGE
+human	I-PRGE
+soluble	I-PRGE
+thrombomodulin	I-PRGE
+(	O
+rhsTM	O
+)	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+associated	O
+coagulopathy	B-DISO
+,	O
+and	O
+so	O
+on	O
+.	O
+
+Abdominal	B-ANAT
+computerized	O
+tomography	O
+and	O
+abdominal	B-ANAT
+ultrasound	O
+with	O
+Doppler	O
+were	O
+unremarkable	O
+.	O
+
+The	O
+virus	B-SPEC
+replicated	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+and	O
+cytopathic	B-DISO
+effects	I-DISO
+were	O
+observed	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+Epidemiological	O
+and	O
+Clinical	O
+Characteristics	O
+of	O
+28	O
+Cases	O
+of	O
+Coronavirus	B-SPEC
+Disease	O
+in	O
+South	O
+Korea	O
+.	O
+
+Establishing	O
+an	O
+early	O
+detection	O
+strategy	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+crucial	O
+for	O
+managing	O
+the	O
+transmission	O
+of	O
+the	O
+disease	O
+.	O
+
+ALI	O
+progresses	O
+to	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+(	O
+PF	O
+)	O
+and	O
+makes	O
+patient	O
+'	O
+s	O
+life	O
+miserable	O
+.	O
+
+Apoptotic	O
+markers	O
+are	O
+detectable	O
+within	O
+IPF	O
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+senescent	O
+cell	B-COMP
+deletion	O
+can	O
+rejuvenate	O
+pulmonary	B-ANAT
+health	O
+.	O
+
+However	O
+,	O
+drug	O
+screening	O
+using	O
+live	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+requires	O
+high	O
+-	O
+level	O
+biosafety	O
+facilities	O
+,	O
+which	O
+imposes	O
+an	O
+obstacle	O
+for	O
+those	O
+without	O
+such	O
+facilities	O
+or	O
+2019	O
+-	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+).	O
+
+RESULTS	O
+:	O
+The	O
+spike	O
+protein	B-CHED
+of	O
+coronavirus	B-SPEC
+GX_P2V	O
+shares	O
+92	O
+.	O
+2	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+with	O
+that	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+isolate	O
+Wuhan	O
+-	O
+hu	O
+-	O
+1	O
+,	O
+and	O
+uses	O
+ACE2	O
+as	O
+the	O
+receptor	O
+for	O
+infection	B-DISO
+just	O
+like	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+Three	O
+drugs	O
+-	O
+cepharanthine	O
+(	O
+CEP	B-DISO
+),	O
+selamectin	O
+and	O
+mefloquine	B-CHED
+hydrochloride	B-CHED
+exhibited	O
+complete	O
+inhibition	B-PROC
+of	O
+cytopathic	B-DISO
+effects	I-DISO
+in	O
+cell	B-COMP
+culture	O
+at	O
+10	O
+μmol	O
+/	O
+L	O
+.	O
+CEP	B-DISO
+demonstrated	O
+the	O
+most	O
+potent	O
+inhibition	B-PROC
+of	O
+GX_P2V	O
+infection	B-DISO
+,	O
+with	O
+a	O
+concentration	O
+for	O
+50	O
+%	O
+of	O
+maximal	O
+effect	O
+[	O
+EC50	O
+]	O
+of	O
+0	O
+.	O
+98	O
+μmol	O
+/	O
+L	O
+.	O
+The	O
+viral	O
+RNA	O
+yield	O
+in	O
+cells	B-COMP
+treated	O
+with	O
+10	O
+μmol	O
+/	O
+L	O
+CEP	B-DISO
+was	O
+15	O
+,	O
+393	O
+-	O
+fold	O
+lower	O
+than	O
+in	O
+cells	B-COMP
+without	O
+CEP	B-DISO
+treatment	O
+([	O
+6	O
+.	O
+48	O
+±	O
+0	O
+.	O
+02	O
+]	O
+×	O
+10vs	O
+.	O
+
+The	O
+virus	B-SPEC
+has	O
+since	O
+rapidly	O
+spread	O
+to	O
+all	O
+provinces	O
+and	O
+autonomous	O
+regions	O
+of	O
+China	O
+,	O
+and	O
+to	O
+countries	O
+outside	O
+of	O
+China	O
+.	O
+
+Most	O
+recently	O
+,	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+identified	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+.	O
+
+This	O
+new	O
+virus	B-SPEC
+seems	O
+to	O
+be	O
+very	O
+contagious	O
+and	O
+has	O
+quickly	O
+spread	O
+globally	O
+.	O
+
+They	O
+are	O
+a	O
+large	O
+family	B-SPEC
+of	O
+single	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+(+	O
+ssRNA	O
+)	O
+that	O
+can	O
+be	O
+isolated	O
+in	O
+different	O
+animal	B-SPEC
+species	B-SPEC
+.[	O
+1	O
+]	O
+For	O
+reasons	O
+yet	O
+to	O
+be	O
+explained	O
+,	O
+these	O
+viruses	B-SPEC
+can	O
+cross	O
+species	B-SPEC
+barriers	O
+and	O
+can	O
+cause	O
+,	O
+in	O
+humans	B-SPEC
+,	O
+illness	O
+ranging	O
+from	O
+the	O
+common	B-DISO
+cold	I-DISO
+to	O
+more	O
+severe	O
+diseases	O
+such	O
+as	O
+MERS	O
+and	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+developed	O
+and	O
+validated	O
+2	O
+species	O
+-	O
+independent	O
+protein	B-CHED
+-	O
+based	O
+assays	O
+to	O
+detect	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+functional	O
+antibodies	B-COMP
+that	O
+can	O
+block	O
+virus	B-SPEC
+receptor	O
+-	O
+binding	B-FUNC
+or	O
+sialic	B-CHED
+acid	I-CHED
+-	O
+attachment	O
+.	O
+
+Here	O
+we	O
+determined	O
+the	O
+cryo	O
+-	O
+EM	O
+structure	O
+of	O
+MHV	B-SPEC
+spike	O
+complexed	O
+with	O
+mouse	B-SPEC
+CEACAM1a	O
+.	O
+
+Together	O
+these	O
+results	O
+reveal	O
+a	O
+new	O
+role	O
+of	O
+receptor	B-FUNC
+binding	I-FUNC
+in	O
+MHV	B-SPEC
+entry	O
+:	O
+in	O
+addition	O
+to	O
+its	O
+well	O
+-	O
+characterized	O
+role	O
+in	O
+viral	O
+attachment	O
+to	O
+host	B-COMP
+cells	B-COMP
+,	O
+receptor	B-FUNC
+binding	I-FUNC
+also	O
+induces	O
+the	O
+conformational	B-PROC
+change	I-PROC
+of	O
+the	O
+spike	O
+and	O
+hence	O
+the	O
+fusion	O
+of	O
+viral	O
+and	O
+host	B-COMP
+membranes	B-ANAT
+.	O
+
+Our	O
+study	O
+provides	O
+new	O
+mechanistic	O
+insight	O
+into	O
+coronavirus	B-SPEC
+entry	O
+and	O
+highlights	O
+the	O
+diverse	O
+entry	O
+mechanisms	O
+used	O
+by	O
+different	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+In	O
+Vitro	O
+Antiviral	B-CHED
+Activity	O
+and	O
+Projection	O
+of	O
+Optimized	O
+Dosing	O
+Design	O
+of	O
+Hydroxychloroquine	O
+for	O
+the	O
+Treatment	O
+of	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+Coronavirus	O
+2	O
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+).	O
+
+In	O
+this	O
+work	O
+,	O
+we	O
+repurposed	O
+in	O
+-	O
+house	O
+anti	O
+-	O
+influenza	B-DISO
+derivatives	O
+based	O
+on	O
+the	O
+1	O
+,	O
+2	O
+,	O
+4	O
+-	O
+triazolo	O
+[	O
+1	O
+,	O
+5	O
+-	O
+
+Breastmilk	O
+samples	O
+were	O
+also	O
+collected	O
+and	O
+tested	O
+from	O
+patients	O
+after	O
+the	O
+first	O
+lactation	B-PROC
+.	O
+
+No	O
+neonatal	B-DISO
+asphyxia	I-DISO
+was	O
+observed	O
+in	O
+newborn	O
+babies	O
+.	O
+
+Amniotic	B-ANAT
+fluid	I-ANAT
+,	O
+cord	B-ANAT
+blood	I-ANAT
+,	O
+neonatal	O
+throat	B-ANAT
+swab	I-ANAT
+,	O
+and	O
+breastmilk	O
+samples	O
+from	O
+six	O
+patients	O
+were	O
+tested	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+and	O
+all	O
+samples	O
+tested	O
+negative	O
+for	O
+the	O
+virus	B-SPEC
+.	O
+
+However	O
+,	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+was	O
+becoming	O
+more	O
+and	O
+more	O
+blurred	O
+after	O
+vanishing	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+Currently	O
+,	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+
+Epidemiological	O
+data	O
+showed	O
+that	O
+the	O
+older	O
+patients	O
+with	O
+chronic	O
+commodities	O
+were	O
+at	O
+high	O
+risk	O
+of	O
+the	O
+involvement	O
+of	O
+the	O
+severe	O
+and	O
+critical	O
+type	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+especially	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+resulting	O
+in	O
+high	O
+mortalities	O
+.	O
+
+Among	O
+these	O
+9	O
+pregnant	O
+women	O
+with	O
+confirmed	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+,	O
+onset	O
+of	O
+clinical	O
+symptoms	O
+occurred	O
+before	O
+delivery	O
+in	O
+4	O
+cases	O
+,	O
+on	O
+the	O
+day	O
+of	O
+delivery	O
+in	O
+2	O
+cases	O
+,	O
+and	O
+after	O
+delivery	O
+in	O
+3	O
+cases	O
+.	O
+
+Perinatal	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+may	O
+have	O
+adverse	B-DISO
+effects	I-DISO
+on	O
+newborns	O
+,	O
+causing	O
+problems	O
+such	O
+as	O
+fetal	B-DISO
+distress	I-DISO
+,	O
+premature	B-DISO
+labor	I-DISO
+,	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+thrombocytopenia	O
+accompanied	O
+by	O
+abnormal	B-DISO
+liver	I-DISO
+function	I-DISO
+,	O
+and	O
+even	O
+death	B-PROC
+.	O
+
+In	O
+neonatal	O
+intensive	O
+care	O
+unit	O
+(	O
+NICU	O
+),	O
+to	O
+prevent	O
+and	O
+control	O
+infection	B-DISO
+,	O
+there	O
+should	O
+be	O
+practical	O
+measures	O
+to	O
+ensure	O
+the	O
+optimal	O
+management	O
+of	O
+children	O
+potentially	O
+to	O
+be	O
+infected	O
+.	O
+
+TITLE	O
+:	O
+Performance	O
+of	O
+radiologists	O
+in	O
+differentiating	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+from	O
+viral	B-DISO
+pneumonia	I-DISO
+on	O
+chest	B-ANAT
+CT	O
+.	O
+
+Compared	O
+to	O
+non	O
+-	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+,	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+was	O
+more	O
+likely	O
+to	O
+have	O
+a	O
+peripheral	O
+distribution	O
+(	O
+80	O
+%	O
+vs	O
+.	O
+57	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+(	O
+91	O
+%	O
+vs	O
+.	O
+68	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+fine	O
+reticular	O
+opacity	B-DISO
+(	O
+56	O
+%	O
+vs	O
+.	O
+22	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+vascular	B-ANAT
+thickening	O
+(	O
+59	O
+%	O
+vs	O
+.	O
+22	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+but	O
+less	O
+likely	O
+to	O
+have	O
+a	O
+central	O
++	O
+peripheral	O
+distribution	O
+(	O
+14	O
+.%	O
+vs	O
+.	O
+35	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+pleural	B-DISO
+effusion	I-DISO
+(	O
+4	O
+.	O
+1	O
+vs	O
+.	O
+39	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+lymphadenopathy	O
+(	O
+2	O
+.	O
+7	O
+%	O
+vs	O
+.	O
+10	O
+.	O
+2	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Multiple	O
+bilateral	O
+lobular	O
+and	O
+subsegmental	O
+areas	O
+of	O
+consolidation	O
+or	O
+bilateral	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+were	O
+the	O
+main	O
+reported	O
+radiological	O
+features	O
+of	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+,	O
+at	O
+least	O
+in	O
+the	O
+early	O
+phases	O
+of	O
+the	O
+disease	O
+.	O
+
+The	O
+new	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+epidemic	O
+is	O
+mainly	O
+associated	O
+with	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+few	O
+extrapulmonary	O
+signs	O
+.	O
+
+Despite	O
+the	O
+given	O
+treatment	O
+,	O
+her	O
+body	B-ANAT
+temperature	O
+rose	B-SPEC
+to	O
+39	O
+.	O
+2	O
+°	O
+C	O
+and	O
+she	O
+was	O
+referred	O
+to	O
+our	O
+clinic	O
+for	O
+further	O
+evaluation	O
+.	O
+
+The	O
+first	O
+pool	O
+was	O
+from	O
+a	O
+Carassius	B-SPEC
+auratus	I-SPEC
+(	O
+crusian	O
+carp	B-DISO
+)	O
+cell	B-ANAT
+line	I-ANAT
+and	O
+the	O
+second	O
+was	O
+from	O
+Ctenopharyngodon	B-SPEC
+idella	I-SPEC
+(	O
+grass	B-SPEC
+carp	I-SPEC
+)	O
+head	B-ANAT
+kidney	B-ANAT
+tissue	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	O
+2	O
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+is	O
+an	O
+emerging	O
+disease	O
+with	O
+fatal	B-DISO
+outcomes	I-DISO
+.	O
+
+The	O
+genome	O
+composition	O
+,	O
+nucleotide	B-CHED
+analysis	O
+,	O
+codon	O
+usage	O
+indices	O
+,	O
+relative	O
+synonymous	O
+codons	O
+usage	O
+,	O
+and	O
+effective	O
+number	O
+of	O
+codons	O
+(	O
+ENc	O
+)	O
+were	O
+analyzed	O
+in	O
+the	O
+four	O
+structural	O
+genes	O
+;	O
+Spike	O
+(	O
+S	O
+),	O
+Envelope	B-COMP
+(	O
+E	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+),	O
+and	O
+Nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+genes	O
+,	O
+and	O
+two	O
+of	O
+the	O
+most	O
+important	O
+nonstructural	O
+genes	O
+comprising	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+and	O
+main	B-PRGE
+protease	I-PRGE
+(	O
+Mpro	O
+)	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+Beta	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+from	O
+pangolins	B-SPEC
+,	O
+bat	B-ENZY
+SARS	B-DISO
+,	O
+MERS	O
+,	O
+and	O
+SARS	B-DISO
+CoVs	O
+.	O
+
+TITLE	O
+:	O
+Co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+and	O
+Influenza	B-SPEC
+A	I-SPEC
+Virus	I-SPEC
+in	O
+Patient	O
+with	O
+Pneumonia	B-DISO
+,	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	I-SPEC
+2	I-SPEC
+from	O
+Patient	O
+with	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+Disease	I-DISO
+,	O
+United	O
+States	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+etiologic	O
+agent	O
+of	O
+an	O
+outbreak	O
+of	O
+pneumonia	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+was	O
+identified	O
+as	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+in	O
+January	O
+2020	O
+.	O
+
+TITLE	O
+:	O
+Zoonotic	O
+implications	O
+of	O
+camel	B-SPEC
+diseases	O
+in	O
+Iran	O
+.	O
+
+Results	O
+show	O
+that	O
+camels	B-SPEC
+are	O
+one	O
+of	O
+the	O
+most	O
+important	O
+sources	O
+of	O
+infections	B-DISO
+and	O
+diseases	O
+in	O
+human	B-SPEC
+;	O
+therefore	O
+,	O
+continuous	O
+monitoring	O
+and	O
+inspection	O
+programs	O
+are	O
+necessary	O
+to	O
+prevent	O
+the	O
+outbreak	O
+of	O
+zoonotic	O
+diseases	O
+caused	O
+by	O
+this	O
+animal	B-SPEC
+in	O
+humans	B-SPEC
+.	O
+
+Oropharyngeal	B-ANAT
+swabs	O
+were	O
+collected	O
+and	O
+subjected	O
+to	O
+viral	O
+RNA	O
+and	O
+DNA	O
+extraction	O
+followed	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Two	O
+percentage	O
+were	O
+Influenza	B-PATH
+A	I-PATH
+positive	O
+and	O
+1	O
+%	O
+positive	O
+for	O
+influenza	B-DISO
+B	O
+.	O
+Mixed	O
+viral	B-DISO
+infection	I-DISO
+was	O
+observed	O
+in	O
+7	O
+%.	O
+
+We	O
+also	O
+discuss	O
+additional	O
+ways	O
+GIS	O
+can	O
+support	O
+the	O
+fight	O
+against	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+and	O
+epidemics	O
+.	O
+
+Although	O
+many	O
+businesses	O
+and	O
+organisations	O
+have	O
+a	O
+pandemic	O
+plan	B-DISO
+or	O
+address	O
+pandemic	O
+preparedness	O
+in	O
+their	O
+business	O
+continuity	O
+plans	O
+,	O
+few	O
+have	O
+recently	O
+tested	O
+and	O
+updated	O
+their	O
+plans	O
+.	O
+
+The	O
+percentage	O
+of	O
+naïve	O
+helper	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+increased	O
+and	O
+memory	B-PROC
+helper	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+decreased	O
+in	O
+severe	O
+cases	O
+.	O
+
+Patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+also	O
+have	O
+lower	O
+level	O
+of	O
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+,	O
+and	O
+more	O
+obviously	O
+damaged	O
+in	O
+severe	O
+cases	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+452	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+recruited	O
+,	O
+286	O
+were	O
+diagnosed	O
+as	O
+severe	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+December	O
+2019	O
+,	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+caused	O
+by	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+emerged	O
+in	O
+China	O
+and	O
+now	O
+has	O
+spread	O
+in	O
+many	O
+countries	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+has	O
+raised	O
+world	O
+concern	O
+since	O
+it	O
+emerged	O
+in	O
+Wuhan	O
+Hubei	O
+China	O
+in	O
+December	O
+,	O
+2019	O
+.	O
+
+The	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+caused	O
+similar	O
+onsets	O
+to	O
+other	O
+pneumonias	B-DISO
+.	O
+
+Compared	O
+to	O
+NON	O
+-	O
+NCOVID	O
+-	O
+19	O
+,	O
+NCOVID	O
+-	O
+19	O
+present	O
+remarkably	O
+more	O
+abnormal	O
+laboratory	O
+tests	O
+including	O
+AST	B-PRGE
+,	O
+ALT	B-FUNC
+,	O
+γ	O
+-	O
+GT	O
+,	O
+LDH	B-PRGE
+and	O
+α	O
+-	O
+HBDH	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+caused	O
+similar	O
+onsets	O
+to	O
+other	O
+pneumonias	B-DISO
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+and	O
+impact	O
+of	O
+cardiovascular	B-ANAT
+metabolic	B-DISO
+diseases	I-DISO
+on	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+China	O
+.	O
+
+We	O
+recorded	O
+findings	O
+at	O
+any	O
+chest	B-ANAT
+CT	O
+performed	O
+in	O
+the	O
+included	O
+children	O
+,	O
+along	O
+with	O
+core	O
+clinical	O
+observations	O
+.	O
+
+Compared	O
+to	O
+reports	O
+in	O
+adults	O
+,	O
+we	O
+found	O
+similar	O
+but	O
+more	O
+modest	O
+lung	B-ANAT
+abnormalities	O
+at	O
+CT	O
+in	O
+our	O
+small	O
+paediatric	O
+cohort	O
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+Identification	O
+of	O
+Potential	O
+Inhibitors	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+Main	I-PRGE
+Protease	I-PRGE
+by	O
+Deep	O
+Docking	B-PROC
+of	O
+1	O
+.	O
+3	O
+Billion	O
+Compounds	O
+.	O
+
+Along	O
+these	O
+efforts	O
+,	O
+the	O
+structure	O
+of	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+main	B-PRGE
+protease	I-PRGE
+(	O
+Mpro	O
+)	O
+has	O
+been	O
+rapidly	O
+resolved	O
+and	O
+made	O
+publicly	O
+available	O
+to	O
+facilitate	O
+global	O
+efforts	O
+to	O
+develop	O
+novel	O
+drug	O
+candidates	O
+.	O
+
+It	O
+expresses	O
+the	O
+opinion	O
+that	O
+the	O
+speed	O
+and	O
+scale	O
+of	O
+the	O
+response	O
+to	O
+the	O
+2019	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+are	O
+affected	O
+by	O
+the	O
+important	O
+role	O
+that	O
+China	O
+plays	O
+in	O
+the	O
+global	O
+economy	O
+.	O
+
+TITLE	O
+:	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+patients	O
+'	O
+clinical	O
+characteristics	O
+,	O
+discharge	B-ANAT
+rate	O
+,	O
+and	O
+fatality	O
+rate	O
+of	O
+meta	O
+-	O
+analysis	O
+.	O
+
+Infection	B-DISO
+control	O
+measures	O
+are	O
+necessary	O
+to	O
+prevent	O
+the	O
+virus	B-SPEC
+from	O
+further	O
+spreading	O
+and	O
+to	O
+help	O
+control	O
+the	O
+epidemic	O
+situation	O
+.	O
+
+TITLE	O
+:	O
+Multicenter	O
+evaluation	O
+of	O
+the	O
+QIAstat	O
+Respiratory	O
+Panel	O
+-	O
+A	O
+new	O
+rapid	O
+highly	O
+multiplexed	O
+PCR	O
+based	O
+assay	O
+for	O
+diagnosis	O
+of	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ARTI	O
+),	O
+including	O
+the	O
+common	B-DISO
+cold	I-DISO
+,	O
+pharyngitis	B-DISO
+,	O
+sinusitis	B-DISO
+,	O
+otitis	B-DISO
+media	I-DISO
+,	O
+bronchiolitis	B-DISO
+and	O
+pneumonia	B-DISO
+are	O
+the	O
+most	O
+common	O
+diagnoses	O
+among	O
+patients	O
+seeking	O
+medical	O
+care	O
+in	O
+western	O
+countries	O
+,	O
+and	O
+account	O
+for	O
+most	O
+antibiotic	B-CHED
+prescriptions	O
+.	O
+
+We	O
+describe	O
+the	O
+first	O
+multicenter	O
+study	O
+of	O
+445	O
+respiratory	B-ANAT
+samples	I-ANAT
+,	O
+collected	O
+through	O
+the	O
+2016	O
+-	O
+2017	O
+and	O
+2018	O
+respiratory	O
+seasons	O
+,	O
+with	O
+performance	O
+compared	O
+against	O
+BioFire	O
+FilmArray	O
+RP	O
+v1	O
+.	O
+7	O
+and	O
+discrepancy	O
+testing	O
+by	O
+Seegene	O
+Allplex	O
+RP	O
+.	O
+
+In	O
+poultry	O
+,	O
+the	O
+genetic	O
+diversity	O
+,	O
+evolution	B-PROC
+,	O
+distribution	O
+,	O
+and	O
+taxonomy	O
+of	O
+CoVs	O
+dominant	O
+in	O
+birds	B-SPEC
+other	O
+than	O
+chickens	B-SPEC
+remain	O
+enigmatic	O
+.	O
+
+This	O
+report	O
+shed	O
+novel	O
+insight	O
+into	O
+the	O
+genetic	O
+diversity	O
+,	O
+distribution	O
+,	O
+evolution	B-PROC
+,	O
+and	O
+taxonomy	O
+of	O
+avian	B-SPEC
+CoVs	O
+.	O
+
+TITLE	O
+:	O
+Estimating	O
+the	O
+reproductive	B-PROC
+number	O
+and	O
+the	O
+outbreak	O
+size	O
+of	O
+Novel	B-DISO
+Coronavirus	I-DISO
+disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+using	O
+mathematical	O
+model	O
+in	O
+Republic	O
+of	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+first	O
+novel	B-DISO
+coronavirus	I-DISO
+disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+patient	O
+was	O
+diagnosed	O
+on	O
+20	O
+-	O
+Jan	O
+,	O
+about	O
+30	O
+patients	O
+were	O
+diagnosed	O
+in	O
+Korea	O
+until	O
+17	O
+-	O
+Feb	O
+.	O
+
+or	O
+5	O
+-	O
+Mar	B-DISO
+.	O
+
+The	O
+published	O
+cohorts	O
+of	O
+2019	O
+new	O
+coronavirus	B-SPEC
+(	O
+n	O
+-	O
+Cov	O
+)	O
+are	O
+single	O
+-	O
+center	O
+studies	O
+,	O
+or	O
+retrospective	O
+studies	O
+.	O
+
+Combination	O
+of	O
+Ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+-	I-PRGE
+α	I-PRGE
+is	O
+recommended	O
+by	O
+the	O
+5	O
+(	O
+th	O
+)	O
+edition	O
+National	O
+Health	O
+Commission	O
+'	O
+s	O
+Regimen	O
+(	O
+Revised	O
+Edition	O
+)	O
+because	O
+of	O
+the	O
+effect	O
+on	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+),	O
+and	O
+the	O
+effectiveness	O
+of	O
+Lopinavir	O
+/	O
+Ritonavir	B-CHED
+and	O
+Remdisivir	O
+needs	O
+to	O
+be	O
+confirmed	O
+by	O
+randomized	O
+controlled	O
+trial	O
+(	O
+RCT	O
+),	O
+given	O
+the	O
+situation	O
+of	O
+no	O
+specific	O
+antivirus	O
+drug	O
+on	O
+NCP	O
+is	O
+unavailable	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+of	O
+22	O
+February	O
+2020	O
+,	O
+more	O
+than	O
+77662	O
+cases	O
+of	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+have	O
+been	O
+documented	O
+globally	O
+with	O
+over	O
+2360	O
+deaths	B-PROC
+.	O
+
+Similar	O
+to	O
+outbreaks	O
+of	O
+other	O
+newly	O
+identified	O
+virus	B-SPEC
+,	O
+there	O
+is	O
+no	O
+proven	O
+regimen	O
+from	O
+conventional	O
+medicine	B-CHED
+and	O
+most	O
+reports	O
+managed	O
+the	O
+patients	O
+with	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+,	O
+ribavirin	B-CHED
+,	O
+beta	B-PRGE
+-	I-PRGE
+interferon	I-PRGE
+,	O
+glucocorticoid	B-CHED
+and	O
+supportive	O
+treatment	O
+with	O
+remdesivir	O
+undergoing	O
+clinical	O
+trial	O
+.	O
+
+We	O
+reviewed	O
+the	O
+latest	O
+national	O
+and	O
+provincial	O
+clinical	O
+guidelines	O
+,	O
+retrospective	O
+cohort	O
+studies	O
+,	O
+and	O
+case	O
+series	O
+regarding	O
+the	O
+treatment	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+by	O
+add	B-DISO
+-	O
+on	O
+Chinese	O
+medicine	B-CHED
+.	O
+
+The	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+spread	O
+illustrates	O
+the	O
+role	O
+of	O
+MGs	B-DISO
+in	O
+exacerbation	O
+of	O
+the	O
+scope	O
+of	O
+pandemics	O
+.	O
+
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+has	O
+already	O
+provided	O
+examples	O
+of	O
+both	O
+clearly	O
+planned	O
+event	O
+cancellations	O
+such	O
+as	O
+the	O
+Umrah	O
+suspension	O
+in	O
+KSA	O
+,	O
+and	O
+where	O
+outbreaks	O
+and	O
+events	O
+were	O
+continued	O
+.	O
+
+This	O
+research	O
+provides	O
+thoughtful	O
+and	O
+varied	O
+considerations	O
+and	O
+advice	O
+from	O
+practising	O
+family	B-SPEC
+physicians	O
+on	O
+how	O
+to	O
+improve	O
+risk	O
+communication	O
+from	O
+public	O
+health	O
+agencies	O
+and	O
+professional	O
+organizations	O
+to	O
+this	O
+group	O
+in	O
+the	O
+event	O
+of	O
+a	O
+public	O
+health	O
+crisis	O
+.	O
+
+Our	O
+results	O
+reveal	O
+that	O
+,	O
+in	O
+common	O
+with	O
+SARS	B-DISO
+-	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+CoV	O
+,	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+is	O
+enhanced	O
+by	O
+TMPRSS2	O
+.	O
+
+However	O
+,	O
+the	O
+recent	O
+report	O
+on	O
+asymptomatic	O
+contact	O
+transmission	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+travelers	O
+who	O
+passed	O
+the	O
+symptoms	O
+-	O
+based	O
+screening	O
+and	O
+tested	O
+positive	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+using	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+challenges	O
+this	O
+approach	O
+as	O
+body	B-ANAT
+temperature	O
+screening	O
+may	O
+miss	O
+travelers	O
+incubating	O
+the	O
+disease	O
+or	O
+travelers	O
+concealing	O
+fever	O
+during	O
+travel	O
+.	O
+
+An	O
+improvement	O
+of	O
+patient	O
+'	O
+s	O
+clinical	O
+conditions	O
+was	O
+observed	O
+only	O
+after	O
+clopidogrel	B-CHED
+and	O
+warfarin	B-CHED
+discontinuation	O
+.	O
+
+TITLE	O
+:	O
+The	O
+novel	B-SPEC
+coronavirus	I-SPEC
+outbreak	O
+:	O
+what	O
+can	O
+be	O
+learned	B-PROC
+from	O
+China	O
+in	O
+public	O
+reporting	O
+?	O
+
+Confirmed	O
+cases	O
+,	O
+dynamic	O
+suspected	O
+cases	O
+,	O
+recovered	O
+cases	O
+,	O
+and	O
+deaths	B-PROC
+have	O
+been	O
+reported	O
+both	O
+in	O
+accumulative	O
+numbers	O
+and	O
+their	O
+daily	O
+updates	O
+.	O
+
+Most	O
+patients	O
+also	O
+received	O
+vasopressors	O
+,	O
+neuromuscular	O
+blockade	O
+,	O
+and	O
+steroids	B-CHED
+.	O
+
+TITLE	O
+:	O
+A	O
+Novel	O
+Approach	O
+for	O
+a	O
+Novel	O
+Pathogen	O
+:	O
+using	O
+a	O
+home	O
+assessment	O
+team	O
+to	O
+evaluate	O
+patients	O
+for	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+).	O
+
+We	O
+draw	O
+on	O
+Taiwan	O
+'	O
+s	O
+SARS	B-DISO
+experience	O
+to	O
+argue	O
+that	O
+a	O
+modified	O
+form	O
+of	O
+Traffic	O
+Control	O
+Bundling	O
+protects	O
+health	O
+care	O
+worker	O
+safety	O
+and	O
+by	O
+extension	O
+strengthens	O
+overall	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+control	O
+.	O
+
+The	O
+disease	O
+is	O
+transmitted	B-DISO
+by	O
+inhalation	B-PROC
+or	O
+contact	O
+with	O
+infected	O
+droplets	O
+and	O
+the	O
+incubation	O
+period	O
+ranges	O
+from	O
+2	O
+to	O
+14	O
+d	O
+.	O
+The	O
+symptoms	O
+are	O
+usually	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+sore	B-DISO
+throat	I-DISO
+,	O
+breathlessness	B-DISO
+,	O
+fatigue	B-DISO
+,	O
+malaise	B-DISO
+among	O
+others	O
+.	O
+
+Common	O
+laboratory	O
+findings	O
+include	O
+normal	O
+/	O
+low	O
+white	B-ANAT
+cell	I-ANAT
+counts	O
+with	O
+elevated	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+city	O
+of	O
+Wuhan	O
+,	O
+Hubei	O
+province	O
+,	O
+China	O
+,	O
+was	O
+the	O
+origin	O
+of	O
+a	O
+severe	O
+pneumonia	B-DISO
+outbreak	O
+in	O
+December	O
+2019	O
+,	O
+attributed	O
+to	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+[	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+]),	O
+causing	O
+a	O
+total	O
+of	O
+2761	O
+deaths	B-PROC
+and	O
+81109	O
+cases	O
+(	O
+25	O
+February	O
+2020	O
+).	O
+
+The	O
+AS	O
+-	O
+SCoV2	O
+located	O
+in	O
+the	O
+acidic	O
+-	O
+domain	O
+of	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+bat	B-PRGE
+-	I-PRGE
+SL	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+RatG13	I-PRGE
+guided	O
+us	O
+to	O
+suggest	O
+that	O
+the	O
+novel	B-SPEC
+2019	I-SPEC
+coronavirus	I-SPEC
+probably	O
+emerged	O
+by	O
+genetic	B-PROC
+drift	I-PROC
+from	O
+bat	B-ENZY
+-	O
+SL	O
+-	O
+CoV	O
+-	O
+RaTG13	O
+.	O
+
+ABSTRACT	O
+:	O
+Starting	O
+around	O
+December	O
+2019	O
+,	O
+an	O
+epidemic	O
+of	O
+pneumonia	O
+,	O
+which	O
+was	O
+named	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+,	O
+broke	O
+out	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+and	O
+is	O
+spreading	O
+throughout	O
+the	O
+world	O
+.	O
+
+At	O
+present	O
+,	O
+the	O
+sensitivity	O
+of	O
+clinical	O
+nucleic	B-CHED
+acid	I-CHED
+detection	O
+is	O
+limited	O
+,	O
+and	O
+it	O
+is	O
+still	O
+unclear	O
+whether	O
+it	O
+is	O
+related	O
+to	O
+genetic	O
+variation	O
+.	O
+
+Establishment	O
+of	O
+the	O
+reference	O
+sequence	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+could	O
+benefit	O
+not	O
+only	O
+biological	O
+study	O
+of	O
+this	O
+virus	B-SPEC
+but	O
+also	O
+diagnosis	O
+,	O
+clinical	O
+monitoring	O
+and	O
+intervention	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+in	O
+the	O
+future	O
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+meta	B-SPEC
+-	O
+analyses	O
+concluded	O
+that	O
+there	O
+was	O
+insufficient	O
+evidence	O
+to	O
+determine	O
+the	O
+effect	O
+of	O
+N95	O
+respirators	O
+.	O
+
+Meta	B-SPEC
+-	O
+analysis	O
+indicated	O
+a	O
+protective	O
+effect	O
+of	O
+N95	O
+respirators	O
+against	O
+laboratory	O
+-	O
+confirmed	O
+bacterial	O
+colonization	O
+(	O
+RR	O
+=	O
+0	O
+.	O
+58	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+43	O
+-	O
+0	O
+.	O
+78	O
+).	O
+
+Risk	O
+factors	O
+for	O
+the	O
+clinical	O
+outcomes	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+have	O
+not	O
+yet	O
+been	O
+well	O
+delineated	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Diabetic	O
+Patient	O
+With	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+Infection	B-DISO
+Who	O
+Recovered	O
+and	O
+Was	O
+Discharged	O
+From	O
+Hospital	O
+.	O
+
+TITLE	O
+:	O
+Estimating	O
+Risk	O
+for	O
+Death	B-PROC
+from	O
+2019	B-DISO
+Novel	I-DISO
+Coronavirus	I-DISO
+Disease	I-DISO
+,	O
+China	O
+,	O
+January	O
+-	O
+February	O
+2020	O
+.	O
+
+ABSTRACT	O
+:	O
+Understanding	O
+the	O
+novel	O
+coronavirus	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+mode	O
+of	O
+host	B-COMP
+cell	I-COMP
+recognition	O
+may	O
+help	O
+to	O
+fight	O
+the	O
+disease	O
+and	O
+save	O
+lives	O
+.	O
+
+Protein	B-PRGE
+-	I-PRGE
+protein	B-CHED
+docking	B-PROC
+was	O
+performed	O
+to	O
+test	O
+the	O
+four	O
+regions	O
+of	O
+the	O
+spike	O
+that	O
+fit	B-DISO
+tightly	O
+in	O
+the	O
+GRP78	O
+Substrate	B-PRGE
+Binding	I-PRGE
+Domain	I-PRGE
+β	I-PRGE
+(	O
+SBDβ	O
+).	O
+
+To	O
+address	O
+this	O
+concern	O
+,	O
+the	O
+study	O
+employed	O
+a	O
+total	O
+of	O
+214	O
+general	O
+public	O
+and	O
+526	O
+nurses	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+234	O
+front	O
+-	O
+line	O
+nurses	O
+and	O
+292	O
+non	O
+-	O
+front	O
+-	O
+line	O
+nurses	O
+)	O
+to	O
+evaluate	O
+vicarious	O
+traumatization	O
+scores	O
+via	O
+a	O
+mobile	O
+app	B-CHED
+-	O
+based	O
+questionnaire	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+vicarious	O
+traumatization	O
+scores	O
+for	O
+front	O
+-	O
+line	O
+nurses	O
+including	O
+scores	O
+for	O
+physiological	O
+and	O
+psychological	B-DISO
+responses	O
+,	O
+were	O
+significantly	O
+lower	O
+than	O
+those	O
+of	O
+non	O
+-	O
+front	O
+-	O
+line	O
+nurses	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+Corona	O
+Virus	B-PROC
+Disease	I-PROC
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+caused	O
+by	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+is	O
+a	O
+Public	O
+Health	O
+Emergency	B-DISO
+of	O
+International	O
+Concern	O
+.	O
+
+Travel	O
+restrictions	O
+and	O
+border	B-ANAT
+control	O
+measures	O
+have	O
+been	O
+enforced	O
+in	O
+China	O
+and	O
+other	O
+countries	O
+to	O
+limit	O
+the	O
+spread	O
+of	O
+the	O
+outbreak	O
+.	O
+
+Moreover	O
+,	O
+lung	B-ANAT
+cells	B-COMP
+that	O
+have	O
+ACE2	B-PRGE
+expression	B-PROC
+may	O
+be	O
+the	O
+main	O
+target	B-ANAT
+cells	I-ANAT
+during	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+.	O
+
+However	O
+,	O
+some	O
+patients	O
+also	O
+exhibit	O
+non	O
+-	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+such	O
+as	O
+kidney	B-DISO
+failure	I-DISO
+,	O
+implying	O
+that	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+could	O
+also	O
+invade	O
+other	O
+organs	B-ANAT
+.	O
+
+This	O
+study	O
+may	O
+provide	O
+potential	O
+clues	O
+for	O
+further	O
+investigation	O
+of	O
+the	O
+pathogenesis	B-DISO
+and	O
+route	O
+of	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+.	O
+
+This	O
+study	O
+is	O
+aimed	O
+to	O
+score	O
+the	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+Saudi	O
+Arabia	O
+using	O
+both	O
+the	O
+original	O
+GFT	O
+and	O
+mGFT	O
+.	O
+
+ABSTRACT	O
+:	O
+Health	O
+professions	O
+preventing	O
+and	O
+controlling	O
+Coronavirus	B-DISO
+Disease	I-DISO
+2019	I-DISO
+are	O
+prone	O
+to	O
+skin	B-ANAT
+and	O
+mucous	B-ANAT
+membrane	I-ANAT
+injury	O
+,	O
+which	O
+may	O
+cause	O
+acute	B-DISO
+and	I-DISO
+chronic	I-DISO
+dermatitis	I-DISO
+,	O
+secondary	B-DISO
+infection	I-DISO
+and	O
+aggravation	O
+of	O
+underlying	O
+skin	B-DISO
+diseases	I-DISO
+.	O
+
+Insufficient	O
+and	O
+excessive	O
+protection	O
+will	O
+have	O
+adverse	B-DISO
+effects	I-DISO
+on	O
+the	O
+skin	B-ANAT
+and	O
+mucous	B-ANAT
+membrane	I-ANAT
+barrier	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+dynamics	O
+of	O
+transmission	O
+and	O
+control	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+a	O
+mathematical	O
+modelling	O
+study	O
+.	O
+
+We	O
+estimated	O
+that	O
+the	O
+median	O
+daily	O
+reproduction	B-PROC
+number	O
+(	O
+R	O
+Our	O
+results	O
+show	O
+that	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+transmission	O
+probably	O
+declined	O
+in	O
+Wuhan	O
+during	O
+late	O
+January	O
+,	O
+2020	O
+,	O
+coinciding	O
+with	O
+the	O
+introduction	O
+of	O
+travel	O
+control	O
+measures	O
+.	O
+
+Prolonged	O
+viral	B-DISO
+shedding	I-DISO
+provides	O
+the	O
+rationale	O
+for	O
+a	O
+strategy	O
+of	O
+isolation	O
+of	O
+infected	O
+patients	O
+and	O
+optimal	O
+antiviral	B-CHED
+interventions	O
+in	O
+the	O
+future	O
+.	O
+
+It	O
+is	O
+now	O
+the	O
+critical	O
+stage	O
+to	O
+fight	O
+against	O
+the	O
+virus	B-SPEC
+.	O
+
+Relevant	O
+strategies	O
+to	O
+prevent	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+are	O
+established	O
+,	O
+serving	O
+as	O
+references	O
+to	O
+the	O
+medical	O
+personnel	O
+and	O
+general	O
+public	O
+during	O
+their	O
+work	O
+or	O
+daily	O
+life	O
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+),	O
+officially	O
+known	O
+as	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+),	O
+emerged	O
+in	O
+China	O
+.	O
+
+Preliminary	O
+trials	O
+of	O
+chloroquine	O
+repurposing	O
+in	O
+the	O
+treatment	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+China	O
+have	O
+been	O
+encouraging	O
+,	O
+leading	O
+to	O
+several	O
+new	O
+trials	O
+.	O
+
+Atypical	O
+clinical	B-DISO
+findings	I-DISO
+of	O
+pregnant	O
+women	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+could	O
+increase	O
+the	O
+difficulty	O
+in	O
+initial	O
+identification	O
+.	O
+
+The	O
+proportion	O
+of	O
+lymphocytes	B-ANAT
+in	O
+the	O
+elderly	O
+group	O
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+in	O
+the	O
+young	O
+and	O
+middle	O
+-	O
+aged	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+the	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+young	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Among	O
+the	O
+5	O
+reactivated	O
+patients	O
+,	O
+other	O
+symptoms	O
+were	O
+also	O
+observed	O
+,	O
+including	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+sore	B-DISO
+throat	I-DISO
+,	O
+and	O
+fatigue	B-DISO
+.	O
+
+The	O
+majority	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+are	O
+mild	O
+.	O
+
+Patients	O
+,	O
+diagnosed	O
+after	O
+Jan	O
+17	O
+,	O
+2020	O
+,	O
+were	O
+given	O
+oral	B-ANAT
+arbidol	O
+and	O
+LPV	O
+/	O
+r	O
+in	O
+the	O
+combination	O
+group	O
+and	O
+oral	B-ANAT
+LPV	O
+/	O
+r	O
+only	O
+in	O
+the	O
+monotherapy	O
+group	O
+for	O
+5	O
+-	O
+21	O
+days	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+could	O
+not	O
+be	O
+detected	O
+for	O
+12	O
+(	O
+75	O
+%)	O
+of	O
+16	O
+patients	O
+'	O
+nasopharyngeal	B-ANAT
+specimens	O
+in	O
+the	O
+combination	O
+group	O
+after	O
+seven	O
+days	O
+,	O
+compared	O
+with	O
+6	O
+(	O
+35	O
+%)	O
+of	O
+17	O
+in	O
+the	O
+monotherapy	O
+group	O
+(	O
+p	O
+<	O
+0	O
+·	O
+05	O
+).	O
+
+After	O
+14	O
+days	O
+,	O
+15	O
+(	O
+94	O
+%)	O
+of	O
+16	O
+and	O
+9	O
+(	O
+52	O
+·	O
+9	O
+%)	O
+of	O
+17	O
+,	O
+respectively	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+could	O
+not	O
+be	O
+detected	O
+(	O
+p	O
+<	O
+0	O
+·	O
+05	O
+).	O
+
+Since	O
+the	O
+traditional	O
+SEIR	O
+model	O
+does	O
+not	O
+evaluate	O
+the	O
+effectiveness	O
+of	O
+control	O
+strategies	O
+,	O
+a	O
+novel	O
+model	O
+in	O
+line	O
+with	O
+the	O
+current	O
+epidemics	O
+process	O
+and	O
+control	O
+measures	O
+was	O
+proposed	O
+,	O
+utilizing	O
+multisource	O
+datasets	O
+including	O
+cumulative	O
+number	O
+of	O
+reported	O
+,	O
+death	B-PROC
+,	O
+quarantined	O
+and	O
+suspected	O
+cases	O
+.	O
+
+Most	O
+infected	O
+cases	O
+have	O
+been	O
+quarantined	O
+or	O
+put	O
+in	O
+suspected	O
+class	B-SPEC
+,	O
+which	O
+has	O
+been	O
+ignored	O
+in	O
+existing	O
+models	O
+.	O
+
+ABSTRACT	O
+:	O
+Background	O
+As	O
+the	O
+number	O
+of	O
+patients	O
+increases	O
+,	O
+there	O
+is	O
+a	O
+growing	O
+understanding	O
+of	O
+the	O
+form	O
+of	O
+pneumonia	O
+sustained	O
+by	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+),	O
+which	O
+has	O
+caused	O
+an	O
+outbreak	O
+in	O
+China	O
+.	O
+
+Results	O
+Antithrombin	B-PRGE
+values	O
+in	O
+patients	O
+were	O
+lower	O
+than	O
+that	O
+in	O
+the	O
+control	O
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+values	O
+of	O
+D	O
+-	O
+dimer	O
+,	O
+fibrin	O
+/	O
+fibrinogen	B-COMP
+degradation	O
+products	O
+(	O
+FDP	O
+),	O
+and	O
+fibrinogen	O
+(	O
+FIB	B-PRGE
+)	O
+in	O
+all	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+cases	O
+were	O
+substantially	O
+higher	O
+than	O
+those	O
+in	O
+healthy	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+zoonotic	O
+coronavirus	B-SPEC
+outbreak	O
+is	O
+spreading	O
+all	O
+over	O
+the	O
+world	O
+.	O
+
+Human	B-SPEC
+infection	B-DISO
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+leads	O
+to	O
+a	O
+wide	O
+range	O
+of	O
+clinical	O
+manifestations	O
+ranging	O
+from	O
+asymptomatic	O
+,	O
+mild	O
+,	O
+moderate	O
+to	O
+severe	O
+.	O
+
+The	O
+outbreak	O
+provides	O
+an	O
+opportunity	O
+for	O
+real	O
+-	O
+time	O
+tracking	O
+of	O
+an	O
+animal	B-SPEC
+coronavirus	B-SPEC
+that	O
+has	O
+just	O
+crossed	O
+species	B-SPEC
+barrier	O
+to	O
+infect	O
+humans	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+review	O
+the	O
+discovery	O
+,	O
+zoonotic	O
+origin	O
+,	O
+animal	B-SPEC
+hosts	B-COMP
+,	O
+transmissibility	O
+and	O
+pathogenicity	O
+of	O
+SARS	O
+-	O
+CoV	O
+-	O
+2	O
+in	O
+relation	O
+to	O
+its	O
+interplay	O
+with	O
+host	B-COMP
+antiviral	B-CHED
+defense	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+systematic	O
+review	O
+was	O
+to	O
+summarize	O
+the	O
+evidence	O
+regarding	O
+chloroquine	B-CHED
+for	O
+the	O
+treatment	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Chloroquine	B-CHED
+seems	O
+to	O
+be	O
+effective	O
+in	O
+limiting	O
+the	O
+replication	O
+of	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+(	O
+virus	B-SPEC
+causing	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+vitro	O
+.	O
+
+Chloroquine	B-CHED
+seems	O
+to	O
+be	O
+effective	O
+in	O
+limiting	O
+the	O
+replication	O
+of	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+(	O
+virus	B-SPEC
+causing	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Recommendations	O
+on	O
+the	O
+clinical	O
+management	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+by	O
+the	O
+«	O
+new	O
+coronavirus	O
+»	O
+SARS	O
+-	O
+CoV2	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+emergence	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+(	O
+formerly	O
+known	O
+as	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+[	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+])	O
+in	O
+Wuhan	O
+,	O
+China	O
+in	O
+December	O
+2019	O
+,	O
+which	O
+is	O
+caused	O
+by	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+),	O
+more	O
+than	O
+75	O
+,	O
+000	O
+cases	O
+have	O
+been	O
+reported	O
+in	O
+32	O
+countries	O
+/	O
+regions	O
+,	O
+resulting	O
+in	O
+more	O
+than	O
+2000	O
+deaths	B-PROC
+worldwide	O
+.	O
+
+However	O
+,	O
+searches	O
+for	O
+handwashing	O
+were	O
+gradually	O
+increased	O
+in	O
+period	O
+of	O
+face	B-DISO
+masks	O
+shortage	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+meta	B-SPEC
+-	O
+analysis	O
+was	O
+to	O
+assess	O
+the	O
+prevalence	O
+of	O
+comorbidities	O
+in	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+patients	O
+and	O
+the	O
+risk	O
+of	O
+underlying	O
+diseases	O
+in	O
+severe	O
+patients	O
+compared	O
+to	O
+non	O
+-	O
+severe	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+assessed	O
+the	O
+prevalence	O
+of	O
+comorbidities	O
+in	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+patients	O
+and	O
+found	O
+underlying	O
+disease	O
+,	O
+including	O
+hypertension	B-DISO
+,	O
+respiratory	B-DISO
+system	I-DISO
+disease	I-DISO
+and	O
+cardiovascular	B-ANAT
+,	O
+may	O
+be	O
+a	O
+risk	O
+factor	O
+for	O
+severe	O
+patients	O
+compared	O
+with	O
+Non	O
+-	O
+severe	O
+patients	O
+.	O
+
+Mainly	O
+initial	O
+symptoms	O
+were	O
+cough	B-DISO
+and	O
+low	O
+fever	B-PROC
+(	O
+37	O
+.	O
+3	O
+-	O
+38	O
+.	O
+0	O
+℃).	O
+
+Levels	O
+of	O
+potassium	B-CHED
+,	O
+albumin	B-PRGE
+,	O
+lymphocyte	B-ANAT
+were	O
+low	O
+,	O
+but	O
+increased	O
+persistently	O
+after	O
+treatment	O
+.	O
+
+Increasing	O
+eosinophils	B-ANAT
+may	O
+be	O
+an	O
+indicator	B-CHED
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+improvement	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+characteristics	O
+of	O
+refractory	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+clarify	O
+the	O
+characteristics	O
+of	O
+patients	O
+with	O
+refractory	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+In	O
+this	O
+retrospective	O
+single	O
+-	O
+center	O
+study	O
+,	O
+we	O
+included	O
+155	O
+consecutive	O
+patients	O
+with	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Zhongnan	O
+Hospital	O
+of	O
+Wuhan	O
+University	O
+from	O
+January	O
+1st	O
+to	O
+February	O
+5th	O
+.	O
+
+Compared	O
+with	O
+general	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+(	O
+45	O
+.	O
+2	O
+%),	O
+refractory	O
+patients	O
+had	O
+an	O
+older	O
+age	O
+,	O
+male	O
+sex	O
+,	O
+more	O
+underlying	O
+comorbidities	O
+,	O
+lower	O
+incidence	O
+of	O
+fever	B-PROC
+,	O
+higher	O
+levels	O
+of	O
+maximum	O
+temperature	O
+among	O
+fever	B-PROC
+cases	O
+,	O
+higher	O
+incidence	O
+of	O
+breath	B-DISO
+shortness	I-DISO
+and	O
+anorexia	B-DISO
+,	O
+severer	O
+disease	O
+assessment	O
+on	O
+admission	O
+,	O
+high	O
+levels	O
+of	O
+neutrophil	B-ANAT
+,	O
+aspartate	B-CHED
+aminotransferase	I-ENZY
+(	O
+AST	B-PRGE
+),	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+lower	O
+levels	O
+of	O
+platelets	B-ANAT
+and	O
+albumin	B-PRGE
+,	O
+and	O
+higher	O
+incidence	O
+of	O
+bilateral	B-DISO
+pneumonia	I-DISO
+and	O
+pleural	B-DISO
+effusion	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+Compared	O
+with	O
+general	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+(	O
+45	O
+.	O
+2	O
+%),	O
+refractory	O
+patients	O
+had	O
+an	O
+older	O
+age	O
+,	O
+male	O
+sex	O
+,	O
+more	O
+underlying	O
+comorbidities	O
+,	O
+lower	O
+incidence	O
+of	O
+fever	B-PROC
+,	O
+higher	O
+levels	O
+of	O
+maximum	O
+temperature	O
+among	O
+fever	B-PROC
+cases	O
+,	O
+higher	O
+incidence	O
+of	O
+breath	B-DISO
+shortness	I-DISO
+and	O
+anorexia	B-DISO
+,	O
+severer	O
+disease	O
+assessment	O
+on	O
+admission	O
+,	O
+high	O
+levels	O
+of	O
+neutrophil	B-ANAT
+,	O
+aspartate	B-PRGE
+aminotransferase	I-PRGE
+(	O
+AST	B-PRGE
+),	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+lower	O
+levels	O
+of	O
+platelets	B-ANAT
+and	O
+albumin	B-PRGE
+,	O
+and	O
+higher	O
+incidence	O
+of	O
+bilateral	B-DISO
+pneumonia	I-DISO
+and	O
+pleural	B-DISO
+effusion	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+some	O
+global	O
+cases	O
+of	O
+2019	O
+novel	O
+coronavirus	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+pneumonia	B-DISO
+have	O
+been	O
+caused	O
+by	O
+second	O
+-	O
+or	O
+third	O
+-	O
+generation	O
+transmission	O
+of	O
+the	O
+viral	B-DISO
+infection	I-DISO
+,	O
+resulting	O
+in	O
+no	O
+traceable	O
+epidemiological	O
+history	O
+.	O
+
+Similar	O
+to	O
+Miller	O
+M6	O
+,	O
+virulent	O
+Purdue	O
+and	O
+China	O
+strain	O
+TS	O
+,	O
+in	O
+S	O
+gene	O
+the	O
+JS2012	O
+maintained	O
+genetic	O
+integrity	O
+and	O
+the	O
+characteristics	O
+of	O
+the	O
+TGEV	B-SPEC
+virulent	O
+strains	O
+.	O
+
+Our	O
+findings	O
+provide	O
+valuable	O
+information	O
+about	O
+genetic	O
+diversity	O
+and	O
+infection	O
+mechanism	O
+of	O
+the	O
+coronavirus	B-SPEC
+family	B-SPEC
+.	O
+
+There	O
+is	O
+,	O
+however	O
+,	O
+not	O
+yet	O
+sufficient	O
+evidence	O
+to	O
+support	O
+the	O
+association	O
+between	O
+hypertension	B-DISO
+and	O
+mortality	O
+as	O
+similar	O
+prevalence	O
+of	O
+hypertension	B-DISO
+was	O
+also	O
+observed	O
+in	O
+the	O
+Hubei	O
+population	O
+.	O
+
+Those	O
+patients	O
+should	O
+now	O
+be	O
+tested	O
+for	O
+both	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+simultaneously	O
+,	O
+and	O
+with	O
+the	O
+continuing	O
+wide	O
+international	O
+spread	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+the	O
+travel	O
+history	O
+to	O
+China	O
+in	O
+the	O
+last	O
+14	O
+days	O
+will	O
+be	O
+of	O
+less	O
+significance	O
+.	O
+
+We	O
+hope	O
+that	O
+this	O
+article	O
+will	O
+serve	O
+as	O
+a	O
+start	O
+for	O
+further	O
+research	O
+into	O
+the	O
+ocular	O
+implications	O
+of	O
+human	B-SPEC
+CoV	O
+infections	B-DISO
+.	O
+
+Most	O
+patients	O
+received	O
+antiviral	B-CHED
+therapy	O
+(	O
+66	O
+[	O
+98	O
+.	O
+5	O
+%]	O
+of	O
+67	O
+patients	O
+)	O
+and	O
+antibiotic	B-CHED
+therapy	O
+(	O
+66	O
+[	O
+98	O
+.	O
+5	O
+%]	O
+of	O
+67	O
+patients	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+first	O
+detected	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+has	O
+spread	O
+rapidly	O
+since	O
+December	O
+2019	O
+,	O
+causing	O
+more	O
+than	O
+100	O
+,	O
+000	O
+confirmed	O
+infections	B-DISO
+and	O
+4000	O
+fatalities	O
+(	O
+as	O
+of	O
+10	O
+March	O
+2020	O
+).	O
+
+Here	O
+,	O
+we	O
+explore	O
+how	O
+seasonal	O
+variation	O
+in	O
+transmissibility	O
+could	O
+modulate	O
+a	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+pandemic	O
+.	O
+
+Contacts	O
+were	O
+people	O
+with	O
+exposure	O
+to	O
+a	O
+patient	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+on	O
+or	O
+after	O
+the	O
+patient	O
+'	O
+s	O
+symptom	B-DISO
+onset	O
+date	O
+.	O
+
+These	O
+43	O
+persons	O
+under	O
+investigation	O
+and	O
+all	O
+32	O
+asymptomatic	O
+health	O
+-	O
+care	O
+personnel	O
+tested	O
+negative	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+There	O
+is	O
+now	O
+grave	O
+concern	O
+regarding	O
+the	O
+Italian	O
+national	O
+health	O
+system	O
+'	O
+s	O
+capacity	O
+to	O
+effectively	O
+respond	O
+to	O
+the	O
+needs	O
+of	O
+patients	O
+who	O
+are	O
+infected	O
+and	O
+require	O
+intensive	O
+care	O
+for	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Anesthetic	O
+Management	O
+of	O
+Patients	O
+With	O
+Suspected	O
+or	O
+Confirmed	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+Infection	I-DISO
+During	O
+Emergency	O
+Procedures	O
+.	O
+
+Twenty	O
+-	O
+five	O
+(	O
+68	O
+%)	O
+patients	O
+presented	O
+with	O
+lymphopenia	B-DISO
+,	O
+and	O
+23	O
+(	O
+62	O
+%)	O
+patients	O
+exhibited	O
+multiple	O
+mottling	O
+and	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+on	O
+computed	O
+tomography	O
+scanning	O
+.	O
+
+The	O
+present	O
+study	O
+indicates	O
+that	O
+COVID	B-DISO
+19	I-DISO
+-	O
+specific	O
+guidelines	O
+for	O
+emergency	B-DISO
+procedures	O
+for	O
+patients	O
+with	O
+confirmed	O
+or	O
+suspected	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+may	O
+effectively	O
+prevent	O
+cross	O
+-	O
+infection	B-DISO
+in	O
+the	O
+operating	O
+room	O
+.	O
+
+Moreover	O
+,	O
+two	O
+consecutive	O
+slow	O
+codons	O
+(	O
+slow	O
+di	O
+-	O
+codons	O
+)	O
+lead	O
+to	O
+a	O
+much	O
+slower	O
+translation	B-PROC
+rate	O
+.	O
+
+Comparison	O
+of	O
+human	B-SPEC
+-	O
+specific	O
+slow	O
+codon	O
+and	O
+slow	O
+di	O
+-	O
+codon	O
+compositions	O
+in	O
+the	O
+genomes	O
+of	O
+590	O
+coronaviruses	O
+infect	O
+humans	B-SPEC
+revealed	O
+that	O
+the	O
+protein	B-CHED
+synthetic	O
+rates	O
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+and	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+-	I-SPEC
+related	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+may	O
+be	O
+much	O
+faster	O
+than	O
+other	O
+coronaviruses	O
+infect	O
+humans	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigate	O
+whether	O
+platelet	B-ANAT
+count	O
+could	O
+differentiate	O
+between	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+with	O
+or	O
+without	O
+severe	O
+disease	O
+.	O
+
+Some	O
+13	O
+.	O
+9	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+6	O
+.	O
+2	O
+-	O
+21	O
+.	O
+5	O
+%)	O
+of	O
+hospitalized	O
+patients	O
+had	O
+fatal	B-DISO
+outcomes	I-DISO
+(	O
+case	O
+fatality	O
+rate	O
+,	O
+CFR	O
+).	O
+
+ICU	O
+was	O
+required	O
+for	O
+approximately	O
+20	O
+%	O
+of	O
+polymorbid	O
+,	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infected	O
+patients	O
+and	O
+hospitalization	O
+was	O
+associated	O
+with	O
+a	O
+CFR	O
+of	O
+>	O
+13	O
+%.	O
+
+We	O
+investigated	O
+the	O
+presence	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+19	O
+in	O
+asymptomatic	O
+carriers	O
+by	O
+testing	O
+all	O
+repatriated	O
+patients	O
+within	O
+the	O
+first	O
+24	O
+h	O
+of	O
+their	O
+arrival	O
+in	O
+France	O
+and	O
+at	O
+day	O
+5	O
+.	O
+
+Viral	O
+RNA	O
+was	O
+extracted	O
+from	O
+pooled	O
+nasal	B-ANAT
+and	O
+oropharyngeal	B-ANAT
+swab	O
+fluids	B-ANAT
+or	O
+sputum	B-ANAT
+in	O
+the	O
+absence	O
+of	O
+nasal	B-ANAT
+/	O
+oropharyngeal	B-ANAT
+swabs	O
+.	O
+
+This	O
+activity	O
+is	O
+conserved	O
+on	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+Cov	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+thus	O
+placing	O
+teicoplanin	O
+as	O
+a	O
+potential	O
+treatment	O
+for	O
+patients	O
+with	O
+this	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Substantial	O
+undocumented	O
+infection	B-DISO
+facilitates	O
+the	O
+rapid	O
+dissemination	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	O
+-	O
+CoV2	O
+).	O
+
+Here	O
+we	O
+use	O
+observations	O
+of	O
+reported	O
+infection	B-DISO
+within	O
+China	O
+,	O
+in	O
+conjunction	O
+with	O
+mobility	O
+data	O
+,	O
+a	O
+networked	O
+dynamic	O
+metapopulation	O
+model	O
+and	O
+Bayesian	O
+inference	O
+,	O
+to	O
+infer	O
+critical	O
+epidemiological	O
+characteristics	O
+associated	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV2	I-PRGE
+,	O
+including	O
+the	O
+fraction	O
+of	O
+undocumented	O
+infections	B-DISO
+and	O
+their	O
+contagiousness	O
+.	O
+
+GA	O
+was	O
+also	O
+reported	O
+to	O
+have	O
+activity	O
+against	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Corona	O
+Virus	B-PROC
+Disease	I-PROC
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+originated	O
+in	O
+Wuhan	O
+
+Limited	O
+data	O
+are	O
+available	O
+for	O
+children	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+especially	O
+for	O
+infected	O
+infants	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+epidemic	O
+caused	O
+by	O
+SARS	B-DISO
+-	I-DISO
+Coronavirus	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+has	O
+spread	O
+unexpectedly	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+,	O
+China	O
+since	O
+December	O
+2019	O
+.	O
+
+We	O
+study	O
+epidemiological	O
+and	O
+clinical	O
+outcome	O
+of	O
+55	O
+asymptomatic	O
+carriers	O
+who	O
+were	O
+laboratory	O
+-	O
+confirmed	O
+positive	O
+for	O
+the	O
+SARS	B-SPEC
+-	I-SPEC
+Coronavirus	I-SPEC
+-	I-SPEC
+2	I-SPEC
+by	O
+testing	O
+the	O
+nucleic	B-CHED
+acid	I-CHED
+of	O
+the	O
+pharyngeal	B-ANAT
+swab	O
+samples	O
+.	O
+
+The	O
+two	O
+confirmed	O
+children	O
+only	O
+presented	O
+with	O
+mild	O
+respiratory	O
+or	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+.	O
+
+There	O
+were	O
+no	O
+deaths	B-PROC
+or	O
+serious	O
+neonatal	B-DISO
+asphyxia	I-DISO
+events	O
+.	O
+
+Both	O
+epidural	B-ANAT
+and	O
+general	B-PROC
+anesthesia	I-PROC
+were	O
+safely	O
+used	O
+for	O
+Cesarean	O
+delivery	O
+in	O
+the	O
+parturients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Proper	O
+patient	O
+transfer	O
+,	O
+medical	O
+staff	O
+access	O
+procedures	O
+,	O
+and	O
+effective	O
+biosafety	O
+precautions	O
+are	O
+important	O
+to	O
+protect	O
+medical	O
+staff	O
+from	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+positive	O
+impact	O
+of	O
+lockdown	O
+in	O
+Wuhan	O
+on	O
+containing	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+in	O
+China	O
+.	O
+
+In	O
+particular	O
+within	O
+the	O
+city	O
+of	O
+Ningbo	O
+,	O
+60	O
+.	O
+52	O
+%	O
+cases	O
+can	O
+be	O
+traced	O
+back	B-ANAT
+to	O
+an	O
+event	O
+held	O
+in	O
+a	O
+temple	B-ANAT
+.	O
+
+In	O
+this	O
+work	O
+,	O
+we	O
+searched	O
+the	O
+homologous	O
+templates	O
+of	O
+all	O
+nonstructural	O
+and	O
+structural	O
+proteins	B-CHED
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+Among	O
+the	O
+nonstructural	O
+proteins	B-CHED
+,	O
+the	O
+leader	O
+protein	B-CHED
+(	O
+nsp1	B-PRGE
+),	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+nsp3	B-PRGE
+),	O
+the	O
+nsp4	B-PRGE
+,	O
+the	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+nsp5	B-PRGE
+),	O
+the	O
+nsp7	O
+,	O
+the	O
+nsp8	O
+,	O
+the	O
+nsp9	O
+,	O
+the	O
+nsp10	O
+,	O
+the	O
+RNA	B-ENZY
+-	I-ENZY
+directed	I-ENZY
+RNA	I-ENZY
+polymerase	I-ENZY
+(	O
+nsp12	O
+),	O
+the	O
+helicase	B-PRGE
+(	O
+nsp13	O
+),	O
+the	O
+guanine	B-PRGE
+-	I-PRGE
+N7	I-PRGE
+methyltransferase	I-PRGE
+(	O
+nsp14	O
+),	O
+the	O
+uridylate	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+endoribonuclease	I-PRGE
+(	O
+nsp15	O
+),	O
+the	O
+2	B-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+methyltransferase	I-PRGE
+(	O
+nsp16	O
+),	O
+and	O
+the	O
+ORF7a	B-PRGE
+protein	I-PRGE
+could	O
+be	O
+built	O
+on	O
+the	O
+basis	O
+of	O
+homology	O
+templates	O
+.	O
+
+It	O
+is	O
+believed	O
+that	O
+these	O
+proteins	B-CHED
+should	O
+be	O
+useful	O
+for	O
+further	O
+structure	O
+-	O
+based	O
+virtual	O
+screening	O
+and	O
+related	O
+computer	O
+-	O
+aided	O
+drug	O
+development	B-PROC
+and	O
+vaccine	O
+design	O
+.	O
+
+In	O
+severe	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+cases	O
+,	O
+the	O
+number	O
+of	O
+platelets	B-ANAT
+,	O
+their	O
+dynamic	O
+changes	O
+during	O
+the	O
+treatment	O
+,	O
+platelet	B-ANAT
+-	O
+to	O
+-	O
+lymphocyte	B-ANAT
+ratio	O
+(	O
+PLR	O
+)	O
+were	O
+a	O
+concern	O
+.	O
+
+Demographic	O
+,	O
+clinical	O
+,	O
+blood	B-ANAT
+routine	O
+results	O
+,	O
+other	O
+laborotary	O
+results	O
+and	O
+treatment	O
+date	O
+were	O
+collected	O
+and	O
+analyzed	O
+.	O
+
+The	O
+patient	O
+with	O
+markedly	O
+elevated	O
+platelets	B-ANAT
+and	O
+longer	O
+average	O
+hospitalization	O
+day	O
+may	O
+be	O
+related	O
+to	O
+the	O
+cytokine	B-DISO
+storm	I-DISO
+.	O
+
+The	O
+PLR	O
+of	O
+patients	O
+means	O
+the	O
+degree	O
+of	O
+cytokine	B-DISO
+storm	I-DISO
+,	O
+which	O
+might	O
+provide	O
+a	O
+new	O
+indicator	B-CHED
+in	O
+the	O
+monitoring	O
+in	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+His	O
+overall	O
+clinical	O
+characteristics	O
+(	O
+symptoms	O
+,	O
+laboratory	O
+examinations	O
+,	O
+and	O
+chest	B-ANAT
+CT	O
+)	O
+were	O
+similar	O
+to	O
+those	O
+of	O
+non	O
+-	O
+transplanted	B-ANAT
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+.	O
+
+This	O
+report	O
+provided	O
+evidence	O
+of	O
+low	O
+risk	O
+of	O
+intrauterine	B-DISO
+infection	I-DISO
+by	O
+vertical	B-DISO
+transmission	I-DISO
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+continues	O
+to	O
+drive	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+after	O
+severe	O
+trauma	O
+.	O
+
+NETs	O
+include	O
+a	O
+DNA	O
+backbone	B-ANAT
+coated	O
+with	O
+cytoplasmic	B-COMP
+proteins	B-CHED
+,	O
+which	O
+drive	O
+pulmonary	B-ANAT
+cytotoxic	O
+effects	O
+.	O
+
+Randomization	O
+of	O
+250	O
+patients	O
+per	O
+treatment	O
+arm	B-ANAT
+will	O
+be	O
+carried	O
+out	O
+through	O
+a	O
+secure	O
+,	O
+web	B-DISO
+-	O
+based	O
+system	O
+.	O
+
+Participant	O
+recruitment	B-DISO
+began	O
+in	O
+March	O
+2019	O
+.	O
+
+As	O
+of	O
+31	O
+January	O
+2020	O
+,	O
+this	O
+epidemic	O
+had	O
+spread	O
+to	O
+19	O
+countries	O
+with	O
+11	O
+791	O
+confirmed	O
+cases	O
+,	O
+including	O
+213	O
+deaths	B-PROC
+.	O
+
+Studies	O
+thus	O
+far	O
+have	O
+shown	O
+that	O
+the	O
+virus	B-SPEC
+'	O
+origination	O
+is	O
+in	O
+connection	O
+to	O
+a	O
+seafood	O
+market	O
+in	O
+Wuhan	O
+,	O
+but	O
+specific	O
+animal	B-SPEC
+associations	O
+have	O
+not	O
+been	O
+confirmed	O
+.	O
+
+We	O
+conducted	O
+statistical	O
+modelling	O
+to	O
+derive	O
+the	O
+delay	O
+-	O
+adjusted	O
+asymptomatic	O
+proportion	O
+of	O
+infections	B-DISO
+,	O
+along	O
+with	O
+the	O
+infections	B-DISO
+'	O
+timeline	O
+.	O
+
+Most	O
+infections	B-DISO
+occurred	O
+before	O
+the	O
+quarantine	O
+start	O
+.	O
+
+This	O
+includes	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+which	O
+has	O
+high	O
+sequence	O
+similarity	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+is	O
+the	O
+best	O
+-	O
+characterized	O
+coronavirus	B-SPEC
+in	O
+terms	O
+of	O
+epitope	B-CHED
+responses	O
+.	O
+
+These	O
+predictions	O
+can	O
+facilitate	O
+effective	O
+vaccine	O
+design	O
+against	O
+this	O
+virus	B-SPEC
+of	O
+high	O
+priority	O
+.	O
+
+TITLE	O
+:	O
+The	O
+cancellation	O
+of	O
+mass	O
+gatherings	O
+(	O
+MGs	B-DISO
+)?	O
+
+Decision	O
+making	O
+in	O
+the	O
+time	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Poor	O
+awareness	O
+for	O
+the	O
+disease	O
+by	O
+patients	O
+and	O
+physicians	O
+,	O
+high	O
+prevalence	O
+of	O
+the	O
+post	O
+-	O
+PE	O
+syndrome	B-DISO
+(	O
+
+ABSTRACT	O
+:	O
+Nonresolving	O
+inflammation	B-DISO
+,	O
+a	O
+hallmark	O
+of	O
+underlying	O
+severe	O
+inflammatory	O
+processes	O
+such	O
+as	O
+sepsis	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+is	O
+a	O
+major	O
+cause	O
+of	O
+admission	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+and	O
+high	O
+mortality	O
+rates	O
+.	O
+
+In	O
+addition	O
+,	O
+active	O
+adjuvant	B-CHED
+therapy	O
+is	O
+also	O
+important	O
+,	O
+such	O
+as	O
+correcting	O
+coagulation	B-PROC
+dysfunction	O
+,	O
+providing	O
+proper	O
+nutritional	O
+support	O
+,	O
+accurate	O
+volume	O
+control	O
+,	O
+and	O
+safe	O
+individualized	O
+blood	O
+glucose	B-CHED
+monitoring	O
+and	O
+control	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+safety	O
+,	O
+feasibility	O
+,	O
+and	O
+possible	O
+adverse	O
+events	O
+of	O
+single	O
+-	O
+dose	O
+human	O
+umbilical	B-ANAT
+cord	I-ANAT
+-	O
+derived	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+in	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+child	O
+evolved	O
+to	O
+refractory	O
+hypoxemia	O
+and	O
+hypercapnia	B-DISO
+,	O
+requiring	O
+high	O
+parameters	O
+of	O
+mechanical	O
+pulmonary	B-PROC
+ventilation	I-PROC
+and	O
+use	O
+of	O
+vasoactive	O
+agents	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Trial	O
+of	O
+Lopinavir	O
+-	O
+Ritonavir	B-CHED
+in	O
+Adults	O
+Hospitalized	O
+with	O
+Severe	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+This	O
+is	O
+particularly	O
+needed	O
+for	O
+the	O
+early	O
+detection	B-PROC
+of	I-PROC
+virus	I-PROC
+infections	B-DISO
+as	O
+now	O
+required	O
+for	O
+Corona	B-CHED
+diagnostic	O
+.	O
+
+In	O
+situ	O
+mRNA	B-CHED
+analysis	O
+,	O
+however	O
+,	O
+is	O
+a	O
+formidable	O
+challenge	O
+and	O
+currently	O
+performed	O
+with	O
+sets	O
+of	O
+single	O
+-	O
+fluorophore	O
+containing	O
+oligonucleotide	B-CHED
+probes	O
+that	O
+hybridize	O
+to	O
+the	O
+mRNA	B-CHED
+at	O
+question	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+implement	O
+the	O
+central	O
+government	O
+'	O
+s	O
+decision	O
+-	O
+making	O
+deployment	O
+and	O
+defeat	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+as	O
+soon	O
+as	O
+possible	O
+,	O
+we	O
+had	O
+focused	O
+on	O
+the	O
+key	O
+points	O
+in	O
+the	O
+clinical	O
+work	O
+of	O
+general	O
+surgery	O
+according	O
+to	O
+latest	O
+relevant	O
+guidelines	O
+,	O
+literature	O
+and	O
+experience	O
+in	O
+epidemic	O
+prevention	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+Guided	O
+Mutagenesis	B-PROC
+Alters	O
+Deubiquitinating	B-PROC
+Activity	O
+and	O
+Attenuates	O
+Pathogenesis	B-DISO
+of	O
+a	O
+Murine	O
+Coronavirus	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+express	O
+a	O
+multifunctional	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+,	O
+termed	O
+PLP2	B-PRGE
+.	O
+
+Here	O
+,	O
+we	O
+evaluated	O
+the	O
+host	B-COMP
+transcriptional	B-PROC
+response	O
+to	O
+infection	B-DISO
+with	O
+murine	B-SPEC
+coronaviruses	O
+encoding	O
+independent	O
+mutations	O
+in	O
+one	O
+of	O
+two	O
+different	O
+viral	O
+antagonists	B-CHED
+:	O
+the	O
+deubiquitinase	B-PROC
+(	O
+DUB	B-PRGE
+)	O
+within	O
+nonstructural	O
+protein	B-CHED
+3	O
+or	O
+the	O
+endoribonuclease	O
+(	O
+EndoU	O
+)	O
+within	O
+nonstructural	O
+protein	B-CHED
+15	O
+.	O
+
+We	O
+highlight	O
+the	O
+current	O
+state	O
+of	O
+knowledge	O
+of	O
+coronavirus	B-SPEC
+biology	O
+while	O
+answering	O
+questions	O
+concerning	O
+the	O
+current	O
+outbreak	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Patients	O
+with	O
+myelodysplastic	B-DISO
+syndrome	I-DISO
+/	O
+myeloproliferative	B-DISO
+neoplasm	I-DISO
+(	O
+MDS	B-DISO
+/	O
+MPN	O
+)	O
+are	O
+often	O
+asymptomatic	O
+and	O
+thus	O
+can	O
+remain	O
+undiagnosed	O
+until	O
+they	O
+become	O
+symptomatic	O
+due	O
+to	O
+progression	O
+to	O
+the	O
+accelerated	O
+phase	O
+(	O
+AP	O
+)	O
+or	O
+transformation	B-DISO
+to	O
+acute	B-DISO
+leukemia	I-DISO
+(	O
+leukemic	O
+transformation	B-DISO
+;	O
+LT	O
+).	O
+
+The	O
+total	O
+area	O
+consists	O
+of	O
+three	O
+zones	O
+crowded	O
+zone	O
+,	O
+mid	O
+zone	O
+and	O
+uncrowded	O
+zone	O
+,	O
+with	O
+different	O
+infection	B-DISO
+probabilities	O
+characterized	O
+by	O
+the	O
+number	O
+of	O
+people	O
+gathered	O
+there	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+the	O
+stagnant	O
+growth	O
+of	O
+Infected	O
+can	O
+be	O
+observed	O
+when	O
+the	O
+time	O
+spent	O
+in	O
+the	O
+crowded	O
+zone	O
+is	O
+reduced	O
+to	O
+4	O
+hours	O
+,	O
+and	O
+the	O
+growth	B-PROC
+number	O
+of	O
+Infected	O
+will	O
+decrease	O
+and	O
+the	O
+spread	O
+of	O
+the	O
+infection	B-DISO
+will	O
+subside	O
+gradually	O
+if	O
+the	O
+time	O
+spent	O
+in	O
+the	O
+crowded	O
+zone	O
+is	O
+further	O
+cut	O
+to	O
+2	O
+hours	O
+.	O
+
+This	O
+means	O
+that	O
+AI	O
+-	O
+driven	O
+tools	O
+help	O
+identify	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreaks	O
+as	O
+well	O
+as	O
+forecast	O
+their	O
+nature	O
+of	O
+spread	O
+across	O
+the	O
+globe	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	O
+-	O
+19	O
+)	O
+caused	O
+by	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+is	O
+an	O
+ongoing	O
+global	O
+health	O
+emergency	B-DISO
+.	O
+
+This	O
+modified	O
+3I	O
+Tool	O
+will	O
+assist	O
+emergency	B-DISO
+and	O
+primary	O
+care	O
+clinicians	O
+,	O
+as	O
+well	O
+as	O
+out	O
+-	O
+of	O
+-	O
+hospital	O
+providers	O
+,	O
+in	O
+effectively	O
+managing	O
+persons	O
+with	O
+suspected	O
+or	O
+confirmed	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+
+Conclusion	O
+The	O
+extent	O
+of	O
+lung	B-ANAT
+abnormalities	O
+on	O
+CT	O
+peaked	O
+during	O
+illness	O
+days	O
+6	O
+-	O
+11	O
+.	O
+
+Materials	O
+and	O
+Methods	O
+In	O
+this	O
+retrospective	O
+and	O
+multi	O
+-	O
+center	O
+study	O
+,	O
+a	O
+deep	O
+learning	B-PROC
+model	O
+,	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+detection	O
+neural	B-PROC
+network	I-PROC
+(	O
+COVNet	O
+),	O
+was	O
+developed	O
+to	O
+extract	O
+visual	O
+features	O
+from	O
+volumetric	O
+chest	B-ANAT
+CT	O
+exams	O
+for	O
+the	O
+detection	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Conclusions	O
+A	O
+deep	O
+learning	B-PROC
+model	O
+can	O
+accurately	O
+detect	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+differentiate	O
+it	O
+from	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+and	O
+other	O
+lung	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+disease	O
+2019	O
+,	O
+abbreviated	O
+to	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+sustained	O
+by	O
+the	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+),	O
+is	O
+the	O
+latest	O
+biological	O
+hazard	O
+to	O
+assume	O
+the	O
+relevance	O
+of	O
+insidious	O
+worldwide	O
+threat	O
+.	O
+
+He	O
+said	O
+that	O
+the	O
+WHO	O
+is	O
+""""	O
+deeply	O
+concerned	O
+both	O
+by	O
+the	O
+alarming	O
+levels	O
+of	O
+spread	O
+and	O
+severity	O
+and	O
+by	O
+the	O
+alarming	O
+levels	O
+of	O
+inaction	O
+","""	O
+and	O
+he	O
+called	O
+on	O
+countries	O
+to	O
+take	O
+action	O
+now	O
+to	O
+contain	O
+the	O
+virus	B-SPEC
+.	O
+
+Here	O
+we	O
+review	O
+strategies	O
+that	O
+could	O
+help	O
+stem	B-ANAT
+the	O
+advance	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+COV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+epidemic	O
+.	O
+
+This	O
+report	O
+analyzes	O
+the	O
+first	O
+100	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+in	O
+Singapore	O
+to	O
+determine	O
+the	O
+effectiveness	O
+of	O
+the	O
+surveillance	O
+and	O
+containment	O
+measures	O
+.	O
+
+Testing	O
+on	O
+its	O
+own	O
+will	O
+not	O
+stop	O
+the	O
+spread	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+Misdiagnosed	O
+infection	B-DISO
+can	O
+progress	O
+to	O
+a	O
+wide	O
+range	O
+of	O
+life	O
+-	O
+threatening	O
+pathologies	O
+,	O
+including	O
+severe	B-DISO
+anemia	I-DISO
+and	O
+cerebral	B-DISO
+malaria	B-PATH
+which	O
+can	O
+lead	O
+to	O
+death	B-PROC
+even	O
+few	O
+days	O
+after	O
+first	O
+symptoms	O
+appearance	O
+.	O
+
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+RT	O
+-	O
+PCR	O
+came	O
+back	B-ANAT
+positive	O
+24	O
+hours	O
+later	O
+.	O
+
+Although	O
+respiratory	O
+viral	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+is	O
+thought	O
+to	O
+be	O
+relatively	O
+uncommon	O
+in	O
+adults	O
+,	O
+this	O
+case	O
+reflects	O
+that	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+testing	O
+algorithms	O
+that	O
+exclude	O
+patients	O
+who	O
+test	O
+positive	O
+for	O
+routine	O
+viral	O
+pathogens	O
+may	O
+miss	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+co	O
+-	O
+infected	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+December	O
+2019	O
+,	O
+a	O
+new	O
+outbreak	O
+of	O
+corona	B-DISO
+virus	B-PROC
+disease	I-PROC
+2019	I-DISO
+began	O
+to	O
+occur	O
+.	O
+
+(	O
+2	O
+)	O
+Colonoscopy	O
+examination	O
+may	O
+cause	O
+cross	B-DISO
+infection	I-DISO
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+to	O
+patients	O
+and	O
+doctors	O
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+Australia	O
+:	O
+Epidemiology	O
+Report	O
+7	O
+(	O
+Reporting	O
+week	O
+ending	O
+19	O
+:	O
+00	O
+AEDT	O
+14	O
+March	O
+2020	O
+).	O
+
+TITLE	O
+:	O
+Investigation	O
+of	O
+three	O
+clusters	B-CHED
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Singapore	O
+:	O
+implications	O
+for	O
+surveillance	O
+and	O
+response	O
+measures	O
+.	O
+
+ABSTRACT	O
+:	O
+Three	O
+clusters	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+linked	O
+to	O
+a	O
+tour	O
+group	O
+from	O
+China	O
+,	O
+a	O
+company	O
+conference	O
+,	O
+and	O
+a	O
+church	O
+were	O
+identified	O
+in	O
+Singapore	O
+in	O
+February	O
+,	O
+2020	O
+.	O
+
+We	O
+reported	O
+the	O
+median	O
+(	O
+IQR	O
+)	O
+incubation	O
+period	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+The	O
+CT	O
+manifestations	O
+and	O
+clinical	O
+data	O
+of	O
+73	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+retrospectively	O
+collected	O
+in	O
+6	O
+hospitals	O
+from	O
+Jan	O
+21	O
+to	O
+Feb	O
+3	O
+,	O
+2020	O
+.	O
+
+In	O
+the	O
+21	O
+patients	O
+(	O
+29	O
+%)	O
+with	O
+severe	O
+type	O
+,	O
+extensive	O
+GGO	O
+and	O
+pulmonary	B-DISO
+consolidation	I-DISO
+were	O
+found	O
+in	O
+16	O
+cases	O
+(	O
+16	O
+/	O
+21	O
+,	O
+76	O
+%)	O
+and	O
+5	O
+cases	O
+(	O
+24	O
+%),	O
+respectively	O
+.	O
+
+On	O
+the	O
+resolutive	O
+phase	O
+of	O
+the	O
+disease	O
+,	O
+CT	O
+abnormalities	O
+showed	O
+complete	O
+resolution	O
+,	O
+or	O
+demonstrated	O
+residual	O
+linear	O
+opacities	B-DISO
+.	O
+
+Traditional	O
+respiratory	O
+support	O
+consists	O
+mainly	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+but	O
+the	O
+prognosis	O
+of	O
+this	O
+condition	B-DISO
+is	O
+still	O
+poor	O
+.	O
+
+In	O
+diagnosis	O
+,	O
+chest	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+manifestations	O
+can	O
+supplement	O
+parts	O
+of	O
+limitations	O
+of	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assay	O
+.	O
+
+•	O
+Emerging	O
+atypical	O
+CT	O
+manifestations	O
+,	O
+including	O
+airway	B-ANAT
+changes	O
+,	O
+pleural	O
+changes	O
+,	O
+fibrosis	O
+,	O
+nodules	B-DISO
+,	O
+etc	O
+.,	O
+were	O
+demonstrated	O
+in	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+.	O
+
+Laboratory	O
+findings	O
+revealed	O
+normal	O
+or	O
+increased	O
+whole	B-ANAT
+blood	I-ANAT
+counts	O
+(	O
+7	O
+/	O
+8	O
+),	O
+increased	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+procalcitonin	O
+and	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+6	O
+/	O
+8	O
+),	O
+and	O
+abnormal	B-DISO
+liver	I-DISO
+function	I-DISO
+(	O
+4	O
+/	O
+8	O
+).	O
+
+ABSTRACT	O
+:	O
+With	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+pandemic	O
+spreading	O
+quickly	O
+in	O
+USA	O
+and	O
+the	O
+world	O
+
+The	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+is	O
+a	O
+novel	O
+virus	B-SPEC
+so	O
+the	O
+majority	O
+of	O
+world	O
+'	O
+s	O
+population	O
+does	O
+not	O
+have	O
+prior	O
+immunity	B-PROC
+to	O
+it	O
+.	O
+
+ABSTRACT	O
+:	O
+BACKGROUND	O
+From	O
+the	O
+end	O
+of	O
+December	O
+2019	O
+,	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+began	O
+to	O
+spread	O
+in	O
+central	O
+China	O
+.	O
+
+Anxiety	O
+was	O
+assessed	O
+using	O
+the	O
+Self	O
+-	O
+Rating	O
+Anxiety	O
+Scale	O
+(	O
+SAS	O
+)	O
+questionnaire	O
+,	O
+stress	O
+was	O
+assessed	O
+using	O
+the	O
+Stanford	O
+Acute	B-DISO
+Stress	I-DISO
+Reaction	I-DISO
+(	O
+SASR	O
+)	O
+questionnaire	O
+,	O
+and	O
+sleep	O
+was	O
+assessed	O
+using	O
+the	O
+Pittsburgh	O
+Sleep	B-PROC
+Quality	O
+Index	O
+(	O
+PSQI	O
+)	O
+questionnaire	O
+.	O
+
+TITLE	O
+:	O
+Prediction	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+3C	O
+-	O
+like	O
+protease	O
+(	O
+3CL	O
+ABSTRACT	O
+:	O
+We	O
+prepared	O
+the	O
+three	O
+-	O
+dimensional	O
+model	O
+of	O
+the	O
+SARS	O
+-	O
+CoV	O
+-	O
+2	O
+(	O
+aka	B-SPEC
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+3C	O
+-	O
+like	O
+protease	O
+(	O
+3CL	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+),	O
+including	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+,	O
+also	O
+known	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+),	O
+lead	O
+global	O
+epidemics	O
+with	O
+high	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+continue	O
+to	O
+pose	O
+a	O
+threat	O
+to	O
+human	B-SPEC
+health	O
+.	O
+
+Healthcare	O
+providers	O
+,	O
+and	O
+particularly	O
+anesthesiologists	O
+,	O
+are	O
+at	O
+the	O
+frontline	O
+of	O
+this	O
+epidemic	O
+,	O
+and	O
+they	O
+need	O
+to	O
+be	O
+aware	O
+of	O
+the	O
+best	O
+available	O
+evidence	O
+to	O
+guide	O
+therapeutic	O
+management	O
+of	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+to	O
+keep	O
+themselves	O
+safe	O
+while	O
+doing	O
+so	O
+.	O
+
+Here	O
+,	O
+the	O
+authors	O
+review	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pathogenesis	B-DISO
+,	O
+presentation	O
+,	O
+diagnosis	O
+,	O
+and	O
+potential	O
+therapeutics	O
+,	O
+with	O
+a	O
+focus	O
+on	O
+management	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+-	O
+associated	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Response	O
+of	O
+Chinese	O
+Anesthesiologists	O
+to	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+Outbreak	O
+.	O
+
+Lung	O
+-	O
+protective	O
+ventilation	O
+,	O
+prone	O
+position	O
+ventilation	O
+,	O
+and	O
+adequate	O
+sedation	B-DISO
+and	O
+analgesia	B-DISO
+are	O
+essential	O
+components	O
+of	O
+ventilation	O
+management	O
+.	O
+
+If	O
+used	O
+in	O
+an	O
+optimal	O
+population	O
+,	O
+PMX	B-PRGE
+-	I-PRGE
+HP	I-PRGE
+may	O
+be	O
+beneficial	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+final	O
+study	O
+cohort	O
+comprised	O
+741	O
+sepsis	B-DISO
+patients	O
+(	O
+92	O
+received	O
+PMX	O
+-	O
+HP	O
+,	O
+625	O
+did	O
+not	O
+).	O
+
+Establish	O
+a	O
+clinically	O
+predictive	O
+score	O
+that	O
+includes	O
+severe	O
+infection	B-DISO
+for	O
+pediatric	O
+patients	O
+to	O
+evaluate	O
+the	O
+risk	O
+of	O
+mortality	O
+in	O
+children	O
+in	O
+order	B-SPEC
+to	O
+improve	O
+poor	O
+outcomes	O
+.	O
+
+Droplet	O
+microfluidic	O
+systems	O
+have	O
+the	O
+capability	O
+to	O
+overcome	O
+such	O
+limitations	O
+by	O
+conducting	B-PROC
+complex	O
+multi	O
+-	O
+step	O
+assays	O
+with	O
+high	O
+reliability	O
+,	O
+resolution	O
+,	O
+and	O
+throughput	O
+in	O
+a	O
+pico	O
+-	O
+liter	O
+volume	O
+water	B-CHED
+-	O
+in	O
+-	O
+oil	O
+emulsion	O
+droplet	O
+format	O
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+a	O
+recommendation	O
+to	O
+examine	O
+the	O
+effect	O
+of	O
+hydroxychloroquine	O
+in	O
+preventing	O
+infection	B-DISO
+and	O
+progression	O
+.	O
+
+The	O
+transition	B-DISO
+from	O
+first	O
+symptoms	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+highly	O
+likely	O
+to	O
+be	O
+due	O
+to	O
+uncontrolled	O
+cytokine	O
+release	B-PATH
+.	O
+
+HCQ	O
+is	O
+likely	O
+to	O
+attenuate	O
+the	O
+severe	O
+progression	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+inhibiting	O
+the	O
+cytokine	B-DISO
+storm	I-DISO
+by	O
+suppressing	O
+T	B-PROC
+cell	I-PROC
+activation	I-PROC
+.	O
+
+This	O
+novel	B-SPEC
+coronavirus	I-SPEC
+has	O
+specifically	O
+high	O
+morbidity	O
+in	O
+the	O
+elderly	O
+and	O
+in	O
+comorbid	O
+populations	O
+.	O
+
+The	O
+most	O
+common	O
+underlying	O
+disease	O
+was	O
+hematologic	B-DISO
+malignancies	I-DISO
+(	O
+47	O
+.	O
+4	O
+%),	O
+followed	O
+by	O
+colorectal	B-PATH
+cancer	I-PATH
+(	O
+21	O
+%)	O
+and	O
+lung	B-DISO
+cancer	B-SPEC
+(	O
+15	O
+.	O
+8	O
+%).	O
+
+CONCLUSIONS	O
+:	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+resulted	O
+in	O
+a	O
+high	O
+case	O
+fatality	O
+rate	O
+in	O
+patients	O
+with	O
+malignancy	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+strain	O
+of	O
+coronavirus	B-SPEC
+is	O
+a	O
+new	O
+one	O
+and	O
+scientists	O
+do	O
+not	O
+yet	O
+know	O
+all	O
+there	O
+is	O
+to	O
+know	O
+about	O
+it	O
+.	O
+
+Immune	B-PROC
+function	I-PROC
+is	O
+a	O
+strong	O
+defense	O
+against	O
+invasive	O
+pathogens	O
+and	O
+there	O
+is	O
+currently	O
+no	O
+specific	O
+antiviral	B-CHED
+drug	I-CHED
+against	O
+the	O
+virus	B-SPEC
+.	O
+
+This	O
+article	O
+reviews	O
+the	O
+immunological	O
+changes	O
+of	O
+coronaviruses	O
+like	O
+SARS	O
+,	O
+MERS	O
+and	O
+other	B-DISO
+viral	I-DISO
+pneumonia	I-DISO
+similar	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+Studies	O
+have	O
+revealed	O
+the	O
+effect	O
+of	O
+temperature	O
+and	O
+humidity	O
+on	O
+respiratory	O
+virus	B-SPEC
+stability	O
+and	O
+transmission	O
+rates	O
+.	O
+
+Newer	O
+laboratory	O
+methods	O
+are	O
+fast	B-FUNC
+,	O
+highly	O
+sensitive	O
+and	O
+specific	O
+,	O
+and	O
+are	O
+gradually	O
+replacing	O
+the	O
+conventional	O
+gold	B-CHED
+standards	O
+.	O
+
+Alternatively	O
+,	O
+repeated	O
+testing	O
+can	O
+be	O
+used	O
+because	O
+over	O
+time	O
+,	O
+the	O
+likelihood	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+being	O
+present	O
+in	O
+the	O
+nasal	B-ANAT
+-	O
+pharynx	B-ANAT
+increases	O
+.	O
+
+One	O
+of	O
+the	O
+five	O
+patients	O
+had	O
+transient	O
+hemostatic	B-PROC
+medication	O
+for	O
+hemoptysis	B-DISO
+.	O
+
+Unlike	O
+common	O
+viral	O
+agents	O
+(	O
+such	O
+as	O
+Adenovirus	B-DISO
+,	O
+Rhinovirus	B-SPEC
+,	O
+Norovirus	B-SPEC
+,	O
+Influenza	B-DISO
+,	O
+Respiratory	B-SPEC
+Syncytial	I-SPEC
+Virus	I-SPEC
+),	O
+Coronaviruses	O
+have	O
+not	O
+shown	O
+to	O
+cause	O
+a	O
+more	O
+severe	O
+disease	O
+in	O
+immunosuppressed	O
+patients	O
+.	O
+
+This	O
+event	O
+documents	O
+early	O
+importation	O
+and	O
+subsequent	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+Europe	O
+.	O
+
+Rapid	O
+clinical	O
+recognition	O
+of	O
+rhabdomyolysis	B-DISO
+symptoms	O
+in	O
+patients	O
+with	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+infection	B-DISO
+can	O
+be	O
+lifesaving	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+first	O
+confirmed	O
+case	O
+of	O
+coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+the	O
+United	O
+States	O
+was	O
+reported	O
+on	O
+January	O
+20	O
+,	O
+2020	O
+,	O
+in	O
+Snohomish	O
+County	O
+,	O
+Washington	O
+.	O
+
+TITLE	O
+:	O
+A	O
+case	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+pneumonia	B-DISO
+returning	O
+from	O
+Macau	O
+in	O
+Taiwan	O
+:	O
+Clinical	O
+course	O
+and	O
+anti	B-PRGE
+-	I-PRGE
+SARS	B-DISO
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+IgG	I-PRGE
+dynamic	O
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+potential	O
+and	O
+severity	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+South	O
+Korea	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+intrinsic	O
+growth	B-PROC
+rate	O
+was	O
+estimated	O
+at	O
+0	O
+.	O
+6	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+6	O
+,	O
+0	O
+.	O
+7	O
+)	O
+and	O
+the	O
+scaling	O
+of	O
+growth	B-PROC
+parameter	O
+was	O
+estimated	O
+at	O
+0	O
+.	O
+8	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+7	O
+,	O
+0	O
+.	O
+8	O
+),	O
+indicating	O
+sub	O
+-	O
+exponential	O
+growth	B-PROC
+dynamics	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+RESULTS	O
+:	O
+We	O
+identified	O
+four	O
+major	O
+clusters	B-CHED
+and	O
+estimated	O
+the	O
+reproduction	B-PROC
+number	O
+at	O
+1	O
+.	O
+5	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+4	O
+-	O
+1	O
+.	O
+6	O
+).	O
+
+TITLE	O
+:	O
+Practical	O
+laboratory	O
+considerations	O
+amidst	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+:	O
+early	O
+experience	O
+from	O
+Singapore	O
+.	O
+
+The	O
+World	O
+Health	O
+Organization	O
+has	O
+classified	O
+this	O
+pandemic	O
+as	O
+a	O
+global	O
+health	O
+emergency	B-DISO
+due	O
+to	O
+its	O
+virulent	O
+nature	O
+of	O
+transmission	O
+,	O
+which	O
+may	O
+lead	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pandemic	O
+caused	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+is	O
+a	O
+global	O
+health	O
+emergency	B-DISO
+.	O
+
+We	O
+here	O
+aim	O
+to	O
+describe	O
+the	O
+time	O
+kinetics	O
+of	O
+various	O
+antibodies	B-COMP
+produced	O
+against	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+and	O
+evaluate	O
+the	O
+potential	O
+of	O
+antibody	B-COMP
+testing	O
+to	O
+diagnose	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+first	O
+coronavirus	B-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+case	O
+was	O
+reported	O
+in	O
+United	O
+States	O
+(	O
+US	O
+),	O
+in	O
+the	O
+state	O
+of	O
+Washington	O
+,	O
+approximately	O
+three	O
+months	O
+after	O
+the	O
+outbreak	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+The	O
+number	O
+of	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+positive	O
+cases	O
+increased	O
+rather	O
+rapidly	O
+and	O
+changed	O
+routine	O
+daily	O
+activities	O
+of	O
+the	O
+community	O
+.	O
+
+This	O
+brief	O
+report	O
+describes	O
+the	O
+response	O
+from	O
+the	O
+hospital	O
+,	O
+the	O
+regional	O
+blood	B-ANAT
+center	O
+,	O
+and	O
+the	O
+hospital	O
+-	O
+based	O
+transfusion	O
+services	O
+to	O
+the	O
+events	O
+that	O
+took	O
+place	O
+in	O
+the	O
+community	O
+during	O
+the	O
+initial	O
+phases	O
+of	O
+the	O
+pandemic	O
+.	O
+
+Blood	B-ANAT
+units	O
+provided	O
+from	O
+blood	B-ANAT
+centers	O
+of	O
+non	O
+-	O
+affected	O
+areas	O
+of	O
+the	O
+country	O
+helped	O
+keep	O
+inventory	O
+stable	O
+and	O
+allow	O
+for	O
+routine	O
+hospital	O
+operations	O
+.	O
+
+The	O
+hospital	O
+-	O
+based	O
+transfusion	O
+service	O
+began	O
+prospective	O
+triaging	O
+of	O
+blood	B-ANAT
+orders	O
+to	O
+monitor	O
+and	O
+prioritize	O
+blood	B-ANAT
+utilization	O
+.	O
+
+Compared	O
+with	O
+the	O
+mild	O
+cases	O
+,	O
+the	O
+severe	O
+cases	O
+had	O
+lower	O
+lymphocyte	B-ANAT
+counts	O
+and	O
+higher	O
+plasma	B-ANAT
+levels	O
+of	O
+Pt	O
+,	O
+APTT	O
+,	O
+D	O
+-	O
+dimer	O
+,	O
+LDH	B-PRGE
+,	O
+PCT	B-DISO
+,	O
+ALB	B-PRGE
+,	O
+CRP	B-PRGE
+,	O
+and	O
+AST	B-PRGE
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+A	O
+Singapore	O
+Orthopedic	O
+resident	O
+'	O
+s	O
+musings	O
+in	O
+the	O
+Emergency	B-DISO
+Department	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+report	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+a	O
+kidney	B-ANAT
+transplant	I-ANAT
+recipient	O
+:	O
+Does	O
+immunosuppression	B-PROC
+alter	O
+the	O
+clinical	O
+presentation	O
+?	O
+
+In	O
+these	O
+high	O
+risk	O
+populations	O
+,	O
+protocols	O
+for	O
+screening	O
+for	O
+SARS	B-DISO
+-	O
+Cov2	O
+may	O
+be	O
+needed	O
+to	O
+be	O
+re	O
+-	O
+evaluated	O
+.	O
+
+Therefore	O
+,	O
+it	O
+is	O
+difficult	O
+to	O
+distinguish	O
+between	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+some	O
+types	O
+of	O
+new	O
+-	O
+onset	O
+ILD	O
+or	O
+other	O
+causes	O
+leading	O
+to	O
+acute	O
+exacerbation	O
+of	O
+ILD	O
+.	O
+
+But	O
+so	O
+far	O
+,	O
+the	O
+pathological	O
+diagnosis	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+has	O
+been	O
+relatively	O
+deficient	O
+：	O
+it	O
+is	O
+still	O
+confined	O
+to	O
+the	O
+pathological	O
+findings	O
+of	O
+punctured	O
+organs	B-ANAT
+,	O
+and	O
+the	O
+majority	O
+of	O
+medical	O
+workers	O
+have	O
+poor	O
+awareness	O
+of	O
+its	O
+pathological	O
+characteristics	O
+.	O
+
+The	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+as	O
+same	O
+as	O
+SARS	B-DISO
+and	O
+MERS	O
+,	O
+is	O
+caused	O
+by	O
+coronaviruses	O
+and	O
+can	O
+cause	O
+viral	B-DISO
+pneumonia	I-DISO
+.	O
+
+32	O
+(	O
+18	O
+%)	O
+countries	O
+had	O
+low	O
+readiness	O
+(	O
+2	O
+[	O
+1	O
+%]	O
+at	O
+level	O
+1	O
+and	O
+30	O
+[	O
+17	O
+%]	O
+at	O
+level	O
+2	O
+),	O
+and	O
+104	O
+(	O
+57	O
+%)	O
+countries	O
+were	O
+operationally	O
+ready	O
+to	O
+prevent	O
+,	O
+detect	O
+,	O
+and	O
+control	O
+an	O
+outbreak	O
+of	O
+a	O
+novel	O
+infectious	B-DISO
+disease	I-DISO
+(	O
+66	O
+[	O
+36	O
+%]	O
+at	O
+level	O
+4	O
+and	O
+38	O
+[	O
+21	O
+%]	O
+at	O
+level	O
+5	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+form	O
+of	O
+Coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+in	O
+Wuhan	O
+has	O
+created	O
+a	O
+confused	B-DISO
+and	O
+rapidly	O
+evolving	O
+situation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+new	O
+coronavirus	O
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+outbreak	O
+from	O
+December	O
+2019	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+,	O
+China	O
+,	O
+has	O
+been	O
+declared	O
+a	O
+global	O
+public	O
+health	O
+emergency	B-DISO
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+may	O
+use	O
+co	O
+-	O
+receptors	O
+/	O
+auxiliary	O
+proteins	B-CHED
+as	O
+ACE2	B-PRGE
+partner	I-PRGE
+to	O
+facilitate	O
+the	O
+virus	B-SPEC
+entry	O
+.	O
+
+TITLE	O
+:	O
+The	O
+characteristics	O
+and	O
+clinical	O
+value	O
+of	O
+chest	B-ANAT
+CT	O
+images	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+main	O
+clinical	O
+manifestations	O
+were	O
+fever	B-PROC
+,	O
+dry	B-DISO
+cough	I-DISO
+,	O
+fatigue	B-DISO
+,	O
+a	O
+little	O
+white	O
+sputum	B-ANAT
+,	O
+or	O
+diarrhoea	B-DISO
+.	O
+
+Research	O
+suggests	O
+remarkable	O
+genomic	O
+resemblance	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+with	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+which	O
+has	O
+a	O
+history	O
+of	O
+a	O
+pandemic	O
+in	O
+2002	O
+.	O
+
+Several	O
+effective	O
+measures	O
+including	O
+restricting	O
+travel	O
+from	O
+China	O
+,	O
+controlling	O
+the	O
+distribution	O
+of	O
+masks	O
+,	O
+extensive	O
+investigation	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+spread	O
+,	O
+and	O
+at	O
+once	O
+daily	O
+press	O
+conference	O
+by	O
+government	O
+to	O
+inform	O
+and	O
+educate	O
+people	O
+were	O
+aggressively	O
+conducted	O
+in	O
+Taiwan	O
+.	O
+
+CNGOF	O
+.]	O
+ABSTRACT	O
+:	O
+A	O
+new	O
+coronavirus	O
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+highlighted	O
+at	O
+the	O
+end	O
+of	O
+2019	O
+in	O
+China	O
+is	O
+spreading	O
+across	O
+all	O
+continents	O
+.	O
+
+Subsequently	O
+,	O
+an	O
+in	O
+-	O
+depth	O
+analysis	O
+of	O
+cases	O
+in	O
+pregnant	O
+women	O
+will	O
+be	O
+necessary	O
+in	O
+order	B-SPEC
+to	O
+improve	O
+knowledge	O
+on	O
+the	O
+subject	O
+.	O
+
+We	O
+hereby	O
+reported	O
+an	O
+asymptomatic	O
+discharged	O
+patient	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+who	O
+was	O
+retested	O
+positive	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+which	O
+arouses	O
+concern	O
+regarding	O
+the	O
+present	O
+discharge	B-ANAT
+standard	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+As	O
+the	O
+clinical	O
+spectrum	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+ranges	O
+widely	O
+from	O
+mild	O
+illness	O
+to	O
+ARDS	B-DISO
+with	O
+a	O
+high	O
+risk	O
+of	O
+mortality	O
+,	O
+there	O
+is	O
+a	O
+need	O
+for	O
+more	O
+research	O
+to	O
+identify	O
+early	O
+markers	O
+of	O
+disease	O
+severity	O
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+and	O
+potential	O
+sources	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+transmission	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+the	O
+infection	B-DISO
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+coronavirus	B-SPEC
+is	O
+quickly	O
+developing	O
+into	O
+a	O
+global	O
+pneumonia	B-DISO
+epidemic	O
+,	O
+the	O
+careful	O
+analysis	O
+of	O
+its	O
+transmission	O
+and	O
+cellular	B-COMP
+mechanisms	O
+is	O
+sorely	O
+needed	O
+.	O
+
+TITLE	O
+:	O
+Spike	O
+protein	B-CHED
+recognition	O
+of	O
+mammalian	B-SPEC
+ACE2	O
+predicts	O
+the	O
+host	B-COMP
+range	O
+and	O
+an	O
+optimized	O
+ACE2	B-PRGE
+for	O
+SARS	O
+-	O
+CoV	O
+-	O
+2	O
+infection	O
+.	O
+
+We	O
+hereby	O
+review	O
+the	O
+peer	O
+-	O
+reviewed	O
+and	O
+preprint	O
+literature	O
+pertaining	O
+to	O
+cardiovascular	B-ANAT
+considerations	O
+related	O
+to	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+highlight	O
+gaps	O
+in	O
+knowledge	O
+that	O
+require	O
+further	O
+study	O
+pertinent	O
+to	O
+patients	O
+,	O
+health	O
+care	O
+workers	O
+,	O
+and	O
+health	O
+systems	O
+.	O
+
+It	O
+is	O
+concluded	O
+that	O
+the	O
+problem	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+is	O
+probably	O
+being	O
+overestimated	O
+,	O
+as	O
+2	O
+.	O
+6	O
+million	O
+people	O
+die	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+each	O
+year	O
+compared	O
+with	O
+less	O
+than	O
+4000	O
+deaths	B-PROC
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+at	O
+the	O
+time	O
+of	O
+writing	O
+.	O
+
+TITLE	O
+:	O
+Drug	O
+targets	O
+for	O
+corona	B-CHED
+virus	B-SPEC
+:	O
+A	O
+systematic	O
+review	O
+.	O
+
+ABSTRACT	O
+:	O
+Up	O
+to	O
+November	O
+2014	O
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+infected	O
+935	O
+individuals	O
+and	O
+killed	O
+371	O
+,	O
+all	O
+originating	O
+in	O
+or	O
+with	O
+links	O
+to	O
+the	O
+Middle	O
+East	O
+.	O
+
+The	O
+mechanisms	O
+of	O
+transmission	O
+of	O
+the	O
+disease	O
+are	O
+not	O
+fully	O
+understood	O
+,	O
+but	O
+MERS	O
+-	O
+CoV	O
+seems	O
+to	O
+sustain	O
+itself	O
+in	O
+the	O
+human	B-SPEC
+population	O
+through	O
+repeated	O
+re	O
+-	O
+introduction	O
+from	O
+a	O
+camel	B-SPEC
+reservoir	O
+and	O
+is	O
+able	O
+to	O
+cause	O
+nosocomial	O
+outbreaks	O
+.	O
+
+Currently	O
+,	O
+there	O
+is	O
+a	O
+lack	O
+of	O
+effective	O
+antiviral	B-CHED
+treatment	O
+options	O
+or	O
+vaccine	O
+available	O
+.	O
+
+This	O
+review	O
+focuses	O
+on	O
+exploring	O
+various	O
+host	B-COMP
+resilience	O
+mechanisms	O
+that	O
+could	O
+be	O
+exploited	O
+for	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+and	O
+other	O
+respiratory	O
+viruses	B-SPEC
+that	O
+cause	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+summarize	O
+the	O
+current	O
+knowledge	O
+on	O
+PTMs	O
+of	O
+CoV	O
+proteins	B-CHED
+,	O
+with	O
+an	O
+emphasis	O
+on	O
+their	O
+impact	O
+on	O
+viral	B-PROC
+replication	I-PROC
+and	O
+pathogenesis	O
+.	O
+
+Recent	O
+studies	O
+have	O
+shown	O
+that	O
+STAT3	B-PRGE
+plays	O
+important	O
+roles	O
+in	O
+viral	B-DISO
+infection	I-DISO
+and	O
+pathogenesis	B-DISO
+.	O
+
+STAT3	B-PRGE
+exhibits	O
+a	O
+proviral	O
+function	O
+in	O
+several	O
+viral	B-DISO
+infections	I-DISO
+,	O
+including	O
+those	O
+of	O
+HBV	B-DISO
+,	O
+HCV	B-SPEC
+,	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+varicella	B-SPEC
+zoster	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+CMV	B-SPEC
+and	O
+measles	B-SPEC
+virus	I-SPEC
+.	O
+
+However	O
+,	O
+in	O
+some	O
+circumstances	O
+,	O
+STAT3	B-PRGE
+has	O
+an	O
+antiviral	B-CHED
+function	O
+in	O
+other	O
+viral	B-DISO
+infections	I-DISO
+,	O
+such	O
+as	O
+enterovirus	B-SPEC
+71	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+.	O
+
+Their	O
+members	O
+include	O
+zoonotic	O
+viruses	B-SPEC
+with	O
+pandemic	O
+potential	O
+where	O
+therapeutic	O
+options	O
+are	O
+currently	O
+limited	O
+.	O
+
+TITLE	O
+:	O
+Renin	B-ENZY
+-	I-ANAT
+angiotensin	B-CHED
+system	I-ANAT
+in	O
+human	B-SPEC
+coronavirus	I-SPEC
+pathogenesis	B-DISO
+.	O
+
+There	O
+were	O
+9	O
+family	B-SPEC
+members	O
+,	O
+including	O
+8	O
+laboratory	O
+-	O
+confirmed	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+and	O
+a	O
+6	O
+-	O
+year	O
+-	O
+old	O
+child	O
+had	O
+no	O
+evidence	O
+of	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Dermatology	O
+staff	O
+participate	O
+in	O
+fight	O
+against	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+China	O
+.	O
+
+At	O
+present	O
+the	O
+epidemic	O
+in	O
+China	O
+has	O
+been	O
+well	O
+controlled	O
+,	O
+but	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+are	O
+currently	O
+spreading	O
+in	O
+many	O
+other	O
+countries	O
+all	O
+over	O
+the	O
+world	O
+.	O
+
+In	O
+this	O
+paper	O
+we	O
+share	O
+our	O
+experiences	O
+in	O
+dealing	O
+with	O
+skin	B-DISO
+diseases	I-DISO
+in	O
+this	O
+special	O
+period	O
+and	O
+hope	O
+to	O
+provide	O
+some	O
+references	O
+for	O
+international	O
+colleagues	O
+in	O
+the	O
+epidemic	O
+situation	O
+.	O
+
+The	O
+two	O
+previously	O
+reported	O
+coronavirus	B-SPEC
+epidemics	O
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+[	O
+SARS	B-DISO
+]	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+[	O
+MERS	O
+])	O
+share	O
+similar	O
+pathogenetic	O
+,	O
+epidemiological	O
+and	O
+clinical	O
+features	O
+as	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+TITLE	O
+:	O
+Prudent	O
+public	O
+health	O
+intervention	O
+strategies	O
+to	O
+control	O
+the	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+transmission	O
+in	O
+India	O
+:	O
+A	O
+mathematical	O
+model	O
+-	O
+based	O
+approach	O
+.	O
+
+In	O
+the	O
+pessimistic	O
+scenario	O
+of	O
+R0	O
+=	O
+4	O
+,	O
+and	O
+asymptomatic	B-DISO
+infections	I-DISO
+being	O
+half	O
+as	O
+infectious	B-DISO
+as	O
+symptomatic	O
+,	O
+this	O
+projected	O
+impact	O
+falls	O
+to	O
+two	O
+per	O
+cent	O
+.	O
+
+Once	O
+the	O
+virus	B-SPEC
+establishes	O
+transmission	O
+within	O
+the	O
+community	O
+,	O
+quarantine	O
+of	O
+symptomatics	O
+may	O
+have	O
+a	O
+meaningful	O
+impact	O
+on	O
+disease	O
+burden	O
+.	O
+
+As	O
+a	O
+public	O
+health	O
+measure	O
+,	O
+health	O
+system	O
+and	O
+community	O
+preparedness	O
+would	O
+be	O
+critical	O
+to	O
+control	O
+any	O
+impending	O
+spread	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+the	O
+country	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+pandemic	O
+has	O
+affected	O
+hundreds	O
+of	O
+thousands	O
+of	O
+people	O
+.	O
+
+ABSTRACT	O
+:	O
+Health	O
+care	O
+workers	O
+exposed	O
+to	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+could	O
+be	O
+psychologically	O
+stressed	O
+.	O
+
+The	O
+degree	O
+of	O
+symptoms	B-DISO
+of	I-DISO
+depression	I-DISO
+,	O
+anxiety	O
+,	O
+insomnia	B-DISO
+,	O
+and	O
+distress	O
+was	O
+assessed	O
+by	O
+the	O
+Chinese	O
+versions	O
+of	O
+the	O
+9	O
+-	O
+item	O
+Patient	O
+Health	O
+Questionnaire	O
+,	O
+the	O
+7	O
+-	O
+item	O
+Generalized	B-DISO
+Anxiety	I-DISO
+Disorder	I-DISO
+scale	O
+,	O
+the	O
+7	O
+-	O
+item	O
+Insomnia	B-DISO
+Severity	O
+Index	O
+,	O
+and	O
+the	O
+22	O
+-	O
+item	O
+Impact	O
+of	O
+Event	O
+Scale	O
+-	O
+Revised	O
+,	O
+respectively	O
+.	O
+
+A	O
+considerable	O
+proportion	O
+of	O
+participants	O
+reported	O
+symptoms	O
+of	O
+depression	O
+(	O
+634	O
+[	O
+50	O
+.	O
+4	O
+%]),	O
+anxiety	O
+(	O
+560	O
+[	O
+44	O
+.	O
+6	O
+%]),	O
+insomnia	B-DISO
+(	O
+427	O
+[	O
+34	O
+.	O
+0	O
+%]),	O
+and	O
+distress	O
+(	O
+899	O
+[	O
+71	O
+.	O
+5	O
+%]).	O
+
+Nurses	O
+,	O
+women	O
+,	O
+frontline	O
+health	O
+care	O
+workers	O
+,	O
+and	O
+those	O
+working	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+reported	O
+more	O
+severe	O
+degrees	O
+of	O
+all	O
+measurements	O
+of	O
+mental	O
+health	O
+symptoms	O
+than	O
+other	O
+health	O
+care	O
+workers	O
+(	O
+eg	O
+,	O
+median	O
+[	O
+IQR	O
+]	O
+Patient	O
+Health	O
+Questionnaire	O
+scores	O
+among	O
+physicians	O
+vs	O
+nurses	O
+:	O
+4	O
+.	O
+0	O
+[	O
+1	O
+.	O
+0	O
+-	O
+7	O
+.	O
+0	O
+]	O
+vs	O
+5	O
+.	O
+0	O
+[	O
+2	O
+.	O
+0	O
+-	O
+8	O
+.	O
+0	O
+];	O
+P	O
+=	O
+.	O
+007	O
+;	O
+median	O
+[	O
+interquartile	O
+range	O
+{	O
+IQR	O
+}]	O
+Generalized	B-DISO
+Anxiety	I-DISO
+Disorder	I-DISO
+scale	O
+scores	O
+among	O
+men	O
+vs	O
+women	O
+:	O
+2	O
+.	O
+0	O
+[	O
+0	O
+-	O
+6	O
+.	O
+0	O
+]	O
+vs	O
+4	O
+.	O
+0	O
+[	O
+1	O
+.	O
+0	O
+-	O
+7	O
+.	O
+0	O
+];	O
+P	O
+<	O
+.	O
+001	O
+;	O
+median	O
+[	O
+IQR	O
+]	O
+Insomnia	B-DISO
+Severity	O
+Index	O
+scores	O
+among	O
+frontline	O
+vs	O
+second	O
+-	O
+line	O
+workers	O
+:	O
+6	O
+.	O
+0	O
+[	O
+2	O
+.	O
+0	O
+-	O
+11	O
+.	O
+0	O
+]	O
+vs	O
+4	O
+.	O
+0	O
+[	O
+1	O
+.	O
+0	O
+-	O
+8	O
+.	O
+0	O
+];	O
+P	O
+<	O
+.	O
+001	O
+;	O
+median	O
+[	O
+IQR	O
+]	O
+Impact	O
+of	O
+Event	O
+Scale	O
+-	O
+Revised	O
+scores	O
+among	O
+those	O
+in	O
+Wuhan	O
+vs	O
+those	O
+in	O
+Hubei	O
+outside	O
+Wuhan	O
+and	O
+those	O
+outside	O
+Hubei	O
+:	O
+21	O
+.	O
+0	O
+[	O
+8	O
+.	O
+5	O
+-	O
+34	O
+.	O
+5	O
+]	O
+vs	O
+18	O
+.	O
+0	O
+[	O
+6	O
+.	O
+0	O
+-	O
+28	O
+.	O
+0	O
+]	O
+in	O
+Hubei	O
+outside	O
+Wuhan	O
+and	O
+15	O
+.	O
+0	O
+[	O
+4	O
+.	O
+0	O
+-	O
+26	O
+.	O
+0	O
+]	O
+outside	O
+Hubei	O
+;	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+(	O
+PsycInfo	O
+Database	O
+Record	O
+(	O
+c	O
+)	O
+2020	O
+APA	B-CHED
+,	O
+all	O
+rights	O
+reserved	O
+).	O
+
+TITLE	O
+:	O
+Recommendations	O
+by	O
+the	O
+SEPD	O
+and	O
+AEG	O
+,	O
+both	O
+in	O
+general	O
+and	O
+on	O
+the	O
+operation	O
+of	O
+gastrointestinal	O
+endoscopy	O
+and	O
+gastroenterology	O
+units	O
+,	O
+concerning	O
+the	O
+current	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+pandemic	O
+(	O
+March	O
+,	O
+18	O
+).	O
+
+The	O
+presence	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+RNA	I-PRGE
+in	O
+the	O
+feces	B-ANAT
+of	O
+patients	O
+infected	O
+with	O
+the	O
+virus	B-SPEC
+,	O
+and	O
+occasionally	O
+in	O
+colonic	B-ANAT
+biopsy	O
+samples	O
+,	O
+has	O
+been	O
+consistently	O
+documented	O
+.	O
+
+In	O
+fact	O
+,	O
+viral	O
+elimination	B-PROC
+in	O
+the	O
+feces	B-ANAT
+may	O
+be	O
+more	O
+prolonged	O
+than	O
+viral	O
+identification	O
+in	O
+respiratory	B-ANAT
+tract	I-ANAT
+secretions	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+:	O
+implication	O
+for	O
+development	O
+of	O
+RBD	B-PRGE
+protein	I-PRGE
+as	O
+a	O
+viral	O
+attachment	O
+inhibitor	B-CHED
+and	O
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+Coronavirus	B-DISO
+Disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+has	O
+posed	O
+a	O
+serious	O
+threat	O
+to	O
+global	O
+public	O
+health	O
+,	O
+calling	O
+for	O
+the	O
+development	B-PROC
+of	O
+safe	O
+and	O
+effective	O
+prophylactics	O
+and	O
+therapeutics	O
+against	O
+infection	B-DISO
+of	O
+its	O
+causative	O
+agent	O
+,	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+),	O
+also	O
+known	O
+as	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+).	O
+
+Here	O
+,	O
+we	O
+identified	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+S	I-PRGE
+protein	B-CHED
+and	O
+found	O
+that	O
+the	O
+RBD	B-PRGE
+protein	I-PRGE
+bound	O
+strongly	O
+to	O
+human	B-SPEC
+and	O
+bat	B-ENZY
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	I-PRGE
+ACE2	I-PRGE
+)	I-PRGE
+receptors	I-PRGE
+.	O
+
+The	O
+number	O
+of	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+who	O
+might	O
+develop	O
+severe	O
+ARDS	B-DISO
+that	O
+is	O
+refractory	O
+to	O
+maximal	O
+medical	O
+management	O
+and	O
+require	O
+this	O
+level	O
+of	O
+support	O
+is	O
+currently	O
+unknown	O
+.	O
+
+Available	O
+evidence	O
+from	O
+similar	O
+patient	O
+populations	O
+suggests	O
+that	O
+carefully	O
+selected	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+who	O
+do	O
+not	O
+benefit	O
+from	O
+conventional	O
+treatment	O
+might	O
+be	O
+successfully	O
+supported	O
+with	O
+venovenous	O
+ECMO	O
+.	O
+
+Ensuring	O
+that	O
+systems	O
+enable	O
+safe	O
+and	O
+coordinated	O
+movement	B-PROC
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+staff	O
+,	O
+and	O
+equipment	O
+is	O
+important	O
+to	O
+improve	O
+ECMO	O
+access	O
+.	O
+
+ABSTRACT	O
+:	O
+Here	O
+,	O
+we	O
+review	O
+the	O
+most	O
+recent	O
+findings	O
+on	O
+the	O
+effects	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+on	O
+kidney	B-DISO
+diseases	I-DISO
+,	O
+including	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+and	O
+examine	O
+the	O
+potential	O
+effects	O
+of	O
+ARBs	O
+on	O
+the	O
+outcomes	O
+of	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Lastly	O
+,	O
+we	O
+discuss	O
+the	O
+clinical	O
+management	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+with	O
+existing	O
+chronic	O
+renal	B-DISO
+disorders	I-DISO
+,	O
+particularly	O
+those	O
+in	O
+dialysis	B-SPEC
+and	O
+with	O
+kidney	B-ANAT
+transplants	B-ANAT
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+is	O
+to	O
+explore	O
+the	O
+impacts	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+on	O
+people	O
+'	O
+s	O
+mental	O
+health	O
+,	O
+to	O
+assist	O
+policy	O
+makers	O
+to	O
+develop	O
+actionable	O
+policies	O
+,	O
+and	O
+help	O
+clinical	O
+practitioners	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+social	O
+workers	O
+,	O
+psychiatrists	O
+,	O
+and	O
+psychologists	O
+)	O
+provide	O
+timely	O
+services	O
+to	O
+affected	O
+populations	O
+.	O
+
+We	O
+sample	O
+and	O
+analyze	O
+the	O
+Weibo	O
+posts	O
+from	O
+17	O
+,	O
+865	O
+active	O
+Weibo	O
+users	O
+using	O
+the	O
+approach	O
+of	O
+Online	O
+Ecological	O
+Recognition	O
+(	O
+OER	O
+)	O
+based	O
+on	O
+several	O
+machine	O
+-	O
+learning	B-PROC
+predictive	O
+models	O
+.	O
+
+People	O
+were	O
+concerned	O
+more	O
+about	O
+their	O
+health	O
+and	O
+family	B-SPEC
+,	O
+while	O
+less	O
+about	O
+leisure	O
+and	O
+friends	O
+.	O
+
+The	O
+recombinant	O
+feIFN	O
+-	O
+ωa	O
+and	O
+feIFN	O
+-	O
+ωb	O
+proteins	B-CHED
+were	O
+expressed	B-PROC
+in	O
+their	O
+soluble	O
+forms	O
+in	O
+
+For	O
+an	O
+appropriate	O
+and	O
+effective	O
+approach	O
+to	O
+treat	O
+severe	O
+pediatric	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+two	O
+main	O
+different	O
+strategies	O
+can	O
+be	O
+proposed	O
+according	O
+to	O
+the	O
+stage	O
+and	O
+severity	O
+of	O
+the	O
+patient	O
+conditions	O
+:	O
+patient	O
+in	O
+the	O
+initial	O
+phase	O
+and	O
+with	O
+non	O
+-	O
+severe	O
+lung	B-ANAT
+pathology	B-DISO
+and	O
+patient	O
+with	O
+severe	O
+initial	O
+respiratory	O
+impairment	B-DISO
+and	O
+/	O
+or	O
+with	O
+delay	O
+in	O
+arrival	O
+to	O
+observation	O
+.	O
+
+At	O
+the	O
+end	O
+of	O
+January	O
+2020	O
+,	O
+the	O
+Working	O
+Group	O
+for	O
+the	O
+Prevention	O
+and	O
+Control	O
+of	O
+Neonatal	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+Infection	I-DISO
+in	O
+the	O
+Perinatal	O
+Period	O
+of	O
+the	O
+Editorial	O
+Committee	O
+of	O
+Chinese	O
+Journal	O
+of	O
+Contemporary	O
+Pediatrics	O
+worked	O
+out	O
+the	O
+perinatal	O
+and	O
+neonatal	O
+management	O
+plan	B-DISO
+for	O
+prevention	O
+and	O
+control	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+(	O
+1st	O
+Edition	O
+).	O
+
+This	O
+plan	B-DISO
+has	O
+been	O
+verified	O
+by	O
+clinical	O
+practice	O
+for	O
+3	O
+weeks	O
+.	O
+
+TITLE	O
+:	O
+[	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infection	I-DISO
+with	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+as	O
+the	O
+first	O
+manifestation	O
+in	O
+a	O
+neonate	O
+].	O
+
+As	O
+for	O
+the	O
+morphology	O
+of	O
+the	O
+lesions	O
+,	O
+6	O
+had	O
+nodular	O
+lesions	O
+and	O
+7	O
+had	O
+patchy	O
+lesions	O
+;	O
+ground	O
+glass	O
+opacity	B-DISO
+with	O
+consolidation	O
+was	O
+observed	O
+in	O
+6	O
+children	O
+,	O
+among	O
+whom	O
+3	O
+had	O
+halo	B-DISO
+sign	I-DISO
+,	O
+and	O
+there	O
+was	O
+no	O
+typical	O
+paving	O
+stone	B-ANAT
+sign	O
+.	O
+
+As	O
+the	O
+special	O
+population	O
+with	O
+immature	O
+immune	B-PROC
+function	I-PROC
+,	O
+newborns	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+have	O
+been	O
+reported	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+disease	O
+is	O
+an	O
+emerging	O
+infection	B-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+is	O
+moving	B-PROC
+rapidly	O
+.	O
+
+TITLE	O
+:	O
+Imaging	O
+Features	O
+of	O
+Coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+):	O
+Evaluation	O
+on	O
+Thin	O
+-	O
+Section	O
+CT	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+retrospectively	O
+analyze	O
+the	O
+chest	O
+imaging	O
+findings	O
+in	O
+patients	O
+with	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+on	O
+thin	O
+-	O
+section	O
+CT	O
+.	O
+
+Two	O
+chest	B-ANAT
+radiologists	O
+independently	O
+evaluated	O
+the	O
+imaging	O
+in	O
+terms	O
+of	O
+distribution	O
+,	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+(	O
+GGO	O
+),	O
+consolidation	O
+,	O
+air	B-CHED
+bronchogram	O
+,	O
+stripe	O
+,	O
+enlarged	O
+mediastinal	B-ANAT
+lymph	I-ANAT
+node	I-ANAT
+,	O
+and	O
+pleural	B-DISO
+effusion	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Fourty	O
+-	O
+seven	O
+cases	O
+(	O
+88	O
+.	O
+7	O
+%)	O
+had	O
+findings	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+,	O
+and	O
+the	O
+other	O
+six	O
+(	O
+11	O
+.	O
+3	O
+%)	O
+were	O
+normal	O
+.	O
+
+TITLE	O
+:	O
+Interrupting	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+transmission	O
+by	O
+implementing	O
+enhanced	O
+traffic	O
+control	O
+bundling	O
+:	O
+Implications	O
+for	O
+global	O
+prevention	O
+and	O
+control	O
+efforts	O
+.	O
+
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+with	O
+and	O
+without	O
+travel	O
+history	O
+to	O
+China	O
+were	O
+divided	O
+into	O
+cohorts	O
+according	O
+to	O
+the	O
+Healthcare	O
+Access	O
+and	O
+Quality	O
+Index	O
+(	O
+HAQ	O
+-	O
+Index	O
+)	O
+of	O
+each	O
+country	O
+.	O
+
+TITLE	O
+:	O
+The	O
+index	O
+case	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+Scotland	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+The	O
+goal	O
+of	O
+this	O
+study	O
+is	O
+to	O
+demonstrate	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+LH	O
+against	O
+the	O
+novel	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+virus	B-SPEC
+and	O
+its	O
+potential	O
+effect	O
+in	O
+regulating	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+.	O
+
+LH	O
+significantly	O
+inhibited	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+replication	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+and	O
+markedly	O
+reduced	O
+pro	B-PRGE
+-	I-PRGE
+inflammatory	I-PRGE
+cytokines	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+CCL	B-PRGE
+-	I-PRGE
+2	I-PRGE
+/	I-PRGE
+MCP	B-FUNC
+-	I-PRGE
+1	I-PRGE
+and	O
+CXCL	O
+-	O
+10	O
+/	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+)	O
+production	O
+at	O
+the	O
+mRNA	B-CHED
+levels	O
+.	O
+
+Unlike	O
+other	O
+CRCoVs	O
+,	O
+there	O
+was	O
+no	O
+evidence	O
+of	O
+recombination	B-PROC
+in	O
+Swedish	O
+CRCoV	O
+isolates	O
+,	O
+further	O
+supporting	O
+a	O
+single	O
+introduction	O
+.	O
+
+Other	O
+viral	B-DISO
+infections	I-DISO
+were	O
+identified	O
+in	O
+49	O
+%	O
+of	O
+the	O
+patients	O
+,	O
+with	O
+most	O
+common	O
+pathogens	O
+being	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+viruses	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+metapneumovirus	B-SPEC
+and	O
+common	O
+coronaviruses	O
+,	O
+notably	O
+HKU1	O
+and	O
+NL63	O
+.	O
+
+Other	O
+viral	B-DISO
+infections	I-DISO
+were	O
+identified	O
+in	O
+49	O
+%	O
+of	O
+the	O
+patients	O
+,	O
+with	O
+most	O
+common	O
+pathogens	O
+being	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+viruses	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+metapneumovirus	B-SPEC
+and	O
+common	O
+coronaviruses	O
+,	O
+notably	O
+HKU1	O
+and	O
+NL63	O
+.	O
+
+Early	O
+rule	O
+-	O
+out	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+allows	O
+public	O
+health	O
+containment	O
+measures	O
+to	O
+be	O
+adjusted	O
+by	O
+reducing	O
+the	O
+time	O
+spent	O
+in	O
+isolation	O
+.	O
+
+TITLE	O
+:	O
+Tilorone	O
+:	O
+A	O
+Broad	O
+-	O
+Spectrum	O
+Antiviral	B-CHED
+For	O
+Emerging	O
+Viruses	B-SPEC
+.	O
+
+This	O
+drug	O
+is	O
+used	O
+as	O
+a	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+in	O
+several	O
+countries	O
+of	O
+the	O
+Russian	O
+Federation	O
+.	O
+
+TITLE	O
+:	O
+Insilico	O
+Alpha	O
+-	O
+Helical	O
+Structural	O
+Recognition	O
+of	O
+Temporin	O
+Antimicrobial	B-CHED
+Peptides	B-CHED
+and	O
+Its	O
+Interactions	O
+with	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+-	O
+Coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+2012	O
+and	O
+to	O
+date	O
+,	O
+outbreak	O
+/	O
+new	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+-	O
+related	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+were	O
+always	O
+reported	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+CoV	B-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+which	O
+is	O
+crucial	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+membrane	B-PROC
+fusion	I-PROC
+via	O
+conformational	O
+changes	O
+,	O
+internalization	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+host	B-COMP
+tissue	B-PROC
+tropism	B-PROC
+and	O
+comprises	O
+crucial	O
+targets	O
+for	O
+vaccine	O
+development	B-PROC
+,	O
+remain	O
+largely	O
+uncharacterized	O
+.	O
+
+The	O
+variation	O
+in	O
+glycosylation	B-PROC
+sites	O
+was	O
+predicted	O
+by	O
+NetNGlyc	O
+1	O
+.	O
+0	O
+and	O
+validated	O
+by	O
+N	O
+-	O
+GlyDE	O
+server	O
+.	O
+
+We	O
+studied	O
+two	O
+prospective	O
+sepsis	B-DISO
+cohorts	O
+drawn	O
+from	O
+the	O
+Early	O
+Assessment	O
+of	O
+Renal	B-ANAT
+and	O
+Lung	B-ANAT
+Injury	O
+(	O
+EARLI	O
+;	O
+n	O
+=	O
+474	O
+)	O
+and	O
+Validating	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+markers	O
+for	O
+Diagnosis	O
+(	O
+VALID	O
+;	O
+n	O
+=	O
+337	O
+)	O
+cohorts	O
+.	O
+
+TITLE	O
+:	O
+How	O
+to	O
+perform	O
+lung	B-ANAT
+ultrasound	O
+in	O
+pregnant	O
+women	O
+with	O
+suspected	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+key	O
+parameters	O
+for	O
+this	O
+assay	O
+were	O
+optimized	O
+,	O
+including	O
+cell	B-COMP
+types	O
+,	O
+cell	B-COMP
+numbers	O
+,	O
+virus	B-SPEC
+inoculum	O
+.	O
+
+We	O
+must	O
+minimize	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+contact	O
+with	O
+vulnerable	O
+populations	O
+.	O
+
+RESULTS	O
+:	O
+Implement	O
+technology	O
+now	O
+:	O
+Minimize	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+contact	O
+with	O
+participants	O
+by	O
+utilizing	O
+digital	B-ANAT
+tools	O
+,	O
+such	O
+as	O
+shifting	O
+to	O
+electronic	O
+informed	O
+consent	O
+and	O
+digital	B-ANAT
+HIPAA	O
+-	O
+compliant	O
+tools	O
+like	O
+emailed	O
+surveys	O
+or	O
+telehealth	O
+assessments	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+CT	O
+findings	O
+of	O
+patients	O
+with	O
+different	O
+clinical	O
+types	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+).	O
+
+CT	O
+images	O
+in	O
+patients	O
+with	O
+different	O
+clinical	O
+types	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+have	O
+characteristic	O
+manifestations	O
+,	O
+and	O
+solid	O
+shadow	O
+may	O
+predict	O
+severe	O
+and	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+Importance	O
+should	O
+be	O
+attached	O
+to	O
+the	O
+preoperative	O
+evaluation	O
+of	O
+pregnant	O
+women	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+the	O
+implementation	O
+of	O
+anesthesia	B-DISO
+plan	B-DISO
+.	O
+
+The	O
+government	O
+initially	O
+assumed	O
+that	O
+the	O
+infection	B-DISO
+was	O
+not	O
+spreading	O
+aboard	O
+and	O
+therefore	O
+indicated	O
+that	O
+any	O
+persons	O
+who	O
+either	O
+tested	O
+negative	O
+for	O
+the	O
+virus	B-SPEC
+or	O
+were	O
+asymptomatic	O
+should	O
+immediately	O
+disembark	O
+.	O
+
+However	O
+,	O
+on	O
+February	O
+5	O
+,	O
+the	O
+government	O
+set	O
+a	O
+14	O
+-	O
+day	O
+health	O
+observation	O
+period	O
+because	O
+of	O
+the	O
+severity	O
+of	O
+the	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Novel	B-SPEC
+2019	I-SPEC
+coronavirus	I-SPEC
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+):	O
+An	O
+updated	O
+overview	O
+for	O
+emergency	B-DISO
+clinicians	O
+ABSTRACT	O
+:	O
+The	O
+novel	O
+coronavirus	O
+,	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+has	O
+quickly	O
+become	O
+a	O
+worldwide	O
+threat	O
+to	O
+health	O
+,	O
+travel	O
+,	O
+and	O
+commerce	O
+.	O
+
+We	O
+set	O
+up	O
+emergency	B-DISO
+management	O
+and	O
+sensing	O
+control	O
+teams	O
+.	O
+
+The	O
+team	O
+formulated	O
+various	O
+measures	O
+,	O
+such	O
+as	O
+reconfiguration	O
+of	O
+the	O
+radiology	O
+department	O
+,	O
+personal	O
+protection	O
+and	O
+staff	O
+training	O
+,	O
+standardized	O
+imaging	O
+examination	O
+procedures	O
+for	O
+fever	B-PROC
+patients	O
+and	O
+common	O
+patients	O
+,	O
+and	O
+so	O
+on	O
+.	O
+
+Professor	O
+Taisheng	O
+Li	B-SPEC
+was	O
+sent	O
+to	O
+Wuhan	O
+to	O
+provide	O
+frontline	O
+medical	O
+care	O
+.	O
+
+TITLE	O
+:	O
+The	O
+different	O
+clinical	O
+characteristics	O
+of	O
+corona	B-CHED
+virus	B-DISO
+disease	I-DISO
+cases	O
+between	O
+children	O
+and	O
+their	O
+families	O
+in	O
+China	O
+-	O
+the	O
+character	O
+of	O
+children	O
+with	O
+COVID	O
+-	O
+19	O
+.	O
+
+The	O
+main	O
+manifestations	O
+were	O
+pulmonary	O
+consolidation	O
+(	O
+70	O
+%),	O
+nodular	O
+shadow	O
+(	O
+50	O
+%),	O
+and	O
+ground	O
+glass	O
+opacity	B-DISO
+(	O
+50	O
+%).	O
+
+Five	O
+discharged	O
+children	O
+were	O
+admitted	O
+again	O
+because	O
+their	O
+stool	B-ANAT
+showed	O
+positive	O
+result	O
+in	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+PCR	O
+.	O
+
+TITLE	O
+:	O
+All	O
+Feet	B-ANAT
+On	O
+Deck	O
+-	O
+The	O
+Role	O
+of	O
+Podiatry	O
+During	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+Pandemic	O
+:	O
+ABSTRACT	O
+:	O
+The	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pandemic	O
+is	O
+driving	O
+significant	O
+change	O
+in	O
+the	O
+healthcare	O
+system	O
+and	O
+disrupting	O
+the	O
+best	O
+practices	O
+for	O
+diabetic	O
+limb	O
+preservation	O
+,	O
+leaving	O
+large	O
+numbers	O
+of	O
+patients	O
+without	O
+care	O
+.	O
+
+Podiatric	O
+care	O
+is	O
+associated	O
+with	O
+fewer	O
+diabetes	B-DISO
+-	O
+related	O
+amputations	O
+,	O
+ER	O
+visits	O
+,	O
+hospitalizations	O
+,	O
+length	O
+-	O
+of	O
+-	O
+stay	O
+,	O
+and	O
+costs	O
+.	O
+
+Because	O
+the	O
+ACE2	B-PRGE
+(	O
+angiotensin	B-CHED
+-	O
+converting	O
+enzyme	O
+2	O
+)	O
+protein	B-CHED
+is	O
+the	O
+receptor	O
+that	O
+facilitates	O
+coronavirus	B-SPEC
+entry	O
+into	O
+cells	B-COMP
+,	O
+the	O
+notion	O
+has	O
+been	O
+popularized	O
+that	O
+treatment	O
+with	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+blockers	O
+might	O
+increase	O
+the	O
+risk	O
+of	O
+developing	O
+a	O
+severe	O
+and	O
+fatal	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+-	O
+2	O
+infection	B-DISO
+.	O
+
+Although	O
+angiotensin	B-PRGE
+II	I-PRGE
+type	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+blockers	O
+have	O
+been	O
+shown	O
+to	O
+upregulate	O
+ACE2	B-PRGE
+in	O
+experimental	O
+animals	B-SPEC
+,	O
+the	O
+evidence	O
+is	O
+not	O
+always	O
+consistent	O
+and	O
+differs	O
+among	O
+the	O
+diverse	O
+angiotensin	B-PRGE
+II	I-PRGE
+type	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+blockers	O
+and	O
+differing	O
+organs	B-ANAT
+.	O
+
+Moreover	O
+,	O
+there	O
+are	O
+no	O
+data	O
+to	O
+support	O
+the	O
+notion	O
+that	O
+ACE	B-CHED
+inhibitor	I-CHED
+or	O
+angiotensin	B-PRGE
+II	I-PRGE
+type	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+blocker	O
+administration	O
+facilitates	O
+coronavirus	B-SPEC
+entry	O
+by	O
+increasing	O
+ACE2	B-PRGE
+expression	B-PROC
+in	O
+either	O
+animals	B-SPEC
+or	O
+humans	B-SPEC
+.	O
+
+In	O
+summary	O
+,	O
+based	O
+on	O
+the	O
+currently	O
+available	O
+evidence	O
+,	O
+treatment	O
+with	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+blockers	O
+should	O
+not	O
+be	O
+discontinued	O
+because	O
+of	O
+concerns	O
+with	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Seven	O
+clusters	B-CHED
+for	O
+human	B-SPEC
+coronaviruses	O
+(	O
+229E	O
+,	O
+NL63	O
+,	O
+OC43	O
+,	O
+HKU1	O
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+were	O
+found	O
+.	O
+
+The	O
+study	O
+may	O
+be	O
+beneficial	O
+for	O
+the	O
+surveillance	O
+of	O
+the	O
+genome	B-PROC
+mutation	I-PROC
+of	O
+coronavirus	B-SPEC
+in	O
+the	O
+field	O
+.	O
+
+Neutralising	O
+antibody	B-PROC
+response	I-PROC
+appeared	O
+within	O
+9	O
+days	O
+along	O
+with	O
+specific	O
+IgM	B-PRGE
+and	O
+IgG	B-PRGE
+response	O
+,	O
+targeting	B-PROC
+particularly	O
+nucleocapsid	B-COMP
+and	O
+spike	O
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Data	O
+concerning	O
+the	O
+transmission	O
+of	O
+the	O
+novel	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+in	O
+paucisymptomatic	O
+patients	O
+are	O
+lacking	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+concerns	O
+study	O
+of	O
+the	O
+genome	O
+of	O
+the	O
+Wuhan	O
+Seafood	O
+Market	O
+isolate	O
+believed	O
+to	O
+represent	O
+the	O
+causative	O
+agent	O
+of	O
+the	O
+disease	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+Rheumatologist	O
+'	O
+s	O
+Role	O
+in	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+2019	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+has	O
+caused	O
+the	O
+outbreak	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+of	O
+China	O
+since	O
+December	O
+2019	O
+.	O
+
+Our	O
+study	O
+enrolled	O
+109	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+who	O
+died	B-PROC
+during	O
+hospitalization	O
+and	O
+116	O
+recovered	O
+patients	O
+.	O
+
+Patients	O
+in	O
+the	O
+death	B-PROC
+group	O
+exhibited	O
+significantly	O
+lower	O
+lymphocyte	B-ANAT
+count	O
+(	O
+0	O
+.	O
+63	O
+[	O
+0	O
+.	O
+40	O
+,	O
+0	O
+.	O
+79	O
+]	O
+×	O
+10	O
+/	O
+L	O
+vs	O
+.	O
+1	O
+.	O
+00	O
+[	O
+0	O
+.	O
+72	O
+,	O
+1	O
+.	O
+27	O
+]	O
+×	O
+10	O
+/	O
+L	O
+,	O
+Z	O
+=	O
+8	O
+.	O
+037	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+lymphocyte	B-ANAT
+/	O
+WBC	B-ANAT
+ratio	O
+(	O
+7	O
+.	O
+10	O
+[	O
+4	O
+.	O
+45	O
+,	O
+12	O
+.	O
+73	O
+]%	O
+vs	O
+.	O
+23	O
+.	O
+5	O
+[	O
+15	O
+.	O
+27	O
+,	O
+31	O
+.	O
+25	O
+]%,	O
+Z	O
+=	O
+10	O
+.	O
+315	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+on	O
+admission	O
+,	O
+and	O
+the	O
+lymphocyte	B-ANAT
+/	O
+WBC	B-ANAT
+ratio	O
+continue	O
+to	O
+decrease	O
+during	O
+hospitalization	O
+(	O
+7	O
+.	O
+10	O
+[	O
+4	O
+.	O
+45	O
+,	O
+12	O
+.	O
+73	O
+]%	O
+vs	O
+.	O
+2	O
+.	O
+91	O
+[	O
+1	O
+.	O
+79	O
+,	O
+6	O
+.	O
+13	O
+]%,	O
+Z	O
+=	O
+5	O
+.	O
+242	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Alanine	B-PRGE
+transaminase	I-PRGE
+(	O
+ALT	B-FUNC
+)	O
+(	O
+22	O
+.	O
+00	O
+[	O
+15	O
+.	O
+00	O
+,	O
+34	O
+.	O
+00	O
+]	O
+U	O
+/	O
+L	O
+vs	O
+.	O
+18	O
+.	O
+70	O
+[	O
+13	O
+.	O
+00	O
+,	O
+30	O
+.	O
+38	O
+]	O
+U	O
+/	O
+L	O
+,	O
+Z	O
+=	O
+2	O
+.	O
+592	O
+,	O
+P	O
+=	O
+0	O
+.	O
+010	O
+),	O
+aspartate	B-PRGE
+transaminase	I-PRGE
+(	O
+AST	B-PRGE
+)	O
+(	O
+34	O
+.	O
+00	O
+[	O
+27	O
+.	O
+00	O
+,	O
+47	O
+.	O
+00	O
+]	O
+U	O
+/	O
+L	O
+vs	O
+.	O
+22	O
+.	O
+00	O
+[	O
+17	O
+.	O
+65	O
+,	O
+31	O
+.	O
+75	O
+]	O
+U	O
+/	O
+L	O
+,	O
+Z	O
+=	O
+7	O
+.	O
+308	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+creatinine	B-CHED
+levels	O
+(	O
+89	O
+.	O
+00	O
+[	O
+72	O
+.	O
+00	O
+,	O
+133	O
+.	O
+50	O
+]	O
+μmol	O
+/	O
+L	O
+vs	O
+.	O
+65	O
+.	O
+00	O
+[	O
+54	O
+.	O
+60	O
+,	O
+78	O
+.	O
+75	O
+]	O
+μmol	O
+/	O
+L	O
+,	O
+Z	O
+=	O
+6	O
+.	O
+478	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+significantly	O
+higher	O
+in	O
+the	O
+death	B-PROC
+group	O
+that	O
+those	O
+in	O
+the	O
+recovered	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+data	O
+from	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+,	O
+real	O
+-	O
+time	O
+case	O
+information	O
+.	O
+
+To	O
+aid	O
+the	O
+analysis	O
+and	O
+tracking	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+we	O
+collected	O
+and	O
+curated	O
+individual	O
+-	O
+level	O
+data	O
+from	O
+national	O
+,	O
+provincial	O
+,	O
+and	O
+municipal	O
+health	O
+reports	O
+,	O
+as	O
+well	O
+as	O
+additional	O
+information	O
+from	O
+online	O
+reports	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+case	O
+of	O
+invasive	B-DISO
+aspergillosis	I-DISO
+complicated	O
+by	O
+pulmonary	B-DISO
+embolism	I-DISO
+after	O
+non	O
+-	O
+fatal	O
+drowning	O
+that	O
+proved	O
+fatal	O
+.	O
+
+A	O
+75	O
+-	O
+year	O
+-	O
+old	O
+Japanese	O
+man	B-CHED
+accidentally	O
+fell	O
+into	O
+a	O
+creek	O
+and	O
+was	O
+brought	O
+to	O
+a	O
+local	O
+hospital	O
+.	O
+
+An	O
+embolus	O
+was	O
+also	O
+detected	O
+in	O
+the	O
+right	B-ANAT
+pulmonary	I-ANAT
+artery	I-ANAT
+.	O
+
+Microscopic	O
+analysis	O
+revealed	O
+diffuse	O
+filamentous	O
+fungi	B-SPEC
+throughout	O
+the	O
+lungs	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+stomach	B-ANAT
+,	O
+thyroid	B-ANAT
+gland	I-ANAT
+,	O
+and	O
+the	O
+pulmonary	B-DISO
+embolus	I-DISO
+,	O
+which	O
+were	O
+identified	O
+as	O
+Invasive	B-DISO
+aspergillosis	I-DISO
+should	O
+also	O
+be	O
+considered	O
+in	O
+immunocompetent	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+after	O
+non	O
+-	O
+fatal	O
+drowning	O
+who	O
+do	O
+not	O
+respond	O
+to	O
+broad	O
+-	O
+spectrum	O
+antibiotics	B-CHED
+.	O
+
+Angioinvasive	O
+aspergillosis	B-DISO
+can	O
+even	O
+result	O
+in	O
+fatal	O
+pulmonary	B-DISO
+embolism	I-DISO
+;	O
+hence	O
+,	O
+early	O
+targeted	B-PROC
+testing	O
+for	O
+
+TITLE	O
+:	O
+Unrevealing	O
+sequence	O
+and	O
+structural	O
+features	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+using	O
+ABSTRACT	O
+:	O
+Direct	O
+-	O
+acting	O
+antivirals	O
+are	O
+effective	O
+tools	O
+to	O
+control	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+This	O
+study	O
+investigates	O
+the	O
+transport	B-PROC
+mechanism	O
+and	O
+deposition	O
+patterns	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+within	O
+a	O
+typical	O
+six	O
+bedded	O
+general	O
+inpatient	O
+ward	O
+cubicle	O
+through	O
+numerical	O
+simulation	O
+.	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+severe	O
+burns	O
+:	O
+prospective	O
+cohort	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Age	O
+and	O
+inhalation	O
+injury	O
+are	O
+important	O
+risk	O
+factors	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+the	O
+burned	O
+patient	O
+;	O
+however	O
+,	O
+the	O
+impact	O
+of	O
+interventions	O
+such	O
+as	O
+mechanical	O
+ventilation	O
+,	O
+fluid	B-PROC
+balance	I-PROC
+(	O
+FB	O
+),	O
+and	O
+packed	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+transfusion	O
+remains	O
+unclear	O
+.	O
+
+The	O
+outcomes	O
+of	O
+interest	O
+were	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+up	O
+to	O
+seven	O
+days	O
+after	O
+admission	O
+and	O
+death	B-PROC
+within	O
+28	O
+days	O
+.	O
+
+Universal	O
+adoption	O
+of	O
+best	O
+practices	O
+for	O
+infection	B-DISO
+control	O
+is	O
+the	O
+surest	O
+way	O
+for	O
+governments	O
+to	O
+prepare	O
+for	O
+mass	O
+gatherings	O
+.	O
+
+This	O
+retrospective	O
+case	O
+-	O
+control	O
+study	O
+involves	O
+subjects	O
+(	O
+7	O
+to	O
+98	O
+years	O
+)	O
+presenting	O
+at	O
+the	O
+designated	O
+national	O
+outbreak	O
+screening	O
+centre	O
+and	O
+tertiary	O
+care	O
+hospital	O
+in	O
+Singapore	O
+for	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+testing	O
+from	O
+January	O
+26	O
+to	O
+February	O
+16	O
+,	O
+2020	O
+.	O
+
+Outbreak	O
+restrictions	O
+can	O
+impact	O
+on	O
+the	O
+IBD	B-DISO
+care	O
+.	O
+
+However	O
+,	O
+information	O
+on	O
+cardiac	B-ANAT
+injury	O
+in	O
+patients	O
+affected	O
+by	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+limited	O
+.	O
+
+All	O
+consecutive	O
+inpatients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+included	O
+in	O
+this	O
+study	O
+.	O
+
+A	O
+total	O
+of	O
+416	O
+hospitalized	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+included	O
+in	O
+the	O
+final	O
+analysis	O
+;	O
+the	O
+median	O
+age	O
+was	O
+64	O
+years	O
+(	O
+range	O
+,	O
+21	O
+-	O
+95	O
+years	O
+),	O
+and	O
+211	O
+(	O
+50	O
+.	O
+7	O
+%)	O
+were	O
+female	O
+.	O
+
+RESULTS	O
+:	O
+Total	O
+788	O
+patients	O
+with	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+selected	O
+,	O
+where	O
+136	O
+were	O
+older	O
+patients	O
+with	O
+corresponding	O
+age	O
+of	O
+68	O
+.	O
+28y	O
+±	O
+7	O
+.	O
+314y	O
+.	O
+
+TITLE	O
+:	O
+Microcirculatory	O
+dysfunction	O
+and	O
+dead	B-PROC
+-	O
+space	O
+ventilation	O
+in	O
+early	O
+ARDS	B-DISO
+:	O
+a	O
+hypothesis	O
+-	O
+generating	O
+observational	O
+study	O
+.	O
+
+We	O
+retrospectively	O
+reviewed	O
+the	O
+initial	O
+chest	B-ANAT
+CT	O
+data	O
+of	O
+62	O
+confirmed	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+patients	O
+(	O
+34	O
+men	O
+,	O
+28	O
+women	O
+;	O
+age	O
+range	O
+20	O
+-	O
+91	O
+years	O
+old	O
+)	O
+who	O
+did	O
+not	O
+receive	O
+any	O
+antiviral	B-CHED
+treatment	O
+between	O
+January	O
+21	O
+and	O
+February	O
+4	O
+,	O
+2020	O
+,	O
+in	O
+Chongqing	O
+,	O
+China	O
+.	O
+
+Significantly	O
+increased	O
+CT	O
+score	O
+may	O
+indicate	O
+the	O
+aggravation	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+the	O
+progressive	O
+stage	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+(	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+outbreak	O
+on	O
+the	O
+cruise	O
+ship	O
+Diamond	B-CHED
+Princess	O
+.	O
+
+Because	O
+the	O
+virus	B-SPEC
+is	O
+new	O
+,	O
+and	O
+no	O
+vaccine	O
+is	O
+yet	O
+available	O
+,	O
+everyone	O
+is	O
+naïve	O
+and	O
+susceptible	O
+to	O
+being	O
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV2	O
+.	O
+
+TITLE	O
+:	O
+Optimizing	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+candidate	O
+therapeutics	O
+:	O
+Thinking	O
+Without	O
+Borders	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+Disease	I-DISO
+2019	I-DISO
+in	O
+Geriatrics	O
+and	O
+Long	O
+-	O
+term	O
+Care	O
+:	O
+The	O
+ABCDs	B-DISO
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Chloroquine	O
+is	O
+a	O
+long	O
+-	O
+established	O
+prescription	O
+drug	O
+that	O
+is	O
+often	O
+used	O
+clinically	O
+to	O
+treat	O
+malaria	B-PATH
+and	O
+connective	B-DISO
+tissue	I-DISO
+diseases	I-DISO
+.	O
+